1# QD(quaque die=one time a day); CKD5(estimated Glomerular filtration rate,eGFR<15ml/min/1.73 m2) 1# QOD(Every other day).
11496711|NCT01377259||1Tissue oxygenation change|Spinal anesthesia may result different changes of tissue oxygenation in blocked area ( upper extrimities ) and non-blocked area ( lower extrimities). The changes of tissue oxygenation saturation between upper and lower extremities in patients under spinal anesthesia for orthopedic surgery
11496712|NCT01377259||2Tissue oxygenation change|The changes of tissue oxygenation saturation between upper and lower extremities in patients under spinal anesthesia for cesarean section
11496713|NCT01377246|Placebo Comparator|Saline solution.|
11496714|NCT01377246|Experimental|Octrotide-LAR|
11496715|NCT01377233|Experimental|Zicronapine open-label lead-in 10 mg daily|
11496716|NCT01377233|Experimental|Zicronapine 10 mg daily|
11496717|NCT01377233|Experimental|Zicronapine 20 mg once weekly|
11496718|NCT01377233|Experimental|Zicronapine 30 mg once weekly|
11496719|NCT01377233|Experimental|Zicronapine 45 mg once weekly|
11496720|NCT01377207|Experimental|Female Arm|Female gender diagnosed with ST segment Elevation Myocardial Infarction (STEMI)
11496721|NCT01377207|Active Comparator|Male Arm|Male Gender diagnosed with ST segment Elevation Acute Myocardial Infarction (STEMI)
11496722|NCT01377194|Experimental|1|40mg Levomilnacipran ER
11496723|NCT01377194|Experimental|2|80mg of Levomilnacipran ER
11496724|NCT01377194|Placebo Comparator|3|Placebo
11496725|NCT01377181||group A|the patients were accepted laparoscopic purse-string knot closing the internal hernia opening only
11496726|NCT01377181||group B|the patients were accepted the lateral umbilicus ligament covering the internal hernia opening region after the laparoscopic purse-string knot
11496727|NCT01377168|Placebo Comparator|Placebo pill|Daily oral placebo.
11496728|NCT01377168|Active Comparator|NTX|Daily oral naltrexone.
11496729|NCT01377155|Other|Insulin determir|
11496730|NCT01377142||Laparoscopic sacral hysteropexy|Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance
11496731|NCT01377142||Vaginal mesh hysteropexy|Vaginal Mesh Hysteropexy using the Uphold device which includes Sacrospinous Ligament Fixation
11496732|NCT01377129|Active Comparator|Single Bundle|These patients are operated using a single bundle technique.
11496733|NCT01377129|Experimental|Double bundle|These patients are operated using a double bundle technique.
11496734|NCT01377103|Placebo Comparator|Placebo|Placebo Gel
11496735|NCT01377103|Active Comparator|Testosterone Supplementation|Testosterone Gel
11496736|NCT01377090||SSc DU-history subgroup|Systemic sclerosis patients with history of digital ulcers
11496737|NCT01377090||SSc with No-DU-history subgroup|Systemic sclerosis patients with no history of digital ulcers
11496738|NCT01377077|Experimental|epidermal 1mm grafting|Epidermal skin biopsies of 1mm diameter
11496739|NCT01377077|Experimental|dermal 1mm grafting|dermal skinbiopsies of 1mm diameter
11496740|NCT01377077|Experimental|dermal 1,5mm grafting|dermal skinbiopsies of 1,5mm diameter
11496742|NCT01377064|Experimental|Physical activity group|Subjects will participant in physical activity program
11496743|NCT01377064|Active Comparator|Standard care group|This group will not receive a physical activity intervention
11496744|NCT01377051|Active Comparator|Bronchodilator|Indacaterol maleate 300 mcg will be administered by a third independent investigator following a randomization list.
11496745|NCT01377051|Placebo Comparator|Placebo|Will be administered with the same device by a third independent investigator
11496746|NCT01377038|Active Comparator|Duloxetine|Phenotype assessment prior to and after treatement with duloxetine 20-30 mg oral daily for eight weeks.
11496747|NCT01377038|Active Comparator|Diclofenac|Phenotype assessment prior to and after treatment with topical diclofenac four times daily
11496748|NCT01377025|Experimental|Sorafenib blinded Phase|400 mg Sorafenib bid until PD
11496749|NCT01377025|Placebo Comparator|Placebo blinded Phase|Two tbl. in the morning and two tbl. in teh evening until PD
11496750|NCT01377025|Experimental|Sorafenib Open Phase|400 mg Sorafenib bid until PD
11496751|NCT01377012|Experimental|AIN457 10mg/kg-75mg|Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks
11496752|NCT01377012|Experimental|AIN457 10mg/kg-150mg|Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks
11496753|NCT01377012|Placebo Comparator|Placebo|Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (>= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24
11496754|NCT01376999|Experimental|Step Down|Step Down: We begin the COS (controlled ovarian stimulation) with 150 IU of FSH-r until 7th day of stimulation. This day we make an adjustment reducing the dose if necessary.
11496755|NCT01376999|Active Comparator|Step Up|Step up: We begin the COS (controlled ovarian stimulation) with 75 IU of FSH-r until 7th day of stimulation.This day we make an adjustment increasing the dose if necessary.
11496756|NCT01376986|Experimental|Activation|All those determined fit for service or who are granted postponement will be included in the activation intervention. The physical activation intervention will be implemented between the call-up and start of military service. The activation group utilises an ICT platform that will be developed.
11496757|NCT01376986|No Intervention|control|no access to the activation platform
11496758|NCT01376973||group A|Not received any oral device (Control)
11496759|NCT01376973||Group B and Group C|Group B - Used Michigan Occlusal Splint (MOS); Group C - Used Planas Oral Appliance (POA).
11496760|NCT01376960|Active Comparator|single shot popliteal fossa block|
11496761|NCT01376960|Active Comparator|ankle blocks|
11496762|NCT01376947||Nulliparous|Nulliparous women who were submitted to IUD device insertion
11496763|NCT01376947||Multiparous with no cesaraen section|Multiparous women with no cesarean sections that were submitted to IUD device insertion
11496764|NCT01376947||Mulitparous with cesarean section|multiparous women with a cesarean section that were submitted to IUD insertion
11496765|NCT01376908|Experimental|Kuvan® + Phe-restricted diet|Subjects will be treated with Kuvan® tablets once daily along with Phe-restricted diet therapy.
11496766|NCT01376908|Other|Phe-restricted diet alone|Subjects will follow a Phe-restricted diet alone.
11496767|NCT01376895|Experimental|POWER|Power is a 3 session intervention delivered through the internet in real time by a trained health educator. It focuses on reducing HIV risk. Each session last from 1 to 2 hours.
11496768|NCT01376895|Active Comparator|Power Health|Power Health is a 1 session general health promotion program designed to be delivered via the internet in real time by a trained health educator. The sessions focus on healthy life styles, cardiovascular health, and prostate health. Participants also receive information regarding safe sex.
11496769|NCT01376882|Experimental|Acute withdrawal|Chronic intervention 100 mg caffeine capsules 3 times per day for 14 days. Acute intervention of placebo capsule on day 15.
11496770|NCT01376882|Experimental|Acute caffeine-independent of withdrawal|Chronic intervention of placebo capsules 3 times per day for 14 days. Acute intervention of 100 mg caffeine capsule on day 15.
11496771|NCT01376882|Experimental|Chronic abstinence|Chronic intervention of placebo capsules 3 times per day for 14 days. Acute intervention of placebo capsule on day 15.
11496772|NCT01376882|Experimental|Acute caffeine-in state of withdrawal|Chronic intervention of 100 mg caffeine capsule 3 times per day for 14 days. Acute intervention of 100 mg caffeine capsule on day 15.
11496773|NCT01376869|Active Comparator|102mg extract 1 hops|Equivalent to 0.5g dry weight
11496774|NCT01376869|Active Comparator|410mg extract 1 hops|Equivalent to 2g dry weight
11496775|NCT01376869|Active Comparator|79mg extract 2 hops|Equivalent to 0.5g dry weight
11496776|NCT01376869|Active Comparator|316mg extract 2 hops|Equivalent to 2g dry weight
11496777|NCT01376869|Placebo Comparator|Placebo|
11496778|NCT01376856||PET/CT and surgical biopsy group|person who performed PET/CT and surgical biopsy of mediastinal lymph node for diagnosis of primary lung cancer of metastatic lung cancer
11496779|NCT01376843||Health care workers|health care workers who performed TST or Quantiferon-TB Gold In tube assay before
11496780|NCT01376830||COPD patients|
11496781|NCT01376817|Experimental|Omega 3|
11496782|NCT01376817|Active Comparator|MCT / LCT|
11496783|NCT01376804|Experimental|Valganciclovir|Participants received a once daily oral dose (solution or tablets) of valganciclovir starting within 10 days of kidney transplant for up to 200 days post-transplant. Dose (in milligrams) was calculated using the algorithm [7 * Body Surface Area * Creatinine Clearance].
11496784|NCT01376778|Active Comparator|CMV hyperimmune globulin - Cytogam®|Infusion of Cytogam®, Cytomegalovirus Immune Globulin Intravenous (Human) (CMV-IGIV)
11496785|NCT01376778|Placebo Comparator|Placebo|IV 5% albumin diluted 1 to 9 with 5% Dextrose in water (D5W)
11496786|NCT01376765|Experimental|Cohort 1|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine received with aluminum hydroxide adjuvant (Alhydrogel®), without adjuvant, or placebo in 2 intramuscular doses, 28 days apart, at 5 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine {(SARS vaccine with aluminum hydroxide adjuvant (Alhydrogel®)}; 4 subjects receive placebo.
11496787|NCT01376765|Experimental|Cohort 3|SARS vaccine with adjuvant, without adjuvant, or placebo; l in 2 intramuscular doses, 28 days apart, at 45 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine (SARS vaccine with adjuvant); 4 subjects receive placebo.
11496788|NCT01376765|Experimental|Cohort 2|SARS vaccine with adjuvant, without adjuvant, or placebo in 2 intramuscular doses, 28 days apart, at 15 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine (SARS vaccine with adjuvant) 4 subjects receive placebo.
11496789|NCT01376752|Active Comparator|maximal cytoreductive surgery without HIPEC|The participant will have a regular cytoreductive surgery without the adjunction of HIPEC.
11496790|NCT01376752|Experimental|maximal cytoreductive surgery with HIPEC|The participant will have a regular cytoreductive surgery, then the adjunction of HIPEC: hyperthermic cisplatin will be used at 75mg/m²
11496791|NCT01376739||Group 1|
11496792|NCT01376726|Experimental|Previous HIV Vaccine Trial Participants (Group 1)|"Participants will receive the study vaccine administered as one 0.5 mL intramuscular injection (IM) in either deltoid at baseline and Month 6.
~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
11496793|NCT01376726|Experimental|No Previous HIV Vaccine Trial (Group 2)|"Participants will receive the study vaccine administered as one 0.5 mL IM in either deltoid at baseline and Month 6.
~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
11496794|NCT01376713|Experimental|Ofatumumab alone|Patients with melanoma unresectable stage III B (T1- 4a, N2b-c), stage III C or stage IV (AJCC 2009) will be included in this study. Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks. Tumor imaging is performed at wk 4 (screening for rapid disease progression), 8, 16 and 24. In case of PD, patients will have the opportunity to receive at least 3 cycles of ofatumumab q4w in combination with DTIC (1000 mg/m2) q4w (see Arm2).
11496795|NCT01376713|Experimental|Ofatumumab plus Dacarbazine|Patients will be treated with a combination of DTIC (1000 mg/m2) q4w plus ofatumumab (1000mg) qw for 8 wks, and thereafter q4w.Tumor imaging is performed at wk 8, 16 and 24.
11496796|NCT01376700|Experimental|ADVATE - Prophylactic Regimen|Weekly infusions of ADVATE. Study visits (physical examination, lab tests including FVIII inhibitor tests) every week during the first 10 exposure days (EDs), every 5 weeks during the next 10 EDs and every 10 weeks thereafter.
11496797|NCT01376687||Pain free|No pain in the cervical spine
11496798|NCT01376687||Pain|Pain of 3 or greater on a VAS scale for the cervical spine
11496799|NCT01376661||Active Surveillance/ Prostate Cancer|
11496800|NCT01376622||Chronically Transfusion Patients|Patients with transfusion dependent anemia (excluding sickle cell disease), ages 2-25, on Deferasirox chelation therapy, to be monitored over 2 years.
11496801|NCT01376622||Controls|Normal controls, ages 2-25, with no known brain abnormality or endocrine dysfunction.
11496802|NCT01376596|Experimental|CBT-based Intervention|Contrast the impact of a CBT intervention for the treatment of social anxiety in schizophrenia with standard care (care as usual)
11496803|NCT01376596|Active Comparator|Treatment as usual|Usual care received by patients at clinic/hospital - randomized to a wait list to receive the CBT intervention at the end of the group that received the intervention immediately
11496804|NCT01376570|Experimental|Contingency Management arm|The Contingency Management arm will receive the abstinence-reinforcing contingency management intervention.
11496805|NCT01376570|Active Comparator|Control arm|The Control arm will receive the performance feedback intervention.
11496806|NCT01376557|Experimental|Treatment A|
11496807|NCT01376557|Experimental|Treatment B|
11496808|NCT01376557|Experimental|Treatment C|
11496809|NCT01376557|Experimental|Treatment D|
11496810|NCT01376557|Placebo Comparator|Placebo|
11496811|NCT01376544|Active Comparator|Assist control ventilation|Assist control ventilation
11496812|NCT01376544|Active Comparator|Pressure support ventilation|
11496813|NCT01376531||acute renal failure|patients at intensive care unit with definition of acute renal failure and the need for continuous veno-venous hemodialysis
11496814|NCT01376518||respiratory failure|patients with respiratory failure and need of high positive end-expiratory pressure ventilation.
11496815|NCT01376505|Experimental|HER-2 Vaccine|"combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with nor-MDP and ISA 720
~This escalation arm has completed. The trial has moved on to the extension arm"
11496816|NCT01376505|Experimental|EXTENSION HER-2 Vaccine at OBD|"Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with nor-MDP and ISA 720 at dose level cohort 2
~This extension arm is ongoing"
11496817|NCT01376492||001|Functioning assessment The functioning will be assessed with 2 scales (Personal and Social Performance Scale (PSP) and Brief Psychiatric Rating Scale)
11496818|NCT01376492||002|Quality of sleep assessment The quality of sleep will be assessed with 2 scales (Pittsburgh Sleep Quality Index (PSQI) and Epworth scale)
11496819|NCT01376479|Experimental|INV21 Low Dose|
11496820|NCT01376479|Experimental|INV21 High Dose|
11496821|NCT01376466||patients with acute appendicitis|Patients who have been clinically diagnosed to have acute appendicitis
11496822|NCT01376453|Experimental|Sorafenib Dose Escalation|Pre-operative Continuous 5-FU, and Sorafenib with External Radiation Therapy. Dose level -1 will only be evaluated if dose level 1 exceeds MTD. The sorafenib and infusional 5-FU will only be given Day 1-5(Monday-Friday) with radiation only.
11496823|NCT01376440|Experimental|Household water treatment|household water treatment with 1.25% sodium hypochlorite
11496824|NCT01376440|No Intervention|control|"Usual practice (the use of Jerrican for water storage, which is considered as safe storage)"
11496825|NCT01376414||Non specific upper abdominal pain|Cohort is patients who present to the Emergency Department with primary complaint of upper abdominal pain without obvious cause.
11496826|NCT01376388|Experimental|GSK573719/GW642444|125/25mcg
11496867|NCT01376167|Active Comparator|Primaquine 15mg (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 15mg Primaquine once daily Days 2-15
11497027|NCT01375075|Experimental|500 mg LY2484595|Administered orally once daily for 12 weeks
11496827|NCT01376362|Experimental|Interferon gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
11496828|NCT01376349|Experimental|Arm I low dose DHEA|Participants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone [DHEA]) gel once daily (QD), at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
11496829|NCT01376349|Experimental|Arm II high dose DHEA|Participants apply a high dose (6.5 mg) of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
11496830|NCT01376349|Placebo Comparator|Arm III placebo|Participants apply a vaginal placebo gel QD, at bed time, for 12 weeks. There is an Optional Continuation Phase (for placebo arm only): Participants apply a high dose of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
11496831|NCT01376336|Experimental|Safe storage device|This arm will be assigned a safe water storage device.
11496832|NCT01376336|No Intervention|Control|This arm of the trial will receive nothing until the end of the trial.
11496833|NCT01376323|Experimental|GSK256073 1mg bid|GSK256073 1mg capsule taken orally twice a day
11496834|NCT01376323|Experimental|GSK256073 2mg qd|GSK256073 2 x 1mg capsule taken orally once a day
11496835|NCT01376323|Experimental|GSK256073 5mg bid|GSK256073 5mg capsule taken orally twice a day
11496836|NCT01376323|Experimental|GSK256073 10mg qd|GSK256073 2 x 5mg capsule taken orally once a day
11496837|NCT01376323|Experimental|GSK256073 10mg bid|GSK256073 10mg capsule taken orally twice a day
11496838|NCT01376323|Experimental|GSK256073 20mg qd|GSK256073 2x 10mg capsule taken orally once a day
11496839|NCT01376323|Experimental|GSK256073 25mg bid|GSK256073 25mg capsule taken orally twice a day
11496840|NCT01376323|Experimental|GSK256073 50mg qd|GSK256073 2x 25mg capsule taken orally once a day
11496841|NCT01376323|Placebo Comparator|Placebo|Matching placebo capsules taken orally either once a day or twice a day
11496842|NCT01376323|Active Comparator|Sitagliptin 100mg qd|Commercially available Sitagliptin 100mg capsules taken once a day
11496843|NCT01376310|Experimental|Cohort A|Subjects on GSK1120212 Monotherapy who have been treated less than 24 weeks in their parent study.
11496844|NCT01376310|Experimental|Cohort B|Subjects on GSK monotherapy who have been treated for 24 weeks or greater in their parent study. Also, subjects entering this study from any GSK1120212 combo trial.
11496845|NCT01376297|Experimental|Netupitant and Palonosetron plus dexamethasone|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
11496846|NCT01376297|Active Comparator|Aprepitant and Palonosetron plus dexamethasone|Oral aprepitant hard capsule 125 mg (on Day 1) + 80 mg daily (for the following two days) and oral palonosetron soft capsule 0.50 mg (on Day 1) given with oral dexamethasone at each scheduled chemotherapy cycle.
11496847|NCT01376284||Subjects prescribed dutasteride capsules|Subjects with BPH prescribed dutasteride capsules during study period
11496848|NCT01376271||Subjects prescribed paroxetine tablets|Subjects with SAD prescribed paroxetine tablets during study period
11496849|NCT01376258||Patients adherent to 5-alpha reductase inhibitor (5ARI)|Patients with benign prostate hyperplasia (BPH) who are adherent (as measured by a medication possession ratio (MPR)) based on 3 MPR threshold values of 70%, 75% and 80%
11496850|NCT01376258||Patients who are non-adherent to 5ARI therapy|Patients with BPH who are not adherent to 5ARI therapy as measured by 3 MPR threshold values of 70%, 75%, and 80%
11496851|NCT01376245|Experimental|fluticasone furoate/vilanterol|Inhaled corticosteroid/long acting beta-agonist
11496852|NCT01376245|Placebo Comparator|placebo|matching placebo
11496853|NCT01376232|Experimental|GSK1278863|100 mg of GSK1278863
11496854|NCT01376232|Experimental|GSK1278863 + food|100 mg of GSK1278863 given with a high fat meal
11496855|NCT01376232|Experimental|GSK1278863 + Gemfibrozil|GSK1278863A 100mg + Gemfibrozil 600mg steady state
11496856|NCT01376219||All patients|All patients entered in the study
11496857|NCT01376206||Subjects prescribed ALLERMIST|Subjects with allergic rhinitis prescribed ALLERMIST during study period
11496858|NCT01376193||Subjects prescribed naratriptan tablets|Subjects with migraine headache prescribed naratriptan tablets during study period
11496859|NCT01376180||Subjects prescribed lamotrigine tablet|Subjects with epilepsy prescribed lamotrigine tablet during study period
11496860|NCT01376167|Experimental|Tafenoquine 50mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 50mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
11496861|NCT01376167|Experimental|Tafenoquine 100mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 100mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
11496862|NCT01376167|Experimental|Tafenoquine 300mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 300mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
11496863|NCT01376167|Experimental|Tafenoquine 600mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 600mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
11496864|NCT01376167|Active Comparator|Primaquine 15mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 15mg Primaquine once daily Days 2-15.
11496865|NCT01376167|Placebo Comparator|Chloroquine only|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered.
11496866|NCT01376167|Experimental|Tafenoquine 300mg (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 300mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
11497028|NCT01375075|Placebo Comparator|Placebo|Administered orally once daily for 12 weeks
11496868|NCT01376167|Placebo Comparator|Chloroquine only (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered
11496869|NCT01376154||Subjects prescribed lamivudine tablet|Subjects with hepatitis B virus-induced liver cirrhosis prescribed lamivudine tablet during study period
11496870|NCT01376141||Subjects prescribed IMIGRAN|Subjects with migraine disorders prescribed IMIGRAN during study period
11496871|NCT01376128||Subjects prescribed PAXIL|Pediatric subjects with panic disorder prescribed PAXIL during study period
11496872|NCT01376115||Subjects administered nelarabine|Subjects with T-cell acute lymphocytic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) prescribed nelarabine during study period
11496873|NCT01376102||BONVIVA(ibandronate)|Patients administrated ibandronate injection with postmenopausal osteoporosis
11496874|NCT01376089|Other|Arm 1-Iodixanol|
11496875|NCT01376089|Active Comparator|Arm 2-Iopamidol|
11496876|NCT01376076|Experimental|1|Sequential, Multiple Dose, titration from 1.5mg to 18mg once daily dose of cariprazine
11496877|NCT01376076|Placebo Comparator|2A|Double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35
11496878|NCT01376076|Placebo Comparator|2B|Double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35
11496879|NCT01376063|Experimental|FG-4592|
11496880|NCT01376050|Active Comparator|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 milliWatts (mW) 635 nanometer (nm) light emitting diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center, and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
11496881|NCT01376050|Placebo Comparator|Placebo Laser|Placebo Laser has the same appearance and application as the Erchonia MLS but does not emit an therapeutic output.
11496882|NCT01376037|Placebo Comparator|inactive placebo laser device|The inactive placebo laser device looks identical to the active laser device, but does not emit any therapeutic light output.
11496883|NCT01376037|Active Comparator|Erchonia ML Scanner (MLS)|The Erchonia ML Scanner (MLS) is a low level laser light therapy device comprising 4 independent rotating diodes, each emitting 17mW 635nm of red laser light. The diodes are mounted in scanner devices positioned 120 degrees apart from each other, tilted at a 30 degree angle. The Erchonia® MLS is activated for 20 minutes per arm during which time the 4 rotating diodes create a spiraling circle pattern that is totally random and independent from the others. These patterns overlap each other to guarantee total coverage within the target area. The total laser energy the test subject is exposed to per treated arm is approximately 3.94 joules per square centimeter. Six procedures are administered evenly across 2 weeks.
11496884|NCT01376011|Experimental|healthy young|
11496885|NCT01376011|Experimental|healthy old|
11496886|NCT01375998||Group 1|
11496887|NCT01375985|Experimental|AVI-7100|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
11496888|NCT01375985|Experimental|Placebo|Vehicle
11496889|NCT01375972|Experimental|SP treatment|S-1 plus cisplatin combination chemotherapy
11496890|NCT01375972|Active Comparator|GP treatment|Gemcitabine plus Cisplatin combination chemotherapy
11496891|NCT01375959|Experimental|Resveratrol|resveratrol 500 mg capsules, 3 each day for 6 weeks
11496892|NCT01375959|Placebo Comparator|Placebo|matching placebo capsule containing lactose, 3 each day for 6 weeks
11496893|NCT01375946|Experimental|AG200-15 location|The subject will wear AG200-15 for 7 days and be exposed to one of 5 external conditions (normal, treadmill, cold water, whirlpool, dry sauna).
11496894|NCT01375933|Active Comparator|NicVAX - Phase 3 Lot|NicVAX - Phase 3 Lot
11496895|NCT01375933|Active Comparator|NicVAX - Commercial Lot|NicVAX - Commercial Lot
11496896|NCT01375920|Active Comparator|Metyrapone, daily medication|500 milligrams Metyrapone to be taken orally twice daily for 3 weeks.
11496897|NCT01375920|Placebo Comparator|placebo|a matched placebo will be given for patients to take twice daily
11496898|NCT01375907|Experimental|Rotavin|Rotavin-M1 vaccine, 10e6.3FFU/dose, 2 doses, 1 month between doses
11496899|NCT01375894|Active Comparator|depresive patients|30 patients suffering from depression
11496900|NCT01375894|Experimental|Schizophrenia patients|30 Schizophrenia patients
11496901|NCT01375881||001|darunavir/ritonavir plus background regimen darunavir/ritonavir oral use in naive and experienced patients at approved dosages
11496902|NCT01375868|Experimental|Vaccine Silgard|vaccination with tetravalent antiviral vaccine, 3 doses
11496903|NCT01375855|Active Comparator|Polimeric-PES|Arm receiving polimeric stent (Taxus)
11496904|NCT01375855|Active Comparator|Non-Polimeric PES|Arm receiving non-polimeric PES (axxion)
11496905|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.01 mg/kg|Participants will receive intravenous (IV) infusion of atezolizumab 0.01 milligrams per kilogram (mg/kg) every 3 weeks (q3w) until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
11496906|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.03 mg/kg|Participants will receive IV infusion of atezolizumab 0.03 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
11496907|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.1 mg/kg|Participants will receive IV infusion of atezolizumab 0.1 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
11496908|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.3 mg/kg|Participants will receive IV infusion of atezolizumab 0.3 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
11496909|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 1 mg/kg|Participants will receive IV infusion of atezolizumab 1 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
11497024|NCT01375088|Active Comparator|propolis|10 patients swish & swallow 15 ml propolis mouth wash for at least 5 min from the first session of radiotherapy until the last session
11496910|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 3 mg/kg|Participants will receive IV infusion of atezolizumab 3 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
11496911|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 10 mg/kg|Participants will receive IV infusion of atezolizumab 10 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
11496912|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 20 mg/kg|Participants will receive IV infusion of atezolizumab 20 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
11496913|NCT01375842|Experimental|Expansion Cohort (Atezolizumab)|Participants will receive IV infusion of atezolizumab q3w up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first. The dose which result in total drug exposure less than or equal to (</=) exposures achieved at the MTD or maximum administered dose (MAD), will be selected for expansion cohort.
11496914|NCT01375829|Experimental|Treatment (ixabepilone, temsirolimus)|Patients receive ixabepilone IV over 3 hours on day 1 and temsirolimus IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11496915|NCT01375816|Active Comparator|FOLFIRI 1 or m FOLFIRI3-Bevacizumab|"FOLFIRI 1-Bevacizumab:
~Day 1 H0 : Bevacizumab 5 mg/kg, 30-90 min infusion H+1: Irinotecan 180 mg/m² in 250 ml NaCl 0.9%, 1h infusion Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) over 2h H + 3: 5-FU bolus 400 mg/m², 15 min infusion H + 3.5: 5-FU continuous infusion 2400 mg/m² 46-h infusion End of cycle: day 14
~modified FOLFIRI3-Bevacizumab H0 :Bevacizumab 5 mg/kg, 30-90 min infusion H+1:Irinotecan 90 mg/m² in 250 ml NaCl 0.9%, 1h infusion H+1: Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) 2-h infusion H + 3: 5-FU continuous infusion 2400 mg/m² 46-h infusion Day 3 (H+49) H0 Irinotecan 90 mg/m² in 250 ml NaCl 0.9%, 1h infusion End of cycle: day 14"
11496916|NCT01375816|Experimental|FUPEP-Bevacizumab|"Day 1 H0 :Bevacizumab 5 mg/kg, 30-90 min infusion H +1 :PEP02 80 mg/m² , 1h30 infusion. The infusion time could be reduced to 1h from cycle 2 if no acute infusion reaction has occured in cycle 1.
~H +1 : Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) , 2-h infusion H +3 : 5-FU continuous infusion 2400 mg/m² 46-h infusion End of cycle: day 14"
11496917|NCT01375803|Experimental|1|3g/day
11496918|NCT01375803|Experimental|2|6g/day
11496919|NCT01375803|Placebo Comparator|Placebo beverage|0g/day
11496920|NCT01375790|Experimental|Exercise with Whole-body vibration platform|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm). Training volume and intensity we will increase systematically over six weeks according to the overload principle.
11496921|NCT01375790|Active Comparator|Exercise|The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli, during a six weeks training period (3sessions/week). Training volume and intensity we will increase systematically over six weeks according to the overload principle
11496922|NCT01375777|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
11496923|NCT01375777|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
11496924|NCT01375777|Active Comparator|Ezetimibe|Participants received 10 mg ezetimibe orally once a day for 12 weeks.
11496925|NCT01375777|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
11496926|NCT01375777|Experimental|Evolocumab 105 mg Q2W|Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
11496927|NCT01375777|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
11496928|NCT01375777|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
11496929|NCT01375777|Experimental|Evolocumab 350 mg Q4W|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
11496930|NCT01375777|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
11496931|NCT01375764|Active Comparator|Ezetimibe|Participants received placebo subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
11496932|NCT01375764|Experimental|Evolocumab + Ezetimibe|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
11496933|NCT01375764|Experimental|Evolocumab 280 mg|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
11496934|NCT01375764|Experimental|Evolocumab 350 mg|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
11496935|NCT01375764|Experimental|Evolocumab 420 mg|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
11496936|NCT01375751|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 4 weeks for 12 weeks.
11496937|NCT01375751|Experimental|Evolocumab 350 mg|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
11496938|NCT01375751|Experimental|Evolocumab 420 mg|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
11496939|NCT01375738|Active Comparator|Gastroduodenostomy|Arm 1: undergo gastroduodenostomy after distal gastrectomy for gastric cancer
11496940|NCT01375738|Experimental|Roux-en Y gastrojejunostomy|Arm 2: undergo Roux-en Y gastrojejunostomy after distal gastrectomy for gastric cancer
11496941|NCT01375725||Coumadin (warfarin)|Subjects currently receiving coumadin (warfarin) treatment.
11496942|NCT01375712|Active Comparator|Fermented milk|Fermented milk containing Lactobacillus casei strain Shirota, 65 ml in a bottle, consume 1 bottle per day.
11496943|NCT01375712|Placebo Comparator|Placebo|Non-fermented milk without Lactobacillus casei strain Shirota, 65 ml in a bottle, consume 1 bottle per day.
11497025|NCT01375075|Experimental|30 milligrams (mg) LY2484595|Administered orally once daily for 12 weeks
11496944|NCT01375699|Experimental|Sildenafil + doxorubicin|"Patients receive sildenafil citrate PO QD* beginning at least 2 days prior to scheduled first dose of doxorubicin hydrochloride and continuing until 2 weeks after last scheduled dose of doxorubicin hydrochloride. Patients also receive doxorubicin hydrochloride IV as clinically indicated and as prescribed by treating provider.
~NOTE: *Patients receive sildenafil citrate PO TID on days that doxorubicin hydrochloride is also administered."
11496945|NCT01375699|Active Comparator|Doxorubicin-based chemotherapy|Patients receive doxorubicin hydrochloride IV as clinically indicated and as prescribed by treating provider.
11496946|NCT01375686||Those at Risk for Type 2 diabetes|All subjects will be at risk for diabetes based on the American Diabetes Association (ADA) Standard of Care Guidelines.
11496947|NCT01375673|Experimental|Exercise|Exercise: Walking Strength Training Bicycling
11496948|NCT01375673|No Intervention|Usual Care|Usual Care
11496949|NCT01375660|Placebo Comparator|Arm 1|Placebo: One capsule weekly
11496950|NCT01375660|Experimental|Arm 2|50K vitamin D2: One capsule weekly
11496951|NCT01375647|Experimental|Rotarix + No IPV|Randomized to receive rotarix vaccine but no IPV boost
11496952|NCT01375647|Experimental|Rotarix + with IPV boost|Randomized to receive both rotarix vaccine and IPV boost
11496953|NCT01375647|No Intervention|No Rotarix + No IPV|Randomized to receive neither rotarix vaccine nor IPV boost
11496954|NCT01375647|Experimental|No Rotarix + with IPV boost|Randomized to receive no rotarix vaccine but to receive IPV boost
11496955|NCT01375634|Placebo Comparator|Placebo|Normal saline
11496956|NCT01375634|Experimental|Midazolam|Midazolam
11496957|NCT01375621||AHS cohort|population of S. aureus asymptomatic rural Iowans
11496958|NCT01375621||Non-AHS group|symptomatic S. aureus infections in rural Iowans.
11496959|NCT01375608|Other|decitabine|active treatment
11496960|NCT01375582|Experimental|Drop Administration|
11496961|NCT01375569|Experimental|TRC105 in Liver Cancer|TRC105 is an experimental cancer drug designed to slow or stop the growth of tumors. It does this by preventing the growth of new blood vessels that feed these tumors. This drug is being used to test the safety and effectiveness to treat liver cancer that has not responded to standard therapy. TRC105 will be given as an intravenous infusion every two weeks.
11496962|NCT01375543||Enrollees|Enrolled study participants in whom genetic sequencing was done
11496963|NCT01375530||1|Healthy adults 18 years old or older
11496964|NCT01375504|Active Comparator|Dietary Counseling|The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
11496965|NCT01375504|Other|Mindfulness Training Program|The mindfulness training program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
11496966|NCT01375491|Experimental|Doxycycline|Participants with DM2 receiving doxycycline 100mg BID
11496967|NCT01375491|Placebo Comparator|Placebo|Pills prepared identical to doxycycline.
11496968|NCT01375478||Cohort|
11496969|NCT01375465|Other|Dior|One arm observational registry using the Dior paclitaxel eluting balloon for the treatment of de novo ostial bifurcated lesions.
11496970|NCT01375452|Active Comparator|Femara|
11496971|NCT01375452|Experimental|Letrozole|
11496972|NCT01375439|Other|Active search of lower genital tract infections|"Active search of lower genital tract infections
~Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome."
11496973|NCT01375413|Experimental|Integrated dual task training|Integrated dual task training delivered by a physiotherapist. In this training mode walking practice will be combined with simultaneously carrying out cognitive discrimination, verbal fluency and memory tasks.
11496974|NCT01375413|Active Comparator|Consecutive task training|Consecutive task gait training delivered by a physical therapist. In this training mode, walking practice will be conducted separately, focusing on the motor task only. Training of cognitive discrimination, verbal fluency and memory tasks will be done consecutively while the subjects are sitting.
11496975|NCT01375387|Experimental|Lacosamide 100 mg, Japanese|1 Lacosamide 100 mg tablet plus 3 placebo tablets
11496976|NCT01375387|Experimental|Lacosamide 100 mg, Chinese|1 Lacosamide 100 mg tablet plus 3 placebo tablets
11496977|NCT01375387|Experimental|Lacosamide 200 mg, Japanese|2 Lacosamide 100 mg tablets plus 2 placebo tablets
11496978|NCT01375387|Experimental|Lacosamide 200 mg, Chinese|2 Lacosamide 100 mg tablets plus 2 placebo tablets
11496979|NCT01375387|Experimental|Lacosamide 400 mg, Japanese|4 Lacosamide 100 mg tablets
11496980|NCT01375387|Experimental|Lacosamide 400 mg, Chinese|4 Lacosamide 100 mg tablets
11496981|NCT01375387|Placebo Comparator|Placebo Comparator, Japanese|4 placebo tablets
11496982|NCT01375387|Placebo Comparator|Placebo Comparator, Chinese|4 placebo tablets
11496983|NCT01375374|Experimental|Lacosamide|commercial 50 mg (pinkish) and 100 mg (yellow) tablets
11496984|NCT01375361|Experimental|Inhaled Albuterol|Patients identified to have Cardiogenic Pulmonary Edema, will receive 2.5mg of Albuterol nebulizer on enrollment in the study and again at 4 hours. Patients will be monitored on telemetry in the emergency department during and after study drug administration. Although study drug administration will cease after 4 hours, we will continue to record ongoing data during the patient's hospitalization.
11496985|NCT01375361|Placebo Comparator|Inhaled Placebo.|Patients identified to have Cardiogenic Pulmonary Edema will receive 2.5mg Normal saline inhaled (Placebo) on enrollment and at 4 hours in the emergency department. Patient will be monitor on telemetry in the emergency department during and after placebo administration.
11497026|NCT01375075|Experimental|100 mg LY2484595|Administered orally once daily for 12 weeks
11496986|NCT01375348|Active Comparator|Remifentanil|"Investigate the effect of remifentanil on cognitive function in healthy volunteers by use of experimental pain models:
~tonic muscle pain induced by the tourniquet pain model
~cognitive tests
~recording of brain activity by use of 64 channel cap"
11496987|NCT01375348|Placebo Comparator|Placebo infusion|"To blind the study and use as comparator in the investigation of the effect of remifentanil on cognitive function in healthy volunteers by use of experimental pain models:
~tonic muscle induced pain by the tourniquet pain model
~cognitive tests
~brain activity by use of a 64 channel cap"
11496988|NCT01375335|Experimental|Dobutamine|
11496989|NCT01375322|Active Comparator|Co-Diovan® Group|The starting dose of Co-Diovan® was 1 capsule (contains 1/2 tablet) (valsartan/ hydrochlorothiazide 40 mg/ 6.25 mg) every morning and could be adjusted up to 2 capsules (contains 1 tablet per capsule) (valsartan/ hydrochlorothiazide 160 mg/ 25.0 mg) every morning if patients did not achieve the criteria of SBP<130 mmHg and DBP< 80 mmHg during treatment period
11496990|NCT01375322|Experimental|Amtrel® Group|The starting dose of Amtrel® was 1 capsule (contains 1/2 tablet) (amlodipine / benazepril hydrochloride 2.5 mg/ 5 mg) every morning and could be adjusted up to 2 capsules (contains 1 tablet per capsule) (amlodipine / benazepril hydrochloride 10 mg/ 20 mg) every morning if patients did not achieve the criteria of SBP<130 mmHg and DBP< 80 mmHg during treatment period
11496991|NCT01375309|Active Comparator|Active|Bifidobacterium bifidum
11496992|NCT01375309|Placebo Comparator|Placebo|Dextrin without Bifidobacterium bifidum
11496993|NCT01375296|Experimental|SES|including two types of China-made SES, i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
11496994|NCT01375296|Other|medicine|
11496995|NCT01375283||lung cancer surgery|
11496996|NCT01375270|Experimental|Glucotoxicity Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.
~The clamp will be performed before and after 24 hours of bed rest, isocaloric meal feeding, and experimental elevation of blood glucose."
11496997|NCT01375270|No Intervention|Control Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.
~The clamp will be performed before and after 24 hours of bed rest and isocaloric meal feeding."
11496998|NCT01375270|Experimental|Lipotoxicity Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.
~The clamp will be performed before and after 24 hours of bed rest, isocaloric meal feeding, and experimental elevation of blood free fatty acids."
11496999|NCT01375257|Active Comparator|Guideline treatment with parenteral antibiotics|Guideline treatment with parenteral antibiotics
11497000|NCT01375257|Experimental|Oral treatment with antibiotics|Oral treatment with antibiotics based on resistens pattern
11497001|NCT01375244|Experimental|A|Subjects received the Par formulated product.
11497002|NCT01375244|Active Comparator|B|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
11497003|NCT01375231|Active Comparator|Measured Resection of patellofemoral joint|The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
11497004|NCT01375231|Active Comparator|Measured resection of patella|The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
11497005|NCT01375218|Active Comparator|Plastizote Brace|
11497006|NCT01375218|Active Comparator|Pavlik Brace|
11497007|NCT01375205|Active Comparator|Standard of Care|Subjects will apply Johnson&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&Johnson cleanser.
11497008|NCT01375205|Experimental|Cetaphil Restoraderm|Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
11497009|NCT01375179|Experimental|KRP203|"Experimental
~Edit
~Experimental"
11497010|NCT01375179|Placebo Comparator|Placebo|Placebo
11497011|NCT01375166||Diabetic retinopathy|Patients with early insulin dependent diabetes and no or mild non-proliferative retinopathy
11497012|NCT01375166||healthy|healthy control subjects
11497013|NCT01375153|Placebo Comparator|Placebo|0,9% NaCl administered as a continuous intravenous infusion during four hours.
11497014|NCT01375153|Active Comparator|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours.
11497015|NCT01375140|Experimental|Ruxolitinib + Lenalidomide|Ruxolitinib 15 mg orally twice daily continuously + Lenalidomide orally 5 mg/day on days 1-21, followed by 7 days of no therapy (28-day cycle). Prednisone will be added for patients who have not responded after 3 cycles of therapy. Prednisone 30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued.
11497016|NCT01375127||Subjects from Study A3921009|
11497017|NCT01375127||Subjects from Study A3921030|
11497018|NCT01375114|Experimental|Panax Ginseng|Panax ginseng 400 mg by mouth twice a day from Day 1-29 for first 30 participants in Part 1. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
11497019|NCT01375114|Experimental|Ginseng (Part 2)|Panax ginseng 400 mg by mouth twice a day from Day 1-29. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
11497020|NCT01375114|Placebo Comparator|Placebo (Part 2)|Oral placebo twice daily for 4 weeks. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
11497021|NCT01375101|Active Comparator|quercetin|quercetin is one of flavonoids , and having therapeutical anti-inflammatory and antioxidant action
11497022|NCT01375101|Placebo Comparator|placebo|placebo capsul is produced with lactose for using in placebo/ control group.
11497023|NCT01375088|Placebo Comparator|placebo mouth wash|10 patients swish & swallow 15 ml placebo mouth wash for at least 5 min from the first session of radiotherapy until the last session
11497029|NCT01375075|Active Comparator|10 mg Atorvastatin|Administered orally once daily for 12 weeks
11497030|NCT01375075|Experimental|100 mg LY2484595 + 10 mg Atorvastatin|Administered orally once daily for 12 weeks
11497031|NCT01375062|No Intervention|tissue from biopsies|
11497032|NCT01375049|Experimental|Aztreonam for Inhalation Solution (AZLI)|Participants will receive one 28-day course of AZLI, then will be followed for a 24-week period (through Day 196).
11497033|NCT01375023|Experimental|Anti-Thymocyte Globulin+radiotherapy|triple negative breast cancer patients treated with radiation and Anti-Thymocyte Globulin iv
11497034|NCT01375010|Placebo Comparator|Group A|Placebo vitamin D3 capsule daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 1000 IU.
11497035|NCT01375010|Experimental|Group B|2000 IU vitamin D3 daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 3000 IU.
11497036|NCT01374997|Other|patients with Fabry disease|detection of this disease in end-stage renal failure patients, transplant or hemodialysis
11497037|NCT01374984||Subjects treated with VIGIV.|"Subjects treated with VIGIV deployed from the US Strategic National Stockpile for any of the following conditions:
~Eczema vaccinatum.
~Progressive vaccinia.
~Severe generalized vaccinia.
~Vaccinia infections in individuals who have skin conditions.
~Aberrant infections induced by vaccinia virus (except in cases of isolated keratitis)."
11497038|NCT01374971|Other|Certolizumab Pegol (CZP)|Certolizumab Pegol (CZP) liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks with arthroscopic synovial tissue biopsy pre- and post-treatment.
11497039|NCT01374945|No Intervention|SOC preparation and colonoscopy|
11497040|NCT01374945|Experimental|Miniprep and Clearpath|
11497041|NCT01374932|Experimental|CPAP (see below)|Adult patients with asthma who require treatment with CPAP because of OSAS (RDI> = 20 events per hour). CPAP will be administered according to SEPAR guidelines and tailored to individual characteristics
11497042|NCT01374919|Other|ferumoxytol|IV administration of 1020 mg of ferumoxytol in 15 minutes
11497043|NCT01374906|Experimental|10 mg LAR dose|Randomization was stratified based on Screening mUFC to ensure balanced distribution of disease severity in the two dose arms.
11497044|NCT01374906|Experimental|30 mg LAR dose|Randomization was stratified based on Screening mUFC to ensure balanced distribution of disease severity in the two dose arms.
11497045|NCT01374893|Active Comparator|Exercise|
11497046|NCT01374893|Placebo Comparator|Control group|Usual care
11497047|NCT01374880||Dyspnea cohort|Dyspnea cohort
11497048|NCT01374880||Stable chronic heart failure|Stable chronic heart failure
11497049|NCT01374880||Valvular heart disease|Valvular heart disease
11497050|NCT01374880||Ventricular assist device|Ventricular assist device
11497051|NCT01374880||Cardiac arrest|Cardiac arrest
11497052|NCT01374880||Cardiac rehabilitation|Cardiac rehabilitation
11497053|NCT01374854|Experimental|Stem Cell Infusion|
11497054|NCT01374854|Active Comparator|traditional therapy control|
11497055|NCT01374841|Experimental|Stem Cell Transplant+Cyclophosphamide|patients with high-risk hematologic malignancies will receive hematopoietic stem cell transplantation from haploidentical donors after treatment with cyclophosphamide
11497056|NCT01374828|Experimental|Ketolorac|
11497057|NCT01374815|Experimental|The Online Advocate|
11497058|NCT01374802|Experimental|BI 201335|capsule for oral administration
11497059|NCT01374802|Experimental|Darunavir 400 mg|tablet for oral administration
11497060|NCT01374802|Experimental|Ritonavir 100 mg|tablet for oral administration
11497061|NCT01374789|Experimental|Arm A (GemCis + Panitumumab)|gemcitabine + cisplatin + panitumumab
11497062|NCT01374789|Active Comparator|Arm B (GemCis)|gemcitabine + cisplatin
11497063|NCT01374763|Active Comparator|Oxycodone|Drug: prolonged-release oxycodone
11497064|NCT01374763|Active Comparator|Oxycodone/naloxone|Prolonged-release oxycodone/naloxone
11497065|NCT01374750|Active Comparator|m-TOR inhibitor free|Immunosuppressive drug
11497066|NCT01374750|Experimental|Sirolimus|Immunosuppressive drug
11497067|NCT01374737|Other|dexmedetomidine, children|
11497068|NCT01374724|Experimental|Ban & Informational Pamphlet|Following 8.5 weeks of cessation subjects are given an informational pamphlet on tobacco cessation and relapse prevention.
11497069|NCT01374724|Experimental|Ban & Tailored Pamphlet|After 8.5 weeks of tobacco use cessation during Basic Military Training subjects are provided a tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force
11497070|NCT01374724|Experimental|Ban & Tailored Pamphlet & Intervention|After 8.5 weeks of tobacco use cessation during Basic Military Training subjects are provided a tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force. In addition they are given a face to face relapse prevention intervention.
11497071|NCT01374711|Placebo Comparator|placebo|LPS will be administered twice on days 1 and 7. In between placebo will be administered on days 2, 4 and 6 subcutaneously.
11497072|NCT01374711|Active Comparator|GM-CSF|LPS will be administered twice on days 1 and 7. In between GM-CSF will be administered on days 2, 4 and 6 subcutaneously.
11497073|NCT01374711|Active Comparator|IFN-y|LPS will be administered twice on days 1 and 7. In between IFN-Y will be administered on days 2, 4 and 6 subcutaneously.
11497074|NCT01374698|Active Comparator|Aspirin|All patients who meet the eligibility criteria will be randomized in a 1:1 manner to receive, before the coronary percutaneous procedure, an oral aspirin reload (325 mg)or placebo.
11497075|NCT01374698|No Intervention|No intervention|No intervention
11497076|NCT01374672||Correlative studies|DNA and RNA extracted from biopsy samples are analyzed for methylation changes and transcription changes by ligation-mediated PCR and mass-array genotyping.
11497166|NCT01373931|Experimental|OC + LY2216684 First, Then OC + Placebo|28-day lead-in period of Ortho Cyclen (OC; 28-day packet), followed by randomization to OC administered orally once daily for 28 days + 18 milligrams (mg) of LY2216684 administered concomitantly orally once daily for 21 days, followed by OC administered orally once daily for 28 days + placebo administered concomitantly orally once daily for 21 days.
11497298|NCT01373086|Experimental|LFF269 high dose|LFF269 high dose + Matching Placebo to Eplerenone 50mg
11497077|NCT01374659||Study patients|Study patients with histologically proven DTC were studied. All patients had previously undergone total thyroidectomy and more than one session of postoperative RI therapy. After the last RI therapy session, all patients showed increasing pathological Tg levels (Tg > 9-10 ng/ml) after TSH stimulation (TSH > 30 mU/l). However, neither tumor recurrence nor metastasis could be detected in any patient by post-therapeutic [131I] scanning, neck US, or chest radiography. Patients with obvious cervical pathology or positive fine-needle aspiration cytology (FNAC) were excluded from the study. The work was approved by our Institutional Review Board and written informed consent was obtained from each patient.
11497078|NCT01374633|Experimental|1:patient with severe traumatic brain|
11497079|NCT01374620|Experimental|Paclitaxel Dose escalation|"A standard dose escalation strategy will be used including 3 to 6 patients at each dose level (Paclitaxel dose escalation + fixed dose of cyclophosphamide)
~+ blood collection"
11497080|NCT01374620|Experimental|Cohort extension|"An additional 10 patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose
~+ blood collection"
11497081|NCT01374594||Healthy adults|
11497082|NCT01374594||Type 2 diabetes|
11497083|NCT01374581|Experimental|Artemether/Lumefantrine|Tablets 20 mg/120 of Artemether/Lumefantrine will be given to 124 trial patients
11497084|NCT01374581|Experimental|Artesunate/Amodiaquine|Tablets 25mg/67,5 mg of Artesunate/Amodiaquine will be given to 124 trial patients.
11497085|NCT01374581|Active Comparator|Quinine + Clindamycin|Quinine tablet 125mg + Clindamycin syrup 75mg/5ml will be given to 60 children.
11497086|NCT01374568|Active Comparator|sitagliptin|Sitagliptin
11497087|NCT01374568|Placebo Comparator|Placebo|Placebo
11497088|NCT01374542||Respiratory endoscopy patients|Patients undergoing respiratory endoscopy at Singapore General Hospital
11497089|NCT01374516|Experimental|CYD Dengue Vaccine Group|Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.
11497090|NCT01374516|Placebo Comparator|Placebo Group|Participants were to receive a placebo vaccine at 0, 6, and 12 months.
11497091|NCT01374503|Experimental|ALX-0651|
11497092|NCT01374503|Placebo Comparator|Placebo|
11497093|NCT01374490|Experimental|Crofelemer|
11497094|NCT01374477||Adolescent with preeclampsia|Patients < 19 years old who delivered in our institution (vaginal birth or cesarean) that developed a hypertensive disorder of pregnancy.
11497095|NCT01374477||Normal adolescent|Patients < 19 years old who delivered in our institution (vaginal birth or cesarean) without developing a hypertensive disorder of pregnancy.
11497096|NCT01374464|Active Comparator|High Volume, High Concentration|
11497097|NCT01374464|Active Comparator|High Volume, Low Concentration|
11497098|NCT01374464|Active Comparator|Low Volume, High Concentration|
11497099|NCT01374464|Active Comparator|Low Volume, Low Concentration|
11497100|NCT01374451|Experimental|Paseriotide LAR + Everolimus|everolimus 10 mg once daily po in combination with pasireotide LAR 60 mg every 28 days (q28d) im
11497101|NCT01374451|Experimental|Everolimus|everolimus 10 mg once daily po alone
11497102|NCT01374438|Experimental|MSDC-0160 capsules|MSDC tablets contained in #00 capsules
11497103|NCT01374438|Placebo Comparator|Placebo capsules|Placebo tablets contained in #00 capsules
11497104|NCT01374425|Experimental|Bevacizumab + mFOLFOX6|Participants will receive bevacizumab plus mFOLFOX6 by intravenous (IV) infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity. Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to oxaliplatin, with bevacizumab continued in 3-week cycles.
11497105|NCT01374425|Experimental|Bevacizumab + FOLFIRI|Participants will receive bevacizumab plus FOLFIRI by IV infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity. Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to irinotecan, with bevacizumab continued in 3-week cycles.
11497106|NCT01374412||osteoporosis|patients with benign osteoporosis
11497107|NCT01374399|Experimental|resistance and endurance exercise|
11497108|NCT01374399|Active Comparator|relaxation|
11497109|NCT01374386|No Intervention|Usual Physical Activity|Participants in this arm are do not have access to Exergames, only usual physical activity at the gym
11497110|NCT01374386|Experimental|Exergaming|Participants in this arm will have access to usual physical activity at the gym as well as access to Exergaming equipment (video games that require physical activity)
11497111|NCT01374373|Other|Open Label|One arm open label
11497112|NCT01374360||Receiving Soliris or Ultomiris|PNH patients of any age, including minors, that are receiving Soliris or Ultomiris
11497113|NCT01374360||Not receiving Soliris or Ultomiris|PNH patients of any age, including minors, that are not receiving Soliris or Ultomiris
11497114|NCT01374347||One dose, Repeat doses|First group recives one dose Second group receives several doses
11497115|NCT01374347||One dose, several doses|15 patients will take one dose of 20 mg cialis, and will have a second brain SPECT 24 hours after cialis administration. 15 other patients (age and risk factor matched) will be prescribed 5 mg of cialis once daily for 7 days, and a second SPECT study will be performed 24 hours after the last dose.
11497116|NCT01374321|Placebo Comparator|Placebo|
11497117|NCT01374321|Experimental|TRO40303|
11497118|NCT01374308|Experimental|NASVAC|NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
11497119|NCT01374308|Active Comparator|Pegylated interferon alpha 2b|Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
11497120|NCT01374295|Experimental|video|If randomized to this arm patient watches a 3 minute video
11497121|NCT01374295|Active Comparator|standard education|If randomized to this arm patient receives standard verbal education from healthcare provider.
11497167|NCT01373931|Experimental|OC + Placebo First, Then OC + LY2216684|28-day lead-in period of OC (28-day packet), followed by randomization to OC administered orally once daily for 28 days + placebo administered concomitantly orally once daily for 21 days, followed by OC administered orally once daily for 28 days + 18 mg of LY2216684 administered concomitantly orally once daily for 21 days.
11497224|NCT01373515|Experimental|Cohort 3; 5x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 5x10E7 DCP-001.
11497122|NCT01374269|Experimental|Excercise|One group will be assigned to protocolized back pain exercise, three times a week for 4 weeks. This program is carried out by physiotherapists from participating institutions who wish to participate in research and who will be given a training which will standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. Treatment, type of exercises, exercise tolerance and adverse reactions will be registered
11497123|NCT01374269|Active Comparator|NSAID|Naproxen 500 mg per day by 10 days or Celecoxib 200 mg per day by 10 days and Acetaminophen 1,5 a 2 g as rescue
11497124|NCT01374256||Combination therapy|Patients with Acinetobacter baumannii bacteremia treated with combination therapy of imipenem and sulbactam
11497125|NCT01374256||Not combination therapy|Patients with Acinetobacter baumannii bacteremia not treated with combination therapy of imipenem and sulbactam
11497126|NCT01374230|Experimental|E1 Tibial bearing|All patients undergoing primary total knee replacement surgery will receive a tibial bearing made of E1 polyethylene, which is the material being monitored in this study.
11497127|NCT01374217|Experimental|Tadalafil|Subject will take tadalafil in combination with with Lenalidomide and dexamethasone (Rd) or Clarithromycin/Lenalidomide/ dexamethasone (BiRd)
11497128|NCT01374191|Active Comparator|onabotulinum toxin type-A|1 injection of Btx-A, or up to 4 injections of Btx-A during the 1-year study period if pain recurs
11497129|NCT01374191|Placebo Comparator|placebo|saline
11497130|NCT01374191|Active Comparator|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
11497131|NCT01374178|Experimental|LY2963016|A single 0.5-unit per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously.
11497132|NCT01374178|Active Comparator|Lantus|A single 0.5-U/kg dose of Lantus will be administered subcutaneously.
11497133|NCT01374165||Low dose SANGUINATE™|"160 mg/kg of SANGUINATE™.
~SANGUINATE™ (PEG-bHb-CO) an OTA is composed of three moieties, polyethylene glycol, bHb and carbon monoxide that act in a specific manner to promote the delivery of oxygen to tissue. SANGUINATE™ was not developed to be used as a blood substitute. It is instead an oxygen transfer agent intended to functionally deliver and release oxygen to hypoxic tissues."
11497134|NCT01374165||High dose of SANGUINATE™|"320 mg/kg of SANGUINATE™.
~SANGUINATE™ (PEG-bHb-CO) an OTA is composed of three moieties, polyethylene glycol, bHb and carbon monoxide that act in a specific manner to promote the delivery of oxygen to tissue. SANGUINATE™ was not developed to be used as a blood substitute. It is instead an oxygen transfer agent intended to functionally deliver and release oxygen to hypoxic tissues."
11497135|NCT01374152|Experimental|Perfetti|Cognitive sensory motor training method for upper extremities rehabilitation every working day, totally training not less than 600 minutes within 4 weeks.
11497136|NCT01374152|No Intervention|conventional rehabilitation|conventional occupational therapy method for upper extremities rehabilitation every working day, totally training not less than 600 minutes within 4 weeks.
11497137|NCT01374139|Experimental|Cohort 1|
11497138|NCT01374139|Experimental|Cohort 2|
11497139|NCT01374126|Experimental|Azithromycin-Artesunate|
11497140|NCT01374126|Active Comparator|Control (artesunate alone)|
11497141|NCT01374113|Experimental|Group 1|Subjects with moderate renal impairment
11497142|NCT01374113|Experimental|Group 2|Subjects with severe renal impairment
11497143|NCT01374113|Experimental|Group 3|Matched subjects with normal renal function
11497144|NCT01374100|Active Comparator|Standard Exercise|See methods below - standard strength and endurance training
11497145|NCT01374100|Experimental|Qigong exercise|See methods below - medical QiGong therapy session
11497146|NCT01374087|Experimental|Brachytherapy + Triptorelin 22.5 mg|Brachytherapy: Low or high dose rate. Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
11497147|NCT01374087|Active Comparator|Brachytherapy|Brachytherapy: Low or high dose rate.
11497148|NCT01374074||White GERD|"Participants who self-identify as not-Hispanic or Latino and White and have been diagnosed by a physician with gastroesophageal reflux disease and do not have Barrett's esophagus."
11497149|NCT01374074||African American GERD|"Participants who self-identify as not-Hispanic or Latino and African American and have been diagnosed by a physician with gastroesophageal reflux disease and do no have Barrett's esophagus."
11497150|NCT01374074||White BE|"Participants who self-identify as not-Hispanic or Latino and White and have been diagnosed by a physician with Barrett's Esophagus."
11497151|NCT01374074||African American BE|"Participants who self-identify as not-Hispanic or Latino and African American and have been diagnosed by a physician with Barrett's Esophagus."
11497152|NCT01374061|Active Comparator|1: Classical intubation|
11497153|NCT01374061|Experimental|2: Glidescope intubation|
11497154|NCT01374035|Experimental|Participating GPs|GPs working at randomly selected GP centers/offices within the region that are invited to participate and signs a written informed consent to participate. (N=30-40)
11497155|NCT01374035|No Intervention|Control group|GPs working at randomly selected GP centers/office within the region that are not invited to participate, will form the control group. (N=30-40)
11497156|NCT01374022|Experimental|ART Strategy|maximum alveolar recruitment plus PEEP titration
11497157|NCT01374022|Active Comparator|ARDSNet Strategy|standard strategy (ARDSNet)
11497158|NCT01373996||Wireless|Measuring of invasive arterial blood pressure through HMW10 Wireless System.
11497159|NCT01373996||Wired|Measuring of invasive arterial blood pressure through conventional wired technology.
11497160|NCT01373983|Other|ziconotide|
11497161|NCT01373970|Placebo Comparator|Placebo|
11497162|NCT01373970|Active Comparator|PPI + Placebo|PPI followed by cross over to placebo
11497163|NCT01373957||1|Patients hospitalized and diagnosed with UA, STEMI or NSTEMI
11497164|NCT01373944||Stress Only SPECT MPI with Anger Camera|Patients undergoing clinically-indicated stress-only sestamibi studies who are imaged on the traditional Anger camera
11497165|NCT01373944||Stress Only SPECT MPI with SD Camera|Patients undergoing clinically-indicated stress-only sestamibi studies who are imaged on the Spectrum Dynamics camera system.
11497168|NCT01373918|Experimental|low dose intravenous fat emulsion|Subjects in this arm will receive approximately 1 g/kg/d IV of intravenous soybean oil (Intralipid).
11497169|NCT01373918|Active Comparator|standard dose intravenous fat emulsion|Subjects in this arm will receive approximately 3 g/kg/d IV of intravenous soybean oil (Intralipid).
11497170|NCT01373905|Active Comparator|Sustained lung inflation|recruitment was done using CPAP of 30 Cm/ H2o for 30 seconds
11497171|NCT01373905|Active Comparator|Stepwise PEEP elevation|Recruitment was done using stepwise elevation of PEEP followed by determination of the alveolar collapsing pressure
11497172|NCT01373892|Active Comparator|Surgery|Slevve vs. Roux-Y
11497173|NCT01373892|No Intervention|Healthy lean volunteers|
11497174|NCT01373879|Experimental|Group 1A|Adults (18-50 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
11497175|NCT01373879|Experimental|Group 1B|Adults (18-50 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME TRAP
11497176|NCT01373879|Experimental|Group 2A|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
11497177|NCT01373879|Experimental|Group 2B|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
11497178|NCT01373879|Active Comparator|Group 2C|Children (2-6 years old) vaccinated with human diploid cell rabies vaccine
11497179|NCT01373879|Experimental|Group 3A|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
11497180|NCT01373879|Experimental|Group 3B|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
11497181|NCT01373879|Active Comparator|Group 3C|Children (2-6 years old) vaccinated with human diploid cell rabies vaccine
11497182|NCT01373866|Experimental|Multimodal MRI-guided rTMS|
11497183|NCT01373866|Active Comparator|Conventional T3-P3 rTMS|
11497184|NCT01373853|Experimental|Femtec Groupe A|In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery
11497185|NCT01373853|Active Comparator|Manual Group B|Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
11497186|NCT01373840||healthy controls|
11497187|NCT01373840||patients with focal dystonias|
11497188|NCT01373827||MC1 Subjects|
11497189|NCT01373801|Active Comparator|Control|
11497190|NCT01373801|Experimental|GuardaCare|
11497191|NCT01373775||Revisit|HF patients who revisit the emergency department before the next appointment date.
11497192|NCT01373775||Non-revisit|HF patients who follow up on the appointment date.
11497193|NCT01373762|Experimental|Exercise Videogame Bike|Families in this group will receive an interactive exercise videogame bike (ie. the Active Cycle) to keep in their home for three months.
11497194|NCT01373762|Other|Stationary Bike|Families will receive a stationary bike to keep in their home for three months. It is required that the family places the stationary bike (Active Cycle without video game controllers) in front of a television.
11497195|NCT01373749|Experimental|NOS|NO inhalation was performed in the first stage(<48h) of PPHN, NO inhalation was replaced by sildenafil in the second stage(>48h).
11497196|NCT01373749|Placebo Comparator|NO|NO inhalation was performed during the whole treatment procedure of PPHN. There is no other methods given to treat PPHN during the therapy course.
11497197|NCT01373723|Experimental|invitation letter|to participate in the screening
11497198|NCT01373723|Experimental|Invitation letter, informative leaflet and phone call reminder|to participate in the screening
11497199|NCT01373723|Experimental|Invitation letter and informative leaflet|to participate in the screening
11497200|NCT01373710|Experimental|Trastuzumab intrathecal|
11497201|NCT01373697|Active Comparator|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
11497202|NCT01373697|Active Comparator|Ibuprofen|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
11497203|NCT01373684|Experimental|Peginterferon alfa-2a add on|All patients are all currently being treated with long-term NA treatment. PEG-IFN will be given in a dose of 180 μg per week s.c. for a total duration of 48 weeks starting at week 0.
11497204|NCT01373684|Active Comparator|Nucleoside analogue|All patients are all currently being treated with long-term Nucleos(t)ide analogue treatment and will continue using this medication during the duration of the study.
11497205|NCT01373671|Other|Mammography exam|Siemens DBT scan
11497206|NCT01373658|Experimental|Yinyi stent|
11497207|NCT01373645|Experimental|Yinyi stent|subjects with Yinyi stent implantation
11497208|NCT01373632|Experimental|Firebird 2 stent group|the patients who receive Firebird 2 stent
11497209|NCT01373632|Active Comparator|Excel stent group|the patients who receive Excel stent
11497210|NCT01373619|Experimental|IVABRADINE, HEART FAILURE WITH NORMAL EF|Patient on hemodialysis with Heart failure with normal ejection fraction treated with ivabradine titrated to 7.5 mg BID to assess changes in echocardiography diastolic function and NYHA class and 6-minutes walking test
11497211|NCT01373606|Experimental|Terlipressin|
11497212|NCT01373593|Experimental|lidocaine|lidocaine block
11497213|NCT01373593|Placebo Comparator|Placebo|
11497214|NCT01373580|Experimental|Raindrop|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near vision.
11497215|NCT01373567|Experimental|TINEFCON|Tablets of 700 mg.
11497216|NCT01373554|Placebo Comparator|Placebo|
11497217|NCT01373554|Experimental|Oltipraz|
11497218|NCT01373541|Active Comparator|InFat group|Infant formula with structured triglycerides (high palmitic acid content at the sn-2 position)
11497219|NCT01373541|Active Comparator|Control group|Infant formula with standard vegetable blend (low palmitic acid content at the sn-2 position)
11497220|NCT01373541|No Intervention|Referance group|Human milk breastfeeding
11497221|NCT01373528|Experimental|Budesonide|
11497222|NCT01373515|Experimental|Cohort 1; 1x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 1x10E7 DCP-001.
11497223|NCT01373515|Experimental|Cohort 2; 2.5x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 2.5x10E7 DCP-001.
11497225|NCT01373515|Experimental|Cohort 4; 5x10E7 DCP-001|n=3; patients, matched for HLA-A2, receiving 4 bi-weekly vaccinations of 5x10E7 DCP-001. Or, in case this turned out toxic, this group will receive the Maximum Tolerated Dose.
11497226|NCT01373502|Experimental|DES Limus Carbostent Coronary Stent|
11497227|NCT01373502|Active Comparator|Taxus Liberté Coronary Stent|
11497228|NCT01373489|No Intervention|Usual Care|The usual care group received the current standards of care at the study clinics.
11497229|NCT01373489|Experimental|Technology Assisted Case Management|The TACM group used the FORA 2-in-1 Telehealth system for diabetes management intervention to link a case manager to patients with poorly controlled type 2 diabetes in real time.
11497230|NCT01373476|Experimental|Qideng Mingmu capsule|High dosage group,Middle dosage group,Low dosage group.
11497231|NCT01373476|Placebo Comparator|Placebo|Placebo group
11497232|NCT01373463|Experimental|Arm A|"Patients will be given the drugs pemetrexed and carboplatin
~Radiation
~Participants evaluated for response
~Lobectomy surgery"
11497233|NCT01373463|Experimental|Arm B|"Patients will be given the drugs pemetrexed and cisplatin
~Radiation
~Participants evaluated for response
~Lobectomy surgery"
11497234|NCT01373450|Experimental|OXM → Lg-0.6 → Pbo → Lg-1.2|Participants received Oxyntomodulin 3.0 pmol/kg/min in the first, Liraglutide 0.6 mg in the second, Placebo in the third, and Liraglutide 1.2 mg in the fourth period
11497235|NCT01373450|Experimental|Lg-0.6 → Pbo → OXM → Pbo|Participants received Liraglutide 0.6 mg in the first, Placebo in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Placebo in the fourth period
11497236|NCT01373450|Experimental|Pbo → OXM → Lg-0.6 → Pbo|Participants received Placebo in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
11497237|NCT01373450|Experimental|Lg-0.6 → OXM → Pbo → Lg-1.2|Participants received Liraglutide 0.6 mg in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Placebo in the third and Liraglutide 1.2 mg in the fourth period
11497238|NCT01373450|Experimental|OXM → Pbo → Lg-0.6 → Pbo|Participants received Oxyntomodulin 3.0 pmol/kg/min in the first; Placebo in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
11497239|NCT01373450|Experimental|Pbo → Lg-0.6 → OXM → Lg-1.2|Participants received Placebo in the first, Liraglutide 0.6 mg in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Liraglutide 1.2 mg in the fourth period
11497240|NCT01373437||Intubate|
11497241|NCT01373424||Cervical dystonia|People diagnosed with cervical dystonia
11497242|NCT01373424||Laryngeal dystonia|People diagnosed with laryngeal dystonia
11497243|NCT01373424||Other voice disorders|People diagnosed with a voice disorder other than laryngeal dystonia - enrollment for this group is complete
11497244|NCT01373424||Craniofacial dystonia|People diagnosed with craniofacial dystonia (including blepharospasm, meige syndrome, and oromandibular dystonia)
11497245|NCT01373424||Limb dystonia|People diagnosed with limb dystonia
11497246|NCT01373424||All other isolated dystonias|People diagnosed with any isolated dystonia not listed in descriptions of other cohorts
11497247|NCT01373424||Myoclonus dystonia|People diagnosed with myoclonus dystonia
11497248|NCT01373424||Dopa-responsive dystonia|People diagnosed with dopa-responsive dystonia
11497249|NCT01373411|Placebo Comparator|Placebo|Placebo twice daily. Study drug will be started within 48 hours of CABG.
11497250|NCT01373411|Active Comparator|ticagrelor 90 mg|Taken twice daily. Study drug will be started within 48 hours of CABG.
11497251|NCT01373385||Surgical|Patients receiving a surgical procedure for vesicoureteral reflux at Connecticut Children's Medical Center.
11497252|NCT01373372|Experimental|Functional Dyspepsia cohort|Cohort of subjects with functional dyspepsia
11497253|NCT01373372|Other|Control cohort|Control group of subjects with no functional dyspepsia
11497254|NCT01373359|Experimental|Sublingual misoprostol|400 µg powdered misoprostol administered sublingually; IM placebo
11497255|NCT01373359|Active Comparator|Oxytocin|10 IU IM oxytocin; placebo powder
11497256|NCT01373346|Experimental|Long limb Roux-en Y reconstruction|Long limb Roux-en Y reconstruction means that the length of Roux limb and biliopancreatic limb are longer than conventional reconstruction method after gastrectomy.
11497257|NCT01373320|Experimental|Early Intervention|Participants in this group are nested in churches which were randomly assigned to the treatment group.
11497258|NCT01373320|No Intervention|Delayed Intervention|Participants in this group are nested in churches which were randomly assigned to the wait-list control group. They receive an educational luncheon focused on stress reduction during the intervention window for the Early Intervention group, and subsequently receive the intervention(s) for their selected target health behaviors at a later date.
11497259|NCT01373307|Experimental|Early Intervention|Participants are nested in churches which were randomly assigned to receive the intervention first.
11497260|NCT01373307|No Intervention|Delayed Intervention|Wait-list control group. Participants are nested in churches which were randomly assigned to receive the intervention at a later date. Delayed Intervention participants receive an educational luncheon addressing stress reduction during the window of no intervention.
11497261|NCT01373294|Experimental|A: Combination Arm|"Bacille Calmette-Guerrin (BCG) and lenalidomide.
~Participants were assigned to receive BCG or BCG and lenalidomide based on their cancer. This group received BCG + lenalidomide)"
11497262|NCT01373294|Active Comparator|B: Control Arm|"Bacille Calmette-Guerrin (BCG) only.
~Participants were assigned to receive BCG or BCG and lenalidomide based on their cancer.
~This group was not eligible to receive the combination of BCG + lenalidomide."
11497263|NCT01373281|Experimental|Dengue Vaccine Group|Participants were to receive CYD dengue vaccine at 0, 6, and 12 months.
11497264|NCT01373281|Placebo Comparator|Control Group|Participants were to receive a placebo vaccine at 0, 6, and 12 months.
11497265|NCT01373255|Experimental|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
11497266|NCT01373255|No Intervention|No intervention|no intervention prior to cesarean
11497267|NCT01373242|Experimental|Peanut ( liquid peanut extract) SLIT|All subjects will receive peanut SLIT upon enrollment for at least the first 48 months. After the desensitization DBPCFC after at least 48 months of treatment, subjects will be randomized off treatment from 1 to 17 weeks. Subjects will then undergo another DBPCFC.
11497268|NCT01373229|Experimental|Lenalidomide + Plerixafor+ Rituximab|"Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.
~Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.
~Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) <100.0 x 109 / L.
~Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:
~Cohort 1: 0.24 mg/kg
~Cohort 2: 0.32 mg/kg
~Cohort 3: 0.42 mg/kg
~Cohort 4: 0.54 mg/kg
~Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.
~Subjects will then continue single agent lenalidomide until disease progression."
11497269|NCT01373216|Experimental|Exenatide|Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving perioperatively i.v. exenatide on top of standard treatment
11497270|NCT01373216|No Intervention|Control|Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving standard treatment
11497271|NCT01373190||Epilepsy Group|Individuals diagnosed with Partial/Focal Onset Epilepsy ICD9CM 345.4 and/or 345.5
11497272|NCT01373190||Control Group|Individuals who do not have the diagnosis of Epilepsy and have no history of seizure disorders
11497273|NCT01373177|Active Comparator|BSID-II, then Bayley-III|Receive BSID-II testing 4-8 weeks before Bayley-III testing
11497274|NCT01373177|Active Comparator|Bayley-III, then BSID-II|Receive Bayley-III testing 4-8 weeks before BSID-II testing
11497275|NCT01373164|Experimental|Phase 1b: 80 mg Galunisertib + Gemcitabine|"Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).
~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
11497276|NCT01373164|Experimental|Phase 1b: 160 mg Galunisertib + Gemcitabine|"Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).
~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
11497277|NCT01373164|Experimental|Phase 1b: 300 mg Galunisertib + Gemcitabine|"Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).
~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
11497278|NCT01373164|Experimental|Phase 2: Recommended dose of Galunisertib + Gemcitabine|"Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).
~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
11497279|NCT01373164|Experimental|Phase 2: Placebo + Gemcitabine|"Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).
~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
11497280|NCT01373151|Placebo Comparator|Arm 1|BMS-945429 Placebo/BMS-945429+Methotrexate+Adalimumab Placebo
11497281|NCT01373151|Experimental|Arm 2|BMS-945429 + Methotrexate + Adalimumab Placebo
11497282|NCT01373151|Experimental|Arm 3|BMS-945429 + Methotrexate + Adalimumab Placebo
11497283|NCT01373151|Experimental|Arm 4|BMS-945429 + Methotrexate + Adalimumab Placebo
11497284|NCT01373151|Experimental|Arm 5|BMS-945429 + Methotrexate/Methotrexate Placebo + Adalimumab Placebo
11497285|NCT01373151|Experimental|Arm 6|BMS-945429 + Methotrexate/Methotrexate Placebo+Adalimumab Placebo
11497286|NCT01373151|Active Comparator|Arm 7|Adalimumab + Methotrexate
11497287|NCT01373138|Experimental|Desloratadine and pseudoephedrine ER tablets 5/240 mg|Desloratadine and pseudoephedrine ER tablets 5/240 mg of Dr. Reddy's Laboratories Limited
11497288|NCT01373138|Active Comparator|Clarinex D 24-hour|Clarinex D-24 of Schering Corporation Inc USA
11497289|NCT01373125||Radiofrequency Ablation (RFA)|Participants in this group are greater than or equal to 12 months status post radiofrequency ablation (RFA).
11497290|NCT01373125||Radiofrequency Ablation Longitudinal (RFAL)|Participants in this group are part of a longitudinal portion of the study and are enrolled prior to their first radiofrequency ablation procedure and followed at 6 and 12 months after completion of RFA.
11497291|NCT01373125||Gastroesophageal Reflux Disease (GERD)|Participants in this group have been diagnosed with gastroesophageal reflux disease.
11497292|NCT01373125||Asymptomatic Controls (AC)|Participants in this group are asymptomatic controls and enrolled as part of the comparison group.
11497293|NCT01373112|Experimental|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
11497294|NCT01373112|Experimental|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
11497295|NCT01373099|Experimental|Static Spacer|Patients in this group will be randomized to a static, nonarticulating, antibiotic-impregnated cement spacer.
11497296|NCT01373099|Experimental|Articulating spacer|Patients in this group will be randomized to an articulating antibiotic-impregnated cement spacer.
11497297|NCT01373086|Experimental|LFF269 low dose|LFF269 low dose + Matching Placebo to Eplerenone 50mg during 4 week double blind period
11498689|NCT01363622||LGA|LGA (large for gestational age)
11497299|NCT01373086|Active Comparator|Eplerenone|Eplerenone 50mg twice daily + matching placebo of LFF269
11497300|NCT01373086|Placebo Comparator|Placebo|Placebo of LFF269 high dose + Placebo of Eplerenone 50 mg
11497301|NCT01373073|Experimental|Experimental Human Milk Fortifier|Experimental human milk fortifier to be added to human milk
11497302|NCT01373073|Active Comparator|Control Human Milk Fortifier|Control human milk fortifier to be added to human milk
11497303|NCT01373060|Experimental|ASP1941 group|
11497304|NCT01373060|Placebo Comparator|placebo group|
11497305|NCT01373047|Experimental|Intrahepatic anti-CEA designer T cells|
11497306|NCT01373034|Experimental|Soy Dietary Fiber|
11497307|NCT01373034|Placebo Comparator|Rice powder|
11497308|NCT01373021|Placebo Comparator|F|Fentanyl+Normal saline
11497309|NCT01373021|Experimental|D|Fentanyl+Dexmedetomidine
11497310|NCT01373008|Experimental|Inhaled QVAR|Inhaled QVAR 100 mic via aerochamber twice daily until 3 month post discharge
11497311|NCT01373008|Placebo Comparator|Inhaled placebo|Inhaled nonmedicated MDI [metered dose inhaler] in a similarly marked aerosol chamber using the same delivery technique, obtained from the drug manufacturer
11497312|NCT01372995|Experimental|Enteral vitamin D3 50,000 IU|An arm where subjects receive 50,000 IU of Vitamin D for 5 days.
11497313|NCT01372995|Experimental|Enteral Vitamin D3 100,000 IU|Arm where subjects receive 100,000 IU of Vitamin D for 5 days
11497314|NCT01372995|Placebo Comparator|Inactive Substance|Arm where patients receive inactive substance for 5 days.
11497315|NCT01372982|Active Comparator|Femara|
11497316|NCT01372982|Experimental|Letrozole|
11497317|NCT01372969|Experimental|Cx601|
11497318|NCT01372956||Dyslipidemia|
11497319|NCT01372943|Experimental|synthetic stool|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
11497320|NCT01372930|Experimental|Etanercept|
11497321|NCT01372930|Placebo Comparator|saline|
11497322|NCT01372917||Allomax|The cohort consists of immediate breast reconstruction patients who have AlloMax placed at the time of their tissue expander based immediate breast reconstruction.
11497323|NCT01372904|Experimental|Dexamethasone|
11497324|NCT01372891||Patients underging PCI|
11497325|NCT01372865|Experimental|Mometasone|
11497326|NCT01372865|Active Comparator|Nasonex®|
11497327|NCT01372852||T2DM patients|newly diagnosed T2DM patients and untreated with any drugs.
11497328|NCT01372852||Non-diabetic Control Group|
11497329|NCT01372839|Active Comparator|Atorvastatin|80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
11497330|NCT01372839|Other|Usual care|statin dose should not be higher than that described in exclusion criteria.
11497331|NCT01372826|Experimental|NKTR118 Group1|Normal Renal Function
11497332|NCT01372826|Experimental|NKTR118 Group 2|Moderate Renal Function
11497333|NCT01372826|Experimental|NKTR118 Group 3|Severe Renal Impairment
11497334|NCT01372826|Experimental|NKTR118 Group 4|End-Stage Renal Disease
11497335|NCT01372813|Other|Clear Cell Renal Carcinoma|Clear cell renal cancer is a highly vascular tumor characterized by mutations in the von Hippel-Lindau (VHL) gene in the majority of patients, an alteration that leads to overexpression vascular endothelial growth factor (VEGF) as well as other genes such as transforming growth factor-alpha, platelet derived growth factor and glucose transporter 1. Patients received ZD6474 300 mg/day by mouth daily on days 1-28.
11497336|NCT01372800||volunteer|
11497337|NCT01372787||Arm I|
11497338|NCT01372774|Active Comparator|Arm I - WBRT|Patients undergo whole brain radiotherapy (WBRT) once a day, 5 days a week, for approximately 3 weeks. Patient observation/follow up occurs at week 12 and months 6, 9, 12, 16 and 24 post registration/randomization. Event monitoring occurs every 6 months until 5 years post registration/randomization.
11497339|NCT01372774|Experimental|Arm II - SRS|Patients undergo stereotactic radiosurgery (SRS) using a gamma knife or a linear accelerator procedure. Patient observation/follow up occurs at week 12 and months 6, 9, 12, 16 and 24 post registration/randomization. Event monitoring occurs every 6 months until 5 years post registration/randomization.
11497340|NCT01372761|Placebo Comparator|Normal Saline|
11497341|NCT01372761|Experimental|ZGN-433|
11497342|NCT01372748|Active Comparator|Standard CPR|American Heart Association (AHA)recommended cardiopulmonary resuscitation (CPR) of 30 compressions with brief pause for 2 ventilations
11497343|NCT01372748|Experimental|Continuous chest compressions|Continuous compression CPR
11497344|NCT01372722|Experimental|Sham then Stimulation|
11497345|NCT01372722|Experimental|Stimulation then Sham|
11497346|NCT01372709||Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Adult male and female patients will be consecutively screened for the study. Eligible patients must meet all of the inclusion criteria and none of the exclusion criteria.
11497347|NCT01372696|Other|Tissue sample|Patients who consent to participate in this study will have a small sample of their polyp and normal tissue sent for molecular testing.
11497348|NCT01372683|Experimental|Test cereal 1|Oat based breakfast cereal
11497349|NCT01372683|Experimental|Test cereal 2|2nd Oat based breakfast cereal
11497350|NCT01372683|Experimental|Leading oat based RTE cereal|3rd oat based breakfast cereal
11497351|NCT01372670|Experimental|Hydroxyzine|Hydroxyzine given TID
11497352|NCT01372670|Placebo Comparator|Sugar Pill|Placebo given 3 times per day
11497353|NCT01372657||cataract patients|cataract patients
11497354|NCT01372644|Experimental|ADH, ALH, LCIS, SOM 230|Women who meet eligibility criteria.
11497355|NCT01372631|Experimental|Pressure assessment|30 patients undergoing lumpectomy, mastectomy or reduction mammoplasty will be enrolled to assess the ideal pressure that should be applied when taking optical measurements.
11497356|NCT01372631|Experimental|Random and Systematic Errors|40 patients undergoing lumpectomy or mastectomy will be enrolled to assess the random and systematic errors of the miniature spectral imaging system.
11497396|NCT01372358|Active Comparator|CIPRO®XR|CIPRO® XR (Bayer Health Care, Bayer Pharmaceuticals Corporation) Tablets
11498690|NCT01363622||AGA|AGA (appropriate-for-gestational-age)
11497357|NCT01372631|Experimental|Sensitivity and Specificity Assessment|150 patient undergoing lumpectomy, mastectomy or reduction mammoplasty will be enrolled in order to determine the sensitivity and specificity of the miniature spectral imaging system.
11497358|NCT01372618|Experimental|SOM 230/Pasireotide|Treatment with SOM230 600mcg twice daily for 20 days.
11497359|NCT01372605|Experimental|Collaborative depression care|Measurement-Based Care: Decision support from paraprofessional to HIV medical provider around initiating and monitoring antidepressant treatment.
11497360|NCT01372605|Other|Enhanced usual care|Usual care. Enhanced through pre-study training of providers, provision of psychiatric diagnostic information at enrollment to HIV provider, and availability of best-practices guidelines for reference in clinic.
11497361|NCT01372592||Degenerative|Patients being treated for degenerative spine conditions.
11497362|NCT01372592||Deformity|Patients being treated for a deformity spine condition.
11497363|NCT01372592||Trauma|Patients being treated for a trauma related spine condition.
11497364|NCT01372579|Experimental|Treatment (neoadjuvant chemotherapy)|Patients receive eribulin mesylate IV over 2-5 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11497365|NCT01372566|Experimental|Platelet Rich Plasma|Concentrated blood platelets from subject will be injected multiple times into the superficial layer of either their arm (Part 1) or one side of their upper face and cheek (Part 2).
11497366|NCT01372566|Placebo Comparator|Sterile Saline|Sterile saline will be injected multiple times into the superficial layer of either their arm (Part 1) or one side of their upper face and cheek (Part 2)that has not been injected with PRP.
11497367|NCT01372553||Family history risk stratification|primary care patients who receive risk stratification and clinical decision support based upon the family health history they entered in to MeTree
11497368|NCT01372540|Experimental|Treatment (filanesib and carfilzomib)|Patients receive filanesib IV over 1 hour on days 1, 2, 15, and 16 and carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 8 courses of therapy, patients may continue with dosing of carfilzomib on days 1, 2, 15, and 16 and filanesib as tolerated. If patient progresses on carfilzomib maintenance with administration on days 1, 2, 15, and 16 they may increase the intensity and add in days 8 and 9 dosing.
11497369|NCT01372527|Experimental|TopCare Intervention|"The TOP-CARE intervention will be based on a medical informatics platform that:
~Identifies all patients eligible for any of the three cancer screening programs
~Links patients with a specific clinician
~Offers a visit-independent method for clinicians to review panels of their eligible patients
~For patients due for one or more cancer screenings, clinicians will access a web-based informatics tool to:
~Screen their panel based upon risk
~Defer patients, document exclusions, and update the EHR
~Order a screening test with patient information material based upon the patient's risk profile and automatically initiate the process of:
~Informing the patient by letter of the need to schedule a test, educating the patient with respect to the benefits of cancer screening, and properly documenting the transaction in the patient's EHR, or
~Referral to a patient navigator for patients most likely to benefit from this more intensive approach"
11497370|NCT01372527|Active Comparator|Augmented Standard Care|In augmented standard care control practices, we will implement a system that includes: 1) a population-based perspective to identify all eligible patients overdue for screening, 2) an automated, centralized process to contact selected patients by letter, 3) a result management system that automatically tracks test scheduling and completion, 4) a web-based, easily accessible tool allowing practice personnel to contact patients not completing testing, and 5) use of patient navigators for high risk patients not responding to initial outreach. In the control arm, the process of escalating the reminder intervention from a letter, to contact by phone call, to a patient navigator, will occur in a standard algorithmic fashion without provider input.
11497371|NCT01372514||suspected thromboembolic disease|Patients with thromboembolic disease according to diagnostic tests (MDTC with angiography, scintigraphy V/Q, dimer d, ecografia doppler, etc. ) required by the physician.
11497372|NCT01372501|Experimental|Experimental: Device|All patients will be implanted with the Endobarrier Liner device
11497373|NCT01372488|Active Comparator|Study group|Study group will be provided with suture removal instructions and suture removal kit and asked to consider removing their own sutures
11497374|NCT01372488|Placebo Comparator|Control group|Control group will be asked to have their sutures removed as they normally would (see family doctor or clinic)
11497375|NCT01372475|Active Comparator|Hymovis Viscoelastic Hydrogel|Intra-articular Injection
11497376|NCT01372475|Placebo Comparator|Placebo|Phosphate Buffered Saline Intra-articular Injection
11497377|NCT01372462|Experimental|NIOV - Room air|Subjects exercise using the NIOV device powered by compressed air (room air, 21% O2).
11497378|NCT01372462|Experimental|NIOV - Oxygen|Subjects exercise using the NIOV device powered by compressed medical oxygen (100% O2).
11497379|NCT01372462|Active Comparator|Nasal Cannula Oxygen|Subjects exercise using a standard nasal cannula using medical oxygen (100% O2).
11497380|NCT01372462|No Intervention|No treatment|Control arm. Subjects exercise without using supplemental oxygen or NIOV.
11497381|NCT01372449|Active Comparator|Memantine|
11497382|NCT01372449|Placebo Comparator|Placebo|Placebo Comparator
11497383|NCT01372436||1|children in high-school
11497384|NCT01372436||2|children in primary school
11497385|NCT01372423|Active Comparator|AMITIZA|Manufactured by Sucampo Pharmaceuticals (24 mcg administered for 7 days)
11497386|NCT01372423|Placebo Comparator|Placebo|Manufactured by Anchen Pharmaceuticals (24 mcg administered for 7 days)
11497387|NCT01372423|Experimental|Lubiprostone|Manufactured by Anchen Pharmaceuticals (24 mcg administered for 7 days)
11497388|NCT01372410|Active Comparator|Tiotropium|18 mcg, inhaled long acting muscarinic antagonist
11497389|NCT01372410|Experimental|GSK573719|inhaled medication
11497390|NCT01372410|Placebo Comparator|Placebo|inactive/excipients only
11497391|NCT01372384|Experimental|Single Arm|
11497392|NCT01372371|Active Comparator|Vancomycin|
11497393|NCT01372371|Active Comparator|Vancomycin and Gentamycin|
11497394|NCT01372371|Active Comparator|Intravenous Antibiotic|
11497395|NCT01372358|Experimental|Ciprofloxacin|Ciprofloxacin Extended Release Tablets of Dr. Reddy's Laboratories Limited
11497397|NCT01372345|Experimental|Ciprofloxacin|Ciprofloxacin Extended Release Tablets of Dr. Reddy's Laboratories Limited
11497398|NCT01372345|Active Comparator|CIPRO®XR|CIPRO® XR (Bayer Health Care, Bayer Pharmaceuticals Corporation) Tablets
11497399|NCT01372332||Normal subjects|Age-related (+ 5 years of age) and gender-matched normal subjects.
11497400|NCT01372332||Patients with homonymous hemianopia|Patients with homonymous visual field defects
11497401|NCT01372319||Glaucoma Patients (OAG, Aulhorn stages II - IV)|Manifest glaucoma (OAG, Aulhorn stages II - IV) with advanced binocular visual loss, as obtained by semi-automated kinetic perimetry (SKP), no study medication
11497402|NCT01372319||Normal subjects|male+female > 18 years
11497403|NCT01372306|Experimental|Galantamine|Galantamine Hydrobromide Tablets of Dr. Reddy's
11497404|NCT01372306|Active Comparator|Reminyl|Reminyl 4 mg tablets of Janssen Pharmaceutical Products
11497405|NCT01372280|Experimental|Galantamine|Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
11497406|NCT01372280|Active Comparator|Reminyl|Reminyl 4 mg tablets of Janssen Pharmaceutical Products
11497407|NCT01372267|Experimental|CBT for pain|
11497408|NCT01372267|Active Comparator|Psychoeducational control group|This group is designed to be an active control which provides detailed information about substance us and chronic pain without providing any CBT or other specific therapy.
11497409|NCT01372254|Active Comparator|Standard smoking cessation|Participants will receive a standard smoking cessation treatment in individual format. Treatment will be delivered in five, 90-minute individual sessions, and with two booster sessions assessed scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
11497410|NCT01372254|Experimental|BA for substance abusing smokers|The Behavioral Activation for Drug Abusing Smokers (BA-DAS) treatment protocol will incorporate elements of the ST along with behavioral activation strategies, modified for smoking. Treatment will consist of five, 90-minute individual sessions, and with two booster sessions scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
11497411|NCT01372241|Experimental|Early Intervention|This group served as the treatment group for analysis of the primary outcome.
11497412|NCT01372241|No Intervention|Delayed Intervention|This group served as a wait-list control group, eventually receiving the intervention after the treatment group completed the intervention and the primary outcomes were assessed for both groups.
11497413|NCT01372228|Experimental|Inherited Metabolic Disorder Patients|Recipients are treated with hematopoietic stem cell infusion from living donors
11497414|NCT01372202|Active Comparator|Arm A|Paclitaxel with Cisplatin along with Radiotherapy and followed by Esophagectomy
11497415|NCT01372202|Active Comparator|Arm B|Cisplatin or Oxaliplatin with 5-Fluorouracil along with Radiotherapy and followed by Esophagectomy
11497416|NCT01372202|Active Comparator|Arm C|Cisplatin with 5-Fluorouracil along with Radiotherapy and followed by Esophagectomy
11497417|NCT01372189||colorectal cancer|Patients with colorectal carcinoma during conventional endoscopic imaging.
11497418|NCT01372189||colorectal adenoma|Patients with colorectal adenoma during conventional endoscopic imaging.
11497419|NCT01372176|Experimental|Early Goal-Directed Nutrition|
11497420|NCT01372176|Active Comparator|ASPEN-guidelines|
11497421|NCT01372163|Experimental|2 mg PF-05190457 or Placebo BID|
11497422|NCT01372163|Experimental|10 mg PF-05190457 or Placebo BID|
11497423|NCT01372163|Experimental|40 mg PF-05190457 or Placebo BID|Dose and dose frequency may be adjusted based on emerging safety and PK data.
11497424|NCT01372163|Experimental|150 mg PF-05190457 or Placebo BID|Dose and dose frequency may be adjusted based on emerging safety and PK data.
11497425|NCT01372163|Experimental|5 mg PF-05190457 or Placebo QD|Dose and dose frequency may be adjusted based on emerging safety and PK data.
11497426|NCT01372163|Experimental|50 mg PF-05190457 or Placebo QD|Dose and dose frequency may be adjusted based on emerging safety and PK data.
11497427|NCT01372163|Experimental|xxx mg PF-05190457 or Placebo|Dose and dose frequency to be determined based on emerging safety and PK data.
11497428|NCT01372150|Experimental|DVS SR|
11497429|NCT01372150|Other|Fluoxetine|Active control for assay sensitivity
11497430|NCT01372150|Experimental|Placebo|
11497431|NCT01372137|Experimental|NOX-H94|Group A: single 15 minutes IV infusion of 0.3 mg/kg NOX-H94 Group B: single 15 minutes IV infusion of 0.6 mg/kg NOX-H94 Group C: single 15 minutes IV infusion of 1.2 mg/kg NOX-H94 Group D: single 15 minutes IV infusion of 2.4 mg/kg NOX-H94 Group E: single 15 minutes IV infusion of 4.8 mg/kg NOX-H94 Group F: single / repeated SC injection of NOX-H94 over a treatment period of 2 weeks Group G: multiple doses of NOX-H94 as a 15 minutes IV infusion over a treatment period of 2 weeks Group H: multiple doses of NOX-H94 as a 15 minutes IV infusion over a treatment period of 2 weeks
11497432|NCT01372137|Placebo Comparator|Glucose 5%|Group A to Group H get NOX-H94 or Placebo
11497433|NCT01372124|Experimental|NOX-E36|All subjects included in this study will receive the same dose of NOX E36.
11497434|NCT01372098|Experimental|NFP + IPV intervention|The protocol for number and timing of visits will be the same for both NFP+IPVI and Standard Care, as follows: weekly for the first four visits, every other week for the remainder of the pregnancy, every week for six weeks in the postpartum and every other week until the infant is 21 months old after which it is once a month for the last three months. We recognize that the intervention might prompt the nurse and mother to alter the regular visit schedule if IPV is present.
11497435|NCT01372098|No Intervention|NFP (standard care)|"The NFP nurses currently receive some training regarding IPV, but it is minimal. Between intake and when the child is 3 months and 12 months old, there is a brief instruction that the nurse assess for IPV. If the client acknowledges current abuse when completing the Abuse Assessment Screen, the nurse should assist her to evaluate threats to personal safety and make referrals as needed. There is a prompt to be mindful of client safety, and to make referrals as needed."
11497436|NCT01372085|Experimental|Part A: 25 mg RF|A single 25 mg dose of LY2584702 RF
11497437|NCT01372085|Placebo Comparator|Part A: Placebo|Placebo taken orally
11497474|NCT01371864||Pediatric Cardiothoracic Team|This group consists of members of the cardiothoracic surgery team: The attending physician, the fellow physician, the nurses, and the physician assistants.
11497892|NCT01369160||3|matched sibling donor stem cell transplantation (MSD-SCT)
11497438|NCT01372085|Experimental|Part B: Sequence 1|A single 10 mg dose of LY2584702 TF during the first intervention period, followed by placebo in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
11497439|NCT01372085|Experimental|Part B: Sequence 2|Placebo during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
11497440|NCT01372085|Experimental|Part B: Sequence 3|A single 10 mg dose of LY2584702 TF during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
11497441|NCT01372085|Experimental|Part B: Sequence 4|A single 10 mg dose of LY2584702 TF during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by placebo in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
11497442|NCT01372072|Active Comparator|Humidification|Patients in this arm of the trial will receive humidification with the non-invasive ventilation.
11497443|NCT01372072|No Intervention|NIV without humidifivation|As per usual practice patients in this arm will not have humidification with their NIV
11497444|NCT01372059|Experimental|Rhythm and music therapy|Since 1993 The RGRM Method is a concept launched in both health and medical care. The method is mainly designed to help people with injuries and diseases of the central nervous system.
11497445|NCT01372059|Active Comparator|Therapeutic riding|Therapeutic riding can be useful for individuals with neurological and muscular impairments. The goal of therapeutic riding as professional treatment is to improve neurological functioning and to achieve functional gains and enhance life skills.
11497446|NCT01372059|Other|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
11497447|NCT01372046|Experimental|Enhanced|A external consultant works with the team to develop skills and trains an in-house coach
11497448|NCT01372046|Experimental|Trainer|External consultant provides booster session
11497449|NCT01372046|Experimental|Standard|Receive agency training
11497450|NCT01372033|Experimental|CBT|Use of cognitive behavioral therapy focused on social skill development and interpersonal relationships
11497451|NCT01372020|Sham Comparator|control group|
11497452|NCT01372020|Experimental|neuromuscular electrical therapy|
11497453|NCT01372007|Experimental|Lanreotide Autogel 120mg|
11497454|NCT01372007|Placebo Comparator|Placebo|
11497455|NCT01371994|Experimental|Solifenacin succinate|Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily.
11497456|NCT01371994|Placebo Comparator|Placebo|Participants received matching placebo tablets once a day for 12 weeks.
11497457|NCT01371981|Experimental|Arm A|See Detailed Description
11497458|NCT01371981|Experimental|Arm B|See Detailed Description
11497459|NCT01371981|Experimental|Arm C (Cohort 1)|See Detailed Description
11497460|NCT01371981|Experimental|Arm C (Cohort 2)|See Detailed Description.
11497461|NCT01371981|Experimental|Arm C (Cohort 3)|See Detailed Description. Different dose.
11497462|NCT01371981|Experimental|Arm D|See Detailed Description. May reassigned to Arm C.
11497463|NCT01371968|Experimental|alfentanil|patient will received a dose of alfentanil in which the dose of alfentanil is determined by response of previously tested patient using Dixon up and down methods
11497464|NCT01371955||diabetic nephropathy group|patient with diabetic nephropathy, defined as Albuminuria > 30 mg/day or urinary Albumine/ creatinine ratio > 3 mg/mmol ; or GFR estimated by MDRD less than 60 ml/min.1,73m². With no other etiology of diabetic nephropathy.
11497465|NCT01371955||diabetic retinopathy group|patient with diabetic retinopathy defined as showing at least one micro aneurysm on retinography. Without nephropathy defined as above
11497466|NCT01371955||no complication group|patient without diabetic nephropathy or retinopathy
11497467|NCT01371929||ICU patients who become septic|Patients considered to be at risk of becoming septic based upon his/her clinical presentation during admittance or transfer to an ICU will be tested for the presence of plasma iNOS using our PliNOSa test on the day of ICU entry and their sepsis status will be followed for three days to determine if they develop sepsis, severe sepsis, or septic shock. Approximately, 50% of the enrolled patients are expected to develop sepsis, severe sepsis, or septic shock.
11497468|NCT01371929||ICU patients who do not become septic|Patients considered to be at risk of becoming septic based upon his/her clinical presentation during admittance or transfer to an ICU will be tested for the presence of plasma iNOS using our PliNOSa test on the day of ICU entry and their sepsis status will be followed for three days to determine if they develop sepsis, severe sepsis, or septic shock. Approximately, 50% of the enrolled patients are expected NOT to develop sepsis, severe sepsis, or septic shock.
11497469|NCT01371916||ESAT-6 positive|
11497470|NCT01371916||ESAT-6 negative|
11497471|NCT01371890||Intradialytic hypertension|Patients with systolic blood pressure increases > 10 mmHg during 4/6 hemodialysis sessions
11497472|NCT01371877|Experimental|Vitamin D3 4000 IU|"Subjects will be randomized 1:1 to high dose vitamin D defined as 4000 IU per day for 3 months.
~Subjects will be given Vitamin D3 supplementation at 4000 IU daily."
11497473|NCT01371877|Active Comparator|Vitamin D3 600 IU|"Subjects will be randomized 1:1 to low dose vitamin D as defined as 600 IU per day for 3 months.
~Subjects will be given Vitamin D3 supplementation at 600 IU daily"
11497639|NCT01370798|Placebo Comparator|Placebo|Control group, children with severe hypospadias treated with Placebo.
11497475|NCT01371864||Critical Care Team|This group consists of the nurses and physicians who work in the pediatric intensive care unit and the neonatal intensive care unit caring for patients who require cardiothoracic surgery.
11497476|NCT01371864||Subspecialty Team|This group consists of physicians and nurses from pediatric cardiology and pediatric anesthesiology who care for children who require cardiothoracic surgery.
11497477|NCT01371864||Parent|This group consists of the parent or legal guardian of the pediatric patient who requires cardiothoracic surgery.
11497478|NCT01371851|Experimental|Doxazosin|Doxazosin extended release will be administered initially at 4 mg/day. On day 8 the dose is increased to 8 mg/day and the participant is maintained on the study until the end of the trial.
11497479|NCT01371851|Placebo Comparator|Placebo|Participants will be maintained on placebo (cellulose) throughout the trial.
11497480|NCT01371838|Experimental|Ceftaroline|
11497481|NCT01371838|Active Comparator|Ceftriaxone plus placebo|
11497482|NCT01371825|Experimental|Open-Label Sebelipase Alfa|Participants received intravenous (IV) infusions of sebelipase alfa during the open-label treatment. Participants initially received 0.35 milligrams (mg)/kilogram (kg) qw and escalated to 1 mg/kg qw after demonstrating acceptable safety and tolerability during at least 2 infusions. One participant initiated treatment under a Temporary Use Authorization prior to enrollment, wherein the participant's dose was gradually escalated from 0.2 to 1 mg/kg over 4 weeks; the participant started the study at this dose. Participants on treatment for 96 weeks and on stable qw dosing for 24 weeks could be switched to an every other week (qow) dosing schedule. In the event of protocol-defined disease progression at any time during treatment, a participant could receive a dose increase from 1 to 3 mg/kg qw and, if necessary, a dose increase to 5 mg/kg qw with Safety Committee approval. Participants dosed qow who met dose-escalation criteria were reverted to qw dosing or escalated to 1 or 3 mg/kg qow.
11497483|NCT01371812|Experimental|Cohort 1|Interlocking design with Cohort 2. Single dose; treatment period over 2 days such that one subject will receive GSK2239633 and one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK2239633 from 150mg, to 600mg, to 1200mg and 1200mg with a FDA high fat/high calorie meal, will be administered over the 13 week long study allowing adequate washout period between doses.
11497484|NCT01371812|Experimental|Cohort 2|Interlocking design with Cohort 1. Single dose; treatment period over 2 days such that one subject will receive GSK2239633 and one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK2239633 from 300mg, to 900mg, and 1500mg, will be administered over the 13 week long study allowing adequate washout period between doses.
11497485|NCT01371799|Experimental|Study drug at 4mg|GSK1034702 at 4mg
11497486|NCT01371799|Experimental|Study drug at 8mg|GSK1034702 at 8mg
11497487|NCT01371799|Placebo Comparator|Placebo|Placebo
11497488|NCT01371786|Experimental|ciclesonide nasal aerosol|A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister followed by a washout period of 120 hours and a radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
11497489|NCT01371786|Active Comparator|mometasone|A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle followed by a washout period of 120 hours and a radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
11497490|NCT01371773|Experimental|Left-sided double lumen tube|
11497491|NCT01371760|Experimental|Intervention|The patients will undergo PTA of the extracranial cerebral veins
11497492|NCT01371760|Sham Comparator|Controls|The patients will undergo sham procedure
11497493|NCT01371747|Experimental|Stratum 1: 8.4 g/d patiromer|Participants with baseline serum potassium > 5.0 to 5.5 mEq/L (milliequivalent)
11497494|NCT01371747|Experimental|Stratum 1: 16.8 g/d patiromer|Participants with baseline serum potassium > 5.0 to 5.5 mEq/L
11497495|NCT01371747|Experimental|Stratum 1: 25.2 g/d patiromer|Participants with baseline serum potassium > 5.0 to 5.5 mEq/L
11497496|NCT01371747|Experimental|Stratum 2: 16.8 g/d patiromer|Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
11497497|NCT01371747|Experimental|Stratum 2: 25.2 g/d patiromer|Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
11497498|NCT01371747|Experimental|Stratum 2: 33.6 g/d patiromer|Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
11497499|NCT01371734|Experimental|Experimental Arm 1 - high dose|
11497500|NCT01371734|Experimental|Experimental Arm 2 - low dose|
11497501|NCT01371734|Placebo Comparator|Placebo Arm|
11497502|NCT01371721|Experimental|Desvenlafaxine Succinate Sustained-Release|
11497503|NCT01371708|Experimental|Desvenlafaxine Succinate Sustained-Release|
11497504|NCT01371682|Other|Session 1|Ropinirole manufactued at Crawley will be compared to that manufactured at Aranda
11497505|NCT01371682|Other|Session 2|Ropinirole manufactured at Crawley will be compared to that manufactured at Aranda.
11497506|NCT01371669||IPAH or CPEPH|Idiopathic pulmonary arterial hypertension (IPAH) or pulmonary hypertension associated with chronic post-embolic pulmonary hypertension (CPEPH)
11497507|NCT01371656|Experimental|Arm I (levofloxacin)|Patients receive levofloxacin PO or IV over 60-90 minutes once or twice daily beginning on day 3 during 2 consecutive courses of chemotherapy or beginning on day -2 during HSCT and continuing until blood counts recover.
11497508|NCT01371656|No Intervention|Arm II (standard of care)|Patients receive established standard of care and receive chemotherapy or HSCT as patients in Arm I.
11497509|NCT01371643|Active Comparator|Medical treatment by Octreotide LAR|Medical therapy with Octreotide LAR 30 mg/month for 3 months preceding surgery
11497510|NCT01371643|Active Comparator|Surgical debulking followed by Octreotide LAR|Surgical debulking of pituitary tumor followed by Octreotide LAR if not surgically cured
11497511|NCT01371630|Experimental|Treatment (inotuzumab ozogamicin, combination chemotherapy)|See Detailed Description
11497512|NCT01371617|Experimental|IPI-926|Single Arm, Phase 2 trial evaluating the safety and efficacy of IPI-926 in patients with myelofibrosis
11497513|NCT01371604|Experimental|IDX184 50 mg + Peg-IFN/RBV|IDX184 50 mg and matching placebo once daily plus peginterferon alfa-2a (Peg-IFN) weekly and ribavirin (RBV) daily for 12 weeks followed by Peg-IFN weekly and RBV daily for an additional 12 or 36 weeks.
11497514|NCT01371604|Experimental|IDX184 100 mg + Peg-IFN/RBV|IDX184 100 mg once daily plus Peg-IFN weekly and RBV daily for 12 weeks followed by Peg-IFN weekly and RBV daily for an additional 12 or 36 weeks.
11497515|NCT01371591|Active Comparator|Pill Cam, clinical evaluation|"This group receives standard of care plus Pill Cam (Video Capsule Endoscopy, VCE). VCE will be read immediately by site PI or co-PI and by site GI doctor. However, if PillCam appears normal or shows a low-risk problem and the patient is stable medically, then the patient will be discharged home. If the patient is discharged, patient will be called to get an endoscopy as an outpatient within 3 days. Patient will be monitored for a minimum of 4 hours. Repeat CBC every 4 hours. If the patient has stable Blood Pressure and pulse for 4 plus hours then the subject will be discharged home with a follow up (standard of care) EGD within 3 days."
11497516|NCT01371591|Placebo Comparator|Pill Cam, archived|"This group also receives standard of care plus Pill Cam (Video Capsule Endoscopy,VCE). VCE video will be archived and read at a later date. Patient will be admitted. VCE will not be used for clinical decisions. Same day or next day (<24 hour) Endoscopic examination of the upper GI tract will be offered to all patients within 24 hours, and hemostasis therapy will be applied as necessary. All patients in this group will be admitted for next day endoscopy in the hospital. This is standard of care."
11497517|NCT01371578|Experimental|Arm 2|"AM Dosing: One GS-5885 30 mg tablet, two GS-9451 100 mg tablets, orally with RBV and with food.
~PM Dosing: RBV with food.
~PEG, 180 µg, will be administered weekly by subcutaneous injection for the specified period of time (see Study Design). Pegasys® prefilled syringes (Hoffman-La Roche) will be supplied by Gilead Sciences."
11497518|NCT01371565|Experimental|mifepristone|
11497519|NCT01371552|Experimental|delefilcon A|Part 1: Delefilcon A contact lenses, followed by filcon II 3 contact lenses and narafilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
11497520|NCT01371552|Active Comparator|filcon II 3|Part 1: Filcon II 3 contact lenses, followed by narafilcon A contact lenses and delefilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
11497521|NCT01371552|Active Comparator|narafilcon A|Part 1: Narafilcon A contact lenses, followed by filcon II 3 contact lenses and delefilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
11497522|NCT01371539|Other|Lotrafilcon B / Comfilcon A|Lotrafilcon B contact lenses worn first, with comfilcon A contact lenses worn second. Both products worn bilaterally on a daily wear basis for one week each.
11497523|NCT01371539|Other|Comfilcon A / Lotrafilcon B|Comfilcon A contact lenses worn first, with lotrafilcon B contact lenses worn second. Both products worn bilaterally on a daily wear basis for one week each.
11497524|NCT01371526|Experimental|Synacthen|active treatment
11497525|NCT01371513||PSA level|more than 2.5ng/ml
11497526|NCT01371487|Experimental|Treatment A|GSK1120212 Dose /Treatment 2.0 mg/Fasted
11497527|NCT01371487|Experimental|Treatment B|GSK1120212 Dose /Treatment 2.0 mg/high fat, high calorie meal
11497528|NCT01371474||Patients prescribed PAXIL|Patients with depression or in a depressed state starting PAXIL at 20 mg/day during study period
11497529|NCT01371461||Patients prescribed PAXIL|Patients with depression or depressed state prescribed PAXIL during study period
11497530|NCT01371448||Patients prescribed PAXIL for long-term use|Patients with depression/depressed state or panic disorder prescribed PAXIL during study period
11497531|NCT01371435||Patients prescribed PAXIL|Patients with depression/depressed state or panic disorder prescribed PAXIL during study period
11497532|NCT01371422|Experimental|A1 (PVB)|PVB technique will be utilized for injection of the anaesthetic under the skin before the procedure.
11497533|NCT01371422|Placebo Comparator|A2 (Placebo)|The placebo is an inactive substance that looks identical to the test intervention but contains no active ingredients and will be administered the same as the PVB by a local skin injection, but no advancement of the needle to the paravertebral space will be made to avoid unnecessary risks.
11497534|NCT01371409|Experimental|active cTBS|
11497535|NCT01371409|Sham Comparator|Sham cTBS|
11497536|NCT01371396|Other|Hispanic subjects|Subjects will identify as Hispanic ethnicity.
11497537|NCT01371396|Other|African American subjects|Subjects will self-identify as African American in origin.
11497538|NCT01371383|Experimental|omega-3 fatty acids|
11497539|NCT01371383|Placebo Comparator|Placebo|
11497540|NCT01371370|Experimental|Resistance exercise training|Lower-body exercises 3 times per wk for 12 wk
11497541|NCT01371370|Experimental|Hypocaloric diet|This arm involves 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
11497542|NCT01371370|Experimental|Resistance exercise training & diet|Lower-body exercise training and diet
11497543|NCT01371370|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 wk.
11497544|NCT01371357|Experimental|TEST1|2.4 g/day of guanidinoacetic acid
11497545|NCT01371357|Experimental|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogen citrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
11497546|NCT01371357|Experimental|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
11497547|NCT01371357|Experimental|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
11497548|NCT01371344|Experimental|Part A: Heart Transplant (Tacrolimus granules)|In Part A of the study, participants who are heart transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
11497893|NCT01369160||4|standard comprehensive care (SCC, control)
11497549|NCT01371344|Experimental|Part A: Liver Transplant (Tacrolimus granules)|In Part A of the study, participants who are liver transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
11497550|NCT01371344|Experimental|Part A: Kidney Transplant (Tacrolimus granules)|In Part A of the study, participants who are kidney transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
11497551|NCT01371344|Experimental|Part B: All Participants (Tacrolimus capsules)|In Part B of the study, participants who are heart, kidney or liver transplant recipients and who are converted from tacrolimus granules-based immunosuppression regimen, receive tacrolimus capsules twice daily for 1 month and thereafter receive commercially available tacrolimus capsules.
11497552|NCT01371331|Experimental|Tacrolimus granules|oral
11497553|NCT01371318|Experimental|OWEMR|Medical centers will be randomized to use the Online Wound Electronic Medical Record to enhance care of patients with diabetic foot ulcers
11497554|NCT01371318|No Intervention|Standard of Care|Medical/wound centers will be randomized to continue routine care of patients with diabetic foot ulcers
11497555|NCT01371305|Experimental|BG00011|Participants will receive 8 consecutive weekly doses of BG00011
11497556|NCT01371305|Placebo Comparator|Placebo|Participants will receive 8 consecutive weekly doses of placebo.
11497557|NCT01371292|Experimental|Transformational teaching condition|Teachers allocated to this condition will receive the transformational teaching intervention.
11497558|NCT01371292|Active Comparator|Standard practice control condition|Teachers allocated to this condition will not receive the transformational teaching intervention. Instead they will take part in a parallel workshop offered by their respective school board (unrelated to transformational leadership training).
11497559|NCT01371266|Active Comparator|Honey|60.7 grams daily orally times 14 days
11497560|NCT01371266|Active Comparator|CHO|50 grams daily orally times 14 days
11497561|NCT01371266|Active Comparator|High Fructose Corn Syrup|65.7 grams daily orally times 14 days
11497562|NCT01371253|Experimental|Nintendo Wii traning|Balance training
11497563|NCT01371253|Placebo Comparator|EVA-soles|
11497564|NCT01371227|Experimental|JNS002|JNS002 30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
11497565|NCT01371214|Experimental|Group 1|PLIÉ exercise program 30-45 minutes, 2-3 days/week for 18 weeks followed by 18 weeks of usual care (20-minutes of chair-based exercises 2-5 days/week).
11497566|NCT01371214|Active Comparator|Group 2|Usual care (20 minutes of chair-based exercises 2-5 days/week) for 18 weeks followed by the PLIÉ exercise program 30-45 minutes/day, 2-3 days/week for 18 weeks.
11497567|NCT01371201|Experimental|Sunitinib|sunitinib 37.5 mg per day
11497568|NCT01371201|Placebo Comparator|Placebo|Placebo 37.5 mg per day
11497569|NCT01371188||Controls|Healthy male volunteers, non-smokers, 20-40yo, living in the city of Mendonça, São Paulo-Brazil.
11497570|NCT01371188||Sugarcane Workers|Healthy male volunteers, non-smokers, 20-40yo, sugarcane workers, living in the city of Mendonça, São Paulo-Brazil.
11497571|NCT01371175|Experimental|Group A|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
11497572|NCT01371175|Experimental|Group B|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
11497573|NCT01371175|Experimental|Group C|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intradermally. Vaccine:Placebo =18/3
11497574|NCT01371175|Experimental|Group D|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
11497575|NCT01371175|Experimental|Group E|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
11497576|NCT01371175|Experimental|Group F|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
11497577|NCT01371175|Experimental|Group G|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
11497578|NCT01371175|Experimental|Groups C2/D2/E2 (Subgroups of C,D,E)|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and Month 12+ (volunteers offered second MVA/placebo more than 12 months (late boost) after their enrollment into their original treatment assignment) delivered ID, SC, or IM according to original randomization. Vaccine:Placebo = blinded ratio, maximum in C2/D2/E2 = 16.
11497579|NCT01371175|Experimental|Group F2/G2 (Subgroup of F and G)|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and Month 12+ (volunteers offered second MVA/placebo more than 12 months (late boost) after their enrollment into their original treatment assignment) delivered either SC or IM according to original randomization. Vaccine:Placebo = blinded ratio, maximum in F/G= 29.
11497580|NCT01371162|Experimental|A1 Healthy Volunteers|
11497581|NCT01371162|Placebo Comparator|A2|
11497582|NCT01371162|Experimental|B1 HCV Infection|
11497583|NCT01371162|Placebo Comparator|B2|
11497584|NCT01371149|No Intervention|Physician led ventilator set up|Patients will be set up on non-invasive ventilation as per the current gold standard physician led approach
11497585|NCT01371149|Experimental|parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
11497640|NCT01370772|Active Comparator|Standard R-FC arm|"Standard R-FC arm 6 cycles every 28 days
~Cycle 1:
~Rituximab : 375 mg/m² i.v on day 1
~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days
~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days For patients with Leucocyte count > 25* G/L : rituximab in two equal doses at D1, D2
~Cycle 2-6:
~Rituximab: 500 mg/m² i.v on day 1, repeated every 28 days
~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days
~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days"
11498691|NCT01363609|Experimental|Liraglutide|12 week treatment with liraglutide in fixed dosage
11497586|NCT01371136|Experimental|Curricular Trained|"Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an easy, medium and hard level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver."
11497587|NCT01371136|No Intervention|conventional residency training|These residents proceed through surgical residency training as usual
11497588|NCT01371123||On long-term PN|
11497589|NCT01371123||Never been on TPN|
11497590|NCT01371110|Active Comparator|Ketamine|Study participants will receive a one-time intravenous infusion of 0.5 mg/kg racemic ketamine hydrochloride
11497591|NCT01371110|Sham Comparator|Midazolam|Study participants will receive a one-time intravenous infusion of 0.045 mg/kg midazolam
11497592|NCT01371097|No Intervention|Control Group|
11497593|NCT01371097|Experimental|Treatment group|
11497594|NCT01371084|Experimental|Physical activity treatment group|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
11497595|NCT01371084|Placebo Comparator|Wait List Control|
11497596|NCT01371071||CIS or early relapsing-remitting MS|
11497597|NCT01371058|Active Comparator|routine dual antiplatelet|asprin 300mg/d for 1 month followed by 100mg/d chronically； clopidogrel 75mg/d for 1year.
11497598|NCT01371058|Experimental|high maintenance clopidogrel|aspirin 300mg/d for 1 month followed by 100mg/d chronically; clopidogrel 150mg/d for 1 month followed by 75mg/d for at least 1 year.
11497599|NCT01371058|Experimental|policosanol plus dual antiplatelet|asprin 300mg/d for 1 month followed by 100mg/d chronically; clopidogrel 75mg/d for at least 1 year; Policosanol 40mg/d for 6months.
11497600|NCT01371045||Acromegaly|Patients carrying the diagnosis of acromegaly who are on long-acting somatostatin for at least 3 months prior to study enrollment.
11497601|NCT01371045||Carcinoid Syndrome|Patients carrying a diagnosis of carcinoid syndrome who are taking long-acting somatostatin for at least 3 months prior to study enrollment.
11497602|NCT01371045||Healthy Controls|
11497603|NCT01371032|Active Comparator|Video-Miller laryngoscope|using the screen (Video laryngoscopy group)
11497604|NCT01371032|Active Comparator|Direct laryngoscopy|without use the screen (Direct laryngoscopy group)
11497605|NCT01371019||Women with preterm delivery|
11497606|NCT01371019||Women without preterm delivery|
11497607|NCT01371006|Experimental|BI201335 low dose Efavirenz|low dose Efavirenz
11497608|NCT01371006|Experimental|BI201335 high dose Efavirenz|normal dose Efavirenz
11497609|NCT01370980||Study population|Adults (18 years old or more) with one of the following oral oncology treatments: letrozole, exémestane, imatinib, sunitinib, nilotinib, evérolimus, déférasirox
11497610|NCT01370967||Study formula-fed only|
11497611|NCT01370967||Human milk-fed only|
11497612|NCT01370967||Mixed-fed using study formula only|
11497613|NCT01370954||CerefolinNAC®|Subjects diagnosed with Early Memory Loss who have been prescribed CerefolinNAC® daily.
11497614|NCT01370941|Active Comparator|Drug A: Chymosin|A: 5 drops of Chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
11497615|NCT01370941|Placebo Comparator|Drug B: Placebo|B: 5 drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
11497616|NCT01370928|Experimental|Prototype colonoscope|The new colonoscope to be tested
11497617|NCT01370928|Active Comparator|Standard colonoscope|The standard colonoscope used world-wide today.
11497618|NCT01370915|Experimental|Pregabalin|Patients receive oral placebo 150 mg 1hour prior to septal surgery, and 12 hours later
11497619|NCT01370915|Placebo Comparator|Placebo|Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
11497620|NCT01370902|Experimental|Single-dose (SD) trial part (i.v.)|
11497621|NCT01370902|Experimental|Single-dose (SD) trial part (s.c.)|
11497622|NCT01370902|Experimental|Multiple-dose (MD) trial part (s.c.)|
11497623|NCT01370889|Experimental|Basic Science (resveratrol)|Patients receive resveratrol PO QD for 12 weeks.
11497624|NCT01370876|Experimental|Oxaliplatin/5-FU|
11497625|NCT01370863|Experimental|SPD557|
11497626|NCT01370863|Placebo Comparator|Placebo|
11497627|NCT01370850||Normal|Normal results from the clinical exam and free of ocular pathology.
11497628|NCT01370850||Glaucoma|Clinical exam results consistent with glaucoma; visual field defects consistent with glaucoma and/or structural damage consistent with glaucoma.
11497629|NCT01370850||Retina|Clinical exam results consistent with retina pathology.
11497630|NCT01370837|Experimental|Healthy controls|
11497631|NCT01370837|Experimental|Diabetes|Patients with diabetes mellitus without polyneuropathy.
11497632|NCT01370837|Experimental|Polyneuropathy|Patients with diabetes and polyneuropathy.
11497633|NCT01370824||Basal cell carcinoma|"- Population: Eligible are patients (men and women) ≥18 years of age who visit the outpatient department of dermatology of the Maastricht University Medical Centre because of a clinically suspected BCC.
~- Inclusion criteria: All patients aged 18 years or older, otherwise healthy, with ≤ three primary (no previous treatment) clinically determined BCC.
~- Exclusion criteria: Patients using immunosuppressive drugs. Genetic skin cancer disorders. Earlier treatments at the same site. Age under 18 years. More than 3 clinical suspected BCCs. Not capable of informed consent."
11497634|NCT01370811|Placebo Comparator|OC oral solution treatment D|Placebo
11497635|NCT01370811|Experimental|OC oral solution treatment C|High dose oxybutynin and clonidine
11497636|NCT01370811|Experimental|OC oral solution treatment A|Low dose oxybutynin and clonidine
11497637|NCT01370811|Experimental|OC oral solution treatment B|Intermediate dose oxybutynin and clonidine
11497638|NCT01370798|Experimental|promestriene|Children with severe hypospadias treated with promestriene 1%
11497641|NCT01370772|Experimental|DenseR-FC arm|"DenseR-FC arm =1 prephase R Dense course +6 R-FC courses
~Prephase:
~- Rituximab: 500 mg on day 0, 2000 mg on days 1, 8, and D15 For patients with Leucocyte count > 25* G/L : rituximab 250 mg D-1, D0 prephase
~Cycle 1-6 (cycle 1 beginning at D22):
~Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days
~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days
~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days"
11497642|NCT01370759|Experimental|Colon-targeted cleaning capsule|
11497643|NCT01370746||Cross-Sectional Study Group|Cross-sectional comparison of perceived barriers to adherence to post-transplant immunosuppressant regimens in parents/legal guardians of children 0-11 years versus adolescents 12-21 years
11497644|NCT01370746||Longitudinal Study Group|Subset of Cross-Sectional Study Group to evaluate whether perceived barriers to adherence increase with time during the first year following transplantation
11497645|NCT01370733|Experimental|Active sTMS|Treatment with the NEST-1 Device
11497646|NCT01370733|Sham Comparator|Sham|Treatment with a sham (inactive) device, identical in sound and appearance to the NEST-1 Device
11497647|NCT01370720|Active Comparator|Recoclix (CM&D Pharma Limited)|Recoclix: two tablets per day for 12 weeks
11497648|NCT01370720|Placebo Comparator|Placebo|IBS patients
11497649|NCT01370707|Active Comparator|Metformin|
11497650|NCT01370707|Experimental|CJ-30001/CJ-30002|
11497651|NCT01370694|Experimental|MK-8808 Combination Therapy|Participants received MK-8808 375 mg/m^2 intravenously (IV) + cyclophosphamide 750 mg/m^2 IV + vincristine 1.4 mg/m^2 IV (maximum dose of 2 mg IV) on Day 1 each cycle, plus prednisolone 40 mg/m^2, orally on Days 1 to 5 of each cycle for a maximum of 8 cycles. Participants receiving clinical benefit could remain on MK-8808 375 mg/m^2 IV starting 8 weeks after last dose of combination therapy, every 2 months for up to 2 years.
11497652|NCT01370681|Experimental|Group1|
11497653|NCT01370681|Experimental|Group2|
11497654|NCT01370668|Experimental|Functional remediation|"Patients assigned to the experimental treatment will receive standard psychiatric care and will be enrolled in the neurocognitive intervention program composed of 21 sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.
~The program will be performed in an 8-to-10 patient group conducted by 2 experienced neuropsychologists. with previous experience with bipolar patients (at least 3 years) and specific training on patients' group management."
11497655|NCT01370668|Active Comparator|Psychoeducation|The group psychoeducation is a tested (Colom et al, 2003) and manualized intervention (Vieta and Colom, 2006) consisting on 21 sessions of 90 minutes, aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences and lifestyle regularity. The program will be performed in an 8-10 patient group conducted by 2 experienced psychologists with previous experience with bipolar patients and specific training on patients' group management. The structure of each session consists of a 30 to 40 minute speech on the topic of the day, followed by an exercise related to the issue (eg. drawing a life chart, writing a list of potential triggering factors) and a discussion.
11497656|NCT01370668|Active Comparator|Treatment as Usual|This arm will not receive any sort of add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
11497657|NCT01370655|Experimental|MK-7145 6 mg (Treatment A)|MK-7145 3 mg (three x 1-mg MK-7145 capsules administered orally) and placebo to HCTZ (two 12.5-mg capsules) then three x 1-mg MK-7145 capsules 4 hours later, daily for 4 weeks.
11497658|NCT01370655|Experimental|MK-7145 3 mg (Treatment B)|MK-7145 3 mg (one 2mg MK-7145 and one MK-7145 placebo capsule) then one 1-mg MK-7145 capsule and two MK-7145 placebo capsules 4 hours later and placebo to HCTZ (2 capsules once daily) daily for 4 weeks.
11497659|NCT01370655|Active Comparator|Hydrochlorothiazide 25 mg (Treatment C)|HCTZ 25 mg (two 12.5-mg capsules) and placebo to MK-7145 (one 3-mg capsule) then placebo for MK-7145 (one 3-mg capsule) 4 hours later daily for 4 weeks.
11497660|NCT01370655|Placebo Comparator|Placebo (Treatment D)|Placebo to MK-7145 (2 x 3-mg capsules) and placebo to HCTZ 25 mg (2 capsules) then placebo to MK-7145 (2 x 3-mg capsules) 4 hours later daily for 4 weeks
11497661|NCT01370642|Experimental|Vaniprevir 12 Week Arm|Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) and then 12 weeks of placebo to vaniprevir along with 24 weeks of treatment with peg-IFN and RBV.
11497662|NCT01370642|Experimental|Vaniprevir 24 Week Arm|Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV.
11497663|NCT01370642|Active Comparator|Control Arm|Participants on this arm receive 24 weeks of treatment with placebo to vaniprevir along with 48 weeks of treatment with peg-IFN and RBV.
11497664|NCT01370629||All participants|Participants treated with vernakalant IV in acute care and inpatient hospital settings
11497665|NCT01370616|Experimental|Ertapenem sodium|Participants received 1.0 g intravenous (IV) ertapenem sodium as a single daily dose at Hour 0 infused over a 30-minute interval , and IV piperacillin/tazobactam-matching placebo at Hours 8 and 16 infused over a 30-minute interval, for 5 to 28 days. Participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
11497666|NCT01370616|Active Comparator|Piperacillin/tazobactam sodium|Participants received 4.5 g IV piperacillin/tazobactam at Hours 0, 8, and 16 infused over a 30-minute interval, for 5 to 28 days. Participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
11497667|NCT01370603|Active Comparator|Ezetimibe and atorvastatin|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including 10 mg ezetimibe, 40 mg atorvastatin, and placebo to ezetimibe/atorvastatin.
11497668|NCT01370603|Experimental|Ezetimibe/atorvastatin combination|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including ezetimibe/atorvastatin 10 mg/40 mg, placebo to ezetimibe, and placebo to atorvastatin.
11497669|NCT01370590|Active Comparator|Ezetimibe and atorvastatin|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including 10 mg ezetimibe, 20 mg atorvastatin, and placebo to ezetimibe/atorvastatin.
11497670|NCT01370590|Experimental|Ezetimibe/atorvastatin combination|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including ezetimibe/atorvastatin 10 mg/20 mg, placebo to ezetimibe, and placebo to atorvastatin.
11497671|NCT01370577||1|Total 300 subjects who was diagnosed with asthma
11497672|NCT01370564|Other|Daily diuretic adjustment|Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
11497673|NCT01370551|Experimental|Gynoflor|This study consists only of this arm.
11497674|NCT01370538|Experimental|Esomeprazole 20 mg|
11497675|NCT01370538|Placebo Comparator|Placebo|
11497676|NCT01370525|Experimental|Esomeprazole 20 mg|
11497677|NCT01370525|Placebo Comparator|Placebo|
11497678|NCT01370512|Active Comparator|Droxidopa / Pyridostigmine|
11497679|NCT01370512|Placebo Comparator|Droxidopa|
11497680|NCT01370512|Placebo Comparator|Pyridostigmine|
11497681|NCT01370499|Experimental|LY2216684 + SSRI|"LY2216684: 12 milligrams (mg) or 18 mg, administered orally, once daily for 52 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI).
~During the open-label phase, all participants started at the 12 mg dose and could have the dose increased to 18 mg after the first week of treatment. During the first 12 weeks, participants were allowed (at scheduled or unscheduled visits) to decrease their dose to 12 mg based on response. After a decrease in dose to 12 mg, participants could have had an increase back up to 18 mg at any scheduled visit based on response and tolerability. After 12 weeks of treatment, participants maintained a stable dose.
~Open-label treatment was followed by a 1-week abrupt discontinuation phase. Participants who either completed study visits through Week 52 or discontinued early from the study for any reason returned 1 week later for follow-up visit. Participants did not receive LY2216684 but continued their SSRI treatment at a stable dose."
11497682|NCT01370486|Active Comparator|melatonin|
11497683|NCT01370486|Placebo Comparator|placebo|
11497684|NCT01370460|Experimental|Tranexamic Acid|Topical tranexamic acid (2g/100mL) applied during unilateral total knee arthroplasty.
11497685|NCT01370460|Placebo Comparator|Placebo|100mL 0.9% NS, applied topically
11497686|NCT01370447|Experimental|EPI-743|Participants will receive EPI-743 at a dose of 50 milligrams (mg) at Day 1, 50 mg twice daily for 13 days, 100 mg on Day 15, and 100 mg twice daily until Day 28; either by mouth with a meal or via their G-tube with feeds. In the absence of clinical or laboratory indications of any safety concerns, participants will receive 100 mg EPI-743 three times daily until end of study.
11497687|NCT01370434|No Intervention|VAD combination|"vincristine 0.4mg iv on D1-4
~doxorubicin 9mg/m2 iv on D1-4
~dexamethasone 40mg/d po on D1-4,9-12,17-20
~Many physicians use vincristine, doxorubicin, and dexamethasone (VAD) for three to four months as induction therapy (Alexandrian et al, 1990). VAD produces partial response (PR) in about 50% patients, with complete response (CR) observed in 5%-10% patients (Kyle et al, 2004)."
11497688|NCT01370421||Knee OA patients undergoing Total Knee Arthroplasty (TKA)|Participants will be 45 years or older, diagnosed with Osteoarthritis of the knee and be scheduled for a unilateral total knee replacement surgery.
11497689|NCT01370408|Experimental|Palonosetron|"All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation
~Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV on the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO"
11497690|NCT01370395||Left ventricular function|According to the result of the echocardiographic exam, the patients will be divided into subgroups with (LV-EF>=55%) and without preserved ejection fraction (LV-EF<55%).
11497691|NCT01370382||Time interval|"Patients are divided according to the interval between the onset of chest pain symptoms and presentation at the hospital in an early(<4 hours) and late(> = 4 hours) group."
11497692|NCT01370369|Experimental|Single Testosterone Dose (Inner Thigh)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the inner thigh followed by a seven day washout period.
11497693|NCT01370369|Experimental|Single Testosterone Dose (Abdomen)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the abdomen followed by a seven day washout period.
11497694|NCT01370369|Experimental|Single Testosterone Dose (shoulder/upper arm)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the shoulder/upper arm.
11497695|NCT01370369|Experimental|Testosterone 1.25|Subjects received testosterone gel 2% at dose of 1.25 mL (one stroke) applied once daily for 10 consecutive days to the shoulder/upper arm.
11497696|NCT01370369|Experimental|Testosterone 2.50|Subjects received testosterone gel 2% at dose of 2.50 mL (two strokes) applied once daily for 10 consecutive days to the shoulder/upper arm.
11497697|NCT01370369|Experimental|Testosterone 3.75|Subjects received testosterone gel 2% at dose of 3.75 mL (three strokes) applied once daily for 10 consecutive days to the shoulder/upper arm.
11497698|NCT01370356|Active Comparator|Varenicline Tartrate|
11497699|NCT01370356|Placebo Comparator|Placebo|
11497700|NCT01370343|Experimental|PF-04991532 alone|
11497701|NCT01370343|Experimental|PF-04991532 + cyclosporine|
11497702|NCT01370317|Experimental|MK-1029|
11497703|NCT01370317|Placebo Comparator|Placebo|
11497704|NCT01370304|Experimental|active rTMS and active Venlafaxine|
11497705|NCT01370304|Experimental|active rTMS and sham Venlafaxine|
11497706|NCT01370304|Sham Comparator|sham rTMS and active Venlafaxine|
11497707|NCT01370291|Active Comparator|active Risperidone and active rTMS|active Risperidone and active rTMS for the first-episode schizophrenia patients
11497708|NCT01370291|Experimental|active rTMS and sham Risperidone|active rTMS and sham Risperidone for the first-episode schizophrenia
11497709|NCT01370291|Sham Comparator|sham rTMS and active Risperidone|sham rTMS and active Risperidone for the first-episode schizophrenia patients
11497710|NCT01370278|Active Comparator|Normal Saline|Normal saline sprayed into stent/airway tubes then suctioned out through bronchoscope.
11497711|NCT01370278|Active Comparator|Sodium Bicarbonate|Sodium bicarbonate sprayed into stent/airway tubes then suctioned out through bronchoscope.
11497712|NCT01370265|Active Comparator|Regadenoson, then Adenosine|Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the first intervention period. Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the second intervention period (after washout period). Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered.
11497796|NCT01369680|Experimental|Ketamine 1.5 mg/kg/dose|The fourth group of three subjects were administered 1.5 mg/kg/dose oral ketamine.
11497713|NCT01370265|Active Comparator|Adenosine, then Regadenoson|Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the first intervention period. Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered. After a washout period, Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the second intervention period.
11497714|NCT01370252||scope technique|
11497715|NCT01370252||open technique|
11497716|NCT01370239|Experimental|Hu3S193|Single arm
11497717|NCT01370226|Active Comparator|CBI|Computer delivered Brief Intervention
11497718|NCT01370226|Active Comparator|TBI|Therapist delivered Brief Intervention
11497719|NCT01370226|No Intervention|EUC|Enhanced Usual Care
11497720|NCT01370213|Experimental|CD34 Schema - High-Risk Acute Myeloid Disease|Patients with high risk acute myeloid disease treated with preparative regimen including Fludara, Cytoxan and total body irradiation followed by haploidentical donor NK cells, Interleukin-2, rabbit anti-thymocyte globulin, and filgrastim mobilized CD34+ selected peripheral blood stem cell graft from the same donor.
11497721|NCT01370213|Experimental|TCRα/β Schema - High-Risk Acute Myeloid Disease|Patients with high risk acute myeloid disease treated with preparative regimen including Fludara, Cytoxan and total body irradiation followed by haploidentical donor NK cells, Interleukin-2, rabbit anti-thymocyte globulin, and same donor TCR α/β-depleted cells infusion.
11497722|NCT01370200|Active Comparator|4% citrate|4% trisodium citrate, starting infusion rate 180 ml/h Interventions according to postfilter ionized calcium, change in 10 ml/h step
11497723|NCT01370200|Active Comparator|15% citrate|15% trisodium citrate, starting infusion rate 50 ml/h Interventions according to postfilter ionized calcium, change in 10 ml/h step
11497724|NCT01370187|No Intervention|Control|Control group
11497725|NCT01370187|Experimental|Montelukast|4mg Montelukast daily for 2 months
11497726|NCT01370174|Active Comparator|Induced Step Training (IST)|The IST group will receive waist-pulls in both the left and right lateral directions by a motorized pulling system to produce stepping.
11497727|NCT01370174|Active Comparator|Hip Strength Training (HST)|The HST group will have muscle strength training, to include hip abduction (AB) and adduction (AD) resistance exercises.
11497728|NCT01370174|Active Comparator|Combined Induced Step and Hip Strength Training|This training group consists of combined induced step training (IST) and hip AB-AD strength training (HST).
11497729|NCT01370174|Placebo Comparator|Standard Flexibility and Relaxation (SFR)|The SFR group will perform a flexibility and relaxation program involving minimal-intensity exercises.
11497730|NCT01370161|Experimental|TIPS treatment|Initial control of the bleeding episode will be obtained by vasoactive drugs (octreotide, somatostatin or terlipressin), endoscopic band ligation (sclerotherapy if technically difficult or not feasible) and prophylactic antibiotics.TIPS will be performed as soon as possible once the patients are enrolled in the study, always within the first 72 hours after the diagnostic endoscopy (preferably in the first 24 hours).Vasoactive drugs will be continued until the TIPS is performed and antibiotics will be continued for 5-7 days.
11497731|NCT01370161|Active Comparator|Medical treatment|Initial control of the bleeding episode will be obtained by vasoactive drugs (octreotide, somatostatin or terlipressin), endoscopic band ligation (sclerotherapy if technically difficult or not feasible) and prophylactic antibiotics.Patients will be treated with non-selective beta-blockers (propranolol)on day 5. In case of contraindications or intolerance to beta-blockers, patients will not receive pharmacological treatment (beta-blockers) and the only treatment to prevent rebleeding will be endoscopic band ligation.
11497732|NCT01370148|Experimental|Subjects with severe hepatic impairment|
11497733|NCT01370148|Active Comparator|Subjects with normal hepatic function|
11497734|NCT01370135|Experimental|Lucentis (Ranibizumab)|
11497735|NCT01370122||Subjects exposed to radiation|
11497736|NCT01370122||Subjects not exposed to radiation|
11497737|NCT01370109||Penn Site|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks, with additional follow-up at 1 and 2 years.
11497738|NCT01370109||Vanderbilt University Medical Center|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
11497739|NCT01370109||Case Medical Center|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
11497740|NCT01370109||University of Wisconsin at Madison|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
11497741|NCT01370083|Experimental|Stroke: TPPT|Adults with dysphagia post stroke (within 4-16 weeks of onset) who have radiographically confirmed difficulties with thin liquid bolus control. Individuals will complete 24 sessions of tongue-pressure-profile training over 8-12 weeks.
11497742|NCT01370083|Active Comparator|Stroke: TPSAT Control|Individuals with dysphagia (within 4-16 weeks post stroke) who demonstrate difficulties with thin liquid control on videofluoroscopy. Individuals will complete 24 sessions of tongue-pressure strength-and-accuracy training over 8-12 weeks.
11497743|NCT01370070|Experimental|MK-2206|
11497744|NCT01370057|Experimental|Treatment Group|Treatment with bracing
11497745|NCT01370057|No Intervention|Control Group|Watchful waiting without bracing
11497746|NCT01370044|Experimental|Verum|Verum arm receiving Carbogen
11497747|NCT01370044|Placebo Comparator|Placebo|Placebo arm receiving oxygen
11497748|NCT01370031|Experimental|Clenil® Modulite® via AeroChamber Plus™|Clenil® Modulite® administered via AeroChamber Plus™ spacer
11497749|NCT01370031|Active Comparator|Clenil® Modulite® via Volumatic™|Clenil® Modulite® administered via Volumatic™ spacer
11497750|NCT01370031|Experimental|Clenil® Modulite® via AeroChamber Plus™ plus charcoal block|Clenil® Modulite® administered via AeroChamber Plus™ spacer plus charcoal block
11497751|NCT01370031|Active Comparator|Clenil® Modulite® via Volumatic™ plus charcoal block|Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block
11497797|NCT01369667|Active Comparator|vitamin D|Capsule, one taken daily
11497798|NCT01369667|Placebo Comparator|Placebo|Capsule, one taken daily
11497752|NCT01370018|Experimental|alpha-1-Proteinase Inhibitor|Although Zemaira® (alpha-1-Proteinase Inhibitor) treatment is the standard treatment for patients with too little alpha-1-Proteinase Inhibitor, its use in HIV-1 patients has not been established. This pilot study was performed to show that Zemaira® treatment can be used in HIV-1 patients to elevate alpha-1-Proteinase Inhibitor and has the added benefit of elevating CD4 cells.
11497753|NCT01370005|Experimental|BI 10773 low dose|BI 10773 low dose once daily
11497754|NCT01370005|Experimental|BI 10773 high dose|BI 10773 high dose once daily
11497755|NCT01370005|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
11497756|NCT01369979||Patients with chronic liver disease|"Inclusion criteria
~Age between 40 and 70 years
~BMI between 20 and 26
~Exclusion Criteria
~Diabetes mellitus
~Glucose intolerance
~Medical treatment of portal hypertension
~People who have undergone surgery for obesity
~Pregnancy"
11497757|NCT01369979||Healthy subjects|"Inclusion criteria
~Age between 40 and 70 years
~BMI between 20 and 26
~Exclusion Criteria
~Diabetes mellitus
~Glucose intolerance
~Medical treatment of portal hypertension
~People who have undergone surgery for obesity
~Pregnancy"
11497758|NCT01369940||NICHD Fetal Growth Study - Twin Gestations|"Women with dichorionic twin gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2012-2013) in this prospective cohort study.
~Intervention: No intervention"
11497759|NCT01369901|Experimental|Group A|Functional exercise
11497760|NCT01369901|Active Comparator|Group B|Stretching exercise
11497761|NCT01369888|Experimental|IL-15 following Young TIL (0.25 mcg)|0.25 mcg/kg/day x 10
11497762|NCT01369888|Experimental|IL-15 following Young TIL (0.50 mcg)|0.50 mcg/kg/day x 10
11497763|NCT01369888|Experimental|IL-15 Following Young TIL (1 mcg)|1 mcg/kg/day x 10
11497764|NCT01369888|Experimental|IL-15 Following Young TIL (2 mcg)|2 mcg/kg/day x 10
11497765|NCT01369875|Experimental|Standard Young TIL|"Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0
~Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
~Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
~Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6"
11497766|NCT01369875|Experimental|ECCE Young TIL|"Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0
~Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
~Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)
~Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6"
11497767|NCT01369862|Placebo Comparator|SPGNH buffer|SPGNH buffer administration by liquid nasal spray
11497768|NCT01369862|Experimental|GHB16L2|Dose level ~7.0 log10 fTCID50/strain/person
11497769|NCT01369849|Experimental|Treatment (Akt inhibitor MK2206, bendamustine, rituximab)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22 (days 1, 8, 15, 22, and 29 of course 1); rituximab IV on day 1 (day 8 of course 1); and bendamustine hydrochloride IV over 30-60 minutes on days 1-2 (days 8-9 of course 1). Treatment repeats every 28 days (35 days for course 1 and 84 days for course 6) for 6 courses in the absence of disease progression or unacceptable toxicity.
11497770|NCT01369836|Experimental|20 mg soft gelatin capsule|
11497771|NCT01369836|Experimental|40 mg (20 mg*2) soft gelatin capsule|
11497772|NCT01369836|Active Comparator|Placebo|
11497773|NCT01369810||1|All patients who was on treatment with fixed combination asthma or COPD therapy by January 1 2010
11497774|NCT01369797|No Intervention|reference|"reference group, where every patient will benefit: of the same GGA at home as those of the  specific intervention  group. The GGA results will not be supplied to the family practioner."
11497775|NCT01369797|Experimental|specific intervention|"specific intervention group, where every patient will benefit: of an GGA at home. According to the frailties or the detected morbidity, a specific plan of intervention will be established for the person. all the preventive actions will be coordinated by UPSAV."
11497776|NCT01369784||refractory/relapsed LDCBG|patients with refractory/relapsed diffuse large B-cell lymphoma
11497777|NCT01369771|Experimental|Tafluprost 0.0015%|Open, one arm study. Patients who have been using latanoprost 0.005% eye drops (Xalatan®) as their prior medication (at least 6 months) and who fulfil all the inclusion criteria including the specified ocular symptoms and signs, will switch from latanoprost to the assigned preservative-free tafluprost 0.0015% (Taflotan®)eye drops for twelve (12) months.
11497778|NCT01369758|Experimental|Intrauterine pathology, myomectomy|Subjects with intrauterine fibroids and/or polyps will undergo intrauterine pathology removal using the MyoSure Tissue Removal System; myomectomy procedure.
11497779|NCT01369745|Active Comparator|Prednisolone|Prednisolone 2.7 mg daily for 12 weeks
11497780|NCT01369745|Active Comparator|dipyridamole|Dipyridamole 360 mg daily for 12 weeks
11497781|NCT01369745|Active Comparator|prednisone|Prednisone 5 mg daily for 12 weeks
11497782|NCT01369745|Experimental|Z102 (2.7/360)|Prednisolone 2.7 mg plus dipyridamole 360 mg daily for 12 weeks
11497783|NCT01369745|Placebo Comparator|placebo|Placebo daily for 12 weeks
11497784|NCT01369732|Placebo Comparator|Saline group|We administrate the saline single bolus (5ml, intravenously) 30 min before the commencement of ischemia.
11497785|NCT01369732|Experimental|erythropoietin group|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
11497786|NCT01369719|Experimental|Osveral|20 mg/kg oral osveral daily
11497787|NCT01369719|Active Comparator|desferal|40mg/kg desferal for 6 nights in a week subcutaneously
11497788|NCT01369706|Other|Hand-held metal detector|Exposure to two hand-held metal detectors
11497789|NCT01369693|Active Comparator|General Portion 1 g pouch|
11497790|NCT01369693|Active Comparator|Catch Licorice Portion 1 g pouch|
11497791|NCT01369693|Active Comparator|Catch Licorice Portion Mini 0.5 g pouch|
11497792|NCT01369693|Active Comparator|Catch Licorice Portion Dry Mini 0.3 g pouch|
11497793|NCT01369680|Experimental|Ketamine 0.25 mg/kg/dose|The first three subjects were administered 0.25 mg/kg/dose oral ketamine.
11497794|NCT01369680|Experimental|Ketamine 0.5 mg/kg/dose|The second group of three subjects were administered 0.5 mg/kg/dose oral ketamine.
11497795|NCT01369680|Experimental|Ketamine 1 mg/kg/dose|The third group of three subjects were administered 1 mg/kg/dose oral ketamine.
11497800|NCT01369641|Experimental|Experimental Ear - Sodium Thiosulfate (STS)|Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.
11497801|NCT01369641|Placebo Comparator|Comparator Ear - Placebo|Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.
11497802|NCT01369628|Experimental|Arm 1|"1 arm with the 3 following dose regimens:
~Regimen 1: Atacicept 25 mg weekly for 12 weeks
~Regimen 2: Atacicept 75 mg weekly for 12 weeks
~Regimen 3: Atacicept 150 mg weekly for 12 weeks"
11497803|NCT01369615|Experimental|Oxycodone HCl controlled-release|Oxycodone hydrochloride controlled-release tablets
11497804|NCT01369602|Experimental|healthy controls|healthy subjects (creatinine clearance > 90 mL/min)
11497805|NCT01369602|Experimental|ESRD / severe renal insufficiency|Severe (creatinine clearance 15 to 29 mL/min) OR ESRD (creatinine clearnace <15 mL/min OR requiring dialysis)
11497806|NCT01369602|Experimental|Moderate renal impairment|Moderate (creatinine clearance = 30 to 59 mL/min)
11497807|NCT01369602|Experimental|Mild renal impairment|Mild (creatinine clearance = 60 to 89 mL/min)
11497808|NCT01369589|Experimental|P-552 on Day 1 and Placebo on Day 2|Randomly assigned subjects will receive a single dose of P-552 on Day 1 followed by a single dose of Placebo on Day 2
11497809|NCT01369589|Experimental|Placebo on Day 1 and P-552 on Day 2|Randomly assigned subjects will receive a single dose of Placebo on Day 1 followed by a single dose of P-52 on Day 2
11497810|NCT01369576|Placebo Comparator|Placebo|Usual sleep apnea and CPAP care Sleep apnea OSR Medical Treatment Plan©
11497811|NCT01369576|Experimental|zopiclone|Sleep apnea OSR Medical Treatment plan ©
11497812|NCT01369550|Placebo Comparator|High-oleic sunflower oil-containing foods|Subjects will consume 3 servings of foods containing high-oleic sunflower oil plus 3x500 mg high-oleic sunflower oils softgels per day.
11497813|NCT01369550|Active Comparator|Eicosapentaenoic acid|Subjects will consume 3 x 500 mg eicosapentaenoic acid ethyl ester in softgels plus 3 servings of high-oleic sunflower oil-containing foods per day
11497814|NCT01369550|Experimental|SDA soybean oil-containing foods|Subjects in this arm will consume 3 servings of SDA soybean oil-containing foods plus 3 x 500 mg high-oleic sunflower oil softgels per day.
11497815|NCT01369537||adults > 65 yrs undergoing noncardiac surgery|
11497816|NCT01369524||ICUpatient with need of fluid|age > 18 - haemodynamic monitoring - informed consent - admission on ICU
11497817|NCT01369511|Placebo Comparator|Placebo|Administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
11497818|NCT01369511|Experimental|35 mg LY2495655|LY2495655: 35 milligrams (mg) administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
11497819|NCT01369511|Experimental|105 mg LY2495655|LY2495655: 105 mg administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
11497820|NCT01369511|Experimental|315 mg LY2495655|LY2495655: 315 mg administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
11497821|NCT01369498|Experimental|Simtuzumab 200 mg|Participants in Stage 1 of study will receive simtuzumab 200 mg for up to 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
11497822|NCT01369498|Experimental|Simtuzumab 700 mg|Participants in Stage 1 of study will receive simtuzumab 700 mg for up to 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
11497823|NCT01369498|Experimental|Simtuzumab 200 mg+Ruxolitinib|In Stage 2, participants on stable doses of ruxolitinib will receive simtuzumab 200 mg for at least 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
11497824|NCT01369498|Experimental|Simtuzumab 700 mg+Ruxolitinib|In Stage 2, participants on stable doses of ruxolitinib will receive simtuzumab 700 mg for at least 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
11497825|NCT01369485|Active Comparator|Active Treatment group|VERV™ System
11497826|NCT01369485|Sham Comparator|Sham Treatment Group|Sham version of (VERV™ System)
11497827|NCT01369472|Experimental|Dilatrend SR capsule 8mg|
11497828|NCT01369472|Experimental|Dilatrend SR capsule 16mg|
11497829|NCT01369472|Experimental|Dilatrend SR capsule 32mg|
11497830|NCT01369472|Experimental|Dilatrend SR capsule 64mg|
11497831|NCT01369472|Experimental|Dilatrend SR capsule 128mg|
11497832|NCT01369459|Experimental|Family Counseling with MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
11497833|NCT01369459|No Intervention|Historical Control|
11497834|NCT01369446||Women undergoing IVF treatment|
11497835|NCT01369433|Experimental|tivozanib renal cell carcinoma (RCC)|Subjects who participated in a Phase 2 monotherapy study in RCC and showed tolerability and clinical benefit will be allowed access to tivozanib (AV-951).
11497836|NCT01369433|Experimental|tivozanib + temsirolimus|Subjects who participated in a Phase 1b study and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951) + temsirolimus combination.
11497837|NCT01369433|Experimental|tivozanib + paclitaxel|Subjects who participated in a Phase 1b study and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951) + paclitaxel combination.
11497838|NCT01369433|Experimental|tivozanib solid tumors - QTC|Subjects who participated in a Phase 1 and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951).
11497839|NCT01369433|Experimental|tivozanib + capecitabine|After Ph 1b study tolerable to Tivo + Xeloda®
11497840|NCT01369433|Experimental|tivozanib Advanced RCC|After biomarker study tolerable to Tivo
11497841|NCT01369407||Enrolled Subjects|Enrolled subjects participate for up to 2 years
11498895|NCT01362153|Experimental|002|Golimumab SC injection of 100 mg every 4 weeks through Week 20
11497842|NCT01369394|Experimental|Tailored information|Individuals assigned to the experimental group will receive individually-tailored educational messages.
11497843|NCT01369394|Active Comparator|Untailored information|Individuals assigned to the control group will receive generic, untailored educational messages.
11497844|NCT01369381|Experimental|Airtraq laryngoscope|The Airtraq is an alternative indirect laryngoscope that appears to cause less cervical spine motion during intubation that conventional direct laryngoscopy (Macintosh blade)
11497845|NCT01369381|Active Comparator|Macintosh laryngoscope|This arm constitutes intubation with a conventional direct laryngoscopy with a Macintosh blade which has been shown to result in cervical spine extension, particularly in the upper cervical segments.
11497846|NCT01369368|Experimental|1|Azacitidine, valproic acid, all-trans retinoic acid, hydroxyurea, eventually donor leukocyte infusions
11497847|NCT01369355|Placebo Comparator|001|Participants who were responders to Intravenous (IV) infusion of ustekinumab induction will be randomized to receive a single dose of placebo subcutaneously (SC) every 4 weeks (q4w).
11497848|NCT01369355|Experimental|002|Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 milligram (mg) SC every 12 weeks (q12w).
11497849|NCT01369355|Experimental|003|Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 mg SC every 8 weeks (q8w).
11497850|NCT01369355|Experimental|004|Participants who were nonresponders to IV ustekinumab induction will receive a single dose of ustekinumab 90 mg SC and one placebo IV at week 0, if then respond will continue to receive one ustekinumab 90 mg SC q8w.
11497851|NCT01369355|Experimental|005|Participants who were nonresponders to IV placebo induction will receive a single dose of ustekinumab 130 mg IV and one placebo SC at week 0, if then respond will continue to receive one ustekinumab 90 mg SC at week 8 then q12w.
11497852|NCT01369355|Placebo Comparator|006|Participants who were responders to IV placebo induction will receive one dose of placebo SC q4w.
11497853|NCT01369342|Placebo Comparator|Placebo IV|Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
11497854|NCT01369342|Experimental|Ustekinumab 130 milligram (mg)|Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
11497855|NCT01369342|Experimental|Ustekinumab approximately (~) 6 milligram per kilogram (mg/kg)|Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg) 390 mg (weight > 55 kg and <= 85 kg) and 520 mg (weight > 85 kg).
11497856|NCT01369329|Placebo Comparator|001|Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
11497857|NCT01369329|Experimental|002|Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
11497858|NCT01369329|Experimental|003|Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg) 390 mg (weight > 55 kg and <= 85 kg) and 520 mg (weight > 85 kg).
11497859|NCT01369316|Experimental|Circumferential Submucosal Incision Resection|
11497860|NCT01369316|Active Comparator|Endoscopic Mucosal Resection|Patients randomised into this arm will receive the conventional treatment Endoscopic Mucosal Resection in which the sessile lesion is injected and snared by piecemeal technique.
11497861|NCT01369303|Experimental|Daily dosing|Tenofovir 1% gel will be inserted each day or evening at about the same time with the last study-sex 12 hours after the final dose
11497862|NCT01369303|Experimental|BAT24 dosing|Tenofovir 1% gel will be inserted 1 hour before and 1 hour after sex
11497863|NCT01369303|Experimental|Pericoital dosing|Tenofovir 1% gel will be inserted either 1 hour before sex OR 1 hour after sex
11497864|NCT01369290||Drug 1|Venlafaxine
11497865|NCT01369290||Drug 2|Bupropion
11497866|NCT01369290||Drug 3|Escitalopram
11497867|NCT01369290||Drug 4|Duloxetine
11497868|NCT01369290||Psychotherapy|Cognitive behaviour therapy
11497869|NCT01369277|Experimental|Japanese cohort|A total of 12 Japanese healthy subjects will be allocated to receive 3 ascending single doses (100 mg, 300 mg and 750 mg) of PF-04991532 or placebo through 3 dosing periods in a randomization ratio of 3:1.
11497870|NCT01369277|Experimental|Weterner Cohort|9 western healthy subjects will be enrolled to receive 2 single ascending doses (300 mg and 750 mg) of PF-04991532 through 2 dosing periods.
11497871|NCT01369264|Experimental|True Left High Frequency|True left high frequency repetitive transcranial magnetic stimulation
11497872|NCT01369264|Placebo Comparator|Passive sham left high frequency|Passive sham left high frequency repetitive transcranial magnetic stimulation
11497873|NCT01369251|Experimental|Hygiene with water and soap|
11497874|NCT01369251|Active Comparator|Usual alcohol care|
11497875|NCT01369238|Experimental|Bee Venom Acupuncture & zaltoprofen|
11497876|NCT01369238|Active Comparator|zaltoprofen|
11497877|NCT01369238|Active Comparator|Bee Venom Acupuncture|
11497878|NCT01369225|Experimental|0.5 mg/kg AAB-003|
11497879|NCT01369225|Experimental|1 mg/kg AAB-003|
11497880|NCT01369225|Experimental|2 mg/kg AAB-003|
11497881|NCT01369225|Experimental|4 mg/kg AAB-003|
11497882|NCT01369225|Experimental|8 mg/kg AAB-003|
11497883|NCT01369212|Experimental|Tenofovir|Tenofovir 192 weeks
11497884|NCT01369212|Experimental|Peginterferon-alfa 2a and tenofovir|A combination of peginterferon-alfa 2a plus tenofovir for 24 weeks and then tenofovir only for 168 weeks
11497885|NCT01369199|Experimental|Peginterferon and entecavir|A combination of 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon.
11497886|NCT01369186|Active Comparator|Morphine|Vendal 5 mg i.v. bolus injection
11497887|NCT01369186|Placebo Comparator|Placebo|Sodium chloride 0.9% i.v. bolus injection
11497888|NCT01369173|Active Comparator|Mexican Menu|24 days, all foods and drinks provided, menu consists of traditional mexican meals
11497889|NCT01369173|Active Comparator|US diet|24 days, all foods and drinks provided, menu consists of foods commonly eaten in contemporary United States
11497890|NCT01369160||1|Chronic Transfusion
11497894|NCT01369147|Experimental|Parenteral nutrition energy dose at 0.6x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake [from parenteral nutrition (PN) + dextrose-containing IV fluids (> 500 mL/day) + propofol/clevidipine + any enteral feedings) at 0.6 x resting energy expenditure (REE).
11497895|NCT01369147|Active Comparator|Parenteral nutrition energy dose at 1.0 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake [from parenteral nutrition (PN) + dextrose-containing IV fluids (> 500 mL/day) + propofol/clevidipine + any enteral feedings) at 1.0 x resting energy expenditure (REE).
11497896|NCT01369147|Experimental|Parenteral nutrition energy dose at 1.3 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake [from parenteral nutrition (PN) + dextrose-containing IV fluids (> 500 mL/day) + propofol/clevidipine + any enteral feedings) at 1.3 x resting energy expenditure (REE).
11497897|NCT01369121|Experimental|Xerecept|All patients will receive hCRF (XERECEPT)
11497898|NCT01369108|Experimental|Flowable composite|Flowable composite
11497899|NCT01369108|Active Comparator|Conventional composite|Highly filled conventional composite restorative
11497900|NCT01369095|Active Comparator|Arm 1: Duloxetine / Escitalopram + BMS-820836 placebo|
11497901|NCT01369095|Experimental|Arm 2: BMS-820836 (0.25 mg) + BMS-820836 placebo|
11497902|NCT01369095|Experimental|Arm 3: BMS-820836 (0.50 mg) + BMS-820836 placebo|
11497903|NCT01369095|Experimental|Arm 4: BMS-820836 (1.0 mg) + BMS-820836 placebo|
11497904|NCT01369095|Experimental|Arm 5: BMS-820836 (2.0 mg) + BMS-820836 placebo|
11497905|NCT01369082||CIT Islet Transplantation Recipients|"Subjects who received an islet-cell transplant for Type 1 Diabetes (T1D) while enrolled in one of the Clinical Islet Transplantation (CIT) parent studies and continue to have islet graft function. All subjects will continue immunosuppressive medications under CIT08. Detailed follow-up evaluations including but not limited to islet function will occur on an annual basis.
~The immunosuppressive medications (e.g., tacrolimus, sirolimus, cyclosporine, mycophenolate mofetil [MMF], mycophenolic sodium) in this study are obtained by prescription unless provided by the study through the drug distributor. Generic brands are allowed, when available. Antibacterial, antifungal, and antiviral prophylaxis, insulin therapy, and other standard therapies will be provided per site-specific practices."
11497906|NCT01369069|Experimental|IV insulin drip with target glucose 80 mg/dL - 130 mg/dL|The intervention arm will have a targeted glucose concentration of 80-130 mg/dL. IV insulin drip will be titrated to keep glucose concentration in this range.
11497907|NCT01369069|Active Comparator|Sub Q insulin to keep glucose less than 180 mg/dL|This standard care arm will get sub q insulin sliding scale to keep glucose concentration less than 180 mg/dL
11497908|NCT01369056|Experimental|Advanced Adherence Counseling (AdvAdh)|Please see the Intervention Description section
11497909|NCT01369056|No Intervention|Control|Standard of care (including counseling regarding antiretroviral treatment adherence) received by HIV/AIDS patients at the study clinic
11497910|NCT01369043|Active Comparator|Vitamin E and Vitamin C|4 weeks with Vitamin E and Vitamin C supplementation with no exercise and 4 weeks of supplementation with prescribed exercise.
11497911|NCT01369043|No Intervention|Placebo|Placebos instead of the Vitamin E and Vitamin C supplements
11497912|NCT01369030||Deplin®|Subjects with depression who have been prescribed Deplin® daily.
11497913|NCT01369017|Active Comparator|Anakinra|All subjects will undergo 2 CCRE challenges. Each subject will be given either anakinra or placebo prior to CCRE challenge
11497914|NCT01369017|Placebo Comparator|Placebo|Normal saline injection
11497915|NCT01369004|Experimental|Daily self-weighing + feedback/lessons|Participants will be instructed to weigh daily and they will receive a smart scale for daily monitoring of weighing via the website bodytrace.com. They will also receive weekly emailed lessons with content related to behavioral weight control (e.g., How to control portion sizes, How to develop an exercise routine) as well as weekly emailed feedback from a registered dietitian on their daily weighing and weight loss progress.
11497916|NCT01369004|No Intervention|Delayed Intervention Control Group|Participants will receive the same components of the experimental group with the exception of the weekly feedback after the 6-month study period is complete.
11497917|NCT01368991|Active Comparator|Kryptonite|Sternal closure with stainless steel and kryptonite
11497918|NCT01368991|Active Comparator|Conventional Closure|Sternal closure with stainless steel wires
11497919|NCT01368978|Experimental|Test (with the InsuPatch device)|Device use
11497920|NCT01368978|No Intervention|Control (without the InsuPatch device)|
11497921|NCT01368965|Experimental|Ulthera® System treatment|
11497922|NCT01368952|Active Comparator|Pure Prone Positioning|Sleeping in prone position by pure prone positioning device, which consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
11497923|NCT01368952|No Intervention|Baseline|No intervention for sleep position
11497924|NCT01368926|Experimental|Part 1|
11497925|NCT01368926|Experimental|Part 2|
11497926|NCT01368913||Patients treated with orally disintegrating tablet|
11497927|NCT01368913||Patients treated with tablets|
11497928|NCT01368900|Experimental|Ulthera System Treatment|Ulthera treatment to the upper face.
11497929|NCT01368887|Experimental|1|DPS-102
11497930|NCT01368887|Placebo Comparator|2|Vehicle
11497931|NCT01368887|Active Comparator|3|Calcipotriol Monotherapy
11497932|NCT01368887|Active Comparator|4|Nicotinamide Monotherapy
11497933|NCT01368874|Active Comparator|Group A|Ulthera® System treatment of the submental and submandibular regions at two treatment depths, and the lower neck region at one treatment depth.
11497934|NCT01368874|Active Comparator|Group B|Ulthera® System treatment of skin above the jawline, as well as the submental, submandibular and lower neck regions.
11497935|NCT01368874|Active Comparator|Group C|Ulthera® System treatment of the submental, submandibular, and the lower neck regions at two treatment depths.
11497936|NCT01368861||control|water and normal physical comfort provided by mom
11497937|NCT01368861||sucrose|sugar and normal physical comfort provided by mom
11497938|NCT01368861||physical intervention|physical intervention using the 5 S's and water
11497939|NCT01368861||physical intervention and sucrose|Physical intervention using the 5 S's and sugar water
11497940|NCT01368835|Experimental|Ulthera treatment|
11497941|NCT01368809|Active Comparator|Fentanyl|Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
11497942|NCT01368809|Placebo Comparator|Saline Solution|Saline Solution 2 ml at induction, 1-2 ml boluses as needed
11497943|NCT01368796|Active Comparator|Trivalent Influenza vaccine subunit|The seasonal vaccine (Agriflu, Novartis) contains egg-derived, inactivated and detergent split versions of the 3 influenza strains (tri-valent). It is given into the muscle of the upper arm at a dose of 0.5 mL.
11497944|NCT01368796|Active Comparator|Adjuvanted Tri-valent Influenza Vaccine|The adjuvanted vaccine (Fluad, Novartis) is made with an immune-stimulator (MF59) that contains squalene oil microdroplets and two surfactants, Tween 80 and Span 65. It is given into the muscle of the upper arm at a dose of 0.5 mL.
11497945|NCT01368796|Active Comparator|Intradermal Tri-valent Influenza vaccine|(Intanza 15ug, Sanofi Pasteur) is an inactivated, split-virion influenza vaccine. Strains are grown in fertilized hen's eggs, inactivated with formalin and split using Triton X-100 detergent, as for TIV. The syringe is attached to a micro-needle injection system (Beckton Dickinson) that limits the depth of injection to just under the skin. It is given into the skin over the upper arm at a dose of 0.1 mL.
11497946|NCT01368796|Active Comparator|Trivalent Split-virion Influenza vaccine|Vaxigrip, Sanofi Pasteur is an inactivated, split-virion Influenza vaccine. The 3 influenza strains are grown on fertilized eggs, concentrated, purified in a sugar-like solution, detergent split, and inactivated by formaldehyde, then diluted in phosphate buffered salt solution. A dose of 0.5 mL is given into the muscle of the arm.
11497947|NCT01368783|Experimental|atazanavir|400 mg/day for 2 days
11497948|NCT01368783|Experimental|Atazanavir and Tenofovir|
11497949|NCT01368783|Experimental|Atazanavir and Ritonavir|
11497950|NCT01368783|Experimental|Atazanavir + tenofovir + ritonavir|
11497951|NCT01368770|Experimental|Coronary CTA|Coronary CTA using standard protocols
11497952|NCT01368770|Active Comparator|Stress MPI SPECT|Stress-rest MPI SPECT using standard protocols
11497953|NCT01368744||OSNA Breast Cancer System|
11497954|NCT01368731|No Intervention|nil prophylactic coagulation|
11497955|NCT01368731|Active Comparator|Prophylactic coagulation|
11497956|NCT01368718|Other|Active/Sham CPAP|
11497957|NCT01368705|Active Comparator|Control Group|
11497958|NCT01368705|Experimental|Intervention Group 1|
11497959|NCT01368705|Experimental|Intervention Group 2|
11497960|NCT01368692|Active Comparator|neutral shoulder|neutral shoulder position during subclavian vein catheterization
11497961|NCT01368692|Experimental|shoulder retraction|position of shoulder retraction during subclavian vein catheterization
11497962|NCT01368679|Experimental|Endoprothesis Scitech|"The endoprothesis of SCITECH is a self-expandable stent mixed (laser cut and wire plotted) covered with polyester fabric. The delivery system has lower profile than the existing market and this approach allows the passage of the delivery system through the femoral artery with ease and without dissection. Fixation has proximal and distal securing lower rates of leakage and displacement.
~The delivery system is done by linear drive or screw diameters greater than 30mm"
11497963|NCT01368666|Experimental|Perceval S Valve Prosthesis|Patients who underwent replacement of diseased or malfunctioning native aortic valve with the Perceval S Valve prosthesis
11497964|NCT01368653|Active Comparator|Standard treatment|In this arm, smokers receive a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling sessions to help them quit smoking
11497965|NCT01368653|Experimental|Standard treatment+practice quitting|In this arm, participants receive standard treatment (a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling session) and an experimental treatment that involves practice quitting 7 times prior to a target quit date (for 4-12 hours per day) and returning to smoking by puffing smoke without inhaling.
11497966|NCT01368653|Experimental|Very low nicotine cigarettes|In this condition, smokers from both the Standard treatment and the Standard treatment+practice quitting arms who have smoked in the last 7-days at a 4-week post-target-smoking-cessation-date follow-up interview may be randomly assigned to this group. Those assigned to this group will receive a 6-week supply of cigarettes that contain tobacco with very low levels of nicotine (in regular or menthol flavors) to smoke instead of regular cigarettes containing nicotine. This treatment is designed to help people stop smoking after slipping (returning to smoking) during an attempt to stop smoking
11497967|NCT01368653|No Intervention|Advice and encouragement only|In this condition, smokers from both the Standard treatment and the Standard treatment+practice quitting arms who have smoked in the last 7-days at a 4-week post-target-smoking-cessation-date follow-up interview may be randomly assigned to this condition. Those in this arm will receive advice and encouragement to try to stop smoking again after they have slipped (returned to smoking) during a stop smoking attempt.
11497968|NCT01368640||healthy adults|The study will cover 130 healthy adults. 65 men and 65 women in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
11497969|NCT01368627|Experimental|Supralimus® Sirolimus-Eluting Coronary Stent|
11497970|NCT01368614|Experimental|AVAPS-AE|AVAPS-AE Mode of ventilation
11497971|NCT01368614|Active Comparator|Respironics OmniLab Advanced BiPAP S mode|OmniLab Advanced BiPAP S Mode of ventilation
11497972|NCT01368614|Active Comparator|Respironics OmniLab Advanced CPAP mode|OmniLab Advanced CPAP Mode of ventilation
11497973|NCT01368601|Active Comparator|CPAP (positive airway pressure)|To evaluate if continuous positive airway pressure(CPAP) on the lung undergoing lobectomy can decrease the inflammatory response PPC (postoperative pulmonary complications).
11497974|NCT01368601|No Intervention|Control without CPAP|
11497975|NCT01368588|Active Comparator|Arm I|Patients undergo high-dose radiotherapy of the prostate and seminal vesicles using intensity-modulated radiotherapy (IMRT)* or 3D-conformal radiation therapy (3D-CRT)* once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo permanent prostate implant (PPI) brachytherapy or high-dose rate brachytherapy (I 125 or Pd 103 may be used as the radioisotope).
11497976|NCT01368588|Experimental|Arm II|Patients undergo whole-pelvic radiotherapy (WPRT)* (3D-CRT or IMRT) once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo brachytherapy as in arm I.
11497977|NCT01368575|Active Comparator|subgroup B1|subgroup B1 will receive CABG combined with MV repair with annuloplasty rigid ring
11498112|NCT01367717|Active Comparator|Creatine Monohydrate|Each of the 25 subjects took Creatine Monohydrate.
11497978|NCT01368575|Active Comparator|subgroup B2|B2 - CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus
11497979|NCT01368575|Active Comparator|subgroup A2|CABG combined with MV repair with remodeling annuloplasty rigid ring
11497980|NCT01368575|Active Comparator|subgroup A1|only CABG
11497981|NCT01368575|Active Comparator|subgroup B3|patients in subgroup B3 will be performed CABG and MV replacement with preservation of subvalvular apparatus
11497982|NCT01368562|Experimental|Methylnaltrexone|Participants will receive single dose of MNTX 0.15 milligrams per kilogram (mg/kg) subcutaneously (SC). Subsequent dosing could be adjusted upward (to a maximum of 0.3 mg/kg) to achieve a desired clinical response or decreased to improve tolerability.
11497983|NCT01368549||Metanx®|Subjects with Diabetic Peripheral Neuropathy who have been prescribed Metanx® daily.
11497984|NCT01368536|Experimental|Valturna|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks.
11497985|NCT01368536|Active Comparator|Valturna + Amlodipine|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks.
11497986|NCT01368536|Active Comparator|Valturna + chlorthalidone|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks.
11497987|NCT01368523|Experimental|nilotinib|
11497988|NCT01368510|Experimental|OCD Active CBT|Adults with obsessive-compulsive disorder (OCD) will be treated with cognitive-behavioral therapy (CBT) from the time of enrollment.
11497989|NCT01368510|Active Comparator|OCD Waitlist|Adults with OCD will receive waitlist treatment at enrollment. Nonresponders will cross over to CBT.
11497990|NCT01368510|No Intervention|Healthy Control|Healthy control adults will be given no intervention.
11497991|NCT01368497|Experimental|Entecavir and peginterferon|Entecavir for 8 weeks followed by 40 weeks of both entecavir and peginterferon
11497992|NCT01368484|Placebo Comparator|Sunflower oil|
11497993|NCT01368484|Experimental|Docosahexanoic acid|
11497994|NCT01368471|Experimental|MGuard|MGuard stent will be deployed
11497995|NCT01368471|Active Comparator|BMS or DES|A regular bare metal stent or drug-eluting stent will be deployed
11497996|NCT01368458|Experimental|Conversion to mono therapy|Conversion from 2 to 1 antipsychotic
11497997|NCT01368458|No Intervention|control|No change in antipsychotics
11497998|NCT01368445|Active Comparator|MP03-36 Nasal Spray|azelastine hydrochloride 0.15%
11497999|NCT01368445|Active Comparator|MP03-36 and Placebo Nasal Spray|azelastine hydrochloride 0.15% and Placebo
11498000|NCT01368445|Active Comparator|Azelastine 0.1%, Nasal Spray|Azelastine 0.1%, Nasal Spray
11498001|NCT01368445|Placebo Comparator|Placebo Nasal Sapray|0mg, 2 sprays per nostril twice daily AM & PM)
11498002|NCT01368432|Placebo Comparator|Placebo|Daily for 12 weeks
11498003|NCT01368432|Experimental|Escitalopram|Escitalopram 10 mg or 20 mg daily for 12 weeks
11498004|NCT01368419|Experimental|Treatment|
11498005|NCT01368406|Experimental|wellness program|12-week weight management intervention in patients with severe mental disorders. In the 1-hour weekly group sessions topics like dietary choices, lifestyle, physical activity and self-esteem were discussed with outpatients and their relatives
11498006|NCT01368406|No Intervention|treatment as usual|patients were on regular visits on psychiatrist
11498007|NCT01368393|Experimental|Electroacupuncture|
11498008|NCT01368393|Active Comparator|Sham acupuncture|
11498009|NCT01368380|Experimental|Psychological Intervention|
11498010|NCT01368380|No Intervention|Usual care|
11498011|NCT01368367|Active Comparator|Intensive exercise group|
11498012|NCT01368367|Placebo Comparator|Stretch exercise only|
11498013|NCT01368354|Active Comparator|CLTS Arm|To induce behavioural changes by confronting the community with their open defecation behaviour. This will lead to voluntary construction and use of latrines and improved hygiene behaviour. CLTS involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination.
11498014|NCT01368354|No Intervention|Control arm|
11498015|NCT01368341|Active Comparator|Doxycycline|Doxycycline, 100 mg, tablets, b.i.d., 14 days
11498016|NCT01368341|Active Comparator|Penicillin|Phenoxymethylpenicillin tablets 650 mg. 2 tablets t.i.d. 14 days
11498017|NCT01368341|Active Comparator|Amoxicillin|Amoxicillin 500 mg capsula, t.i.d., 14 days
11498018|NCT01368328|Placebo Comparator|Placebo|
11498019|NCT01368328|Active Comparator|Chromium nicotinate 50 mcg|
11498020|NCT01368328|Active Comparator|Chromium nicotinate 200 mcg|
11498021|NCT01368315|Experimental|CT327|Cream
11498022|NCT01368315|Placebo Comparator|Placebo|Cream (Vehicle only)
11498023|NCT01368315|Active Comparator|Active comparator|Cream
11498024|NCT01368315|No Intervention|No intervention|
11498025|NCT01368302|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to normalize threat-related attention biases.
11498026|NCT01368302|Placebo Comparator|Placebo|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns.
11498027|NCT01368289||Colonic Polyps|Patients who present with colonic polyps >20mm
11498113|NCT01367717|Active Comparator|Creatine Ethyl Ester|Each of the 25 subjects took Creatine Ethyl Ester.
11499031|NCT01361061||patients with liver cirrhosis|
11498028|NCT01368276|Active Comparator|GM-CSF|Granulocyte macrophage colony-stimulating factor (GM-CSF) was administered at a dose of 125 μg/m²/day subcutaneously for 14 consecutive days followed by 14 days of rest, in 28-day treatment cycles for up to 12 months or until a complete response, occurrence of an unacceptable toxicity, death or another criterion for withdrawal from treatment was met. Participants who demonstrated a partial response after being on treatment for 12 months could continue to be treated until disease progression or another treatment discontinuation criterion was met.
11498029|NCT01368276|Experimental|Talimogene Laherparepvec|Talimogene laherparepvec was administered at a concentration of 10⁸ plaque forming units (PFU)/mL injected into 1 or more skin or subcutaneous tumors on Days 1 and 15 of each 28-day cycle for up to 12 months or until a complete response, occurrence of an unacceptable toxicity, death or another criterion for withdrawal from treatment was met. Participants who demonstrated a partial response after being on treatment for 12 months could continue to be treated until disease progression or another treatment discontinuation criterion was met.
11498030|NCT01368263|Experimental|Group 1 (Ki67 <10%, E2 <= 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Neoadjuvant treatment repeats every 28 days for a total of 16-18 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Recommendations for postsurgical treatment will be based on PEPI score and physician discretion.
11498031|NCT01368263|Experimental|Group 2 (Ki67 >= 10%, E2 <= 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Patients receive standard neoadjuvant chemotherapy in the absence of disease progression or unacceptable toxicity. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Postsurgical treatment at physician discretion.
11498032|NCT01368263|Experimental|Group 3 (E2 > 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Patients receive standard neoadjuvant therapy at the discretion of the physician. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Postsurgical treatment at physician discretion.
11498033|NCT01368250||1|Elderly patients with symptomatic severe aortic stenosis, deemed at high risk for conventional aortic valve replacement
11498034|NCT01368237||Patients|Patients awaiting invasive coronary angiography
11498035|NCT01368224|Placebo Comparator|Maltodextrin|
11498036|NCT01368224|Experimental|Lactobacillus paracasei NCC 2461 (ST 11)|1x1010 CFU of Lactobacillus paracasei NCC 2461 (ST 11)
11498037|NCT01368224|Experimental|Lactobacillus paracasei+ Bifidobacterium longum|1x1010 CFU of Lactobacillus paracasei NCC 2461 (ST 11) + 1x1010 CFU of Bifidobacterium longum (NCC3001)
11498038|NCT01368211|Active Comparator|Mirasol first, then Reference|This study arm will receive first a 2-4-day-old Mirasol-treated platelets transfusion and then a reference 2-4-day-old untreated platelets transfusion (Mirasol-Reference sequence).
11498039|NCT01368211|Active Comparator|Reference first, then Mirasol|This study arm will receive first a reference 2-4-day-old untreated platelets transfusion and then a 2-4-day-old Mirasol-treated platelets transfusion (Reference-Mirasol sequence).
11498040|NCT01368198|Active Comparator|Ocular Emulsion|An Ocular Emulsion
11498041|NCT01368198|Active Comparator|OPTIVE™|An OPTIVE™
11498042|NCT01368185||All Participants|Participants with hypertension who had been treated with MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg) for at least three months
11498043|NCT01368172|Experimental|Physical Activity Guidelines|Participants randomized to this arm received training/guidance on following the physical activity guidelines for adults with spinal cord injury
11498044|NCT01368172|No Intervention|Control|
11498045|NCT01368159|Active Comparator|pressure centred at 25 mm Hg|
11498046|NCT01368159|Active Comparator|pressure between 20 and 36 mm Hg|
11498047|NCT01368159|Placebo Comparator|pressure between 10 and 15 mm Hg|
11498048|NCT01368146|Experimental|IV Clear™|
11498049|NCT01368146|Active Comparator|Tegaderm CHG™|
11498050|NCT01368146|Placebo Comparator|Control Vehicle Dressing|
11498051|NCT01368120|Experimental|IV Clear™|
11498052|NCT01368120|Active Comparator|Tegaderm CHG™|
11498053|NCT01368120|Placebo Comparator|Vehicle Control Dressing|
11498054|NCT01368107|Placebo Comparator|Placebo Arm|the patients will receive Placebo before the 1st and during the 3rd CT cycle (N=6)
11498055|NCT01368107|Experimental|CYT107 treatment before CT|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle and the placebo during the 3rd CT cycle (N=6)
11498056|NCT01368107|Experimental|CYT107 treatment during CT|patients will receive the placebo before the 1st CT cycle and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (N=6)
11498057|NCT01368107|Experimental|CYT107 treatment before and during CT|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (N=6).
11498058|NCT01368094|Active Comparator|Standard drainage|
11498059|NCT01368094|Experimental|Short drainage|
11498060|NCT01368081|Experimental|BI 10773 low dose|BI 10773 low dose tablet once daily
11498061|NCT01368081|Experimental|BI 10773 high dose|BI 10773 high dose tablet once daily
11498062|NCT01368081|Active Comparator|Metformin|Metformin tablets 500-2250 mg a day (twice or three times per day)
11498063|NCT01368068|Experimental|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial.
11498064|NCT01368068|Active Comparator|Escitalopram|10mg of escitalopram will be taken by participants daily for the duration of the 12 week trial period.
11498065|NCT01368068|Placebo Comparator|Placebo|Placebo arm containing sweetener has been approved and will be used as placebo arm.
11498066|NCT01368055|Experimental|Low Risk|70 Gy/CGE
11498067|NCT01368055|Experimental|Intermediate Risk|72.5 Gy/CGE
11498068|NCT01368042||Chronic Kidney Disease, Secondary Hyperpathyroidism|All eligible participants treated with paricalcitol iv according to the approved Summary of Product Characteristics (SmPC)
11498211|NCT01367028|Other|A: Trastuzumab+Docetaxel|
11498212|NCT01367028|Experimental|B: Trastuzumab+Docetaxel+Bevacizumab|
11498069|NCT01368029|Experimental|LGG|Lactobacillus rhamnosus GG (LGG) containing 1x10^10 LGG per capsule will be given to volunteers with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day on an outpatient basis.
11498070|NCT01368029|Placebo Comparator|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis.
11498071|NCT01368016|Experimental|Experimental NRT|A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits.
11498072|NCT01368016|Active Comparator|Nicotine GUM|A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits.
11498073|NCT01368003|Experimental|STA9090 with Dutasteride|STA9090 with Dutasteride
11498074|NCT01368003|Experimental|STA9090|STA9090
11498075|NCT01367990|Experimental|Norepinephrine|
11498076|NCT01367977||Ehlers-Danlos patients|Patients with diagnosed or suspected Classic or Hypermobile Ehlers-Danlos Syndrome
11498077|NCT01367964|Experimental|ACTH treatment|Infants with a Type 3 EEG (pre-hypsarhythmia) will be treated with ACTH for 2 weeks.
11498078|NCT01367951|Experimental|Surgical fixation|"The fractures will be reduced and stabilized by use of plates and screws
~Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.
~Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.
~Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted."
11498079|NCT01367951|No Intervention|non-operative|"Mechanical ventilation: Patients in respiratory distress will receive endotracheal intubation, and placed on mechanical ventilation. PEEP will be utilized as needed, at the discretion of the ICU and respiratory therapy team.
~Other conservative means/Pulmonary toilet:Patients will receive aggressive pulmonary toilet (suctioning of ET tube as needed), chest physiotherapy (as per standard local protocol), and will have the head of the bed elevated to 30° unless contraindicated (ie unstable C-spine injury).
~Pain control:Epidural catheters, intercostal nerve block, PCA, IV/PO pain medication"
11498080|NCT01367938||OMNI Apex Ultracongruent Knee Device|
11498081|NCT01367925||Cruciate Substituting Tibial Insert|
11498082|NCT01367925||Posterior Stabilized Tibial Insert|
11498083|NCT01367912|No Intervention|Progesterone only group|received a single daily application of vaginal progesterone gel beginning from the day of OPU and continued at least until pregnancy was ruled out by a negative serum ß-hCG measurement performed on the 14th day after embryo transfer with no E2 added
11498084|NCT01367912|Active Comparator|Progesterone+Early Estradiol group|received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
11498085|NCT01367912|Active Comparator|Progesterone+Late estradiol group|received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel
11498086|NCT01367899||CONSERVE® Plus hip resurfacing|Recipients/C Plus (IDE)study
11498087|NCT01367886|Other|Fesoterodine|Females with overactive bladder symptoms will be given Fesoterodine 4 mg. daily for six weeks.
11498088|NCT01367873|Placebo Comparator|Placebo|
11498089|NCT01367873|Experimental|VIA-3196|Multiple, single-dose, ascending dosing groups (cohorts) will be evaluated.
11498090|NCT01367873|Experimental|VIA-3196 with Food|Second, single dose administered after a standard high-fat breakfast.
11498091|NCT01367873|Placebo Comparator|Placebo with Food|
11498092|NCT01367860|Active Comparator|OMicro|This group will be formed by randomization, which gets out surgery to open microdiscectomy
11498093|NCT01367860|Experimental|SJet|This group will be formed by randomization, and receive the discectomy procedure addressed by the technique of Percutaneous Diskectomy SpineJet
11498094|NCT01367847|Active Comparator|Helping the Noncompliant Child (HNC)|Standard HNC (see HNC Arm/Title) Program plus Technology-Enhancement (smartphones, which are being used for mid-week video calls to check-in re: skill-building, videotaping of family practice of skills at home, daily surveys re: skills practice & child behavior, reminders re: practice & sessions.
11498095|NCT01367847|Experimental|Technology-Enhanced HNC (TE-HNC)|Standard HNC (see HNC Arm/Title) Program plus Technology-Enhancement (smartphones, which are being used for mid-week video calls to check-in re: skill-building, videotaping of family practice of skills at home, daily surveys re: skills practice & child behavior, reminders re: practice & sessions.
11498096|NCT01367834|Experimental|Growth Hormone|Subjects in the somatotropin (growth hormone, GH) arm will receive GH injections from 12-24 months of life.
11498097|NCT01367834|No Intervention|Control|Subjects will receive no GH or placebo.
11498098|NCT01367821||Patients with obstructive jaundice|Patients with obstructive jaundice
11498099|NCT01367821||Healthy volunteers|Healthy volunteers
11498100|NCT01367808|Placebo Comparator|Placebo|
11498101|NCT01367808|Active Comparator|Vorikonazole|
11498102|NCT01367808|Active Comparator|Posakonazole|
11498103|NCT01367795||palliative tumor disease|Patients in a known palliative setting with symptoms due to tumor growth.
11498104|NCT01367782|Active Comparator|Active repetitive Transcranial Stimulation|Each patient will be given 12 stimulation sessions, over a period of 4 weeks, and then a maintenance phase consisting of 8 stimulation sessions for the first 4 weeks and additional 4 stimulation sessions during the following 4 weeks.
11498105|NCT01367782|Sham Comparator|Sham Stimulation|The control arm group will receive sham stimulations in identical treatment and maintenance schedules.
11498106|NCT01367769||Thrombosis|"Patients with acute, idiopathic or provoked, unilateral proximal DVT (involving the popliteal vein or further proximal veins) and SVT of the lower-extremity detected with duplex ultrasound.
~Age and sex matched controls (volunteers)"
11498107|NCT01367756|Experimental|1|
11498108|NCT01367756|Placebo Comparator|2|
11498109|NCT01367743|Active Comparator|epinephrine|
11498110|NCT01367743|Active Comparator|norepinephrine|
11498111|NCT01367730||osteoporosis and osteopenia|Subjects will be stratified based on DXA BMD T-scores.
11498213|NCT01367028|Experimental|C: Trastuzumab+Docetaxel+NPLD|
11498114|NCT01367704|Active Comparator|Control School|Control schools (where the coaches do not receive the Coaching Boys into Men (CBIM) training until following academic year 'wait list control')
11498115|NCT01367704|Experimental|Intervention School|Intervention schools (where coaches receive the CBIM training at start of sports season)
11498116|NCT01367678|Experimental|Laryngeal Mask Airway Supreme|Directly measured mucosal pressures
11498117|NCT01367678|Experimental|i-Gel|Directly measured mucosal pressures
11498118|NCT01367665|Experimental|Vismodegib - Locally Advanced|Participants received vismodegib 150 mg orally once a day until one of the following occurs: Disease progression, intolerable toxicity most probably attributable to vismodegib, consent withdrawal, death, study termination by the Sponsor, or other reason deemed by the Investigator. vismodegib: 150 mg once daily until disease progression or unacceptable toxicity
11498119|NCT01367665|Experimental|Vismodegib - Metastatic|Participants received vismodegib 150 mg orally once a day until one of the following occurs: Disease progression, intolerable toxicity most probably attributable to vismodegib, consent withdrawal, death, study termination by the Sponsor, or other reason deemed by the Investigator. vismodegib: 150 mg once daily until disease progression or unacceptable toxicity
11498120|NCT01367652|Active Comparator|Letrozole|2.5 mg tablet
11498121|NCT01367652|Active Comparator|Femara|2.5 mg tablet
11498122|NCT01367639|Experimental|intervention|Inquiry Based Stress Reduction (IBSR) program
11498123|NCT01367626|Active Comparator|letrozole|2.5 mg tablet
11498124|NCT01367626|Active Comparator|Fermara|2.5 mg tablet
11498125|NCT01367613|Experimental|Arm 1|
11498126|NCT01367600|Experimental|Arm 1|
11498127|NCT01367587|Experimental|Arm 1|
11498128|NCT01367574|Experimental|Arm 1|
11498129|NCT01367574|Experimental|Arm 2|
11498130|NCT01367574|Experimental|Arm 3|
11498131|NCT01367561|Experimental|Arm 1|
11498132|NCT01367561|Experimental|Arm 2|
11498133|NCT01367561|Placebo Comparator|Arm 3|
11498134|NCT01367548|Experimental|Arm 1|
11498135|NCT01367548|Placebo Comparator|Arm 2|
11498136|NCT01367535|Experimental|Arm 1|
11498137|NCT01367535|Experimental|Arm 2|
11498138|NCT01367535|Active Comparator|Arm 3|
11498139|NCT01367535|Placebo Comparator|Arm 4|
11498140|NCT01367522|Experimental|Arm 1|
11498141|NCT01367509|Experimental|Arm 1|SC Methylnaltrexone (MNTX)
11498142|NCT01367496|Experimental|Arm 1|
11498143|NCT01367496|Experimental|Arm 2|
11498144|NCT01367496|Experimental|Arm 3|
11498145|NCT01367496|Experimental|Arm 4|
11498146|NCT01367483|Experimental|Arm1|MNTX active treatment
11498147|NCT01367470|Active Comparator|VSL#3 probiotic preparation|30 mothers in the last 4 weeks of gestation and in the first month of breastfeeding will be given (after obtaining their informed consent) 1 sachet per day of probiotics (VSL#3) during the last four weeks of pregnancy and the first month of breastfeeding for four weeks under the usual fasting dosage scheme (1 sachet before meal).
11498148|NCT01367470|Placebo Comparator|Placebo VSL#3|30 mothers in the last 4 weeks of gestation and in the first month of breastfeeding will be given (after obtaining their informed consent) a placebo comparable to VSL#3 during the last four weeks of pregnancy and the first month of breastfeeding for four weeks under the usual fasting dosage scheme (1 sachet/day, before meal)
11498149|NCT01367457||Patients that received treatment with Temsirolimus|Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
11498150|NCT01367444|Experimental|SAR422459 (Dose 1)|Starting dose of SAR422459 given through subretinal injection
11498151|NCT01367444|Experimental|SAR422459 (Dose 2)|Escalating dose of SAR422459 given through subretinal injection
11498152|NCT01367444|Experimental|SAR422459 (Dose 3)|Maximum tolerated dose (MTD) of SAR422459 given through subretinal injection
11498153|NCT01367431||20 mg|Single dose 20 mg Xanthohumol
11498154|NCT01367431||60 mg|Single dose 60 mg Xanthohumol
11498155|NCT01367431||180 mg|Single dose 180 mg Xanthohumol
11498156|NCT01367418|Experimental|Thoracic Epidural Analgesia (TEA)|TEA is used for perioperative pain management, having been used both intra- and postoperatively, up to 48 h.
11498157|NCT01367418|Active Comparator|Patient controlled analgesia (PCA)|PCA is the standard of pain management and is usually used for up to 48 h postoperative for pain management following radical prostatectomy.
11498158|NCT01367405|Experimental|surgical decompression|surgical decompression within 24 hours post-injury
11498159|NCT01367405|Active Comparator|Conservative treatment|Normal conservative treatment without surgical intervention
11498160|NCT01367392|Experimental|interventional procedure|The patients undergo the required interventional procedure, biopsy or ablation
11498161|NCT01367379||Physician of internal medicine in Taipei city hospital|
11498162|NCT01367366||Mediastinal malignant lymphadenopathy|
11498163|NCT01367353|Experimental|ovarian cancer|
11498164|NCT01367340|Experimental|Exercise and physical activity|
11498165|NCT01367340|Active Comparator|Exercise only|
11498166|NCT01367327|Experimental|Exercise with music|Loaded sit-to-stand exercise with music for 6 weeks
11498167|NCT01367327|Active Comparator|Exercise without music|Loaded sit-to-stand exercise without music for 6 weeks
11498168|NCT01367314|Experimental|NVC-422 Dermal Gel, 1.5%|
11498169|NCT01367314|Experimental|NVC-422 Dermal Gel, 0.5%|
11498170|NCT01367314|Experimental|NVC-422 Dermal Gel, 0.1%|
11498171|NCT01367301|Experimental|Treatment (paclitaxel, carboplatin, radiotherapy)|"CHEMOTHERAPY (weeks 1-9, 14-22): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 14-22.
~RADIATION THERAPY (weeks 8-16): Patients undergo external beam pelvic radiation therapy once a day, 5 days a week for 5 weeks during weeks 8-13. Patients then undergo HDR brachytherapy or IMRT once weekly during weeks 14-16."
11498172|NCT01367288|Experimental|A (Neoadjuvant therapy + Zometa)|Patients will be treated every 3 weeks (+/- 2 days ) for 8 cycles in total. The 4 first cycles : Zometa 4 mg (in a 15 min. infusion) + doxorubicin (60 mg/m²) + cyclophosphamide (600 mg/m²). The 4 last cycles with Zometa 4 mg (in a 15 min. infusion) + docetaxel (100 mg/m²)
11498173|NCT01367288|Active Comparator|B (Neoadjuvant therapy)|Patients will be treated every 3 weeks (+/- 2 days) for 8 cycles in total. The 4 first cycles : doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²). The 4 last cycles with docetaxel (100 mg/m²)
11498174|NCT01367275|Experimental|Brivanib + Irinotecan|Brivanib 800 mg orally daily Days 1-14, and Irinotecan intravenously 180 mg/m^2 on Day 1.
11498175|NCT01367262|Experimental|Radiolabeled LY2886721|Single 25 milligram (mg) oral dose containing 80 microCuries of radiolabeled LY2886721
11498176|NCT01367249|Experimental|Bromfenac Ophthalmic Solution|Bromfenac ophthalmic solution 0.07% one drop into study eye, once daily (QD) starting the day before cataract surgery and continued for 14 days post surgery for a total of 16 days.
11498177|NCT01367249|Placebo Comparator|Placebo|One drop of placebo into study eye, once daily (QD) starting the day before cataract surgery and continued for 14 days post surgery for a total of 16 days.
11498178|NCT01367236|Active Comparator|standard care|"treatment with:
~atazanavir 300 mg daily
~ritonavir 100 mg daily
~tenofovir 245 mg daily*
~emtricitabine 200 mg daily* * as the fixed dose combination Truvada™"
11498179|NCT01367236|Active Comparator|Novel therapeutic approach|"darunavir 800 mg daily
~ritonavir 100 mg daily
~lamivudine 300 mg daily**
~abacavir 600 mg daily**
~maraviroc 150 mg once daily ** as the fixed dose combination Kivexa ™"
11498180|NCT01367223|Experimental|solution of amino acids with glutamine|Group 1 as the experimental group who will be administered a solution of amino acids supplemented with glutamine
11498181|NCT01367223|Other|amino acids solution without glutamine|Group 2:control group will be administered a solution of amino acids (Aminoven Infant® or Vamin®) not supplemented with glutamine
11498182|NCT01367210|Experimental|MARAVIROC, DARUNAVIR/r|"Treatment simplification from a standard combined antiretroviral therapy including 3 drugs to Maraviroc plus Darunavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy"
11498183|NCT01367210|Sham Comparator|current ART with 3 drugs|Patients on HAART with three drugs and HIV RNA below 50 copies/mL
11498184|NCT01367197|No Intervention|No intervention|Observation only
11498185|NCT01367197|Experimental|Exercise training group|Group exercise training, three times weekly high-intensity
11498186|NCT01367158|Experimental|3ABCWY|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of the same in current study
11498187|NCT01367158|Experimental|2ABCWY|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of Tdap in current study
11498188|NCT01367158|Experimental|3ABx2CWY|two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of the same in current study
11498189|NCT01367158|Experimental|2ABx2CWY|two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of Tdap in current study
11498190|NCT01367158|Experimental|3ABCWY+OMV|Two doses Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus outer membrane vesicles (OMV) in previous study and one dose of the same in current study
11498191|NCT01367158|Experimental|2ABCWY+OMV|Two doses Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus outer membrane vesicles (OMV) in previous study and one dose of Tdap in current study
11498192|NCT01367158|Experimental|3ABCWYqOMV|Two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of outer membrane vesicles (qOMV) in previous study and one dose of the same in current study
11498193|NCT01367158|Experimental|2ABCWYqOMV|Two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of outer membrane vesicles (qOMV) in previous study and one dose of Tdap in current study
11498194|NCT01367158|Active Comparator|3B|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine in previous study and one dose of the same in current study
11498195|NCT01367158|Active Comparator|2B|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine in previous study and one dose of Tdap in current study
11498196|NCT01367158|Active Comparator|1ACWY|One dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine followed by one dose of placebo and one dose of Tdap in current study
11498197|NCT01367145|Active Comparator|Omacor|
11498198|NCT01367145|Placebo Comparator|Placebo|
11498199|NCT01367119|Active Comparator|Ketamine|Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic prior to electroconvulsive therapy (ECT).
11498200|NCT01367119|Active Comparator|Methohexital|Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic prior to electroconvulsive therapy.
11498201|NCT01367106|Experimental|exposed offspring|
11498202|NCT01367106|Other|controls|
11498203|NCT01367093||ICU patients admitted for severe illness|
11498204|NCT01367080|Experimental|A Group|"1st administration - DWETR10
~2nd administration - DWETR25"
11498205|NCT01367080|Experimental|B Group|"1st administration - DWETR25
~2nd administration - DWETR10"
11498206|NCT01367067||Psychometric Questionnaire|Adult inpatients and outpatients with a clinical indication of any part of the body who have been referred to Charité for MR imaging and have filled out a psychometric questionnaire
11498207|NCT01367067||No Psychometric Questionnaire|Adult inpatients and outpatients with a clinical indication of any part of the body who have been referred to Charité for MR imaging and did not fill out a psychometric questionnaire
11498208|NCT01367054|Experimental|Metformin|500 mg
11498209|NCT01367041|Experimental|Bone loss|Postmenopausal women with osteoporosis, whole body vibration will be applied at 40 Hz, 2mm amplitude, 30+30s
11498210|NCT01367041|Experimental|Normal|Postmenopausal women without osteoporosis, whole body vibration will be applied at 40 Hz, 2mm amplitude, 30+30s
11498215|NCT01367015|Experimental|Early Feeding|Early feeding group received minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours after randomization followed by regular feeding with feed increments of 20ml/kg/day to reach 150 ml/kg.
11498216|NCT01367015|Active Comparator|Late feeding|Late feeding group was kept NPO for a period of 48 hours after randomization followed by minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours and thereafter received regular feeding with feed increments of 20ml/kg/day till full enteral feeds of 150 ml/kg/day were achieved
11498217|NCT01367002|Active Comparator|Carboplatin/Paclitaxel|Chemotherapy
11498218|NCT01367002|Experimental|Trastuzumab|Monoclonal antibody
11498219|NCT01366989||Total Ankle Arthroplasty with calcaneal stem|Patients received the TAA with calcaneal stem between 12/6/05 & 11/13/07 at approximately 28 sites.
11498220|NCT01366976|Placebo Comparator|Placebo|
11498221|NCT01366976|Active Comparator|Acetaminophen|Acetaminophen will ge given as 1g every 6 hours for 4 doses over a 24 hours study period
11498222|NCT01366963||Normal Controls / Healthy Volunteers|Age and gender matched individuals without postural orthostatic tachycardia syndrome
11498223|NCT01366963||Patients with Postural Tachycardia Syndrome (POTS)|Individuals with Postural Tachycardia Syndrome
11498224|NCT01366950|Experimental|Excercise group|
11498225|NCT01366950|No Intervention|Reference|
11498226|NCT01366924|No Intervention|Muscle protein turnover and intracellular signaling at rest|Muscle protein turnover and intracellular signaling are measured at rest for comparison to post-exercise muscle metabolism.
11498227|NCT01366924|Active Comparator|Muscle metabolism after endurance exercise|Post-exercise muscle protein metabolism was measured to determine if endurance exercise affects muscle metabolism compared to rest.
11498228|NCT01366924|Experimental|Muscle Metabolism after endurance exercise|Muscle metabolism response to endurance exercise with essential amino acid supplementation
11498229|NCT01366924|Experimental|Muscle anabolism after endurance exercise|Muscle anabolism after endurance exercise with essential amino acid supplementation.
11498230|NCT01366911||stem cell QCT testing|
11498231|NCT01366898|Experimental|Chemotherapy|
11498232|NCT01366885|Experimental|Intervention during pregnancy|5000 IU Vitamin D3 to be given to the mother during pregnancy. 7000 IU Vitamin D3 to be given during breast feeding if breast feeding. If not breastfeeding, infant to be given 400 IU Vitamin D3 during first year of age, then increased to 1000 IU D3 until completion of research trial.
11498233|NCT01366859|Experimental|Whey Protein (Immunocal®)|The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
11498234|NCT01366859|Placebo Comparator|Placebo: Rice Protein|The control or placebo study arm will consist of thirty children who will receive a dose of 0.5 g/kg of weight a day up to 18 kg of weight a day or a dose of 10 g/day for those over 18 kg for three months.
11498235|NCT01366846|Experimental|Peanut avoidance after continuous peanut consumption|These participants were the peanut consumption group of the ITN032AD (LEAP) study
11498236|NCT01366846|Experimental|Continued peanut avoidance|These participants were the peanut avoidance group of the ITN032AD (LEAP) study
11498237|NCT01366833|Active Comparator|Self-expanding stent alone|All patients in Arm A will receive self-expanding stent alone
11498238|NCT01366833|Experimental|Brachytherapy and Stent therapy|
11498239|NCT01366820|Experimental|NNZ-2566|20 mg/kg intravenous bolus infusion of NNZ-2566 over 10 minutes followed by a continuous intravenous infusion of 6 mg/kg/h (n=133) intravenous infusion of NNZ-2566 for a total of 72 consecutive hours.
11498240|NCT01366820|Placebo Comparator|Sodium Chloride (0.9%) for Injection|Intravenous bolus infusion of Sodium Chloride (0.9%) for Injection over 10 minutes followed by a continuous intravenous infusion of Sodium Chloride (0.9%) for Injection for a total of 72 consecutive hours.
11498241|NCT01366794|Experimental|Type 2 diabetes|Administration of macronutrients in type 2 diabetes
11498242|NCT01366794|Experimental|Healthy volunteers|Administration of macronutrients in healthy volunteers
11498243|NCT01366781|Experimental|Healthy males|Meal ingestion in healthy males
11498244|NCT01366781|Experimental|Healthy females|Meal ingestion in healthy females
11498245|NCT01366768|Experimental|Oral amino acid mixture|Oral administration of amino acid mixture in healthy volunteers
11498246|NCT01366768|Experimental|Intravenous amino acid administration|Intravenous infusion of amino acid mixture in healthy volunteers
11498247|NCT01366742||HPV Cohort|Sexually active young women aged 12 to 22 years of age without a previous history of CIN. Women are not eligible for entry if pregnant or known immunosuppression.
11498248|NCT01366729|Experimental|TheraTogs|
11498249|NCT01366729|Active Comparator|Cane walking|
11498250|NCT01366716|Experimental|Voucher CM|Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
11498251|NCT01366716|Experimental|Cash CM|Participants in the cash CM condition will be assigned to the identical 12-week escalating schedule of reinforcement, except that the contingencies will be provided in cash rather than vouchers, and no negotiation process will be involved (although counselors may recommend how clients might best spend their money).
11498252|NCT01366716|No Intervention|Non-CM Control|Participants in the non-CM control condition will provide urine specimens during the 12-week period as do the two experimental conditions, but will receive no contingent rewards other than praise from the RAs.
11498253|NCT01366703||heart failure patients|stable heart failure patients, NYHA 1-2, EF > 35%, no AF, No OAC, CHADS score >2
11498254|NCT01366690|Experimental|Peer Support|Peer supporter assigned to participant.
11498255|NCT01366690|No Intervention|Standard of Care|No peer assigned. Current standard of care.
11498256|NCT01366677|Experimental|Yoga Therapy|
11498257|NCT01366664|Experimental|001|Treatment sequence 1 Treatment Period 1 (stable dose of terazosin [2 to 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2 to 10 mg] + placebo administered orally once daily for 5 days)
11499025|NCT01361126|Experimental|On-demand|The routine prophylactic therapy interval is targeted at every 7 days.
11498258|NCT01366664|Experimental|002|Treatment sequence 2 Treatment Period 1 (stable dose of terazosin [2 to 10 mg] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2 to 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days)
11498259|NCT01366651|Experimental|Doripenem|Doripenem Type=exact number unit=mg/kg number=10 form=solution for injection route=intravenous use every 8 hours for 2 days (total of 5 doses) for patients <12 weeks of age.Doripenem 500-mg sterile powder will be supplied for the study in single use glass vials.,Doripenem Type=exact number unit=mg/kg number=30 form=solution for injection route=intravenous use every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to <1 year of age. Doripenem 500-mg sterile powder will be supplied for the study in single use glass vials.
11498260|NCT01366638|Experimental|Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks), followed by PR until Week 24 or Week 48. Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
11498261|NCT01366638|Experimental|Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
11498262|NCT01366638|Experimental|Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.
11498263|NCT01366625|Experimental|Renal Denervation|Renal Denervation and maintenance of anti-hypertensive medications and continuous positive airway pressure therapy
11498264|NCT01366625|No Intervention|Maintenance of Medications|Maintenance of anti-hypertensive medications and continuous positive airway pressure therapy
11498265|NCT01366612|Active Comparator|Group 1|FLUDARABINE AND BUSULFAN
11498266|NCT01366612|Experimental|Group 2|FLUDARABINE, BUSULFAN AND LOW DOSE TOTAL BODY IRRADIATION
11498267|NCT01366599||Patients enrolled in IHCIS in 2006|Patients enrolled in IHCIS in 2006
11498268|NCT01366573|Experimental|GSK1521498 &amp; alcohol|GSK1521498 20 mg and alcohol (0.5g/kg ethanol mixed with orange juice)
11498269|NCT01366573|Experimental|GSK1521498 & orange juice|GSK1521498 20 mg and orange juice approximately matching alcoholic beverage for volume and colour
11498270|NCT01366573|Experimental|Placebo &amp; alcohol|Placebo and alcohol (0.5g/kg ethanol mixed with orange juice)
11498271|NCT01366573|Placebo Comparator|Placebo &amp; orange juice|Placebo and orange juice approximately matching alcoholic beverage for volume and colour
11498272|NCT01366560|Experimental|GSK962040|The subjects will be administered GSK962040 125 mg tablet as a single dose on Day 1 of study treatment visit. After 2 hours, the subjects will be administered wireless motility capsule. The subjects will be observed for expulsion of WMC in stool. Each subject will attend the clinical unit for two study treatment visits which will be separated by at least one week.
11498273|NCT01366560|Placebo Comparator|Placebo|The subjects will be administered placebo tablet as a single dose on Day 1 of study treatment visit. After 2 hours, the subjects will be administered wireless motility capsule. The subjects will be observed for expulsion of WMC in stool. Each subject will attend the clinical unit for two study treatment visits which will be separated by at least one week.
11498274|NCT01366547|Experimental|Single Arm|Subjects will be randomized in a three-way crossover design to receive a single dose of each of two different tablet formulations of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg or dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg). There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
11498275|NCT01366534|Experimental|Ad35.CS.01 Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered one dose of Ad35.CS.01 vaccine at Month 0, and 2 doses of GSK257049 at Months 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
11498276|NCT01366534|Experimental|GSK257049 Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered 3 doses of GSK257049 vaccine at Months 0, 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
11498277|NCT01366534|Experimental|Control Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were volunteers who did not receive any immunization but were subjected to the sporozoite challenge. The duration of the study was approximately 8 months for infectivity control subjects.
11498278|NCT01366521|Experimental|Mepolizumab 250 mg subcutaneous (SC)|250 mg subcutaneous (SC)
11498279|NCT01366521|Experimental|Mepolizumab 125 mg subcutaneous (SC)|125 mg subcutaneous (SC)
11498280|NCT01366521|Experimental|Mepolizumab 12.5 mg subcutaneous (SC)|12.5 mg subcutaneous (SC)
11498281|NCT01366521|Experimental|Mepolizimab 75 mg intravenously (I.V.)|75 mg intravenously (I.V.)
11498282|NCT01366508|Other|Visit B|At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at ~11:00 and at ~13:00. During this period the subject will be required to remain in the unit.
11498283|NCT01366508|Other|Visit A|At approximately 13:00 the subject will be given a standard high calorie lunch that the subject is required to finish
11498284|NCT01366495|Experimental|On-site Rapid HIV Testing|On-site rapid testing conducted by research staff co-located for the purposes of this study at the probation/parole office.
11498285|NCT01366495|No Intervention|Off-site Referral for HIV Testing|Off-site referral for rapid HIV testing at a community health center or HIV testing clinic
11498286|NCT01366495|Experimental|Project Bridge|Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
11498287|NCT01366495|No Intervention|Treatment as Usual|Passive referral to HIV community treatment provider.
11499032|NCT01361048|Active Comparator|oral metronidazole|control arm
11498288|NCT01366482|Experimental|Drug-eluting balloon|Subjects are randomized to have a lesion treated with a paclitaxel-coated balloon Intervention: Cotavance Drug-Eluting Balloon
11498289|NCT01366482|Experimental|Plaque excision + drug-eluting balloon|Subjects are randomized to have a lesion treated with plaque excision (PE) followed by treatment with a paclitaxel-coated balloon Intervention: SilverHawk/TurboHawk + Cotavance Drug-Eluting Balloon
11498290|NCT01366482|Experimental|Severely Ca++ Group|Subjects with a severely calcified lesion will be assigned to a non-randomized arm and treated with plaque excision followed by a drug-eluting balloon Intervention: SilverHawk/TurboHawk + Cotavance Drug-Eluting Balloon
11498291|NCT01366456|Active Comparator|Shingigu|Treat with Shingigu
11498292|NCT01366456|Active Comparator|Charcoal|Treat with Charcoal
11498293|NCT01366443||women pregnant|Healthy pregnant women between 15 or greater weeks gestation reporting with signs or symptoms of rupture of membranes.
11498294|NCT01366430|Active Comparator|Gefoni manenuver|Gefoni manenuver for Geotropic HC-BPPV
11498295|NCT01366430|Active Comparator|sham maneuver|sham maneuver for geotropic HC-BPPV
11498296|NCT01366430|Active Comparator|barbecue maneuver|barbecue maneuver for geotropic HC-BPPV
11498297|NCT01366404||FFR|Patients who had FFR measurement
11498298|NCT01366391|Other|Metformin|study parallel with one arm only.
11498299|NCT01366378|Experimental|Arm 1|methylnaltrexone (MNTX)
11498300|NCT01366365|Experimental|Arm 1|IV methylnaltrexone (MNTX)
11498301|NCT01366365|Placebo Comparator|Arm 2|placebo
11498302|NCT01366352|Experimental|Arm 1|MNTX tablet
11498303|NCT01366352|Experimental|Arm 2|MNTX tablet
11498304|NCT01366339|Experimental|Arm 1|Oral methylnaltrexone
11498305|NCT01366339|Experimental|Arm 2|Oral methylnaltrexone
11498306|NCT01366339|Experimental|Arm 3|Oral methylnaltrexone
11498307|NCT01366339|Placebo Comparator|Arm 4|Oral placebo
11498308|NCT01366326|Experimental|Arm 1|Methylnaltrexone bromide
11498309|NCT01366313|Experimental|Paracetamol|initial doses was 1.5g g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
11498310|NCT01366313|Experimental|Morphine|Initial doses of morphine was 5mg, with dose adjustment intervals of 1 mg .
11498311|NCT01366313|Experimental|Paracetamol-morphine|The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
11498312|NCT01366300|Active Comparator|Intravenous lidocaine infusion|Intravenous lidocaine infusion during total intravenous anesthesia with propofol administered by target controlled infusion
11498313|NCT01366300|Placebo Comparator|Intravenous 0.9% saline infusion|Intravenous 0.9% saline infusion during total intravenous anesthesia with propofol administered by target controlled infusion
11498314|NCT01366287|Experimental|Suspension/fasted|
11498315|NCT01366287|Experimental|Tablet/fasted|
11498316|NCT01366287|Experimental|Tablet/fed|
11498317|NCT01366274|Active Comparator|Usual method of MHI|
11498318|NCT01366274|Experimental|Protective MHI|
11498319|NCT01366261|Experimental|semirigid thoracoscopy|Semirigid instrument which we compare was autoclavable Olympus LTF-160 (Olympus Tokyo, Japan). Handle and its controls were similar to flexible fiberoptic bronchoscope, with the insertion portion composed of 22 cm long rigid part and distal 5 cm flexible tip with angulation range 1600 up / 1300 down. The external diameter of insertion portion was 7 mm with 2,8 mm inner channel diameter. The instrument was compatible with Olympus EVIS Exera 160 and 145 and EVIS 100 and 140 video processors and light sources, otherwise employed in video-bronchoscopy. Forceps, which we used was flexible FB-55CD-1 Olympus forceps with 5 mm long cusps and diameter, which fitted the diameter of inner channel of semirigid thoracoscope.
11498320|NCT01366261|Active Comparator|rigid thoracoscopy|The rigid instrument was autoclavable OP EndoEYE WA50120A (Olympus Tokyo, Japan) video thoracoscope. The length of the instrument was 29 cm with 00 direction of view and 700 field of view. The external diameter of the instrument was 10 mm with 5,2 mm inner channel diameter. The instrument was compatible with Olympus Visera OTV-S7V and EVIS Exera II CV-180 video processors. Cusps of rigid forceps had outer diameter 5 mm and length 10 mm.
11498321|NCT01366248||IO Clinic Breast Cancer Patients|Includes patients who are receiving care for their breast cancer at participating Seattle area IO clinics.
11498322|NCT01366248||CSS Match-Control Patients|For each IO clinic patient, an average of two (up to four) matched comparison cases will be recruited from the Washington State Cancer Surveillance System (CSS). Matched comparison cases from CSS will be identified by CSS and confirmed by the FHCRC investigator.
11498323|NCT01366235|Experimental|Southeast Asians|
11498324|NCT01366235|Experimental|Korean|
11498325|NCT01366235|Experimental|Caucasians|
11498326|NCT01366235|Experimental|Africans|
11498327|NCT01366222|Placebo Comparator|Placebo|
11498328|NCT01366222|Active Comparator|Food concentrates (FC)|Food concentrates (FC) was including fruit and vegetable, fish and probiotics.
11498329|NCT01366209|Active Comparator|Active Arm|
11498330|NCT01366209|Placebo Comparator|Placebo Arm|
11498331|NCT01366196|Placebo Comparator|Control Group (C)|Patients in the control group will receive a placebo tablet with a sip of water one hour prior to surgery and a placebo tablet twice a day for a total of two weeks.
11498332|NCT01366196|Experimental|Pregabalin Group (P)|Patients in the treatment group will receive 150 mg of pregabalin with a sip of water one hour prior to surgery, and then 150 mg daily (75 mg BID) for a total of two weeks.
11498333|NCT01366183||Observational (quality of life questionnaire)|"Patients receive chemotherapy comprising carboplatin, paclitaxel, and filgrastim (regimen 1) or carboplatin alone (regimen 2) every 21 days for 4 courses according to their physicians and/or patients' choice. Patients may undergo surgery and/or further chemotherapy at the discretion of treating physician. Patients undergo blood sample collection at baseline and periodically during course 1 for pharmacokinetic studies.
~Patients' quality of life is assessed by the FACT-O, the FACT-Ntx subscale, the IADL, and the Ability to Complete Social Activity questionnaires at baseline, prior to courses 1 and 3, and then 3-6 weeks after completion of course 4. Nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment are also assessed."
11499026|NCT01361126|Experimental|Prophylactic|On-demand subjects will receive rIX-FP only for the treatment of a bleeding episode.
11498334|NCT01366144|Experimental|Treatment (veliparib, paclitaxel, carboplatin)|"Patients receive veliparib* PO BID on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~NOTE: * All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day)."
11498335|NCT01366131|Experimental|A|
11498336|NCT01366131|Experimental|B|
11498337|NCT01366118|Experimental|TT tailored Ch plus IMRT|
11498338|NCT01366105|No Intervention|Dry Dressing|Incisions that were dressed with a sterile dry dressing at end of operation.
11498339|NCT01366105|Experimental|Negative Pressure Wound Therapy|Incisions dressed with a V.A.C. (NPWT) postoperatively.
11498340|NCT01366092|Experimental|Interleukin-2|Each study participant will receive daily subcutaneous IL-2 (1 x 106 IU/m2/day) for self-administration for 12 weeks, followed by a 4-week hiatus. IL-2 will be typically administered on an outpatient basis. After completing the 16 week study (12 weeks of IL-2 study treatment and a mandatory 4 weeks off-IL-2), patients experiencing clinical benefit (complete or partial response; as well as minor response not meeting NIH criteria for partial response) with an acceptable toxicity profile will be permitted to continue extended-duration treatment indefinitely at the discretion of the treating physician.
11498341|NCT01366079|Experimental|Position change|Position change group
11498342|NCT01366079|Active Comparator|Left lateral|Left lateral position
11498343|NCT01366066|Active Comparator|TMNS treatment - Stress incontinence|Women with stress incontinence treated with active TMNS (vibration)
11498344|NCT01366066|No Intervention|No treatment - stress incontinence|Women with stress incontinence NOT treated with TMNS (vibration)
11498345|NCT01366066|Active Comparator|TMNS treatment - Urge incontinence|Women with stress incontinence treated with TMNS (vibration)
11498346|NCT01366066|No Intervention|No treatment - urge incontinence|Women with urge incontinence NOT treated with TMNS (vibration)
11498347|NCT01366053||Prostate Cancer|Males who have been diagnosed with Prostate Cancer and are experiencing PSA rise, while taking androgen agonist therapy.
11498348|NCT01366014|Experimental|ARRY-371797|
11498349|NCT01366014|Active Comparator|Oxycodone HCl ER|
11498350|NCT01366014|Placebo Comparator|Placebo|
11498351|NCT01366001|Experimental|ALKS 33-BUP|
11498352|NCT01366001|Experimental|ALKS 33|
11498353|NCT01366001|Placebo Comparator|Placebo|
11498354|NCT01365975||Community Intervention Program Population: The Chinese Childre|Community sample of mothers, fathers and offspring from 2 provinces in China who participated in a community public health study in 1994-1996.
11498355|NCT01365936|Active Comparator|menotrophin|In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
11498356|NCT01365936|Active Comparator|recombinant FSH|Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
11498357|NCT01365923|Active Comparator|Remifentanil group|Remifentanil group : remifentanil effect site-TCI 2-4ng/ml
11498358|NCT01365923|Active Comparator|Dexmedetimidine group|Dexmedetomidine group: remifentanil effect site-TCI 2-4ng/ml + dexmedetomidine 0.5mcg/kg
11498359|NCT01365910|Experimental|Treatment (enzyme inhibitor)|Patients receive linifanib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11498360|NCT01365897|Placebo Comparator|Placebo|Control Group
11498361|NCT01365897|Experimental|Modafinil 200mg|Modafinil 200mg taken orally.
11498362|NCT01365871|Active Comparator|basal injection|basal injection of anesthetics
11498363|NCT01365871|Active Comparator|basal + apical injection|basal + apical injection of anesthetics
11498364|NCT01365858|Experimental|Virtual reality-based cognitive training|
11498365|NCT01365858|Active Comparator|Cognitive rehabilitation (without extra computer training)|
11498366|NCT01365845|Active Comparator|1|Conventional photon plan
11498367|NCT01365845|Experimental|2|3D-Proton/Conventional plan or 3D-proton only
11498368|NCT01365832|Experimental|Sleep apnea|"Participants with Obstructive Sleep Apnea (OSA).This arm will undergo a pre-treatment blood draw, six months of Continuous Positive Airway Pressure (CPAP) to treat OSA, and a post-treatment blood draw 3 and 6 months later.
~Intervention: Procedure: Continuous Positive Airway Pressure (CPAP)"
11498369|NCT01365819|Placebo Comparator|Sugar pill|Placebo
11498370|NCT01365819|Experimental|Varenicline|Varenicline (Chantix (R))
11498371|NCT01365793|Experimental|Rapid rehydration using 0.45% saline replacement fluid|This arm will involve more rapid intravenous fluid treatment which will include a second 10cc/Kg bolus of 0.9% saline and assume a 10% fluid deficit. 0.45% saline will be used as the replacement fluid for this arm.
11498372|NCT01365793|Experimental|Rapid rehydration using 0.9% saline replacement fluid|This arm will involve more rapid intravenous fluid treatment which will include a second 10cc/Kg bolus of 0.9% saline and assume a 10% fluid deficit. 0.9% saline will be used as the replacement fluid.
11498373|NCT01365793|Experimental|Slower rehydration using 0.45% saline intravenous fluid|This arm will involve slower rehydration (assumed 5% fluid deficit and no additional fluid bolus) with 0.45% saline used as the replacement fluid.
11498374|NCT01365793|Experimental|Slower rehydration using 0.9% saline intravenous fluid|This arm will involve slower rehydration (assumed 5% fluid deficit and no additional fuid bolus) with 0.9% saline used as the replacement fluid.
11498375|NCT01365780|Active Comparator|With HBOT|Patients, who receive hyperbaric Oxygen Therapy after their surgical treatment
11498376|NCT01365780|No Intervention|Without HBOT|"Patients who receive the same surgical treatment of their radius fracture than the patients of the group with HBOT, but no hyperbaric oxygen therapy (comparison group)"
11498377|NCT01365767||Crohn Disease|Patients with Crohns Disease referred to referred to a Magnetic Resonance Imaging Scan.
11498378|NCT01365754|Active Comparator|A|A - Fusion
11498379|NCT01365754|Active Comparator|B|B - Dynamic (new)
11498380|NCT01365741|No Intervention|Standard administration of Efient|The test person will ingest Efient in supine position, and remain supine during 2 hours, mimicing the way Efient is used for pre-PCI treatment today
11498381|NCT01365741|Active Comparator|Upright administration of Efient|The test person will ingest Efient in an upright position, and remain supine during 2 hours.
11498382|NCT01365715|Experimental|Preoperative embolization|32 patients with spinal metastasis/metastases will undergo arteriography and receive transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
11498383|NCT01365715|Active Comparator|Control group|32 patients with spinal metastasis/metastases will undergo arteriography of spinal metastasis/metastases without receiving transcatheter arterial embolization prior to surgery.
11498384|NCT01365702||Tiotropium in TB destroyed lung|
11498385|NCT01365676|Experimental|GAMALINE® + HIPERICIN® 25-44 years old|Fertile women 24-44 years old with PMS symptoms
11498386|NCT01365676|Active Comparator|GAMALINE® 25-44 years old|Fertile women 24-44 years old with PMS symptoms
11498387|NCT01365676|Experimental|GAMALINE® + HIPERICIN® 45-55 years old|Climacteric women with PMS symptoms
11498388|NCT01365676|Active Comparator|GAMALINE® 45-55 years old|Climacteric women with PMS symptoms
11498389|NCT01365663|Experimental|Cohort 1|0.25 mg/kg in Healthy Subjects
11498390|NCT01365663|Experimental|Cohort 2|0.5 mg/kg in Healthy Subjects
11498391|NCT01365663|Experimental|Cohort 3|1.0 mg/kg in Healthy Subjects
11498392|NCT01365663|Experimental|Cohort 4|1.5 mg/kg in Healthy Subjects
11498393|NCT01365663|Experimental|Cohort 5|2.0 mg/kg in Healthy Subjects
11498394|NCT01365663|Placebo Comparator|Saline 0.9%|
11498395|NCT01365650|Experimental|Ketorolac Tromethamine|
11498396|NCT01365650|Experimental|Oxymetazoline Hydrochloride|
11498397|NCT01365650|Experimental|Fluticasone Propionate|
11498398|NCT01365637|Experimental|Cohort 1 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
11498399|NCT01365637|Experimental|Cohort 2 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
11498400|NCT01365637|Experimental|Cohort 3 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo either twice or thrice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
11498401|NCT01365637|Experimental|Cohort 4 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo either twice or thrice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
11498402|NCT01365624|Experimental|Ketorolac tromethamine|
11498403|NCT01365611|Experimental|Ketorolac tromethamine|
11498404|NCT01365598|Placebo Comparator|Placebo|Non-active drug
11498405|NCT01365598|Experimental|Low dose primaquine (PQ1)|Lowest experimental dose of primaquine base: 0.1mg/kg
11498406|NCT01365598|Experimental|Intermediate dose primaquine (PQ2)|Intermediate experimental dose of primaquine base: 0.4mg/kg
11498407|NCT01365598|Active Comparator|Reference dose primaquine (PQ-R)|WHO-recommended dose of primaquine base: 0.75mg/kg
11498408|NCT01365585||Sildenafil ≥20mg three times daily|Subjects receiving sildenafil ≥20mg three times daily for the treatment of PAH
11498409|NCT01365572|Active Comparator|Xience V, drug-eluting stent|randomized implantation for DES restenotic lesion
11498410|NCT01365572|Active Comparator|Endeavor Resolute, drug-eluting stent|randomized implantation for DES restenotic lesion
11498411|NCT01365559|Experimental|Group A: Carfilzomib & Non-IMiD containing regimen|Bortezomib is replaced with carfilzomib in a combined regimen identical to the patient's previous regimen. Regimen cannot include thalidomide or lenalidomide.
11498412|NCT01365559|Experimental|Group B: Carfilzomib & IMiD containing regimen.|Bortezomib is replaced with carfilzomib in a regimen that includes IMiDs (lenalidomide or thalidomide). Thus, the regimen is carfilzomib in an IMiD-containing regimen.
11498413|NCT01365546|Experimental|human VWF/FVIII concentrate|
11498414|NCT01365533|Active Comparator|Roflumilast|
11498415|NCT01365533|Placebo Comparator|Placebo|
11498416|NCT01365520|Experimental|N8|
11498417|NCT01365507|Experimental|IDegAsp Simple|
11498418|NCT01365507|Experimental|IDegAsp Step wise|
11498419|NCT01365494|Active Comparator|Group A-Zagreb|Purified Chick Embryo Cell Inactivated Rabies Vaccine, administered intramuscularly (IM) according to the 2-1-1 (Zagreb) schedule (i.e., 2 doses of vaccine administered on day 0 and 1 dose of vaccine each administered on day 7 and day 21)
11498420|NCT01365494|Active Comparator|Group B-Essen|Purified Chick Embryo Cell Inactivated Rabies Vaccine, administered IM according to the 1-1-1-1-1 (Essen) schedule (i.e., 1 dose of vaccine administered on day 0, 3, 7, 14, and 28)
11498421|NCT01365481|Experimental|valsartan|Valsartan starting dose: ≥18 kg to <35 kg is 40 mg, ≥35 kg to <80 kg is 80 mg, ≥80 kg to ≤160 kg is 160 mg for 1 week then Valsartan maintenance dose: ≥18 kg to <35 kg is 80 mg, ≥35 kg to <80 kg is 160 mg, ≥80 kg to ≤160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study.
11498422|NCT01365468|Experimental|Everolimus (RAD001)|enrolled patients received everolimus (RAD001) in an open label manner. Recommended starting dose of everolimus depend on body surface area, starting from 2.5 mg once daily to 7.5 mg once daily.
11498423|NCT01365455|Experimental|AIN457 150 mg|AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week
11498547|NCT01364649|Experimental|Vortioxetine|Vortioxetine 10 mg, tablets, orally, once daily for 1 week, then dose adjustment to a maximum 20 mg, tablets, orally, once daily for up to 7 weeks. At week 8, vortioxetine placebo-matching capsules, orally, once daily for 1 week only.
11498424|NCT01365455|Experimental|AIN457 300 mg|AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week
11498425|NCT01365455|Placebo Comparator|placebo|placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
11498426|NCT01365455|Experimental|AIN457 150mg from Placebo|Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase because they were PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
11498427|NCT01365455|Experimental|AIN457 300mg from Placebo|Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase. PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
11498428|NCT01365442||Consenting, eligible participants|All consenting eligible participants in the study area will receive the oral cholera vaccine
11498429|NCT01365429|Experimental|EVLP Group|EVLP Group are those recipient lung transplant patients that received donor lungs that had been placed on the XPS™ with Steen Solution™ and undergone ex-vivo lung perfusion before being transplanted.
11498430|NCT01365429|No Intervention|Control Group|Control Group are those recipient lung transplant patients that receive donor lungs via conventional transplant.
11498431|NCT01365403|Experimental|Single Arm|
11498432|NCT01365390||Cohort A|Subjects aged < 6 years who are registered in primary care clinics of any of the participating countries (Estonia, Lithuania, Poland, Romania and Slovenia).
11498433|NCT01365377|Experimental|Booklet|Referent member of the family is designated to receive a written detailed information on Critical care.
11498434|NCT01365377|No Intervention|No booklet|daily information to the family is given as usual.
11498435|NCT01365364|Active Comparator|PLM group|Individuals with increased periodic leg movement index (>5)
11498436|NCT01365364|Active Comparator|Non-PLM group|Individuals with PLM index <5
11498437|NCT01365351||Growth hormone|Children with growth hormone deficiency
11498438|NCT01365338|Placebo Comparator|Placebo|Participants will receive placebo as a single oral dose.
11498439|NCT01365338|Experimental|Cohort 1|Participants will receive 0.075 milligrams (mg) of PF-04958242 as a single oral dose.
11498440|NCT01365338|Experimental|Cohort 2|Participants will receive 0.15 mg of PF-04958242 as a single oral dose.
11498441|NCT01365325|Experimental|handled echocardiography|home monitoring care program based on clinical and electrocardiographic evaluations and periodical handled echocardiographic examinations
11498442|NCT01365325|Active Comparator|home monitoring program|home monitoring care program based on clinical and electrocardiographic evaluations
11498443|NCT01365312|Experimental|Ethanol|Assigned intervention is a 70% ethanol lock, placed every 72 hours for 15 minutes, for the duration of the PICC line.
11498444|NCT01365312|Placebo Comparator|Heparinized saline|Intervention is to place a heparinized saline lock every 72 hours for 15 minutes, for the duration of the line.
11498445|NCT01365286|Active Comparator|Ivabradine-Placebo|
11498446|NCT01365286|Active Comparator|Placebo-Ivabradine|
11498447|NCT01365273|No Intervention|Bridal Veil together with staples|Standard of care. Bridal Veil is fixed over the graft with staples.
11498448|NCT01365273|Active Comparator|Mepitel One|Device, dressing
11498449|NCT01365260|Experimental|MM-II|
11498450|NCT01365260|Active Comparator|DurolaneTM|hyaluronic acid
11498451|NCT01365247|Experimental|COPE|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure
11498452|NCT01365247|Active Comparator|RPT|Relapse Prevention Therapy
11498453|NCT01365247|Active Comparator|Active Monitoring Control Group|
11498454|NCT01365234|Experimental|20066 Lead|Non-randomized study. Intervention: Device: Pacing Lead
11498455|NCT01365221|Experimental|Patients who have received loading dose of clopidogrel|
11498456|NCT01365221|Active Comparator|Patients who have not received loading dose of clopidogrel|
11498457|NCT01365208||advanced nasopharyngeal carcinoma|
11498458|NCT01365195|Placebo Comparator|Control|"Loading and Infusion:
~Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate"
11498459|NCT01365195|Active Comparator|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
11498460|NCT01365195|Active Comparator|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
11498461|NCT01365182|Other|BF+SUPPORT|
11498462|NCT01365182|Other|BF+PHONE|
11498463|NCT01365182|No Intervention|Usual Care|
11498464|NCT01365169|Experimental|Arm I (colorectal cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a heart rate monitor, a GPS device, and a smart phone that prompts patients to electronically answer questions about exercise and health-related symptoms and feelings. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
11498465|NCT01365169|Experimental|Arm II (head and neck cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a weight scale, and a smart phone that prompts patients to electronically answer questions about diet and health-related symptoms. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
11498466|NCT01365169|Experimental|Arm III (head and neck cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a smart phone that prompts patients to electronically answer questions about diet, health-related symptoms, and swallowing exercises. Patients also take video recordings of their neck while performing swallowing exercises. The device is used for 5 consecutive days. After a 2 week period, patients resume use of the device for an additional 5 days.
11498549|NCT01364636||Acute Heart Failure|Patients admitted to emergency room in Acute Heart Failure at Hospital PróCardíaco and Hospital Universitario Antonio Pedro
11499271|NCT01359397|Experimental|Herceptin +|
11498467|NCT01365169|Experimental|Arm IV (cancer survivors that are current/former smokers)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a CO monitor and a smart phone that prompts patients to electronically answer questions about smoking. Patients also take video recordings of themselves while exhaling into the CO monitor. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
11498468|NCT01365169|Experimental|PCS (pancreatic surgery patients)|Patients receive post-surgical wellness program consisting of physical activity, nutrition counseling, and daily monitoring (physical activity, weight, and self-reported data) for up to 7 months post-op.
11498469|NCT01365156|Experimental|EPLND + Chemoradiation|Group 1: Extraperitoneal laparoscopic lymphadenectomy followed by chemoradiation therapy
11498470|NCT01365156|Active Comparator|Chemoradiation|Group 2: standard-of-care chemoradiation therapy only
11498471|NCT01365143|Active Comparator|Open Radical Prostatectomy|
11498472|NCT01365143|Active Comparator|Robotic radical prostatectomy|
11498473|NCT01365130|Experimental|real drug|patients will receive Jevtana 25mg/m2, IV every 21 days until disease progression or unacceptable toxicity
11498474|NCT01365117|Experimental|Cohort 1|
11498475|NCT01365117|Experimental|Cohort 2|
11498476|NCT01365104|Experimental|Healthy young|Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.
11498477|NCT01365104|Experimental|healthy old|Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.
11498478|NCT01365091|Experimental|Arm 1: Treatments A,B/B,A|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.
~Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A)."
11498479|NCT01365091|Experimental|Arm 2: Treatments C,D/D,C|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.
~Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C)."
11498480|NCT01365091|Experimental|Arm 3: Treatments E, F/F,E|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.
~Period 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E)."
11498481|NCT01365091|Experimental|Arm 4: Treatments G,H/H,G|"Period 1: Participants received a single oral dose of saxagliptin , 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.
~Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G)."
11498482|NCT01365078|Experimental|Echium oil (SDA-rich oil)|
11498483|NCT01365078|Placebo Comparator|High-oleic acid sunflower oil (HOSO)|low in SDA
11498484|NCT01365065|Experimental|Vorinostat|Vorinostat 400mg ( 4 X 100mg ) orally daily for 14 days
11498485|NCT01365052|Experimental|Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|
11498486|NCT01365052|Placebo Comparator|Placebo|
11498487|NCT01365039|Experimental|Test lens|Test contact lens will be worn on a daily disposable wear basis.
11498488|NCT01365039|Active Comparator|SofLens lens|The currently marketed Bausch + Lomb SofLens daily disposable contact lens. Worn on a daily disposable wear basis.
11498489|NCT01365026|Experimental|PVS intervention|
11498490|NCT01365026|No Intervention|Control group|
11498491|NCT01365013|Experimental|Lifestyle counseling|
11498492|NCT01365013|Active Comparator|control group|
11498493|NCT01365000|Experimental|NKTR118 Formulation 1|Fasted
11498494|NCT01365000|Experimental|NKTR118 Formulation 2|Fasted
11498495|NCT01365000|Experimental|NKTR118 Formulation 3|Fasted
11498496|NCT01365000|Experimental|NKTR118 Formulation 1a|Fed
11498497|NCT01365000|Experimental|NKTR118 Formulation 3a|FED
11498498|NCT01364987|Experimental|ASP015K and Mycophenolate Mofetil|
11498499|NCT01364974|Experimental|Group A|low dose, all male
11498500|NCT01364974|Experimental|Group B|medium dose, all male
11498501|NCT01364974|Experimental|Group C|high dose, all male
11498502|NCT01364974|Experimental|Group D|medium dose, all female
11498503|NCT01364974|Placebo Comparator|Placebo|
11498504|NCT01364961|Placebo Comparator|Cellulose capsules|
11498505|NCT01364961|Experimental|Resveratrol capsules|
11498548|NCT01364649|Active Comparator|Escitalopram|Escitalopram 10 mg, tablets, orally, once daily for 1 week, then escitalopram dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks. At week 8, escitalopram 10 mg, capsules, capsules, orally, once daily for 1 week only.
11498687|NCT01363635||severe sepsis|severe sepsis/septic shock, organ failure, ICU death
11498506|NCT01364948|Experimental|Coconut oil application|The oil (coconut oil) was applied by the trained nurse to the entire body surface of infant except the face two times a day starting at 12 hrs of life. Four ml of coconut oil was applied using both hands of the caregiver in four strokes. First stroke was from the clavicles over the chest and abdomen till the groin, second from the front of thighs over the knee and leg upto the sole, the third one from the shoulders over the arm and forearm till the palm continuing medially over the forearm and arm till the axilla and the final stroke was used for the back, starting from the upper back, continuing over the back of the thighs till the heel. Just prior to the first application, and thereafter prior to the subsequent applications the TEWL was recorded using the portable closed chamber evaporimeter. The oil application was continued twice daily (every 12 hrs at the same time as the hour of birth e.g. 11 am and 11pm) till the completion of the seventh day (168 hrs of life).
11498507|NCT01364948|No Intervention|No Oil Application|Babies in this group were not subjected to oil application. TEWL measurement was recorded every 12 hrs for the first week of life, at the same time as the hour of birth.
11498508|NCT01364922|Experimental|Open-label Hydrocodone/Acetaminophen Extended Release|Hydrocodone/acetaminophen extended release, 2 tablets twice daily
11498509|NCT01364922|Experimental|Double-blind Hydrocodone/Acetaminophen Extended Release|Hydrocodone/acetaminophen extended release, 1 tablet twice daily
11498510|NCT01364922|Placebo Comparator|Double-blind Placebo|Placebo, 1 tablet twice daily
11498511|NCT01364909|Placebo Comparator|Control (usual practice)|
11498512|NCT01364909|Experimental|Exercise|
11498513|NCT01364896||Inflammatory bowel disease, Immunosuppressive agent|Men and women 18 years + with a histological diagnosis of IBD (ulcerative colitis or Crohn's disease) who are undergoing a colonoscopy prior to starting a non-corticosteroid immunosuppressive agent
11498514|NCT01364883|Experimental|Group 1|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16
11498515|NCT01364883|Experimental|Group 2|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24
11498516|NCT01364883|Experimental|Group 3|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, MVA ME-TRAP boost W8, MVA ME-TRAP boost W12
11498517|NCT01364883|Experimental|Group 4|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24
11498518|NCT01364883|Experimental|Group 5|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16
11498519|NCT01364883|Experimental|Group 6|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W12
11498520|NCT01364883|Experimental|Group 7|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
11498521|NCT01364870|Active Comparator|Active TENS|High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
11498522|NCT01364870|Placebo Comparator|Placebo TENS|"Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working."
11498523|NCT01364870|No Intervention|Standard Care|"Subjects randomized to Standard Care will be given no TENS unit."
11498524|NCT01364857|Other|PWS cohort|search for polymorphisms of RASA1 gene
11498525|NCT01364844|Experimental|DS7423|
11498526|NCT01364818||Placebo Comparator: Placebo|No treatment/ performance of somatosensory task (cortical metrics) without any intervention. The somatosory task will be performed before any intervention/at the midpoint/ and finally at the end.
11498527|NCT01364818||Active Comparator: Active Medication|Treatment (memantine, lurasidone)/ performance of somatosensory task (cortical metrics) with intervention. The somatosory task will be performed before any intervention has started/at the midpoint/ and finally at the end.
11498528|NCT01364805|Experimental|PK Intravenous Vitamin C and Gemcitabine|Week 1: 2 visits for escalating doses of intravenous ascorbic acid (IV C). First dose 25 gm followed by 50 gm 2nd visit. Week 2: 3 visits escalating doses of IV C, 75 grams, 100 grams, and 125 grams. Week 3: 2 visits pharmacokinetic evaluation of intravenous ascorbic acid alone at 125 grams; return to the infusion clinic the following morning for a 24 hour blood draw; 2nd visit receive the first infusion of gemcitabine chemotherapy for PK evaluation of gemcitabine alone. Week-4: gemcitabine and IV C co-administered for pharmacokinetics of both drugs to assess for PK variability related to drug-drug interactions. Subjects will return to the infusion clinic the following morning for 24 hour blood draw.
11498529|NCT01364792|Experimental|Valaciclovir|The patients in the experimental group will be treated with 4 times 2 grams valaciclovir per day for seven days.
11498530|NCT01364792|Placebo Comparator|Placebo|Patient receives placebo four times a day for seven days.
11498531|NCT01364753||Pilots|No intervention; observational study
11498532|NCT01364740|Experimental|PMP-300E, In-Lab PSG|PMP-300E, A 7-channel (nasal pressure, effort, snoring, SpO2, pulse rate, body position and movement) Level 3 portable monitor (11.2 x 3.3 x 5.5cm, 80g, Pacific Medico Co., LTD) to measure sleep-related breathing will be tested against conventional gold-standard In-Lab Polysomnography (sleep study)
11498533|NCT01364727|Experimental|Amrubicin|Amrubicin 35mg/m2 IV days 1-3 every 3 weeks
11498534|NCT01364714||ICU survivors|Male ICU survivors 12 month after discharge
11498535|NCT01364714||Controls|Age and gender matched controls
11498536|NCT01364701|Active Comparator|Maximal dose sildenafil|4 tablets of sildenafil 100mg are given for on demand use
11498537|NCT01364701|Active Comparator|Tadalafil 20mg maximal dose|4 tablets of tadalafil 20mg are given for on demand use
11498538|NCT01364701|Active Comparator|Combination half dose|4 tablets of sildenafil 50mg and tadalafil 10mg are given for on demand use
11498539|NCT01364688|Experimental|Treatment|oral alfacalcidol
11498540|NCT01364688|No Intervention|Control|No drug
11498541|NCT01364675|Experimental|Metformin+Enalapril+Simvastatin|
11498542|NCT01364675|Placebo Comparator|Placebo tablet|
11498550|NCT01364623|Experimental|Low dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.24% testosterone gel to deliver a single dose of 300 μg of testosterone per nostril, for a total dose of 600 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 1 (Low dose testosterone nasal gel, single dose)
11498551|NCT01364623|Experimental|Medium dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.48% testosterone gel to deliver a single dose of 600 μg of testosterone per nostril, for a total dose of 1200 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 2 (Medium dose testosterone nasal gel, single dose)
11498552|NCT01364623|Experimental|High dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.72% testosterone gel to deliver a single dose of 900 μg of testosterone per nostril, for a total dose of 1800 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 3 (High dose testosterone nasal gel, single dose)
11498553|NCT01364623|Experimental|Medium dose TBS-2 multiple doses|TBS-2 dispensers prefilled with 0.48% testosterone gel to deliver a single dose of 600 μg of testosterone per nostril, for a total dose of 1200 μg given t.i.d. daily at 0800 hours (± 30 minutes), 1600 hours (± 30 minutes), and 2400 hours (± 30 minutes) on Days 1 and 2 of Period 2, and once in the morning at 0800 hours (± 30 minutes) on Day 3 of Period 2 (Multi-dose group) (Medium dose testosterone nasal gel, multiple dose)
11498554|NCT01364610|Active Comparator|Standard Care|Group 1 will have standard catheter based pH-metry. All participants will answer a questionnaire assessing tolerance and satisfaction of both the siting and placement methods and the 24 hour monitoring period.
11498555|NCT01364610|Active Comparator|Bravo pH Monitoring System|Group 2 will undergo unsedated peroral placement of the Bravo capsule. All participants will answer a questionnaire assessing tolerance and satisfaction of both the siting and placement methods and the 24 hour pH monitoring period.
11498556|NCT01364597|Experimental|Brivaracetam|
11498557|NCT01364584|Experimental|Exenatide|Pre-dosed inject-able pen (an automatic device which injects under the skin) 10 mcg twice a day of exenatide for 2.5 months
11498558|NCT01364584|Placebo Comparator|Placebo|Pre-dosed inject-able pen (an automatic device which injects under the skin) 10 mcg twice a day of placebo for 2.5 months
11498559|NCT01364571|Experimental|1|SA4Ag vaccine low dose
11498560|NCT01364571|Experimental|2|SA4Ag vaccine mid dose
11498561|NCT01364571|Experimental|3|SA4Ag vaccine high dose
11498562|NCT01364571|Placebo Comparator|4|Placebo
11498563|NCT01364558|Experimental|Diazepam Nasal Spray Suspension|Diazepam Nasal Suspension - 10 mg
11498564|NCT01364558|Experimental|Diazepam Nasal Spray Solution|Diazepam Nasal Spray Solution - 10 mg
11498565|NCT01364558|Active Comparator|Diazepam injection|Diazepam injection IV - 5 mg
11498566|NCT01364545|Other|Ketone ester drink Vs placebo drink|Ketone ester drink Vs placebo drink (cross over study - all patients will recieve both)
11498567|NCT01364532|Experimental|Transulnar arterial access|Transulnar arterial access for coronary angiography, ad-hoc or elective PCI
11498568|NCT01364532|Active Comparator|Transradial arterial access|Transradial arterial access for coronary angiography, ad-hoc or elective PCI
11498569|NCT01364519|Experimental|Arm 1|
11498570|NCT01364519|Placebo Comparator|Arm 2|
11498571|NCT01364506|Experimental|Water exercise|
11498572|NCT01364506|No Intervention|Control|
11498573|NCT01364493|Experimental|Trastuzumab+Capecitabine+Oxaliplatin|"Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.
~Capecitabine 2000mg/m2d, d1-14; q3w, Oxaliplatin 130mg/m2 d1; q3w, 6 cycles"
11498574|NCT01364480|Experimental|Brain-Machine Interface Users|All participants enrolled in the study will undergo Implantation of NeuroPort Arrays in the motor cortex. There is no control group.
11498575|NCT01364467|Placebo Comparator|Placebo|Placebo is provided by the sponsor and is identical in composition to the treatment only lacking active drug.
11498576|NCT01364467|Active Comparator|Guaifenesin|
11498577|NCT01364454|Experimental|Eligible patients' paper-based reminder|
11498578|NCT01364454|No Intervention|Control group|
11498579|NCT01364441|Placebo Comparator|P|
11498580|NCT01364441|Experimental|E|
11498581|NCT01364428|Experimental|IDeg 200 U/mL|
11498582|NCT01364428|Experimental|IDeg 100 U/mL|
11498583|NCT01364415|Experimental|Pasireotide LAR|
11498584|NCT01364402|Experimental|Erythropoietin|
11498585|NCT01364402|Placebo Comparator|Placebo|
11498586|NCT01364389|Experimental|ACZ885|On day 1, patients received a single intravenous dose of ACZ885 3mg/kg along with a placebo intravenous infusion in a double dummy manner to maintain the blind. On day 15, partial and complete responders continued in the open label phase of this treatment arm where they were eligible to receive one re-dose of ACZ885 upon confirmed disease flare. Non-responders started a 20 mg dose cycle of prednisone or prednisolone followed by standard steroid tapering.
11498587|NCT01364389|Experimental|AIN457|On day 1, patients received a single intravenous dose of AIN457 3mg/kg along with a placebo intravenous infusion in a double dummy manner to maintain the blind. On day 15, partial and complete responders continued in the open label phase of this treatment arm where they were eligible to receive one re-dose of AIN457 upon confirmed disease flare. Non-responders started a 20 mg dose cycle of prednisone or prednisolone followed by standard steroid tapering.
11498588|NCT01364389|Other|Prednisone|On day 1, patients received daily oral doses of prednisone 20 mg along with daily oral placebo doses to in a double-dummy manner to maintain the blind. On day 15, partial and complete responders continued in the study and tapered their steroid treatment according to standard care. Non-responders were discontinued from the study.
11498589|NCT01364376|Active Comparator|FOLFOX|
11498590|NCT01364376|Experimental|SOX|
11498591|NCT01364363|Other|Total Body Irradiation/VP16|Acute Leukemias, Myelodysplastic syndromes
11498592|NCT01364363|Other|Cytoxan/Total Body Irradiation|Chronic Leukemias, Bone Marrow Failure States, Lymphomas, Hodgkin's Disease
11498593|NCT01364363|Other|Busulfan/Cytoxan|Acute Leukemia, Myelodysplastic syndromes, Chronic Leukemias, Bone Marrow Failure states
11498594|NCT01364363|Other|BEAM (BCNU, etoposide, Ara-C, melphalan)|Lymphomas, Hodgkin's Disease
11498595|NCT01364363|Other|Total Lymphoid Irradiation|For patients with Multiple Myeloma, or prior autologous transplantation, or age in excess of 55
11498688|NCT01363622||SGA|SGA (small for gestational age)
11498596|NCT01364363|Other|Cladribine/Melphalan|For patients with Multiple Myeloma, or prior autologous transplantation, or age in excess of 55
11498597|NCT01364363|Other|FLAG (fludarabine, Ara-C, G-CSF)|For patients undergoing a second allogeneic transplant
11498598|NCT01364350||TODAY cohort|The cohort of participants diagnosed with type 2 diabetes ages 10 to <18 and obese at time of diagnosis who participated in the TODAY clinical trial are recruited, consented and followed.
11498599|NCT01364337|Active Comparator|DASH diet|
11498600|NCT01364337|Active Comparator|lower carbohydrate DASH diet|
11498601|NCT01364324||Gastrectomy|Twenty gastrectomized patients with pulmonary TB, treated with standard first line anti-TB drugs(isoniazid/rifampicin/ethambutol/pyrazinamide), administered daily, orally
11498602|NCT01364324||Non-gastrectomy|Twenty non-gastrectomized patients with pulmonary TB, treated with standard first line anti-TB drugs(isoniazid/rifampicin/ethambutol/pyrazinamide), administered daily, orally
11498603|NCT01364298|Experimental|Gabapentin/B-complex|
11498604|NCT01364298|Active Comparator|Pregabalin|
11498605|NCT01364259|Placebo Comparator|Placebo|Placebo and SRS
11498606|NCT01364259|Experimental|Amifostine|Amifostine and CyberKnife stereotactic radiosurgery
11498607|NCT01364246|Experimental|Human umbilical cord mesenchymal stem cells transplantation|Intervention group
11498608|NCT01364233|Other|MotifMesh|Condensed polytetrafluoroethylene (cPTFE, MotifMESH) mesh
11498609|NCT01364220|Experimental|Rosuvastatin|Rosuvastatin 20mg tablet, once daily, for 14 days
11498610|NCT01364220|Placebo Comparator|Placebo|Placebo tablet, once daily, for 14 days
11498611|NCT01364207|Experimental|Caffeinated Coffee 1st Visit, Decaffeinated Coffee 2nd Visit|Participants will be given an 8 oz cup of caffeinated coffee on their first visit and 8 oz cup of decaffeinated coffee on their second visit.
11498612|NCT01364207|Experimental|Decaffeinated Coffee 1st Visit, Caffeinated Coffee 2nd Visit|Participants will be given an 8 oz cup of decaffeinated coffee on their first visit and 8 oz cup of caffeinated coffee on their second visit.
11498613|NCT01364194|Active Comparator|0.25% Bupivacaine|Periarticular injection with 20 ml of 0.25% bupivacaine before wound closure.
11498614|NCT01364194|Placebo Comparator|0.9% normal saline|Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
11498615|NCT01364181|Experimental|Udenafil|Udenafil 50mg qd po
11498616|NCT01364168||First ever acute ischemic stroke|Patients over 18 years and without prior stroke according to WHO criteria, displaying an ischemic stroke, onset within the last 7 days, language German
11498617|NCT01364155|Experimental|600 mg LIM-0705 BID for 28 days|
11498618|NCT01364155|Placebo Comparator|Placebo LIM-0705 for 28 days|
11498619|NCT01364142||thoracic surgery|Patients undergoing thoracic surgery in which one lung ventilation is needed.
11498620|NCT01364129|Experimental|Telemedicine|Participants in this group have digital images of their retina captured with a non-mydriatic camera and are encouraged to see an eye care provider yearly.
11498621|NCT01364129|No Intervention|Traditional Surveillance|Participants in this group are encouraged to see an eye care provider each year for a diabetic eye exam.
11498622|NCT01364090|Active Comparator|Standard Treatment Duration (24 weeks)|Subjects with detectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 24 and follow-up for an additional 24 weeks following treatment completion (48 weeks in total).
11498623|NCT01364090|Experimental|Shortened Treatment Duration (12 Weeks)|Subjects with undetectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 12 and follow-up for an additional 24 weeks following treatment completion (36 weeks in total).
11498624|NCT01364077|Active Comparator|Ivabradine|
11498625|NCT01364077|Placebo Comparator|Control|
11498626|NCT01364064|Active Comparator|Conventional adjuvant Temozolomide|TMZ d 1-5 of 28-d cycle 6 cycles
11498627|NCT01364064|Experimental|Dose intensive Temozolomide|TMZ d 1-21 of 28-d cycle 6 cycles
11498628|NCT01364051|Experimental|Treatment (cediranib maleate, selumetinib)|Patients receive cediranib maleate PO QD and selumetinib sulfate PO QD or BID on days 1-28 (days 8-28 of cycle 1). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cycles may be extended to 12 weeks after 1 year of study treatment.
11498629|NCT01364025|Experimental|uterosacral ligament suspension|uterosacral ligament suspension colpopexy sutures will be placed bilaterally at the time of hysterectomy
11498630|NCT01364025|No Intervention|hysterectomy alone|
11498631|NCT01364012|Experimental|Bevacizumab + Paclitaxel/Carboplatin|Participants will receive bevacizumab on Day 1 of each 3-week cycle in combination with paclitaxel and carboplatin for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive bevacizumab on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
11498632|NCT01364012|Active Comparator|Placebo + Paclitaxel/Carboplatin|Participants will receive bevacizumab matching placebo on Day 1 of each 3-week cycle in combination with paclitaxel and carboplatin for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive bevacizumab matching placebo on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
11498633|NCT01363999|Experimental|A|RO5317116/F01 bilayer tablet
11498634|NCT01363999|Experimental|B|RO5317116/F03 bilayer tablet
11498635|NCT01363999|Experimental|C|RO5317116/F04 active-coated tablet
11498636|NCT01363999|Experimental|D|RO4607381/F49 tablet
11498637|NCT01363986|Experimental|Trastuzumab Monotherapy|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.), followed by weekly doses of 2 mg/kg i.v. for up to 18 weeks.
11498638|NCT01363973|Experimental|Sensory stimulation|Transcutaneous electrical stimulation at 75% of motor threshold
11498639|NCT01363973|Experimental|Motor stimulation|Transcutaneous electrical stimulation at motor threshold
11498640|NCT01363960||neonates with retinopathy of prematurity|"all neonates meet the criteria:
~a BW of less than 1501 gram (g)
~born at a GA of 34 weeks (wk) or less and
~selected infants with an unstable clinical course were included"
11498641|NCT01363947|Experimental|Dose Escalation Cohort (DNIB0600A)|Participants will receive IV infusions of DNIB0600A at doses ranging from 0.2 milligrams/kilogram (mg/kg) to 2.8 mg/kg q3w until dose-limiting toxicity (DLT) is reached, or up to 28 cycles.
11498642|NCT01363947|Experimental|Expansion Cohort (DNIB0600A)|Participants will receive 2.4 mg/kg, by IV infusion, of DNIB0600A q3w for up to 26 cycles.
11498643|NCT01363934|Experimental|Group A|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
11498644|NCT01363934|Experimental|Group B|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
11498645|NCT01363934|Experimental|Group C|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
11498646|NCT01363934|Experimental|Group D|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
11498647|NCT01363934|Active Comparator|Darbepoetin alfa 30ug/kg by IV|Darbepoetin alfa 30ug/kg once intravenously
11498648|NCT01363934|Experimental|Group H|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
11498649|NCT01363934|Experimental|Group I|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
11498650|NCT01363934|Experimental|Group J|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
11498651|NCT01363934|Experimental|Group K|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
11498652|NCT01363934|Active Comparator|Darbepoetin alfa 30ug/kg by SC|Darbepoetin alfa 30ug/kg once subcutaneously
11498653|NCT01363921|Experimental|Dialysis treatment with HCO1100|
11498654|NCT01363908|Experimental|SPD602 (26 mg/kg)|Oral SSP-004184AQ taken once daily for 48 weeks
11498655|NCT01363908|Experimental|SPD602 (36 mg/kg)|Oral SSP-004184AQ taken once daily for 48 weeks. Starting dose based on transfusion burden and iron overload status. Doses may range from 8-60mg/kg/day depending on clinical response.
11498656|NCT01363908|Experimental|SPD602 (16 mg/kg)|A single dose given in the initial pharmacokinetic phase.
11498657|NCT01363895|Active Comparator|Percutaneous closure of LAA|Percutaneous closure of LAA
11498658|NCT01363895|Active Comparator|Catheter ablation of AF|Catheter ablation of AF
11498659|NCT01363882|Active Comparator|Standard NIV|Noninvasive ventilation (NIV) will be initiated and managed as per current standard of practice guided by the American Academy of Neurology (AAN) Practice Parameters (updated in 2009), in all subjects with amyotrophic lateral sclerosis (ALS) and a forced vital capacity of <50% predicted. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months, but will not influence management of the NIV.
11498660|NCT01363882|Experimental|Sleep study titrated NIV|ALS subjects in this arm, who are offered NIV for Forced Vital Capacity (FVC) <50% as per AAN Practice Parameters, will have their initial level of NIV determined polysomnographically. They will be followed with sleep studies at 1 month, 3 months and 6 months to reassess NIV efficacy and NIV will be adjusted as necessary to optimize parameters of oxygenation and ventilation.
11498661|NCT01363869|Experimental|Green tea extracts 2 gm/day|Green tea extracts 2 gm/day for 14 days
11498662|NCT01363869|Experimental|Green tea extracts 4 gm/day|Green tea extracts 4 gm/day for 14 days
11498663|NCT01363869|Experimental|Green tea extracts 6 gm/day|Green tea extracts 6 gm/day for 14 days
11498664|NCT01363856||First ever acute stroke|Patients over 18 years and without prior stroke according to WHO criteria, displaying an ischemic stroke, onset within the last 7 days, language German
11498665|NCT01363843|Experimental|treatment|"Induction therapy - Modified FOLFOX6 - Oxaliplatin 85 mg/m2 + Leucovorin 400 mg/m2 IV, followed by 5-FU 400 mg/m2 IV, followed 5-FU 2400 mg/m2 IV by continuous infusion over 46 hours - Repeat q14 days x 8 cycles
~Concurrent Chemoradiation
~50.4 Gy Radiation in 28 fractions (45 Gy IMRT, 5.4 Gy 3D conformal boost)
~Surgery"
11498666|NCT01363830|Experimental|Two-Week Post-Operative Restriction|Restrict bending, lifting, and twisting for two-weeks following discectomy.
11498667|NCT01363830|Active Comparator|Six-Week Post-Operative Restriction|Restrict bending, lifting, and twisting for six-weeks following discectomy.
11498668|NCT01363817|Experimental|Escalation Phase: BMS-906024|BMS-906024 escalating doses starting at 0.3 mg solution for intravenous (IV) administration once weekly continuously until disease progression or unacceptable toxicity
11498669|NCT01363817|Experimental|Expansion Phase: BMS-906024 + Dexamethasone|BMS-906024 maximum tolerated dose (To be determined) solution for IV administration once weekly and Dexamethasone 20mg/day tablet by mouth (Oral) for 3-4 days every week for 3-4 weeks per cycle continuously until disease progression or unacceptable toxicity
11498670|NCT01363804|Experimental|Tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
11498671|NCT01363778|Experimental|tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
11498672|NCT01363765|Experimental|Xpert MTB/Rif|Sputum specimens arriving during intervention period will be submitted to this technology, a real-time automated polymerase chain reaction test
11498673|NCT01363765|Active Comparator|Sputum smear|Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining
11498674|NCT01363752|Active Comparator|Advagraf + MMF + Steroids|Without sirolimus
11498675|NCT01363752|Experimental|Advagraf + MMF + Steroids + Sirolimus|With sirolimus; MMF withdrawn on Day 28; Sirolimus introduced on Day 28
11498676|NCT01363726||2|Jewish and Bedouin children < 5 years of age in southern Israel
11498677|NCT01363713|Experimental|1|
11498678|NCT01363700|Experimental|1|
11498679|NCT01363700|Placebo Comparator|2|
11498680|NCT01363700|Active Comparator|3|
11498681|NCT01363687|Experimental|Remote ischemic postconditioning group|Recipients receive remote ischemic postconditioning after declamping of renal artery during kidney transplantation
11498682|NCT01363687|No Intervention|Control group|Patients who have a deflated cuff placed on the upper limb free of arteriovenous fistula during the surgery
11498683|NCT01363661|Experimental|Molsidomine|Coruno (molsidomine 16 mg tablet; per os; once daily)
11498684|NCT01363661|Placebo Comparator|Placebo|Placebo (16 mg tablet; once a day)
11498685|NCT01363648|Experimental|Choline alfoscerate|choline alfoscerate 400mg, 3 times a day, for 12 weeks.
11498686|NCT01363648|Placebo Comparator|placebo (for choline alfoscerate )|placebo tablet, 3 times a day, for 12 weeks.
11498692|NCT01363609|Active Comparator|Insulin glargine|12 week treatment, once daily, with insulin glargine. Dosage based on fasting blood glucose measurements
11498693|NCT01363609|Other|before start of treatment period|before start of the treatment period, one day with tests will be performed. During this test a GLP-1 receptor antagonist will be administered In the group with obesity and planned gastric bypass surgery, the GLP-1 receptor agonist will be administered during 1 test before and 1 test after the surgery
11498694|NCT01363596||Natural Procreative Technology (NPT)|Patients who are treated or who consider being treated with Natural Procreative Technology (NPT) for infertility or history of spontaneous abortion.
11498695|NCT01363583|Active Comparator|epoprostenol, Flolan®|Measurement on the effect of epoprostenol on lactate/pyruvate ratio measured by cerebral microdialysis
11498696|NCT01363583|Placebo Comparator|normal saline|Effect of saline on the lactate/pyruvate ratio measured by cerebral microdialysis
11498697|NCT01363570|Other|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
11498698|NCT01363557|Experimental|Arm A : Gefitinib + WBRT|Arm A : WBRT and Concurrent Gefitinib followed by Gefitinib Maintenance
11498699|NCT01363557|Experimental|Arm B : Gefitinib|Arm B : Gefitinib alone
11498700|NCT01363544|Experimental|Neurofeedback|
11498701|NCT01363544|Experimental|Exercise|
11498702|NCT01363544|Active Comparator|methylphenidate|optimum dose of methylphenidate (assessed by a double blind placebo-controlled procedure)
11498703|NCT01363531|Active Comparator|Direct antibiotic treatment|The doctor gives to patient an antibiotic prescription for his respiratory infection, which he should start immediately.
11498704|NCT01363531|No Intervention|No antibiotic treatment|The doctor doesn't give to patient an antibiotic prescription for his respiratory infection.
11498705|NCT01363531|Experimental|Delayed antibiotic prescription 1|The doctor gives to patient an antibiotic prescription for his respiratory infection with the advice to use it if needed, in case of worsening of symptoms or not improving.
11498706|NCT01363531|Experimental|Delayed antibiotic prescription 2|The doctor leaves the antibiotic prescription, for the respiratory infection of the patient, at the reception of the primary care center 3 days after the first medical visit. This prescription can be collected by patient if he needed, in case of worsening of symptoms or not improving.
11498707|NCT01363518||Operative|Operative group would have had surgery to treat their broken humerus.
11498708|NCT01363518||Nonoperative|Nonoperative group would have been treated with a brace, no surgery.
11498709|NCT01363505||Acute CHF patients|Acute CHF patients with BARD Intra-abdominal pressure monitors in ICU
11498710|NCT01363492|Experimental|Replagal 0.2 mg/kg every other week (EOW)|
11498711|NCT01363479|Experimental|Oral palonosteron plus dexamethasone|Oral palonosetron (Aloxi 0.50 mg softgel capsule) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
11498712|NCT01363479|Active Comparator|I.V. palonosetron plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
11498713|NCT01363466|Experimental|with hysterectomy|
11498714|NCT01363466|No Intervention|without hysterectomy|
11498715|NCT01363453||Patients with Ulcerative Colitis|
11498716|NCT01363440|Active Comparator|Macular Laser Photocoagulation Treatment (Control)|Participants received macular laser treatment at baseline and as-needed at visits at which laser re-treatment criteria were met, but no more frequently than every 12 weeks.
11498717|NCT01363440|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4|Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks.
11498718|NCT01363440|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8|Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks for 5 visits followed by injections every 8 weeks.
11498719|NCT01363427||Crohn's disease|Patients with initially diagnosed Crohn's disease
11498720|NCT01363414|Experimental|Artificial tear|One drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
11498721|NCT01363414|Placebo Comparator|Control|one drop of sterile 0.9% sodium chloride solution in the other eye
11498722|NCT01363401|Experimental|Test group|Treatment group with HYNR-CS inj.
11498723|NCT01363401|Experimental|Control group|No treatment with HYNR-CS inj.
11498724|NCT01363388|Placebo Comparator|Placebo|
11498725|NCT01363388|Experimental|CCX168|Active study medication
11498726|NCT01363375||normal foot|Subjects with normal foot structure
11498727|NCT01363375||flat foot|Subjects with flat foot structure.
11498728|NCT01363375||high arch foot|Subjects with high arch foot structure.
11498729|NCT01363362|Experimental|glaucoma patients|Glaucoma patients undergoing selective laser trabeculoplasty for further IOP reduction
11498730|NCT01363349|Experimental|CYP-1020|Dose titration 15-35mg/day for 6 months
11498731|NCT01363349|Active Comparator|Risperidone|Dose titration 2-6mg/day for 6 months
11498732|NCT01363336||Group 1|
11498733|NCT01363323|Experimental|Arm 1|
11498734|NCT01363323|Experimental|Arm 2|
11498735|NCT01363323|Experimental|Arm 3|
11498736|NCT01363323|Placebo Comparator|Arm 4|
11498737|NCT01363323|Active Comparator|Arm 5|
11498738|NCT01363310|Active Comparator|Quetiapine XR|
11498739|NCT01363310|Active Comparator|Escitalopram|
11498740|NCT01363297|Experimental|Inotuzumab Ozogamicin|
11498741|NCT01363284|Experimental|Duloxetine|The first week of the treatment is the placebo treatment. The effect of placebo will be taken into consideration for further evaluation the duloxetine effect on clinical pain and descending pain inhibition capabilities.
11498742|NCT01363271||complicated skin and skin structure infections (cSSSI)|Identified through a pre-specified list of ICD-9 codes in study protocol.
11498743|NCT01363271||Pneumonia|Identified through a pre-specified list of ICD-9 codes in study protocol.
11499436|NCT01358305|Experimental|Protein Blend (soy, whey and casein)|
11498744|NCT01363258|Experimental|Care-resistant mouth care (MOUTh)|These nursing home residents with dementia receive mouth care from study personnel who use strategies to reduce care-resistant behavior (Managing Oral Hygiene Using Threat Reduction or MOUTh) while providing evidence-based mouth care.
11498745|NCT01363258|Active Comparator|Evidence Base Mouth Care|Nursing home residents with dementia received mouth care from study personnel who were trained in evidence-based mouth care only.
11498746|NCT01363245|Experimental|Hospital phone counseling|multisession telephone counseling by hospital/study's smoking cessation staff
11498747|NCT01363245|Active Comparator|Fax-to-quit|Faxed referral to the state Quitline, which will then perform phone outreach as per Quitline protocol
11498748|NCT01363232|Experimental|BKM120 + MEK162|
11498749|NCT01363206|Experimental|Single arm open label|GM-CSF and Ipilimumab
11498750|NCT01363180||Control|
11498751|NCT01363180||Trauma-exposed without PTSD|
11498752|NCT01363180||Trauma-exposed with PTSD|
11498753|NCT01363167|Active Comparator|400 IU Cholecalciferol - Vitamin D|
11498754|NCT01363167|Placebo Comparator|Placebo|Placebo contains Fractionated Coconut Oil
11498755|NCT01363154|Active Comparator|Mozart K448|Treatment: music exposure to Mozart K448
11498756|NCT01363154|Placebo Comparator|Beethoven's Für Elise|Placebo: music exposure to Beethoven's Für Elise for piano
11498757|NCT01363154|No Intervention|No music exposure|Control: no music exposure
11498758|NCT01363141|Active Comparator|Regular AGE Diet|Regular AGE Diet
11498759|NCT01363141|Active Comparator|Low AGE Diet|One year reduction in dietary AGE intake
11498760|NCT01363128|Experimental|Treatment (hyper-CVAD, ofatumumab)|"COURSES 1, 3, 5, 7: Patients receive hyper-CVAD comprising cyclophosphamide IV over 3 hours every 12 hours on days 1-3; doxorubicin hydrochloride IV over 24 hours on day 4; vincristine sulfate IV over 15 minutes on days 4 and 11; and dexamethasone IV over 30 minutes or PO QD on days 1-4 and 11-14. Patients also receive ofatumumab IV over 4-6 hours on days 1 and 11 of courses 1 and 3.
~COURSES 2, 4, 6, 8: Patients receive high-dose methotrexate IV over 2 hours and then over 22 hours on day 1 and cytarabine IV over 2 hours every 12 hours on days 2-3. Patients also receive ofatumumab IV over 4-6 hours on days 1 and 8 of courses 2 and 4.
~Treatment repeats every 21-28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients may receive maintenance therapy for an additional 30 months."
11498761|NCT01363115|Experimental|OJ fortified with Ca and VitD|Regular OJ fortified with Calcium (350 mg/8 fluid oz serving) and Vitamin D3 (100 IU/8 fluid oz serving): one 8 fluid oz serving three times/day (treatment) in combination with nutritional counseling
11498762|NCT01363115|Active Comparator|OJ without VitD and Ca|Regular OJ without Calcium or Vitamin D3: one 8 fluid oz serving three times/day (control)
11498763|NCT01363102|No Intervention|Control group|Group will undergo usual mobilization per standard SICU care
11498764|NCT01363102|Experimental|Study Group|Patient mobilization discussed on rounds, SOMS score goal created, specific attempt to mobilize patient and achieve goal throughout day.
11498765|NCT01363089|Experimental|Ketorolac tromethamine|
11498766|NCT01363089|Experimental|Oxymetazoline hydrochloride|
11498767|NCT01363076|Experimental|Ketorolac Tromethamine (15 mg)|Ketorolac Tromethamine - single dose (15 mg) administered intranasally (IN) for subjects weighing <50 kg.
11498768|NCT01363076|Experimental|Ketorolac Tromethamine (30 mg)|Ketorolac Tromethamine - single dose (30 mg) administered intranasally (IN) for subjects weighing ≥50 kg.
11498769|NCT01363063|Experimental|Ketorolac tromethamine (Part A)|
11498770|NCT01363063|Experimental|Ketorolac tromethamine (Part B)|
11498771|NCT01363050|Experimental|Ketorolac tromethamine|
11498772|NCT01363037|Experimental|Dapivirine-Maraviroc Vaginal Ring|
11498773|NCT01363037|Placebo Comparator|Placebo Vaginal Ring|
11498774|NCT01363037|Active Comparator|Maraviroc Vaginal Ring|
11498775|NCT01363037|Active Comparator|Dapivirine Vaginal Ring|
11498776|NCT01363024|Experimental|A|
11498777|NCT01363011|Experimental|E/C/F/TDF (Cohort 1)|"Participants who have not received prior antiretroviral (ARV) treatment and who are virologically unsuppressed at baseline will initiate treatment with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) single-tablet regimen (STR) for up to 96 weeks.
~Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of E/C/F/TDF was received in the applicable country."
11498778|NCT01363011|Experimental|COBI+PI+2 NRTI (Cohort 2)|"Participants who have received prior ARV treatment and who are virologically suppressed at baseline will continue their treatment regimen, switching the regimen's pharmacoenhancer component from ritonavir to cobicistat (COBI), and continuing their existing protease inhibitor (PI; either atazanavir (ATV) or darunavir (DRV)) plus 2 nucleoside reverse transcriptase inhibitor (NRTI) regimen for up to 96 weeks.
~Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of cobicistat was received in the applicable country."
11498779|NCT01362998|Active Comparator|Preservative free morphine|This group will receive 3mg of preservative free morphine epidurally during the procedure.
11498780|NCT01362998|Active Comparator|Fentanyl infusion|This group will receive an epidural infusion of fentanyl (60 micrograms per hour), which will be started during the Cesarean section and which will continue for the next two days.
11498781|NCT01362972||plerixafor + granulocyte colony stimulating factor (G-CSF)|Patients who receive plerixafor+granulocyte colony stimulating factor (G-CSF) for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
11498782|NCT01362972||plerixafor + G-CSF + chemotherapy|Patients who receive plerixafor+granulocyte colony stimulating factor (G-CSF)+chemotherapy for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
11498783|NCT01362972||granulocyte colony stimulating factor (G-CSF) + chemotherapy|Patients who receive granulocyte colony stimulating factor (G-CSF) + chemotherapy for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
11498784|NCT01362972||granulocyte colony stimulating factor (G-CSF) alone|Patients who receive granulocyte colony stimulating factor (G-CSF) alone for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
11498785|NCT01362959|Experimental|Nicotine patch|
11498786|NCT01362959|Placebo Comparator|Control patch|The control product is a look-alike patch compared to the test product, containing no nicotine or other active substances.
11498787|NCT01362946|Experimental|Reward-Emphasized treatment|This treatment consisted of behavior therapy modified to match the unique learning styles of children with CPCU. This was accomplished by emphasizing rewards and de-emphasizing punishments. This treatment was administered using a summer treatment program.
11498788|NCT01362946|Active Comparator|Standard treatment|This treatment consisted of standard behavior therapy, in which reward and punishment components were used in a balanced manner, as is typically done in outpatient settings. This treatment was administered using a summer treatment program.
11498789|NCT01362933||VTE treatment in cancer patient|All patients with cancer present in the clinic, hospital, out patient diagnosed with a VTE during the 6 previous months.
11498790|NCT01362920||Sepsis or Septic shock cohort|
11498791|NCT01362920||Non-sepsis or non-Septic shock cohort|
11498792|NCT01362907|Other|Delefilcon A / etafilcon A|Delefilcon A contact lenses worn first, with etafilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
11498793|NCT01362907|Other|Etafilcon A / delefilcon A|Etafilcon A contact lenses worn first, with delefilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
11498794|NCT01362894|Other|nelfilcon A / etafilcon A|Nelfilcon A lenses worn first, with etafilcon A lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
11498795|NCT01362894|Other|etafilcon A / nelfilcon A|Etafilcon A lenses worn first, with nelfilcon A lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
11498796|NCT01362829||Patients with severe sepsis|Patients who are admitted to medical ICU with severe sepsis
11498797|NCT01362816||Palliative care cancer patients|"Inclusion criteria are:
~Patient has a cancer diagnosis (radiological, histological, cytological or operative evidence), local, loco-regional or metastatic disease, defined as a palliative care patient; enrolled in a palliative care programme, age 18 years or older, able to provide written informed consent, able to complete the data collection tool, preferably without help, available for follow up registration"
11498798|NCT01362803|Experimental|Arm 1|Phase 1: AZD6244 PO BID x 28 DAYS
11498799|NCT01362803|Experimental|Arm 2|Phase 2: AZD6244 PO BID x 28 DAYS
11498800|NCT01362790|Experimental|Mesothelioma Pilot Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle
~Other Names:
~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle
~Other Names:
~• Cytoxan Drug: SS1 (dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg days 10, 12, and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
11498801|NCT01362790|Experimental|Mesothelioma Pilot Phase Regimen B|"Drug: Pentostatin Regimen B: Cycle 1: 4 mg/m^2 or 2 mg/m^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m^2 on days 1 and 5 of 25 day cycle Regimen B: Cycle 1: 4 mg/m^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m^2 on days 1 and 5 of 25 day cycle
~Other Names:
~• Nipent Drug: Cyclophosphamide Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle
~Other Names:
~• Cytoxan Drug: SS1 (dsFv)PE38 Regimen B: Cycle 1: 35mcg/kg days 18, 20, and 22. Cycles 2-4: (Days 6, 8, and 10), for a maximum of six treatment cycles."
11498802|NCT01362790|Experimental|Phase 2 Peritoneal Mesothelioma Pilot Expansion Phase|"Drug: Pentostatin Regimen B: Cycle 1: 4 mg/m^2 or 2 mg/m^2 on days 1, 5 and 9 of 38 day cycle Cycles 2-6: 4 mg/m^2 on day 1 and 5 of 25 day cycle
~Other Names:
~• Nipent Drug: Cyclophosphamide Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle
~Other Names:
~• Cytoxan Drug: SS1(dsFv)PE38 Regimen B: Cycle 1: 35 mcg/kg or 25 mcg/kg days 18, 20 and 22. Cycles 2-4: Days 6, 8, and 10, for a maximum of six treatment cycles."
11498803|NCT01362790|Experimental|Phase 2 Pleural Mesothelioma Pilot Expansion Phase|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle
~Other Names:
~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle
~Other Names:
~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
11498804|NCT01362790|Experimental|Mesothelioma Positive Ca Dose De-escalation Pilot Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle
~Other Names:
~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle
~Other Names:
~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
11498805|NCT01362790|Experimental|Phase 2 Pancreatic Adenocarcinoma Pilot Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle
~Other Names:
~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle
~Other Names:
~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
11498806|NCT01362790|Experimental|Phase 2 Lung Adenocarcinoma Pilot Expansion Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle
~Other Names:
~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle
~Other Names:
~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
11498807|NCT01362777|Experimental|In-Patient Rehabilitation|"Sessions of rehabilitation contains :
~Individualized exercise training
~Educational activities
~Dietary advices"
11498808|NCT01362777|Active Comparator|Educational activities alone|"Out-patient control arm contains only :
~-Educational activities"
11498809|NCT01362764|Other|001|Abiraterone acetate tablets Type=exact unit=mg number= 250 form=tablet route=oral use as a single dose
11498810|NCT01362764|Other|002|Abiraterone acetate suspension Formulation 1 Type=exact unit=mg/mL number=25 form=oral suspension route=oral use as a single dose of 10 mL
11499027|NCT01361113|Other|Single Arm Neoadjuvant Pazopanib|Pazopanib 800 mg PO once daily for 8 weeks
11498811|NCT01362764|Other|003|Abiraterone acetate suspension Formulation 2 Type=exact unit=mg/mL number=25 form=oral suspension route=oral use as a single dose of 10 mL
11498812|NCT01362751||Nursing home residents|In this study, patients from both the somatic and the psychogeriatric department are included. For the primary endpoint 'successful rehabilitation' only the patients from the somatic departments are included.
11498813|NCT01362738|Active Comparator|Ablation of PV and extra-PV triggers|Conventional approach which includes pulmonary vein isolation (PVI) and ablation of extra-pulmonary triggers
11498814|NCT01362738|Active Comparator|LAA isolation along with the conventional ablation strategy|LAA isolation along with the conventional ablation strategy
11498815|NCT01362725|Experimental|Spinal cord stimulation|
11498816|NCT01362699|Experimental|JNJ-31001074|
11498817|NCT01362699|Placebo Comparator|Placebo|
11498818|NCT01362686|Experimental|Donepezil|See intervention note.
11498819|NCT01362686|Experimental|Galantamine|See intervention note.
11498820|NCT01362686|Experimental|Rivastigmine|See intervention note.
11498821|NCT01362673|Experimental|Single dose|
11498822|NCT01362673|Experimental|Multiple dose|
11498823|NCT01362660||Infants with potential exposure in utero|
11498824|NCT01362634|Experimental|CAPI Intervention|an interviewer-administered comprehensive health and social risk assessment intervention
11498825|NCT01362634|Experimental|ACASI Intervention|self-administered comprehensive health and social risk assessment intervention
11498826|NCT01362634|No Intervention|Control|waitlist control condition
11498827|NCT01362621||Children 6 to less than 12 years of age|
11498828|NCT01362608|Experimental|Canakinumab and placebo matching to triamcinolone acetonide|ACZ885H
11498829|NCT01362608|Active Comparator|Triamcinolone acetonide 40 mg|ACZ885H
11498830|NCT01362595|Other|Leucine|No alternative treatment arm
11498831|NCT01362582|No Intervention|Chemotherapy, Nutritional Care|"5-Fluorouracil (5-FU) 2000mg/m2 IV (24-hour)/folinic acid (FA) 200mg/m2 IV (30 min) will be administered weekly over four weeks with additional oxaliplatin 85 mg/m2 IV (2-hour) on days 8 and 22. Therapy will be interrupted between days 23 to 42. The next cycle will be started on day 43.
~Subjects in the control group receive Best Supportive Nutritional Care. BSNC is defined as nutritional consultation and recommendation by experienced ecotrophologists."
11498832|NCT01362582|Experimental|PN, Chemotherapy, Nutritional Care|"5-Fluorouracil (5-FU) 2000mg/m2 IV (24-hour)/folinic acid (FA) 200mg/m2 IV (30 min) will be administered weekly over four weeks with additional oxaliplatin 85 mg/m2 IV (2-hour) on days 8 and 22. Therapy will be interrupted between days 23 to 42. The next cycle will be started on day 43.
~Patients receive also Best Supportive Nutritional Care defined as nutritional consultation and recommendation by experienced ecotrophologists.
~Intervention: Supportive Parenteral Nutrition"
11498833|NCT01362569||predialytic renal insufficiency|Patents without renal replacement therapy
11498834|NCT01362569||hemodialysis/hemofiltration patients|patients undergoing regular hemodialysis/hemofiltration
11498835|NCT01362569||peritoneal dialysis patients|patients undergoing peritoneal dialysis
11498836|NCT01362569||acute renal failure|patients with acute renal failure
11498837|NCT01362569||post renal transplantation|patients after renal transplantation
11498838|NCT01362569||healthy controls|control group
11498839|NCT01362556|Placebo Comparator|Sodium Chloride|Group receiving sodium chloride 0.9% after arterial blood gas analysis in cardiac arrest.
11498840|NCT01362556|Active Comparator|Sodium Bicarbonate|Group receiving targeted sodium bicarbonate 8% therapy after arterial blood gas analysis in cardiac arrest.
11498841|NCT01362543|Active Comparator|Stress Management|
11498842|NCT01362543|Active Comparator|Cognitive restructuring|
11498843|NCT01362530|Experimental|Aprepitant Regimen|"Cycle 1:
~Participants 12 to 17 years of age, Day 1: aprepitant 125 mg capsule orally (PO) + ondansetron, Days 2 to 3: aprepitant 80 mg capsule PO. Participants 6 months to <12 years of age, Day 1: aprepitant powder for suspension (PFS), 3.0 mg/kg (up to 125 mg) + ondansetron, Days 2 to 3: aprepitant PFS, 2.0 mg/kg (up to 80 mg).
~Optional Cycles 2-6:
~Open-label aprepitant administered in the same manner as in Cycle 1."
11498844|NCT01362530|Placebo Comparator|Control Regimen|Cycle 1: Participants 12 to 17 years of age, Day 1: matching placebo for aprepitant 125 mg capsule oral (PO) + ondansetron Days 2 to 3: matching placebo for aprepitant 80 mg capsule PO. Participants 6 months to <12 years of age, Day 1: matching placebo PFS: 3.0 mg/kg (up to 125 mg) + ondansetron, Days 2 to 3: matching placebo PFS: 2.0 mg/kg (up to 80 mg). Optional Cycles 2-6: Open-label aprepitant administered in the same manner as in Cycle 1.
11498845|NCT01362517|Experimental|Quinvaxem|
11498846|NCT01362504||Clinical sepsis|
11498847|NCT01362504||Proven sepsis|
11498848|NCT01362504||Control group|healthy neonates
11498849|NCT01362491|Experimental|Treatment A|
11498850|NCT01362491|Active Comparator|Treatment B|
11498851|NCT01362491|Placebo Comparator|Treatment C|
11498852|NCT01362478||Case group|
11498853|NCT01362478||Control group|
11498854|NCT01362465|Experimental|Cardiac Resynchronization Therapy (CRT)|Implanting device to measure delays between paced chambers in heart failure patients.
11498855|NCT01362452|Experimental|Double Umbilical Cord Blood (UCB)|"Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.
~Starting dose level of T-cells not to exceed 106/m2.
~The investigational component of the treatment plan of this study is the infusion of CD19-specific T cells derived from cord blood (CB) to be infused Day +42 to Day +100 following stem cell transplantation. The transplant component of the treatment plan will include CB transplant regimens that are commonly use for CB transplantation."
11498856|NCT01362452|Experimental|Single Umbilical Cord Blood (UCB)|"Single UCB unit arm does not start enrollment until Dose Level A2 in the double UCB unit arm has been deemed safe.
~Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.
~Starting dose level of T-cells not to exceed 106/m2.
~The investigational component of the treatment plan of this study is the infusion of CD19-specific T cells derived from cord blood (CB) to be infused Day +42 to Day +100 following stem cell transplantation. The transplant component of the treatment plan will include CB transplant regimens that are commonly use for CB transplantation"
11498857|NCT01362439|Experimental|Paliperidone ER|
11499028|NCT01361100|Experimental|Oncoral test|
11498858|NCT01362426||001|paliperidone palmitate Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
11498859|NCT01362400|Active Comparator|ARM 1: IPI 504 + Docetaxel|Drug: IPI-504 plus Docetaxel
11498860|NCT01362400|Placebo Comparator|Placebo + Docetaxel|Placebo plus Docetaxel
11498861|NCT01362387|No Intervention|Group 1|Women assigned to Group 1 will receive the standard post-abortion follow-up currently used at bpas and will be undertaken as usual by staff at the treating clinic
11498862|NCT01362387|Experimental|Group 2|Follow-up after medical abortion using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test.
11498863|NCT01362374|Experimental|Arm A (Ipatasertib + Docetaxel)|Participants will receive ipatasertib at a starting dose of 100 milligrams (mg) once daily for 14 consecutive days (beginning on Day 2) in combination with docetaxel on Day 1, in 21-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurs first.
11498864|NCT01362374|Experimental|Arm B (Ipatasertib + mFOLFOX6)|Participants will receive ipatasertib at a starting dose of 100 mg once daily for 7 consecutive days (beginning on Day 1) in combination with mFOLFOX6 chemotherapy (comprising of oxaliplatin, leucovorin, and 5-FU) on Day 1, in 14-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurs first.
11498865|NCT01362374|Experimental|Arm C (Ipatasertib + Paclitaxel)|Participants will receive ipatasertib at a dose of 600 mg once daily for 21 consecutive days (beginning on Day 1) in combination with paclitaxel on Days 1, 8, and 15, in 28-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurs first.
11498866|NCT01362374|Experimental|Arm D (Ipatasertib + Enzalutamide)|Participants will receive ipatasertib at a dose of 400 mg once daily alone for 8 days, then from Day 9, ipatasertib will be administered in combination with enzalutamide once daily for 27 days (Cycle 1 duration = 35 days). Participants will receive both ipatasertib and enzalutamide once daily continuously in subsequent 28-days cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurs first. Higher (up to 600 mg) or lower dose of ipatasertib may be evaluated in subsequent cycles depending upon safety, tolerability, and pharmacokinetics of the first cycle.
11498867|NCT01362361|Experimental|Arm A|mFOLFOX6 + BIBF 1120
11498868|NCT01362361|Placebo Comparator|Arm B|mFOLFOX6+placebo
11498869|NCT01362348|Experimental|pazopanib eye drops|pazopanib topical ocular administration
11498870|NCT01362335||patients, that are having a routine surgical procedure.|
11498871|NCT01362322|Experimental|BOOSTRIX NEW GROUP|Subjects, aged 10 to 15 years, received one dose of Boostrix™ vaccine administered using a new syringe presentation (prefilled syringes from a different manufacturer) in the deltoid of the non-dominant arm, at Day 0.
11498872|NCT01362322|Active Comparator|BOOSTRIX PREV GROUP|Subjects, aged 10 to 15 years, received one dose of Boostrix™ vaccine administered using a previous syringe presentation (single dose vial or a prefilled disposable syringe without a needle) in the deltoid of the non-dominant arm, at Day 0.
11498873|NCT01362309|Placebo Comparator|Placebo|Inert filler in matched pill.
11498874|NCT01362309|Active Comparator|d-cycloserine 50 mg|50 mg d-cycloserine.
11498875|NCT01362296|Experimental|GSK1120212|Oral once daily
11498876|NCT01362296|Active Comparator|docetaxel|IV once every 3 weeks
11498877|NCT01362283||Hypertension|Subject who meet eligible criteria
11498878|NCT01362270|Experimental|Verum Acupuncture|Subjects will receive acupuncture using real acupuncture needles.
11498879|NCT01362270|Sham Comparator|Sham acupuncture|Subjects will receive sham acupuncture therapy using the Streitberger needle at the same points and on the same schedule as patients in the treatment group. Streitberger needles are blunt tipped and retract into themselves rather than penetrating the skin.
11498880|NCT01362257|Experimental|14C-GSK573719 Oral Solution|single dose of 1000µg
11498881|NCT01362257|Experimental|14C-GSK573719 IV Solution|single dose of 65µg
11498882|NCT01362244|Experimental|Treatment Periods 1-8|Part A comprises eight outpatient visits (Visits 1 - 8). For six of these visits, subjects will receive a dose of either 750 mg mepolizumab or placebo. Dosing occurs in four week intervals. Assessment for entry into Part B will take place at the last visit in Part A (Visit 8). Subjects not eligible for Part B will have study exit procedures performed and be discontinued.
11498883|NCT01362244|Other|Run In period|10-14 day run in period to assess the patients suitability for entry into Part A of the trial.
11498884|NCT01362244|No Intervention|Treatment periods 9-13|Subjects eligible for Part B will attend the clinic for up to 5 more outpatient visits (Visits 9 - 13) for assessments. Visits occur every four weeks. There is no dosing in Part B. At the point when each subject meets Study Exit criteria, study exit procedures will be performed and the subject will exit the study.
11498885|NCT01362231|Experimental|GS-6624 125mg|
11498886|NCT01362231|Experimental|Experimental: GS-6624 200mg|
11498887|NCT01362218|Experimental|Fixed Dose Combination Pill|A fixed dose combination of acetylsalicylic acid, simvastatin, and ramipril Intervention: Drug: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)
11498888|NCT01362218|Active Comparator|Simvastatin|Simvastatin given together with the reference drugs ramipril and acetylsalicylic acid
11498889|NCT01362205|Experimental|Dexmedetomidine|Dexmedetomidine titrated to achieve predefined goals on selected components of the MINDS score using the minimum amount of medication possible. Blinded study medication will be started at a rate determined by the MINDS score. The maximum infusion rate is 1.4 μg/kg per hour. Uncontrolled SAWS/D symptoms, will be treated with open label lorazepam according to the MINDS score algorithm. Persistent SAWS/D symptoms despite maximum infusion rate of study medication treatment limiting symptoms while receiving higher infusion rates of study medication, ancillary therapies will be administered according to the MINDS score algorithm, at the discretion of the treating physician.
11498890|NCT01362205|Placebo Comparator|Placebo|Blinded placebo study drug administration in equal volume per hour as active study medication arm.
11498891|NCT01362192|Other|532 nm KTP Laser Treatment|
11498892|NCT01362179||unstimulated BM donors|Observational (non-interventional) study.
11498893|NCT01362179||filgrastim-mobilized PBSC donors|Observational (non-interventional) study.
11498894|NCT01362153|Experimental|001|Golimumab IV infusions of 2 mg/kg golimumab on Days 1 and 85.
11498896|NCT01362140|Experimental|Darbepoetin alfa|Participants received darbepoetin alfa 500 µg every three weeks (Q3W) for 24 weeks in the double-blind treatment period, and continued to receive darbepoetin alfa 500 µg Q3W during the active treatment period for an additional 48 weeks.
11498897|NCT01362140|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection every 3 weeks (Q3W) for 24 weeks during the double-blind treatment period. From week 25 participants received darbepoetin alfa 500 µg Q3W during the active treatment period for 48 weeks.
11498898|NCT01362127|Active Comparator|Radiochemotherapy|Arm I: Radiochemotherapy + Surgery
11498899|NCT01362127|Active Comparator|Chemotherapy|Arm II: Chemotherapy + surgery
11498900|NCT01362114|Experimental|Sihogayonggolmoryeo-tang extract|"name of product: 'SIHOGAYONGGOLMORYU TANG EXTRACT GRAN'
~standard code for item: 200005676
~shape, type: extract(brown)
~usage, content: adults;three times a day, each taken before or between meals
~dose, standard: 2.5g for each sack, capsulated
~storage : airtight container, stored in room temperature
~expiration date : 36months after manufacture
~macufacturing company: KyungBangnShinYak inc."
11498901|NCT01362114|Placebo Comparator|Placebo; corn flour,|"raw material: total contents(500㎎); cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)
~shape, type: extract(brown)
~usage, dose: adults: three times a day, 1 sack before or between meals
~dose, standard: 2.5g for each sack, capsulated
~storage : airtight container, stored in room temperature
~expiration date : 36 months after manufacture
~manufacturing company: KyungBangnShinYak inc."
11498902|NCT01362101|Active Comparator|Traditional behavioral intervention|
11498903|NCT01362101|Active Comparator|Mindfulness behavioral intervention|
11498904|NCT01362088||CVVH patients|
11498905|NCT01362075|Experimental|Local infiltration analgesia|
11498906|NCT01362075|Active Comparator|Interscalene catheter|
11498907|NCT01362062||RA Cohort|Participants with active RA who had an inadequate clinical response to current non-biologic disease modifying anti-rheumatoid drug (DMARD) and/or anti-tumor necrosis factor (anti-TNF) therapy being treated with tocilizumab according to the routine clinical practice and in line with prescribing information will be observed for a total duration of 12 months.
11498908|NCT01362049|Active Comparator|'Eligible' Subject Group - STAB|"Subjects between the ages of 21-55 years with low back pain >12 months who are eligible for Treatment-Based Classification (TBC) stabilization exercises based on current criteria:
~straight leg raise > 90 degrees
~aberrant trunk movement with trunk forward flexion
~positive prone instability test AND/OR
~passive lumbar mobility testing that is judged to be hypermobile at any level."
11498909|NCT01362049|Active Comparator|'Ineligible' Subject Group - STAB|Subjects between the ages of 21-55 years with low back pain >12 months who are not eligible for the TBC-based stabilization exercises based on current criteria
11498910|NCT01362049|Active Comparator|'Eligible' Subject Group - MSI|"Subjects between the ages of 21-55 years with low back pain >12 months who are eligible for Treatment-Based Classification (TBC) stabilization exercises based on current criteria:
~straight leg raise > 90 degrees
~aberrant trunk movement with trunk forward flexion
~positive prone instability test AND/OR
~passive lumbar mobility testing that is judged to be hypermobile at any level."
11498911|NCT01362049|Active Comparator|'Ineligible' Subject Group -MSI|Subjects between the ages of 21-55 years with low back pain >12 months who are not eligible for the TBC-based stabilization exercises based on current criteria
11498912|NCT01362036|Experimental|TXA127 sc injectable|All cohorts will recieve TXA127; Cohorts receive either 300, 600, or 900 ug/kg daily
11498913|NCT01362023|No Intervention|control|Control pupils follow their usual activities
11498914|NCT01362023|Experimental|lifestyle counseling|"In 3 academic years, the intervention program consisted of three components:
~Classroom practice by HPA to highlight healthy lifestyle habits
~Teaching practice by HPA using books designed to include the nutritional objectives
~Parental activities included with their children
~In each of 12 activities (1 h/activity), the classroom practice consisted of three components:
~Experimental development of activities regarding each healthy lifestyle habit
~Assessment of activity performed in classroom
~An activity developed for use at home"
11498915|NCT01362010|Experimental|Topical Minocycline Foam FXFM244 - 4%|Active ingredient: Minocycline Concentration: 4% Route: Topical Dosage schedule: Once daily, evening.
11498916|NCT01362010|Experimental|Topical Minocycline Foam FXFM244 - 1%|Active ingredient: Minocycline Concentration: 1% Route: Topical Dosage schedule: Once daily, evening.
11498917|NCT01362010|Placebo Comparator|Placebo foam|Active ingredient: None Route: Topical Dosage schedule: Once daily, evening
11498918|NCT01361997|Experimental|Chlorhexidine in isopropyl alcohol|This arm is composed of 545 hospitalized patients with suspected blood stream infection, to test 2% chlorhexidine gluconate in 70% isopropyl alcohol.
11498919|NCT01361997|Experimental|Isopropyl alcohol|This arm is composed of 572 hospitalized patients with suspected blood stream infection, to test 70% isopropyl alcohol.
11498920|NCT01361984|Experimental|Brovana (nebulized arformoterol)|Brovana (nebulized arformoterol) treatment for 2 weeks
11498921|NCT01361984|Experimental|Serevent (Salmeterol dry powder inhaler)|Serevent (Salmeterol dry powder inhaler) treatment for 2 weeks
11498922|NCT01361958|Experimental|T1 received 0.625 mg NOMAC + 1.5 mg E2|
11498923|NCT01361958|Experimental|T2 received 1.25 mg NOMAC + 1.5 mg E2|
11498924|NCT01361958|Experimental|T3 received 2.5 mg NOMAC + 1.5 mg E2|
11498925|NCT01361958|Experimental|T4 received 2.5 mg NOMAC + Lactose|
11498926|NCT01361945|Experimental|AUY922|Single Arm
11498927|NCT01361932|Experimental|Video of ED Discharge Instructions|
11498928|NCT01361932|No Intervention|Control (usual standard of care)|
11498929|NCT01361919|Experimental|Feedback During CPR Training and Testing|"A feedback defibrillator (ZOLL R series) will be used at teaching, immediate testing and 12 week (retention) testing. A simulation manikin with an attached accelerometer pad on its sternum will be used to collect CPR performance data. Subjects will be told to perform compressions on top of the accelerometer pad and will be taught to use and follow the audio and visual feedback to optimize their CPR performance. After training, the raw data collected by the accelerometer will be used as a demonstration and training tool, to correct the subjects' performance by visually demonstrating the difference between ideal and suboptimal CPR performance. Testing will be carried out with the use of a feedback defibrillator."
11499029|NCT01361074|Experimental|In Vivo Exposure|
11499030|NCT01361074|Experimental|Augmented Reality Exposure|
11498930|NCT01361919|Active Comparator|Feedback during CPR Training Not Testing|"A feedback defibrillator will be used for teaching, with a standard no feedback defibrillator used at immediate and 12 week (retention) testing to assess if the techniques the students' learned during training are transferable to devices without feedback. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest."
11498931|NCT01361919|Placebo Comparator|No Feedback Group|"A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur."
11498932|NCT01361906|No Intervention|Untreated control|Untreated control
11498933|NCT01361906|Experimental|Sensomotoric training|Treatment with Sensomotoric training
11498934|NCT01361893|Other|Lifestyle Counseling|Parents who qualify for the study will be asked to participate in the survey portion of the study. informed consent will be obtained. After completing the survey each parent will be asked if they would be willing to participate in and additional interview (focus group or semi-structured in-debth interview) at a later date.
11498935|NCT01361880|Other|Reduce infant mortality|The overall purpose of this study is to develop and evaluate a systematic approach to improve African-American parental behaviors specifically with regards to the infant sleep environment
11498936|NCT01361867|Other|Robot-induced perturbations|The subject walks on a treadmill with his/her legs strapped to a robotic system (Lokomat by Hocoma AG) that generates mechanical perturbations aimed to modify the subject's walking pattern.
11498937|NCT01361854|Experimental|polysomnography for suspicion of SDB|adults, suspects of suffering from sleep disordered-breathing, who must undergo a diagnostic polysomnography
11498938|NCT01361841|Other|ophtalmic solution,|Travoprost, latanoprost and bimatoprost, ophthalmic solution are topical medications used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. they are synthetic prostaglandin F 2α analogue (and prodrug for bimatoprost) that works by increasing the outflow of aqueous fluid from the eyes.
11498939|NCT01361828||Patients with choroidal neovascularization|CNV due to Age-Related Macular Degenerations and Myopia were included.
11498940|NCT01361815|Other|H-Coil Deep TMS Treatment|
11498941|NCT01361802|Active Comparator|Ambroxol Spray 2.5mg|Ambroxol Spray Low Dose
11498942|NCT01361802|Active Comparator|Ambroxol Spray 5mg|Ambroxol Spray Medium Dose
11498943|NCT01361802|Active Comparator|Ambroxol Spray 10mg|Ambroxol Spray High dose
11498944|NCT01361802|Placebo Comparator|Placebo Spray|Placebo Spray
11498945|NCT01361789|Active Comparator|COXIB|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.
~After retraction of parecoxib from the market:
~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
11498946|NCT01361789|Active Comparator|Dexamethasone|dexamethasone 8 mg iv
11498947|NCT01361789|Active Comparator|COXIB and dexamethasone|combination of coxib AND dexamethasone
11498948|NCT01361776|Active Comparator|TBE vaccine at 0+30 days|This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later
11498949|NCT01361776|Active Comparator|TBE vaccine at 0+7+21 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later
11498950|NCT01361776|Active Comparator|TBE vaccinte at 0+30+90 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later
11498951|NCT01361776|Active Comparator|younger participants|This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later
11498952|NCT01361763|Experimental|Dabigatran|
11498953|NCT01361763|Active Comparator|Antiplatelets|
11498954|NCT01361750|Experimental|gastirc tube group|conduit will be perfomed by narrowed gastric tube
11498955|NCT01361750|No Intervention|control group|conduit will be traditional subtotal stomach without any surgical modification
11498956|NCT01361737||preeclampsia|"Control group: 86 healthy women not developing preeclampsia (PE)
~Case group: 43 women developing PE"
11498957|NCT01361724|Other|One on one with a PT|The participant will work one-on-one with a trained for PT for 3 days a week for four weeks.
11498958|NCT01361724|Other|Group exercise class|The participant will be in a group exercise class. That will meet 3 days a week for 4 weeks.
11498959|NCT01361724|Other|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
11498960|NCT01361711|Experimental|Treatment (monoclonal antibody therapy)|Patients receive alemtuzumab SC three times a week in weeks 1-18 and ofatumumab IV over 4-6 hours on day 1 of weeks 3, 5, 7, 9, 11, 13, 15, and 17.
11498961|NCT01361698|Experimental|IMR program|The program is organised into 11 curriculum topic areas: recovery strategies, practical facts about mental illness, the stress-vulnerability model, building social support, using medication effectively, drug and alcohol use, reducing relapses, healthy lifestyle, coping with stress, coping with problems and symptoms, and getting your needs met in the mental health system. In this Danish trial IMR will be implemented in group format with 10 patients assigned to each group and two IMR facilitators, and the IMR program will require nine months of weekly sessions to complete.
11498962|NCT01361698|No Intervention|Treatment as usual|Patients randomised to the control group will get 'treatment as usual' only. This means individual adapted interdisciplinary treatment including medication, individual support, occupational therapy, psycho-education and group therapy.
11498963|NCT01361646|Experimental|LC350189|
11498964|NCT01361646|Active Comparator|Febuxostat|
11498965|NCT01361646|Placebo Comparator|Placebo|
11498966|NCT01361633|Experimental|Medication|250 mg d-cycloserine
11498967|NCT01361633|Placebo Comparator|Sugar Pill|
11498968|NCT01361620|Other|Aspirin|All subjects took 7-10 days of 81 mg aspirin
11498969|NCT01361607|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligram [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
11498970|NCT01361607|Placebo Comparator|Placebo (GA-0034)|Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorings.
11498971|NCT01361594|Active Comparator|Intensive insulin treatment|Intensive insulin treatment (BG target: 100-140 mg/dL)
11498972|NCT01361594|Active Comparator|Conventional insulin treatment|Conventional insulin treatment (BG target: 141-180 mg/dl)
11498973|NCT01361581||ACD (acid-citrate-dextrose)|
11498974|NCT01361581||4% trisodium citrate|
11498975|NCT01361581||unfractionated heparin (UFH)|
11498976|NCT01361568|Experimental|CR845|Peripheral kappa opioid receptor agonist
11498977|NCT01361568|Placebo Comparator|Placebo|Matched Placebo
11498978|NCT01361555|Experimental|Arm 1: Placebo + BMS-820836 (0.5 mg/day)|
11498979|NCT01361555|Experimental|Arm 2: Placebo + BMS-820836 (1 mg/day)|
11498980|NCT01361555|Experimental|Arm 3: Placebo + BMS-820836 (2 mg/day)|
11498981|NCT01361542|Experimental|Anti TNF|Anti TNF alpha therapy including either infliximab or etanercept with data obtained before and after the study duration.
11498982|NCT01361529|Experimental|safty test|FLP,dose escalation,MTD
11498983|NCT01361516|Experimental|Intravenous sedation, General anaesthesia|IV sedation-ESWL under spontaneous respiration GA - ESWL under controlled respiration
11498984|NCT01361503||Autism Spectrum Disorder (ASD)|
11498985|NCT01361503||Controls|
11498986|NCT01361477||patient|"Prolonged ICU stay
~Unplanned ICU admission
~Complication/adversel during ICU admission
~Result of intraoperative complications and admission to ICU"
11498987|NCT01361464|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib orally twice daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11498988|NCT01361425|Experimental|methildopa|pregnant women with stable severe pre-eclampsia will use methildopa (1,5g/day)
11498989|NCT01361425|Placebo Comparator|placebo|stable pregnant women with severe preeclampsia will use placebo
11498990|NCT01361412|Experimental|ToleroMune Ragweed 4|
11498991|NCT01361412|Experimental|ToleroMune Ragweed Regimen 3|
11498992|NCT01361412|Experimental|ToleroMune Ragweed Regimen 2|
11498993|NCT01361412|Placebo Comparator|Placebo|Placebo
11498994|NCT01361412|Experimental|ToleroMune Ragweed Regimen 1|
11498995|NCT01361399|Experimental|Arm 1|
11498996|NCT01361399|Active Comparator|Arm 2|
11498997|NCT01361399|Active Comparator|Arm 3|
11498998|NCT01361399|Placebo Comparator|Arm 4|
11498999|NCT01361386||1|
11499000|NCT01361373|Active Comparator|DOPAMINE|Sinemet up to 10 mg/kg/day
11499001|NCT01361373|Placebo Comparator|Placebo|placebo
11499002|NCT01361360||control|
11499003|NCT01361360||hypercapnia|
11499004|NCT01361347|Placebo Comparator|placebo|"rice/soy/oat milkdrink, masked"
11499005|NCT01361347|Experimental|milk|cow's milk
11499006|NCT01361334|Experimental|Pazopanib|Pazopanib treatment
11499007|NCT01361321||patients after GBR procedure|The study will comprise of patients who already underwent a routine Guided Bone Regeneration (GBR) procedure in order to augment a bony ridge before dental implant insertion. The patients will be followed up in order to determine bone quality and quantity formed after the usage of routinely used bone substitutes during GBR procedure.
11499008|NCT01361308|Experimental|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate)
11499009|NCT01361308|Placebo Comparator|Placebo Capsules|Placebo Capsules
11499010|NCT01361295|Active Comparator|PVI with PVAC gold|Patient for pulmonal vein isolation using the PVAC Gold Catheter. Intervention.
11499011|NCT01361295|Active Comparator|PVI with Cooled-RF|Patient for pulmonal vein isolation using the Cooled-RF catheter.
11499012|NCT01361282||Triple Procedure|All qualifying patients will have received DSAEK with concurrent cataract extraction and intraocular lens placement. Data collection will occur between 6-18 months post-operation.
11499013|NCT01361269|Experimental|Fosmidomycin and clindamycin treatment|All the subject will be given fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
11499014|NCT01361256|Experimental|WA- NG Telescope Prothesis|Implantable Miniature Telescope for end stage AMD (Age-related Macular Degeneration)
11499015|NCT01361243|Experimental|NOURISH+|Participants will receive a 6-week face-to-face intervention, NOURISH+. Weekly topics teach parents skills to role model and encourage healthy lifestyle behaviors for their children.
11499016|NCT01361243|Placebo Comparator|Wellness Group|"Participants will receive an in-person Family Wellness Night followed by 6 mailings of information regarding pediatric overweight and obesity."
11499017|NCT01361230|Experimental|Protocol|Using sedation monitoring and protocol
11499018|NCT01361230|No Intervention|Control|Standard practice
11499019|NCT01361217|Experimental|Fluoxetine DDI|Only arm in the study. Successive Control (Study Days 1 and 3) and fluoxetine multiple-dose treatment (Study Days 16 and 18) Sessions.
11499020|NCT01361204|Experimental|Theanine|Experimental Comparator, theanine Taking 4 tablets of theanine two times daily for 16 days Placebo Comparator, sucrose Taking 4 tablets of sucrose two times daily for 16 days
11499021|NCT01361178|No Intervention|Transplant patients who do not receive SQ IVIG|Patients participating in the observational arm of the study who do not need to receive IgG replacement.
11499022|NCT01361178|Active Comparator|Transplant patients who receive SQ IVIG|Patients participating in the observational arm of the study who are randomized to receive a dosage of SQ IVIG due to low IgG level.
11499023|NCT01361152|Experimental|Fixed-bearing group|Fixed-bearing group
11499024|NCT01361152|Experimental|Mobile-bearing group|Mobile-bearing group
11499033|NCT01361048|Experimental|neo penotran forte|neo penotran forte vaginal suppository twice a day for 7 days
11499034|NCT01361048|Experimental|neo penotran forte once a day|neo penotran forte vaginal suppository once a day for 7 days
11499035|NCT01361035|No Intervention|No communication training|Physicians enrolled in the control arm do not undergo training in health literacy, cancer screening and shared decision making
11499036|NCT01361035|Other|Cancer risk ommunication skills training|Physicians enrolled in the intervention arm undergo training in health literacy, cancer screening and shared decision making
11499037|NCT01361022|Active Comparator|Brotizolam tablet|Brotizolam tablets 250mcg : at least 6 and 24 subjects will be enrolled in the pre-study and main study, respectively
11499038|NCT01361022|Experimental|Lendormin tablet|Lendormin tablets 250mcg: at least 6 and 24 subjects will be enrolled in the pre-study and main study, respectively
11499039|NCT01361009||pramipexole group|It's a open-label, non-intervention,observation post marketing surveillance to observe the safety and efficacy of pramipexole in real world.
11499040|NCT01360996|Experimental|3 mg DRSP/20 μg EE--normal weight|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
~Normal weight -BMI 18-24.9 kg/ m2"
11499041|NCT01360996|Experimental|3 mg DRSP/20 μg EE- Overweight|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
~BMI 25-29.9 kg/ m2"
11499042|NCT01360996|Experimental|3 mg DRSP/20 μg EE- Grade 1 obese|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
~BMI 30-34.9 kg/ m2"
11499043|NCT01360957|Placebo Comparator|Water flavored placebo|to be given orally in a dosage of 30 ml trice daily for 60 days
11499044|NCT01360957|Experimental|Black cumin water extract as a traditional medicine|Black cumin water extract as a traditional medicine to be given orally in a dosage of 30 ml trice daily for 60 days
11499045|NCT01360944|Experimental|LAS 41004, variant 1, once daily|variant 1, once daily
11499046|NCT01360944|Experimental|LAS41004, variant 2, once daily|variant 2, once daily
11499047|NCT01360944|Experimental|LAS41004, variant 3, once daily|variant 3, once daily
11499048|NCT01360944|Experimental|LAS41004, variant 4, once daily|variant 4, once daily
11499049|NCT01360944|Experimental|LAS41004, variant 5, once daily|variant 5, once daily
11499050|NCT01360944|Experimental|LAS41004, variant 6, once daily|variant 6, once daily
11499051|NCT01360944|Placebo Comparator|reference|once daily, 100microgram
11499052|NCT01360944|Active Comparator|reference, once daily|once daily
11499053|NCT01360931||Lung Cancer group|Subject with histological confirmation of lung cancer
11499054|NCT01360931||Control group|Subjects with no diagnosis of lung cancer
11499055|NCT01360918|Active Comparator|Usual care|
11499056|NCT01360918|Active Comparator|Pulmonary vein isolation|
11499057|NCT01360866|Experimental|OPC-34712 (Brexpiprazole) and Escitalopram|OPC-34712: Oral tablet; 0.5 to 3 mg/day Escitalopram: Oral tablet; 10 or 20 mg/day
11499058|NCT01360866|Experimental|OPC-34712 and Fluoxetine|OPC-34712: Oral tablet; 0.5 to 3 mg/day Fluoxetine: Oral capsules; 20 or 40 mg/day
11499059|NCT01360866|Experimental|OPC-34712 and Paroxetine CR|OPC-34712: Oral tablet; 0.5 to 3 mg/day Paroxetine CR: Oral controlled-release tablets; 37.5 or 50 mg/day
11499060|NCT01360866|Experimental|OPC-34712 and Sertraline|OPC-34712: Oral tablet; 0.5 to 3 mg/day Sertraline: Oral tablets; 100, 150, or 200 mg/day
11499061|NCT01360866|Experimental|OPC-34712 and Duloxetine|OPC-34712: Oral tablet; 0.5 to 3 mg/day Duloxetine: Oral delayed-release capsules; 40 or 60 mg/day
11499062|NCT01360866|Experimental|OPC-34712 and Venlafaxine XR|OPC-34712: Oral tablet; 0.5 to 3 mg/day Venlafaxine XR: Oral extended-release capsules; 75, 150, or 225 mg/day
11499063|NCT01360853|Experimental|Arm A: Combination|Arm A: Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle, + ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
11499064|NCT01360853|Active Comparator|Arm B: Gemcitabine only|Arm B: Gemcitabine only, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
11499065|NCT01360840|Placebo Comparator|Placebo + Standard of care (SoC)|
11499066|NCT01360840|Experimental|EMD 525797 750 mg + SoC|
11499067|NCT01360840|Experimental|EMD 525797 1500 mg + SoC|
11499068|NCT01360827|Experimental|Arm 1 (Part 1)|
11499069|NCT01360827|Experimental|Arm 2 (Expansion cohorts -Part 2 and Part 2a)|
11499070|NCT01360814||GROUP A (multidisciplinary intervention)|Patients receive six 90-minute sessions of a multidisciplinary structured intervention comprising physical therapy, education, a cognitive-behavioral intervention, discussion and support, spiritual reflection, and a relaxation exercise over 2-4 weeks. Caregivers are invited to sessions 1, 3, 4, and 6. Patients may also receive brief telephone contact during the 6 month follow-up period.
11499071|NCT01360814||GROUP B (standard medical care)|Patients receive standard medical care only. Patients may also receive brief telephone contact during the 6 month follow-up period.
11499072|NCT01360788||Healthy control subjects|Subjects with a significant smoking history (more than 10 pack-years) and a normal lung function.
11499073|NCT01360788||Asymptomatic GOLD stage I COPD patients|GOLD stage I COPD (post-bronchodilator forced expiratory volume in 1 second [FEV1] > 80% predicted and FEV1/ forced vital capacity [FVC] < 0.7 and a smoking history > 10 pack-years) were recruited. A Medical Research Council (MRC) dyspnea score ≥ 2 was used to define the presence of symptoms (dyspnea). Concretely, this group did not present any respiratory symptoms, with a MRC dyspnea score of 1/5.
11499074|NCT01360788||Symptomatic GOLD stage I COPD patients|GOLD stage I COPD (post-bronchodilator forced expiratory volume in 1 second [FEV1] > 80% predicted and FEV1/ forced vital capacity [FVC] < 0.7 and a smoking history > 10 pack-years) were recruited. A Medical Research Council (MRC) dyspnea score ≥ 2 was used to define the presence of symptoms (dyspnea) in this group.
11499075|NCT01360775|Experimental|nutritional counseling|Supervision and monitoring of nutritional status of patients in the home care program, after making nutritional advice
11499076|NCT01360775|No Intervention|Not nutritional counseling|
11499077|NCT01360762|Experimental|Pentamidine Secondary Prophylaxis (PSP)|"Patients with co-infection of human immunodeficiency virus (HIV)and visceral leishmaniosis (VL), having being treated for VL, are allocated to pentamidine secondary prophylaxis, to prevent VL relapses. The treatment period is of 12 months, plus an extended treatment period of 0 to 6 months depending on the immunosuppression status, plus 12 months follow-up after the extended treatment period."
11499078|NCT01360749|Experimental|Lambdalina and placebo|Eligible patients will receive lambdaline (lidocaine cream 40 mg/g) in Left Lower Extremity and placebo in Right Lower Extremity.
11499079|NCT01360749|Experimental|Placebo and lambdalina|Eligible patients will receive placebo in Left Lower Extremity and lambdaline (lidocaine cream 40 mg/g) in Right Lower Extremity.
11499080|NCT01360736|Experimental|Safety Planning - Military (SAFE-MIL)|Brief Safety Planning Using Stanley and Brown (2012) Model
11499081|NCT01360736|No Intervention|E-CARE|Treatment As Usual and Assessment Services of Study; Control Condition
11499082|NCT01360723||urothelial carcinoma|Pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists.
11499083|NCT01360723||Healthy controls group|Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
11499084|NCT01360710|Experimental|Moxonidine|
11499085|NCT01360710|Active Comparator|Irbesartan|
11499086|NCT01360697|Experimental|JADE- JA|Use the JADE portal to monitor the delivery of structured care.
11499087|NCT01360697|Active Comparator|Usual care|Patients will receive usual care in between two annual comprehensive assessments.
11499088|NCT01360671|Experimental|Sildenafil|iv sildenafil
11499089|NCT01360658|Experimental|Intravenous immunoglobulins|Intravenous immunoglobulins
11499090|NCT01360645|Experimental|Phase B|"Drug: OPC-34712 + ADT
~Drug: Placebo + ADT"
11499091|NCT01360645|Placebo Comparator|Phase A|Intervention: Drug: Placebo + ADT
11499092|NCT01360632|Experimental|Phase B|"Drug: OPC-34712 + ADT
~Drug: Placebo + ADT"
11499093|NCT01360632|Placebo Comparator|Phase A|Drug: Placebo + ADT
11499094|NCT01360606|Other|SBRT|
11499095|NCT01360593|Other|Gem, Xeloda, SBRT|
11499096|NCT01360567|Placebo Comparator|B formula|placebo
11499097|NCT01360567|Experimental|A formula|Green tea extract
11499098|NCT01360554|Experimental|A|Blinded active PF-00299804 + blinded placebo comparator (erlotinib)
11499099|NCT01360554|Active Comparator|B|Blinded active comparator (erlotinib) + blinded placebo PF-00299804
11499100|NCT01360541|Experimental|Radiofrequency ablation|Endoscopic radiofrequency ablation of BE
11499101|NCT01360541|Active Comparator|Surveillance|Endoscopic surveillance and PPI treatment
11499102|NCT01360528||Extremely low birth weight|Extremely low birth weight under 1000 gram
11499103|NCT01360528||Very low birth weight|Between 1000-1500 gram babies
11499104|NCT01360528||Low birth weight|Between 1500-2500 gram
11499105|NCT01360476|Active Comparator|Vitamin D|
11499106|NCT01360476|Placebo Comparator|placebo|
11499107|NCT01360463|Experimental|Behavioral and Drug Risk Counseling|Participants assigned to this arm will receive bi weekly Behavioral and Drug Risk Counseling (BDRC) counseling for six months.
11499108|NCT01360463|Active Comparator|Treatment as Usual|Participants assigned to this arm will receive methadone treatment without and alterations.
11499109|NCT01360450|Experimental|Treatment|Interventions: Infants will receive intravenous or oral clonidine(Duraclon) for the treatment of pain and sedation: Duration: (Clonidine HCL) 1 mcg/kg/dose q4 either iv or po.
11499110|NCT01360450|Placebo Comparator|Control|Intervention: Infants will receive place (saline) (if receiving it IV) or orally (sterile water) if receiving it orally
11499111|NCT01360437|Active Comparator|Prasugrel|
11499112|NCT01360437|Experimental|Ticagrelor|
11499113|NCT01360424|Experimental|teriparatide|
11499114|NCT01360411||Pancreatic lesions|"Any patient with a solid pancreatic lesion of unknown histology may be recruited. Cystic lesions are not included.
~Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively."
11499115|NCT01360411||Intramural upper GI-lesions|Patients with intramural lesions discovered by endoscopy or other imaging modalities are recruited. Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively.
11499116|NCT01360411||Lymph nodes|Patients with visible mediastinal lymph nodes or retroperitoneal lymph nodes in patients with inflammatory or malignant diseases are recruited. Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively.
11499117|NCT01360398|Other|Cohort|COPD male and female patients between 40 and 85 years of age, recruited among the patients of the Southampton General Hospital and referring practices.
11499118|NCT01360385||Central Retinal Vein Occlusion|CRVO-patients with planned treatment with intravitreal injections of ranibizumab, who receive three monthly injections of ranibizumab and a 3 month follow-up period, during which ranibizumab injections are provided as needed.
11499119|NCT01360372|Active Comparator|Methylnaltrexone|
11499120|NCT01360372|Placebo Comparator|saline placebo injection|
11499121|NCT01360359|Experimental|Core Stabilization|"8-week core stabilization program in 3 stage that emphasizes use of specific local trunk stabilizing muscles to restore active control and stability to the trunk.
~8-week exercise program, 1-2 sessions/ week, 30-60 minute sessions"
11499122|NCT01360359|Active Comparator|Trunk Motion and Fitness|"8-week exercise program in 3 stages emphasizing spine motion, general trunk flexibility and strengthening and cardiovascular fitness.
~8-week exercise program, 1-2 sessions/ week, 30-60 minute sessions"
11499123|NCT01360346|Experimental|Enteral Sedation (EN)|Melatonin, Hydroxyzine, and Lorazepam. At every work shift, it will be checked the possibility to decrease the Lorazepam and then the Hydroxyzine dosage to quickly obtain and continuously maintain a RASS level = 0
11499124|NCT01360346|Active Comparator|Intravenous Sedation (IV)|Intravenous propofol or midazolam administration at the ICU admission to discharge at the compatible lowest level with harsh ICU environment. At every shift nurses are requested to give intravenous lowest dosage to obtain RASS=0
11499125|NCT01360333|Other|Tap water, sodium chloride, carbohydrate rich fluid|
11499126|NCT01360320|Experimental|Green tea extract|Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG, bid for 3 years
11499127|NCT01360320|Placebo Comparator|Placebo|Placebo, packed in hard gelatine capsules, bid for 3 years
11499128|NCT01360307||Major Depressive Disorder Patients|
11499129|NCT01360294||Asthma with small airway disease|
11499130|NCT01360294||Asthma without small airway disease|
11499131|NCT01360281|Experimental|ECR|
11499132|NCT01360281|No Intervention|Control|
11499133|NCT01360281|Experimental|NMES|
11499134|NCT01360255||Patients treated with TACE|Patients treated with transarterial chemoembolisation (TACE) are included in this clinical trial
11499135|NCT01360242|Active Comparator|MIMI procedure (two-step strategy)|Thrombus aspiration is performed to achieve TIMI-3 flow. Once TIMI-3 flow is restored and sustained for > 10 minutes, the initial procedure is stopped regardless of the presence of any residual stenosis. A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
11499136|NCT01360242|Sham Comparator|Immediate Stenting (one-step strategy)|The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
11499137|NCT01360229|Sham Comparator|Randomized Subjects receive a sham acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
11499138|NCT01360229|Active Comparator|Randomized Subjects receive real acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
11499139|NCT01360216|Experimental|LARC education and training|Clinicians and contraceptive educators practicing in clinics assigned to this arm receive a special half-day Continuing Medical Education (CME/CEU) accredited LARC education and training session.
11499140|NCT01360216|No Intervention|Standard practice- control|Clinicians and contraceptive educators practicing in clinics assigned to this arm do not receive special LARC training and education session. Standard practice will be followed at clinics assigned to the control arm.
11499141|NCT01360203|No Intervention|Current Care|Patients will receive the current care provided to heart failure patients at each of the study sites
11499142|NCT01360203|Experimental|Care Transition Intervention|Care transition intervention beginning prior to discharge and through six months post-discharge.
11499143|NCT01360190|Active Comparator|fluoxetine|
11499144|NCT01360190|Placebo Comparator|placebo|
11499145|NCT01360177|Experimental|Radioactive Iodide and PET/CT|
11499146|NCT01360164|Experimental|Human umbilical cord mesenchymal stem cells transplantation|Participants will be given umbilical cord mesenchymal stem cells transplantation with a 1 year follow-up.
11499147|NCT01360151|Experimental|experimental|Arm 1 : combination treatment of ranibizumab(Lucentis) and verteporfin(Visudyne) injection
11499148|NCT01360151|Active Comparator|active comparator|Arm 2 : Treatment of verteporfin(Visudyne)
11499149|NCT01360151|No Intervention|normal control group|Arm 3 : normal control group
11499150|NCT01360138|Active Comparator|midline approach|cervical epidural steroid injection with 18G Touhy epidural needle by midline approach
11499151|NCT01360138|Active Comparator|paramedian approach|cervical epidural steroid injection with 18G Touhy epidural needle by paramedian approach
11499152|NCT01360086|Experimental|Perioperative CT with 5FU-Cisplatine-Cetuximab|6 cycles of intravenous Cetuximab (500mg/m²), Cisplatine (50mg/m²) and LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks. Surgery was planned 3-4 weeks after the end of neaodjuvant CT and postoperative CT, with the same regimen, planned for 6-8 weeks after surgery.
11499153|NCT01360073||Cases|Cases with nonfatal MI or coronary death
11499154|NCT01360073||Controls|Age, sex, and calendar-year matched controls sampled from the original study cohort to be a round number of at least four times the number of cases
11499155|NCT01360060||Group N|parturients who had undergone Cesarean section under the diagnosis of non-preeclampsia
11499156|NCT01360060||Group P|parturients who had undergone Cesarean section under the diagnosis of preeclampsia
11499157|NCT01360047||Cases|Cases with nonfatal MI or coronary death
11499158|NCT01360047||Controls|Age, sex, and calendar-year matched controls sampled from the original study cohort to be a round number of at least four times the number of cases
11499159|NCT01360034|Experimental|Nifedipine|108 patients will receive nifedipine as tocolytic for 48 hours.
11499160|NCT01360034|Experimental|Indomethacin|108 patients will receive indomethacin as tocolytic for 48 hours.
11499161|NCT01360021|Active Comparator|1 Symbicort/inhaler|Symbicort BA MDI 2x160/4.5 μg twice daily
11499162|NCT01360021|Active Comparator|Symbicort/inhaler|Symbicort AC pDMI 2x160/4.5 μg twice daily
11499163|NCT01360021|Active Comparator|Budesonide/inhaler|Budesonide AC pMDI 2x160 μg twice daily
11499164|NCT01360008||Cryo ablation|Patients with first Ablation of atrial fibrillation treated by cryo ablation
11499165|NCT01360008||RF ablation|Patients with first Ablation of atrial fibrillation treated by Radio frequency ablation
11499166|NCT01359982|Experimental|RRx-001|
11499167|NCT01359969|Experimental|Recombinant Human C1 Inhibitor|Patients presented to the clinic within 5 hours of onset received rhC1INH 50 U/kg body weight up to a maximum of 4200 U.
11499168|NCT01359956|Experimental|A1|combination chemotherapy without interferon
11499169|NCT01359956|Experimental|A2|combination chemotherapy with interferon
11499170|NCT01359956|Active Comparator|B1|single agent dacarbazine without interferon
11499171|NCT01359956|Experimental|B2|single agent dacarbazine plus interferon
11499172|NCT01359943|Experimental|secukinumab 10 mg/kg i.v. loading|secukinumab 10mg/kg i.v. loading at Weeks 0, 2 and 4, and placebo s.c. at weeks 0, 1, 2, 3 and 4, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 8
11499173|NCT01359943|Experimental|secukinumab 150 mg s.c. loading|secukinumab 150mg s.c. loading at Weeks 0, 1, 2, 3 and 4, and placebo i.v. at weeks 0, 2 and 4, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 8
11499174|NCT01359943|Placebo Comparator|placebo|placebo at Weeks 0, 1, 2, 3, 4, 8 & 12, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 16
11499175|NCT01359930|Active Comparator|Naltrexone and Bupropion SR|
11499176|NCT01359930|Placebo Comparator|Placebo|
11499177|NCT01359917||autologous fat transfer|patients received fat transfer for HIV lipodystrophy
11499178|NCT01359917||polylactic acid|treatment with polylactic acid (PLA) for HIV lipodystrophy
11499179|NCT01359917||bio-alcamid|bio-alcamid injections
11499180|NCT01359904|Active Comparator|high dialysate bath|additive is put in the dialysate to increase the concentration of glucose to 10mmol/l
11499181|NCT01359904|No Intervention|Standard dialysate glucose concentration|Standard 5.5 mmol/L dialysate glucose concentration.
11499182|NCT01359891||Cohort 1|"All patients >18 years admitted to the University Hospital Graz, Austria, with positive blood cultures tested in the Microbiology Laboratory, Department of Internal Medicine, Medical University Graz, or the Institute for Hygiene, Microbiology and Environmental Medicine, Medical University Graz, are screened for study inclusion. Patients eligible for the study have to have Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Enterococcus faecium, Enterococcus faecalis, Streptococcus pneumoniae, Klebsiella pneumoniae or medically relevant fungi / viral pathogens identified as causative pathogen.
~The estimated total number of patients included in this first study cohort will be 500."
11499183|NCT01359891||Cohort 2|"All patients >18 years admitted to the University Hospital Graz, Austria, will be screened for study inclusion if the attending emergency department physicians on the very first visit suspects bacteremia/fungemia/sepsis and consecutively orders blood cultures. Patients will be included in this second cohort if these initially taken blood culture turns positive (n=200) or stays negative (n=50) at the Microbiology Laboratory, Department of Internal Medicine, Medical University Graz. As soon as the number of 50 is reached for the control group enrollment will be stopped for this group.
~As soon as the proposed number of 250 patients is reached enrolment for this second cohort will be stopped. Patients enrolled in cohort 2 may also be consecutively enrolled in cohort 1."
11499184|NCT01359891||Validation Cohort|To verify the employed Presage™ST2 assay established in our study laboratory for its intended use, a total number of 70 left over plasma samples obtained from septic patients which have prior been tested for sST2 with the same assay at the Department of Laboratory Medicine, Barmherzige Brueder Linz, Austria, will be retested. This cohort therefore serves as a validation cohort.
11499185|NCT01359878|Experimental|Fibrinogen Concentrate|
11499186|NCT01359878|Placebo Comparator|Placebo|Isotonic Saline
11499187|NCT01359865|No Intervention|Lumbar plexus Block|This group will recieve pre-operative lumbar plexus block plus general anesthesia
11499188|NCT01359852|Experimental|001|"[11C] JNJ-42491293 + JNJ-40411813 Part C:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan,[11C] JNJ-42491293 + JNJ-40411813 Part D:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.
~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain,[11C] JNJ-42491293 Part A: [11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.,[11C] JNJ-42491293 Part B:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection have a 90 minute PET scan and have arterial and venous blood sampling."
11499189|NCT01359839|Experimental|Relaxation Response Mind Body Intervention|The Relaxation Response (RR) Mind Body Intervention Arm receives the Behavioral: Relaxation Response and Cognitive Behavioral Therapy Intervention which is a RR based Mind Body Group consisting of 1½ hour group classes held weekly for 8 weeks, in a conference room at the health center.
11499190|NCT01359826|Experimental|Milnacipran|Patients administered milnacipran will receive a dose escalation to 50 mg twice a day over 12 days and continued at this dose until week 6. If tolerated and a 15% improvement in fatigue from baseline is achieved by assessment on the FSS, then patients will continue taking 50 mg twice a day until the end of the study on day 98 (week 14). Otherwise, the dose of milnacipran will be titrated upward to 100 mg twice a day over 12 days and continued at this dose until day 98 (week 14).
11499191|NCT01359826|Placebo Comparator|Placebo|Placebo tablets administered orally twice a day for 14 weeks.
11499192|NCT01359813|No Intervention|Usual treatment|intravenous injection of Human Albumin. 1,5g/kg on first day and 1g/kg on third day
11499193|NCT01359813|Experimental|Human Albumin|1,5g/kg on first day and 1g/kg on third day.
11499194|NCT01359800||Treatment-naive HIV+ subjects|
11499195|NCT01359800||HAART-treated HIV+ subjects|
11499196|NCT01359787|Active Comparator|Mapracorat 0.01% Ointment|Lowest concentration
11499197|NCT01359787|Active Comparator|Mapracorat 0.03% Ointment|Middle concentration
11499198|NCT01359787|Active Comparator|Mapracorat 0.1% Ointment|Highest concentration
11499199|NCT01359787|Placebo Comparator|Vehicle without active|
11499200|NCT01359774|Other|Healthy volunteers|
11499201|NCT01359774|Other|Huntington patients|
11499202|NCT01359761|Experimental|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Post Admission Cognitive Therapy Individual Sessions; Up to Two (2) Inpatient Booster Sessions; Up to Four (4) Telephone Booster Sessions Following Psychiatric Discharge; 12-Months Case Management
11499203|NCT01359761|No Intervention|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services; 12-Months Case Management
11499204|NCT01359748|Other|Wrist Size <= 14.25 Cm|"Blood pressure measured using the reference sphygmomanometer.
~Blood pressure measured using the Sphygmomanometer under test."
11499205|NCT01359748|Other|Wrist Size >=14.26 <16.50 Cm|"Blood pressure measured using the reference sphygmomanometer.
~Blood pressure measured using the Sphygmomanometer under test."
11499206|NCT01359748|Other|Wrist size >=16.5 <17.75 Cm|"Blood pressure measured using the reference sphygmomanometer.
~Blood pressure measured using the Sphygmomanometer under test."
11499207|NCT01359748|Other|Wrist Size >=17.75 Cm|"Blood pressure measured using the reference sphygmomanometer.
~Blood pressure measured using the Sphygmomanometer under test."
11499208|NCT01359735|Active Comparator|HP802-247|allogeneic, growth arrested keratinocytes and fibroblasts: final concentration of 5.0 M cells/mL with a ratio of 1:9 keratinocytes:fibroblasts, applied weekly
11499209|NCT01359735|Active Comparator|Bacitracin Ointment|bacitracin antibiotic ointment
11499210|NCT01359722|Experimental|N-Acetylcysteine|N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.
11499211|NCT01359722|Placebo Comparator|Control|This group will receive only the infusion of saline in the same doses and infusion rate.
11499212|NCT01359709|Experimental|Contingency Management|
11499213|NCT01359709|Placebo Comparator|Noncontingent control|
11499214|NCT01359696|Experimental|A|
11499215|NCT01359683|Other|A|This is a prospective observational study. 100 patients in one arm scheduled for cardiac surgery will be enrolled. ECG tracings will be obtained when subject is at rest, in supine position, before induction of anesthesia (within 24 hours prior to induction), after induction of general anesthesia, right before emergence from anesthesia (or before transportation to the ICU if the subject remains intubated), and within 24 hours post-operatively; additional ECG readings may be obtained during the surgery if deemed necessary.
11499216|NCT01359670|Experimental|Tadalafil|
11499217|NCT01359670|Experimental|Sildenafil|
11499218|NCT01359657|Experimental|Arm A: Anti-CXCR4 (BMS-936564)+Lenalidomide+Dexamethasone|
11499219|NCT01359657|Experimental|Arm B: Anti-CXCR4 (BMS-936564)+Bortezomib+Dexamethasone|
11499220|NCT01359644|Experimental|Treatment A: PSI-7977 + Daclatasvir|Genotype 1a or 1b
11499221|NCT01359644|Experimental|Treatment B: PSI-7977 + Daclatasvir|Genotype 2 or 3
11499222|NCT01359644|Experimental|Treatment C: PSI-7977 + Daclatasvir|Genotype 1a or 1b
11499223|NCT01359644|Experimental|Treatment D: PSI-7977 + Daclatasvir|Genotype 2 or 3
11499224|NCT01359644|Experimental|Treatment E: PSI-7977 + Daclatasvir + Ribavirin|Genotype 1a or 1b
11499225|NCT01359644|Experimental|Treatment F: PSI-7977 + Daclatasvir+ Ribavirin|Genotype 2 or 3
11499226|NCT01359644|Experimental|Treatment G: PSI-7977 + Daclatasvir|"Hepatitis C virus genotype 1, treatment-naive patients
~Genotype 1a or 1b"
11499227|NCT01359644|Experimental|Treatment H: PSI-7977 + BMS-790052 + Ribavirin|"Hepatitis C virus genotype 1, treatment-naive patients
~Genotype 1a or 1b"
11499228|NCT01359644|Experimental|Treatment I: PSI-7977 + Daclatasvir|"Patients who experienced telaprevir/boceprevir treatment failure
~Genotype 1a or 1b"
11499229|NCT01359644|Experimental|Treatment J: PSI-7977 + Daclatasvir + Ribavirin|"Patients who experienced telaprevir/boceprevir treatment failure
~Genotype 1a or 1b"
11499230|NCT01359618|Experimental|Part A 1|TC-5214
11499231|NCT01359618|Experimental|Part A 2|TC-5214 placebo
11499232|NCT01359618|Experimental|Part B 1|TC-5214 8 mg + moxifloxacin placebo
11499233|NCT01359618|Experimental|Part B 2|TC-5214 supratherapeutic dose + moxifloxacin placebo
11499234|NCT01359618|Active Comparator|Part B 3|TC-5214 placebo + moxifloxacin 400 mg
11499235|NCT01359618|Placebo Comparator|Part B 4|TC-5214 placebo + moxifloxacin placebo
11499236|NCT01359605|Experimental|varespladib methyl|
11499237|NCT01359592|Active Comparator|PET Negative: R-CHOP|R-CHOP x 3 Cycles
11499238|NCT01359592|Experimental|PET Positive: IFRT +Zevalin|Standard IFRT+ Zevalin IV per ABW
11499239|NCT01359579|Experimental|Subjects with mild renal impairment|
11499240|NCT01359579|Experimental|Subjects with moderate renal impairment|
11499241|NCT01359579|Experimental|Subjects with normal renal function|
11499242|NCT01359579|Experimental|Subjects with severe renal impairment|
11499243|NCT01359566|Active Comparator|Arbaclofen placarbil 15 mg BID|Arbaclofen placarbil (XP19986 SR4) 15 mg every morning and every evening
11499244|NCT01359566|Active Comparator|Arbaclofen placarbil 30 mg BID|Arbaclofen placarbil (XP19986 SR4) 30 mg every morning and every evening
11499245|NCT01359566|Active Comparator|Arbaclofen placarbil 45 mg BID|Arbaclofen placarbil (XP19986 SR4) 45 mg every morning and every evening
11499246|NCT01359566|Placebo Comparator|Placebo|Placebo every morning and every evening
11499247|NCT01359553||Knee pain|Group with knee pain problems referred to an arthroscopy.
11499248|NCT01359540||APEX Modular|APEX Modular Stem group
11499249|NCT01359540||ARC Stem|ARC Stem group
11499250|NCT01359527||Hip Resurfacing|
11499251|NCT01359527||Total Hip Arthroplasty|
11499252|NCT01359514|Active Comparator|Duloxetine|
11499253|NCT01359514|Active Comparator|Pregabalin|
11499254|NCT01359501|Experimental|Chinese medical treatment|
11499255|NCT01359501|Placebo Comparator|Placebo|
11499256|NCT01359488|Experimental|VRS-317 Safety Arm 1|"VRS-317 Single injection SC of dose level 1 (based on 90 kg patient)
~Placebo Single SC injection Dose Volume matched to active treatment volume"
11499257|NCT01359488|Experimental|VRS-317 Safety Arm 2|"VRS-317 Single injection SC of dose level 2 (based on 90 kg patient)
~Placebo Single SC injection Dose Volume matched to active treatment volume"
11499258|NCT01359488|Experimental|VRS-317 Safety Arm 3|"VRS-317 Single injection SC of dose level 3 (based on 90 kg patient)
~Placebo Single SC injection Dose Volume matched to active treatment volume"
11499259|NCT01359488|Experimental|VRS-317 Safety Arm 4|"VRS-317 Two injections SC of dose level 4 (based on 90 kg patient)
~Placebo Two SC injection Dose matched to treatment volume"
11499260|NCT01359488|Experimental|VRS-317 Safety Arm 5|"VRS-317 Two injections SC of dose level 5 (based on 90 kg patient)
~Placebo Two SC injections Dose Volume matched to active treatment volume"
11499261|NCT01359475|Experimental|Acetal crown|Clinical performance of acetal crowns for treatment of primary molars
11499262|NCT01359462|Experimental|Tolvaptan 15mg tablet|
11499263|NCT01359449|Experimental|Menactra® Vaccine Group|Meningococcal vaccine naive participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate vaccine (Menactra®) at 12 months of age and at 18 months of age concomitantly with routine vaccines administered as per provincial schedule
11499264|NCT01359449|Active Comparator|Menjugate® Vaccine Group|Meningococcal vaccine naive participants will receive MenC vaccine (Menjugate) given concomitantly at 12 months of age with routine vaccines administered as per provincial schedule.
11499265|NCT01359436|Experimental|Electrosensing antibody probing system (e- Ab sensing)|
11499266|NCT01359423|Experimental|long coverage|Primary long full coverage stenting
11499267|NCT01359423|Active Comparator|short spot|primary short spot stenting
11499268|NCT01359410|Active Comparator|Stapled transection with mesh reinforcement|Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)
11499269|NCT01359410|No Intervention|Stapled transection without mesh reinforcement|
11499270|NCT01359397|Active Comparator|Herceptin -|
11499272|NCT01359384||affected patients|25 patients suffering from severe immune deficiency under immunoglobulin therapy
11499273|NCT01359384||non-affected patients|25 matched controls not suffering from severe immune deficiency
11499274|NCT01359371||Peer telephone cessation counseling|The cohort is 131 veteran smokers who received the standard-of-care Tobacco Tactics intervention while in the hospital follow up volunteer peer telephone cessation counseling
11499275|NCT01359345|Experimental|A|The patients with renal failure in whom Gadollinume has being used
11499276|NCT01359332|Experimental|hypothermia|
11499277|NCT01359332|No Intervention|control|
11499278|NCT01359319|Experimental|650 mg (single dose only)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
11499279|NCT01359319|Experimental|1,950 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
11499280|NCT01359319|Experimental|2,925 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
11499281|NCT01359319|Experimental|4,875 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
11499282|NCT01359319|Experimental|6,000 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
11499283|NCT01359280|Experimental|Adherence Counseling + Text Messages|Participants receive one office-based adherence counseling session and 4 phone-delivered counseling sessions focused on antiretroviral adherence strategies using a model of behavioral self regulation skills building. Participants also receive follow-up medication reminder text messages delivered by cell phone.
11499284|NCT01359280|Experimental|Adherence Counseling Only|Participants receive one office-based adherence counseling session and 4 phone-delivered counseling sessions focused on antiretroviral adherence strategies using a model of behavioral self regulation skills building.
11499285|NCT01359280|Placebo Comparator|General Health Counseling Only|Participants receive one office-based counseling session and 4 phone-delivered counseling sessions focused on general health and nutrition strategies using a model of behavioral self regulation skills building.
11499286|NCT01359280|Placebo Comparator|General Health Messages + Text Messages|Participants receive one office-based counseling session and 4 phone-delivered counseling sessions focused on general health and nutrition strategies using a model of behavioral self regulation skills building. Participants also receive follow-up medication reminder text messages delivered by cell phone.
11499287|NCT01359267|Experimental|Imaging|
11499288|NCT01359254|Experimental|Conditioning Regimen I|Arm I contains fludarabine, melphalan, and antithymocyte globulin (ATG)
11499289|NCT01359254|Experimental|Conditioning Regimen II|Arm II contains fludarabine, busulfan, antithymocyte globulin (ATG), and total body irradiation (TBI).
11499290|NCT01359241|Experimental|closed-loop insulin delivery|Subcutaneous insulin delivery adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
11499291|NCT01359241|Active Comparator|Usual diabetes treatment regimen|Usual non-insulin glucose-lowering medications
11499292|NCT01359228|Experimental|Rifaximin|rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
11499293|NCT01359228|Placebo Comparator|sugar pill|Placebo 1 tablet three times a day for 14 days.
11499294|NCT01359215||Treatment|Children who received an anesthetic prior to age 2
11499295|NCT01359215||Control|Children who have never been anesthetized
11499296|NCT01359202|Active Comparator|Niastase RT|Niastase RT 80ug/kg IV bolus
11499297|NCT01359202|Placebo Comparator|Placebo|saline IV bolus
11499298|NCT01359189|Experimental|Suspected Primary Prostate Cancer|Patients with suspected prostate cancer will be evaluated for initial proof of concept and feasibility of a scintigraphic rectal probe (ProxiScanTM) utilizing a PSMA receptor radiopharmaceutical (ProstaScint®). To explore the adjunctive benefit/feasibility of PSMA distribution in the normal prostate versus prostate cancer gland utilizing TRUS and CT/SPECT hybrid imaging, biopsy negative patients will be considered as normal controls. This is an exploratory, open label trial and randomization is not required. Subject blinding is not needed and investigator blinding in not possible.
11499299|NCT01359176||Healthy volunteers|
11499300|NCT01359163|Active Comparator|Femulen commercial tablets|
11499301|NCT01359163|Experimental|Femulen reformulated tablets|
11499302|NCT01359150|Experimental|Treatment Group 1: 10 mg BID CP-690,550 (100 subjects).|CP-690,550 will be administered for 4 weeks, vaccines will be administered at week 4. CP-690,550 will then continue for another 5 weeks at which point the immune response will be evaluated.
11499303|NCT01359150|Placebo Comparator|Treatment Group 2:Placebo CP-690,550 (100 subjects).|Placebo will be administered for 4 weeks, vaccines will be administered at week 4. Placebo will then continue for another 5 weeks at which point the immune response will be evaluated.
11499304|NCT01359137|Experimental|Probation as usual|Routine supervision with no deferred jail condition.
11499305|NCT01359137|Experimental|Deferred jail|Discretionary deferred jail in response to violations of probation conditions.
11500297|NCT01352299|Active Comparator|Macintosh|Laryngoscopy performed with Macintosh Laryngoscope
11499306|NCT01359137|Experimental|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) which uses non-discretionary brief jail sanctions for probation violations.
11499307|NCT01359124||Water Treadmill|These subjects will participate in three monitored exercise sessions per week for 8 weeks using a water-based treadmill.
11499308|NCT01359124||Land Treadmill|These subjects will participate in three monitored exercise sessions per week for 8 weeks using a land-based treadmill.
11499309|NCT01359124||Exercise Cycle|These subjects will participate in three monitored exercise sessions per week for 8 weeks using an upright exercise cycle.
11499310|NCT01359098|Active Comparator|Ciprodex Otic Suspension|Ciprodex Sterile Otic Solution (Alcon, Inc.)
11499311|NCT01359098|Experimental|Ciprodexa Otic Foam|Ciprodexa Otic Foam (0.3% Ciprofloxacin, 0.1% Dexamethasone otic foam)
11499312|NCT01359085|Active Comparator|Pregabalin|
11499313|NCT01359085|Active Comparator|ISBPB|Interscalene brachial plexus block
11499314|NCT01359072|Experimental|Immediate Intervention Treatment|
11499315|NCT01359072|Experimental|Wait list|
11499316|NCT01359059|Active Comparator|IV-PCA (Patient-controlled analgesia) morphine|
11499317|NCT01359059|Active Comparator|Patient controlled epidural analgesia (PCEA) fentanyl|
11499318|NCT01359046|Experimental|silver SPC|Subjects randomized to receive silver-impregnated SPC.
11499319|NCT01359046|Active Comparator|standard SPC|subjects randomized to receive standard SPC.
11499320|NCT01359033||MINAP cohort|The Myocardial Ischaemia National Audit Project (MINAP) was established in 1999, in response to the national service framework (NSF) for coronary heart disease, to examine the quality of management of heart attacks (myocardial infarction) in hospitals in England and Wales.
11499321|NCT01359033||RIKS-HIA cohort|The Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) has been established to record clinical and treatment information for all patients admitted to the coronary care units in Sweden from 1995.
11499322|NCT01359020|Experimental|Ibuprofen|10 milligram per kilo, oral administration
11499323|NCT01359020|Active Comparator|Acetaminophen|10 milligram per kilo, oral administration
11499324|NCT01359020|Active Comparator|Dipyrone|10 milligram per kilo, oral administration
11499325|NCT01359007|Experimental|FOLFIRINOX|Combination of drugs (Irinotecan, Oxaliplatin, Leucovorin, and 5-Fluorouracil (5-FU)) known as FOLFIRINOX every 2 weeks for 4 treatments. At the end of 4 cycles, patients will be re-evaluated for resectability by CT scan within 28 days of the last dose of chemo. If found amendable to surgery, patient will proceed with resection, and type of resection (R0 or R1) will be recorded.
11499326|NCT01358981|Experimental|LY2881835|"One cohort of healthy participants will receive single oral doses of LY2881835 in up to 3 of the 4 periods in Part A (dose escalation: 0.5 milligram (mg), 1.5 mg, subsequent doses determined based on review of safety, tolerability, glycaemic response and available pharmacokinetic (PK) data from the first 2 dose levels). One cohort of participants with Type 2 Diabetes Mellitus (T2DM) will receive single oral doses of LY2881835 in up to 2 of the 3 periods in Part B (dose escalation: starting dose based on review of safety, tolerability, glycaemic response and available PK data from Part A).
~There is a washout period of at least 5 days between periods (doses)."
11499327|NCT01358981|Placebo Comparator|placebo|"One cohort of healthy participants will receive a single oral dose of placebo in 1 of the 4 periods in Part A. Another cohort of participants with T2DM will receive a single oral dose of placebo in 1 of the 3 periods in Part B.
~There is a washout period of at least 5 days between periods (doses)."
11499328|NCT01358968|Experimental|LY2603618|"Single 50 milligrams (mg) oral dose of desipramine on day 1 of study period 1. Single 275 mg intravenous infusion over one hour of LY2603618 followed by single 50 mg oral dose of desipramine on day 1 of study period 2. Participants may then receive additional doses of LY2603618 in combination as follows: 1000 milligrams per square meter (mg/m²) intravenous administration over 30 minutes of gemcitabine on days 1, 8 and 15 and 230 mg intravenous dose of LY2603618 on days 2, 9 and 16 of 28-day cycles OR 500 mg/m² intravenous administration over 10 minutes of pemetrexed on day 1 and 275 mg intravenous dose of LY2603618 on day 2 of 21-day cycles.
~Participants will be allowed to continue to receive the combination therapy until fulfilling one of the criteria for discontinuation, such as unacceptable toxicity or disease progression."
11499329|NCT01358955|Active Comparator|Group cognitive intervention|The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
11499330|NCT01358955|Active Comparator|Home-based cognitive intervention|The participants will do their homework for 30 minutes every business days for 12 weeks.
11499331|NCT01358955|No Intervention|Wait list Control|They will participate in cognitive intervention after ending this study.
11499332|NCT01358942||Cohort|
11499333|NCT01358929|Experimental|1|
11499334|NCT01358929|Placebo Comparator|2|
11499335|NCT01358916|No Intervention|Usual information policy|No specific intervention
11499336|NCT01358916|Other|Antibiotic therapy guidelines|
11499337|NCT01358903|Experimental|A|
11499338|NCT01358903|Experimental|B|
11499339|NCT01358890|Experimental|B|Subjects will be supplied with low carbohydrate diet for 12 weeks.
11499340|NCT01358890|Experimental|A|Subjects will be supplied with calories restricted diet for 12 weeks
11499341|NCT01358877|Experimental|Pertuzumab + Trastuzumab + Chemotherapy|Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m^2 + epirubicin 90-120 mg/m^2 or doxorubicin 50 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m^2 for 3 cycles, 75 mg/m^2 in first cycle and 100 mg/m^2 in subsequent cycles, or 75 mg/m^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m^2 or epirubicin 90-120 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).
11499437|NCT01358292|Experimental|Semi-extended surgical technique|The experimental technique for implanting an intramedullary tibia nail is with the knee in 10-20 degrees of flexion.
11499342|NCT01358877|Placebo Comparator|Placebo + Trastuzumab + Chemotherapy|Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram [mg/kg] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m^2) + epirubicin 90-120 mg/m^2 or doxorubicin 50 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m^2 for 3 cycles, 75 mg/m^2 in first cycle and 100 mg/m^2 in subsequent cycles, or 75 mg/m^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m^2 or epirubicin 90-120 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m^2 + carboplatin AUC 6 (up to 900 milligrams [mg]).
11499343|NCT01358864|Active Comparator|Placebo/PegIFN/RBV|patient to receive two capsules identical to those containing BI201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks
11499344|NCT01358864|Experimental|BI201335 12 weeks|patient to receive two capsules containing BI 201335 once a day for 12 weeks and PegIFN/RBV for 48 weeks
11499345|NCT01358864|Experimental|BI201335 24 weeks|patient to receive two capsules containing BI 201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks
11499346|NCT01358851|Experimental|1|Drug Las41005
11499347|NCT01358851|Other|2|Cryotherapy
11499348|NCT01358838|Active Comparator|laser|
11499349|NCT01358838|No Intervention|no laser|
11499350|NCT01358825|Experimental|Infanrix hexa Group|Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix hexa™ (DTPa-HBV-IPV/Hib) administered intramuscularly in study NCT00307034.
11499351|NCT01358825|Experimental|Infanrix-IPV/Hib Group|Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix-IPV/Hib™ (DTPa-IPV/Hib) administered intramuscularly in study NCT00307034.
11499352|NCT01358812|Experimental|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
11499353|NCT01358786|No Intervention|no quilting sutures but drains|
11499354|NCT01358786|Experimental|quilting sutures and drains|
11499355|NCT01358786|Experimental|quilting sutures but no drains|
11499356|NCT01358773|Other|Lifestyle counseling|Obese adolescents are encouraged to improve their lifestyle
11499357|NCT01358760|Placebo Comparator|Placebo|
11499358|NCT01358760|Experimental|0.25% DHEA|
11499359|NCT01358760|Experimental|0.5% DHEA|
11499360|NCT01358747|Active Comparator|Standard arm|Induction treatment: Patients will be treated by a BEACOPPesc regimen every 3 weeks for 4 cycles. A PET will be performed after 2 cycles of chemotherapy (PET2) with no decisional value, and after 4 cycles with decisional value. Consolidation treatment: depends on the reviewed PET4 result. In case of PET4 negative result, patient will received 2 additional cycles of BEACOPPesc, whatever the result of the PET2. In case of PET4 positive, the patient will be considered in treatment failure and proposed to a salvage therapy after pathologic confirmation of failure by biopsy of the hypermetabolic residual mass when possible.
11499361|NCT01358747|Experimental|Experimental arm|"Induction treatment: Patients will be treated by a BEACOPPesc regimen every 3 weeks for 2 cycles followed by a PET scan (PET2).
~After PET2 central review:
~In case of positive PET2, the induction treatment will be completed by 2 additional cycles of BEACOPPesc
~In case of negative PET2, the induction treatment will be completed by 2 cycles of ABVD delivered every 4 weeks. The first cycle of ABVD will start at day 21 of the second cycle of BEACOPPesc.
~Consolidation treatment: depends on the reviewed PET4 result In case of PET4 negative result, consolidation treatment will depends on PET2 results:
~If PET2 was positive, patient will received 2 additional cycles of BEACOPPesc delivered every 3 weeks
~If PET2 was negative, patient will received 2 additional cycles of ABVD delivered every 4 weeks In case of PET4 positive, the patient will be considered as treatment failure."
11499362|NCT01358734|Experimental|Lenalidomide in combination with azacitidine|Repeated cycles of azacitidine 75 mg/m^2/day subcutaneous (SC) on Days 1-7 and lenalidomide 50 mg/day by mouth (PO) on Days 8-28 followed by a 14-day break plus best supportive care
11499363|NCT01358734|Experimental|Lenalidomide - single agent|Lenalidomide 50 mg PO daily for 28 days for the first 2 cycles and lenalidomide 25 mg daily for 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg daily PO plus best supportive care
11499364|NCT01358734|Experimental|Azacitidine-single agent|Repeated cycles of azacitidine 75mg/m^2/day subcutaneous on Days 1-7 followed by a 21-day break plus best supportive care
11499365|NCT01358721|Experimental|Arm 1: BMS-936558|
11499366|NCT01358721|Experimental|Arm 2: BMS-936558|
11499367|NCT01358721|Experimental|Arm 3: BMS-936558|
11499368|NCT01358721|Experimental|Arm 4: BMS-936558|(treatment naive)
11499369|NCT01358708|Experimental|LACTEOL® 340 mg|
11499370|NCT01358708|Placebo Comparator|PLACEBO|
11499371|NCT01358695|Placebo Comparator|Placebo Comparator|
11499372|NCT01358695|Experimental|Dose 1|Dose 1
11499373|NCT01358695|Experimental|Dose 2|Dose 2
11499374|NCT01358695|Experimental|Dose 3|Dose 3
11499375|NCT01358695|Experimental|Dose 4|Dose 4
11499376|NCT01358695|Experimental|Dose 5|Dose 5
11499377|NCT01358669|Active Comparator|Denosumab|In this study we explore the potential for giving a medication (denosumab) that may prevent the loss of bone around the hip replacement implant
11499378|NCT01358669|Placebo Comparator|Placebo|Placebo
11499379|NCT01358656|Active Comparator|Single Bundle Reconstruction|Subjects will undergo single bundle acl reconstruction
11499380|NCT01358656|Active Comparator|Double bundle reconstruction|Subjects will undergo double bundle acl reconstruction
11499381|NCT01358643|Other|P90X + Sparkpeople|"For six weeks of the study participants will use the P90X tools and for the other six weeks participants will use Sparkpeople tools.
~Sparkpeople is a web based diet and exercise program in which the participant can track their diet and exercise progress and read and post messages to a large online community of others who are also trying to lose weight.
~P90X is A DVD based home exercise program that guides the participant through a daily exercise routine."
11500681|NCT01349803|Experimental|PT003 MDI|PT003 MDI
11499382|NCT01358643|Other|P90X + BodyMedia Fit|"For six weeks participants will use the P90X tools and for the other six weeks participants will use the BodyMedia Fit Device.
~P90X is a DVD based home exercise program that guides the participant through a daily exercise routine.
~BodyMedia Fit is a program in which the participants wears a small device on their arm that measures their physical activity and allows you to upload detailed physical activity data to a web site to help them track your progress."
11499383|NCT01358643|Other|BodyMedia Fit + Sparkpeople|"For six weeks participants will use the BodyMedia Fit devise and for the other six weeks participants will use the Sparkpeople program.
~BodyMedia Fit is a program in which the participants wears a small device on their arm that measures their physical activity and allows you to upload detailed physical activity data to a web site to help them track your progress.
~Sparkpeople is A web based diet and exercise program in which the participant can track their diet and exercise progress and read and post messages to a large online community of others who are also trying to lose weight"
11499384|NCT01358617||Biomarker analysis|Archived tissue microarray samples are analyzed for ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) expression by UCHL1 monoclonal antibody and peroxidase technique.
11499385|NCT01358591|Sham Comparator|Control Breakfast|Normal calcium breakfast.
11499386|NCT01358591|Experimental|High calcium breakfast|High calcium breakfast.
11499387|NCT01358578|Experimental|AIN457 150mg|AIN457 150mg
11499388|NCT01358578|Experimental|AIN457 300mg|AIN457 300mg
11499389|NCT01358578|Placebo Comparator|Placebo|Placebo
11499390|NCT01358578|Active Comparator|Etanercept|Etanercept
11499391|NCT01358578|Experimental|AIN457 150mg from Placebo|Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase
11499392|NCT01358578|Experimental|AIN457 300mg from Placebo|Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase
11499393|NCT01358565|Active Comparator|Mild and Moderate Hepatic Dysfunction|Patients with mild and moderate hepatic dysfunction
11499394|NCT01358565|Active Comparator|Healthy Volunteers|Healthy volunteers
11499395|NCT01358552||Néevo®/NéevoDHA®|Subjects who have been prescribed Néevo/NéevoDHA® daily.
11499396|NCT01358539|Experimental|Pain education|Patients receiving pain education
11499397|NCT01358539|No Intervention|No Pain education|Control group, patients receiving no pain education
11499398|NCT01358526|Experimental|OXN|Oxycodone/Naloxone Controlled-release Tablets (OXN)
11499399|NCT01358526|Placebo Comparator|Placebo|Placebo tablets to match OXN
11499400|NCT01358513||Control Patients|Patients with normal aortic valves
11499401|NCT01358513||Aortic sclerosis|To undergo PET imaging and follow up with CT and echo for 2 years
11499402|NCT01358513||Mild Aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
11499403|NCT01358513||Moderate Aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
11499404|NCT01358513||Severe aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
11499405|NCT01358500|Experimental|Fentanyl|
11499406|NCT01358487|Active Comparator|Online self-help mood management course|Online self-help mood management course based on cognitive behavioral therapy and social cognitive theory, plus automated online follow ups using email reminders and incentives for completing follow-ups
11499407|NCT01358487|Experimental|Online self-help course plus live follow-up if needed|Intervention and automated follow ups with incentives as in the active comparator condition. The experimental procedure is adding live phone follow-ups if participant does not complete online assessment surveys at 1, 3, and 6 months in response to automated emails.
11499408|NCT01358474||PD Subjects|Subjects diagnosed with Parkinson's disease (PD)
11499409|NCT01358474||At-risk for PD|Subjects at-risk for developing PD (e.g., those with idiopathic rapid eye movement sleep disorder (iRBD) and those who are heterozygous or homozygous for Gaucher's disease (GBA) mutations)
11499410|NCT01358474||Healthy Controls|Healthy volunteers
11499411|NCT01358461||Patients with vagal syncopes|Patients with vagal syncopes (n=120 : 60 adults & 60 children)
11499412|NCT01358461||Subjects controls without vagal syncopes|Subjects controls without vagal syncopes (n=120:60 adults & 60 children
11499413|NCT01358448|No Intervention|Newsletter|
11499414|NCT01358448|Experimental|Growth Monitoring|
11499415|NCT01358448|Experimental|Growth Monitoring plus Family-based Behavioral Counseling|
11499416|NCT01358435|Experimental|Wosulin 70/30|Wosulin 70N /30R is a recombinant Human Insulin with 30 % Regular Insulin Human Neutral and 70% Isophane Insulin, 600 nmol/ml, 100 IU/ml.
11499417|NCT01358435|Active Comparator|Novolin 70/30|Novolin 70/30 is a Recombinant Human Insulin with 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection
11499418|NCT01358422||In Patients|
11499419|NCT01358409|Experimental|Nebivolol|Nebivolol (Bystolic® by Forest/Mylan) is a third-generation beta-blocker; it selectively blocks β1-adrenergic receptors and increases peripheral vasodilation.
11499420|NCT01358396||HBA1c|
11499421|NCT01358357|Experimental|Lurasidone 20-80 mg flexible dose|
11499422|NCT01358357|Placebo Comparator|Placebo|
11499423|NCT01358344|Experimental|Standard Percentage|
11499424|NCT01358344|Experimental|High Percentage|
11499425|NCT01358331|Experimental|MK-8353 100 mg twice daily (BID)|100 mg capsules administered orally twice daily for 28 days for each cycle
11499426|NCT01358331|Experimental|MK-8353 200 mg BID|200 mg capsules administered orally twice daily for 28 days for each cycle
11499427|NCT01358331|Experimental|MK-6353 300 mg BID|300 mg capsules administered orally twice daily for 28 days for each cycle
11499428|NCT01358331|Experimental|MK-8353 350 mg BID|350 mg capsules administered orally twice daily for 28 days for each cycle
11499429|NCT01358331|Experimental|MK-8353 400 mg BID|400 mg capsules administered orally twice daily for 28 days for each cycle
11499430|NCT01358331|Experimental|MK-8353 800 mg BID|800 mg capsules administered orally twice daily for 28 days for each cycle
11499431|NCT01358318|Placebo Comparator|Control|
11499432|NCT01358318|Experimental|Soy Protein|
11499433|NCT01358318|Experimental|Soy Fiber|
11499434|NCT01358318|Experimental|Soy Protein and Soy Fiber|
11499435|NCT01358305|Active Comparator|Whey Protein Isolate|
11499438|NCT01358292|Active Comparator|Standard Surgical Technique|The standard surgical technique in intramedullary tibia nailing is with the knee in almost 90 degrees of flexion.
11499439|NCT01358279|Experimental|migraine|
11499440|NCT01358266|Active Comparator|Ophthalmic solution low dose|
11499441|NCT01358266|Active Comparator|Ophthalmic solution medium dose|
11499442|NCT01358266|Active Comparator|Ophthalmic solution high dose|
11499443|NCT01358253|Active Comparator|HyperCVAD|"Consolidation:
~HyperCVAD(odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses.
~Maintenance:
~6-Mercaptopurine+Methotrexate for 24 months. Vincristine+Prednisone for the first 12 months. L-asparaginase in month 3 and 9."
11499444|NCT01358253|Experimental|R-HyperCVAD|"Consolidation:
~R-HyperCVAD(odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses.
~Maintenance:
~6-Mercaptopurine+Methotrexate for 24 months. Vincristine+Prednisone for the first 12 months. L-asparaginase in month 3 and 9. Rituximab in month 6 and 12."
11499445|NCT01358240|Experimental|Econazole Nitrate Foam 1%|Study medication
11499446|NCT01358240|Placebo Comparator|Vehicle Foam|Placebo medication
11499447|NCT01358240|Active Comparator|Econazole Nitrate Cream 1%|Econazole Nitrate Cream 1%
11499448|NCT01358240|Sham Comparator|Placebo Cream|Placebo Cream
11499449|NCT01358227|Experimental|PR104|
11499450|NCT01358214||Patients treated with a surgical mesh|This arm of study patients is defined by patients treated with a TiLOOP® Tape mesh between 2007 and 2009 at the Franziskus Krankenhaus, Berlin. The sample of the treated population represents the patient population for which the medical device is intended. To minimize selection bias without compromising patients' rights and welfare, all treated patients will be invited. These patients will be asked to participate in the validation of the questionnaire on quality of life. In addition to this safety and effectiveness of the surgical mesh implantation will be collected
11499451|NCT01358214||Intended to be treated with a mesh|This arm of the study populations is defined by patients in whom a clinical anamnesis independent of the requirements of this study suggests that a sub-urethral sling operation is indicated. These patients will be asked to participate in the validation of the questionnaire on quality of life.
11499452|NCT01358214||Non-symptomatic Population|This arm of the study population is defined by women that show no symptoms of incontinence. They will be asked to participate in the validation of the questionnaire on quality of life.
11499453|NCT01358188||Gaucher disease group|Subjects will include individuals with GD
11499454|NCT01358188||Control group|Controls will include healthy individuals and individuals with primary immune dysfunction
11499455|NCT01358175|Experimental|Secukinumab 10 mg/kg i.v. / 75 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
11499456|NCT01358175|Experimental|Secukinumab 10 mg/kg i.v. / 150 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
11499457|NCT01358175|Placebo Comparator|Placebo|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
11499458|NCT01358162|Experimental|SQ109|300 mg of SQ109, orally, given daily for 14 consecutive days
11499459|NCT01358162|Placebo Comparator|Placebo|Placebo given orally, daily for 14 consecutive days
11499460|NCT01358149|Placebo Comparator|placebo|cocoa-based food 1
11499461|NCT01358149|Active Comparator|Treatment 1|cocoa-based food 2
11499462|NCT01358136||Hemithyroidectomy|Patients with benign nontoxic goiter who have an indication for hemithyroidectomy
11499463|NCT01358110|Experimental|Early palliative care consultation|Early palliative care consultation for ED patients with advanced cancer.
11499464|NCT01358110|Other|Care as usual|Care as usual, may or may not receive palliative care consultation
11499465|NCT01358097||Patients with HPV positive tumors|
11499466|NCT01358097||Patients with HPV negative tumors|
11499467|NCT01358097||Control|
11499468|NCT01358084|Experimental|Arm A: NGR-hTNF + Best Supportive Care|NGR-hTNF + Best Supportive Care
11499469|NCT01358084|Placebo Comparator|Arm B: Placebo + Best Supportive Care|Placebo + Best Supportive Care
11499470|NCT01358071|Experimental|Arm A: NGR-hTNF+ anthracycline|NGR-hTNF+Pegylated Liposomal Doxorubicin or Doxorubicin
11499471|NCT01358071|Active Comparator|Arm B: anthracycline|Pegylated Liposomal Doxorubicin or Doxorubicin
11499472|NCT01358058|Experimental|Proton radiation therapy|Single arm study delivering fractionated proton therapy over 6 week (54-59.4 Gy(RBE))
11499473|NCT01358045|Active Comparator|Solaraze|
11499474|NCT01358045|Active Comparator|Solaraze + Silkis|
11499475|NCT01358045|Active Comparator|Silkis|
11499476|NCT01358045|No Intervention|No treatment|
11499477|NCT01358032|Experimental|Cognitive behavioral program|an in-home cognitive behavioral program on managing concerns about falling and associated activity avoidance in frail community-dwelling older people facilitated by trained community nurses.
11499478|NCT01358032|No Intervention|Control group|no program, only care as usual
11499479|NCT01358019|Experimental|LY2523355|
11499480|NCT01358006|Experimental|001|JNJ-40411813 Cohort 1: Type=2 to 3 unit=mg number=200 to 300 form=capsule route=oral use.Capsule(s) taken in the fed state Capsule(s) taken in the fed state.,JNJ-40411813 Cohort 2: Type=up to 7 unit=mg number=up to 700 mg form=capsule route=oral use. Capsule(s) taken in the fed state.
11499481|NCT01357993|Experimental|001|JNS001 18 mg 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
11499482|NCT01357980|Experimental|Dysport 750 U (15 injection sites)|
11499483|NCT01357980|Placebo Comparator|Placebo (15 injection sites)|
11499484|NCT01357980|Experimental|Dysport 750 U (30 injection sites)|
11499485|NCT01357980|Placebo Comparator|Placebo (30 injection sites)|
11499533|NCT01357616|Active Comparator|AZOPT + Timolol|Brinzolamide 1% ophthalmic suspension, 1 drop instilled in the affected eye(s), followed by Timolol 0.5% ophthalmic solution, 1 drop instilled in the affected eye(s). Approximately 10 minutes separated the 2 instillations. The study drugs were instilled twice daily (9AM and 9PM) for 8 weeks. Both eyes were dosed unless there was a potential safety issue to the patient in the opinion of the Investigator.
11499486|NCT01357967|Experimental|Seroquel XR adjunctive|"The quetiapine XR adjunct group will be titrated up to 300mg. Initial dosing will begin at 50mg on Day 1 and 2, increased to 150mg on Day 3 and 4. Further adjustments will be able to be made upwards or downwards within the recommended dose range of 50mg to 300mg depending upon the clinical response and tolerance of the patient. Seroquel XR will be administered daily in the evening.
~The dosage of SSRIs will be maintained as low (es-citalopram 5mg, paxil CR 6.25mg, fluoxetine 10mg, and sertraline 25mg)."
11499487|NCT01357967|Active Comparator|SSRI monotherapy|active comparator
11499488|NCT01357954|Experimental|Targeted Training|
11499489|NCT01357954|Other|Control|
11499490|NCT01357941||Prior VTE minor transient risk factor|Pregnant women with a single prior VTE episode that was either unprovoked or associated with a minor transient risk factor - Prophylaxis with fixed-dose LMWH
11499491|NCT01357941||Prior VTE major transient risk factor|Pregnant women with a single prior VTE episode that was provoked by a major transient risk factor - Surveillance
11499492|NCT01357928||Healthy Volunteers|
11499493|NCT01357915|Experimental|GSK149203A S- Group|Male subjects who received 3 doses of GSK Biologicals' candidate GSK149203A vaccine according to a 0-1-6 month schedule in the primary study 108890 (NCT00435396).
11499494|NCT01357915|Other|GSK149203A S+ Group|Male subjects who were assessed as being naturally infected with Cytomegalovirus (CMV) at the screening visit of the primary study 108890 (NCT00435396).
11499495|NCT01357902|Experimental|Lamictal|Chinese healthy male subjects were randomized to receive single dose of either 5 mg lamotrigine dispersible/chewable tablets or 25mg compressed/standard tablets.
11499496|NCT01357889|Active Comparator|process 2 albiglutide|albiglutide 30mg from process 2 drug substance
11499497|NCT01357889|Active Comparator|process 3 albiglutide|albiglutide 30mg from process 3 drug substance
11499498|NCT01357876|Other|Type two diabetics|Type two diabetics
11499499|NCT01357863||Patients on second line treatment|Patients treated with Lapatinib-capecitabine immediately after first Trastuzumab-containing regimen progression
11499500|NCT01357863||Patients on third or more lines treatment|Patients treated with Lapatinib-capecitabine after 2 or more lines of treatment after first Trastuzumab-containing regimen progression
11499501|NCT01357850|Experimental|GSK716155 (3.75mg)|GSK716155 (3.75mg)
11499502|NCT01357850|Experimental|GSK716155 (15mg)|GSK716155 (15mg)
11499503|NCT01357850|Experimental|GSK716155 (30mg)|GSK716155 (30mg)
11499504|NCT01357850|Placebo Comparator|GSK716155-matched placebo|GSK716155-matcued placebo
11499505|NCT01357837|Placebo Comparator|Matching Placebo|Once daily oral administration of matching placebo for 4 weeks.
11499506|NCT01357837|Experimental|75 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
11499507|NCT01357837|Experimental|200 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
11499508|NCT01357837|Experimental|400 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
11499509|NCT01357824||Patients admitted for elective surgery|The patient admitted for elective surgery can be included, and will both the case and control, as we intubate the same patient twice, with and without Sellick´s maneuver.
11499510|NCT01357811|Active Comparator|digoxin|
11499511|NCT01357811|Experimental|eliglustat with digoxin|
11499512|NCT01357798|Active Comparator|Btx-A: Active Comparator|Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
11499513|NCT01357798|Placebo Comparator|Placebo Comparator|0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
11499514|NCT01357772|Experimental|Tamoxifen|tamoxifen at daily dose of 5 mg for a total treatment time of 3 years
11499515|NCT01357772|Placebo Comparator|placebo|placebo at daily dose of 5 mg for a total treatment time of 3 years
11499516|NCT01357759|Experimental|Escalating doses of MORAb-022|Subjects with RA will be randomized into Cohorts 8 to 11, with each cohort consisting of five RA subjects per cohort (four active and one placebo).
11499517|NCT01357759|Placebo Comparator|Placebo|Subjects with RA will be also randomized into Cohorts 8 to 11, with each cohort consisting of five RA subjects per cohort (four active and one placebo).
11499518|NCT01357733|Other|Interim FDG PET/CT|Single arm study with diagnostic imaging study as the intervention.
11499519|NCT01357720|Experimental|Quinvaxem|
11499520|NCT01357720|Active Comparator|Tritanrix Hib/HepB + Quinvaxem|
11499521|NCT01357707||West Syndrome (idiopathic)|Patients with idiopathic infantile seizures
11499522|NCT01357694|Experimental|psychotherapeutic contacts|
11499523|NCT01357694|No Intervention|control group|
11499524|NCT01357681|Experimental|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) p.o. Month 02:800 mg /day (400-0-400) p.o. Month 03 -12: 1200 mg /day (600-0-600) p.o.
11499525|NCT01357681|Placebo Comparator|Placebo|Placebo
11499526|NCT01357668||Patients with JIA who are treated with Abatacept|Patients with JIA who are treated with Abatacept according to physicians'/families' decisions
11499527|NCT01357655|Active Comparator|Arm 1: Dasatinib|
11499528|NCT01357655|Experimental|Arm2: Dasatinib + BMS-833923|Dasatinib for 1 year followed by dasatinib plus BMS-833923 for 2 years followed by dasatinib alone for approximately 2 years; depending on response
11499529|NCT01357642|Experimental|Arm T|Arm T is the experimental treatment arm consisting of 2 x 125 mcg/inhalations of E004, QID, with 4-6 hr intervals
11499530|NCT01357642|Placebo Comparator|Arm P|Placebo comparator as 2×Placebo QID, with 4-6 hr intervals
11499531|NCT01357642|Active Comparator|Arm A|Active comparator, Primatene Mist, 2×220 mcg/inhalation, QID, with 4-6 hr intervals
11499532|NCT01357616|Experimental|AZARGA|Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension, 1 drop in the affected eye(s) dosed twice daily (9AM and 9PM) for 8 weeks. Both eyes were dosed unless there was a potential safety issue to the patient in the opinion of the Investigator.
11499534|NCT01357603|Experimental|Glaritus arm|Insulin glargine (Glaritus: 100 U/ml), Penfill® cartridges 3.0ml
11499535|NCT01357603|Active Comparator|Lantus arm|Insulin glargine (Lantus: 100 U/ml), Penfill® cartridges 3.0ml
11500298|NCT01352299|Active Comparator|McCoy|Laryngoscopy performed with MacCoy Laryngoscope
11499536|NCT01357577|Experimental|Arm 1: TAU + CBT|The experimental group will receive treatment as usual (TAU) plus cognitive behavioral therapy (CBT).
11499537|NCT01357577|No Intervention|Arm 2: TAU|"The no intervention group will receive treatment as usual (TAU)."
11499538|NCT01357564|Experimental|Tailored Activity Program|Occupational therapists assess the person's home environment, preserved capabilities, daily routines, interests and the caregiver's readiness and ability to use activities. Activities are developed that reflect the Veteran's previous or current interests and are modified to match their preserved capabilities without taxing the most impaired areas of cognition (e.g., memory, new learning). TAP-VA provides caregivers with the knowledge and skills to use activities. The overall goal is to provide predictability, familiarity, and structure in the daily life of the Veteran and establish a level of environmental stimulation appropriate to that person's abilities.
11499539|NCT01357564|Active Comparator|Attention Control|Caregivers in this group receive bi-weekly telephone contact by a trained healthcare professional. In each session, caregivers are provided important information about dementia and strategies for disease management. Each telephone contact begins with a brief overview of the specific purpose of the session, followed by a description of the key facts about the session topic, and concludes with a question and answer period. The attention control group intervention is delivered by a member of the research team who is knowledgeable about dementia and has had prior experience working with family caregivers.
11499540|NCT01357551|Experimental|Maintenance intervention|Participants receive a theoretically-informed maintenance intervention for 42 weeks, followed by 14 weeks of no intervention contact to examine sustainability. The maintenance intervention involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
11499541|NCT01357551|No Intervention|Usual care|Participants receive usual care for 56 weeks
11499542|NCT01357538|Active Comparator|Posiformin 2 %|Eye ointment applied to the eye lid
11499543|NCT01357538|Placebo Comparator|Placebo|corresponding vehicle, eye ointment applied to the eye lid
11499544|NCT01357525|Other|Stereotactic Body Radiotherapy|
11499545|NCT01357512|Experimental|MRI done|Subjects with MRI prior prostate biopsies
11499546|NCT01357512|No Intervention|no MRI|No MRI before prostate biopsies
11499547|NCT01357499||control group|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg but without inflating the cuff and without stimulating the muscle. Now 25 minutes will have to pass by before beginning the coronary angioplasty.
11499548|NCT01357499||intervention group 1|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. There will be no electrical muscle stimulation in this group.
11499549|NCT01357499||intervention group 2|A Blood pressure cuff and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle
11499550|NCT01357486|Experimental|A|patients receiving sorafenib 400 mg - twice a day
11499551|NCT01357486|Experimental|B|patients receiving pravastatin 40 mg - once a day
11499552|NCT01357486|Experimental|C|patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
11499553|NCT01357486|Other|D|patients receiving best supportive care
11499554|NCT01357447|Experimental|Dornase alfa (Pulmozyme)|Dornase alfa is a highly purified solution of recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.
11499555|NCT01357447|Placebo Comparator|Saline|Normal saline 0.9% solution
11499556|NCT01357434||Adolescents|Participants 12-21 years old.
11499557|NCT01357421|Experimental|TT301|Investigational drug TT301
11499558|NCT01357421|Placebo Comparator|Placebo|Normal saline
11499559|NCT01357408||REVEAL XT device|Subjects implanted at time of admission for HF or to be implanted within 14 days of discharge from HF hospitalization for clinical indications>
11499560|NCT01357395|Experimental|Amuvatinib|Amuvatinib 300 mg PO TID + standard-of-care platinum-etoposide
11499561|NCT01357382|No Intervention|low fat diet|replace high fat, energy dense foods with foods rich in whole grains, fruits and vegetables. The macronutrient distribution of this diet will be approximately 55% carbohydrate, 15% protein and 30% fat. Individuals will also be instructed to reduce sodium intake to < 2300 mg / day and in individuals with hypertension, < 1500 mg / day.
11499562|NCT01357382|Experimental|low carbohydrate diet|restrict carbohydrate consumption to < 20 grams / day while not restricting caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' to increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
11499563|NCT01357369||Ondansetron/Cefazolin treatment|Pregnant women undergoing uncomplicated cesarean section deliveries who have consented to participate, and will receive Ondansetron and Cefazolin in the course of their clinical care will have PK blood samples drawn.
11499564|NCT01357356|Experimental|SER120 (750 ng/day)|SER120 (750 ng/day)
11499565|NCT01357356|Experimental|SER120 (1000 ng/day)|SER120 (1000 ng/day)
11499566|NCT01357356|Experimental|SER120 (1500 ng/day)|SER120 (1500 ng/day)
11499567|NCT01357356|Placebo Comparator|Placebo|Placebo
11499568|NCT01357343|Active Comparator|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping
11499569|NCT01357343|Active Comparator|Chiropractic care|Chiropractic adjustments and active and passive physical modalities.
11499570|NCT01357343|Active Comparator|Integrated Chiropractic and Acupuncture|
11499571|NCT01357330|Experimental|Dose Escalation|Dose escalation phase The starting dose of SAR245408 will be 25-mg once daily (up to 200-mg). The starting dose of MSC1936369B will be 15- mg once daily (up to 90-mg)
11499572|NCT01357317|Active Comparator|Lanthanum Carbonate|Lanthanum Carbonate: initial dose 500 mg TID with meals, titrated at monthly intervals in 500 mg increments or decrements, with goal of returning to normal the level of the abnormal baseline marker(s) of phosphorus homeostasis (serum phosphorus, PTH or TRP). Normality for this marker will be defined as serum phosphorus of 2.6-4.6 mg/dl, PTH of 10-65pg/ml and TRP>=80%.
11500925|NCT01348126|Active Comparator|Single agent docetaxel|
11499573|NCT01357317|Active Comparator|Calcium Acetate|Calcium Acetate: initial dose 667 mg TID with meals, titrated at monthly intervals in 667 mg increments or decrements, with goal of returning to normal the level of the abnormal baseline marker(s) of phosphorus homeostasis. The maximum daily intake of elemental calcium should not exceed 1500 mg in order to comply w/recommendations from K-DOQI [5](this is approximately equal to three 667mg tablets of calcium acetate TID).
11499574|NCT01357317|Active Comparator|Dietary instructions|Dietary instructions consisting of pamphlets describing foods high in phosphorus and consultation with a renal dietitian if necessary, with the goal of return to normal the level of the abnormal marker of phosphorus homeostasis. Rescue therapy with a phosphorus binder of the treating physician's choice will be allowed in patients who fail to normalize elevated baseline serum phosphorus levels after 3 months following dietary instructions.
11499575|NCT01357304|Experimental|Group treatment and PAR|
11499576|NCT01357304|No Intervention|Usual care|
11499577|NCT01357291|Experimental|Recidivism Reduction Program|Inmates who were assigned to the RRP intervention.
11499578|NCT01357291|Active Comparator|Business-as-usual|Business-as-usual are those inmates not assigned to RRP and who receive standard inmate programming.
11499579|NCT01357278|Experimental|Rehabilitation and patient education|"Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.
~Patient education will be offered every eight week."
11499580|NCT01357278|No Intervention|Patient education|Patient education will be offered every eight week.
11499581|NCT01357265|Other|1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
11499582|NCT01357252|Experimental|vildagliptin|
11499583|NCT01357252|Placebo Comparator|placebo|
11499584|NCT01357239|Experimental|25 mg bid|
11499585|NCT01357239|Experimental|50 mg bid|
11499586|NCT01357239|Experimental|100 mg bid|
11499587|NCT01357239|Placebo Comparator|Placebo|
11499588|NCT01357226||All patients over the age of 18|
11499589|NCT01357213|Placebo Comparator|Arm 2|Placebo in all three cohorts
11499590|NCT01357213|Experimental|Arm 1|XOMA 3AB in 3 dose levels/cohorts A, B or C.
11499591|NCT01357200||critically ill obese adults|Age ≥ 18 years, body mass index (BMI) ≥ 30, in intensive care unit (ICU) requiring tube feeding ≥ 3 days
11499592|NCT01357187|Other|Control|
11499593|NCT01357187|Experimental|Treatment|
11499594|NCT01357174||All Participants|Infants who were vaccinated with ROTATEQ™
11499595|NCT01357161|Experimental|Part 1: MK-1775 225 mg + paclitaxel +carboplatin|During the open-label run-in, participants receive 225 mg MK-1775 twice daily (BID) starting on Day 1 of Cycle 1 (cycle=21 days) for a total of 5 doses. Participants receive MK-1775 in combination with paclitaxel (175 mg/m2) and carboplatin (area under the curve [AUC] 5).
11499596|NCT01357161|Experimental|Part 2: MK-1775 225 mg + paclitaxel +carboplatin|During Part 2, participants receive 225 mg MK-1775 BID starting on Day 1 of each 21 day cycle for a total of 5 doses. Participants receive MK-1775 in combination with paclitaxel (175 mg/m2) and carboplatin (AUC 5).
11499597|NCT01357161|Placebo Comparator|Part 2: Placebo + paclitaxel +carboplatin|During Part 2, participants receive matched placebo to MK-1775 BID starting on Day 1 of each 21 day cycle for a total of 5 doses. Participants receive placebo in combination with paclitaxel (175 mg/m2) and carboplatin (AUC 5).
11499598|NCT01357148||Participants treated with sitagliptin phosphate/metformin HCl|
11499599|NCT01357135||Metformin + Sitagliptin|Participants taking metformin + sitagliptin (Januvia®/Xelevia®) as prescribed in routine clinical practice.
11499600|NCT01357135||Metformin + Sulfonylurea|Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride.
11499601|NCT01357135||Sitagliptin +/- Other Antihyperglycemic Medication|Participants taking sitagliptin +/- other antihyperglycemic medication (other than metformin) as prescribed in routine clinical practice. These other antihyperglycemic medications could include: insulin, glinides, sulfonylurea, glitazone, an alpha-glucosidase inhibitor, or combinations thereof.
11499602|NCT01357122|Experimental|NCI Insertion|
11499603|NCT01357122|Active Comparator|Standard Forceps Insertion|
11499604|NCT01357109|Experimental|Bosentan|
11499605|NCT01357109|Placebo Comparator|Placebo|
11499606|NCT01357096|No Intervention|Comparison group|
11499607|NCT01357096|Experimental|Integrated health care team|
11499608|NCT01357083||Major Depression Disorder|This study is analytical cross-sectional and randomized. Two groups of depressed patients and healthy subjects were selected.The individual were submitted to a medical examination, and responded to the Beck depression inventory (BDII-II). Those, who got a score above 20, were included in the depressed group. Among this group, 50 patients were chosen randomly. those who obtained a depressive score below 9, 50 of them were chosen and they were included in the healthy group. The control group was chosen to match to the depressed patients for education, social occasion, occupational and economical situation. All of the subjects were interviewed psychiatrically, and the depression disorder was confirmed on the basis of the DSM criteria. eight out of 50 depressed patients were excluded from the study due to suffering from other psychiatric disorders .
11499609|NCT01357070|Active Comparator|Brocco-sprout homogenate|
11499610|NCT01357070|Sham Comparator|Alfalfa sprout homogenate|
11499611|NCT01357057||Derivation cohort|Arm 1: Derivation cohort (from 2003 to 2007)
11499612|NCT01357057||Validation cohort|Arm 2: Validation cohort (from 2008 to 2009)
11499613|NCT01357044|Active Comparator|Plant extracts|
11499614|NCT01357044|Placebo Comparator|Placebo|
11499615|NCT01357031|Experimental|Melatonin|Melatonin 3 mg at bedtime
11499616|NCT01357031|Placebo Comparator|Placebo|Placebo
11499617|NCT01357031|Active Comparator|Amitriptyline|Amitriptyline 25 mg
11499618|NCT01357018||patients with rheumatoid arthritis|
11499619|NCT01357018||patients with ankylosing spondylitis|
11499620|NCT01357005||Schizophrenia Family|
11499621|NCT01356992|Active Comparator|Clexane® (enoxaparin - Sanofi)|
11499622|NCT01356992|Experimental|Versa® (enoxaparin - Eurofarma)|
11499725|NCT01356264|Active Comparator|Multimodal prehabilitation begun postop|The prehabilitation program will begin after the surgery.
11499623|NCT01356979||Patients underwent medical thoracoscopy|Patients who require medical thoracoscopy for undiagnosed exudative pleural effusion by other clinical or radiological investigations.
11499624|NCT01356966|Experimental|Tetrahydrobiopterin + Folate|Male subjects with hypertension and chronic kidney disease stage 2 or 3 will receive Tetrahydrobiopterin (6R-BH4) 200 mg twice daily and folic acid 1 mg daily
11499625|NCT01356966|Placebo Comparator|Placebo + Folate|Male subjects with hypertension and chronic kidney disease stage 2 or 3 will receive 2 placebo pills twice daily and folic acid 1 mg daily
11499626|NCT01356953|Experimental|Aerobic Exercise|
11499627|NCT01356940|Active Comparator|dalfampridine ER 10mg bid-placebo|4 week administration of dalfampridine ER 10mg bid followed by 2 week washout and 4 weeks of placebo control
11499628|NCT01356940|Placebo Comparator|placebo-dalfampridine ER 10mg bid|placebo tablet administered bid for four weeks followed by 2 week washout and 4 weeks of dalfampridine ER 10mg bid
11499629|NCT01356927||DMPA|DMPA given at the time of mifepristone for medical abortion
11499630|NCT01356927||Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone for medical abortion
11499631|NCT01356914|Experimental|Treatment A: BMS-914392|
11499632|NCT01356914|Experimental|Treatment B: BMS-914392|
11499633|NCT01356914|Experimental|Treatment C: BMS-914392|
11499634|NCT01356914|Placebo Comparator|Treatment D: Placebo|
11499635|NCT01356901||Treatment naïve and pre-treated CHB patients|subanalysis with migrant and non-migrant patients
11499636|NCT01356888|Active Comparator|Abbott Laboratories - Xience Prime DES|
11499637|NCT01356888|Experimental|Biotronik - Orsiro DES|
11499638|NCT01356875|Experimental|HIDRA/VPA|In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycles of hydralazine and valproic acid.
11499639|NCT01356875|Active Comparator|best supportive care (BSC)|The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
11499640|NCT01356862|Experimental|PASIREOTIDE|INTRAMUSCULAR INJECTION OF PASIREOTIDE 60 MG
11499641|NCT01356862|Placebo Comparator|PLACEBO|INTRAMUSCULAR INJECTION OF PLACEBO
11499642|NCT01356849|Placebo Comparator|Group A - Placebo QD|
11499643|NCT01356849|Active Comparator|Group B - Low dose Atrasentan QD|
11499644|NCT01356849|Active Comparator|Group C - High dose Atrasentan QD|
11499645|NCT01356836||Good-poor collateral|Patients who had good and poor collaterals formed 2 groups
11499646|NCT01356836||Good collateral, Poor collateral|
11499647|NCT01356823|Experimental|30μg HPV|Participants in this arm would receive 30μg HPV vaccines which contains 20μg HPV 16 antigen and 10μg HPV 18 antigen
11499648|NCT01356823|Experimental|60μg HPV|Participants in this arm would receive 60μg HPV vaccines which contains 40μg HPV 16 antigen and 20μg HPV 18 antigen
11499649|NCT01356823|Experimental|90μg HPV|Participants in this arm would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
11499650|NCT01356823|Placebo Comparator|hepatitis B vaccine|Participants in this arm would receive hepatitis B vaccine.
11499651|NCT01356810|Placebo Comparator|Standard Care|Delirium management defined by the attending physician.
11499652|NCT01356810|Experimental|Environmental Intervention|
11499653|NCT01356797|Active Comparator|hyperbaric bupivacaine|
11499654|NCT01356797|Experimental|hypobaric levobupivacaine with fentanyl|
11499655|NCT01356784|Experimental|Tailored Physical Activity|
11499656|NCT01356784|Active Comparator|"Chronic Pain Self-management Programme"|
11499657|NCT01356784|Other|Health Counselling|
11499658|NCT01356771|Other|Control Group|
11499659|NCT01356771|Other|Tailored Intervention|We will mail three separate pamphlets created specifically for the participant. The information in the pamphlets will be based on answers from the first survey.
11499660|NCT01356758||Psoriasis topical treatment|Psoriasis topical treatment. No systemic drugs.
11499661|NCT01356758||Psoriasis biological treatment|Psoriasis biological treatment. Anti-Tnf and anti-il12/23.
11499662|NCT01356758||Severe atopic dermatitis|Severe atopic dermatitis
11499663|NCT01356758||Control|No intervention. No inflammatory skin disease.
11499664|NCT01356745|Experimental|premixed 50% nitrous oxide and oxygen|
11499665|NCT01356745|Placebo Comparator|medical air|
11499666|NCT01356732|Experimental|Sufentanil|
11499667|NCT01356706||CRLM|patients with colorectal liver metastases (CRLM) who undergo their primary surgery at UZ. Leuven (single-center academic study)
11499668|NCT01356693|Experimental|Active drug|Bromelin. Extract from Ananas comosus, 3,3g on vehicle (methylparaben, propylparaben, honey from apis mellifera, sodium benzoate, ethylic alcohol, water) 5ml.
11499669|NCT01356693|Placebo Comparator|Placebo|Placebo comparator with the same characteristics of experimental drug, 5ml, single dose.
11499670|NCT01356680|Active Comparator|Arm A|2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy IF-RT irrespective of FDG-PET results after chemotherapy
11499671|NCT01356680|Experimental|Arm B|2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy IN-RT if FDG-PET is positive after chemotherapy; 2 cycles BEACOPPescalated plus 2 cycles ABVD and treatment stop if FDG-PET is negative after chemotherapy
11499672|NCT01356667|Active Comparator|Treatment-As-Usual|Substance Abuse treatment typically received
11499673|NCT01356667|Experimental|DARTNA|12-week DARTNA program
11499674|NCT01356654|Sham Comparator|SHAM TDCS|
11499675|NCT01356654|Active Comparator|True TDCS|
11499676|NCT01356641|Experimental|Antibiotic treatment alone|"Intravenous administration:
~Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7mg/kg once daily
~Oral administration of:
~Amoxicillin/clavulanic acid 50/12.5 mg/kg/day (in three doses)"
11499677|NCT01356641|Active Comparator|Appendectomy|Routine appendectomy either laparoscopic or open depending on the surgeon's preference
11499678|NCT01356628|Experimental|PD-0332991|PD-0332991 in the Treatment in Patients with Advanced Hepatocellular Carcinoma
11499679|NCT01356615|Experimental|enoxaparin|enoxaparin sodium (Clexane) (40 mg) followed prospectively for 3 months (36 dialyses)
11499680|NCT01356615|Active Comparator|standard unfractionated heparin|standard unfractionated heparin followed prospectively for 3 months (36 dialyses)
11499681|NCT01356602|Experimental|Canakinumab, pre-filled syringes (PFS)|Patients on this arm received 150 mg subcutaneously (s.c.) at randomization and upon new flare. The doses were provided as pre-filled syringes. The patients were given 3 injections: two placebo and one active drug.
11499682|NCT01356602|Active Comparator|Canakinumab, lyophilizate (LYO)|The patients on this arm received 150 mg s.c. at randomization and upon new flare. The doses were provided as lyophilized powder and had to be reconstituted with water for injection before application. The patients were given 3 injections: two placebo and one active drug.
11499683|NCT01356602|Active Comparator|Triamcinolone Acetonide|The patients on this arm received 40 mg intramuscular (i.m.) at randomization and upon new flare. The patients were given 3 injections: two placebo and one active drug.
11499684|NCT01356589||Cohort|
11499685|NCT01356563|Experimental|clinical pharmacist intervention|
11499686|NCT01356563|No Intervention|usual care|Patients randomized to usual care group will receive routine review of medication by outpatient department pharmacists and nurse.
11499687|NCT01356550|Experimental|Healthy subjects|
11499688|NCT01356550|Experimental|Hepatic impairment|
11499689|NCT01356537||Gaucher's Disease under VPRIV|
11499690|NCT01356524|Active Comparator|Supplementary progesterone|Women with mid-luteal progesterone levels that are less than 15 ng/dl will receive higher doses of supplementary progesterone
11499691|NCT01356524|No Intervention|No additional progesterone|No additional progesterone given to women with mid-luteal progesterone levels below 15 ng/dl
11499692|NCT01356511|Experimental|Prednisone group|Patients in the PDN arm received PDNorally at 1.0mg/kg body weight daily for 4 consecutive weeks.
11499693|NCT01356511|Experimental|Dexamethasone group|DXM was administered orally at 40 mg daily for 4 consecutive days and then stopped
11499694|NCT01356498|Experimental|q2 RCT|Pegloticase every 2 wk arm of Randomized Controlled Trial(RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
11499695|NCT01356498|Experimental|q4 RCT|Pegloticase every 4 wk arm of Randomized Controlled Trial (RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
11499696|NCT01356498|Experimental|Placebo in RCT|Placebo arm in Randomized Controlled Trial (RCT), received pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in OLE
11499697|NCT01356485|Experimental|MP4CO|Escalating doses of MP4CO, administered intravenously
11499698|NCT01356485|Placebo Comparator|Saline|Normal saline (0.9% sodium chloride solution)
11499699|NCT01356472|No Intervention|Linezolid alone|the control group is designed for linezolid alone treated MRSA VAP (standard treatment).
11499700|NCT01356459|Experimental|Intervention|Patients in this arm will have Mepilex dressings applied to their sacrum and heels
11499701|NCT01356459|No Intervention|Control|Patients in this arm will have standard care
11499702|NCT01356446|No Intervention|before surgical checklist|
11499703|NCT01356446|Active Comparator|after implementation surgical checklist|
11499704|NCT01356433|Other|arm1, vitamin C treated first|Arm 1(50cases): intervention with oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.
11499705|NCT01356433|Other|Arm 2 control first|
11499706|NCT01356420|Experimental|Cholesterol supplementation|All new subjects will come to their first visit with an least 3 weeks of stable cholesterol intake. Typically and preferably this will include egg yolk as cholesterol supplement, but in some instances e.g. intolerance to egg yolk it may include a new encapsulated cholesterol preparation, Sloesterol.
11499707|NCT01356407|Experimental|PICOPREP|"Split Dose method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day before the colonoscopy."
11499708|NCT01356407|Active Comparator|PEG-ELS|PEG-ELS was used according to the approved labeled dosage and administration instructions. Only received one dose of 2 boxes (6 packets), administrated on the day of colonoscopy examination.
11499709|NCT01356381|Experimental|vildagliptin|
11499710|NCT01356381|Experimental|Placebo|
11499711|NCT01356368|Experimental|Cisplatin,Docetaxel,Gemzar, Premetrexed|Patients will receive treatment for up to six cycles of the assigned regimen unless there is disease progression or unacceptable toxicities. After treatment, the patients will be seen every 2 months for the first year, then every 3 months for the second year and every 6 months afterwards.
11499712|NCT01356355|Experimental|Herbmed plus|One capsule twice a day daily till ureteral stent in situ
11499713|NCT01356355|Placebo Comparator|Placebo|One capsule twice a day daily till ureteral stent in situ
11499714|NCT01356355|Active Comparator|Tolterodine|One capsule twice a day daily till ureteral stent in situ
11499715|NCT01356342|Experimental|AdimFlu-S 2010-2011, 6 months~<3 years|
11499716|NCT01356342|Experimental|AdimFlu-S 2010-2011,3~<9 years|
11499717|NCT01356342|Experimental|AdimFlu-S 2010-2011,9~<18 years|
11499718|NCT01356329|Experimental|Lovenox|Group A : Low Molecular Weight Heparin (LMWH), LovenoxTM (Enoxaparin)
11499719|NCT01356329|Experimental|Heparin|Group B:HeparinTM (Unfractionated Heparin)
11499720|NCT01356316|Experimental|AdimFlu-S Influenza Vaccine|
11499721|NCT01356303|Experimental|Cisplatin, Docetaxel|Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of D5W or NS administered as a 1-hour intravenous infusion, followed by cisplatin at dose of 75 mg/m2administered as a 2-hour intravenous infusion every 3 weeks per cycle for 4-6 cycles
11499722|NCT01356277|Experimental|Multi-component Intervention|"Multi-component Intervention consisting of:
~Adherence Support Team (patient, parent, Coach)
~standardized education on immunosuppressive medications
~identification of adherence barriers
~Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals
~'Action-Focused Problem-Solving' to address barriers selected as most important by the patient
~text message, email, or visual cue dose reminders"
11499723|NCT01356277|No Intervention|Attention control|Control group study visits were conducted at the same intervals as intervention visits and consisted of the Coach engaging in active listening and providing non-specific support only. Adherence was NOT discussed with control participants.
11499724|NCT01356264|Experimental|multimodal prehabilitation begun preop|The prehabilitation program will begin several weeks preop and continue in the postoperative period
11500926|NCT01348126|Experimental|Combination of ganetespib and docetaxel|
11499726|NCT01356251|Experimental|Surgical group with mesothelioma|The study proposed here has two parts: part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life through a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. In part 2, patients are invited to participate in an Internet-based discussion group.
11499727|NCT01356251|Experimental|Non Surgical group with mesothelioma|The study proposed here has two parts: part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life through a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. In part 2, patients are invited to participate in an Internet-based discussion group
11499728|NCT01356238|Experimental|MRC media|Use MRC media in the human IVF-ET program
11499729|NCT01356238|Active Comparator|Sydney IVF media|Use Sydney IVF media in the human IVF-ET program
11499730|NCT01356225|Experimental|Intranasal Ketorolac tromethamine|
11499731|NCT01356225|Placebo Comparator|Intranasal placebo|
11499732|NCT01356212|Experimental|Regimen A: Ketorolac tromethamine (Gentle Sniff - Upright)|Gentle sniff-inhalation with the volunteer upright for dosing and imaging
11499733|NCT01356212|Experimental|Regimen B: Ketorolac tromethamine (Vigorous Sniff - Upright)|Vigorous sniff-inhalation with the volunteer upright for dosing and imaging
11499734|NCT01356212|Experimental|Regimen C: Ketorolac tromethamine (Gentle Sniff - Semi-supine)|Gentle sniff-inhalation with the volunteer semi-supine for dosing and imaging
11499735|NCT01356199|Experimental|ARTRONAT|
11499736|NCT01356199|Placebo Comparator|PLACEBO|
11499737|NCT01356186|Experimental|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Sessions of Post Admission Cognitive Therapy Delivered Preferably Over 3 Consecutive Days of Inpatient Stay
11499738|NCT01356186|No Intervention|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services
11499739|NCT01356173|Experimental|A|
11499740|NCT01356160|Active Comparator|Arm 1|RGT with GS-5885 30 mg QD + GS-9451 200 mg QD + PEG/RBV
11499741|NCT01356160|Placebo Comparator|Arm 2|RGT with GS-5885 30 mg QD + GS-9451 placebo QD + PEG/RBV
11499742|NCT01356147|Sham Comparator|Sham placebo|No therapy will be given to placebo arm. Respiratory therapist will shield infant from view and nebulize saline solution into incubator rather than into ventilator circuit.
11499743|NCT01356147|Active Comparator|Dornase alfa|Dornase alfa 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
11499744|NCT01356134||Multiple sclerosis and or Ehlers-Danlos|Patients with suspected or confirmed cases of Ehlers Danlos Syndrome and or Multiple Sclerosis
11499745|NCT01356134||Age matched normals|Age matched normals
11499746|NCT01356121|Active Comparator|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
11499747|NCT01356121|Active Comparator|Propofol|Propofol will be initiated with a 0.5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
11499748|NCT01356121|No Intervention|No Sedation|No sedation given in this group
11499749|NCT01356095|Active Comparator|PALM-Plus control|Health centers randomized to Palm-Plus intervention in larger trial this trial is embedded in, but not receiving the adherence intervention.
11499750|NCT01356095|Experimental|Adherence intervention|Intervention arm.
11499751|NCT01356095|No Intervention|Control|
11499752|NCT01356082||Arterial blood pressure line|Patients receiving an arterial blood pressure line
11499753|NCT01356069|Experimental|SB-APP Psychotherapy|Patients, who signed the informed consent, were randomly assigned to SB-APP in addition to TAU (n=18) or to TAU alone (n=17) groups. The SB-APP group received the usual treatment plus SB-APP (40 weekly sessions) for 10 or 11 months. At the term of the first year (T12) the TAU group continued with the TAU management with supportive weekly session whilst the SB-APP group was carried on with the psychiatric, nurse, educational management without any individual psychological support. The number of sessions performed by the two groups in the first year (T0-T12) was programmed to be almost the same to reduce the number of sessions bias comparing the specific quality of treatments.
11499754|NCT01356069|Active Comparator|TAU treatment|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators. The medication was administered according to the APA guidelines [18] for good clinical practice with regard to BPD.
11499755|NCT01356056||Kinesia HomeView Monitoring|Uses Kinesia HomeView at home once per week
11499756|NCT01356056||Control|Assessed in the clinic every 4 weeks using traditional methods
11499757|NCT01356043|Experimental|Free combination of S-amlodipine and Telmisartan|Subjects received S-amlodipine 5mg and Telmisartan 80mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
11499758|NCT01356043|Active Comparator|S-amlodipine monotherapy|Subjects received S-amlodipine 5mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
11499759|NCT01356030|Active Comparator|EUS-FNA|
11499760|NCT01356030|Active Comparator|ERCP Brushing and Biopsy|
11499761|NCT01356017|Experimental|Free combination of Telmisartan and S-amlodipine|Subjects received Telmisartan 80mg and S-amlodipine 5mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
11499762|NCT01356017|Active Comparator|Telmisartan monotherapy|Subjects received Telmisartan 80mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
11499763|NCT01356004|Experimental|chicken pox vaccine, efficacy|
11499764|NCT01356004|Placebo Comparator|saline, efficacy|
11499765|NCT01355991|Active Comparator|Anticholinergic Agent|
11499766|NCT01355991|Active Comparator|Long Acting Beta 2 Agonist|
11499767|NCT01355978|Experimental|Noninvasive Open Ventilation System|Portable noninvasive open ventilator & nasal interface.
11499768|NCT01355965|Experimental|Cohort 1 - One dose of cells|Subjects receive one dose of 1x108 cells on day 0 followed by one dose of 1x109 autologous transfected anti-mesothelin CAR T cells on day 7.
11499860|NCT01355289|Active Comparator|Avatrombopag 20 mg (Core Study)|Avatrombopag 20 mg, will be administered orally, once daily, preferably with food for up to 21 days.
11499769|NCT01355965|Experimental|Cohort 2 - three doses of cells|receive three doses of 1x108 cells on day 0, 2, 4 (Monday-Wednesday-Friday (MWF) of Cycle 1) followed by three doses of 1x109 T cells on day 7, 9, 11 (MWF of Cycle 2). Total target dose for Cohort 2 is 3.3x109 cells.
11499770|NCT01355952|Experimental|Alpha Lipoic Acid|taking 1800mg daily (600mg 3 times per day) Alpha Lipoic Acid (ALA) open-label for 10 weeks.
11499771|NCT01355939||Abdominal surgery after prior VHR with barrier-coated mesh|
11499772|NCT01355939||Abdominal surgery after prior VHR with nonbarrier-coated mesh|
11499773|NCT01355939||Lap adhesiolysis during abdominal surgery after prior VHR|
11499774|NCT01355939||Open adhesioloysis during abdominal surgery after prior VHR|
11499775|NCT01355926|Experimental|Flexible Fiber-based CO2 Laser|In the CO2 excised group, the resection will be performed at 15W, at a distance of 1cm from the tissue. Here too, if required, the bipolar will be used to achieve hemostasis The study will focus on post operative pain and quality of life outcomes for both surgical interventions.
11499776|NCT01355926|Experimental|electrocautery resection|In the electrocautery excised group, the cut and coagulation modes used will be each at 25 Malis power setting. First, cut mode will be used to mark out the lesion. Subsequently, coagulation mode will be used for excision. Bipolar cautery will then be used at 25 Malis for hemostasis. The study will focus on post operative pain and quality of life outcomes for both surgical interventions.
11499777|NCT01355900|Other|I tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before incision, deflation- after bone cement set.
11499778|NCT01355900|Other|II tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before cement application, deflation- after bone cement set.
11499779|NCT01355900|Other|III tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before incision, deflation- after wound closure
11499780|NCT01355900|Other|IV control group|Do not use volume loading test. Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before cement application, deflation- after bone cement set.
11499781|NCT01355874|Experimental|Iferanserin|
11499782|NCT01355874|Experimental|Placebo|
11499783|NCT01355874|Experimental|Iferanserin + Placebo|
11499784|NCT01355861|Experimental|1|Exercise group 1: Negative work exercise
11499785|NCT01355861|Other|2|Exercise group 2: Negative work exercise (delayed start for single-arm crossover trial)
11499786|NCT01355848|Experimental|Brief Intervention|The brief intervention consists of stepped care protocol, including building rapport, functional analysis of suicidal behavior, and crisis planning
11499787|NCT01355848|No Intervention|care as usual|Patients randomized to the care as usual arm will not receive the brief intervention.
11499788|NCT01355835|Active Comparator|[STNmono]|Conventional stimulation on subthalamic contacts
11499789|NCT01355835|Experimental|[STN+SNr]|Combined subthalamic and nigral stimulation
11499790|NCT01355822|Placebo Comparator|Placebo|
11499791|NCT01355822|Experimental|PETN|Pentalong, Actavis Germay: 80 mg twice a day
11499792|NCT01355809|Active Comparator|Inhalation Nitrogen/Oxygen|Nitrogen/Oxygen (65%/35%)
11499793|NCT01355809|Experimental|Inhalation Helium/Oxygen|Helium/Oxygen (65%/35%)
11499794|NCT01355809|Experimental|Inhalation gas|Medicinal oxygen 100% via NIV with FiO2 of 0.35
11499795|NCT01355796|Experimental|Aerosolized Hypertonic xyltiol|Aerosolized xylitol (5 ml) twice daily for 14 days
11499796|NCT01355796|Active Comparator|Hypertonic saline|Aerosolized 7% hypertonic saline (4 ml) twice daily for 14 days
11499797|NCT01355783|Active Comparator|E7777 + CHOP Chemotherapy|
11499798|NCT01355783|Active Comparator|CHOP alone|
11499799|NCT01355757|Experimental|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
11499800|NCT01355757|Active Comparator|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
11499801|NCT01355744||Spider bite patients|All patients treated for an actual spider bite by a Swiss physician during study period.
11499802|NCT01355731||Registered Nurse|This is quality improvement study that is descriptive and is utilizing a convenience sample of direct care registered nurses employed full-time for at least one year at St. Jude Children's Research Hospital.Participants will take a onetime researcher generated therapeutic boundaries questionnaire which will describe behaviors and attitudes regarding therapeutic boundaries.
11499803|NCT01355718||Repaglinide|
11499804|NCT01355705|Experimental|Amrubicin + Lenalidomide + Dexamethasone|"Amrubicin will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.
~Concurrent therapeutic medications:
~Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14
~Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)
~Other drugs:
~Aspirin: 81 or 325 mg daily oral
~Pegfilgrastim subcutaneous on Day 2"
11499805|NCT01355692|Experimental|Laser therapy|
11499806|NCT01355679|Experimental|Guided therapy|A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
11499807|NCT01355666|Experimental|DermaTherapy® Linen group|The DermaTherapy® Linen group uses bed sheets and underpads made with DermaTherapy® fabric.
11499808|NCT01355653|Experimental|Treatment A|thermal therapy
11499809|NCT01355653|Active Comparator|Treatment B|ThermaCare Lower Back/Hip heatwrap
11499810|NCT01355640|Experimental|breast-feeding group|Mothers console their babies by breast-feeding during heel lance.
11499811|NCT01355640|Experimental|non-nutritive sucking|"Every mother was given a vacuum pacifier( the brand is Goodbaby) to console her baby during heel lance."
11499861|NCT01355289|Active Comparator|Avatrombopag 30 mg (Core Study)|Avatrombopag 30 mg, will be administered orally, once daily, preferably with food for up to 21 days.
11499812|NCT01355640|No Intervention|control group|A research nurse also explained the study to the control group parents. Standard clinic procedure for infant injection was also implemented. Mothers in control group also lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed.
11499813|NCT01355627|Experimental|TachoSil®|
11499814|NCT01355627|Active Comparator|Current practice group|
11499815|NCT01355614|Experimental|QAX576|
11499816|NCT01355614|Other|Infliximab|
11499817|NCT01355601|Experimental|Group 1 - Control A|Nutritional beverage containing varying types and levels of carbohydrates
11499818|NCT01355601|Experimental|Group 2 - Experimental A|Nutritional Beverage with varying types and levels of carbohydrates
11499819|NCT01355588|Experimental|Ketorolac Tromethamine|
11499820|NCT01355588|Experimental|Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)|
11499821|NCT01355588|Experimental|Ketorolac Tromethamine with 5% Lidocaine HCl|
11499822|NCT01355588|Experimental|Ketorolac Tromethamine with 6% Lidocaine HCl|
11499823|NCT01355575|Experimental|Rifaximin for 6-weeks followed by 6-week observation period|All patients receiving 6 weeks Rifaximin 400mg twice daily, followed by a 6 week observation period.
11499824|NCT01355549|Experimental|Platelet-rich plasma therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
11499825|NCT01355536||Preterm birth group|Women with prior preterm birth
11499826|NCT01355536||Term birth group|Women with prior term birth
11499827|NCT01355523|Active Comparator|Melatonin|6 mg oral melatonin daily
11499828|NCT01355523|Placebo Comparator|Placebo|6 mg oral placebo daily
11499829|NCT01355497|Experimental|GTx-024 3mg once daily|subjects will be randomized to receive GTx-024 3mg sofgel capsule once daily for the duration of the trial
11499830|NCT01355497|Placebo Comparator|placebo|subjects will be randomized to receive matching placebo once daily for the duration of the trial
11499831|NCT01355484|Experimental|GTx-024|subject will receive GTx-024 treatment for the duration of the trial
11499832|NCT01355484|Placebo Comparator|Placebo|subject will receive placebo for the duration of the trial
11499833|NCT01355471|Experimental|CD07805/47 gel|
11499834|NCT01355471|Placebo Comparator|Placebo|
11499835|NCT01355458|Experimental|CD07805/47 gel|
11499836|NCT01355458|Placebo Comparator|Placebo|
11499837|NCT01355445|Active Comparator|Vincristine / Irinotecan|Vincristine, Irinotecan Vincristine :1.5 mg/m² (max 2mg), IV Irinotecan : Irinotecan 50 mg/m²/d, IV
11499838|NCT01355445|Experimental|Vincristine / Irinotecan / Temozolomide|Vincristine, Irinotecan, Temozolomide
11499839|NCT01355432||Propofol|
11499840|NCT01355419||obstructive sleep apnea, CPAP|moderate to severe obstructive sleep apnea requiring CPAP therapy
11499841|NCT01355406|Other|PAD|This is a prospective single-arm multi-center clinical trial designed to evaluate the safety and efficacy of the Flexible Stenting Solutions Flext Stent® Femoropopliteal stenting system in subjects with lower limb peripheral arterial desease (PAD). Subjects targeted for enrollment must have a single de-novo lesion located in the superficial femoral artery and/or proximal popliteal artery with at > 70% stenosis. Subjects must meet all enrollment criteria and provide written informed consent prior to participation in the study.
11499842|NCT01355393|Experimental|Stage I, Arm 1 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 1: HER2 peptide vaccine + 4 mcg Ampligen®
~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
11499843|NCT01355393|Active Comparator|Stage II, Arm I (HER-2/neu peptide vaccine and sargramostim)|Patients receive synthetic HER-2/neu peptide vaccine admixed with GM-CSF ID.
11499844|NCT01355393|Experimental|Stage II, Arm II (HER-2 vaccine, sargramostim, rintatolimod)|Patients receive synthetic HER-2/neu peptide vaccine admixed with GM-CSF and rintatolimod ID
11499845|NCT01355393|Experimental|Stage I, Arm 2 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 2: HER2 peptide vaccine + 20 mcg Ampligen®
~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
11499846|NCT01355393|Experimental|Stage I, Arm 3 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 3: HER2 peptide vaccine + 79 mcg Ampligen®
~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
11499847|NCT01355393|Experimental|Stage I, Arm 4 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 4: HER2 peptide vaccine + 495 mcg Ampligen®
~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
11499848|NCT01355393|Experimental|Stage I; Arm 5 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 5: HER2 peptide vaccine + 2000 mcg Ampligen®
~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
11499849|NCT01355380||Group 1|Drug (incl. Placebo)
11499850|NCT01355367|Experimental|Arm 1|
11499851|NCT01355354|Experimental|1|Digoxin
11499852|NCT01355354|Experimental|2|Fostamatinib
11499853|NCT01355341|Experimental|HERBMED PLUS|Herbal formulation of four constituents i.e.Varuna,Yav,Aghada,Kadali as per ayurvedic literature.
11499854|NCT01355328|Experimental|laser|
11499855|NCT01355328|No Intervention|control|
11499856|NCT01355302|Experimental|Phase Ib: Cohort 1 and 2 and 3|"Phase Ib: Cohort 1; 200 mg E7050 + 80 mg/m2 cisplatin + 1000 mg/m2 capecitabine
~Cohort 2; 300 mg E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine Cohort 3; 400 mg E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine"
11499857|NCT01355302|Active Comparator|Phase II: Arm 1; E7050 + cisplatin+ capecitabine|Phase II: Arm 1; MTD E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine
11499858|NCT01355289|Placebo Comparator|Placebo (Core Study)|Placebo, will be administered orally, once daily for up to 21 days.
11499859|NCT01355289|Active Comparator|Avatrombopag 10 mg (Core Study)|Avatrombopag 10 mg, will be administered orally, once daily, preferably with food for up to 21 days.
11499914|NCT01354743|Other|Dysport|Dysport injections into the glabella and orbicularis oculi muscles with dose based on muscle mass
11499862|NCT01355289|Experimental|Avatrombopag (Open-Label Extension)|Avatrombopag will be initiated at a dose of 20 mg, once daily in the open-label extension (OLE) period. The avatrombopag dose will be titrated up or down in accordance with the participant's individual response, within the range of a minimum of 5 mg and a maximum of 50 mg for up to 48 weeks.
11499863|NCT01355276|Experimental|1|
11499864|NCT01355276|Active Comparator|2|
11499865|NCT01355263|Experimental|iron tablet, vitamin a capsule|children in Group I received a 200,000 IU vitamin A capsule just one time initially; Group II received ferrous sulfate (element Fe 1-2 mg/kg•day) once a day for 6 months;.
11499866|NCT01355237||OCC Patients|Patients being treated for chronic low back pain at the Osher Clinical Center of Brigham and Women's Hospital
11499867|NCT01355237||Comparison|Patients being treated for chronic low back pain at Brigham and Women's Hospital, other than at Osher Clinical Center
11499868|NCT01355224|No Intervention|No risk feedback|No obesity risk information given (control)
11499869|NCT01355224|Experimental|Genetic risk feedback|Only personal genetic risk information provided
11499870|NCT01355224|Experimental|Lifestyle risk feedback|Only personal lifestyle risk information provided
11499871|NCT01355224|Experimental|Both genetic or lifestyle risk feedback|Personal genetic and lifestyle information provided
11499872|NCT01355198|Experimental|Cysteine/glycine|Subjects will be studied before and after receiving oral cysteine (as n-acetylcysteine) and glycine for 2 weeks
11499873|NCT01355159|Experimental|Folic Acid 4 mg|Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
11499874|NCT01355159|Placebo Comparator|Placebo|Women will be randomised in a 1:1 ratio to folic acid 4.0 mg or placebo
11499875|NCT01355146||Fabry's Disease under Replagal|
11499876|NCT01355120|Experimental|a human immunoglobulin|Four infusions (i.v.) of 3mg/kg Ipilimumab in week 1, week 4, week 7 and week 10
11499877|NCT01355107||chronic hcv, no liver cirrhosis, no HCC|patients with chronic hepatitis c- infection: no cirrhosis of the liver (= Desmet IV), no HCC - suspected lesion in the liver
11499878|NCT01355107||chronic hcv, liver cirrhosis, no HCC|patients with hcv- associated cirrhosis of the liver, but with no HCC - suspected lesions in the liver
11499879|NCT01355107||hcv-infection, HCC|patients with hcv- associated HCC
11499880|NCT01355094|Active Comparator|"Stampede VAC"|"Calgary-home-made Stampede VAC system with only closed drain bulb suction"
11499881|NCT01355094|Experimental|KCI AbThera|commercial AbThera vacuum assisted abdominal closure at 125 mmHg suction
11499882|NCT01355081|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.
11499883|NCT01355081|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.
11499884|NCT01355081|Placebo Comparator|Placebo|Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.
11499885|NCT01355068|Active Comparator|Treatment A|Epanutin Infatabs 50 mg (sourced from Germany), 1 x 50 mg (REFERENCE)
11499886|NCT01355068|Experimental|Treatment B|Dilantin Infatabs 50 mg (sourced from Australia), 1 x 50 mg (TEST)
11499887|NCT01355042||Severe Sepsis and Septic Shock|
11499888|NCT01355042||Other Critical Ill with or without Shock|Severe Trauma, Neurological Injury, Other Shock (not Septic)
11499889|NCT01355016|Experimental|MDT-637|Active formulation
11499890|NCT01355016|Placebo Comparator|Placebo|Matched Placebo Comparator
11499891|NCT01355003||All Participants|Participants who were vaccinated with GARDASIL™ by their physician
11499892|NCT01354990||Participants treated with sitagliptin|
11499893|NCT01354977|Experimental|Resveratrol|Each participant will receive a 28 days' supply of resveratrol capsules on day 0.
11499894|NCT01354964|Experimental|Vitamin D|Participants received weekly oral vitamin D drops using a weight-based calculated dosage for up to six months.
11499895|NCT01354964|Placebo Comparator|Placebo|Participants received weekly oral placebo drops (similar in taste and appearance to vitamin D) for up to six months.
11499896|NCT01354951|Experimental|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|This is a non-randomized, Phase II study examining the tolerance profile (primary endpoint) as well as the secondary endpoints of QOL changes, efficacy and the correlation of post-treatment MRI findings with post-treatment biopsy outcomes in men with early stage low volume prostate cancer treated with focal brachytherapy.
11499897|NCT01354938||Acute Exacerbation of Chronic Bronchitis (AECB)|Participants with a diagnosis of chronic bronchitis and signs and symptoms of an acute exacerbation who were prescribed Klaricid XL (500 mg of modified release clarithromycin) at a dose of one tablet once a day or two tablets once a day based on physician's decision of severity of symptoms per routine clinical care.
11499898|NCT01354925|Active Comparator|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. .
11499899|NCT01354925|Active Comparator|Standard treatment during Ramadan|Standard of care according to physicians choice
11499900|NCT01354860|Experimental|Moxibustion treatment plus usual care|
11499901|NCT01354860|No Intervention|usual care alone|
11499902|NCT01354847||cardiac surgery patients|cardiac surgery patients scheduled for elective complex cardiac surgery
11499903|NCT01354834||hMG|
11499904|NCT01354821|Active Comparator|Endovascular therapy branched|Endovascular therapy branched or fenestrated stent-graft
11499905|NCT01354821|Other|Open surgical repair|Open surgical repair or aortic replacement with revascularization of visceral arteries
11499906|NCT01354808|Active Comparator|DAPT|
11499907|NCT01354808|Experimental|TAPT|
11499908|NCT01354795|Experimental|1.EUS-FNA with or without suction|During EUS FNA is performed, with or without self-retracting 10-mL syringe
11499909|NCT01354795|Experimental|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet into the needle or injecting air
11499910|NCT01354782|Experimental|Roflumilast|(This is a pharmacokinetic study)
11499911|NCT01354769||Non-intubated patients|
11499912|NCT01354769||Intubated patients|
11499913|NCT01354756||bariatric population|obese patients in whom a bariatric surgery is planified
11499915|NCT01354730||Exposed cohort|The woman received AdimFlu-S (A/H1N1) vaccination between 2009/10 and 2010/02. The woman was pregnant at the time of vaccination.
11499916|NCT01354730||Unexposed cohort|The woman was gestation after April 2009.
11499917|NCT01354717|Active Comparator|Brand Carac|Treatment of actinic keratosis with active ingredient
11499918|NCT01354717|Active Comparator|Generic 0.5% 5-fluorouracil cream|Treatment of actinic keratosis with active ingredient
11499919|NCT01354717|Placebo Comparator|Placebo|treatment of actinic keratosis with placebo cream
11499920|NCT01354704|Active Comparator|lovenox|patient under lovenox 4000 IU
11499921|NCT01354704|Active Comparator|enoxa|patients under Enoxa 4000 IU
11499922|NCT01354704|No Intervention|total knee replacement|patients undergoing total knee replacement
11499923|NCT01354704|No Intervention|total hip replacement|patient undergoing total knee replacement
11499924|NCT01354691|Experimental|ladostigil hemitartrate|Ladostigil capsules 80 mg
11499925|NCT01354691|Placebo Comparator|Placebo|Placebo capsules
11499926|NCT01354678|Active Comparator|group of bone marrow cell therapy|
11499927|NCT01354678|Sham Comparator|group of sham therapy|
11499928|NCT01354665||Group 1|
11499929|NCT01354652|Experimental|entecavir|"Oral 0.5mg/day until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18.
~Participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
11499930|NCT01354652|Active Comparator|lamivudine|"Oral 100mg/day lamivudine until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18.
~Participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
11499931|NCT01354652|No Intervention|no NRTI group|hepatitis C virus associated LC patients for the calculation of lactic acidosis incidence
11499932|NCT01354639||Group 1|Group 1 : conventional open thyroidectomy group (papillary thyroid carcinoma patient who underwent conventional open bilateral total thyroidectomy procedure and postoperative low dose RAI therapy)
11499933|NCT01354639||Group 2|Group 2 : robotic thyroidectomy group (papillary thyroid carcinoma patient who underwent robotic bilateral total thyroidectomy procedure and postoperative low dose RAI therapy)
11499934|NCT01354626|Experimental|High fat diets|High-fat-Low-protein or High-fat-high-protein
11499935|NCT01354626|Other|Control group|Low-protein-low-fat (according to healthy eating guidelines)
11499936|NCT01354613|Experimental|HFpEF|25 patients with clinically diagnosed heart failure with preserved ejection fraction, confirmed by Framingham criteria, with EF > 50% and without evidence of active ischemia or known severe CAD, valvular or pericardial disease, infiltrative or hypertrophic cardiomyopathy, cor pulmonale, severe pulmonary disease, or primary renal disease. Subjects will receive amlodipine, oral administration for a period of 12 weeks.
11499937|NCT01354613|Experimental|Pulmonary Disease|20 patients with pulmonary disease and no clinical evidence of cardiovascular disease
11499938|NCT01354613|Experimental|LVH/HTN|20 subjects with known left ventricular hypertrophy and clinically diagnosed hypertension without the diagnosis of heart failure.
11499939|NCT01354613|Placebo Comparator|HFpEF placebo|25 patients with clinically diagnosed heart failure with preserved ejection fraction, confirmed by Framingham criteria, with EF > 50% and without evidence of active ischemia or known severe CAD, valvular or pericardial disease, infiltrative or hypertrophic cardiomyopathy, cor pulmonale, severe pulmonary disease, or primary renal disease. Subjects will be administered a placebo for a period of 12 weeks.
11499940|NCT01354600|Other|Energy Balance|
11499941|NCT01354600|Other|Positive Energy Balance|
11499942|NCT01354587|Active Comparator|Hizentra|Compare IgG levels and site reaction in subjects transitioning from Vivaglobin to Hizentra
11499943|NCT01354574|Experimental|High Glycemic Index meals|Three days of run-in diet with meals containing high glycemic index carbohydrates followed by test day with breakfast meal containing high glycemic index carbohydrates.
11499944|NCT01354574|Experimental|Low Glycemic Index meals|Three days of run-in diet with meals containing low glycemic index carbohydrates followed by test day with breakfast meal containing low glycemic index carbohydrates.
11499945|NCT01354561|Sham Comparator|control group|Physiotherapy in the control group were also done at hospital, in dorsal decubitus position at 30-degree elevation, all receiving the same treatment given for the paediatric inpatients, except nasotracheal suction, which was not performed due to ethical reasons.
11499946|NCT01354561|Active Comparator|respiratory disease group|Respiratory disease group consisting of hospitalized children with acute viral bronchiolitis
11499947|NCT01354548|Experimental|TheraBite grupp|
11499948|NCT01354548|No Intervention|Conventional treatment|
11499949|NCT01354535|Active Comparator|Cable plating with strut|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
11499950|NCT01354535|Active Comparator|isolated plating|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
11499951|NCT01354522|Active Comparator|TAC|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
11499952|NCT01354522|Experimental|TCX|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
11499953|NCT01354509||Current protocol group|Patients treated with current standards based on physician discretion.
11499954|NCT01354509||Normothermia group|Normothermia protocol, using Hydrogel cooling Pads(Arctic Sun) applied for 96 hrs starting upon admission to the ICU
11499955|NCT01354496|Experimental|Cohort 1 - LY2409021 reference form|A 20 milligram (mg) LY2409021 dose, reference form administered orally in the fasted state
11499956|NCT01354496|Experimental|Cohort 1 - LY2409021 medium test form fed|Single 20 mg LY2409021 test form with medium particle size administered orally immediately after ingestion of a standardized high-fat meal
11499957|NCT01354496|Experimental|Cohort 1 - LY2409021 medium test form fasted|Single 20 mg LY2409021 test form with medium particle size administered orally in the fasted state
11499958|NCT01354496|Experimental|Cohort 2 - LY2409021 low test form fasted|Single 20 mg LY2409021 test form with low particle size administered orally in the fasted state
11499959|NCT01354496|Experimental|Cohort 2 - LY2409021 medium test form fasted|Single 20 mg LY2409021 test form with medium particle size administered orally in the fasted state
11499960|NCT01354496|Experimental|Cohort 2 - LY2409021 high test form fasted|Single 20 mg LY2409021 test form with high particle size administered orally in the fasted state
11499961|NCT01354483|Experimental|Treatment Group A|Umbilical cord blood mononuclear cell, 1.6 million
11499962|NCT01354483|Experimental|Treatment Group B|Umbilical cord blood mononuclear cell, 3.2 million
11499963|NCT01354483|Experimental|Treatment Group C|Umbilical cord blood mononuclear cell, 6.4 million
11499964|NCT01354483|Experimental|Treatment Group D|Umbilical cord blood mononuclear cell, 6.4 million; mehtylprednisolone
11499965|NCT01354483|Experimental|Treatment Group E|Umbilical cord blood mononuclear cell, 6.4 million; methylprednisolone; 6 week course of lithium carbonate tablet
11499966|NCT01354470|Experimental|Modafinil|
11499967|NCT01354470|Placebo Comparator|placebo (cornstarch)|
11499968|NCT01354457|Experimental|Epratuzumab and 90Y-Epratuzumab|Escalating dose schedule with 5 cohort. For each cohort 3 patients will receive Radio-immunotherapy (RIT ) at Day 1 and Day 8 ± 2 First cohort : 92,5 MBq/m² of 90Y-DOTA-hLL2 associated with hLL2 Second cohort : 185 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Third cohort : 277,5 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Fourth cohort : 370 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Fifth cohort : 462.5 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2
11499969|NCT01354444|Active Comparator|Carvedilol|Carvedilol is a is a beta-blocker. Beta-blockers are generally used to reduce the workload on the heart and help it to beat more regularly.
11499970|NCT01354444|Placebo Comparator|Placebo|Non active substance
11499971|NCT01354431|Experimental|Arm 1: nivolumab - 0.3 mg/kg|
11499972|NCT01354431|Experimental|Arm 2: nivolumab - 2.0 mg/kg|
11499973|NCT01354431|Experimental|Arm 3: nivolumab - 10.0 mg/kg|
11499974|NCT01354418|Experimental|Phenylephrine HCl Extended Release - Fasted|Single dose phenylephrine HCl extended release tablet administered under fasted conditions on Day 1 in one of four study periods
11499975|NCT01354418|Experimental|Phenylephrine HCl Extended Release - Fed|Single dose phenylephrine HCl extended release tablet administered after a high-fat, high-calorie breakfast on Day 1 in one of four study periods
11499976|NCT01354418|Active Comparator|Phenylephrine HCl Immediate Release - Fasted|Three single doses of phenylephrine HCl immediate release tablet four hours apart, with the first dose administered under fasted conditions on Day 1 in one of four study periods
11499977|NCT01354418|Active Comparator|Phenylephrine HCl Immediate Release - Fed|Three single doses of phenylephrine HCl immediate release tablet four hours apart, with the first dose administered after a high-fat, high-calorie breakfast on Day 1 in one of four study periods
11499978|NCT01354405||Lanreotide|
11499979|NCT01354392|Experimental|AZD1152|
11499980|NCT01354379|Active Comparator|Fluzone 15 mcg HA 200 mcl IN by Pipette|
11499981|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 200 mcl IN by Pipette|
11499982|NCT01354379|Active Comparator|Fluzone 15 mcg HA 200 mcl IN by Nasal Spray|
11499983|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 200 mcl IN by Nasal Spray|
11499984|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 400 mcl IN by Nasal Spray|
11499985|NCT01354366||Control|Marketed hypoallergenic infant formula containing a probiotic
11499986|NCT01354366||Experimental 1|An investigational hypoallergenic infant formula with a different protein content, containing the same probiotic as the control
11499987|NCT01354366||Experimental 2|An investigational hypoallergenic infant formula with a different protein content, without a probiotic
11499988|NCT01354353|Active Comparator|Aripiprazole|Part A: Continue current prescribed dosing regimen -- Study Day 1 to discharge (Study Day 21). Part B: Continue current prescribed dosing regimen -- Study Day 1 to discharge (Study Day 23, 25 or 28 based on adaptive design)
11499989|NCT01354353|Experimental|Part A: 160 mg LY2140023|Administered orally, twice daily for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
11499990|NCT01354353|Experimental|Part A: 240 mg LY2140023|Administered orally, twice daily for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
11499991|NCT01354353|Experimental|Part A: 320 mg LY2140023|Administered orally, twice daily for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
11499992|NCT01354353|Experimental|Part A: 400 mg LY2140023|Administered orally, twice daily for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
11499993|NCT01354353|Experimental|Part A: 480 mg LY2140023|Administered orally, twice daily for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
11499994|NCT01354353|Experimental|Part B: LY2140023|If doses up to or equal to 400 mg twice daily are not tolerated, Part B of the study may be started. The dose of LY2140023 will be titrated in the same subject from highest dose that was tolerated in Part A, with the intention to reach a dose of 480 mg LY2140023.
11499995|NCT01354340|Experimental|Limicol simple dose|
11499996|NCT01354340|Experimental|Limicol double doses|
11499997|NCT01354340|Placebo Comparator|Placebo|
11499998|NCT01354327|Experimental|Limicol|
11499999|NCT01354327|Placebo Comparator|Placebo|
11500000|NCT01354314|Experimental|Fluconazole|Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine
11500001|NCT01354314|Experimental|Paroxetine|Paroxetine 20 mg orally once per day; placebo in place of fluconazole
11500002|NCT01354314|Experimental|Paroxetine and Fluconazole|Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
11500003|NCT01354314|Placebo Comparator|Placebo|Placebo in place of both fluconazole and paroxetine
11500004|NCT01354301|Experimental|Thymoglobulin and everolimus|single dose antithymocyte globulin, reduced concentration tacrolimus, everolimus starting at day 2 posttransplant and prednisone
11500166|NCT01353261||Elective Cases|Patients with stable CAD undergoing PCI
11500005|NCT01354301|Experimental|Basiliximabe and everolimus|basiliximab, reduced concentration tacrolimus, everolimus starting at day 2 posttransplant and prednisone
11500006|NCT01354301|Active Comparator|Basiliximabe and mycophenolate|basiliximab, reduced concentration tacrolimus, mycophenolate and prednisone.
11500007|NCT01354288|Experimental|Therapeutic education|
11500008|NCT01354288|No Intervention|Classical management|
11500009|NCT01354275|Active Comparator|GnRH Agonist|oral contraceptive pill and GnRH Agonist IVF/ICSI cycle
11500010|NCT01354275|Active Comparator|GnRH Agonist Arm|Oral contraceptive pill and day 21 GnRH agonist began, Day 3 of menstruation 150 IU FSH will be started. If 3 or more follicle reach >17 mm hCG will be administered.
11500011|NCT01354262|Experimental|Lower dose vitamin D|Fixed daily doses of 600 IU vitamin D oral supplementation.
11500012|NCT01354262|Experimental|Higher dose vitamin D|50,000 IU supplementation bi-monthly.
11500013|NCT01354262|No Intervention|Control Group|Patients will be followed from baseline to 12 and 24 week follow up. Patients do not receive any research treatment or intervention beyond the standard care of their diabetes. This group are patients with normal levels of Vitamin D.
11500014|NCT01354249|Placebo Comparator|water|Patients will receive water 3h before operation in the same volume of the study group
11500015|NCT01354249|Experimental|whey protein plus carbohydrate|The CHO-P group will receive 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
11500016|NCT01354236||School dropouts|Students who quit school without graduation
11500017|NCT01354236||Controls|Normally enrolled students matched for age, gender, school and educational level
11500018|NCT01354223|Experimental|stenfilcon A contact lens|Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode
11500019|NCT01354223|Active Comparator|ocufilcon B contact lens|Randomized to ocufilcon B contact lens worn in a daily wear, daily disposable mode
11500020|NCT01354210|No Intervention|Standard of care only|The SOC for ART adherence consists of viewing a 20-minute animated tutorial which explains the importance of adherence to antiretroviral medication. It is specifically designed for viewers who have no science background and is appropriate for adolescents and young adults.
11500021|NCT01354210|Experimental|Intervention|This study will test a tailored, personalized SMS Text Message Reminder intervention to improve adherence to ART among non-adherent YLH. Participants will use their own cell phones for receipt of the intervention. Participants will have the option to choose a tailored personalized message that may be changed as requested throughout the study period (six months). Taking advantage of the Intelecare technology, participants will be asked to send a text message response indicating that that have successfully (or not) taken their meds per schedule. No identifying patient information will be included in the SMS text to protect patient confidentiality.
11500022|NCT01354197||All ICU admission patients|All ICU admission to surgical intensive care unit at cohort time
11500023|NCT01354184|Experimental|CRD007 10 mg tablet|
11500024|NCT01354184|Experimental|CRD007 25 mg tablet|
11500025|NCT01354184|Experimental|CRD007 40 mg tablet|
11500026|NCT01354184|Placebo Comparator|CRD007 matching placebo tablet|
11500027|NCT01354171|No Intervention|TRUS guided biopsy|
11500028|NCT01354171|Experimental|MRI Assisted TRUS guided biopsy|
11500029|NCT01354158|Experimental|Droxidopa|The dose-titration response to ascending doses of Droxidopa (placebo, 100mg, 200mg, 400mg) will be measured four separate days.
11500030|NCT01354145|Experimental|Chondroitin sulfate (Condrosan)|CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
11500031|NCT01354145|Active Comparator|Celecoxib|CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
11500032|NCT01354132|Active Comparator|n-acetyl-cysteine|N-Acetyl cysteine effervescent tablets in water 2 in am and 1 in pm for 28 weeks
11500033|NCT01354132|Placebo Comparator|Placebo|matching effervescent tablets in water 2 in am and 1 in pm
11500034|NCT01354119|Active Comparator|Early intervention|Early intervention: stent-graft just after acute phase
11500035|NCT01354119|No Intervention|Conservative|Conservative: medial follow-up without early intervention
11500036|NCT01354106|Experimental|3M Kind Removal Silicone Tape|"investigational medical Silicone tape, 1 x 1.5 sample, applied on time, worn for 24 hours."
11500037|NCT01354106|Other|3M Micropore Medical Tape|"Commercially available Medical Paper Tape, 1 x 1.5 sample, applied on time, worn for 24 hours. Study Control."
11500038|NCT01354093||MacTel Type 2 20 mg/day dose group|Participants will have macular telangiectasis type 2 as confirmed by the reading center. Participants will take 20 mg of zeaxanthin per day.
11500039|NCT01354093||MacTel Type 2 10 mg/day dose group|Participants will have macular telangiectasia type 2 as confirmed by the reading center. Participants will take 10 mg of zeaxanthin per day.
11500040|NCT01354080|Experimental|tensegrity massage|In this group of patients massage sessions based on the tensegrity method were applied.
11500041|NCT01354080|Active Comparator|classical massage|In this group of patients classical massage sessions were applied
11500042|NCT01354067|Active Comparator|Control group|The control group will receive standardized patient education four times, once every two weeks, during the eight week intervention period.
11500043|NCT01354067|Experimental|High-repetitive single limb training|The experimental group will receive a high-repetitive single limb exercise regime, three times a week for two months. In addition, the exercise group will receive patient education at four occasions during the intervention period.
11500044|NCT01354054|Experimental|High frrequency TENS|100 Hz TENS, 100 usec
11500045|NCT01354054|Experimental|Low frequency TENS|4 Hz, 100 usec TENS
11500046|NCT01354054|Experimental|Placebo TENS|100 Hz, 100 usec, set at motor minus 10% then ramps to off in 45 sec, 40 minutes
11500047|NCT01354054|No Intervention|Control|Age matched controls, no intervention
11500048|NCT01354041|No Intervention|Treatment-as-usual|Participants in the Treatment as usual (TAU) arm will not receive any specific Fear of Cancer Recurrence (FCR) intervention during the study period. However, they will be offered an optional full-day workshop at the end of the study.
11500167|NCT01353261||AMI Cases treated with clopidogrel|Patient with AMI undergoing PCI
11500049|NCT01354041|Experimental|Acceptance and Commitment Therapy|"Participants in the intervention arm will receive seven sessions of a mindfulness and values-based living intervention, led by a trained licensed facilitator, conducted in groups of 10-12 participants and include components specifically designed to reduce FCR. The intervention arm will include six weekly 90 minute group sessions and one followup 90 minute group session booster session held three weeks later. The group sessions will be interactive and experiential and include homework practice for generalizing skills."
11500050|NCT01354028|Experimental|Massage therapy|Massage therapy for 10 minutes during quiet alert state following 9 AM feeding. Actigraph in place to measure sleep for 3 hours.
11500051|NCT01354028|No Intervention|No massage therapy|This was a crossover trial with two arms. On one day, infants received massage therapy for 10 minutes. On the other day, infants were monitored as usual with the Actigraph to measure sleep efficiency, but received no massage therapy. This was the control or no intervention arm.
11500052|NCT01354015|Experimental|Use of messaging system|Use of DRMS
11500053|NCT01354015|No Intervention|Usual Care|Usual Care
11500054|NCT01354002||Protocol Participants|All participants enrolled on protocols
11500055|NCT01353989||>60 years|
11500056|NCT01353989||< 40 years|
11500057|NCT01353976|Experimental|Econazole Nitrate Foam 1%|Study medication
11500058|NCT01353976|Placebo Comparator|Vehicle Foam|Placebo medication
11500059|NCT01353963||1|
11500060|NCT01353950||Adult Cystic Fibrosis Patients|Adults with Cystic Fibrosis will be followed longitudinally for 2 years
11500061|NCT01353937|No Intervention|Standard of Care|All patients will be receiving the Standard of Care treatments regardless of whether or not they are receiving study drug.
11500062|NCT01353937|Active Comparator|Novel Combination Therapy|AMD3100 (Plerixafor) injection with Regranex Gel topical application
11500063|NCT01353937|Active Comparator|Becaplermin (Regranex Gel)|Topical application
11500064|NCT01353924|Active Comparator|Bet v 1aF1 + Bet v 1aF2 -Alum|
11500065|NCT01353924|Placebo Comparator|Alum-Placebo|
11500066|NCT01353911|Experimental|Grazoprevir 100 mg|TN non-cirrhotic (NC) participants receive Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
11500067|NCT01353911|Experimental|Grazoprevir 200 mg|TN NC participants receive Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
11500068|NCT01353911|Experimental|Grazoprevir 400 mg|TN NC participants receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
11500069|NCT01353911|Experimental|Grazoprevir 800 mg|TN NC participants receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
11500070|NCT01353911|Active Comparator|Boceprevir 800 mg|TN NC participants start a 4 week lead-in with Peg-IFN + RBV, then receive Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.
11500071|NCT01353911|Experimental|Grazoprevir 400 mg/100 mg|As the result of an interim analysis, TN NC participants assigned to the 400 mg grazoprevir group were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV and will remain in the study.
11500072|NCT01353911|Experimental|Grazoprevir 800 mg/100 mg|As the result of an interim analysis, TN NC participants assigned to the 800 mg grazoprevir group were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV and will remain in the study.
11500073|NCT01353911|Experimental|OL Grazoprevir 100 mg|TN cirrhotic participants receive open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
11500074|NCT01353898|Experimental|MK-1972 50 mg once daily (Part I)|Ten capsules containing a total daily dose of 50 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
11500075|NCT01353898|Experimental|MK-1972 200 mg once daily (Part I)|Ten capsules containing a total daily dose of 200 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
11500076|NCT01353898|Experimental|MK-1972 800 mg once daily (Part I)|Ten capsules containing a total daily dose of 800 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
11500077|NCT01353898|Experimental|MK-1972 25 mg twice daily (Part I)|Ten capsules containing a total daily dose of 25 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part I)
11500078|NCT01353898|Experimental|MK-1972 100 mg twice daily (Part I)|Ten capsules containing a total daily dose of 100 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part I)
11500079|NCT01353898|Placebo Comparator|Placebo twice daily (Part I)|Ten capsules containing placebo were taken orally, twice per day for 10 days (Part I)
11500080|NCT01353898|Experimental|MK-1972 800 mg twice daily (Part II)|Ten capsules containing a total daily dose of 800 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part II)
11500081|NCT01353898|Placebo Comparator|Placebo twice daily (Part II)|Ten capsules containing placebo were taken orally, twice per day for 10 days (Part II)
11500082|NCT01353885||Anterior Approach THA|500 Patients will be included who have received a total hip arthroplasty using the Anterior Approach. The anterior approach to total hip arthroplasty refers to an internervous approach to the hip, where the incision is made from the middle of the iliac crest, then curved distally and laterally to the anterior superior iliac spine (Kelmanovich et al., 2003). To optimize feasibility and applicability of our results, we will not standardize the use of cemented components, the implant manufacturer, or the femoral head size. Surgeons will use the manufacturer specific guides for insertion of the total hip arthroplasty.
11500083|NCT01353885||Posterior Approach THA|100 patients will be enrolled who have received a total hip arthroplasty using the posterior approach. The posterior approach is performed by making a curved incision posteriorly on the greater trochanter (Jolles & Bogoch, 2004). The fascia lata is then incised and the fibers of the gluteus maximus split using dissection (Jolles & Bogoch, 2004). To ensure the feasibility and applicability of our findings, we will not standardize the use of cemented components, the implant manufacturer, or the femoral head size used in the posterior approach.
11500168|NCT01353261||AMI Cases treated with prasugrel|Patients with AMI undergoing PCI
11500169|NCT01353248|Active Comparator|Arm 1|GS-5885, GS-9451 and Tegobuvir in combination with ribavirin (Copegus®) for 24 weeks.
11500927|NCT01348113|Experimental|Brief Alcohol Intervention|
11500084|NCT01353885||Anterolateral Approach THA|100 patients will be enrolled who have had a total hip arthroplasty using the anterolateral approach. An anterolateral approach to THA utilizes an intermuscular approach by incising the patient posteriorly and distally to the anterior superior iliac spine, extending distally to the greater trochanter along the shaft of the femur (Kelmanovich et al., 2003). To optimize the feasibility and applicability of our results, the implant manufacturer, femoral head size or the use of cemented components will not be standardized in this study.
11500085|NCT01353872|Experimental|Sports Drinks|3 drinks : Nutrattente (before each match) / Nutraperf (during each match) / Nutrarecup (after each match)
11500086|NCT01353872|Placebo Comparator|Placebo|3 drinks : Nutrattente placebo (before each match) / Nutraperf placebo(during each match) / Nutrarecup placebo (after each match)
11500087|NCT01353859|Experimental|Single Arm|
11500088|NCT01353846|Active Comparator|Natural cycle|
11500089|NCT01353846|Active Comparator|Artificial cycle|"Drugs: Agonist GnRH Acetate Triptoreline Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose. Estradiol Valerate, orally Initially 4 pills daily during 4 days, and after increase the dose to 6 mg orally daily.
~Natural micronized progesterone, 400 mg/12 hours vaginal administration"
11500090|NCT01353833|Placebo Comparator|IL2-4|
11500091|NCT01353833|Experimental|IL2-2|1 millions IU of IL-2 per day
11500092|NCT01353833|Experimental|IL2-3|3 millions IU of IL-2 per day
11500093|NCT01353833|Experimental|IL2-1|0.33 millions IU of IL-2 per day
11500094|NCT01353820|Active Comparator|1 = Tested product|
11500095|NCT01353820|Sham Comparator|2 = Control product|
11500096|NCT01353807|Active Comparator|Fish oil supplementation|These women received 4 1-g capsules of fish oil per day providing 2,7 grams long chain n-3 fatty acids per day, from gestation week 30 until delivery
11500097|NCT01353807|Placebo Comparator|Olive oil|These women received 4 1-g capsules with olive oil per day from gestational week 30 until delivery
11500098|NCT01353807|No Intervention|No oil supplement|These women received no capsules with oil
11500099|NCT01353794||Group 1|
11500100|NCT01353781|Experimental|AZD5363|Ascending doses of AZD5363 administered orally to patients to define the maximum tolerated dose (MTD)
11500101|NCT01353768||No treatment|zanamivir aqueous solution administered previously as part of the Compassionate Use Program
11500102|NCT01353755|Experimental|recombinant Phleum (rPhleum) allergen cocktail|The recombinant Phleum (rPhleum) allergen cocktail is prepared by mixing equivalent volumes of each single allergen adsorbate. The recombinant Phleum (rPhleum) allergen cocktail contains Phleum pratense (Phl p) allergens: Type 1, 2, 5 and 6 at equimolar quatities. The total protein concentration in the highest strength is 200μg protein per 1mL aluminium hydroxide suspension.
11500103|NCT01353755|Placebo Comparator|Placebo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
11500104|NCT01353742|Active Comparator|Lamivudine and Adefovir dipivoxil|One 100mg Lamivudine tablet and One 10mg Adefovir dipivoxil tablet
11500105|NCT01353742|Experimental|Fixed dose combination|One capsule (100mg lamivudine and 10mg adefovir dipivoxil)
11500106|NCT01353729|Experimental|Treatment A|Treatment A will include combination of zanamivir 600 mg IV plus placebo for moxifloxacin
11500107|NCT01353729|Experimental|Treatment B|Treatment A will include combination of zanamivir 1200 mg IV plus placebo for moxifloxacin
11500108|NCT01353729|Experimental|Treatment C|Treatment C will include zanamivir placebo plus placebo for moxifloxacin
11500109|NCT01353729|Experimental|Treatment D|Treatment D will include moxifloxacin plus zanamivir placebo
11500110|NCT01353716|Experimental|Cohort 1|Healthy subjects matched to the renal impaired subjects by gender, age and body mass index to the renal impaired subjects. There will be a screening visit within 30 days of dose, a single dose of study drug and a follow-up visit 7-10 days after the dose of study drug.
11500111|NCT01353716|Experimental|Cohort 2|Subjects with severe renal impairment. There will be a screening visit within 30 days of dose, a single dose of study drug and a follow-up visit 7-10 days after the dose of study drug.
11500112|NCT01353703|Experimental|INFANRIX HEXA 6-10-14 GROUP|Healthy male or female subjects, aged between and including 6 and 10 weeks of age at the time of first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 6, 10 and 14 weeks of age, administered intramuscularly in the right side of the thigh.
11500113|NCT01353703|Active Comparator|INFANRIX HEXA 2-4-6 GROUP|Healthy male or female subjects, aged between and including 6 and 10 weeks of age at the time of first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 2, 4 and 6 months of age, administered intramuscularly in the right side of the thigh.
11500114|NCT01353690|Experimental|AMDC|
11500115|NCT01353677||HSCT recipients|"Adult (≥ 18 years), or pediatric (≥ 2 years and < 18 years) allogeneic HCT recipient (related, unrelated, or CBU) at participating pilot study transplant centers.
~Signed informed consent form from adult patient or parent/guardian of pediatric patient.
~Patient must have a valid mailing address within the United States to receive QOL surveys.
~Ability to speak and read English.
~Patients with access to a telephone."
11500116|NCT01353664|Experimental|Romidepsin|This study is an open-label, single-arm study. The study is divided into the Screening Period, Treatment Period, and Follow-up Period.
11500117|NCT01353651|Experimental|Endovascular treatment|
11500118|NCT01353651|Active Comparator|Open repair treatment|
11500119|NCT01353638|Other|Arm A|Arm A includes 14 patients. In treatment period 1, arm A receives standard PDF with the interventional drug alanyl-glutamine-dipeptide as add-on. As it is a cross-over study design, in treatment period 2, group A receives standard PDF without add-on.
11500120|NCT01353638|Other|Arm B|Arm B includes 14 patients who in treatment period 1 receive standard PDF without the investigational drug. As it is a cross-over study design, in treatment period 2 arm B receives standard PDF with alanyl-glutamine-dipeptide as add-on.
11500121|NCT01353625|Experimental|CC-115|
11500122|NCT01353599|Experimental|Asmanex|Study participants will receive inhaled Mometasone Furoate (Asmanex) 220mcg once daily for 8 weeks.
11500170|NCT01353248|Active Comparator|Arm 2|GS-5885, GS-9451 and Tegobuvir in combination with ribavirin (Copegus®) for 12 or 24 weeks.
11500171|NCT01353235|Sham Comparator|usual care|
11500172|NCT01353235|Active Comparator|Prednisolone|1mg/kg/day prednisolone for the entire ICU stay and a maximum of 10 days
11500123|NCT01353586|Experimental|nMARQ™ System|The nMARQ™ System (Circular and Crescent Mapping and Ablation Catheters as well as the Multi-Channel Radiofrequency Generator) as part of the Multi-Electrode Irrigated Pulmonary Vein (PV) Isolation System will serve as a treatment method for subjects undergoing radiofrequency catheter ablation for drug refractory, symptomatic Paroxysmal Atrial Fibrillation (PAF). The study later included a Subpopulation Neurological Assessments (SNA) substudy which is a prospective, non-randomized, controlled, acute assessment to compare subjects treated with the nMARQ™ System against control subjects treated with the NAVISTAR® THERMOCOOL® Irrigated Tip Catheter.
11500124|NCT01353573|Active Comparator|Fixed Gantry Radiosurgery|Single fraction radiosurgery will be prescribed using a Fixed Gantry Linear Accelerator
11500125|NCT01353573|Experimental|Robotic Radiosurgery|Single fraction radiosurgery will be prescribed using a robotic linear accelerator
11500126|NCT01353560||New patients of Osher Clinical Center|
11500127|NCT01353547||Received anti-TNFa therapy|Received anti-TNFa therapy
11500128|NCT01353547||First-degree relative of MS patients|"First-degree relative (child, parent or sibling) of a diagnosed MS patient
~A subgroup will be asked to undergo magnetic resonance imaging (MRI). Participants may be asked to donate a stool sample for gut flora analysis and a blood sample for ribonucleic acid (RNA) sequencing."
11500129|NCT01353547||Referred by the Partners MS Center|Referred by the Partners MS Center
11500130|NCT01353534|Experimental|Group 1|3.8 mcg with AS03 adjuvant at D0 and 21
11500131|NCT01353534|Experimental|Group 2|15 mcg at D0 and 21
11500132|NCT01353534|Experimental|Group 3|15 mcg + 50 mcg VEP at D0 and 21
11500133|NCT01353534|Experimental|Group 4|30 mcg + 50 mcg VEP at D0
11500134|NCT01353521|Experimental|Contrast-enhanced ultrasound|
11500135|NCT01353508|Experimental|LCZ696 to Valsartan - Heart Failure (HF) cohort|Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.
11500136|NCT01353508|Experimental|Valsartan to LCZ696 - HF Cohort|Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.
11500137|NCT01353508|Experimental|LCZ696 to Valsartan - Hypertension (HTN) cohort|Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.
11500138|NCT01353508|Experimental|Valsartan to LCZ696 - HTN cohort|Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.
11500139|NCT01353482|Active Comparator|Phase II only - Arm I|If the patient is randomised into the Vorinostat arm they will be given Pemetrexed (500mg/m2 iv) and Cisplatin (75mg/m2 iv) on day one of a 21 day cycle plus the dose of Vorinostat determined in the phase I study.
11500140|NCT01353482|Placebo Comparator|Phase II only - Arm 2|If the patient is randomised into the placebo arm they will be given Pemetrexed (500mg/m2 iv) and Cisplatin (75mg/m2 iv) on day one of a 21 day cycle with the placebo for the same number of days as in the vorinostat arm.
11500141|NCT01353469|Experimental|Insuman Comb 25|Insuman Comb 25 will be self-injected subcutaneously twice daily 30-45 minutes before breakfast and dinner. The dose will be adjusted individually by monitoring the blood glucose values and symptoms, and following China guideline.
11500142|NCT01353469|Active Comparator|Novolin® 30R|Novolin® 30R will be self-injected subcutaneously twice daily within 30 minutes before breakfast and dinner. The dose will be adjusted individually by monitoring the blood glucose values and symptoms, and following China guideline and the package insert of Novolin® 30R
11500143|NCT01353456|Active Comparator|Dexmedetomidine|
11500144|NCT01353456|Placebo Comparator|Normal saline|
11500145|NCT01353443|No Intervention|Group A|Monofilament absorbable MonoPlus® suture material will be used for closing of the midline incision.
11500146|NCT01353443|Other|Group B|Abdominal wall closure with monofilament absorbable MonoPlus® suture material and onlay placement of Optilene® Mesh Elastic fixed by sutures.
11500147|NCT01353443|No Intervention|Group C|Monofilament, absorbable MonoMax suture material will be used for the closure of the abdominal cavity.
11500148|NCT01353430||VCP families|Patients with a personal or family history of VCP associated disease.
11500149|NCT01353417||Renal allograft|
11500150|NCT01353404|Experimental|fenofibrate 65mg, fed condition, per oral|
11500151|NCT01353404|Experimental|fenofibrate 65mg, fasting condition, per oral|
11500152|NCT01353404|Active Comparator|fenofibrate 160mg, fed condition, per oral|
11500153|NCT01353391|Active Comparator|Metformin|
11500154|NCT01353391|Placebo Comparator|Placebo|
11500155|NCT01353378|Experimental|dexmedetomidine|intravenously injecting 0.125microgram/kg and 0.25microgram/kg within 10 minutes as soon as the operation begins respectively.
11500156|NCT01353352|Other|Cervical spine injury|We enrolled consecutive alert adults who were in stable condition and who presented with potential cervical spine injury after acute blunt trauma, including patients with posterior neck pain and those presenting by ambulance with immobilization of the cervical spine.
11500157|NCT01353339|Placebo Comparator|sugar pill|
11500158|NCT01353339|Active Comparator|levofloxacin|
11500159|NCT01353326|Active Comparator|Cementless Hip Resurfacing|Patients randomized into the Cementless Hip Resurfacing Group will have their hip resurfaced with the cementless Cormet / Corin Hip Resurfacing System.
11500160|NCT01353326|Active Comparator|Cemented Hip Resurfacing|Patients randomized into the Cemented Hip Resurfacing Group will have their hip resurfaced with the cemented Conserve Plus Total Resurfacing Hip System.
11500161|NCT01353313|Placebo Comparator|Placebo|Saline placebo
11500162|NCT01353313|Experimental|Hydrocortisone|hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents)
11500163|NCT01353287||TAVI live case or video-taped transmission|
11500164|NCT01353287||TAVI without transmission|
11500165|NCT01353274||Patients with hypertension|
11500173|NCT01353222|Experimental|DN24-02|Subjects received infusion of DN24-02, at 2-week intervals, for a total of 3 infusions.
11500174|NCT01353222|Other|Standard of Care|Subjects randomized to the control arm were treated per standard of care, which in this patient population is generally observation, as there is currently no evidence that treatment with non-cisplatin containing chemotherapy is beneficial in the adjuvant setting for this patient population.
11500175|NCT01353209|Experimental|Letrozole|
11500176|NCT01353209|Placebo Comparator|Placebo|
11500177|NCT01353196||stenosis|carotid stenosis
11500178|NCT01353196||no stenosis|no stenosis
11500179|NCT01353183|Experimental|Colonic biopsies|Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy
11500180|NCT01353170|Experimental|Prevalent hd patients|Patients undergoing three consecutive cross-over hd session with 3 different dialysate calcium concentrations
11500181|NCT01353157||patients with elective cardiac surgery|
11500182|NCT01353144|No Intervention|esomeprazole|esomeprazole (40 mg/day) for 8 weeks
11500183|NCT01353144|Active Comparator|esomeprazole plus aspirin|esomeprazole (40 mg/day) plus aspirin (100 mg/day) for 8 weeks
11500184|NCT01353131||ECG Screening|1000 patients with moderate to high risk determined by stratification algorithm based on the electronic analysis of 69,088 routine 12-lead ECGs performed in a large medical institution during a 6 month period by combining previously established indices of abnormal repolarization (wide QRS-T angle) with validated measures of myocardial damage (Selvester QRS score) excluding those > 70 years of age or with LV ejection fraction ≤ 35%, or at a high risk of dying within 3 years from cancer, end stage cardiac, pulmonary, renal, immunologic or neurologic diseases excluded on clinical data obtained through medical record.
11500185|NCT01353118|No Intervention|gastric bypass|Group A: Patients will undergo gastric bypass surgery within 3 months after randomisation without any pre operative optimisation of glycaemic control.
11500186|NCT01353118|Active Comparator|Gastric bypass 2|Gastric bypass 2 (Group B):Patients will undergo gastric bypass 3-6 months after randomisation. During this period the group will receive modern best medical care based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines. Glycaemic optimisation will be achieved in a gradual manner with particular attention to the avoidance of hypoglycaemia
11500187|NCT01353118|No Intervention|Best medical care|Group C: Obese patients with T2DM (who choose not to have surgery) will be treated with best medical care based on the ADA/EASD guidelines including anti-diabetes/obesity pharmacotherapy, access to a trained dietician and exercise programme.
11500188|NCT01353105|Experimental|Ex vivo lung transplantation|single-group studies
11500189|NCT01353092|Experimental|Active PEMF twice daily|"Re5 treatment helmet using Pulsating ElectroMagnetic Field:
~Intervention: 30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon"
11500190|NCT01353092|Active Comparator|Active PEMF once daily|"Re5 treatment helmet using Pulsating ElectroMagnetic Field:
~Intervention: 30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)"
11500191|NCT01353079|Experimental|Short Ragweed Pollen Allergenic Extract|
11500192|NCT01353079|Placebo Comparator|Glycero-COCAs|
11500193|NCT01353066|Active Comparator|Intensive Medical Treatment|
11500194|NCT01353066|Experimental|Intensive medical treatment (IMM)+RYGBP|
11500195|NCT01353053||Tacrolimus, Everolimus|Immunosuppression is the same for all patients in the study until the period between the 3rd and 5th weeks, when patients will be randomized to initial regimen and remain or be converted to everolimus tacrolimus.
11500196|NCT01353040|Experimental|AVI-6003|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
11500197|NCT01353040|Placebo Comparator|Placebo|Normal saline
11500198|NCT01353027|Placebo Comparator|Placebo|
11500199|NCT01353027|Experimental|AVI-6002|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
11500200|NCT01353014|Experimental|Dietary advice with genetic information|This group will receive dietary advice for caffeine, vitamin C, sugar and sodium based on genetic information.
11500201|NCT01353014|Active Comparator|General dietary recommendations|This group will receive general dietary recommendations for caffeine, vitamin C, sugar and sodium from recognized health institutions (caffeine: Health Canada; sugar: the World Health Organization; vitamin C and sodium: the Institute of Medicine).
11500202|NCT01353001|Experimental|Diet Only|
11500203|NCT01353001|Experimental|Diet plus Aerobic Training|
11500204|NCT01353001|Experimental|Diet plus Resistance Training|
11500205|NCT01352988|Experimental|Fumaric acid esters|
11500206|NCT01352975||Group 0|participants without AMD (no large drusen or advanced AMD in either eye)
11500207|NCT01352975||Group 1|Participants with large drusen in the study eye and no large drusen or advanced AMD or GA in the fellow eye.
11500208|NCT01352975||Group 2|Participants with bilateral large drusen with or without retinal pigment epithelial hypo/hyperpigmentary changes
11500209|NCT01352975||Group 3|Participants with large drusen in the study eye and advanced AMD (CNV or GA) in the fellow eye
11500210|NCT01352975||Group 4|Participants with findings of RPD
11500211|NCT01352962|Experimental|Arm 1|Standard of Care plus escalating doses of Lenalidomide
11500212|NCT01352962|Experimental|Arm 2|Lenalidomide Lead for 14 days + standard of care +lenalidomide MTD
11500213|NCT01352949||Healthy Volunteers|Healthy volunteers without scoliosis or obesity
11500214|NCT01352949||Obesity|Healthy volunteers with obesity
11500215|NCT01352949||Scoliosis|Healthy volunteers with scoliosis but no obesity
11500216|NCT01352936||Experimental Group|
11500217|NCT01352936||Control Group|
11500218|NCT01352923|Experimental|peripheral blood|healthy voluntary donors
11500219|NCT01352910|Experimental|effective rTMS|
11500220|NCT01352910|Sham Comparator|Sham rTMS|
11500221|NCT01352884|Experimental|Stage 1|Stage 1 will identify the recommended Stage 2 dose using a dose-escalation process. Dose-escalation will continue until either a maximum tolerated dose is established, or a therapeutic dose is reached.
11500259|NCT01352611|Experimental|baclofen, intrathecal|A single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
11500222|NCT01352884|Experimental|Stage 2|Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood specimens will be evaluated for pharmacodynamic markers/activity at specified timepoints throughout the study.
11500223|NCT01352871||Concentration / meditation|The subject will try to influence the innate immune response by concentration / meditation in advance of and during endotoxemia
11500224|NCT01352858|Experimental|TolDC|Experimental arm - TolDC administered arthroscopically
11500225|NCT01352858|Placebo Comparator|Control|Arthroscopy & saline irrigation alone
11500226|NCT01352845|Experimental|rLP2086|
11500227|NCT01352845|Placebo Comparator|Control|Steril normal saline solution
11500228|NCT01352832|Experimental|Interactive DVD|"Patients randomized to this arm will receive a DVD DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate stories through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor."
11500229|NCT01352832|Placebo Comparator|Usual Care|Patients randomized to this arm receive their usual care.
11500230|NCT01352806|Experimental|fluoroscopy, palpation, ultrasound|in the same subject we will compare the accuracy of identifying the intralaminar space by three technique, fluoroscopy, ultrasound, palpation.
11500231|NCT01352793|Experimental|rLP2086 vaccine|rLP2086 vaccine
11500232|NCT01352793|Other|control|The control treatment will be HAVRIX vaccine at month 0 and 6 and a normal saline injection at month 2.
11500233|NCT01352780|No Intervention|usual care|Motivational interviewing
11500234|NCT01352767|Experimental|InsuPad Device|Use of the InsuPad which heats the injection site.
11500235|NCT01352767|No Intervention|CONTROL|no treatment
11500236|NCT01352741|Experimental|Tapentadol Prolonged Release|Tapentadol Prolonged Release (100 - 500 mg per day) Oral administration twice daily
11500237|NCT01352741|Active Comparator|Tapentadol Prolonged Release with Pregabalin|Tapentadol Prolonged Release (100 - 300 mg per day) with Pregabalin (150 - 300 mg per day) Both administered orally twice a day.
11500238|NCT01352728|Experimental|TACE+Axitinib|
11500239|NCT01352715|Experimental|Arm A: LPV/r plus RAL|Participants were administered LPV/r plus RAL orally twice daily throughout follow-up.
11500240|NCT01352715|Experimental|Arm B: LPV/r plus best available NRTIs|"Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs (listed below) throughout follow-up-
~FTC/TDF orally twice daily
~ABC/3TC/ZDV orally twice daily
~ABC/3TC orally once daily
~3TC/ZDV orally twice daily
~ABC 300mg orally twice daily or 600 mg once daily
~3TC orally twice daily
~ZDV orally twice daily"
11500241|NCT01352702|Experimental|Arm 1|Dabigatran Therapy
11500242|NCT01352702|Active Comparator|Arm 2|Phenprocoumon Therapy
11500243|NCT01352689|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 80mg/S-Amlodipine 2.5mg
11500244|NCT01352689|Experimental|Free combination Therapy|Co-administration of single oral doses of a 80mg tablet of Telmisatan and a 2.5 mg tablet of S-Amlodipine
11500245|NCT01352663|Experimental|Wockhardt's Insulin Analogue (Recomb)|Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
11500246|NCT01352663|Active Comparator|Lantus®|Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
11500247|NCT01352650|Active Comparator|Cohort 1A|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5
11500248|NCT01352650|Active Comparator|Cohort 1B|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10
11500249|NCT01352650|Active Comparator|Cohort 2A|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5
11500250|NCT01352650|Active Comparator|Cohort 2B|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 2 decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 4 decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10
11500251|NCT01352650|Active Comparator|Cohort 3A|Cycle 1: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 3: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5
11500252|NCT01352650|Active Comparator|Cohort 3B|Cycle 1: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 2: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 4: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10
11500253|NCT01352637|Placebo Comparator|Placebo + Prolonged Imaginal Exposure|Drug: Placebo (sugar pill) + Prolonged Imaginal Exposure (PE) PTSD treatment
11500254|NCT01352637|Placebo Comparator|Placebo + VR exposure|Drug: Placebo (sugar pill) + Virtual Reality Exposure (VR) PTSD treatment
11500255|NCT01352637|Active Comparator|DCS + Prolonged Imaginal Exposure|Drug: 50mg DCS (D-Cycloserine ) + Prolonged Imaginal Exposure (PE) PTSD treatment
11500256|NCT01352637|Active Comparator|DCS+VR exposure|Drug: 50mg DCS (D-Cycloserine ) + Virtual Reality Exposure (VR) PTSD treatment
11500257|NCT01352624|Experimental|Experimental|$teps for Achieving Financial Empowerment ($AFE)
11500258|NCT01352624|No Intervention|Usual Care|Veterans in control arm will receive usual care at VA
11500928|NCT01348113|No Intervention|No intervention|
11500260|NCT01352598|Other|Stereotactic Body Radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
11500261|NCT01352585||Anagrelide hydrochloride|
11500262|NCT01352572|Experimental|antidepressant response|antidepressant response are refered the patients having a 50 ≤ Decrease rate(%) of HAM-D score
11500263|NCT01352572|Active Comparator|antidepressant non-response|antidepressant non-response are refered the patients having a 50 > Decrease rate(%) of HAM-D score
11500264|NCT01352559|Experimental|responders|50 ≤ Decrease rate(%) of HAM-D score
11500265|NCT01352559|Active Comparator|non-responders|nonresponders is a patients having 50 > Decrease rate(%) of HAM-D score
11500266|NCT01352546|Experimental|BOTOX|intravaginal Botox injections and progressive dilation under anesthesia to cure vaginismus.
11500267|NCT01352533|Active Comparator|Running polypropylene closure|Half of every linear wound will be closed with running polypropylene sutures. This technique is Standard of Care.
11500268|NCT01352533|Experimental|Tissue Adhesive (Derma-Bond)|The experimental half of the wound will be randomized to receive closure with tissue adhesive alone.
11500269|NCT01352533|Experimental|Subcuticular polyglactin-910 combined with tissue adhesive|The experimental half of the wound will be randomized to receive closure with running subcuticular polyglactin-910 combined with tissue adhesive.
11500270|NCT01352520|Experimental|SGN-35|1.8 mg/kg intravenously Day 1 of 21-day cycle.
11500271|NCT01352507|Experimental|Tadalafil then Sildenafil|"20 mg tadalafil taken orally, as needed, for 8 weeks, followed by 100 mg sildenafil taken orally, as needed, for an additional 8 weeks. There is a washout period of 7-10 days between treatments.
~At the end of the two 8-week treatment periods, participants will be allowed to enter an 8-week extension phase on their preferred medication for erectile dysfunction (ED)."
11500272|NCT01352507|Active Comparator|Sildenafil then Tadalafil|"100 mg sildenafil taken orally, as needed, for 8 weeks, followed by 20 mg tadalafil taken orally, as needed, for an additional 8 weeks. There is a washout period of 7-10 days between treatments.
~At the end of the two 8-week treatment periods, participants will be allowed to enter an 8-week extension phase on their preferred medication for ED."
11500273|NCT01352494|Experimental|docetaxel/gemcitabine|All the patients are locally advanced breast cancer. Patients with a measurable lesion at chest CT. (at least 1 measurable lesion)
11500274|NCT01352481|Experimental|Intervention group|
11500275|NCT01352481|No Intervention|Control group|
11500276|NCT01352468|Experimental|Multifaceted Cognitive Training|Cognitive Training with 4 different tasks each of which gets progressively more difficult as children obtain proficiency.
11500277|NCT01352468|Sham Comparator|Sham Cognitive Training|Cognitive Training with 4 different tasks which does not get progressively more difficult throughout training
11500278|NCT01352455|Experimental|5 days per week hemodialysis|5 days per week, 2 hours 20 minutes per session versus 3 days per week, 4 hours per session
11500279|NCT01352442|Experimental|AcuFocus Corneal Inlay|The AcuFocus Corneal Inlay ACI 7000PDT, which is a small medical device, will be surgically implanted in one eye of each subject.
11500280|NCT01352429||Phase 1 Feasibility|
11500281|NCT01352429||Phase 2 Registration|
11500282|NCT01352416|Active Comparator|CABG surgery with Ranolazine|Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Ranolazine 1000 mg (2-500mg tablets) twice daily. If intolerant to the study drug due to adverse effects,or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice daily.
11500283|NCT01352416|Placebo Comparator|CABG surgery with placebo|Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Placebo 1000mg mg (2-500mg tablets)twice daily. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily.
11500284|NCT01352416|Active Comparator|Heart Valve surgery with Ranolazine|Patient will undergo heart Valve surgery and will receive, Ranolazine1000mg (2-500 mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice a day.
11500285|NCT01352416|Placebo Comparator|Heart Valve surgery with placebo|Patient will undergo heart Valve surgery and will receive, Placebo 1000mg (2-500mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice a day.
11500286|NCT01352403|Other|intensive life style intrvention|intensive life style intervention over 18 months including movement, psychological meetings and change in food intake
11500287|NCT01352403|Other|gastric bypass|
11500288|NCT01352390|Active Comparator|Control Condition|A basic reminder mailing will prompt each subject to receive a health test as specified on the mailing
11500289|NCT01352390|Experimental|Artwork Prompt Condition|A basic reminder mailing will prompt each subject to give their child a reminder postcard to color
11500290|NCT01352364|Experimental|deaf children|
11500291|NCT01352351|Experimental|Breastfeeding promotion intervention|"Intervention:
~Group breastfeeding counseling during monthly microcredit borrower group meetings
~Weekly cell phone messages about breastfeeding"
11500292|NCT01352351|No Intervention|No intervention|The no intervention group will participate in their regular microcredit borrower group meetings, but will not receive breastfeeding counseling or cell phone messages.
11500293|NCT01352338|Experimental|lenalidomide, endoxan, prednisone|"lenalidomide 25mg, oral therapy, once a day, 4 weeks cycles. Lenalidomide is used 3 of the 4 weeks.
~Lenalidomide is combined with endoxan and prednisone"
11500294|NCT01352325|Experimental|system constellations seminar (exp. group)|Study participants randomized to this group receive the intervention (system constellation seminar) 4 months prior to the control group
11500295|NCT01352325|Experimental|system constellations seminar (control group)|Study participants randomized to this group receive the intervention (system constellations seminar) 4 months after the experimental group.
11500296|NCT01352312|Experimental|Treatment (pentostatin, bendamustine, ofatumumab)|Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, pentostatin IV on day 1, and ofatumumab IV on day 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11500299|NCT01352299|Active Comparator|Miller|Laryngoscopy performed with Miller Laryngoscope
11500300|NCT01352299|Active Comparator|TrueView|Laryngoscopy performed with TrueView Laryngoscope
11500301|NCT01352286|Experimental|Autologous Genetically modified T cells|Patients with advanced myeloma and who are candidates for autologous stem cell transplants, or syngeneic stem cell transplants (SSCT), will be eligible. Prior to full screening on this study, patients will undergo prescreening to evaluate HLA-A type and presence of NY-ESO-1c259T/LAGE antigen. Patients will undergo a steady-state mononuclear cell apheresis for T cell collection, with an optional second collection. Once mononuclear cells have been collected, patients (or donors in the case of SSCT) will then undergo hematopoietic stem cell mobilization. Patients will receive a dose >0.1-1 x 10¹º anti-CD3/anti-CD28-costimulated autologous T cells which have been genetically modified to express high affinity NY-ESO-1c259 TCRs.
11500302|NCT01352273|Experimental|MEK162 + RAF265|
11500303|NCT01352260||Cardiac Disease|Total Aortic Arch Replacement
11500304|NCT01352247|Experimental|Unicompartmental Knee Replacement|"TOPKAT will be pragmatic in terms of implant selection for the knee replacement operation. Providing the inclusion criteria are met, surgeons will be entirely free to use an implant of their choice or will use the current implants used at their institution. Implant type used on each patient will be recorded.
~A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure."
11500305|NCT01352247|Experimental|Total Knee Replacement|"TOPKAT will be pragmatic in terms of implant selection for the knee replacement operation. Providing the inclusion criteria are met, surgeons will be entirely free to use an implant of their choice or will use the current implants used at their institution. Implant type used on each patient will be recorded.
~A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position."
11500306|NCT01352234|Experimental|Group A|Acetylsalicylic Acid 160mg administered at bedtime
11500307|NCT01352234|Active Comparator|Group B|Acetylsalicylic Acid 80mg administered at bedtime
11500308|NCT01352221|Experimental|ST10|ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day
11500309|NCT01352221|Placebo Comparator|Placebo|Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day
11500310|NCT01352208|Experimental|ASP9521|
11500311|NCT01352195|Active Comparator|Usual Care (UC)|This condition will comprise a single, high quality booklet that is currently in dissemination: NCI's Clearing the Air (NCI, 2003).
11500312|NCT01352195|Active Comparator|Standard Repeated Mailings (Stand-RM)|Stand-RM will be the same 8 Forever Free booklets (edited for cessation) distributed over 12 months as in our preliminary studies.
11500313|NCT01352195|Active Comparator|Intensive Repeated Mailings (Inten-RM)|Inten-RM will add two additional booklets to extend the intervention out to 18 months, plus additional monthly contacts.
11500314|NCT01352182|Experimental|Pioglitazone hydrochloride|Pioglitazone hydrochloride treatment group
11500315|NCT01352182|No Intervention|Normal standard care|Normal standard care control group
11500316|NCT01352130|Active Comparator|Ondansetron|Patients given Ondansetron
11500317|NCT01352130|Active Comparator|Granisetron|Patients given Granisetron
11500318|NCT01352117|Active Comparator|Arm A: ART alone or with delayed ET|Participants were prescribed ART (co-formulated efavirenz/emtricitabine/tenofovir disoproxil fumarate, EFV/FTC/TDF) for 96 weeks. Arm A participants who experienced KS progression on ART alone could receive ET in addition to EFV/FTC/TDF in Step 2 of the study.
11500319|NCT01352117|Experimental|Arm B: ART with immediate ET|Participants were prescribed ART (co-formulated efavirenz/emtricitabine/tenofovir disoproxil fumarate, EFV/FTC/TDF) for 96 weeks with immediate ET for up to 16 weeks.
11500320|NCT01352104|Experimental|waiting-intervention-course|
11500321|NCT01352091|Experimental|Switch to Zoladex + AI for 3-2 years|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
11500322|NCT01352091|Experimental|TAM|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
11500323|NCT01352078||Non Healing Ulcer|
11500324|NCT01352078||Hidradenitis suppurativa|
11500325|NCT01352065|Experimental|BOSENTAN|
11500326|NCT01352065|Experimental|AMBRISENTAN|
11500327|NCT01352065|Placebo Comparator|PLACEBO|
11500328|NCT01352052|No Intervention|waiting list assignment|6 months waiting list assignment followed by the 2-week interdisciplinary rehabilitation programme
11500329|NCT01352052|Active Comparator|Intervention: interdisciplinary rehabilitation programme|A two-weeks non-residential, group-based, psycho-educative treatment course conducted by an interdisciplinary team.
11500330|NCT01352039|Experimental|Heparin Sodium - Eurofarma|
11500331|NCT01352039|Active Comparator|Heparin Sodium - APP Pharmaceuticals|
11500332|NCT01352026|Experimental|Metformin|
11500333|NCT01352013|Placebo Comparator|Colored olive oil|
11500334|NCT01352013|Active Comparator|Omega-3 (oil)|
11500335|NCT01352000|Active Comparator|Usual Care (UC)|Receive Quitline services
11500336|NCT01352000|Active Comparator|Repeated Mailings (RM)|Receive the 8 Forever Free booklets sent by mail at regular intervals over a period of 12 months
11500337|NCT01352000|Active Comparator|Massed Mailings (MM)|Receive all 8 booklets in a single mailing
11500338|NCT01351961|Other|Elderly hypertensive patients with mnemonic subjective|"Elderly hypertensive patients with mnemonic subjective without dementia. Interventions :
~blood sampling brain MRI Assessment of cognitive functions brain MRI and TEP cerebral Electrocardiogram and blood pressure Pulse wave velocity Quality of life questionnaire Urine sample Vascular explorations"
11500339|NCT01351948|Experimental|Group 1|AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
11500340|NCT01351948|Experimental|Group 2|AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
11500341|NCT01351948|Experimental|Group 3|AdCh63 AMA1 + AMA1-C1/Alhydrogel®
11500342|NCT01351948|Experimental|Group 4|AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909
11500343|NCT01351948|Experimental|Group 5|AdCh63 AMA1 + MVA AMA1
11500344|NCT01351935|Experimental|AVL-292|
11500345|NCT01351922||A|
11500346|NCT01351909|Experimental|Treatment (veliparib, cyclophosphamide)|Patients receive veliparib orally PO QD and cyclophosphamide PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11500347|NCT01351896|Experimental|Arm A (Concurrent PCV13 and lenalidomide)|Patients receive low-dose lenalidomide PO once daily on days 1-28. Treatment repeats every 28 days for at least 24 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive PCV13 IM on day 1 of courses 3 and 5.
11500348|NCT01351896|Experimental|Arm B (Sequential PCV13 and lenalidomide)|Patients receive PCV13 IM on days 1 and 78 (cycles 1 and 3). Patients also receive low-dose lenalidomide as in arm 1 beginning on day 1 of course 4. Treatment repeats every 28 days for at least 24 cycles in the absence of disease progression or unacceptable toxicity.
11500349|NCT01351883|No Intervention|Standard enteral nutrition supplement|regular standard enteral nutrition(SEN) was made by hospital for patient
11500350|NCT01351870|Active Comparator|Standard Fractionation Regimen|"1.8 Gy daily, 5 fractions per week
~Cranio-spinal axis:
~23.4 Gy in 13 fractions of 1.8 Gy
~Posterior fossa:
~30.6 Gy in 17 fractions of 1.8 Gy"
11500351|NCT01351870|Experimental|Hyperfractionated radiotherapy|"1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week
~Craniospinal axis:
~36 Gy in 36 fractions of 1 Gy
~Posterior fossa:
~24 Gy in 24 fractions of 1 Gy
~Tumour Bed:
~8 Gy in 8 fractions of 1 Gy"
11500352|NCT01351857|Other|Transition Coordinator|A Transition Coordinator, a Certified Diabetes Educator, will provide transition support and the link between pediatric and adult diabetes care. The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
11500353|NCT01351857|No Intervention|Current Standard of Care|Subjects in the control group will transition to adult care equal to the intervention group and will differ only by exclusion of Transition Coordinator. Control group will receive the current standard of diabetes care otherwise unchanged. Three months following randomization, subjects in the control group will be referred to the adult endocrinologist in the same way as subjects in the intervention group
11500354|NCT01351844|Active Comparator|Education and exercise intervention|"The intervention module will contain a brief series of slides with a voice-over. An occupational therapist will review recommended exercises."
11500355|NCT01351844|Placebo Comparator|Education and general exercise|"The control module will contain a brief series of slides with a voice-over. A physical therapist with experience in treating breast cancer patients will demonstrate a series of 4-5 general stretching and toning exercises."
11500356|NCT01351831|Experimental|Rehabilitation with strength training|
11500357|NCT01351831|Active Comparator|Rehabilitation without strength training|
11500358|NCT01351818||Growth hormone|Patients with a condition
11500359|NCT01351805|Experimental|Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
11500360|NCT01351805|Experimental|Vitamin D|Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.
11500361|NCT01351805|Placebo Comparator|placebo|Subjects will receive placebo pill.
11500362|NCT01351805|Experimental|Vitamin D and Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
11500363|NCT01351792|Experimental|Foster®|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
11500364|NCT01351792|Active Comparator|Symbicort® Turbohaler®|Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
11500365|NCT01351779||Progressive glaucoma|Patients with primary open angle glaucoma identified to have an optic disc hemorrhage
11500366|NCT01351766|Experimental|Behavioral Activation Treatment for Smoking|BATSY includes standard smoking cessation strategies and identifying life areas, values, and daily activities to help manage mood. Participants will complete between group exercises and will also monitor and plan daily activities in line with their values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period.
11500367|NCT01351753|Active Comparator|Metformin|
11500368|NCT01351753|Experimental|Metformin + Orlistat|
11500369|NCT01351753|Experimental|Metformin + Topiramate|
11500370|NCT01351753|Experimental|Topiramate|
11500371|NCT01351753|Experimental|Metformin + Topiramate + Orlistat|
11500372|NCT01351753|Placebo Comparator|Placebo|
11500373|NCT01351740|Experimental|Switch|switch to unboosted atazanavir 400mg daily with the same nucleoside (NRTI) backbone
11500374|NCT01351740|Active Comparator|Continuation|continue on current regimen of atazanavir/ritonavir 300mg/100mg with the same nucleoside (NRTI) backbone
11500375|NCT01351727||Seniors with Seizures|Seniors aged 65 or older with newly diagnosed seizures (consistent with epilepsy) or epilepsy as of October, 2010.
11500376|NCT01351714|Other|D3 resection|Radical D3 resection of the right colon through the use of preoperative MDCT angiography
11500377|NCT01351688|Experimental|AZD3514|Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD)
11500378|NCT01351675|Placebo Comparator|Placebo|
11500379|NCT01351675|Experimental|Bardoxolone Methyl|
11500380|NCT01351662|Experimental|Self management program|"The Arthritis Self-Management Program (ASMP) will be administered to 15 African American lupus patients participating in an ongoing SLE Clinic Database Project at the Medical University of South Carolina (MUSC). Fifteen other patients will serve as controls and receive usual care."
11500381|NCT01351649|Other|attention control|Sessions with school nurse to discuss health-promoting topics and after-school health-promoting workshop. Physical activity and healthy eating were not addressed.
11500382|NCT01351649|Experimental|physical activity|
11500383|NCT01351636|Experimental|Arotinolol Hydrochloride|Antihypertensive medications plus arotinolol hydrochloride
11500384|NCT01351636|Placebo Comparator|Non arotinolol group|Antihypertensive medications without arotinolol hydrochloride
11500964|NCT01347853|Placebo Comparator|Placebo|
11500385|NCT01351623|Experimental|Carfilzomib|A single arm, open-label, single institution phase 2 clinical trial is planned.
11500386|NCT01351610|Experimental|Group B|
11500387|NCT01351610|Experimental|Group A|
11500388|NCT01351597|Experimental|docetaxel/ oxaliplatin|All the patients are recurrent or metastatic breast cancer. Patients with a measurable lesion.
11500389|NCT01351571||Cohort|
11500390|NCT01351558|No Intervention|Control|No intervention for 12 weeks
11500391|NCT01351558|Active Comparator|Knee muscle strengthening exercises|
11500392|NCT01351558|Active Comparator|Upper extremity strengthening exercises|
11500393|NCT01351558|Active Comparator|Cardiovascular fitness exercises|
11500394|NCT01351545||Unlicensed CBU|The cohort includes recipients of any age receiving unlicensed cryopreserved cord blood units (CBUs) for designated indications.
11500395|NCT01351532|Experimental|Lifestyle counseling, smoking cessation drug|
11500396|NCT01351532|Active Comparator|Lifestyle counseling|
11500397|NCT01351519|Experimental|Aminolevulinic Acid (AL)|
11500398|NCT01351493|Active Comparator|Nitric oxide gel|
11500399|NCT01351493|Placebo Comparator|placebo|
11500400|NCT01351480|Other|abatacept|open label use of abatacept for 12 months
11500401|NCT01351467||Parkinson's disease patients|People diagnosed with Parkinson's disease by a physician
11500402|NCT01351454|Active Comparator|ACT HEALTHY|ACT HEALTHY is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001) and Life Steps, an HIV medication adherence intervention (Safren, Otto, & Worth, 1999). ACT HEALTHY is based on the belief that the best way to improve mood, remain sober, increase medication adherence, and make long-term life changes is by changing and increasing one's activity level. Treatment includes 16 individual sessions over a 12-week period.
11500403|NCT01351454|Placebo Comparator|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, & Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
11500404|NCT01351441|Other|Age 65 years or over AND at least 5 chronic medications|
11500405|NCT01351428|Experimental|NICOM group|Vasodilator therapy begins when SVR increases by 20% or greater than baseline. Therapy is titrated according to hemodynamic profile and clinical signs and symptoms.
11500406|NCT01351415|Experimental|Bevacizumab + Standard of Care|Participants will receive bevacizumab on Day 1 of every 21-days cycle along with standard of care (Erlotinib or Docetaxel or Pemetrexed) as second line treatment, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).
11500407|NCT01351415|Active Comparator|Standard of Care|Participants will receive investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).
11500408|NCT01351389|Active Comparator|Brief Motivational Intervention (BMI)|
11500409|NCT01351389|Active Comparator|Brief Advice|
11500410|NCT01351376|Placebo Comparator|Placebo|CDT + inactive LLL
11500411|NCT01351376|Active Comparator|LLL combined with CDT|CDT + active LLL
11500412|NCT01351363|Experimental|Electrical pain threshold measrement patients|
11500413|NCT01351350|Experimental|MLN0128P 30 mg QW|MLN0128 and paclitaxel (MLN0128P): MLN0128 30 mg, capsule, orally, once weekly (QW) + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
11500414|NCT01351350|Experimental|MLN0128P 40 mg QW|MLN0128 40 mg, capsule, orally, once a week (QW) + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
11500415|NCT01351350|Experimental|MLN0128P 6 mg QD×3d QW|MLN0128 6 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
11500416|NCT01351350|Experimental|MLN0128P 7 mg QD×3d QW|MLN0128 7 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
11500417|NCT01351350|Experimental|MLN0128P 8 mg QD×3d QW|MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
11500418|NCT01351350|Experimental|MLN0128P 9 mg QD×3d QW|MLN0128 9 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
11500419|NCT01351350|Experimental|MLN0128P 10 mg QD×3d QW|MLN0128 10 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
11500420|NCT01351350|Experimental|MLN0128P 7 mg QD×5d QW|MLN0128 7 mg, capsule, orally, once daily 5 days on/2 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
11500421|NCT01351350|Experimental|MLN0128P 8 mg QD×3d QW HER2-|MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in human epidermal growth factor receptor 2 negative (HER-) cancer participants until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.
11500422|NCT01351350|Experimental|MLN0128PH 8 mg QD×3d QW HER2+|MLN0128 + paclitaxel + trastuzumab (MLN0128PH): MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 plus trastuzumab 4 mg/kg loading dose on Day 1 followed by 2 mg/kg, intravenous each week of a 4-week cycle in HER+ cancer participants until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.
11500423|NCT01351337|Other|intraoperative functional monitoring|intraoperative functional monitoring
11500424|NCT01351324|Experimental|SFA|Oral dose of palmitic acid (SFA) given as a chocolate-flavoured drink every 30 min (0-390 min) with a continuous infusion of heparin (60-390 min).
11500521|NCT01350765|Active Comparator|Control|This would be the comparative group of the study in which the LHWs would perform the usual routine tasks assigned to them by their program.
11500425|NCT01351324|Experimental|SFA + LC n-3 PUFA|Oral dose of palmitic acid and DHA-rich fish oil (SFA + LC n-3 PUFA) given as a chocolate-flavoured drink every 30 min (0-390 min) together with a continuous infusion of heparin (60-390 min).
11500426|NCT01351311|Experimental|Exercise Group|Resistance exercise with swiss ball and drug treatment
11500427|NCT01351311|Other|Control Group|Drug treatment
11500428|NCT01351298|Placebo Comparator|Saline spray|
11500429|NCT01351298|Experimental|Decongestant|
11500430|NCT01351298|Experimental|Decongestant and local anesthetic|
11500431|NCT01351285|Experimental|Sevo group|undergoing sevoflurane-remifentanil anesthesia
11500432|NCT01351285|Active Comparator|Des group|undergoing desflurane-remifentanil anesthesia
11500433|NCT01351285|Active Comparator|Pro group|undergoing propofol-remifentanil anesthesia
11500434|NCT01351272|Experimental|methylphenidate, non-retard|
11500435|NCT01351259|Experimental|Pneumatic device, tapered cuff|Intervention: continuous control of cuff pressure using a pneumatic device, tapered polyurethane cuff
11500436|NCT01351259|Experimental|Pneumatic device, cylindrical cuff|Continuous control of cuff pressure using a pneumatic device in patients intubated with cylindrical polyurethane cuffed tracheal tubes
11500437|NCT01351259|Active Comparator|Routine care, tapered cuff|Routine care of cuff pressure using a manometer, tapered polyurethane cuff
11500438|NCT01351259|Active Comparator|Routine care, cylindrical cuff|Routine care of cuff pressure using a manometer, cylindrical polyurethane tracheal cuff
11500439|NCT01351246|Experimental|Intervention|
11500440|NCT01351220|Active Comparator|Basic dissemination|
11500441|NCT01351220|Active Comparator|Organizational dissemination|
11500442|NCT01351207|Active Comparator|pork sausages and hash brown potatoes plus eggs|
11500443|NCT01351207|Placebo Comparator|pork sausages and hash brown potatoes plus egg-free pudding|
11500444|NCT01351207|Placebo Comparator|pork sausages and hash brown potatoes|
11500445|NCT01351194|Experimental|RFA group|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
11500446|NCT01351194|Experimental|HR group|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
11500447|NCT01351181|Experimental|Exercise advice|Behavioural
11500448|NCT01351181|Other|Normal Care|Normal care
11500449|NCT01351168|Placebo Comparator|Sugar pill|
11500450|NCT01351168|Active Comparator|Levodopa|
11500451|NCT01351168|Experimental|Zolpidam second dose|
11500452|NCT01351168|Experimental|Zolpidam first dose|
11500453|NCT01351155|Active Comparator|polyurethane foam (Allewyn adesive)|Polyurethane foam is applied as skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
11500454|NCT01351155|Active Comparator|polyurethane film (Tegaderm)|The polyurethane film is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
11500455|NCT01351155|Active Comparator|Hydrocolloid (Duoderm)|Hydrocolloid is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
11500456|NCT01351155|No Intervention|Control|In this no-intervention arm, any skin protective dressing devices is applied before NIV starting
11500457|NCT01351129|Experimental|Formulation 1|
11500458|NCT01351129|Experimental|Formulation 2|
11500459|NCT01351129|Experimental|Formulation 3|
11500460|NCT01351116|Experimental|EBR plus HDRIB|External Beam Radiation (EBR) plus High Dose Rate Intraluminal Brachytherapy (HDRIB)
11500461|NCT01351116|Active Comparator|EBR|External Beam Radiation (EBR)
11500462|NCT01351103|Experimental|LGK974|
11500463|NCT01351103|Experimental|LGK974 in combination with PDR001|
11500464|NCT01351090|Experimental|Ketorolac tromethamine (5%)|
11500465|NCT01351090|Experimental|Ketorolac tromethamine (15%)|
11500466|NCT01351090|Placebo Comparator|Placebo|
11500467|NCT01351077|Experimental|CHICA DevScreen Module|This arm will get the CHICA Developmental Screening Module
11500468|NCT01351077|No Intervention|CHICA DevScreen Control|This arm will get CHICA without the developmental screening module
11500469|NCT01351064|Experimental|CHICA ADHD Module|This arm received The CHICA ADHD Module
11500470|NCT01351064|No Intervention|CHICA ADHD Control|This arm received CHICA without the ADHD module
11500471|NCT01351051||No endometriosis|
11500472|NCT01351051||Superficial endometriosis|
11500473|NCT01351051||Endometrioma|
11500474|NCT01351051||Deep infiltrating endometriosis|
11500475|NCT01351038|Experimental|treatment|3 cycles(repeated q21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Capecitabine 500mg/m² bid d1-d21 Panitumumab 9mg/kg i.v. d1
11500476|NCT01351025|Experimental|Arm A: atorvastatin / placebo|"At study entry (week 0), participants continued the entry boosted PI-based antiretroviral regimen (not provided by the study) and initiated atorvastatin at a daily dose of 10 mg for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, the dose of atorvastatin was increased to 20 mg daily at the week 4 visit. At week 20, atorvastatin was stopped for a 4-week washout period.
~At week 24, placebo was started for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, the placebo dose was doubled at week 28. At week 44, the placebo was stopped to allow for another 4-week washout period."
11500520|NCT01350765|Experimental|Intervention|This would be the interventional arm of the study, where the LHWs would receive additional training for identification and management of birth asphyxia, lbw, and sepsis.
11500477|NCT01351025|Experimental|Arm B: placebo / atorvastatin|"At study entry (week 0), participants continued the entry boosted PI-based antiretroviral regimen (not provided by the study) and initiated placebo for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, the dose of placebo was doubled at the week 4 visit. At week 20, the placebo was stopped for a 4-week washout period.
~At week 24, atorvastatin was started at a daily dose of 10 mg for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, the dose of atorvastatin was increased to 20 mg daily at week 28. At week 44, atorvastatin was stopped to allow for another 4-week washout period."
11500478|NCT01351012|Placebo Comparator|Corn and safflower oil|
11500479|NCT01351012|Active Comparator|Canola oil|
11500480|NCT01351012|Active Comparator|High oleic acid canola oil|
11500481|NCT01351012|Active Comparator|DHA enriched high oleic acid canola oil|
11500482|NCT01351012|Active Comparator|Flax and safflower oil|
11500483|NCT01350999|Experimental|TAK-085 2 g|TAK-085 2 g, orally, once daily for up to 52 weeks.
11500484|NCT01350999|Experimental|TAK-085 4 g|TAK-085 2 g, orally, twice daily for up to 52 weeks.
11500485|NCT01350999|Active Comparator|EPA-E 1.8 g|Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.
11500486|NCT01350986|Experimental|Directive|
11500487|NCT01350986|Active Comparator|Non-Directive|
11500488|NCT01350973|Experimental|TAK-085 2 g|TAK-085 2 g, orally, once daily for up to 12 weeks.
11500489|NCT01350973|Experimental|TAK-085 4 g|TAK-085 2 g, orally, twice daily for up to 12 weeks.
11500490|NCT01350973|Experimental|EPA-E 1.8 g|Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.
11500491|NCT01350960|Placebo Comparator|saline 0.9%|
11500492|NCT01350960|Experimental|Cohort 1|0.5 mg/kg in Healthy Subjects
11500493|NCT01350960|Experimental|Cohort 2|1.5 mg/kg in Healthy subjects
11500494|NCT01350960|Experimental|Cohort 3|5.0 mg/kg in Healthy subjects
11500495|NCT01350960|Experimental|Cohort 4|10 mg/kg in Healthy subjects
11500496|NCT01350960|Experimental|Cohort 5|TBD mg/kg in FH subjects
11500497|NCT01350947|Experimental|All patients|All participants enrolled.
11500498|NCT01350934|Experimental|Fosamax Plus|Participants received alendronate 70 mg plus vitamin D3 5600 IU in a combination tablet (FOSAMAX PLUS D) once weekly for 6 months (base study), and then once weekly for another 6 months (extension study).
11500499|NCT01350934|Active Comparator|Calcitriol|Participants received calcitriol 0.25 μg once daily orally for 6 months (base study), and then once daily orally for another 6 months (extension study).
11500500|NCT01350908|Other|Blood sampling|
11500501|NCT01350895||Experimental Group|
11500502|NCT01350895||Control Group|
11500503|NCT01350882|Experimental|A|Patients randomized into the arm blind A. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
11500504|NCT01350882|Placebo Comparator|B|Patients randomized into the arm blind B. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
11500505|NCT01350869||Xience stent|Real world patients treated with XIENCE stents
11500506|NCT01350856|Active Comparator|Artesunate 2|Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
11500507|NCT01350856|Experimental|Artesunate 4|Artesunate 4 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
11500508|NCT01350843|Experimental|Orange Juice|Juice high in flavonoids
11500509|NCT01350843|Placebo Comparator|Orange Drink|Sugars matched, low flavonoids orange drink
11500510|NCT01350830|Active Comparator|pre-trasversalis mesh repair group|
11500511|NCT01350830|Active Comparator|trans-inguinal preperitoneal patch group|
11500512|NCT01350817|Active Comparator|Docetaxel|
11500513|NCT01350817|Experimental|Erlotinib|
11500514|NCT01350804|Experimental|AIN457 10mg/kg - 75 mg|Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks
11500515|NCT01350804|Experimental|AIN457 10mg/kg - 150 mg|Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks
11500516|NCT01350804|Placebo Comparator|Placebo|Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (>= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.
11500517|NCT01350804|Active Comparator|Abatacept|Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).
11500518|NCT01350791||Promus Element stent|Patients receiving Promus Element stents
11500519|NCT01350778||Biomatrix stent|patients treated with Biomatrix stent
11500960|NCT01347879|Placebo Comparator|Vehicle cream with PDT|Placebo treatment, Light dose 37 Joule/cm2
11500522|NCT01350752|No Intervention|Control|"In Cameroon: Existing practice (with microscopy widely available)
~In Nigeria: Expected practice (RDTs will be provided with basic instructions)"
11500523|NCT01350752|Active Comparator|Provider Intervention|"Cameroon: Introduce malaria RDTs with basic provider training and job aids on malaria diagnosis and treatment. This involved 1-day training on: 1) Malaria Diagnosis; 2) Rapid Diagnostic Testing; 3) Malaria Treatment. These modules explain that all febrile patients should be tested for malaria; procedures for using an RDT; that confirmed cases of uncomplicated malaria should be treated with an ACT; and test-negative patients should not be given an antimalarial.
~Nigeria: Introduce malaria RDTs with provider training and job aids on malaria diagnosis and treatment. This involved a 2-day training workshop and support visits. The training covered the following topics: causes and symptoms of malaria; demonstration on how to use an RDT; updated malaria guidelines; and communications skills. The training used a combination of seminars and facilitated small-group work, such as a treatment algorithm game, problem-solving exercises, self-developed participatory drama and role-playing."
11500524|NCT01350752|Active Comparator|Extended intervention|"Cameroon: Introduce malaria RDTs with basic provider training and job aids on malaria diagnosis and treatment AND enhanced provider training on improving quality of care. Clinicians received 3-days of training: the first day was identical to the basic intervention, while the remainder of the course covered three additional modules targeting improvements in quality of care: 4) Adapting to Change; 5) Professionalism; 6) Communicating Effectively.
~Nigeria: Introduce malaria RDTs with provider training and job aids on malaria diagnosis and treatment AND School-based malaria education intervention (with drama, peer-health education and distribution of health education materials). In addition, teachers and Peer Health Educators were offered support to hold malaria events in which parents, guardians, and other community members could participate in the same types of activities."
11500525|NCT01350739|Other|intraumbilical incision|an intraumbilical vertical incision is made
11500526|NCT01350739|Other|infraumbilical incision|incision is done in circular fashion at the inferior boarder of umbilicus
11500527|NCT01350726||Normal control|Subjects without liver cirrhosis and normal volunteers.
11500528|NCT01350726||Cirrhosis group|Subjects with liver cirrhosis.
11500529|NCT01350713|Experimental|povidone iodine|
11500530|NCT01350713|Active Comparator|cold water|treatment by cold water after burn
11500531|NCT01350700||Patients that were treated in MW2004-011-02 study with Debrase|
11500532|NCT01350700||Patients that were treated in MW2004-011-02 with SOC|
11500533|NCT01350674|Experimental|EBUS|patients undergoing EBUS
11500534|NCT01350661||Asthma control level assessment|
11500535|NCT01350648||HBV and HCV Co-infection|HBV and HCV Co-infection
11500536|NCT01350648||Hepatitis B|Hepatitis B alone
11500537|NCT01350648||Hepatitis C|Hepatitis C alone
11500538|NCT01350648||HIV and HBV and HCV Tri-Infection|HIV and HBV and HCV Tri-Infection
11500539|NCT01350648||HIV and HBV Co-infection|HIV and HBV Co-infection
11500540|NCT01350648||HIV/HCV Co-Infection|HIV and HCV Co-infection
11500541|NCT01350622|Experimental|Pennsaid|Active Pennsaid and oral placebo
11500542|NCT01350622|Active Comparator|Oral Diclofenac|Oral diclofenac and placebo lotion (2.3% DMSO solution)
11500543|NCT01350609|Experimental|Nifedipine/Candesartan (fixed dose)|
11500544|NCT01350609|Active Comparator|Nifedipine/Candesartan (loose)|
11500545|NCT01350596|Active Comparator|Reference Drug|
11500546|NCT01350596|Active Comparator|Test Drug|
11500547|NCT01350583|Experimental|Sodium Bicarbonate Therapy|Dose Escalation
11500548|NCT01350570|Experimental|acupuncture group 1|Acupoints ST25 and BL25 will be used in the group. ST25 locate at the abdomen, while BL25 locate at the back.
11500549|NCT01350570|Experimental|acupuncture group 2|Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
11500550|NCT01350570|Experimental|acupuncture group 3|All acupoints used in acupuncture group1 and acupuncture group2 will be used in this group.
11500551|NCT01350570|Active Comparator|Loperamide|Loperamide will be used as an active comparator to the acupuncture groups.
11500552|NCT01350557|No Intervention|Control group|Patients receive only usual hospital care
11500553|NCT01350557|Other|Subacute care group|Patients receive hospital usual care and subacute care. Subacute care consisted of geriatric consultation, a rehabilitation program, and early discharge planning.
11500554|NCT01350557|Experimental|Comprehensive care group|Patients receive not only the subacute care (geriatric consultation, rehabilitation program, and discharge planning), but also health-maintenance interventions to prevent falls, consult on nutrition, and manage depression.
11500555|NCT01350544|No Intervention|Wait-list control|Participants in the wait-list control group will not receive the intervention until after the 6-month follow-up assessment.
11500556|NCT01350544|Experimental|treatment advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with AIDS Project Los Angeles' (APLA) social service programs, as necessary.
11500557|NCT01350531|Experimental|Skills training|
11500558|NCT01350531|Experimental|Contingency Management|
11500559|NCT01350518|Placebo Comparator|Study prepared meals and placebo|Participants will have meals designed specifically for them based on their caloric needs. Participants will choose a weeks worth of meals (from a menu) and pick them up from the Clinical Research Unit twice a week. Participants will not receive any fiber (Benefiber) supplementation in their TrueLemon mixture.
11500560|NCT01350518|Active Comparator|Nutritional Counseling with fiber|Participants receiving nutritional education will have two individual sessions (spaced approx. 2 weeks apart). The nutritional sessions will focus on knowledge, self-regulation, motivation, experience and environment. Participants will receive fiber (Benefiber) supplementation as the fiber intervention in their TrueLemon mixture .
11500642|NCT01350024|Active Comparator|Frontal Nerve Block|Patients will receive a frontal nerve block for anesthesia
11500561|NCT01350518|Placebo Comparator|Nutrition counseling and placebo|Participants receiving nutritional education will have two individual sessions (spaced approx. 2 weeks apart). The nutritional sessions (interventions) will focus on knowledge, self-regulation, motivation, experience and environment.Participants will receive no fiber supplementation in their TrueLemon mixture .
11500562|NCT01350518|Active Comparator|Study prepared meals and fiber|Participants will have meals designed specifically for them based on their caloric needs. Participants will choose a weeks worth of meals (from a menu) and pick them up from the Clinical Research Unit twice a week. Participants will receive fiber (Benefiber) supplementation as the fiber intervention in their TrueLemon mixture.
11500563|NCT01350505|Experimental|All subjects|13 minutes of light at night (2 hours after bedtime)
11500564|NCT01350492|Experimental|Arm 1|Resistance exercise training
11500565|NCT01350492|No Intervention|Arm 2|Waitlist Control
11500566|NCT01350479||MRSA colonized|Residents with history of MRSA in the past year
11500567|NCT01350479||Not MRSA colonized|Residents without history of MRSA in the past year
11500568|NCT01350466||FESS patients|
11500569|NCT01350466||Controls|
11500570|NCT01350453|Experimental|LifeCIT|Participants will be asked to aim to wear the C-MIT for 9 hours a day for 5 days/week, including 4-6 hours of structured activities per day: two 30-60 minute sessions of web-based activities and 3-4 hours practicing everyday activities.
11500571|NCT01350453|Active Comparator|Standard Care|Participants received their usual care which included home exercises
11500572|NCT01350440|Experimental|IVIG|Intravenous Immune Globulin
11500573|NCT01350427|Experimental|Leucine|
11500574|NCT01350427|Experimental|BCAA|
11500575|NCT01350427|Placebo Comparator|Placebo|
11500576|NCT01350414||Alair Group|Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02, NCT00231114)
11500577|NCT01350401|Experimental|NY-ESO-1/LAGE-1 and HLA-A*02 Positive Subjects|
11500578|NCT01350388|Active Comparator|Febuxostat|80 mg/day of febuxostat for 24 weeks
11500579|NCT01350388|Placebo Comparator|Placebo|1 placebo tablet per day for 24 weeks
11500580|NCT01350375|Placebo Comparator|Saline|
11500581|NCT01350375|Active Comparator|Botox|
11500582|NCT01350362|Experimental|Tideglusib 1000 mg Q.D.|Group dosed with 1000 mg once daily for 26 weeks/extension
11500583|NCT01350362|Experimental|Tideglusib 1000 mg Q.O.D.|Group dosed with 1000 mg once every other day for 26 weeks/extension
11500584|NCT01350362|Experimental|Tideglusib 500 mg Q.D.|Group dosed with 500 mg once daily for 26 weeks/extension
11500585|NCT01350362|Placebo Comparator|Placebo|Once daily administration for 26 weeks/extension
11500586|NCT01350349|Experimental|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
11500587|NCT01350349|Active Comparator|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
11500588|NCT01350336|Experimental|Alair|Alair system
11500589|NCT01350323|Active Comparator|Type 3 NV|Wet-AMD related type 3 neovascularization
11500590|NCT01350323|Active Comparator|Type 2 NV|Wet-AMD related type 2 neovascularization
11500591|NCT01350323|Active Comparator|Type 1 NV|Wet-AMD related type 1 neovascularization
11500592|NCT01350323|Other|Controls|Aqueous sample (0.1ml) in patients undergoing cataract extraction
11500593|NCT01350310|Experimental|Intramyocardial Injections|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Electromechanical mapping will be used to identify viable myocardium and intramyocardial injections in the target areas will be performed with NOGA catheter. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure.
11500594|NCT01350310|Active Comparator|Intracoronary Injections|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Patients will undergo myocardial perfusion scintigraphy and CD34+ cells will be injected intracoronary in the artery supplying segments of reduced viability. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure.
11500595|NCT01350310|Active Comparator|Ischemic heart disease|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Electromechanical mapping will be used to identify viable myocardium and intramyocardial injections in the target areas will be performed with NOGA catheter. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure
11500596|NCT01350297|Experimental|Patients|Patients
11500597|NCT01350284|Experimental|Dietary supplementation|3g of cinnamon or placebo control were added to a test-meal.
11500598|NCT01350271|Placebo Comparator|Placebo|Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
11500599|NCT01350271|Active Comparator|Mebendazole polymorph A and C 500 mg|Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
11500600|NCT01350271|Experimental|Mebendazole polymorph C 500 mg|Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
11500601|NCT01350258|Experimental|Transplant Treatment Group|All patients treated on this research study.
11500602|NCT01350245|Experimental|TJU 2 Step Regimen|All patients treated on this trial will have hematological malignancies that are in remission at the time of the transplant. Their diseases would be expected to relapse with standard therapy alone.
11500639|NCT01350037|Active Comparator|remifentanil|sedative mixture for PCS consisting of propofol 10mg/ml 20 ml and remifentanil 50 mkg/ml 5 ml
11500640|NCT01350037|Active Comparator|alfentanil 0.04 mg/ml|sedative mixture for PCS consisting of propofol10 mg/ml 20 ml,alfentanil 0.5 mg/ml 2 ml, NaCL 9 mg/ml 3 ml
11500641|NCT01350037|Active Comparator|alfentanil 0.08 mg/ml|sedative mixture for PCS consisting of propofol 10 mg/ml 20 ml, alfentanil 0.5 mg/ml 4 ml,NaCl 9mg/ml 1ml
11500603|NCT01350232|Experimental|HSCT|"Subjects receive the preparative regimen in 2 steps. The first step will be with fludarabine and cytarabine and a low dose of total body irradiation. This will be followed by the first step of the transplant graft - the donor lymphocytes. The second step of the chemotherapy will be two doses of cyclophosphamide. This will then be followed by the second step of the transplant graft - the stem cells.
~Only subjects with prior alloimmunization against donor will receive desensitization. Subjects who demonstrate alloimmunization against the HLA of the donor will receive bortezomib and rituximab in combination with plasmapheresis prior to the admission for transplant."
11500604|NCT01350219|Experimental|Cord blood stem cell|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations.
11500605|NCT01350206|Experimental|HR group|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
11500606|NCT01350206|Experimental|TACE group|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
11500607|NCT01350193|Active Comparator|Saline Nasal Irrigation|Saline Nasal Irrigation is actively being used as the standard of care. It does not contain any active ingredients.
11500608|NCT01350193|Experimental|Manuka Honey Irrigation|Manuka Honey Irrigation involves the experimental treatment of manuka honey nasal irrigation.
11500609|NCT01350167|Active Comparator|Triphasic CT|Triphasic CT of the abdomen with and without contrast every 12 months with alpha-fetoprotein every 6 months.
11500610|NCT01350167|Active Comparator|Ultrasound|Ultrasound of the upper left quadrant with alpha-fetoprotein testing every 6 months.
11500611|NCT01350154|Experimental|Sildenafil (Revation) 20 mg|This arm will receive sildenafil for 4 weeks followed by 2 weeks washout and 4 weeks placebo.
11500612|NCT01350154|Experimental|Placebo|This arm will receive placebo for 4 weeks followed by 2 weeks washout and 4 weeks sildenafil
11500613|NCT01350141|Placebo Comparator|Treatment A|
11500614|NCT01350141|Experimental|Treatment B|
11500615|NCT01350141|Experimental|Treatment C|
11500616|NCT01350128|Experimental|PT001 MDI (Dose 1)|PT001 MDI
11500617|NCT01350128|Experimental|PT001 MDI (Dose 2)|PT001 MDI
11500618|NCT01350128|Experimental|PT001 MDI (Dose 3)|PT001 MDI
11500619|NCT01350128|Experimental|PT001 MDI (Dose 4)|PT001 MDI
11500620|NCT01350128|Active Comparator|Ipratropium Bromide HFA Inhalation Aerosol|Ipratropium Bromide HFA Inhalation Aerosol
11500621|NCT01350128|Placebo Comparator|Placebo MDI|PT001 Placebo MDI
11500622|NCT01350115|Active Comparator|LDE225|Participants received 400 mg once daily.
11500623|NCT01350115|Placebo Comparator|Placebo|Participants received matching placebo.
11500624|NCT01350102|Active Comparator|Bacitracin wound care dressing alone|Bacitracin wound care dressing alone
11500625|NCT01350102|Active Comparator|Bacitracin with Vit C|Bacitracin wound care dressing with Vitamin C supplementation
11500626|NCT01350102|Active Comparator|AmeriGel® wound care dressing alone|AmeriGel® wound care dressing alone
11500627|NCT01350102|Active Comparator|AmeriGel® with Vit C|AmeriGel® wound care dressing with Vitamin C supplementation
11500628|NCT01350089|Placebo Comparator|Placebo|
11500629|NCT01350089|Active Comparator|Comparator 1 (with alcohol)|
11500630|NCT01350089|Active Comparator|Comparator 2 (with alcohol and coffeine)|
11500631|NCT01350089|Experimental|Comparator 3 (with alcohol and energy drink)|
11500632|NCT01350076|Active Comparator|control group|Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
11500633|NCT01350076|Experimental|study group|"Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).
~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index"
11500634|NCT01350063|Experimental|Aquatabs and Safe Storage Vessel|Households in this group will receive Aquatabs for water purification, a safe water storage container to prevent contamination during storage in the home, and training and encouragement to treat and safely store their water using the provided products.
11500635|NCT01350063|Experimental|Safe Storage Vessel|Households in this group will receive a safe water storage container, and training and encouragement to safely store their water using the provided products. If our study shows that treatment of tubewell water at the household level is effective in protecting children's health, they will receive a six-month supply of water treatment tablets at the end of the study.
11500636|NCT01350063|Other|Standard practice|Households in this group will not receive any water treatment or storage intervention during the study. They will continue their usual water collection and storage practices. If our study shows that treatment and safe storage of tubewell water at the household level is effective in protecting children's health, they will receive the same safe water storage container as Groups 1 and 2 as well as a six-month supply of water treatment tablets at the end of the study.
11500637|NCT01350050|Active Comparator|articaine|Pharyngeal anesthesia with articaine 4% or placebo should randomly and double-blindly applied in turns for every volunteer. In details: 3 ml of Articaine 4%solution or placebo (NaCl 0,9%) will be sprayed into the pharynx 5 minutes before beginning of gastroscopy. Also gastroscope will be lubricated with articaine (or placebo) gel(prepared by adding 4% articaine or 0,9%NaCl in placebo grope to Endopurin® endoscopic lubricant at the day of study).
11500638|NCT01350050|Placebo Comparator|placebo|Pharyngeal anesthesia with placebo or articaine 4% should be randomly and double-blindly applied in turns for every volunteer. In details: 3 ml of placebo or Articaine 4% solution should be sprayed into the pharynx 5 minutes before beginning of gastroscopy. Also gastroscope will be lubricated with placebo(or articaine) gel(prepared by adding 4% articaine or 0,9%NaCl in placebo grope to Endopurin® endoscopic lubricant at the day of study).
11500643|NCT01350024|Active Comparator|Subconjucntival Injection|Patients will receive a subconjunctival injection for anesthesia
11500644|NCT01350011|Active Comparator|Innovative System (IS)|The innovative intervention uses the treatment system to support motivational counseling treatment entrance and treatment utilization. It has two components, a Motivational Intervention component via Expert System Counseling, and a Treatment Component that incorporates both pharmacological and behavioral long-term components. An innovative aspect of the IS is the use of the pharmacist as an intervention agent, who queries participants on their readiness to quit smoking, encourages involvement in the motivational intervention and in treatment, and who, along with the counselors, is available to answer medication questions.
11500645|NCT01350011|Active Comparator|Standard Treatment Control|After a baseline interview, patients in this condition will be given a packet of brochures on quitting, including descriptions of self-quitting and help-lines. Participants in this condition will continue to have access to their primary care providers, and through that system have access to pharmacotherapy for smoking cessation, if they wish to receive it. They will receive written instructions on how to approach their primary care provider about smoking cessation medication, and a written description of the medications used in smoking cessation and a list of those that are available to them through the public health system. At each assessment, patients will be queried about their use of these resources.
11500646|NCT01349998|Experimental|Safety Population|
11500647|NCT01349985|Experimental|AGATE|To evaluate whether AGATE, a smartphone medication reminder and assessment system, effectively measures and enhances medication adherence in the context of naltrexone treatment for problem drinking.
11500648|NCT01349985|Active Comparator|SASED|The control condition for the proposed study is a smartphone alcohol and side-effects diary (SASED, a smartphone alcohol and side effects diary).
11500649|NCT01349972|Experimental|Arm I (alvocidib, cytarabine, mitoxantrone hydrochloride)|Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Patients who achieve complete or partial response to the first course (completion of all doses) may receive a second course of treatment or high-dose cytarabine after 21-63 days following blood count recovery, and/or undergo allogeneic bone marrow transplant.
11500650|NCT01349972|Active Comparator|Arm II (cytarabine, daunorubicin hydrochloride)|Patients receive cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients who have residual disease on day 14 may receive additional cytarabine for 5 days and daunorubicin hydrochloride for 2 days.
11500651|NCT01349959|Experimental|Treatment (entinostat and azacitidine)|Patients receive azacitidine SC on days 1-5 and 8-10, and entinostat PO on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may continue azacitidine and entinostat in combination with hormonal therapy, at treating physician discretion, or undergo event monitoring.
11500652|NCT01349933|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive 200 mg Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11500653|NCT01349920||Infliximab 5 mg/kg|Infliximab treatment and endoscopy.
11500654|NCT01349907|Experimental|Asenapine/Asenapine|Participants treated with asenapine in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg twice per day (BID), then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7. After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
11500655|NCT01349907|Experimental|Placebo/Asenapine|Participants treated with placebo in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg BID, then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7. After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
11500656|NCT01349894||SNaP® Wound Care System|
11500657|NCT01349881|Placebo Comparator|eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets, PO, daily for 3 years. Sulindac placebo, 1 tablet, PO, daily for 3 years.
11500658|NCT01349881|Experimental|Eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo one tablet PO daily for 3 years.
11500659|NCT01349881|Experimental|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
11500660|NCT01349881|Experimental|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
11500661|NCT01349868|Experimental|PT005 MDI (Dose 1)|PT005 MDI (Dose 1)
11500662|NCT01349868|Experimental|PT005 MDI (Dose 2)|PT005 MDI (Dose 2)
11500663|NCT01349868|Experimental|PT005 MDI (Dose 3)|PT005 MDI (Dose 3)
11500664|NCT01349868|Placebo Comparator|Placebo MDI|Placebo MDI
11500665|NCT01349868|Active Comparator|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 12 μg
11500666|NCT01349868|Active Comparator|Formoterol Fumarate 24 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 24 μg
11500667|NCT01349855|Experimental|Cohort 1|Dose Level 1
11500668|NCT01349855|Experimental|Cohort 2|Dose Level 2
11500669|NCT01349842|Experimental|Circulating Tumor Cells|Centralized determination of CTC by CellSearch® technology (Veridex), the only technology currently validated in clinical practice for the early evaluation of response to chemotherapy of breast cancers. This evaluation is performed by blood sampling comparing the CTC level before the first injection of each new line of chemotherapy. Chemotherapy can only be continued in the case of a positive CTC response. Discontinuation of chemotherapy can also be decided by the clinician on the basis of other clinical or radiological arguments.
11500670|NCT01349842|Other|Clinical and radiological criteria|Management of chemotherapy according to the usual clinical and radiological criteria adopted by the patient's attending physician.
11500671|NCT01349829|Experimental|HAVpur|
11500672|NCT01349829|Active Comparator|Havrix|
11500673|NCT01349816|Experimental|PT003 (Dose 1)|PT003 MDI Dose 1
11500674|NCT01349816|Experimental|PT003 (Dose 2)|PT003 MDI Dose 2
11500675|NCT01349816|Experimental|PT003 (Dose 3)|PT003 MDI Dose 3
11500676|NCT01349816|Experimental|PT003 (Dose 4)|PT003 MDI Dose 4
11500677|NCT01349816|Experimental|PT001|PT001 MDI
11500678|NCT01349816|Experimental|PT005|PT005 MDI
11500679|NCT01349803|Experimental|PT005 MDI|PT005 MDI
11500680|NCT01349803|Experimental|PT001 MDI|PT001 MDI
11500682|NCT01349803|Active Comparator|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
11500683|NCT01349790|Experimental|NewGam|Each participant received 1 g/kg NewGam intravenously on 2 consecutive days.
11500684|NCT01349777|Experimental|Pregrel®|clopidogrel
11500685|NCT01349777|Active Comparator|Plavix®|clopidogrel
11500686|NCT01349764||No vitamin D replacement|The control arm will not receive vitamin D replacement, but patients in both study arms will receive care consistent with best care practices for stone disease. All patients will be evaluated by the stone clinic clinical nutritionist and full nutritional evaluation will be performed. All patients will be advised to maintain adequate hydration (>2L/day), no-added salt diet (Na 80-100mmol/day), low protein diet (1 g/kg/day). Patients with hyperoxaluria will be advised to follow low-oxalate diet. All patients will be advised to maintain moderate calcium intake; 800-1200mg/day.
11500687|NCT01349764||Vitamin D3 tabs|The active arm of randomization will receive vitamin D repletion in the form of oral vitamin D3 tablets 10 000 IU twice/ week for 8 consecutive weeks, followed by a maintenance dose of 1 000 IU daily for further 22 months.
11500688|NCT01349751|Active Comparator|isobaric levobupivacaine|spinal isobaric levobupivacaine
11500689|NCT01349751|Active Comparator|hyperbaric levobupivacaine|hyperbaric levobupivacaine
11500690|NCT01349738||Positive Group|Positive for ASB
11500691|NCT01349738||Negative Group|Negative for ASB
11500692|NCT01349725|Experimental|ARRY-502|
11500693|NCT01349725|Placebo Comparator|Placebo|
11500694|NCT01349712||Coumadin (warfarin)|Subjects are required to be currently receiving coumadin (warfarin) treatment.
11500695|NCT01349699|Active Comparator|Iron loading|Subjects will receive 1.25 mg/kg iron sucrose intravenously 1 hour before endoxin administration 2ng/kg.
11500696|NCT01349699|Active Comparator|Iron chelation|Subjects will receive 30mg/kg deferasirox orally 2 hours before endotoxin administration 2ng/kg.
11500697|NCT01349699|Placebo Comparator|Placebo|Subjects will receive placebo instead of iron chelation or iron loading before endotoxin administration
11500698|NCT01349686|Experimental|Oral intake of fluids|Intake of oral fluids during labour.
11500699|NCT01349686|Placebo Comparator|Fasting|No intake of oral fluids during labour.
11500700|NCT01349673|Experimental|Budesonide Foam|Participants administered topical rectal budesonide foam at 2 mg/25 mL BID (morning and 12 hours later) for 2 weeks followed by 2 mg/25 mL QD (in the evenings) for 4 weeks for up to 8 cycles. After Cycle 1, participants needed to qualify to be able to participate in subsequent cycles. Participants underwent a 48-hour study drug washout period between each cycle.
11500701|NCT01349660|Experimental|BKM120/Bevacizumab|"Phase I:
~BKM 120 orally (PO) once daily (dose is 60mg or 80mg). Bevacizumab: 10mg/kg intravenous (IV) every 2 weeks
~Phase II:
~BKM 120 orally (PO) once daily - dose is optimal dose determined in Phase I. Bevacizumab: 10mg/kg intravenous (IV) every 2 weeks"
11500702|NCT01349647|Experimental|Vaccine and Chemotherapy|This is a pilot trial evaluating the safety and immunogenicity of a pentavalent vaccine for patients with small cell lung cancer (SCLC). Patients with SCLC who have completed all planned initial therapy and have maintained a partial or complete response will be enrolled.
11500703|NCT01349647|Experimental|Vaccine Alone|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.
11500704|NCT01349634|No Intervention|Comparison group|This arm will use the salt that is on the open market, which is primarily non-iodized salt. Iodized salt may enter in these communities through the normal trade route. No active interference with salt trade will occur in these communities.
11500705|NCT01349634|Experimental|Early delivery of iodized salt|Iodized salt that is produced nationally for the open market (which meets only about 10% of national needs) will be directed to these communities through the normal trade system or by direct delivery to the communities.
11500706|NCT01349621||Standard and polarized light colposcopy|Standard and polarized light colposcopy
11500707|NCT01349608|Experimental|Health coaching|
11500708|NCT01349595|Experimental|Bortezomib|Bortezomib is a type of targeted chemotherapy
11500709|NCT01349595|No Intervention|Standard Post-transplant Treatment|Mayo Clinic standard post kidney transplant follow-up.
11500710|NCT01349582|Active Comparator|flow diversion|
11500711|NCT01349582|Active Comparator|Best standard treatment|
11500712|NCT01349582|Other|Registry for flow diversion|Flow diversion when randomization between flow diversion and best standard treatment is not possible and the only alternative is flow diversion for compassionate use. In this case there will be no random allocation but the patient will be entered into a registry
11500713|NCT01349569|Experimental|Myeloma Vaccine, Prevnar, & Lenalidomide|Lenalidomide will be continued on the same dose as was being administered prior to the study. The allogeneic myeloma vaccine and Prevnar-13 vaccine will be given on four days over the course of the study.
11500714|NCT01349556|Experimental|Tretinoin pre-treatment|
11500715|NCT01349543|Experimental|Viral Challenge|
11500716|NCT01349530|Experimental|Anticoagulation clinic care|Monitoring by CREATIF
11500717|NCT01349530|Active Comparator|Usual care|Monitoring by GP.
11500718|NCT01349517|Other|MIE Group|The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)
11500719|NCT01349517|Other|Three-incision esophagectomy group|The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)
11500720|NCT01349517|Other|Ivor-Lewis esophagectomy group|The patients in this group would underwent Ivor-Lewis esophagectomy
11500721|NCT01349517|Other|Sweet esophagectomy group|The patients in this group would underwent Sweet esophagectomy.
11500722|NCT01349504||Mesalmine|
11500723|NCT01349491|Experimental|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated.
11500724|NCT01349491|Placebo Comparator|Placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion.
11500725|NCT01349478|Experimental|study arm|
11500726|NCT01349465|Other|Group 1: TMC 435 - Patients With SVR at LPVPS|Patients with sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) [Phase IIb or Phase III] in which they received a TMC435-containing regimen for the treatment of HCV infection.
11500727|NCT01349465|Other|Group 2: TMC 435 - Patients With No SVR at LPVPS|Patients with no sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) [Phase IIb or Phase III] in which they received a TMC435-containing regimen for the treatment of HCV infection.
11500728|NCT01349452|Experimental|Ganciclovir|
11500729|NCT01349452|Sham Comparator|Artificial tear|
11500730|NCT01349439|Experimental|Propranolol + Memory Reactivation|This arm involves recalling the traumatic event after administration of propranolol
11500731|NCT01349439|Experimental|Placebo + Memory reactivation|This arm involves recalling the traumatic event after administration of a placebo
11500732|NCT01349439|Experimental|Placebo + No Memory Reactivation|This arm involves administration of a placebo without recalling the traumatic event
11500733|NCT01349439|Experimental|Propranolol + No Memory Reactivation|This arm involves administration of propranolol without recalling the traumatic event
11500734|NCT01349439|Other|Open-label Propranolol + Memory Reactivation|All participants terminating the double-blind phase of the study will receive open-label reconsolidation blockade treatment with propranolol combined with recall of the traumatic event for six weeks.
11500735|NCT01349426|Experimental|LigaSure|"Arm 1
~Patients undergoing lung surgery"
11500736|NCT01349426|Active Comparator|Automatic Staplers|"Arm 2
~Patients undergoing lung surgery"
11500737|NCT01349413|Placebo Comparator|Placebo|Identical looking placebo (once daily)
11500738|NCT01349413|Experimental|Esomeprazole 20mg daily|Esomeprazole 20mg daily Oral for 8 weeks
11500739|NCT01349400|Experimental|watchful waiting|"After informed consent and randomization into the watchful waiting group patients will receive standardized verbal information and written instructions on symptoms of acute incarceration. In case of acute symptoms they will be told to visit a physician immediately. On follow-up visits at 1 month, 12 months and 24 months the hernia size will be determined by physical examination, and the pain/ discomfort and the functional status will be monitored.
~Control intervention/ reference test:
~Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided. Divergent types of repair are permitted but have to be documented."
11500740|NCT01349400|Active Comparator|Hernia repair|Intervention: Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided. Divergent types of repair are permitted but have to be documented.
11500741|NCT01349387|Experimental|Arm1|"During their visit of consultation on the follow-up to the type 2 diabetes, les patients will be selected on the basis of active metformin treatment at a dose greater than or equal to 1400 mg/day. Patients will have to achieve a 10 ml blood sample. The blood will be processed by Ficoll gradient centrifugation to remove the red cells and isolate circulating leukocytes: this stage will be conducted in the CERITD. Analysis on circulating leukocytes and in particular the quantification of expressions of isoforms A and B of the INSR1 by quantitative RT - PCR gene will be conducted in the laboratory of the Professor Marc Peschanski (unit INSERM 861 I - STEM of Evry).
~After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31."
11500742|NCT01349374|Experimental|Group1|healthy volunteers
11500743|NCT01349374|Experimental|group2|Unaffected siblings of MODY patients
11500744|NCT01349374|Experimental|Group3|Type2 Diabetic patients
11500745|NCT01349374|Experimental|Group4|MODY patients
11500746|NCT01349361|Experimental|Daylight-PDT|
11500747|NCT01349348|Experimental|Tolvaptan 15mg|Tablet;15mg/tab
11500748|NCT01349348|Experimental|Tolvaptan 7.5mg|Tablet;7.5mg/tab
11500749|NCT01349348|Placebo Comparator|Placebo|Tolvaptan 0mg/tab
11500750|NCT01349335|Experimental|1. tolvaptan|15 mg, P.O., Qd, for 7 days,
11500751|NCT01349335|Experimental|2 tolvaptan|30 mg, P.O., Qd, for 7 days,
11500752|NCT01349335|Experimental|3. Placebo|30mg,P.O.,Qd, for 7 days.
11500753|NCT01349322|Active Comparator|Arm I|Patients undergo standard whole-breast radiotherapy (WBI) comprising intensity-modulated radiation therapy (IMRT) or three-dimensional conformal radiotherapy (3D-CRT) 5 days a week for 3-5 weeks followed by a sequential radiotherapy boost to the lumpectomy area 5 days a week for 1-1½ weeks in the absence of disease progression or unacceptable toxicity.
11500754|NCT01349322|Experimental|Arm II|Patients undergo accelerated hypofractionated WBI comprising IMRT or 3D-CRT with a concurrent boost to the lumpectomy area 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity.
11500755|NCT01349309|Experimental|Swallowing Exercise Group|Swallowing Exercise Group: This arm will undergo the protocol that involves intensive swallowing exercises to begin at the start of the cancer treatment. Those patients randomized to the intensive therapy protocol will be required to participate in weekly swallowing therapy sessions either in person or over the phone and perform the learned swallowing exercises three times a day. In addition, these patients will document their swallowing practice on a daily basis.
11500756|NCT01349309|No Intervention|Control|Control Arm: This arm will receive the standard of care which provides swallowing evaluation and treatment once symptoms of swallowing dysfunction are experienced by the patient.
11500757|NCT01349296|Experimental|BIBF 1120 + RAD001|
11500758|NCT01349283|Experimental|HepavaxGene Stratum 1a|Subjects of mothers with chronic hepatitis B (positive for both HBsAg and hepatitis B envelope antigen - HBeAg)
11500759|NCT01349283|Active Comparator|Comparator vaccine Stratum 1a|Subjects of mothers with chronic hepatitis B (positive for both HBsAg and HBeAg)
11500760|NCT01349283|Experimental|HepavaxGene Stratum 1b|Subjects of mothers with chronic hepatitis B (positive for HBsAg only)
11500761|NCT01349283|Active Comparator|Comparator vaccine Stratum 1b|Subjects of mothers with chronic hepatitis B (positive for HBsAg only)
11500762|NCT01349283|Experimental|HepavaxGene Stratum 2|Subjects of mothers without chronic hepatitis B (negative for both HBsAg and HBeAg)
11500763|NCT01349283|Active Comparator|Comparator vaccine Stratum 2|Subjects of mothers without chronic hepatitis B (negative for both HBsAg and HBeAg)
11500764|NCT01349270|Experimental|immunoglobulin|patient who received monthly 2g/kg cure of intravenous Immunoglobulin during 6 months
11500961|NCT01347866|Experimental|Arm D: PF-05212384 + PD-0325901|
11500765|NCT01349270|Active Comparator|prednisone|patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
11500766|NCT01349231|Experimental|Ketamine|Ketamine will be given at a dose of 0.5mg/kg over 40 minutes. This dose is identical to that used in previous anti-depressant studies of ketamine.
11500767|NCT01349218|Experimental|Blood sample drawn from a vein and from a heel stick|0.5 ml will be drawn from a vein when an IV is started for the surgery or from an IV already in place. The blood will be placed into a heparinized, 1 ml syringe for venous blood gas analysis. A second blood sample, 0.3 ml will be drawn into a capillary pipette from a heel stick for capillary blood gas analysis.
11500768|NCT01349205|Experimental|Caffeine and Sodium Benzoate 10 mg/kg IV|Group 1 of randomized study.
11500769|NCT01349205|Experimental|Caffeine and Sodium Benzoate 20 mg/kg IV|Group 2 of randomized study
11500770|NCT01349205|Placebo Comparator|0.9 NS Saline|Control group of randomized study.
11500771|NCT01349192|Experimental|Treatment|Subjects are treated with two oral antibiotics, topical antibiotics, and are instructed to use environmental decontamination techniques.
11500772|NCT01349192|No Intervention|Observational|Subjects are tracked and not treated for their MRSA. If the subject reaches a protocol defined exacerbation within the first 28 days then they will be treated per choice of their primary Pulmonologist.
11500773|NCT01349153|Active Comparator|Facebook-based Self-help Comparison|Participants will receive a pedometer and twelve weekly messages with links to Internet resources that have educational materials related to exercise and cancer survivorship.
11500774|NCT01349153|Experimental|Facebook-based Messages/Website|Participants will receive a pedometer, twelve weekly messages, and be encouraged to participate in sixteen Facebook group discussions and use a website for exercise goal-setting and tracking activity.
11500775|NCT01349140|Experimental|Nerve Block|The dominant side (left or right) will be randomized to one of two treatment groups: the higher or lower concentration of the local anesthetic EXPAREL. The non-dominant contralateral side will receive the other possible treatment. The volume of each and every single-injection femoral nerve block will be 30 mL (standard for femoral nerve blocks is 30-40 mL).3 Since volume will remain constant, we will vary the dose of EXPAREL by varying concentration (volume x concentration = dose). Of note, EXPAREL may be mixed with normal saline to vary the concentration. Randomization will be based on computer-generated codes. Randomization will be in blocks of two, and stratified by sex.
11500776|NCT01349127|Active Comparator|20µg Vitamin D3|Arm will receive per day one gelatin capsule containing 20µg (800IU) of vitamin D3 (Cholecalciferol).
11500777|NCT01349127|Active Comparator|20µg Vitamin D3 + 500 mg Calcium|Arm will receive per day one gelatin capsule containing 20µg (800IU) of vitamin D3 (Cholecalciferol) and one tablet of calcium carbonate containing 500mg of calcium.
11500778|NCT01349127|Placebo Comparator|Placebo|Arm will receive one gelatin capsule containing 0µg (0IU) of vitamin D3 (Cholecalciferol).
11500779|NCT01349114|Active Comparator|aliskiren 300 mg once daily for 12 weeks|aliskiren 300 mg daily
11500780|NCT01349114|Placebo Comparator|Sugar pill/ placebo|Patients were double-blind placebo-controlled randomized to either aliskiren 300 mg once daily or sugar pill/ placebo
11500781|NCT01349101|Experimental|Myeloablative HSCT|Myeloablative Hematopoietic Stem Cell Transplantation (HSCT): Patients will receive myeloablative transplants or nonmyeloablative transplants depending on their disease type.
11500782|NCT01349101|Experimental|Reduced Intensity HSCT|Reduced Intensity Hematopoietic Stem Cell Transplantation (HSCT): Patients who have received a previous transplant, patients who have received dose limiting radiation, and patients with a DLCO <45% will receive the reduced intensity conditioning regimen.
11500783|NCT01349088|Experimental|Motesanib|Eligible patients will be enrolled to receive ixabepilone, capecitabine, plus motesanib.
11500784|NCT01349075||TheraSphere|
11500785|NCT01349062|Other|"Kallunk oxide (Immunotherapy)"|"The participants will be received a daily regimen of Kallunk oxide(Immunotherapy) ."
11500786|NCT01349049|Experimental|oral dose of 3000 mg/day PLX3397 (RP2D)|Subjects will be dosed at the recommended Phase 2 dose (RP2D)
11500787|NCT01349049|Experimental|oral dose of 800 mg/day of PLX3397|Level 0
11500788|NCT01349049|Experimental|oral dose of 1000 mg/day PLX3397|Level 1
11500789|NCT01349049|Experimental|oral dose of 1200 mg/day PLX3397|Level 2
11500790|NCT01349049|Experimental|oral dose of 1400 mg/day PLX3397|Level 3
11500791|NCT01349049|Experimental|oral dose of 2000 mg/day PLX3397|Level 4
11500792|NCT01349049|Experimental|oral dose of 3000 mg/day PLX3397|Level 5
11500793|NCT01349049|Experimental|oral dose of 4000 mg/day PLX3397|Level 6
11500794|NCT01349049|Experimental|oral dose of 5000 mg/day PLX3397|Level 7
11500795|NCT01349036|Experimental|PLX3397-Cohort 1|10 patients with recurrent glioblastoma who require reoperation will be treated with PLX3397 for 7 days prior to surgery and their tumor tissue will be evaluated for pharmacokinetic levels and pharmacodynamic effects.
11500796|NCT01349036|Experimental|PLX3397-Cohort 2|30 patients will be orally dosed with PLX3397 continuously on 28 day cycles.
11500797|NCT01349023|Experimental|Standard Energy content/Standard ED|
11500798|NCT01349023|Experimental|Standard Energy content/Reduced ED|
11500799|NCT01349023|Experimental|Reduced Energy content/Standard ED|
11500800|NCT01349023|Experimental|Reduced Energy content/Reduced ED|
11500801|NCT01349010|Placebo Comparator|Placebo|Placebo Arm: Placebo 1 tablet bid. p.o
11500802|NCT01349010|Active Comparator|Probucol|Probucol Arm: Imported Probucol 250 mg (1 tablet) bid. p.o
11500803|NCT01348997|Active Comparator|Project Onward website + 16 person social network|
11500804|NCT01348997|Active Comparator|Project Onward website + 8 person social network|
11500805|NCT01348984|Active Comparator|group 1|group 1 = transdermal fentanyl patch
11500806|NCT01348984|Placebo Comparator|group 2|placebo patch
11500807|NCT01348971|Experimental|Sodium nitrate|Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
11500808|NCT01348971|Placebo Comparator|Placebo|Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
11500809|NCT01348958|Experimental|Post-operative knee replacement|Subjects that have had a hemi knee replacement of one knee at least 8 weeks ago had the post-operative knee scanned using the orthopedic hip application and the Lunar orthopedic knee application.
11500810|NCT01348945|Experimental|Stump Preserving ACL Surgery|Patients of partial tear ACL injury fulfilling inclusion criteria received stump preserving ACL surgery, entered conventional ACL reconstruction rehabilitation program
11500811|NCT01348945|Active Comparator|ACL Reconstruction|Patients with complete tear ACL injury received ACL reconstruction entered conventional ACL rehabilitation program
11500812|NCT01348932||Asthma|The relationship between single nucleotide polymorphisms of chitinase 3-like 1 gene, YKL-40 serum levels and adult asthma
11500813|NCT01348919|Experimental|CEP-18770 in Combination With Lenalidomide and Dexamethasone|
11500814|NCT01348906|Experimental|Intermittent normoxia|Repeated brief normoxic reperfusion during cardioplegia arrest in adult valve replacement
11500815|NCT01348893|No Intervention|Physical education as usual|High school physical education curriculum established by the school, including competitive sports, aerobic and anaerobic activities, balance and coordination skills. Yoga is not a component of the curriculum.
11500816|NCT01348893|Experimental|Yoga during physical education|
11500817|NCT01348880|Experimental|Arm1|
11500818|NCT01348880|Placebo Comparator|Arm2|
11500819|NCT01348867|No Intervention|Usual Care|These 120 controls will undergo a comprehensive assessment at baseline then again at 12 months, which is similar to the intervention group. However, in between these 2 time points the 'control' patients will receive usual care and hence will not be monitored under the structured care protocol by a diabetes nurse consultant led team.
11500820|NCT01348867|Experimental|Structured Care|"120 patients will be randomised to the structured care group, and these patients will receive repeated follow-ups and contact with the structured care team in between the two comprehensive assessments at week 0 and week 52.
~Patients will be seen by Diabetes Nurse Consultant at week 0, 6, 12, 24 38 during the year. At each visit, clinical and laboratory measurements will be performed; treatment compliance and self care will be assessed and medications will be adjusted to optimise metabolic and cardiovascular risk factors control.
~Patients will be seen by the doctors in their clinic follow up at week 0, 24 and 52.
~Technical service assistance will telephone patient at week 18, 30 and 44 to reinforce patient to take medications, attend clinical follow up."
11500821|NCT01348854|Experimental|Natural Astigmatism|Use of the iFS Femtosecond Laser System to make arcuate incisions to correct naturally occurring corneal astigmatism in eyes with no prior history of ophthalmic surgery. May include eyes with cataracts.
11500822|NCT01348854|Experimental|Post Cataract with Residual Astigmatism|Use of the iFS Femtosecond Laser System to make arcuate incisions to correct residual astigmatism in eyes that have undergone cataract extraction. May also include eyes with residual astigmatism following implantation of a phakic intraocular lens implanted.
11500823|NCT01348841|No Intervention|Control Arm|Usual care is care as currently delivered to clients with chronic wounds in the community.
11500824|NCT01348841|Experimental|Intervention Arm|"Systematic referral to MDWCT and comprehensive primary care:
~Intervention consists of systematic referral to MDWCT in conjunction with comprehensive primary care.Systematic referral to, and follow up, by MDWCTs, co-ordinated by the CM, will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4."
11500825|NCT01348802|Experimental|Push + Pull|Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.
11500826|NCT01348802|Placebo Comparator|Pull|Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
11500827|NCT01348789|Experimental|Hair2Go (Mē)|Treatment with Hair2Go (Mē)device
11500828|NCT01348776|Experimental|Hair2Go (Mē)|Subjects treated with Hair2Go (Mē) Device
11500829|NCT01348763|Experimental|Truvada, Darunavir/r and Maraviroc|Participants will be taking Truvada, Darunavir/r before entering the study. On day 1 they will add maraviroc then on day 11 they will stop the Truvada
11500830|NCT01348750|Other|Group A|This group receives 6 Healing Touch & Guided Imagery treatments in addition to standard medical care.
11500831|NCT01348750|No Intervention|Group B|This group receives standard medical care but NO Healing Touch and Guided Imagery.
11500832|NCT01348737|Experimental|AZD3839|Oral Treatment
11500833|NCT01348737|Placebo Comparator|AZD3839 Placebo|Oral Treatment
11500834|NCT01348724|Experimental|[14C] NKTR-118|
11500835|NCT01348698||Adrenal Gland Neoplasm|To collect adrenal tumor tissue biopsy samples in order to study and evaluate new methods that may help identify cancerous or precancerous cells. Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor.
11500836|NCT01348672||1. ARMD Study arm|"The ARMD study arm (n=150) consists of 3 groups. The groups are organised according to established risk criteria for clinical progression (AREDS, 2003).
~Group 1A (n=50); Early stage ARMD with low risk of progression; several small drusen, or a few medium-sized drusen, in one or both eyes. One eye will be randomly selected for the study.
~Group 2A (n=50); Intermediate ARMD with high risk of progression to advanced ARMD; many medium-sized drusen, or one or more large drusen, in one or both eyes. More severely affected eyewill be selected for the study.
~Group 3A (n=50); In one eye only, either a break-down of light-sensitive cells and supporting tissue in the central retinal area (i.e. geographic atrophy), or abnormal and fragile blood vessels under the retina (i.e. choroidal neovascular membrane formation). The fellow eye is at high risk of progression to advanced ARMD. The fellow eye will be selected for the study."
11500837|NCT01348672||2. POAG study arm|"Patient groups are organised according to established risk criteria for clinical progression (EMGT, 2003).
~Group 1P (n=36); Stable, early to moderate, treated patients with POAG. Early to moderate POAG is defined as having an untreated IOP prior to treatment of >21mmHg and a repeatable visual field defect with a Mean Deviation of <12dB and/or documented but stable ONH appearance, consistent with a diagnosis of glaucoma.
~Group 2P (n=36); Early to moderate, treated patients with normal tension glaucoma (NTG). Normal Tension Glaucoma is defined using the same criteria as POAG but with an untreated IOP of <21mmHg throughout the day. This group has NTG and is thought to be at increased risk of vascular dysfunction due to loss of ONH perfusion.
~Group 3P (n=36); Early to moderate, treated patients with POAG or NTG with recurrent disc hemorrhage (indicative of progression)."
11500838|NCT01348672||3. DR study arm|"DR patient groups are organised according to established risk factors for the clinical progression of DR (increasing from Groups 1 A to 3 A, ETDRS, 1991). We will recruit 41 patients per group (Klein et al, 1984).
~Group 1D (n=41); Type 2 diabetic patients with no, or minimal, clinically visible DR. These patients are at low risk of developing sight-threatening DR.
~Group 2D (n=41); Type 2 diabetic patients with microaneurysms and / or hard exudates within 2 disc diameters of the fovea and no clinical evidence of retinal thickening. These patients are at increased risk of developing DME.
~Group 3D (n=41); Type 2 diabetic patients with the typical features of moderate-to-severe DR i.e. venous beading, intra-retinal microvascular abnormalities (IRMA) and dark blot intra-retinal haemorrhages. These patients are at a much increased risk of developing proliferative DR and/or ischemic maculopathy."
11500839|NCT01348659|Active Comparator|7.2% NaCl/hydroxyethyl starch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) (Hyperhaes®, Fresenius Kabi)
11500840|NCT01348659|Active Comparator|0.9% NaCl|250 ml of NaCl 0.9% (Natriumklorid Braun 9 mg/ml)
11500841|NCT01348646|Other|Lifestyle counseling|
11500842|NCT01348633||Sub-study 1|The Quantitative, Doppler SD-OCT Blood Flow Technology will be validated and calibrated by manipulating end-tidal blood gases using the computer-controlled gas sequencer (Slessarev et al, 2005) in 15 healthy controls. Homeostatic inner retina blood flow values and the magnitude of vascular reactivity will be compared between Doppler SD-OCT blood flow technology and the Canon Laser Blood Flowmeter, an established standard, at specific locations within the retinal vascular tree.
11500843|NCT01348633||Sub-study 2|The Quantitative, Hyper-Spectral Imaging Derived Oxygen Saturation Maps of the major retinal vessels and capillary beds will be validated and calibrated in human volunteers using our novel and exact technique that allows the precise control of the partial pressure of oxygen (PO2) to induce controlled and safe levels of hypoxia. Oxygen saturation values will be compared to measured PO2 values (i.e. recognized standard) for various levels of hypoxia and will be used to provide in-sight into the properties of the data output e.g. effective operating range, linearity of response. At the end of the study, subjects will be returned to normoxic conditions to assess reproducibility of oxygen saturation maps.
11500844|NCT01348633||Sub-study 3|Subjects with symptoms of branch and central retinal artery and vein occlusion within the past 2 months will be used to validate the Doppler SD-OCT blood flow technology and the hyperspectral imaging derived oxygen saturation maps. In cases of central retinal vein and artery occlusion, imaging values (i.e. inner retinal and choroidal blood flow, oxygen saturation values of the major retinal vessels and the capillary beds of the retina and ONH) will be compared between the affected and unaffected eyes. In cases of branch occlusion, imaging values will be compared between the affected and unaffected quadrants of the affected eye and between the affected and unaffected eyes. The difference in inner retinal and choroidal blood flow for each eye will be calculated and compared between eyes.
11500845|NCT01348633||Sub-study 4|Calibration for retinal melanin, crystalline lens absorption, macular pigment, morphological variation and pre-retinal autofluorescence in healthy subjects (n=20 per decade, range 40 to 80yrs). Established reflectometric techniques to derive absorption values and autofluorescence techniques will be used to calculate correction values for each parameter that influences the hyper-spectral retinal and ON oxygen saturation imaging data (Keilhauer and Delori, 2006; Delori et al, 2007).
11500846|NCT01348633||Sub-study 5|Establishment of a database of healthy control imaging values (n=20 per decade, range 40 to 80yrs). A database of healthy control values will be established for each technology taking into account extraneous factors such as age (range 40 to 70 years) and gender. The healthy control database will be compared to the results of each individual patient in the prospective study phase of this proposed Research Program (see Prospective Study Phase, 3, Control group). Statistical confidence limits for abnormality at each time point, and for progression overtime, will be established. Measurements will be repeated at separate visits to establish repeatability.
11500847|NCT01348620|Experimental|Single port laparoscopic device|
11500848|NCT01348620|Active Comparator|Four-port laparoscopic device|
11500849|NCT01348607|Experimental|Arm I - methylphenidate hydrochloride|Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.
11500850|NCT01348607|Experimental|Arm II -modafinil|Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.
11500851|NCT01348607|Placebo Comparator|Arm III placebo|Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.
11500852|NCT01348594||Vitamin D deficient|
11500853|NCT01348594||Vitamin D sufficient|
11500854|NCT01348581|Experimental|Marigen Wound Dressing|
11500855|NCT01348568|Experimental|Low glycemic index diet with canola oil bread|Subjects will be given whole wheat bread which includes canola oil, and advised to follow a diabetic diet using low glycemic index foods.
11500856|NCT01348568|Active Comparator|high fiber diet|Subjects will be given whole wheat bread, and advised to follow a healthy high fiber diabetic diet.
11500857|NCT01348555|Experimental|V0162|
11500858|NCT01348555|Placebo Comparator|Placebo|
11500859|NCT01348542|Active Comparator|Trazodone|
11500860|NCT01348542|Active Comparator|Cognitive Behavioral Therapy|
11500861|NCT01348529|Experimental|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
11500862|NCT01348516|Experimental|KM-023|
11500863|NCT01348516|Placebo Comparator|Placebo for KM-023|
11500864|NCT01348503|Experimental|Open Label, Single Arm|Dose escalation of lenalidomide in combination with sorafenib at standard doses in patients with advanced, unresectable hepatocellular carcinoma.
11500865|NCT01348490|Experimental|Ruxolitinib 5 mg|Participants began administration with 5 mg ruxolitinib twice daily (BID) orally. Beginning at the Week 4 visit, doses of ruxolitinib could be increased in 5 mg once a day (QD) increments every 4 weeks every 4 weeks not to exceed a dose of 25 mg BID.
11500866|NCT01348477|Experimental|Elliptical domed mesh technique|84 adult patients with primary uncomplicated inguinal hernia, treated with an open preperitoneal elliptical mesh technique
11500867|NCT01348477|Active Comparator|Lichtenstein technique|84 adult patients with primary uncomplicated inguinal hernia treated with the Lichtenstein technique (gold standard)
11500868|NCT01348464||lifestyle, wound satisfaction|single site access three site access for appendectomy
11500962|NCT01347866|Experimental|Arm C: PF-05212384 + irinotecan|
11500963|NCT01347853|Experimental|Ketorolac tromethamine|
11500869|NCT01348451|Experimental|surgery|A sequential design of five groups will be utilized to reduce risk to subjects. The first group (Group A) will include six subjects and the subsequent groups will include three subjects per group. Each group represents both different inclusion criteria and location of surgery.
11500870|NCT01348438|Other|Single arm study|
11500871|NCT01348425|Experimental|Longer Stents|
11500872|NCT01348425|Experimental|Shorter Stents|
11500873|NCT01348412|Experimental|ARM A|Hepatic artery infusion through an implanted arterial catheter of the combination of raltitrexed (3 mg/m ²) and oxaliplatin (100 mg/m ²) every 21 days.
11500874|NCT01348412|Active Comparator|ARM B|Intravenous standard chemotherapy.
11500875|NCT01348399||XIENCE PRIME stents|
11500876|NCT01348386|Experimental|KOH 10%|Treatment consists of the application of topical 10% KOH in an aqueous solution.
11500877|NCT01348386|Experimental|KOH 15%|Treatment consists of the application of topical 15% KOH in an aqueous solution
11500878|NCT01348386|Placebo Comparator|PLACEBO|100 milliliters of saline solution
11500879|NCT01348373||GENOUS EPC-coated stent|Patients treated with GENOUS EPC-coated stent
11500880|NCT01348360||NOBORI stent|
11500881|NCT01348347|Experimental|Volasertib|Patient to receive low, middle and high doses of Volasertib IV
11500882|NCT01348334|Active Comparator|Vypromesh®(Ethicon,USA)|Vypromesh®(semiabsorbable multiflament mesh;non-absorbable Polypropylene+absorbable Poliglactin)
11500883|NCT01348334|Active Comparator|Ultrapromesh®(Ethicon,USA)|Ultrapromesh®(semiabsorbable monofilament mesh;non-absorbable Polypropylene+absorbable polyglecaprone).
11500884|NCT01348334|Active Comparator|Prolene light mesh®(Johnson&Johnson,USA)|Prolene light mesh®(cpp-Condensed monofilament non absorbable polypropylene mesh)
11500885|NCT01348321|Experimental|Azithromicine plus levamisole|
11500886|NCT01348321|Experimental|Azithromicin|
11500887|NCT01348308|Active Comparator|Maraviroc|Maraviroc 300, 600 or 1200mg per day
11500888|NCT01348308|Placebo Comparator|Placebo|Placebo 300, 600 or 1200mg per day
11500889|NCT01348295||Mechanically ventilated children|All children under 16 years of age who are needing mechanical ventilation for any reason.
11500890|NCT01348282|Experimental|Lithium|Lithium group: Patients who will initiate therapy with lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
11500891|NCT01348282|Active Comparator|Rivastigmine|rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
11500892|NCT01348282|No Intervention|Control group|Patients who will not initiate treatment
11500893|NCT01348269|Active Comparator|Aclasta|
11500894|NCT01348269|Placebo Comparator|NaCl Solution|
11500895|NCT01348256|No Intervention|Observation|Observation after standard treatment
11500896|NCT01348256|Experimental|Dendritic cells vaccine|Adjuvant treatment with dendritic cells vaccine after standard treatment
11500897|NCT01348243|Experimental|Clodronate 200 mg|
11500898|NCT01348243|Active Comparator|Clodronate 100 mg|
11500899|NCT01348230||prior preterm delivery at 24-32 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
11500900|NCT01348230||prior preterm delivery at 32-34 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
11500901|NCT01348230||prior preterm delivery at 34-36 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
11500902|NCT01348217|Active Comparator|ARM A|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph nodes:
~Radiotherapy 40 Gy, in 20 fractions / 4 weeks: PTV (1cm in every direction)
~Boost 10 Gy in 5 fr: PTV = +1cm.
~Chemotherapy FOLFOX 4: 6 treatments in 3 courses concomitant to the radiotherapy (D1, D15, D29)"
11500903|NCT01348217|Experimental|ARM B|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph nodes:
~40 Gy in 20 fractions / 4 weeks, PTV (1cm in every direction)
~Boost 26 Gy in 13 fr: PTV = +1cm.
~Chemotherapy: FOLFOX 4: 6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43)."
11500904|NCT01348204|Experimental|quercetin|health food supplement
11500905|NCT01348191||Elective caesarean section|"Population: ten pregnant women, scheduled for elective caesarean section with a term pregnancy ( > 37 weeks).
~Inclusion criteria
~Elective caesarean section
~Term pregnancy > 37 weeks
~Age > 18 years
~Exclusion criteria
~Previous caesarean scar
~Gestational age < 37 weeks
~Maternal temperature > 37.8 degrees Celsius
~Meconium stained liquor
~Foetal distress
~Maternal diabetes
~Seropositivity
~Use of thyroid medication
~Maternal thyroid disease
~Age < 18 years"
11500906|NCT01348178||developmental dysplasia of the hip, PAO|All patients who underwent periacetabular osteotomy from 1999-2007 at the University Hospital of Aarhus
11500907|NCT01348165|Experimental|BI 137882 Dose 1|Powder for oral solution
11500908|NCT01348165|Experimental|BI 137882 Dose 2|Powder for oral solution
11500909|NCT01348165|Experimental|BI 137882 Dose 3|Powder for oral solution
11500910|NCT01348165|Experimental|BI 137882 Dose 4|Powder for oral solution
11500911|NCT01348165|Experimental|BI 137882 Dose 5|Powder for oral solution
11500912|NCT01348165|Experimental|BI 137882 Dose 6|Powder for oral solution
11500913|NCT01348165|Experimental|BI 137882 Dose 7|Powder for oral solution
11500914|NCT01348165|Experimental|BI 137882 Dose 8|Powder for oral solution
11500915|NCT01348165|Experimental|BI 137882 Dose 9|Powder for oral solution
11500916|NCT01348165|Placebo Comparator|Placebo|Powder for oral solution
11500917|NCT01348152|Placebo Comparator|Placebo|Placebo TID
11500918|NCT01348152|Experimental|DAIKENCHUTO (TU-100) 15 g/day|TU-100 5g TID
11500919|NCT01348139|Experimental|1|AZD3199 800 µg inhaled via single inhaler device (SID), single dose
11500920|NCT01348139|Experimental|2|AZD3199 880 µg inhaled via SID, single dose
11500921|NCT01348139|Experimental|3|AZD3199 1400 µg inhaled via SID, single dose
11500922|NCT01348139|Experimental|4|AZD3199 300 µg inhaled via Turbuhaler inhaler, single dose
11500923|NCT01348139|Experimental|5|AZD3199 1200 µg inhaled via Turbuhaler inhaler, single dose
11500924|NCT01348139|Placebo Comparator|6|Placebo inhaled via Turbuhaler inhaler and SID, single dose
11500929|NCT01348100|Experimental|Iloperidone 50 mg crystalline formulation - Phase A|Participants received a crystalline formulation of iloperidone 50 mg in a depot intramuscular (IM) injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.
11500930|NCT01348100|Experimental|Iloperidone 125 mg crystalline formulation - Phase A|Participants received a crystalline formulation of iloperidone 125 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.
11500931|NCT01348100|Experimental|Iloperidone 250 mg crystalline formulation - Phase B|Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
11500932|NCT01348100|Experimental|Iloperidone 250 mg microparticle formulation - Phase B|Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
11500933|NCT01348100|Experimental|Iloperidone 250 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
11500934|NCT01348100|Experimental|Iloperidone 500 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 500 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
11500935|NCT01348100|Experimental|Iloperidone 625 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
11500936|NCT01348087|Experimental|AFQ056 100 mg (Bid)|All patients initiated treatment with AFQ056 at a starting dose of 25 milligram (mg) twice daily. The dose was titrated from 25mg bid to 50mg bid, 75mg bid and 100mg bid at weekly intervals. Dose adjustments (up- and down titrations) were permitted as needed to manage any tolerability issues and to ensure that patients reach their highest tolerated dose not to exceed 100mg bid.
11500937|NCT01348074|Experimental|Double dose|Re-initiation with warfarin at twice the usual maintenance dose the first 2 days, then maintenance dose.
11500938|NCT01348074|No Intervention|Usual maintenance dose|Usual maintenance dose from Day 1, i.e. no postoperative loading dose.
11500939|NCT01348061||Elderly Healthy Control (EHV)|No clinically significant deviation from healthy in medical history, physical examination, ECGs, MRI and clinical laboratory determinations for their respective age group.
11500940|NCT01348061||Progressive Supranuclear Palsy (PSP)|A diagnosis of possible or probable PSP according to clinical criteria of National Institute of Neurologic Diseases and Stroke - the Society for PSP plus a MRI at screening to exclude other potential causes of parkinsonism as well as a mild-to-moderate stage of disease severity according to a score of 1 to 3 in Golbe Staging System.
11500941|NCT01348061||Alzheimer's Disease (AD)|A diagnosis of probable AD Based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association and The Diagnostic and Statistical Manual of Mental Disorders as determined by a mini-mental state examination (MMSE) score of 16 to 26, inclusive.
11500942|NCT01348048|Experimental|Specialised palliative care (SPC) group|Patients continue with their standard treatment (typically they receive treatment in one or more hospitals departments and from their GP). In addition, they are offered a consultation in the SPC out-patient clinic (or at home if the patient cannot attend the hospital) as soon as possible and no more than one week after randomization. If possible, each patient will have at least two contacts to the SPC in the trial period.
11500943|NCT01348048|No Intervention|Standard care group|Patients continue with their standard treatment. They are instructed to contact either their GP or their hospital department if they feel that additional treatment or care is needed.
11500944|NCT01348035||Water Load Group|Water load group: 2.5 ~ 3 L water intake daily for 12 months (50ml/Kg body weight/day). When large amount water intake is not sustainable, patients can reduce the amount of water intake to the levels as much as large he or she can sustain.
11500945|NCT01348035||Non-Water Loaded Group|Non-water load group: The patients are free to access water intake, as they like.
11500946|NCT01348022||Xience V stent|unprotected Left Main Coronary Artery stenting treated with Xience V stent
11500947|NCT01348009|Experimental|Tesetaxel-capecitabine-cisplatin|
11500948|NCT01347996|Experimental|histamine dihydrochloride and IL-2|histamine and IL-2 subcutaneous injections
11500949|NCT01347970|Experimental|Arm I (beta-adrenergic/alpha-1 adrenergic blocker)|Patients receive low-dose carvedilol PO QD or BID for 24 months.
11500950|NCT01347970|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD or BID for 24 months.
11500951|NCT01347957|Experimental|Nitric Oxide (NO) Gel|
11500952|NCT01347957|Placebo Comparator|Placebo Gel|
11500953|NCT01347931|Experimental|NIOV System|Noninvasive ventilation and oxygen delivered via NIOV System oxygen using an open nasal interface. Connected to standard portable oxygen cylinder
11500954|NCT01347931|Active Comparator|Standard Oxygen Therapy|Supplemental oxygen using standard oxygen cannula connected to a portable oxygen cylinder.
11500955|NCT01347918||control|Healthy controls
11500956|NCT01347918||IBS|Patients that fulfil the Rome III criteria for irritable bowel syndrome (IBS)
11500957|NCT01347905||Obese women and men|Obese women and men undergoing restrictive bariatric surgery. Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
11500958|NCT01347892||DeNovo NT Subject|Subjects who have received or who are scheduled to receive a DeNovo NT Graft for repair of a cartilage lesion in the ankle.
11500959|NCT01347879|Experimental|Visonac cream with PDT|active treatment with light dose of 37 Joule/cm2
11500965|NCT01347840||All Subjects|This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.
11500966|NCT01347827||on pump|Coronary artery bypass grafting (CABG)with with cardiopulmonary bypass
11500967|NCT01347827||off pump|off-pump CABG surgery
11500968|NCT01347801|Placebo Comparator|2C - 1|TNF and OGTT and saline
11500969|NCT01347801|Active Comparator|2C - 2|TNF and OGTT and GLP-1
11500970|NCT01347801|Placebo Comparator|2C - 3|TNF and IVGTT and saline
11500971|NCT01347801|Active Comparator|2C - 4|TNF and IVGTT and GLP-1
11500972|NCT01347801|Placebo Comparator|2A-1|Saline infusion and OGTT
11500973|NCT01347801|Placebo Comparator|2A-2|Saline and IVGTT
11500974|NCT01347801|Active Comparator|2A-3|TNF and OGTT
11500975|NCT01347801|Active Comparator|2A-4|TNF and IVGTT
11500976|NCT01347801|Experimental|1C|OGTT and corresponding IVGTT
11500977|NCT01347788|Experimental|Cohort 1|Dose level 0: cabozantinib 40 mg daily
11500978|NCT01347788|Experimental|Cohort 2|Dose level -1: cabozantinib 20 mg daily
11500979|NCT01347788|Experimental|Expansion cohort|Dose level 0: cabozantinib 40 mg daily
11500980|NCT01347775|Sham Comparator|Sham inspiratory muscle training|Patients in the sham group used the threshold trainer (Threshold at IMT device URES HS730, Respironics, New Jersey, Inc, Cedar Grove, NJ, USA), with the diaphragm removed.
11500981|NCT01347775|Experimental|Inspiratory muscle training|Inspiratory muscle training will be by a threshold trainer (Threshold at IMT device URES HS730, Respironics, New Jersey, Inc, Cedar Grove, NJ, USA), a commercially available spring-loaded inspiratory muscle training device. It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
11500982|NCT01347762|Experimental|Nabilone|nabilone titrated to 2 mg daily
11500983|NCT01347762|Placebo Comparator|Placebo|Placebo
11500984|NCT01347749|Experimental|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
11500985|NCT01347749|Active Comparator|Present Centered Therapy for PTSD|This is a more standard from of group psychotherapy (talk therapy) which focusses on current symptoms and stressors
11500986|NCT01347736|Experimental|Treatment (pain therapy)|Patients undergo scrambler therapy for approximately 30 minutes. Treatment continues for 10 days in the absence of pain progression or unacceptable toxicity.
11500987|NCT01347723||Supportive care (pain therapy)|Patients undergo scrambler therapy for 30 minutes daily for up to 10 consecutive days. Treatment continues in the absence of unacceptable toxicity.
11500988|NCT01347710|Experimental|Flurpiridaz F18|Open-label study of a single dose of Flurpiridaz F18 injection for PET MPI compared to a single dose of 99mTc sestamibi or tetrofosmin for SPECT MPI in patients with suspected or known coronary artery disease referred for coronary catheterization
11500989|NCT01347697|Experimental|Porcine collagen implant|Reconstruction with an acellular porcine collagen implant.
11500990|NCT01347697|Active Comparator|Gluteus maximus flap|Reconstruction with a gluteus maximus myocutaneous flap.
11500991|NCT01347684|Active Comparator|Standard care using current drugs|Standard care with drug intervention
11500992|NCT01347684|Experimental|Behavioral therapy, splint therapy and physical therapy|Using rehabilitation for comparing use of drug
11500993|NCT01347671|Active Comparator|25 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 25 µg GRT6005 per day
11500994|NCT01347671|Active Comparator|75 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 75 µg GRT6005 per day
11500995|NCT01347671|Active Comparator|200 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 200 µg GRT6005 per day
11500996|NCT01347671|Placebo Comparator|Matching Placebo|Participants allocated to this treatment arm will receive a dose of matched placebo once a day.
11500997|NCT01347658|Experimental|Etravirine + echinacea|etravirine + root of Echinacea purpurea
11500998|NCT01347645|Active Comparator|1|Experimental Irinotecan plus E7820
11500999|NCT01347645|Active Comparator|2|FOLFIRI alone
11501000|NCT01347632|Other|BV pre treatment|Open Label Study. All participants had BV and took metronidazole 500 mg po BID for 7 days.
11501001|NCT01347619|Active Comparator|Arm 1. Toolkit only with Web Access|NHs in this arm will receive the toolkit only and web access to the materials.
11501002|NCT01347619|Active Comparator|Arm 2.Toolkit, Audit/Feedback, Education|NHs in the second arm will receive the toolkit, web access, periodic audit and feedback reports of antipsychotic prescribing to NH leadership, and faxed educational messages adapted from the AHRQ atypical antipsychotic CERSG to prescribers.
11501003|NCT01347619|Active Comparator|Arm 3. All above plus academic detailing|NHs in the third arm will receive the previous items plus face-to-face academic detailing.
11501004|NCT01347593|Experimental|ceftizoxime (cefizox) injection|ceftizoxime (cefizox) as single dose of 1 g at the interval of 30-60 minutes before the incision
11501005|NCT01347580|Experimental|Ticagrelor|Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
11501006|NCT01347580|Experimental|Placebo|Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
11501007|NCT01347567|Experimental|BNP + Health Management|Subjects will provide information from home regarding weight,signs and symptoms, and will perform BNP self testing. This information including BNP results will be used by the investigator as an aid to treatment decisions. BNP results are blinded to subjects.
11501008|NCT01347567|Active Comparator|Health Management|Subjects will provide information from home regarding weight, signs and symptoms, and will perform BNP self testing . BNP results will be blinded to the investigator and subject; weight, signs and symptoms will be used by the investigator as an aid to treatment decisions
11501009|NCT01347567|Placebo Comparator|Control|Subject will provide information from home regarding weight, signs and symptoms and will perform BNP self testing. All these data will be blinded to the investigator. BNP results will be blinded to the subject.
11501010|NCT01347554|Active Comparator|Xience V stent group|Xience V (Everolimus eluting stent) insertion in patients with acute myocardial infarction
11501011|NCT01347554|Active Comparator|Endeavor resolute group|Endeavor resolute (Zotarolimus eluting stent) insertion in patients with acute myocardial infarction
11501012|NCT01347541|Experimental|Stepped care|Combination of behavioral therapy and drug therapy
11501013|NCT01347541|Active Comparator|Standard care provided to injured trauma survivors|
11501014|NCT01347528|Experimental|TELEmonitoring intervention|
11501015|NCT01347528|No Intervention|Usual care|
11501016|NCT01347515|Placebo Comparator|FOO250|FOO250 ppm, the standard virgin olive oil
11501017|NCT01347515|Active Comparator|FOO500|Olive oil enriched with its own broad-spectrum phenolic compounds; FOO500 ppm
11501018|NCT01347515|Active Comparator|FOO750|Olive oil enriched with its own broad-spectra phenolic compounds; FOO750 ppm
11501019|NCT01347502||HCPs with smartphone|healthcare providers in MICU who have smart cellular phones
11501020|NCT01347502||HCP with non-smart phones|healthcare providers in MICU who have non-smart cellular phones
11501021|NCT01347476||patients older than 70 years|
11501022|NCT01347476||patients 70 years or younger|
11501023|NCT01347463||Traditional|
11501024|NCT01347450|Experimental|Cocoa, Placebo|
11501025|NCT01347437|No Intervention|Condition|In the comparison condition, participants will receive MEMS only.
11501026|NCT01347437|Experimental|Positive STEPS|"Participants will receive one on one Positive STEPS counseling sessions (~1 hour sessions per week for 5 weeks).
~Participants will receive motivational reminders to take medications sent via text message to their cell phones.
~Participants will receive the Medication Event Monitoring Systems (MEMS) pill cap monitoring device to measure antiretroviral medication adherence."
11501027|NCT01347424|Experimental|Test group|
11501028|NCT01347424|Active Comparator|control group|
11501029|NCT01347411|No Intervention|Control|Usual treatment
11501030|NCT01347411|Experimental|CPAP|Treatment with CPAP
11501031|NCT01347398|Experimental|MicroMESAM|Sleep study made by MicroMESAM system
11501032|NCT01347398|Active Comparator|PSG|Sleep study made by PSG (polysomnography)
11501033|NCT01347385|Experimental|Barbed suture|
11501034|NCT01347385|Active Comparator|Traditional suture material|
11501035|NCT01347359|Experimental|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, either face-to-face or by telephone.
11501036|NCT01347359|Active Comparator|Control - Standard of care|"Standard of care is at the discretion of the treating rheumatologist."
11501037|NCT01347333|Other|liver metastases|Oligometastases (1-3) with aggregate tumor diameter < 6 cm Metastases from neuroendocrine tumors with functional endocrine syndromes
11501038|NCT01347333|Other|Primary Liver Tumors|Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma
11501039|NCT01347320|No Intervention|No preoperative MRI|control arm of the study
11501040|NCT01347320|Active Comparator|MRI group|preoperative MRI
11501041|NCT01347307|Other|SBRT for Benign Extradural Spine Tumors|Benign extradural spine tumors such as chordomas, meningiomas, schwannomas, neurofibromas, paragangliomas, and arteriovenous malformations (AVMs).
11501042|NCT01347307|Other|SBRT for Vertebral/Paraspinal Metastases|Vertebral and/or paraspinal metastases, with or without prior surgery and/or fractionated radiotherapy
11501043|NCT01347294|Experimental|Bleomycin + Fibrovein|
11501044|NCT01347294|Active Comparator|Bleomycin|
11501045|NCT01347294|Experimental|Natrium Tetradecyl Sulphate (Fibrovein )|
11501046|NCT01347281|Experimental|[18F]HX4 PET|Injection of [18F]HX4
11501047|NCT01347268|Experimental|withdrawing GnRH agonists|
11501048|NCT01347268|Experimental|GnRH antagonist administration|
11501049|NCT01347255|Experimental|LEO 90100 cutaneous spray ointment|LEO 90100 cutaneous spray, ointment, is a new product containing calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate).
11501050|NCT01347255|Active Comparator|LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone|Vehicle cutaneous spray, ointment, with betamethasone 0.5 mg/g (as dipropionate)
11501051|NCT01347255|Placebo Comparator|LEO 90100 Cutaneous Spray, Ointment, Vehicle|LEO 90100 vehicle served as a negative control for the two cutaneous spray ointments with active ingredients.
11501052|NCT01347255|Active Comparator|Daivobet® Ointment|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
11501053|NCT01347203|Experimental|Treatment A|DPOC-4088 prolonged release tablet 100 mg (Formulation A= 16 hr release formulation)
11501054|NCT01347203|Experimental|Treatment B|DPOC-4088 prolonged release tablet 200 mg (Formulation A= 16 hr release formulation)
11501055|NCT01347203|Experimental|Treatment C|DPOC-4088 prolonged release tablet 100 mg (Formulation B= 20 hr release formulation)
11501056|NCT01347203|Experimental|Treatment D|DPOC-4088 prolonged release tablet 200 mg (Formulation B= 20 hr release formulation)
11501057|NCT01347190|Experimental|Liquid API|
11501058|NCT01347190|Placebo Comparator|Placebo|
11501059|NCT01347177|Experimental|Zirconia-based adhesive bridges|Patients in this group will be treated with the employment of zirconia-based adhesive bridges to replace the missing tooth/teeth.
11501060|NCT01347177|Experimental|Metal-based adhesive bridges|Patients in this group will be treated with the employment of metal-based adhesive bridges.
11501061|NCT01347164|Experimental|Life coaching sessions|6 2-hour counseling session with trained therapist/counselor. The sessions deal with coping and stress reduction as well as sexual health.
11501062|NCT01347164|Active Comparator|HIV counseling session|One 60-minute counseling session, based on standard HIV counseling content.
11501063|NCT01347151|Experimental|Glide scope|
11501064|NCT01347151|Experimental|Pentax airway scope|
11501065|NCT01347138|Experimental|case management|case management regulary
11501066|NCT01347138|No Intervention|Control|usual care
11501067|NCT01347125|Experimental|ImCardia|Aortic Stenosis patients candidates for Aortic Valve Replacement (AVR) implanted with the ImCardia device
11501068|NCT01347125|No Intervention|AVR control group|Aortic stenosis patients candidates for aortic valve replacement
11501069|NCT01347112|Active Comparator|Varenicline|varenicline 1.0 mg twice daily for 12 weeks
11501070|NCT01347112|Placebo Comparator|Sugar Pil|Varenicline look alike sugar pill twice daily for 12 weeks
11501071|NCT01347099|Experimental|Internet CBT|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks.
11501072|NCT01347099|Placebo Comparator|Support therapy|10 weeks. Therapist support contact through e-mail.
11501073|NCT01347086|Experimental|BI 207127 NA (low dose)|Single dose of BI 207127 NA
11501074|NCT01347086|Placebo Comparator|Matching placebo (low dose)|Single dose of matching placebo
11501075|NCT01347086|Experimental|BI 207127 NA (medium dose)|Single dose of BI 207127 NA
11501076|NCT01347086|Placebo Comparator|Matching placebo (medium dose)|Single dose of matching placebo
11501077|NCT01347086|Experimental|BI 207127 NA (high dose)|Single dose of BI 207127 NA
11501078|NCT01347086|Placebo Comparator|Matching placebo (high dose)|Single dose of matching placebo
11501079|NCT01347073|Experimental|HPN-100|Switch over from sodium phenylbutyrate to open label HPN-100 oral liquid over 10 days then open label, long term treatment for 12 months
11501080|NCT01347060||Medicare-eligible subjects with asthma|Asthma subjects at least 65 years of age enrolled in a large Medicare managed care health plan.
11501081|NCT01347034|Active Comparator|External Beam Radiation Therapy (RT)|Arm A - University of Florida - External Beam Radiation Therapy (RT) - As outlined in Intervention Description
11501082|NCT01347034|Experimental|External Beam RT + DC Injection|Arm B - Moffitt Cancer Center - External Beam RT + Autologous Dendritic Cells (DC) Injection - As outlined in Intervention Description
11501083|NCT01347021|Active Comparator|sacrospinous, pelvic prolapse.|Women with pelvic prolapse grade III/IV were randomly allocated to the sacrospinous colpopexy (25 women) or high uterosacral (26 women)
11501084|NCT01347021|Active Comparator|uterosacral , pelvic prolapse.|Women with pelvic prolapse grade III/IV were randomly allocated to the sacrospinous colpopexy (25 women) or high uterosacral (26 women)
11501085|NCT01347008|Active Comparator|Sildenafil citrate|Oral Sildenafil citrate, 50mg, b.i.d.
11501086|NCT01347008|Placebo Comparator|Sugar pill|Placebo pill (identical to Sildenafil citrate 50mg), b.i.d.
11501087|NCT01346995|Experimental|Experimental Knee Pain|Experimental knee pain induced by injections of 1 ml hypertonic saline in to the infrapatellar fat pad
11501088|NCT01346995|Active Comparator|Control|non-painful injections of isotonic saline into the infrapatellar fatpad.
11501089|NCT01346982|Experimental|Silimarine|darunavir + ritonavir + silimarine
11501090|NCT01346969|Active Comparator|Group 1|
11501091|NCT01346969|Placebo Comparator|Group 2|
11501092|NCT01346969|Placebo Comparator|Group 3|
11501093|NCT01346969|Placebo Comparator|Group 4|
11501094|NCT01346943|Experimental|AAA Stent Graft System|Altura Medical AAA Stent Graft System
11501095|NCT01346930|Experimental|Macitentan|Macitentan tablet, 10 mg, once daily
11501096|NCT01346917|Experimental|Lidocaine|
11501097|NCT01346917|Placebo Comparator|Placebo|
11501098|NCT01346891||Hyponatremia Group (Cases)|Patients over 21 years old, with confirmed antecedent of thiazide-induced hyponatremia who required hospitalization with a serum sodium concentration lower than 125 meq/L.
11501099|NCT01346891||Good Thiazide Tolerance (Controls)|Patients over 21 years old, who have consumed thiazide diuretics for more than 2 years, with a serum sodium concentration persistently over 135 meq/L.
11501100|NCT01346865|Experimental|cilostazol|cilostazol 100mg
11501101|NCT01346865|Placebo Comparator|dual therapy group|Placebo
11501102|NCT01346852||Pediatric participants|Pediatric participants (age 4 to 17) with a diagnosis of asthma
11501103|NCT01346852||Adult participants|Adult participants (age 18 and older) with a diagnosis of asthma
11501104|NCT01346839|Experimental|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
11501105|NCT01346839|No Intervention|Usual Care Control|"The usual care at MEDVAMC consists of providers using an advanced EHR and its notification system (the View Alert system) that immediately alerts providers about clinically significant events. The system relies primarily on computerized notification (alerts) displayed prominently through a View Alert window that is displayed in the EHR every time a provider signs on or switches between patient records. The system does not require providers to read alerts, and providers do have an option of ignoring the View Alert window to bypass it. At SWHS there is a navigation program for patients who have received a cancer diagnosis by tissue biopsy. However, currently there is no routine tracking of patients if they do not show for their scheduled appointments and tests at SWHS."
11501106|NCT01346826|Active Comparator|2 hours-infusion group|Number of patients: 57 (Standard 2 hours-infusion group)
11501107|NCT01346826|Experimental|1 hour-infusion group|Number of patients: 59 (1 hour-infusion group)
11501108|NCT01346826|Experimental|30 minutes-infusion group|Number of patients: 59 (30 minutes-infusion group)
11501109|NCT01346800|Experimental|Prasugrel 10mg po|
11501110|NCT01346800|Experimental|Prasugrel 10mg po + ritonavir 100mg po|
11501111|NCT01346787|Experimental|Carfilzomib Cyclophosphamide Dexamethasone|The treatment period includes administration of Carfilzomib Cyclophosphamide Dexamethasone for 9 courses. In order to assess the toxicity of treatment, patients will attend the study centre visits at each scheduled carfilzomib administration. The response will be assessed after each cycle.
11501112|NCT01346774|Experimental|Cranberry powder capsules|"TheraCran® cranberry: based upon proanthocyanidin content, the four cranberry capsules are equivalent to two 8-ounce servings of cranberry juice.
~Participants were directed to take two capsules by mouth twice each day (once in the morning and once in the evening) starting at time of discharge for 4-6 weeks, or until their return for their post-operative doctor's visit. Participants were instructed to drink an 8 oz glass of water while taking the capsule with or without food."
11501113|NCT01346774|Placebo Comparator|Placebo capsules|Placebo: participants were directed to take two capsules by mouth twice each day (once in the morning and once in the evening) starting at time of discharge for 4-6 weeks, or until their return for their post-operative doctor's visit. Participants were instructed to drink an 8 oz glass of water while taking the capsule with or without food.
11501114|NCT01346761|Experimental|Telephone genetic counseling|Participants randomly assigned to telephone counseling are mailed packets that included a sealed envelope containing an educational brochure about hereditary breast and ovarian cancer (HBOC) genetic counseling with visual aids. At the time of their session, participants open their envelope and counselors use the visual aids to explain breast-ovarian cancer genetics and administer BRCA1/BRCA2 genetic counseling. Women receiving in-person counseling are given these same materials during their session at the community clinic. In-person and telephone counseling are delivered by the same five board-certified genetic counselors.
11501115|NCT01346761|Active Comparator|In-person genetic counseling|In-person BRCA1/BRCA2 genetic counseling is delivered by board-certified genetic counselors using a guide-line-concordant semistructured protocol that allows for personalization of counseling and is similar to that used by others. All sessions are audiotaped for treatment fidelity assessments. In-person and telephone counseling are delivered by the same five board-certified genetic counselors.
11501116|NCT01346748|Experimental|Statin|
11501117|NCT01346735||ICU infections|Infections acquired during the ICU stay
11501118|NCT01346722|Other|Group A|zinc biofortified rice-based diet (Diet-ZBfR) will be compared with conventional rice-based diet (Diet- CR)
11501119|NCT01346722|Other|Group B|zinc biofortified rice-based diet (Diet-ZBfR) will be compared with a rice-based diet plus zinc fortificant (Diet-CR+Z)
11501120|NCT01346709||In-patient Adult Non-obstetricSurgical|"Consecutive patients admitted to participating centres undergoing surgery Non-obstetric in-hospital surgical procedure, elective or emergent, under general anaesthesia (alone or in combination with regional/neuraxial anaesthesia), neuraxial anaesthesia or plexus block (with and without sedation).
~All eligible patients undergoing surgery within the seven day study period will be recruited wherever possible."
11501121|NCT01346696|Experimental|OsseoSpeed™ TX implants|OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.
11501122|NCT01346683|Experimental|OsseoSpeed TX|OsseoSpeed TX implants of lengths 8-17 mm
11501123|NCT01346670|Experimental|LipoCol and Mevacor|To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor Tablet after single oral administration in healthy subjects using a 2x2 crossover design
11501124|NCT01346657|Experimental|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects
11501125|NCT01346644|Active Comparator|No probiotics|Infant formula with no probiotics
11501126|NCT01346644|Experimental|Probiotic|Infant formula supplemented with probiotic
11501127|NCT01346631|Experimental|paleolithic diet|Subjects will adhere to a paleolithic diet for the duration of three months
11501128|NCT01346618||children ages 4-17 years|Participants are children and youth ages 4-17 years (inclusive) who performed or will perform a X-ray of the left hand for bone age assessment as part of any clinical work up, within 2 months of enrollment in this study.
11501129|NCT01346605||CCTA patients|Prior stress SPECT with intermediate to high likelihood to be referred to the cardiac catheterization laboratory for an invasive coronary angiogram or patients presenting with chest pain and clinical indication of Coronary CT Angiography and an initial calcium score above 300
11501130|NCT01346592|Active Comparator|aTIV (6 to <72 months)|Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29
11501131|NCT01346592|Active Comparator|Comparator TIV (6 to <72 months)|Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29
11501132|NCT01346592|Active Comparator|TIV (6 to <72 months)|Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29
11501133|NCT01346553|Experimental|ESVV treatment|using ESVV device
11501134|NCT01346540|Experimental|BIBF 1120|VEGF inhibitor
11501135|NCT01346540|Placebo Comparator|Placebo|BIBF 1120 placebo
11501136|NCT01346527||Type 2 diabetes|"Women will be diagnosed with type 2 DM (pre-gestational, White classification B or C class). Since the majority of women with B or C class DM are on insulin therapy in our clinic, we will recruit only women on insulin therapy (i.e. no oral diabetes medications).
~HbA1C ≤ 8 for greater than 3 months32, 33.
~All women will have confirmed singleton pregnancies.
~Receive care at the Women's Health Clinic at Barnes Jewish Hospital.
~Pre-pregnancy BMI is anticipated to be >30 (i.e. obese) from the data regarding the patient population of our clinic. Women with pre-pregnancy BMI between 23-40 will be included."
11501137|NCT01346527||Healthy, obese pregnant controls|"No diagnosis of type 1 or 2 diabetes or previous gestational DM.
~Women with pre-pregnancy BMI between 30-45: control participants will be BMI matched to women with DM.
~A normal routine, standard of care 1 hour 50 gram gestational diabetes screen.
~Receive care at the Women's Health Clinic at Barnes Jewish Hospital.
~Patients will have a singleton pregnancy with no fetal abnormalities (as determined by routine standard of care ultrasonography)."
11501138|NCT01346527||Healthy, Lean Controls|No diagnosis of type 1 or 2 diabetes or previous gestational DM. 2) Women with pre-pregnancy BMI between 21-25.9 3) A normal routine, standard of care 1 hour 50 gram gestational diabetes screen.
11501139|NCT01346514|Experimental|Arm 1: Addiction/Housing Case Management(AHCM)|The AHCM condition provided individual case management, delivered at the VA and in the community, designed to assist homeless Veterans with SUD issues who may be unable to take advantage of housing opportunities available in the VA due to difficulty navigating multiple services and maintaining stability with respect to SUD and co-occurring mental health conditions.
11501140|NCT01346514|Active Comparator|Arm 2: Housing Support Group(HSG)|The HSG condition involved a weekly drop-in housing support group.
11501141|NCT01346501||Adalimumab|"Participants with Rheumatoid Arthritis (RA) who continued adalimumab treatment after completion of study M06-859, participated in the observational period of studies P12-069 and P12-707.
~Other name for adalimumab is Humira."
11501142|NCT01346501||Non-adalimumab|Patients who discontinued adalimumab treatment after completion of the study M06-859.
11501185|NCT01346176|Experimental|Positive default|Patients in this arm will receive AD forms where specific life-extending interventions will be provided unless patients specifically opt-out from such selections
11501143|NCT01346488||Adalimumab|Participants with RA treated with adalimumab who are either engaged in paid work for more than 35 hours per week (paid workers) or those who are either engaged in paid work for less than 35 hours per week or who perform basic activities of daily life other than paid work (home workers).
11501144|NCT01346475|Active Comparator|valacyclovir|
11501145|NCT01346475|Experimental|high dose valacyclovir|
11501146|NCT01346462|Experimental|PaCT|The Patient-Centered Transition Arm
11501147|NCT01346462|No Intervention|Control|Control group patients will receive routine care from the admitting hospital, including routine patient management, and discharge planning.
11501148|NCT01346449|Active Comparator|Visual cue absent|
11501149|NCT01346449|Experimental|Calorie information present|
11501150|NCT01346449|Active Comparator|Calorie information absent|
11501151|NCT01346449|Experimental|Visual cue present|
11501152|NCT01346436|Active Comparator|Robotic|Use of daVinci surgical system (Intuitive Surgical Inc, Sunnyvale, CA) for the treatment of complex pelvic floor dysfunction
11501153|NCT01346436|Active Comparator|Laparoscopy|Use of standard laparoscopy for the treatment of complex pelvic floor dysfunction
11501154|NCT01346423|Experimental|Intervention group|Treatment team with a physician, a physiotherapist, a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The patient meets at the outpatient clinic three times; at baseline, after 2 weeks and after 3 months. One year after baseline the patient has a telephone-follow-up. At baseline, the patient and the team works out a rehabilitation plan and in this process a new visual, educational tool is central.
11501155|NCT01346423|Active Comparator|Controll group|The brief intervention is a standardized intervention based on the studies by Indahl and Hagen. Therapist treatment manuals will be written for the intervention. The essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. Unless symptoms and clinical findings indicate some serious disease, the patients will be informed about the good prognosis, and the importance of staying active to avoid development of muscle dysfunction.
11501156|NCT01346410|Experimental|A|Stereotactic Radiation to Pancreas
11501157|NCT01346397||cyclosporine group|cyclosporine group - after alemtuzumab induction cyclosporine was administered
11501158|NCT01346397||tacrolimus group|tacrolimus group - after alemtuzumab induction tacrolimus was administered
11501159|NCT01346384||intracuff pressure N2O|measured intracuff pressure of LT with N2o during operative period
11501160|NCT01346371|Placebo Comparator|Refresh Tears® eye drops|Must add drops twice a day every day during trial enrollment.
11501161|NCT01346371|Experimental|Bepreve® 1.5% solution|Must add drops twice a day every day while enrolled in trial.
11501162|NCT01346358|Experimental|IMC-CS4 Weight Based Dosing|Participants receiving IMC-CS4 intravenously (weight based dosing)
11501163|NCT01346358|Experimental|IMC-CS4 Non-Weight Based Dosing|Participants receiving IMC-CS4 intravenously (non-weight based dosing)
11501164|NCT01346332||Anesthetization|
11501165|NCT01346319|Active Comparator|Testosterone undecanoate|
11501166|NCT01346319|Placebo Comparator|Placebo|
11501167|NCT01346306|Experimental|DCS 1|
11501168|NCT01346306|Experimental|DCS 2|
11501169|NCT01346293|Experimental|Study Group 1|Participants will receive concomitantly a dose of DTap-IPV, a dose of M-M-R®II, and a dose of VARIVAX® vaccine on Day 0
11501170|NCT01346293|Experimental|Study Group 2|Participants will receive concomitantly a dose of DAPTACEL®, a dose of IPOL®, a dose of M-M-R®II, and a dose of VARIVAX® vaccines on Day 0
11501171|NCT01346293|Experimental|Study Group 3|Participants will receive concomitantly a dose of DTap-IPV with or without a dose of M-M-R®II and a dose of VARIVAX® on Day 0
11501172|NCT01346293|Experimental|Study Group 4|Participants will receive concomitantly a dose of DAPTACEL® vaccine, a dose of IPOL® vaccine with or without a dose of M-M-R®II and a dose of VARIVAX® vaccines on Day 0
11501173|NCT01346267|Experimental|Arm I- Real Acupressure bands|Patients wear Sea-Band acupressure wristbands on each wrist beginning approximately 30 minutes prior to the first cisplatin-containing chemotherapy course and continually for 24 hours after the last chemotherapy dose (acute phase), and for a maximum of 7 days or until the next chemotherapy course starts (delayed phase). Patients are allowed to take bands off intermittently (up to 4 times a day, for no more than 15 minutes each time) to relieve pressure or to bathe. Patients also receive standard of care anti-emetic prophylaxis comprising granisetron, ondansetron, or dexamethasone during chemotherapy according to institutional or physician preference.
11501174|NCT01346267|Sham Comparator|Arm II- Placebo Acupressure Bands|Patients wear placebo wristbands on each wrist and receive standard of care anti-emetic prophylaxis during chemotherapy as patients in arm I.
11501175|NCT01346254|Experimental|Vildagliptin|16 patients randomized into this arm will receive vildagliptin (Galvus) 50mg orally once daily
11501176|NCT01346254|Experimental|Pioglitazone|16 patients randomized into this arm will receive pioglitazone (Actos) 30mg orally once daily
11501177|NCT01346254|Placebo Comparator|Placebo|16 patients randomized into this arm will receive placebo medication orally once daily
11501178|NCT01346215|Experimental|Actparin® - Laboratorio Bergamo|
11501179|NCT01346215|Active Comparator|Heparin sodium - APP Pharmaceuticals|
11501180|NCT01346202||chronic pain|260 consecutive patients with verified chronic pain syndromes
11501181|NCT01346189|Active Comparator|Physician Incentives|"(with adherence feedback)
~Quarterly payments to physician combined based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL with daily patient statin adherence information made available."
11501182|NCT01346189|Active Comparator|Patient Incentives|"(with adherence feedback)
~Quarterly payments to patient based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL."
11501183|NCT01346189|Active Comparator|Physician and Patient Combined Incentives|"(with adherence feedback)
~Quarterly payments shared evenly by physician and patient based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL. Physicians will receive daily information about patients' statin adherence."
11501184|NCT01346189|No Intervention|Usual Care|
11501186|NCT01346176|Experimental|Negative default|Patients in this arm will receive AD forms where specific life-extending interventions will not be provided unless patients specifically opt-into such selections
11501187|NCT01346176|Experimental|Forced Choice|Patients in this arm will receive AD forms in which they must actively choose whether to receive each intervention.
11501188|NCT01346163|Active Comparator|PF-03654746|H3 receptor antagonist currently being developed for the treatment of cognitive impairment associated with schizophrenia (CIAS) as well as with Alzheimer's disease.
11501189|NCT01346163|Placebo Comparator|Placebo|
11501190|NCT01346150||Stratum A -Typical SCID|Typical Severe Combined Immunodeficiency (SCID), Adenosine Deaminase-Deficient ADA SCID, and X-linked SCID (XSCID) who received a transplant
11501191|NCT01346150||Stratum B - Atypical SCID|Leaky SCID, Omenn Syndrome, and Reticular Dysgenesis who received a transplant
11501192|NCT01346150||Stratum C - SCID w/Non-HCT Treatments|SCID who received Polyethylene Glycol -Adenosine Deaminase Enzyme Replacement Therapy (PEG-ADA ERT) or gene therapy
11501193|NCT01346137|Experimental|meloxicam|15 mg versus 30 mg per day P.O for 15 days, during 3 menstrual cycles
11501194|NCT01346124|Experimental|IMPT|High dose IMPT
11501195|NCT01346111||generation cohort|Included 5 hospitals from Buenos Aires, Argentina
11501196|NCT01346098|Experimental|GROUP B|At the time of surgery the surgeon will directly assess pancreatic consistency and the pancreatic duct size. In the presence of a soft pancreas and a small duct (diameter <3 mm), the patient will be randomly assigned to receive either a pancreaticoduodenectomy with pancreatic anastomosis (group A) or a total pancreatectomy with IAT (group B).
11501197|NCT01346098|Active Comparator|GROUP A|
11501198|NCT01346085|Experimental|CNI-free single-group|
11501199|NCT01346072|Other|Tolvaptan|Single arm study
11501200|NCT01346059|Placebo Comparator|Saline|The saline arm will receive normal saline through the catheter as a placebo.
11501201|NCT01346059|Experimental|Vancomycin|The vancomycin arm will receive vancomycin solution through the catheter.
11501202|NCT01346046||Those with Type 2 diabetes|270 subjects with Type 2 diabetes
11501203|NCT01346046||Non diabetic|30 healthy subjects
11501204|NCT01346033||Those with Type 2 diabetes|All subjects have been diagnosed with type 2 diabetes.
11501205|NCT01346020||CLL|
11501206|NCT01346007|Active Comparator|patients|Children with idiopathic nephrotic syndrome in remission treated with low-dose prednisolone and/or mycophenolate mofetil and/or cyclosporine A
11501207|NCT01346007|Active Comparator|controls|
11501208|NCT01345994|Experimental|Acupuncture - local|acupuncture on forearm only
11501209|NCT01345994|Experimental|acupuncture - distal|acupuncture on both arm and leg
11501210|NCT01345981|Experimental|lidocaine 20 mg|intravenous lidocaine
11501211|NCT01345981|Experimental|lidocaine 40 mg|intravenous lidocaine 40 mg
11501212|NCT01345981|Placebo Comparator|normal saline|2 ml
11501213|NCT01345968|Placebo Comparator|NaCl 0.9%|
11501214|NCT01345968|Experimental|Ferinject|
11501215|NCT01345942|Experimental|A food|
11501216|NCT01345942|Experimental|B without food|
11501217|NCT01345929|Experimental|CXA-201 as treatment for cUTI|CXA-201 IV infusion (1500mg q8) for 7 days
11501218|NCT01345929|Active Comparator|Levofloxacin as treatment for cUTI|Levofloxacin IV infusion (750mg qd) for 7 days
11501219|NCT01345916|Experimental|CHF 1535 100/6 NEXT Dry Powder Inhaler®|CHF1535 100/6 NEXT DPI® 1 inhalation bis in day (b.i.d) (daily dose BDP 200/FF 12 µg)
11501220|NCT01345916|Active Comparator|CHF1535 100/6 pMDI|CHF1535 100/6 pressurisedMeterDoseInhaler 1 inhalation b.i.d (total daily dose BDP 200/FF 12 µg)
11501221|NCT01345916|Active Comparator|beclomethasone dipropionate DPI|beclomethasone dipropionate 100 µg DPI, 1 inhalation b.i.d (total daily dose BDP 200 µg)
11501222|NCT01345903|Experimental|Treatment (surgery)|Patients undergo robotic-assisted surgery using the da Vinci robot
11501223|NCT01345890|Experimental|electrical stimulation|stroke patients
11501224|NCT01345877|Other|gender|
11501225|NCT01345864|Other|Cohort A|Parallel design with 5 unique treatment groups Donepezil tablets and matching placebo tablets may be overencapsulated as needed.
11501226|NCT01345851|Experimental|Treatment (dose-escalation of RT)|Patients undergo image-guided hypofractionated RT over 35 minutes 5 days a week for 2 weeks followed by 5 fractions of hypofractionated RT boost. Patients also receive standard carboplatin and paclitaxel for 3 weeks.
11501227|NCT01345838||Dysplasia|Patients with developmental dysplasia of the hip undergoing PAO
11501228|NCT01345825|Experimental|resistance training|
11501229|NCT01345812|Active Comparator|urine-derived FSH|Follicle stimulating hormone
11501230|NCT01345812|Active Comparator|recombinant FSH|Follicle stimulation hormone
11501231|NCT01345799|Experimental|TRK-170 Low Dose|
11501232|NCT01345799|Experimental|TRK-170 Middle Dose|
11501233|NCT01345799|Experimental|TRK-170 High Dose|
11501234|NCT01345799|Placebo Comparator|Placebo|
11501235|NCT01345786|Experimental|Commercial NOMAC-E2, Part 1|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Participants in Part 1 were from Site 1."
11501236|NCT01345786|Active Comparator|Phase 3 NOMAC-E2, Part 1|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program (Batch A), either on the first day of Period 2 and Period 4 (for participants randomized to Sequence 1) or on the first day of Period 1 and Period 3 (for participants randomized to Sequence 2). Participants in Part 1 were from Site 1."
11501237|NCT01345786|Experimental|Commercial NOMAC-E2, Part 2|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Participants in Part 2 were from Site 2."
11501295|NCT01345344|Active Comparator|Disease Education|8 individual weekly visits with a psychologist for fibromyalgia education (this is an active comparator arm, matched for provider contact).
11501238|NCT01345786|Active Comparator|Phase 3 NOMAC-E2, Part 2|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program (Batch B), either on the first day of Period 2 and Period 4 (for participants randomized to Sequence 1) or on the first day of Period 1 and Period 3 (for participants randomized to Sequence 2). Participants in Part 2 were from Site 2."
11501239|NCT01345773||Patients receiving gastric cancer surgery|
11501240|NCT01345760||Basal Cell Carcinoma|
11501241|NCT01345760||Squamous Cell Carcinoma|
11501242|NCT01345760||Actinic Keratosis|
11501243|NCT01345760||healthy non-lesional skin|
11501244|NCT01345747|Experimental|laryngeal tube|laryngeal tube suction has suction port
11501245|NCT01345747|Experimental|endotracheal tube|
11501246|NCT01345734||Liraglutide|
11501247|NCT01345721|Experimental|MenACWY (2 primary + 1 booster dose)|Subjects who had previously received two primary doses of MenACWY-CRM vaccine (at 6-8 months and 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
11501248|NCT01345721|Experimental|MenACWY (1 primary + 1 booster dose)|Subjects who had previously received one primary dose of MenACWY-CRM vaccine (at 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
11501249|NCT01345721|Experimental|MenC (1 primary dose)+MenACWY (1 booster dose)|Subjects who had previously received one primary dose of the comparator MenC vaccine (at 12 months of age) in parent study, were administered one booster dose MenACWY-CRM vaccine in this extension study.
11501250|NCT01345695||Treatment|Data collected on persons living in the catchment area for a WHP telemedicine center
11501251|NCT01345695||Control|Data collected on persons living in the catchment area where there is not a WHP telemedicine center
11501252|NCT01345682|Experimental|Afatinib (BIBW 2992)|Once daily
11501253|NCT01345682|Active Comparator|Methotrexate|Weekly
11501254|NCT01345669|Experimental|Afatinib (BIBW 2992)|Once daily
11501255|NCT01345669|Placebo Comparator|Placebo|Once daily
11501256|NCT01345656|Experimental|Arm 1|
11501257|NCT01345656|Experimental|Arm 2|
11501258|NCT01345656|Experimental|Arm 3|
11501259|NCT01345656|Experimental|Arm 4|
11501260|NCT01345656|Placebo Comparator|Arm 5|
11501261|NCT01345656|Active Comparator|Arm 6|
11501262|NCT01345643|Experimental|Hemoglobin level based on WCPT Score|According to WCPTS, the patient's hemoglobin level will be maintained not less than 7,8,9,or 10g/dL. Determination of whether a patient need red blood cells transfusion is based on WCPT Score.
11501263|NCT01345643|Active Comparator|Hemoglobin level 100g/L|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
11501264|NCT01345630|Experimental|Maraviroc|Maraviroc 150 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for emtricitabine/tenofovir once daily.
11501265|NCT01345630|Active Comparator|Emtricitabine/tenofovir|Emtricitabine/tenofovir 200/300 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for maraviroc once daily.
11501266|NCT01345617||cystic fibrosis patients|cystic fibrosis patients
11501267|NCT01345617||non-cystic fibrosis patients|non-cystic fibrosis patients
11501268|NCT01345604|Placebo Comparator|Saline|
11501269|NCT01345604|Active Comparator|Ropivicaine|
11501270|NCT01345591|Experimental|Fat Grafting|Twenty (20) subjects who have had severe facial trauma, 18 years of age and older enrolled to clinical trial will receive Fat grafting intervention procedure
11501271|NCT01345578|Experimental|Hepatocyte Transplantation|See Below
11501272|NCT01345565|Experimental|Hepatocyte Transplantation|See Below
11501273|NCT01345552|Other|SBRT|
11501274|NCT01345539|Other|SBRT|
11501275|NCT01345526|Experimental|Metastatic colorectal cancer, Doxycycline, Vitamin K1 Cream|
11501276|NCT01345526|Placebo Comparator|Metastatic colorectal cancer, Doxycycline, Cream|
11501277|NCT01345513||Solid Tumor Cancer|
11501278|NCT01345500|Experimental|Higher Carbohydrate/Lower Fat Diet|
11501279|NCT01345500|Experimental|Lower Carbohydrate/Higher Fat Diet|
11501280|NCT01345500|Active Comparator|Individualized Counseling|
11501281|NCT01345487|Other|Low Vegetable Protein|Meal with 10 E% protein from fava beans/split peas
11501282|NCT01345487|Experimental|High Vegetable protein|Meal with 20 E% protein from fava beans/split peas
11501283|NCT01345487|Experimental|High Animal Protein|Meal with 20 E% protein from pork/beef
11501284|NCT01345461||Healthy adult volunteers|Twelve healthy adult volunteers (6 men, 6 women)
11501285|NCT01345435|Experimental|Telemonitoring group|"A Smart Care PC, blood glucose meter and body composition analyzer will be provided
~transmitting the results to the Smart Care Server via Smart Care PC
~At Smart care Center,care manager will provide remote blood glucose monitoring and individual diabetes case management"
11501286|NCT01345435|Experimental|Telemonitoring & Telemedicine group|"A Smart Care PC, blood glucose meter and body composition analyzer will be provided
~transmitting the results to the Smart Care Server via Smart Care PC
~At Smart care Center,care manager will provide remote blood glucose monitoring and individual diabetes case management
~taking telemedicine through video telephone instead of visiting hospital"
11501287|NCT01345435|Other|Control group|"Blood glucose meter and body composition analyzer will be provided
~Self-monitoring Blood Glucose (SMBG)"
11501288|NCT01345422|Experimental|Wii Balance Board|Wii Balance Board Training
11501289|NCT01345396|Experimental|Education|
11501290|NCT01345396|No Intervention|No education|
11501291|NCT01345383||Current smokers|
11501292|NCT01345370||Stupp protocole|All subjects enrolled must be treated according to the Stupp schedule : surgical resection followed by Temozolomide (TMZ) chemotherapy with concomitant radiotherapy, and then 6 cycles of adjuvant Temzolomide.
11501293|NCT01345357|Experimental|CEP-9722 in combination with Gemcitabine and Cisplatin|Study drugs will be administered in cycles of 21 days for up to 6 cycles. CEP-9722 treatment will be initiated at cycle 2. After cycle 3, patients may discontinue gemcitabine and/or cisplatin for reasons of tolerability, at the discretion of the investigator.
11501294|NCT01345344|Experimental|Cognitive-Behavioral Therapy|8 individual weekly visits with a psychologist for pain-related CBT.
11501296|NCT01345344|No Intervention|Healthy Controls|No intervention.
11501297|NCT01345331|Experimental|Real Stimulation|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain.
11501298|NCT01345331|Sham Comparator|Sham|The sham treatment will use the same equipment as the real treatment, but the participant will not receive any real stimulation to the ear.
11501299|NCT01345318|Experimental|Open-label Treatment|
11501300|NCT01345292|Experimental|12027-027|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
11501301|NCT01345292|Active Comparator|310158077046|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
11501302|NCT01345292|Placebo Comparator|037000003212|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
11501303|NCT01345279||cisplatin|
11501304|NCT01345279||cisplatin + topotecan|
11501305|NCT01345279||cisplatin + paclitaxel|
11501306|NCT01345266|Other|Inhalation Profiling|All subjects have Inhaltion profiling, there are no other arms.
11501307|NCT01345253|Experimental|Belimumab|10mg/kg
11501308|NCT01345253|Placebo Comparator|Placebo|placebo
11501309|NCT01345240|Experimental|RTS,S Regimen A Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
11501310|NCT01345240|Experimental|RTS,S Regimen A Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. In addition, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
11501311|NCT01345240|Experimental|RTS,S Regimen A Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
11501312|NCT01345240|Experimental|RTS,S Regimen B Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
11501313|NCT01345240|Experimental|RTS,S Regimen B Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
11501325|NCT01345175|Placebo Comparator|Pts receiving placebo|This group will receive a placebo bid for 4 weeks. At 1 - 24 months after completion of the phase III portion of the trial, patients will be contacted by phone and given the option of receiving metronidazole in a followup, single arm study in which all patients receive the antibiotic. Patients who wish to participate will be mailed a drug prescription for a 3 week course of metronidazole 500mgs tid as well as the BFI forms and stool diary. Pretreatment and post treatment BFI scores will be collected and analyzed for change in bowel function as was done in the initial Phase III study.
11501428|NCT01344421||hip dysplasia|Patients with hip dysplasia
11501314|NCT01345240|Experimental|RTS,S Regimen B Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
11501315|NCT01345240|Experimental|RTS,S Regimen C Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
11501316|NCT01345240|Experimental|RTS,S Regimen C Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
11501317|NCT01345240|Experimental|RTS,S Regimen C Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
11501318|NCT01345240|Active Comparator|Engerix B Regimen A Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the Engerix-B Vaccination Regimen A. This regimen included 3 doses of Engerix B™ co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™ at Weeks 0, 4 and 8, and 2 doses of Rotarix™, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. Engerix B™ was administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
11501319|NCT01345240|Active Comparator|Engerix B Regimen B Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the Engerix-B Vaccination Regimen B. This regimen included 3 doses of Engerix B™ co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™ vaccine, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. Engerix B™ was administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
11501320|NCT01345227|Experimental|Intra BM islet infusion|single intra BM islet infusion at the level of the iliac crest will be performed in patients having contraindications for intraportal infusion
11501321|NCT01345214|Experimental|E|
11501322|NCT01345188|Active Comparator|Ranolazine|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
11501323|NCT01345188|Placebo Comparator|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
11501324|NCT01345175|Experimental|Pts receiving Rifaximin|This group will receive rifaximin 400mg bid for 4 weeks. At 1 - 24 months after completion of the phase III portion of the trial, patients will be contacted by phone and given the option of receiving metronidazole in a followup, single arm study in which all patients receive the antibiotic. Patients who wish to participate will be mailed a drug prescription for a 3 week course of metronidazole 500mgs tid as well as the BFI forms and stool diary. Pretreatment and post treatment BFI scores will be collected and analyzed for change in bowel function as was done in the initial Phase III study.
11501326|NCT01345162|Other|ketorolac|Patients will be given intraoperative analgesia with Ketorolac and tramadol before the the end of surgery, then Ketorolac postoperative 10mg 1cp x 3/die, from the day of surgery for 4 days after surgery.
11501762|NCT01342380||Pioglitazone|Participants who received pioglitazone
11501327|NCT01345162|Other|acetaminophene+tramadol|Patients will be given intraoperative analgesia with Ketorolac and tramadol before the the end of surgery, then postoperative Patrol (acetaminophene 325mg+tramadol 37,5mg) 1cp x 3/die for 4 days after surgery.
11501328|NCT01345149|Experimental|Diet + Exercise|"Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.
~Exercise: Individual counselling"
11501329|NCT01345149|Experimental|Exercise|Exercise: Individual counselling
11501330|NCT01345149|No Intervention|Control|Standard treatment without intervention.
11501331|NCT01345136|Experimental|RAD001 Treatment|All subjects will be given RAD001 for 1 year (12 months).
11501332|NCT01345123|Experimental|Decision Aid with Health Coaching|
11501333|NCT01345123|Experimental|Decision Aid only|
11501334|NCT01345123|No Intervention|No condition specific support|
11501335|NCT01345097|Experimental|Younger Group|
11501336|NCT01345097|Experimental|Elderly Group|
11501337|NCT01345084|Experimental|Radiation therapy, cisplatin and nimotuzumab|"Nimotuzumab - (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes. Pre-drugs are optional, at the investigator's discretion)- 200 mg, IV, weekly doses during the radiation therapy until completing 6 months.
~Radiation therapy- 66 -70 Gy, external,fractions of 2 Gy per day, 5 days a week
~Cisplatin - 75 mg/m2, IV, Doses every 3 weeks (a total of three doses)"
11501338|NCT01345084|Active Comparator|Radiation therapy and cisplatin|"Radiation therapy: 66- 70 Gy, fractions of 2 Gy per day, 5 days a week
~Cisplatin:75 mg/m2, IV, doses every 3 weeks (a total of three doses)"
11501339|NCT01345071||RA patients|RA patients with active disease or current use of anti-TNF. Treatment is according to treat to target principles.
11501340|NCT01345058|Experimental|Lacosamide + Low-Dose Levetiracetam|Participants received lacosamide 50 mg twice a day for one week followed by 100 mg twice daily added to low dose levetiracetam ≤1500 mg/day (polytherapy) for 6 months in patients with breakthrough seizures on low-dose levetiracetam.
11501341|NCT01345058|Other|Control Group (High-Dose Levetiracetam)|Historical chart review of patients whose dose of levetiracetam was raised to high dose levetiracetam >1500 mg/day (monotherapy) after a breakthrough seizure. No intervention was administered in the study.
11501342|NCT01345045|Experimental|ABT-639|ABT-639 twice daily for 6 weeks
11501343|NCT01345045|Active Comparator|pregabalin|pregabalin starting dose twice daily for week one then titrated up to maintenance dose twice daily for duration of the study
11501344|NCT01345045|Placebo Comparator|Placebo|Placebo twice daily for 6 weeks
11501345|NCT01345032|Experimental|Home visits|Nutritional follow-up after discharge, conducted as nutritional counselling performed as in-person counselling in the participants homes
11501346|NCT01345032|Experimental|Telephone consultation|Nutritional follow-up after discharge, conducted as nutritional counselling performed as telephone consultation
11501347|NCT01345032|No Intervention|Control|No follow-up after discharge
11501348|NCT01345019|Active Comparator|Zoledronic acid|Zoledronic acid 4 mg intravenously plus placebo to denosumab subcutaniously (SC) once every 4 weeks (Q4W) in the double-blind treatment period (Since denosumab was determined to have a positive benefit:risk profile in the primary analysis of the study, per protocol, participants who were still undergoing Q4W scheduled assessments were offered open-label denosumab 120 mg SC Q4W for up to 2 years)
11501349|NCT01345019|Experimental|Denosumab|Denosumab 120 mg subcutaniously (SC) plus placebo to zoledronic acid intravenously once every 4 weeks (Q4W) in the double-blind treatment period (Since denosumab was determined to have a positive benefit:risk profile in the primary analysis of the study, per protocol, participants who were still undergoing Q4W scheduled assessments were offered open-label denosumab 120 mg SC Q4W for up to 2 years)
11501350|NCT01345006|Experimental|MA09-hRPE|Patients will undergo subretinal injection of MA09-hRPE
11501351|NCT01344993|Experimental|MA09-hRPE|"Experimental: Subretinal injection of MA09-hRPE
~Cohort 1 50,000 cells
~Cohort 2 100,000 cells
~Cohort 2a Better Vision 100,000 cells
~Cohort 3 150,000 cells
~Cohort 4 200,000 cells"
11501352|NCT01344980|Experimental|Stainless steel MGH|Patients in this study arm will have their flexor tendon laceration repaired using stainless steel suture (size 3-0) in an MGH repair technique. They will then undergo aggressive early active range of motion rehabilitation post-operatively.
11501353|NCT01344980|Active Comparator|Polypropylene DOLL|Patients in this study arm will have their flexor tendon laceration repaired using polypropylene suture (size 3-0) in a double-locking loop repair technique. They will then undergo aggressive early active range of motion rehabilitation post-operatively.
11501354|NCT01344967|Experimental|Zometa, Bone Suppression, Active Ingredient|
11501355|NCT01344954|Experimental|25mg TB-402|
11501356|NCT01344954|Experimental|50mg TB-402|
11501357|NCT01344954|Active Comparator|10mg QD Rivaroxaban|
11501358|NCT01344941||Group 1|The first group will comprise individuals who have received a St. Jude HIV-1 vaccine and who have exhibited sustained immune responses
11501359|NCT01344941||Group 2|Groups 2 will be HIV-1-infected. The first visit of individuals in groups 2 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.
11501360|NCT01344941||Group 3|Groups 3 will be HIV-1-uninfected. The first visit of individuals in groups 3 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.
11501361|NCT01344928|Experimental|HIT training|
11501362|NCT01344928|Active Comparator|Aerobic exercise training|
11501363|NCT01344915|Active Comparator|Knee brace|
11501364|NCT01344915|Active Comparator|Locked knee brace|
11501365|NCT01344902|Experimental|Hexaminolevulinate|
11501366|NCT01344889||Cohort|
11501367|NCT01344876|Experimental|OPB-51602|OPB-51602 1, 2, 4 and 6 mg/day oral once daily (QD) in a 4 week cycle
11501368|NCT01344863|Experimental|1|
11501369|NCT01344863|Active Comparator|2|
11501423|NCT01344486|Active Comparator|carbon dioxide|induction pneumoperitoneum with carbon dioxide 100%
11501424|NCT01344473|Experimental|Casein phosphopeptide in the form of TM|Experimental group will be given TM to use daily for 12 weeks
11501425|NCT01344473|No Intervention|No intervention|Standard oral care
11501426|NCT01344460|Experimental|Arm 1|
11501427|NCT01344447|Experimental|Arm 1|
11501370|NCT01344837||Observational|Archived serum and tumor tissue samples are analyzed for synuclein-γ (SNCG) expression and other biomarker expression, including TP53 (p53), HER-2, folate receptor alpha (FOLR1), estrogen receptor (ER), progesterone receptor (PR), phosphatase and tensin homolog (PTEN), phosphorylated AKT (pAKT), pERK, and p16 by microarray analysis, IHC assays, and western blot. Results are then compared with patients' existing clinical, demographic, and pathology data, including history of breast cancer (metachronous) or breast cancer diagnosed at the same time as the endometrial cancer (synchronous).
11501371|NCT01344824|Other|Single Arm Trial|Bevacizumab, Carboplatin, and Pemetrexed disodium, with option for second line erlotinib hydrochloride
11501372|NCT01344811|Experimental|Telemonitoring group|"A Smartphone, body composition analyzer and Pedometer will be provided
~transmitting the results to the Smart Care Server via Smartphone
~At Smart care Center,care manager will provide remote body weight and activity monitoring and individual obesity case management"
11501373|NCT01344811|Other|Control group|"A weighing scale and Pedometer will be provided
~recording in a self diary of body weight and the number of steps"
11501374|NCT01344798|Experimental|Dose level 1|AAV1-gamma-sarcoglycan vector dose level: 3x10e9 vg/100µl
11501375|NCT01344798|Experimental|Dose level 2|AAV1-gamma-sarcoglycan vector dose level: 1.5x10e10 vg/100µl
11501376|NCT01344798|Experimental|Dose level 3|AAV1-gamma-sarcoglycan vector dose level: 4.5x10e10 vg/300µl
11501377|NCT01344785||Patients with a intertrochanteric fracture|Patients with a intertrochanteric fracture, n=100
11501378|NCT01344772|Active Comparator|Internal fixation|Displaced femoral neck fracture treated with internal fixation using two parallel cannulated screws.
11501379|NCT01344772|Active Comparator|Total hip replacement|Displaced femoral neck fracture treated with total hip replacement through a posterior approach.
11501380|NCT01344759|Active Comparator|Propofol|
11501381|NCT01344759|Active Comparator|Dexmedetomidine|
11501382|NCT01344746||Snoring group|"Subjects with snoring and AHI ≥ 20 episodes/h (severe SDB).
~Snorers with AHI < 20 episodes/h and ≥ 5 episodes/h (moderate SDB)
~Snorers with AHI < 5 episodes/h and ≥ 1 episodes/h (mild SDB)"
11501383|NCT01344746||Non-snoring group|"When testing serum and urinal samples, healthy children without snoring will be chosen as controls.
~When testing lymphoid tissue samples, patients with recurrent infectious tonsillitis (at least five tonsillar infections in less than 6 months) but without snoring will be selected as controls before surgery and recruited to the study, because adenotonsillar tissue can't be obtained from normal children for obvious ethical reasons."
11501384|NCT01344733||MDD|Patients with treatment resistant major depressive disorder will be evaluated in order to assess the presence of hypomanic symptoms as cause of resistance.
11501385|NCT01344720|Active Comparator|etoricoxib|etoricoxib up to 60mg/day as monotherapy
11501386|NCT01344720|Active Comparator|etoricoxib plus controlled-release oxycodone|combination treatment of etoricoxib (30 mg/day) plus controlled-release oxycodone (10 mg/day)
11501387|NCT01344694||patient with liver fat|30 patients with liver fat
11501388|NCT01344694||excess of visceral fat|50 pts. with excess of visceral fat
11501389|NCT01344694||control|30 control subjects
11501390|NCT01344681|Experimental|Arm A|Micafungin sodium
11501391|NCT01344681|Active Comparator|Arm B|Itraconazole
11501392|NCT01344668|Other|Standard Diabetes Education|Standard Diabetes Education
11501393|NCT01344668|Other|Enhanced Diabetes Education|Enhanced Diabetes Education
11501394|NCT01344655|Experimental|Formoterol 12 μg pMDI (Atimos®)|
11501395|NCT01344655|Active Comparator|Salmeterol 25 µg pMDI HFA (Serevent™)|
11501396|NCT01344655|Placebo Comparator|Matched Placebo|
11501397|NCT01344629|Experimental|Telmisartan80mg/Amlodipin5mg FDC|single-dose, four-period replicated crossover design
11501398|NCT01344629|Experimental|Telmisartan80mgtab + Amlodipin5mg tab|single-dose, four-period replicated crossover design
11501399|NCT01344616|No Intervention|usual clinical care|usual clinical care with no intervention
11501400|NCT01344616|Experimental|lifestyle counseling|computer-based clinical support to patient
11501401|NCT01344603||epidural|
11501402|NCT01344603||standard|
11501403|NCT01344590|Active Comparator|saline lock maintenance|Standard saline lock maintenance
11501404|NCT01344590|Experimental|ethanol maintenance|Instillation of 70% pharmaceutical grade ethanol solution into the central line in a volume calculated to fill the catheter lumen and hub.
11501405|NCT01344577||Group1#|bone graft material used: Apatos Cortical® (porcine cortical bone 600-1000 µm)
11501406|NCT01344577||Group2#|bone graft material used: MP3® (porcine cortic-cancellous collagenated bone mix 600-1000 µm)
11501407|NCT01344577||Group3#|control group
11501408|NCT01344564|Other|ADT|All subjects receive ADT, degarelix acetate for 3 months followed by one 3 month leuprolide depot.
11501409|NCT01344551|Active Comparator|High Flavanol|High Flavanol cocoa drink containing 495mg cocoa
11501410|NCT01344551|Placebo Comparator|Low Flavanol|Low Flavanol cocoa drink (23mg)
11501411|NCT01344538|Experimental|Ginger Root Extract|
11501412|NCT01344538|Placebo Comparator|Lactose Capsule|
11501413|NCT01344525|No Intervention|Control group|Nutritional counselings every 6 months, no further intervention
11501414|NCT01344525|Experimental|"low-calorie-diet (LCD)-based lifestyle intervention"|12 months multidisciplinary weight loss program including three months low-calorie formula diet (800 kcal) (OPTIFAST®52 program)
11501415|NCT01344525|Experimental|Laparoscopic gastric sleeve intervention|
11501416|NCT01344525|Experimental|Conventional bariatric surgery|Gastric Banding and Gastric Bypass
11501417|NCT01344512|Experimental|Patients treated with Ceftazidime|
11501418|NCT01344512|Experimental|Patients treated with Ciprofloxacin|
11501419|NCT01344512|Experimental|Patients treated with Voriconazole|
11501420|NCT01344499|Experimental|Adept|1000ml Adept will be left in the abdomen and measured over time
11501421|NCT01344499|Active Comparator|Ringer-lactate|1000 ml of Ringer lactate left in the abdomen and measured over time
11501422|NCT01344486|Experimental|Full conditioing|Intervention by alteration of laparoscopic gas with addition of oxygen and nitrous oxide, regulation of humidification and temperature (32°C), injection of 5mg Dexamethasone and application of Hyalobarrier Gel Endo (Nordic Pharma) at the surgical wound
11501429|NCT01344421||Healthy people|Enrolled from the patients acquaintance circle
11501430|NCT01344408|Experimental|Computer-training|The computer-training program, Move it to improve it was installed in the participants homes using an internet-connected computer with a web camera connected to a cloud-based specifically adapted interactive training program.
11501431|NCT01344408|Experimental|Printed instructions|A training program delivered as printed instructions
11501432|NCT01344395|Experimental|RK-group|
11501433|NCT01344395|Active Comparator|K-group|
11501434|NCT01344382|Experimental|CRAFT|All parents will be scheduled for 12 individual Community Reinforcement and Family Training for parents (CRAFT-P) training sessions within 120 days and allowed to use up to 6 additional emergency sessions at any time up to the 12-mo follow-up. The first session will last 90 min; the remaining sessions will be 50 - 60 min in duration. Emergency sessions typically last 30 - 60 min and are used to assist the parent with crisis situations during the treatment period (e.g., adolescent violence, arrest) or for booster sessions after.
11501435|NCT01344382|Active Comparator|Al-Anon Facilitation|All parents will be scheduled for 12 individual Alanon/Naranon Facilitation Training (ANF) sessions within 120 days and allowed to use up to 6 additional emergency sessions at any time up to the 12-mo follow-up. The first session will last 90 min; the remaining sessions will be 50 - 60 min in duration. Emergency sessions typically last 30 - 60 min and are used to assist the parent with crisis situations during the treatment period (e.g., adolescent violence, arrest) or for booster sessions after.
11501436|NCT01344369|Experimental|Investigational Test Product|Norethindrone/Ethinyl Estradiol 0.4 mg/0.035 mg Chewable Tablets (Teva)
11501437|NCT01344369|Active Comparator|Reference Listed Drug|FEMCON® Fe 0.4 mg/0.035 mg Chewable tablets (Warner Chilcott)
11501438|NCT01344356|Other|Benign Tumors|Benign head and neck tumors will be treated with SBRT
11501439|NCT01344356|Other|Malignant Tumors|Malignant Head and Neck Tumors will be treated with SBRT.
11501440|NCT01344343|Experimental|Accelerated hip fracture surgery|Arrival in the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair
11501441|NCT01344343|No Intervention|Standard care|Surgical hip fracture repair according to the standard timing
11501442|NCT01344330||Screening colonoscopy patients|Men and women age 50 to 75 scheduled for screening colonoscopy
11501443|NCT01344317||Caffeine group|Premature infants below 30 weeks of gestation who receive Caffeine treatment
11501444|NCT01344317||Caffeine and Doxapram group|Premature infants below 30 weeks of gestation who receive Caffeine and Doxapram treatment
11501445|NCT01344317||Group with no treatment|Premature infants below 30 weeks of gestation with no stimulating treatment
11501446|NCT01344304|No Intervention|Standard therapy|The patients are treated with 5HT3-receptor antagonist + dexamethasone during the first course, then treated with aprepitant / fosaprepitant + 5HT3-receptor antagonist + dexamethasone
11501447|NCT01344304|Experimental|Aprepitant / Fosaprepitant therapy|The patients are treated with aprepitant / fosaprepitant + 5HT3-receptor antagonist + dexamethasone during first and second courses.
11501448|NCT01344278|Experimental|Lifestyle Counseling|
11501449|NCT01344278|No Intervention|Control|
11501450|NCT01344265||consecutive patients|there is only one group in our study
11501451|NCT01344252|Experimental|Topical|
11501452|NCT01344252|Active Comparator|subtenon|
11501453|NCT01344239|Experimental|Limb RIPC|The limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
11501454|NCT01344239|No Intervention|convention|Adult patients undergoing elective open abdominal aortic aneurysm repair received no treatment after induction of anaesthesia
11501455|NCT01344213|Active Comparator|Pregabalin|Oral single-dose of pregabalin (150 mg) and 1 capsule of placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
11501456|NCT01344213|Active Comparator|Celecoxib|Oral single-dose of celecoxib (400 mg) and 1 capsule of placebo (C) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
11501457|NCT01344213|Active Comparator|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
11501458|NCT01344213|Placebo Comparator|Placebo|Oral single-dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
11501459|NCT01344200|Active Comparator|Dose Timing Cohort|"1. All patients and CSF Dose timing Cohort (Oral celecoxib 10 mg/kg pharmacokinetic profile)
~Mean Total and unbound plasma concentration ug/L at approximately the following time intervals (mins): 30, 60, 90, 120, 180, 300, 900
~Mean CSF concentration ug/L at approximately the following time intervals (mins): 60, 120, 180, 300 and 900
~Ratio CSF/unbound plasma concentration at approximately the following time intervals (mins): 60, 120, 180, 300 and 900
~This information will be used to determine plasma and CSF mean +/- SD values for Maximum concentration (Cmax [ug/L]); Area under concentration curve from time 0 to infinity (AUC (0-∞) [ug/L∙h]); Apparent oral volume of distribution (Vd/F [L/kg]); Apparent oral clearance (CL/F [L∙h-1∙kg-1] and terminal elimination half -life (t1/2 [h]). A median value will be determined for time to maximum concentration (tmax[h])"
11501460|NCT01344200|Active Comparator|Dose Escalation Cohort|"2. Dose escalation cohort (Oral celecoxib 6 mg/kg and 14 mg/kg pharmacokinetic profile)
~Mean Total and unbound plasma concentration ug/L at approximately the following time intervals (mins): 60,180 and 300
~Mean CSF concentration ug/L at approximately 180 minutes
~Ratio CSF/unbound plasma concentration at approximately 180 minutes
~This information in conjunction with the pharmacokinetic profile established in the dose timing cohort (10 mg/kg) will be used to predict plasma and CSF values for tmax, Cmax, AUC, Vd/F, CL/F and t1/2 for 6 and 14 mg/kg oral doses respectively."
11501461|NCT01344187|Experimental|riboflavin solution and KXL System|Subjects will receive riboflavin solution followed by UVA irradiation for 4 minutes
11501462|NCT01344187|Placebo Comparator|placebo solution and KXL System|Subjects will receive placebo solution followed by UVA irradiation for 4 minutes
11501463|NCT01344174|Other|glucocorticoids treatment|
11501464|NCT01344161|Placebo Comparator|Lactose|
11501465|NCT01344161|Experimental|Vitamin D|
11501466|NCT01344148|Experimental|Anti- TB therapy HAART|
11501467|NCT01344135|Placebo Comparator|Group 1 (placebo control)|60 clinically stable COPD patients with muscle atrophy, eligible for out-patient pulmonary rehabilitation
11501468|NCT01344135|Experimental|Group 2 (nutritional intervention)|60 clinically stable COPD patients with muscle atrophy, eligible for out-patient pulmonary rehabilitation
11501469|NCT01344122|Active Comparator|KPI training only|Study sites randomized to this arm will receive a knowledge, perceptions and information (KPI) training for community correctional and treatment staff to address knowledge, perceptions, and information regarding local resources about MAT.
11501470|NCT01344122|Experimental|KPI plus OLI|Study sites randomized to this arm will receive the KPI training plus a Organizational Linkage Intervention (OLI) that will: (a) establish a local Pharmacotherapy Exchange Council (PEC) among agencies important for the implementation of MAT in community corrections; (b) facilitate a strategic planning process within the PEC to increase the availability of MAT for opiate and/or alcohol dependent individuals who are on probation/parole; and (c) identify a community corrections coordinator in one of the local agencies to operationalize and implement the strategic plan.
11501471|NCT01344109||Breast cancer patients|Newly diagnosed patients with breast cancer presenting with operable breast tumor prior to initiation of of neoadjuvant chemotherapy (choice of chemotherapy will be the the treating physician's discretion)
11501472|NCT01344109||Healthy volunteers|Adult women without a cancer diagnosis.
11501473|NCT01344083|Experimental|T1210|
11501474|NCT01344083|Active Comparator|Olopatadine hydrochloride|
11501475|NCT01344070|Active Comparator|Reference formulation of each drug|Innovator formulation
11501476|NCT01344070|Active Comparator|generic formulation a|one of the several generic formulations in the market, randomly selected for each drug
11501477|NCT01344070|Active Comparator|generic formulation b|second of the several generic formulations in the market, randomly selected for each drug
11501478|NCT01344070|Active Comparator|generic formulation c|third of the several generic formulations in the market, randomly selected for each drug
11501479|NCT01344057|Other|Sub unit, Inactivated, MF59C.1 Adjuvanted Influenza Vaccine|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
11501480|NCT01344044|Active Comparator|BCI treatment|BCI treatment will commence during the week of the Baseline.
11501481|NCT01344044|Other|Wait-list control|BCI treatment will commence 8 weeks after Baseline
11501482|NCT01344044|Experimental|BCI pilot arm|This is a experimental arm to test out the safety and effectiveness of BCI in improving ADHD symptoms. This pilot arm is necessary as the BCI device, incorporating dry electrode sensors and intervention game, is newly developed and have not been tested out in children with ADHD. This preliminary study will also allow us to test out the treatment protocol (24 sessions of BCI training over 8 weeks) to see if it is efficacious.
11501483|NCT01344031|Experimental|Arm A (anastrozole and Akt inhibitor MK2206)|"Patients receive anastrozole PO on days 1-28. Beginning in course 2, patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
11501484|NCT01344031|Experimental|Arm B (Akt inhibitor MK2206 and anastrozole)|"The RPTD of Akt inhibitor MK2206 with anastrozole is determined after 3 courses, administered as in Arm A.
~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
11501485|NCT01344031|Experimental|Arm C (Akt inhibitor MK2206 and fulvestrant)|"Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22, fulvestrant IM on day 1and day 15 of course 1 and then on day 1 of each course in each subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
11501486|NCT01344031|Experimental|Arm D (Akt inhibitor MK2206, anastrozole, fulvestrant)|"Patients receive Akt inhibitor MK2206 PO as in Arm A, anastrozole PO on days 1-28 and fulvestrant IM on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
11501487|NCT01344018|Active Comparator|Surgery alone|En-bloc resection of surrounding tissues and organs when located within 1 to 2 cm from the surface tumor, even when not infiltrated.
11501488|NCT01344018|Experimental|Preoperative radiotherapy followed by en-bloc surgery|3D-CRT or IMRT to a dose of 50.4 Gy/28 daily fractions
11501489|NCT01343992|Active Comparator|Bedrest|Patients will rest in bed ten minutes after the embryo transfer.
11501490|NCT01343992|Experimental|No bed rest|Patients will not rest after the embryo transfer.
11501491|NCT01343979||positive|Patients with clinically suspected H1N1 infection confirmed by positive H1N1 PCR
11501492|NCT01343979||negative|Patients with clinically suspected H1N1 infection and negative H1N1 PCR
11501493|NCT01343966|Experimental|Part 1: Subcutaneous cohort exp|
11501494|NCT01343966|Experimental|Part 2: Intravenous cohort exp|
11501495|NCT01343966|Placebo Comparator|Part 1: Subcutaneous cohort|Repeating subcutaneous injection
11501496|NCT01343966|Placebo Comparator|Part 2: Intravenous cohort|Repeating intravenous infusion
11501497|NCT01343953|Experimental|Cord Blood Transplantation|
11501498|NCT01343940|Experimental|Dulce family partner intervention|"Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services."
11501499|NCT01343940|Active Comparator|Safety intervention|Participating family is assigned a safety specialist who will provide the parent with guidance, equipment and instruction to reduce risk of newborn injury during transport (car seat) and while sleeping (Pack-and-Play).
11501500|NCT01343927|Active Comparator|Yoga|12 weeks of weekly yoga classes plus 40 weeks of either drop-in classes or home practice.
11501501|NCT01343927|Active Comparator|Physical Therapy|15 individual physical therapy treatment sessions over 12 weeks plus 40 weeks with either 5 booster sessions or home practice.
11501502|NCT01343927|Active Comparator|Education|"The Back Pain Helpbook which gives exercises and tips for self-care pain management."
11501503|NCT01343914||Cohort|
11501555|NCT01343706|Placebo Comparator|Placebo 2|Immediate release solid oral dosage
11501504|NCT01343901||Bevacizumab|Participants with metastatic colorectal cancer (mCRC) with exclusively liver or liver and lung metastases, who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases will be observed.
11501505|NCT01343888|Active Comparator|PegIFN/RBV|PegIFN/RBV for 48 weeks
11501506|NCT01343888|Experimental|BI 201335 for 12 or 24 weeks|BI 201335 once daily low dose for 12 or 24 weeks in combination with PegIFN/RBV for 24 or 48 weeks
11501507|NCT01343888|Active Comparator|Placebo and PegIFN/RBV|Placebo (oral) once daily plus PegIFN/RBV (subcutaneous injection/oral) for 24 weeks, followed by PegIFN/RBV alone up to Week 48.
11501508|NCT01343875||surgery, biceps tear|
11501509|NCT01343862|Experimental|D- Cycloserine|
11501510|NCT01343862|Placebo Comparator|sugar pill|
11501511|NCT01343849||Suspected Breast cancer subjects|
11501512|NCT01343836|Experimental|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte implantation) injection with eccentric exercises
11501513|NCT01343836|Placebo Comparator|Saline injection|Intratendinous saline injection with eccentric exercises
11501514|NCT01343823|Active Comparator|ecallantide 10mg|Administered as one 3 mL SC injection containing 10 mg ecallantide and one 3 mL SC injection of matching placebo.
11501515|NCT01343823|Placebo Comparator|placebo|Administered as two SC 3 mL injections
11501516|NCT01343823|Active Comparator|ecallantide 60mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
11501517|NCT01343823|Active Comparator|ecallantide 30mg|Administered as one 3 mL SC injection containing 30 mg ecallantide and one 3 mL SC injection of matching placebo.
11501518|NCT01343810|Experimental|Meditation|Both arms will undergo 8-weeks of Mindfulness-Based Stress Reduction (MBSR) training. The experimental arm will be randomly assigned to practice meditation immediately following the emotional stress task in the lab during the post-MBSR lab visit.
11501519|NCT01343810|Active Comparator|No meditation|Both arms will undergo 8-weeks of Mindfulness-Based Stress Reduction (MBSR) training. The active comparator arm will be randomly assigned to not practice meditation, but rather listen to a non-meditative audio track of equal length, immediately following the emotional stress task in the lab during the post-MBSR lab visit.
11501520|NCT01343784|Active Comparator|Standard Voiding Trial|Subjects in this group will undergo backfill-assisted voiding trial that involves infusing 300ml of fluid in the bladder, removing the catheter and allowing the patient to void. All subjects will be asked to use visual analog scale (VAS) to assess their force of stream (FOS) and the voided amount as well as post-void residual (PVR) (measured by the bladder ultrasound) will be measured and recorded. Subjects will be discharged without a catheter if the voided amount is more than 200ml, or 2/3rds of the infused volume (300ml).
11501521|NCT01343784|Experimental|Force of Stream Voiding Trial|Subjects in this group will undergo backfill-assisted voiding trial that involves infusing 300ml of fluid in the bladder, removing the catheter and allowing the patient to void. All subjects will be asked to use visual analog scale (VAS) to assess their force of stream (FOS) and the voided amount as well as post-void residual (PVR) (measured by the bladder ultrasound) will be measured and recorded. Subjects in the FOS group will be discharged home without a catheter if they are able to void any amount and report an FOS of at least 50% their typical FOS based on a visual analog scale
11501522|NCT01343758|Active Comparator|5% dextrose in normal saline|This group will receive a bolus of normal saline that contains 5% dextrose
11501523|NCT01343758|No Intervention|Normal Saline Bolus|
11501524|NCT01343745|Placebo Comparator|Placebo|Placebo pMDI
11501525|NCT01343745|Experimental|Low dose|BDP/formoterol pMDI low dose
11501526|NCT01343745|Experimental|High dose|BDP/Formoterol pMDI high dose
11501527|NCT01343732|No Intervention|healthy volunteeres|this arm will undergo only EEG measurement
11501528|NCT01343732|Active Comparator|real - low frequency|this arm will receive DTMS treatment with low frequency
11501529|NCT01343732|Active Comparator|real - high frequency|this arm will receive DTMS treatment with high frequency
11501530|NCT01343732|Sham Comparator|sham - low / high frequency|this arm will receive DTMS sham treatment with low or high frequency
11501531|NCT01343719|Experimental|BI 661051 low dose, low|solution for oral administration, single dose
11501532|NCT01343719|Experimental|BI 661051 low dose, medium|solution for oral administration, single dose
11501533|NCT01343719|Experimental|BI 661051 low dose, high|solution for oral administration, single dose
11501534|NCT01343719|Experimental|BI 661051 medium dose, low|solution for oral administration, single dose
11501535|NCT01343719|Experimental|BI 661051 medium dose, medium|solution for oral administration, single dose
11501536|NCT01343719|Experimental|BI 661051 medium dose, high|solution for oral administration, single dose
11501537|NCT01343719|Experimental|BI 661051 high dose, low|solution for oral administration, single dose
11501538|NCT01343719|Experimental|BI 661051 high dose, medium|solution for oral administration, single dose
11501539|NCT01343719|Experimental|BI 661051 low dose|tablet
11501540|NCT01343719|Experimental|BI 661051 medium dose|tablet
11501541|NCT01343719|Placebo Comparator|Placebo|solution for oral administratrion
11501542|NCT01343706|Experimental|BI 409306 dose 1|Solution for oral administration
11501543|NCT01343706|Experimental|BI 409306 dose 2|Solution for oral administration
11501544|NCT01343706|Experimental|BI 409306 dose 3|Solution for oral administration
11501545|NCT01343706|Experimental|BI 409306 dose 4|Solution for oral administration
11501546|NCT01343706|Experimental|BI 409306 dose 5|Immediate release solid oral dosage
11501547|NCT01343706|Experimental|BI 409306 dose 6|Immediate release solid oral dosage
11501548|NCT01343706|Experimental|BI 409306 dose 7|Immediate release solid oral dosage
11501549|NCT01343706|Experimental|BI 409306 dose 8|Immediate release solid oral dosage
11501550|NCT01343706|Experimental|BI 409306 dose 9|Immediate release solid oral dosage
11501551|NCT01343706|Experimental|BI 409306 dose 10|Immediate release solid oral dosage
11501552|NCT01343706|Experimental|BI 409306 dose 11|Immediate release solid oral dosage
11501553|NCT01343706|Experimental|BI 409306 dose 12|Immediate release solid oral dosage
11501554|NCT01343706|Placebo Comparator|Placebo|Solution for oral administration
11501694|NCT01342692|Experimental|Azacitidine + Idarubicine|
11501556|NCT01343693||Anterior cervical discectomy and fusion|Any subject with DDD, tumor, deformity ot trauma to the cervical spine in which the investigator determines the subject will require an ACDF using the MaxAn Plate.
11501557|NCT01343680|Active Comparator|10U/l heparin|
11501558|NCT01343680|Experimental|normal saline|
11501559|NCT01343667|Other|GFRS EPD|Carotid artery stenting with Gore Flow Reversal System embolic protection device
11501560|NCT01343667|Other|GEF EPD|Carotid artery stenting with Gore Embolic Filter embolic protection device
11501561|NCT01343654|Experimental|Text messaging|Participants randomized to this arm will receive a mobile phone if needed, and the 12 week personalized text messaging/EMA intervention
11501562|NCT01343654|Active Comparator|Treatment as usual|Participants randomized to this arm will receive treatment as usual in the ID clinics and in the communities for nonadherence and drug use problems
11501563|NCT01343641|Experimental|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck & Co, Inc.
11501564|NCT01343641|Placebo Comparator|Placebo|Inactive Pill used as a comparator
11501565|NCT01343628|Placebo Comparator|Placebo, Atomoxetine|
11501566|NCT01343628|Active Comparator|Atomoxetine, Placebo|
11501567|NCT01343615|Active Comparator|carotid stenting|
11501568|NCT01343615|Active Comparator|carotid endarterectomy|
11501569|NCT01343602|Experimental|mod. Constraint-Induced Movement Therapy|CIMT at home is applied in the patients' home over the course of four weeks including (i.e. 20 consecutive days) 2 hours of daily training together with an instructed non-professional coach (e.g. family member) applying shaping techniques.
11501570|NCT01343602|Other|Therapy as usual|Patients in this arm will receive usual care dose-matched to the intervention group (250-300 minutes).
11501571|NCT01343563|Active Comparator|Low frequency to High|For the first six weeks, subjects randomized to this group will receive low frequency stimulation. At the six week point, the low frequency group subjects will be crossed over to high frequency for the remaining six weeks.
11501572|NCT01343563|Active Comparator|High frequency|Subjects randomized to this group will receive high frequency stimulation for the entire 12 weeks of the first phase of this study.
11501573|NCT01343550|Experimental|Creativity group for persons diagnosed with BPD|
11501574|NCT01343537|Experimental|Monitoring|
11501575|NCT01343524||all subjects|all subjects who are enrolled in an industry-sponsored study that utilizes a sponsor-supplied spirometer.
11501576|NCT01343511|Experimental|Rehabilitation plus hCB-MNCs treatment|Participants will be given rehabilitation therapy plus human cord blood mononuclear cells transplantation with a 6 months follow-up.
11501577|NCT01343511|Experimental|Rehabilitation plus hCB-MNCs and hUC-MSCs therapy|Participants will be given rehabilitation therapy plus combination of hCB-MNCs together with hUC-MSCs transplantation with a 6 months follow-up.
11501578|NCT01343498|Experimental|BEZ235|
11501579|NCT01343485|No Intervention|Control, standard care for HPV vaccine|Study participants in control sites will receive standard care for HPV vaccine administration and follow-up per PPFA protocol
11501580|NCT01343485|Experimental|Intervention, computer reminder system|Study participants in the intervention sites will receive standard care for HPV vaccine administration per PPFA protocol, reminder messages for subsequent vaccination appointments, and real-time determination of financial assistance for HPV vaccine.
11501581|NCT01343472|Experimental|WISP supervision|Parolee supervised under WISP parole model.
11501582|NCT01343472|Active Comparator|Parole-as-usual|Parolees supervised under Washington State's parole-as-usual
11501583|NCT01343459|Experimental|IOERT followed by hypofractionated WBRT|HIOB: IOERT of 11.1 Gy followed by WBRT with 15 times 2.7 Gy per fraction.
11501584|NCT01343446||Patients with Diabetes|Patients with diabetes suffer from sleep impairment or not
11501585|NCT01343433||Control group|Chamber allocation will determine which patient receives bright light therapy. We selected four patient chambers at the Intensive Care Unit, each with the capacity of two patient beds. In two chambers patients will receive bright light therapy. Patients in the other two rooms are only exposed to environmental light
11501586|NCT01343433||Treatment group (bright light therapy)|Chamber allocation will determine which patient receives bright light therapy. We selected four patient chambers at the Intensive Care Unit, each with the capacity of two patient beds. In two chambers patients will receive bright light therapy. During our study, light therapy will be applied with instrument 'Litepod' (manufactured by Goodlite, Donker Curtiusstraat 7/407, Amsterdam), which gives an intensity of 10000 lux at a distance of 22 centimetres.Patients will receive bright light therapy for three hours in the morning, from eight o'clock till eleven o'clock.
11501587|NCT01343420|Active Comparator|Dog Hair Extract, ALK-Abelló, Inc.|
11501588|NCT01343407|Experimental|MK-1029 60 mg|Part 2 - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design
11501589|NCT01343407|Experimental|MK-1029 500 mg|Part 2 - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design
11501590|NCT01343407|Placebo Comparator|Placebo|Part II - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design
11501591|NCT01343394|Experimental|Biologic; Autologous Cell Injection|
11501592|NCT01343381|Active Comparator|Hepalean Heparin|
11501593|NCT01343381|Active Comparator|PPC Heparin|
11501594|NCT01343368|Experimental|Interventional - Received Leuprolide|Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
11501595|NCT01343368|Active Comparator|Observational Arm|Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
11501596|NCT01343342|Experimental|capsules omega-3|Omega-3 supplementation (3g EPA+DHA/d)
11501597|NCT01343329|Experimental|Subjects Receiving Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment.
11501598|NCT01343329|Active Comparator|Subjects receiving Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
11501599|NCT01343316||Transgastric tube|Nasogastric (NG tube)
11501600|NCT01343316||Transpyloric tube - Tiger2|Self-propelled by paristaltic waves of the stomach
11501601|NCT01343316||Transpyloric tube - Syncro BlueTube|Magnetically placed
11501602|NCT01343303|Experimental|001|JNJ-39439335 2 x 5 mg tablets once daily for 21 days
11501603|NCT01343303|Experimental|002|JNJ-39439335 2 x 25 mg tablets once daily for 21 days
11501604|NCT01343303|Other|003|Naproxen 500 mg capsule every 12 hours for 21 days
11501605|NCT01343303|Placebo Comparator|004|Placebo Placebo tablet/capsule every 12 hours for 21 days
11501606|NCT01343290|Experimental|001|Canagliflozin Type = 1 unit = mg number = 300 form = tablet route = oral use. Single tablet taken with or without a meal during 2 treatment periods
11501607|NCT01343277|Experimental|Trabectedin|
11501608|NCT01343277|Active Comparator|Dacarbazine|
11501609|NCT01343251||HeRO Graft|patients who are evaluated and receive a HeRO Graft implant for hemodialysis
11501610|NCT01343251||Control|control group of non-HeRO patients who are evaluated but do not receive a HeRO Graft for any reason
11501611|NCT01343238|Experimental|Diet|12 week diet modification intervention by dietician
11501612|NCT01343238|Experimental|Exercise|12 week physical exercise modification intervention by physical therapist
11501613|NCT01343238|Experimental|Diet and Exercise|12 week diet and exercise behavioral modification by dietician and physical therapist
11501614|NCT01343238|No Intervention|Control|Standard procedure
11501615|NCT01343225|Active Comparator|atripla|comparator
11501616|NCT01343225|Experimental|darunavir ritonavir raltegravir|experimental
11501617|NCT01343212||newly diagnosed HCC|"Subjects with newly diagnosed untreated hepatocellular carcinoma (HCC) will be enrolled.
~Subjects with the following conditions will be excluded:
~liver cancer other than HCC, treated HCC, post major abdominal surgery, contraindications to liver tumor biopsy, contraindications to local percutaneous treatment of liver tumors, low quality ARFI measurement"
11501618|NCT01343186|Other|Arm 1|
11501619|NCT01343186|Other|Arm 2|
11501620|NCT01343186|Other|Arm 3|
11501621|NCT01343186|Other|Arm 4|
11501622|NCT01343173|Experimental|Patients|
11501623|NCT01343160|Other|GORE VIABIL® Biliary Endoprosthesis|Placement of GORE VIABIL® Biliary Endoprosthesis to establish duct patency
11501624|NCT01343147|Other|Deep hyperthermia|Microwave diathermy
11501625|NCT01343147|Other|Superficial hyperthermia|Hot packs
11501626|NCT01343134||Retinal detachment cohort|
11501627|NCT01343121|Other|sample collection|"This is a single arm study. Patients will be seen on day 1, 8, 15 and 22 and will have the following samples collected:
~Pre gemcitabine urine sample
~Blood sample 30 minutes post Gemcitabine infusion
~Urine and blood sample 2 hours post Gemcitabine infusion"
11501628|NCT01343095|No Intervention|Usual Care|Usual Care between 10pm-6am
11501629|NCT01343095|Active Comparator|Earplugs|Application of foam earplugs from 10pm-6am nightly for seven nights or until ICU discharge.
11501630|NCT01343095|Active Comparator|Earplugs and Headphones|Foam Earplugs and Noise canceling headphones applied from 10pm-6am nightly for 7 nights or until ICU discharge.
11501631|NCT01343082|Experimental|1|DE-111 ophthalmic solution
11501632|NCT01343069|No Intervention|before surgical checklist|
11501633|NCT01343069|Active Comparator|after implementation surgical checklist|
11501634|NCT01343056|Active Comparator|Office Staff follow up education|"A designee in the office staff shall be assigned to follow up with the patient for for behavioral goal setting attainment. The office staff will call patients monthly to monitor goal attainment. It will be suggested that they phone the participant monthly but researchers will observe how and if they provide follow up.
~The intervention is the follow up goal attainment and office staff have been trained on elements of goal attainment."
11501635|NCT01343056|Active Comparator|Peer follow up education|"A person with diabetes trained as a peer shall meet the participant at their 6 week follow up visit and then call the participant monthly to monitor behavioral goal attainment.The intervention is the follow up goal attainment and peers have been trained on elements of goal attainment."
11501636|NCT01343056|Active Comparator|Usual Care|ADA Recognition maintains the standard that a follow up to diabetes education must occur from 3-6 month post education. This one phone call will be made by the diabetes educator. The intervention is the diabetes educator making a phone call to the patient to ask how they are doing.
11501637|NCT01343056|Active Comparator|Educator support follow up|A diabetes educator will provide follow up support and make monthly call to the patient to ascertain behavioral goal setting attainment. The diabetes educator uses behavioral goal setting as an education intervention. The educator calls patient to determine goal attainment. That is the intervention.
11501638|NCT01343043|Experimental|Cohort 1 treated with NY-ESO-1 T Cells|High NY-ESO-1 expression and the use of cyclophosphamide plus fludarabine. (COMPLETE)
11501639|NCT01343043|Experimental|Cohort 2 treated with NY-ESO-1 T Cells|Low NY-ESO-1 expression and the use of cyclophosphamide plus fludarabine.
11501640|NCT01343043|Experimental|Cohort 3 treated with NY-ESO-1 T Cells|High NYESO-1 expression and the use of cyclophosphamide only for lymphodepletion rather than fludarabine. (COMPLETE)
11501641|NCT01343043|Experimental|Cohort 4 treated with NY-ESO-1 T Cells|High NY-ESO-1 expression and the use of reduced dose cyclophosphamide plus fludarabine regimen.
11501642|NCT01343030||Patients with implants|Patients with silicone implants and fat grafting.
11501643|NCT01343017|Other|Increased tidal volume (IVT)|In the group with increased tidal volume (IVT), initial plateau pressure (Pplateau) will be monitored and then tidal volume will be increased until Pplateau was 0.04 cm H2O/kg over the initial Pplateau. The PETCO2 will be then adjusted to 4.5 kPa with a flexible corrugated hose placed between the Y-piece of the anaesthesia circle system and the heat and moisture filter (HME) attached to the endotracheal tube.
11501644|NCT01343017|Other|Normal tidal volume (NVT), with PEEP|In the group with normal tidal volume (NVT), a PEEP to10 cmH2O will be applied. When required, VT will then adjusted to maintain PETCO2 at 4.5 kPa
11501645|NCT01343004|Placebo Comparator|Placebo|Placebo identical in appearance to BA058 study drug
11501646|NCT01343004|Experimental|BA058 80 mcg (abaloparatide)|
11501647|NCT01343004|Active Comparator|teriparatide|Blinded until after randomization, then open-label
11501648|NCT01342991|Active Comparator|Milligan-Morgan Haemorrhoidectomy|Control arm
11501649|NCT01342991|Experimental|Laser Haemorrhoidectomy|This new method of haemorrhoidectomy is being compared to the standard Milligan-Morgan Haemorrhoidectomy.
11501650|NCT01342978||oropharyngeal cancer case|208 oropharyngeal cancer cases were enrolled
11501651|NCT01342978||partner or spouse of case|110 partners of patients with oropharyngeal cancer were enrolled
11501652|NCT01342978||control|A convenience group of 106 non-cancer controls were enrolled at some study sites at cancer screening events
11501653|NCT01342965|Experimental|Erlotinib|Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity.
11501654|NCT01342965|Active Comparator|Chemotherapy|Participants received gemcitabine 1250 mg/m^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first.
11501655|NCT01342952|Experimental|Ambrisentan|Open label, flexible dosing from 2.5 mg to 10 mg (not to exceed 0.25 mg/kg) per day
11501656|NCT01342939||MODY2|Also called GCK (glucokinase) MODY. They have a specific mutation in the GCK gene.
11501657|NCT01342939||MODY3|Also called HNF1 alfa MODY. They have a specific mutation in the HNF1 alfa gene.
11501658|NCT01342939||Healthy control subjects|
11501659|NCT01342926|Experimental|GSK933776 3 mg/kg|3 mg/kg administration of GSK933776 via intravenous infusion
11501660|NCT01342926|Experimental|GSK933776 6 mg/kg|6 mg/kg administration of GSK933776 via intravenous infusion
11501661|NCT01342926|Placebo Comparator|Placebo|Placebo via intravenous infusion
11501662|NCT01342926|Experimental|GSK933776 15 mg/kg|15 mg/kg administration of GSK933776 via intravenous infusion
11501663|NCT01342913|Experimental|Fluticasone Furoate/Vilanterol|Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA)
11501664|NCT01342913|Active Comparator|Fluticasone Propionate/Salmeterol|Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA
11501665|NCT01342900|No Intervention|standard care|The data from the InSPectra Monitor in the Control group will be inaccessible for the Investigator since this is not a part of their daily medical practice
11501666|NCT01342900|Active Comparator|Treatment group,|The data given by the monitor will be available for the Investigator and used to apply the optimization protocol
11501667|NCT01342887|Experimental|Treatment (immunosuppression, enzyme inhibitor, and chemo)|Patients receive cyclosporine IV continuously on days 5-9. Patients also receive pravastatin sodium PO every 6 hours on days 1-10, etoposide IV continuously on days 5-9, and mitoxantrone hydrochloride IV continuously on days 5-9. Treatment repeats for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR/CRi may receive 2 additional courses in the absence of disease progression or unacceptable toxicity.
11501668|NCT01342874||Inositol group|Inositol dietary exposure 4000 mg/day
11501669|NCT01342874||Control group|folic acid 400 mcg/day
11501670|NCT01342861|Sham Comparator|Observational period|A first period of follow-up on the 400 patients was designed to survey and evaluate current nutrition administration policy
11501671|NCT01342861|Experimental|Intervention period|The second period of follow-up on the 400 patients was designed to evaluate the impacts of adding milky food to the breakfast and of educating health care professionals on the early detection of undernutrition.
11501672|NCT01342835|Active Comparator|drug: propofol|Drug:Propofol and sevoflurane The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
11501673|NCT01342835|Active Comparator|Sevoflurane group:sevoflurane|Drug:Sevoflurane and Propofol Mask induction is perform with sevoflurane (4-6%) follow by 1.5-2% sevoflurane in a 50:50 mixture of N2O and O2.
11501674|NCT01342822||PROMUS Element™|All patients enrolled will be randomized 2:1 to receive the PROMUS Element™ stent (N=1987)
11501675|NCT01342822||Xience™ Prime stent|All patients enrolled will be randomized 2:1 to receive the PROMUS Element™ stent (N=1987) versus the Xience™ Prime Stent (N=993).
11501676|NCT01342809|Experimental|Follow up|Close follow up from written guidelines, supervision provided.
11501677|NCT01342809|No Intervention|Usual Treatment|
11501678|NCT01342796|Experimental|Arm 1|
11501679|NCT01342796|Active Comparator|Arm 2|
11501680|NCT01342770|Experimental|Treatment (pioglitazone hydrochloride)|Patients receive pioglitazone hydrochloride PO QD for 14-42 days. Patients then undergo surgery.
11501681|NCT01342757|Experimental|Arm I|"Patients receive vorinostat once daily on days -7 to -1 (course 1 only) and days 8-14 and 22-28 and temozolomide on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Patients undergo magnetic resonance spectroscopic imaging at baseline and at approximately 1 and 8 weeks on treatment. Patients also undergo a survey administration of Inventory of Depression Symptomatology Self-Reported (IDS-SR) assessment at baseline and periodically during study."
11501682|NCT01342744|Experimental|Metformin|Metformin (850mg) 1 tab oral twice a day
11501683|NCT01342744|Placebo Comparator|Placebo|Placebo 1 tab oral twice a day
11501684|NCT01342731|Experimental|Tigecycline|Tigecycline 100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 d
11501685|NCT01342718|Experimental|GJS/Duolac7S|GJS: Real herbal extract granule/Duolac7S: Real probiotics
11501686|NCT01342718|Placebo Comparator|GJS-P/Duolac7S|GJS-P: Placebo herbal extract granule/Duolac7S: Real probiotics
11501687|NCT01342718|Placebo Comparator|GJS/Duolac7S-P|GJS: Real herbal extract granule/Duolac7S-P: Placebo probiotics
11501688|NCT01342718|Placebo Comparator|GJS-P/Duolac7S-P|GJS-P: Placebo herbal extract granule/Duolac7S-P: Placebo probiotics
11501689|NCT01342705|Experimental|phlebotomy|
11501690|NCT01342705|No Intervention|control|
11501691|NCT01342692|Active Comparator|Azacitidine alone|
11501692|NCT01342692|Experimental|Azacitidine +Valproic acid|
11501693|NCT01342692|Experimental|Azacitidine +Lenalidomide|
11501696|NCT01342666|Experimental|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
11501697|NCT01342666|Placebo Comparator|Cucumber consumption|Daily consumption of 300g of cucumber.
11501698|NCT01342653|Experimental|NIPS plus HIPEC plus adjuvant chemotherapy|
11501699|NCT01342640|Experimental|Single Arm|
11501700|NCT01342627|Experimental|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.
~In case of toxicities, dose reduction/interruption is permitted according to protocol.
~In case of disease progression Sorafenib administration will be discontinued."
11501701|NCT01342614|Active Comparator|Fosinopril group|Fosinopril group received fosinopril, 10mg, once per day.
11501702|NCT01342614|Experimental|Metformin group|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
11501703|NCT01342601|Active Comparator|Ectoin products|
11501704|NCT01342601|Placebo Comparator|Placebo products|
11501705|NCT01342588|Experimental|Electrical stimulation|Only arm of the study, the experimental
11501706|NCT01342575|Experimental|Intra-operative maneuver group|
11501707|NCT01342562|Experimental|DXM-bupivacaine|
11501708|NCT01342562|Placebo Comparator|saline-bupivacaine|
11501709|NCT01342549|Active Comparator|Arm 1|sodium valproate
11501710|NCT01342549|Active Comparator|Arm 2|naltrexone
11501711|NCT01342536|Experimental|lifestyle counseling (OHDC)|Oh Happy Day Class (OHDC) is a culturally-specific, 12-week cognitive behavioral group counseling intervention designed for African American adults experiencing depression
11501712|NCT01342536|Active Comparator|lifestyle counseling (CWD)|Coping with Depression Course (CWD) is a 8-week cognitive behavioral group counseling depression intervention
11501713|NCT01342523|Experimental|No CIS/No loz/No Email/Lite Website/Brief Booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~No CIS calls, No nicotine lozenge, No motivational emails, lite website, brief mailed booklet"
11501714|NCT01342523|Experimental|CIS/No loz/No email/Lite Website/Brief booklet|"This arm of the project will address the following question:
~Does the following treatment provide efficacy relative to others:
~CIS calls, no NRT lozenge, no motivational email, Lite website, Brief mailed booklet"
11501715|NCT01342523|Experimental|no CIS/Loz/No email/lite website/brief booklet|"This arm of the project will address the following question:
~Does this combination of services achieve effectiveness compared to others:
~No CIS phone counseling, NRT lozenge, no motivational email, lite website, brief mailed booklet"
11501716|NCT01342523|Experimental|No CIS/no loz/email/lite website/brief booklet|"This arm of the project will address the following question:
~Does this combination of services lead to greater abstinence:
~No CIS counseling calls, no NRT lozenge, motivational emails, lite website, brief mailed booklet."
11501717|NCT01342523|Experimental|No CIS/No loz/No email/Full website/Brief booklet|"This arm of the project will address the following question:
~Does this combination of services lead to greater abstinence?
~No CIS counseling, no NRT lozenge, no motivational email, full website, brief mailed booklet"
11501718|NCT01342523|Experimental|No CIS/No loz/No email/lite website/full booklet|"This arm seeks to answer the question:
~Does this combination of services achieve efficacy compared to others:
~No CIS counseling, no NRT lozenge, no motivational email, lite website, full mailed booklet"
11501719|NCT01342523|Experimental|CIS/Loz/No email/Lite website/Brief booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~CIS calls, nicotine lozenge, No motivational emails, lite website, brief mailed booklet"
11501720|NCT01342523|Experimental|CIS/No loz/Emails/Lite Website/Brief booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~CIS calls, No nicotine lozenge, motivational emails, lite website, brief mailed booklet"
11501721|NCT01342523|Experimental|CIS/No loz/no email/full website/brief booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~CIS calls, No nicotine lozenge, No motivational emails, full website, brief mailed booklet"
11501722|NCT01342523|Experimental|CIS/No loz/no email/lite website/full booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~CIS calls, No nicotine lozenge, No motivational emails, lite website, full mailed booklet"
11501723|NCT01342523|Experimental|No CIS/Loz/emails/Lite Website/brief booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~No CIS calls, nicotine lozenge, motivational emails, lite website, brief mailed booklet"
11501724|NCT01342523|Experimental|No CIS/Loz/No emails/lite website/full booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~No CIS calls, nicotine lozenge, No motivational emails, lite website, full mailed booklet"
11501725|NCT01342523|Experimental|No CIS/Loz/No emails/full website/brief booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~No CIS calls, nicotine lozenge, No motivational emails, full website, brief mailed booklet"
11501726|NCT01342523|Experimental|no CIS/no loz/emails/full website/brief booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~No CIS calls, no nicotine lozenge, motivational emails, full website, brief mailed booklet"
11501727|NCT01342523|Experimental|no CIS/no loz/emails/lite web/full booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~No CIS calls, no nicotine lozenge, motivational emails, lite website, full mailed booklet"
11501728|NCT01342523|Experimental|no CIS/no loz/no email/full website/full booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~No CIS calls, no nicotine lozenge, No motivational emails, full website, full mailed booklet"
11501729|NCT01342523|Experimental|CIS/loz/emails/lite website/brief booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~CIS calls, nicotine lozenge, motivational emails, lite website, brief mailed booklet"
11501760|NCT01342432|Other|General exercise only|general exercise for stretch and strength of paraspinal and abdominal muscles
11501761|NCT01342380||Seroquel|Participants who received Seroquel
11501730|NCT01342523|Experimental|CIS/loz/no email/full website/brief booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~CIS calls, nicotine lozenge, No motivational emails, full website, brief mailed booklet"
11501731|NCT01342523|Experimental|CIS/loz/no email/lite website/full booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~CIS calls, nicotine lozenge, No motivational emails, lite website, full mailed booklet"
11501732|NCT01342523|Experimental|CIS/no loz/emails/full website/brief booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~CIS calls, no nicotine lozenge, motivational emails, full website, brief mailed booklet"
11501733|NCT01342523|Experimental|CIS/no loz/emails/lite website/full booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~CIS calls, no nicotine lozenge, motivational emails, lite website, full mailed booklet"
11501734|NCT01342523|Experimental|CIS/no loz/no email/full website/full booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~CIS calls, no nicotine lozenge, No motivational emails, full website, full mailed booklet"
11501735|NCT01342523|Experimental|No CIS/loz/emails/full website/brief booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~No CIS calls, nicotine lozenge, motivational emails, full website, brief mailed booklet"
11501736|NCT01342523|Experimental|No CIS/loz/emails/lite website/full booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~No CIS calls, nicotine lozenge, motivational emails, lite website, full mailed booklet"
11501737|NCT01342523|Experimental|No CIS/loz/no emails/full website/full booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~No CIS calls, nicotine lozenge, No motivational emails, full website, full mailed booklet"
11501738|NCT01342523|Experimental|no CIS/no loz/emails/full website/full booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~No CIS calls, no nicotine lozenge, motivational emails, full website, full mailed booklet"
11501739|NCT01342523|Experimental|CIS/loz/emails/full website/brief booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~CIS calls, nicotine lozenge, motivational emails, full website, brief mailed booklet"
11501740|NCT01342523|Experimental|CIS/loz/emails/lite website/full booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~CIS calls, nicotine lozenge, motivational emails, lite website, full mailed booklet"
11501741|NCT01342523|Experimental|No CIS/loz/emails/full website/full booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~No CIS calls, nicotine lozenge, motivational emails, full website, full mailed booklet"
11501742|NCT01342523|Experimental|CIS/no loz/emails/full website/full booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~CIS calls, no nicotine lozenge, motivational emails, full website, full mailed booklet"
11501743|NCT01342523|Experimental|CIS/Loz/no Emails/Full Website/Full Booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~CIS calls, nicotine lozenge, No motivational emails, full website, full mailed booklet"
11501744|NCT01342523|Experimental|CIS/Loz/Emails/Full Website/Full Booklet|"This arm of the project will address the following question:
~How effective is the following intervention?
~CIS calls, nicotine lozenge, motivational emails, full website, full mailed booklet"
11501745|NCT01342510|Experimental|Lidocaine|Lidocaine 50 mg in a 10 cc syringe
11501746|NCT01342510|Experimental|Magnesium|Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe
11501747|NCT01342510|Experimental|Lidocaine/Magnesium|Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe
11501748|NCT01342510|Placebo Comparator|Control|0.9% saline in a 10 cc syringe
11501749|NCT01342497|Experimental|BBR-012|
11501750|NCT01342497|Placebo Comparator|Placebo|
11501751|NCT01342484|Experimental|linagliptin low dose|linagliptin low dose for children once daily
11501752|NCT01342484|Experimental|linagliptin high dose|linagliptin high dose for children once daily
11501753|NCT01342484|Placebo Comparator|placebo|matching placebo for each linagliptin dose once daily
11501754|NCT01342471|Active Comparator|30-min walk|"Instructed to use brisk walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Participants were permitted to exercise in one long bout (30 min) or divide the exercise into multiple bouts as long as the bout length was 10 min or greater."
11501755|NCT01342471|Experimental|TV commercial stepping|"Instructed to stand and briskly step in place, or briskly walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Rather than exercising continuously for at least 10-minute bouts, participants performed multiple (~9 or 10), short (~3-5 min) bouts, conveniently incorporated into their daily TV viewing time."
11501756|NCT01342458|Experimental|Intervention Group|Daily use of the intervention Flexible footwear (Moleca®) for 6 months, for at least 42 hours/week (approximately 6 hours/day, 7 days/week). The Moleca® shoe (Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a low-cost women's double canvas, flexible, flat, walking shoe without heels, with a 5-mm anti-slip rubber sole and a 3-mm flat insole of ethylene vinyl acetate that provides only protection but no correction. The mean weight of the shoe is 0.172±0.019 kg (range 0.091 to 0.182 kg), depending on size. This minimalist footwear is commonly worn by the elderly of all social classes and its average cost is US$ 6.25.
11501757|NCT01342458|No Intervention|Control Group|During the intervention period, patients from the Control Group (CG) were instructed not to wear Flexible footwear (Moleca®) or other similar minimalist footwear. During everyday activities, the CG group was only permitted to wear a standard, neutral tennis shoe. At the end of the intervention period, all CG participants also received one pair of Moleca® shoes at no cost.
11501758|NCT01342445|Experimental|lisdexamfetamine dimesylate|All participants will be assessed across five conditions (baseline, placebo, 30-mg, 50-mg, & 70-mg) in a double-blind, crossover design
11501759|NCT01342432|Experimental|Balance reeducation plus exercise|exercises that challenge postural control are performed in addition to general exercises for stretch and strength of abdominal and paraspinal muscles
11501763|NCT01342367|Experimental|Oral Androgen Therapy|Subjects will receive two oral hormonal drugs (bicalutamide with dutasteride or bicalutamide with finasteride)
11501764|NCT01342354|Experimental|Stereotactic Radiation|Escalating doses of SBRT in three doses over ten days.
11501765|NCT01342341|Experimental|Parafon Forte first, then Placebo|Experimental: Forty moderate to heavy social alcohol users (women=10-25 drinks/week, men=14-30 drinks/week) will receive either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (1st intervention; 14 days), followed by a washout (7 days), and then followed by placebo (2nd intervention; 14 days).
11501766|NCT01342341|Placebo Comparator|Placebo first, then Parafon Forte|Experimental: Forty moderate to heavy social alcohol users (women=10-25 drinks/week, men=14-30 drinks/week) will receive placebo (1st intervention; 14days) followed by a washout (7 days), and then followed by either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (2nd intervention; 14 days).
11501767|NCT01342328|Placebo Comparator|Control|For this arm, the volunteer subject will receive a saline infusion during the sleep session.
11501768|NCT01342328|Experimental|Dexmedetomidine (DEX)|For this arm, the volunteer subject will receive a DEX infusion for sedation during the sleep session.
11501769|NCT01342328|Experimental|Propofol|For this arm, the volunteer subject will receive a propofol infusion for sedation during the sleep session.
11501770|NCT01342315|Experimental|Active|Product 33525
11501771|NCT01342315|Experimental|Placebo|Product 33525 Placebo
11501772|NCT01342302|Other|Couples Intervention|Single arm study design
11501773|NCT01342289|Experimental|Tacrolimus 60|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 60 days.
11501774|NCT01342289|Experimental|Tacrolimus 90|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 90 days.
11501775|NCT01342289|Experimental|Tacrolimus 120|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 120 days.
11501776|NCT01342276|Experimental|vHFC|Patients will get to participate in the interactive heart failure website (vHFC).
11501777|NCT01342276|No Intervention|Usual Care|Patients will not get to participate in the interactive heart failure website (vHFC).
11501778|NCT01342263|No Intervention|Usual Care|Does not get to participate in the interactive chronic disease website.
11501779|NCT01342263|Experimental|iCDM|The iCDM will support patient self-management through collaborative planning and goal setting, education and skill development, support for behaviour change, and regular patient monitoring with follow-up. For each chronic condition, we have outlined sample patient signs and symptoms to be monitored, frequency of patient provider contact and frequency of patient prompt questions on their condition. The main premise of the iCDM is that only those patients who generate 'alerts' will be contacted by the iCDM nurse allowing for the potential to manage more patients than through traditional means of required patient follow-up regardless of patient condition . Across these five diseases are the following cross-cutting features: nutrition therapy, exercise therapy, psychological support, medication adherence and smoking cessation.
11501780|NCT01342250|Experimental|Conventional plus hUC-MSCs treatment (low dose)|
11501781|NCT01342250|Experimental|conventional therapy plus hUC-MSCs treatment （medium dose）|
11501782|NCT01342250|Experimental|conventional therapy plus hUC-MSCs treatment （high dose）|
11501783|NCT01342237|Experimental|topotecan|
11501784|NCT01342224|Experimental|tadalafil and vaccination|Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV). This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine.
11501785|NCT01342211|Placebo Comparator|Treatment A|
11501786|NCT01342211|Experimental|Treatment B|
11501787|NCT01342211|Experimental|Treatment C|
11501788|NCT01342211|Experimental|Treatment D|
11501789|NCT01342211|Experimental|Treatment E|
11501790|NCT01342198|Experimental|1|Single Dose Pregabalin Controlled Release
11501791|NCT01342198|Experimental|2|Single Dose Pregabalin Controlled Release with Multiple Doses of Erythromycin
11501792|NCT01342185|Experimental|Medical ozone therapy with tianyi|
11501793|NCT01342185|Active Comparator|medical ozone therapy with humares|
11501794|NCT01342185|Placebo Comparator|Diammonium glycyrrhizinate Capsules|
11501795|NCT01342172|Experimental|Lenalidomide|capsules for oral administration
11501796|NCT01342159|Active Comparator|Intravitreal bevacizumab injection|
11501797|NCT01342159|Active Comparator|Intravitreal Triamcinolone injection|
11501798|NCT01342159|Active Comparator|intravitreal bavacizumab with triamcinolone|
11501799|NCT01342133||Newborns|
11501800|NCT01342133||Mothers|
11501801|NCT01342120||Quetiapine|Quetipine users
11501802|NCT01342120||All other atypical antipsychotics|All other atypical antipsychotics users
11501803|NCT01342120||Risperidone|Risperidone users
11501804|NCT01342120||Olanzapine|Olanzapine users
11501805|NCT01342107|Experimental|FID 114675A|Contact lens soaked overnight in an investigational multi-purpose disinfecting solution randomly assigned to one eye, with contact lens removed directly from the blister pack assigned to the fellow eye for contralateral wear. Both products worn for one day, 16 hours.
11501806|NCT01342107|Active Comparator|Blister Pack|Contact lens removed directly from the blister pack randomly assigned to one eye, with contact lens soaked overnight in an investigational multi-purpose disinfecting solution assigned to the fellow eye for contralateral wear. Both products worn for one day, 16 hours.
11501807|NCT01342094|Experimental|DE-111 ophthalmic solution|DE-111 ophthalmic solution (one drop at a time, once daily) and Placebo ophthalmic solution (one drop at a time, BID) in both eyes.
11501927|NCT01341379|Experimental|N-carbamylglutamate (Carbaglu)|
11501808|NCT01342094|Active Comparator|Timolol ophthalmic solution 0.5%|Timolol ophthalmic solution 0.5% (one drop at a time, BID) and Placebo ophthalmic solution (one drop at a time, once daily) in both eyes.
11501809|NCT01342081|Experimental|1|DE-111 ophthalmic solution
11501810|NCT01342081|Active Comparator|2|Tafluprost ophthalmic solution 0.0015%
11501811|NCT01342081|Active Comparator|3|Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
11501812|NCT01342055|Experimental|Group 1 : Megace 800mg - Apetrol ES 650mg - Apetrol ES 675mg|
11501813|NCT01342055|Experimental|Group 2 : Apetrol ES 650mg - Apetrol ES 675mg -Megace 800mg|
11501814|NCT01342055|Experimental|Group 4: Megace 800mg - Apetrol ES 675mg - Apetrol ES 650mg|
11501815|NCT01342055|Experimental|Group 5: Apetrol ES 650mg - Megace 800mg - Apetrol ES 675mg|
11501816|NCT01342055|Experimental|Group 3: Apetrol ES 675mg - Apetrol ES 650mg - Megace 800mg|
11501817|NCT01342055|Experimental|Group 6 : Apetrol ES 675mg - Megace 800mg - Apetrol ES 650mg|
11501818|NCT01342042|Active Comparator|Metformin|
11501819|NCT01342042|Active Comparator|exenatide-4|
11501820|NCT01342029|Experimental|Ranolazine|147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
11501821|NCT01342029|Placebo Comparator|Placebo|147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
11501822|NCT01342016|Experimental|tacrolimus group|tacrolimus capsule + leflunomide placebo
11501823|NCT01342016|Active Comparator|leflunomide group|tacrolimus placebo + leflunomide tablet
11501824|NCT01342003||Subtype 1a|subtype 1a patients treated with peginterferon plus ribavirin
11501825|NCT01342003||subtype 1b|subtype 1b patients treated with peginterferon plus ribavirin
11501826|NCT01341990|Experimental|FID 114675A|Multi-purpose disinfecting solution used per protocol-specified instructions for cleaning, rinsing, disinfecting/storing, and reinserting study contact lenses
11501827|NCT01341990|Active Comparator|ReNu MultiPlus|Multi-purpose solution used per protocol-specified instructions for cleaning, rinsing, disinfecting/storing, and reinserting study contact lenses
11501828|NCT01341977|Experimental|Alcon MPDS|Alcon Multi-Purpose Disinfecting Solution (MPDS)
11501829|NCT01341977|Active Comparator|ReNu Fresh Multi-Purpose Solution|ReNu Fresh Multi-Purpose Solution
11501830|NCT01341964|Experimental|Higher dose aspirin group|Clopidogrel 600 mg plus aspirin 325mg
11501831|NCT01341964|Active Comparator|Low dose aspirin group|Clopidogrel 600mg plus aspirin 81mg
11501832|NCT01341951|Experimental|G-CSF therapy in acute liver failure and alcoholic hepatitis|G-CSF therapy given in cases with acute liver failure and alcoholic hepatitis
11501833|NCT01341938|Experimental|lozenges (4 mg), Phone, Self-help|Commit® nicotine lozenges (4 mg)
11501834|NCT01341938|Experimental|LSH: Nicotine Lozenge, Self Help|Commit® nicotine lozenges (4 mg)
11501835|NCT01341938|Experimental|ASH: Counseling, Self Help|
11501836|NCT01341925|Placebo Comparator|Placebo Supplement and No PEP|Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
11501837|NCT01341925|Experimental|Omega-3 and PEP|"Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
11501838|NCT01341925|Experimental|Omega-3 and No PEP|Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
11501839|NCT01341925|Experimental|Placebo Supplement and PEP|"Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
11501840|NCT01341912|Experimental|Human-cl rhFVIII|Recombinant FVIII derived from a human cell line.
11501841|NCT01341899|Experimental|stem cell transplantation|
11501842|NCT01341886|Active Comparator|metformin|patients who receive metformin in addition to levothyroxine
11501843|NCT01341886|Placebo Comparator|levothyroxine|patients who receive only levothyroxine
11501844|NCT01341873|Experimental|Group I (FCI)|FCs receive 4 sessions of an APN FCI beginning during the admission for transplant and continuing for up to 100 days after transplant.
11501845|NCT01341873|Other|Group II (control)|FCs receive standard supportive care.
11501846|NCT01341860||controls|control group with a BMI of less thatn 25kg/m2
11501847|NCT01341860||obese group|Obese patients with BMI 25-30 kg/m2
11501848|NCT01341847|Active Comparator|Water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of the colonoscope during insertion since the scope is inserted into the anus until reach the cecum. Water will be infused as needed under endoscopist judgement through the adaptor on biopsy channel with endoscopic washer pump. The usual air insufflation will be used during colonoscope withdrawal to facilitate mucosal examination and perform any other intervention, such as biopsy
11501849|NCT01341847|Other|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
11501850|NCT01341834|Experimental|LBH589-RAD001|LBH589-RAD001, single arm dose finding study
11501851|NCT01341808|Experimental|IBD patients|"Patients diagnosed with IBD
~-> receive Epaxal Berna (virosomal hepatitis A vaccine)"
11501852|NCT01341782|Experimental|Paricalcitol|Participants received paricalcitol at an initial dose of 2 µg, and maxacalcitol placebo administered 3 times per week at each hemodialysis via intravenous catheter for 12 weeks. After 2 weeks the dose could be adjusted ± 1 µg based on protocol-specified criteria up to a maximum of 7 µg.
11501928|NCT01341366|Experimental|Fast-track perioperative program|
11501929|NCT01341366|Active Comparator|Traditional perioperative program|
11501853|NCT01341782|Active Comparator|Maxacalcitol|Participants received maxacalcitol at an initial dose of 5 µg (iPTH < 500 pg/mL at Screening) or 10 µg (iPTH ≥ 500 pg/mL at Screening), and paricalcitol placebo administered 3 times per week at each hemodialysis via intravenous catheter for 12 weeks. After 2 weeks the dose could be adjusted ± 2.5 µg based on protocol-specified criteria up to a maximum of 20 µg.
11501854|NCT01341769|Placebo Comparator|Control Test Food|Snack base
11501855|NCT01341769|Experimental|Experimental Test Food 1|Snack Base containing ingredient 1
11501856|NCT01341769|Experimental|Experimental Test Food 2|Snack base containing ingredient 2
11501857|NCT01341769|Experimental|Experimental Test Food 3|Snack base containing ingredients 1 and 2
11501858|NCT01341756|Experimental|Radiotherapy for gastric cancer|Single arm study
11501859|NCT01341743|Active Comparator|A|oral entecavir 1mg daily for 104 weeks
11501860|NCT01341743|Active Comparator|B|oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
11501861|NCT01341743|Active Comparator|C|oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
11501862|NCT01341730|Active Comparator|Atorvastatin 20 mg|"After the subject take PET CT, he or she is randomized to either  Atorvastatin 20 mg group or  Atorvastatin 20 mg+ Pioglitazone 30 mg. The  Atorvastatin 20 mg group is to take atorvastatin 20 mg and take follow up PET CT in 3 months"
11501863|NCT01341730|Experimental|Atorvastatin 20 mg + Pioglitazone 30 mg|"After the subject take PET CT, he or she is randomized to either  Atorvastatin 20 mg group or  Atorvastatin 20 mg+ Pioglitazone 30 mg. The  Atorvastatin 20 mg + Pioglitazone 30 mg group is to take atorvastatin 20 mg + pioglitazone 30 mg and take follow up PET CT in 3 months"
11501864|NCT01341717|Experimental|Sitagliptin along with metformin and insulin|
11501865|NCT01341717|Active Comparator|Glimepiride as an active comparator to Sitagliptin|
11501866|NCT01341704|Experimental|MSP3-LSP/AlOH|Synthetic polyprotein of 96 amino acids (186-276 in 3D7 strain) manufactured by solid-phase synthesis by SYNPROSIS, France; lyophilized product was formulated extemporaneously with aluminum hydroxide (Reheis). 30 microgram per dose; three dose schedule on study day 0, 28 and 56 for primary series
11501867|NCT01341704|Placebo Comparator|Control|Primary series: Verorab Rabies vaccine; Secondary/Booster series: 0.9% NaCL/Normal Saline
11501868|NCT01341691|Placebo Comparator|Placebo 20mg|
11501869|NCT01341691|Active Comparator|K2CG 60 mg extender|
11501870|NCT01341691|Active Comparator|K2CG 60 mg|
11501871|NCT01341691|Active Comparator|K2CG 20mg extender|
11501872|NCT01341691|Active Comparator|K2CG 20mg|
11501873|NCT01341691|Placebo Comparator|Placebo 60mg|
11501874|NCT01341678|Other|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
11501875|NCT01341678|Other|Restricted Phosphorus Diet|Diet containing 750mg of phosphorus per day and administration of a phosphate binder (lanthanum carbonate)
11501876|NCT01341678|Other|High Phosphorus Diet|Diet containing 3000mg of phosphorus per day and phosphorus supplementation (NeutraPhos)
11501877|NCT01341652|Experimental|pTVG-HP vaccine with GM-CSF|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
11501878|NCT01341652|Active Comparator|GM-CSF alone|rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
11501879|NCT01341639|Experimental|PR5I|V419 + RotaTeq + Prevenar 13 + ProQuad
11501880|NCT01341639|Active Comparator|INFANRIX™ hexa|INFANRIX™ hexa + RotaTeq + Prevenar 13 + ProQuad
11501881|NCT01341626|Experimental|Treatment Foster Care Oregon (TFCO)|Youth are placed individually in well-trained and supervised foster homes. Basic components include: (a) daily telephone contact with TFCO parents using the Parent Daily Report; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation.
11501882|NCT01341626|Active Comparator|Group Care|Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%).
11501883|NCT01341613|Experimental|Cardioviva™ supplement capsule|
11501884|NCT01341613|Placebo Comparator|Placebo capsule|
11501885|NCT01341600|Experimental|Clopidogrel in poor metabolizers|"Healthy subjects who have been genotyped for CYP2C19*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 poor metabolizers (PM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
11501886|NCT01341600|Experimental|Clopidogrel in intermediate metabolizers|"Healthy subjects who have been genotyped for CYP2C19*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 intermediate metabolizers (IM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
11501930|NCT01341353|Active Comparator|Antiarrythmic Drugs|
11501931|NCT01341353|Experimental|ablation|
11501932|NCT01341340|Experimental|Everolimus Eluting BVS|Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS)
11502058|NCT01340352||control group:previous term delivery|
11501887|NCT01341600|Experimental|Clopidogrel in extensive metabolizers|"Healthy subjects who have been genotyped for CYP2C19*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 extensive metabolizers (EM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
11501888|NCT01341600|Experimental|Omeprazole/Clopidogrel in PM|PM participants who have completed Arm 1 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
11501889|NCT01341600|Experimental|Omeprazole/Clopidogrel in IM|IM participants who have completed Arm 2 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
11501890|NCT01341600|Experimental|Omeprazole/Clopidogrel in EM|EM participants who have completed Arm 3 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
11501891|NCT01341587|No Intervention|Control|Provider-driven care, based in office, no special diabetes management; Patient self-monitoring of blood glucose (SMBG)
11501892|NCT01341587|Active Comparator|Intervention|"Home diabetes monitoring by patient using cellular enabled glucometer to communicate information and receive feedback.
~Care provider can access raw and analyzed patient data; Physician receives report summary."
11501893|NCT01341574|Experimental|Early phase, experimental|Neglect patients, randomized in the experimental group (Prism adaptation, optical shift of 10 degrees) in the early phase after stroke.
11501894|NCT01341574|Experimental|Delayed phase, experimental|Neglect patients, randomized in the experimental group (Prism adaptation, optical shift of 10 degrees) in the delayed phase after stroke.
11501895|NCT01341574|Placebo Comparator|Early phase, placebo|Neglect patients, randomized in the placebo group (Prism adaptation, optical shift of 0 degrees) in the early phase after stroke.
11501896|NCT01341574|Placebo Comparator|Delayed phase, placebo|Neglect patients, randomized in the placebo group (Prism adaptation, optical shift of 0 degrees) in the delayed phase after stroke.
11501897|NCT01341574|Experimental|Delayed phase postural, experimental|Neglect patients, randomized in the experimental group (Prism adaptation, optical shift of 10 degrees) in the delayed phase after stroke. In this group, postural aspects are taken into account.
11501898|NCT01341561||weaning patients|
11501899|NCT01341548|Active Comparator|Civamide Nasal Solution 0.01%|
11501900|NCT01341548|Placebo Comparator|Vehicle Solution|
11501901|NCT01341535|Experimental|adaptive DPBN|"This patient group will be treated by adaptive dose-painting-by-numbers, while patients in the control arm will receive standard treatment.
~Patients will have a 50 % chance of being allocated to the experimental arm and a 50 % chance of being allocated to the control arm."
11501902|NCT01341535|Active Comparator|standard IMRT|"This patient group will be treated by standard intensity-modulated radiotherapy (IMRT), while patients in the experimental arm will receive adaptive dose-painting-by-numbers.
~Patients will have a 50 % chance of being allocated to the experimental arm and a 50 % chance of being allocated to the control arm."
11501903|NCT01341522|Active Comparator|Control|Control
11501904|NCT01341522|Experimental|MRI|experimental
11501905|NCT01341509|Active Comparator|FHL tendon transferred|Surgical group in which the FHL tendon was transferred
11501906|NCT01341509|Active Comparator|FHL tendon not transferred|
11501907|NCT01341496|Experimental|1|autologous tumor vaccine plus chemotherapy
11501908|NCT01341470|Experimental|Single IV dose LY2495655|Single 70 milligram (mg) dose LY2495655 administered intravenously (IV)
11501909|NCT01341470|Experimental|Multiple SC dose 17.5 mg LY2495655|17.5 mg of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total of 5 doses)
11501910|NCT01341470|Experimental|Multiple SC dose 140 mg LY2495655|140 mg of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total 5 doses)
11501911|NCT01341470|Experimental|Multiple SC dose 420 mg LY2495655|420 mg dose of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total 5 doses)
11501912|NCT01341470|Placebo Comparator|Single IV dose placebo|Single Placebo dose administered intravenously (IV)
11501913|NCT01341470|Placebo Comparator|Multiple SC dose placebo|Placebo dose administered subcutaneously (SC) every 2 weeks for 8 weeks (total of 5 doses)
11501914|NCT01341457|Experimental|LY2603618 + Gemcitabine|"Gemcitabine 1000 milligrams per meter squared (mg/m^2) administered intravenously on days 1, 8 and 15 of at least one 28-day cycle. 170 or 230 mg LY2603618 administered intravenously on days 2, 9 and 16 of at least one 28-day cycle.
~Participants experiencing benefit may continue on the combination therapy until discontinuation criteria are met."
11501915|NCT01341444|Experimental|Prevena Incision Management System|Negative Pressure Therapy Device
11501916|NCT01341444|Placebo Comparator|Standard of Care for Surgical Incisions|Sterile gauze and a non-penetrable barrier
11501917|NCT01341431|Experimental|bee venom|
11501918|NCT01341431|Placebo Comparator|saline|
11501919|NCT01341418|Active Comparator|Suprapatellar approach|surgical approach for intramedullary nailing of the tibia
11501920|NCT01341418|Active Comparator|Infrapatellar approach|surgical approach for intramedullary nailing of the tibia
11501921|NCT01341405|Experimental|CG100649 2 mg|capsule, once daily
11501922|NCT01341405|Experimental|CG100649 4 mg|capsule, 4 mg, once daily for 28 days
11501923|NCT01341405|Active Comparator|celecoxib 200 mg|capsule, once daily
11501924|NCT01341392|Experimental|CKD-501 0.5mg|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
11501925|NCT01341392|Experimental|CKD-501 Amlodipine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
11501926|NCT01341392|Experimental|Amlodipine 10mg|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
11501933|NCT01341327||Left Main disease|Consecutive patients with unprotected LMCA diseases at participating centers will be evaluated for the entry into the study.
11501934|NCT01341301|Experimental|Allogeneic HSCT|"CONDITIONING: Patients undergo Total Body Irradiation (TBI) twice daily (BID) on days -10 to -7. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2.
~TRANSPLANTATION: Patients receive DLI on day -6 and undergo cluster of differentiation 34 (CD34+) selected allogeneic HSCT on day 0
~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO on days -1 with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID or PO on days -1 to 28."
11501935|NCT01341288|Experimental|Implant|Robotic implantation of brachytherapy seeds to treat prostate cancer
11501936|NCT01341275|Experimental|birth, lower dose booster|Adolescents who received their first dose of hepatitis B vaccine at or before day 7 of life who received a 10 ug dose of hepatitis B vaccine as a booster
11501937|NCT01341275|Experimental|birth, higher dose booster|Adolescents who received their first dose of hepatitis B vaccine at or before day 7 of life who received a 20 ug dose of hepatitis B vaccine as a booster
11501938|NCT01341275|Experimental|4 weeks, lower dose booster|Adolescents who received their first dose of hepatitis B vaccine at or after 4 weeks of life who received a 10 ug dose of hepatitis B vaccine as a booster
11501939|NCT01341275|Experimental|4 weeks, higher dose booster|Adolescents who received their first dose of hepatitis B vaccine at or after 4 weeks of life who received a 20 ug dose of hepatitis B vaccine as a booster
11501940|NCT01341249|Experimental|DW224aa|DW224aa given by oral administration
11501941|NCT01341249|Active Comparator|DW224a|DW224aa given by oral administration
11501942|NCT01341236|Active Comparator|continuous nutrition|
11501943|NCT01341236|Active Comparator|bolus nutrition|
11501944|NCT01341197||Subjects undergoing bidirectional endoscopy and fecal tests|Subjects participating in the health check-up at National Taiwan University Hospital (Health Management Center)
11501945|NCT01341197||Patients with screening detected GI tract cancers|Patients with screening detected GI tract cancer, such as throat cancer, esophageal cancer, gastric cancer and colorectal cancers, from other screening sites in Taiwan and were referred to the National Taiwan University Hospital for confirmatory diagnosis and treatment.
11501946|NCT01341184|Experimental|Group 1|16 subjects: TMC207 400mg orally on days 1 and 29, rifabutin 300mg orally, every day on day 20-41
11501947|NCT01341184|Experimental|Group 2|16 subjects: TMC207 400mg orally on days 1 and 29, rifampin 600mg orally, every day on day 20-41
11501948|NCT01341171||tamoxifen or aromatase inhibitors|
11501949|NCT01341158|Experimental|Experimental arm|
11501950|NCT01341145|Experimental|Aerobic Exersice|12-week moderate aerobic exercise program
11501951|NCT01341145|Active Comparator|Relaxation|12-week at home progressive muscle relaxation program
11501952|NCT01341132||Suspected Liver Disease|"Alpha-feto protein > 400 ng / mL or
~prior ultrasound with mass suspicious for hepatic malignancy or.
~clinical risk of hepatocellular carcinoma or
~prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma"
11501953|NCT01341106|Experimental|Treatment Arm|Patients will be treated with entecavir
11501954|NCT01341093|Active Comparator|usual care|
11501955|NCT01341093|Experimental|educational program+telephone follow up|
11501956|NCT01341080|Experimental|Varenicline|
11501957|NCT01341080|Placebo Comparator|Sugar pill|
11501958|NCT01341067||Basal insulin, approved oral medications|
11501959|NCT01341054|Experimental|mouthwash with Chamomilla extract 1%|The Chamomile recutita mouthwash 1% was administered two times daily for 30 days.
11501960|NCT01341054|Experimental|mouthwash with Chamomilla extract 2%|The Chamomile recutita mouthwash 2% was administered two times daily for 30 days.
11501961|NCT01341054|Active Comparator|standard oral care protocol|The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12%; oral hygiene teaching. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.
11501962|NCT01341054|Experimental|mouthwash with Chamomilla extract 0.5%|The Chamomile recutita mouthwash 0.5% was administered two times daily for 30 days, starting on the first day of chemotherapy.
11501963|NCT01341041|Experimental|chlorine dioxide|2 arms
11501964|NCT01341041|Active Comparator|saline|one time wash with 50-100cc of normal saline
11501965|NCT01341028|Active Comparator|Roux-en-Y gastric bypass (LRYGBP)|Twelve subjects underwent laparoscopic Roux-en-Y gastric bypass
11501966|NCT01341028|Experimental|LRYGBP plus gastric fundus resection|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass plus gastric fundus resection
11501967|NCT01341015|Experimental|ultrasound for fracture|All patients receive ultrasound for potential ankle fracture.
11501968|NCT01341002|Experimental|SCVO2 < 70%|guidelines transfusion + SCVO2 < 70%
11501969|NCT01341002|Active Comparator|currently intervention|guidelines transfusion
11501970|NCT01340989|Experimental|4% oxygen|addition of 4% oxygen to the CO2 pneumoperitoneum
11501971|NCT01340989|Experimental|full conditioning|full conditioning of the peritoneal cavity by the laparoscopic gas: 4% oxygen, 10% nitrous oxide, humidification and set temperature of 32°C
11501972|NCT01340989|Active Comparator|CO2 pneumoperitoneum|standard laparoscopy with CO2 pneumoperitoneum
11501973|NCT01340976|Experimental|LY2787106 Dose Escalation|Part A: Dose escalation starting at 0.3 milligram/kilogram (mg/kg), intravenously (IV), day one of up to three 21-day cycles.
11501974|NCT01340976|Experimental|10 mg/kg LY2787106|Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator.
11501975|NCT01340976|Experimental|10 mg/kg LY2787106+Iron|Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles with daily oral iron supplementation. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator.
11501976|NCT01340963||Class I|Structurally normal heart, no bundle branch block
11502056|NCT01340365|Experimental|Tai Chi|Individuals will take part in community-based Tai Chi classes twice a week for 6 months as well as practice Tai Chi outside of class twice a week for the same 6 month period.
11501977|NCT01340963||Class II|Mild symptoms, bundle brunch block or hemi-block on resting surface electrocardiogram, normal cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction as relaxation deficit (type I), none or mild global left ventricular systolic dysfunction
11501978|NCT01340963||Class III|Overtly symptomatic, enlarged cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction, global systolic dysfunction, ventricular tachycardia, atrio-ventricular block (any degree)
11501979|NCT01340950|Active Comparator|Better-Penetrating ART|zidovudine 300 mg orally every 12 hours lamivudine 300 mg orally daily nevirapine 200 mg orally every 12 hours
11501980|NCT01340950|Active Comparator|Worse-Penetrating ART|tenofovir disoproxil fumarate 300 mg orally daily lamivudine 150 mg orally every 12 hours efavirenz 600 mg orally daily
11501981|NCT01340937|Experimental|V419 Lot A|V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
11501982|NCT01340937|Experimental|V419 Lot B|V419 (Lot B) 0.5 mL IM at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
11501983|NCT01340937|Experimental|V419 Lot C|V419 (Lot C) 0.5 mL IM at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
11501984|NCT01340937|Active Comparator|Control|Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age
11501985|NCT01340911|Active Comparator|Part 1A, Cohorts 1-6|"Approximately 48 healthy male subjects will be enrolled into 6 separate cohorts (8 subjects per cohort). Each Cohort of subjects will be dosed sequentially, approximately one week apart, at escalating doses. Within each cohort, 6 subjects will be randomized to receive a single dose of SRT3025, and 2 will be randomized to receive a single dose of placebo.
~The following are the planned doses for Cohorts 1-6, with Cohort 1 being the lowest dose and Cohort 6 being the highest dose: 50, 150, 500, 1000, 2000, and 3000mg of SRT3025. Dose level may be altered as appropriate during the study based on real time analysis of the safety, tolerability, and /or PK data. Dose adjustment may involve an increase or decrease in dose or dividing the total daily dose allowing for twice-daily dosing. Total daily dosing will not exceed 3000mg."
11501986|NCT01340911|Active Comparator|Part 1B, Cohorts 7-8|One to two of the doses administered in Part 1A may be selected for administration with food, based on expected changes in SRT3025 exposures with food, as well as safety, tolerability, and PK data from Part 1A. If initiated, the effect of a single dose of SRT3025 with a moderate fat/calorie meal may be initiated concurrently with a cohort in Part 2 of the study. Approximately 6 subjects would be enrolled into each cohort in Part 1B.
11501987|NCT01340911|Active Comparator|Part 2A, Cohorts 9-11|Approximately 16-24 healthy subjects will be enrolled into 2 to 3 cohorts (8 subjects per cohort) in Part 2A. Within each cohort, 6 subjects will be randomized to receive multiple doses of SRT3025, and 2 will be randomized to receive multiple doses of placebo. The repeat dosing component of the study will be initiated, and doses selected, based on the evaluation of safety, tolerability, and PK data from Part 1A. Subjects in Part 2A will be randomized to receive 14 consecutive days of dosing with SRT3025 or matched-placebo. Subjects in these Cohorts will be dosed sequentially (in the fasted state) approximately two weeks apart.
11501988|NCT01340911|Active Comparator|Part 2B, Cohorts 12-13|If initiated, the effect of repeat doses of SRT3025 with moderate fat/calorie meals would occur in Part 2B (Cohorts 12 and 13). Each of these cohorts would enroll approximately 6 subjects.
11501989|NCT01340898|Experimental|Nimenrix 3+1 Group|Subjects, male and female, received 4 doses of Nimenrix™ vaccine (3 doses at 2, 4 and 6 months of age followed by a booster dose at 15-18 months of age) and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age). All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
11501990|NCT01340898|Experimental|Nimenrix 1+1 Group|Subjects, male and female, received 2 doses of Nimenrix™ vaccine (1 dose at 6 months of age followed by a booster dose at 15-18 months of age) and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age). All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
11501991|NCT01340898|Experimental|Nimenrix Control Group|Subjects, male and female, received 1 dose of Nimenrix™ at 15-18 months of age and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age). All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
11501992|NCT01340885|Active Comparator|atomoxetine|Strattera 10-30 mg b.i.d.
11501993|NCT01340885|Active Comparator|rivastigimine|Exelon 1.5-4.5 mg b.i.d.
11501994|NCT01340885|Placebo Comparator|Placebo|sugar pill
11501995|NCT01340872|Experimental|ST10|ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day
11501996|NCT01340872|Placebo Comparator|Placebo|Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day
11501997|NCT01340859|Experimental|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Sessions of Post Admission Cognitive Therapy Delivered Preferably Over 3 Consecutive Days of Inpatient Stay
11501998|NCT01340859|No Intervention|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services
11501999|NCT01340846|Experimental|Part A|Warfarin dosed at 15mg
11502000|NCT01340846|Experimental|Part B|Ketoconazole dosed at 400mg
11502001|NCT01340846|Experimental|Part C|Gemfibrozil dosed at 600mg
11502002|NCT01340846|Experimental|Part D|GSK2118436 dosed alone
11502003|NCT01340833|Experimental|Study Medication|GSK2118436
11502004|NCT01340820|Experimental|AERAS-422 Low dose|>=10^5 to < 10^6 CFU
11502005|NCT01340820|Experimental|AERAS-422 High Dose|>=10^6 CFU
11502006|NCT01340820|Active Comparator|BCG Tice|BCG Tice 1-8 x 10^5 CFU
11502007|NCT01340807|Experimental|Prosthetic Feet|Randomized to 4 different prosthetic feet (SACH, SAFE, TALUX, and Proprio Foot)
11502008|NCT01340794|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28 (days 1-14 of courses 1 and 2). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11502057|NCT01340352||study group: previous preterm labor|
11502009|NCT01340781||Hospitalized medical patients|"Adult age 18-65 years old admitted to the general medical floors at MetroHealth Medical Center who are expected to stay a minimum of 48 hours.
~Potential subjects cannot have a known diagnosis of OSA, a tracheostomy, respiratory failure requiring noninvasive ventilation, currently pre or post surgical intervention, or clinically unstable patients with plans for transfer to a higher acuity of care or transferred from intensive care."
11502010|NCT01340768|Experimental|Sitagliptin|Sitagliptin 100mg taken orally once daily with or without metformin
11502011|NCT01340768|Active Comparator|Sulfonylurea Therapy|Usual sulfonylurea therapy with or without metformin
11502012|NCT01340755|Experimental|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
11502013|NCT01340742|Active Comparator|1|Arm remote preconditioning
11502014|NCT01340742|Placebo Comparator|2|Control group.
11502015|NCT01340729|Experimental|TPI 287|Starting dose TPI 287 of 125 mg/m2 intravenous (IV) for 3 weeks of 4 week schedule.
11502016|NCT01340716|Active Comparator|stretching exercise|patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style.
11502017|NCT01340716|Experimental|Tai Chi Chuan exercise|patients in this group held weekly classes of two stretching for 12 weeks.
11502018|NCT01340703|Other|optic disc pit maculopathy|
11502019|NCT01340690|Active Comparator|ω-3 fatty acids suspension|2 bags of Esprico(R) suspension each day. Each 4ml suspension bag includes 400mg eicosapentaenoic acid (EPA), 40mg docosahexaenoic acid (DHA), 5.4 mg gamma-linolenic acid (GLA), 80 mg magnesium, 5 mg zinc and consists of linseed oil, xylitol, sea fish oil with high portion of omega-3-acids, magnesium citrate, vegetable oil, orange flavour, evening primrose oil, zink gluconate, soya lecithin, citric acid, acesulfame k (E950)
11502020|NCT01340690|Placebo Comparator|placebo suspension|2 bags of Esprico (R) placebo suspension. Includes no ω-3 fatty acids, no ω-6 fatty acids, no magnesium and no zinc, but other vegetable oils, orange flavor, etc.
11502021|NCT01340677|Experimental|001|Canagliflozin 100 mg Type=1 unit=mg number=100 form=tablet route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.,Canagliflozin 300 mg Type=1 unit=mg number=300 form=tablet route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.,Canagliflozin 50 mg Type=1 unit=mg number=50 form=tablet route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
11502022|NCT01340664|Experimental|Canagliflozin 50 mg bid|Each patient will receive 50 mg canagliflozin twice daily for 18 weeks.
11502023|NCT01340664|Experimental|Canagliflozin 150 mg bid|Each patient will receive 150 mg canagliflozin twice daily for 18 weeks
11502024|NCT01340664|Placebo Comparator|Placebo|Each patient will receive matching placebo twice daily for 18 weeks
11502025|NCT01340651|Experimental|Ruxolitinib 25 mg SR/10, 15, or 20 mg IR|Participants began administration with 25 mg ruxolitinib sustained release (SR) once daily (QD). After 8 weeks, if there was inadequate efficacy, the dose level could be titrated to 50 mg SR QD or 25 mg SR every other day (QOD) alternating with 50 mg SR QOD. At Week 16, participants transitioned to ruxolitinib 10, 15, or 20 mg immediate release (IR) orally twice daily. Participants who continued to demonstrate benefit in the opinion of the investigator could remain on ruxolitinib IR until the last participant completed Week 36 or the commercial availability of ruxolitinib IR, whichever was earlier; the dose received was based on platelet counts at the time of transition.
11502026|NCT01340638|Active Comparator|Cookgas|This group will be assigned to use cookgas mask
11502027|NCT01340638|Active Comparator|LMA mask|This group will be assigned to use LMA mask
11502028|NCT01340625|Experimental|Investigational Test Product|Norethindrone/Ethinyl Estradiol 0.4 mg/35 mcg Chewable Tablets (Teva)
11502029|NCT01340625|Active Comparator|Reference Listed Drug|Ovcon® 35 Fe 0.4 mg/35 mcg Chewable Tablets (Warner Chilcott)
11502030|NCT01340612|Active Comparator|coiling|
11502031|NCT01340612|Active Comparator|coiling plus stenting|
11502032|NCT01340599|Experimental|Arm I (Polyphenon E)|Patients receive defined green tea catechin extract PO once daily QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.
11502033|NCT01340599|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.
11502034|NCT01340586|Experimental|Group A: Apixaban|
11502035|NCT01340586|Experimental|Group B: Apixaban|
11502036|NCT01340573||Genotype 1 CHC Participants|
11502037|NCT01340573||Non-genotype 1 CHC participants|
11502038|NCT01340547|Other|Single Arm|Single Arm, non-blinded, non-randomized
11502039|NCT01340534|Experimental|Oxygen 80% FIO2|Group of 181 patients that will receive supplemental oxygen 80% FIO2 during surgery (cesarean) and two hours after the procedure.
11502040|NCT01340534|Placebo Comparator|Use of air (no oxygen during surgery)|Group of 181 patients that will not receive supplemental oxygen during surgery (cesarean).
11502041|NCT01340508|Experimental|Intensity modulated Radiotherapy|Intensity modulated radiotherapy, dose escalation, rectal cancer, volumetric modulated arc therapy
11502042|NCT01340495|Experimental|Proton Radiation|Radiation therapy with proton beam
11502043|NCT01340482|Experimental|KRN23|Escalating doses of KRN23 (0.05, 0.10, 0.30 and 0.60 mg/kg) will be administered SC every 28 days (up to 4 doses)
11502044|NCT01340469|Active Comparator|study|Probiotics supplementation .
11502045|NCT01340469|Placebo Comparator|control|The control group received daily placebo liquid .
11502046|NCT01340456|Experimental|Rifampicin 10 mg QD|
11502047|NCT01340456|Experimental|Rifampicin 20 mg QD|
11502048|NCT01340456|Experimental|Rifampicin 100 mg QD|
11502049|NCT01340443||Cohort|
11502050|NCT01340430|Experimental|FEC-paclitaxel-trastuzumab|fluorouracil 600 mg/m2; epirubicin 90 mg/m2; cyclophosphamide 600 mg/m2 for 4 cycles followed by paclitaxel 80 mg/m2/week in combination with trastuzumab for 12 weeks
11502051|NCT01340417|Experimental|one label|Measurements of melatonin levels in urine, blood, milk.
11502052|NCT01340404|Experimental|Stem Cell Transplantation|
11502053|NCT01340404|Active Comparator|Transfusion program|
11502054|NCT01340391|Experimental|splinting method|A new splinting method has been invented. This is a study using the splint / cast in treatment of distal radius fractures.
11502055|NCT01340365|Other|Usual Care|
11502059|NCT01340339|Experimental|BILITRON BED®|Super-LED reverse phototherapy
11502060|NCT01340339|Active Comparator|BILIBERÇO®|Fluorescent Reverse Phototherapy
11502061|NCT01340326|Active Comparator|Valsartan,high dose|high dose group (valsartan up to 320 mg/day)
11502062|NCT01340326|Other|Valsartan, usual dose|usual dose group (valsartan 80 mg/day)
11502063|NCT01340313||Group 1|4 times evaluation according to doses in 1 group
11502064|NCT01340300|Active Comparator|Exercise training|Exercise training with exercise physiologist
11502065|NCT01340300|Active Comparator|Exercise training with metformin|Exercise training with exercise physiologist with oral metformin
11502066|NCT01340300|Active Comparator|Metformin|Metformin
11502067|NCT01340300|Active Comparator|Control|Educational information
11502068|NCT01340287|Active Comparator|1 = Tested product|
11502069|NCT01340287|Sham Comparator|2 = Control product|
11502070|NCT01340274|Active Comparator|Treatment as Usual|"Clients will receive 12 sessions of Treatment as usual , delivered 1 session per week for 12 consecutive weeks."
11502071|NCT01340274|Experimental|CRAFT Treatment|"Clients will receive 12 sessions of CRAFT, delivered 1 session per week for 12 consecutive weeks."
11502072|NCT01340261||Pediatric Pain Rehab Patients|
11502073|NCT01340248|Experimental|Dilatrend 64mg capsule|"* Randomized, open-label, single dose, two-period, two-way, crossover study
~group : Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet
~group : Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting"
11502074|NCT01340235|Experimental|Oral erythromycin|Oral erythromycin
11502075|NCT01340209|Experimental|Tiotropium Respimat (low dose)|Tiotropium low dose once daily delivered with Respimat inhaler
11502076|NCT01340209|Experimental|Tiotropium Respimat (high dose)|Tiotropium high dose once daily delivered with Respimat inhaler
11502077|NCT01340209|Placebo Comparator|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
11502078|NCT01340196|Experimental|sequence 1|tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through day 22 (morning dose on day 22 only)
11502079|NCT01340183|Experimental|AZD5099|IV Dose
11502080|NCT01340183|Placebo Comparator|Placebo|IV Dose
11502081|NCT01340170|Experimental|Soft bone drilling protocol|A soft bone drilling protocol will be used in bone quality 3 and 4
11502082|NCT01340170|Active Comparator|Standard drilling protocol|A standard drilling protocol will be used in bone quality 1 and 2
11502083|NCT01340157|Experimental|Fasting|Treatment A: 1200mg fexinidazole administered in fasting conditions by oral route
11502084|NCT01340157|Experimental|Meal 1: Plumpy Nuts|Treatment B: 1200mg fexinidazole administered in fed conditions (meal 1) by oral route
11502085|NCT01340157|Experimental|Meal 2: Rice + beans|Treatment B: 1200mg fexinidazole administered in fed conditions (meal 2) by oral route
11502086|NCT01340144||PFC Sigma PS TKA|one group received primary TKA using the PFC Sigma PS TKA
11502087|NCT01340144||PFC Sigma HP PS TKA|One group received primary TKA using the PFC Sigma HP PS TKA.
11502088|NCT01340131|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 40mg/S-Amlodipine 5mg Intervention
11502089|NCT01340131|Active Comparator|Free combination Therapy|Co-administration of single oral doses of a 40mg tablet of Telmisatan and a 5 mg tablet of S-Amlodipine
11502090|NCT01340118|Experimental|Budesonide|Patients with FeNO level greater than 25 ppb were randomly allocated to one of two groups. Randomisation was stratified by baseline FeNO. In one group (treatment group), participants were assigned to once daily treatment with 400 µg budesonide. In the other group (non-treatment group), participants did not receive any medication.
11502091|NCT01340118|No Intervention|remain untreated|
11502092|NCT01340105|Experimental|Microwave|
11502093|NCT01340105|Active Comparator|Radiofrequency|
11502094|NCT01340092|Active Comparator|Family Navigator|Family navigation
11502095|NCT01340092|No Intervention|Standard Care|standard care
11502096|NCT01340079|Experimental|Virtual world|Virtual world delivery method
11502097|NCT01340079|Active Comparator|face to face|face to face method of health education
11502098|NCT01340066|Experimental|UISH001|
11502099|NCT01340066|Placebo Comparator|Matching placebo|
11502100|NCT01340053|Placebo Comparator|Placebo|Capsule that is identical in size and color to other treatments
11502101|NCT01340053|Experimental|Low Dose|10 mg capsule of tenapanor
11502102|NCT01340053|Experimental|Mid Dose|30 mg capsule of tenapanor
11502103|NCT01340053|Experimental|High Dose|100 mg capsule of tenapanor
11502104|NCT01340040|Experimental|MEDI-573|MEDI-573
11502105|NCT01340027|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once a day for 12 weeks
11502106|NCT01340027|Active Comparator|Mirabegron 25 mg|Participants received mirabegron 25 mg tablets orally once a day for 12 weeks
11502107|NCT01340027|Active Comparator|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks
11502108|NCT01340027|Active Comparator|Solifenacin 2.5 mg|Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks
11502109|NCT01340027|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg tablets orally once a day for 12 weeks
11502110|NCT01340027|Active Comparator|Solifenacin 10 mg|Participants received solifenacin 10 mg tablets orally once a day for 12 weeks
11502111|NCT01340027|Experimental|Solifenacin 2.5 mg and Mirabegron 25 mg|Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
11502112|NCT01340027|Experimental|Solifenacin 2.5 mg and Mirabegron 50 mg|Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
11502113|NCT01340027|Experimental|Solifenacin 5 mg and Mirabegron 25 mg|Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
11502114|NCT01340027|Experimental|Solifenacin 5 mg and Mirabegron 50 mg|Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
11502115|NCT01340027|Experimental|Solifenacin 10 mg and Mirabegron 25 mg|Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
11502116|NCT01340027|Experimental|Solifenacin 10 mg and Mirabegron 50 mg|Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
11502117|NCT01340014|Other|AZARGA/COSOPT|1 drop AZARGA instilled in each eye twice a day for 7 days, followed by 1 drop COSOPT instilled in each eye twice a day for 7 days. A 48-hour washout period separated the two treatment periods.
11502118|NCT01340014|Other|COSOPT/AZARGA|1 drop COSOPT instilled in each eye twice a day for 7 days, followed by 1 drop AZARGA instilled in each eye twice a day for 7 days. A 48-hour washout period separated the two treatment periods.
11502119|NCT01340001|Sham Comparator|Sham Electrical stimulation of the nucleus basalis of Meynert|Deep brain stimulation
11502120|NCT01340001|Experimental|Electrical stimulation of the nucleus basalis of Meynert|Deep brain stimulation
11502121|NCT01339988|Experimental|Busulfan/Cyclophosphamide|
11502122|NCT01339975||Group A. Surgically treated patients|Patients having a radical or partial nephrectomy.
11502123|NCT01339975||Group B. Patients treated with targeted therapies|Patients treated by RCC-directed targeted therapy
11502124|NCT01339962||Non-Interventional Study|Outcomes Research Study
11502125|NCT01339949|Experimental|24 Gy radiation|
11502126|NCT01339949|Sham Comparator|Sham 24 Gy radiation|
11502127|NCT01339936|Experimental|Investigational eye drop|Formulation 1: Carboxymethylcellulose sodium, glycerin and polysorbate 80 based eye drops formulated for the relief of ocular surface irritation and symptoms of dryness
11502128|NCT01339923|Experimental|B_2h3h5_11|Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.
11502129|NCT01339923|Experimental|B_3h5_11|Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.
11502130|NCT01339923|Experimental|B_68_11|Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.
11502131|NCT01339923|Experimental|B_02_2_5|Subjects, 2-5 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
11502132|NCT01339923|Experimental|B_02_6_10|Subjects, 6-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
11502133|NCT01339923|Experimental|BC_35_12|Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
11502134|NCT01339923|Experimental|C_35_12|Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 and 15 months of age.
11502135|NCT01339910|Experimental|Reduced Intensity Conditioning (RIC)|One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
11502136|NCT01339910|Active Comparator|Myeloablative Conditioning Regimen (MAC)|One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
11502137|NCT01339897|Active Comparator|5 mg/N6022|Injectable formulation, given at doses per cohort of 5 mg given QD each day over 7 days.
11502138|NCT01339897|Placebo Comparator|Placebo|Injectable formulation normal saline
11502139|NCT01339897|Active Comparator|10mg/N6022|Injectable formulation, given at doses of 10 mg given QD each day over 7 days.
11502140|NCT01339897|Active Comparator|20mg/N6022|Injectable formulation, given at doses per cohort of 20 mg given QD each day over 7 days.
11502141|NCT01339884|Active Comparator|Resveratrol, 1g daily|15 participants will receive resveratrol 1g daily
11502142|NCT01339884|Active Comparator|Resveratrol, 5g daily|15 participants will receive resveratrol, 5g daily
11502143|NCT01339871|Experimental|Pazopanib + Vorinostat|Starting doses Pazopanib 400 mg orally daily and Vorinostat 100 mg orally daily
11502144|NCT01339858|Experimental|N-Acetyl Cysteine|NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 600 mg of NAC. Dosing will begin at 600 mg/d and titrated up over 5 weeks until a maximum dose of 3600 mg/d is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose.
11502145|NCT01339858|Placebo Comparator|Sugar Pill|matched placebo
11502146|NCT01339845|Active Comparator|Vaccine arm|Thirty clusters (approximately 80,000 people) will receive cholera vaccine alone
11502147|NCT01339845|Active Comparator|Vaccine plus hygiene and safe water arm|Thirty clusters (approximately 80,000 people)will receive both cholera vaccine and behaviour change
11502148|NCT01339845|No Intervention|Non-intervention arm|30 neighbourhoods(approximately 80,000 people) will continue their standard habits and practices
11502149|NCT01339832||Cohort|
11502150|NCT01339819|Experimental|Arm 1|Dabigatran Therapy
11502151|NCT01339819|Active Comparator|Arm 2|Phenprocoumon Therapy
11502152|NCT01339806|Other|Standard of Care for mTBI Provider Arm|Arm 1: Psychoeducational Control Group. Individuals assigned to arm 1 will receive psychoeducational materials specifically adapted for persistent management of symptoms and routine follow-up with medical providers (every three weeks). Additionally, subjects assigned to this group will receive medical care (e.g., psychopharmacological management of depression) and/or referral for symptom management (e.g., vestibular rehabilitation) of non-cognitive complaints, consistent with the current standard of care treatment model for managing post-concussive symptoms (see Figure below adapted with permission from authors; Brenner et al., 2009).
11502188|NCT01339507||Bepreve|Subjects with a history of allergic conjunctivitis.
11502189|NCT01339507||Lastacaft|Subjects with a history of allergic conjunctivitis.
11502190|NCT01339494|Active Comparator|arginine supplementation|Oral L-arginine supplementation will be administered to subjects with MELAS for 48 hours at a dose of 10 grams per M2 per day. Arginine will be given every 4 hours.
11502153|NCT01339806|Experimental|Computer Based Therapy Group|"Arm 2: Non-therapist directed computerized cognitive rehabilitation. Individuals assigned to treatment arm 2 will receive ten hours of in-clinic, computerized treatment per week throughout the 6-week treatment trial. Participants will be scheduled for 2 hours per day, proctored by clinic staff (certified recreation therapist or neuropsychology technician) who will be responsible for recording daily performance, providing positive reinforcement of participation, and effort. Computer programs selected for this treatment trial include both skill-specific training (e.g., attention processes) and general cognitive activation. These computer programs are commercially available and advertised as brain fitness or brain training."
11502154|NCT01339806|Experimental|Cognitive Rehab Group|"Arm 3: Therapist-directed individualized cognitive rehabilitation. Individuals assigned to treatment arm 3 will receive 10 hours of individual and group cognitive rehabilitation treatment (including homework assignments) per week conducted by credentialed speech therapists and occupational therapists. The treatment components will include five hours of weekly individual therapy (one-hour sessions; two hours focused on compensatory strategies and three hours focused on restorative strategies), two hours of weekly group therapy (one hour sessions focused on compensatory strategies), and three hours of weekly computer-based homework proctored by clinic staff who will be responsible for recording performance, and providing positive reinforcement of participation and effort."
11502155|NCT01339806|Experimental|Cognitive and Psychological Based Rehab|"Arm 4: Integrated interdisciplinary cognitive rehabilitation combined with cognitive-behavioral psychotherapy. Individuals assigned to treatment arm 4 will receive 10 hours of individual and group treatment per week conducted by credentialed therapists and doctoral-level psychologists. The treatment components will include four hours of weekly 1 hr individual therapy sessions; 2 hrs of cognitive rehabilitation, 1 hr of cognitive rehab & 1 hr of individual psychotherapy targeting anxiety/combat stress symptoms including relaxation training & exposure therapy and cognitive-behavioral principles, 3 hrs of weekly group therapy & three hours of weekly homework including 30-mins relaxation training, 30-mins cognitive-behavioral psychotherapy homework, and 2 hrs of computerized cognitive rehabilitation exercises proctored by clinic staff."
11502156|NCT01339780|Experimental|Breast Cancer|
11502157|NCT01339780|Experimental|Prostate Cancer|
11502158|NCT01339754|Experimental|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
11502159|NCT01339741|Active Comparator|Vitamin D|
11502160|NCT01339741|Placebo Comparator|Placebo|
11502161|NCT01339702||"Pre-implementation cohort (before)"|This cohort is a combination of retrospective and some prospective severe TBI patients cared for in the EMS systems of Arizona BEFORE implementation of the national prehospital TBI management guidelines
11502162|NCT01339702||"Post-implementation cohort (after)"|"This cohort is a comprised of prospective severe TBI patients cared for in the EMS systems of Arizona AFTER training EMS providers in the implementation of the national prehospital TBI management guidelines. It is intended that these patients will receive the bundle of care specified in the TBI Guidelines."
11502163|NCT01339689|Experimental|Ganaxolone|active
11502164|NCT01339689|Placebo Comparator|Placebo|non-active
11502165|NCT01339676|Experimental|1|Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D
11502166|NCT01339676|Placebo Comparator|2|Identically appearing once weekly peroral capsules
11502167|NCT01339663|Experimental|Treatment (dose-escalation, T-APC boost, CTL)|"INFUSION I: Patients receive high-dose cyclophosphamide IV on day days -4 and -3 and low-dose IL-2 SC BID on days 0-14. Patients also receive CTL IV on day 0.
~INFUSION II: Beginning 6-48 hours later, patients receive high-dose cyclophosphamide, low-dose IL-2, and CTL as in Infusion I. Patients also receive T-APC vaccine IV within 18-36 hours following CTL infusion and in week 4, and IL-2 SC BID on days 0-14 following second T-APC vaccination."
11502168|NCT01339650|Experimental|ABT-767|ABT-767 monotherapy
11502169|NCT01339637||Diabetes risk factors|Very dark skin subjects with with diabetes risk factors
11502170|NCT01339624|Active Comparator|NASAL FENTANYL,|
11502171|NCT01339624|Active Comparator|KETOROLAC + MORPHINE|
11502172|NCT01339611|Experimental|Educational Program|Patients who are going to use of oral anticoagulant will participate in an individual orientation, using instructional material (slides and illustrative booklet) during hospitalization period and the telephone follow-up at a week and four weeks after discharge
11502173|NCT01339611|Other|usual care|Patients who are going to use of oral anticoagulant will have usual orientation from the health service (illustrative booklet) during hospitalization time. No telephone follow-up after discharge.
11502174|NCT01339598|Sham Comparator|Sham transcranial direct current stimulation|
11502175|NCT01339598|Active Comparator|Transcranial direct current stimulation|
11502176|NCT01339598|Active Comparator|Different transcranial direct current stimulation montage|
11502177|NCT01339585|Experimental|Timing of tDCS|
11502178|NCT01339585|Experimental|Alternative timing of tDCS|
11502179|NCT01339572|Experimental|Plerixafor|All subjects will receive filgrastim as part of their primary mobilization regimen. If a subject does not meet minimum peripheral blood CD34+ cell count levels or fails to adequately collect a threshold number of CD34+ cells, plerixafor will be added to the mobilization regimen.
11502180|NCT01339572|Active Comparator|Observation|All subjects will receive filgrastim as part of their primary mobilization regimen. If the subject meets minimum peripheral blood CD34+ cell count levels or adequately collects a threshold number of CD34+ cells, plerixafor will not be added to the mobilization regimen.
11502181|NCT01339559|Experimental|Brivaracetam|Brivaracetam with a maximum of 200 mg/day
11502182|NCT01339546||Study population|All ambulatory visits for otitis media, myringotomy tube insertion, skin rash or trauma among children age 5 or under during the periods of study
11502183|NCT01339533|Experimental|APRV ls|APRV low stretch will titrate Plow to maintain release volumes between 4 and 8 cc/kg.
11502184|NCT01339533|Active Comparator|AC/VC Conventional Ventilation|Standard volume control ventilation with the ARDS Net protocol.
11502185|NCT01339533|Experimental|APRV h|APRV Habashi protocol which sets Plow equal to 0.
11502186|NCT01339520|Experimental|Scorecard|Score of points for variables.
11502187|NCT01339520|No Intervention|Control|Standard of care for diabetes subjects
11502191|NCT01339494|Active Comparator|citrulline supplementation|Oral L-citrulline supplementation will be administered to subjects with MELAS for 48 hours at a dose of 10 grams per M2 per day. Citrulline will be given every 4 hours
11502192|NCT01339481||Subjects with RA initiating abatacept treatment regimen|Subjects naïve to both abatacept and belatacept
11502193|NCT01339468|Experimental|Arm 1|Intravenous Prograf therapy followed by oral Advagraf therapy
11502194|NCT01339468|Active Comparator|Arm 2|Intravenous Prograf therapy followed by oral Prograf therapy
11502195|NCT01339455|Experimental|AHSCT|All patients undergo autologous hematopoietic stem cell transplantation in a two stage process.
11502196|NCT01339442|Experimental|Dose Level 1 - Phase 1A|"BKM120 80 mg PO daily.
~Fulvestrant 500 mg IM on Days 1 & Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
11502197|NCT01339442|Experimental|Dose Level 2 - Phase IA|"BKM120 100 mg PO daily.
~Fulvestrant 500 mg IM on Days 1 & Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
11502198|NCT01339442|Experimental|Phase IB|"BKM120 (dose to be determined in Phase IA)PO 5 days on/ 2 days off per week.
~Fulvestrant 500 mg IM on Days 1 & Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
11502199|NCT01339442|Experimental|Cohort C|"BKM120 (dose determined in Phase IA) PO daily.
~Fulvestrant 500 mg IM on Day 1 and Day 15 during Cycle 1 then monthly on Day 1 of subsequent cycles."
11502200|NCT01339429|Experimental|simplified Negative Pressure Wound Therapy|The simplified Negative Pressure device will be placed on subjects selected from the hospital ward and meeting the eligibility criteria.
11502201|NCT01339416||HIV infected cohort|HIV infected patients in the HIV cohorts at the three participating hospitals
11502202|NCT01339403||HIV infected|No study specific intervention, non-interventional trial
11502203|NCT01339403||HIV-uninfected|No study specific intervention, non-interventional trial
11502204|NCT01339390|Experimental|Arm 1: MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE! program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
11502205|NCT01339390|Active Comparator|Arm 2: MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the primary care provider (PCP) to determine if the person would benefit from a weight loss program, and to refer them to MOVE! if they and the patient agree that it would be beneficial. The MOVE! program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
11502206|NCT01339377|Experimental|AO-1000 Treatment|Oxygen-ozone treatment with the AO-1000 device
11502207|NCT01339364|Active Comparator|Didactic Lecture|
11502208|NCT01339364|Experimental|Lecture plus Case Disscussion|
11502209|NCT01339364|Experimental|Lecture plus Small Group Education|
11502210|NCT01339351|No Intervention|Usual Psychosocial Care|Participants are free to use any psychosocial care available to cancer patients. No restrictions to participation in other groups or services.
11502211|NCT01339351|Experimental|Therapeutic Group by teleconference|ten 90 minute group sessions by teleconference. Lead by social workers. Sessions focus on information, story sharing and coping.
11502212|NCT01339338|Experimental|warm media|Subjects undergo HSG using a warm media heated with a 37℃ water-bathing
11502213|NCT01339338|No Intervention|cold media|the contrast media under room temperature without heat
11502214|NCT01339325|Active Comparator|LESS cholecystectomy|Laparo-endoscopic single site cholecystectomy, the entire surface of the patient's abdomen is covered by plaster at the end of the operation. Patient does not know which kind of procedure he underwent before discharge.
11502215|NCT01339325|Active Comparator|Standard LAP-CHOLE|Standard laparoscopic cholecystectomy. The entire surface of the patient's abdomen is covered by plaster at the end of the operation. Patient does not know which kind of procedure he underwent before discharge.
11502216|NCT01339325|Active Comparator|LESS Cholecystectomy not blind|Laparo-endoscopic single site cholecystectomy. The patient is aware of the procedure he underwent.
11502217|NCT01339312|Experimental|VRVg Vaccine Group 1|Participants aged 18 years or older will receive Purified Vero Rabies Vaccine Serum Free (VRVg)
11502218|NCT01339312|Experimental|VRVg Vaccine Group 2|Participants aged 10 to 17 years will receive Purified Vero Rabies Vaccine Serum Free (VRVg)
11502219|NCT01339312|Active Comparator|Verorab Vaccine Group 1|Participants aged 18 years or older will receive Verorab Vaccine
11502220|NCT01339312|Active Comparator|Verorab Vaccine Group 2|Participants aged 10 to 17 years will receive Verorab Vaccine
11502221|NCT01339299|Experimental|recombinant luteinizing hormone|150 IU r-LH, recombinant luteinising hormone, from treatment day 1 (stimulation day 1) until day of r-hCG administration (normally treatment day 10 to 14)
11502222|NCT01339299|Active Comparator|recombinant human chorionic gonadotrofin|25 IU of r-hCG from treatment day 1 (stimulation day 1) until day of r-hCG administration (normally treatment day 10 to 14 )
11502223|NCT01339286|Experimental|atomoxetine|
11502224|NCT01339273|Experimental|TAP block|Patients in this arm will receive ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
11502225|NCT01339273|Active Comparator|Local anaesthetic infiltration|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
11502226|NCT01339260|Experimental|Netupitant and Palonosetron+dexamethasone-cycle 1|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle
11502227|NCT01339260|Active Comparator|Palonosetron+dexamethasone-cycle 1|Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle
11502228|NCT01339260|Experimental|Netupitant and Palonosetron+dexamethasone-multicycle extension|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle
11502373|NCT01338311|Placebo Comparator|placebo|200mcg twice daily for a total of 7 doses
11502229|NCT01339260|Active Comparator|Palonosetron+dexamethasone-multicycle extension|Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle
11502230|NCT01339247|Active Comparator|Paxil CR Reference|Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, in Period 1, followed by Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada, in Period 2
11502231|NCT01339247|Active Comparator|Paxil CR Test|Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada, in Period 1, followed by Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, in Period 2
11502232|NCT01339234|Experimental|Body-weight supported treadmill training|
11502233|NCT01339221||Cohort A|Children confirmed with G1 and/or P[8] cases from the RotaBel study
11502234|NCT01339221||Cohort B|Children hospitalized for severe gastroenteritis in the study hospitals and tested positive for rotavirus
11502235|NCT01339208|Experimental|Telemedicine Diabetes Intervention|
11502236|NCT01339195|Experimental|Behavioral|Behavioral: French adaptation of NINDS-Canadian Stroke Network battery
11502237|NCT01339182|Experimental|Pegylated-Somatropin, 10mcg/kg|
11502238|NCT01339182|Experimental|Pegylated-Somatropin, 30mcg/kg|
11502239|NCT01339182|Experimental|Pegylated-Somatropin, 60mcg/kg|
11502240|NCT01339182|Experimental|Pegylated-Somatropin, 120mcg/kg|
11502241|NCT01339182|Experimental|Pegylated-Somatropin, 200mcg/kg|
11502242|NCT01339169|Experimental|YF476 treatment|
11502243|NCT01339156|Experimental|P3914|
11502244|NCT01339156|Placebo Comparator|Placebo|
11502245|NCT01339143|Active Comparator|Pioglitazone|pioglitazone: 15mg, QD, PO, 16 weeks
11502246|NCT01339143|Experimental|vildagliptin|vildagliptin 50mg,BID,PO,16 weeks
11502247|NCT01339130|Other|behavioral and physiological tests|Computerized tests and Electrophysiological measurements
11502248|NCT01339117|Experimental|High fermentable substrate diet|High fermentable substrate diet provided for two days
11502249|NCT01339117|Experimental|Low fermentable substrate diet|Low fermentable substrate diet provided for two days
11502250|NCT01339104|Experimental|Regorafenib|
11502251|NCT01339091|Experimental|Dalbavancin|
11502252|NCT01339091|Active Comparator|Vancomycin with possible switch to oral linezolid|
11502253|NCT01339078|Active Comparator|Plastic stenting|Patients will be randomized towards plastic stenting.
11502254|NCT01339078|Experimental|Kaffes stenting|Patients will be randomized towards Kaffes stenting.
11502255|NCT01339065|Active Comparator|Ketamine|will be given low sub-anesthetic doses of Ketamine 0.5mg/kg.
11502256|NCT01339065|Placebo Comparator|Placebo|will get placebo treatment
11502257|NCT01339052|Experimental|Cohort 1: Surgical subjects|"Subjects scheduled for surgery
~BKM120: 100 mg once daily, orally, for 8-12 days prior to surgery
~Surgery: Surgery
~BKM120: 100 mg once daily, orally, for 28-day cycles
~Patients continued treatment until disease progression or unacceptable toxicity."
11502258|NCT01339052|Experimental|Cohort 2: Non-surgical subjects|"Subjects not candidates for surgery
~BKM120: 100 mg once daily, orally, for 28-day cycles
~Patients continued treatment until disease progression or unacceptable toxicity."
11502259|NCT01339039|Experimental|Part 1|Maximum Tolerated Dose Determination of Plerixafor (3 weeks on, 1 week off) and Bevacizumab (every 2 weeks)
11502260|NCT01339039|Experimental|Part 2|Surgical Arm: Safety evaluation of Plerixafor (3 weeks on, 1 week off) and Bevacizumab (every 2 weeks)
11502261|NCT01339039|Experimental|Part 3|Safety and tolerability of Plerixafor (daily) at MTD dose from Part 1 and Bevacizumab (every 2 weeks)
11502262|NCT01339026|Active Comparator|Prasugrel|Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
11502263|NCT01339026|Active Comparator|Clopidogrel|Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
11502264|NCT01339013|Active Comparator|AnaConDa|
11502265|NCT01339000|Experimental|Arm A -Sequence 1 Immunizations|Receive vaccine of Sequence 1 first, then vaccines of Sequence 2, 7 weeks later, after receiving interleukin-7 (IL-7)
11502266|NCT01339000|Experimental|Arm B - Sequence 2 Immunizations|Receive vaccines of Sequence 2 first then vaccines of Sequence1, 7 weeks later, after receiving IL-7
11502267|NCT01338987|Active Comparator|Arm1 First Transplt/males/leuprolide/+/-FLT Imaging|"Males randomized to leuprolide for first transplant.
~[18F]fluorothymidine (FLT) imaging"
11502268|NCT01338987|Active Comparator|Arm2 First Transplt/males/No Leuprolide/+/- FLT Imaging|"Males not receiving leuprolide for first transplant
~[18F]fluorothymidine (FLT) imaging"
11502269|NCT01338987|Experimental|Arm3 First Transplt/females/leuprolide+/- FLT Imaging|"Females receiving leuprolide for first transplant.
~[18F]fluorothymidine (FLT) imaging"
11502270|NCT01338987|Experimental|Arm4-Second Transplt/leuprolide and FLT Imaging|Second transplant with leuprolide and [18F]fluorothymidine (FLT) imaging
11502271|NCT01338987|No Intervention|Healthy Volunteer - Arm 5|Healthy Volunteer
11502272|NCT01338961|No Intervention|Normothermic CPB|Standard management. Patients will be kept at normothermia throughout the procedure (>36oC).
11502273|NCT01338961|Active Comparator|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC.
11502274|NCT01338935|Experimental|Part I|Ascending dose tolerance, PK, and estimation of ED95 for CW 002
11502275|NCT01338935|Experimental|Part II|Safety, efficacy and PK of increasing bolus doses and infusions of CW 002, and exploration of Neostigmine reversal
11502276|NCT01338935|Experimental|Part III|Intubation with CW 002 and Neostigmine reversal
11502277|NCT01338922|Experimental|Insulin pump therapy (CSII)|Continuous subcutaneous insulin infusion therapy using different devices with marketing approval and different insulins
11502278|NCT01338922|Active Comparator|Multiple daily injection therapy (MDI)|Multiple daily injection therapy using different devices with marketing approval and different insulin types
11502279|NCT01338909|Experimental|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
11502280|NCT01338909|Active Comparator|Clopidogrel|Clopidogrel 150mg/day starting from Day 1 until Day 5
11502281|NCT01338896|Experimental|Sequence A-B|4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 h, test product PR 2.2.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 h reference patch PR 2.1.1)
11502282|NCT01338896|Experimental|Sequence B-A|4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 h reference patch PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 h, test product PR 2.2.1)
11502283|NCT01338883|Experimental|CVC 100 mg + Truvada|
11502284|NCT01338883|Experimental|CVC 200 mg + Truvada|
11502285|NCT01338883|Active Comparator|Sustiva + Truvada|
11502286|NCT01338870|Placebo Comparator|Placebo|Placebo for PF-04991532 and sitagliptin
11502287|NCT01338870|Experimental|25 mg PF-04991532|
11502288|NCT01338870|Experimental|75 mg PF-04991532|
11502289|NCT01338870|Experimental|150 mg PF-04991532|
11502290|NCT01338870|Experimental|300 mg PF-04991532|
11502291|NCT01338870|Active Comparator|Sitagliptin 100 mg|
11502292|NCT01338857|Experimental|Sorafenib (Nexavar)|Sorafenib will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.
11502293|NCT01338844|Experimental|D-Chiro-inositol|Patients will receive 1.2g/day of D-chiro-inositol
11502294|NCT01338844|Active Comparator|Myo-inositol|Patients will receive 4g/day of myo-inositol
11502295|NCT01338831|Experimental|Breast & Prostate Cancer Group|Dose Escalation
11502296|NCT01338831|Experimental|Breast Cancer Group|Dose Expansion
11502297|NCT01338831|Experimental|Prostate Cancer Group|Dose Expansion
11502298|NCT01338831|Experimental|Uterine Leiomyoma Group|Dose Expansion
11502299|NCT01338818|Experimental|Ritalin LA|All participants started with Ritalin LA 20 mg/day and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 40, 60 or 80 mg/day).
11502300|NCT01338805|Experimental|BGG492|
11502301|NCT01338792|Experimental|Treatment (chemotherapy and enzyme inhibitor)|Patients receive oxaliplatin IV over 2 hours and pemetrexed disodium IV on day 1. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
11502302|NCT01338779||Group 1 - kidney tolerant|Renal allograft recipients showing functional tolerance (normal and stable renal function) after discontinuation of immunosuppressive medications for at least 1 year (or based on the investigator's discretion).
11502303|NCT01338779||Group 2 - acceptor|Enrollment for group 2 was closed. Renal transplant recipients with functioning allografts (not on dialysis) who had not received immunosuppressive medications for at least 1 year (or at investigator's discretion) but who had moderately impaired or gradually deteriorating renal function, defined as creatinine clearance (CrCl) < 40 mL/min and/or creatinine > 50% above baseline value, and thus did not qualify for group 1.
11502304|NCT01338779||Group 3 - kidney graft loss|Enrollment for group 3 is closed. These were renal transplant recipients who had subsequently rejected and lost function of their transplanted kidney.
11502305|NCT01338779||Group 4 - kidney monotherapy|Renal transplant recipients showing stable and normal renal function after receiving only prednisone 10 mg/day for at least 1 year (or based on the investigator's discretion).
11502306|NCT01338779||Group 5 - kidney standard immunotherapy|Enrollment for group 5 is closed. Stable renal transplant recipients currently on standard immunosuppression.
11502307|NCT01338779||Group 6 - kidney chronic rejector|Enrollment for group 6 is closed. Chronic allograft nephropathy group.
11502308|NCT01338779||Group 7 - kidney identical twin|Enrollment for group 7 is closed.
11502309|NCT01338779||Group 8 - living kidney donors|Corresponding to recipients in group 1 or 4.
11502310|NCT01338779||Group 9 - healthy controls|Enrollment for group 9 is closed.
11502311|NCT01338779||Group 10 - liver tolerant|Enrollment for group 10 is closed. Liver allograft recipients with functional tolerance (stable and normal liver function) after cessation of immunosuppressive medications for at least three years (or at investigator's discretion).
11502312|NCT01338779||Group 11 - liver standard immunotherapy|Enrollment for group 11 is closed. Subjects with a liver transplant who never had an attempt made to discontinue gradually their immunosuppression and who are currently taking standard immunosuppressive medications and have stable and normal liver allograft function after at least 1 year of receiving these drugs.
11502313|NCT01338766|Experimental|Surgery|Decompression using the iO-Flex® system
11502314|NCT01338740||Switch from Adalimumab to Infliximab|Moderately to severely active Crohn's disease patients with primary non-response or loss of response to Adalimumab, will switch to Infliximab.
11502315|NCT01338727|Experimental|Breastfeeding Peer Counseling|
11502316|NCT01338727|No Intervention|Standard Care|
11502317|NCT01338714|Experimental|A foumula|Compound Herbal Formula (RHD-1)
11502318|NCT01338714|Placebo Comparator|B formula|dilute Compound Herbal Formula
11502319|NCT01338701|Experimental|Auricular (Ear) Acupuncture|Auricular (Ear) Acupuncture is administered in a step-wise, algorithmic acupuncture approach in which needles are inserted at specific auricular landmarks. The sequence and location of needled points is determined by the participant's severity of headache pain at presentation and response to needling. Between six and nine points are needled in each treatment session depending on the individual's response (i.e., a decrease or persistence of headache pain). In-dwelling ASP needles are inserted at the end of each session. Participants are instructed to remove the needles after 3 days, or sooner if pain or redness developed at a needle site. Ten 45-minute acupuncture treatment sessions are administered over 6 weeks.
11502370|NCT01338337|No Intervention|Support treatment|Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed.
11502371|NCT01338337|Experimental|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
11502372|NCT01338311|Active Comparator|salbutamol|
11502320|NCT01338701|Experimental|Traditional Chinese Acupuncture (TCA)|A semi-standardized form of Traditional Chinese Acupuncture (TCA) is administered, incorporating the insertion of up to 22 acupuncture needles associated with each individual participant's: (1) primary headache pattern (up to three pairs of points); (2) secondary headache pattern (up to 2 pairs of points); (3) Ah-Shi or tender points (up to 4 points); (4) constitutional points (source points on two meridians); and, (5) up to 2 pairs of additional points from a selected list. Point selection was reassessed every two weeks per TCM diagnostic and treatment principles. While the majority of points were located on the limbs, points also included local points of tenderness to the head, as well as the front and back of the torso. Ten 60-minute TCA sessions are administered over 6 weeks.
11502321|NCT01338701|Other|Usual Care|All study participants continue to receive routine usual care for their TBI, headaches and associated symptoms as determined by their clinical team.
11502322|NCT01338688||Td ,Td and TIG|
11502323|NCT01338675|Experimental|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
11502324|NCT01338662||Group A-1|"study enroll number 3n+1 (N=0,1,2...)
~initial treatment- amantadine
~add levodopa when the patient become to need further treatment."
11502325|NCT01338662||Group A-2|"study enroll number 3n+2 (N=0,1,2...)
~initial treatment: amantadine
~add dopamine agonist when the patient become to need further treatment."
11502326|NCT01338662||Group B|"study enroll number 3n+3 (N=0,1,2...)
~initial treatment: dopamine agonist
~add levodopa when the patient become to need further treatment. but cannot use amantadine"
11502327|NCT01338649|Active Comparator|Bright White|Exposure to bright white light treatment.
11502328|NCT01338649|Placebo Comparator|Dim red light|Exposure to dim red light treatment.
11502329|NCT01338636|Other|Exercise-induced PAH|Open-label ambrisentan
11502330|NCT01338623|Experimental|Tansulosine|
11502331|NCT01338610|Experimental|ESBA105|ESBA105 ophthalmic solution, 1 drop in each eye 3 times per day for 4 weeks
11502332|NCT01338610|Placebo Comparator|Vehicle|ESBA105 vehicle, 1 drop in each eye 3 times per day for 4 weeks
11502333|NCT01338597|Experimental|standard|3 trocars are needed. two in the circumareolar region and one in the parasternal region. the dissection area begins from the trocar site and extends to the neck.
11502334|NCT01338597|Experimental|limited dissection|the dissection is reduced by creating a long tunnel from the trocar site and the dissection area confined in the upper chest wall and in the neck.
11502335|NCT01338584|Experimental|Pelvic floor muscle training, post prostatectomy|Pelvic floor muscle training will be taught on the day of admission
11502336|NCT01338571||Healthly children|Children will be given yogurt twice a day for four weeks. The dose for an adult is 8 ounces of yogurt twice a day. The dose will be scaled to the children based upon surface area dosing charts, but will not exceed a resistant starch load of 1 gram per year of age plus 10 grams10.
11502337|NCT01338558|Experimental|K-RAS mutated|
11502338|NCT01338558|Experimental|K-RAS native A|
11502339|NCT01338558|Active Comparator|K-RAS native B|
11502340|NCT01338545||Cohort|
11502341|NCT01338532|Active Comparator|Supervised exercise + patient education|
11502342|NCT01338532|Active Comparator|Patient education|
11502343|NCT01338519||PCOS and hirsutism|
11502344|NCT01338506|Experimental|COPE Therapy|Combined prolonged exposure therapy for PTSD with cognitive behavioral therapy for substance use disorder.
11502345|NCT01338506|Active Comparator|Treatment as usual|CBT for substance use disorder.
11502346|NCT01338493||lumbar spinal arthroplasty + Maverick™|Patients requiring total disc replacement
11502347|NCT01338480|Experimental|video|Participants in the intervention group watched an educational video illustrating informed consent information
11502348|NCT01338480|No Intervention|control|Participants in the control group read an informed consent document.
11502349|NCT01338467|Experimental|EYEOP Treatment|Open label, all subject treated by the EYEOP device
11502350|NCT01338454|Active Comparator|tranexamic acid|TA administered intravenously over a 5 min period at delivery of the anterior shoulder
11502351|NCT01338454|No Intervention|saline|10 mL of saline was administered intravenously over a 5 min period at delivery of the anterior shoulder
11502352|NCT01338441|Experimental|Erythromycin|
11502353|NCT01338441|Placebo Comparator|Placebo|
11502354|NCT01338428|Active Comparator|Brochure|
11502355|NCT01338428|Experimental|Enhanced AAA Sexual Assault Education|
11502356|NCT01338415|Experimental|bosentan 2mg/kg b.i.d.|Patients who received 2 mg/kg bosentan twcie daily (b.i.d.) during the FUTURE 3 core study and continued with the same dose regimen during the extension study
11502357|NCT01338415|Experimental|bosentan 2mg/kg t.i.d.|Patients who received 2 mg/kg bosentan 3 times a day (t.i.d.) during the FUTURE 3 core study and continued with the same dose regimen during the extension study
11502358|NCT01338402|Other|AIR OPTIX® AQUA|Lotrafilcon B contact lenses worn in both eyes on a daily wear basis for one week in Phase 1.
11502359|NCT01338402|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color randomly assigned to one eye, with phemfilcon A contact lens with color in the fellow eye for contralateral wear. Both products worn on a daily wear basis for 4 weeks in Phase 2. A replacement phemfilcon A lens was dispensed at the Week 2 visit.
11502360|NCT01338402|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color randomly assigned to one eye, with lotrafilcon B contact lens with color in the fellow eye for contralateral wear. Both products worn on a daily wear basis for 4 weeks in Phase 2. A replacement phemfilcon A lens was dispensed at the Week 2 visit.
11502361|NCT01338389|Experimental|CITICOLINE|Daily oral administration of 800 mg citicoline
11502362|NCT01338389|Placebo Comparator|Placebo|Daily oral administration of placebo
11502363|NCT01338376|Experimental|Structured Education Group|Subjects received structured diabetes education
11502364|NCT01338376|Active Comparator|Conventional Care Group:|Subjects received conventional diabetes education
11502365|NCT01338363||All first time users of esomeprazole|
11502366|NCT01338363||All first time users of other PPIs|
11502367|NCT01338363||All first time users of H2-receptor antagonists|
11502368|NCT01338350|Experimental|1|
11502369|NCT01338350|Placebo Comparator|2|
11502374|NCT01338298|Active Comparator|Aripiprazole|
11502375|NCT01338298|Placebo Comparator|Placebo|
11502376|NCT01338285||1|Workers exposed to high levels of formaldehyde and unexposed workers in Guangdong Province, China.
11502377|NCT01338142|Placebo Comparator|CCC|Crystalline calcium carbonate (CCC)
11502378|NCT01338142|Experimental|ACC|Amorphous calcium carbonate (ACC)
11502379|NCT01338129|Experimental|vitamin c|administration of vitamin c for 45 days following ankle fracture operation
11502380|NCT01338129|Placebo Comparator|placebo|placebo pills
11502381|NCT01338116|Experimental|Management by TREAT/PCR|The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly.
11502382|NCT01338116|No Intervention|Usual management|Patients will be managed by physicians as in regular clinical practice.
11502383|NCT01338103|Experimental|Rituximab|
11502384|NCT01338090||89Zr-bevacizumab|
11502385|NCT01338077|Experimental|Sodium alginate|Oral suspension, 50 mg/ml
11502386|NCT01338077|Active Comparator|Omeprazole|20 mg/cap
11502387|NCT01338064||exposed workers|At least six months of occupational exposure to Caesar stone
11502388|NCT01338025|Active Comparator|Arm A, non-suppressive HAART regimen|"In Step 1, subjects were randomized to continue their non-suppressive HAART regimen.
~In Step 2, subjects either began a new HAART regimen, continued randomized treatment, or discontinued therapy while remaining on follow-up, as decided by their provider."
11502389|NCT01338025|Active Comparator|Arm B, 3TC or FTC monotherapy|"In step 1, subjects were randomized to receive 3TC or FTC (the choice of 3TC or FTC was left to the provider).
~In Step 2, subjects either began a new HAART regimen, continued randomized treatment, or discontinued therapy while remaining on follow-up, as decided by their provider."
11502390|NCT01338012|Experimental|sipuleucel-T|Men with metastatic castrate resistant prostate cancer previously treated with sipuleucel-T in the androgen dependent setting in the Dendreon P-11 study. Subjects received one infusion of sipuleucel-T every two weeks for for a total of three infusions.
11502391|NCT01337999||HE-4 levels, healthy premenopausal women|
11502392|NCT01337986|Active Comparator|Group B: Dalfampridine First|Dalfampridine/Placebo: Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.
11502393|NCT01337986|Active Comparator|Group A: Dalfampridine Second|Placebo/Dalfampridine: Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks
11502394|NCT01337973|Experimental|Arm 1: MI-CBT|MI-CBT (six sessions during acute treatment phase integrating motivational interviewing and cognitive behavioral approaches)
11502395|NCT01337973|Experimental|Arm 2: MI-CBT+CC|MI-CBT+CC (acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention)
11502396|NCT01337973|Active Comparator|Arm 3: E-TAU|E-TAU (enhanced treatment as usual - includes brief session and provision of resources)
11502397|NCT01337960|Experimental|Arm 1|Seated robot training group. Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
11502398|NCT01337960|Experimental|Arm 2|Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
11502399|NCT01337960|Active Comparator|Arm 3|Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
11502400|NCT01337947||exercise training|12 weeks of exercise treatment/program for DM1 subjects
11502401|NCT01337934|Placebo Comparator|Lactated Ringer|Patients randomized for this group will receive 500 ml of lactated Ringer solution in early phase of sepsis or septic shock (less than six hour from sepsis onset) if mean arterial pressure was under 65mmHg, or blood lactate concentration higher than 4 mmol/L or base excess under - 4mmol/L until the target of central venous pressure of 8 mmHg or higher or recovery of hypotension.
11502402|NCT01337934|Active Comparator|Albumin|Patients randomized for Albumin group will receive 500 ml of 4% Albumin solution in early phase of sepsis (less than six hour from sepsis onset) if mean arterial pressure was under 65mmHg or blood lactate concentration higher than 4 mmol/L or base excess under - 4mmol/L until the target of central venous pressure of 8 mmHg or higher or recovery of hypotension.
11502403|NCT01337921|Experimental|Multi-strain Synbiotic|Multi-strain probiotic with prebiotics
11502404|NCT01337921|Active Comparator|Multi-strain Probiotic|Multi-strain Probiotic without prebiotics.
11502405|NCT01337895|Active Comparator|Lifestyle counselling|These participants will be assigned to a 500 kcal/day energy-restricted diet that is low in dairy products (no more than 1 serving per day).
11502406|NCT01337895|Experimental|High dairy|These participants will be assigned a 500 kcal/day energy-restricted diet that is high in dairy (4 or more servings per day).
11502407|NCT01337882|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust (approximate PM10 concentration 300 mcg/m3) during intermittent exercise
11502408|NCT01337882|Experimental|Biodiesel exhaust exposure|1 hour exposure to dilute biodiesel exhaust (approximate PM10 concentration 300 mcg/m3) during intermittent exercise
11502409|NCT01337869|Active Comparator|Bascom Cleft Lift Technique|
11502410|NCT01337869|Active Comparator|Limberg Flap Technique|
11502411|NCT01337856|Other|WHO alcohol handrub protocol|handrubbing with alcohol using the standard 7-step technique (WHO alcohol handrub protocol)
11502412|NCT01337856|Other|CDC alcohol handrub protocol|Handrubbing with alcohol covering all hand surfaces in no particular order (CDC alcohol handrub protocol)
11502413|NCT01337856|Other|Chlorhexidine handwashing|chlorhexidine handwashing using the standard 7-step technique (WHO handwashing protocol)
11502414|NCT01337843|Active Comparator|Control Group|Control Group participants will receive a well-regarded book for back pain patients.
11502415|NCT01337843|Experimental|Wellnes Workbook|Participants will receive the Wellness Workbook, a web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase their physical activity and manage stress with relaxation and mindfulness training
11502416|NCT01337830|Experimental|Ariva® Silver Wintergreen|Subjects allow study product lozenge to dissolve in the mouth, smoke a cigarette, then answer questionnaires about the effect of the product on both their desire to smoke and on cigarette taste.
11502417|NCT01337830|Active Comparator|Silver Wintergreen|Subjects allow comparator product lozenge to dissolve in the mouth, smoke a cigarette, then answer questionnaires about the effect of the product on both their desire to smoke and on cigarette taste.
11502418|NCT01337817|Experimental|Ariva Silver Wintergreen|Subjects allow study product lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
11502419|NCT01337817|Active Comparator|Ariva Wintergreen|Subjects allow study comparator lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
11502420|NCT01337804|Experimental|Zegerid-Prilosec|Participants receive Zegerid in Period 1 and Prilosec in Period 2, with a 10- to 21-day washout between study drug administrations.
11502421|NCT01337804|Experimental|Prilosec-Zegerid|Participants receive Prilosec in Period 1 and Zegerid in Period 2, with a 10- to 21-day washout between study drug administrations.
11502422|NCT01337791|No Intervention|control|
11502423|NCT01337791|No Intervention|telbivudine|
11502424|NCT01337778|Active Comparator|Primary Care for DILs|Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced gender-based violence. A comprehensive health examination for mothers-in-law will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
11502425|NCT01337778|Experimental|Standard Care plus Dil Mil Intervention|The Dil Mil intervention will be implemented during the second and third trimesters of the daughter-in-law's (DILs) pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with mothers-in-law (MILs), and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce gender-based violence (GBV) and protect and promote their family's health.
11502426|NCT01337765|Experimental|BEZ235 + MEK162|
11502427|NCT01337752|Experimental|BHQ880 + bortezomib and dexamethasone|
11502428|NCT01337752|Placebo Comparator|BHQ880 Placebo + bortezomib and dexamethasone|
11502429|NCT01337739|Placebo Comparator|Placebo Comparator|Continuous infusion of placebo during operative procedure
11502430|NCT01337739|Active Comparator|Active Comparator|Administration of Dexmedetomidine
11502431|NCT01337726|Active Comparator|Illness Management Only|
11502432|NCT01337726|Experimental|Combined Psychotherapy & Illness Management|
11502433|NCT01337713|Experimental|Swedish Massage|
11502434|NCT01337713|Sham Comparator|Light Touch|
11502435|NCT01337700|Experimental|Milnacipran|
11502436|NCT01337700|Placebo Comparator|Placebo|
11502437|NCT01337687|Experimental|Oxytocin|
11502438|NCT01337687|Placebo Comparator|Placebo|
11502439|NCT01337674|Experimental|Panel A: MK-4618 + Met → PBO + Met|Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.
11502440|NCT01337674|Experimental|Panel A: PBO + Met → MK-4618 + Met|Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.
11502441|NCT01337674|Experimental|Panel B: MK-4618 + Amlo → PBO + Amlo|Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.
11502442|NCT01337674|Experimental|Panel B: PBO + Amlo → MK-4618 + Amlo|Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.
11502443|NCT01337661||COPD subjects|Adult male and female subjects with COPD
11502444|NCT01337648||TBI prior to stem cell transplantation|
11502445|NCT01337635|Active Comparator|Standard dose vitamin D|Treatment with cholecalciferol 400 IU daily at home.
11502446|NCT01337635|Active Comparator|High dose vitamin D|Treatment with ergocalciferol 300,000 IU (6 capsules of 50,000 IU) as a single oral dose observed in clinic.
11502447|NCT01337622|Experimental|No routine check for gastric residuals|
11502448|NCT01337622|Active Comparator|Routine check for gastric residuals|
11502449|NCT01337609|Experimental|GanedenBC30|Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.
11502450|NCT01337609|Placebo Comparator|Sugar pill|Arm 2 will take placebo (sugar pill) for 60 days.
11502451|NCT01337609|Other|Ganeden BC30, Sugar pill|Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.
11502452|NCT01337596|Experimental|Single dose 1 milligram (mg) LY2951742|Administered single subcutaneous injection
11502453|NCT01337596|Experimental|Single dose 5 mg LY2951742|Administered single subcutaneous injection
11502454|NCT01337596|Experimental|Single dose 25 mg LY2951742|Administered single subcutaneous injection
11502455|NCT01337596|Experimental|Single dose 75 mg LY2951742|Administered single subcutaneous injection
11502456|NCT01337596|Experimental|Single dose 200 mg LY2951742|Administered single subcutaneous injection
11502457|NCT01337596|Experimental|Single dose 600 mg LY2951742|Administered single subcutaneous injection
11502458|NCT01337596|Placebo Comparator|Single dose placebo|Administered single subcutaneous injection
11502459|NCT01337596|Placebo Comparator|Multiple dose placebo|Administered subcutaneously every 2 weeks for 6 weeks (4 doses)
11502460|NCT01337596|Experimental|150 mg LY2951742|Administered subcutaneously every 2 weeks for 6 weeks (4 doses)
11502461|NCT01337583|Experimental|Dapivirine|Vaginal ring containing 25mg of dapivirine
11502462|NCT01337583|Placebo Comparator|Placebo Ring|Vaginal ring containing no drug substance
11502463|NCT01337570|Experimental|Dapivirine|Vaginal ring containing 25mg of dapivirine
11502464|NCT01337570|Placebo Comparator|Placebo Ring|Vaginal ring containing no drug substance
11502465|NCT01337557|Experimental|Bepotastine|
11502466|NCT01337544|Experimental|IL-15 STIMULATED NK CELLS|
11502467|NCT01337531|Experimental|gonadotropin|recombinant or highly purified gonadotropin
11502468|NCT01337531|Active Comparator|Gonadotropins|recombinant versus highly purified gonadotropin
11502469|NCT01337518|Experimental|EZN-4176|
11502470|NCT01337505|Experimental|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 doxorubicin equivalents of 165, 260, and 325 mg/m2)will be administered as a 30 minute IVI on Day 1 of each cycle.
11502471|NCT01337492|Experimental|Sorafenib|
11502472|NCT01337479||Participants of specific phase III entecavir studies|Those who participated in the specific Phase III entecavir studies as described; all had Hepatitis B infections
11502473|NCT01337466|Experimental|[124I]FIAU|single dose study of [124I]FIAU in healthy volunteers or subjects with prosthetic joint infection who will undergo PET-CT scanning
11502474|NCT01337453||Flu-like symtoms, incidence|The frequency of FLS will be estimated by number of patients and number of Botox treatments.
11502475|NCT01337440|Active Comparator|UDCA pretreatment|"Ursodeoxycholic Acid (UDCA) for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.
~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
11502476|NCT01337440|Active Comparator|Sitagliptin pretreatment|"Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.
~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
11502477|NCT01337427|Placebo Comparator|Placebo for 48 weeks, BIIB017 for 48 weeks|Placebo every 2 weeks for 48 weeks followed by 125 mcg BIIB017 SC every 2 or 4 weeks for 48 weeks.
11502478|NCT01337427|Experimental|BIIB017 every 2 weeks for 96 weeks|125 mcg BIIB017 SC every 2 weeks for 96 weeks.
11502479|NCT01337427|Experimental|BIIB017 every 4 weeks for 96 weeks|125 mcg BIIB017 SC every 4 weeks for 96 weeks.
11502480|NCT01337414|Experimental|VMS diary booklet|
11502481|NCT01337414|Active Comparator|Usual Care (e.g. Amsler grid monitoring)|
11502482|NCT01337401|Experimental|Blinded Cediranib|
11502483|NCT01337401|Placebo Comparator|Blinded Placebo|
11502484|NCT01337388||Cohort|
11502485|NCT01337375|Experimental|A/B|
11502486|NCT01337375|Experimental|C/D|
11502487|NCT01337362|Active Comparator|Patients with hypoglycemia awareness|Patients who have symptoms when the blood sugar level is low
11502488|NCT01337362|Experimental|patients with hypoglycaemic unawareness.|Patients who do not feel any symptoms when the blood sugar levels are low
11502489|NCT01337349|Placebo Comparator|Sugar Pill|Placebo control Group with sugar pill three times daily for 6 months
11502490|NCT01337349|Experimental|Pentoxifylline|Pentoxifylline 400mg tablets to be taken three times daily for 6 months
11502491|NCT01337336||COPD patients with comorbid depression/anxiety|Patients aged 40 and over with COPD and comorbid depression/anxiety. Managed care enrolees (aged >40 years) having newly initiated drug therapy with FSC or AC during the identification period (01/01/2004 to 06/30/2008) to treat COPD with a medical or pharmacy claim for depression before and 60 days post index date were the target population. The first fill date of FSC or AC was the index date.
11502492|NCT01337323||New prescription for fluticasone furoate nasal spray|patients receiving their first prescription for fluticasone furoate nasal spray and who have active seasonal allergic rhinitis with a history of using another intranasal steriod (INS) and other concomitant allergic rhinitis medications to treat their seasonal allergy symptoms.
11502493|NCT01337310|Experimental|Tesetaxel|Tesetaxel administered orally once every 21 days for at least 2 cycles
11502494|NCT01337297|Placebo Comparator|sham-tDCS|the electrodes are positioned in the same manner as the active-tDCS, activated for 20 s (time to climb ramp of the current until reach the current intensity used in the experiment), enough to produce the sensation of itch, and turned off until the end of the session.
11502495|NCT01337297|Experimental|active-tDCS|low-intensity transcranial Direct Current Stimulation (tDCS)applied over the dorsolateral prefrontal cortex
11502496|NCT01337271|Active Comparator|PSV|
11502497|NCT01337271|Experimental|NAVA|
11502498|NCT01337258||Men at increased risk for Prostate Cancer (PCA)|
11502499|NCT01337245|Experimental|Antivenom|For comparison with historical mortality rate, all patients prospectively enrolled will receive antivenom (Snake [Micrurus] North American immune F(ab')2 Equine) for treatment of coral snake bite.
11502500|NCT01337232|Active Comparator|1 session per week|
11502501|NCT01337232|Experimental|2 sessions per week|
11502717|NCT01335724|Placebo Comparator|placebo gel|
11502502|NCT01337219|Other|Arm A|experimental treatment (Nebcinal/Aeroneb Idehaler pocket) - 6day-wash out period - standard treatment (Tobi/Pari LC Plus)
11502503|NCT01337219|Other|Arm B|standard treatment (Tobi/Pari LC Plus) - 6day-wash out period - experimental treatment (Nebcinal/Aeroneb Idehaler)
11502504|NCT01337206|Experimental|Stenting Arm|Stenting Arm
11502505|NCT01337206|Active Comparator|Dilation Arm|Dilation Arm
11502506|NCT01337193|Active Comparator|Pelvic floor muscle exercises|Three pelvic floor muscle exercises will be performed with verbal cueing from the instructor.
11502507|NCT01337193|Experimental|Pelvic floor exercises with biofeedback|Pelvic floor exercises will be performed with biobeedback cueing.
11502508|NCT01337180||Main study group|"Inclusion criteria: Employment at one of the plants (SiC I) and (SiC II) in Porsgrunn. Both administrative/office workers and workers in the production and maintenance departments will be invited to participate. Non-smokers and smokers and male and female workers will be included in the main study group (study A).
~Sputum part of study: nonsmokers."
11502509|NCT01337167|Experimental|V419|V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.
11502510|NCT01337167|Active Comparator|Control|Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.
11502511|NCT01337154|Experimental|Tamibarotene|Subjects will receive tamibarotene, 6 mg/m2, divided as twice daily orally starting 1 week before chemotherapy and continuing through all 6 cycles and through the duration of the study. Chemotherapy will include paclitaxel (IV; 200 mg/m2) and carboplatin (IV; AUC=6)administered once every 3 weeks for up to 6 cycles.
11502512|NCT01337154|Placebo Comparator|Placebo|Subjects will take an equal number of placebo tablets as the group receiving tamibarotene divided as twice daily orally, starting 1 week before chemotherapy and continuing through all 6 cycles and through the duration of the study. Paclitaxel (IV; 200 mg/m2) and carboplatin (IV; AUC=6) will be administered once every 3 weeks for up to 6 cycles.
11502513|NCT01337141|Experimental|Interventional telematic|80 patients will be included in this arm. They will receive 5 telematic visits (Telecare system) and 2 face to face visits.
11502514|NCT01337141|Other|Control|80 patients will be included in this arm. They will receive 7 face-to-face visits (not telematic).
11502515|NCT01337128|Experimental|Carotid endarterectomy (CEA)|Patients with carotid stenosis who are randomly assigned to a carotid endarterectomy.
11502516|NCT01337128|Experimental|Carotid Stenting (CAS)|Patients with carotid stenosis who are randomly assigned to a carotid stenting.
11502517|NCT01337128|No Intervention|matched control group|Matched control group.
11502518|NCT01337115|Active Comparator|Continuous femoral nerve block (CFNB)|A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
11502519|NCT01337115|Experimental|Single shot SNB plus CFNB|A single shot sciatic nerve block (SNB) is performed before surgery with 25ml of 0.2% ropivacaine in addition to the continuous femoral nerve block (CFNB) performed in the control group before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in Post anesthesia care unit (PACU) and maintained for 48h
11502520|NCT01337102|Other|Physician to receive results|Arm 1 Physician to receive the results of the Lung QoL scale
11502521|NCT01337102|Other|Physician Does Not Receive Results|Arm 2 Physician does not receive the results of the Lung QoL scale
11502522|NCT01337089|Experimental|Non-comparative, open-label Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray, in the morning and evening, up to a maximum of 10 sprays per day for 6 months. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligrams [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
11502523|NCT01337076|Other|cochlear implant|
11502524|NCT01337063|No Intervention|Pre-intervention|Usual care regarding medication reconciliation as currently practiced at each participating site.
11502525|NCT01337063|Experimental|Intervention|Improved medication reconciliation process using continuous quality improvement methods, mentored implementation, and an implementation guide.
11502526|NCT01337050|Experimental|A|PF-03446962
11502527|NCT01337037||standard VATS group|patients undergo standard VATS lobectomy using non-modified equipments,without limits of staples
11502528|NCT01337037||modified equipments group|patients undergo VATS lobectomy with modified VATS lobectomy equipments designed designed according to the experience of chinese lobectomy surgery: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.).
11502529|NCT01337037||less staples group|patients undergo VATS lobectomy with at most 4 staples used.
11502530|NCT01337037||open group|patients undergo lobectomy by thoracotomy approach
11502531|NCT01337024||Control group|Healthy volunteers, examined with ECG without any treatment (controls)
11502532|NCT01337024||100 BoNT/A|patients with neurogenic detrusor overactivity, examined with ECG, injection of 100 units BoNT/A
11502533|NCT01337024||300 BoNT/A|patients with neurogenic detrusor overactivity, examined with ECG, injection of 300 units BoNT/A
11502534|NCT01337011|Experimental|intra-coronary administration|Application of stem cells using the intra-coronary route.
11502535|NCT01337011|Experimental|intra-myocardial administration|Application of stem cells using the intra-myocardial route.
11502536|NCT01336972|Experimental|Group A - eGFR > 60 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM [8 hours later]) to the maximally tolerated dose.
11502537|NCT01336972|Experimental|Group B - eGFR 30 to 60 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM [8 hours later]) to the maximally tolerated dose.
11502538|NCT01336972|Experimental|Group C - eGFR < 30 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM [8 hours later]) to the maximally tolerated dose.
11502539|NCT01336959|Experimental|Open Label - BCT197 Part A|10mg single dose of BCT197
11502540|NCT01336959|Experimental|BCT197 Part B|Single dose of 50mg BCT197
11502541|NCT01336959|Placebo Comparator|BCT 197 Placebo Part B|Single dose of matching placebo to 50mg BCT197
11502542|NCT01336946|Experimental|health promotion program|Psycho education and behavioural group sessions and supervised walking sessions will be performed.
11502543|NCT01336946|No Intervention|Control group|No intervention will be performed in this control group.
11502544|NCT01336933|Experimental|Treatment|"A Treatment: Cyclophosphamide,Etoposide, Vincristine and Prednisone (CEOP) B Treatment: Pralatrexate (P)
~A cycles (CEOP) of the treatment regimen are 14 days, followed by  B cycles (P) which are 21 days, followed by 7 days of rest for a total of 42 days per course, unless criteria are met for stopping or holding treatment or to a maximum of 6 courses.
~Patients with Complete Response (CR) or Partial Response (PR), per investigators discretion, may then undergo hematopoietic stem cell collection and administration of standard preparative regimen followed by hematopoietic stem cell transplantation."
11502545|NCT01336920|Experimental|Treatment (carfilzomib)|Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11502546|NCT01336907||naive CNV subjects|Newly diagnosed CNV, before any treatment (naïve)
11502547|NCT01336907||previously diagnosed CNV subjects|Previously diagnosed CNV if last treatment is older than 4 months (reactivated)
11502548|NCT01336894|Active Comparator|Arm I (SR+Brachytherapy)|Patients undergo sublobar resection comprising either a wedge resection or anatomical segmentectomy with or without intraoperative brachytherapy comprising an iodine I 125 implant at the resection margin.
11502549|NCT01336894|Experimental|Arm II (SBRT)|Patients undergo 3 fractions of stereotactic body radiation therapy at 2-8 days apart.
11502550|NCT01336881||Correlative (tissue analysis)|Archived tumor tissue samples are analyzed for hepatoblastoma and other liver tumor biomarkers by microRNA array profiling and exome sequencing. Results are then compared with patients' clinical data.
11502551|NCT01336855||HIV Positive|HIV-1 positive subjects
11502552|NCT01336855||HIV negative subjects|HIV-1 seronegative control group
11502553|NCT01336842|Experimental|Phase I dose-escalation|Drug: panobinostat Drug: cisplatin Drug: pemetrexed Other: Biomarker studies
11502554|NCT01336829|Experimental|001|ETR/telaprevir Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18 and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
11502555|NCT01336829|Experimental|002|telaprevir/ETR Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18 and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
11502556|NCT01336829|Experimental|003|TMC278/telaprevir Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18 and TMC278 25 mg once daily from Day 8 to Day 18.
11502557|NCT01336829|Experimental|004|telaprevir/TMC278 Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18 and TMC278 25 mg once daily from Day 8 to Day 18.
11502558|NCT01336816|Experimental|Ariva Silver Wintergreen|Subjects allow study product lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
11502559|NCT01336816|Placebo Comparator|Placebo Wintergreen|Subjects allow study placebo lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
11502560|NCT01336803|Experimental|Feraheme|Intravenous injection of Feraheme, 5 mg Fe/kg
11502561|NCT01336777||Insulin resistant group|there is no intervention
11502562|NCT01336777||Insulin sensitive group|There is no intervention
11502563|NCT01336764|Experimental|Active|individual coping self-statements and stimulus guided paced breathing.
11502564|NCT01336764|Sham Comparator|Control|Coping self statements and breathing retraining will be replaced with undirected passive behaviors such as listening to music.
11502565|NCT01336751|Experimental|Insulin glargine|"Lantus (insulin glargine) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by Self-monitoring blood glucose (SMBG).
~The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator."
11502566|NCT01336751|Active Comparator|Lispro mix|"Humalog Mix 75/25 (lispro mix) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by self-monitoring blood glucose (SMBG).
~The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator."
11502567|NCT01336738|Placebo Comparator|Placebo|Matching placebo for PF-04991532 and Sitagliptin
11502568|NCT01336738|Experimental|150 mg PF-04991532|
11502569|NCT01336738|Experimental|450 mg PF-04991532|
11502570|NCT01336738|Experimental|750 mg PF-04991532|
11502571|NCT01336738|Active Comparator|Sitagliptin 100 mg|
11502572|NCT01336725||Morbid obesity|All attending learning and mastery courses for persons with morbid obesity
11502573|NCT01336712|Experimental|Myeloablative Haploidentical Transplant|Haplo transplant
11502574|NCT01336699|Experimental|Cohort A|WRSs2 vaccine 1x10^3 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^3 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
11502575|NCT01336699|Experimental|Cohort B|WRSs2 vaccine 1x10^4 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^4 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
11502576|NCT01336699|Experimental|Cohort C|WRSs2 vaccine 1x10^5 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^5 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
11502577|NCT01336699|Experimental|Cohort D|WRSs2 vaccine 1x10^6 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^6 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
11502578|NCT01336699|Experimental|Cohort E|WRSs2 vaccine 1x10^7 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^7 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
11502579|NCT01336686|Experimental|Arhalofenate 400 mg|
11502580|NCT01336686|Experimental|Arhalofenate 600 mg|
11502581|NCT01336686|Placebo Comparator|Placebo|
11502582|NCT01336660|Experimental|Equine F(ab')2 antivenom|Intensive care support and Equine F(ab')2 antivenom
11502583|NCT01336660|Placebo Comparator|Placebo|Intensive care support plus placebo
11502584|NCT01336647|Experimental|Group A|Group A Low-Dose Ha44 Gel 0.37% w/w topically administered to head and scalp.Single application for 10 minutes.
11502585|NCT01336647|Experimental|Group B|Group B High-Dose Ha44 Gel 0.74% w/w. Topically administered to hair and scalp. Single application for 10 minutes of duration.
11502586|NCT01336647|Placebo Comparator|Group C|Group C Placebo/ vehicle Ha44 Gel. Topically administered to hair and scalp.Single application for 10 minutes of duration.
11502587|NCT01336634|Experimental|Cohort A|Subjects will receive dabrafenib 150mg BID and will continue on treatment until disease progression, death, or unacceptable adverse event. Subjects receiving and adequately tolerating dabrafenib as a single agent and who continue to meet the inclusion and exclusion criteria will have the option to switch to dabrafenib (150 mg BID) and trametinib (2 mg once daily) combination treatment within 4 weeks of radiologic disease progression with prior approval from a GSK medical monitor
11502588|NCT01336634|Experimental|Cohort B|Subjects enrolled in Cohort B will receive dabrafenib 150 mg BID in combination with trametinib 2 mg once daily and will continue on treatment until disease progression, death, or unacceptable adverse event.
11502589|NCT01336634|Experimental|Cohort C|Subjects enrolled in Cohort C will receive dabrafenib 150 mg BID in combination with trametinib 2 mg once daily and will continue on treatment until disease progression, death, or unacceptable adverse event
11502590|NCT01336621|Experimental|Retigabine IR|Open label flexible dose between 300 mg/day (Minimum) and 1200 mg/day (maximum).
11502591|NCT01336608|Experimental|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
11502592|NCT01336608|Experimental|vilanterol|Inhaled long acting beta-agonist
11502593|NCT01336608|Placebo Comparator|placebo|Placebo
11502594|NCT01336595|Experimental|Zirconium Femoral Component|Oxidized zirconium femoral component of Genesis II TKR system is used.
11502595|NCT01336595|Active Comparator|Cobalt Chrome|Cobalt-Chromium Femoral component of Genesis II system is used.
11502596|NCT01336582|Experimental|docetaxel|
11502597|NCT01336582|Active Comparator|Taxotere|Docetaxel-PM 75 mg/m2 (70 mg/m2 for age of ≥ 65) Taxotere 75mg/m2 (70 mg/m2 for age of ≥ 65)
11502598|NCT01336569|Experimental|DuoTrav|Travoprost 0.004%/timolol maleate 0.5% fixed combination, one drop to the study eye nightly for up to 6 weeks
11502599|NCT01336543|Experimental|Active Treatment|"ACTIVE TREATMENT intervention below:
~NSCLC (Non-Small Cell Lung Cancer)
~PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 60 mg/m2 days 1-3 and 29-31)
~Radiation 59.4 Gy with 2 cycles of PE
~(Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles
~(Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
11502600|NCT01336530|Experimental|Tepilta®|
11502601|NCT01336530|Active Comparator|Oxetacaine|
11502602|NCT01336530|Active Comparator|Antacids|
11502603|NCT01336530|Placebo Comparator|Placebo|
11502604|NCT01336465|Experimental|rhuMAb Beta7|
11502605|NCT01336465|Placebo Comparator|placebo|
11502606|NCT01336452|Other|CCRTx|consecutive patients who plan to undertake CCRTx due to advanced hepatocellular carcinoma
11502607|NCT01336439|Active Comparator|M group|A total of 25U of botulinum toxin type A was injected into each side masseter muscle in this arm.
11502608|NCT01336439|Active Comparator|MT group|A total of 25U of botulinum toxin type A was injected into each side masseter and temporal muscle in this arm.
11502609|NCT01336413|Active Comparator|Arm 1|Pregnenolone
11502610|NCT01336413|Placebo Comparator|Arm 2|Placebo
11502611|NCT01336400||PGD-FISH|"Following couples opting for preimplantation genetic diagnosis on the basis of FISH:
~couples suffering a complex chromosomal rearrangement (CCR)
~couples with X-linked recessive disorders
~couples that carry a balanced chromosomal rearrangement"
11502612|NCT01336400||PGD-PCR|"Following couples opting for preimplantation genetic diagnosis on the basis of PCR:
~-couples at risk for the transmission of monogenic diseases"
11502613|NCT01336387|Experimental|Arm I (retinoid 9cUAB30)|Participants receive retinoid 9cUAB30* PO on days 1-28.
11502614|NCT01336387|Placebo Comparator|Arm II (placebo)|Participants receive placebo* PO on days 1-28.
11502615|NCT01336374||Greened Vacant Lot|A cluster of vacant lots is greened. People living around this area make up this cohort.
11502616|NCT01336374||Control Site|The control site is a cluster of vacant lots that will not be greened. The people living around these lots make up the control group.
11502617|NCT01336361||Physical Therapists|Physical Therapists who are members of the American Physical Therapy Association (APTA) and live in the United States .
11502618|NCT01336348|Experimental|prasugrel|Prasugrel 60 mg loading dose
11502619|NCT01336348|Active Comparator|Tirofiban|Tirofiban will be at a bolus only of 25uM or followed by 2 hour infusion
11502620|NCT01336335|Experimental|CPAP|OSA treatment with CPAP
11502621|NCT01336335|No Intervention|control|no intervention
11502622|NCT01336322|Active Comparator|Metformin|Metformin 850 mg bid
11502623|NCT01336322|Active Comparator|Sitagliptin|Sitagliptin 100 mg qd
11502624|NCT01336322|Active Comparator|Sitagliptin+Metformin|Sitagliptin 100 mg qd plus Metformin 850 mg bid
11502718|NCT01335711|Experimental|IMP_C/C IL28B|C/C IL28B subjects to whom IMP will be administrated prior to SOC
11502625|NCT01336309||Focus Group|We conducted three focus groups per site, at three sites, with around eight people each. These data were used to guide refinement and selection of the items we developed for Phase III data collection. We will administer the Yoga Research Tool.
11502626|NCT01336309||Cognitive Interviews|We conducted cognitive interviews at three different sites, with about ten in each group. These data were used to guide refinement and selection of the items we developed for Phase III data collection. We collected this data via a large, online survey and administered the Yoga Research Tool.
11502627|NCT01336309||Survey Prototype Administration|We administered a prototype of the study measure to a large group of yoga students, with about 450 total participants. These data were used to further inform the refinement and selection of items to be used in the final measure.
11502628|NCT01336309||Reliability and Validity Testing|We are conducting yoga classes at community partner facilities near each site, with about ten participants in each class. Participants at each class will complete the study measure and related questionnaires, in order to test the reliability and validity of the study measure.
11502629|NCT01336296|Active Comparator|Myfortic preload|Initiation of mycophenolic acid (Myfortic) 2 weeks prior to transplantation (with Simulect induction at time of transplant)
11502630|NCT01336296|Active Comparator|Myfortic standard|mycophenolic acid (Myfortic) at time of transplant with Thymoglobulin induction
11502631|NCT01336283|Active Comparator|COPD with emphysema|Analyze what type of training is more appropriate and beneficial as the patient characteristics that apply to you.
11502632|NCT01336283|Active Comparator|COPD non-emphysema|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
11502633|NCT01336270||MELANOMA 10mm|patients with a melanoma larger than 10mm or with cutaneous metastasis
11502634|NCT01336270||STAGE III MELANOMA|stage III melanoma patients who shall undergo a regional lymph node dissection
11502635|NCT01336270||SENTINEL NODE PROCEDURE|retrospective study of patients who underwent a sentinel node procedure
11502636|NCT01336270||STAGE IV MELANOMA|stage IV patients achieves of inoperable melanomas the stage(stadium) III or IV that must receive in treatment(processing) a chemotherapy (by the dacarbazine or by the cisplatin or by the inhibitor of B-raf) and carrier of at least two cutaneous metastases
11502637|NCT01336257|Experimental|Electronic Reminder|alert from SEBASTIAN decision support system
11502638|NCT01336257|No Intervention|control|
11502639|NCT01336244|Experimental|GLPG0778 ascending doses|Multiple ascending doses for 13 days, ranging from 50 mg twice daily upto a maximum to be determined during escalation.
11502640|NCT01336244|Placebo Comparator|Placebo|Twice daily for 13 days, matching the scheme of the multiple ascending dose.
11502641|NCT01336231||patients group|Patients with a metastatic kidney cancer and must beginning a treatment by antiangiogenic
11502642|NCT01336218|Experimental|1|Fostamatinib
11502643|NCT01336218|Experimental|2|Rifampicin
11502644|NCT01336205|Experimental|1|Oral Treatment
11502645|NCT01336205|Active Comparator|2|Oral treatment
11502646|NCT01336192|No Intervention|Best supportive care|Best supportive care
11502647|NCT01336192|Experimental|Maintenance gemcitabine|Maintenance therapy of gemcitabine alone
11502648|NCT01336179|Experimental|Miswak, dental plaque and gingivitis|
11502649|NCT01336179|Active Comparator|Toothbrush, dental plaque and gingivitis|
11502650|NCT01336166|Experimental|split-virion, non-adjuvanted vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
11502651|NCT01336166|Experimental|split-virion, non-adjuvanted vaccine of 30 μg|split-virion, non-adjuvanted H1N1 vaccine of 30 μg.
11502652|NCT01336166|Experimental|split-virion, non-adjuvanted vaccine of 45 μg|split-virion, non-adjuvanted H1N1 vaccine of 45 μg.
11502653|NCT01336166|Placebo Comparator|Placebo control|Placebo control
11502654|NCT01336153|Experimental|MLC601|MLC601 (NeuroAideTM) is a TCM which is used extensively in China to improve recovery after stroke. It combines several herbal and animal components.
11502655|NCT01336153|Placebo Comparator|Placebo|
11502656|NCT01336140|Experimental|Aminophylline|75 mg of intravenous aminophylline.
11502657|NCT01336140|Placebo Comparator|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
11502658|NCT01336127|Experimental|occupational therapy|10 weeks occupational therapy according to a protocol (OTiP protocol) based on the Dutch guidelines of occupational therapy in Parkinson's disease
11502659|NCT01336127|No Intervention|No occupational therapy|Patients and their caregivers in the control group will have no occupational therapy intervention until their last measurement has taken place (6 months).
11502660|NCT01336101|Other|SFA stenting|
11502661|NCT01336088|Experimental|ADX48621|
11502662|NCT01336088|Placebo Comparator|ADX48621 Matching Placebo|
11502663|NCT01336075|Active Comparator|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic radiofrequency ablation
11502664|NCT01336075|Active Comparator|Percutaneous ablation|Percutaneous radiofrequency catheter ablation
11502665|NCT01336062|Experimental|Nanoparticle Albumin-Bound Paclitaxel|The study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;
11502666|NCT01336049|Experimental|Nimotuzumab|
11502667|NCT01336023|Experimental|IDeg|
11502668|NCT01336023|Experimental|IDegLira|
11502669|NCT01336023|Experimental|Lira|
11502670|NCT01336010|Experimental|Group A - 8 weeks therapy|8 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 2 weeks of therapy.
11502671|NCT01336010|Experimental|Group B - 16 weeks therapy|16 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 4 weeks of therapy.
11502672|NCT01336010|Experimental|Group C - 24 weeks therapy|24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 6 weeks of therapy.
11502673|NCT01336010|Experimental|Group D - 32 weeks (gt1) or 24 weeks (gt 2/3)|32 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 8 weeks of therapy (genotype 1) or 24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 8 weeks of therapy.
11502719|NCT01335711|Active Comparator|SOC_C/C IL28B|C/C IL28B subjects to whom only SOC will be administrated
11502720|NCT01335711|Experimental|IMP_non-C/C IL28B|non-C/C IL28B subjects to whom IMP will be administrated prior to SOC
11502674|NCT01336010|Experimental|Group E - 48 weeks (gt 1) or 24 weeks (gt 2/3)|48 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 12 weeks of therapy (genotype 1) or 24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 12 weeks of therapy (genotype 2/3).
11502675|NCT01336010|No Intervention|Untreated Group|Observation only. No treatment for hepatitis C administered. Subjects who have undetectable HCV RNA at baseline, do not wish to commence treatment or are ineligible for treatment.
11502676|NCT01335997|Experimental|ERN/LRPT/SIM → ERN/LRPT+SIM|Weeks 0-4 (Period 1): Participants will take ERN/LRPT/SIM 1 g/10 mg and SIM-matching placebo tablets daily; Weeks 5-12 (Period 2): Participants will be advanced to ERN/LRPT/SIM 2 g/20 mg and SIM-matching placebo tablets daily; Weeks 13-20 (Period III): Participants will crossover to ERN/LRPT 2 g + SIM 20 mg coadministration treatment.
11502677|NCT01335997|Active Comparator|ERN/LRPT+SIM → ERN/LRPT/SIM|Weeks 0-4 (Period I): Participants will take ERN/LRPT co-administered with SIM (ERN/LRPT 1g + SIM 10 mg tablets) daily; Weeks 5-12 (Period II): Participants will be advanced to ERN/LRPT 2 g + SIM 20 mg daily; Weeks 13-20 (Period III): Participants will crossover to the ERN/LRPT/SIM 2 g/20 mg combination treatment and SIM-matching placebo tablets.
11502678|NCT01335984|Experimental|Telemonitoring group|The subjects who are assigned in the Telemonitoring group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring group require site visit once per 2 months (8weeks)
11502679|NCT01335984|Experimental|Telemonitoring & Telemedicine group|The subjects who are assigned in the Telemonitoring & Telemedicine group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring & Telemedicine group take remote medical treatment through video telephone instead of visiting study site.
11502680|NCT01335984|Other|Control group|The subjects who are assigned in the Control group require site visit once per 2 months (8weeks)
11502681|NCT01335971|Active Comparator|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
11502682|NCT01335971|Active Comparator|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
11502683|NCT01335971|Placebo Comparator|Placebo|Microcrystalline cellulose
11502684|NCT01335958|Experimental|A|
11502685|NCT01335945|Other|Cryoablation|Freezing of the celiac plexus
11502686|NCT01335932|Experimental|IV Ganciclovir|5mg/kg IV twice daily for 5 days, then followed by either IV ganciclovir or oral valganciclovir once daily until hospital discharge
11502687|NCT01335932|Placebo Comparator|Placebo|normal saline IV twice daily for 5 days, then followed by either IV normal saline or oral placebo once daily until hospital discharge
11502688|NCT01335919||Neonate|Subjects admitted for surgery or to the pediatric intensive care unit (PICU) or neonatal intensive care unit (NICU) who require daily and/or multiple blood samples for hemoglobin measurement.
11502689|NCT01335906|Experimental|Evidence-based informed consent|
11502690|NCT01335906|No Intervention|Usual information|
11502691|NCT01335893|Experimental|ICG injection group|This group will receive a single dose of ICG, diluted in saline solution, prior to surgery. Then, during their surgery, they will be imaged with the camera and imaging probe we have developed.
11502692|NCT01335880|Active Comparator|Promotion I|Three month time horizon
11502693|NCT01335880|Experimental|Promotion II|One week time horizon
11502694|NCT01335867|Experimental|Vigabatrin|Vigabatrin titrated to 3 grams daily for 8 weeks
11502695|NCT01335867|Placebo Comparator|Placebo|Identical placebo daily for three weeks
11502696|NCT01335854|No Intervention|Usual Care|Usual care for 3 months. This consists of a phone call after one week of treatment, and clinic appointments at the sleep center following one month and three months of CPAP treatment.
11502697|NCT01335854|Experimental|Web-Access to CPAP Data|Usual care and web-based access to CPAP adherence data for 3 months. Participants in this group will be asked to review their CPAP use daily in the first week of treatment and as desired over the next 3 months by accessing a password protected website.
11502698|NCT01335854|Experimental|Web-Access to CPAP Data & Incentive|Usual care and web-based access to CPAP data for 3 months with financial incentives. Participants in this group will be asked to review their CPAP use daily in the first week of treatment and as desired over the next 3 months by accessing a password protected website. Financial incentive terminated after 1 week.
11502699|NCT01335841|Experimental|3D fluoroscopy and navigation station|
11502700|NCT01335841|Active Comparator|2D and anatomical landmarks|
11502701|NCT01335828|Other|echography/elastography|
11502702|NCT01335815||elective knee and limb endoprothesis|
11502703|NCT01335802||Subclinical hypothyroidim|Women having subclinical hypothyroidism and/or TPOab-positive.
11502704|NCT01335802||Controls|Women having normal levels of TSH and TPOab-negative.
11502705|NCT01335789|Active Comparator|Oxytocin|intranasal administration
11502706|NCT01335789|Placebo Comparator|saline|intranasal administration
11502707|NCT01335776|Experimental|Cognitive Behavior Therapy|Cognitive Behavior Therapy for insomnia consists of stimulus control therapy, sleep restriction therapy, cognitive therapy and relaxation.
11502708|NCT01335776|Experimental|Mindfulness-Based Stress Reduction|The program consists of three primary components: theoretical material related to relaxation, meditation, and the mind-body connection; experiential practice of meditation and yoga and home based practice; group process focused on problem solving and support.
11502709|NCT01335763|Other|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of <=5.5mmol/L
11502710|NCT01335750|Experimental|Multipurpose Solution #1|B&L Renu Fresh Multipurpose Solution
11502711|NCT01335750|Experimental|Multipurpose Solution #2|OptiFree Replenish Multipurpose Solution
11502712|NCT01335750|Experimental|Multipurpose Solution #3|Ciba ClearCare Multipurpose Solution
11502713|NCT01335750|Active Comparator|Multipurpose Solution #4|Saline Solution
11502714|NCT01335737|Experimental|aerobic training|12 weeks of aerobic training, 4 times/week
11502715|NCT01335737|Placebo Comparator|wait list control|wait list control condition, 12 weeks + 4 to parallel the deconditioning protocol in active intervention group
11502716|NCT01335724|Experimental|Diclofenac diethylamine 1.16% gel|
11502721|NCT01335711|Active Comparator|SOC_non-C/C IL28B|non-C/C IL28B subjects to whom only SOC will be administrated
11502722|NCT01335698|Experimental|Stage 1: Atazanavir + Ritonavir|Participants received atazanavir powder orally (dosed by weight: 5 to <10 kg=150 mg, 5 to <10 kg=200 mg, 10 to <15 kg=200 mg, 15 to <25 kg=250 mg, 25 to <35 kg=300 mg) once daily for 24 to 48 weeks or a weight ≥35 kg. Participants also received ritonavir once daily for 24 to 48 weeks or weight ≥35 kg in the form of 80-mg/mL solution, orally (dosed by weight 5 to <25 kg=80 mg, 25 to <35 kg=100 mg); 100-mg capsule, orally (dosed by weight 25 to <35 kg=100 mg); or 100-mg tablet, orally (dosed by weight 25 to <35 kg=100 mg)
11502723|NCT01335685|Experimental|Arm A: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 4, 8, 11, 22, 25, 29, 32 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle for up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 23 maintenance cycles; overall up to 32 cycles [34 months]).
11502724|NCT01335685|Experimental|Arm A: Ixazomib 3.7 mg|Ixazomib 3.7 mg, capsules, orally, on Days 1, 4, 8, 11, 22, 25, 29, 32 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 10 maintenance cycles; overall up to 19 cycles [21 months]).
11502725|NCT01335685|Experimental|Arm B: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 15 maintenance cycles; overall up to 27 cycles [25 months]).
11502726|NCT01335685|Experimental|Arm B: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 cycle plus melphalan 6 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 49 maintenance cycles; overall up to 61 cycles [58 months]).
11502727|NCT01335685|Experimental|Arm B: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m^2, tablets orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 12 maintenance cycles; overall up to 24 cycles [24 months]).
11502728|NCT01335685|Experimental|Arm C: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 8, 15, 22, and 29 plus melphalan 9 mg/m^2, tablets orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 30 maintenance cycles; overall up to 39 cycles [40 months]).
11502729|NCT01335685|Experimental|Arm C: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15, 22, and 29 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 12 maintenance cycles; overall up to 21 cycles [24 months]).
11502730|NCT01335685|Experimental|Arm D: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 22, and 29 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally, on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 28 maintenance cycles; overall up to 37 cycles [38 months]).
11502731|NCT01335672||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
11502732|NCT01335659||ostial lesion|ostial lesion will be evaluated by IVUS and FFR
11502733|NCT01335646|Active Comparator|Surgery|
11502734|NCT01335646|Active Comparator|Non-operative|
11502735|NCT01335620|Other|Tenofovir/Emtricitabine and Raltegravir|"Single arm study
~tenofovir/emtricitabine 245/200 mg once daily and raltegravir 400 mg twice daily"
11502736|NCT01335607|Active Comparator|Part A: Samatasvir cap→tab→tab; Part B: cap|Part A: Samatasvir capsule as a single dose on Day 1 (fasting state) followed by samatasvir tablet as a single dose on Day 8 (fasting state) followed by samatasvir tablet as a single dose on Day 15 (fed state); Part B: samatasvir capsule as a single dose on Day 1 (fed state)
11502737|NCT01335607|Active Comparator|Part A: Samatasvir tab→cap→tab; Part B: cap|Part A: Samatasvir tablet as a single dose on Day 1 (fasting state) followed by samatasvir capsule as a single dose on Day 8 (fasting state) followed by samatasvir tablet as a single dose on Day 15 (fed state); Part B: samatasvir capsule as a single dose on Day 1 (fed state)
11502738|NCT01335581|Experimental|Laser treatment|Laser treatment added to microdermabrasion and topical lightening agent regimen
11502739|NCT01335568|Experimental|surgery|chronic liver insufficiency, cirrhosis
11502740|NCT01335555||Patients Pre and Post-chemotherapy|
11502741|NCT01335542|Active Comparator|Epidural Pathway (PCEA+FNB)|
11502742|NCT01335542|Active Comparator|Peri-Articular Injection|
11502743|NCT01335529|Experimental|Boceprevir, PegIFN alfa 2b, Ribavirin|"Standard Treatment :
~Peg-Interferon (PegIFN) alfa 2b by subcutaneous injection 1,5 µg/kg/week
~Ribavirin capsules 200mg: dosage delivered in weight categories (< 65 kg: 800 mg ; 65-80 kg: 1000 mg; 81-105 kg: 1200mg; > 105 kg: 1400mg)
~Three-drug-regimen:
~Peg-Interferon alfa 2b by subcutaneous injection 1,5 µg/kg/week
~Ribavirin capsules 200mg: dosage delivered in weight categories like in standard treatment
~Boceprevir tablets 200mg: 800 mg 3 times a day (2400 mg/j) with food"
11502744|NCT01335503|Active Comparator|AN-PEP with low caloric meal|
11502745|NCT01335503|Active Comparator|AN-PEP with high caloric meal|
11502746|NCT01335503|Placebo Comparator|Placebo with low caloric meal|
11502747|NCT01335503|Placebo Comparator|Placebo with high caloric meal|
11502748|NCT01335490|Experimental|Biolite Cook Stove|Provision of two cook stoves to each subject. Each stove burns wood fuel, but more efficiently than a traditional three stone fire.
11502749|NCT01335490|Experimental|LPG Cook Stove|Provision of a two-burner liquified petroleum gas stove to each subject, along with fuel needed for the family during the follow up period.
11502750|NCT01335490|No Intervention|Control|
11502751|NCT01335477|Placebo Comparator|placebo|patient receives capsules identical to those containing active drug
11502752|NCT01335477|Experimental|BIBF 1120|patient receives capsules containing BIBF 1120 twice a day
11502753|NCT01335464|Experimental|BIBF 1120|patient receives capsules containing BIBF 1120 twice a day
11502754|NCT01335464|Placebo Comparator|placebo|patient receives capsules identical to those containing active drug
11502755|NCT01335451|Experimental|Active|Each cohort will have 6 subjects that will receive AZD5213
11502756|NCT01335451|Placebo Comparator|Placebo|Each cohort will have 2 subjects that will receive placebo
11502757|NCT01335438|Experimental|Cementless Nexgen CR|Cementless fixation of Nexgen CR TKR
11502758|NCT01335438|Active Comparator|Cemented Nexgen CR|Cemented fixation of Nexgen CR TKR
11502759|NCT01335412||IXIARO exposed group|Male and female active duty U.S. military personnel ≥ 17 years of age who either received at least one dose of IXIARO
11502760|NCT01335412||Comparison group|Male and female active duty U.S. military personnel ≥ 17 years of age who either received at least one dose of JE-VAX
11502761|NCT01335399|Active Comparator|Lenalidomide + Dexamethasone|
11502762|NCT01335399|Experimental|Lenalidomide + Dexamethasone + Elotuzumab|
11502763|NCT01335386|Experimental|KLYX|
11502764|NCT01335386|Active Comparator|Glycerine|
11502765|NCT01335373||Group 1|
11502766|NCT01335360||Subjects >80kg|As above
11502767|NCT01335360||Subjects <70kg|As above
11502768|NCT01335360||Subjects 70-80kg|As above
11502769|NCT01335347|Experimental|Experimental Low Dose|Biological: One dose of a live replication incompetent adenovirus given in a capsule
11502770|NCT01335347|Experimental|Experimental Medium Dose|"Biological: One or two doses of replication incompetent adenovirus given in a capsule
~Other: Placebo capsules of the same size and shape"
11502771|NCT01335347|Experimental|Experimental High Dose|Biological: One dose of replication incompetent adenovirus in a capsule
11502772|NCT01335347|Placebo Comparator|Placebo Control|Capsules of the same size and shape as the experimental
11502773|NCT01335321|Active Comparator|Hylan GF-20 alone|This arm will receive a knee infiltration with 6ml of Hylan GF-20 only
11502774|NCT01335321|Experimental|Triamcinolone|This arm will receive a knee infiltration with 6ml of Hylan GF-20 associated with 1ml of triamcinolone
11502775|NCT01335308|Active Comparator|Standard Care with Education Materials|Measure height and weight only. usual care
11502776|NCT01335308|Experimental|Moderate Dose Motivational Interviewing|MI delivered by PCP, 4 sessions
11502777|NCT01335308|Experimental|Higher Dose Motivational Interviewing|MI delivered by PCP, 4 sessions plus MI delivered by RD, 6 sessions
11502778|NCT01335269|Experimental|Treatment arm|BI 853520 once daily in a dose escalation schedule
11502779|NCT01335256|Experimental|Arm 1|
11502780|NCT01335243|Experimental|TLIF surgery|
11502781|NCT01335230||10 HIV mono-infected subjects|10 subjects infected with HIV only
11502782|NCT01335230||10 HCV mono-infected subjects|10 subjects infected with HCV only
11502783|NCT01335230||10 HIV/HCV co-infected subjects|10 subjects infected with both HIV and HCV
11502784|NCT01335230||10 control subjects|10 subjects without HIV, HCV, or both
11502785|NCT01335217|Other|Open-label TNS treatment|There is only one arm in this open label treatment of MDD co-occuring with PTSD.
11502786|NCT01335204|Experimental|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle. Bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
11502787|NCT01335191|Experimental|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0 and Week 3.
11502788|NCT01335191|Placebo Comparator|Placebo|Two subcutaneous injections of placebo at Day 0 and Week 3.
11502789|NCT01335178|Experimental|Intervention|Participants received the behavioral intervention, which was designed to motivate parents to protect their children from tobacco smoke exposure
11502790|NCT01335165|Experimental|TT30 (ALXN1102 Formulation)|IV: 0.1, 0.3, and 1.0 mg/kg
11502791|NCT01335165|Experimental|TT30 (ALXN1103 Formulation)|"IV: 3.0, 6.0, and 10.0 mg/kg
~SC: 1.0 and 3.0 mg/kg"
11502792|NCT01335152|Experimental|Web-based workbook|Participants will use one chapter of the web-based workbook each week for 10 weeks. The workbook consists of stress management education, cognitive behavioral interventions and relaxation training exercises.
11502793|NCT01335152|No Intervention|Waitlist control group|Participants will no intervention for the first 10 weeks of the study and then will receive the web-based intervention.
11502794|NCT01335139|Experimental|SCIT + Placebo|Subcutaneous immunotherapy (SCIT) + sublingual immunotherapy (SLIT) placebo
11502795|NCT01335139|Experimental|SLIT + Placebo|Sublingual immunotherapy (SLIT) + subcutaneous immunotherapy (SCIT) placebo
11502796|NCT01335139|Placebo Comparator|Placebo + Placebo|Sublingual immunotherapy (SLIT) placebo + subcutaneous immunotherapy (SCIT) placebo
11502797|NCT01335126|Experimental|Test|
11502798|NCT01335100||ambulatory CP|ambulatory children with cerebral palsy undergoing Botulinum toxin injections to lower limbs
11502799|NCT01335100||controls|age and gender matched sibilings
11502800|NCT01335087|Active Comparator|Lifestyle|Standard care for OSA: lifestyle, and sleep hygiene counselling
11502801|NCT01335087|Experimental|Continuous positive airway pressure CPAP|CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling
11502802|NCT01335087|No Intervention|Reference|This group will be followed according to cardiovascular protocols and will be evaluated as a reference group.
11502803|NCT01335074|Experimental|Temsirolimus + Sorafenib|
11502804|NCT01335061|Other|BeneFIX|
11502805|NCT01335048|Experimental|Atorvastatin-Clopidogrel group|Patients who receive Atorvastatin 80 mg/day and Clopidogrel 150 mg/day
11502806|NCT01335048|Active Comparator|Clopidogrel group|Patients who receive clopidogrel 150 mg daily
11502807|NCT01335035|Experimental|ICL670|
11502808|NCT01335022|Experimental|Cardiovascular Disease Education|6 lectures on cardiovascular disease were given over a 2 month time period
11502809|NCT01335009|Experimental|MORAb-004, 2 mg/kg|Biologic (monoclonal antibody)
11502810|NCT01335009|Experimental|MORAb-004, 4 mg/kg|Biologic (monoclonal antibody)
11502811|NCT01334983|Experimental|REST|Participants instructed in individualized Rapid Easy Strength Training and pedometer-based walking programs
11502812|NCT01334983|No Intervention|Wait list control|Participants instructed in REST after completing week 8 outcome measures
11502813|NCT01334957|Experimental|Intravenous ibuprofen|Intravenous ibuprofen (800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 10 minute Treatment Period.
11502814|NCT01334944|Experimental|Intravenous ibuprofen|Intravenous ibuprofen (400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 5-10 minute Treatment Period.
11502815|NCT01334931|Experimental|Large field of view|Patients will have coronary angiography performed with large field of view lens
11502816|NCT01334931|Active Comparator|Medium field of view|Patients will have coronary angiography performed with medium field of view lens
11502817|NCT01334918|Experimental|Single Photon Emission Computed Tomography (SPECT)|"Resting SPECT imaging was performed prior to regadenoson stress SPECT
~imaging. Imaging was conducted with one of two radiotracers (99mTc sestamibi or tetrofosmin). Regadenoson 0.4 mg was administered prior to stress SPECT as a single bolus injection."
11502818|NCT01334918|Experimental|Multidetector Computed Tomography (MDCT)|Multidetector Computed Tomography (MDCT), composed of CCTA and regadenoson CTP. Regadenoson stress CTP was performed prior to rest CCTA/CTP imaging. Regadenoson 0.4 mg was administered prior to stress CTP as a single bolus injection. The rest CCTA/CTP was performed at least 30 minutes after completion of the stress CTP, after resolution of any symptoms brought on by the regadenoson infusion and after the participant's heart rate had returned to baseline.
11502819|NCT01334905|Experimental|Part A group|fasted condition then fed condition
11502820|NCT01334905|Experimental|Part B group|fed condition then fasted condition
11502821|NCT01334892|Active Comparator|L-CsA|Twice daily inhalation of 2.5 ml/10 mg L-CsA for 96 weeks
11502822|NCT01334892|Placebo Comparator|L-CsA placebo|Twice daily inhalation of 2.5 ml aerosolised placebo (carrier) for 96 weeks (24 months)
11502823|NCT01334879|Active Comparator|With Loading Doses|5 patients will receive intravitreal injections every 30 days (+/- 7 days) for the first 4 months and every month thereafter until month 12 (maximum of 12 injections)
11502824|NCT01334879|Active Comparator|Physician Discretion|5 patients will receive intravitreal ranibizumab every 30 days (+/- 7 days) on as needed basis based on the criteria defined in the study.
11502825|NCT01334853||Cohort 1|50 eosinophilic subjects to be evaluated
11502826|NCT01334853||Cohort 2|50 non-eosinophilic subjects to be evaluated
11502827|NCT01334840|Experimental|BW|Bicarbonated mineral water without meal
11502828|NCT01334840|Experimental|BW with meal|Bicarbonated mineral water with meal
11502829|NCT01334840|Active Comparator|CW|Mineral water low in mineral content (control) without meal
11502830|NCT01334840|Active Comparator|CW with meal|Mineral water low in mineral content (control) with a meal
11502831|NCT01334801||Aortic Stenosis|Restricted aortic valve motion and a peak Doppler aortic velocity > 2.5 m/sec blood draw
11502832|NCT01334801||Aortic regurgitation|Echocardiographic and Doppler evaluation revealing aortic regurgitation with data adequate to calculate regurgitant volume
11502833|NCT01334801||Aortic valve replacement|Mechanical or biological aortic valve replacement
11502834|NCT01334801||Mitral regurgitation|Echocardiographic and Doppler evaluation revealing mitral regurgitation with data adequate to calculate regurgitant volume
11502835|NCT01334801||Mitral valve replacement|Mechanical or biological mitral valve replacement
11502836|NCT01334801||Hypertrophic cardiomyopathy|Patients with known hypertrophic cardiomyopathy who are referred for clinically indicated echocardiography
11502837|NCT01334801||Severe TR with pacemaker / ICD lead|Patients referred for clinically indicated echocardiography who have severe tricuspid regurgitation associated with a pacemaker or defibrillator lead documented by echocardiography
11502838|NCT01334801||Prosthetic valve dysfunction|Patients with prior heart valve replacement or repair referred for clinically indicated echocardiography who demonstrate stenosis, regurgitation, dehiscence.
11502839|NCT01334801||Normal controls|Patients with no heart murmur or history of valve replacement, stenosis, regurgitation, or hypertrophic cardiomyopathy
11502840|NCT01334801||Left ventricular assist device patients|Patients with previously implanted LVAD
11502841|NCT01334801||Renal dialysis patients|Patients on hemodialysis, peritoneal dialysis, or chronic kidney disease with dialysis fistula to be created.
11502842|NCT01334788|Experimental|sleep deprivation|These are subjects who are randomized to undergo sleep deprivation.
11502843|NCT01334788|Other|Normal sleep|These are subjects who are randomized to sleep normally.
11502844|NCT01334775|Experimental|Experimental - Cousin Biotech Adhesix|Placement of a self-adhering (sutureless) surgical mesh in open anterior inguinal hernia repair
11502845|NCT01334775|Active Comparator|Conventional - Cousin Biotech Biomesh P8|Placement of the conventional (sutured) surgical mesh in open anterior inguinal hernia repair
11502846|NCT01334762|Experimental|Letrozole/IUI|Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
11502847|NCT01334762|Active Comparator|CC/IUI|Patients received 100 mg CC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
11502848|NCT01334749||Acute Stroke|Patients over 18 years and without pre-stroke dementia, displaying an ischemic or hemorrhagic stroke, onset within the last 72 hours, language German
11502849|NCT01334736|Placebo Comparator|Usual care|
11502850|NCT01334736|Active Comparator|Lung Age|
11502851|NCT01334736|Active Comparator|Contingency Management|
11502852|NCT01334736|Active Comparator|Lung age + Contingency Management|
11502853|NCT01334723||Acute Urinary Retention|This subset of the Integrated Health Care Information Solutions (ICHIS) benign prostate hyperplasia (BPH) study population was used to assess acute urinary retention as a clinical outcome.
11502854|NCT01334723||Prostate Surgery|This subset of the ICHIS BPH study population was used to assess surgery as a clinical outcome.
11502855|NCT01334710|Experimental|Sorafenib and OSI-906|This is a single arm phase II trial designed to evaluate the effect of adding OSI-906 to sorafenib in patients with hepatocellular cancer. The study is designed to evaluate the safety of the regimen in the first six patients.
11502856|NCT01334697|Experimental|Cardiotrophin-1|
11502857|NCT01334697|Placebo Comparator|Placebo|
11502858|NCT01334684|Other|Metformin|"At study entry, all oral hypoglycemic agents will be discontinued for 5 days and then metformin (2,550 mg/daily) will be given for 3 months. Fasting plasma glucose will be measured at baseline and 3 months after metformin treatment. Patients will be stratified according to the median value of metformin efficacy as indicated by fasting glucose change after metformin treatment (i.e. baseline fasting glucose minus 3-month fasting glucose).
~So, two subgroups of patients will be obtained, defined as relatively high responders (individual fasting glucose change > median value) or relatively low responders (individual fasting glucose change < median value) to metformin monotherapy."
11502859|NCT01334671|Experimental|group 1, Atorvastatin|STEMI patients will be randomly divided into three groups Group 1 which has been give 80mg atorvastatin before PCI will be administered with atorvastatin 40mg per day for one month,then 20mg per day until the end of the trial
11502860|NCT01334671|Experimental|group 2 , Atorvastatin|Group 2 will be administered with atorvastatin 40mg per day for one month,then 20mg per day until the end of the trial
11502861|NCT01334671|Experimental|group 3 , Atorvastatin|Group 3 will be administered with atorvastatin 20mg per day until the end of the trial
11502862|NCT01334658|Active Comparator|Balanced Salt Solution (BSS®)|Subjects who received Balanced Salt Solution.
11502863|NCT01334658|Active Comparator|Glucose-bicarbonate-Ringer Lactate (GBRL)|Subjects who received glucose-bicarbonate-Ringer Lactate.
11502864|NCT01334632|Active Comparator|Continuous interscalene block|Continuous interscalene block with bolus ropivacaine 0.5% and then continuous infusion of ropivacaine 0.2% 4 - 6 ml/h, associated with paracetamol and ibuprofen. Each group will contain 60 patients.
11502865|NCT01334632|Placebo Comparator|PCA morphine|Patients with iv self-administration of morphine, associated with paracetamol and ibuprofen. Each group will contain 60 patients.
11502866|NCT01334619|Other|ropivacaine volume titration|
11502867|NCT01334606|Experimental|Nano: 4mm x 32G Pen Needle|Subjects will use the 4mm x 32G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.
11502868|NCT01334606|Experimental|Short: 8mm x 31G Pen Needle|Subjects will use the 8 mm x 31G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.
11502869|NCT01334593||Rectal Cancer|
11502870|NCT01334580|Active Comparator|Methadone Drug Counseling|Methadone Drug Counseling is provided by skilled drug counselors over a 12 week period and focuses on cessation of illicit drugs
11502871|NCT01334580|Experimental|Cognitive-Behavioral Therapy for Pain and Opioid Dependence|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
11502872|NCT01334567|Experimental|Tenofovir DF|
11502873|NCT01334554|Experimental|Sildenafil|Sildenafil 20 mg three times a day
11502874|NCT01334554|Placebo Comparator|Placebo|placebo
11502875|NCT01334541||SAFE VET|
11502876|NCT01334541||E-CARE|
11502877|NCT01334528||OEF/OIF Veterans mTBI|Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF) Veterans with a history of mild traumatic brain injury (mTBI) with persistent self-reported symptoms.
11502878|NCT01334515|Experimental|Disease measured by standard radiographic criteria|Treatment (hu14.18-Interleukin 2(IL2) fusion protein and isotretinoin). Patients receive sargramostim (SC [preferred]) or IV over 2 hours on days 1-2 and 8-14, hu14.18-IL2 fusion protein IV over 4 hours on days 4-6, and isotretinoin PO twice daily on days 11-24. Treatment repeats every 28 days for 4-10 courses in the absence of disease progression or unacceptable toxicity. Patients in stratum-1 who achieve stable disease (SD) after course 4 are removed from protocol therapy. Patients in stratum-2 who achieve SD after course 4 receive 2 additional courses of study treatment. Patients may undergo blood and bone marrow sample collection periodically for correlative studies.
11502879|NCT01334515|Experimental|Disease evaluable only by I-MIBG or BM histology|Treatment (hu14.18-Interleukin 2(IL2) fusion protein and isotretinoin). Patients receive sargramostim (SC [preferred]) or IV over 2 hours on days 1-2 and 8-14, hu14.18-IL2 fusion protein IV over 4 hours on days 4-6, and isotretinoin PO twice daily on days 11-24. Treatment repeats every 28 days for 4-10 courses in the absence of disease progression or unacceptable toxicity. Patients in stratum-1 who achieve stable disease (SD) after course 4 are removed from protocol therapy. Patients in stratum-2 who achieve SD after course 4 receive 2 additional courses of study treatment. Patients may undergo blood and bone marrow sample collection periodically for correlative studies.
11502880|NCT01334502|Experimental|everolimus and RCHOP|Patients registered to the study will receive an assigned dose of everolimus by mouth and RCHOP for a maximum of six cycles. Each cycle is a total of 21 days. RCHOP consists of 375 mg/m2 IV rituximab, 750 mg/m2 IV cyclophosphamide, 50 mg/m2 IV doxorubicin, 1.4 mg/m2 IV vincristine and 100 mg/m2 by mouth QD prednisone. The study includes a Phase I component to determine the maximum tolerated dose of everolimus and the second component determines the feasibility of therapy administered to lymphoma patients.
11502881|NCT01334489|No Intervention|Usual management|Usual management of monochorionic pregnancy without the pessary placement
11502882|NCT01334489|Other|Arabin Cervical Pessary|"The pessary will be inserted 24 hours after fetal surgery in the exploration room. This procedure does not need anaesthesia and it does not need to be done in a surgery room. During the following explorations the correct placement of the pessary is assessed, and if it does not, it can be easily adjusted.
~The pessary will be removed at 37 weeks of gestation, or before if any unexpected event occurs."
11502883|NCT01334463||mTBI+PTSD|History of active duty-related mild TBI and history of active duty-related PTSD
11502884|NCT01334463||mTBI Only|History of active duty-related mild TBI and no history of active duty-related PTSD
11502885|NCT01334463||PTSD Only|No history of active duty-related mild TBI and history of active duty-related PTSD
11502886|NCT01334463||No mTBI, No PTSD|No history of active duty-related mild TBI and no history of active duty-related PTSD
11502887|NCT01334450|Active Comparator|High Frequency TMS to prefrontal cortex|
11502888|NCT01334450|Active Comparator|Low Frequency TMS to Prefrontal cortex|
11502889|NCT01334450|Sham Comparator|Sham TMS on Prefrontal Cortex|
11502890|NCT01334424|Placebo Comparator|no propofol|induction anesthesia with midazolam 0.2 - 0.3 mg/kg
11502891|NCT01334424|Experimental|propofol induction|induction anesthesia with propofol 2 - 2.5 mg/kg
11502892|NCT01334424|Experimental|propofol maintenance|induction anesthesia with midazolam 0.2 - 0.3 mg/kg and maintain anesthesia with propofol 2 mg/kg.h (maintenance dose)
11502893|NCT01334424|Experimental|propofol induction and maintenance|induction anesthesia with propofol 2 - 2.5 mg/ kg and maintain anesthesia with propofol 2 mg/kg.h (maintenance dose)
11502894|NCT01334398||Initial Treatment Group|
11502895|NCT01334398||Deferred Treatment Group|
11502896|NCT01334385||OEF/OIF Veterans through VA ECHCS|
11502897|NCT01334372|No Intervention|Treatment as Usual|Treatment as usual (TAU) outpatient care will consist of existing outpatient clinical practices utilized in the Mental Health Clinic.
11502898|NCT01334372|Experimental|CAMS|First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
11502899|NCT01334359|Experimental|Treatment Group|Participants randomized to the afterschool intervention
11502900|NCT01334359|Placebo Comparator|Wait List Group|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
11502901|NCT01334346|Active Comparator|Neutral Shoe|Conventional, non-minimalist, footwear.
11502902|NCT01334346|Experimental|Partial minimalist shoe|
11502903|NCT01334346|Experimental|Full minimalist|
11502904|NCT01334333|Active Comparator|Prograf®|Prograf® is a twice daily formulation of tacrolimus
11502905|NCT01334333|Experimental|Advagraf®|Advagraf® is a once daily formulation of tacrolimus
11502906|NCT01334320|Experimental|elective neck dissection|patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
11502907|NCT01334320|No Intervention|wait and see|patient underwent primary tumor excision transorally as initial treatment, and without a cervical intervention
11502908|NCT01334307|Experimental|Lung Volume Reduction Coil (LVRC)|Lung Volume Reduction Coil (LVRC)
11502909|NCT01334307|Placebo Comparator|Control|Standard of Care
11502910|NCT01334294||1. Received therapy for CNV|
11502911|NCT01334281||Blood: Undergoing Desensitization|Transplant subjects give blood at specified time points. Sensitization to HLA antigens is a barrier to transplant. Several U.S. institutions have protocols for desensitization where patients are treated with IV immunoglobulins (IVIg) and plasmapheresis (PP) to reduce circulating HLA-directed antibody levels. Labs provide doctors information on circulating donor-specific antibody (DSA) levels. These results are the main indicator whether to proceed with transplant. However, no information is given on the fate of the B cells that produce the DSA.
11502912|NCT01334281||Blood: NOT Undergoing Desensitization|Transplant subjects give blood at specified time points. Sensitization to HLA antigens is a barrier to transplant. Several U.S. institutions have protocols for desensitization where patients are treated with IV immunoglobulins (IVIg) and plasmapheresis (PP) to reduce circulating HLA-directed antibody levels. Labs provide doctors information on circulating donor-specific antibody (DSA) levels. These results are the main indicator whether to proceed with transplant. However, no information is given on the fate of the B cells that produce the DSA.
11502913|NCT01334268|Active Comparator|Taxus Liberte Paclitaxel-Eluting Coronary Stent System|Subjects will be randomized to be treated with Taxus Liberte Paclitaxel-Eluting Coronary Stent System by an interactive voice response system (IVRS).
11502914|NCT01334268|Experimental|Medtronic Resolute (Zotarolimus-eluting stent)|Subjects will be randomized to be treated with Medtronic Resolute (Zotarolimus-eluting stent) by an interactive voice response system (IVRS).
11502915|NCT01334255|Experimental|0.5 mg of iSONEP (sonepcizumab/LT1009)|iSONEP (sonepcizumab/LT1009) is a humanized murine monoclonal antibody to sphingosine 1-phosphate
11502916|NCT01334255|Experimental|2.0 mg of iSONEP (sonepcizumab/LT1009)|iSONEP (sonepcizumab/LT1009) is a humanized murine monoclonal antibody to sphingosine 1-phosphate
11502917|NCT01334242|Experimental|LX4211|400 mg of LX4211 administered orally
11502918|NCT01334242|Placebo Comparator|Placebo|Nonidentical placebo administered orally
11502919|NCT01334229|Experimental|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
11502920|NCT01334229|Placebo Comparator|Placebo|Placebo for 6 weeks
11502921|NCT01334216|Active Comparator|CHICA Smoking Cessation Module|This arm had the CHICA smoking cessation module turned on
11502922|NCT01334216|Placebo Comparator|CHICA Placebo|This arm had CHICA without the smoking cessation module
11502923|NCT01334203|Experimental|Ranolazine|
11502924|NCT01334203|Placebo Comparator|Placebo|
11502925|NCT01334177|Experimental|Treatment (immunotherapy and monoclonal antibody therapy)|Patients receive cetuximab IV over 60-120 minutes on days -28, -21, -14, -7 of weeks -4 to -1. Patients then receive cetuximab IV on days 1, 8, 15, and 22 and TLR8 agonist VTX-2337 SC on days 1, 8, 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11502971|NCT01333839|Active Comparator|modified 2 exercise intervention|combined endurance + strength exercise training + oral protein supplements
11502972|NCT01333826|Experimental|Unconditional cash transfers|Monthly cash transfers given to households with school aged girls with no strings attached. Transfer amounts randomized within this arm.
11502973|NCT01333826|Experimental|Conditional Cash Transfer|Monthly cash transfers given to households with school aged girls conditional on regular school attendance (80%). Transfer amounts randomized within this arm.
11502974|NCT01333826|No Intervention|Control Group|No cash transfer program implemented in this group.
11502926|NCT01334164|Experimental|Recovery Management Checkup (RMC)|Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
11502927|NCT01334164|Active Comparator|Outcome Monitoring|Outcome monitoring only, however participates are still able (and do) enter treatment on their own.
11502928|NCT01334151|Active Comparator|Humalog®|Humalog®, administered subcutaneously on 1 occasion
11502929|NCT01334151|Experimental|BIOD- 105|BIOD- 105 administered subcutaneously on 1 occasion
11502930|NCT01334151|Experimental|BIOD-107|BIOD-107 administered subcutaneously on 1 occasion
11502931|NCT01334138|Experimental|4-week diet, low in sodium|The study subjects go on a 4-week diet, low in sodium.
11502932|NCT01334125|Experimental|Metformin|Metformin 1000 mg once daily by mouth for 9 months
11502933|NCT01334125|Placebo Comparator|Placebo|2 capsules once daily by mouth for 9 months
11502934|NCT01334112|Experimental|Axitinib|Oral Axitinib (5mg, twice daily) will be administered to all patients
11502935|NCT01334099|Experimental|Radiation combined with CP-675,206|
11502936|NCT01334086|Experimental|Aprepitant|
11502937|NCT01334073|Experimental|Axitinib plus everolimus|
11502938|NCT01334060|No Intervention|CML HLA A2-|
11502939|NCT01334060|No Intervention|AML HLA A2-|
11502940|NCT01334060|Experimental|AML HLA A2+|
11502941|NCT01334060|Experimental|CML HLA A2+|
11502942|NCT01334047|Experimental|DC vaccine|Dendritic cells loaded with amplified ovarian cancer stem cell mRNA, hTERT and Survivin.
11502943|NCT01334034|Experimental|Dose levels 1-7|
11502944|NCT01334021|Experimental|Diagnostic (biopsy, surgery, genetic testing)|Patients undergo biopsy or surgery to obtain tumor sample for genetic testing. Patients are then assigned to 4 treatment cohorts as determined by genetic test results.
11502945|NCT01334008|Other|Blood sampling|
11502946|NCT01333995|No Intervention|Usual Health Message|No intervention mothers will recieve standard maternal and child care education
11502947|NCT01333995|Sham Comparator|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
11502948|NCT01333982|Experimental|Referral compliance|Health workers will receive a basic maternal, newborn and child health training under the MNCS programme. Newborn sepsis management training will be organised for the study. The Bangladesh Perinatal Society (BPS) will take the lead in developing and implementing the training programme with support from Saving Newborn Lives (SNL) and other partners.Referral slips will be used in the intervention unions for all the sick newborns identified so that they seek care on a timely fashion.
11502949|NCT01333982|Experimental|Neonatal sepsis|Existing health delivery systems in the community level in managing neonatal sepsis.
11502950|NCT01333969|Active Comparator|Ishcemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components).
11502951|NCT01333969|No Intervention|Control|In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
11502952|NCT01333956|Placebo Comparator|Control|Patients will receive 0mg of pregabalin
11502953|NCT01333956|Experimental|50mg Arm|Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of post-operative day (POD)14 and one capsule at bedtime POD15, POD16.
11502954|NCT01333956|Experimental|100mg Arm|Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
11502955|NCT01333956|Experimental|150mg Arm|Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
11502956|NCT01333943|Experimental|Experimental|Saphenous (Adductor Canal) Nerve Block
11502957|NCT01333943|Active Comparator|Control|Femoral Nerve Block
11502958|NCT01333930|Experimental|Test product (Active O2)|
11502959|NCT01333930|Placebo Comparator|Placebo (Adelholzener Mineralwasser)|
11502960|NCT01333917|Experimental|Curcumin|4g Curcumin C3 tablet daily
11502961|NCT01333904|Experimental|PUR118|
11502962|NCT01333891|Active Comparator|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
11502963|NCT01333891|Active Comparator|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
11502964|NCT01333891|Active Comparator|Suction Cup|suction force of 25, 50, 75, and 100 mmHg
11502965|NCT01333878|Experimental|Open-Label Subcutaneous Abatacept|Open-Label Subcutaneous Abatacept
11502966|NCT01333865|Experimental|Memantine (Namenda) Treatment|
11502967|NCT01333852|Active Comparator|Paclitaxel, placebo|Paclitaxel 175mg/m² q21d until disease progression, unacceptable toxicity or consent withdrawal
11502968|NCT01333852|Experimental|Paclitaxel plus metformin|Paclitaxel 175mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal
11502969|NCT01333839|Active Comparator|standard exercise intervention|12 weeks of endurance exercise training
11502970|NCT01333839|Active Comparator|modified exercise intervention|combined endurance + strength exercise training
11502975|NCT01333813|Experimental|Engerix-B Kinder Group|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 7-8 years of age.
11502976|NCT01333800|Active Comparator|Ciclesonide|
11502977|NCT01333800|Placebo Comparator|Beclomethasone|
11502978|NCT01333787|Active Comparator|Dietary Fiber Mixture|The dietary fiber mixture was composed of six different types of fibers. It was used for treatment of chronic constipation in children.
11502979|NCT01333787|Placebo Comparator|Maltodextrine|Blinded control group
11502980|NCT01333774||Group 1|
11502981|NCT01333761|Experimental|TCD/Cardiox FDS/TEE testing|All patients enrolled will be evaluated with TCD and Cardiox FDS and TEE for the presence of RTLS.
11502982|NCT01333748|Experimental|patients group|Patients with ovarian and/or breast cancer
11502983|NCT01333748|Other|control population|control population without history of breast and/or ovarian cancer
11502984|NCT01333735||Patients with chemotherapy group|Patients with breast or colon cancer must beginning a chemotherapy (colon group was ended)
11502985|NCT01333735||Patients without chemotherapy group|patient with breast or colon cancer should not receive chemotherapy (colon group was ended)
11502986|NCT01333722|Placebo Comparator|Placebo|placebo, 1 oral tablet every 12 hours
11502987|NCT01333722|Experimental|Hydrocodone/Acetaminophen Extended Release|hydrocodone/acetaminophen extended release, 1 oral tablet every 12 hours
11502988|NCT01333709|Experimental|Arm A: immediate rectal surgery|"Very good responder patients will be randomly assigned to proctectomy within 2-4 weeks after the end of the induction chemotherapy."
11502989|NCT01333709|Other|Arm B: RCT Cap 50 and then rectal surgery|"Very good responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy)."
11502990|NCT01333709|Other|Arm C: RCT Cap 50 and then rectal surgery|"Good or poor responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy)."
11502991|NCT01333709|Experimental|Bras D: RCT Cap 60 and then rectal surgery|"Good or poor responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 60 grays (2Gy/day, 5 days a week, 6 weeks, boost 14 Gy)."
11502992|NCT01333696|Experimental|Pemetrexed|500 mg/m2, repeated every 3 weeks until disease progression or intolerable toxicity
11502993|NCT01333683||Control|Normal subjects
11502994|NCT01333683||AH|Arterial hypertension patients
11502995|NCT01333670|Experimental|Prontosan wound irrigation solution|
11502996|NCT01333670|Active Comparator|Standard care|
11502997|NCT01333657||SIRS|"temperature >38 ℃ or <36℃;
~pulse rate>90 beats/min;
~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;
~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
11502998|NCT01333657||Sepsis|"sepsis: SIRS plus infection;
~severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;
~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
11502999|NCT01333644||HIV-Infection|Treated HIV-infected individuals with an undetectable HIV RNA level (< 75 copies RNA/mL, untreated HIV-infected individuals, and HIV-uninfected individuals.
11503000|NCT01333631|Experimental|Valporoic acid + chemoradiotherapy|
11503001|NCT01333618|Experimental|curving introducer|
11503002|NCT01333618|Placebo Comparator|straight introducer|
11503003|NCT01333605|Experimental|IGEV regimen|Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles
11503004|NCT01333592|Experimental|KAD-1229|
11503005|NCT01333579|Active Comparator|Active rTMS|1Hz active rTMS delivered to the unaffected hemisphere
11503006|NCT01333579|Placebo Comparator|Placebo rTMS|1Hz placebo rTMS delivered to the vertex
11503007|NCT01333566|Experimental|Intervention Group|
11503008|NCT01333566|Placebo Comparator|Control Group|
11503009|NCT01333553||Image-guided remove Port Wine Stain|Image-guided surgery remove Port Wine Stain
11503010|NCT01333540|Experimental|Active|Escalating Doses of TD-1211
11503011|NCT01333540|Placebo Comparator|Placebo|
11503012|NCT01333527|Experimental|Group A (early ROM)|Group A (early ROM) will use the sling for comfort only
11503013|NCT01333527|Active Comparator|Group B (usual care)|Group B (usual care) will be immobilized in a sling for 6 weeks.
11503014|NCT01333514|Experimental|Carbohydrate based prandial insulin dosing|Subjects will received prandial insulin based on the amount of carbohydrates consumed.
11503015|NCT01333514|Active Comparator|Usual Care Prandial insulin dosing|Subjects will received prandial insulin if they consume 50% or more of their meal-tray as is the usual care.
11503016|NCT01333501|Experimental|Fingolimod|0.5 mg in capsules for oral administration once daily
11503017|NCT01333501|Active Comparator|Interferon beta 1b|250 μg injected s.c. every other day
11503018|NCT01333488|No Intervention|Conventional Therapy|
11503019|NCT01333488|Experimental|Hypothermia|Subjects will have their core body temperatures lowered to 34C.
11503020|NCT01333488|Experimental|Hypothermia plus supplemental magnesium sulfate infusion|
11503021|NCT01333475|Experimental|TAC1:MK-2206 & AZD6244 in Pts with Colorectal Ca|Cycle = 28 days:MK-2206:90 mg PO days 1, 8, 15, and 22 AZD6244 Hydrogen sulfate: 75 mg PO QD (every day) MK-2206 + AZD6244: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
11503125|NCT01332825|Other|normal olfaction|normal olfaction, randomized to saline nasal irrigation for 7 days
11503164|NCT01332539||controlled partial epilepsy|
11503657|NCT01329107|No Intervention|No intervention|Standard Care
11503022|NCT01333475|Experimental|TAC1A:MK-2206 & AZD6244 in Pts with Colorectal Ca|"Cycle = 28 days:MK-2206:135 mg PO days 1, 8, 15, and 22 AZD6244 Hydrogen sulfate: 100 mg PO QD
~MK-2206 + AZD6244: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression."
11503023|NCT01333462|Placebo Comparator|Phosphate Buffered Saline (PBS) IN|
11503024|NCT01333462|Active Comparator|Fluzone 4 mcg HA IN|
11503025|NCT01333462|Active Comparator|Fluzone 15 mcg HA IM|
11503026|NCT01333462|Experimental|NB-1008 4 mcg HA 5% W805EC|
11503027|NCT01333462|Experimental|NB-1008 4 mcg HA 10% W805EC|
11503028|NCT01333462|Experimental|NB-1008 4 mcg HA 15% W805EC|
11503029|NCT01333462|Experimental|NB-1008 4 mcg HA 20% W805EC|
11503030|NCT01333462|Active Comparator|Fluzone 10 mcg HA IN|
11503031|NCT01333462|Experimental|NB-1008 10 mcg HA 5% W805EC|
11503032|NCT01333462|Experimental|NB-1008 10 mcg HA 10% W805EC|
11503033|NCT01333462|Experimental|NB-1008 10 mcg HA 15% W805EC|
11503034|NCT01333462|Experimental|NB-1008 10 mcg HA 20% W805EC|
11503035|NCT01333449|Experimental|Single Arm|Decitabine 20mg/m^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
11503036|NCT01333436|Experimental|Diabetic participants|Diabetic participants with normal to moderately high LDL-C
11503037|NCT01333436|Experimental|Nondiabetic participants|Non-diabetic participants with normal to moderately high LDL-C
11503038|NCT01333423|Experimental|Doxil + Seliciclib|Doxil (Liposomal doxorubicin) 40 mg/m2 intravenous (IV) over 2 -3 hours on Day 4 and Seliciclib starting dose 200 mg orally twice a day on Days 1 - 3 of 28 day cycle
11503039|NCT01333410|Active Comparator|0.1% tacrolimus ointment|
11503040|NCT01333410|Active Comparator|0.1% mometasone furoate cream|
11503041|NCT01333397|Experimental|Dysport RU 20 U|
11503042|NCT01333397|Experimental|Dysport RU 50 U|
11503043|NCT01333397|Experimental|Dysport RU 75 U|
11503044|NCT01333397|Active Comparator|Dysport (Azzalure) 50 U|
11503045|NCT01333397|Placebo Comparator|Placebo|
11503046|NCT01333371|Active Comparator|closed reduction with percutaneous k-wire fixation and casted|
11503047|NCT01333371|Active Comparator|open reduction internal fixation with a volar locked plate|
11503048|NCT01333332|Experimental|Capecitabine, Radiation|
11503049|NCT01333306|Experimental|tDCS and cognitive training|
11503050|NCT01333293|Experimental|Omalizumab|
11503051|NCT01333293|Placebo Comparator|Placebo|
11503052|NCT01333280|Experimental|Double Trouble (DTR) group|Double Trouble in Recovery groups
11503053|NCT01333280|Active Comparator|Treatment as usual|Treatment as usual while on a waiting list for DTR groups
11503054|NCT01333267|Experimental|PTHrP group|Subjects receive PTHrP(1-36) starting with doses of 2 picomoles (pmols)/kg/hr for one week. Subsequent dosing groups are determined by the response to PTHrP doses.
11503055|NCT01333267|Experimental|PTH dosing group|Subjects receive PTH(1-34) starting with doses of 2 picomoles (pmols)/kg/hr for one week. Subsequent dosing groups are determined by the response to PTH doses.
11503056|NCT01333254|No Intervention|Indwelling urinary catheter|Patients in this group with hip fracture will get an indwelling catheter at arrival to the orthopaedic ward. The patients with arthrosis get the indwelling catheter in the morning at the day of surgery. In both cases the indwelling catheter is inserted after shower with skin disinfectant. The catheter system is kept close. The catheter will be removed in the morning on day 2 after surgery. The patients are bladder-scanned every four-hour until normal bladder function is recaptured. If the bladder volume exceeds 400ml and the patient is unable to urinate, the patient will be re-catheterised. The procedure of the patients in this arm is in accordance with common practice in the Orthopaedic clinic.
11503057|NCT01333254|Experimental|Intermittent urinary catheterisation|Patients randomised to this arm will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 400 ml urine in the bladder, the patient will be intermittent catheterised.
11503058|NCT01333241|Experimental|Lifestyle behavior intervention group|The 6-month lifestyle behavior intervention includes group education and individual teaching and coaching.
11503059|NCT01333241|Sham Comparator|Control group|Disaster Preparedness/Home Safety group education and teaching
11503060|NCT01333228|Experimental|Endothelial Progenitors Cells|Autologous bone marrow-derived endothelial progenitor cells
11503061|NCT01333215||Group 1|Depressed older suicide non-attempters
11503062|NCT01333215||Group 2|Depressed older suicide attempters
11503063|NCT01333202|Experimental|Fresh lime|Those who were randomly assigned to receive fresh lime were instructed to use it every time they began to crave cigarettes and as often as they needed. Fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible. All participants in this group had to report the number of fresh lime slices used per day in the self-report card.
11503064|NCT01333202|Active Comparator|Nicotine gum|"The dosage of nicotine gum used in this group was primarily based on the participants' FTND scores. Those with FTND score of 4 or above were given 4-mg nicotine gum. The 2-mg gum was assigned only to light smokers. Appropriate gum use by chew and park technique was instructed to all subjects in this group. They were advised to use the gum whenever they began to crave a cigarette but not to exceed more than 20 pieces per day. All participants in this group also had to report the total number pieces of gum used per day in the self-report card. Like the lime use group, phone calls were also made every 2-3 days during the initial month of study to remind them of technique and record keeping."
11503161|NCT01332552|Experimental|Part 2: Repeat dose escalation|GSK2485852 planned repeat doses are placebo, 420mg BID, 420mg TID, 630mg BID
11503162|NCT01332552|Experimental|Part 3: GSK2485852 + Ritonavir|GSK2485852 single dose 70mg, 210 mg +Ritonavir 100mg x 1 day; GSK2485852 210mg + Ritonavir 100mg single dose x 3 days;
11503065|NCT01333189|Experimental|RELOAD: Weight-bearing biofeedback exercise|RELOAD participants participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games. These biofeedback training sessions were provided in addition to the standard of care rehabilitation that the CONTROL group received. Total dose of exercise across groups was matched.
11503066|NCT01333189|Active Comparator|CONTROL: Standard of care exercise|CONTROL participants were provided two weeks of home rehabilitation (6 visits) by a physical therapist. Patients then progressed to outpatient rehabilitation, consisting of 4 weeks of treatment for a total of 6 weeks of standard of care rehabilitation. Total dose of exercise across groups was matched.
11503067|NCT01333176|Experimental|All volunteers have HbA1c test|All candidates receive same procedure
11503068|NCT01333163|Active Comparator|GLP-1|
11503069|NCT01333163|Placebo Comparator|Placebo|
11503070|NCT01333150|Experimental|Propranolol|
11503071|NCT01333150|Experimental|Placebo|
11503072|NCT01333137|Active Comparator|Gemcitabine and Carboplatin|Gemcitabine 1000 mg/m2/day on Days 1 & 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
11503073|NCT01333137|Experimental|P276-00 along with Gemcitabine and carboplatin|P276-00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 & 8 every 21 days.In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
11503074|NCT01333124|Experimental|Radiation: chemoradiotherapy with Gemcitabine|Radiation: chemoradiotherapy with Gemcitabine All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.
11503075|NCT01333111|Experimental|Prophylaxis, high dose (trial duration 52 weeks)|
11503076|NCT01333111|Experimental|Prophylaxis, low dose (trial duration 52 weeks)|
11503077|NCT01333111|Experimental|On-demand (trial duration 28 weeks)|
11503078|NCT01333098|Experimental|mifepristone|1 week mifepristone or placebo (followed by 3 weeks open label mifepristone)
11503079|NCT01333085|Experimental|RAD001-paclitaxel-carboplatin|RAD001: 20,30 or 50 mg PO 9 weekly cycles Paclitaxel: 60 mg/m²IV, in 1 hour, 9 weekly cycles Carboplatin AUC2 IV in 1 hour,9 weekly cycles
11503080|NCT01333072|Active Comparator|Risperidone|Atypical antipsychotic
11503081|NCT01333072|Active Comparator|Aripiprazole|Atypical antipsychotic
11503082|NCT01333059|Experimental|Experimental Group|"In this arm Fentanyl and Midazolam was replaced with placebo (normal saline) during cycling.
~At cycling time for midazolam, the continuous infusion of midazolam was stopped by the bedside nurse. The nurse started a pump containing a syringe labeled Study Drug M which contained the placebo drug (normal saline). The switch to Study Drug M occurred twice daily at 0800 and 2000 for a period of 3 hours each. At cycling time for fentanyl, the continuous infusion of fentanyl was stopped by the bedside nurse. The pump containing a syringe labeled Study Drug F, which contained the placebo drug (normal saline), was started. The switch Study Drug F occurred twice daily at 1400 and 0200 for a period of 3 hours each.
~Dosing was done per standard of care and not prescribed per protocol"
11503083|NCT01333059|Active Comparator|Control Group|"In this arm, midazolam and fentanyl were administered during cycling.
~At cycling time for midazolam, the continuous infusion of midazolam was stopped by the bedside nurse. The nurse started a pump containing a syringe labeled Study Drug M which contained the control drug (midazolam). The switch to Study Drug M occurred twice daily at 0800 and 2000 for a period of 3 hours each. At cycling time for fentanyl, the continuous infusion of fentanyl was stopped by the bedside nurse. The pump containing a syringe labeled Study Drug F, which contained the control drug (fentanyl), was started. The switch to Study Drug F occurred twice daily at 1400 and 0200 for a period of 3 hours each.
~Dosing was done per standard of care and not prescribed per protocol."
11503084|NCT01333046|Experimental|Antigen-Escalation Stage|"The first stage will be an antigen-escalation stage using a fixed total dose of cells (5 x 10^6 cells/m^2 x 2) to evaluate the safety of the T cells primed against PRAME pepmix, and then SSX pepmix, and then MAGE A4 pepmix, and then NY-ESO pepmix, and then SURVIVIN pepmix."
11503085|NCT01333046|Experimental|Dose-Escalation Study Stage|"In the dose escalation stage, three dose levels will be studied. Patients in the dose escalation portion of the study will be entered and stratified separately to the following two groups:
~Group A: Patients receiving CTLs as therapy for Hodgkin's or non-Hodgkin's lymphoma.
~Group B: Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant."
11503086|NCT01333046|Experimental|azacytidine and multiTAA T cells Stage|This phase will administer aza intravenously at a dose of 75 mg/m2 after premedication with an anti-emetic such as ondansetron po or IV (up to a maximum dose of 16 mg ondansetron or equivalent). This phase will determine whether infusion of TAA-specific T cells (at dose level 2 - 1x10^7) targeting multiple tumor antigens in combination with azacytidine is safe, and whether CTL infusions (with or without azacytidine) increase the spectrum of epitopes/antigens targeted by endogenous T cells (epitope spreading).
11503087|NCT01333046|Experimental|Pediatric multiTAA T cells Stage|This phase will give patients < 18 years old two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10^7 cells/m2. This phase will test the safety and efficacy of multiTAA-specific T cells in pediatric patients with active HL/NHL.
11503088|NCT01333033|Experimental|Arm I (FOLFOX regimen)|Patients receive modified FOLFOX-6 therapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously on days 1-5. Treatment repeats every 14 days for 3 courses. Patients then undergo PET/CT scan. Patients with responsive disease (tumor metabolic activity decreased by >= 35%) receive 3 additional courses of FOLFOX-6 therapy and undergo concurrent RT (3D-conformal or intensity-modulated) once daily, 5 days a week, for approximately 6 weeks. Patients without responsive disease (tumor metabolic activity did not decrease by 35%) cross over to Arm II during RT.
11503163|NCT01332539||drug-resistant partial epilepsy|
11503089|NCT01333033|Experimental|Arm II (carboplatin + paclitaxel + radiation)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 2 courses. Patients then undergo PET/CT scan. Patients with responsive disease (tumor metabolic activity decreases >= 35%) continue to receive carboplatin IV over 30 minutes and paclitaxel IV over 1 hour once weekly for 5 weeks and undergo RT (3D-conformal or intensity-modulated) once a day, 5 days a week, for approximately 6 weeks. Patients without responsive disease (metabolic activity did not decrease by 35%) cross over to Arm I during RT
11503090|NCT01333020|Experimental|transglutaminase cross-linking of emulsion|The impact of enzyme cross linking of the protein stabilising the test emulsion on gastric emptying rate will be assessed. In this crossover study the subjects will also consume ( on a separate day)an emulsion of the same formulation but not cross-linked.
11503091|NCT01333007||Cohort|
11503092|NCT01332994|Experimental|1|
11503093|NCT01332994|Experimental|2|
11503094|NCT01332981||Cohort|
11503095|NCT01332968|Active Comparator|Rituximab+Chemotherapy|Participants will receive either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.
11503096|NCT01332968|Experimental|Obinutuzumab+Chemotherapy|Participants will receive either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.
11503097|NCT01332955|Experimental|Telaprevir-pegIFN alfa-2a-ribavirine|Single Group Assignment
11503098|NCT01332942|Placebo Comparator|Placebo|
11503099|NCT01332942|Experimental|Molidustat (BAY85-3934) 5 mg|
11503100|NCT01332942|Experimental|Molidustat (BAY85-3934) 10 mg|
11503101|NCT01332942|Experimental|Molidustat (BAY85-3934) 25 mg|
11503102|NCT01332942|Experimental|Molidustat (BAY85-3934) 50 mg|
11503103|NCT01332942|Experimental|Molidustat (BAY85-3934) 75 mg|
11503104|NCT01332929|Experimental|Bevacizumab|first level dose : 5 mg/kg Second level dose : 10 mg/kg Third level dose : 15 mg/kg
11503105|NCT01332916|Experimental|patients aged 45 and over group|patients aged 45 and over with breast cancer and should receive an adjuvant chemotherapy
11503106|NCT01332916|Active Comparator|healthy volunteers (controls) aged 45 and over|healthy volunteers (controls) aged 45 and over
11503107|NCT01332903|Experimental|1|[14C] AZD5069
11503108|NCT01332890|Experimental|Sequence 1|
11503109|NCT01332890|Experimental|Sequence 2|
11503110|NCT01332890|Experimental|Sequence 3|
11503111|NCT01332890|Experimental|Sequence 4|
11503112|NCT01332890|Experimental|Sequence 5|
11503113|NCT01332890|Experimental|Sequence 6|
11503114|NCT01332877|Experimental|enriched breakfast|high carbohydrate, high protein breakfast providing 600 kcal, 50% carbohydrate, 20% protein, 30% fat
11503115|NCT01332864|Active Comparator|OMT to the head and rest of body|OMT is the intervention that will be applied to areas of somatic dysfunction as well as to the head using a compression of the fourth ventricle (CV4) technique.
11503116|NCT01332864|Placebo Comparator|Light touch|Light touch will be applied to the head region for 10 minutes with the patient at rest in the supine position.
11503117|NCT01332864|Experimental|OMT with CV4 to head|OMT is the intervention using the CV4 technique to the head region for 10 minutes with patient at rest.
11503118|NCT01332864|Active Comparator|OMT to the body except the head region|OMT is the intervention that will be applied to areas of somatic dysfunction in any region except the head.
11503119|NCT01332851|Experimental|Promoting First Relationships (PFR)|"PFR is a strengths-based 10 week in-home parenting intervention based on attachment theory. Each week has a theme for discussion, an activity, and time for joining - checking in with the parent, listening to their concerns and establishing a positive, supportive relationship. The sessions include handouts which focus on the content area covered that day and applying a topic to their relationship with their child. The provider also videotapes playtime between parent and child. On alternate weeks, the provider watches the video with the parent, reflecting on both the parent's and the child's needs. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent identify her own feelings and needs around parenting."
11503120|NCT01332851|Active Comparator|Resource & Referral|This condition consists of 1) Resource and Referral assistance provided over the phone, and 2) Local Services Resource Packet. The participant receives a phone call from a Resource and Referral Specialist to conduct a needs assessment to identify the particular needs or concerns of the family (such as housing needs, mental health, tangible goods). If a need is identified, the Referral and Referral Specialist will provide the family with local information regarding the stated need. The R&R provider makes two follow-up check in calls with the families. In addition, families can call the Research and Referral Specialist if additional needs arise. The resource packet includes information organized by type of need or resource. These packets are updated regularly as services change over time.
11503121|NCT01332838|Experimental|Sigvaris special compression stocking|
11503122|NCT01332838|Active Comparator|Standard Compression|
11503123|NCT01332825|No Intervention|olfactory dysfunction|subjects diagnosed with olfactory dysfunction
11503124|NCT01332825|No Intervention|normal olfaction, no saline|no smell dysfunction, not randomized to saline nasal irrigation for 7 days
11503126|NCT01332812|Experimental|Dexamethasone, POCD, psycological tests|"Subjects will be randomly assigned in two groups: For the Dexamethasone group, 8mg of dexamethasone will be administered intravenously before the induction of general anesthesia. For Control Group, no Dexamethasone will be administered.
~Tests for evaluation of quality of life, depressive symptoms and neuropsychological battery to assess general mental status, learning, attention, visuospatial perception, immediate memory, operational and executive skills and recall, including processing speed. This assessment will be applied before surgery, and 3, 7, 21, 90 and 180 days after surgery."
11503127|NCT01332812|Sham Comparator|Control, POCD, psycological tests|"Subjects will be randomly assigned in two groups: For the Dexamethasone group, 8mg of dexamethasone will be administered intravenously before the induction of general anesthesia. For Control Group, no Dexamethasone will be administered.
~Tests for evaluation of quality of life, depressive symptoms and neuropsychological battery to assess general mental status, learning, attention, visuospatial perception, immediate memory, operational and executive skills and recall, including processing speed. This assessment will be applied before surgery, and 3, 7, 21, 90 and 180 days after surgery."
11503128|NCT01332799|Active Comparator|Allopurinol|
11503129|NCT01332799|Placebo Comparator|Placebo (sugar pill)|
11503130|NCT01332786|Experimental|Tigecycline|
11503131|NCT01332773|Experimental|Artery first group|"The basic principle of the artery first approach is the early identification of the SMA at its origin at the aorta with the further resection then being guided by its anatomic course.
~The dissection is carried cephalad along the aorta until the origin of the SMA is reached. The posterior and right aspect of the SMA is then dissected over a few centimeters. On the right side of the SMA a replaced or accessory right hepatic artery, if present, will be identified and preserved. This maneuver should be done, if infiltration of the SMA is suspected as the procedure can be terminated at this point. Once the situation at the SMA is assessed and resectability is confirmed resection will be done."
11503132|NCT01332773|Active Comparator|Conventional Group|A wide Kocher manoeuver is performed to fully mobilize the duodenum and the head of the pancreas. The colonic mesentery on the right side is separated from the anterior surface of the duodenum and the head of the pancreas. The size of the tumor and its relation to the superior mesenteric artery, the celiac trunk, the mesentery, the portal vein, and the superior mesenteric vein is assessed. If resectability is given a Kausch-Whipple's resection is performed.
11503133|NCT01332760|Active Comparator|narrow diameter heavy dental tool|periodontal tools for dental scaling and cleaning provided that have a narrow diameter (8mm) made of heavy material (steel).
11503134|NCT01332760|Experimental|light large diameter dental tool|periodontal tools for scaling and tooth cleaning provided with large diameter (11mm) handle made of light weight material
11503135|NCT01332747|Experimental|Safoof e Muhazzil in its conventional powder form|safoof e muhazzil in its conventional powder form 5 gms twice daily given orally
11503136|NCT01332747|Experimental|compressed tablet of safoof e muhazzil|compressed tablet of safoof e muhazzil is given in equivalent dose orally
11503137|NCT01332747|Active Comparator|atorvastatin|atorvastatin 10mg daily as a standard control
11503138|NCT01332734||severe sepsis and septic shock|
11503139|NCT01332721|Experimental|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
11503140|NCT01332708|Experimental|Obese and overweight subjects|The participants are overweight and obese people with and without metabolic syndrome that will participate in diet groups.
11503141|NCT01332695|Experimental|ST101|ST101 oval tablets
11503142|NCT01332695|Placebo Comparator|Placebo|oval tablets to match ST101 tablet
11503143|NCT01332682|Experimental|Resistance Training and Nutrition Counseling|
11503144|NCT01332682|Other|Nutrition Counseling|
11503145|NCT01332669|Active Comparator|chemoembolization|HCC patients received chemoembolization
11503146|NCT01332669|Other|Historical use of c-TACE using Lipiodiol and doxorubicin|The control arm will be of the patients that have been treated historically in the centers with conventional TACE (that is Lipiodiol plus doxorubicin).
11503147|NCT01332656|Experimental|Arm A|Ombrabulin, Paclitaxel and Carboplatin
11503148|NCT01332656|Placebo Comparator|Arm B|Placebo, Paclitaxel and Carboplatin
11503149|NCT01332643|Active Comparator|Test|The test group will consist of patients undergoing blastocyst biopsy followed by vitrification (embryo freezing), and in which the biopsied cells will be analyzed with a comprehensive chromosome analysis technique (array Comparative Genome hybridization or aCGH) and only one chromosomally normal embryo will be replaced in a thawed cycle.
11503150|NCT01332643|No Intervention|control|The control group will consist of patients in which one embryo will be replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patient does not become pregnant, successive embryo transfers of frozen embryos will be performed, but not as part of the study.
11503151|NCT01332630|Experimental|TPI 287|TPI 287 administered at 160 mg/m2 by vein on Day 1 and repeated every three weeks. Day 1 of each subsequent cycle is equivalent of day 22 of the previous cycle; pre TPI 287: Dexamethasone 6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, Dexamethasone 10 mgby vein may be given 30-60 minutes prior to treatment with TPI 287, Benadryl 12.5-25 mg IV push over 30-60 minutes, and Ranitidine 1mg/kg IV over 30-60 minutes.
11503152|NCT01332617|Experimental|Treatment with combination therapy|Treatment with combination therapy of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine, and Methylprednisolone.
11503153|NCT01332604|Experimental|A|
11503154|NCT01332604|Experimental|B|
11503155|NCT01332591|Active Comparator|Complete revascularization|"Percutaneous coronary intervention of non-infarct coronary arteries"
11503156|NCT01332591|No Intervention|Conservative management|standard guideline-based medical therapy
11503157|NCT01332578|Experimental|Test Product|Paracetamol, phenylephrine and ascorbic acid to be administered in 150 milliliters (mL) of hot water.
11503158|NCT01332578|Active Comparator|Paracetamol tablet|Two paracetamol 500 mg tablets to be administered with 150 mL of hot water.
11503159|NCT01332565|Experimental|Single Arm|All subjects will receive a 50 mg single dose of GSK1349572
11503160|NCT01332552|Experimental|Part 1: Single dose escalation|GSK2485852 planned single doses are placebo, 70 mg, 420 mg, 70 mg with food
11503165|NCT01332526||Patients with BMI> 30 and metabolic syndrome ( ATP III).|Patients with BMI> 30 and metabolic syndrome ( ATP III).
11503166|NCT01332526||Patient with BMI> 30 without metabolic syndrome.|Patient with BMI> 30 without metabolic syndrome.
11503167|NCT01332526||Normal healthy control|healthy persons( without renal disease, cardiovascular diseases, diabetes mellitus, BMI < 25;normotensives ).
11503168|NCT01332526||Patients with CKD stage III and uric acid < 7 mg/dl|"Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid < 7 mg/dl.
~without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressives agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)"
11503169|NCT01332526||Patients with CKD stage III and uric acid > 7 mg/dl|"Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid > 7 mg/dl
~without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)"
11503170|NCT01332526||Patient with asymptomatic hyperuricemia|Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function
11503171|NCT01332526||Hemodialysis patients|"Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function Hemodialysis patients.
~CKD: nondiabetic nephropathy
~duration hemodialysis 3-48 months
~Hb-11-13 g/dl
~well controlled hypertension ( < 140/90 mmHg)
~without ACEi, ARB, allopurinol treatment
~residual diuresis will be estimated for last 48 hours-between mid and next dialysis"
11503172|NCT01332513|Experimental|ABFCED sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 milligram (mg) twice daily (BID) dosing of ezogabine modified release (MR) tablet in periods A, B, C, D and E and will receive 200 mg three times daily (TID) dosing of ezogabine immediate release (IR) tablet in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
11503173|NCT01332513|Experimental|BCADFE sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
11503174|NCT01332513|Experimental|CDBEAF sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
11503175|NCT01332513|Experimental|DECFBA sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
11503176|NCT01332513|Experimental|EFDACB sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
11503177|NCT01332513|Experimental|FAEBDC sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
11503178|NCT01332500||adult migraineurs with/without aura|Adult migraine patients >18-65 years who have initiated treatment for migraine with Treximet ™ or other orally administered triptan.
11503179|NCT01332487||Early initiation of 5ARI therapy|Patients starting 5ARI therapy within 30 days of initiating AB therapy
11503180|NCT01332487||Delayed initiation of 5ARI therapy|Patients starting 5ARI therapy more than 30 days but less than 6 months from the initiation of AB therapy
11503181|NCT01332474||JCP|treatment of Equinus Foot due to Lower Limb Spasticity in Juvenile Cerebral Palsy Patients Aged 2-year or Older
11503182|NCT01332461||COPD Patients|Patients over the age of 40 with a COPD-related hospital or ER visit
11503183|NCT01332448||Orlistat 120|Orlistat 120mg tid
11503184|NCT01332448||Orlistat 60|Orlistat 60 mg tid
11503185|NCT01332448||Placebo|No active drug
11503186|NCT01332435||Early 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with early initiation of 5ARI (within 30 days of initiation of AB)
11503187|NCT01332435||Late 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with late initiation of 5ARI (more than 30 days but less than 6 months after initiation of AB)
11503188|NCT01332422||Pediatric patients prescribed ADOAIR|Pediatric patients with asthma prescribed ADOAIR during study period
11503189|NCT01332409||Patients prescribed salmeterol and fluticasone|Patients with chronic obstructive pulmonary disease prescribed salmeterol and fluticasone during study period
11503190|NCT01332396||Patients prescribed TYKERB|Patients with HER2 overexpressing inoperable or recurrent breast cancer
11503191|NCT01332383||Patients prescribed AMERGE|Patients with migraine disorders prescribed AMERGE during study period
11503192|NCT01332370||Adults with Type 2 Diabetes|Subjects with a diagnosis (ICD-9 code) of diabetes
11503193|NCT01332357||Fluticasone propionate/salmeterol combination ED MD|Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the ED physician
11503194|NCT01332357||Fluticasone propionate/salmeterol combination OP MD|Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the OP physician
11503195|NCT01332344||Asthma patients treated with inhaled corticosteroids|Asthma subjects newly prescribed inhaled corticosteriods
11503196|NCT01332331|Experimental|Low Dose Ambrisentan|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
11503197|NCT01332331|Experimental|High Dose Ambrisentan|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
11503198|NCT01332318|Placebo Comparator|Placebo|XP13512 Placebo + Diphenhydramine Placebo
11503199|NCT01332318|Experimental|XP13512 1200 mg|XP13512 1200 mg/day + Diphenhydramine Placebo
11503200|NCT01332318|Experimental|XP13512 1800 mg|XP13512 1800 mg/day + Diphenhydramine Placebo
11503201|NCT01332318|Active Comparator|Placebo + Diphenhydramine|XP13512 Placebo + 50 mg Diphenhydramine
11503202|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 600 mg|GEn (XP13512/GSK1838262) 600 mg
11503203|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 1200 mg|GEn (XP13512/GSK1838262) 1200 mg
11503204|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 1800 mg|GEn (XP13512/GSK1838262) 1800 mg
11503205|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 2400 mg|GEn (XP13512/GSK1838262) 2400 mg
11503206|NCT01332305|Placebo Comparator|Placebo|Placebo
11503207|NCT01332292|Active Comparator|COHORT 1 RANDOMISATION A|(8-11 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Day 2-13 = home dosing
11503208|NCT01332292|Placebo Comparator|COHORT 1 RANDOMISATION B|(8-11 years old) Repeat dose session: matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
11503209|NCT01332292|Active Comparator|COHORT 2 RANDOMISATION A|(5-7 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
11503210|NCT01332292|Placebo Comparator|COHORT 2 RANDOMISATION B|(5-7 years old) Repeat dose session: Matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
11503211|NCT01332279|Experimental|Treatment (enzyme inhibitor and radiation therapy)|Patients receive RAD001 PO and erlotinib hydrochloride PO QD. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo EBRT BID 5 days a week for 5 weeks.
11503212|NCT01332266|Active Comparator|Active Comparator; Phase IB: Cohort 1,2,and 3|"Phase Ib:
~Cohort 1; 200 mg E7050 + 250 mg/m2 cetuximab Cohort 2; 300 mg E7050 + 250 mg/m2 cetuximab Cohort 3; 400mg E7050 + 250mg/m2 cetuximab
~Phase II: Arm 1; MTD E7050 + 250 mg cetuximab Arm 2; 250 mg cetuximab
~Interventions: Drug cetuximab"
11503213|NCT01332266|Active Comparator|Phase II|"Phase II:
~Arm 1; MTD E7050 + 250 mg/m2 cetuximab Arm 2; 250 mg/m2 cetuximab"
11503214|NCT01332253|Experimental|Intravenous Ibuprofen|
11503215|NCT01332253|Placebo Comparator|Normal Saline|
11503216|NCT01332240|Experimental|Endosonography|Endoscopic ultrasonography (EBUS-TBNA +/- EUS-FNA) for invasive mediastinal nodal staging
11503217|NCT01332227|Experimental|Atazanavir/Ritonavir + Raltegravir|Atazanavir + Ritonavir (heat-stable) + Raltegravir
11503218|NCT01332227|Other|Atazanavir/Ritonavir + Tenofovir/Emtricitabine|"Reference
~Atazanavir + Ritonavir (heat-stable) + Tenofovir/Emtricitabine"
11503219|NCT01332214|Experimental|AZD2820|
11503220|NCT01332214|Placebo Comparator|Placebo|
11503221|NCT01332201|Experimental|Advagraf|
11503222|NCT01332201|Active Comparator|Prograf|
11503223|NCT01332188|Experimental|AC-170 0.05%|
11503224|NCT01332188|Experimental|AC-170 0.1%|
11503225|NCT01332188|Experimental|AC-170 0.24%|
11503226|NCT01332188|Placebo Comparator|AC-170 0%|
11503227|NCT01332175|Active Comparator|Provent|
11503228|NCT01332175|Placebo Comparator|Placebo-Provent|
11503229|NCT01332175|Active Comparator|CPAP|
11503230|NCT01332162|Experimental|Biventricular pacing|All patients will be pacing during two years
11503231|NCT01332162|Active Comparator|No Pacing during the first year|No Pacing during the first year. In the second year all patients will be pacing
11503232|NCT01332149|Experimental|300 mg/day pregabalin (Lyrica)|Patient take pregabalin capsule twice a day
11503233|NCT01332149|Placebo Comparator|Placebo|
11503234|NCT01332136||Endoscopic sinus surgery|Patients electing endoscopic sinus surgery for chronic rhinosinusitis
11503235|NCT01332136||Medical management|Continued medical management for symptoms of chronic rhinosinusitis
11503236|NCT01332123|Experimental|Alignment perturbations|The following modifications will be applied to the prostheses: increased foot plantar flexion, increased foot dorsal flexion, increased foot supination, increased foot pronation (always 2 degrees from the neutral position)
11503237|NCT01332110|Experimental|Knee abduction moment-reducing footwear|Footwear that is known to decrease knee abduction moments of force in healthy subjects. May include orthotics, or footwear that allows relative movement between the heel section of the outsole and rest of the shoe.
11503238|NCT01332110|Placebo Comparator|Control footwear|Standard, off-the-shelf running shoes with no mechanical modifications.
11503239|NCT01332097|Experimental|Treatment A|single 75mg oral dose of BCT197 capsules + single oral dose of prednisone placebo capsules
11503240|NCT01332097|Placebo Comparator|Treatment B|single oral dose of BCT197 placebo capsules + single oral dose of prednisone placebo capsules
11503241|NCT01332097|Active Comparator|Treatment C|single oral dose of BCT 197 placebo capsules + single oral dose of 40mg prednisone capsules
11503242|NCT01332097|Experimental|Treatment D|single oral dose of 20mg dose of BCT197 capsules
11503243|NCT01332097|Placebo Comparator|Treatment E|single oral dose of BCT 197 placebo capsules
11503244|NCT01332097|Experimental|Treatment F|single oral dose of 20 mg dose of BCT197 capsules on Day 1 and Day 6
11503245|NCT01332097|Placebo Comparator|Treatment G|single oral dose of BCT 197 placebo capsules on Day 1 and Day 6
11503246|NCT01332097|Experimental|Treatment H|single oral dose of 75mg dose of BCT197 capsules on Day 1 and Day 6
11503247|NCT01332097|Placebo Comparator|Treatment I|single oral dose of BCT 197 placebo capsules on Day 1 and Day 6
11503248|NCT01332084|Experimental|hypoallergenic wheat cereals|HA wheat cereal used in a SOTI test
11503249|NCT01332071|Active Comparator|Avandamet test product|Test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 miligrams (mg) + 1000 mg in Period 1, followed by a 7-day washout period during which no medication was administered, followed by reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 mg + 500 mg in Period 2
11503339|NCT01331473|Active Comparator|Carotid Artery Stenting without Protection|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and without embolic protection device
11503250|NCT01332071|Active Comparator|Avandamet reference product|Reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 miligrams (mg) + 500 mg in Period 1; followed by a 7-day washout period during which no medication was administered; followed by test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 mg + 1000 mg in Period 2
11503251|NCT01332058|Experimental|Motivational Interviewing (MI)|
11503252|NCT01332045|Sham Comparator|Saline boluses in nerve catheter|A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
11503253|NCT01332045|Active Comparator|Continuous saphenous nerve block|Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
11503254|NCT01332032||Reminder Letter|"A letter sent to women reminding them that are coming due or overdue for a mammogram. It contains a reminder that their primary care provider (PCP) recommends mammography screening every 1-2 years. It urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. Repeat Booster letters will be sent in subsequent years to those failing to get a mammogram."
11503255|NCT01332032||Reminder Call|"A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a mammogram within 2 weeks, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offer to schedule a mammogram for her. Repeat Booster letters will be sent and repeat scheduler calls made in subsequent years to those failing to get a mammogram."
11503256|NCT01332032||Counselor Call|"A reminder letter as above is sent first. If a woman does not call in to schedule a mammogram within 2 weeks, a second letter is sent along with a mammography educational booklet. The second letter also reiterates a reminder that her PCP recommends screening every 1-2 years, and offers a special number to call to schedule. If a woman does not schedule within 8-10 days, a counselor will call. The protocol script included tailored barriers counseling, correction of misinformation and motivational interviewing. Repeat booster letters will be sent and repeat counselors calls made in subsequent years to those failing to get a mammogram. techniques. Average calls last 20-30 minutes."
11503257|NCT01332019|Experimental|peginterferon beta-1a Q4W|125 µg peginterferon beta-1a administered by subcutaneous (SC) injection every 4 weeks (Q4W) for at least 2 years and up to 4 years.
11503258|NCT01332019|Experimental|peginterferon beta-1a Q2W|125 μg peginterferon beta-1a administered by SC injection every 2 weeks (Q2W) for at least 2 years and up to 4 years.
11503259|NCT01332006|Experimental|Intra-bone injection|Intra-bone transplantation of hematopoietic stem cells from cord blood
11503260|NCT01331993|Experimental|1|Treatment order : A, B, C
11503261|NCT01331993|Experimental|2|Treatment order : B, C, A
11503262|NCT01331993|Experimental|3|Treatment order : C, A, B
11503263|NCT01331993|Experimental|4|Treatment order : A, C, B
11503264|NCT01331993|Experimental|5|Treatment order : B, A, C
11503265|NCT01331993|Experimental|6|Treatment order : C, B, A
11503266|NCT01331980||cystic fibrosis|children aged 6-12 years of age and Tanner stage 1 with a diagnosis of cystic fibrosis
11503267|NCT01331980||healthy controls|children ages 6-12 years and Tanner stage 1 without cystic fibrosis or other chronic disease that affects bone health
11503268|NCT01331967|Experimental|Pioglitazone, Placebo|
11503269|NCT01331954|Experimental|HIFU|
11503270|NCT01331941|Experimental|Group 1|Cancer subjects with normal renal function.
11503271|NCT01331941|Experimental|Group 3|Cancer subjects with moderate renal impairment.
11503272|NCT01331941|Experimental|Group 4|Cancer subjects with severe renal impairment.
11503273|NCT01331941|Experimental|Group 2|Cancer subjects with mild renal impairment.
11503274|NCT01331928|Experimental|Capecitabine, Oxaliplatin, Docetaxel , Gastric cancer|
11503275|NCT01331915|Experimental|Theravac|Theravac® is a recombinant adenylate cyclase toxin from Bordetella pertussis that has been detoxified by mutation of its catalytic domain, and which has been coupled to the Tyrosinase.A2 epitope YMDGTMSQV.
11503276|NCT01331902|Experimental|Adenosine Followed by Nicorandil|
11503277|NCT01331902|Experimental|Nicorandil Followed by Adenosine|
11503278|NCT01331889||Potassium concentration|plasma potassium concentrations in the Fluid Management System (FMS) reservoir, arterial blood, and central venous blood
11503279|NCT01331876|Experimental|reference therapy|20 OCD patients following 15 sessions of the reference CBT (Bouvard,2006)
11503280|NCT01331876|Experimental|experimental therapy|20 OCD patients following 15 sessions of reference CBT associated with a new psychopedagogic task developed by our team.
11503281|NCT01331863|Experimental|single arm surgery|Airway and/or pulmonary Vessels Transplantation
11503282|NCT01331850|Experimental|Previous null responders (Cohort B): Group 4|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 4 will receive RO5024048 1000 mg twice a day and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
11503283|NCT01331850|Experimental|Previous null responders (Cohort B): Group 5|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 5 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
11503284|NCT01331850|Experimental|Previous null responders (Cohort B): Group 6|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 6 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks. In addition, patients in Group 6 will receive another 24 weeks of Pegasys plus Copegus treatment.
11503285|NCT01331850|Experimental|Previous partial responders (Cohort A): Group 1|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 1 will receive RO5024048 1000 mg twice a day and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
11503286|NCT01331850|Experimental|Previous partial responders (Cohort A): Group 2|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 2 will receive Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
11503390|NCT01331057||3: Mali|Children aged of four to six years old, in the nursery school and if their first language is unique : SONINKE.
11503287|NCT01331850|Experimental|Previous partial responders (Cohort A): Group 3|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 3 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
11503288|NCT01331837|Active Comparator|Etanercept|
11503289|NCT01331837|Experimental|Tocilizumab|
11503290|NCT01331824|Experimental|Amrubicin|35 mg/m2/day intravenously
11503291|NCT01331798|Experimental|Test: TissuGlu Adhesive|Patients received the TissuGlu Adhesive Treatment
11503292|NCT01331798|Active Comparator|Control|Control Arm received no TissuGlu- Standard of Care received.
11503293|NCT01331785|Experimental|Midodrine|
11503294|NCT01331772|Other|Control arm|Dietetic follow-up only
11503295|NCT01331772|Experimental|Intervention arm|Dietetic + adapted physical activity
11503296|NCT01331759|Experimental|Immediate Neuropattern™|The experimental group will undergo Neuropattern™ stress diagnostics immediately after inclusion in the study.
11503297|NCT01331759|Placebo Comparator|Later Neuropattern™|The control group will undergo Neuropattern™ stress diagnostics three months after inclusion in the study.
11503298|NCT01331746|Experimental|APD515|Active APD515 treatment 20 mg qds for 7 days
11503299|NCT01331746|Placebo Comparator|Placebo|
11503300|NCT01331733||hMG-HP|Patients with a condition
11503301|NCT01331733||hMG-HP + GnRH antagonist|Patients with a condition
11503302|NCT01331720||FSH:LH 1:1 - Treatment Group A|"Patients with a condition
~LH (luteinizing hormone)"
11503303|NCT01331720||FSH:LH 3:2 - Treatment Group B|Patients with a condition
11503304|NCT01331720||FSH:LH 3:1 - Treatment Group C|Patients with a condition
11503305|NCT01331720||FSH:LH 3:0 - Treatment Group D|Patients with a condition
11503306|NCT01331720||Initially FSH:LH 3:0 and on S6 FSH:LH 1:1 - Treatment Group E|Patients with a condition
11503307|NCT01331707|Active Comparator|Promus Element|
11503308|NCT01331707|Active Comparator|Resolute Integrity|
11503309|NCT01331694||COPD|copd patients 65 years and older
11503310|NCT01331681|Experimental|Intravitreal Aflibercept Injection 2Q4|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
11503311|NCT01331681|Experimental|Intravitreal Aflibercept Injection 2Q8|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
11503312|NCT01331681|Active Comparator|Macular Laser Photocoagulation (Control)|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
11503313|NCT01331668||renal allograft donors and recipients|All de novo renal allograft recipients transplanted at the University Hospitals Leuven
11503314|NCT01331655|Experimental|Arm 1|
11503315|NCT01331655|Experimental|Arm 2|
11503316|NCT01331655|Active Comparator|Arm 3|
11503317|NCT01331642||Observation|Patients with Gaucher disease or high-grade suspicion for Gaucher disease
11503318|NCT01331629|Experimental|ART-THERAPIE|supported in art therapy with other supportive care available in the facility
11503319|NCT01331629|No Intervention|standard group|standard care (supportive care available in each facility)
11503320|NCT01331616|Experimental|Bevacizumab (Avastin)|
11503321|NCT01331603||MDS and primary myelofibrosis patients|patients with in iron overloaded MDS patients (low and high risk ), and also patients with primary myelofibrosis. The risk stratification of these patients will be calculated according to the IPSS (International Prognostic Scoring System).
11503322|NCT01331590|Experimental|G-CSF + Ifosfamide + Etoposide + Dexamethasone + Mesna|"G-CSF = 10 mcg/kg/d SQ starting on day 1 and continuing until ANC >=1000/mcL x 2 days
~Ifosfamide = 3330 mg/m2/d CIVI over 24 hours on Days 4-6
~Etoposide = 150 mg/m2 IV over 2 hours BID on Days 4-6
~Dexamethasone = 5 mg/m2 PO or IV BID on Days 4-10
~Mesna = 2660 mg/m2/d continuous IV infusion over 24 hours on Days 4-6. 2000 mg/m2 continuous IV infusion over 12 hours on Day 7 to be started immediately after completion of ifosfamide."
11503323|NCT01331577|Experimental|Cognitive behavioural Intervention|
11503324|NCT01331577|Experimental|Integrative Kinesiology Intervention|
11503325|NCT01331577|No Intervention|Waiting-List control group|
11503326|NCT01331564|Experimental|electronic intervention group 2|(e-intervention 2) receives a behavioral intervention through a website during pregnancy and until 18 months postpartum
11503327|NCT01331564|Experimental|electronic intervention group 1|(e-intervention 1) receives a behavioral intervention through a website during pregnancy. During the postpartum period this arm receives the same non-weight-related information as the control arm
11503328|NCT01331564|Placebo Comparator|Control|
11503329|NCT01331551||men with inflammatory bowel disease|Men between the ages of 18-55 with inflammatory bowel disease who are taking mesalamine medication.
11503330|NCT01331538||adolescents with TMD|adolescents with temporomandibular dysfunction
11503331|NCT01331538||No TMD|adolescents without temporomandibular dysfunction
11503332|NCT01331525|Experimental|Single stage non-randomised|"Patients will receive Carboplatin and Etoposide. Both Chemotherapy drugs will be delivered as a 21 day cycle (q21) with up to a maximum of 6 cycles delivered according to response unless progressive disease (RECIST Version 1.0) and or excessive toxicity.
~Ipilimumab will be administered at a dose of 10mg/kg IV on day 1 of cycles 3-6 of Chemotherapy.
~In the absence of immune related progression of disease or unacceptable toxicity, subsequent maintenance doses of Ipilimumab will be delivered every 12 weeks starting at week 30 at a dose of 10 mg/kg until unacceptable toxicity or immune related disease progression"
11503333|NCT01331499|Experimental|Bipolar Sealer|Standard of care blood sparing techniques with bipolar sealer
11503334|NCT01331499|Active Comparator|Control|Standard of care blood sparing techniques without the use of bipolar sealer
11503335|NCT01331486|Placebo Comparator|Placebo|Placebo capsule
11503336|NCT01331486|Active Comparator|Low dose|
11503337|NCT01331486|Active Comparator|Mid dose|
11503338|NCT01331486|Active Comparator|High dose|
11503391|NCT01331044|Experimental|RUTF|Ready to use Therapeutic Food (RUTF) Plumpy nut.
11503392|NCT01331044|Active Comparator|Khichuri - Halwa|Cereal Legume
11503340|NCT01331473|Active Comparator|Carotid Artery Stenting with Proximal Protection|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and with a proximal embolic protection device provided by the GORE Neuro Protection System
11503341|NCT01331460|Experimental|RBT Experimental|
11503342|NCT01331460|Active Comparator|Case-Management: Treatment as Usual|
11503343|NCT01331408|Experimental|Macrolane VRF30|Injection of Macrolane VRF30 in buttocks
11503344|NCT01331395|No Intervention|IVF-No Acupuncture|IVF with no Traditional Chinese Medicine: Acupuncture
11503345|NCT01331395|Active Comparator|IVF-Acupuncture|IVF with Traditional Chinese Medicine: Acupuncture
11503346|NCT01331382|Experimental|250mg trans- resveratrol|
11503347|NCT01331382|Experimental|250mg trans-resveratrol with 20mg piperine|
11503348|NCT01331382|Placebo Comparator|Placebo|
11503349|NCT01331369|Active Comparator|Control|Usual care. It means routine medical care that include free demand consultation and free medicines.
11503350|NCT01331369|Experimental|Intervention|Intensification of care. Besides routine medical care that include free demand consultation and free medicines, subjects were invited to have 6 structured medical encounters based on a social-psychological approach. Doctors must follow a protocol to conduct the encounter that have around 30 minutes each.
11503351|NCT01331356|Experimental|Injection of botulinum toxin type A|
11503352|NCT01331330|Active Comparator|Group B|Low Programming
11503353|NCT01331330|Experimental|Group A|Normal Programming
11503354|NCT01331317|Other|Paricalcitol|Crossover study between paricalcitol and placebo
11503355|NCT01331304|Other|Li + APT|Study participants will take lithium in addition to any other medications recommended by the study physician.
11503356|NCT01331304|Other|QTP + APT|Study participants will take quetiapine in addition to any other medications recommended by the study physician.
11503357|NCT01331291|Experimental|Arm A|Patients who are surgical candidates. Participants are given oral bosutinib, 400mg daily, for 7-9 days prior to resection. After at least 10 days elapsed post-operatively, bosutinib dosing was resumed.
11503358|NCT01331291|Experimental|Arm B|Patients that are not surgical candidates. Participants are given oral bosutinib, 400 mg daily in 28 day cycles until disease progression, intolerability or withdrawal of consent.
11503359|NCT01331278|Active Comparator|Custom Cutting Blocks|
11503360|NCT01331278|Active Comparator|Computer Assisted Surgery|
11503361|NCT01331265||no treatment|
11503362|NCT01331252|Experimental|supine body position|Consecutive patients admitted with severe tetanus to the tetanus intensive care ward will be eligible to be included in the study. An envelope for the next study number will be opened in which patients will be randomly allocated to either semi-recumbent (30 degree) or supine (0 degree) body position
11503363|NCT01331252|Experimental|semi-recumbent|Consecutive patients admitted with severe tetanus to the tetanus intensive care ward will be eligible to be included in the study. An envelope for the next study number will be opened in which patients will be randomly allocated to either semi-recumbent (30 degree) or supine (0 degree) body position
11503364|NCT01331239|Experimental|LCI699|Participants too an ascending dose from 2mg bid or 5 mg bid, up to 30 mg bid
11503365|NCT01331226|Experimental|3 session telephone counseling|
11503366|NCT01331226|Experimental|1 session telephone counseling|
11503367|NCT01331226|Active Comparator|written materials|
11503368|NCT01331213|Active Comparator|Pregabalin|Subjects randomized to this arm received a single dose of pregabalin 200mg orally.
11503369|NCT01331213|Placebo Comparator|Placebo|Subjects randomized to this arm received a single dose of placebo orally.
11503370|NCT01331187|Active Comparator|Usual care|Usual care diagnostics. No routinely ultrasound examination
11503371|NCT01331187|Experimental|Routinely ulasonography|Patients will routinely be examined with ultrasound at admittance in addition to usual care diagnostics
11503372|NCT01331174|Experimental|High dose PSW groups|The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W. These settings were based on the fact that applications with mean power below 20W minimize the thermal effects
11503373|NCT01331174|Placebo Comparator|Placebo|A placebo group was also established, in which the PSW device was turned on but kept in stand-by mode during 19 minutes without any electrical current being applied in the patients
11503374|NCT01331174|No Intervention|Control|The control group was composed of patients that were not submitted to any form of treatment and all patients were instructed to maintain their daily activities
11503375|NCT01331161|Experimental|Older group|Participants between the ages of 60-79
11503376|NCT01331161|Experimental|Younger group|Participants between the ages of 25-40
11503377|NCT01331148|Active Comparator|Vitamin D|10,000 IU per caplet, with vitamin D dose based on weight, ranging from 240,000 IU to 600,000 IU. Patients will receive calcium/vitamin D daily soft chew as well.
11503378|NCT01331148|Placebo Comparator|Placebo|placebo only, all patients will receive calcium/vitamin D chew
11503379|NCT01331135|Experimental|sirolimus treatment|Dose escalation of sirolimus with starting dose at 1 mg/m2 and increasing to a possible 3 mg/m2.
11503380|NCT01331122|Experimental|droxidopa|Northera (2R,3S)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid L-DOPS L-threo-dihydroxyphenylserine Droxidopa SM-5688
11503381|NCT01331122|Placebo Comparator|placebo|placebo
11503382|NCT01331109|Experimental|Milnacipran|oral administration, twice daily dosing
11503383|NCT01331096||Anesthetic drugs manually administrated|
11503384|NCT01331096||Automated anesthesia delivery system|
11503385|NCT01331083|Experimental|PX-866|
11503386|NCT01331070|Experimental|PATIENT|Patients, half with moderate (GOLD II) and half with severe (GOLD III) COPD
11503387|NCT01331070|Other|Accepts Healthy Volunteers|Control arm with the same intervention
11503388|NCT01331057||1:Sri Lankais|Children aged of four to six years old, in the nursery school and if their first language is unique : tamil.
11503389|NCT01331057||2: Algerian|Children aged of four to six years old, in the nursery school and if their first language is unique : arabic.
11503393|NCT01331031||Adolescents|Adolescents between 10 and 20 years of age and enrolled in a municipal school system.
11503394|NCT01331018|Experimental|Treatment (hematopoietic stem progenitor cells)|"STEM CELL MOBILIZATION FOR CELL COLLECTION: Patients receive filgrastim SC BID for up to 6 days (on days 1-6 of mobilization). Patients receive plerixafor SC QD on days 4-6 of mobilization. PBSC count will be checked daily starting on day 4 of mobilization. Patients who have a PBSC count of >= 5 CD34+ cells/mcL will undergo up to 2 apheresis collections on consecutive days.
~BONE MARROW HARVEST FOR CELL COLLECTION: Patients with inadequate PBSC counts undergo bone marrow harvest for collection of stem/progenitor cells.
~REINFUSION: Patients receive methylprednisolone IV or prednisone PO on days -1 to 7 followed by a rapid taper over approximately 1 week and undergo reinfusion of genetically modified hematopoietic stem/progenitor cells on day 0."
11503395|NCT01331005|Placebo Comparator|Placebo|Placebo will be given three times per day for one year
11503396|NCT01331005|Active Comparator|nepafenac 0.1% drops|Nepafenac drops will be given three times per day for one year
11503397|NCT01330992|Experimental|Ocular Light or Dark Exposure|Ocular Light or Dark Exposure
11503398|NCT01330966|Experimental|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
11503399|NCT01330953|Placebo Comparator|Placebo|Single intravenous placebo dose.
11503400|NCT01330953|Experimental|30 mg LY2928057 (Cohort 1)|Day 1: single 30-milligram (mg) LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 30-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 30-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 30 mg LY2928057.
11503401|NCT01330953|Experimental|100 mg LY2928057 (Cohort 2)|Day 1: single 100-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 100-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 100-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 100 mg LY2928057.
11503402|NCT01330953|Experimental|300 mg LY2928057 (Cohort 3)|Day 1: single 300-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 300-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 300-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 300 mg LY2928057.
11503403|NCT01330953|Experimental|1000 mg LY2928057 (Cohort 4)|Day 1: single 1000-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 1000-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 1000-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 1000 mg LY2928057.
11503404|NCT01330940|Placebo Comparator|Water drinking|32 ounces of water/24 hours
11503405|NCT01330940|Active Comparator|orange soda drinking|32 ounces orange soda
11503406|NCT01330927|Experimental|VA106483 0.5 mg|
11503407|NCT01330927|Experimental|VA106483 1 mg|
11503408|NCT01330927|Experimental|VA106483 2 mg|
11503409|NCT01330927|Experimental|VA106483 4 mg|
11503410|NCT01330927|Placebo Comparator|Sugar pill|
11503411|NCT01330914||Gastric Bypass Surgery Patients|Obese men and women undergoing gastric bypass surgery
11503412|NCT01330901|Experimental|Ustekinumab|Ustekinumab 90 mg subcutaneously at week 0, 4 and 16
11503413|NCT01330888||Group 1|ARNG Chaplains
11503414|NCT01330849|Experimental|Toolkit intervention|
11503415|NCT01330849|No Intervention|Waiting List Control Group|Children eligible for the study according to the inclusion criteria, but randomly allocated to the waiting list control group are promised to receive the intervention AFTER the study is finished.
11503416|NCT01330823|Active Comparator|L-Carnitine|L-Carnitine 4 g daily for Intervention
11503417|NCT01330823|Placebo Comparator|Placebo|Placebo (tartaric acid)
11503418|NCT01330810|Active Comparator|C3 tablet|4g C3 tablet
11503419|NCT01330810|Active Comparator|Meriva|2g Meriva powder
11503420|NCT01330797||LOCS III|Cohort is composed of cases with a diagnosis of wet age-related macular degeneration and those that received intravitreal ranibizumab
11503421|NCT01330784||hMG-HP|Patients with a condition
11503422|NCT01330771||hMG-HP/r-FSH|Patients with a condition
11503423|NCT01330758|Active Comparator|40 mg AZD8931 wet granulation tablet formulation|
11503424|NCT01330758|Experimental|40 mg AZD8931 roller compacted tablet formulation|
11503425|NCT01330745|Other|aortic valve replacement|
11503426|NCT01330732||1|Main group: patients examined in scoliosis clinic for kyphosis with recent lateral spine X-rays.
11503427|NCT01330719|Experimental|Diseased periodontal treatment|Scaling and root planing along with systemic antibiotics (Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days).
11503428|NCT01330719|Active Comparator|Conventional periodontal treatment|Standard periodontal prophylaxis
11503429|NCT01330706|Experimental|Sterile Saline solution|The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
11503430|NCT01330693|Active Comparator|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children
11503431|NCT01330693|Placebo Comparator|Placebo|Sugar pill
11503432|NCT01330680|Experimental|Coffee|
11503433|NCT01330680|Active Comparator|Decaffeinated coffee|
11503434|NCT01330667|Experimental|Formula Supplementation|Participants will supplement feedings with early limited formula following nursing.
11503435|NCT01330667|No Intervention|Control|Participants will be instructed to continue exclusively breastfeeding with no formula supplementation.
11503436|NCT01330654|Active Comparator|Beta blocker|These patients will be randomized to receive a standard dose of metoprolol (50mg) starting two weeks prior to surgery
11503437|NCT01330654|No Intervention|Control|This arm will receive no additional treatment prior to surgery
11503438|NCT01330641|Active Comparator|Anterior injection Route|Group of patients injected with medication using the anterior route
11503439|NCT01330641|Active Comparator|Posterior Injection|Group of patients receiving injection through a posterior route
11503481|NCT01330355|Active Comparator|Gatifloxacin|Gatifloxacin 0.3% ophthalmic solution
11503440|NCT01330641|Active Comparator|Lateral Injection|Group of patients receiving subacromial injection through a lateral route
11503441|NCT01330628|Experimental|Laser atherectomy and PTA|laser, then balloon angioplasty
11503442|NCT01330628|Active Comparator|Balloon angioplasty|
11503443|NCT01330615|Active Comparator|Cryotherapy with EMLA|EMLA applied before cryotherapy
11503444|NCT01330615|Placebo Comparator|Cryotherapy with placebo analgesia|Placebo cream applied instead of EMLA
11503445|NCT01330602|Experimental|Lifestyle counseling|"All participants randomised into the IMPRESS Intervention group will undergo tailored health profiling.This individual assessment will be carried out within the clinic setting.
~The key elements of the IMPRESS intervention include:
~Promoting a healthy lifestyle
~Supporting lifestyle and risk modification
~Encouraging active self-management of risk and chronic disease
~Improving coordination of care
~Pharmacological therapy All the individuals in the intervention group will receive a comprehensive report on their risk status and ideal goals."
11503446|NCT01330602|No Intervention|Usual care arm|"Usual Care Following the assessment of absolute cardiovascular risk, usual care participants will be provided a report outlining areas in which improvements could be made for the prevention of atherosclerotic burden.
~No restrictions will be made in respect to usual care management. As such, the prescription of standard medications for primary prevention of atherosclerotic burden based on individual risk factors is anticipated in 20-30% of usual care participants.
~At 18 months and three years those in the usual care arm will be invited to undergo repeat CIMT measurements, pathology, absolute risk score calculation and health-related questionnaires as part of the structured study follow-up"
11503447|NCT01330589|Experimental|AB: Placebo (A); St. Johns Wort (B)|Receive placebo for 7 days, 7 days washout and 7 days of St. Johns Wort
11503448|NCT01330589|Experimental|BA: St. Johns Wort (B); Placebo (A)|Receive St. Johns Wort for 7 days, 7 days washout and 7 days of placebo
11503449|NCT01330576|Placebo Comparator|Standard treatment of care at normothermia|Control group: Standard treatment of care at normothermia
11503450|NCT01330576|Experimental|cooling blanket/mattress|Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress
11503451|NCT01330563|Experimental|CKD-501|"Subjects received Ketoconazole 200 mg twice daily for 5 days in one period and in the other period, Subjects don't receive Ketoconazole.
~In addition, The CKD-501 is administered on day 5"
11503452|NCT01330563|Experimental|ketoconazole|"Subjects received Ketoconazole 200 mg twice daily for 5 days in one period and in the other period, Subjects don't receive Ketoconazole.
~In addition, The CKD-501 is administered on day 5"
11503453|NCT01330550|Experimental|high fiber sugar free biscuit.|High fiber sugar free biscuit will regulate Blood sugars.
11503454|NCT01330524|Active Comparator|Avastin and Triamcinolone|
11503455|NCT01330524|Placebo Comparator|Placebo|
11503456|NCT01330511||Bilateral Hydronephrosis Grade I-II|Patients with Bilateral Hydronephrosis Grade I-II
11503457|NCT01330511||Bil. Hydronephrosis Grade III-IV, Other|Patient with Bilateral Hydronephrosis Grade III-IV and others with any hydronephrosis and distended bladder or MCKD
11503458|NCT01330511||Unilateral Hydronephrosis Grade I-II|Patients with Unilateral Hydronephrosis Grades I-II
11503459|NCT01330511||Unilateral Hydronephrosis Grade III-IV|Patients with Unilateral Hydronephrosis Grade III-IV
11503460|NCT01330498||Tysabri (natalizumab) infusing|Patients with relapsing forms of MS who participated in 001-001-TY and are currently still infusing with Tysabri (natalizumab).
11503461|NCT01330485|Experimental|Affect Regulation Training|Affect Regulation Training as described in Berking & Whitley, 2014.
11503462|NCT01330485|Active Comparator|Common Factor Control Condition (CFC)|Common factor based therapy control condition
11503463|NCT01330485|No Intervention|Waitlist Control Condition|Wait List Control
11503464|NCT01330472|Active Comparator|Xanax XR tablets 3 mg (sourced from Caugus)|Xanax XR tablets 3 mg (sourced from Caugus), 1 x 3 mg (REFERENCE)
11503465|NCT01330472|Experimental|Xanax XR tablets 3 mg (sourced from Barceloneta),|Xanax XR tablets 3 mg (sourced from Barceloneta), 1 x 3 mg (TEST)
11503466|NCT01330459|Active Comparator|Hydrocodone/acetaminophen|"Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure.
~Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure."
11503467|NCT01330459|Placebo Comparator|Placebo|"Subject will receive placebo 45-90 minutes prior to abortion procedure.
~Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure."
11503468|NCT01330446|Experimental|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
11503469|NCT01330446|Placebo Comparator|Placebo|1 Placebo by mouth every morning for a 28 day cycle.
11503470|NCT01330433|No Intervention|No CoSeal Surgical Spray|A patient randomized to the No CoSeal Surgical Spray group will not have CoSeal Surgical Spray applied at the end of their first staged procedure.
11503471|NCT01330433|Experimental|CoSeal Spray Group|CoSeal Spray will be applied at the end of the first staged procedure in patients randomized to the experimental group.
11503472|NCT01330420|Experimental|Relaxation Response Resiliency Program for Depression|"The Relaxation Response Resiliency Program for Depression (3RP-D) is a low-cost, easily replicable, 6-session, 1.5 hour, mind body intervention.
~The 3RP-D was designed to promote resiliency by reducing the harmful effects of stress through the elicitation of the relaxation response, and through skill training to enhance positive attitudes and beliefs, nutrition, exercise, recuperative sleep, social support, and coping. Specific interventions include: cognitive behavioral therapy (CBT), enhancing social support (SS), cultivating positive attitudes and beliefs (CPE), and promoting Healthy Lifestyle Habits(HL). The 3RP-D program has been manualized for use by group facilitators and health center patients."
11503473|NCT01330407|Experimental|gp2|Cultured Epidermal Autografts
11503474|NCT01330407|Active Comparator|gp1|cryopreserved skin allografts.
11503475|NCT01330394|Sham Comparator|sham-tDCS control|simulate control for transcranial Direct Current Stimulation
11503476|NCT01330394|Active Comparator|active tDCS|active transcranial Direct Current Stimulation
11503477|NCT01330381|Experimental|prucalopride|drug
11503478|NCT01330381|Placebo Comparator|Placebo|
11503479|NCT01330381|Active Comparator|PEG 4000|4-20g administered as an oral solution once daily
11503480|NCT01330355|Experimental|Besivance|Besifloxacin 0.6% ophthalmic suspension
11503482|NCT01330342||HIV patients without lymphoma|HIV-infected subjects on cART without a diagnosis of lymphoma
11503483|NCT01330342||HIV patients with lymphoma|HIV seropositive individuals with lymphoma
11503484|NCT01330329|Experimental|SBT + technology system (SBT+FIT)|Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention.
11503485|NCT01330329|Experimental|Standard behavioral treatment (SBT)|Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program.
11503486|NCT01330316|Experimental|BI 201335 for 24 weeks|BI 201335 once daily dose for 24 weeks in combination with PegIFN/RBV for 24 or 48 weeks
11503487|NCT01330303|Active Comparator|tamsulosin - Reference|Reference drug administration followed by Test drug administration
11503488|NCT01330303|Active Comparator|tamsulosin - Test|Test drug administration followed by Reference drug administration
11503489|NCT01330290||Neupro® Treatment|Routine treatment (2, 4, 6, 8, 10, 12, 14, 16 mg/24 hours) as per approved label in European Union (EU)/in accordance with the terms of the local marketing authorization for Neupro®
11503490|NCT01330277||Participants with Hunter syndrome|Participants diagnosed with Hunter syndrome (Mucopolisaccharidosis type 2) aged between 2 months to 50 years
11503491|NCT01330264||Dyad|
11503492|NCT01330251||Patients with diabetes having Roux-en-Y gastric bypass|
11503493|NCT01330251||Patients without diabetes having Roux-en-Y gastric bypass|
11503494|NCT01330251||Control subjects (patients having gastroscopy, no surgery)|
11503495|NCT01330238|Active Comparator|Zoledronic acid|Single infusion of 5 mg zoledronic acid I.V.
11503496|NCT01330238|Placebo Comparator|Placebo|Single infusion of 100 ml isotonic NaCl-solution I.V.
11503497|NCT01330199|Experimental|TDF 150mg + MVC 150mg|Subjects will receive a single dose of tenofovir 150 mg and maraviroc 150 mg.
11503498|NCT01330199|Experimental|TDF 300mg + MVC 300mg|Subjects will receive a single dose of tenofovir 300 mg and maraviroc 300 mg.
11503499|NCT01330199|Experimental|TDF 600mg +MVC 600mg|Subjects will receive a single dose of tenofovir 600 mg and maraviroc 600 mg.
11503500|NCT01330199|Experimental|FTC 100mg + RAL 200mg|Subjects will receive a single dose of emtricitabine 100 mg and raltegravir 200 mg.
11503501|NCT01330199|Experimental|FTC 200mg + RAL 400mg|Subjects will receive a single dose of emtricitabine 200 mg and raltegravir 400 mg.
11503502|NCT01330199|Experimental|FTC 400mg + RAL 800mg|Subjects will receive a single dose of emtricitabine 400 mg and raltegravir 800 mg.
11503503|NCT01330186||Anal cancer|
11503504|NCT01330173|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity.
11503505|NCT01330160||cohort of stroke patients|patients, over 40 years old and without dementia, displaying an hemorrhagic or an ischemic stroke, with a sus-tentorial localization, and included 72h before the onset of symptoms
11503506|NCT01330147||Tonsillectomy|Subjects undergoing tonsillectomy for non-cancer reasons including operations for: recurrent tonsillitis, asymmetric tonsils, snoring surgery or obstructive sleep apnoea.
11503507|NCT01330134|Experimental|lidocaine onto skin prior to lidocaine subcutaneous injection|1-2ml of 1% lidocaine dripped onto the surface of the skin immediately prior to subcutaneous injection of 1% lidocaine.
11503508|NCT01330134|Active Comparator|lidocaine subcutaneous injection alone|1% lidocaine subcutaneous injection alone by standard approach
11503509|NCT01330121|Active Comparator|Pharmacist Counseling|"Pharmacist Counseling includes but is not limited to:
~Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic & non-glycemic goal levels Explaining the importance of compliance with medications & appointments Educating on the basics of nutrition and physical activity"
11503510|NCT01330121|No Intervention|Standard therapy|Standard therapy: Nurses distribute a education pamphlet on diabetes
11503511|NCT01330108|Experimental|Ambrisentan|patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
11503512|NCT01330095|Active Comparator|Eearly administration|Administration of Bifidobacterium within 48h after birth
11503513|NCT01330095|Active Comparator|Late administration|Administration of Bifidobacterium more than 48h after birth
11503514|NCT01330082|Experimental|Photodynamic therapy|will be treated by PDT using Light-emitting diod(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark) in the presence of toluidine blue O (TBO)
11503515|NCT01330082|Experimental|Light-emitting diode Irradiation|will be treated only by using Light-emitting diode(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark)
11503516|NCT01330082|Experimental|applying photosensitizer|will be treated only by toluidine blue O
11503517|NCT01330056|Active Comparator|FOPS|"Functional organ preservation surgery (FOPS) group as a first-line treatment modality
~Postoperative RT or CRT may be included for the patients of this group"
11503518|NCT01330056|Active Comparator|CRT|"Concurrent chemoradiotherapy or radiotherapy group as a first-line treatment modality
~Salvage surgery may be applied for the patients for persistent or recurrent cancers after CRT or RT"
11503519|NCT01330043|Active Comparator|Non-extended treatment|"26 weeks of CBT
~10 weeks of combination bupropion plus nicotine patch
~Additional 16 weeks of bupropion plus nicotine patch if increased craving or depression scores or varenicline if smoking at 10 weeks"
11503520|NCT01330043|Experimental|Extended treatment|"26 weeks of CBT
~10 weeks of combination bupropion plus nicotine patch
~Additional 16 weeks of bupropion plus nicotine patch if increased craving or depression scores or varenicline if smoking at 10 weeks
~24 additional weeks of CBT"
11503521|NCT01330030|Experimental|Drug Selegiline|6 mg selegiline patch (transdermal) worn for 24 hours for 8 weeks
11503522|NCT01330030|Placebo Comparator|Matching placebo|matching placebo worn 24 hours for 8 weeks
11503523|NCT01330017|Experimental|PE 10 mg|
11503524|NCT01330017|Experimental|PE 20 mg|
11503525|NCT01330017|Experimental|PE 30 mg|
11503526|NCT01330017|Experimental|PE 40 mg|
11503527|NCT01330017|Placebo Comparator|Placebo|
11503528|NCT01330004||Hemodialysis patients|
11503655|NCT01329120||Pectus excavatum|Patients who has undergone minimally invasive repair of pectus excavatum
11503529|NCT01329991|Active Comparator|oral dose of 200 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
11503530|NCT01329991|Active Comparator|oral dose of 400 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
11503531|NCT01329991|Active Comparator|oral dose of 800 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
11503532|NCT01329991|Active Comparator|oral dose of PLX5622-dose to be determined|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
11503533|NCT01329991|Placebo Comparator|Placebo Comparator|2 patients per cohort will be randomly assigned to take placebo. 8 patients total will be randomized to take placebo in this study.
11503534|NCT01329978|Experimental|SOF+PEG+RBV 12 weeks|Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks.
11503535|NCT01329978|Experimental|SOF+PEG+RBV 24 weeks|Participants were randomized to receive sofosbuvir+PEG+RBV for 24 weeks.
11503536|NCT01329978|Experimental|SOF+PEG+RBV 12 week/Rerandomization Group|Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks, then were rerandomized to receive sofosbuvir only or sofosbuvir+RBV for 12 additional weeks.
11503537|NCT01329965|Experimental|LPS|LPS will be injected at a dose of 0.6 ng/kg body weight through a catheter by a trained GCRC staff member involved with this study.
11503538|NCT01329965|Placebo Comparator|Saline|A saline solution will be injected through a catheter by a trained GCRC staff member involved with this study.
11503539|NCT01329952||Current intravenous drug users|Those who were actively injecting drugs at the time of their hepatitis C treatment.
11503540|NCT01329952||Past drug users|Those who stopped injecting drugs intravenously at least 6 months prior to the start of treatment for hepatitis C
11503541|NCT01329939|Experimental|Obese atopic asthmatics, montelukast|Obese/overweight (BMI 85%ile or above for children and > 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive montelukast in a double blinded fashion.
11503542|NCT01329939|Placebo Comparator|Lean atopic asthmatics, placebo|Normal weight (BMI less than 85%ile or above for children and < 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive placebo in a double blinded fashion.
11503543|NCT01329939|Active Comparator|Lean atopic asthmatics, montelukast|Normal weight (BMI less than 85%ile or above for children and < 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive montelukast in a double blinded fashion.
11503544|NCT01329939|Placebo Comparator|Obese atopic asthmatics, Placebo|Obese/overweight (BMI 85%ile or above for children and > 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive placebo in a double blinded fashion.
11503545|NCT01329926||Neural stem cells|
11503546|NCT01329913|Experimental|GT1-HCV 200 mg|
11503547|NCT01329913|Experimental|GT1-HCV 400 mg|
11503548|NCT01329913|Experimental|GTI-HCV 800 mg|
11503549|NCT01329913|Experimental|GT3-HCV 200 mg|
11503550|NCT01329913|Experimental|GT3-HCV 400 mg|
11503551|NCT01329913|Experimental|GT3-HCV 800 mg|
11503552|NCT01329900|Experimental|Ofatumumab + Stem Cell Collection|Ofatumumab 1000 mg by vein on Day 1 and 2000 mg by vein on Day 8. Ifosfamide 3.33 gm/m2 by vein on Days 2, 3, and 4 continuously. Etoposide 150 mg/m2 by vein over 2 hours every 12 hours for 6 doses. Mesna 2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts). Mesna 2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide). After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose. G-CSF 6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis. Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
11503553|NCT01329887|Other|administration of ketanserin|
11503554|NCT01329874|No Intervention|Gow gates ,conventional block injection|Patients will be selected from a group with acute irreversible pulpitis in mandibular molars. Half of the patients randomly selected for receiving gow gates block injection and half will receive traditional inferior block injection by 3.6 ml Lidocaine plus epinephrine.Teeth with no response to anesthetizing will be randomly divided into two group of either buccal or lingual infiltration.
11503555|NCT01329874|No Intervention|Buccal infiltration, Lingual infiltration|
11503556|NCT01329861|Experimental|Internet delivered CBT|Internet delivered cognitive behavioral intervention, 8 weeks treatment.
11503557|NCT01329861|No Intervention|Control condition|Wait-list condition, received treatment after post-treatment assessment.
11503558|NCT01329848||discomfort symptoms|level of discomfort symptoms while performing near work
11503559|NCT01329835|Experimental|Written information via brochure|Written information by a brochure
11503560|NCT01329835|No Intervention|standard care|standard prenatal care
11503561|NCT01329835|Experimental|Lifestyle counseling|Psycho-education based on principles of motivational interviewing and positive reinforcement
11503562|NCT01329822|Experimental|Caloric restriction group|CR group were educated by a dietitian to reduce their usual energy intake to 1400 kcal/day (-500 kcal/day, -26% from baseline) for weight reduction and the recommended macronutrient composition was the 50-55% of energy intake as carbohydrate, 15-20% as protein and 20-25% as fat. Daily energy intake and nutrient composition were determined using a computer-aided nutritional analysis program (CAN-Pro 3.0; Korean Nutrition Society, Seoul, South Korea).
11503563|NCT01329822|No Intervention|Control group|Control group - ad libitum diet
11503564|NCT01329809|Experimental|JX-594 Intravenous infusion|JX-594 will be administered intravenously to patients with measurable intra-hepatic disease who are not eligible for intratumoral injection of JX-594.
11503565|NCT01329809|Experimental|JX-594 Intratumoral Injection|JX-594 will be injected directly into the liver tumor of patients who have at least two measurable intra-hepatic tumors, one of which must be at least 1.5cm in diameter and safety injectable.
11503566|NCT01329796|Experimental|Pertubation with Endole® (lignocaine)|Three treatments were to be given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
11503567|NCT01329796|Placebo Comparator|Placebo|Pertubation with Ringer solution, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
11503568|NCT01329783||EuroSIDA sub-cohort|HIV infected patients in the EuroSIDA cohort who meet the entry criteria for maraviroc pivotal clinical trials (MOTIVATE 1 and MOTIVATE 2)
11503569|NCT01329770|Experimental|Ascorbic Acid and alpha-tocopherol|Two daily doses of the combination of antioxidants, administered at breakfast and dinner
11503570|NCT01329770|Placebo Comparator|Placebo|Two daily doses of placebo, administered at breakfast and dinner
11503571|NCT01329757|Active Comparator|GH|Administration of a daily dose of GH (0.4mg)for 1 year
11503572|NCT01329757|Placebo Comparator|Placebo|Administration of a daily dose of placebo for 1 year
11503573|NCT01329744|Experimental|Treatment|Recombinant IGF-I
11503574|NCT01329744|Placebo Comparator|Placebo|
11503575|NCT01329731|Active Comparator|Test|1.25% fluoride (elmex® gelée)
11503576|NCT01329731|Placebo Comparator|Control|0% fluoride (negative control)
11503577|NCT01329718|Experimental|CRC Group|
11503578|NCT01329705|Active Comparator|Control|All patients will be treated with the current standard of care including onabotulinum toxin
11503579|NCT01329705|Experimental|Dynasplint|Patients in the experimental Dynasplint group will be treated with the current standard of care, including onabotulinum toxin, and use the Ankle Dorsiflexion Dynasplint
11503580|NCT01329692|Experimental|Lifestyle counseling|"This is a seven-week group education, counseling, nutrition, exercise, and journaling program of the Duke Metabolic and Weight Loss Surgery Center designed to help postoperative bariatric surgery patients who are failing to progressively lose weight resume an expected pattern of weight loss and improved overall outcome.
~Weeks 1 and 2 consist primarily of a review of current dietary habits. Weeks 3, 4, & 5 introduces counseling, with specific emphasis on emotional aspects of eating and behavioral modification strategies. Week 6 focuses on the metabolic impact of exercise, and includes an exercise session with a personal trainer. Week 7 incorporates a question and answer session with a sharing of discoveries, as well as an option for additional individual follow-up as needed."
11503581|NCT01329692|No Intervention|RYGB regular post-op care|Regular care and follow-up after RYGB surgery
11503582|NCT01329679|Experimental|Energy Drink|Energy drink, 2 oz twice daily for 7 days
11503583|NCT01329679|Placebo Comparator|Placebo|Water, lime juice and cherry flavoring, 2 oz twice daily for 7 days
11503584|NCT01329666|Experimental|50,000 IU Vitamin D3|
11503585|NCT01329666|Placebo Comparator|Placebo (inactive Vitamin D3)|
11503586|NCT01329653|Experimental|aerobic training|12 weeks of aerobic training, 4X/week
11503587|NCT01329653|Placebo Comparator|wait list control|wait list control condition, 12 weeks to parallel the active intervention group
11503588|NCT01329640|Experimental|Paclitaxel, trastuzumab, doxorrubicin, ciclophosphamide|
11503589|NCT01329627|Experimental|Paclitaxel/doxorubicin/cyclophosphamide|
11503590|NCT01329614|Experimental|Nicotine Replacement Therapy, 7mg dose|
11503591|NCT01329614|Experimental|Nicotine Replacement Therapy, 21mg dose|
11503592|NCT01329614|Placebo Comparator|Nicotine Replacement Therapy, Placebo|
11503593|NCT01329614|Experimental|Nicotine Replacement Therapy, 42mg dose|
11503594|NCT01329601|Experimental|Cognitive Intervention|StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
11503595|NCT01329601|Active Comparator|Booklet-based training|Home based training of episodic memory using paper-pencil exercizes
11503596|NCT01329588|Placebo Comparator|Sugar pill|
11503597|NCT01329588|Experimental|Treatment arm|
11503598|NCT01329562|Active Comparator|Treximet|"Subjects randomized to Group A will be provided with 1 tablet of Treximet to be taken at onset of menstrual migraine headache pain.
~All subjects will be provided with 1 tablet of Treximet for treatment of persistent or recurring headache between 2 and 24 hours following treatment with study medication at headache onset."
11503599|NCT01329562|Placebo Comparator|Placebo|"Subjects randomized to Group B will be provided with 1 tablet of placebo to be taken at onset of menstrual migraine headache pain.
~All subjects will be provided with 1 tablet of Treximet for treatment of persistent or recurring headache between 2 and 24 hours following treatment with study medication at headache onset."
11503600|NCT01329549|Experimental|BIBF 1120 (low) + Carboplatin + PLD|BIBF 1120 (low dose) + carboplatin (AUC5 mg/mL*min) + PLD (30 mg/m2)
11503601|NCT01329549|Experimental|BIBF 1120 (medium) + Carboplatin + PLD|BIBF 1120 (medium dose) + carboplatin (AUC5 mg/mL*min) + PLD (30 mg/m2)
11503602|NCT01329549|Experimental|BIBF 1120 (high) + Carboplatin + PLD|BIBF 1120 (high dose) + carboplatin (AUC5 mg/mL*min) + PLD (30 mg/m2)
11503603|NCT01329536||AD Patients with Agitation|Patients with a diagnosis of probable Alzheimer's Disease who show signs of agitation based on the Cohen-Mansfield Agitation Inventory
11503604|NCT01329536||AD Patients without Agitation|Patients with a diagnosis of probable Alzheimer's Disease who do not show signs of agitation based on the Cohen-Mansfield Agitation Inventory and are matched in both age and gender to the AD Patients with Agitation
11503605|NCT01329523||Subjects with AD|Subjects with a diagnosis of dementia
11503606|NCT01329523||Family Members|Younger biological family members of the patients with dementia
11503607|NCT01329523||Control Group|Individuals without dementia matched in age to the patients with a dementia diagnosis
11503608|NCT01329510|Experimental|methylphenidate|
11503609|NCT01329497|Experimental|interventional group|
11503610|NCT01329484|Experimental|Cognitive training|
11503611|NCT01329484|Experimental|Reminiscence therapy|
11503612|NCT01329484|Other|Control|This group will receive neither of the above interventions or any other similar interventions
11503613|NCT01329471||Umbilical cord blood|
11503614|NCT01329458||Focal liver lesions|Focal liver lesions: patients discovered with new, uncharacteristic focal liver lesions at standard ultrasound
11503615|NCT01329445||DeNovo NT patient|Patients who have received or who are scheduled to receive a DeNovo NT graft for repair of 1-2 knee cartilage lesions.
11503656|NCT01329120||Pectus carinatum|Patients who has undergone open surgical repair of pectus carinatum
11503616|NCT01329432|Sham Comparator|take care|In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing
11503617|NCT01329432|Experimental|InSurE|infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration
11503618|NCT01329419||adefovir dipivoxil|Patients administrated adefovir at the site
11503619|NCT01329406|Experimental|Milnacipran|If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The milnacipran arm will take milnacipran at 200mg/day (100mg twice daily).
11503620|NCT01329406|Placebo Comparator|Placebo|If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The placebo group will take 1 tablet twice daily.
11503621|NCT01329393|Experimental|Benefits Management|Money-management intervention consisting of brief advice on budgeting, assessment of ability to follow a budget, and assessment of need for a representative payee.
11503622|NCT01329393|Active Comparator|Illness Management and Recovery|
11503623|NCT01329380||Adalimumab|Participants with ankylosing spondylitis (AS) receiving treatment with adalimumab (Humira) as prescribed by their physician.
11503624|NCT01329367|Active Comparator|Control group|"Control group: Subjects will receive Nutritional education together with weight management counselling for overweight and obesity.
~-10 weekly personal interviews with a registered nutritionist for body weight control."
11503625|NCT01329367|Experimental|Protein group|"Protein group: Participants will receive Nutritional education and personalised structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of legumes and fish (protein rich diets).
~-10 weekly personal interviews with a registered nutritionist for body weight control."
11503626|NCT01329367|Experimental|Antioxidant group|"Antioxidant group: Participants will receive Nutritional education and personalized structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of fruits and vegetables (antioxidant rich diets).
~-10 weekly personal interviews with a registered nutritionist for body weight control."
11503627|NCT01329354|Experimental|Autologous effector lymphocytes|
11503628|NCT01329341|Experimental|Arm 1|Service Dogs
11503629|NCT01329328|No Intervention|CONTROL|NO VIBRATION EXERCISE
11503630|NCT01329328|Experimental|VIBRATION EXERCISE|WHOLE-BODY VIBRATION EXERCISE ON A VIBRATION DEVICE (BIOPLATE RF, BIOS, MILAN, ITALY
11503631|NCT01329328|Experimental|VIBRATION EXERCISE PLUS RADIOFREQUENCY ADMINISTRATION|WHOLE-BODY VIBRATION EXERCISE ON A VIBRATION DEVICE (BIOPLATE RF, BIO, MILAN, ITALY PLUS LOCAL ADMINISTRATION OF RADIOFREQUENCY
11503632|NCT01329315|Active Comparator|BMI-T|Brief Motivational Intervention (BMI-T): social worker/therapist-delivered intervention (25-minute tailored structured module).
11503633|NCT01329315|Active Comparator|BMI-C|Computer-delivered intervention (BMI-C): computerized tailored 25-minute intervention.
11503634|NCT01329315|No Intervention|DPB|Drug Prevention Booklet (DPB)- National Institute on Drug Abuse (NIDA)-developed drug prevention booklet to address preventing marijuana initiation, and marijuana use.
11503635|NCT01329302|Active Comparator|Group A: Direct aspiration|
11503636|NCT01329302|Active Comparator|Follicular Flushing|
11503637|NCT01329289|Experimental|SOM230 with Bortezomib and Dexamethasone|
11503638|NCT01329276|Other|Symbicort® forte Turbohaler®|
11503639|NCT01329276|Placebo Comparator|Placebo (lactose)|
11503640|NCT01329263|Experimental|Nonmenthol|Participants switch from menthol to non-menthol cigarettes.
11503641|NCT01329263|No Intervention|Menthol|Participants smoke own brand of menthol cigarettes.
11503642|NCT01329250|Experimental|Moxifloxacin|Moxifloxacinin escalating dose
11503643|NCT01329237|Other|dynamic physical exercise OCT|dynamic physical exercise and optical coherence tomography imaging
11503644|NCT01329224||TAM patients|All consecutive patients under chronic ASA treatment (100mg/d) seen at our outpatient clinic.
11503645|NCT01329211||Gastroparesis Patients|
11503646|NCT01329211||Gastroparesis Patients' Caregivers|
11503647|NCT01329198|Active Comparator|Delayed Activation - Deep Brain Stimulation (DBS)|"Delayed Activation stimulation in which no electrical charge is delivered through the Neuropace RNS (responsive neurostimulation) system for the first 59 days. On Day 60, all subjects will be programmed to receive active stimulation.
~There will be a one month post-operative period during which stimulation is not turned on.
~One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.
~By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.
~Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days."
11503648|NCT01329198|Active Comparator|Immediate Activation - Deep Brain Stimulation (DBS)|"Active stimulation through the Neuropace RNS (responsive neurostimulation) system at settings to maximally reduce tic frequency & severity, while limiting potential stimulation-induced side-effects.
~There will be a one month post-operative period during which stimulation is not turned on.
~One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.
~By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.
~Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days."
11503649|NCT01329185|Placebo Comparator|Placebo|Eligible consenting kidney transplant donors who are randomized to receive placebo will be given 1 placebo in morning and 1 in evening for 14 days prior to transplant date
11503650|NCT01329185|Experimental|Valganciclovir|Eligible consenting kidney transplant donors who are randomized to the experimental arm of the study will receive 450mg of Valganciclovir twice a day for 14 days prior to the transplant date
11503651|NCT01329172|Experimental|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 (PUFA n-3)
11503652|NCT01329172|Placebo Comparator|placebo|sun flower oil
11503653|NCT01329133|Active Comparator|DBS of subthalamic nucleus|
11503654|NCT01329133|Active Comparator|DBS of ventral striatum|
11503658|NCT01329107|Experimental|Multimodal intervention|Intervention group will be assigned to specific decribed multimodal intervention
11503659|NCT01329094||Patients with severe mental illness|In-patients and out-patients with severe mental illness attending treatment at Aarhus University Hospital, Risskov.
11503660|NCT01329094||Healthy controls|Healthy controls recruited from staff members at Aarhus University Hospital, Risskov
11503661|NCT01329081|Experimental|Six weeks strength training in teams and patient education|
11503662|NCT01329081|Experimental|Supervised home training with focus on activities|
11503663|NCT01329068|Active Comparator|Individual consult|regular individual consult
11503664|NCT01329068|Active Comparator|group medical consult|regular group medical consult
11503665|NCT01329055||Hemodialysis patients|
11503666|NCT01329029|Active Comparator|Roflumilast|concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
11503667|NCT01329029|Placebo Comparator|Placebo|concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
11503668|NCT01329016|Active Comparator|GDM Subjects|Women with GDM requiring treatment
11503669|NCT01329016|No Intervention|Non-pregnant Type 2 Diabetes Milletus Subjects|Non-pregnant women with Type 2 diabetes mellitus who plan to use metformin treatment
11503670|NCT01329016|No Intervention|Healthy Pregnant Women|Healthy pregnant women with normal 1-hour glucose tolerance test
11503671|NCT01329003||exposed workers|At least six months of occupational exposure to Caesar stone
11503672|NCT01328977|Active Comparator|emails, book|
11503673|NCT01328977|Active Comparator|didactic teaching from experts|
11503674|NCT01328977|Experimental|personal coaching by development profs|
11503675|NCT01328964||Children Ages 4-11 with asthma|Children ages 4 to 11 with a diagnosis of asthma receiving a prescription for an asthma therapy
11503676|NCT01328951|Experimental|Early Erlotinib|Participants will receive blinded erlotinib as 150 mg PO once daily in the maintenance setting until disease progression, death, or unacceptable toxicity. Those who demonstrate disease progression may be unblinded to receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. Participants may be observed during a final SFU period after discontinuation from study treatment.
11503677|NCT01328951|Placebo Comparator|Late Erlotinib|Participants will receive blinded placebo tablets PO once daily in the maintenance setting until disease progression, death, or unacceptable toxicity. Those who demonstrate disease progression may be unblinded to receive second-line erlotinib as 150 mg PO once daily until disease progression, death, or unacceptable toxicity. Participants may be observed during a final SFU period after discontinuation from study treatment.
11503678|NCT01328938|Experimental|Stage I - Arm I: GCPGC I (3.6mg)|GCPGC 3.6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)
11503679|NCT01328938|Experimental|Stage I - Arm II: GCPGC II (6mg)|GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)
11503680|NCT01328938|Experimental|Stage II - Arm I: GCPGC|"GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1).
~The recommended dose in Stage II was determinated as GCPGC 6mg in Stage I."
11503681|NCT01328938|Active Comparator|Stage II - Arm II: Neulasta|Neulasta 6mg, sc, once at Day 3 per cycle (in patients receiving chemotherapy at Day 1)
11503682|NCT01328925|Experimental|Nitazoxanide Oral Suspension|Nitazoxanide Oral Suspension 100 mg/5 ml
11503683|NCT01328925|Placebo Comparator|Placebo Oral Suspension|Placebo Oral Suspension
11503684|NCT01328912|Experimental|Remote ischemic preconditioning stimulus|
11503685|NCT01328912|Placebo Comparator|Control|
11503686|NCT01328899|Experimental|Lung Volume Reduction Coil (LVRC)|Lung Volume Reduction Coil (LVRC)
11503687|NCT01328886|Experimental|Omalizumab|
11503688|NCT01328873|Experimental|Laboratory testing|All patients will receive the lab testing on bronchoscopy specimens
11503689|NCT01328860|Experimental|Biologic; Stem Cells|
11503690|NCT01328834|Experimental|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase
11503691|NCT01328821|Placebo Comparator|Part A|"Single ascending dose administration of four doses of CTP-499 as tablets under fasting condition.
~8 subjects per dose group will be enrolled with a 3:1 randomization of active drug to placebo.
~Dose levels: 600mg -> 1200mg -> 1800mg -> 2400mg"
11503692|NCT01328821|Active Comparator|Part B|Part B will consist of a single 400 mg dose of an immediate release capsule of CTP-499 administered under fasting conditions. In Part B 6 subjects will be enrolled.
11503693|NCT01328808|Experimental|group 2 Pain management|"In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.
~In preterm and term neonates with a GA of less than 28 weeks 15 mg/kg dose of APAP will be given every 12 hrs by an intravenous infusion over 30-minute"
11503694|NCT01328782|Active Comparator|The group receiving oral pain medicine|This group will receive Oxycodone with Acetaminophen orally
11503695|NCT01328782|Active Comparator|The group receiving bupivacaine and oral pain medicine|This group will receive an intra-articular shot during surgery and will then be sent to the recovery room to receive pain medication as needed.
11503696|NCT01328782|Active Comparator|The group receiving ropivacaine and oral pain medicine|This group will receive an intra-articular shot of ropivacaine during surgery and will be sent to the recovery room to receive pain medicine as needed.
11503697|NCT01328769|Active Comparator|Febuxostat|Investigational
11503698|NCT01328769|Placebo Comparator|Placebo|Placebo
11503699|NCT01328756|Experimental|Lisdexamfetamine Dimesylate|
11503700|NCT01328743|No Intervention|Treatment as usual|Treatment as usual in an HIV primary care setting. Participants receive assessment of alcohol use but not counseling or advice regarding drinking.
11503701|NCT01328743|Experimental|Brief Alcohol Intervention|Participants receive 3 face-to-face sessions of counseling on alcohol use and 2 follow-up phone calls
11503702|NCT01328730|Experimental|Firebird 2 stent group|patients who were implated with Firebird 2 SES
11503703|NCT01328730|Active Comparator|Cypher Stent Group|patients who were implanted with Cypher SES
11503704|NCT01328717|Experimental|Intended Users of the System|Subjects with diabetes used Contour Link Investigational Blood Glucose Monitoring System
11504258|NCT01324648|Experimental|TG + GP TAU|
11503705|NCT01328704||Triathletes|Group of individuals who are participating in a triathlon training program at the Avera Sports Institute
11503706|NCT01328678||Alopecia Areata|Individuals with Alopecia Areata (AA)
11503707|NCT01328665|Experimental|Expressive Writing|Affectionate Writing Intervention for 20 minutes per day, 2 times per week, 6 weeks.
11503708|NCT01328665|No Intervention|No writing|Control Group -- No writing
11503709|NCT01328652|Experimental|Proton Pump Inhibitor|Treatment with dexlansoprazole 60 mg once daily for 3 months
11503710|NCT01328639|Active Comparator|Usual Care|Participants in this arm will be actively screened for depression and will receive the usual standard care for diabetes from their family physicians based on available clinical practice guidelines.
11503711|NCT01328639|Experimental|TeamCare Depression Intervention|Participants in this arm will be actively screened for depression, and will receive care for depression and diabetes based on the collaborative teamcare model for the management of diabetes and co-morbid depression.
11503712|NCT01328626|Experimental|Arm A (CLL/SLL subjects)|Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) subjects
11503713|NCT01328626|Experimental|Arm B (NHL subjects)|Non-Hodgkin lymphoma (NHL) subjects
11503714|NCT01328587|Experimental|Eltrombopag|Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 50mg/day (East Asian ancestry 25mg/day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
11503715|NCT01328574|Experimental|Single Arm - TRC105 in Urothelial Carcinoma|TRC105 15 mg/kg/dose every two weeks
11503716|NCT01328548||Nursing Home Elderly Cases|Non-ambulatory nursing home residents >= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs (single nucleotide polymorphisms). A case will be considered failure to mount a high response.
11503717|NCT01328548||Nursing Home Elderly Controls|Non-ambulatory nursing home residents >= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs. A control will be a participant who mounted an adequate response as defined in primary outcomes.
11503718|NCT01328548||Community dwelling seniors|Community dwelling seniors ages 60-75 will be enrolled as a control group for the laboratory testing. They will be vaccinated and will provide pre- and post-vaccination blood. If nursing home residents do not show a response it is important to know that it is not a failure of the laboratory's measurement of immunogenicity.
11503719|NCT01328535|Experimental|Treatment (individualized chemotherapy)|Patients with an established biorhythm receive TMZ PO on recommended day for 5 days. Treatment repeats every 21-42 days until disease progression or unacceptable toxicity. Patients without an established biorhythm receive TMZ PO on days 1-5. Courses repeat every 28 days until disease progression or unacceptable toxicity.
11503720|NCT01328522|Experimental|SAR153191 drug product 1|"SAR153191 drug product 1 in a single injection.
~Methotrexate (stable dose) and folic/folinic acid are continued as background therapy."
11503721|NCT01328522|Experimental|SAR153191 drug product 2|"SAR153191 drug product 2 in a single injection.
~Methotrexate (stable dose) and folic/folinic acid are continued as background therapy."
11503722|NCT01328509||Sepsis|Patients with sepsis
11503723|NCT01328509||Control|Patients with no clinical evidence of sepsis, but who are critically ill
11503724|NCT01328496|Other|Research Arm|"Participant with high-risk hematologic malignancies undergoing Hematopoietic Cell Transplantation, who do not have a suitable Human Leukocyte Antigen -matched related/sibling donor, Matched Unrelated Donor or Killer immunoglobulin receptors ligand mismatched haploidentical donor identified, will receive a single UCB unit.
~Intervention: Preparative Regimen"
11503725|NCT01328496|Other|Observation Arm|"Patients requiring two UCB units will be eligible for UCBT01 on the observational arm.
~Intervention: Preparative Regimen"
11503726|NCT01328483|No Intervention|No Intrapartum Oropharyngeal (IP-OP) Suction|Neonates randomized to No IP-OP group received supportive treatment as per standard unit protocols. They were also assessed as vigorous or non-vigorous and received care according to NRP 2005.
11503727|NCT01328483|Experimental|Intrapartum Oropharyngeal (IP-OP) suction|The neonates randomized to IP-OP group were provided oropharyngeal suctioning at the delivery of head before the delivery of shoulder, using suction machine at a negative pressure of 100mm of Hg or Dee Lee's suction trap in the event of electricity failure or non availability of suction machine.Subsequently, all the neonates born through MSAF were assessed by pediatrician as vigorous or non vigorous and provided care as per NRP guidelines 2005.
11503728|NCT01328470|Active Comparator|clopidogrel 75 mg/day|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 75 mg/day for 14 days.
11503729|NCT01328470|Active Comparator|clopidogrel 150 mg/day|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 150 mg/day for 14 days.
11503730|NCT01328470|Active Comparator|adjunctive cilostazol|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive co-administration of adjunctive cilostazol (100 mg twice daily) and clopidogrel (75 mg/day; [group 3, 20 patients]) for 14 days.
11503731|NCT01328470|Active Comparator|75mg clopidogrel|control group undergoing PCI for stable angina will be also maintained on clopidogrel (75 mg/day for 14 days).
11503732|NCT01328444|Experimental|GSK 573719 + GW642444 125/25|125mcg/25mcg nDPI
11503733|NCT01328444|Experimental|GSK 573719 +GW642444 62.5/25|62.5mcg/25mcg nDPI
11503734|NCT01328444|Experimental|GSK 573719 125|125mcg nDPI
11503735|NCT01328444|Experimental|GSK 573719 62.5|62.5 mcg nDPI
11503736|NCT01328444|Experimental|GW 642444 25|25mcg nDPI
11503737|NCT01328444|Placebo Comparator|Plb|Plb nDPI
11503738|NCT01328431|No Intervention|Standard Care|Subjects receive a brochure for the state's Smokers' Quitline only.
11503739|NCT01328431|Experimental|SBIRT+NRT|Subjects receive a 6 week course of NRT, a motivational Brief Negotiated Interview, and a facilitated referral to the state's Smokers' Quitline.
11503740|NCT01328418|Other|Achondroplasia lengthening|
11503741|NCT01328405|Experimental|Air-Q LMA|Air-QⓇ intubating laryngeal mask (Mercury Medical, Clearwater, Fl.)
11503742|NCT01328405|Experimental|Proseal LMA|LMA-Proseal TM (LMA North America, San Diego, Ca.)
11503743|NCT01328379|Active Comparator|Dalfampridine-ER 5mg|5mg, twice daily
11503744|NCT01328379|Active Comparator|Dalfampridine-ER 10mg|10mg, twice daily
11503745|NCT01328379|Placebo Comparator|Placebo|placebo, twice daily
11503746|NCT01328366||Participants with severe psoriasis|The participants had severe disease as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and had not responded to standard systemic therapies.
11503747|NCT01328353|No Intervention|control group|Control group arm follows usual care
11503748|NCT01328353|Experimental|Intervention group arm 1|Intervention group arm 1 receives aprn/telephone care coordination
11503749|NCT01328353|Experimental|Intervention group arm 2|Intervention group arm 2 receives aprn/telephone/video care coordination
11503750|NCT01328340|Active Comparator|High-speed power training|Volunteers randomized into SHPT will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength for leg press (LP) and seated knee extension (KE) exercises.
11503751|NCT01328340|Active Comparator|Slow-speed strength training|Volunteers randomized into STR will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength for LP and KE exercises.
11503752|NCT01328340|No Intervention|Control|Volunteers randomized into CON will undergo a placebo exercise intervention consisting of lower extremity range of motion and flexibility exercises performed 2 times per week with the assistance of the research staff.
11503753|NCT01328301|Experimental|Speed-dependent treadmill training (SDT)|Subjects underwent short interval of walking trials with stepwise increases in the treadmill speed
11503754|NCT01328301|Active Comparator|speed-stable treadmill training|Control subjects received gait training on the treadmill with a steady speed.
11503755|NCT01328288||1|long-term follow-up of HIV-infected children
11503756|NCT01328275||1|long-term follow-up of HIV-infected patients on ART
11503757|NCT01328262|Experimental|Hemoglobin dose|Intervention: Calculated red blood cell transfusion
11503758|NCT01328262|Active Comparator|Standard treatment|Intervention: Standard red blood cell transfusion
11503759|NCT01328249|Experimental|Doxorubicin and cyclophosphamide followed by eribulin mesylate|
11503760|NCT01328236|Experimental|V-DD single arm|"INDUCTION THERAPY: V-DD induction therapy for 6 cycles，28 Days per Cycle. Bortezomib - 1.3 mg/m2 IV, Days 1, 4, 8 , 11 of every treatment; Liposomal Doxorubicin - 30 mg/m2 IV, Day 4 of every treatment; Dexamethasone - 40 mg/d IV, Days 1 - 4 of every treatment.
~Maintenance treatment for 4 cycles,28 Days per Cycle. Thalidomide - 100mg Qn ; Bortezomib - 1.3 mg/m2 IV ,Days 1, 4, 8 and 11 of every treatment; Dexamethasone - 40 mg/d IV ,Days 1 - 4; Interferon - 300 u Qod,（Specially for IgA type）. Interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
11503761|NCT01328223||radiotherapy efficacy|"Concurrent stage with RT: sorafenib 400mg twice daily
~Maintenance stage after RT: sorafenib 400mg twice daily Treatment can be continued until the occurrence of clinical or radiologic progression, the occurrence of either unacceptable adverse events, death, or any criteria met for removal from the protocol treatment. Basically, minimum maintenance duration of 6 months is recommended, not mandatory."
11503762|NCT01328210|Experimental|blood letting|Blood letting was performed immediately after baseline assessment and after 4 weeks. First blood removal consisted of 400ml, second blood removal was tailored according to subsequent serum ferritin levels between 300- 400 ml.
11503763|NCT01328210|No Intervention|waiting list control|This group received no specific treatment but was offered treatment after termination of the 6-week study phase
11503764|NCT01328197|Experimental|Treovance|
11503765|NCT01328184|Experimental|Reference|multiple doses of Microgynon
11503766|NCT01328184|Active Comparator|Test|multiple doses of Microgynon + BI 10773
11503767|NCT01328171|Experimental|A (FOLFOXIRI + Panitumumab)|FOLFOXIRI + Panitumumab
11503768|NCT01328171|Active Comparator|B (FOLFOXIRI)|FOLFOXIRI
11503769|NCT01328158||Lopinavir/Ritonavir|Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated
11503770|NCT01328145|Active Comparator|ASA|
11503771|NCT01328145|Placebo Comparator|Placebo|
11503772|NCT01328132|Active Comparator|Saline|
11503773|NCT01328132|Experimental|25% albumin|
11503774|NCT01328119|Other|hemodialysis patients|conventional hemodialysis patients
11503775|NCT01328106|Experimental|1|
11503776|NCT01328093|Experimental|LY2140023|Double Blind Phase: 40 mg administered orally, given twice daily for 24 weeks. Dose may be adjusted to a minimum of 20 mg and a maximum of 80 mg. Open Label Phase: 40 mg administered orally, given twice daily for an additional 28 weeks.
11503777|NCT01328093|Active Comparator|Aripiprazole|Double Blind Phase: 15 mg administered orally, given once daily for 24 weeks. Dose can be adjusted to a minimum of 10 mg or a maximum of 30 mg. Open Label Phase: LY2140023, 40 mg administered orally, given twice daily for an additional 28 weeks.
11503778|NCT01328080|Experimental|Targeted UV-B (Left)|Targeted UV-B on left side of the scalp.
11503779|NCT01328080|Experimental|Targeted UV-B (Right)|Targeted UV-B on right side of the scalp.
11503780|NCT01328067|Active Comparator|Treatment|MR guided Focused Ultrasound
11503781|NCT01328067|Active Comparator|Surgery|Myomectomy
11503782|NCT01328054|Experimental|lapatinib/placebo|This is a crossover study where subjects will receive placebo that mimics lapatinib for 2 days and lapatinib for 2 days. Subjects will not know when they are receiving placebo vs. lapatinib.
11503783|NCT01328041|Experimental|dolutegravir|dolutegravir plus background antiretroviral therapy optimised at Day 8
11503784|NCT01328028||Group A|Subjects diagnosed with invasive cervical cancer
11503785|NCT01328015|Active Comparator|Oxybuynin, hyperhidrosis|
11503786|NCT01328015|Placebo Comparator|placebo - sugar pill|
11503787|NCT01328002|Experimental|Milnacipran|oral administration, twice daily dosing
11503788|NCT01328002|Placebo Comparator|Placebo|oral administration, twice daily dosing
11503789|NCT01327989||Solitaire™ FR device|Eligible subjects treated with the Solitaire™ FR device.
11504259|NCT01324648|Experimental|UG + GP TAU|
11503790|NCT01327976|Active Comparator|vBloc (Active Device)|The treatment group will receive a functional device that will deliver charge to the vagus nerve during the study period
11503791|NCT01327976|Sham Comparator|Sham (Non-active Device)|The control group will receive a functional, but non-active device that will deliver no charge to the vagus nerve during the study period
11503792|NCT01327963|Experimental|Transoral Incisionless Fundoplication|"Intervention: Transoral Incisionless Fundoplication: TIF 2.0 technique iteration.
~With patient in general anesthesia. The EsophyX device is introduced through the mouth, over a standard endoscope, into the stomach. Multiple gastro -esophageal plications are performed, apposing the fundus to the distal part of the esophagus and repositioning the GEJ below the diaphragm, into the abdomen. multiple prolene fasteners are used to sescure and keep in place the plications."
11503793|NCT01327950||Superficial Femoral Lesions|Patients undergoing percutaneous treatment of Superficial Femoral Artery lesions
11503794|NCT01327937|Active Comparator|Apligraf Group|Apligraf group - Applied at Day 0, Weeks 1-4 (maximum of 5 applications) Also cross-over at Week 4 for Control NPTH group - Apligraf applied at Week 4, Weeks 5-8 (maximum of 5 applications)
11503795|NCT01327937|Placebo Comparator|Standard of Care Dressing Group|Standard of care dressing regimen - Foam dressing (eg, Mepilex) and 4 layered compression system (eg, Profore)
11503796|NCT01327924||Norditropin NordiFlex® users|
11503797|NCT01327911|Experimental|Ciliary Neurotrophic Factor (CNTF)/NT-501|Biological/Vaccine:NT-501 implant
11503798|NCT01327898|Experimental|1|empowerment theory-based small group discussion
11503799|NCT01327898|Active Comparator|2|single session individual resilience counseling
11503800|NCT01327885|Experimental|Arm A|
11503801|NCT01327885|Active Comparator|Arm B|
11503802|NCT01327872|Experimental|Treatment A|
11503803|NCT01327872|Experimental|Treatment B|
11503804|NCT01327872|Experimental|Treatment C|
11503805|NCT01327872|Experimental|Treatment D|
11503806|NCT01327859|Experimental|Prior Donepezil 5mg|
11503807|NCT01327859|Experimental|Prior Donepezil 10mg|
11503808|NCT01327859|Placebo Comparator|Prior Placebo|
11503809|NCT01327846|Experimental|Canakinumab Dose 50 mg|"Pivotal Phase:
~Blinded Canakinumab 50 mg quarterly subcutaneous + standard of care therapy.
~Extension Phase:
~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
11503810|NCT01327846|Experimental|Canakinumab Dose 150 mg|"Pivotal Phase:
~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
11503811|NCT01327846|Experimental|Canakinumab Dose 300 mg|"Pivotal Phase:
~Blinded Canakinumab 300 mg quarterly subcutaneous (with one additional dose at week 2) + standard of care therapy.
~Extension phase:
~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
11503812|NCT01327846|Placebo Comparator|Placebo|"Pivotal Phase:
~Blinded matching placebo quarterly subcutaneous + standard of care therapy.
~Extension Phase:
~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
11503813|NCT01327833||Cardiac Arrest|
11503814|NCT01327820||Open aortic aneurysm repair|
11503815|NCT01327820||Endovascular aortic aneurysm repair|
11503816|NCT01327820||Infra-inguinal lower limb revascularisation|
11503817|NCT01327807||Cystinsosis patients|Those with a diagnosis of cystinosis.
11503818|NCT01327794||Group 1|Participants in this correlative study (CALGB 151006) were enrolled in CALGB 80303, which was a national, multi-center, double-blind phase III study that randomly assigned patients (1:1) with advanced pancreatic cancer to gemcitabine plus bevacizumab vs gemcitabine plus placebo. Blood samples were collected from consenting participants in CALGB 80303 at the time of study registration at respective institutions and shipped to the CALGB Pathology Coordinating Office for storage (Columbus, OH).Baseline serum 25-hydroxyvitamin D (25[OH]D) levels were measured and examined associations between baseline 25(OH)D levels and progression-free survival and OS using the Cox rank score test.
11503819|NCT01327781|Experimental|Treatment (Z-endoxifen hydrochloride)|Patients receive Z-endoxifen hydrochloride PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11503820|NCT01327768|Experimental|OECs, Medicine, Rehabilitation|Stroke patients are received intracerebral implantation of Olfactory ensheathing cells(OECs), Antiplatelet Medication, and Rehabilitation.
11503821|NCT01327755|Experimental|Selenium|
11503822|NCT01327755|Placebo Comparator|Placebo|
11503823|NCT01327729|Active Comparator|YPEG-IFN α-2a one week|this arm will be treated with: YPEG-IFN α-2a 180mcg/ week for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks
11503824|NCT01327729|Active Comparator|YPEG-IFN α-2a Ten days|this arm will be treated with: YPEG-IFN α-2a 180mcg/10 days for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks
11503825|NCT01327729|Active Comparator|YPEG-IFN α-2a two weeks|"The third group will be treated with:
~YPEG-IFN α-2a 180mcg/ 2 weeks for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks."
11503826|NCT01327703|Experimental|Panzytrat® 25,000|
11503827|NCT01327703|Active Comparator|Kreon® 25,000|
11503828|NCT01327690|No Intervention|Wait List|Wait Period corresponding in length to treatment period
11503829|NCT01327690|Experimental|EFT (Emotional Freedom Techniques)|EFT group therapy sessions.
11503830|NCT01327690|Active Comparator|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
11503831|NCT01327677|Active Comparator|Pro re nata (PRN) fentanyl|A nurse can give the patient up to 3 doses of fentanyl intravenously (through a vein) each hour whenever a patient indicates that he or she is in pain.
11503832|NCT01327677|Active Comparator|Intravenous Patient-controlled Analgesia (IVPCA) fentanyl|Fentanyl will be given with a Patient Controlled Analgesia (PCA) pump.
11503833|NCT01327664|Experimental|AIN457 300mg s.c every 2 weeks|
11503834|NCT01327651|Active Comparator|Daily dosing|Participants will receive oral FTC/TDF daily.
11503835|NCT01327651|Experimental|Time-driven dosing|Participants will receive oral FTC/TDF twice weekly with a post-exposure dose.
11503836|NCT01327651|Experimental|Event-driven dosing|Participants will receive oral FTC/TDF before and after a potential exposure to HIV infection.
11503837|NCT01327638||Patients with SpA/AS and etoricoxib treatment|
11503838|NCT01327638||Patients with SpA/AS and other COX-2 inhibitor treatment|
11503839|NCT01327638||Patients with SpA/AS and nsNSAIDs treatment|
11503840|NCT01327625|Experimental|Azithromycin|Patient who are diagnosed as bronchiolitis obliterans according to the WHO criteria
11503841|NCT01327612|Experimental|Combination Treatment|Combination treatment: Conatumumab Q2W or Q3W + ongoing chemotherapy or ganitumab.
11503842|NCT01327612|Experimental|Monotherapy Treatment|Monotherapy treatment: Conatumumab Q2W or Q3W; or AMG 479 Q3W or Q4W
11503843|NCT01327599|Experimental|DUOTRAV®|Travoprost 0.004%+Timolol 0.5% ophthalmic solution, 1 drop to the study eye(s) once a day at 8:00 PM for 12 weeks
11503844|NCT01327586|Experimental|ATM|Advisor-Teller Money Manager
11503845|NCT01327586|Active Comparator|Individual Drug Counseling|
11503846|NCT01327573|Experimental|Eculizumab|"eculizumab will be given in addition to standard immunosuppression regimen (oral tacrolimus or equivalent, MMF [mycophenolate mofetil
~], prednisone)"
11503847|NCT01327573|No Intervention|no additional therapy|patients in this arm will receive standard immunosuppression regimen (oral tacrolimus or equivalent, MMF, prednisone only, no additional therapy
11503848|NCT01327547|Experimental|1.0|
11503849|NCT01327547|Placebo Comparator|2|
11503850|NCT01327534|Experimental|prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
11503851|NCT01327534|Active Comparator|clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
11503852|NCT01327508|Experimental|TRIGEN SURESHOT Distal Targeting|TRIGEN SURESHOT Distal Targeting Instrumentation is utilized to find screw holes.
11503853|NCT01327508|Active Comparator|Standard Nailing Instrumentation.|Free-hand technique utilizes x-rays to find screw holes
11503854|NCT01327495|Placebo Comparator|Arm 1: Placebo|Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
11503855|NCT01327495|Active Comparator|Arm 2:1.25g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
11503856|NCT01327495|Active Comparator|Arm 3: 2.5g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
11503857|NCT01327495|Active Comparator|Arm 4: 5g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
11503858|NCT01327495|Active Comparator|Arm 5: 10g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
11503859|NCT01327495|Active Comparator|Arm 6: 15g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
11503860|NCT01327482|Experimental|All|All patients were part of the intervention arm, as this was a pharmacokinetic study. All women took Raltegravir 400mg orally, twice daily for 3 weeks.
11503861|NCT01327469|Experimental|Albendazole 400mg|albendazole, 1 x 400mg
11503862|NCT01327469|Experimental|Albendazole 2 x 400mg|albendazole, 2 x 400mg
11503863|NCT01327469|Experimental|Mebendazole 500mg|mebendazole, 1 x 500mg
11503864|NCT01327469|Experimental|Mebendazole 2 x 500mg|mebendazole, 2x 500mg
11503865|NCT01327469|Experimental|Pyrantel-oxantel + mebendazole|pyrantel-oxantel (10mg/kg)+ mebendazole (500mg)
11503866|NCT01327456|Experimental|Self-Management Intervention|participants who receive the one-on-one self-management intervention
11503867|NCT01327456|No Intervention|Usual Care|group receives no additional education or intervention then they would as usual care of their COPD
11503868|NCT01327443|Other|Weight loss|10% weight loss in 24 weeks time period through nutritional counseling.
11503869|NCT01327443|Active Comparator|Exercise without weight loss|24 weeks under direct supervision.
11503870|NCT01327443|No Intervention|Control|No change in usual exercise levels or food intake.
11503871|NCT01327430|Experimental|Phospholipid supplementation|Supplementation of milk phospholipid
11503872|NCT01327417||Depressed|Patients with Major Depressive Disorder
11503873|NCT01327417||Healthy Controls|
11503874|NCT01327404||Depressed|Patients with Major Depressive Disorder
11503875|NCT01327404||Diabetic|Patients with Type 2 Diabetes
11503876|NCT01327404||Diabetic/Depressed|Patients with both diabetes and major depressive disorder
11503877|NCT01327404||Healthy Controls|
11503878|NCT01327391|Active Comparator|On line Hemodiafiltration|Hemodialysis patients treated with on line hemodiafiltration technic
11503879|NCT01327391|Other|hemodialysis|Hemodialysis patients treated with conventional hemodialysis technic using high flux dialyzers
11503880|NCT01327378||Dialysis, normal glucose tolerance|Chronic dialysis treatment, N=10 OGTT,120 min < 7.8 mmol/L
11503881|NCT01327378||Dialysis, impaired glucose tolerance|Chronic dialysis treatment, N=10 OGTT,120 min 7.7<11.1 mmol/L
11503882|NCT01327378||Control, normal glucose tolerance|Healthy Control subjects, N=10 OGTT,120 min <7.8 mmol/L
11503883|NCT01327365|Experimental|Sheathless group|patient randomized to the sheathless guiding catheter group
11503884|NCT01327365|Active Comparator|Conventional group|patients randomized to the conventional guiding catheter group
11503885|NCT01327352|Experimental|Oshadi D|"2 dose levels of Oshadi D in 2 food regimen will be administered as following:
~Subjects will receive placebo on the morning of day 1 during fast. Late breakfast will be provided 4 hours following placebo administration.
~On day 8 a single dose of 180mg Oshadi D will be administrated during fast. Late breakfast will be provided 4 hours following drug administration
~On day 16 subjects will be administered with 360mg of Oshadi D during fast. Late breakfast will be provided 4 hours following drug administration.
~On day 24, 180mg of Oshadi D will be administrated immediately after breakfast.
~On day 32, subject will be administered with 360mg of Oshadi immediately after breakfast."
11503886|NCT01327339||Subjects eligible for REQUIP prescription|Male and female subjects who were considered appropriate to be prescribed REQUIP according to the prescribing information will be included in this study.
11503887|NCT01327326|Active Comparator|TMD patients|"Intervention:
~Drug: Naltrexone
~Drug: placebo"
11503888|NCT01327326|Active Comparator|Healthy controls|"Intervention:
~Drug: Naltrexone
~Drug: placebo"
11503889|NCT01327313|Experimental|EMD525797 250 milligram (mg)|
11503890|NCT01327313|Experimental|EMD525797 500 mg|
11503891|NCT01327313|Experimental|EMD525797 1000 mg|
11503892|NCT01327313|Experimental|EMD525797 1500 mg|
11503893|NCT01327300|Active Comparator|Mesalamine|This group received the drug Mesalamine for 12 weeks then a wash out for 3 weeks prior to crossing over to the placebo arm.
11503894|NCT01327300|Placebo Comparator|Placebo|This group will receive the Placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
11503895|NCT01327287||Trauma patients eligible to receive thoracic epidural|Patients admitted to the hospital suffering from blunt thoracic injury and who meet inclusion/exclusion criteria and receive thoracic epidural for pain
11503896|NCT01327287||Control Arm|Trauma patients eligible to receive thoracic epidural but did not receive thoracic epidural for pain
11503897|NCT01327274|Experimental|Treatment Arm|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI > 3.5) will undergo the interventional treatment arm by having outpatient surgery and the Magnetic MIni-Mover Magnimplant procedure is performed during which the magnetic implant is surgically placed. After 2 years of treatment with the implanted magnet and brace treatment, the Magnetic Mini-Mover Magnimplant will be explanted. After surgery and recovery, all subjects will be fitted for an orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo 3MP treatment for 18-24 months, enough to attempt to improve their PSI (< 3.25).
11503898|NCT01327261|Experimental|Levodopa + benserazide (test formulation)|A randomized-sequence, open-label, 2-period crossover study assessing relative bioavailability of two drug products containing the association levodopa + benserazide.
11503899|NCT01327261|Active Comparator|Levodopa + benserazide (reference formulation)|
11503900|NCT01327248||affected patients|20 Patients suffering from bronchiolitis obliterans
11503901|NCT01327248||non-affected patients|20 matched controls not suffering from bronchiolitis obliterans
11503902|NCT01327235|Active Comparator|Endostar|
11503903|NCT01327235|Active Comparator|Cisplatin|
11503904|NCT01327235|Experimental|Endostar and Cisplatin|
11503905|NCT01327222|Experimental|bevacizumab|three-monthly intravitreal bevacizumab, followed by PRN monthly injection on the basis of the detection of any fluid on the optical coherence tomography
11503906|NCT01327222|No Intervention|control|monthly follow-up
11503907|NCT01327209||Patients with diabetes|
11503908|NCT01327183|Experimental|20 mg/kg RO4905417 before PCI|
11503909|NCT01327183|Experimental|5 mg/kg RO4905417 before PCI|
11503910|NCT01327183|Placebo Comparator|Placebo before PCI|
11503911|NCT01327170|Active Comparator|Subthreshold diode micropulse laser|Subthreshold diode micropulse laser in patients with chronic central serous chorioretinopathy
11503912|NCT01327170|Sham Comparator|Sham|Sham group simulating the laser treatment
11503913|NCT01327157|Placebo Comparator|Visual Analog Scale (VAS)|"Initial consultation, dental cleaning and performing the visual analog scale. Consultation three months after achieving visual analog scale final
~VAS and dental cleaning at the first query.
~VAS at the last query. In the second period (91-180 days) that participants have been moved from the Placebo group (VAS) to the Experimental group(Occlusal Adjustment)."
11503914|NCT01327157|Experimental|Occlusal adjustment|In all consultations, was performed VAS and occlusal adjustment. Three sessions of intervention are doing. The Gnathostatic models were performed in the first and last query. To reach a terminal axis of rotation of the jaw the patient to perform the act of swallowing for 3 times, and after palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth and started the adjustment following the rules of Guichet with a cylindrical drill with a thin cut.. The rules to guide the occlusal adjustment selective grinding were in this sequence: Occlusal adjustment to the centric relation: with sliding towards anterior; with sliding towards the medium line; with sliding opposite to the medium line; No sliding.
11503915|NCT01327144|Experimental|Famciclovir 500mg|1 tablet each 8 hours for 7 days
11503916|NCT01327144|Active Comparator|Aciclovir 400mg|2 tablets of Aciclovir 400 mg each 4 hours for 7 days
11503917|NCT01327118|Placebo Comparator|Isoton sodium chloride|
11503918|NCT01327118|Active Comparator|Prostaglandin F2alpha|
11503919|NCT01327105|Experimental|TVU|
11503920|NCT01327092|No Intervention|Literacy Group|Families in the Literacy Group (control group)will receive a program which seeks to promote literacy by providing developmentally appropriate books and other reading-related materials to children and encouraging mothers to develop an interest in reading with their child. After enrollment and randomization, CHIP staff will visit these control group homes, assess the mother's interest in and barriers to reading with her child, council mothers about the importance of literacy and reading books to their child, and children will be given age appropriate books and other materials to promote literacy.
11503921|NCT01327092|Experimental|Injury Intervention Group|Injury Intervention Group: In homes of children who are randomized to the injury intervention arm of the trial, a comprehensive survey of injury hazards in living spaces will be undertaken. In addition to quantifying hazards, the area of living spaces will be obtained to allow the determination of both the number and density (number of hazards per 100 sq ft) of injury hazards. If one or more injury hazards are identified, they will be removed and/or modified to reduce exposure and injury risk. The intervention is focused on areas in living spaces below 1 meter (~39 inches) in height from (the 75th percentile in height or eye-level for a 3-year old US male toddler) which might be easily reached or climbed on by children less than 4 years
11503922|NCT01327079|Experimental|Group 1|"Gestational age less than 29 weeks We will substitute for one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.
~Administration of inulin:
~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
11503923|NCT01327079|Experimental|Group 2|"Gestational age greater then 29 weeks We will substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.
~Administration of inulin:
~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
11503924|NCT01327066|Experimental|Droxidopa - Therapeutic|Droxidopa 600 mg
11503925|NCT01327066|Experimental|Droxidopa - Supratherapeutic Dose|Droxidopa 2000 mg
11503926|NCT01327066|Placebo Comparator|Placebo|Placebo
11503927|NCT01327066|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg dose
11504018|NCT01326416|No Intervention|C: Lifestyle counseling|Usual advice given in consultation on the need for a balanced diet and regular physical activity
11503928|NCT01327053|Experimental|LDE225 200 mg|The study was double blinded and enrolled at least 50 evaluable patients in the 200 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.
11503929|NCT01327053|Experimental|LDE225 800 mg|The study was double blinded and enrolled at least 100 evaluable patients in the 800 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.
11503930|NCT01327040|Experimental|sensitization duration 1.375h|This group will experience a 1.375h sensitization duration prior to the 12h light exposure
11503931|NCT01327040|Experimental|sensitization duration 5.5h|This group will experience a 5.5h sensitization duration prior to the 12h light exposure
11503932|NCT01327040|Experimental|sensitization duration 22h|This group will experience a 22h sensitization duration prior to the 12h light exposure
11503933|NCT01327040|Experimental|sensitization duration 0.33h|This group will experience a 0.33h sensitization duration prior to the 12h light exposure
11503934|NCT01327027|Experimental|Vasopressin, Arginine, ADH|We will test how vasopressin affects emotional responses to facial stimuli in healthy men and women.
11503935|NCT01327027|Placebo Comparator|Sterile Salilne|Sterile saline will be administered intranasally and emotional responses to facial stimuli measured.
11503936|NCT01327014|Placebo Comparator|Placebo group|
11503937|NCT01327014|Experimental|1,200 mg/day of XZK group|
11503938|NCT01327014|Experimental|2,400 mg/day of XZK group|
11503939|NCT01326988||Patients requiring spinal anesthesia for lower limb surgery|Patients of at least 18 years of age undergoing spinal anesthesia for elective lower limb surgery will be recruited. Therefore inclusion and exclusion criteria are the same as for traditionally administered spinal anesthesia as below. Additionally we will exclude those patients who are incapable of providing fully informed consent, patients who are currently enrolled in other studies and patients with communication difficulties
11503940|NCT01326975||EAdi 1|babies in this group will first receive CPAP through IF-CPAP for 30 minutes. After another 45 minutes, they will be switched to HFNC for 30 minutes. EAdi will be recorded for the last 15 minutes of each 30 minutes period.
11503941|NCT01326975||EAdi 2|babies in this group will first receive CPAP through HFNC for 30 minutes. After another 45 minutes, they will be switched to IF-CPAP for 30 minutes. EAdi will be recorded for the last 15 minutes of each 30 minutes period.
11503942|NCT01326962|Experimental|Single Arm|
11503943|NCT01326949|Active Comparator|ET+NSBB|"Endoscopic treatment(ET)- Endoscopic variceal ligation (EVL)
~Non-selective beta blocker(NSBB)-Propranolol.
~Anticoagulation(AT)- Heparin followed by warfarin."
11503944|NCT01326949|Active Comparator|TIPS|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS.
11503945|NCT01326936|Experimental|Unworked VP|Online education using typical virtual patient (VP) approach. Five unworked VPs presented to subjects for study.
11503946|NCT01326936|Experimental|Guided Learning|Online education replaces two unworked VPs in Arm 1 with identical worked example VPs (case studies) for learners to study
11503947|NCT01326923|Other|Single arm|Single arm Phase II Study Induction Chemo then Concurrent Chemoradiotherapy with Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
11503948|NCT01326910|Experimental|19306-127|Experimental Topical cream applied twice daily (or as needed)
11503949|NCT01326910|Other|19306-137|Marketed Topical cream applied twice daily (or as needed)
11503950|NCT01326897|Active Comparator|Comparison Group|Comparison group participants will be given health education materials.
11503951|NCT01326897|Experimental|Intervention'|This group will receive the intervention (Healthy Homes/Healthy Families) as described below.
11503952|NCT01326884|Other|1|Endovascular Repair
11503953|NCT01326871|Experimental|ALT-801 with Cisplatin and Gemcitabine (Phase Ib and Phase II)|
11503954|NCT01326871|Experimental|ALT-801 and Gemcitabine (Phase II only)|
11503955|NCT01326858|Experimental|Olopatadine, 0.7%|Olopatadine hydrochloride ophthalmic solution, 0.7%, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic vehicle and ketotifen fumarate ophthalmic solution, 0.025%, Periods 2 and 3, as randomized
11503956|NCT01326858|Placebo Comparator|Vehicle|Olopatadine hydrochloride ophthalmic solution vehicle, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic solution, 0.7% and ketotifen fumarate ophthalmic solution, 0.025%, Periods 2 and 3, as randomized
11503957|NCT01326858|Active Comparator|Zaditor|Ketotifen fumarate ophthalmic solution, 0.025%, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic solution, 0.7% and olopatadine hydrochloride ophthalmic solution vehicle, Periods 2 and 3, as randomized
11503958|NCT01326845|Experimental|Deferasirox am|Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food
11503959|NCT01326845|Experimental|Deferasirox pm|Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal
11503960|NCT01326832||Primoris|50 patients included in RSA cohort of total of 350 anticipated Primoris cases
11503961|NCT01326806|Experimental|Sex Education + Standard Care|Participating mothers will receive sex education information while their child is having a physical exam.
11503962|NCT01326806|Active Comparator|Hygiene & Nutrition Education + Standard Care|Participating mothers will receive information on hygiene and nutrition while their child is having a physical exam.
11503963|NCT01326806|No Intervention|No Education + Standard Care|Participating mothers who are passive controls will not receive any additional information while their child is having a physical exam.
11503964|NCT01326780|Experimental|1.2% Facial Cream|1.2% JNJ 10229570-AAA
11503965|NCT01326780|Experimental|2.4% Facial Cream|2.4% JNJ 10229570-AAA
11503966|NCT01326780|Experimental|3.6% Facial Cream|3.6% JNJ 10229570-AAA
11503967|NCT01326780|Placebo Comparator|0% Facial Cream|Vehicle control
11503968|NCT01326767|Active Comparator|Paclitaxel dosing according to SmPC|
11504260|NCT01324648|Active Comparator|GP TAU|
11504907|NCT01319786|Active Comparator|High-polyphenol diet|
11503969|NCT01326767|Experimental|Individualized pharmacokinetically driven paclitaxel dosing|In the first treatment cycle, the Paclitaxel dose is adapted depending on the age and the gender of the patient. In the treatment cycles 2-6 the Paclitaxel dose is adapted based on individual PK data and toxicities.
11503970|NCT01326754|Other|Artemether-lumefantrine|
11503971|NCT01326754|Other|Artesunate-amodiaquine|
11503972|NCT01326754|Other|Dihydroartemisinin-piperaquine|
11503973|NCT01326728||Allogeneic Stem Cell Transplant|Allogeneic hematopoietic stem cell transplantation (or allotransplant; donor blood stem cells)
11503974|NCT01326715|Active Comparator|mangafodipir|see protocol
11503975|NCT01326702|Experimental|Treatment (veliparib, bendamustine hydrochloride, rituximab)|"Patients receive veliparib PO BID on days 1-7 and bendamustine hydrochloride IV over 30-60 minutes on days 1-2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~Once the maximum-tolerated dose is determined, a cohort of patients receives veliparib and bendamustine hydrochloride as above and rituximab IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
11503976|NCT01326689|Experimental|KW-2246|
11503977|NCT01326689|Placebo Comparator|Placebo|
11503978|NCT01326676|Experimental|polypill|Red Heart Pill Version 1 and Red Heart Pill Version 2.
11503979|NCT01326676|Active Comparator|usual medication|participants continuing to receive cardiovascular disease medications as separate tablets prescribed by their usual physician
11503980|NCT01326663|Active Comparator|divalproex sodium|
11503981|NCT01326663|Placebo Comparator|sugar pill|
11503982|NCT01326650|Experimental|Vitamin D|daily vitamin D supplement
11503983|NCT01326650|Placebo Comparator|placebo|daily placebo supplement
11503984|NCT01326637|Experimental|intervention|Received the intervention: previsit planning phone call with filled out patient overview document & clinician huddle
11503985|NCT01326637|No Intervention|observation|Received usual care
11503986|NCT01326624||NYHA class III or IV|"Patients with NYHA class III or IV during the past month and one or more of the following:
~Hospitalization for cardiac decongestion and stabilization.
~Advanced heart failure receiving intravenous diuretics/inotropics in an outpatient clinic.
~Awaiting cardiac transplantation"
11503987|NCT01326624||left ventricular ejection fraction ≤ 35%|"Patients with left ventricular ejection fraction ≤ 35% and either one of the following:
~Coronary revascularization within 3 calendar months prior to enrollment.
~Heart failure of non-ischemic origin diagnosed within 3 calendar months prior to enrollment."
11503988|NCT01326624||Awaiting ICD re-implantation|
11503989|NCT01326624||Acute myocardial infarction|Patients hospitalized with acute myocardial infarction and Killip Class III/IV.
11503990|NCT01326611|Active Comparator|Clarithromycine Group: Active Comparator|Drug: Clarithromycin intravenous clarithromycin (10 mg/kg twice a day for 10 days)
11503991|NCT01326611|Placebo Comparator|Placebo Group: Placebo Comparator|Drug: D5W Dose given daily, IV same volume that Clarithromycin would be to equal 10 mg/kg for first 10 days.
11503992|NCT01326598||T2DM patients with A1C<7.0%|
11503993|NCT01326585|Experimental|Dexamethasone|Subjects receive intravenous intraoperative dexamethasone
11503994|NCT01326585|Placebo Comparator|Saline solution|Subjects receive intravenous intraoperative normal saline solution
11503995|NCT01326572||female, male, HIV, lung disease|All participants in the University of Pittsburgh Multicenter AIDS Cohort Study are eligible for this protocol. All participants in the UCSF Women's HIV study are eligible and all Men from the UCLA men's HIV study are eligible
11503996|NCT01326559|Experimental|Experimental 1|Induction chemotherapy using Docetaxel, Cisplatin and 5-FU for week 1 to week 9 and followed by concurrent chemoradiation plus cetuximab from week 10 to week 16
11503997|NCT01326546|Experimental|Therapeutic HBV vaccine+Entecavir|Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
11503998|NCT01326546|Placebo Comparator|placebo+Entecavir|Placebo comparator: Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
11503999|NCT01326533|Experimental|hydroxychloroquine|Thirteen weeks of daily hydroxychloroquine following FSIGTT testing
11504000|NCT01326533|Placebo Comparator|Placebo|Thirteen weeks of daily placebo following FSIGTT testing
11504001|NCT01326520|Experimental|Phospholipid enriched dairy product|
11504002|NCT01326520|Placebo Comparator|dairy product|
11504003|NCT01326494|Active Comparator|Arm 1 Oral Cortico Steroid|A filled prescription will be given to be used upon early onset of symptoms.
11504004|NCT01326494|No Intervention|Usual care for Asthma treatment|monitor the readmission of URTI induced asthma in children over a 12 month period
11504005|NCT01326481|Experimental|Single|All patients received TRC105 + capecitabine
11504006|NCT01326468|Experimental|Cohort A - Temsirolimus with Cisplatin|Temsirolimus with cisplatin, Erbitux and radiation therapy
11504007|NCT01326468|Experimental|Cohort B - Temsirolimus|Temsirolimus with Erbitux and radiation therapy
11504008|NCT01326455|No Intervention|Terumo Control|
11504009|NCT01326455|Active Comparator|Terumo Fast Release|
11504010|NCT01326455|Active Comparator|Clo-Sur P.A.D.|
11504011|NCT01326442|Experimental|diet only|low glycemic index diet, calorie restricted with exercise 3 times per week.
11504012|NCT01326442|Active Comparator|supplemented|2000 IU vitamin D3 plus 1.8 g EPA + DHA
11504013|NCT01326429||Hypernatremia|Patients admitted to the emergency department with a serum sodium exceeding 145 mmol/L.
11504014|NCT01326429||Hyponatremia|Patients admitted to the emergency room with a serum sodium below 135 mmol/L.
11504015|NCT01326416|Active Comparator|S: Nutritional Supplementation alone|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g of L-Leucine and 9 g of L-arginine), to distribute during each of the 3 main meals.
11504016|NCT01326416|Active Comparator|A: Physical Reconditioning alone|Physical reconditioning sessions led by a trainer three times a week for 6 months.
11504017|NCT01326416|Active Comparator|AS: Physical Reconditioning + Nutritional Supplementation|Association for six months of a specific nutritional supplementation by 21 g of L-Leucine and 9 g of L-arginine per day (to distribute during each of the 3 main meals) and of physical reconditioning sessions three times a week.
11504019|NCT01326403|Experimental|Group A|Patients will receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.
11504020|NCT01326403|Experimental|GROUP B|Patients will receive IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.
11504021|NCT01326403|Placebo Comparator|GROUP C|A control group will only receive placebo in the emergency room and in the OR.
11504022|NCT01326351|Experimental|Regenerative Injection Therapy|
11504023|NCT01326351|Sham Comparator|Dry needle|
11504024|NCT01326351|Active Comparator|Exercise|
11504025|NCT01326338|Experimental|Nitazoxanide Suspension|Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years
11504026|NCT01326338|Placebo Comparator|Placebo Suspension|Placebo Oral Suspension 5 ml for patients aged 1-3 years and Placebo Oral Suspension 10 ml for patients aged 4-11 years
11504027|NCT01326325|Experimental|Ketamine|Ketamine PANFARMA
11504028|NCT01326325|Placebo Comparator|Not Ketamine|NaCl
11504029|NCT01326312|Experimental|GTX 758|GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
11504030|NCT01326312|Experimental|GTx-758|GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
11504031|NCT01326312|Active Comparator|Lupron Depot|Luteinizing Hormone Releasing Hormone Agonist
11504032|NCT01326299|Active Comparator|Nutritional ingredient|Dissolve in water and consume with meal
11504033|NCT01326299|Placebo Comparator|Carbohydrate|dissolve in water and consume with meal
11504034|NCT01326299|Experimental|#1 Nutrtitional ingredient + Fiber|Dissolve in water and consume with meal
11504035|NCT01326299|Experimental|#2 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
11504036|NCT01326299|Experimental|#3 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
11504037|NCT01326286||Open Radical Prostatectomy|262
11504038|NCT01326286||Robotic Radical Prostatectomy|1303
11504039|NCT01326286||Intensity-Modulated Radiotherapy|638
11504040|NCT01326286||Interstitial Brachytherapy|171
11504041|NCT01326286||combined EBRT and Brachytherapy|143
11504042|NCT01326286||Active Surveillance|448
11504043|NCT01326286||Various other treatments|300
11504044|NCT01326260||THAM Patients|Patients who were managed with the use of THAM
11504045|NCT01326260||Non-THAM Patients|Patients who did not use THAM but were resuscitated with crystalloids and colloids and may have received sodium bicarbonate for the treatment of acidosis
11504046|NCT01326247|No Intervention|0.9% NaCl solution|
11504047|NCT01326234|Active Comparator|Personalized Feedback|The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
11504048|NCT01326234|Sham Comparator|Treatment as Usual|Practitioners are able to provide normal care with regard to smoking; participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred.
11504049|NCT01326221||1|Single dose of Truvada
11504050|NCT01326208|Experimental|Acute Lung Injury / ARDS|Patient under mechanical suffering from ALI or ARDS
11504051|NCT01326195|Experimental|Skills|Cognitive-Behavioral Dating Violence and HIV Prevention Group
11504052|NCT01326195|Active Comparator|Health Promotion|Psycho-educational Dating Violence and HIV Prevention group
11504053|NCT01326182|Experimental|MAADRE|Group-based intervention combining asthma education and cognitive behavioral treatment for depressive symptoms
11504054|NCT01326182|Active Comparator|MAAS|Group-based treatment combining asthma education and general information regarding child health
11504055|NCT01326169|Active Comparator|Standard care|No intervention
11504056|NCT01326169|Experimental|Counseling|Telephone-delivered counseling
11504057|NCT01326156|Experimental|Avon patellofemoral replacement|Knee arthroplasty with insertion of patellofemoral joint replacement.
11504058|NCT01326156|Active Comparator|PFC Sigma CR total knee replacement|Knee arthroplasty with total (tricompartmental) knee replacement.
11504059|NCT01326143||ORM Narval MRD|
11504060|NCT01326130|Active Comparator|Chronic care management 1|Content of chronic care model implemented in territory 1 and level of implementation
11504061|NCT01326130|Active Comparator|Chronic care management 2|Content of chronic care model implemented in territory 2 and level of implementation
11504062|NCT01326130|Active Comparator|Chronic care management 3|Content of chronic care model implemented in territory 3 and level of implementation
11504063|NCT01326130|Active Comparator|Chronic care management 4|Content of chronic care model implemented in territory 4 and level of implementation
11504064|NCT01326130|Active Comparator|Chronic care management 5|Content of chronic care model implemented in territory 5 and level of implementation
11504065|NCT01326130|Active Comparator|Chronic care management 6|Content of chronic care model implemented in territory 6 and level of implementation
11504066|NCT01326117|Experimental|tadalafil|
11504067|NCT01326104|Experimental|TTRNA-xALT & TTRNA-DCs|TTRNA-xALT 3 x 10^7/kg by intravenous injection once. TTRNA-DCs 1 x 10^7 by intradermal injection every 2 weeks for 3 total doses.
11504068|NCT01326091|No Intervention|Standard Positioning|
11504069|NCT01326091|Active Comparator|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
11504070|NCT01326078|Experimental|propofol nanoemulsion|3-4 mg/kg of propofol nanoemulsion will be administered by 1mL per 5 seconds, adjustment dose can be given.
11504071|NCT01326078|Active Comparator|propofol lipid emulsion|3-4 mg/kg will be administered by 1 ml per 5 seconds.
11504072|NCT01326052|Experimental|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
11504451|NCT01323270|Placebo Comparator|Saline and Repevax|Saline and Repevax
11504073|NCT01326052|Active Comparator|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
11504074|NCT01326039|Active Comparator|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
11504075|NCT01326039|Placebo Comparator|saline|perineural isotonic saline 20 ml
11504076|NCT01326026|Experimental|IDeg Simple|
11504077|NCT01326026|Experimental|IDeg Step wise|
11504078|NCT01326013||Blinded, Prospective Arm|Diagnostic accuracy for higher prevalence targets will be evaluated in prospectively collected, anonymized, leftover, stool specimens.
11504079|NCT01326013||Blinded, Pre-selected Arm|For targets that exhibit lower prevalence rates in the intended use population, banked, pre-selected, positive clinical specimens will be tested.
11504080|NCT01326000|Experimental|KRAS WT A|
11504081|NCT01326000|Active Comparator|KRAS WT B|
11504082|NCT01326000|Experimental|KRAS mutant A|
11504083|NCT01326000|Active Comparator|KRAS mutant B|
11504084|NCT01325987|Placebo Comparator|sugar pill|Subjects with vitamin D deficiency (serum 25(OH)D <20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
11504085|NCT01325987|Experimental|vitamin D2|Subjects with vitamin D deficiency (serum 25(OH)D <20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
11504086|NCT01325948||Patients with COPD|
11504087|NCT01325935|Experimental|Short-term DAPT group|1,200 patients to be newly registered: Undergo 3-month (+ 30 days) DAPT (aspirin and clopidogrel)
11504088|NCT01325935|No Intervention|Long-term DAPT group|1,200 patients to be appropriated from E-Japan post-marketing surveillance who meet all inclusion criteria and do not fall under any exclusion criteria of the present clinical study: Undergo 12-month DAPT (aspirin and clopidogrel)
11504089|NCT01325922|Other|50/50% Tilt|
11504090|NCT01325909|Active Comparator|Exercise|
11504091|NCT01325909|No Intervention|No Exercise|
11504092|NCT01325896|Other|All patients are receiving PEG-Intron|
11504093|NCT01325870|Experimental|ACD-CPR +ITD|Active Compression Decompression CPR with the ResQPRO device and ResQPOD ITD device.
11504094|NCT01325870|Experimental|S-CPR + ITPR|
11504095|NCT01325870|Active Comparator|S-CPR|
11504096|NCT01325857|Experimental|Group B|Group B = Nerve block group
11504097|NCT01325857|Placebo Comparator|Group L|Group L = Local wound infiltration group
11504098|NCT01325857|Active Comparator|Group C|Group C = Control group
11504099|NCT01325844|No Intervention|G group|G group = General anesthesia group
11504100|NCT01325844|Experimental|G+E group|G+E group = General anesthesia + epidural anesthesia group
11504101|NCT01325831|Experimental|transcranial magnetic stimluation|
11504102|NCT01325831|Sham Comparator|rTMS_sham|
11504103|NCT01325818|Active Comparator|1:pravastatin, 2:rosuvastatin|"Active Comparator Drug:pravastatin
~Active Comparator Drug:rosuvastatin"
11504104|NCT01325805|Experimental|Structured Weight Loss|Women randomized to this arm will meet with a registered dietician regularly for review of calorie recommendations and food diary. As well as regular clinic visits to measure patients weight.
11504105|NCT01325805|Active Comparator|Routine Weight Loss Counseling|Patients are counseled by a physicians about the impact of maternal weight on fertility and pregnancy outcomes.
11504106|NCT01325792||GORE® BIO-A® Tissue Reinforcement|Single-staged open complex ventral incisional repair of primary or recurrent anterior abdominal wall hernia.
11504107|NCT01325779|Active Comparator|subcutaneous heparin|
11504108|NCT01325779|Active Comparator|subcutaneous enoxaparin|
11504109|NCT01325766|Active Comparator|Yoga (immediate start) group|This arm will start yoga sessions immediately after screening and will continue sessions for 8 weeks. This group will then continue with home yoga for an additional 8 weeks.
11504110|NCT01325766|Active Comparator|Yoga (waitlist) group|This arm will continue regular CF therapies for 8 weeks and will start yoga sessions at week 9.
11504111|NCT01325753|Experimental|Treatment (cryoablation)|Patients undergo CT-guided CA.
11504112|NCT01325740|Active Comparator|STX107 10 mg|
11504113|NCT01325740|Placebo Comparator|Placebo|
11504114|NCT01325740|Active Comparator|STX107 30 mg|
11504115|NCT01325727|Experimental|Brief computerized feedback|Brief computerized feedback
11504116|NCT01325727|Active Comparator|Resources only|
11504117|NCT01325714|Experimental|Arm 1: PAVeD Intervention|In the experimental arm, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
11504118|NCT01325714|Active Comparator|Arm 2: Enhanced Usual Care|In the comparison arm, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.
11504119|NCT01325701|Experimental|PCI-32765: 560 mg|Treatment Group 1: Subjects received 560 mg of ibrutinib once daily, on a continuous basis.
11504120|NCT01325701|Experimental|PCI-32765: 840 mg|Treatment Group 2: Subjects received 840 mg of ibrutinib once daily, on a continuous basis.
11504121|NCT01325688|Experimental|Group 1|PEP005 0.05% gel applied and occluded with an aluminium disk for up to three consecutive days
11504122|NCT01325688|Experimental|Group 2|PEP005 0.05% Gel applied and occluded with an OpSite(TM) disk up to three consecutive days
11504123|NCT01325688|Experimental|Group 3|PEP005 0.05% applied with no occlusion for up to three consecutive days
11504124|NCT01325675|Experimental|Interval training|Interval training
11504125|NCT01325675|No Intervention|Control|Live as usual
11504126|NCT01325662||Continuous drip sampling|Sampling at ~0.6 cc / hour (~1.2 cc / 2 hours, or lowest feasible rate given technical requirements and volume requirements for core analytes assays)
11504127|NCT01325662||Intermittent sampling|Sampling at 4 cc every 2 hours (+ 2 cc dead space clearance, total = 6 cc / 2 hours)
11504168|NCT01325350|Active Comparator|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
11504128|NCT01325649||advanced rectal cancer|Patients with carcinoma of the middle rectum with positive mrCRM (≤ 1 mm), with cT3 low rectal carcinoma, and with cT4 Tumors Arm 1 Long course radiochemotherapy before total mesorectal excision Arm 2 total mesorectal excision without radiochemotherapy
11504129|NCT01325636|Experimental|CD4 and CD8 T cell|Injection of specific CD4 and CD8 T cell
11504130|NCT01325623|Other|Model 106 VNS Therapy System|Model 106 VNS Therapy System includes a new Seizure Detection Algorithm (SDA) and corresponding Automatic Magnet Mode (AMM) feature.
11504131|NCT01325597|Experimental|Combined training|Training with functional electrical stimulation added by inspiratory muscle training.
11504132|NCT01325597|Experimental|Electrical stimulation|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks
11504133|NCT01325597|Experimental|Inspiratory muscle training|IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure
11504134|NCT01325597|No Intervention|Control group|No intervention.
11504135|NCT01325584|Experimental|Omegaven (compassionate use)|This is a compassionate use study. All participants will receive intravenous Omegaven (10% fish oil emulsion) with parenteral nutrition for 4 weeks.
11504136|NCT01325571|Experimental|tacrolimus group|
11504137|NCT01325571|Placebo Comparator|placebo group|
11504138|NCT01325545||Cryptogenic stroke|Patients with stroke of unknown cause after comprehensive conventional evaluation
11504139|NCT01325545||Stroke of known cause|Patients with stroke of known cause determined by comprehensive conventional evaluation
11504140|NCT01325532|Experimental|Active CES|"Active CES: The FW-100 Cranial Stimulator headset was placed on the scalp over the two dorsolateral prefrontal cortex areas. The power knob was turned to maximum setting. The waveform contains a 15000Hz square wave carrier from 0-4 mAmp. The first 15Hz modulating signal provides 50msec of on and 16.7msec of off time (total 66.7msec, 50% duty cycle). A second 500Hz modulating signal changes the on time series of 15000Hz pulses (750 pulses/50msec) into 25 smaller bursts of 15 pulses of the 15000Hz carrier signal, for 375 pulses in 50msec. The consecutive positive burst and off time is followed by an opposite negative burst and off time, balancing the current component to zero. Output voltage ranges from 0-40V, positive and negative. CES automatically shut off after 20 mins."
11504141|NCT01325532|Sham Comparator|Sham CES|Shame CES: The sham devices were modified to not deliver current to the headset. The current from the active device departs from the posts at the top of the device into the headsets, creating a loop when the headset is worn by the subject with the wet electrode sponges. This loop is eliminated in the sham devices by wrapping wire around the posts, thus containing the loop within the device, with no electricity leaving the headsets. This approach allows the loop to be maintained, and therefore all of the device's green and yellow amperage lights still light up, protecting the blind.
11504142|NCT01325519|No Intervention|no intervention control group|control subjects
11504143|NCT01325519|Experimental|experimental intervention group|video decision aid viewed by subjects
11504144|NCT01325506||Prostatectomy subjects|
11504145|NCT01325493|Placebo Comparator|Normal Saline|Normal Saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
11504146|NCT01325493|Active Comparator|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
11504147|NCT01325480||Patients with heart failure and wide QRS|Patients undergoing a cardiac resynchronization therapy procedure
11504148|NCT01325454||Patients with parapneumonic effusions|Patients with pleural effusions of unknown causes admitted to Taipei Medical University Hospital were included if parapneumonic effusion was diagnosed as one associated with pneumonia according to the criteria of the American Thoracic Society (ie, patients with newly acquired respiratory symptoms, fever, and abnormal breath sounds, plus a new lung infiltrate seen on a chest radiograph).
11504149|NCT01325441|Experimental|BBI608 and Paclitaxel|Patients will receive BBI608 orally continuously at dose levels specified for their respective dose cohorts. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
11504150|NCT01325428|Experimental|Afatinib once daily (OD)|Patients receive afatinib monotherapy once daily until progression of their disease
11504151|NCT01325415|Experimental|A|NKTR-118 25 mg (1x25 mg tablet + 5x placebo tablets)
11504152|NCT01325415|Experimental|B|NKTR-118 150 mg (6x25 mg tablet)
11504153|NCT01325415|Placebo Comparator|C|NKTR-118 placebo (6x placebo tablets)
11504154|NCT01325415|Active Comparator|D|Moxifloxacin (1 x 400 mg tablet)
11504155|NCT01325402|Experimental|Part 1 Cohort 1|Patients with mild to moderate Alzheimer's Disease
11504156|NCT01325402|Experimental|Part 1 Cohort 2|Patients with mild to moderate Alzheimer's Disease. To run if Maximum Detective Mass is detected in cohort 1.
11504157|NCT01325402|Experimental|Part 2|Healthy Volunteers
11504158|NCT01325389|Experimental|Myo+Mel|Patients are treated with 2g of myo + 3mg of melatonin daily
11504159|NCT01325389|Placebo Comparator|Placebo|
11504160|NCT01325376|No Intervention|Self directed|
11504161|NCT01325376|Active Comparator|Technology assisted health behavior|The intervention arm will have access to a dynamic online environment with social networking and device data uploads that include activity data, weight data and laboratory data at frequent intervals to nudge optimal health behavior.
11504162|NCT01325363|Experimental|Schizophrenia|Schizophrenic patients
11504163|NCT01325363|Experimental|Control|Neurotypical subjects
11504164|NCT01325350|Experimental|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
11504165|NCT01325350|Experimental|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
11504166|NCT01325350|Experimental|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
11504167|NCT01325350|Placebo Comparator|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
11504169|NCT01325337|Experimental|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
11504170|NCT01325337|Experimental|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
11504171|NCT01325337|Experimental|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
11504172|NCT01325337|Placebo Comparator|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
11504173|NCT01325337|Active Comparator|minoxidil 5% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
11504174|NCT01325324|Other|Study group|Study group
11504175|NCT01325311|Experimental|Arm I (cholecalciferol, genistein)|Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
11504176|NCT01325311|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
11504177|NCT01325298|Active Comparator|20 Minute UV-X Light Treatment Duration|"20 Minute UV-X Light Treatment Duration
~Note: UV-X is the trademark of Peschke GmbH"
11504178|NCT01325298|Active Comparator|30 Minute UV-X Light Treatment Duration|30 Minute UV-X Light Treatment Duration
11504179|NCT01325272||preterm newborn|
11504180|NCT01325272||term newborn|
11504181|NCT01325259|Experimental|Alzheimer's disease|30 patients suffering from Alzheimer's disease
11504182|NCT01325259|Experimental|Mild Cognitive Impairment|20 patients suffering from Mild Cognitive Impairment
11504183|NCT01325259|Experimental|Control|15 subjects with no cognitive impairment
11504184|NCT01325233|Experimental|PG2 Injection|Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
11504185|NCT01325233|Placebo Comparator|Placebo|Powder for Injection, 500 ml normal saline, tiw, 2 weeks
11504186|NCT01325220|Active Comparator|STX209 5 mg BID|
11504187|NCT01325220|Active Comparator|STX209 10 mg BID|
11504188|NCT01325220|Active Comparator|STX209 10 mg TID|
11504189|NCT01325220|Placebo Comparator|Placebo|
11504190|NCT01325207|Experimental|intravenous trastuzumab infusions|A Phase I single dose study (H0407g) of intravenous trastuzumab infusions ranging from 10-500 mg resulted in dose-dependent pharmacokinetics (PK) with serum clearance of trastuzumab decreasing with an increasing dose at doses <250 mg. PK modeling of trastuzumab concentration-time data from 7 patients that were administered doses of 250 mg and 500 mg had in a mean halflife of 5.8 days (range 1-32 days).
11504191|NCT01325194|Experimental|CNS prophylaxis|
11504192|NCT01325181|Active Comparator|Low-fluence PDT with Verteporfin|Half the regular laser fluence PDT(Visudyne®; Novartis); a total light energy of 25J/cm2, a light dose rate of 300mW/cm2. If subretinal fluid was sustained after primary treatment, rescue treatment(ranibizumab injection) was considered
11504193|NCT01325181|Active Comparator|Ranibizumab|Consecutive Intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months. If subretinal fluid was sustained after primary treatment, rescue treatment(low-fluence photodynamic therapy) was considered
11504194|NCT01325168|Experimental|study group|32 PTSD patients intervention: Drug: syntocinon nasal spray / placebo nasal spray nasal OT - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
11504195|NCT01325168|Other|control group|control group - 30 healthy control subjects intervention: Drug: syntocinon nasal spray / placebo nasal spray nasal OT - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
11504196|NCT01325142||ONJ|Patient with cancer involving the bone treated with osteoclast inhibitor (bisphosphonate) and has developed ONJ
11504197|NCT01325142||No ONJ|Patient with cancer involving the bone treated with osteoclast inhibitor (bisphosphonate) and has NOT developed ONJ
11504198|NCT01325116|Active Comparator|Control|Usual post-STEMI care
11504199|NCT01325116|Experimental|Intervention|Recurrent, personalized, educational reminders sent via post on behalf of the interventional cardiologist to the patient and their family physician urging long-term adherence to secondary prevention medications post-STEMI. A copy of the letter will be provided to the patient to take to their pharmacist.
11504200|NCT01325103|Experimental|Stem Cell Transplantation|Patients with spinal cord injury that will undergo autologous bone marrow stem cell transplantation.
11504201|NCT01325090|Experimental|BOTOX|Patients will receive in one session multiple intradermal injections of Botox, in order to cover the whole painful area
11504202|NCT01325090|Placebo Comparator|PLACEBO|Patients will receive in one session multiple intradermal injections of placebo , in order to cover the whole painful area
11504203|NCT01325077|Experimental|Conventional model, Study model|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
11504204|NCT01325051|No Intervention|Raltegravir|To test raltegravir to see if it can be detected in gastrointestinal tissue of healthy men.
11504205|NCT01325038|Active Comparator|extra protein supplement|isometric training with addition of extra protein
11504206|NCT01325038|Active Comparator|extra food supplement|isometric exercise with addition of extra food and calories: one fast food meal/day
11504207|NCT01325025|Other|Patients|Patients with a metachromatic leukodystrophy
11504208|NCT01325025|Other|Control|Epileptic population
11504209|NCT01325012|Active Comparator|Subgluteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle.
11504210|NCT01325012|Active Comparator|Popliteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
11504211|NCT01324999|Experimental|Sarcoid Associated Pulm. Hypertension|Single-arm open-label proof of concept study of tadalafil in patients with sarcoidosis associated pulmonary hypertension.
11504212|NCT01324986|Active Comparator|Nissen fundoplication|
11504213|NCT01324986|Active Comparator|Toupet fundoplication|
11504214|NCT01324973|Experimental|eWellness program|A comprehensive program that delivers web-based, evidence-based weight management; and structured peer supports. The program is designed to meet the needs of individuals with mental illness.
11504215|NCT01324973|No Intervention|Control group|Care as usual
11504216|NCT01324960|Experimental|Ceplene® / IL2 + Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene (EpiCept Corporation, Tarrytown, NY) at 0.5 mg subcutaneous twice daily and human recombinant IL-2 (aldesleukin; Novartis) 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
11504217|NCT01324960|Active Comparator|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
11504218|NCT01324947|Experimental|Pomalidomide|Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
11504219|NCT01324934|Active Comparator|Study Group|immunosuppressive treatment consisting of ATG-Fresenius/TAC/MMF or Myfortic
11504220|NCT01324934|No Intervention|Control Group|immunosuppressive treatment consisting of TAC, MMF or Myfortic, and corticosteroids.
11504221|NCT01324921|Placebo Comparator|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
11504222|NCT01324921|Active Comparator|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
11504223|NCT01324921|Experimental|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
11504224|NCT01324908|Experimental|Treatment (Treg predictor of response to ECP)|Patients undergo ECP twice a week for 4 weeks and then twice a week every 2 weeks for 8 weeks.
11504225|NCT01324882|Experimental|Study Arm|This is the group who will have a colonoscopy with the Olympus Technically Improved Colonoscope.
11504226|NCT01324882|Active Comparator|Control|This is the group who will have a colonoscopy with the traditional colonoscope Olympus CF-H180.
11504227|NCT01324869|Experimental|Group A|Patients will receive an intravitreal injection of 0.5mg KH902 in the study eye at the first month, following the fixed injection, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.
11504228|NCT01324869|Experimental|Group B|Patients will receive continuously monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye; following the initial 3-month fixed-dosing phase of the trial, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.
11504229|NCT01324856|Experimental|Pancreaticogastro anastomosis|
11504230|NCT01324856|Active Comparator|Pancreaticojejuno anastomosis|
11504231|NCT01324830|Experimental|arm A|14 days once a day oral intake of BI 847325 followed by 7 days break in 3-week cycles
11504232|NCT01324830|Experimental|arm B|5 days once daily oral intake of BI 847325 followed by 2 days break, repeated every week
11504233|NCT01324817||Hopitalized|Patients admitted to the hospital
11504234|NCT01324804||CABG - subjects|only one group
11504235|NCT01324791|Active Comparator|laparoscopic antireflux surgery|
11504236|NCT01324791|Active Comparator|endoscopic full-thickness-gastroplication|
11504237|NCT01324778|Experimental|A|
11504238|NCT01324778|Active Comparator|B|
11504239|NCT01324765|Experimental|TARGET|12-session affect regulation therapy for PTSD
11504240|NCT01324765|Active Comparator|SGT|12 session supportive group therapy
11504241|NCT01324752|Experimental|PA21 and Losartan with food|
11504242|NCT01324752|Experimental|No PA21; Losartan with food|
11504243|NCT01324752|Experimental|PA21 with food and Losartan 2 hrs later|
11504244|NCT01324739|Active Comparator|B-type natriuretic peptide|the effect of B-type natriuretic peptide on glucose metabolism will be compared with placebo during an intravenous glocose tolerance test
11504245|NCT01324739|Placebo Comparator|Placebo|comparison of the effect of b-type natriuretic peptide on glucose metabolism and placebo
11504246|NCT01324713||Males|
11504247|NCT01324713||Females|
11504248|NCT01324700|Active Comparator|High severity group: Escitalopram|Participants with Baseline score of 20 or above on the 17-item Hamilton Rating Scale for Depression (HRSD) AND 3 or more courses of oral corticosteroids in the past 12 months were stratified into high severity group. Then these participants were further stratified into escitalopram group.
11504249|NCT01324700|Active Comparator|Low severity group: Escitalopram|Participants with Baseline HRSD score of less than 20 AND fewer than 3 courses of oral corticosteroids in the past 12 months were stratified into low severity group. Then these participants were further stratified into escitalopram group.
11504250|NCT01324700|Placebo Comparator|High severity group: Placebo|Participants with Baseline score of 20 or above on the 17-item Hamilton Rating Scale for Depression (HRSD) AND 3 or more courses of oral corticosteroids in the past 12 months were stratified into high severity group. Then these participants were further stratified into placebo group.
11504251|NCT01324700|Placebo Comparator|Low severity group: Placebo|Participants with Baseline HRSD score of less than 20 AND fewer than 3 courses of oral corticosteroids in the past 12 months were stratified into low severity group. Then these participants were further stratified into placebo group.
11504252|NCT01324687||Control|Group without access to telemedicine in the home for acute care issues.
11504253|NCT01324687||Telemedicine care|Cohort with access to telemedicine in the home for acute care issues.
11504254|NCT01324674|Placebo Comparator|Placebo group|Is the group of subjects that will take placebo
11504255|NCT01324674|Experimental|experimental group|Is the group of subjects that will take Bach´s Flower remedies
11504256|NCT01324661|No Intervention|Control|Individuals who receive the ball during a computerized ball tossing game about the same number of times as the other players in the game.
11504257|NCT01324661|Other|Ostracism|Participant would receive the ball of a ball-tossing game once or twice in the beginning and then never again for the duration of the game.
11504261|NCT01324635|Experimental|Arm A (panobinostat, multiple fractions of SBRT)|Patients receive panobinostat PO thrice weekly for 2 weeks and undergo 10 fractions of SBRT over 2 weeks (recurrent gliomas) OR 30 fractions of SBRT over 6 weeks (high grade meningiomas).
11504262|NCT01324635|Experimental|Arm B (panobinostat, stereotactic radiosurgery)|Patients receive panobinostat as in Arm A and undergo a single fraction of stereotactic radiosurgery on day 1 of week 1.
11504263|NCT01324622|Active Comparator|Laminectomy|Control
11504264|NCT01324622|Active Comparator|Laminoplasty|Treatment group
11504265|NCT01324596|Active Comparator|Arm A: R-CHOP|Participants receive 6 cycles of conventional R-CHOP chemotherapy on a standard 21 day schedule: Rituximab 375mg/m2 intravenous Cyclophosphamide 750mg/m2 Intravenous Doxorubicin 50mg/m2 Intravenous Vincristine intravenous Prednisolone 100mg od orally
11504266|NCT01324596|Experimental|Arm B: RB-CHOP|"Participants in this arm will receive 1 cycle of conventional R-CHOP chemotherapy, followed by 5 cycles of R-CHOP:
~Cyclophosphamide 750mg/m2 Intravenous Doxorubicin 50mg/m2 Intravenous Vincristine intravenous bortezomib - Intravenous Prednisolone 100mg od orally
~."
11504267|NCT01324583|Experimental|Arm 1|"Patients will receive cabazitaxel as the dose of corresponded level
~1-hour intravenous infusion every 3 weeks plus prednisolone 10 mg orally given daily: Dose Level Cabazitaxel Dose Level -1: 15 mg/m², Level 1: 20 mg/m², Level 2: 25 mg/m²"
11504268|NCT01324570|Experimental|Overall BTDS|Buprenorphine transdermal system
11504269|NCT01324557|Experimental|CSII|Optimized subcutaneous insulin infusion by means of continuous subcutaneous insulin infusion (CSII)
11504270|NCT01324557|No Intervention|MDI|MDI: Control Optimized subcutaneous insulin by multiple daily injections (MDI)
11504271|NCT01324544|Experimental|Buprenorphine IV|Buprenorphine IV
11504272|NCT01324531|Active Comparator|Bankart repair|
11504273|NCT01324531|Active Comparator|Bankart repair and remplissage|
11504274|NCT01324518|Experimental|Low dose of ORM-12741|
11504275|NCT01324518|Experimental|High dose of ORM-12741|
11504276|NCT01324518|Placebo Comparator|Placebo|
11504277|NCT01324505|Experimental|One-sequence cross-over arm|
11504278|NCT01324492|Experimental|RAD001|
11504279|NCT01324479|Experimental|INC280|
11504280|NCT01324466|Placebo Comparator|Vehicle|Vehicle
11504281|NCT01324466|Active Comparator|Active|Active NB-001(0.3%)
11504282|NCT01324453|Experimental|Post conditioning + PCI|
11504283|NCT01324453|Active Comparator|Standard PCI|
11504284|NCT01324440|Experimental|V710 without MAA|
11504285|NCT01324440|Active Comparator|V710 with MAA|
11504286|NCT01324427|Experimental|virtual medical visit|"This is a pilot trial involving a maximum of 84 patients undergoing either allogeneic or autologous stem cell transplant aimed at determining the feasibility and acceptance of a virtual medical visit by patients and health care personnel. During this pilot trial we expect to perform 84 virtual medical visits using telemedicine."
11504287|NCT01324401|No Intervention|Control|The subjects randomized to the observational control group will have follow-up visits every 6 months. Each visit will involve a medical history and physical examination. These subjects are then offered to cross-over to active treatment.
11504288|NCT01324401|Experimental|Peanut OIT|The subjects randomized to the active treatment group will receive defatted peanut flour per protocol.
11504289|NCT01324388|Experimental|LY2189265 + Lisinopril|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Days 1, 8, 15, and 22 of Part 1 of the study.
~Lisinopril: Dose as prescribed by participant's established course of therapy, oral, daily dosing throughout Part 1 of the study."
11504290|NCT01324388|Placebo Comparator|Placebo + Lisinopril|"Placebo: 1.5 milligrams (mg), subcutaneous (SC), on Days 1, 8, 15, and 22 of Part 1 of the study.
~Lisinopril: Dose as prescribed by participant's established course of therapy, oral, daily dosing throughout Part 1 of the study."
11504291|NCT01324388|Experimental|LY2189265 (Treatment 1)/Metoprolol + LY2189265 (Treatment 2)|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Day 1 of Treatment 1 and on Day 5 of Treatment 2 in Part 2 of the study.
~Metoprolol: 100 mg, oral, on Days 1 through 7 of Treatment 2 in Part 2 of the study.
~There was a washout period of at least 21 days between the LY2189265 and metoprolol doses of each treatment period (Day 1 of Treatment 1 to Day 1 of Treatment 2 in Part 2 of the study)."
11504292|NCT01324388|Experimental|Metoprolol + LY2189265 (Treatment 2)/LY2189265 (Treatment 1)|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Day 5 of Treatment 2 and on Day 1 of Treatment 1 in Part 2 of the study.
~Metoprolol: 100 mg, oral, on Days 1 through 7 of Treatment 2 in Part 2 of the study.
~There was a washout period of at least 21 days between the LY2189265 and metoprolol doses of each treatment period (Day 7 of Treatment 2 to Day 1 of Treatment 1 in Part 2 of the study)."
11504293|NCT01324375||THA (total hip arthroplasty)|Patients undergoing THA, preoperatively heat tested
11504294|NCT01324362|Active Comparator|Fluticasone propionate|
11504295|NCT01324362|Active Comparator|Fluticasone propionate/salmeterol combination|
11504296|NCT01324349|Experimental|Veriset Hemostatic Patch|Veriset Hemostatic Patch
11504297|NCT01324349|Active Comparator|Fibrin Sealant (TachoSil®)|Fibrin Sealant (TachoSil®)
11504298|NCT01324336||4-17 years, receiving 6-MP|
11504299|NCT01324323|Experimental|Romidepsin and rifampin|"Romidepsin 14 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.
~Rifampin 600 mg oral once daily on Days 4-8"
11504300|NCT01324310|Experimental|Romidepsin and ketoconazole|"Romidepsin 8 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.
~Ketoconazole 400 mg oral once daily on Days 4-8"
11504301|NCT01324297||Healthy Control|Caucasian males and females between 19 and 30 years of age.
11504302|NCT01324297||First Episode Psychosis|Caucasian males and females between 19 and 30 years of age within twelve months of initial DSM IV TR diagnosis of schizophreniform psychosis, schizophrenia, schizoaffective disorder or psychotic disorder NOS.
11504303|NCT01324284|Experimental|Lubiprostone|Lubiprostone with PEG solution versus Placebo with PEG solution
11504304|NCT01324284|Placebo Comparator|lubiprostone versus placebo|
11504305|NCT01324271|Experimental|Tympanostomy tube placement|placement of tympanostomy tube under local anesthesia in office/clinic setting
11504306|NCT01324258|Experimental|GSK1120212|Part 1-Dose escalation will be conducted to assess PK after single dosing and safety, tolerability, PK and efficacy of GSK1120212 in Japanese subjects with solid tumors using a continuous daily dosing schedule.
11504307|NCT01324258|Experimental|GSK1120212+Gemcitabine|Part 2-Further evaluate the safety, tolerability, PK, and efficacy of GSK1120212 in combination with gemcitabine in subjects with non-small cell lung cancer, pancreatic cancer, biliary cancer, urothelial cancer or other tumor types for which 4-week schedule of gemcitabine has been approved using the recommended dose from Part 1 (single agent).
11504308|NCT01324245|Experimental|Enalapril|2.5 mg every 12 hours for two doses
11504309|NCT01324232|Placebo Comparator|Placebo|
11504310|NCT01324232|Experimental|AVP-923-45|
11504311|NCT01324232|Experimental|AVP-923-30|
11504312|NCT01324232|Experimental|AVP-923-20|
11504313|NCT01324219|Active Comparator|Staff|
11504314|NCT01324219|Experimental|Resident|
11504315|NCT01324206||Healthy Volunteers|Healthy Volunteers 18 years or older
11504316|NCT01324193|Other|Pre-diaylsis patients|Chronic Kidney Disease patients not receiving dialysis getting pomegrante Supplementation
11504317|NCT01324193|Other|Dialysis patients|Chronic Kidney Disease patients receiving dialysis getting pomegranate supplementation
11504318|NCT01324180|Experimental|VLPD Regimen|Induction will consist of vincristine, dexamethasone, doxorubicin and PEG asparaginase (so called VPLD - dexamethasone is substituted for prednisone and PEG asparaginase is substituted for L-asparaginase) in combination with metformin. Eligible patients will receive 24 hours of metformin followed by induction. Intrathecal chemotherapy with standard dose cytarabine will be administered at the start of each cycle, with central nervous system (CNS) therapy afterwards determined by findings on staging lumbar puncture.
11504319|NCT01324141|Experimental|1|Chemo + Radiation
11504320|NCT01324128|Experimental|PA21 (2.5 g tablet)|
11504321|NCT01324128|Active Comparator|Sevelamer carbonate|
11504322|NCT01324128|Other|PA21-1 (1.25 g tablet)|
11504323|NCT01324102|Active Comparator|1. Yoga therapy|The intervention is an 8 week Yoga therapy class adapted to the specific needs of the veteran. The class meets two times per weeks for 90 minutes. A series of poses are instructed, with adaptations used as provided by a physical therapist.
11504324|NCT01324102|No Intervention|2. Wait list|The comparative intervention is an 8 week wait list control group for which there is no intervention provided within the study protocol.
11504325|NCT01324089|Active Comparator|Arm 1|Resveratrol 2.5 grams x 1 dose
11504326|NCT01324089|Experimental|Arm 2|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
11504327|NCT01324089|Other|Arm 3|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
11504328|NCT01324050|Experimental|Internet-based Psychodynamic Therapy|
11504329|NCT01324050|Active Comparator|Internet-delivered therapist support|
11504330|NCT01324037|Experimental|clinically suspected upper extremity deep vein thrombosis|Patients with suspected upper extremity DVT
11504331|NCT01324024|Experimental|Lisdexamfetamine, then placebo|Participants first received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks followed by a 2-week washout, then they received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks.
11504332|NCT01324024|Experimental|Placebo, then Lisdexamfetamine|Participants first received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks followed by a 2-week washout, then they received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks.
11504333|NCT01324011|Experimental|Family-based intervention|Special intervention (20 weekly group-based sessions) to be compared with a delayed intervention control group.
11504334|NCT01324011|Other|Delayed intervention controls|The delayed intervention controls will continue with usual care (if patients with diabetes)and at the end of the experimental period (6 months), they will receive a 6-session weight loss intervention delivered over a 2 month period.
11504335|NCT01323998||5ARI monotherapy|Patients with BPH receiving 5ARI monotherapy
11504336|NCT01323998||AB monotherapy|Patients with BPH receiving AB monotherapy
11504337|NCT01323998||Early combination (5ARI + AB) therapy|Patients receiving early initiation of combination therapy with a 5ARI plus AB. Early initiation defined as starting 5ARI therapy within 30 days of initiating AB therapy
11504338|NCT01323998||Delayed combination (5ARI + AB) therapy|Patients receiving delayed initiation of combination therapy with a 5ARI plus AB. Delayed initiation defined as starting 5ARI therapy more than 30 days but less than 6 months after initiating AB therapy
11504339|NCT01323985|Experimental|GSK2315698|Intravenous infusion single dose
11504340|NCT01323972|Experimental|GSK 257049-Lot 1 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine from the commercial scale lot 1 (formulation 1 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
11504341|NCT01323972|Experimental|GSK 257049-Lot 2 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine, from the commercial scale lot 2 (formulation 2 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
11504342|NCT01323972|Experimental|GSK 257049-Lot 3 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine, from the commercial scale lot 3 (formulation 3 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
11504343|NCT01323972|Experimental|GSK 257049-Pilot Group|Healthy male or female children aged 5 to 17 received 3 doses of the GSK 257049 vaccine from the pilot scale (pilot formulation of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
11504344|NCT01323959|Experimental|BOOSTRIX POLIO GROUP|Healthy subjects who had received one booster dose Boostrix™ Polio vaccine in the NCT01277705 study received one additional booster dose of Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
11504345|NCT01323959|Experimental|BOOSTRIX+POLIORIX GROUP|Healthy subjects who had received one booster dose of the co-administered Boostrix™ and Poliorix™ vaccines in the NCT01277705 study received one booster dose Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
11504346|NCT01323959|Experimental|REVAXIS GROUP|Healthy subjects who had received one booster dose of Revaxis® vaccine in the NCT01277705 study received one booster dose of Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
11504590|NCT01322152|Experimental|wXELIRI regimen|
11504347|NCT01323946|Experimental|GSK1562902A 6 to 12 M Group|Subjects between 6 and 12 months of age (6 to 12 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
11504348|NCT01323946|Experimental|GSK1562902A 12 to 24 M Group|Subjects between 12 and 24 months of age (12 to 24 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
11504349|NCT01323946|Experimental|GSK1562902A 24 to 36 M Group|Subjects between 24 and 36 months of age (24 to 36 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
11504350|NCT01323933|Experimental|AB0024|"The starting dose for Part A will be 1 mg/kg. Subsequent doses of 3, 10, and 20 mg/kg are planned. Three to 6 patients will be enrolled using a 3 + 3 design. Doses of AB0024 will be administered on Days 1, 15, 29, and 43 to characterize the safety, tolerability, and PK.
~The dose expansion phase of the study will begin upon completion of the dose escalation phase. Up to 20 patients will be enrolled into one or two cohorts of Part B. The first expansion cohort will be dosed up to the MTD defined as the highest dose level with an observed incidence of DLT in <33% of patients enrolled from Part A."
11504351|NCT01323920|Experimental|Velcade/Tac/MTX|"Drug: Bortezomib. Other Names: Velcade. Bortezomib 1.3 mg/m^2 IV
~Drug: Tacrolimus. Tacrolimus 0.05 mg/kg PO bid
~Drug: Methotrexate. Methotrexate 15 mg/m^2 IV"
11504352|NCT01323907|Experimental|Omegaven|Omegaven IV lipid emulsion administration for infants with life threatening parenteral nutrition associated liver disease
11504353|NCT01323881|Experimental|intermittent theta burst stimulation|
11504354|NCT01323881|Placebo Comparator|sham stimulation|
11504355|NCT01323855|Experimental|Part 1: Severe Renal Impairment|Participants with severe CRI, defined as creatinine clearance of <30 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
11504356|NCT01323855|Experimental|Part 2: Moderate Renal Impairment|Participants with moderate CRI defined as creatinine clearance of ≥30 and <50 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
11504357|NCT01323855|Experimental|Part 2: Mild Renal Impairment|Participants with mild CRI, defined as creatinine clearance of ≥50 and ≤80 mL/min/1.73m^2, were treated with a single tablet of 5 mg preladenant, administered orally
11504358|NCT01323855|Experimental|Part 1: Normal Renal Function|Participants with normal renal function, defined as creatinine clearance of >80 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
11504359|NCT01323855|Experimental|Part 2: Normal Renal Function|Participants with normal renal function, defined as creatinine clearance of >80 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
11504360|NCT01323842||rule in renal colic|ED patients with abdominal/flank pain where a diagnosis of renal colic is being considered and undergoing formal imaging while in the ED
11504361|NCT01323816||Traditional|ICU staffed by a resident, pulmonary fellow and attending
11504362|NCT01323816||Non-Traditional|ICU staffed by Nurse Practitioners as the direct care deliverer, a pulmonary fellow, and an attending
11504363|NCT01323790|Experimental|1|Oral treatment
11504364|NCT01323790|Experimental|2|Oral treatment
11504365|NCT01323790|Placebo Comparator|3|Oral treatment
11504366|NCT01323777|Experimental|ReSTOR +3.0|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
11504367|NCT01323764|Active Comparator|Radionuclide SPS|Radionuclide Shunt Patency Study
11504368|NCT01323751|Experimental|Treat Regimen|ACY-1215 Bortezomib Dexamethasone
11504369|NCT01323738|No Intervention|Treatment as Ususal|Patients participate in the Treatment as Usual including a non-specific information group.
11504370|NCT01323738|Experimental|Psychoeducation|Intervention group
11504371|NCT01323725|Experimental|Team-based financial incentives|Team-based financial incentives
11504372|NCT01323712|Placebo Comparator|Placebo|
11504373|NCT01323699|Experimental|Behavioral Therapy|
11504374|NCT01323686|Experimental|Imaging guided LV lead placement|
11504375|NCT01323686|No Intervention|Empiric LV lead placement|LV lead placement using standard clinical routine.
11504376|NCT01323673|Active Comparator|Clobetasol Propionate 0.05%|
11504377|NCT01323673|Placebo Comparator|Vehicle|
11504378|NCT01323660|Experimental|GSK573719/GW642444 125/25|125mcg/25mcg nDPI
11504379|NCT01323660|Experimental|GSK573719/GW642444 62.5/25|62.5mcg/25mcg nDPI
11504380|NCT01323660|Experimental|GSK573719/ 125|125mcg nDPI
11504381|NCT01323660|Experimental|GSK573719 62.5|62.5mcg nDPI
11504382|NCT01323660|Experimental|GW642444 25|25mcg nDPI
11504383|NCT01323660|Placebo Comparator|Placebo|Plb nDPI
11504384|NCT01323647|Experimental|Group A|Subjects in this group will receive the GSK Biologicals' IPV vaccine at 18 months of age. Subjects will also receive a dose of DTPa/Hib (Infanrix+Hib) as part of the local standard of care.
11504385|NCT01323647|Active Comparator|Group B|Subjects in this group will receive only a booster dose of GSK Biologicals' DTPa/Hib vaccine (Infanrix+Hib) as part of the local standard of care and will not be associated with any study endpoint.
11504386|NCT01323634|Experimental|Fluticasone Furoate / GW642444 (vilanterol)|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
11504387|NCT01323634|Active Comparator|Fluticasone Propionate / salmeterol|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
11504388|NCT01323621|Experimental|Fluticasone Furoate / GW642444 (vilanterol)|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
11504389|NCT01323621|Active Comparator|Fluticasone Propionate / salmeterol|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
11504390|NCT01323608|Placebo Comparator|Placebo|
11504391|NCT01323608|Experimental|Low Vitamin D Group|Subjects in this group will receive the equivalent of 400 IU/day.
11504392|NCT01323608|Experimental|Intermediate Vitamin D group|
11504393|NCT01323608|Experimental|High Vitamin D Group|
11504394|NCT01323595|Experimental|Celecoxib|Celecoxib will be given for 6 days after surgery
11504395|NCT01323595|Placebo Comparator|Sugar pill|Sugar pill for 6 days after surgery.
11505607|NCT01314989|Active Comparator|Cyproheptadine|Cross-over study
11504396|NCT01323582|Active Comparator|erythromycin|200mg/5ml elixir administered orally three times a day half an hour prior to meals.
11504397|NCT01323582|Experimental|Azithromycin|The dose of Azithromycin was determined based on our dose response curve obtained on 10 healthy subjects who were given three different doses of Azithromycin, 50 mg, 100 mg and 133 mg and underwent breath testing to determine the gastric emptying half-time. These doses were determined based on a maximum safe dosage per day of Azithromycin of 400 mg given the medication would then be administered three times daily before meals. The appearance of the medication (azithromycin) and administration period was then identical to that of Erythromycin, i.e. 5ml elixir administered orally three times a day half an hour prior to meals. The total daily dosage of Azithromycin was determined after obtaining the dose- response analysis.
11504398|NCT01323569|Placebo Comparator|Placebo|
11504399|NCT01323569|Experimental|Sativex 4 sprays|
11504400|NCT01323569|Experimental|Sativex 8 sprays|
11504401|NCT01323569|Experimental|Sativex 16 sprays|
11504402|NCT01323569|Active Comparator|Marinol low dose|
11504403|NCT01323569|Active Comparator|Marinol high dose|
11504404|NCT01323556|Experimental|Exposure with fear augmentation|exposure-based CBT, including interoceptive exposure and in-vivo exposure with fear augmentation by interoceptive exercises (e.g. hyperventilation)
11504405|NCT01323556|Experimental|Exposure without fear augmentation|exposure-based CBT, including interoceptive and in-vivo exposure without fear augmentation during in-vivo exposure
11504406|NCT01323543|Experimental|Elaspine™|Impantation of Elaspine™ device
11504407|NCT01323530|Experimental|Schedule 1|
11504408|NCT01323530|Experimental|Schedule 2|
11504409|NCT01323517|Experimental|Ipilimumab, Melphalan and Dactinomycin|This is a single-institution phase II trial with a primary outcome of progression free survival (PFS).
11504410|NCT01323504|Experimental|Music therapy group|Local care with music
11504411|NCT01323504|No Intervention|control group|Local care without music
11504412|NCT01323491||routine smokers|would-be non-smokers, no actual nicotine replacement therapy
11504413|NCT01323478|Experimental|Vortioxetine|
11504414|NCT01323465|Experimental|Sequence 1A|Sativex and rifampicin
11504415|NCT01323465|Experimental|Sequence 1B|Sativex and rifampicin
11504416|NCT01323465|Experimental|Sequence 2C|Sativex and ketoconazole
11504417|NCT01323465|Experimental|Sequence 2D|Sativex and ketoconazole
11504418|NCT01323465|Experimental|Sequence 3E|Sativex and omeprazole
11504419|NCT01323465|Experimental|Sequence 3F|Sativex and omeprazole
11504420|NCT01323452||Chronic HBV patients|Patients with chronic hepatitis B Treated for at least 3 months No HIV, HCV or HDV.
11504421|NCT01323439||Axium™ MicroFX™ PGLA Treated Subjects|This observational evaluation will evaluate early experience using the Axium™ MicroFX™ PGLA COILS as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ Bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol
11504422|NCT01323426|Experimental|periurethral injection|Periurethral injection of autologous muscle fibers
11504423|NCT01323413||stroke|acute ischemic stroke patients
11504424|NCT01323400|Experimental|Pazopanib|"Pazopanib (800 mg/day) + Best supportive care according to the investigator's judgement.
~Pazopanib treatment is started on the day after randomization until radiological progression according to RECIST or until documented toxicity. In case of radiological progression, pazopanib may be continued (if the investigator wishes so) if a clinical benefit (pain reduction, 1 point increase in performance status) is observed."
11504425|NCT01323400|Other|Best supportive care|Best supportive care according to the investigator's judgment. Upon progression, compassionate treatment by pazopanib is possible according to eligibility criteria.
11504426|NCT01323387|Other|Treatment|Interbody fusions with Anterior Plating
11504427|NCT01323374|Experimental|Droxidopa 200mg TID|
11504428|NCT01323374|Experimental|Droxidopa 400mg TID|
11504429|NCT01323374|Experimental|Droxidopa 600mg TID|
11504430|NCT01323374|Active Comparator|Carbidopa 25mg TID|
11504431|NCT01323374|Active Comparator|Carbidopa 50 mg TID|
11504432|NCT01323374|Experimental|Droxidopa/carbidopa 200mg/25mg TID|
11504433|NCT01323374|Experimental|Droxidopa/carbidopa 400mg/25mg TID|
11504434|NCT01323374|Experimental|Droxidopa/carbidopa 600mg/25mg TID|
11504435|NCT01323374|Experimental|Droxidopa/carbidopa 200mg/50mg TID|
11504436|NCT01323374|Experimental|Droxidopa/carbidopa 400mg/50mg TID|
11504437|NCT01323374|Experimental|Droxidopa/carbidopa 600mg/50mg TID|
11504438|NCT01323374|Placebo Comparator|Placebo TID|
11504439|NCT01323361|No Intervention|Non-immunosupressed|Normal population
11504440|NCT01323348|Experimental|Diabetes Educational Intervention|Study participants in the intervention group will receive a diabetes management educational intervention at baseline and at follow-up visits. For those on an annual follow-up schedule, educational intervention will take place at baseline and 12 months. For those whose standard care involves more frequent, than annual, visits the educational intervention will take place no more than once every 12 weeks.
11504441|NCT01323348|No Intervention|Standard Care|Usual care
11504442|NCT01323322||HANDLS|A fixed cohort as an area probability sample of Baltimore City from August 2004 through November 2009.
11504443|NCT01323309||Individual Meaning-Centered Psychotherapy (IMCP)|
11504444|NCT01323309||standard Individual Supportive Psychotherapy (ISP)|
11504445|NCT01323309||enhanced usual care (EUC)|
11504446|NCT01323296|Active Comparator|Ferumoxytol|Patients will be administered intravenous ferumoxytol 1 - 3 days following myocardial infarction after baseline cardiac magnetic resonance scanning.
11504447|NCT01323296|No Intervention|Control|Subjects who have suffered myocardial infarction will undergo cardiac magnetic resonance imaging at the same time points as those in the 'ferumoxytol' arm but will not receive ferumoxytol or placebo.
11504448|NCT01323283|Active Comparator|Omega-3 supplementation|50 % of all included children will be randomized to this arm and administered capsules containing an omega-3 fatty acid composition.
11504449|NCT01323283|Placebo Comparator|Placebo|50 % of included children will be randomized to this arm and will be administered placebo capsules for the 15 week intervention.
11504450|NCT01323270|Experimental|rLP2086|rLP2086 and Repevax
11504452|NCT01323257|Experimental|001|TMC435 150 mg capsule once daily for 7 days (Trt A C D)
11504453|NCT01323257|Experimental|002|erythromycin 500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
11504454|NCT01323257|Experimental|003|erythromycin 500 mg tablets three times a day for 7 days (Trt C)
11504455|NCT01323257|Experimental|004|TMC435 50 mg capsule once daily for 7 days (Trt F)
11504456|NCT01323257|Experimental|005|Darunavir 2 x 400 mg tablet once daily for 7 days (Trt E F)
11504457|NCT01323257|Experimental|006|Ritonavir 100 mg tablet once daily for 7 days (Trt E F)
11504458|NCT01323244|Experimental|TMC435|TMC435 Type=exact number unit=mg number=150 form=capsule route=oral use once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
11504459|NCT01323231|Experimental|Communities in Schools Services|Communities in Schools services include case management, mental health services, mentorship services, after school programs, and academic assistance.
11504460|NCT01323205|Experimental|JNJ-40411813 (Part A)|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.
11504461|NCT01323205|Experimental|JNJ-40411813 (Part B)|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 10 weeks.
11504462|NCT01323205|Experimental|Placebo and JNJ-40411813 (Part B)|Placebo capsule (s) orally twice daily with a meal for 4 weeks followed by JNJ-40411813 according to tolerability dose range increased from 50 mg to 150 mg twice daily with a meal to 6 weeks.
11504463|NCT01323192|Experimental|JNS001|
11504464|NCT01323192|Placebo Comparator|Placebo|
11504465|NCT01323179||Strong opioids|Patients taking strong opioids preoperatively
11504466|NCT01323179||Weak opioids|Patients taking weak opioids preoperatively
11504467|NCT01323179||Opioid native|Patients not taking opioids preoperatively
11504468|NCT01323166||Excision of the levator muscle|The abdominal part of the operation is performed as an TME and the perineal part of the operation is performed with the intent to get a cylindrical specimen thus removing part of or the entire levator muscle with the specimen
11504469|NCT01323166||Traditional perineal operation|The abdominal part of the operation performed as a TME. The perineal operation performed with the intent of removing the tumour with CRM free of tumour and the levator left in place
11504470|NCT01323153|Experimental|Dalcetrapib|
11504471|NCT01323153|Placebo Comparator|Placebo|
11504472|NCT01323140|Experimental|TMTS treatment|Following a lead-in dose-proportionality phase (Days 1-2) and a site-to-site bioavailability phase (Days 2-9), subjects were dosed for efficacy analysis beginning on Day 9 at dose level B (a single 48 cm2 testosterone matrix transdermal system). Based on pharmacokinetic (PK) analysis of blood samples drawn on Day 16, on Day 22 subjects could be dose-titrated up to dose level C (one 28 cm2 plus one 48 cm2 TMTS), down to dose level A (one 28 cm2 TMTS), or remain at dose level B. Subjects at all dose levels were pooled for primary efficacy analysis on Days 29/30.
11504473|NCT01323127||Chronic back pain|This group of patients has had chronic back pain for longer than 3 months.
11504474|NCT01323127||Non chronic back pain|This group of patients is hospitalized for cardio physical therapy, and has no lumbar-pelvic complications. Patients are selected from the hospitalized population according to age, sex, and BMI in order to match chronic back pain patients.
11504475|NCT01323114|Active Comparator|Medical Control Group|Control group of patients who will receive conventional medical treatment for type 2 diabetes, along with regular dietary and diabetic education, under the monitoring of the study endocrinologist.
11504476|NCT01323114|Experimental|Surgical Treatment Group|Experimental group in which patients will undergo the laparoscopic duodenal bypass procedure along with regular dietary and diabetic education, under the monitoring of the study endocrinologist.
11504477|NCT01323101|Sham Comparator|Control|No doxycycline
11504478|NCT01323101|Experimental|Doxycycline|
11504479|NCT01323088|Other|Control|Standard care control (no-exercise)
11504480|NCT01323088|Active Comparator|Aerobic Exercise|
11504481|NCT01323088|Active Comparator|Resistance Exercise|
11504482|NCT01323075||Renal insufficiency group|Patients in this group have renal insufficiency as defined by a creatinine clearance of < 30 ml/min without dialysis. These patients do not have diabetes.
11504483|NCT01323075||Diabetic group|These patients have diabetes, but not renal insufficiency.
11504484|NCT01323075||Non-exposed group|These patients have neither a neurological nor a metabolic disease and a creatine clearance of > 90 ml/min
11504485|NCT01323062|Other|Single-arm trial|Single-arm trial
11504486|NCT01323049|Active Comparator|Positive pressure extubation|Positive pressure extubation will be used for patients waking up from general anesthesia in this group
11504487|NCT01323049|Active Comparator|Aspiration/suction extubation|Aspiration/suction extubation will be used for patients waking up from general anesthesia in this group
11504488|NCT01323036|Experimental|Krill Oil|
11504489|NCT01323036|Experimental|Fish Oil|
11504490|NCT01323010|Experimental|Albuterol - Experimental|Albuterol dosages during the first hour include 900 mcg (up to 15 kg), 1200 mcg (> 15 to 20 kg), 1500 mcg (> 20 to 25 kg) and 1800 mcg (> 25 kg).
11504491|NCT01323010|Active Comparator|Albuterol - Control|Albuterol dosages during the first hour include either 600 mcg (up to 25 kg) or 1200 mcg (> 25 kg).
11504492|NCT01322997|Experimental|Myomo + RTP|This group will be administered a regimen comprised of repetitive task specific practice (RTP) in conjunction with use of the robotic brace described elsewhere in this record.
11504493|NCT01322997|Active Comparator|Myomo|Patients in this group will only be administered the robotic brace described elsewhere in this record.
11504494|NCT01322997|Active Comparator|RTP only|Patients in this group will be administered repetitive task specific practice (RTP), emphasizing use of their affected arms during performance of valued, functional tasks.
11504495|NCT01322984|Active Comparator|Normal controls|Normal children and youths
11504496|NCT01322984|Experimental|ASD|Children and youths diagnosed with autism spectrum disorder (ASD)
11504497|NCT01322971|Active Comparator|Metronidazole|Patients randomized to the metronidazole arm will receive metronidazole 500mg orally twice daily for seven days.
11504498|NCT01322971|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive placebo orally twice daily for seven days(control arm
11504499|NCT01322958||At Risk of Ectopic Pregnancy|Women who present to the emergency department at UCSF who are at risk of ectopic pregnancy.
11504500|NCT01322945||Endonasal surgery|Single cohort of patients undergoing endonasal surgery
11504501|NCT01322919|Experimental|Myopic Treatment Arm|Patients treated in this arm will have preoperative measurements that indicate a myopic condition of the eye in conjunction with a presbyopic condition
11504502|NCT01322919|Experimental|Hyperopic Treatment Arm|Patients treated in this arm will have preoperative measurements that indicate a hyperopic condition of the eye in conjunction with a presbyopic condition
11504503|NCT01322906|Other|Group A|Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
11504504|NCT01322893||Blood sampling.|Blood samples will be taken before start of treatment, at month 1, month 3, month 4 and month 6.
11504505|NCT01322880|Other|Control Arm|The project, administered by the International Rescue Committee (IRC), involved 25 village savings and loans association (VSLA) groups across the province. The VSLA groups initially formed through local members of the community designated as community based facilitators (CBF).
11504506|NCT01322880|Experimental|Treatment Group|"Half of the VSLA participants were invited to participate in an additional set of discussion groups to be attended along with their spouse. All participants were informed that due to space constraints, only half of the members would be able to attend. In each VSLA, individuals drew numbers from a bag or hat, and those with winning slips were the ones who entered the discussion groups with spouses."
11504507|NCT01322867|Active Comparator|Reference Drug|
11504508|NCT01322867|Active Comparator|Test Drug|
11504509|NCT01322854|Experimental|IMRT + integrated boost|28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed by an integrated boost
11504510|NCT01322854|Other|Conventional RT + sequential boost|Conventional radiotherapy of the whole breast in 28 fractions to a dose of 50.4 Gy and a consecutive boost in 8 fractions to a total dose of 66.4 Gy
11504511|NCT01322841|Active Comparator|CHICA Diagnosis Module|This arm had the CHICA screening module turned on
11504512|NCT01322841|Placebo Comparator|CHICA Placebo|This arm had CHICA but no additional module
11504513|NCT01322828|Active Comparator|Single incision repair of distal bicep tendon rupture|In this treatment arm patients will have a single incision technique used to repair their distal bicep tendon rupture
11504514|NCT01322828|Active Comparator|Double incision repair of distal bicep tendon rupture|In this treatment arm, patients will have a double incision technique used to repair their distal bicep tendon rupture.
11504515|NCT01322815|Experimental|Chemotherapy and GI-4000|"Standard chemotherapy and bevacizumab 40 yeast units (YU) GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.
~maintenance of GI-4000 injection and bevacizumab every 2 weeks"
11504516|NCT01322815|Experimental|GI-4000 and bevacizumab|maintenance with GI-4000 and bevacizumab for patients who have completed first-line chemotherapy
11504517|NCT01322802|Experimental|Treatment (pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine)|Patients receive pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine ID monthly for 3 months.
11504518|NCT01322789|Experimental|Intravenous mesenchymal stem cell|This group wil receive 8 intravenous infusions of mesenchymal stem cells. Four infusions 1 week apart and 4 infusions a month apart
11504519|NCT01322776|Experimental|Bortezomib,Fludarabine,Cyclophosphamide|
11504520|NCT01322750||With CTCs|Those individuals whom are identified with CTCs
11504521|NCT01322750||Without CTCs|Those individuals whom present and did not have CTCs
11504522|NCT01322737|Experimental|SUMO Tissue Access and Resection System|
11504523|NCT01322724|Active Comparator|Warm water|Body temperature (95-100 degrees F) water
11504524|NCT01322724|Experimental|Cool water|Room temperature (68-73 degrees F) water
11504525|NCT01322711|Active Comparator|Atorvastatin|"Each day accordingly to randomization patients allocated to Atorvastatin received a pill of 40 mg of atorvastatin. In diabetic patients the concomitant aspirin treatment include a previous 30 days treatment with 100 mg daily of aspirin.
~All patients followed the diet used in the placebo group."
11504526|NCT01322711|Placebo Comparator|Diet|Low-fat diet with mean macronutrient profiles that were close to the present Adult Treatment Panel III guidelines (7% energy from saturated fat and, 200 mg dietary cholesterol per day)
11504527|NCT01322698||The study population|The target population includes patients in ICUs at the Nîmes and Montpellier University hospitals. This is a population of non-neutropenic patients (polynuclear neutrophils > 500/mm3) at risk of developing invasive candidiasis.
11504528|NCT01322685||Health Group|
11504529|NCT01322685||Tuberculosis Group|Tuberculosis or lung cancer group
11504530|NCT01322659|Active Comparator|Helmet NPPV|Weaning from mechanical ventilation with noninvasive positive pressure ventilation (NPPV)delivered by means of the helmet
11504531|NCT01322659|Sham Comparator|ETT IMV|Weaning from mechanical ventilation with standard invasive mechanical ventilation (IMV) delivered by means of the endotracheal tube (ETT)
11504532|NCT01322646|Active Comparator|Driver Training|Driver Education Program Practice driving on a driving simulator Provision of the CarChipPro to the family
11504533|NCT01322646|Experimental|STEER Program|Driver Education STEER Program
11504534|NCT01322633||Pantoprazole|Patients who received treatment with pantoprazole tablets for at least 240 days within a 12-month period from 2000 through 2003.
11504535|NCT01322633||Other proton pump inhibitors|Patients who received treatment with any other proton pump inhibitor for at least 240 days within a 12-month period from 1996 through 2003.
11504536|NCT01322620||A|
11504537|NCT01322607|Other|Arm 1: High-Intensity Program|High-intensity treadmill-based exercise
11504538|NCT01322607|Other|Arm 2: Low-Intensity Program|Low-intensity lifestyle intervention (group exercise)
11504539|NCT01322594|Experimental|MEDI2338 10 MG|MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump
11504540|NCT01322594|Experimental|MEDI2338 30 MG|MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
11505608|NCT01314989|Placebo Comparator|Sugar pill|Cross-over study
11504541|NCT01322594|Experimental|MEDI2338 100 MG|MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
11504542|NCT01322594|Experimental|MEDI2338 300 MG|MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
11504543|NCT01322594|Experimental|MEDI2338 1000 MG|MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
11504544|NCT01322594|Placebo Comparator|Placebo|Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
11504545|NCT01322581||observational cohort|This observational-cohort study of individuals (3 months and 40 years of age) will be conducted in the rural village of Kalifabougou, Mali, where Pf transmission is intense and seasonal
11504546|NCT01322503|Experimental|Norovirus Challenge|
11504547|NCT01322503|Experimental|Norovirus challenge|
11504548|NCT01322490|Experimental|PROSTVAC-V/F-TRICOM + GM-CSF|"PROSTVAC-V-TRICOM
~PROSTVAC-F-TRICOM
~GM-CSF"
11504549|NCT01322490|Experimental|PROSTVAC-V/F-TRICOM + GM-CSF placebo|"PROSTVAC-V-TRICOM
~PROSTVAC-F-TRICOM
~GM-CSF placebo"
11504550|NCT01322490|Placebo Comparator|Placebo Control|PROSTVAC V/F Placebo + GM-CSF Placebo
11504551|NCT01322477||Hepatocellular Carcinoma|Patients with advanced HCC
11504552|NCT01322464|Experimental|Group 1 Fasted-Fed|"4 sprays Sativex in fasted state, followed by wash-out followed by 4 sprays Sativex in fed state.
~Followed by 4 sprays daily in fasted state."
11504553|NCT01322464|Experimental|Group 1 Fed-Fasted|"4 sprays sativex in fed state followed by wash-out followed by 4 sprays Sativex in fasted state.
~Followed by 4 sprays daily in fasted state."
11504554|NCT01322464|Experimental|Group 2|2 sprays Sativex daily in fasted state.
11504555|NCT01322464|Experimental|Group 3|8 sprays sativex daily in fasted state.
11504556|NCT01322451|Experimental|Single oral dose, single capsule|
11504557|NCT01322451|Experimental|Single oral dose, two capsules|
11504558|NCT01322438|Experimental|Arm 1|
11504559|NCT01322412||Arm A : physical activity program|Arm A : physical activity program (aerobic and strength training) during the 27 weeks of treatment (chemotherapy and radiotherapy) and conventional follow-up during 27 weeks
11504560|NCT01322412||Arm B : conventional management|Arm B : conventional management during and after treatment
11504561|NCT01322399|Experimental|Structural Integration plus usual care|Each subject in this arm will receive ten Structural Integration treatments at intervals of between one and three weeks, and will also receive usual care for chronic low back pain as standard practice at Spaulding Medford Rehabilitation Clinic, which may include pain medication, exercise and physical therapy. Usual care will be provided on average twice weekly for between 3 and 7 weeks, at the discretion of the clinic's medical director
11504562|NCT01322399|Active Comparator|Usual care|Each subject in this arm will receive care for chronic low back pain as standard practice at Spaulding Medford Rehabilitation Clinic, which may include pain medication, exercise and physical therapy. Usual care will be provided on average twice weekly for between 3 and 7 weeks, at the discretion of the clinic's medical director
11504563|NCT01322386|Experimental|Oral Vancomycin|Vancocin
11504564|NCT01322373||Healthy control subjects (HC)|Subjects who met criteria as healthy control subjects and completed Orasi Protocol ADG-08-01.
11504565|NCT01322373||Alzheimer's disease subjects (AD)|Subjects with a diagnosis of DAT according to DSM-IV-TR criteria who completed Orasi Protocol ADG-08-01.
11504566|NCT01322360|Other|Morphine Sulfate|oral solution (10 mg/5 mL or 20 mg/5 mL) or tablets (15 mg or 30 mg)given based on based on the current pediatric prescribing guidelines
11504567|NCT01322347|Active Comparator|Soluble Ferric Pyrophosphate (SFP) in dialysate|11 micrograms (µg) of iron / deciliter (dL) of dialysate.
11504568|NCT01322347|Placebo Comparator|Standard Dialysate|0 micrograms (µg) of iron / deciliter (dL) of dialysate.
11504569|NCT01322334|Experimental|Singing exercises|
11504570|NCT01322321|Experimental|ACZ885|
11504571|NCT01322321|Placebo Comparator|Placebo|
11504572|NCT01322308|Placebo Comparator|sugar pill|tablet similar to comparator
11504573|NCT01322308|Active Comparator|pioglitazone|30 mg tablets QD (taken once daily)
11504574|NCT01322282|Experimental|ODT with Water|Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken with 240 mL of water
11504575|NCT01322282|Experimental|ODT Without Water|Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken without 240 mL of water
11504576|NCT01322282|Active Comparator|FCT with Water|Marketed Cetirizine 10 mg Film-Coated Tablet (FCT) taken with 240 mL of water
11504577|NCT01322269|Experimental|HQK-1001 (30 mg/kg)|
11504578|NCT01322269|Experimental|HQK-1001 (40 mg/kg)|
11504579|NCT01322269|Experimental|HQK-1001 (50 mg/kg)|
11504580|NCT01322256|Experimental|Included patients|"Patients included in the study according to stated inclusion and exclusion criteria
~Intervention: Bone scintigraphy Intervention: Leukoscan Intervention: PET / CT Intervention: Bone biopsy Intervention: Bloodwork"
11504581|NCT01322243|Other|Dietary Intervention: Fasted State|Participants will be randomized to a dietary intervention of a fasted or fed group upon admission.
11504582|NCT01322243|Other|Dietary Intervention: Fed State|Participants will be randomized to a dietary intervention of a fasted or fed group upon admission
11504583|NCT01322230|Experimental|Control|Screen shots with voiceover and no interactivity
11504584|NCT01322230|Experimental|WISEMD Original|Learner control of pacing through multi-media content
11504585|NCT01322230|Experimental|Social Networking|social networking features (Forum and Social Presence)
11504586|NCT01322230|Experimental|Social Networking plus Emotional Design|Social networking features plus user interface enhancements
11504587|NCT01322217||AMTU Clients|All HIV-infected adolescents and young adults engaged in care at sites newly participating in ATN III and their affiliates who are between 12 and 24 years of age, inclusive, are aware of their HIV status and understand written and/or verbal English will be eligible for inclusion in the study. In addition, new patients who have their initial clinic visit within the enrollment period will also be eligible for participation.
11504588|NCT01322204|Experimental|1|Neonates 0-30 days, no more than 2,000 grams, receiving mechanical ventilation.
11504589|NCT01322191|Experimental|1|Random assignment to a single dose of morphine 0.1 mg/kg infused by syringe pump over 10 minutes; urine and blood sample frozen at -80 degrees Celsius
11504591|NCT01322139|Placebo Comparator|High dose placebo and oral moxifloxacin placebo|24 or 36 placebo sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
11504592|NCT01322139|Active Comparator|Low dose Sativex and oral moxifloxacin placebo|8 Sativex sprays (4 sprays twice daily) + 16 or 28 placebo sprays (8 or 14 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
11504593|NCT01322139|Active Comparator|High dose Sativex and oral moxifloxacin placebo|24 or 36 Sativex sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
11504594|NCT01322139|Active Comparator|High dose placebo and single oral moxifloxacin 400 mg tablet|24 or 36 placebo sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
11504595|NCT01322126|Experimental|ultrasound ,without ultrasound|ultrasound group will be passed the neuraxial anesthesia with ultrasound,the secoud group will be passed the neuraxial anesthesia without ultrasound .
11504596|NCT01322113||Na+, K+-ATPase/DLC system in BD|Bipolar patients in the various phases of the disease.
11504597|NCT01322087|Experimental|Nutritional intervention|
11504598|NCT01322074||Total knee arthroplasty|Patients operated with elective, unilateral total knee arthroplasty.
11504599|NCT01322061|Active Comparator|Vitamin C|
11504600|NCT01322061|Placebo Comparator|mirinda|
11504601|NCT01322048|Experimental|Adrenergic Blockade|Propranolol and Clonidine
11504602|NCT01322048|Placebo Comparator|Placebo|Placebo
11504603|NCT01322022|Experimental|Parent Training|Behavioral Intervention
11504604|NCT01322022|Active Comparator|Parent Education|5 Sessions of individual parent education
11504605|NCT01322009|Experimental|Drug|Probenecid and N-acetyl cysteine will be administered at standard doses for the first 4 days after TBI.
11504606|NCT01322009|Placebo Comparator|Placebo|Placebos will be prepared for the two experimental drugs and administered at identical time periods.
11504607|NCT01321996|Other|68Ga-DOTANOC PET/CT in patients with IPF and NSIP|one arm study: all patients were studied by 68Ga-DOTANOC PET/CT
11504608|NCT01321970|Other|Severe coronary artery disease|Patients in this group have coronary artery disease with a stenosis of >70%.
11504609|NCT01321970|Other|Coronary artery disease|Patients in this group have coronary artery disease with stenosis < 70%.
11504610|NCT01321957|Active Comparator|FOLFOX+Bevacizumab|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
11504611|NCT01321957|Experimental|FOLFOX+Bevacizumab+Irinotecan|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
11504612|NCT01321944|No Intervention|Usual clinical care|Usual clinical care provided by health care system
11504613|NCT01321944|Experimental|DTS intervention|Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP that encourages the smoker to quit, and offers a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC), free nicotine patches, and referral to additional treatment resources including the state's free telephone quitline.
11504614|NCT01321931|Experimental|NRT 60|A 6 mg dose of an experimental Nicotine Replacement Therapy (NRT) given every hour for 11 hours, with a 36-hour washout between visits
11504615|NCT01321931|Active Comparator|NFG 60|A 4 mg dose of a marketed Nicotine Fruit Gum (NFG) given every hour for 11 hours, with a 36-hour washout between visits
11504616|NCT01321931|Experimental|NRT 90|A 6 mg dose of NRT given every 90 minutes for 10.5 hours, with a 36-hour washout between visits
11504617|NCT01321931|Active Comparator|NFG 90|A 4 mg dose of NFG given every 90 minutes for 10.5 hours, with a 36-hour washout between visits
11504618|NCT01321931|Active Comparator|NIQ 60|A 4 mg dose of marketed nicotine mint lozenge (NIQ), given every hour for 11 hours, with a 36-hour washout between visits
11504619|NCT01321918|Other|Case subjects|
11504620|NCT01321918|Other|Control subjects|
11504621|NCT01321905|Experimental|Ergocalciferol|"Patients younger than 16 years of age are administered 35,000 IU ergocalciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.
~Patients 16 or more years of age are administered 50,000 IU ergocalciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
11504622|NCT01321905|Experimental|Cholecalciferol|"Patients younger than 16 years of age are administered 35,000 IU cholecalciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.
~Patients 16 or more years of age are administered 50,000 IU cholecalciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
11504623|NCT01321905|No Intervention|Control|Patients continue their ordinary vitamin supplementation without getting extra vitamin D supplements.
11504624|NCT01321892||Squamous cell carcinoma|Patients included in this study will be receiving surgical treatment for their biopsy-proven squamous cell carcinoma.
11504625|NCT01321879|Experimental|Telavancin|10 or 7.5 mg/kg intravenous daily
11504626|NCT01321866|Experimental|Experimental arm|Patients in this arm will have angioplasty of a fistula stenosis using a cutting balloon
11504627|NCT01321866|Active Comparator|Standard arm|Patients in this arm will have angioplasty of a fistula stenosis using a non-cutting balloon.
11504628|NCT01321853|Experimental|Machine and NCC|Medications dispensed to subject via MD2 machine and nurse care coordination used to coordinate care among providers and fill machine at least every 2 weeks.
11504629|NCT01321853|Experimental|Medplanner and NCC|Medications loaded in medplanner by nurse care coordinator who coordinates care among providers and visits subject at least every 2 weeks
11504630|NCT01321853|No Intervention|Usual Care Group|Admitted post home health care with no intervention.
11504631|NCT01321840|Experimental|Treatment|This group will be treated with SART.
11504632|NCT01321840|No Intervention|No treatment|This group will not be treated with SART but will regularly be examined by a gynecologist to detect sudden aggravation of the disease.
11504633|NCT01321827|Experimental|Itraconazole group|Itraconazole 200 mg BD for 4 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
11504634|NCT01321827|Active Comparator|Glucocorticoid group|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
11504635|NCT01321814|Experimental|Cognitive behavioural therapy (CBT)|Patients receiving 6 sessions of CBT conducted by a licensed psychologist. Sessions include psychoeducation, exposure treatment, behavioral activation and applied relaxation.
11504636|NCT01321814|No Intervention|Waiting list|Patient waits for CBT treatment for 6 months.
11504637|NCT01321801|Active Comparator|Pregabalin|Preoperative administration of pregabalin 600mg to patients undergo laparoscopic cholecystectomy.Patients receive oral Pregabalin 300 mg the night before the surgery, and another one dose of 300 mg 1 hour prior to surgery
11504638|NCT01321801|Placebo Comparator|Placebo|Preoperative administration of placebo to patients undergo laparoscopic cholecystectomy.Patients receive oral Placebo the night before the surgery, and another one dose 1 hour prior to surgery.
11504639|NCT01321788||STUDY GROUP|will receive the study drug Innohep ® for 14 days
11504640|NCT01321788||CONTROL|The group that will receive placebo for 14 days
11504641|NCT01321775|Experimental|Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet|
11504642|NCT01321762||1|Pregnant Women with singleton pregnancy
11504643|NCT01321749|Experimental|RIPC+stroke secondary prevension|"Procedure/Surgery: Remote Ischemic Preconditioning (RIPC) The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
~Procedure:stroke secondary prevention(Such as Antiplatelet therapy, Cholesterol-lowering therapymaintain blood pressure and blood sugar normal)"
11504644|NCT01321749|No Intervention|stroke secondary prevention|Procedure:stroke secondary prevention(Such as Antiplatelet therapy, Cholesterol-lowering therapymaintain blood pressure and blood sugar normal)
11504645|NCT01321723|Experimental|PTH analog tablet|PTH(1-31) 5 mg tablet, once daily
11504646|NCT01321723|Placebo Comparator|Placebo|Placebo matching tablet, once daily
11504647|NCT01321723|Active Comparator|Forsteo|Forsteo (teriparatide) 20 mcg SC Injection, once daily
11504648|NCT01321710|Active Comparator|Dietary information & standard care|"Mothers in this arm receive dietary information aimed at reducing postpartum sleep disturbance.
~Infants in this arm receive no intervention beyond standard immunization care."
11504649|NCT01321710|Experimental|Sleep hygiene & standard care|"Mothers in this arm receive a sleep hygiene intervention aimed at improving their postpartum sleep.
~Infants in this arm receive standard immunization care."
11504650|NCT01321710|Experimental|Sleep hygiene & acetaminophen|"Mothers in this arm receive a sleep hygiene intervention aimed at improving postpartum sleep.
~Infants in this arm receive an acetaminophen intervention (12.5mg per kg infant weight, 1 dose 30 minutes prior to immunization and q4-6h thereafter, for a total of 5 doses) to minimize sleep disturbance following immunization."
11504651|NCT01321697||Vulvar Cancer|
11504652|NCT01321671|Experimental|Pregabalin controlled release, 330 mg, 600- 750 calorie|
11504653|NCT01321671|Experimental|Pregabalin controlled release, 330 mg, fasted|
11504654|NCT01321671|Other|Pregabalin immediate release, 300 mg|
11504655|NCT01321658|Experimental|Geriatric intervention|
11504656|NCT01321658|No Intervention|Control|
11504657|NCT01321619|Experimental|Varicell|Drug A(Varicell) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
11504658|NCT01321619|Experimental|Placebo daflon (Drug D)|Drug D (Placebo Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
11504659|NCT01321606|Experimental|Arm 1: Probiotic|subjects will be given a capsule formulation of a 1x10^10 colony-forming units of probiotic L. rhamnosus HN001 to be taken once a day, for 4 weeks
11504660|NCT01321606|Placebo Comparator|Arm 2: Placebo|Placebo identical to the active product will be given
11504661|NCT01321593||hemoglobin determination|emergency unit patients
11504662|NCT01321580|Experimental|Group A|
11504663|NCT01321567||Rabeprazole Sodium|
11504664|NCT01321554|Experimental|Lenvatinib (Randomization Phase)|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
11504665|NCT01321554|Placebo Comparator|Placebo (Randomization Phase)|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
11504666|NCT01321554|Experimental|Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)|Participants will receive lenvatinib 24 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
11504667|NCT01321554|Experimental|Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)|Participants will receive lenvatinib 20 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
11504668|NCT01321541|Experimental|Pixantrone + Rituximab|
11504669|NCT01321541|Active Comparator|Gemcitabine + Rituximab|
11504670|NCT01321528||IBSR Intervention group|30 nurses in the geriatric departments in TASMC
11504671|NCT01321489|Experimental|Sildenafil Citrate 20mg Tablet Sublingual|Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
11504811|NCT01320475|Active Comparator|Sufentanil|Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
11504672|NCT01321489|Active Comparator|Viagra ® 50mg tablet Coated|Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
11504673|NCT01321463|Experimental|PH-797804|
11504674|NCT01321463|Placebo Comparator|Placebo|
11504675|NCT01321450||Group A|Preparation with Harmonic WAVE
11504676|NCT01321450||Group B|Preparation with conventional modalities
11504677|NCT01321437|Experimental|Axitinib|Patients receive axitinib PO BID on days 1-28. Treatment repeats every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 14-21 days after completion of treatment. Beginning 28-56 days after surgery, patients receive axitinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
11504678|NCT01321424||Aqueous Dificiency Dry Eye|20 Participants
11504679|NCT01321424||Meibomian Gland Disease Dry Eye|20 Participants
11504680|NCT01321424||Normal Eye|20 Participants
11504681|NCT01321411||1. ARDS/COPD|Critically ill patients with either ARDS or COPD weaning from mechanical ventilation.
11504682|NCT01321411||2. Healthy Volunteers|
11504683|NCT01321398||Critically Ill patients receiving HFO|
11504684|NCT01321359|Placebo Comparator|Vehicle|Vehicle
11504685|NCT01321359|Active Comparator|Active|Active NB-001(0.3%)
11504686|NCT01321346|Experimental|Leukemia Patients|Patients with ALL and AML will be treated in one arm of the study.
11504687|NCT01321346|Experimental|Lymphoma Patients|Patients with NHL or HD will be treated in one arm of the study.
11504688|NCT01321333|Experimental|HuCNS-SC cells|Single dose intramedullary administration of HuCNS-SC cells
11504689|NCT01321320|Experimental|Active stimulation|This group will receive active muscle stimulation for 1 week to the quadriceps muscle - the leg will be randomly assigned.
11504690|NCT01321307||Sorend|Group no. 1 shall receive Sorend following diagnosis of aphtostomatitis or mucositis.
11504691|NCT01321307||Sorend placebo|Group no. 2 shall receive Sorend placebo following diagnosis of aphtostomatitis or mucositis.
11504692|NCT01321294|Active Comparator|Nissen fundoplication|
11504693|NCT01321294|Active Comparator|Toupet fundoplication|
11504694|NCT01321281|Experimental|AquaCal|Osteoarthritis and healthy volunteers
11504695|NCT01321281|Active Comparator|AquaPT|Osteoarthritis
11504696|NCT01321268|Experimental|dietary supplement for cellulite|PUFA, resveratrol, lycopene, beta carotene, lutein
11504697|NCT01321268|Active Comparator|Control|Vitamin E
11504698|NCT01321255|Experimental|FDC Fixed Dose Combination|
11504699|NCT01321255|Active Comparator|Conventional treatment|
11504700|NCT01321242||achieving resting HR goals|Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects achieving resting HR goals, according to ACC/AHA/ACP-ASIM Guidelines
11504701|NCT01321242||non-achieving HR goals|Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects non-achieving HR goals, according to ACC/AHA/ACP-ASIM Guidelines
11504702|NCT01321229||With sleep APNEA|Sleeping Apnea Syndrome (SAS) screening usin an APNEA LINK device within the 10 first days following the admission Diagnosis and medical care by a sleeping disorder qualified specialist
11504703|NCT01321229||Without sleep APNEA|Sleeping Apnea Syndrome (SAS) screening usin an APNEA LINK device within the 10 first days following the admission
11504704|NCT01321216||Hospitalized Gastroenteritis|Children under 5 years of age hospitalized with gastroenteritis
11504705|NCT01321203||Group-A, use of air;|
11504706|NCT01321203||Group-B use of CO2|
11504707|NCT01321190||Low Back Pain|Individuals who experience bothersome low back pain.
11504708|NCT01321190||Headache|Individuals who experience bothersome headaches.
11504709|NCT01321190||Fibromyalgia|Individuals who experience bothersome fibromyalgia-related pain.
11504710|NCT01321177|Experimental|Integrated Treatment|Integrated program of treatments and services delivered by a coordinated team of providers.
11504711|NCT01321177|Active Comparator|Community Care|Standard mental health treatments and services offered at the local agency.
11504712|NCT01321164|Active Comparator|Fumaric acid esters|Fumaric acid esters monotherapy
11504713|NCT01321164|Experimental|fumaric acid esters plus narrow band UVB|Combination therapy of fumaric acid esters plus narrow band type B ultraviolet therapy (UVB)
11504714|NCT01321151|Placebo Comparator|Sugar Pill|Placebo control
11504715|NCT01321151|Experimental|Resveratrol|Intervention
11504716|NCT01321138|Active Comparator|Femoral nerve block|Continuous femoral nerve block with bolus of ropivacaine 0.5% and then continuous infusion of ropivacaine 0.2 % 4 - 6 ml/h, associated with paracetamol and ibuprofen. Each group will contain 30 patients.
11504717|NCT01321138|Placebo Comparator|PCA morphine|Patients with iv morphine with self administration with a PCA-system, associated with paracetamol and ibuprofen.
11504718|NCT01321125|Experimental|Whole group of 30 volunteers|The arm is composed of 30 human volunteers to test 2% chlorhexidine gluconate in 70% isopropyl alcohol (ChloraPrep ®, Enturia, Texas, USA ), hypochlorite 10% of electrochemical production (Except 10% ®, Pisa, Guadalajara, Mexico), and two controls.
11504719|NCT01321125|Experimental|test group of substantivity|The arm is composed of 10 human volunteers to test 2% chlorhexidine gluconate in 70% isopropyl alcohol (ChloraPrep ®, Enturia, Texas, USA ), hypochlorite 10% of electrochemical production (Except 10% ®, Pisa, Guadalajara, Mexico), and 10% povidone-iodine (Isodine Solucion ®, Boehringer-Ingelheim Promeco, Mexico City)
11504720|NCT01321112|Experimental|Conversion arm|After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
11504721|NCT01321099|Experimental|NaFeEDTA|
11504722|NCT01321099|Experimental|Phatase|
11504723|NCT01321099|Experimental|Vitamin C|
11505609|NCT01314976|Experimental|Metronidazole|Active treatment.
11504724|NCT01321086|Active Comparator|Motivational Interviewing|Motivational Interviewing (MI) is an effective counseling method in individuals who are less ready to change their behavior. 9 MI sessions will be conducted over the course of the six month intervention.
11504725|NCT01321086|Active Comparator|PACE|Patient-centered Assessment and Counseling for Exercise (PACE) is a protocol that targets known modifiable determinants of behavior change to motivate participants to increase their physical activity (walking).
11504726|NCT01321086|No Intervention|Control|
11504727|NCT01321073|Experimental|DelIVery for Pulmonary Arterial Hypertension Single Arm|All subjects were enrolled for implantation of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection.
11504728|NCT01321060|Active Comparator|Conservative treatment|Conservative treatment group with only drugs.
11504729|NCT01321060|Experimental|Continuous catheter drainage|Once the diameter of the fluid collection is more than 6cm, continuous catheter drainage will be applied.
11504730|NCT01321060|Experimental|Repeated aspiration|Once the diameter of the fluid collection is more than 6cm, aspiration is applied and draw the tube out immediately after aspiration.
11504731|NCT01321047|Active Comparator|Propofol group|the conventional propofol group (P group), sedation was induced by an intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age > 70 or ASA class III-IV).
11504732|NCT01321047|Active Comparator|BPS group|the balanced propofol sedation group (BPS group), both midazolam (0.05 mg/kg body weight; 1 mg if age > 70 or ASA class III-IV) and fentanyl (50 µg; 25 µg if age > 70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, an initial bolus of propofol (0.5 mg/kg body weight) was given intravenously. Sedation was maintained with repeated doses of 10 to 20 mg propofol.
11504733|NCT01321034|Other|Niacin/Laropiprant|Subjects with normal Lp(a) will be use as comparative group for the other two groups, so no placebo group is required is this study
11504734|NCT01321021|Experimental|Losartan, Diphenhydramine, Placebo|placebo controlled crossover study with two arms: Losartan, Diphenhydramine
11504735|NCT01321008|Experimental|Radiation + Chemotherapy|Radiation therapy total dose of 50.4 to 54 Gy over 28 to 30 treatments; CHOP Chemotherapy of Cyclophosphamide 750 mg/m2 intravenous piggyback (IVPB), Doxorubicin 50 mg/m2 IVPB, Vincristine 1.4 mg/m2 (max dose 2 mg) IVPB on Day 1, and Oral Prednisone 100 mg daily days 1-5 for four 21-day cycles.
11504736|NCT01320995|Experimental|Experimental arm|In this arm, perineal ultrasound is used directly after delivery in order to hypothetically better detect anal lesions.
11504737|NCT01320995|No Intervention|Standard arm|No perineal ultrasound immediately after delivery.
11504738|NCT01320982|Active Comparator|minocycline|minocycline
11504739|NCT01320982|Active Comparator|pramipexole|pramipexole
11504740|NCT01320982|Active Comparator|acetylsalicylic acid|acetylsalicylic acid
11504741|NCT01320982|Placebo Comparator|Placebo|Placebo
11504742|NCT01320969|Experimental|Mindfulness-Based Stress Reduction course|an eight week mindfulness-based stress reduction course
11504743|NCT01320969|No Intervention|Waitlist group|waitlist group
11504744|NCT01320956|Experimental|Hypnosis|"Pre operative nurse consultation and Hypnosis:
~will have hypnosis"
11504745|NCT01320956|Active Comparator|Control|"Pre operative nurse consultation:
~usual nurse consultation without hypnosis"
11504746|NCT01320943|Experimental|Stop TDF|Participants randomized to this arm will stop TDF therapy at baseline.
11504747|NCT01320943|Active Comparator|Continue TDF|Participants randomized to this arm will continue TDF therapy.
11504748|NCT01320930|Active Comparator|Pulmonary rehabilitation|A standardized 7 week rehabilitation program, including physical training and education.
11504749|NCT01320930|Placebo Comparator|Control|Conventional care
11504750|NCT01320917|Active Comparator|LNG-IUS|Insertion of a LNG-IUS device
11504751|NCT01320917|Placebo Comparator|Cu-IUD|Insertion of a Cu-IUD
11504752|NCT01320904|Placebo Comparator|Closed Kinetic Chain and NMES placebo|"During the stimulation period the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
~We used a 10-channel electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings."
11504753|NCT01320904|Other|Closed Kinetic Chain Group|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
11504754|NCT01320891|Experimental|balanced|arm in which the subjects received only balanced solutions
11504755|NCT01320891|Experimental|not balanced|arm in which the subjects received only not balanced solutions that means only normal saline and colloid dissolved in normal saline
11504756|NCT01320878|Active Comparator|iloprost low dose group|iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
11504757|NCT01320878|Active Comparator|iloprost high dose group|iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
11504758|NCT01320878|Placebo Comparator|placebo group|distilled water 2 ml per session
11504759|NCT01320865||Subjects with PAH treated with nilotinib|
11504760|NCT01320852|Active Comparator|Milan Criteria|Patients meeting the Milan Criteria
11504761|NCT01320852|Other|No Milan Criteria|Patients not meeting the Milan Criteria
11504762|NCT01320839||Stroke|People who have had a stroke and have an ankle-foot orthosis.
11504812|NCT01320462|Experimental|Smoking cessation group|Counselling, Pharmacotherapy and Smokers Help Line
11504813|NCT01320462|Other|Control group|Brief informatin about quitting and smokers help line
11505610|NCT01314976|Placebo Comparator|Placebo|Passive treatment.
11504763|NCT01320826||Physician colonoscopists|"All primary care physicians (family physicians and general internists) who perform colonoscopies were approached to voluntarily participate in the APC-Endo study.
~All patients having a colonoscopy done by an APC-Endo study physician endoscopist were approached at the time of their endoscopy to consent to the post procedure telephone survey."
11504764|NCT01320813|Experimental|Robot arm|Patients in this arm will have a thyroidectomy performed using a robot-assisted endoscopic technique.
11504765|NCT01320813|Active Comparator|Open surgery|Patients in this arm will have a thyroidectomy using an open surgical technique.
11504766|NCT01320800|Active Comparator|Expert-led CBT|Expert SASS is the Skills for Academic and Social Success protocol delivered by a postdoctoral fellows.
11504767|NCT01320800|Experimental|School Counselor-led CBT|"School Counselor SASS is the Skills for Academic and Social Success protocol delivered by School Counselors.
~Intervention: Behavioral: Skills for Social and Academic Success"
11504768|NCT01320800|Active Comparator|Skills for Life|SFL is the Skills for Life Protocol delivered by school counselors. Intervention: Behavioral: Skills for Life
11504769|NCT01320787|Experimental|18F-fluoroacetate|18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.
11504770|NCT01320761|Experimental|Group 1A|"Left side injected first:
~Left submental - ATX-101-BA Right submental - ATX-101-BA-free"
11504771|NCT01320761|Experimental|Group 1B|"Right side injected first:
~Left submental - ATX-101-BA Right submental - ATX-101-BA-free"
11504772|NCT01320761|Experimental|Group 2A|"Left side injected first:
~Left submental - ATX-101-BA-free Right submental - ATX-101-BA"
11504773|NCT01320761|Experimental|Group 2B|"Right side injected first:
~Left submental - ATX-101-BA-free Right submental - ATX-101-BA"
11504774|NCT01320748|Experimental|Dual Processing|
11504775|NCT01320748|Active Comparator|Relapse Prevention|
11504776|NCT01320735||Advanced PCa|Participants with advanced PCa
11504777|NCT01320722|Experimental|Vitamin D|Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.
11504778|NCT01320722|Experimental|Probenecid|Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).
11504779|NCT01320722|Experimental|Allopurinol|Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).
11504780|NCT01320722|Placebo Comparator|Placebo- Vitamin D|Placebo soft gel once per week for 8 weeks.
11504781|NCT01320722|Placebo Comparator|Placebo- Uric Acid|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).
11504782|NCT01320709|Experimental|Arm 1|
11504783|NCT01320709|Experimental|Arm 2|
11504784|NCT01320709|Placebo Comparator|Arm 3|
11504785|NCT01320709|Experimental|Arm 4|
11504786|NCT01320696|Experimental|Cohort 1|50 subjects will be randomized 1:1:1:1:1 to 5 dose groups (10 subjects per treatment group) to receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22
11504787|NCT01320696|Experimental|Cohort 2|After a safety data review of the first 50 subjects, a further 225 subjects will be randomized 1:1:1:1:1 to 5 dose groups and will receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22
11504788|NCT01320683|Experimental|Treatment (combination chemotherapy and radioimmunotherapy)|FOLFOX* + BEVACIZUMAB CHEMOTHERAPY: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes. Treatment repeats for up to 12 courses in the absence of disease progression or unacceptable toxicity. RIT: Within 4-12 weeks after completion of post-hepatic resection therapy chemotherapy, patients receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV over 25 minutes. Treatment repeats every 6-10 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. NOTE:*Patients previously failing oxaliplatin regimen receive FOLIFIRI chemotherapy comprising irinotecan hydrochloride IV over 90 minutes, leucovorin calcium over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes. Treatment repeats for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11504789|NCT01320657|Active Comparator|InOvation C|Active Self-ligating Bracket
11504790|NCT01320657|Placebo Comparator|Ovation|Conventional Bracket
11504791|NCT01320657|Experimental|Damon Q|Self-ligating bracket
11504792|NCT01320644||vaginal mesh placement|
11504793|NCT01320605|Experimental|Weekly HP802247 treatment|
11504794|NCT01320592|Experimental|PD0332991 and Paclitaxel|PD0332991 in combination with weekly paclitaxel at a fixed dose of 80 mg/m2
11504795|NCT01320579|Experimental|Group 2 Cis-UCA 5% emulsion cream|
11504796|NCT01320579|Placebo Comparator|Group 3 Placebo cis-UCA emulsion cream|
11504797|NCT01320579|Active Comparator|Group 4 Protopic® 0.1% ointment|
11504798|NCT01320579|Experimental|Group 1 Cis-UCA 2.5% emulsion cream|
11504799|NCT01320553|Experimental|SPARC1102 I|1334H 0.15% eye drops will be administered in both eyes at 3 occasions
11504800|NCT01320553|Experimental|SPARC1102 II|1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions
11504801|NCT01320553|Experimental|SPARC1102 III|1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions
11504802|NCT01320553|Placebo Comparator|Vehicle|Placebo eye drops (solution)will be administered in both eyes at 3 occasions
11504803|NCT01320540||Breast Center Patients|Patients newly diagnosed with breast cancer who did or did not have genetic testing (retrospectively and prospectively).
11504804|NCT01320540||Staff from the Lynn Sage Comprehensive Breast Cancer Center|Members of the Northwestern staff to include but not limited the Lynn Sage Comprehensive Breast Cancer Center and/or Breast Cancer Genetics Program provider staff (including physicians, nurses, schedulers, physician assistants and/or genetic counselors).
11504805|NCT01320527|Experimental|Nutriceutical formulation|Nutritional supplement
11504806|NCT01320527|Placebo Comparator|Placebo 1|
11504807|NCT01320527|Placebo Comparator|Placebo 2|
11504808|NCT01320514||Fibrin Sealant (Artiss)|
11504809|NCT01320501|Experimental|Erlotinib|150 mg PO daily
11504810|NCT01320475|Experimental|iv Ketamine|Epidural infusion of levobupivacaine and saline (placebo for sufentanil)and iv infusion of ketamine Up to the third postoperative day (6 PM)
11504814|NCT01320449|Placebo Comparator|No training + placebo|10 young men being investigated with 10 weeks apart. The will receive placebo injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
11504815|NCT01320449|Active Comparator|No training + EPO|10 young men being investigated with 10 weeks apart. During the 10 weeks participants will receive EPO injections twice a week. Blood samples, blood pressures as well as VO2-mas tests will be obtained during the 10 weeks.
11504816|NCT01320449|Active Comparator|Training + placebo|10 young men will be trained for 10 weeks and investigated before and after. They will receive placebo injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
11504817|NCT01320449|Active Comparator|Training + EPO|10 young men will be investigated with 10 weeks apart. During the ten weeks they will train 3 times a week and receive EPO injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
11504818|NCT01320436|Active Comparator|Treatments arm|Patients allocated for this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (total of 820 mg each,containing 500 mg curcumin ) curcumin twice daily after meals.
11504819|NCT01320436|Placebo Comparator|Control arm|Patients allocated to this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (820gr each) of placebo twice a day after meals.
11504820|NCT01320423|Other|surgery|
11504821|NCT01320397|Experimental|Rostafuroxin 6 micrograms capsules|1 capsule of ROSTAFUROXIN (6 micrograms) once a day before breakfast.
11504822|NCT01320397|Experimental|Rostafuroxin 50 micrograms capsules|1 capsule of ROSTAFUROXIN (50 micrograms) once a day before breakfast.
11504823|NCT01320397|Experimental|Rostafuroxin 500 micrograms|1 capsule of ROSTAFUROXIN (500 micrograms) once a day before breakfast.
11504824|NCT01320397|Experimental|Losartan 50 mg encapsulated|1 capsule containing one cpr of Losartan 50 mg once a day before breakfast.
11504825|NCT01320384|Active Comparator|O2 conventional : standard low flow therapy|in order to obtain a SpO2>92%
11504826|NCT01320384|Experimental|O2-HNF : high flow nasal oxygen therapy|set between 30 to 50 l/min,adjusted in order to obtain a SpO2 >92%.
11504827|NCT01320384|Experimental|O2-HFN/NPPV|cycling of NIV and O2-HDN
11504828|NCT01320371||Barbed sutures|Barbed sutures are self-anchoring, requiring no knots for wound closure.
11504829|NCT01320371||Knotted sutures|Knotted sutures used for traditional surgical closures.
11504830|NCT01320358|Experimental|ECMPS-IEM|
11504831|NCT01320345|Experimental|Fenofibrate|145 mg tablet of fenofibrate administered daily for 36 months.
11504832|NCT01320345|Placebo Comparator|Placebo|Inert lactose tablet (otherwise matching active) administered daily for 36 months.
11504833|NCT01320332|Experimental|ASP3291 low dose|
11504834|NCT01320332|Experimental|ASP3291 high dose|
11504835|NCT01320332|Placebo Comparator|Placebo|
11504836|NCT01320319|Placebo Comparator|Placebo|
11504837|NCT01320319|Experimental|Nutritional Supplementation with EPA|This arm will receive the nutritional supplementation of EPA 960mg Three times a day.
11504838|NCT01320306||Subarachnoid hemorrhage|A group of patients suffering aneurismal subarachnoid hemorrhage will participate in a fMRI study.
11504839|NCT01320306||Prophylactic surgical treatment of un-ruptured aneurysms|A retrospective follow-up study of patients who have received prophylactic surgical treatment of un-ruptured aneurysms
11504840|NCT01320306||Conservative treatment|A retrospective follow-up of patients receiving conservative (life stile etc.) treatment of un-ruptured aneurysms.
11504841|NCT01320306||Control group of healthy subjects|Control group of healthy subjects
11504842|NCT01320293|Experimental|Adalimumab 40mg|Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA] Dose administered every other week for 6 months
11504843|NCT01320280|Experimental|BIBW 2992 (Afatinib)|BIBW 2992 (Afatinib) 50mg daily continuously (oral medication)
11504844|NCT01320267|Experimental|SILS right hemicolectomy|Single arm with intervention only.
11504845|NCT01320254|Experimental|Cisplatin, Gemcitabine and Panitumumab|Experimental Arm with cisplatin 25mg/sq.m. at day 1 + 8, gemcitabine 1000mg/ sq.m.at day 1 + 8 and panitumumab 9mg/kg BW at day 1. Cycle will be repeated every 3 weeks.
11504846|NCT01320254|Active Comparator|Cisplatin and Gemcitabine|Cisplatin 25mg/sq.m. at day 1 + 8 and Gemcitabine 1000 mg/sq.m. at day 1 + 8. Cycle will be repeated every 3 weeks.
11504847|NCT01320241|Active Comparator|novel radiation stent|"Patients undergo placement of a novel biliary stent loaded with 125I seeds on day 1.
~Intervention: Device: self-expandable 125I radioactive seeds-loaded-stent"
11504848|NCT01320241|Experimental|conventional stent|"Patients undergo placement of a conventional nitinol SEMS on day1.
~Intervention: Device: self-expandable biliary nitinol alloys stent"
11504849|NCT01320228|Placebo Comparator|Control|Alli treatment plus placebo (rice flour)
11504850|NCT01320228|Experimental|Capolac|Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
11504851|NCT01320228|Experimental|Flax fiber|Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
11504852|NCT01320228|Experimental|Capolac+Flax fiber|Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
11504853|NCT01320215|Experimental|Robot arm|The patients in this arm will have a robot-assisted promontofixation.
11504854|NCT01320215|Active Comparator|Non-robot arm|The patients in this arm with have a promotofixation via a laparoscopy, but without robot assistance.
11504855|NCT01320202|Active Comparator|Soluble Ferric Pyrophosphate (SFP) in dialysate|11 micrograms (µg) of iron / deciliter (dL) of dialysate.
11504856|NCT01320202|Placebo Comparator|Standard Dialysate|0 micrograms (µg) of iron / deciliter (dL) of dialysate.
11504857|NCT01320189|Experimental|Protein intake of 5 energy percent|
11504858|NCT01320189|Experimental|Protein intake of 15 energy percent|
11504859|NCT01320189|Experimental|Protein intake of 30 energy percent|
11504860|NCT01320176|Experimental|Group A|Subjects received dose A of the investigational HIV vaccine
11504861|NCT01320176|Experimental|Group B|Subjects received dose B of the investigational HIV vaccine
11504862|NCT01320150||PPP and Non-PPP|Study Subjects with PPP and without PPP at followup
11504863|NCT01320137|Other|Allergy Group|Subjects with ages ranging from 18-45 years and inclusive, presenting symptomatic allergy to birch pollen.
11504864|NCT01320137|Other|Control Group|Subjects with ages ranging from 18-45 years and inclusive, with no known allergies.
11504865|NCT01320124||osteoarthritis, total knee arthroplasty|The main cohort will have a total knee arthroplasty and will not develop a contracture post surgery. We will analyze differntial gene expression in all subjects.
11504866|NCT01320124||contracture post arthroplasty|A small group (1.3%) will develop a contracture post total knee arthroplasty. A second sample will be taken at the time of corrective surgery. The 2 samples will be compared for gene expression in the same subject. This group will also be compared to the main cohort for differential gene expression.
11504867|NCT01320111|Active Comparator|Arm 1: PA|patient is treated with paclitaxel only
11504868|NCT01320111|Experimental|Arm 2: PASO|patient is treated with paclitaxel AND sorafenib
11504869|NCT01320098|Experimental|Home-Based Parenting Program|
11504870|NCT01320098|Experimental|Clinic-Based Parenting Program|
11504871|NCT01320098|Other|Wait-List Control Group|
11504872|NCT01320085|Experimental|BRAFV600 mutant, 45mg bid MEK162|BRAFV600 mutant, 45mg bid MEK162
11504873|NCT01320085|Experimental|NRAS mutant, 45mg bid MEK162|NRAS mutant, 45mg bid MEK162
11504874|NCT01320085|Experimental|BRAFV600 mutant, 60mg bid MEK162|BRAFV600 mutant, 60mg bid MEK162
11504875|NCT01320072||Aspirin-sensitive asthmatics|asthma patients with aspirin allergy
11504876|NCT01320072||aspirin-tolerant asthmatics|asthma patients without aspirin allergy
11504877|NCT01320059|Experimental|Imaging with 18F-PEG6-IPQA|Radioactive injection given by vein before multiple (3) PET scans.
11504878|NCT01320046||Patients with urinary incontinence|Patients attending the urogynecological clinic for urinary incontinence-100 patients. In this group we will recruit patients with UI, and will assess co-existence of VCD
11504879|NCT01320046||Patients with vulvar contact dermatitis|Patients attending the vulvovaginal clinic with vulvar contact dermatitis (100 patients). In this group we will recruit patients with VCD, and will assess co-existence of UI.
11504880|NCT01320046||Age matched control group|"Patients attending the general clinic for annual checkup, which will be matched for age with the two other groups (200 patients).
~These patients will be evaluated for symptoms of UI and VCD"
11504881|NCT01320033|Experimental|CD2475/101 40 mg|Participants receive 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.
11504882|NCT01320033|Active Comparator|Doxycycline 100 mg|Participants receive 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.
11504883|NCT01320033|Placebo Comparator|Placebo|Participants receive matching placebo tablet plus placebo capsule orally once daily for 16 weeks.
11504884|NCT01320020|Experimental|catumaxomab|
11504885|NCT01320007|Experimental|Group 1: Optivol Group|
11504886|NCT01320007|Active Comparator|Group 2: Optivol alarm muted|
11504887|NCT01319994|Experimental|Metformin|Metformin 850mg TDS (12 weeks)
11504888|NCT01319994|Placebo Comparator|Placebo|Placebo 850mg TDS (12 weeks)
11504889|NCT01319981|Experimental|Hyper-CMAD + Rituximab|Odd Courses 1, 3, 5, 7: Rituximab 375 mg/m2 IV Day 1 & 8 Courses 1 & 3; Imatinib oral 600 mg days 1-14 Course 1 then continuously; Cyclophosphamide 300 mg/m2 IV every; 12 hours for 6 doses; Mesna 600 mg/m2/day IV Days 1-3; Doxorubicin 50 mg/m2 IV CVC Day 4; VSLI 2.25 mg/M2 IV Day 1 & 8; Pegfilgrastim 6 mg/kg after chemotherapy + G-CSF 10 µg/kg/day; Dexamethasone 40 mg IV or P.O. daily days 1-4 and days 11-14 +/- 3 days.
11504890|NCT01319981|Experimental|Hyper-CVAD|Courses 2, 4, 6, 8: Rituximab 375 mg/m2 IV Day 1 & 8 Courses 2 & 4; Imatinib oral 600 mg; Methotrexate 200 mg/m2 IV over 2 hours followed by 8-0- mg/m2 over 22 hours on Day 1; Solu-Medrol 40 mg IV hours approximately every 12 hours +/- 2 hours for 6 doses days 1-3 +/- 3 days; Decadron 40 mg IV or orally 4 times Days 1-4; Ara-C 3 gm/m2 IV every 2 hours, 4 doses on Days 2-3; Pegfilgrastim 6 mg/kg after chemotherapy + G-CSF 10 mg/kg/day.
11504891|NCT01319968||Postpartum patients|100 postpartum women attending the clinic for their postpartum visit will be evaluated for vaginal atrophy, vaginal symptoms and dyspareunia.
11504892|NCT01319955|Experimental|Influenza vaccine (trivalent inactivated vaccine)|
11504893|NCT01319955|Active Comparator|Inactivated polio vaccine|
11504894|NCT01319942||Unresectable hepatoma|Unresectable hepatoma, unsuitable for transarterial embolization or local failure after transarterial embolization
11504895|NCT01319929|Experimental|LY2828360 then Placebo|80 milligrams (mg) of LY2828360 daily by mouth for 4 weeks: placebo daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments.
11504896|NCT01319929|Experimental|Placebo then LY2828360|Placebo daily by mouth for 4 weeks: LY2828360 daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments.
11504897|NCT01319890||Right Colectomy for colonic tumors|The group of patients enrolled will be patients with biopsy proven right colon tumors, both benign and malignant. These patients will then be subdivided into those having conventional laparoscopic right colectomy and SILS right colectomy
11504898|NCT01319877||First Line Treatment|Participants received bevacizumab in combination with 5-FU based chemotherapy as a first line therapy.
11504899|NCT01319877||Second Line Treatment|Participants received bevacizumab in combination with 5-FU based chemotherapy as a second line therapy.
11504900|NCT01319864|Experimental|Plerixafor, Dose Escalation|Dose escalation of plerixafor administered intravenously in combination with IV cytarabine and IV etoposide in pediatric patients wtih relapsed/refractory AML/ALL.
11504901|NCT01319851|Experimental|Alefacept|Pediatric subjects with non-malignant diseases (NMD) will receive pre-conditioning with alefacept 0.5 mg/kg/dose i.v. with the first dose split on days -40 and -39 and the remaining doses given on days -33, -26, -19, and -12 (e.g. weekly for 5 doses).
11504902|NCT01319838|Experimental|isotretinoin prolongation|Prolonged treatment with isotretinoin, extending standard 6 month duration to 2 years
11504903|NCT01319812|Experimental|Astron Stent Group|"Participants indicated for stenting in iliac atherosclerotic lesions.
~Intervention: Device: Astron Stents"
11504904|NCT01319812|Experimental|Pulsar Stent Group|"Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.
~Intervention: Device: Pulsar Stents"
11504905|NCT01319799||Surgical aortic valve replacement|Single observational study. Count of microembolic signals during open heart surgery and measurement of properative vs postoperative levels of markers in cerebrospinal fluid of neuronal damge.
11504906|NCT01319786|Other|Low- polyphenol diet|
11504908|NCT01319773|Experimental|cyclosporine ophthalmic emulsion Formulation A (Formulation A)|Parallel-Group Phase (PGP): cyclosporine ophthalmic emulsion Formulation A
11504909|NCT01319773|Experimental|cyclosporine ophthalmic emulsion Formulation B (Formulation B)|PGP: cyclosporine ophthalmic emulsion Formulation B
11504910|NCT01319773|Other|Formulation A and cyclosporine ophthalmic emulsion 0.05%|Paired-Eye Phase (PEP): cyclosporine ophthalmic emulsion Formulation A and cyclosporine ophthalmic emulsion 0.05%
11504911|NCT01319773|Other|Formulation B and cyclosporine ophthalmic emulsion 0.05%|PEP: cyclosporine ophthalmic emulsion Formulation B and cyclosporine ophthalmic emulsion 0.05%
11504912|NCT01319773|Experimental|Formulation A and Formulation B|PEP: cyclosporine ophthalmic emulsion Formulation A and cyclosporine ophthalmic emulsion Formulation B
11504913|NCT01319760|Sham Comparator|Standard of care|Patients in the control arm will be treated with standard of care for post-PCI STEMI patients in accordance with the the 2004 ACC/AHA Guidelines for the Management of Patients with ST-elevation Myocardial Infarction.
11504914|NCT01319760|Experimental|Impella 2.5|24 hours of support with the Impella 2.5 post-PCI for acute myocardial infarction.
11504915|NCT01319747|Active Comparator|Percutaneous therapy|
11504916|NCT01319747|Active Comparator|VATS therapy|
11504917|NCT01319734|Experimental|Vitamin C supplementation plus oral hypoglycemic agents arm|This group will receive vitamin C supplementation 500mg daily for one month and then assessment will done for the patients.
11504918|NCT01319734|Active Comparator|Type 2DM patients receiving oral hypoglycemic agents alone|this group is the control group who receive oral hypoglycemic agents alone
11504919|NCT01319721|Active Comparator|Group LCAG|After extensive excision of recurrent pterygium, intraoperative 0.2 mg/ml MMC (0.02%) for 3 minutes will be applied topically onto the exposed surgical area and then limbal conjunctival autograft for repairing the conjunctival defect.
11504920|NCT01319721|Active Comparator|Group AMG|After excision of recurrent pterygium, intraoperative 0.2 mg/ml MMC (0.02%) for 3 minutes will be applied topically onto the exposed surgical area and then an amniotic membrane graft for repairing the conjunctival defect.
11504921|NCT01319708|Experimental|mild ovarian stimulation|100 mg CC by day 2 till 6, plus antagonist plus gonadotrophin 150-200IO until HCG triggering
11504922|NCT01319708|Active Comparator|conventional ovarian stimulation|300-450 IU of FSH starting by day 2 of menstrual cycle together with a fixed dose of GnRH antagonist starting by day 6 till egg recovery, or same doses using a GnRH agonist long protocol
11504923|NCT01319695|Experimental|corifollitropin alfa|
11504924|NCT01319695|Active Comparator|recombinant follicle stimulating hormone (FSH)|150-300 IU of FSH for ovarian stimulation in women undergoing IVF
11504925|NCT01319682|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
11504926|NCT01319682|Placebo Comparator|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
11504927|NCT01319669|Experimental|Treatment group|rhTPO(recombinant human thrombopoietin) is given on the second, 4th and 9th day of the chemotherapy cycle in a dosage of 15000U once subcutaneously.
11504928|NCT01319669|Active Comparator|Control group|15000U of rhTPO(recombinant human thrombopoietin) is given subcutaneously 6 to 24 hours within the end of chemotherapy cycle, that is, the 8th day for 3 consecutive days (d9 to d11)
11504929|NCT01319656|Active Comparator|Group A|Intervention group(n = 163)
11504930|NCT01319656|Active Comparator|Group B|Delayed intervention (n = 163)
11504931|NCT01319656|No Intervention|Group C|No intervention group (n = 163)
11504932|NCT01319643|Experimental|Oxygenation, rigorous normal|Patients admitted in intensive care unit for 3 days. Administration of the lowest inspiratory fraction dose of oxygen to maintain oxygen peripheral saturation (SpO2) between 94 and 98% or an arterial partial pressure of oxygen (PaO2) between 70 and 100 mmHg. No oxygen addition administer for transports or diagnostic manoeuvres. Conventional clinical criteria for airways control and ventilation technique.
11504933|NCT01319643|No Intervention|Oxygen, free conventional|Patients admitted in intensive care units for 3 days. Administration of oxygen inspiratory fractions to maintain SpO2 over 97%, up to a PaO2 of 150 mmHg. Oxygen addition administer for transports or diagnostic manoeuvres. Conventional clinical criteria for airways control and ventilation technique.
11504934|NCT01319630||Normal Saline|patients with severe sepsis/septic shock randomized to receive 1500 cc of Normal saline bolus as the resuscitation fluid.
11504935|NCT01319630||Albumin|patients with severe sepsis/septic shock randomized to receive 500 cc of Albumin 5% bolus as the resuscitation fluid.
11504936|NCT01319630||HES|patients with severe sepsis/septic shock randomized to receive 500 cc of Hydroxyethyl starch (HES 130kD) bolus as the resuscitation fluid.
11504937|NCT01319617|Experimental|SENSIMED Triggerfish|
11504938|NCT01319604|Experimental|Study device during 3 hours|
11504939|NCT01319604|Experimental|Study device during 6 hours|
11504940|NCT01319604|Experimental|Study device during 9 hours|
11504941|NCT01319604|Experimental|Study device during 12 hours|
11504942|NCT01319604|Experimental|Study device during 15 hours|
11504943|NCT01319604|Experimental|Study device during 18 hours|
11504944|NCT01319604|Experimental|Study device during 21 hours|
11504945|NCT01319604|Experimental|Study device during 24 hours|
11504946|NCT01319604|Active Comparator|Tonometric assessment during 24 hours|
11504947|NCT01319591||CNS lymphoma patients|
11504948|NCT01319578|Active Comparator|Chewing Arm 1|
11504949|NCT01319578|Placebo Comparator|Chewing Arm 2|
11504950|NCT01319578|Active Comparator|Chewing Arm 3|
11504951|NCT01319578|Active Comparator|Chewing Arm 4|
11504952|NCT01319565|Experimental|1/ACT|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young TIL + highdose aldesleukin
11504953|NCT01319565|Experimental|2/ACT+TBI|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young TIL + highdose aldesleukin + TBI
11504954|NCT01319552|Other|Fresh transfusion|1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
11504955|NCT01319552|Experimental|Old transfusion|1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
11504956|NCT01319539|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy (therapeutic conventional surgery) on day 0. Patient samples will be processed for pharmacological study and laboratory biomarker analysis.
11504957|NCT01319513|Experimental|protein feeding|Participants will complete 2 trials in a cross-over fashion in which they will consume whey protein either as a single bolus or as 10 small divided doses
11504958|NCT01319500||Yasmin|"Users of the drospirenone/ethinylestradiol (DRSP/EE) containing OC Yasmin"
11504959|NCT01319500||Other OCs|"Users of OCs except Yasmin (Other OCs)"
11504960|NCT01319487|Experimental|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
11504961|NCT01319487|Experimental|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
11504962|NCT01319487|Placebo Comparator|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
11504963|NCT01319474|Other|Ultrasound for suspected DVT|Enrolled subjects suspected to have deep vein thrombosis undergo whole-leg compression ultrasound. Those with a normal result undergo clinical follow-up for thrombotic outcomes over the following three months.
11504964|NCT01319461|Placebo Comparator|sterile normal saline injection|
11504965|NCT01319461|Experimental|Hyalgan injection|
11504966|NCT01319448|Active Comparator|Daily proguanil|Standard policy of a supply of proguanil tablets to be taken daily
11504967|NCT01319448|Experimental|IPT with MQ+AS bimonthly|Intermittent Preventive Treatment (IPT) consisting of a bimonthly course of treatment with mefloquine-artesunate (MQ+AS)
11504968|NCT01319448|Experimental|IPT with SP+AQ bimonthly|IPT with bimonthly course of treatment with sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ)
11504969|NCT01319435|Other|Pharmacokinetics of ciprofloxacin|Patients receiving ciprofloxacin following clinical decision by attending physician
11504970|NCT01319422|Experimental|Pomalidomide 2 mg/d on 28 days/28 day cycle|
11504971|NCT01319422|Experimental|Pomalidomide 4 mg/d on 21 days/28 day cycle|
11504972|NCT01319409|Experimental|Anatomic Double-Bundle ACL Reconstruction|Subjects in this arm will undergo anatomic double-bundle ACL reconstruction using an autograft quadriceps tendon with a bone block. The graft will be split into 2 strands, 1 to recreate the posterolateral (PL) bundle, the other to recreate the anteromedial (AM) bundle of the ACL. The bone block will be placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft will be placed in tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle will be fixed with the knee in full extension and the AM bundle will be fixed with the knee at 45 degrees of flexion.
11504973|NCT01319409|Active Comparator|Anatomic Single-Bundle ACL Reconstruction|Subjects in this arm will undergo anatomic single-bundle ACL reconstruction using an autograft quadriceps tendon with a bone block. The graft will not be split. The bone block will be placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free end of the graft will be placed in single tunnel located in the center of the tibial ACL insertion site. The graft will be fixed with the knee at 10 20 20 degrees of flexion.
11504974|NCT01319383|Experimental|Open Label, Translational Research|Vorinostat will be administered to all eligible participants in each step of each phase (period) of the study
11504975|NCT01319370|Placebo Comparator|vehicle of 5% Minoxidl topical foam|vehicel foam in twice daily application in temple and vertex region
11504976|NCT01319370|Active Comparator|5% Minoxidil topical foam|5% Minoxidil topical in twice daily application in temple and vertex region
11504977|NCT01319357|Placebo Comparator|Placebo|Placebo
11504978|NCT01319357|Active Comparator|Saxagliptin|saxagliptin 5 mg/day during 6 weeks
11504979|NCT01319344|Experimental|Eplerenone|
11504980|NCT01319331|Experimental|Alpha-1 Antitrypsin (AAT, Aralast NP)|Alpha-1 Antitrypsin (AAT, Aralast NP) as prescribed for study duration
11504981|NCT01319318||Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
11504982|NCT01319305||BREATHE I participatants|
11504983|NCT01319292||Asthma children|children with asthma symptoms through screening
11504984|NCT01319292||normal children|children without symptoms of asthma
11504985|NCT01319279|Experimental|Normal Hepatic Function|Intervention Drug: Hydrocodone bitartrate extended-release tablet
11504986|NCT01319279|Experimental|Moderate Hepatic Impairment|Intervention Drug: Hydrocodone bitartrate extended-release tablet
11504987|NCT01319266|Experimental|Normal Renal Function|Subjects with normal renal function
11504988|NCT01319266|Experimental|Mild Renal Impairment|Subjects with mild renal impairment (defined by an estimated creatinine clearance of > 50 and up to 80 mL/min)
11504989|NCT01319266|Experimental|Moderate Renal Impairment|Subjects with moderate renal impairment (defined by an estimated creatinine clearance of 30-50 mL/min)
11504990|NCT01319266|Experimental|Severe Renal Impairment|Subjects with severe renal impairment (defined by an estimated creatinine clearance of less than 30 mL/min)
11504991|NCT01319266|Experimental|End Stage Renal Disease (ESRD)|Subjects with ESRD (defined as being on hemodialysis for at least 6 months prior to enrollment and be receiving standard in-center dialysis treatments three times a week)
11504992|NCT01319253||Cayston Only Cohort|This cohort will be on a previously established medication regiment of Cayston inhaled antibiotic alternating regimen every other month.
11504993|NCT01319253||Tobi Only Cohort|This Cohort will be on a previously established medication regiment that includes Tobi inhaled antibiotic regimen alternating every other month.
11504994|NCT01319253||Cayston and Tobi Cohort|This Cohort will be on a previously established medication regiment that includes Cayston and Tobi inhaled antibiotic alternating every other month
11504995|NCT01319240|Experimental|IDegLira|
11504996|NCT01319240|Active Comparator|IDeg|
11504997|NCT01319240|Active Comparator|Lira|
11504998|NCT01319227|Experimental|Hip Arthroplasty, ultra-short stem, conventional cup|Hip replacement with a hydroxy-apatite covered ultra-short uncemented femoral stem and a conventional uncemented acetabular cup with hydroxy-apatite covered porous coating and a moderately cross-linked polyethylene cup liner
11505093|NCT01318642|Experimental|AMG 479 20 mg/kg + Gemcitabine|ARM 1: AMG 479 20mg/kg IV days 1 and 15 plus gemcitabine 1000mg/m2 IV days 1, 8, and 15 of a 28 day cycle.
11505094|NCT01318616|Experimental|Training group|
11504999|NCT01319227|Experimental|Hip Arthroplasty, conventional stem, trabecular-titanium cup|Hip replacement with an uncemented tapered femoral stem and an uncemented acetabular cup with trabecular-Titanium backside and E-vitamin-treated polyethylene cup liner
11505000|NCT01319214|Experimental|Inderal, neutral cues|
11505001|NCT01319214|Experimental|Inderal, drug cues|
11505002|NCT01319214|Experimental|Placebo, neutral cues|
11505003|NCT01319214|Experimental|Placebo, drug cues|
11505004|NCT01319201||Impaired glucose regulation|This group of subjects was diagnosed as impaired glucose regulation using oral glucose tolerance test.
11505005|NCT01319201||Type 2 diabetes|This group of subjects was diagnosed as type 2 diabetes using oral glucose tolerance test.
11505006|NCT01319201||Normal glucose regulation|This group of subjects was considered normal regarding glucose metabolism using oral glucose tolerance test.
11505007|NCT01319188|Active Comparator|0.5 mg of ranibizumab|
11505008|NCT01319188|Active Comparator|injection + photodynamic therapy|
11505009|NCT01319188|Sham Comparator|Sham injection|
11505010|NCT01319175|Experimental|Training group|
11505011|NCT01319162||Women with PCOS|All obese women between 18 and 50 years diagnosed with PCOS referred to a weight reduction treatment program at the Sahlgrenska Obesity Center at Sahlgrenska University hospital
11505012|NCT01319162||Women without PCOS|All obese women between 18 and 50 years not diagnosed with PCOS referred to a weight reduction treatment program at the Sahlgrenska Obesity Center at Sahlgrenska University hospital
11505013|NCT01319149||No treatment|Patient records would be extracted from the electronic health record system of Southwest Regional Wound Care Center and placed in a separate bin.
11505014|NCT01319123|Other|wound dressing|The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers.
11505015|NCT01319110|Experimental|CoenzymeQ10|Patients will receive CoenzymeQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
11505016|NCT01319110|Placebo Comparator|Placebo|Patients will receive 20 ml chocolate Ensure (as a placebo) three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). Placebo will be given through pre-existing NG or OG tube.
11505017|NCT01319097|Other|Sorbion Sachet S|Subject will evaluate Sorbion Sachet S dressing for 4 weeks.
11505018|NCT01319084||ARMES group|Surgeons who watch Tilepro program before da Vinci Robotic Surgery.
11505019|NCT01319084||normal group|Surgeons who do not watch Tilepro program before da Vinci Robotic Surgery.
11505020|NCT01319071||Top-level athletes|
11505021|NCT01319071||Control group|
11505022|NCT01319058|Active Comparator|Electrocautery tonsillectomy|Children undergoing tonsillectomy and adenoidectomy for obstructive sleep apnea
11505023|NCT01319058|Active Comparator|Debrider tonsillotomy|Children undergoing debrider tonsillotomy + adenoidectomy for obstructive sleep apnea.
11505024|NCT01319058|Active Comparator|Laser tonsillotomy|Children undergoing laser tonsillotomy + adenoidectomy for obstructive sleep apnea.
11505025|NCT01319045|Experimental|Iloprost|Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.
11505026|NCT01319032||I. Top-level swimmers|
11505027|NCT01319032||II. Control|Other swimmers
11505028|NCT01319019|Experimental|GSK961081 100 mcg QD|
11505029|NCT01319019|Experimental|GSK961081 100mcg BD|
11505030|NCT01319019|Experimental|GSK961081 200mcg QD|
11505031|NCT01319019|Experimental|GSK961081 400mcg QD|
11505032|NCT01319019|Experimental|GSK961081 400mcg BD|
11505033|NCT01319019|Experimental|GSK961081 800mcg QD|
11505034|NCT01319019|Active Comparator|Salmeterol 50mcg BD|
11505035|NCT01319019|Placebo Comparator|Placebo|
11505036|NCT01319006|Experimental|GSK1278863A 100mg (X90=13um)|single dose
11505037|NCT01319006|Experimental|GSK1278863A 100mg (x90=29Um)|single dose
11505038|NCT01319006|Experimental|GSK1278863 100mg (X90=41um)|single dose
11505039|NCT01318993|Experimental|GSK1605786A|500 milligrams twice daily
11505040|NCT01318980|Experimental|Period 1 Cohort 1 - GSK2190915 100mg|Period 1 - GSK2190915 100mg tablet.
11505041|NCT01318980|Experimental|Period 1 Cohort 2 - GSK2190915 100mg plus microtracer|Period 1 - GSK2190915 100mg tablet plus [14C] radiolabelled GSK2190915 microtracer solution.
11505042|NCT01318980|Experimental|Period 2 GSK2190915 100mg to proximal small bowel|100mg of ground half 200mg GSK2190915 tablet administered to the proximal small bowel via Enterion capsule.
11505043|NCT01318980|Experimental|Period 3 GSK2190915 100 mg to distal small bowel|100mg of ground half 200mg GSK2190915 tablet administered to the distal small bowel via Enterion capsule.
11505044|NCT01318980|Experimental|Period 4 - GSK 100mg enteric-coated tablet|100mg enteric-coated GSK2190915 coated tablet.
11505045|NCT01318967|Placebo Comparator|PAH|PAH measure of renal blood flow is first performed on subjects prior to administration of furosemide
11505046|NCT01318967|Active Comparator|MRI after furosemide|After the PAH measurement is complete, subjects receive 20 mg furosemide and undergo BOLD MRI to estimate renal blood flow
11505047|NCT01318954||Subjects on allergen immunotherapy|Measurements of Nitric Oxide by NIOX MINO. This device is now FDA approved.
11505048|NCT01318941||Ranibizumab|
11505049|NCT01318928|Placebo Comparator|Periodontal intervention, sugar pill|Group 1: metronidazole + mechanical treatment in one day, Group 2: Placebo + mechanical treatment in one day Group 3: metronidazole + mechanical treatment on day 1 and 21 Group 4: Placebo + mechanical treatment on day 1 and 21
11505050|NCT01318915|Experimental|Induction (Rituximab and ATG)|Study participants will undergo induction with rituximab and ATG and an initial maintenance therapy with tacrolimus, mycophenolate mofetil (MMF) and sirolimus. MMF will be discontinued on day 12. Participants will be evaluated for eligibility for tacrolimus withdrawal which must be initiated between weeks 26 and 38. Tacrolimus withdrawal must be completed in no fewer than 4 weeks and no more than 8 weeks. Then after at least 26 weeks on sirolimus monotherapy, participants will be evaluated for eligibility for sirolimus withdrawal which must be initiated between weeks 56 and 88. Sirolimus withdrawal must be completed in no fewer than 12 weeks and no more than 26 weeks.
11506217|NCT01310686||Wet AMD Non-Responders to Anti-VEGF|
11505051|NCT01318902|Experimental|Dose Escalation Cohort: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsule, orally, once weekly on Days 1, 8 and 15 during each 28-day treatment cycle for 3 cycles. If there was no hematologic response, dexamethasone 40 mg, tablet, orally was added once on Days 1 to 4 of every cycle, beginning in Cycle 4 for 3 additional cycles. If there was no hematologic response the participant was discontinued. Participants with hematologic response continued treatment up to maximum 12 cycles.
11505052|NCT01318902|Experimental|Dose Escalation Cohort: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsule, orally, once weekly on Days 1, 8 and 15 during each 28-day treatment cycle for 3 cycles. If there was no hematologic response, dexamethasone 40 mg, tablet, orally was added once on Days 1 to 4 of every cycle, beginning in Cycle 4 for 3 additional cycles. If there was no hematologic response the participant was discontinued. Participants with hematologic response continued treatment up to maximum 12 cycles.
11505053|NCT01318902|Experimental|Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)|Ixazomib 4.0 mg, capsule, orally, on Days 1, 8 and 15 during a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity, for participants with relapsed or refractory amyloidosis and who were not treated with any other proteasome inhibitor (PI). Duration of treatment was up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months.
11505054|NCT01318902|Experimental|Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)|Ixazomib 4.0 mg, capsule, orally, on Days 1, 8 and 15 during a 28-day treatment cycle until PD or unacceptable toxicity, for participants with relapsed or refractory amyloidosis and who were previously treated with any other PI. Duration of treatment was up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months.
11505055|NCT01318889|Experimental|normal saline|mouth wash of normal saline ,three times a day, 10 cc each time
11505056|NCT01318876||BC Children's and Women's Hospital, Vancouver.|
11505057|NCT01318876||University of British Columbia, Vancouver.|
11505058|NCT01318876||Health care workers in Halifax|
11505059|NCT01318876||Health care workers from CHUQ hospitals|
11505060|NCT01318876||Health care workers from Toronto|
11505061|NCT01318876||Centre hospitalier et universitaire de Sherbrooke|
11505062|NCT01318876||The Ottawa General Hospital, Ottawa|
11505063|NCT01318850|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Therapy -Frontal/Executive Program (Delahunty)- (Wykes and Reeder, 2005)
11505064|NCT01318850|Active Comparator|Psychoeducation|Symptom Management Module from the University of California. Liberman & Kopelowicz (1995)
11505065|NCT01318850|Other|Healthy Controls|Healthy controls
11505066|NCT01318837|Experimental|sofilenacin group|
11505067|NCT01318837|No Intervention|control group|age and sex matched patients without OAB symptom who will answer demographic questionaire and OABSS once
11505068|NCT01318824|Placebo Comparator|I=NIPPV|This group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment.
11505069|NCT01318824|Experimental|II=BiPAP|This group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
11505070|NCT01318811|Active Comparator|Dilute heparin|Arm A will receive dilute heparin delivered as an intravenous infusion proximal to the dialysis filter.
11505071|NCT01318811|Active Comparator|Standard concentrated heparin|Arm B will receive standard concentrated heparin and will be delivered as an intravenous infusion proximal to the dialysis filter.
11505072|NCT01318798||Patients with post-operative ARF|"Patients developing acute renal failure (ARF) following liver surgery
~ARF was defined according to the RIFLE criteria as an absolute increase in serum-creatinine of more than 0.3 mg/dl above baseline, or an increase of more than 1.5 times the pre-operative baseline value within 48 hours after surgery, or a reduction of urinary output less than 0.5 ml/kg/h for at least 6 hrs."
11505073|NCT01318798||Patients without post-operative ARF|Patients with normal kidney function (without acute renal failure (ARF)) following liver surgery
11505074|NCT01318785|Active Comparator|Compression ArmsleevesType A|Product A: armsleeves of type SoraLife KKl. 2 according to RAL GZ 387
11505075|NCT01318785|Active Comparator|Compression Armsleeves Type B|Product B: armsleeves of type Elvarex KKl. 2 according to RAL GZ 387
11505076|NCT01318772||Fluoroscopy and Angiography Procedure|Patient that have been scheduled for routine diagnostic fluoroscopy and angiography procedures by their physician.
11505077|NCT01318746||Healthy group|15 persons with normal renal function
11505078|NCT01318746||Renal failure|15 persons with renal failure (GFR < 60 ml/min)
11505079|NCT01318733|Experimental|CD07805/47 Gel 0.5%|
11505080|NCT01318720|Experimental|Manipulation|The experimental group is receiving thoracic spine thrust manipulation and cervical spine non-thrust manipulation.
11505081|NCT01318694|Experimental|Treatment Arm A|"Alisporivir (ALV) 600 mg twice daily (BID) with Peginterferon alfa-2a (PEG) and ribavirin (RBV) for 1 week, followed by an additional 23 or 47 weeks according to response-guided treatment duration (RGT):
~Participants with a viral load below the level of detection (< LOD) at Week 4 stop study treatment after 24 weeks
~Participants with a viral load ≥ LOD at Week 4 complete 48 weeks of study treatment"
11505082|NCT01318694|Experimental|Treatment Arm B|Alisporivir (ALV) 400 mg twice daily (BID) with PEG and RBV for 24 or 48 weeks according to response-guided treatment duration (RGT)
11505083|NCT01318694|Experimental|Treatment Arm C|Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg once daily (QD) for 47 weeks
11505084|NCT01318694|Active Comparator|Treatment Arm D|ALV Placebo with PEG and RBV for 48 weeks
11505085|NCT01318681|Experimental|Pollen provocation with systemic treatment|Subjects are treated with Cetirizine 10 mg after a nasal challenge with a pollen solution
11505086|NCT01318681|Experimental|Pollen provocation with topical treatment|treatment with 25ug fluticasone furoate after a nasal pollen challenge
11505087|NCT01318681|Placebo Comparator|placebo treatment after pollen challenge|Placebo treatment after a nasal challenge with pollen solution
11505088|NCT01318681|No Intervention|control condition|A placebo drug is administered after a sham nasal challenge with a pollen solution
11505089|NCT01318668|Experimental|Nicotine vaccination|18 week treatment with Nicvax
11505090|NCT01318655|Experimental|NKTR-118|
11505091|NCT01318655|Placebo Comparator|Placebo|
11505092|NCT01318642|Active Comparator|Placebo + Gemcitabine|Arm 2: AMG479-placebo IV days 1 and 15 plus gemcitabine 1000mg/m2 IV days 1, 8, and 15 of a 28 day cycle
11505095|NCT01318590|Experimental|Celiac bloc|The experimental arm will consist of the fractional injection on both sides of the celiac trunk, via EUS, of a local anesthetic (10 ml of Bupivacaine 0.5% (gr / ml)) and an injection of steroids (Triamcinolone 40 mg). In this group antibiotic prophylaxis will be administered after administration of sedation (Cephazolin 1gr IV or Gentamycin).
11505096|NCT01318590|Sham Comparator|Conservative treatment|Subject will undergo standard EUS without any additional interventions.
11505097|NCT01318577|Experimental|Investigational Solution|Hydrogen peroxide system for cleaning, protein removal, disinfecting and storing of contact lenses.
11505098|NCT01318577|Active Comparator|Clear Care Solution|Hydrogen peroxide system for cleaning, protein removal, disinfecting and storing of contact lenses
11505099|NCT01318564||Group 1: Unit-dose - Pill Bottle|Unit-dose (blister) packages used first week, followed second week by pill bottles usage.
11505100|NCT01318564||Group 2: Pill Bottle - Unit Dose|Pill bottle usage the first week followed second week by Unit-dose (blister) packages.
11505101|NCT01318551|Experimental|Arm 1|
11505102|NCT01318551|Experimental|Arm 2|
11505103|NCT01318551|Experimental|Arm 3|
11505104|NCT01318538|Experimental|Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
11505105|NCT01318538|Active Comparator|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
11505106|NCT01318525|Experimental|ALF-5755|
11505107|NCT01318525|Placebo Comparator|Saline solution (0.9% NaCl)|
11505108|NCT01318512||Chronic Kidney Disease|Participants with CKD, not undergoing haemodialysis in clinical practice setting and started treatment with methoxy polyethylene glycol-epoetin beta (MIRCERA) subcutaneously (SC) as per summary of product characteristics (SPC) due to decreased levels of haemoglobin.
11505109|NCT01318499|Experimental|Nepafenac 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
11505110|NCT01318499|Active Comparator|Nepafenac 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
11505111|NCT01318499|Placebo Comparator|Nepafenac Vehicle 0.3%|Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
11505112|NCT01318486|Active Comparator|Heparin free dialysis standard of care|Standard of care: can be either saline flushes or predilution (on-line or bags)
11505113|NCT01318486|Experimental|Heparin free dialysis with Evodial|
11505114|NCT01318473|Other|ActiSight™ Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
11505115|NCT01318460|Active Comparator|Levosimendan|Patients treated with prophylactic administration of levosimendan
11505116|NCT01318460|Placebo Comparator|Placebo group|Patients managed with placebo administration
11505117|NCT01318447|Experimental|CyberKnife SBRT|
11505118|NCT01318434|Experimental|EB-1010 25 mg BID|Experimental Active
11505119|NCT01318434|Experimental|EB-1010 50 mg BID|Experimental Active
11505120|NCT01318434|Active Comparator|SSRI/SNRI|Active Comparator
11505121|NCT01318434|Placebo Comparator|EB-1010 0 mg BID|Placebo comparator
11505122|NCT01318421|Experimental|ELND002|ELND002 sc injection
11505123|NCT01318408|Experimental|Levetiracetam|Levetiracetam was titrated over 4 weeks, with initial dosing of 250 mg bis in die (BID). Dosing was flexible and was based on the prescribing physician's discretion.
11505124|NCT01318395|Active Comparator|Aliskiren|
11505125|NCT01318395|Placebo Comparator|Placebo|
11505126|NCT01318382|Experimental|TOF-Watch SX®|Participants who have undergone elective open or laparoscopic abdominal surgery, received general anesthesia, received at least one dose of non-depolarizing neuromuscular blocker and had the extent of their recovery from NMB monitored by a TOF-Watch SX®.
11505127|NCT01318369|Experimental|Namisol|Namisol (dronabinol) single dose 8 mg
11505128|NCT01318369|Active Comparator|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
11505129|NCT01318356|Experimental|Cognitive behavioral therapy|
11505130|NCT01318356|Experimental|Doxycycline|
11505131|NCT01318356|Placebo Comparator|Placebo|
11505132|NCT01318343||Treatment Group 1|Eight (8) subjects will receive one (1) treatment with the eZ8 Large Applicator.
11505133|NCT01318343||Treatment Group 2|Eight (8) subjects will receive two (2) treatments two (2) months apart with the eZ8 Large Applicator.
11505134|NCT01318343||Treatment Group 3|Four (4) subjects will receive one (1) treatment, six (6) months after the previous treatment with the eZ App 8 large applicator to the abdomen. This is the same applicator that is being evaluated in this study. These subjects have been treated on-site at the Laser & Skin Surgery Center of New York by the study doctor.
11505135|NCT01318317|Experimental|Treatment (cellular adoptive immunotherapy following PBSCT)|Patients receive standard salvage chemotherapy per standard practice and undergo standard mobilization for stem cell collection with Granulocyte-Colony Stimulating Factor (G-CSF) and/or plerixafor. Some patients may also receive rituximab IV within 4 weeks of transplantation. Patients receive standard myeloablative conditioning followed by autologous Peripheral Blood Stem Cell Transplant (PBSCT). Patients then undergo infusion of ex vivo expanded autologous central memory (TCM)-enriched CD8+ T cells expressing CD19-specific chimeric antigen receptor (CAR) on day 2 or 3 after transplantation.
11505136|NCT01318304||Pregnant, HIV- negative|This cohort has completed accrual as of 12/28/11.
11505137|NCT01318304||Pregnant, HIV-positive|
11505138|NCT01318304||Non-pregnant, HIV-negative|This cohort has completed accrual as of 12/28/11.
11505139|NCT01318304||Non-pregnant, HIV-positive|This cohort has completed accrual as of 12/28/11.
11505140|NCT01318291|Placebo Comparator|Control|
11505141|NCT01318291|Experimental|CCRI Group|
11505142|NCT01318278|Active Comparator|Dopamine treatment|Dopamine treatment beginning at 5 mcg/kg/min and titrated by 5 mcg/kg/min to effect up to maximum of 20 mcg/kg/min
11505143|NCT01318278|Active Comparator|Vasopressin treatment|Arginine Vasopressin treatment beginning at 0.01 units/kg/hr and titrated up by 0.01 units/kg/hr to effect up to a maximum of 0.04 units/kg/hr
11505144|NCT01318278|No Intervention|Comparison Arm|Infants who did not require vasopressor support for hypotension during the first 24 hours of life
11505145|NCT01318265|Experimental|Arm1|
11505146|NCT01318252|Experimental|AL-54478|AL-54478 0.005%, single dose, followed 7 days later with 14 days of once daily dosing
11505147|NCT01318252|Active Comparator|Latanoprost|Latanoprost 0.005%, single dose, followed 7 days later with 14 days of once daily dosing
11505148|NCT01318252|Placebo Comparator|Vehicle|AL-54478 Vehicle, single dose, followed 7 days later with 14 days of once daily dosing
11505149|NCT01318239|Experimental|Standard Chemotherapy with Avastin|
11505150|NCT01318239|Active Comparator|Standard Chemotherapy only|
11505151|NCT01318226|Placebo Comparator|Placebo|Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
11505152|NCT01318226|Experimental|ATx08-001 2.5 mg bid|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg, twice a day approximately every 12 hours over an 8 day period.
11505153|NCT01318226|Experimental|ATx08-001 7.5 mg bid|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
11505154|NCT01318213||Intervention Arm|The intervention will consist of wearing gloves and gowns for all patient contact in the ICUs that are randomized to receive the intervention. During the intervention phases of the study, all healthcare workers (nurses, physicians, nurse extenders, respiratory therapists, social workers etc.) in the intervention group will be required to wear gloves and gowns for patient contact and when entering any patient room. In essence, healthcare workers will apply the CDC Contact Precautions guidelines for ALL patients.
11505155|NCT01318213||Non-intervention - Usual Standard of Care|The non-intervention units will follow their present standard of care. For all of these units, this will consist of healthcare workers following Contact Precautions (gloves and gowns) only for patients known to have antibiotic-resistant bacteria such as VRE and MRSA based on previous admission clinical and surveillance cultures or clinical cultures from the present admission. This represents on average 20-25% of patients on Contact Precautions. For the rest of the patients standard precautions will be followed.
11505156|NCT01318200|Active Comparator|Transarterial Chemoembolization|
11505157|NCT01318200|Active Comparator|CyberKnife SBRT|
11505158|NCT01318187|Experimental|Paracetamol|
11505159|NCT01318187|Active Comparator|Morphine|
11505160|NCT01318161|Experimental|Epidural anesthesia and analgesia|
11505161|NCT01318161|Active Comparator|Patient controlled analgesia|
11505162|NCT01318148|Experimental|Caspofungin|
11505163|NCT01318135|Active Comparator|Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID|
11505164|NCT01318135|Active Comparator|Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID|
11505165|NCT01318135|Active Comparator|Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID|
11505166|NCT01318135|Active Comparator|Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID|
11505167|NCT01318122|Active Comparator|Alogliptin 12.5 mg QD and Pioglitazone 15 or 30 mg QD|
11505168|NCT01318122|Active Comparator|Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD|
11505169|NCT01318109|Active Comparator|Alogliptin 12.5 mg QD and metformin 500mg BID or 750mg TID|
11505170|NCT01318109|Active Comparator|Alogliptin 25mg QD and metformin 500mg BID or 750mg TID|
11505171|NCT01318109|Active Comparator|Metformin 500mg BID or 750mg TID|
11505172|NCT01318096|Experimental|A:Raltegravir + tenofovir+lamivudine|
11505173|NCT01318096|Active Comparator|B:Efavirenz+tenofovir+lamivudine|
11505174|NCT01318083|Active Comparator|Alogliptin 12.5 mg QD and Glimepiride QD or BID|
11505175|NCT01318083|Active Comparator|Alogliptin 25 mg QD and Glimepiride QD or BID|
11505176|NCT01318083|Active Comparator|Glimepiride 1, 2, 3 or 4 mg QD or BID|
11505177|NCT01318070|Experimental|Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD|
11505178|NCT01318070|Experimental|Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD|
11505179|NCT01318070|Active Comparator|Pioglitazone (15mg or 30mg ) QD|
11505180|NCT01318057||Wild-Type|Wild-Type are those individuals who were non-carriers of any functional (loss-of-function)variant in CYP2C9 and/or VKORC1 genes
11505181|NCT01318057||Carriers|Those patients who were identified as having any functional CYP2C9 and/or VKORC1 polymorphism
11505182|NCT01318044|Active Comparator|Propofol group: propofol|
11505183|NCT01318044|Active Comparator|Thiopental group: thiopental|
11505184|NCT01318031|Experimental|DDI|
11505185|NCT01318018||Magnetic Seizure Therapy Group|Patients receiving magnetic seizure therapy for depression
11505186|NCT01318018||Electroconvulsive Therapy Group|Patients receiving electroconvulsive therapy for depression
11505187|NCT01318005|Active Comparator|Ortho-Novum® 1/35|Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.
11505188|NCT01318005|Active Comparator|Ovcon® 35|Ovcon® 35 is an oral contraceptive that contains less progestin.
11505189|NCT01318005|Active Comparator|Microgestin Fe® 1/20|is an oral contraceptive that contains less estrogen.
11505190|NCT01317992|Experimental|Ibudilast|To receive ibudilast 40mg twice daily for 8 weeks.
11505191|NCT01317992|Placebo Comparator|Placebo|To receive placebo twice daily for 8 weeks.
11505192|NCT01317979||Diabetes group I|metabolic surgery, laparoscopicly
11505193|NCT01317966||rhIL-11Combinating Low-dose Rituximab|"rhIL-11 (interleukin-11, Juheli) 50 mcg/kg subcutaneously daily for 14 days
~Rituximab 100mcg weekly for 4 weeks"
11505194|NCT01317940|Experimental|Group A (Newly Diagnosed Subjects)|
11505195|NCT01317940|No Intervention|Standard of Care Group A|
11505196|NCT01317940|Experimental|Group B (Early Survivors)|
11505197|NCT01317940|No Intervention|Observation Only - Group B|
11505198|NCT01317940|No Intervention|Group C (Siblings of Group A)|
11505199|NCT01317927|Experimental|Warfarin, Belinostat|Warfarin 5 mg po will be given on Day -14 and Day 3. Belinostat 1000 mg/m² will be given as a 30 minute IV infusion on Days 1 - 5
11505200|NCT01317914|Experimental|Dietary instruction on Gluten Free Diet|
11505201|NCT01317901|Experimental|TRU-016+bendamustine+rituximab|Two dose levels (10 and 20 mg/kg) of TRU 016 combined with rituximab 375 mg/m2 and bendamustine 90 mg/m2 were evaluated during up to 6 cycles (28 days each). TRU-016 was administered by intravenous (IV) infusion on Days 1 and 15 of each cycle. Rituximab was administered by IV infusion on Day 2 of each cycle. Bendamustine was administered by IV infusion on Days 1 and 2 of each cycle. Subjects received study treatment for up to 6 cycles.
11505202|NCT01317888|Experimental|Treated with MAB-425|All patients receive the same treatment of MAb-425 +Iodine 125 in a total of three injections.
11505203|NCT01317875|Experimental|Ruxolitinib|
11505204|NCT01317862|Active Comparator|Transcervical foley catheter|
11505205|NCT01317862|Active Comparator|Prostaglandins|
11505206|NCT01317849|Experimental|vitamin supplements|
11505207|NCT01317849|Placebo Comparator|Placebo|
11505208|NCT01317836||Patients having pancreatic cystic lesion|
11505209|NCT01317823|Active Comparator|Bishop score|
11505210|NCT01317823|Active Comparator|transvaginal ultrasound|
11505211|NCT01317810||Subjects with Overactive Bladder (OAB)|Combination of new OAB subjects and existing subjects on OAB medication
11505212|NCT01317797|Experimental|Namilumab 150 mg|Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.
11505213|NCT01317797|Experimental|Namilumab 300 mg|Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.
11505214|NCT01317797|Placebo Comparator|Placebo|Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.
11505215|NCT01317784|Experimental|All tests.|Choose from all 16 possible tests.
11505216|NCT01317784|Active Comparator|HIV/HCV|Choice of 10 different HIV and hepatitis C tests in the bundle.
11505217|NCT01317784|Active Comparator|HIV/Syphilis|Choice of 7 different tests for HIV and syphilis.
11505218|NCT01317784|Active Comparator|HIV only|Choice of 4 rapid tests for HIV only.
11505219|NCT01317771||Proximal Biceps Tendon Tenodesis|
11505220|NCT01317758|Placebo Comparator|Group 6|Two doses of sanofi H5N1 antigen 15 mcg plus PBS diluent
11505221|NCT01317758|Placebo Comparator|Group 5|Two doses of sanofi H5N1 antigen 7.5 mcg plus PBS diluent
11505222|NCT01317758|Placebo Comparator|Group 4|Two doses of sanofi H5N1 antigen 3.75 mcg plus Phosphate Buffered Saline (PBS) diluent
11505223|NCT01317758|Experimental|Group 3|Two doses of sanofi H5N1 antigen 15 mcg plus GSK AS03 adjuvant
11505224|NCT01317758|Experimental|Group 1|Two doses of sanofi H5N1 antigen 3.75 mcg plus GSK AS03 adjuvant
11505225|NCT01317758|Experimental|Group 2|Two doses of sanofi H5N1 antigen 7.5 mcg plus GSK AS03 adjuvant
11505226|NCT01317745|Placebo Comparator|Group 5|Two doses of sanofi H5N1 antigen 7.5 mcg plus PBS diluent
11505227|NCT01317745|Placebo Comparator|Group 4|Two doses of sanofi H5N1 antigen 3.75 mcg plus Phosphate Buffered Saline (PBS) diluent
11505228|NCT01317745|Experimental|Group 3|Two doses of sanofi H5N1 antigen 15 mcg plus Novartis MF59 adjuvant
11505229|NCT01317745|Experimental|Group 2|Two doses of sanofi H5N1 antigen 7.5 mcg plus Novartis MF59 adjuvant
11505230|NCT01317745|Experimental|Group 1|Two doses of sanofi H5N1 antigen 3.75 mcg plus Novartis MF59 adjuvant
11505231|NCT01317745|Placebo Comparator|Group 6|Two doses of sanofi H5N1 antigen 15 mcg plus PBS diluent
11505232|NCT01317732|Experimental|MOTIONPOD (TM)|
11505233|NCT01317719||Distal Biceps Ruptures|
11505234|NCT01317706|Active Comparator|Bishop score|
11505235|NCT01317706|Active Comparator|transvaginal ultrasound|
11505236|NCT01317693|Experimental|Treatment LI-ESWT|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
11505237|NCT01317680|Active Comparator|Treatment LI-ESWT|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
11505238|NCT01317680|Placebo Comparator|Sham control|We use the same probe that induces the same sensation on the penis and the same noise yet no energy.
11505239|NCT01317667|Experimental|Group 1|RVEc vaccine 20 μg/dose x 3 doses
11505240|NCT01317667|Experimental|Group 2|RVEc vaccine 50 μg/dose x 3 doses
11505241|NCT01317667|Experimental|Group 3|RVEc vaccine 100 μg/dose x 1 dose
11505242|NCT01317654||Survivors of TBM trial 2001-2005|
11505243|NCT01317641|Experimental|ODM-201 Phase I|
11505244|NCT01317641|Experimental|ODM-201 Phase II Dose 1|
11505245|NCT01317641|Experimental|ODM-201 Phase II Dose 2|
11505246|NCT01317641|Experimental|ODM-201 Phase II Dose 3|
11505292|NCT01317290|Experimental|linseed oil; young|ALA rich linseed oil to younger subjects (18-35 years)
11505293|NCT01317290|Experimental|linseed oil; older|ALA rich linseed oil to older, normalweight subjects (BMI <25, age 49-69 years)
11505247|NCT01317628|Other|Lifestyle counseling|Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.
11505248|NCT01317615|Experimental|RAD001 plus paclitaxel/carboplatin|Participants received RAD001 5 mg orally once daily in combination with carboplatin and paclitaxel for a maximum 4 cycles or until discontinuation.
11505249|NCT01317589|Active Comparator|fentanyl|active pain treatment with fentanyl patch
11505250|NCT01317589|Experimental|methadone|active pain treatment with methadone
11505251|NCT01317576|Experimental|Healthy control|This group will exist of healthy obese that are matched for BMI and age with the type 2 diabetes group and non-alcoholic fatty liver disease group.
11505252|NCT01317576|Experimental|Non-alcoholic fatty liver disease|This group will exist of people that suffer from non-alcoholic fatty liver disease. They will be matched for BMI and age according to the Type 2 diabetes group
11505253|NCT01317576|Experimental|Type 2 diabetes patients|This group will exist of patients that suffer from type 2 diabetes
11505254|NCT01317563|Active Comparator|Antioxidant arm|Two capsules twice daily (total daily dose = Vitamin A 10000 IU, Vitamin C 1200mg, Vitamin E 400 IU, Selenium 300mcg)
11505255|NCT01317563|Placebo Comparator|Placebo arm|two capsules twice daily (total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose)
11505256|NCT01317550|Experimental|Armodafinil + Placebo|Armodafinil orally 150 mg/day + Placebo capsules for 10 weeks
11505257|NCT01317550|Experimental|Minocycline + Placebo|Minocycline orally 100 mg twice/day + Placebo capsules for 10 weeks
11505258|NCT01317550|Experimental|Armodafinil + Minocycline|Armodafinil orally 150 mg/day for 10 weeks + Minocycline orally 100 mg twice/day for 10 weeks
11505259|NCT01317550|Placebo Comparator|Placebos|Placebo Capsules orally once/day for 10 weeks
11505260|NCT01317537|Experimental|Received personal health record|received personal health record access
11505261|NCT01317537|No Intervention|No personal health record|did not receive personal health record
11505262|NCT01317524|Experimental|Homogenized Milk|900 mL homogenized milk is consumed within a mixed meal
11505263|NCT01317524|Experimental|Unhomogenized Milk|900 mL unhomogenized milk is consumed within a mixed meal
11505264|NCT01317524|Experimental|Skimmed Milk|900 mL skimmed milk and 44 g of butter are consumed within a mixed meal
11505265|NCT01317511|Experimental|Protein|Protein drink
11505266|NCT01317511|Placebo Comparator|Placebo|water
11505267|NCT01317498|Placebo Comparator|Standard Monitoring|The patients in the standard monitoring arm will receive routine laboratory monitoring as provided to all patients in public HIV clinics in Vietnam, including CD4 count, complete blood count, and liver functions tests every 6 months.
11505268|NCT01317498|Active Comparator|Virological Monitoring|The patients in the virological monitoring arm will have routine laboratory monitoring as in the standard monitoring arm and in addition will have a viral load test performed every 6 months while in treatment. The first test will be done 6 months after initiating ART.
11505269|NCT01317485|Experimental|Purulent peritonitis|"Patients with purulent peritonitis are randomised at a 2:1:1 ratio between
~Laparoscopic lavage and drainage
~Sigmoidectomy with primary anastomosis
~Sigmoidectomy with end-colostomy"
11505270|NCT01317485|Experimental|Fecal peritonitis or overt perforation|"Patients with fecal peritonitis or an overt perforation are randomised between
~Sigmoidectomy with primary anastomosis
~Sigmoidectomy with end-colostomy"
11505271|NCT01317472|Experimental|Dexlansoprazole|Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC).
11505272|NCT01317472|Placebo Comparator|Sugar pill|Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC) or 1 tablet of placebo QAM (1 hour AC).
11505273|NCT01317459|Experimental|Lifestyle counselling|
11505274|NCT01317459|Experimental|No intervention|Care as usual
11505275|NCT01317446|Experimental|amine fluoride/stannous fluoride|Amine fluoride/stannous fluoride mouthrinse in addition to mechanical oral hygiene
11505276|NCT01317446|No Intervention|No rinsing|Mechanical oral hygiene only
11505277|NCT01317433|Experimental|Arm A|Intensified FOLFIRI plus Cetuximab + Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks + skin moisturizers (Dexeryl), sun protection.
11505278|NCT01317433|Active Comparator|Arm B|Intensified FOLFIRI plus Cetuximab + skin moisturizers (Dexeryl), sun protection.
11505279|NCT01317420|Experimental|Monotherapy|BI 836845 dose escalation, infusion, once every three weeks, monotherapy
11505280|NCT01317381||ICU patients|Admitted patients to the ICU
11505281|NCT01317368|Active Comparator|TAP block|"TAP block with Ropivacaine
~Wound infiltration with Saline"
11505282|NCT01317368|Active Comparator|Wound infiltration|"TAP block with Saline.
~Wound infiltration with Ropivacaine."
11505283|NCT01317368|Placebo Comparator|Placebo|"TAP block with Saline.
~Wound infiltration with Saline."
11505284|NCT01317355||cancer patients|in and out patients of 5 German university hospitals currently undergoing cancer treatment
11505285|NCT01317342|Active Comparator|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 1 hour
11505286|NCT01317342|No Intervention|Control group: no intervention|Conventional cold storage (IGL-1)
11505287|NCT01317329|Other|Clinically prescribed CPAP therapy|Clinically prescribed CPAP therapy
11505288|NCT01317303|Experimental|PAS25|PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
11505289|NCT01317303|Experimental|cTBS-PAS|40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
11505290|NCT01317303|Experimental|iTBS|190 seconds of intermittent theta-burst stimulation
11505291|NCT01317303|Experimental|cTBS-iTBS|40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation
11505294|NCT01317290|Experimental|linseed oil older, overweight|ALA-rich linseed oil to older, normalweight subjects (BMI >25, age 49-69 years)
11505295|NCT01317290|Experimental|olive oil|n3-PUFA free control oil to normalweight subjects (BMI <25)
11505296|NCT01317277|Experimental|Texting + Psychoeducation|Participants in the individualized Texting for Adherence Building (iTAB) arm will receive daily text messaging reminders for antiretroviral medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Participants will also receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV medications.
11505297|NCT01317277|Active Comparator|Psychoeducation|Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV medications. They will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.
11505298|NCT01317264|Placebo Comparator|Placebo milk drink|
11505299|NCT01317264|Experimental|Millk drink with oat β-glucan|
11505300|NCT01317264|Experimental|Milk drink with barley β-glucan|
11505301|NCT01317264|Experimental|Milk drink with mutant-barley β-glucan|
11505302|NCT01317251|Experimental|Control diet|Diet without dairy products
11505303|NCT01317251|Experimental|Milk diet|Diet with a high content of milk
11505304|NCT01317251|Experimental|Cheese diet|Diet with a high content of cheese
11505305|NCT01317238|Experimental|CJ Vaccination arm|healthy vaccinia-experienced volunteers who received CJ smallpox vaccine
11505306|NCT01317225|Experimental|17 α hydroxyprogesterone caproate|17α-Hydroxyprogesterone caproate.
11505307|NCT01317225|Placebo Comparator|Placebo|Saline solution.
11505308|NCT01317199|Experimental|Phase 1: Dose-escalation of Muscadine Plus Grape Skin Extract|Muscadine Plus Grape Skin Extract (MPX): Phase I Dose-escalation starts at 500mg daily for 1 cycle (28 days), then increased to 1000mg for 2nd cycle, then increased to 2000mg daily for 3rd cycle, then increased to 3000mg daily for 4th cycle, then increased to maximum dose of 4000mg daily for final cycle. Pills given by mouth once daily for 28 days per cycle.
11505309|NCT01317199|Placebo Comparator|Phase 2: Placebo control|Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
11505310|NCT01317199|Experimental|Phase 2: Low-dose MPX|Randomly-assigned participants receive low-dose (500mg) MPX
11505311|NCT01317199|Experimental|Phase 2: High-dose MPX|Randomly-assigned participants receive high-dose (4000mg) MPX
11505312|NCT01317186||Group I|Stage 2 Non-diabetic Chronic Kidney Disease
11505313|NCT01317186||Group II|Stage 3 Non-diabetic Chronic Kidney Disease
11505314|NCT01317186||Group III|Stage 4 Non-diabetic Chronic Kidney Disease
11505315|NCT01317173||Progressive disease|Serum creatinin level rise more than 2 times
11505316|NCT01317173||Non-progressive disease|Serum creatinin level rise less than 2 times
11505317|NCT01317160|No Intervention|Routine care: Plaster Cast Treatment|Two weeks of postoperative conventional lower limb plaster cast immobilization in 30 degrees of plantarflexion
11505318|NCT01317160|Experimental|Intermittent pneumatic compression (IPC)|Two weeks of calf IPC by Aircast® VenaFlow® Elite System during immobilization in an orthosis Aicast® XP Walker.
11505319|NCT01317147||Gastric bypass patients|
11505320|NCT01317134|Active Comparator|Therapy-naive|"This group consists of patients with a newly diagnosed PH (Class I or IV). First blood sampling takes place before initiation of PH therapy (0 months), the following measurements will be performed after 3, 6, 9 and 12 months under specific therapy.
~Initiation of standard therapy is performed directly after baseline visit / study inclusion. No special study medication will be used.
~Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood Test"
11505321|NCT01317134|Active Comparator|Under therapy|"This group consists of patients under ERA monotherapy at timepoint of inclusion. Observation period is one year to detect intraindividual changes in endothelial dysfunction measured by L-arginine/NO-metabolites after 0, 3, 6, 9 and 12 months under investigation.
~Specific PAH therapy has been started prior to the study for medical reasons and will be continued throughout.
~Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood"
11505322|NCT01317134|Active Comparator|Healthy controls|This group consists of healthy individuals. Sex and age matching is intended. Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood
11505323|NCT01317121||Subjects at risk for psychosis|Identification and clinical characterization of subjects with prodromal symptoms will be done in the early diagnosis outpatient center of the University Department of Psychiatry in Hamburg, Germany. Subjects At Risk Mental State (ARMS) for psychosis will be identified if they meet the criteria of the Structured Interview for Prodromal Syndromes (SIPS) (McGlashan et al 2001).
11505324|NCT01317121||Patients with a first episode of schizophrenia|Patients with a first episode of schizophrenia will be recruited from inpatients at the Clinic for Psychiatry and Psychotherapy at the University Hospital (UKE) in Hamburg, Germany. All patients have to meet criteria for DSM-IV and ICD-10 diagnosis for schizophrenia.
11505325|NCT01317121||Healthy control subjects|Healthy control subjects will be recruited from the hospital staff and students at the University Hospital Hamburg-Eppendorf (UKE), Hamburg, Germany. They have to be free from any neurological or psychiatric disorder, according to DSM-IV and ICD-10 criteria.
11505326|NCT01317108|No Intervention|A|Low uPA/PAI-1: Observation
11505327|NCT01317108|No Intervention|B2|High uPA/PAI-1: Observation
11505328|NCT01317108|No Intervention|B3|High uPA/PAI-1: refused randomization
11505329|NCT01317108|Active Comparator|B1|High uPA/PAi-1: CMF chemotherapy
11505330|NCT01317095|Active Comparator|Wire closure is the intervention|Patients will have their sternum closed using stainless steel wires.
11505331|NCT01317095|Active Comparator|Rigid fixation|Patients will have their sternum closed by rigid fixation using Starnalock plates.
11505332|NCT01317069|Experimental|Fluorouracil implant|
11505333|NCT01317030||Contact Lens Wear|Senofilcon A Lenses, using Sensitive Eyes Saline Solution and/or Biotrue Multipurpose Solution
11505334|NCT01317030||Non-Contact Lens Wear|
11505335|NCT01317004|Experimental|Fingolimod|Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period.
11505515|NCT01315665|Experimental|Healthy volunteers|100 grams of raw broccoli sprouts once daily for 5 consecutive days
11505336|NCT01317004|Active Comparator|Multiple Sclerosis Disease Modifying Treatment (MS DMT)|Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months.
11505337|NCT01316991|Active Comparator|Chewing gum|Subject will chew gum at defined intervals
11505338|NCT01316991|Placebo Comparator|No Gum|No chewing gum will be provided to subject
11505339|NCT01316978|Experimental|Experimental|Experimental Ibuprofen
11505340|NCT01316978|Active Comparator|Nurofen|Nurofen Meltlets Orodispersible Tablet
11505341|NCT01316978|Active Comparator|Motrin|Junior Strength Motrin Chewable Tablet
11505342|NCT01316965|Experimental|multifaceted prevention program|
11505343|NCT01316965|No Intervention|usual care|
11505344|NCT01316952||LabRx database Oct. 1st 2004 to Sep. 30th 2009|The study cohort from which cases and controls are drawn is all subjects in the LabRx database between Oct. 1st 2004 to Sep. 30th 2009.
11505345|NCT01316939|Placebo Comparator|Placebo|Placebo
11505346|NCT01316939|Experimental|GSK1605786A once daily|500 milligrams once daily
11505347|NCT01316939|Experimental|GSK1605786A twice daily|500 milligrams twice daily
11505348|NCT01316926|Active Comparator|Paxil CR Reference|Reference drug administration followed by test drug administration
11505349|NCT01316926|Active Comparator|Paxil CR Test|Test drug administration followed by Reference drug administration
11505350|NCT01316913|Experimental|GSK573719/GW642444 125/25|125/25 mcg once-daily
11505351|NCT01316913|Experimental|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
11505352|NCT01316913|Experimental|GSK573719|125 mcg once-daily
11505353|NCT01316913|Active Comparator|tiotropium bromide|18 mcg once-daily
11505354|NCT01316900|Experimental|GSK573719/GW642444 125/25|125/25 mcg once-daily
11505355|NCT01316900|Experimental|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
11505356|NCT01316900|Experimental|GW642444|25 mcg once-daily
11505357|NCT01316900|Active Comparator|tiotropium bromide|18 mcg once-daily
11505358|NCT01316887|Experimental|GSK573719/GW642444|125/25 mcg once-daily
11505359|NCT01316887|Experimental|GSK573719|125 mcg once-daily
11505360|NCT01316887|Placebo Comparator|Placebo|inactive
11505361|NCT01316874|Experimental|AD32 (valrubicin)|800mg, once weekly for 6 weeks
11505362|NCT01316861|Experimental|EMS Acarbose|
11505363|NCT01316861|Active Comparator|Bayer Acarbose|
11505364|NCT01316848|Experimental|Fasted dosing followed by fed dosing|Dosing in the fasted state followed by fed dosing
11505365|NCT01316848|Experimental|Fed dosing followed by fasted dosing|Dosing in the fed state followed by fasted dosing
11505366|NCT01316835||Type 2 Diabetes Mellitus, No treatment|
11505367|NCT01316822|Experimental|ARRY-382|
11505368|NCT01316809|Experimental|A|Surgical arm
11505369|NCT01316809|Experimental|B|Non-surgical arm
11505370|NCT01316783||Healthy Volunteers|African ancestry and whites (who will serve as a comparison group)
11505371|NCT01316770|Placebo Comparator|Placebo Parotid Irrigation|Within-Subject, Double-Blind, Placebo-Controlled Study. This parotid gland is irrigated with saline (placebo). { UPDATE: drug(generic) was administered at what time pt, dose of drug, route administration, frequency}
11505372|NCT01316770|Experimental|Dexamethasone Parotid Irrigation|Within-Subject, Double-Blind, Placebo-Controlled Study. This parotid gland is irrigated with dexamethasone {UPDATE: drug (generic) was administered at what time pt, dose of drug, route administration, frequency}
11505373|NCT01316757|Experimental|Treatment|Patients receive cetuximab IV over 60 minutes, paclitaxel IV over 1 hour, and carboplatin IV over 30 minutes on day 1. Beginning in course 2, patients also receive erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11505374|NCT01316731|Experimental|Exercise|
11505375|NCT01316718|Experimental|Mesalazine Granules|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
11505376|NCT01316718|Placebo Comparator|Placebo Granules|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
11505377|NCT01316692|Experimental|MLN8237|Patients receive oral Aurora A kinase inhibitor MLN8237 every 12 hours on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11505378|NCT01316679||group A|Patients with known HCC
11505379|NCT01316679||Group B|Patients with liver disease but no HCC
11505380|NCT01316679||Group C|Control; patients with no known liver disease or HCC
11505381|NCT01316666||Neurogenic Hypotension|Patients with neurogenic hypotension, which includes those with Pure Autonomic Failure (PAF), Multiple System Atrophy (MSA) and Parkinson Disease (PD)
11505382|NCT01316653|Active Comparator|GROW Smarter|Library based program to promote early literacy
11505383|NCT01316653|Experimental|GROW Healthier|Healthy lifestyle intervention focused on building healthy lifestyle skills for preschool children and participating parents and building new social networks between the intervention group members.
11505384|NCT01316627|Experimental|Crooked Mirror Externalization Therapy|"Of recent, the crooked mirror externalization therapy, developed by Dr. Eda Gorbis, has been put to use with much success (Gorbis 2004). This method involves the use of crooked or fun house mirrors made from highly reflective surfaces that can be bent in different directions, which distort and exaggerate the patient's perceived defects (Gorbis 2005). In turn, this process externalizes or reverses the patient's internalized distorted body image, and allows the patient to habituate to the reflection of the imagined defect that is even more distorted than the internalized image (Rosen et al. 1995)."
11505385|NCT01316627|Active Comparator|Mirror Retraining Method|"In treating BDD, the cognitive-behavioral technique, mirror retraining, uses ordinary and/or magnifying mirrors to amplify the supposed defect, which teaches patients to see their appearance in a more holistic way. Since BDD patients tend to only focus on their perceived flaws when looking in the mirror, and tend to think about their flaws in negative terms, in mirror retraining, patients learn how to change their negative evaluations of their appearance into more objective and nonjudgmental descriptions. Generally, this method is designed to intentionally exaggerate anxiety regarding appearance concerns through exposures with mirrors. However, using exclusively ordinary and/or magnifying mirrors does not address the internal distorted image that many patients with BDD experience (Rosen et al. 1995, Osman et al. 2004, Veale 2004)."
11505386|NCT01316614|Experimental|With Stylet & Without Stylet|There will only be one arm in this study. This arm will undergo EUS-guided FNA with the use of a stylet for half of their FNA passes and without a stylet for the other half. Patients will be exposed to an equal number of passes with and without a stylet. Each pass will be individually assessed by a skilled cytopathologist who is blinded to the technique used. We will compare the adequacy of both techniques to determine whether or not a stylet leads to a higher diagnostic accuracy rate in patients with solid lesions.
11505387|NCT01316588|Experimental|Plastic adesive drape|Intraoperative: Plastic adhesive drape on the chest and bare skin on the leg
11505388|NCT01316588|Experimental|Microbial Sealant|Intraoperative: Microbial Sealant on the leg and bare skin on the chest
11505389|NCT01316575|Experimental|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
11505390|NCT01316575|Active Comparator|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
11505391|NCT01316562||Group 1|Healthy controls
11505392|NCT01316562||Group 2|Patients with an Alzheimer's disease or related disorders
11505393|NCT01316536|Experimental|With Music|This randomized group will receive music
11505394|NCT01316536|Placebo Comparator|Control Arm|Will not receive music but will receive audio loop of recorded ICU sounds
11505395|NCT01316523|Experimental|Lenalidomide + Rituximab|Patients will receive lenalidomide 20 mg daily (oral), on days 1-21 of a 28 day cycle. Rituximab 375 mg/m2 (into the vein) will be administered weekly for 4 doses starting day 15 of cycle 1, to be repeated if patient does not achieve a complete response after cycle 4, on days 1, 8, 15 and 22 of cycle 5.
11505396|NCT01316510|Active Comparator|Bifidobacteria infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge (whichever happens first)
11505397|NCT01316510|Placebo Comparator|Placebo|A dilute formulation of the elemental formula Nutramigen (diluted to look like the probiotic arm).
11505398|NCT01316497|Experimental|Remote ischemic preconditioning (RIPC)|See intervention description
11505399|NCT01316497|Placebo Comparator|Control|
11505400|NCT01316484||No Treatment|Adult subjects with diabetes mellitus and a diagnosis of gastroparesis
11505401|NCT01316471|Experimental|Online Behavioral Intervention|In addition to standard medical care, children and parents in the online behavioral intervention will receive access to the full web-based program including education about chronic pain, training in behavioral and cognitive coping skills, instruction in increasing activity participation, and education about pain behaviors and parental operant strategies using an engaging, interactive format on the Internet.
11505402|NCT01316471|Active Comparator|Online Patient Education|The Online Patient Education group will serve as an attention control condition. In addition to standard medical care, children and parents will be provided with access to a modified version of the study website that will provide information from publicly available educational websites about pediatric chronic pain management.
11505403|NCT01316458|Experimental|imatinib mesylate|
11505404|NCT01316445|Experimental|nasal Midazolam|3 mg of the standard IV solution of midazolam (5 mg/mL) was given via a metered-dose nasal sprayer (6 sprays × 0.1 ml/spray, or 6 × 0.5 mg/spray) divided between the two nostrils within 1-2 min. During the EEG, vital signs (blood oxygen saturation, blood pressure, pulse and respiratory rate) were monitored and a nurse and a physician were available at all times. Subjects were monitored for 2 hours after administration of midazolam to ensure adequate recovery from sedation.
11505405|NCT01316432|Experimental|SQ Bolus Cenderitide|
11505406|NCT01316432|Experimental|SQ Infusion Cenderitide|24 hour SQ infusion of cenderitide
11505407|NCT01316432|Placebo Comparator|Placebo|24 hrs of SQ placebo infusion
11505408|NCT01316419||Patients with essential hypertension|
11505409|NCT01316406|Experimental|ATH008 cream 3%|ATH008 cream 3%
11505410|NCT01316406|Experimental|ATH008 cream 8%|ATH008 cream 8%
11505411|NCT01316406|Placebo Comparator|ATH008 cream placebo|ATH008 cream placebo
11505412|NCT01316393|Experimental|XER2020|mucoprotective product
11505413|NCT01316393|Active Comparator|Saliva Natura|salivary substitute
11505414|NCT01316393|Placebo Comparator|XER2020 placebo|
11505415|NCT01316380|Experimental|tiotropium 5 mcg|once daily delivered via Respimat inhaler
11505416|NCT01316380|Experimental|tiotropium 2.5 mcg|once daily delivered via Respimat inhaler
11505417|NCT01316380|Placebo Comparator|placebo|once daily delivered via Respimat inhaler
11505418|NCT01316367|Active Comparator|Conventional Health Promotion Education (CHPE).|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
11505419|NCT01316367|Experimental|PRECEDE HPE model|
11505420|NCT01316354|Experimental|Beta-glucan|Bread with purified beta-glucan
11505421|NCT01316354|Experimental|Rye kernels|Rye bread with kernels
11505422|NCT01316354|Experimental|White bread|White bread
11505423|NCT01316354|Experimental|Arabinoxylan|Bread with Purified arabinoxylan
11505424|NCT01316341|Experimental|BI10773 low dose Per Os(p.o.)|patient to receive a tablet containing low dose BI10773 Per Os(p.o.) plus one placebo
11505425|NCT01316341|Placebo Comparator|Placebo|patient to receive two placebos
11505426|NCT01316341|Experimental|BI10773 high dose Per Os(p.o.)|patient to receive a tablet containing high dose BI10773 Per Os(p.o.) plus one placebo
11505427|NCT01316328||BC patients after SSPBI|breast cancer (BC) patients following single shot partial breast irradiation (SSPBI) after breast conservative surgery
11505428|NCT01316315|Experimental|Active|N6022 - 5 mg
11505429|NCT01316315|Placebo Comparator|Placebo|Placebo
11505430|NCT01316302|Experimental|Pristiq|Flexible dose, 50-100mg QD
11505431|NCT01316302|Placebo Comparator|Placebo|Matching placebo
11505606|NCT01315002|Placebo Comparator|Placebo patch|Placebo patch
11505432|NCT01316276|Experimental|LAI|590 mg LAI QD via a PARI Investigational eFlow® Nebulizer System (eFlow®) for 28 days followed by a 28-day off-treatment period. This cycle (28 days on treatment, 28 days off treatment) was to be repeated for up to 12 cycles, divided into 2 periods of 6 cycles each (approximately 12 months each).
11505433|NCT01316263|Experimental|PDGFRα mutation negative|Participants with GIST with genotypes that do not have a PDGFRα mutation given 20 milligrams per kilogram (mg/kg) Olaratumab intravenously (IV) every 14 days.
11505434|NCT01316263|Experimental|PDGFRα mutation positive|Participants with GIST with genotypes that have a PDGFRα mutation given 20 mg/kg Olaratumab IV every 14 days.
11505435|NCT01316250|Other|Nilotinib, cytogenetic response|Newly diagnosed CML patients
11505436|NCT01316237|Other|Cohort 1|(N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2) 50 mg GS-6620 or placebo QD in the morning with food [total daily dose (TDD) = 50 mg] for 5 days
11505437|NCT01316237|Other|Cohort 2|"(N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)
~100 mg GS-6620 or placebo QD in the morning with food (TDD = 100 mg) for 5 days"
11505438|NCT01316237|Other|Cohort 3|"Cohort 3 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)
~300 mg GS 6620 or placebo QD in the morning with food (TDD = 300 mg) for 5 days"
11505439|NCT01316237|Other|Cohort 4|"Cohort 4 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)
~100 mg GS 6620 or placebo QD in the morning without food (TDD = 100 mg) for 5 days"
11505440|NCT01316237|Other|Cohort 5|"Cohort 5 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)
~300 mg GS 6620 or placebo QD in the morning without food (TDD = 300 mg) for 5 days"
11505441|NCT01316237|Other|Cohort 6|"Cohort 6 (N = 10, genotype 2 or genotype 3): (Active drug: 8, Matching Placebo: 2)
~900 mg GS 6620 or placebo QD in the morning without food (TDD = 900 mg) for 5 days"
11505442|NCT01316237|Other|Cohort 7|"Cohort 7 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)
~450 mg GS 6620 or placebo, administered BID with food (TDD = 900 mg) for 5 days"
11505443|NCT01316237|Other|Cohort 9|"Cohort 9 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)
~900 mg GS 6620 or placebo BID in the with food (TDD = 1800 mg) for 5 days"
11505444|NCT01316237|Other|Cohort 11|"Cohort 11 (N = 10, genotype 1 : (Active drug: 8, Matching Placebo: 2)
~Up to 450 mg GS-6620 or placebo as an oral solution, BID, 12 hours apart in the fasted state, 2 hours after a meal (up to TDD = up to 900 mg) for 5 days."
11505445|NCT01316224||Moderate or severe plaque psoriasis|Participants with moderate or severe plaque psoriasis treated with adalimumab
11505446|NCT01316211|Active Comparator|coflex™|Implantation of coflex™ device in assigned patients
11505447|NCT01316211|Active Comparator|Surgical decompression|Surgical decompression in patients with spinal stenosis without stabilization by an additional implant.
11505448|NCT01316198|Experimental|Lutein and zeaxanthin|
11505449|NCT01316198|Experimental|Placebo|
11505450|NCT01316185|Experimental|Group 1|Low Dose for 28 days: n=4
11505451|NCT01316185|Experimental|Group 2|High Dose for 28 days; n=4
11505452|NCT01316172|Experimental|5 Cs|Educational intervention
11505453|NCT01316172|No Intervention|Control|
11505454|NCT01316146|Experimental|CAR.CD30 T cells|Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection (IV) according to the dosing schedules: starting with the lowest cell dose (2×10^7 cells/m2) and then escalate the cell dose to the highest cell dose (2×10^8/m2) as per study design.
11505455|NCT01316133|Experimental|Tacrolimus group|Oral
11505456|NCT01316120|Experimental|HPV Dry first|"Randomization will determine the sequence of the two tests, avoiding potential bias that may advantage the first test. All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic tests"
11505457|NCT01316120|Experimental|HPV standard transport medium|"Randomization will determine the sequence of the two tests, avoiding potential bias that may advantage the first test. All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic tests"
11505458|NCT01316107|Experimental|ASP group|Concomitant administration of ASP1941 and nateglinide
11505459|NCT01316094|Experimental|ASP group|oral
11505460|NCT01316094|Placebo Comparator|placebo group|oral
11505461|NCT01316081|Experimental|Antioxidant Group|500mg Vitamin C 400 I.E. Vitamin E 50 mcg Selenium
11505462|NCT01316081|Placebo Comparator|Placebo Group|identical appearing placebo supplements
11505463|NCT01316068|Experimental|sequencial use of sulodexide|Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks. Then patients will receive 1000 LSU per day orally for 50 weeks.
11505464|NCT01316068|Active Comparator|oral use of sulodexide|Patients allocated to oral group will received 1000 LSU per day orally for 52 weeks
11505465|NCT01316055|Active Comparator|Healthy: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in healthy volunteers
11505466|NCT01316055|Active Comparator|Mild renal: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with mild renal impairment
11505467|NCT01316055|Active Comparator|Moderate renal: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with moderate renal impairment
11505468|NCT01316042|Placebo Comparator|sugar pill|2 pills per day for 12 months
11505469|NCT01316042|Active Comparator|Metformin|2 212.5mg pill/day for 12 months
11505470|NCT01316029||laying-on-of-hands|44,587 Japanese volunteers with/without illness, who were interested in receiving laying-on-of-hands
11505471|NCT01316016|Experimental|Rose hip|
11505472|NCT01316003||Normal subjects|Thirty-seven eyes of 37 individuals without eye diseases
11505473|NCT01315990|Experimental|FOLFIRI + Cetuximab|
11505474|NCT01315964|Active Comparator|plant stanol ester|3 grams of plant stanol esters per day in a margarine product as part of daily diet for 6 months
11505475|NCT01315964|Placebo Comparator|Placebo|a margarine product as part of daily diet, which is not containing plant stanol esters
11505476|NCT01315951|Experimental|Petroleum Jelly|Every patient will be applying petroleum jelly to the affected areas per protocol.
11505477|NCT01315938|Other|Active treatment|Abatacept will be administered intravenously at a dose based on body weight at the screening visit (baseline): participants weighing <60 kg received 500 mg, 60-100 kg received 750 mg and those >100 kg received 1000 mg.
11505478|NCT01315938|Other|Delayed-onset treatment|Abatacept will be administered intravenously at a dose based on body weight at 3 months: participants weighing <60 kg received 500 mg, 60-100 kg received 750 mg and those >100 kg received 1000 mg.
11505479|NCT01315925||Newly disgnosed AML|Adult and pediatric patients with newly diagnosed acute myeloid leukemia, both eligible and not eligible for intensive chemotherapy. Since this is a non-interventional study, therapeutic strategies remains related to local guidelines. Will be treated as cases all patients with acute leukemia in first induction developing an Invasive Fungal Infection according to international EORTC criteria for possible/probable/proven infections. Patients who do not develop the infection will be used as a control group.
11505480|NCT01315899|Experimental|ORM-12471 30mg|
11505481|NCT01315899|Placebo Comparator|placebo|
11505482|NCT01315899|Experimental|ORM-12471 100mg|
11505483|NCT01315886|Experimental|SL Fentanyl conversion|"Baseline period: 7-15 episodes of breakthrough cancer pain treated with prior IR opioid medication
~Treatment period: Conversion to SL Fentanyl at a Fentanyl:Prior opioid conversion factor of 1:50 (using the estimated Morphine Sulphate Equivalent dose for the prior opioid). SL Fentanyl use was followed for 8-15 episodes of breakthrough cancer pain. SL Fentanyl dose could be titrated between episodes."
11505484|NCT01315873|Experimental|Bortezomib and Bendamustine|
11505485|NCT01315860||Pregnant Females|Pregnant females in their second or third trimester that meet the inclusion and exclusion criteria.
11505486|NCT01315847|Experimental|Healthy Participants (Part I)|Baseline PET imaging of the brain using [11C]MK-4232 tracer (~300 megabecquerel [MBq]) was performed in healthy participants; this PET data served as the baseline for both Period 1 and 2 of Part I. Subsequently in study Part I, Period 1 the healthy participants received a single 1120 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~3 hours post telcagepant dose. In Part I, Period 2 the healthy participants received a single 140 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~2 hours post telcagepant dose. Interval between Part I Period 1 and 2 was to be at least 1 week.
11505487|NCT01315847|Experimental|Participants with Migraine (Part III)|In study Part III, Period 1 baseline PET imaging of the brain using [11C]MK-4232 tracer (~300 MBq) was performed in participants with migraine during a migraine attack (ictal phase). Later in Part III, Period 1 the participants with an ongoing migraine attack (ictal phase) received a single 140 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~2 hours post telcagepant dose. In Part III, Period 2 baseline PET imaging of the brain using [11C]MK-4232 tracer (~300 MBq) was performed in participants with migraine, however, without a migraine attack ongoing (interictal phase). Later in Part III, Period 2 participants with migraine without a migraine attack ongoing (interictal phase) received a single 140 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~2 hours post telcagepant dose. Interval between Part III Period 1 and 2 was to be at least 1 week.
11505488|NCT01315834||Couples coping with CHD|The target group will be 127 male patients and their partners. The couples will be recruited during the patients' first hospitalization for ACS. The participants will complete questionnaires during the hospitalization and again six months later. The patients will also be asked to be weighed and have their blood drawn and at the six-month follow-up for measurement of blood Cholesterol level. Relevant data will be obtained from their medical files.
11505489|NCT01315834||control group|The control group will be 100 couples who are not coping with a life threatening illness. The couples will complete self report questionnaires at one point of time.
11505490|NCT01315821|Experimental|Saccharomyces boulardii|Saccharomyces boulardii 5 million unit/day for 3 months
11505491|NCT01315821|Placebo Comparator|control|Placebo- for 3 months
11505492|NCT01315808||Low risk group|Patients will be stratified based on risk factors significantly contributing to diabetes type 2.
11505493|NCT01315808||Intermediate risk group|
11505494|NCT01315808||High risk group|
11505495|NCT01315795|Experimental|Symptomatic polycystic liver disease (PCLD) patients|Symptomatic polycystic liver disease (PCLD) patients
11505496|NCT01315782||Multi-organ failure|Alveolar dead space on mechanically ventilated patients with severe sepsis or septic shock.
11505497|NCT01315769||non pregnant nulliparous|Group 1
11505498|NCT01315769||primiparous women|Group 2
11505499|NCT01315756|No Intervention|Control group|Treatment as usual.
11505500|NCT01315756|Experimental|Few Touch Application (FTA)|"This arm will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user."
11505501|NCT01315756|Experimental|FTA and health counseling|This arm will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via sms from the diabetes nurse which is based on the patient's initiative (via sms). In addition, the diabetes nurse will call the patients three times during this period and discuss progress.
11505502|NCT01315743|Experimental|Intervention|
11505503|NCT01315730|Experimental|Device: Tactile Stimulation|"A new medical grade device (FDA - category exempt) has been newly designed and built at the University of Mississippi within the departments of Communication Sciences & Disorders, Exercise Science, and Computer and Electrical Engineering. The device records either sound waves (via a small standard microphone) or three dimensional accelerometer data from the throat of a stuttering subject. This data is digitally signal processed, and fed back to the user in the form of a small vibrating disk/film that can be held between the fingers or mounted on the skin. This feedback data does not require the subject to attend to the incoming signal."
11505504|NCT01315717||Group 1|Healthy subjects
11505505|NCT01315717||Group 2|Patients with Mild Cognitive Impairment
11505506|NCT01315717||Group 3|Patients with Mild AD
11505507|NCT01315717||Group 4|Patients with Moderate AD
11505508|NCT01315704||Group 1|Patients with Mild Cognitive Impairment
11505509|NCT01315704||Group 2|Patients with Mild Alzheimer's disease or related disorders
11505510|NCT01315704||Group 3|Patients with Moderate Alzheimer's disease or related disorders
11505511|NCT01315691|Experimental|Arikace™|Liposomal amikacin for inhalation
11505512|NCT01315691|Placebo Comparator|Placebo|Placebo for liposomal amikacin for inhalation
11505513|NCT01315678|Experimental|Arikayce™|Arikayce™ is liposomal amikacin for inhalation
11505514|NCT01315678|Active Comparator|TOBI®|TOBI® is tobramycin inhalation solution
11505516|NCT01315665|Experimental|Subjects with cystic fibrosis|100 grams of raw broccoli sprouts once daily for 5 consecutive days
11505517|NCT01315652|Experimental|Auto DAS|"Auto-DASNumber of patients with a modification in their treatment between baseline and 6 months visits"
11505518|NCT01315652|Active Comparator|Comorbidities treatment|
11505519|NCT01315639|Other|biomarkers, MRI and CSF|"Longitudinal multicenter study including 1300 subjects with amnestic impairment (MCI, n=650 and AD, n=650) derived from the main French national Memory Resources and Research Centers.
~Participants will undergo at baseline and every 6 months a neurological examination, a neuropsychological assessment (and an oculomotor examination for those included from Broca Hospital).
~Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
11505520|NCT01315626||Immediately preceding intervention|3 months immediately before the education event. Charts of patients with a primary respiratory complaint will be reviewed so evaluate if they 1) have experienced 3 or more suppurative respiratory infections and 2) have required 3 or more courses of antibiotic therapy for respiratory infection over the period of one year. 4) Whether or not they underwent a HRCT, and if so, and 5) Were the patients diagnosed with BE.
11505521|NCT01315626||3 months after educational event|3 months immediately after the education event. An active assessment will be preformed as per the proposed diagnostic algorithm (attachment B) Patients that meet all criteria in the algorithm are considered at risk for bronchiectasis and based on these criteria, physicians will be encouraged to order HRCT, and the number/ proportion of patients identified with BE will be noted and compared to the other time periods.
11505522|NCT01315626||Seasonal prior year|As respiratory illnesses are commonly seasonal, an assessment of rate of Bronchiectasis diagnosis during the months of Period 2 in the year prior to the educational intervention will also be assessed as described in Period 1
11505523|NCT01315613||Acute pancreatitis|Patients admitted in our institution for an episode of acute pancreatitis
11505524|NCT01315587|Active Comparator|intermittent theta burst stimulation|
11505525|NCT01315587|Active Comparator|repetitive Transcranial Magnetic Stimulation|
11505526|NCT01315587|Placebo Comparator|Sham TMS|
11505527|NCT01315574|Active Comparator|Latanoprost (Xalatan)|7 Patients were randomized to receive BAK-containing Xalatan for treatment of their glaucoma.
11505528|NCT01315574|Active Comparator|Travoprost (Travatan Z)|7 Patients were randomized to receive BAK-free Travatan Z for treatment of their glaucoma.
11505529|NCT01315561|Experimental|acupuncture|MSAT is a treatment method in which the patient is exposed to active or passive movement and exercise during acupuncture, as opposed to conventional acupuncture.
11505530|NCT01315561|Active Comparator|injections of diclofenac|the control group was treated with intramuscular injections of diclofenac(NSAID). All administrations were limited to 1 session
11505531|NCT01315548||Pancreatic adenocarcinoma|Patients diagnosed with solid pancreatic adenocarcinoma masses, with cytological / histologicalconfirmation
11505532|NCT01315548||Chronic pancreatitis|Patients diagnosed with solid pancreatic tumor masses with all the criteria fulfilled to exclude pancreatic cancer
11505533|NCT01315535||Fast Titration|
11505534|NCT01315535||Regular Titration|
11505535|NCT01315535||Fast Tritation Including Mandibular Exercises|
11505536|NCT01315535||Regular Tritation Including Mandibular Exercises|
11505537|NCT01315522|Active Comparator|ComVi stent|ComVi stent (Niti-S stent, ComVi type, Taewoong Medical Inc, Korea)
11505538|NCT01315522|Active Comparator|Uncovered SEMS|uncovered nitinol metal stent (HANAROSTENT, M.I. Tech Co., Ltd., Korea)
11505539|NCT01315496|Experimental|Imunoglobulin G|The enrolled patients will be randomized to receive supplementation of IVIG in ICU within 48 hours after hospital arrival admission for 3 consecutive days.
11505540|NCT01315496|Placebo Comparator|Placebo control|The enrolled patients will be randomized to receive supplementation of placebo (0.9% NaCl) in ICU within 48 hours after hospital arrival admission for 3 consecutive days.
11505541|NCT01315483|Experimental|Low fat, high carb weight loss diet|Ornish-like weight loss dietary pattern
11505542|NCT01315483|Experimental|Low carb, high fat weight loss diet|South-Beach-like weight loss diet pattern
11505543|NCT01315483|No Intervention|Control|Usual care
11505544|NCT01315470|Experimental|neupogen|
11505545|NCT01315470|No Intervention|no intervantion|
11505546|NCT01315457||Alemtuzumab|Patients treated with alemtuzumab
11505547|NCT01315444|Active Comparator|PPI abrupt cessation|Abrupt cessation
11505548|NCT01315444|Active Comparator|PPI gradual step down cessation|Gradual cessation
11505549|NCT01315431|Experimental|Tesetaxel-capecitabine|
11505550|NCT01315418|Active Comparator|1 = Tested product|
11505551|NCT01315418|Sham Comparator|2 = Control product|
11505552|NCT01315392|Active Comparator|delayed closure|wounds packed open with normal saline wet to dry gauze dressings and were returned to the operating room 36 to 72 hours after initial procedure for debridement and definitive closure.
11505553|NCT01315392|Active Comparator|immediate wound closure|traumatic and surgical wounds closed at initial surgical intervention
11505554|NCT01315379||PTSD without TBI|"children and adolescents with a diagnosis of PTSD and without head injury, following a motor vehicle accident.
~This group will be treated using the Prolonged Exposure Therapy protocol."
11505555|NCT01315379||PTSD with m-TBI|"children and adolescents with a diagnosis of PTSD and a diagnosis of mild traumatic brain injury, following a motor vehicle accident.
~This group will be treated using the Prolonged Exposure Therapy protocol."
11505556|NCT01315366|Active Comparator|High dose vitamin D|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) Ci-Cal D daily, plus a supplement of vitamin D3 EuroD (20,000 IU/wk) for one year.
11505557|NCT01315366|Placebo Comparator|Low dose Vitamin D|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) Ci-Cal D daily, plus a weekly placebo (EURO D Placebo) supplement for one year.
11505558|NCT01315353|Experimental|Arm A: Immediate cryotherapy (HPV test-and-treat)|Participants in Arm A (HPV test-and-treat) had cervical cryotherapy at entry. Post entry, participants in Arm A were seen at regular intervals for the collection of cervical specimens, cytology, and as needed, cervical colposcopy, directed biopsies, and LEEP.
11505559|NCT01315353|Experimental|Arm B: cytology-based strategy|Participants in Arm B followed a cytology-based management plan involving three steps- cytology, colposcopy with directed biopsies, and LEEP (as needed).
11505560|NCT01315353|Experimental|Arm C : Ineligible for randomization to Arm A or B|Participants were eligible for Arm C under the conditions noted in the inclusion criteria. Participants in Arm C had colposcopy and directed biopsies at entry. If CIN2+ was found by biopsy, then LEEP was performed and a follow-up visit 26 weeks after these procedures was scheduled for the collection of cervical specimens, cytology, and as needed, cervical colposcopy, directed biopsies, and LEEP. After the week 26 visit, Arm C participants went off study.
11505561|NCT01315340|Experimental|Glaucoma Patients|
11505562|NCT01315340|Active Comparator|Control subjects|
11505563|NCT01315327|Experimental|Omega-3 Fatty Acids|Omega-3 Fatty Acids (fish oil), flexibly titrated up to 6000 mg/day.
11505564|NCT01315327|Placebo Comparator|Placebo|Olive oil placebo, looks and tastes identical to active intervention.
11505565|NCT01315314|No Intervention|conventional PDF (Stay safe)|
11505566|NCT01315314|Active Comparator|low GDP PDF (Balance)|
11505567|NCT01315301|Active Comparator|Arm-A|Immediate Treatment Group
11505568|NCT01315301|Active Comparator|Arm-B|Deferred Treatment Group-1
11505569|NCT01315301|Active Comparator|Arm-C|Deferred Treatment Group-2
11505570|NCT01315288|Other|Video presentation|
11505571|NCT01315275|Experimental|Ranibizumab|
11505572|NCT01315262|Active Comparator|Viagra 100 mg daily|
11505573|NCT01315262|Active Comparator|Viagra 100mg on demand|
11505574|NCT01315249|Experimental|QVA149|Participants received indacaterol and glycopyrronium (QVA149) and placebo to fluticasone/salmeterol.
11505575|NCT01315249|Active Comparator|fluticasone/salmeterol|Participants received fluticasone/salmeterol and placebo to indacaterol and glycopyrronium (QVA149).
11505576|NCT01315236|Experimental|LAI 590 mg QD|LAI 590 mg QD
11505577|NCT01315236|Placebo Comparator|Placebo|placebo QD
11505578|NCT01315223|No Intervention|Conventional treatment CHF patients|One hundred and fifty patients with CHF will be treated according to current guidelines (conventional treatment).
11505579|NCT01315223|Experimental|Lung impedence-guided treatment|
11505580|NCT01315210|Experimental|D-Ribose|
11505581|NCT01315210|Placebo Comparator|Placebo|
11505582|NCT01315197|Experimental|massage|The massage Anma has Japanese origin and a protocol was used with smoothing, kneading and pressure points on the bladder meridian.
11505583|NCT01315184|Experimental|Recovery Line Support System|Patients assigned to the Recovery Line Support System will be trained on the system and provided 24-hr access to the system for a four week period, provided with a Recovery notebook, and given reminder calls to contact the system.
11505584|NCT01315184|No Intervention|Treatment as Usual|Patients assigned to the TAU condition will receive any services provided by their buprenorphine provider and any additional services that their provider refers or recommends that patients attend. No additional services will be provided by the study.
11505585|NCT01315171|Experimental|Medium chain supplemented diet|Subjects will have a diet during which all meals are supplemented with 4 tablespoons of medium chain triglyceride oil.
11505586|NCT01315171|No Intervention|Standard group|Subjects will continue with a standard western diabetes diet.
11505587|NCT01315158|Active Comparator|Propofol+Benzo/Opioids|"If the patient is randomized into this arm the recommended Versed and Fentanyl doses are standardized:
~Recommended Versed:
~a. Prior to intubation
~patient is < 50 kg = 1 mg Versed
~patient is 50-75 kg = 1.5 mg Versed
~patient is > 75 kg = 2 mg Versed
~Recommended Fentanyl
~Prior to intubation = 0.5 ug/kg
~Total procedural dose = 1 ug/kg"
11505588|NCT01315158|Active Comparator|Propofol Alone|"The patients randomized into the sedation with propofol alone are able to cross over if they are unable to be successfully sedated under propofol alone. The the recommended doses before considering crossover are standardized:
~Induction Dose: 2-2.5 mg/kg
~Maintenance Dose: 0.1-0.2 mg/kg/min"
11505589|NCT01315145|Active Comparator|Percutaneous Lumbar Decompression|Patients receiving percutaneous decompression using the mild® Device Kit.
11505590|NCT01315145|Active Comparator|Lumbar Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
11505591|NCT01315132|Experimental|Allogeneic Transplantation|Matched Sibling Allogeneic Transplantation
11505592|NCT01315093|Experimental|Heparin, Low-Molecular-Weight group|LMWH was administered during an IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders. Drug was started at the beginning of the cycle and stopped at the time of pregnancy test if negative, or continued if pregnancy occurred until the 32th weeks of gestation
11505593|NCT01315093|Active Comparator|Non Heparin, Low-Molecular-Weight group|IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders.
11505594|NCT01315080||Saline|Percutaneous drainage and saline solution irrigation
11505595|NCT01315080||Triamcinolone|Percutaneous drainage and saline solution irrigation plus percutaneous triamcinolone
11505596|NCT01315054|Other|Control arm|Using currently practiced methadone dosage prescription methods
11505597|NCT01315054|Experimental|MMT provider dosage training|Intensive health care provider training on prescribing methadone dosage based on national guidelines
11505598|NCT01315054|Experimental|MMT provider dosage training/counseling|Intensive health care provider training on prescribing methadone dosage, plus providing on-site psychosocial counseling services and peer support to clients .
11505599|NCT01315041|Active Comparator|"Pi medicine"|
11505600|NCT01315041|Placebo Comparator|Placebo|
11505601|NCT01315028|Experimental|Psychological Therapy|Cognitive Interpersonal Therapy (CIT) was a psychological therapy which emphasised assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive-behavioural and interpersonal strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley & Schwannauer, 2006).
11505602|NCT01315028|Active Comparator|Treatment As Usual|All participants continued to receive their usual care from their local community mental health team and other psychological therapies were not withheld during the conduct of the trial.
11505603|NCT01315015|Experimental|Contrast enhanced breast MRI|The additional MRI will take place biennially after the regular screening mammogram for a study period of 6 years.
11505604|NCT01315015|No Intervention|Regular breast cancer screening|No further follow-up until next scheduled screening examination two years later (according to the current Dutch guideline).
11505605|NCT01315002|Active Comparator|Nicotine Patch|Transdermal nicotine patch
11505611|NCT01314963|Experimental|Intraoperative handheld Gamma Camera (pIHGC)|The prototype intraoperative handheld gamma camera (pIHGC)
11505612|NCT01314963|Active Comparator|Gamma probes (GP)|Standard of care intraoperative gamma probes (GP) currently in use.
11505613|NCT01314950|Active Comparator|Best practices primary care|Best practices primary care encompasses the collaborative care intervention tested in a prior clinical trial (Callahan CM et al. JAMA 2006).
11505614|NCT01314950|Experimental|Home based occupational therapy|The intervention group receives all of the components of best practice primary care in addition to a home-based intervention designed to slow functional decline.
11505615|NCT01314937|Experimental|Deworming at 12 months of age|
11505616|NCT01314937|Experimental|Deworming at 18 months of age|
11505617|NCT01314937|Experimental|Deworming at 12 and 18 months of age|
11505618|NCT01314937|Placebo Comparator|Usual care|
11505619|NCT01314924|Experimental|Responders|Patients who present an increase in flow-mediated dilation of brachial artery.
11505620|NCT01314924|Experimental|Non responders|Patients who do not present an increase in flow-mediated dilation of brachial artery.
11505621|NCT01314911|Experimental|Oseltamivir|
11505622|NCT01314911|Placebo Comparator|Placebo|
11505623|NCT01314898|Experimental|Treatment|
11505624|NCT01314885|Experimental|PF-03715455|
11505625|NCT01314885|Experimental|PH-797804|
11505626|NCT01314885|Placebo Comparator|Placebo for PF-03715455|
11505627|NCT01314885|Placebo Comparator|Placebo for PH-797804|
11505628|NCT01314872|Placebo Comparator|Part 1: placebo|Participants received two placebo matching vibegron tablets and one placebo matching tolterodine extended release (ER) capsule, taken orally each morning, for 8 weeks.
11505629|NCT01314872|Experimental|Part 1: vibegron 3 mg|Participants received one vibegron 3 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
11505630|NCT01314872|Experimental|Part 1: vibegron 15 mg|Participants received one vibegron 15 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
11505631|NCT01314872|Experimental|Part 1: vibegron 50 mg|Participants received one vibegron 50 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
11505632|NCT01314872|Experimental|Part 1: vibegron 100 mg|Participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
11505633|NCT01314872|Active Comparator|Part 1: tolterodine ER 4 mg|Participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 8 weeks.
11505634|NCT01314872|Experimental|Part 1: vibegron 50 mg + tolterodine ER 4 mg/vibegron 50 mg|Participants received one vibegron 50 mg tablet and one placebo matching vibegron tablet, taken orally each morning, for 8 weeks. They also received one tolterodine ER 4 mg capsule for the first 4 weeks and one placebo matching tolterodine ER capsule for the second 4 weeks, both taken orally each morning.
11505635|NCT01314872|Placebo Comparator|Part 2: placebo|Participants received two placebo matching vibegron tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 4 weeks.
11505636|NCT01314872|Experimental|Part 2: vibegron 100 mg|Participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 4 weeks.
11505637|NCT01314872|Active Comparator|Part 2: tolterodine ER 4 mg|Participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 4 weeks.
11505638|NCT01314872|Experimental|Part 2: vibegron 100 mg + tolterodine ER 4 mg|Participants received two vibegron 50 mg tablets and one tolterodine ER 4 mg capsule, taken orally each morning, for 4 weeks.
11505639|NCT01314872|Experimental|Extension Study: vibegron 50 mg|Participants in Base Study/Part 1 who received vibegron 50 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received vibegron 3 mg received vibegron 50 mg in the Extension Study. Also, participants in Base Study/Part 1 who received vibegron 50 mg + tolterodine ER for 4 weeks, followed by vibegron 50 mg alone for 4 weeks, remained on vibegron 50 mg in the Extension Study. In the extension, participants received one vibegron 50 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 52 weeks.
11505640|NCT01314872|Experimental|Extension Study: vibegron 100 mg|Participants in Base Study/Part 1 or Part 2 who received vibegron 100 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received vibegron 15 mg received vibegron 100 mg in the Extension Study. In the extension, participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 52 weeks.
11505641|NCT01314872|Experimental|Extension Study: tolterodine ER 4 mg|Participants in Base Study/Part 1 or Part 2 who received tolterodine ER 4 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received placebo also received tolterodine ER 4 mg in the Extension Study. In the extension, participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 52 weeks.
11505642|NCT01314872|Experimental|Extension Study: vibegron 100 mg + tolterodine ER 4 mg|Participants in Base Study/Part 1 who received vibegron 100 mg + tolterodine ER 4 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 2 who received placebo were assigned to the vibegron 100 mg + tolterodine ER 4 mg arm in the Extension Study. In the extension, participants received two vibegron 50 mg tablets and one tolterodine ER 4 mg capsule, taken orally each morning, for 52 weeks.
11505643|NCT01314859|Experimental|Nifedipine|"Oral Treatment with Nifedipine capsules (10 mg)
~Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).
~Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.
~Maximum Duration of the treatment: 48 hours."
11505644|NCT01314859|Active Comparator|Atosiban|"Intravenously Treatment with Atosiban (7.5mg/ml)
~Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.
~Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.
~Maximum Duration of the treatment: 48 hours."
11505645|NCT01314846||Control Group|sequential culture system
11505646|NCT01314846||Co-culture system|
11505686|NCT01314495|Active Comparator|Abatacept|Abatacept administered as a 30 minute intravenous infusion
11505647|NCT01314833|Experimental|TC*6|6 cycles of (Docetaxel 75mg/m2 ivgtt d1+ Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) .
11505648|NCT01314833|Experimental|CEF*3-T*3|3 cycles of CEF (Epirubicin 100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
11505649|NCT01314833|Experimental|EC*4-wP*12|4 cycles of EC (Epirubicin 90 mg/m2 ivgtt d1+Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) followed by 4 cycles of Paclitaxel (Paclitaxel 80mg/m2, ivgtt d1,8,15, 21days per cycle)
11505650|NCT01314820|Active Comparator|normal saline injection|20 cc normal saline injection into the knee joint
11505651|NCT01314820|Sham Comparator|sham injection|knee injection without saline
11505652|NCT01314807||patients with COPD|patients who were defined as COPD, based on post-bronchodilator spirometry (GOLD criteria). Patients will have at least 10 pack years
11505653|NCT01314807||smoking controls|patients with at least 10 pack years who have no COPD (based on post-bronchodilator spirometry)
11505654|NCT01314807||non-smoking controls|patients with < 1 pack year who have no COPD (based on post-bronchodilator spirometry)
11505655|NCT01314781|Experimental|solifenacin 5mg, PFMT and WBVT|Patients randomized to group A will receive solifenacin 5mg tablet once daily and a training programme for PFMT and WBVT once a week.
11505656|NCT01314781|Active Comparator|solifenacin 5mg|Subjects randomised to group B will receive solifenacin 5mg tablet once daily.
11505657|NCT01314768|Active Comparator|Brief intervention|Behavioural brief intervention delivered by GP
11505658|NCT01314768|Placebo Comparator|Business as usual|Business as usual according to individual GP
11505659|NCT01314768|Other|Chronic headache control|Screening and outcome control only. Non-intervention Control, screened and followed-up at final time point
11505660|NCT01314768|Other|Population control|Screening and outcome control only. Non-intervention Control, screened and followed-up at final time point
11505661|NCT01314755|Experimental|immune-enhancing feed IMPACT|immune-enhancing feed IMPACT
11505662|NCT01314755|Active Comparator|control arm|iso-nitrogenous, iso-caloric control feed
11505663|NCT01314742|Experimental|Biotene OralBalance® gel Arm|Biotene OralBalance® gel contains antibacterial active ingredients: lactoperoxidase, lysozyme and lactoferrin. These enzymes occur naturally in the human milk and colostrum and have mimicking properties of the human saliva activity in vivo.
11505664|NCT01314742|Placebo Comparator|Sterile Water Arm|Sterile Water moisten cotton tipped applicator
11505665|NCT01314729|Active Comparator|Fiber-reinforced-composite retainer|
11505666|NCT01314729|Active Comparator|composite-wire retainer|
11505667|NCT01314716|Experimental|AZLI-AZLI|Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
11505668|NCT01314716|Placebo Comparator|Placebo-AZLI|Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
11505669|NCT01314677|Experimental|Group A (FDG PET/CT between RT fractions 5-6)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.
~Patients undergo a FDG PET/CT scan between RT fractions 5-6 (before course 2 of chemotherapy).
~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
11505670|NCT01314677|Experimental|Group B (FDG PET/CT between RT fractions 10-11)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.
~Patients undergo a FDG PET/CT scan between RT fractions 10-11 (before course 3 of chemotherapy).
~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
11505671|NCT01314677|Experimental|Group C (FDG PET/CT between RT fractions 15-16)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.
~Patients undergo a FDG PET/CT scan between RT fractions 15-16 (before course 4 of chemotherapy).
~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
11505672|NCT01314651|Experimental|Sleep Management|Instructions in stimulus control and sleep restriction.
11505673|NCT01314651|Sham Comparator|Lifestyle Modification|Instructions to change general lifestyle habits (maintain consistent liquid consumption, range of motion exercises, etc.)
11505674|NCT01314638||Single group|Single group, Identical investigations for all subjects
11505675|NCT01314625||one arm|
11505676|NCT01314612|Experimental|Group Intervention|Subjects randomly assigned to this arm of the study will receive the 9-week insomnia and nightmare intervention group once per week for 90 minutes in addition to continuing treatment as usual with medical and mental health providers.
11505677|NCT01314612|No Intervention|Treatment as Usual|This group is randomly assigned to receive only treatment as usual and does not receive the active intervention of the insomnia and nightmare group treatment. This treatment will be made available to these members once the study is completed
11505678|NCT01314599|Experimental|Arm 1|PM01183 will be administered i.v. as a 1-hour infusion through a pump device at escalating doses according to the respective dose level, on Days 1 and 8 of each treatment phase.
11505679|NCT01314586|Placebo Comparator|placebo|placebo pill, diet counseling to comply with NCEP Step I diet
11505680|NCT01314586|Experimental|150 mg/day Beneflax|2 pills taken at breakfast and dinner containing a total of 150 mg secoisolariciresinol (SDG) per day for 12 weeks
11505681|NCT01314586|Experimental|300 mg/day Beneflax|2 pills taken at breakfast and dinner containing a total of 300 mg secoisolariciresinol (SDG) per day for 12 weeks
11505682|NCT01314573|Experimental|Interval maximal exercise|Interval exercise involving repeated Wingate tests (30s durations of maximal exercise on a cycle ergometer).
11505683|NCT01314573|Experimental|Continuous maximal exercise|Continuous exercise of maximal exertion that has been work matched to an initial bout of interval exercise of 4 x 30s of maximal exercise. This exercise is performed on a cycle ergometer.
11505684|NCT01314560|Experimental|1|experimental
11505685|NCT01314508|Other|All patients will be treated with IGF-1 factors|Patients will serve as their own control.
11506218|NCT01310673|Active Comparator|Allopurinol|
11505687|NCT01314495|Placebo Comparator|Inactive infusion|Placebo will be administered as a 30 minute intravenous infusion.
11505688|NCT01314482|Experimental|Minocycline|
11505689|NCT01314469||Patients with intermediate uveitis|
11505690|NCT01314456|Experimental|NaviGo|Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
11505691|NCT01314443|Experimental|Placebo + Smoking Cessation|Individuals will quit smoking without use of nicotine replacement therapy (NRT) and ingest a placebo for 7 days
11505692|NCT01314443|Experimental|Supplement + Smoking Cessation|Individuals will quit smoking without the use of nicotine replacement therapy (NRT) and ingest a gamma-tocopherol supplement for 7 days
11505693|NCT01314443|Experimental|Placebo + Nicotine Replacement Therapy|Individuals will quit smoking with the use of nicotine replacement therapy (NRT) and ingest a placebo for 7 days
11505694|NCT01314443|Experimental|Supplement+Nicotine Replacement Therapy|Individuals will quit smoking with the use of nicotine replacement therapy (NRT) and ingest a gamma-tocopherol supplement for 7 days
11505695|NCT01314417|Experimental|Methotrexate|400 μg/100 μL injection
11505696|NCT01314404||KAP/WTP study population|"The participants will range in age from 12 to 50 and will be selected randomly. The study population will be representative of the following categories: men, women, adolescent boys, and adolescent girls.
~As our study seeks to take a broad-based view of knowledge related to cervical cancer and HPV, our study population is necessarily wide-ranging. Adolescent boys and girls will be between the ages of 12 and 18; men and women will be older than 18, with at least one child that falls within the adolescent age range."
11505697|NCT01314404||Prevalence study population|"We plan to identify and recruit women diagnosed with cervical cancer who are being treated by a doctor from the department of gynecology of the Hospital Gabriel Touré in Bamako, Mali. These patients will have been previously identified and diagnosed by clinical exam by an obstetrician-gynecologist at Gabriel Touré, and will have been identified as surgical candidates by a doctor.
~The subject has expressed a willingness to have a biopsy or other gynecological operation and have a doctor collect tissue samples during a standard medical appointment, has agreed to have blood drawn, was older than 18, and has the capacity to give informed consent."
11505698|NCT01314378|Active Comparator|Cognitive-Behavioral Therapy|
11505699|NCT01314378|Experimental|Mindfulness Training|
11505700|NCT01314352|Experimental|Desloratadine Tablets, 5 mg|Desloratadine Tablets, 5 mg of Dr. Reddy's Laboratories
11505701|NCT01314352|Active Comparator|Clarinex|Clarinex® 5 mg Tablets of Schering-Plough
11505702|NCT01314339|Experimental|Desloratadine Tablets, 5 mg|Desloratadine Tablets, 5 mg of Dr. Reddy's Laboratories
11505703|NCT01314339|Active Comparator|Clarinex|Clarinex® 5 mg Tablets of Schering-Plough
11505704|NCT01314326||Perimetric Glaucoma (PG)|Patients with clinically confirmed abnormal VF and glaucomatous ONH or NFL defect
11505705|NCT01314326||Glaucoma Suspects and Pre-Perimetric Glaucoma (GSPPG) Group|Patients who are at high risk to develop perimetric glaucoma
11505706|NCT01314326||Normal Group|Volunteers with healthy eyes
11505707|NCT01314313|Experimental|PIIA - SAPIEN XT|PIIA is operable group
11505708|NCT01314313|Active Comparator|Control: SAVR|SAVR (surgical aortic valve replacement) is the control arm
11505709|NCT01314300|Experimental|Efficacy of Lidocaine 5% plaster|Treatment of pain by Lidocaine 5% plaster
11505710|NCT01314274|Experimental|bevacizumab|submucosal intranasal bevacizumab on day 0
11505711|NCT01314274|Placebo Comparator|placebo|0.9% NaCl intranasal submucosal on day 0
11505712|NCT01314261|Experimental|ABT-267 (5 mg) once daily + pegIFN/RBV|Participants were given 5 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
11505713|NCT01314261|Experimental|ABT-267 (50 mg) once daily + pegIFN/RBV|Participants were given 50 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
11505714|NCT01314261|Experimental|ABT-267 (200 mg) once daily + pegIFN/RBV|Participants were given 200 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
11505715|NCT01314261|Placebo Comparator|Placebo + pegIFN/RBV|Participants were given matching placebo to ABT-267 once daily in combination with pegIFN/RBV for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
11505716|NCT01314248||children weighing 10 to 15 kg|
11505717|NCT01314222|Other|Arm 1: BMS-954561 40mg or 80mg|"BMS-954561 40mg or 80mg TID to Placebo OR Placebo to 40mg or 80mg TID
~Active to Placebo or Placebo to Active (cross-over)"
11505718|NCT01314222|Other|Arm 2: BMS-954561 150mg or 300mg|"BMS-954561 150mg or 300mg TID to Placebo OR Placebo to 150mg or 300mg TID
~Active to Placebo or Placebo to Active (cross-over)"
11505719|NCT01314222|Other|Arm 3: Pregabalin 100mg|"Pregabalin 100mg TID to Placebo OR Placebo to 100mg TID
~Active to Placebo or Placebo to Active (cross-over)"
11505720|NCT01314209|Experimental|dexmedetomidine|
11505721|NCT01314196|Active Comparator|therapeutic exercises|therapeutic exercises for the shoulder and scapula stabilizers
11505722|NCT01314196|Experimental|progressive resistance training biceps|therapeutic exercises for the shoulder and scapula stabilizers and biceps resistance training.
11505723|NCT01314183|Active Comparator|exercise|Subjects in this arm receive 12 exercise sessions in 9 weeks.
11505724|NCT01314183|Active Comparator|exercise + manual therapy|Subjects in this group receive exercise combined with manual therapy techniques for 12 sessions in 9 weeks.
11505725|NCT01314183|Experimental|exercise + booster|subjects in this arm will receive exercise sessions delivered with booster sessions (8 sessions in the first 9 weeks, 2 sessions at 5 months, 1 session at 8 months, and 1 session at 11 months).
11505726|NCT01314183|Experimental|exercise + manual therapy + booster|Subjects in this arm will receive exercise combined with manual therapy techniques and booster sessions.
11505727|NCT01314170|No Intervention|Susanna Implant|Patients with refractory glaucoma neovascular type or that failed in trabeculectomy will undergo surgery to place implants Susana.
11505728|NCT01314157|Experimental|Physiotherapy treatment technique|"Randomized clinical trial controlling and using at the time of allocation, toss with sealed envelopes, sealed and opaque. The study group will be dealt with technical isostretching and the other group is control group."
11505729|NCT01314144|Experimental|Bupivacaine|Patients will receive intraoperative wound soakage with 20ml of 0.5% bupivacaine with adrenaline by the surgeon before closure and receive a continuous infusion of 4ml/hr of 0.2% bupivacaine delivered by an elastomeric pump the catheter of which will be placed by the surgeon in the wound before closure. Postoperative anlagesia will be provided with oxycodone, paracetamol and diclofenac.
11505730|NCT01314144|No Intervention|Control|Patients will receive morphine up to 0.1mg/kg intraoperatively. Postoperative analgesia will be provided with oxycodone, paracetamol and diclofenac.
11505731|NCT01314131|Experimental|Intervention group|
11505732|NCT01314118|Experimental|001|abiraterone acetate in combination with prednisone Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
11505733|NCT01314105|Experimental|BIBF 1120 L+ Carboplatin + PLD|BIBF 1120 (100 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
11505734|NCT01314105|Experimental|BIBF 1120 M + Carboplatin + PLD|BIBF 1120 (150 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
11505735|NCT01314105|Experimental|BIBF 1120 H + Carboplatin + PLD|BIBF 1120 (200 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
11505736|NCT01314092|Experimental|Group 1|Low dose group
11505737|NCT01314092|Experimental|Group 2|high dose group
11505738|NCT01314066|Experimental|Bevacizumab 5 mg/kg|Receive drug solution as a single dose. Treatment will be given as 90 minute IV infusion.
11505739|NCT01314066|Experimental|Bevacizumab at 10 mg/kg|Receive drug solution as a single dose. Treatment will be given as 90 minute IV infusion.
11505740|NCT01314066|Placebo Comparator|Placebo|In addition to receiving the best standard supportive care for both diagnosis and treatment for individuals diagnosed with severe sepsis, they will receive an IV saline solution.
11505741|NCT01314040|Other|Run in|
11505742|NCT01314040|Experimental|High meat protein diet|
11505743|NCT01314040|Experimental|High dairy protein diet|
11505744|NCT01314040|Experimental|High grain protein diet|
11505745|NCT01314027|Experimental|neoadjuvant + adjuvant chemotherapy|neoadjuvant chemotherapy is based on gemcitabine/oxaliplatin adjuvant therapy is based on gemcitabine
11505746|NCT01314027|Active Comparator|adjuvant chemotherapy|adjuvant therapy is based on gemcitabine
11505747|NCT01314014|Experimental|Imexon|Subjects will be treated on Days 1-5 of 21-day treatment cycles for up to one year. Following pre-treatment with anti-emetics Amplimexon will be given by intravenous infusion over 60 minutes.
11505748|NCT01314001|Placebo Comparator|Placebo (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.
~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.
~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.
~All subjects in this arm will receive smoking cessation counseling during their sessions."
11505749|NCT01314001|Active Comparator|Varenicline (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take active varenicline pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.
~When taking the active varenicline, subjects will follow the same treatment regimen per the manufacturer.
~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.
~All subjects in this arm will receive smoking cessation counseling during their sessions."
11505750|NCT01314001|Active Comparator|Transdermal Nicotine (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & will wear an active transdermal nicotine patch daily for eleven weeks.
~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.
~When wearing the active transdermal nicotine, subjects will follow the same treatment regimen per the manufacturer.
~All subjects in this arm will receive smoking cessation counseling during their sessions."
11505751|NCT01314001|Placebo Comparator|Placebo (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.
~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.
~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.
~All subjects in this arm will receive smoking cessation counseling during their sessions."
11505752|NCT01314001|Active Comparator|Varenicline (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take active varenicline pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.
~When taking the active varenicline, subjects will follow the same treatment regimen per the manufacturer.
~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.
~All subjects in this arm will receive smoking cessation counseling during their sessions."
11505795|NCT01313715|Experimental|640U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 45 children aged 13-60 months old on day0,28
11505796|NCT01313715|Experimental|160U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 45 infants aged 6-12 months old on day0,28
11506219|NCT01310673|Placebo Comparator|Placebo|
11505753|NCT01314001|Active Comparator|Transdermal Nicotine (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & will wear an active transdermal nicotine patch daily for eleven weeks.
~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.
~When wearing the active transdermal nicotine, subjects will follow the same treatment regimen per the manufacturer.
~All subjects in this arm will receive smoking cessation counseling during their sessions."
11505754|NCT01313988|Active Comparator|Dose 1|Spread that contains plant sterols and fish oil
11505755|NCT01313988|Active Comparator|Dose 2|Spread that contains plant sterols and fish oil
11505756|NCT01313988|Active Comparator|Dose 3|Spread that contains plant sterols and fish oil
11505757|NCT01313988|Placebo Comparator|Placebo|Placebo spread
11505758|NCT01313988|Active Comparator|Control|Spread that contains plant sterols
11505759|NCT01313975||1|Patients with non-traumatic subarachnoid hemorrhage
11505760|NCT01313975||2|Patients with severe traumatic brain injury
11505761|NCT01313962|Experimental|Flufirvitide-3|
11505762|NCT01313962|Placebo Comparator|Placebo|
11505763|NCT01313949|No Intervention|Usual Care|A total of 90 patients with diabetes will be recruited. Thirty will be selected for the training course and the other 60 will be compared as controls. These controls will receive their usual diabetes care.
11505764|NCT01313949|Experimental|Peer leader training|"Peer leaders are people with diabetes who had volunteered to undertake an extensive program of training. The purpose of this training is to make them effective in the provision of support and advice to their peers on a one-to-one basis via telecommunication.
~These diabetes patients will undergo a 32-hour 'Train the trainer' program (4 workshops, 8-hours each) led by health care experts in nutrition, physical activity, psychology and neuro-linguistic program [NLP] trainer to ensure the adequacy of knowledge and skills of these mentors."
11505765|NCT01313936|Experimental|15 mCi/kg of 131I-MIBG|The first cohort for safety will be 3-6 patients treated with vincristine and irinotecan and 15 mCi/kg of 131I-MIBG.
11505766|NCT01313936|Experimental|18 mCi/kg of 131I-MIBG|The second cohort will be 3-6 patients at the same doses of vincristine and irinotecan and 18 mCi/kg of 131I-MIBG.
11505767|NCT01313923|Experimental|Sirolimus (formerly known as Rapamycin)|Subjects with stable pemphigus vulgaris already on treatment with prednisone will be enrolled. Subjects will start taking oral sirolimus and have it up-titrated while decreasing the prednisone dosage. Their disease state will be monitored during this time.
11505768|NCT01313910|Experimental|ImmunoLin®|8-week treatment course
11505769|NCT01313897|Experimental|Velcade for Anti-MM therapy|Day(s) -9,-6,-2 3 doses of Bortezomib at 1.0 mg/m2, i.v.
11505770|NCT01313884|Experimental|Combination Therapy|"Regimen A alternating with Regimen B every 21 days
~Regimen A:
~Cytoxan 1200mg/m2
~Doxorubicin, starting dose 75 mg/m2 to a maximum of 450mg/m2
~Vincristine, starting dose 2 mg/m2 to a maximum of 2 mg
~Pegfilgrastim, 6 mg subcutaneous within 24 to 48 hours after each cycle
~Regimen B:
~Irinotecan 50 mg/m2/day x 5 days
~Temozolomide 100 mg/m2/day x 5 days followed by 2 weeks treatment-free"
11505771|NCT01313871||All Participants|Adults with a confirmed diagnosis of rheumatoid arthritis
11505772|NCT01313858||Participants with Rheumatoid Arthritis|Simponi®-naïve participants with rheumatoid arthritis given Simponi® 50 mg once a month as a subcutaneous injection. Combination use with methotrexate was recommended.
11505773|NCT01313858||Participants with Psoriatic Arthritis|Simponi®-naïve participants with psoriatic arthritis given Simponi® 50 mg once a month as a subcutaneous injection.
11505774|NCT01313858||Participants with Ankylosing Spondylitis|Simponi®-naïve participants with ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.
11505775|NCT01313845|Active Comparator|amantadine|administration of intravenous amantadine sulfate 200mg/500ml/bottle 1 bottle infusion over 3 hours, twice a day for consecutive 5 days
11505776|NCT01313845|Placebo Comparator|placebo|administration of 0.9% sodium chloride 500ml/bottle 1 bottle infusion over 3 hours twice a day for consecutive 5 days
11505777|NCT01313832|Experimental|remote ischemic preconditioning|
11505778|NCT01313819|Active Comparator|Group 1|Give IV amantadine first then IV placebo(normal saline) drug
11505779|NCT01313819|Active Comparator|Group 2|Give IV placebo drug first then IV amantadine
11505780|NCT01313806|Active Comparator|Resonator|Treatment with active Resonator device using low level magnetic fields
11505781|NCT01313806|Placebo Comparator|Placebo|
11505782|NCT01313793|Experimental|Sequence 1|Subjects will receive clinical formulation (treatment A) followed by commercializable formulation (treatment B).
11505783|NCT01313793|Experimental|Sequence 2|Subjects will receive commercializable formulation (treatment B) followed by clinical formulation (treatment A).
11505784|NCT01313780|Experimental|'Oxycodone/Naloxone'|Trade name is Targin(fixed combination drug).
11505785|NCT01313780|Active Comparator|Oxycodone|Trade name is Oxycontin(single compound).
11505786|NCT01313767|Experimental|Meditoxin®|Botulinum toxin type A
11505787|NCT01313767|Active Comparator|Botox®|Botulinum Toxin type A
11505788|NCT01313754|Other|Vicryl|These patients will receive the standard monocryl suture on their right sided inguinal incision and then will receive the vicryl material on the left.
11505789|NCT01313754|Experimental|Dermabond|The patients will receive the standard monocryl suture on their right sided inguinal incision and then will receive dermabond skin glue on the left
11505790|NCT01313741|Experimental|Single arm shoulder arthroplasty|
11505791|NCT01313728|Experimental|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks - all subjects participate in both arms in a split-face model
11505792|NCT01313728|Active Comparator|Tretinoin Gel Alone|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks - all subjects participate in both arms in a split-face model
11505793|NCT01313715|Experimental|160U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 45 children aged 13-60 months old on day0,28
11505794|NCT01313715|Experimental|320U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 45 children aged 13-60 months old on day0,28
11506220|NCT01310660||Nulliparous|
11505797|NCT01313715|Experimental|320U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 45 infants aged 6-12 months old on day0,28
11505798|NCT01313715|Experimental|640U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 45 infants aged 6-12 months old on day0,28
11505799|NCT01313715|Placebo Comparator|0/0.5ml placebo in children|0/0.5ml placebo in 45 children aged 13-60 months old on day0,28
11505800|NCT01313715|Placebo Comparator|0/0.5ml placebo in infants|0/0.5ml placebo in 45 infants aged 6-12 months old on day0,28
11505801|NCT01313702|Experimental|polipillV1|poli pill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
11505802|NCT01313702|Experimental|polipillV2|Polipill versão2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
11505803|NCT01313702|Active Comparator|usual care|
11505804|NCT01313689|Experimental|Ofatumumab|Biological
11505805|NCT01313689|Active Comparator|Physicians' Choice|Physicians' choice of treatment
11505806|NCT01313676|Experimental|fluticasone furoate/vilanterol|Combination of both products in one inhaler
11505807|NCT01313676|Experimental|fluticasone furoate|comparator of individual component
11505808|NCT01313676|Experimental|vilanterol|comparator of individual component
11505809|NCT01313676|Placebo Comparator|placebo|once daily via inhaler
11505810|NCT01313663|Experimental|Pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
11505811|NCT01313663|Active Comparator|Pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
11505812|NCT01313650|Experimental|GSK573719/GW642444|62.5/25mcg
11505813|NCT01313650|Experimental|GSK573719|62.5mcg
11505814|NCT01313650|Experimental|GW642444|25mcg
11505815|NCT01313650|Placebo Comparator|Placebo|Placebo
11505816|NCT01313637|Experimental|GSK573719/GW642444|125/25mcg
11505817|NCT01313637|Experimental|GSK573719|125mcg
11505818|NCT01313637|Experimental|GW642444|25mcg
11505819|NCT01313637|Placebo Comparator|Placebo|Placebo
11505820|NCT01313624|Experimental|AZLI-AZLI|Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
11505821|NCT01313624|Placebo Comparator|Placebo-AZLI|Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
11505822|NCT01313611|Experimental|Rituximab + bendamustine|
11505823|NCT01313598|Experimental|GLPG0187|GLPG0187 for infusion
11505824|NCT01313585||IPDA salbutamol MDI|receive a recorded increase in ICS therapy as BDP Easibreathe at the index date and also receive salbutamol MDI
11505825|NCT01313585||IPDA salbutamol EB|receive a recorded increase in ICS therapy as BDP Easibreathe at the index date and also receive salbutamol Easibreathe
11505826|NCT01313585||IPDI salbutamol EB|initiate ICS therapy as BDP Easibreathe at the index date and also receive salbutamol Easibreathe
11505827|NCT01313585||IPDI salbutamol MDI|initiate ICS therapy as BDP Easibreathe at the index date and also receive salbutamol MDI
11505828|NCT01313572|Experimental|Apadenoson|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson
11505829|NCT01313572|Active Comparator|Adenosine|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with the active comparator: adenosine.
11505830|NCT01313559|Active Comparator|Cohort A (pasireotide)|Patients receive pasireotide IM once every 4 weeks
11505831|NCT01313559|Experimental|Cohort B (pasireotide and everolimus)|Patients receive pasireotide as in cohort A and everolimus PO QD
11505832|NCT01313546|Active Comparator|quadriceps|quadriceps muscular contraction
11505833|NCT01313546|Active Comparator|sartorius|stimulation of sartorius muscle through femoral nerve
11505834|NCT01313533|Active Comparator|Lactated Ringers Solution with Arginine|100 ml of LRS with arginine
11505835|NCT01313533|Placebo Comparator|Lactated Ringers Solution|Lactated ringers solution
11505836|NCT01313520|Experimental|Infliximab|3 mg/kg of Infliximab intravenous infusion
11505837|NCT01313520|Placebo Comparator|Placebo|saline via intravenous infusion
11505838|NCT01313507|Experimental|NewGam|Participants received NewGam 200-800 mg/kg intravenously every 3 or 4 weeks for 3 months (5 or 4 total infusions, respectively).
11505839|NCT01313494|Experimental|Roflumilast|Roflumilast 500 μg, tablet, oral, once daily for up to 24 weeks.
11505840|NCT01313494|Placebo Comparator|Placebo|Placebo to roflumilast, tablet, oral, once daily for up to 24 weeks.
11505841|NCT01313481|Experimental|Group exercise|Otago exercise performed in groups
11505842|NCT01313481|Active Comparator|Home exercise|Otago exercise performed as home exercise
11505843|NCT01313468|Experimental|4 x 4 Interval|4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
11505844|NCT01313468|Experimental|1 4 minutes interval|1 x 4 minutes intervals at 90-95% of HR max
11505845|NCT01313468|Experimental|Moderate continuous Training|47 minutes of Moderate continuous Training
11505846|NCT01313442||1/ Cohort 1|Subjects with a diagnosis of cancer
11505847|NCT01313429|Experimental|1|tumor cell vaccine administered with chemotherapy
11505848|NCT01313416|Experimental|Single arm|Combination CT-011 and Gemcitabine
11505849|NCT01313377|Experimental|ARM A: Gemox 85|Adjuvant chemotherapy for six months with gemcitabine - oxaliplatin 85mg / m² ( GEMOX 85)
11505850|NCT01313377|Other|ARM B:|Observation until progression or death
11505851|NCT01313364|Experimental|All subjects to self-administer 4 IM injections|Subjects will be recruited and stratified into BMI groups: <18.5 kg/m2, 18.5 to 24.9 kg/m2, 25 to 29.99 kg/m2, and >30 kg/m2 all with 20 subjects. To maintain a balance between sexes that is representative of the MS population, approximately 50 to 70% of subjects within each BMI group should be female.
11505852|NCT01313338||Acute coronary syndrome|
11506344|NCT01309841|Placebo Comparator|3|Oral treatment
11505853|NCT01313325|Experimental|Treatment group|Children between 5-17 years who have balance deficits related to any movement disorder (preferably neuromuscular)
11505854|NCT01313312|Experimental|Total Dysport®|A total of 254 subjects in the open label study received between 1 and 5 intramuscular (i.m) injections of Dysport® according to their individual needs, for a period of up to 12 months. All subjects were administered an appropriate dosage of Dysport® (1000 Units [U] or 500 U) on Day 1 of treatment Cycle 1. At each study visit from Week 12 onwards, subjects were assessed to determine whether a subsequent treatment cycle was required and treatment cycles were administered at intervals of a minimum of 12 weeks apart depending on the subject's safety and efficacy response. From Cycle 2 onwards, a total dose of 1500 U could be administered in subjects requiring treatment with Dysport® in their shoulder and other upper limb muscles. Subjects who showed improvement in their upper limb during the first two treatment cycles were able to receive concomitant injections of Dysport® 500 U into at least one calf muscle, from Cycle 3 onwards as long as the total dose did not exceed 1500 U.
11505855|NCT01313299|Experimental|Dysport 500 U|
11505856|NCT01313299|Experimental|Dysport 1000 U|
11505857|NCT01313299|Placebo Comparator|Placebo|
11505858|NCT01313286|Experimental|LY2608204 Reference, LY2608204 Test|Single oral 80 mg dose of LY2608204 reference formulation in period 1; single oral 80 mg dose of LY2608204 test formulation in period 2. There is a washout period of at least 14 days between dosing periods.
11505859|NCT01313286|Experimental|LY2608204 Test, LY2608204 Reference|Single oral 80 mg dose of LY2608204 test formulation in period 1; single oral 80 mg dose of LY2608204 reference formulation in period 2. There is a washout period of at least 14 days between dosing periods.
11505860|NCT01313273|Other|Arm A|
11505861|NCT01313273|Experimental|Arm B|
11505862|NCT01313260||Epilepsy patients|Epilepsy patients selected before undergoing intracranial EEG recordings
11505863|NCT01313260||control group|Healthy volunteers
11505864|NCT01313247|Placebo Comparator|Placebo pills|Placebo tablets resembling paracetamol 500 mg are given as alternative 2 tablets 4 times daily
11505865|NCT01313247|Active Comparator|oral paracetamol 4 g daily|Patients are given 2 tablets of 500 mg paracetamol on a regular basis 4 times daily
11505866|NCT01313234|Experimental|Education|Educational theory based intervention and systematic daily pain assessment
11505867|NCT01313234|No Intervention|Control|Control group with care as usual
11505868|NCT01313221|Active Comparator|Etanercept 50 mg BIW|Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg etanercept twice weekly for 12 weeks.
11505869|NCT01313221|Experimental|Etanercept 50 mg QW + Topical|Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg etanercept once weekly plus as needed topical agents.
11505870|NCT01313208|Placebo Comparator|Placebo|"Participants received placebo subcutaneous injections once a week for 12 weeks and then open-label etanercept 50 mg subcutaneous injection once weekly for the next 12 weeks.
~All participants continued their disease modifying anti-rheumatic drug (DMARD) treatment throughout the 24-week study period."
11505871|NCT01313208|Experimental|Etanercept|"Participants received etanercept 50 mg subcutaneous injection once weekly for 12 weeks and then open-label etanercept 50 mg subcutaneous injection for the next 12 weeks.
~All participants continued their DMARD treatment throughout the 24-week study period."
11505872|NCT01313182|Active Comparator|3M Skin and Nasal Antiseptic|Povidone-iodine solution 5% w/w (0.5% available iodine) USP Patient Preoperative Skin Preparation
11505873|NCT01313182|Active Comparator|Bactroban Nasal|Mupirocin calcium ointment, 2%
11505874|NCT01313169|Experimental|EMR reminder|EMR reminder
11505875|NCT01313169|Experimental|EMR reminder + Panel management|EMR reminder + Panel manager
11505876|NCT01313169|No Intervention|Control|Control
11505877|NCT01313143|Experimental|AOP200704, infusion|
11505878|NCT01313143|Active Comparator|Esmolol, infusion|
11505879|NCT01313130||blast-related TBI|100 active duty US military personnel identified clinically as having suffered blast-related TBI
11505880|NCT01313130||non-blast-related TBI|100 active duty US military personnel identified clinically as having suffered non-blast-related TBI. TBI caused by other mechanisms such as motor vehicle crashes, falls, struck by blunt objects etc.
11505881|NCT01313130||other blast-related injuries|100 active duty US military personnel with blast-exposure and other blast-related injuries but no clinical evidence of TBI
11505882|NCT01313130||other non-blast injuries|100 active duty US military personnel with other non-blast injuries and no clinical evidence of TBI
11505883|NCT01313117|Experimental|Alpha lipoic acid|Oral administration three times daily (morning, mid-day, night)
11505884|NCT01313104|Experimental|Screening|See Detailed Description
11505885|NCT01313078|Experimental|Pegaspargase in women with cancer|Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks
11505886|NCT01313065|Experimental|VX15/2503|VX15/2503 monoclonal antibody at a concentration of 0.3 mg/kg - 20 mg/kg to be administered intravenously on a weekly dosing cycle.
11505887|NCT01313052|Experimental|Forensic Assertive Community Treatment (FACT)|Individuals in this arm will receive the services of an Assertive Community Treatment team and close supervision of a judge trained in the FACT model.
11505888|NCT01313052|Active Comparator|Enhanced Treatment as Usual|Individuals in this arm of the study will receive an expedited appointment at a clinic specializing in the treatment of psychotic disorders. These individuals will receive the services of a therapist, psychiatrist, and case manager.
11505889|NCT01313039|Experimental|AZD6244|
11505890|NCT01313026|Active Comparator|PNE first|patients randomised to start with PNE stimulation over 4 weeks. Then the stimulator will be removed and after a wash out period of 4 weeks they will be trained in transanal irrigation
11505891|NCT01313026|Active Comparator|TAI first|Patients randomised to start with transanal irrigation treatment in 8 weeks, thereafter a wash out period of 4 weeks before being implanted with a neuro stimulator
11505892|NCT01313013|Experimental|intervention|question prompt sheet
11505893|NCT01313013|No Intervention|control|no question prompt sheet
11505894|NCT01313000||Autologous fat transfer|
11505895|NCT01312987|Experimental|Nutrition intervention|Receives a month's supply of the nutrition supplement, Plumpy'doz®, in addition to food voucher for each month. Participants were also allowed to attend monthly educational sessions.
11506386|NCT01309542|Experimental|DVS|
11505896|NCT01312987|No Intervention|Control|Receives food vouchers each month.
11505897|NCT01312961|Placebo Comparator|Placebo (for Dupilumab)|Placebo (for Dupilumab) subcutaneous (SC) injection once weekly (qw) for 12 weeks added to background therapy of inhaled corticosteroids/long-acting beta2-adrenergic agonist (ICS/LABA) (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.
11505898|NCT01312961|Experimental|Dupilumab 300 mg qw|Dupilumab 300 mg SC injection qw for 12 weeks added to background therapy of ICS/LABA (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.
11505899|NCT01312948|Experimental|Prototype mask|
11505900|NCT01312935|Experimental|Heparin and PMX-60056|
11505901|NCT01312922|Experimental|PNB01|oral, once daily administration
11505902|NCT01312922|Active Comparator|citalopram|oral, once daily administration
11505903|NCT01312922|Sham Comparator|pipamperone|oral, once daily administration
11505904|NCT01312909|Experimental|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
11505905|NCT01312909|Experimental|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
11505906|NCT01312909|Placebo Comparator|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
11505907|NCT01312883|No Intervention|Treatment as usual|Participants will receive standard postpartum education and discharge materials provided by the hospital and a list of community and Internet resources by mail.
11505908|NCT01312883|Experimental|Behavioral education|Participants will receive behavioral education on postpartum depression and a list of community and Internet resources by mail.
11505909|NCT01312870|Experimental|postoperative nutritional supplements|postoperative nutritional supplements in addition to standard hospital diet
11505910|NCT01312870|Placebo Comparator|standard hospital diet|patients receiving standard hospital diet
11505911|NCT01312857|Experimental|Randomization to panitumumab|Patients whose liver metastases have been completely resected will be randomized Arm A will receive Panitumumab in addition to HAI FUDR/Dexamethasone plus systemic CPT-11/5FU/LV
11505912|NCT01312857|Experimental|Randomization to No Panitumumab|Patients whose liver metastases have been completely resected will be randomized and patients randomized to Arm B will receive HAI FUDR/Dex plus systemic CPT-11/5FU/LV alone.
11505913|NCT01312844|Experimental|Scopolamine|Patients receiving IV scopolamine at ECT treatment
11505914|NCT01312844|Placebo Comparator|Placebo|Patients receiving IV placebo at ECT treatment
11505915|NCT01312831|Experimental|Oral Eligen® B12|Eligen® B12 1000 μg oral tablet taken in the fasted state as a single tablet with 50 mL water. Each dose self-administered daily, for 90 days, after an overnight fast and 1 hour before the morning meal.
11505916|NCT01312831|Active Comparator|IM B12|Commercially available 1000 μg cyanocobalamin administered IM as 1 mL from a vial containing 1000 μg/mL drug administered by study personnel, in the research clinic, in the morning, in the fasted state and at least 1 hour prior to the morning meal on study Days 1, 3, 7, 10, 14, 21, 30, 60 and 90.
11505917|NCT01312818|Experimental|Chemotherapy|Bortezomib IV Vorinostat PO Dexamethasone PO Intrathecal Methotrexate Imatinib Mesylate PO (for Ph+ ALL patients only)
11505918|NCT01312805|Active Comparator|CHICA Control|This arm received CHICA without the asthma module
11505919|NCT01312805|Experimental|CHICA Asthma Module|This arm received the CHICA asthma module
11505920|NCT01312792|Experimental|Modified IMCI guideline|Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
11505921|NCT01312792|Active Comparator|Current IMCI guideline|Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
11505922|NCT01312779|Other|All subjects receive implant|Subjects serve as own control
11505923|NCT01312766|Experimental|hMG-IBSA|New hMG preparation.
11505924|NCT01312766|Active Comparator|Menopur|
11505925|NCT01312727|Other|HTIN|HTIN
11505926|NCT01312714|Active Comparator|Cholecalciferol|
11505927|NCT01312714|Placebo Comparator|Placebo|
11505928|NCT01312701||cancer patients|as described patietns with solid cancer about to be treated with anticancer therapies
11505929|NCT01312701||control group|normal populations who domated blood for further use
11505930|NCT01312688|Other|Standard hemodynamic therapy|Standard hemodynamic therapy currently accepted in our ICU
11505931|NCT01312688|Experimental|Early Goal Directed Hemodynamic Therapy|Early Goal Directed Hemodynamic Therapy according to the Surviving Sepsis Campaign Guidelines
11505932|NCT01312675|Experimental|Group A|S.A.F.E.BT plus Standard of Care therapy
11505933|NCT01312675|No Intervention|Group B|Standard of Care therapy alone
11505934|NCT01312662||normal ophthalmological status|
11505935|NCT01312662||opacity of the refractive media|
11505936|NCT01312662||maculopathy|
11505937|NCT01312662||optic neuropathy|
11505938|NCT01312662||chiasmal and postchiasmal visual pathway pathologies|
11505939|NCT01312662||amblyopia (deprivation)|
11505940|NCT01312662||amblyopia (strabism)|
11505941|NCT01312649|Experimental|Arm 1|Healthy volunteers
11505942|NCT01312649|Experimental|Arm 2|Schizophrenia with history of delusions of control
11505943|NCT01312649|Experimental|Arm 3|Schizophrenia without history of delusions of control
11505944|NCT01312649|Experimental|Arm 4|Bipolar disorders
11505945|NCT01312649|Active Comparator|Arm 5|Matched healthy controls
11505946|NCT01312636||A|
11505947|NCT01312623|Experimental|Remote ischemic preconditioning|Remote ischemic preconditioning at the left leg.
11505948|NCT01312623|No Intervention|Control|No ischemic preconditioning
11505949|NCT01312610|Experimental|High flavonone orange juice drink|
11505950|NCT01312610|Placebo Comparator|Control orange juice drink|Juice drink matched for sugar content
11505951|NCT01312597|Experimental|Fruit beverage|
11505952|NCT01312597|Experimental|Control beverage|
11505953|NCT01312584|Placebo Comparator|Non alkalised High Flavanol|Non-alkalised high flavanol cocoa drink containing 1745 mg of total flavanols
11505954|NCT01312584|Active Comparator|Alkalised high Flavanol|Alkalised high flavanol cocoa drink (medium alkalisation) containing 410 mg of total flavanols
11505955|NCT01312584|Active Comparator|Alkalised Low Flavanol|Alkalised low flavanol cocoa drink (heavily alkalised) containing 1.26 mg of total flavanols
11505956|NCT01312571|Active Comparator|Cognitive behavior therapy via the internet|Cognitive behavior therapy via the internet with therapist support.
11505957|NCT01312571|Active Comparator|Attentional retraining|Attentional retraining as described by Nader Amir.
11505958|NCT01312558|Experimental|Prudent diet group|Participants follow CPAP therapy, a prudent diet while receiving counselling to increase their physical activity.
11505959|NCT01312558|Experimental|Mediterranean diet group|Participants follow CPAP therapy, Mediterranean diet, while receiving counselling to increase their physical activity.
11505960|NCT01312545|Experimental|local made implant (3DP)|Enucleation and local made implant (3DP) insertion
11505961|NCT01312545|Experimental|imported implant (Medpor)|Enucleation and imported implant (Medpor) insertion
11505962|NCT01312532|Other|fixed-bearing|fixed-bearing device is a kind of prosthesis
11505963|NCT01312532|Other|mobile-bearing|mobile-bearing device is a kind of prosthesis
11505964|NCT01312519|Active Comparator|Manual bone marrow sampling device|Hollow needle with a t-shaped handle manually pushed into the bone for the purpose of bone marrow aspiration and core biopsy collection. Manual Bone Marrow Sampling Device.
11505965|NCT01312519|Active Comparator|OnControl Bone Marrow System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest. OnControl Bone Marrow Biopsy and Aspiration System.
11505966|NCT01312506||Subjects undergoing a craniotomy|This group will include those subjects who have consented to have either a craniotomy or a laminectomy to resect an intramedullary tumor.
11505967|NCT01312506||Metastases, no craniotomy|These subjects have metastases but have either chosen not to undergo removal of the cancer or their neurosurgeon does not recommend surgical approach or they have been diagnosed with metastatic melanoma but do not have CNS metastases.
11505968|NCT01312506||Healthy Volunteers|Subjects who do not have known melanoma or metastases.
11505969|NCT01312480|Other|Intervention Group|The smoking cessation intervention is a Public Health Services-approved intervention based on the 5A's Model, which includes (1) Ask if the patient smokes, (2) Advise every patient to quit, (3) Assess readiness to quit, (4) Assist in quitting and finding services and (5) Arrange for cessation services and follow up. Practitioners will complete a 5A checklist for each patient in this arm.
11505970|NCT01312480|Other|Control Group|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
11505971|NCT01312467|Experimental|Prevention (metformin hydrochloride)|Patients receive metformin hydrochloride PO QD during week 1 and then BID during weeks 2-12. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.
11505972|NCT01312454|Experimental|AL-59412C Concentration 1|AL-59412C injectable solution, single intravitreal injection
11505973|NCT01312454|Experimental|AL-59412C Concentration 2|AL-59412C injectable solution, single intravitreal injection
11505974|NCT01312454|Active Comparator|Travoprost|Travoprost injectable solution, single intravitreal injection
11505975|NCT01312454|Placebo Comparator|Vehicle|AL-59412C Vehicle, single intravitreal injection
11505976|NCT01312441|Experimental|Ergocalciferol|Ergocalciferol 50,000 IU by mouth once weekly for 6 months
11505977|NCT01312441|Placebo Comparator|Placebo|Placebo by mouth once weekly for 6 months
11505978|NCT01312428|Other|Pelvic Alignment Level (PAL)|Pelvic Alignment Level Instrument Used
11505979|NCT01312428|Other|No Pelvic Alignment Level (PAL)|No Pelvic Alignment Level Instrument Used
11505980|NCT01312415|Experimental|levobupivacaine infiltration|Patients will receive spinal anaesthesia with intrathecal bupivacaine (17.5 or 15 mg) without morphine, and will receive peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% at 8am the following morning.
11505981|NCT01312415|Other|Control|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
11505982|NCT01312402|Active Comparator|Topical Brinzolamide (Azopt)|ophthalmic drop given three times a day
11505983|NCT01312402|Placebo Comparator|placebo ophthalmic drop in 5 mL solution|masked non-active eye drop (absence of Brinzolamide)
11505984|NCT01312389|Experimental|Arm A|10 patients will receive vaccine (OC-L, an autologous vaccine comprised of autologous oxidized tumor cell lysate, admixed with Montanide ISA 51 VG) injected by intradermal/subcutaneous injection in both groin regions.
11505985|NCT01312389|Experimental|Arm B|10 patients will receive vaccine (OC-L, an autologous vaccine comprised of autologous oxidized tumor cell lysate, admixed with Montanide ISA 51 VG) injected by intradermal/subcutaneous injection in both groin regions, administered in combination with intravenous Ampligen.
11505986|NCT01312350|Active Comparator|CCRT only arm|no neoadjuvant chemotherapy before definitive CCRT
11505987|NCT01312350|Experimental|neoadjuvant chemotherapy arm|2 cycles of TPF chemotherapy before definitive CCRT
11505988|NCT01312337|Experimental|Iressa for EGFR wild group|salvage Iressa therapy for patients with EGFR mutation negative NSCLC patients
11505989|NCT01312324|Experimental|neoadjuvant chemotherapy|3 cycles of docetaxel/cisplatin before operation
11505990|NCT01312311|Experimental|weekly docetaxel and cisplatin|Docetaxel 35mg/m2 D1 & D8 Cisplatin 70mg/m2 D1 every 3 weeks maxinum 6 cycles
11505991|NCT01312298|Experimental|General Anesthesia|Patients allocated to this arm will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml in a Target Controlled Infusion (TCI)
11505992|NCT01312298|Active Comparator|Regional anesthesia|Patients will receive intrathecal anesthesia
11505993|NCT01312285|Placebo Comparator|Placebo|
11505994|NCT01312285|Experimental|Resonator Device|
11505995|NCT01312272|Placebo Comparator|Inactive nasal spray|A placebo nasal spray will be prepared to be otherwise identical to the active treatment nasal spray except lacking oxytocin. The ingredients in the inactive nasal spray are mannitol, glycerin, and preserved water.
11505996|NCT01312272|Experimental|Intranasal Oxytocin|Oxytocin nasal spray (40 units/ml) will be administered in a single intranasal dose of 40 IU. Its formula is: oxytocin 1 unit/mg mannitol trituration 0.2Gm + glycerin USP 0.1ml + preserved water 5ml.
11505997|NCT01312259|Active Comparator|Interstim Parameter Frequency 14 HZ|Subjects in this arm will receive 14 Hx as their frequency for the first three months. For the second 3 months, these patients will receive 40 Hz. Six months after the devise has been implanted, the patient has the option to choose which frequency they feel allows for better symptom control, and this is how the devise will be programmed.
11505998|NCT01312259|Experimental|Interstim Parameter Frequency 40 HZ|Subjects in this arm will receive 40 Hz as their frequency for the first three months. For the second 3 months, these patients will receive 14 Hz. Six months after the devise has been implanted, the patient has the option to choose which frequency they feel allows for better symptom control, and this is how the devise will be programmed.
11505999|NCT01312233|Active Comparator|Medical Care|Conventional medical care alone
11506000|NCT01312233|Active Comparator|Dual Care|Unlinked co-occurrence of conventional medical care and chiropractic care
11506001|NCT01312233|Active Comparator|Shared Care|Co-management of medical care and chiropractic care
11506002|NCT01312194|Experimental|One vist group|All patients included in this treatment group will receive the complete endodontic treatment in a single visit.
11506003|NCT01312194|Active Comparator|Two-vist group|All patients included in this treatment group will receive treatment in two visits. The first will be done chemo mechanical root canal preparation, the placement of the intracanal medication the basis of calcium hydroxide and coronal sealing. Ten to twelve days later, this medication is removed and the root canal will be permanently filled.
11506004|NCT01312181|Active Comparator|HealthCall +Motivational Interviewing|Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
11506005|NCT01312181|Active Comparator|Motivational Interviewing (MI)|The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
11506006|NCT01312181|Placebo Comparator|HIV/AIDS health education - DVD control|HIV/AIDS health education - DVD control. The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.
11506007|NCT01312168|No Intervention|Healthy non-OSA control|
11506008|NCT01312168|Experimental|OSA receiving therapeutic CPAP|
11506009|NCT01312168|Sham Comparator|OSA receiving subtherapeutic CPAP|
11506010|NCT01312155||Patients undergoing general anesthesia|
11506011|NCT01312142||patients with difficult weaning|
11506012|NCT01312129|Experimental|Sulfasalazine|Sulfasalazine 1500 mg
11506013|NCT01312129|Placebo Comparator|Placebo|Placebo capsule x 3 doses 12 hours apart
11506014|NCT01312116|Experimental|Internet-delivered CBT|Active treatment: Internet-delivered Cognitive Behavior Therapy, 8 weeks treatment, guided self-help
11506015|NCT01312116|Experimental|Internet-delivered PDT|Active treatment: Internet-delivered Psychodynamic Therapy Active treatment: Internet-delivered Psychodynamic Therapy, 8 weeks treatment, guided self-help
11506016|NCT01312116|No Intervention|Control condition|Wait-list condition, received treatment 3 months after initial treatment period
11506017|NCT01312103|Experimental|Internet Based Safety Decision Aid|
11506018|NCT01312103|Active Comparator|Control Website|
11506019|NCT01312090|Active Comparator|Conventional weight loss treatment group|Eating and physical activity counseling and behavioral therapy for weight loss.
11506020|NCT01312090|Experimental|Cryo group|"Eating and physical activity counseling and behavioral therapy for weight loss will be provided to all subjects.
~The subjects in the cryo group will be given whole-body cryotherapy 1-3 times a week for the 4-month-treatment period"
11506021|NCT01312077|Experimental|Levobupivacaine infiltration|Patients will receive spinal anaesthesia with intrathecal bupivacaine, and will receive peri- and intraarticular surgical site infiltration during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure and this will be left in situ in the wound. The catheter will be sited under the fascia lata exiting antero-superior to the incision. A bacterial filter will be attached and it will be connected to an elastomeric pump which will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.
11506022|NCT01312077|Other|Control|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.2 mg).
11506023|NCT01312064|Active Comparator|rituximab and everolimus|Patients of the study arm will receive rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus will be given with an initial dose of 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
11506024|NCT01312064|Active Comparator|thymoglobulin and tacrolimus|The control arm will receive thymoglobulin induction and tacrolimus-based immunosuppressive therapy. The dose of thymoglobulin would be 1.0mg/kg/d for 3 days25. The first dose of thymoglobulin will be administered before graft kidney reperfusion, and so is rituximab. All patients will receive corticosteroid therapy as usual. The initial daily dose of tacrolimus will be 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation. The doses of tacrolimus will be adjusted to target the whole blood trough levels between 8 to 12 ng/ml during the first 30 days after transplantation, and tapered to 6 to 10 ng/ml at 6 months.
11506025|NCT01312051||Protocol 1|Healthy, overweight 11 to 17 year old black and white adolescents
11506026|NCT01312051||Protocol 2|Healthy, normal-weight 11 to 17 year old black and white adolescents
11506027|NCT01312051||Protocol 3|Healthy, normal-weight 8 to 12 year old black and white adolescents
11506028|NCT01312051||Protocol 4|Healthy, overweight 11 to 17 year old black and white adolescents
11506029|NCT01312038|Experimental|simethicone|125 mg tablet
11506030|NCT01312038|Placebo Comparator|placebo|chewable calcium tablet
11506031|NCT01312025|Placebo Comparator|conventional laparoscopic cholecystectomy|
11506032|NCT01312025|Active Comparator|modified laparoscopic cholecystectomy|
11506033|NCT01312012|Experimental|The effectiveness and feasibility, using antiviral therapy|Experimental: Subjects receive tenofovir disoproxil fumarate (TDF) oral use prior to delivery in pregnant women with positive serum HBeAg and HBsAg and high HBV DNA levels > 10^8copies / mL, to reduce the rate of mother to infant transmission of HBV infection, and also to monitor the safety of the therapy.
11506034|NCT01312012|No Intervention|Control|Subjects receive no intervention, but with blood tests for mothers and infants before and after delivery, as a comparative group to experimental arm.
11506035|NCT01311999||IGRA-positive group|The subjects who have positive results of interferon-gamma release assay
11506036|NCT01311999||IGRA-negative group|The subjects who have negative results of interferon-gamma release assay
11506037|NCT01311986||Patients with atopic dermatitis|
11506038|NCT01311986||Patients with nummular eczema|
11506039|NCT01311986||Normal control|
11506040|NCT01311973||Renal Function Group #1|Creatinine clearance > 90 mL/min
11506041|NCT01311973||Renal Function Group #2|Creatinine clearance 60-69 mL/min
11506042|NCT01311973||Renal Function Group #3|Creatinine clearance 50-59 mL/min
11506043|NCT01311973||Renal Function Group #4|Creatinine clearance 40-49 mL/min
11506044|NCT01311973||Renal Function Group #5|Creatinine clearance 30-39 mL/min
11506045|NCT01311973||Renal Function Group #6|Creatinine clearance 20-29 mL/min
11506046|NCT01311973||Renal Function Group #7|Creatinine clearance < 20 mL/min (not on dialysis)
11506047|NCT01311960|Experimental|bevacizumab eye drop|
11506048|NCT01311960|Experimental|placebo normal saline eye drop|
11506049|NCT01311934||HBV-infected|
11506050|NCT01311934||HCV-infected|
11506051|NCT01311908||Surgery, Roux-en-Y , reflux esophagitis|Patients with roux-en-Y reconstruction (study group)
11506052|NCT01311908||surgery, traditional gastrojejunostomy|Traditional gastrojejunostomy reconstruction (control group).
11506053|NCT01311895|Experimental|H2O|2 mg IV hydromorphone administered over 2-3 minutes as initial dose
11506054|NCT01311895|Experimental|1+1|"1 mg IV hydromorphone followed by an additional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the following question: Do you want more pain medication?"
11506055|NCT01311882|Experimental|MK-4305 40 mg|Day 1 and Day 8- 4 x 10 mg MK-4305 and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 4 x 10 mg MK-4305
11506056|NCT01311882|Experimental|MK-4305 20 mg|Day 1 and Day 8- 2 x 10 mg MK-4305 and 2 x 10 mg MK-4305 matching placebo and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 2 x 10 mg MK-4305 and 2 x 10 mg MK-4305 matching placebo
11506057|NCT01311882|Active Comparator|Zopiclone 7.5 mg|Day 1 and Day 8- 1 x 7.5 mg zopiclone and 4 x 10 mg MK-4305 matching placebo; Days 2-7- 4 x 10 mg MK-4305 matching placebo
11506058|NCT01311882|Placebo Comparator|Placebo|Day 1 and Day 8- 4 x 10 mg MK-4305 matching placebo and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 4 x 10 mg MK-4305 matching placebo
11506059|NCT01311869|Active Comparator|EGCG ( Green Tea extract)|40 subjects will receive 800 mg EGCG orally per day for 6 months versus 40 subjects will receive Brown Rice pill for 6 months
11506060|NCT01311869|Placebo Comparator|Brown Rice pills|40 subjects will receive 800 mg brown rice pills orally per day for 6 months versus 40 subjects will receive EGCG capsule for 6 months
11506061|NCT01311856||Standard Arm (mail/telephone)|
11506062|NCT01311856||Internet Arm|
11506063|NCT01311830|Active Comparator|Telephone Counseling|
11506064|NCT01311830|Placebo Comparator|Written Materials|
11506065|NCT01311817|Placebo Comparator|Saline Patch|1mL saline applied to the vaccine patch
11506066|NCT01311817|Experimental|Bacteria plus CT|0.95mL bacterial vector plus 0.05mL cholera toxin
11506067|NCT01311804|Experimental|periarticular parecoxib sodium|patients will be given periarticular parecoxib sodium injection
11506068|NCT01311804|Active Comparator|intravenous parecoxib sodium|intravenous parecoxib sodium will be given during total knee arthroplasty
11506069|NCT01311791|Experimental|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure.
11506070|NCT01311791|Active Comparator|Standard Medical Therapy|as per protocol
11506071|NCT01311778|Placebo Comparator|Placebo|Subjects will receive placebo
11506072|NCT01311778|Experimental|CBD 400 mg|Subjects will receive 400 mg CBD
11506073|NCT01311778|Experimental|CBD 800mg|Subjects will receive 800 mg CBD
11506074|NCT01311765|Active Comparator|8 day-antibiotherapy|Duration of antibiotic therapy limited to 8 days: Antibiotics received for up to 8 days following surgery for postoperative peritonitis in patients hospitalised in intensive care unit
11506338|NCT01309867|Experimental|Investigational Toric Lens|Bausch + Lomb investigational toric contact lenses
11506075|NCT01311765|No Intervention|15 day-antibiotherapy|Antibiotics received for up to15 days following surgery for postoperative peritonitis in patients hospitalised in intensive care unit corresponding to usual practice and recommendations
11506076|NCT01311739|Experimental|10 mg Eligen® B12 (Cyanocobalamin/SNAC)|A single oral dose of Eligen® B12, cyanocobalamin/SNAC (5 mg cyanocobalamin/100 mg SNAC) administered in the fasted state as 2 tablets taken with 50 mL of water resulting in a total dose of 10 mg cyanocobalamin and 200 mg SNAC.
11506077|NCT01311739|Experimental|5 mg Eligen® B12 (Cyanocobalamin/SNAC)|A single oral dose of Eligen® B12, cyanocobalamin/SNAC (5 mg cyanocobalamin/100 mg SNAC) administered in the fasted state as a tablet taken with 50 mL of water resulting in a total dose of 5 mg cyanocobalamin and 100 mg SNAC.
11506078|NCT01311739|Active Comparator|5 mg Oral Cyanocobalamin|A single oral dose of cyanocobalamin alone (5 mg cyanocobalamin, commercial: VITALABS, INC) administered in the fasted state as a tablet taken with 50 mL of water resulting in a total dose of 5 mg cyanocobalamin.
11506079|NCT01311739|Active Comparator|1 mg Intravenous Cyanocobalamin|A single intravenous (IV) dose of cyanocobalamin (1 mg cyanocobalamin) administered in the fasted state. Each subject will receive a 1 mL IV injection of a 1 mg/mL (1000 μg/mL) solution resulting in a total dose of 1 mg cyanocobalamin.
11506080|NCT01311713|Experimental|(Part 1): CEP-9722|
11506081|NCT01311713|Experimental|(Part 2): CEP-9722|
11506082|NCT01311700|Active Comparator|Early metoprolol initiation strategy|
11506083|NCT01311700|No Intervention|Delayed metoprolol initiation strategy|
11506084|NCT01311687|Experimental|Pomalidomide + Low-Dose Dexamethasone|Participants received 4 mg pomalidomide administered by mouth on Days 1 to 21 of each 28-day treatment cycle and 40 mg dexamethasone (or 20 mg for participants > 75 years of age) administered by mouth once per day on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression.
11506085|NCT01311687|Active Comparator|High-Dose Dexamethasone|Participants received 40 mg dexamethasone (or 20 mg for participants > 75 years of age) administered by mouth once per day on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day treatment cycle until disease progression.
11506086|NCT01311674|Active Comparator|Schedule 1|
11506087|NCT01311674|Experimental|Schedule 2|
11506088|NCT01311661|Experimental|Olodaterol medium daily dose|Olodaterol medium daily dose given either as once daily or split into two low doses daily or placebo only in randomised sequence of three cross-over treatment phases
11506089|NCT01311661|Experimental|Olodaterol high daily dose|Olodaterol high daily dose given either as once daily or split into two medium doses daily or placebo only in randomised sequence of three cross-over treatment phases
11506090|NCT01311648|Experimental|Part A: PTPs 0-<6 years|Previously treated patients (PTPs) aged below 6 years received BAY81-8973 25-50 IU/kg at least 2x/week for 6 months and at least 50 exposure days (ED)
11506091|NCT01311648|Experimental|Part A: PTPs 6-12 years|Previously treated patients (PTPs) aged 6 to 12 years received BAY81-8973 25-50 IU/kg at least 2x/week for 6 months and at least 50 exposure days (ED)
11506092|NCT01311648|Experimental|Part B: PUPs/MTPs 0-<6 years|Previously untreated patients (PUPs) or minimally treated patients (MTPs, patients who had no more than 3 exposure days [EDs] with any FVIII product) received BAY81-8973 15-50 IU/kg at least 1x/week for 50 EDs
11506093|NCT01311635|Experimental|Treatment A|
11506094|NCT01311635|Experimental|Treatment B|
11506095|NCT01311635|Experimental|Treatment C|
11506096|NCT01311635|Experimental|Treatment D|
11506097|NCT01311622|Experimental|warfarin|
11506098|NCT01311622|Experimental|warfarin and fostamatinib|
11506099|NCT01311609|Experimental|Systane|Systane Lubricant Eye Drops
11506100|NCT01311596||No icons|"Clinic - Children who are established patients, 4-18 years old, and presented to the NeuroDevelopmental Science Center for a follow-up office visit during the first 2 weeks of the study period
~Lab -Patients 4-18 years old with a documented diagnosis who were seen in the NeuroDevelopmental Science Center and were given a prescription for lab work during the first 2 weeks of the study period"
11506101|NCT01311596||Icons|"Clinic - Children who are established patients, 4-18 years old, and presented to the NeuroDevelopmental Science Center for a follow-up office visit during the last 2 weeks of the study period
~Lab - Patients 4-18 years old with a documented diagnosis who were seen in the NeuroDevelopmental Science Center and were given a prescription for lab work during the last 2 weeks of the study period"
11506102|NCT01311583|Active Comparator|usual care plus Teach Back intervention|Trained nurses will provide Teach Back to the intervention group. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
11506103|NCT01311583|No Intervention|usual care|"All participants will experience the current practice of discharge teaching: daily interaction with the interdisciplinary team members via rounds, counseling on diet and medications with a dietician and pharmacist when referred, view the Heart Failure Discharge Video, and receive a Congestive Heart Failure education package which includes the Heart and Stroke Managing Congestive Heart Failure booklet."
11506104|NCT01311570|Experimental|Buprenorphine|
11506105|NCT01311557|Experimental|Adacel Vaccine Group 1|Participants enrolled at 10 to < 11 years of age
11506106|NCT01311557|Experimental|Adacel Vaccine Group 2|Participants enrolled at 11 to < 12 years of age
11506107|NCT01311531|Active Comparator|TriMed fragment-specific fixation|
11506108|NCT01311531|Active Comparator|TriMed volar locking plate|
11506109|NCT01311518|Placebo Comparator|Placebo|
11506110|NCT01311518|Active Comparator|Drug: Thymosin Beta 4 injectable|
11506111|NCT01311505|Active Comparator|A|Test
11506112|NCT01311505|Active Comparator|B|Reference
11506113|NCT01311492|Placebo Comparator|Healthy Lifestyle Program|The purpose of the healthy lifestyle group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest.
11506114|NCT01311492|Active Comparator|Physical Activity Intervention|The physical activity program includes aerobic, strenth, flexibility and balance training.
11506165|NCT01311089||Robotic thyroidectomy group|Robotic thyroidectomy group is the patient group who underwent robot-assisted endoscopic thyroid surgery using a gasless, trans-axillary approach.
11506115|NCT01311479|Active Comparator|Osteopathic Manipulation|"Patients will be evaluated and examined by an Osteopathic physician. This examination will consist of full osteopathic structural exam, and a focused examination of the sacroiliac joint and the surrounding musculature.
~Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction."
11506116|NCT01311479|Active Comparator|Massage Therapy|Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment.
11506117|NCT01311466|Experimental|Liver transplantation|The liver transplantation will be performed as described by the standard protocol, Liver Transplantation Protocol (Version 2006) at the Oslo University Hospital
11506118|NCT01311440|Experimental|Modified Atkins diet treatment|12 weeks of Modified Atkins diet treatment, recording seizures
11506119|NCT01311440|No Intervention|No intervention|12 weeks seizure record
11506120|NCT01311427|Active Comparator|Group education|The control condition received standard group education, which met in small groups two times weekly for 60 minutes over 12 weeks.
11506121|NCT01311427|Experimental|8-form Yang-style Tai chi program|This arm tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in small groups two times weekly for 60 minutes over 12 weeks.
11506122|NCT01311414|Experimental|cafedrine/theodrenalin|
11506123|NCT01311401||Rehania village (Kfar Rehania)|Circassian community
11506124|NCT01311401||Kama village (Kfar Kama )|Circassian community
11506125|NCT01311375|Experimental|w3 supplement + capsule CA-D|Mor DHA :w3 supp will be given to this group + capsule Ca(500 mg)-D(200 micro gram)
11506126|NCT01311375|Placebo Comparator|placebo+ CA-D|placebo in the same color,shape,size
11506127|NCT01311362||CYP2C19 wild type|"CYP2C19 wild type =extensive metaboliser
~Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20
~Administration of St. Johns wort: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
11506128|NCT01311362||CYP2C19 mutant|"CYP2C19 *2/*2 or *2/*3 or *3/*3 = poor metaboliser
~Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20
~Administration of St. Johns wort: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
11506129|NCT01311349||1|A listing of all isolates meeting the inclusion criteria will be maintained.
11506130|NCT01311336|Active Comparator|Loratadine|Loratadine 10 mg once a day for 7 days beginning the day of pegfilgrastim treatment in patients with pegfilgrastim-induced back and leg pain during the previous treatment cycle
11506131|NCT01311336|Placebo Comparator|Placebo|Placebo once a day for 7 days beginning the day of pegfilgrastim treatment in patients with pegfilgrastim-induced back and leg pain during the previous treatment cycle
11506132|NCT01311323|Experimental|PCI with DES implantation|Percutaneous Coronary Intervention Implantation of Drug-Eluting Stents
11506133|NCT01311323|Active Comparator|CABG|Coronary Artery Bypass Grafting.On-pump or Off-pump CABG
11506134|NCT01311310|Experimental|remote ischemic preconditioning|
11506135|NCT01311297||Perioperative ovarian cancer patients|
11506136|NCT01311297||Pregnant patients|
11506137|NCT01311297||Female healthy volunteers|
11506138|NCT01311284|Active Comparator|Macintosh|
11506139|NCT01311284|Active Comparator|Mcgrath|
11506140|NCT01311284|Active Comparator|Airtraq Nasotracheal|
11506141|NCT01311271|Sham Comparator|Sham rTMS-Sham rTMS|Sham rTMS for 2 weeks
11506142|NCT01311271|Experimental|Sham rTMS-Real rTMS|Sham rTMS in the first week and real rTMS in the second week
11506143|NCT01311271|Experimental|Real rTMS-Real rTMS|Real rTMS for 2 weeks
11506144|NCT01311245|Experimental|Stage-tailored|At baseline and three months later
11506145|NCT01311245|Experimental|Non-stage-tailored|At baseline and three months later
11506146|NCT01311245|No Intervention|Control group|Assessment only
11506147|NCT01311232||Case|Patients with HBV reactivation
11506148|NCT01311232||Control|Patients without HBV reactivation
11506149|NCT01311219|Active Comparator|No surgery|Non-operative Treatment
11506150|NCT01311219|Active Comparator|Plate fixation|Operative Treatment-Plate fixation
11506151|NCT01311219|Active Comparator|Intramedullary pinning|Operative Treatment-Intramedullary Pinning
11506152|NCT01311206|Experimental|PBFR|Partial Blood Flow Restriction (PBFR) during Low-Intensity Exercise.
11506153|NCT01311206|Active Comparator|PBFR control|Low-Intensity Exercise without partial blood flow restriction.
11506154|NCT01311193|Experimental|light therapy|Morning bright light treatment (at 8000 lux for 40min, daily during 3 weeks)
11506155|NCT01311180|Experimental|Sensoril®|
11506156|NCT01311180|Placebo Comparator|Placebo|
11506157|NCT01311167|Experimental|Dexamethasone|
11506158|NCT01311167|Placebo Comparator|Placebo|
11506159|NCT01311141|Experimental|Doripenem i.v.|no comparator, PK study
11506160|NCT01311128||Heart rate and blood pressure determination|All subjects have the same conditions (T-line, blood pressure cuff, and radial artery catheter), in order to compare them within-subjects.
11506161|NCT01311115|Experimental|Group commitment contracts|"In addition to education and counseling, the intervention includes the following components:
~Each participant is encouraged to deposit his cigarette money on a weekly basis, to be returned only if the smoker quits successfully within three months.
~The project gives a series of two matching contributions of 150 baht each to participants who meet certain deposit requirements.
~Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt."
11506162|NCT01311115|Active Comparator|Education and counseling|Participants in this group receive educational pamphlets about quitting smoking and one-time, group counseling from a nurse trained in smoking cessation counseling.
11506163|NCT01311102|Experimental|2% Lidocaine liquid|1.33cc of 2% liquid lidocaine infused in endo cervix and endometrium
11506164|NCT01311102|Placebo Comparator|Normal Saline|1.33cc of normal saline infused in endo cervix and endometrium
11506166|NCT01311089||conventional open thyroidectomy group|Conventional open thyroidectomy group is th patient group who underwent thyroid surgery via neck incision.
11506167|NCT01311076|Experimental|TAK-329 50 mg|
11506168|NCT01311076|Experimental|TAK-329 200 mg|
11506169|NCT01311076|Active Comparator|Insulin 0.2 U/kg|
11506170|NCT01311076|Placebo Comparator|Placebo|
11506171|NCT01311024||Sibling vaccinated with PCV GSK1024850A|"Older sibling of a child vaccinated with Pneumococcal conjugate vaccine GSK1024850A in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
~NOTE: the primary analysis cohort include siblings of the PCV-vaccinated according to infant schedules (excluding siblings of catch-up vaccinated children)"
11506172|NCT01311024||Control-vaccinated sibling|"Older sibling of a child vaccinated with control vaccine (hepatitis B vaccine or hepatitis A vaccine) in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
~NOTE: the primary analysis cohort include siblings of the PCV-vaccinated according to infant schedules (excluding siblings of catch-up vaccinated children)"
11506173|NCT01310998|Experimental|schizophrenic disorder|
11506174|NCT01310998|Experimental|other psychotic disorder|
11506175|NCT01310998|Experimental|no mental disorder|
11506176|NCT01310933||Kikuchi's disease|
11506177|NCT01310933||Malignant lymphoma|
11506178|NCT01310920||sick sinus syndrome|
11506179|NCT01310920||control|
11506180|NCT01310907||sinus node dysfunction|
11506181|NCT01310907||Atrioventricular block|
11506182|NCT01310907||control|
11506183|NCT01310894|Experimental|TOOKAD® Soluble|TOOKAD® Soluble, lyophilized formulation, given at a dose of 4mg/Kg.
11506184|NCT01310894|No Intervention|Active Surveillance|Active surveillance is one of the management strategy in men who have low-risk prostate cancer
11506185|NCT01310881|Experimental|Dose 1|
11506186|NCT01310881|Experimental|Dose 2|
11506187|NCT01310881|Experimental|Dose 3|
11506188|NCT01310881|Experimental|Dose 4|
11506189|NCT01310881|Experimental|Dose 5|
11506190|NCT01310881|Experimental|Dose 6|
11506191|NCT01310881|Experimental|Dose 7|
11506192|NCT01310868|Experimental|5-ALA and Gliadel wafers|This is a single arm feasibility study to evaluate the safety and tolerability of combining 2 technologies (5-ALA and Gliadel wafers) in the surgical management of patients with GBM.
11506193|NCT01310855|Active Comparator|Cediranib & Gefitinib|Cediranib maleate 30mg od orally and gefitinib 500mg od orally. Each cycle of treatment lasts 6 weeks. Treatment will continue until confirmation of progression, patient decision or the development of unacceptable toxicity (if there is radiological progression only treatment can continue if the investigator has the opinion that the patient is receiving benefit.
11506194|NCT01310855|Placebo Comparator|Cediranbib & placebo|Cediranib maleate 30mg od orally and placebo 500mg od orally. Each cycle of treatment lasts 6 weeks. Treatment will continue until confirmation of progression, patient decision or the development of unacceptable toxicity (if there is radiological progression only treatment can continue if the investigator has the opinion that the patient is receiving benefit.
11506195|NCT01310842||Pilot Smoking Cessation|4 weeks nicotine patch therapy, self-help materials, and 5 in-person counseling sessions.
11506196|NCT01310842||Smoking Cessation|4 weeks nicotine patch therapy, self-help materials, and 7 in-person counseling sessions.
11506197|NCT01310829||Virtual Reality|Board-eligible or board-certified genetic counselors and students evaluate a virtual reality-based intervention using questionnaires and physiological measurements.
11506198|NCT01310816|Active Comparator|IPI-926|IPI-926
11506199|NCT01310816|Placebo Comparator|Sugar Pill|Placebo Arm, sugar pill
11506200|NCT01310803|Experimental|Maintenance therapy|Chemotherapeutic: EN3329-301 (VALSTAR)
11506201|NCT01310803|Other|No Maintenance (Standard of care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
11506202|NCT01310777|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months
11506203|NCT01310777|Active Comparator|Brinz|Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months
11506204|NCT01310777|Active Comparator|Brim|Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye 2 times a day for 6 months
11506205|NCT01310764|Sham Comparator|Mitomycin C|Those with trabeculectomy and intraoperative application of mitomycin C.
11506206|NCT01310764|Active Comparator|Bevacizumab|Those with trabeculectomy and adjunctive intraoperative subconjunctival injection of bevacizumab.
11506207|NCT01310751|Experimental|iloprost nebuliser solusion|50 ng/kg/min
11506208|NCT01310751|Placebo Comparator|distilled water|2ml
11506209|NCT01310738|Active Comparator|Meglumine antimoniate|Antimoniate of N-methylglucamine 20mg/kg/d, I.V. for 20 consecutive days.
11506210|NCT01310738|Experimental|Liposomal Amphotericin B|Liposomal amphotericin B 3mg/kg/d I.V. for 7 consecutive days.
11506211|NCT01310738|Experimental|Amphotericin B|Amphotericin B deoxycholate 1mg/kg/d I.V. for 14 consecutive days. This arm was suspended in September 19th, 2012, because of a relevant excess of adverse events and serious adverse events associated with this experimental intervention in comparison with the active comparator and the other two experimental arms. The suspension of this study arm was supported by a DSMB statement.
11506212|NCT01310738|Experimental|Combination therapy|Liposomal amphotericin B 10mg/kg/d, I.V. single dose on day 0 plus Antimoniate of N-methylglucamine 20mg/kg/d for 10 consecutive days on days 1 to 10.
11506213|NCT01310712|Experimental|oxybutynin|patients will receive in the end of the treatment, 10 mg of oxybutynin a day
11506214|NCT01310712|Placebo Comparator|Placebo|Placebo
11506215|NCT01310699|Experimental|High Definition NBI Colonoscopy|Use of high definition narrow band imaging colonoscopy during examination for polyp detection. The same intervention is used on both arms: the Olympus Colonoscope CFHQ190AL, a technically improved colonoscope with close focus high definition narrow band imaging.
11506216|NCT01310699|Placebo Comparator|High Definition White Light Colonoscopy|Use of high definition white light colonoscopy during examination for polyp detection. The same intervention is used on both arms: the Olympus Colonoscope CFHQ190AL, a technically improved colonoscope with close focus high definition narrow band imaging.
11506221|NCT01310647|Experimental|Testosterone|Transdermal testosterone (20µg/day) from day 24 of the previous cycle until day 2 of the ICSI cycle
11506222|NCT01310647|Experimental|Estradiol|Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle
11506223|NCT01310647|Experimental|CombEq|"(150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI
~Estradiol valerate 4 mg/day during 10 days, starting the second day of the cycle prior to the ICSI cycle."
11506224|NCT01310634|Experimental|Comprehensive intervention|Parents of hospitalized neonates received Comprehensive intervention program.
11506225|NCT01310634|Other|Conventional treatment|Usual educational program
11506226|NCT01310621|No Intervention|No Lavage|Neonate randomized to this group will be managed as per the standard protocol in the neonatal ward. The evaluation of respiratory distress will be done using Downe's score at hourly intervals till 24 hrs, followed by 2 hourly intervals till 72 hrs and finally 4 hourly intervals till resolution of clinical distress.
11506227|NCT01310621|Experimental|Surfactant Lavage|The diluted surfactant is instilled into endotracheal tube over a period of 15 to 20 seconds. Once the instillation is complete, 5 manual breaths will be provided and infant will be repositioned supine. The suction catheter will be inserted and advanced to a position approximately 5mm past the end of endotracheal tube. Suction will be activated for no more than 10 seconds and would be temporarily halted earlier if the oxygen saturation value falls by > 5% of the prelavage value. The same shall be resumed once prelavage oxygen saturation has been restored. The infant's bed will now be moved back to horizontal position. Once the neonate is STABLE, suctioning will be again repeated. The total retrieved volume is measured and recorded.This procedure will be done in both right and left lateral decubitus position
11506228|NCT01310608|Experimental|A-View|
11506229|NCT01310608|No Intervention|No A-View|
11506230|NCT01310595|Experimental|Manual mobilization on cervical spine|Manual mobilization given on cervical spine with infra-red therapy and self exercise and advice pamphlet.
11506231|NCT01310595|Active Comparator|Infra-red radiation therapy|Infra-red radiation therapy with self exercise pamphlet given to patients with chronic mechanical neck pain.
11506232|NCT01310582|Active Comparator|Desflurane|During the surgery the subjects were given Desflurane, general anesthesia, that will keep the patient asleep during the surgery. The dosage form was inhalation gas, dosage equivalent to 1 MAC, frequency was once and the duration was throughout the surgery (30-45 minutes).
11506233|NCT01310582|Active Comparator|Sevoflurane|During the surgery the subjects were given Sevoflurane, general anesthesia, that will keep the patient asleep during the surgery. The dosage form was inhalation gas, dosage equivalent to 1 MAC, frequency was once and the duration was throughout the surgery (30-45 minutes).
11506234|NCT01310556||coronary artery disease|patients with coronary artery disease
11506235|NCT01310543|Experimental|Teens and Toddlers|The T&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
11506236|NCT01310543|No Intervention|Comparison|Girls in the comparison group will continue with their normal afternoon of schooling, which is missed by girls attending the T&T intervention for the 20 weeks of their attendance.
11506237|NCT01310530|Experimental|Partial Breast Proton Therapy|Two weeks of daily proton therapy delivered to the lumpectomy site.
11506238|NCT01310517||Radial Coronary Angiography|The subjects enrolled in this study will be adults referred for radial coronary angiography with left ventriculography for clinical indications.
11506239|NCT01310504|Active Comparator|Non peritoneal dialysis patient|
11506240|NCT01310504|Active Comparator|Peritoneal dialysis patient|
11506241|NCT01310491|No Intervention|Usual Care|
11506242|NCT01310478|Experimental|Endostar combined with mFOLFOX6|
11506243|NCT01310465|Experimental|Experimental group|Three days postoperatively, patients in this group are given one infusion of zoledronic acid intravenously.
11506244|NCT01310465|Placebo Comparator|Placebo Comparator|Three days postoperatively, patients in this group are given one infusion of sodium chloride intravenously.
11506245|NCT01310452|Active Comparator|neutral protamine insulin, metformin|NPH insulin once daily plus oral metformin twice or thrice daily during 26 weeks
11506246|NCT01310452|Experimental|insulin detemir, metformin|Insulin detemir once daily plus oral metformin twice or thrice daily during 26 weeks
11506247|NCT01310439||ADHD adolescents and adults|30 adolescents and adults diagnosed with Combined-subtype AD/HD
11506248|NCT01310426||anal sphincter damage|After assessing women after vaginal delivery, a comparison will be made between those with anal sphincter damage and those women without.
11506249|NCT01310413|Experimental|Influenza A (H5N1) adjuvanted 6-<36M Group|Subjects aged at enrolment between 3 and 36 months, 36 months excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly. For children aged up to 12 months, 12 months excluded (< 12 months), Dose 1 was administered in the left anterolateral thigh and Dose 2 in the right anterolateral thigh. For children older than (>=) 12 months, Dose 1 was administered in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
11506250|NCT01310413|Experimental|Influenza A (H5N1) Virus monovalent vaccine 3-<9Y Group|Subjects aged at enrolment between 3 and 9 years, 9 years excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
11506339|NCT01309867|Active Comparator|PureVision Toric Lens|Currently marketed Bausch + Lomb PureVision toric contact lenses
11506340|NCT01309854|Experimental|pioglitazone|
11506341|NCT01309854|Experimental|pioglitazone and fostamatinib|
11506251|NCT01310413|Experimental|Influenza A (H5N1) Virus monovalent vaccine 9-<18Y Group|Subjects aged at enrolment between 9 and 18 years, 18 years excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
11506252|NCT01310413|Placebo Comparator|Placebo 6-<36M Group|Subjects aged at enrolment between 3 and 36 months, 36 months excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly. For children aged up to 12 months, 12 months excluded (< 12 months), Dose 1 was administered in the left anterolateral thigh and Dose 2 in the right anterolateral thigh. For children older than (>=) 12 months, Dose 1 was administered in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
11506253|NCT01310413|Placebo Comparator|Placebo 3-<9Y Group|Subjects aged at enrolment between 3 and 9 years, 9 years excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
11506254|NCT01310413|Placebo Comparator|Placebo 9-<18Y Group|Subjects aged at enrolment between 9 and 18 years, 18 years excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
11506255|NCT01310413|Experimental|Placebo/Influenza A (H5N1) adjuvanted Group|Subjects in this group were those who were administered the saline placebo solution in the Blinded Phase of the study (either in the Placebo 6-<36M, Placebo 3-<9Y or Placebo 9-<18Y Group). These were subjects aged at enrolment between 6 months and 18 years, 18 years excluded, who had received 2 doses of saline placebo at Days 0 and 21 in the Blinded Phase of the study, as per described in the descriptions of the Placebo 6-<36M, Placebo 3-<9Y and Placebo 9-<18Y groups. After consenting to participating to the Unblinded Phase of the study, these subjects received in addition 2 doses of Influenza A (H5N1) Virus monovalent vaccine at Days 385 (Day U0) and Day 385 + 21 days (Day U21). Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly. Dose 1 of was administered in the deltoid region of the non-dominant arm and Dose 2 in the deltoid region of the dominant arm.
11506256|NCT01310400|Experimental|Inflexal 0.5 mL|
11506257|NCT01310400|Experimental|Inflexal 0.25 mL|
11506258|NCT01310400|Experimental|Agrippal 0.25 mL|
11506259|NCT01310387|Experimental|active pain management|active pain management (APM) by specialized nurses for cancer pain
11506260|NCT01310361|Experimental|Amoxicillin|Once-daily Therapy for Streptococcal Pharyngitis With Amoxicillin
11506261|NCT01310361|Active Comparator|Benzathin Penicillin G|Once-daily Therapy for Streptococcal Pharyngitis With Intramuscular Benzathin Penicillin G
11506262|NCT01310348|Placebo Comparator|Very low magnitude vibration|Very low magnitude vibration
11506263|NCT01310348|Experimental|Training|The whole-body vibration (WBV) training
11506264|NCT01310335|Experimental|Training|The whole-body vibration (WBV) training
11506265|NCT01310322|Experimental|1|AZD5423 iv
11506266|NCT01310322|Experimental|2|AZD5423 inhalation, Spira
11506267|NCT01310322|Experimental|3|AZD5423 inhalation I-neb
11506268|NCT01310322|Experimental|4|AZD5423 oral
11506269|NCT01310309||EXecutive Registry|A prospective controlled registry to analyze the clinical efficacy and safety at mid and long-term follow-up in patients with MVD treated with the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS).
11506270|NCT01310296|Other|Radiolabeled Lofexidine Oral Solution|Participants will receive a radiolabeled lofexidine oral solution followed by safety evaluations, and plasma, urine and fecal sampling for up to 216 hours post dose.
11506271|NCT01310296|Experimental|Lofexidine Intravenous Solution|Participants will receive 200 mcg of lofexidine in an intravenous solution infusion over 200 minutes followed by 72 hours of safety evaluation and plasma sampling.
11506272|NCT01310283|No Intervention|control group|Conventional pediatric dental care.
11506273|NCT01310270|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation
11506274|NCT01310270|Placebo Comparator|Placebo|
11506275|NCT01310257||Knee osteoarthritis|Patients will have osteoarthritis (OA) of the knee defined and scored radiologically in Study 1. Patients in Study 2 will also have OA of the knee, but a clinical diagnosis will suffice. All patients will report knee pain.
11506276|NCT01310244|Experimental|Single arm, open label|"At the study entry each patient will receive a dose level assignment which will include a specific dose level and the dose of IV belinostat in mg/m2 to be administered during the study treatment.
~Belinostat will be infused over 30 minutes once daily on Days 1-5 of each 21-day cycle. On Day 3, the infusion of belinostat must be completed at least 1 hour prior to the start of the paclitaxel infusion. Dose of belinostat will be assigned at study entry. The same dose and level will remain throughout the entire study for each patient and no dose adjustment will be allowed, except due to toxicity."
11506277|NCT01310231|Active Comparator|Metformin|Metformin plus standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
11506278|NCT01310231|Placebo Comparator|Placebo|Placebo and standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
11506279|NCT01310218|Other|extended postoperative dressing|Bulky dressing for 2 weeks
11506280|NCT01310218|Other|short postoperative dressing|2 day bulky dressing followed by bandaid.
11506281|NCT01310205||Hepatitis C treatment|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
11506282|NCT01310205||non cirrhotic subjects|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
11506283|NCT01310192|Experimental|1|Investigational Imaging Device
11506342|NCT01309841|Experimental|1|Oral treatment
11506343|NCT01309841|Experimental|2|Oral treatment
11506284|NCT01310179|Experimental|Ad/PNP and fludarabine monophosphate|Ad/PNP will be injected three times into the tumor over 2 days followed by three daily intravenous infusions of F-araAMP (fludarabine monophosphate). Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
11506285|NCT01310166|Experimental|Fingolimod|
11506286|NCT01310153|Active Comparator|Prone Positioning|Newly born infant placed in prone position (face up) for the first 30 60 seconds of life after delivery by Cesarean birth.
11506287|NCT01310153|Active Comparator|Supine Positioning|newly born infant placed in supine position (face down) for the first 30 60 seconds of life after delivery by Cesarean birth.
11506288|NCT01310140||Major Depressive Disorder|
11506289|NCT01310140||Major Depressive Disorder with Psychotic Features|
11506290|NCT01310127|Experimental|Bromday|Patients receiving Bromday self-administered one drop of bromfenac 0.09% daily as a topical ophthalmic drop three days prior to cataract surgery, on the day of cataract surgery and 21 days post operatively.
11506291|NCT01310127|Active Comparator|Nevanac|Patients in this arm self-administered nepafenac topical ophthalmic drops three times daily beginning 3 days prior to cataract surgery, on the day of surgery and for 21 days postoperatively in addition to usual cataract procedure.
11506292|NCT01310114|Experimental|Cohort 1|1 unit PDA001 [approximately 2 x 108 cells] in 240 mL per infusion on Day 1.
11506293|NCT01310114|Experimental|Cohort 2A - Experimental|1 unit PDA001 [approximately 2 x 108 cells] or placebo in 240 mL per infusion on Day 1
11506294|NCT01310114|Experimental|Cohort 2B - Experimental|4 units PDA001 [approximately 8 x 108 cells] or placebo in 240 mL per infusion on Day 1
11506295|NCT01310101|Experimental|Ofatumumab plus dexamethasone|
11506296|NCT01310088|Experimental|Lifestyle counseling|Treatment protocol The Children's Obesity Clinic Department of Paediatrics Holbaek Hospital, University of Copenhagen Denmark
11506297|NCT01310088|No Intervention|Control|Healthy age and gender matched control subjects. Recruited from school visits.
11506298|NCT01310075|Experimental|Alloderm Mesh|Alloderm Mesh - 6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
11506299|NCT01310075|Experimental|Surgimend Mesh|Surgimend Mesh - 10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
11506300|NCT01310075|No Intervention|Control (no mesh)|
11506301|NCT01310049|Experimental|LP0058 oral solution (0.050 mg/mL)|LEO 32731
11506302|NCT01310049|Experimental|LP0058 oral solution (0.200 mg/mL)|LEO 32731
11506303|NCT01310049|Placebo Comparator|LP0058 oral solution (placebo)|Placebo
11506304|NCT01310049|Experimental|LP0058 capsule 1-120 mg|LEO 32731
11506305|NCT01310049|Placebo Comparator|LP0058 capsule (placebo)|Placebo
11506306|NCT01310036|Experimental|Erlotinib|Erlotinib 150 mg daily
11506307|NCT01310023||Static Cohort|HIV-uninfected children < 12 years of age at the time of enrollment, born of HIV-infected mothers
11506308|NCT01310023||Dynamic Cohort|HIV-uninfected children born of HIV-infected mothers enrolled from prior to birth through ≤ 72 hours of age
11506309|NCT01310023||Reference Cohort|HIV-uninfected children born to a mother HIV uninfected at the time of the child's birth enrolled at 1, 3, 5, or 9 years of age(± 3 months) at the time of the study visit
11506310|NCT01310023||Young Adult Cohort|Former Dynamic and Static Cohort participants ≥ 18 years of age.
11506311|NCT01310010|Experimental|Dasatinib|
11506312|NCT01309997|Experimental|Arm I (enzyme inhibitor)|Patients receive imatinib mesylate PO QD for 6 months in the absence of progression of sclerosis or unacceptable toxicity.
11506313|NCT01309997|Experimental|Arm II (monoclonal antibody)|Patients receive rituximab IV on days 1, 8, 15, and 22. A second treatment cycle is repeated at 3 months for a total of 8 doses of rituximab in the absence of progression of sclerosis or unacceptable toxicity.
11506314|NCT01309984|Active Comparator|arm 1|
11506315|NCT01309984|Active Comparator|arm 2|
11506316|NCT01309971||Questionable occlusal lesions|
11506317|NCT01309958||intervention|design instruments and test feasibility of an intervention aimed at increasing the proportion on non-invasive treatment for early caries
11506318|NCT01309945|Active Comparator|Arm 1: Duloxetine 30mg|
11506319|NCT01309945|Placebo Comparator|Arm 2: BMS-820836 placebo|
11506320|NCT01309945|Experimental|Arm 3: BMS-820836 0.5-2.0 mg/day|
11506321|NCT01309945|Active Comparator|Arm 4: Duloxetine 30mg|
11506322|NCT01309945|Placebo Comparator|Arm 5: Duloxetine placebo|
11506323|NCT01309932|Experimental|A1: pegIFNλ+BMS-790052+Placebo for BMS-650032+Ribavirin|Part A
11506324|NCT01309932|Experimental|A2: pegIFNλ+BMS-650032+Placebo for BMS-790052+Ribavirin|Part A
11506325|NCT01309932|Active Comparator|A3: pegIFNα-2a+PBO for BMS-790052+PBO for BMS-650032+RBV|Part A
11506326|NCT01309932|Experimental|A4: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (24 weeks)|Part B
11506327|NCT01309932|Experimental|A5: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (16 weeks)|Part B
11506328|NCT01309932|Experimental|A6: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (24 weeks)|Part B
11506329|NCT01309932|Experimental|A7: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (16 weeks)|Part B
11506330|NCT01309919|Active Comparator|IUD Arm|Subjects who receive an IUD within 48 hours of delivery (vaginal or cesarean birth)
11506331|NCT01309919|Other|Diary Arm|Subjects who will not have an IUD placed postpartum; they may use another form of contraception, or no form at all
11506332|NCT01309906|Experimental|Investigational lens|Bausch & Lomb investigational silicone hydrogel lens
11506333|NCT01309906|Active Comparator|Air Optix Aqua lens|Ciba Vision Air Optix Aqua contact lens
11506334|NCT01309893|Experimental|Investigational Lens|Bausch & Lomb investigational silicone hydrogel contact lens for 1 week; then issued Air Optix Aqua Lens for 1 week.
11506335|NCT01309893|Active Comparator|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens for 1 week; then issued Investigational Lens for 1 week.
11506336|NCT01309880|Active Comparator|Air Optix Aqua|Ciba Vision daily wear contact lens
11506337|NCT01309880|Experimental|Test Lens|Investigational silicone hydrogel contact lens
11506345|NCT01309828|Experimental|Azilsartan Medoxomil + Chlorthalidone|United States and Europe: Azilsartan medoxomil 20 mg plus chlorthalidone 12.5 mg fixed dose combination tablets, titrated up to azilsartan medoxomil 40 mg plus chlorthalidone 25 mg orally, once daily for up to 52 weeks.
11506346|NCT01309828|Active Comparator|Olmesartan Medoxomil + Hydrochlorothiazide|United States: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 40 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks. Europe: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 20 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks.
11506347|NCT01309815||Cancer in elderly people|other
11506348|NCT01309802|No Intervention|placebo|no intervention
11506349|NCT01309802|Active Comparator|onabotulinum toxin type-A|up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
11506350|NCT01309789|Experimental|1|Sequential
11506351|NCT01309789|Experimental|2|Combination
11506352|NCT01309789|Experimental|3 Brentuximab vedotin/CH-P|Combination
11506353|NCT01309776|Experimental|Tianeptine|
11506354|NCT01309776|Active Comparator|Escitalopram|
11506355|NCT01309763|Active Comparator|AFFITOPE AD03|s.c. injection
11506356|NCT01309763|Experimental|AFFITOPE AD03 + Alum|s.c. injection
11506357|NCT01309750||C. diff|Patients with Clostridium difficile colitis admitted to the intensive care unit will be the study group.
11506358|NCT01309737|Experimental|Active Treatment 10 mg BID|
11506359|NCT01309737|Experimental|Active Treatment 5 mg BID|
11506360|NCT01309737|Placebo Comparator|Placebo Treatment|
11506361|NCT01309724|No Intervention|Control|No measurements are made on the control group.
11506362|NCT01309724|Experimental|USCOM|Patients undergo hemodynamic measurements with the ultrasound cardiac output monitor (USCOM). Fluid resuscitation is guided by USCOM measurements.
11506363|NCT01309711||HIE|Moderate of severe neonatal encephalopathy
11506364|NCT01309698|Experimental|Treatment Sequence 1|
11506365|NCT01309698|Experimental|Treatment Sequence 2|
11506366|NCT01309698|Experimental|Treatment Sequence 3|
11506367|NCT01309698|Experimental|Treatment Sequence 4|
11506368|NCT01309698|Experimental|Treatment Sequence 5|
11506369|NCT01309698|Experimental|Treatment Sequence 6|
11506370|NCT01309672|Experimental|Abiraterone acetate + prednisone|"Abiraterone, 1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); to be taken daily
~Prednisone, 5 mg, oral, 5 mg twice daily"
11506371|NCT01309659|Experimental|Immediate Intervention Group|Subjects randomized to the immediate treatment group will be scheduled to begin treatment with IV iron infusion immediately (or within 2 business days). They will receive 200mg IV iron sucrose a week for 5 weeks followed by 19 weeks of follow up.
11506372|NCT01309659|Experimental|Wait List Control|Subjects randomized to the wait list control group will have an observation visit at week 6 and week 12. After that they will begin treatment with IV iron infusion. They will receive 200mg IV iron sucrose a week for 5 weeks followed by 7 weeks of follow up
11506373|NCT01309646|Experimental|Infanrix-IPV+Hib Group|Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.
11506374|NCT01309646|Active Comparator|Infanrix IPV Group|Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.
11506375|NCT01309633|Experimental|Arm A|"1) Arm A
~Day -6 to Day 0 (total 7 days):
~Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
11506376|NCT01309633|Experimental|Arm B|"Arm B
~Day -6 to Day 0 (total 7 days):
~Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
11506377|NCT01309633|Experimental|Arm C|Arm C Day -7: IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered.
11506378|NCT01309633|Experimental|Arm D|Arm D Day -7: IV bevacizumab 2.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered
11506379|NCT01309620|Placebo Comparator|Placebo|
11506380|NCT01309620|Experimental|Zinc supplement|
11506381|NCT01309607|Experimental|Pre-operative Therapy|Neoadjuvant paclitaxel/carboplatin/lapatinib x 12 weeks
11506382|NCT01309594|Experimental|Hematopoietic stem cell transplantation|Extraction of bone marrow cells from HIV positive patients with advanced liver cirrhosis and transplant their bone marrow back into the patients
11506383|NCT01309581|Experimental|Ketamine|Participants receiving ECT for depression will be randomized 1:1 to either ketamine (experimental condition) or methohexital (standard anesthetic).
11506384|NCT01309581|Active Comparator|Methohexital|Participants receiving ECT for depression will be randomized 1:1 to either ketamine (experimental condition) or methohexital (standard anesthetic).
11506385|NCT01309568||Investigational testing|Pending the outcome of culture, the subject may be treated with an approved antiviral medication at the doctors discretion.
11506387|NCT01309529||thoracic surg, epidural, urine retention|
11506388|NCT01309516|Experimental|Complex Intervention (LTP-TH)|The 12 sessions of complex intervention (LTP-TH) will be delivered to mothers.
11506389|NCT01309516|No Intervention|Control group|Control group will receive standard postnatal follow-up.
11506390|NCT01309503||Normal hearing|Children and adults
11506391|NCT01309503||Unilateral hearing loss|
11506392|NCT01309503||Severe hearing loss high frequencies|
11506393|NCT01309503||Adult CI users|Unilateral and bilateral CI
11506394|NCT01309503||Bilateral CI users|"Children and adults
~Sequential CIs
~Simultaneous CIs"
11506395|NCT01309490|Experimental|Ribavirin, nucleoside analog|
11506396|NCT01309477|Experimental|ADVAGRAF|All subjects in the study will take the Tacrolimus Sustained-release Capsules (ADVAGRAF) orally at the basis of low dose prednisone treatment
11506397|NCT01309451|Active Comparator|Bevacizumab alone|
11506398|NCT01309451|Active Comparator|Combined group|Bevacizumab plus Ozurdex
11506399|NCT01309438|Experimental|Normal renal function|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
11506400|NCT01309438|Experimental|Mild renal impairment|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 5 mg rivaroxaban on Day 5) followed, up to 14 days later, by Treatment Period 3 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
11506401|NCT01309438|Experimental|Moderate renal impairment|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 5 mg rivaroxaban on Day 5) followed, up to 14 days later, by Treatment Period 3 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
11506402|NCT01309425|Experimental|001|tapentadol (CG5503) ER 25-mg TRF 25mg TRF single oral dose
11506403|NCT01309425|Experimental|002|tapentadol (CG5503) ER 50-mg TRF 50mg TRF single oral dose
11506404|NCT01309425|Experimental|003|tapentadol (CG5503) ER 100-mg TRF 100mg TRF single oral dose
11506405|NCT01309425|Experimental|004|tapentadol (CG5503) ER two 100-mg TRF 200mg TRF single oral dose
11506406|NCT01309412|Experimental|Siltuximab|Siltuximab 5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
11506407|NCT01309399|Active Comparator|teriparatide|six weeks of teriparatide
11506408|NCT01309399|Placebo Comparator|placebo|placebo identical in appearance to teriparatide
11506409|NCT01309386|Experimental|Tapentadol ER|Tapentadol extended-release (ER) (JNS024ER) oral tablets 100 to 400 milligram (mg) daily for 8 weeks (maximum dose could be up to 500 mg daily), as per Investigator's discretion.
11506410|NCT01309386|Active Comparator|Morphine SR|Morphine sustained-release (SR) oral tablets 30 to 120 mg daily for 8 weeks (maximum dose could be up to 140 mg daily), as per Investigator's discretion.
11506411|NCT01309373||001|Patient assessment 2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
11506412|NCT01309360|Active Comparator|group A : 40ml Prilocaine 1%|40 outpatients : 40ml Prilocaine 1% were administered for axillary plexus block
11506413|NCT01309360|Active Comparator|group B : 30ml Prilocaine 1%|40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
11506414|NCT01309360|Active Comparator|group C : 20ml Prilocaine 1%|40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block
11506415|NCT01309321|Experimental|Perinatal Handwashing Intervention Arm|
11506416|NCT01309321|Active Comparator|Neonatal Health Promotion|
11506417|NCT01309308|Experimental|The membranes swept group|This group will have a sweeping of the membranes after the 38th of gestation at hospital, in order to reduce the latency period until labor. Sweeping of the membranes is done by the insertion of examiners finger between the decidua and fetal membranes and by the circular movement of the finger, the membranes are detached from the decidua.
11506418|NCT01309308|Sham Comparator|No sweeping group|This group will not have sweeping of the membranes, will only have vaginal ultrasound
11506419|NCT01309295||Cohort|
11506420|NCT01309282||Rituximab|Sero-positive [Rheumatoid Factor (RF) and/or anti-Cyclic Citrullinated Peptide (CCP+)] rheumatoid arthritis (RA) patients, who had initiated therapy with Rituximab (MabThera) following lack of response or intolerance to a single tumour necrosis factor (TNF)-inhibitor will be included in this arm
11506421|NCT01309269||Cohort|
11506422|NCT01309256||R-robot group|retrospective robot group
11506423|NCT01309256||P-robot group|prospective robot group
11506424|NCT01309256||P-laparoscopic group|prospective laparoscopic group
11506425|NCT01309243|Experimental|FTC/RPV/TDF|
11506426|NCT01309243|Experimental|EFV/FTC/TDF|
11506427|NCT01309230|Experimental|Vigil™|intradermal autologous Vigil™ (1.0 x 10^7 cells/injection; maximum of 12 vaccinations)
11506428|NCT01309217|Active Comparator|Usual Care|The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. See below for a complete description.
11506429|NCT01309217|Experimental|Tobacco Tactics Intervention|"At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals."
11506430|NCT01309204|Experimental|Brinz/Brim|Vehicle, 1 drop instilled in each eye, followed by Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension, 1 drop instilled in each eye. A 10-minute waiting period separated the instillations. Study drugs were instilled twice a day for 6 months.
11506518|NCT01308567|Experimental|Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.
11506431|NCT01309204|Active Comparator|Brinz+Brim|Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye, followed by Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye. A 10-minute waiting period separated the instillations. Study drugs were instilled twice a day for 6 months.
11506432|NCT01309191|Experimental|Minoxidil|Patients received Minoxidil (same strength as sold over the counter) twice a day for 8 weeks.
11506433|NCT01309191|Placebo Comparator|Placebo|Placebo arm
11506434|NCT01309178|Active Comparator|Amitriptyline|After the experience with the treatment of 18 CF-patients phase IIa study), the medication will be therefore 25 mg daily in two doses (2 x 12,5 mg). Because of a higher rate of side effects (tiredness, dry mucous membrane) the higher dose of 50 mg (2 x 25 mg) is not chosen first, but will be adapted after 2 weeks of treatment.
11506435|NCT01309178|Placebo Comparator|Mannite|The placebo will be given 25 mg daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
11506436|NCT01309165|Experimental|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10 one-hour sessions intervention format. Participants randomized to the CO-OP group will continue to receive usual out-patient services, such as physiotherapy or speech-language therapy, but will receive CO-OP instead of usual occupational therapy.
11506437|NCT01309165|Active Comparator|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
11506438|NCT01309139|Experimental|Treatment A: Tiotropium medium dose|Oral inhalation daily for 21 days
11506439|NCT01309139|Experimental|Treatment A: BI 54903 high dose|Oral inhalation daily for 21 days
11506440|NCT01309139|Experimental|Treatment B: Tiotropium medium dose|Oral inhalation daily for 21 days
11506441|NCT01309139|Experimental|Treatment C: BI 54903 high dose|Oral inhalation daily for 21 days
11506442|NCT01309126|Experimental|Arm 1: Imprime PGG + cetuximab|Biological/Vaccine + Drug
11506443|NCT01309126|Active Comparator|Arm 2: cetuximab|Drug
11506444|NCT01309113|Placebo Comparator|Placebo of VAC BNO 1095|1 tablet of placebo in the morning, 1 tablet of placebo in the evening
11506445|NCT01309113|Active Comparator|10 mg VAC BNO 1095|1 tablet of VAC BNO 1095 10 mg in the morning, 1 tablet of placebo in the evening
11506446|NCT01309113|Active Comparator|20 mg VAC BNO 1095|1 tablet of VAC BNO 1095 10 mg in the morning, 1 tablet of VAC BNO 1095 10 mg in the evening
11506447|NCT01309100|Experimental|Investigational Lens|Bausch & Lomb investigational silicone hydrogel lens.
11506448|NCT01309100|Active Comparator|Acuvue Oasys Lens|Johnson & Johnson Acuvue Oasys contact lens.
11506449|NCT01309100|Active Comparator|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens.
11506450|NCT01309074|Experimental|Pregabalin|Pregabalin is an antiepileptic medication which has been found in double blind placebo controlled trials to be effective and safe in the treatment of primary generalized anxiety disorder. It has an indication for the treatment of this condition in Europe & Canada but not in the US.
11506451|NCT01309074|Active Comparator|Sertraline|Sertraline is an SSRI found to be an effective treatment of generalized anxiety disorder in controlled trials. It does not have an indication for this in this country.
11506452|NCT01309048|Experimental|Patients with painful bone metastasis|Patients with bone metastasis causing pain
11506453|NCT01309035|Active Comparator|With Tourniquet|Total Knee Arthroplasty. Surgery performed during use of a tourniquet.
11506454|NCT01309035|Experimental|Without Tourniquet|Total Knee Arthroplasty. Surgery performed without use of a tourniquet.
11506455|NCT01309009|Experimental|Nepadutant High Dose|
11506456|NCT01309009|Experimental|Nepadutant Low Dose|
11506457|NCT01309009|Placebo Comparator|Placebo|
11506458|NCT01308996|Experimental|INFUSE® Bone Graft|
11506459|NCT01308996|Active Comparator|Autogenous bone graft|
11506460|NCT01308983|Other|Amiloride|
11506461|NCT01308970|Experimental|Stress Management Group 1|
11506462|NCT01308970|Experimental|Stress Management Group 2|
11506463|NCT01308970|Experimental|Stress Management Group 3|
11506464|NCT01308957|Experimental|Long chain omega-3 fatty acids|
11506465|NCT01308957|Placebo Comparator|Corn oil|
11506466|NCT01308957|No Intervention|Young healthy controls|Young subjects' muscle mass and physical function will be evaluated once (i.e., during baseline testing only). The data in young subjects will be used to determine the magnitude of the aging-induced decline in muscle mass and physical function in the older subjects prior to starting the interventions.
11506467|NCT01308944|Experimental|Arm 1|"Propranolol 40mg po orally twice daily to begin at least 48 hours prior to surgical debulking. This will ideally be titrated in order to maintain a heart rate between 60 and 80 without hypotension.
~After surgery, the patient will resume the propranolol once tolerating clear liquids in the hospital and will remain on them until completion of chemotherapy.
~After completion of chemotherapy, the patient will be weaned off the medication over the following two weeks."
11506468|NCT01308931||Tubal ligation|Patients who elect to have tubal ligation
11506469|NCT01308931||Essure|Group that elects to have Essure placement
11506470|NCT01308931||Levonorgestrel IUD|Patients that elect to have a levonorgestrel intra-uterine device placement
11506471|NCT01308918||GlideScope DLT intubation|Patients having a thoracic surgery (non cardiac) via either thoracoscopy or thoracostomy. Patients were all 18 years old or over, and have read, understood and signed an informed consent at the preoperative evaluation or on surgery morning.
11506516|NCT01308580|Experimental|Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.
11506517|NCT01308567|Experimental|Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until disease progression (DP), unacceptable toxicity or participant's refusal.
11506570|NCT01308177|Placebo Comparator|PPI+placebo|
11506472|NCT01308905|Experimental|FLT-PET|"Patients will be managed per COG protocol ANBL00B1 (low risk, LR), ANBL0521 (intermediate risk, IR), ANBL0531 (high risk, HR) or other future neuroblastoma studies according to their risk group (risk assignment, treatment schema and protocols are available in COG website). The following is a brief description of the treatment.
~Low risk patients: observation only.
~Intermediate risk patients: chemotherapy stratified according to risk sub-groups followed by surgical resection.
~High risk patients: 6 courses of induction chemotherapy, surgical resection and high dose chemotherapy with autologous stem cell transplant (SCT), involved field radiation and 6 months of Isotrenitoin.
~PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection)."
11506473|NCT01308892|Active Comparator|High flavaonol chocolate|
11506474|NCT01308892|Placebo Comparator|Low flavanol chocolate|
11506475|NCT01308879|Experimental|Weekly feedback|After clinical questionnaires are entered into the system (CFStm), an automated online report is available weekly to clinicians in the experimental group that shows current mental health status of youths, alerts, and trends over time based on youth, caregiver, and clinician responses. Reports also show some clinical data on caregivers.
11506476|NCT01308879|Other|No feedback|Clinicians in the control group do not have access to weekly feedback. Instead, they receive reports every 90 days after the youth is enrolled in CFStm. Because the average duration of CFS enrollment was 3.8 months, many youths would have been discharged before the first 90-day report became available three months after treatment start. Thus, we considered the 90-day feedback group to be essentially a no-feedback group.
11506477|NCT01308866|No Intervention|Control|Usual care
11506478|NCT01308866|Experimental|Intervention|Intervention arm using a share-decision tool for cardiovascular patients
11506479|NCT01308853|Other|Macrolane|Open label
11506480|NCT01308840|Experimental|Panitumumab|Panitumumab 6mg/kg on days 1 and 15 of every cycle (28 days); Gemcitabine 1000mg/m2 on days 1 and 15 of every cycle (28 days); Oxaliplatin 85mg/m2 on days 1 and 15 of every cycle (28 days)
11506481|NCT01308827||Children with suspected pneumococcal invasive disease|
11506482|NCT01308814|Placebo Comparator|Placebo|Placebo patches for 12 months and placebo pills for 12 days every 2 months.
11506483|NCT01308814|Experimental|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months and oral micronized progesterone (200 mg/day) for 12 days every two months.
11506484|NCT01308801|Experimental|active rTMS + rehabilitation exercise|14 weeks of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise
11506485|NCT01308801|Placebo Comparator|placebo rTMS + rehabilitation exercise|14 weeks of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise
11506486|NCT01308788||aqueous suppressant|aqueous suppressant treated
11506487|NCT01308788||aqueous outflow|aqueous outflow treated
11506488|NCT01308775|Active Comparator|SIS.NET, Routine Follow up|
11506489|NCT01308762|Experimental|IMM-101|"Patients received an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28. Doses used were:
~'Heat killed whole cell M. obuense (IMM-101) 0.1 mg', 'Heat killed whole cell M. obuense (IMM-101) 0.5 mg', or 'Heat killed whole cell M. obuense (IMM-101) 1.0 mg'"
11506490|NCT01308749|Placebo Comparator|Placebo|Intervention: Drug: placebo
11506491|NCT01308749|Active Comparator|Oxytocin|Intervention: Drug: Syntocinon® Nasal Spray
11506492|NCT01308736|Active Comparator|varenicline|
11506493|NCT01308736|Placebo Comparator|placebo pill|
11506494|NCT01308723|Experimental|Part I|
11506495|NCT01308723|Experimental|Part II (A)|
11506496|NCT01308723|Active Comparator|Part II (B)|
11506497|NCT01308697|Active Comparator|Operative|Operative intervention
11506498|NCT01308697|Active Comparator|Non Operative Treatment|Non Operative management
11506499|NCT01308684|Experimental|1|
11506500|NCT01308684|Experimental|2|
11506501|NCT01308671|Active Comparator|varenicline|On 3 day after received clopidogrel 75mg/day, Varenicline group will be administered with varenicline 0.5mg Qd,after 3 days, 0.5mg Bid,after 7days,1mg Bid .And received counseling and psychosocial support.
11506502|NCT01308671|Other|Blank|Blank group will be only administered with Counseling and psychosocial support,beside antiplatelet etc.conventional therapy for 14 days.
11506503|NCT01308658|Experimental|001|Darunavir (DRV) 2x400-mg DRV tablet or 800-mg tablet on Day 3
11506504|NCT01308658|Experimental|002|ritonavir 100-mg once daily on Day 1 to Day 5
11506505|NCT01308632|Experimental|Temozolamide, irinotecan|"Phase I trial:
~TMZ will be administered in a fixed schedule as follows:
~TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.
~100 mg/m2 in a morning single dose on days 8 and 22
~CPT-11 starting dose:
~100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)
~One cycle = 28 days
~CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 ."
11506506|NCT01308619|Active Comparator|Oracea®|Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules
11506507|NCT01308619|Active Comparator|placebo|placebo
11506508|NCT01308606|Experimental|001|TMC435 gelatin capsule Single intake of one 150-mg capsule without food
11506509|NCT01308606|Experimental|002|TMC435 HPMC capsule Single intake of one 150-mg capsule without food
11506510|NCT01308606|Experimental|003|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule without food
11506511|NCT01308606|Experimental|004|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after standardized breakfast
11506512|NCT01308606|Experimental|005|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after high-fat breakfast
11506513|NCT01308593|Active Comparator|Juvederm XC|Juvederm XC
11506514|NCT01308593|Active Comparator|Botox|Medication used to block neuromuscular transmission
11506515|NCT01308580|Experimental|Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.
11506568|NCT01308190|Active Comparator|Chemoradiotherapy+TEM|Preoperative chemotherapy: capecitabine 825 mg/m2 every 12 hours orally, plus Radiotherapy (50.4 Gy). After 6-8 weeks, transanal endoscopic microsurgery (TEM)is done
11506519|NCT01308567|Active Comparator|Docetaxel 75 mg/m^2|Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.
11506520|NCT01308554|Placebo Comparator|Sterile normal saline|Control group will receive sterile normal saline in the block
11506521|NCT01308554|Active Comparator|Marcaine|Study group will receive a bilateral TAP block using 20 ml of Marcaine 2,5 mg/ml on each side.
11506522|NCT01308541|Active Comparator|LUSEDRA (arm 1)|
11506523|NCT01308541|Active Comparator|LUSEDRA (arm 2)|
11506524|NCT01308541|Active Comparator|Propofol (arm 3)|
11506525|NCT01308528|Experimental|Sodium enoxaparin|Endocris - 40 mg/0,4mL
11506526|NCT01308528|Experimental|sodium enoxaparin Clexane|Clexane - 40 mg/ 0,4mL
11506527|NCT01308515|Other|Posterior Stabilized|Patients who received a PS (Posterior Stabilized) Tibial Bearing.
11506528|NCT01308515|Other|Anterior Stablized|Patients who received an AS (Anterior Stabilized) Tibial Bearing
11506529|NCT01308502|Experimental|Probe|Children with airway obstruction
11506530|NCT01308489|Experimental|Arm I (posterior spinal tumor resection)|Patients undergo posterior spinal tumor resection on day 0.
11506531|NCT01308489|Experimental|Arm II (anterior and posterior spinal tumor resection)|Patients undergo anterior and posterior tumor resection on day 0.
11506532|NCT01308476||SMS group|
11506533|NCT01308476||control group|
11506534|NCT01308450||Single Arm, Non ADHD Control Group|Single site, single visit study. Subjects will be administered Standard Rating Scales (Defined) and the Quotient ADHD System Test (Adolescent and Adult Version). Subject's assessed to be Non-ADHD will be eligible to have their Quotient tests added to the Quotient Adolescent and Adult Normative Database.
11506535|NCT01308437|Experimental|Wosulin (N or 70/30 with R)|Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
11506536|NCT01308437|Active Comparator|Novolin® (N or 70/30 with R)|Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
11506537|NCT01308424|Experimental|BTL TML HSV|
11506538|NCT01308424|Placebo Comparator|Matching Placebo|
11506539|NCT01308411|Experimental|50% reduction in ICS dose|All patients will reduce their inhaled corticosteroid dose by 50%
11506540|NCT01308385||Patients with pectus excavatum|
11506541|NCT01308372||1|For this group of patients, the cardiovascular risk will be evaluated by several tools: the SCORE scale, the Framingham 2008 scale d'Agostino and the 1998 scale Wilson ;
11506542|NCT01308359|Experimental|glucose 5%|glucose 5%
11506543|NCT01308359|Active Comparator|saline|saline
11506544|NCT01308346|Experimental|Bioresorbable Vascular Scaffold (BVS)|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)
11506545|NCT01308346|Active Comparator|XIENCE V® or XIENCE PRIME®|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) or XIENCE PRIME®
11506546|NCT01308333||XLHED children|
11506547|NCT01308333||XLHED adults|
11506548|NCT01308333||Control children|
11506549|NCT01308333||Control adults|
11506550|NCT01308320|Placebo Comparator|saline|control group
11506551|NCT01308320|Active Comparator|F1 group|F1 group : fentanyl 1 mcg/kg
11506552|NCT01308320|Active Comparator|F1.5 group|F1.5 group : fentanyl 1.5 mcg/kg
11506553|NCT01308320|Active Comparator|F2 group|F2 group : fentanyl 2 mcg/kg
11506554|NCT01308307|Experimental|one arm|
11506555|NCT01308294|Experimental|2 vaccine injections in 1 limb|9 patients initially planned: patients received peptides with IMP321/LAG-3Ig and Montanide in 2 injections sites at 5 cm distance from each other 2 vaccine injections in same limb (vaccine 1 : NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2 : Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)
11506556|NCT01308294|Experimental|2 vaccine injections in distinct limbs|Groupe2: 2 vaccine injections in different limb should include 9 patients that were initially planned: patients received the same vaccine in 2 syringes injected each in a distinct limb (vaccine 1: NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2: Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)
11506557|NCT01308294|Experimental|"2 vaccine injections in distinct limbs"|Groupe3: 2 vaccine injections in distinct limb should include 9 patients that were initially planned; due to premature trial termination, no patients could be enrolled. Patients of this group should have received the same vaccine but without the MHC class II peptide (MAGE-A3)
11506558|NCT01308281|Experimental|PCI with IVUS guidance|PCI(percutaneous coronary intervention) with IVUS(IntraVascular UltraSound) group
11506559|NCT01308281|Active Comparator|PCI without IVUS guidance|PCI(percutaneous coronary intervention) group
11506560|NCT01308255|Experimental|Infliximab Arm|For those randomised to the infliximab arm, infliximab will be administered at a dose of 3mg/kg according to the standard treatment protocol.
11506561|NCT01308255|Placebo Comparator|Steroid/Placebo Arm|Patients randomised to this arm will receive an IV infusion of 250mg methylprednisolone at week 0 & those without an adequate clinical response after 26 wks will receive additional steroid as IM methylprednisolone 120mg. Patients on this arm will receive an IV placebo infusion of 250ml of 9mg/l NaCl.
11506562|NCT01308242|Experimental|Treatment|Patients enrolled will receive Renvela for a 3 month time frame.
11506563|NCT01308229|Experimental|Nile PAX®|
11506564|NCT01308216|Experimental|Transcranial low level laser therapy|Transcranial laser therapy is applied by automatic scanning over both hemispheres and the patients undergoing also a standard rehabilitation program based on therapeutic exercises.
11506565|NCT01308216|Active Comparator|Control|The patients undergoing only a standard rehabilitation program based on therapeutic exercises.
11506566|NCT01308203|Experimental|Extended release niacin /laropiprant|The patients will be randomized to one of two arms. The intervention is with the extended release niacin laropiprant combination, that is an add on of the usual medication that the primary care physician gave them to treat their lipid disorder (statin, ezetimibe or the combination of both).
11506567|NCT01308203|Placebo Comparator|placebo|The patients will received placebo added to the usual therapy their primary care physician gave them to treat their lipid disorder (statin, ezetimibe or the combination of both).
11506569|NCT01308190|Other|Total Mesorectal Excision|Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer
11506571|NCT01308177|Active Comparator|PPI+ES|
11506572|NCT01308164|Experimental|MD logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
11506573|NCT01308164|No Intervention|Control Group|Regular treatment, no change will be made in the insulin pump setting during the study (unless there is a medical need or any safety concern) Only segment 2 of the study, which is conducted as RCT (randomized controlled trial) , will include control group
11506574|NCT01308151|Experimental|Experimental Arm|Culturally Adapted Manualised Cognitive Behavioral Therapy (CBT) Sessions will be offered weekly in the first month and then fortnightly.
11506575|NCT01308151|No Intervention|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
11506576|NCT01308138|Experimental|ExerciseTr|
11506577|NCT01308138|Experimental|Remote ischemic preconditioning group|
11506578|NCT01308138|No Intervention|Control patient group|
11506579|NCT01308112|Experimental|Supplemental iron|
11506580|NCT01308112|Placebo Comparator|Placebo|
11506581|NCT01308099||POTS & Controls|"Participants will have a physical prior to the study day and collect urine for 24 hours.
~On the study day the following procedures take place:
~After blood samples taken (about 2 tbsp), the subject will lie down. A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The arm blood pressure cuff will be inflated 60 points above the highest number on your normal blood pressure for five minutes. The blood pressure and forearm blood flow will be recorded. At the end of 5 minutes, the cuff will be released and the measurements of blood pressure and calf blood flow will be repeated. The brachial artery diameter and flow will be measured at baseline, during cuff inflation and for 3 minutes after deflation.
~The study lasts about 2 hours."
11506582|NCT01308086|Active Comparator|FOLFOX 4 - 6months or XELOX -6months|
11506583|NCT01308086|Experimental|FOLFOX4 -3months or XELOX -3months|
11506584|NCT01308073||EMIC 2 dialysis|Patients on ICU requiring dialysis for acute renal insufficiency
11506585|NCT01308060|Experimental|Botulinum Toxin type A|During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo
11506586|NCT01308060|Placebo Comparator|Placebo|During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo
11506587|NCT01308047|Experimental|bupivacaine S75:R25|3 ml for subarachnoid block
11506588|NCT01308047|Active Comparator|bupivacaine (S50:R50)|3 ml subarachnoid block
11506589|NCT01308034|Experimental|association sunitinib radiotherapy|
11506590|NCT01308021|Experimental|gpASIT400|gpASIT+TM 400 µg
11506591|NCT01308021|Experimental|gpASIT800|gpASIT+TM 800 µg
11506592|NCT01308021|Placebo Comparator|Placebo|
11506593|NCT01308008|Experimental|Functional exercise- home physical activity|On-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with telephonic behavioral support
11506594|NCT01308008|Active Comparator|Flex and tone- home health education|Initial on-site flex and toning program continued on follow-up along with health education
11506595|NCT01307995||GDM|Patients with Gestational Diabetes Mellitus found during pregnancy by means of 75g OGTT
11506596|NCT01307995||NGT|Pregnant patients with normal glucose tolerance as observed in 75g OGTT
11506597|NCT01307982|Active Comparator|Fundoplication|During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
11506598|NCT01307982|Active Comparator|Gastrojejunal (GJ) feeding tube|Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
11506599|NCT01307969|Experimental|Anesthetic efficacy|Local anesthetics were injected at the apex of the maxillary right canine.
11506600|NCT01307956|Experimental|Treatment (panitumumab, chemotherapy, radiation)|Patients receive panitumumab IV over 1 hour on day 1. Patients also receive oxaliplatin IV and leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1 (FOLFOX chemotherapy). Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Within 24 hours of the start of chemotherapy, patients undergo radiation therapy 5 days a week for 5.5 weeks. Patients then undergo surgery within 6-8 weeks after completion of radiation therapy. Patients with residual disease receive 4 additional courses of FOLFOX chemotherapy on days 1, 15, 29, and 42.
11506601|NCT01307943|Experimental|Mindfulness Based Stress Reduction|"Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat at the completion of the eight sessions to review and consolidate experience with the various mindfulness practices. The MBSR concepts and techniques will emphasize portability. Participants will be encouraged to find moments throughout their day in which to practice the techniques. The language used to describe mindfulness practices will be accessible to youth. Mindfulness concepts will be linked with tag phrases like breathing break, autopilot, and choice points. Homework will emphasize experiential, concrete tasks (notice five new things today; eat one meal mindfully this week)."
11506602|NCT01307943|Active Comparator|Usual Care|The control group will be youth receiving therapies and programs already used at the site. The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
11506603|NCT01307930|Experimental|Anidulafungin|Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
11506604|NCT01307917|Experimental|healthy controls high flavonoid|20 healthy adolescents (12-21 years old) receiving the flavonoid-rich capsule/supplement
11506605|NCT01307917|Active Comparator|healthy controls low flavonoid|20 healthy adolescents (12-21 years old) receiving the placebo
11506606|NCT01307917|Experimental|T1DM or T2DM high flavonoid|20 adolescents (12-21 years old) with Type 1 diabetes mellitus or Type 2 diabetes mellitus receiving the capsule/supplement
11506607|NCT01307917|Active Comparator|T1DM or T2DM low flavonoid|20 adolescents (12-21 years old) with Type 1 diabetes mellitus or Type 2 diabetes mellitus receiving the placebo
11506608|NCT01307904|Active Comparator|dates|Each healthy and diabetic subjects received 50 grams equivalent of carbohydrates of the tested dates, On five separate days.
11506609|NCT01307904|Active Comparator|sugar|Each healthy and diabetic subjects received 50 grams of glucose
11506610|NCT01307891|Experimental|Abraxane + Tigatuzumab|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles. Patients will be evaluated for response every 8 weeks. Patients with disease progression will be taken off the study.
11506611|NCT01307891|Experimental|Abraxane alone|Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals. Patients will have the option to crossover to the combination arm based upon the pre-clinical data.
11506612|NCT01307878|Experimental|arm A|chemotherapy ± targeted therapy before resection of primary colorectal cancer
11506613|NCT01307878|No Intervention|arm B|resected the primary colorectal cancer and then given chemotherapy ± targeted therapy
11506614|NCT01307865|Experimental|Sculptra Aesthetic|Patients receiving Sculptra Aesthetic
11506615|NCT01307852|Experimental|In Vivo Dosimetry|Modified endorectal device capable of real-time dose measurement during prostate radiation therapy
11506616|NCT01307839|Active Comparator|5% lidocaine patch|If the patient chooses to participate, the resident will place the patch over the lower lumbar area of the back.
11506617|NCT01307839|Placebo Comparator|placebo patch|If the patient chooses to participate, the resident will place the patch over the lower lumbar area of the back.
11506618|NCT01307826|Experimental|tensegrity massage|In this group of patients massage sessions based on the tensegrity method were applied.
11506619|NCT01307826|Active Comparator|classical massage|In this group of patients 10 classical massage sessions were applied
11506620|NCT01307813|Experimental|Endoscopic suturing device|Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.
11506621|NCT01307800|Experimental|80 mg LY2140023|40 mg LY2140023 administered orally, twice daily (BID) for up to 7 weeks of treatment.
11506622|NCT01307800|Experimental|40 mg LY2140023|20 mg LY2140023 administered orally, BID for up to 7 weeks of treatment.
11506623|NCT01307800|Experimental|10 mg LY2140023|5 mg LY2140023 administered orally, BID for up to 7 weeks of treatment.
11506624|NCT01307800|Placebo Comparator|Placebo|Administered orally, BID for up to 7 weeks of treatment.
11506625|NCT01307787|Experimental|fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component.
11506626|NCT01307787|No Intervention|waiting list control group|The waiting-list control group was allowed to enter the FIT program for rehabilitation after the study period.
11506627|NCT01307761||Patients with thyroid nodule received US-FNA exam|Patients with thyroid nodules which underwent head and neck ultrasound(US) examination and US-FNA cytology at Department of Otolaryngology, Far Eastern Memorial Hospital, Taipei, Taiwan. No patient included in this series had a previous diagnosis of thyroid malignancy before US exam.
11506628|NCT01307748|Experimental|stress reducing aroma|aroma with reported stress reducing effects
11506629|NCT01307748|Placebo Comparator|Placebo aroma 1|
11506630|NCT01307748|Placebo Comparator|Placebo aroma 2|
11506631|NCT01307735||Myocarditis negative on CMR|Patients with suspected myocarditis referred for CMR and not fulfilling at least 2 of the 3 CMR criteria (Lake Louise Criteria)for myocarditis.Lake Louise Criteria are edema, hyperaemia, and necrosis/fibrosis.
11506632|NCT01307735||Myocarditis positive on CMR|Patients with suspected myocarditis referred for CMR and fulfilling at least 2 of the 3 CMR criteria (Lake Louise Criteria)for myocarditis.Lake Louise Criteria are edema, hyperaemia, and necrosis/fibrosis.
11506633|NCT01307722|Experimental|Patients under LA distensibility-guiding management|The management of guide group will be adjusted by LA distensibility, including the adjustments of inotropic agents, diuretics, beta-blocker, ACEI, and AIIB.
11506634|NCT01307722|No Intervention|patients under conservative monitor and management|This group will be treated by conventional management and traditional echocardiography can be performed as in-charge doctor request. Renal function will be checked 1 time per 3 months.
11506635|NCT01307683|Active Comparator|Mindful Moms|Based on the Mindful Motherhood Training (developed by Cassandra Vieten, PhD), Mindfulness-Based-Eating and Awareness Training (MB-EAT) (developed by Jean Kristeller, PhD), and other mindfulness- and acceptance-based interventions
11506636|NCT01307683|No Intervention|Comparison Group|Usual prenatal care
11506637|NCT01307657|Other|clopidogrel 600 mg loading dose|
11506638|NCT01307644|Experimental|Web-based only (WO) weight intervention|A comprehensive lifestyle modification intervention for healthy eating and activity delivered by web only to facilitate Phase I weight loss (weekly messages baseline to 6 months), Phase 2 guided weight loss and weight maintenance (bi-weekly hot topics news, 6-18 months) and Phase 3 self-managed weight maintenance (6 monthly and 3 bi-monthly new content, 18-30 months).
11506639|NCT01307644|Experimental|WO & peer-led discussion board (WD)|Includes WO intervention, including all 3 Phases for weight loss and weight maintenance, supplemented with peer-lead discussion board. A peer leader will facilitate the asynchronous discussion group. The primary purpose of this group is to provide support, increase self-efficacy (role modeling by successful women and leader) and discuss progress toward goals.
11506640|NCT01307644|Experimental|WO & professional email counseling (WE)|Includes WO intervention, including all 3 Phases for weight loss and weight maintenance, supplemented with professional email-counseling by experienced counselor who will review women's web-logs of eating, activity, weight and goal-setting on web-site and send e-mail feedback.
11506641|NCT01307631|Experimental|Treatment (Akt inhibitor MK2206|Patients receive Akt inhibitor MK2206 PO once weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11506642|NCT01307618|Experimental|Arm I (vaccine therapy)|Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.
11506643|NCT01307618|Experimental|Arm II (vaccine therapy, IL-12)|Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.
11506644|NCT01307605|Active Comparator|Rituximab|Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
11506645|NCT01307605|Active Comparator|Rituximab plus Lenalidomide|Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
11506646|NCT01307579|Experimental|Arm I (caspofungin acetate)|Patients receive caspofungin acetate IV over one hour QD beginning within 24-72 hours following the last dose of chemotherapy for each course. and continuing until ANC > 100-500/uL following the nadir or the next chemotherapy course begins.
11506647|NCT01307579|Active Comparator|Arm II (fluconazole)|Patients receive fluconazole IV over 1-2 hours or PO QD beginning within 24-72 hours following the last dose of chemotherapy for each course.
11506648|NCT01307566|Experimental|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure (CPAP)
11506649|NCT01307553||PCS Group|
11506650|NCT01307540|Experimental|Active light therapy|oral mucosa is exposed to a light source (broad band of wavelengths, 400-800 nm)
11506651|NCT01307540|Placebo Comparator|Inactive light therapy|Oral mucosa is exposed to a extremely low-intensity light which is assumed to have no effect.
11506652|NCT01307501|Other|Cryoablation|Participants will undergo a cryoablation procedure with the Galil Medical Cryoablation System according to the manufacturer's guidelines. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators. No more than 3 tumors in 1 lung can be treated in a single session, and no more than 5 total lung tumors (across both lungs) can be treated during the study.
11506653|NCT01307488|Experimental|ATV/r+3TC|Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
11506654|NCT01307488|Active Comparator|ATV/r+2 NRTIs|Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
11506655|NCT01307475||Proband Group|Patients identified with FSS or a related condition
11506656|NCT01307475||Family Group|Persons who are genetically or legally related to a person with FSS or related condition
11506657|NCT01307475||Other Affected Individuals Group|Persons who have had significant and meaningful contact with a person with FSS or related condition but do not qualify for family group enrolment
11506658|NCT01307462|Experimental|Treatment (BOS therapy)|Patients receive fluticasone propionate inhaled PO BID, azithromycin PO 3 days a week, and montelukast sodium PO QD. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
11506659|NCT01307449|Experimental|Older Group on PREVNAR|Participants between the ages of 60-89 received PREVNAR
11506660|NCT01307449|Experimental|Younger Group on PREVNAR|Participants between the ages of 25-40 years received PREVNAR
11506661|NCT01307449|Experimental|Older Group on PNEUMOVAX|Participants between the ages of 60-89 received PNEUMOVAX
11506662|NCT01307449|Experimental|Younger Group on PNEUMOVAX|Participants between the ages of 25-40 years received PNEUMOVAX
11506663|NCT01307436|Experimental|Group A|Epaxal + concomitant administration of DTPaHibIPV, MMR, OPV
11506664|NCT01307436|Experimental|Group B|Epaxal, with administration of DTPaHibIPV, MMR, OPV one month later
11506665|NCT01307436|Active Comparator|Group C|Havrix 720 + concomitant administration of DTPaHibIPV, MMR
11506666|NCT01307423|Experimental|Apremilast 20mg|Apremilast 20mg twice daily, orally
11506667|NCT01307423|Experimental|Apremilast 30mg|Apremilast 30mg twice daily, orally
11506668|NCT01307423|Placebo Comparator|Placebo + 20mg Apremilast|Placebo + 20mg Apremilast tablets administered twice daily
11506669|NCT01307423|Placebo Comparator|Placebo + 30mg Apremilast|Placebo + 30mg Apremilast tablets administered twice daily
11506670|NCT01307410||with CAD|Patients with hypertension and dyslipidemia with prior CAD
11506671|NCT01307410||without CAD|Patients with hypertension and dyslipidemia without prior CAD
11506672|NCT01307397|Experimental|Vemurafenib|Participants will receive vemurafenib at a dose of 960 milligrams (mg) twice daily (bid) until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
11506673|NCT01307384||Continuum Acetabular System|Patients receiving primary hip arthroplasty using the Continuum Metal on Polyethylene Acetabular System
11506674|NCT01307371||Diabetes|Patients with diabetes.
11506675|NCT01307371||non-diabetes|Patients without diabetes.
11506676|NCT01307358|Experimental|Manual Toothbrush + Sonicare Interproximal Cleaning Prototype|Manual Toothbrush + Sonicare Interproximal (IP) Cleaning Prototype
11506677|NCT01307358|Active Comparator|Manual Toothbrush|Manual Toothbrush
11506678|NCT01307358|Active Comparator|Manual Toothbrush + Floss|Manual Toothbrush + Floss
11506679|NCT01307358|Active Comparator|Manual Toothbrush + Waterpik Ultra Water Flosser|Manual Toothbrush + Waterpik Ultra Water Flosser
11506680|NCT01307345|No Intervention|Monitoring Alone|Research assistants will phone or text participants and request videorecordings of breathalyzer samples up to 21 times per week. Participants will receive compensation for each valid videorecording that occurs within the requested one-hour time frame, and bonus compensation each time all requested videorecordings are submitted within the timeframe over a 7-day period, and/or if >90% of prompts are returned over the study period.
11506681|NCT01307345|Experimental|Monitoring plus contingency management for abstinence|Participants assigned to this condition will receive the same monitoring schedule outlined above, plus the same payment for compliance. In addition, they will receive contingent reinforcement for submission of videorecordings that demonstrate negative breath alcohol samples. For each sample submitted that reads below the cut point, participants will receive vouchers for payment.
11506735|NCT01307020|Experimental|DKP-TRIS low dose - TRAM.HCl high dose|
11506682|NCT01307332|Experimental|MabCampath-1h|Single arm, single cohort study, all subjects will be dosed with alemtuzumab.
11506683|NCT01307319|Experimental|BDP HFA 80 mcg/day|Participants/parents administer 40 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
11506684|NCT01307319|Experimental|BDP HFA 160 mcg/day|Participants/parents administer 80 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
11506685|NCT01307319|Placebo Comparator|Placebo nasal aerosol once daily|Participants/parents administer placebo (a spray with no medication in each nostril) once daily for 15 days.
11506686|NCT01307306|Experimental|Metformin|
11506687|NCT01307306|Experimental|Insulin|
11506688|NCT01307306|No Intervention|Control|
11506689|NCT01307293|Experimental|Cognitive Behavior Therapy|6-12 sessions of Cognitive Behavior Therapy to address PTSD symptoms and parenting issues related to premature infants.
11506690|NCT01307293|No Intervention|Placebo comparison|Education regarding NICU parenting issues.
11506691|NCT01307280|Experimental|Basic HEALTH|Participants received the bookHEALTH manual and eHEALTH tools, the basic Internet component of the intervention
11506692|NCT01307280|Experimental|Interactive Internet|Intervention intensity increased in RCT2, which included bookHEALTH and an interactive version of eHEALTH that provided tailored computerized feedback whenever participants submitted weekly assessments.
11506693|NCT01307280|Experimental|Behavioral Counseling|RCT3 included bookHEALTH, the interactive version of eHEALTH, and telephonic coaching support provided by trained health lifestyle coaches every 2 weeks alternating between a telephone call (typically 15 to 20 minutes) and a personalized e-mail. The coaches used motivational interviewing, helped participants solve problems, and reinforced their successes.
11506694|NCT01307267|Experimental|Portion A|PF-05082566 single agent in patients with advanced cancer
11506695|NCT01307267|Experimental|Portion B|PF-05082566 in combination with rituximab in patients with Non-Hodgkin's Lymphoma
11506696|NCT01307254||Non alcoholic fatty liver disease|
11506697|NCT01307254||control|
11506698|NCT01307241||one cohort|Adult patients with ALL attending at the Instituto Nacional de Cancerologia Mexico.
11506699|NCT01307228|Experimental|Full-serve evidence service|"The full-serve evidence service consists of:
~database (Health Systems Evidence) access;
~monthly e-mail alerts; and
~full-text article availability."
11506700|NCT01307228|Active Comparator|Self-serve evidence service|"Participants allocated to the self-serve evidence service will receive only database access, which is already publicly available at www.healthsystemsevidence.org"
11506701|NCT01307215|Experimental|20mLs of 0.5% ropivacaine per side|
11506702|NCT01307215|Experimental|30mLs of 0.33% ropivacaine per side|
11506703|NCT01307215|Experimental|40mLs of 0.25% ropivacaine per side|
11506704|NCT01307202|Experimental|Gabapentin|Gabapentin 600 mg will be given per oral two hours preoperatively and 200 mg three times daily after surgery (600 mg/day).
11506705|NCT01307202|Placebo Comparator|Placebo|Placebo will match the the gabapentin pill and will be given orally.
11506706|NCT01307189|Active Comparator|Tiotropium|
11506707|NCT01307189|Placebo Comparator|Placebo|
11506708|NCT01307176|Experimental|Home exercise program|Balance and walking exercise program
11506709|NCT01307150||Before and after treatment|SCORAD of each patient before and after treatment.
11506710|NCT01307137|Experimental|Telehealth (TAP)|
11506711|NCT01307137|Experimental|Peer-led care (PC)|
11506712|NCT01307124|Active Comparator|standard dose|Arm 1:LPV/r Standard dose BW 25-35 kg 300/75 mg BW >35-50 kg 400/100 mg
11506713|NCT01307124|Experimental|low dose|Arm 2:Low dose BW 25-35 kg 200/50 mg BW >35-50 kg 300/75 mg
11506714|NCT01307111|Experimental|Misoprostol|Misoprostol 400 micrograms inserted buccally or vaginally, per the participants desire.
11506715|NCT01307111|Placebo Comparator|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
11506716|NCT01307098|Experimental|Sebelipase alfa 0.35 mg/kg|Cohort 1: Participants were administered once weekly (qw) infusions of 0.35 mg/kg sebelipase alfa.
11506717|NCT01307098|Experimental|Sebelipase alfa 1 mg/kg|Cohort 2: Participants were administered qw infusions of 1 mg/kg sebelipase alfa.
11506718|NCT01307098|Experimental|Sebelipase alfa 3 mg/kg|Cohort 3: Participants were administered qw infusions of 3 mg/kg sebelipase alfa.
11506719|NCT01307085|Experimental|preconditioning|Adult patients undergoing elective pulmonary lobectomy were received a remote ischemic preconditioning group after induction of anaesthesia.
11506720|NCT01307085|No Intervention|conventional|Adult patients undergoing pulmonary lobectomy were received no treatment after induction of anaesthesia.
11506721|NCT01307072||Never-treated group|The patients who had no previous ophthalmic examination until the first visit when vitreous surgery was prescribed
11506722|NCT01307072||The non-compliant group|The patients with a history of missing ophthalmic examination over a one year period
11506723|NCT01307072||The compliant group|The patients who had ophthalmic examinations at least once a year
11506724|NCT01307046|Experimental|MK-0954A|Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks.
11506725|NCT01307046|Active Comparator|Losartan|Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks.
11506726|NCT01307033|Active Comparator|MK-954H (L50/H12.5)|One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will then receive open label MK-0954A (L100/H12.5) orally, once daily for 44 weeks (extension)
11506727|NCT01307033|Experimental|MK-0954A (L100/H12.5)|One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will continue to receive MK-0954A orally, once daily for 44 week extension
11506728|NCT01307020|Placebo Comparator|Placebo|
11506729|NCT01307020|Active Comparator|Ibuprofen|
11506730|NCT01307020|Active Comparator|TRAM.HCl high dose|
11506731|NCT01307020|Active Comparator|TRAM.HCl low dose|
11506732|NCT01307020|Active Comparator|DKP-TRIS high dose|
11506733|NCT01307020|Active Comparator|DKP-TRIS low dose|
11506734|NCT01307020|Experimental|DKP-TRIS low dose - TRAM.HCl low dose|
11506736|NCT01307020|Experimental|DKP-TRIS high dose - TRAM.HCl low dose|
11506737|NCT01307020|Experimental|DKP-TRIS high dose - TRAM.HCl high dose|
11506738|NCT01307007|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0
11506739|NCT01307007|Active Comparator|Iron Dextran Injection|Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
11506740|NCT01306994||Syndrome Group|Individuals with Freeman-Sheldon, Sheldon-Hall, distal arthrogryposis type 1, or distal arthrogryposis type 3
11506741|NCT01306994||Control Group|Healthy individuals
11506742|NCT01306981|Experimental|Ranibizumab|
11506743|NCT01306981|Placebo Comparator|Saline|
11506744|NCT01306968|No Intervention|Standard TBI Care|Routine post-concussive symptoms (PCS) care as practiced within Departments of Defense (DoD)
11506745|NCT01306968|Experimental|HBO2 Group|Routine PCS care supplemented with hyperbaric oxygen (HBO2) at the dose of 1.5 ATA for 60 minutes administered over 40 sessions given daily Monday through Friday
11506746|NCT01306968|Sham Comparator|Sham Group|Routine PCS care supplemented with an otherwise identical sham hyperbaric air exposure at 1.2 atmospheres absolute (ATA)
11506747|NCT01306968|No Intervention|PTSD With no History of TBI|Subjects who have been diagnosed with PTSD but have no diagnosed or suspected brain injuries. This group does not receive HBO2.
11506748|NCT01306955|Active Comparator|methylprednisolone|patients who received methylprednisolone
11506749|NCT01306955|Placebo Comparator|dextrose water 5%|patients who received dextrose water 5% as placebo
11506750|NCT01306942|Experimental|Dasatinib + trastuzumab + paclitaxel|Eligible patients will be enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days. Dasatinib will be administered orally in two dose levels 100 and 140 mg once daily (QD) (a -1 dose level is included just in case dose de-escalation is needed). Treatment will be repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occurs. Only in the phase I, the first cycle will last 38 days.
11506751|NCT01306929|Experimental|pridopidine|45mg bid
11506752|NCT01306916||Group 1 of 1|diagnosis of primary and secondary hyperparathyroidism scheduled to undergo parathyroid resection.
11506753|NCT01306903|Experimental|MECC|Minimal extracorporeal circuit
11506754|NCT01306903|Placebo Comparator|MOPS|
11506755|NCT01306903|Placebo Comparator|Super MOPS|
11506756|NCT01306890||sipuleucel-T|
11506757|NCT01306877|Experimental|EEA Hemorrhoid and Prolapse Stapling Set|
11506758|NCT01306877|Active Comparator|Endosurgery Proximate PPH03 Stapling Set|
11506759|NCT01306864|Experimental|Hemospray Treatment|Hemospray Kit
11506760|NCT01306851|Active Comparator|Fibrin glue|
11506761|NCT01306838|Experimental|Treatment|The treatment arm is given early enteral supplementation with MicroLipid and Fish oil.
11506762|NCT01306838|Active Comparator|Control Group|Routine care
11506763|NCT01306799||Barrett's Esophagus, Erosive Esophagitis, GERD|
11506764|NCT01306786|Active Comparator|Quadruple therapy|"First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.
~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d"
11506765|NCT01306786|Active Comparator|Triple Therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
11506766|NCT01306773|Active Comparator|H1N1 convalescent plasma and oseltamivir|Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma
11506767|NCT01306773|Active Comparator|Oral Oseltamivir alone|Oseltamivir 75mg bid during ICU hospitalization
11506768|NCT01306760|Experimental|Ketamine|Ketamine used as the anaesthetic during ECT.
11506769|NCT01306760|Active Comparator|Propofol|Propofol, the standard anaesthetic, used during ECT.
11506770|NCT01306747|Experimental|Chronic Pain Self-Management|
11506771|NCT01306747|No Intervention|Control group|
11506772|NCT01306734||Gradient cooling group|Study group receiving gradient cooling during the procedure using extracorporeal circulation (ECC). The procedure is used routinely in the department and is not an experimental procedure. A maximum of 10 degrees celsius is allowed between the measured nasopharyngeal body temperature and the heater-cooler unit of the ECC-machine, when cooling or rewarming.
11506773|NCT01306734||Crash cooling group|Study group receiving rapid cooling using extracorporeal circulation. The protocol for rapid cooling is using routinely in the department and is not an experimental procedure. When cooling, the investigators aim for maximal difference in temperature between the heater-cooler unit of the ECC-machine.
11506774|NCT01306721|Active Comparator|FEX 60 mg|"Study medications is administered one hour before or two hours after a meal twice a day.
~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination)
~Double-blind treatment period:
~1 tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg /pseudoephedrine 60 mg (fixe dose combination)"
11506775|NCT01306721|Experimental|FEX 60 mg/PSE 60 mg|"Study medications is administered one hour before or two hours after a meal twice a day.
~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination
~Double-blind treatment period:
~1 tablet of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 60 mg / pseudoephedrine 60 mg (fixe dose combination)"
11506776|NCT01306721|Experimental|FEX 60 mg/PSE 120 mg|"Study medications is administered one hour before or two hours after a meal twice a day.
~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination)
~Double-blind treatment period:
~2 tablets of fexofenadine 30 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 30 mg"
11507011|NCT01305070|Active Comparator|Standart balloon angioplasty|Admiral Xtreme, Invatec
11506777|NCT01306708|Active Comparator|nimesulide|Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral non-steroidal anti-inflammatory (nimesulide 100 mg, twice per day, for 14 days);
11506778|NCT01306695|Experimental|NYUCI|New York University Caregiver Intervention (NYUCI) in addition to community-based case management using community health workers: The first component consists of two individual and four family counseling sessions that include relatives suggested by the caregiver.
11506779|NCT01306695|Other|CHW Intervention|Community-based case management using community health workers (CHWs): The CHW intervention will consist of 2 visits in month 1, followed by monthly visits until month 6.
11506780|NCT01306682|Active Comparator|Trivalent Influenza vaccine|0.5ml of TIV will be administered into deltoid muscle of non dominant arm
11506781|NCT01306682|Placebo Comparator|Normal saline|0.5ml of normal saline administered into deltoid muscle of non dominant arm
11506782|NCT01306669|Active Comparator|Trivalent influenza vaccine|Single dose administration of trivalent influenza vaccine prior to onset of influenza season
11506783|NCT01306669|Placebo Comparator|Normal saline|
11506784|NCT01306656|Experimental|Group 1|10,000 IU Vitamin D3 plus a multivitamin with 400 IU vitamin D
11506785|NCT01306656|Placebo Comparator|Group 2|Placebo plus a multivitamin with 400 IU vitamin D
11506786|NCT01306643|Experimental|Idelalisib|
11506787|NCT01306630|Other|tivozanib + capecitabine|
11506788|NCT01306617|Experimental|ABT-450/r (250/100 mg) and ABT-333 plus RBV in treatment-naïve|ABT-450/r (250/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID for 12 weeks in treatment-naïve participants.
11506789|NCT01306617|Experimental|ABT-450/r (150/100 mg) and ABT-333 plus RBV in treatment-naïve|ABT-450/r (150/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID for 12 weeks in treatment-naïve participants.
11506790|NCT01306617|Experimental|ABT-450/r (150/100 mg) and ABT-333 plus RBV in non-responders|ABT-450/r (150/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID in previous non-responders to pegylated interferon (pegIFN) and RBV.
11506791|NCT01306604||Observation|Patients from the first day of life with Niemann Pick Type C syndrome NPC1/NPC2 or profound suspicion for Niemann Pick Type C syndrome NPC1/NPC2 disease
11506792|NCT01306591|Active Comparator|Bevacizumab 1|
11506793|NCT01306591|Active Comparator|Bevacizumab 2|
11506794|NCT01306578|Active Comparator|IVIG group|20 children randomized to receive IVIG for 5 days at a dose of 0.4 g/kg/day
11506795|NCT01306578|Active Comparator|Plasma Exchange|21 children randomized to receive 5 sessions of 1 volume plasma exchange per day for 5 consecutive days
11506796|NCT01306565|Active Comparator|High dose atorvastatin|Three 80mg daily doses of atorvastatin
11506797|NCT01306565|Experimental|Low dose Atorvastatin|80mg atorvastatin followed by two 20mg daily atorvastatin
11506798|NCT01306552|Active Comparator|Student-intervention only group|"Schools randomized to intervention only (arm 1) will agree to visit the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?).
~One school class of students will visit the parcours once during a school day. The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
11506799|NCT01306552|Active Comparator|Multi-component intervention|Schools randomized to the student-parent intervention arm also will agree to visit the KARUNA e.V. smoking prevention parcours. In addition, the schools will agree to have one parents' night presented by trained health coaches informing parents about smoking prevention topics in youth during the school year. Trained health coaches will give an evaluated smoking prevention presentation for parents at the parents' nights at the end of the first school year. Also, participating parents will receive information about successful ways to prevent smoking and promote smoking cessation in their children once by mail.
11506800|NCT01306552|Active Comparator|Control Group|Schools randomized to the control school will be offered to participate in the nutrition and exercise prevention program offered by KARUNA e.V. during the 2-year study.
11506801|NCT01306539|Experimental|Deep Brain Stimulation|Parkinson's patients with deep brain stimulation in the subthalamic nucleus.
11506802|NCT01306526||Moderate to Severe OSA|
11506803|NCT01306513|Experimental|cells|
11506804|NCT01306500|Experimental|Gastric lavage Group|In neonates randomized to intervention Group (gastric lavage group) gastric lavage was done in the labor room after initial stabilization
11506805|NCT01306500|No Intervention|No gastric lavage|Neonates randomized to 'No gastric lavage group' will receive supportive treatment as per standard unit protocol.
11506806|NCT01306487||Macular hole patients|The patients who underwent vitreous surgery for idiopathic macular hole.
11506807|NCT01306474||Prednisone|profess to convinced 1-1.5mg/Kg.d
11506808|NCT01306474||methotrexate to band prednisone|profess to convinced 7.5-15mg/w, concoction prednisone profess to convinced 0.5-1mg/Kg.d
11506809|NCT01306461|Active Comparator|Timolol and Tafluprost|Concomitant administration of preservative-free timolol and tafluprost eye drops
11506810|NCT01306461|Experimental|Fixed Dose Combination of tafluprost and timolol|Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops
11506811|NCT01306448|Experimental|vibrating capsule|
11506812|NCT01306435|Experimental|Laser Group|
11506813|NCT01306435|Placebo Comparator|Placebo Group|
11506814|NCT01306422|Placebo Comparator|Stage 2: Placebo|Placebo product, twice-daily, 65 minutes before breakfast and dinner
11506815|NCT01306422|Active Comparator|Stage 2: H.g.PE 1110 mg b.d.|Hoodia gordonii Purified Extract (H.g.PE) formulated product (1110 mg), twice-daily, 65 minutes before breakfast and dinner
11506816|NCT01306422|Placebo Comparator|Stage 1: placebo, breakfast & dinner|Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
11506871|NCT01306084||4|Healthy and immunocompromised subjects exposed to someone who has a viral infection or is suspected of having a viral infection
11506817|NCT01306422|Active Comparator|Stage 1: H.g.PE 1110 mg breakfast/dinner|Hoodia gordonii purified extract (H.g.PE) formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
11506818|NCT01306422|Placebo Comparator|stage 1: Placebo breakfast/lunch|Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
11506819|NCT01306422|Active Comparator|Stage 1: H.g.PE 1110 mg breakfast/lunch|Hoodia gordonii purified extract (H.g.PE) formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
11506820|NCT01306409|Experimental|A|Sequential application of different ESA
11506821|NCT01306396|Other|Intervention group|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake about 50%.
11506822|NCT01306396|No Intervention|Control group|"Families participating in the control group are given only one dietary counseling based on the references of the DGE at the beginning of the study if they wish."
11506823|NCT01306383|Active Comparator|SODIS Bottles given|Caregivers in the intervention group were given two 2-litre plastic bottles. Bottle was filled with available water and placed in direct sunlight for a minimum of 6 hours. Water was consumed the next day while second bottle was being consumed.
11506824|NCT01306383|Active Comparator|Usual practices|Caregivers in this group were asked to maintain their usual practices regarding drinking water so that disease rates could be compared with the SODIS arm
11506825|NCT01306370|Experimental|Tranexamic acid|Tranexamic acid is a synthetic derivative of the amino acid lysine. It inhibits fibrinolysis by blocking the lysine binding sites on plasminogen and facilitates the coagulation process.
11506826|NCT01306370|Experimental|Fibrin glue BSTC|It is homologous fibrin glue from a single blood donor.
11506827|NCT01306370|Experimental|Tissucol|It is fibrin glue commercialized from multiple donors.
11506828|NCT01306370|Other|Habitual haemostasis|Electrocoagulation of blood vessels was performed during surgery in all patients (routine hemostasis)
11506829|NCT01306357||Zomacton® with Zomajet® needle-free device|Zomacton® 4 mg delivered by percutaneous transjection (needle-free) using the Zomajet® 2 Vision device or Zomacton® 10 mg delivered by percutaneous transjection (needle-free) using the Zomajet® Vision X needle-free device.
11506830|NCT01306344||Patients|Heterogeneous groups of patients (age, gender)
11506831|NCT01306344||Nurses|Heterogeneous groups of nurses (age, gender, working experience)
11506832|NCT01306344||Physicians|Heterogeneous groups of physicians (age, gender, working experience)
11506833|NCT01306331|Active Comparator|Conceptrol|100 mg (4% concentration) of nonoxynol-9 in 2.5 mL volume of gel
11506834|NCT01306331|Experimental|Amphora|Citric acid USP, potassium bitartrate USP, and L-lactic acid USP
11506835|NCT01306318|Experimental|1|
11506836|NCT01306318|Active Comparator|2|
11506837|NCT01306305|Experimental|Elderly|Elderly subjects aged over 60 years
11506838|NCT01306305|Experimental|Adults|Adults from 18 to 60 years old inclusive
11506839|NCT01306292|Experimental|SonoVue|Ultrasound contrast agent under development
11506840|NCT01306292|Placebo Comparator|Placebo|normal saline 0.9% for injection used as the comparator
11506841|NCT01306279||Cystic Fibrosis, infection|Cystic Fibrosis patients with an infective exacerbation
11506842|NCT01306266|Active Comparator|rizatriptan|initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo
11506843|NCT01306266|Placebo Comparator|Placebo|Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg
11506844|NCT01306253|Experimental|Elderly|Elderly subjects aged over 60 years
11506845|NCT01306253|Experimental|Adults|Adults from 18 to 60 years old inclusive
11506846|NCT01306240|Experimental|Early strategy|Intratracheal poractant alpha (Curosurf®) after tracheal intubation
11506847|NCT01306240|Active Comparator|Delayed strategy|Nasal Continous Positive Airways Pressure. Intratracheal poractant alpha as a rescue treatment if FiO2 > 60%
11506848|NCT01306227|Placebo Comparator|water|Oral treatment with water for 6 weeks
11506849|NCT01306227|Experimental|L-Thyroxine|Oral treatment with L-Thyroxine for 6 weeks
11506850|NCT01306214|Experimental|BI 10773 low dose|BI 10773 low dose once daily
11506851|NCT01306214|Experimental|BI 10773 high dose|BI 10733 high dose once daily
11506852|NCT01306214|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
11506853|NCT01306201||In-patient Volunteers|In-patients from the hospital who choose to participate in the study
11506854|NCT01306188||Breast cancer|Metastatic breast cancer
11506855|NCT01306188||Lung cancer|Metastatic lung cancer
11506856|NCT01306175|Experimental|Digoxin alone (Reference)|Tablet, oral administration with 240 mL water
11506857|NCT01306175|Experimental|Digoxin plus BI 10773 (Test)|Tablets, oral administration with 240 mL water
11506858|NCT01306162|Experimental|A: Dabigatran alone (Reference)|Capsule, oral administration with 240 mL water
11506859|NCT01306162|Experimental|B: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
11506860|NCT01306162|Experimental|C: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
11506861|NCT01306162|Experimental|D: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
11506862|NCT01306162|Experimental|E: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
11506863|NCT01306136|Experimental|Prolonged Exposure|
11506864|NCT01306136|Active Comparator|Usual care|
11506865|NCT01306123|Experimental|Nascobal nasal spray (cyanocobalamin USP)|One single administration of intranasal cyanocobalamin (initially)
11506866|NCT01306123|Active Comparator|Vitamin B12-ratiopharm N, injection solution|One single injection of IM cyanocobalamin (initially)
11506867|NCT01306097|Experimental|Zinc sulfate|daily zinc supplementation for 3 months. (10mg daily for under 1 years old children and 20mg daily for above 1 years old children)
11506868|NCT01306084||1|NIH campus workers who have recently recovered from COVID-19
11506869|NCT01306084||2|Clinical Center health care workers and ancillary staff who have close patient contact and possible exposures to SARS-CoV-2
11506870|NCT01306084||3|Healthy and immunocompromised subjects who have or are suspected to have a viral infection
11506872|NCT01306058|Experimental|Sorafenib & TRC105 in Hepatocellular CA|CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day
11506873|NCT01306045|Active Comparator|A/ Erlotinib|Erlotinib
11506874|NCT01306045|Active Comparator|B/ AZD6244|AZD6244
11506875|NCT01306045|Active Comparator|C/ MK-2206|MK-2206
11506876|NCT01306045|Active Comparator|D/ Lapatinib|Lapatinib
11506877|NCT01306045|Active Comparator|E/Sunitinib|Sunitinib
11506878|NCT01306045|Other|F/ NOS|NOS (not otherwise specified)
11506879|NCT01306032|Experimental|Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
11506880|NCT01306032|Experimental|Triple-negative Breast Cancer: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
11506881|NCT01306032|Experimental|BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
11506882|NCT01306032|Experimental|BRCA- positive Ovarian Cancer: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
11506883|NCT01306032|Experimental|Non-Hodgkin's: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
11506884|NCT01306032|Experimental|Non-Hodgkin's: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
11506885|NCT01306019|Experimental|1|Gene Therapy
11506886|NCT01306006|Active Comparator|MV-for-all|Measles vaccine provided to all children aged 9 months -3 years of age
11506887|NCT01306006|No Intervention|National policy|Measles vaccine provided to children aged 9-11 months, if there are sufficient children to open a measles vaccine vial.
11506888|NCT01305941|Experimental|Everolimus +Vinorelbine + trastuzumab|daily everolimus plus weekly (Days 1, 8, and 15) vinorelbine and trastuzumab
11506889|NCT01305928|Active Comparator|Fax|
11506890|NCT01305928|Experimental|Warm Hand-off|
11506891|NCT01305915|No Intervention|Control|participant will receive standard print material
11506892|NCT01305915|Experimental|Intervention|patient will receive standard print material and a single session group psychoeducational intervention (GBOT)
11506893|NCT01305902|No Intervention|walking recommendations|Participants assigned to this condition will be instructed to wear a pedometer daily and scheduled for weekly meetings over for the next 12 weeks. Each week, they will be congratulated if they walked the target goal on any days, and encouraged to meet the goals for the upcoming week. However, they will not receive any tangible reinforcement for walking. The meetings will be brief (about 15 minutes) and will include discussions and handouts related to the health benefits of walking.
11506894|NCT01305902|Experimental|contingency management for walking|Participants assigned to this condition will be asked to wear a pedometer daily and scheduled for weekly meetings over for the next 12 weeks. The meeting duration and structure will be similar to that in the standard treatment condition including the handouts, with one exception. Participants in this condition will earn tangible reinforcement in the form of prizes for walking the target number of steps per day.
11506895|NCT01305889|Experimental|problem solving therapy|subjects will receive 12 weeks of weekly problem solving therapy
11506896|NCT01305889|Experimental|sertraline|12 weeks of sertraline
11506897|NCT01305876|Experimental|one group with yoga intervention|one group with yoga intervention
11506898|NCT01305863|Active Comparator|Propaten graft|Untreated Propaten vascular graft
11506899|NCT01305863|Experimental|ASC-Coated ePTFE graft|ASC Coated BARD IMPRA® ePTFE Vascular Graft
11506900|NCT01305850|Active Comparator|Aliskiren|
11506901|NCT01305850|Active Comparator|Aliskiren plus Losartan|
11506902|NCT01305850|Active Comparator|Enalapril plus Losartan|
11506903|NCT01305850|Placebo Comparator|placebo|
11506904|NCT01305837|Experimental|methylprednisolone|all patients will be treated with the active drug methylprednisolone 500 mg in 3 days every month for 60 weeks.
11506905|NCT01305824|Active Comparator|PRT 201 (10 micrograms)|
11506906|NCT01305824|Placebo Comparator|Placebo|
11506907|NCT01305824|Active Comparator|PRT-201 (30 micrograms)|
11506908|NCT01305811|Experimental|Bi-weekly acupuncture treatment|Bi-weekly acupuncture treatment
11506909|NCT01305811|Active Comparator|Wait list|Wait list for 2 months followed by weekly acupuncture for 4 months
11506910|NCT01305798|Experimental|Control Arm|The control arm will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment.
11506911|NCT01305798|Experimental|Active Choice and Default Option Arm|The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email.
11506912|NCT01305798|Experimental|Active Choice Only Arm|The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
11506913|NCT01305772|Experimental|Surgery|Patients who underwent surgery after research PET/CT scans and subsequent radiation therapy with panitumumab administration
11506914|NCT01305772|Active Comparator|Radiation Therapy|Patients who underwent radiation therapy only, in conjunction with panitumumab therapy.
11506915|NCT01305759||YoungTKA|Adults under 60 years who are having primary TKA
11506916|NCT01305759||YOUNGTHA|Adults under 60 years who are having primary THA
11506917|NCT01305759||PAOAarhus|Adults under 60 years who are having primary PAO
11506918|NCT01305746|Experimental|A-623 high dose weekly|High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
11507235|NCT01303601|Placebo Comparator|placebo|
11506919|NCT01305746|Experimental|A-623 low dose weekly|Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
11506920|NCT01305746|Experimental|A-623 high dose every 4 weeks|High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
11506921|NCT01305733|Active Comparator|local infiltration analgesia|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
11506922|NCT01305733|Placebo Comparator|saline injection|The normal saline injection are used in the control group in the same manner than in the RKA group.
11506923|NCT01305707|Experimental|C-ECT and Pharmacotherapy|Consolidation treatment with ECT will be considered finished after 9 months of being started, at which time patients will stay only on the pharmacological treatment they already had. The study will be completed within 15 months of patient inclusion (six months after the end of C-ECT). Patient assessment and follow-up will be conducted by participant researchers. Blind rater will conduct clinical and adverse effects ratings. A neuropsychologist will conduct neuropsychological assessments.
11506924|NCT01305707|Active Comparator|Pharmacotherapy|Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet.
11506925|NCT01305694|Experimental|MSC|Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with relapsed/refractory aplastic anemia.
11506926|NCT01305681|Active Comparator|LoFric® catheters|LoFric® catheters during clean intermittent catheterization will be compared to non-LoFric® catheters during clean intermittent catheterization
11506927|NCT01305668||Emphysema phenotype|
11506928|NCT01305668||No-Emphysema phenotype|
11506929|NCT01305655|Experimental|Glucarpidase arm|In the NOPHO ALL-2008 protocol patients with delayed methotrexate elimination (DME) in high-dose methotrexate treatments should be given Glucarpidase (50 ie/kg) with-in 60 hours from start of the methotrexate treatment.
11506930|NCT01305642|Experimental|Individualized fortification of breast milk|
11506931|NCT01305629|Experimental|Intervention Condition|Twelve sessions of spiritual self schema counseling, adapted to target target medication adherence and substance use.
11506932|NCT01305629|Active Comparator|Education Condition|Eight sessions of education with content designed to mirror the information covered in the intervention condition.
11506933|NCT01305616|Active Comparator|Group 1, glaucoma and cataract|Group1 were those patients with visually significant cataract (less than grade 2) and mild to moderate open angle glaucoma
11506934|NCT01305616|Sham Comparator|Group2, cataract patients|This group included those patients with visually significant cataract and normal other eye examination.
11506935|NCT01305603|Active Comparator|Dual TAP block|Dual TAP block on one side on the abdomen. Classical (or single) TAP on the contra lateral side of the abdomen; supplemented with a sham injection to ensure double blindness.
11506936|NCT01305603|Active Comparator|Classical (or single) TAP block|Dual TAP block on one side on the abdomen. Classical (or single) TAP on the contra lateral side of the abdomen; supplemented with a sham injection to ensure double blindness
11506937|NCT01305590|Other|Survey|"We will survey participants to see if they would prefer more commitment, in the form of a Take-Medication-Get-Paid plan; less commitment, in the form of an Attend-Clinic-Get-Paid plan; or if they would prefer to designate their own levels of commitment."
11506938|NCT01305577|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
11506939|NCT01305577|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
11506940|NCT01305577|Experimental|Deoxycholic Acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
11506941|NCT01305564|Experimental|Denali inferior vena cava filter|All subjects enrolled will receive the Denali vena cava filter.
11506942|NCT01305551|Experimental|Treatment A-Saxagliptin+Metformin XR|5mg Saxagliptin + 500 mg Metformin XR Tablets, once on Day 1 only, administered together in the fasted state.
11506943|NCT01305551|Experimental|Treatment B-Saxagliptin/Metformin XR FDC|5mg Saxagliptin / 500 mg Metformin XR FDC tablet, once on Day 1 only, administered in the fasted state.
11506944|NCT01305551|Experimental|Treatment C-Saxagliptin+Metformin XR|5mg Saxagliptin + 500 mg Metformin XR Tablets, once on Day 1 only, administered together in the fed state.
11506945|NCT01305551|Experimental|Treatment D-Saxagliptin/Metformin XR FDC|5mg Saxagliptin / 500 mg Metformin XR FDC tablet, once on Day 1 only, administered in the fed state.
11506946|NCT01305538|Other|Arm 1 BMS-954561 40mg or 80mg|"Arm description: BMS-954561 40mg or 80mg three times daily (TID) to Placebo OR Placebo to 40mg or 80mg TID.
~Arm type: Active to Placebo or Placebo to Active (cross-over)"
11506947|NCT01305538|Other|Arm 2 BMS-954561 150mg or 300mg|"Arm description: BMS-954561 150mg or 300mg TID to Placebo OR Placebo to 150mg or 300mg TID
~Arm type: Active to Placebo or Placebo to Active(cross-over)"
11506948|NCT01305525||Spinal Cord Stimulation|
11506949|NCT01305512|Experimental|SPARC1028|
11506950|NCT01305499|Experimental|A: 5AC days 1-10 / entinostat days 3, 10|Arm A will be given an overlapping schedule of drugs with 5AC given at 50mg/m2 subcutaneously daily for 10 days on days 1 - 10 of a 28 day cycle and entinostat given at a flat dose of 8 mg orally on days 3 and 10.
11506951|NCT01305499|Experimental|B: 5AC days 1-10 / entinostat days 10,17|In Arm B the agents will be administered sequentially with 5AC given at 50mg/m2 subcutaneously daily for 10 days on days 1 - 10 of a 28 day cycle followed by entinostat at a 8 mg flat dose on days 10 and 17.
11506952|NCT01305486||XenMatrix|
11506953|NCT01305473||Sepramesh Group|
11506954|NCT01305460|Experimental|Azacitidine intensified dose|
11507007|NCT01305096|Experimental|Yoga group|Participants in this group will take part in six to eight weeks of yoga classes. The classes will be held once a week and each class will be approximately one hour long. The classes will consist of yoga inversions, sun salutations and other yoga postures with deep breathing.
11507008|NCT01305096|No Intervention|Control group|Matched control
11506955|NCT01305447|Experimental|Exercise Maintenance|"Randomization and Group-Mediated Cognitive Behavioural therapy (GMCB) sessions will begin on week 8 of the program. Topics of self-regulation related to exercise (Social cognitive theory of self-regulation, Albert Bandura, 1991) will be discussed: monitoring, scheduling, goal setting, coping, overcoming barriers, rewards, social support.
~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) intervention strategies over the phone to continue to enhance the GMCB principles on how to maintain exercise behavior."
11506956|NCT01305447|Experimental|Ex. Maintenance + relapse prevention|"The same topics of self-regulation related to exercise maintenance(Social cognitive theory of self-regulation, Albert Bandura, 1991) will be discussed: monitoring, scheduling, goal setting, coping, overcoming barriers, rewards, social support.
~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) intervention strategies over the phone to continue to enhance the Group-Mediated Cognitive Behavioural therapy (GMCB) principles on how to maintain exercise behavior.
~Participants in this arm will also receive the Brandon et al. (2004) Forever Free smoking relapse prevention booklets."
11506957|NCT01305447|Active Comparator|relapse prevention|"Randomization and group discussion sessions will begin on week 8 of the program. Topics of women's health, unrelated to exercise will be discussed (control).
~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to continue to maintain contact time.
~Participants in this arm will also receive the Brandon et al. (2004) Forever Free smoking relapse prevention booklets."
11506958|NCT01305447|Active Comparator|Contact Control|"Randomization and group discussion sessions will begin on week 8 of the program. Topics of women's health, unrelated to exercise will be discussed (control).
~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to continue to maintain contact time."
11506959|NCT01305434|Other|Placebo then mulberry leaf|These patients receive placebo for two weeks, then 1 week washout, then two weeks of mulberry leaf extract.
11506960|NCT01305434|Other|Mulberry leaf then placebo|These patients receive mulberry leaf extract for two weeks, then 1 week washout, then two weeks of placebo.
11506961|NCT01305408|Placebo Comparator|Placebo|Participants began taking placebo to match armodafinil and following the same titration procedure. Treatment was administered for a total of 8 weeks.
11506962|NCT01305408|Experimental|Armodafinil 150 mg/day|Participants began taking armodafinil at a dosage of 50 mg/day; the dosage was increased by 50 mg/day on days 2 and 4, up to a dosage of 150 mg/day. Treatment was administered for a total of 8 weeks.
11506963|NCT01305395|Experimental|Early Intervention Arm|Initiate sirolimus within 6 months of heart transplant
11506964|NCT01305395|Experimental|Late Intervention Arm: Group 2A|Initiate sirolimus after CAV is diagnosed by angiogram
11506965|NCT01305395|Experimental|Retrospective Arm: Angiogram group|Start sirolimus after CAV diagnosed is by angiogram
11506966|NCT01305395|Experimental|Late Intervention Arm: Group 2B|Start sirolimus after CAV is diagnosed by IVUS
11506967|NCT01305395|Experimental|Retrospective Arm: Intravascular Ultrasound|Sirolimus after CAV is diagnosed by IVUS
11506968|NCT01305382||Heart Transplant Cohort|This group consist of transplant subjects within 10 years of heart transplant
11506969|NCT01305382||Heart Failure Sub group|Consist of subjects with advanced heart failure (NYHA class III and IV)
11506970|NCT01305382||Healthy Volunteer|This groups consist of healthy individuals
11506971|NCT01305356|Experimental|Augment® Injectable Bone Graft|Standard rigid fixation + Augment® Injectable Bone Graft (beta-TCP/bovine collagen matrix + rhPDGF-BB)
11506972|NCT01305356|Active Comparator|Autologous bone graft|Standard Rigid Fixation + Autologous bone graft
11506973|NCT01305343||Surgical treatment|This observational study is examining the outcomes of standard surgical treatments for adult spinal deformity.
11506974|NCT01305317|Experimental|lipitor|atorvastatin 20mg daily
11506975|NCT01305304||1|"15 healthy male veteran runners (marathon, triathlon, orienteering) aged between 40 and 65 years with a history of competitive running at a national level during a period of at least 5 years, implicating normally a runner career with at least 50km per week over more than 10 years"
11506976|NCT01305304||2|15 healthy male volunteers, matched for age and bmi, without a history of competitive physical exercise (i.e. sedentary controls)
11506977|NCT01305291|Placebo Comparator|tea only without fibersol-2|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.
~The evening meal will be a standardized meal for all subjects (11).
~They are allowed to consume water up until 1 hr before the test.
~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling (11).
~The beverage will be consumed at 10 am.
~Blood samples will be taken at specified time points prior to after the treatments."
11506978|NCT01305291|Active Comparator|tea only with fibersol-2 (10 g)|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.
~The evening meal will be a standardized meal for all subjects.
~They are allowed to consume water up until 1 hr before the test.
~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling (11).
~The beverage will be consumed at 10 am.
~Blood samples will be taken at specified time points prior to and after the treatments.
~Ingredient only test will be done without the meal to determine independent effects of Fibersol-2."
11506979|NCT01305291|Placebo Comparator|tea without fibersol-2 and meal|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.
~The evening meal will be a standardized meal for all subjects.
~They are allowed to consume water up until 1 hr before the test.
~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.
~The test meal and beverage will be consumed at 10 am.
~The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).
~Tea containing test materials will accompany the meal.
~Blood samples will be taken at specified time points prior to and after the treatments."
11506980|NCT01305291|Experimental|tea with 5 g fibersol-2 and meal|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.
~The evening meal will be a standardized meal for all subjects.
~They are allowed to consume water up until 1 hr before the test.
~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.
~The test meal and beverage will be consumed at 10 am.
~The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).
~Tea containing test materials will accompany the meal.
~Blood samples will be taken at specified time points prior to and after the treatments."
11506981|NCT01305291|Experimental|tea with 10 g fibersol-2 and meal|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.
~The evening meal will be a standardized meal for all subjects.
~They are allowed to consume water up until 1 hr before the test.
~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.
~The test meal and beverage will be consumed at 10 am.
~The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).
~Tea containing test materials will accompany the meal.
~Blood samples will be taken at specified time points prior to and after the treatments."
11506982|NCT01305278|No Intervention|Control|No Wii balance gaming undertaken
11506983|NCT01305278|Active Comparator|Wii during vestibular rehab only|To start Wii Balance Gaming from the beginning of vestibular rehabilitation.
11506984|NCT01305278|Active Comparator|Wii whilst on waiting list and rehab|Wii Balance Gaming whilst on waiting list for vestibular rehabilitation. To continue with Wii Balance Gaming until end of vestibular rehabilitation.
11506985|NCT01305265|Active Comparator|intervention|Endotracheal tube will be adjusted to 22-26 cm H20 pressure immediately post intubation using a cuff manometer
11506986|NCT01305265|No Intervention|control|endotracheal tube cuff will be inflated using standard technique
11506987|NCT01305252|Active Comparator|tadalafil alone|tadalafil 40mg QD(Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated).
11506988|NCT01305252|Active Comparator|tadalafil and treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation & gradually increasing to 9 breaths.Each breath provides approximately 6 mcg of treprostinil.Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated.
11506989|NCT01305239||Postmenopausal ER+ patients treated by Aromasin.|
11506990|NCT01305226|Experimental|Test - THR-100|120 subjects are to be recruited into the trial, with patients randomized in a 1:1 allocation ratio to THR-100 and Streptokinase 60 subjects are to be recruited into Test arm, and administered 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
11506991|NCT01305226|Active Comparator|Streptokinase|120 subjects are to be recruited into the trial, with patients randomized in a 1:1 allocation ratio to THR-100 and Streptokinase Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
11506992|NCT01305213|Active Comparator|Arm I (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11506993|NCT01305213|Experimental|Arm II (bevacizumab, fosbretabulin tromethamine)|Patients receive bevacizumab IV over 30-90 minutes and fosbretabulin tromethamine IV over 10-20 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11506994|NCT01305200|Placebo Comparator|Arm I (placebo)|Patients rinse and gargle with placebo over 1 minute QID beginning the first day (about day -7) of the conditioning regimen. Treatment continues until day 20 post-transplantation.
11506995|NCT01305200|Experimental|Arm II (supersaturated calcium phosphate rinse)|Patients rinse and gargle with supersaturated calcium phosphate rinse over 1 minute QID beginning on the first day (about day -7) of the conditioning regimen. Treatment continues until day 20 post-transplantation.
11506996|NCT01305187|Experimental|Hyaluronic Acid Filler - Medical Device|
11506997|NCT01305174|Active Comparator|Balloon expandable stent arm|"First placement of the sheath and successful passage of a 0.018 or 0.035 guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the balloon-expandable stent (Visi-Pro™, ev3 Endovascular, Inc., Plymouth, MN, USA), which was premounted on a balloon catheter, was deployed by inflation of the balloon. The nominal stent diameter had to approximate the reference vessel diameter of the target lesion. Postdilation was permitted"
11506998|NCT01305174|Active Comparator|Selfexpanding stent arm|"First placement of the sheath and successful passage of a 0.018 or 0.035 guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the the self-expanding stent (Protege™, ev3 Endovascular, Inc., Plymouth, MN, USA), which had to exceed in the nominal diameter the reference vessel diameter at least by 1 mm, was released. Postdilation was mandatory. The inflated postdilation-balloon should approximate the reference vessel diameter."
11506999|NCT01305148|Experimental|Randomized - Genetic|Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
11507000|NCT01305148|No Intervention|Randomized - Clinical|Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from clinical information alone through the warfarindosing.org website
11507001|NCT01305148|Experimental|Registry|Subjects who are followed 30 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
11507002|NCT01305135|Experimental|azacitidine 75mg/m²/d + idarubicin 5mg/m²/d|"phase I : palier 1 have 10 patients and palier 2 have to 10 patients.
~palier 1: Ida 5mg/m²/d (D8) + AZACITIDINE 75mg/m²/d (D1-D7)"
11507003|NCT01305135|Experimental|Azacitidine 75mg/m²/d + idarubicin 10mg/m²/d|palier 2: Ida 10mg/m²/d (D8)+ Azacitidine 75mg/m²/d (D1-D7)
11507004|NCT01305122|Other|OMS grade II glioma|neurocognitive tests
11507005|NCT01305109|Experimental|Oral Rotavirus Vaccine 116E (ORV 116E)|Oral Rotavirus Vaccine 116E (ORV 116E), 10^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5 mL at 4 week intervals
11507006|NCT01305109|Placebo Comparator|Placebo|3 doses of 0.5 mL at 4 week intervals
11507009|NCT01305083|Active Comparator|Udenafil|Active Ingredient
11507010|NCT01305083|Placebo Comparator|Placebo|Placebo
11507236|NCT01303588|No Intervention|Waiting Group|
11507012|NCT01305070|Active Comparator|Paclitaxel-eluting balloon arm|In.Pact Admiral, Invatec
11507013|NCT01305057|Experimental|Evaluation of P-IP on hydration and barrier function|Effects of P-IP on improvement of skin hydration and TEWL were examined.
11507014|NCT01305044|Experimental|Tai Chi Chih|The Tai Chi Chih classes were 60 minutes sessions, held three times a week, over twelve weeks. The classes were led by an instructor who was certified and licensed in the Tai Chi Chih form.
11507015|NCT01305044|Active Comparator|Health Education Classes|Health Education classes were 60 minute sessions that occurred three times a week, over twelve weeks. These classes were taught by specialists in the class topic and focused on topics related to aging (e.g., sleep quality, nutrition, pain, etc.).
11507016|NCT01305031|Experimental|Room air|Initiation of resuscitation with 21% Oxygen, adjustments to the inspired oxygen concentration (increased 10%) will be made every 60 seconds for infants to achieve a target SpO2 range of 85-92%
11507017|NCT01305031|Active Comparator|100% Oxygen|Initiation of resuscitation with 100% Oxygen and achieve oxygen saturation in the preset limits 85-92%
11507018|NCT01305018|Experimental|Exercise and BCAA|
11507019|NCT01305018|Experimental|Exercise and Leucine|
11507020|NCT01305018|Placebo Comparator|Exercise and Placebo|
11507021|NCT01305005||patients with active-fluidics system|patients who underwent phacoemulsification surgery using active-fluidics system
11507022|NCT01305005||patients with gravity-fluidics system.|patients who underwent phacoemulsification surgery using gravity-fluidics system
11507023|NCT01304992|Experimental|Lupin Protein|Lupin protein (cultivar: Lupinus angustifolius Boregine; incorporated in a drink)
11507024|NCT01304992|Active Comparator|Reference protein|Reference Protein (75% sodium caseinate (EM7; DMV international) and 25% milk protein (Megglosat HP; Meggle), incorporated in a drink)
11507025|NCT01304992|No Intervention|Wash out|Wash out (four weeks without any intervention between interventional periods)
11507026|NCT01304979|No Intervention|Usual care alone|Subjects receive usual care alone before and after spine fusion surgery
11507027|NCT01304979|Experimental|Active Intervention|Acupuncture therapies, ear seeds, acupuncture treatment and gua sha, designed to reduce pain and facilitate recovery for low back spine fusion patients.
11507028|NCT01304979|Sham Comparator|Control Arm|Indirect therapies with same encounter time and timing as direct care group.
11507029|NCT01304953|Placebo Comparator|P+P|
11507030|NCT01304953|Experimental|P+T|
11507031|NCT01304953|Placebo Comparator|S+P|
11507032|NCT01304953|Experimental|S+T|
11507033|NCT01304940||PTSD group|Individuals in this group meet criteria for PTSD as defined by DSM-IV
11507034|NCT01304940||trauma control group|individuals in this group do not meet criteria for any Axis I diagnosis as defined by DSM-IV
11507035|NCT01304927|Active Comparator|Cholecalciferol + calcium|Group of intervention: Each man will receive 300,000 IU (7500 ug) Cholecalciferol (VD3) orally once after blood and semen sampling and performed DXA scan. Thereafter they will receive VD tablets of 1,400 IU (35 ug) + 500 mg calcium daily for 3 months. At 3 months a clinical control and blood sampling will be performed, followed by continued daily intake of 1400 IU VD3 + 500 mg calcium. At end of treatment at five months after inclusion the men deliver two semen samples, have a blood sample drawn and a DEXA scan performed.
11507036|NCT01304927|Placebo Comparator|placebo|Group receiving placebo: Each man will receive placebo oral mixture once after blood- and semen sampling and performed DXA scan. Thereafter they will receive placebo tablets daily for 3 months. At 3 months a clinical control and blood sampling will be performed, followed by continued daily intake of placebo. At end of treatment at five months after inclusion the men deliver two semen samples, have a blood sample drawn and a DEXA scan performed.
11507037|NCT01304914||Healthy, term-delivered babies|
11507038|NCT01304901|Active Comparator|1-Montelukast|Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.
11507039|NCT01304901|Placebo Comparator|2- Placebo|Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
11507040|NCT01304888|Experimental|Food basket w/o nutrition education|
11507041|NCT01304888|Experimental|Food basket + nutrition education|
11507042|NCT01304888|Experimental|Control|
11507043|NCT01304888|Experimental|Cash + health and nutrition education|
11507044|NCT01304862|Experimental|Self-management intervention|
11507045|NCT01304862|Active Comparator|Educational Videos about Healthy Living|
11507046|NCT01304849|Experimental|Primary|Patients with aHL will receive 2 cycles of ABVD and undergo interim PET-2 scan- those with positive scans will receive 4 additional cycles of Esc BEACOPP while those with negative scans will receive 4 additional cycles of ABVD.
11507047|NCT01304836|Active Comparator|10 Days of Steroids|Advagraf + Basiliximab + MMF + Steroids (10 days)
11507048|NCT01304836|Experimental|Optional Steroid bolus only|Advagraf + Basiliximab + MMF + Steroids (bolus only)
11507049|NCT01304823|Active Comparator|glucose|intraduodenal perfusion of glucose (29.3 g glucose per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min)
11507050|NCT01304823|Active Comparator|glucose + lactisole|intraduodenal perfusion of glucose (29.3 g glucose per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min) + 450 ppm lactisole
11507051|NCT01304823|Active Comparator|mixed liquid meal|intraduodenal perfusion of a mixed liquid meal (20.20 g carbohydrate, 4.92 g fat and 6.25 g protein per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min)
11507052|NCT01304823|Active Comparator|mixed liquid meal + lactisole|intraduodenal perfusion of a mixed liquid meal (20.20 g carbohydrate, 4.92 g fat and 6.25 g protein per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min) + 450 ppm lactisole
11507053|NCT01304823|Placebo Comparator|saline + lactisole|saline (0.9 %; rate: 2.5 mL/min for 180 min) + 450 ppm lactisole
11507054|NCT01304810||NicVAX|NicVAX vaccine
11507055|NCT01304810||Placebo vaccine|Placebo vaccine
11507056|NCT01304797|Experimental|MM-302|
11507057|NCT01304797|Experimental|MM-302 in Combination with Trastuzumab|
11507058|NCT01304797|Experimental|MM-302 in Combination with Trastuzumab q3w|
11507059|NCT01304797|Experimental|MM-302 in Combination with Trastuzumab and Cyclophosphamide|
11507237|NCT01303588|Active Comparator|Qigong|
11507238|NCT01303588|Active Comparator|Yoga|
11507060|NCT01304784|Experimental|Arm 1|"Regimen follows a 3-week treatment cycle.
~Cisplatin 80mg/m2 given on day 1 by IV infusion over two hours every three weeks.
~Capecitabine 1000 mg/m2 given orally twice daily for fourteen days each 3-week cycle.
~Up to six 3-week cycles of Cisplatin and Capecitabine to be administered. Trastuzumab given as 8 mg/kg loading dose at week 1 over 90 minutes followed by 6 mg/kg every 3 weeks over 30-90 minutes.
~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.
~Trastuzumab (every 3 weeks) and MM-111 (weekly) will continue until disease progression, unacceptable toxicity, or withdrawal of consent."
11507061|NCT01304784|Experimental|Arm 2|"Regiment follows a 4-week treatment cycle.
~The following Lapatinib and Trastuzumab regimen will be given in combination with MM-111 in the following order:
~Trastuzumab 4 mg/kg loading dose week 1 over 90 minutes
~Followed by Trastuzumab 2 mg/kg weekly thereafter
~Lapatinib 1000 mg by mouth (PO) daily
~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter
~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
11507062|NCT01304784|Experimental|Arm 3|"Regimen follows a 4-week treatment cycle Paclitaxel dosing should begin first dose on cycle 1 day 1. Paclitaxel will be administered at 80 mg/m2 weekly, as an IV infusion over 60 minutes. The infusion should be prepared as directed in the Paclitaxel package insert. All patients receiving Paclitaxel should be premedicated as per the local institutional guidelines.
~Trastuzumab will be administered via IV over 90 minutes at a 4 mg/kg loading dose for the first infusion followed by weekly infusion of 2 mg/kg over 60 minutes thereafter.
~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.
~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
11507063|NCT01304784|Experimental|Arm 4|"4-week treatment cycle. Lapatinib given orally. Paclitaxel dosing on cycle 1 day 1. Paclitaxel given at 80 mg/m2 weekly, as an IV infusion over 60 minutes. The infusion should be prepared as directed in the Paclitaxel package insert. All patients receiving Paclitaxel should be premedicated as per the local institutional guidelines.
~Trastuzumab given via IV over 90 minutes at a 4 mg/kg loading dose for the first infusion followed by weekly infusion of 2 mg/kg over 60 minutes thereafter.
~MM-111 given over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.
~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
11507064|NCT01304784|Experimental|Arm 5|"Docetaxel, trastuzumab and MM-111 3-week treatment cycles with therapies given in the following order: 1) docetaxel, 2) trastuzumab, and 3) MM-111
~Docetaxel given as an IV infusion over 60 minutes every three weeks. The infusion should be prepared as directed in the Docetaxel package insert and any institutional guidelines. All patients receiving Docetaxel should be pre-medicated as per the local institutional guidelines.
~The first dose of trastuzumab is a loading dose of 8 mg/kg administered over 90 minutes followed by every three week dosing at 6 mg/kg over 60 minutes via IV infusion.
~The first dose of MM-111 given over 90 minutes followed by 3 week dosing over 60 minutes in the absence of infusion-related reactions"
11507065|NCT01304771|Active Comparator|Synbiotic AKSB|Participants (healthy > 65 year old persons) will be randomized to take the synbiotic AKSB. All participants will also receive inactivated trivalent Influenza vaccine while being on the AKSB. We will assess safety of the AKSB in this setting. We will also assess the stool microbiology in relation to vancomycin-resistant enterococcus and probiotic strain enterococcus. We will also assess influenza vaccine response in patients on AKSB
11507066|NCT01304771|Placebo Comparator|Talc Placebo|Participants (healthy > 65 year old persons) will be randomized to take the placebo. All participants will also receive inactivated trivalent Influenza vaccine while being on the placebo. We will also assess the stool microbiology in relation to vancomycin-resistant enterococcus. We will also assess influenza vaccine response in patients on placebo.
11507067|NCT01304758|Experimental|ExAblate Treatment|
11507068|NCT01304745|Experimental|Physical traning in group|
11507069|NCT01304745|Experimental|Educational and counselling group|
11507070|NCT01304745|No Intervention|Control group|
11507071|NCT01304719|Experimental|Computer Assisted home visitation|Home visitation with computer modules added
11507072|NCT01304719|Experimental|Home Visitation TAU|Home Visitation Treatment as Usual
11507073|NCT01304719|No Intervention|Community Referral|Community Referral
11507074|NCT01304706|Experimental|Fluocinolone Acetonide|
11507075|NCT01304693|Experimental|ESBA1008|ESBA1008 solution, single intravitreal injection
11507076|NCT01304693|Active Comparator|LUCENTIS|Ranibizumab 0.5 mg, single intravitreal injection
11507077|NCT01304654||ALI/ARDS oncologic patients|Consecutively admitted patients at GRAACC's PICU with malignancy diagnosis according to IDC-10, in a 24mo consecutive period, under mechanical ventilation for over 24h and with ALI/ARDS criteria, not younger than 29 days or older than 17 years 11 months
11507078|NCT01304641||Atorvastatin Initiators|
11507079|NCT01304641||Simvastatin Initiators|
11507080|NCT01304628|Experimental|PL-3994 (4 escalating doses)|
11507081|NCT01304628|Placebo Comparator|Placebo|
11507082|NCT01304615|Active Comparator|Web-Based|Participants will receive a web-based behavioral intervention that decreases dietary energy density and increases physical activity combined with a life skills training program. Life skills training topics include stress management, coping with change, time management, and thoughts and emotions in weight control.
11507083|NCT01304615|Experimental|Web-Based plus Culinary Training|Participants will receive a web-based behavioral intervention that decreases dietary energy density and increases physical activity combined with a hands-on culinary skills training program designed to increase food purchasing and meal self-preparation and consumption of meals low in energy density.
11507084|NCT01304602|Experimental|Irinotecan + BKM120|Irinotecan + BKM120 at the assigned cohort dose level.
11507085|NCT01304589|Experimental|Milnacipran|This was an 18-week, open-label, flexible-dose exploratory trial where eligible patients were treated with 200 mg/day of milnacipran (or the maximum tolerated dose) for a total of 12 weeks. The study design involved 3 phases: screening and baseline assessment, dose escalation and stable-dose phase. All women received 12 weeks of stable dose treatment after a 6-week dose-escalation period for a total of 18 weeks of drug exposure.
11507086|NCT01304576|Experimental|patient with right parietal lesions|
11507087|NCT01304576|Active Comparator|patient with left parietal lesions|
11507088|NCT01304563|Active Comparator|IM15|15 mcg TIV 2010/2011 influenza vaccine delivered via intramuscular injection (control)
11507089|NCT01304563|Active Comparator|ID1|Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection (MicronJet)
11507090|NCT01304563|Active Comparator|ID2|Higher low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection (MicronJet)
11507091|NCT01304563|Active Comparator|INT|Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device
11507092|NCT01304537|Experimental|Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 40 mg/kg throughout the study.
11507093|NCT01304537|Experimental|Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 60 mg/kg throughout the study.
11507094|NCT01304537|Experimental|Alpha-1 Antitrypsin 80mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 80 mg/kg throughout the study.
11507095|NCT01304524|Experimental|VGX 3100|
11507096|NCT01304524|Placebo Comparator|Placebo|
11507097|NCT01304511||Participants Treated|Women undergoing controlled ovarian COH for ART
11507098|NCT01304498|Experimental|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
11507099|NCT01304498|Active Comparator|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
11507100|NCT01304485|Experimental|Sodium Acetate C11 PET Imaging|
11507101|NCT01304472|Experimental|Prasugrel|Prasugrel 10mg per day
11507102|NCT01304472|Active Comparator|Clopidogrel|
11507103|NCT01304446|Experimental|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
11507104|NCT01304433||1|hydroxyethyl starch (HES) 130/0.42
11507105|NCT01304407|Other|RTS Subjects, Calcium Isotope|Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.
11507106|NCT01304394|Other|parenteral nutrition solution|
11507107|NCT01304381|Experimental|Integrated care|Multidisciplinary approach and collaboration between specialist palliative and heart failure (HF) caregivers in a shared structured person-centred and identity-promoting homecare
11507108|NCT01304381|No Intervention|control|Usual care is performed for the control group
11507109|NCT01304368|Active Comparator|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
11507110|NCT01304368|No Intervention|Waiting list|Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
11507111|NCT01304355||Controls|Healthy Control Subjects
11507112|NCT01304355||IBS Group|Subjects diagnosed with IBS
11507113|NCT01304342|Active Comparator|Remifentanil|Remifentanil 1 microgram/kg/h along with propofol infusion
11507114|NCT01304342|Active Comparator|Fentanyl|Fentanyl 200 micrograms intranasally
11507115|NCT01304342|Placebo Comparator|Normal saline|Normal saline intravenously and intranasally
11507116|NCT01304329|Experimental|treatment A, reference|1 tablet BI 10773, oral administration with 240 ml water
11507117|NCT01304329|Experimental|treatment B, reference|1 tablet simvastatin, oral administration with 240 ml water
11507118|NCT01304329|Experimental|treatment C, test|1 tablet BI 10773 + 1 tablet simvastatin, oral administration with 240 ml water
11507119|NCT01304316|Experimental|Kovacaine Nasal Spray|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 6 sprays of 0.1 mL - total of 18 mg tetracaine HCl and 0.3 mg oxymetazoline HCl followed by 12 sprays of 0.1 mL - total of 36 mg tetracaine HCl and 0.6 mg oxymetazoline HCl
11507120|NCT01304303|Experimental|SPARC1023 I|
11507121|NCT01304303|Experimental|SPARC1023 II|
11507122|NCT01304290|No Intervention|Control|
11507123|NCT01304290|Experimental|Glucose/Insulin Clamp|
11507124|NCT01304277|Experimental|Replagal® (0.2 mg/kg, IV, EOW)|"Screening period of approximately 14 days during which all patients received 1 infusion of 0.2 mg/kg Replagal RB (Week 0)
~Treatment period of 14 weeks during which all patients received 7 infusions of 0.2 mg/kg Replagal AF"
11507125|NCT01304264||combination topical glaucoma treatment|timolol or dorzolamide add on latanoprost monotherapy
11507126|NCT01304251|Active Comparator|Short-term fasting|short term fasting (i.e. 24 hours before and 24 hours after administration of chemotherapy) in 20 breast cancer patients
11507127|NCT01304251|Placebo Comparator|Healthy nutrition|20 breast cancer patients eat according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy.
11507128|NCT01304238||lepirudin|lepirudin treated subjects
11507129|NCT01304238||danaparoid|danaparoid treated subjects
11507130|NCT01304238||argatroban|argatroban treated subjects
11507131|NCT01304238||fondaparinux|fondaparinux treated subjects
11507132|NCT01304225|Active Comparator|100ms single-shot|Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion
11507133|NCT01304225|Experimental|20ms multiple-shot|Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion
11507134|NCT01304225|Experimental|20ms multiple-shot, barely visible|Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
11507135|NCT01304212|Active Comparator|femoral block|
11507136|NCT01304212|Experimental|local infiltration + femoral nerve block|Combination of local infiltration with drugs and femoral nerve block
11507137|NCT01304212|Active Comparator|several drugs local infiltration|
11507138|NCT01304199||Adult Cancer Survivors|"Intervention:
~Behavioural:
~Questionnaires for patient/family caregiver interview"
11507139|NCT01304186|Experimental|Tailored Information|Participants in this arm receive the computer-based tailored information application that focuses on improving health literacy related to treatment of HIV infection.
11507140|NCT01304160|Experimental|strereotactic radiotherapy, gemcitabine|stereotactic radiotherapy (30Gray in 5 fractions) followed by gemcitabine
11507141|NCT01304147|Experimental|Ketamine|Subjects randomized to this arm will receive the active study medication, intranasal ketamine.
11507142|NCT01304147|Placebo Comparator|Placebo|Subjects randomized to this arm will receive intranasal saline.
11507143|NCT01304134|Experimental|Oxycodone i.v.|To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)
11507144|NCT01304134|Active Comparator|Morphine i.v.|To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)
11507145|NCT01304121|Experimental|Bioactive glass|Resorbable bioactive glass granules
11507146|NCT01304108|Experimental|Order Set|"Insertion of VTE-P Order Set tollgate in all active admission and transfer orders."
11507147|NCT01304108|Experimental|Clinical Decision Support Pop-up|Deploy rules-based pop-up that reminds ordering clinicians when patients do not have an active VTE-P plan.
11507148|NCT01304108|Active Comparator|Usual Care|Usual care, without the experimental additions
11507149|NCT01304095|Active Comparator|Ranolazine|Ranolazine in addition to standard of care medical therapy
11507150|NCT01304095|No Intervention|Standard of Care|
11507151|NCT01304082|Placebo Comparator|normal saline|
11507152|NCT01304082|Active Comparator|lidocaine|
11507153|NCT01304082|Experimental|alkalinized lidocaine|
11507154|NCT01304069|Placebo Comparator|Placebo|
11507155|NCT01304069|Active Comparator|Selecoxib|
11507156|NCT01304069|Active Comparator|Etoricoxib|
11507157|NCT01304056||Critically ill patients|Patients that are treated in intensive care unit and given ventilatory therapy.
11507158|NCT01304056||Interventional volunteer group|Healthy volunteers
11507159|NCT01304030|Experimental|Experimental Group|The experimental group receives Empathy Training. The control Group receives residency training as usual
11507160|NCT01304030|Active Comparator|Control Group|The control group receives residency training as usual
11507161|NCT01304017|Experimental|Virtual Reality Therapy|The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing.
11507162|NCT01304017|Active Comparator|Traditional Therapy|The traditional therapy will include exercises for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
11507163|NCT01304004|Experimental|Experimental drinking yogurt|
11507164|NCT01304004|Placebo Comparator|Placebo drinking yogurt|
11507165|NCT01303991|Experimental|Hexvix PDT|
11507166|NCT01303978|Experimental|APD421 starting dose|
11507167|NCT01303965|Experimental|Open Label, Single Arm|Use sirolimus and tacrolimus as GvHD prophylaxis with sirolimus and lenalidomide as post-transplant maintenance
11507168|NCT01303952|Experimental|Eculizumab|
11507169|NCT01303939|Other|Glaucoma Patients|Patients who were outliers from two previous studies: Assessment of Ability Related to Vision (AARV) or Assessment of Disability Related to Vision (ADREV) with mini mental status exam score of 25 or higher underwent magnetic resonance imaging (MRI) of the brain to look at structures and volume.
11507170|NCT01303939|Other|Control Patients|Age, gender and race matched (to each glaucoma patient) group of healthy individuals with no ocular diseases with mini mental status exam score of 25 or higher underwent magnetic resonance imaging (MRI) of the brain to look at structures and volume.
11507171|NCT01303926|Active Comparator|Cisplatin and Pemetrexed|
11507172|NCT01303926|Active Comparator|Carboplatin paclitaxel bevacizumab|
11507173|NCT01303913||Walking desaturation group|COPD patients that at the end of 6MWT have SO2 nadir <88-90%
11507174|NCT01303913||Walking No-desaturation group|COPD patients that at the end of 6MWT have SO2 nadir >88-90%
11507175|NCT01303887|Active Comparator|R-CVP|Repeated every 21 days for up to 8 cycles with response assessment after 4 cycles. Responders (PR/CR) after 8 cycles will receive Rituximab maintenance therapy for 2 years (12 bi-monthly cycles).
11507176|NCT01303887|Experimental|R-FC|Repeated every 21 days for 4 cycles. Responders (PR/CR) after 4 cycles will receive 4 further cycles of Rituximab only. Responders after 8 cycles will receive Rituximab maintenance therapy for 2 years (12 bi-monthly cycles).
11507177|NCT01303874|Experimental|Combination Therapy|Methotrexate & Etanercept
11507178|NCT01303874|Placebo Comparator|Single-agent therapy|Methotrexate (MTX)
11507179|NCT01303861|Active Comparator|varenicline|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline.
11507180|NCT01303861|Active Comparator|Nicotine Patches only|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation nicotine patches(assessed at Session P2). They will continue to receive only nicotine patches.
11507181|NCT01303861|Active Comparator|Nicotine Patches with Nicotine Inhaler|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will continue to receive nicotine patches and will receive a nicotine inhaler to use as needed after their quit date.
11507182|NCT01303861|Active Comparator|varenicline with bupropion|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline in combination with bupropion.
11507183|NCT01303848||Healthy probands|Healthy probands, age between 18 and 40 years
11507184|NCT01303835|Experimental|Naltrexone|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
11507185|NCT01303835|Placebo Comparator|Placebo|Randomized patients received placebo to be taken every night before bed.
11507186|NCT01303822|Experimental|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
11507187|NCT01303809|Active Comparator|ERAS|The perioperative management of the patients in this arm will be according to a fast-track protocol designed by the investigators. The preoperative component of this program is the same as routine practice. Intraoperative and postoperative components which are different to routine practice are as described in the intervention section. This protocol is based on current literature regarding Enhanced Recovery After Surgery (ERAS).
11507188|NCT01303809|No Intervention|non ERAS|The perioperative management of patients in this arm will be according to routine practice currently implemented at our institution.
11507189|NCT01303796|Experimental|Sapacitabine-decitabine alternating|Arm A sapacitabine administered in alternating cycles with decitabine
11507190|NCT01303796|Active Comparator|Decitabine|Arm C Decitabine
11507191|NCT01303783|Experimental|Nifedipine GITS 20 mg|Subjects received 20 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
11507192|NCT01303783|Experimental|Nifedipine GITS 30 mg|Subjects received 30 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
11507193|NCT01303783|Experimental|Nifedipine GITS 60 mg|Subjects received 60 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
11507194|NCT01303783|Experimental|Candesartan cilexetil 4 mg|Subjects received 4 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
11507195|NCT01303783|Experimental|Candesartan cilexetil 8 mg|Subjects received 8 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
11507196|NCT01303783|Experimental|Candesartan cilexetil 16 mg|Subjects received 16 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
11507197|NCT01303783|Experimental|Candesartan cilexetil 32 mg|Subjects received 32 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
11507198|NCT01303783|Experimental|Nifedipine/candesartan 20/4 mg|Subjects received the combination of 20 mg of nifedipine GITS/4 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
11507199|NCT01303783|Experimental|Nifedipine/candesartan 20/8 mg|Subjects received the combination of 20 mg of nifedipine GITS/8 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
11507200|NCT01303783|Experimental|Nifedipine/candesartan 20/16 mg|Subjects received the combination of 20 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
11507201|NCT01303783|Experimental|Nifedipine/candesartan 30/8 mg|Subjects received the combination of 30 mg of nifedipine GITS/8 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
11507202|NCT01303783|Experimental|Nifedipine/candesartan 30/16 mg|Subjects received the combination of 30 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
11507203|NCT01303783|Experimental|Nifedipine/candesartan 30/32 mg|Subjects received the combination of 30 mg of nifedipine GITS/32 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
11507204|NCT01303783|Experimental|Nifedipine/candesartan 60/16 mg|Subjects received the combination of 60 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
11507205|NCT01303783|Experimental|Nifedipine/candesartan 60/32 mg|Subjects received the combination of 60 mg of nifedipine GITS/32 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
11507206|NCT01303783|Placebo Comparator|Placebo|Subjects received placebo (3 tablets and 1 capsule) once daily for 8 weeks
11507207|NCT01303770|Experimental|Cognitive intervention group|Cognitive rehabilitation program designed to be tested in this study
11507208|NCT01303770|Active Comparator|Control group|
11507209|NCT01303757|Experimental|Low glycemic load diet|Low glycemic load diet
11507210|NCT01303757|Active Comparator|Low fat diet|Low fat diet
11507211|NCT01303744|Experimental|CHF 5074 1x|oral tablet, multidose
11507212|NCT01303744|Experimental|CHF 5074 2x|oral tablet, multidose
11507213|NCT01303744|Experimental|CHF 5074 3x|oral tablet, multidose
11507214|NCT01303744|Placebo Comparator|Placebo|placebo, oral tablet, multidose
11507215|NCT01303731|Active Comparator|Standard dose Marcaine Spinal 0.5% Heavy|Standard group - will receive spinal anesthesia induced by Marcaine Spinal 0.5% Heavy 12.5 mg (2.5 ml).
11507216|NCT01303731|Experimental|Minidose of Marcaine Spinal 0.5% Heavy|Minidose group - will receive spinal anesthesia induced by Marcaine Spinal 0.5% Heavy 7.5 mg (1.5 ml) diluted in 0.75ml of patient's CSF (0.25 ml)with addition of Fentanyl 12.5 mcg (total 2.5 ml)
11507217|NCT01303718|Experimental|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
11507218|NCT01303718|Active Comparator|Standard of Care|Usual care (no CardioFit System implant)
11507219|NCT01303705|Experimental|Cyclophosphamide - Cohort 1|Cyclophosphamide 300 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
11507220|NCT01303705|Experimental|Cyclophosphamide - Cohort 2|Cyclophosphamide 600 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
11507221|NCT01303705|Experimental|Cyclophosphamide - Cohort 3|Cyclophosphamide 900 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
11507222|NCT01303692||A|Total of 250 prostate cancer patients receiving GnRH agonist
11507223|NCT01303692||B|Total of 250 prostate cancer patients receiving GnRH agonist plus anti-androgen agent
11507224|NCT01303679|Active Comparator|paclitaxel-bevacizumab|Paclitaxel, 80mg/m² at d1, d8, d15 bevacizumab, 10 mg/kg at d1, d15
11507225|NCT01303679|Experimental|exemestane-bevacizumab|exemestane, 25 mg daily dose bevacizumab, 15mg/kg every 3 weeks
11507226|NCT01303666|Active Comparator|TI of the knee|
11507227|NCT01303666|Active Comparator|Intra-articular CSI|
11507228|NCT01303640|Active Comparator|Biolimus-eluting stent|Biolimus-eluting stent
11507229|NCT01303640|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent
11507230|NCT01303627|Active Comparator|ultiva,remifentanil,opioid,analgesic|Remifentanil:1.5ng/ml remifentanil infusion maintained at the end of the surgery
11507231|NCT01303627|No Intervention|control|Control:Remifentanil stopped at the end of the surgery
11507232|NCT01303614|Active Comparator|Lidocaine-Prilocaine cream|
11507233|NCT01303614|Placebo Comparator|Placebo|purified water, ethylene glycol stearate, palm, palm stearate, polyethylene glycol, liquid paraffin, benzoic acid
11507234|NCT01303601|Experimental|olanzapine|
11507239|NCT01303575|Experimental|HIV, STI, and Pregnancy Prevention Curriculum|
11507240|NCT01303575|Active Comparator|Control curricula: Science Education|No sexual health elements
11507241|NCT01303562|Placebo Comparator|Placebo muffin made with no whole grains|
11507242|NCT01303562|Active Comparator|Test muffin made with whole oats|
11507243|NCT01303562|Active Comparator|Test muffin made with whole barley|
11507244|NCT01303549|Experimental|Anidulafungin|Anidulafungin IV once a day: initial dose 200 mg/day, following doses 100 mg/day.
11507245|NCT01303549|Active Comparator|Liposomal Amphotericin B|Liposomal amphotericin B once a day: 3 mg/kg/day
11507246|NCT01303536|Experimental|obsessive compulsive disorder|obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
11507247|NCT01303510|Experimental|Group A|Adults from 18 to 60 years old inclusive
11507248|NCT01303510|Experimental|Group B|Elderly subjects aged over 60 years
11507249|NCT01303497|Other|Arm A : Paclitaxel|administration of paclitaxel drug during cycle of 28 days (6 cycles Max) + blood sample on day 1, 8, 15, 29 and 57
11507250|NCT01303497|Other|Arm B : Paclitaxel + Bevacizumab|"administration of paclitaxel drug during per cycle of 28 days (6 cycles Max) + Bevacizumab every two weeks during paclitaxel cycles then every 3 weeks during P cycles until disease progression or inacceptable toxicity
~+ blood sample on day 1, 8, 15, 29 and 57"
11507251|NCT01303484|Placebo Comparator|MDn|Maltodextrin
11507252|NCT01303484|Active Comparator|B-GOS|Prebiotic
11507253|NCT01303471|Experimental|opioïd|Different levels of remifentanyl of each group during nociceptive stimulation
11507254|NCT01303458|Experimental|Intervention arm|Study subjects will receive the Basic Needs Surveillance (BNS) intervention.
11507255|NCT01303458|No Intervention|Control arm|Study subjects in the control arm will receive the standard of care.
11507256|NCT01303445|Active Comparator|Treatment A|Aggrenox alone
11507257|NCT01303445|Experimental|Treatment B|Aggrenox and omeprazole
11507258|NCT01303445|Active Comparator|Treatment C|Omeprazole alone
11507259|NCT01303445|Experimental|Treatment D|Aggrenox and omeprazole
11507260|NCT01303432|Experimental|Mobilee yogurt|Subjects eating daily on yogurt supplemented with Mobilee
11507261|NCT01303432|Placebo Comparator|Placebo yogurt|Subjects receiving daily a standard yogurt
11507262|NCT01303419|Experimental|CE-BMRI|Subject will undergo bilateral CE-BMRI as per usual clinical practice within 30 days after the new breast cancer diagnosis. Subject will then undergo bilateral DE-CEDM examination within 8 weeks after the CE-BMRI exam.
11507263|NCT01303406|Placebo Comparator|Placebo|"Following the body weight, patients will be allocated to one of the following regimen:
~Placebo Patients < 45 kg - 3 tablets 3 times a day with meals
~Placebo Patients > 45 kg - 5 tablets 3 times a day with meals"
11507264|NCT01303406|Experimental|idebenone|"Following the body weight, patients will be allocated to one of the following regimen:
~Idebenone Patients < 45 kg - 3 tablets 3 times a day with meals
~Idebenone Patients > 45 kg - 5 tablets 3 times a day with meals"
11507265|NCT01303393||Surgery for colorectal cancer|Patients that had surgery for colorectal cancer without receiving a stoma, and their next of kin.
11507266|NCT01303380|Experimental|Canakinumab|
11507267|NCT01303367||antipsychotic agents|
11507268|NCT01303367||non-antipsychotic agents|
11507269|NCT01303354|Experimental|DXM 4 mg|Dexamethasone 4 mg
11507270|NCT01303354|Experimental|DXM 8 mg|Dexamethasone 8 mg
11507271|NCT01303354|Experimental|DXM 12 mg|Dexamethasone 12 mg
11507272|NCT01303341|Experimental|Treatment (riluzole and sorafenib tosylate)|Patients receive riluzole PO BID and sorafenib tosylate PO QD or BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11507273|NCT01303328|Experimental|Treatment group|
11507274|NCT01303328|Placebo Comparator|Placebo group|
11507275|NCT01303315|Other|GLP-1 receptor agonist therapy|Group A: Subjects on GLP-1 receptor agonist therapy only. After run in of 12 weeks on GLP-1 receptor agonist therapy, Patients with HbA1c < 7.5 are moved to Group A, continue GLP-1 receptor agonist therapy, and then start the Evaluation Period These patients will not be implanted with the TANTALUS system.
11507276|NCT01303315|Experimental|GLP-1 receptor agonist and TANTALUS|Group B: subjects on GLP-1 receptor agonist therapy and TANTALUS therapy After run in of 12 weeks on GLP-1 receptor agonist therapy, Patients with HbA1c > 7.5 are moved to Group B, continue GLP-1 receptor agonist therapy, implanted with TANTALUS within 4 weeks, and then start the Evaluation Period
11507277|NCT01303315|Active Comparator|Subjects on TANTALUS therapy only|Group C: subjects on TANTALUS therapy only After run in of 12 weeks on GLP-1 receptor agonist therapy, patients intolerant to low dosage of GLP-1 receptor agonist therapy will be implanted with the TANTALUS system
11507278|NCT01303302|Active Comparator|GCM stimulation|The patient will be implanted with a gastric contractility modulation (GCM) stimulation system using the TANTALUS System for treatment of type 2 diabetic patients.
11507279|NCT01303302|Sham Comparator|Device off|The TANTALUS System is implanted but is off
11507280|NCT01303289|Experimental|Group 1|The group 1 will receive the experimental product T-Diet plus Standard for 3 months.
11507281|NCT01303289|Active Comparator|Group 2|The group 2 will receive the control product Jevity (Abbott Laboratories) for 3 months.
11507282|NCT01303276||Anti-VEGF group|Patients who are clinically indicated for the intravitreal injection of ranibizumab
11507283|NCT01303276||Age-matched controls|Group of healthy participants who will be age and gender matched
11507284|NCT01303263|Other|Intervention Group|Residents Randomized to Receive Educational Intervention
11507285|NCT01303263|No Intervention|Control Group|Residents randomized not to receive a teaching intervention.
11507286|NCT01303250|Experimental|Group 1|A balanced hydroxyethyl starch 130/0.4 will be used
11507287|NCT01303250|Active Comparator|Group 2|A balanced crystalloid will be used
11507288|NCT01303224|Experimental|Ibodutant low dose|Oral tablet, to be given once daily in fasting conditions.
11507289|NCT01303224|Experimental|Ibodutant intermediate dose|Oral tablet, to be given once daily in fasting conditions.
11507290|NCT01303224|Experimental|Ibodutant high dose|Oral tablet, to be given once daily in fasting conditions.
11507291|NCT01303224|Placebo Comparator|Placebo|Oral tablet, to be given once daily in fasting conditions.
11507292|NCT01303211||serogroup A meningococcal disease|Cases of serogroup A meningococcal disease
11507293|NCT01303211||Community controls|Healthy members of the community controls matched with cases for age, sex and place of residence
11507294|NCT01303211||Hospital controls|Patients admitted to the hospital with an acute illness other than meningitis or septicemia
11507295|NCT01303198|Active Comparator|CPAP|Use of CPAP as treatment for sleep apnea
11507296|NCT01303198|Active Comparator|APAP|Use of APAP as treatment for sleep apnea
11507297|NCT01303185||Experimental Group|
11507298|NCT01303185||Control Group|
11507299|NCT01303172|Active Comparator|gemcitabine chemotherapy|Patients in the control arm will receive normal standard of care - up to 12 cycles of Gemcitabine. Dosing of Gemcitabine is as per the normal orescribing information for pancreatic cancer.
11507300|NCT01303172|Experimental|IMM-101 in addition to gemcitabine|"Patients in the experiemental arm will recieve IMM-101 in addition the current standard of care, namely chemotherapy (Gemcitabine). The treatment regimen with IMM-101 will be every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.
~For patients in the active group, chemotherapy (GEM) will begin at least 14 days after first dose of IMM-101.
~Chemotherapy plus IMM-101 will be offered until intolerable toxcity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks)."
11507301|NCT01303159|Experimental|Radiofrequency probe (ENDOHPB)|"Intervention:
~The EndoHPB is an endoscopic bipolar catheter designed to ablate tissue in malignant tumors within luminal structures, such as the biliary tree or pancreatic ducts. EndoHPB can be deployed via an ERCP or Percutaneous Transhepatic Cholangiographic (PTC) route. By using radiofrequency (RF) energy to heat the tissue in the duct prior to insertion of the stent, the surrounding tissue becomes coagulated and this may delay tumour growth and the time before the stent lumen becomes blocked. Thereby, allowing increased periods between the need for intervention and further stent deployment"
11507302|NCT01303146|Experimental|Enzyme replacement therapy|intravenous infusion 100U/kg every other week for 18 months
11507303|NCT01303133||Adults with Down Syndrome ages 30+ (PiB-/-)|We will be recruiting healthy adults with Down syndrome ages 30 and over. Participants cannot have a diagnosis of dementia.
11507304|NCT01303133||Adults with Down Syndrome ages 30+ (PiB-/+)|
11507305|NCT01303133||Adults with Down Syndrome ages 30+ (PiB+/+)|
11507306|NCT01303120|Active Comparator|Femoral Nerve Block|
11507307|NCT01303120|Active Comparator|Combined Nerve Blocks|
11507308|NCT01303120|Active Comparator|Patient-controlled analgesia|
11507309|NCT01303107|Active Comparator|bupivacaine S50:R50|3 ml subarachnoid block
11507310|NCT01303107|Experimental|bupivacaine S75:R25|3 ml for subarachnoid block
11507311|NCT01303094|Other|Continuation of Trabectedin|patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle, every 3 weeks until progression/ toxicity
11507312|NCT01303094|Other|"Drug holiday therapy"|patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle and he stops the drug until progression and re-challenge
11507313|NCT01303081|Active Comparator|Usual Care|Participants will be offered free smoking cessation programs, and be provided web-based education regarding the health and economic benefits of smoking cessation. Participants will also have the opportunity to submit weekly reports on their smoking habits. They will be informed that they will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days and 3 months (among those eligible).
11507314|NCT01303081|Experimental|Individual Rewards|Same as USUAL CARE arm, plus financial incentive as follows: if participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators.
11507315|NCT01303081|Experimental|Fixed Deposits|Same as USUAL CARE arm, plus financial incentive as follows: participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
11507316|NCT01303081|Experimental|Chosen Deposits|Same as USUAL CARE, plus financial incentive as follows: participants will choose their deposit amount (XX = chosen deposit); this same amount will be returned upon success (that is, quit smoking by the target quit date, and having this confirmed by cotinine or anabasine tests). If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. The default deposit will be set to a certain monetary amount for consistency with other arms, and participants can increase or decrease this amount until they reach the amount they want to deposit.
11507317|NCT01303081|Experimental|Competitive Deposits (Pari-Mutuel)|"Same as USUAL CARE, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, and the payout for quitting on this arm will be Y x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
11507318|NCT01303068|Experimental|CF patients, 13C urea breath test kit|CF patients with Pseudomonas infection tested with 13C urea breath test
11507319|NCT01303068|Active Comparator|Healthy controls, 13C urea breath test kit|Healthy subjects using 13C urea breath test kit
11507320|NCT01303055|Experimental|Alogliptin|Alogliptin 25 mg
11507321|NCT01303055|Active Comparator|Metformin|Metformin 750 mg
11507322|NCT01303042|Experimental|Insulin lispro mix 50/50|
11507323|NCT01303029|Active Comparator|Control|Gemcitabine+erlotinib
11507324|NCT01303029|Experimental|Experimental|Gemcitabine+erlotinib+capecitabine
11507325|NCT01303016|Experimental|Nutrition supplement|Receives a month's supply of the nutrition supplement, Chispuditos, in addition to a voucher for 1lb of powdered milk each month and a voucher for 1lb of sugar every other month.
11507326|NCT01303016|No Intervention|Control|Receives a voucher for 1lb of powdered milk each month and a voucher for 1lb of sugar every other month. Participants in the control group will receive the nutrition supplement, Chispuditos, for one year after the study is complete.
11507327|NCT01303003|Experimental|Treatment Arm 1|Bilateral TAP block consisting of 40cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
11507328|NCT01303003|Active Comparator|Treatment Arm 2|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
11507329|NCT01302990|Experimental|5 micrograms H1 VLP|
11507330|NCT01302990|Experimental|13 micrograms H1 VLP|
11507331|NCT01302990|Experimental|28 micrograms H1 VLP|
11507332|NCT01302990|Active Comparator|45 micrograms Fluzone|
11507333|NCT01302990|Placebo Comparator|Placebo|
11507334|NCT01302977|Experimental|Fetal intervention|Composed of fetuses that undergo to fetal tracheal occlusion at 26-28 weeks.
11507335|NCT01302977|No Intervention|Control|Composed of fetuses that do not undergo fetal intervention
11507336|NCT01302964|Experimental|Mirtazapine|The starting dose for subjects is 7.5 mg daily. The maximum daily dose will be 45 mg.
11507337|NCT01302964|Placebo Comparator|Placebo|Subjects randomized to placebo arm will receive capsules identical in size and appearance to those subjects receiving study drug. Placebo capsules contain inactive ingredients.
11507338|NCT01302951|Experimental|Moxifloxacin|Moxifloxacin 400 mg i.v.
11507339|NCT01302951|No Intervention|No drug|2 Patients were included as controls- no MXF given
11507340|NCT01302938|Experimental|Tolterodine ER|
11507341|NCT01302938|Placebo Comparator|Placebo|
11507342|NCT01302925|Experimental|PEP005 Gel 0.05%/2 days|Subjects will be exposed to investigational product for 2 consecutive days.
11507343|NCT01302925|Experimental|PEP005 Gel 0.015%/3 days|Subjects will be exposed to investigational product for 3 consecutive days.
11507344|NCT01302899|Experimental|Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)+HCTZ/Ram+Ali/Ram|"Period 1(Day 1 to end of week 6): 1 tablet ramipril 10 mg once daily (o.d.) + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule Hydrochlorothiazide (HCTZ) 25 mg o.d.
~Period 2 (Weeks 7 to 12): 1 tablet ramipril 10 mg o.d.+ 1 tablet aliskiren 150 mg in 1st week of period; thereafter, 2 tablets aliskiren 150mg o.d.+ 1 capsule HCTZ 25 mg o.d.
~Period 3 (Weeks 13 to 18): 1 tablet ramipril 10 mg o.d. + 2 tablets aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d.
~Period 4 (Weeks 19 to 26): 1 tablet ramipril 10 mg o.d. + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d."
11507345|NCT01302899|Experimental|Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)/Ram+Ali + HCTZ/Ram|"Period 1(Day 1 to end of week 6): 1 tablet ramipril 10 mg once daily (o.d.) + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule Hydrochlorothiazide (HCTZ) 25 mg o.d.
~Period 2 (Weeks 7 to 12): 1 tablet ramipril 10 mg o.d.+ 1 tablet aliskiren 150 mg in 1st week of period; thereafter, 2 tablets aliskiren 150mg o.d.+ 1 capsule placebo to HCTZ 25 mg o.d.
~Period 3 (Weeks 13 to 18): 1 tablet ramipril 10 mg o.d. + 2 tablets aliskiren 150mg o.d. + 1 capsule HCTZ 25 mg o.d.
~Period 4 (Weeks 19 to 26): 1 tablet ramipril 10 mg o.d. + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d."
11507346|NCT01302886|Experimental|BHQ880|
11507347|NCT01302873|Experimental|BGG492|
11507348|NCT01302873|Placebo Comparator|Placebo|
11507349|NCT01302860|Experimental|Canakinumab|Canakinumab s.c. injection (2 mg/kg) was administered every 8 weeks.
11507350|NCT01302847|Experimental|Cohort I: Adolescents 12 to younger than 18 years of age|DTG film-coated tablets
11507351|NCT01302847|Experimental|Cohort IIA: Children 6 to younger than 12 years of age|DTG film-coated tablets
11507352|NCT01302847|Experimental|Cohort IIB: Children 6 to younger than 12 years of age|DTG granules for suspension or DTG dispersible tablets
11507353|NCT01302847|Experimental|Cohort III: Children 2 to younger than 6 years of age|DTG granules for suspension or DTG dispersible tablets
11507354|NCT01302847|Experimental|Cohort III-DT: Children 2 to younger than 6 years of age|DTG dispersible tablets
11507355|NCT01302847|Experimental|Cohort IV: Children 6 months to younger than 2 years of age|DTG granules for suspension or DTG dispersible tablets
11507356|NCT01302847|Experimental|Cohort IV-DT: Children 6 months to younger than 2 years of age|DTG dispersible tablets
11507357|NCT01302847|Experimental|Cohort V-DT: Infants 4 weeks to younger than 6 months of age|DTG dispersible tablets
11507358|NCT01302834|Active Comparator|IMRT + Cisplatin|Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin
11507359|NCT01302834|Active Comparator|IMRT + Cetuximab|Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab
11507360|NCT01302821|Experimental|Radiotherapy|AMT positron emission tomography with integrated computed tomography (PET/CT)scanning in metastatic breast cancer patients to identify tumors with increased AMT uptake due to up-regulated IDO expression.
11507361|NCT01302795|Experimental|Canakinumab|Canakinumab s.c. 150-300mg Week 0, (2), 8
11507362|NCT01302769|Experimental|battlefield auricular acupuncture|battlefield auricular acupuncture
11507363|NCT01302769|No Intervention|placebo|
11507364|NCT01302743|Active Comparator|Metformin|oral extended-release Metformin 1000 mg once a day for 90 days
11507365|NCT01302743|Experimental|Cinnamon Bark|Cinnamon Bark 1000 mg once a day for 90 days
11507366|NCT01302743|Experimental|Cinnulin PF|Cinnulin PF 500 mg once a day for 90 days
11507367|NCT01302717|Active Comparator|Right ventricular pacing|
11507368|NCT01302717|Experimental|Left ventricular pacing|
11507369|NCT01302691|Experimental|L50/H12.5/A5|Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.
11507370|NCT01302691|Active Comparator|L50 + A5|Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.
11507371|NCT01302652||GH deficient after acromegaly cure (on GH replacement)|Men and women with growth hormone deficiency following cure of acromegaly who are receiving growth hormone treatment.
11507372|NCT01302652||GH deficient after acromegaly cure (not on GH replacement)|Men and women with growth hormone deficiency following cure of acromegaly who are not receiving growth hormone treatment.
11507373|NCT01302639|Experimental|EGCG and resveratrol|
11507374|NCT01302639|Experimental|EGCG, resveratrol and genistein|
11507375|NCT01302639|Placebo Comparator|placebo|
11507376|NCT01302626||1: Surgery alone or combined with (chemo)radiotherapy|"Fresh frozen tumor tissue and normal tissue;
~Recording of clinical characteristics, imaging, surgery features.
~After treatment: FU at 2-3 weeks post surgery, 3,6,12,24 and 36 months post-surgery"
11507377|NCT01302626||2: Radiotherapy alone|"(including stereotactic radiotherapy)
~Before start RT (during staging):Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;
~Day 0 (before start RT): Recording of clinical characteristics, imaging, and radiotherapy features;
~Day 8-12 (during RT): Scoring of toxicity.
~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
11507378|NCT01302626||3: Sequential chemotherapy and radiotherapy|"Day -30 (before start CT):
~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;
~Recording of clinical characteristics, imaging, and chemotherapy features.
~Day 0 (before start RT):
~Recording of clinical characteristics, imaging, and radiotherapy features.
~Scoring of toxicity.
~Day 8-12 (during RT):
~Scoring of toxicity.
~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
11507379|NCT01302626||4: Concurrent chemoradiotherapy with induction chemotherapy|"Day -30 until-18 (before start CT):
~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;
~Recording of clinical characteristics, imaging, and chemotherapy features.
~Day 0 (before start RT):
~Recording of clinical characteristics, imaging, and radiotherapy features.
~Scoring of toxicity.
~Day 8-12 (during RT):
~Scoring of toxicity.
~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
11507380|NCT01302626||5: Concurrent chemoradiotherapy without induction chemotherapy|"Day 0 (before start CRT):
~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;
~Recording of clinical characteristics, imaging, chemotherapy features, and radiotherapy features.
~Day 8-12 (during CRT):
~Scoring of toxicity.
~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
11507381|NCT01302626||6: Stage IV lungcancer, any systemic therapy & supportive care|"Day 0:
~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;
~Recording of clinical characteristics, imaging, surgery or any systemic (MoAb) features.
~After treatment: FU at 2-3 weeks post treatment, 3,6,12,24 and 36 months post-treatment"
11507382|NCT01302613|Other|arm one|RT + Chemo + surgery
11507383|NCT01302600|Experimental|Olesoxime|100 patients in this arm. liquid suspension
11507384|NCT01302600|Placebo Comparator|Placebo|50 patients enrolled in this arm. liquid suspension
11507385|NCT01302587||Albuterol MDI|All participants in this study will receive an albuterol MDI inhaler.
11507386|NCT01302574|Placebo Comparator|mixed liquid meal|500 mL mixed liquid meal + 50 mg 13C-sodium-acetate
11507387|NCT01302574|Active Comparator|mixed liquid meal + lactisole|500 mL mixed liquid meal + 50 mg 13C-sodium-acetate + 450 ppm lactisole
11507388|NCT01302561|Placebo Comparator|Sugar Pill|
11507389|NCT01302561|Experimental|Galactooligosaccharide 5 g|
11507390|NCT01302548|Experimental|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
11507391|NCT01302548|Active Comparator|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
11507392|NCT01302535|Active Comparator|Yoga group with supervision/trainer|
11507393|NCT01302535|Active Comparator|Yoga at home|
11507394|NCT01302535|No Intervention|Control|No changes will be made for the participants in the control group, but they will undergo the same measurements and evaluations as the intervention groups.
11507395|NCT01302509|Active Comparator|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
11507396|NCT01302496|Experimental|TriMix-DC and Ipilimumab|
11507397|NCT01302483|Experimental|Kovacaine Nasal Spray|3% tetracaine HCL with 0.05% oxymetazoline HCL - Delivered via 3 sprays (100 uL) in each nostril
11507398|NCT01302483|Active Comparator|Lidocaine Injection|.5 to 1 catridge of 2% lidocaine HCL with 1:100,000 epinephrine
11507399|NCT01302470|Active Comparator|Robotic placement of CS lead|CS leads placed epicardially in the area of increased dyssynchrony as demonstrated by low dose dobutamine stress testing.
11507400|NCT01302470|Active Comparator|Transvenous placement of CS lead|CS lead will be placed transvenously
11507401|NCT01302457||Healthy Same Subjects|The control group will be 19 years or older and be randomly picked from from volunteer staff at Saint Elizabeth Regional Medical Center. This is a prospective study that will look at the similarities and difference of both groups. This will help us determine if there is a need to improve oral hygiene protocol given to burn/intensive care patients. Each group will consist of 25 subjects
11507402|NCT01302457||Health Volunteers|"The control group will be 19 years or older and be randomly picked from volunteer staff at Saint Elizabeth Regional Medical Center.
~DESIGN This is a prospective study that will look at the similarities and difference of both groups. This will help us determine if there is a need to improve oral hygiene protocol given to burn/intensive care patients. Each group will consist of 25 subjects"
11507403|NCT01302444|Active Comparator|Tadalafil|first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort
11507404|NCT01302444|Placebo Comparator|Placebo|first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks
11507405|NCT01302431|Experimental|Nurse-Led Manualised Telephone support|Participants assigned to this arm of the study will receive 4 nurse-led telephone support calls over a three month time-frame
11507406|NCT01302431|No Intervention|Usual care|Participants randomised to this arm of the study will receive their usual care which comprises caregivers calling nurse specialists when they needs advice and support
11507407|NCT01302418||Symptomatic|Individuals with signs and symptoms of an acute respiratory tract infection where it is suspected that such signs and symptoms are caused by a respiratory virus infection.
11507408|NCT01302405|Experimental|PRI-724|
11507409|NCT01302392|Active Comparator|Best Supportive Care|
11507410|NCT01302392|Experimental|Carfilzomib|
11507411|NCT01302379|Active Comparator|Metformin + lifestyle intervention|
11507412|NCT01302379|Active Comparator|Placebo + lifestyle intervention|
11507413|NCT01302379|Active Comparator|Metformin + standard dietary guidelines|
11507414|NCT01302379|Placebo Comparator|Placebo + standard dietary guidelines|
11507415|NCT01302366|Experimental|Sea cucumber extract|TBL12 is administered orally at a dose of 2 units (of 20 mL each) twice a day, in 4-week cycles, until disease progression or there is sign of disease progression.
11507416|NCT01302353|Experimental|Arm 1 (0.0024 ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0024ml/kg.
11507417|NCT01302353|Experimental|Arm 2 (0.006ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.006ml/kg.
11507418|NCT01302353|Experimental|Arm 3 (0.012ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.012ml/kg.
11507419|NCT01302353|Experimental|Arm 4 (0.02ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.02ml/kg.
11507420|NCT01302353|Experimental|Arm 5 (0.0301ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0301ml/kg.
11507421|NCT01302353|Experimental|Arm 6 (0.0391ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0391ml/kg.
11507422|NCT01302353|Experimental|Arm 7 (0.0508ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0508ml/kg.
11507423|NCT01302353|Experimental|Arm 8 (0.066ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.066ml/kg.
11507424|NCT01302353|Experimental|Arm 9 (0.0859ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0859ml/kg.
11507425|NCT01302353|Experimental|Arm 10 (0.1116ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1116ml/kg.
11507426|NCT01302353|Experimental|Arm 11 (0.1451ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1451ml/kg.
11507427|NCT01302353|Experimental|Arm 12 (0.1886ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1886ml/kg.
11507428|NCT01302353|Experimental|Arm 13 (0.2452ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.2452ml/kg.
11507429|NCT01302353|Experimental|Arm 14 (0.3188ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.3188ml/kg.
11507430|NCT01302353|Experimental|Arm 15 (0.4144ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.4144ml/kg.
11507431|NCT01302353|Experimental|Arm 16 (0.5387ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.5387ml/kg.
11507432|NCT01302340|Active Comparator|Delta-THC|THC will be administered twice daily during three consecutive days per treatment block(0.75 or 1.5 mg twice daily)
11507433|NCT01302340|Placebo Comparator|placebo|Placebo will be administered twice daily during three consecutive days per treatment block.
11507434|NCT01302327|Experimental|Exenatide|
11507435|NCT01302314|Experimental|cognitive rehabilitation|
11507436|NCT01302275|Experimental|oxcarbazepine|Oxcarbazepine is gradually increased during 21 days from 300 mg x 1 daily to 2400 mg, and kept on that dose ( 2400 mg) for three weeks.
11507437|NCT01302275|Placebo Comparator|placebo|
11507438|NCT01302262||Healthy smokers|Healthy male and female smokers. Each subject will undergo PET scan (along with craving and anxiety questionnaires) on two conditions - Smoking and Non-smoking - on two separate visits.
11507439|NCT01302249|Experimental|AR-12286|AR-12286 Ophthalmic Solution 0.5%
11507440|NCT01302249|Active Comparator|Timolol|Timolol maleate ophthalmic solution 0.5%
11507441|NCT01302236|Experimental|Eplerenone|
11507442|NCT01302223||Minor Burns|Total burn surface area less than 5% of second and third degree.
11507443|NCT01302223||Major Burns.|Total Burn Surface Area more than 25% of second and third degree, and less than 50%.
11507444|NCT01302210||Intervention|Active surveillance testing for MRSA and decolonization of positive subjects
11507445|NCT01302210||control|Usual standard of care
11507446|NCT01302184|Experimental|Experimental Group|Lokomat®
11507447|NCT01302184|Active Comparator|Control Group|Treadmill training
11507448|NCT01302171|Experimental|Peripheral|Half the patients will be randomised to the non-interventional part of the trial. In this subgroup of patients will be randomised 1:1 to 5 day course of subcutaneous placebo injections or a 5 day course of G-CSF(Granocyte™) subcutaneous injections
11507449|NCT01302171|Experimental|Interventional arm|In the subgroup of the interventional arm patients will be randomised 1:1 to receive a 5 day course of subcutaneous G-CSF (Granocyte™) injections and bone marrow aspiration at day 5, they will then receive either stem cells or placebo via intracoronary injection
11507450|NCT01302145|Experimental|ASP1941 + metformin|Oral
11507451|NCT01302145|Placebo Comparator|Placebo + metformin|Oral
11507452|NCT01302119|Experimental|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%
11507453|NCT01302119|Placebo Comparator|Solution Vehicle|Solution Vehicle
11507454|NCT01302106|Experimental|Arm 1|Clofarabine combined with low dose Ara-C
11507455|NCT01302093|Experimental|Experimental Tablet|A single 100 mg dose of an experimental Racecadotril Film-Coated Tablet (FCT)
11507456|NCT01302093|Active Comparator|Marketed Capsule|A single 100 mg dose of a marketed Racecadotril capsule
11507457|NCT01302080||Sertraline-treated|inception cohort of enrolled subjects beginning treatment for one of the study qualifying disorders with sertraline
11507458|NCT01302080||pyschotherapy only|inception cohort of enrolled subjects beginning treatment for one of the study qualifying disorders with psychotherapy
11507459|NCT01302067|Experimental|Fesoterodine 8mg|
11507460|NCT01302067|Experimental|Fesoterodine 4mg|
11507461|NCT01302067|Placebo Comparator|Placebo|
11507462|NCT01302054|Experimental|Fesoterodine|
11507463|NCT01302054|Placebo Comparator|Placebo|
11507464|NCT01302041|Experimental|Enzalutamide|Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.
11507465|NCT01302028|Active Comparator|Healthy volunteers with normal renal function|Oral
11507466|NCT01302028|Experimental|T2DM patient with normal renal function|Oral
11507467|NCT01302028|Experimental|T2DM patient with mild renal impairment|Oral
11507468|NCT01302028|Experimental|T2DM patient with moderate renal impairment|Oral
11507469|NCT01302028|Experimental|T2DM patient with severe renal impairment|Oral
11507712|NCT01300195||lung cancer surgery|Patients undergoing video-assisted thoracic surgery
11507470|NCT01302015|Experimental|RNL-Vascostem®|drug name and ingredients : RNL-Vascostem[Autologous adipose tissue derived mesenchymal stem cells] dosage : Intramuscular infusion, 5 x 10e6 cells/kg
11507471|NCT01302002|Experimental|Metformin Pre-Surgery|Patients will take metformin twice a day for three weeks prior surgery
11507472|NCT01301989|Placebo Comparator|Sleep Education Control|"The control group receives a low intensity intervention that provides information about sleep and the benefits of adequate sleep. We will give parents the National Sleep Foundation's handout, Information about Children's Sleep for Parents and Teachers (in English and Spanish)."
11507473|NCT01301989|Experimental|Sleep Counselor Intervention|"The sleep counselor visits are to assess the family's understanding of their child's sleep problems; help parents recognize the child's sleep deficiency; discuss how sleep problems affect behavior, learning, and health; and reassure parents that the sleep counselor can help them with these problems.
~Additionally, sleep counselors: review parent's sleep goals to monitor changes to the child's bedtime routine and sleep environment; help them solve problems with implementation; provide positive feedback to help the parent recognize success; and help parents set additional goals for improving sleep."
11507474|NCT01301963|Active Comparator|Arm I|Patients receive G-CSF SC QD on days 1-4.
11507475|NCT01301963|Experimental|Arm II|Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.
11507476|NCT01301950|Active Comparator|TruMatch® Personalized Solutions|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using TruMatch® Personalized Solutions (Custom Patient Instrumentation)
11507477|NCT01301950|Active Comparator|Conventional Total Knee Replacement|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments
11507478|NCT01301937|Active Comparator|High continuous dose|Meglumine antimoniate 20 mg/kg/day for 30 continuous days
11507479|NCT01301937|Active Comparator|Low continuous dose|Meglumine antimoniate 5 mg/kg/day for up to 120 continuous days according to clinical cure
11507480|NCT01301924|Active Comparator|High dose|High dose: 20 days of 20 mg/kg/day meglumine antimoniate
11507481|NCT01301924|Experimental|Low dose|Low dose: 30 days of 5 mg/kg/day meglumine antimoniate
11507482|NCT01301911|Experimental|Cipatinib|Each subject will receive a single dose of cipatinib on treatment day 1, followed by 4-day observation period, and then will receive cipatinib once daily in cycles consisting of 21 days.
11507483|NCT01301898|Experimental|GC1111_0.5mg/kg|
11507484|NCT01301898|Experimental|GC1111_1.0mg/kg|
11507485|NCT01301898|Active Comparator|Elaprase_0.5mg/kg|
11507486|NCT01301885||Endometriosis|Women (19-38 years of age) with surgically confirmed endometriosis
11507487|NCT01301885||Healthy women|Healthy women (32-48 years of age), symptom free, existence of endometriosis ruled out during laparoscopy for tubal ligation
11507488|NCT01301872|Other|1|All patients meet ALI/less severe ARDS criteria
11507489|NCT01301859|Active Comparator|TIP Adherence Intervention|The TIP program is a brief, individualized intervention designed as an adjunct to pharmacotherapy for depression prescribed by a primary care physician. The key to the intervention is the involvement of the older adult in creating an adherence strategy tailored to his/her barriers and needs.
11507490|NCT01301859|Placebo Comparator|Usual Care|Treatment as usual in a primary care setting
11507491|NCT01301846||Wheelchair users|People who have a wheelchair for home and community use.
11507492|NCT01301833|Experimental|teneligliptin|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )
11507493|NCT01301833|Experimental|teneligliptin and glinide|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide
11507494|NCT01301833|Experimental|teneligliptin and biguanide|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide
11507495|NCT01301833|Experimental|teneligliptin and alpha-glucosidase inhibitor|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor
11507496|NCT01301820|Other|ARM A|maintenance study treatment: azacitidine sc 75 mg/m²/d (d1- d7) in first cycle: months 1,3,5,7,9 ,11 then lenalidomide 10mg/d (d1- d21) months 2,4,6,8,10,12
11507497|NCT01301820|Other|ARM B|maintenance study treatment: lenalidomide 10mg/d (d1- d21)in first cycle and months 1,3,5,7,9 ,11 then azacitidine sc 75 mg/m²/d (d1- d7) months 2,4,6,8,10,12
11507498|NCT01301807|Experimental|Treatment (carfilzomib, panobinostat)|Participants receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 and panobinostat PO QD on days 1, 3, 5, 8, 10, and 12 of each course. Courses repeat every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. After 8 courses, participants may continue carfilzomib IV on days 1, 2, 15, and 16, and panobinostat PO on days 1, 3, 5, 8, 10, and 12 of each course. If the disease becomes worse, participants can receive carfilzomib on the original dosing schedule (days 1, 2, 8, 9, 15, and 16 of each course).
11507499|NCT01301781|Experimental|BLI801 laxative|BLI801 laxative - oral solution
11507500|NCT01301781|Placebo Comparator|Placebo|BLI801 placebo - oral solution
11507501|NCT01301768|Experimental|Group Education|Group educational workshops about dietary habits in the first trimester because it is when organogenesis occurs and therefore when the iodine deficiency in the mother is an important risk in the development of the fetal central nervous system.
11507502|NCT01301768|No Intervention|Usual care|Women in the control group receive the usual care during the pregnancy
11507503|NCT01301755||1|
11507504|NCT01301742|Active Comparator|BI 10773|Subject to receive one single dose BI 10773
11507505|NCT01301742|Experimental|BI 10773 plus gemfibrozil|Subject to receive one single dose BI 10773 plus 600 mg gemfibrozil bid for 5 days
11507506|NCT01301729|Experimental|Trastuzumab|Participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams per meter square (mg/m^2), every 3 weeks or paclitaxel 90 mg/m^2 once a week until progression of disease, occurrence of intolerable toxicity, the participant discontinues the study or dies.
11507507|NCT01301716|Experimental|A|
11507508|NCT01301716|Experimental|B|
11507509|NCT01301716|Experimental|C|
11507862|NCT01299142|Placebo Comparator|Placebo|Intervention: Drug-Placebo
11507510|NCT01301703|Active Comparator|Tdap vaccination|Patients and controls will be vaccinated with BOOSTRIX (Tdap vaccine)
11507511|NCT01301690||Neck masses|Neck mass received US and US-FNA
11507512|NCT01301677|Active Comparator|Hydrocortisone|
11507513|NCT01301677|Experimental|2PX+|strontium chloride hexahydrate in a penetration enhancing vehicle
11507514|NCT01301677|Experimental|2PX-|strontium chloride hexahydrate without a penetration enhancing vehicle
11507515|NCT01301651|Experimental|virtual reality balance training|balance board training with virtual reality intervention
11507516|NCT01301651|Experimental|conventional balance training|physical therapy conventional balance training
11507517|NCT01301651|No Intervention|control group|No physical therapy
11507518|NCT01301625||MitraClip Implant|Eligible patients undergoing a MitraClip procedure in Australia and New Zealand
11507519|NCT01301612|Active Comparator|Radiation therapy and Cisplatin|Cisplatin, 40 mg/m2, IV - Weekly doses for 6 weeks Pelvic radiation therapy, 45 Gy External, Fractions of 1.8 Gy per day, 5 days a week Dose boosts,15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week Brachytherapy (if indicaed), 40 Gy at spot A(low dose rate), Intracavitary 1 or 2 separate fractions for 1 to 3 weeks. 28 Gy at spot A, (high dose rate) Intracavitary,4 fractions of 7.0 Gy once or twice a week.
11507520|NCT01301612|Experimental|Nimotuzumab and|"Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks.
~Nimotuzumab, 200 mg, Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes, Weekly doses for 14 weeks.
~Pelvic radiation therapy, 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.
~Dose boosts, 15 Gy ± 5%, External,Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week
~Brachytherapy (In case there is indication, should it be performed, not to be longer than the expected 70 days for the entire radiation therapy), 40 Gy at spot A (low dose rate) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks 28 Gy at spot A (high dose rate), Intracavitary, 4 fractions of 7.0 Gy once or twice a week."
11507521|NCT01301599|Experimental|combination group|combination therapy of alpha blocker and 5-alpha-reductase inhibitor medication
11507522|NCT01301599|Active Comparator|alpha blocker group|alpha blocker monotherapy
11507523|NCT01301599|Active Comparator|5 ARI group|5 alpha-reductase inhibitor group
11507524|NCT01301586|Active Comparator|Oral antibiotic plus soy extract|
11507525|NCT01301586|Active Comparator|Oral antibiotic|
11507526|NCT01301573||rAAV-GAD Treated Subjects|rAAV-GAD treated subjects who are being observed for long-term effects of the gene therapy product which they received from participating in a previous clinical study.
11507527|NCT01301560|Experimental|Radiosurgery arm|Radiosurgery before palliative chemotherapy
11507528|NCT01301560|No Intervention|Observation arm|No radiotherapy or local treatment until specific symptoms or sign developed
11507529|NCT01301534||T-Con|1. Nurse initiated Telephone Consult (T-Con)
11507530|NCT01301534||Mail-Out|2. Mail-0ut Letter to the patient
11507531|NCT01301534||Education|3. Provider, Nurse and Technician Education with point-of-care patient referrals , Exam Room Flyer
11507532|NCT01301534||Control group|4. Control group (i.e. usual care)
11507533|NCT01301521|Experimental|Cinnulin PF|Will take (by mouth) 2 gelatin capsules that contains 1 gram (2-500 mg capsules) water-soluble cinnamon extract (Cinnulin PF) once a day for 1 year plus 1 year of follow-up plus standard of care aggressive lifestyle therapy.
11507534|NCT01301521|Placebo Comparator|Placebo|Will take (by mouth) 2 placebo capsules (gelatin capsule filled with wheat bran) once a day for 1 year plus 1 year of follow-up plus standard of care aggressive lifestyle therapy.
11507535|NCT01301508|Experimental|AN2898 ointment, 1%, vs. ointment vehicle|"AN2898 ointment applied twice daily for 6 weeks to one target lesion, and AN2898 ointment vehicle applied twice daily for 6 weeks to a second target lesion.
~Treatments will be randomly assigned to target lesions A and B."
11507536|NCT01301508|Experimental|AN2728 ointment, 2%, vs. ointment vehicle|"AN2728 ointment applied twice daily for 6 weeks to one target lesion, and AN2728 ointment vehicle applied twice daily for 6 weeks to a second target lesion.
~Treatments will be randomly assigned to target lesions A and B."
11507537|NCT01301495|Experimental|HANAROSTENT covered Esophageal Stent|
11507538|NCT01301482|Experimental|battlefield auricular acupuncture|
11507539|NCT01301482|No Intervention|placebo|
11507540|NCT01301469|Experimental|1|6% HES 130/0.42 in plasma adapted Ringer's solution (balanced solution)
11507541|NCT01301469|Active Comparator|2|HES 130/0.4 in a saline solution
11507542|NCT01301456|Placebo Comparator|Treatment Arm 1 (Stage 1A)|
11507543|NCT01301456|Experimental|Treatment Arm 2 (Stage 1A)|
11507544|NCT01301456|Experimental|Treatment Arm 3 (Stage 1A)|
11507545|NCT01301456|Experimental|Treatment Arm 4 (Stage 1A)|
11507546|NCT01301456|Placebo Comparator|Treatment Arm 5 (Stage 1B)|
11507547|NCT01301456|Experimental|Treatment Arm 6 (Stage 1B)|
11507548|NCT01301456|Experimental|Treatment Arm 7 (Stage 1B)|
11507549|NCT01301456|Experimental|Treatment Arm 8 (Stage 1B)|
11507550|NCT01301456|Placebo Comparator|Treatment Arm 9 (Stage 2)|
11507551|NCT01301456|Experimental|Treatment Arm 10 (Stage 2)|
11507552|NCT01301456|Experimental|Treatment Arm 11 (Stage 2)|
11507553|NCT01301456|Experimental|Treatment Arm 12 (Stage 2)|
11507554|NCT01301456|Experimental|Treatment Arm 13 (Stage 2)|
11507555|NCT01301443|Experimental|Subretinally Injected RetinoStat|Subretinally injected RetinoStat
11507556|NCT01301430|Experimental|H-1 parvovirus (H-1PV)|
11507557|NCT01301417||ColonRing™|Adult Patients who underwent a laparoscopic or open colorectal resection with the creation of an anastomosis using the ColonRing™ in routine clinical practice
11507558|NCT01301404|No Intervention|control|patient receive nothing
11507559|NCT01301404|Experimental|carbohydrate drink|10%carbohydrate drink
11507560|NCT01301391|Experimental|Milciclib|Milciclib Maleate capsules
11507561|NCT01301378|Active Comparator|KeraSys Tissue Patch Graft|20 patients needing a Molteno 3 glaucoma drainage shunt implant will receive the KeraSys patch graft
11507562|NCT01301378|Active Comparator|Tutoplast tissue patch graft|20 patients need Molteno 3 glaucoma drainage surgery will receive tutoplast patch graft
11507563|NCT01301352|No Intervention|Nasojejunal feeding (control)|
11507564|NCT01301352|Experimental|Nasogastric feeding (intervention)|
11507565|NCT01301339||failed and passed physical fitness test|520 subjects who have failed their Air Force physical fitness test and 520 volunteers who have passed their physical fitness test both within the last 6 months
11507566|NCT01301326|Experimental|subthreshold laser treatment|
11507567|NCT01301326|Active Comparator|threshold laser treatment|
11507568|NCT01301313|Experimental|Levosimendan|
11507569|NCT01301313|Active Comparator|Conventional intensified inotropic treatment|
11507570|NCT01301300|Active Comparator|Glenbrook Hospital|Immediate implementation of the disinfecting cap, no baseline contamination assessment, historical infection data only.
11507571|NCT01301300|Active Comparator|Evanston, Highland Park, Skokie Hospitals|"Phase 1: Assess baseline contamination rate for patients with PICC catheters for 3-12 months.
~Phase 2: Implement intervention. Assess contamination 3-12 months. Phase 3: (optional): Remove cap asses contamination rate (3-6 months)"
11507572|NCT01301287|Experimental|Chlorella|
11507573|NCT01301274|Active Comparator|Hypotonic|Subjects in this arm will receive 0.45% NaCl/5% dextrose intravenous maintenance fluids.
11507574|NCT01301274|Experimental|Isotonic|Subjects in this arm will receive 0.9% NaCl/5% dextrose intravenous maintenance fluids.
11507575|NCT01301261|Active Comparator|sugammadex 2 mg/kg|2 mg/kg of sugammadex are given when a response of two counts of train of four are present
11507576|NCT01301261|Active Comparator|4 mg/kg of sugammadex|4 mg/kg of sugammadex are given when a posttetanic count 1-3 appears
11507577|NCT01301261|Active Comparator|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg are given three minutes after the injection of cis-atracurium
11507578|NCT01301248|Active Comparator|Radiotherapy/Cisplatin(GroupA)|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)
11507579|NCT01301248|Experimental|Radiotherapy/Cisplatin/Cetuximab(GroupB)|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
11507580|NCT01301235||Subjects with mitochondrial disease|
11507581|NCT01301222|Experimental|octreotide|octreotide arm 100mcg for 5 days. control has no octreotide
11507582|NCT01301209||treatment|patients undergoing treatment
11507583|NCT01301196|Experimental|Behaviour change|Attendance at 3-h workshop
11507584|NCT01301183|Experimental|Rh IGF-1 + Transdermal estradiol|RhIGF-1 with transdermal 17-beta estradiol
11507585|NCT01301183|Placebo Comparator|Placebo + Transdermal estradiol|Placebo and transdermal 17-beta estradiol
11507586|NCT01301157|Experimental|25ug M518101|
11507587|NCT01301157|Placebo Comparator|Vehicle|
11507588|NCT01301157|Active Comparator|Dovonex|
11507589|NCT01301157|Experimental|50ug M518101|
11507590|NCT01301131|Experimental|Probiotic|80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily
11507591|NCT01301131|No Intervention|control|
11507592|NCT01301105|Placebo Comparator|Health Enhancement Program (HEP)|Intervention designed to be effective and structurally equivalent to Mindfulness Based Stress Reduction (MBSR) but without a mindfulness component. Designed as an active control for MBSR to isolate mindfulness as an active ingredient.
11507593|NCT01301105|Active Comparator|Mindfulness Based Stress Reduction (MBSR)|
11507594|NCT01301092|Experimental|Part A: LY2189265 intravenous|Single intravenous (IV) dose, starting at 0.1 milligrams (mg) of LY2189265. Dose may be increased to 0.2 mg or decreased to 0.05 mg for subsequent patients, dependent on safety assessments of the first 3 patients.
11507595|NCT01301092|Experimental|Part B: LY2189265 subcutaneous, intravenous|Patients are randomized to 2 sequences of 2 treatments. Single 1.5 mg subcutaneous (SC) dose of LY2189265 in Period 1; single intravenous (IV) dose of LY2189265 (determined by Part A IV arm data) in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.
11507596|NCT01301092|Experimental|Part C: LY2189265 subcutaneous, intramuscular|Patients are randomized to 2 sequences of 2 treatments. Single 0.75 mg subcutaneous (SC) dose of LY2189265 in Period 1; single 0.75 mg intramuscular (IM) of LY2189265 in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.
11507597|NCT01301079|Active Comparator|Ketamine|"A cardioscope, a capnograph, a pulse oximeter, and a noninvasive blood pressure meter were used to monitor the patients. Propofol (2-4 mg/kg), remifentanil (1 μg/kg), and atracurium (0.5 mg/kg) were administered for intubation. Atracurium was titrated to maintain muscle relaxation. Anesthesia was maintained with remifentanil, 0.8% isoflurane, and 50% oxygen without nitrous oxide. Infusion of the solutions was continued until skin closure.
~The patients in group ketamine received remifentanil (0.4 μg/kg/min) and ketamine (5 μg/kg/min).
~Remifentanil was administered as necessary until skin closure. Neostigmine was used for antagonizing the neuromuscular block."
11507598|NCT01301079|Placebo Comparator|Saline|"A cardioscope, a capnograph, a pulse oximeter, and a noninvasive blood pressure meter were used to monitor the patients. Propofol (2-4 mg/kg), 1 μg/kg remifentanil, and atracurium (0.5 mg/kg) were administered for intubation. Atracurium was titrated to maintain muscle relaxation. Anesthesia was maintained with remifentanil, 0.8% isoflurane, and 50% oxygen without nitrous oxide. Infusion of the solutions was continued until skin closure.
~The patients in group saline received remifentanil (0.4 μg/kg/min) and saline solution.
~Remifentanil was administered as necessary until skin closure. Neostigmine was used for antagonizing the neuromuscular block."
11507599|NCT01301066|Experimental|Pitavastatin 4 mg QD|
11507600|NCT01301066|Active Comparator|Pravastatin 40 mg QD|
11507601|NCT01301053|Other|Current UVA intensive care insulin protocol without brakes|Studies the safety and feasibility of the continuous glucose monitor in 10 critically ill patients for 7 days and uses the current UVA intensive care insulin for insulin management for 12 hours.
11507602|NCT01301053|Active Comparator|Current UVA intensive care insulin protocol with brakes|"Studies the safety and feasibility of the continuous glucose monitor in 10 critically ill patients for 7 days. Uses the current UVA intensive care insulin protocol for insulin management for 12 hours with the addition of brakes that reduce insulin administration based on continuous glucose monitoring data between hourly reference glucose data."
11507603|NCT01301040|Active Comparator|Epirubicin/Cyclophosphamide|Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles
11508020|NCT01297998|Experimental|gemcitabine , cisplatin|
11507604|NCT01301040|Active Comparator|docetaxel/cyclophosphamide|Treatment Arm 2: TC - docetaxel (Taxotere) (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.
11507605|NCT01301027|Active Comparator|Pioglitazone|15 mg/day pioglitazone for 2 weeks, then 30 mg/day for remaining 24 weeks
11507606|NCT01301027|Placebo Comparator|Placebo|1 placebo pill a day matching the pioglitazone treatment for 26 weeks
11507607|NCT01301001|Placebo Comparator|Placebo oral capsule|Placebo capsule daily in first intervention period and Gabapentin capsule 3000 mg daily in in second intervention (after washout period)
11507608|NCT01301001|Active Comparator|Gabapentin|Gabapentin capsule 3000 mg daily in first intervention period and Placebo capsule in second intervention (after washout period)
11507609|NCT01300988|Active Comparator|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
11507610|NCT01300988|Placebo Comparator|Placebo|Aprepitant (Emend®) placebo for 14 days
11507611|NCT01300975|Experimental|Intralesional antimony|3 intralesional injections of antimony at D1, D3 and D7
11507612|NCT01300975|Active Comparator|Cryotherapy|Liquid nitrogen until freezing at DF1 and D14
11507613|NCT01300975|Placebo Comparator|Topical cream|topical treatment 3 times a day during 21 days with an emollient cream
11507614|NCT01300962|Experimental|BYL719 ARM B|Treatment with BYL719 and Capecitabine
11507615|NCT01300962|Experimental|BKM120 ARM A|Treatment with BKM120 and capecitabine
11507616|NCT01300962|Experimental|ARM C|BKM 120 plus capecitabine plus trastuzumab
11507617|NCT01300962|Experimental|ARM D|BKM120 plus capecitabine plus lapatinib
11507618|NCT01300949|Active Comparator|Glaucoma|154 glaucoma, ocular hypertension and glaucoma suspect patients will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart.
11507619|NCT01300949|Active Comparator|Controls|125 patients with no eye diseases will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart. This included patients with refractive errors (needing glasses) and nuclear sclerosis (cataract).
11507620|NCT01300949|Active Comparator|Age-Related Macular Degeneration (ARMD)|35 retina patients with age-related macular degeneration (ARMD) will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart.
11507621|NCT01300936||patients with abdominal wall hernias|
11507622|NCT01300923|Active Comparator|Acamprosate|The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 60kg and 1332 mg per day for those less weighing less than 60kg.
11507623|NCT01300923|No Intervention|Autism Spectrum Disorder|This baseline comparison group will participated in only the psychophysiological and biomarker portion of subject characterization.
11507624|NCT01300910|Active Comparator|1|One group of men will undergo a circumcision using the Shang Ring and men are to return for regular follow-up visits to evaluate pain and wound healing. . The Shang Ring will be removed at 7 days, and the last scheduled follow-up visit is at 60 days.
11507625|NCT01300910|Active Comparator|2|One group of men will undergo a conventional circumcision using a WHO recommended surgical technique, either the forceps-guided method or the dorsal slit method. Men are to return for regular follow-up visits to evaluate pain and wound healing, with the last scheduled follow-up visit at 60 days.
11507626|NCT01300897||Healthy Volunteer|healthy volunteers will serve as controls. In each subject the cortical evoked potentials, transcranial motor evoked potentials and translumbosacral motor evoked potentials will be measured.
11507627|NCT01300897||Constipated patients|Patients with chronic constipation and rectal hypersensitivity or hyposensitivity and/or dyssynergic defecation.In each subject the cortical evoked potentials, transcranial motor evoked potentials and translumbosacral motor evoked potential will be measured
11507628|NCT01300884||healthy volunteers|
11507629|NCT01300884||patients with fecal incontinence|
11507630|NCT01300884||patients with constipation|
11507631|NCT01300871||Postmenopausal Women on Endocrine Therapy|Postmenopausal women with Breast Cancer that undergo Endocrine Therapy.
11507632|NCT01300858|Experimental|EGEN-001|
11507633|NCT01300845|Active Comparator|Humidification|
11507634|NCT01300845|Experimental|No Humidification|
11507635|NCT01300832|Experimental|Duplex scan|Subjects undergo preoperative and post-operative duplex scanning of the lower extremities
11507636|NCT01300819|Placebo Comparator|Placebo|
11507637|NCT01300819|Experimental|Rotigotine|
11507638|NCT01300806||myHERO SBIRT|
11507639|NCT01300806||clinician administered SBIRT|
11507640|NCT01300780|Active Comparator|Experimental|The participants from the placebo group received a placebo (Talco pharma SM-200-Henrifarma produtos químicos e farmacêuticos LTDA, São Paulo, SP, Brazil) and participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil). All the participants were watched to ensure that they took the drugs or placebo 1 h before treatment. The drugs were similar in appearance. A second dose of placebo or etoricoxib (60 mg) was administered 24 h after the first dose. At the time the participants were required to take the second dose of the medicine, the research auxiliary called him/her and asked him/her to take the medicine.
11507641|NCT01300780|Placebo Comparator|placebo group|The participants from the placebo group received a placebo (Talco pharma SM-200-Henrifarma produtos químicos e farmacêuticos LTDA, São Paulo, SP, Brazil) and participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil). All the participants were watched to ensure that they took the drugs or placebo 1 h before treatment. The drugs were similar in appearance. A second dose of placebo or etoricoxib (60 mg) was administered 24 h after the first dose. At the time the participants were required to take the second dose of the medicine, the research auxiliary called him/her and asked him/her to take the medicine.
11507642|NCT01300767|Experimental|Lotrafilcon B|Lotrafilcon B commercially marketed contact lens randomly assigned to one eye, with balafilcon A commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW) modality.
11507713|NCT01300182|Experimental|Whole body vibration therapy|Whole body vibration therapy on top of conventional physiotherapy treatment.
11509403|NCT01288482|Experimental|Asthma Subjects|
11507643|NCT01300767|Active Comparator|Balafilcon A|Balafilcon A commercially marketed contact lens randomly assigned to one eye, with lotrafilcon B commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW) modality.
11507644|NCT01300754|Active Comparator|Dextrose|
11507645|NCT01300754|Active Comparator|Lidocaine|
11507646|NCT01300754|Active Comparator|Usual Care|
11507647|NCT01300741|Experimental|Lotrafilcon B|Lotrafilcon B commercially marketed contact lens randomly assigned to one eye, with galyfilcon A commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW modality).
11507648|NCT01300741|Active Comparator|Galyfilcon A|Galyfilcon A commercially marketed contact lens randomly assigned to one eye, with lotrafilcon B commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW modality).
11507649|NCT01300728|Experimental|intravenous immunoglobulin (IVIG)|IVIG (NewGam 10%)at 0.4 g/kg
11507650|NCT01300728|Placebo Comparator|Saline solution|0.9% saline solution
11507651|NCT01300715|Active Comparator|MBRF|
11507652|NCT01300702||lung cancer surgery|Patients undergoing thoracotomy for lung cancer
11507653|NCT01300676|Active Comparator|Tualang Honey|Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.
11507654|NCT01300676|No Intervention|Group 2|Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia.
11507655|NCT01300663||post-surgery symptom experience|women with vulvar intraephitelial neoplasia or vulvar cancer
11507656|NCT01300650|Experimental|Anakinra|
11507657|NCT01300637|Active Comparator|metformin|metformin intervention group
11507658|NCT01300637|Placebo Comparator|placebo|placebo-controlled
11507659|NCT01300624|Experimental|Verb Network Strengthening Treatment|Verb Network Strengthening Treatment (VNeST) tasks involve the retrieval of nouns related to a target verb. For example, for the verb measure, participants would come up with people who measure and what they measure (e.g., carpenter/lumber, chef/sugar). They would then answer questions related to why, where, and when these things might occur (e.g., for carpenter/measure, they might say to get the right length of board, (why) at a construction site, (where) and when building a house (where). Cues and assistance are provided to the participants when they are unable to complete any given task. As the participants improve, cues are reduced.
11507660|NCT01300611|Experimental|TXA127 300 mcg/kg/day|Treatment group 1 (300 mcg/kg/day) of a two-arm, dose-escalation pilot feasibility trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect.
11507661|NCT01300611|Experimental|TXA127 1000 mcg/kg/day|Treatment group 2 (1000 mcg/kg/day) of a two-arm, dose-escalation pilot feasibility trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect.
11507662|NCT01300585|Other|MRI|All patients on study will undergo an MRI of the breast(s).
11507663|NCT01300572|Experimental|Y-90-BC8 & Allogeneic Transplant|"PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.
~TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.
~GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180."
11507664|NCT01300559|Experimental|Treatment Group|Tissuelink device plus Unipolar electrocautery will be used in this arm of the study.
11507665|NCT01300559|No Intervention|No treatment|Unipolar electrocautery without Tissuelink device will be used in this arm of the study.
11507666|NCT01300546|Active Comparator|Sumatriptan/Naproxen Sodium|In Treatment Period, subjects randomized to Sumatriptan/Naproxen Sodium will be provided with 14 tablets of Sumatriptan/Naproxen Sodium to treat migraine within 1 hour of onset on 14 or fewer days per month. Subjects will be provided with 14 tablets of Sumatriptan/Naproxen Sodium per month for rescue of persistent or recurring headache.
11507667|NCT01300546|Active Comparator|Naproxen Sodium|In Treatment Period, subjects randomized to Naproxen Sodium 500mg will be provided with 14 tablets of Naproxen Sodium to treat migraine within 1 hour of onset on 14 or fewer days per month. Subjects will be provided with 14 tablets of Naproxen Sodium per month for rescue of persistent or recurring headache.
11507668|NCT01300520|No Intervention|Target Tape|Including target tape in the procedure
11507669|NCT01300520|Other|Control|Without target tape in the procedure
11507670|NCT01300468|Experimental|Dose-escalation|
11507671|NCT01300455|Experimental|Suvorexant (40 mg)|In Period 1, suvorexant (40 mg tablets) administered orally once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. Period 2 consists of placebo administered once daily for 4 consecutive days in the evening.
11507672|NCT01300455|Placebo Comparator|Placebo|In Period 1, placebo administered orally once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. In Period 2, suvorexant (40 mg tablets) administered once daily for 4 consecutive days in the evening.
11507673|NCT01300442|Experimental|Control|The transcutaneous electrical diaphragmatic stimulation will be applied in healthy and COPD subjects.
11507674|NCT01300442|Experimental|Chronic Obstructive Pulmonary Disease|The intervention will be the TEDS in patients with Chronic Obstructive Pulmonary Disease (COPD)
11507714|NCT01300182|Active Comparator|Control|Conventional post-operative physical therapy rehabilitation exercises.
11509970|NCT01284296|Experimental|Digital block|
11507675|NCT01300429||patients with Non Small Cell Lung cancer|This is a protocol to obtain and/or analyze tissue specimens of patients with NSCLC harboring an activating ALK inversion or translocation that have had a previous clinical response to tyrosine kinase inhibitor therapy and subsequently experience progressive disease. The tissue will be used to identify changes in the ALK gene that are acquired during treatment with an ALK TKI and may account for acquired resistance.
11507676|NCT01300416||With Gastro-Intestinal (GI) symptoms|
11507677|NCT01300416||Without GI symptoms|
11507678|NCT01300403|Experimental|FLUTTER|Since this was a crossover study, all patients performed all interventions in a randomized order.
11507679|NCT01300403|Experimental|ELTGOL|Since this was a crossover study, all patients performed all interventions in a randomized order.
11507680|NCT01300403|Active Comparator|CONTROL|Since this was a crossover study, all patients performed all interventions in a randomized order.
11507681|NCT01300390||End-stage liver disease pre-transplant|Patients with end-stage liver disease (non-fulminant) awaiting liver transplant
11507682|NCT01300377|Active Comparator|Bupivacaine / Lidocaine|Lidocaine/Bupivacaine mixture - 5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
11507683|NCT01300377|Active Comparator|Lidocaine|Lidocaine - 10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
11507684|NCT01300364|Placebo Comparator|sugar pill|
11507685|NCT01300364|Active Comparator|reboxetine (NRI)|
11507686|NCT01300364|Active Comparator|citalopram (SSRI)|
11507687|NCT01300351|Experimental|Fulvestrant 500mg|Fulvestrant 500mg (2 syringes of Fulvestrant 250mg), Fulvestrant 500 mg i.m. every 28 (+/- 3) days plus an additional 500 mg on day 14 (+/-3) of first month only
11507688|NCT01300351|Active Comparator|Fulvestrant 250mg|Fulvestrant 250mg (1 syringe of fulvestrant 250mg + 1 syringe matching placebo), Fulvestrant 250 mg and matching placebo i.m. every 28 (+/- 3) days plus an additional 2 placebo syringes on day 14 (+/-3) of first month only
11507689|NCT01300338|Experimental|Blood pressure with telemetry|Home blood pressure monitor with telemetry
11507690|NCT01300338|Active Comparator|Blood pressure without telemetry|Home blood pressure self monitor without telemetry.
11507691|NCT01300325|Placebo Comparator|0.9% saline|patients receive every 6 hours the nebulized 0.9% saline (placebo comparator) (group I) or the 3% HS (group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
11507692|NCT01300325|No Intervention|3% hypertonic saline|Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
11507693|NCT01300312|Experimental|1|
11507694|NCT01300312|Active Comparator|2|
11507695|NCT01300299|Experimental|All subjects|Subjects will receive chemotherapy after stereotactic body radiation therapy.
11507696|NCT01300286|Experimental|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
11507697|NCT01300273|Experimental|Ketosteril|
11507698|NCT01300260|Experimental|LY2189265 then Placebo|"LY2189265 (Dulaglutide) then Placebo: A single 1.5 milligram (mg) subcutaneous (SC) injection of LY2189265 on Day 1 in Period 1, followed by a single SC injection of Placebo on Day 1 in Period 2.
~On Day 3 of each period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose bolus (0.3 gram/kilogram [g/kg] over approximately 2 minutes). Three hours later, participants were administered a second IV dextrose bolus of 25 g of 50% dextrose or a suitably adjusted dose according to glycemic status (20 g of 50% dextrose for participants with 3-hour glucose between 5.2 and 10 millimole/liter [mmol/L] or 15 g of 50% dextrose for participants with 3-hour glucose >10 mmol/L), followed by a 20% dextrose at the set infusion rate of 600 milliliter/hour [mL/h] for 35 minutes. Fifteen minutes after the start of the 20% dextrose infusion, an IV 1-mg glucagon bolus was administered.
~There was a washout period of at least 28 days between Periods 1 and 2."
11507699|NCT01300260|Experimental|Placebo then LY2189265|"Placebo then LY2189265 (Dulaglutide): A single subcutaneous injection of Placebo on Day 1 in Period 1, followed by a single 1.5 milligrams (mg) subcutaneous injection of LY2189265 on Day 1 in Period 2.
~On Day 3 of each period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose bolus (0.3 gram/kilogram [g/kg] over approximately 2 minutes). Three hours later, participants were administered a second IV dextrose bolus of 25 g of 50% dextrose or a suitably adjusted dose according to glycemic status (20 g of 50% dextrose for participants with 3-hour glucose between 5.2 and 10 millimole/liter [mmol/L] or 15 g of 50% dextrose for participants with 3-hour glucose >10 mmol/L), followed by a 20% dextrose at the set infusion rate of 600 milliliter/hour [mL/h] for 35 minutes. Fifteen minutes after the start of the 20% dextrose infusion, an IV 1-mg glucagon bolus was administered.
~There was a washout period of at least 28 days between Periods 1 and 2."
11507700|NCT01300247|Experimental|Obinutuzumab + Fludarabine + Cyclophosphamide|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab (1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6), fludarabine (25 mg/m^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6), and cyclophosphamide (250 mg/m^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6).
11507701|NCT01300247|Experimental|Obinutuzumab + Bendamustine|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab (1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6) and bendamustine (90 mg/m^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6).
11507702|NCT01300234|Experimental|A (TDF tablets)|Tenofovir disoproxil fumarate (TDF) tablets
11507703|NCT01300234|Active Comparator|B (ADV tablets)|Adefovir dipivoxil (ADV) tablets
11507704|NCT01300221||Group 1|Subjects who are healthy normal children.
11507705|NCT01300221||Group 2|Subjects who have congenital heart disease.
11507706|NCT01300221||Group 3|Subjects who have sickle cell disease
11507707|NCT01300221||Group 4|Subjects who have Duchenne muscular dystrophy
11507708|NCT01300221||Group 5|Patients who have Marfan syndrome and other aortic disease
11507709|NCT01300208|Experimental|Cohort 1|CC-11050 (50 milligrams twice per day and Placebo)
11507710|NCT01300208|Experimental|Cohort 2|CC-11050 (100 milligrams twice per day and Placebo)
11507711|NCT01300208|Experimental|Cohort 3|CC-11050 (200 milligrams twice per day and Placebo)
11507823|NCT01299454|Active Comparator|Severe|
11507715|NCT01300169|Experimental|CAMS--Collaborative Driver-Treatment|"The Collaborative Assessment and Management of Suicidality (CAMS) is a suicide-specific clinical intervention that targets and treats patient-defined suicidal drivers over the course of clinical care."
11507716|NCT01300169|Active Comparator|Enhanced Care as Usual--E-CAU|This control group treatment will reflect current clinical practices for treating suicidal soldiers in the research site setting. These are providers were on site clinicians who provided care according to their usual and customary practices for working with suicidal risk within outpatient care.
11507717|NCT01300156|Experimental|ESHAOx arm|Patients who are planned to be treated with ESHAOx chemotherapy
11507718|NCT01300143|Active Comparator|TACE|Patients will be treated by 2 or 3 cures of hyperselective TACE. The first one at week 0 and the second one at week 8. If required, a third cure of TACE could be done at week16.
11507719|NCT01300143|Experimental|TACE + RTC|Patients will be treated by one cure of TACE at week 0. Then, patients will be treated within two weeks by external conformational radiotherapy of 54 grey fractioned in 18 sessions during 3-4 weeks.
11507720|NCT01300130|Experimental|low docosahexaenoic acid formula|
11507721|NCT01300130|Experimental|medium docosahexaenoic acid formula|
11507722|NCT01300130|Experimental|high docosahexaenoic acid formula|
11507723|NCT01300130|Active Comparator|human milk|
11507724|NCT01300117||with extracorporeal circulation|Patients undergoing cardiac surgery with the use of an extracorporeal circulation
11507725|NCT01300117||without extracorporeal circulation|Patients undergoing cardiac surgery without the use of extracorporeal circulation (OPCAB)
11507726|NCT01300104|Experimental|Exercise and whole grain rye|
11507727|NCT01300104|Active Comparator|No prescriptions|
11507728|NCT01300078|Experimental|MF101 10 grams/day|
11507729|NCT01300078|Experimental|MF101 15 grams/day|
11507730|NCT01300065|Experimental|Experimental- Soflens|Bausch & Lomb experimental soflens daily disposable contact lens packaged in an investigational storage solution.
11507731|NCT01300065|Active Comparator|Marketed - Soflens|Bausch & Lomb daily disposable marketed soflens contact lens packaged with: 0.5% poloxamine in buffered saline solution.
11507732|NCT01300052|Experimental|AN2728 ointment, 2%|AN2728 ointment, 2%
11507733|NCT01300052|Placebo Comparator|Ointment Vehicle|Ointment Vehicle
11507734|NCT01300039||Antibiotics for H. pylori|Patients who underwent upper endoscopy and were found to have H. pylori, and were then to be treated with antibiotics for eradication of H. pylori
11507735|NCT01300039||Control group, no H. pylori|Patients who underwent upper endoscopy and found to not have H. pylori, and then would not receive antibiotics
11507736|NCT01300026|Experimental|Part II Dose Expansion|Dose selected from Part I dose exploration
11507737|NCT01300026|Experimental|Part I Dose Exploration|The AMG 319 doses proposed for this study are 25, 50, 100, 200, 300 and 400 mg administered by mouth once daily.
11507738|NCT01300013|Experimental|Omecamtiv mecarbil|
11507739|NCT01300013|Placebo Comparator|Placebo|
11507740|NCT01300000|Active Comparator|Human Milk|ad lib
11507741|NCT01300000|Active Comparator|Milk based standard infant formula|ad lib
11507742|NCT01300000|Experimental|Milk based investigational infant formula|ad lib
11507743|NCT01299987|Experimental|Intraoperative radiotherapy|single arm with intraoperative radiotherapy
11507744|NCT01299974|Other|Parents and Residents in Session|Parents and Residents in Session
11507745|NCT01299961|Experimental|Subcutaneous Abatacept|All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.
11507746|NCT01299948|Active Comparator|prednisolone|5 mg prednisolone per os daily administration
11507747|NCT01299948|Placebo Comparator|placebo|The placebo is designed to the equal look like the study medication.
11507748|NCT01299935|Experimental|Stress reduction|Stress reduction program utilizing the Transcendental Meditation (TM) technique
11507749|NCT01299935|Active Comparator|health education|health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
11507750|NCT01299922|Experimental|cyclosporine+mycophenolic acid+prednison|Triple therapy
11507751|NCT01299922|Active Comparator|mycophenolic acid + prednison|Mycophenolic acid+prednison 106 weeks
11507752|NCT01299909|Active Comparator|Mindfulness Training for Smokers|MTS participants will receive 8 classes of training in mindfulness meditation, access to the MTS website, and 2 weeks of nicotine patches.
11507753|NCT01299909|Active Comparator|Integrated Training for Smokers|ITS participants will receive 8 classes of training in smoking cessation strategies, access to the Freedom From Smoking online program, and 2 weeks of nicotine patches.
11507754|NCT01299909|Other|Quitline|Quitline participants will consist of participants who elect not to participate in the high-intensity treatments (Mindfulness Training for Smokers; Integrated Training for Smokers. This Quitline group is a Non-Randomized, Treatment as Usual group.
11507755|NCT01299896|Active Comparator|Usual Care|Participants will continue to receive all the care currently offered in the VAPHS, including medications for smoking cessation and use of the in-person or telephone counseling options for quit smoking classes. For veterans with a co-pay, incurred fees with be reimbursed.
11507756|NCT01299896|Active Comparator|Coordinated Care|A CTQ Coordinator will coordinate the delivery of smoking related care.
11507757|NCT01299883|Active Comparator|Cancer and CVD Education|Participants receive education about both cancer and CVD risk factors and their relationship to dietary and physical activity health behaviors.
11507758|NCT01299883|Active Comparator|CVD Education|Participants receive education about CVD risk factors and their relationship to dietary and physical activity health behaviors.
11507759|NCT01299870|Active Comparator|AED treatment plus placebo|
11507760|NCT01299870|Experimental|Keishibukuryogan|
11507761|NCT01299844|No Intervention|Standard Care|
11507762|NCT01299844|Experimental|Diabetes Peer Counseling|
11507763|NCT01299831|Experimental|72 hour fast|
11507764|NCT01299831|Experimental|12 hours fast|
11507765|NCT01299831|Experimental|12 hour fast, growth hormone bolus|
11507766|NCT01299831|Experimental|72 hour fast, inhibition of lipolysis|
11507767|NCT01299818||spinal surgery|patients who undergo spinal surgery
11507768|NCT01299805|Experimental|Vortioxetine|Vortioxetine 20 mg, encapsulated tablet, orally, once daily for up to 14 days.
11507769|NCT01299805|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 14 days.
11507770|NCT01299792||one arm; neurogenic bladder dysfunction|evaluation of the clinical utility of bladder wall thickness as a diagnostic tool in patients with spinal cord injury
11507771|NCT01299779|Active Comparator|PEG-ELS|
11507772|NCT01299779|Active Comparator|PEG-SD|
11507773|NCT01299766|Experimental|Behavior Activation|BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
11507774|NCT01299766|Placebo Comparator|Supportive Therapy (ST)|ST is a person-centered treatment in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
11507775|NCT01299753|Placebo Comparator|Control|
11507776|NCT01299753|Experimental|Beta blockade|
11507777|NCT01299740|Other|Control Group|Treatment as usual
11507778|NCT01299740|Experimental|Research Group|Participation in the DBT skills group
11507779|NCT01299727|Experimental|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
11507780|NCT01299727|Experimental|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
11507781|NCT01299727|Experimental|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
11507782|NCT01299701|Experimental|ASA404|
11507783|NCT01299675||Chronic Performance|Subjects enrolled prior to or within 30 days post implant of SureScan pacing system. In office follow-up visits required every 6 months.
11507784|NCT01299675||Multiple MRI Scan Characterization|Subject enrolled into study at the time of MRI Scan indication. Subject followed per clinic standard of care.
11507785|NCT01299662|Experimental|Poly ICLC|One 1.6 mg subcutaneous injection of the adjuvant, poly ICLC, in the upper arm.
11507786|NCT01299649||Non-contrast echocardiography|Non-contrast echocardiography
11507787|NCT01299649||Contrast Echocardiography|Contrast Echocardiography
11507788|NCT01299636|Experimental|PM060184|
11507789|NCT01299623|Active Comparator|Evidential Group|Participants in this group will receive education about breast cancer prevention and specific information about African American women and breast cancer risk.
11507790|NCT01299623|Active Comparator|Non-Evidential Group|Participants in this group will receive general information about breast cancer prevention without anything specific to African American women.
11507791|NCT01299610|Experimental|GW870086 2.0% &amp; 0.2%|GW870086 2.0%, GW870086 0.2% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
11507792|NCT01299610|Experimental|GW870086 2.0% & FP 0.05%|GW870086 2.0%, FP 0.05% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
11507793|NCT01299610|Experimental|GW870086 0.2% & FP 0.05%|GW870086 0.2%, FP 0.05% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
11507794|NCT01299597|Experimental|Cohort 1: Atorvastatin|single dose session with Atorvastatin with PK samples collected up to 72h post dose, then 14 days repeat dose session with SB649868 with Atorvastatin single dose co-administered on day 8 (same time as SB649868) and on day 12 (2 hours before SB649868).
11507795|NCT01299597|Experimental|Cohort 2: Simvastatin|single dose session with Simvastatin with PK samples collected up to 24h post dose, then 14 days repeat dose session with SB649868 with Simvastatin single dose co-administered on day 12 (same time as SB649868) and on day 14 (2 hours before SB649868).
11507796|NCT01299584||Remifentanil|Patients administrated remifentanil at the site
11507797|NCT01299571||Dutasteride|Patients administrated dutasteride at the site
11507798|NCT01299558|Other|Treatment period 1|Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder given once daily in the morning on Day 1 of Treatment period 1
11507799|NCT01299558|Other|Treatment Period 2|Single IV dose of FF (250mcg) given over 20 mins on Day 1 of Treatment period 2
11507800|NCT01299558|Other|Treatment Period 3|Single IV dose of GW642444M (55mcg) given over 60 mins on Day 1 of Treatment period 3
11507801|NCT01299545||a single group of patients -200 expected|polyarthrite rhumatoid patients
11507802|NCT01299532|Experimental|Macrolane VRF30|
11507803|NCT01299519|Experimental|Weight Loss|Half of the subjects in the weight loss arm will lose 5% of their weight through a low-calorie diet, and half will also lose 10% and 15% body weight.
11507804|NCT01299519|Active Comparator|Weight Maintenance|Subjects in the weight maintenance arm will maintain a steady body weight (plus or minus 2% of initial body weight) for six months.
11507805|NCT01299506||Trabectedin|The administration of chemotherapy regimen with trabectedin will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
11507806|NCT01299506||Conventional care|This includes other palliative chemotherapy or biological therapy or best supportive care.
11507807|NCT01299493|Experimental|Interventional|Access to systems-level interventions to increase colorectal cancer screening.
11507808|NCT01299493|No Intervention|Usual Care|Practices will receive access to intervention components after outcomes data collection is complete.
11507809|NCT01299480|Experimental|Group 1|rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
11507810|NCT01299480|Experimental|Group 2|rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
11507811|NCT01299480|Experimental|Group 3|rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
11507812|NCT01299480|Experimental|Group 4|rLP2086 at visits 1 and 3, saline at visits 2 and 5
11507813|NCT01299480|Experimental|Group 5|rLP2086 at visits 3 and 5, saline at visits 1 and 2
11507814|NCT01299467|Experimental|Dose 1 (0.5 hours)|
11507815|NCT01299467|Experimental|Dose 1 (8 hours)|
11507816|NCT01299467|Placebo Comparator|Dose 1 (placebo)|
11507817|NCT01299467|Experimental|Dose 2 (0.5 hr)|
11507818|NCT01299467|Experimental|Dose 2 (8 hours)|
11507819|NCT01299467|Placebo Comparator|Dose 2 (placebo)|
11507820|NCT01299454|Active Comparator|Normal|
11507821|NCT01299454|Active Comparator|Mild|
11507822|NCT01299454|Active Comparator|Moderate|
11507824|NCT01299441||OLT patients intubated with ECOM ETT|Patients undergoing liver transplantation and intubated with ECOM endotracheal tube (ETT).
11507825|NCT01299428|Active Comparator|cerebral oxygenation|
11507826|NCT01299415|Experimental|ASA404 + Fluvoxamine|ASA404 + Fluvoxamine (Core Phase), ASA404 + either paclitaxel or docetaxel or paclitaxel plus carboplain chemotherapy combination (Extension Phase)
11507827|NCT01299402|Experimental|Soulera Herbal Blend|
11507828|NCT01299402|Placebo Comparator|Placebo Blend|
11507829|NCT01299389|Experimental|Paliperidone palmitate|
11507830|NCT01299389|Placebo Comparator|Placebo|
11507831|NCT01299376|Experimental|L50/H12.5/A5→L50/H12.5/A5|One combination tablet containing L50 mg, H12.5 mg, and A5 mg, orally, once daily, for up to 8 weeks (double-blind treatment period). Participants continue with once daily L50/H12.5/A5 for 44 weeks during open label extension.
11507832|NCT01299376|Active Comparator|L50/H12.5→L50/H12.5/A5|One combination tablet containing L50 mg and H12.5 mg, orally, once daily, for up to 8 weeks during double-blind treatment period. Participants then receive once daily L50/H12.5/A5 for 44 weeks during open-label extension
11507833|NCT01299363|No Intervention|No dilator use|
11507834|NCT01299363|Active Comparator|Dilator use|Women randomized to vaginal dilators will be given instructions to perform softening exercises from postoperative weeks 4 to 8
11507835|NCT01299350|No Intervention|Usual|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged according to routine clinical practice based on symptoms, physical examination and other data that the cardiologist deems appropriate, except for Nt-proBNP.
11507836|NCT01299350|Experimental|Nt-proBNP guided|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops >30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies
11507837|NCT01299337||placebo|Subjects will be randomized either receiving T3 or placebo.
11507838|NCT01299324|Experimental|BMAC Infusion|Infusion of autologous bone marrow aspirate concentrated nucleated sells into the coronary sinus
11507839|NCT01299324|No Intervention|Control|Standard of care only. No infusion
11507840|NCT01299311|No Intervention|Inactivity|4 days of inactivity, mainly sitting
11507841|NCT01299311|Active Comparator|NEAT|4 days of NEAT (everyday activities)
11507842|NCT01299311|Active Comparator|Exercise|4 days of inactivity combined with 1 hour of exercise
11507843|NCT01299298|Experimental|mipomersen|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose
11507844|NCT01299298|Placebo Comparator|placebo|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose
11507845|NCT01299285|Experimental|LY3009104|Single 10-milligram (mg) oral dose containing 100 microcuries of 14C-labeled LY3009104
11507846|NCT01299272|Experimental|LY2216684 + SSRI|"Acute Open-label (OL) Period: Participants received a starting dose of 12 milligrams (mg) LY2216684, administered orally, once daily for at least 2 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI). Then, based on efficacy and tolerability, the dose could be increased to 18 mg (and decreased back to 12 mg) over the next 6 weeks.
~Stabilization OL Period: Participants meeting remission criteria continued on the same dose of LY2216684 for an additional 12 weeks. Participants who discontinued early during either OL Period were discontinued abruptly from LY2216684.
~Double-blind (DB) Randomized Withdrawal Period: At 20 weeks, participants meeting criteria for randomization continued their current dose of LY2216684 for another 24 weeks. Participants who completed this period or discontinued early were randomized to abrupt (placebo for 2 weeks) or tapered (12 mg LY2216684 for 4 days, 6 mg LY2216684 for 4 days, then placebo for 6 days) discontinuation of LY2216684."
11507847|NCT01299272|Placebo Comparator|Placebo + SSRI|"Acute Open-label (OL) Period: Participants received a starting dose of 12 milligrams (mg) LY2216684, administered orally, once daily for at least 2 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI). Then, based on efficacy and tolerability, the dose could be increased to 18 mg (and decreased back to 12 mg) over the next 6 weeks.
~Stabilization OL Period: Participants meeting remission criteria continued on the same dose of LY2216684 for an additional 12 weeks. Participants who discontinued early during either OL Period were discontinued abruptly from LY2216684.
~Double-blind (DB) Randomized Withdrawal Period: At 20 weeks, participants meeting criteria for randomization were tapered from their LY2216684 dose to placebo following the regimen of 12 mg for 7 days, 6 mg for 7 days, and placebo for the remaining 22 weeks. Participants who completed this period or discontinued early continued to receive placebo for an additional 2 weeks"
11507848|NCT01299259|Experimental|Text Message Reminders|Subjects randomized to the the intervention group will receive a total of 4 text messages on days 2 through 5 to remind them to schedule and attend a PCP follow-up appointment
11507849|NCT01299259|No Intervention|Control Group|The control group will not receive any additional reminders to follow-up with PCP.
11507850|NCT01299246|Experimental|improving self-care|
11507851|NCT01299233||control group|age matched healthy controls
11507852|NCT01299233||Glaucoma|patients with diagnosis of primary open angle glaucoma
11507853|NCT01299207||CAD treated with Xience stents|Patients with CAD who undergo successful stenting with the Xience drug-eluting stent will represent the patient population.
11507854|NCT01299194|Active Comparator|ATORVASTATIN|Atorvastatin 80mg once daily for 3 months, 1.5 month wash out, then Placebo for 3 months
11507855|NCT01299194|Placebo Comparator|PLACEBO|Placebo 3 months, then washout for 1.5 months, then Atorvastatin 80mg once daily
11507856|NCT01299181|Active Comparator|Atorvastatin|Atorvastatin 80mg once daily
11507857|NCT01299181|Placebo Comparator|Placebo|Placebo
11507858|NCT01299168||Kidney Transplant Biopsies for Cause|The study population includes patients with a functioning kidney transplant undergoing a biopsy for clinical indications as standard of care to determine the cause of their graft dysfunction (deterioration in graft function, delayed graft function, proteinuria).
11507859|NCT01299155|Experimental|ReSTOR +3|Bilateral implantation of a ReSTOR +3 Intraocular Lens (IOL) Model SN6AD1
11507860|NCT01299155|Active Comparator|LENTIS MPlus|Bilateral implantation of a LENTIS MPlus Intraocular Lens (IOL) Model
11507861|NCT01299142|Experimental|FGI-101-1A6|Intervention: Drug-FGI-101-1A6
11507863|NCT01299116|Other|Preference SARC|Participants received one of a variety of oral contraceptives or DMPA
11507864|NCT01299116|Experimental|Randomized LARC|"Participants receive one of the following interventions:
~Implanon® or Nexplanon®; ParaGard®; Mirena®"
11507865|NCT01299116|Active Comparator|Randomized SARC|Participants received one of a variety of oral contraceptives or DMPA
11507866|NCT01299103|Active Comparator|Single Treatment|Treatment of facial wrinkle with one treatment only
11507867|NCT01299103|Active Comparator|Double Treatment|Treatment of facial wrinkle with two treatments
11507868|NCT01299103|Active Comparator|Triple treatment|Treatment of facial wrinkle with three treatments
11507869|NCT01299090|Experimental|Treatment Group|All subjects enrolled were in the treatment group.
11507870|NCT01299077||Lumbar disc degenerative disease|Triple therapy (MBL+ MYO+ NSAIDs) which prescribed by doctors (Drs) based on disease condition
11507871|NCT01299064||Buddhist Clergy and Laypersons|
11507872|NCT01299051|Active Comparator|Steps to Health|Steps to Health worksite weight management program at Duke.
11507873|NCT01299051|Experimental|Steps to Health Plus!|Steps to Health Plus! worksite weight management program at Duke. Also known as Pathways to Change.
11507874|NCT01299051|No Intervention|Observational Comparison|Observational comparison group consisting of employees who are eligible for the study but do not take part will also be used in analyses (approximately 1500 subjects).
11507875|NCT01299038|Active Comparator|Group 1|Rosuvastatin 20mg taken orally once a day for 4 weeks
11507876|NCT01299038|Active Comparator|Group 2|Rosuvastatin 40mg taken orally once a day for 4 weeks
11507877|NCT01299025|No Intervention|Control|Participants allocated as controls receive no treatment. They may be physically active as usual.
11507878|NCT01299025|Experimental|Training with Nintendo Wii Fit|Training 6 weeks with Nintendo Wii Fit, 30 minutes 2 times per week
11507879|NCT01298999|Experimental|YF476|YF476 (gastrin-receptor antagonist)
11507880|NCT01298999|Placebo Comparator|Placebo|Placebo pill (identical in appearance to YF476 pills)
11507881|NCT01298986|Active Comparator|Pulmonary Vein Isolation|Patients who have paroxysmal or persistent atrial fibrillation but whose left atrium is < /= 5.0
11507882|NCT01298986|Experimental|Hybrid procedure for patients with a left atrium < /= 5.0 cm|A combined procedure where the cardiac surgeon will place the ablation lesions on top of the heart and the electrophysiologist will place the lesions inside the heart. 3D mapping with be used to guide the procedure. The left atrial appendage will be surgically managed.
11507883|NCT01298986|Active Comparator|Cox Maze Procedure|All lesions of the Cox Maze procedure will be completed as originally described by Dr. James Cox using crypthermia. Patients will be randomized if there left atrium is >5.0 cm but < 6.1 cm and are experiencing paroxysmal or persistent atrial fibrillation
11507884|NCT01298986|Experimental|Hybrid Procedure|A collaborative approach between electrophysiologist and surgeons for patients with a left atrium <5.0 cm and < 6.1 cm where the surgeon will epicardially place the ablation lesions and the electrophysiologist will place the lesion lines endocardially. 3D mapping will be used and the left atrial appendage will be surgically managed.
11507885|NCT01298973|Experimental|Saline|One group will receive Saline to irrigate the wound
11507886|NCT01298973|Experimental|Viscoat|One group will receive Viscoat to close the surgical wound
11507887|NCT01298960|Experimental|rGH Group|
11507888|NCT01298960|No Intervention|Non rGH group|
11507889|NCT01298947|Active Comparator|Laser atherectomy and drug-coated balloon|Laser atherectomy and Paclitaxel-coated balloon angioplasty in treatment of instent lesions of femoropopliteal arteries
11507890|NCT01298947|Active Comparator|Drug eluting Ballon PTA|Paclitaxel-coated balloon angioplasty
11507891|NCT01298934|Experimental|LBH589|Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
11507892|NCT01298921|Active Comparator|Continous Flow Oxygen|
11507893|NCT01298921|Experimental|Oxygen Demand Valve|
11507894|NCT01298908|Other|Operative treatment|vein stripping
11507895|NCT01298908|Other|Laser ablation|Ultrasound guided laser ablation
11507896|NCT01298908|Other|Foam sclerotherapy|Ultrasound guided foam sclerotherapy
11507897|NCT01298895||PEX group|The first group consisted of 47 eyes with cataract complicated with pseudoexfoliation syndrome (PEX).
11507898|NCT01298895||control group|The control group included 177 eyes with uncomplicated cataract in eyes without other ocular pathology
11507899|NCT01298882|Experimental|Diacerein|
11507900|NCT01298882|Placebo Comparator|Placebo|
11507901|NCT01298869||Chronic kidney disease|Chronic kidney disease stage IV and V
11507902|NCT01298856|Active Comparator|hydrotherapy|hydrotherapy and ankle taping and land based exercise
11507903|NCT01298856|Active Comparator|land-based|land-based and ankle taping program
11507904|NCT01298843|Other|Study of Blood Levels of Ceftaroline Fosamil|Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital
11507905|NCT01298830|Experimental|GLP-1 CellBeads|
11507906|NCT01298817|Experimental|Soy, Prepared Meals|Soy-based meal replacement weight loss group with additional meals provided
11507907|NCT01298817|Active Comparator|Non soy prepared meals|Non-soy based meal replacement weight loss group with additional meals provided
11507908|NCT01298804|Experimental|Problem Solving Education|
11507909|NCT01298804|No Intervention|Control|
11507910|NCT01298791|Experimental|Provider sitting|Providers seated during communication through hospitalization
11507911|NCT01298791|Experimental|Provider standing (control)|Providers standing during communication through hospitalization
11507912|NCT01298778|Placebo Comparator|Standard of care|Spinal consists of duramorph 150 mcg combined with fentanyl and bupivacaine in conjunction with placebo capsules 2 PO q 6 hrs x 4 doses in first 24 hrs postop. Ibuprofen given as standard of care.
11507913|NCT01298778|Active Comparator|Acetaminophen and increased dose of Duramorph|Spinal consists of duramorph 300 mcg combined with fentanyl and bupivacaine in conjunction with Acetaminophen 1 Gm PO q 6 hrs x 4 doses in first 24 hrs postop. Ibuprofen given as standard of care.
11507914|NCT01298765|Experimental|BEMA Buprenorphine|buprenorphine buccal soluble film
11507915|NCT01298752|Experimental|Mapracorat|Mapracorat ophthalmic suspension
11507916|NCT01298752|Placebo Comparator|Vehicle|Vehicle of mapracorat ophthalmic suspension
11507917|NCT01298726|Other|PHARMACEUTICAL CARE|
11507918|NCT01298726|Other|HEALTH USUAL CARE|
11507919|NCT01298713|Active Comparator|A|Tamoxifen 20mg/d
11507920|NCT01298713|Experimental|B|Tamoxifen 20mg/d + RAD001 10mg/d
11507921|NCT01298700|Experimental|Bimatoprost 0.01% Ophthalmic Solution|One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
11507922|NCT01298700|Active Comparator|Bimatoprost 0.03% Ophthalmic Solution|One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
11507923|NCT01298687|Experimental|Trav 0.00013%|Travoprost Ophthalmic Solution, 0.00013%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
11507924|NCT01298687|Experimental|Trav 0.00033%|Travoprost Ophthalmic Solution, 0.00033%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
11507925|NCT01298687|Experimental|Trav 0.001%|Travoprost Ophthalmic Solution, 0.001%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
11507926|NCT01298687|Experimental|Trav 0.00267%|Travoprost Ophthalmic Solution, 0.00267%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
11507927|NCT01298687|Active Comparator|TRAVATAN|Travoprost Ophthalmic Solution, 0.004%, 1 drop administered in each eye at 8 pm for 5 days, with 1 drop of vehicle administered at all other timepoints (2-hour intervals)
11507928|NCT01298687|Placebo Comparator|Vehicle|Travoprost vehicle, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
11507929|NCT01298661|Other|Healthy Young Subjects|Subjects apparently healthy, with age of 18 to 27 years old.
11507930|NCT01298661|Other|Healthy Elderly subjects|Subjects apparently healthy, with age of 60 to 75 years old.
11507931|NCT01298661|Other|COPD Patients|Patients with clinical and spirometric diagnosis of COPD
11507932|NCT01298648||Humira|Participants who were prescribed Humira per approved prescribing information of Humira in Japan.
11507933|NCT01298635|Active Comparator|trab|
11507934|NCT01298635|Active Comparator|phacotrab|
11507935|NCT01298622||controls|
11507936|NCT01298622||OCD patients|
11507937|NCT01298622||OCD parents|
11507938|NCT01298609|Active Comparator|Suprathreshold Stimulation|Patients will be stimulated at supra-sensory threshold levels for two weeks using occipital stimulation
11507939|NCT01298609|Sham Comparator|minimal stimulation|Patients will be stimulated at minimal stimulation for two weeks using occipital stimulation
11507940|NCT01298609|Active Comparator|Subthreshold Stimulation|Patients will be stimulated at sub-sensory threshold stimulation for two weeks using occipital stimulation
11507941|NCT01298596|Experimental|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
11507942|NCT01298596|Experimental|Loop Electrosurgical Excision Procedure|Loop Electrosurgical Excision Procedure (LEEP) uses a low-voltage electrified wire loop to cut out diseased part of cervix
11507943|NCT01298583|Experimental|ankle tracking|subjects track a target with ankle movement
11507944|NCT01298583|No Intervention|ankle movement|
11507945|NCT01298570|Active Comparator|Regorafenib + FOLFIRI|regorafenib 160 mg + FOLFIRI
11507946|NCT01298570|Placebo Comparator|Placebo + FOLFIRI|Placebo + FOLFIRI
11507947|NCT01298557||Traumatic brain injured patients|This group consists of participants who suffered a traumatic brain injury an average of 4 months to 4 years prior to testing. Patients must not have history of prior head injury, substance abuse, psychiatric illness, or contraindications to MRI.
11507948|NCT01298557||Controls (no traumatic brain injury)|This group consists of participants who do not have a history of brain trauma. Furthermore, controls must not suffer from substance abuse, psychiatric illness, or have contraindications to the MRI.
11507949|NCT01298544|Other|All subjects|
11507950|NCT01298531|Active Comparator|etanercept|Group A: etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
11507951|NCT01298531|Placebo Comparator|etanercept-placebo|Group B: placebo subcutaneous (SC) injections once weekly for (how many) weeks follwed by etanercept 50 mg SC injections once weekly.
11507952|NCT01298518|Experimental|PF-04620110|
11507953|NCT01298518|Placebo Comparator|placebo|
11507954|NCT01298505|Experimental|PF-03654764 2.5mg plus fexofenadine 60mg|
11507955|NCT01298505|Experimental|PF-03654764 5mg plus fexofenadine 60mg|
11507956|NCT01298505|Placebo Comparator|placebo|
11507957|NCT01298492|Experimental|Open-Label Treatment|Subjects eligible for this study will have completed the 12 week double blind induction period in study A7281006 and will be stratified by responders or non responders based on change in CDAI in that study, without unblinding treatment assignment from study A7281006. Additionally, subjects who have completed study A7281008
11507958|NCT01298479||Group 1|All subjects
11507959|NCT01298466|Experimental|Pregabalin|Open label study. All patients fulfilling the protocol inclusion/exclusion criteria will receive pregabalin in a flexible-dosing regimen.
11507960|NCT01298401|Experimental|Arm A|Dose level -1A (Ganitumab 6 mg/kg, Capecitabine 825mg/m2)
11507961|NCT01298401|Experimental|Arm B|Dose level 1A (Ganitumab 12 mg/kg, Capecitabine 825mg/m2)
11507962|NCT01298401|Experimental|Arm C|Dose level 2A (Ganitumab 20 mg/kg, Capecitabine 825mg/m2)
11507963|NCT01298401|Experimental|Arm D|Dose level -1B (Ganitumab 6 mg/kg, Capecitabine 625mg/m2)
11507964|NCT01298401|Experimental|Arm E|Dose level 1B (Ganitumab 12 mg/kg, Capecitabine 625mg/m2)
11507965|NCT01298401|Experimental|Arm F|Dose level 2B (Ganitumab 20 mg/kg, Capecitabine 625mg/m2)
11507966|NCT01298362||AIs as first line therapy|Patients in postmenopausal status, with ER-positive early breast cancer, treated with an AI as first line therapy for 12 months.
11507967|NCT01298362||AIs after chemotherapy|Patients in postmenopausal status, with ER-positive early breast cancer, treated with an AI as maintenance therapy for 12 months after initial treatment with anthracycline- and/or taxane-based chemotherapy (chemotherapy treatment duration: 1-6 months).
11507968|NCT01298349||schizophrenic patients|
11507969|NCT01298349||normal population|
11507970|NCT01298336|Experimental|Clarithromycin|
11507971|NCT01298336|Experimental|Moxifloxacin|
11507972|NCT01298323|Active Comparator|Vandetanib Control|Control - treatment 300mg vandetanib opel label
11507973|NCT01298323|Experimental|Experimental|Experimental - treatment 300mg vandetanib opel label
11507974|NCT01298310|Active Comparator|Xylocaine_1mg|1 injection of Xylocaine (1 mg/mL)
11507975|NCT01298310|Active Comparator|Xylocaine_10mg|1 injection of Xylocaine (10 mg/mL)
11507976|NCT01298310|Placebo Comparator|Placebo|1 injection of placebo
11507977|NCT01298297|Active Comparator|Buprenorphine + Placebo|
11507978|NCT01298297|Placebo Comparator|Morphine + Placebo|
11507979|NCT01298284|No Intervention|EVL\GVS Alone|Endoscopic ligation treatment in the 2nd prevention of gastroesophageal variceal bleeding in patients with HCC
11507980|NCT01298284|Active Comparator|EVL\GVS Combined Propranolol|"Propranolol and endoscopic ligation treatment is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.
~<EVL\GVS Combined Propranolol>"
11507981|NCT01298271|No Intervention|Cyanoacrylate|Endoscopic Cyanoacrylate Injection treatment of primary prevention GVB
11507982|NCT01298271|Active Comparator|Propranolol|Propranolol is used for primary prevention of GVB
11507983|NCT01298258|Placebo Comparator|placebo|control group
11507984|NCT01298258|Experimental|Aliskiren|Aliskiren 150 mh
11507985|NCT01298245||Case: diabetic retinopathy|Patients with diabetes who have received ophthalmic fundus examination within 6 months before the study and those with known positive results of diabetic retinopathy
11507986|NCT01298245||Control: no diabetic retinopathy|Patients with diabetes who have received ophthalmic fundus examination within 6 months before the study and those without known positive results of diabetic retinopathy
11507987|NCT01298232|No Intervention|EMAT-guided therapy|electromechanical activation time (EMAT, obtain by phonocardiogram, Audicor, USA)
11507988|NCT01298232|No Intervention|Symptomatic-guided therapy|HF therapy guided by clinical symptoms
11507989|NCT01298219|Experimental|Lubiprostone|24 mcg capsules twice daily (BID)
11507990|NCT01298219|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
11507991|NCT01298206||H1N1 not exposed controls|For every enrolled H1N1 case, the study will enroll 2 sex matched controls. On the date of enrollment of a case, 2 sex-matched controls will be located from the same clinic from which the case was enrolled. Enrolled controls will then be verified to be free from influenza infection at the time of enrollment by RT-PCR.
11507992|NCT01298206||H1N1 exposed Cases|A swab will be collected from cases to verify presence of pandemic influenza. Testing positive for influenza A/H1N1 by RT PCR to be enrolled will be confirmed as a case. The participant will be presented with a questionnaire that will capture exposure data through a group of variables assessing underlying health conditions, symptoms, use of influenza vaccine, travel, occupational setting, and other demographic variables. Cases will be contacted once during the study.
11507993|NCT01298193|Experimental|Aprepitant|"Observational phase (first cycle):
~Day 0 (Dexamethasone 8mg) Day 1 (5-HT3 antagonist, Ondansetron: 8 mg x2, Granisetron: 1mg x2,Tropisetron: 5 mg, Dexamethasone 24 mg) + Chemotherapy (Docetaxel 75mg/m2 and Cyclophosphamide 600mg/m2 ).
~Days 2 and 3 (Dexamethasone 16 mg).
~If not complete response:
~Efficacy phase (second cycle):
~Day 0 (Dexamethasone 8mg) Day 1 (Aprepitant: 125 mg,5-HT3 antagonist, Ondansetron: 8 mg x2, Granisetron: 1mg x2, Tropisetron: 5 mg, Dexamethasone 12 mg)+ Chemotherapy: Docetaxel 75mg/m2 and Cyclophosphamide 600mg/m2 .
~Days 2 and 3 (Aprepitant: 1 capsule of 80 mg daily, Dexamethasone 8 mg)."
11507994|NCT01298180|Experimental|SPW|Children presenting a Prader-Willi Syndrome
11507995|NCT01298180|Experimental|GHD|Patient deficient in Growth Hormone
11507996|NCT01298180|Experimental|SPW-B|Patient with Prader-Willi Syndrome who has Biopsy
11507997|NCT01298180|Experimental|T|Patient Control
11507998|NCT01298180|Experimental|SPW-GH-B|Patient with Prader-Willi Syndrome taking growth Hormone and who has biopsy
11507999|NCT01298167|Active Comparator|Cyanoacrylate Superior/Inferior|This arm contains data from only the Cyanoacrylate used on superior ½ of wounds & inferior ½ of wounds in randomized patients to determine the impact of Cyanoacrylate tissue glue versus Fast Absorbing Gut suture.
11508000|NCT01298167|Active Comparator|Fast Absorbing Gut Suture Superior/Inferior|This arm contains data from only the Fast Absorbing Gut Suture used on superior ½ of wounds & inferior ½ of wounds in randomized patients to determine the impact of Cyanoacrylate tissue glue versus Fast absorbing gut suture.
11508001|NCT01298154|Experimental|Intact Pea Protein (20 g)|
11508002|NCT01298154|Experimental|Hydrolyzed Pea Protein (20 g)|
11508003|NCT01298154|Experimental|Intact Whey Protein|
11508004|NCT01298154|Experimental|Hydrolyzed Whey Protein|
11508005|NCT01298154|Experimental|Water|
11508006|NCT01298141|Experimental|Replagal®|All eligible patients may receive Replagal produced by the bioreactor process (AF Replagal) on this treatment plan until AF Replagal is commercially available for the patient, the patient's participation is discontinued, or the study is discontinued, whichever comes first.
11508007|NCT01298128|Experimental|NuvaRing|NuvaRing for IVF pre-treatment
11508008|NCT01298128|Active Comparator|Combined oral contraceptive pill|OCP for IVF pre-treatment
11508009|NCT01298115||Stage 5 chronic kidney disease|Incident patients commencing renal replacement therapy or conservative care
11508010|NCT01298102|Experimental|influenza vaccine|Pandemrix vaccine (Influenza A/H1N1 2009)to be injected to renal transplant patients, haemodialyzed patients, and controls
11508011|NCT01298076|Active Comparator|AVASTIN|intravitreal bevacizumab
11508012|NCT01298076|Active Comparator|OZURDEX|intravitreal dexamethasone
11508013|NCT01298063|Experimental|Afatinib Group A, B (2), D|healthy subjects, mild and moderate liver impaired subjects to receive one single dose treatment containing the highest dose afatinib
11508014|NCT01298063|Experimental|Afatinib Group B (3), D|healthy subjects, moderate liver impaired subjects to receive one single dose treatment containing the medium dose of afatinib
11508015|NCT01298063|Experimental|Afatinib Group B (1), D|healthy subjects, moderate liver impaired subjects to receive one single dose treatment containing the low dose of afatinib
11508016|NCT01298050||Extracorporeal Membrane Oxygenation|All patients have to start ECMO under CPR, by insertion of peripheral VA cannulas.
11508017|NCT01298024|Experimental|Early neuromusclar exercise|
11508018|NCT01298024|Active Comparator|Treatment as usual (late training)|
11508019|NCT01298011|Experimental|Gemcitabine & Abraxane Pancreatic Cancer|
11508021|NCT01297985|Experimental|BRIDGES Intervention|The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses. For this intervention study, the BRIDGES curriculum was modified from a 10-week course to an 8-week course, meeting for 2 1/2 hours once a week.
11508022|NCT01297985|No Intervention|Comparison Wait-list Group|Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend the BRIDGES program after their final research interview.
11508023|NCT01297959|Experimental|E-101 Solution 300 GU/mL|
11508024|NCT01297959|Placebo Comparator|Saline solution|
11508025|NCT01297946|Placebo Comparator|Open-loop|Conventional continuous subcutaneous insulin infusion (CSII) therapy
11508026|NCT01297946|Experimental|Dual-hormone closed-loop|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. The infusion rates are based on continuous glucose sensor reading and a control algorithm.
11508027|NCT01297920|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 3 times a day for 3 months
11508028|NCT01297920|Active Comparator|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, 1 drop instilled in each eye 3 times a day for 3 months
11508029|NCT01297920|Active Comparator|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, 1 drop instilled in each eye 3 times a day for 3 months
11508030|NCT01297907||Crohn's Patients|Random Crohn's Disease Patients that can perform Methacholine Challenge Test (MCT)
11508031|NCT01297907||Negative MCT|Patients evaluated for functional cough who had negative Methacholine Challenge Test (MCT)
11508032|NCT01297894|Active Comparator|colistin|Colistimethate sodium 2.5-5mg/kg iv
11508033|NCT01297894|Active Comparator|colistin plus fosfomycin|colistimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
11508034|NCT01297881||Caucasian outpatients with respiratory symptoms|all consecutive new Caucasian outpatients with respiratory symptoms like dyspnoea, cough, sputum but without diagnosis who are being examined for the first time.
11508035|NCT01297868||exercise group|
11508036|NCT01297855|Active Comparator|Colistin|Colistate
11508037|NCT01297855|Experimental|Colistin plus Rifampicin|Colistate Rifampin
11508038|NCT01297842|Experimental|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
11508039|NCT01297842|Active Comparator|Meropenem or Imipenem|Meropenem or Imipenem o.5 or 1 gram 3 to 4 times a day for 7 to 14 days
11508040|NCT01297829|Active Comparator|IV Caldolor|
11508041|NCT01297829|Placebo Comparator|Placebo|
11508042|NCT01297816|Placebo Comparator|placebo|100mg-
11508043|NCT01297816|Placebo Comparator|minocyclin|
11508044|NCT01297803|Active Comparator|Mitomycin_c application before sclera flap dissection|
11508045|NCT01297803|Active Comparator|Mitomycin_c application after sclera flapdissection|
11508046|NCT01297790||Asthma|Subjects with asthma more than 18 years old with minimal or no smoking history and evidence of bronchial hyperreactivity
11508047|NCT01297790||Chronic obstructive pulmonary disease|Subjects with diagnosis of COPD who must be ex smokers and have evidence of airflow obstruction on breathing tests.
11508048|NCT01297790||Healthy Volunteers|Healthy non smoking adults.
11508049|NCT01297790||Healthy smokers|Current smokers with normal breath tests (spirometry)
11508050|NCT01297790||Chronic cough|Subjects with idiopathic chronic cough.
11508051|NCT01297777|Experimental|Imatinib mesylate|Imatinib mesylate 300 or 400 mg daily for 12 months.
11508052|NCT01297764|Experimental|carfilzomib for MML|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone - This study will be conducted as an open-label Phase I/II, single-center study in which subjects will receive carfilzomib, lenalidomide, vorinostat and dexamethasone, for relapsed and/or refractory multiple myeloma. Study treatment will be administered in sequential cohorts, with 3-6 subjects in each cohort. Treatment will be administered in 28-day cycles, with the fourth week as a rest week, for 12 cycles or until disease progression or unacceptable toxicity develops.
11508053|NCT01297738|Experimental|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a liquid meal which is high in fat and sugar (Nutridrink®)
11508054|NCT01297738|Experimental|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume this caloric surplus with their meals, which results in an increase in meal size.
11508055|NCT01297738|Experimental|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a liquid meal which has a high fat and sugar content(Nutridrink®). Subjects consume the Nutridrink 3 times a day in between meals. which results in an increase in meal frequency.
11508056|NCT01297738|Experimental|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
11508057|NCT01297738|No Intervention|Control group|Subjects will not follow any diet but their own ad-libitum, healty diet.
11508058|NCT01297725|Experimental|Right sharp, left blunt|Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
11508059|NCT01297725|Experimental|Right blunt, left sharp|Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.
11508060|NCT01297712|Active Comparator|Hi Line|This arm is examined with latest generation HDTV colonoscopes
11508061|NCT01297712|No Intervention|Classic Line|control group undergoing colonoscopy with older generation scope currently in use in most centers
11508062|NCT01297699|Experimental|Tocilizumab|
11508063|NCT01297699|Placebo Comparator|Sterile 0.9% Sodium Chloride|
11508064|NCT01297686|Experimental|Exercise|Multi-element exercise protocol involving static and dynamic stretches, deep massage, and balance training.
11508065|NCT01297686|Active Comparator|Standard of Care|This arm will consist of a single injection of a corticosteroid, followed by stretching exercises for the calf.
11508066|NCT01297673||Spinal cord injury|Patients with neurogenic lower urinary tract dysfunction due to spinal cord injury with regular urodynamic examination
11508067|NCT01297660||patients with SCI for at least 5 years|Ages Eligibility: minimum 18 years Genders Eligibility: female and male
11508068|NCT01297647|Experimental|Spinal cord injured|Patients with neurogenic lower urinary tract infection (Spinal Cord Injury,MS,M. Parkinson)
11508069|NCT01297634|Other|Botulinum Toxin Type-A 1U|
11508070|NCT01297634|Other|Botulinum Toxin Type-A 2U|
11508071|NCT01297634|Other|Botulinum Toxin Type-A 3U|
11508072|NCT01297621|Experimental|Breast reduction|Breast hypertrophy women allocated to this arm will undergo reduction mammaplasty
11508073|NCT01297621|Other|Control|Patients in this arm will be assessed twice, without surgical intervention
11508074|NCT01297608|Experimental|treatment|
11508075|NCT01297608|Placebo Comparator|placebo|
11508076|NCT01297595|Experimental|crizotinib|
11508077|NCT01297582|Experimental|E|
11508078|NCT01297582|Placebo Comparator|P|
11508079|NCT01297569|Experimental|Ranibizumab|
11508080|NCT01297556|No Intervention|Control group|Patients in this group will receive conventional treatment for IBS, including anti-diarrhea agents, laxatives, bulking agents and anti-spasmodic.
11508081|NCT01297556|Experimental|Treatment|Patients in this group will receive conventional treatment for IBS, but in addition will receive 6 weeks of CBT
11508082|NCT01297543|Experimental|Consolidation Group A|Low dose CLT-008 (human myeloid progenitor cells)
11508083|NCT01297543|Experimental|Consolidation Group B|Intermediate dose CLT-008 (human myeloid progenitor cells)
11508084|NCT01297543|Experimental|Consolidation Group C|Intermediate dose CLT-008 (human myeloid progenitor cells), no G-CSF
11508085|NCT01297543|Experimental|Consolidation Group D|High dose CLT-008 (human myeloid progenitor cells)
11508086|NCT01297543|Active Comparator|Induction Group A1 (cytarabine 7+3)|G-CSF
11508087|NCT01297543|Experimental|Induction Group A2 (cytarabine 7+3)|Intermediate dose CLT-008 (human myeloid progenitor cells)
11508088|NCT01297543|Experimental|Induction Group A3 (cytarabine 7+3)|High dose CLT-008 (human myeloid progenitor cells)
11508089|NCT01297543|Active Comparator|Induction Group B1 (cytarabine HIDAC)|G-CSF
11508090|NCT01297543|Experimental|Induction Group B2 (cytarabine HIDAC)|Intermediate dose CLT-008 (human myeloid progenitor cells)
11508091|NCT01297543|Experimental|Induction Group B3 (cytarabine HIDAC)|High dose CLT-008 (human myeloid progenitor cells)
11508092|NCT01297530|Experimental|Arm 1|
11508093|NCT01297517|Experimental|Brinzolamide/Brimonidine|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, one drop instilled in each eye three times a day for 3 months
11508094|NCT01297517|Active Comparator|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, one drop instilled in each eye three times a day for 3 months
11508095|NCT01297517|Active Comparator|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, one drop instilled in each eye three times a day for 3 months
11508096|NCT01297504||Palivizumab|Infants at risk for respiratory syncytial virus infection received palivizumab prescribed in accordance with the terms of the local marketing authorization.
11508097|NCT01297491|Experimental|Squamous BKM120 100mg qd|Diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease.
11508098|NCT01297491|Experimental|Non-Squamous BKM120 100mg qd|Diagnosed patients with non-squamous NSCLC that progressed after one or two prior antineoplastic therapy lines for metastatic disease.
11508099|NCT01297465|Active Comparator|Gonal-f® Plus Pergoveris®|
11508100|NCT01297465|Experimental|Pergoveris®|
11508101|NCT01297452|Experimental|BKM120 (days 1 - 21) + paclitaxel + carboplatin|This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered with paclitaxel + carboplatin on both a 21-day cycle with growth factor support (Group 1)
11508102|NCT01297452|Experimental|BKM120 (days 1 - 28, ) + paclitaxel + carboplatin|This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered + paclitaxel with carboplatin on a 28-day cycle with growth factor support and a 28-day cycle (Group 2).
11508103|NCT01297452|Experimental|BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)|EXPANSION COHORT A BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT A.
11508104|NCT01297452|Experimental|BKM120 (days 1 - 21) + paclitaxel + carboplatin exp B|Expansion Cohort B will be restricted to patients with tumors known to harbor PTEN mutation or homozygous deletion. The regimen in Expansion Cohort B will be the same regimen established in Group 1 of the protocol, with BKM120 (now called buparlisib) at 100 mg/day per oral + paclitaxel (175 mg/m2) + carboplatin (AUC 5), both given intravenously (IV) on day 1 of a 21-day cycle
11508105|NCT01297439|Other|group M|"Normal delivery without pushing maneuver suctioning of fetal nose and mouth during delivery"
11508106|NCT01297439|Experimental|group C|"Pushing maneuver on the fetal head"
11508107|NCT01297426||Group 1|Lean and obese, diabetic and non diabetics
11508108|NCT01297413|Experimental|Stem cells|All subjects will receive allogeneic adult mesenchymal bone marrow stem cells
11508109|NCT01297400|Experimental|Investigational Drug, MW-III|Investigational Drug, MW-III
11508110|NCT01297400|Active Comparator|Standard of care|Silvadene® Cream 1% [Silver Sulfadiazine]
11508111|NCT01297387||Revascularization of limb ischemia|Procedure/Surgery
11508112|NCT01297374|Experimental|dietetic counseling|
11508113|NCT01297374|Experimental|physical activities|
11508114|NCT01297374|Experimental|Lifestyle counseling|
11508115|NCT01297361|Other|Plasma Vitamin B12 and Folic acid levels|Blood sample was drawn
11508116|NCT01297348||Lybrel®|Current users of 90 ug levonorgestrel / 20 ug ethinyl estradiol - cases and controls (i.e., women diagnosed with new venus thromboembolism [VTE] and women not diagnosed with VTE).
11508169|NCT01296932|Experimental|Patients with relapsed CLL|Patients with relapsed CLL after at least two prior treatment regimens will receive BI 836826.
11508117|NCT01297348||Other OCs containing 20μg of ethinyl estradiol|Current users of oral contraceptives containing 20μg of ethinyl estradiol - cases and controls (i.e. women diagnosed with new VTE and women not diagnosed with VTE)
11508118|NCT01297335|Experimental|Intrathecal Clonidine|Subject will receive one time Clonidine injection via lower lumber interspace. Clonidine (Duraclon), 100 μg/ml, 1.5 ml will be diluted to 2 ml with preservative free saline, and total of 150 μg will be delivered. Supine and sitting blood pressures and heart rate will be measured at 10 minute intervals until 60 minutes after clonidine administration, then at 15 minutes for next 3 hours.
11508119|NCT01297322|Active Comparator|Manual compression|Using manual compression to reach hemostasis
11508120|NCT01297322|Experimental|VASCADE™ Vascular Closure System|The Cardiva VASCADETM Vascular Closure System (VCS) is indicated for the percutaneous closure of common femoral artery access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular catheterization procedures utilizing 6 Fr or 7 Fr procedural sheaths.
11508121|NCT01297309|Experimental|NPSP558|titration of 25, 50, 75 or 100 μg
11508122|NCT01297283|Experimental|Leadless ECG first|Measurement of pacing thresholds are done first with the support of a leadless ECG provided by the implanted device
11508123|NCT01297283|Active Comparator|Programmer ECG first|Measurements of pacing thresholds are done first with the support of the programmer ECG
11508124|NCT01297270|Active Comparator|PegIFN/RBV|48 weeks
11508125|NCT01297270|Experimental|BI 201335 for 24 weeks|BI 201 335 QD dosing in combination with IFN/RBV
11508126|NCT01297270|Experimental|BI201335 for 12 weeks|BI 201335 QD doing in combination with PEFG IFN/RBV
11508127|NCT01297270|Placebo Comparator|Placebo|
11508128|NCT01297244|Experimental|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
11508129|NCT01297231||Breast cancer|This prospective study will recruit patients with stage 0-3 breast cancer who have had or are scheduled for a breast MRI prior to treatment.
11508130|NCT01297218|Experimental|NEUROSTEM®-AD|
11508131|NCT01297205|Experimental|PNEUMOSTEM®|
11508132|NCT01297192|Other|Treatment Arm 1|The effect of mirabegron on the pharmacokinetics of solifenacin
11508133|NCT01297192|Other|Treatment Arm 2|The effect of solifenacin on the pharmacokinetics of mirabegron
11508134|NCT01297166|Experimental|LEO 27989 ointment|
11508135|NCT01297153|Active Comparator|Aphakia|"The patient is randomly assigned for aphakia / pseudophakia. This is done only after vitrectomy. If it is aphakia,IOL will not be implanted.Aphakia will be corrected with aphakic glasses / contact lenses. Bilateral aphakes are given both contact lenses and glasses. So when they do not wear contact lenses they can put on aphakic glasses. Unilateral aphakes are given only contact lenses. Contact lenses should be fitted in the eye in OT immediately after the operation.
~Aphakic glasses :
~Prescribed within 2 weeks of surgery for both eyes."
11508136|NCT01297153|Active Comparator|Pseudophakia|The patient is randomly assigned for aphakia / pseudophakia. This is done only after vitrectomy. Hydrophobic Acrysof IOL is implanted.All pseudophakic children will be refracted and given the residual correction within a month of surgery.
11508137|NCT01297140|Experimental|questionary|
11508138|NCT01297127||Cohort|
11508139|NCT01297114||Participants aged 60-70|Participants age 60-70 will receive Florbetaben PET tracer to identify presence of amyloid burden.
11508140|NCT01297114||Participants aged 20-30|Younger participants will not undergo PET scanning that will be studied with other methods.
11508141|NCT01297088|Experimental|Arm 1|
11508142|NCT01297075|Experimental|Outreach visits|Practices allocated to outreach visits may receive up to three outreach visits in order to motivate and support general practice clinics in implementing two chronic care programmes for chronic obstructive Pulmonary disease and Type 2 diabetes.
11508143|NCT01297075|No Intervention|Control (late intervention)|These practices are allocated to outreach visits after the initial evaluation stops at 12 months.
11508144|NCT01297062|Experimental|Exenatide|
11508145|NCT01297062|Placebo Comparator|Placebo|
11508146|NCT01297062|Active Comparator|Moxifloxacin|
11508147|NCT01297049|Experimental|Lifestyle counseling|
11508148|NCT01297036|Active Comparator|Reference arm|Treated with Reference (Aricept, 10 mg donepezil tablet)
11508149|NCT01297036|Experimental|Test arm|Treated with Test (Neuropezil, 10 donepezil ODT, orally disintegrating tablet)
11508150|NCT01297023|Experimental|calcium phosphate|
11508151|NCT01297023|Experimental|vitamin d|
11508152|NCT01297023|Experimental|calcium phosphate and vitamin d|
11508153|NCT01297023|Placebo Comparator|placebo|
11508154|NCT01297010|Placebo Comparator|Dexamethasone|Children randomized to this group received a 10 ml syringe containing dexamethasone (0.15 mg / kg) at the beginning of the procedure.
11508155|NCT01297010|Placebo Comparator|Dexamethasone and ondasetron|Children randomized to this group received a 10 ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling) and ondansetron (0.1 mg / kg dose of 4mg ceiling)at the beginning of the procedure.
11508156|NCT01296997|Experimental|calcium phosphate|
11508157|NCT01296997|Placebo Comparator|placebo|
11508158|NCT01296984||Extralevator APR|The perineal part of the APR is done with the intent to create a cylindrically shaped specimen thus removing part of or the entire levator muscle with the specimen.
11508159|NCT01296984||Traditional APR|The perineal part of the APR is performed with the intent to remove the tumour with CRM free of tumour and the levator left in place.
11508160|NCT01296971|Experimental|A|genotype 1, treatment-naive
11508161|NCT01296971|Experimental|B|genotype 2 and 3, treatment-naive
11508162|NCT01296971|Experimental|C|all genotypes, non-responders or relapses
11508163|NCT01296958|Experimental|Targeted screening|Screening for intestinal tapeworm carrier followed by treatment with niclosamide as indicated.
11508164|NCT01296958|Active Comparator|Education|Community education about Taenia solium prevention.
11508165|NCT01296945|Active Comparator|Kiosk|
11508166|NCT01296945|Active Comparator|Paper|
11508167|NCT01296945|Active Comparator|Kiosk PLUS paper|
11508168|NCT01296945|Active Comparator|kiosk PLUS web|
11510268|NCT01282047|Experimental|Lenalidomide|
11508170|NCT01296919||Sinus drainage|Adult patients with chronic rhinosinusitis who failed treatment with antibiotics and topical corticosteroids and underwent endoscopic sinus surgery. Preoperative evaluation included paranasal sinus CT scans. The diagnosis was confirmed by endoscopic examination showing purulent and/or mucopurulent discharge in the middle and/or superior meatus.
11508171|NCT01296906|Experimental|Population-based Reminder/Recall|Recall is performed centrally by public health departments for all children in need of immunizations in a geographic area.
11508172|NCT01296906|Experimental|Practice-based Reminder/Recall|Reminder/Recall is performed by individual private practices for their patients who appear in need of immunizations.
11508173|NCT01296893|No Intervention|Delayed exercise control|Participants asked to maintain usual lifestyle and provided with abbreviated version of intervention upon completion of end of study testing.
11508174|NCT01296893|Experimental|Exercise|Aerobic exercise Intervention as per below
11508175|NCT01296880||LCM group|Patients who are having lacosamide (LCM) added to their anti-epileptic drug regimen
11508176|NCT01296880||control group|Patients who are NOT having lacosamide (LCM) added to their anti-epileptic drug regimen
11508177|NCT01296854|No Intervention|Standard|The patients randomized into this arm of the study will not have spa therapy.
11508178|NCT01296854|Experimental|Spa Therapy|The patients randomized into this arm of the study will have 3 weeks of spa therapy
11508179|NCT01296841|No Intervention|Standard encounter|"Standard in-house clinical visit between patient and physician."
11508180|NCT01296841|Experimental|Telemedicine Encounter|Remote clinical appointment between patient and physician.
11508181|NCT01296828||MOUTH BREATHING CHILDREN|
11508182|NCT01296815|No Intervention|HAART|Patients received antiretroviral treatment according to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
11508183|NCT01296815|Experimental|HAART+ Bevacizumab injection|Patients received antiretroviral treatment according to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Patients received 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) in the target lesion every 2 weeks. Bevacizumab was injected using an insulin syringe in a submucosal plane. The volume injected was based on the size of the target lesion; the dose was 0.2 mL (5 mg) per cm2.
11508184|NCT01296802|Placebo Comparator|Placebo|
11508185|NCT01296802|Experimental|Dexfenfluramine|Dexfenfluramine HCL
11508186|NCT01296789|Active Comparator|Tissue perfusion guided protocol|Active comparator group, where parameters of tissue perfusion are used to guide hemodynamic therapy
11508187|NCT01296789|Other|Usual Care|Usual Care
11508188|NCT01296776|Active Comparator|whole-body electromyostimulation|20 min of whole-body electromyostimulation with sequences of 6 sec of current and 4 sec at 85 Hz performed during low-intensity/low amplitude movements. 3 sessions / 14 days for 12 months
11508189|NCT01296776|Placebo Comparator|wellness control group|Low intensity, low frequency exercise that focus on well being. 1 session/week for 10 weeks. 10 blocks of exercise with intermittent periods of 100 weeks of rest
11508190|NCT01296763|Experimental|Irinotecan, Cisplatin, Olaparib, then add Mitomycin-C|A 3+3 dose escalation design will be used starting with dose 1. The maximally tolerated dose is defined as the highest dose for which at most 1 out of 6 patients experiences a DLT. We will use 3 patients per dose cohort. If 0 of 3 patients have a DLT (see section 5a) then the escalation will be continued at the next dose level. If 1 of 3 patients have a DLT then three more patients will be enrolled at this dose. If 1 of 6 patients has a DLT then the dose escalation will continue. If 2 or more of the first 3 patients, or >2 of 6 patients treated have a DLT at the dose level, we will reduce the dose to the previous dose level of Olaparib for the phase 2 and then test Mitomycin C (phase 1 dose 5). If DLTs are observed at our dose 1 regimen, we will reduce the duration of Olaparib from day 1 and day 8 to just day 1 (dose level -1) and we will not test Mitomycin C in the trial.
11508191|NCT01296750|Active Comparator|Early Physiotherapy|Physiotherapy to begin within 1 day post op.
11508192|NCT01296750|No Intervention|Late Physiotherapy|Physiotherapy to start 6 weeks post op
11508193|NCT01296724|Other|newborn with digestive pathology|Preterm or term newborn admitted in paediatric intensive care unit with an urethral catheter and digestive pathology
11508194|NCT01296724|Other|Newborn without digestive pathology|Preterm or term newborn admitted in paediatric intensive care unit with an urethral catheter and without digestive pathology
11508195|NCT01296711|Experimental|CDP6038|
11508196|NCT01296698|Placebo Comparator|Placebo|0 mg Oral NRT, up to 4 times per hour for 12 weeks
11508197|NCT01296698|Experimental|Nicotine|1 mg Oral NRT, up to 4 times per hour for 12 weeks
11508198|NCT01296685||oxygenator with arterial filter|
11508199|NCT01296685||arterial filter|
11508200|NCT01296672|Experimental|Finasteride|Finasteride 5mg tablets every day by mouth for 3 months
11508201|NCT01296672|Placebo Comparator|Placebo|Placebo 5mg tablet every day by mouth for 3 months
11508202|NCT01296659|Experimental|AIM Arm|Ridaforolimus combined with doxorubicin/ifosfamide/mesma (AIM)
11508203|NCT01296659|Experimental|TG Arm|Ridaforolimus combined with docetaxel and gemcitabine (TG)
11508204|NCT01296646|Active Comparator|Arm 1|Sweet Liker, High Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions
11508205|NCT01296646|Active Comparator|Arm 2|Sweet Liker - Low Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions
11508206|NCT01296646|Active Comparator|Arm 3|Sweet Disliker - High Craver. Half of this group will be on naltrexone the other half will be on Placebo. All subjects will receive Brenda Therapy Sessions
11508207|NCT01296646|Active Comparator|Arm 4|Sweet Disliker - Low Craver; half of this group will be on naltrexone the other half on placebo. All subjects will receive Brenda Therapy Sessions
11508236|NCT01296490|Experimental|Stress test|The men will run on a treadmill for 10 minutes until exhaustion. Blood will be drawn before, 5 minutes after and an hour after the test.
11508237|NCT01296477||Asthma IQ Primary Care Tool|
11508238|NCT01296477||Usual Asthma Care in Primary Care|
11508239|NCT01296464|Experimental|Stalevo|levodopa/carbidopa/entacapone
11508240|NCT01296464|Placebo Comparator|Placebo|
11508704|NCT01293084|Placebo Comparator|0.12% saline|5mL 0.12% saline inhaled once during 20 minutes
11508208|NCT01296633|Experimental|Medtable|The Medtable is a patient education tool used for collaborative planning. The Medtable focuses patients on how to take their medication and prompts them to anchor this task to familiar routines. The tool serves as an external workspace that helps provider and patient jointly visualize how to integrate constraints from medications (e.g., which can be taken together; dose spacing) and patients' routine (e.g., typical meal times) in order to create an optimal daily schedule. The completed Medtable shows providers how patients are thinking about taking their medications, allowing them to clear up any confusion. It encourages teach-back and teach-to-goal strategies recommended for patients with low health literacy. Completing the Medtable helps patients implement as well as create plans by encouraging them to think about when and where they will actually take their medication. It also provides a template developed with their providers that could help patients load pill organizers at home.
11508209|NCT01296633|Active Comparator|Usual care|Patients in the usual care condition at both research sites will receive the medication counseling and communication that is standard of care at these sites. This includes a medication reconciliation process, where patients are given a card with list of medications that is periodically checked. This provides an opportunity for providers to correct patient knowledge of their medications, and is similar to the process of creating a list for the Medtable. However, the Medtable also encourages patients and providers to collaborate in order to organize this list in terms of the patient's routine to create a patient-specific, concrete plan for taking the medications.
11508210|NCT01296620|Experimental|Experimental 1|
11508211|NCT01296620|Experimental|Experimental 2|
11508212|NCT01296620|Placebo Comparator|Placebo|
11508213|NCT01296607|Other|Urocortin 2|This arm studies the onset/ offset of action and the reproducibility of effect on forearm blood flow of of intra-arterial Urocortin 2 in the presence and absence of a saline washout between incremental doses.
11508214|NCT01296607|Other|Urocortin 3|This arm studies the onset/ offset of action and the reproducibility of effect on forearm blood flow of of intra-arterial Urocortin 3 in the presence and absence of a saline washout between incremental doses.
11508215|NCT01296594|Active Comparator|Usual Care|
11508216|NCT01296594|Experimental|usual care with cell phone monitoring and CM|In the CM condition, patients will carry a cell phone and record and send in time- and date-stamped self videos of medication ingestion.
11508217|NCT01296581|Experimental|X-82|
11508218|NCT01296568|Experimental|LY2603618|"Single 250 milligram (mg) intravenous dose of LY2603618 containing carbon-14-labeled LY2603618 ([^14C]LY2603618).
~After the completion of a minimum 7-day washout period, participants may receive additional doses of LY2603618 in combination as follows:
~Gemcitabine 1000 milligrams per square meter (mg/m^2) on Days 1, 8, and 15 with 230 mg LY2603618 being administered on Days 2, 9 and 16 of a 28-day cycle OR
~Pemetrexed 500 mg/m^2 on Day 1 and 275 mg LY2603618 on Day 2 of a 21-day cycle
~Participants will be allowed to continue to receive the combination therapy until fulfilling one of the criteria for discontinuation, such as unacceptable toxicity or disease progression."
11508219|NCT01296555|Experimental|Phase I, Stage 1: GDC-0032 as Single Agent|Participants with locally advanced or metastatic solid tumors will receive increasing doses of GDC-0032 administered orally daily in 28-day cycles. Dose escalation decisions will be based upon the observed incidence of DLTs.
11508220|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 + Fulvestrant|Participants (Cohorts F, J, K, L, and M) will receive GDC-0032 in combination with fulvestrant until disease progression.
11508221|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 + Letrozole|Participants (Cohorts E, N, P, Q, R, and S) will receive GDC-0032 in combination with letrozole until disease progression.
11508222|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 as Single Agent|Participants (Cohorts A, B, C, D, G, H, T, T2, and X) will receive GDC-0032 until disease progression.
11508223|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 + Midazolam|Participants (Cohort C) will receive GDC-0032 in combination with midazolam.
11508224|NCT01296555|Experimental|Phase II: GDC-0032 + Fulvestrant|Post-menopausal females with locally advanced or metastatic HER2-negative, hormone receptor-positive breast cancer will receive GDC-0032 in combination with fulvestrant until disease progression.
11508225|NCT01296542||VIGAMOX|Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection
11508226|NCT01296542||Besivance|Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection
11508227|NCT01296529||HIV monoinfection|Evidence should include a copy of a laboratory report of testing positive for HIV antibodies and/or HIV viral RNA, and a negative antibody test for HCV
11508228|NCT01296529||HCV monoinfection|Evidence should include a copy of a laboratory report of testing positive for HCV antibodies and HCV viral RNA, and a negative antibody test for HIV
11508229|NCT01296529||HIV and HCV coinfection|Evidence should include a copy of a laboratory report of testing positive for HIV or HIV viral RNA, and positive tests for HCV antibodies and HCV RNA.
11508230|NCT01296529||HIV/HCV coinfection with HCV clearance|Evidence should include a copy of a laboratory report of testing positive for HIV or HIV viral RNA, a positive tests for HCV antibodies, and undetectable HCV RNA without hepatitis C treatment (spontaneous clearance) or >6 months after hepatitis therapy (sustained virologic response)
11508231|NCT01296516|Placebo Comparator|Control Group|A group matched for age and BMI will be selected to serve as control subjects in this study.
11508232|NCT01296516|Active Comparator|Face-to-face group|Participants randomized to the face-to-face intervention will attend motivational meetings held once per week in Phase I and biweekly in Phase II. Behavioral sessions will be led by a trained interventionist and will take place at Pennington Biomedical Research Center.
11508233|NCT01296516|Active Comparator|Telehealth Group|Participants randomized to the Telehealth intervention will receive behavioral counseling through Trestletree, phone system.
11508234|NCT01296503|Active Comparator|Dexamethasone (Arm A)|Sixty days (D+60) after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days)
11508235|NCT01296503|Experimental|Thalidomide and Dexamethasone (Arm B)|"D+60 after ASCT: dexamethasone plus thalidomide 200 mg by mouth daily for 12 months or until disease progression.
~The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event."
11508241|NCT01296451|Experimental|Arm A, group1|Intervention: MVA-NSmut. Administration schedule: 1 dose MVA-NSmut 2 x 10^8 pfu. Subjects: 4 healthy volunteers
11508242|NCT01296451|Experimental|Arm A, group 2|"Interventions: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.
~Subjects: 10 healthy volunteers"
11508243|NCT01296451|Experimental|Arm B, group 1|"Interventions: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 14 and 1 dose MVA-NSmut 2 x 10^8pfu at week 22, after starting PEG-IFN and ribavirin therapy.
~Subjects: 5 patients"
11508244|NCT01296451|Experimental|Arm B, group 2|"Interventions: AdCh3NSmut; MVA-NSmut.. Administration schedule: 1 dose AdCh3NSmut 2.5 x 1010vp at week 2 and 1 dose MVA-NSmut 2 x 108pfu at week 10, after starting PEG-IFN and ribavirin therapy.
~Subjects: 5 patients"
11508245|NCT01296451|Experimental|Arm C, group 1|"Interventions: AdCh3NSmut; MVA-NSmut Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 0 and 1 dose MVA-NSmut 2 x 10^8pfu at week 8.
~Subjects: 4 patients"
11508246|NCT01296451|Experimental|Arm A, group 3|"Interventions: AdCh3NSmut; MVA-NSmut Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 0, 1 dose MVA-NSmut 2 x 10^8pfu at week 8, 1 dose AdCh3NSmut 2.5 x 10^10vp at week 16 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 24.
~Subjects: 5 healthy volunteers"
11508247|NCT01296451|Experimental|Arm A, group 4|"Intervention: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp (at least 6 months after they were initially enrolled) and 1 dose MVA-NSmut 2 x 10^8 pfu 8 weeks later.
~Subjects: up to 5 healthy volunteers who were previously in group A2"
11508248|NCT01296451|Experimental|Experimental: Arm A, group5|"Intervention: AdCh3NSmut1. MVA-NSmut. Administration schedule:1 dose AdCh3NSmut1 2.5 x 10^10vp at week 0, 1 dose MVA-NSmut 2 x 10^8 pfu at week 8 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 40.
~Subjects: 5 healthy volunteers"
11508249|NCT01296451|Experimental|Arm A, group 6|"Interventions: AdCh3NSmut1. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^7 pfu at week 8.
~Subjects: 5 healthy volunteers"
11508250|NCT01296451|Experimental|Arm A, group 7|"Interventions: AdCh3NSmut1; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^6 pfu at week 8.
~Subjects: 5 healthy volunteers"
11508251|NCT01296438|Experimental|Treatment sequence 1|
11508252|NCT01296438|Active Comparator|Treatment sequence 2|
11508253|NCT01296412|Experimental|Sitagliptin +/- glimepiride|Sitagliptin 100 mg tablet orally once daily for 26 weeks. Participants continued their stable dose of metformin >=1500 mg orally daily. Participants may have received glimepiride orally for glycemic control.
11508254|NCT01296412|Active Comparator|Liraglutide|Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin >=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.
11508255|NCT01296399||Bare metal stent|patients, with a patent previously deployed intra coronary bare metal stent, receiving intra coronary bare metal stent, for de-novo stenosis
11508256|NCT01296399||Drug eluting stent|patients, with a patent previously deployed intra coronary bare metal stent, receiving intra coronary drug eluting stent, for de-novo stenosis
11508257|NCT01296386|Experimental|IC84, 75 µg w/ Alum|75 µg w/ Alum (microgram with Alum)
11508258|NCT01296386|Experimental|IC84, 75 µg w/o Alum|75 µg w/o Alum (microgram without Alum)
11508259|NCT01296386|Experimental|IC84, 200 µg w/ Alum|200 µg w/ Alum (microgram with Alum)
11508260|NCT01296386|Experimental|IC84, 200 µg w/o Alum|200 µg w/o Alum (microgram without Alum)
11508261|NCT01296373||HIV-1-infected, off ART|HIV-1-infected, antiretroviral naive or off antiretroviral therapy for at least 12 months with CD4+ T-cell counts less than or equal to 350 cells/µL who are about to commence combination antiretroviral therapy
11508262|NCT01296360|Active Comparator|>14 months to <2 years|IXIARO 0.25 ml i.m. (milliliter, intramuscular)
11508263|NCT01296360|Active Comparator|>3 years - <18 years|IXIARO 0.5 ml i.m (milliliter, intramuscular)
11508264|NCT01296347|No Intervention|Saline|Patients will receive a placebo infusion of 0.9% sodium chloride, which will start 10 minutes prior to the start of the operation and continue for 96 hours.
11508265|NCT01296347|Experimental|ketamine|Patients will receive intravenous ketamine, starting 10 minutes prior to surgery and will continue for 96 hours
11508266|NCT01296334|Experimental|morphine low dose|morphine infusion 10 mg over a 210 min period
11508267|NCT01296334|Experimental|morphine high dose|morphine infusion 20 mg over a 210 min period
11508268|NCT01296334|Experimental|buprenorphine low dose|buprenorphine infusion 0.3 mg over a 210 min period
11508269|NCT01296334|Experimental|buprenorphine high dose|buprenorphine infusion 0.6 mg over a 210 min period
11508270|NCT01296334|Placebo Comparator|placebo|placebo (normal saline) infusion 0.6 mg over a 210 min period
11508271|NCT01296321|Experimental|Tailored Internet-delivered CBT|Behavioral: Tailored Internet-delivered CBT
11508272|NCT01296321|Active Comparator|Waitlist|Waitlist.
11508273|NCT01296308||type 2 diabetics with neuropathy|
11508274|NCT01296295|Experimental|Spirometry and lifestyle counseling|Intervention group: The intervention is to give brief structured smoking cessation advice combined with a detailed and structured discussion of the spirometric results.
11508275|NCT01296295|No Intervention|Lifestyle counseling|No intervention group: the patients of the control group will receive a brief structured smoking cessation advice.
11508276|NCT01296282||Heart failure patients|
11508277|NCT01296269|Experimental|Vasopressin|vasopressin condition
11508278|NCT01296269|Experimental|oxytocin|oxytocin condition (syntocinon)
11508279|NCT01296269|Placebo Comparator|placebo|
11508280|NCT01296256|Experimental|Bendamustine-EAM|
11508281|NCT01296243|Experimental|Tesetaxel once every 3 weeks|
11508282|NCT01296230|Experimental|Hormone/semen measurements before and after varicocelectomy|We will measure sex-hormone and semen quality in patients both before and after varicocelectomy. The purpose is to asses if preoperative hormone levels are predictive for who will have improved semen quality after surgery.
11508283|NCT01296217|Experimental|lymph nod detection|
11508284|NCT01296204|Experimental|BB4 antibody-Iodine 131|
11508285|NCT01296191|Active Comparator|VIGAMOX|Subjects undergoing cataract surgery, randomized to the VIGAMOX group Generic name is moxifloxacin eye drops, drops to be used 1 drop 4 times daily for 3 days prior to surgery and 1 drop on day of surgery.
11508286|NCT01296191|Active Comparator|Besivance|Subjects scheduled for cataract surgery, randomized to the Besivance group Generic name is besifloxacin eye drops, drops to be used 1 drop 4 times daily for 3 days prior to surgery and 1 drop on day of surgery.
11508287|NCT01296165||Travellers visiting India|People that are older than 18 years and planning to visit India for a period of at least 5 days will be approached by the personal at the travel clinics to participate in the study. Informed consent will be obtained prior to enrolling subjects.
11508288|NCT01296152|Experimental|Depo-medroxyprogesterone acetate (DMPA)|At study entry/ Day 0, subjects will receive depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
11508289|NCT01296139|Experimental|A|All subjects will receive 7.5 mg/kg Fe
11508290|NCT01296113|Experimental|A|
11508291|NCT01296100|Experimental|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
11508292|NCT01296100|Experimental|Lifestyle counseling (physical activity)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
11508293|NCT01296087|Experimental|TC-6987|
11508294|NCT01296087|Placebo Comparator|Placebo|
11508295|NCT01296074|Experimental|Corticosteroid|Methylprednisolone will be given during cardiopulmonary bypass.
11508296|NCT01296061||Failed Kidney Transplant|Adults ≥ 18 years, initiating chronic dialysis
11508297|NCT01296048||Body Analysis|
11508298|NCT01296035|Experimental|Panitumumab and Gemcitabine|Panitumumab and Gemcitabine
11508299|NCT01296022|Active Comparator|Subcutaneous ICD|Subcutaneous Implantable Cardioverter Defibrillator
11508300|NCT01296022|Active Comparator|Transvenous ICD|Transvenous Implantable Cardioverter Defibrillator
11508301|NCT01296009|Experimental|traditional Chinese medicine|The pregnancy rate in traditional Chinese medicine group is higher than the control group
11508302|NCT01295970|Active Comparator|Radiosurgery (SRS)|
11508303|NCT01295970|Active Comparator|Surgery|
11508304|NCT01295957|Active Comparator|reminiscence therapy, story telling|24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. Refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography. Three main variables contributed to successful reminiscing: individuality, evaluation and structure.
11508305|NCT01295957|Placebo Comparator|comparison|control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, but they didn't participate in reminiscence sessions to rule out the possibility that improvement in quality of life was due only to attention received and social stimulation.
11508306|NCT01295957|No Intervention|control|control group was administered counseling and informal social contacts in bi-weekly sessions of one hour,
11508307|NCT01295944|Experimental|1|The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued, but bevacizubab may be continued at the descretion of the treating physician.
11508308|NCT01295931|Experimental|IC-Green + Imaging|Indocyanine Green (IC-Green) Injections + Imaging
11508309|NCT01295918|No Intervention|Placebo, antibiotic, diarrhea|
11508310|NCT01295918|Placebo Comparator|L. reuteri, Antibiotic, diarrhoea|L. reuteri will be ingested by patients on antibiotic therapy, effect of probiotic on AAD will be assessed.
11508311|NCT01295905|Experimental|delefilcon A|Investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for 3 months.
11508312|NCT01295905|Active Comparator|narafilcon B|Commercially marketed contact lenses worn in both eyes on a daily wear, daily disposable basis for 3 months.
11508313|NCT01295892|Placebo Comparator|placebo|placebo (transdermal gel)
11508314|NCT01295892|Experimental|Estrogen|1mg of 17B-estradiol/day (transdermal gel)
11508315|NCT01295879|Experimental|Ergocalciferol|Subjects will take Ergocalciferol (vitamin D), 50,000 IU's orally per week for 8 weeks
11508316|NCT01295866||nasal nitric oxide, atypy status|
11508317|NCT01295853|Active Comparator|t3 sympathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
11508318|NCT01295853|Active Comparator|t4 sypathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
11508319|NCT01295840|No Intervention|CRT therapy|Cardiac Resynchronization Therapy Defibrillator (CRT-D)
11508320|NCT01295827|Experimental|Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)|During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2.
11508321|NCT01295827|Experimental|Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)|During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.
11508322|NCT01295827|Experimental|Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)|During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.
11508323|NCT01295827|Experimental|Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.
11508324|NCT01295827|Experimental|Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.
11508325|NCT01295827|Experimental|Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.
11508326|NCT01295827|Experimental|MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)|Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
11508327|NCT01295827|Experimental|MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
11508328|NCT01295827|Experimental|MEL: Pembrolizumab 10 mg/kg Q2W (Part B)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
11508329|NCT01295827|Experimental|NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)|Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
11508330|NCT01295827|Experimental|NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
11508331|NCT01295827|Experimental|NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
11508332|NCT01295827|Experimental|NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 2 mg/kg Q3W. No participants were enrolled in this arm.
11508333|NCT01295827|Experimental|NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 5 mg/kg Q3W. No participants were enrolled in this arm.
11508334|NCT01295827|Experimental|NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 10 mg/kg Q3W. No participants were enrolled in this arm.
11508335|NCT01295814|Experimental|adalimumab|Adalimumab 80mg subcutaneous loading dose followed by 40 mg subcutaneous every 2 weeks for 12 weeks
11508336|NCT01295814|Placebo Comparator|Inactive drug|Placebo in identical syringe subcutaneous every 2 weeks for 12 weeks
11508337|NCT01295801||Linezolid+vitamin B6|
11508338|NCT01295801||Linezolid|
11508339|NCT01295788|Experimental|Simultaneous RT-CGM and Pump Initiation|The experimental group will initiate RT-CGM at the same time as they begin insulin pump therapy.
11508340|NCT01295788|Active Comparator|Delayed RT-CGM Initiation|The control group will use standard pump therapy until the 6 month study visit at which time RT-CGM will be initiated.
11508341|NCT01295775|Active Comparator|Sulodexide group|50 mg of sulodexide a day will be administered by oral route (1+1 capsule/day) for 360 days
11508342|NCT01295775|Placebo Comparator|Placebo group|Sulodexide placebo will be administered at the same schedule (1+1 capsule/day) and for the same lengths of time (for 360 days) as Sulodexide group
11508343|NCT01295762|Other|Type of neuroblastoma|Neonatal stages I Localized immediately resectable stages Localized immediately unresectable stages High-risk neuroblastoma Relapsed neuroblastoma
11508344|NCT01295749|Active Comparator|ventilation by laryngeal tube|ventilation by laryngeal tube and continuous chest compression
11508345|NCT01295749|Sham Comparator|ventilation by bag valve mask|ventilation by bag valve mask and interrupted chest compression
11508346|NCT01295736|Active Comparator|Actif arm|Sildenafil 20mg TID during 90 days
11508347|NCT01295736|Placebo Comparator|Sugar pill|Placebo pills TID during 90 days
11508348|NCT01295723|Experimental|Intraoperative Electron Radiation Therapy|A single dose of electron irradiation given at the surgical site during the operation to remove the cancerous tumor will replace the usual 5-8 days of localized radiation. Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days post operatively.
11508349|NCT01295710|Active Comparator|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
11508350|NCT01295710|Placebo Comparator|Placebo|250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
11508351|NCT01295697|Experimental|EZN-2208|Cytotoxic Agent
11508352|NCT01295684|Placebo Comparator|placebo|Base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage.
11508353|NCT01295684|Experimental|Cranberry Juice|Base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day.
11508354|NCT01295671|Active Comparator|Sugar-Sweetened Beverages|Provision of beverages: Sugar-sweetened beverages
11508355|NCT01295671|Experimental|Artificially-sweetened Beverages|Provision of beverages: Artificially-sweetened beverages
11508356|NCT01295671|Experimental|Unsweetened Beverages|Provision of beverages: Unsweetened beverages
11508405|NCT01295294|Experimental|tranexamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive treatments with tranexamic acid
11508357|NCT01295658||Cancer Survivors|"This is a broad observational study conducted online at www.cancerexperienceregistry.org, or via pen and paper survey obtained by calling the cancer support helpline at 888-793-9355
~Any individual who has ever received a cancer diagnosis, regardless of disease type, stage, treatment, and time since diagnosis, can take part in this study."
11508358|NCT01295645|Experimental|Standard of Care + Cidofovir|Cidofovir 0.5 mg/kg IV 3 x week for 4 weeks
11508359|NCT01295645|Active Comparator|No Cidofovir|Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
11508360|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-2206 90 mg|
11508361|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-2206 135 mg|
11508362|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 90 mg|
11508363|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 135 mg|
11508364|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 200 mg|
11508365|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-2206 135 mg|
11508366|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-2206 200 mg|
11508367|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
11508368|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
11508369|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
11508370|NCT01295619|Experimental|I-020805|This was a prospective, open, multi-center, single-arm study to investigate I-020805 in patients following elective cranial surgery. If they met the inclusion/ exclusion criteria, they receive I-020805 after suturing of the dura. If necessary, autologous grafts were to be used to augment dural closure.
11508371|NCT01295606|No Intervention|Cefazolin, antibiotic prophylaxis|All included patients will received iv cefazolin
11508372|NCT01295593|Experimental|valproic acid combined with CdA|valproic acid, oral daily intake, combined with 2-chlorodeoxyadenosine administered intravenously for 4 cycles
11508373|NCT01295580|Active Comparator|Hyaluronic acid, stabilized|
11508374|NCT01295580|Active Comparator|Hyaluronic acid|
11508375|NCT01295567|Placebo Comparator|placebo|
11508376|NCT01295567|Experimental|dipyridamole|
11508377|NCT01295554||Peripheral arterial disease|Peripheral arterial disease
11508378|NCT01295541||4 months of observation|CVICU
11508379|NCT01295528||Blood Pressure, Heart Rate, Monitor|
11508380|NCT01295515|Experimental|Interferon treatment|Interferon treatment The intervention is administration of Pegylated Interferon Alpha 2b (PEGINTRON) weekly for four weeks
11508381|NCT01295502|Experimental|Treatment (radiation, cisplatin, paclitaxel, carboplatin)|Patients receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 and undergo extended-field radiotherapy daily 5 days a week for 6 weeks followed by brachytherapy. Beginning 4-6 weeks after completion of chemoradiation, patients receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11508382|NCT01295489||Group A (IP catheter removed)|Archival formalin-fixed, paraffin-embedded tumor (collected during previous surgery), peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolation) samples are collected before course one and blood (for cell, plasma, and serum isolations) is collected before courses two and three for translational research.
11508383|NCT01295489||Group B (IP catheter in place)|Archival formalin-fixed, paraffin-embedded tumor (collected during previous surgery), peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolation) samples are collected before course one and peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolations) before courses two and three for translational research.
11508384|NCT01295450|Active Comparator|Vitamin Complex|A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
11508385|NCT01295450|Experimental|Apevinat BC|"Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).
~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily."
11508386|NCT01295437|Active Comparator|Vypro II mesh|A partly absorbable polypropylene-polyglactin mesh (50g/m2).
11508387|NCT01295437|Active Comparator|Premilene LP|A lightweight polypropylene mesh (55 g/m2)
11508388|NCT01295437|Placebo Comparator|Premilene mesh|A conventional polypropylene mesh (82 g/m2)
11508389|NCT01295424||Single group study|
11508390|NCT01295411|Other|schizophrenia PATIENTS|
11508391|NCT01295398|Other|conventional jet-nebulizer|(particles diameter of 4-5 µm)
11508392|NCT01295398|Experimental|a jet-nebulizer adapted for infants|(particles diameter of 2-2.5 µm),
11508393|NCT01295398|Experimental|a mesh-nebulizer adapted for infants|(particles diameter of 2-2.5 µm).
11508394|NCT01295385|Experimental|healthy volunteers|
11508395|NCT01295385|Active Comparator|patients with a diabetic cardiomyopathy|
11508396|NCT01295372|Experimental|Zicronapine|
11508397|NCT01295372|Active Comparator|Risperidone|
11508398|NCT01295359|Experimental|Trained Group|This group will receive the usual care of the hospital and a ground walking training program associated with respiratory exercises.
11508399|NCT01295359|No Intervention|Usual Care Group|This group will only receive the usual care of the hospital, including physical therapy
11508400|NCT01295346||Traumatic Brain Injury|Patients who present to the health care facility with mild or moderate traumatic brain injury (Glasgow Coma Scale 9-15) within 4 hours of injury
11508401|NCT01295333|Other|conventional approach|conventional traitment
11508402|NCT01295333|Experimental|experimental approach|early and systematic traitment
11508403|NCT01295320|Experimental|GSK1437173A Group|Subjects who received 2 doses of HZ vaccine in the intermediate dose study group in study 108494 (NCT00434577). No treatment was given in this current study (NCT01295320).
11508404|NCT01295307|Experimental|Single Arm|Induction therapy with clofarabine/cytarabine. Post-remission therapy with either allogeneic HCT after conditioning with clofarabine/melphalan if a donor is available, or clofarabine/cytarabine if no donor is available
11508406|NCT01295294|Experimental|mefenamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive treatments with mefenamic acid
11508407|NCT01295294|Placebo Comparator|placebo + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive placebo
11508408|NCT01295281|Experimental|LoFric POBE 2.0 - PVC|First period (7 days) use of LoFric POBE 2.0 followed by second period (7 days) use of LoFric PVC
11508409|NCT01295281|Experimental|LoFric PVC - POBE 2.0|First period (7 days) use of LoFric PVC followed by second period (7 days) use of LoFric POBE 2.0.
11508410|NCT01295268|Active Comparator|Emu Oil|
11508411|NCT01295268|Placebo Comparator|inert oil|
11508412|NCT01295229|Active Comparator|Lifestyle Intervention|
11508413|NCT01295229|Active Comparator|Surgery|
11508414|NCT01295216|Experimental|Intervention|Pre-hypertensive subjects who receive mHealth support for 12 months
11508415|NCT01295216|No Intervention|Control|Individuals who receive the usual primary health care
11508416|NCT01295203|No Intervention|Control group|The control group were not given access to the intervention website and received no additional information.
11508417|NCT01295190||Propofol|Patients receiving Propofol during cardiopulmonary bypass.
11508418|NCT01295190||Sevoflurane|Patients receiving sevoflurane during cardiopulmonary bypass
11508419|NCT01295177|Placebo Comparator|vehicle cream|Intervention: Placebo cream vehicle. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream (cream with the same constitution but without insulin). The placebo cream vehicle was used for 8 weeks.
11508420|NCT01295177|Placebo Comparator|cream insulin|Intervention: insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with insulin cream (cream with the same constitution but with insulin). The insulin cream was used for 8 weeks.
11508421|NCT01295164|Active Comparator|Group 1|Measurement of aberrations in patients with keratoconus of grade 1
11508422|NCT01295164|Active Comparator|Group 2|patients with keratoconus of grade 2
11508423|NCT01295164|Experimental|Group 3|patients with keratoconus of grade 3
11508424|NCT01295164|Experimental|Group 4|patients with keratoconus of grade 4
11508425|NCT01295151|Experimental|TNF-blocking drug|
11508426|NCT01295151|Experimental|Abatacept|
11508427|NCT01295151|Active Comparator|Rituximab|
11508428|NCT01295138|Experimental|Lactulose group|Group receives 48 hours of lactulose post Caesarean section.
11508429|NCT01295138|No Intervention|Non-lactulose group|Group receives no lactulose post Caesarean section.
11508430|NCT01295125|Experimental|XenMATRIX|Use of XenMATRIX mesh to repair hernia
11508431|NCT01295125|Active Comparator|Native tissue|Repair with participants native tissue
11508432|NCT01295112|Sham Comparator|Group 1|Active bevacizumab (Avastin®) and Sham Ozurdex®
11508433|NCT01295112|Active Comparator|Group 2|Active bevacizumab (Avastin®) and Active Ozurdex®
11508434|NCT01295099|Active Comparator|5-Fluorouracil|Patients with small keloidal scars to have intralesional 5FU injected
11508435|NCT01295099|Active Comparator|Radiotherapy|Large keloid scars undergo extralesional excision and radiotherapy
11508436|NCT01295099|Active Comparator|TAC|
11508437|NCT01295086|Experimental|Her-TEX|
11508438|NCT01295073|Active Comparator|A|Oral Trientine 1500mg x 1 week before cataract surgery and 3 days post surgery
11508439|NCT01295073|Placebo Comparator|B|Oral Placebo x 1 week before cataract surgery and 3 days post surgery
11508440|NCT01295060|Experimental|Octreotide Implant|
11508441|NCT01295047|Active Comparator|ATENOLOL|ATENOLOL 75MG FOR 4 WEEKS
11508442|NCT01295047|Active Comparator|VERAPAMIL|240MG VERAPAML FOR 4 WEEKS
11508443|NCT01295047|Active Comparator|PERINDOPRIL|4MG PERINDOPRIL FOR 4 WEEKS
11508444|NCT01295034|Placebo Comparator|conventional vitamin D treatment|Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
11508445|NCT01295034|Experimental|tiered/titrated vitamin D dosing|Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
11508446|NCT01295008||Patients with the classic form|
11508447|NCT01295008||Fabry disease and healthy controls|
11508448|NCT01294995|Experimental|Tea-flavor Liquor, taken with meal|including 12 males and 11 females
11508449|NCT01294995|Placebo Comparator|Guizhou Meijiao Liquor, taken with meal|including 11 males and 11 females
11508450|NCT01294982|Experimental|1.6 g AOBO-001 Group|AOBO-001 400 mg Oral Capsules
11508451|NCT01294982|Experimental|3.2 g AOBO-001 Group|AOBO-001 400 mg Oral Capsules
11508452|NCT01294982|Placebo Comparator|Placebo|Matching Placebo Capsules
11508453|NCT01294969|Experimental|AL-4943A|One drop per day in both eyes
11508454|NCT01294956|Experimental|FID 115958D|Lubricant Eye Drop
11508455|NCT01294956|Active Comparator|Refresh Liquigel|Lubricant Eye Drop
11508456|NCT01294943||Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
11508457|NCT01294930||hip fracture|Patients operated for hip fracture, giving informed consent
11508458|NCT01294917|Experimental|Investigational MPS|AMO Investigational MPS.
11508459|NCT01294917|Active Comparator|Clear Care|Peroxide-based lens care regimen.
11508460|NCT01294917|Active Comparator|Opti-Free RepleniSH|Multi-purpose disinfecting solution (Alcon).
11508461|NCT01294904||renal transplant patients|Patients undergoing transplantation
11508462|NCT01294904||dialysis patients|hemodialysis patients and peritoneal dialysis patients. Before and after a dialysis session
11508463|NCT01294904||patients with renal insufficiency|outpatient patients with chronic kidney disease stage 2, 3 and 4
11508464|NCT01294904||Chronic kidney disease|outpatient cohort. Those with mild renal insufficiency
11508465|NCT01294891||Control|Age matched healthy subjects
11508466|NCT01294891||Sickle Cell Patients|Patients with established SCD
11508467|NCT01294891||Paroxysmal Nocturnal Hemoglobinuria patients|Patients with PNH
11508583|NCT01294059|Placebo Comparator|Sugar pill|One sugar pill twice daily over 6 weeks
11508468|NCT01294878|Experimental|treatment with omalizumab|Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used
11508469|NCT01294865||septic|Infants having clinical suspected late-onset neonatal sepsis enrolled in the study. Blood samples for suPAR were obtained before initiating antibiotic treatment and at the end of the treatment with other laboratory tests.
11508470|NCT01294865||non-septic|Infants without any clinical or hematological septic signs. Blood samples will be taken only once.
11508471|NCT01294852|Experimental|immediate bolus surfactant|
11508472|NCT01294852|Experimental|post-resuscitation surfactant|
11508473|NCT01294839|Experimental|RVOTs|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in RVOTs arm, the RV lead of this group patients will be implanted in right ventricular outflow tract septum,the accumulated ventricular pacing percentage should be over 80% by adjusting AV delays.
11508474|NCT01294839|Experimental|AAI|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in AAI arm, the RV lead of this group patients will be implanted in right ventricular apex.
11508475|NCT01294839|Active Comparator|RVA|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in RVA arm, the RV lead of this group patients will be implanted in right ventricular apex, the accumulated ventricular pacing percentage should be over 80% by adjusting AV delays.
11508476|NCT01294826|Experimental|AUY922 plus Cetuximab|
11508477|NCT01294813|Experimental|Bronchoscopy-EIT|Patients who routinely undergo bronchoscopy will be measured by EIT directly before, directly after and 10, 30, 60 minutes after bronchoscopy with a rubber belt which is placed around their chest. The EIT measurements will take 1-2 minutes; the total examination will last 1.5 hours.
11508478|NCT01294800|Experimental|Preladenant 2 mg|Participants will receive preladenant 2 mg taken orally twice daily (BID), one tablet in the morning and one tablet in the evening, for 12 weeks.
11508479|NCT01294800|Experimental|Preladenant 5 mg|Participants will receive preladenant 5 mg taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
11508480|NCT01294800|Experimental|Preladenant 10 mg|Participants will receive preladenant 10 mg taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
11508481|NCT01294800|Placebo Comparator|Placebo|Participants will receive a placebo to preladenant tablet taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
11508482|NCT01294787|Experimental|indacaterol and glycopyrronium bromide (QVA149)|QVA149 delivered once daily via single-dose dry powder inhaler.
11508483|NCT01294787|Placebo Comparator|placebo|Placebo, delivered once daily via single-dose dry powder inhaler.
11508484|NCT01294787|Active Comparator|tiotropium|Tiotropium delivered once daily via HandiHaler® device.
11508485|NCT01294774|Experimental|KRP203 - 1.2 mg|
11508486|NCT01294774|Placebo Comparator|Placebo to KRP203 - 1.2 mg|
11508487|NCT01294761|Experimental|Raltegravir, Darunavir/r|"An arm to change the regimen from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD
~to: Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID"
11508488|NCT01294761|No Intervention|Tenofovir, Emtricitabine, Lopinavir/r|An arm continuing on the same regimen before the randomization as Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD
11508489|NCT01294748|Experimental|MiStent DES|The MiStent SES is a sirolimus-eluting absorbable polymer stent for coronary artery revascularization.
11508490|NCT01294748|Active Comparator|Endeavor DES|The Endeavor DES is an everolimus-eluting durable polymer stent for coronary artery revascularization.
11508491|NCT01294735|Experimental|Part A, MK-4827 + temozolomide dose escalation cohort|
11508492|NCT01294735|Experimental|Part B, MK-4827 + temozolomide melanoma cohort|
11508493|NCT01294735|Experimental|Part B, MK-4827 + temozolomide glioblastoma multiforme cohort|
11508494|NCT01294709|Experimental|Telcagepant/ Placebo|Participants receive single oral dose of 600 mg (two 300 mg capsules or two bioequivalent 280 mg tablets) or 900 mg telcagepant (three 300 mg capsules) in Period 1 and single oral dose of two capsules or tablets of placebo for telcagepant (or three capsules of placebo for telcagepant) in Period 2 of the crossover. Each treatment period is separated by a washout of 96-240 hours.
11508495|NCT01294709|Experimental|Placebo/Telcagepant|Participants receive single oral dose of two capsules or tablets of placebo for telcagepant (or three capsules of placebo for telcagepant) in Period 1 and a single oral dose of 600 mg (two 300 mg capsules or two bioequivalent 280 mg tablets) or 900 mg telcagepant (three 300 mg capsules) in Period 2 of the crossover. Each treatment period is separated by a washout of 96-240 hours.
11508496|NCT01294696||All Enrolled Participants|All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
11508497|NCT01294683|Experimental|Sequence 1: MK-0524B 2g/40g→MK-0524A 2g + Simvastatin 40 mg|After a 2-week placebo run-in, participants received extended release (ER) niacin/laropiprant (N/LRPT) 1 g/20 mg combination tablet (MK-0524B) once daily for 4 weeks, then ERN/LRPT/Simvastatin (SIM) 2 g/40 mg combination tablet once daily for 8 weeks. Participants then received ERN/LRPT 2 g (MK-0524A) co-administered with SIM 40 mg once daily for 8 weeks.
11508498|NCT01294683|Experimental|Sequence 2: MK-0524A 2g + Simvastatin 40 mg→ MK-0524B 2g/40g|After a 2-week placebo run-in, participants received ERN/LRPT 1 g (MK-0524A) co-administered with SIM 20 mg once daily for 4 weeks then received ERN/LRPT 2 g (MK-0524A) co-administered with SIM 40 mg once daily for 8 weeks. Participants then received ERN/LRPT/SIM 2 g/40 mg combination tablets (MK-0524B) once daily for 8 weeks.
11508499|NCT01294670|Experimental|Vorinostat and Etoposide|This is a multi-center, open label, phase I/II trial of escalating doses of vorinostat in combination with etoposide.
11508500|NCT01294657||HE Group|Health Education [HE] - Counseling, referrals to resources + self-help materials; 2 HE interventions at Baseline + 6 month visits.
11508501|NCT01294657||MAPS Group|Motivation And Problem Solving (MAPS) - HE + 12 telephone counseling sessions over 1-year period (average 1 call/month).
11508584|NCT01294059|Active Comparator|Milnacipran|Milnacipran 50 mg bid over 6 weeks
11508502|NCT01294644|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
11508503|NCT01294644|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
11508504|NCT01294644|Experimental|Deoxycholic Acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
11508505|NCT01294631|Experimental|001|"Canagliflozin 300 mg once daily and HCTZ 25 mg once daily Period 1: canagliflozin tablets oral 300 mg once daily on Days 1 to 7 followed 14 days later by Period 2.
~Period 2: HCTZ tablets oral 25 mg once daily for Days 1 to 28 followed by canagliflozin tablets oral 300 mg once daily taken with HCTZ tablets oral 25 mg once daily on Days 29 to 35.."
11508506|NCT01294618|Experimental|nilotinib + pegylated interferon alpha 2a (PEG-IFN).|
11508507|NCT01294605|Experimental|Group A|
11508508|NCT01294605|Experimental|Group B|
11508509|NCT01294605|Active Comparator|Group C|
11508510|NCT01294592|Active Comparator|Dutasteride plus tamsulosin|Dutasteride plus tamsulosin arm + lifestyle advice
11508511|NCT01294592|Experimental|Watchful waiting with escalation to tamsulosin|Watchful waiting with escalation to tamsulosin
11508512|NCT01294579|Experimental|ofatumumab and bendamustine|"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase and 1000 mg IV every 2 months for 2 years.
~Bendamustine 90 mg/m2 was given on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)"
11508513|NCT01294566|Experimental|Cohort 1|GSK1322888 (1 mg, 2 mg, 5 mg, 10 mg; 6 subjects) and Placebo (32 subjects)
11508514|NCT01294566|Experimental|Cohort 2|GSK1322888 (20 mg, 40 mg, 80 mg, and dose to be determined; 6 subjects) and Placebot (2 subjects)
11508515|NCT01294553||rosiglitazone/metformin group|Korean subjects who are administered rosiglitazone/metformin according to the prescription information
11508516|NCT01294540|Experimental|Experimental: 1|
11508517|NCT01294540|Placebo Comparator|Placebo Comparator: 2|
11508518|NCT01294527|Experimental|Implant|Implant of the WiCS-LV system
11508519|NCT01294514||Healthy Volunteers|Healthy volunteers ASA Class 1
11508520|NCT01294501|Experimental|Fever assessment and management|Medication administration educational module for low literacy subjects on how to administer common medications appropriately and safely.
11508521|NCT01294488|Experimental|Phone Consultation|Therapists receive phone consultation for 6 months during the course of the project.
11508522|NCT01294488|Experimental|Remote Real-Time Consultation|Therapists receive consultation for 6 months via polycommunication technology.
11508523|NCT01294475|Experimental|Cell Phone Enhanced Parent Training|Cell phones will be provided to mothers participating in Planned Activities Training.
11508524|NCT01294462|Experimental|1|Ticagrelor (AZD6140)
11508525|NCT01294462|Active Comparator|2|Clopidogrel
11508526|NCT01294449||MADIT-CRT ICD|
11508527|NCT01294449||MADIT-CRT CRT-D|
11508528|NCT01294436|Experimental|Open label treatment|
11508529|NCT01294423|Experimental|1|Dapagliflozin 5 mg
11508530|NCT01294423|Experimental|2|Dapagliflozin 10 mg
11508531|NCT01294423|Placebo Comparator|3|
11508532|NCT01294410|Experimental|Cohort 1: Induction|Placebo or Anti-IP-10 Antibody
11508533|NCT01294410|Experimental|Cohort 2: Induction|Placebo or Anti-IP-10 Antibody
11508534|NCT01294410|Experimental|Cohort 3: Induction|Placebo or Anti-IP-10 Antibody
11508535|NCT01294410|Experimental|Maintenance|Placebo or Anti-IP-10 Antibody
11508536|NCT01294410|Other|Open Label|
11508537|NCT01294397|Experimental|Etanercept + Denosumab|Participants received etanercept 50 mg subcutaneously once weekly for 25 weeks. On study day 8, participants were administered a single 60 mg subcutaneous injection of denosumab.
11508538|NCT01294384|Experimental|New Eye Drop Formulation 1|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.
11508539|NCT01294384|Experimental|New Eye Drop Formulation 2|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.
11508540|NCT01294384|Active Comparator|Refresh Tears®|1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
11508541|NCT01294371||Leuprorelin|"Patients with genital endometriosis received leuprorelin (Lucrin Depot®) in accordance with the respective marketing authorization/manufacturer's directions. All participants received leuprorelin for up to 6 months intramuscularly at a dose of 3.75 mg once a month. If intramuscular administration was not possible, leuprorelin was injected subcutaneously at a dose of 3.75 mg once a month. The first injection was to be carried out on the 3rd day of a menstrual period.
~Accepted options for add-back therapy included: monophasic combined low-dose products for hormonal replacement therapy; combined oral contraceptives; and, if use of hormones was not possible, phytoestrogens with calcium products."
11508542|NCT01294358|Experimental|Gemcitabine Dose Escalation|gemcitabine dose escalation
11508543|NCT01294345||personalized genomics|genetic/genomic syndromes
11508544|NCT01294332|Experimental|Excercise|Aerobic exercise performed for 12 weeks
11508545|NCT01294319|Experimental|Sedentary young adults, SMCP|Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone
11508546|NCT01294319|Experimental|Endurance-trained young athletes, SMCP|Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone
11508547|NCT01294319|Experimental|Sedentary young adults, MSPC|Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone
11508548|NCT01294319|Experimental|Endurance-trained young athletes, MSPC|Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone
11508549|NCT01294319|Experimental|Sedentary young adults, CPSM|Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone
11508550|NCT01294319|Experimental|Endurance-trained young athletes, CPSM|Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone
11508585|NCT01294046|Experimental|Deep brain stimulation of SPG for migraine|Electrical SPG for Treatment of Migraine
11508551|NCT01294319|Experimental|Sedentary young adults,PCMS|Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone
11508552|NCT01294319|Experimental|Endurance-trained young athletes,PCMS|Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone
11508553|NCT01294306|Experimental|Treatment (Akt inhibitor MK2206, erlotinib hydrochloride)|Patients receive Akt inhibitor MK2206 PO QOD of a 28-day course, and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11508554|NCT01294293|Experimental|Treatment (TLR8 agonist VTX-2337, PLD, and Paclitaxel)|Patients receive TLR8 agonist VTX-2337 SC on days 3, 10, and 17 and pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 or TLR8 agonist VTX-2337 SC on days 1, 8, and 15 and paclitaxel IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11508555|NCT01294280||Ancillary-Correlative (IHC)|Previously collected tissue samples are analyzed by IHC.
11508556|NCT01294267|Other|Circulatory Support System|Percutaneous use of left ventricular assist device, Impella 2.5 Circulatory Support System to facilitate mapping and ablation of ongoing VT by maintaining near-normal hemodynamics, reducing myocardial workload and preservice organ perfusion.
11508557|NCT01294254|Experimental|experimantal: wound site will be treated with Oleogel-S10|"The patients will be randomised in a ratio of 1:1 with regard to the part of the skin graft donor site that is treated with Oleogel-S10.
~Arm A: application of Oleogel-S10 towards the periphery of the body, i.e. the lower part of the leg
~Arm B: application of Oleogel-S10 towards the centre part of the body, i.e. the upper part of the leg
~Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)
~Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site"
11508558|NCT01294254|Active Comparator|Moist wound healing dressing alone|Treatment with moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site
11508559|NCT01294241|Experimental|Oleogel-S10|The eligible wound (half) was topically treated with Oleogel-S10 and covered with a non-adhesive wound dressing (Mepilex®) on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
11508560|NCT01294241|Other|Non-adhesive wound dressing|Mepilex® soft silicone faced polyurethane foam dressing was used as non-active comparator. The eligible wound (half) was covered with Mepilex® as control on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
11508561|NCT01294215|Experimental|Arm 1|
11508562|NCT01294202|Experimental|AT13387 and imatinib|AT13387 administered on days 1, 8 and 15, imatinib administered daily
11508563|NCT01294189||ICU-patients that died on the ICU|ICU-patients (post-operative and non operative patients) will be enrolled in the study. All patients are followed until their death on the ICU.
11508564|NCT01294176|Active Comparator|Oral Lipoic Acid|Lipoic acid is a natural antioxidant available as an oral dietary supplement. A higher than average dose of 1200mg will be administered in this trial.
11508565|NCT01294176|Placebo Comparator|Avicel™|The placebo is Avicel™ (microcellulose crystal) and 4.3 mg quercetin (a bioflavanoid).
11508566|NCT01294163|Experimental|Xenon|
11508567|NCT01294163|Active Comparator|Sevoflurane|
11508568|NCT01294163|Active Comparator|Total intravenous anaesthesia|
11508569|NCT01294150|Active Comparator|UroLift System|The treatment group subjects underwent the UroLift system procedure. The subject was blinded to his randomization into control or treatment group. Unblinding will occurred at 3 months post procedure after the assessments were completed. Between 3 and 12 month follow-up assessments, a subject was allowed to retreat with the UroLift system if he met the retreatment inclusion and exclusion criteria. Subjects that went on to UL retreatment within the first 12 months started their follow-up schedule over and were considered treatment failures. All UL subjects will be followed a minimum of 5 years.
11508570|NCT01294150|Sham Comparator|Cystoscopy|The control group subjects underwent a cystoscopy procedure. The subject was blinded to his randomization into the control or treatment group. Unblinding will occurred at 3 months post procedure, after follow-up assessments were completed. Between 3 and 12 month follow-up assessments, a subject was allowed to crossover and undergo a UL procedure if he met crossover inclusion and exclusion criteria. Subjects crossing over will then be followed for 5 years post-treatment. The subject can also be treated by other approved therapies, or receive no treatment at all, which would require participation through 12 months.
11508571|NCT01294150|Active Comparator|Crossover|Between 3 and 12 month follow-up assessments, a subject was allowed to crossover and undergo a UL procedure if he met crossover inclusion and exclusion criteria. Subjects crossing over will then be followed for 5 years post-treatment. The subject can also be treated by other approved therapies, or receive no treatment at all, which would require participation through 12 months.
11508572|NCT01294137|Active Comparator|ventilatory polygraphy|
11508573|NCT01294124||No Tinnitus|The absence of tinnitus will be based on the participants' responses to questions 8a, 9c, and 9d of the Post-Deployment Health Assessment (PDHA).
11508574|NCT01294124||Tinnitus|The presence of tinnitus will be based on the participants' responses to questions 8a, 9c, and 9d of the Post-Deployment Health Assessment (PDHA).
11508575|NCT01294111|Experimental|Tai Chi training|Participation in a group of 15 patients, completing a 60 minutes tai chi training programme twice-weekly for 16 weeks.
11508576|NCT01294111|No Intervention|Control|Living as usual, following ordinary care plans and personal activities. Participants will be called to hospital for data collection. Participants are asked not to start any of the activities Tai Chi, Qui Gong or Yoga during the study period.
11508577|NCT01294098|No Intervention|PCA only|this group will only get a pain control anesthesia pump to use for post-operative pain
11508578|NCT01294098|Experimental|PCA and femoral nerve block|this group will be receiving a femoral nerve block during surgery and have a PCA post-operatively
11508579|NCT01294098|Experimental|PCA + hematoma block|patient will receive hematoma block during surgery
11508580|NCT01294072|Experimental|Arm 1: Curcumin alone|Subjects take curcumin orally.
11508581|NCT01294072|Experimental|Arm 2: Curcumin with plant exosomes|Subjects take curcumin conjugated with plant exosomes.
11508582|NCT01294072|Experimental|Arm 3: no treatment|
11508586|NCT01294033|Placebo Comparator|Fractional inspired oxygen 0.21|Cardiopulmonary exercise test performed by subject on Fractional inspired oxygen 0.21
11508587|NCT01294033|Active Comparator|Fractional inspired oxygen 0.28|Cardiopulmonary exercise test performed on supplemental oxygen (Fractional inspired oxygen 0.28)
11508588|NCT01294020|Experimental|Tacrolimus Prolonged Release|Participants receive tacrolimus prolonged release once daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus prolonged release once daily up to end of Part B of the study.
11508589|NCT01294007|Experimental|Study Graft Composite|
11508590|NCT01294007|Active Comparator|Control Graft Composite|
11508591|NCT01293981||Lumbar Degenerative Disc Disease|
11508592|NCT01293968|Experimental|5cc Ibuprofen100mg,10 cc Diphenhydramine25mg,10 cc AlMgS550mg|
11508593|NCT01293968|Active Comparator|100 cc Diphenhydramine, 25 mg and 100 cc AlMgS 550 mg|
11508594|NCT01293955|Experimental|JOINS 200mg|One tablet of JOINS 200mg is administered three times a day for 1 year. The subjects who consent to participate in an extension study are treated with JOINS 200mg for another 1 year.
11508595|NCT01293955|Placebo Comparator|Placebo|One tablet of Placebo is administered three times a day for 1 year. The subjects who consent to participate in an extension study are treated with Placebo for another 1 year.
11508596|NCT01293942|Experimental|IXO+A|IXO regimen with Avastin
11508597|NCT01293929||Non- obese group|
11508598|NCT01293929||Obese group|
11508599|NCT01293916|Active Comparator|Double leg spica cast|The current accepted treatment is the double leg spica cast in the treatment of pediatric diaphyseal femur fractures.
11508600|NCT01293916|Experimental|Single leg spica casts|The study group is the single leg spica cast group
11508601|NCT01293903|Experimental|Qiliqiangxin capsule|
11508602|NCT01293903|Placebo Comparator|Placebo|
11508603|NCT01293890||COPD patients with hospital admission for exacerbation|
11508604|NCT01293877|Other|LGP|Patient underwent surgery for morbid obesity treatment between 18 to 60 years, and BMI of 40 ore more will divided in two groups, one hundred will be schedule for laparoscopic gastric plication. Our theory for this arm is that the procedure can offer the same results than the second arm with less cost and safety, reversibility included.
11508605|NCT01293877|Other|LSG|The patients in a total of one hundred will be schedule for laparoscopic sleeve gastrectomy. The is our control for development of the study.
11508606|NCT01293825|Experimental|Medication Adherence Bipolar Disorder|There was only one group in this study. All participants received the study drug Ziprasidone.
11508607|NCT01293812|Experimental|sucrose po|"88% sucrose solution (Syrup B.P.). The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution."
11508608|NCT01293812|Placebo Comparator|placebo po|"The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
11508609|NCT01293799|Experimental|The follow-up group|The intervention in the follow-up group consists of regular tests of the patients´ theoretical and practical skills regarding peritoneal dialysis. The test goals should be passed. If not, retraining will be given if needed til the goals are reached. The peritonitis rate in this group will be compared with that of the control group.
11508610|NCT01293799|No Intervention|Control group|Patients randomised to the control group will be treated according to the routines of the clinic.
11508611|NCT01293786||Kidney transplant recipients|
11508612|NCT01293786||Chronic kidney disease|
11508613|NCT01293773|Active Comparator|Taxus Element|Patients treated with paclitaxel-eluting stent (Taxus Element, Boston Scientific, MN)
11508614|NCT01293773|Active Comparator|Xience Prime|Patients treated with Everolimus-eluting stent (Xience Prime, Abbott, IL)
11508615|NCT01293773|Active Comparator|Integrity Resolute|Patients treated with ABT 578-eluting stent (Integrity Resolute, Medtronic, MA)
11508616|NCT01293760|Other|6 weeks interval insertion|IUD is inserted 6 weeks following c-section delivery of baby and placenta
11508617|NCT01293760|Experimental|Immediate insertion|IUD is inserted immediately following c-section delivery of baby and placenta
11508618|NCT01293747|Experimental|Estradiol 0.5 mg/Progesterone 15 mg microspheres|Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension
11508619|NCT01293747|Experimental|Estradiol 1 mg/Progesterone 20 mg microspheres|Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension
11508620|NCT01293734|Experimental|cold type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in cold type
11508621|NCT01293734|Experimental|heat type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in heat type.
11508622|NCT01293734|Experimental|Asthenia type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in Asthenia type.
11508623|NCT01293734|Active Comparator|Western medicine control group|
11508624|NCT01293721|No Intervention|control|
11508625|NCT01293721|Experimental|Treatment|Receive vibration therapy
11508626|NCT01293708||80+ year olds|All 80+ year old that had had an ICU stay of >=24 hrs.
11508627|NCT01293695|Active Comparator|Hypnosis|Receives 5 weeks of hypnotic relaxation therapy
11508628|NCT01293695|Placebo Comparator|Structured Attention|Meets with therapist for five weekly sessions, but receives no hypnotic relaxation therapy
11508629|NCT01293682|Experimental|Calcitriol|Calcitriol 45mcg/week
11508630|NCT01293669|Experimental|TC-6987|
11508631|NCT01293669|Placebo Comparator|Placebo|
11508632|NCT01293656||CD and UC participants|All participants with CD or UC visiting their physician over a period of one year, newly and already diagnosed, regardless of treatment pattern.
11508633|NCT01293643|Experimental|clindamycin/ketoconazole combination|
11508634|NCT01293643|Active Comparator|tetracycline hydrochloride/amphotericin B combination|
11508635|NCT01293630|Experimental|Cohort - 1 through 5|AVE8062 combined with paclitaxel and carboplatin will be administered once every 3 weeks
11508636|NCT01293617|Placebo Comparator|Gelatin|
11508637|NCT01293617|Experimental|Blackberries|
11508703|NCT01293084|Experimental|7% saline|5 mL of 7% saline was inhaled once over a 20 minute period.
11508638|NCT01293604|Experimental|Whole Grain Barley Diet|A controlled diet containing at least 4 daily servings of whole grain barley.
11508639|NCT01293604|Active Comparator|Whole Grain Oats Diet|A diet containing at least 4 servings of whole grain oats.
11508640|NCT01293604|Other|Low Whole Grain Diet|A control diet containing 0.7 daily servings of whole grain.
11508641|NCT01293591|Other|Control|270 kcal White bread with 15 g margarine
11508642|NCT01293591|Other|Garlic Treatment|270 kcal white bread with 15 g margarine and 5 g crushed garlic
11508643|NCT01293578|No Intervention|Usual Care|Clinicians will present diabetes medication options to patients, in their usual way.
11508644|NCT01293578|Experimental|Diabetes Medication Decision Aid|In the decision aid arm, clinicians will use the diabetes medication decision aid cards (if they choose) when discussing diabetes medication options with their patients.
11508645|NCT01293565||HED Affected Males|
11508646|NCT01293565||Male Controls|
11508647|NCT01293552|Placebo Comparator|Control|blank vehicle formulation
11508648|NCT01293552|Experimental|Dose 1|Dose 1
11508649|NCT01293552|Experimental|Dose 2|Dose 2
11508650|NCT01293552|Experimental|Dose 3|Dose 3
11508651|NCT01293552|Experimental|Dose 4|Dose 4
11508652|NCT01293539|Other|Intraocular Retinoblastoma Patients|Single group assignment of patients with intraocular retinoblastoma, unilateral or bilateral.
11508653|NCT01293526|Experimental|Experimental 1|Patients who respond will have their leads placed based on study measurements.
11508654|NCT01293526|Experimental|Control|Leads will be placed using standard procedures.
11508655|NCT01293526|Experimental|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
11508656|NCT01293487|Experimental|Arm 1|
11508657|NCT01293474||glaucoma patients|patients with diagnosis of primary open angle glaucoma
11508658|NCT01293474||control group|age matched healthy controls
11508659|NCT01293461|Experimental|CBX129801|
11508660|NCT01293461|Placebo Comparator|Placebo|
11508661|NCT01293448|Experimental|Intervention|CryoBalloon ablation of esophageal tissue in patients scheduled for esophagectomy for reasons unrelated to the objective of the study.
11508662|NCT01293435||1|
11508663|NCT01293422|Experimental|Rifampicin|
11508664|NCT01293409|Placebo Comparator|Placebo|The amount of photic energy of light is considered to be non-therapeutical
11508665|NCT01293409|Experimental|Intermediate dose|"The amount of photic energy of bright light is considered to be intermediate"
11508666|NCT01293409|Experimental|High dose bright light|The amount of photic energy of bright light is considered to be fully therapeutic
11508667|NCT01293396|Active Comparator|Biphasic Insulin Aspart 30|
11508668|NCT01293396|Active Comparator|Biphasic Insulin Aspart 70|
11508669|NCT01293396|Active Comparator|Insulin Aspart|
11508670|NCT01293383|Other|LEO 90105|
11508671|NCT01293383|Other|Vehicle|
11508672|NCT01293370||vocational rehabilitation|Admitted and discharged psychiatric patients receiving vocational rehabilitation
11508673|NCT01293357|Experimental|Patches|
11508674|NCT01293344|Experimental|Men and Mediterranean diet|Men who are assigned to a 4 weeks experimental diet formulated to be concordant with characteristics of the traditional Mediterranean diet.
11508675|NCT01293344|Experimental|Women and Mediterranean diet|Women who are assigned to a 4 weeks experimental diet formulated to be concordant with characteristics of the traditional Mediterranean diet.
11508676|NCT01293331||Study Cohort (Case )|Participants will be examined for fever in dengue endemic regions
11508677|NCT01293318||Acute pancreatitis|
11508678|NCT01293305|Experimental|Chondroitin Sulfate + Glucosamine sulfate|Pharmaceutical form capsule.
11508679|NCT01293305|Experimental|Chondroitin Sulfate + Glucosamine Sulfate|Oral powder.
11508680|NCT01293305|Active Comparator|Condroflex®|Pharmaceutical form capsule.
11508681|NCT01293305|Active Comparator|CONDROFLEX®|Oral powder
11508682|NCT01293279||HCV Patients who are treatment naive|Han ethnic Chinese male or female ≥ 18 years old with recent a confirmation of anti-HCV-antibody positive and HCV RNA positive but antiviral or interferon treatment naive at the time this study starts from 28 university affiliated hospital throughout China.
11508683|NCT01293266|Active Comparator|Propofol|Anesthesia is changed from Sevoflurane to Propofol after obtaining baseline blood gas analysis from the heart catheterisation sheath.
11508684|NCT01293266|No Intervention|Sevoflurane|Sevoflurane anesthesia is maintained after obtaining a baseline blood gas analysis.
11508685|NCT01293253|Experimental|Stair walking|Participants of this group is encouraged to use the stairs for 10 minutes a day at the workplace
11508686|NCT01293253|Active Comparator|Control|Receives a health examination before and after the intervention period, and are advised to stay active
11508687|NCT01293240|Experimental|Lotrafilcon B|
11508688|NCT01293214|Experimental|Transplantation|Subjects will undergo single or multiple limb transplantation
11508689|NCT01293201|Experimental|STAHIST Investigational Medical Product|STAHIST Tablet, dosed one tablet BID
11508690|NCT01293201|Placebo Comparator|Placebo|Placebo tablet, identical appearance to IMP, dosed one tablet BID
11508691|NCT01293188||Biopresthetic aortic valve replacement.|
11508692|NCT01293175|Experimental|Whole grains|Subjects will consume whole grains every day for two months
11508693|NCT01293175|No Intervention|Control|Subjects will consume their habitual diet
11508694|NCT01293162||placebo|
11508695|NCT01293149|Experimental|Ropivacaine plus clonidine|Ropivacaine plus clonidine for femoral block
11508696|NCT01293149|Active Comparator|Ropivacaine|Ropivacaine alone for femoral block
11508697|NCT01293136||intravenous opioids|
11508698|NCT01293136||femoral nerve block|
11508699|NCT01293123|Experimental|Raltegravir|
11508700|NCT01293123|Active Comparator|Efavirenz|
11508701|NCT01293097|Active Comparator|Intensive statin therapy|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
11508702|NCT01293097|Other|Usual care|Usual care, but statin dose should not be higher than that described in exclusion criteria.
11508876|NCT01291810|Placebo Comparator|Placebo|
11508705|NCT01293071|Active Comparator|Mixing arm|Antibiotic rotation, each consecutive initiated antibiotic treatment a different class (one of 3 classes: cephalosporins, piperacillin-tazobactam, carbapenems)
11508706|NCT01293071|Active Comparator|Cycling|Antibiotic rotation, every 1.5 month a different preferred antibiotic treatment from a different class (one of 3 classes: cephalosporins, piperacillin-tazobactam, carbapenems) is used for empiric treatment.
11508707|NCT01293058|Other|Intravenous|The investigators administered intravenous naloxone for our opioid overdose patients
11508708|NCT01293058|Other|Intranasal|The investigators administered intranasal naloxone for treatment of our patients
11508709|NCT01293045|Experimental|HC Group|Group of volunteers fed with Hydrolyzed Collagen
11508710|NCT01293045|Active Comparator|CT Group|Group of volunteers fed with wheat proteins
11508711|NCT01293032|Experimental|Group 1 (RS < 11)|"Patients with a Recurrence Score (RS) less than 11 (RS <11) are assigned to Group 1, neoadjuvant hormonal therapy either tamoxifen (pre-menopausal women) or an aromatase inhibitor (post-menopausal women) for 4-6 months in the absence of disease progression or unacceptable toxicity.
~Treatment:
~Neoadjuvant therapy
~Therapeutic conventional surgery
~Laboratory biomarker analysis/Correlative studies
~Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System
~Hormonal therapy:
~Tamoxifen Citrate (pre-menopausal women) OR
~Aromatase Inhibition Therapy (post-menopausal women)"
11508712|NCT01293032|Experimental|Group 2 Arm 1 (RS 11-25)|"Patients with an intermediate RS (11-25) assigned to Group 2. Randomized to Arm 1, neoadjuvant hormonal therapy as in Group 1.
~Treatment:
~Neoadjuvant therapy
~Therapeutic conventional surgery
~Laboratory biomarker analysis/Correlative studies
~Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System
~Hormonal therapy:
~Tamoxifen Citrate (pre-menopausal women) OR
~Aromatase Inhibition Therapy (post-menopausal women)"
11508713|NCT01293032|Experimental|Group 2 Arm 2 (RS 11-25)|"Patients with an intermediate RS(11-25) assigned to Group 2. Randomized to Arm 2, neoadjuvant chemotherapy 6-8 courses of anthracycline/taxane based regimen over 4-6 months in the absence of disease progression or unacceptable toxicity.
~Treatment:
~Neoadjuvant therapy
~Therapeutic conventional surgery
~Laboratory biomarker analysis/Correlative studies
~Gene Expression Analysis/Oncotype DX Gene Expression Profiling System
~Systemic chemotherapy"
11508714|NCT01293032|Experimental|Group 3 (RS > 25)|"Patients with a high RS (> 25) assigned to Group 3, neoadjuvant chemotherapy as in Group 2 Arm 2.
~Treatment:
~Neoadjuvant therapy
~Therapeutic conventional surgery
~Laboratory biomarker analysis/Correlative studies
~Gene Expression Analysis/Oncotype DX Gene Expression Profiling System
~Systemic chemotherapy"
11508715|NCT01293019|Experimental|Experimental|Osteopathic treatment
11508716|NCT01293019|Placebo Comparator|Placebo|Sham osteopathic treatment
11508717|NCT01293019|Active Comparator|Usual care|Classic treatment of cystic fibrosis patients
11508718|NCT01293006|Experimental|Suvorexant first, then placebo|"During Period 1, participants <65 years of age were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening and participants ≥65 years of age were administered a 30-mg oral dose of
~suvorexant once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening."
11508719|NCT01293006|Experimental|Placebo first, then suvorexant|"During Period 1, participants <65 years of age received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening and participants ≥65 years of age received one placebo tablet matching
~suvorexant, orally, once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening."
11508720|NCT01292993|Experimental|Treatment A|400 mg LX4211
11508721|NCT01292993|Experimental|Treatment B|1000 mg metformin
11508722|NCT01292993|Experimental|Treatment C|400 mg LX4211 + 1000 mg metformin
11508723|NCT01292967|Placebo Comparator|Low flavanol|Low-flavanol chocolate contained 48 mg of cocoa flavanols. macro- and micro-nutrient matched with active comparator
11508724|NCT01292967|Active Comparator|High-flavanol with sugar|High-flavanol chocolate made with added sugar containing 251 mg of cocoa flavanols
11508725|NCT01292967|Active Comparator|High flavanol Maltitol|High-flavanol chocolate made with the sugar substitute maltitol containing 266 mg cocoa flavanols
11508726|NCT01292954|Active Comparator|Low dose blueberry|
11508727|NCT01292954|Active Comparator|medium dose blueberry|
11508728|NCT01292954|Active Comparator|high dose blueberry|
11508729|NCT01292954|Placebo Comparator|control|
11508730|NCT01292941|Active Comparator|Active comparator/Yellow catheter|SpeediCath coated catheter
11508731|NCT01292941|Experimental|NonCE marked intermittent catheter/red|
11508732|NCT01292941|Experimental|NonCE marked intermittent catheter/green|
11508733|NCT01292941|Experimental|NonCE marked intermittent catheter/Blue|
11508734|NCT01292928|Experimental|Stent|Stent implantation into SFA/PPA
11508735|NCT01292915||1|
11508736|NCT01292902|Active Comparator|healthy volunteers|
11508737|NCT01292902|Other|chronic heart failure|
11508738|NCT01292889||Seasonal Affective Disorder|Consists of Individuals with Seasonal Affective Disorder
11508739|NCT01292889||Subsyndromal Seasonal Affective Disorder|Consists of individuals who do not meet SAD criteria,but present more symptoms for the disorder than do controls.
11508740|NCT01292889||Major Depressive Disorder|Consists of individuals who have MDD.
11508741|NCT01292889||Controls|Consists of individuals who do not present symptoms of SAD or MDD.
11508742|NCT01292876|Other|Extracellular Matrix|Implantation of Extracellular Matrix
11508743|NCT01292863|Active Comparator|Conventional peritoneal dialysis solution|Subjects will be randomized to perform dialysis with the conventional peritoneal dialysis solution for 3 months. At the end of three months mesothelial cell shedding and apoptosis will be measured.
11508744|NCT01292863|Experimental|Novel biocompatible dialysis solution Delflex neutral pH|
11508745|NCT01292850||Healthy Volunteers|15 healthy volunteers were recruited
11508746|NCT01292837|Experimental|Levetiracetam|Twice daily (morning and evening) orally
11508747|NCT01292824|No Intervention|Standard liver transplant care|Liver Transplantation as per Standard of Care
11508748|NCT01292824|Experimental|ITX 5061|Liver Transplantation as per Standard of Care + ITX5061
11508749|NCT01292811|Experimental|Functional electrical Stimulation|The functional electrical stimulation for the treatment group will begin by designing a stimulation protocol that can generate the palmar and/or the lateral grasp on demand. In other words, the stimulation sequence (protocol) will be developed for each patient individually using either Compex Motion or HEWHS stimulator; this will allow the patient, who otherwise cannot grasp, to do so with the system. Both stimulators will be used to deliver the same FES therapy. Stimulation parameters are: 1) balanced, biphasic, current regulated electrical pulses; 2) pulse amplitude from 8 to 50 mA (typical values 17-26 mA); 3) pulse width from 250 to 300 μs; and 4) pulse frequency from 20 to 70 Hz (typical value 25 to 40 Hz).
11508750|NCT01292811|Other|Control Group|"The Control group will receive conventional occupational therapy pertaining to hand function [15].
~The conventional therapy represents control activities against which the FES therapy will be assessed. The conventional occupational therapy includes: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training."
11508751|NCT01292798|Experimental|0.5mg and 2.0mgRanibizumab|Three consecutive intravitreal ranibizumab 0.5mg injections followed by three consecutive intravitreal ranibizumab 2.0mg injections if specific criteria is met.
11508752|NCT01292785||Transsexual|Female-to-Male and Male-to-Female Transsexuals receiving hormonal therapy
11508753|NCT01292785||Healthy control subjects|receiving no hormonal therapy
11508754|NCT01292746|Experimental|Erchonia ML Scanner (MLS)|Erchonia MLS employs four diodes emitting 10 milliwatts (mW) 635 nanometer (nm) red laser light
11508755|NCT01292733|Experimental|Ovarian Cancer Screening|CA125 tumor marker, Transvaginal Ultrasound, Health Status Questionnaires
11508756|NCT01292720|Placebo Comparator|Placebo|Placebo (herbal oil)
11508757|NCT01292720|Experimental|Vitamin D|
11508758|NCT01292707|Active Comparator|Control|Prescribing staff in control facilities will receive the standard package of RDT training that is being provided by NMCP in Tanzania
11508759|NCT01292707|Active Comparator|HW|Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial.
11508760|NCT01292707|Active Comparator|HWC|The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
11508761|NCT01292694|Experimental|Losartan|Angiotensin II AT1 receptor antagonist which blocks the actions of angiotensin II
11508762|NCT01292694|Experimental|Captopril|ACE inhibitor which blocks the formation of angiotensin II
11508763|NCT01292694|Placebo Comparator|Placebo Tablet|A placebo tablet will be provided by the Vanderbilt Investigational Drug Service for these studies.
11508764|NCT01292681|Other|Multi-modality imaging|
11508765|NCT01292668|Experimental|Group I|Patients apply methyl-5-aminolevulinate hydrochloride (MAL) cream on the lesions and the surrounding normal skin. Beginning 3 hours later, patients undergo laser light treatment for 3-5 minutes.
11508766|NCT01292668|Experimental|Group II|Patients apply MAL cream on the lesions and the surrounding normal skin. Beginning 3 hours later, patients undergo light emitting diode treatment for 5-10 minutes.
11508767|NCT01292655|Experimental|Arm A1 (Escalation): BMS-906024|BMS-906024 solution intravenously as specified
11508768|NCT01292655|Experimental|Arm A2 (Expansion): BMS-906024|BMS-906024 solution intravenously as specified
11508769|NCT01292655|Experimental|Arm B1 (Escalation): BMS-906024|BMS-906024 solution intravenously as specified
11508770|NCT01292655|Experimental|Arm B2 (Expansion): BMS-906024|BMS-906024 solution intravenously as specified
11508771|NCT01292642|Experimental|Treatment|Cognitive behavioral therapy (CBT) plus transdermal patch nicotine replacement therapy (NRT) to treat co-occurring nicotine and cannabis dependence during a 10-week study.
11508772|NCT01292629|Experimental|Investigational intraocular lens|iSert 251 intraocular lens
11508773|NCT01292603|Experimental|1|
11508774|NCT01292603|Experimental|2|
11508775|NCT01292603|Experimental|3|
11508776|NCT01292590|Experimental|High fat meal|
11508777|NCT01292577|Experimental|CET/PT|Behavioral Intervention: Participants will receive adapted Cognitive Enhancement Therapy/Personal Therapy.
11508778|NCT01292577|Active Comparator|Treatment as Usual|Behavioral Intervention: Participants will receive treatment as usual.
11508779|NCT01292564|Active Comparator|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
11508780|NCT01292564|Placebo Comparator|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
11508781|NCT01292551|Active Comparator|Bosentan|
11508782|NCT01292551|Placebo Comparator|Placebo|
11508783|NCT01292538|Experimental|Erchonia GLS 532nm|532nm green laser light therapy.
11508784|NCT01292538|Sham Comparator|Placebo laser|Sham light output with no therapeutic benefit
11508785|NCT01292525|Active Comparator|Tacrolimus|
11508786|NCT01292525|Experimental|Withdrawal of Tacrolimus|
11508787|NCT01292512|Experimental|Intervention group|"A) Professional level. B) Patient level.
~Intervention
~Professional level:
~General Practitioners (GP) receive updated information on bereavement related symptoms, how to identify complicated grief, and the Dual Process Model (DPM) of coping.
~GPs receive suggestions on how to provide psycho-educational support for the patient.
~GPs are informed about the results of the initial assessment of their patient prognostic screening for complicated grief.
~Patient level:
~Patients receive updated information on bereavement related symptoms, the DPM of coping and suggestions on when to seek professional help.
~Patients are informed of the results of their initial assessment of their prognostic grief screening.
~Patients are encouraged to contact their GP if they worry about handling their bereavement reaction."
11508788|NCT01292512|Other|Control group|Treatment as usual (in the Danish health care system).
11508789|NCT01292499|No Intervention|Pharmacological treatment|Pharmacological treatment consists of the administration of a single antidepressant drug. The treatment will be administered as currently done by the mental health center, taking into due account patient's age, general health, previous response to antidepressant drugs, comorbidity, and potential side effects of drugs.
11508790|NCT01292499|Experimental|Psychotherapy|Will receive psychotherapy as well (10 sessions). Psychoterapy will consist of 10 weekly sessions, lasting about 50 minutes each. Psychotherapy will begin after 4-6 weeks from the beginning of the pharmacological treatment, to allow drugs to be effective. The overall list of visits scheduled for the patients is defined during the second psychiatric visit, to allow a reasonable planning of all of the appointments required for that particular patient. Psychotherapists will be free to follow the approach they were trained.
11508791|NCT01292499|Experimental|Psychoeducation|Will receive psychoeducation as well, with phone monitoring and regular follow-ups. Psychoeducation does not simply mean making the patient aware of depression etiology and drugs effect. In fact, patients should receive additional counselling about how to integrate the pharmacological treatment in their daily routine and to solve possible problems, in order to allow them to be actively and constantly involved in the treatment they are going to receive. Patients will receive 7 sessions of psychoeducation and 7 phone calls during the first 5 months. In addition, all of the patients will receive a brochure explaining the most important aspects of their disorder.
11508792|NCT01292499|Experimental|Psychoeducation and psychotherapy|Will receive both psychoeducation and psychotherapy sessions.
11508793|NCT01292486|Experimental|Patients with multiple myeloma|Multiple myeloma patients who receive autologous stem-cell transplants, collected using the Spectra Optia Apheresis System, following myeloablative therapy. The study is limited to subjects who are expected demonstrate normal neutrophil recovery.
11508794|NCT01292473|Experimental|Placebo|Placebo subcutaneously (sc) every 4 weeks
11508795|NCT01292473|Experimental|Omalizumab 75 mg|Omalizumab 75 mg sc every 4 weeks
11508796|NCT01292473|Experimental|Omalizumab 150 mg|Omalizumab 150 mg sc every 4 weeks
11508797|NCT01292473|Experimental|Omalizumab 300 mg|Omalizumab 300 mg sc every 4 weeks.
11508798|NCT01292460|Active Comparator|Preservative-free timolol|
11508799|NCT01292460|Experimental|Preservative-free FDC and placebo|
11508800|NCT01292460|Active Comparator|Preservative-free tafluprost|
11508801|NCT01292460|Experimental|Preservative-free FDC|
11508802|NCT01292447|Placebo Comparator|Control Group|Will receive placement of inert glycerin gel on ectocervix and in cervical canal prior to IUD placement.
11508803|NCT01292447|Experimental|Study Group|Will receive placement of 2% lidocaine gel on ectocervix and in cervical canal prior to IUD placement.
11508804|NCT01292434|Experimental|Lunch in the Bag Intervention|Lunch is in the Bag behavioral intervention: Parents receive a behavioral intervention that includes handouts/newsletters sent to parents from the early care and education (ECE) center, classroom activities and projects, an implementation support calendar, and teacher training.
11508805|NCT01292434|No Intervention|Control|Parents received no specific nutrition education intervention at the ECE center, other than usual practice.
11508806|NCT01292421|Placebo Comparator|Arm I|Participants consume placebo HBV-EPV on days 0, 14, 28, and 56.
11508807|NCT01292421|Experimental|Arm II|Participants consume HBV-EPV expressing HBsAg on days 0 and 28 and placebo HBV-EPV on days 14 and 56.
11508808|NCT01292421|Experimental|Arm III|Participants consume HBV-EPV expressing HBsAg on days 0, 28, and 56 and placebo HBV-EPV on day 14.
11508809|NCT01292421|Experimental|Arm IV|Participants consume HBV-EPV expressing HBsAg on days 0, 14, 28, and 56.
11508810|NCT01292408|Experimental|Daily HCQ|Between tumor biopsy and surgery, during 2-3 weeks, breast cancer patients will take daily HCQ, an anti-malaria and anti-rheumatic drug that precludes tumor cells from surviving hypoxia by inhibiting the process of autophagy in these cells
11508811|NCT01292395|Experimental|Protein level 1|
11508812|NCT01292395|Experimental|Protein level 2|
11508813|NCT01292395|Experimental|Protein level 3|
11508814|NCT01292382|Sham Comparator|rTMS versus Sham|rTMS: active coil Sham: inactive coil
11508815|NCT01292382|Active Comparator|rTMS versus sham|rTMS group: active coil Sham group: inactive coil
11508816|NCT01292369||Breast cancer|Women diagnosed with breast cancer by a positive biopsy test after mammography.
11508817|NCT01292369||Breast control|Women with negative biopsy result done due to a suspicious mammography exam.
11508818|NCT01292369||Colon cancer|Men and women diagnosed with colon cancer by a positive colonoscopy and biopsy.
11508819|NCT01292369||Colon control|Men and women with negative colonoscopy and biopsy tested due to complaints indicating the possibility of colon cancer.
11508820|NCT01292356|Experimental|cetuximab|
11508821|NCT01292317|Active Comparator|intravenous hydration|intravenous application of 0.9% saline
11508822|NCT01292317|Active Comparator|oral hydration only|
11508823|NCT01292304|Experimental|Tolvaptan|Tolvaptan 15 mg tablet once daily for 7 days followed by Tolvaptan 30 mg (two 15 mg tablets) once daily according to efficacy and tolerability
11508824|NCT01292278||aSAH|consecutive patients with spontaneous or aneurysmal subarachnoid hemorrhage
11508825|NCT01292278||control group|no neurological disease but spinal anesthesia
11508826|NCT01292265|Experimental|CZP 200 mg|Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
11508827|NCT01292252|Experimental|Treatment|Forteo, Terapeptide 20 ug subcutaneous injection
11508828|NCT01292252|Placebo Comparator|Control|Saline placebo
11508829|NCT01292239|Experimental|TMC435 100 mg 12 Wks + PR 24/48|Participants received TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment was stopped at Week 24 for participants who achieved HCV RNA < 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable HCV RNA at Week 12. All other participants continued PR until Week 48.
11508830|NCT01292239|Experimental|PBO 12 Wks + PR 48|Participants received placebo (PBO) once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.
11508924|NCT01291472|Other|ketorolac|Ketorolac will be given to all patients as a part of routine medical care
11510269|NCT01282034|Active Comparator|Marrow stimulation|
11508831|NCT01292226|Experimental|Mycophenolate Mofetil Monotherapy|Participants received an initial dose of mycophenolate mofetil (MMF), 1 gram (g), orally (PO), twice per day (BID), within 5 days of transplant for 24 weeks. Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.
11508832|NCT01292213||Cases|Subjects diagnosed with chronic cough who are undergoing general anaesthesia and bronchoscopy/BAL as part of the diagnostic process for chronic cough.
11508833|NCT01292213||Controls|Subjects without respiratory symptoms who are undergoing general anaesthesia for elective surgery or endoscopy of non-respiratory-related conditions.
11508834|NCT01292200|Experimental|watch DVD and small group discussion|Participants will watch the video in a group and discuss the video.
11508835|NCT01292200|Placebo Comparator|watch video only|watch a 22 minutes long video at home by herself.
11508836|NCT01292187|Experimental|Oral calcitonin at dinner-or bedtime|Intervention: Oral calcitonin at dinnertime or oral calcitonin at bedtime. Postmenopausal subjects with osteopenia were treated for one year (also with vitamin D and calcium supplements) to determine if oral calcitonin tablets would prevent the loss of bone mineral density compared with placebo. Randomization to active or placebo was done 2:1. After randomization, further randomization was done to divide each arm into two groups, one in which dosing was at dinnertime and the other in which dosing was at bedtime to determine if food affected efficacy or safety.
11508837|NCT01292187|Experimental|Oral placebo at dinner- or bedtime|Intervention: oral placebo at dinnertime or oral placebo at bedtime
11508838|NCT01292174|Experimental|Group 1 - lowest dosage|120 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
11508839|NCT01292174|Experimental|Group 2 - middle dosage level|240 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
11508840|NCT01292174|Experimental|Group 3 - highest dosage level|480 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
11508841|NCT01292161|Other|Silymarin|Silymarin drived from Silybum marianum (milk thistle), a flowering member of the daisy family, may benefit liver function in people infected with the hepatitis C virus.
11508842|NCT01292135|Experimental|PCI-32765 plus fludarabine/cyclophosphamide/rituximab (FCR)|
11508843|NCT01292135|Experimental|PCI-32765 plus bendamustine/rituximab (BR)|
11508844|NCT01292122|Experimental|VCT-01-treated STSG donor site wound|Application of VCT-01 to STSG donor site wound at Day 0
11508845|NCT01292109||PICOPREP®|
11508846|NCT01292083|Experimental|Treatment|See Detailed Description
11508847|NCT01292070|Experimental|Control-Experimental arm|Each subject will serve as their own control with the left arm receiving the control protein (Histamine prick, intradermal diluent and intradermal CAT) and right arm receiving the experimental protein (GFD).
11508848|NCT01292057|Active Comparator|Aripiprazole|Medication
11508849|NCT01292057|Placebo Comparator|Sugar pill|
11508850|NCT01292044|Experimental|The study population|The study population consists of patients for whom an echo-guided fine-needle aspiration was performed for one or more thyroid nodes, and for whom surgical node excision is required.
11508851|NCT01292031|Experimental|Colistin|Colistin 4.5 MU/iv.plus Colistin 3 MU/iv./8 h. 30 minutes infusion
11508852|NCT01292031|Active Comparator|Meropenem|Meropenem 2 g/iv/ 8 h. 30 minutes infusion
11508853|NCT01292005|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
11508854|NCT01292005|Placebo Comparator|Placebo|Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
11508855|NCT01291992||Continuous EEG Monitoring|Immediately after surgery, while still sedated and in the cardiac surgery recovery unit, 9 sticker electrodes applied to the skin just below the hairline, which record brain activity onto a computer. The EEG will be recorded for 24 hours. This brain activity (EEG) will later be interpreted by a neurologist who will be looking for evidence of seizure activity in the brain waves. Other relevant information: age, sex, the nature of other health problems, drugs used, complications and whether or not seizures are found will be stored on our computer for further evaluation.
11508856|NCT01291979|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
11508857|NCT01291979|Placebo Comparator|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
11508858|NCT01291966|Experimental|Motivational interview|
11508859|NCT01291953|Experimental|Screening|Opportunist Screening asymptomatic patients. Taking the arterial pulse. Will invite patient to realize an ECG, if pulse is irregular
11508860|NCT01291953|Active Comparator|Control|Case finding of patient whith symptoms of atrial fibrilation. Taking the arterial pulse. ECG if pulse is irregular
11508861|NCT01291940|Experimental|Pediatric Moisturizer Intervention|Apply one of four moisturizers to one arm daily for four weeks.
11508862|NCT01291940|Experimental|Adult Moisturizer Intervention|Apply moisturizer to one arm once a day for four weeks.
11508863|NCT01291940|No Intervention|Adult Control|No intervention.
11508864|NCT01291927|Experimental|Pancreas-sparing duodenectomy|
11508865|NCT01291927|Active Comparator|Pancreaticoduodenectomy|
11508866|NCT01291914|Experimental|FX005|
11508867|NCT01291914|Placebo Comparator|Placebo 1 (Carrier)|
11508868|NCT01291914|Placebo Comparator|Placebo 2 (Diluent)|
11508869|NCT01291901|Experimental|Active NP2|Single intradermal dose of active NP2. An open label study extension will offer up to two additional doses of active NP2 between weeks 4-10 following the previous dose.
11508870|NCT01291901|Placebo Comparator|Placebo|Single intradermal dose of placebo (vehicle). An open label study extension will offer up to two additional doses of active NP2 between weeks 4-10 following the previous dose.
11508871|NCT01291875|Experimental|Intensive periodontal treatment|
11508872|NCT01291875|Active Comparator|Supragingival biofilm control|
11508873|NCT01291849|Experimental|remifentanil for intranasal surgery|
11508874|NCT01291823|Experimental|Concomitant Gefitinib and radiotherapy|Patients received Gefitinib and radiation therapy
11508875|NCT01291810|Experimental|TNF Kinoid|
11508877|NCT01291797||Neonates with congenital heart disease|The case group will consist of newborns born between 32 and 41 weeks gestation diagnosed with a congenital cardiac anomaly requiring surgical repair during their hospitalization and managed in the Mount Sinai Neonatal Intensive Care Unit. The control arm will include newborns born between 32 and 41 weeks without congenital cardiac anomalies. Both groups will undergo a neurological screening assessment and receive an AEEG to look at sleep wake cycles.
11508878|NCT01291784|Experimental|monoclonal antibody to TGF-beta|starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
11508879|NCT01291771|Other|comparator|One group of patients with no myocardial ischemia on non invasive testing will be followed up for 2 years
11508880|NCT01291771|Experimental|coronary angiography group|One group of patients with myocardial ischemia on non invasive testing will undergo coronary angiography and measure of FFR + CFR to detect myocardial microvascular disease
11508881|NCT01291758||GWI|Veterans of the 1990-1991 Persian Gulf War who have autonomic, neurological and other symptoms
11508882|NCT01291758||HC|Healthy veterans of the 1990-1991 Persian Gulf War
11508883|NCT01291745||Patients with MYELODYSPLASTIC SYNDROMES|Patients diagnosed with MDS according to FAB, WHO and IPSS classifications. Patients who necessitate to start a treatment (i.e. EPO, Lenalidomide, Azacytidine).
11508884|NCT01291732|Experimental|BI 135585 XX|single dose of BI 135585
11508885|NCT01291732|Placebo Comparator|matching placebo|single dose of matching placebo
11508886|NCT01291719|Experimental|insulin and glucose infusion|trial of experimental technique in outpatient setting; the group under study will be comprised of type 1 and type 2 diabetic individuals ; they will have automated treatment using algorithm which regulates balancing infusions of glucose and/or insulin intravenously without manual intervention; blood glucose target of 80-180 mg/dl will be guide for the automated system
11508887|NCT01291706||Mild TBI with mild lesions on CT scan|Negative predictive value of transcranial doppler for patients with mild to moderate traumatic brain injury and mild brain lesions on initial CT scan (TCDB II)
11508888|NCT01291693|Experimental|Personal counseling|
11508889|NCT01291693|Experimental|Computer generated feedback letters|
11508890|NCT01291693|No Intervention|Control group|Treatment as usual
11508891|NCT01291680||Pre - delivery pregnant women|Participants in the study will be pregnant women attending the obstetric ER for routine term followup. This evaluation is generally conducted at week 39-41 of pregnancy. The current study will focus on women attending a regular followup, not considered to be at high risk.
11508892|NCT01291654|Experimental|Paracetamol|Babies with hsPDA will be treated with paracetamol 15 mg/kg/dose x 4/day for three days
11508893|NCT01291654|Experimental|NSAID|Babies with hsPDA will be randomized to treatment with IV indomethacin 17 mcg/kg/hr x 36 hr
11508894|NCT01291641|Placebo Comparator|Group A|HMGCoA reductase inhibitor continued
11508895|NCT01291641|Active Comparator|Group B|HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID
11508896|NCT01291641|Active Comparator|Group C|HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID + Cilostazol 100 mg PO, BID
11508897|NCT01291628|Experimental|socks containing copper-oxide fibers|
11508898|NCT01291615|Experimental|Gemcitabine group|800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
11508899|NCT01291615|Experimental|S-1 group|S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks
11508900|NCT01291602|Experimental|NXL104|Six Japanese subjects to receive single and repeated 500 mg IV infusions of NXL104
11508901|NCT01291602|Placebo Comparator|Placebo|Three Japanese subjects to receive placebo IV doses
11508902|NCT01291602|Experimental|Ceftazidime NXL104 (CAZ104)|Six Japanese subjects to receive single and repeated IV infusions of 500 mg NXL104 with 2000 mg ceftazidime
11508903|NCT01291589|Experimental|Cognitive-behavioral counseling|
11508904|NCT01291576|Active Comparator|Rectal/colorectal segmental resection|
11508905|NCT01291576|Active Comparator|Rectal nodule excision|
11508906|NCT01291563|Experimental|001|TMC207 8 tablets of TMC207 (100 mg/tablet) on Day 1
11508907|NCT01291563|Placebo Comparator|002|TMC207 placebo 8 tablets of TMC207 placebo on Day 1
11508908|NCT01291563|Active Comparator|003|Moxifloxacin 1 capsule of moxifloxacin (400 mg/capsule) on Day 2
11508909|NCT01291563|Placebo Comparator|004|Moxifloxacin placebo 1 capsule of moxifloxacin placebo on Day 2
11508910|NCT01291550||Nerodegenerative diseases|Patients with parkinsonism and patients with dementia
11508911|NCT01291550||Controls|
11508912|NCT01291550||ADHD|Subjects diagnosed with ADHD
11508913|NCT01291537|Experimental|Duodopa|
11508914|NCT01291537|Active Comparator|Best medical treatment|
11508915|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, 400-500 calorie|
11508916|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, 600- 750 calorie|
11508917|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, bedtime|
11508918|NCT01291524|Other|Pregabalin immediate release, 300 mg|Reference Treatment
11508919|NCT01291511|Experimental|Iloperidone|After meeting all entry criteria, completing a 1-week open-label iloperidone titation period (up to 12 mg/day), followed by a 14-24 week open-label iloperidone flexible dose-stabilization period (up to 24 mg/day), approximately 260 patients will be randomized to one of two arms in a 1:1 ratio of iloperidone (flexible dosing 8-24 mg/day) to placebo. Post-randomization double-blind study medication will be administered orally twice daily for up to 26 weeks to evaluate relapse prevention. Subsequently, during the extension period, after a 1-week mock double-blind titration, open-label iloperidone (8-24 mg/day) is administered for up to 51 weeks to evaluate long-term safety.
11508920|NCT01291511|Placebo Comparator|Iloperidone (including Placebo)|Post-randomization matching placebo is administered orally bid during the double-blind period.
11508921|NCT01291498|Other|HIFU Treatment|High Intensity Focused Ultrasound. This is not a comparative study
11508922|NCT01291485|Experimental|Lifestyle counseling|Intervention includes education about HIV and medication adherence, motivational interviewing, cognitive behavioral techniques, and problem-solving strategies to improve HIV medication adherence and clinical outcomes.
11508923|NCT01291485|No Intervention|Treatment as Usual|
11510270|NCT01282034|Experimental|Medical device: MaioRegen|
11508925|NCT01291459|Experimental|single arm|Maraviroc/raltegravir/emtricitabine/tenofovir 24 weeks followed by Maraviroc/Raltegravir 24 weeks
11508926|NCT01291446|Sham Comparator|High flatulogenic diet|3-day diet containing fermentable residues
11508927|NCT01291433|Experimental|PENTOCLO|Association pentoxifylline, tocopherol and clodronate
11508928|NCT01291433|Placebo Comparator|Placebo|Triple placebo
11508929|NCT01291407|Experimental|S-1,peroral BID,capsule|
11508930|NCT01291381|Active Comparator|Dermatophagoides pteronyssinus extract|Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
11508931|NCT01291381|Active Comparator|Pharmacotherapy|Persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
11508932|NCT01291355|Experimental|Specific maternal position|"women allocated to intervention group will be invited to adopt a posture all fours type:support on the knees, torso tilted forward, back stretched for a minimum of 10 minutes. A cushion is placed between the legs of the woman to limit the cuts. According to Dr de Gasquet, author of the description of this posture, the effect on the variety of presentation would be almost immediate."
11508933|NCT01291355|No Intervention|Control|Not specific intervention for this group- Only usual care
11508934|NCT01291342||Preeclampsia|30 preeclamptic pregnant women with gestational age >24 weeks and no chronic medical disorders who are not in labor and their fetus is alive.
11508935|NCT01291342||Normal pregnancy|30 normotensive pregnant women with gestational age >24 weeks and no chronic medical disorders who has no obstetrical problems, not in labor and their fetus is alive.
11508936|NCT01291342||Healthy non-pregnant|30 healthy non-pregnant control women not on medications and has not delivered a baby or conceived during the year before the breath collection
11508937|NCT01291329|Experimental|WJ-MSC|Wharton's jelly- Derived Mesenchymal Stem Cells Transfer
11508938|NCT01291316|Experimental|clobazam|
11508939|NCT01291316|Active Comparator|clonazepam|
11508940|NCT01291316|Placebo Comparator|tolterodine|
11508941|NCT01291303|Experimental|1- optimized ventilation|35 COPD patients ventilated for acute exacerbations in NIV with pressure support mode.
11508942|NCT01291303|Experimental|2-standard setting of ventilation|35 COPD patients ventilated for acute exacerbations in NIV with pressure support mode.
11508943|NCT01291290|No Intervention|Control treatment|Usual transfusion regime to patients with rAAA
11508944|NCT01291290|Experimental|Thrombocyte|Early thrombocyte administration to patients with rAAA
11508945|NCT01291277|Active Comparator|Ligation: 1-week interval|Endoscopic variceal ligation performed at 1-week intervals
11508946|NCT01291277|Active Comparator|Ligation 2-week interval|Endoscopic variceal ligation performed at 2-week intervals
11508947|NCT01291238|Experimental|Healthy lifestyle habits|Increased physical activity and healthy food with decreased sugar and fat content
11508948|NCT01291225|Other|Playground|"The playground arm of the study will consist of playground audits and KAP surveys about playground safety in both Chillicothe and Circleville, Ohio.
~The intervention is Playground Safety Renovations and Development."
11508949|NCT01291225|Other|Farms|The Farm Arm will consist of farm audits with safety checklists and KAP surveys about farm safety. The intervention is a Safety Educational Campaign.
11508950|NCT01291212|Active Comparator|Testosterone and FSHr|
11508951|NCT01291212|Active Comparator|testosterone and FSHr-LHr|
11508952|NCT01291199|Experimental|Vardenafil 10 mg bid|
11508953|NCT01291199|Placebo Comparator|Placebo|
11508954|NCT01291186|Experimental|BPV6NO|
11508955|NCT01291186|Experimental|BPV7NO|
11508956|NCT01291186|Experimental|BPV8NO|
11508957|NCT01291186|Experimental|BPV9NO|
11508958|NCT01291186|Experimental|BPV10NO|
11508959|NCT01291186|Experimental|BPV11NO|
11508960|NCT01291186|Active Comparator|BPV6O|
11508961|NCT01291186|Active Comparator|BPV7O|
11508962|NCT01291186|Active Comparator|BPV8O|
11508963|NCT01291186|Active Comparator|BPV9O|
11508964|NCT01291186|Active Comparator|BPV10O|
11508965|NCT01291186|Active Comparator|BPV11O|
11508966|NCT01291173|Experimental|SPD489 30 mg|
11508967|NCT01291173|Experimental|SPD489 50 mg|
11508968|NCT01291173|Experimental|SPD489 70 mg|
11508969|NCT01291173|Placebo Comparator|Placebo|
11508970|NCT01291160|Experimental|Epiflo Treatment|The cohort will comprise of 2 populations: the Treatment Arm of up to 90 subjects; and the Control Arm of up to 90 subjects, in order to collect 120 invaluable subjects. The Treatment Arm includes subjects with DFU who will receive EPIFLO in addition to standard wound care therapy during the Treatment Period.
11508971|NCT01291160|Sham Comparator|Sham Device|The cohort will comprise of 2 populations: the Treatment Arm of up to 90 subjects; and the Control Arm of up to 90 subjects, in order to collect 120 invaluable subjects. Control Arm includes subjects with Diabetic Foot Ulcers who will receive sham units of EPIFLO along with standard wound care therapy during the treatment Period.
11508972|NCT01291147|Active Comparator|Levobupivicaine|
11508973|NCT01291147|Placebo Comparator|0.9% Saline|
11508974|NCT01291134||Cervical Degenerative Disc Disease|
11508975|NCT01291121|Active Comparator|group 1|Intravitreal ranibizumab 0.5mg only group
11508976|NCT01291108|Experimental|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1.
11508977|NCT01291108|Experimental|AGN-210669 + bimatoprost|AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% applied as 1 drop of each treatment in both eyes every evening during Month 2.
11508978|NCT01291108|Experimental|AGN-210669 + bimatoprost vehicle|AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.
11508979|NCT01291108|Active Comparator|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1.
11508980|NCT01291108|Experimental|bimatoprost + AGN-210669|bimatoprost ophthalmic solution 0.03% + AGN-210669 0.05% applied as 1 drop of each treatment in both eyes every evening during Month 2.
11510271|NCT01282021||Region 1|Northern part: Gonder, Gojam, Tigray
11508981|NCT01291108|Other|bimatoprost + bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.
11508982|NCT01291095|Active Comparator|CONCURRENT CHEMO-RADIOTHERAPY ARM|Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy).
11508983|NCT01291095|Experimental|ACCELERATED FRACTIONATION RADIOTHERAPY ARM|Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
11508984|NCT01291082||Breast cancer patients|Breast cancer patients
11508985|NCT01291069|Experimental|Tadalafil Citrate|The study subjects will be given Tadalfil citrate, encapsulated, 0.8-1 mg/kg/day in 1 dose orally. Max dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
11508986|NCT01291069|Placebo Comparator|Sugar pill|If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a sugar pill. All patients will receive either study drug or placebo for a total of 20 days.
11508987|NCT01291056|Active Comparator|Clomphine|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
11508988|NCT01291056|Placebo Comparator|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
11508989|NCT01291043|Experimental|Shiatsu Group|
11508990|NCT01291043|No Intervention|Control Group|
11508991|NCT01291030|Experimental|hypomagnesemic + magnesium supplement|The patient group of hypomagnesesemic renal transplant recipients randomized to magnesium supplementation (number = 30). The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion,which are repeated after 6 months.
11508992|NCT01291030|No Intervention|hypomagnesemic without magnesium supplement|The patient group of hypomagnesesemic renal transplantation recipients, randomized to no magnesium supplementation (number = 30). During 6 months, no magnesium supplementation is started, provided that the serum magnesium level remains > 1,2 milligram/deciliter. In case of cramps, intermittent supplementation is allowed, but will be recorded. The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion,which are repeated after 6 months.
11508993|NCT01291030|No Intervention|normomagnesemic without magnesium supplement|In the control group of normomagnesemic renal transplantation recipients (number = 10), only a baseline assessment will be performed. The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion.
11508994|NCT01291017|Experimental|PD0332991|PD0332991 125 mg PO days 1 - 21
11508995|NCT01291004|Experimental|28-day Desogestrel Oral Contraceptive|
11508996|NCT01291004|Active Comparator|28-day Drospirenone Oral Contraceptive|
11508997|NCT01291004|Active Comparator|28-day Levonorgestrel Oral Contraceptive|
11508998|NCT01290991|Other|Bone Graft|Single Arm.. Augment Bone Graft for Osteochondral Defects
11508999|NCT01290978|Active Comparator|ChloraPrep|Applied ChloraPrep on the application site per manufacturer's instruction
11509000|NCT01290978|Active Comparator|DuraPrep|Apply DuraPrep to the application site per manufacturer's instruction
11509001|NCT01290965|Placebo Comparator|Placebo comparator|
11509002|NCT01290965|Active Comparator|SCY-635 30 mg once daily|
11509003|NCT01290965|Active Comparator|SCY-635 100 mg once daily|
11509004|NCT01290965|Active Comparator|SCY-635 300 mg once daily|
11509005|NCT01290965|Active Comparator|SCY-635 100 mg three times daily|
11509006|NCT01290965|Active Comparator|SCY-635 200 mg three times daily|
11509007|NCT01290965|Active Comparator|SCY-635 300 mg three times daily|
11509008|NCT01290952|Experimental|Off-pump bypass surgery|Off-pump coronary artery bypass graft (OPCAB) using mandatory a stabilization device and advisable, but not mandatory, a heart positioner
11509009|NCT01290952|Active Comparator|On-pump bypass surgery|coronary artery bypass graft with cardiopulmonary bypass (CPB/CAB)
11509010|NCT01290939|Experimental|Arm 1|Lomustine 90 mg/m² every 6 weeks (cap. 160 mg) + bevacizumab 10 mg/kg every 2 weeks (at further progression treatment will be according to investigators discretion). In the absence of hematological toxicity > grade 1 during the first cycle the dose of lomustine can be escalated to 110 mg/m² (cap 200 mg) in their second cycle.
11509011|NCT01290939|Active Comparator|Arm 2|Lomustine single agent 110 mg/m² every 6 weeks (cap. 200 mg) (at further progression treatment will be according to investigators discretion).
11509012|NCT01290926|Experimental|Capecitabine & Sorafenib|Sorafenib 200mg in the morning,400mg in the evening; escalation to 400mg twice daily after 1 cycle, Oral, Continuous dosing Capecitabine 850mg/m2 twice daily, Oral Days 1-14, weeks 1-2
11509013|NCT01290913|Experimental|omalizumab, oral desensitization|Patients receive omalizumab along with oral peanut desensitization.
11509014|NCT01290900|Experimental|CXL104|2000 mg NXL104 + 1500 mg Ceftaroline (IV)
11509015|NCT01290900|Experimental|CAZ104|Placebo Infusion (saline) + 2000 mg NXL104 + 3000 mg Ceftazidime (IV)
11509016|NCT01290900|Active Comparator|Moxifloxacin|Moxifloxacin 400mg (1 tablet)
11509017|NCT01290900|Placebo Comparator|Placebo|Placebo Infusion (saline)
11509018|NCT01290887|Experimental|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months.
11509019|NCT01290874|Experimental|Tiotropium|Tiotropium bromide will be evaluated as a treatment for asthma.
11509020|NCT01290874|Active Comparator|Salmeterol or Formoterol|Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
11509021|NCT01290861||pre-manifest HD|
11509022|NCT01290861||early manifest HD|
11509023|NCT01290861||healthy controls|
11509024|NCT01290848|Experimental|Township of Uxbridge|The Take TIME for Your Child's Health campaign will target parents and caregivers of children up to 8 years of age.
11509025|NCT01290848|No Intervention|Township of Guelph/Ermosa|For a control group the investigators have selected a community that is similar in size, household composition, population density, distance from Toronto and economic status to the Township of Uxbridge.
11509026|NCT01290835|Experimental|Stereotactic radiotherapy|Accelerated stereotactic radiotherapy as an adjuvant treatment for early stage breast cancer.
11509027|NCT01290822|Experimental|BiVP Pacing|BIVP optimize AVD, VVD, and LVPS parameters and assess the effect on cardiac output.
11509028|NCT01290822|Active Comparator|AAI Pacing|Traditional atrial (AAI) pacing
11509029|NCT01290809||Prophylactic Cranial Irradiation|NSCLC patients treated with whole brain PCI: cognitive functioning as assessed by neuropsychological tests?
11509030|NCT01290809||no Prophylactic Cranial Irradiation|NSCLC patients not treated with whole brain PCI: cognitive functioning as assessed by neuropsychological tests?
11509031|NCT01290796|Other|Ajust Adjustable Single-Incision Sling|Urinary incontinence sling
11509032|NCT01290783|Active Comparator|FOLFIRI|
11509033|NCT01290783|Experimental|FOLF(HA)iri|
11509034|NCT01290770||obese men|obese men with chest pain like angina
11509035|NCT01290757|Experimental|Dabigatran etexilate 150 mg (T)|Capsugel (T), oral administration
11509036|NCT01290757|Experimental|Dabigatran etexilate 150 mg (R)|Qualicaps (R), oral administration
11509037|NCT01290744|Placebo Comparator|Placebo group|These patients will receive placebo for 12 months after completion of MDT.
11509038|NCT01290744|Experimental|Clofazimine for 12 months after MDT|Patients will be given clofazimine (100mg daily) for 12 months after completion of MDT.
11509039|NCT01290731|Experimental|TMC435 100 mg 12 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24 (PR 24). Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels less than (<) 1.2 log10 IU/mL detectable or undetectable of at Week 4, and undetectable HCV RNA levels at Week 12. All other participants will continue PR until Week 48 (PR 48).
11509040|NCT01290718|Experimental|Single Arm|
11509041|NCT01290705|Experimental|high exercise|High dose, high repetition exercise therapy, 3 times weekly in 12 weeks
11509042|NCT01290705|Experimental|low exercise|low dose, low repetition exercise therapy, 3 times weekly in 12 weeks
11509043|NCT01290692|Experimental|TVI-Brain-1|All patients will receive the full TVI-Brain-1 treatment.
11509044|NCT01290679|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) (PegIFN alpha-2a/b) and ribavirin (Copegus or Rebetol) for 24 or 48 weeks
11509045|NCT01290679|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) (PegIFN alpha-2a/b) and ribavirin (Copegus or Rebetol) for 48 weeks
11509046|NCT01290666||GORE® BIO-A® Fistula Plug|All patients in study receive the GORE® BIO-A® Fistula Plug.
11509047|NCT01290653|Experimental|Dry Needling of trigger point|Deep dry needling will be applied on the upper trapezius myofascial trigger point
11509048|NCT01290653|Experimental|Strain-counterstraing technique|This manual technique will be applied at the upper trapezius.
11509049|NCT01290653|Placebo Comparator|Placebo manual technique|A technique simulating strain-counterstrain, but without any therapeutic manoeuvre will be applied at the upper trapezius site.
11509050|NCT01290640||TC3 TKA|Subjects implanted with a DePuy fixed-bearing Total Condylar III (TC3) TKA
11509051|NCT01290640||PFC RP TC3 TKA|Subjects implanted with a DePuy PFC Rotating Platform TC3 TKA
11509052|NCT01290627||Knee Prosthesis LCS PS RP TKA|Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
11509053|NCT01290627||Knee Prosthesis Sigma PS RP TKA|Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
11509054|NCT01290627||Control|Subjects with normal knees
11509055|NCT01290614|Experimental|Pharmacist intervention|
11509056|NCT01290614|Active Comparator|Control - usual care|Patients assigned to control will continue to receive care from their VA provider.
11509057|NCT01290601|Experimental|Cohort 1 Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
11509058|NCT01290601|Active Comparator|Cohort 1-Chloroquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
11509059|NCT01290601|Experimental|Cohort 2 Tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
11509060|NCT01290601|Active Comparator|Cohort 2 Chloroquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
11509061|NCT01290588||Children of Caucasian descent|Healthy children of Caucasian descent.
11509062|NCT01290588||Adults of Caucasian descent|Healthy adult eyes of Caucasian descent.
11509063|NCT01290588||Children of African-American descent|Healthy children of African-American descent.
11509064|NCT01290588||Adults of African-American descent|Healthy adults of African-American descent.
11509065|NCT01290575|Active Comparator|Arm 1 BMS-820132 or placebo|
11509066|NCT01290575|Active Comparator|Arm 2 BMS-820132 or placebo|
11509067|NCT01290575|Active Comparator|Arm 3 BMS-820132 or placebo|
11509068|NCT01290575|Active Comparator|Arm 4 BMS-820132 or placebo|
11509069|NCT01290575|Active Comparator|Arm 5 BMS-820132 or placebo|
11509070|NCT01290575|Active Comparator|Arm 6 BMS-820132 or placebo|
11509071|NCT01290575|Active Comparator|Arm 7 BMS-820132 or placebo|
11509072|NCT01290575|Active Comparator|Arm 8 BMS-820132 or placebo|
11509073|NCT01290575|Active Comparator|Arm 9 BMS-820132 or placebo|
11509074|NCT01290562|Experimental|Stereotactic Body Radiotherapy (SBRT)|Cohort 1: Patients with spinal metastases and no prior radiation Cohort 2: Patients with spinal metastases in a previously radiated field Cohort 3: Post-operative patients with spinal metastases
11509075|NCT01290549|Experimental|Polatuzumab Vedotin|Polatuzumab vedotin will be administered by an IV infusion of escalating doses (starting dose of 0.1 mg/kg, potentially to be followed by 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, and 4.0 mg/kg doses) every 3 weeks (q3w) (Day 1 of each 21 day cycle).
11509076|NCT01290549|Experimental|Polatuzumab Vedotin + Rituximab|Polatuzumab vedotin will be administered by an IV infusion q3w (Day 1 of each 21 day cycle). Rituximab was administered by an IV infusion at 375 milligrams per square meter (mg/m^2) body surface area dose q3w.
11509077|NCT01290536|Experimental|Yttrium-90 liver radioembolization|
11509078|NCT01290523|Experimental|Yttrium-90 liver radioembolization|Patients who receive liver-directed therapy with Yttrium-90 glass microspheres (TheraSphere)
11509079|NCT01290510|Experimental|hyaluronic acid sodium salt|
11509080|NCT01290497|Active Comparator|Hyaluronic acid 5 x 2.5 ml|
11509081|NCT01290497|Experimental|Hyaluronic acid 1 X 5 ml|
11509082|NCT01290497|Experimental|Hyaluronic acid 2 x 5 ml|
11509083|NCT01290484|Experimental|Open Label|Sildenafil oral tablet three times daily
11509084|NCT01290471|Experimental|Part 1 Dose Escalation|Dose escalation of U3 1565 will follow a modified 3+3 study design with a starting intravenous (IV) dose of 2 mg/kg. A maximum of 2 new subjects will receive their first dose of U3-1565 per 24-hour period during the dose-escalation phase. Subsequent escalating doses of 8, 16, and 24 mg/kg are planned. Three to 6 subjects will be enrolled in 4 sequential dose level cohorts.
11509085|NCT01290471|Experimental|Part 2a Dose Expansion|For Part 2a, 6 or 12 subjects with advanced solid malignant tumors will be enrolled and treated at the MTD or MAD to further define the safety and tolerability of U3-1565. These additional subjects are expected to permit the detection of relatively rare toxicities that would not likely be observed during the dose escalation part of the study, whose 3+3 design implies a maximum of 6 subjects only will be treated at the MTD or MAD. Six subjects will be treated; however, if toxicities meeting the definition of DLT are observed during the first cycle of treatment, 6 more subjects will be treated for a total of 12 subjects.
11509086|NCT01290471|Experimental|Part 2b Dose Expansion and Anti-tumor Impact|For Part 2b, up to 30 subjects with advanced solid malignant tumors, with a preference for those with advanced ovarian cancer, will be enrolled and treated at the MTD or MAD. This number of subjects should allow demonstrating U3-1565 has anti-tumor impact by showing treatment-induced changes in pharmacodynamic biomarkers and clinical activity. Ovarian cancer may be more likely to be impacted by U3 1565 than other tumors, considering that in this cancer, high levels of HB-EGF have been associated with an unfavorable clinical outcome. Six subjects will be initially treated; at which point, a safety analysis will be conducted after these initial subjects have completed the first cycle of treatment, to allow the reevaluation of the appropriateness of the dosing level.
11509087|NCT01290458|Experimental|Vitamin|
11509088|NCT01290458|Placebo Comparator|Control|
11509089|NCT01290445||Exposed|Infants exposed in utero to varenicline
11509090|NCT01290445||Unexposed|infants exposed in utero to cigarette smoke from maternal smoking
11509091|NCT01290445||Reference|infants not exposed in utero to either varenicline or cigarette smoke from maternal smoking
11509092|NCT01290432|Experimental|Inofolic Plus|Patients are given Inofolic Plus to see if the AMH changes over a period of up to 90 days.
11509093|NCT01290419|Experimental|A: Dose 1 + adjuvant|
11509094|NCT01290419|Experimental|B: Dose 2 + adjuvant|
11509095|NCT01290419|Experimental|C: Dose 3 + adjuvant|
11509096|NCT01290419|Experimental|D: Dose 3 alone|
11509097|NCT01290419|Placebo Comparator|E: Placebo control|
11509098|NCT01290419|Experimental|F: Dose 4 alone|
11509099|NCT01290419|Experimental|G: Dose 4 +adjuvant|
11509100|NCT01290406|Experimental|BEZ235|
11509101|NCT01290393||Exposed vaccinated cohort|Women with last menstrual period between 30 days before and 90 days after any CERVARIX dose. The target sample size of the Exposed vaccinated cohort is 150 subjects.
11509102|NCT01290393||Non-exposed vaccinated cohort|Women with last menstrual period between 120 days and 18 months after the last CERVARIX or GARDASIL dose. The target sample size of the Non-exposed vaccinated cohort is 300 subjects.
11509103|NCT01290380|Experimental|ASA 404 + standard chemotherapy|ASA 404 in combination with in combination with standard chemotherapy (paclitaxel + carboplatin or docetaxel) and a cocktail of caffeine, diclofenac, simvastatin and omeprazole
11509104|NCT01290367|Experimental|High Dose MPCs|Injection of High Dose MPCs with Hyaluronic Acid
11509105|NCT01290367|Experimental|Low Dose MPCs|Injection of Low Dose MPCs with Hyaluronic Acid
11509106|NCT01290367|Sham Comparator|Saline injection|Injection of saline solution.
11509107|NCT01290367|Placebo Comparator|Hyaluronic acid injection|Injection of hyaluronic acid solution
11509108|NCT01290354|Experimental|lapatinib|unlabelled, administered orally
11509109|NCT01290341|Experimental|NAFT-600 ( naftin 2 % gel)|Topical; applied once daily for two weeks
11509110|NCT01290341|Placebo Comparator|Placebo|Topical; applied once daily for two weeks.
11509111|NCT01290328|No Intervention|Standard of care|
11509112|NCT01290328|Experimental|Epoetin alfa|150 units/kg/week
11509113|NCT01290315|Experimental|Ferric Carboxymaltose (FCM)|Intravenous iron
11509114|NCT01290315|Active Comparator|Iron Sucrose / Iron Dextran|Intravenous iron
11509115|NCT01290302|Experimental|Luitpold Azacitidine|
11509116|NCT01290302|Active Comparator|Vidaza®|
11509117|NCT01290289|Active Comparator|Epidura, combined spinal epidura & IV|"Gp 1: received CSE analgesia, 25µg of fentanyl injected intrathecally & a bolus of 10 ml of 0.5% lidocaine injected epidurally.
~Gp 2: received CSE analgesia, 25µg of fentanyl injected intrathecally & a bolus of 10 ml of 0.0625% bupivacaine injected epidurally.
~Gp 3: received 50µg of E fentanyl analgesia, injected intrathecally & a bolus of 10 ml of 0.5% lidocaine, followed by lidocaine E top-ups.
~Gp 4: received 50µg of E fentanyl injected intrathecally and a bolus dose of 10 ml of 0.125% bupivacaine, followed by E bupivacaine top-ups.
~Gp 5: 50mg of IV pethidine was administered as a loading dose, followed by 0.5 mg/kg."
11509118|NCT01290276|Experimental|Ond-PR1 followed by (Ond-PR1 + MPh-IR)|Oral dose of 8 mg of ondansetron pulsatile-release formulation 1 followed by Oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)
11509154|NCT01290029|Experimental|Cinacalcet|Participants received a single, oral dose of 0.25 mg/kg cinacalcet.
11509119|NCT01290276|Experimental|Ond-PR2 followed by (Ond-PR2 + MPh-IR)|Oral dose of 8 mg of ondansetron pulsatile-release formulation 2 followed by Oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
11509120|NCT01290263|Experimental|Amgen 386|Cohort A will assess recurrent Glioblastoma Multiforme (GBM) patients who receive AMG 386 monotherapy at 30mg/kg every week. As of August 1, 2013, Cohort A was closed to new accrual following early interim analysis of first 10 participants enrolled on study. None of these patients had achieved stable disease or response at their initial evaluation after 1-2 months of study therapy. Therefore, study investigators and sponsor agreed that the level of single-agent anti-tumor activity associated with AMG386 for recurrent glioblastoma patients is most likely insufficient to satisfy the stopping rule for low efficacy outlined in Section 14.5 for Cohort A.
11509121|NCT01290263|Experimental|Amgen 386 and Bevacizumab|Cohort B will assess recurrent Glioblastoma Multiforme(GBM) patients who receive AMG 386 plus bevacizumab. Because the maximum tolerated dose of this combination therapy has not yet been established, a 3x3 Phase I study was used to determine the maximum tolerated dose. As of June 6, 2014, the MTD was determined to be AMG386 30 mg/kg administered intravenously every week(dose level +1) in combination with bevacizumab at 10mg/kg administered intravenously every other week. As of July 25, 2014 the Cohort B, Phase II portion of the study was opened to accrual.
11509122|NCT01290250|Experimental|Orange juice based beverage enriched in polyphenols|2 daily doses (250 ml each) during 3 months
11509123|NCT01290250|Placebo Comparator|Orange juice with low levels of polyphenols|2 daily doses (250 ml each) during 3 months
11509124|NCT01290237|Experimental|Vancomycin loading dose|Intervention: administer intravenous vancomycin 30 mg/kg/dose once, followed 8 hours later by 20 mg/kg/dose every 8 hours
11509125|NCT01290237|Active Comparator|Control|No intervention. Administer intravenous vancomycin 20 mg/kg/dose every 8 hours as per hospital guideline.
11509126|NCT01290224|Experimental|Supportive Care|See Detailed Description
11509127|NCT01290211|Experimental|Cohort 1|Twice daily regimen
11509128|NCT01290211|Experimental|Cohort 2|Once daily regimen
11509129|NCT01290198|Placebo Comparator|Vehicle without ANESDERM (lidocaine, prilocaine)|
11509130|NCT01290198|Active Comparator|Vehicle with ANESDERM (lidocaine, prilocaine)|
11509131|NCT01290198|Active Comparator|Fluconazole without ANESDERM (lidocaine, prilocaine)|
11509132|NCT01290198|Active Comparator|Fluconazole with ANESDERM (lidocaine, prilocaine)|
11509133|NCT01290185|Experimental|Coiled Catheter|Placement of the coiled catheter for continuous infusion of local anesthetics close to the femoral nerve: To place coiled catheters ab 18-gauge Tuohy needle (Sonoline Curl Catheter Set, Pajunk® Medizintechnologie GmbH, Geisingen, Germany) of 8 cm length is placed adjacent to the nerve by ultrasound guidance and nerve stimulator control. At this position and after injection of 5 ml dextrose 5% in water to dilate the space the coiled catheter is blindly advanced 2 cm through the needle and the final position verified with ultrasound.
11509134|NCT01290185|Active Comparator|Conventional stimulating Catheter|For the control group a conventional stimulating catheter is placed adjacent to the femoral nerve as follows: To place the simulating catheter an 18-gauge Tuhoy needle s placed adjacenit to the nerve by ultrasound guidance. At this position a stimulation catheter is introduced through the needle and stimulated with a decreasing current from 1 mA to 0.4 mA, with a pulse width 0.1ms to verify the appropriate motor response of the quadriceps muscle. The catheter is slowly advanced 3 cm beyond the needle tip under continuous electric stimulation using a current that is subsequently adapted according to the motor response achieved. If muscles twitches disappear during catheter placement at a current above 1 mA, either the catheter or the needle are manipulated until muscle twitches reappear.
11509135|NCT01290172|Experimental|Somatostatin|Patients in this group receive treatment with Somatostatin for 5 days.
11509136|NCT01290172|Placebo Comparator|Placebo|Patients in this group receive a placebo for 5 days.
11509137|NCT01290159||post heat stroke heat tolerant|
11509138|NCT01290159||post heat stroke heat intolerant|
11509139|NCT01290159||healthy controls|
11509140|NCT01290146|Active Comparator|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
11509141|NCT01290146|Experimental|Levosimendan|"Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.
~Starting doses will be based on baseline SBP levels
~SBP ≥ 85-99mmHg: 0.05 mcg/kg/min
~SBP ≥100 mmHg: 0.1 mcg/kg/min"
11509142|NCT01290133|Experimental|Active Drug|
11509143|NCT01290133|Placebo Comparator|Placebo|
11509144|NCT01290094|Experimental|Single Arm|
11509145|NCT01290081|Active Comparator|Active referral|Case management intervention group - study personnel scheduled the TB doctor appointment for the participant, reminded to keep it, and transportation to the clinic was organized when needed.
11509146|NCT01290081|No Intervention|Passive referral|Participants were instructed to schedule an appointment with TB services themselves.
11509147|NCT01290068|Experimental|ReSTOR +3|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL, bilateral implantation
11509148|NCT01290068|Experimental|ReSTOR +3 Toric|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative corneal astigmatism, bilateral implantation, or implanted in 1 eye with AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL in the other eye
11509149|NCT01290068|Active Comparator|Monofocal|Monofocal IOL, bilateral implantation
11509150|NCT01290055|Experimental|Group 1|In group 1, participants will receive the Yellow fever vaccine or YFV-17D and will be asked to drink Deuterium (70% enriched 2H2O) labeled water for 2 weeks. They will undergo phlebotomy on Day 0, 14, 28 and 3 to 6 months, 1-2 years and >5 years after vaccination.
11509151|NCT01290055|Experimental|Group 2|In group 2, participants will receive the Yellow fever vaccine or YFV-17D and will be asked to drink Deuterium (70% enriched 2H2O) labeled water for 3 weeks. They will undergo phlebotomy on Day 0, 14, 28 and 3 to 6 months, 1-2 years and >5 years after vaccination.
11509152|NCT01290042|Active Comparator|Placebo arm|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
11509153|NCT01290042|Active Comparator|Active arm|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
11509155|NCT01290016|Active Comparator|Control 6-8 yrs|The group will receive information during the study about diet and exercise but will not receive the intervention till the end of the study protocol.
11509156|NCT01290016|Experimental|2 servings dairy + exercise 6-8 yrs|Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.
11509157|NCT01290016|Experimental|4 servings dairy + exercise 6-8 yrs|Subjects in this group will receive family based counselling to maintain the intake of 4 servings of dairy per day and also receive instruction on how to improve their physical activity.
11509158|NCT01290016|Experimental|4 servings dairy + exercise 9-12 yrs|Subjects in this group will receive family based counselling to maintain the standard recommended intake of 4 servings of dairy per day for 9-14 year olds according to the Canada's Food Guide and also receive instruction on how to improve their physical activity.
11509159|NCT01290016|Active Comparator|Control 9-12 yrs|The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
11509160|NCT01290003|Experimental|Antibiotic Group|Neonates randomized to intervention Group(Antibiotic group)will receive the first line antibiotics (Piperacillin-Tazobactam and Amikacin) as per the unit policy for 72 hours. These neonates will also be monitored by performing sepsis screens and blood culture for development of sepsis.
11509161|NCT01290003|No Intervention|No Antibiotic Group|Neonates randomized to 'No antibiotic group' will receive supportive treatment as per standard unit protocol. These neonates will be monitored by performing sepsis screens and blood culture for development of sepsis.
11509162|NCT01289990|Experimental|BI 10773 low (drug naive)|BI 10773 tablets once daily
11509163|NCT01289990|Experimental|BI 10773 high (drug naive)|BI 10773 tablets once daily
11509164|NCT01289990|Placebo Comparator|Placebo (drug naive)|Placebo tablets matching BI 10773 / Sitagliptin once daily
11509165|NCT01289990|Active Comparator|Sitagliptin 100mg (drug naive)|Sitagliptin once daily
11509166|NCT01289990|Experimental|BI 10773 low (pioglitazone)|BI 10773 tablets once daily
11509167|NCT01289990|Experimental|BI 10773 high (pioglitazone)|BI 10773 tablets once daily
11509168|NCT01289990|Placebo Comparator|Placebo (pioglitazone)|Placebo tablets matching BI 10773 once daily
11509169|NCT01289990|Experimental|BI 10773 low (metformin)|BI 10773 tablets once daily
11509170|NCT01289990|Experimental|BI 10773 high (metformin)|BI 10773 tablets once daily
11509171|NCT01289990|Placebo Comparator|Placebo (metformin)|Placebo tablets matching BI 10773 once daily
11509172|NCT01289990|Experimental|BI 10773 low (metformin+sulfonylurea)|BI 10773 tablets once daily
11509173|NCT01289990|Experimental|BI 10773 high (metformin+sulfonylurea)|BI 10773 tablets once daily
11509174|NCT01289990|Placebo Comparator|Placebo (metformin+sulfonylurea)|Placebo tablets matching BI 10773
11509175|NCT01289977||Phlebotomus group|Those in the Phlebotomus group will have exposure to P. duboscqui sand fly
11509176|NCT01289977||Lutzomyia group|Those placed in this group will receive exposure to L. longipalpis sand fly bites.
11509177|NCT01289964|No Intervention|Waiting list control group|No treatment within the study period, were allowed to continue physiotherapy and medication. Were offered the treatment after finishing the study
11509178|NCT01289964|Active Comparator|Treatment group|Received the 5 cupping treatments, application twice a week, non standardised application - individual determinations of trigger points
11509179|NCT01289951|Experimental|Patients with Child-Pugh C hepatic-cirrhosis.|VIH/VHC coinfected patients with advanced (Child-Pugh C) hepatic cirrhosis.
11509180|NCT01289951|Active Comparator|VIH/VHC coinfected patients without liver damage.|
11509181|NCT01289938|Active Comparator|Metoclopramide|Metoclopramide treatment
11509182|NCT01289938|Active Comparator|Diphenhydramine|Diphenhydramine treatment
11509183|NCT01289925|Experimental|Selenium|
11509184|NCT01289925|Placebo Comparator|Sugar Pill|
11509185|NCT01289912|Experimental|RAD001|RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis.
11509186|NCT01289912|Placebo Comparator|Placebo|Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10.
11509187|NCT01289899|Experimental|Arm A|BR-A-657 120mg or placebo
11509188|NCT01289899|Experimental|Arm B|BR-A-657 360mg or placebo
11509189|NCT01289886|Other|Arm A|BR-A-657 20mg or placebo
11509190|NCT01289886|Other|Arm B|BR-A-657 60mg or placebo
11509191|NCT01289886|Other|Arm C|BR-A-657 120mg or placebo
11509192|NCT01289886|Other|Arm D|BR-A-657 240mg or placebo
11509193|NCT01289886|Other|Arm E|BR-A-657 480mg or placebo
11509194|NCT01289860|Active Comparator|Blueberry drink|30g of blueberry powder (equivalent to 200g fresh blueberries) and 300ml of semi-skimmed milk
11509195|NCT01289860|Placebo Comparator|Control drink|29g of powder consisting of sugars and vitamin C, values of which were matched to that of the blueberry drink, with 1 g of citric acid to match for taste.
11509196|NCT01289847|Experimental|Gammaplex|
11509197|NCT01289834|Active Comparator|Hi-Fatigue Bone Cement|CPT femoral stems fixed with Hi-Fatigue Bone Cement
11509198|NCT01289834|Active Comparator|Palacos Bone Cement|CPT femoral stems fixed with Palacos Bone Cement
11509199|NCT01289821|Experimental|Regorafenib + oxaliplatin/folinic acid/5-FU (mFOLFOX6)|On Day 1, participants received 85 mg/m^2 oxaliplatin as a 2-hour intravenous (IV) infusion and folinic acid (either 400 mg/m^2 D/L-folinic acid or 200 mg/m^2 L-folinic acid) as a 2-hour IV infusion. Once the initial infusion was completed, participants received 5-FU 400 mg/m^2 IV bolus injection immediately followed by a 5-FU 2400 mg/m^2 IV infusion for 46 hours. The next cycle of mFOLFOX6 was administered on Day 15 to 17. Participants received Regorafenib (Stivarga, BAY73-4506) 160 mg orally (po) once daily (qd) on Days 4 to 10 and Days 18 to 24. One cycle comprised 28 days.
11509247|NCT01289483|Active Comparator|fospropofol 2 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 2 mg/kg.
11509248|NCT01289457|Experimental|Clofarabine + Idarubicin + Cytarabine|Phase I: Clofarabine Starting dose 15 mg/m2 by vein for 5 days (days 1-5) + Idarubicin 10 mg/m2 by vein on day 1-3 + Cytarabine 1 g/m2 by vein on day 1-5.
11509442|NCT01288248|Experimental|Airway laryngeal mask classic|Ventilation with Airway laryngeal mask classic during surgery
11509200|NCT01289808|Experimental|glucose 25%|"180 healthy babies born term in the Baruch Padeh Medical Center, Poriya.
~There will be three study groups:
~Study Group: 60 newborn infants who will receive 1cc 25% Glucose, 2-3 minutes prior red-reflex examination.
~Base line (control) Group 1: 60 newborn infants who will receive 1cc Water for Injection (WFI), 2-3 minutes prior red-reflex examination.
~Base line (control ) Group 2: 60 newborn infants who will not receive neither glucose nor Water for Injection (WFI), 2-3 minutes prior red-reflex examination"
11509201|NCT01289795||first-ever ischemic stroke|first-ever ischemic stroke according to the WHO definition
11509202|NCT01289782|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alpha-2a (PegIFN alpha-2a) and ribavirin (RBV) for 24 or 48 weeks
11509203|NCT01289782|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition to PegIFNα-2a and RBV for 48 weeks
11509204|NCT01289769|Active Comparator|dexmedetomidine|
11509205|NCT01289769|Placebo Comparator|control|
11509206|NCT01289756|Experimental|CYP2D6 EM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
11509207|NCT01289756|Experimental|CYP2D6 IM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
11509208|NCT01289756|Experimental|CYP2D6 PM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
11509209|NCT01289756|Experimental|CYP2D6 UM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
11509210|NCT01289743|Experimental|Etanercept 25 mg|Etanercept 25 mg subcutaneously twice weekly
11509211|NCT01289730|Experimental|Etanercept 25 mg|Etanercept 25 mg subcutaneously twice a week
11509212|NCT01289704|Experimental|TreSPE|Treatment with treadmill, proprioceptive and stretching exercises
11509213|NCT01289704|Active Comparator|SPE|Proprioceptive and stretching exercises
11509214|NCT01289691|Experimental|Air/Oxygen Mixture|Patients in this group will be ventilated with a mixture of air and oxygen during one lung ventilation.
11509215|NCT01289691|Active Comparator|Oxygen|Patients in this group will be ventilated with only oxygen during one lung ventilation.
11509216|NCT01289678|Experimental|interleukin-2|interleukin-2 therapy during lymphocyte recovery
11509217|NCT01289665|Experimental|Lubricating Gel|
11509218|NCT01289665|Active Comparator|Water|
11509219|NCT01289652||HCV + HIV|
11509220|NCT01289652||HCV|
11509221|NCT01289639|Placebo Comparator|Placebo|matching placebo 1 po qd
11509222|NCT01289639|Experimental|Fenofibrate|micronized fenofibrate 200 mg 1 po qd
11509223|NCT01289639|Experimental|Pioglitazone|pioglitazone 30 mg po qd
11509224|NCT01289613||Children|Children
11509225|NCT01289613||Adults|Adults
11509226|NCT01289600|Active Comparator|Pressure support ventilation, ARDSnet|"Mechanical ventilator is set to pressure support ventilation (6 ml/kg) for 30 min with positive end expiratory pressure (PEEP) set according to the higher arm of the ARDS network consensus."
11509227|NCT01289600|Active Comparator|Pressure control ventilation, ARDSnet|"Mechanical ventilator is set to pressure control ventilation (6 ml/kg) for 30 min with PEEP set according to the higher arm of the ARDS network consensus."
11509228|NCT01289600|Active Comparator|Neurally adjusted ventilatory assist, ARDSnet|"Mechanical ventilator is set to NAVA for 30 min with PEEP set according to the higher arm of the ARDS network consensus."
11509229|NCT01289600|Active Comparator|Neurally adjusted ventilatory assist, titrated|Mechanical ventilator is set to NAVA for 30 min with PEEP titrated using the diaphragm EMG signal.
11509230|NCT01289587|Experimental|Alternative frequency variant|An alternative variant of the DIAfit program (progressive increase of the number of administered PA sessions per week, namely one PA session per week during 4 weeks and then twice a week over a period of 16 weeks)
11509231|NCT01289587|Active Comparator|Standard frequency program|Standard usual program (3 times per week over a period of 12 weeks)
11509232|NCT01289574|Placebo Comparator|Vehicle control cream|
11509233|NCT01289574|Experimental|0.025% ASC-J9 cream|
11509234|NCT01289574|Experimental|0.1% ASC-J9 cream|
11509235|NCT01289561|Experimental|Alcohol self-administration|All participants will participate in seven sessions. In three sessions, each participant will consume a beverage containing alcohol and caffeine. In three separate sessions, participants will consume a beverage containing alcohol and caffeine-placebo. In the final session, all participants may choose which beverage they consume. Participants and research assistants will be blinded to inclusion of caffeine/caffeine-placebo in beverage, but each beverage will be labeled for identification (e.g., A or B).
11509236|NCT01289548|No Intervention|control|patients (both donors and recipients) had a deflated cuff placed on the left lower limb for 30 min
11509237|NCT01289548|Experimental|donor|Donors receive remote ischaemic preconditioning after anaesthesia induction and before surgery started; recipients only have a deflated blood pressure cuff around their leg for 30 minutes.
11509238|NCT01289548|Experimental|recipient|recipients receive remote ischaemic preconditioning after anaesthesia induction and before surgery started; donors only have a deflated blood pressure cuff around their leg for 30 minutes.
11509239|NCT01289535|Experimental|antibody rates|
11509240|NCT01289522|Experimental|cetuximab|Patients receive four cycles of chemotherapy comprising cetuximab IV plus docetaxel IV over 1 hour and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of the fourth cycle of chemotherapy, patients receive a maintenance therapy with cetuximab every 2 weeks. Treatment will be continued until disease progression or unacceptable toxicities according
11509241|NCT01289509|Experimental|Experimental 1|Drug: E5501
11509242|NCT01289509|Experimental|Experimental 2|Drug: E5501
11509243|NCT01289496|Experimental|Peg-interferon alpha-2a, Ribavirin|"Adult patients with chronic hepatitis C and failure of prior treatment with peginterferon plus ribavirin(non-response or relapse).
~This is a pilot study with no control group."
11509244|NCT01289483|Active Comparator|fospropofol 6.5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 6.5 mg/kg.
11509245|NCT01289483|Active Comparator|fospropofol 5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 5 mg/kg.
11509246|NCT01289483|Active Comparator|fospropofol 3.5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 3 mg/kg.
11509497|NCT01287858|Active Comparator|AC430|AC430
11509249|NCT01289457|Experimental|Group 1 CIA|Phase II, Group 1 CIA (Clofarabine + Idarubicin + Cytarabine): Clofarabine Maximum Tolerated Dose (MTD) based on Phase I by vein on days 1-5; Idarubicin 10 mg/m2 by vein on days 1-3; Cytarabine 1 g/m2 by vein on days 1-5.
11509250|NCT01289457|Experimental|Group 2 FLAI|Phase II, Group 2 FLAI (Fludarabine + Idarubicin + Cytarabine): Fludarabine 30 mg/m2 by vein on days 1-5; Idarubicin 10 mg/m2 by vein on days 1-3; Cytarabine 1 g/m2 by vein on days 1-5.
11509251|NCT01289444|Active Comparator|Healthy Living Control|"Session 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered, with all medical questions removed to prevent any risk of contamination with the experimental condition.
~Session 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.
~Session 3. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides. The Administered by the trained RA-Control to prevent contamination with the FACE condition."
11509252|NCT01289444|Experimental|FAmily CEntered (FACE) ACP|Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care & when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care & prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
11509253|NCT01289431|Experimental|Mapracorat|
11509254|NCT01289431|Placebo Comparator|Mapracorat Vehicle|
11509255|NCT01289418||Health care workers in Québec|Health care workers from CHUQ hospitals
11509256|NCT01289418||Health care workers in Toronto|Health care workers from the Mount Sinai Hospital
11509257|NCT01289418||Health care workers in Halifax|Health care workers from the Queen Elizabeth Hospital
11509258|NCT01289405|Placebo Comparator|placebo exercices|relaxation exercises and stretching neck, without therapeutic purpose.
11509259|NCT01289405|Active Comparator|phonoaudiologic therapy|isometric and isotonic exercises to improve posture, mobility and muscle tone of the soft palate, pharyngeal constrictor muscles, tip and base of tongue, cheeks and lips.
11509260|NCT01289392|Active Comparator|Continuous Positive Airway Pressure (CPAP)|CPAP is the gold standard treatment
11509261|NCT01289392|Active Comparator|Oral Appliance|Alternative treatment for obstructive sleep apnea patients
11509262|NCT01289392|Active Comparator|Physical Exercise|Aerobic and resistance physical exercises
11509263|NCT01289379|Experimental|HFJV|
11509264|NCT01289366||Patients with IBD|
11509265|NCT01289353|Experimental|ChemoRT|Concurrent Carboplatin and Radiotherapy
11509266|NCT01289340||Polymem (R)|superficial burns treated with Polymem wound dressing until complete wound healing
11509267|NCT01289340||Biaten IBU|burns treated with Biaten IBU until complete wound healing.
11509268|NCT01289340||Hartmen dressing|burns treated with hartman or saline wet dressing until wound healing
11509269|NCT01289327|Active Comparator|propofol|
11509270|NCT01289327|Active Comparator|midazolam+alfentanil|
11509271|NCT01289314|Active Comparator|Total laparoscopic hysterectomy|
11509272|NCT01289314|Active Comparator|Laparoscopic supracervical hysterectomy|
11509273|NCT01289301|Experimental|mTOR-receiving arm|switching from calcineurin-inhibitor-based immunosuppression to mTOR-based immunosuppression
11509274|NCT01289301|Active Comparator|calcineurin-inhibitor keeping arm|continuing calcineurin-inhibitor based immunosuppression
11509275|NCT01289288|Experimental|Mailed printed materials and in-office training|
11509276|NCT01289288|No Intervention|Control|Usual care
11509277|NCT01289275|Experimental|Telephone Counseling|Up to 5 proactive counseling sessions
11509278|NCT01289275|Experimental|Nicotine Patches|8 weeks of nicotine patches
11509279|NCT01289275|Experimental|Telephone Counseling + Patches|5 proactive sessions, 8 weeks patches
11509280|NCT01289275|Active Comparator|Brief hospital counseling|brief in hospital counseling, no proactive sessions or patches
11509281|NCT01289262|Active Comparator|Purse string closure technique|Uterine Kerr incision will be closed with purse string suture.
11509282|NCT01289262|Active Comparator|Continuously locked closure technique|Uterine Kerr incision will be closed with continuously locked closure technique.
11509283|NCT01289249||Children receiving meropenem|Children aged from 3 months to 18 years that receive treatment with meropenem.
11509284|NCT01289236|Placebo Comparator|Placebo|Placebo BID (twice daily, approximately 12 hours apart)
11509285|NCT01289236|Active Comparator|milnacipran 200 mg|200mg- 1 100mg tablet BID (twice daily, approximately 12 hours apart)
11509286|NCT01289236|Active Comparator|milnacipran 100 mg|100mg- 1 50mg tablet BID (twice daily, approximately 12 hours apart)
11509287|NCT01289223|Active Comparator|Treatment of Physicians Choice|Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
11509288|NCT01289223|Experimental|Bendamustine IV|Up to 8 cycles of Bendamustine (120mg/m2 Days 1 and 2, every 21 days (+ 3 days).
11509289|NCT01289210|Other|VTX-2337 plus radiation|
11509290|NCT01289197|No Intervention|No Feedback or services offered.|The Family Check-Up is not offered.
11509291|NCT01289197|Other|Intervention|Family Check Up is offered.
11509292|NCT01289184||control|
11509293|NCT01289184||exposure 2-3 years|
11509294|NCT01289184||exposure 3-5 years|
11509295|NCT01289184||exposure 5-10 years|
11509296|NCT01289184||exposure >15 years|
11509297|NCT01289171|Experimental|Glycolic acid|All who met the study criteria commenced once daily use of 15% glycolic acid lotion.
11509298|NCT01289158||non-classical CMAMMA, classical CMAMMA|
11509357|NCT01288781|Experimental|Acetazolamide|Arm 1: ACETAZOLAMIDE (250mg) will be given to subjects at fifteen, twenty and thirty two hours post hypoxic exposure (3777m).
11509498|NCT01287845|Experimental|Arm 1|
11509299|NCT01289145|Experimental|Intervention|"Participants will be allocated to a motivational intervention, a volitional intervention or the active control group.
~The motivational intervention promotes positive outcome expectancies on physical activity. The volitional intervention promotes the formulation of action plans for physical activity. Participants in the active control group, receive a quiz on physical activity and sports."
11509300|NCT01289132|Placebo Comparator|Placebo|
11509301|NCT01289132|Experimental|Azilsartan 5 mg QD|
11509302|NCT01289132|Experimental|Azilsartan 10 mg QD|
11509303|NCT01289132|Experimental|Azilsartan 20 mg QD|
11509304|NCT01289132|Experimental|Azilsartan 40 mg QD|
11509305|NCT01289132|Experimental|Azilsartan 80 mg QD|
11509306|NCT01289132|Active Comparator|Candesartan Cilexetil 8 mg titrated to12 mg QD|
11509307|NCT01289119|Placebo Comparator|Placebo|Participants received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
11509308|NCT01289119|Experimental|Alogliptin Monotherapy|Participants received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
11509309|NCT01289119|Other|Metformin|Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
11509310|NCT01289119|Experimental|Metformin + Alogliptin Add-on Therapy|Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
11509311|NCT01289119|Other|Pioglitazone|Participants continued to receive their stable dose of pioglitazone with or without metformin, and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
11509312|NCT01289119|Experimental|Pioglitazone + Alogliptin Add-on Therapy|Participants continued to receive their stable dose of pioglitazone with or without metformin and also received alogliptin, 25 mg tablets orally once daily for up to 16 weeks.
11509313|NCT01289106|Active Comparator|Arm A|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
11509314|NCT01289106|Experimental|Arm B|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
11509315|NCT01289106|Experimental|Arm C|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
11509316|NCT01289093||laparoscopic ingunal herniotomy|
11509317|NCT01289093||laparoscopic incisional herniotomy|
11509318|NCT01289093||Lichtenstein inguinal herniotomy|
11509319|NCT01289093||laparoscopic umbilical hernia repair|
11509320|NCT01289080|Active Comparator|Group 1|subjects with normal renal function
11509321|NCT01289080|Active Comparator|Group 2|severely renally impaired subjects
11509322|NCT01289067|Other|Satraplatin, Single Arm|
11509323|NCT01289054||Cohort 1 - Pregnancy/Fetal Exposure|
11509324|NCT01289054||Cohort 2 - Interrupted TKI|
11509325|NCT01289041|Experimental|All Patients|
11509326|NCT01289028|Experimental|Nilotinib|nilotinib 400 mg twice daily (bid).
11509327|NCT01289015|Experimental|NAFT-600 ( naftin 2 % gel)|
11509328|NCT01289015|Placebo Comparator|Placebo|
11509329|NCT01288989|Experimental|IMC-3C5|Participants receiving IMC-3C5 intravenously
11509330|NCT01288976||MitraClip Therapy|Patients treated with the MitraClip System.
11509331|NCT01288976||Medical Management|Patients with MR managed non-surgically based on standard hospital clinical practice.
11509332|NCT01288976||Mitral Valve Surgery|Patients with MR managed surgically (repair or replacement) based on standard hospital clinical practice.
11509333|NCT01288963||IL-2 subjects|Subjects receiving IL-2 for advanced melanoma
11509334|NCT01288950|Experimental|Vitamin D3|
11509335|NCT01288950|No Intervention|Placebo|
11509336|NCT01288937|Experimental|Milnacipran|Patients will receive Milnacipran
11509337|NCT01288937|Placebo Comparator|Placebo|Patients will receive Placebo
11509338|NCT01288924|Active Comparator|Parecoxib|Parecoxib 2 ml intravenous
11509339|NCT01288924|Placebo Comparator|Control|0.9% sodium chloride 2 ml intravenous
11509340|NCT01288911|Experimental|Enzalutamide|Participants received enzalutamide 160 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.
11509341|NCT01288911|Active Comparator|Bicalutamide|Participants received bicalutamide 50 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.
11509342|NCT01288872|Experimental|Praziquantel|45 women in 3 cohorts (15 early pregnancy: 12-16 weeks gestation; 15 late pregnancy: 30-36 weeks gestation; and 15 lactating nonpregnant women who are 5-7 months (inclusive) postpartum) given praziquantel (PZQ), 60 mg/kg orally in split dose (30 mg/kg each) separated by 3 hours.
11509343|NCT01288859|Experimental|encapsulated curcumin|
11509344|NCT01288859|Experimental|encapsulated curcumin + PQG|PQG means Piperine, Quercetin and Genistein
11509345|NCT01288859|Active Comparator|free cocoa polyphenol|
11509346|NCT01288859|Placebo Comparator|control|
11509347|NCT01288859|Experimental|encapsulated cocoa polyphenols|
11509348|NCT01288859|Active Comparator|free curcumin|Subjects will consume bread added with free curcumin
11509349|NCT01288846||Acutly ill, Medical ward, consent|group of acutely ill patient who uses three or more drugs, must be able to give consent.
11509350|NCT01288833|Experimental|Close focus HD NBI Colonoscopy System|Use of close focus to make optical diagnosis
11509351|NCT01288833|No Intervention|Current HD NBI Colonoscopy System|Use of standard focus for optical diagnosis
11509352|NCT01288820|Experimental|DHP+PQ|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
11509353|NCT01288820|Active Comparator|AS-AQ +PQ|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
11509354|NCT01288807|Experimental|Treatment|Titrated Milnacipram doses
11509355|NCT01288794|Active Comparator|Standard medical treatment plus albumin|The patients will receive standard medical treatment (diuretics) plus weekly albumin infusion
11509356|NCT01288794|Other|Standard medical treatment|The patients will receive the standard medical treatment (diuretics), but non albumin for the therapy of ascites
11509358|NCT01288781|Placebo Comparator|Placebo|Placebo (LACTOSE MONOHYDRATE) will be given to subjects at fifteen, twenty and thirty two hours post hypoxic exposure (3777m).
11509359|NCT01288768|Active Comparator|Arthroscopy|Knee arthroscopy + Exercise therapy
11509360|NCT01288768|No Intervention|Exercise therapy|Exercise therapy alone
11509361|NCT01288755|Experimental|001|TMC278 One 25 mg tablet once daily for 11 days (TrtA and C)
11509362|NCT01288755|Experimental|002|Raltegravir One 400 mg tablet twice daily for 4 days (Trt B) and for 11 days (TrtC)
11509363|NCT01288742|Experimental|001|TMC435 One 150-mg capsule once daily for 7 days (Trts B and D).
11509364|NCT01288742|Experimental|002|Digoxin One 0.25-mg tablet for 1 day (Trt A)
11509365|NCT01288742|Experimental|003|Digoxin One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
11509366|NCT01288742|Experimental|004|Rosuvastatin One 10-mg tablet for 1 day (Trt C).
11509367|NCT01288742|Experimental|005|Rosuvastatin One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
11509368|NCT01288729|Experimental|Group 1 - Steel Cathetar, then Teflon|Participants will alternate between wearing the Sure-T Steel Infusion Set Catheter for 7 days, then the Quick-Set Teflon for 7 days.They will wear each set twice starting with the Sure-T Steel Infusion Set.
11509369|NCT01288729|Experimental|Group 2 - Teflon Cathetar, the Steel|Participants will alternate between wearing the Quick-Set Teflon catheter for 7 days, then the Quick-Set Teflon for 7 days. They will wear each set twice starting with the Quick-Set Teflon set.
11509370|NCT01288716|Placebo Comparator|Placebo|
11509371|NCT01288716|Active Comparator|Arbaclofen|
11509372|NCT01288690|No Intervention|Wait List Control|This condition is a wait-list control and receives no intervention during the study period, but is offered treatment after the final assessment.
11509373|NCT01288690|Experimental|Narrative Exposure Therapy|Patients in this condition receive 3 sessions of Narrative Exposure Therapy
11509374|NCT01288677|Experimental|001|TMC649128 Escalated doses
11509375|NCT01288664|Experimental|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase for 6 months
11509376|NCT01288638|Experimental|Pulse-based diet|The pulse based-diet will include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils.
11509377|NCT01288638|Placebo Comparator|TLC diet|Grocery gift cards will be provided weekly for 16 weeks to those participants in the placebo group. Recipe booklet will be given to follow Therapeutic Lifestyle Changes (TLC) guidelines, recommended by National Cholesterol Education Program (NCEP) and will be based on lean-meats for the protein source. The recipes will exclude pulses.
11509378|NCT01288625|Experimental|Cytofos group A|Amifostine 500 mg sc, qod, 3 times per week Radiation treatment 30 min after amifostine treatment, 1.8-2.0 Gy/day × 30-35 times
11509379|NCT01288625|Experimental|Cytofos group B|Amifostine 500mg rinsing wash, qod, 3 times per week Radiation treatment 5 min after amifostine treatment, 1.8-2.0 Gy/day × 30-35 times
11509380|NCT01288625|Active Comparator|Control group|Radiation treatment 1.8-2.0 Gy/day × 30-35 times
11509381|NCT01288612|Active Comparator|Sedated Endoscopy|Sedated esophagogastroduodenoscopy with biopsy
11509382|NCT01288612|Active Comparator|Transnasal Endoscopy at Hospital Unit|Unsedated transnasal endoscopy at hospital unit.
11509383|NCT01288612|Active Comparator|Transnasal Endoscopy at Mobile Unit|Unsedated transnasal endoscopy in mobile research van
11509384|NCT01288599|Experimental|Single port access laparoscopy|Single port access laparoscopy for benign adnexal disease.
11509385|NCT01288599|Active Comparator|Conventional laparoscopy|Conventional laparoscopy for benign adnexal disease.
11509386|NCT01288586||Device|Scandinavian Total Ankle Replacement System (STAR Ankle)
11509387|NCT01288573|Experimental|Plerixafor 160 μg/kg|Patients will receive subcutaneous (SC) injection of 160 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
11509388|NCT01288573|Experimental|Plerixafor 240 μg/kg|Patients will receive subcutaneous (SC) injection of 240 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
11509389|NCT01288573|Experimental|Plerixafor 320 μg/kg|Patients will receive subcutaneous (SC) injection of 320 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
11509390|NCT01288560|Active Comparator|Advanced cardiac imaging (PET/CT or CMR)|Patients will undergo cardiac imaging as evaluation of heart failure using 1 of the following alternate/advanced imaging modalities: Positron Emission Tomography (PET/CT), Cardiac Magnetic Resonance (CMR)
11509391|NCT01288560|Active Comparator|Standard cardiac imaging (SPECT)|Patients will undergo standard cardiac imaging procedures for evaluation of heart failure such as single photon emission computed tomography (SPECT).
11509392|NCT01288547|Active Comparator|theobromine|theobromine (700 mg) in capsule
11509393|NCT01288547|Active Comparator|caffeine|caffeine (120 mg) in capsule
11509394|NCT01288547|Placebo Comparator|Placebo capsule|no theobromine or caffeine
11509395|NCT01288547|Active Comparator|theobromine + caffeine|Combined theobromine and caffeine treatment, consisting of 700 mg theobromine and 120 mg caffeine
11509396|NCT01288534|Experimental|Radiation Treatment|
11509397|NCT01288521|Experimental|Tacrolimus + Ketoconazole, Then Tacrolimus alone|Participants first received tacrolimus in combination with with ketoconazole. After a 1-2 week washout they received tacrolimus alone.
11509398|NCT01288521|Experimental|Tacrolimus alone, Then Tacrolimus + Ketoconazole|The participants first received tacrolimus alone. After a 1-2 week washout period they received tacrolimus in combination with ketoconazole.
11509399|NCT01288508|Active Comparator|Supra Fiber|
11509400|NCT01288508|Active Comparator|Psyllium|
11509401|NCT01288495|Experimental|L-alanine|Subjects will consume l-alanine prior to eating fructose-containing foods.
11509402|NCT01288495|Placebo Comparator|Placebo|Subjects will consume the placebo prior to eating fructose-containing foods.
11509404|NCT01288469|Placebo Comparator|Placebo + Atorvastatin 80 mg|Placebo (for alirocumab) subcutaneous (SC) administration every 2 weeks (Q2W) in combination with atorvastatin 80 mg orally once daily for 8 weeks.
11509405|NCT01288469|Experimental|Alirocumab + Atorvastatin 10 mg|Alirocumab 150 mg SC administration Q2W in combination with atorvastatin 10 mg orally once daily for 8 weeks.
11509406|NCT01288469|Experimental|Alirocumab + Atorvastatin 80 mg|Alirocumab 150 mg SC administration Q2W in combination with atorvastatin 80 mg orally once daily for 8 weeks.
11509407|NCT01288443|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
11509408|NCT01288443|Experimental|Alirocumab 50 mg Q2W|Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
11509409|NCT01288443|Experimental|Alirocumab 100 mg Q2W|Alirocumab 100 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
11509410|NCT01288443|Experimental|Alirocumab 150 mg Q2W|Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
11509411|NCT01288443|Experimental|Alirocumab 200 mg Q4W|Alirocumab 200 mg every 4 weeks (Q4W) and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.
11509412|NCT01288443|Experimental|Alirocumab 300 mg Q4W|Alirocumab 300 mg Q4W and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.
11509413|NCT01288430|Experimental|DS-2248|"Study Part 1: DS-2248 oral capsule(s) of increasing strength in a dose escalation study in subjects with advanced solid tumors, administered once daily in 21-day cycles, with no interruption between cycles if no unacceptable treatment-related toxicity or tumor progression is observed.
~Study Part 2: DS-2248 oral capsule(s) dose of 4.5 mg/m^2, in subjects with non-small cell lung cancer who have developed acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors or whose tumors carry an ALK translocation and are resistant to ALK inhibitor therapy, administered once daily in 21 day-cycles, with no interruption between cycles if no unacceptable treatment-related toxicity or tumor progression are observed."
11509414|NCT01288417|Experimental|boceprevir + raltegravir|9 days of boceprevir 800mg TID; day 10 two doses of boceprevir 800mg and one dose of raltegravir 400mg
11509415|NCT01288417|Active Comparator|raltegravir alone|single dose of raltegravir 400mg
11509416|NCT01288404|Placebo Comparator|Control|topical 0.1% fluorometholone eye drops
11509417|NCT01288404|Active Comparator|Bevacizumab group 1|Bevacizumab 1.25 mg/0.05mL
11509418|NCT01288404|Active Comparator|Bevacizumab group 2|Bevacizumab 2.5 mg/0.1mL
11509419|NCT01288404|Active Comparator|bevacizumab group 3|bevacizumab 3.75 mg/0.15mL
11509420|NCT01288391|Experimental|100 mcg/kg|
11509421|NCT01288391|Experimental|200 mcg/kg|
11509422|NCT01288378|Active Comparator|Empirical|Empirical approach (fever driven) for starting antifungal therapy
11509423|NCT01288378|Experimental|Pre-emptive|Pre-emptive approach (diagnostic driven) for starting antifungal therapy
11509424|NCT01288365|Experimental|Exercise training|Protocol of 3 month exercise training program.
11509425|NCT01288365|No Intervention|Control|Control group
11509426|NCT01288352|No Intervention|Usual care|Usual care closely follows the suggestions laid out in the current European Society of Cardiology (ESC) guidelines for AF treatment. In addition to antithrombotic therapy and therapy of underlying heart disease, usual care usually consists of an initial attempt to control symptoms by rate control therapy. Rhythm control interventions are recommended when symptoms can not be controlled by optimal rate control therapy in the usual care group.
11509427|NCT01288352|Other|early standardised rhythm control|"Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.
~Early-onset rhythm control therapy can consist of:
~Optimal antiarrhythmic drug therapy (Dronedarone, Amiodarone, Flecainide, Propafenone),
~Catheter ablation with the aim of pulmonary vein isolation (PVI),
~Antiarrhythmic drug therapy and catheter ablation may be supplemented by early cardioversion in patients with persistent AF.
~All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences."
11509428|NCT01288339|Experimental|Panitumumab + FOLFOX (DP)|Panitumumab and FOLFOX will be administered to patients with DP (MMP7+/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
11509429|NCT01288339|Experimental|Panitumumab + FOLFOX (no-DP)|Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
11509430|NCT01288326||A|
11509431|NCT01288313|Experimental|rapeseed oil|
11509432|NCT01288313|Experimental|n-3 margarine and rapeseed oil|
11509433|NCT01288313|Experimental|n-3 margarine|
11509434|NCT01288313|Active Comparator|Olive oil|
11509435|NCT01288300|Active Comparator|Comprehensive diabetes self-management intervention|Diabetes education, self-empowerment training, exercise, patient navigator
11509436|NCT01288300|Other|Control|Diabetes self-management lecture
11509437|NCT01288287||Week 12 Disease Activity Score (DAS) Responders|Patients achieving a reduction from Baseline in a Disease Activity Score 28-joint count (Erythrocyte Sedimentation Rate) [DAS28(ESR)] score of greater than 1.2 points at Week 12
11509438|NCT01288287||Week 12 Disease Activity Score (DAS) Non-Responders|Patients who fail to achieve a reduction from Baseline in a Disease Activity Score 28-joint count (Erythrocyte Sedimentation Rate) [DAS28(ESR)] score of greater than 1.2 points at Week 12
11509439|NCT01288274|Active Comparator|Injection by Health Extension Worker|Women who receive injectable contraceptive from clinic based health extension workers (HEWs) during the study period
11509440|NCT01288274|Active Comparator|Injection by Community Health Worker|Women who receive injectable contraceptive through community based distributors from community based reproductive health agents (CBRHAs) during the study period
11509441|NCT01288261|Experimental|Treatment|Paclitaxel, bavituximab, laboratory biomarker analysis and pharmacological study
11509443|NCT01288248|Active Comparator|endotracheal tube|Ventilation with endotracheal tube during surgery
11509444|NCT01288235|Experimental|Proton Radiotherapy|Proton Radiotherapy
11509445|NCT01288222|Experimental|Unrelated Donor Transplant Patients|Patients with acute myeloid leukemia who have received KIR genotype from an unrelated donor transplant.
11509446|NCT01288209|Experimental|TMC435 100 mg 12 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment will be stopped at Week 24 if participants achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels < 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
11509447|NCT01288209|Experimental|TMC435 100 mg 24 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin ( PR) for 24 weeks (Wks). Treatment will be stopped at Week 24 if participants achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels < 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
11509448|NCT01288196|Experimental|001|CNTO 6785 1 mg/kg IV A single 30-minute IV infusion of CNTO 6785 1 mg/kg
11509449|NCT01288196|Experimental|002|CNTO 6785 3 mg/kg IV A single 30-minute IV infusion of CNTO 6785 3 mg/kg
11509450|NCT01288196|Experimental|003|CNTO 6785 10 mg/kg IV A single 30-minute IV infusion of CNTO 6785 10 mg/kg
11509451|NCT01288196|Placebo Comparator|004|Placebo IV A single 30-minute IV infusion of placebo
11509452|NCT01288196|Experimental|005|CNTO 6785 SC A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
11509453|NCT01288196|Placebo Comparator|006|Placebo SC A single SC dose of placebo administered in up to 3 SC injections
11509454|NCT01288183|Sham Comparator|sham tDCS|sham transcranial direct current stimulation The anode (7 x 5 cm) is placed on the right dorsolateral prefrontal cortex. A large cathode (10 x 10cm) is placed on the left occipital region
11509455|NCT01288183|Active Comparator|active tDCS|active anodal tDCS over the right dorsolateral prefrontal cortex The anode (7 x 5 cm) is placed on the right dorsolateral prefrontal cortex. A large cathode (10 x 10cm) is placed on the left occipital region Intensity of the stimulation: 2 mA Duration of the stimulation: 20 min 10 sessions, 2 per day
11509456|NCT01288170|Other|Nebcinal Tobi|crossover design
11509457|NCT01288170|Other|Tobi Nebcinal|crossover design
11509458|NCT01288157|Experimental|001|Golimumab Single dose of 50 mg subcutaneously
11509459|NCT01288157|Experimental|002|Golimumab Single dose of 100 mg subcutaneously
11509460|NCT01288144|Experimental|Intervention|Quality improvement initiative using computerized decision support
11509461|NCT01288144|No Intervention|Usual care|In control clinics, women will continue to receive usual care.
11509462|NCT01288131|Active Comparator|CSA+MMF|Cyclosporine 100 mg BID combine with Mycophenolate mofetil 750 mg BID for 24 weeks
11509463|NCT01288131|Active Comparator|Cyclophosphamide + pred|Cyclophosphamide 100 mg QD and prednisolone 1.0 mg/kg/day
11509464|NCT01288105|Experimental|Optical Coherence Tomography|Patients enrolled in the study will undergo optical coherence tomography to evaluate the extent of stent strut coverage.
11509465|NCT01288092|Experimental|BEZ235|
11509466|NCT01288079|Experimental|1|TC-5214, 1 mg BID
11509467|NCT01288079|Experimental|2|TC-5214, 4 mg BID
11509468|NCT01288079|Active Comparator|3|Duloxetine 60 mg Q Day
11509469|NCT01288079|Placebo Comparator|4|Placebo
11509470|NCT01288066|Other|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system.
11509471|NCT01288066|Other|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system.
11509472|NCT01288053|Experimental|Allogeneic Stem Cell Therapy|Allogeneic Stem Cell Therapy will be performed after conditioning
11509473|NCT01288040|Experimental|Treadmill exercise|Split-belt treadmill training
11509474|NCT01288027|Experimental|Alglucosidase Alfa|
11509475|NCT01288014||Edlerly Recipients of Zoster Vaccine|Blood samples are collected before and after vaccination in people age 60 or more, who are getting the zoster vaccine as part of their routine health care.
11509476|NCT01288001|Experimental|Ostenil plus|Patient will get Ostenil plus injection and standard treatment of Osteoarthritis
11509477|NCT01287988||Ocriplasmin|Subjects who were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study (TG-MV-006 or TG-MV-007)
11509478|NCT01287988||Placebo|Subjects who were exposed to a single intravitreal injection of placebo in a previous phase III study (TG-MV-006 or TG-MV-007)
11509479|NCT01287975|Active Comparator|Standard Occupational Therapy|Standard Occupational Therapy for Wrist and Hand Training
11509480|NCT01287975|Experimental|BCI Haptic Knob|BCI controlled robotic-assisted training for wrist and hand
11509481|NCT01287975|Experimental|Haptic Knob|Robotic-assisted training for wrist and hand
11509482|NCT01287962|Experimental|Apatinib|750 mg，po，QD； 28 days every cycle
11509483|NCT01287962|Placebo Comparator|Placebo|
11509484|NCT01287949|Experimental|REPEVAX followed by REVAXIS administration|
11509485|NCT01287936|Experimental|SB623|Administration of modified stem cells, SB623
11509486|NCT01287923||DLBCL|DLBCL patients included 075-GOELAMS trial or 075-like patient.
11509487|NCT01287923||Healthy controls|Blood donors from the EFS (French Blood Bank) of Rennes.
11509488|NCT01287923||Septic patients|septic patients included at the Rennes University Hospital.
11509489|NCT01287923||DLBCL in completed remission|DLBCL patients from the 075 GOELAMS study in completed remission.
11509490|NCT01287910|Other|All Patients|All patients undergo the same study procedures
11509491|NCT01287897|Placebo Comparator|Placebo- SC injection|
11509492|NCT01287897|Experimental|Drug Dose level 1 - SC injection|
11509493|NCT01287897|Experimental|Drug Dose level 2 - SC injection|
11509494|NCT01287884|No Intervention|Venous Blood Gas|All subjects have an ABG and VBG drawn. No intervention.
11509495|NCT01287871||Social media intervention|Women between the ages of 18-70 who have not been diagnosed with any type of cancer and are of African descent or Latina
11509496|NCT01287858|Placebo Comparator|Placebo|Placebo
11509500|NCT01287832|Active Comparator|High dose vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
11509501|NCT01287832|Experimental|High-dose daptomycin|Daptomycin dosed at 8 mg/kg/daily (every 48 hours in end-stage renal disease)
11509502|NCT01287819||APOE4 (+) and APE4 (-)|APOE4 (+) 10 people APOE4 (-) 20 people from 200 participants
11509503|NCT01287806|Sham Comparator|blank control group|
11509504|NCT01287806|Experimental|ulinastatin group|ulinastatin is a multivalent kunitz-type serine protease inhibitor refined from human urine
11509505|NCT01287793|Experimental|high dose tigecycline|
11509506|NCT01287793|Experimental|regular dose tigecycline|
11509507|NCT01287793|Active Comparator|moxifloxacin|
11509508|NCT01287793|Placebo Comparator|placebo|
11509509|NCT01287780|Active Comparator|Collagen-gentamicin sponges|Two sponges of collagen-gentamicin will be inserted into the hip immediately before closure of the wound. Each sponge (10 by 10 cm) contains 280 mg of collagen and 130 mg of gentamicin.
11509510|NCT01287780|No Intervention|No intervention|
11509511|NCT01287767|No Intervention|Control group, ordinary support|Home care as usual.
11509512|NCT01287767|Experimental|A multidimensjonalt support program|•Behavioral (e.g., Psychotherapy, Lifestyle Counseling) The family will receive individual consulting, teaching and problem solving in support groups.
11509513|NCT01287754|Experimental|Single Arm|
11509514|NCT01287741|Active Comparator|Rituximab+Chemotherapy|Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.
11509515|NCT01287741|Experimental|Obinutuzumab+Chemotherapy|Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.
11509516|NCT01287728|Experimental|treatment BY METROMIDAZOLE|
11509517|NCT01287715|Experimental|STOP-arm|Discontinuation of etanercept
11509518|NCT01287715|No Intervention|CONTROL-arm|Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
11509519|NCT01287702|Experimental|Early feeding|patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
11509520|NCT01287702|Active Comparator|Dealyed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL.
11509521|NCT01287689||Patient treated with any IgG|Any marketed SC or IV IgG can be documented
11509522|NCT01287663|Placebo Comparator|no permethrin|
11509523|NCT01287663|Experimental|permethrin|
11509524|NCT01287637|Experimental|Early reversal group|Early reversal of temporary ileostomy
11509525|NCT01287637|Active Comparator|Control group|Standard reversal of temporary ileostomy
11509526|NCT01287624|Experimental|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin)
11509527|NCT01287624|Active Comparator|Gemcitabine, Paclitaxel|GT (gemcitabine and paclitaxel combination)
11509528|NCT01287611|Active Comparator|Purse string closure technique|Eighty four patients were allocated to the study group. Due to expanded Kerr incisions 4 patients in study group did not receive their allocated intervention. In addition, 29 patients in the study group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 51 study group.
11509529|NCT01287611|Active Comparator|Continuously locked closure technique|Eighty four patients were allocated to the control group. Due to expanded Kerr incisions 3 patients in control group did not receive their allocated intervention. In addition, 16 patients in the control group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 65 study group.
11509530|NCT01287598|Experimental|Arm 1|Regorafenib (Stivarga, BAY73-4506) + warfarin + omeprazole + midazolam
11509531|NCT01287598|Experimental|Arm 2|Regorafenib (Stivarga, BAY73-4506) + rosiglitazone
11509532|NCT01287585|Experimental|ADI-PEG 20|Arginine deiminase formulated with polyethylene glycol.
11509533|NCT01287585|Placebo Comparator|Placebo|an inert treatment with no therapeutic value.
11509534|NCT01287572||Conscious sedation group|Pediatric patients 0 to 18 years requiring conscious sedation for procedures done in the pediatric ICU excluding burned patients or patients with severe eczema or other skin disease.
11509535|NCT01287559||Subjects with NEC|Infants in which a possible diagnosis of NEC is suspected
11509536|NCT01287559||Control Infants|Age-matched and illness-severity matched to NEC subjects, controls are infants NOT suspected of having NEC.
11509537|NCT01287546|Experimental|LY2875358|
11509538|NCT01287546|Experimental|LY2875358 + erlotinib|
11509539|NCT01287546|Experimental|LY2875358 at Part A highest dose|
11509540|NCT01287546|Experimental|LY2875358 at Part A highest dose + trametinib|
11509541|NCT01287533|Experimental|Ibandronate treatment|Ibandronate 150mg PO once every 4 weeks
11509542|NCT01287533|Placebo Comparator|Placebo arm|Placebo PO once every 4 weeks
11509543|NCT01287520|Experimental|LY2090314/pemetrexed/carboplatin|"Part A, Cycle 1 (28 days): Intravenous doses of LY2090314 starting at 10 milligram (mg) were given on Day 1 followed by 10 mg LY2090314, 500 milligram per square meter (mg/m^2) pemetrexed (intravenous dose), and 5 or 6 area under the concentration-time curve (AUC) intravenous dose of carboplatin on Day 8.
~Part A, Cycle 2 (21 days): Pemetrexed and carboplatin given on Day 1 at the same dose administered in Cycle 1.
~Part A, Cycle 3 (21 days) and beyond: LY2090314, Pemetrexed and carboplatin were given on Day 1 at the same dose administered in Cycle 1. LY2090314 doses were escalated until the maximum tolerated dose (MTD) was reached.
~Part B: Dose determined in Part A was administered. Participants were allowed to continue the combination treatment if they were receiving therapeutic benefit until they fulfilled one of the criteria for discontinuation."
11509544|NCT01287507|Placebo Comparator|Placebo|In born VLBW infants with parental consent form signed will be given oral saline daily as placebo until discharge
11509584|NCT01287273||Group B|Transfer of thawed embryos 24-72 hours post thawing
11509545|NCT01287507|Experimental|Lactoferrin|In born VLBW infants with parental consent form signed will be given oral bovine lactoferrin daily until discharge
11509546|NCT01287494|Experimental|Depression Care Management|"DCM Intervention for Depressed Elders in Primary Care
~Treatment guidelines (TG): Eight weeks treatment with Sertraline, another 8 weeks treatment augmentation with Bupropion if patients fail to respond in the initial trial, For more complicated cases, the transfer to psychiatrists is indicated.
~Care managers: Screening, Adherence support, psychoeducation and communication.
~Psychiatric Consultation"
11509547|NCT01287494|No Intervention|Care as Usual|
11509548|NCT01287481|Experimental|Stress and Emotions|Seeks to reduce stress and physical symptoms by helping individual become aware of their emotions, express them, and resolve emotional difficulties. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
11509549|NCT01287481|Active Comparator|Thoughts and Behaviors|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms of fibromyalgia. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
11509550|NCT01287481|Active Comparator|Brain and Body|Seeks to help individuals improve health by educating about fibromyalgia so that one can better understand and more effectively communicate about their health. It will explain the latest scientific information about fibromyalgia, including its causes, the role of the nervous system and body, various medical and alternative treatments, and how to understand research findings.
11509551|NCT01287468||Experimental Group|
11509552|NCT01287468||Control Group|
11509553|NCT01287455|Active Comparator|vitamin D|vitamin D deficient asthmatic patients receiving vitamin D supplement
11509554|NCT01287455|Placebo Comparator|placebo|vitamin D deficient asthmatic patients receiving placebo
11509555|NCT01287429||acute dyspnea|
11509556|NCT01287416|Experimental|Applied Suicide Intervention Skills Training (ASIST)|"ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The training is designed for anyone (especially those in a position of trust), from professionals and volunteers to members of the community. Participants range from those in caring roles to people concerned about family members or friends. The theory is that suicide can be pre¬vented with the help of prepared caregivers. ASIST is designed to help all caregivers become more willing, ready and able to help persons at risk. Just as CPR skills make physical first aid possible, training in suicide intervention develops the skills used in suicide first aid."
11509557|NCT01287416|Active Comparator|Resilience Retreat|The two days will be divided into cultural activities, sharing circles, small group discussions, story telling and dance. Two First Nations community leaders will be identified to lead each of the two retreats.
11509558|NCT01287403|Placebo Comparator|Refined wheat flour|A negative control flour to serve as a reference.
11509559|NCT01287403|Active Comparator|Esterase wholegrain wheat flour|Wholegrain wheat flour treated with esterases to release phenolics (positive control for phenolic acids)
11509560|NCT01287403|Experimental|Wholegrain wheat flour|Flour with unknown response
11509561|NCT01287403|Experimental|Liquid whole grain wheat flour|Test flour with unknown response.
11509562|NCT01287403|Experimental|Wholegrain barley flour|Test flour with unknown response.
11509563|NCT01287403|Experimental|Liquid wholegrain barley flour|Test flour with unknown response.
11509564|NCT01287390|Active Comparator|standard radiotherapy treatment|These patients receive the normal standard treatment.
11509565|NCT01287390|Experimental|adaptive radiotherapy|These patients receive the adaptive image-guided intensity-modulated radiotherapy (IMRT) for head and neck cancer.
11509566|NCT01287377|Experimental|Pre-Patch and Telephone Counseling|"Nicotine patches (2 weeks' worth) are mailed directly to the subject. Clients will be encouraged to start using these patches PRIOR to their quit date.
~Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls."
11509567|NCT01287377|Active Comparator|Post-Patch and Telephone Counseling|"Nicotine patches (2 weeks' worth) are mailed directly to the subject. Clients are encouraged to start using their patches ON their quit date.
~Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls."
11509568|NCT01287377|Active Comparator|Telephone Counseling and no patches sent|Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls.
11509569|NCT01287364|Experimental|ciclesonide HFA followed by mometasone|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily in first intervention period, followed by a 7-14 day washout period, after which the second intervention of mometasone nasal inhalation 200 μg once daily will be administered.
11509570|NCT01287364|Active Comparator|mometasone followed by ciclesonide HFA|mometasone nasal inhalation 200 μg once daily in first intervention period followed by a 7-14 day washout period after which the second intervention of ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily will be administered
11509571|NCT01287351||IPDI: Qvar|ICS initiation as Qvar
11509572|NCT01287351||IPDI FP|ICS initiation as fluticasone
11509573|NCT01287351||IPDA Qvar|ICS step-up as Qvar
11509574|NCT01287351||IPDA FP|ICS step-up as fluticasone
11509575|NCT01287338|Experimental|Lower Puncta Delivery|
11509576|NCT01287338|Experimental|Double Puncta Delivery|
11509577|NCT01287325|Experimental|DNK333|
11509578|NCT01287325|Placebo Comparator|Placebo|
11509579|NCT01287299|Experimental|Low Glycemic Load Diet|Counseled to consume a diet with a low or higher intake of carbohydrate sources that cause rapid or significant intakes in blood glucose. The average glycemic load of the diet should be less than 55 per 1000 calories or greater than 55 per 1000 calories.
11509580|NCT01287299|Experimental|Low Fat Diet|Pregnant women were counseled to consume a diet providing less that 25% of the energy as fat.
11509581|NCT01287286|Experimental|AC-Can|Antrodia cinnamomea and concomitant chemotherapy
11509582|NCT01287286|Placebo Comparator|control|Placebo and concomitant chemotherapy
11509583|NCT01287273||Group A|Transfer at the day of embryo thawing
11509587|NCT01287247||Cervical Dystonia|The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of cervical dystonia.
11509588|NCT01287247||Blepharospasm|The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of blepharospasm.
11509589|NCT01287234|Other|All Patients|All patients will have an echocardiogram and SonR sensor readings completed.
11509590|NCT01287221|Active Comparator|Rifampicin|Subjects randomized to this arm will receive 300 mg Rifampicin two times a day for 12 months.
11509591|NCT01287221|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo capsules twice daily for 12 months. The capsules will contain riboflavin (vitamin B2).
11509592|NCT01287208|Active Comparator|Unblinded activity monitor|Subjects wear the activity device and can see the data on the device and on a website where the data is uploaded.
11509593|NCT01287208|Placebo Comparator|Blinded activity monitor|Subjects wear a blinded activity device and cannot see the activity on the device and cannot log on to the website where the data gets uploaded.
11509594|NCT01287195|Experimental|Oral OKT3|Participants with ulcerative colitis will receive Oral OKT3 given with Omeprazole once daily for 30 days.
11509595|NCT01287182|Placebo Comparator|Placebo|
11509596|NCT01287182|Active Comparator|Ateronon|
11509597|NCT01287156||1|Subjects with diagnosed or suspected TBI or postconcussive syndrome
11509598|NCT01287130|Experimental|DL 1|AZD6244 once daily on days 1, 8, 15 and 22. Cetuximab 400 mg/m2 IV loading dose over 120minutes on day 1 and cetuximab 250 mg/m2 IV loading dose over 60 minutes on days 8, 15,22
11509599|NCT01287130|Experimental|DL 2|AZD6244 twice daily on days 1, 8, 15 and 22. Cetuximab 400 mg/m2 IV loading dose over 120minutes on day 1 and cetuximab 250 mg/m2 IV loading dose over 60 minutes on days 8, 15,22
11509600|NCT01287117|Placebo Comparator|Placebo|Participants received placebo subcutaneously every 4 weeks during the 24 week treatment period.
11509601|NCT01287117|Experimental|Omalizumab 75 mg|Participants received omalizumab 75 mg subcutaneously every 4 weeks during the 24 week treatment period.
11509602|NCT01287117|Experimental|Omalizumab 150 mg|Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 24 week treatment period.
11509603|NCT01287117|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24 week treatment period.
11509604|NCT01287104|Experimental|Pre-Bone Marrow Transplant (BMT) Prep Regimen|Pre-bone marrow transplant (BMT) Prep Regimen with Stem Cell and natural killer (NK) Cell Infusions coupled with Induction therapy
11509605|NCT01287091|Experimental|Part 1|
11509606|NCT01287091|Experimental|Part 2|
11509607|NCT01287091|Experimental|Part 3: Group A|
11509608|NCT01287091|Experimental|Part 3: Group B|
11509609|NCT01287078|Experimental|Inhaled Cyclosporine in Lung Transplant and HSCT Recipients|Subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.
11509610|NCT01287065|Experimental|FF(100mcg)/Vilanterol(25mcg) - AM dosing|FF(100mcg)/Vilanterol(25mcg) in the morning (approx 09.00) for 14 days (± 2 days).; placebo in evening (approx 21.00) for 14 days (± 2 days).
11509611|NCT01287065|Experimental|FF(100mcg)/Vilanterol(25mcg) - PM dosing|Placebo in morning (approx 09.00) for 14 days (± 2 days); FF(100mcg)/Vilanterol(25mcg) in evening (approx 21.00) for 14 days (± 2 days).
11509612|NCT01287065|Placebo Comparator|Placebo|Placebo given in morning (approx 09.00) and in evening (approx (21.00) for 14 days (± 2 days).
11509613|NCT01287052|Experimental|Nitrous Oxide|
11509614|NCT01287039|Placebo Comparator|Placebo|Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
11509615|NCT01287039|Experimental|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
11509616|NCT01287026|Experimental|1|Open Label
11509617|NCT01287013|Other|Cone Beam CT|Procedure performed with Xperguide cone-beam Computed Tomography (CT) navigation
11509618|NCT01287013|Other|Conventional CT|Procedure performed with Conventional Computed Tomography (CT) image guidance
11509619|NCT01287000||1|Workers and volunteers engaged or potentially engaged in oil spill clean-up operations in the Gulf of Mexico
11509620|NCT01286987|Experimental|Talazoparib|
11509621|NCT01286974|Experimental|ADME|[14C]linifanib
11509622|NCT01286974|Experimental|Extension|linifanib
11509623|NCT01286961||outpatient colonoscopy, bowel preparation, split dose PEG|adult outpatients who undergo colonoscopy
11509624|NCT01286948|Active Comparator|Levonorgestrel (LNG) gel (Levogel)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).
~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
11509625|NCT01286948|Active Comparator|oral LNG (1.5mg)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).
~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
11509626|NCT01286935|Experimental|Low Dose (50mg/day)|
11509627|NCT01286935|Experimental|High Dose (100mg/day)|
11509628|NCT01286935|Placebo Comparator|Placebo|
11509629|NCT01286922|Experimental|Interval Training|"The target intensity for the INT group is 2 min at about 95% of baseline VO2max followed by 2 min of recovery at 40-50% of VO2max. Regardless of the training method each participant will be locked into a weekly energy expenditure of 12 kilocalories per kilogram of body weight per week (KKW)."
11509630|NCT01286922|Placebo Comparator|Aerobic Conditioning|During the first AER training condition, we will train all participants at an energy expenditure of 12 kcal/kg/wk (KKW). The target exercise intensity for the AER group will be 50%-70% of baseline V02max.
11509631|NCT01286909|Experimental|LaFlavon|
11509632|NCT01286909|No Intervention|Placebo|
11509633|NCT01286896|Experimental|Sunitinib|Sunitinib is administered in oral capsules of 12.5 mg. Patients will start with a continuous once-daily dose of 37.5 mg.
11509634|NCT01286883||Blood draws|Laboratory studies will be performed at baseline; Cycle 1, Day 1; Cycle 1, Day 7; Cycle 2, Day 1; Cycle 3, Day 1; Cycle 4, Day 1; Cycle 6, Day 1; Cycle 12, Day 1.
11509635|NCT01286870|Other|Reconstruction|"The study population will consist of women aged 18 or over who are undergoing primary breast reconstruction.
~The Reconstruction cohort will include subjects with loss of breast tissue due to mastectomy, contralateral breast for post-reconstruction symmetry or subjects with deformities secondary to disease, malignancy, trauma, and congenital deformity. Subjects in this cohort cannot have been implanted with breast implants, but may have tissue expanders. A Becker implant is considered a tissue expander until the port and fill tube have been removed. Women who undergo surgery primarily for a mastopexy will not be part of the reconstruction cohort."
11509636|NCT01286844|Experimental|Cohort 1|Subjects ≥4 and< 12 years. First 6 subjects included, ≥8 and< 12 yrs and weigh ≥21kg, receive 1 SD (10mg) and an 8 day RD period (100mg). Remaining subjects in cohort: Subjects < 21kg receive 2 SD periods (10mg and 50mg), Subjects > 21kg receive 2 SD periods (10mg and 50mg) and an 8 day RD (100mg)
11509637|NCT01286844|Experimental|Cohort 2|Subjects ≥1 and< 4 years, receive 2 SD (5mg and 25mg)
11509638|NCT01286831|Experimental|[14C]GW642444|Single 200μg dose of [14C]GW642444 given on Day 1.
11509639|NCT01286818|Experimental|FOLFIRI plus Ramucirumab (IMC-1121B)|
11509640|NCT01286805|Experimental|Lumbar Plexus Blockade + CSE|The study group will receive a lumbar plexus blockade with 30 mL of 0.25% bupivacaine with 1:200,000 epinephrine, followed by a combined spinal-epidural.
11509641|NCT01286805|Placebo Comparator|Control Group|The control group will receive only a combined spinal-epidural.
11509642|NCT01286779|Experimental|BAX 326|
11509643|NCT01286766|Active Comparator|DCS|DCS: docetaxel with cisplatin with TS-1
11509644|NCT01286766|Active Comparator|DCF|DCF : docetaxel with cisplatin with 5-FU
11509645|NCT01286753|Experimental|Tyrosine Kinase Inhibitor (TKI) Naive|Vemurafenib in participants naive to any prior systemic TKI therapy.
11509646|NCT01286753|Experimental|TKI Experienced|Vemurafenib in participants previously treated with TKI therapy active against vascular endothelial growth factor receptor 2 (VEGFR).
11509647|NCT01286740|Experimental|FTC/RPV/TDF|Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.
11509648|NCT01286727|Placebo Comparator|Normal Saline|Placebo
11509649|NCT01286727|Active Comparator|BB3|
11509650|NCT01286714|Experimental|clips OST|
11509651|NCT01286701|Experimental|Terbinafine Hydrochloride|Terbinafine Hydrochloride Tablets, 250 mg of Dr.Reddy's Laboratories Limited
11509652|NCT01286701|Active Comparator|Lamisil® 250 mg Tablets|Lamisil® 250 mg Tablets of Novartis
11509653|NCT01286688|Experimental|Terbinafine Hydrochloride|Terbinafine Hydrochloride Tablets, 250 mg of Dr.Reddy's Laboratories Limited
11509654|NCT01286688|Active Comparator|Lamisil® 250 mg Tablets|Lamisil® 250 mg Tablets of Novartis
11509655|NCT01286675|Experimental|Eltrombopag|0 mg Eltrombopag
11509656|NCT01286649|Other|Injection of verum and control|Patients will receive randomized, blinded, injections of BOTH autologous hair follicle cells in medium (verum) and of medium alone (control) into two separate pre-defined treatment areas on their scalp.
11509657|NCT01286636|Experimental|artificial neural network|
11509658|NCT01286636|Active Comparator|Polysomnogram|
11509659|NCT01286610|Other|vibration therapy and electrical muscle stimulation|
11509660|NCT01286597|Experimental|dietary|
11509661|NCT01286584|Active Comparator|varenicline group|
11509662|NCT01286584|Placebo Comparator|placebo group|
11509663|NCT01286571|Experimental|BI 135585 (T)|single dose per subject as tablet formulation after high fat, high caloric meal
11509664|NCT01286571|Experimental|BI 135585 (R)|single dose per subject as tablet formulation after an overnight fast
11509665|NCT01286558|Experimental|80mg telmisartan and 5mg amlodipine FDC|once daily
11509666|NCT01286558|Active Comparator|40mg telmisartan and 5mg amlodipine FDC|once daily
11509667|NCT01286545||Ankylosing spondylitis, long term treatment with infliximab|Patients with ankylosing spondylitis under long term treatment with infliximab within the open label clinical trials EASIC and DIKAS are now followed up in a registration study. No intervention is planned. Patients will be followed up for clinical outcome parameters and for radiographic progression.
11509668|NCT01286532||1|Children (male or female) aged 5 to 11 years inclusive on step 3 asthma combination therapy with ICS(inhalation glucocorticosteroids) and LABA ( long-acting b2-agonist) who have completed at least one valid CACT assessment after the study entry
11509669|NCT01286506||Mechanically ventilated patients|
11509670|NCT01286506||Non-mechanically ventilated patients|
11509671|NCT01286493|Experimental|Rabies vaccines on day 0 and 3|Cell culture Rabies vaccines on day 0 and 3
11509672|NCT01286480|Experimental|Clinic-based Educational Intervention|This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
11509673|NCT01286480|No Intervention|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies. Time-pressured clinic visits limit the opportunity to discuss many of the topics noted above.
11509674|NCT01286467|Experimental|1|
11509675|NCT01286454|Experimental|A|4 mg fesoterodine IR beads in capsule under fasting condition
11509676|NCT01286454|Experimental|B|4 mg fesoterodine 10% coated ER beads in capsule under fasting condition
11509677|NCT01286454|Experimental|C|4 mg fesoterodine 15% coated ER beads in capsule under fasting condition.
11509678|NCT01286454|Experimental|D|4 mg fesoterodine 20% coated ER beads in capsule under fasting condition.
11509679|NCT01286454|Experimental|E|4 mg fesoterodine ER tablets under fasting condition.
11509680|NCT01286454|Experimental|F|4 mg fesoterodine TBD % coated ER beads in capsule under fed condition.
11509681|NCT01286441|Placebo Comparator|Placebo|Placebo for East Indian Sandalwood Oil ointment administered topically twice daily
11509682|NCT01286441|Active Comparator|10% EISO|East Indian Sandalwood Oil ointment, 10% (w/w), applied topically twice daily
11509683|NCT01286441|Active Comparator|20% EISO|East Indian Sandalwood Oil ointment, 20% (w/w), applied topically twice daily
11509684|NCT01286441|Active Comparator|30% EISO|East Indian Sandalwood Oil ointment, 30% (w/w), applied topically twice daily
11509685|NCT01286415|Experimental|Group Cognitive Processing Therapy-Cognitive Only|
11509686|NCT01286415|Active Comparator|Group Present Centered Therapy|
11509687|NCT01286402|Experimental|Bupropion SR (sustained release)|Group receiving bupropion SR medication
11509688|NCT01286402|Placebo Comparator|Placebo|
11509689|NCT01286389|Active Comparator|Conventional medical care|Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)
11509690|NCT01286389|Experimental|caloric restriction +medical care|Nutritional counseling individually and in groups, aiming to promote weight loss (10% of body weight) through caloric restriction, +Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise)
11509691|NCT01286376|Active Comparator|symbiotic|
11509692|NCT01286376|Placebo Comparator|placebo|
11509693|NCT01286363||Brachyfacial|Subjects with a horizontal facial growth pattern
11509694|NCT01286363||Mesofacial|Subjects with a balanced facial growth pattern
11509695|NCT01286363||Dolichofacial|Subjects with a vertical facial growth pattern
11509696|NCT01286350|No Intervention|Control|Participants randomized control will continue with usual clinical care.
11509697|NCT01286350|Experimental|Intervention|"Participants randomized to intervention will receive the FL3X Flexible Lifestyle Empowering Change intervention. Adolescents will be paired with a health coach to help learn strategies for improving diabetes control"
11509698|NCT01286337|Experimental|vessel sealing|axilla dissection using this device
11509699|NCT01286337|Active Comparator|control|standard surgical technique
11509700|NCT01286324|Experimental|Chamomile High Grade Extract|Each capsule contains 90 mg dry extract of chamomile flowering tops [6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet
11509701|NCT01286324|Placebo Comparator|Placebo Tablet|Contained lactose
11509702|NCT01286311|Experimental|Direct-to-patient tailored cardiovascular risk message system|Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.
11509703|NCT01286311|No Intervention|Control|
11509704|NCT01286298|Experimental|Laser gingivectomy|
11509705|NCT01286272|Experimental|Arm A (ofatumumab, bendamustine hydrochloride)|"INDUCTION: Patients receive ofatumumab IV over 2-8 hours on day 1 and bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.
~MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive ofatumumab IV over 2-8 hours on day 1. Treatment repeats every 56 days for up to 4 courses."
11509706|NCT01286272|Experimental|Arm B (ofatumumab, bendamustine hydrochloride, bortezomib)|"INDUCTION: Patients receive ofatumumab IV over 2-8 hours on day 1, bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, and bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 35 days for up to 6 courses. Patients without disease progression continue on to maintenance therapy.
~MAINTENANCE: Beginning 8 weeks after the start of induction course 6, patients receive ofatumumab IV over 2-8 hours on day 1 and bortezomib IV over 3-5 seconds or SC on days 1, 8, 15, and 22. Treatment repeats every 56 days for up to 4 courses."
11509707|NCT01286259|Experimental|Intervention Arm|
11509708|NCT01286246|Experimental|Vaginal progesterone|
11509709|NCT01286246|Placebo Comparator|Placebo|
11509710|NCT01286233||Group 1: Metformin|850 mg orally twice a day for 5 years
11509711|NCT01286233||Group 2: Placebo|One caplet orally twice a day for 5 years
11509712|NCT01286220|Active Comparator|Dilute bleach baths|Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.
11509713|NCT01286220|Placebo Comparator|Water|Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
11509714|NCT01286207|Experimental|Rizatriptan 5 mg|Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
11509715|NCT01286207|Experimental|Rizatriptan 10 mg|Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
11509716|NCT01286207|Active Comparator|Standard Care|Standard care at onset of migraine attack
11509717|NCT01286194||Experimental 1|
11509718|NCT01286181|Experimental|Device-guided slow breathing|
11509719|NCT01286168|Experimental|Antisepsis Side|A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days. The drainage bulb will be irrigated with 10ml of 0.125% sodium hypochlorite (Dakin's solution) twice a day.
11509720|NCT01286168|Other|Control Side|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
11509721|NCT01286155||with gastroesophageal reflux disease(GERD)|Subjects with gastroesophageal reflux disease (GERD)
11509722|NCT01286155||Non-GERD|Subjects with no history of gastroesophageal reflux disease (GERD)
11510272|NCT01282021||Region 2|Southern Ethiopia: Bale, Sidamo, Gambela
11509723|NCT01286155||Barrett's esophagus|Subjects with confirmed barrett's esophagus in Olmsted county
11509724|NCT01286142||Influenza treatment with oseltamivir|Patients 24 months of age and younger initially presenting with confirmed or presumed influenza A or B infection treated with oseltamivir.
11509725|NCT01286142||Influenza prophylaxis with oseltamivir|Patients 24 months of age and younger prescribed oseltamivir for influenza prophylaxis
11509726|NCT01286142||Influenza patients with no antiviral treatment|A comparator group of patients 24 months of age and younger presenting with confirmed or presumed influenza A or B and not treated with any influenza antiviral.
11509727|NCT01286129|Active Comparator|Allergic asthmatic|Subjects with allergic asthma will undergo nasal allergen provocations with either house dust mite or cat pelt.
11509728|NCT01286129|Active Comparator|Allergic rhinitic without asthma|Subjects with allergic rhinitis without asthma will undergo nasal allergen provocations with either house dust mite or cat pelt.
11509729|NCT01286116|Experimental|Treatment|Parachute implant
11509730|NCT01286103|Experimental|001|Canagliflozin 300 mg once daily and 150 mg twice daily Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
11509731|NCT01286103|Experimental|002|Canagliflozin 100 mg once daily and 50 mg twice daily Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
11509732|NCT01286090|Experimental|001|Cisapride One 10-mg tablet taken orally 4 times a day for up to 8 weeks.
11509733|NCT01286090|Experimental|002|Placebo One tablet taken orally 4 times a day for up to 8 weeks.
11509734|NCT01286077|Experimental|bortezomib|bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles
11509735|NCT01286077|No Intervention|Non-treated control|no treatment, observation only
11509736|NCT01286064|Experimental|patient with colo-rectal cancer|fluorescence spectra will be mainly characterized by the presence of an emission peaking at 620-630 nm
11509737|NCT01286064|Active Comparator|patient without colo-rectal cancer|fluorescence spectra will be characterized by the absence of an emission peaking at 620-630 nm
11509738|NCT01286051|Active Comparator|Follistim|standard treatment
11509739|NCT01286051|Experimental|Follistim plus single ganirelix injection|
11509740|NCT01286038|Experimental|Eltrombopag Treatment|Phase I: Dose Escalation. Phase II: Treatment at Maximum Tolerated Dose (MTD)
11509741|NCT01286025|Active Comparator|Video modality|
11509742|NCT01286025|Active Comparator|Text modality|
11509743|NCT01286012|Active Comparator|SFP in liquid bicarbonate|
11509744|NCT01286012|Placebo Comparator|Placebo: Conventional Liquid Bicarbonate|Control concentrate lacking SFP does not contain SFP (total iron = 0)
11509745|NCT01285999|Experimental|PROMUS Element|PROMUS Element Everolimus-Eluting Coronary Stent System (PROMUS Element)
11509746|NCT01285999|Active Comparator|TAXUS Liberté|TAXUS Liberté Paclitaxel-Eluting Coronary Stent System (TAXUS Liberté)
11509747|NCT01285986|Experimental|Vein collar at distal anastomosis|Vein collar at the distal anastomosis
11509748|NCT01285986|Experimental|No vein collar at the distal anastomosis|No vein collar at the distal anastomosis
11509749|NCT01285960|Experimental|ExAblate treatment UF V2|ExAblate MRgFUS Treatment
11509750|NCT01285947|Other|Naive Subjects|Subjects who have not previously undergone energy-based dermatologic procedures in the past.
11509751|NCT01285947|Other|Non-Naive Subjects|Subjects who have previously undergone energy-based dermatologic procedures in the past.
11509752|NCT01285934|Experimental|Hematopoietic Stem Cell Transplantation|Patients who meet eligibility and have completed pre-HSCT testing in section 7.0 (study parameters) may be enrolled in the transplant arm and will undergo an Autologous Hematopoietic Stem Cell Transplantation
11509753|NCT01285934|Other|control arm of intensive insulin therapy|The control arm of intensive insulin therapy (IIT) will enroll all patients who meet eligibility but decline HSCT or whose insurance does not approve payment for HSCT before expiration of eligibility (within 5 months of disease onset)
11509754|NCT01285921|Experimental|hippocampal surgery|"Vestibular test before and after hippocampal surgery
~Principal criterion:
~Research for an asymmetry of the vestibular responses (Caloric test, Vestibular Evoked Myogenic potentials: VEMp, Head Impulse Test: HIT, Eye Rotational Test: ERI). Investigator performs a blind vestibular test (single blind)"
11509755|NCT01285908|No Intervention|Baseline|Baseline values measured at various tilt angles, so that each participant may serve as their own control.
11509756|NCT01285908|Placebo Comparator|Saline infusion|Subjects received a saline IV infusion as a placebo, while measurements were taken at various tilt angles.
11509757|NCT01285908|Active Comparator|Norepinephrine Infusion|Subjects were given an norepinephrine infusion at various tilt angles, while measurements were taken.
11509758|NCT01285882||Representations|
11509759|NCT01285869|Experimental|Multidisciplinar intervention|Patients that will receive the multidimensional intervention during the ambulatory follow-up.
11509760|NCT01285869|No Intervention|Conventional follow up|This is an observation only group and outpatient follow up will be indicated in accordance with usual and customary practices.
11509761|NCT01285856|Active Comparator|buprenorphine|populations of patients treated with HDB will be recruited during consultations at a center for addiction treatment. One hundred and ten patients will be included. Written informed consent will be obtained from each patient. Anonymity will be respected at inclusion and throughout. Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. Treatment efficacy will also be assessed using Handelsman's subjective and objective opiate withdrawal scales. Lastly, polymorphisms of the metabolic enzymes of methadone and HDB will be sought by real-time PCR in a saliva sample, a method which gives similar results without the need for venous blood sampling.
11509805|NCT01285531|No Intervention|Lumbar puncture|The participants randomly assigned to this arm will receive a lumbar puncture using standard procedures and equipment
11509908|NCT01284686|Experimental|without dopa|OFF Dopa: The patient will be deprived of his treatment usual dopaminergique for at least 12 hours
11509762|NCT01285856|Active Comparator|methadone|populations of patients treated with methadone will be recruited during consultations at a center for addiction treatment. One hundred and ten patients will be included. Written informed consent will be obtained from each patient. Anonymity will be respected at inclusion and throughout. Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. Treatment efficacy will also be assessed using Handelsman's subjective and objective opiate withdrawal scales. Lastly, polymorphisms of the metabolic enzymes of methadone and HDB will be sought by real-time PCR in a saliva sample, a method which gives similar results without the need for venous blood sampling.
11509763|NCT01285843|Active Comparator|Quadra Group|
11509764|NCT01285843|Active Comparator|AMIStem Group|
11509765|NCT01285830|Placebo Comparator|Placebo|
11509766|NCT01285830|Active Comparator|Lactobacillus reuteri|
11509767|NCT01285817|Experimental|traetment|
11509768|NCT01285804|Active Comparator|Cuffed ETT|
11509769|NCT01285804|Active Comparator|Uncuffed ETT|
11509770|NCT01285791||patients undergoing laparoscopic adjustable gastric banding|morbid obese patients undergoing laparoscopic adjustable gastric banding will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased.
11509771|NCT01285791||patients undergoing laparoscopic sleeve gastrectomy|morbid obese patients undergoing laparoscopic sleeve gastrectomy will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased
11509772|NCT01285791||patients undergoing laparoscopic gastric bypass|morbid obese patients undergoing laparoscopic gastric bypass will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased
11509773|NCT01285778|Experimental|Panitumumab, mytomicin C, 5-FU, radiation|
11509774|NCT01285765|Experimental|Early-PET-result-adapted treatment|4 to 6 RCHOP21
11509775|NCT01285765|Active Comparator|standard treatment|6 RCHOP21
11509776|NCT01285752|Experimental|1|
11509777|NCT01285752|Experimental|2|
11509778|NCT01285752|Active Comparator|3|
11509779|NCT01285739||NIMV COPD|Patients with chronic obstructive pulmonary disease (COPD), who underwent tracheostomy for acute respiratory failure and who were discharged with tracheostomy but in domiciliary non invasive ventilation
11509780|NCT01285739||IMV COPD|Patients with chronic obstructive pulmonary disease (COPD), who underwent tracheostomy for acute respiratory failure and who were discharged in domiciliary invasive mechanical ventilation (IMV)
11509781|NCT01285713|Experimental|5% Dextrose (D5) in Normal Saline (NS)|10cc/kg D5NS, followed by 30cc/kg NS
11509782|NCT01285713|Active Comparator|Normal Saline (NS)|10cc/kg NS, followed by 30cc/kg NS
11509783|NCT01285700|Active Comparator|Lamazym 25|25 U/kg
11509784|NCT01285700|Active Comparator|Lamazym 50|50 U/kg
11509785|NCT01285687|No Intervention|Standard Analgesic Treatment|
11509786|NCT01285687|Experimental|Standard Analgesic Treatment with Acupuncture|Patients will receive standard analgesic treatment and in addition acupuncture.
11509787|NCT01285674|Experimental|Intra-tympanic steroid injection|
11509788|NCT01285661|Experimental|Proximal DVT|Patients whose veins have recanalized (either at the recruitment or later on during the follow-up) will receive the D-dimer determination before discontinuing sodium warfarin. Veins are defined as recanalized when the vein diameter under maximum compressibility is lower than 4 mm both at the common femoral and at the popliteal vein. In those with negative D-dimer sodium warfarin will be discontinued. These patients will have two further determinations of D-dimer (after 1 and 3 months, respectively). While patients with persistently negative D-dimer will no longer receive sodium warfarin, those in whom D-dimer is positive or reverts to positive values in the following determinations will have their sodium warfarin resumed and no longer discontinued.
11509789|NCT01285648|Other|Cpap|This group joined chest physiotherapy with CPAP via nasal masks for two hours.CPAP was continued from the immediate postoperative day until the second postoperative day, twice a day.
11509790|NCT01285648|Other|Chest Physiotherapy|Chest Physiotherapy consisted of bronchial hygiene techniques and pulmonary expansion, in addition to exercises, and received oxygen supplementation to maintain the pulse oxymetry saturations > 90%.
11509791|NCT01285635|Active Comparator|Docetaxel Alone|
11509792|NCT01285635|Experimental|Pulse Dose AT-101 Arm|
11509793|NCT01285635|Experimental|Metronomic AT-101 Arm|
11509794|NCT01285622||Gynecology patients|female subjects scheduled for elective robotic gynecological surgery under general anesthesia.
11509795|NCT01285609|Experimental|Ipilimumab + Paclitaxel and Carboplatin|"Ipilimumab + Active Chemo Backbone
~Ipilimumab: IV solution, intravenous (IV), 10 mg/kg, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)
~Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses
~Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses"
11509796|NCT01285609|Placebo Comparator|Placebo + Paclitaxel and Carboplatin|"Placebo + Active Chemo Backbone
~Placebo: IV solution, IV, 0.9% sodium chloride or 5% dextrose, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)
~Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses
~Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses"
11509797|NCT01285583|Other|Olesoxime|All patients will receive the IMP as add-on to riluzole 50 mg bid orally, 50 mg morning and evening on an empty stomach ie at least 20 min before the meal.
11509798|NCT01285570|Experimental|Experimental 2|
11509799|NCT01285570|Experimental|experimental 1|
11509800|NCT01285570|Placebo Comparator|Placebo|Placebo comparator daily (QD)
11509801|NCT01285557|Experimental|S-1/cisplatin|
11509802|NCT01285557|Active Comparator|5-FU/cisplatin|
11509803|NCT01285544|Experimental|Lipinon-test formulation of atrovastain - 20mg|
11509804|NCT01285544|Active Comparator|Lipitor- branded formuation of atorvastatin-20mg|
11509969|NCT01284309|Placebo Comparator|Placebo|
11509806|NCT01285531|Experimental|Lumbar puncture with the Compass device|The participants randomly assigned to this group will receive a lumbar puncture with the use of the Compass device.
11509807|NCT01285518|Experimental|Treatment|
11509808|NCT01285518|Placebo Comparator|Placebo|0.9% w/v sodium chloride injection, USP
11509809|NCT01285505|Active Comparator|Alprazolam commercial sublingual tablet|
11509810|NCT01285505|Experimental|Alprazolam test sublingual tablet|
11509811|NCT01285492|Experimental|QVA149|QVA149 110/50 μg once a day (o.d)
11509812|NCT01285492|Active Comparator|Tiotropium|tiotropium 18 μg o.d.
11509813|NCT01285479||prescribed fingolimod 0.5 mg/day|
11509814|NCT01285466|Experimental|BEZ235 + paclitaxel|
11509815|NCT01285466|Experimental|BKM120 + paclitaxel|
11509816|NCT01285466|Experimental|BEZ235 + paclitaxel + trastuzumab|
11509817|NCT01285466|Experimental|BKM120 + paclitaxel + trastuzumab|
11509818|NCT01285453|Experimental|ASA404|
11509819|NCT01285440||Diagnostic Imaging|
11509820|NCT01285427||DNA loci (SeCore vs. SSP UniTray platforms)|
11509821|NCT01285414|Experimental|Verubulin & standard of care (RT & TMZ)|Verubulin, at the dose selected in Part A, plus standard of care Radiation Therapy and Temozolomide
11509822|NCT01285414|Active Comparator|Standard of care (RT & TMZ)|Standard of care Radiation Therapy and Temozolomide
11509823|NCT01285401|Experimental|VigantOL® oil|VigantOL oil plus Rebif in subjects with 25-hydroxy-vitamin D plasma levels below 150 nmol/L
11509824|NCT01285401|Placebo Comparator|Placebo|Placebo daily plus Rebif in subjects with 25-hydroxy-vitamin D plasma levels below 150 nmol/L
11509825|NCT01285401|Experimental|Rebif|Rebif alone in subjects with 25-hydroxy-vitamin D plasma levels equal or higher than 150 nmol/L
11509826|NCT01285388|Experimental|MB12066 10mg|
11509827|NCT01285388|Active Comparator|MB12066 30mg|
11509828|NCT01285388|Active Comparator|MB12066 100mg|
11509829|NCT01285388|Active Comparator|MB12066 150mg|
11509830|NCT01285388|Active Comparator|MB12066 200mg|
11509831|NCT01285388|Placebo Comparator|placebo|
11509832|NCT01285375|Active Comparator|CDC graft perfusion|Flushing of kidney allografts prior to transplantation with UW-solution containing CDC
11509833|NCT01285375|Sham Comparator|Sham perfusion|
11509834|NCT01285362|Active Comparator|Fish Oil Supplementation (Group A)|Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.
11509835|NCT01285362|Placebo Comparator|Placebo Supplementation (Group B)|Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
11509836|NCT01285349|Experimental|Couple-based HIV prevention|7-session couple-based HIV/STI risk reduction intervention (CSTI)
11509837|NCT01285349|Active Comparator|Individual HIV/STI Prevention|7-session individual HIV/STI intervention comparison condition (ISTI) provided to the index participant alone, which is identical in content to the CSTI.
11509838|NCT01285349|Placebo Comparator|Couple Wellness Promotion|7-session couple-based stress reduction intervention (CSR) that serves as an attentional control condition.
11509839|NCT01285336|Experimental|The genetic and the functional study|
11509840|NCT01285323|Placebo Comparator|Placebo|Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
11509841|NCT01285323|Experimental|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
11509842|NCT01285310|Experimental|Apremilast 30 mg|
11509843|NCT01285310|Experimental|Apremilast 20 mg|
11509844|NCT01285310|Placebo Comparator|Placebo|
11509845|NCT01285297|Experimental|TMR plus BMAC injection|Injection of bone marrow aspirate concentrate into reversibly ischemic myocardium with transmyocardial revascularization during the same open procedure.
11509846|NCT01285284|Experimental|Music|A previously defined list of songs will be administered by headphones to these patients during the colonoscopy.
11509847|NCT01285284|Sham Comparator|Control|These patients will receive an MP3 device (and headphones) which will be functioning but without volume.
11509848|NCT01285271|Experimental|Xenon|Xenon will be administered for balanced general anesthesia for CABG surgery before and after the extracorporal circulation.
11509849|NCT01285271|Active Comparator|Sevoflurane|Sevoflurane will be administered for balanced general anesthesia for CABG surgery before and after the extracorporal circulation.
11509850|NCT01285258|Other|peripartum|patients whom underwent peripartum hysterectomy
11509851|NCT01285245|Experimental|kineret|
11509852|NCT01285232|Experimental|Anakinra|Anakinra 150 mg/day during four weeks
11509853|NCT01285232|Placebo Comparator|Placebo|Placebo during four weeks
11509854|NCT01285219|Active Comparator|AOB,pegylated filgrastim to filgrastim|patients were administered pegylated filgrastim 100 ug/kg in cycle 1 and ﬁlgrastim 5 ug/kg/d in cycle 2
11509855|NCT01285219|Active Comparator|BOA,ﬁlgrastim to pegylated filgrastim|patients received ﬁlgrastim 5 ug/kg/d in cycle 1 and pegylated filgrastim 100 ug/kg in cycle 2
11509856|NCT01285206|Experimental|Routine practice|
11509857|NCT01285193|Experimental|Breath control|A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
11509858|NCT01285180||DINO|
11509859|NCT01285167||DACOTA|
11509860|NCT01285154||Traditional Steel Triple Osteotomy|Traditional technique
11509861|NCT01285154||Modified Triple Osteotomy|Modified technique
11509862|NCT01285141|Experimental|Vaginal immunisation|CN54gp140 glycoprotein-hsp70 conjugate vaccine
11509863|NCT01285115|Placebo Comparator|Placebo; corn flour,|"raw material total contents(500㎎) cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)
~shape, type: extract(brown)
~usage, content: adults;three times a day each sack taken before or between meals
~dose, standard: for each sack 7.67g
~storage : airtight container, stored in room temperature
~expiration date : after manufacture 36 month
~macufacturing company: KyungBangnShinYak inc."
11509907|NCT01284686|Active Comparator|dopamine|ON DOPA:The patient will take his usual treatment with dopamine
11509864|NCT01285115|Active Comparator|Gamisoyosan extract|"name of product: KyungBangn-Gamisoyosan-x-gwarip
~standard code for item : 200005799
~shape, type: extract(grayish brown)
~usage, content : adults;three times a day , each sack taken before or between meals
~dose, standard: 7.67g for each sack
~storage : airtight container, stored in room temperature expiration date : after manufacture 36 month macufacturing company: KyungBangnShinYak inc."
11509865|NCT01285115|Active Comparator|Gamisoyosan extract powder|"name of product: KyungBangn Gamisoyosan
~standard code for item: 200005591
~shape, type: powder(brown)
~usage, content: adults;three times a day each sack taken before or between meals
~dose, standard: 7.67g for each sack
~storage : airtight container, stored in room temperature
~expiration date : after manufacture 36 month
~macufacturing company: KyungBangnShinYak inc."
11509866|NCT01285102|Experimental|Arm I|Patients receive irinotecan-eluting beads via hepatic artery embolization every 3 weeks for up to 3 (unilobar disease) or 4 (bi-lobar disease) courses in the absence of disease progression or unacceptable toxicity.
11509867|NCT01285089||A|
11509868|NCT01285076||All Enrolled Participants|Adults with Type 2 DM ≥30 years of age who have been treated with SU monotherapy or SU + MF combination therapy for at least 6 months by a cardiologist, nephrologist, neurologist, or family practice doctor.
11509869|NCT01285063|Experimental|physical activiy & nutrition|"25 kindergarten children in the ages of 4-6 who defined as suffering from overweigh (BMI percentage 85-95) or obesity (above BMI percentage 95).
~Non-generalization criteria: children who suffer from obesity due to organic disease or children who take medicine which may influence body weight (e.g., steroids) will be excluded from the research."
11509870|NCT01285050|Other|pre post ART|HCV and HIV viral load pre and post antiretroviral therapy (ART). ART is the intervention and the comparison is the HIV and HCV viral load reductions as determined by RT-PCR after administration of interferon alfa in each instance (before and after ART)
11509871|NCT01285037|Experimental|LY2801653|"This study consists of a dose escalation of LY2801653 (Part A) followed by dose confirmation cohorts in four tumor types (adenocarcinoma of the colon or rectum, head and neck squamous cell carcinoma, uveal melanoma with liver metastasis, and cholangiocarcinoma) (Part B).
~Part C consists of dose determination for LY2801653 in combination with cetuximab in participants with head and neck squamous cell carcinoma followed by an expansion cohort.
~Part D consists of dose determination for LY2801653 in combination with cisplatin in participants with cholangiocarcinoma followed by an expansion cohort.
~Part E consists of dose determination for LY2801653 in combination with gemcitabine and cisplatin.
~Part F consists of dose determination for LY2801653 in combination with ramicirumab."
11509872|NCT01285024|No Intervention|Control|No Vitagel used during total hip arthroplasty
11509873|NCT01285024|Experimental|Vitagel|Vitagel applied just prior to closure during total hip arthroplasty
11509874|NCT01285011||Ipp-On|Patient implanted with the Ipp-On
11509875|NCT01284998||B-BOP lock|Subjects who needs a fixation of osteotomy of the basis of the first metatarsal and for whose surgeon has recommended that a B-BOP® Lock plate from INTEGRA be implanted can be enrolled in this study
11509876|NCT01284985||METIS|Patient who has an indication of : Hallux Rigidus, Hallux Limitus with degenerative joint disease, Painful Hallux Valgus, Osteoarthritis, Rheumatoid arthritis, Post-traumatic arthritis and for which surgeon has recommended that a METIS® prosthesis be implanted.
11509877|NCT01284972||HINTEGRA|Patient Implanted with the HINTEGRA Total Ankle Prosthesis more than 2 years ago
11509878|NCT01284959|Experimental|risperidone|Drug: risperidone 3mg, PO two times Groups: risperidone
11509879|NCT01284959|Placebo Comparator|placebo|drug: lactose, PO 3 times group: placebo
11509880|NCT01284959|Experimental|paliperidone ER|drug : Paliperidone ER 6mg PO, two times group: paliperidone ER
11509881|NCT01284946|Experimental|Exjade|Safety and efficacy
11509882|NCT01284933||Acute Ischemic Stroke, TIA|Patients admitted to a specialized stroke service because of an acute ischemic stroke or a transient ischemic attack (TIA).
11509883|NCT01284920|Experimental|dose-escalation cohort-1|MDV3100 low dose arm
11509884|NCT01284920|Experimental|dose-escalation cohort-2|MDV3100 middle dose arm
11509885|NCT01284920|Experimental|dose-escalation cohort-3|MDV3100 high dose arm
11509886|NCT01284920|Experimental|dose-expansion cohort|dose expansion with MDV3100 middle dose
11509887|NCT01284907|Active Comparator|Vit D|
11509888|NCT01284907|Placebo Comparator|Placebo drops|
11509889|NCT01284894|Other|Conventional manometry|
11509890|NCT01284894|Experimental|High resolution manometry|
11509891|NCT01284881||OSAHS|
11509892|NCT01284868|Experimental|Mirabegron|
11509893|NCT01284855|Active Comparator|Low initial dose|This arms corresponds to Nepal national protocol and involves the initial administration of 2 vials of antivenom over one hour followed by the slow infusion of 4 vials over 4 hours
11509894|NCT01284855|Experimental|High initial dose|This arms corresponds to Indian national protocol and involves the initial administration of 10 vials of antivenom over one hour followed by the slow infusion of saline over 4 hours
11509895|NCT01284829|Experimental|adrenal tumors|adrenal tumors
11509896|NCT01284816|Other|severely obese patients|35 patients addressed for severe obesity in the Endocrinology department of Marseille North Hospital before (V1) and 6 months (V2) after bariatric surgery
11509897|NCT01284803|Experimental|experimental arm|
11509898|NCT01284790|Experimental|Cochlear implants|
11509899|NCT01284777||patients|
11509900|NCT01284764|No Intervention|midnight fasting|The patients in this group will have midnight fasting the day before endoscopic examination
11509901|NCT01284764|Active Comparator|Mosapride, low volume of water|The patients in this group will take mosapride and a 500mL water at evening of the day before endoscopic examination.
11509902|NCT01284751||Breast cancer patients|Patients aged 30-70 years having a lumpectomy or mastectomy at the Department of Breast Surgery at Herlev Hospital, Copenhagen, Denmark.
11509903|NCT01284738|Active Comparator|TM patients|thalassemia major (TM) Need transfusion for survive
11509904|NCT01284738|Active Comparator|TI patients|thalassemia intermedia (TI) Patients with TI have a milder clinical phenotype than those with TM
11509905|NCT01284725|Experimental|immunosuppressive treatment discontinuation,|
11509906|NCT01284725|Active Comparator|Continuation of immunosuppressive therapy|with MMF or AZA, with a background therapy with hydroxychloroquine, and possibly low-dose corticosteroids
11509909|NCT01284660|Active Comparator|I. DHA|Oral ingestion 5 tablets DHA + EPA (daily ingestion DHA 2040 mg and EPA 2710 mg)- (Omega 3 - 950,the Solgar Pharmaceutical Co., Israel).
11509910|NCT01284660|Placebo Comparator|II. Placebo|Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
11509911|NCT01284647|Experimental|Teprenone capsule|
11509912|NCT01284647|Active Comparator|sucralfate|
11509913|NCT01284634|Experimental|GWP42003 200 milligrams (mg)/day Dose|Participants self-administered one x 100 mg GWP42003 capsule twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
11509914|NCT01284634|Experimental|GWP42003 400 mg/day Dose|Participants self-administered two x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
11509915|NCT01284634|Experimental|GWP42003 800 mg/day Dose|Participants self-administered four x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
11509916|NCT01284634|Experimental|Placebo|Participants self-administered one, two or four placebo capsules twice daily, for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]). Each capsule exactly matched the GWP42003 capsules in terms of appearance, size, smell and taste.
11509917|NCT01284621|Experimental|BI 10773|1 tablet per days for 5 days, oral administration with 240 mL water for each treatment
11509918|NCT01284621|Other|Ramipril|1 tablet on day 1 and 2 tablets per day on day 2-5, oral administration with 240 mL water for each treatment
11509919|NCT01284621|Other|BI 10773 + Ramipril|1 tablet BI 10773 and 1 tablet on day 1 and 2 tablets ramipril per day on day 2-5, oral administration with 240 mL water for each treatment
11509920|NCT01284595|Experimental|AZD8931|[14C] AZD8931
11509921|NCT01284582|Experimental|ATH03 Group A|ATH03, 10 µg, 0.2% Alum
11509922|NCT01284582|Experimental|ATH03 Group B|ATH03, 30 µg, 0.2% Alum
11509923|NCT01284582|Experimental|ATH03 Group C|ATH03, 100 µg, 0.2% Alum
11509924|NCT01284569|Experimental|ALX-0061|
11509925|NCT01284569|Placebo Comparator|Placebo|
11509926|NCT01284556|Placebo Comparator|Placebo|placebo tablets
11509927|NCT01284556|Experimental|60 mg group|Patients titrated to 60mg phenobarbital for maintenance period, then titrated down.
11509928|NCT01284556|Experimental|100 mg group|Patients titrated to 100mg phenobarbital maintenance period, then titrated down
11509929|NCT01284543|Active Comparator|Busin glide delivery of donor graft|Use of the Busin glide to insert the donor graft
11509930|NCT01284543|Experimental|Tan EndoGlide for insertion of the donor graft|Use of the Tan EndoGlide for insertion of the donor graft
11509931|NCT01284530|Experimental|Conversion-25|25 mg
11509932|NCT01284530|Experimental|Conversion-50|50 mg
11509933|NCT01284530|Experimental|Conversion-100|100 mg
11509934|NCT01284530|Experimental|Conversion-200|200 mg
11509935|NCT01284517|Experimental|Lurasidone 20-120 mg flexible dose|
11509936|NCT01284517|Placebo Comparator|Placebo|
11509937|NCT01284504|Experimental|Celecoxib|Celecoxib, 200 mg tab
11509938|NCT01284504|Placebo Comparator|Placebo|placebo, tab
11509939|NCT01284491|Active Comparator|Standard of Care (SOC)|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
11509940|NCT01284491|Experimental|PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
11509941|NCT01284478|Other|Dexamethasone Implant|Patients will be treated with the Ozurdex (Dexamethasone Implant)
11509942|NCT01284465|Experimental|Intervention group|Education and patient liaison combination
11509943|NCT01284465|Experimental|Control group|Education only
11509944|NCT01284452|Placebo Comparator|Placebo|Normal saline 50 ml intravenous every 6 hours for 7 days
11509945|NCT01284452|Active Comparator|Hydrocortisone|Hydrocortisone 50 mg intravenous every 6 hours for 7 days
11509946|NCT01284439|Experimental|TearA|
11509947|NCT01284439|Experimental|TearB|
11509948|NCT01284426||Chronic urticaria|Chronic urticaria, Natural history
11509949|NCT01284413|Experimental|S-1, Gemcitabine, Cisplatin|
11509950|NCT01284400|Experimental|Disease management|
11509951|NCT01284400|No Intervention|Usual treatment and care|
11509952|NCT01284387|Experimental|3 μg ACC-001 / QS-21 50 μg IM dose 1|3 μg ACC-001 / QS-21 50 μg IM
11509953|NCT01284387|Experimental|10 μg ACC-001 / QS-21 50 μg IM dose 2|10 μg ACC-001 / QS-21 50 μg IM
11509954|NCT01284387|No Intervention|Placebo - Phosphate buffered saline (PBS) IM dose|Placebo - Phosphate buffered saline (PBS) IM
11509955|NCT01284374||Male Adolescents|Male adolescents, 13-17 years old, who are seen at community adolescent health clinics and are offered HPV vaccine
11509956|NCT01284374||Parents of Male Adolescents|Parents of Male Adolescents, whose adolescents are being seen at community adolescent health clinics and are offered HPV vaccine
11509957|NCT01284374||Health Care Providers for Males 13-17 yo|Health care providers who provide medical care to male adolescents in pediatric and adolescent clinics
11509958|NCT01284361|Experimental|30 cm Intermittent Catheter|Intervention was the test of a 30 cm catheter compared to standard commercial 40 cm catheter in a cross-over design.
11509959|NCT01284361|Active Comparator|40 cm Intermittent Catheter|Active comparator 40 cm commercial catheter was compared to experimental 30 cm catheter in a cross-over design.
11509960|NCT01284348|Experimental|Sotatercept - 15 mg|Sotatercept 15 mg Subcutaneous (SC) Day 1 every 42 days
11509961|NCT01284348|Experimental|Sotatercept 30 mg|Sotatercept 30 mg SC Day 1 every 42 days
11509962|NCT01284335|Experimental|Gemcitabine plus LY573636|
11509963|NCT01284335|Experimental|Docetaxel plus LY573636|
11509964|NCT01284335|Experimental|Temozolomide plus LY573636|
11509965|NCT01284335|Experimental|Cisplatin plus LY573636|
11509966|NCT01284335|Experimental|Erlotinib plus LY573636|
11509967|NCT01284322|Experimental|Fresolimumab|
11509968|NCT01284309|Experimental|Mirabegron|
11509971|NCT01284283|Other|Single|Device: Scandinavian Total Ankle Replacement System (STAR Ankle)
11509972|NCT01284270|Other|All Patients|All patients undergo the same study procedures
11509973|NCT01284257||Enteric coated mycophenolate sodium (EC-MPS) arm|Patients to whom EC-MPS is prescribed by their practitioner.
11509974|NCT01284257||MMF arm|Patients to whom MMF is prescribed by their practitioner.
11509975|NCT01284244|Experimental|Uresta|
11509976|NCT01284244|Sham Comparator|Silastic vaginal ring|
11509977|NCT01284231|Experimental|MEDI-565 - Dose Escalation|Up to 15 dose-escalation cohorts will be enrolled
11509978|NCT01284231|Experimental|MEDI-565 Dose Expansion Arm 1|20 subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biologic dose
11509979|NCT01284231|Experimental|MEDI-565 Dose Expansion Arm 2|20 subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biologic dose
11509980|NCT01284231|Experimental|MEDI-565 Dose Expansion Arm 3|Subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biological dose
11509981|NCT01284218||Aripiprazole cohort|
11509982|NCT01284218||Other atypical cohort|
11509983|NCT01284218||Other antidepressant cohort|
11509984|NCT01284218||Mood stabilizer cohort|
11509985|NCT01284218||Stimulant cohort|
11509986|NCT01284205|Experimental|MCC|Intravesical Administration of Mycobacterial Cell-Wall DNA Complex
11509987|NCT01284205|Active Comparator|BCG|Intravesical Administration of Bacillus Calmette-Guerin
11509988|NCT01284192|Experimental|ASP3026|Subjects will receive escalated doses of ASP3026 to determine the maximum tolerated dose (MTD)
11509989|NCT01284179|Experimental|Hypnotherapy|Participants will be randomized to either the home hypnotherapy or educational group. The HHT protocol will consist of sequences of two different types of sessions, longer biweekly sessions (LS), each approximately 30-40 minutes in length, and shorter daily sessions (SS), approximately 12 minutes in length. On the first day of each sequence, the patient will listen to the appropriate LS. The patients will listen to the SS on a daily basis in between each LS. Every 2 weeks a new sequence will begin, for a total of 12 weeks of treatment.
11509990|NCT01284179|Other|Educational|Participants will be randomized to receive either home hypnotherapy or an educational program. The control group will receive an educational digital audio program on MP3 players. These digital audio files will contain general information about FCP and FGIDs. These audio files will be similar to the intervention audio files in length. Patients will be instructed to begin listening on the day of randomization. Patients will be instructed to continue their other medical treatment for chest pain during the study. The control group will be assessed at the same times as the HHT group.
11509991|NCT01284166|Experimental|Triple Combination Therapy|Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
11509992|NCT01284140|Experimental|Sleep promotion protocol|Behavioral: 48 hours of sleep and circadian rhythm promotion including timed light exposure.
11509993|NCT01284140|Active Comparator|Usual care|Behavioral: 48 hours of usual care.
11509994|NCT01284127||Deferiprone|All patients must have MRI evidence of superficial siderosis and be treated with deferiprone according to standard of care guidelines.
11509995|NCT01284114|Active Comparator|Aliskiren|
11509996|NCT01284101|Active Comparator|Forceps delivery of donor graft|Using the forceps to insert the donor graft.
11509997|NCT01284101|Experimental|Tan Endoglide for insertion of the donor graft|Use of the Tan Endoglide for insertion of the donor graft.
11509998|NCT01284088|Experimental|PrePex™|Adult male circumcision by the PrePex™ Device
11509999|NCT01284088|Active Comparator|Surgical|Adult male surgical circumcision
11510000|NCT01284075|Experimental|Guided Imagery and Music therapy group (GIMT)|Participants will undergo a standardized regimen of peri-operative guided imagery and music therapy guided by CDs (compact disc). The peri-operative regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
11510001|NCT01284075|Active Comparator|White Noise Group (WN)|Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
11510002|NCT01284075|Active Comparator|No Interventions Group (CP)|Control group (CP) will have no intervention at all and will follow our current peri-operative procedures.
11510003|NCT01284062|Experimental|Arm 1|200 mg PF-05230917, Anrukinzumab active dose level
11510004|NCT01284062|Experimental|Arm 2|400 mg PF-05230917, Anrukinzumab active dose level
11510005|NCT01284062|Experimental|Arm 3|600 mg PF-05230917, Anrukinzumab active dose level
11510006|NCT01284062|Placebo Comparator|Arm 4|Matching placebo - administered at matching dose level 200 mg, 400 mg or 600 mg.
11510007|NCT01284049|Active Comparator|Intralipid 20%®|reference treatment by standard lipid emulsion not enriched in n-3 EFA (Intralipid 20%®)+ vitamin E.
11510008|NCT01284049|Experimental|OMEGAVEN 10%®|Interventional treatment by a lipid emulsion enriched in n-3 EFA (OMEGAVEN 10%®).
11510009|NCT01284036|Other|PF-05230905|9 subjects will participate in each dose cohort. 6 subjects will receive investigational product (PF-05230905) and 3 subjects will receive placebo
11510010|NCT01284023||Controls|Uninjured volunteers
11510011|NCT01284010||Group 1|Diagnostic, complete remission, and germ-line specimens are analyzed for DNA profiling and gene resequencing by the Affymetrix SNP6.0 microarray platform, PCR, and fluorescence in situ hybridization (FISH). Frequency of genetic alterations are performed by the Agilent 2100 Bioanalyzer. Results are then compared with the data already generated from pediatric patients.
11510012|NCT01283997|Placebo Comparator|Placebo Group|1 dose on first day of induction therapy, then every 12 hours for 10 weeks.
11510013|NCT01283997|Experimental|Minocycline Group|200 mg orally for 1 dose, then 100 mg orally every 12 hours for 10 weeks.
11510014|NCT01283984|Experimental|1|AZD2115
11510015|NCT01283984|Placebo Comparator|2|Placebo to AZD2115
11510016|NCT01283971|Experimental|Tocilizumab + Methotrexate|Tocilizumab 8 mg/kg intravenous (IV) every 4 weeks + Placebo to adalimumab subcutaneous (SC) every 2 weeks for 24 weeks. All participants received methotrexate 10-25 mg and folate at least 5 mg/kg weekly.
11510017|NCT01283971|Active Comparator|Adalimumab + Methotrexate|Adalimumab 40 mg SC every 2 weeks + Placebo to tocilizumab IV every 4 weeks for 24 weeks. All participants received methotrexate 10-25 mg and folate at least 5 mg/kg weekly.
11510018|NCT01283945|Experimental|Lucitanib|
11510019|NCT01283932|Experimental|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited
11510020|NCT01283932|Active Comparator|Protonix|Protonix 40 mg DR Tablets of Wyeth Laboratories
11510021|NCT01283919|Experimental|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited
11510022|NCT01283919|Active Comparator|Protonix|Protonix 40 mg DR Tablets of Wyeth Laboratories
11510023|NCT01283906|Experimental|MuGard|Mucoadhesive Oral Wound Rinse
11510024|NCT01283906|Sham Comparator|Control Rinse|Aqueous Control Rinse.
11510025|NCT01283893||Laparoscopy group|Laparoscopy group: patients who underwent laparoscopic distal gastrectomy with D2 lymphadenectomy
11510026|NCT01283893||Open group|Open group: patients who underwent open distal gastrectomy with D2 lymphadenectomy
11510027|NCT01283867|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets of Dr. Reddy's Laboratories Limited
11510028|NCT01283867|Active Comparator|Cellcept|Cellcept 500 mg tablets of Roche Laboratories Inc.
11510029|NCT01283854|Experimental|Exercise group|Each participant randomised to the exercise group will receive routine, regular antenatal care. In addition, these women will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist.
11510030|NCT01283854|No Intervention|Control group|Women allocated to the control group will not participate in the home-based exercise program, and will continue their normal physical activity throughout pregnancy. This group will receive routine, regular antenatal care, together with the additional outcome assessments at baseline (14 weeks gestation) and cessation of the study (28 weeks gestation).
11510031|NCT01283841|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets of Dr. Reddy's Laboratories Limited
11510032|NCT01283841|Active Comparator|Cellcept|Cellcept 500 mg tablets of Roche Laboratories Inc.
11510033|NCT01283815|Active Comparator|Conservative management|Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
11510034|NCT01283815|Experimental|Laparoscopic appendectomy|Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group
11510035|NCT01283802||IOCUS|
11510036|NCT01283789|Experimental|Lapatinib and RAD-001|"RAD-001 will be administered orally as a once-daily dose of 5 mg (one 5 mg tablet) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD-001 in the morning, at the same time each day.
~Lapatinib will be administered orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take lapatinib at bedtime, at the same time each day. Lapatinib should be taken by the patient in a fasting state."
11510037|NCT01283776|Experimental|treatment arm|Cyclophosphamide
11510038|NCT01283763|Experimental|Topical Imiquimod|16 weeks topical Imiquimod
11510039|NCT01283763|Active Comparator|Conization|Large loop excision of the transformation zone
11510040|NCT01283750|No Intervention|Augmented Usual Care|
11510041|NCT01283737|Experimental|DBX|DBX Putty in glass syringe
11510042|NCT01283737|Active Comparator|Mosaicplasty|
11510043|NCT01283724|Experimental|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
11510044|NCT01283711|Experimental|apollo|
11510045|NCT01283698|Experimental|LAS 41004 dosage 1|dosage 1, once daily
11510046|NCT01283698|Experimental|LAS 41004 dosage 2|dosage 2, once daily
11510047|NCT01283698|Experimental|LAS 41004 dosage 3|dosage 3, once daily
11510048|NCT01283698|Placebo Comparator|placebo|once daily
11510049|NCT01283698|Active Comparator|Reference|once daily
11510050|NCT01283659|Active Comparator|Standard imaging (coronary angiography)|Subjects will undergo a coronary angiogram as planned by their attending doctor
11510051|NCT01283659|Active Comparator|Advanced imaging (CTA)|Subjects will undergo a CTA scan first. Based on the CTA results, subjects may or may not proceed to coronary angiography. CTA results will be reviewed by the attending physician.
11510052|NCT01283646|Experimental|Apevitin BC|Children (5 to 6 years): 3.5 ml 3 times a daily Children (7 to 15 years): 5 ml 3 times a daily
11510053|NCT01283646|Active Comparator|Vitamin B Complex + Vitamin C|Children (5 to 6 years): 3.5 ml 3 times a daily Children (7 to 15 years): 5 ml 3 times a daily
11510054|NCT01283633|Experimental|programming with non-experienced nurse|Programming done by an experienced neuromodulation clinician will be compared to the patient satisfaction of a programming session with an inexperienced nurse via remote presence robotics, which will be directed by the experienced clinician
11510055|NCT01283620|Other|Usual Care|
11510056|NCT01283620|Experimental|modified CIMT (mCIMT)|
11510057|NCT01283607|Active Comparator|Digicoach|Women randomized in the Digicoach group will be treated by the Digicoach therapy. Digicoach is an e-health cognitive behavioral therapy with 4-12 weekly sessions especially developed for in vitro fertilization (IVF) women. Digicoach is facilitated by an e-therapist. The investment for the weekly home work assignments is about one and a half hour. Digicoach consist of different modules (e.g. stress reduction, acceptance). Digicoach starts before the hormonal down regulation as the start of the IVF procedure and ends three weeks after the pregnancy test.
11510058|NCT01283607|No Intervention|Control|Women in the control group will get the usual treatment, there will be no additional intervention.
11510059|NCT01283594|Experimental|Tozadenant (SYN115) 60 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
11510060|NCT01283594|Experimental|Tozadenant (SYN115) 120 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
11510061|NCT01283594|Experimental|Tozadenant (SYN115) 180 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
11510062|NCT01283594|Experimental|Tozadenant (SYN115) 240 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
11510063|NCT01283594|Placebo Comparator|Sugar Pill|White-coated, modified-oval placebo tablets.
11510064|NCT01283581|Experimental|Delafloxacin|300 mg IV (intravenous) every 12 hours for 5-14 days
11510065|NCT01283581|Active Comparator|Vancomycin|15 mg/kg, up to 1250 mg, IV every 12 hours for 5-14 dyas
11510066|NCT01283581|Active Comparator|Linezolid|600 mg IV every 12 hours for 5-14 days
11510067|NCT01283568||1 - Gamaline+Hipericin - fertile women|
11510068|NCT01283568||2- Gamaline+Hipericin - climateric women|
11510069|NCT01283568||3- Gamaline- control - fertile women|
11510070|NCT01283568||4 - Gamaline control - climateric women|
11510071|NCT01283555|Experimental|User-Filled Applicator|
11510072|NCT01283555|Other|Prefilled applicator|
11510073|NCT01283542|Experimental|Pasireotide LAR|All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks
11510074|NCT01283529||Children 0 - 15 years|Children undergoing neurosurgery in general anesthesia
11510075|NCT01283516|Experimental|LDK378 750 mg: Arm 1A and Arm 1B|NSCLC patients previously treated with an ALK inhibitor
11510076|NCT01283516|Experimental|LDK378 750 mg: Arm 2|NSCLC patients not previously treated with an ALK inhibitor
11510077|NCT01283516|Experimental|LDK378 750 mg: Arm 3|Patients with other tumors that are ALK positive other than NSCLC
11510078|NCT01283503|Experimental|BKM120|
11510079|NCT01283490|Active Comparator|DASD Group|Benzocaine 20% will be placed using the DASD for one minute. Immediately after DASD application a needle puncture with a 27 gauge needle to the depth of 3 millimeters will be performed.
11510080|NCT01283490|Sham Comparator|Sonic Vibration (SV)|A modified tooth brush which only allows sonic vibration (SV), that has the appearance and sound of the DASD will be used to apply the benzocaine 20% for one minute. Following application with the SV a needle puncture with a 27 gauge needle to the depth of 3millimeters.
11510081|NCT01283477|Experimental|ACUPUNCTURE|
11510082|NCT01283477|Sham Comparator|SHAM ACUPUNCTURE|
11510083|NCT01283464|Active Comparator|Retinol|Retinol 1.0% cream
11510084|NCT01283464|Active Comparator|Tretinoin|Tretinoin 0.02% cream
11510085|NCT01283451||Exercise|NIRS values of all participants will be measured at baseline and following each 30-60 second exercise.
11510086|NCT01283438|Experimental|Barricaid Device|Intervention: Barricaid Device
11510087|NCT01283438|Active Comparator|Standard of Care|Standard (Limited) Discectomy Only
11510088|NCT01283425|Experimental|Test|InsuPatch use for 3 months.
11510089|NCT01283425|No Intervention|Control|
11510090|NCT01283412|Active Comparator|Arm P|Placebo infusion
11510091|NCT01283412|Experimental|Arm D|Dexmedetomidine infusion
11510092|NCT01283399||Rituximab + Methotrexate|All participants with active refractory RA who were eligible to receive treatment with methotrexate and rituximab in the Investigators' opinion as per the routine clinical practice following inadequate response to a single cycle of anti-TNF therapy.
11510093|NCT01283386|Experimental|FCR-lite|Rituximab, fludarabine, and cyclophosphamide
11510094|NCT01283386|Active Comparator|LR Therapy|Rituximab and chlorambucile
11510095|NCT01283373|Experimental|A|Dose escalation cohorts
11510096|NCT01283373|Experimental|B|Dose expansion cohorts
11510097|NCT01283360|Placebo Comparator|HEC Placebo Gel|In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel. Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
11510098|NCT01283360|Active Comparator|Tenofovir 1% Gel|In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel. Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
11510099|NCT01283347|Experimental|18F-DTBZ for Parkinson's Disease|"25 age-matched healthy volunteers will be enrolled. For assessing the correlation between the 18F-DTBZ binding and the severity of disease, the patients with PD will be divided into three groups according to their motor scores: mild, moderate, and advanced. We will enroll 25 patients in each group. Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study, as one screening visit, one imaging visit, and one safety evaluation visit.
~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
11510100|NCT01283334|Experimental|A|Treatment arm with carboplatin, cetuximab and RAD001
11510101|NCT01283321|Experimental|Group A: RiaSTAP|Human fibrinogen concentrate
11510102|NCT01283321|Active Comparator|Group B: apheresis platelets|single apheresis unit
11510103|NCT01283308|Active Comparator|Standard of Care|Participants randomized to the standard of care group will receive standard lifestyle advice for diabetes prevention consistent with expert recommendations for a healthy lifestyle, including losing 5-10% of their excess body weight, following standard dietary recommendations to reduce calorie and fat intake, and exercising at least 150 minutes per week.
11510181|NCT01282749|Other|SisterTalk Hartford Second|Participants received general film series on healthy lifestyles while waiting to participate in the experimental arm.
11510273|NCT01282021||Region 3|Northeastern and Southeastern Ethiopia
11510104|NCT01283308|Experimental|Lifestyle Intervention|Intervention arm participants will participate in a step-wise model of diabetes prevention with the goal of reducing diabetes risk, primarily through (1) a weight loss of at least 7% and (2) 150 minutes or more per week of moderate level physical activity.
11510105|NCT01283295||Immune complications|Transplant recipients who develop a clinically recognized complication with potential immune etiology or ramifications. Examples include opportunistic infection, rejection, malignancy, alloantibody formation or immunosuppressive drug toxicity.
11510106|NCT01283295||Stable Transplant Recipient|Patients who demonstrate immune stability characterized by stable graft function without evident complication. These patients serve as comparators for Group 1
11510107|NCT01283295||Pre-Transplant Longitudinal|Patients who are candidates for kidney, pancreas, liver or lung transplant will be enrolled and followed longitudinally.
11510108|NCT01283295||Organ Donors|Donors for individuals meeting the criteria for Cohorts 1-3
11510109|NCT01283295||Disease state|Individuals with liver, renal or pulmonary diseases that may lead to the development or organ failure.
11510110|NCT01283295||Normal Volunteers|
11510111|NCT01283282|Active Comparator|Clopidogrel/Placebo|Subjects were randomized to clopidogrel 75 mg daily for 6 weeks. Then immediately transitioned to a placebo daily for 6 weeks.
11510112|NCT01283282|Active Comparator|Placebo/Clopidogrel|Subjects were randomized to a placebo daily for 6 weeks. Then immediately transitioned to clopidogrel 75 mg daily for 6 weeks.
11510113|NCT01283269|Experimental|Memory Support System or Computer|
11510114|NCT01283256||Experimental|
11510115|NCT01283243||HIV patients with normal liver status|HIV patients without abnormal liver function and chronic liver disease
11510116|NCT01283230||chronic liver disease|Any cause of liver disease that involves a process of progressive destruction and regeneration of the liver parenchyma leading to fibrosis and cirrhosis such as hepatitis B, hepatitis C, alcoholic liver disease.
11510117|NCT01283230||Healthy liver and kidney donor|Healthy liver and kidney donor who have normal liver condition
11510118|NCT01283217|Experimental|DS(Docetaxel with S-1)|Docetaxel with S-1
11510119|NCT01283217|Active Comparator|SP(S-1 with cisplatin)|S-1 with cisplatin
11510120|NCT01283204|Active Comparator|SP(S-1 with cisplatin)|"SP <Every 3 weeks>
~Day 1~14 : TS-1 80mg/m2/day (PO)
~Day 1 : CDDP 60mg/m2/day IVF 2hours
~Day 15~21 : Rest"
11510121|NCT01283204|Active Comparator|FL/Tax(Paclitaxel with Leucovorin with 5-FU)|"FL/Tax <Every q 3 weeks>
~Day1 : Paclitaxel 175mg/m2 IVF for 2hours
~Day1 : Leucovorin 20mg/m2 IVF for 1hour
~Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
11510122|NCT01283204|Active Comparator|FL/Doc(Decetaxel with Leucovorin with 5-FU)|"FL/Doc <Every q 3 weeks>
~Day1 : Docetaxel 75mg/m2 IVF for 1hour
~Day1 : Leucovorin 20mg/m2 IVF for 1hour
~Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
11510123|NCT01283204|Active Comparator|FOLFOX(Oxaliplatin with Leucovorin with 5-FU)|FOLFOX <Every q 2 weeks> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1~2 : 5-FU 1200mg/m2 IVF for 24hours
11510124|NCT01283191|Experimental|Behavioral Incentives|Vouchers for complying with target behavior
11510125|NCT01283191|Placebo Comparator|Education Control|Education class
11510126|NCT01283178|Experimental|Arm I|Patients undergo intensity-modulated image-guided adaptive radiotherapy once daily 5 days a week for 6 weeks. Patients also receive cisplatin IV on days 1 and 22. Treatment continues in the absence of disease progression or unacceptable toxicity.
11510127|NCT01283165||health education|This was an intervention follow up Knowledge Attitude and Practice study that investigated the distribution of polyparasitism with schistosomiasis, STHs and P. falciparum among primary schoolchildren.
11510128|NCT01283152|Active Comparator|Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)|
11510129|NCT01283152|Other|Lactulose|Per standard of care
11510130|NCT01283139|Experimental|Sifalimumab 200 milligram (mg)|Sifalimumab 200 milligram (mg) will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
11510131|NCT01283139|Experimental|Sifalimumab 600 mg|Sifalimumab 600 mg will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
11510132|NCT01283139|Experimental|Sifalimumab 1,200 mg|Sifalimumab 1,200 mg will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
11510133|NCT01283139|Placebo Comparator|Placebo|Placebo matching to sifalimumab will be administered intravenously at a fixed dose every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
11510134|NCT01283126|Experimental|Euglycemic and hypoglycemic clamp|Subjects will complete clamp study visit.
11510135|NCT01283100|Experimental|Treatment A|GSK1349572 50mg q24h x 7 days
11510136|NCT01283100|Experimental|Treatment B|GSK2248761 200mg q24h x 7 days
11510137|NCT01283100|Experimental|Treatment C|GSK1349572 50mg q24h x 7 days + GSK2248761 200mg q24h x 7 days
11510138|NCT01283074||Cohort|
11510139|NCT01283061|Experimental|zafirlukast|Zafirlukast Tablets 20 mg of Dr. Reddys Laboratories Limited
11510140|NCT01283061|Active Comparator|Accolate|ACCOLATE tablets manufactured by IPR pharmaceuticals and manufactured for Astrazeneca Pharmaceuticals
11510141|NCT01283048|Experimental|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
11510142|NCT01283035|Experimental|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 will be taken PO once a week for four weeks (one cycle). Treatment will continue for as long as a subject is benefiting from the study drug.
11510143|NCT01283022|Experimental|MVI 200|MVI 200 mcg vaginal insert
11510144|NCT01283009|Placebo Comparator|Arm 1: Inactive substance|Inactive substance
11510145|NCT01283009|Active Comparator|Arm 2: Methylprednisolone|Methylprednisolone
11510146|NCT01282983|Active Comparator|fiber|
11510147|NCT01282983|Placebo Comparator|Placebo|
11510148|NCT01282970|Experimental|BI 135585|once daily doses as oral solution or tablet formulation over 14 days
11510149|NCT01282970|Placebo Comparator|Placebo to BI 135585|once daily doses as oral solution or tablet formulation over 14 days
11510150|NCT01282957|No Intervention|Active Control|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 6 months
11510226|NCT01282398|Placebo Comparator|placebo|the control group wiil take placebo pills for at least two years.
11510151|NCT01282957|Experimental|Financial Incentive Group I|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 3 months. If all three devices used daily, participant entered in lottery with 1 in 100 odds of winning $100 and 2 in 10 odds of winning $10. Financial incentive terminated after 3 months. Daily use of devices continues for additional 3 months. (Intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.)
11510152|NCT01282957|Experimental|Financial Incentives Group II|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 3 months. If all three devices used daily, participant entered in lottery with 1 in 100 odds of winning $50 and 2 in 10 odds of winning $5. Financial incentive terminated after 3 months. Daily use of devices continues for additional 3 months. (Intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.)
11510153|NCT01282944|Experimental|Combined Financial Incentive & Peer Network Arm|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Subjects connected with 4 other participants in the same study arm to form a peer network of 5 individuals. Each peer network participant given access to a secure online message board that will allow the 5 participants in each peer network to communicate online. Participants also receive weekly feedback regarding which participants in the peer group achieved their walking goals during the previous week.
~Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will be entered in lottery with an approximate 3 in 10 chance of winning $50 and an approximate 3 in 100 chance of winning $200.
~Financial incentive and peer network terminated after 4 months. Daily use of pedometer continues for an additional 2 months."
11510154|NCT01282944|No Intervention|Active Control|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
~Subjects in the Control Group will only receive pedometers and weekly feedback on their performance through the same mechanisms and with the same frequency as participants in the other three study arms. There will be no financial incentives or peer networks in this group."
11510155|NCT01282944|Experimental|Financial Incentive Arm|Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will be entered in lottery with an approximate 3 in 10 chance of winning $50 and an approximate 3 in 100 chance of winning $200. Financial incentive is terminated after 4 months. Daily use of pedometer continues for an additional 2 months.
11510156|NCT01282944|Experimental|Peer Network Arm|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period.
~Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
~Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals. Each peer network participant will be given access to a secure online message board that will allow the 5 participants in each peer network to communicate online. All participants in a peer network will receive a list of ways in which his or her new network could support each individual's walking goals. Participants will also receive weekly feedback regarding which participants in the peer group were successful in achieving their walking goals during the previous week.
~Peer network is terminated after 4 months. Daily use of pedometer continues for an additional 2 months."
11510157|NCT01282918|Other|Study group|Patients without DF (Defibrillation) testing during ICD implantation
11510158|NCT01282918|Other|Control group|Patients with DF testing during ICD implantation (according to standardized procedure)
11510159|NCT01282905||Healthy controls|
11510160|NCT01282905||Ulcerative colitis|
11510161|NCT01282892||patients with NAFLD|
11510162|NCT01282892||excess of visceral fat|
11510163|NCT01282879|Experimental|itraconazole, prophylaxis, Oral solution|For GVHD patients who are required systemic glucocorticoids therapy, itraconazole oral solution will be administered at a dose of 200mg every 12 hours.
11510164|NCT01282866|Experimental|HS treatment|Treatment with HS handpiece
11510165|NCT01282853|Active Comparator|A1|one biopsy specimen taken from gastric antrum was put into RUT kit
11510166|NCT01282853|Experimental|A4|4 biopsy specimens taken from gastric antrum were put into RUT kit
11510167|NCT01282853|Experimental|B1|one biopsy specimen taken from gastric body was put into RUT kit
11510168|NCT01282840|Other|Bladder wall blood perfusion pattern|
11510169|NCT01282827|Experimental|rtACS (Verum condition)|Repetitive transorbital alternating current stimulation (rtACS)
11510170|NCT01282827|Placebo Comparator|Placebo stimulation|no intervention (Sham stimulation)
11510171|NCT01282814|Experimental|Investigational Test Product|Venlafaxine Hydrochloride 150 mg Extended-Release Capsules.
11510172|NCT01282814|Active Comparator|Reference Listed Drug|Effexor® XR 150 mg Extended-Release Capsules
11510173|NCT01282801|Experimental|Investigational Test Product|Venlafaxine Hydrochloride 150 mg Extended-Release Capsules
11510174|NCT01282801|Active Comparator|Reference Listed Drug|Effexor® XR 150 mg Extended-Release Capsules
11510175|NCT01282788|No Intervention|Traditional Diet|Infants in communities randomized to the traditional diet arm will not receive food supplements.
11510176|NCT01282788|Experimental|Cereal|All infants in communities randomized to the Cereal Arm will receive caterpillar cereal from 6-18 months of age.
11510177|NCT01282775|No Intervention|Environment / Usual Care|
11510178|NCT01282775|Other|WEB+ Environment|Web-based weight loss program (WEB) + Environment - Participants have access to a proven Web-based weight loss program with weekly lessons focused on lifestyle behavior changes
11510179|NCT01282775|Other|WEB + Cash Incentive for Weight Loss|Web-based Weight Loss Program + Cash Incentive for Weight Loss - participants have access to a proven web-based weight loss program plus they are paid cash based on the percent weight lost at 12 months compared to baseline.
11510180|NCT01282749|Experimental|SisterTalk Hartford First|12-week group support and film-based healthy lifestyle education program, including information on healthy nutrition and food preparation, increasing activity and exercise, healthy lifestyle behavior modification, and supportive spiritual materials.
11510182|NCT01282736|Experimental|Integrative Response Therapy|IRT is based on affect regulation theories of binge eating and adds emphasis on cognitive restructuring techniques. IRT is a 10 session, group-based, guided-self-help treatment that works to decrease binge eating by primarily enhancing emotion coping skills, in addition to transforming faulty interpretations and reducing vulnerabilities (e.g., interpersonal events) that risk overwhelming emotion and problematic cognitions.
11510183|NCT01282736|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy guided self-help (CBT-GSH), based on the restraint model of binge eating, has been adapted from individual format to a 10 session, group-based therapy for the purpose of this study. The book 'Overcoming Binge Eating' is employed in the present study and consists of Part 1, an educational background on BED, and Part 2, a 6 step treatment program to overcome binge eating.
11510184|NCT01282723||Pregnant, In Labor|
11510185|NCT01282710||Pregnant, In Labor|
11510186|NCT01282697|Experimental|rapamycin+irinotecan at a given dose|
11510187|NCT01282684|Active Comparator|single oral dose of 200 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
11510188|NCT01282684|Active Comparator|single oral dose of 400 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
11510189|NCT01282684|Active Comparator|single oral dose of 800 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
11510190|NCT01282684|Active Comparator|single oral dose of 1600 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
11510191|NCT01282684|Active Comparator|single oral dose of 1000 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
11510192|NCT01282684|Active Comparator|single oral dose of 1400 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
11510193|NCT01282684|Placebo Comparator|Placebo|2 patients per cohort will be randomly assigned to take placebo. 12 patients total will be randomized to take placebo in this study.
11510194|NCT01282671|Experimental|Breathing exercises|On the fourth postoperative day the patients are randomly assigned to a Treatment group continuing to perform deep breathing exercises for 2 months postoperatively and to a Control group who will perform no breathing exercises after the third postoperative day. Patient management is otherwise similar in the groups. The patients in the Deep breathing group will be instructed to perform breathing exercises (3 x 10 deep breaths) 5 times a day (document compliance) during the two postoperative months.
11510195|NCT01282671|No Intervention|Control group|No breathing exercises.
11510196|NCT01282658||Colorectal cancer|
11510197|NCT01282645||PSI in PEEK|All study subjects have received a Patient Specific Implant (PSI) made of PEEK to repair a cranial defect
11510198|NCT01282632|Experimental|Risperidone|Commence at 0.5 mg once daily Increase, blindly, to 1 mg and then by 1 mg at discretion of clinicians through weeks 1-4 to a maximum of 3 mg.
11510199|NCT01282632|Experimental|Olanzapine|Commence at 2.5 mg once daily Increase to 5.0 mg, blindly, and then by 5 mg at the discretion of the clinician through weeks 1 - 4 to a maximum of 15 mg
11510200|NCT01282619|Experimental|Huperzine A Sustained-Release Tablet|
11510201|NCT01282619|Active Comparator|Huperzine A Tablet|
11510202|NCT01282619|Placebo Comparator|Placebo|
11510203|NCT01282606|Experimental|Drug I: SI-6603 (Low)|
11510204|NCT01282606|Experimental|Drug II: SI-6603 (Middle)|
11510205|NCT01282606|Experimental|Drug III: SI-6603 (High)|
11510206|NCT01282593|Other|CD9 expression level|Impact of CD9 expression level on motility assays
11510207|NCT01282580|Experimental|Dietary fish (canned salmon, albacore)|Fish products: Canned albacore and salmon will be provided at no cost to the patient. Supplies of tuna and salmon will be provided in quantities sufficient for one month of daily intake by the subject. If desired, a subject can request a sufficient amount to allow for preparation of a meal for the family or household at no more than two times per week. Labels or portions of labels from the cans will be collected at the monthly study visits, and canned supplies will be replenished monthly or at more frequent intervals if needed. Subjects will be allowed to keep unused cans.
11510208|NCT01282580|Experimental|Lovaza-Omega 3 fatty acid capsules|Lovaza capsules will be provided at no cost to the patient. Pill bottles will be provided to the patient, with the start date and number of pills recorded. The supplement will be provided in sufficient supply for one month at a time. Pill bottles will be collected at monthly follow-up visits, and any unused capsules will be documented and discarded as biohazardous waste.
11510209|NCT01282567|Other|diabetic patients|
11510210|NCT01282554|Experimental|stimulated group|stimulated group
11510211|NCT01282554|No Intervention|control group|Control group : non stimulated group.
11510212|NCT01282541|Active Comparator|Transconjunctival|
11510213|NCT01282541|Active Comparator|Transcutaneous|
11510214|NCT01282515|Experimental|ELP active|one PDT treatment
11510215|NCT01282515|Active Comparator|topical steroids|
11510216|NCT01282502|Experimental|Midostaurin with chemoradiation|
11510217|NCT01282476|Experimental|Panobinostat/Rituximab|single-arm, open-label; Panobinostat with Rituximab: Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
11510218|NCT01282463|Active Comparator|Docetaxel|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
11510219|NCT01282463|Experimental|Docetaxel + Ramucirumab DP|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
11510220|NCT01282463|Experimental|Docetaxel + Icrucumab|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
11510221|NCT01282450|Experimental|Single arm|Eligible patients
11510222|NCT01282437|Experimental|Prophylactic Cranial Irradiation|
11510223|NCT01282437|No Intervention|Observation|Patients will not receive PCI, but will be observed and the same items will be measured as in the PCI-arm.
11510224|NCT01282424|Experimental|Idelalisib|Treatment with idelalisib will be continued until tumor progression or development of unacceptable toxicity.
11510225|NCT01282398|Experimental|simvastatin|The experimental group will take simvastatin 40mg for at least two years.
11510227|NCT01282385|Experimental|simvasatin|"a) patients responding to treatment with beta-blockers, in which she was treated with nadolol Subsequently randomized into two treatment arms, double-blind:
~a.1: simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance.
~a.2: placebo capsules with external characteristics similar to simvastatin.
~b) non-responders to treatment with beta blockers, receive treatment with carvedilol.Subsequently randomized into two treatment arms, double-blind
~b.1: simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance.
~b.2: placebo capsules with external characteristics similar to simvastatin."
11510228|NCT01282385|Placebo Comparator|placebo|
11510229|NCT01282372||Participants with moderate to severe rheumatic disease|Participants with moderate to severe rheumatic disease (RA, PsA, or AS), who received adalimumab in accordance with approved label
11510230|NCT01282359|Other|Clinical Practice Group|Patients collected in centres randomized as usual clinical practice, who will not receive the limited educational asthma program.
11510231|NCT01282359|Other|"Gold Standard educational group"|Patients will receive a formal program of structured and individualized education, enrolled in centres recognized by using high standard procedures in asthma education.
11510232|NCT01282359|Other|Intervention group|This group will receive a limited educational asthma program (minimal educational intervention)
11510233|NCT01282346|Experimental|SOLX Gold Shunt|
11510234|NCT01282333|Experimental|Treatment (veliparib, gemcitabine hydrochloride, cisplatin)|Patients receive veliparib orally every 12 hours on days 1-12, gemcitabine hydrochloride IV over 30 minutes on days 3 and 10, and cisplatin IV over 60-120 minutes on day 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with suspected or known germline BRCA mutations may continue to receive single-agent veliparib continuously in the absence of disease progression or unacceptable toxicity. Patients may undergo blood, tumor tissue, and hair follicle sample collection periodically for pharmacokinetic and correlative studies.
11510235|NCT01282320|Experimental|Increased Physical Activity|Individually tailored training one hour, 2-3 sessions per week.
11510236|NCT01282320|No Intervention|"Activity as usual (Buisness as usual)"|
11510237|NCT01282307|Experimental|Method Guided Self-Determination|The Method Guided Self-Determination consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
11510238|NCT01282307|No Intervention|Treatment as usual|
11510239|NCT01282294||ETN PROtect|There is only 1 cohort in this case series
11510240|NCT01282281||Individuals aged 14-18 and 19-65 with a diagnosis of BD|
11510241|NCT01282268|Active Comparator|Arbaclofen|
11510242|NCT01282268|Placebo Comparator|Placebo|
11510243|NCT01282255|Experimental|A|
11510244|NCT01282255|Placebo Comparator|B|
11510245|NCT01282242|Experimental|IV rt-PA|open-label
11510246|NCT01282229|Active Comparator|LANAP Quadrant|Treated with LANAP
11510247|NCT01282229|No Intervention|Modified Widman Flap|Quadrant treated with Modified Widman Flap surgery
11510248|NCT01282229|No Intervention|Scaling and Root Planing|Quadrant treated with scaling and root planing alone
11510249|NCT01282229|No Intervention|Coronal Debridement|Quadrant treated with coronal debridement
11510250|NCT01282216|Active Comparator|Donor PCV13|Donors receive PCV13 prior to bone marrow donation.
11510251|NCT01282216|Active Comparator|Donor Havrix|Donors receive Havrix prior to bone marrow donation.
11510252|NCT01282216|Active Comparator|Recipient vaccine|Recipients receive Havrix and PCV13 post bone marrow transplant.
11510253|NCT01282203||Adults requiring anesthesia for surgery|This post-marketing observational study will be conducted in a prospective, multi-centre format. It is a non-interventional, observational study in which Sevorane is prescribed for adult patients undergoing general surgery for induction and maintenance of anesthesia in the usual manner in accordance with the terms of the local marketing authorization. Sevorane is used for induction and maintenance anesthesia by the choice of anesthesiologist. No additional procedures (other than standard of care) shall be applied to the patients. Each patient will be observed from the start of anesthesia through anesthesia end. Markers of myocardial ischemia will be detected up to the first 24 hours after anesthesia (if available). Additionally the correlation between the experience and training background of anesthesiologists and patient related outcomes of general anesthesia with Sevorane as a single anesthetic will be assessed.
11510254|NCT01282190|Experimental|Motivational interview|
11510255|NCT01282164|Experimental|Study patients|patients with growth hormone deficiency or hypothalamic-pituitary disorders underwent fixed-dose glucagon stimulation test (GST), weight-based GST and insulin tolerance test (ITT).
11510256|NCT01282164|Active Comparator|Control|"The control group will consist of healthy volunteers matched to the study group for age, gender, Body mass index (BMI) and estrogen status. Note: Allegheny site is not enrolling in the control group.
~Control subjects underwent fixed-dose glucagon stimulation test (GST), weight-based GST and insulin tolerance test (ITT)."
11510257|NCT01282151|Experimental|Taxotere|Docetaxel plus Cisplatin
11510258|NCT01282151|Active Comparator|Pemetrexed|Pemetrexed plus Cisplatin
11510259|NCT01282138|Experimental|Patanol|One drop twice daily in each eye for five days prior to allergen provocation testing, followed by an additional drop in each eye approximately 15 minutes prior to start of testing.
11510260|NCT01282138|Placebo Comparator|Tears Naturale II|One drop twice daily in each eye for five days prior to allergen provocation testing, followed by an additional drop in each eye approximately 15 minutes prior to start of testing.
11510261|NCT01282125||sleep apnea|100 patients suffering from obstructive sleep apnea syndrome
11510262|NCT01282125||controls|100 subjects matching cases to age, sex, and body weight
11510263|NCT01282099||Cardiac patients|Postoperative congenital heart disease patients requiring stay in the PICU
11510264|NCT01282099||non-cardiac patients|non-cardiac patients requiring stay in the PICU
11510265|NCT01282086||Adults requiring anesthesia for surgery|Adult patients requiring general anesthesia for surgery
11510266|NCT01282073|Experimental|Mycophenolate mofetil, low dose steroid|
11510267|NCT01282073|Active Comparator|Cyclosporin, low dose steroid|
11510274|NCT01282008||Focus Groups|Focus Groups about smoking messages
11510275|NCT01281969|Experimental|Group A|Drug: Gamunex Intravenous Immunoglobulin 2.0 gm/kg total, IV (in the vein), over 2 days
11510276|NCT01281969|Placebo Comparator|Group B|Drug: Placebo Normal saline, IV (in the vein), over 2 day
11510277|NCT01281956|Experimental|Placebo Then PRX|Subjects are administered Placebo x3 months followed by PRX (selective 5HT1A agonist) x3 months
11510278|NCT01281956|Experimental|PRX Then Placebo|Subjects are administered PRX (selective 5HT1A agonist) x3 months followed by Placebo x3 months
11510279|NCT01281943|Experimental|Temsirolimus and Pegylated Liposomal Doxorubicin|Temsirolimus 25mg andPegylated liposomal doxorubicin 25mg/m2
11510280|NCT01281930|Experimental|Wick placement into abscess cavity|
11510281|NCT01281930|Active Comparator|Full packing of abscess cavity|
11510282|NCT01281917|Experimental|Velcade plus Temsirolimus|"Velcade 1.6 mg/m2 weekly (days 1, 8, 15, and 22) Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)
~Treat for up to 6 cycles, cycles are 35 days long."
11510283|NCT01281904|No Intervention|Standard of Care|Participants randomized into the standard of care group will be asked to continue following the instructions of the healthcare provider throughout the 10 week study period. They will not be asked to perform any study intervention.
11510284|NCT01281904|Active Comparator|Relaxation Acupressure|In addition to their standard of care, participants will be asked to apply pressure on each of 9 acupressure points (bilaterally where indicated) that have been carefully selected for their relaxing effect. (There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes done once daily over a period of 6 weeks followed by 4 weeks of intervention wash-out where the participant will be asked to perform no acupressure at all.
11510285|NCT01281904|Active Comparator|Stimulating Acupressure|In addition to their standard of care, participants will be asked to apply pressure on each of 9 acupressure points (bilaterally where indicated) that have been carefully selected for their excitatory effect. (There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. There are 6 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 10 points to stimulate. Each of the 10 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 30 minutes done once daily over a period of 6 weeks followed by 4 weeks of intervention wash-out where the participant will be asked to perform no acupressure at all.
11510286|NCT01281891|Experimental|Local Infiltration Analgesia|Combination of ropivacaine, ketorolac and adrenaline
11510287|NCT01281891|Active Comparator|Intrathecal morphine|Morphine special (preservative-free) injected intrathecally
11510288|NCT01281878|Experimental|Pyridoxal-phosphate|Treatment with pyridoxal-phosphate in increasing dosages every six weeks starting with 5mg/kg body weight up to 20 mg/kg body weight. treatment duration 24 weeks
11510289|NCT01281865|Experimental|Treatment (everolimus and imatinib mesylate)|Patients receive everolimus PO once daily and imatinib mesylate PO once daily on days 1-28. Course repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood and tumor tissue sample collection at baseline and periodically during study for correlative biomarker and protein expression studies.
11510290|NCT01281852|Experimental|Treatment (paclitaxel, cisplatin, veliparib)|Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IV over 1 hour on day 2, and veliparib PO on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11510291|NCT01281839|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
11510292|NCT01281839|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
11510293|NCT01281813|Experimental|001|Darunavir (DRV) 400 milligram (mg) tablet intake of 2 tablets once daily in combination with Ritonavir (rtv)
11510294|NCT01281813|Experimental|002|Darunavir 600 mg tablet intake of 1 tablet twice a day in combination with Ritonavir
11510295|NCT01281813|Experimental|003|Ritonavir 100 mg capsule to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
11510296|NCT01281813|Experimental|004|Ritonavir 100 mg tablet to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
11510297|NCT01281813|Experimental|005|Darunavir 375 mg composed via various tablets (2x150mg DRV tablets + 1x 75mg DRV tablet) in combination with Ritonavir (1x 100mg rtv tablet) twice daily
11510298|NCT01281813|Experimental|006|Darunavir 375 mg composed via various tablets (2x 150mg DRV tablets + 1x 75mg DRV tablet) in combination with Ritonavir oral solution 80 milligram per milliLitre (mg/mL) (dose dependent on weight) twice daily
11510299|NCT01281813|Experimental|007|Darunavir 375 mg composed via various tablets (2x 150mg DRV tablets + 1x 75mg DRV tablet) in combination with Ritonavir powder for oral suspension prepared as 100mg/10mL (dose dependent on weight) twice daily
11510300|NCT01281813|Experimental|008|Darunavir oral suspension (dose dependent on weight) in combination with Ritonavir 100mg tablet twice daily
11510301|NCT01281813|Experimental|009|Darunavir oral suspension (dose dependent on weight) in combination with Ritonavir oral solution as 80 mg/mL (dose dependent on weight) twice daily
11510302|NCT01281813|Experimental|010|Darunavir oral suspension (dose dependent on weight) in combination with Ritonavir powder for oral suspension prepared as 100 mg/10 mL (dose dependent on weight) twice daily
11510303|NCT01281800|Active Comparator|Cisplatin with pemetrexed|
11510304|NCT01281800|Experimental|Cisplatin with gemcitabine in long infusion|
11510305|NCT01281787|Active Comparator|Losartan|angiotensin II-receptor blocker
11510306|NCT01281787|No Intervention|no treatment|no preventive treatment
11510307|NCT01281787|Active Comparator|Metoprolol|beta-adrenergic antagonist
11510308|NCT01281774|Experimental|CSL112|Multiple ascending intravenous doses of CSL112
11510309|NCT01281774|Placebo Comparator|Placebo|Multiple intravenous infusions of placebo
11510310|NCT01281761|Experimental|cetuximab/irinotecan/simvastatin|"D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- [C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV [over 90min] D1-14 Simvastatin 80mg P.O(continuous, daily)
~every 2weeks"
11510311|NCT01281748|Experimental|methylprednisolone|
11510312|NCT01281748|Placebo Comparator|normal saline solution|
11510313|NCT01281722||healthy adults|healthy adults with the age among 20 to 95 years old
11510314|NCT01281722||melanoma cases|the people who are diagnosed melanoma in NTU hospital
11510315|NCT01281696|Experimental|Bevacizumab, etoposide, cisplatin (BEEP)|
11510316|NCT01281683||TACE|
11510317|NCT01281683||RFA|
11510318|NCT01281670|No Intervention|No vibration|
11510319|NCT01281670|Active Comparator|vibration|
11510320|NCT01281657||Prescribed fingolimod 0.5 mg/day|
11510321|NCT01281644|No Intervention|No Laser Treatment|
11510322|NCT01281644|Active Comparator|45-60 J Diode Laser Therapy|Diode laser therapy will be initiated at 45-60 J for 30 ms to 100 ms.
11510323|NCT01281631|Experimental|Low dose NP001|Low drug dose
11510324|NCT01281631|Experimental|High dose NP001|High drug dose
11510325|NCT01281631|Placebo Comparator|Placebo|normal saline
11510326|NCT01281618||Those with barrett's esophagus|Those with barrett's esophagus: no dysplasia or low grade dysplasia
11510327|NCT01281605|Active Comparator|Active titration algorithm|titrate insulin dose by contacting with investigator by telephone weekly.
11510328|NCT01281605|Experimental|Usual titration algorithm|contact with investigator only at routine study visit.
11510329|NCT01281592|Experimental|LOR-253 HCl|LOR-253 HCl will be given in ascending doses until the maximum administered dose or appropriate target dose is reached. A biomarker study of up to 10 patients will be conducted upon achieving appropriate dose level.
11510330|NCT01281579|Experimental|001|Canagliflozin 50 mg Tablets oral 50-mg once daily on Day 1 and on Days 4 through 9.
11510331|NCT01281579|Experimental|002|Canagliflozin 100 mg Tablets oral 100-mg once daily on Day 1 and on Days 4 through 9.
11510332|NCT01281579|Experimental|003|Canagliflozin 300 mg Tablets oral 300-mg once daily on Day 1 and on Days 4 through 9.
11510333|NCT01281566|Experimental|001|Cisapride 0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
11510334|NCT01281566|Placebo Comparator|002|Placebo liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
11510335|NCT01281553|Experimental|001|Cisapride 0.2 mg/kg suspension q.i.d.for 8 weeks.
11510336|NCT01281553|Placebo Comparator|002|Placebo Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
11510337|NCT01281540|Experimental|001|Cisapride one 10 mg tablet 4 times a day for 8 weeks
11510338|NCT01281540|Placebo Comparator|002|Placebo one placebo tablet 4 times a day for 8 weeks
11510339|NCT01281527|Experimental|Paliperidone Palmitate|Paliperidone Palmitate 50 - 150 mg eq. every 30 days for 6 months during the core phase and for 12 months during an optional extension phase after the last patient has completed the 6-month core treatment phase or until product will be available on market (whichever comes first)
11510340|NCT01281514|Experimental|Treatment|See Detailed Description
11510341|NCT01281501|Active Comparator|Conventional|Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline
11510342|NCT01281501|Experimental|Pantoprazole|Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole
11510343|NCT01281488|Experimental|Treatment 1 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.018 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
11510344|NCT01281488|Experimental|Treatment 2 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.036 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
11510345|NCT01281488|Experimental|Treatment 3 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.07 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
11510346|NCT01281488|Experimental|Treatment 4 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.14 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
11510347|NCT01281488|Experimental|Treatment 5 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.21 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
11510348|NCT01281475|Experimental|Levodopa|Levodopa is prescribed as a combination of levodopa/carbidopa (4:1) to reduce the peripheral side effects. The dosage used was 15 mg/kg/day in 3 divided doses.
11510349|NCT01281475|Placebo Comparator|Placebo|The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa, so it is not expected to have any effect.
11510350|NCT01281462|Experimental|Ceftaroline fosamil and NXL104 (q8h)|
11510351|NCT01281462|Experimental|Ceftaroline fosamil and NXL104 (q12h)|
11510352|NCT01281462|Active Comparator|Doripenem|
11510353|NCT01281436|Other|Web-based Provider training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
11510354|NCT01281436|Active Comparator|HeartSmartKids with web-based training|The providers assigned to Group 2 will receive the web-based training described in the other arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
11510355|NCT01281410|No Intervention|Standard physiotherapy|Standard Physiotherapy without Inspiratory Muscle Training
11510356|NCT01281410|Experimental|Inspiratory muscle training|Inspiratory muscle training with a device named Respifit in addition to the usual physiotherapy program
11510357|NCT01281397||Patients undergoing elective cardiac surgery|Patients undergoing elective cardiac surgery will be enrolled in study. Data about antiplatelet therapy ingestion prior to surgery will be included.
11511395|NCT01274299||Infants|Healthy 0-4 years of age both boys and girls
11510358|NCT01281384|Active Comparator|Standard imaging (echocardiography)|Subjects will undergo their clinically indicated echocardiogram as ordered by their attending physician.
11510359|NCT01281384|Active Comparator|Advanced Imaging (Cardiac MRI)|Subjects will undergo their clinically indicated echo as ordered by their attending physician, plus a cardiac MRI, which will be scheduled within 14 days of the echo.
11510360|NCT01281358|Experimental|HOP-ON intervention|Participants will receive a CD-ROM (or DVD and booklet if no access to computer) highlighting motor skills which could be encouraged with premature infants
11510361|NCT01281358|Active Comparator|SMILES|Participants will received a CD-ROM (or DVD and booklet if no access to a computer) which contains information on interacting with their premature infant
11510362|NCT01281332|Active Comparator|Menopod device|Menopod®
11510363|NCT01281332|Sham Comparator|Sham device|Inactive device.
11510364|NCT01281319||Asymptomatic normal pregnant women|
11510365|NCT01281319||Women with high risk pregnancy|Women at risk for preterm birth or recurrent abortions that are being followed at the high risk pregnancy unit (outpatients clinic, high risk day care center)
11510366|NCT01281319||Women admitted with preterm labor|Women that are admitted to the gynecology department due to pregnancy complications: preterm labor with intact membranes (PTL) or with preterm PROM.
11510367|NCT01281306|Experimental|VAL + AHU 400 mg|Participants were started with AHU377 100 mg + valsartan 160 mg every day (qd) for 1 week, then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for another week, and then were uptitrated to AHU377 400 mg + valsartan 320 mg for the remaining 6 weeks.
11510368|NCT01281306|Experimental|VAL + AHU 200 mg|Participants were started with AHU377 100 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for the remaining 7 weeks.
11510369|NCT01281306|Experimental|VAL + AHU 100 mg|Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 100 mg + valsartan 320 mg for the remaining 7 weeks.
11510370|NCT01281306|Experimental|VAL + AHU 50 mg|Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 50 mg + valartan 320 mg qd for the remaining 7 weeks.
11510371|NCT01281306|Experimental|VAL 320 mg|Participants were started with valsartan 160 mg qd for 1 week and then were uptitrated to valsartan 320 mg qd for the remaining 7 weeks.
11510372|NCT01281306|Experimental|LCZ 400 mg|Participants were started with LCZ696 200 mg qd for 1 week and then were uptitrated to LCZ696 400 mg qd for the remaining 7 weeks.
11510373|NCT01281306|Experimental|Placebo|Participants received matching placebo to LCZ696, AHU377 and valsartan for 8 weeks.
11510374|NCT01281280||VNS Therapy|
11510375|NCT01281280||Best Medical Practice|
11510376|NCT01281267|Experimental|Face transplantation|
11510377|NCT01281254|Placebo Comparator|Placebo plus PLD|Arm B: PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)
11510378|NCT01281254|Experimental|AMG386 plus PLD|Arm A: PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
11510379|NCT01281228|Experimental|exenatide|Infusion of exenatide; loading dose 50 ng/min during 30 min, followed by a maintenance dose 20ng/min for the rest of the tests.
11510380|NCT01281228|Experimental|exenatide + exendin (9-39)|exenatide infusion: loading dose 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the test. And infusion of exendin(9-39) 600pM/kg/min.
11510381|NCT01281228|Placebo Comparator|saline|saline infusion, with the same infusion speed
11510382|NCT01281215|Experimental|Pharmaceutical Education|The patients will receive pharmaceutical education.
11510383|NCT01281215|No Intervention|Control|
11510384|NCT01281202|Active Comparator|CPP-109 Vigabatrin Tablets|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -2 to -4 week Screening/Baseline Phase
~During treatment, subjects received 3 CPP-109 Vigabatrin 500 mg Tablets, bid, for 9 weeks
~Subjects were provided with on-site, supervised, standardized, manualized Individual Drug Counseling 1x per week for 9 weeks and the first 4 weeks for the follow-up phase (weeks 10-13)"
11510385|NCT01281202|Placebo Comparator|Placebo|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -2 to -4 week Screening/Baseline Phase
~During treatment, subjects received Vigabatrin matching placebo tablets, bid, for 9 weeks
~Subjects were provided with on-site, supervised, standardized, manualized Indivdiual Drug Counseling 1x per week for 9 weeks and the first 4 weeks for the follow-up phase (weeks 10-13)"
11510386|NCT01281189|Experimental|Dexpramipexole|
11510387|NCT01281189|Placebo Comparator|Placebo|
11510388|NCT01281176|Experimental|Arm I (high- and low-dose vorinostat and carboplatin)|Patients receive high-dose vorinostat PO QD on days 1-3 and low-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive high-dose vorinostat PO QD on days 1-3 and carboplatin IV over 30 minutes on day 3 of all subsequent courses.
11510389|NCT01281176|Experimental|Arm II (high- and low-dose vorinostat and carboplatin)|Patients receive high-dose vorinostat and low-dose vorinostat as in Arm I. After 5 days, patients receive lower-dose vorinostat PO QD on days 1-3 and carboplatin IV over 30 minutes on day 3.
11510390|NCT01281176|Experimental|Arm III (low- and high-dose vorinostat and carboplatin)|Patients receive low-dose vorinostat PO QD on days 1-3 and high-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive vorinostat and carboplatin as in Arm I.
11510391|NCT01281176|Experimental|Arm IV (low- and high-dose vorinostat and carboplatin)|Patients receive low-dose vorinostat and high-dose vorinostat as in Arm III. After 5 days, patients receive vorinostat and carboplatin as in Arm II.
11510392|NCT01281176|Experimental|Arm V (low- and mid-dose vorinostat and paclitaxel)|Patients receive low-dose vorinostat PO QD on days 1-3 and mid-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive mid-dose vorinostat PO QD on days 1-3 and paclitaxel IV over 3 hours on day 3.
11510393|NCT01281176|Experimental|Arm VI (mid- and low-dose vorinostat and paclitaxel)|Patients receive mid-dose vorinostat PO QD on days 1-3 and low-dose vorinostat PO QD on days 8-10. After 5 days, patients receive vorinostat and paclitaxel as in Arm V.
11510474|NCT01280604|Experimental|Intervention 'Fenofibrate 54mg'|Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.
11510475|NCT01280604|No Intervention|Control 'Fenofibrate 160mg'|Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).
11510394|NCT01281163|Experimental|Treatment (Akt inhibitor MK2206 and lapatinib ditosylate)|Patients receive lapatinib ditosylate PO QD on days 1 and 15-28 of course 1 and on days 1-28 of subsequent courses. Patients also receive AKT inhibitor MK2206 PO QD on days 8, 15, and 22 of course 1 and on days 1, 8, 15, and 22 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11510395|NCT01281150|Experimental|Treatment (veliparib, paclitaxel, carboplatin)|"DOSE-ESCALATION: Patients receive veliparib PO twice daily BID on days 1-5, 8-12, and 15-19 and paclitaxel IV over 1 hour and carboplatin IV over 30 minutes in course 1 and 3 hours in subsequent courses on days 3, 10, and 17. After 4 courses, patients receive paclitaxel and carboplatin on days 3 and 10 only. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (Completed as of 12/2012)
~EXPANSION COHORT: Patients receive veliparib PO BID on days 1-21 and paclitaxel IV over 1 hour and carboplatin IV over 3 hours on days 3 and 10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
11510396|NCT01281124|Experimental|Treatment (azacitidine)|Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11510397|NCT01281111|Experimental|BG00012 plus ASA|
11510398|NCT01281111|Experimental|BG00012 plus ASA matching placebo|
11510399|NCT01281111|Placebo Comparator|BG00012 Placebo plus ASA|
11510400|NCT01281111|Experimental|BG00012 Placebo plus ASA matching placebo|
11510401|NCT01281111|Experimental|BG00012|modified dose regimen
11510402|NCT01281098|Active Comparator|Panretinal Photocoagulation (PRP)|Group 1: Panretinal photocoagulation treatment (PRP) at week-0 that can be repeated every 6 weeks.
11510403|NCT01281098|Experimental|Pegaptanib + Panretinal Photocoagulation (PRP)|Group 2: Combination treatment of pegaptanib intravitreous injections at weeks 0, 6 and 12 that can be repeated every 6 weeks. Plus PRP after first injection (2 weeks +/- 1 week)and that can be repeated every 12 weeks.
11510404|NCT01281085||No treatment|Shoulder conditions including rotator cuff condition treated conservatively, shoulder instability treated conservatively, diaphyseal humerus fracture or subcapital humerus fracture treated surgically and frozen shoulder
11510405|NCT01281033|Active Comparator|thrombus-aspiration group|In patients in the thrombus-aspiration group, the thrombus-aspiration is manually performed.
11510406|NCT01281033|Experimental|AngioJet Rheolytic Thrombectomy|AngioJet Rheolytic Thrombectomy (RT) System consists of a drive unit console, disposable pump set, and disposable catheter.
11510407|NCT01281020||Treatment with fixed combination|Patients who receive treatment with latanoprost/timolol fixed combination
11510408|NCT01281020||Treatment with unfixed therapy|Patients who receive latanoprost and timolol therapy
11510409|NCT01281007|Experimental|Famciclovir 125 mg|1 tablet every 12 hours for 5 days
11510410|NCT01281007|Active Comparator|Aciclovir 200 mg|1 tablet every 4 hours (excluding nocturnal dose) for 5 days
11510411|NCT01280981|Experimental|Tranexamic acid|Two 650 mg tablets orally 3 times per day with liquids for up to 5 days (not to exceed 3 doses in 1 day or 15 doses during the menstrual period).
11510412|NCT01280968|Experimental|NIC002 Vaccine in Aluminum hydroxide|4 subcutaneous vaccinations were performed over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 100 μg of NIC002 and 0.46 mg aluminum hydroxide.
11510413|NCT01280968|Placebo Comparator|Placebo Vaccine - Aluminum hydroxide|4 placebo injections were administered subcutaneously over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 0.46 mg aluminum hydroxide.
11510414|NCT01280955|Experimental|Transplant Recipients|Transplant recipients from matched sibling donors and dual cord donors. Subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
11510415|NCT01280942|No Intervention|Control|Patients admitted to 4 GHWs designated as controls. Nurses will not be notified when patients on these GHWs satisfy the EWS algorithm. They will also not wear the wireless sensor devices.
11510416|NCT01280942|Experimental|Nurse notification of EWS alert|Patients admitted to 4 GHWs designated as intervention wards at BJH. Nurses will be notified when patients on these wards satisfy the EWS algorithm. Some patients will be asked to wear the wireless remote sensors.
11510417|NCT01280929|Active Comparator|Panretinal Photocoagulation (PRP)|Group 1: Panretinal photocoagulation treatment (PRP) at month-0 that can be repeated after month-3.
11510418|NCT01280929|Experimental|Ranibizumab|Group 2: Intravitreous injections of ranibizumab every 4 weeks at month-0, month-1 and month-2 that can be repeated after month-3.
11510419|NCT01280929|Experimental|Ranibizumab + Panretinal Photocoagulation (PRP)|Group 3: Combination treatment of ranibizumab intravitreous injections plus PRP (2 weeks +/- 1 week after injection), at month-0, month-1 and month-2 that can be repeated after month-3.
11510420|NCT01280916|Experimental|Mind-body intervention|Mindful Awareness in Body-oriented Therapy
11510421|NCT01280916|No Intervention|Treatment as Usual|
11510422|NCT01280903|Experimental|STAR Intervention|Staying Active with Arthritis Intervention
11510423|NCT01280903|Placebo Comparator|Attention-Control|Senior Health Information Intervention
11510424|NCT01280890|Experimental|Staff training using VIPS framework|The staff will be trained to give person-centred care using the VIPS framework
11510425|NCT01280890|Experimental|Staff training using DCM|Staff will be supervised in how to give person-centred care using Dementia Care Mapping
11510426|NCT01280890|Placebo Comparator|Control group|Traditional lectures using films will be given to care staff
11510427|NCT01280877|Experimental|Verum stimulation|Complete treatment with transorbital alternating current stimulation (tACS)
11510428|NCT01280877|Sham Comparator|Sham stimulation|Same electrode montage set-up is used during tACS- and placebo-stimulation. Sham stimulation condition consists of minimal treatment with low intensity/few impulses tACS.
11510429|NCT01280864||Interstitial Cystitis Alone|
11510430|NCT01280864||Irritable Bowel Syndrome Alone|
11510431|NCT01280864||Healthy Controls|
11510476|NCT01280591|Experimental|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|
11510477|NCT01280591|Experimental|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|
11510478|NCT01280591|Active Comparator|Naproxen sodium 440 mg (BAYH6689)|
11510479|NCT01280591|Active Comparator|DPH 50 mg|
11510432|NCT01280838|Experimental|Theory-based behavioral intervention|Participants in this arm will receive a single-session, theory-based intervention (Hombre Seguro) at baseline that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and Motivational Interviewing (MI) to increase clients' use of condoms with FSWs. The intervention lasts approximately 45 minutes.
11510433|NCT01280838|Active Comparator|Didactic attention-control condition|The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
11510434|NCT01280825||Adult Patients|Adults receiving health care at the University of Chicago Medical Center.
11510435|NCT01280812|Experimental|PA intervention and Maintenance plus|3-month physical activity intervention and 6-month maintenance intervention-Plus program
11510436|NCT01280812|Experimental|PA intervention and Maintenance regular|3-month physical activity intervention and 6-month maintenance - Regular program
11510437|NCT01280812|Active Comparator|Pedometer|Non-intervention group
11510438|NCT01280799|Experimental|Active Treatment|
11510439|NCT01280786|Experimental|Elesclomol Sodium|
11510440|NCT01280773|No Intervention|PSV weaning|Patinens in the PSV group will be weaned using PSV mode.
11510441|NCT01280773|Experimental|NAVA weaning|Patients in NAVA group will eb weaned using NAVA mode.
11510442|NCT01280760||Non invasive ventilation|Non-invasive ventilation after invasive mechanical ventilation weaning
11510443|NCT01280747||1|Eligible fibromyalgia patients receive usual care with pregabalin prior authorization requirements in place
11510444|NCT01280747||2|Eligible fibromyalgia patients receive usual care without pregabalin prior authorization requirements in place
11510445|NCT01280747||3|Eligible painful diabetic peripheral neuropathy patients receive usual care with pregabalin prior authorization requirements in place
11510446|NCT01280747||4|Eligible painful diabetic peripheral neuropathy patients receive usual care without pregabalin prior authorization requirements in place
11510447|NCT01280734|Active Comparator|Melatonin|Circadin(R) 2 mg tablet 2 hours at 23:00
11510448|NCT01280734|Active Comparator|Zolpidem|Stilnox (R) 10 mg tablet at 23:00
11510449|NCT01280734|Placebo Comparator|Placebo|
11510450|NCT01280721|Experimental|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
11510451|NCT01280708||Capture data|
11510452|NCT01280695|Placebo Comparator|Placebo|Placebo capsule once daily
11510453|NCT01280695|Experimental|MSDC-0602 100 mg|MSDC-0602 capsule 100 mg once daily
11510454|NCT01280695|Experimental|MSDC-0602 250 mg|MSDC-0602 capsule 250 mg once daily
11510455|NCT01280695|Experimental|MSDC-0602 500 mg|MSDC-0602 capsule 500 mg once daily
11510456|NCT01280695|Active Comparator|Pioglitazone 45 mg|Pioglitazone capsule 45 mg once daily
11510457|NCT01280682|Experimental|rituximab|
11510458|NCT01280669|Experimental|Group 1|Intravitreal injections of 440mcg sirolimus (low-dose monthly group)
11510459|NCT01280669|Experimental|Group 2|Intravitreal injections of 880mcg sirolimus (high-dose every other month group)
11510460|NCT01280656||Conventional Interferon Plus Ribavirin|Eligible participants who will receive conventional interferon plus ribavirin for Chronic Hepatitis C (CHC) according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
11510461|NCT01280656||Peginterferon Alfa-2a Plus Ribavirin|Eligible participants who will receive peginterferon alfa-2a plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
11510462|NCT01280656||Peginterferon Alfa-2b Plus Ribavirin|Eligible participants who will receive peginterferon alfa-2b plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
11510463|NCT01280643|Experimental|Arm A|Patients receive FOLFIRI (FOLolinic acid (leucovorin) Fluorouracil (5-FU) IRInotecan (irinotecan)) chemotherapy comprising fluorouracil intravenously (IV) over 46 hours continuously, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
11510464|NCT01280643|Experimental|Arm B|Patients receive FOLFOX (FOL- Folinic acid (leucovorin) F - Fluorouracil (5-FU) OX - Oxaliplatin (Eloxatin)) chemotherapy comprising fluorouracil IV over 46 hours continuously on day 1 and leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
11510465|NCT01280643|Experimental|Arm C|Patients receive FOLFIRI chemotherapy as in Arm A and bevacizumab IV over 30-90 minutes on days 1 and 15.
11510466|NCT01280643|Experimental|Arm D|Patients receive FOLFOX chemotherapy as in Arm B and bevacizumab IV over 30-90 minutes on days 1 and 15.
11510467|NCT01280643|Experimental|Arm E|Patients receive CapeIRI (Capecitabine and Irinotecan) chemotherapy comprising capecitabine orally (PO) twice daily (BID) on days 1-14 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
11510468|NCT01280643|Experimental|Arm F|Patients receive CapeOX (capecitabine (Xeloda) and oxaliplatin (Eloxatin)) chemotherapy comprising capecitabine PO BID on days 1-14 and oxaliplatin IV over 2 hours on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
11510469|NCT01280643|Experimental|ARM G|Patients receive CapeIRI chemotherapy as in Arm E and bevacizumab IV over 30-90 minutes on day 1.
11510470|NCT01280643|Experimental|Arm H|Patients receive CapeOX chemotherapy as in Arm F and bevacizumab IV over 30-90 minutes on day 1.
11510471|NCT01280643|Experimental|Arm I|Patients receive treatment as in Arm D.
11510472|NCT01280617|Experimental|Thymoglobulin 1.25mg/kg dose|The safety and efficacy of low dose Thymoglobulin (1.25mg/kg) as an induction agent in renal transplant subjects.
11510473|NCT01280617|Experimental|Thymoglobulin 0.75mg/kg dose|The safety and efficacy of low dose Thymoglobulin (0.75mg/kg) as an induction agent in renal transplant subjects.
11510480|NCT01280565|Experimental|Masitinib|Participants receive masitinib (7.5 mg/kg/day), given orally twice daily.
11510481|NCT01280565|Active Comparator|Dacarbazine|Participants receive dacarbazine, given via IV bolus at 1,000 mg/m2 once every 3 weeks. Following a protocol amendment, the dacarbarzine treatment group has been closed
11510482|NCT01280552|Experimental|ICT-107|Autologous dendritic cells pulsed with immunogenic peptides from tumor antigens
11510483|NCT01280552|Placebo Comparator|Control|Autologous dendritic cells that have not been pulsed with antigens
11510484|NCT01280539|Experimental|TENS|Transcutaneous electrical nerve stimulation will be applied on the impaired hand
11510485|NCT01280539|Sham Comparator|Sham TENS|Sham TENS will be applied to the impaired hand
11510486|NCT01280526|Experimental|Romidepsin dose 10mg/m²|Romidepsin dose 10mg/m²
11510487|NCT01280526|Experimental|Romidepsin dose 12mg/m²|Romidepsin dose 12mg/m²
11510488|NCT01280526|Experimental|Romidepsin dose 14mg/m²|Romidepsin dose 14mg/m²
11510489|NCT01280526|Experimental|Romidepsin dose 8mg/m²|Romidepsin dose 8mg/m²
11510490|NCT01280513|Experimental|High Protein intake|
11510491|NCT01280513|Experimental|Low Protein intake|
11510492|NCT01280500|Placebo Comparator|Group A - Usual Care Controls|Group A will consist of 20 primary care clinics who are part of the Carolinas Healthcare System network but have not yet adopted the Electronic Medical Record System. These practices do use the same billing databases as the remaining clinics, allowing easy identification of asthma patients and their health services utilization patterns. Data from the billing systems will be used to retrospectively populate a database for these clinics from January 2009 forward.
11510493|NCT01280500|Active Comparator|Group B - EMR Control Practices|There are currently 65 primary care practices within the Carolinas Healthcare System network that have electronic medical record with decision support (EAP)access at baseline. These practices will serve as a second level of control for comparison with the intervention groups. Each of these practices is currently using Cerner PowerChart and at the start of the study and will have access to the asthma decision support tools; an electronically generated Asthma Action Plan (AAP); and a built-in system of population management reports which will be pushed to the practices on an on-going basis to help in patient recall and management. The EAP approach to care has been developed with input from clinicians, hospital administrators, hospital information services personnel, and Cerner consultants.
11510494|NCT01280500|Active Comparator|C Integrated Approach to Care|There are 10 practices within the Carolinas Healthcare System (CHS) network that have already received additional training for improving outcomes for patients with chronic diseases termed the Integrated Approach to Care (IAC). This IAC approach developed by CHS is based on the Chronic Care Model (CCM). The IAC approach includes a heavy emphasis on the use of health information technology that practices receive during the initial EAP rollout.
11510495|NCT01280500|Active Comparator|Group D - Shared Decision Making (SDM)|This approach has great potential for improved patient outcomes and provides an additional step in the successful implementation of patient self-management. The research team will develop the SDM intervention during the first 6 months of the study. In particular, the Shared decision making (SDM) intervention will be designed to be deployed within the 4 large clinics that care for the majority of the community's underserved and disadvantaged patients. The SDM intervention development will be overseen by the study advisory board and actively recruit providers from within the clinics for feedback about the intervention.
11510496|NCT01280500|Active Comparator|School Based Care (SBC)|Activities included: spending individual time with students to assess, treat, and monitor and to educate students in proper asthma management; facilitate access to health care and medicine; and communicate with parents.
11510497|NCT01280487|Experimental|Oral ZSTK474|Daily oral dosing for 21 days per cycle
11510498|NCT01280461||Experimental Group|
11510499|NCT01280461||Control Group|
11510500|NCT01280448||Case Group|
11510501|NCT01280448||Control Group|
11510502|NCT01280409|Placebo Comparator|Placebo|Compounded placebo
11510503|NCT01280409|Experimental|Metformin|Compounded metformin as the intervention
11510504|NCT01280396||SGAs|patients receiving SGAs
11510505|NCT01280383|Experimental|non-invasive NAVA|application of non-invasive NAVA in critically ill patients
11510506|NCT01280370||1|1.patients treated in a laparoscopic manner
11510507|NCT01280370||2.|2. patients treated in open operative manner
11510508|NCT01280357|Active Comparator|Monitor Philips 50XM (K954351)|CTG Fetal Monitor If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
11510509|NCT01280357|Experimental|Monica AN24 (K101801)|EHG Fetal Monitor
11510510|NCT01280344|Experimental|0.03 mg/kg BID|Ipamorelin 0.03 mg/kg, BID (2 investigational drug infusions and 1 placebo infusion)
11510511|NCT01280344|Experimental|0.06 mg/kg BID|Ipamorelin 0.06 mg/kg, BID (2 investigational drug infusions and 1 placebo infusion)
11510512|NCT01280344|Experimental|0.06 mg/kg TID|Ipamorelin 0.06 mg/kg, TID (3 investigational drug infusions)
11510513|NCT01280344|Placebo Comparator|Placebo|Matching placebo, TID (3 placebo infusions)
11510514|NCT01280331|Experimental|Q8003 12 mg/8 mg|Combination
11510515|NCT01280331|Active Comparator|Morphine sulfate 24 mg|Single component
11510516|NCT01280331|Active Comparator|Oxycodone HCl 16 mg|Single component
11510517|NCT01280318|Other|1|patients with operable head and neck squamous cell carcinoma
11510518|NCT01280318|Other|2|patients treated by neck ansd head surgery for a non-oncological disease
11510519|NCT01280318|Experimental|3|patients treated before surgery with 3 doses of neoadjuvant cetuximab
11510520|NCT01280305|Experimental|raloxifene|
11510521|NCT01280305|Placebo Comparator|Placebo|
11510522|NCT01280279||group with nocturnal polyuria and nocturia|Patients were enrolled when they had the urine volume at nighttime more than one third of total daily urine volume (NPU) and voided more than two times at nighttime (nocturia)
11510523|NCT01280266|Experimental|Amlodipine-Udenafil (AU) arm|Amlodipine 10mg PO QD for 4 weeks, washout period, then Udenafil 100mg PO QD for 4 weeks
11510524|NCT01280266|Experimental|Udenafil-Amlodipine (UA) arm|Udenafil 100mg PO QD for 4 weeks, washout period, then Amlodipine 10mg PO QD for 4 weeks
11510525|NCT01280240|Active Comparator|Monofer 500 mg|
11510526|NCT01280240|Active Comparator|Monofer 250 mg|
11510527|NCT01280227|Experimental|1|Patients uses the symptom assessment tool SiSom. A summary of their reported symptoms are printed out and given to the pediatrician and nurse before the consultation. The consultation is videotaped.
11510528|NCT01280227|No Intervention|2|"The control group do not use the symptom assessment tool SiSom before the consultation. The control group receives usual care and the consultation is videoptaped."
11510529|NCT01280214|Experimental|Triamcinolone|
11510530|NCT01280201|Experimental|Pazopanib|
11510531|NCT01280188|Experimental|Desmopressin|Day 1 - participants continue desmopressin intranasal. Day 2 up to Day 4 - Desmopressin oral melt to optimum dose. Continue optimum dose for the four week treatment and one year follow-up periods.
11510532|NCT01280175|Experimental|pMDI + charcoal block|BDP/formoterol 100/6 µg pMDI with charcoal ingestion
11510533|NCT01280175|Experimental|pMDI + Aerochamber Plus|BDP/formoterol 100/6 µg with Aerochamber Plus
11510534|NCT01280175|Active Comparator|pMDI|BDP/formoterol 100/g µg pMDI
11510535|NCT01280162|Experimental|3 day therapy|Total dose split over 3 days (3 tablets per day)
11510536|NCT01280162|Experimental|2 day therapy|Total dose split over 2 days (4.5 tablets per day)
11510537|NCT01280149|Experimental|substance P-low dose allergen|Substance P injections with 8 sequential, increasing doses of allergen
11510538|NCT01280149|Experimental|substance P-moderate dose allergen|Substance P with sequential, increasing doses of allergen
11510539|NCT01280149|Experimental|substance P-low/moderate dose allergen|substance P with 16 sequential increasing doses of allergen
11510540|NCT01280149|Active Comparator|substance P-placebo|Placebo injections of substance P and placebo
11510541|NCT01280149|Experimental|placebo-low dose allergen|Placebo injections with 8 sequential increasing low dose allergen injections
11510542|NCT01280149|Placebo Comparator|placebo-placebo|substance P placebo and allergen placebo (weekly)
11510543|NCT01280136|Experimental|It's Your Game Tech|An interactive web-based HIV, sexually transmitted infection (STI), and pregnancy prevention program for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game…Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
11510544|NCT01280123|Experimental|15 mg pioglitazone|15 mg pioglitazone
11510545|NCT01280123|Experimental|45 mg pioglitazone|45 mg pioglitazone
11510546|NCT01280123|Placebo Comparator|Matching Placebo|Placebo
11510547|NCT01280110|Active Comparator|Preserved (BAK 0.006%) lubricating drop|One group will receive preserved lubricating drops 4 times a day for 1 month.
11510548|NCT01280110|Active Comparator|Preservative-free lubricating drops|The second group will receive preservative-free lubricating drops 4 times a day for 1 month.
11510549|NCT01280097||Prospective cohort study|Observational only
11510550|NCT01280084||No labour analgesia/nitrous oxide|Women who use no analgesia during labour or who only used nitrous oxide.
11510551|NCT01280084||Systemic opioids|Women who receive only systemic opioids for analgesia during, either intravenously or intramuscularly
11510552|NCT01280084||Intermediate dose epidural fentanyl|Women who receive a total epidural fentanyl dose less than 150 micrograms
11510553|NCT01280084||High dose epidural fentanyl|Women who receive a total epidural fentanyl dose more than 150 micrograms
11510554|NCT01280071|Experimental|dipyridamole, aminophylline|
11510555|NCT01280058|Experimental|Arm I (wild-type reovirus, carboplatin, paclitaxel)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and wild-type reovirus IV over 60 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11510556|NCT01280058|Experimental|Arm II (carboplatin, paclitaxel)|Patients receive paclitaxel and carboplatin as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.
11510557|NCT01280045|Experimental|AROMATASE INHIBITOR|this would be compared before and after VAGINAL HYSTERECTOMY
11510558|NCT01280045|Active Comparator|GNRH ANALOG|this would be compared before and after VAGINAL HYSTERECTOMY
11510559|NCT01280032|Experimental|Kypho-IORT|
11510560|NCT01280019|Experimental|FRC guided|Patients receive an alveolar recruitment manoeuvre if FRC falls below 94% of baseline FRC
11510561|NCT01280019|Active Comparator|Saturation guided|Patients receive an alveolar recruitment manoeuvre if peripheral oxygen saturation falls below 90%
11510562|NCT01279993|Experimental|Kerato refractive Surgery|
11510563|NCT01279980|Active Comparator|Epidural|Subjects will have an epidural catheter placed to provide postoperative pain relief. This is standard care for those undergoing an enhanced recovery program.
11510564|NCT01279980|Active Comparator|Painbuster|Subjects will have a local anaesthetic wound catheter inserted into the wound at time of surgery rather than an epidural for the provision of postoperative pain relief.
11510565|NCT01279967|No Intervention|A|Arm A is control arm with best supportive care.
11510566|NCT01279967|Experimental|B|Arm B is the treatment arm with best supportive care plus ADI-PEG20.
11510567|NCT01279954|Experimental|open-label abatacept first, then 5 mg/kg abatacept|10 mg/kg abatacept (6 months). Then 5 mg/kg abatacept (18 months)
11510568|NCT01279954|Experimental|open-label abatacept first, then 10 mg/kg abatacept|10 mg/kg abatacept (6 months). Then 10 mg/kg abatacept (18 months)
11510569|NCT01279941|No Intervention|Testing Only|
11510570|NCT01279941|Experimental|Testing & Intervention|
11510571|NCT01279928||Type 1 Diabetes Paediatric|Paediatric patients aged 8-18 with diagnosed Diabetes Mellitis Type 1 attending paediatric clinic at John Hunter Hospital.
11510572|NCT01279915|Experimental|ASP group|ASP0456 receiving group
11510573|NCT01279915|Placebo Comparator|Placebo group|Placebo treatment
11510574|NCT01279902|Experimental|Rituximab plus CHOP Immunochemotherapy|"Interventions: conventional R-CHOP every 3 weeks for 3 cycles
~Rituximab 375 mg/M2 IV day 1
~Cyclophosphamide 750 mg/M2 IV day1
~Vincristine 1.5 mg/M2 (max. 2 mg) IV day1
~Prednisolone 50 mg bid day 1-5, every 3 weeks"
11510575|NCT01279889||Cesarean Delivery|Healthy pregnant women having an elective cesarean delivery
11510576|NCT01279876|Active Comparator|Melatonin|
11510577|NCT01279876|Placebo Comparator|Placebo|
11510578|NCT01279850||Pregabalin (Lyrica) capsule|"Patients administered Pregabalin capsule."
11510579|NCT01279837|No Intervention|Usual care|Control (Usual care) group in which patients will receive swallowing and prescribed dietary intervention during the radiotherapy period prescribed by the attending physician.
11510580|NCT01279837|Experimental|High Intensity Pharyngocise|Patients receive twice daily swallowing intervention by a speech language pathologist, consisting of the battery of isometric / isotonic exercises.
11510581|NCT01279837|Active Comparator|Low Intensity Pharyngocise|Patients will receive a one time only swallowing intervention session by a speech language pathologist, instructing them in the battery of isometric / isotonic exercises plus a home practice instruction digital video tape to support self directed practice of this program at home.
11510582|NCT01279824|Active Comparator|Usual Care|Patients will receive behavioral swallowing therapy comprising combination's of treatment strategies / exercises chosen from an approved hierarchy. This formulation of treatment will be designed and applied by the treating clinician.The treatment will be provided daily for a one-hour over a consecutive 3-week period.
11510583|NCT01279824|Placebo Comparator|sham NMES|Patients will receive behavioral swallowing therapy comprising combinations of treatment strategies / exercises chosen from an approved hierarchy with the addition of non stimulating electrodes. A faux NMES device will be utilized with an active current display and non stimulating electrodes. The treatment will be provided daily for a one-hour over a consecutive 3-week period.
11510584|NCT01279824|Experimental|NMES therapy|Patients will receive a protocol of standardized behavioral swallowing intervention combined with NMES. This formulation of treatment will be prescribed from a standard protocol and will be applied daily for one-hour over a consecutive 3-week period.
11510585|NCT01279811|Other|Single Arm|Vasopressor Crossover - Dopamine & NORepinephrine
11510586|NCT01279785||Prostate Cancer Patients|Male participants who are scheduled to undergo standard of care prostatectomy for presumed localized prostate cancer at the NIH Clinical Center and have evidence of a recent (within 12 months of study entry) trans-rectal biopsy documenting adenocarcinoma of the prostate.
11510587|NCT01279746||ultrasond compression of deep veins|
11510588|NCT01279733||Microarray Analysis|
11510589|NCT01279720|Experimental|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
11510590|NCT01279707|Experimental|A: Veltuzumab and chemotherapy|Veltuzumab and modified UKALL XII chemotherapy
11510591|NCT01279707|Experimental|B: epratuzumab and chemotherapy|epratuzumab and modified UKALL XII chemotherapy
11510592|NCT01279707|Experimental|C: veltuzumab and epratuzumab and chemotherapy|Veltuzumab and Epratuzumab and modified UKALL XII chemotherapy
11510593|NCT01279681|Active Comparator|Arm A [fluoropyrimidine + bevacizumab (BEV)]|Patients receive either 5FU/LV or Capecitabine, plus BEV. 5FU/LV + BEV is comprised of 5FU IV over 46-48 hours, LV calcium IV over 2 hours, and BEV IV over 10-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Capecitabine + BEV is comprised of capecitabine PO BID on days 1-14 and BEV IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11510594|NCT01279681|Experimental|Arm B [fluoropyrimidine/oxaliplatin (OXAL) + BEV]|Patients receive either mFOLFOX7 plus BEV, or Capecitabine + OXAL (XELOX) plus BEV. mFOLFOX7 + BEV is comprised of OXAL IV over 2 hours, LV calcium IV over 2 hours, and 5FU IV over 46-48 hours on day 1. Patients also receive BEV IV over 10-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. XELOX + BEV is comprised of OXAL IV over 2 hours on day 1 and capecitabine PO BID on days 1-14. Patients also receive BEV IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11510595|NCT01279668|Experimental|Montelukast|
11510596|NCT01279668|Placebo Comparator|Placebo|
11510597|NCT01279655|Experimental|tDCS and training|Transcranial Direct current stimulation (tDCS) is applied together with a bimanual learning task. tDCS is delivered through two gel-sponge electrodes (eldith DC Stimulator, neuroConn GmbH, Ilmenau, Germany) embedded in a saline-soaked solution. tDCS will be applied for 20 min, with a current intensity of 1mA.
11510598|NCT01279655|No Intervention|Control|No intervention is applied
11510599|NCT01279655|Placebo Comparator|Sham tDCS + Training|The training consists of a bimanual training task. tDCS is only applied for a few seconds and will than be ramped-down.
11510600|NCT01279642|Experimental|ultrasound|Use of ultrasound to PICC placement
11510601|NCT01279642|Active Comparator|Control group|PICC placement by inspection and visualization of site
11510602|NCT01279629||Tazarotene 0.1%|
11510603|NCT01279629||Calcipotriol 0.005%|
11510604|NCT01279616|Experimental|Hematopoietic Stem Cell Transplant|Stem cell infusion on Day 0.
11510605|NCT01279603|Experimental|GO-203-2c|
11510606|NCT01279590|Experimental|PPD10558|Dosing will be forced-titrated as follows: 40 mg orally twice daily for 4 weeks and 80 mg orally twice daily for 8 weeks
11510607|NCT01279590|Active Comparator|Atorvastatin|Dosing will be forced titrated as 40 mg orally once daily for 4 weeks, and 80 mg orally once daily for 8 weeks
11510608|NCT01279590|Placebo Comparator|Placebo|Dosing will be 2 placebo capsules twice daily for 12 weeks
11510609|NCT01279577|Experimental|Low dose TSO|Low dose suspension of TSO
11510610|NCT01279577|Experimental|Medium dose TSO|Medium dose suspension of TSO
11510611|NCT01279577|Experimental|High dose TSO|High dose suspension of TSO
11510612|NCT01279577|Placebo Comparator|Placebo|Placebo solution
11510613|NCT01279564|Experimental|ETview|ETview TVT endotracheal tube
11510614|NCT01279564|Sham Comparator|Control|Endotracheal tube
11510615|NCT01279551|Experimental|GTN|In this arm the investigators administer local application of 0.4% nitroglycerin ointment and ketorolac tromethamine 10 mg
11510616|NCT01279551|Active Comparator|Control|In this arm the investigators administer local application of lidocaine cloridrato 2.5% and ketorolac tromethamine 10 mg.
11510617|NCT01279538|Experimental|ASKP1240 lowest dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
11511396|NCT01274273|Experimental|Interleukin-2, interferon, bevacizumab|
11510618|NCT01279538|Experimental|ASKP1240 low dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
11510619|NCT01279538|Experimental|ASKP1240 high dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
11510620|NCT01279538|Experimental|ASKP1240 highest dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
11510621|NCT01279538|Placebo Comparator|Placebo|Participants received a single 30-minute matching placebo infusion on Study Day 1, followed by a 90-day follow-up period.
11510622|NCT01279525|Experimental|Multifactorial intervention|Multifactorial intervention to prevent falls
11510623|NCT01279512|Experimental|Metformin reciepiants|Infertile overweight women with PCO who received Metformin
11510624|NCT01279512|Experimental|Acarbose reciepiants|Infertile overweight women with PCO who received Acarbose
11510625|NCT01279499|Active Comparator|SEVO group|Anaesthesia will be induced with IV Propofol (2 mg/kg TW [TW = ideal body weight, IBW + 0.4 * difference to the excess weight]), Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR > 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes.If the positive sympathetic response persists, then Nifedipine 10 mg will be administered sublingual, if HR < 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR > 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of positive sympathetic stress responses that required pharmacologic intervention will be recorded.
11510626|NCT01279499|Active Comparator|SEVO-BIS group|Anaesthesia will be induced with IV Propofol (2 mg/kg TW [TW = ideal body weight, IBW + 0.4 * difference to the excess weight]), Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).Intraoperatively Sevoflurane will be guided by a target BIS of 40 - 50 .Every rise of BP or HR > 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes. If the positive sympathetic response persists, then Nifedipine 10 mg will be administered sublingual, if HR < 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR > 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of positive sympathetic stress responses that required pharmacologic intervention will be recorded.
11510627|NCT01279499|Active Comparator|Propo- Remi group|"General Anaesthesia (GA) will be induced with a continuous IV Propofol (P) infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (R, 1 μg/kg IBW) and succinylcholine (1mg/kg IBW). GA will be maintained with continuous intravenous administration of P at 150-300mcg/kg/min (doses based on ideal body weight).
~Every rise of BP or HR > 15% of baseline will be followed by a R bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of R to 1.0 μg/kg/min . If HR < 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR > 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of stress responses that required intervention is recorded."
11510628|NCT01279499|Active Comparator|Propo-Remi-BIS group|"General Anaesthesia (GA) will be induced with a continuous IV Propofol (P) infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (R, 1 μg/kg IBW) and succinylcholine (1mg/kg IBW). GA will be maintained with continuous intravenous administration of P at 150-300mcg/kg/min (IBW).
~The depth of anesthesia will be adjusted to accomplish a BIS score 40 -50. If BP or HR is > 15% of baseline will a bolus of R IV (1 μg/kg IBW) will be given and an the infusion rate of R will be increased to 1.0 μg/kg/min . If this response persists and HR < 70/ min, Nifedipine 10 mg will be given s.l. and if HR > 70/ min Diltiazem 10-20 mg IV will be given, followed by esmolol infusion if no response is observed."
11510629|NCT01279473|Experimental|Nilotinib|
11510630|NCT01279460||CKD Cohort of patients with renal insufficiency|patients with renal insufficiency grade II-IV
11510631|NCT01279447|Sham Comparator|Placebo|A sham infrapatellar block performed under US guidance with normal saline
11510632|NCT01279447|Experimental|Infrapatellar nerve block|An infrapatellar nerve block performed under US guidance with 0.25% bupivacaine
11510633|NCT01279434|Experimental|Vitamin E plus Pentoxiphyllin|
11510634|NCT01279434|Active Comparator|Vitamin E|
11510635|NCT01279421|Experimental|Social Network HIV Testing|Participants in this arm will be recruited through social networks and will receive an HIV test.
11510636|NCT01279421|Experimental|Peer Network Intervention|Eight (8) current or former crack users will be recruited to facilitate small networks of crack users in a three-day intervention. They will also facilitate monthly meetings open to all community members regarding HIV prevention and interpersonal violence.
11510637|NCT01279395||naproxen|Patients age 40-70 who fulfill the American College of Rheumatology (ACR) criteria for a diagnosis of primary osteoarthritis are considered eligible. This group has been prescribed naproxen (1000 mg/day) for a minimum of two weeks.
11510638|NCT01279395||diclofenac|Patients age 40-70 who fulfill the ACR criteria for a diagnosis of primary osteoarthritis. The group consists of patients who have been prescribed diclofenac (150 mg/day)for a minimum of two weeks.
11510639|NCT01279395||celecoxib|Patients age 40-70 who fulfill the ACR criteria for a diagnosis of primary osteoarthritis are considered eligible. This group has been prescribed celecoxib (200 mg/day) for a minimum of two weeks.
11510640|NCT01279382|Other|Care as usual (CON)|CON was given to a subgroup of patients as control treatment in IBS treatment
11510641|NCT01279382|Other|Hypnotherapy (HYP)|HYP was given to a subgroup of patients as intervention in IBS treatment
11510642|NCT01279382|Other|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
11510643|NCT01279356||Patients with liver diseases of various etiologies|"viral hepatitis
~cholestatic liver diseases
~auto-immune hepatitis
~NAFLD
~ALD
~sarcoidosis of the liver"
11510644|NCT01279343|Experimental|Foley Bulb plus Misoprostol|
11510645|NCT01279343|No Intervention|Misoprostol|
11510646|NCT01279330|No Intervention|Control|Patients receive by mail the materials needed for stool samples.
11510647|NCT01279330|Experimental|Co-signed Letter|
11510648|NCT01279317|Experimental|vinegar co-ingestion|25 ml vinegar is added to glucose containing beverage
11510649|NCT01279317|Placebo Comparator|Placebo co-ingestion|25 ml vinegar is substituted by 25 ml water
11510754|NCT01278576|Experimental|Intramuscular ending Targeting|Botox 200 units placed at the upper 2/10-3/10 length of the GCM
11510650|NCT01279304||Group 1. Low risk|"Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:
~a. all nodes negative: ycN0
~or
~Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:
~a. only micrometastases in the SN, and no risk factors (grade 3, LVI, tumour size > 3 cm)
~or
~Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:
~no metastases in the post chemo SN"
11510651|NCT01279304||Group 2: Intermediate risk|"Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:
~a. 1-3 nodes positive: ypN1
~or
~Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:
~micrometastases in the SN and at least 1 risk factor; or
~≤ 2 macrometastases and no risk factor
~or
~Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:
~micrometastases in the post chemo SN and no risk factors (grade 3, LVI, tumour size > 3 cm)"
11510652|NCT01279304||Group 3. High risk|"Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:
~a. 4 or more nodes positive: ypN2
~or
~Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:
~≤ 2 macrometastases in the sentinel node prior to primary systemic treatment in the presence of risk factors like Grade 3, lymphangioinvasion, tumour size > 3 cm; or
~3 macrometastases, 2 macrometastases and 1 micrometastase, 1 macrometastase and 2 micrometastases.
~or
~Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:
~Micrometastases in the post chemo SN, and at least one risk factor
~≤ 3 macrometastases in the post chemo SN; or
~2 macrometastases and 1 micrometastase, 1 macrometastase and 2 micrometastases"
11510653|NCT01279291|Experimental|KHK2866 as monotherapy|Groups of subjects will receive a weekly infusions of KHK2866 as treatment for advanced cancer. If there no severe side effects, the dose will be increased for future subjects. A total of four groups are anticipated. Once an acceptable dose is determined an additional seven subjects will be treated at that dose.
11510654|NCT01279291|Experimental|KHK2866, gemcitabine+carboplatin|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.
~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with gemcitabine and carboplatin. The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
11510655|NCT01279291|Experimental|KHK2866, weekly paclitaxel|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.
~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with weekly paclitaxel (80 mg/m2). The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
11510656|NCT01279291|Experimental|KHK2866, pegylated liposomal doxorubicin|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.
~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with monthly PLD (40 mg/m2). The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
11510657|NCT01279278|No Intervention|Control|
11510658|NCT01279278|Experimental|Co-signed Letter|
11510659|NCT01279265|Active Comparator|Nutramigen Lipil with Enflora|Formula with probiotics (Lactobaccillus Rhamnosus GG)
11510660|NCT01279265|Placebo Comparator|Nutramigen A+|Hypoallergenic formula without probiotics (Lactobaccillus Rhamnosus GG)
11510661|NCT01279252|Experimental|Antibiotic regimen|
11510662|NCT01279239||Poly trauma|20 Patients suffering from poly trauma who meet inclusion criteria would be recruited
11510663|NCT01279239||Healthy control|20 healthy volunteers would be recruited to obtain basal metabonomics fingerprinting
11510664|NCT01279213|Active Comparator|paliperidone clozapine BPRS|patients assigned to clozapine plus paliperidone controls at 6 and 12 weeks
11510665|NCT01279213|Placebo Comparator|clozapine plus placebo BPRS|patients assigned to placebo plus clozapine should show less improvement
11510666|NCT01279200|Active Comparator|Urinary LH Kits|Patients randomized to this arm will monitor ovulation with home-based urinary LH kits (Ovulation Predictor Kits, OPK's).
11510667|NCT01279200|Active Comparator|Midcycle ultrasound + hCG injection|Patients randomized to this arm will undergo ovulation monitoring with midcycle ultrasound and receive hCG injection if evidence of a mature size follicle.
11510668|NCT01279187|Experimental|Teriparatide|demeclocycline HCl (150 mg, four times per day for 3d) followed by a 12 day intermission then 3 more days of demeclocycline HCl (150 mg, four times per day). One day after the last demeclocycline dosage, subjects will be instructed to self-administer teriparatide (or placebo) for 7 weeks. Twenty-five days after the last demeclocycline dosage, subjects will begin their second set of tetracycline labels:(250 mg, four times per day) for three days, followed by 12 days off, and then repeat another 3 days of tetracycline HCl (250 mg, four times per day). On day of the last teriparatide (or placebo) injection, subjects will present for bone core removal and dental implant placement.
11510669|NCT01279187|Placebo Comparator|Control|demeclocycline HCl (150 mg, four times per day for 3d) followed by a 12 day intermission then 3 more days of demeclocycline HCl (150 mg, four times per day). One day after the last demeclocycline dosage, subjects will be instructed to self-administer teriparatide (or placebo) for 7 weeks. Twenty-five days after the last demeclocycline dosage, subjects will begin their second set of tetracycline labels:(250 mg, four times per day) for three days, followed by 12 days off, and then repeat another 3 days of tetracycline HCl (250 mg, four times per day). On day of the last teriparatide (or placebo) injection, subjects will present for bone core removal and dental implant placement.
11510670|NCT01279174|Other|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
11510755|NCT01278576|Active Comparator|Midbelly Targeting|A total of 200 units will be placed at the four quadrants of the midbelly portion of the GCM.
11510671|NCT01279174|Experimental|Whole-body-vibration exercises|Patients in this study group will attend whole body vibration exercise sessions of one hour three times a week for six weeks, using the Galileo® Fitness device. Initial training sessions will focus on patient acclimatization, and afterwards improved on muscular capacity and body coordination. During exercise sessions, patients will do 6 training cycles of 3 minutes each. The goals of this treatment are improved proprioception of the ankle and knee joints, as well as optimization of neuronal reactivation of the muscles and thereby improved joint stability. This should also increase endogenous analgesia
11510672|NCT01279161||diabetes|The study will include 1500 children with type 1 diabetes, aged 6-18 years. These will be patients from Diabetes Outpatient Clinics and patients hospitalized in Departments of Paediatrics, Endocrinology and Diabetology in University and Municipal Hospitals from Poland (Białystok, Warszawa, Łódź, Gdańsk, Wrocław, Katowice).
11510673|NCT01279161||control|Reference group will be made of 1500 children from the above mentioned Clinics and Departments in whom type 1 diabetes was excluded. In these children diagnostics procedures will be conducted for reasons other than body weigh related diseases (excluding simple obesity). The children will not receive any treatment that might influence their body weight.
11510674|NCT01279148||Biopsy/Ablation - CONTROL GROUP|The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded by pushing the start button again.
11510675|NCT01279148||Biopsy/Ablation - STUDY GROUP:|"The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. The physician will then be un-blinded and shown the PercuNav screen and will correct the desired approach path and another screen capture will be taken. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded. At the end of the procedure, and if clinically indicated, a verification CT computed tomography scan will be taken with the needle in place and, sent to the PercuNav. Radiation dosage, due to CT imaging, will also be recorded."
11510676|NCT01279135|Active Comparator|Conventional RT|Patients in this arm will receive conventional radiation with or without chemotherapy
11510677|NCT01279135|Experimental|Tomotherapy based IGRT|Patients in this arm will receive Tomotherapy based IGRT with or without chemotherapy
11510678|NCT01279122|No Intervention|Nanoflex IOL|
11510679|NCT01279109|Experimental|Social network building intervention|Healthy lifestyle intervention focused on building healthy lifestyle skills and reciprocal social ties between the intervention group members
11510680|NCT01279109|Active Comparator|Home visit|Home visits focused on preventable infant injuries
11510681|NCT01279083|Experimental|Concentration 1|
11510682|NCT01279083|Experimental|Concentration 2|
11510683|NCT01279083|Experimental|Concentration 3|
11510684|NCT01279083|Experimental|Concentration 4|
11510685|NCT01279083|Placebo Comparator|Vehicle Solution|
11510686|NCT01279083|Active Comparator|Timolol Maleate Ophthalmic Solution|
11510687|NCT01279070|Experimental|REPYFLEC cognitive remediation training|REPYFLEC cognitive remediation as a Problem solving and Cognitive flexibility group training.
11510688|NCT01279070|Active Comparator|Leisure group|"Leisure group is a stimulating activity focused on socialization through group dynamics, board games, coffee and talk."
11510689|NCT01279057|Experimental|Fluticasone furoate (Lek Pharmaceuticals) nasal spray|
11510690|NCT01279057|Active Comparator|Fluticasone furoate (Veramyst®) nasal spray|
11510691|NCT01279057|Placebo Comparator|Placebo nasal spray|
11510692|NCT01279044|Active Comparator|1|HIV testing with adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)
11510693|NCT01279044|Placebo Comparator|2|HIV testing with information only
11510694|NCT01279031|Experimental|Abbott WHITESTAR Signature System|Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound
11510695|NCT01279031|Experimental|Alcon Infiniti|Alcon Infiniti with the OZIL Torsional Handpiece
11510696|NCT01279018||Patients treated with docetaxel|Patients treated according to the DBCG 07 protocol, that have received docetaxel as part of the adjuvant treatment.
11510697|NCT01279005||20-50 YEARS OLD MSM|
11510698|NCT01278979|Active Comparator|Assessment of perineal tears|Consenting women sustaining perineal tear after child birth
11510699|NCT01278979|Other|Visual and digital assessment|Consenting women that sustained perineal tear after child birth.
11510700|NCT01278966|Experimental|The Modified Atkins Diet|Treatment with the Modified Atkins Diet for 6 months
11510701|NCT01278953|Experimental|TactiCath|Catheter ablation to treat paroxysmal AF using the TactiCath catheter with contact force capability
11510702|NCT01278953|Active Comparator|Control|Catheter ablation to treat paroxysmal AF using a catheter with no contact force sensing capability
11510703|NCT01278940|Experimental|Dendritic Cells (DC) malignant melanoma|22 patients were included in this arm.
11510704|NCT01278940|Experimental|DC vaccine plus IL-2|To improve the efficacy of the DC vaccine, IL-2 was administrated at the vaccination site through direct lymph node injection. 9 patients were included in this arm.
11510705|NCT01278927|Active Comparator|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief (10 minute) personalized introduction to the home-based exercise intervention. On Day 30 post hematopoietic cell transplantation (HCT), participants will meet briefly with the same interventionist when possible. To minimize contamination across intervention conditions, participants randomized to Exercise will be provided with only general advice regarding stress management (i.e., to continue using any techniques they currently use to manage stress). The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant.
11510756|NCT01278550||Average risk cohort|Patients having no history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have H. pylori positive OR negative
11510914|NCT01277445|Active Comparator|Prebiotic|Consumption of 15g/day of inulin-fructan for 28 days
11510706|NCT01278927|Active Comparator|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief standardized introduction to the self-administered intervention. On Day 30 post HCT, the interventionist will meet with the participant to answer any questions about the intervention, encourage the continued use of stress management techniques as recommended, and monitor for any adverse reactions to use of the techniques. The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant. Whenever possible, the interventionist meeting with the patient at 30 and 60 days should be the same interventionist who previously met with the patient.
11510707|NCT01278927|Active Comparator|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions. On Day 30 post HCT, the same interventionist will meet with the participant briefly to answer any questions about the interventions, encourage the continued use of the interventions as recommended, and monitor for any adverse reactions. The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant. Whenever possible, the interventionist meeting with the patient at 30 and 60 days should be the same interventionist who previously met with the patient.
11510708|NCT01278927|Other|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive a digital video disc (DVD). The interventionist will briefly discuss the topics of the DVD and elicit questions. To minimize contamination across intervention conditions, participants randomized to the control group will be provided with only general advice about exercise and stress management during treatment (i.e., to maintain any usual patterns of exercise to the extent possible and to continue using any techniques they currently use to manage stress).
11510709|NCT01278901||Cohort of consecutive patients undergoing EGD treated with PPI|Patients positive for helicobacter pylori undergoing EGD, started on PPI therapy for a month, repeated diagnostic tests for Helicobacter pylori after a month of therapy (urease test, histology and breath test)
11510710|NCT01278888|Active Comparator|PLEACE 1|Anterolateral vs. posterolateral thoracotomy
11510711|NCT01278888|Active Comparator|PLEACE 2|Video assisted thoracic surgery (VATS) vs. anterolateral thoracotomy
11510712|NCT01278875||Acute Coronary Syndrome|Subjects with ACS within 72 hours of clinical presentation
11510713|NCT01278875||Stable CAD subjects|Patients with stable, chronic CAD
11510714|NCT01278875||Control subjects|Healthy individuals
11510715|NCT01278862|Experimental|DVS veneer|veneer made by CAD/CAM method
11510716|NCT01278862|Active Comparator|Conventional veneer|Veneer made by laboratory technician
11510717|NCT01278849|Experimental|ASA404 + standard therpy|
11510718|NCT01278836|Other|fascio-cutaneous flap|flaps which include skin, subcutaneous tissue, and the underlying fascia.
11510719|NCT01278823|Experimental|surgery|Surgery: laparoscopic roux en y gastric bypass operation
11510720|NCT01278823|Active Comparator|Medical treatment|Medical Treatment: Comprehensive medical management of diabetes including medications, diet intervention, lifestyle modification, exercise regimen
11510721|NCT01278810|Experimental|Icaritin|
11510722|NCT01278797|Active Comparator|Telmisartan/Amlodipine Fixed Dose|Telmisartan/Amlodipine medium fixed dose combination tablet once daily.
11510723|NCT01278797|Active Comparator|Amlodipine Monocomponent|Amlodipine Monocomponent 10mg tablet once daily
11510724|NCT01278784|Experimental|Healthy volunteer|
11510725|NCT01278758|Experimental|ASA404 + standard therpy|
11510726|NCT01278745|Experimental|Rituximab|Rituximab induction/conventional immunosuppression
11510727|NCT01278745|Placebo Comparator|Rituximab Placebo|Rituximab Placebo / conventional immunosuppression
11510728|NCT01278732||untreated persons with suspected hypertension|
11510729|NCT01278719||Antrochaonal polyp; non recurrent type|
11510730|NCT01278719||Antrochoanal polyp; recurrent type|
11510731|NCT01278719||Ethmoidal polyp - non recurrent type|
11510732|NCT01278719||Ethmoidal polyp - recurrent type|
11510733|NCT01278706|No Intervention|no treatment|
11510734|NCT01278706|Experimental|one biopsy, proliferative phase|
11510735|NCT01278706|Experimental|one biopsy, secretory phase|
11510736|NCT01278706|Experimental|two biopsies|
11510737|NCT01278693|Other|placebo|it is as like as L-carnitine in shape
11510738|NCT01278693|Other|L-carnitine|it is kind of supplement
11510739|NCT01278680|No Intervention|Hold-out control|Hold-out control: participants will be asked to refrain from using the walkstations for the duration of the study (90 days).
11510740|NCT01278680|Active Comparator|Personal incentive|Personal incentive: Participants will receive $3 for each time they use the walkstation.
11510741|NCT01278680|Experimental|Charitable incentive|Charitable incentive: $3 will be donated to charity every time the participant uses the walkstation.
11510742|NCT01278654|Active Comparator|Personal incentive|If participants attain their walkstation usage goal, they are entered into bi-weekly lotteries to win money.
11510743|NCT01278654|Active Comparator|Token incentive|Participants who attain their walkstation usage goal will be entered into a bi-weekly prize to win a token reward.
11510744|NCT01278641|Experimental|1|Intervention i arm 1 comprises graded strength resistance training, 75 minutes twice a week for 12 weeks.
11510745|NCT01278641|Experimental|2|Intervention in arm 2 comprises low intensive temperate pool exercise 50 minutes, twice a week for 12 weeks.
11510746|NCT01278641|No Intervention|3|Reference group, continues with normal activities during the study period of 12 weeks.
11510747|NCT01278628|Experimental|Lifestyle modification|
11510748|NCT01278615|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity
11510749|NCT01278602|Experimental|R-ESHAP|Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
11510750|NCT01278589|Experimental|• Plantago asiatica L. extract 5g|
11510751|NCT01278589|Experimental|Plantago asiatica L. extract 10g|
11510752|NCT01278589|Experimental|Plantago asiatica L. extract 20g|
11510753|NCT01278589|Placebo Comparator|Placebo|
11510757|NCT01278550||High risk cohort|Patients have history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have successful eradication of H. pylori based on histology
11510758|NCT01278537|Experimental|Empowerment, shared-decision making,|Patients receive a booklet with informations. Assessment of health-related risk factors. Assessment of psychological and physical social support Delirium protection. Early mobilization.
11510759|NCT01278537|No Intervention|control group|
11510760|NCT01278524||Critically ill patients|Patients staying in the ICU on the 25th of January
11510761|NCT01278511|Experimental|Canadian C-Spine Rule|
11510762|NCT01278498|Experimental|escitalopram|prevention of poststroke depression in patients with acute stroke.
11510763|NCT01278498|Placebo Comparator|placebo|prevention of poststroke depression in patients with acute stroke.
11510764|NCT01278485||Sulphonylurea (SU) Monotherapy or SU + Metformin|Participants with Type 2 diabetes that have been treated with SU monotherapy for at least 6 months by a cardiologist, nephrologist, or family practice doctor.
11510765|NCT01278472|Experimental|Single Port Cholecystectomy|Laparoscopic Cholecystectomy with single port transumbilical access
11510766|NCT01278472|Active Comparator|4 Port Cholecystectomy|Laparoscopic Cholecystectomy using 4 separate conventional trocars
11510767|NCT01278459|Experimental|Atorvastatin first|Participants receive 4 week treatment with atorvastatin 20mg/day, followed by 4 week washout, followed by 4 week treatment with placebo.
11510768|NCT01278459|Experimental|Placebo first|Participants receive 4 week treatment with placebo, followed by 4 weeks washout, followed by 4 weeks treatment with atorvastatin 20mg/day.
11510769|NCT01278446|Experimental|Test Formula|New hydrolyzed whey formula
11510770|NCT01278446|Active Comparator|Control Formula|Commercially available hydrolyzed infant formula
11510771|NCT01278433|Experimental|Study Group|Participants receiving their first dose of polio vaccine
11510772|NCT01278420|Other|Tecnis MF|
11510773|NCT01278420|Other|ReSTOR|
11510774|NCT01278407|Placebo Comparator|Placebo - Confirmatory Phase|Participants received donepezil matched placebo tablets orally, once daily for 12 weeks in the confirmatory phase.
11510775|NCT01278407|Experimental|Donepezil 5 mg - Confirmatory Phase|Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 10 weeks in the confirmatory phase.
11510776|NCT01278407|Experimental|Donepezil 10 mg - Confirmatory Phase|Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 4 weeks. Thereafter, the dose was increased to 10 mg for 6 weeks in the confirmatory phase.
11510777|NCT01278407|Experimental|Placebo to Donepezil (5 +10 mg) - Extension Phase|Participants previously receiving donepezil matched placebo up to Week 12 in the Confirmatory Phase, continued placebo until Week 16 (at the beginning of the Extension Phase). Participants received 3 mg of donepezil, and the dose was then increased to 5 mg at Week 18 and to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.
11510778|NCT01278407|Experimental|Donepezil (5 +10 mg) - Extension Phase|Participants previously receiving donepezil (5 mg or 10 mg) up to Week 12 in the Confirmatory Phase, maintained allocated treatment and dosages until Week 24. In the 5 mg group of the Confirmatory Phase, the dose was increased to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.
11510779|NCT01278394|Experimental|Group 1|AN2690 Solution, 5.0%
11510780|NCT01278381||Pancreaticoduodenectomy (PD)|Patients undergoing PD from 2002 to 2010
11510781|NCT01278368|Active Comparator|Preoperative chemotherapy (PCHT)|Patients who underwent pancreatic resection after PCHT.
11510782|NCT01278368|Active Comparator|Control|Patient who underwent pancreatic resection without preoperative therapy
11510783|NCT01278355||Pain Patients|
11510784|NCT01278342|Active Comparator|Sandostatin LAR high dose Alone|All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with controlled GH and IGF-I after 3 months of Sandostatin LAR monotherapy continued to receive Sandostatin LAR 40 mg i.m. every 28 days for an additional 4 months.
11510785|NCT01278342|Experimental|Sandostatin LAR high dose + Pegvisomat|All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with uncontrolled GH and or IGF-I received Sandostatin LAR40 mg every 28 days in combination with weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for a further 4 months
11510786|NCT01278342|Experimental|Sandostatin LAR high dose + Cabergoline|"All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with uncontrolled GH and or IGF-I received Sandostatin LAR 40 mg every 28 days in combination with weekly cabergoline for a further 4 months, with cabergoline doses as follows:
~st week: 0.25 mg twice a week (0.50 mg/week)
~nd week: 0.50 mg/week twice a week (1 mg/week)
~rd week: 0.50 mg four times a week (2 mg/week)
~th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)"
11510787|NCT01278329|Experimental|Music|"Mothers in the music group were provided a pre-recorded Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India) with a running duration of approximately 50 minutes and a cassette player with headphones. They were asked to listen to the recorded music daily in the evening just before going to the bed with a minimum of ambient noise."
11510788|NCT01278329|No Intervention|Control|Standard routine ante-natal care.
11510789|NCT01278316|Experimental|Cognitive training|Cognitive Intervention Tasks Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
11510790|NCT01278316|Active Comparator|Control|The control group will perform computerized tasks that utilize cognitive performance, but were not systematically developed to improve cognitive performance.
11510791|NCT01278303|Other|Treatment of Aortic Wall Injury|Repair of aortic wall injury with covered CP Stents
11510792|NCT01278290|Active Comparator|Triptorelin test AND LHRH test|Patients undergo two tests with a test interval of at least 15 days
11510793|NCT01278290|Active Comparator|LHRH test AND Triptorelin test|Patients undergo two test with a test interval of al least 15 days.
11510794|NCT01278277|Placebo Comparator|placebo supplementation|patients will be assigned, in a cross-over design, to placebo or supplement administration
11510795|NCT01278277|Active Comparator|Saffron|Saffron Supplementation 20 mg/die
11510796|NCT01278264|Active Comparator|iTAP-group|Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
11510797|NCT01278264|Active Comparator|aTAP-group|Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
11510798|NCT01278251||Endobutton|
11510799|NCT01278238|Active Comparator|Phenylephrine|
11510800|NCT01278238|Active Comparator|Lower limb compression|
11510801|NCT01278238|Placebo Comparator|Placebo|
11510802|NCT01278225||EEG biofeedback (BF) Group|Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions. After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
11510803|NCT01278225||Wait-List Control (WLC) Group|Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits. After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
11510804|NCT01278212|Experimental|AHF-RT|"accelerated hypofractionated radiotherapy (AHF-RT)
~30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy"
11510805|NCT01278199|Other|2|Medicals measures in the treatment of non-severe acute hemoptysis
11510806|NCT01278199|Experimental|1|bronchial artery embolization (BAE)
11510807|NCT01278186|Experimental|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon catheter (SeQuent Please, B. Braun)
11510808|NCT01278186|Experimental|Paclitaxel-eluting stent|Paclitaxel-eluting stent
11510809|NCT01278173|Other|Sabril|
11510810|NCT01278160|Experimental|BIAsp 30 (2:1)|After discontinuation of previous treatment of once daily biphasic insulin aspart 30 (BIAsp 30) or insulin glargine combined with metformin and glimepiride in trial BIAsp-3756, subjects were adminstered BIAsp 30 twice daily with initial dosage split regimen of 2/3 and 1/3 total daily dose before breakfast and before dinner, respectively combined with metformin administered orally with meals
11510811|NCT01278160|Experimental|BIAsp 30 (1:1)|After discontinuation of previous treatment of once daily biphasic insulin aspart 30 (BIAsp 30) or insulin glargine combined with metformin and glimepiride in trial BIAsp-3756, subjects were adminstered BIAsp 30 twice daily with initial dosage split regimen of 1/2 and 1/2 total daily dose before breakfast and before dinner, respectively combined with metformin administered orally with meals
11510812|NCT01278147|No Intervention|controle|patient without fatigue education program
11510813|NCT01278147|Experimental|Education program|the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
11510814|NCT01278134|Experimental|Arm B Extension|All patients in treatment arm B were offered to receive Pegasys/Cogepus therapy for an additional 24 weeks.
11510815|NCT01278134|Experimental|RO5024048 & ritonavir-boosted danoprevir without Ribavirin (B)|
11510816|NCT01278134|Experimental|RO5024048 and ritonavir-boosted danoprevir with Ribavirin (A)|
11510817|NCT01278121|Other|Diet A: High-fat diet|"Diet given for 3 days to reset all of the participants"
11510818|NCT01278121|Active Comparator|Diet B: A carbohydrate-restricted diet|The diet will be given for 10 days, 6 meals a day
11510819|NCT01278108|Experimental|1|single ascending doses
11510820|NCT01278108|Placebo Comparator|2|single dose placebo
11510821|NCT01278108|Experimental|3|multiple dose, 7 days, capsules (dosing depends on outcome of single-dose part; can be once or twice daily).
11510822|NCT01278108|Placebo Comparator|4|multiple dose, capsules, 7 days; scheme to match that of Study Arm 3.
11510823|NCT01278095|Experimental|GLPG0555 solid dispersion, fasting|50 mg as solid dispersion capsule, in fasting condition
11510824|NCT01278095|Experimental|GLPG0555 solid dispersion, fed|50 mg as solid dispersion capsule, after breakfast
11510825|NCT01278095|Experimental|GLPG0555 nanosuspension, fed|50 mg as nanosuspension, given after breakfast
11510826|NCT01278082|Experimental|A|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
11510827|NCT01278082|Placebo Comparator|B|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
11510828|NCT01278056|Experimental|Exjade|
11510829|NCT01278030|No Intervention|Control group|Patients will be implanted according to the standard of care with the LV lead in the traditional LV lead position.
11510830|NCT01278030|Experimental|3D echo-guided LV lead placement group|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on Real-Time 3-Dimensional Echocardiography (RT3DE) will be available to the physician at the time of implant. This location will be used as the target for optimal LV lead placement.
11510831|NCT01278017|Experimental|ceftriaxone|
11510832|NCT01278004|Placebo Comparator|Placebo|Placebo capsule
11510833|NCT01278004|Experimental|Drug|
11510834|NCT01277991|Experimental|Sequence 1|
11510835|NCT01277991|Experimental|Sequence 2|
11510836|NCT01277978||Carbetocin|Women undergoing elective caesarean sectio in regional anesthesia randomised to receive 100 ug Carbetocin (the clinical standard dose) following delivery of the baby.
11510837|NCT01277978||Oxytocin|Women undergoing elective caesarean sectio in regional anesthesia randomised to receive 5 IU oxytocin (the clinical standard dose) following delivery of the baby.
11510838|NCT01277965|Other|50% VO2 max, BFR reduced by 50%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%
11511397|NCT01274273|Active Comparator|Interleukin-2 and interferon-alfa|
11510839|NCT01277965|Other|50% VO2 max,BFR reduced by 80%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%
11510840|NCT01277965|Other|75% VO2 max, BFR reduced by 80%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%.
11510841|NCT01277965|Other|75% VO2 max, pump switched off|Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed.
11510842|NCT01277965|Other|Rest|Patient will be in rest, basal insulin flow rate will not be change.
11510843|NCT01277952|Experimental|DBS Surgery|Deep brain stimulation (DBS) will be the treatment option in this study along with behavioral interventions for participants with severe disability due to Traumatic Brain Injury (TBI) 24 months post their injury, the participants will have severe disabilities in behavioral and emotional self-regulation, cognitive impairments and somatic symptoms.
11510844|NCT01277939|Experimental|Therapeutic Education System (TES)|Experimental (E) condition, the Therapeutic Education System (TES) delivered via effective informational technologies and multimedia learning tools.
11510845|NCT01277939|Active Comparator|Standard Care|The Control (C) condition, Standard Care, consisting of psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
11510846|NCT01277913|Experimental|Vitamin D 1000 IU|vitamin D will be given 1000 IU for 12 months
11510847|NCT01277913|Active Comparator|Vitamin D 500IU|vitamin D 500 IU will be given for 12 months once daily
11510848|NCT01277900||Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
11510849|NCT01277887|Active Comparator|Cognitive-Behavioral Counseling|The intervention consists of 8 sessions provided over 10 weeks. Counseling commences 4 weeks before quitting smoking. Participants will also receive the nicotine patch for 6 weeks starting on the day of quit date.
11510850|NCT01277887|Placebo Comparator|Smoking Cessation Counseling|The intervention consists of 8 sessions provided over 10 weeks. Counseling commences 4 weeks before quitting smoking. Participants will also receive the nicotine patch for 6 weeks starting on the day of quit date.
11510851|NCT01277874|Active Comparator|Nasal CPAP|Standard Nasal CPAP
11510852|NCT01277874|Active Comparator|Oscillatory NCPAP|NCPAP will be given to infant via prongs in the infant's nose. A Bird Industries pneumatic oscillating diaphragm to drive a Bird Industries phasatron which is attached by T-connector to the NCPAP patient circuit.
11510853|NCT01277861|Active Comparator|FENTANYL|FENTANYL
11510854|NCT01277861|Placebo Comparator|SALINE|SALINE
11510855|NCT01277835|Experimental|Lidocaine Infusion|
11510856|NCT01277835|Placebo Comparator|Placebo|Saline Infusion
11510857|NCT01277822|Experimental|Losartan/amlodipine Treatment Arm|One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks.
11510858|NCT01277822|Active Comparator|Amlodipine Treatment Arm|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks.
11510859|NCT01277809|No Intervention|Usual Care|Participants will receive care as usual (Usual Care Group; UCG) that is provided by their long-term care unit.
11510860|NCT01277809|Active Comparator|Interpersonal Interaction|Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program. This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the walking group. This interaction time will occur with the participant stationary, rather than walking with the researcher.
11510861|NCT01277809|Experimental|Walking Program|Participants will walk five times per week under the supervision of a licensed physiotherapist.
11510862|NCT01277783|Experimental|Endocardial Left Ventricular pacing|All patients will undergo the intervention, and are followed at 1, 3, 6, and 12 months (minimum) and biannually thereafter until 1 year after enrollment of the last patient.
11510863|NCT01277770||Kidney Transplant Recipients|Kidney Transplant Recipients at the University of Minnesota since 1984. The study looks at a 10 year followup of steroid-free maintenance immunosuppression, post-transplant infections and evaluation of the DGF nomogram in Thymoglobulin on patients at the University of Minnesota.
11510864|NCT01277757|Experimental|Treatment (Akt inhibitor MK-2206)|Akt Inhibitor MK-2206 mg orally once a week on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11510865|NCT01277744|Experimental|HIPEC + Cisplatin|HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions. Cisplatin 100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the Cisplatin.
11510866|NCT01277731|Experimental|Methylprednisolone replacement|"This study will enroll the patients who were previously experienced dexamethasone-induced hiccup. Patients who experienced dexamethasone-induced hiccup during chemotherapy will enroll to study arm.
~Run-in period * Dexamethasone 10mg-20mg q day iv during chemotherapy
~▶ measure hiccup and nausea/vomiting severity
~Treatment period * Methylprednisolone 60mg-125mg iv during chemotherapy
~▶ measure hiccup and nausea/vomiting severity
~Response will be evaluated by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE) and NRS to hiccup at 24hrs after start methylprednisolone.
~Nausea and vomiting will be assessed as CTCAE 4.0"
11510910|NCT01277471|Experimental|Arm A: 6 and 2 meals/day|6 meals/day for the first 12 weeks followed by 2 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
11510911|NCT01277471|Active Comparator|Arm B: 2 and 6 meals/day|2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
11510912|NCT01277458||Non white HIV positive men who have sex with men|
11510913|NCT01277445|Placebo Comparator|Placebo|15g/day maltodextrin for 28 days
11512215|NCT01268618|Placebo Comparator|Placebo|
11510867|NCT01277718|Experimental|Treatment A first, then Treatment B, followed by Treatment C|Treatment A in Period 1: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliters (mL) room temperature water after at least an 8-hour fast. Treatment B in Period 2: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1, 20 mg rabeprazole will be administered in fasted state followed by one 20-mg tablet of cobimetinib administration orally with 240 mL room temperature water after at least an 8-hour fast. Treatment C in Period 3: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1, 20 mg rabeprazole will be administered in fasted state. Approximately 30 minutes later, participants will be provided a standardized Food and Drug Administration (FDA) high-fat meal, and approximately 30 minutes after starting meal, one 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water. There will be a 13-day washout between cobimetinib doses of each period.
11510868|NCT01277718|Experimental|Treatment A first, then Treatment C, followed by Treatment B|Treatment A in Period 1: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast. Treatment C in Period 2: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1 of the treatment period, 20 mg rabeprazole will be administered in fasted state. Approximately 30 minutes later, participants will be provided a standardized FDA high-fat meal, and approximately 30 minutes after starting meal, one 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water. Treatment B in Period 3: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1 of treatment period, 20 mg rabeprazole will be administered in fasted state followed by one 20-mg tablet of cobimetinib administration orally with 240 mL room temperature water after at least an 8-hour fast. There will be a 13-day washout between cobimetinib doses of each period.
11510869|NCT01277705|Experimental|Group A|
11510870|NCT01277705|Experimental|Group B|
11510871|NCT01277705|Active Comparator|Group C|
11510872|NCT01277692|Experimental|Part 1: Single Dose Escalation in Healthy Subjects|The doses currently planned are 10, 30mg, 100mg, 200mg
11510873|NCT01277692|Experimental|Part 2: Repeat Dose Escalation in Healthy Subjects|The first planned dose is currently 10mg QD and the planned maximum dose is 100mg QD
11510874|NCT01277692|Experimental|Part 3: Single Dose Escalation in HCV Infected Subjects|The planned doses for Part 3 are 5mg, 30mg, and 100 mg.
11510875|NCT01277679|Other|Healthy Volunteer|Healthy Volunteer cohort
11510876|NCT01277679|Other|Heart Failure|Heart Failure cohort
11510877|NCT01277666|Placebo Comparator|Placebo|orally administered
11510878|NCT01277666|Experimental|GSK1605786A 500mg once daily|orally administered
11510879|NCT01277666|Experimental|GSK1605786A 500mg twice daily|orally administered
11510880|NCT01277653||PIVKA-II and AFP 6 months|PIVKA-II and AFP measurement every 6 months
11510881|NCT01277653||tumor maker interval every 6 month|tumor maker interval every 6 month
11510882|NCT01277640|Placebo Comparator|matched placebo|
11510883|NCT01277640|Placebo Comparator|universal placebo|
11510884|NCT01277640|Active Comparator|dapivirine|
11510885|NCT01277627|Active Comparator|Nevirapine|
11510886|NCT01277627|Active Comparator|Non-nevirapine|
11510887|NCT01277614|Experimental|Lifestyle counseling|This is a 6-month intervention in which participants with 2 or more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
11510888|NCT01277614|Placebo Comparator|Health Literature|
11510889|NCT01277601|Experimental|TDF+Peg-IFN 48 Weeks|TDF plus Peg-IFN for 48 weeks
11510890|NCT01277601|Experimental|TDF 48 Weeks + Peg-IFN 16 Weeks|TDF plus Peg-IFN for 16 weeks, followed by TDF alone for an additional 32 weeks
11510891|NCT01277601|Active Comparator|TDF 120 Weeks|TDF monotherapy for 120 weeks
11510892|NCT01277601|Active Comparator|Peg-IFN 48 Weeks|Peg-IFN monotherapy for 48 weeks
11510893|NCT01277588||Patient|
11510894|NCT01277588||Physcician|
11510895|NCT01277575|Experimental|Verum stimulation|repetitive transorbital alternating current stimulation (rtACS)
11510896|NCT01277575|Sham Comparator|Placebo stimulation|Sham stimulation (placebo condition) no intervention
11510897|NCT01277562||Breast Cancer|Non-metastatic breast cancer with recent diagnosis of osteopenia or osteoporosis
11510898|NCT01277562||Prostate Cancer|Non-metastatic prostate cancer with recent diagnosis of osteopenia or osteoporosis
11510899|NCT01277549||Non-mobilized donors|In this arm the collection efficiency of mononuclear cells from non-mobilized donors will be studied.
11510900|NCT01277549||G-CSF mobilized donors|In this arm the collection efficiency of CD34+ cells will be studied.
11510901|NCT01277536||hospitalization >24 hours|
11510902|NCT01277523|Experimental|A|
11510903|NCT01277523|Experimental|B|
11510904|NCT01277523|Placebo Comparator|C|
11510905|NCT01277510|Placebo Comparator|Placebo|Participants received standard of care and placebo once daily for 30 weeks during the double-blind phase. During the open-label phase, participants received cinacalcet with standard of care for an additional 30 weeks. The starting dose of cinacalcet was ≤ 0.20 mg/kg based on dry weight, and could be titrated up according to plasma iPTH and serum calcium levels every 4 weeks up to Week 54 to a maximum dose of 4.2 mg/kg.
11510906|NCT01277510|Experimental|Cinacalcet|Participants received standard of care and cinacalcet once daily for 30 weeks during the double-blind phase. The starting dose of cinacalcet was ≤ 0.20 mg/kg based on dry weight, and could be titrated up according to plasma iPTH and serum calcium levels every 4 weeks until Week 24 to a maximum dose of 4.2 mg/kg. During the open-label phase participants continued to receive cinacalcet with standard of care for an additional 30 weeks.
11510907|NCT01277497|Experimental|Sevelamer carbonate|1,600 mg (2 x 800 mg) three times daily with meals for a total of 12 weeks
11510908|NCT01277497|Active Comparator|Calcium acetate|1,334 mg (2 x 667 mg) three times daily with meals for a total of 12 weeks
11510909|NCT01277484|Experimental|Decitabine, MDS treatment, IV injection|For the patients who achieve remission after allogeneic BMT and meet the enrollment criteria, decitabine will be given at a dose of 5mg/kg/day ~ 15mg/kg/day iv over 1 hour for 5 consecutive days starting 42-90 days after transplantation. The drug will be repeated every 4 weeks for up to 12 cycles.
11510915|NCT01277432||Psychiatrist interview|"All patients will receive the same assessments as the 'active comparator' arm, but in addition those patients found to have positive symptoms for mild to severe depression by PHQ9 or CESD (PHQ>10 and/or CES>16) and a random sample of subjects with no or mild symptoms will also undergo a face-to-face interview by a trained clinician or psychiatrist using the following instruments:
~MINI
~SSI-28 (somatization)"
11510916|NCT01277432||Depression screening|"All study participants will undergo a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal.
~All patients will also undergo detailed psychological and behavioral assessments using validated questionnaires.
~Several specialist questionnaires will also be conducted with all patients, including those on depression, self care and quality of life;
~Patient Health Questionnaire (PHQ-9)
~Depression Anxiety and Stress Scale (DASS-21)
~Diabetes Distress Scale (DDS-17)
~Life events questions (Inter-Heart Study)
~Diabetes Empowerment Scale (C-DES 20)
~Summary of Diabetes Self Care Activities (SDSCA-15)
~Euroqol-5D (EQ-5D)"
11510917|NCT01277419||Ankylosing spondylitis|Ankylosing spondylitis according to the modified New York criteria
11510918|NCT01277419||Non-radiographic axial spondyloarthritis|Patients with clinical characteristics of axial SpA but not fulfilling the modified New York criteria for which radiographic sacroiliitis is essential.
11510919|NCT01277419||Juvenile spondyloarthritis|Patients with juvenile spondyloarthritis (juvenile ankylosing spondylitis, juvenile non-AS-spondyloarthritis).
11510920|NCT01277419||Crohn's disease|Crohn's disease with duration of symptoms ≤5 years
11510921|NCT01277419||Acute anterior uveitis|Patients with acute anterior uveitis
11510922|NCT01277419||Axial psoriatic arthritis|Patients with psoriatic arthritis with axial involvement (sacroiliac joints and/or spine)
11510923|NCT01277406|Experimental|4SC-201+FOLFIRI|
11510924|NCT01277406|Active Comparator|FOLFIRI|
11510925|NCT01277393||Experimental Group|
11510926|NCT01277393||Control Group|
11510927|NCT01277380||Experimental Group|
11510928|NCT01277380||Control Group|
11510929|NCT01277380||Negative control group|
11510930|NCT01277367|Active Comparator|A|These members will be offered no additional incentives
11510931|NCT01277367|Experimental|B|These members will receive regular communications by Discovery Vitality.
11510932|NCT01277367|Experimental|C|These members will nominate a charity which will benefit financially based on participants' level of physical activity.
11510933|NCT01277367|Experimental|D|These members are entered into a prize draw for a monthly cash prize if they achieve physical activity targets.
11510934|NCT01277367|Experimental|E|These members will receive a direct payment.
11510935|NCT01277367|Experimental|F|These members will be offered the opportunity to choose one of three incentive options at the time of enrollment in the study.
11510936|NCT01277354|Active Comparator|Cognitive Processing Therapy|Participants are seen weekly for six weeks for therapy. At visits 2, 4, and 6 they also complete ratings.
11510937|NCT01277354|Placebo Comparator|Waitlist|Participants come in at the end of weeks 2, 4, and 6 to complete ratings but do not receive therapy.
11510938|NCT01277341|Experimental|2% Twice a day|Bepotastine Besilate Nasal Spray 2% Twice a day
11510939|NCT01277341|Experimental|3% Twice a day|Bepotastine Besilate Nasal Spray 3% Twice a day
11510940|NCT01277341|Experimental|4% Twice a day|Bepotastine Besilate Nasal Spray 4% Twice a day
11510941|NCT01277341|Placebo Comparator|Placebo|Placebo nasal spray
11510942|NCT01277328||Cohort|Cohort
11510943|NCT01277302|Experimental|Ranibizumab 0.5 mg monthly - randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific visual acuity and spectral-domain optical coherence tomography (VA-OCT) stability criteria were met and randomization occurred to the monthly arm. At subsequent monthly visits after randomization, injections were given whether the VA-OCT stability criteria were met or not met. Subjects were to receive 15 ranibizumab 0.5 mg injections.
11510944|NCT01277302|Experimental|Ranibizumab 0.5 mg PRN - randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific VA-OCT stability criteria were met and randomization occurred to the PRN arm. No injection was given at the randomization visit. At subsequent monthly visits after randomization, injections were given if the VA-OCT stability criteria were not met and no injections were given if the VA-OCT stability criteria were met. Subjects could receive between 7 and a maximum of 14 ranibizumab 0.5 mg injections.
11510945|NCT01277302|Experimental|Ranibizumab 0.5 mg monthly - non-randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections and then never met the study-specific VA-OCT stability criteria from month 7 to month 14. Subjects were to receive 15 ranibizumab 0.5 mg injections.
11510946|NCT01277289|Experimental|Ery-dex|Ery-dex (dexamethasone sodium phosphate)is administered as intra-erythrocyte drug at monthly interval
11510947|NCT01277289|Placebo Comparator|Placebo|placebo comparator (sodium chloride instead of dexamethasone sodium phosphate) is administered in infusion at monthly interval.
11510948|NCT01277276||Diagnostic tool|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
11510949|NCT01277250|Other|Usual Care|Standard smoking cessation information provided to all hospitalized patients as part of discharge packet.
11510950|NCT01277250|Experimental|Smoking Cessation Program|"Web-based program tailored to patients who smoke and are hospitalized. Program is tailored to participant's specific hospital experience and other characteristics. E-messages, social support and a transition coach are provided to each participant in this condition."
11510951|NCT01277237|Active Comparator|Omacor|
11510952|NCT01277237|Placebo Comparator|Lactose tablet|
11510953|NCT01277224|Experimental|Movi2 Program|
11510954|NCT01277224|No Intervention|Control|
11510955|NCT01277211|Experimental|ENG-EE (NuvaRing)|Participants were to complete 13 cycles of etonogestrel (ENG) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day ring-free period. Participants used one ring per cycle. Each ring contained 11.7 mg ENG and 2.7 mg EE, and released on average 120 mcg/day of ENG and 15 mcg/day of EE.
11511014|NCT01276873|Experimental|Closed System|Application of Tracheal aspiration closed system, controlled by the use of Open system to tracheal aspiraiton.
11510956|NCT01277211|Active Comparator|DRSP-EE|Participants were to complete 13 cycles of drospirenone (DRSP) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received a total of 21 tablets of DRSP-EE per cycle. Each tablet contained 3 mg DRSP and 30 μg EE.
11510957|NCT01277198||surgery without using a flexible cystoscopy|surgery without using a flexible cystoscopy: patients who did not undergo a flexible cystoscopy during laparoscopic stone surgery
11510958|NCT01277198||surgery with using a flexible cystoscopy|surgery with using a flexible cystoscopy: patients who underwent a flexible cystoscopy during laparoscopic stone surgery
11510959|NCT01277185|Active Comparator|Low Calcium Diet (600-1200 mg/d)|
11510960|NCT01277185|Active Comparator|High Calcium Diet (1100-2300mg/d)|
11510961|NCT01277172|Experimental|Group 1 / PBO-326|This group will be treated three cycles with PBO-326, after the third cycle the patients will receive Mabthera for another three cycles.
11510962|NCT01277172|Active Comparator|Group 2 / Mabthera|This group will be treated three cycles with Mabthera, after the third cycle the patients will receive PBO-326 for another three cycles.
11510963|NCT01277172|Experimental|Group 3 / PBO-326|This group will be treated six cycles with PBO-326
11510964|NCT01277172|Active Comparator|Group 4 / Mabthera|This group will be treated six cycles with Mabthera
11510965|NCT01277159|Experimental|Control Nerve Block. IV Dexamethasone (4 mg).|Control Nerve Block. IV Dexamethasone (4 mg).
11510966|NCT01277159|Experimental|Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
11510967|NCT01277159|Experimental|Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp|Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
11510968|NCT01277159|Experimental|Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (|Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
11510969|NCT01277159|Experimental|Nerve Block with Dexamethasone (4 mg) / block Buprenorphine|Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
11510970|NCT01277146|Experimental|OMP-59R5|
11510971|NCT01277133||Cohort|
11510972|NCT01277120||Cohort|
11510973|NCT01277107|Experimental|Zaleplon AP formulation|Gastric Retentive Dual Release Zaleplon (Zaleplon AP)
11510974|NCT01277107|Placebo Comparator|Placebo|Identical placebo capsule
11510975|NCT01277094|Experimental|1|
11510976|NCT01277094|Placebo Comparator|2|
11510977|NCT01277081|Active Comparator|Paracetamol hot drink|Hot drink containing paracetamol
11510978|NCT01277081|Active Comparator|Paracetamol tablets|Paracetamol tablets
11510979|NCT01277068|Active Comparator|the adjustable gastric banding|
11510980|NCT01277068|Active Comparator|the sleeve gastrectomy|
11510981|NCT01277068|Active Comparator|the gastric bypass|
11510982|NCT01277042|Experimental|Cervarix Group|Subjects received a 3-dose vaccination course of the Cervarix™ vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
11510983|NCT01277042|Active Comparator|Engerix Group|Subjects received a 3-dose vaccination course of the Engerix™-B vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
11510984|NCT01277029||lower urinary tract symptoms|
11510985|NCT01277016|No Intervention|MDex:|"MDex:
~Administration of oral melphalan (M) at 0.22 mg/kg and dexamethasone (Dex) at 40 mg daily for 4 consecutive days every 28 days (MDex) until end of therapy"
11510986|NCT01277016|Experimental|BMDex|"BMDex:
~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle."
11510987|NCT01277003|Experimental|Aculife Magnetic Wave Therapist|patients with carpal tunnel syndrome treated with Aculife
11510988|NCT01277003|Active Comparator|TENS|patients with carpal tunnel syndrome treated by TENS
11510989|NCT01276990|Placebo Comparator|Placebo|Matching placebo in dosing regimen 1-8
11510990|NCT01276990|Experimental|BI 224436 dosing regimen 1|Dosing regimen 1
11510991|NCT01276990|Experimental|BI 224436 dosing regimen 2|Dosing regimen 2
11510992|NCT01276990|Experimental|BI 224436 dosing regimen 3|Dosing regimen 3
11510993|NCT01276990|Experimental|BI 224436 dosing regimen 4|Dosing regimen 4
11510994|NCT01276990|Experimental|BI 224436 dosing regimen 5|Dosing regimen 5
11510995|NCT01276990|Experimental|BI 224436 dosing regimen 6|Dosing regimen 6
11510996|NCT01276990|Experimental|BI 224436 dosing regimen 7|Dosing regimen 7
11510997|NCT01276990|Experimental|BI 224436 dosing regimen 8|Dosing regimen 8
11510998|NCT01276977|Experimental|Zolmitriptan 5 mg nasal spray|
11510999|NCT01276977|Active Comparator|Eletriptan 40 mg Tablet|
11511000|NCT01276964||1. Women in the fertile age|Healthy women in the fertile age (between 20-45 years) with apparently normal periods
11511001|NCT01276951|Placebo Comparator|Placebo|
11511002|NCT01276951|Active Comparator|6,5g Dose Group|
11511003|NCT01276951|Active Comparator|12g Dose Group|
11511004|NCT01276951|Active Comparator|25g Dose Group|
11511005|NCT01276951|Active Comparator|50g Dose Group|
11511006|NCT01276938|Active Comparator|IORT 21 Gy|Single fraction 21 Gy Intraoperative Radiation Therapy for breast tumors with diameter between 10 and 25 mm
11511007|NCT01276938|Experimental|IORT 18 Gy|Single fraction 18 Gy Intra Operative Radiation Therapy in breast tumors smaller than 10 mm.
11511008|NCT01276925|Active Comparator|B3: Blockade of three nerves|Peripheral nerve blockade of the femoral nerve, the anterior division of the obturator nerve, and the lateral femoral cutaneous nerve with ropivacaine.
11511009|NCT01276925|Active Comparator|B2: Blockade of 2 nerves|"Peripheral nerve blockade of the anterior division of the obturator nerve and the lateral femoral cutaneous nerve with ropivacaine.
~Sham blockade of the femoral nerve with saline."
11511010|NCT01276925|Sham Comparator|K: Control group|Sham blockade of the femoral nerve, the anterior division of the obturator nerve, and the lateral femoral cutaneous nerve with saline.
11511011|NCT01276899||Neoadjuvant setting|
11511012|NCT01276899||Metastatic setting|
11511013|NCT01276886||Acute Diverticulitis|
11511015|NCT01276860|Other|Psychomotor Vigilance Testing|The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
11511016|NCT01276847|Experimental|Ustekinumab|
11511017|NCT01276847|Active Comparator|Etanercept|
11511018|NCT01276847|No Intervention|No treatment|
11511019|NCT01276834|Experimental|everolimus-based immunosuppression|immunosuppression with everolimus, prednisone and mycophenolate
11511020|NCT01276834|Active Comparator|standard immunosuppression|immunosuppression with tacrolimus, prednisone and mycophenolate
11511021|NCT01276821|Placebo Comparator|Standard Treatment|L-Epinephrine and Normal Saline (0.9%)
11511022|NCT01276821|Active Comparator|Study Treatment|L-Epinephrine and Hypertonic Saline (3%)
11511023|NCT01276808|Experimental|Magnetic navigation PCI|These patients will be treated with magnetically navigated percutaneous coronary intervention
11511024|NCT01276808|Active Comparator|Conventional PCI|These patients will be treated with normal standard percutaneous coronary intervention
11511025|NCT01276795|Experimental|Glucose and whey protein|Patients who are randomly allocated to this group will receive a drink made of anhydrous beet dextrose and pressurized whey protein in water (200 g/L + 100g/L). Patients will sip the drink for 4 hours of the 6 hour study.
11511026|NCT01276795|Active Comparator|Glucose only|The patients who are randomly allocated to this arm will receive a drink composed of anhydrous beet dextrose in water (200g/L). They will sip the drink for 4 hours of the 6 hour study.
11511027|NCT01276782|Placebo Comparator|Pregnant SLE|Pregnant SLE patients with autoimmune thyroid antibodies will be randomized to levothyroxine or Placebo
11511028|NCT01276769|Active Comparator|ET|The control arm receive the paclitaxel plus epirubicin
11511029|NCT01276769|Experimental|PC|the experimental arm which receive the paclitaxel combined with carboplatin
11511030|NCT01276756|Active Comparator|Standard of care|Group A: comprises 50 treatment-naive chronic hepatitis c patients who will receive the standard of care treatment: peginterferon Alfa 2a 160 ug once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
11511031|NCT01276756|Experimental|Triple therapy|Group B: comprises 50 treatment-naive chronic HCV patients who will receive oral Nitazoxanide 500 mg twice daily for 4 weeks (lead-in phase) followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (160ug once weekly) and weight-based ribavirin 1000-1200 mg daily (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
11511032|NCT01276743||T1DM|Children and adolescents with T1DM
11511033|NCT01276743||Unaffected Population|Population not known to be affected by T1DM
11511034|NCT01276730|Experimental|Group A|Treatment consists of Interferon, given as a sub-cutaneous injection, 3 times per week for 4 weeks, 20 mg Retinoic Acid tablets, 2 times a day for 30 days. starting from the first day of radiation.
11511035|NCT01276730|Active Comparator|Group B|"Treatment consists of radiation and chemotherapy using Cisplatin. Cisplatin, given intravenously, will be administered on the first day of each week, mixed with saline solution, before and after the Cisplatin infusion.
~Radiation will be given for a few minutes daily, five days a week, for approximately 5 weeks.
~Two weeks after completion of external radiotherapy, subject will receive internal radiation (brachytherapy) once a week for two weeks. For this internal radiation a specially designed instrument will be inserted into the vagina that will be connected to a machine for a few minutes."
11511036|NCT01276717|Experimental|Vorinostat + Carfilzomib|
11511037|NCT01276704|Experimental|flaxseed lignan, SDG|Secoisolariciresinol diglycoside
11511038|NCT01276704|Placebo Comparator|Placebo|Matched Placebo
11511039|NCT01276691|Active Comparator|Acute, Aspirin|81 mg asprin provided 30 minutes prior to firefighting- Acute single dosage
11511040|NCT01276691|Placebo Comparator|Acute, Placebo|Acute single dosage of placebo provided 30 minutes prior to firefighting
11511041|NCT01276691|Active Comparator|Chronic, Aspirin|81 mg asprin provided prior to firefighting- 14 day dosage
11511042|NCT01276691|Placebo Comparator|Chronic, Placebo|14 day dosage of placebo provided prior to firefighting
11511043|NCT01276678||Control|300 healthy controls free from any pharmacologic therapy
11511044|NCT01276678||Suspected CAD - Cardiac Cathetrization|subject's ≥18 years undergoing coronary angiography (inpatient cohort)or who have undergone coronary angiography within 5 years
11511045|NCT01276665|Experimental|Restrictive regimen group|treated with a restrictive fluid regimen of 2ml/kg/h of crystalloids in combination with sympathicomimetics.
11511046|NCT01276665|Active Comparator|Control group|treated according to an internationally accepted standard fluid regimen (6 ml/kg/h of crystalloids and correction of the hypotony with fluid boluses)
11511047|NCT01276652|Active Comparator|Environmental modification|Subjects assigned to this group receive the environmental modification intervention for 48 hours beginning the morning after enrollment.
11511048|NCT01276652|No Intervention|Usual care (randomized)|"Usual care is provided for the first 48 hours. Subsequently, in the initial protocol, subjects received 48 hours of the environmental modification intervention so long as they remained in the ICU during this time. The opportunity to receive the Delayed intervention was later removed from the protocol."
11511049|NCT01276652|No Intervention|Usual care (observational)|Usual care was provided.
11511050|NCT01276639|Experimental|Active Treatment 10 mg BID|
11511051|NCT01276639|Experimental|ActiveTreatment 5 mg BID|
11511052|NCT01276639|Placebo Comparator|Placebo Treatment|
11511053|NCT01276626|Experimental|Bifidobacterium longum|
11511054|NCT01276626|Placebo Comparator|Maltodextrin|
11511055|NCT01276613|Experimental|Intraoperative Gemcitabine|Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min. Drug infusion started 100 minutes prior to complete gross tumor removal in order to have drug administration complete at tumor removal.
11511150|NCT01276054|Experimental|SNB plus ARM or ALND (+/- SNB) plus ARM|Patients undergo sentinel lymph node biopsy (SNB) and/or axillary lymph node biopsy (ALND) using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node. Patients then undergo an axillary reverse mapping.
11511056|NCT01276613|Experimental|Intraoperative Gemcitabine + Losartan|"Losartan 50 mg by mouth daily for one week and 50 to 100 mg of Losartan by mouth daily for at least 1 week and at most 3 weeks prior to surgical resection.
~Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min. Drug infusion started 100 minutes prior to complete gross tumor removal in order to have drug administration complete at tumor removal."
11511057|NCT01276600|Experimental|Arm 1|1 tablet orally weekly
11511058|NCT01276600|Experimental|Arm 2|One tablet orally twice weekly
11511059|NCT01276600|Experimental|Arm 3|Two tablets orally twice weekly
11511060|NCT01276600|Experimental|Arm 4|One tablet orally daily
11511061|NCT01276587|Experimental|Single arm|
11511062|NCT01276561|Active Comparator|Single Incision Splenectomy|Patients will undergo splenectomy through a single incision in the umbilicus regardless of the technique or equipment used
11511063|NCT01276561|Active Comparator|Laparoscopic Splenectomy|Patient will undergo standard laparoscopic splenectomy, port placement is surgeon dependent
11511064|NCT01276548|Experimental|Genexol®-PM plus Carboplatin|
11511065|NCT01276548|Active Comparator|Genexol® plus Carboplatin|
11511066|NCT01276535|Experimental|Erchonia MLS + Erchonia THL|"The Erchonia® MLS contains 5 independent diodes: 4 each emitting 17 milliwatt (mW) 635 nanometers (nm) of red laser light and the fifth diode emitting 17 mW, 405 nm of blue laser light.
~The Erchonia THL is a single diode pulsed laser that emits 4.9 milliwatts (mW) of red 635 nanometer (nm) light."
11511067|NCT01276522|Experimental|Canakinumab|A 6-month open-label, single treatment arm study of canakinumab 150 or 300 mg (in case of insufficient response to 150 mg) subcutaneous injection once per month.
11511068|NCT01276509|Placebo Comparator|Placebo-SC Injection|Placebo delivered SC, 3 doses separated by 4 weeks.
11511069|NCT01276509|Experimental|Drug Dose level 1- SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks.
11511070|NCT01276509|Experimental|Drug Dose level 2-SC injection|Drug dose level 2 delievered SC, 3 doses separated by 4 weeks.
11511071|NCT01276509|Experimental|Drug Dose level 3- SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks.
11511072|NCT01276496|Experimental|Treatment (cilengitide, paclitaxel)|"Patients receive cilengitide IV over 1 hour on days* 1, 8, and 15 and paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~NOTE: *Some patients receive cilengitide IV over 1 hour on days 1, 2, 8, 9, 15, and 16."
11511073|NCT01276470||1|150 subjects with the anti-synthetase syndrome
11511074|NCT01276470||2|150 subjects with myositis without anti-synthetase syndrome
11511075|NCT01276470||3|150 matched volunteers without autoimmune disease
11511076|NCT01276457|Experimental|Upper everolimus blood target + very low dose cyclosporine|Patients received everolimus orally twice daily at a dose that was adjusted to achieve a drug blood trough level in the range of 8-12 ng/mL. Patients also received a very low dose of cyclosporine (150-300 ng/mL) orally twice daily that was adjusted to maintain a drug blood level of 200 ng/mL 2 hours after the morning dose. Both drugs were taken in the morning and again 12 hours later. The drugs were taken consistently either before, during, or after meals. No grapefruit or grapefruit juice was allowed throughout the study.
11511077|NCT01276457|Active Comparator|Standard everolimus blood target + low dose cyclosporine|Patients received everolimus orally twice daily at a dose that was adjusted to achieve a drug blood trough level in the range of 3-8 ng/mL. Patients also received a low dose of cyclosporine (350-500 ng/mL) orally twice daily that was adjusted to maintain a drug blood level of 400 ng/mL 2 hours after the morning dose. Both drugs were taken in the morning and again 12 hours later. The drugs were taken consistently either before, during, or after meals. No grapefruit or grapefruit juice was allowed throughout the study.
11511078|NCT01276444|Active Comparator|Pulmonary artery catheter (PAC)|PAC was used to guide hemodynamic therapy after combined valve repair
11511079|NCT01276444|Active Comparator|COMPLEX|An combination of transpulmonary thermodilution and continuous monitoring of central venous saturation was used to guide hemodynamic therapy after combined valve repair surgery.
11511080|NCT01276431|Other|Buprenorphine transdermal patch|For two age groups: 50-60 years and >= 75 years of age
11511081|NCT01276418|Experimental|Treatment|
11511082|NCT01276405||Cohort|
11511083|NCT01276392||Heparin|10 Patients undergoing continuous renal replacement therapy using heparin for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
11511084|NCT01276392||CiCa|10 Patients undergoing continuous renal replacement therapy using citrate for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
11511085|NCT01276379|Experimental|FOLFIRI (m) or FOLFOX-6 (m) + cetuximab|FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.
11511086|NCT01276366|Active Comparator|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
11511087|NCT01276366|Active Comparator|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
11511088|NCT01276366|Active Comparator|Breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
11511089|NCT01276353|Experimental|1|
11511090|NCT01276353|Active Comparator|2|
11511091|NCT01276340||1|women with urinary incontinence
11511092|NCT01276327|Experimental|1 Linagliptin/Pioglitazone (Test)|Fixed-Dose-Combination-Tablet, oral administration with 240 mL water
11511093|NCT01276327|Experimental|2 Linagliptin + Pioglitazone (Ref)|Tablets, oral administration with 240 mL water for each treatment
11511094|NCT01276327|Experimental|3 Linagliptin/Pioglitazone (Test)|Fixed-Dose-Combination-Tablet, oral administration with 240 mL water
11511095|NCT01276327|Experimental|4 Linagliptin + Pioglitazone (Ref)|Tablets, oral administration with 240 mL water for each treatment
11511151|NCT01276054|Active Comparator|SNB or ALND (+/- SNB)|Patients undergo SNB and/or ALND using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node.
11511367|NCT01274546||"In Office"|These subjects will come into the office to perform the consenting process, and complete all evaluations required at the only visit in the study.
11511096|NCT01276314|Experimental|anti- TNF-a treatment|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
~Fill out the case report form
~Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
~Etanercept administration:
~The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks"
11511097|NCT01276314|Active Comparator|control group|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF
~Fill out the case report form
~Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis
~Drug administration:
~The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose."
11511098|NCT01276301|Experimental|Reference|single dose BI 10773
11511099|NCT01276301|Active Comparator|Test|single dose BI 10773 + single dose verapamil
11511100|NCT01276288|Active Comparator|Reference 1|administration of BI 10773 once daily for 5 days (20 patients)
11511101|NCT01276288|Active Comparator|Reference 2|administration of hydrochlorothiazide (HTC) once daily for 4 days (10 patients)
11511102|NCT01276288|Active Comparator|Reference 3|administration of torasemide (TOR) once daily for 4 days (10 patients)
11511103|NCT01276288|Experimental|Test 1|administration of BI 10773 + HTC once daily for 5 days (10 patients)
11511104|NCT01276288|Experimental|Test 2|administration of BI 10773 + TOR once daily for 5 days (10 patients)
11511105|NCT01276275||Exposure Group 1|First time users of ticagrelor
11511106|NCT01276275||Exposure Group 2|First time users of clopidogrel
11511107|NCT01276275||Exposure Group 3|First time users of prasugrel
11511108|NCT01276262|Placebo Comparator|Treatment A|Monophasic oral contraceptive (Microgynon® 30) with placebo tablets
11511109|NCT01276262|Experimental|Treatment B|Monophasic oral contraceptive (Microgynon® 30) and fostamatinib
11511110|NCT01276249||Fortevo Endograft|All subjects diagnosed with a qualifying AAA suitable for elective endovascular repair, who meet the inclusion/exclusion criteria for the registry, are eligible for enrollment if treated with the Fortevo Endograft.
11511111|NCT01276236|Experimental|Treatment Arm (single-arm study)|The subjects in this arm will receive Maraviroc as treatment, while continuing their current antiretroviral medication regimen.
11511112|NCT01276223|Experimental|Durezol|Difluprednate 0.05% ophthalmic emulsion, 1 drop to the study eye 2 times a day for 4 weeks, followed by 1 drop to the study eye once daily for 1 week to allow for tapering of the steroid exposure.
11511113|NCT01276223|Placebo Comparator|Vehicle|Difluprednate vehicle, 1 drop to the study eye 2 times a day for 4 weeks, followed by 1 drop to the study eye once daily for 1 week.
11511114|NCT01276210|Experimental|Treatment|See Detailed Description
11511115|NCT01276197|Experimental|Arm 1: Story-Telling DVD|Participant will receive a DVD with informational and story-telling components
11511116|NCT01276197|Active Comparator|Arm 2: Non-Storytelling DVD|Participant will receive an informational DVD
11511117|NCT01276184|No Intervention|Usual Care|Participants follow the usual practices for scheduling their follow up visit(s) for vaccination at the clinic. Participants will receive the standard reminder from the clinic for their scheduled appointment(s) (phone call, letter, etc, as appropriate).
11511118|NCT01276184|Experimental|SMS Text Message|Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their scheduled appointment(s) (phone call, letter, etc, as appropriate). Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit.
11511119|NCT01276171|Active Comparator|Ultrasound|Participants will place arterial line using ultrasound technique
11511120|NCT01276171|Active Comparator|Doppler|Participants will place arterial line using doppler technique
11511121|NCT01276171|Active Comparator|Palpation|Participants will place arterial line using palpation technique
11511122|NCT01276158|Active Comparator|Ultrasound|Arterial line placed with Ultrasound guidance.
11511123|NCT01276158|Active Comparator|Doppler|Arterial line placed with doppler guidance
11511124|NCT01276132||Subjects who are designated to receive same-day PCI|
11511125|NCT01276132||Subjects who had been admitted to the hospital after their PCI|
11511126|NCT01276119|Experimental|Cohort A, CDP6038 0.001 mg/kg, iv|
11511127|NCT01276119|Experimental|Cohort B, CDP6038 0.01 mg/kg, iv|
11511128|NCT01276119|Experimental|Cohort C, CDP6038 0.03 mg/kg, iv|
11511129|NCT01276119|Experimental|Cohort D, CDP6038 0.1 mg/kg, iv|
11511130|NCT01276119|Experimental|Cohort E, CDP6038 0.3 mg/kg, iv|
11511131|NCT01276119|Experimental|Cohort G, CDP6038 1.0 mg/kg, iv|
11511132|NCT01276119|Experimental|Cohort I, CDP6038 3.0 mg/kg, iv|
11511133|NCT01276119|Experimental|Cohort K, CDP6038 10.0 mg/kg, iv|
11511134|NCT01276119|Placebo Comparator|Cohort A, Placebo, iv|
11511135|NCT01276119|Placebo Comparator|Cohort B, C, D, E, G, I, K, Placebo, iv|
11511136|NCT01276119|Experimental|Cohort F, CDP6038 0.3 mg/kg, sc|
11511137|NCT01276119|Experimental|Cohort H, CDP6038 1.0 mg/kg, sc|
11511138|NCT01276119|Experimental|Cohort J, CDP6038 3.0 mg/kg, sc|
11511139|NCT01276119|Placebo Comparator|Cohort F, H, J, Placebo, sc|
11511140|NCT01276106|Experimental|AC-201, 25mg|25mg BID for 24 weeks
11511141|NCT01276106|Experimental|AC-201, 50mg|50mg BID for 24 weeks
11511142|NCT01276106|Experimental|AC-201, 75mg|75mg BID for 24 weeks
11511143|NCT01276106|Placebo Comparator|Placebo|Placebo BID for 24 weeks
11511144|NCT01276093|Experimental|PVI ablation|Pulmonary Vein Ablation
11511145|NCT01276093|Active Comparator|Amiodarone medical treatment|Amiodarone medical treatment
11511146|NCT01276080|Experimental|1|Donepezil Hydrochloride 10 mg Tabletof OHM Laboratories, Inc.
11511147|NCT01276080|Active Comparator|2|ARICEPT® (donepezil hydrochloride) 10 mg Tablet of Eisai, Inc.
11511148|NCT01276067|Experimental|1|Donepezil Hydrochloride 10 mg Tabletof OHM Laboratories, Inc.
11511149|NCT01276067|Active Comparator|2|ARICEPT® (donepezil hydrochloride) 10 mg Tablet of Eisai, Inc.
11511152|NCT01276041|Experimental|pertuzumab in combination with trastuzumab and paclitaxel|This is a phase II study of pertuzumab in combination with trastuzumab and paclitaxel for the treatment of patients with Stage IV HER2 (+) breast cancer.
11511153|NCT01276028|Experimental|Acupuncture|This group will start acupuncture treatments within 3 weeks of consent and continue to receive up to 20 treatments over a six month period. The number of treatments will be jointly determined by the participant and the acupuncturist.
11511154|NCT01276028|Other|Waitlist|This group of participants will be asked to wait 6 months and will then be allowed to receive acupuncture.
11511155|NCT01276015|Experimental|botulinum toxin A|botulinum toxin A diffusion in cerebral palsy
11511156|NCT01276002|No Intervention|No stenting|Control group, no stenting of the pancreatic duct in case of a disrupted duct
11511157|NCT01276002|Active Comparator|Pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting in this arm
11511158|NCT01275989|Sham Comparator|21|sham acupuncture
11511159|NCT01275989|No Intervention|15|Control
11511160|NCT01275989|Active Comparator|20|intervention
11511161|NCT01275976|Active Comparator|C1-esterase inhibitor|C1-esterase inhibitor, 100 U/kg bodyweight
11511162|NCT01275976|Placebo Comparator|Saline 0.9%|Saline 0.9%
11511163|NCT01275963||Control|Healthy individuals without structural heart disease
11511164|NCT01275963||CAD|Patients with coronary artery disease
11511165|NCT01275963||DCM|Participants with dilated cardiomyopathy
11511166|NCT01275963||HNCM|Patients with hypertrophic non-obstructive cardiomyopathy
11511167|NCT01275963||HOCM|Patients with hypertrophic obstructive cardiomyopathy
11511168|NCT01275963||RCM|Patients with restrictive cardiomyopathy
11511169|NCT01275963||Amyloidosis|Patients with cardiac manifestation of amyloidosis
11511170|NCT01275963||HFPEF|Patients with heart failure with preserved ejection fraction (diastolic heart failure)
11511171|NCT01275937|Other|Esomeprazole|Esomeprazole 40 mg IV daily is given for three days followed by40mg once daily orally for two months.
11511172|NCT01275937|Active Comparator|esomeprazole|esomeprazole 160 mg/day continuous infusion is given for three days followed by 40mg once daily orally for two months.
11511173|NCT01275924|Active Comparator|Tightrope|Treatment with Tightrope Syndesmosis Repair Kit
11511174|NCT01275924|Active Comparator|Syndesmotic screw|Treatment with a quadricortical syndesmotic screw
11511175|NCT01275911|Experimental|Esmolol|
11511176|NCT01275911|Active Comparator|Remifentanil|
11511177|NCT01275898||Beach chair|Patients scheduled for surgical procedure in beach chair position (Shoulder surgery)
11511178|NCT01275898||Sitting position|Patients scheduled for surgical procedure in sitting position (Neurosurgery)
11511179|NCT01275898||Head down position|Patients scheduled for surgical procedure in head down position (daVinci robotic surgery)
11511180|NCT01275898||Prone position|Patients scheduled for surgical procedure in prone position
11511181|NCT01275885|Active Comparator|Vitamin D3 10µg|
11511182|NCT01275885|Active Comparator|Vitamin D3 30µg|
11511183|NCT01275885|Active Comparator|Vitamin D3 40µg|
11511184|NCT01275872|Experimental|Guided Imagery and Progressive Muscle Relaxation|
11511185|NCT01275859|Experimental|Letrozole, Lapatinib|Letrozole 2.5mg po qd + Lapatinib 1500mg po qd for 18-21 wks
11511186|NCT01275846|Experimental|Health Guide using AHA protocols|Participants in the study will receive the use of the Intel Health Guide, a telehealth device, with AHA customized heart failure protocols, response algorithms and educational content. Participants interact with the Intel Health Guide device, receiving immediate feedback when transmitting vitals measures and health question responses to a site monitored by their nurse case managers. Nurse case managers review and address concerns raised in vitals and/or question responses through standard care protocols established by their institution. Nurse case managers strive to enhance the participants quality of life, support continuity of care, facilitate provision of services in the appropriate setting to promote positive health outcomes.
11511187|NCT01275833|Experimental|Device programming modifies AV timing|DDD-40-BiV
11511188|NCT01275833|No Intervention|Device programming allows intrinsic AV timing.|VVI-40-RV
11511189|NCT01275820||Nutralin|All 10 subjects in the study will consume the investigational food product.
11511190|NCT01275807|Experimental|acupuncture|10 acupuncture sessions
11511191|NCT01275807|Active Comparator|self care|psychological support, phisical exercice, diet, self care groups
11511192|NCT01275794||1|Patients have an established diagnosis of T2D, Age 35 years and more, Experience of therapy with one OAD during the from 6 months to 5 years before the registration in the Program
11511193|NCT01275781|Experimental|A|[14C]-AZD9742 1000 mg intravenous over 2 hours
11511194|NCT01275768|Experimental|Experimental arm|Insertion and activation of the endo-biliary RF catheter at the site of the stricture before insertion of a Self-expandable Metal Stent (SEMS)
11511195|NCT01275768|Placebo Comparator|Control arm|Insertion and sham activation of the endo-biliary RF catheter at the site of the stricture before insertion of a SEMS
11511196|NCT01275755|Placebo Comparator|Placebo|Each participant received 1 placebo capsule orally every day (QD) during the Run-in Placebo Period (1 week), the Double-blind Treatment Period (4 weeks), and the Run-out Placebo Period (1 week).
11511197|NCT01275755|Experimental|ADL5945 0.25 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally QD for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.25-milligrams (mg) ADL5945 capsule orally QD for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally QD for 1 week.
11511198|NCT01275742|No Intervention|Usual Care|
11511199|NCT01275729|Experimental|Lasix|Pt to get dose of furosemide after meeting entry criteria - dose dependent on previous exposure to diuretics
11511200|NCT01275716|Experimental|Patients who are shown the images|
11511201|NCT01275716|No Intervention|Patients who are not shown the images|
11511202|NCT01275703||patients with PH undergoing exercise testing|
11511203|NCT01275690||subjects with PH undergoing right heart catheterization|
11511277|NCT01275170|Experimental|Panel A Mild Renal Impairment|Participants with an eGFR of >50 to <80 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
11511204|NCT01275677|Active Comparator|Arm I (chemotherapy)|"GROUP IA: Patients receive docetaxel IV over 60 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity.
~GROUP IB: Patients receive doxorubicin hydrochloride IV over 15 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 2 or 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2-3 weeks after last dose of doxorubicin hydrochloride and cyclophosphamide, patients also receive paclitaxel IV over 60 minutes once weekly for 12 doses in the absence of disease progression or unacceptable toxicity."
11511205|NCT01275677|Experimental|Arm II (chemotherapy, trastuzumab)|"GROUP IIA: Patients receive docetaxel and cyclophosphamide as in Group IA. Patients also receive trastuzumab IV over 30-90 minutes on day 1. Courses repeat every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity.
~GROUP IIB: Patients receive doxorubicin hydrochloride, cyclophosphamide, and paclitaxel as in Group IB. Patients also receive trastuzumab IV over 30-90 minutes weekly for 12 doses and then every 3 weeks for subsequent doses. Treatment repeats every 3 weeks for 1 year in the absence of disease progression or unacceptable toxicity."
11511206|NCT01275664|Experimental|Treatment (granisetron, dexamethasone, aprepitant)|Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.
11511207|NCT01275651||Ancillary-Correlative (AR activity in CRPC)|Previously collected bone marrow tissue and blood samples are analyzed for AR activity, AR splice variations, expression of androgen transport/synthesis/metabolism genes, AKR1C3 protein levels, and testosterone and dihydrotestosterone levels via RT-PCR, SNP microarrays, IHC, gene expression analysis, and mass spectrometry methods.
11511208|NCT01275638|Placebo Comparator|Prednisolone (20 mg/day) for 10 days.|
11511209|NCT01275625|Experimental|Treatment|Single arm study of combivir and maraviroc for 48 weeks
11511210|NCT01275612|Experimental|Cell therapy|
11511211|NCT01275599|Experimental|Open-Label Arm|"The treatment period will include 3 phases:
~14 day run-in period
~7 day co-administration period
~31 day follow-up period"
11511212|NCT01275586|Experimental|Tasigna|Following enrollment each subject will initially receive the drug Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated. Subjects will have his/her dose increased as tolerated dose during the first three months of therapy. The maximum targeted dose is 400mg twice daily.
11511213|NCT01275573|Other|healthy volunteers|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
11511214|NCT01275573|Other|painful Parkinson's disease patients|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
11511215|NCT01275573|Other|painless Parkinson's disease patients|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
11511216|NCT01275560|Experimental|Metronidazole|3 intakes per day during 10 days
11511217|NCT01275560|Active Comparator|Carbosylane|3 intakes per daysduring 10 days
11511218|NCT01275547|Experimental|S-ketamine & midazolam spray|all 20 minutes as a patient controlled analgesia alternating s-ketamine / midazolam
11511219|NCT01275547|Active Comparator|morphine, patient controlled analgesia|morphine as an active comparator as a patient controlled analgesia system
11511220|NCT01275521|Experimental|BONT-A intra-prostatic injection|
11511221|NCT01275521|Active Comparator|optimized medical BPH treatment|
11511222|NCT01275508|Experimental|FITC-Adalimumab|
11511223|NCT01275495|Experimental|Telephone Assessment and Skill-Building Kit (TASK II)|The TASK II group will fill out a checklist about their needs and concerns, and will receive written tip sheets by mail that address the needs and concerns that they feel are most important. A nurse will call by telephone (lasting about 30 minutes or less) once a week for a total of 8 weeks, with another call at 12 weeks, to provide more information, answer questions, and to discuss more written tip sheets based on the caregiver's needs and concerns.
11511224|NCT01275495|Active Comparator|Information, Support, and Referral (ISR)|The ISR group will receive existing educational materials about stroke and caregiving developed by the American Stroke Association and weekly telephone calls by a nurse (lasting about 30 minutes or less) for a total of 8 weeks, with another call at 12 weeks.
11511225|NCT01275482|Experimental|isolated contractions caused|The investigators do TFM causing isolated contractions in de muscle fibers containing de latent trigger point.
11511226|NCT01275482|Active Comparator|No isolated contraction caused|The investigators don´t cause contraction during the TFM
11511227|NCT01275469|Experimental|GFT505 80mg|
11511228|NCT01275469|Placebo Comparator|Matching placebo|
11511229|NCT01275443|Experimental|300mg TMC278LA|Single gluteal intramuscular injection (300mg) at day 1
11511230|NCT01275443|Experimental|1200mg TMC278LA|Single gluteal intramuscular injection (1200mg) at day 1
11511231|NCT01275443|Experimental|600mg TMC278LA|Single gluteal intramuscular injection (600mg) at day 1
11511232|NCT01275443|Experimental|150mg TMC278LA|This arm was included in the adaptive design of the study, but was not recommended for use based on the review of results from 300mg and 600mg arms by the protocol steering committee
11511233|NCT01275430|Experimental|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
11511234|NCT01275430|Active Comparator|"Blind Placement"|"PICCs will be placed blindly, without the use of any tip location/positioning device."
11511235|NCT01275417||adult|100 volunteers age ranged 18-80 years old
11511236|NCT01275417||children|60 children under 10 years old.
11511278|NCT01275170|Experimental|Panel B Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel A and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
11511279|NCT01275170|Experimental|Panel C Moderate Renal Impairment|Participants with an eGFR of 30 to 50 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
11511237|NCT01275404|Experimental|(SMRP) + nurse practitioner information phone calls|Part A will use focus groups to gain feedback and refine the intervention. Part B will consist of a randomized pilot study where 70 men will be randomly assigned to one of two conditions: Sexual Medicine Rehabilitation (SMRP) plus nurse practitioner information phone calls and monitoring (SMRP+I), or SMRP plus the novel psychological intervention of Acceptance and Commitment Therapy for ED (SMRP+ACT-ED).
11511238|NCT01275404|Experimental|SMRP+ACT-ED|Part A will use focus groups to gain feedback and refine the intervention. Part B will consist of a randomized pilot study where 70 men will be randomly assigned to one of two conditions: Sexual Medicine Rehabilitation (SMRP) plus nurse practitioner information phone calls and monitoring (SMRP+I), or SMRP plus the novel psychological intervention of Acceptance and Commitment Therapy for ED (SMRP+ACT-ED).
11511239|NCT01275391|No Intervention|Treatment as Usual Group 1|Participants will receive treatment as usual and will complete a baseline and 1-month post-visit assessment
11511240|NCT01275391|No Intervention|Treatment as Usual Group 2|Participants will receive treatment as usual and complete only the 1-month post-visit assessment
11511241|NCT01275391|Experimental|Intervention Group 1|Computer Screening, Brief Intervention, Referral toTreatment. Participants will receive the intervention and complete a baseline and 1-month post-visit assessment
11511242|NCT01275391|Experimental|Intervention Group 2|Computer Screening, Brief Intervention, Referral toTreatment Participants will receive the intervention and complete only the 1-month post-visit assessment
11511243|NCT01275378|Active Comparator|Collaborative Care Plus|Collaborative care model with specific theory-based elements to address common reasons for ADHD treatment failure
11511244|NCT01275378|Active Comparator|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
11511245|NCT01275365|No Intervention|Placebo/Low Protein|Placebo injections weekly; 0.8 g/kg/day protein
11511246|NCT01275365|No Intervention|Placebo/High Protein|Placebo injections weekly; 1.3 g/kg/day protein
11511247|NCT01275365|Other|Testosterone/Low Protein|Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
11511248|NCT01275365|Other|Testosterone/High Protein|Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
11511249|NCT01275352|Active Comparator|Arm 1|Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele
11511250|NCT01275352|Active Comparator|Arm 2|Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele
11511251|NCT01275352|Placebo Comparator|Arm 3|Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele
11511252|NCT01275352|Placebo Comparator|Arm 4|Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele
11511253|NCT01275339|Active Comparator|Tadalafil in Diabetic Cohort|
11511254|NCT01275339|Placebo Comparator|Placebo in Diabetic Cohort|
11511255|NCT01275339|Active Comparator|Tadalafil in Non-Diabetic Cohort|
11511256|NCT01275339|Placebo Comparator|Placebo in Non-Diabetic Cohort|
11511257|NCT01275313|Experimental|Custom-Fitted Lightweight Wheelchair & Cushion|Receive a new custom-fitted lightweight wheelchair, skin protection cushion and wheelchair skills training
11511258|NCT01275313|Other|Cushion Only|Receive a skin protection cushion and wheelchair training, but remain in facility-issued wheelchair
11511259|NCT01275300|Placebo Comparator|Placebo phase I|Subjects were given 5 days of placebo. On day 5, they were given a single dose of niacin (600 mg) administered 30 minutes after the last dose of placebo. Urine was collected sequentially for analysis. The same subjects came back for cross-over study and were assigned to Aspirin group. There was a 2-week washout period between each treatment.
11511260|NCT01275300|Active Comparator|Aspirin phase I|Subjects were given 5 days of 81 mg aspirin. On day 5, they were given a single dose of niacin (600 mg) administered 30 minutes after the last dose of aspirin or placebo. Urine was collected sequentially for analysis.
11511261|NCT01275300|Active Comparator|Aspirin phase II|In phase II study, subjects were given 5 days of 81 mg aspirin. On day 6, they were given a single dose of niacin (600 mg) administered 24 hours after the last dose of aspirin. Urine was collected sequentially for analysis
11511262|NCT01275287|Active Comparator|Standard of care|Standard of care for ANCA vasculitis treatment- depends on severity of disease and individual characteristics and medical history of each patient so this won't be described here.
11511263|NCT01275287|Experimental|Eculizumab arm|"Standard of care for ANCA vasculitis + eculizumab treatment
~Standard of care for ANCA vasculitis treatment- depends on severity of disease and individual characteristics and medical history of each patient so this won't be described here."
11511264|NCT01275274|Active Comparator|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone.
11511265|NCT01275274|Experimental|Retinoic acid|Tretinoin in addition to standard of care
11511266|NCT01275261|No Intervention|Foley catheter|Usual care - patients will have a Foley catheter placed on admission.
11511267|NCT01275261|Experimental|Nursing protocol to avoid Foley Catheter|No catheter will be placed on admission, and a nursing order protocol will be followed to avoid catheterization and avoid complications.
11511268|NCT01275248|Experimental|Ondansetron 0.5 mg|Ondansetron oral tablet 0.5 mg taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
11511269|NCT01275248|Experimental|Ondansetron 0.75 mg|Ondansetron oral tablet 0.75 mg taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
11511270|NCT01275248|Placebo Comparator|Placebo|Placebo oral tablet taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
11511271|NCT01275235||Exposure to Type II Diabetes for two siblings|Two sibling pairs with the same parents, between the ages of 20 to 34 in the Baton Rouge Area, having mother with diabetes while pregnant with one.
11511272|NCT01275222|Experimental|RAD001 + Glivec|
11511273|NCT01275209|Experimental|HCD122|
11511274|NCT01275196|Experimental|Nilotinib|
11511275|NCT01275196|Active Comparator|Imatinib|
11511276|NCT01275183|Experimental|Raltegravir and cisplatin|
11511394|NCT01274325|Active Comparator|Seretide|Seretide (25/125)
11511280|NCT01275170|Experimental|Panel D Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel C and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
11511281|NCT01275170|Experimental|Panel E Severe Renal Impairment|Participants with an eGFR <30 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
11511282|NCT01275170|Experimental|Panel F Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel E and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
11511283|NCT01275170|Experimental|Panel G End Stage Renal Disease with Hemodialysis (ESRD/HD)|Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2). In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg predialysis (Part 2, Period 1) and postdialysis (Part 2, Period 2).
11511284|NCT01275170|Experimental|Panel H Healthy Volunteers|A subset of healthy control participants were matched specifically to participants in Panel G and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
11511285|NCT01275157|Experimental|LY2452473|15 mg, containing 100 micro curies of 14C labeled LY2452473 taken once only
11511286|NCT01275144|Experimental|LY2216684+lorazepam, placebo+lorazepam|Oral 18 mg doses of LY2216684 on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 1. Oral doses of placebo on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 2. There is a washout period of at least 7 days between dosing periods.
11511287|NCT01275144|Experimental|Placebo+Lorazepam, LY2216684+Lorazepam|Oral doses of placebo on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 1. Oral 18 mg doses of LY2216684 on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 2. There is a washout period of at least 7 days between dosing periods.
11511288|NCT01275131|Active Comparator|Stage 1: Insulin aspart first, then insulin aspart-rHuPH20|"Participants first received 0.15 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4.
~After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8."
11511289|NCT01275131|Active Comparator|Stage 1: Insulin aspart-rHuPH20 first, then insulin aspart|"Participants first received 0.15 units per kilogram (U/kg) insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4.
~After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart alone as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8."
11511290|NCT01275131|Active Comparator|Stage 3: Insulin aspart first, then insulin aspart + rHuPH20|"Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a sham injection was administered 2.5 hr prior to the 6-hr euglycemic clamp.
~After a 5- to 14-day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the 6-hr euglycemic clamp."
11511291|NCT01275131|Active Comparator|Stage 3: Insulin aspart + rHuPH20 first, then insulin aspart|"Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6- hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the euglycemic clamp .
~After a 5- to 14- day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a sham injection was administered 2.5 hr prior to the 6-hour euglycemic clamp."
11511292|NCT01275105|Other|Vehicle|
11511293|NCT01275105|Active Comparator|Brimonidine Tartrate 0.01%|
11511294|NCT01275105|Active Comparator|Oxymetazoline HCl 0.025%|
11511295|NCT01275105|Active Comparator|Brimonidine Tartrate 0.025%|
11511296|NCT01275092|Experimental|CorPath robotic-assisted PCI|CorPath 200 robotic-assisted PCI
11511297|NCT01275066|Placebo Comparator|Placebo|
11511298|NCT01275066|Experimental|BMN 110 Weekly|
11511299|NCT01275066|Experimental|BMN 110 Every Other Week|
11511300|NCT01275053|Experimental|Leptin|
11511301|NCT01275040|Experimental|Mobile screening team|The Primary Health Care clinics where the mobile screening team will visit and active screening for DM complications will take place.
11511302|NCT01275040|Active Comparator|No mobile screening team|No mobile team will visit clinics and active screening for DM complications will not be done. Patients and Health Workers will receive Education, same as intervention arm but no enhanced care.
11511303|NCT01275027|Experimental|Nutralin|Individuals with Type 2 Diabetes
11511304|NCT01275027|Placebo Comparator|Placebo|Individuals with Type 2 Diabetes
11511305|NCT01275014|Placebo Comparator|Placebo|
11511306|NCT01275014|Experimental|Dexamethasone|
11511307|NCT01275001||Intervention children|Children who are receiving a Suzuki-like violin instruction through their participation in an Early Childhood/Headstart preschool program
11511308|NCT01275001||Control Group|Preschool-age children who are not receiving Suzuki-like violin instruction
11511309|NCT01274988|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
11511310|NCT01274988|Active Comparator|Standard Control|methadone maintenance treatment
11511311|NCT01274962|Experimental|A - neoadjuvant chemotherapy|Patients in arm A will receive 6 cycles of FOLFOX chemotherapy prior to radiotherapy and surgery as well as 6 cycles of chemotherapy in adjuvant
11511312|NCT01274962|Experimental|Arm B - adjuvant chemotherapy|Patients in arm B will receive 12 cycles of FOLFOX after radiotherapy and surgery
11511313|NCT01274949|Experimental|LI-ESWT|Low intensity shock wave treatment- 12 sessions
11511314|NCT01274936|Experimental|Qishe|
11511315|NCT01274936|Placebo Comparator|Control|Qishe Placebo
11511316|NCT01274923|Sham Comparator|shock wave treatment|
11511317|NCT01274923|Sham Comparator|"MEDISPEC Sham"|"MEDISPEC Probe does not deliver energy but creates same noise and sensation of active probe"
11511318|NCT01274910|Active Comparator|Fish oil group|Treatment Group.
11511319|NCT01274910|Placebo Comparator|Control group|Placebo group
11511320|NCT01274897|Experimental|MenACWY-CRM|Subjects received one dose of MenACWY-CRM conjugate vaccine.
11511321|NCT01274897|Placebo Comparator|Placebo|Subjects received the saline placebo.
11511322|NCT01274884|Active Comparator|Acromioclavicular joint dislocation|Surgery: Arthroscopic repair using the Tightrope fixation device
11511323|NCT01274871||lung cancer surgery|
11511324|NCT01274858||lung cancer surgery|
11511325|NCT01274845|Other|Heliox|
11511326|NCT01274832||Late-treated PD patients|Patients affected by Parkinson Disease, implanted with STN DBS and with an history of disease > 10 years
11511327|NCT01274832||Early-treated PD patients|Patients affected by Parkinson Disease, implanted with STN DBS and with an history of disease <7 years
11511328|NCT01274819|Experimental|Dynamic light|ICU patients exposed to dynamic light during ICU stay
11511329|NCT01274819|No Intervention|Normal Light|control group is exposed to normal light during ICU stay
11511330|NCT01274806|No Intervention|Usual care|
11511331|NCT01274806|Experimental|Physical therapy|
11511332|NCT01274793|Active Comparator|Mosapride|In the control group were orally administered 5 mg mosapride citrate tablet s three times a day for 4 continu ous weeks if no severe adverse effects were found.
11511333|NCT01274793|Experimental|Low-dose acupuncture|In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants
11511334|NCT01274793|Experimental|High-dose acupuncture|In this group,the current was strong enough to reach the patients'tolerance threshold value.
11511335|NCT01274780|Experimental|Darunavir / Ritonavir|
11511336|NCT01274780|Experimental|Atazanavir / Ritonavir|
11511337|NCT01274767||High risk cohort|Patients having history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have a negative test for H. pylori based on histology
11511338|NCT01274767||Average risk cohort|Patients having no history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have H. pylori positive OR negative
11511339|NCT01274754||erythromycin group|Patients of erythromycin group: 25mg/kg erythromycin intravenously 12 hours before surgery and 12 hours after the end of surgery.
11511340|NCT01274754||control group|no administration of erythromycin
11511341|NCT01274741|Active Comparator|Seeking Safety (SS)|17 sessions of present-focused therapy Seeking Safety
11511342|NCT01274741|Experimental|Creating Change (CC)|17 sessions of past-focused Creating Change
11511343|NCT01274728||ST-elevated myocardial infarction|Those with a condition of chestpain (or equal complains) and ECG changes confirming STEMI.
11511344|NCT01274715|Experimental|Behavioral Health Coaching arm|This is a single-arm, pilot study of a health behavior coaching intervention to consist of 12 sessions of coaching over a 3 month period. There is no control arm for this pilot study.
11511345|NCT01274702|Experimental|Visual Reconstitution Therapy|
11511346|NCT01274702|Active Comparator|Saccadic Eye Movement Training|
11511347|NCT01274689||cohort|cohort of consecutively enrolled patients with lagophthalmos
11511348|NCT01274676|Active Comparator|carotid stenting with MOMA|
11511349|NCT01274676|Active Comparator|Carotid stenting with filter wire EZ|
11511350|NCT01274663|Experimental|10 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
11511351|NCT01274663|Experimental|30 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
11511352|NCT01274663|Experimental|100 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
11511353|NCT01274663|Experimental|300 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
11511354|NCT01274663|Experimental|600 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
11511355|NCT01274663|Experimental|800 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
11511356|NCT01274663|Experimental|xxx mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
11511357|NCT01274650|Other|Decubitis Ulcer|Patients admitted to the hospital with decubitus ulcers in the ischial, sacral, or coccyx area.
11511358|NCT01274637|Experimental|low molecular weight heparin|Prophylactic-dose (5000 IU/0.2ml)low molecular weight heparin (LMWH), administered subcutaneously once daily in pre-filled glass syringes for 10 days (+/- 3 days) for a total of 10 (+/-3) study drug injections.
11511359|NCT01274637|No Intervention|Control Group|No treatment control group.
11511360|NCT01274611|Active Comparator|Suction-Curettage|
11511361|NCT01274611|Experimental|Botox|
11511362|NCT01274598|Experimental|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|Lactobacillus rhamnosus GG ATCC 53103 1 x 10^10 twice a day for 28 days
11511363|NCT01274585|Sham Comparator|No active treatment|
11511364|NCT01274585|Experimental|stimulation/treatment|
11511365|NCT01274559|Experimental|Extended-release niacin/laropiprant|ERN/LRPT 1 g (1 tablet for 4 wks) followed by ERN/LRPT 2 g (2 tablets for 8 wks); Each 1-g tablet contains 1 g of ER niacin and 20 mg of laropiprant.
11511366|NCT01274559|Placebo Comparator|Placebo|Matching 1 g Placebo (1 tablet for 4 wks) followed by 2 g placebo (2 tablets for 8 weeks)
11511368|NCT01274546||"Telephone Arm"|These subjects will be consented over the phone and give a verbal consent to participate. They will complete all aspects of the study over the phone except for the knee society score evaluation and the x-ray.
11511369|NCT01274533|Experimental|Lenalidomide|Oral lenalidomide is initiated on Day 1 of Cycle 1 and continues once daily days 1-21 of a 28 day cycle. Subjects may continue participation in the Treatment Phase of the study for 24 months unless disease progression or drug is discontinued for safety reasons.
11511370|NCT01274520|Experimental|Experimental: Hypothermic Machine Perfusion Group|The Medtronic Portable Bypass System (PBS®) with Model 550 Bioconsole and the BioCal® blood temperature control module will be used for machine perfusion of liver grafts. These products are commercially available and used in clinical practice for cardiopulmonary bypass and extracorporeal membrane oxygenation. The Medtronic system utilizes an atraumatic centrifugal pump that can deliver the flow rates approximating portal venous flow in human livers, and it has modules for online membrane oxygenation, and electronic flow measurement.
11511371|NCT01274520|No Intervention|Matched control group|The proposed study is a matched cohort design. Subjects will be matched with 24 historical control patients who received similar cold stored ECD grafts. Subjects will be matched on known covariates including donor age, donation after cardiac death, steatosis, both warm and cold ischemia times, recipient age, MELD score and disease etiology. Additional analyses will be performed on historical control blood and/or tissue samples previously collected and stored in the study's sample repository.
11511372|NCT01274507|Other|All participants|
11511373|NCT01274481|Experimental|Iloprost|All patients will have their response to Iloprost compared to baseline pre-treatment.
11511374|NCT01274455|Experimental|Therapy|
11511375|NCT01274442|Active Comparator|CONTROL: no dental implants lost|Group of patients who received an implant during a dental implant surgery in the University Hospital in Ghent in 2004-2007, who did not lose their implants.
11511376|NCT01274442|Experimental|CASE: patients lost one or more implants|Group of patients who received an implant during a dental implant surgery in the University Hospital in Ghent in 2004-2007, but who lost one or more implants.
11511377|NCT01274429|Experimental|Open label peanut flour|Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.
11511378|NCT01274403|Experimental|Melphalan, prednisone plus Thalidomide|
11511379|NCT01274403|Active Comparator|Melphalan and Prednisone|
11511380|NCT01274390||Shorter-storage red blood cell units|Red blood cell units stored <= 10 days
11511381|NCT01274390||Longer-storage red blood cell units|Red blood cell units stored >= 21 days
11511382|NCT01274377|Experimental|Recipients Using 3-5/6 Matched Donors|There will be an equal number of subjects (10) receiving transplants from 3-5/6 Human Leukocyte Antigen (HLA) Matched Donors as those receiving transplants from 6/6 HLA Matched Donors for a total of 20 subjects on study.
11511383|NCT01274377|Experimental|Recipients Using 6/6 Matched Donors|There will be an equal number of subjects (10) receiving transplants from 3-5/6 HLA Matched Donors as those receiving transplants from 6/6 HLA Matched Donors for a total of 20 subjects on study.
11511384|NCT01274364|Experimental|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
11511385|NCT01274364|Active Comparator|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
11511386|NCT01274351|Experimental|Nilotinib|administered orally at a dose of 300 mg twice daily for 24 months
11511387|NCT01274338|Experimental|Arm A (age >= 18, high-dose ipilimumab)|Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (closed accrual as of 4/4/14) (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
11511388|NCT01274338|Experimental|Arm B (age >= 18, recombinant interferon alfa-2b)|Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
11511389|NCT01274338|Experimental|Arm C (age >= 18, low-dose ipilimumab)|Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
11511390|NCT01274338|Experimental|Arm D (age 12-17, high-dose ipilimumab)|Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.
11511391|NCT01274338|Experimental|Arm E (ages 12-17, recombinant interferon alfa-2b)|Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (ages 12-17)
11511392|NCT01274338|Experimental|Arm F (ages 12-17, low-dose ipilimumab)|Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 90 days for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (ages 12-17)
11511393|NCT01274325|Experimental|Sereflo|Sereflo (25/125)
11511398|NCT01274260|Active Comparator|Experimental Group|Intervention: Subjects in this study group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
11511399|NCT01274260|Placebo Comparator|Placebo Group|Intervention: The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline. The placebo group with receive the masked study drug in infusion rates that mimic the infusions received by the experimental group.
11511400|NCT01274247|Active Comparator|Topical Benzocaine|For infants treated with topical benzocaine prior to the procedure
11511401|NCT01274247|No Intervention|no benzocaine|No benzocaine applied
11511402|NCT01274234|Experimental|COMBO Stent|COMBO Stent
11511403|NCT01274221|Placebo Comparator|Placebo|
11511404|NCT01274221|Active Comparator|SPD489|
11511405|NCT01274208||Gaucher Disease with Hepatitis C|
11511406|NCT01274195|Experimental|Busulfan|
11511407|NCT01274182|Experimental|GP2013|
11511408|NCT01274182|Active Comparator|MabThera|
11511409|NCT01274182|Active Comparator|Rituxan|
11511410|NCT01274156|Active Comparator|shock wave treatment|
11511411|NCT01274156|Sham Comparator|"MEDISPEC Sham"|"MEDISPEC Probe does not deliver energy but creates same noise and sensation of active probe"
11511412|NCT01274143|Active Comparator|Telephone-delivered risk intervention|Participants in this arm receive a personalized telephone-risk assessment intervention provided by a trained cancer risk counselor.
11511413|NCT01274143|Active Comparator|Mailed pamphlet intervention group|Participants in this group receive a mailed pamphlet containing information about familial colorectal cancer risk and screening.
11511414|NCT01274130|Experimental|Ranitidine|
11511415|NCT01274130|Experimental|Verapamil|
11511416|NCT01274117|Placebo Comparator|One-stage transposition of the basilic vein|One-stage transposition of the basilic vein
11511417|NCT01274117|Experimental|Two-stage transposition of the basilic vein|Two-stage transposition of the basilic vein
11511418|NCT01274104|Active Comparator|Vitamin D|Subjects will take 5,000 IU-capsules of vitamin D3 three times a day (for a total of 15,000 IU) for 14 days
11511419|NCT01274104|Placebo Comparator|Control|Subjects will take 3 capsules of placebo every day for 14 days
11511420|NCT01274091|Experimental|P/S-ratio 1.0|"Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:
~polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0."
11511421|NCT01274091|Experimental|P/S-ration 0.3|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:. Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
11511422|NCT01274078|No Intervention|conventional food|Regular eating habits during exercise period
11511423|NCT01274078|Active Comparator|Blueberries|Intervention: Addition of blueberries (150g/day) to regular food during the exercise period on days with exercise
11511424|NCT01274065||Psychiatric illnesses|Participants will reside at the South Dakota Developmental Center (SDDC), which serves a unique population of people with developmental disabilities and co-occuring psychiatric disorders.
11511425|NCT01274052||Gestational Diabetes Mellitus|Women with Gestational Diabetes Mellitus
11511426|NCT01274052||Normal Glucose Tolerance|Women with Normal Glucose Tolerance
11511427|NCT01274039||Patient with a trabeculectomy planed|
11511428|NCT01274026||evaluation of benefit of sapropterin|Intervention 'sapropterin dihydrochloride': 20 individuals, either known to be non-responsive, or naive to sapropterin, are given a 4 week administration of sapropterin. Pre-, and Post- evaluation of behavior, executive function, neurotransmitter function, and genomic expression are assessed and evaluated for change.
11511429|NCT01274013||Study Group|Individuals with chronic Hepatitis C
11511430|NCT01274013||Control Group|Healthy individuals
11511431|NCT01274000|Placebo Comparator|placebo group|
11511432|NCT01274000|Experimental|YM060 low-dose group|
11511433|NCT01274000|Experimental|YM060 middle-dose group|
11511434|NCT01274000|Experimental|YM060 high-dose group|
11511435|NCT01273987|Experimental|neobladder with round lig|ileal neobladder suspened with round ligament
11511436|NCT01273987|No Intervention|standard neobladder|conventional standard neobladder
11511437|NCT01273974|Experimental|intradermal influenza vaccine|
11511438|NCT01273974|Active Comparator|intramuscular influenza vaccine|
11511439|NCT01273948|Experimental|Bavituximab 3 mg/kg|Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
11511440|NCT01273948|Experimental|Bavituximab 0.3 mg/kg|Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
11511441|NCT01273948|Active Comparator|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
11511442|NCT01273935||Responder|Responder versus Non-Responder as a result of platelet function test
11511443|NCT01273935||Non-Responder|According to the result of platelet function test
11511444|NCT01273922|Placebo Comparator|Low Dose NDV-3 investigational vaccine|15 subjects will receive vaccine and 5 subjects will receive placebo.
11511445|NCT01273922|Placebo Comparator|High Dose NDV-3 investigational vaccine|15 subjects will receive vaccine and 5 subjects will receive placebo
11511446|NCT01273909||Perforator Flap Breast Reconstruction|Patients who undergo perforator flap breast reconstruction with or without concomitant vascularized lymph node transfer
11511447|NCT01273909||Vascularized Lymph Node Transfer|Patients who undergo perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction
11511448|NCT01273896|Experimental|STA-9090|This will be a monotherapy, open-label phase 2 study of STA-9090 in patients who have metastatic breast cancer.
11511449|NCT01273883|Experimental|Magnesium first, then placebo|Magnesium 532 mg daily for 25 days followed by 2 weeks of washout followed by 25 days of placebo.
11511450|NCT01273883|Placebo Comparator|Placebo first, then magnesium|Placebo daily for 25 days followed by 2 weeks of washout followed by magnesium 532 mg daily for 25 days.
11511451|NCT01273857|Sham Comparator|Control|Subjects will undergo standard staged-procedures without cell infusion
11511452|NCT01273857|Experimental|Cell infusion|Subjects will receive transcoronary infusion of autologous cardiosphere-derived cells 1 month after staged shunt procedure
11511453|NCT01273844|Experimental|Bortezomib|Patients will receive two 21-day cycles of induction therapy with vel / dex regimen. Bortezomib 1.3mg/m2 on days 1, 4, 8 and 11 will be given by intravenous bolus injection while Dexamethasone 40 mg/d will be taken orally on days 1-4.
11511454|NCT01273831|Other|atracurium|Patients who underwent general anesthesia received atracurium
11511455|NCT01273831|Other|cisatracurium|Patients who underwent general anesthesia received cisatracurium
11511456|NCT01273818|Active Comparator|gentamicin|80 mg gentamicin topical application intraoperatively
11511457|NCT01273818|Active Comparator|Cefazolin|Application of 1000 mg cefazolin intra venously 1 hour before surgery
11511458|NCT01273818|Active Comparator|gentamicin and cefazolin|1000 mg cefazolin application 1 hour before surgery and topical 80 mg gentamicin intraoperatively
11511459|NCT01273805|Experimental|Hydroxychloroquine 400 mg b.i.d.|Patients received 400 mg hydroxychloroquine orally twice per day. Cycle duration was 4 weeks. Patients remained on treatment indefinitely without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision.
11511460|NCT01273805|Experimental|Hydroxychloroquine 600 mg b.i.d.|Patients received 600 mg hydroxychloroquine orally twice per day. Cycle duration was 4 weeks. Patients remained on treatment indefinitely without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision.
11511461|NCT01273792||Patients with Susac syndrome|
11511462|NCT01273792||Matched healthy controls|
11511463|NCT01273779|Placebo Comparator|Placebo|
11511464|NCT01273779|Experimental|Talactoferrin alfa|
11511465|NCT01273766|Experimental|Arm I|Patients receive oral deferasirox once daily for up to 6 months or until blood counts recover in the absence of disease progression or unacceptable toxicity.
11511466|NCT01273766|No Intervention|control arm|blood tested on healthy patients
11511467|NCT01273766|No Intervention|correlative|treated off study with or without oral deferasirox (patient choice) but lab draws to gather lab analysis
11511468|NCT01273753|Active Comparator|Exercise|After baseline measurements, all subjects will undergo a phase involving intradialytic exercise. Subjects will serve as their own controls.
11511469|NCT01273740|Experimental|External support|Bypass graft with external support
11511470|NCT01273740|Experimental|No external support|Bypass with graft without external support
11511471|NCT01273727|No Intervention|No Ozurdex|Arm 1(control) - Patients who have had epi-retinal membrane peeling and have macular edema at least 3 months (90 days) after surgery. These patients will followed without Ozurdex. The patients will be treated with current standard of care, including topical and intravitreal or subtenon's medication.
11511472|NCT01273727|Experimental|Ozurdex 3 months after surgery|Patients who have had epi-retinal membrane peeling and have residual macular edema 3 months after surgery. These patients will receive an Ozurdex implant
11511473|NCT01273727|Experimental|Ozurdex 6 months or longer after surgery|Patients who have had epiretinal membrane peeling and have residual macular edema at least 6 months after surgery
11511474|NCT01273714|Active Comparator|BST|bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each)
11511475|NCT01273714|Experimental|TT|extracapsular total thyroidectomy
11511476|NCT01273701|Experimental|TSTSU-N|TSTSU-N stands for Treatment for Schedule Two Substance Use, No Telephone Reminding. Subjects will be referred by the Yunlin District Prosecutors Office for one-year psychosocial interventions to get slow prosecutions. After the referral, they will be randomized in a 1:1 ratio to either TSTSU-N group or TSTSU-T group. During the intervention, subjects of TSTSU-N will not receive telephone reminding before each visit.
11511477|NCT01273701|Experimental|TSTSU-T|TSTSU-T stands for Treatment for Schedule Two Substance Use, Telephone Reminding. Subjects will be referred by the Yunlin District Prosecutors Office for one-year psychosocial interventions to get slow prosecutions. After the referral, they will be randomized in a 1:1 ratio to either TSTSU-N group or TSTSU-T group. During the intervention, subjects of TSTSU-T will receive telephone reminding before each visit.
11511478|NCT01273701|Active Comparator|OPD|OPD stands for Outpatient Department. Subjects in this arm will be methamphetamine users who voluntarily visit psychiatric clinics for treatment of mental disorders in National Taiwan University Hospital, Yunlin Branch. They will be referred to this study by their treating psychiatrists.
11511479|NCT01273688|Active Comparator|Eccentric training only|Eccentric training only active control group (Flex-Bar)
11511480|NCT01273688|Experimental|Eccentric training and elbow brace|Combined eccentric training (Flex-Bar) and elbow brace (Epi-Hit)
11511481|NCT01273662|Experimental|Axitinib|
11511482|NCT01273649|Experimental|ice, rate of force development|to monitor the long term effect of cryotherapy in rate of force development.
11511483|NCT01273623|Experimental|Patients with PAD|Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention who have moderate to severe obstructive intraluminal calcium
11511484|NCT01273610|Experimental|Lapatinib and trastuzumab|Patients receive lapatinib ditosylate PO QD and trastuzumab IV once weekly OR once every 3 weeks. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11511485|NCT01273597||End-stage kidney disease with secondary hyperparathyroidism|Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)
11511486|NCT01273584|Active Comparator|Metformin|"Tablet Metformin 500 mg, starting dose of 1 tablet twice a day with meals, gradually titrated upwards by 1 tablet every week to a maximum dose of 2 tablets three times a day.
~Tablets started at recruitment and continued till the delivery of the baby"
11511487|NCT01273584|Placebo Comparator|Placebo|"Tablet Placebo 500 mg, starting dose of 1 tablet twice a day with meals, gradually titrated upwards by 1 tablet every week to a maximum dose of 2 tablets three times a day.
~Tablets started at recruitment and continued till the delivery of the baby"
11511488|NCT01273571|Experimental|001|Canagliflozin/Metformin Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8 followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
11511489|NCT01273558|No Intervention|Part 1: no Intervention|In Part 1 of the study, patients will not receive any study drug.
11511490|NCT01273558|Experimental|Part 2: canagliflozin|In Part 2 of the study, patients will receive canagliflozin once daily on Days 1 through 8.
11511491|NCT01273545||001|PRILIGY (dapoxetine hydrochloride) The study will observe characteristics of the patients to whom PRILIGY 30-mg and 60-mg tablets are prescribed in Germany by general practitioners and (separately) by urologists and in Italy by urologists
11511492|NCT01273532|Experimental|001|tapentadol (CG5503) ER 50-mg TRF 100 mg TRF single oral dose
11511493|NCT01273532|Experimental|002|tapentadol (CG5503) ER 100-mg TRF 100mg TRF single oral dose
11511494|NCT01273519||RA, PsA, AS|Participants with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) prescribed Humira (adalimumab) in the usual manner and in accordance with the terms of the local marketing authorization with regards to dose, population and indication.
11511495|NCT01273506|Experimental|001|tapentadol (CG5503) ER 25-mg TRF 50 mg TRF single oral dose
11511496|NCT01273506|Experimental|002|tapentadol (CG5503) ER 50-mg TRF 50 mg TRF single oral dose
11511497|NCT01273493|Experimental|Trabectedin 1.3 mg/m^2 plus Dexamethasone|Control group Trabectedin 1.3 mg/m^2 i.v.will be administered on Day 1. Dexamethasone will be administered 30 minutes prior to trabectedin.
11511498|NCT01273493|Experimental|Trabectedin 0.58 mg/m^2 plus Dexamethasone|Hepatic dysfunction group Trabectedin 0.58 mg/m^2 (or adjusted dose) i.v. will be administered on Day 1. Dexamethasone will be administered 30 minutes prior to trabectedin.
11511499|NCT01273480|Experimental|002|Sequence 2 Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
11511500|NCT01273480|Experimental|001|Sequence 1 Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
11511501|NCT01273467|Experimental|001|CNTO 0007 or placebo (Stage A) a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
11511502|NCT01273467|Experimental|002|CNTO 0007 or placebo (Stage B) a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
11511503|NCT01273454||001|OROS Hydromorphone 8 16 32 mg once a day for 4 weeks
11511504|NCT01273441|Active Comparator|Sequential treatment:|
11511505|NCT01273441|Experimental|Concomitant treatment|
11511506|NCT01273428|Active Comparator|HP011-101|
11511507|NCT01273428|Active Comparator|HP828-101|
11511508|NCT01273428|Other|Standard Care|
11511509|NCT01273415||hormone receptor-positive breast cancer|postoperative hormone receptor-positive breast cancer
11511510|NCT01273402|Experimental|TF2 and IMP288|TF2 will be administered at least 4 days before the radiolabeled IMP-288.
11511511|NCT01273389|Experimental|CNTO 136|CNTO 136 is used in the form of final vialed product, as a single-use, sterile solution in a 2 ml glass vial. Each 1 mL of the solution contains sirukumab 100mg active drug substance, sorbitol, acetate buffer, and polysorbate 20, at a pH of 5.0, without any preservatives.
11511512|NCT01273389|Placebo Comparator|Placebo|
11511513|NCT01273376|Experimental|RX-10100 high dose|"RX-10100
~Study drug is to be given orally, in tablet form, twice daily, for 8 weeks"
11511514|NCT01273376|Experimental|RX-10100 low dose|"RX-10100
~Study drug is to be given orally, in tablet form, twice daily, for 8 weeks"
11511515|NCT01273376|Placebo Comparator|Placebo|Matching placebo is to be given orally, in tablet form, twice daily, for 8 weeks
11511516|NCT01273363||1|Male and female over 18. Patients with asthma diagnosed in accordance with the Global Initiative for Asthma within 6 months before inclusion into the study and without changes in treatment for 2 months before inclusion
11511517|NCT01273350|Other|Single arm|"Single arm observational study looking at a low risk cohort of individuals with carotid stenosis"
11511518|NCT01273337|Experimental|ALD-401|ALD-401 is derived from Autologous Bone Marrow of the Stroke Subject
11511519|NCT01273337|Sham Comparator|Sham Comparitor|Sham Bone Marrow harvest and sham dosing procedure.
11511520|NCT01273324||ADM|ADM Cup
11511521|NCT01273298|Experimental|Bisoprolol|
11511522|NCT01273298|Placebo Comparator|Sugar pill|
11511523|NCT01273272|Experimental|Cognitive Behavioral Therapy (CBT)|Comprehensive, CBT-based, multi-component treatment. Comprehensive CBT intervention in addition to standard treatment
11511524|NCT01273272|Active Comparator|Treatment as usual (TAU)|Standard Treatment (medical and psychosocial)
11511525|NCT01273259|Experimental|200 mg /day arm|
11511526|NCT01273259|Experimental|25 mg/day arm|
11511527|NCT01273246|Experimental|Children Group 1: 200U EV71 vaccine|12 children received 3 doses of 200U EV71 vaccine 28 days apart
11511528|NCT01273246|Placebo Comparator|Children Group 1: Placebo|6 children received 3 doses of placebo 28 days apart
11511529|NCT01273246|Experimental|Children Group 2: 400U EV71 vaccine|12 children received 3 doses of 400U EV71 vaccine 28 days apart
11511530|NCT01273246|Placebo Comparator|Children Group 2: Placebo|6 children received 3 doses of placebo 28 days apart
11511531|NCT01273246|Experimental|Infants Group 1: 100U EV71 vaccine|24 infants received 3 doses of 100U EV71 vaccine 28 days apart
11511532|NCT01273246|Placebo Comparator|Infants Group 1: Placebo|8 infants received 3 doses of placebo 28 days apart
11511533|NCT01273246|Experimental|Infants Group 2: 200U EV71 vaccine|24 infants received 3 doses of 200U EV71 vaccine 28 days apart
11511534|NCT01273246|Placebo Comparator|Infants Group 2: Placebo|8 infants received 3 doses of placebo 28 days apart
11511535|NCT01273246|Experimental|Infants Group 3: 400U EV71 vaccine|24 infants received 3 doses of 400U EV71 vaccine 28 days apart
11511536|NCT01273246|Placebo Comparator|Infants Group 3: Placebo|8 infants received 3 doses of placebo 28 days apart
11511537|NCT01273233|Experimental|Group 1: 200U EV71 vaccine|12 adults received 3 doses of 200U EV71 vaccine 14 days apart
11511538|NCT01273233|Experimental|Group 2: 400U EV71 vaccine|12 adults received 3 doses of 400U EV71 vaccine 14 days apart
11511539|NCT01273233|Placebo Comparator|Group 1: Placebo|6 adults received 3 doses of placebo 14 days apart
11511540|NCT01273233|Placebo Comparator|Group 2: Placebo|6 adults received 3 doses of placebo 14 days apart
11511541|NCT01273207|Experimental|Inhaled Cyclosporine in HSCT Participants|Hemopoietic Stem Cell transplant (HSCT) subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) at maximum tolerated dose not exceeding 300 mg administered three times per week
11511542|NCT01273181|Experimental|Ph I:Anti-MAGE A3/12 TCR PBL 5x10e9|"Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)
~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses
~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :
~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
~Note for phase I: The study will begin by evaluating the safety of two ranges of cells, 5x10^9-3x10^10, and greater than 3x10^10-1x10^11 in a standard phase I dose escalation fashion using a 3+3 design."
11511543|NCT01273181|Experimental|Ph I:Anti-MAGE A3/12 TCR PBL 3x10e10|"Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)
~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses
~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :
~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
~Note for phase I: The study will begin by evaluating the safety of two ranges of cells, 5x10^9-3x10^10, and greater than 3x10^10-1x10^11 in a standard phase I dose escalation fashion using a 3+3 design."
11511544|NCT01273181|Experimental|Ph II:Anti-MAGE TCR PBL MTD+HD IL-2|"Phase II:Anti-MAGE A3/12 TCR PBL MTD + HD IL-2, Melanoma, RCC
~Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)
~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses
~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :
~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
~Note for phase II:patients will be entered into two cohorts based on histology:cohort 1 will include patients with metastatic melanoma or renal cell cancer; cohort 2 will include patients with other types of metastatic cancer."
11511545|NCT01273181|Experimental|Ph II:Anti-MAGE A3/12 TCR PBL MTD|"Phase II: Anti-MAGE A3/12 TCR PBL MTD + HD-IL2 Other Cancer
~Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)
~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses
~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :
~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
~Note for phase II:patients will be entered into two cohorts based on histology:cohort 1 will include patients with metastatic melanoma or renal cell cancer; cohort 2 will include patients with other types of metastatic cancer."
11511546|NCT01273168|Experimental|0|Z-endoxifen will be administered orally once a day in 28-day cycles
11511547|NCT01273155|Active Comparator|Normal Function-Belinostat 1000 mg/m(2)|Normal Liver Function was defined as bilirubin ≤Upper Limit of Normal (ULN) and aspartate aminotransferase (AST) ≤ ULN.
11511548|NCT01273155|Experimental|Mild Dysfunction-Belinostat 750 mg/m(2)|Mild Liver Dysfunction was defined as bilirubin >Upper Limit of Normal (ULN) but ≤1.5 x ULN and/or aspartate aminotransferase (AST) > ULN.
11511549|NCT01273155|Experimental|Mild Dysfunction-Belinostat 1000 mg/m(2)|Mild Liver Dysfunction was defined as bilirubin >Upper Limit of Normal (ULN) but ≤1.5 x ULN and/or aspartate aminotransferase (AST) > ULN.
11511550|NCT01273155|Experimental|Moderate Dysfunction-Belinostat 500 mg/m(2)|Moderate Liver Dysfunction was defined as bilirubin >1.5 to ≤ 3 x ULN and any aspartate aminotransferase (AST).
11511551|NCT01273155|Experimental|Moderate Dysfunction-Belinostat 750 mg/m(2)|Moderate Liver Dysfunction was defined as bilirubin >1.5 to ≤ 3 x ULN and any aspartate aminotransferase (AST).
11511552|NCT01273155|Experimental|Severe Dysfunction-Belinostat 250 mg/m(2)|Severe Liver Dysfunction was defined as bilirubin >3 but ≤ 10 x ULN and any aspartate aminotransferase (AST).
11511553|NCT01273155|Experimental|Severe Dysfunction-Belinostat 350 mg/m(2)|Severe Liver Dysfunction was defined as bilirubin >3 but ≤ 10 x ULN and any aspartate aminotransferase (AST).
11511554|NCT01273129|Other|Patients|Patients undergoing brain surgery to treat drug resistant epilepsy and are enrolled in protocol 11-N-0051 Epilepsy Surgery.
11511555|NCT01273116|Experimental|CWS in Hospital|CWS in Hospital in addition to usual care
11511556|NCT01273103|Experimental|Treatment|[14C]- GSK2248761 200 mg
11511557|NCT01273090|Experimental|Treatment|
11511558|NCT01273077||Evaluation of Rotarix Program|All infants in Nova Scotia DHA 9 and PEI born after October1, 2010 until September 31, 2012 will be eligible for Rotarix immunization as part of the publicly funded immunization program. New Brunswick will serve as the non-intervention control location.
11511559|NCT01273077||Retrospective Surveillance|All laboratory- confirmed cases of rotavirus gastroenteritis and all cause diarrhea admitted to the trial hospitals from 2008-2010 will be entered in the database.
11511560|NCT01273077||Prospective Surveillance|Will begin on December 1, 2010. Data will be collected to identify hospitalizations for all cause diarrhea and rotavirus gastroenteritis at all 3 sites through the first two consecutive rotavirus seasons following vaccination.
11511561|NCT01273077||Safety Intussusception|Each trial hospital will identify cases of severe diarrhea and intussusception in Rotarix vaccine recipients through the first two consecutive rotavirus seasons following vaccination.
11511562|NCT01273077||ED Rotavirus Snap Shot Study|During rotavirus peak season, a prospective study of a sample of children under the age of 2 years presenting with diarrhea with or without vomiting to the ER of participating trial centers will be conducted.
11511563|NCT01273077||KAB Questionnaire for HCP and Parents|Data will be collected by a validated survey given to Parents, Healthcare providers and Program organizers throughout the 2 year program.
11511564|NCT01273064|Experimental|CTS-1027 60 mg + ribavirin + peglyated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027, 60 mg (supplied in a blinded kit containing two bottles of 30 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 120 mg.
11511659|NCT01272453||Prospective Patient Group|Data from patients in the Flash group will be obtained prospectively from scanner consoles and medical records.
11511565|NCT01273064|Experimental|CTS-1027 30 mg + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027 30 mg, supplied in a blinded kit containing one bottle of 30 mg tablets, and one bottle of placebo tablets (in order to maintain blind). One tablet from each of the bottles is taken twice daily, for a total daily dose of 60 mg of CTS-1027.
11511566|NCT01273064|Experimental|CTS-1027 15 mg + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027 15 mg (supplied in a blinded kit containing one bottle each of of 5 mg and 10 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 30 mg.
11511567|NCT01273064|Active Comparator|placebo + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus placebo (supplied in a blinded kit containing two bottles of placebo tablets). One tablet is taken from each of the placebo bottles twice daily, for a total daily dose of 4 tablets.
11511568|NCT01273038|Active Comparator|SenSura|The reference product is the CE marked and launched SenSura product which is commercially available
11511569|NCT01273038|Experimental|Morfeus|The test product is the product with the proposed new Morfeus filter
11511570|NCT01273012|Placebo Comparator|Placebo|The group of patients treated with placebo.
11511571|NCT01273012|Experimental|Infloran|The group of patients treated with Infloran.
11511572|NCT01272999||1|Otitis media cases
11511573|NCT01272986|Placebo Comparator|Healthy patients|
11511574|NCT01272986|Active Comparator|Asymptomatic myocardial Ischemic patients|
11511575|NCT01272986|Active Comparator|Acute Coronary Syndrome Patients|
11511576|NCT01272973|Experimental|Oral 1|
11511577|NCT01272973|Experimental|Oral 2|
11511578|NCT01272973|Experimental|Oral 3|
11511579|NCT01272973|Active Comparator|S.c.|
11511580|NCT01272960|Active Comparator|Interval Insertion|Will receive Mirena at 4-8 weeks post-partum after vaginal delivery.
11511581|NCT01272960|Experimental|Post-Placental Mirena Insertion|Will receive Mirena insertion within 10 minutes of delivery of placenta
11511582|NCT01272947|Experimental|Diclofenac sodium topical gel 1%|
11511583|NCT01272947|Placebo Comparator|placebo|
11511584|NCT01272934|Placebo Comparator|Placebo|
11511585|NCT01272934|Experimental|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%
11511586|NCT01272921|Active Comparator|Bupivacaine|Varying does to determine duration of analgesia following a sciatic nerve block
11511587|NCT01272921|Active Comparator|Ropivacaine|Varying does to determine duration of analgesia following a sciatic nerve block
11511588|NCT01272908|Experimental|Single arm|
11511589|NCT01272895|Experimental|GENOUS stent|
11511590|NCT01272882|Experimental|Adults with ARDS or ALI|Adults with PaO2/FiO2 ratio less than 300. Consented patients will be placed on EIT monitor. The only intervention is the addition of Electrical Impedance Tomography monitoring using the Chest belt with 16 electrodes connected to the EIT device. No changes to standard patient care will occur other than collecting EIT monitor data.
11511591|NCT01272869|Active Comparator|Sensura|SenSura is the reference product and the product is already commercially available
11511592|NCT01272869|Experimental|Morfeus|The test product is the product with the proposed new filter (Morfeus)
11511593|NCT01272856|Experimental|Open Label Abatacept|
11511594|NCT01272843||Carotid endarterectomy patients|
11511595|NCT01272843||Lumbar stenosis laminectomy patients|
11511596|NCT01272830|Experimental|oral Apatone®B|An amalgam of Vitamins C & K3
11511597|NCT01272830|Placebo Comparator|Placebo|Oral capsule of similar appearance and taste without Apatone®B
11511598|NCT01272817|Other|Cladribine + melphalan|Cladribine + melphalan conditioning
11511599|NCT01272817|Other|TLI|Total lymphoid irradiation conditioning
11511600|NCT01272804|Experimental|PF-04937319|
11511601|NCT01272804|Placebo Comparator|Placebo|
11511602|NCT01272791|Experimental|Gemcitabine, bavituximab|Gemcitabine will be administered on Days 1, 8, 15 of each 28-day (4 weeks) cycle until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will receive 3 mg/kg weekly (in addition to gemcitabine) until disease progression or unacceptable toxicities
11511603|NCT01272791|Active Comparator|Gemcitabine|Patients randomized to Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities.
11511604|NCT01272778|Experimental|Lorazepam 0.2 mg|All subjects receive lorazepam 0.2 mg in this crossover design.
11511605|NCT01272778|Experimental|Lorazepam, 0.5 mg|All subjects receive lorazepam 0.5 mg in this crossover design.
11511606|NCT01272778|Experimental|Lorazepam, 1.0 mg|All subjects receive lorazepam 1.0 mg in this crossover design.
11511607|NCT01272778|Experimental|Lorazepam, 2.0 mg|All subjects receive lorazepam 2.0 mg in this crossover design
11511608|NCT01272778|Placebo Comparator|Sugar pill|All subjects receive a sugar pill in this crossover design.
11511609|NCT01272765|Placebo Comparator|Control Group|
11511610|NCT01272765|Experimental|Risperdal Group|Subjects who are on a stable dose of Ripserdal and taking 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
11511611|NCT01272765|Experimental|Seroquel Group|Subjects who are on a stable dose of Seroquel and taking 500 mg of IHBG-10 15 minutes before the three main meals of the day.
11511612|NCT01272765|Experimental|Zyprexa Group|Subjects who are on a stable dose of Zyprexa and taking 500 mg of IHBG-10 15 minutes prior to the three main meals of the day.
11511613|NCT01272752|Experimental|Study Group|Subjects will take 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
11511614|NCT01272752|Placebo Comparator|Control Group|Subjects will take a placebo 15 minutes prior to the three main meals of the day.
11511615|NCT01272739|Experimental|Study Group|Subjects will take 500 mg of the investigational product 15 minutes prior to the 3 main meals of the day.
11511616|NCT01272739|Placebo Comparator|Control Group|Subjects will take a placebo 15 minutes prior to the three main meals of the day.
11511617|NCT01272726||ADHD|Women with symptoms of ADHD. Women who either think they may have ADHD or have been previously diagnosed with ADHD but have not been treated for it.
11511660|NCT01272427|Experimental|noncaloric beverage|noncaloric sweetened beverage administered 30 min prior to mealtime
11511618|NCT01272713|Other|Oxygen therapy|"Standard acute coronary syndrome treatment as per hospital protocol
~Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min
~In-hospital oxygen as per hospital protocol"
11511619|NCT01272713|Other|No oxygen therapy|"Standard acute coronary syndrome treatment as per hospital protocol
~No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%."
11511620|NCT01272700|Experimental|PCV|Peak airway pressure were set to deliver a tidal volume of 10 ml/kg of ideal body weight
11511621|NCT01272700|Active Comparator|VCV|After anesthetic induction, anesthesia maching were set to deliver a tidal volume of 10 ml/kg of ideal body weight
11511622|NCT01272687||Observation|Adults (>18 years) with a confirmed diagnosis of Parkinson's disease
11511623|NCT01272674|Active Comparator|exercise training|4 weeks of supervised physical exercise training
11511624|NCT01272674|No Intervention|control|sedentary lifestyle
11511625|NCT01272674|No Intervention|healthy control|
11511626|NCT01272661|Active Comparator|Enhanced Curriculum|New Enhanced Breastfeeding Curriculum with 11 brief modules
11511627|NCT01272661|Active Comparator|Enhanced Curriculum+Breastfeeding Doula|"Enhanced Curriculum + mother selects a support person to learn about breastfeeding with her and support her postpartum (breastfeeding doula)"
11511628|NCT01272661|Active Comparator|Enhanced Curriculum +Father Support|Enhanced Curriculum+ mother provides father-friendly information about breastfeeding to her partner plus an invitation to an educational group for fathers
11511629|NCT01272648|Active Comparator|Rehabilitation|note intervention
11511630|NCT01272648|Placebo Comparator|Control|same radiotherapy but no rehabilitation
11511631|NCT01272635|Experimental|Azythromycin (APRIL) and Prednisolone (OCELOT)|
11511632|NCT01272635|Experimental|Azythromycin (APRIL) and Placebo (OCELOT)|
11511633|NCT01272635|Experimental|Placebo (APRIL) and Prednisolone (OCELOT)|
11511634|NCT01272635|Placebo Comparator|Placebo (APRIL) and Placebo (OCELOT)|
11511635|NCT01272622|Other|Arm I|"Children and adolescents >= 18 years of age new diagnosed with craniopharyngioma
~>= 5 years of age and with incomplete resected tumor => randomized in two arms: immediate irradiation after surgery"
11511636|NCT01272622|Other|Arm II|incomplete resection, wait and watch, MRI-controls every 3 months, and irradiation at the time of progression of residual tumor
11511637|NCT01272609|Experimental|LCP + Timolol|Three sessions of LCP in 595 nm (diameter of spot 7mm; duration of shooting 1,5 ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
11511638|NCT01272609|Active Comparator|LCP|Three sessions of LCP in 595 nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure © spaced out of 1 month.
11511639|NCT01272596||Multiple Sclerosis Patients|Patients with Clinically Isolated Syndrome or definite Multiple Sclerosis (either relapsing-remitting or secondary progressive)
11511640|NCT01272583|Other|Sequence A (sitagliptin→placebo)|Cross-over, both arms reveived the same intervention in different order.
11511641|NCT01272583|Other|Sequence B (placebo→sitagliptin)|Cross-over, both arms reveived the same intervention in different order.
11511642|NCT01272570||Aromatase Inhibitor|"Diagnosis of BCa- Histologic confirmed diagnosis of BCa: Stage 0, I, II, or III with no evidence of metastatic disease.
~Treatment- AI as clinically indicated (AI may be anastrozole, exemestane or letrozole). Subjects may have had prior tamoxifen or raloxifene. Subjects may have had chemotherapy and/or radiation therapy. Must be within the first year of consecutive AI therapy. If a subject started AI, discontinued, then restarted, they will be accepted into the study as long as the past therapy did not exceed 12 months and the current therapy has not exceeded 12 months."
11511643|NCT01272570||Control|• No Diagnosis of cancer.- Patients must not have a diagnosis of any cancer (Not including a history of thyroid or skin cancer).
11511644|NCT01272557|Active Comparator|Sorafenib 400 mg bid (oral) continuously|Sorafenib 400 mg bid (oral) continuously until progression or unacceptable toxicity).
11511645|NCT01272557|Experimental|q22d: Doxorubicin 60 mg/m2 i.v d1, Sorafenib 400 mg bid d3-19|During trial therapy period in Arm-A treated patients will receive doxorubicin infusion with 60mg/m² on day 1 every 21 days for maximum of 18 weeks (or 6 cycles) until a maximal dose of 360mg/m² are reached. Sorafenib 400mg bid (oral) will be administered from day 3-19 every 21 days during the trial therapy period
11511646|NCT01272544||participation in a dental health program|Group 1 - children who participated to a dental health program Group 2 - children who did not participate to dental health program
11511647|NCT01272544||participation in a preventive program|Group 1 - children who participated to the preventive program Group 2 - children who did not participate
11511648|NCT01272531||lithium|All study subjects will be started on lithium and taken off other medications, such as antidepressants, antipsychotic or other mood stabilizers used to control their mood. They will be stabilized over a 3 month time period, observed for one month, the followed every 2 months for 2 years.
11511649|NCT01272531||valproate|Subjects that do not achieve stabilization or relapse while on lithium monotherapy will be started on valproate (VPA), in an identically designed prospective trial of VPA.
11511650|NCT01272505|Placebo Comparator|conventional SILC|Conventional method of single incision laparoscopic cholecystectomy
11511651|NCT01272505|Active Comparator|HS-SILC|
11511652|NCT01272492|Experimental|Computer Use|Participants use the computer with the infant/toddler nutrition/feeding education modules
11511653|NCT01272492|No Intervention|Control|Only answers survey questions.
11511654|NCT01272479||HCV (+)|Hemodialysis patients with chronic hepatitis C
11511655|NCT01272479||HCV (-)|Hemodialysis patients without chronic hepatitis C
11511656|NCT01272479||Control|Healthy volunteers
11511657|NCT01272466|Experimental|peptides from antiapoptotic proteins|
11511658|NCT01272453||Control Group|Data from patients in the control group will be obtained retrospectively from patient medical records and stored image data
11511661|NCT01272427|Experimental|noncaloric beverage (60 min)|noncaloric sweetened beverage administered 60 min prior to mealtime
11511662|NCT01272427|Experimental|glucose beverage|glucose beverage administered 30 min prior to mealtime
11511663|NCT01272427|Experimental|glucose beverage (60 min)|glucose beverage administered 60 min prior to mealtime
11511664|NCT01272427|Experimental|whey protein beverage|whey protein beverage administered 30 min prior to mealtime
11511665|NCT01272427|Experimental|whey protein beverage (60 min)|whey protein beverage administered 60 min prior to mealtime
11511666|NCT01272414|Experimental|BoTox Treatment|Subjects receive BoTox injection to levator complex
11511667|NCT01272414|Placebo Comparator|Saline injection|Saline injection to levator complex
11511668|NCT01272401||Breast cancer patients and survivors|
11511669|NCT01272388|Active Comparator|Tadalafil|
11511670|NCT01272388|Placebo Comparator|Placebo|
11511671|NCT01272375|Experimental|Treatment A PF-04764793|PF-04764793 using inhaler A
11511672|NCT01272375|Experimental|Treatment B PF-04764793|PF-04764793 using inhaler A
11511673|NCT01272375|Experimental|Treatment C PF-04764793|PF-04764793 using inhaler A
11511674|NCT01272375|Experimental|Treatment D PF-04764793|PF-04764793 using inhaler A
11511675|NCT01272375|Experimental|Treatment E PF-04764793|PF-04764793 using inhaler B
11511676|NCT01272375|Experimental|Treatment F PF-04764793|PF-04764793 using inhaler B
11511677|NCT01272375|Experimental|Treatment G PF-04764793|PF-04764793 using inhaler B
11511678|NCT01272362|Experimental|Indacaterol|
11511679|NCT01272349|Experimental|Low oxygen|
11511680|NCT01272349|Sham Comparator|Room Air|
11511681|NCT01272336|Active Comparator|AIH/Sham|Subjects with chronic, motor-incomplete SCI receive AIH and then SHAM
11511682|NCT01272336|Active Comparator|Sham/AIH|Subjects with chronic, motor-incomplete SCI receive SHAM and then AIH
11511683|NCT01272323||Placebo|Subjects previously randomised to receive placebo in study CP005
11511684|NCT01272323||Cat-PAD Group 1|Subjects previously randomised to receive Cat-PAD dose 1 in study CP005
11511685|NCT01272323||Cat-PAD Group 2|Subjects previously randomised to receive Cat-PAD dose 2 in study CP005
11511686|NCT01272310|Experimental|Combination therapy|
11511687|NCT01272297|Experimental|LI-ESWT|Low intensity shock wave treatment- 12 sessions
11511688|NCT01272284|Other|Altis® SIS|Subjects enrolled with Altis® SIS
11511689|NCT01272271||Children|
11511690|NCT01272271||Adults|
11511691|NCT01272258|Experimental|Arm 1|PRO 140
11511692|NCT01272258|Placebo Comparator|Arm 2|Placebo
11511693|NCT01272245|Experimental|Omacetaxine and Cytarabine|Omacetaxine 1.25 mg/m2 SQ every 12 hours x 3 days + Cytarabine 20 mg SQ x 7 days of 4-7 week cycle.
11511694|NCT01272232|Experimental|Lira 3.0 mg|
11511695|NCT01272232|Experimental|Lira 1.8 mg|
11511696|NCT01272232|Experimental|Placebo|
11511697|NCT01272219|Experimental|Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)|
11511698|NCT01272219|Experimental|Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)|
11511699|NCT01272219|Placebo Comparator|Liraglutide Placebo, no Pre-diabetes|
11511700|NCT01272219|Experimental|Liraglutide 3.0mg, Pre-diabetes|
11511701|NCT01272219|Placebo Comparator|Liraglutide Placebo, Pre-diabetes|
11511702|NCT01272206|Experimental|A|
11511703|NCT01272206|Experimental|B|
11511704|NCT01272193|Experimental|IDegAsp OD|
11511705|NCT01272193|Active Comparator|IGlar OD|
11511706|NCT01272180|Experimental|ABCWY+OMV|"Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus Outer Membrane Vesicles (OMV) administered two months apart."
11511707|NCT01272180|Experimental|ABCWY+qOMV|"Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of Outer Membrane Vesicles (qOMV) administered two months apart."
11511708|NCT01272180|Active Comparator|rMenB+OMV|"Subjects in this group received two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine,administered two months apart."
11511709|NCT01272180|Active Comparator|MenACWY|"Subjects in this group received a dose of placebo followed by one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine administered two months later."
11511710|NCT01272154|Experimental|Primary cervical dystonia Patients|
11511711|NCT01272154|Experimental|Primary upperlimb Dystonia Patients|
11511712|NCT01272154|Experimental|Secondary Cervical or Upperlimb Dystonia due to cerebral palsy|
11511713|NCT01272154|Other|Healthy volunteers|
11511714|NCT01272141|Experimental|Arm A: Lapatinib plus Everolimus|
11511715|NCT01272102||Glaucoma|subjects with glaucoma
11511716|NCT01272089|Experimental|Pataday|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once daily for one week
11511717|NCT01272076||Dry AMD and geographic atrophy|Patients diagnosed with dry AMD and geographic atrophy
11511718|NCT01272063||Dry AMD with macular drusen|Patients diagnosed with dry AMD with macular drusen
11511719|NCT01272050|Active Comparator|Arm A: 64 Gy - Radiation Therapy|Arm A: 64 Gy (32 x 2 Gy) without hormonal treatment
11511720|NCT01272050|Active Comparator|Arm B: 70 Gy - Radiation Therapy|Arm B: 70 Gy (35 x 2 Gy) without hormonal treatment
11511721|NCT01272037|Experimental|Arm I (chemotherapy and endocrine therapy)|Patients receive a protocol-approved chemotherapy regimen based on the patient and/or physician preference. Patients then receive a protocol-approved adjuvant endocrine therapy comprising tamoxifen citrate, an aromatase inhibitor (anastrozole, letrozole, or exemestane), or both for 5-10 years in the absence of disease progression or unacceptable toxicity.
11511722|NCT01272037|Experimental|Arm II (endocrine therapy)|Patients receive a protocol-approved endocrine therapy comprising tamoxifen citrate, an aromatase inhibitor (anastrozole, letrozole, or exemestane), or both for 5-10 years in the absence of disease progression or unacceptable toxicity.
11511723|NCT01272024|Active Comparator|Information/Education Group|Assistance in using Symptom Management Toolkit
11511840|NCT01271244|Active Comparator|PTSD Depression Group|Escitalopram 10-20 mg/day
11512492|NCT01266733|No Intervention|Usual treatment|
11511724|NCT01272024|Experimental|Nurse Intervention|Participants are given intensive nurse contacts to reduce uncertainty and maximize problem solving, and later, to transition to the treatment phase of their cancer.
11511725|NCT01272011|Experimental|Phase 1 Arm (Pilot)|Individuals were exposed to intermittent hypoxia and locomotor training to establish our interventions (set up lab, train personnel, develop study protocols/interventions, etc)
11511726|NCT01272011|Experimental|Phase 2 Arm (LTF)|Individuals were exposed to 10 days of intermittent hypoxia to determine the effect of this intervention on ventilatory long-term facilitation, as measured by minute ventilation
11511727|NCT01272011|Other|Phase 3 Arm (Ventilatory Loading)|Individuals were exposed to 10 days of intermittent hypoxia to determine changes in ventilatory loading.
11511728|NCT01271998|Experimental|healthy volunteer|healthy volunteers
11511729|NCT01271985|Active Comparator|PolyPill|PolyPill once daily and Minimal Care
11511730|NCT01271985|Active Comparator|Minimal care|Minimal care.
11511731|NCT01271985|No Intervention|Usual care|Basic primary health care provided by the local physicians and Community Health Workers consistent with the current Iranian Health Care System guidelines.
11511732|NCT01271972|Experimental|Cohort 1|Dose 1
11511733|NCT01271972|Experimental|Cohort 2|Dose 2
11511734|NCT01271972|Experimental|Cohort 3|Dose 3
11511735|NCT01271972|Experimental|Cohort 4|Dose 4
11511736|NCT01271972|Experimental|Cohort 5|Dose 5
11511737|NCT01271972|Experimental|Expansion Cohort 1|Dose 4
11511738|NCT01271972|Experimental|Expansion Cohort 2|Dose 5
11511739|NCT01271946|Other|Diagnostic Procedure|
11511740|NCT01271933|Experimental|Pregabalin|
11511741|NCT01271933|Placebo Comparator|Placebo|
11511742|NCT01271920|Experimental|AUY922 + Trastuzumab|
11511743|NCT01271907|Experimental|Cohort 0|Drosophila generated CTL + SQ IL-2 Drug: 1 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL) (CTL-05), aldesleukin Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
11511744|NCT01271907|Experimental|Cohort 1|2 Experimental Lymphodepleting regimen +Cells+Low dose IL-2 Drug: 2 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL), aldesleukin Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
11511745|NCT01271907|Experimental|Cohort 2|1 Experimental Lymphodepleting regimen +Cells Drug: 3 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL) Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells
11511746|NCT01271894|Experimental|Reduced dose Efavirenz arm|Participants randomized in main study to receive EFV (400 mg once daily; 2 x 200 mg + 1 x placebo once daily) plus tenofovir/emtricitabine (300/200 mg) fixed-dose combination once daily
11511747|NCT01271894|Active Comparator|Normal Efavirenz dose arm|Patients randomized in the main study to receive EFV (600 mg once daily; 3 x 200 mg once daily) plus tenofovir/emtricitabine (300/200 mg) fixed-dose combination once daily
11511748|NCT01271881|Active Comparator|Percutaneous Transluminal Angioplasty (PTA) alone|Intervention: Procedure: PTA alone without use of the GORE VIABAHN
11511749|NCT01271881|Experimental|PTA with covered stent|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
11511750|NCT01271868|Experimental|IB1001|
11511751|NCT01271855|Placebo Comparator|Glycerin suppository|Women assigned to this arm receive a glycerin suppository (placebo) every 8 hours after delivery during the first 24 hours postpartum
11511752|NCT01271855|Experimental|Belladonna and opioid suppository|Women assigned to this arm receive a belladonna and opioid (B&O) suppository every 8 hours after delivery during the first 24 hours postpartum
11511753|NCT01271842||Extra corporeal oxygenation|Survivors of ARDS due to influenza A (H1N1)2009 infection who needed an extracorporeal oxygenation at the time of infection
11511754|NCT01271842||No extracorporeal oxygenation|Survivors of ARDS due to influenza A (H1N1) 2009 infection who did not need an extracorporeal oxygenation at the time of infection
11511755|NCT01271829|No Intervention|Control|While on the control arm subjects will be given a meal with no avocado.
11511756|NCT01271829|Active Comparator|Avocado supplement|While on the avocado supplement arm subjects will be given a meal in which a given amount of calories will be replaced by calories contributed by avocados.
11511757|NCT01271829|Active Comparator|Avocado included|While on the avocado included arm subjects will be given a meal in which the calories of avocado will be added to the calories of the control meal.
11511758|NCT01271816||Presymptomatic ARVC gene carriers|ARVC gene positive patients without manifest ARVC after standard screening clinical testing.
11511759|NCT01271803|Experimental|DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 milligrams (mg) cobimetinib once daily (QD) on Days 1-14, followed by 14 days off on Days 15-28 (14/14 dosing schedule) and oral 720 mg vemurafenib twice daily (BID) on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
11511760|NCT01271803|Experimental|DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on Days 1-21, followed by 7 days off on Days 22-28 (21/7 dosing schedule) and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
11511761|NCT01271803|Experimental|DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
11511762|NCT01271803|Experimental|DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on Days 1-28 (28/0 dosing schedule) and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
11511841|NCT01271244|Active Comparator|Major Depression Group|Escitalopram 10-20 mg/day
11511842|NCT01271231|Placebo Comparator|Group IP1|
11511843|NCT01271231|Experimental|Group IP2|
11511763|NCT01271803|Experimental|DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 28/0 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
11511764|NCT01271803|Experimental|DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 80 mg cobimetinib QD on 14/14 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
11511765|NCT01271803|Experimental|DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 100 mg cobimetinib QD on 14/14 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
11511766|NCT01271803|Experimental|DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 14/14 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
11511767|NCT01271803|Experimental|DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 80 mg cobimetinib QD on 14/14 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
11511768|NCT01271803|Experimental|Cobimetinib Monotherapy (100 mg or 60 mg)|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule, or oral 100 mg cobimetinib QD on 14/14 dosing schedule of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
11511769|NCT01271803|Experimental|CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
11511770|NCT01271803|Experimental|CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
11511771|NCT01271790|Active Comparator|Arm 1|GS-9451 and Tegobuvir (GS-9190) in combination with Pegasys® and Copegus® for 16 or 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
11511772|NCT01271790|Active Comparator|Arm 2|GS-9451 (active) and Tegobuvir (GS-9190) placebo in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
11511773|NCT01271790|Placebo Comparator|Arm 3|Placebo matching Tegobuvir (GS-9190) and GS-9451 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® will be continued for up to 48 weeks total duration
11511774|NCT01271777|Experimental|GFT505 80mg|
11511775|NCT01271777|Placebo Comparator|Matching placebo|
11511776|NCT01271764|No Intervention|endometrial cancer|
11511777|NCT01271751|Experimental|GFT505 80mg|
11511778|NCT01271751|Placebo Comparator|Matching placebo|
11511779|NCT01271738|Active Comparator|Breast Conserving Surgery (BCS)|
11511780|NCT01271738|Active Comparator|Breast Conserving Surgery with Additional 5 Margins (BCS + M)|
11511781|NCT01271725|Experimental|Afatinib 40mg once daily (OD)|Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
11511782|NCT01271725|Experimental|Paclitaxel 80 mg/m2 weekly|Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
11511783|NCT01271725|Experimental|Vinorelbine 25 mg/m2 weekly|Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
11511784|NCT01271712|Experimental|Regorafenib (Stivarga, BAY73-4506)|Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
11511785|NCT01271712|Placebo Comparator|Placebo|Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
11511786|NCT01271699||Observation|Patients at age 18-50 with a confirmed or probably diagnosis of Multiple Sclerosis according to the McDonald diagnostic criteria for MS
11511787|NCT01271686|Experimental|0.01% bimatoprost|bimatoprost 0.01% one time per day at bedtime for 4 weeks.
11511788|NCT01271673||Women undertaking Breast Self Examination|Women attending Preventive Oncology Clinic during the month of November- December 2010,and undertaking BSE training whose Residential address mentioned as Mumbai and whose Contact number is available.
11511789|NCT01271660|Active Comparator|Pregabalin|"30 randomly allocated patients after a 4-week run-in period, who will take part in a 6-week treatment period with pregabalin.
~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as standard dose period + 75mg twice a day for a week as tapering period."
11511790|NCT01271660|Placebo Comparator|Placebo|"30 randomly allocated patients after a 4-week run-in period, who will take part in a 6-week treatment period with placebo.
~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as standard dose period + 75mg twice a day for a week as tapering period."
11511791|NCT01271647|Experimental|chinese herb|
11511792|NCT01271647|Experimental|placebo|
11511793|NCT01271621|Active Comparator|Macintoch group|Intubation with Macintoch Laryngoscope
11511794|NCT01271621|Experimental|Glidescope|Inubation by Glidescope
11511795|NCT01271595|Active Comparator|acupuncture|12 sessions of acupuncture according to TCM
11511796|NCT01271595|Sham Comparator|sham acupuncture|superficial acupuncture at non acupuncture sites
11511797|NCT01271582|Experimental|FOLFIRI|Patients with colorectal cancer or gastric cancer will be treated with FOLFIRI(Irinotecan, 5FU, leucovorin) regimen upto 12 cycles. (Single arm study)
11511798|NCT01271569|Other|In the treatment arm|
11511844|NCT01271231|Active Comparator|Group IP3|
11511933|NCT01270568|Active Comparator|Relaxation Response|Meditation-based treatment
11511799|NCT01271556|Experimental|1, salmeterol, saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to each test day. Salmeterol 50 mcg on days A was administered between 8 AM and 10 AM. Patients and healthy subjects underwent a rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment (salmeterol 50 mcg MDI), and mixed venous blood was withdrawn for measurements of hematocrit (Htc), Hb, and albumin concentration 10 minutes before and 10 minutes after the infusion. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
11511800|NCT01271556|Placebo Comparator|2, placebo, saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Placebo was administered between 8 AM and 10 AM. Patients and healthy subjects underwent a rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment (placeboI), and mixed venous blood was withdrawn for measurements of hematocrit (Htc), Hb, and albumin concentration 10 minutes before and 10 minutes after the infusion. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
11511801|NCT01271556|Active Comparator|3, salmeterol, no saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Salmeterol 50 mcg on days A was administered between 8 AM and 10 AM. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
11511802|NCT01271556|Placebo Comparator|4, placebo, no saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Placebo was administered between 8 AM and 10 AM. 240 and 290 minutes after inhalatory treatment (placebo), pulmonary function tests were performed.
11511803|NCT01271543|Active Comparator|MacIntosh group|
11511804|NCT01271543|Experimental|Shikani optical stylet|
11511805|NCT01271530|Experimental|Exercise|
11511806|NCT01271530|No Intervention|Control|
11511807|NCT01271517|Active Comparator|Insulatard|Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugars
11511808|NCT01271517|Active Comparator|Lantus|Treatment once daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
11511809|NCT01271517|Active Comparator|Levemir|Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
11511810|NCT01271504|Active Comparator|Phase Ib: Cohort 1,2, and 3|Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib
11511811|NCT01271504|Active Comparator|Phase II: Arm 1; E7050 + Sorafenib|Phase II: Arm 1; E7050 + 400 mg Sorafenib Arm 2; 400 mg Sorafenib
11511812|NCT01271491||Cases|Children hospitalized in the ICU with bronchiolitis
11511813|NCT01271491||Controls|Children hospitalized in the general ward with bronchiolitis
11511814|NCT01271478|Experimental|Telmisartan plus Captopril|captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day)
11511815|NCT01271478|Experimental|Telmisartan plus Placebo|telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day) plus 1 tablet of placebo orally twice a day
11511816|NCT01271478|Experimental|Captopril plus Placebo|patients received captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
11511817|NCT01271478|Placebo Comparator|Placebo|2 tablets of placebo orally twice a day
11511818|NCT01271452|Active Comparator|Vistabel®|botulinum toxin type A (Vistabel®)
11511819|NCT01271452|Active Comparator|Bocouture®|botulinum toxin type A (Bocouture®)
11511820|NCT01271439|Experimental|cetuximab|
11511821|NCT01271413|Experimental|Adaptive cognitively stimulating activities|
11511822|NCT01271413|Active Comparator|Non-adaptive cognitively stimulating activities|
11511823|NCT01271387|Experimental|Moderate Hepatic Impairment|
11511824|NCT01271387|Experimental|Mild Hepatic Impairment|
11511825|NCT01271387|Experimental|Healthy Volunteers|
11511826|NCT01271374|Active Comparator|Hyzaar-Treatment Arm B|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
11511827|NCT01271374|Active Comparator|Azor-Treatment A|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
11511828|NCT01271361|Experimental|primary PCI with thrombectomy|thrombectomy before implantation of drug eluting stent
11511829|NCT01271361|Active Comparator|primary PCI without thrombectomy|implantation of a drug eluting stent without thrombectomy
11511830|NCT01271348|Active Comparator|Etoricoxib|
11511831|NCT01271348|Placebo Comparator|Placebo tablet|
11511832|NCT01271335|Experimental|Collagenase (MZ-004)|Local intra-coronary administration of MZ-004 at or into the CTO
11511833|NCT01271309||Acute Myocardial Infarction patients|Patients with thoracic pain lasting at least 20 min and ST changes or left B block, not present in previous ECG.
11511834|NCT01271296|Active Comparator|Liquorice|Liquorice eq to 150 mg glycyrrhizinic acid. Results are compared to a baseline assessment without liquorice/grapefruit juice ingestion.
11511835|NCT01271296|Active Comparator|Grapefruit juice|200 ml pink grapefruit juice three times a day. Results are compared to a baseline assessment without liquorice/grapefruit juice ingestion.
11511836|NCT01271296|No Intervention|Baseline|Baseline assessment without intake of liquorice or grapefruit juice
11511837|NCT01271283|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (by morphological criteria but have persistent minimal residual disease by molecular criteria) or partial response may continue treatment beyond 8 courses. Patients may undergo bone marrow, peripheral blood, and/or lymph node sample collection at baseline and periodically during study for correlative studies.
11511838|NCT01271257|Experimental|hourly misoprostol|20 microgram misoprostol intake per hour
11511839|NCT01271257|Active Comparator|traditional misoprostol|80 microgram misoprostol intake per 4 hours
11511845|NCT01271218|Placebo Comparator|Placebo|Participants ingested 2,200 mg/day of a placebo or active dietary supplement. Participants ingested three caplets in the morning and the remaining three caplets in the evening 30-minutes before a meal for 14-weeks. The supplements were prepared in caplet form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.
11511846|NCT01271218|Active Comparator|Active Supplement|Participants were randomly assigned to ingest in a double-blind manner caplets containing a commercially available glucosamine/chondroitin (GC) dietary supplement (Curves Joint and Connective Support™, Curves International, Waco, TX) or a suitable placebo (P). The GC supplement provided a total of 1,500 mg/d of glucosamine, 1,200 mg/d of chondroitin sulfate, 120 mg/d of niacin, 120 mg/d of sodium, 45 mg/d of zinc, 900 mg/d MSM, 300 mg/d of boswellia serrata extract, 180 mg/d of white willow bark extract, and 15 mg/d of rutin powder. Participants ingested three caplets in the morning and the remaining three caplets in the evening 30-minutes before a meal for 14-weeks.
11511847|NCT01271192|Active Comparator|Surgical resection and adjuvant therapy|Patients receive surgical resection and undergo FOLFIRI for 12 cycles, from 2-4 weeks after operation. Patients undergo radiotherapy once daily 5 days a week for 5-6 weeks, from 8-12 weeks after operation
11511848|NCT01271192|Experimental|Neoadjuvant followed by operation|Patients receive neoadjuvant chemoradiotherapy (mFOLFIRI for 5 cycles and undergo radiotherapy as in arm I from the second cycle of FOLFIRI), surgery and FOLFORI for 7 cycles from 2-4 weeks after operation.
11511849|NCT01271179|Active Comparator|sequential perfusion|sequential perfusion of liver grafts with low-viscosity improved Ross solution and high-viscosity UW solution.
11511850|NCT01271179|Placebo Comparator|sole perfusion|sole perfusion of liver grafts with high-viscosity UW solution only
11511851|NCT01271166|Experimental|Glivec®, modified FOLFOX, Avastin®|
11511852|NCT01271153|Active Comparator|Dobutamine|Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours
11511853|NCT01271153|Placebo Comparator|Placebo|An equivalent infusion of placebo will be infused for 2.5 h
11511854|NCT01271140|Experimental|Insulin/dextrose clamp|
11511855|NCT01271114|Experimental|Hypertonic Saline and Terlipressin|
11511856|NCT01271114|Active Comparator|Normal Saline and norepinephrine|
11511857|NCT01271101||anticoagulant|
11511858|NCT01271088|Experimental|N-acetylcysteine|N-acetylcysteine: Experimental N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin
11511859|NCT01271088|No Intervention|Control|Vancomycine and/or amikacin alone
11511860|NCT01271075|Active Comparator|Bilastine A|A: Crossover Bilastine 20 mg, Bilastine 40 mg, Placebo, Bilastine 80 mg
11511861|NCT01271075|Active Comparator|Bilastine B|B: Crossover Bilastine 80 mg, Placebo, Bilastine 40 mg, Bilastine 20 mg
11511862|NCT01271062|Active Comparator|T2DM patients before gastric bypass surgery|oral glucose tolerance test , botnia clamp, preoperative as well as 10 days postoperative and 1 year postoperative, gastric bypass surgery.
11511863|NCT01271062|Active Comparator|Non-diabetic patient before gastric bypass surgery|oral glucose tolerance test , botnia clamp, preoperative as well as 10 days postoperative and 1 year postoperative, gastric bypass surgery.
11511864|NCT01271062|Active Comparator|non diabetic patients, non-bariatric abdominal surgery|oral glucose tolerance test , botnia clamp, elective laparoscopic abdominal surgery.
11511865|NCT01271062|Active Comparator|severely obese T2DM patients following a very low caloric diet|oral glucose tolerance test , botnia clamp, before as well after following a very low caloric diet. Very low caloric diet.
11511866|NCT01271049|Placebo Comparator|Control Food Product|Consumption of placebo food product
11511867|NCT01271049|Experimental|Novel Food Product|Consumption of novel food product
11511868|NCT01271036|Experimental|Formula PD-F-7716|Apply a dime-size amount on each application site as instructed during the 1-week study period
11511869|NCT01271023|Experimental|Closed-Loop Control|The Control to Range algorithm will be used in conjunction with continuous glucose monitoring and insulin pump delivery to manage the subject's blood glucose.
11511870|NCT01271010|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants received rituximab 375 milligrams per square meter (mg/m^2) intravenously (IV) on Day 1 of Cycle 1, then 500 mg/m^2 IV on Day 1 of each subsequent cycle; fludarabine 25 mg/m^2 IV or 40 mg/m^2 orally on Days 1-3 of each cycle and cyclophosphamide 250 mg/m^2 IV or 250 mg/m^2 orally on Days 1-3 of each cycle. Treatment duration was 6 cycles, 28 days each.
11511871|NCT01270997|Experimental|HD203|Subcutaneous injection (SC) HD203 25mg twice a week for 48 weeks
11511872|NCT01270997|Active Comparator|Enbrel|Subcutaneous injection (SC) Enbrel® 25mg twice a week for 48 weeks.
11511873|NCT01270984|Experimental|Luckyvec 400mg film coated tablet|400mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
11511874|NCT01270984|Active Comparator|Glivec 100mg film coated tablet|100mg/tablet, PO, 4 tablets once daily for Period I & II D1(crossover)
11511875|NCT01270971|Experimental|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%
11511876|NCT01270971|Placebo Comparator|Solution Vehicle|Solution Vehicle
11511877|NCT01270958|Experimental|TREATMENT|50 adult patients with Perennial Allergic Rhinities treated with Avamys.
11511878|NCT01270945|Experimental|CV-18C3 and standard of care|CV-18C3 and standard of care
11511879|NCT01270945|Active Comparator|standard of care|Percutaneous revascularization
11511880|NCT01270932|Experimental|Lenalidomide and Dexamethasone|"Lenalidomide:Daily for 21 days of a 28 day cycle
~Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4."
11511881|NCT01270919|Other|BioDuct Meniscal Repair Device|BioDuct Meniscal Repair Device
11511882|NCT01270906|Experimental|CHIR-258 (TKI258)|
11511883|NCT01270893|Experimental|Nilotinib and Surgical Resection|
11511884|NCT01270893|Experimental|Nilotinib and Potential Resection|
11511885|NCT01270880|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11511886|NCT01270867|Active Comparator|Merci Retriever|Merci Retriever is the predicate product that received FDA clearance in 2004. Merci Retriever a first generation mechanical thrombectomy device intended to remove clot and restore blood flow in a neurovascular vessel in the setting of acute ischemic stroke.
11513183|NCT01262170|Active Comparator|Tobacco Lozenge|Tobacco Lozenge
11511887|NCT01270867|Experimental|Trevo Stentriever|Trevo Retriever is a second generation mechanical thrombectomy device intended to remove clot and restore blood flow in a neurovascular vessel in the setting of acute ischemic stroke. The Trevo Retriever is a type of stent, specifically design to allow for clot integration into the device. The clot in the retriever is then removed and blood flow is restored.
11511888|NCT01270854|Experimental|Plasmalyte|Administration of Plasmalyte A as the standard intravenous fluid during the first 24 hours after arrival to the hospital
11511889|NCT01270854|Active Comparator|Normal Saline|Administration of Normal Saline as the standard intravenous fluid during the first 24 hours after arrival to the hospital
11511890|NCT01270841|Placebo Comparator|Placebo|Placebo
11511891|NCT01270841|Active Comparator|Testim (topical testosterone)|Testim (topical testosterone)
11511892|NCT01270841|Experimental|Androxal 12.5 mg|Androxal 12.5 mg/day
11511893|NCT01270841|Experimental|Androxal 25 mg|Androxal 25 mg/day
11511894|NCT01270828|Experimental|Pregablain CR tablet 82.5 to 660mg|
11511895|NCT01270828|Placebo Comparator|Placebo|
11511896|NCT01270815|Experimental|Pregabalin controlled release, 330 mg, 400 to 500 calories|
11511897|NCT01270815|Experimental|Pregabalin controlled release, 330 mg, 600 to 750 calories|
11511898|NCT01270815|Experimental|Pregabalin controlled release, 330 mg, 800 to 1000 calories|
11511899|NCT01270815|Other|Pregabalin immediate release, 300 mg|Reference
11511900|NCT01270802|Active Comparator|Tenofovir/emtricitabine/efavirenz|Tenofovir/emtricitabine/efavirenz
11511901|NCT01270802|Experimental|Tenofovir/emtricitabine plus raltegravir|Tenofovir/emtricitabine/efavirenz is switched to tenofovir/emtricitabine plus raltegravir
11511902|NCT01270789|Experimental|Liraglutide|
11511903|NCT01270789|Placebo Comparator|Placebo|
11511904|NCT01270776|Experimental|Aqueous Chlorhexidine|The group received skin antisepsis using 2% aqueous chlorhexidine solution.
11511905|NCT01270776|Active Comparator|2% Chlorhexidine 70% isopropyl alcohol|The group will receive skin antisepsis with 2% chlorhexidine solution in alcohol.
11511906|NCT01270763||The Look AHEAD Study|The Look AHEAD Study includes intensive lifestyle intervention treatment, focusing on caloric intake and physical activity, and a treatment arm focused on diabetes support and education.
11511907|NCT01270737|Active Comparator|Whole soy|
11511908|NCT01270737|Active Comparator|daidzein|
11511909|NCT01270737|Placebo Comparator|milk powder|
11511910|NCT01270724|Experimental|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)|Two to four cycles of induction therapy with open label GemPOx followed by consolidation and autologous stem cell transplant (ASCT).
11511911|NCT01270711||Cabergoline users|cohort of patients, who are treated with cabergoline during the study period ( from January 1st, 2006 to July 1st 2012)
11511912|NCT01270698|Experimental|IMMU-130|
11511913|NCT01270685||1|Veterans with spinal cord injuries and disorders
11511914|NCT01270685||2|Comparison group: general Veteran population (without spinal cord injuries or disorders)
11511915|NCT01270685||3|Health care providers with face-to-face contact with Veterans with SCI/D
11511916|NCT01270685||4|Infection control Chiefs/Officers
11511917|NCT01270672|Experimental|carvedilol, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
11511918|NCT01270659|Experimental|Low-FBT|Subject will receive FBT and placebo at a low dose
11511919|NCT01270659|Experimental|High-FBT|Subject will receive the high dose regimen of FBT and a high dose placebo
11511920|NCT01270659|Active Comparator|Low control|"Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl placebo"
11511921|NCT01270659|Active Comparator|High control|"Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl placebo"
11511922|NCT01270646|Experimental|Intraventricular Electrical Activation|
11511923|NCT01270633|Other|Treatment|PriMatrix applied to appropriately debrided wound bed and covered with a non-adherent dressing. Dressings applied to maintain moist wound therapy.
11511924|NCT01270633|Active Comparator|Standard of Care|Non adherent dressing applied to appropriately debrided wound bed and moist wound therapy maintained.
11511925|NCT01270620|Active Comparator|Propofol|Patients will receive propofol as general anesthetics.
11511926|NCT01270620|Active Comparator|Desflurane|Patients will receive desflurane as general anesthetics.
11511927|NCT01270607|Experimental|Acupuncture|
11511928|NCT01270594|Experimental|COPD Counseling Intervention|Pharmacist counseling intervention delivered via telephone.
11511929|NCT01270594|Other|Usual Care|
11511930|NCT01270581|Experimental|High Flow Nasal Cannula|Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7. Newborns randomized to HFNC will be started on a flow rate of 4L/min and supplemental oxygen will be provided to maintain oxygen saturations between 88-93% (experimental group). Once initiated, the gas flow rate will be titrated as needed by the attending neonatologist to ameliorate signs of respiratory distress to a maximum flow rate of 6L/min. The nasal cannula size (0.2 cm or 0.3 mm outer diameter) will determined by the caliber of the subject's nares).
11511931|NCT01270581|Active Comparator|Control Group- Bubble Nasal CPAP|NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
11511932|NCT01270568|Experimental|Positive Psychology|8 weekly positive psychology exercises
11513232|NCT01261884|Experimental|Exercise intervention|
11511934|NCT01270568|Sham Comparator|Recollection|Recollection of daily events, recorded weekly
11511935|NCT01270555|Experimental|Bupropion|
11511936|NCT01270542|Experimental|Avastin Injection Group (AIG)|Subjects in this group will get single 0.05 mL intravitreal injection of bevacizumab 1.25 mg 3-7 days prior to surgery for tractional retinal detachment secondary to Proliferative Diabetic Retinopathy.
11511937|NCT01270542|Sham Comparator|Sham Injection Group (SIG)|Subjects in this group will get a sham injection 3-7 days prior to surgery for tractional retinal detachment secondary to Proliferative Diabetic Retinopathy.
11511938|NCT01270529|Experimental|CKD Stages 1-4|
11511939|NCT01270529|Experimental|ESRD on Dialysis|
11511940|NCT01270529|Experimental|Kidney Transplant recipients|
11511941|NCT01270516|Placebo Comparator|Control, to be given saline solution|Intervention: This group will be given saline (30 ml every 12 hours) for 10 days
11511942|NCT01270516|Experimental|EPA, eicosapentaenoic acid|This group will be given 1000 mg EPA every 12 hours for 10 days
11511943|NCT01270516|Experimental|HMB, hydroxymethylbutyrate|This arm will be given HMB (1500 mg) every 12 hours for 10 days.
11511944|NCT01270516|Experimental|EPA and HMB|Intervention: This group will be given EPA (1000 mg every 12 hours given via the GI tract) and HMB (1500 mg every 12 hours given via the GI tract) for 10 days.
11511945|NCT01270503|Experimental|Menactra® Group 1|Participants aged 2 to 11 on enrollment
11511946|NCT01270503|Experimental|Menactra® Group 2|Participants aged 12 to 17 on enrollment
11511947|NCT01270503|Experimental|Menactra® Group 3|Participants aged 18 to 55 on enrollment
11511948|NCT01270490|Experimental|Interferon-gamma|
11511949|NCT01270490|No Intervention|No intervention|No adjunctive treatment
11511950|NCT01270477|Experimental|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment in an hyperbaric oxygen treatment chamber on an recognized treatment table.
11511951|NCT01270464|Placebo Comparator|Placebo|Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses.
11511952|NCT01270464|Experimental|Reslizumab - 0.3 mg/kg|0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses
11511953|NCT01270464|Experimental|Reslizumab - 3.0 mg/kg|3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses.
11511954|NCT01270451|Other|Lifestyle group counseling|Included patients will be randomised into two groups: to the intervention group or to the control group.
11511955|NCT01270438|Experimental|Arm I (RO4929097, combination chemotherapy, bevacizumab)|Patients receive FOLFOX6 regimen comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46 hours, and bevacizumab IV over 30-90 minutes on days 1-2. Patients also receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11511956|NCT01270438|Experimental|Arm II (combination chemotherapy, bevacizumab)|Patients receive FOLFOX6 regimen and bevacizumab as in arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11511957|NCT01270412|Experimental|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml of platelet-derived preparation rich in growth factors
11511958|NCT01270412|Active Comparator|Hyaluronic acid|Drug: hyaluronic acid 20 mg / 2 ml Other Name: Arthrease
11511959|NCT01270399||malignant neoplasm's cells|
11511960|NCT01270399||natural cells|
11511961|NCT01270386|Experimental|Apatinib|Apatinib 750 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11511962|NCT01270386|Placebo Comparator|Placebo|Placebo qd p.o., and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11511963|NCT01270373|Active Comparator|FAC x 3 followed by Docetaxel x 3|
11511964|NCT01270373|Experimental|Docetaxel x 3 followed by FAC x 3|
11511965|NCT01270360||asymptomatic subjects with positive FOBT|individuals having undergone a positive faecal occult blood test (FOBT) and a reference colonoscopy
11511966|NCT01270347|Experimental|Aeroquin|Aeroquin, Inhaled Levofloxacin (MP-376)
11511967|NCT01270347|Active Comparator|TIS|Tobramycin Inhalation solution (TIS) [TOBI® Novartis Pharmaceuticals]
11511968|NCT01270334||ph above cutoff|
11511969|NCT01270334||PH under cutoff|
11511970|NCT01270321|Experimental|Arm A (Everolimus alone)|CURRENTLY CLOSED TO ACCRUAL--Everolimus alone followed by Everolimus + Pasireotide at the time of progression
11511971|NCT01270321|Experimental|Arm B (Pasireotide alone)|CURRENTLY CLOSED TO ACCRUAL--Pasireotide alone followed by Everolimus + Pasireotide at the time of progression
11511972|NCT01270321|Experimental|Arm C (Everolimus + Pasireotide)|CURRENTLY CLOSED TO ACCRUAL
11511973|NCT01270308|Experimental|Lansoprazole DR Capsules 30 mg|Lansoprazole DR Capsules 30 mg of Dr.Reddy's Laboratories Limited
11511974|NCT01270308|Active Comparator|Prevacid 30 mg Capsules|Prevacid 30 mg Capsules of TAP Pharmaceuticals Inc. USA
11511975|NCT01270282|Experimental|AM-101 0.81 mg/mL|Gel for injection; single or triple injection
11511976|NCT01270282|Placebo Comparator|Placebo|Gel for injection; single or triple injection
11511977|NCT01270269|No Intervention|Patients (Controls)|Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
11511978|NCT01270269|Experimental|Behavioral: Phys & Func Rehab|A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.
11511979|NCT01270269|Experimental|Behavioral: Cog/Phys/Func Rehab|A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
11511980|NCT01270256|Active Comparator|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
11511981|NCT01270256|Placebo Comparator|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
11511982|NCT01270243||Control|No tonsilar or adenoid problems
11511983|NCT01270243||Adenotonsillectomy (recurrent)|Recurrent adenotonsillitis
11511984|NCT01270243||Adenotonsillectomy (obstruction)|Upper airway obstruction
11511985|NCT01270230|Experimental|Comparison Group, Standard HIV-CT|The comparison group will receive standardized HIV counseling and testing (HIV-CT), with referrals to case management.
11511986|NCT01270230|Experimental|Intervention Group, Bruthas Counseling|Participants assigned to this arm receive four individual HIV prevention counseling sessions.
11511987|NCT01270217|Experimental|Brief motivational interview|
11511988|NCT01270217|No Intervention|No discussion|
11511989|NCT01270204||Normal Volunteers|Patients older than 55 years of age with no history of voice, swallowing, reflux, or progressive neurologic disease affecting the swallowing mechanism.
11511990|NCT01270204||Patients with Dysphagia|Patients older than 55 years of age with the following condition: Dysphagia (the sensation of swallowing difficulty), globus, gastroesophageal reflux, or any other condition requiring referral for a dynamic swallowing study.
11511991|NCT01270191|Experimental|Exenatide|In the exenatide therapy group, subjects will be instructed in the techniques for injection and be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months. If FPG still greater than 200 mg/dL after 4 weeks of exenatide treatment, they will use insulin for rescue therapy and will be withdrawn from this study.
11511992|NCT01270191|Active Comparator|Humulin-N|In the insulin therapy group (Humulin-N), subjects will be instructed in the techniques for insulin injection and home capillary glucose monitoring. The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
11511993|NCT01270178||Entecavir|
11511994|NCT01270152|Experimental|group 50 mg ascorbic acid|this arm received a dose of 50 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
11511995|NCT01270152|Experimental|group 100mg ascorbic acid|this arm received a dose of 100 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
11511996|NCT01270152|Experimental|group 200mg ascorbic acid|this arm received a dose of 200 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
11511997|NCT01270139|Experimental|Nano group|60 patients in Nano group were treated with transplantation of nanoparticles (NP), particularly with a bioengineered patch that was grown with allogenous stem cells pre-cultivated in the medium with NP. After the admission, patients were examined with QCA, and allocated to the trial. The implantation of the patch onto the artery was undergone by the minimally invasive cardiac surgery (MICS CABG) with fixation of the graft to the epicardial myocardium. MICS CABG implies a beating-heart multi-vessel heart surgery performed through several small incisions under direct vision through an anterolateral mini-thoracotomy in the 4th-6th intercostal spaces. The patients can expect high quality of life resuming all everyday activities within a few weeks of their operation. NP were activated with NIR laser at 7 days after the intervention. Patients were treated with bolus of bivalirudin on the day of NP detonation.
11511998|NCT01270139|Active Comparator|Ferro group|60 patients in Ferro group were managed with transplantation of iron-bearing nanoparticles (NP), particularly with intracoronary infusion of allogenous stem cells or CD68 targeted micro-bubbles pre-cultivated in the medium with iron-bearing NP. Cells and/ or micro-bubbles were infused with QCA- and IVUS-guidance to the target coronary artery via micro-catheter on the day of admission. The destruction of CD68 targeted micro-bubbles was obtained by using a Sonos 5500 machine with an S3 transducer operating in ultraharmonic mode (transmit, 1.3MHz/ receive, 3.6 MHz) with a mechanical index of 1.5 and a depth of 4 cm. The AXIOM Artis dBC (Siemens) magnetic navigation system was used for precise delivery of NP to the atheroma through two permanent computer-controlled external magnets generating a navigational magnetic field of 0.08 Tesla in any direction. NP were detonated with NIR laser under the protection of anti-platelet therapy.
11511999|NCT01270139|Other|Stenting control|In case of control group (stenting control), XIENCE V stent was implanted to 60 patients. Patients with a single de novo native coronary stenosis of less than 12 mm lesion length, more than 50% stenosis and reference diameter of 3.0 mm as assessed by online QCA were stented by a single stent of 3.0 x 18 mm. The procedure of implantation had to be performed according to common interventional practices including the administration of intracoronary nitroglycerine 0.2 mg of glycerol trinitrate or isosorbide dinitrate and intra-arterial heparin (50-100 U/kg body weight). Predilation with a conventional balloon catheter was recommended before DES deployment according to the manufacturer's recommendation. The protocol recommended the study stent should cover 2 mm of non-diseased tissue on either side of the target lesion. Postdilatation was allowed with a balloon that was shorter than was the study device.
11512000|NCT01270126|Experimental|rtACS (Verum condition)|Repetitive transorbital alternating current stimulation (rtACS)
11512001|NCT01270126|No Intervention|Sham stimulation (placebo condition)|A clicking sound was presented and the same electrode montage set-up was used during rtACS- and placebo-stimulation, except that placebo patients received no current (stimulator turned off)
11512002|NCT01270100|Experimental|Recovery management intervention|
11512003|NCT01270087|Other|Adalimumab|
11512004|NCT01270074|Experimental|azithromycin liquid preparation|azithromycin will be given at a dose of 10mg/kg given three times per week from three months of age to three years of age
11512005|NCT01270074|Active Comparator|inert liquid preparation|inert liquid preparation will be given three times per week from three months of age to three years of age
11512006|NCT01270061|Active Comparator|HIV testing|Group 1 (Control) is the current standard of care in HIV testing. A trained counselor provides required information to obtain informed consent for HIV testing and provides rapid HIV testing on site.
11512007|NCT01270061|Experimental|General Health Screening|In Group 2 (Intervention), a theory-based video is used to obtain informed consent for a free general health screening that includes a blood pressure check, blood glucose measurement, and an HIV test.
11512008|NCT01270048|Experimental|Bunsimgieum extract|"name of product: 'mild-x-gwarip'
~standard code for item: 200005689
~shape, type: extract(brown)
~usage, content: adults;three times a day, each taken before or between meals
~dose, standard: 2.5g for each sack, capsulated
~storage : airtight container, stored in room temperature
~expiration date : 36months after manufacture
~macufacturing company: KyungBangnShinYak inc."
11512052|NCT01269736|Experimental|Education|Online ECG monitoring education program and strategies to implement and sustain change for nurses
11512053|NCT01269736|No Intervention|Control|Usual in-service education for nurses
11512009|NCT01270048|Placebo Comparator|Placebo; corn flour,|"raw material: total contents(500㎎); cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)
~shape, type: extract(brown)
~usage, dose: adults: three times a day, 1 sack before or between meals
~dose, standard: 2.5g for each sack, capsulated
~storage : airtight container, stored in room temperature
~expiration date : 36 months after manufacture
~manufacturing company: KyungBangnShinYak inc."
11512010|NCT01270035|Experimental|ADA 80 mg eow + MTX|
11512011|NCT01270022|Experimental|Implementation|
11512012|NCT01270022|Active Comparator|dissemination|
11512013|NCT01269996|Active Comparator|Metformin followed by gliclazide and protaphane|
11512014|NCT01269996|Active Comparator|Janumet followed by Lantus insulin injection|
11512015|NCT01269983|Experimental|fascial manipolation|8 treatment sessions: 4 of fascial manipulation treatment, and 4 of standard physiotherapy (rexing exercise, stretching, abdominal and paravertebral isometric muscular recruiting)
11512016|NCT01269983|Active Comparator|physiotherapy|8 treatment sessions of standard physiotherapy (rexing exercise, stretching, abdominal and paravertebral isometric muscular recruiting)
11512017|NCT01269970||locally advanced esophageal carcinoma (cT2-3N0/+)|
11512018|NCT01269957||Mouth breathing|
11512019|NCT01269957||Nasal breathing|
11512020|NCT01269944||Medial compartment knee osteoarthritis|Patients with medial compartment osteoarthritis of the knee, as proven by x-rays and clinical examination
11512021|NCT01269931||Group 1 (EBUS-TBNA simulator training)|Group 1 (EBUS-TBNA simulator training): pulmonary medicine trainees with >30 bronchoscopy procedures experience, >nine months of pulmonary fellowship training and no clinical EBUS-TBNA experience (n=4).
11512022|NCT01269931||Group 2 (Clinical EBUS-TBNA training)|Group 2 (Clinical EBUS-TBNA training): pulmonary medicine trainees in the 2nd half of their final year of pulmonary training or recent graduates (within one year), with >50 bronchoscopy procedures experience who completed a one-month elective with the Interventional Pulmonary Medicine (IPM) service with ≥15 and ≤25 EBUS-TBNA procedures experience (n=4).
11512023|NCT01269918|Active Comparator|Remifentanil|Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
11512024|NCT01269918|Active Comparator|Dexmedetomidine|a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
11512025|NCT01269905||Group A|Group A patients received mechanical heart valve replacement MHVR (and were educated in INR self-management using the Coagu-Check monitor.
11512026|NCT01269905||Group B|Group B patients received MHVR and their anticoagulation was managed by their general practitioners.
11512027|NCT01269905||Group C|Group C patients received stentless bioprosthesis, with initial 6 weeks on oral anticoagulation managed by their general practitioners.
11512028|NCT01269892|Other|lactose-free milk|it is kind of nutritional regime
11512029|NCT01269892|Other|conventional milk|it is kind of nutritional regime
11512030|NCT01269879|Active Comparator|Active control (Flexi-Bar only)|Flexi-Bar vibration training only over 12 weeks with three distinct exercises and 10min training twice daily
11512031|NCT01269879|Experimental|Intervention Flexi-Bar + XCO-Trainer|Combination intervention using vibration device Flexi-Bar and XCO-Trainer (oscillating mass witin a tube moved during running 40-60min/week suggested)
11512032|NCT01269866|Other|Cymbalta|Cymbalta 60 to 120 mg
11512033|NCT01269853|Experimental|Arm 2|
11512034|NCT01269853|Experimental|Arm 1|
11512035|NCT01269827|Experimental|pentoxifylline|
11512036|NCT01269827|Placebo Comparator|placebo|
11512037|NCT01269814||Go-home group|The patients with a Rockall score of 0 or 1 will be prescribed medical therapy, and will be scheduled for elective gastroscopy.
11512038|NCT01269801|Active Comparator|Botox Cosmetic|onabotulinumtoxinA for injection
11512039|NCT01269801|Active Comparator|JUVÉDERM|JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel
11512040|NCT01269788|Active Comparator|pH positive-omeprazole|
11512041|NCT01269788|Placebo Comparator|pH positive-placebo|
11512042|NCT01269788|Active Comparator|pH positive-fluoxetine|
11512043|NCT01269788|Active Comparator|pH negative-omeprazole|
11512044|NCT01269788|Active Comparator|pH negative-fluoxetine|
11512045|NCT01269788|Placebo Comparator|pH negative-placebo|
11512046|NCT01269775|Experimental|Face to face lecture|The lecturer allocated 1.5 hours for delivering the lecture by using provided slides about the topic and 0.5 hours for question and answer.
11512047|NCT01269775|Experimental|Internet based teaching|For providing materials for interactive internet-based group the professor's lecture was converted to an interactive electronic content. This content started with a case introduction followed with asking questions and then based on each student's answer a learning pathway would be assigned to his/her.
11512048|NCT01269775|Experimental|Computer based teaching|For providing material for computer-based group the lecture of the same professor was recorded in studio environment and was synchronized with the slides that were similar to those for lecture-based group. Then the lecture and the slides were converted to a CD as a multimedia CD.
11512049|NCT01269762|Experimental|LipoCol Forte|Subject will receive single dose of one, two and four 600 milligram (mg) red yeast rice capsules (LipoCol Forte)and multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days.
11512050|NCT01269749|Other|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
11512051|NCT01269749|Other|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
11512164|NCT01269021|Active Comparator|Prednisone|
11512054|NCT01269723|Active Comparator|Broccoli sprout homogenate|"The broccoli sprouts and water are chopped in a blender until a uniform mix is obtained. Salt or sugar may be added to the shake."
11512055|NCT01269723|Placebo Comparator|alfalfa sprout homogenate|"Alfalfa sprouts and water are chopped in a blender until a uniform mix is obtained. Salt or sugar may be added to the shake."
11512056|NCT01269697|Active Comparator|Nutrof|patient receive the treatment of Nutrof Total
11512057|NCT01269697|Placebo Comparator|Placebo of Nutrof|Patient receive the treatment of the placebo of Nutrof Total
11512058|NCT01269684|Experimental|1|Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
11512059|NCT01269671|Experimental|Melatonin, Peppermint Oil, Simethicone|
11512060|NCT01269671|Placebo Comparator|Sugar pill|
11512061|NCT01269658|Experimental|Azithromycin ophthalmic solution, 1%|
11512062|NCT01269658|Placebo Comparator|Vehicle|
11512063|NCT01269645|Active Comparator|Usual care|"Usual care and provision of National Cancer Institute brochure Taking Part in Cancer Treatment Research Studies. Participants will be asked to read this brochure after completion of the baseline surveys and will be given a copy to take home with them."
11512064|NCT01269645|Experimental|Clinical Trial educational materials|Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
11512065|NCT01269632|Other|HIV infected|young adult infected by HIV
11512066|NCT01269632|Other|HIV uninfected|a control group of HIV uninfected young adult will be included for comparison in physiopathological module (metabolic, cardiovascular, and immunological)
11512067|NCT01269619|Experimental|Dynamic|Use of Dynamic back support
11512068|NCT01269619|Active Comparator|Static|Use of static back support
11512069|NCT01269606|Experimental|Treatment sequence 1 - IM treatment group|
11512070|NCT01269606|Experimental|Treatment sequence 2 - IM treatment group|
11512071|NCT01269606|Experimental|Treatment sequence 1 - IV treatment group|
11512072|NCT01269606|Experimental|Treatment sequence 2 - IV treatment group|
11512073|NCT01269593|Experimental|PET Imaging Using 124 IPUH71|Patients will receive an injection of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71, followed by serial PET scanning and blood draws, over a period of 3 days. Optional with a fourth day of PET scanning is to be pursued, in willing patients.
11512074|NCT01269580||Diabetic|Adult diabetic patients type 1 or 2, with chronic critical ischemia as defined by TASC 2007 criteria
11512075|NCT01269580||Not diabetic|Adult not diabetic with chronic critical ischemia
11512076|NCT01269567|Active Comparator|Drainage|Rectal excision with aspiration pelvic drainage
11512077|NCT01269567|Experimental|No drainage|Rectal excision without aspiration pelvic drainage
11512078|NCT01269554||Children with diarrhea in Bissau|
11512079|NCT01269554||Children without diarrhea in Bissau|
11512080|NCT01269554||Children without diarrhea in Finland|
11512081|NCT01269554||Children with diarrhea in Finland|
11512082|NCT01269554||Adults without diarrhea in Finland|
11512083|NCT01269554||Adults with diarrhea in Finland|
11512084|NCT01269554||Adults without diarrhea in Bissau|
11512085|NCT01269554||Adults with diarrhea in Bissau|
11512086|NCT01269541|Active Comparator|Mupirocin|Topical treatment
11512087|NCT01269541|Active Comparator|Rifampicin+Clindamycine or Trimethoprimsulfa|Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3xVII Trimethoprimsulfa 400mg/80mg 2x2
11512088|NCT01269528||Born in 2007-2008|Methacholine Challenge Test (MCT). Monthly telephone contact. Visits to the study site. Fractional exhaled nitric oxide. Blood test.
11512089|NCT01269528||Born in 2009-2010|Methacholine Challenge Test (MCT). Monthly telephone contact. Visits to the study site. Fractional exhaled nitric oxide. Blood test.
11512090|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 25 weeks ART-|Etoricoxib for 25 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 5 weeks.
11512091|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 2 weeks ART-|Etoricoxib for 2 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
11512092|NCT01269515|No Intervention|Control ART-|No Etoricoxib. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
11512093|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 25 weeks ART+|Etoricoxib for 25 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 5 weeks.
11512094|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 2 weeks ART+|Etoricoxib for 2 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
11512095|NCT01269515|No Intervention|Control ART+|No Etoricoxib. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
11512096|NCT01269502|Experimental|Skin temperature measurement|Regular measurement of skin temperature on feet for one year
11512097|NCT01269502|Active Comparator|Active control|Daily inspection of feet for one year
11512098|NCT01269489||general population|a representative sample from general Slovenian population
11512099|NCT01269476|Experimental|SNX-001|
11512100|NCT01269476|Placebo Comparator|Placebo|
11512101|NCT01269463|Active Comparator|Methylphenidate HCl ER Capsules|Methylphenidate hydrochloride extended release capsules
11512102|NCT01269463|Placebo Comparator|Capsule without active drug|Double blind crossover assignment of the placebo comparator.
11512103|NCT01269450|Active Comparator|Utrogestan|
11512104|NCT01269450|Placebo Comparator|placebo|
11512105|NCT01269437|Experimental|Budesonide, Novolizer|Budesonide Dry Powder Inhaler
11512106|NCT01269437|Active Comparator|BudesonideTurbuhaler|Budesonide Dry Powder Inhaler
11512107|NCT01269424|Active Comparator|Cohort 1|LV gene transfer after concurrent chemo-radiotherapy
11512108|NCT01269424|Active Comparator|Cohort 2|LV gene transfer prior to concurrent chemo-radiotherapy
11512109|NCT01269424|Active Comparator|Cohort 3|Intra patient dose escalation of TMZ in patients with evidence of P140K marked cells
11512110|NCT01269411|Experimental|Treatment (RO4929097 and surgery)|"PART A: Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~PART B: Patients receive oral RO4929097 once daily on days 1-7 and undergo surgery on day 8. Beginning 28 days later, patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
11512111|NCT01269398|No Intervention|GO-LIF procedure, posetrior facets fusion|
11512112|NCT01269398|Other|solid fusion, GO-LIF procedure|ability to achieve solid fusion, comibing the GO-LIF procedure for spinal fixation and stabilization with percutaneous posetrior facets fusion
11512113|NCT01269385|Experimental|Arm I|Patients receive PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31; alemtuzumab subcutaneously on days 3, 4, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; and rituximab IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity.
11512114|NCT01269372|Other|PillCam Colon 2 and Standard Colonoscopy|All subjects received Capsule Endoscopy (CE) using the PillCam Colon 2 followed by a standard colonoscopy.
11512115|NCT01269359||radiation|
11512116|NCT01269346|Experimental|1|
11512117|NCT01269333|Active Comparator|fluvoxamine|
11512118|NCT01269333|Experimental|omeprazole|
11512119|NCT01269333|Placebo Comparator|placebo|
11512120|NCT01269307|Active Comparator|1:1 ketamine - propofol mixture|
11512121|NCT01269307|Active Comparator|propofol|propofol
11512122|NCT01269294|Experimental|001|TMC435 2 capsules of 75 mg once daily for 7 days in Treatment A
11512123|NCT01269294|Other|002|Placebo for TMC435 2 placebo capsules once daily for 7 days in Treatment A
11512124|NCT01269294|Other|003|Placebo for moxifloxacin 1 placebo tablet on Day 7 of Treatments A B and D
11512125|NCT01269294|Experimental|004|TMC435 2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
11512126|NCT01269294|Other|005|Placebo for TMC435 4 placebo capsules once daily for 7 days in Treatment C
11512127|NCT01269294|Other|006|Moxifloxacin 1 tablet of 400 mg on Day 7 of Treatment C
11512128|NCT01269294|Placebo Comparator|007|Placebo for TMC435 4 placebo capsules once daily for 7 days in Treatment D
11512129|NCT01269281|Experimental|Sumatriptan Succinate tablets 100 mg|Sumatriptan Succinate tablets 100 mg of Dr.Reddy's Laboratories Limited
11512130|NCT01269281|Active Comparator|Imitrex 100 mg Tablets|Imitrex 100 mg Tablets of Glaxosmithkline
11512131|NCT01269268||active tuberculosis|active TB patients : diagnosed with TB through microbiologic examination
11512132|NCT01269268||healthy control|healthy control : no evidence of respiratory disease, no respiratory symptoms, and no history of close contact of active pulmonary TB patients
11512133|NCT01269255|Experimental|Combination group|
11512134|NCT01269242|Experimental|bindarit 600 mg|
11512135|NCT01269242|Experimental|bindarit 1200 mg|
11512136|NCT01269242|Placebo Comparator|placebo|
11512137|NCT01269216|Active Comparator|5-FU with leucovorin|
11512138|NCT01269216|Active Comparator|TS-1 with Irinotecan|
11512139|NCT01269203|Active Comparator|Curcumin|1000 mg/day Curcumin + 5 -15 mg/day Lenalidomide
11512140|NCT01269203|Placebo Comparator|Placebo|Placebo daily + 5 -15 mg/day Lenalidomide
11512141|NCT01269190|Experimental|Diagnostic (widefield multispectral imaging and HRME)|Patients undergo evaluation of oral cavity using a widefield multispectral imaging device and a high-resolution optical system (HRME) at baseline, after induction of general anesthesia, and prior to surgery.
11512142|NCT01269177||Patients with acute cardiogenic pulmonary edema|
11512143|NCT01269164|Experimental|Face Transplantation|Surgical Procedure Composite Facial Transplant
11512144|NCT01269151|Experimental|Lucentis (Ranibizumab)|
11512145|NCT01269138||Factor VII Deficient Patients|Patients affected by Inherited Factor VII deficiency undergoing treatment for bleeding episodes, surgery , prophylaxis.Any patient with levels of FVII less than 50% of normal or a mutation known to be associated to a FVII deficiency. Any patient with a FVII deficiency for whom treatment of bleeding episodes, prevention related to surgery and primary/secondary prophylaxis is considered necessary by his/her treating physician can be enrolled.
11512146|NCT01269125|Active Comparator|Endometriosis, leuprolide, IVF|Women with stage II endometriosis received GnRH-a (leuprolide) prior to an IVF attempt.
11512147|NCT01269125|Active Comparator|Endometriosis, IVF|Women with mild endometriosis who underwent an IVF attempt without prior administration of GnRH-a.
11512148|NCT01269125|Active Comparator|Tubal infertility, IVF|Women with tubal infertility underwent an IVF attempt.
11512149|NCT01269112|Placebo Comparator|heparin|CVVHDF performed using unfractionated heparin as anticoagulant and Prismasol as reinjection and dialysate fluids
11512150|NCT01269112|Active Comparator|citrate regional anticoagulation|CVVHDF performed using Prismocitrate 18/0 solution (Trisodium citrate 18 mmol/L
11512151|NCT01269099|Active Comparator|Control|Control-group
11512152|NCT01269099|Experimental|IV-PCA|IV-PCA group
11512153|NCT01269086|No Intervention|Usual Care|Traditional care with no systematic assessment of family member´s health problems or risk factors.
11512154|NCT01269086|Experimental|Family Preventive Visit|Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
11512155|NCT01269060|Experimental|Single incision sigmoidectomy|Single incision laparoscopic sigmoidectomy for sigmoid colon cancer
11512156|NCT01269047|Experimental|Pramlintide + Insulin Group|These kids will get Pramlintide (Symlin) along with insulin before breakfast and supper.
11512157|NCT01269047|Experimental|Exenatide + Insulin Group|This group will get Exenatide(Byetta) along with insulin before breakfast and supper.
11512158|NCT01269047|Active Comparator|Insulin monotherapy|This group will be on their regular insulin therapy.
11512159|NCT01269034|Experimental|Part A|Exenatide and long acting insulin before the boost.
11512160|NCT01269034|Active Comparator|Part B|Rapid and long acting insulin before the boost
11512161|NCT01269034|Active Comparator|Part C|long acting insulin+ rapid acting+1.25 mcg Exenatide before the boost
11512162|NCT01269034|No Intervention|Healthy controls|healthy controls without any medication before the boost.
11512163|NCT01269021|Experimental|mycophenolate mofetil|
11512165|NCT01268995|Experimental|Cyclosporine A|Patients in this arm will be switched from immunosuppressive therapy with Tacrolimus to Cyclosporine A. Furthermore, patients in this arm will commence insulin treatment with NPH-insulin to reach normoglycemia. After the achievement of normoglycemia the insulin treatment will be continued for three more weeks and than terminated.
11512166|NCT01268995|Active Comparator|Tacrolimus|Patients in this arm will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, patients in this arm will commence insulin treatment with NPH-insulin to reach normoglycemia. After the achievement of normoglycemia the insulin treatment will be continued for three more weeks and than terminated.
11512167|NCT01268982|Experimental|preserved socket|sockets will be filled with DFDBA and covered with absorbable membrane. Primary coverage will be achieved by full thickness mucosal flap advancement over each socket.
11512168|NCT01268969|Active Comparator|excision and krydakis reconstruction|The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
11512169|NCT01268969|Active Comparator|surgical excision and limberg closure|The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia . The fasciocutaneous flap was transposed medially so that the defect would be covered without any tension.
11512170|NCT01268956||Lymphatic progenitor cell|Circulating lymphatic progenitor cell
11512171|NCT01268956||Control|healthy people
11512172|NCT01268943|Experimental|1000mg|capecitabine 1000mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
11512173|NCT01268943|Experimental|1200mg|capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
11512174|NCT01268943|Experimental|1400mg|capecitabine 1400mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
11512175|NCT01268943|Experimental|1500mg|capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
11512176|NCT01268930|Active Comparator|Bipolar coagulation|In this arm, after the complete excision of ovarian endometrioma, ovarian hemostasis is provided by bipolar electrocoagulation.
11512177|NCT01268930|Active Comparator|Hemostatic matrix|In this arm, after complete excision of ovarian endometrioma, ovarian hemostasis is provided by hemostatic matrix.
11512178|NCT01268917|Experimental|preoperative aspirin use|
11512179|NCT01268917|No Intervention|preoperative aspirin nonuse|
11512180|NCT01268904||Pediatric status epilepticus|
11512181|NCT01268891|Placebo Comparator|Placebo|
11512182|NCT01268891|Experimental|Azilect®|
11512183|NCT01268865||HBV-infected|
11512184|NCT01268865||HCV-infected|
11512185|NCT01268852|Active Comparator|Damon|Standard self ligating orthodontic Damon brackets
11512186|NCT01268852|Experimental|Insignia|Innovative self ligating orthodontic bracket
11512187|NCT01268839|Experimental|001|Efavirenz 600mg tablet once daily for 14 days,TMC278 25mg tablet once daily for 14 days,TMC278 25mg tablet once daily for 28 days
11512188|NCT01268826||dosage of the urinary osmolality|dosage of the urinary osmolality
11512189|NCT01268813|Experimental|Exhaled breath uptake blood test|Diabetic patients receiving oral hypoglycemic drug will be tested for biomarkers in their breath and blood samples
11512190|NCT01268813|No Intervention|Exhaled breath and blood test|Breath and blood samples will be collected from healthy volunteers and analyzed using Gas Chromatography-Mass Spectroscopy. The results will be compared to the experimental arm.
11512191|NCT01268800||AML induction|Adults AML patients who were referred for intensive induction therapy
11512192|NCT01268787|Active Comparator|EV 71 vaccine 5ug|EV71 Vaccine 5ug
11512193|NCT01268787|Experimental|EV 71 vaccine 10ug|EV71 vaccine 10ug
11512194|NCT01268761|Experimental|GnRH antagonist|• GnRH antagonist (Cetrorelix 0.25)
11512195|NCT01268761|Placebo Comparator|Placebo (saline solution)|• Placebo (saline solution)
11512196|NCT01268748|Other|4 ports laparoscopic cholecystectomy|
11512197|NCT01268748|Other|One port transumb. laparoscopic surgery|
11512198|NCT01268735|Experimental|Lubricating eyedrops containing HP-guar|
11512199|NCT01268722|Active Comparator|Balloon|
11512200|NCT01268722|Experimental|Stent|
11512201|NCT01268709|Active Comparator|doxepin|
11512202|NCT01268709|Active Comparator|nortriptyline|
11512203|NCT01268709|Placebo Comparator|placebo|
11512204|NCT01268696||control group|healthy volunteers
11512205|NCT01268696||Metabolic group|Patients with metabolic syndrome
11512206|NCT01268683|Experimental|RP-1127 (Glyburide for Injection)|This arm is administered a RP-1127 bolus followed by continuous infusion of RP-1127 for 72 hours
11512207|NCT01268670|Active Comparator|Ibuprofen|Subjects will receive topical LET and oral ibuprofen.
11512208|NCT01268670|Active Comparator|Oxycodone|Subjects will receive topical LET and oral oxycodone.
11512209|NCT01268670|Placebo Comparator|Placebo|Subjects will receive topical LET and oral placebo.
11512210|NCT01268657|Experimental|Cognitive Behavioral Exposure Therapy|
11512211|NCT01268644|Experimental|active open label Leptin|Active open label Leptin for type 1 Diabetes
11512212|NCT01268631|Active Comparator|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks. The assessing person will contact patients by phone every week during the treatment period to receive the pain score for the last 24 hours, so we will have an indication of the effect among patients will discontinue medication. Patients will be asked to visit the clinic during the last week of treatment, for assessment of clinical pain (questionnaires) and pain modulation.
11512213|NCT01268631|Active Comparator|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 4 weeks. Drug should not be taken with meals. Same protocol will be applied as for Duloxetine.
11512216|NCT01268605|Active Comparator|Restoration with a dentin bonding agent (DBA)|Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.
11512217|NCT01268605|Active Comparator|Restoration with a resin modified glass ionomer liner (RMGI)|Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
11512218|NCT01268592|Experimental|positive cancer diagnosis|female patients diagnosed with cancer who wish to preserve their fertility by vitrifying their oocytes
11512219|NCT01268579|Experimental|ribavirin|This will be a single institution non-randomized study for patients with tonsil and/or base of tongue squamous cell cancer. This is a pilot study to obtain pharmacodynamic data regarding the effects of ribavirin on tonsil squamous cell cancer.
11512220|NCT01268566|Experimental|MEDI-575, 25 mg/kg|MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minutes on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participants withdrawal.
11512221|NCT01268553|Experimental|Active treatment|This is the only arm in the trial. All enrolled subjects will be attempted to transition to inhaled treprostinil. There is no placebo and control arm.
11512222|NCT01268540|Experimental|NHT15|Aspheric Toric Intraocular Lens Models NHT15
11512223|NCT01268540|Active Comparator|FY-60AD|Aspheric Non-toric Intraocular Lens: Model FY-60AD
11512224|NCT01268540|Experimental|NHT30|Aspheric Toric Intraocular Lens Model NHT30
11512225|NCT01268540|Experimental|NHT53|Aspheric Toric Intraocular Lens Models NHT53
11512226|NCT01268527|Experimental|Cohort 1|Three concentrations of E6201 topical gel (0.03%, 0.1%, and 0.2%) and active comparator, calcipotriene cream (0.005%), were applied once daily for 12 days to specific test fields determined at Baseline. The 3 concentrations of E6201 gel were dosed first in Cohort 1 to establish the safety and tolerability prior to dosing in Cohort 2.
11512227|NCT01268527|Experimental|Cohort 2|Three concentrations of E6201 topical gel (0.005%, 0.01%, and 0.05%) and active comparator, calcipotriene cream (0.005%), were applied once daily for 12 days to specific test fields determined at Baseline. Cohort 2 participants were not dosed until all participants in Cohort 1 completed treatment and safety data were collected and evaluated.
11512228|NCT01268501|Experimental|Lotrafilcon B multifocal|Lotrafilcon B multifocal contact lenses worn bilaterally for 3 weeks on a daily wear basis
11512229|NCT01268488|Experimental|Intended Users of the System|Untrained subjects with diabetes obtained capillary fingerstick, palm, and forearm blood and performed Blood Glucose (BG) tests using a Ninja 2 investigational blood glucose meter and the Contour® sensor. This BG monitoring system will not proceed to marketed product.
11512230|NCT01268462|Experimental|Heliox + PEP (Group 1)|
11512231|NCT01268462|Experimental|Oxygen+PEP(Group 2)|
11512232|NCT01268462|Experimental|Heliox ( Group 3)|
11512233|NCT01268462|Active Comparator|Oxygen (Group 4)|
11512234|NCT01268449|Active Comparator|Laser group|
11512235|NCT01268449|Placebo Comparator|Placebo group|Randomly,half of the patients receive placebo.
11512236|NCT01268436||Injectable pain medication|Patients who receive an injectable form of pain medication.
11512237|NCT01268436||Oral pain medication|Patients who receive oral pain medication only
11512238|NCT01268423|Experimental|Early percutaneous tracheostomy|
11512239|NCT01268423|Active Comparator|Prolonged translaryngeal intubation|
11512240|NCT01268410||acute respiratory failure|
11512241|NCT01268397|Active Comparator|ORIF|Open reduction and internal fixation with a volar plate
11512242|NCT01268397|Active Comparator|plaster treatment|Closed reduction and plaster treatment
11512243|NCT01268384|Experimental|FDR_GX|Fixed dose rate gemcitabine plus capecitabine every 3 weeks for 3-9 cycles
11512244|NCT01268371|Active Comparator|Promus Element|Everolimus-eluting stent
11512245|NCT01268371|Active Comparator|Nobori|Biolimus-eluting stent with biodegradable polymer
11512246|NCT01268358|Experimental|Lamazym 6.25|
11512247|NCT01268358|Experimental|Lamazym 12.5|
11512248|NCT01268358|Experimental|Lamazym 25|
11512249|NCT01268358|Experimental|Lamazym 50|
11512250|NCT01268358|Experimental|Lamazym 100|
11512251|NCT01268345|Experimental|Andon|Andon blood glucose test strips with test meter
11512252|NCT01268345|Active Comparator|Lifescan|
11512253|NCT01268332|Experimental|Intravaginal Ring|Insertion of intravaginal ring at enrollment. The intravaginal ring should stay in place for 12 consecutive weeks and will be removed by a physician at the Week 12 study visit.
11512254|NCT01268332|No Intervention|No Intravaginal Ring|Intravaginal ring will not be inserted into participants.
11512255|NCT01268319|Experimental|(+)HR-LCP and EPD|These subjects will meet all angiographic criteria.The target plaque will contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 27 Subjects who meet this criteria will be randomized to standard pre-dilation and stent implantation with an embolic protection device (EPD)in place prior to any angioplasty.
11512256|NCT01268319|Placebo Comparator|(+)HR-LCP and No EPD (standard of care)|These subjects will meet all angiographic criteria.The target plaque will contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 27 Subjects who meet this criteria will be randomized to standard pre-dilation and stent implantation without an embolic protection device (EPD)in place prior to any angioplasty.
11512257|NCT01268319|Placebo Comparator|(-)HR-LCP and No EPD (standard of care)|These subjects will meet all angiographic criteria.The target plaque will NOT contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 54 Subjects who meet this criteria will be assigned (not randomized) to standard pre-dilation and stent implantation without an embolic protection device (EPD)in place prior to any angioplasty.
11512258|NCT01268306|Experimental|B+L Biotrue MPS and B+L PureVision|Successful contact lens wearers switched to B&L BioTrue MPS while wearing B+L PureVision lenses
11512259|NCT01268293|Experimental|1|
11512260|NCT01268280|Experimental|Treatment Sequence 1|Dosing Period 1 Placebo; Dosing Period 2 CK-2017357 250 mg; Dosing Period 3 CK-2017357 500 mg
11512261|NCT01268280|Experimental|Treatment Sequence 2|Dosing Period 1 Placebo; Dosing Period 2 CK-2017357 500 mg; Dosing Period 3 CK-2017357 250 mg
11512262|NCT01268280|Experimental|Treatment Sequence 3|Dosing Period 1 CK-2017357 250 mg; Dosing Period 2 Placebo; Dosing Period 3 CK-2017357 500 mg
11512263|NCT01268280|Experimental|Treatment Sequence 4|Dosing Period 1 CK-2017357 250 mg; Dosing Period 2 CK-2017357 500 mg; Dosing Period 3 Placebo
11512264|NCT01268280|Experimental|Treatment Sequence 5|Dosing Period 1 CK-2017357 500 mg; Dosing Period 2 Placebo; Dosing Period 3 CK-2017357 250 mg
11512265|NCT01268280|Experimental|Treatment Sequence 6|Dosing Period 1 CK-2017357 500 mg; Dosing Period 2 CK-2017357 250 mg; Dosing Period 3 Placebo
11512266|NCT01268267|Experimental|Intended Users of the System|Untrained subjects with diabetes obtained capillary fingerstick, palm, and forearm blood and performed Blood Glucose (BG) tests using an investigational blood glucose monitoring system (development name Ninja 2).
11512267|NCT01268254||red wine|red wine usual consumer versus abstemious
11512268|NCT01268241||Observation|Hemizygous male or heterozygous female patients of any age with genetically confirmed diagnosis of Anderson-Fabry disease.
11512269|NCT01268228||Residual ic ECG ST elevation in SB|
11512270|NCT01268228||Residual ic ECG ST elevation in MB|
11512271|NCT01268215|Experimental|A (two study drugs group)|The standard management + two study drugs (endotracheal instillation of a mixture containing budesonide and Infasurf)
11512272|NCT01268215|Active Comparator|B (one study drug group)|The standard management + one study drug (endotracheal instillation of Infasurf only).
11512273|NCT01268215|Sham Comparator|C (no study drug group)|The standard management only.
11512274|NCT01268202|Experimental|Pravastatin|Pravastatin : 40mg/day during 12 months
11512275|NCT01268189|Experimental|Burn wound patients with donor sites|Oxygen diffusing dressing applied to wound vs standard of care dressing (Xeroform) applied to wound (patient serves as own control as s/he receives 1 dressing on 1 donor site and the other on a 2nd donor site)
11512276|NCT01268176|Active Comparator|Low fat meal|Those subjects who receive a low fat meal prior to vitamin D3 administration
11512277|NCT01268176|Active Comparator|High fat meal|Those subjects who receive a high fat meal prior to vitamin D3 administration
11512278|NCT01268176|Active Comparator|No meal|Those subjects who do not receive a meal and continue to fast. They only receive the vitamin D3 dose.
11512279|NCT01268163|Active Comparator|1|European Taxotere® (Taxotere EU) 60-100 mg/m^2
11512280|NCT01268163|Experimental|3|Hospira Docetaxel Injection 60-100 mg/m^2
11512281|NCT01268163|Active Comparator|2|American Taxotere® (Taxotere US) 60-100 mg/m^2
11512282|NCT01268150|Experimental|Experimental|
11512283|NCT01268137|Active Comparator|stimulation on|At first stage, electrodes will be implanted in all patients, who will be continuously stimulated for several months. After this stage, the random-crossed part of the study will start, and patients who responded to DBS will be randomly distributed in two groups: on stimulation or off stimulation group, for the next three months. Subsequently, patients will be allocated in the other group (on or off, crossed part) for three months
11512284|NCT01268137|Placebo Comparator|Stimulation off|At first stage, electrodes will be implanted in all patients, who will be continuously stimulated for several months. After this stage, the random-crossed part of the study will start, and patients who responded to DBS will be randomly distributed in two groups: on stimulation or off stimulation group, for the next three months. Subsequently, patients will be allocated in the other group (on or off, crossed part) for three months
11512285|NCT01268124|Experimental|Treatment|
11512286|NCT01268111|Experimental|Vitamin D|ERgocalcifoerol 50,000 units q weekly for 8 weeks
11512287|NCT01268111|Placebo Comparator|Placebo|
11512288|NCT01268098|Experimental|25 µg dose|25 µg
11512289|NCT01268098|Experimental|50 µg dose|50 µg
11512290|NCT01268085|Experimental|Radiation Safety Alert|A provider placing an electronic order for a CAT scan will receive a radiation safety pop-up alert with a message about the dangers of cumulative ionizing radiation, the patient's cumulative CAT scan history, and the most recent imaging test from any modality of the same body part.
11512291|NCT01268085|Active Comparator|Control|Parallel control with no intervention
11512292|NCT01268072||Cohort 2|Subjects who are recruited on admission to hospital for AECOPD.
11512293|NCT01268072||Cohort 1|Subjects with COPD who are stable, but at risk of presenting with an AECOPD.
11512294|NCT01268059|Active Comparator|MEDI-575 Dose Determination|
11512295|NCT01268059|Active Comparator|Arm A|
11512296|NCT01268059|Active Comparator|Arm B|
11512297|NCT01268046|Experimental|Young postmenopausal women - estrogen|transdermal estrogen patch OR estradiol oral capsule for 1 month
11512298|NCT01268046|Experimental|Older postmenopausal women - estrogen|transdermal estrogen patch OR estradiol oral capsule for 1 month
11512299|NCT01268046|Placebo Comparator|Young postmenopausal women - placebo|transdermal placebo patch for 1 month or placebo oral capsule for 1 month
11512300|NCT01268046|Placebo Comparator|Older postmenopausal women - placebo|transdermal placebo patch for 1 month or placebo oral capsule for 1 month
11512301|NCT01268033|Experimental|Rituximab|two infusions of Rituximab - at the dose of 375 mg/m²
11512302|NCT01268033|Placebo Comparator|placebo|two infusions of placebo
11512303|NCT01268020|Experimental|[18F]-FMH3-01 PET Imaging|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) or 2 ug of [18F]-FMH3, whichever is greatest.
11512304|NCT01268007||Normal ECG measurements|Observational, un-blinded, non-interventional study designed to collect ECG data on at least one (1) male patient in an outpatient setting.
11512305|NCT01267994|Experimental|Single Arm-Open Label|Single Arm-Open Label use of Anakinra
11512306|NCT01267981|Placebo Comparator|Preparation 1|Standard diet: the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.
11512307|NCT01267981|Active Comparator|Preparation 2|"Standard diet : the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.
~500 ml of polyethylene glycol 30 minutes after the ingestion of video-capsule endoscopy."
11512493|NCT01266720|Experimental|Phase 1 study|"Interventions:
~Biological: VEGFR1, VEGFR2 Drug: Gemcitabine"
11512494|NCT01266707|Experimental|Vaccine|VEGRF1, VEGFR2
11512308|NCT01267981|Active Comparator|Preparation 3|"Standard diet : the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.
~2 liters of polyethylene glycol between 7 pm and 9 pm.
~500 ml of polyethylene glycol, 30 minutes after the ingestion of video-capsule endoscopy."
11512309|NCT01267968|Experimental|Cohort 1|GSK2251052 1500 mg Single dose (i.v., 60 min)
11512310|NCT01267968|Experimental|Cohort 2|GSK2251052 1500 mg IV q12h x 5 doses infused over 60 minutes
11512311|NCT01267955|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11512312|NCT01267942|Experimental|Intravenous intraoperative Enhancin|Patients received a dose of intravenous Enhancin at induction and only oral Paracetamol in the postoperative period.
11512313|NCT01267942|Active Comparator|Postoperative oral Enhancin.|Patients received postoperative oral Enhancin for five days in addition to oral Paracetamol for the same duration. They did not receive an antibiotic during the operation.
11512314|NCT01267929|Experimental|The mirror neurons stimulation based VCD program|The children receive the mirror neurons stimulation based VCD program and practice at home three times a day for six months. The mirror neurons stimulation based VCD program that contained four volumes. The first volume includes activities activities for improving balance in sitting position. The second volume includes activities of sitting to standing. The third volume includes activities for improving balance in standing position. The last one includes activities of sideway walking. The running time of each volume is 30 minutes. The children had been practicing for two weeks per volume. Their parents were trained for practicing their children by VCD program at home and were asked to complete daily record of children's activities. The children were scheduled to meet a pediatric physical therapist once a week to monitor possible side effects.
11512315|NCT01267929|Active Comparator|The conventional physical therapy|The children receive manual physical therapy regularly at the hospital once a week for first two months and twice a month for last four months. The conventional physical therapy technique in this study derive from the manual technique including the Bobath concept, stretching exercise and functional training for 30-45 minutes at a time.
11512316|NCT01267916|Experimental|RR 6 + 0|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
11512317|NCT01267916|Experimental|RR 10 + 0|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
11512318|NCT01267916|Experimental|RR 16 + 0|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
11512319|NCT01267916|Experimental|RR 6 + 5|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
11512320|NCT01267916|Experimental|RR 10 + 5|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
11512321|NCT01267916|Experimental|RR 16 + 5|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
11512322|NCT01267903|Experimental|320U /0.5ml in young adults|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 20 young adults aged 16-22 years old on day0,28
11512323|NCT01267903|Experimental|640U /0.5ml in young adults|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 20 young adults aged 16-22 years old on day0,28
11512324|NCT01267903|Experimental|160U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 20 children aged 5-15 years old on day0,28
11512325|NCT01267903|Experimental|320U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 20 children aged 6-15 years old on day0,28
11512326|NCT01267903|Experimental|640U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 20 children aged 6-15 years old on day0,28
11512327|NCT01267877|Active Comparator|Guideline unfavorable article|
11512328|NCT01267877|Active Comparator|Guideline favorable article|
11512329|NCT01267864|Active Comparator|Metoclopramide|Metoclopramide 10mg IVSS
11512330|NCT01267864|Active Comparator|Ketorolac|Ketorolac 30mg IV
11512331|NCT01267864|Active Comparator|Valproate|1gm IV
11512332|NCT01267838|Active Comparator|T Stenting group|PCI of bifurcation lesion with modified T Stenting.
11512333|NCT01267838|Active Comparator|Culotte stenting group|PCI of bifurcation lesion with Culotte stenting
11512334|NCT01267825|Experimental|CT-guided intervention|CT guided perineural injection of corticosteroid+ bupivicaine Also get typical medical care
11512335|NCT01267825|Active Comparator|Standard medical care|
11512336|NCT01267812|Experimental|Treatment (bortezomib and rituximab)|Patients receive bortezomib SC or IV over 3-5 seconds and rituximab IV on days 1, 8, 15, and 22. Treatment with bortezomib repeats every 3 months for up to 8 courses and treatment with rituximab repeats every 6 months for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11512337|NCT01267799||photocopier exposure|
11512338|NCT01267799||control|
11512339|NCT01267786|Active Comparator|Sevoflurane|1MAC intraoperatively
11512340|NCT01267786|Active Comparator|desflurane|1 MAC intraoperatively
11512341|NCT01267773|Active Comparator|Sequential Treatment|
11512342|NCT01267773|Experimental|Integrated Treatment|
11512343|NCT01267760|Active Comparator|conventional HD|conventional 4-hour HD
11512344|NCT01267747||Atrial fibrillation or flutter patients|Patients with 'lone' paroxysmal, persistent, or permanent atrial fibrillation
11512345|NCT01267734|Experimental|EECSS + DDAT|Promus Element stent + double-dose clopidogrel anti-platelet therapy
11512346|NCT01267734|Active Comparator|ZECSS + DDAT|Endeavor Resolute stent + double-dose clopidogrel anti-platelet therapy
11512347|NCT01267734|Experimental|EECSS + TAT|Promus Element stent + triple anti-platelet therapy
11512348|NCT01267734|Active Comparator|ZECSS + TAT|Endeavor Resolute stent + triple anti-platele therapy
11512349|NCT01267721||Study Group|A single group of 100 consecutive patients will undergo additional blood sampling at different time points
11512350|NCT01267708||Study Group|All those tested
11512351|NCT01267682|No Intervention|Usual care|Participants receive standard clinical care
11512352|NCT01267682|Experimental|Treatment|Behavioral: cognitive stimulation
11512353|NCT01267669|Experimental|EVL plus Somatostatin|Emergency EVL plus Somatostatin (250 mcg/hr) infusion for 5 days
11512354|NCT01267669|Placebo Comparator|EVL plus Placebo|Emergency EVL plus placebo infusion for 5 days
11512495|NCT01266694|Experimental|Cochicine|Colchicine arm: patient receiving 1 mg per day for 14 days
11512355|NCT01267656|Experimental|Lubricating and Rewetting Drops|Lubricating and Rewetting Drops, after one week of using the first rewetting drops, the subjects will return for an exam and crossover to the second rewetting drops for one week.
11512356|NCT01267656|Active Comparator|AMO Blink Contacts Lubricant Eye Drops|AMO Blink Contacts Lubricant Eye Drops, After one week of using the first rewetting drops, the subjects will return for an exam and crossover to the second rewetting drops for one week
11512357|NCT01267643|Experimental|Alefacept|
11512358|NCT01267630||Surgical ICU|Patients are admitted to the surgical ICU of Chiang Mai University Hospital within 48 hours .
11512359|NCT01267617||chronic hemodialysis outpatients|
11512360|NCT01267604|Active Comparator|Recombinant FSH|225IU rFSH
11512361|NCT01267604|Experimental|Recombinant FSH Inositol Melatonin|225IU rFSH, 4g Inositol and 3mg Melatonin
11512362|NCT01267591||control|
11512363|NCT01267591||type 1 diabetes|
11512364|NCT01267591||obesity|
11512365|NCT01267578|Experimental|peptide vaccination|
11512366|NCT01267565|Other|intubated and ventilated patients|patients undergoing mechanical ventilation for an anticipated length of more than 48h
11512367|NCT01267565|Other|non intubated patients|non intubated patients with an independant indication of bronchoscopy including an endotracheal aspiration during the procedure
11512368|NCT01267552|Experimental|Non drainage arm|No drains will be placed during operation
11512369|NCT01267552|Active Comparator|Drainage arm|Closed suction drains will be placed during operation
11512370|NCT01267513||normal volunteers|Normal individuals, aged 18 -75
11512371|NCT01267513||Hospitalized patients|Pulmonary and cardiac ICU, Trauma
11512372|NCT01267500|Experimental|Non-surgical therapy|patching or fusion exercises
11512373|NCT01267487|Active Comparator|Fixed doses plus PO protamine|"Intraoperative fixed dose schemes (as in fixed doses plus placebo group) plus continuous infusion of 25mg/hour of protamine during first 6 PO hours"
11512374|NCT01267487|Active Comparator|Titrated doses plus PO protamine|"Same as titrated doses arm, plus continuous infusion of 25mg/ hour of protamine during first 6 PO hours"
11512375|NCT01267487|No Intervention|Fixed doses plus placebo|"Before CPB, fixed heparin dose of 400 Units per kg of body weight to achieve an Activated Coagulation Time (ACT) > 480 seconds.
~Reversal of heparin after CPB using 1 : 1 ratio (1 mg of protamine for each 100 units (1mg) of heparin), plus 0.8 mg/kg of protamine at the end of the surgery.
~Continuous infusion of placebo (saline 0.9%) during the first 6 PO hours."
11512376|NCT01267487|Active Comparator|Titrated doses plus placebo|"Titrated doses of heparin before and during CPB and reversal with protamine after CPB calculated by the construction of individualized Bull's dose-response curve.
~Continuous infusion of placebo (saline 0.9%) during first 6 PO hours."
11512377|NCT01267474|Experimental|Nutritional education|
11512378|NCT01267474|No Intervention|Control|
11512379|NCT01267448|Active Comparator|Saxagliptin + Metformin XR|Saxagliptin 5 mg + Metformin XR 1000 mg will be automatically titrated weekly in 2 weeks to Saxagliptin 5 mg + Metformin XR 2000 daily for a total duration of 12 weeks.
11512380|NCT01267448|Active Comparator|the Control goup Glipizide XL|The control group will receive Sulphonylurea (Glipizide XL 10mg orally) for a total duration of 12 weeks.
11512381|NCT01267435|Other|determining correct tunnel positions|
11512382|NCT01267422|Experimental|rAAV2-ND4|injection
11512383|NCT01267396|Experimental|Sertraline Hydrochloride tablets 100 mg|Sertraline Hydrochloride tablets 100 mg of Dr.Reddy's Laboratories Limited
11512384|NCT01267396|Active Comparator|Zoloft 100 mg Tablets|Zoloft 100 mg Tablets of Pfizer
11512385|NCT01267383|Experimental|Sertraline Hydrochloride tablets 100 mg|Sertraline Hydrochloride tablets 100 mg of Dr.Reddy's Laboratories Limited
11512386|NCT01267383|Active Comparator|Zoloft 100 mg Tablets|Zoloft 100 mg Tablets of Pfizer
11512387|NCT01267370|Active Comparator|Soy polysaccharide fiber|Dietary fiber for treatment of chronic constipation in children
11512388|NCT01267370|Placebo Comparator|purified soy extract, with no fiber)|blinded control group
11512389|NCT01267357||Serous papillary endometrial ca patients|30 patients diagnosed with SP endometrial ca
11512390|NCT01267357||Endometrioid endometrial ca|32 patients diagnosed with Endometrioid endometrial ca
11512391|NCT01267344|Active Comparator|GEMOX|Intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks.
11512392|NCT01267344|Experimental|E-GEMOX|Arm A will receive E-GEMOX with additional intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above.
11512393|NCT01267331|Experimental|stem cells injection|Direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG
11512394|NCT01267331|Placebo Comparator|palcebo intramyocardial injection|Direct intramyocardial injection of placebo containing saline and 5% human serum albumin during CABG.
11512395|NCT01267305|Active Comparator|lung lmwh1|use LMWH once daily after lung resection
11512396|NCT01267305|Experimental|lung lmwh2|use LMWH twice daily after lung resection
11512397|NCT01267305|Experimental|lung Fondaparinux|use Fondaparinux once daily after lung resection
11512398|NCT01267305|Active Comparator|eso lmwh1|use LMWH once daily after esophagectomy
11512399|NCT01267305|Experimental|eso lmwh2|use LMWH twice daily after esophagectomy
11512400|NCT01267305|Experimental|eso Fondaparinux|use Fondaparinux once daily after esophagectomy
11512401|NCT01267292|Experimental|Buspirone plus Methylphenidate|[week 1: Buspirone 30 mg twice a day (9am and 6pm) on Monday through Sunday; no Methylphenidate or Methylphenidate placebo] [week 2: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday; 0mg Methylphenidate (placebo) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday; Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
11512496|NCT01266694|Placebo Comparator|Placebo|patients placebo controlled
11512497|NCT01266681|Active Comparator|Amiodarone|this group will be given Amiodarone to maintain sinus rhythm powst cardioversion.
11513370|NCT01261026||Abnormal intrauterine pregnancy|
11512402|NCT01267292|Placebo Comparator|Placebo for Buspirone plus Methylphenidate|[week 1: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; no Methylphenidate or Methylphenidate placebo] [week 2: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
11512403|NCT01267279|Placebo Comparator|Placebo|
11512404|NCT01267279|Experimental|Zoledronic Acid|
11512405|NCT01267266|Experimental|Arm I (saracatinib)|Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11512406|NCT01267266|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Upon progression, patients may crossover to arm I.
11512407|NCT01267253|Experimental|Treatment (brivanib alaninate)|Patients receive brivanib alaninate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11512408|NCT01267240|Experimental|Arm I (capecitabine, vorinostat)|Patients receive capecitabine PO BID and vorinostat PO daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11512409|NCT01267227|Active Comparator|High Dose|Pterostilbene 125 mg twice daily
11512410|NCT01267227|Active Comparator|Low Dose|Pterostilbene 50 mg twice daily
11512411|NCT01267227|Active Comparator|Low Dose Combination|Pterostilbene 50 mg/Grape Extract 100 mg twice daily
11512412|NCT01267227|Placebo Comparator|Placebo|Matching placebo twice daily
11512413|NCT01267214|Experimental|Osteotomy plus Hyalgan|Osteotomy at Week 0 Hyalgan injection at Week 2, 3, 4, 5, 6, 24, 25, 26, 27, 28
11512414|NCT01267214|Other|Osteotomy alone|
11512415|NCT01267201|Experimental|POS formulation #1|
11512416|NCT01267201|Experimental|POS formulation #2|
11512417|NCT01267201|Active Comparator|commercial tablet|
11512418|NCT01267188|Experimental|NBI-98854|Open-label, dose titration of active drug
11512419|NCT01267175|Experimental|X54 pump|All subjects transferred from current pump to X54
11512420|NCT01267162||TDF Treatment|
11512421|NCT01267136|Experimental|Capital® with Codeine Suspension|
11512422|NCT01267136|Active Comparator|Tramadol suspension|
11512423|NCT01267123|Experimental|Trendelenburg position|The endoscopist places the patient in 15° Trendelenberg position immediately prior to the initiation of the colonoscopy.
11512424|NCT01267123|Other|Standard care|The patient will have colonoscopy in the standard horizontal position
11512425|NCT01267110|Experimental|Intervention|
11512426|NCT01267110|Active Comparator|Control|
11512427|NCT01267097|Experimental|Cognitive Behavioural Therapy (CBT)|Group-based lifestyle counseling for parents
11512428|NCT01267097|Experimental|Psycho-Education Program (PEP)|Group-based lifestyle counseling for parents
11512429|NCT01267084|Experimental|Part 1|Patients will receive trabectedin+ketoconazole followed by trabectedin alone. Each cycle will be will be separated by 21 days. Patients will receive 6 total consecutive doses of ketoconazole. Dexamethasone or equivalent steroid will be administered before trabectedin in each cycle.
11512430|NCT01267084|Experimental|Part 2|Patients will receive 1 of 2 treatment sequences; Sequence 1: trabectedin+ketoconazole followed by trabectedin alone or Sequence 2: trabectedin alone followed by trabectedin+ketoconazole. Each cycle will be separated by 21 days. Patients will receive 15 total consecutive doses of ketoconazole. Dexamethasone or equivalent steroid will be administered before trabectedin in each cycle.
11512431|NCT01267071|Experimental|A|GSK962040 (50 mg, SD, oral)
11512432|NCT01267071|Experimental|B|14C GSK962040 (100 μg, SD, iv)
11512433|NCT01267058|Experimental|Group A|Subjects will receive the combined diphtheria, tetanus, acellular pertussis vaccine
11512434|NCT01267058|Active Comparator|Group B|Subjects will receive the acellular pertussis vaccine and one month later the combined diphtheria and tetanus vaccine
11512435|NCT01267058|Active Comparator|Group C|Subjects will receive the combined diphtheria and tetanus vaccine and one month later the acellular pertussis vaccine
11512436|NCT01267045|Experimental|Arm 1|Participants in this arm undergo the mindfulness training intervention through taking part in a Mindfulness-Based Stress Reduction course
11512437|NCT01267045|No Intervention|Arm 2|Treatment as usual for Gulf War Syndrome symptoms (medications, psychotherapy, etc.)
11512438|NCT01267032|Experimental|Arm 1|Integrated Care + Cognitive-Behavioral Treatment for Insomnia
11512439|NCT01267032|Sham Comparator|Arm 2|Integrated Care + Desensitization Treatment for Insomnia
11512440|NCT01267019|Experimental|Arm 1: vivo augmentation|social cognitive training with in vivo augmentation
11512441|NCT01267019|Active Comparator|Arm 2: social cognitive|social cognitive training
11512442|NCT01267019|Active Comparator|Arm 3: non-social skills|non-social skills training
11512443|NCT01267006|Placebo Comparator|Placebo|Part A - Cohort 1 subjects will be administered GSK1325756 matching placebo tablets twice daily following a light meal for one day in accordance with the randomization schedule.
11512444|NCT01267006|Experimental|GSK1325756 200 mg|Part A - Cohort 1 subjects will be administered GSK1325756 200 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule.
11512445|NCT01267006|Experimental|GSK1325756 50 mg|Part A - Cohort 1 subjects will be administered GSK1325756 50 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule.
11512446|NCT01267006|Experimental|GSK1325756 100 mg|Part B - Cohort 2 subjects will be administered GSK1325756 100 mg following a light meal (Fed) or in the fasted state twice daily for one day in accordance with the randomization schedule.
11512447|NCT01266993|Experimental|Nimenrix Group|Healthy male or female subjects aged 2 through 10 years old, who were primed with one dose of Nimenrix vaccine during the primary 111414 study (NCT00674583), additionally received one booster dose of Nimenrix vaccine in the current study, at Month 68, administered intramuscularly in the deltoid region of the non-dominant arm.
11512448|NCT01266993|Experimental|Menjugate Group|Healthy male or female subjects aged 2 through 10 years old, who were primed with one dose of Menjugate vaccine during the primary 111414 study (NCT00674583), additionally received one booster dose of Menjugate vaccine in the current study, at Month 68, administered intramuscularly in the deltoid region of the non-dominant arm.
11512449|NCT01266980|Experimental|Severe Renal Imparement|Nine subjects with severe renal impairment (as defined by a Clcr<30mL/min) will be recruited for this study. they will receive FF/ GW642444M (200/25mcg) once daily for 7 days.
11512450|NCT01266980|Experimental|Matched healthy volunteers|For each of the 9 renally impaired subjects a healthy control subject (as defined by a Clcr>80mL/min matched to the severe subjects based on gender, ethnicity, body mass index (±15%) and age (±5 years)) will be recuited. They will receive FF/ GW642444M (200/25mcg) once daily for 7 days.
11512451|NCT01266967|Experimental|Single Arm|Single arm with 2 cohorts; Cohort A no previous brain therapy and Cohort B previous brain therapy
11512452|NCT01266954|Experimental|Stage 1|Three to six patients on a medium dose of GSK2141795 for four weeks
11512453|NCT01266954|Experimental|Stage 2|Nine to eighteen subjects on a low, medium or high dose of GSK2141795 for four weeks
11512454|NCT01266941|Experimental|Mild Hepatic Impairment|Mild and moderate hepatic patients will be recruited first, approximately 9 subjects should complete each of these treatment arms.
11512455|NCT01266941|Experimental|Moderate Hepatic Impairment|Mild and moderate hepatic patients will be recruited first, approximately 9 subjects should complete each of these treatment arms.
11512456|NCT01266941|Experimental|Matched healthy volunteers|Once a moderate subject has been recruited, a healthy control subject should be recruited (matched to the moderate subject on gender, ethnicity, body mass index +/-15%, age +/-5 years). In total there will be 9 matched healthy volunteers 1 for each subject with moderate hepatic impairment.
11512457|NCT01266941|Experimental|Severe Hepatic Impairment|Severe subjects will not be enrolled into the study until 9 moderate subjects and their matched control subjects have completed the study and the safety and PK data have been reviewed.
11512458|NCT01266928|Active Comparator|vitaminCE|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
11512459|NCT01266928|No Intervention|no drug|no drug
11512460|NCT01266915||Control group|Normal disease free (non lupus) subjects
11512461|NCT01266915||Diseased Control|
11512462|NCT01266915||Diseased group 1|Those subjects with systemic lupus erythematosus.
11512463|NCT01266915||Diseased group 2|Subjects diagnosed with cutaneous lupus.
11512464|NCT01266902|Experimental|Rilpivirine|Rilpivirine 25 mg once daily
11512465|NCT01266889||study group, control group|
11512466|NCT01266876|Placebo Comparator|Placebo|Placebo SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
11512467|NCT01266876|Experimental|Alirocumab 150 mg Q4W|Alirocumab 150 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
11512468|NCT01266876|Experimental|Alirocumab 200 mg Q4W|Alirocumab 200 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
11512469|NCT01266876|Experimental|Alirocumab 300 mg Q4W|Alirocumab 300 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
11512470|NCT01266876|Experimental|Alirocumab 150 mg Q2W|Alirocumab 150 mg SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
11512471|NCT01266863|Experimental|E test method|
11512472|NCT01266850|Active Comparator|Group 1, RotaTeq® x 3|2, 4 and 6 months of age: RotaTeq®
11512473|NCT01266850|Experimental|Group 5, Rotarix®, RotaTeq® x2|2 months of age: Rotarix®; 4 and 6 months of age: RotaTeq®
11512474|NCT01266850|Active Comparator|Group 4, Rotarix® x 2|2 and 4 months of age: Rotarix®
11512475|NCT01266850|Experimental|Group 2, RotaTeq®, Rotarix® x 2|2 months of age: RotaTeq®; 4 and 6 months of age: Rotarix®
11512476|NCT01266850|Experimental|Group 3, RotaTeq® x 2, Rotarix®|2 and 4 months of age: RotaTeq®; 6 months of age: Rotarix®
11512477|NCT01266837|Other|single arm|Treatment with Everolimus
11512478|NCT01266824|Experimental|Proparacaine|Infants in this group will receive 1 drop of Proparacaine Hydrochloride Ophthalmic Solution (anesthetic eye drop) into each eye prior to receiving mydriatic eye drops
11512479|NCT01266824|No Intervention|Standard of Care|Infants in this arm will not receive Proparacaine Hydrochloride Ophthalmic Solution (anesthetic eye drop) prior to mydriatic eye drops.
11512480|NCT01266811|Experimental|001|Siltuximab Velcade and dexamethasone Given in 21-day treatment cycles Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle Velcade 1.3 mg/m2 IV push on Days 1 4 8 and 11 for Cycles 1-8 and on Days 1 and 8 for Cycles 9 and higher Dexamethasone 20 mg orally on the day of and the day after each Velcade dose
11512481|NCT01266811|Other|002|Placebo Velcade and dexamethasone Given in 21-day treatment cycles Placebo as 1-hour IV infusion on Day 1 of every cycle Velcade 1.3 mg/m2 IV push on Days 1 4 8 and 11 for Cycles 1-8 and on Days 1 and 8 for Cycles 9 and higher Dexamethasone 20 mg orally on the day of and the day after each Velcade dose
11512482|NCT01266798|Experimental|Portal arm|
11512483|NCT01266798|No Intervention|Treatment as usal|
11512484|NCT01266772|Active Comparator|montelukast group|Children with asthma treated with montelukast and budesonide.
11512485|NCT01266772|Placebo Comparator|Placebo group|Children with asthma treated with placebo tablet and budesonide.
11512486|NCT01266759|Experimental|NuvaRing|For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
11512487|NCT01266759|Active Comparator|Norethisterone Acetate|Norethisterone Acetate tablets at a dose of 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
11512488|NCT01266746||Macular hole|The patients of idiopathic macular hole enrolled in the study
11512489|NCT01266746||Macular hole retinal detachment|The patients of macular hole retinal detachment enrolled in the study
11512490|NCT01266746||Myopic traction maculopathy|The patients of macular hole with myopic traction maculopathy enrolled in the study
11512491|NCT01266733|Experimental|Interdisciplinary treatment|
11512498|NCT01266681|Active Comparator|Dronedarone|this group will be given dronedarone to maintain sinus rhythm post DC cardioversion
11512499|NCT01266668||Primary breast DLBCL|Primary breast DLBCL was defined as that involving single extranodal organ (i.e. breast) regardless of the status of nodal disease.
11512500|NCT01266668||Nodal DLBCL|The disease was only limited to the lymph nodes or lymphoid organs without extranodal organ involvements.
11512501|NCT01266655|Experimental|Baclofen|
11512502|NCT01266655|Placebo Comparator|Placebo|
11512503|NCT01266642|Experimental|HF-WBI|Shorter radiation (Group 1), Hypofractionated Whole Breast Irradiation (HF-WBI)
11512504|NCT01266642|Experimental|CF-WBI|Standard radiation (Group 2), Conventionally Fractionated Whole Breast Irradiation (CF-WBI)
11512505|NCT01266629||capsule patients|All patients that will undergo endoscopic capsule
11512506|NCT01266616|Experimental|Cohort 1: Vaccine alone IM/EP|HIV MAG pDNA alone IM/EP
11512507|NCT01266616|Placebo Comparator|Cohort 1: Placebo|Placebo given as an injection in each upper arm
11512508|NCT01266616|Experimental|Cohort 2: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 50 mcg of IL-12 pDNA IM/EP
11512509|NCT01266616|Placebo Comparator|Cohort 2: Placebo|Placebo given as an injection in each upper arm
11512510|NCT01266616|Experimental|Cohort 3: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 250 mcg of IL-12 pDNA IM/EP
11512511|NCT01266616|Placebo Comparator|Cohort 3: Placebo|Placebo given as an injection in each upper arm
11512512|NCT01266616|Experimental|Cohort 4: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 1,000 mcg of IL-12 pDNA IM/EP
11512513|NCT01266616|Placebo Comparator|Cohort 4: Placebo|Placebo given as an injection in each upper arm
11512514|NCT01266616|Experimental|Cohort 5: Vaccine plus IL-12 IM|HIV MAG pDNA plus 1,000 mcg (or highest dose reached) IL-12 pDNA IM
11512515|NCT01266616|Placebo Comparator|Cohort 5: Placebo|Placebo given as an injection in each upper arm
11512516|NCT01266603|Experimental|HDIL-2 + recMAGE-A3 + AS15|HDIL-2 720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle. recMAGE-A3 300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
11512517|NCT01266590|Experimental|LY2216684 + digoxin|Two oral 0.5-milligrams (mg) (two 0.25-mg tablets) doses of digoxin separated by 12 hours on Day 1, followed by once daily 0.25-mg (single 0.25-mg tablet) dose of digoxin on Days 2-14. Daily oral 18-mg (two 9-mg tablets) doses of LY2216684 on Days 8-14.
11512518|NCT01266577|Other|One Arm|Subjects receive the same scan
11512519|NCT01266564||Cohort|
11512520|NCT01266551|No Intervention|lifestyle counseling|The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring. In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.
11512521|NCT01266538||IBD patients|Patients diagnosed with Inflammatory Bowel Disease (IBD)
11512522|NCT01266538||patients after a Large Bowel Resection|Patients after a Large Bowel Resection, with or without a pouch.
11512523|NCT01266538||Control group|Family members of IBD patients, Patients with Irritable Bowel Syndrome (IBS), Fap (familial polyposis)patients after a large bowel resection, Patient performing screening endoscopy
11512524|NCT01266525|Experimental|SAR110894 - 0.5 mg|SAR110894, 0.5 mg once daily along with Donepezil.
11512525|NCT01266525|Experimental|SAR110894 - 2 mg|SAR110894, 2 mg once daily along with Donepezil.
11512526|NCT01266525|Experimental|SAR110894 - 5 mg|SAR110894, 5 mg once daily along with Donepezil.
11512527|NCT01266525|Placebo Comparator|Placebo|Placebo (for SAR110894) once daily along with Donepezil.
11512528|NCT01266512|Experimental|IMRT & docetaxel-cisplatin|"Concurrent chemo-RT:
~Radiotherapy: IMRT - Docetaxel 20mg/m2 + cisplatin 20mg/m2 weekly for 6 weeks -
~Resting period: 2 weeks -
~Adjuvant chemotherapy: Q3W for 2 cycles Docetaxel 35 mg/m² IV infusion for 1 hour on D1&8 - Cisplatin 35 mg/m² on D1&8 -
~Dexamethasone for a total of 3 doses is to be given at a dose of 4 mg at 12 hours, 1 hour before and 12 hours after docetaxel administration"
11512529|NCT01266499|Active Comparator|Group 1: will receive PO Garamycin 80mg x 4/d|will receive PO Garamycin 80mg x 4/d
11512530|NCT01266499|Active Comparator|Group 2 : will receive PO Colistin (Polymyxin E) 100mg x 4/d|
11512531|NCT01266499|Active Comparator|Group 3: will receive both medications|
11512532|NCT01266499|Placebo Comparator|Group 4: will not receive PO treatment|
11512533|NCT01266486|Experimental|Metformin|
11512534|NCT01266473|Experimental|Physiotherapy techniques|Cough Technique vs Forced Expiration Technique
11512535|NCT01266460|Experimental|Treatment (ADXS11-001)|Patients receive live-attenuated Listeria monocytogenes cancer vaccine ADXS11-001 IV over 30 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11512536|NCT01266447|Experimental|Treatment (veliparib, topotecan hydrochloride, filgrastim)|Patients receive veliparib PO twice daily and topotecan hydrochloride IV over 30 minutes once daily on days 1-5. Patients also receive, according to institutional standard, filgrastim SC beginning on day 6, 7, or 8 and continuing until hematopoietic recovery or pegfilgrastim SC on day 6, 7, or 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11512537|NCT01266434|Experimental|simvastatin|
11512538|NCT01266434|Placebo Comparator|B1-6-12|
11512539|NCT01266421||Dienogest (DNG)|Women using DNG) for the treatment of endometriosis
11512540|NCT01266421||Other approved endometriosis drugs (OAED)|Women using hormonal medications approved for endometriosis treatment in all particiapting countries other than DNG.
11512541|NCT01266421||Non-approved endometriosis drugs (NAED)|Women using hormonal medications not approved for endometriosis treatment in all particiapting countries.
11512542|NCT01266408||DRSP/EE/metafolin|Women using oral contraceptives containing drospirenone, ethinylestradiol and metafolin
11512543|NCT01266408||Other OC users|Women using oral contraceptives containing other estrogen/progestogen combinations
11512544|NCT01266369|Experimental|masitinib 3 mg/kg/day|masitinib 3 mg/kg/day
11512545|NCT01266369|Experimental|masitinib 6 mg/kg/day|masitinib 6 mg/kg/day
11512546|NCT01266356||Experimental Group|
11512547|NCT01266356||Control Group|
11512550|NCT01266330|Active Comparator|Low Dairy|<0.5 standard dairy servings/day
11512551|NCT01266330|Experimental|Adequate dairy|3.5 standard dairy servings per day
11512552|NCT01266317|Experimental|Combined PEX, Rituximab and Steroids|"Standard Steroid Treatment: One gm of methylprednisolone I.V., on day 0, followed by 40 mg/day I.V. on days 1-4, and days 6-12 (or the P.O. prednisone equivalent). Methylprednisolone 100 mg I.V. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone I.V. (or P.O. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the principle investigator.
~Plasma exchange (PEX) will consist of 1.5x estimated plasma volume exchanges for 3 successive days (0, 1,2) and then, after a one day interval to enable equilibration of autoantibodies sequestered in tissues, two more daily treatments on days 4 and 5.
~Rituximab: One gm I.V. will be administered on day 5 (after completion of the last PEX) and day 13."
11512553|NCT01266304||community members|Pittsburgh area community members, including people who attend an integrative medicine clinic and people who attend a conventional medicine clinic.
11512554|NCT01266291|Other|Treatment with Sabril (vigabatrin)|This is a single arm study. All subjects who are eligible for treatment will begin taking vigabatrin (Sabril) during the third month of the study. Treatment will be in accordance with the FDA-approved prescribing information: upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
11512555|NCT01266278|Experimental|Kinesiotape|Kinesiotape will be applied to the correct shoulder position of the participants.
11512556|NCT01266265||Tyvaso|The Tyvaso group will consist of patients receiving Tyvaso and may be receiving another FDA approved PAH therapy as part of routine care.
11512557|NCT01266265||Control|The control group will consist of patients with no previous Tyvaso exposure and not taking Tyvaso at the time of the Baseline visit, but receiving any other FDA approved PAH therapy as part of routine care.
11512558|NCT01266252|Experimental|Dexmedetomidine|
11512559|NCT01266239|Active Comparator|SES-KB|Sirolimus-eluting stent (SES) is deployed in the main vessel (MV)and subsequent kissing balloon inflation is performed in the bifurcation.
11512560|NCT01266239|Active Comparator|SES-NK|SES is deployed in the MV without kissing balloon inflation.
11512561|NCT01266239|Active Comparator|EES-KB|Everolimus-eluting stent (EES) is deployed in the MV and subsequent kissing balloon inflation is performed in the bifurcation.
11512562|NCT01266239|Active Comparator|EES-NK|EES is deployed in the MV without kissing balloon inflation.
11512563|NCT01266226|Experimental|ACP treated|The patients are going to get an injection of 4mL autologous conditioned plasma under the footprint following an arthroscopic repair of the rotator cuff.
11512564|NCT01266226|Placebo Comparator|Control group|The patients are going to get an injection of 4mL saline solution under the footprint following an arthroscopic repair of the rotator cuff.
11512565|NCT01266213|Experimental|Fulvestrant plus Goserelin|
11512566|NCT01266213|Experimental|Anastrozole plus Goserelin|
11512567|NCT01266213|Active Comparator|Goserelin alone|
11512568|NCT01266200|Active Comparator|Minimal-invasive treatment (Mantis)|Patients, who received a minimal-invasive surgery and the fracture was fixed by a system called Mantis
11512569|NCT01266200|Active Comparator|Conventional technique (XIA)|Patients who received a surgical treatment including one long cut (conventional operation technique) and the fracture was fixed by a conventional system called XIA
11512570|NCT01266187|Experimental|Arm B|"12 weeks FOLFOX + cetuximab -> 4 weeks rest -> surgery
~-> 4-8 weeks rest -> 12 weeks FOLFOX + cetuximab"
11512571|NCT01266187|Active Comparator|Arm A|surgery -> 4-8 weeks rest -> 24 weeks FOLFOX + cetuximab
11512572|NCT01266174|Experimental|Eltoprazine|eltoprazine pill 2.5mg bid, eltoprazine pill 5mg bid, eltoprazine 7.5mg bid
11512573|NCT01266174|Placebo Comparator|Placebo|placebo pill 2.5mg bid, placebo pill 5mg bid, placebo 7.5mg bid
11512574|NCT01266161|Experimental|Ibuprofen 600 mg extended release|
11512575|NCT01266161|Placebo Comparator|Placebo|
11512576|NCT01266148|Experimental|Everolimus|Participants started immunosuppressive regimen consisting of low dose CsA, everolimus, MMF and CS. After week 11, the participants regimen consisted of everolimus, MMF and CS.
11512577|NCT01266148|Experimental|Control|Participants received an immunosuppressive regimen consisting of CsA, MMF and CS throughout the study.
11512578|NCT01266135|Experimental|Arm 1: QAX576 10 mg/kg|
11512579|NCT01266135|Placebo Comparator|Arm 2: Placebo|
11512580|NCT01266122|No Intervention|HIV/STI voluntary counseling and testing|Participants enrolled in the control arm will receive study assessments only.
11512581|NCT01266122|Experimental|Behavioral intervention|Participants enrolled in the experimental condition will receive 4 group sessions and 4 individual sessions over 3 months. This intervention focuses on psychosocial concerns and HIV risk for MSM in India.
11512582|NCT01266109|Experimental|CM-FAM|
11512583|NCT01266109|Active Comparator|US|
11512584|NCT01266096|Experimental|newly diagnosed or recurrent head/neck melanoma|This is a two-year microdosing study that will enroll 5 metastatic melanoma patients and 18 malignant brain tumor patients (surgical (n=13) and non-surgical candidates (n=5)). We have already accrued 5 melanoma patients and expect to accrue brain tumor patients within a 1 year period.
11512585|NCT01266083|Experimental|WT1 peptide vaccine|This is a Phase II study evaluating the safety and efficacy of the WT1 peptide vaccine in patients who are in CR from Acute Myeloid Leukemia (AML).
11512586|NCT01266070|Experimental|Dovitinib|500 mg/day on a 5 day on, 2 day off schedule
11512587|NCT01266057|Experimental|Hydroxychloroquine + Sirolimus|Hydroxychloroquine starting dose of 200 mg by mouth every day for a 21 day cycle. Sirolimus starting dose of 2 mg by mouth every day for a 21 day cycle.
11512588|NCT01266057|Experimental|Hydroxychloroquine + Vorinostat|Hydroxychloroquine starting dose of 200 mg by mouth every day for a 21 day cycle. Vorinostat starting dose of 200 mg by mouth per day for a 21 day cycle.
11512624|NCT01265797|Sham Comparator|Sham device|wears sham device for 20 minutes daily for 28 days
11512735|NCT01265043|Experimental|OHI|Patients provided with oral hygiene instruction and electric toothbrush
11513744|NCT01258569|Active Comparator|Entereg|
11512589|NCT01266044|Experimental|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
11512590|NCT01266044|Active Comparator|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
11512591|NCT01266044|Other|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
11512592|NCT01266031|Experimental|Bevacizumab|10 mg/kg/dose by vein on days 1 and 15 of a 28 day cycle.
11512593|NCT01266031|Experimental|Vorinostat and Bevacizumab|"Vorinostat: 400 mg/day by mouth on days 1 to 7 and days 15 to 21 of a 28 day cycle.
~Bevacizumab: 10 mg/kg/dose by vein on days 1 and 15 of a 28 day cycle."
11512594|NCT01266018|Experimental|Cohort 1: Sensitive Disease|"Cohort 1 comprised subjects with sensitive disease, defined as subjects who were treated with 1 previous line of chemotherapy and maintained an appropriate response for 90 days or more. Subjects received 4 administrations of ADI-PEG 20 (320 IU/m^2) followed by 1 week of follow-up in each treatment cycle."
11512595|NCT01266018|Experimental|Cohort 2: Refractory Disease|"Cohort 2 comprised subjects with refractory disease, defined as subjects who either (a) were treated with 1 previous line of chemotherapy and either had no response or progressed < 90 days after completing treatment or (b) required third-line therapy, i.e., had completed 2 previous lines of chemotherapy, regardless of response. Subjects received 4 administrations of ADI-PEG 20 (320 IU/m^2) followed by 1 week of follow-up in each treatment cycle."
11512596|NCT01266005|Experimental|1|Clevudine 30mg
11512597|NCT01266005|Active Comparator|2|Entecavir 0.5mg
11512598|NCT01265992||Paricalcitol capsules|Patients with secondary hyperparathyroidism associated with Stage 3 - 5 CKD and not yet on dialysis and prescribed paricalcitol capsules in accordance with the terms of the marketing authorization in Sweden.
11512599|NCT01265979||GIST treated with regorafenib/placebo|patients with advanced, metastatic gastro-intestinal stromal tumors treated with regorafenib or placebo
11512600|NCT01265966||Moderate Sedation|Children undergoing moderate sedation for procedures.
11512601|NCT01265966||Deep Sedation|Children undergoing deep sedation for procedures.
11512602|NCT01265953|Experimental|SFN-rich broccoli sprout extract capsules|Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of sulforaphane (SFN) daily, 2 capsules (1 capsule B.I.D.) daily
11512603|NCT01265953|Placebo Comparator|Placebo capsules|Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
11512604|NCT01265940|Experimental|Pazopanib + Vinflunine|
11512605|NCT01265927|Experimental|GRN163L + Trastuzumab|
11512606|NCT01265914|Placebo Comparator|placebo|
11512607|NCT01265914|Experimental|FP-01.1|
11512608|NCT01265901|Active Comparator|Sunitinib|Sunitib as Standard therapy per Label.
11512609|NCT01265901|Experimental|IMA901 plus GM-CSF added to sunitinib after single dose of cy|After 1 cycle of sunitinib, intradermal vaccinations with IMA901 plus GM-CSF as adjuvant after a single dose of cyclophosphamide will be applied for a period of 4 months while continuing treatment with sunitinib
11512610|NCT01265888|Experimental|Dosing Group 1|1 Liter per Minute (LPM)of inhaled nitric oxide via nasal cannula: approximately 5 parts per million (ppm)
11512611|NCT01265888|Experimental|Dosing Group 2|2 LPM of inhaled nitric oxide via nasal cannula: approximately 15 ppm
11512612|NCT01265888|Experimental|Dosing Group 3|4 LPM of inhaled nitric oxide via nasal cannula: approximately 20 ppm
11512613|NCT01265875|Other|human secretin|intravenous secretin administration in escalating doses three times daily for three days. After each infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion.
11512614|NCT01265862|Active Comparator|LMA-Fastrach® and GlideRite® tube|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.
~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification
~Insertion of LMA-Fastrach®, establishment of ventilation
~Evaluation of glottic view through LMA-Fastrach® using fibrescope
~Tracheal intubation with the GlideRite® tube through the LMA-Fastrach®
~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
11512615|NCT01265862|Experimental|I-gel® and GlideRite® tube|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.
~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification
~Insertion of I-gel®, establishment of ventilation
~Evaluation of glottic view through I-gel® using fibrescope
~Tracheal intubation with the GlideRite® endotracheal tube through the I-gel®
~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
11512616|NCT01265849|Experimental|LI + CIZ + SOC|LI plus CIZ (cyclophosphamide, indomethacin and zinc) is given as adjuvant therapy prior to standard of care (SOC).
11512617|NCT01265849|Active Comparator|Standard of Care (SOC)|SOC for previously untreated SCCHN patients is currently surgery followed by either radiotherapy or combined radiochemotherapy depending the patient's risk status for relapse determined at surgery.
11512618|NCT01265849|Experimental|LI + SOC|LI is administered without CIZ to determine the contribution of CIZ to the effects of LI.
11512619|NCT01265836||1|
11512620|NCT01265823|Experimental|Adalimumab|
11512621|NCT01265810|Other|sodium chloride -> supersaturated calcium-phosphate|Patients in this arm start first with sodium chloride 0.9% mouth rinses and go crossover to supersaturated calcium-phosphate mouth rinses.
11512622|NCT01265810|Other|supersaturated calcium-phosphate -> sodium chloride|Patients in this arm start first with supersaturated calcium-phosphate mouth rinses and go crossover to sodium chloride 0.9% mouth rinses.
11512623|NCT01265797|Active Comparator|Cranial Electrostimulator|wears active cranial electrostimulation device for 20 minutes daily for 28 days
11512625|NCT01265784|Experimental|TP-434, 1.5 mg/kg q24h|TP-434 was administered intravenously (IV) at a dose of 1.5 milligrams per kilogram of body weight (mg/kg) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). TP-434 treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
11512626|NCT01265784|Experimental|TP-434, 1.0 mg/kg q12h|TP-434 was administered IV at a dose of 1.0 mg/kg every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). TP-434 treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
11512627|NCT01265784|Active Comparator|Ertapenem, 1 g q24h|Ertapenem was administered IV at a dose of 1 gram (g) q24h for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
11512628|NCT01265771|Experimental|Telemetry ordered by a Cardiologist|
11512629|NCT01265771|Experimental|24 hours standard Holter monitoring|
11512630|NCT01265771|Experimental|Telemetry ordered by a Pediatrician|
11512631|NCT01265758|Experimental|Telemetric ECG monitoring|Telemetric 14-days Full Disclosure ECG recording.
11512632|NCT01265758|Active Comparator|Standard 24-hours Holter ECG recording|Standard 24-hours Holter ECG recording repeated 3 times unless arrhythmia is diagnosed earlier.
11512633|NCT01265745|Active Comparator|Valortim|Valortim 1mg,5mg,10mg
11512634|NCT01265745|Placebo Comparator|Placebo|Saline solution will be used as the placebo
11512635|NCT01265732|Active Comparator|oral single dose dispersion 100mg|Subjects receive a single dose of PF-04191834 as a dispersion
11512636|NCT01265732|Active Comparator|oral wet milled suspension 100mg|Subjects receive a single dose of PF-04191834 as a suspension
11512637|NCT01265732|Active Comparator|oral wet milled suspension 300mg|Subjects receive a single dose of PF-04191834 as a suspension
11512638|NCT01265719||Latanoprost-treatment group|
11512639|NCT01265719||Non-topical prostaglandin analogue treatment group|
11512640|NCT01265680|Experimental|Erythropoietin|80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital
11512641|NCT01265680|No Intervention|Control|No added administration other than our standard of care.
11512642|NCT01265667|Experimental|CF101 2 mg|CF101 2mg oral tablets
11512643|NCT01265667|Placebo Comparator|Placebo|Placebo oral tablets
11512644|NCT01265654||All patients|Patients with ABC and two lines of hormonal treatment
11512645|NCT01265641|Experimental|1|
11512646|NCT01265641|Experimental|2|
11512647|NCT01265641|Experimental|3|
11512648|NCT01265641|Placebo Comparator|4|
11512649|NCT01265628||Glaucoma|
11512650|NCT01265628||Retinitis pigmentosa (RP)|
11512651|NCT01265628||Anterior Ischemic Optic Neuropathy (AION)|
11512652|NCT01265615|Active Comparator|Paricalcitol treatment|6-8 μg daily per os (orally) without special diet
11512653|NCT01265615|Active Comparator|Calcitriol treatment|2-4 μg daily orally under with dietary restrictions of vitamin D
11512654|NCT01265615|Active Comparator|Cholecalciferol|alendronate sodium/ cholecalciferol capsules with recommended daily allowance equals 1200-2400 IU per day
11512655|NCT01265615|Other|Supplemental|intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
11512656|NCT01265602|Experimental|LAS41007|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
11512657|NCT01265602|Active Comparator|LASW1510|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
11512658|NCT01265602|Placebo Comparator|vehicle|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
11512659|NCT01265589|Placebo Comparator|I=surfactant|Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
11512660|NCT01265589|Experimental|II=surfactant+vitamin A|Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
11512661|NCT01265576|Placebo Comparator|Sorafenib with placebo|Participants randomized to the Control Arm (sorafenib with placebo) receive sorafenib as the standard of care, and placebo for the same periods as participants randomized to the Treatment Arm (sorafenib plus VT-122). Participants randomized to the Control Arm will undergo the same visits and procedures as would the participants randomized to the Treatment Arm.
11512662|NCT01265576|Experimental|Sorafenib plus VT-122|
11512663|NCT01265563|Placebo Comparator|NAC placebo and Silibin placebo|Drug: N-acetylcysteine placebo and Drug: Silibin placebo
11512664|NCT01265563|Experimental|NAC active and Silibin placebo|Drug: N-acetylcysteine and Drug: Silibin placebo
11512665|NCT01265563|Experimental|NAC placebo and Silibin active|Drug: N-acetylcysteine placebo and Drug: Silibin active
11512666|NCT01265563|Experimental|NAC active and Silibin active|Drug: N-acetylcysteine active and Drug: Silibin active
11512667|NCT01265563|Experimental|NAC active and High-dose Silibin active|Drug: N-acetylcysteine active and Drug: Silibin higher dose active
11512668|NCT01265550|Other|Medical Treatment Group|Omeprazole or Omeprazole + baclofen or Omeprazole + desipramine
11512669|NCT01265550|Other|Surgical Treatment Group|Laparoscopic nissen fundoplications
11512670|NCT01265550|Other|Placebo Medical Treatment Group|Omeprazole + placebo
11512732|NCT01265069|Experimental|concomitant therapy|Group B - concomitant therapy (rabeprazole 20 mg, amoxicillin 1000 mg, metronidazole 500 mg, clarithromycin 500 mg, bid for 10 days).
11512733|NCT01265056|Placebo Comparator|Sugar Pill|Placebo
11512671|NCT01265537|Experimental|Low target tacrolimus (Advagraf)|"This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and low-target Advagraf."
11512672|NCT01265537|Active Comparator|Standard target tacrolimus (Advagraf)|"This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and standard target Advagraf."
11512673|NCT01265524|Active Comparator|CLP|Investigational drug: 15 g CLP per day given as capsules
11512674|NCT01265524|Placebo Comparator|Placebo|Placebo, capsules
11512675|NCT01265511|Placebo Comparator|Placebo|Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
11512676|NCT01265511|Active Comparator|SCY-635 600 mg|SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
11512677|NCT01265498|Active Comparator|Obeticholic acid|obeticholic acid
11512678|NCT01265498|Placebo Comparator|Placebo|Placebo
11512679|NCT01265485|Experimental|treatment|
11512680|NCT01265459|Experimental|Durolane 3ml|Durolane 3 ml is an Intraarticular hyaluronic acid
11512681|NCT01265459|Experimental|Durolane 4.5|Durolane 4.5 is an Intraarticular hyaluronic acid
11512682|NCT01265459|Experimental|Durolane 6 ml|Durolane 6 ml is an Intraarticular hyaluronic acid
11512683|NCT01265446|Experimental|Lidocaine 8mg +CPC 2mg|one single dose
11512684|NCT01265446|Active Comparator|Lidocaine 1mg + CPC 2mg|one single dose
11512685|NCT01265433|Experimental|WT-1-vaccine Montanide + GM-CSF|The study will be a randomized phase II trial to determine the 1-year progression free survival after treatment with WT-1 analog peptide vaccine in patients with MPM after completion of combined modality therapy.
11512686|NCT01265433|Active Comparator|Montanide adjuvant + GM-CSF (This arm is closed)|The study will be a randomized phase II trial to determine the 1-year progression free survival after treatment with WT-1 analog peptide vaccine in patients with MPM after completion of combined modality therapy.
11512687|NCT01265420|Experimental|Injectable clostridial collagenase|Patients with thumb 1st web contracture secondary to Dupuytren's disease will be treated with 0.58mg of collagenase
11512688|NCT01265394|Experimental|(18F) Flutemetamol|
11512689|NCT01265381||Cohort of Chernobyl Cleanup Workers in Ukraine|Thyroid cancer cases and matched controls in the cohort
11512690|NCT01265368|Experimental|Study medication|
11512691|NCT01265355|Experimental|Anti-rotavirus protein|
11512692|NCT01265355|Placebo Comparator|Maltodextrin|
11512693|NCT01265342|Placebo Comparator|Placebo|
11512694|NCT01265342|Experimental|Beclomethasone|Beclometasone suspension 400 mcg will be administered through a nebuliser twice a day, in the morning and in the evening, for 10 days
11512695|NCT01265329|No Intervention|Control|No sperm selection
11512696|NCT01265329|Experimental|Annexine V negative|Sperm selection with Annexine V protein
11512697|NCT01265303|Other|Catheter ablation|
11512698|NCT01265303|Other|Pacemaker implantation|
11512699|NCT01265303|Other|Pharmacotherapy|
11512700|NCT01265290|Experimental|Telemetric ECG monitoring|Telemetric Full Disclosure ECG monitoring
11512701|NCT01265290|Experimental|24 hours standard Holter monitoring|
11512702|NCT01265277||at home|Infants 0-3 months who will stay at home with a parent
11512703|NCT01265277||child care|Infant 0-3 months who will attend a licensed child care center
11512704|NCT01265264|Experimental|ulodesine Placebo + Allopurinol 300mg|Oral dose administered daily for 84 days.
11512705|NCT01265264|Experimental|ulodesine 5mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
11512706|NCT01265264|Experimental|ulodesine 10mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
11512707|NCT01265264|Experimental|ulodesine 20mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
11512708|NCT01265264|Experimental|ulodesine 40mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
11512709|NCT01265251||Test-retest|Forty-four healthy elderly 60-82 years old
11512710|NCT01265251||Validity|Twenty six patients with various diseases and various ages
11512711|NCT01265251||Feasibility|Twenty seven patients under the preoperative investigation for INPH
11512712|NCT01265186||Ventilated term newborns|Ventilated newborns with a corrected gestational age ≧ 37 weeks of gestation until the 28th day of life respectively ≦ 44 weeks of gestation
11512713|NCT01265186||Control group: healthy term newborns|Control group: healthy newborns with a corrected gestational age ≧ 37 weeks of gestation until the 28th day of life respectively ≦ 44 weeks of gestation
11512714|NCT01265173|Active Comparator|Cefotaxime|iv 2G q 8hrs for general, dose titration if needed (eg.CKD)
11512715|NCT01265173|Experimental|Ceftriaxone|iv 2G q 24hrs
11512716|NCT01265173|Experimental|Ciprofloxacine|iv 400mg q 12hrs for general, dose titration if needed (eg.CKD)
11512717|NCT01265160||the group of Jiangzhuo prescription|
11512718|NCT01265160||the group of fenofibrate|
11512719|NCT01265160||the group of placebo|
11512720|NCT01265147|Active Comparator|Cisplatin|cisplatin combine with IMRT
11512721|NCT01265147|Experimental|Nedaplatin|Nedaplatin combine with IMRT
11512722|NCT01265134||Experimental Group|the healthy elders
11512723|NCT01265134||Control Group|the elders who have fallen once
11512724|NCT01265121|Experimental|CPAP treatment|This acromegalic patients is going to have sleep apnea treated for 3 months with a with a continuous positive air pressure device (CPAP)
11512725|NCT01265121|Placebo Comparator|Nasal adhesive|This acromegalic patients will be treated will an external nasal dilator adhesive intended to serve as a placebo treatment
11512726|NCT01265108|Experimental|Intravenous iron sucrose|Infusion of 200 mg iron sucrose (Venofer) in 100 ml normal (0.9%) saline.
11512727|NCT01265108|Placebo Comparator|Intravenous normal saline|Infusion of 100 ml normal (0.9%) saline.
11512728|NCT01265095||VRE bacteremia|VRE bacteremia patients
11512729|NCT01265082||Patients in remission with pruritus|
11512730|NCT01265082||Patients in remission without pruritus|
11512731|NCT01265069|Active Comparator|high dose dual therapy|Group A - high dose dual therapy (rabeprazole 20 mg qid, amoxicillin 750 mg qid for 14 days)
11512734|NCT01265056|Experimental|Gabapentin|Gabapentin
11512736|NCT01265043|Experimental|OHI + CHX mouthrinse|Patients provided with oral hygiene instruction and Corsodyl mouthrinse
11512737|NCT01265043|Experimental|OHI + CHX mouthrinse + assisted brushing|Oral hygiene instruction, Corsodyl mouthrinse, and assisted brushing
11512738|NCT01265030|Experimental|Sirolimus|"Preoperative sirolimus:
~loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligram)
~starting 24 hours after the initial loading dose, subjects will receive a dose of 4 milligram/meters2 daily; Per Os (PO), by mouth days 2 through 28"
11512739|NCT01265017|Experimental|Active Treatment|"interventions include Estradiol, medroxyprogesterone, hydrocortisone, GH as follows
~Estradiol 1mg every 8 hours administered orally
~Medroxyprogesterone 2.5 mg every 24 hours administered orally
~Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally
~Growth hormone 2 mg once a day administered by subcutaneous injection"
11512740|NCT01265017|Placebo Comparator|Placebo|Matching placebo
11512741|NCT01265004||Stitches, rupture of achilles tendon|Patients, in who the achilles tendon rupture was treated with tendon surgery including a special way of stitching to preserve the sliding ability of the tendon.
11512742|NCT01265004||Fibrin-glue, rupture of achilles tendon|Patients, who received a surgical treatment including a fixing of the tendon with fibrin-glue.
11512743|NCT01265004||Stiches and Fibrin-glue|Patients, in who the achilles rupture was treated with stitches and fibrin-glue.
11512744|NCT01264991|Experimental|APM group|
11512745|NCT01264991|Placebo Comparator|Sham group|
11512746|NCT01264978|Experimental|repetitive neuromuscular stimulation|repetitive neuromuscular stimulation of the quadriceps arm are patients actively stimulated at increasing intensity to afford maximal contraction during training sessions
11512747|NCT01264965|Active Comparator|Acetaminophen|
11512748|NCT01264965|Active Comparator|Long Acting Oxycodone|
11512749|NCT01264939|Placebo Comparator|Placebo|Participants received placebo subcutaneously every 4 weeks during the 24 week treatment period.
11512750|NCT01264939|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24 week treatment period.
11512751|NCT01264926||rotator cuff tear, pain|
11512752|NCT01264913||Shift Workers|
11512753|NCT01264913||Day Workers|
11512754|NCT01264900|Experimental|Cognitive Behavioral Therapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment
11512755|NCT01264900|Active Comparator|Supportive Psychotherapy|Twelve weekly 50-minute sessions of individual supportive (client-centered) psychotherapy
11512756|NCT01264887|Experimental|Tapentadol Prolonged Release|Participants allocated to this treatment arm can be flexibly dosed between 100 to 250 mg tapentadol twice daily (50 and 100 mg tablets to be dispensed).
11512757|NCT01264874|Experimental|Vitamin D3|Vitamin D3 administration
11512758|NCT01264874|Placebo Comparator|placebo|matched placebo
11512759|NCT01264861|Experimental|Arm 1:|Arm 1: Eligible subjects will receive escalating doses of safinamide for the 6-week duration of treatment. Each dose level will be last 10-14 days. Doses 200mg and 300mg will have a 3 day intermediate step up dose, 150mg and 250mg dose.
11512760|NCT01264848|Experimental|Balloon angioplasty and/or stenting|Balloon angioplasty and/or stenting of stenosed internal jugular vein and/or azygous vein and/or brachiocephalic vein
11512761|NCT01264822||Treatment Arm 1 Rabeprazole Sodium|
11512762|NCT01264809|Experimental|A : immediate physical activity counseling|Participants randomized in the experimental group (group A) will receive physical activity counseling during a one-to-one consultation at both baseline and 3 months.
11512763|NCT01264809|Active Comparator|B : later physical activity counseling|Exercise consultation will be realised only at 3 months in the control group(group B). Furthermore, patients of group B will not received any physical activity counseling at baseline.
11512764|NCT01264796|Experimental|behavioral intervention, counseling|2hr group education for 6 weeks
11512765|NCT01264796|No Intervention|delyed intervention|control group
11512766|NCT01264783|Experimental|RNS60|RNS60
11512767|NCT01264783|Placebo Comparator|Placebo|Placebo
11512768|NCT01264770|Experimental|Dosing Group A|Oral treatment and subcutaneous injection
11512769|NCT01264770|Experimental|Dosing Group B|Oral treatment and subcutaneous injection
11512770|NCT01264770|Experimental|Dosing Group C|Oral treatment and subcutaneous injection
11512771|NCT01264770|Active Comparator|Dosing Group D|Oral treatment and subcutaneous injection
11512772|NCT01264770|Placebo Comparator|Dosing Group E|Oral treatment and subcutaneous injection
11512773|NCT01264757|Active Comparator|Education|Educational brochure about physical activity provided.
11512774|NCT01264757|Experimental|Pedometer|A pedometer was provided in addition to educational materials.
11512775|NCT01264731|Active Comparator|peptide vaccine plus imiquimod|Peptide Vaccine: Days 1, 8, 15, 36, 57, 78 Imiquimod: Applied daily on days 1-85.
11512776|NCT01264731|Active Comparator|Imiquimod|Imiquimod: Applied daily on days 1-85.
11512777|NCT01264718|No Intervention|Control|After randomization to the control group, minority low-income parents of uninsured, Medicaid/CHIP-eligible children received only traditional Medicaid/Children's Health Insurance Program (CHIP) outreach and enrollment.
11512778|NCT01264718|Experimental|Parent Mentors|After randomization to the Parent Mentor group, minority low-income parents of uninsured Medicaid/CHIP-eligible children received face-to-face instruction and guidance from Parent Mentors on obtaining and keeping Medicaid/CHIP for their child; getting a doctor, dentist, and pharmacist; and addressing social determinants of health.
11512779|NCT01264705|Experimental|Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 1: Participants were administered Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily
11512780|NCT01264705|Experimental|Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 2: Participants were administered Bavituximab:1.0 mg/kg weekly Sorafenib: 400mg PO twice daily
11512781|NCT01264705|Experimental|Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 3: Participants were administered Bavituximab:3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
11512782|NCT01264692|Experimental|Treatment A|ACT-280778
11512783|NCT01264692|Placebo Comparator|Treatment B|Placebo
11512784|NCT01264692|Other|Treatment C|Amlodipine
11512929|NCT01263691|Placebo Comparator|Control|Saline control
11512785|NCT01264679|Experimental|Ferumoxytol|When a participant has persistent or recurrent IDA (defined as hemoglobin <12.0 grams [g]/deciliter [dL] and with either transferrin saturation <40% or ferritin <100 nanograms/milliliter), the participant will begin a 7-week treatment period. Participants will receive 2 IV injections of ferumoxytol 7.0 milligrams (mg) iron/kilogram (maximum of 510 mg/dose), the first dose administered on Day 1 and the second on Days 3 through 9 of the Treatment Period.
11512786|NCT01264666|Experimental|Chinese tea flavor liquor|
11512787|NCT01264666|Placebo Comparator|Water|Water combined with meal as control.
11512788|NCT01264666|Placebo Comparator|Chinese Meijiao Liquor|
11512789|NCT01264653|Experimental|experimental group,control group|Intraocular adrenalin,topical mydriatics, experimental group: Intervention: Procedure:refractive cataract surgery with Intraocular adrenalin, control group:refractive cataract surgery with topical mydriatics
11512790|NCT01264640|Experimental|A|Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
11512791|NCT01264627|Experimental|Mindful Breathing (MB)|"The MB intervention is based off of the Mindfulness Based Stress Reduction Program developed by Jon Kabat-Zinn. Participants will be organized into cohorts of eight, and attend eight weekly MB sessions. Mindful breathing consists of closely following the breath, throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, perceptions and events, from a non-evaluative, non-judgmental perspective. No other intervention is included. No FDA drug or device is involved."
11512792|NCT01264627|Other|Usual Care (UC)|Usual Care consists of the standard care made available to participants through their primary physician. No intervention is included. No FDA drug or device is involved.
11512793|NCT01264614|Experimental|Early stage dementia|Individuals with early stage dementia who attended a Adult Day Care Program at least twice a week. Participants engaged in a strengthening exercise program three to five times per week for 10 weeks.
11512794|NCT01264614|Active Comparator|Normative older adults|Normative older adults with no known neurological condition. Participants engaged in a strengthening exercise program three to five times per week for 10 weeks.
11512795|NCT01264601|Experimental|Single Dose|This arm will receive TIV as 2 doses, the first of which will be normal saline administered at approximately 10% of the total age appropriate dose volume, followed 30 minutes later by the full age appropriate dose. For children receiving a 0.25ml dose, a 20%/80% split will be used for ease of administration in drawing up the dose.
11512796|NCT01264601|Experimental|Graded Challenge|Subjects in this arm will receive TIV by standard 10%/90% 2-step graded challenge split of the age appropriate dose, separated by 30 minutes. For children receiving a 0.25ml dose, a 20%/80% split will be used for ease of administration in drawing up the dose.
11512797|NCT01264588|Active Comparator|topical calcium glycerophosphate lotion|
11512798|NCT01264588|No Intervention|standard-of-care|
11512799|NCT01264575|Experimental|BPV6E1|
11512800|NCT01264575|Experimental|BPV7E1|
11512801|NCT01264575|Experimental|BPV8E1|
11512802|NCT01264575|Experimental|BPV9E1|
11512803|NCT01264575|Experimental|BPV10E1|
11512804|NCT01264575|Experimental|BPV11E1|
11512805|NCT01264575|Experimental|BPV6E2|
11512806|NCT01264575|Experimental|BPV7E2|
11512807|NCT01264575|Experimental|BPV8E2|
11512808|NCT01264575|Experimental|BPV9E2|
11512809|NCT01264575|Experimental|BPV10E2|
11512810|NCT01264575|Experimental|BPV11E2|
11512811|NCT01264562||Chemotherapy group|Breast cancer patients treated with chemotherapy
11512812|NCT01264562||Non-chemotherapy group|Breast cancer patients not treated with chemotherapy
11512813|NCT01264562||Healthy controls|Women without a cancer diagnosis, matched for age and education
11512814|NCT01264549|Experimental|PCT guided arm|
11512815|NCT01264549|No Intervention|Control|Standard treatment
11512816|NCT01264536|Experimental|Lactoferrin|Lactoferrin is a freeze-dried protein purified directly from fresh bovine milk.
11512817|NCT01264536|Placebo Comparator|maltodextrin|Maltodextrin is an inert sugar.
11512818|NCT01264510|Other|patients implanted with a Bone-anchored hearing aid(Baha)|
11512819|NCT01264484||Advantage prosthetic heart valve|All patients who were enrolled and implanted with an Advantage valve in the Herzzentrum Nordrhein-Westfalen (Bad Oeynhausen, Germany) and Deutsches Herzzentrum München (Munich, Germany) during the previous Advantage clinical study study and who agree to participate in this long-term follow-up study by informed consent.
11512820|NCT01264471||Gulf War Syndrome patients|Gulf War veterans who have been diagnosed with Gulf War Syndrome.
11512821|NCT01264458||Traumatic Injury|Trauma patients arriving at Saint Mary's Emergency Department
11512822|NCT01264458||Control group|
11512823|NCT01264445|Experimental|Group A|Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.
11512824|NCT01264445|Experimental|Group B|Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.
11512825|NCT01264445|Experimental|Group C|Ad35-GRIN investigational HIV vaccine at Month 0 followed by Adjuvanted GSK investigational HIV vaccine at Months 3 and 4.
11512826|NCT01264445|Experimental|Group D|Adjuvanted GSK investigational HIV vaccine and Ad35-GRIN investigational HIV vaccine co-administered (simultaneous administration with separate injections)at Months 0, 1, and 4.
11512827|NCT01264432|Experimental|Treatment (veliparib, LDRWAR)|Patients receive veliparib PO BID on days 1-21 (days 5-21 of course 1). Patients undergo LDFWAR in BID on days 1 and 5 of weeks 1-3. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
11512828|NCT01264419|Experimental|Silk Road Embolic Protection System|Eligible subjects who are to receive a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
11512829|NCT01264406||Exercise Group (20 KKW)|Exercise group will obtain 20 KKW, perform in 4-5 sessions per week for approximately 50-70 minutes per session.
11513087|NCT01262794|Experimental|CDP6038 3 mg/kg|
11512830|NCT01264406||Exercise Group (8 KKW)|One exercise group will obtain 8KKW (kcal/kg/week) over 3-4 sessions per wee, which will result in each session lasting approximately 30 minutes
11512831|NCT01264406||Control group|This group will be instructed to maintain their baseline level of exercise.
11512832|NCT01264393|Active Comparator|Shape Up Rhode Island + Online weight loss program + groups|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an internet-based weight loss program, and the option of attending face-to-face group sessions
11512833|NCT01264393|Active Comparator|Shape Up Rhode Island + Online Weight Loss Program|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention in addition to an internet-based weight loss program
11512834|NCT01264393|Active Comparator|Shape Up Rhode Island + Internet Resources|Participants in this arm will receive the Standard Shape Up Rhode Island statewide intervention plus access to internet resources
11512835|NCT01264380|Experimental|1|
11512836|NCT01264380|Experimental|2|
11512837|NCT01264380|Experimental|C|
11512838|NCT01264367|Experimental|1|Clevudine 30mg
11512839|NCT01264367|Active Comparator|2|Clevudine 30mg + peg-interferon 180mcg
11512840|NCT01264354|Experimental|1|Clevudine 30mg
11512841|NCT01264354|Experimental|2|Clevudine 20mg+Adefovir dipivoxil 10mg
11512842|NCT01264354|Experimental|3|Clevudine 20mg
11512843|NCT01264341|Experimental|Bevacizumab combined with temsirolimus|Bevacizumab 10mg/kg intravenous every 2 weeks Temsirolimus 25mg intravenous once weekly
11512844|NCT01264328|Experimental|Panitumumab + Paclitaxel|Treatment consisted of intravenous panitumumab 6 mg/kg q2w, administered in one hour the first day and in 30 minutes thereafter (if no infusional reaction was observed) plus intravenous paclitaxel 80 mg/m2 weekly administered one hour after panitumumab in one hour infusion, until progression or unacceptable toxicity. Panitumumab does not require prophylactic premedication from the first infusion. Paclitaxel was administered with: dexamethasone 10 mg, diphenhydramine 30 mg and antiH2 (cimetidine 300 mg or ranitidine 50 mg). Dose modifications of paclitaxel included 4.8 mg/kg (80% of the initial dose) and 3.6 mg/kg (60%) when recovered from a grade 3-4 skin toxicity to grade ≤2. Continuing paclitaxel on the day of the planned infusion required no grade ≥2 mucositis and hematologic recovery with an absolute neutrophil count ≥1,500/ml and a platelet count ≥75,000.
11512845|NCT01264315|Other|Lenalidomide in maintenance|
11512846|NCT01264302|Experimental|Finasteride tablets 5 mg|Finasteride tablets 5 mg of Dr.Reddy's Laboratories Limited
11512847|NCT01264302|Active Comparator|Proscar 5 mg Tablets|Proscar 5 mg Tablets of Merck & Co. Inc
11512848|NCT01264289|Experimental|Finasteride tablets 5 mg|Finasteride tablets 5 mg of Dr.Reddy's Laboratories Limited
11512849|NCT01264289|Active Comparator|Proscar 5 mg Tablets|Proscar 5 mg Tablets of Merck & Co. Inc
11512850|NCT01264263||1|
11512851|NCT01264250|Experimental|1|
11512852|NCT01264250|Placebo Comparator|2|
11512853|NCT01264237|Experimental|Etoricoxib|The study will use an Enriched Enrollment Randomized Withdrawal (EERW) design consisting of a 2-week open-label enrichment phase, during which subjects will receive etoricoxib. Patients who experience at least a 30% reduction in pain intensity will be randomized to either continued treatment with etoricoxib 90 mg qd or matching placebo (at a 1:1 ratio) for 4 weeks.
11512854|NCT01264237|Placebo Comparator|Placebo|The study will use an Enriched Enrollment Randomized Withdrawal (EERW) design consisting of a 2-week open-label enrichment phase, during which subjects will receive etoricoxib, followed by a 4-week randomized, double-blind, placebo-controlled treatment phase, during which subjects will receive either etoricoxib or placebo.
11512855|NCT01264224|Experimental|PAC-14028|
11512856|NCT01264211|Experimental|Diacerein|
11512857|NCT01264211|Placebo Comparator|Placebo|
11512858|NCT01264198|Sham Comparator|Stretching Exercises|The patients will perform twice weekly home based static stretching workout.
11512859|NCT01264198|Experimental|Resistance Training|The patients will perform twice weekly supervised RT for 3 months
11512860|NCT01264185||Asia--Thailand; S. America--Brazil|
11512861|NCT01264185||Africa--Zambia|
11512862|NCT01264172|Active Comparator|PCCP, Proximal femur fracture|Patients, who received a minimal-invasive surgical treatment with the PCCP-plate
11512863|NCT01264172|Active Comparator|Osteosythesis with nails, prox. femur frac.|Patients, who received a minimal-invasive surgical treatment including a osteosynthesis with nails
11512864|NCT01264172|Active Comparator|DHS, proximal femur fracture|Patients, who received a conventional surgical treatment with the dynamic hip screw (DHS)
11512865|NCT01264159|Placebo Comparator|Control|
11512866|NCT01264159|Active Comparator|Lung impedence-guided treatment|
11512867|NCT01264146|Active Comparator|calcaneal plating HBOT|Open reduction and internal fixation of calcaneal fracture + HBOT
11512868|NCT01264146|Placebo Comparator|calcaneal plating|Open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
11512869|NCT01264120|Experimental|Health Psychology Intervention|A 50 minute health psychology behavioural intervention with sessions pre-surgery, post-surgery and at 3 month follow up.
11512870|NCT01264120|No Intervention|Control Group|The control group receive usual care through the bariatric surgery process.
11512871|NCT01264081|Experimental|Lapatinib|Lapatinib will be administered as an oral dose of 500 mg twice daily in the morning and evening one hour before or after meals.
11512872|NCT01264068|No Intervention|Insomnia control|
11512873|NCT01264068|Experimental|Suan Tsao Jen Tang|
11512874|NCT01264068|Experimental|Jia-Wey Shiau-Yau San|
11512875|NCT01264055||1|Adults with idiopathic bronchiectasis
11512876|NCT01264042|Experimental|FeSo4|
11512877|NCT01264029|Experimental|Group A|Movement meditation for 2 hours
11512878|NCT01264029|Active Comparator|Group B|Non-moving sitting meditation for 2 hours
11512879|NCT01264029|Active Comparator|Group C|Mall Walking for 2 hours
11512880|NCT01264029|Active Comparator|Group D|Weekly Discussion
11512881|NCT01264016|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use an investigational blood glucose monitoring system.
11512882|NCT01264003|Active Comparator|1|Antibiotic prohylaxis / Lichtenstein repair
11512883|NCT01263990|No Intervention|Nexfin|Nexfin is used in all patients
11512884|NCT01263977|Experimental|Thermodilution controlled volume management|Volume management based on parameters: GEDI, ELWI, CI
11512885|NCT01263977|Active Comparator|Volume management based on surviving sepsis campaign|volume management based on surviving sepsis campaign guidelines: CVP, Urin output, MAP, ScvO2
11512886|NCT01263964||stroke, troponin elevation|Patients with stroke (proven by cerebral imaging) and troponin elevation undergoing coronary angiogram
11512887|NCT01263964||non-stemi (controll group)|Patients with troponin elevation suggesting non-stemi undergoing coronary angiogram
11512888|NCT01263951|Experimental|Everolimus and sorafenib|All patients will receive everolimus and sorafenib daily.
11512889|NCT01263938|Other|Atorvastatin|
11512890|NCT01263925|Experimental|Alprostadil|Alprostadil (Prostaglandin E1) intravenous and matching Placebo to Pentoxifylline oral
11512891|NCT01263925|Active Comparator|Pentoxifylline|Pentoxifylline oral and matching Placebo to Alprostadil (Prostaglandin E1) intravenous
11512892|NCT01263912|Active Comparator|LCPUFA Supplement|DHA/ARA supplement providing 200 mg/day docosahexaenoic acid (DHA) from DHASCO®-S oil and 200 mg/day arachidonic acid (ARA) from ARASCO® oil (DSM Nutritional Products).
11512893|NCT01263912|Placebo Comparator|A Placebo|400 mg/day corn oil
11512894|NCT01263899|Experimental|SB1518|
11512895|NCT01263886|Experimental|AVE8062 and combination|"Day 1: AVE8062
~Day 2: docetaxel followed by cisplatin or paclitaxel followed by carboplatin"
11512896|NCT01263886|Placebo Comparator|Placebo|"Day 1: placebo
~Day 2: docetaxel followed by cisplatin or paclitaxel followed by carboplatin"
11512897|NCT01263873|Active Comparator|Mallinckrodt (ETT)|Artifical Airway Device
11512898|NCT01263873|Experimental|Parker Flex Tip (ETT)|Artifical Airway Device
11512899|NCT01263860|Experimental|24-Week treatment group|Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 20 weeks
11512900|NCT01263860|Active Comparator|48-Week treatment group|Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 44 weeks
11512901|NCT01263847|Placebo Comparator|No Galactooligosaccharide|0 g galactooligosaccharide added to calcium-containing yogurt beverage
11512902|NCT01263847|Active Comparator|5 g Galactooligosaccharide|5 g galactooligosaccharide provided in two calcium-containing yogurt beverage (2.5 g in each drink) per day
11512903|NCT01263847|Active Comparator|10 g Galactooligosaccharide|10 g galactooligosaccharide added to two calcium-containing yogurt beverage (5 g in each drink) per day
11512904|NCT01263834|Active Comparator|Mitomycin c|Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
11512905|NCT01263834|Experimental|Bevacizumab|Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
11512906|NCT01263821|Experimental|Arm I|Patients undergo magnetic resonance spectroscopic imaging, functional magnetic resonance imaging (MRI), diffusion-weighted MRI, and perfusion-weighted MRI. Patients then undergo maximum surgical resection followed by intensity-modulated radiation therapy (IMRT) 5 days a week for 6 weeks.
11512907|NCT01263808|Experimental|Indacaterol 150 µg|Indacaterol 150 µg
11512908|NCT01263808|Experimental|Indacaterol 300 µg|Indacaterol 300 µg
11512909|NCT01263808|Experimental|Indacaterol 600 µg|Indacaterol 600 µg
11512910|NCT01263808|Placebo Comparator|Placebo|Placebo
11512911|NCT01263808|Active Comparator|Placebo/moxifloxacin|Placebo/moxifloxacin
11512912|NCT01263782|Experimental|Carboplatin + Pemetrexed|"The chemotherapy will be Carboplatin (AUC 6) and Pemetrexed (500 mg/m2) every 3 weeks for 4 cycles.
~Then maintenance Pemetrexed (500 mg/m2 every 3 weeks) will be administered until disease progression or excessive toxicity.
~If patients are randomized into one of the arms with a biologic therapy, patients will take the chemotherapy prescribed above, but will also receive the biologic therapy during the same time period."
11512913|NCT01263782|Experimental|Chemo (Carbo/Peme) + Bevacizumab|Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle. Bevacizumab 15 mg/kg by vein on day 1 of each 21 day cycle.
11512914|NCT01263782|Experimental|Chemo (Carbo/Peme)|Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle.
11512915|NCT01263782|Experimental|Chemo (Carbo/Peme) + Cixutumumab|"Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle.
~Cixutumumab 20 mg/kg by vein on day 1 of each 21 day cycle."
11512916|NCT01263769|Experimental|Axitinib|Axitinib Starting dose: 5 mg by mouth twice each day for 12 weeks.
11512917|NCT01263756||ASD group|Adolescents and adults with Autism Spectrum Disorders (ASDs).
11512918|NCT01263743|Experimental|This is a single arm study|Relaxation Response training will be given to all participants
11512919|NCT01263730|Active Comparator|Tai Chi Training|The active group will be given 12 weeks of tai chi training
11512920|NCT01263730|No Intervention|Waitlist control group|There is a waitlist control group that will receive the training following a 12 week no treatment period of time
11512921|NCT01263717|Experimental|Tesamorelin|Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
11512922|NCT01263717|Placebo Comparator|Placebo (inactive injection)|Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase
11512923|NCT01263704|Experimental|Rituximab plus Fludarabine and Cyclophosphamide|Elderly participants with chronic lymphocytic leukemia (CLL) will receive combination treatment with low-dose fludarabine and cyclophosphamide combined with standard-dose of rituximab for 6 months. Treatment is followed by a follow up period of 36 months.
11512924|NCT01263691|Active Comparator|BioThrax|BioThrax, 0.5 mL AVA per dose
11512925|NCT01263691|Experimental|AV7909 Formulation 1|0.5 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose
11512926|NCT01263691|Experimental|AV7909 Formulation 2|0.5 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose
11512927|NCT01263691|Experimental|AV7909 Formulation 3|0.25 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose
11512928|NCT01263691|Experimental|AV7909 Formulation 4|0.25 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose
11512930|NCT01263678|Other|Non-Coaching|Usual care for patients with a diagnosis of spinal stenosis after viewing a DA and completing a survey.
11512931|NCT01263678|Other|Coaching|Patients randomized to coaching group will receive one week post viewing of Decisional Aid.
11512932|NCT01263665|Experimental|25cm Gore VIABAHN|25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface
11512933|NCT01263652|Active Comparator|IMmed|Patients receiving intra-muscular medication and oral placebo
11512934|NCT01263652|Active Comparator|POmed|Patients receiving intra-muscular placebo and oral medication
11512935|NCT01263639|Experimental|Intervention Group, biosketch card|The investigators aim to improve the patient-physician relationship and improve patient satisfaction by providing a biosketch card of the attending orthopaedic trauma surgeon to the patient. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies.
11512936|NCT01263639|Active Comparator|Control group, standard care|"The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The control group will receive the usual/standard care as provided to all orthopaedic trauma admission patients without receiving a biosketch card."
11512937|NCT01263626||Cough as Primary Complaint|"Male and female volunteers 18 years of age and older
~Cough as chief complaint
~Referred to the GI clinic to evaluate if reflux is the cause of their chief complaint
~pH testing for standard of care purposes"
11512938|NCT01263626||Healthy Volunteers|"Male and female volunteers 18 years of age and older
~No history of chronic or acute cough and throat clearing
~Ability to read a 5th grade script written in English for approximately 20 minutes"
11512939|NCT01263613|Other|Biopsy|biopsy
11512940|NCT01263574|Placebo Comparator|Heparinized Saline|This group will maintain their central lines patent with heparinized saline.
11512941|NCT01263574|Experimental|Ethanol lock solution group|Administration of the 70% ethanol lock solution will occur between cycles of parenteral nutrition. Randomized lock solutions will be administered three days per week. When patients have completed their parenteral nutrition, their central venous catheters will be flushed with 5mL saline, per current standards
11512942|NCT01263561|Active Comparator|trabeculectomy|trabeculectomy filtering surgery
11512943|NCT01263561|Experimental|ExPRESS|ExPRESS miniature glaucoma drainage device
11512944|NCT01263548||Vyvanse|This is an open-label study which means that all study participants will be taking active study medication, Vyvanse.
11512945|NCT01263535|Experimental|SENSIMED Triggerfish|
11512946|NCT01263522|Experimental|Endurance training|
11512947|NCT01263522|Experimental|interval training|
11512948|NCT01263522|Experimental|strength endurance training|
11512949|NCT01263522|Placebo Comparator|control|
11512950|NCT01263509|Experimental|Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID|
11512951|NCT01263509|Experimental|Alogliptin 25 mg QD and Voglibose 0.2 mg TID|
11512952|NCT01263496|Experimental|Alogliptin 6.25 mg QD|
11512953|NCT01263496|Experimental|Alogliptin 12.5 mg QD|
11512954|NCT01263496|Experimental|Alogliptin 25 mg QD|
11512955|NCT01263496|Experimental|Alogliptin 50 mg QD|
11512956|NCT01263496|Active Comparator|Voglibose 0.2-mg TID|
11512957|NCT01263483|Active Comparator|Voglibose 0.2 mg TID|
11512958|NCT01263483|Experimental|Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID|
11512959|NCT01263483|Experimental|Alogliptin 25 mg QD and Voglibose 0.2 mg TID|
11512960|NCT01263470|Placebo Comparator|Placebo|
11512961|NCT01263470|Experimental|Alogliptin 6.25 mg QD|
11512962|NCT01263470|Experimental|Alogliptin 12.5 mg QD|
11512963|NCT01263470|Experimental|Alogliptin 25 mg QD|
11512964|NCT01263470|Experimental|Alogliptin 50 mg QD|
11512965|NCT01263470|Active Comparator|Voglibose 0.2 mg TID|
11512966|NCT01263444|Experimental|Azarga|Brinzolamide 1% / timolol 0.5% Fixed Combination administered as 1 drop in study eye(s) twice a day (8:00 AM and 8:00 PM) for 12 weeks, at a 5 minute interval from the habitual prostaglandin monotherapy.
11512967|NCT01263431|Active Comparator|Hemorrhoidectomy|Excision of hemorrhoid cushions
11512968|NCT01263431|Experimental|Hemorrhoidal dearterialization|Ligation of therminbal branches oh hemorrhoid arteries
11512969|NCT01263418|Experimental|Ofatumumab|
11512970|NCT01263405||Normal|normal volunteers without sarcoma
11512971|NCT01263405||Sarcoma|Sarcoma
11512972|NCT01263392|Active Comparator|Polyvinyl Chloride Catheter|Re-use clean polyvinyl chloride catheters for intermittent catheterization of children with spina bifida.
11512973|NCT01263392|Active Comparator|Hydrophilic catheter|Use hydrophilic catheters (Speedicath) for intermittent catheterization of children with spina bifida.
11512974|NCT01263379|Experimental|LEAES treatment|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)
11512975|NCT01263366|Experimental|Norepinephrine|
11512976|NCT01263353|Experimental|Functional tumors, pre-treated|
11512977|NCT01263353|Experimental|Functional tumors, treatment naïve|
11512978|NCT01263353|Experimental|Nonfunctional tumors, pretreated 1|
11512979|NCT01263353|Experimental|Nonfunctional tumors, pretreated 2|
11512980|NCT01263353|Experimental|Nonfunctional tumors, treatment-naïve 1|
11512981|NCT01263353|Experimental|Nonfunctional tumors, treatment-naïve 2|
11512982|NCT01263340||People with COPD|
11512983|NCT01263327|Experimental|HPV 16/18|Participants in this arm would intramuscularly receive 90mcg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
11512984|NCT01263314|Experimental|Panel A MK-8266 0.3 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.3 mg
11512985|NCT01263314|Experimental|Panel A MK-8266 0.6 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.6 mg
11512986|NCT01263314|Experimental|Panel A MK-8266 0.7/0.3 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours
11512987|NCT01263314|Placebo Comparator|Panel A Placebo to MK-8266 (Elderly Males with Mild/Mod. HTN)|Placebo to MK-8266 single dose
11512988|NCT01263314|Experimental|Panel B MK-8266 0.3 mg (Elderly Females with Mild/Mod. HTN)|MK-8266 single dose 0.3 mg
11513088|NCT01262794|Experimental|CDP6038 6 mg/kg|
11512989|NCT01263314|Experimental|Panel B MK-8266 0.6 mg (Elderly Females with Mild/Mod. HTN)|MK-8266 single dose 0.6 mg
11512990|NCT01263314|Experimental|Panel B MK-8266 0.7/0.3 mg (Elderly Fem. with Mild/Mod. HTN)|MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours
11512991|NCT01263314|Placebo Comparator|Panel B Placebo to MK-8266 (Elderly Fem. with Mild/Mod. HTN)|Placebo to MK-8266 single dose
11512992|NCT01263301|Active Comparator|carotid duplex for hemolytic patients wtih SSS|assigned intervention:carotid duplex
11512993|NCT01263301|Active Comparator|carotid duplex for nonhemolytic patients with SSS|
11512994|NCT01263288|Active Comparator|Vitamin D3 (cholecalciferol) 400 IU|
11512995|NCT01263288|Active Comparator|Vitamin D3 (cholecalciferol) 1000 IU|
11512996|NCT01263288|Placebo Comparator|Placebo|
11512997|NCT01263275|Experimental|Active tDCS|
11512998|NCT01263249|Active Comparator|Catheter Anterior to Femoral Nerve|Each subject will have one lower extremity (Right or Left) randomized to receive a perinural catheter, placed anterior to the femoral nerve, with a continuous infusion of local anesthetic and then the outcomes will be measured.
11512999|NCT01263249|Active Comparator|Catheter Posterior to Femoral Nerve|Each subject will have the opposite lower extremity (Right or Left) randomized to receive a perinural catheter, placed posterior to the femoral nerve, with a continuous infusion of local anesthetic and then the outcomes will be measured.
11513000|NCT01263236|Experimental|LY2940094 - single dose|Single oral dose of 2-800 milligram (mg) LY2940094
11513001|NCT01263236|Experimental|LY2940094 - multiple dose|Daily oral dose of 2-200 mg LY2940094 for 14 days
11513002|NCT01263236|Experimental|Placebo|Single oral dose or daily oral dose for 14 days
11513003|NCT01263223|Experimental|LY2216684, placebo, LY or placebo|"Period 1: 18 milligrams (mg) LY2216684 administered orally once daily on Days 1-4
~Period 2: placebo administered orally once daily on Days 1-4
~Period 3: 36 mg LY2216684 or placebo administered orally daily on Days 1-4"
11513004|NCT01263223|Experimental|Placebo, LY2216684, placebo or LY|"Period 1: placebo administered orally once daily on Days 1-4
~Period 2: 18 mg LY2216684 administered orally once daily on Days 1-4
~Period 3: 36 mg LY2216684 or placebo administered orally daily on Days 1-4"
11513005|NCT01263210|Active Comparator|Pneumococcal vaccine|Half of the children were randomized to receive heptavalent pneumococcal conjugate vaccine (before this vaccine was included in the national immunization programme).
11513006|NCT01263210|No Intervention|Control|Half of the children were randomized to no vaccination and functioned as controls.
11513007|NCT01263197|Experimental|LY2216684, albuterol, LY2216684+albuterol|LY2216684 as an 18 milligram (mg) oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
11513008|NCT01263197|Experimental|albuterol, LY2216684+albuterol, LY2216684|Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in third intervention period. There is a minimum 7 day washout between each intervention period.
11513009|NCT01263197|Experimental|LY2216684+albuterol, LY2216684, albuterol|LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in second intervention period, Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
11513010|NCT01263197|Experimental|LY2216684, propranolol, LY2216684+propranolol|LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
11513011|NCT01263197|Experimental|propranolol, LY2216684+propranolol, LY2216684|Placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in third intervention period. There is a minimum 7 day washout between each intervention period.
11513012|NCT01263197|Experimental|LY2216684+propranolol, LY2216684, propranolol|LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in second intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
11513013|NCT01263184||sportive wheelchair users|
11513014|NCT01263184||sportive non disabled|
11513015|NCT01263184||non sportive wheelchair users|
11513016|NCT01263171|Other|Neo-adjuvant chemotherapy|Neo-adjuvant chemotherapy prior to short course pre-operative radiotherapy followed by adjuvant chemotherapy.
11513017|NCT01263158|Experimental|Expectant group|Arrest in labour progress for 2-3 hours and no progress after amniotomy. Expectancy of standard oxytocin treatment for 3 hours.
11513018|NCT01263158|No Intervention|Early oxytocin group|Arrest in labour progress for 2-3 hours and no progress after amniotomy. Oxytocin treatment started within 20 minutes.
11513019|NCT01263145|Experimental|Treatment (Akt inhibitor MK2206 and paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and Akt inhibitor MK2206 PO QD on days 2, 9, and 16. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11513020|NCT01263132|Experimental|F0434|
11513021|NCT01263132|Active Comparator|Gabapentin|
11513022|NCT01263119|Experimental|Warfarin, LY2216684 + Warfarin|Period 1: Single 10-milligram (mg) warfarin oral dose on Day 1; Washout Period of at least 14 days; Period 2: 18-mg LY2216684 oral dose, once daily on Days 1 to 12, with single 10-mg warfarin oral dose coadministered on Day 3.
11513023|NCT01263106|Experimental|Theophylline, LY2216684 + Theophylline|Period 1: single 200-milligram (mg) theophylline oral dose on Day 1; Washout period of at least 7 days; Period 2: 18 mg LY2216684 orally, once daily on Days 1-5 with single 200-mg theophylline oral dose coadministered on Day 3
11513024|NCT01263106|Experimental|LY2216684 + Theophylline, Theophylline|Period 1: 18 mg LY2216684 orally, once daily on Days 1-5 with single 200-mg theophylline oral dose coadministered on Day 3; Washout period of at least 7 days; Period 2: single 200-mg theophylline oral dose on Day 1
11513025|NCT01263093|Experimental|Clopidogrel First, Then LY2216684 + Clopidogrel|"Period 1: a single 300-milligram (mg) dose of clopidogrel administered orally on Day 1 (Treatment 1).
~Period 2: an 18-mg dose of LY2216684 administered orally, once daily (QD) on Days 1 through 3, plus a single 300-mg dose of clopidogrel administered orally on Day 3 (Treatment 2).
~There was a washout period of at least 14 days between the last dose of study drug in Period 1 and the first dose in Period 2."
11513026|NCT01263093|Experimental|LY2216684 + Clopidogrel First, Then Clopidogrel|"Period 1: an 18-milligram (mg) dose of LY2216684 administered orally, once daily (QD) on Days 1 through 3, plus a single 300-mg dose of clopidogrel administered orally on Day 3 (Treatment 2).
~Period 2: a single 300-mg dose of clopidogrel administered orally on Day 1 (Treatment 1).
~There was a washout period of at least 14 days between the last dose of study drug in Period 1 and the first dose in Period 2."
11513027|NCT01263080|Active Comparator|mirtazapine+folic acid|mirtazapine 30mg QD, folic acid 0.4mg QD
11513028|NCT01263080|Active Comparator|mirtazapine+folic acid placebo|mirtazapine 30mg QD, folic acid placebo 1 tablet QD
11513029|NCT01263080|Active Comparator|mirtazapine placebo+folic acid|mirtazapine placebo 1 tablet QD, folic acid 0.4mg QD
11513030|NCT01263080|Placebo Comparator|mirtazapine placebo+folic acid placebo|mirtazapine placebo 1 tablet QD, folic acid placebo 1 tablet QD
11513031|NCT01263067|Experimental|Lifespan Integration Therapy (LI)|
11513032|NCT01263067|Active Comparator|Waitlist Control- Lifespan Integration|
11513033|NCT01263054|Experimental|TransDiscal System|Kimberly-Clark TransDiscal System in addition to standard medical management
11513034|NCT01263054|Other|Medical Management|Standard medical management
11513035|NCT01263041|Experimental|glutamine, PT, sepsis|enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding up to 30 says post natal age + usual care and medications
11513036|NCT01263041|No Intervention|Control|after been allocated, will receive nothing and observed for the same outcomes
11513037|NCT01263041|Experimental|L-arginine,NEC, PT|enteral or via NG tube dose of 260 mg/kg/day divided every 12 hours from starting feeding up to 30 says post natal age + usual care and medications
11513038|NCT01263028|Experimental|Ergocalciferol supplementation|
11513039|NCT01263015|Experimental|Dolutegravir (N=~394):|Dolutegravir 50mg once daily + abacavir/lamivudine as the fixed-dose combination once daily + Atripla placebo once daily
11513040|NCT01263015|Active Comparator|Atripla (N=~394):|Atripla once daily + Dolutegravir placebo once daily + abacavir/lamivudine as the fixed-dose combination placebo once daily
11513041|NCT01262989|Active Comparator|tamsulosin Reference|Reference drug administration followed by Test drug administration
11513042|NCT01262989|Active Comparator|tamsulosin Test|Test drug administration followed by Reference drug administration
11513043|NCT01262976|Experimental|HIV(+)-HA/GSK692342|HIV-infected subjects between and including 18 to 59 years of age, who were on Highly Active Anti-Retroviral Therapy (HAART) at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
11513044|NCT01262976|Placebo Comparator|HIV(+)-HA/Placebo|HIV-infected subjects between and including 18 to 59 years of age, who were on Highly Active Anti-Retroviral Therapy (HAART) at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
11513045|NCT01262976|Experimental|HIV(+)-TN/GSK692342|HIV-infected subjects between and including 18 to 59 years of age, who were HAART-treatment naive (TN) at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
11513046|NCT01262976|Placebo Comparator|HIV(+)-TN/Placebo|HIV-infected subjects between and including 18 to 59 years of age, who were HAART-treatment naive (TN) at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
11513047|NCT01262976|Experimental|HIV(-)/GSK692342|Subjects between and including 18 to 59 years of age, who were HIV-negative at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
11513048|NCT01262976|Placebo Comparator|HIV(-)/Placebo|Subjects between and including 18 to 59 years of age, who were HIV-negative at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
11513049|NCT01262963|Experimental|Study Medication|GSK2118436 suspension
11513050|NCT01262937||Biliary Confocal Imaging|
11513051|NCT01262937||Esophageal Confocal Imaging|
11513052|NCT01262924|Experimental|Group A|dTPa vaccine
11513053|NCT01262924|Experimental|Group B|Pa vaccine
11513054|NCT01262924|Active Comparator|Group C|Tedivax-Adult™/ Td-Rix™
11513055|NCT01262911|Active Comparator|1.0 g SRT2379|Single dose of 1.0g of SRT2379
11513056|NCT01262911|Placebo Comparator|1.0 g Placebo|Single dose of 1.0g of placebo
11513057|NCT01262898|Experimental|GSK962040 (10 mg)|GSK962040 10 mg
11513058|NCT01262898|Experimental|GSK962040 (50 mg)|GSK962040 50 mg
11513059|NCT01262898|Experimental|GSK962040 (125 mg)|GSK962040 125 mg
11513060|NCT01262898|Experimental|Placebo|Placebo
11513061|NCT01262885|Experimental|Part A Cohort 1|GSK2251052 500 mg (6 subjects), Placebo (1 subject)
11513062|NCT01262885|Experimental|Part A Cohort 2|GSK2251052 1000 mg (6 subjects), Placebo (1 subject)
11513063|NCT01262885|Experimental|Part A Cohort 3|GSK2251052 2000 mg (6 subjects), Placebo (1 subject)
11513064|NCT01262885|Experimental|Part A Cohort 2 - fed|GSK2251052 1000 mg (6 subjects), Placebo (1 subject)
11513065|NCT01262885|Experimental|Part B Cohort 1|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
11513066|NCT01262885|Experimental|Part B Cohort 2|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
11513089|NCT01262794|Placebo Comparator|Placebo|
11513067|NCT01262885|Experimental|Part B Cohort 3|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
11513068|NCT01262885|Experimental|Part A Cohort 4|Placebo (1 subject), GSK2251052 (6 subjects) dose to be determined
11513069|NCT01262872|Experimental|10PP-HD 1d Group|This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation at Day 0. The 10PP vaccine was administered intramuscularly in the non-dominant deltoid.
11513070|NCT01262872|Active Comparator|Prevnar13 1d Group|This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of Prevnar 13™ at Day 0. Prevnar 13™ was administered intramuscularly in the non-dominant deltoid.
11513071|NCT01262872|Experimental|10PP-LD 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its low-dose (LD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, LD formulation, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
11513072|NCT01262872|Experimental|10PP-HD 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, HD formulation, co-administered with the Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
11513073|NCT01262872|Active Comparator|Synflorix 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of Synflorix™ and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the Synflorix™, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. Synflorix™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
11513074|NCT01262872|Active Comparator|Prevnar13 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of Prevnar 13™ and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of Prevnar 13™, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. Prevnar 13™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
11513075|NCT01262872|Experimental|10PP-HD 2+1d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received the GSK 2189242A (or 10PP) vaccine, in its high-dose (HD) formulation, and EPI vaccines according to a 2+1 Schedule. That is, subjects received 2 doses of the 10PP vaccine, HD formulation co-administered with Tritanrix™-Hep B/Hib and Polio Sabin™ at 2-4 months of age (at Day 0 and Month 2), followed by a third dose of the same formulation co-administered with M-Vac™, Stamaril™ and Polio Sabin™ at approximately 9 months of age.. The 2nd doses of Tritanrix™-Hep B/Hib and Polio Sabin™ in EPI vaccines were administered without any pneumococcal vaccine at 3 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
11513076|NCT01262872|Active Comparator|Synflorix 2+1d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received Synflorix™ and EPI vaccines according to a 2+1 Schedule. That is, subjects received 2 doses of the Synflorix™ co-administered with Tritanrix™-Hep B/Hib and Polio Sabin™ at 2-4 months of age (at Day 0 and Month 2), followed by a third dose of Synflorix™ co-administered with M-Vac™, Stamaril™ and Polio Sabin™ at approximately 9 months of age. The 2nd doses of Tritanrix™-Hep B/Hib and Polio Sabin™ in EPI vaccines were administered without any pneumococcal vaccine at 3 months of age. Synflorix™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
11513077|NCT01262859|Experimental|Study Intervention|Induction therapy consists of 3 cycles of bevacizumab 15mg/kg on day 1, cetuximab weekly days 1,8,15 (loading dose of cetuximab 400mg/m2 on cycle 1, day 1, then 250 mg/m2 on all subsequent administrations), cisplatin 75mg/m2 on day 1, docetaxel 75mg/m2 on day 1, repeated every 21 days. After 3 cycles of induction therapy, patients will receive standard radiation 70-74 Gy/ 200 cGy/ daily, 5 days/ week with concurrent weekly cisplatin 30mg/m2, cetuximab 250mg/m2 and bevacizumab 15mg/kg every 3 weeks x 3. There is optional surgery for non-responders in the primary (stable disease) after TPE-A.
11513078|NCT01262846|Active Comparator|Fluzone SD|Fluzone® Standard dose
11513079|NCT01262846|Experimental|Fluzone® High dose|Fluzone® High dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
11513080|NCT01262833||Cases|Patients with erectile dysfunction by ILEF questionnaire
11513081|NCT01262833||Controls|Patients without erectile dysfunction by ILEF questionnaire
11513082|NCT01262820|Experimental|Single Intervention|Subjects will take Pazopanib, 800 mg daily by mouth throughout the time in study
11513083|NCT01262807|Experimental|Exercise|This group will receive instructions on specific exercises to perform after randomization.
11513084|NCT01262807|No Intervention|Standard Care|This group will receive standard care
11513085|NCT01262794|Experimental|CDP6038 0.3 mg/kg|
11513086|NCT01262794|Experimental|CDP6038 1 mg/kg|
11513090|NCT01262768|Experimental|2D Portion Size Measurment Aids (PSMAs)|The 2D PSMAs are life-size photographs of the 3D PSMAs.
11513091|NCT01262768|Experimental|3D Portion Size Measurement Aids (PSMAs)|The 3D PSMAs include foam rubber replicas of a golf ball, a hockey puck, a tennis ball and a baseball.
11513092|NCT01262755||African Americans|Consists of 450 African Americans living in the zip code surrounding Temple Hospital between the ages of 18 and 80.
11513093|NCT01262742|Active Comparator|Carbetocin 80mcg|
11513094|NCT01262742|Active Comparator|Carbetocin 90mcg|
11513095|NCT01262742|Active Comparator|Carbetocin 100mcg|
11513096|NCT01262742|Active Comparator|Carbetocin 110mcg|
11513097|NCT01262742|Active Comparator|Carbetocin 120mcg|
11513098|NCT01262729|Experimental|Xenon-Arm|Patients in Xenon-Arm will be inhalated with xenon within 2 hours additionally to therapeutical hypothermia after successful cardiopulmonary resuscitation.
11513099|NCT01262729|Active Comparator|MTH|Patients after successful cardiopulmonary resuscitation will be treated only with therapeutical hypothermia
11513100|NCT01262703|Experimental|REVA Medical ReZolve Stent|ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent
11513101|NCT01262690|Experimental|Dose|6 treated, 3 placebos
11513102|NCT01262677|Experimental|pregabalin CR 330 mg|
11513103|NCT01262677|Experimental|pregabalin CR 165 mg|
11513104|NCT01262677|Placebo Comparator|Placebo|
11513105|NCT01262664|Experimental|Prohibitin-TP01|Prohibitin-TP01 starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
11513106|NCT01262651|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligram [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
11513107|NCT01262651|Placebo Comparator|Placebo (GA-0034)|Placebo Comparator: Placebo (GA-0034) Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol: propylene glycol (50:50)
11513108|NCT01262638|Experimental|ETC-1002 120 mg (Group 1)|Subjects with hypercholesterolemia and normal triglycerides
11513109|NCT01262638|Experimental|ETC-1002 80 mg (Group 2)|Subjects with hypercholesterolemia and normal triglycerides
11513110|NCT01262638|Experimental|ETC-1002 40 mg (Group 3)|Subjects with hypercholesterolemia and normal triglycerides
11513111|NCT01262638|Experimental|Placebo (Group 4)|Subjects with hypercholesterolemia and normal triglycerides
11513112|NCT01262638|Experimental|ETC-1002 120 mg (Group 5)|Subjects with hypercholesterolemia and elevated triglycerides
11513113|NCT01262638|Experimental|ETC-1002 80 mg (Group 6)|Subjects with hypercholesterolemia and elevated triglycerides
11513114|NCT01262638|Experimental|ETC-1002 40 mg (Group 7)|Subjects with hypercholesterolemia and elevated triglycerides
11513115|NCT01262638|Experimental|Placebo (Group 8)|Subjects with hypercholesterolemia and elevated triglycerides
11513116|NCT01262625|Experimental|Group A: CCTA Diagnostic|Participants randomized to diagnostic evaluation using CCTA to determine therapeutic course of action.
11513117|NCT01262625|Active Comparator|Group B: SPECT MPI/ICA Diagnostic|Standard-of-care diagnostic assessment using SPECT MPI, possibly followed by diagnostic ICA dependent on SPECT MPI results.
11513118|NCT01262612|Active Comparator|immediate treatment with cediranib|8 patients with ascites and 8 patients with pleural effusion will start immediate treatment with cediranib
11513119|NCT01262612|Active Comparator|start cediranib after 28 days BSC|patients in group B will start with cediranib after one month best supportive care.
11513120|NCT01262599|Sham Comparator|Sham PEMF Device|Patients will receive inactive device
11513121|NCT01262599|Active Comparator|PEMF Device|Patients will receive Ivivi Torino II PEMF Device
11513122|NCT01262586|Experimental|Vildagliptin|
11513123|NCT01262586|Active Comparator|Glimepiride|
11513124|NCT01262573|Experimental|Barbed|Vaginal cuff closure with barbed suture
11513125|NCT01262573|Active Comparator|Smooth|Vaginal cuff closure with smooth suture
11513126|NCT01262560|Active Comparator|Supportive Care|Standard supportive care
11513127|NCT01262560|Experimental|Liquid Manuka Honey|Manuka honey in liquid form
11513128|NCT01262560|Experimental|Lozenge Manuka Honey|Manuka honey in lozenge form
11513129|NCT01262547|Experimental|Dermabrasion-Micrografting|Dermabrasion-Micrografting
11513130|NCT01262547|Active Comparator|Dermabrasion alone|Dermabrasion alone
11513131|NCT01262547|No Intervention|Control|Control
11513132|NCT01262534||1|Clinical profile of patients Comorbidities and associated type of treatments will be collected.
11513133|NCT01262534||2|Quality of Life The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire to analyze the overall quality of life of patients and Dermatology Life Quality Index (DLQI) to analyze the quality of life of patients in dermatological terms).
11513134|NCT01262534||3|Patient Preferences about treatment Patient Benefit Index (PBI) for treatment to record patient preferences regarding psoriasis treatment.
11513135|NCT01262521|Experimental|Dietary nitrate|150 ml tab water with 150 umol/kg sodium-nitrate
11513136|NCT01262521|Placebo Comparator|Water|150 ml Chapelle mineral water
11513137|NCT01262508||Risk Population|Patients being suspected to be at risk of hemodynamic instability due to medical history
11513138|NCT01262495|Other|orchidectomy|as specified in the summary
11513139|NCT01262482|Experimental|Oxaliplatin + Sorafenib|
11513140|NCT01262469|Experimental|Lapatinib + Capecitabine|lapatinib 1250 mg/day (once daily) Capecitabine 2x850 mg/m2/day, days 1-14 during the first cycle and 2x1000 mg/m2/day, days 1-14, every 21 days for following cycles ( if no unacceptable toxicity is observed).
11513141|NCT01262456|Experimental|Desmopressin 50 μg Double-Blind / 100 μg Open-Label|Participants took 1 orally disintegrating tablet of desmopressin 50 μg every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
11513182|NCT01262170|Experimental|CigRx Lozenge|CigRx Lozenge
11513142|NCT01262456|Experimental|Desmopressin 75 μg Double-Blind / 100 μg Open-Label|Participants took 1 orally disintegrating tablet of desmopressin 75 μg every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
11513143|NCT01262456|Placebo Comparator|Placebo Double-Blind / Desmopressin 100 μg Open-Label|Participants took 1 orally disintegrating tablet of placebo every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
11513144|NCT01262443|Experimental|Therapy Cool Flex catheter group|Therapy Cool Flex Catheter . No more available data
11513145|NCT01262430|Active Comparator|OtisMed|
11513146|NCT01262430|Active Comparator|Computer Assisted Surgery (CAS)|
11513147|NCT01262417|Experimental|- Seprafilm group|patients receiving resorbable barrier membrane during the first surgery
11513148|NCT01262417|Other|- No-treatment control group|patients without seprafilm barrier during the first surgery
11513149|NCT01262404||HealthEd,Minfdulness,Compassion|HealthEd receives training health education. Mindfulness receives training in mindfulness meditation. Compassion receives training in compassion meditation.
11513150|NCT01262391|Experimental|AD-PED 2.5 mg|Male and female adolescents aged 12 to less than 18 years old who receive pediatric equivalent dose (PED) of 2.5 mg of solifenacin succinate.
11513151|NCT01262391|Experimental|AD-PED 5 mg|Male and female adolescents aged 12 to less than 18 years old who receive PED of 5 mg of solifenacin succinate.
11513152|NCT01262391|Experimental|AD-PED 10 mg|Male and female adolescents aged 12 to less than 18 years old who receive PED of 10 mg of solifenacin succinate.
11513153|NCT01262391|Experimental|CH-PED 2.5 mg|Male and female children aged 5 to less than 12 years old who receive PED of 2.5 mg of solifenacin succinate.
11513154|NCT01262391|Experimental|CH-PED 5 mg|Male and female children aged 5 to less than 12 years old who receive PED of 5 mg of solifenacin succinate.
11513155|NCT01262391|Experimental|CH-PED 10 mg|Male and female children aged 5 to less than 12 years old who receive PED of 10 mg of solifenacin succinate.
11513156|NCT01262378|Other|Harmonic knife|surgery using the Harmonic knife
11513157|NCT01262378|Active Comparator|HF knife|
11513158|NCT01262365|Placebo Comparator|Placebo (Weekly infusion)|Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles
11513159|NCT01262365|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
11513160|NCT01262365|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles
11513161|NCT01262352|Experimental|Treatment Sequence 1|Ivacaftor administered in Treatment Period 1 and placebo administered in Treatment Period 2.
11513162|NCT01262352|Experimental|Treatment Sequence 2|Placebo administered in Treatment Period 1 and ivacaftor administered in Treatment Sequence 2.
11513163|NCT01262339|Active Comparator|Comparator of Hand A intervention vs Hand B|Hand A will receive 100U of BTX-A injected intradermally (SOC) Hand B will receive 100U delivered via iontophoresis.
11513164|NCT01262326|Experimental|Low Carbohydrate Diet|Subjects are placed on a low carbohydrate diet where only 5% of energy intake is derived from dietary carbohydrate.
11513165|NCT01262326|Active Comparator|Low Calorie Diet|Subjects have there caloric intake reduced to 1200 or 1500 kcal/day (women and men respectively).
11513166|NCT01262313|Sham Comparator|Control Group|"The Control group will have an hour-long meeting of instruction by a registered dietitian on using the provided A Healthier You: Everyday Healthy Eating and Physical Activity for Life book, based on the Dietary Guidelines for Americans 2005."
11513167|NCT01262313|Experimental|lifestyle counseling intervention|"This group will participate in the weekly Healthy Creations classes for 8 weeks presented by a Registered Dietitian and a certified fitness trainer. This is a community based lifestyle intervention program."
11513168|NCT01262300|Experimental|VZV vaccine|"Varicella Zoster Virus vaccine (Zostavax), single dose X 1 injection
~All subjects in this trial will receive the VZV vaccine. The Investigators will primarily compare immune responses in those that are receiving high dose vs. standard dose vitamin D supplementation and those that have high and low 25-hydroxyvitamin D levels."
11513169|NCT01262287|Experimental|dutasteride|dutasteride (1 mg oral daily dose) for 8-week treatment period
11513170|NCT01262287|Placebo Comparator|Placebo|placebo daily for 8-week treatment period
11513171|NCT01262274|Active Comparator|ANA|
11513172|NCT01262274|Experimental|ANA+UFT|
11513173|NCT01262261|Experimental|Probuphine|patients are first inducted on sublingual buprenorphine then switched to 4 Probuphine Implants
11513174|NCT01262248||patients with colorectal polyps|
11513175|NCT01262235|Experimental|TKM-080301|
11513176|NCT01262222||pts undergoing major surg procedure referred to cardiology|Patients deemed to be at intermediate to high risk for postoperative cardiovascular events by clinical criteria will be the subject of this study. Cardiac risk will be determined according to the Revised Cardiac Risk Index (RCRI). RH-PAT testing and BNP evaluation will take place within 30 days before surgery and may occur on separate days. The blood may be drawn on the day of the RH-PAT testing or at a time of routine blood drawing within the 30 day period. After surgery the patient will be monitored and examined in the PACU for evidence of cardiac events.
11513177|NCT01262209|Experimental|Low Vision Aids|"All patients will receive:
~A low vision examination:
~Low vision refraction
~Distance best corrected visual acuity
~Near best corrected visual acuity
~Contrast Sensitivity
~Quality of life questionnaire
~Low vision therapy: to teach strategies for more effective use of remaining vision and use of low-vision devices
~Prescribed low vision devices including binocular telescope (2.1x or 3.5x), monocular telescope, 6x telemicroscopes, microscopes, magnifiers, portable CCTV and absorptive filters."
11513178|NCT01262196|Experimental|MP4OX|250-mL dose
11513179|NCT01262196|Placebo Comparator|Control|250-mL of normal saline solution
11513180|NCT01262183|Experimental|Concurrent chemoradiation therapy with panitumumab|
11513181|NCT01262183|Active Comparator|Concurrent chemoradiation therapy without panitumumab|
11513184|NCT01262157|Sham Comparator|placebo|We use the same probe that induces the same sensation on the penis and the same noise yet no energy
11513185|NCT01262157|Active Comparator|Shock wave therapy|12 treatment sessions twice a week during 9 weeks with an interim of 3 weeks no treatment
11513186|NCT01262144||Case group|
11513187|NCT01262131|Active Comparator|Resonator Protocol A|
11513188|NCT01262131|Active Comparator|Resonator Protocol B|Application of magnetic fields using the Resonator device Protocol B
11513189|NCT01262131|Placebo Comparator|Inactive Resonator|
11513190|NCT01262118|Experimental|CP-690,550 (tasocitinib) 10 mg twice daily (BID)|
11513191|NCT01262118|No Intervention|Healthy Volunteers|No intervention
11513192|NCT01262105|No Intervention|No device|
11513193|NCT01262105|Experimental|Device deployed|
11513194|NCT01262092|Active Comparator|Gabapentin|Buprenorphine will be given along with 2 capsules of gabapentin in the morning and 2 take-home capsules of gabapentin for night.
11513195|NCT01262092|Placebo Comparator|Placebo|Buprenorphine will be given, with 2 capsules of placebo in the morning and 2 take-home capsules of placebo in the evening
11513196|NCT01262079||Group 1: 6-15 years old|
11513197|NCT01262079||Group 2: 16-25 years old|
11513198|NCT01262079||Group 3: 26-35 years old|
11513199|NCT01262079||Group 4: 36-45 years old|
11513200|NCT01262079||Group 5: 46-55 years old|
11513201|NCT01262079||Group 6: 56-65 years old|
11513202|NCT01262079||Group 7: 66-75 years old|
11513203|NCT01262079||Group 8: 76-85 years old|
11513204|NCT01262079||Group 9: > 85 years old|
11513205|NCT01262066|Experimental|LifeSkills workshop intervention|Participants attended 10 1-hr weekly sessions. The content of the groups followed the LifeSkills Workshop manual and Video(Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
11513206|NCT01262066|No Intervention|Enhanced usual care|The Usual Care group received a self-help brochure on BP control developed by the National Heart, Lung, and Blood Institute (NHLBI). In addition, with the participants' permission, their BP readings were sent to their listed physicians, along with the 1-page JNC-7 express summary for the management of high BP.
11513207|NCT01262053|Experimental|Passive Intervention|When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated.
11513208|NCT01262053|Experimental|Active Intervention|The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders.
11513209|NCT01262053|Active Comparator|Control|Parallel control with no intervention
11513210|NCT01262040|Experimental|pts having a thorascopic, laparoscopic or robotic procedure|The procedure will begin with washings (peritoneal) and two assessments of the extent of peritoneal disease. First, a four quadrant inspection of the peritoneal cavity under white light, this is the standard of care assessment. Then, a repeat four quadrant inspection of the peritoneal cavity under NBI will be done, this is the only experimental component of the design. White light imaging will always be done first, followed by NBI. For those patients scheduled for thorascopic procedures: The procedure will begin with sampling of pleural effusions when clinically indicated. Then there will be two assessments of the pleural surfaces. First, an inspection of the pleural cavity under white light, this is the standard of care assessment. Then, a repeat inspection under NBI, this is the only experimental component of the design. White light imaging will always be done first, followed by NBI.
11513211|NCT01262027|Experimental|Dovitinib|A complete treatment cycle defined as 28 days or 4 weeks (+/- 2 days). Patients receive a single daily oral dose of 500 mg of dovitinib for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule).
11513212|NCT01262014|Experimental|Experimental single arm|Single arm of pazopanib 800 mg (2x400mg) given as a single agent.
11513213|NCT01262001|Experimental|Cohort 1/1-EX|Subjects with moderate to severe idiopathic pulmonary fibrosis (IPF) who have evidence of disease progression
11513214|NCT01262001|Experimental|Cohort 2/2-EX|Subjects with mild to moderate idiopathic pulmonary fibrosis (IPF) who have evidence of disease progression
11513215|NCT01261975|Experimental|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial microincision
11513216|NCT01261975|Active Comparator|Coaxial Small Incision Cataract Surgery|2.75 mm standard incision
11513217|NCT01261962|Experimental|Chemotherapy and zinc|Patients in adjuvant chemotherapy supplemented with zinc
11513218|NCT01261962|Placebo Comparator|Chemotherapy placebo|Patients in adjuvant chemotherapy with placebo
11513219|NCT01261962|Other|Control and zinc|Healthy patients supplemented with zinc
11513220|NCT01261962|Other|Control Placebo|Healthy volunteers received placebo
11513221|NCT01261949|Experimental|Combined frontal and temporal rTMS|Combined low frequency frontal and temporal transcranial magnetic stimulation of auditory cortex and right DLPFC
11513222|NCT01261949|Experimental|Temporal low frequency rTMS|temporal low frequency rTMS of auditory cortex
11513223|NCT01261936||women with a diagnosis of CBD|women in the fertile age, with an ascertained diagnosis of CBD, followed up for heavy periods and needing a specific treatment.
11513224|NCT01261923|Experimental|Alitretinoin - Hepatic Insufficiency|metabolism of 30 mg alitretinoin single dose in 8 patients with Hepatic Insufficiency
11513225|NCT01261923|Experimental|Alitretinoin - Hepatic Insufficiency Controls|metabolism of 30 mg alitretinoin single dose in 8 healthy controls.
11513226|NCT01261910|No Intervention|Usual education (standard care)|On the day of the transplant evaluation at the transplant center, participants receive usual transplant education regarding living donor kidney transplant.
11513227|NCT01261910|Experimental|Intensive initial education|On the day of the transplant evaluation at the transplant center, participants receive usual transplant education regarding living donor kidney transplant. In addition, participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
11513228|NCT01261897|Active Comparator|Adductor-Canal-Blockade with Ropivacaine|
11513229|NCT01261897|Placebo Comparator|Adductor-Canal-blockade with saline|
11513230|NCT01261884|No Intervention|Routine prenatal care|
11513231|NCT01261884|Experimental|Exercise support|
11513233|NCT01261871||Robotic laparoscopic prostatectomy|Patients who are undergoing primary surgical treatment for a diagnosis of prostate operatively will be enrolled. IOP will be measured throughout the case to assess for change. The various techniques employed for a radical prostatectomy will be compared. Patients undergoing RRP (open surgery) will act as controls. Those undergoing LRP (minimally invasive surgery) will be compared with the control group to assess for differences in IOP that may result from the different approaches. three arms will be used for the comparison: open, laparoscopic intraperitoneal approach), and laparoscopic (extraperitoneal approach).
11513234|NCT01261858|Experimental|Stainless steel and Kryptonite|Sternal closure with stainless steel and kryptonite
11513235|NCT01261858|Active Comparator|Stainless steel|Sternal closure with only stainless steel
11513236|NCT01261832|Experimental|Dual antiplatelet therapy for 1 year|Dual antiplatelet therapy for 1 year : dual antiplatelet combination therapy with aspirin and clopidogrel for 1 year
11513237|NCT01261832|Experimental|Triple antiplatelet therapy for 1 month|Triple antiplatelet therapy for 1 month : triple antiplatelet therapy including cilostazol for 1 month and after then, dual antiplatelet therapy for 11 months
11513238|NCT01261832|Experimental|Triple antiplatelet therapy for 6 months|Triple antiplatelet therapy for 6 months : triple antiplatelet combination therapy including cilostazol for 6 months and after then, dual antiplatelet therapy for 6 months and cilostazol
11513239|NCT01261819|Experimental|transurethral laparoscope|These patients had cystoscopy performed with the transurethral laparoscope.
11513240|NCT01261819|Active Comparator|Traditional cystoscopy|"These patients had cystoscopy performed with the traditional cystoscope, which is considered to be the gold standard."
11513241|NCT01261806|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up: 10 session intervention in foster families' homes designed to enhance parental nurturance, synchrony, and provide skills such that parents can help children calm down when overwhelmed.
11513242|NCT01261806|Active Comparator|Developmental Education for Families|10 session intervention in foster families' homes that targets cognitive and motor skills of children
11513243|NCT01261793|Placebo Comparator|Placebo (Weekly infusion)|Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles
11513244|NCT01261793|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles
11513245|NCT01261793|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles
11513246|NCT01261780|Sham Comparator|Sham device|Sham therapy device to area of painful chemotherapy induced peripheral neuropathy (CIPN) for 45 minutes daily x 10 days
11513247|NCT01261780|Active Comparator|MC-5A treatment|MC-5A therapy to the area of painful CIPN for 45 minutes daily for a total of 10 days.
11513248|NCT01261767|Experimental|Anti-IL-20|
11513249|NCT01261767|Placebo Comparator|Placebo|
11513250|NCT01261754|Active Comparator|Metastatic prostate adenocarcinoma|
11513251|NCT01261754|Active Comparator|Healthy Volunteers|
11513252|NCT01261754|Active Comparator|Newly Diagnosed, High-Risk Prosate Cancer Patients|
11513253|NCT01261741|Experimental|Memantine|
11513254|NCT01261741|Placebo Comparator|Placebo|
11513255|NCT01261728|Experimental|Gemcitabine and Cisplatin|This is a Phase II Study of Gemcitabine and Cisplatin (GC) as neoadjuvant chemotherapy in patients with upper tract high-grade urothelial carcinoma who are candidates for radical nephroureterectomy or distal ureterectomy.
11513256|NCT01261715|Active Comparator|Woman with previous ceasarean section - staples|
11513257|NCT01261702|Placebo Comparator|Placebo|Normal saline IV
11513258|NCT01261702|Experimental|Magnesium sulphate|Magnesium sulphate 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
11513259|NCT01261689|Active Comparator|Epidural analgesia|Women will be allocated to the EA group. In the EA group, women are given an EA as soon as they are in labour.
11513260|NCT01261689|Other|Care as-usual pain treatment|Women will be allocated to the care-as-usual group. In this care-as-usual(restrictive) group, women receive pain relief only on their explicit request. If necessary epidural analgesia.
11513261|NCT01261676||Caesarean section|
11513262|NCT01261676||Vaginal birth (control)|
11513263|NCT01261663||NOS intake either at end of meals or as snackings.|
11513264|NCT01261650|Active Comparator|transcranial direct current stimulation|transcranial direct current stimulation of the primary motor cortex
11513265|NCT01261650|Sham Comparator|sham treatment|
11513266|NCT01261637|Experimental|0.25% Ropivicaine|0.25% ropivicaine (maximum 1.5mg/kg)
11513267|NCT01261637|Placebo Comparator|Placebo|20ml saline
11513268|NCT01261624|Experimental|Givinostat 1.0 mg/kg daily|
11513269|NCT01261624|Experimental|Givinostat 1.5 mg/kg daily|
11513270|NCT01261611|Experimental|Dysport NG|"500U (1mL) administered as intramuscular injection on day 1 of treatment cycle 1 and 2.
~250U (0.5mL), 500U (1mL) or 750U (1.5mL) administered as intramuscular injection on day 1 of treatment cycle 3.
~250U (0.5mL), 500U (1mL), 750U (1.5mL) or 1000U (2mL) administered as intramuscular injection on day 1 of treatment cycle 4 and 5."
11513271|NCT01261611|Active Comparator|Dysport|500U (1mL) injected as intramuscular injection on day 1 of treatment cycle 1.
11513272|NCT01261611|Placebo Comparator|Placebo|1mL administered as, intramuscular injection on day 1 of treatment cycle 1.
11513273|NCT01261598|Other|1|Patients treated with curative and exclusive radiotherapy (60 Gy minimum), with possibly prior chemotherapy
11513274|NCT01261598|Other|2|Patient treated with concomitant chemotherapy and radiotherapy (60 Gy minimum), with possibly prior chemotherapy chemotherapy Treatment
11513275|NCT01261572|Experimental|High dose group|ASP3350 high dose
11513276|NCT01261572|Experimental|Low dose group|ASP3350 low dose
11513277|NCT01261559|No Intervention|Standard CT|Women assigned to undergo CT using the standard dose reduction methods (including bismuth shielding and tube current modulation) but without the Chrysalis device.
11513278|NCT01261559|Experimental|Chrysalis CT|Women assigned to undergo CT using the standard dose reduction methods (including bismuth shielding and tube current modulation) plus application of the Chrysalis device for breast displacement.
11513279|NCT01261546|Experimental|Dexamethasone|"Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.
~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present
~Ranitidine 5 mg/kg IV, q.d. for 2 days
~Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days."
11513280|NCT01261546|Placebo Comparator|Placebo|"Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.
~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.
~Ranitidine 5 mg/kg IV, q.d. for 2 days.
~Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days."
11513281|NCT01261533|Experimental|FCVB team|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB)
11513282|NCT01261520|Other|Culturally-tailored video|The culturally-tailored video was designed to focus on Chinese women's cultural health beliefs and align with Chinese customs, norms, and values, which includes two segments: 1) a soap-opera and 2) recommendation from a Chinese female physician.
11513283|NCT01261494|Experimental|GFT505 80mg|
11513284|NCT01261494|Placebo Comparator|Matching placebo|
11513285|NCT01261481|Experimental|Tolvaptan Intact Tablet Orally|
11513286|NCT01261481|Experimental|Tolvaptan via Nasogastric Tube|
11513287|NCT01261468|Active Comparator|Active SCS|
11513288|NCT01261468|Sham Comparator|Inactive SCS|
11513289|NCT01261455|Active Comparator|Superior Conjunctival Autograft|Conjunctival autograft following pterygium excision is taken from superior conjunctival tissue.
11513290|NCT01261455|Experimental|Inferior Conjunctival Autograft|Conjunctival autograft following pterygium excision is taken from inferior conjunctival tissue.
11513291|NCT01261442||Diabetic patients with DSPN|
11513292|NCT01261442||Diabetic patients without DSPN|
11513293|NCT01261429|Experimental|Nilotinib|
11513294|NCT01261416||Infants with seizures|
11513295|NCT01261403|Experimental|Group 1|1 Unit of PDA001 or 4 units Vehicle Control intravenous on Day 0 and Day 7
11513296|NCT01261403|Experimental|Group 2|4 Units PDA001 or 4 units Vehicle Control intravenous (Placebo) on Day 0 and Day 7
11513297|NCT01261403|Placebo Comparator|Vehicle control|Placebo - Vehicle Control Arm
11513298|NCT01261390|Placebo Comparator|Conservative Medical Therapy (CMT)|All participants will meet with a research assistant who will provide ~30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breath Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
11513299|NCT01261390|Sham Comparator|Sham PAP (Sham)|"In addition to receiving CMT, participants in this treatment arm will receive a sham-CPAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active PAP arms.
~The treatment visit schedule is outlined below.
~PAP Initial Set-Up
~1-week follow up
~1-month follow up
~3-month follow up
~6-month follow up
~9-month follow up (will not occur if on a 6-month follow-up protocol)
~It is estimated that each in-person follow-up adherence visit with the PAP specialist would last ~30 minutes."
11513300|NCT01261390|Active Comparator|Active PAP with RT Support (Active-Beh)|"In addition to receiving CMT, participants will receive active-PAP. The treatment visit schedule is outlined below.
~PAP Initial Set-Up
~1-week follow up (FU)
~1-month FU
~3-month FU
~6-month FU
~9-month FU (12-month follow-up protocol only)
~All visits will take place with a PAP specialist. All follow-up visits will be anchored to the initial PAP set-up visit. At these visits, using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. Each follow-up visit with the PAP specialist will last 30 minutes."
11513301|NCT01261390|Active Comparator|Active PAP with Behavioral Modification (Active+Beh)|"In addition to receiving CMT and active-PAP, participants will have behavioral intervention sessions to promote PAP adherence. The treatment visit schedule is outlined below:
~Visits with Behavioral Interventionist (in addition to active-PAP treatment visits):
~PAP Initial Set-Up (in-person, 1-hr)
~1-week follow-up (FU) (in-person, 1-hr)
~1-month FU
~2-month FU
~3-month FU
~5-month FU
~8-month FU (12-month follow-up protocol only)
~All follow-up visits will be anchored to the initial PAP set-up visit. PAP treatment visits will occur as outlined in the active-PAP arm.
~All behavioral intervention visits will be 30-min phone calls, unless otherwise noted. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training."
11513302|NCT01261377|Active Comparator|Bi-level positive airway pressure (BPAP)|bi-level will be titrated to optimize oxygenation and ventilation.
11513303|NCT01261377|Active Comparator|Nocturnal oxygen|oxygen will be provided as per standard of care.
11513304|NCT01261377|Active Comparator|Continuous positive airway pressure|The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
11513305|NCT01261364|Active Comparator|Treatment as Usual|
11513306|NCT01261364|Experimental|Pharmacogenetic guided treatment|
11513307|NCT01261338|Experimental|olestra|Non-absorbable fat administered in the form of 24 potato crisps per day (12 each with mid-day and evening meal) providing approximately 15g/day of olestra.
11513308|NCT01261338|Placebo Comparator|Vegetable oil|Absorbable fat administered in the form of 12 potato crisps per day (6 each with mid-day and evening meal) in order to match the caloric intake provided by the crisps with Olestra.
11513309|NCT01261325|Placebo Comparator|Placebo|Matching placebo tablets administered twice daily
11513310|NCT01261325|Experimental|Brivaracetam 100 mg/ day|Brivaracetam 50 mg/ day administered twice daily.
11513311|NCT01261325|Experimental|Brivaracetam 200 mg/ day|Brivaracetam 100 mg/ day administered twice daily
11513312|NCT01261312|Experimental|Daily Regimen|"SGI-110 daily x5 dosing on a 28-day course
~SGI-110 daily x10 dosing on a 28-day course"
11513313|NCT01261312|Experimental|Weekly Regimen|"SGI-110 weekly dosing for three weeks on a 28-day course
~SGI-110 twice weekly dosing for three weeks on a 28-day course"
11513371|NCT01261013||keratoconus stage I in whom KeraRing ICRS were implanted|
11513314|NCT01261299|Experimental|Carbon-14-labeled carboplatin|Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
11513315|NCT01261273||Stable angina|Patient admitted with stable angina
11513316|NCT01261273||Acute Coronary Syndrome|Patients admitted with Acute Coronary Syndrome
11513317|NCT01261273||Female|Participant female patients
11513318|NCT01261273||Bifurcation|One or more lesions treated during the baseline in bifurcation
11513319|NCT01261273||Insulin Dependent Diabetes Mellitus|Patients that were insulin-dependent diabetes mellitus at admission
11513320|NCT01261273||Non-Insulin Dependent Diabetes Mellitus|Patients that were non-insulin-dependent diabetes mellitus at admission
11513321|NCT01261273||Small Vessels|vessels smaller or equal to 2.75mm
11513322|NCT01261273||NOBORI Long Lesions|Lesions longer or equal to 20mm
11513323|NCT01261273||Renal Insufficiency|Patients that at admission had renal insufficiency (> 2.0 mg/dL - 176 µmol/mL) at admission
11513324|NCT01261273||Elderly|Patients more or equal 80 years old
11513325|NCT01261273||Restenosis|One or more lesions treated during the baseline in were restenotic lesions
11513326|NCT01261273||Multivessel Treatment|Patients who underwent the treatment of more than 1 vessel during the index procedure
11513327|NCT01261273||Complex Lesions|Patients who underwent a PCI on the Left Main Trunk, on a Chronic Total Occluded lesion or located on a Saphenous Vein Graft
11513328|NCT01261273||Overall|Total Population
11513329|NCT01261260|Placebo Comparator|Uridine|1g BID
11513330|NCT01261247|Experimental|Arm I|Patients receive oral panobinostat 3 times weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11513331|NCT01261234|Experimental|Cilostazol group|Continuous administration of cilostazol (unrestricted use of other antiplatelet agents and concomitant drugs)
11513332|NCT01261234|Active Comparator|Non-Cilostazol group|Antiplatelet agent other than cilostazol (unrestricted use of concomitant drugs)
11513333|NCT01261182|Experimental|In School Feeding|
11513334|NCT01261182|Experimental|Take Home Rations|
11513335|NCT01261182|No Intervention|Control|
11513336|NCT01261169||Myfortic|
11513337|NCT01261156|Experimental|Study Arm 1|
11513338|NCT01261156|Experimental|Study Arm 2|
11513339|NCT01261143|Experimental|BK-C-0701, diabetic neuropathy|
11513340|NCT01261143|Active Comparator|alpha lipoic acid, diabetic neuropathy, capsule|
11513341|NCT01261130|Experimental|Part I-A: 10μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation A
11513342|NCT01261130|Experimental|Part I-B: 30μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation B
11513343|NCT01261130|Experimental|Part I-C: 100μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation C
11513344|NCT01261130|Experimental|Part I-D: 10μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation D
11513345|NCT01261130|Experimental|Part I-E: 30μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation E
11513346|NCT01261130|Experimental|Part I-F: 100μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation F
11513347|NCT01261130|Experimental|Part II-A: 10μgNaGST1/Alhydrogel|Part II (endemic area), Formulation A
11513348|NCT01261130|Experimental|Part II-B: 30μgNaGST1/Alhydrogel|Part II (endemic area), Formulation B
11513349|NCT01261130|Experimental|Part II-C: 100μgNaGST1/Alhydrogel|Part II (endemic), Formulation C
11513350|NCT01261130|Experimental|Part II-D: 10μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation D
11513351|NCT01261130|Experimental|Part II-E: 30μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation E
11513352|NCT01261130|Experimental|Part II-F: 100μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation F
11513353|NCT01261130|Active Comparator|Part II-G: Butang® hepatitis B vaccine|Part II (endemic), HepB comparator
11513354|NCT01261117|Active Comparator|intravenous ibuprofen|Extremely low birth weight patients receiving iv ibuprofen
11513355|NCT01261117|Active Comparator|Oral ibuprofen|Extremely low birth weight patients receiving oral ibuprofen
11513356|NCT01261104||Hearing impaired elderly|
11513357|NCT01261104||Hearing impaired adults|
11513358|NCT01261091|Experimental|Early Tracheostomy|Patients randomized to early tracheostomy receive (preferably dilatative) tracheostomy within 3 days from intubation.
11513359|NCT01261091|Active Comparator|Prolonged Intubation|Patients randomized to this arm will be tried to wean off the ventilator and get (an) extubation trial(s) if regarded feasible. In case of failure or non-feasibility, they receive tracheostomy between days 7 to 14 from intubation.
11513360|NCT01261078|Placebo Comparator|Placebo|8 mg bupivacaine only
11513361|NCT01261078|Active Comparator|Epi 25|8 mg of bupivacaine mixed with 25 mcg of epinephrine
11513362|NCT01261078|Active Comparator|Epi 50|8 mg of bupivacaine mixed with 50 mcg of epinephrine
11513363|NCT01261078|Active Comparator|Epi 100|8 mg of bupivacaine mixed with 0.1 mg of epinephrine
11513364|NCT01261078|Active Comparator|Epi 200|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
11513365|NCT01261052|Active Comparator|FMPD/APD intervention|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 33 hours. For the first 13 hours, the original artificial pancreas algorithm FMPD, will be used to control the subject's blood glucose. After 13 hours, the adaptive component or APD will be used to control the subject's blood glucose for the remaining 20 hours.
11513366|NCT01261052|Active Comparator|APD only intervention|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 33 hours. For the entire study, the adaptive component or APD will be used to control the subject's blood glucose.
11513367|NCT01261039|Active Comparator|Solar bed UV-radiation|Solar bed UV-radiation
11513368|NCT01261039|Sham Comparator|Solar bed with UV filter|Solar bed with UV filter
11513369|NCT01261026||Ectopic pregnancy, extra-uterine pregnancy|Ectopic pregnancy, control
11513372|NCT01261013||keratoconus stage II in whom KeraRing ICRS were implanted|
11513373|NCT01261013||keratoconus stage III in whom KeraRing ICRS were implanted|
11513374|NCT01261000|Experimental|Pegvisomant|
11513375|NCT01260987|Active Comparator|AK split-face treatment|Split-face treatment of two symmetrical areas with moderate to severe actinic keratoses. One area is treated with conventional PDT the other with fractional laser assisted PDT.
11513376|NCT01260987|Active Comparator|Fractional laser assisted PDT for BCC|Difficult to treat nodular basal cell carcinomas in the face is pretreated with fractional CO2 laser followed by methyl-aminolevulinate PDT.
11513377|NCT01260987|Active Comparator|Konventional PDT for BCC|Difficult to treat nodular basal cell carcinomas in the face is treated with methyl-aminolevulinate PDT.
11513378|NCT01260974|Experimental|Caspofungin|Study group
11513379|NCT01260961|Active Comparator|Docosa Hexanoic Acid|
11513380|NCT01260961|Placebo Comparator|Placebo|
11513381|NCT01260948|Experimental|Investigational Test Product|Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg
11513382|NCT01260948|Active Comparator|Reference Listed Drug|Aricept® Orally Disintegrating Tablets, 10 mg
11513383|NCT01260935|Active Comparator|Arm A|Laparoscopic Hill
11513384|NCT01260935|Active Comparator|Arm B|Laparoscopic Nissen
11513385|NCT01260922|Experimental|Investigational Test Product|Donepezil Hydrochloride 10 mg Orally Disintegrating Tablets
11513386|NCT01260922|Active Comparator|Reference Listed Drug|Aricept® 10 mg Orally Disintegrating Tablets
11513387|NCT01260909||Real-time kV/MV Prostate Imaging|
11513388|NCT01260896|Experimental|Investigational Test Product|150 mg Venlafaxine Hydrochloride Extended-Release Capsules
11513389|NCT01260896|Active Comparator|Reference Listed Drug|150 mg Effexor® XR Extended-Release Capsules
11513390|NCT01260883|Experimental|ketorolac 1 mg/kg|ketorolac 1 mg/kg iv given by 10 min infusion
11513391|NCT01260883|Active Comparator|ketorolac 0.5 mg/kg|ketorolac 0.5 mg/kg iv given by 10 min infusion
11513392|NCT01260883|Sham Comparator|placebo|placebo group received D5W 10 min infusion
11513393|NCT01260870|Experimental|Cotavance|
11513394|NCT01260870|Active Comparator|Standard balloon angioplasty|POBA
11513395|NCT01260844|Experimental|single dose of briakinumab|single dose briakinumab cocktail of CYP substrates
11513396|NCT01260831|Experimental|Intervention Hospitals|hospitals randomized to implement bedsidePEWS documentation system (vital sign assessment record)
11513397|NCT01260831|Active Comparator|Control Hospitals|hospitals randomized to continue with their pre existing documentation system (vital sign assessment record)
11513398|NCT01260818|Experimental|Tranexamic Acid|
11513399|NCT01260818|Placebo Comparator|control group|
11513400|NCT01260805|Active Comparator|Reference Drug|
11513401|NCT01260805|Active Comparator|Test Drug|
11513402|NCT01260792||Children|Children between 5 and 18 years old.
11513403|NCT01260792||Adults|Parents of children between 5 and 18 years old
11513404|NCT01260766|Active Comparator|Active Comparator: Oplon Active Patch|
11513405|NCT01260766|Placebo Comparator|Placebo Comparator: Placebo patch|
11513406|NCT01260753|Experimental|UR-63325|
11513407|NCT01260753|Active Comparator|Fluticasone propionate nasal spray|
11513408|NCT01260753|Placebo Comparator|Placebo|
11513409|NCT01260727|Experimental|Group 1|Participants will receive PENNVAX-G vaccine administered by intramuscular injection (IM) via Biojector 2000 needleless device in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
11513410|NCT01260727|Experimental|Group 2|Participants will receive PENNVAX-G vaccine administered via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
11513411|NCT01260727|Experimental|Group 3: Subgroup 1|Participants will receive PENNVAX-G vaccine administered IM via Biojector 2000 needleless device in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
11513412|NCT01260727|Placebo Comparator|Group 3: Subgroup 2|Participants will receive placebo vaccine for PENNVAX-G administered IM via Biojector 2000 needless device in either deltoid on Days 0 and 28. They will then receive placebo vaccine for MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
11513413|NCT01260727|Experimental|Group 4: Subgroup 1|Participants will receive PENNVAX-G vaccine administered IM via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
11513414|NCT01260727|Placebo Comparator|Group 4: Subgroup 2|Participants will receive placebo vaccine for PENNVAX-G administered IM via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive placebo vaccine for MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
11513415|NCT01260714|Experimental|Treatment (azacitidine, mitoxantrone hydrochloride, etoposide)|Patients receive induction therapy comprising azacitidine SC QD on days 1-7, mitoxantrone hydrochloride IV over 30 minutes, and etoposide IV over 1 hour on days 4-8. Patients may receive up to 2 additional courses of the same treatment as re-induction or consolidation therapy beginning 35-60 days from the start of the previous course.
11513416|NCT01260701|Experimental|Treatment (CLOSED TO ACCRUAL 05/01/13)|Patients receive Akt inhibitor MK2206 PO every other day on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11513417|NCT01260688|Experimental|Arm I|Patients receive oral cediranib maleate once daily and oral dasatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11513418|NCT01260688|Experimental|Arm II|Patients receive cediranib maleate as in arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11513419|NCT01260675||NanoBUP Capsules|Investigational Formulation of Buprenorphine HCl/Naloxone HCl 8 mg/2 mg oral capsules
11513420|NCT01260675||Suboxone Sublingual Tablets|Buprenorphine HCl/Naloxone HCl 8 mg/2 mg sublingual tablets
11513421|NCT01260662|Active Comparator|Propofol|Deep sedation using propofol
11513422|NCT01260662|Experimental|1:1 Propofol/Ketamine|Propofol and ketamine mixed 1:1, given at 0.1 cc/kg as initial bolus, followed by 1/2 that dose every 3 minutes as need for sedation
11513423|NCT01260662|Experimental|4:1 Propofol/Ketamine|Propofol and ketamine mixed 4:1, given at 0.1 cc/kg as initial bolus, followed by 1/2 that dose every 3 minutes as need for sedation
11513424|NCT01260649|Experimental|ketamine|ketamine (0.5 mg/kg) followed by anesthetic agent titrated to sedation and succinylcholine titrated to muscle relaxation Right unilateral ECT at 5-6x seizure threshold three times a week
11513425|NCT01260649|Placebo Comparator|placebo|"IV saline, followed by anesthestic agent titrated to sedation and succinylcholine titrated to muscle relaxation.
~Right unilateral ECT at 5-6x seizure threshold three times a week"
11513426|NCT01260636|Experimental|MultiHance contrast agent|MultiHance administered at a dose of 0.1 mmol/kg (0.2 mL/kg)
11513427|NCT01260636|Active Comparator|Magnevist|Magnevist administered at a dose of 0.2 mmol/kg
11513428|NCT01260610|Active Comparator|Tenofovir|
11513429|NCT01260610|Active Comparator|Telbivudine|
11513430|NCT01260610|Experimental|Tenofovir plus Telbivudine|
11513431|NCT01260597|Experimental|Life Style Counseling|For individuals who report being quit, a brief congratulatory message will be delivered, independent of each arm of the study they were randomized to. For individuals who report not being quit and are randomized to the intervention condition, tailored messages are delivered via the IVR system. The automated calls would include an assessment of the individual's interest in another quit attempt and deliver brief, tailored messages to perceived barriers for re-engaging into treatment. The system is programmed to transfer the caller to a live quit line counselor if the individual is willing to re-engage in cessation treatment.
11513432|NCT01260597|Active Comparator|Life Counseling|For individuals who report being quit, a brief congratulatory message will be delivered, independent of each arm of the study they were randomized to. For individuals who report still smoking the IVR will thank them for their time and the call will end.
11513433|NCT01260584|Experimental|Prasugrel|Prasugrel 10 mg film-coated tablet daily dose × 10 days. To maintain blinding, placebo film-coated tablets matching clopidogrel in appearance will be given daily × 10 days to subjects in the prasugrel treatment group. In addition, aspirin 81 mg to 325 mg daily will be taken.
11513434|NCT01260584|Active Comparator|Clopidogrel|Clopidogrel 75 mg film-coated tablet daily dose x 10 days To maintain blinding, placebo film-coated tablets matching prasugrel in appearance will be given daily × 10 days to subjects in the clopidogrel treatment group. In addition, aspirin 81 mg to 325 mg daily will be taken.
11513435|NCT01260571|Experimental|Benzoyl Peroxide and Sulfur|Topical Medications containing benzoyl peroxide and sulfur
11513436|NCT01260558|Active Comparator|Arm 1|Sirolimus-Permanent-Polymer Eluting Stent
11513437|NCT01260558|Active Comparator|Arm 2|Sirolimus-Polymer-free Eluting Stent
11513438|NCT01260545|Experimental|Infusion|A standard 3+3 design will be employed to determine maximum tolerated dose
11513439|NCT01260532||Graves' disease|no intervention
11513440|NCT01260532||Hashimoto's thyroiditis|no intervention
11513441|NCT01260532||Healthy subjects|no intervention
11513442|NCT01260519|Experimental|active arm: heparin|
11513443|NCT01260506|Experimental|VB-111|Antiangiogenic and vascular disruptive agent
11513444|NCT01260493|No Intervention|Conventional care, controlgroup|conventional care, control group
11513445|NCT01260493|Experimental|integrated health care chain|integrated health care chain. Geriatric assessment at emergency department (ED), case manager with multiprofessional team in the community, support for informal caregivers
11513446|NCT01260480|Experimental|[18F]-ML-10|
11513447|NCT01260467|Experimental|memantine arm|
11513448|NCT01260454|Experimental|Qutenza patch|All participants actively treated with Qutenza
11513449|NCT01260441|Active Comparator|Standard CPR|"Individuals will learn the Standard form of CPR (30:2, compressions:breathes) Main data points being collected over various increments are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect and 3) CPR Skills"
11513450|NCT01260441|Active Comparator|Chest Compressions Only CPR|"Individuals will learn the chest compression only form of CPR (no rescue breathes) Main data points being collected at various increments are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect and 3) CPR Skills"
11513451|NCT01260428||healthy active subjects|with and without high altitude intolerance
11513452|NCT01260415|Experimental|Folfox/Folfiri, Panitumumab|Eligible patients will recieved chemotherapy/panitumumab for 2 months (4 cycles) pre-operatively and 4 months post-operatively, plus a further 6 months of pantimumab post-chemotherapy
11513453|NCT01260402|Active Comparator|Epicardial|
11513454|NCT01260402|Experimental|Endocardial|
11513455|NCT01260389|No Intervention|control group|Usual pharmacist care in patients with Chronic Obstructive Pulmonary Disease (COPD).
11513456|NCT01260389|Experimental|pharmaceutical care intervention|A pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
11513457|NCT01260376|Experimental|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
11513458|NCT01260376|No Intervention|Placebo|Placebo tablets will be administered 4 times previous to and during the investigation day
11513459|NCT01260363|Active Comparator|Naropin, Adrenalin, applicationsite|
11513460|NCT01260363|Active Comparator|Femoral nerve block|
11513461|NCT01260350|Experimental|Group 1: SOF+RBV 12 wk: GT 2 or 3, TN|Treatment-naive (TN) participants with genotype (GT) 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
11513462|NCT01260350|Experimental|Group 2: SOF+RBV 12 wk+PEG 4 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks plus PEG 180 µg once weekly for 4 weeks.
11513463|NCT01260350|Experimental|Group 3: SOF+RBV 12 wk+PEG 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks plus PEG 180 µg once weekly for 8 weeks.
11513464|NCT01260350|Experimental|Group 4: SOF+RBV+PEG 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily+weight-based RBV (1000-1200 in a divided daily dose) plus PEG 180 µg once weekly for 12 weeks.
11513549|NCT01259882|Experimental|Cohort 5: Experimental intervention: PF-05089771 or placebo|Cohort 5
11513465|NCT01260350|Experimental|Group 5: SOF 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily for 12 weeks.
11513466|NCT01260350|Experimental|Group 6: SOF+RBV+PEG 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus PEG 180 µg once weekly for 8 weeks.
11513467|NCT01260350|Experimental|Group 7: SOF+RBV 12 wk: GT 1, TE|Treatment-experienced (TE) participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
11513468|NCT01260350|Experimental|Group 8: SOF+RBV 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
11513469|NCT01260350|Experimental|Group 9: SOF+RBV 12 wk: GT 2 or 3, TE|Treatment-experienced participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
11513470|NCT01260350|Experimental|Group 10: SOF+RBV 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 8 weeks.
11513471|NCT01260350|Experimental|Group 11: SOF+RBV 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus split-dose RBV (800 mg in a divided daily dose) for 12 weeks.
11513472|NCT01260350|Experimental|Group 12: SOF+RBV+LDV 12 wk: GT 1, TE|Treatment-experienced participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus LDV 90 mg once daily for 12 weeks.
11513473|NCT01260350|Experimental|Group 13: SOF+RBV+LDV 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus LDV 90 mg once daily for 12 weeks.
11513474|NCT01260350|Experimental|Group 14: SOF+RBV+GS-9669 12 wk: GT 1, TE|Treatment-experienced participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus GS-9669 500 mg once daily for 12 weeks.
11513475|NCT01260350|Experimental|Group 15: SOF+RBV+GS-9669 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus GS-9669 500 mg once daily for 12 weeks.
11513476|NCT01260350|Experimental|Group 16: LDV/SOF FDC 12 wk: GT 1, fibrosis|Treatment-experienced participants with genotype 1 HCV infection and Stage F4 fibrosis who did not respond to prior treatment will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
11513477|NCT01260350|Experimental|Group 17: LDV/SOF FDC+RBV 12 wk: GT 1, fibrosis|Treatment-experienced participants with genotype 1 HCV infection with Stage F4 fibrosis who did not respond to prior treatment will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
11513478|NCT01260350|Experimental|Group 18: LDV/SOF FDC 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
11513479|NCT01260350|Experimental|Group 19: LDV/SOF FDC 12 wk: GT 2 or 3, TE|Treatment-experienced participants with genotype 2 or 3 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
11513480|NCT01260350|Experimental|Group 20: LDV/SOF FDC+RBV 12 wk: GT 1, hemophiliac|Hemophiliac participants with genotype 1 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
11513481|NCT01260350|Experimental|Group 21: LDV/SOF FDC+RBV 6 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 6 weeks.
11513482|NCT01260350|Experimental|Group 22: LDV/SOF FDC 6 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection were randomized to receive LDV 90 mg/SOF 400 mg FDC once daily for 6 weeks.
11513483|NCT01260337|Active Comparator|Diabetes Support and Education (DSE)|
11513484|NCT01260337|Experimental|Portion controlled diet (PCD)|behavior modification
11513485|NCT01260324||NAION cases|From the study population, patients with a claim associated with an ischemic optic neuropathy diagnosis code were identified as potential NAION cases (n = 3,732). From the potential NAION cases, definite and possible NAION cases were identified using medical record review and a claims algorithm (n=1,283). Data from definite and possible NAION cases contributed to the analysis.
11513486|NCT01260324||Controls|From the study population, patients without a claim associated with an ischemic optic neuropathy diagnosis code were randomly selected as controls (n = 20,000)
11513487|NCT01260311||Patients prescribed with Fesoterodine|Patients diagnosed with Over-active bladder and prescribed with fesoterodine.
11513488|NCT01260298||MC1 Ultrasonic Device|
11513489|NCT01260285|Experimental|Vardenafil|
11513490|NCT01260272|Active Comparator|Alternative Snack Group|This group will receive 100 calorie alternative snack packs to consume three times a day with meals. Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables
11513491|NCT01260272|Experimental|Raisin Group|This group will receive raisins to consume three times a day with meals
11513492|NCT01260259|Experimental|Remote Ischemic Preconditioning (RIPC)|
11513493|NCT01260259|Sham Comparator|Control|
11513494|NCT01260246|Experimental|sitagliptin|sitagliptin 100mg/daily for 6 months
11513495|NCT01260246|Placebo Comparator|placebo|placebo match for 6 months
11513496|NCT01260233|No Intervention|Control|No intervention. Patients will receive standard of care.
11513497|NCT01260233|Experimental|Smoking cessation program|Receives smoking cessation program
11513498|NCT01260220|Active Comparator|Circumferential|Completing a complete circle of RF lesions around the left and right pulmonary veins
11513499|NCT01260220|Experimental|Segmental|Isolating the left and right pulmonary veins through RF lesions with a segmental antral approach.
11513550|NCT01259882|Experimental|Cohort 6: Experimental intervention: PF-05089771 or placebo|Cohort 6
11513551|NCT01259869|Experimental|PX-866|
11513745|NCT01258569|Placebo Comparator|Placebo|
11513500|NCT01260207|Experimental|IVR group|Patients in this arm will receive IVR follow-up telephone calls at 1,3,6,9 and 12 months post-discharge consisting of predetermined questions related to medication management, smoking cessation, diet, exercise and education as recommended by the ACC/AHA BPG for ACS. Upon completion of the IVR follow-up, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
11513501|NCT01260207|No Intervention|Usual care|Patients in this arm will not receive IVR follow-up. One year after discharge, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
11513502|NCT01260194|Experimental|1|
11513503|NCT01260181|Experimental|Erlotinib|Participants will receive erlotinib 150 millgrams (mg) orally daily until disease progression.
11513504|NCT01260168||Colorectal cancer patients|Subjects will be men and women, 40-90 years of age, inclusive, each with a colonoscopic biopsy-based diagnosis of colorectal cancer (CRC) and/or an intact pre-malignant colorectal lesion large enough to require surgical excision or complex colonoscopic polypectomy.
11513505|NCT01260155|Experimental|Treatment A Fasted|
11513506|NCT01260155|Experimental|Treatment B Fasted|
11513507|NCT01260155|Experimental|Treatment C Food Effect|
11513508|NCT01260142|Experimental|Arm 1|
11513509|NCT01260142|Experimental|Arm 2|
11513510|NCT01260142|Experimental|Arm 3|
11513511|NCT01260129|Experimental|Silodosin 8 mg|
11513512|NCT01260129|Experimental|Silodosin 4 mg|
11513513|NCT01260116||1|Ziprasidone,Zeldox capsule
11513514|NCT01260103|Active Comparator|Temozolomide (TMZ)|Study subjects receive TMZ for 13 cycles
11513515|NCT01260103|Experimental|ANP Therapy|Escalating doses of ANP therapy are given daily for 52 weeks.
11513516|NCT01260090|Experimental|Vagus Nerve Stimulation|"Name of the Device:
~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).
~FDA Facility Registration Number: 1644487"
11513517|NCT01260090|Sham Comparator|No Stimulation|
11513518|NCT01260077||Experimental group|The sample was composed of 78 individuals (156 ears), 40 females (80 ears) and 38 males (76 ears).
11513519|NCT01260064|Active Comparator|Open appendectomy|The subjects will have open appendectomy procedure.
11513520|NCT01260064|Active Comparator|Metal endoclip|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
11513521|NCT01260064|Active Comparator|Intracorporeal suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
11513522|NCT01260051||Epidural Recipients|
11513523|NCT01260051||Non-Epidural Recipients|
11513524|NCT01260025|Experimental|PEDylated Recombinant Human Endostatin|PEDylated Recombinant Human Endostatin
11513525|NCT01260012|Experimental|praziquantel+antioxidant|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In additions, antioxidant suppliment will be given daily for a period of one year
11513526|NCT01260012|Active Comparator|Praziquantel +placebo 2mths then antioxidant for 10 months|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.
11513527|NCT01260012|No Intervention|Praziquantel therapy with placebo supplement|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for a period of one year.
11513528|NCT01259999|Experimental|Energy dense formula|
11513529|NCT01259986|Experimental|Laser treatment|
11513530|NCT01259973|Experimental|Risperidone|
11513531|NCT01259973|Placebo Comparator|Placebo|
11513532|NCT01259973|Experimental|Haloperidol|
11513533|NCT01259960||BMI < 25|Body Mass Index (BMI) according to WHO definition. BMI < 25 is defined as 'normal weight'.
11513534|NCT01259960||25 <= BMI < 30|Body Mass Index (BMI) according to WHO definition. BMI >= 25 and < 30 is defined as 'overweight'.
11513535|NCT01259960||BMI >= 30|Body Mass Index (BMI) according to WHO definition. BMI >= 30 is defined as 'obese'.
11513536|NCT01259947|Experimental|Lippia alba|
11513537|NCT01259934|No Intervention|Arm A|Observation only - no therapy
11513538|NCT01259934|Experimental|Arm B Interferon 1 year|Interferon Therapy: Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 12 months
11513539|NCT01259934|Experimental|Arm C Interferon 2 years|"Two year arm Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months"
11513540|NCT01259921|Experimental|Neurofeedback T4-P4|40 sessions of SMR neurofeedback training using T4-P4 placement administered twice weekly
11513541|NCT01259921|Active Comparator|Neurofeedback T3-T4|40 sessions of SMR neurofeedback using T3-T4 placement training administered twice weekly
11513542|NCT01259908||Laparoscopic vs open Ygraft|Patients with advanced atherosclerosis in aorto iliac segment operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared on the basis of the operative procedure for the primary endpoint, composite endpoint (all-cause mortality, systemic morbidity and graft thrombosis).
11513543|NCT01259895||Obesity|BMI > 30kg/m2
11513544|NCT01259895||Normal weight|BMI between 19 and 24,9kg/m2
11513545|NCT01259882|Experimental|Cohort 1: Experimental intervention: PF-05089771 or placebo|Cohort 1
11513546|NCT01259882|Experimental|Cohort 2: Experimental intervention: PF-05089771 or placebo|Cohort 2
11513547|NCT01259882|Experimental|Cohort 3: Experimental intervention: PF-05089771 or placebo|Cohort 3
11513548|NCT01259882|Experimental|Cohort 4: Experimental intervention: PF-05089771 or placebo|Cohort 4
11513746|NCT01258556|Experimental|Probiotic yogurt|
11513552|NCT01259856|Experimental|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
11513553|NCT01259856|Active Comparator|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
11513554|NCT01259843||Acute Aortic Syndrome|Patients admitted to cardiology, radiology or surgery for a clinical picture suggestive of acute aortic syndrome whose diagnosis was subsequently confirmed in due course of hospitalization by further investigations.
11513555|NCT01259830|Experimental|Arcoxia® 120 mg|
11513556|NCT01259830|Placebo Comparator|Sugar pill|
11513557|NCT01259817|Experimental|PEGASYS|Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously.
11513558|NCT01259817|Active Comparator|Aspirin|81 or 100 mg daily.
11513559|NCT01259804|Experimental|Peanut immunotherapy|Peanut flour
11513560|NCT01259791|Experimental|Statin|Individual-specific statin causing myopathy - i.e., Patients will receive the specific statin previously associated with myopathic symptoms in them (can be any of the following statins: rosuvastatin, atorvastatin, simvastatin, fluvastatin, pravastatin in any of the doses causing symptoms previously).
11513561|NCT01259791|Placebo Comparator|Placebo|Identical placebo to patient-specific statin
11513562|NCT01259765|Active Comparator|VHH|"The active substance is VHH batch 203027."
11513563|NCT01259765|Placebo Comparator|Placebo|Placebo product
11513564|NCT01259752|Experimental|compression stockings|
11513565|NCT01259752|Placebo Comparator|standard non compressive stockings|
11513566|NCT01259739|Experimental|Flavanol rich cocoa|(596 mg), dissolved in water, twice daily intervention
11513567|NCT01259739|Experimental|flavanol poor cocoa drink|( 13mg) dissolved in water, twice daily intervention
11513568|NCT01259726|Placebo Comparator|Placebo|
11513569|NCT01259726|Experimental|VP20621 Low Dose and Placebo|
11513570|NCT01259726|Experimental|VP20621 High Dose and Placebo|
11513571|NCT01259726|Experimental|VP20621 High Dose|
11513572|NCT01259713|Experimental|Liposomal amphotericin B|Liposomal amphotericin B 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
11513573|NCT01259713|Placebo Comparator|Placebo|Placebo to match liposomal amphotericin B twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
11513574|NCT01259700|Experimental|High risk management|
11513575|NCT01259700|Experimental|Salt reduction|
11513576|NCT01259700|Experimental|high risk management and salt reduction|
11513577|NCT01259700|No Intervention|Usual care|
11513578|NCT01259687||Study group|
11513579|NCT01259674|Experimental|AboMeg-B-09 syrup|Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
11513580|NCT01259674|Placebo Comparator|Placebo|Placebo syrup
11513581|NCT01259661|Experimental|Experimental Group|
11513582|NCT01259661|Active Comparator|Control Group|
11513583|NCT01259648|Experimental|0.5 µg / kg remifentanil|Induction anesthesia includes 0.5 µg/kg remifentanil in addition to classic induction anesthesia protocol.
11513584|NCT01259648|Experimental|1.0 µg/kg remifentanil|Induction anesthesia includes 1.0 µg/kg remifentanil in addition to the classic induction protocol.
11513585|NCT01259648|Placebo Comparator|NaCl|An equivalent volume (1 ml for 10 kg of weight) of isotonic 0.9% NaCl is injected in addition to the classic anesthesia induction protocol
11513586|NCT01259635|Experimental|Bio feedback for freezing|When ever freezing occures, a metronom sound will be heard
11513587|NCT01259622|Placebo Comparator|placebo|
11513588|NCT01259622|Experimental|K201|intravenous K201
11513589|NCT01259609|Experimental|Diabetic Macular Edema Group|
11513590|NCT01259609|Active Comparator|Epiretinal Membrane Group|
11513591|NCT01259609|No Intervention|Healthy Control|
11513592|NCT01259596|Active Comparator|Cognitive behavioral therapy|Cognitive-behavioral therapy consists of psychoeducation, relaxation techniques, cognitive therapy, problem-solving, thought stopping, behavioral activation, exposure, coping with pain, sleep, and relapse prevention
11513593|NCT01259596|Active Comparator|Nondirective supportive therapy|Nondirective supportive therapy consists of providing a warm and accepting environment in which a person can reflect on their experiences, thoughts, and feelings
11513594|NCT01259583|Experimental|CO2|CO2 insufflation instead air insufflation in unsedated colonoscopy
11513595|NCT01259583|Experimental|Warm Water irrigation|warm water irrigation during the insertion phase of colonoscopy
11513596|NCT01259570|Active Comparator|Skimmilk enriched with VD encapsulated in CM|
11513597|NCT01259570|Active Comparator|VD will be dissolved in milkfat and homogenized into skimmilk|VD will be dissolved in milkfat and homogenized into skimmilk
11513598|NCT01259570|Active Comparator|3% fat milk wherein the VD will be in CM|3% fat milk wherein the VD will be in CM
11513599|NCT01259570|Active Comparator|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk.
11513600|NCT01259557|Experimental|Botulinum toxin type A(Meditoxin®)|
11513601|NCT01259544|Active Comparator|Di -petide breath tests and ePFT secretin induced|Di peptide breath tests will be performed on subjects with known chronic pancreatitis
11513602|NCT01259544|Active Comparator|c13 di peptide breath tests|Healthy volunteers to compare breath tests results to subjects with chronic pancreatitis
11513603|NCT01259531|Experimental|Silodosin|Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
11513604|NCT01259518|Experimental|Once monthly administration of TRIN2755|
11513605|NCT01259518|Experimental|Once weekly administration of TRIN2755|
11513606|NCT01259505|Experimental|Safety|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
11513607|NCT01259492|Experimental|Ritalin LA 40 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2, continued in same dose till week 9. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 40 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14. In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
11513608|NCT01259492|Experimental|Ritalin LA 60 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2 and to 60 mg at week 3. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 60 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14.In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
11513609|NCT01259492|Experimental|Ritalin LA 80 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2 and to 60 mg at week 3 and to 80 mg at week 4. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 60 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14. In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
11513610|NCT01259492|Placebo Comparator|Placebo|Period 1- Placebo controlled Period 2 - The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose (40, 60 or 80 mg). In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
11513611|NCT01259479|Experimental|1|Dose escalation, continuous treatment without DLTs
11513612|NCT01259466|Experimental|Cognitive Behavioral + Nicotine Patch|Cognitive Behavioral Therapy + Nicotine Replacement Patch
11513613|NCT01259466|Active Comparator|Health Education + Nicotine Patch|Health Education + Nicotine Replacement Patch
11513614|NCT01259453|Active Comparator|Standard vaccination schedule|Standard dosing at 0, 1, and 6 months
11513615|NCT01259453|Active Comparator|Accelerated Schedule|Accelerated dosing at 0, 1, and 2 months
11513616|NCT01259440|Active Comparator|Video Teleconferencing Care|Video teleconferencing care
11513617|NCT01259440|Placebo Comparator|Usual Care|Usual Care
11513618|NCT01259427|Experimental|Arm 1: Ending Self Stigma|Ending Self Stigma (ESS): Ending Self Stigma (ESS) is a 9-session small-group (4-8 persons) course designed to help individuals with serious mental Illness (SMI) develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
11513619|NCT01259427|Active Comparator|Arm 2: Health and Wellness Group|Health and Wellness Group: The Health and Wellness group is a 9-session small-group (4-8 persons) course designed for individuals with serious mental illness (SMI). Each session focuses on discussion of specific health and wellness related issues and education on ways to better manage health related concerns (e.g., physical activity/exercise, nutrition, managing fatigue/sleep, tobacco and other substance use, etc).
11513620|NCT01259414|Experimental|group1|Chemoembolization with solvent with specific gravity less than lipiodol
11513621|NCT01259414|Experimental|group2|Chemoembolization with Solvent with specific gravity equivalent to lipiodol
11513622|NCT01259401|Experimental|SIP group|The Sleep Intervention Program group received a sleep education program based on behavioral principles, delivered in 4 individual sessions carried out within the Adult Day Health Care program.
11513623|NCT01259401|Active Comparator|Control group|The Control group received basic sleep education, delivered in 4 individual sessions carried out within the Adult Day Health Care
11513624|NCT01259388|Experimental|Lithium|"Lithium-treatment phase
~Lithium Carbonate: Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time."
11513625|NCT01259388|No Intervention|Observation|During observation subjects continue on their standard of care disease modifying agent (or no agent at all if judged not appropriate by the treating physician).
11513626|NCT01259375|Experimental|All patients|All participants who received Amrubicin.
11513627|NCT01259362|Active Comparator|Transcranial Magnetic Stimulation|Cocaine addicted will receive a 20 day TMSr to right dorsolateral prefrontal cortex.
11513628|NCT01259362|Sham Comparator|Transcranial Magnetic Stimlation|cocaine addicted will receive a 20 day sham TMSr to right dorsolateral prefrontal cortex
11513629|NCT01259349|Experimental|one percent ultrasound|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at one percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
11513630|NCT01259349|Active Comparator|40 percent ultrasound|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at 40 percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
11513631|NCT01259336|Active Comparator|Itraconazole|Role of itraconazole in CCPA
11513632|NCT01259336|Experimental|treatment in cavitary pulmonary aspergillosis|Patients in this arm are given conservative management with antitussives, brochial artery embolisation.
11513633|NCT01259323|Experimental|Cohort 1|
11513634|NCT01259323|Experimental|Cohort 2|
11513635|NCT01259323|Experimental|Cohort 3|
11513747|NCT01258556|Placebo Comparator|Placebo yogurt.|
11513636|NCT01259310||Women with epilepsy|Women with epilepsy, age 18-40 years, who express a desire to conceive and have stopped or plan to stop taking birth control.
11513637|NCT01259310||Women without epilepsy|Healthy women, age 18-40 years, who express a desire to conceive and have stopped or plan to stop taking birth control.
11513638|NCT01259297|Experimental|Aliskiren + Amlodipine|"In run-in period (4-5 weeks) , patients on thiazide background therapy and approximately 50% of patients on neither CCB nor thiazide background therapy received Amlodipine 5 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.
~In double blind period, patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
~Patients randomized to this arm received Aliskiren 300 mg + Amlodipine 5 mg once daily during the double blind period."
11513639|NCT01259297|Experimental|Aliskiren + Hydrochlorothiazide (HCTZ)|"In run-in period (4-5 weeks) , patients on CCB background therapy and approximately 50% of patients on neither thiazide nor CCB background therapy: received Hydrochlorothiazide 12.5/25 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.
~In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
~Patients randomized to this arm received Aliskiren 300 mg + HCTZ 25 mg once daily."
11513640|NCT01259297|Experimental|Aliskiren + Placebo for Amlodipine|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
~In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for Amlodipine 5 mg"
11513641|NCT01259297|Experimental|Aliskiren + Placebo for HCTZ|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
~In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for HCTZ 25 mg once daily"
11513642|NCT01259297|Experimental|Amlodipine + Placebo for Aliskiren|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
~In double blind period, randomized patients to this arm received Amlodipine 5 mg + placebo for Aliskiren 300 mg once daily"
11513643|NCT01259297|Experimental|HCTZ + Placebo for Aliskiren|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
~In double blind period, randomized patients to this arm received HCTZ 25 mg + placebo for Aliskiren 300 mg once daily"
11513644|NCT01259297|Placebo Comparator|Placebo for Aliskiren + Placebo for Amlodipine|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.
~In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for Amlodipine 5 mg once daily"
11513645|NCT01259297|Placebo Comparator|Placebo for Aliskiren + Placebo for HCTZ|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.
~In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for HCTZ 25 mg once daily"
11513646|NCT01259284|Experimental|Atorvastatin|1 Atorvastatin capsule daily plus 3 Placebo capsules twice a day orally, 5 days pre-surgery.
11513647|NCT01259284|Experimental|Fish Oil Supplement|3 Fish Oil capsules twice a day plus 1 Placebo capsule daily orally 5 days pre-surgery.
11513648|NCT01259284|Placebo Comparator|Placebo|4 capsules orally every morning and 3 every evening for 5 days pre-surgery.
11513649|NCT01259271|Experimental|Supra-threshold|Supra-threshold is defined as the nerve stimulation amplitude at which a subject can tolerate sensory responses (like tingling, tapping in the thumb, index or middle fingers) but will not cause pain or duress to the subject. The intervention (TAMS device), is stimulating through tyco extended wear electrodes that are placed directly on top of non dominant hand healthy median nerve fibers and they feel the paresthesia or tingling sensation.
11513650|NCT01259271|Experimental|Sub-threshold|Sub-threshold is defined as the nerve stimulation amplitude just below the sensory perception of the subject. The intervention (TAMS device), is stimulating through tyco extended wear electrodes that are placed directly on top of non dominant hand healthy median nerve fibers. Subjects do not feel the paresthesia or tingling sensation despite there being a signal transmitted..
11513651|NCT01259271|Sham Comparator|Sham Control|All subjects in the sham arm will go through the same process / experimental setup as in each of the active stimulation arms; however there will be no stimulation signal during the sham stimulation (output set and SNS box locked at 0 V). As this is the Sham control, there is no intervention but rather the intevention (TAMS device) setup (Tyco electrodes, wires and stimulator) are sent with the subject as if it were on (and just like Subthreshold arm the subjects cannot feel the stimulation). Audible alerts (to signify that the box is unplugged) will be disabled throughout the duration of the study. This sham arm will be used to assess the placebo effect caused by the stimulation and hence isolate the true effect of stimulation.
11513652|NCT01259258|Active Comparator|varicocelectomy with dye|subinguinal varicocelectomy for 40 patients who received 2 ml intratunical space injection of methylene blue before spermatic vein ligation
11513653|NCT01259258|Active Comparator|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
11513654|NCT01259245|Experimental|Tai chi + PRP|Tai chi elements in incorporated into the exercise component of standard pulmonary rehabilitation program. The exercise content was totally identical to the PRP group except 15 minutes of Tai Chi exercises was substituted to 15 minutes of relaxation exercise. The 5 forms of Sun Style of Tai Chi were taught.
11513655|NCT01259245|Active Comparator|PRP|PRP is a formal pulmonary rehabilitation program consisted of physical training including warm up and cool down exercise and aerobic exercises in addition to breathing control exercises, safety precautions for physical training, Thera-Band strengthening exercises and overview of COPD management.
11513656|NCT01259232||schizophrenia patients,untreated|
11513657|NCT01259232||schizophrenia relatives|
11513658|NCT01259232||controls|
11513739|NCT01258608|Placebo Comparator|Sorafenib plus Placebo|Placebo intravenously on Day 1 of each cycle (i.e. every 21 days) plus sorafenib 400 mg orally twice daily continuously in each cycle until radiologic disease progression or unacceptable toxicity
11513740|NCT01258595|Experimental|High-Dose Trivalent Inactivated Influenza Vaccine|
11513741|NCT01258595|Active Comparator|Trivalent Inactivated Influenza Vaccine|
11513659|NCT01259219|Experimental|Rifabutin (Mycobutin)|Rifabutin is a red-violet powder souble in chloroform and methanol, sparingly souluble in ethanol, and very slightly soluble in water. Mycobutin capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. Mycobutin capsules for oral administered contain 150mg of rifabutin, USP, per capsule, along with the inactive ingredients microcrystalline cellulose magenesium stearate, red iron oxide3, silica gel, sodium lauryl sulfate, titanium dioxide, and edible white ink.
11513660|NCT01259206||diabetic patients|
11513661|NCT01259206||diabetic patients and healty controls|there are two groups in this study. One group is obese type 2 diabetic patiens and other group is healty controls.
11513662|NCT01259193|Experimental|Sorafenib and Zoledronic Acid|
11513663|NCT01259180|Experimental|Acupuncture group|twice a week, 6 weeks real acupuncture treatment, 12 sessions
11513664|NCT01259180|Sham Comparator|Sham acupuncture group|twice a week, 6 weeks real acupuncture treatment, 12 sessions
11513665|NCT01259180|No Intervention|Control group|observation.
11513666|NCT01259167||BACK group|training with a traditional protocol of Therapeutic Physical Exercise
11513667|NCT01259167||"Group C."|Control group with sedentary people undergoing usual care.
11513668|NCT01259167||JOBA group|training with JOBA® Core Trainer
11513669|NCT01259154||RFITT+UPPP|
11513670|NCT01259154||UPPP|
11513671|NCT01259141|Experimental|Moxifloxacin|
11513672|NCT01259141|Experimental|Cephalosporins and azithromycin|
11513673|NCT01259128|Experimental|SER120 500 ng/day|SER120 Level 1 (500 ng/day)
11513674|NCT01259128|Experimental|SER120 750 ng/day|SER120 Level 2 (750 ng/day)
11513675|NCT01259115|Experimental|Sequence A|BTDS 10 with ketoconazole 200 mg tablets twice daily in period 1 and BTDS 10 with ketoconazole placebo tablets twice daily in period 2.
11513676|NCT01259115|Experimental|Sequence B|BTDS 10 with ketoconazole placebo tablets twice daily in period 1 and BTDS 10 with ketoconazole 200 mg twice daily in period 2.
11513677|NCT01259102|Experimental|No Rest|BTDS 10 with no application site rest period prior to application of second BTDS
11513678|NCT01259102|Experimental|7-Day Rest|BTDS 10 with 7-day rest period prior to application of second BTDS
11513679|NCT01259102|Experimental|14-Day Rest|BTDS 10 with 14-day rest period prior to application of second BTDS
11513680|NCT01259102|Experimental|21-Day Rest|BTDS 10 with 21-day rest period prior to application of second BTDS
11513681|NCT01259102|Experimental|28-Day Rest|BTDS 10 with 28-day rest period prior to application of second BTDS
11513682|NCT01259089|Experimental|Arm I|Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11513683|NCT01259076||Group 1|Participants who are eligible for and have opted to undergo gastric bypass surgery
11513684|NCT01259076||Group 2|Participants who are eligible for but decided not to undergo gastric bypass surgery.
11513685|NCT01259063|Experimental|Pts who failed or relapsed after intravesical BCG|Phase I: Everolimus will be administered as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be administered at the dose determined in Phase .Everolimus will be continued for 12 months in the patients who achieve a CR or a Partial Response. Patients demonstrating a CR (by cystoscopy and cytology) or a Partial Response at their Cycle 12 cystoscopy will be observed with serial cystoscopies every 3 months.
11513686|NCT01259050|Experimental|Zinc and Copper|
11513687|NCT01259024|Experimental|doxorubicin-eluting LC Bead|transarterial chemoembolization using doxorubicin-eluting LC Beads
11513688|NCT01259011|No Intervention|control|Written information on advance directives and the patient's right to have an advance directive is provided to every patient on the first day of dialysis treatment by a social worker at the clinic. A social worker documents whether the patient has an advance directive, a surrogate decision maker, and/or a Do-Not-Resuscitate (DNR) Order on a Comprehensive Interdisciplinary Assessment form. The social worker encourages patients to complete an advance directive and addresses their questions about life-sustaining treatment options. If completed, the advance directive is placed in the medical record.
11513689|NCT01259011|Experimental|SPIRIT intervention|The SPIRIT intervention is a two-session, 1½ hour-long, structured intervention that is composed of six steps (assessing representations, identifying and exploring gaps and concerns, creating conditions for conceptual change, introducing replacement information, summarizing, and setting goals and planning), presented to both patient and surrogate by a trained nurse interventionist in a face-to-face interview format based on the representational approach.
11513690|NCT01258998|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11513691|NCT01258985|Active Comparator|Tai Chi|12 weeks of Tai Chi classes
11513692|NCT01258985|Active Comparator|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of Supervised Home Exercise
11513693|NCT01258972|Active Comparator|Angioplasty POBA|Side Branch balloon angioplasty with main branch DES
11513694|NCT01258972|Experimental|Tryton Side Branch Stent|Side Branch treated with Tryton Side Branch Stent with main branch DES
11513695|NCT01258959||Ophthalmic surgery patients|Patients (men and women) of at least 18 years of age undergoing an ophthalmic procedure on the posterior section of the eye under local anaesthesia, i.e. with a peribulbar block. Inclusion and exclusion criteria for the study are the same as for the peribulbar anaesthesia.
11513696|NCT01258933|Experimental|Ofatumumab|Ofatumumab 300 mg dose 1, then 1,000 mg weekly * 7, (treatment) then 1,000 mg every 2 months beginning on week 12 for a total of 2 years of treatment or until progression (maintenance) of disease. The follow-up period will be the period after completion of maintenance.
11513697|NCT01258920|Experimental|Paliperidone palmitate|Paliperidone palmitate Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
11513698|NCT01258907|Experimental|A|
11513699|NCT01258907|Experimental|B|
11513700|NCT01258907|Placebo Comparator|C|
11513701|NCT01258868|Experimental|1|Celebrex+ tumor cell vaccine
11513702|NCT01258855|Experimental|Arm I (ziv-aflibercept and aldesleukin)|Patients receive ziv-aflibercept IV over at least 1 hour in weeks 1, 3, 5, and 7 (and in week 9 of course 1 only) and high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in weeks 1 and 3 (and in weeks 3 and 5 of course 1 only). Treatment repeats every 8 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising ziv-aflibercept IV on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11513703|NCT01258855|Experimental|Arm II (aldesleukin)|Patients receive high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in weeks 1 and 3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11513704|NCT01258842|Experimental|B. lactis HN019|
11513705|NCT01258842|Placebo Comparator|Placebo|
11513706|NCT01258829|Experimental|Non-invasive haemodynamic optimisation|Optimization of pressure production by the heart, as measured by systolic blood pressure in the systemic circulation
11513707|NCT01258829|Active Comparator|ECHO optimisation|Optimization of AV/VV delay using the guideline recommendations
11513708|NCT01258803|Experimental|Sequence 1|Treatment Period 1: Placebo MDI with spacer; Treatment Period 2: MF/F MDI without spacer; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: F DPI
11513709|NCT01258803|Experimental|Sequence 2|Treatment Period 1: F DPI; Treatment Period 2: MF/F MDI without spacer; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: Placebo MDI with spacer
11513710|NCT01258803|Experimental|Sequence 3|Treatment Period 1: MF/F MDI without spacer; Treatment Period 2: F DPI; Treatment Period 3: Placebo MDI with spacer; Treatment Period 4: MF/F MDI with spacer
11513711|NCT01258803|Experimental|Sequence 4|Treatment Period 1: Placebo MDI without spacer; Treatment Period 2: MF/F MDI with spacer; Treatment Period 3: F DPI; Treatment Period 4: MF/F MDI without spacer
11513712|NCT01258803|Experimental|Sequence 5|Treatment Period 1: MF/F MDI without spacer; Treatment Period 2: F DPI; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: Placebo MDI without spacer
11513713|NCT01258803|Experimental|Sequence 6|Treatment Period 1: MF/F MDI with spacer; Treatment Period 2: Placebo MDI without spacer; Treatment Period 3: MF/F MDI without spacer; Treatment Period 4: F DPI
11513714|NCT01258790|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation|Eight sessions of Repetitive Transcranial Magnetic Stimulation, in the form of Continuous Theta Burst Stimulation, was delivered over the Supplementary Motor Area over 2 days using a Sham TMS coil.
11513715|NCT01258790|Experimental|Active Repetitive Transcranial Magnetic Stimulation|Eight sessions of Repetitive Transcranial Magnetic Stimulation, Continuous Theta Burst Stimulation, was delivered over the Supplementary Motor Area over 2 days using an Active Magstim Figure-8 TMS coil.
11513716|NCT01258777|Experimental|001|200 mg golimumab or placebo Single dose of 200 mg subcutaneously
11513717|NCT01258777|Experimental|002|400 mg golimumab or placebo Single dose of 400 mg subcutaneously
11513718|NCT01258764|Active Comparator|Lisinopril|
11513719|NCT01258764|Active Comparator|Hydrochlorothiazide|
11513720|NCT01258751|Experimental|PF-05212377|
11513721|NCT01258738|Active Comparator|etanercept|In Period 1 : Subjects will receive via a prefilled syringe an active dose equivalent to 1.0ml of Etanercept solution once weekly SC once weekly. Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
11513722|NCT01258738|Placebo Comparator|PLACEBO|In Period 1: Subjects will receive in a prefilled syringe with a PLACEBO dose equivalent to 1.0 ml of placebo solution once weekly SC Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
11513723|NCT01258725|Experimental|amnioinfusion|The investigators propose an open trial comparing baseline Doppler waveforms in the uteroplacental and fetal pulmonary circulation in patients presenting with severe, idiopathic olighydramnios (AFI<5, no apparent ethiopathology), managed either with single or with serial amnioinfusions. The patients will be followed up weekly in the fetomaternal unit, Dept. of ObGyn for measuring AFI repeatedly to assess the need for further infusions. These will be carried out when the AFI falls below 5cm again
11513724|NCT01258712|Experimental|1|
11513725|NCT01258712|Placebo Comparator|2|
11513726|NCT01258699|Experimental|3|BK-C-0701 480mg
11513727|NCT01258699|Experimental|2|BK-C-0701 320mg
11513728|NCT01258699|Active Comparator|1|Thioctacid HR tab 600mg
11513729|NCT01258686|Experimental|silymarin, treatment|
11513730|NCT01258686|Placebo Comparator|placebo|
11513731|NCT01258673|Experimental|Fimasartan/HCTZ combination group|
11513732|NCT01258673|Active Comparator|Fimasartan group|
11513733|NCT01258660|Experimental|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
11513734|NCT01258660|Experimental|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
11513735|NCT01258647|Experimental|Feeding group|The feeding group will include 20 mother/infant dyads. The infants will be between 8 and 10 months of age.
11513736|NCT01258634|Other|Pre-op treatment|
11513737|NCT01258621|Experimental|Laparoscopic Distal Pancreatectomy|
11513738|NCT01258608|Experimental|Sorafenib plus mapatumumab|Mapatumumab 30 milligrams (mg)/kilogram (kg) intravenously on Day 1 of each cycle (i.e. every 21 days) plus sorafenib 400 mg orally twice daily continuously in each cycle until radiologic disease progression or unacceptable toxicity
11513742|NCT01258582|Experimental|Oral HIV testing|
11513743|NCT01258582|Active Comparator|Fingerstick HIV testing|
11513749|NCT01258530|Experimental|Treatment A|Over-encapsulated oseltamivir 75 mg (1 capsule)
11513750|NCT01258530|Experimental|Treatment B|oseltamivir 75 mg (1 capsule)
11513751|NCT01258517||group 1, group 2, group 3, group 4|administration of beractant with single lumen ET tube administration of poractant with single lumen ET tube administration of beractant with double lumen ET tube administration of poractant with double lumen ET tube
11513752|NCT01258504||CYP2C9 wild type|"CYP2C9 wild type =extensive metaboliser
~Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19
~Administration of St. Johns Wort: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
11513753|NCT01258504||CYP2C9 mutant|"CYP2C9 *2/*2 or 2*/*3 or *3/*3 = poor metaboliser
~Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19
~Administration of St. Johns Wort: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
11513754|NCT01258478|Experimental|rehabilitation|Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
11513755|NCT01258478|Sham Comparator|usual care|Usual care before surgery is provided
11513756|NCT01258465|Active Comparator|Pivotal Response Training|A naturalistic behavioral intervention designed to facilitate verbal communication.
11513757|NCT01258465|Active Comparator|Picture Exchange Communication System|Pictorially-based behavioral protocol designed to facilitate communication via picture icons.
11513758|NCT01258452|Experimental|CHF 5074 (fed group)|oral tablet, single dose
11513759|NCT01258452|Experimental|CHF 5074 (fasting group)|oral tablet, single dose
11513760|NCT01258439|Active Comparator|1.Raltegravir plus truvada|Raltegravir 400mg twice daily plus truvada 300mg/200mg once daily for 24 weeks
11513761|NCT01258439|Active Comparator|2. ritonavir boosted darunavir plus truvada|Darunavir 800mg with ritonavir 100mg plus truvada 300mg/200mg once daily for 24 weeks
11513762|NCT01258426||Normal, IGT, T2DM|
11513763|NCT01258413|Experimental|Laparoscopic Radical Hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament are removed + pelvic lymphadenectomy
11513764|NCT01258413|Active Comparator|Abdominal radical hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament are removed + pelvic lymphadenectomy
11513765|NCT01258387|Placebo Comparator|GGF2|Seven dosing cohorts: 2 patients randomized to receive 1 GGF2, 1 placebo; if no drug-related dose-limiting toxicities in GGF2-treated patient, other 4 patients in cohort will be randomized (3:1) and dosed
11513766|NCT01258374||Single arm with dual therapy|Dual therapy RAL 400 mg bid + DRV/r 800/100 mg QD
11513767|NCT01258361||The study population|Patients will be recruited during anesthesia consultations carried out before programmed pelvic or visceral surgeries.
11513768|NCT01258348|Experimental|LY573636 +sunitinib|
11513769|NCT01258335|Active Comparator|Omega 3 Fatty acids|"II. Study arms:
~a. Participants in the dry AMD study group will be randomized into two arms with a 4:1 ratio: i. Omega-3-fatty acids 4 gm oral daily (Total:840mg EPA/2520mg DHA) (1:3 ratio of EPA to DHA) ( 6 capsules fatty acids)"
11513770|NCT01258335|Placebo Comparator|Olive Oil|ii. Placebo oral daily (6 softgel capsules, each contains 1100 mg olive oil)
11513771|NCT01258322|Experimental|pioglitazone|
11513772|NCT01258309|Experimental|1|olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution
11513773|NCT01258309|Active Comparator|2|olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution
11513774|NCT01258296|Active Comparator|Active fentanyl patch|25 mcg/hr fentanyl patch
11513775|NCT01258296|Placebo Comparator|Placebo patch|Inactive patch that resembles treatment patch but contains no drug
11513776|NCT01258283||The study population|See inclusion and exclusion criteria.
11513777|NCT01258270|Active Comparator|(AQUACEL® Ag Surgical Dressing|
11513778|NCT01258270|Active Comparator|Standard island gauze and tape dressing|A standard island dressing consists of adhesive tape and gauze.
11513779|NCT01258257|Active Comparator|Lumbar drain (LD) / Tuohy drain|Intervention: Insertion of a lumbar drain All patients in the LD group receives a lumbar drain during anesthesia required for aneurysm treatment. Drainage of CSF is started after the post-procedural CT scan on day one after aneurysm securement.
11513780|NCT01258257|No Intervention|No Lumbar drain (NoLD)|Patients randomized to the control group should not receive a lumbar drain before the planned control angiography to be performed on day 7 to 10 after SAH. If the patient develops hydrocephalus, and no EVD was placed initially for CSF drainage, a lumbar drain may be installed at the discretion of the local investigator. These patients are analyzed in the intention-to-treat analysis, but are not suitable for per-protocol analysis.
11513781|NCT01258244||Audiovisual feedback on CPR|EMS technicians will receive audiovisual feedback from the ZOLL device on depth, frequency, and interruptions to cardiac compressions
11513782|NCT01258231||Cardiac surgery|Adult patients undergoing cardiac surgery
11513783|NCT01258218||Accent MRI Group|
11513784|NCT01258205|Experimental|Part B|One dose level of AMG 139 administered as a multiple doses IV in subjects with mild-severe Crohn's disease.
11513785|NCT01258205|Experimental|Part A|Three dose levels of AMG 139 administered as a multiple doses IV or SC in healthy subjects.
11513786|NCT01258192|Experimental|nab-paclitaxel plus cisplatin|
11513787|NCT01258179||Sepsis Group|Patients suffering from sepsis in the postoperative course after major abdominal surgery
11513788|NCT01258179||Control Group|Patients without suffering sepsis during postoperative follow up after major abdominal surgery
11513789|NCT01258166||Tramuatic ulnar translocation|Patients who suffered a traumatic ulnar translocation following injury.
11513790|NCT01258153|Experimental|Nepadutant Low Dose|
11513791|NCT01258153|Experimental|Nepadutant High Dose|
11513792|NCT01258153|Placebo Comparator|Placebo|
11513793|NCT01258140|Active Comparator|1|Patients examined with normal-dose Computed tomography pulmonary angiography
11513794|NCT01258140|Active Comparator|2|Patients examined with low-dose Computed tomography pulmonary angiography
11513841|NCT01257828|Placebo Comparator|Placebo|Placebo medication and decompressive cervical spine surgery
11513842|NCT01257828|Experimental|Riluzole|Riluzole in dose 50mg BID for 14 days prior to surgery and 28 days after the decompressive spine surgery
11513843|NCT01257815|Experimental|Ranibizumab 0.5mg|
11513795|NCT01258127||Pemetrexed and Carboplatin|For patients in arm pemetrexed/carboplatin, folic acid (350-1000 μg) must be given daily beginning approximately 5-7 days prior to first dose of pemetrexed and continuing daily until 3 weeks after the last dose of study therapy. Vitamin B12 (1000 μg) will be administered as an intramuscular injection approximately 1 to 2 weeks prior to first dose of pemetrexed and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy. Dexamethasone (4 mg of oral or equivalent) given twice daily should be taken on the day before, the day of, and the day after each dose of pemetrexed, for rash prophylaxis unless medically contraindicated. Patients must receive pemetrexed at day 1 at the dose of 500 mg/m2 as an IV infusion over approximately 10 minutes, then carboplatin target area under the concentration curve (AUC) 6 (i.v. infusion over 30 minutes) on day 1 of a 21-day cycle. A total of four cycles is intended.
11513796|NCT01258127||Vinorelbine and Carboplatin|Patients in arm vinorelbine and carboplatin follow the regimen: The scheduled infusion time is 6-10 minutes for IV vinorelbine at the dose of 25 mg/m2 d1,8, then carboplatin target area under the concentration curve (AUC) 6 (i.v. infusion over 30 minutes) on day 1 of a 21-day cycle. A total of four cycles is intended.
11513797|NCT01258114|Active Comparator|SPA treatment (ST)|"Drug : spa treatment during 18 days soon after randomization the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises) ;
~nutritional counseling (french nutritional recommendations booklet) ;
~caloric restriction and physical training on demand (non mandatory)."
11513798|NCT01258114|Sham Comparator|Non SPA treatment (NST)|"Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)"
11513799|NCT01258101|Experimental|Peginterferon/Ribavirin 800 mg (24 Weeks)|Participants received peginterferon alfa-2a (PEG-IFNα-2a) 180 mcg once weekly + Ribavirin 800 mg daily for 24 weeks (W).
11513800|NCT01258101|Experimental|Peginterferon/Ribavirin 400 mg (24 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 400 mg daily for 24 W.
11513801|NCT01258101|Experimental|Peginterferon/Ribavirin 800 mg (16 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 800 mg daily for 16 W.
11513802|NCT01258101|Experimental|Peginterferon/Ribavirin 400 mg (16 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 400 mg daily for 16 W.
11513803|NCT01258088|Active Comparator|Cohort 1: AN2728 Ointment|
11513804|NCT01258088|Placebo Comparator|Cohort 1: AN2728 Vehicle|
11513805|NCT01258088|Active Comparator|Cohort 3: AN2728 Ointment|
11513806|NCT01258088|Placebo Comparator|Cohort 3: AN2728 Vehicle|
11513807|NCT01258075|Experimental|Colesevelam|High-dose colesevelam suspended in a drink for oral administration once daily with dinner
11513808|NCT01258075|Experimental|Placebo proxy|Low-dose colesevelam suspended in a drink for oral administration once daily with dinner
11513809|NCT01258062|Experimental|of GelVac™ nasal powder H5N1 influenza vaccine.|
11513810|NCT01258062|Placebo Comparator|Placebo|
11513811|NCT01258049|Experimental|ArTiMist|
11513812|NCT01258049|Active Comparator|Quinine|
11513813|NCT01258036||Fractured Mothers|Fractured Mothers and their daughters
11513814|NCT01258036||Non fractured mothers|Mothers non fractured and their daughters
11513815|NCT01258023|Experimental|transplant recipients|Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation
11513816|NCT01258010|Experimental|Tranexamic acid|Study subjects will be randomized to receive a bolus dose of 30 mg/kg of tranexamic acid administered over 30 minutes starting after the induction of anesthesia followed by a continuous intravenous infusion of tranexamic acid of 16 mg/kg/h administered up to 6 hours after surgery.
11513817|NCT01258010|Placebo Comparator|Normal saline (NaCl 0.9%)|Study subjects will be randomized to receive a bolus dose of normal saline (NaCl 0.9%) of equivalent volume administered over 30 minutes starting after the induction of anesthesia followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
11513818|NCT01257997||Healthy subjects|18-49 year old healthy men and women. Free of significant chronic medical illness and illicit substance abuse. Body mass index from 20 to 27.
11513819|NCT01257984|Experimental|Arm 1|
11513820|NCT01257984|Experimental|Arm 2|
11513821|NCT01257971||1|Patients with hypercholesterolaemia
11513822|NCT01257958|Experimental|19 nor vitamin d|
11513823|NCT01257945|Experimental|Flexibility & Function|Subjects take part in an exercise program based on flexibility and function.
11513824|NCT01257945|Experimental|Aerobic Exercise|Subjects will take part in an aerobic exercise program
11513825|NCT01257945|Other|Home exercise|Standard of care home exercise program
11513826|NCT01257932||Diagnostic Tool|Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
11513827|NCT01257919|Experimental|Azelaic Acid Foam 15%|Dermal application of Azelaic Acid Foam 15%
11513828|NCT01257919|Active Comparator|Azelaic Acid Gel 15%|Dermal application of Azelaic Acid Gel 15%
11513829|NCT01257906|Experimental|CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL|Topical Gel Test Product
11513830|NCT01257906|Active Comparator|ZIANA®|Topical Gel Reference Product
11513831|NCT01257906|Placebo Comparator|Vehicle Control|Topical Gel Placebo
11513832|NCT01257893|Experimental|Aspirin 81 mg|Subjects will take 81 mg aspirin per day for 10-14 consecutive days
11513833|NCT01257893|Placebo Comparator|Placebo|Subjects will take matching placebo capsule (excipient: methylcellulose) for 10-14 consecutive days.
11513834|NCT01257880||Control (absence of PFO)|Persons who have migraine aura and no evidence of PFO, based on transcranial Doppler evaluation.
11513835|NCT01257880||Large PFO|Persons who have migraine aura and large PFO, as assessed by transcranial Doppler evaluation.
11513836|NCT01257867|Experimental|Lithia spring water|Lithia water (active) for 4 weeks then placebo water for 4 weeks
11513837|NCT01257867|Placebo Comparator|Natural spring water|Placebo water for 4 weeks then lithia water (active) for 4 weeks
11513838|NCT01257854||Busulfan, pharmacogenetic, pharmacokinetic, children|Children who receive Busulfan IV and have a pharmacokinetic of Busulfan
11513839|NCT01257841|Placebo Comparator|Fasting alone|
11513840|NCT01257841|Active Comparator|Fasting plus leptin|
11513844|NCT01257802|Active Comparator|LUPRON|Monthly depot leuprolide acetate 3.75 mg injection during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
11513845|NCT01257802|Placebo Comparator|Placebo|Monthly placebo injection during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses.
11513846|NCT01257789||gastric bypass patients|Consecutive series of 300 patients undergoing laparoscopic gastric bypass
11513847|NCT01257776|Active Comparator|Mesenchymal stem cells 0,5 million * weight (kg)|Group of low dose of Mesenchymal stem cells.
11513848|NCT01257776|Active Comparator|Mesenchymal stem cells 1 million * weight (kg)|Group of mid dose of mesenchymal stem cells
11513849|NCT01257776|No Intervention|Controlled group|Controlled group with no intervention
11513850|NCT01257763|Experimental|Study device|The study device is a transdermal microneedle array designed to introduce microscopic channels into the skin. The study device arm will receive application of this device.
11513851|NCT01257763|Sham Comparator|Sham device|The sham device will be very similar in appearance to the study device. The sham device arm will receive application of this device.
11513852|NCT01257750|Experimental|Pazopanib|This is a single site, open label, safety and efficacy study of pazopanib (5mg/ml) where all 20 patients with corneal neovascularization in a single arm will receive pazopanib in one eye.
11513853|NCT01257737|Experimental|HPN-100|Participants continued HPN-100 treatment after completion of HPN-100-005SE, HPN-100-007, or HPN-100-012SE.
11513854|NCT01257724|Experimental|Full-serve evidence service|"The full-serve evidence service consists of:
~an online searchable database of HIV-relevant systematic reviews;
~monthly email updates highlighting new reviews;
~access to user-friendly summaries produced by us or by others (when available);
~links to scientific abstracts;
~peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;
~an interface for participants to leave comments in the records of systematic reviews in the database;
~links to full-text articles (when publicly available); and
~access to worksheets that help CBOs find and use research evidence"
11513855|NCT01257724|Active Comparator|Self-serve evidence service|Organizations allocated to the control group will only be provided website access to a listing of systematic reviews that are organized by year of publication with links to the record on PubMed (or another publicly available source when not available on PubMed) and access to worksheets that help community-based organizations find and use research evidence.
11513856|NCT01257711|Other|Radical Distal Subtotal Gastrectomy|Following the removal of the stomach, patient will be randomised to restore the continuity of the intestine with the stomach using either of the two procedure named Roux-en-Y or Billroth II reconstruction by randomisation
11513857|NCT01257698|Active Comparator|Dorzolamide-timolol topical drops|
11513858|NCT01257698|No Intervention|Standard of care|
11513859|NCT01257685||Control Group|Normal group
11513860|NCT01257685||NAFLD Group|NAFLD in the present study was defined a value of LAI <5 HU using an unenhaned CT.
11513861|NCT01257672|Experimental|ondansetron|ondansetron, syrup, 0,15 mg/Kg of body weight, 1 dose
11513862|NCT01257672|Active Comparator|domperidon|domperidone, syrup, 0,5 mg/Kg of body weight, one dose
11513863|NCT01257672|Placebo Comparator|placebo|placebo, syrup, one dose
11513864|NCT01257659|Experimental|STARR arm|In this group of patients, the STARR transanal stapling system is used to treat the rectocele.
11513865|NCT01257659|Active Comparator|Elevate arm|In this group of patients, a posterior Elevate mesh is placed transvaginally to treat the rectocele.
11513866|NCT01257646||Recent stroke group|These patients have hemiplegia following a stroke within the last 6 months
11513867|NCT01257646||Old stroke group|The patients have hemiplegia following a stroke that took place at least a year ago
11513868|NCT01257633||The study population|Laryngeal cancer patients requiring surgical tumor resection.
11513869|NCT01257620|Placebo Comparator|Placebo|Placebo
11513870|NCT01257620|Experimental|Probiotic|Life Start Two
11513871|NCT01257607|Experimental|1% MIM-D3 Ophthalmic Solution|
11513872|NCT01257607|Experimental|5% MIM-D3 Ophthalmic Solution|
11513873|NCT01257607|Placebo Comparator|Placebo Ophthalmic Solution|
11513874|NCT01257594|Experimental|No cytoreductive surgery planned|Patients who are not candidates for surgery as part of their routine care will enroll into the medical arm of the trial. They will initiate pulsatile erlotinib dosing and continue therapy until either disease progression or intolerable toxicity.
11513875|NCT01257594|Experimental|Cytoreductive surgery planned|"Patients scheduled for salvage resection as part of their routine care will be considered for this cohort. They will receive 1 pre-operative dose of 2000 mg erlotinib. Resection will occur ≤ 3 hours after the pre-operative dose. After recovery from surgery, patients will resume pulsatile erlotinib dosing."
11513876|NCT01257581|Experimental|Creatine 30gm|"Creatine will be taken as a powder mixed into food or liquid twice a day. Volunteers in this arm will take a total of 30gm of creatine per day for 38 weeks. Volunteers will also take placebo capsules twice a day for 38 weeks.
~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.
~Creatine is a nutritional supplement and is not approved by the U.S. Food and Drug Administration (FDA) for treating ALS."
11513877|NCT01257581|Experimental|Tamoxifen 40mg|"Tamoxifen will be taken as capsules twice a day. Volunteers in this arm will take a total of 40mg of tamoxifen per day for 38 weeks. Volunteers will also take placebo powder twice a day for 38 weeks.
~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.
~Tamoxifen is approved by the U.S. Food and Drug Administration (FDA) for breast cancer treatment but is not approved for treating ALS."
11513878|NCT01257581|Experimental|Tamoxifen 80mg|"Tamoxifen will be taken as capsules twice a day. Volunteers in this arm will take a total of 80mg of tamoxifen per day for 38 weeks. Volunteers will also take placebo powder twice a day for 38 weeks.
~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.
~Tamoxifen is approved by the U.S. Food and Drug Administration (FDA) for breast cancer treatment but is not approved for treating ALS."
11513879|NCT01257568|Other|Rejuvenate Modular Hip System|Rejuvenate Modular Hip
11513880|NCT01257555||Treatment Group|
11513882|NCT01257542|Placebo Comparator|Placebo|
11513883|NCT01257529|Experimental|Pregabalin controlled release, 330 mg, low-fat|
11513884|NCT01257529|Experimental|Pregabalin controlled release, 330 mg, medium-fat|
11513885|NCT01257529|Experimental|Pregabalin controlled release, 330 mg, high-fat|
11513886|NCT01257529|Other|Pregabalin immediate release, 300 mg|Reference Treatment
11513887|NCT01257516|Other|Pregabalin immediate release, 300 mg|Reference Treatment
11513888|NCT01257516|Experimental|Pregabalin controlled release, 330 mg|
11513889|NCT01257503|Experimental|Homeopathic cold remedy|5 ml of homeopathic cold remedy given by mouth up to 6 times per day as needed for cold symptoms
11513890|NCT01257503|Placebo Comparator|placebo|5 ml of placebo given by mouth up to 6 times per day as needed for cold symptoms
11513891|NCT01257490|Experimental|Intensive counseling|4 sessions of intensive counseling plus bupropion
11513892|NCT01257490|Active Comparator|Brief Counseling|Brief physician advice to quit plus bupropion
11513893|NCT01257464|Active Comparator|Sitagliptin|
11513894|NCT01257464|Placebo Comparator|Placebo|
11513895|NCT01257451|Experimental|Vildagliptin|
11513896|NCT01257451|Placebo Comparator|Placebo|
11513897|NCT01257438|Experimental|Fluency Plus Endovascular Stent Graft|Fluency Plus Endovascular Stent Graft
11513898|NCT01257438|Active Comparator|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty only
11513899|NCT01257425|Other|Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.|
11513900|NCT01257425|Other|Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.|
11513901|NCT01257412|Experimental|1|
11513902|NCT01257412|Experimental|2|
11513903|NCT01257412|Placebo Comparator|3|
11513904|NCT01257399|Experimental|Asacol®|Import Mesalazine
11513905|NCT01257399|Active Comparator|Mesalazine|Marketed Mesalazine
11513906|NCT01257386|Experimental|Asacol®|Import Mesalazine
11513907|NCT01257386|Active Comparator|Mesalazine|Marketed Mesalazine
11513908|NCT01257373||patiens with Firebird 2 stent|The group of 1300 patients, in which only Fireibrd2 stent is implanted, will be collected. All inclusive patients should be definitely diagnosed type 2 diabetic mellitus （DM）, either before or during the present hospitalization and with complex coronary lesion.
11513909|NCT01257347|Other|Concealment (control)|Clinicians in the control arm will not receive any electronically-monitored medication adherence information (collected via MedSignals pillbox) at the 1-month visit and will be expected to manage hypertension according to their usual care.
11513910|NCT01257347|Experimental|Disclosure (intervention)|"Disclosure of adherence report to clinician:
~At clinic visits with patients with uncontrolled hypertension, clinicians in the intervention arm were provided with a quantitative summary of their patients' electronic adherence to antihypertensive medications (collected via MedSignals pillbox)."
11513911|NCT01257334|Experimental|Treatment Group|BI 10773 10 mg, 25 mg administered once daily
11513912|NCT01257334|Placebo Comparator|Control Group|Placebo administered once daily
11513913|NCT01257321||post tonsillectomy|children
11513914|NCT01257295|Placebo Comparator|control|No additions of fiber to a breakfast meal
11513915|NCT01257295|Active Comparator|low viscous, low gelling|low viscous, low gelling fibre added to breakfast meal
11513916|NCT01257295|Active Comparator|high viscous, low gelling|high viscous, low gelling fibre added to breakfast meal
11513917|NCT01257295|Active Comparator|low viscous, high gelling|low viscous, high gelling fibre added to breakfast meal
11513918|NCT01257295|Active Comparator|high viscous, high gelling|high viscous, high gelling fibre added to breakfast meal
11513919|NCT01257295|Active Comparator|fibre supplement|high viscous, high gelling fibre is added, not to the breakfast meal, but as supplement
11513920|NCT01257269||1|Patients with confirmed hereditary TTP due to congenital ADAMTS13 deficiency
11513921|NCT01257269||2|Family members of patients with confirmed hereditary TTP
11513922|NCT01257256||infertile patients|male infertile patients(ICD-9:606),female infertile patients(ICD-9:628)
11513923|NCT01257243|Experimental|DRUG 1|Syrup of oxomemazine, guaifenesin and potassium iodate
11513924|NCT01257243|Active Comparator|DRUG 2|Syrup of guaifenesin
11513925|NCT01257230|Placebo Comparator|placebo|once daily, delivered with Respimat inhaler
11513926|NCT01257230|Experimental|tiotropium low dose|once daily, delivered with Respimat inhaler
11513927|NCT01257230|Experimental|tiotropium high dose|once daily, delivered with Respimat inhaler
11513928|NCT01257217|Experimental|ReSTOR +3|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1 or AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT, lens assignment and model determined by preoperative keratometric astigmatism, bilateral implantation
11513929|NCT01257217|Active Comparator|Acri.LISA|Acri.LISA® 366D IOL or Acri.LISA® 466TD Toric IOL, lens assignment determined by preoperative keratometric astigmatism, bilateral implantation
11513930|NCT01257204|Active Comparator|Control|Placebo + Pegylated interferon alfa-2a + Ribavirin
11513931|NCT01257204|Experimental|12 Week Cohort|Daclatasvir + Pegylated interferon alfa-2a + Ribavirin
11513932|NCT01257204|Experimental|16 Week Cohort|Daclatasvir + Pegylated interferon alfa-2a + Ribavirin
11513933|NCT01257191|Experimental|Carbon Black|
11513934|NCT01257191|Experimental|Diesel Exhaust Particles|
11513935|NCT01257191|Experimental|Fine Concentrated Ambient Particles|
11513936|NCT01257191|Experimental|Ultrafine Concentrated Ambient Particles|
11513937|NCT01257191|Placebo Comparator|Placebo|
11513938|NCT01257178|Experimental|Normal hepatic function|6mg, oral, once on day 1
11513939|NCT01257178|Experimental|Mild hepatic impairment|6 mg, oral, once on day 1
11513940|NCT01257178|Experimental|Moderate hepatic impairment|6 mg, oral, once on day 1
11513941|NCT01257178|Experimental|Severe hepatic impairment|6 mg, oral, once on day 1
11513942|NCT01257165|Experimental|Zopiclone 5 mg|Zopiclone 5 mg pill + placebo pill + placebo drink
11513943|NCT01257165|Experimental|Zopiclone 10 mg|2 x zopiclone 5 mg pills + placebo drink
11513944|NCT01257165|Active Comparator|Ethanol 0.8 g/L|2 x placebo pills + ethanol 50 g/70 kg
11513945|NCT01257165|Placebo Comparator|Placebo|2 x placebo pills + placebo drink
11513946|NCT01257139|No Intervention|dual-agent therapy or docetaxel alone|dual-agent therapy based on Carboplatin (Carboplatin-Pemetrexed for non epidermoid forms, Carboplatin-Gemcitabin for epidermoid forms) or Docetaxel alone, according to PS or age
11513947|NCT01257139|Experimental|dual-agent therapy or docetaxel or best supportive care|dual-agent therapy based on Carboplatin (Carboplatin-Pemetrexed for non epidermoid forms, Carboplatin-Gemcitabin for epidermoid forms) or Docetaxel alone, or best supportive care, allocated on the basis of a simplified geriatric scale, plus a more thorough geriatric evaluation if necessary
11513948|NCT01257126|Experimental|diclofenac potassium|
11513949|NCT01257126|Active Comparator|nimesulide|
11513950|NCT01257113|Experimental|supervised exercise|The group gets 10 supervised exerciseclasses at the physiotherapy clinic in addition to homebased exercises
11513951|NCT01257113|Experimental|homebased exercises|The group gets 1 supervised exerciseclass before they do all their exercises at home
11513952|NCT01257100||Cases with NPC|Cases with NPC
11513953|NCT01257100||Hospital based controls|Hospital based controls
11513954|NCT01257087|Experimental|Intensive glycaemic control|Intensive glycaemic control All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
11513955|NCT01257087|Active Comparator|Conservative glycaemic control|Conservative glycaemic control All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
11513956|NCT01257074|Experimental|Drug 1|Penciclovir 10mg/g
11513957|NCT01257074|Active Comparator|Drug 2|Acyclovir 50mg/g
11513958|NCT01257061|Experimental|Group 1|Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g
11513959|NCT01257061|Active Comparator|Group 2|Dexchlorpheniramine maleate 10 mg/g
11513960|NCT01257048|Placebo Comparator|1|Single Dose evaluation placebo (V5)
11513961|NCT01257048|Active Comparator|2|Single Dose evaluation formoterol (V5)
11513962|NCT01257035||18F-FAZA-PET/CT|
11513963|NCT01257022|Experimental|Family Function Intervention|Familias Unidas Intervention Program
11513964|NCT01257022|No Intervention|Treatment as Usual|Control
11513965|NCT01257009|Other|1|Arm 1: cessation of any statin therapy for at least 6 weeks, then the first sympathetic activity measurement will be done.Subsequently, atorvastatin 20mg is added for 6 weeks. Then the second sympathetic measurement will be performed.
11513966|NCT01257009|Other|2|Patients will receive atorvastatin for 6 weeks, then the first sympathetic measurement will be done. Then atorvastatin will be stopped and 6 weeks the second measurement will be done
11513967|NCT01256996|Experimental|Low-abrasive powder|
11513968|NCT01256983|Experimental|Bright Light Therapy|Bright Light Therapy with 10000 lux beginning at day 21 until day 42
11513969|NCT01256983|Other|Wait-list intervention|Wait-list design Intervention. Bright Light Therapy with 10000 lux beginning at day 63 until day 84, when the 9 study weeks were over.
11513970|NCT01256970||Polycystic Ovary Syndrome.|Polycystic ovary syndrome was diagnosed according to the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria: PCOM, chronic anovulation and hyperandrogenism.
11513971|NCT01256970||Normal Control|Normal control women were women who did not present with any of three PCOS criteria.
11513972|NCT01256957|Active Comparator|Indoor air HEPA filtration|HEPA filters operating in the participant's bedroom and living room.
11513973|NCT01256957|No Intervention|Control|Control
11513974|NCT01256944||Control|The normal reproductive-aged women
11513975|NCT01256944||PCOS|"Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:
~Oligo- or anovulation
~Clinical and/or biochemical signs of hyperandrogenism
~Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)"
11513976|NCT01256931||organ transplant patients|
11513977|NCT01256931||healthy controls|
11513978|NCT01256879|Experimental|CimTest-A|200mg cimetidine (as 2 capsules)
11513979|NCT01256879|Experimental|CimTest-B|200mg cimetidine (as 2 capsules)
11513980|NCT01256879|Active Comparator|Sorbitol-free cimetidine solution|200mg cimetidine (as oral liquid)
11513981|NCT01256879|Experimental|Commercial cimetidine solution|200mg cimetidine (as oral liquid)
11513982|NCT01256866|Active Comparator|DEXMEDETOMIDINE, SEDATION|
11513983|NCT01256866|Active Comparator|Midazolam, sedation,|
11513984|NCT01256853|Experimental|MVA Vaccine|
11513985|NCT01256840||Calorie Restricting Group|
11513986|NCT01256840||Normal-eating controls|
11513987|NCT01256840||Obese comparison group|
11513988|NCT01256827||ranibizumab in MARINA/ANCHOR|Exudative AMD patients previously enrolled in the ranibizumab treatment arms of the MARINA or ANCHOR studies with subsequent enrollment into the HORIZON extension study.
11513989|NCT01256814|Experimental|Behaviorial Intervention|SystemCHANGE-HIV is a 10-week, small-group intervention that will promote behavior changes to improve the following: physical activity, sleep behaviors and mental wellness. S
11513990|NCT01256814|Active Comparator|Control|"The control group will receive the manual Symptom Management Manual: Strategies for People Living with HIV/AIDS."
11513991|NCT01256801||cytokine|The patients are randomized to receive the cytokine infusion in the pleural cavity
11513992|NCT01256788|Experimental|Viscosupplementation|Hyaluronic acid injection
11513993|NCT01256788|Placebo Comparator|Saline injection|
11513994|NCT01256775|Placebo Comparator|NCX4016 placebo|NCX4016 placebo b.i.d for 6 months
11513995|NCT01256775|Active Comparator|NCX4016|ncx4016,800 mg b.i.d., on top of aspirin 100 mg o.d.
11513996|NCT01256762|Experimental|Imetelstat + Paclitaxel (with or without bevacizumab)|
11513997|NCT01256762|Experimental|Paclitaxel (with or without bevacizumab) alone|
11513998|NCT01256736|Experimental|Tocilizumab 8mg/kg + DMARDs|
11513999|NCT01256723||J-LESSON Central committee|
11514000|NCT01256710||Trifecta Valve Group|
11514001|NCT01256697|Experimental|Alga Dunaliella Bardawil|
11514002|NCT01256697|Placebo Comparator|Sugar pill|
11514003|NCT01256684|Placebo Comparator|Placebo|
11514006|NCT01256671|Experimental|DHEA|0.5% DHEA (intravaginal)
11514007|NCT01256658|Experimental|Intervention|Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.
11514008|NCT01256658|Experimental|Control|Participants received COA566 treatment for symptomatic malaria episodes only.
11514009|NCT01256645|No Intervention|restrictive transfusion|No transfusion given to correct anemia unless vital indication is given
11514010|NCT01256645|Experimental|liberal transfusion|transfusions are given in single units until Hb is > 12 mg/dl
11514011|NCT01256632|Active Comparator|Subfoveal CNV, secondary to AMD with PVD|20 eyes with Subfoveal Choroidal Neovascularization, secondary to Age Related Macular Degeneration, with Posterior Vitreous Detachment (PVD Positive). All study eyes will receive 0.5mg, of intravitreous monthly injections of Ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
11514012|NCT01256632|Active Comparator|Subfoveal CNV, secondary to AMD w/o PVD|20 eyes with Subfoveal Choroidal Neovascularization, secondary to Age Related Macular Degeneration, without Posterior Vitreous Detachment (PVD Negative). All study eyes will receive 0.5mg, of intravitreous monthly injections of Ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after the first 4 injections, will be on an as needed basis, based on predefined criteria.
11514013|NCT01256619|Active Comparator|marvelon|
11514014|NCT01256606||Positive for fetal aneuploidy|
11514015|NCT01256606||Negative for fetal aneuploidy|
11514016|NCT01256593||Pregabalin (Lyrica) capsule|"Patients administered Pregabalin capsule."
11514017|NCT01256580|Active Comparator|Monotherapy|Bevacizumab (Avastin; Genentech, Inc.)1.25 mg by intravitreal injection on day 0 and then prn (as-needed) based on ophthalmic examination and OCT findings
11514018|NCT01256580|Active Comparator|Combination therapy|Intravitreal injection of bevacizumab 1.25 mg (Avastin; Genentech, Inc.) combined with reduced fluence PDT(Visudyne®; Novartis,) and 200 ug of intravitreal dexamethasone(4mg/ml, American regent, Inc) on Day 0 and then monthly retreatment with bevacizumab as-needed and triple therapy every 3 months as-needed.
11514019|NCT01256567|Experimental|ramucirumab and docetaxel combination|
11514020|NCT01256554|Experimental|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation. Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
11514021|NCT01256541|Experimental|Kristalose|Kristalose as Bowel Evacuant
11514022|NCT01256528|Experimental|Delayed Breast Reconstruction|Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
11514023|NCT01256515|Experimental|Health Education Training Group 1|One form of health education training
11514024|NCT01256515|Active Comparator|Health Education Training Group 2|Another form of health education training
11514025|NCT01256502|Other|Implanted Participants|Participants with breast reconstruction surgery implanted with SERI® Surgical Scaffold.
11514026|NCT01256489|Other|Infliximab|Every patient enrolled in the study will receive monthly infusions of Infliximab throughout the term of the study. Infliximab will be administered intravenously.
11514027|NCT01256476|Experimental|pitavastatin 4 mg once daily (QD)|
11514028|NCT01256476|Active Comparator|pravastatin 40 mg once daily (QD)|
11514029|NCT01256463|No Intervention|Comparison|
11514030|NCT01256463|Experimental|HIV prevention intervention|The HIV prevention intervention will be delivered to HIV-seropositive patients in HIV care and treatment clinics during all routine visits. Health care providers (including physicians, clinical officers, and nurses) will deliver HIV prevention messages on correct and consistent condom use, disclosure of serostatus, partner HIV testing, adherence and alcohol reduction during clinic visits. Health care providers will also assess and treat sexually transmitted infections (STIs), and provide basic contraceptives and brief safer pregnancy counseling.
11514031|NCT01256450|Experimental|BEMA Buprenorphine|buprenorphine buccal soluble film
11514032|NCT01256450|Placebo Comparator|BEMA Placebo|placebo buccal soluble film
11514033|NCT01256437|Experimental|ointment Threolone|Treatment with topical application of combined anti inflammatory and anti bacterial agent.
11514034|NCT01256437|Active Comparator|ointment Synthomycine|ointment once daily for 1 month
11514035|NCT01256437|Placebo Comparator|Aqua cream|
11514036|NCT01256424|Experimental|HAL 5% with illumination|HAL PDT 5%
11514037|NCT01256424|Experimental|HAL 1% with illumination|HAL PDT 1%
11514038|NCT01256424|Experimental|HAL 0.2% with illumination|HAL PDT 0.2%
11514039|NCT01256424|Placebo Comparator|Placebo ointment without illumination|Placebo without illumination
11514040|NCT01256411|Experimental|LCZ696|
11514041|NCT01256398|Experimental|Treatment (chemotherapy, transplant)|See Detailed Description
11514042|NCT01256385|Experimental|Arm A (cetuximab and temsirolimus)|Patients receive temsirolimus IV over 30-60 minutes and cetuximab IV over 1-2 hours once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11514043|NCT01256385|Experimental|Arm B (temsirolimus)|Patients receive temsirolimus as in Arm A. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over to Arm A.
11514044|NCT01256372|Experimental|AP214; dose-level 1|AP214; dose-level 1
11514045|NCT01256372|Experimental|AP214; dose-level 2|AP214; dose-level 2
11514046|NCT01256372|Placebo Comparator|Placebo to AP214|Placebo
11514047|NCT01256359|Experimental|Docetaxel and AZD6244|Docetaxel with AZD6244
11514048|NCT01256359|Experimental|Docetaxel and Placebo|Docetaxel without AZD6244
11514049|NCT01256346||Babies|Preterm newborn infants thought to be 24-32 weeks gestational age.
11514050|NCT01256320|No Intervention|Control Group|no shell egg consumption and usual dietary practices
11514189|NCT01255397|Experimental|Male Infertility Protocol|
11514051|NCT01256320|Active Comparator|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
11514052|NCT01256320|Active Comparator|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
11514053|NCT01256307|Experimental|training group|training and educational program
11514054|NCT01256307|Other|control group|
11514055|NCT01256294|Experimental|Sequence 1 - Branded Tacrolimus / Generic Tacrolimus|In Period 1 (Days 1-14) participants received branded tacrolimus (Prograf) orally twice a day and in Period 2 (Days 15 - 28) participants received generic tacrolimus (Sandoz) orally twice a day. Participants received the same stable dosage of tacrolimus they had been taking prior to enrollment (on a milligram for milligram basis).
11514056|NCT01256294|Active Comparator|Sequence 2 - Generic Tacrolimus / Branded Tacrolimus|In Period 1 (Days 1 - 14) participants received generic tacrolimus (Sandoz) orally twice a day and in Period 2 (Days 15 - 28) participants received branded tacrolimus (Prograf) orally twice a day. Participants received the same stable dosage of tacrolimus they had been taking prior to enrollment (on a milligram for milligram basis).
11514057|NCT01256281|Experimental|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
11514058|NCT01256268|Experimental|Endometrial Cancer|Phase 1A + Cohort 1B - Recurrent or Metastatic Endometrial Cancer. Patients with recurrent or metastatic endometrial cancer with up to 1 prior chemotherapy. Ridaforolimus at the Phase 1A MTD and schedule will be administered with paclitaxel at the Phase 1A MTD (175 mg/m2) IV and carboplatin at the phase 1 MTD (AUC 5 to 6) in mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Treatment will continue until disease progression or adverse events prohibit further therapy.
11514059|NCT01256268|Experimental|Ovarian Cancer|Phase 1 A + Cohort 1B - Recurrent or Metastatic Ovarian Cancer. Patients with platinum-sensitive, recurrent ovarian cancer with up to 2 prior chemotherapy regimens. Ridaforolimus at the phase 1A MTD and schedule will be administered with paclitaxel at the phase 1 MTD (175 mg/m2) IV and carboplatin at the phase 1 MTD (AUC 5 to 6) in mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Treatment will continue until disease progression or adverse events prohibit further therapy.
11514060|NCT01256255||influenza infection|Patients with the diagnosis of influenza infection by standard laboratory technique
11514061|NCT01256242|Experimental|Group 1|Standard Suture Repair + Augment Rotator Cuff
11514062|NCT01256242|Active Comparator|Group 2|Standard Suture Repair
11514063|NCT01256229|Experimental|Developmentally delayed - Hearing aids|This arm contains deaf children that have developmental delays and are randomized to be treated with the conventional therapy, hearing aids.
11514064|NCT01256229|Experimental|Developmentally Delayed - Cochlear implant|This arm contains deaf children that have developmental delays and are randomized to be treated with cochlear implantation.
11514065|NCT01256229|Active Comparator|Not developmentally delayed|This control arm contains deaf children that do not have developmental delays and will be treated with cochlear implantation.
11514066|NCT01256216|Other|Signature Custom Cutting Guides|Patients receiving a Vanguard Total Knee implanted utilizing non implantable Signature Cutting Guides Surgical Technique.
11514067|NCT01256216|Other|CAS (Computer Assisted Surgery)|Patients receiving a Vanguard Total Knee implanted utilizing non implantable Computer Assisted Surgery Technique.
11514068|NCT01256203|Experimental|Sunscreen|Solar Protection Formula SPF® 60 will be applied on the skin of each subject. Applications will be followed by photobiological testings to assess skin protection.
11514069|NCT01256190|Experimental|Fibrocaps + Gelatin sponge|Topical Fibrocaps powder followed by application of gelatin sponge
11514070|NCT01256190|Active Comparator|Gelatin Sponge|approved device for surgical bleeding
11514071|NCT01256177|Experimental|1|
11514072|NCT01256177|Placebo Comparator|2|
11514073|NCT01256164|Experimental|Fibrocaps + Gelfoam|After identification of a Target Bleeding Site (TBS), topical Fibrocaps should be applied using the Fibrospray device for general surgeries; and either the Fibrospray device or direct application for spinal and vascular surgeries, followed by application of Gelfoam and manual pressure with sterile gauze.
11514074|NCT01256164|Active Comparator|Gelfoam|Treatment is Gelfoam followed by manual pressure with sterile gauze. If hemostasis is not achieved within 10 minutes of the Start Time,the subject should be considered a treatment failure and the surgeon should implement additional hemostatic measures.
11514075|NCT01256151|Active Comparator|Alprazolam conventional tablet|Alprazolam conventional tablet
11514076|NCT01256151|Experimental|Alprazolam sublingual tablet|Alprazolam sublingual tablet
11514077|NCT01256138||transplantation|
11514078|NCT01256138||control|
11514079|NCT01256125||Allogene MSCs transplantation|Allogene MSCs transplantation were performed in patients with chronic liver diseases through peripheral vein plus the same medical treatments.
11514080|NCT01256125||control|only medical treatments were performed in patients with chronic liver diseases.
11514081|NCT01256112|Experimental|NAE + Behavioral Intervention|Parents of participants receive training in behavioral support at home, in addition to a standard nutrition and physical activity education (NAE) program.
11514082|NCT01256112|Active Comparator|Nutrition/Activity Education|Parents and participants receive a standard nutrition and physical activity education (NAE) program.
11514083|NCT01256099|Experimental|Guided Internet-CBT for insomnia|
11514084|NCT01256099|Placebo Comparator|Control treatment|
11514085|NCT01256099|Experimental|Guided Internet-CBT for insomnia (9)|(9 weeks instead of 8)
11514086|NCT01256099|Active Comparator|Guided Internet-CBT for depression|
11514087|NCT01256086|Experimental|24 µg Formoterol Novolizer|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
11514088|NCT01256086|Experimental|12µg Formoterol Novolizer|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
11514089|NCT01256086|Active Comparator|24 µg Formoterol Aerolizer|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
11514231|NCT01255059||Female lung cancer group|Female, non-smoker, non-small cell lung cancer
11514090|NCT01256086|Active Comparator|12µg Formoterol Aerolizer|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
11514091|NCT01256073|Experimental|IPH2101|
11514092|NCT01256060|Experimental|Intanasal Oxytocin|A modified dose finding method will be used to determine safety among four dose levels for Intranasal Oxytocin. Half the dose (0.2 IU/kg /dose) is the minimum dose and two intermediate doses will also be evaluated (0.26 and 0.33 IU/kg / dose) Dose-finding escalations will be done in groups of three patients.Three patients will be studied at the first dose level. If none of these patients experience dose limiting toxicity, the dose will be escalated. If one experiences dose limiting toxicity, up to three more will be accrued at the same level. If none of these experience dose limiting toxicity, the dose will be escalated. If one or more of these experience dose-limiting toxicity, entry at that dose level will be stopped. Up to three more patients will be treated at the next lower dose. If zero out of these experience dose limiting toxicity, an additional three patients will be treated at that dose.
11514093|NCT01256047|Active Comparator|group A|preoperative immunonutrition
11514094|NCT01256047|No Intervention|group B|ordinary diet
11514095|NCT01256034|Active Comparator|Group A|preoperative immunonutrition
11514096|NCT01256034|No Intervention|Group B|ordinary diet
11514097|NCT01256021|Experimental|Treatment Group 1|Meditoxin
11514098|NCT01256008|Placebo Comparator|stage 1 Clinical Management|The group will receive clinical management treatment only each session.
11514099|NCT01256008|Experimental|stage1 CBT|The experimental group will receive CBT
11514100|NCT01256008|No Intervention|stage1 Control group|Participants with breast cancer in the control group received standard medical care, but don't receive any other interventions.
11514101|NCT01255995||Control Patients|Controls without PXF who require cataract surgery
11514102|NCT01255995||Pseudo Exfoliation patients|PXF subjects with or without glaucoma who require cataract surgery
11514103|NCT01255982||1|Diagnosed with bipolar I or II disorder, and with an acute episode of bipolar depression at inclusion
11514104|NCT01255969|No Intervention|Control|
11514105|NCT01255969|Experimental|Exercise|Patients in this arm will undergo to personalized exercise program.
11514106|NCT01255956|Experimental|Rapamycin eluting stent|Patients treated with rapamycin eluting stent (n=100)
11514107|NCT01255956|Experimental|Paclitaxel eluting balloon catheter|Patients treated with paclitaxel eluting balloon catheter (n=100)
11514108|NCT01255943||prevalent hemodialysis patients|These patients are observed in two outpatient dialysis units with a combined census of approximately 175 patients
11514109|NCT01255917||Chronic pancreatitis|
11514110|NCT01255904|Experimental|Arm 1|Oral Chloral and intranasal placebo
11514111|NCT01255904|Experimental|Arm 2|oral placebo and intranasal dexmedetomidine
11514112|NCT01255891|Other|Adjuvant|Adjuvant suppression plus radiation therapy
11514113|NCT01255878|Experimental|stabilization splint|
11514114|NCT01255878|Experimental|Gabapentine|
11514115|NCT01255865||A1 - up to 1 month|Age group 0 up to 1 month
11514116|NCT01255865||A2 - 1 to 3 months|Age group from 1 month to 3 months
11514117|NCT01255865||A3 - 3 months to 1 year|Age group from 3 months to 1 year
11514118|NCT01255865||B - 1 year to 5 years|Age group from older than 1y and younger than 5 years
11514119|NCT01255865||C - 5 years to 12 years|Age group from older than 5y and younger than 12 years
11514120|NCT01255865||D - 12 years to 21 years|Age group from older than 12 years and younger than 21 years
11514121|NCT01255865||E - 21 years and older|Age group older than 21 years
11514122|NCT01255852|Experimental|Atorvastatin group|Patients in atorvastatin group will received 40 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
11514123|NCT01255852|No Intervention|Control group|Patients in control group will receive 20mg atorvastatin daily treatment.
11514124|NCT01255839|Active Comparator|Double-balloon|The Double Balloon Catheter was applied (Atad 5) with 80 ml NaCl installed intrauterine above the intern orificium and 80 ml below in cervix/vagina.
11514125|NCT01255839|Active Comparator|Prostglandin E2|The prostaglandin 2 minprostin (3mg) was applied vaginally
11514126|NCT01255826|Active Comparator|Sustained lung inflation followed by CPAP|"Sustained pressure-controlled inflation using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher & Paykel, Auckland, New Zealand).
~This will be followed by early CPAP."
11514127|NCT01255826|Active Comparator|Conventional self inflating bag and mask ventilation|Intermittent bag and mask ventilation using a self-inflating bag with an oxygen reservoir.
11514128|NCT01255813|Placebo Comparator|Placebo|
11514129|NCT01255813|Experimental|Sub-perception|
11514130|NCT01255813|Experimental|Full Stimulation|
11514131|NCT01255800|Experimental|IPI-926 and Cetuximab|"Patients will receive Cetuximab IV every week.
~Starting on Day 15 of the first cycle, Patients will take the study drug by mouth every day."
11514132|NCT01255787|Experimental|Placebo|Vortioxetine placebo-matching tablets, orally, once daily for up to 10 weeks.
11514133|NCT01255787|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, tablets, orally, once daily for 8 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily for 2 weeks.
11514134|NCT01255787|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, tablets, orally, once daily for 8 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily for 2 weeks.
11514135|NCT01255787|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, tablets, orally, once daily for 1 week, followed by vortioxetine 20 mg, tablets, orally, once daily for 7 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily, for 2 weeks.
11514136|NCT01255774|Experimental|Ranibizumab|Open Label use of Ranibizumab for wet age related macular degeneration
11514137|NCT01255761|Other|RAPID3 to assess response to Cimzia|"RAPID3 is a subject-based assessment tool used to assess subject's response to Cimzia.
~Subjects will be randomized to a patient measure tool, a tool based on patient-report outcomes (RAPID3); using a total score of 30 points"
11514138|NCT01255761|Other|CDAI to assess response to Cimzia|"CDAI is an investigator-based assessment tool used to assess subject's response to Cimzia.
~Subjects will be randomized to a clinical measures tool, a tool based on Investigator measures without the need for a lab value (CDAI)"
11514325|NCT01254461|Experimental|B|
11514139|NCT01255748||Treatment with Radiation Therapy|Includes 9 different arms to capture patient data by disease site
11514140|NCT01255735||Vocal nodules|Two groups of children who are hoarse and have vocal nodules will be examined to see whether voice therapy is effective as a treatment strategy
11514141|NCT01255722|Experimental|Iobitridol|Patients were IV injected with a single dose of iobitridol before a coronary CT angiography
11514142|NCT01255722|Active Comparator|Iopromide|Patients were IV injected with a single dose of iopromide before a coronary CT angiography
11514143|NCT01255722|Active Comparator|Iomeprol|Patients were IV injected with a single dose of iomeprol before a coronary CT angiography
11514144|NCT01255709|Experimental|Arm T1 Primatene Mist HFA|epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
11514145|NCT01255709|Active Comparator|Arm C Primatene Mist|epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
11514146|NCT01255709|Experimental|Arm T2 Primatene Mist HFA|epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
11514147|NCT01255696|Experimental|ALV003|ALV003 is an orally administered mixture of two recombinant proteases (cysteine endoprotease B-isoform 2 and prolyl endopeptidase) engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues common in gluten.
11514148|NCT01255696|Placebo Comparator|Placebo|Excipients for ALV003 absent the experimental compounds
11514149|NCT01255683||Chronic rhinosinusitis|
11514150|NCT01255670|Active Comparator|penicillin and metronidazole|After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess
11514151|NCT01255670|Placebo Comparator|penicillin and placebo|After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess
11514152|NCT01255657|Experimental|ABT-806 Arm|
11514153|NCT01255644|Experimental|Antiviral drug|
11514154|NCT01255631|Sham Comparator|Sham PEMF device|
11514155|NCT01255631|Active Comparator|PEMF Device|
11514156|NCT01255618||study group, control group|
11514157|NCT01255592|Experimental|1|Treatment arm AZD5069
11514158|NCT01255592|Placebo Comparator|2|Placebo dose.
11514159|NCT01255579|Active Comparator|SF|Extrafine Fluticasone/Salmeterol
11514160|NCT01255579|Active Comparator|FB|Extrafine Formoterol and beclometasone HFA
11514161|NCT01255566||Medical therapy cohort|For patients electing continued medical therapy, medication was prescribed based on the disease process and the judgment of the treating rhinologist. Treatment was not specifically dictated or prescribed by the study protocol.
11514162|NCT01255566||Surgical cohort|For patients electing ESS, surgery was performed by the enrolling rhinologist. In addition, medical management was administered in the perioperative and postoperative periods as dictated by the disease process and the judgment of the treating rhinologist. Treatment was not specifically dictated or prescribed by the study protocol.
11514163|NCT01255527|Active Comparator|Busulfan|
11514164|NCT01255527|Active Comparator|Melphalan|
11514165|NCT01255514|Experimental|VAD|VAD : high dose dexamethasone -> response(CR, PR)-> VAD chemotherapy(vincristine + doxorubicin + dexamethasone)-> PBSC -> aSCT
11514166|NCT01255514|Experimental|PAD|PAD : high dose dexamethasone -> response(MR,NC,PD)-> PAD chemotherapy(bortezomib + doxorubicin + dexamethasone)-> PBSC -> aSCT
11514167|NCT01255501|Experimental|NI-0701|
11514168|NCT01255501|Placebo Comparator|Placebo|
11514169|NCT01255488|Experimental|EBN-Search (without full-text manuscripts)|In the intervention arm research subjects will be provided access to EBN-Search (a fictitious search engine) with nine abstracts relating to the clinical case but no full-text manuscripts.
11514170|NCT01255488|Active Comparator|EBN-Search (with full text manuscripts)|Research subjects will be exposed to 9 abstracts and corresponding full-text manuscripts related to the simulated clinical encounter.
11514171|NCT01255475|Experimental|Intervention|
11514172|NCT01255475|Placebo Comparator|Control|
11514173|NCT01255462|Experimental|LFG316 0.15mg|
11514174|NCT01255462|Experimental|LFG316 0.5mg|
11514175|NCT01255462|Experimental|LFG316 1.5mg|
11514176|NCT01255462|Experimental|LFG316 5mg|
11514177|NCT01255449|Experimental|albuterol|Twenty-six consecutive patients undergoing allogeneic HSCT for hematological malignancies were studied. All patients were in stable clinical conditions at the time of study. All patients received a myeloablative conditioning regimen either including or not including total body irradiation. Spirometry, lung volumes, FOT and lung CT scan were obtained before the start of conditioning treatment and, approximately, two months after HSCT. On each study day, all the above measurements were taken before and 30 min after inhaling four consecutive albuterol doses, of 100 mcg each, through a valved-holding chamber. DLco was measured only after bronchodilator inhalation.
11514178|NCT01255436|Experimental|SMS text reminders|Participants in this arm will receive SMS text messages on top of the usual care they receive from their physicians.
11514179|NCT01255436|Other|Usual Care|Participants in this arm will receive the usual care they receive from their physicians.
11514180|NCT01255423|Experimental|Diclofenac sodium topical gel 1%|
11514181|NCT01255423|Placebo Comparator|Placebo|
11514182|NCT01255410|Experimental|Healthy Adults (Group 1)|Healthy adults will receive a single dose of 10^6 plaque forming unit (PFU) rHMPV-Pa vaccine intranasally.
11514183|NCT01255410|Experimental|Seropositive Children-Vaccine (Group 2)|Seropositive children will receive a single dose of 10^6 PFU rHMPV-Pa vaccine intranasally.
11514184|NCT01255410|Placebo Comparator|Seropositive Children-Placebo (Group 2)|Seropositive children will receive a single dose of placebo vaccine intranasally.
11514185|NCT01255410|Experimental|Seronegative Infants and Children-Vaccine (10^5) (Group 3)|Seronegative infants and children will receive a single dose of 10^5 PFU rHMPV-Pa vaccine intranasally.
11514186|NCT01255410|Placebo Comparator|Seronegative Infants and Children-Placebo (Group 3)|Seronegative infants and children will receive a single dose of placebo vaccine intranasally.
11514187|NCT01255410|Experimental|Seronegative Infants and Children-Vaccine (10^6) (Group 4)|Seronegative infants and children will receive a single dose of 10^6 PFU rHMPV-Pa vaccine intranasally.
11514188|NCT01255410|Placebo Comparator|Seronegative Infants and Children-Placebo (Group 4)|Seronegative infants and children will receive a single dose of placebo vaccine intranasally.
11514190|NCT01255384||Non Diabetic-Controls|Pregnant women with uncomplicated pregnancy will be followed, their offsprings will be evaluated and followed for 5 years
11514191|NCT01255384||Diabetic Pregnancy|Pregnant women followed in the high risk clinic because of diabetes will be followed and their offspring's will be evaluated and followed for 5 years
11514192|NCT01255371|Active Comparator|Arm A : Lopinavir|"Emtricitabine/tenofovir :
~TDF300mg.FTC200mg (Fixed Dose Combination)
~1 tablet per day
~Lopinavir/ritonavir :
~LPV200mg/RTV50mg
~2 tablets twice a day"
11514193|NCT01255371|Experimental|Arm B : Atazanavir|"Lamivudine/tenofovir :
~3TC300mg/TDF300mg (Fixed Dose Combination)
~1 tablet per day
~Atazanavir/ritonavir :
~ATV300mg/RTV100mg
~2 tablets once a day"
11514194|NCT01255358|Experimental|Ery-Dex|Patients treated with monthly treatment of Ery-Dex (dexamethasone sodium phosphate encapsulated in autologous erythrocytes)
11514195|NCT01255345||Adult females with CPP living in Denmark|
11514196|NCT01255332||C13-urea breath test: positive|lansoprazole 30mg bid, amoxicillin 1000mg bid and clarithromycin 500mg bid for 7 days
11514197|NCT01255306||NO IOP|Patients without raised IOP
11514198|NCT01255306||RAISED IOP|Patients with raised IOP
11514199|NCT01255293|Active Comparator|1000 centistoke silicone oil|
11514200|NCT01255293|Active Comparator|5000 centistoke silicone oil|
11514201|NCT01255280|Active Comparator|Information, Motivation, Behavioral skills|The comparison condition will only receive the two IMB risk reduction sessions. The intervention will begin with modules that focus directly with sexual risk reduction practices. It will begin with a discussion of one's sexual history, sexual risk limits, and barriers (e.g., motivation or skills) to staying in their sexual risk limits. This session will also involve a Q&A discussion and the use of a fact sheet regarding HIV acquisition risk behaviors (information). The next session will involve motivational interviewing and the formulation of an individualized behavioral skills plan as needed.
11514202|NCT01255280|Experimental|Behavioral Activation Therapy and Risk Reduction Counseling|This intervention is given to patients in the experimental condition only and is comprised of 10 sessions-1 baseline session focused on orienting and rationale, 2 focused on risk reduction (consistent with the IMB model: information, motivation, and behavioral skills), 6 incorporating behavioral activation therapy/risk reduction counseling, and 1 final session on relapse prevention. Each session will last approximately fifty minutes in length; and will also involve a review of the previous materials,and hence the behavioral activation approach will be woven back into the risk reduction content.
11514203|NCT01255267||Acute coronary syndrome patients|
11514204|NCT01255267||Chronic coronary artery disease patients|
11514205|NCT01255267||Healthy control|
11514206|NCT01255254|Experimental|A: Scaling group|The experimental group will receive oral hygiene instruction (OHI) and full-mouth scaling using standard rigid Gracey curettes (Hu-Friedy® Manufacturing Inc., Chicago, IL, USA) and ultrasonic instrumentation (EMS piezoelectric system, Electro Medical Systems, Nyon, Switzerland) at week 1-2 and at a second reinforcement visit at 6-8 weeks. Subjects will also be instructed to rinse with 10ml of Chlorhexidine 0.2% mouthrinse twice daily for 30 seconds for the duration of the study.
11514207|NCT01255254|No Intervention|B: Control group|The control group will receive no periodontal treatment during the study. After completion of the study, these patients will be given oral hygiene instruction and a full mouth scaling.
11514208|NCT01255241||othopaedic surgical intervention|children with lower limbs deformities
11514209|NCT01255228|Experimental|Low glycemic index diet|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
11514210|NCT01255228|Experimental|diet intervention|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
11514211|NCT01255215|Experimental|Inhaled Nitric Oxide|iNO, a gaseous molecule, will be administered by inhalational route over a maximum period of 72 hours.
11514212|NCT01255215|Placebo Comparator|Room air|Room air will be delivered by air compressor through an indistinguishable mask system.
11514213|NCT01255202||twin preganacies|
11514214|NCT01255189|Experimental|Device: near infrared spectroscopy: invos 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements
11514215|NCT01255176|No Intervention|placebo group|not receive physical therapy intervention, there will only support the achievement of a handbook on the abdomen of the baby.
11514216|NCT01255176|No Intervention|control group|not receive any type of intervention, and infants remain at rest
11514217|NCT01255176|Experimental|Thoracoabdominal rebalancing|infants who receive physical therapy through the application of the handlings of the RTA.
11514218|NCT01255163|Experimental|Exendin-4|Exenatide 5 mcg or 10 mcg SC twice daily
11514219|NCT01255163|Placebo Comparator|Placebo|Placebo SC twice daily
11514220|NCT01255137|Experimental|Adrenal Cortex Neoplasms|Aggressive cancer that starts in the adrenal gland located at the top of the kidneys.
11514221|NCT01255124||Health infants (ClinicalTrials.gov ID: NCT01183611)|The subjects participated in the clinical trial 'The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates' in 2007 (ClinicalTrials.gov ID: NCT01183611).
11514222|NCT01255098||Experimental Group|
11514223|NCT01255098||Control Group|
11514224|NCT01255085|Experimental|10 g of yellow pea fiber|
11514225|NCT01255085|Experimental|20 g of yellow pea fiber|
11514226|NCT01255085|Experimental|10 g of yellow pea protein|
11514227|NCT01255085|Experimental|20 g of yellow pea protein|
11514228|NCT01255085|Experimental|Control Tomato Soup|
11514229|NCT01255072|Active Comparator|Active rTMS + placebo|Patients, free from medication for at least one week (washout of 3 weeks for fluoxetine users) will receive 20 sessions of active rTMS delivered to the left Dorsolateral PreFrontal Cortex. Each patient will take placebo pills for 60 day,starting parallel on the first rTMS day.
11514230|NCT01255072|Sham Comparator|SHAM|Patients, free from medication at least for one week (washout of 3 weeks for fluoxetine users)receiving 20 sessions of Sham TMS delivered to the left dordolateral prefrontal cortex, at the same time this washed out of antidepressives patients start taking Citalopram 20mg/day, for 60 days.
11514232|NCT01255059||Health control|Female, non-smokers, no lung cancer or other types of cancers' healthy population
11514233|NCT01255046|Active Comparator|Donepezil plus STA-1|
11514234|NCT01255046|Placebo Comparator|Donepezil plus placebo|
11514235|NCT01255033||Pulmonary surgical patients|Patients submitted for scheduled lung surgery requiring one-lung ventilation
11514236|NCT01255020|Active Comparator|α-Keto Acid plus restricted protein diet|Participants randomized to this group will receive 12 months treatment of α-Keto Acid. The dose of α-Keto Acid is 100mg/kg per day and will divided into three times per day, and the α-Keto Acid will be asked to be taken during the meal. In addition, the participants will be asked to restrict the protein intake. The protein intake is restricted as 1g/kg/d.
11514237|NCT01255020|Placebo Comparator|Placebo plus restricted protein diet|All participants will receive 12 months treatment of placebo, at the same time they will be asked to restrict the protein intake.The dose of placebo is 100mg/kg per day, and the protein intake is restricted as 1g/kg/d.
11514238|NCT01255007|Experimental|Post chemotherapy group|The first group consists of patients with colorectal liver metastases who have had treatment with chemotherapy and are now awaiting surgery. This group would have had Multidetector Liver CT (MDCT) imaging prior to the chemotherapy, and will now undergo post chemotherapy MDCT as part of standard clinical care in addition to Gd-EOB-DTPA enhanced liver MRI and Diffusion Weighted MRI (DW-MRI). The MRI will be performed as an additional imaging investigation after obtaining informed consent.
11514239|NCT01255007|Experimental|Pre and Post Chemotherapy Group|The second group consists of patients with colorectal liver metastases who are due to receive neoadjuvant chemotherapy. This group will be imaged prior to receiving and after receiving chemotherapy. This will all be done prior to surgical resection of their colorectal liver metastases.
11514240|NCT01254994|Active Comparator|Control group|The patients were prescribed the tradition comprehensive medical treatment without entecavir.
11514241|NCT01254994|Experimental|ETV group|All the patients were prescribed the tradition comprehensive medical treatment with entecavir. Entecavir was supplied by the Sino-US Shanghai Squibb Pharmaceutical Co., Ltd. Patients took 0.5 mg entecavir following oral fasting one time per day.
11514242|NCT01254981|Experimental|Nobori|Percutaneous coronary intervention with implantation of coronary stent (Nobori)
11514243|NCT01254981|Experimental|Cypher|Percutaneous coronary intervention with implantation of coronary stent (Cypher)
11514244|NCT01254968||examining group|20 healthy subjects (11 men, 9 women, average age 23.94)
11514245|NCT01254968||control group|6 healthy subjects (3 men, 3 women, average age 23.6)
11514246|NCT01254955||organ transplant patients|
11514247|NCT01254955||healthy controls|
11514248|NCT01254942|Active Comparator|Usual Care|Usual care following hip fracture
11514249|NCT01254942|Experimental|Intervention|Follow-up Fracture Clinic
11514250|NCT01254929||F-18 PET bone scan group|Patients with a diagnosis of cancer and clinical concern for bone metastases. They will undergo an F-18 PET bone scan for diagnostic imaging.
11514251|NCT01254929||Tc-99m MDP bone scan group|Patients with a diagnosis of cancer and clinical concern for bone metastases. They will undergo a Tc-99m MDP bone scan for diagnostic imaging.
11514252|NCT01254916||Patients with chronic rhinosinusitis|
11514253|NCT01254903|Experimental|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation treatment.
11514254|NCT01254890|Experimental|Azacitidine + Sorafenib|Azacitidine (AZA) 75 mg/m^2 subcutaneously (SQ) or intravenously (IV) daily for 7 days; Sorafenib 200 mg orally twice a day.
11514255|NCT01254877|Placebo Comparator|Placebo Ondansetron - sugar pill|Placebo is an oral preparation made to appear and taste like the active drug preparation.
11514256|NCT01254877|Experimental|low dose ondansetron (0.2 mg bid)|
11514257|NCT01254877|Experimental|moderate dose ondansetron (0.8 mg bid)|
11514258|NCT01254864|Experimental|Abiraterone Acetate + Prednisone (AP)|Abiraterone Acetate at 1000 mg orally each day, given in combination with 5 mg of Prednisone orally twice daily.
11514259|NCT01254864|Experimental|Group 1: AP + Sunitinib|AP (Abiraterone Acetate + Prednisone) Plus Sunitinib; Randomized from AP group to receive Sunitinib if disease worsens. Assignment to crossover group AP + Dasatinib with further disease progression.
11514260|NCT01254864|Experimental|Group 2: AP + Dasatinib|AP (Abiraterone Acetate + Prednisone) Plus Dasatinib; Randomized from AP group to receive Dasatinib if disease worsens. Assignment to crossover group AP + Sunitinib with further disease progression.
11514261|NCT01254851|Active Comparator|goal-augmented post-operative care.|Patients in this group will be given a goal number of steps to take on each post-operative day.
11514262|NCT01254851|No Intervention|Usual care|routine post-operative ambulation
11514263|NCT01254825|Experimental|Adductor-Canal-Block, Ropivacain|Adductor-Canal-Block, 30 mL Ropivacain 7,5 mg/mL. Single dose. Ultrasound-guided application. 36 patients
11514264|NCT01254825|Placebo Comparator|Adductor-Canal-Block (ACB) - Saline|Adductor-Canal-Block, Placebo (30 mL Saline). Ultrasound-guided application. 36 patients.
11514265|NCT01254812||Bilateral dual TAP-block|
11514266|NCT01254812||Placebo Bilateral dual TAP-block|
11514267|NCT01254799|Placebo Comparator|Placebo|Women in this arm will receive identical Placebo capsules twice daily for 5 days
11514268|NCT01254799|Active Comparator|Doxycycline|Women in this arm will receive 100 mg doxycycline capsules twice daily for 5 days
11514269|NCT01254786|Active Comparator|CPAP2 - HFPPV group|the non-dependent lung will be ventilated with CPAP of 2 cm H2O for 30 min followed with HFPPV for min.
11514270|NCT01254786|Active Comparator|HFPPV-CPAP2 group|the non-dependent lung will be ventilated with HFPPV for 30 min followed with CPAP of 2 cm H2O for 30 min.
11514271|NCT01254773|Experimental|Bapineuzumab SC Dose 1; 2 mg|
11514272|NCT01254773|Experimental|Bapineuzumab SC Dose 2; 7 mg|
11514273|NCT01254773|Experimental|Bapineuzumab SC Dose 3; 20 mg|
11514274|NCT01254773|Placebo Comparator|Placebo|
11514275|NCT01254760|Other|Investigational multifocal / Commercial multifocal|Investigational multifocal contact lenses worn first, with commercial multifocal contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 5 days.
11514326|NCT01254448|Placebo Comparator|Placebo|Subjects will receive a placebo capsule orally once a day for 28 days (Group 1) or 10 days (Group 2).
11514276|NCT01254760|Other|Commercial multifocal / Investigational multifocal|Commercial multifocal contact lenses worn first, with investigational multifocal contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 5 days.
11514277|NCT01254747|Experimental|Delefilcon A|Delefilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
11514278|NCT01254747|Active Comparator|Lotrafilcon B|Lotrafilcon B contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
11514279|NCT01254747|Active Comparator|Nelfilcon A|Nelfilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
11514280|NCT01254747|Active Comparator|Narafilcon A|Narafilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
11514281|NCT01254734|Experimental|Arm I|Patients undergo transoral robotic microsurgery.
11514282|NCT01254721|Experimental|1|Seroquel XR tablet
11514283|NCT01254721|Active Comparator|2|Seroquel XR + lithium
11514284|NCT01254708|Active Comparator|Control|Standard of care group. Medication as prescribed by the primary physician would be used by this group. Such medications might include azoles as voriconazole
11514285|NCT01254708|Experimental|liposomal amphotericin B (AmBisome ®)|Inhaled Liposomal preparation of Amphotericin B.
11514286|NCT01254695|Active Comparator|Standard settings|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 210 μsec
11514287|NCT01254695|Experimental|Experimental Setting 1|Amplitude: Sensory threshold Frequency:6.9 Hz Pulse width 210 μsec
11514288|NCT01254695|Experimental|Experimental setting 2|Amplitude: Sensory threshold Frequency:31 Hz Pulse width 210 μsec
11514289|NCT01254695|Experimental|Experimental setting 3|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 330 μsec
11514290|NCT01254695|Experimental|Experimental setting 4|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 90 μsec
11514291|NCT01254682|Active Comparator|Hyaluronic acid sodium salt (1%, 20mg/2ml)|
11514292|NCT01254682|Other|Standard arthroscopic procedure|
11514293|NCT01254669|No Intervention|control, standard of care|Mothers assigned to the Control Group received the low-literacy, standard-practice, HPV-vaccine information sheet
11514294|NCT01254669|Experimental|BNI-brief Negotiated Interview|The BNI intervention addressed mothers' beliefs, values, and concerns about HPV prevention and takes their priorities for health and well-being into account.
11514295|NCT01254656|Experimental|LRV 500mg|
11514296|NCT01254656|Experimental|LRV 750mg +TVD|
11514297|NCT01254656|Active Comparator|EFV|
11514298|NCT01254656|Experimental|LRV 750mg+ DRV/r + OBT|
11514299|NCT01254656|Experimental|LRV 1000mg +DRV/r + OBT|
11514300|NCT01254656|Active Comparator|ETR|
11514301|NCT01254643|Experimental|All Enrolled|9-valent human papillomavirus (9vHPV) L1 VLP vaccine (V503), 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6.
11514302|NCT01254630|Experimental|V212-STM|Participants with STM receiving chemotherapy randomized to receive V212 vaccine given as a 4-dose regimen administered ~30 days apart.
11514303|NCT01254630|Experimental|V212-HM|Participants with HM randomized to receive V212 vaccine given as a 4-dose regimen administered ~30 days apart.
11514304|NCT01254630|Placebo Comparator|Placebo-STM|Participants with STM receiving chemotherapy randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered ~30 days apart.
11514305|NCT01254630|Placebo Comparator|Placebo-HM|Participants with HM randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered ~30 days apart.
11514306|NCT01254617|Experimental|Treatment (lenalidomide and cetuximab)|Patients receive lenalidomide PO QD on days 1-21 and cetuximab IV over 1-2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11514307|NCT01254604|Experimental|Tafluprost|One drop of preservative-free vehicle (contains no active drug) per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for four weeks. Morning dose with vehicle only allows blinding to match twice daily dosing of comparator arm.
11514308|NCT01254604|Active Comparator|Timolol|One drop of preservative-free timolol maleate (0.05%) per eye twice daily (morning and evening) for four weeks.
11514309|NCT01254578|Experimental|Treatment (lenalidomide)|"Patients receive oral lenalidomide once daily on days 1-28. Courses repeat every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
~Patients undergo blood and bone marrow biopsies and aspirate collection at baseline and periodically during study for pharmacokinetic and pharmacodynamic studies. Buccal swab samples are also collected at baseline and analyzed for genetic polymorphisms."
11514310|NCT01254565|Experimental|Etelcalcetide|Participants received etelcalcetide administered by intravenous injection at the end of each hemodialysis session three times a week (TIW). The starting dose level was 5 mg; dose escalation was to proceed to 10 and 20 mg pending safety review of the prior cohort.
11514311|NCT01254565|Placebo Comparator|Placebo|Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW).
11514312|NCT01254552|Experimental|Dotarem and Xenetix 350|
11514313|NCT01254539|Experimental|Autologous bone marrow stem cells intraspinal transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
11514314|NCT01254539|Experimental|Intrathecal infusion of autologous bone marrow stem cells|Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells.
11514315|NCT01254539|Placebo Comparator|Intrathecal infusion of placebo (saline solution).|Patients were infused 2 ml of saline solution
11514316|NCT01254526|Experimental|A|
11514317|NCT01254526|Experimental|B|
11514318|NCT01254513|Experimental|Arm A - Docetaxel every 3 weeks + Prednisone|"Docetaxel: 60 mg/m²/day at C1 then 70 mg/m²/day for subsequent cycles every 3 weeks
~Prednisone 10 mg/day continuously"
11514319|NCT01254513|Experimental|Arm B - Docetaxel weekly + Prednisone|"Docetaxel weekly 35 mg/m²/day on day 1 and day 8 of each cycle (J1 = J21)
~Prednisone 10 mg/day continuously"
11514320|NCT01254500||patients with brain lesions|
11514321|NCT01254500||young normal controls|
11514322|NCT01254500||old normal controls|
11514323|NCT01254474|Experimental|MAP 4 procedure|Assess MAP 4 mapping capabilities in cardiac chambers in patients suffering from regular or fibrillating tachycardia's
11514324|NCT01254461|Experimental|A|
11514327|NCT01254448|Experimental|TC-5619|Subjects will receive a TC-5619 orally once a day for 28 days (Group 1) or 10 days (Group 2).
11514328|NCT01254435|Active Comparator|'Free' positioning withdrawal|Withdrawal of the colonoscope with the patient positioned at the discretion of the endoscopist
11514329|NCT01254435|Experimental|'Fixed' position withdrawal|Patient positioned in the left lateral position to visualise the caecum, ascending colon and hepatic flexure; supine to visualise the transverse colon; and in the right lateral position to visualise the splenic flexure, descending colon and the sigmoid colon
11514330|NCT01254422|Experimental|CYD Dengue vaccine group|Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months.
11514331|NCT01254422|Placebo Comparator|Placebo Group|Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months.
11514332|NCT01254409|Experimental|PRM-151|PRM-151 administered at escalating doses of 1, 5, and 10 mg/kg by 30 minute intravenous (IV) infusion days 1, 3, 5, 8 and 15.
11514333|NCT01254409|Placebo Comparator|Placebo|0.9% saline administered by 30 minute IV infusion Days 1, 3, 5, 8, and 15.
11514334|NCT01254396|Active Comparator|Sildenafil ODT tablet 50 mg, Fasted|Treatment A: Sildenafil ODT tablet 50 mg, administered without water under fasted conditions.
11514335|NCT01254396|Experimental|Sildenafil ODT tablet 50 mg, Fed|Treatment B: Sildenafil ODT tablet 50 mg, administered without water under fed conditions.
11514336|NCT01254383|Active Comparator|Treatment A|Viagra 50 mg tablet, administered with approximately 240 mL water under fasted conditions
11514337|NCT01254383|Experimental|Treatment B|Sildenafil ODT tablet 50 mg, administered without water under fasted conditions
11514338|NCT01254383|Experimental|Treatment C|Sildenafil ODT tablet 50 mg, administered with water under fasted conditions.
11514339|NCT01254370|Experimental|Catioprost|
11514340|NCT01254370|Active Comparator|Travatan Z|
11514341|NCT01254357||YA Burned Subjects|Any person between the years of 19-30 years old treated for a burn injury, having incurred within past 12 months.
11514342|NCT01254344|Experimental|Ertapenem sodium 1 g|Ertapenem sodium 1 g administered intravenously (IV) as a single dose followed by matching placebo to metronidazole administered IV as a single dose
11514343|NCT01254344|Active Comparator|Ceftriaxone sodium 2 g|Ceftriaxone sodium 2 g administered intravenously (IV) as a single dose followed by metronidazole 500 mg administered IV as a single dose
11514344|NCT01254331|Experimental|Single arm|
11514345|NCT01254318||Participants at high risk for IFI|Participants will be considered high risk if they are undergoing high dose chemotherapy for leukemia. This includes, but is not limited to participants with acute myelogenous leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. Participants are also considered to be at high risk for IFI if they have undergone allogeneic hematopoietic stem-cell transplantation.
11514346|NCT01254305|Experimental|1|40 -120 mg/day Levomilnacipran ER capsules, oral administration
11514347|NCT01254305|Active Comparator|2|Randomized to treatment with 1 of 4 Selective Serotonin Reuptake Inhibitors (SSRIs) - Paroxetine, Sertraline, Citalopram or Fluoxetine Oral administration, once daily dosing
11514348|NCT01254305|Placebo Comparator|3|Matching placebo capsules, oral administration
11514349|NCT01254292|Experimental|LCS12 (Skyla, BAY86-5028)|Participants received LCS12 (low dose levonorgestrel [LNG] intrauterine delivery system [IUS]) with an initial in vitro release rate of 12 μg LNG per day for 18 months with optional extension to 36 months
11514350|NCT01254292|Active Comparator|EE30/DRSP (Yasmin, BAY86-5131)|Participants received combined oral contraceptive (COC) tablet Yasmin containing 30 μg ethinyl estradiol (EE) and 3 mg drospirenone (DRSP) for 18 months/19 cycles
11514351|NCT01254279|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously every 3 weeks, in combination with oral prednisone or prednisolone 10 mg daily
11514352|NCT01254266|Experimental|conservative treatment|conservative weight reduction treatment in an inpatient unit.
11514353|NCT01254266|Experimental|bariatric surgery|inpatient program as a pre- and post- operational 'envelope' for bariatric surgeries.
11514354|NCT01254253|Experimental|Group a|no severe cardiac perfusion defects
11514355|NCT01254253|Experimental|Gooup b|reversible cardiac perfusion defects
11514356|NCT01254253|Experimental|Group c|irreversible cardiac perfusion defects
11514357|NCT01254240|Experimental|UVA/B phototherapy treatment|UVA/B phototherapy units, stand alone cabins, patients undress, step in the cabin and receive treatment in a duration of seconds to minutes. The noticable difference between the UVA/B and UVB treatment is only in the settings of the cabin.
11514358|NCT01254240|Active Comparator|UVB phototherapy treatment|UVB phototherapy units, stand alone cabins, patients undress, step in the cabin and receive treatment in a duration of seconds to minutes. The noticable difference between the UVA/B and UVB treatment is only in the settings of the cabin.
11514359|NCT01254227|Experimental|Deferasirox|Deferoxamine combination followed by Deferasirox monotherapy
11514360|NCT01254214|Experimental|tMBSR|telephone-adapted Mindfulness Based Stress Reduction (tMBSR) is an 8-week program of training in mindfulness meditation consisting of two in-person group meetings and 6 conference calls, led by a trained meditation teacher.
11514361|NCT01254214|Active Comparator|Support Group|The Support Group is a group intervention led by a trained facilitator and designed to match the intervention for time, attention and social support
11514362|NCT01254201||Dry Eye|Female patients over the age of 18 years with ocular complaints of dryness, grittiness, irritation, or related symptoms, without any identifiable cause.
11514363|NCT01254201||Fibromyalgia|Female patients over the age of 18 years diagnosed with Fibromyalgia.
11514364|NCT01254201||Healthy Control|Female patients over the age of 18 years with no symptoms of dry eyes and with no known diagnosis of Fibromyalgia.
11514365|NCT01254188|Experimental|Nilotinib|300 mg BID
11514366|NCT01254175|Experimental|rHPIV3cp45 Vaccine|Participants will receive one dose of the rHPIV3cp45 vaccine at baseline and a second dose at Month 6.
11514367|NCT01254175|Placebo Comparator|Placebo Vaccine|Participants will receive one dose of the placebo vaccine at baseline and a second dose at Month 6.
11514368|NCT01254162|Experimental|Placebo Gel|
11514369|NCT01254136|Experimental|Treatment A - INCB007839 300mg BID|This is a single arm, open label study in which all patients will receive a single dose of the investigational product INCB007839 in combination with a standard regimen of trastuzumab and vinorelbine.
11514370|NCT01254123|Active Comparator|Exenatide|
11514371|NCT01254123|Placebo Comparator|Placebo|
11514372|NCT01254110||1|Enterally fed with leucine
11514373|NCT01254110||2|Enterally fed with glutamine
11514374|NCT01254110||3|Enterally fed with protein powder
11514375|NCT01254097|Placebo Comparator|Probiotic|Participants are provided in double blinded fashion, probiotic given to take with antibiotics prescribed by their provider.
11514376|NCT01254097|Placebo Comparator|Placebo|Participants are provided in double blinded fashion, Look alike placebo given to take with antibiotics prescribed by their provider.
11514377|NCT01254084|Placebo Comparator|Placebo tea|Dietary Supplement: Placebo tea 3 gram twice daily, orally
11514378|NCT01254084|Active Comparator|Gynostemma pentaphyllum Tea|Gynostemma Pentaphyllum tea 3 grams twice daily, orally
11514379|NCT01254071|Experimental|Fixed dose combination product|Fixed Dose Combination capsule containing dutasteride 0.5mg and tamsulosin 0.2 mg
11514380|NCT01254058||Glaucoma Group|
11514381|NCT01254058||Age-Matched Controls|
11514382|NCT01254045|Experimental|placebo, oxytocin 24IU, oxytocin 48IU|intranasal placebo (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
11514383|NCT01254045|Experimental|oxytocin 24IU, placebo, oxytocin 48IU|intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
11514384|NCT01254045|Experimental|oxytocin 48IU, oxytocin 24IU, placebo|intranasal oxytocin (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
11514385|NCT01254045|Experimental|oxytocin 24IU, oxytocin 48IU, placebo|intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
11514386|NCT01254045|Experimental|oxytocin 48IU, placebo, oxytocin 24IU|intranasal oxytocin (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles ; intranasal oxytocin (24 international units) and intranasal placebo (24 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
11514387|NCT01254045|Experimental|placebo, oxytocin 48IU, oxytocin 24IU|intranasal placebo (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
11514388|NCT01254019|Experimental|GSK2402968|6mg/kg
11514389|NCT01254019|Experimental|Placebo|dose-matched
11514390|NCT01253980|Active Comparator|Amoxicillin|Amoxicillin
11514391|NCT01253980|Placebo Comparator|Placebo suspension|Placebo
11514392|NCT01253967||Group A|Subjects who are hospitalised for acute gastroenteritis
11514393|NCT01253967||Group B|Subjects who visit an emergency room for acute gastroenteritis
11514394|NCT01253967||Group C|Subjects who have rotavirus positive laboratory results and developed acute gastroenteritis at least 48 hours after hospitalisation.
11514395|NCT01253954||ICU patients with IFI|1
11514396|NCT01253941|Experimental|Mud Bath therapy|
11514397|NCT01253941|No Intervention|no Mud Bath Therapy|
11514398|NCT01253928|Active Comparator|Pioglitazone 45mg per day|Pioglitazone 45mg qd will be added to the current treatment
11514399|NCT01253928|Placebo Comparator|placebo|placebo qd will be added to current treatment
11514400|NCT01253915|Experimental|Carbon Dioxide|
11514401|NCT01253915|Placebo Comparator|Placebo|
11514402|NCT01253902|Active Comparator|bimatoprost ophthalmic solution 0.01%|One drop of bimatoprost ophthalmic solution 0.01% (Lumigan®) administered to affected eye(s), once daily in the evening for 12 weeks.
11514403|NCT01253902|Active Comparator|travoprost ophthalmic solution 0.004%|One drop of travoprost ophthalmic solution 0.004% (Travatan Z®) administered to affected eye(s), once daily in the evening for 12 weeks.
11514404|NCT01253902|Active Comparator|latanoprost ophthalmic solution 0.005%|One drop of latanoprost ophthalmic solution 0.005% (Xalatan®) administered to affected eye(s), once daily in the evening for 12 weeks.
11514405|NCT01253889|Active Comparator|Oral Glucose with soother|Oral Glucose 25% first given two minutes before the first contact by the physician performing the np-ECHO. A soother will be held in the infant's mouth to ensure that continuous contact is maintained throughout the testing period. Repeat application of solution as per study protocol. No other non-pharmaceutical interventions for stress reduction will be applied. During each np-ECHO, infants have additional handling only if it is required to maintain physiological stability.
11514406|NCT01253889|Placebo Comparator|Oral water with soother|Oral water first given two minutes before the first contact by the physician performing the np-ECHO. A soother will be held in the infant's mouth to ensure that continuous contact is maintained throughout the testing period. Repeat application of solution as per study protocol. No other non-pharmaceutical interventions for stress reduction will be applied. During each np-ECHO, infants have additional handling only if it is required to maintain physiological stability.
11514606|NCT01252511|Active Comparator|long Roux limb, 150 cm|
11514707|NCT01251809|Experimental|PEG-rASNase 1500|1500 U/m2 at day 0
11514407|NCT01253889|Active Comparator|Oral glucose with soother and tucking|For the infants randomized to receive facilitated tucking throughout the procedure, the bedside nurse will provide gentle, firm containment of the extremities. The facilitated tucking will commence immediately after the baseline BIIP score is taken, but before the glucose/water is administered.
11514408|NCT01253889|Placebo Comparator|Oral water with soother and tucking|For the infants randomized to receive facilitated tucking throughout the procedure, the bedside nurse will provide gentle, firm containment of the extremities. The facilitated tucking will commence immediately after the baseline BIIP score is taken, but before the glucose/water is administered.
11514409|NCT01253876|Experimental|Soy milk|
11514410|NCT01253876|Experimental|Caw's milk|
11514411|NCT01253863|Other|determining damaged tissue|
11514412|NCT01253837|Experimental|L19TNFa|"Phase I: Prospective, open-label, dose escalation study.
~Phase II: Prospective, single-arm, open-label study, equivalent to the stage 1 of the Simon two-stage phase II design."
11514413|NCT01253824|Experimental|NPC-01|1mg norethisterone and 0.02mg ethinyl estradiol
11514414|NCT01253824|Active Comparator|IKH-01|1mg norethisterone and 0.35mg ethinyl estradiol
11514415|NCT01253811|Experimental|rFXIII 35 IU/kg|
11514416|NCT01253798|Active Comparator|Group training on land|Group training in water and on land are carried out by the same principles, which is to improve general function, and to improve function and strength around the operated hip.
11514417|NCT01253798|Active Comparator|Group training in water|Group training in water and on land are carried out by the same principles, which is to improve general function, and to improve function and strength around the operated hip
11514418|NCT01253759||1|Combined treatment of Transpupillary Thermotherapy and ICG-based photodynamic therapy (PDT)
11514419|NCT01253733|Experimental|SMS and Internet|The SMS and Internet group will receive information, tips, strategies, and questions related to the self management of chronic disease (cystic fibrosis, inflammatory bowel disease, or type 1 diabetes) on a web-based program and via SMS messages.
11514420|NCT01253733|No Intervention|Control|The Control group will receive monthly tip sheets on various health topics for adolescents and young adults.
11514421|NCT01253720|Experimental|PACE CALL/Fit4Life|"Fit4Life intervention activities:
~Website: Provides weekly nutrition, physical activity, and weight loss information.
~Counseling Calls: Participants and their parents will get phone calls from their Health Coach to assess progress & problems.
~Health Coach Question & Answer: Participants will be assigned a Health Coach that they can contact at any time to ask questions or express any concerns.
~Text & Picture Messages: Participants will receive daily text messages to help remind them of being healthy. Messages will relate to the weekly topics and general checking in questions.
~Parent Materials: Parents will receive a packet of printed materials that relate to parenting skills regarding being a healthy role model for their child and healthy eating and exercise tips."
11514422|NCT01253720|No Intervention|Control|The Control group will receive monthly mailings on basic nutrition and physical activity information.
11514423|NCT01253707|Experimental|Dose Escalation|
11514424|NCT01253694|Experimental|Patients with 3-5 consecutive Avastin injections|These patients will receive 0.5 mg of intravitreal Ranibizumab monthly for 6 months.
11514425|NCT01253694|Experimental|Patients with 6 or more consecutive injections of Bevacizumab|Patients will receive 0.5 mg of intravitreal Ranibizumab during the first 6 months.
11514426|NCT01253681|Experimental|AMG 386, paclitaxel and carboplatin|15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
11514427|NCT01253668|Experimental|Arm 1|Patients receive oral brivanib alaninate daily in the absence of disease progression or unacceptable toxicity.
11514428|NCT01253655|Experimental|PF-05212365|
11514429|NCT01253642|Experimental|Treatment (antiangiogenesis, chemosensitizer, chemotherapy)|Patients receive phenelzine sulfate PO QD on days -7 to -4, and then BID on days -3 to 21. Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for at least 12 weeks in the absence of disease progression or unacceptable toxicity.
11514430|NCT01253629|Experimental|25 mg bid AFQ056|1 capsule of 25 mg and 1 capsule of placebo per intake
11514431|NCT01253629|Experimental|50 mg bid AFQ056|2 capsules of 25 mg per intake
11514432|NCT01253629|Experimental|100 mg bid AFQ056|1 capsule of 100 mg and 1 capsule of placebo per intake
11514433|NCT01253629|Placebo Comparator|Placebo|2 capsules of placebo per intake
11514434|NCT01253616|Experimental|VNS plus tones|
11514435|NCT01253603|Experimental|1|QAW039 capsules once daily for 28 days
11514436|NCT01253603|Experimental|2|Placebo to QAW039 capsules once daily for 28 days
11514437|NCT01253603|Experimental|3|Fluticasone propionate inhaler twice daily for 28 days
11514438|NCT01253590||post op cancer patients experiencing atrial fibrillation|This small study aims to assess the feasibility and acceptance of remote cardiac monitoring of postoperative cancer patients experiencing atrial fibrillation and will collect continuous data on heart beat over a period of 4-6 weeks upon discharge.
11514439|NCT01253577|Active Comparator|Drug Coated|Sinus stent coated with steroid
11514440|NCT01253577|Placebo Comparator|Non coated|Sinus stent without drug coating
11514441|NCT01253564|Experimental|Single Arm|
11514442|NCT01253551|Experimental|001|Treatment sequence AB Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6 with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10 with a morning dose of raltegravir and a morning and afternoon dose of telaprevir on Day 11.
11514443|NCT01253551|Experimental|002|Treatment sequence BA Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6 with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10 with a morning dose of raltegravir and a morning and afternoon dose of telaprevir on Day 11.
11514444|NCT01253525|Experimental|Ramucirumab (IMC-1121B ) and Pacitaxel|Each treatment cycle is 4 weeks (28 days)
11514445|NCT01253512|Experimental|THR-18 0.25mg/kg|Treatment with combination with Tissue Plasminogen Activator (tPA) treatment
11514446|NCT01253512|Placebo Comparator|Placebo treatment|Treatment in combination with Tissue Plasminogen Activator (tPA) treatment
11514447|NCT01253512|Experimental|THR-18 0.5mg/kg|Treatment in combination with Tissue Plasminogen Activator (tPA) treatment
11514448|NCT01253499|Experimental|TRx0037|Double blind placebo controlled study of TRx0037 in healthy elderly volunteers to assess safety, tolerability, bioavailability and pharmacokinetics
11514449|NCT01253486|Experimental|Disease-related expressive writing|Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period
11514450|NCT01253486|Active Comparator|Traditional expressive writing|Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period
11514451|NCT01253486|Sham Comparator|Neutral writing|Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
11514452|NCT01253486|No Intervention|Control condition|Participants in the control condition do not receive any intervention and complete only the assessments
11514453|NCT01253473|Active Comparator|ipratropium/albuterol|1 puff 4 times daily
11514454|NCT01253473|Experimental|Budesonide|budesonide 180 ug 2 puffs 4 times daily + ipratropium/albuterol 1 puffs four times daily
11514455|NCT01253473|Experimental|budesonide/formoterol|budesonide/formoterol 160/4.5 ug 2 puffs 4 times daily + ipratropium/albuterol 1 puffs four times daily
11514456|NCT01253460|Experimental|Cyclophosphamide, Rituximab + Sapacitabine|After Sapacitabine 350 mg orally Days 1-3, Cyclophosphamide 250 mg/m2 IV 2 hours, followed by Rituximab 375 mg/m2 IV Day 3, Course 1, and 500 mg/m2 Day 1, subsequent courses.
11514457|NCT01253447|Experimental|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 200 mg orally once a week for each 28 day treatment cycle
11514458|NCT01253434|Experimental|1|
11514459|NCT01253434|Experimental|2|
11514460|NCT01253434|Experimental|3|
11514461|NCT01253434|Experimental|4|
11514462|NCT01253434|Experimental|5|
11514463|NCT01253421|Active Comparator|MDD-amisulpride|Subjects experiencing a current episode of major depression who are randomized to receive amisulpride
11514464|NCT01253421|Placebo Comparator|MDD-placebo|Subjects experiencing a current episode of major depression who are randomized to receive placebo
11514465|NCT01253421|Active Comparator|HC-amisulpride|Subjects having no history of mental disorder (healthy controls, HC) who are randomized to receive amisulpride
11514466|NCT01253421|Placebo Comparator|HC-placebo|Subjects having no history of mental disorder who are randomized to receive placebo
11514467|NCT01253408|Experimental|Dronabinol 2.5 mg bid|Dronabinol 2.5 mg will be taken orally with water twice per day for two days.
11514468|NCT01253408|Experimental|Dronabinol 5 mg bid|Dronabinol 5 mg will be taken orally with water twice per day for two days.
11514469|NCT01253408|Placebo Comparator|Placebo|Placebo will be taken orally with water twice per day for two days.
11514470|NCT01253395|Experimental|Strength training|Supervised strength training.
11514471|NCT01253395|Active Comparator|Aerobic exercise|Supervised aerobic exercise.
11514472|NCT01253382|Active Comparator|ecallantide|
11514473|NCT01253382|Placebo Comparator|placebo|phosphate buffered saline
11514474|NCT01253369|Experimental|Pazopanib|Pazopanib was given at a dose of 800 mg orally once per day for 28 day cycles (+/- 3 days). Patients received treatment as long as they were receiving clinical benefit.
11514475|NCT01253356|No Intervention|No IABP|Standard of care and no IABP
11514476|NCT01253356|Active Comparator|Intra-Aortic Balloon Pump (IABP)|Standard of care, IABP inserted < or = 3 hours before noncardiac surgery, maintained for > or = 12-24 hours after surgery
11514477|NCT01253343||inpatient high aggression|
11514478|NCT01253343||inpatient low aggression|
11514479|NCT01253330|No Intervention|Comparison 1st|Not enrolled in the CMSText website text messaging system during last 3 months of study participation.
11514480|NCT01253330|Experimental|Participant 1st|Enrollment in the CMSText website text messaging system during first 3 months of study participation.
11514481|NCT01253317|Experimental|rhIGF-1|Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the OLE.
11514482|NCT01253304|Experimental|Normal hepatic function|LY2189265: A single, subcutaneous (SC) 1.5-milligram (mg) injection on Day 1 in participants with normal hepatic function
11514483|NCT01253304|Experimental|Mild hepatic impairment|LY2189265: A single, SC 1.5-mg injection on Day 1 in participants with mild hepatic impairment (Child-Pugh A)
11514484|NCT01253304|Experimental|Moderate hepatic impairment|LY2189265: A single, SC 1.5-mg injection on Day 1 in participants with moderate hepatic impairment (Child-Pugh B)
11514485|NCT01253304|Experimental|Severe hepatic impairment|LY2189265: A single, SC-1.5 mg injection on Day 1 in participants with severe hepatic impairment (Child-Pugh C)
11514486|NCT01253291|Experimental|30mg/120 mg LY2127399|Participants in the 30 milligrams (mg) every 4 weeks arm of the lead-in study will receive 30 mg every 4 weeks until the safety of the 120 mg every 4 weeks dose is confirmed in the lead-in study.
11514487|NCT01253291|Experimental|120 mg LY2127399|Participants in the 60 mg every 4 weeks, 120 mg every 4 weeks and 120 mg every 2 weeks arms of the lead-in study will receive 120 mg every 4 weeks as these participants will enroll in this study after the safety of the 120 mg every 4 weeks dose in the lead-in study is confirmed.
11514488|NCT01253278|Experimental|20 mg LY2393910|
11514489|NCT01253278|Experimental|60 mg LY2393910|
11514490|NCT01253278|Experimental|150 mg LY2393910|
11514491|NCT01253278|Experimental|450 mg LY2393910|
11514492|NCT01253278|Placebo Comparator|Placebo|
11514493|NCT01253265|Experimental|30 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
11514494|NCT01253265|Experimental|80 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
11514495|NCT01253265|Experimental|180 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
11514496|NCT01253265|Placebo Comparator|Placebo|Placebo is administered subcutaneously in the same manner as active drug in each dose group
11514497|NCT01253265|Experimental|120 mg LY2439821|Administered subcutaneously at 240 mg as a single loading dose followed by 120 mg every week
11514607|NCT01252498||Radiotherapy|Patients receiving radiotherapy or chemoradiotherapy for head and neck cancer
11514498|NCT01253252|Experimental|Specific procedure|"A [18F] Fluorodeoxyglucose PET Scan Imaging will be added to their conventional follow up (CT scan, usual blood sampling, ECG…) i.e. within one month before endovascular surgery (inclusion visit), at one month and 6 month of follow-up.
~Furthermore, blood sampling for biological investigations (biological markers of the inflammation, proteolysis and coagulation potentially related to morphology and evolution of AAA) will be done."
11514499|NCT01253239||TECNIS/ReZoom|Patients who received a TECNIS multifocal IOL in one eye and a ReZoom multifocal IOL in the opposite eye.
11514500|NCT01253239||TECNIS/TECNIS|Patients who received TECNIS multifocal IOLs in both eyes
11514501|NCT01253226|Experimental|30 milligrams (mg) Tabalumab|30 mg tabalumab every 4 weeks (Q4W) for 20 weeks (6 doses of study drug)
11514502|NCT01253226|Experimental|60 mg Tabalumab|60 mg tabalumab Q4W for 20 weeks (6 doses of study drug)
11514503|NCT01253226|Experimental|120 mg Tabalumab|120 mg tabalumab Q4W for 20 weeks (6 doses of study drug)
11514504|NCT01253226|Placebo Comparator|Placebo Q4W|Q4W for 20 weeks
11514505|NCT01253226|Experimental|120 mg once every 2 weeks (Q2W) Tabalumab|Initial loading dose of 240 mg tabalumab followed by 120 mg Q2W for 20 weeks (10 doses of study drug)
11514506|NCT01253226|Placebo Comparator|Placebo Q2W|Q2W for 20 weeks
11514507|NCT01253213|Experimental|BR55|
11514508|NCT01253200|Experimental|Blazer® Open-Irrigated Ablation Catheter|Patients treated with the Blazer® Open-Irrigated Ablation Catheter
11514509|NCT01253200|Active Comparator|Control Catheter|Patients treated with an open-irrigated radiofrequency ablation catheter that has received FDA market approval for the treatment of type 1 atrial flutter( Biosense Webster ThermoCool® ablation catheters (NaviStar™, EZ Steer, or SF) or St. Jude Medical ablation catheters (Therapy™ Cool Path™ or Safire BLU™),
11514510|NCT01253187|Experimental|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|single oral administration of 1 film-coated SHT00186D tablet (YAZ), containing 0.020 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)
11514511|NCT01253187|Experimental|EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)|single oral administration of 1 film-coated SHT04532B tablet, containing 0.020 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
11514512|NCT01253187|Experimental|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated SHT04532C tablet, containing 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
11514513|NCT01253174|Experimental|EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|single oral administration of 1 film-coated SHT470FA tablet (Yasmin with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
11514514|NCT01253174|Experimental|EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|single oral administration of 1 film-coated SHT04532A tablet (with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
11514515|NCT01253174|Active Comparator|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated tablet SHT04532C, containing 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
11514516|NCT01253161|Experimental|Pasireotide LAR Treatment|The investigational drug used in this study is pasireotide long acting release (LAR) 60 mg.
11514517|NCT01253148|Experimental|Arterial Injection of 90-Y Microspheres|Intrahepatic Arterial Injection of 90-Y Glass Microspheres as First-Line Treatment For Cholangiocarcinoma
11514518|NCT01253135|Placebo Comparator|Control|White Petrolatum
11514519|NCT01253135|Other|Test article|Vehicle (fibrinogen)
11514520|NCT01253122|Experimental|TRx0037|
11514521|NCT01253122|Active Comparator|TRx0014|
11514522|NCT01253109||SENSIMED Triggerfish|
11514523|NCT01253096|Experimental|L19IL2|
11514524|NCT01253070|Experimental|Treatment (daunorubicin, cytarabine, sorafenib tosylate)|"INDUCTION THERAPY: Daunorubicin hydrochloride 60 mg/m^2/day by IV push or short IV on days 1-3, cytarabine 100 mg/m^2/day by continuous IV on days 1-7, and sorafenib tosylate orally every 12 hours on days 1-7.
~CONSOLIDATION THERAPY - Every 28 days for 2 cycles: Cytarabine 2 g/m^2/day by IV on days 1-5 and sorafenib tosylate 400 mg orally every 12 hours on days 1-28.
~MAINTENANCE - Every 28 days for up to 12 cycles: Sorafenib tosylate 400 mg orally every 12 hours on days 1-28."
11514525|NCT01253057||Experimental Group|
11514526|NCT01253057||Control Group|
11514527|NCT01253044|Experimental|Acceptance and Commitment Therapy|12 weeks of individually delivered Acceptance and Commitment Therapy
11514528|NCT01253044|Active Comparator|Present Centered Therapy|12 weeks of individually delivered Present Centered Therapy
11514529|NCT01253031||Group 1|young normal hearing
11514530|NCT01253031||Group 2|older normal hearing
11514531|NCT01253031||Group 3|older hearing impaired
11514532|NCT01253018|Experimental|Robot Therapy|12 weeks of robotic therapy
11514533|NCT01253018|Active Comparator|Transition to Task Training|12 weeks of task specific practice combined with robotic therapy
11514534|NCT01252992||1:paradoxical reaction negative (RP-)|control group with tuberculosis but without paradoxical reaction
11514535|NCT01252992||1:paradoxical reaction negative (RP+)|group with tuberculosis and paradoxical reaction
11514536|NCT01252979|Experimental|Medium Chain Triglyceride|
11514537|NCT01252966|Experimental|Cognitive Training|Participants in this arm received computerized cognitive training in addition to nicotine patch and smoking cessation counseling.
11514538|NCT01252966|Placebo Comparator|Control Training|Participants in this arm received computerized control training in addition to nicotine patch and smoking cessation counseling
11514539|NCT01252953|Experimental|Anacetrapib|
11514540|NCT01252953|Placebo Comparator|Placebo anacetrapib|
11514541|NCT01252940|Experimental|FTC/RPV/TDF|Participants will switch from their existing treatment regimen to the emtricitabine (FTC)/rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF) single-tablet regimen (STR) at the beginning of the study.
11514542|NCT01252940|Experimental|SBR/Delayed Switch|Participants will stay on baseline regimen (SBR; their existing treatment regimen of PI+RTV plus 2 NRTIs) at the beginning of the study through Week 24, and may switch to the FTC/RPV/TDF STR (Delayed Switch) at the Week 24 visit.
11514608|NCT01252472||Flomax|Male patients scheduled for cataract surgery with current or past use of Flomax
11514609|NCT01252472||Control|Male adult patients scheduled for cataract surgery with no history of Flomax use
11514543|NCT01252927|Experimental|ASIST intervention|The gatekeeper training intervention group received the Applied Suicide Intervention Skills Training (ASIST) 10.0 in addition to TAU. ASIST is a two-day (fourteen hour), intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The intervention was offered to students on a weekend and was conducted by three senior ASIST trainers and one junior trainer, with two trainers assigned to each training group.
11514544|NCT01252927|No Intervention|Control group: training as usual|Training as usual consisted of didactic teaching and a tutorial with case-based examples around suicide risk factors in their first year of medical school. Third- and fourth-year students may also have the opportunity to practice their skills with real patients during their clerkship rotations or in the emergency department.
11514545|NCT01252914|Experimental|One iStent Supra Stent and medication|The study assesses the efficacy and safety of one iStent Supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma
11514546|NCT01252888|Experimental|Two iStent devices and medication|Implantation of two iStents through small temporal clear corneal incision
11514547|NCT01252875|Other|LDL-C to100 mg/dL (+/-10 mg/dL)|"Target : 100 mg/dL (+/-10 mg/dL):
~Patients recruited in this arm will receive statin +/-other lipid lowering therapy in order to reach a LDL-C concentration of 100 mg/dL(+/-10 mg/dL)."
11514548|NCT01252875|Other|LDL-C < 70 mg/dL|70 mg/dL: Patients recruited in this arm will receive statin +/-other lipid lowering therapy in order to reach a LDL-C concentration of less than 70 mg/dL.
11514549|NCT01252862|Experimental|Two iStents devices|Two iStents devices will be implanted
11514550|NCT01252849|Experimental|First Arm: One iStent, medication|Device: One iStent, medication
11514551|NCT01252849|Experimental|Second Arm: Two iStents, medication|Device: Two iStent devices, medication
11514552|NCT01252849|Experimental|Third Arm: Three iStents, medication|Device: Three iStent devices, medication
11514553|NCT01252836|Placebo Comparator|Control|Treatment with Tegaderm
11514554|NCT01252836|Experimental|AWBAT-D|Application of AWBAT-D on donor site.
11514555|NCT01252823|Experimental|Implantable loop recorder (ILR) in hemodialysis patients|implantation of loop recorder in hemodialysis patients
11514556|NCT01252810|Experimental|GE 145 320mg I/ml injection|
11514557|NCT01252810|Active Comparator|Iopamidol 370mg I/ml injection|
11514558|NCT01252797|Active Comparator|Stereotactic Radiosurgery (15 Gy)|Group A: If the tumor which will be surgically removed is at least 2 cm and up to 4 cm in maximum diameter, then this group will receive Dose Level II (15 Gy) of radiation: stereotactic radiosurgery (SRS) followed by surgery to remove the tumor.
11514559|NCT01252797|Experimental|Stereotactic Radiosurgery (12Gy)|Group B: If the tumor which will be surgically removed is larger than 4 cm and up to 6 cm in diameter, then this group will receive Dose Level I (12 Gy) of radiation: stereotactic radiosurgery (SRS) followed by surgery to remove the tumor.
11514560|NCT01252771|Experimental|PKM report and algorithm|Phosphate kinetic modeling was performed and displayed in graphical form laboratory results and an estimated phophorus protein ratio
11514561|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 1|
11514562|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 2|
11514563|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 3|
11514564|NCT01252758|Placebo Comparator|placebo|
11514565|NCT01252758|Active Comparator|Ventolin HFA dose 1|
11514566|NCT01252758|Active Comparator|Ventolin HFA dose 2|
11514567|NCT01252745|Experimental|10.0 mg of TBS-1, 4.0% T.I.D.|TBS-1 syringes pre-filled with 125 μL 4.0% gel to deliver 5.0 mg of Testosterone per nostril (intra-nasal) given t.i.d. at 2100, 0700, and 1300 hours. (total dose 30 mg/day)
11514568|NCT01252745|Experimental|13.5 mg of TBS-1, 4.5% B.I.D|TBS-1 syringes pre-filled with 150 μL 4.5% gel to deliver 6.75 mg of Testosterone per nostril (intra-nasal) given b.i.d. at 2100 and 0700 hours. (total dose 27.0 mg/day)
11514569|NCT01252745|Experimental|11.25 mg of TBS-1, 4.5% T.I.D|TBS-1 syringes pre-filled with 125 μL 4.5% gel to deliver 5.625 mg of Testosterone per nostril (intra-nasal) given t.i.d. at 2100, 0700, and 1300 hours. (total dose 33.75 mg/day)
11514570|NCT01252732|Experimental|Single-Dose IV Oritavancin Diphosphate|
11514571|NCT01252732|Active Comparator|IV Vancomycin|
11514572|NCT01252719|Experimental|Single-Dose IV Oritavancin Diphosphate|
11514573|NCT01252719|Active Comparator|IV Vancomycin|
11514574|NCT01252693|Experimental|Ozarelix|
11514575|NCT01252693|Active Comparator|Goserelin|
11514576|NCT01252680|Experimental|Group 1: Healive+Healive|75 subjects to receive two doses of Healive 6 months apart
11514577|NCT01252680|Experimental|Group 2: Healive+Havrix|75 subjects to receive one dose of Healive and another dose of Havrix 6 months apart
11514578|NCT01252680|Experimental|Group 3: Havrix+Havrix|75 subjects to receive two doses of Havrix 6 months apart
11514579|NCT01252680|Experimental|Group 4: Havrix+Healive|75 subjects to receive one dose of Havrix and another dose of Healive 6 months apart
11514580|NCT01252667|Experimental|Part 1 - Dose 1 (30 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 30 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.
~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.
~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.
~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT
~Clofarabine: Given IV
~Cyclosporine: Given PO
~Laboratory Biomarker Analysis: Correlative studies
~Mycophenolate Mofetil: Given PO
~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT
~Pharmacological Study: Optional correlative studies
~Total-Body Irradiation: Undergo TBI"
11514610|NCT01252459|Experimental|Arm A: AA-PET based target volume delineation|Experimental intervention (Arm A): High-precision re-irradiation. Target volume delineation based on AA-PET.
11514611|NCT01252459|Active Comparator|Arm B: T1Gd-MRI based target volume delineation|Control intervention (Arm B): High-precision re-irradiation. Target volume delineation based on T1Gd-MRI.
11514708|NCT01251809|Active Comparator|Oncaspar|2000 U/m2 at day 0
11514709|NCT01251796|Experimental|ARQ 197 and Erlotinib|ARQ 197 and erlotinib hydrochloride
11514581|NCT01252667|Experimental|Part 1 - Dose 2 (40 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 40 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.
~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.
~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.
~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT
~Clofarabine: Given IV
~Cyclosporine: Given PO
~Laboratory Biomarker Analysis: Correlative studies
~Mycophenolate Mofetil: Given PO
~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT
~Pharmacological Study: Optional correlative studies
~Total-Body Irradiation: Undergo TBI"
11514582|NCT01252667|Experimental|Part 1 - Dose 3 (50 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 50 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.
~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.
~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.
~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT
~Clofarabine: Given IV
~Cyclosporine: Given PO
~Laboratory Biomarker Analysis: Correlative studies
~Mycophenolate Mofetil: Given PO
~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT
~Pharmacological Study: Optional correlative studies
~Total-Body Irradiation: Undergo TBI"
11514583|NCT01252667|Experimental|Part 2 - Dose 1 (30 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 30 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.
~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.
~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.
~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT
~Clofarabine: Given IV
~Cyclosporine: Given PO
~Laboratory Biomarker Analysis: Correlative studies
~Mycophenolate Mofetil: Given PO
~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT
~Pharmacological Study: Optional correlative studies
~Total-Body Irradiation: Undergo TBI"
11514584|NCT01252667|Experimental|Part 2 - Dose 2 (40 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 40 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.
~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.
~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.
~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT
~Clofarabine: Given IV
~Cyclosporine: Given PO
~Laboratory Biomarker Analysis: Correlative studies
~Mycophenolate Mofetil: Given PO
~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT
~Pharmacological Study: Optional correlative studies
~Total-Body Irradiation: Undergo TBI"
11514585|NCT01252667|Experimental|Part 2 - Dose 3 (50 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 50 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.
~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.
~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.
~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT
~Clofarabine: Given IV
~Cyclosporine: Given PO
~Laboratory Biomarker Analysis: Correlative studies
~Mycophenolate Mofetil: Given PO
~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT
~Pharmacological Study: Optional correlative studies
~Total-Body Irradiation: Undergo TBI"
11514586|NCT01252654||1 IntraLase flaps|Patients who have undergone flap creation with IntraLase laser
11514587|NCT01252654||2 Visumax flaps|Patients who have undergone flaps created with Visumax laser
11514588|NCT01252641|Experimental|SB-728-T|Subjects will receive one intravenous infusion of SB-728-T
11514589|NCT01252628|Experimental|PX-866 (SCCHN)|Phase 2 (Squamous Cell Carcinoma of the Head and Neck)
11514590|NCT01252628|Active Comparator|Cetuximab (SCCHN)|Phase 2 (Squamous Cell Carcinoma of the Head and Neck)
11514591|NCT01252628|Experimental|PX-866 (CRC)|Phase 2 (Colorectal Carcinoma)
11514592|NCT01252628|Active Comparator|Cetuximab (CRC)|Phase 2 (Colorectal Carcinoma)
11514593|NCT01252615|Experimental|patient only|Patient with the ICD is involved in the intervention
11514594|NCT01252615|Experimental|patient and partner|patient with the ICD and intimate partner are involved in the intervention
11514595|NCT01252602||Prenatally depressed|Women who tested positive for prenatal depression with a score of > 12 on the Edinburgh Postnatal Depression Scale
11514596|NCT01252602||Not Prenatally Depressed|Women who tested not depressed on the prenatal depression scale with a score < 13
11514597|NCT01252589||Adults with CML|Adult patients (18 years of age or older) with confirmed diagnosis of CML
11514598|NCT01252576||women with and without sexual dysfunction|women with and without female sexual dysfunction
11514599|NCT01252563||Amlodipine 10mg Tablet|Subjects taking Amlodipine 10mg Tablet.
11514600|NCT01252550|Active Comparator|Activia®|Activia® (125g/pot)
11514601|NCT01252550|Placebo Comparator|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
11514602|NCT01252537||Initiation of antituberculosis therapy|Patients initiating treatment for tuberculosis with and without HIV co-infection in primary health care centres in Ethiopia
11514603|NCT01252524|Placebo Comparator|Placebo|A placebo tablet PO TID before each meal with 8 oz of water for 6 months.
11514604|NCT01252524|Experimental|Calcium polycarbophil|Calcium polycarbophil 625 mg PO TID before each meal with 8 oz of water for 6 months
11514605|NCT01252511|Active Comparator|long biliopancreatic limb, 75 cm|
11514612|NCT01252446||ADHD|The sample of 187 children and adolescent in the age of 6 to 17 years referred to the Child and Adolescent Clinic, Haugesund, Norway during the period of one year and diagnosed in ICD 10 system as ADHD.
11514613|NCT01252433|Experimental|Entree energy density 100%|100% energy density
11514614|NCT01252433|Experimental|Entree energy density 85%|85% energy density
11514615|NCT01252433|Experimental|Entree energy density 75%|75% energy density
11514616|NCT01252407|Experimental|tens|
11514617|NCT01252394||Hemodialysis patients|
11514618|NCT01252381|Active Comparator|Vitamin D|
11514619|NCT01252381|Placebo Comparator|Calcium tablet|
11514620|NCT01252368||RAS active drugs|ACE inhibitors and sartanes
11514621|NCT01252368||healthy participants|
11514622|NCT01252355|Experimental|Teriflunomide 7 mg + IFN-beta|Teriflunomide 7 milligram (mg) once a day concomitantly with IFN-beta therapy.
11514623|NCT01252355|Experimental|Teriflunomide 14 mg + IFN-beta|Teriflunomide 14 mg once a day concomitantly with IFN-beta therapy.
11514624|NCT01252355|Placebo Comparator|Placebo + IFN-beta|Placebo (for teriflunomide) once a day concomitantly with IFN-beta therapy.
11514625|NCT01252342|Experimental|Intramyometrial oxytocin|
11514626|NCT01252342|Placebo Comparator|Intramyometrial Saline|
11514627|NCT01252329|Active Comparator|Elective lymph node treatment arm|Patients entering this arm will undergo selective nodal dissection of the draining lymph nodes with subsequent radiation and/or chemotherapy if indicated.
11514628|NCT01252329|No Intervention|Clinical observation arm|Patients who enter into this arm will undergo regular, periodic clinical nodal observation with subsequent evaluation and treatment if indicated upon discovery of a palpable lymph node.
11514629|NCT01252316|Active Comparator|Standard CPR|"Individuals will learn the Standard form of CPR (30:2, compressions:breathes) Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect 3) CPR Skills"
11514630|NCT01252316|Active Comparator|Recruitment with Volunteers|UPHS volunteer subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
11514631|NCT01252316|Active Comparator|Recruitment with Nurses|UPHS Nurse subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
11514632|NCT01252316|Active Comparator|Chest Compressions Only CPR|"Individuals will learn the chest compression only form of CPR (no rescue breathes) Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect 3) CPR Skills"
11514633|NCT01252303|Experimental|Nutrisystem|Group will receive Nutrisystem meals in addition to the behavioral weight loss program.
11514634|NCT01252303|Active Comparator|Control|Group will receive a behavioral weight loss program only.
11514635|NCT01252290|Experimental|Lovaza™|Lovaza™ (two 1 gram capsules twice daily) for six months
11514636|NCT01252277|Experimental|Lovaza™|Lovaza™ (two 1 gram capsules twice daily) for six months
11514637|NCT01252264||Individuals with craniofacial anomalies|Individuals who have a craniofacial anomaly (head, face, or eye disorder)
11514638|NCT01252264||Control Subjects|Family members of individuals with a craniofacial anomaly
11514639|NCT01252251|Experimental|RAD001 and pasireotide LAR|This study will be an open-label, single-arm, phase II study of RAD001 and pasireotide LAR.
11514640|NCT01252238|Placebo Comparator|Valsartan and Aliskiren|Valsartan 150 mg and Aliskiren (150 mg followed by force titration to 300 mg)
11514641|NCT01252238|Experimental|Aliskiren|
11514642|NCT01252238|Placebo Comparator|Placebo Group|Only taking Amlodipine
11514643|NCT01252225|Active Comparator|Nebulised Lidocaine followed by Placebo throat spray|
11514644|NCT01252225|Active Comparator|Nebulised Placebo followoed by Lidocaine Throat Spray|
11514645|NCT01252225|Placebo Comparator|Nebulised placebo followed by placebo throat spray|
11514646|NCT01252212|Experimental|Receiving SMS alerts|The patients randomized to this arm will have a SMS message sent to them regarding medication adherence for antiretroviral medications, anti-hypertensive medications, anti-depressants, hyperglycemic controlling medications and hypercholesterolemia controlling medications as well as life style supportive suggestions.
11514647|NCT01252212|Active Comparator|No SMS messages|The patients randomized to this arm will have a SMS message sent to them regarding healthy life style supportive suggestions.
11514648|NCT01252199|Experimental|cαStx1/cαStx2|
11514649|NCT01252199|Placebo Comparator|Control|
11514650|NCT01252186|Experimental|91-day Levonorgestrel Oral Contraceptive|Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10 µg EE monotherapy in each 91-day cycle for a total of two 91-day cycles.
11514651|NCT01252186|Active Comparator|28-day Levonorgestrel Oral Contraceptive|Participants received 21 days of active combination tablets containing 150 µg LNG/30 µg EE, followed by no treatment for 7 days in each 28-day cycle for a total of six 28-day cycles.
11514652|NCT01252186|Active Comparator|28-day Desogestrel Oral Contraceptive|Participants received 21 days of active combination tablets (containing 150 µg desogestrel (DSG)/30 µg EE, followed by no treatment for 7 days in each 28-day cycle for a total of six 28-day cycles.
11514653|NCT01252160|Experimental|QUTENZA|Cutaneous patch
11514654|NCT01252134|Other|Synergi, then Biotrue, then OTE|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
11514655|NCT01252134|Other|Synergi, then OTE, then Biotrue|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
11514656|NCT01252134|Other|Biotrue, then OTE, then Synergi|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
11514657|NCT01252134|Other|Biotrue, then Synergi, then OTE|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
11514658|NCT01252134|Other|OTE, then Biotrue, then Synergi|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
11514659|NCT01252134|Other|OTE, then Synergi, then Biotrue|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
11514660|NCT01252121|Other|Systane, Hialid, Unisol|1 drop Systane in study eye at Visit 2, 1 drop Hialid in study eye at Visit 3, 1 drop Unisol in study eye at Visit 4, with a minimum of 24 hours between each visit.
11514661|NCT01252121|Other|Systane, Unisol, Hialid|1 drop Systane in study eye at Visit 2, 1 drop Unisol in study eye at Visit 3, 1 drop Hialid in study eye at Visit 4, with a minimum of 24 hours between each visit.
11514662|NCT01252121|Other|Hialid, Systane, Unisol|1 drop Hialid in study eye at Visit 2, 1 drop Systane in study eye at Visit 3, 1 drop Unisol in study eye at Visit 4, with a minimum of 24 hours between each visit.
11514663|NCT01252121|Other|Hialid, Unisol, Systane|1 drop Hialid in study eye at Visit 2, 1 drop Unisol in study eye at Visit 3, 1 drop Systane in study eye at Visit 4, with a minimum of 24 hours between each visit.
11514664|NCT01252121|Other|Unisol, Systane, Hialid|1 drop Unisol in study eye at Visit 2, 1 drop Systane in study eye at Visit 3, 1 drop Hialid in study eye at Visit 4, with a minimum of 24 hours between each visit.
11514665|NCT01252121|Other|Unisol, Hialid, Systane|1 drop Unisol in study eye at Visit 2, 1 drop Hialid in study eye at Visit 3, 1 drop Systane in study eye at Visit 4, with a minimum of 24 hours between each visit.
11514666|NCT01252108|Experimental|Treatment|All subjects receive SQ109
11514667|NCT01252095|Experimental|PG545|
11514668|NCT01252082|Active Comparator|Scalig and Rootplaning|patients will receive scaling and root planing therapy
11514669|NCT01252082|No Intervention|control|patients in control group will not receive periodontal treatment in the time period of the study
11514670|NCT01252069|Experimental|A|PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ended by a drug free period until return of menses.
11514671|NCT01252069|Experimental|B|PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of progestin (oral tablets) during 3 periods each ended by a drug free period until return of menses.
11514672|NCT01252056|No Intervention|Control|
11514673|NCT01252056|Active Comparator|Probucol|Probucol treatment
11514674|NCT01252056|Active Comparator|Combination|Probucol and Cilostazol
11514675|NCT01252043||cohort|cholestatic children without esophageal variceal bleeding
11514676|NCT01252043||study|cholestatic children with esophageal variceal bleeding
11514677|NCT01252043||cholestatic children without EV|cholestatic children without esophageal variceal bleeding
11514678|NCT01252030|Experimental|intervention|stimulation of physical activity by messages sent through e mail or SMS; in combination with monitoring of physical activity with physical activity monitors
11514679|NCT01252030|Placebo Comparator|control|no stimulation of physical activity
11514680|NCT01252017|Experimental|Nilotinib|Single arm, open label study
11514681|NCT01252004||TT Syndrome|Will be included over a period of one year, prospectively, all patients newly diagnosed
11514682|NCT01251991|Experimental|Combinatorial treatment|
11514683|NCT01251991|Active Comparator|Single treatment: Psyllium husks|
11514684|NCT01251991|Active Comparator|Single treatment: Isolated soy protein|
11514685|NCT01251991|Placebo Comparator|Control|
11514686|NCT01251978|Active Comparator|High dose Ranibizumab|6 patients will receive 3 injections of Ranibizumab (2 mg) a month apart.
11514687|NCT01251978|Active Comparator|Standard Dose Ranibizumab|6 patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.
11514688|NCT01251965|Experimental|Ruxolitinib 50 mg BID|Phase I - Starting dose of Ruxolitinib 50 mg by mouth twice a day for 28 day cycle.
11514689|NCT01251965|Experimental|Ruxolitinib 100 mg BID|Phase I dose of Ruxolitinib 100 mg by mouth twice a day for 28 day cycle.
11514690|NCT01251965|Experimental|Ruxolitinib 200 mg BID|Phase I dose of Ruxolitinib 200 mg by mouth twice a day for 28 day cycle.
11514691|NCT01251952|Experimental|Denileukin Diftitox (Ontak)|Denileukin Diftitox (Ontak) administered Post Autologous Transplantation.
11514692|NCT01251939||Treatment with ibuprofen|Gestational age <32 weeks and <1500 g, postnatal age older than 48 hours and echocardiographic evidence of hemodynamically significant PDA
11514693|NCT01251939||Controls|Gestational age <32 weeks and <1500 g, postnatal age older than 48 hours and without significant PDA
11514694|NCT01251900||Patients|Hispanic women, over the age of 18, with breast cancer will be eligible.
11514695|NCT01251874|Experimental|Treatment (veliparib, F 18 fluorothymidine, carboplatin)|Patients receive carboplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-7 or 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo fluorothymidine PET scan and peripheral blood cell and tumor tissue collection periodically for correlative studies.
11514696|NCT01251861|Active Comparator|Arm A (observation and bicalutamide)|Patients undergo observation on weeks 1-12. Patients then receive bicalutamide PO QD on weeks 13-44. Patients with a PSA decline of >= 50% may continue on bicalutamide until week 72 in the absence of disease progression or unacceptable toxicity.
11514697|NCT01251861|Experimental|Arm B (Akt inhibitor MK2206 and bicalutamide)|Patients receive Akt inhibitor MK2206 PO once per week on weeks 1-44 and bicalutamide PO QD on weeks 13-44. Patients with a PSA decline of >= 50% may continue on Akt inhibitor MK2206 and bicalutamide until week 72 in the absence of disease progression or unacceptable toxicity.
11514698|NCT01251848|Active Comparator|Treatment A|
11514699|NCT01251848|Active Comparator|Treatment B|
11514700|NCT01251848|Experimental|Treatment C|
11514701|NCT01251835|Active Comparator|Sitaxsentan|
11514702|NCT01251835|Experimental|Sitaxsentan plus Rifampin|
11514703|NCT01251822|Experimental|PEG 3350|PEG 3350 plus electrolytes in solution plus placebo tablets
11514704|NCT01251822|Active Comparator|Prucalopride|Prucalopride tablets plus placebo solution
11514705|NCT01251809|Experimental|PEG-rASNase 500|500 U/m2 BSA at day 0
11514706|NCT01251809|Experimental|PEG-rASNase 1000|1000 U/m2 BSA at day 0
11514710|NCT01251783|Active Comparator|Infant Formula|Infant Formula without lactobaillus or Metlin or Metlos
11514711|NCT01251783|Active Comparator|Fully breast milk|Group non randomized with fully breast milk
11514712|NCT01251783|Experimental|Metlin+Metlos+Lactobacillus GG|Infant Formula added with Metlin+Metlos (6g/L) and Lactobacillus GG 0.3x107UFC
11514713|NCT01251783|Active Comparator|Metlin+Lactobacillus GG|Infant Formula added with Metlin (6g/L) + Lactobacillus GG 0.3x107 UFC
11514714|NCT01251783|Active Comparator|Metlos+Lactobacillus GG|Infant Formula added with Metlos (6g/L)+Lactobacillus GG 0.3x107UFC
11514715|NCT01251783|Active Comparator|Lactobacillus GG|Infant Formula added with Lactobacillus GG 0.3x107UFC without Metlin or Metlos
11514716|NCT01251770|Experimental|half saline|Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.
11514717|NCT01251770|Active Comparator|third saline|Subjects in this arm will receive 0.3% NaCl/dextrose 5% intravenous (IV) maintenance fluids.
11514718|NCT01251757|No Intervention|Usual Care (UC)|Participants in this arm received their usual care with no restrictions.
11514719|NCT01251757|Active Comparator|Interactive Voice Recognition (IVR)|automated phone calls
11514720|NCT01251757|Active Comparator|Enhanced IVR (IVR+)|automated phone calls & Educational mailings and follow-up for nonadherence
11514721|NCT01251744|Experimental|CMV Mothers' Group|Pregnant subjects with confirmed primary CMV infection.
11514722|NCT01251744|Experimental|CMV Newborns' Group|Offsprings of the CMV Mothers' Group, also tested for CMV infection, comprising infants that were live born.
11514723|NCT01251731|Experimental|Treatment Group 1|
11514724|NCT01251731|Experimental|Treatment Group 2|
11514725|NCT01251731|Experimental|Treatment Group 3|
11514726|NCT01251731|Experimental|Treatment Group 4|
11514727|NCT01251718||Donepezil Hydrochloride|
11514728|NCT01251692|Experimental|1|A retrospective chart review of 26 eyes of 23 patients with recurrent corneal erosions treated by PTK from 1996 to 2000 was performed. All eyes had failed to respond to conventional therapy. Data regarding the preoperative and postoperative best-corrected visual acuity (BCVA), spherical equivalent (SE), symptomatic relief, incidence of recurrence, and complications arising from the laser treatment were analyzed. The mean duration of symptoms prior to PTK was 18 months (range, 8 to 36 months). The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser. Mean postoperative follow-up was 12 years (range, 10 to 14 years).
11514729|NCT01251679|No Intervention|Control|Control: nutrition, physical activity and smoking cessation education
11514730|NCT01251679|Experimental|Hand washing|Intervention 1: hand washing education and material
11514731|NCT01251679|Experimental|Hand washing and surgical mask|Intervention 2: hand washing education and material AND paper surgical face masks
11514732|NCT01251666|Other|Magstream + Oc Sensor + Hemoccult II|"Each patient will perform all three tests:
~Magstream: 2 samples (each on a different stool)
~OC Sensor: 2 samples (each on a different stool)
~Hemoccult II: 6 samples (2 samples per stool, on 3 different stools)
~Each test will be considered as positive if at least one sample is positive (cutoff for Magstream 55 ng/ml and for OC Sensor 150 ng/ml).
~Screening will be considered as positive if at least one of the three tests is positive, leading to a colonoscopy"
11514733|NCT01251653||Afatinib and docetaxel|
11514734|NCT01251653||Afatinib and gemcitabine|
11514735|NCT01251640|Experimental|Arm 1|
11514736|NCT01251627|Experimental|Decitabine|Eligible patients will recieve Dacogen 20mg/m2 in 1 hour iv infusion for 5 days every 28 days (1 cycle)plus Best Supportive Care.A total of 6 courses is planned.
11514737|NCT01251614|Experimental|Adalimumab 0.4 mg/kg|In Period A participants received a single subcutaneous loading dose of adalimumab 0.4 mg/kg (up to a maximum of 20 mg) at Week 0 followed by every other week dosing beginning at Week 1. To maintain the blind, participants also received weekly dosing of methotrexate placebo tablets. Participants who were non-responders in Period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.4 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.4 mg/kg eow.
11514738|NCT01251614|Experimental|Adalimumab 0.8 mg/kg|In Period A participants received a single subcutaneous loading dose of adalimumab 0.8 mg/kg (up to a maximum of 40 mg) at Week 0 followed by every other week dosing beginning at Week 1. To maintain the blind, participants also received weekly dosing of methotrexate placebo tablets. Participants who were non-responders in Period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.8 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.8 mg/kg eow.
11514739|NCT01251614|Active Comparator|Methotrexate|Participants received 0.1 mg/kg methotrexate at Baseline (Week 0), and up to 0.4 mg/kg weekly (maximum dose of 25 mg/week) in Period A. Participants also received adalimumab placebo as a single subcutaneous loading dose at Week 0, followed by every other week (eow) dosing from Week 1. Participants who were non-responders in period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.8 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.8 mg/kg eow.
11514740|NCT01251601||Raltegravir in Pregnancy|HIV positive pregnant women currently on raltegravir as part of combination antiretroviral therapy
11514880|NCT01250496|Experimental|Aminophylline|75 mg of intravenous aminophylline.
11514741|NCT01251588||MACI|autologous cultured chondrocytes on porcine collagen membrane implant received in previous MACI00206 study
11514742|NCT01251588||Microfracture|Microfracture treatment received in previous MACI00206 study
11514743|NCT01251575|Experimental|Treatment (fludarabine, transplant, immunosuppression)|"CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2. Patients also undergo total-body irradiation on day 0.
~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation.
~IMMUNOSUPPRESSION: Patients receive sirolimus PO QD on days -3 to 180 with taper to day 365; cyclosporine PO BID on days -3 to 150 with taper to day 180; and mycophenolate mofetil PO TID on days 0-30 and then BID to day 100 with taper to day 150."
11514744|NCT01251562|Experimental|Cohort 1|"5.62 mg/kg
~Sterile Compound C31510 for Injection"
11514745|NCT01251562|Experimental|Cohort 2|"11.25 mg/kg
~Sterile Compound C31510 for Injection"
11514746|NCT01251562|Experimental|Cohort 3|"22.5 mg/kg
~Sterile Compound C31510 for Injection"
11514747|NCT01251562|Experimental|Cohort 4|33.0 mg/kg
11514748|NCT01251562|Experimental|Cohort 5|"44.0 mg/kg
~Sterile Compound C31510 for Injection"
11514749|NCT01251562|Experimental|Cohort 6|"58.7 mg/kg
~Sterile Compound C31510 for Injection"
11514750|NCT01251562|Experimental|Cohort 7|"78.2 mg/kg
~Sterile Compound C31510 for Injection"
11514751|NCT01251562|Experimental|Cohort 8|"104.3 mg/kg
~Sterile Compound C31510 for Injection"
11514752|NCT01251562|Experimental|Cohort 9|"139.0 mg/kg
~Sterile Compound C31510 for Injection"
11514753|NCT01251549|Experimental|Experimental: A|A group of paraplegics.
11514754|NCT01251536|Other|Arm B - standard dose of cetuximab|Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab 250 mg/m2 weekly. No comparison between arms was planned.
11514755|NCT01251536|Experimental|Arm A - dose escalation of cetuximab|Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly.
11514756|NCT01251523|Active Comparator|PACE Plus|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
11514757|NCT01251523|Active Comparator|PACE|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
11514758|NCT01251523|No Intervention|Control|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
11514759|NCT01251510||Healthy adults|
11514760|NCT01251510||Type 2 diabetes|
11514761|NCT01251471|Experimental|Escitalopram|Escitalopram, p.o., 10 mg/d; optional 20 mg/d after 2 weeks for 8 weeks
11514762|NCT01251458|Experimental|Torisel|
11514763|NCT01251432||chronic otitis media|adults who have had tympanostomy tube(s) inserted for chronic otitis media
11514764|NCT01251432||Eustachian tube dysfunction|adults who have had tympanostomy tube(s) inserted for the clinical diagnosis of Eustachian tube dysfunction
11514765|NCT01251419|Experimental|Testimonial and Union Arm|The testimonial and union arm will receive the same letter as the testimonial treatment arm but with the addition of the union affiliation of the employee giving the testimonial.
11514766|NCT01251419|Experimental|Control|The control arm will receive a letter signed by our partner company's Chief Medical Officer, explaining the health and monetary benefits of switching from brand name prescription medication to generic prescription medication.
11514767|NCT01251419|Experimental|Testimonial Treatment Arm|The testimonial treatment arm will receive the exact same letter as the control arm, but the letter will feature an employee's testimonial along with the first name, last initial, city and state of the employee giving the testimonial.
11514768|NCT01251406|Placebo Comparator|Placebo|Subcutaneous administration for daily for 8 hours a day for 10 days
11514769|NCT01251406|Experimental|rhNRG-1 Dose 1|Subcutaneous administration for daily for 8 hours a day for 10 days
11514770|NCT01251406|Experimental|rhNRG-1 Dose 2|Subcutaneous administration for 8 hours a day for 10 days
11514771|NCT01251393|Experimental|Biperiden|Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
11514772|NCT01251393|Placebo Comparator|Placebo|Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
11514773|NCT01251380|Experimental|Dysport|Dysport was injected into either one or both lower limbs in up to 4 cycles of treatment, a minimum of 12 weeks apart and up to a maximum of 40 weeks apart. Doses varied from 5 Units (U)/Kg to 20 U/kg for one leg, or from 10 U/Kg to 30 U/kg for two legs, with a maximum dose of no more than 30 U/Kg overall, or 1000 U, whichever was reached first.
11514774|NCT01251367|Experimental|Dysport®|Dysport® is injected into lower limbs across 4 cycles of treatment, a minimum of 12 weeks between 2 injections. Doses vary from 1000 U to 1500 U.
11514775|NCT01251354|Experimental|BN83495|
11514776|NCT01251341|Experimental|Compassion Meditation Group|
11514777|NCT01251341|Active Comparator|Health Education and Wellness Group|
11514778|NCT01251341|Experimental|Mindful Attention Training|
11514779|NCT01251328|Active Comparator|General anaesthesia|General anaesthesia is performed under standardized conditions
11514780|NCT01251328|Active Comparator|Sedation|Sedation is performed under standardized conditions
11514781|NCT01251315|Placebo Comparator|Placebo low dose|Placebo for low dose group given as a single dose.
11514782|NCT01251315|Active Comparator|N Acetyl cysteine, 600mg (low dose)|N-Acetyl Cysteine (NAC)600 mg (low dose) given as a single dose.
11514783|NCT01251315|Active Comparator|Proimmune 200(FT061452)|Proimmune 200(FT061452) low dose group 3000 mg given as a single dose.
11514784|NCT01251315|Placebo Comparator|Placebo high dose|Placebo given to high dose group given as a single dose.
11514785|NCT01251315|Active Comparator|N Acetyly cysteine, 1200mg (high dose)|N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
11514786|NCT01251315|Active Comparator|FT061452, 6000mg high dose|Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
11514881|NCT01250496|Placebo Comparator|Placebo|Matching normal saline placebo (sterile salt water).
11514787|NCT01251302||Prospective Cohort|Patient presenting with chest pain or anginal equivalent and receiving a resulted age, sex and gene expression score (ASGES) to assist in diagnosis.
11514788|NCT01251302||Retrospective Cohort|Patients presenting with chest pain or anginal equivalent who did not receive an age, sex and gene expression score (ASGES) to assist in diagnosis. Note: this cohort was historical.
11514789|NCT01251276|Experimental|Modified Process Hepatitis B Vaccine in Base Study|Participants who received 3 doses of Modified Process Hepatitis B Vaccine in the Base Study were eligible to receive a single challenge dose of Modified Process Hepatitis B Vaccine on Day 1 of the Challenge Dose Study
11514790|NCT01251276|Experimental|ENGERIX-B™ Vaccine in Base Study|Participants who received 3 doses of ENGERIX-B™ vaccine in the Base Study were eligible to receive a single challenge dose of Modified Process Hepatitis B Vaccine on Day 1 of the Challenge Dose Study
11514791|NCT01251263|Other|Group 1|Cyclic OC users prior to initiating study OC. Estradiol or placebo given in a certain sequence depending on the randomization.
11514792|NCT01251263|Other|Group 2|Spontaneous ovulation group prior to initiating study OC. Estradiol or placebo given in a certain sequence depending on the randomization.
11514793|NCT01251250|Experimental|Arm I|Patients receive oral Azadirachta indica once daily on days 1-28. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
11514794|NCT01251237|Experimental|Moviprep Orange|All patients receive 2 litres of NRL0706 solution.
11514795|NCT01251224|Active Comparator|Education Group|This group will receive IPM education at baseline, and then the full IPM intervention after completing the study.
11514796|NCT01251224|Experimental|IPM Group|This group will receive the full IPM intervention at baseline.
11514797|NCT01251211|Active Comparator|botulinum toxin type A|botulinum toxin type A will be injected subcutaneously in the painful area (maximum 300 units)
11514798|NCT01251211|Placebo Comparator|sodium chloride 9 %|sodium chloride 9 % will be used as a neutral placebo
11514799|NCT01251198||Acute coronary Syndrome|Patients affected are patients with acute coronary syndrome with ST segment elevation ST (myocardial infarction) in 48 hospitalized in one of the centers (emergency, ambulance, intensive care unit, cardiac catheterization lab).
11514800|NCT01251185|Experimental|CHF|Single-arm, open label, subjects with Congestive Heart Failure, with ischemic etiology.
11514801|NCT01251172|Experimental|Treatment (RO4929097 after autologous stem cell transplant)|"STEM CELL TRANSPLANTATION AND CHEMOTHERAPY: Patients undergo standard mobilization and collection of autologous peripheral stem cells (>= 4.0 x 10^6 CD34+ cells/kg). Patients then receive high-dose melphalan IV on days -3 and -2 and undergo autologous stem cell transfusion on day 0. Patients with progressive disease, stable disease, partial response, stringent complete response, or complete response are taken off study; patients with residual/persistent disease (VGPR) continue to therapeutic treatment.
~THERAPEUTIC TREATMENT: Beginning 100-110 days after transplantation, patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
11514802|NCT01251146|Experimental|Bisoprolol|
11514803|NCT01251146|Active Comparator|Atenolol|
11514804|NCT01251133|Experimental|LBVH0101|
11514805|NCT01251133|Active Comparator|Hiberix|
11514806|NCT01251120|Experimental|1|
11514807|NCT01251120|Active Comparator|2|
11514808|NCT01251107|Experimental|Arm B|BEACOPP (Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) for 4 escalated cycles followed by 4 standard cycles
11514809|NCT01251107|Active Comparator|Arm A|ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 6 to 8 cycles
11514810|NCT01251081|Experimental|extra high volume hemofiltration|extra high volume hemofiltration (85 mL/kg/h, EHVHF)
11514811|NCT01251081|Sham Comparator|high volume hemofiltration|high volume hemofiltration (50 mL/kg/h, HVHF)
11514812|NCT01251068|Experimental|gest age, cerebral ,somatic oxygenation measurement|
11514813|NCT01251055|Placebo Comparator|Placebo|
11514814|NCT01251055|Experimental|GlyT-1 inhibitor-1|GlyT-1 inhibitor-1 4000 mg/day
11514815|NCT01251042|Experimental|Sangvia and retransfusion|
11514816|NCT01251042|Sham Comparator|Sangvia and no retransfusion|
11514817|NCT01251029|Experimental|sugar pil and saline|
11514818|NCT01250990|Active Comparator|Niacin|Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
11514819|NCT01250990|Placebo Comparator|Placebo|Placebo tablet with 50 mg niacin for the first 4 weeks to maintain blinding of the study team and subjects, changed to pure placebo after that.
11514820|NCT01250977|Placebo Comparator|Placebo|Participants are instructed to take one placebo pill every night before going to bed with a glass of water for 28 days.
11514821|NCT01250977|Experimental|Donepezil|Participants are instructed to take one 5mg pill (donepezil HCL [Aricept®]) every night before going to bed with a glass of water for 28 days.
11514822|NCT01250964|Active Comparator|Wound-assisted lens injection|Wound-assisted lens injection is considered neither superior or inferior to wound-directed lens injection.
11514823|NCT01250964|Active Comparator|Wound-directed lens injection|Wound-directed lens injection is neither considered superior nor inferior to wound-assisted lens injection.
11514824|NCT01250951|Experimental|Deferasirox|
11514825|NCT01250938|Experimental|ESI - Community Outreach|All families receive the same Early Social Intervention - Community Outreach (ESI-CO) treatment for 3 months in addition to 6 months of community resource support.
11514826|NCT01250925|Active Comparator|OPTI-FREE® RepleniSH®|33 participants will be assigned to use this lens care regimen during the six-week assessment period
11514827|NCT01250925|Active Comparator|Clear Care®|33 participants will be assigned to use this lens care regimen during the six-week assessment period
11514828|NCT01250925|Active Comparator|ReNu MultiPlus® MultiPurpose Solution|33 participants will be assigned to use this lens care regimen during the six-week assessment period
11514829|NCT01250912|Experimental|Imaging Tracer|No arms, the Radio tracer will be used in all subjects imaging tests.
11514830|NCT01250899|No Intervention|Vitamin D Sufficient|HIV-infected men and women with HIV-1 viral load <200 copies/mL on stable ART and 25(OH)D level ≥30ng/mL receive no intervention.
11514831|NCT01250899|Experimental|Vitamin D Insufficient|HIV-infected men and women with HIV-1 viral load <200 copies /mL on stable ART and 25(OH)D level <30ng/mL receive 50,000 IU twice weekly for 5 weeks followed by 2000 IU daily to complete 12 weeks.
11514832|NCT01250886|Placebo Comparator|Normal saline solution|Blood sample is obtained from patient in either forearm immediately before a Normal saline solution administered on the same site. The volume of fluid administration is calculated by means of Holliday and Segar formula.
11514833|NCT01250886|Active Comparator|Lactated Ringer's solution|Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
11514834|NCT01250886|Active Comparator|Acetate Ringer's solution|Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
11514835|NCT01250873|Experimental|LY2216684/sertraline/LY2216684 + sertraline|"Period 1: LY2216684 18 milligram (mg) oral (po) dose on Days 1-3.
~Period 2: Sertraline 50 mg po dose on Day 4 followed by sertraline 100 mg po dose on Days 5-10.
~Period 3: LY2216684 18 mg po dose + sertraline 100 mg po dose on Days 11-13."
11514836|NCT01250860|Sham Comparator|Control Group|Control DoboMed group - only specific active exercises: symmetrical positions for exercising; asymmetrical active movements; thoracic spine kyphotization; transverse plane derotation; apical area involvement; concave ribs mobilization; exteroceptive facilitation; respiration-directed movements of the thorax and spine; three-dimensional displacement of vertebra; active autocorrection.
11514837|NCT01250860|Experimental|Experimental group|"Experimental DoboMed and Kaltenborn manual therapy. Suitable techniques were chosen according to manual examination: cervical spine; thoracic spine; lumbar spine; costovertebral articles; pelvis position. During the 15 sessions in group DK we used:derotational manual terapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method; the manual techniques used in continuation study were different from techniques in pilot study."
11514838|NCT01250847|Experimental|Seroquel-XR|The subjects At-Risk Mental States will be treated with Quetiapine(Seroquel-XR) from baseline to end of trial.
11514839|NCT01250847|Experimental|Schizophrenia Comparator|The subject with schizophrenia will be treated with standard treatment
11514840|NCT01250847|No Intervention|Healthy Control Comparator|The subjects will not be required to treat
11514841|NCT01250834|Experimental|LY2189265 + Atorvastatin|"Period 1: Participants received a single 40-milligram (mg) oral dose of atorvastatin on Day 1, followed by a 7- to 10-day washout period between Period 1 and Period 2.
~Period 2: Participants received a single 1.5-mg subcutaneous dose of LY2189265 on Day 1, followed by a single 40-mg oral dose of atorvastatin on Day 3."
11514842|NCT01250821|Experimental|Ovulation induction|
11514843|NCT01250795|Experimental|15 ug HAI-05 plus Alhydrogel|vaccine
11514844|NCT01250795|Experimental|45 ug HAI-05 plus Alhydrogel|vaccine
11514845|NCT01250795|Experimental|90 ug HAI-05 plus Alhydrogel|vaccine
11514846|NCT01250795|Experimental|90 ug HAI-05 in saline|vaccine
11514847|NCT01250795|Placebo Comparator|Saline|placebo
11514848|NCT01250782|Placebo Comparator|Physiological Serum|
11514849|NCT01250782|Active Comparator|Glutamine|
11514850|NCT01250769|Active Comparator|Manual Toothbrush 1|Manual Toothbrush used for 1 minute twice a day
11514851|NCT01250769|Active Comparator|Manual Toothbrush 2|Manual Toothbrush used for 2 minutes twice a day
11514852|NCT01250769|Experimental|Manual Toothbrush + Interproximal Cleaning 1|Manual Toothbrush used twice a day for 2 minutes plus Interproximal Cleaning Device used once a day
11514853|NCT01250769|Experimental|Manual Toothbrush + Interproximal Cleaning 2|Manual Toothbrush used twice a day for 2 minutes plus Interproximal Cleaning Device used twice a day
11514854|NCT01250756|Experimental|1|Experimental
11514855|NCT01250756|Experimental|2|Active comparator
11514856|NCT01250743|Experimental|Ascorbic Acid (Vitamin C)|
11514857|NCT01250730|Experimental|1.0|This study will consist of three cohorts: PF-02341066 150 mg treatment group (n = 6), PF-02341066 250 mg treatment group (n = 6) and PF-02341066 400 mg treatment group (n = 6).
11514858|NCT01250717|Experimental|Docetaxel Followed by Radical Prostatectomy|Docetaxel,Dexamethasone,Estramustine,Zoladex,Casodex,Prostatectomy
11514859|NCT01250691||hospital acquired pneumonia|
11514860|NCT01250691||isolated rooms|
11514861|NCT01250691||ward-type ICU|
11514862|NCT01250678||neurocognitive impaired|MS patients treated with natalizumab who at the beginning of the study suffer from cognitive impairment
11514863|NCT01250678||neurocognitive non-impaired|MS patients treated with natalizumab who at the beginning of the study do not suffer from cognitive impairment
11514864|NCT01250665||clinically isolated syndrome|In this study the term clinically isolated syndrome (CIS) is defined according to the Task Force on Differential Diagnosis in MS, as a monophasic presentation of neurological symptoms with suspected underlying inflammatory demyelinating disease (Miller 2008).
11514865|NCT01250665||remitting, relapsing MS|remitting relapsing MS according to the criteria by Poser (Poser 1983) or McDonald (McDonald 2001)
11514866|NCT01250652|Active Comparator|Levocetirizine|24 patients will received 20 mg Levocetirizine daily
11514867|NCT01250652|Experimental|Levocetirizine plus Hydroxyzine|24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
11514868|NCT01250626||a single-group study|Pediatric OPD, age < 18 y/o.
11514869|NCT01250600|Experimental|Remote-care|Home exercise monitored by the remote care system
11514870|NCT01250600|Active Comparator|Control|Home exercise under expert's instruction
11514871|NCT01250587|Experimental|PDC31|
11514872|NCT01250574||Postoperative infections|
11514873|NCT01250574||Bacterial infections in the GI tract|
11514874|NCT01250548|Active Comparator|2|
11514875|NCT01250548|Placebo Comparator|Apremilast|Placebo Compared to apremilast arm
11514876|NCT01250535|Experimental|Warfarin plus lovastatin|Warfarin plus lovastatin
11514877|NCT01250535|Placebo Comparator|Warfarin plus placebo|Warfarin plus placebo
11514878|NCT01250509|Experimental|CALMM|Participants receiving the 'Craving and Lifestyle Management through Mindfulness' intervention, i.e. program that combines stress reduction with mindful eating practices.
11514879|NCT01250509|No Intervention|Waitlist Control|Participants were waitlisted for the intervention during the experimental phase.
11514882|NCT01250483||BPH|men aged more than 40 years who presented with BPH/LUTS and showed negative results of transrectal prostate biopsy before the period of AB medication
11514883|NCT01250483||prostate cancer|men aged more than 40 years who presented with BPH/LUTS and showed positive results of transrectal prostate biopsy before the period of AB medication
11514884|NCT01250470|Experimental|Treatment (vaccine therapy)|"Patients receive Montanide ISA-51/survivin peptide vaccine SC followed by sargramostim SC on day 0. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
~TREATMENT EXTENSION: After completion of study treatment, select patients may receive additional doses of Montanide ISA-51/survivin peptide vaccine SC and sargramostim SC. Treatment repeats every 3 months in the absence of disease progression or unacceptable toxicity."
11514885|NCT01250457|Experimental|Topical timolol|topical Timolol 0.5% solution applied twice daily
11514886|NCT01250444|Experimental|Inspiratory Muscle Training|It will me performed a loaded training of ventilatory muscles in patients with Hypertension. Its is done with the practice of breathing exercises associated to an training device, specific for this kind of intervention.
11514887|NCT01250431|Experimental|EFT (Emotional Freedom Techniques)|10 sessions of EFT.
11514888|NCT01250431|No Intervention|Wait List|10 week wait period.
11514889|NCT01250418|Active Comparator|Ketamine Group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
11514890|NCT01250418|No Intervention|No ketamine|No ketamine added to anesthesia regimen
11514891|NCT01250405|Active Comparator|Cinacalcet|
11514892|NCT01250405|Placebo Comparator|Placebo|
11514893|NCT01250392|Other|Control Arm|The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment.
11514894|NCT01250392|Experimental|Active Choice Only Arm|The active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
11514895|NCT01250379|Active Comparator|1|
11514896|NCT01250379|Experimental|2|
11514897|NCT01250366|Experimental|Arm 1: INX-08189 (9 mg) or Placebo|
11514898|NCT01250366|Experimental|Arm 2: INX-08189 (25 mg) or Placebo|
11514899|NCT01250366|Experimental|Arm 3: INX-08189 (50 mg + 9 mg) or Placebo|
11514900|NCT01250366|Experimental|Arm 4: INX-08189 (50 mg) or Placebo|
11514901|NCT01250366|Experimental|Arm 5: INX-08189 (9 mg) or Placebo + Ribavirin|
11514902|NCT01250366|Experimental|Arm 6: INX-08189 (25 mg) or Placebo + Ribavirin|
11514903|NCT01250366|Experimental|Arm 7: INX-08189 (100 mg) or Placebo|
11514904|NCT01250353|Experimental|conjunctival autograft|The conjunctival autograft was performed after the pterygium surgery like usual technique.
11514905|NCT01250353|Experimental|latex biomembrane application|The latex biomembrane was applied after pterygium surgery to recover the bare sclera area. This device was closed to conjunctiva with running suture anchored at some places to episclera. The sutures was removed at fourteenth day after surgery.
11514906|NCT01250340|Experimental|Aspirin|100 mg/day for 30 days
11514907|NCT01250340|Placebo Comparator|Placebo|1 cp /day for 30 days
11514908|NCT01250327|Experimental|Melody|insertion of a pulmonic valved stent
11514909|NCT01250327|Active Comparator|Bare stent|insertion of a bare metal stent
11514910|NCT01250327|Active Comparator|Surgery|conventional surgery methode.
11514911|NCT01250314|Other|With fracture|Patients with fracture
11514912|NCT01250314|Other|Without fracture|Patients without fracture
11514913|NCT01250301|Experimental|De-nicotinised cigarettes + standard treatment|
11514914|NCT01250301|Active Comparator|Standard treatment|
11514915|NCT01250288||Consumers|Consumers (patients or their designated proxies) who have registered to use the personal health management technology platform offered by the Brooklyn Health Information Xchange (BHIX) or Long Island Patient Information Xchange (LIPIX).
11514916|NCT01250288||Providers|Providers who are authorized to view the data entered by consumers in either (1) BHIX's personal health management system, along with BHIX health information exchange data; OR LIPIX's secure messaging system (SMS), along with LIPIX health information exchange data.
11514917|NCT01250275|Experimental|Acute Phase: traditional canola oil|Participants will receive banana bread containing traditional canola oil once weekly during the 5-week schedule
11514918|NCT01250275|Active Comparator|Acute Phase: high oleic canola oil|Participants will receive banana bread containing high oleic canola oil once weekly during the 5-week schedule
11514919|NCT01250275|Active Comparator|Acute Phase: soybean oil|Participants will receive banana bread containing soybean oil once weekly during the 5-week schedule
11514920|NCT01250275|Active Comparator|Acute Phase: high linoleic safflower oil|Participants will receive banana bread containing high linoleic safflower oil once weekly during the 5-week schedule
11514921|NCT01250275|Active Comparator|Acute Phase: coconut oil|Participants will receive banana bread containing coconut oil once weekly during the 5-week schedule
11514922|NCT01250275|Experimental|Chronic Phase: traditional canola oil|A total of 25 participants with peripheral arterial disease will be assigned foods containing traditional canola oil for a total of 8 weeks
11514923|NCT01250275|Active Comparator|Chronic Phase: safflower oil|A total of 25 participants with peripheral arterial disease will be assigned foods containing an oil mixture representing the typical western diet for a total of 8 weeks
11514924|NCT01250262|Active Comparator|Standard care|Subjects will receive normal medical care and follow up during the four month study period if assigned to this group.
11514925|NCT01250262|Active Comparator|Isolated Lumbar Resistance Exercise Program|Lumbar extension exercise protocol to increase strength and reduce pain.
11514926|NCT01250262|Active Comparator|Total Body Resistance Exercise Program|Training protocol for 1 set for each exercise: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl
11514961|NCT01249963|Experimental|Experimental Group|Patients of this group will receive 400 ml per day of T-Diet plus Atémpero product during 28 days.
11514962|NCT01249963|Active Comparator|Control Diet|Patients of this group will receive 2 packets (76 g) per day of AlitraQ (Abbott) product during 28 days.
11514963|NCT01249950||adolescents|adolescents with morbid obesity
11514927|NCT01250249|Active Comparator|BCG Vaccine - Intradermal injection|"Subjects must be in the age group of 0 - 14 years of age.
~2. Subject's parent should be able to understand and have to sign the informed consent form after being explained by the investigator. They must be aware of the experimental nature of the therapy, its potential benefits, side effects and risks.
~3. Ability to comply with the schedule of treatment and follow-up.
~4. Absence of BCG scar
~5. Tuberculin negative
~6. No evidence of any other infection
~7. No evidence of skin disease
~Skin testing with tuberculin is not generally carried out before giving BCG but when performed, those who are found to be positive reactors need not to be immunized"
11514928|NCT01250236||verum|brimonidine 0.1% eye drops twice daily
11514929|NCT01250236||placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
11514930|NCT01250210|Experimental|AG200-15|Drug intervention with levonorgestrel and ethinyl estradiol : AG200-15 a transdermal contraceptive system containing 2.60 mg of levonorgestrel and 2.30 mg of ethinyl estradiol.
11514931|NCT01250210|Experimental|AG200|Drug intervention with levonorgestrel and ethinyl estradiol: AG200 a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.92 of ethinyl estradiol.
11514932|NCT01250210|Experimental|AG200LE|Drug intervention with levonorgestrel and ethinyl estradiol: AG200LE a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.28 mg of ethinyl estradiol.
11514933|NCT01250197|Experimental|Formulation A|AR-12286 Ophthalmic Solution Formulation A
11514934|NCT01250197|Experimental|Formulation B|AR-12286 Ophthalmic Solution Formulation B
11514935|NCT01250184|Active Comparator|Physical Therapy|Twelve sessions, 3 per week.
11514936|NCT01250184|Active Comparator|Lidocaine injection|Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
11514937|NCT01250184|Experimental|Lidocaine injection + physical therapy|Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
11514938|NCT01250171|Experimental|Secukinumab 10 mg/kg|Patients received a single dose of secukinumab 10 mg/kg infused intravenously over a 2 hour period.
11514939|NCT01250171|Experimental|Canakinumab 10 mg/kg|Patients received a single dose of canakinumab 10 mg/kg infused intravenously over a 2 hour period.
11514940|NCT01250171|Placebo Comparator|Placebo|Patients received a single placebo infusion intravenously over a 2 hour period.
11514941|NCT01250158|Experimental|Liver-PILP kit|Liver-PILP kit
11514942|NCT01250145|Experimental|LY333334 + placebo|"Part A:
~Both a placebo and an 80 microgram active patch will be applied to the same arm for at least 6 hours daily, test arms will be alternated daily, for 22 days
~Part B:
~Induction phase: Both a placebo and an 80 microgram active patch will be applied to the same arm for at least 6 hours daily, test arms will be alternated daily, 4 times a week for 3 weeks
~Rest phase: 2 weeks with no patch application
~Challenge phase: 80 microgram active patch given once for at least 6 hours"
11514943|NCT01250132|Other|Moderate to severe Traumatic Brain Injury|"Assessment of hypopituitarism. Blood tests at different moments:
~day 0
~when leaving intensive care unit
~month 3
~month 12"
11514944|NCT01250119|Experimental|Single Arm|
11514945|NCT01250106|Experimental|Probiotic capsule|
11514946|NCT01250106|Placebo Comparator|placebo capsule|
11514947|NCT01250080|Experimental|Glutamine|
11514948|NCT01250080|Sham Comparator|Control|
11514949|NCT01250054|Other|Lotrafilcon B / Comfilcon A|Lotrafilcon B multifocal contact lenses worn first, with comfilcon A multifocal contact lenses worn second. Each product worn bilaterally on a daily wear basis for one week.
11514950|NCT01250054|Other|Comfilcon A /Lotrafilcon B|Comfilcon A multifocal contact lenses worn first, with lotrafilcon B multifocal contact lenses worn second. Each product worn bilaterally on a daily wear basis for one week.
11514951|NCT01250041|Active Comparator|femoral block|
11514952|NCT01250041|Experimental|saphenous block|
11514953|NCT01250015||control|given standard nhs advice leaflet
11514954|NCT01250015||interventional|given standard nhs advice leaflet with numerical information and pictograms
11514955|NCT01250002|Active Comparator|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
11514956|NCT01250002|Placebo Comparator|Placebo|Placebo will receive the same volume of saline infusion.
11514957|NCT01249989|Experimental|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
11514958|NCT01249989|Experimental|Simultaneous MBC Condition|Participants in the simultaneous condition will target FV+, Sed- and PA+ simultaneously. Participants will wear accelerometers and enter diet and sedentary activity 5 days/week on their Smartphone. All 3 goal thermometers will be activated from the outset of prescription (FV, Sed, PA). In week 1-2, participants will close 1/3 of the gap between their baseline FV, Sed, and PA behavior and their goals. In week 3-4 participants will close 2/3 of the gap, and 100% of their goals in weeks 5-6. Participants will maintain their target behaviors for FV, Sed and PA through week 12.
11514959|NCT01249989|Active Comparator|Stress Management Control|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
11514960|NCT01249976|Experimental|catheter-spearing diagnostic methods|experimental
11514964|NCT01249937|Placebo Comparator|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
11514965|NCT01249937|Active Comparator|Ranibizumab and Triamcinolone acetonide|"Recent research has discovered that persons with wet or dry ARMD show an immune response, as if the body is fighting off an infection. The body creates a complex immune response to the growth of blood vessels into the eye tissue, which triggers side effects. It is believed that preventing this inflammation can lead to greater visual gains and a need for fewer treatment injections.
~Animal studies have shown that Triamcinolone Acetonide, a corticosteroid (class of drugs that reduce inflammation) can prevent damage to vision from this inflammation. The hypothesis is that treatment with both Ranibizumab and Triamcinolone Acetonide will allow even greater vision improvements than Ranibizumab treatment alone for wet age-related macular degeneration."
11514966|NCT01249924|Other|CPAP Group|CPAP Treatment
11514967|NCT01249924|Other|Control Group|Routine care
11514968|NCT01249911|Experimental|Lreuteri|Group of 130 infants allocated to receive L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.
11514969|NCT01249911|Placebo Comparator|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
11514970|NCT01249872|Active Comparator|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Group A patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline. Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
11514971|NCT01249872|Active Comparator|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Group B patients receive an epidural bolus dose of 1mg of morphine intra-operatively (45 min before the estimated end of the surgery). Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
11514972|NCT01249872|Active Comparator|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Group C patients receive an epidural bolus dose 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
11514973|NCT01249872|Active Comparator|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Group D patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline, epidurally. Postoperatively,patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
11514974|NCT01249872|Active Comparator|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Group E patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 1mg of morphine.Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
11514975|NCT01249872|Active Comparator|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Group F patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 2 mg of morphine. Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
11514976|NCT01249859||Signet ring cell carcinoma|
11514977|NCT01249859||non signet ring cell adenocarcinoma|
11514978|NCT01249846|Experimental|Arm 1|Each one of the two selected periodontal pockets (target pockets) will be randomized to the Frequent PerioChip® treatment or to the Routine PerioChip®.
11514979|NCT01249846|Placebo Comparator|Arm 2|Each one of the two selected target pockets will be randomized to the Frequent PerioChip® treatment or to the Frequent Placebo Chip treatment.
11514980|NCT01249833|Active Comparator|Oseltamivir|Added to standard of care for influenza
11514981|NCT01249833|No Intervention|Standard of care alone|Standard of care for influenza
11514982|NCT01249820|Experimental|group A|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
11514983|NCT01249820|Experimental|group B|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
11514984|NCT01249807||1|Patients, Family, Community member
11514985|NCT01249794|No Intervention|Best available treatment|
11514986|NCT01249794|Experimental|non invasive ventilation|
11514987|NCT01249781||resilience in caregivers whose child with ALL|
11514988|NCT01249768||Cohort|The cohort will consist of 150 patients with a hypokinetic rigid syndrome and a disease duration of maximum 36 months
11514989|NCT01249755||delirious patients|The cohort is divided in delirious and non-delirious patients
11514990|NCT01249690|Experimental|PAD|
11514991|NCT01249690|Experimental|TAD|
11514992|NCT01249677|Experimental|insulin glargine|patients with type 2 diabetes on previous therapy with metformin were examined before and after eight weeks of treatment with insulin glargin, aimed to normalize fasting plasma glycaemia
11514993|NCT01249664|Experimental|Arm 1|
11514994|NCT01249664|Sham Comparator|Arm 2|
11514995|NCT01249651|Other|1|One arm: esomeprazole 40 mg
11514996|NCT01249638|Experimental|Cap+Bev until PD followed by CAPIRI +Bev|"Capecitabine + Bevacizumab
~In case of Progression Escalation to:
~Capecitabine + Irinotecan + Bevacizumab"
11514997|NCT01249638|Active Comparator|Capiri + Bev|Capecitabine + Irinotecan + Bevacizumab
11514998|NCT01249625|Active Comparator|N95 Respirator|The investigators are comparing specific N95 respirator against specific medical masks.
11514999|NCT01249625|Active Comparator|Medical/surgical mask|The investigators are comparing medical/surgical masks against the N95 respirator.
11515000|NCT01249612|Placebo Comparator|Control treatment|Elbow joint icing using two plastic bags with crushed ice
11515001|NCT01249612|Active Comparator|Active treatment|Knee joint icing using two plastic bags with crushed ice
11515002|NCT01249586|Placebo Comparator|Traditional teaching|A traditional class of blindness prevention.
11515003|NCT01249573|Experimental|fascia therapy|arm where fascia therapy is used as a treatment for an acute ankle distortion
11515004|NCT01249573|Experimental|transcutaneous fibrolysis|arm where transcutaneous fibrolysis is used as a treatment for an acute ankle distortion
11515005|NCT01249573|Placebo Comparator|placebo|arm where placebo therapy is used as a treatment for an acute ankle distortion
11515006|NCT01249560||raltegravir|"To illustrate the cause and effect relationship between the abnormalities of the distribution(casting) of the molecules of co-activation and the rate of apoptose, we compare also 2 groups: a first group of patients with a rate of apoptose normal ( n=10 ), and another group of patients having a rate of apoptose aggravated ( n=10 ).
~20 eligible patients will receive their treatment to J1 and will be estimated for the residual concentration of the raltegravir ®, the antiretroviral activity, the tolerance and the observance at the treatments of the study in the visits of evaluation of M1, M2, M3, M6, M12, and / or in case of premature stop(ruling) of the try(essay). Every visit will give rise to a clinical evaluation of the patient. The arisen of unwanted events"
11515007|NCT01249547|Experimental|axitinib arm|
11515008|NCT01249534||Patients after gastroesophageal cancer surgery|
11515009|NCT01249508|Experimental|implemented nutrition label|A one-group pre-/post-design is used for the evaluation of the university canteen-based nutrition labeling program. This means that all participants of the program are exposed to the nutrition label implemented in the university canteen. The subject essentially serves as its own control based on pre-test behaviour. The nutrition label implemented is a star rating label calculated and assigned to each meal offered at the university canteens and based on the content of energy, saturated fat, sodium and fibre (expressed as vegetable portion).
11515010|NCT01249482||Late eradication|Group B (n=100) will be given rabeprazole 20 mg qd for 8 weeks and discontinued for 2 weeks. Then, H. pylori eradication with triple therapy will be given for one week, followed by rabeprazole 20 mg qd for 7 weeks.
11515011|NCT01249482||Negative HP|For patients with negative H. pylori infection (n=100), proton-pump inhibitor with rabeprazole 20 mg qd will be given for 8 weeks and discontinued.
11515012|NCT01249482||Early eradication|Group A (n=100) will be given initial H. pylori eradication with triple therapy for one week, followed by proton-pump inhibitor with rabeprazole 20 mg qd for 7 weeks.
11515013|NCT01249469|Placebo Comparator|Vehicle|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand.
11515014|NCT01249469|Experimental|Skin whitening cosmetic product|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand.
11515015|NCT01249456||Femara(Letrozole)|
11515016|NCT01249443|Experimental|Treatment (carboplatin, paclitaxel)|"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~Before February 1, 2013, patients also received vorinostat PO once daily on days 1-5 with paclitaxel and carboplatin."
11515017|NCT01249430|Experimental|Treatment (azacitidine, mitoxantrone, etoposide, cytarabine)|Patients receive azacitidine IV over 30 minutes on days 1-8 and mitoxantrone hydrochloride IV over 10 minutes, etoposide phosphate IV over 30-60 minutes, and cytarabine IV over 6 hours on days 3-8. Treatment continues for 1 course in the absence of disease progression or unacceptable toxicity.
11515018|NCT01249417|Experimental|Dysport 10 U/Kg|10 U/Kg per lower limb. Either one or both lower limbs can be treated. Total volume injected, 2ml per leg.
11515019|NCT01249417|Experimental|Dysport 15 U/Kg|15 U/Kg per lower limb. Either one or both lower limbs can be treated. Total volume injected, 2ml per leg.
11515020|NCT01249417|Placebo Comparator|Placebo|Total volume to be injected per lower limb - 2ml. Either one or both lower limbs can be treated.
11515021|NCT01249404|Experimental|Dysport® 1000 U, IM|1000 U, I.M. (in the muscle), on day 1 (single treatment cycle)
11515022|NCT01249404|Experimental|Dysport® 1500 U, IM|1500 U, I.M., on day 1 (single treatment cycle)
11515023|NCT01249404|Placebo Comparator|Placebo|I.M., on day 1 (single treatment cycle)
11515024|NCT01249391|Active Comparator|Intervention (splinting)|Splinting of nominated joint in this group
11515025|NCT01249391|No Intervention|Control|Observation and usual treatment only.
11515026|NCT01249378|Active Comparator|10 g non emulsified of milk fat|They are compared using the repeated measurements taken within subjects
11515027|NCT01249378|Active Comparator|40 g non emulsified of milk fat|The subjects receive three sequences of different breakfasts. They are compared using the repeated measurements taken within subjects.
11515028|NCT01249378|Active Comparator|40 g finely emulsified of milk fat|The subjects receive three sequences of different breakfasts. They are compared using the repeated measurements taken within subjects.
11515029|NCT01249365|Experimental|HPV vaccine|Healthy female subjects aged 26 years and above, who received control vaccine in the primary study NCT00294047, were administrated 3 intramuscular injections of Cervarix vaccine into the deltoid of the non-dominant arm, according to a 0, 1, 6-month schedule in the current study.
11515030|NCT01249352|Active Comparator|STANDARD CHEMORADIATION|"Cisplatin 75 mg/m2, IV IV doses on D1 of each chemotherapy cycle, for 4 cycles Fluorouracil 1000 mg/m2, IV IV doses in a 24-hour continuous infusion, from D1 to D4 of each chemotherapy cycle, for 4 cycles.
~Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day Equivalent to 28 fractions for 5 and a half weeks."
11515031|NCT01249352|Experimental|CHEMORADIATION + NIMOTUZUMAB|"Nimotuzumab 200 mg, IV weekly IV doses for up to 26 weeks. Cisplatin 75 mg/m2, IV IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.
~Fluorouracil 1000 mg/m2, IV IV dose in a 24-hour continuous infusion, from D1 to D4 of each chemotherapy cycle, for 4 cycles.
~Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day Equivalent to 28 fractions for 5 and a half weeks."
11515032|NCT01249339|Active Comparator|General 1 g pouch|Oral pouch 0.3-1g, single dose. One pouch administered over 30 minutes.
11515033|NCT01249339|Active Comparator|Catch Licoice 1 g pouch|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
11515034|NCT01249339|Active Comparator|Catch Licorice Mini 0.5 g pouch|Oral pouch 0.5g, single dose. One pouch administered over 30 minutes.
11515035|NCT01249339|Active Comparator|Catch Licorice dry mini 0.3 g pouch|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
11515036|NCT01249300||Dysphagia|Patients with CVA which causes dysphagia
11515037|NCT01249274|Placebo Comparator|Placebo|Matched placebo pills to be taken twice daily
11515038|NCT01249274|Experimental|Progesterone|100 mgs progesterone twice daily
11515039|NCT01249261|Placebo Comparator|Placebo/Risedronate|Placebo years 1-5, Risedronate 5mg/day years 6 & 7, no drug year 8
11515040|NCT01249261|Active Comparator|Risedronate|Risedronate 5mg years 1-7, no drug year 8
11515041|NCT01249248||Male basketball players|
11515042|NCT01249248||Female basketball players|
11515043|NCT01249248||Baseball players|
11515044|NCT01249248||Softball players|
11515045|NCT01249248||Football players|
11515046|NCT01249248||Female vollyball players|
11515047|NCT01249248||Male soccer players|
11515048|NCT01249248||Female soccer players|
11515049|NCT01249235|Active Comparator|Patch|The operative eye will be patched.
11515050|NCT01249235|Experimental|Bandage Contact Lens|The operative eye will have a bandage contact lens
11515051|NCT01249222|No Intervention|conventional treatment|
11515052|NCT01249222|Experimental|Plasmapheresis|
11515053|NCT01249209|Other|lifestyle advice|
11515054|NCT01249196|Placebo Comparator|Placebo|
11515055|NCT01249196|Experimental|SK-PC-B70M 200mg bid|
11515056|NCT01249196|Experimental|SK-PC-B70M 300mg bid|
11515057|NCT01249196|Other|Donepezil|
11515058|NCT01249183|Experimental|1- VAXIGRIP and REPEVAX concomitantly|
11515059|NCT01249183|Active Comparator|2-REPEVAX 28 days after VAXIGRIP|
11515060|NCT01249170|Other|First year fellow|
11515061|NCT01249170|Other|Second Year Fellow|
11515062|NCT01249157|Experimental|MRI and PEM scans|All consenting patients who are to have staging breast MRI, will be offered 18FDG PEM (Positron Emission Mammography) within 30 days. If the patient had a previous breast MRI that was done within 30 days at an outside institution, this MRI can be used if a radiologist determines that it is an adequate study. The surgery date will not be affected by the additional PEM evaluation. All imaging will be done and reviewed by MSKCC breast imagers. MRI and PEM findings suggestive of malignancy will be prospectively recorded in both the ipsilateral and contralateral breast.
11515063|NCT01249144|Active Comparator|Tecnis Z9002 Intraocular Lens (IOL)|
11515064|NCT01249144|Active Comparator|Softec HD Intraocular Lens (IOL)|
11515065|NCT01249131|Experimental|Treatment A first, then Treatment B, followed by Treatment C|Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliter (mL) room temperature water after at least an 8-hour fast, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard Food and Drug Administration (FDA) high-fat meal, in third intervention period. The washout period between each period will be a minimum of 10 days.
11515066|NCT01249131|Experimental|Treatment A first, then Treatment C, followed by Treatment B|Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib administered will be orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
11515067|NCT01249131|Experimental|Treatment B first, then Treatment A, followed by Treatment C|Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in third intervention period.
11515068|NCT01249131|Experimental|Treatment B first, then Treatment C, followed by Treatment A|Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
11515069|NCT01249131|Experimental|Treatment C first, then Treatment A, followed by Treatment B|Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
11515070|NCT01249131|Experimental|Treatment C first, then Treatment B, followed by Treatment A|Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
11515071|NCT01249118|Experimental|Part 1: GDC-0973 IV Infusion First, Then GDC-0973 Capsules|Participants will receive single dose of GDC-0973 2 milligrams (mg) IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
11515072|NCT01249118|Experimental|Part 2: GDC-0973 IV Infusion First, Then GDC-0973 Capsules|Participants will receive single dose of GDC-0973 2 mg IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
11515613|NCT01245166|Experimental|Metformin/Acarbose|
11515073|NCT01249118|Experimental|Part 2: GDC-0973 Capsules First, Then GDC-0973 IV Infusion|Participants will receive single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in first intervention period followed by single dose of GDC-0973 2 mg IV infusion in second intervention period. The washout period between each period will be a minimum of 10 days.
11515074|NCT01249105|Experimental|Part 1|Patients with recurrent glioblastoma multiforme (GBM) who require reoperation.
11515075|NCT01249105|Experimental|Part 2|Participants with GBM and with anaplastic glioma
11515076|NCT01249092|Experimental|Pentoxifylline 400 mg TID|This study is an open label pilot with only one arm.
11515077|NCT01249079||Schizophrenia Family|
11515078|NCT01249027||Observational|Single arm prospective, observational, single-arm, open-label, multicenter, postapproval registry study using XIENCE V® Everolimus Eluting Coronary Stent System (EECSS).
11515079|NCT01249014|No Intervention|Control|No peri-operative warming.
11515080|NCT01249014|Experimental|Warmed fluids|Patients will receive warmed i.v. fluids administered pre- and intra-operatively.
11515081|NCT01249014|Experimental|Warmed fluids and warm air|Patients will receive warmed i.v. fluids administered pre- and intra-operatively, and warmed air blown into a blanket covering the body intra-operatively.
11515082|NCT01249001|Experimental|Group 1|This group will receive oral aprepitant on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the capsule on the first day of the second study cycle of chemotherapy.
11515083|NCT01249001|Experimental|Group 2|This group will receive an aprepitant capsule on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the oral aprepitant on the first day of the second study cycle of chemotherapy.
11515084|NCT01248988||Synflorix Group|Infants and children who received at least one dose of Synflorix™ as a part of routine practice at a private clinic or hospital
11515085|NCT01248975|Experimental|FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)|FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)
11515086|NCT01248975|Active Comparator|FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)|FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)
11515087|NCT01248975|Placebo Comparator|FP/SAL 250/50mcg BID plus placebo BID|P/SAL 250/50mcg BID plus placebo BID
11515088|NCT01248962|Experimental|Standard 30-minute infusion|This is a non-blinded randomized study comparing standard 30-minute infusion carboplatin to extended 3-hour infusion carboplatin in women with recurrent, ovary, fallopian tube, and primary peritoneal cancer who will be treated with a carboplatin containing chemotherapy regimen.
11515089|NCT01248962|Experimental|extended 3-hour infusion|This is a non-blinded randomized study comparing standard 30-minute infusion carboplatin to extended 3-hour infusion carboplatin in women with recurrent, ovary, fallopian tube, and primary peritoneal cancer who will be treated with a carboplatincontaining chemotherapy regimen.
11515090|NCT01248949|Experimental|MEDI3617 SINGLE AGENT TOTAL|Participants will receive MEDI3617 via intravenous (IV) infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
11515091|NCT01248949|Experimental|MEDI3617 + BEVACIZUMAB Q3W ESCALATION|Participants will receive MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
11515092|NCT01248949|Experimental|MEDI3617 + BEVACIZUMAB Q2W TOTAL|Participants will receive MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.
11515093|NCT01248949|Experimental|MEDI3617 + PACLITAXEL TOTAL|Participants will receive MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.
11515094|NCT01248949|Experimental|MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL|Participants will receive MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
11515095|NCT01248936|Experimental|Overall Trial|Participants received vemurafenib 960 milligram (mg) orally two times a day for up to one year. Participants were treated until disease progression, unmanageable toxicity most probably attributable to vemurafenib, withdrawal of consent, and study termination by the sponsor
11515096|NCT01248923|Experimental|ARRY-520 (Schedule 1) + bortezomib + G-CSF|
11515097|NCT01248923|Experimental|ARRY-520 (Schedule 1) + bortezomib + dexamethasone + G-CSF|
11515098|NCT01248923|Experimental|ARRY-520 (Schedule 2) + bortezomib + dexamethasone + G-CSF|
11515099|NCT01248910|Experimental|Alpine Skiing|
11515100|NCT01248910|No Intervention|Control group|
11515101|NCT01248897||erbB2+/Her2 Breast Cancer Patients|erbB2+/Her2 Breast Cancer Patients Treated with Lapatinib and Other Anti-erbB2/Her2 Therapy
11515102|NCT01248884|Experimental|GSK217744 Group 1|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of GSK217744 formulation A vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The GSK217744 and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
11515103|NCT01248884|Experimental|GSK217744 Group 2|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of GSK217744 formulation B vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The GSK217744 and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
11515104|NCT01248884|Active Comparator|Infanrix hexa Group|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of Infanrix hexa™ vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The Infanrix hexa™ and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
11515105|NCT01248871|Active Comparator|SEVO|sevoflurane-remifentanil/sufentanil combination
11515106|NCT01248871|Active Comparator|SERE|volatile agent only during reperfusion
11515107|NCT01248871|Active Comparator|propofol|propofol-remifentanil/sufentanil
11515148|NCT01248468|Active Comparator|Sumatriptan (100 mg)|1 tablet containing sumatriptan 100 mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets
11515108|NCT01248858|Experimental|GSK2126458 and GSK1120212|The first combination schedule that will be tested involves giving both GSK2126458 and GSK1120212 continuously once a day in the morning until the subjects withdraw from the study. Other dosing schedules with both drugs will also be tested and these schedules are described below GSK2126458 will be dosed twice per day (morning and evening) continuously and GSK1120212 will be dosed once a day in the morning on a continuous schedule. Subjects will be treated with both drugs and remain in the study as long as they are benefiting from therapy. Another schedule that will be tested involves giving GSK2126458 twice each day (morning and evening) on an intermittent schedule (4 days of treatment, 10 days rest, then 4 days treatment, 10 days rest). GSK1120212 will be dosed once each day in the morning on a continuous schedule. Subjects will be treated with both drugs as long as they are benefiting from therapy.
11515109|NCT01248832|Experimental|Telephone Counseling|Telephone Counseling
11515110|NCT01248832|Active Comparator|Self-help Materials|Self-help Materials
11515111|NCT01248819|Active Comparator|Instillation|Instillation of Ropivacaine 100 mg in the abdominal cavity
11515112|NCT01248819|Experimental|Nebulization|Nebulization of Ropivacaine 60 mg in the abdominal cavity
11515113|NCT01248806||Smokers or former smokers, Aged ≥ 50|Men and women current daily smokers or former smokers, Aged ≥ 50
11515114|NCT01248793|Experimental|Placebo|
11515115|NCT01248793|Experimental|Golimumab|
11515116|NCT01248780|Experimental|Golimumab + methotrexate (MTX)|Participants will receive golimumab 50 mg as subcutaneous (SC) (under the skin) injections administered every 4 weeks for up to 48 weeks. In addition, participants will receive a stable dose of MTX.
11515117|NCT01248780|Experimental|Placebo + methotrexate (MTX)|Participants will be administered Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48. In addition, participants will receive a stable dose of MTX.
11515118|NCT01248754|Experimental|18F-DOPA PET imaging|Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
11515119|NCT01248741|Experimental|HDR prostate brachytherapy|
11515120|NCT01248728|Active Comparator|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea high-EPA (HP) (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2.
11515121|NCT01248728|Placebo Comparator|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2.
11515122|NCT01248715|Experimental|Oseltamirvir|These patients will receive early oseltamivir plus current, standard empiric antibacterial therapy.
11515123|NCT01248715|No Intervention|Standard of care|These patients will be treated with the current, standard care, including currently recommended antibiotics or antiviral therapy based on national recommendations from the IDSA/ATS guidelines for management of hospitalized patients with CAP and ACIP antiviral use guidelines for hospitalized patients with confirmed of suspect influenza, per clinician discretion. In addition these patients with have a NP swab collected for influenza PCR testing and clinical information will be extracted from the medical record.
11515124|NCT01248702|Experimental|Critical Pathway|
11515125|NCT01248702|No Intervention|Standard Practice|
11515126|NCT01248689|Active Comparator|concentration profile 1|"IOP will be measured under this order of sevoflurane concentrations:
~7%, 5%, 2%, 0.5%"
11515127|NCT01248689|Active Comparator|concentration profile 2|"IOP will be measured under this order of sevoflurane concentrations:
~7%, 2%, 5%, 0.5%"
11515128|NCT01248689|Active Comparator|concentration profile 3|"IOP will be measured under this order of sevoflurane concentrations:
~7%, 0.5%, 5%, 2%"
11515129|NCT01248663|Active Comparator|antecolic reconstruction|After completion of pancreaticoduodenectomy and reconstruction of the pancreaticojejunostomy and hepaticojejunostomy, the reconstruction of the intestinal passage will be conducted by performing an antecolic duodeno-jejunostomy
11515130|NCT01248663|Experimental|retrocolic reconstruction|After completion of pancreaticoduodenectomy and reconstruction of the pancreaticojejunostomy and hepaticojejunostomy, the reconstruction of the intestinal passage will be conducted by performing a retrocolic duodeno-jejunostomy
11515131|NCT01248650|Active Comparator|TRK-820 5 μg|Taking TRK-820 5μg(two 2.5μg soft capsules) once on the first day of hospitalization by oral route
11515132|NCT01248650|Active Comparator|TRK-820 2.5μg|Taking TRK-820 2.5μg(one 2.5μg soft capsule) once on the first day of hospitalization by oral route
11515133|NCT01248637||Pimonidazole hydrochloride|Oral pimonidazole is administered at a dose of 0.5gm/m2 once approximately 24 hrs prior to surgery
11515134|NCT01248624|Active Comparator|Early Palliative Care Referral|The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
11515135|NCT01248624|Placebo Comparator|Conventional Cancer Care|This control arm receives standard cancer care.
11515136|NCT01248611|Experimental|fentanyl|cancer patients with pain
11515137|NCT01248585|Active Comparator|Dexamethasone|2 x 4 mg dexamethasone tablets taken once daily for 5 days
11515138|NCT01248585|Placebo Comparator|Placebo|2 placebo tablets taken once daily for 5 days
11515139|NCT01248572|Experimental|Softec HD IOL|
11515140|NCT01248546||Digital mammography|
11515141|NCT01248520|Placebo Comparator|General health information|Pregnant women receiving text messages containing general health messages without including information regarding the importance of the influenza vaccination
11515142|NCT01248520|Active Comparator|Influenza and general health information|Pregnant women receiving text messages with influenza facts and the importance of the influenza vaccination, as well as general health messages Intervention: Text messages with influenza facts
11515143|NCT01248494|Experimental|BEZ235 + Letrozole|
11515144|NCT01248494|Experimental|BKM120 + Letrozole|
11515145|NCT01248494|Experimental|Intermittent BKM120 + Letrozole|
11515146|NCT01248481||Group 1|
11515147|NCT01248468|Experimental|Aspirin, acetaminophen and caffeine|AAC: 2 tablets, each containing acetaminophen 250 mg, aspiring 250 mg, caffeine 65 mg and 1 placebo tablet matching sumatriptan 100 mg tablets
11515238|NCT01247883|Active Comparator|single dose PF-04634817 solution|subjects receive a single dose of PF-04634817 as a solution
11515149|NCT01248468|Placebo Comparator|Placebo|1 placebo tablet matching sumatriptan 100mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets
11515150|NCT01248455|Experimental|anti-KIR in Smoldering Multiple Myeloma Patients|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
11515151|NCT01248442|Experimental|Cholecalciferol|
11515152|NCT01248442|Placebo Comparator|Placebo|
11515153|NCT01248429||Patient treated by TKI|Any patient with solid tumor and treated by Thyrosine Kinase Inhibitor for at least 1 week
11515154|NCT01248416|Active Comparator|Aromatase Inhibitor|Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
11515155|NCT01248416|Active Comparator|Growth Hormone|Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
11515156|NCT01248416|Active Comparator|Aromatase Inhibitor and Growth Hormone|Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
11515157|NCT01248403|Active Comparator|paclitaxel + placebo|"Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.
~+ Placebo (2 tablets / day) d1-d28"
11515158|NCT01248403|Experimental|paclitaxel + RAD001|"Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.
~+ RAD001 10mg (2 x5 mg tablets / day) d1-d28"
11515159|NCT01248390|Experimental|Interactive Metronome therapy|Fifteen one-hour training sessions using Interactive Metronome system, in addition to treatment as usual.
11515160|NCT01248390|No Intervention|Treatment as Usual|Standard of care symptom management.
11515161|NCT01248377||Cephalosporins allergic patients|
11515162|NCT01248364|Experimental|BI 10773 Arm|BI 10773 high dose once daily
11515163|NCT01248351|Experimental|autologous stored platelets|
11515164|NCT01248338|Active Comparator|metoprolol, tablets|metoprolol succinate 50-100 mg orally daily for one year
11515165|NCT01248338|Experimental|nebivolol|nebivolol 5 mg capsule once daily for one year
11515166|NCT01248325|Experimental|Luffa Operculate Nasal Solution 5mg/mL|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
11515167|NCT01248325|Active Comparator|Saline Solution (NaCl 0,9%)|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
11515168|NCT01248312||morbidly obese|BMI >45
11515169|NCT01248312||thin patients|BMI <45
11515170|NCT01248299|Experimental|Chemotherapy plus best supportive care|Chemotherapy plus best supportive care with follow up at each cycle of the treatment with FU-CDDP; LV5FU2-CDDP; FOLFOX; TPF
11515171|NCT01248299|Active Comparator|Best supportive care|Best supportive care with follow up every 6 weeks
11515172|NCT01248286|Experimental|Whole grain rice|
11515173|NCT01248286|Active Comparator|Refined grain rice|
11515174|NCT01248273|Experimental|immunization|This trial will investigate the safety and immune responses following immunization with the unimolecular pentavalent Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21. This is a phase I study to assess toxicity and immunogenicity.
11515175|NCT01248260|Experimental|Higher-strength folic acid|Higher-strength folic acid (4mg).
11515176|NCT01248260|No Intervention|Low-strength folic acid|Low-strength (0.8mg) folic acid (standard of care)
11515177|NCT01248247|Experimental|Group 1 - Erlotinib|Erlotinib 150 mg by mouth each day of a 28 day cycle.
11515178|NCT01248247|Experimental|Group 2 - Erlotinib + MK-2206|"Erlotinib 150 mg by mouth each day of a 28 day cycle.
~MK-2206 135 mg by mouth every week of a 28 day cycle."
11515179|NCT01248247|Experimental|Group 3 - AZD6244 + MK-2206|AZD6244 100 mg by mouth daily of a 28 day cycle. MK-2206 100 mg by mouth every week of a 28 day cycle.
11515180|NCT01248247|Experimental|Group 4 - Sorafenib|Sorafenib 400 mg by mouth twice a day for a 28 day cycle.
11515181|NCT01248234|Active Comparator|Propofol|Propofol alone will be used to put an elderly hypertensive patient to sleep for surgery.
11515182|NCT01248234|Active Comparator|Etomidate|Etomidate alone will be used to put an elderly hypertensive patient to sleep.
11515183|NCT01248234|Active Comparator|Propofol and Etomidate|A combination of Etomidate and Propofol will be used to put an elderly hypertensive patient to sleep for surgery.
11515184|NCT01248221|Experimental|Healthy subjects|The subject will consume the test meal containing [13C]-Spirulina platensis and 99mTc sulfur colloid, after which gastric emptying will be assessed simultaneously by scintigraphy and breath tests. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
11515185|NCT01248221|Experimental|Dyspeptic subjects|The subject will consume the test meal containing [13C]-Spirulina platensis and 99mTc sulfur colloid, after which gastric emptying will be assessed simultaneously by scintigraphy and breath tests. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
11515186|NCT01248208|Experimental|FluMist (LAIV) group|FluMist influenza vaccine 0.2 mL intranasal vaccine once
11515187|NCT01248208|Active Comparator|Flu shot (TIV) group|"Patients 6 months to 2 yrs or > 49 years or WITH a history of asthma symptoms / treatment within the past 12 months will receive intramuscular influenza vaccination. History/Treatment of asthma in the past 12 months is defined as follows:
~wheezing in the past 12 months
~use of inhaled corticosteroids (ICS), combined ICS / long acting beta agonist (LABA), or oral steroid in the past 12 months
~emergency room or acute care visit or hospitalization for asthma or wheezing in the past 12 months."
11515188|NCT01248195|Other|Phase I: 1 arm 'amisulpride open label'|For 4 weeks, all patients will be treated with amisulpride open label.
11515189|NCT01248195|Active Comparator|Phase II: 'amisulpride double blind'|Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'amisulpride double blind'
11515239|NCT01247870|Experimental|Metformin|Metformin 1 g twice daily for 28-35 days
11515240|NCT01247870|Placebo Comparator|Placebo|Matched placebo capsules
11515190|NCT01248195|Active Comparator|Phase II 'olanzapine double blind'|Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'olanzapine double blind'
11515191|NCT01248195|Other|Phase III: 1 arm 'clozapine open label'|Patients who do not meet remission criteria during phase II (6-week double blind amisulpride vs olanzapine), flow to phase III, where only 1 arm is available: 'clozapine open label'
11515192|NCT01248195|Experimental|Psychosocial intervention|Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Psychosocial Intervention' arm.
11515193|NCT01248195|No Intervention|Psychosocial Intervention phase: 'TAU'|Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Treatment as usual' arm.
11515194|NCT01248169||Hydralazine|This group will receive administration of the antihypertensive Hydralazine for the attempted control of their blood pressure and stabilization of their hemodynamic state.
11515195|NCT01248169||Labetalol|This group will receive administration of the antihypertensive Labetalol for the attempted control of their blood pressure and stabilization of their hemodynamic state.
11515196|NCT01248156||Intervention|Patients with persistent, long standing persistent and paroxysmal AF, who will receive ablation at sites that potentially maintain human AF.
11515197|NCT01248156||Control|Patients with persistent, long standing persistent and paroxysmal AF, who receive conventional ablation as determined by the operator at each site, and based upon Heart Rhythm Society guidelines.
11515198|NCT01248143|Experimental|Green tea|
11515199|NCT01248143|Experimental|FPP|
11515200|NCT01248130|Active Comparator|Omega-3 Fatty Acid Treatment|
11515201|NCT01248130|Placebo Comparator|Placebo (Sugar Pill)|
11515202|NCT01248117|Experimental|Previously Treated|With prior anti-vegf therapy, only, no sooner than 30 days prior to enrollment into trial
11515203|NCT01248117|Experimental|Treatment-Naive|Treatment-Naive: no previous treatment for PCV
11515204|NCT01248104|Active Comparator|Tranexamic Acid|The research pharmacist used computer randomization to assign patients to receive either TXA or EACA. The TXA group re- ceived a bolus of 10 mg / kg over 15 minutes fol- lowed by an infusion of 1 mg/kg/hr.
11515205|NCT01248104|Active Comparator|Aminocaproic Acid|The research pharmacist used computer randomization to assign patients to receive either TXA or EACA. The EACA group received a bolus of 100 mg / kg given over 15 minutes shortly after induction of anesthesia followed by an infusion of 10 mg/kg/hr.
11515206|NCT01248091|Placebo Comparator|Placebo gel|
11515207|NCT01248091|Experimental|Nitroprusside Gel|
11515208|NCT01248078|Active Comparator|Cefazolin A|administered before skin incision
11515209|NCT01248078|Active Comparator|Cefazolin B|after umbilical cord clamping
11515210|NCT01248078|Placebo Comparator|saline solution|administered before skin incision
11515211|NCT01248065|Placebo Comparator|Ciclesonide + placebo|
11515212|NCT01248065|Experimental|Ciclesonide + Vitamin D|
11515213|NCT01248052|Experimental|LY2979165 (Part A)|single oral doses at dose levels ranging from 20 to 1000 mg
11515214|NCT01248052|Placebo Comparator|Placebo (Part A)|single oral dose
11515215|NCT01248052|Experimental|LY2979165 - low dose (Part B)|single oral low dose of LY297165 (dose to be determined by Part A)
11515216|NCT01248052|Experimental|LY2979165 - high dose (Part B)|single oral high dose of LY2979165 (dose determined from Part A)
11515217|NCT01248052|Placebo Comparator|Placebo - Part B|single oral dose
11515218|NCT01248039||Total arthroplasty|Patients with osteoarthrosis going for hip or knee arthroplasty
11515219|NCT01248026|Experimental|Buttermilk|
11515220|NCT01248026|Placebo Comparator|Placebo|
11515221|NCT01248000||classical Hodgkin lymphoma|All cases of classical Hodgkin lymphoma diagnosed between 2006 and 2008 in the province of Modena, Reggio Emilia, Parma and Ferrara will be considered eligible for this study.
11515222|NCT01247987|Active Comparator|Blastocyst cryopreservation|Subjects randomly assigned to this arm of the study will have all of their embryos cryopreserved at the blastocyst stage, followed by thaw and transfer in a subsequent menstrual cycle.
11515223|NCT01247987|Experimental|Bipronuclear oocyte cryopreservation|Subjects randomly assigned to this arm of the study will have all of their bipronuclear oocytes cryopreserved, followed by thaw, extended culture, and transfer in a subsequent menstrual cycle.
11515224|NCT01247974|Experimental|CorMatrix ECM for Pericardial Closure|Pericardial closure with CorMatrix ECM
11515225|NCT01247974|No Intervention|Control|No Pericardial Closure
11515226|NCT01247961|Experimental|10 mg intravenous dexamethasone|Subjects randomized to intervention arm will receive single dose of 10 mg intravenous dexamethasone.
11515227|NCT01247961|Placebo Comparator|Placebo|Equal volume of normal saline administered as a single intravenous dose at enrollment.
11515228|NCT01247948|Experimental|navigation assisted spine surgery|
11515229|NCT01247935|Experimental|Acupuncture|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
11515230|NCT01247935|Experimental|transcutaneous electrical stimulation|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
11515231|NCT01247935|No Intervention|Control|patient are monitored for pain and discomfort
11515232|NCT01247922|Experimental|Erlotinib|Participants who received erlotinib in a continuous oral dose of 85 mg/m^2 per day until dose modification, interruption or study discontinuation occurred.
11515233|NCT01247909|Experimental|Ceftriaxone|Ceftriaxone in infants with sepsis and bacterial meningitis
11515234|NCT01247909|Active Comparator|Penicillin and gentamicin|Penicillin and Gentamicin in infants with sepsis and bacterial meningitis
11515235|NCT01247896|Experimental|Active|
11515236|NCT01247896|Placebo Comparator|Placebo|
11515237|NCT01247883|Active Comparator|single dose PF-04634817 tablet|subjects receive a single dose of PF-04634817 as a tablet
11515241|NCT01247857|Active Comparator|Preoperative Nebulization|Nebulization of 30 mg of Ropivacaine in the peritoneal cavity before surgery
11515242|NCT01247857|Active Comparator|Postoperative Nebulization|Nebulization of 30 mg of Ropivacaine in the peritoneal cavity after surgery
11515243|NCT01247857|Placebo Comparator|Control|Nebulization of normal saline 3 ml before and after surgery
11515244|NCT01247844|Other|Day 7|removal of Shang Ring at 7 days
11515245|NCT01247844|Other|Day 14|removal of Shang Ring at 14 days
11515246|NCT01247844|Other|Day 21|removal of Shang Ring at 21 days
11515247|NCT01247831|Other|glaucoma patients|All of the patients treated with SLT need further IOP reduction for control of their glaucoma.
11515248|NCT01247818|Experimental|PH-10 Treatment (High Dose Cohort)|
11515249|NCT01247818|Experimental|PH-10 Treatment (Mid Dose Cohort)|
11515250|NCT01247818|Experimental|PH-10 Treatment (Low Dose Cohort)|
11515251|NCT01247818|Placebo Comparator|Vehicle Control|
11515252|NCT01247805|Experimental|Treatment A|Revatio: 1 x 20 mg IR oral tablet.
11515253|NCT01247805|Experimental|Treatment B|2 x 10 mg sildenafil citrate IR oral tablet.
11515254|NCT01247805|Experimental|Treatment C|2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).
11515255|NCT01247792|No Intervention|"Before"|No Intervention Observation of current practice
11515256|NCT01247792|Other|"After"|SOPs for decision-making and communication Assessment of practice after implementation of SOPs
11515257|NCT01247779|Active Comparator|Standard Coelioscopy|gynecologic surgery - standard coelioscopy
11515258|NCT01247779|Experimental|Robot-assisted coelioscopy|gynecologic surgery - robot assisted coelioscopy
11515259|NCT01247766||Patients with rheumatoid arthritis (RA) who receive abatacept|
11515260|NCT01247766||Patients with RA who receive BDM drugs|biologic disease-modifying (BDM)
11515261|NCT01247766||Patients with RA who receive non-biologic DMARDs|disease-modifying anti-rheumatic drugs (DMARDs)
11515262|NCT01247753|Experimental|Intervention|
11515263|NCT01247753|No Intervention|Control|
11515264|NCT01247740|Experimental|1|three chamber bag for parenteral nutrition containing lipids, glucose, amino acids and electrolytes
11515265|NCT01247740|Active Comparator|2|compounded monobag including lipids, glucose, amino acids and electrolytes
11515266|NCT01247714|Active Comparator|Group 1|The group 1 will receive the experimental product T-Diet plus Diabet NP for the first month followed by a reference diet corresponding to a current marketed product (Glucerna SR, Abbott) for the second month, then the patients will receive a control product non specific for diabetic patients (T-Diet plus Standard)for the third month, and finally a specific diet for diabetic patients (Novasource, Nestlé Healthcare Nutrition)for the fourth month.
11515267|NCT01247714|Active Comparator|Group 2|The group 2 will receive a reference diet corresponding to a current marketed product (Glucerna SR, Abbott)for the first month, followed by the experimental product T-Diet plus Diabet NP for the second month, then the patients will receive a specific diet for diabetic patients (Novasource, Nestlé Healthcare Nutrition)for the third month, and finally a control product non specific for diabetic patients (T-Diet plus Standard)for the fourth month
11515268|NCT01247701|Experimental|Umbilical Cord Blood Transplant|Busulfan,Cyclophosphamide, Fludarabine, Cord Blood Stem Cell Infusion
11515269|NCT01247688|Experimental|Umbilical Cord Blood Transplant Treatment Plan|Cytoxan, Fludarabine, Total Body Irradiation (TBI), Cord Blood Stem Cell Infusion
11515270|NCT01247675|Experimental|ACP-001, 0.02 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.02 mg hGH/kg/week for 4 weeks
11515271|NCT01247675|Experimental|ACP-001, 0.04 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.04 mg hGH/kg/week for 4 weeks
11515272|NCT01247675|Experimental|ACP-001, 0.08 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.08 mg hGH/kg/week for 4 weeks
11515273|NCT01247675|Active Comparator|Omnitrope, 0.04 mg hGH/kg/wk|Once daily subcutaneous injection of human Growth Hormone (Omnitrope) equivalent to 0.04 mg hGH/kg/week for 4 weeks
11515274|NCT01247662||ASD group|
11515275|NCT01247662||ADHD group|
11515276|NCT01247662||Normally developing control group|
11515277|NCT01247649|Experimental|Study group|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
11515278|NCT01247636|Experimental|Home-exercise|
11515279|NCT01247610||ADHD group|
11515280|NCT01247610||Control group|
11515281|NCT01247597||Controls|People without pathogenic DICERl germline variation
11515282|NCT01247597||DICERl (cases)|People with pathogenic DICERl germline variation or history of DICERl-associated tumors
11515283|NCT01247571|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11515284|NCT01247558||Test Cohort|100 randomized subjects administered Metanx®
11515285|NCT01247558||Control Cohort|400 subjects with diabetes mellitus meeting the same inclusion and exclusion criteria as the test cohort who have not been treated with Metanx®.
11515286|NCT01247545|Placebo Comparator|Control|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
11515287|NCT01247545|Active Comparator|Remote ischaemic conditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
11515288|NCT01247532|Experimental|Waitlist|
11515289|NCT01247519|No Intervention|observation|
11515290|NCT01247519|Experimental|Intervention|
11515291|NCT01247506||1|tumor tissues of HCC patients
11515292|NCT01247506||2|paired nontumor tissues of HCC patients
11515293|NCT01247480||Breast cancer patients|
11515294|NCT01247467||Breast Tumor|Breast Tumor Blocks
11515295|NCT01247454|Other|academic detailing|All arms will receive this intervention
11515296|NCT01247454|Experimental|Electronic Health Record (EHR) prompt|One intervention arm will receive the EHR prompt along with the academic detailing
11515343|NCT01247155||first day review|
11515297|NCT01247454|Experimental|EHR prompt and patient prompt|The final arm will receive this combined intervention plus the academic detailing
11515298|NCT01247428|Experimental|MiStent SES|The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
11515299|NCT01247415||Anaphylaxis|Anaphylaxis: these patients will have to meet at least level 3 of diagnostic certainty according to the Brighton Collaboration criteria for anaphylaxis
11515300|NCT01247415||Allergic-like reactions|Allergic-like reactions: These patients will have to have displayed at least one sign or symptom of an allergic reaction (any of the minor or major criteria of anaphylaxis) but will exclude patients with conjunctivitis who will belong to the ORS group
11515301|NCT01247415||ORS cases|ORS cases: According to the Public Health Agency case definition, these patients should have presented a bilateral conjunctivitis plus ≥1 of the seven respiratory symptoms (cough, wheeze, chest tightness, difficulty breathing, difficulty swallowing, hoarseness or sore throat) that started within 24 hrs of vaccination, with or without facial oedema (no restriction for duration) (ref: Public Health Agency of Canada: User Guide: Report of Adverse Events Following Immunization (AEFI) Appendix III National Case Definitions of AEFIs of Special Interest: oculo-respiratory Syndrome. http://www.phac-pc.gc.ca/im/aefi_guide/ann3-eng.php
11515302|NCT01247415||Controls|Controls will be individuals who received the pH1N1 vaccine but did not present any of the above mentioned adverse events after their vaccine.
11515303|NCT01247402|Active Comparator|Paclitaxel eluting balloon|Freeway 0.035 Paclitaxel eluting balloon (3 microgram Paclitaxel/mm2)
11515304|NCT01247402|Active Comparator|Standard balloon angioplasty|standard balloon angioplasty
11515305|NCT01247389|Active Comparator|midline incision|
11515306|NCT01247389|Active Comparator|transverse incision|
11515307|NCT01247376|No Intervention|No Cooling and compression|
11515308|NCT01247376|Experimental|Intervention with cooling and compression|
11515309|NCT01247363|Experimental|LY2608204|Oral capsules of LY2608204 given once daily at a starting dose of 160 milligram (mg), which may be titrated in 3 dose escalations to 240 mg, 320 mg and 400 mg, with a 7-day treatment duration at each dose level for up to 28 days total treatment.
11515310|NCT01247350|Experimental|2 mg LY3009104 (Cohort 1)|2mg administered once on day 1 (single dose)
11515311|NCT01247350|Experimental|5 mg LY3009104 (Cohort 2)|5mg administered once on day 1 (single dose)
11515312|NCT01247350|Experimental|10 mg LY3009104 (Cohort 3)|10 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
11515313|NCT01247350|Experimental|14 mg LY3009104 (Cohort 4 )|14 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
11515314|NCT01247350|Placebo Comparator|Placebo|administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
11515315|NCT01247337|Experimental|Single arm chemotherapy treatment|
11515316|NCT01247324|Active Comparator|Interferon beta-1a 44 mcg SC|Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
11515317|NCT01247324|Experimental|Ocrelizumab|Ocrelizumab 600 mg intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.
11515318|NCT01247311|Active Comparator|1.|"1,25 Vitamin D (0.50ug *3 per week)
~This is a prospective randomized double blind placebo controlled study of 125 stable CKD subjects examining the impact of vitamin D supplementation (1,25 vitamin D or 25 vitamin D formulations) compared to placebo on arterial stiffness and other parameters of vascular health"
11515319|NCT01247311|Active Comparator|2.|"25 Vitamin D (5000IU * 3 per week)
~This is a prospective randomized double blind placebo controlled study of 125 stable CKD subjects examining the impact of vitamin D supplementation (1,25 vitamin D or 25 vitamin D formulations) compared to placebo on arterial stiffness and other parameters of vascular health"
11515320|NCT01247311|Placebo Comparator|3.|Placebo given orally 3xweek for six months
11515321|NCT01247298|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive stereotactic body radiation therapy (SBRT) which is 3 radiation treatments at 15 Gy, for a total of 45 Gy. Patients will be given Trans-Arterial Chemoembolization (TACE), prior to enrollment. (TACE is not performed as part of this clinical study, even though it is part of the inclusion criteria.)
11515322|NCT01247285|Experimental|Investigational Test Product|90 mg Fluoxetine Hydrochloride Capsules (Teva)
11515323|NCT01247285|Active Comparator|Reference Listed Drug|90 mg PROZAC WEEKLY® Capsules (Eli Lilly)
11515324|NCT01247272|Active Comparator|Reference Listed Drug|90 mg PROZAC WEEKLY® Capsules (Eli Lilly)
11515325|NCT01247272|Experimental|Investigational Test Product|90 mg Fluoxetine Hydrochloride Capsules (Teva)
11515326|NCT01247259|Active Comparator|SLIT-mono|
11515327|NCT01247259|Active Comparator|SLIT-poly|
11515328|NCT01247246|Placebo Comparator|Placebo|
11515329|NCT01247246|Active Comparator|SCV-07 0.1mg/kg|
11515330|NCT01247246|Active Comparator|SCV-07 0.3mg/kg|
11515331|NCT01247246|Active Comparator|SCV-07 1.0mg/kg|
11515332|NCT01247233|Active Comparator|Standard or Hypofractionated radiotherapy|"Whole breast RT, 50Gy + boost 16Gy. Whole breast hypofractionated RT without boost, either 40Gy or 42,5Gy."
11515333|NCT01247233|Experimental|Accelerated Partial Breast Irradiation (APBI)|APBI using 3D CRT technique, in 5 days, 38.5 Gy to the tumor bed .
11515334|NCT01247220|Experimental|Peripheral Laser + Ranibizumab|Angiography-directed peripheral laser + ranibizumab
11515335|NCT01247220|Active Comparator|Ranibizumab|Ranibizumab
11515336|NCT01247207|Experimental|Ataluren|Participants will receive 3 doses of ataluren oral suspension per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20 mg/kg in the evening).
11515337|NCT01247194|Active Comparator|Cohort A|"PPI-461 50 mg
~or placebo"
11515338|NCT01247194|Active Comparator|Cohort B|"PPI-461 100 mg
~or placebo"
11515339|NCT01247194|Active Comparator|Cohort C|"PPI-461 200 mg
~or placebo"
11515340|NCT01247181|Experimental|Mobile phone text message|
11515341|NCT01247181|Active Comparator|No Mobile phone text message|Usual care provided at clinic
11515342|NCT01247168|Experimental|1|
11515345|NCT01247142||Invasive pulmonary aspergillosis (IPA)|Patients with proven or probable invasive pulmonary aspergillosis (IPA) (EORTC/MSG criteria) or putative IPA (Blot et al. Am J Respir Crit Care Med 2012)
11515346|NCT01247142||Controls|Patients without signs of infection.
11515347|NCT01247129|Experimental|SIEA,delay procedure,widening of diameter|
11515348|NCT01247103|Placebo Comparator|Part A: single ascending dose|AZD4316: single oral dose, with 1 group with/without food
11515349|NCT01247103|Placebo Comparator|Part B: multiple ascending dose|AZD4316: multiple oral doses
11515350|NCT01247090|Active Comparator|Group 1: Vasopressin - Very Low Dose|0.15 mU per kg per minute
11515351|NCT01247090|Active Comparator|Group 2: Vasopressin - Low Dose|0.30 mU per kg per minute
11515352|NCT01247090|Placebo Comparator|Group 3: Placebo|No Dose
11515353|NCT01247077|Active Comparator|placebo|Placebo and thyroxin + methimazole
11515354|NCT01247077|Placebo Comparator|selenium|selenium + methimazole + thyroxin
11515355|NCT01247064|Experimental|Nebulized 3% Saline|
11515356|NCT01247064|Placebo Comparator|Nebulized 0.9% Normal Saline|
11515357|NCT01247051|Experimental|Precoating|
11515358|NCT01247051|Active Comparator|Standard priming|
11515359|NCT01247038|Experimental|Metal on ceramic articulation|The arm consists of patients with Ceramic femoral heads articulating with metal acetabular cups
11515360|NCT01247038|Active Comparator|Metal-on-metal|The arm consists of patients with Metal femoral heads articulating with metal acetabular cups
11515361|NCT01247025||Veterans|Veterans receiving mental health services at the Eastern Colorado Healthcare System (ECHCS)/Denver Veterans Affairs Medical Center (VAMC)
11515362|NCT01247012|Active Comparator|Lipid minimization|
11515363|NCT01247012|Experimental|Omegaven|
11515364|NCT01246999|Active Comparator|Live Attenuated Influenza vaccine|LAIV 0.2 ml will be given intranasally followed by LAIV 0.2 mg given intranasally 28 days later
11515365|NCT01246999|Active Comparator|Trivalent Influenza Vaccine 2010-2011|TIV will be given in a dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 8 years intramuscularly followed by a second dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 9 years intramuscularly 28 days later
11515366|NCT01246999|Active Comparator|TIV followed by LAIV|TIV will be given in a dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 9 years intramuscularly followed by LAIV given in a dose of .2 ml intranasally 28 days later
11515367|NCT01246999|Active Comparator|LAIV followed by TIV|LAIV will be given in a dose of .2 ml intranasally followed by a dose of TIV given in a dose of .25 ml 2 years to 36 months or .5 ml 37 months to 9 years intramuscularly 28 days later
11515368|NCT01246986|Experimental|Part A Cohort 1-160 milligram (mg) LY2157299|"Per the protocol, following an interim analysis, the decision was taken to no longer randomize participants to the 160 mg LY2157299 arm. As of May 25,2012, all newly enrolled participants will receive 300 mg LY2157299.
~80 mg LY2157299 given orally twice daily (BID) for 14 days followed by 14 days off (28-day cycle).
~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
11515369|NCT01246986|Experimental|Part A Cohort 2 - 300 mg LY2157299|"150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).
~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
11515370|NCT01246986|Experimental|Part B - 300 mg LY2157299|"150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).
~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
11515371|NCT01246986|Experimental|Part C Cohort 1 - 160 mg LY2157299 + 800 mg Sorafenib|"80 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).
~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
11515372|NCT01246986|Experimental|Part C Cohort 2 - 300 mg LY2157299 + 800 mg Sorafenib|"150 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).
~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
11515373|NCT01246986|Experimental|Part D Cohort 1 - 160 mg LY2157299 + 8 mg/kg Ramucirumab|"80 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kilogram (kg) intravenous (IV) on days 1 and 15 (28-day cycle).
~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
11515374|NCT01246986|Experimental|Part D Cohort 2 - 300 mg LY2157299 + 8 mg/kg Ramucirumab|"150 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kg IV on days 1 and 15 (28-day cycle).
~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
11515375|NCT01246973|Experimental|curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
11515376|NCT01246973|Placebo Comparator|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
11515377|NCT01246960|Experimental|Ramucirumab|"Oxaliplatin 85 milligrams per square meter (mg/m^2) given on Day 1 of a 2-week cycle
~Leucovorin 400 mg/m^2 given on Day 1 of a 2-week cycle
~5-Fluorouracil (5-FU) 400 mg/m^2 bolus given on Day 1 of a 2-week cycle
~5-FU 2400 mg/m^2 continuously given over 46-48 hours on Day 1 of a 2-week cycle
~Ramucirumab 8 milligrams per kilogram (mg/kg) given on Day 1 of a 2-week cycle
~Participants will receive study treatment every 2 weeks until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
11515378|NCT01246960|Placebo Comparator|Placebo|"Oxaliplatin 85 mg/m^2 given on Day 1 of a 2-week cycle
~Leucovorin 400 mg/m^2 given on Day 1 of a 2-week cycle
~5-FU 400 mg/m^2 bolus given on Day 1 of a 2-week cycle
~5-FU 2400 mg/m^2 continuously given over 46-48 hours on Day 1 of a 2-week cycle
~Placebo given on Day 1 of a 2-week cycle
~Participants will receive study treatment every 2 weeks until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
11515379|NCT01246947|Active Comparator|Mitral surgery alone|Mitral valve surgery randomization for no repair of the moderate tricuspid regurgitation
11515380|NCT01246947|Active Comparator|Mitral surgery w/Tricuspid valve repair|Mitral valve surgery with randomization to repair the moderate tricuspid regurgitation
11515381|NCT01246934|No Intervention|COMPLICATION|
11515724|NCT01244438|Experimental|FP-1039|FP-1039
11515382|NCT01246921|Active Comparator|fluticasone proprionate 0.05 %|Group reveiving 12 months NB-UVB phototherapy twice a week in combination with fluticasone proprionate 0.05 % cream in an intermittent scheme
11515383|NCT01246921|No Intervention|no intervention|Group receiving 12 months NB-UVB phototherapy twice weekly, without any topical treatment
11515384|NCT01246908|Experimental|CX157 (TriRima)|CX157 (TriRima) in a reversible monoamine oxidase inhibitor (MAOI)
11515385|NCT01246908|Placebo Comparator|Placebo|
11515386|NCT01246895||Experimental|Microfracture with BST-CarGel
11515387|NCT01246895||Control|Microfracture without BST-CarGel
11515388|NCT01246882|Experimental|Augmented activity feedback|Feedback three times per week about 10-m walking speed, plus amount and types of physical activity measured using wireless bilateral ankle sensors that detect bouts of walking and cycling speed, duration, and distance.
11515389|NCT01246882|Active Comparator|speed-only feedback|Feedback three times per week about overground walking speed over 10 meters.
11515390|NCT01246843||metastatic Renal Cell Carcinoma without treatment|patients with metastasized RCC who did not receive treatment
11515391|NCT01246843||mRCC with treatment|"patients with metastastic renal cell cancer or GIST who are on treatment with Sunitinib or Sorafenib for
~≥ 8 weeks"
11515392|NCT01246830||3D cephalometric analysis|
11515393|NCT01246830||2D cephalometric analysis|
11515394|NCT01246804|Experimental|ginkgo biloba + raltegravir|15 days ginkgo biloba 120mg BID + raltegravir 400mg SD
11515395|NCT01246804|Active Comparator|raltegravir|single dose raltegravir 400mg
11515396|NCT01246791|Experimental|NPC-01|Single oral administration of NPC-01
11515397|NCT01246778||With/without sunitinib|Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction during 200 minutes.
11515398|NCT01246778||With/without sunitinib IP|Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction and ischemia/reperfusion
11515399|NCT01246765||Pregnant women using atypical antipsychotic(s)|Pregnant women who have taken at least one type of atypical antipsychotic at some point during this pregnancy.
11515400|NCT01246765||Pregnant women not using atypical antipsychotics|Pregnant women who have not taken an atypical antipsychotic during pregnancy.
11515401|NCT01246752|Experimental|Human Stem Cell Transplantation|Patients receive an allogenic stem cell transplantation from an HLA-matched unrelated or related donor
11515402|NCT01246752|Active Comparator|Consolidating Chemotherapy|Patients receive a standard chemotherapy as consolidation therapy
11515403|NCT01246739|No Intervention|Follow-up|Patients who are diagnosed with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), who are followed only.
11515404|NCT01246739|Experimental|Surgery|Patients diagnosed with adrenal tumour and with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), operated with adrenalectomy
11515405|NCT01246713|Placebo Comparator|Acetaminophen solid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
11515406|NCT01246713|Active Comparator|Acetaminophen liquid formulation|Subjects in this arm will receive a 15mg/kg dose of a liquid acetaminophen formulation.
11515407|NCT01246700|Experimental|Group A|Participants received 12 weeks of Sensory Attention Focused Exercise, then received 12 weeks of no exercise.
11515408|NCT01246700|Experimental|Group B|Participants received no treatment for 12 weeks, then received Sensory Attention Focused Exercise for 12 weeks.
11515409|NCT01246687|Experimental|e-Intervention group|Receive stage-specific dietary intervention via the website & standard care at the outpatient clinic.
11515410|NCT01246687|No Intervention|Control group|Continue with the standard diabetes care at the outpatient clinic without getting access to the web-based intervention.
11515411|NCT01246674||Hypothesis generating study|Consecutive total hip arthroplasty patients
11515412|NCT01246648|Active Comparator|chronic periodontitis|
11515413|NCT01246648|Active Comparator|agressive periodontitis|
11515414|NCT01246648|Active Comparator|healthy patients|
11515415|NCT01246635|Experimental|TRUFIT CB with accelerated rehab.|
11515416|NCT01246635|Experimental|TRUFIT CB with standard rehab.|
11515417|NCT01246635|Active Comparator|• Microfracture with rehabilitation|
11515418|NCT01246622|Experimental|Treatment (biological therapy)|Patients receive lenalidomide PO on days 6-26 and cytarabine IV over 3 hours on days 1-5. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11515419|NCT01246596|Active Comparator|chronic periodontitis|
11515420|NCT01246596|Active Comparator|aggressive periodontitis|
11515421|NCT01246596|Active Comparator|healthy patient (orthodontics extraction)|
11515422|NCT01246583|Experimental|Treatment Group A|
11515423|NCT01246583|Placebo Comparator|Treatment Group B|
11515424|NCT01246583|Experimental|Treatment Group C|
11515425|NCT01246583|Placebo Comparator|Treatment Group D|
11515426|NCT01246570|Experimental|Maintenance program|"Patients will attend a motivational exercise session once monthly. They will also be tested (exercise test with measurement of peak oxygen uptake) every third months."
11515427|NCT01246570|Active Comparator|Control|Usual care. The patients will receive the usual care provided by the hospital and community health services
11515428|NCT01246544||Data collection group: physicians|Online survey for physicians/members of the innovation alliance Berlin-Brandenburg (INABBRA)
11515429|NCT01246531||Urolithiasis|Case arm: men above fifty years-old with urolithiasis
11515430|NCT01246531||Control|Control arm: men above fifty years-old without urolithiasis
11515431|NCT01246518|Active Comparator|MOB015 for 3 months|
11515432|NCT01246518|Active Comparator|MOB015 for 9 months|
11515433|NCT01246492|Placebo Comparator|45g glucose|glucose water
11515434|NCT01246492|Active Comparator|45g glucose + 150mg aspartame|glucose water aspartame
11515435|NCT01246492|Active Comparator|45g glucose + 20 mg saccharin|glucose water saccharin
11515436|NCT01246492|Active Comparator|45g glucose + 85mg asculfame - K|glucose water aseulfame- k
11515437|NCT01246479|Other|No treatment|subjects will be followed up on immunity (analysis of blood samples) and safety
11515438|NCT01246466|Experimental|AtriCure Bipolar System combined with a catheter ablation|procedure using the AtriCure Bipolar System plus a catheter ablation
11515439|NCT01246453|Active Comparator|urokinase|
11515440|NCT01246453|Active Comparator|Alteplase|
11515441|NCT01246440|Experimental|Catumaxomab|
11515442|NCT01246427|Experimental|BRN01|"A 2 to 4 weeks run-in period is planned, during which all patients receive single blinded hot flash evaluation treatment which is actually a placebo (2 tablets every morning and every evening during 2 to 4 weeks). At the end of this period, the hot flash score is calculated. If the score is ≥10, the patient can be randomized to one of the 2 arms:
~Experimental: BRN01
~Placebo Comparator: Placebo"
11515443|NCT01246427|Placebo Comparator|Placebo|"A 2 to 4 weeks run-in period is planned, during which all patients receive single blinded hot flash evaluation treatment which is actually a placebo (2 tablets every morning and every evening during 2 to 4 weeks). At the end of this period, the hot flash score is calculated. If the score is ≥10, the patient can be randomized to one of the 2 arms:
~Experimental: BRN01
~Placebo Comparator: Placebo"
11515444|NCT01246414||Allergic asthma|Patients with allergic asthma
11515445|NCT01246414||Non-allergic asthma|Patients with non-allergic asthma
11515446|NCT01246414||Non-asthmatic controls|Non-asthmatic controls
11515447|NCT01246401|Active Comparator|Extended-Release Naltrexone|Participants will receive intramuscular (IM) injections of Naltrexone once monthly for 6 months, the first injection being prior release
11515448|NCT01246401|Placebo Comparator|Placebo|Participants will receive IM injections of Placebo once monthly for 6 months, the first injection being prior release
11515449|NCT01246388||Chronic Liver Disease|
11515450|NCT01246362|Placebo Comparator|Control|Given placebo tablets preoperatively
11515451|NCT01246362|Active Comparator|Etoricoxib|Given etoricoxib preoperatively
11515452|NCT01246349|Experimental|Motivational Interviewing Group|For the Motivational Interviewing (MI) treatment group, a clinical psychology doctoral student trained in Motivational Interviewing administered six individual motivational interviewing treatment sessions, each 30 minutes in length.
11515453|NCT01246349|Active Comparator|Control Group|The comparison group received six social skills training sessions instead of Motivational Interviewing (MI).
11515454|NCT01246336||Patients with parkinsonism|Patients suffering from Parkinson's disease or parkinsonism
11515455|NCT01246336||Healthy controls|Patients not suffering from Parkinson's disease or any other neurological disorder
11515456|NCT01246323|Active Comparator|combined anesthesia|Patients will receive spinal and general anesthesia for benign laparoscopy gynecological surgery
11515457|NCT01246323|No Intervention|Control|
11515458|NCT01246310|Experimental|Inositol|
11515459|NCT01246310|Placebo Comparator|Placebo|
11515460|NCT01246297|Other|Control|Usual Care
11515461|NCT01246297|Active Comparator|Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of twice weekly exercise classes with an educational component.
11515462|NCT01246284|Active Comparator|A|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
11515463|NCT01246284|Active Comparator|B|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
11515464|NCT01246284|Active Comparator|C|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
11515465|NCT01246284|Placebo Comparator|D|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment.
11515466|NCT01246271||Sub urethral sling|
11515467|NCT01246271||sus with anterior vainal wall repair|
11515468|NCT01246258||Test group|Standard tests of balance function
11515469|NCT01246232|Experimental|Amisulpride|400mg, 2 x 200mg amisulpride capsules for the first 4 weeks, then the option of titrating up to 800mg, 4 x 200mg amisulpride capsules for the remaining 8 weeks.
11515470|NCT01246232|Placebo Comparator|Placebo|400mg, 2 x 200mg amisulpride capsules, or 2 matching placebo capsules for the first 4 weeks, then the option of titrating up to 800mg, 4 x 200mg amisulpride capsules, or 4 matching placebo capsules for the remaining 8 weeks.
11515471|NCT01246219|Experimental|GH treatment|4 years of GH treatment
11515472|NCT01246219|Placebo Comparator|Placebo|1 year treatment with placebo followed by optional 3 years of GH treatment
11515473|NCT01246219|No Intervention|Non treatment group|
11515474|NCT01246206|Experimental|Tacrolimus and Thymoglobulin|Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis
11515475|NCT01246193|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 80mg/S-Amlodipine 2.5mg
11515476|NCT01246193|Active Comparator|Combination Therapy|Co-administration of single oral doses of a 80mg tablet of Telmisatan and a 2.5 mg tablet of S-Amlodipine
11515477|NCT01246167|Active Comparator|Conservative|Active physiotherapy and self-training
11515478|NCT01246167|Active Comparator|Philos locking plate|After operative treatment active physiotherapy and self-training
11515479|NCT01246167|Active Comparator|Epoca prosthesis|After operative treatment active physiotherapy and self-training
11515480|NCT01246154||EXERCISE TOLERANCE|
11515481|NCT01246141||Repair group|patients in repair group underwent tricuspid repair for functional tricuspid regurgitation.
11515482|NCT01246141||replacement group|In this group, patients underwent tricuspid valve replacement for functional tricuspid regurgitation.
11515483|NCT01246102|Experimental|1|starting at 20 mg/m2
11515484|NCT01246089|Experimental|Ranabizumab|Myopic eyes with retinal neovascularization
11515485|NCT01246076|Experimental|Lenalidomide|"Lenalidomide 50 mg/day for two 28 day cycles.
~Patients who have bone marrow aplasia as defined by a cellularity of <10% will be observed till counts recover. If patients do not progress following 2 cycles of HD lenalidomide, they will receive low dose lenalidomide 10 mg daily for 12 cycles."
11515486|NCT01246063|Experimental|Phase I - Part 1 Dose Level 0 (Carfilzomib 20/27 mg/m^2)|Dose Level 0: Carfilzomib IV (20 mg/m^2) D1&D2 of C1 and carfilzomib IV (27 mg/m^2)D8, D9, D15, D16 of C1. Carfilzomib IV (27 mg/m^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (27 mg/m^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m^2)D8 C1-6.
11515487|NCT01246063|Experimental|Phase I - Part 1 Dose Level 1 (Carfilzomib 20/36 mg/m^2)|"Dose Level 1: Carfilzomib IV (20 mg/m^2) D1&D2 of C1 and carfilzomib IV (36 mg/m^2)D8, D9, D15, D16 of C1. Carfilzomib IV (36 mg/m^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (36 mg/m^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m^2)D8 C1-6.
~Dose Level 1: Carfilzomib IV (1 dose level above MTD) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (1 dose level above MTD) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (1 dose level above MTD) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.
~Dose Level 2: Carfilzomib IV (2 dose levels above MTD) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (2 dose levels above MTD) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (2 dose levels above MTD) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib."
11515488|NCT01246063|Experimental|Phase I - Part 1 Dose Level 2 (Carfilzomib 20/45 mg/m^2)|Dose Level 2: Carfilzomib IV (20 mg/m^2) D1&D2 of C1 and carfilzomib IV (45 mg/m^2)D8, D9, D15, D16 of C1. Carfilzomib IV (45 mg/m^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (45 mg/m^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m^2)D8 C1-6.
11515489|NCT01246063|Experimental|Phase I - Part 1 Dose Level 3 (Carfilzomib 20/56 mg/^2)|Dose Level 3: Carfilzomib IV (20 mg/m^2) D1&D2 of C1 and carfilzomib IV (56 mg/m^2)D8, D9, D15, D16 of C1. Carfilzomib IV (56 mg/m^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (56 mg/m^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m^2)D8 C1-6.
11515490|NCT01246063|Experimental|Phase I -Part 2 Cohort 0 (Carfilzomib 56 mg/m^2+Dexamethasone)|Cohort 0: Carfilzomib IV (56 mg/^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.
11515491|NCT01246063|Experimental|Phase 2 (Carfilzomib 56 mg/m^2+ Dexamethasone)|Carfilzomib IV (56 mg/^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.
11515492|NCT01246050|Experimental|Arm 1: Received HF Training|Providers will receive 3 days of HF training, receive access to clinical pharmacist medication titration serviced and receive performance feedback
11515493|NCT01246050|Active Comparator|Arm 2: No HF Training|CBOC Providers in the same CBOC who did not received HF Training, access to clinical pharmacist services or performance feedback
11515494|NCT01246037|Experimental|First placebo|First half year placebo, second half year bisoprolol
11515495|NCT01246037|Experimental|First Bisoprolol|First half year bisoprolol, second half year placebo
11515496|NCT01246024|Experimental|Hypoxia|
11515497|NCT01246011|Experimental|Heparin PF4 antibody positive -Drug (argatroban and warfarin)|Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive argatroban and warfarin
11515498|NCT01246011|No Intervention|Heparin PF4 antibody positive no drug|Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive no medication
11515499|NCT01246011|No Intervention|Heparin PF4 antibody negative|Post-CABG heparin PF4 antibody negative with no signs or symptoms of HIT randomized to receive no medication
11515500|NCT01245998|Active Comparator|dalteparin 5000 I.U./24 h s.c.|
11515501|NCT01245998|Active Comparator|dalteparin 15000 I.U./24 h s.c.|
11515502|NCT01245985|Experimental|treatment arm|patients receive induction chemotherapy with TPF for a maximum of 3 cycles followed by radioimmunotherapy with cetuximab as intensity-modulated radiotherapy (IMRT) plus carbon ion boost
11515503|NCT01245972|No Intervention|Control|No treatment administered
11515504|NCT01245972|Experimental|PDL Setting 1|PDL Setting 1: 15 J/cm2, 3ms pulse length, no dynamic cooling, 7mm spot size, 10% overlap between the pulses, 2 passes
11515505|NCT01245972|Experimental|PDL Setting 2|PDL Setting 2: 7.5 J/cm2, 3ms pulse length, no dynamic cooling, 10mm spot size, 10% overlap between the pulses, 2 stacked pulses
11515506|NCT01245959|Experimental|Induction chemotherapy and concurrent chemoradiotherapy|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
11515507|NCT01245959|Active Comparator|Concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
11515508|NCT01245946|Experimental|Photodynamic therapy|
11515509|NCT01245946|Experimental|Conventional therapy|
11515510|NCT01245920|Experimental|FDBA + Membrane Group|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
11515511|NCT01245920|Active Comparator|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
11515512|NCT01245907|Experimental|Applied relaxation|Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
11515513|NCT01245907|No Intervention|Waiting-list/control|No intervention for 10 weeks but the same registrations and diaries and forms as the interventional group
11515514|NCT01245894|Active Comparator|Low-dose Rosuvastatin|5mg Rosuvastatin/day
11515515|NCT01245894|Active Comparator|High-dose Rosuvastatin|Rosuvastatin 40mg/day
11515516|NCT01245881|Experimental|Treatment group|Broad-spectrum UV block plus non-ablative 1,550-nm fractional treatment
11515517|NCT01245881|Active Comparator|Control group|
11515518|NCT01245868|Experimental|Bupivacaine|Bupivacaine as used routinely
11515519|NCT01245868|Placebo Comparator|Lidocaine added to bupivacaine|lidocaine is added to bupivacaine
11515520|NCT01245855|No Intervention|PGE1 group and control group|the control group: received only the conventional medications, the PGE1 group: received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
11515521|NCT01245842|No Intervention|Usual care|
11515522|NCT01245842|Experimental|Exercise group|
11515830|NCT01243710|Experimental|Taurolidine with heparin|
11515523|NCT01245829|Placebo Comparator|Matt|A standard non antimicrobial laminated chart which will form the control group (group 1).
11515524|NCT01245829|Experimental|Cellomed|Observation charts coated in a laminate with antimicrobial properties (Cellomed) will form group 2.
11515525|NCT01245816|Experimental|Eflornithine plus Sulindac|Eflornithine 500 mg and Sulindac 150 mg
11515526|NCT01245816|Active Comparator|Elfornithine plus Placebo|Eflornithine 500 mg and Placebo
11515527|NCT01245816|Active Comparator|Sulindac plus Placebo|Sulindac 150 mg and Placebo
11515528|NCT01245803|Experimental|rosuvastatin,one month,lipid lowering|additional rosuvastatin(10mg) is given at 18hr and 4-6hr before PCI
11515529|NCT01245803|Placebo Comparator|sugar pill, one month|sugar pill is given 18-24hr and 4-6hr before PCI as control
11515530|NCT01245790|Experimental|1|Healthy subjects (Stage 1)
11515531|NCT01245790|Experimental|2|Mild renal impairment (Stage 2)
11515532|NCT01245790|Experimental|3|Moderate renal impairment (Stage 2)
11515533|NCT01245790|Experimental|4|Severe renal impairment (Stage 2)
11515534|NCT01245790|Experimental|5|End stage renal disease (Stage 1)
11515535|NCT01245777|Experimental|ferric carboxymaltose|Hb> 11 g/dl and Ferritin < 35 (controlled by CRP): 500mg to correct iron deficiency Hb ≥ 10 and < 11g/dl; Ferritin < 35 (controlled by CRP): 700 mg Hb ≥9 and < 10 g/dl; Ferritin < 35 (controlled by CRP): 800 mg Hb < 9g/dl; Ferritin < 35 (controlled by CRP): 900 mg
11515536|NCT01245764|Experimental|GARDASIL™ 9 to 12 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
11515537|NCT01245764|Experimental|GARDASIL™ 13 to 15 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
11515538|NCT01245764|Experimental|GARDASIL™ 16 to 26 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
11515539|NCT01245764|Placebo Comparator|Placebo 9 to 12 Years Old|Placebo to GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. After database lock and unblinding for study Phase A, participants will have the option to receive GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase B.
11515540|NCT01245751|Experimental|Group 1: Booster Dose Participants ≥70 years of age|Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study V211-004 NCT00007501)
11515541|NCT01245751|Experimental|Group 2: First Dose Participants ≥70 years of age|Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age
11515542|NCT01245751|Experimental|Group 3: First Dose Participants ≥60 and <70 years of age|Herpes zoster history-negative participants ≥60 and <70 years of age who have never received Zoster Vaccine, Live
11515543|NCT01245751|Experimental|Group 4: First Dose Participants ≥50 and <60 years of age|Herpes zoster history-negative participants ≥50 and <60 years of age who have never received Zoster Vaccine, Live
11515544|NCT01245738||Participants|Participants admitted to participating tertiary cardiac care centers who experienced a first coronary event.
11515545|NCT01245725|Experimental|Tirofiban (Aggrastat)|
11515546|NCT01245725|Placebo Comparator|Placebo|
11515547|NCT01245712|Experimental|Treatment (APBI)|Within 10 weeks of last breast cancer surgery, patients undergo APBI delivered with proton radiation BID for 5 days.
11515548|NCT01245699|No Intervention|Before RTAVF and post-event debriefing|Before scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing
11515549|NCT01245699|Active Comparator|After RTAVF and post-event debriefing|After scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing
11515550|NCT01245686|Active Comparator|One-on-one counseling|Participants in this arm will receive 4 intensive one-on-one counseling sessions (either in person or on the phone) and 3 brief maintenance sessions.
11515551|NCT01245686|Active Comparator|Web counseling|Participants in this arm will receive 4 intensive counseling sessions over the web. They will also receive 3 maintenance sessions over the web.
11515552|NCT01245673|Experimental|Prevnar, T Cells, Lenalidomide, MAGE A-3|All patients will receive a priming immunization with a MAGE-A3/GM-CSF vaccine with adjuvant Hiltonol® (Poly-ICLC) along with the pneumococcal conjugate vaccine/PCV control vaccine about 10 days before a steady-state mononuclear cell apheresis. Patients will then undergo hematopoietic stem cell mobilization. All patients will receive high-dose melphalan followed by hematopoietic stem cells on day 0. On day +2, patients will receive anti-CD3/anti-CD28-costimulated autologous T cells. At days 14, 42, and 90, patients will receive MAGEA3/GM-CSF (+Hiltonol® Poly-ICLC) and PCV booster immunizations followed by restaging studies and immune assessments at day +100. At day 100, after immunizations and restaging, patients will start Revlamid® (Lenalidomide) maintenance therapy followed by 2 additional MAGE-A3 and PCV immunizations at days 120 and 150.
11515553|NCT01245660|Experimental|Patient|
11515554|NCT01245647|Placebo Comparator|Sugar Pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
11515555|NCT01245647|Active Comparator|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
11515556|NCT01245634|Experimental|A|
11515557|NCT01245634|Placebo Comparator|B|
11515558|NCT01245621|Active Comparator|Early entry group|Early entry group will begin the intervention at time of diagnosis of advanced cancer
11515559|NCT01245621|Active Comparator|Later entry group|Later entry group will begin the intervention 12 weeks after enrollment in the study.
11515560|NCT01245608|Experimental|Polypill|Single daily dose of PolyPill and 6-monthly visits
11515561|NCT01245608|No Intervention|Control|Only 6-monthly visits
11515562|NCT01245595|Active Comparator|Aminophylline|Patients to receive aminophylline 5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
11515563|NCT01245595|Placebo Comparator|Placebo|Normal Saline Placebo
11515727|NCT01244386||Inflammatory bowel disease|Patients with inflammatory bowel disease requiring CT for clinical purposes will be studied.
11515564|NCT01245582|Experimental|SECOX regimen|Oxaliplatin (Eloxatin) 85mg/m2 , 2 hour infusion, day 1 Capecitabine (Xeloda) 850 mg/m2 BID orally daily, from day 1 to 7 Sorafenib (Nexavar) 400 mg BID orally daily, from day 1 to 14 (continuously)
11515565|NCT01245582|Active Comparator|Sorafenib alone|Sorafenib (Nexavar) 400 mg BID orally daily, from day 1 to 14 (continuously)
11515566|NCT01245569|Experimental|Foster®|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
11515567|NCT01245569|Active Comparator|Seretide® Accuhaler®|Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
11515568|NCT01245556|Experimental|BMS-908662 or Ipilimumab (A)|
11515569|NCT01245556|Experimental|BMS-908662 or Ipilimumab (B)|
11515570|NCT01245543|Experimental|AC480IV|Dose range finding study
11515571|NCT01245543|Experimental|Docetaxel|Dose range finding study in subjects with solid tumors
11515572|NCT01245530|Active Comparator|Aricept|Intervention: Drug: Aricept
11515573|NCT01245530|Experimental|INM-176|Intervention: Drug: INM-176
11515574|NCT01245517|Experimental|Dietary Phosphorus Education Program|
11515575|NCT01245504||Lower-limb amputee|Subjects with at least one lower limb amputated at teh trans-tibial level
11515576|NCT01245465|Experimental|Profermin|Daily oral intake of a food for special medical purposes (Profermin)
11515577|NCT01245452|Experimental|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
11515578|NCT01245452|Active Comparator|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
11515579|NCT01245439|Experimental|1|
11515580|NCT01245426|Experimental|GW870086 2mg|GW870086 2mg once daily in the morning for 27 ± 2 days
11515581|NCT01245426|Experimental|GW870086 4mg|GW870086 4mg once daily in the morning for 27 ± 2 days
11515582|NCT01245426|Placebo Comparator|Placebo|Placebo once daily in the morning for 27 ± 2 days
11515583|NCT01245426|Experimental|GW870086 1mg|GW870086 1mg once daily in the morning for 27 ± 2 days
11515584|NCT01245426|Experimental|GW870086 3mg|GW870086 3mg once daily in the morning for 27 ± 2 days
11515585|NCT01245413|Active Comparator|SenSura Adhesive (device)|Sensura is a commercially available adhesive, that is designed to collect output from a stoma.
11515586|NCT01245413|Experimental|Athena adhesive|Athena = new test adhesive. The Athena baseplate is intended for collecting output from a stoma.
11515587|NCT01245400|Experimental|Z-Lig|Z-Lig Anterior Cruciate Ligament Reconstruction (ACLR) graft implantation performed under anesthesia during an arthroscopic procedure.
11515588|NCT01245400|Active Comparator|Allograft|Allograft bone/tendon graft implantation performed under anesthesia during an arthroscopic procedure.
11515589|NCT01245387||Macugen|
11515590|NCT01245374|Experimental|Nordiflex Norditropin®|Individually adjusted dose administered with Norditropin NordiFlex® for 6 weeks. Dosage depended on age, weight, etiologies and according to the summary of product characteristics (SPC)
11515591|NCT01245361|Experimental|Infliximab|Group I: Infliximab 3 mg/kg wk 0,2,6
11515592|NCT01245361|Placebo Comparator|sodium chloride|RA 1 solution for infusion, intravenous use Sterile normal saline 0.9% sodium chloride
11515593|NCT01245348||Schizophrenia|Patient with schizophrenia
11515594|NCT01245348||Bipolar|Patient with bipolar disorder
11515595|NCT01245335|Active Comparator|BMAC Treatment|Intervention- Injection of 40 ml of autologous bone marrow concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
11515596|NCT01245335|Placebo Comparator|Placebo Injection|Injection of placebo (diluted peripheral blood) into ischemic tissue of the lower extremity
11515597|NCT01245322|Active Comparator|Lactobacilli|different lactobacilli.
11515598|NCT01245309|Experimental|scratching|endometrial scratching prior ivf cycle
11515599|NCT01245309|Placebo Comparator|PLACEBO|PLACEBO PROCEDURE
11515600|NCT01245296|Other|Early cord clamping (ECC)|Early cord clamping consisted of early (< 10 s) clamping of the umbilical cord and obtaining blood gas samples after clamping.
11515601|NCT01245296|Other|Delayed cord clamping (DCC)|Delayed cord clamping consisted of delayed (> 180 s) clamping of the umbilical cord and obtaining blood gas samples before clamping (within 30 seconds).
11515602|NCT01245283|Active Comparator|Wait-list Non-exercise Control (CON)|Subjects will continue to participate in their normal activities and clinical care during the four month study period if assigned to this group.
11515603|NCT01245283|Active Comparator|Concentric Focused RX (CRX)|Training protocol for 1 set of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
11515604|NCT01245283|Active Comparator|Eccentric Focused RX (ERX)|"The Human Dynamics Laboratory features prototype equipment that increases resistance loads during the eccentric phase of the contraction while assistance is provided by the machine during the concentric phase. One set of each exercise - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press."
11515605|NCT01245270|Experimental|Bilberry capsule first, then control cap|"Volunteers will be given a single capsule of 0.47 grams of mirtoselect (a concentrated bilberry extract) followed by a 14 day washout period then a single control placebo capsule.
~First Intervention (1 day), Washout (14 days), Second Intervention (1 day)"
11515606|NCT01245270|Experimental|Control capsule first, then bilberry cap|"Volunteers will be given a single control placebo capsule followed by a 14 day washout period the a single capsule of 0.47 grams of mirtoselect (a concentrated bilberry extract)
~First Intervention (1 day), Washout (14 days), Second Intervention (1 day)"
11515607|NCT01245257||Alcoholic Hepatitis|Patients with alcoholic hepatitis
11515608|NCT01245244|Experimental|Morphine|
11515609|NCT01245244|Placebo Comparator|Placebo|
11515610|NCT01245205|Experimental|Treatment (Akt inhibitor MK2206 and lapatinib ditosylate)|Patients receive Akt inhibitor MK2206 PO QOD for 28 days (35 days for course 1) and lapatinib ditosylate PO QD or BID on days 1-28 (days 9-35 for course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11515611|NCT01245179|Experimental|Panobinostat|All patients will receive Panobinostat at specified dose levels and dosing schedules.
11515612|NCT01245166|Active Comparator|Acarbose|
11515614|NCT01245153|Experimental|Rectal Balloon Training|Subjects in combined RBT and PFMT group are taught Foley catheter insertion technique. The catheter is inserted into the rectum until the lower end of the balloon is 1 cm inside from the anus. Then the balloon is blown with clean water. Subjects will contract pelvic floor muscle in standing position by contracting the pelvic floor muscle, hold and count 1 to 5, then relax and count 1 to 5. Subjects are instructed to do the exercise 15 times/set, 3 sets/day, every day for 6 weeks.
11515615|NCT01245153|Active Comparator|Control group|Patients receive Pelvic floor muscle training without inserting any kinds of equipment.
11515616|NCT01245140|Active Comparator|Active|to receive study drug (alitretinoin, 20 patients)
11515617|NCT01245140|Placebo Comparator|Placebo|to receive placebo (dummy drug, 10 patients)
11515618|NCT01245127|Experimental|Canakinumab|"Canakinumab 150 mg (or 2 mg/kg for patients weighing <40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).
~At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing <40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing <40 kg) every 8 weeks beginning at Week 8.
~Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.
~If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks."
11515619|NCT01245101|Experimental|Raltegravir and then Observation|The total duration of the study will be 40 weeks. This will include Part 1 (16 weeks) followed by Part 2 (8 weeks) followed by the crossover to Part 2 (16 weeks). During Part 1 participants in Group A will receive open-label raltegravir in addition to their established antiretroviral regimen while Group B participants will continue taking their established antiretroviral regimen for 16 weeks. After completion of Part 1, both groups will enter Part 2 that will consist of a washout period of 8 weeks during which both groups will only take their established antiretroviral regimen without raltegravir. This will be followed by Part 3 during which the two study groups will undergo a crossover with respect to the treatment assignment during Part 1 so that Group A will continue to receive their established antiretroviral regimen while Group B will receive open-label raltegravir in addition to their established antiretroviral regimen for 16 weeks.
11515620|NCT01245101|Active Comparator|Observation and then Raltegravir|The total duration of the study will be 40 weeks. This will include Part 1 (16 weeks) followed by Part 2 (8 weeks) followed by the crossover to Part 2 (16 weeks). During Part 1 participants in Group A will receive open-label raltegravir in addition to their established antiretroviral regimen while Group B participants will continue taking their established antiretroviral regimen for 16 weeks. After completion of Part 1, both groups will enter Part 2 that will consist of a washout period of 8 weeks during which both groups will only take their established antiretroviral regimen without raltegravir. This will be followed by Part 3 during which the two study groups will undergo a crossover with respect to the treatment assignment during Part 1 so that Group A will continue to receive their established antiretroviral regimen while Group B will receive open-label raltegravir in addition to their established antiretroviral regimen for 16 weeks.
11515621|NCT01245088|Experimental|chondroitin sulfate|400 mg (one table) TID
11515622|NCT01245075|Active Comparator|Deep Brain Stimulation|Stimulator setting is ON
11515623|NCT01245075|Sham Comparator|Placebo|Stimulator setting is OFF
11515624|NCT01245062|Experimental|GSK1120212|MEK inhibitor
11515625|NCT01245062|Active Comparator|Chemotherapy|Investigator Choice of DTIC or paclitaxel
11515626|NCT01245062|Experimental|Crossover|MEK inhibitor after documented progression on Chemotherapy Arm
11515627|NCT01245049|Experimental|BOOSTRIX POLIO GROUP|Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Boostrix™ Polio vaccine co-administered with Priorix™ vaccine at Day 0. Boostrix™ Polio vaccine was administered intramuscularly in the deltoid muscle of the left arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arm or as an intramuscular injection into the deltoid muscle of the right arm.
11515628|NCT01245049|Active Comparator|REPEVAX GROUP|Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Repevax™ vaccine co-administered with Priorix™ vaccine at Day 0. Repevax™ vaccine was administered intramuscularly in the deltoid muscle of the arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arn or as an intramuscular injection into the deltoid muscle of the right arm.
11515629|NCT01245036|Active Comparator|Glucocorticoid arm|Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 6 weeks (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 6 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
11515630|NCT01245023|Active Comparator|laparoscopy|laparoscopic adhesiolysis and application of Sprayshield spray to prevent further adhesions
11515631|NCT01245023|Placebo Comparator|placebo-control|anaethesia and skin incisions without laparoscopy or related procedures
11515632|NCT01245010|Experimental|Water|Water and education provision
11515633|NCT01245010|Active Comparator|Control|Education only
11515634|NCT01244997|Experimental|Immediate implant placement|This arm is an immediate placement of a dental implant following tooth extraction.
11515635|NCT01244997|Active Comparator|Delayed Implant|This is the traditional method for implants. This arm will be done following a healing of the area.
11515636|NCT01244984|Experimental|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
11515637|NCT01244984|Experimental|Fluticasone Furoate|Inhaled corticosteroid
11515638|NCT01244971|Active Comparator|Acarbose|
11515639|NCT01244971|Active Comparator|Exercise|
11515640|NCT01244971|Experimental|Exercise + Acarbose|
11515641|NCT01244958|Active Comparator|Rituximab 1000 mg|Administration of 1000 mg Rituximab in Part I, followed by either re-treatment with 1000 mg Rituximab or with 500 mg Rituximab in Part II of the study
11515728|NCT01244373||Patients with senile cataract|Patients with senile cataract
11515831|NCT01243710|Active Comparator|Heparin|
11515642|NCT01244958|Placebo Comparator|Placebo|Administration of Placebo in Part I followed by re-treatment with either 1000 mg Rituximab or with 500 mg Rituximab in Part II of the study
11515643|NCT01244945|Experimental|L. reuteri DSM 17938|
11515644|NCT01244945|Placebo Comparator|Placebo|
11515645|NCT01244906|Experimental|Reduced Intensity Allogeneic Stem Cell Transplantation|All patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
11515646|NCT01244893|Other|Acuvue Advance Plus prePQ/Acuvue Advance Plus postPQ|Acuvue Advance Plus silicone hydrogel contact lens manufactured prior to process qualification will be worn first and Acuvue AdvancePlus silicone hydrogel contact lens manufactured after process qualification will be worn second.
11515647|NCT01244893|Other|Acuvue Advance Plus postPQ/Acuvue Advance Plus prePQ|Acuvue Advance Plus silicone hydrogel contact lens manufactured prior to process qualification worn first and Acuvue Advance Plus silicone hydrogel contact lens manufactured after process qualification worn second.
11515648|NCT01244880|Experimental|Saline/PF-02545920|Treatments are co-administered
11515649|NCT01244880|Experimental|Ketamine/PF-02545920|Treatments are co-administered
11515650|NCT01244880|Placebo Comparator|Saline/Placebo|Treatments are co-administered
11515651|NCT01244880|Experimental|Ketamine/Placebo|Treatments are co-administered
11515652|NCT01244867|Experimental|20 microgram H5 VLP vaccine + Alhydrogel|
11515653|NCT01244867|Experimental|30 micrograms H5 VLP vaccine + Alhydrogel|
11515654|NCT01244867|Experimental|45 micrograms H5 VLP vaccine + Alhydrogel|
11515655|NCT01244867|Experimental|45 micrograms H5 VLP vaccine|
11515656|NCT01244867|Placebo Comparator|Placebo|
11515657|NCT01244854|Other|Arm 1|Enhanced Usual Care; patients receive care as usual, with additional mailings on wellness newsletter topics
11515658|NCT01244841|No Intervention|Standard care|Randomised to standard post MI care and length of hospital stay decided by treating physician.
11515659|NCT01244841|Active Comparator|Early discharge|Randomised patient where all post MI investigations, treatment, follow-up plans and information will be performed within 3 days, and the patients are thereafter discharged.
11515660|NCT01244828|Experimental|Asenapine|Asenapine 5 mg twice daily (BID) for the first week of treatment, then either 5 mg or 10 mg BID.
11515661|NCT01244815|Experimental|Asenapine 2.5 mg twice daily (BID)|Participants receive asenapine 2.5 mg BID for 21 days.
11515662|NCT01244815|Experimental|Asenapine 5.0 mg BID|Participants receive asenapine 2.5 mg BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive asenapine 5.0 mg BID for the remainder of the 21-day treatment period.
11515663|NCT01244815|Experimental|Asenapine 10.0 mg BID|Participants receive asenapine 2.5 mg BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. On Day 5 and 6 participants receive asenapine 5.0 mg BID. On Day 7 participants receive asenapine 5.0 mg in the morning and 10.0 mg in the evening. Participants receive asenapine 10.0 mg BID for the remainder of the 21-day treatment period.
11515664|NCT01244815|Placebo Comparator|Placebo|Participants receive placebo BID for 21 days.
11515665|NCT01244802||Group 1: 18 to 45 years of age|Between the ages of 18 and 45 at the time of yellow fever vaccination
11515666|NCT01244802||Group 2: 55 years of age and above|Aged 55 or greater at the time of yellow fever vaccination
11515667|NCT01244789|Active Comparator|Observation|postoperative observation only
11515668|NCT01244789|Experimental|Combination chemotherapy|postoperative 6 courses of 3 weekly iv carboplatin-paclitaxel combination chemotherapy
11515669|NCT01244776|Experimental|Acellular corneal matrix|
11515670|NCT01244763|Experimental|Experimental Drug|
11515671|NCT01244750||First line TKI treatment: Imatinib|Diagnosed CML patients who receive first line TKI treatment: Imatinib
11515672|NCT01244750||First line TKI treatment: Nilotinib|Diagnosed CML patients who receive first line TKI treatment: Nilotinib
11515673|NCT01244750||First line TKI treatment: Dasatinib|Diagnosed CML patients who receive first line TKI treatment: Dasatinib
11515674|NCT01244750||Imatinib treated patients|Imatinib treated patients if their study index date is between January 2, 2008 and September 30, 2010
11515675|NCT01244737|Experimental|New diagnosis of brain tumor|In children with a new diagnosis of central nervous system tumor, a PET scan will be performed using [18F] FLT.
11515676|NCT01244737|Experimental|Possible recurrent brain tumor|In children in whom there is concern for recurrent central nervous system tumor, a PET scan will be performed using [18F] PET.
11515677|NCT01244737|Experimental|Brain tumor response to chemotherapy|In children with a newly diagnosed central nervous system tumor who will be treated with post-operative chemotherapy, a PET scan will be performed using [18F] FLT before the start and after two cycles of chemotherapy.
11515678|NCT01244724|Experimental|Lexapro|escitalopram 10 mg or 20 mg/d
11515679|NCT01244711|Experimental|Quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
11515680|NCT01244698|Other|Antibiotics until Drain Removal|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil until the final drain is removed. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin.
11515681|NCT01244698|Experimental|Early discontinuation of antibiotics|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics.
11515725|NCT01244425|Experimental|FS VH S/D 500 s-apr|Fibrin Sealant, Vapor Heated, Solvent/Detergent treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), not to exceed 20mL per participant. Hemostasis will be assessed at 4, 6, 8 and 10 minutes after application of the study treatment.
11515726|NCT01244425|Active Comparator|Manual compression - Control|A dry surgical gauze swab will be used to apply by hand an even light pressure onto the oozing resection surface of the liver. Hemostasis will be assessed at 4, 6, 8 and 10 minutes after application of the study treatment.
11515828|NCT01243723|Experimental|Eductyl suppository|
11515682|NCT01244685|Active Comparator|probe|Patients in the 'goal-directed fluid' Lactated Ringers solution according to ideal body weight for the first 24 hours. The fluids will be changed after the first 24 hours and continued until the patient is tolerating a regular diet. The Deltex CardioQ esophageal probe will be evaluated every 15 minutes in the Post Anesthesia Care Unit (PACU) by the Anesthesia service. Stroke Volume (SV), Flow Time Corrected (FTc), and Peak Velocity (PV) will be measured. A short FTc (<330 ms) indicative of hypovolemia will receive a 3cc/kg fluid challenge with Lactated Ringers crystalloid solution over 5 minutes. A SV increase of >10% will receive a further 3cc/kg fluid challenge. A SV increase of <10% will not receive further fluid challenge.
11515683|NCT01244685|No Intervention|Standard Fluid|Patients in the 'standard fluid' group will receive Lactated Ringers solution for 24 hours post-operatively at 1 times maintenance rate according to ideal body weight. Then the fluids will be changed to physiologic maintenance with D5½NS at the same rate. Fluids will be decreased by ½ once the patient is tolerating a clear liquid diet, and then discontinued once the patient is tolerating a regular diet.
11515684|NCT01244672|Active Comparator|Trans-anal dearterialization|24 patients were assigned to the Transanal hemorrhoidal dearterialization with mucopexy arm, which is a Doppler guided procedure for suture ligation of hemorrhidal arteries rather than excisional
11515685|NCT01244672|Active Comparator|Ferguson|17 patients were randomized to Ferguson method, which is the operative gold standard for hemorrhoids. This is an excisional surgery.
11515686|NCT01244659|Experimental|Tacrolimus from EMS|Group 1: Tacrolimus from EMS + Myfortic® + Steroids
11515687|NCT01244659|Active Comparator|Prograf|Group 2: Prograf® + Myfortic® + Steroids
11515688|NCT01244646||1|Patients with Diabetes Mellitus Type 2
11515689|NCT01244633|Experimental|Ecopipam|Active treatment
11515690|NCT01244620|Experimental|Treatment A|sitaxsentan 100 mg QD for 6 days (Treatment A)
11515691|NCT01244620|Experimental|Treatment B|tadalafil 40 mg QD for 6 days
11515692|NCT01244620|Experimental|Treatment C|sitaxsentan 100 mg QD co-administered with tadalafil 40 mg QD for 6 days
11515693|NCT01244620|Experimental|Treatment D|sitaxsentan 100 mg QD co-administered with sildenafil 20 mg TID for 6 days
11515694|NCT01244607|Placebo Comparator|Placebo|
11515695|NCT01244607|Experimental|NI-0801|
11515696|NCT01244594|Experimental|High cadence, low resistance|Subjects in this arm will cycle with functional electrical stimulation at a higher cadence (speed) and a lower resistance.
11515697|NCT01244594|Experimental|Low cadence, high resistance|Subjects in this arm will cycle with functional electrical stimulation at a lower cadence (speed) and a higher resistance.
11515698|NCT01244581|Experimental|Amoxicillin-clavulanate|Oral amoxicillin-clavulanate 40 mg/kg/day divided in two daily doses for 7 days
11515699|NCT01244581|Placebo Comparator|Placebo|
11515700|NCT01244568|No Intervention|Usual care|
11515701|NCT01244568|Experimental|Prostate cancer treatment DESI|
11515702|NCT01244555|Experimental|Massage treatment|
11515703|NCT01244555|Experimental|Ultrasound|
11515704|NCT01244555|No Intervention|Wait-list|
11515705|NCT01244542|Experimental|Patients with schizophrenia|
11515706|NCT01244542|Active Comparator|Healthy controls|controls matched with patients on age, sex and education level
11515707|NCT01244529|Other|galy A Plus/ galy A / seno A|"Pair 1: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).
~Pair 2: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).
~Pair 3: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8)."
11515708|NCT01244529|Other|galy A Plus / seno A / galy A|"Pair 1: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).
~Pair 2: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).
~Pair 3: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
11515709|NCT01244529|Other|galy A / galy A Plus / seno A|"Pair 1: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).
~Pair 2: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).
~Pair 3: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8)."
11515710|NCT01244529|Other|galy A / seno A / galy A Plus|"Pair 1: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).
~Pair 2: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).
~Pair 3: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
11515711|NCT01244529|Other|seno A / galy A / glay A Plus|"Pair 1: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).
~Pair 2: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).
~Pair 3: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
11515712|NCT01244529|Other|seno A / galy A Plus / galy A|"Pair 1: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).
~Pair 2: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).
~Pair 3: galy A -subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
11515713|NCT01244516|Other|galyfilcon A|Subjects that were randomized to receive the galyfilcon A lens with a base curve of 8.30 throughout the entire course of the study.
11515714|NCT01244516|Other|lotrafilcon B|Subjects that were randomized to wear lotrafilcon B lens throughout the course of the study.
11515715|NCT01244516|Other|comfilcon A|Subjects that were randomized to wear comfilcon A lens throughout the course of the study.
11515716|NCT01244503|Experimental|Sodium Octanoate Breath Test|Only subjects with metabolic syndrome and suspected non alcoholic fatty liver disease will undergo breath test. They must not have any other liver disease.
11515717|NCT01244490|Experimental|Extended-release Guanfacine Hydrochloride|
11515718|NCT01244490|Other|Atomoxetine Hydrochloride|Active Reference
11515719|NCT01244490|Placebo Comparator|Placebo|
11515720|NCT01244477|Experimental|CPT-C|Participants in group CPT-C
11515721|NCT01244477|No Intervention|Treatment-as-Usual|Participants randomly assigned to the Waitlist Control Group (who will participate in CPT-C after 12 weeks).
11515722|NCT01244464|Experimental|Study Group|
11515723|NCT01244451|Experimental|Bendofa|Bendamustine + Ofatumumab
11515729|NCT01244360|Placebo Comparator|Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
11515730|NCT01244360|Active Comparator|Dietary Supplement: resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
11515731|NCT01244347|Experimental|folic acid 4 mg|
11515732|NCT01244347|Active Comparator|folic acid 0.4 mg|
11515733|NCT01244334|Active Comparator|Difluprednate Ophthalmic Emulsion 0.05%|
11515734|NCT01244334|Active Comparator|Prednisolone acetate suspension 0.1%|
11515735|NCT01244321||CoSeal Group|Subjects with indication for LVAD implantation, meeting the requirements for LVAD implantation. Patients for whom LVAD removal is anticipated not earlier than 6 weeks after LVAD implantation.
11515736|NCT01244321||CoSeal Control Group|Subjects who had a LVAD for more than 6 weeks.
11515737|NCT01244295|Experimental|Complicated Grief Treatment|Targeted psychotherapy for complicated grief
11515738|NCT01244295|Active Comparator|Interpersonal Therapy|Standard IPT is a comparator treatment
11515739|NCT01244282|Experimental|All Participants|fMRI studies with sensory stimulation in the presence of 0 mg, 250 mg, 350 mg, and 510 mg cumulative doses of ferumoxytol
11515740|NCT01244269|Experimental|Methylphenidate 10|Methylphenidate 10mg three times daily for a total of 7 doses.
11515741|NCT01244269|Placebo Comparator|Placebo 10|Placebo capsule three times daily for a total of 7 doses.
11515742|NCT01244269|Experimental|Methylpheindate 20|Methylphenidate 20mg three times daily for a total of 7 doses.
11515743|NCT01244269|Placebo Comparator|Placebo 20|Placebo capsule three times daily for a total of 7 doses.
11515744|NCT01244256|Experimental|Treatment with Clotrimazole + Gentamicin + Beclomethasone|
11515745|NCT01244256|Active Comparator|Treatment with Clotrimazole + Gentamicin|
11515746|NCT01244243|Experimental|Active therapy|All subjects receive the same active robotic therapy, there is no placebo arm, as a key goal of this study is to define predictors of response to active treatment.
11515747|NCT01244230|Experimental|Age 6 months - 2 years|Patients between 6 months and 2 years old - Type: Experimental
11515748|NCT01244230|Experimental|Age 2 - 11 years|Patients between 2 and 11 years (and under 10.5 kg)
11515749|NCT01244230|Experimental|Age 2 - 11 years (and over 10.5 kg)|Patients between 2 and 11 years (and over 10.5 kg)
11515750|NCT01244217|Experimental|Age 6 months - 2 years|Patients between 6 months and 2 years old
11515751|NCT01244217|Experimental|Age 2 - 11 years|Patients between 2 and 11 years (and under 10.5 kg)
11515752|NCT01244217|Experimental|Age 2 - 11 years (and over 10.5 kg)|Patients between 2 and 11 years (and over 10.5 kg)
11515753|NCT01244204|Experimental|Vitamin D|
11515754|NCT01244204|Placebo Comparator|Placebo|
11515755|NCT01244191|Experimental|Tivantinib and erlotinib|Tivantinib 720 mg daily (360 mg twice a day) in combination with 150 mg of erlotinib, given once a day
11515756|NCT01244191|Active Comparator|Placebo and erlotinib|Tivantinib placebo given twice a day in combination with 150 mg of erlotinib, given once a day
11515757|NCT01244178|Experimental|Tight Glucose Control Hyperinsulinemic Group|
11515758|NCT01244178|Experimental|Non-Tight Glucose Control Hyperinsulinemic Group|
11515759|NCT01244178|Active Comparator|Standard Insulin Protocol Group|
11515760|NCT01244165|Other|Cytrix|Observational Study
11515761|NCT01244165|Other|Control Group|Patients with similar indications who were treated at the same centers using other products
11515762|NCT01244152|Experimental|Intervention|
11515763|NCT01244152|Active Comparator|Control Group|
11515764|NCT01244139|Experimental|Active study drug|Treatment
11515765|NCT01244139|Experimental|Comparator|Dummy drug
11515766|NCT01244126|Active Comparator|IM morphine|0.1 mg/kg morphine IM
11515767|NCT01244126|Active Comparator|IV morphine|0.1 mg/kg morphine IV
11515768|NCT01244126|Active Comparator|fentanyl IN|Intranasal fentanyl 2 mcg/kg IN
11515769|NCT01244100|Experimental|PL2200|
11515770|NCT01244074|Experimental|biofeedback|
11515771|NCT01244061|Experimental|Varenicline|
11515772|NCT01244061|Placebo Comparator|Placebo|
11515773|NCT01244035|Experimental|Part I - Sequence ABC|Treatment A in Period 1, Treatment B in Period 2, and Treatment C in Period 3
11515774|NCT01244035|Experimental|Part I - Sequence ACB|Treatment A in Period 1, Treatment C in Period 2, and Treatment B in Period 3
11515775|NCT01244035|Experimental|Part I - Sequence BCA|Treatment B in Period 1, Treatment C in Period 2, and Treatment A in Period 3
11515776|NCT01244035|Experimental|Part I - Sequence BAC|Treatment B in Period 1, Treatment A in Period 2, and Treatment C in Period 3
11515777|NCT01244035|Experimental|Part I - Sequence CAB|Treatment C in Period 1, Treatment A in Period 2, and Treatment B in Period 3
11515778|NCT01244035|Experimental|Part I - Sequence CBA|Treatment C in Period 1, Treatment B in Period 2, and Treatment A in Period 3
11515779|NCT01244035|Experimental|Part II - Sequence DEF|Treatment D in Period 1, Treatment E in Period 2, and Treatment F in Period 3
11515780|NCT01244035|Experimental|Part II - Sequence DFE|Treatment D in Period 1, Treatment F in Period 2, and Treatment E in Period 3
11515781|NCT01244035|Experimental|Part II - Sequence EFD|Treatment E in Period 1, Treatment F in Period 2, and Treatment D in Period 3
11515782|NCT01244035|Experimental|Part II - Sequence EDF|Treatment E in Period 1, Treatment D in Period 2, and Treatment F in Period 3
11515783|NCT01244035|Experimental|Part II - Sequence FDE|Treatment F in Period 1, Treatment D in Period 2, and Treatment E in Period 3
11515784|NCT01244035|Experimental|Part II -Sequence FED|Treatment F in Period 1, Treatment E in Period 2, and Treatment D in Period 3
11515785|NCT01244022||Colorectal cancer patients|Patients with pathohistologically verified colorectal cancer or adenoma with epithelial dysplasia
11515786|NCT01244009|Experimental|MK-4827|All Participants
11515787|NCT01243996|Experimental|Infant treated with high dose ibuprofen|
11515788|NCT01243983|Experimental|LX211|
11515789|NCT01243983|Placebo Comparator|Placebo|
11515790|NCT01243970|Active Comparator|phenylephrine infusion|
11515791|NCT01243970|Active Comparator|Ephedrine infusion|
11515829|NCT01243723|Placebo Comparator|Placebo suppository|
11515792|NCT01243957|Experimental|LY2216684 + fluoxetine|"LY2216684: 18 milligrams (mg) oral (po) once daily (QD) on Days 1, 2, and 3 and Days 25-27
~Fluoxetine: 60 mg po QD for 7 days (Days 4-10) then 20 mg po QD for 17 days (Days 11-27)"
11515793|NCT01243944|Experimental|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg once a day (QD) to 25 mg BID based on safety and efficacy
11515794|NCT01243944|Other|Best Available Therapy|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
11515795|NCT01243931|Experimental|Surgery|OCT is assisting in surgery guidance.
11515796|NCT01243918|Experimental|VNI/Optiflow, Immunodeficient patients|VNI = non invasive ventilation
11515797|NCT01243918|Experimental|Optiflow/VNI, Immunodeficient patients|VNI = non invasive ventilation
11515798|NCT01243918|Experimental|Ospal/Optiflow, Immunocompetent patients|
11515799|NCT01243918|Experimental|Optiflow/Ospal, Immunocompetent patients|
11515800|NCT01243905|Active Comparator|Family psychoeducation plus TAU|Family psychoeducational therapy in addition to treatment as usual for the child (TAU)
11515801|NCT01243905|Placebo Comparator|Treatment as usual|Treatment as usual for the child (TAU)
11515802|NCT01243892||Cohort 1: IGHD participants|Isolated growth hormone deficient (IGHD) participants who initiated somatropin (Deoxyribonucleic acid [DNA] origin) (recombinant human growth hormone [rhGH]) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
11515803|NCT01243892||Cohort 2: ISS participants|Idiopathic short stature (ISS) participants who initiated somatropin (DNA origin) (rhGH) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
11515804|NCT01243879|Active Comparator|Fasting with stimuli|Fasting in the presence of food-related stimuli
11515805|NCT01243879|Sham Comparator|Fasting without stimuli|Fasting in the absence of food-related stimuli
11515806|NCT01243866|Experimental|Early treatment|comprehensive dental treatment
11515807|NCT01243866|No Intervention|Regualr treatment|Regular treatment consisted of children who would be on a waiting list for regular dental treatment at KFAFH for at least 8 months
11515808|NCT01243853|Active Comparator|Alpha-galactosidase|
11515809|NCT01243853|Placebo Comparator|Placebo|
11515810|NCT01243827|Experimental|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP <140/90 mmHg.
11515811|NCT01243827|Experimental|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP <140/90 mmHg.
11515812|NCT01243814|Active Comparator|supartz|active intervention arm
11515813|NCT01243814|Placebo Comparator|saline injection|placebo intervention arm
11515814|NCT01243801|Active Comparator|Epidural ketamine|"Bolus of epidural ketamine during the induction of anesthesia
~Epidural infusion of ketamine during the first 48 h after surgery
~Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine and fentanyl"
11515815|NCT01243801|Active Comparator|Intravenous ketamine|"Bolus of intravenous ketamine administered during the induction of anesthesia
~Intravenous infusion during the first 48 hours after surgery
~Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine plus fentanyl"
11515816|NCT01243801|Placebo Comparator|Placebo|"Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine and fentanyl"
11515817|NCT01243788|Active Comparator|Ipratropium/Albuterol|Ipratropium/Albuterol 36/206ug QID
11515818|NCT01243775|Experimental|Belotaxel plus Belloxa|Belotaxel 60 mg/m2 3 weekly (day 1) Belloxa 70 mg/m2 3 weekly (day 2)
11515819|NCT01243762|Experimental|Dalotuzumab 7.5 mg/kg + MK-0752 1800 mg|Participants in Part 1 of the study receive dalotuzumab 7.5 mg/kg intravenously (IV) weekly + MK-0752 1800 mg orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy.
11515820|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-0752 1800 mg|Participants in Parts 1 and 2 of the study receive dalotuzumab 10 mg/kg IV weekly + MK-0752 1800 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
11515821|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 90 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK-2206 90 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
11515822|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 135 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 135 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
11515823|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 150 mg|Participants in Parts 1 and 2 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 150 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
11515824|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 200 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 200 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
11515825|NCT01243762|Experimental|Dalotuzumab + Ridaforolimus|Participants in Part 2 of the study receive dalotuzumab 10 mg/kg IV weekly + ridaforolimus 20 mg PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy.
11515826|NCT01243736|No Intervention|Standard prep|One group will receive the standard bowel preparation, which consists of eating no solid foods after 7 p.m. the evening prior to the capsule endoscopy test and being able to consume clear liquids up to 4 hours prior to the capsule endoscopy test
11515827|NCT01243736|Active Comparator|Combination Prep|"The other group will receive the combination bowel preparation, which consists of taking the standard bowel preparation plus:
~drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;
~drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;
~drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;
~lying on your right side for 30 minutes following the swallowing of the capsule endoscope."
11515832|NCT01243697|Experimental|desogestrel|Tablets of 75 µg, once daily during 112 days
11515833|NCT01243684|Active Comparator|Healty volunteers|
11515834|NCT01243684|Experimental|Patients|
11515835|NCT01243671|Experimental|Adalimumab|Adalimumab 160 mg at Week 0, 80 mg at Week 2 and 40 mg every other week (eow) starting at Week 4 to Week 50, subcutaneous injection. After Week 52, participants could continue the treatment with 40 mg eow until the day before approval of adalimumab for intestinal Behçet's disease in Japan.
11515836|NCT01243658|Experimental|Oxytocin|Oxytocin
11515837|NCT01243658|Placebo Comparator|Placebo|Placebo
11515838|NCT01243619|Experimental|FLT PET|This is a single arm trial, in which all patients receive three FDG-PET scans and three FLT-PET scans, before, during and after pre-operative chemoradiation for esophageal cancer.
11515839|NCT01243606|Experimental|Single Diagnosis Treatment Protocols|Four disorder-specific cognitive-behavioral treatments will be conducted in accordance with treatment manuals of demonstrated efficacy. SDPs will be matched to the principal anxiety disorder diagnosis.
11515840|NCT01243606|Experimental|Unified Protocol|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders will be individually administered in accordance with a treatment protocol.
11515841|NCT01243606|No Intervention|Waitlist Control|Waitlist participants will not receive treatment during a 16-week waitlist period, but will receive the treatment of their choice immediately following the 16 week waiting period.
11515842|NCT01243593|Experimental|Treatment Group|
11515843|NCT01243593|Active Comparator|Control Group|
11515844|NCT01243580|Active Comparator|Ortho-Cyclen®|Ortho-Cyclen® is a comparator drug intervention
11515845|NCT01243580|Experimental|AG200-15|AG200-15 is an investigational transdermal contraceptive delivery system that is a drug intervention
11515846|NCT01243567|Active Comparator|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
11515847|NCT01243567|Active Comparator|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
11515848|NCT01243554|Experimental|Exercise training|Supervised exercise training at the hospital during pregnancy: the women will attend at least 2 weekly sessions consisting of aerobic exercise (walking on treadmills), strength training (for upper body, back, abdomen and legs) as well as pelvic floor muscle exercises. Each session is 60 minutes and lead by a physiotherapist or experienced exercise physiologist. The women will also go through motivational interviewing sessions throughout the intervention period and are encouraged to do home exercise training in addition to the exercise at the hospital
11515849|NCT01243554|No Intervention|Control|Usual care as provided by the health services in Norway. The investigators will not advice the women to be inactive
11515850|NCT01243541|Experimental|Arm I|Patients wear an Elasto-Gel cold glove and sock on their dominant hand and foot every two weeks on days the patient is scheduled for paclitaxel.The glove and sock is worn for 15 minutes prior to paclitaxel infusion, 3 hours during treatment, and for 15 minutes after completion of chemotherapy for a total of 210 minutes.
11515851|NCT01243541|Experimental|Arm II|Patients wear an Elasto-Gel cold glove and sock on their non-dominant hand and foot every two weeks on days the patient is scheduled for paclitaxel. The glove and sock is worn for 15 minutes prior to paclitaxel infusion, 3 hours during treatment, and for 15 minutes after completion of chemotherapy for a total of 210 minutes.
11515852|NCT01243528||Patients in neurological rehabilitation|Patients suffering from a neurological disease
11515853|NCT01243515||Chronic Kidney Disease|minimum 7 subjects (male and female)
11515854|NCT01243515||Healthy subjects|minimum 3 subjects (male and female)
11515855|NCT01243502|Experimental|0.01% CT327 (or placebo)|Six (of eight) subjects received a single topical dose of 0.01% CT327 followed by a 7 day wash-out period. The subjects then received a single topical dose of CT327 on five consecutive days. Two subjects received placebo.
11515856|NCT01243502|Experimental|0.001% CT327 (or placebo)|Six (of eight) subjects received a single topical dose of 0.001% CT327 followed by a 7 day wash-out period. The subjects then received a single topical dose of CT327 on five consecutive days. Two subjects received placebo.
11515857|NCT01243489|Other|patient diary|compliance supporting measure: patients uses patient diary from month 6 to 12
11515858|NCT01243489|Other|"Information service Leben mit CML"|"compliance supporting measure: patient uses the Information service Leben mit CML"
11515859|NCT01243476|Experimental|lenalidomide|Experimental treatment branch with Lenalidomide 5 mg/day (oral use)
11515860|NCT01243476|Placebo Comparator|placebo|Placebo branch (oral use)
11515861|NCT01243450|Active Comparator|Active generic|Treatment of acne for 12 weeks with generic tretinoin
11515862|NCT01243450|Placebo Comparator|Placebo|Treatment of acne for 12 weeks with Placebo
11515863|NCT01243450|Active Comparator|Brand|Treatment of acne over 12 weeks with tretinoin Brand
11515864|NCT01243437|Experimental|ciprofloxacin|
11515865|NCT01243437|Active Comparator|doxycycline|
11515866|NCT01243424|Experimental|linagliptin|patient to receive linagliptin or glimepiride placebo over encapsulated tablet Quaque die (QD)
11515867|NCT01243424|Active Comparator|glimepiride 1-4 mg QD|patient to receive glimepiride 1-4 mg or linagliptin placebo tablet Quaque die (QD)
11515868|NCT01243411|Experimental|AA4500|collagenase clostridium histolyticum
11515869|NCT01243398|Experimental|Gefitinib 500mg once daily|Gefitinib 500mg once daily
11515870|NCT01243398|Placebo Comparator|Placebo|Gefitinib 500mg once daily
11515871|NCT01243385|Other|Metformin|Metformin at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
11515872|NCT01243372||Correlative (BRAF V600E mutation analysis)|Previously collected formalin-fixed and paraffin-embedded baseline tumor samples are analyzed for BRAF V600E mutation. Mutation status is correlated with clinical response and outcome data from patients enrolled on CALGB-C80405.
11515873|NCT01243359|Experimental|Treatment (sunitinib malate, bevacizumab)|Patients receive sunitinib malate PO on days 1-28 and bevacizumab IV over 30-90 minutes on day 29. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11515874|NCT01243346|Experimental|Crenolanib (CP-868,596)|
11515924|NCT01242917|Placebo Comparator|Placebo|
11515875|NCT01243333|Experimental|Diagnostic (multi-tracer PET scans)|Patients undergo Positron Emission Tomography (PET) scans with [F-18]fluorodeoxyglucose and [F-18]fluorothymidine at baseline and within 7 days of completion of 1 or 2 (if the course is less than 3 weeks) therapeutic agent courses.
11515876|NCT01243320|Experimental|10ppm Oral Silver|Oral Dose of 10ppm
11515877|NCT01243320|Experimental|32ppm Oral Silver|Oral Dose of 32ppm
11515878|NCT01243307|Experimental|CT327 treatment period 1|Subjects in Group 1 will receive CT327 during treatment/testing period 1 and placebo during treatment/testing period 2
11515879|NCT01243307|Experimental|CT327 treatment period 2|Subjects in Group 2 will receive placebo during treatment/testing period 1 and CT327 during treatment/testing period 2
11515880|NCT01243294|Active Comparator|SenSura|"CE marked and launched (The letters CE do not represent any specific words, though may have initially stood for Communauté Européenne (European Community) or Conformité Européenne (European Conformity). By affixing the CE marking to a product, the manufacturer declares that it meets EU safety and health and environmental requirements."
11515881|NCT01243294|Active Comparator|New ostomy appliance (SS)|SS = New ostomy appliance. Due to company confidentiality the product is just called SS and this is not short for any other names.
11515882|NCT01243281|Active Comparator|drug combination|
11515883|NCT01243268||Patients with essential hypertension|
11515884|NCT01243255||1|Patients with hypercholesterolemia on lipid lowering pharmacological treatment
11515885|NCT01243242|Experimental|METADOXINE|Eligible subjects will be randomly assigned to receive MG01CI (1,400 mg)
11515886|NCT01243242|Placebo Comparator|Placebo|Eligible subjects will be randomly assigned to receive Placebo (1,400 mg)
11515887|NCT01243216|Experimental|Ultrasound Group|Patients in the Ultrasound Group will have a pre-procedure ultrasound of the spine prior to needle placement
11515888|NCT01243216|No Intervention|No Ultrasound Group|Patients in the No Ultrasound Group will not have a pre-procedure ultrasound of the spine performed prior to needle placement.
11515889|NCT01243203|Placebo Comparator|Placebo|patient will receive placebo pills
11515890|NCT01243190|Experimental|Ofatumumab|Loading dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).
11515891|NCT01243177|Experimental|Lacosamide|
11515892|NCT01243177|Active Comparator|Carbamazepine-Controlled Release (CBZ-CR)|
11515893|NCT01243164|Experimental|Wheelchair Skills Training Program|A standardized wheelchair skills training program to teach 32 specific wheelchair skills.
11515894|NCT01243151|Placebo Comparator|A|
11515895|NCT01243151|Experimental|B|
11515896|NCT01243151|Experimental|C|
11515897|NCT01243151|Experimental|D|
11515898|NCT01243151|Experimental|E|
11515899|NCT01243125|Experimental|NVC-422|
11515900|NCT01243125|Placebo Comparator|Saline|
11515901|NCT01243112|Experimental|Lidocaine w/ Epi|0.2ml 1% Lidocaine with Epinephrine (1:100,000)
11515902|NCT01243112|Experimental|Bupivacaine with epi|0.2 ml 0.25% Bupivacaine with epinephrine (1:200,000)
11515903|NCT01243112|Experimental|Low dose Lido and Bupi w/ Epi|0.2ml 0.5% Lidocaine + 0.125% Bupivacaine with Epinephrine (1:150,000)
11515904|NCT01243112|Experimental|High Dose Lido and Bupi with epi|0.2ml 1% Lidocaine + 0.25% Bupivacaine with Epinephrine (1:150,000)
11515905|NCT01243099||In-stent (BMS) restenosis|
11515906|NCT01243099||De-novo coronary lesion|
11515907|NCT01243086|Placebo Comparator|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
11515908|NCT01243086|Active Comparator|Ranibizumab and OZURDEX|Recent research has discovered that persons with wet or dry ARMD show an immune response, as if the body is fighting off an infection. The body creates a complex immune response to the growth of blood vessels into the eye tissue, which triggers side effects. It is believed that preventing this inflammation can lead to greater visual gains and a need for fewer treatment injections. Animal studies have shown that Triamcinolone Acetonide, a corticosteroid (class of drugs that reduce inflammation) can prevent damage to vision from this inflammation. The hypothesis is that treatment with both Ranibizumab and OZURDEX will allow even greater vision improvements than Ranibizumab treatment alone for wet age-related macular degeneration.
11515909|NCT01243073|Experimental|imetelstat|Induction dosing of 9.4 mg/kg weekly, followed by intermittent maintenance dosing.
11515910|NCT01243060|Experimental|Almorexant 100mg|Subjects will receive a one-time dose of Almorexant 100mg.
11515911|NCT01243060|Experimental|Almorexant 200mg|Subjects will receive a one-time dose of Almorexant 200mg.
11515912|NCT01243060|Active Comparator|Zolpidem|Subjects will receive a one-time dose of Zolpidem 10mg.
11515913|NCT01243060|Placebo Comparator|Placebo|Subjects will receive a one-time dose of Placebo.
11515914|NCT01243047|Active Comparator|Arm A|Continuous erlotinib administration (21-day cycle). Erlotinib dose given at 100mg daily
11515915|NCT01243047|Active Comparator|Arm B|Intermittent erlotinib administration (21-day cycle). Erlotinib dose given at 150mg.
11515916|NCT01242995||pancreatobiliary disorders/thin scope|All patients will be evaluated with cholangioscopy and/or pancreatoscopy using the thin scope.
11515917|NCT01242982|Experimental|Operation|Closed reduction and operated for fixation with 2 antegrade intramedullary Kirschner wires.
11515918|NCT01242982|Active Comparator|Conservative treatment|Treated conservatively with reduction and then Plaster of Paris.
11515919|NCT01242956|Experimental|Verum group|video-based training after stroke
11515920|NCT01242956|Placebo Comparator|Placebo group|non-video group
11515921|NCT01242943|Experimental|L19SIP I131|"Phase I: Multicentre, open-label, two-step single-arm dose escalation study in sequential cohorts of patients with cancer.
~Phase II: Prospective, open-label, single-arm, multicentre study of 131I-L19SIP, given at the RD as determined in phase I."
11515922|NCT01242930|Experimental|Imetelstat (7.5 mg/kg)|Imetelstat (7.5 mg/kg) with or without lenalidomide standard of care
11515923|NCT01242930|Experimental|Imetelstat (9.4 mg/kg)|Imetelstat (9.4 mg/kg) with or without lenalidomide standard of care
11515925|NCT01242917|Experimental|CCX354-C 100mg twice daily|
11515926|NCT01242917|Experimental|CCX354-C 200mg once daily|
11515927|NCT01242904|Experimental|bimodal solution|200 mls of 30% glucose in sterile water is added by the patient to the usual icodextrin day dwell, to create the bimodal solution intraperitoneally
11515928|NCT01242904|Active Comparator|icodextrin|200 mls of icodextrin is added by the patient to the usual icodextrin day dwell
11515929|NCT01242878||healthy volunteers|ethnically matched people who do not have sickle cell disease
11515930|NCT01242878||patients|sickle cell disease patients
11515931|NCT01242865|Other|Attention and Interpretation Therapy|
11515932|NCT01242852|Experimental|Additional diagnostic tests|Participants in the experimental arm will undergo standard hysteroscopy with treatment-on-the spot of predefined intrauterine abnormalities. In two of the participating clinics, also a 'Saline Infusion Sonography' (SIS) will be performed, 1 week before the hysteroscopy. After the additional diagnostic test(s), standard IVF/ICSI treatment will be initiated.
11515933|NCT01242852|No Intervention|Routine fertility workup|Patients allocated to the conventional strategy will be scheduled for IVF and undergo standard treatment, without SIS or hysteroscopy.
11515934|NCT01242839|Experimental|CACICOL20|Arm that receives CACICOL20 treatment each 2 days for 3 months/until closure of the ulcer
11515935|NCT01242839|Placebo Comparator|Placebo|The placebo is applicated each 2 days on patient cornea for 3 months/ until ulcer closure.
11515936|NCT01242839|Experimental|CACICOL20 and Placebo|Patient applies the treatment each 2 days for 3 months or until closure of the ulcer. This treatment is alternatively CACICOL20 or Placebo : so the patient receives CACICOL20 each 4 days. CACICOL20 and placebo strips are strictly similar and cannot be identified.
11515937|NCT01242826|Experimental|A|
11515938|NCT01242813|Experimental|Canakinumab|This was an open-label, single treatment arm, multicenter study of monthly canakinumab 150 mg (2 mg/kg for patient ≤ 40 kg) subcutaneous injections in patients with active recurrent or chronic TRAPS.
11515939|NCT01242800|Active Comparator|Arm I|Patients receive standard palliative therapy, if needed, to address symptoms such as tumor ulceration, pain, bulky adenopathy causing arm symptoms, and other similar situations. Therapy may consist of radiotherapy alone, surgery alone, or a combination of both.
11515940|NCT01242800|Experimental|Arm II|Patients undergo surgery comprising breast-conserving therapy (BCT) or total mastectomy according to patient and treating physician preference. Free surgical margins must be achieved with re-excision or mastectomy for patients undergoing BCT. After completion of BCT, patients undergo radiotherapy once a day, 5 days per week. Patients who had mastectomy undergo radiotherapy at the discretion of treating physician.
11515941|NCT01242787|Active Comparator|Entecavir 0.5 mg|Entecavir 0.5 mg
11515942|NCT01242787|Experimental|LB80380|Optimal dose of LB80380 (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)
11515943|NCT01242774|Experimental|Panobinostat|
11515944|NCT01242761||Symptomatic rotator cuff tear|Patients with symptomatic rotator cuff tears presenting to hospital clinic after having ultrasound exam in community with indications for surgery
11515945|NCT01242748|Experimental|Degarelix 240 mg/480 mg|
11515946|NCT01242748|Active Comparator|Goserelin acetate|
11515947|NCT01242735|Experimental|Exercise|12-week moderate-intensity behavioral exercise intervention (AE)
11515948|NCT01242735|Active Comparator|Health and Wellness|12-week health and wellness education control (HEC)
11515949|NCT01242722||1|Two experimental and/or intervention groups under 1 arm.
11515950|NCT01242696||Coronary artery stenting|All subjects who are candidates for coronary artery stenting, signed the Informed Consent Form and are eligible to receive a TAXUS Element stent will be evaluated for enrollment in this study.
11515951|NCT01242683|Experimental|Case-Management for Behavior Change|Individual and group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator. 12 month of intensive intervention followed by 12 months of maintenance intervention.
11515952|NCT01242683|Experimental|Case-Management plus Home Visits|Community health worker lifestyle support for weight loss strategies conducted in participants' homes and neighborhood. Also, receive individual and group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator. 12 month of intensive intervention followed by 12 months of maintenance intervention.
11515953|NCT01242683|Placebo Comparator|Usual Primary Care|Continuation of usual primary care managed by the participants' usual physician or nurse practitioner source of care.
11515954|NCT01242670|Experimental|Ross River Virus Vaccine|Subjects will be randomized in equal numbers (1:1:1) to receive one of three different lots of the vaccine on Day 1, Day 22 and Day 181. (The study is blinded with regard to which vaccine lot is administered to a subject but all subjects will receive 3 injections with a 2.5 µg aluminum hydroxide adjuvanted dose of RRV vaccine.)
11515955|NCT01242657|No Intervention|Brief Advice|Standard of care arm with no intervention; includes standard communication regarding youth tobacco cessation such as a brief discussion and printed materials
11515956|NCT01242657|Active Comparator|Not On Tobacco (N-O-T) Program|Teens randomized to this arm participated in the N-O-T program, a proven teen cessation program.
11515957|NCT01242657|Experimental|Quit & Fit|Teens randomized to this arm participated in the Not On Tobacco (N-O-T) program with an added physical activity module.
11515958|NCT01242644|Experimental|pain pump , injectable medication|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour;
11515959|NCT01242644|Active Comparator|saline pain pump , injectable medication|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline administered at 4 mL/hour
11515960|NCT01242644|Active Comparator|injectable medication only|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected and no pain pump.
11515961|NCT01242631|Experimental|Everolimus 10 mg daily|
11515962|NCT01242618|Experimental|engineered nasal cartilage graft|Biological intervention: autologous nasal chondrocytes expanded in vitro and cultured in a collagen Type I/III scaffold
11515963|NCT01242605|Experimental|single armed|This is not a randomised trial, there is only one study group. All patients will receive cisplatin/gemcitabine chemotherapy in addition to oral daily dosing of selumetinib
11515964|NCT01242592|Experimental|Homeopathy|
11515965|NCT01242592|Placebo Comparator|Placebo|
11515966|NCT01242579|Active Comparator|Maraviroc Vaginal Gel|Drug: Maraviroc dosage form: vaginal gel dosage: 2.5g frequency: once daily duration: 11 days
11515967|NCT01242579|Active Comparator|Dapivirine Vaginal Gel|Drug: Dapivirine dosage form: vaginal gel dosage: 2.5g dapivirine frequency: once daily duration: 11 days
11515968|NCT01242579|Placebo Comparator|Matching Placebo Gel|Drug: placebo dosage form: vaginal gel dosage: 2.5g placebo frequency: once daily duration: 11 days
11515969|NCT01242579|Experimental|Maraviroc/Dapivirine Gel|Drug: Maraviroc/Dapivirine dosage form: combination vaginal gel dosage: 2.5g - Maraviroc 0.1%, Dapivirine 0.05% frequency: once daily duration: 11 days
11515970|NCT01242566|Experimental|temozolomide|Administration of temozolomide 150-200 mg/m2/day for 5 consecutive days every 4 weeks for a maximum of 12 cycles or until disease progression or prohibited toxicity
11515971|NCT01242553||Normal|Normal results from clinical exam and free of ocular pathology.
11515972|NCT01242553||Retina|Clinical exam results consistent with retina pathology
11515973|NCT01242553||Glaucoma|Clinical exam results consistent with glaucoma and visual field defects consistent with glaucoma.
11515974|NCT01242553||Cornea|Clinical exam results consistent with cornea pathology.
11515975|NCT01242527|Placebo Comparator|placebo|
11515976|NCT01242527|Experimental|Epanova 2 g|
11515977|NCT01242527|Experimental|Epanova 3 g|
11515978|NCT01242527|Experimental|Epanova 4 g|
11515979|NCT01242514|Experimental|A|Oral treatment
11515980|NCT01242514|Experimental|B|Oral treatment
11515981|NCT01242514|Experimental|C|Oral treatment
11515982|NCT01242501|Experimental|60 Min. Risk Reduction Counseling|Single 60 min theory-based counseling session delivered in STI clinic setting in Cape Town South Africa.
11515983|NCT01242501|Active Comparator|20-min single session education|Single brief HIV/STI education only session for men and women receiving sexually transmitted infection clinic services in South Africa.
11515984|NCT01242488|Experimental|CDP6038 60 mg sc every 2 weeks plus methotrexate|
11515985|NCT01242488|Experimental|CDP6038 60 mg sc every 4 weeks plus methotrexate|
11515986|NCT01242488|Experimental|CDP6038 120 mg sc every 2 weeks plus methotrexate|
11515987|NCT01242488|Experimental|CDP6038 120 mg sc every 4 weeks plus methotrexate|
11515988|NCT01242488|Experimental|CDP6038 240 mg sc every 2 weeks plus methotrexate|
11515989|NCT01242488|Experimental|CDP6038 240 mg sc every 4 weeks plus methotrexate|
11515990|NCT01242488|Active Comparator|Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate|
11515991|NCT01242488|Placebo Comparator|Placebo sc every 2 weeks plus methotrexate|
11515992|NCT01242488|Placebo Comparator|Placebo sc every 4 weeks plus methotrexate|
11515993|NCT01242475|Experimental|0.1µg/0.1 mL C-Tb|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
11515994|NCT01242475|Active Comparator|2TU Tuberculin PPD RT 23 SSI|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
11515995|NCT01242462|Active Comparator|AB|2 hours of treatment with conventional ventilation strategy, then crossover to 2 hours of treatment with mid-frequency ventilation strategy
11515996|NCT01242462|Active Comparator|BA|2 hours of treatment with mid-frequency ventilation strategy, then crossover to 2 hours of treatment with conventional ventilation strategy
11515997|NCT01242423|Experimental|superficial 2nd degree burn|Group A (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who have sustained a superficial 2nd degree burn on ≥1% and ≤30% of the surface of the body.
11515998|NCT01242423|Experimental|deep 2nd degree burn|Group B (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who have sustained a deep 2nd degree burn on ≥1% and ≤30% of the surface of the body.
11515999|NCT01242423|Experimental|skin excision for the purpose of a skin graft|Group C (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of BBS.
11516000|NCT01242410|No Intervention|Expectant Management|
11516001|NCT01242410|Experimental|Placement of cervical pessary since 23 weeks until 37 weeks|
11516002|NCT01242397|Other|CRT ON|After implant, patients will be randomized to CRT pacing ON vs OFF in crossover fashion with 3 months in each period
11516003|NCT01242397|Other|CRT- OFF|After implant, patients will be randomized to CRT pacing OFF vs ON in crossover fashion with 3 months in each period
11516004|NCT01242384|No Intervention|Expectant Management|
11516005|NCT01242384|Experimental|Placement of cervical pessary since 23 weeks until 37 weeks|
11516006|NCT01242371|Active Comparator|Probiotic Supplement|Probiotic supplement 1 tablet by mouth daily for 14 weeks after 2 week placebo run-in
11516007|NCT01242371|Placebo Comparator|Identical-appearing Placebo|Identical appearing placebo 1 tablet by mouth daily for 14 weeks after 2 week placebo run-in
11516008|NCT01242358|Experimental|Capnography|Arm with capnographic monitoring
11516009|NCT01242358|Placebo Comparator|Standard monitoring|Standard monitoring
11516010|NCT01242345|No Intervention|No Intervention|Standard monitoring.
11516011|NCT01242345|Experimental|Capnography|Arm with capnographic monitoring
11516012|NCT01242332|No Intervention|placebo|po 2 hrs before surgery
11516013|NCT01242332|Experimental|Pregabalin|75 mg po 2 hrs before surgery
11516014|NCT01242319||Multi-modal practice intervention|15 intervention practices receive academic detailing, patient activation computer kiosk, decision supported PDA, and coronary risk factor management toolbox
11516015|NCT01242319||Usual care|15 practices receive academic detailing reviewing the ATP III cholesterol management guidelines
11516016|NCT01242306|Placebo Comparator|BMS arm|bare metal stent arm
11516017|NCT01242306|Active Comparator|SES arm|sirolimus eluting stent arm
11516018|NCT01242293|Active Comparator|0.9% Saline with glucose 5%|rate of infusion is 125cc/h
11516019|NCT01242293|Active Comparator|Ringer lactate|rate of infusion is 250cc/h
11516020|NCT01242293|Active Comparator|Ringer lactate - Controls|rate of infusion is 125cc/h
11516021|NCT01242280|Active Comparator|Self-expandable esophageal stent|"The patient will receive a self-expandable esophageal stent (SX-Ella-Danis) without endoscopical guidance but under slight sedation. An immediate X-ray will be done to assess the correct placement of the stent.
~After a maximum of 7 days, the stent will be removed by using the specifically designed devices."
11516022|NCT01242280|Active Comparator|Sengstaken-Blakemore tube|The esophageal tamponade will be done as described elsewhere. The gastric content will be checked hourly and the correct placement of the tube will be checked by an immediate X-ray. The esophageal balloon will be inflated a maximum of 24 hours.
11516023|NCT01242267|Other|Thalidomide with melphalan|Safety/Efficacy -
11516024|NCT01242254|Experimental|Group A|Patients will receive an intravitreal injection of KH902 0.5mg/eye/time monthly, after 3-time treatment patients will go on an as needed (PRN) dosing phase till week 52
11516025|NCT01242254|Experimental|Group B|Patients will receive an intravitreal injection of KH902 2.0mg/eye/time monthly, after 3-time treatment patients will go on an as needed (PRN) dosing phase till week 52
11516026|NCT01242241|Other|Non-obese|Non-obese children categorized as those with a body mass index(BMI)between 25-84th percentile
11516027|NCT01242241|Active Comparator|Obese children|Obese children are categorized as those with a body mass index >95th percentile
11516028|NCT01242228|Experimental|ASP group|Concomitant administration of ASP1941 and DPP-4 inhibitor
11516029|NCT01242215|Experimental|ASP group|ASP1941 and sulfonylurea
11516030|NCT01242215|Placebo Comparator|Placebo group|placebo and sulfonylurea
11516031|NCT01242202|Experimental|ASP group|Concomitant administration of ASP1941 and α- glucosidase inhibitor
11516032|NCT01242176|Experimental|BI 10773 Final Formulation|one single film-coated tablet in the morning
11516033|NCT01242176|Experimental|BI 10773 XX Trial Formulation 2|one single dose tablet in the morning
11516034|NCT01242150|Experimental|NCPAP Helmet|Infants with mild Acute Respiratory Failure who need NCPAP
11516035|NCT01242150|Active Comparator|NCPAP facial mask|Infants with mild Acute Respiratory failure who need NCPAP
11516036|NCT01242137||Extensive metabolizers|
11516037|NCT01242137||Intermediate mtabolizers|
11516038|NCT01242137||Poor metabolizers|
11516039|NCT01242124|Experimental|side-to-side stapled esophagogastric anastomosis arm|
11516040|NCT01242124|Active Comparator|circular-stapled esophagogastric anastomosis arm|
11516041|NCT01242111|Experimental|BMN 110|
11516042|NCT01242098||Fostair switch cohort|Seretide patients who, at an index date, had a step down in therapy (reduction in ICS dose of ≥50%) and switch to Fostair
11516043|NCT01242098||Seretide continuation cohort|Seretide patients who, at an index date, had a step down in therapy (reduction in ICS dose of ≥50%) and continue on Seretide
11516044|NCT01242085|Active Comparator|control group|control group will have standard instrumentation of their knee replacement
11516045|NCT01242085|Experimental|trumatch group|the trumatch patient will have custom instruments made from preop CT scans
11516046|NCT01242072|Experimental|PaCE|Palifosfamide, Carboplatin and Etoposide
11516047|NCT01242059|Experimental|Control Tomato Soup|
11516048|NCT01242059|Experimental|10 g of yellow pea fiber|
11516049|NCT01242059|Experimental|20 g of yellow pea fiber|
11516050|NCT01242059|Experimental|10 g of yellow pea protein|
11516051|NCT01242059|Experimental|20 g of yellow pea protein|
11516052|NCT01242046|Experimental|Caffeine|Participants will ingest a tablet with 400 mg caffeine
11516053|NCT01242046|Placebo Comparator|Placebo|Participants will ingest an inert placebo tablet
11516054|NCT01242033|Experimental|one cup red raspberries|treatment meal consists of one cup red raspberries
11516055|NCT01242033|Experimental|two cups red raspberries|treatment meal consists of two cups red raspberries
11516056|NCT01242033|Experimental|four cups red raspberries|treatment meal consists of four cups red raspberries
11516057|NCT01242033|Placebo Comparator|bread|treatment meal consists of two slices white bread
11516058|NCT01242033|Active Comparator|vitamin C|treatment meal consists of two slices white bread and 200 mg vitamin C in the form of supplemental ascorbic acid
11516059|NCT01242020|Other|Lean Healthy Subjects|"Lean defined as (BMI ≥18 and ≤25)"
11516060|NCT01242020|Other|Obese Healthy Subjects|Obese grade I-II defined as (BMI>30 and ≤35)
11516061|NCT01241994|No Intervention|basal hemodialysis|
11516062|NCT01241994|Active Comparator|AASD|
11516063|NCT01241981||Digital Breast Tomosynthesis|Digital Breast Tomosynthesis
11516064|NCT01241968|Active Comparator|A|A - Treatment group. Patients in this group receive actual shockwave therapy.
11516065|NCT01241968|Placebo Comparator|B|Placebo group. This group of patients undergo the same procedure as the treatment group, however shockwaves are not delivered to the heart.
11516066|NCT01241955|No Intervention|verbal description of CPR|verbal description of CPR
11516067|NCT01241955|Experimental|Video decision aid|Video decision aid of CPR
11516068|NCT01241942|Experimental|EVLP with STEEN Solution™|The perfusion of the lungs will be performed using STEEN Solution™ and then physiologically assessed. Lungs deemed suitable will be transplanted after Ex-vivo Perfusion w/ STEEN Solution™.
11516069|NCT01241942|Active Comparator|Conventional Lung transplant|No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
11516070|NCT01241929|Experimental|video decision aid|Video decision aid arm
11516071|NCT01241929|No Intervention|Usual Care -- Verbal Description Arm|Verbal description of CPR (i.e., without the video).
11516072|NCT01241916|Experimental|Static-progressive splint|
11516073|NCT01241916|Experimental|Dynamic Splint|
11516074|NCT01241903|Experimental|Crestor|
11516075|NCT01241903|Placebo Comparator|sugar pill|
11516076|NCT01241890||Children with Cystic Fibrosis, care as usual|Treatment according to the Dutch Central Guidance Committee (CBO) guidelines for CF. Assessments: home monitoring, symptoms, lung function, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
11516077|NCT01241877|Experimental|astaxanthin|
11516078|NCT01241877|Placebo Comparator|placebo|
11516079|NCT01241864|Experimental|Allogenic islet cells (human, U. Chicago)|
11516080|NCT01241851|Active Comparator|Aerobic exercise|
11516081|NCT01241851|Active Comparator|Resistance exercise|
11516082|NCT01241851|No Intervention|Control|
11516083|NCT01241838|Placebo Comparator|Normal left ventricular size|Postoperative patient with normal left ventricular size
11516084|NCT01241838|Active Comparator|Left ventricular hypertrophy|Postoperative patient with left ventricular hypertrophy
11516085|NCT01241825|Active Comparator|1.|The subject group will chew sugarless chewing gum for a specific amount of time while undergoing capsule endoscopy.
11516086|NCT01241825|Placebo Comparator|2.|The control group will not chew chewing gum while undergoing capsule endoscopy.
11516087|NCT01241812|Experimental|A.|10 weeks of partially supervised lower limb muscle strengthening targeting the following muscles groups: quadriceps, hamstrings, hip abductors.
11516088|NCT01241812|No Intervention|B|
11516089|NCT01241799|Experimental|1|Pancreatic biopsy with stylet in then stylet out
11516090|NCT01241799|Experimental|2|Pancreatic biopsy with stylet out then stylet in
11516091|NCT01241773|Experimental|001|TMC435 Two 75 mg capsules once daily for 14 days
11516092|NCT01241773|Experimental|002|efavirenz One 600 mg tablet once daily for 14 days
11516093|NCT01241773|Experimental|003|TMC435 + efavirenz Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet once daily for 14 days
11516094|NCT01241773|Experimental|004|TMC435 Two 75 mg capsules once daily for 7 days
11516095|NCT01241773|Experimental|005|raltegravir One 400 mg tablet twice daily for 7 days
11516096|NCT01241773|Experimental|006|TMC435 + raltegravir Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
11516097|NCT01241760|Experimental|001 T(q8h) / PR|Telaprevir (T) 750 mg (2 oral tablets) every 8 hours for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
11516098|NCT01241760|Experimental|002 T(b.i.d.) / PR|Telaprevir (T) 1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
11516099|NCT01241747|Experimental|Supervised Exercise|Supervised program consisting of graded treadmill walking, with progressive increments in exercise duration from 15 to 40 minutes at an exercise intensity of 40% of exercise capacity.
11516100|NCT01241747|Active Comparator|Control|Light resistance training without any walking
11516101|NCT01241734|Experimental|Revlimid (Lenalidomide) in Combination|Study of Lenalidomide in Combination with Rituximab, Ifosphamide, Etoposide, and Carboplatin (RICE-R) as Salvage Therapy with Single Agent Lenalidomide as Maintenance Therapy Post-Autologous Stem Cell Transplantation
11516102|NCT01241721|Experimental|Positron Emission Mammography (PEM)|Positron Emission Mammography (PEM)
11516103|NCT01241708|Experimental|Tandem Transplantation with Melphalan and Bortezomib|Tandem autologous hematopoietic stem cell transplantation with melphalan followed by melphalan and bortezomib in patients with multiple myeloma
11516104|NCT01241695|Experimental|Test|Diben DRINK (200 ml) / a diabetes-specific oral nutritional supplement
11516105|NCT01241695|Placebo Comparator|Control|Fresubin(R) energy fibre DRINK / an isoenergetic standard oral nutritional supplement
11516106|NCT01241682|Experimental|DC immunotherapy + CTX|Patients with mesothelioma who are fit enough to be treated with chemotherapy and enough tumor material was available are asked for participation in this study. After 4 cycles of Alimta chemotherapy, a leukapheresis is performed of which the monocytes are used for differentiation to DCs using different cytokines. The procedure to grow DCs in vitro and pulse them with tumor lysate is performed according to our earlier performed phase I study that was approved by our local ethics committee. Three doses of properly pulsed autologous DCs (MesoCancerVac) are then re-injected every two weeks. Patients will be treated with a low dose of CTX for seven day in a row the week before the 1st vaccination, the weeks in between the 2nd, and for one week after the 3rd vaccination.
11516107|NCT01241669|Experimental|Arm 1|
11516108|NCT01241669|Experimental|Arm 2|
11516109|NCT01241656|Experimental|Mail DVD|
11516110|NCT01241656|Experimental|Invite to SMA to view and discuss DESI|
11516111|NCT01241656|Experimental|SMA and DVD|
11516112|NCT01241656|No Intervention|Encouraged to talk to physician|
11516113|NCT01241643|Experimental|CYT107|repeated cycles of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
11516114|NCT01241643|No Intervention|Control|Control arm with possible CYT107 injection after 12 months of study participation
11516115|NCT01241617|Active Comparator|Duet TRS|Endo GIA with integrated Duet TRS
11516116|NCT01241617|Active Comparator|Endo GIA|Endo GIA stapler with Single Use Loading units
11516117|NCT01241604|Active Comparator|Respironics BiPAP S/T|Control Arm using Respironics BiPAP S/T
11516118|NCT01241604|Active Comparator|Respironics BiPAP Auto SV3|Treatment arm using Respironics BiPAP Auto SV3
11516119|NCT01241591|Experimental|CP 690,550 5 mg BID+Placebo BIW|
11516120|NCT01241591|Experimental|CP 690,550 10 mg BID+Placebo BIW|
11516121|NCT01241591|Active Comparator|Placebo BID+Etanercept 50 mg BIW|
11516122|NCT01241591|Placebo Comparator|Placebo BID+Placebo BIW|
11516123|NCT01241578|Experimental|Mobile Phone Intervention|Participants receive a behavioral intervention via mobile phone and brief in-person counseling sessions.
11516124|NCT01241565|Experimental|ENDO GIA™ Stapler with TRI-STAPLE™ Technology|Single arm study, all patients will receive the study device.
11516125|NCT01241552|Experimental|MK-3415 + SOC|Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI
11516126|NCT01241552|Experimental|MK-6072 + SOC|Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI
11516127|NCT01241552|Experimental|MK-3415A + SOC|Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI
11516128|NCT01241552|Placebo Comparator|Placebo + SOC|Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI
11516129|NCT01241539|Experimental|Dabigatran etexilate 110 mg|Capsule, oral
11516130|NCT01241539|Experimental|Dabigatran etexilate 75 mg|Capsule, oral
11516131|NCT01241539|Experimental|Dabigatran etexilate 150 mg|Capsule, oral
11516132|NCT01241526|Experimental|Disease management program|
11516133|NCT01241526|Active Comparator|Usual site management|
11516134|NCT01241513|Experimental|N-acetyl-L-Cysteine|N-Acetyl-L-Cysteine
11516135|NCT01241513|Placebo Comparator|Placebo|placebo
11516136|NCT01241500|Experimental|ON 01910.Na + best supportive care (BSC)|Patients will receive ON 01910.Na 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards and best supportive care (BSC).
11516137|NCT01241500|No Intervention|Best supportive care (BSC)|Patients will receive best supportive care (BSC).
11516138|NCT01241487|Experimental|1|valsartan/amlodipine
11516139|NCT01241474|Experimental|Fish oil|
11516140|NCT01241474|Placebo Comparator|Maize (corn) oil|
11516141|NCT01241461|Experimental|LY2584702|
11516142|NCT01241448|Placebo Comparator|Placebo|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
11516143|NCT01241448|Experimental|2.5 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
11516144|NCT01241448|Experimental|10 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
11516145|NCT01241448|Experimental|20 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
11516146|NCT01241435|Experimental|LY2216684|LY2216684: A single dose of 18 milligrams (mg) administered orally in participants with normal hepatic function, mild hepatic impairment (Child-Pugh A), moderate hepatic impairment (Child-Pugh B), or severe hepatic impairment (Child-Pugh C)
11516147|NCT01241422|Experimental|Treatment A: JNJ 40929837|
11516148|NCT01241422|Placebo Comparator|Treatment B: Placebo|
11516149|NCT01241422|Other|Treatment C: Montelukast|
11516150|NCT01241409|Experimental|Treatment sequence ABC|
11516151|NCT01241409|Experimental|Treatment sequence ACB|
11516152|NCT01241409|Experimental|Treatment sequence BAC|
11516153|NCT01241409|Experimental|Treatment sequence BCA|
11516154|NCT01241409|Experimental|Treatment sequence CAB|
11516155|NCT01241409|Experimental|Treatment sequence CBA|
11516156|NCT01241396||001|Any MMY treatment Any line of treatment for MMY
11516157|NCT01241383|Experimental|Bosentan|Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
11516158|NCT01241370||Lean healthy subjects|Homeostasis Model Assessment score (HOMAs) ≤ 2, Body Mass Index (BMI) ≤ 28 kg/m2
11516159|NCT01241370||Insulin-resistnat subjects|HOMAs > 2, BMI > 28 kg/m2
11516160|NCT01241370||Type 2 diabetic patients|
11516161|NCT01241357||Observation only|This study has a single arm and no intervention.
11516162|NCT01241344|Active Comparator|CMX001|"Adults: 200mg CMX001 given as four 50mg tablets orally either QW OR BIW.
~Peds: 4mg/kg (NTE a total single dose of 200mg) given using a 5 mg/mL liquid formulation taken orally either QW OR BIW"
11516163|NCT01241344|Placebo Comparator|Placebo|"Adults: Two matching placebo tablets taken orally QW OR BIW.
~Peds: Matching liquid placebo taken orally QW OR BIW"
11516164|NCT01241331|Experimental|BLI1100|BLI1100 topical cream
11516165|NCT01241331|Placebo Comparator|Vehicle cream|Vehicle topical cream
11516166|NCT01241318|Experimental|Chlorhexidine cord care|Mothers located in health facility catchment areas assigned to this arm will apply Chlorhexidine gluconate (4%) to their infants daily until three days after the cord completely separates. Bottles of chlorhexidine is provided to women during antenatal care.
11516167|NCT01241318|Active Comparator|Dry cord care|Mothers in health facility catchment areas assigned to this arm will use dry cord care - keeping their babies' umbilical stumps clean and dry - as per normal routine standard of care and in accordance with Zambia Ministry of Health policy.
11516168|NCT01241292|Experimental|BMS-901608 (Elotuzumab) 10mg|
11516169|NCT01241292|Experimental|BMS-901608 (Elotuzumab) 20mg|
11516170|NCT01241279|Experimental|Crystalens AO|A silicone multi-piece accommodating intraocular lens
11516171|NCT01241279|Active Comparator|SoftPort LI61AO|A silicone multi-piece foldable aspheric intraocular lens
11516172|NCT01241266||1|Target subject population are the consecutive patients hospitalized due to peptic ulcer bleeding. Subjects should be: ≥18 years; admitted to the hospital with an overt upper GI bleed (hematemesis/coffee ground vomiting, melena, hematochezia and other clin
11516173|NCT01241253|No Intervention|Cross-over study|beans and rice in a 50 gram carbohydrate dose
11516174|NCT01241240|Experimental|Triple Combination Therapy|Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
11516175|NCT01241240|Active Comparator|Combigan®|Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
11516176|NCT01241227||Chronic liver disease|All patients with chronic liver disease followed using FibroScan and non-invasive markers
11516177|NCT01241214|Experimental|Investigational drug - Dose 1|
11516178|NCT01241214|Experimental|Investigational drug - Dose 2|
11516179|NCT01241214|Experimental|Investigational drug - Dose 3|
11516180|NCT01241214|Experimental|Investigational Drug - Dose 4|
11516181|NCT01241214|Other|Active Matching Reference|
11516182|NCT01241214|Placebo Comparator|Matching Placebo|
11516183|NCT01241201|Placebo Comparator|Placebo|placebo for probiotic treatment
11516184|NCT01241188|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
11516185|NCT01241188|Active Comparator|2 TU Tuberculin PPD RT 23 SSI|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
11516186|NCT01241175|Experimental|magnesium sulfate|
11516187|NCT01241175|Placebo Comparator|normal saline|
11516188|NCT01241162|Experimental|Single arm study|Biological/Vaccine: Autologous dendritic cell vaccine with adjuvant
11516189|NCT01241149|Active Comparator|Normal pH, abnormal Impedance|After 24hr pH-metry and impedance, those patients with normal pH (i.e. DeMeester score <14.7) but with abnormal impedance scores will be offered anti-reflux surgery
11516190|NCT01241149|Placebo Comparator|Abnormal pH|After 24hr pH-metry and impedance, those with abnormal pH scores (i.e. DeMeester score >14.7)will be offered anti-reflux surgery
11516191|NCT01241136|Placebo Comparator|Open traditional pilonidal cystectomy|traditional complete wide-excision pilonidal cystectomy
11516192|NCT01241136|Experimental|Minimal invasive pilonidal cystotomy|Using only Keyes Trephines to unroof and curette the pilonidal cyst cavity
11516193|NCT01241123|Placebo Comparator|Traditional Ambulation regimen|All patients will receive pedometers to record the total amount of ambulation. These patients will ambulate without limitations or goals. Most surgeons request that post-operative patients ambulate at least 2 to 3 times a day.
11516194|NCT01241123|Active Comparator|Walkers|All patients will receive pedometers to record the total amount of ambulation. Patients in the experimental group will have assigned nursing staff assisting in ambulation in these patients at least three times a day.
11516195|NCT01241110|Active Comparator|azitromicin,PID treatment,ofluxacin|
11516196|NCT01241097|Experimental|high-dose simvastatin, combined, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
11516197|NCT01241084|Placebo Comparator|Placebo|Antileukotrienes+Placebo
11516198|NCT01241084|Active Comparator|Lactobacillus reuteri|Antileukotrienes+Lactobacillus reuteri
11516199|NCT01241071|Experimental|Myofascial treatment|Myofascial release techniques of different muscles implicated in low back pain
11516200|NCT01241071|Placebo Comparator|Placebo|
11516201|NCT01241045||misoprostol|"2 groups:-
~Group 1:-those with Ph<5. (n=50).
~Group 2:-those with Ph > or=5. (n=50). -Each group is subdivided into another two groups:-
~Group 1A (n=25). - Group 1B (n=25).
~Group 2A (n=25). - Group 2B (n=25).
~All the women in group 1A and group 2A will receive intravaginal misoprostol tablets moistened with 3 ml of 5% acetic acid, and all the women in group 1B and group 2B will receive intravaginal misoprostol tablets moistened with water, 400 micrograms every 4 hours for a maximum of 5 doses within 24 hours. If the patient will not have adequate uterine contractions, the same regimen will be repeated over the following 24 hours"
11516202|NCT01241032|Experimental|Udenafil|Udenafil 200mg
11516203|NCT01241032|Active Comparator|Udenafil + Alcohol|Udenafil 200mg + Alcohol
11516204|NCT01241019|Experimental|Topiramate|Newborns with hypoxic ischemic encephalopathy treated with mild hypothermia and topiramate
11516205|NCT01241019|No Intervention|Control|Newborns with hypoxic ischemic encephalopathy treated with mild hypothermia
11516206|NCT01241006|Active Comparator|Dexamethasone|Single dose of Dexamethasone 12 mg PO and 4 days of placebo capsules
11516207|NCT01241006|Active Comparator|Prednisone|Prednisone 60mg PO capsules for 5 days
11516208|NCT01240993|Active Comparator|Parent Education|PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs (e.g., health care, child care, housing and education). The PE counselor will also provide a choice of pamphlets on age-related parenting topics each week from a series of pamphlets designed specifically for this study.
11516209|NCT01240993|Experimental|Mothers and Toddlers Program|This intervention is an introductory, short-term, supportive, psychodynamic therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing. Mothers meet with an individual, MBT-trained psychodynamically-oriented therapist for 12 sessions. The intervention is conducted a clinic where mothers are enrolled in treatment for their substance abuse.
11516210|NCT01240980|Experimental|BMS-903452 (0.1 mg) or Placebo - A1|(Healthy Subjects)
11516211|NCT01240980|Experimental|BMS-903452 (0.6 mg) or Placebo - A2|(Healthy Subjects)
11516212|NCT01240980|Experimental|BMS-903452 (3.0 mg) or Placebo - A3|(Healthy Subjects)
11516213|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - A4|(Healthy Subjects)
11516214|NCT01240980|Experimental|BMS-903452 (30 mg) or Placebo - A5|(Healthy Subjects)
11516215|NCT01240980|Experimental|BMS-903452 (60 mg) or Placebo - A6|(Healthy Subjects)
11516216|NCT01240980|Experimental|BMS-903452 (120 mg) or Placebo - A7|(Healthy Subjects)
11516217|NCT01240980|Experimental|BMS-903452 (0.6 mg) or Placebo - B1|(Subjects with type 2 Diabetes Mellitus)
11516218|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - B2|(Subjects with type 2 Diabetes Mellitus)
11516219|NCT01240980|Experimental|BMS-903452 (120 mg) or Placebo - B3|(Subjects with type 2 Diabetes Mellitus)
11516220|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - A11|(Healthy Subjects)
11516221|NCT01240980|Experimental|BMS-903452 (60 mg) or Placebo - A12|(Healthy Subjects)
11516222|NCT01240954|Active Comparator|OSIRIS|
11516223|NCT01240954|Experimental|OSIRIS other concentration 1|
11516224|NCT01240954|Experimental|OSIRIS other concentration 2|
11516225|NCT01240941|Experimental|MK-2206|MK-2206 maximum tolerated dose found from Phase Ib trial (under a separate NCT number) taken orally on a weekly basis
11516226|NCT01240928|Experimental|MK-2206 + exemestane +/- goserelin|Oral MK-2206 and oral exemestane and subcutaneous goserelin (for pre-menopausal participants only)
11516227|NCT01240915|Experimental|Cohort 1|The first 9 subjects will be recruited into Cohort 1 and will receive either placebo (n=3) or MultiStem low dose (n=6) as an intravenous infusion on Day 1. The first five patients enrolled constitute a subgroup of Cohort 1 and these patients will receive multiple doses, once every day for 7 days for 3 doses (Day 1 and Weeks 1 & 2).
11516228|NCT01240915|Experimental|Cohort 2|This group will receive either placebo (n=3) or MultiStem high dose (n=6) as an intravenous infusion on Day 1. The subjects then receive the opposite dose of study medication at Week 8.
11516229|NCT01240915|Experimental|Cohort 3|These subjects (total n=88 evaluable patients) will receive either Placebo or MultiStem (1:1 randomization) as an intravenous infusion on Day 1. In addition all subjects in Cohort 3 will receive a single infusion of either MultiStem or Placebo at Week 8, depending on their randomization schedule. A total of ~22 patients will receive an additional infusion of MultiStem, ~44 patients will receive the alternative blinded therapy to that which they received for Day 1 infusion, and ~22 patients will receive an additional infusion of placebo.
11516279|NCT01240512|Active Comparator|High Dose Arm|4000 IU/day Vitamin D3 (cholecalciferol) supplementation
11516230|NCT01240902|Experimental|Extreme Risk: TAVI Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Iliofemoral Access
11516231|NCT01240902|Experimental|Extreme Risk: TAVI Non-Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Non-Iliofemoral Access
11516232|NCT01240902|Experimental|High Risk: TAVI|High Risk Surgical Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
11516233|NCT01240902|Active Comparator|High Risk: SAVR|High Risk Surgical Patients: Surgical Aortic Valve Replacement (SAVR)
11516234|NCT01240889|Active Comparator|montelukast|luekotriene inhibitor
11516235|NCT01240889|Active Comparator|Fluticasone|Nasal steroid
11516236|NCT01240876|Experimental|CEP-37247|
11516237|NCT01240876|Placebo Comparator|Matching placebo|
11516238|NCT01240863|Placebo Comparator|Placebo|Participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the treatment period, participants were administered placebo tablets every 12 hours that matched the dosage deemed successful for managing their pain during the titration period. A step-wise, double-blind schedule to tamper off active drug was implemented during the first 2 weeks of the 12-week, double-blind, placebo-controlled treatment period to reduce the risk of withdrawal effects in participants randomly assigned to placebo.
11516239|NCT01240863|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the 12-week, double-blind, placebo-controlled treatment period, participants randomly assigned to hydrocodone ER were administered tablets every 12 hours at the dosage deemed successful for managing their pain during the titration period.
11516240|NCT01240850|Active Comparator|Prednisone|
11516241|NCT01240850|Experimental|Methotrexate+Prednisone|
11516242|NCT01240837|Active Comparator|glucose|
11516243|NCT01240837|Active Comparator|sucrose|
11516244|NCT01240837|Experimental|palm sugar|
11516245|NCT01240824|Experimental|BCG + aminophylline|Bacillus Calmette-Guerin (BCG) plus one of three escalating doses of aminophylline administered intravesically.
11516246|NCT01240811|No Intervention|Control-No IUD|Healthy volunteers not at risk of pregnancy and not using any hormonal contraception.
11516247|NCT01240811|Experimental|Levonorgestrel IUS|Healthy volunteers seeking contraception with IUD. Randomized to LNG IUS.
11516248|NCT01240811|Experimental|Copper T380A IUD|Healthy volunteers seeking contraception with IUD. Randomized to Copper T380A IUD.
11516249|NCT01240798||Depression, anxiety|
11516250|NCT01240785|Active Comparator|Metformin|Metformin 500 mg 1-2 tablets twice daily according to plasma glucose values
11516251|NCT01240785|Active Comparator|insulin|NPH insulin once or twice daily and/or insulin lispro or aspart according to preprandial and postprandial glucose values
11516252|NCT01240772|Experimental|DGALM|doppler-guided arterial ligation with mucopexy
11516253|NCT01240772|Active Comparator|SH|stapled haemorrhoidopexy according to Longo
11516254|NCT01240759|Experimental|S-707106 Dose A|One S-707106 A tablet + 3 Placebo A tablets
11516255|NCT01240759|Experimental|S-707106 Dose B|One S-707106 B tablet + 3 Placebo A tablets
11516256|NCT01240759|Experimental|S-707106 Dose C|S-707106 Dose C = Four S-707106 B tablets
11516257|NCT01240759|Active Comparator|Metformin|The standard of care dose of metformin for the individual patient + 3 Placebo A tablets
11516258|NCT01240746|Active Comparator|Group 1: Licensed 2010-2011 TIV|Participants will receive the Licensed 2010-2011 Trivalent Influenza Vaccine containing the primary B strain.
11516259|NCT01240746|Experimental|Group 2: Investigational TIV|Participants will receive the Investigational Trivalent Influenza Vaccine containing the alternate B strain
11516260|NCT01240746|Experimental|Group 3: Investigational QIV|Participants will receive the investigational Quadrivalent Influenza Vaccine
11516261|NCT01240720|Experimental|I131-F16SIP|"Phase I: Multicentre, open-label, two-step singlearm dose escalation study in sequential cohorts of patients with cancer.
~Phase II: Prospective, open-label, single-arm, multicentre study of 131I-F16SIP, given at the RD of 55.5 mCi/m2, as determined in phase I."
11516262|NCT01240707|Other|LF tests, Fiberoptic bronchoscopy|Spirometry, Peak Expiratory Flow (PEF). Bronchoscopic assessment of soot in central airways.
11516263|NCT01240694|Experimental|CEP-33457|200 mcg of CEP-33457
11516264|NCT01240681|Other|FLT PET and BOLD MRI scan|All subjects will have the study intervention of FLT PET and BOLD MRI at baseline and after the first cycle of chemotherapy
11516265|NCT01240668||Hyponatremia Patients|Euvolemic or hypervolemic hyponatremia with serum sodium ≤130 mmol/L
11516266|NCT01240655|Experimental|LCL161 + Paclitaxel|
11516267|NCT01240642|Experimental|ASA404|
11516268|NCT01240629|Experimental|Arm I|Patients receive doxorubicin-GnRH agonist conjugate AEZS-108 intravenously (IV) over 2 hours once every 21 days (21 days = 1 cycle). Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11516269|NCT01240590|Experimental|Ph I Level -1: Cisplatin + Crolibulin|75mg/m(2) Cisplatin + 8 mg/m(2) Crolibulin
11516270|NCT01240590|Active Comparator|Ph I Level 1: Cisplatin + Crolibulin|75mg/m(2) Cisplatin + 13 mg/m(2) Crolibulin
11516271|NCT01240590|Active Comparator|Ph I Level 2: Cisplatin + Crolibulin|100mg/m(2) Cisplatin + 13 mg/m(2) Crolibulin
11516272|NCT01240590|Active Comparator|Ph II Level 3: Cisplatin + Crolibulin|100mg/m(2) Cisplatin + 20 mg/m(2) Crolibulin
11516273|NCT01240590|Active Comparator|Ph II Level 4: Cisplatin|100mg/m(2) Cisplatin
11516274|NCT01240551|Active Comparator|Mets via NaF-18 PET/CT|Patients with known bone metastases (i.e. mets).
11516275|NCT01240551|Active Comparator|No-Mets via NaF-18 PET/CT|Patients with no clinical evidence of bone metastases
11516276|NCT01240538|Experimental|Treatment (virus and chemotherapy)|Patients receive wild-type reovirus IV over 60 minutes QD on days 1-5. Some patients also receive cyclophosphamide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11516277|NCT01240525|Other|CD4 DLI|Patients will receive trial product manipulated CD4 DLI post transplant as trial treatment.
11516278|NCT01240525|Other|No DLI|Patients will receive no DLI post transplant as trial treatment.
11516280|NCT01240512|Active Comparator|Low Dose Arm|400 IU/day Vitamin D3 (cholecalciferol) supplementation
11516281|NCT01240499|Experimental|Health-At-Every-Size (HAES)|
11516282|NCT01240499|Active Comparator|Social Support (SS)|
11516283|NCT01240499|No Intervention|Control|
11516284|NCT01240460|Experimental|1|Twice-daily dosing (every 12 hours) XL765
11516285|NCT01240460|Experimental|2|Once-daily dosing XL147
11516286|NCT01240460|Experimental|3|Once-daily dosing XL765
11516287|NCT01240447|Other|Best support treatment|
11516288|NCT01240447|Experimental|Racotumomab vaccine|
11516289|NCT01240434|Active Comparator|Fascia closure of the surgical trocars|Arm in which all the surgical trocar orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone)
11516290|NCT01240434|No Intervention|Trocar site without closure|All the orifices of the trocar site are left open, closing only the skin.
11516291|NCT01240408|Experimental|Treatment group 1|10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
11516292|NCT01240408|Experimental|Treatment group 2|10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
11516293|NCT01240395|Experimental|MBCT intervention|
11516294|NCT01240395|No Intervention|Control group|
11516295|NCT01240382|Experimental|3% DE-089|
11516296|NCT01240382|Active Comparator|0.1% HA|
11516297|NCT01240369||VEGF-C low|
11516298|NCT01240369||VEGF-C high|
11516299|NCT01240369||miR-326 low|
11516300|NCT01240369||miR-326 high|
11516301|NCT01240356|Experimental|Phase I: Healthy Volunteers|Subjects without history of Central Nervous System Disease will receive 2-hours of hands-free 2-megahertz (MHz) transcranial Doppler ultrasound insonation continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
11516302|NCT01240356|Experimental|Phase II: 0-3 hour Patients|Ischemic stroke patients who present between 0-3 hours will receive 2-hours of hands-free 2-MHz transcranial Doppler ultrasound Continuously to the intracranial vessels.
11516303|NCT01240304|Experimental|Gemcitabine, radiation therapy, surgery|
11516304|NCT01240291|Experimental|alanyl-glutamine|Intravenous alanyl-glutamine (0.5 g/kg body weight/day)
11516305|NCT01240291|Placebo Comparator|normal saline|Intravenous placebo (normal saline; 0.9 %)
11516306|NCT01240265|Experimental|Vitamin D 150,000 units once|Single dose of vitamin D3 150,000 IU given orally once
11516307|NCT01240265|Experimental|Vitamin D 5000 units daily|Vitamin D3 5000 IU daily given orally for 28 days
11516308|NCT01240252|Experimental|Type 2 Diabetes Mellitus Subjects|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
11516309|NCT01240252|Experimental|Overweight or Obese Subjects with Normal Glucose Tolerance|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
11516310|NCT01240252|Placebo Comparator|Non-Obese Control Subjects|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
11516311|NCT01240239||telephone group|The telephone group must be healthy adults scheduled for an ENT surgery.
11516312|NCT01240239||telemedicine group|This group if qualified will randomly be chosen to be in the telemedicine group.
11516313|NCT01240239||pre-anesthesia consultation|This will be the group that will be randomized to the pre-anesthesia clinic.
11516314|NCT01240226|Experimental|A|
11516315|NCT01240226|Experimental|B|
11516316|NCT01240213|Active Comparator|Vitamin D|2000 IU per day of Vitamin D
11516317|NCT01240213|Placebo Comparator|Placebo|
11516318|NCT01240200|Active Comparator|Vial & Syringe (Period 1) / Pen (Period 2)|Crossover phase: patients randomized to the sequence: Insulin glargine vial and syringe in Period 1 and Insulin glargine SoloSTAR pen in Period 2.
11516319|NCT01240200|Experimental|Pen (Period 1) / Vial & Syringe (Period 2)|Crossover phase: patients randomized to the sequence: Insulin glargine SoloSTAR® pen in Period 1 and Insulin glargine vial and syringe in Period 2.
11516320|NCT01240187|Experimental|Experimental 1|
11516321|NCT01240187|Experimental|Experimental 2|
11516322|NCT01240174|Other|Intervention Arm|Single arm in the study of doctors receiving feedback about their antibiotic prescribing rate for acute bronchitis.
11516323|NCT01240161||Patients with high grade gliomas|All subjects will have radiographically suspected or surgically proven de novo high grade gliomas. There are no control patients.
11516324|NCT01240148|Experimental|1|150 μL intradermal injection of 1 μmol/L AZD3161
11516325|NCT01240148|Experimental|2|150 μL intradermal injection of 6 μmol/L AZD3161
11516326|NCT01240148|Experimental|3|150 μL intradermal injection of 30 μmol/L AZD3161
11516327|NCT01240148|Active Comparator|4|150 μL intradermal injection of 10 mg/mL Lidocaine
11516328|NCT01240148|Placebo Comparator|5|150 μL intradermal injection of AZD3161 placebo
11516329|NCT01240135|Other|FID 114576A / renu fresh|FID 114675A used for contact lens care per protocol-specified instructions for 14 days, followed by a minimum 1-day washout period, after which renu fresh used for contact lens care for an additional 14 days.
11516330|NCT01240135|Other|renu fresh / FID 114675A|Renu fresh used for contact lens care per protocol-specified instructions for 14 days, followed by a minimum 1-day washout period, after FID 114675A used for contact lens care for an additional 14 days.
11516331|NCT01240122|Active Comparator|Biotrue MPS|
11516332|NCT01240122|Experimental|Investigational MPS|
11516333|NCT01240109|Active Comparator|propofol|
11516334|NCT01240109|Active Comparator|sevoflurane|
11516335|NCT01240096|Active Comparator|Mirtazapine|mirtazapine 15 mg daily
11516336|NCT01240096|Placebo Comparator|Placebo|Placebo once daily
11516337|NCT01240083|Experimental|Thetaburst Stimulation|1: Thetaburst stimulation: right DLPFC continuous TBS followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 stimuli, 80% motorthreshold
11516338|NCT01240083|Experimental|High frequency rTMS|2: Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC, 110% motor threshold, followed by 1000 stimuli of 10 Hz over the left DLPFC , 110% motorthreshold
11516339|NCT01240083|Experimental|Placebo Stimulation|3: Sham Stimulation (Sham coil): right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
11516340|NCT01240070|Active Comparator|Usual Care|Clinical practice in type 2 diabetes treatment
11516341|NCT01240070|Active Comparator|Intensive Care|Intensive multi-factorial treat-to-target intervention, according to international guidelines, that includes both lifestyle intervention and a step-wise strategy for pharmacological treatment with a treat-to-target approach.
11516342|NCT01240057|Placebo Comparator|expectant management during pregnancy|watchful waiting during pregnancy
11516343|NCT01240057|Experimental|fetal endoluminal tracheal occlusion|fetoscopic balloon occlusion at 27 to 29+6 weeks of gestation
11516344|NCT01240044|No Intervention|Control Group|In this group the newborns remained at rest 20 minutes and receive no intervention of respiratory therapy.
11516345|NCT01240044|Experimental|Physical Therapy|In this group the newborns are submitted to the mechanical vibrator.
11516346|NCT01240044|Experimental|Thoracoabdominal rebalancing|In this group the newborns receive the thoracoabdominal rebalancing.
11516347|NCT01240018|Placebo Comparator|Placebo|
11516348|NCT01240018|Active Comparator|High dose Lb. casei|
11516349|NCT01240005|Experimental|DCIK|
11516350|NCT01239992|Experimental|Niacin/ Laropiprant|
11516351|NCT01239979||Stable, Unstable , control|
11516352|NCT01239953|Active Comparator|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon (SeQuent Please, B. Braun)
11516353|NCT01239953|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent (Xience Prime, Abbott Vascular)
11516354|NCT01239940|Active Comparator|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon (SeQuent Please, B. Braun)
11516355|NCT01239940|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent (Xience Prime, Abbott Vascular)
11516356|NCT01239888|Active Comparator|Oxytocin|
11516357|NCT01239888|Active Comparator|Oxytocin and Tibolone|
11516358|NCT01239888|Placebo Comparator|Placebo|
11516359|NCT01239875|Experimental|Arm A|Patients receive pneumococcal polyvalent vaccine intramuscularly in weeks -4, 2, and 10. Patients undergo cryoablation followed by dendritic cell vaccine (CA-DC) intratumorally in weeks 0, 2, 4, 6, 10, 14, 18, and 22.
11516360|NCT01239875|Experimental|Arm B|Patients receive pneumococcal polyvalent vaccine as in arm A. Patients also receive autologous dendritic cell-tumor fusion vaccine (TL-DC) intradermally in weeks 0, 2, 4, 6, 10, 14, 18, and 22.
11516361|NCT01239862|Experimental|Autologous cell transplantation|We conducted a prospective, non-randomized, single-center longitudinal study in five patients. Inclusion criteria were age 18-50 years, chronic and accelerated silicosis, forced expiratory volume in 1s <60% and >40%, forced vital capacity ≥60% and arterial oxygen saturation >90%. BMDMCs were administered through bronchoscopy (2×107 cells) into both lungs. Physical examination, laboratory evaluations, quality of life questionnaires, thoracic computed tomography scans, lung function tests, and perfusion scintigraphy were performed before the beginning of treatment and up to 360 days after BMDMC (Bone Marrow Derived Mononuclear Cells) therapy. Additionally, whole-body and planar scans were evaluated 2 and 24 h after instillation.
11516362|NCT01239836|Experimental|Self-management|
11516363|NCT01239836|Sham Comparator|General Health Lecture|
11516364|NCT01239836|Experimental|Combined workshop and self-management|
11516365|NCT01239836|Experimental|Workshop|
11516366|NCT01239823|Experimental|Whole Body Vibration Training|The subjects will participate in a 12-week whole body vibration exercise program with 2 sessions (1/2 hour) per week.
11516367|NCT01239823|Experimental|Exercise without vibration|The subjects will participate in a 12-week exercise program with 2 sessions (1/2 hour) per week.
11516368|NCT01239810||Control group|Receiving no treatment
11516369|NCT01239810||hyaluronic acid|treatment group receiving intraarticular hyaluronic acid
11516370|NCT01239797|Active Comparator|Lenalidomide + Dexamethasone|
11516371|NCT01239797|Experimental|Lenalidomide + Dexamethasone +Elotuzumab|
11516372|NCT01239784|Experimental|All Subjects|A total of 20 children and their parents will be recruited for this study. Ten children will have had the Glenn procedure and 10 infants will have had the arterial switch operation.
11516373|NCT01239771|Experimental|1|TC-5214
11516374|NCT01239771|Placebo Comparator|2|Placebo matched to TC-5214
11516375|NCT01239758|Experimental|ACE-031 (Extension of cohort 1 from core study, A031-03)|
11516376|NCT01239758|Experimental|ACE-031 (Extension of cohort 2 from core study, A031-03)|
11516377|NCT01239758|Experimental|ACE-031 (Extension of cohort 3 from core study, A031-03)|
11516378|NCT01239745||1|
11516379|NCT01239732|Experimental|Bevacizumab + Paclitaxel + Carboplatin|Participants will receive bevacizumab 15 mg/kg IV on Day 1 every 3 weeks from Cycle 1 to Cycle 36 (initially concurrent with chemotherapy, then continued as a single agent following the completion of chemotherapy), or until protocol defined disease progression or until unacceptable toxicity (whichever occurred first). Participants will receive paclitaxel 175 mg/m^2 IV on Day 1 every 3 weeks or 80 mg/m^2 IV every week and carboplatin (AUC 5-6) IV on Day 1 every 3 weeks for a minimum of 4 and maximum of 8 cycles (including up to 4 pre-surgical cycles), or until protocol defined disease progression, or unacceptable toxicity (whichever occurred first).
11516380|NCT01239719|Experimental|Dexamethasone + Clemastine|Dexamethasone + clemastine fumarate cream
11516381|NCT01239719|Active Comparator|Dexamethasone|Dexamethasone 0.5 mg
11516382|NCT01239706|Experimental|NTx 265|
11516383|NCT01239693|Active Comparator|IFA group|Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
11516384|NCT01239693|Active Comparator|MMN group|Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients' Children from 6 to 18 months of age: None
11516385|NCT01239693|Experimental|LNS group|Women during pregnancy: 1 sachet of LNS-P&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
11516537|NCT01238627|Active Comparator|Microtab-4|2 x 2 mg Nicotine tablet
11516386|NCT01239680|Placebo Comparator|Ringer's Lactate and Placebo for Glutamine|Ringer's Lactate 1 liter once over 6 hours
11516387|NCT01239680|Experimental|Ringer's Lactate with 25 grams Glutamine|Ringer's Lactate with 25 grams Glutamine (1 liter) once over 6 hours
11516388|NCT01239667|Experimental|Life style counseling|Individual oriented rehabilitation plan in collaboration with the patient followed by measuring health related quality of life and self care behavior
11516389|NCT01239654|Active Comparator|everolimus|everolimus-eluting stent
11516390|NCT01239654|Active Comparator|zotarolimus|zotarolimus-eluting stent
11516391|NCT01239615||healthy volunteers|
11516392|NCT01239602||Normal control|
11516393|NCT01239602||with Stem cell therapy plus G-CSF|
11516394|NCT01239602||G-CSF along|
11516395|NCT01239589||1|patients admitted as for an acute bipolar manic episode and treated with quetiapine IR
11516396|NCT01239589||2|patients admitted as for an acute bipolar manic episode and treated with quetiapine XR
11516397|NCT01239563|Experimental|Thymoglobulin|Thymoglobulin induction group
11516398|NCT01239563|Active Comparator|Basiliximab|Basiliximab induction - 20 mg, day 0 and day 4
11516399|NCT01239550|Experimental|Insulin Detemir Treatment|"Insulin detemir treatment: Insulin detemir will be administered subcutaneously, once daily. Dose ranges from approximately 0.1 U/kg up to 0.6 u/kg or higher. The dosing regimen will employ a strategy similar to the 303algorithm, where, with close interaction with study personnel (rather than self-titration), bedtime insulin dosing will be titrated up by 3 units until AM fasting sugars within the prescribed protocol range are achieved (90-110 mg/dl). Subjects will have contact with study personnel on weekly basis for glycemia monitoring and adjustments. Similarly, documented hypoglycemia (blood sugars less than 70) will trigger a dose reduction, and it is expected that with weight loss, tolerable insulin dosages will drift downward. The treatment period is 24 weeks."
11516400|NCT01239550|No Intervention|Comparator: No insulin|"The main hypothesis is that diabetes can be changed  with early and careful insulinization capturing effects on brain function ultimately leading to weight loss. . Seek to determine in a quantitative manner whether insulin detemir restores brain dopamine neurotransmission, a control group not treated with insulin is required. The strength of this study is our ability to test the specific molecular (D2R, DAT, functional MRI responses) and integrated output (functional brain responses, mood, cognitive function, reward responses etc.) of CNS dopaminergic pathways in order to shed unprecedented light upon mechanisms of detemir action in obesity and diabetes."
11516401|NCT01239537||Baxter H1N1 vaccine|Previously received 2 dose schedule of Baxter H1N1 vaccine
11516402|NCT01239537||GSK H1N1 vaccine|Previously received 2 dose schedule of GSK H1N1 vaccine
11516403|NCT01239524|Other|DE-group|surgical denervation by excising 1 cm of proximal thoracodorsal nerve
11516404|NCT01239524|Other|IN group|thoracodorsal nerve is saved intact
11516405|NCT01239511|Placebo Comparator|Placebo group|placebo capsule 2# t.i.d./day
11516406|NCT01239511|Experimental|Treatment Group A|150 mg STA-2, 2 capsules t.i.d., after meal (900 mg STA-2 total dose per day)
11516407|NCT01239511|Experimental|Treatment Group B|300 mg STA-2, 2 capsules t.i.d., after meal (1800 mg STA-2 total dose per day)
11516408|NCT01239511|Experimental|Treatment Group C|450 mg STA-2, 2 capsules t.i.d., after meal (2700 mg STA-2 total dose per day)
11516409|NCT01239498|Experimental|Saline + Lidocaine/Adrenaline|
11516410|NCT01239498|Placebo Comparator|Lidocaine/Adrenaline only|
11516411|NCT01239485|Experimental|Irinotecan|
11516412|NCT01239472|No Intervention|tacrolimus|Kidney transplant patients with living or deceased donors using tacrolimus, mycophenolate sodium and prednisone.
11516413|NCT01239472|Active Comparator|everolimus|Kidney transplant patients with living or deceased donors using tacrolimus, mycophenolate sodium and prednisone, and converted for everolimus, mycophenolate sodium, and prednisone 90 days after renal transplantation.
11516414|NCT01239459|Experimental|Severe impaired renal function|Subjects with severe renal impairment as defined by Cockroft-Gault formula
11516415|NCT01239459|Experimental|Normal renal function|Subjects with normal renal function as defined by Cockroft-Gault formula
11516416|NCT01239433||mechanically ventilated patients|ICU patients on mechanical ventilation. Daily endotracheal suctioning performed to reduce secretions. Data recorded during these therapeutic interventions.
11516417|NCT01239407|No Intervention|Treatment as usual|"The treatment as usual arm consists of two phone or in-person interviews:
~Patients are asked questions about their mental health, their views of mental health, and how they cope with their mental health (including any treatment they might be receiving).
~Patients are asked the same questions 6 months after the initial interview."
11516418|NCT01239407|Experimental|Culturally focused psychiatric consultation|"The consultation is comprised of 3 visits:
~1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).
~1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.
~2. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).
~3. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person)."
11516419|NCT01239394|Other|ofatumumab|single-arm, open-label, interventional
11516420|NCT01239381|Experimental|SBRT-Proton|Stereotactic body radiotherapy by proton radiation
11516421|NCT01239368|Experimental|Cohort B - Relapsed Multiple Myeloma|Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) .Rapamycin (Rapa) for Relapsed Multiple Myeloma
11516422|NCT01239368|Experimental|Cohort A - Prevention of Relapse|Th1/Tc1.Rapa Prevention of Relapse
11516423|NCT01239355|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive oral Akt inhibitor MK2206 on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11516424|NCT01239342|Experimental|Arm I (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who are progression free after 1 year may receive a 12 week study drug supply of Akt inhibitor MK2206.
11516425|NCT01239342|Experimental|Arm II (everolimus)|Patients receive everolimus PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11516426|NCT01239329||Complex multiple disabilities|People with complex multiple disabilities, living in a care institution participating in the Governor Kremers Centre (GKC.)
11516427|NCT01239316|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
11516428|NCT01239303|Active Comparator|citrulline|
11516429|NCT01239303|Placebo Comparator|alanine|
11516430|NCT01239277|Experimental|protein (elderly)|
11516431|NCT01239277|Experimental|protein and carbohydrate (elderly)|
11516432|NCT01239277|Experimental|protein and carbohydrate (young)|
11516433|NCT01239277|Experimental|protein and leucine (elderly)|
11516434|NCT01239251||breast cancer patients taking endocrine therapy|Breast cancer patients, currently taking adjuvant endocrine therapy will be equipped with a GlowCap device for a period of 30 days. The GlowCap will become part of their medication taking routine.
11516435|NCT01239238||Care as usual|Therapy is guided based on symptoms and lung function. Assessments: home monitoring, symptoms, lung function, FeNO, asthma control, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
11516436|NCT01239225|Experimental|Abdominal ultrasound|Abdominal ultrasound
11516437|NCT01239199|Experimental|Exhaled NO|
11516438|NCT01239186||Oligozoospermia|infertile patients presenting a reduced sperm count (less than 20 Millions of spermatozoa/ml)
11516439|NCT01239173|Active Comparator|1|Post-traumatic stress disorder patient receiving propanolol 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
11516440|NCT01239173|Placebo Comparator|2|Post-traumatic stress disorder receiving placebo 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
11516441|NCT01239173|Active Comparator|3|Controls receiving propanolol 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
11516442|NCT01239173|Placebo Comparator|4|Controls receiving placebo 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
11516443|NCT01239160|Experimental|Advanced PCD|The use of an advanced PCD device to reduce and maintain limb volume
11516444|NCT01239160|Active Comparator|Simple PCD|The use of the Simple PCD is to reduce and maintain limb volume
11516445|NCT01239147|Other|Whole grain diet|
11516446|NCT01239147|Other|Refined grain diet|
11516447|NCT01239134|Experimental|TRX518|
11516448|NCT01239121|Experimental|HIE-Enhanced Medication Reconciliation|Health Information Exchange (HIE)-Enhanced Medication Reconciliation for Veterans admitted to James J Peters VA hospital units 6B, 7B, 7C, and 8B (each unit crossing over between intervention and control every 3-4 months)
11516449|NCT01239121|Active Comparator|Optimal Medication Reconciliation without HIE|Optimal Medication Reconciliation without Health Information Exchange (HIE) for Veterans admitted to James J Peters VA hospital units 6B, 7B, 7C, and 8B (each unit crossing over between intervention and control every 3-4 months)
11516450|NCT01239121|Other|Pilot HIE-Enhanced Outpatient Medication Reconciliation|Health Information Exchange (HIE)-Enhanced Medication Reconciliation for Veterans seen as outpatients in Geriatrics Primary care clinic
11516451|NCT01239095|Experimental|Green Tea and Milk Thistle Supplements|Patients will receive green tea extract and milk thistle extract supplements for one week prior to surgery and for 30 days after surgery.
11516452|NCT01239082|Other|Arm 1|Colonoscopy (one time screening)
11516453|NCT01239082|Other|Arm 2|FIT (annually)
11516454|NCT01239069|Experimental|DE-110 ophthalmic suspension high dose|
11516455|NCT01239069|Experimental|DE-110 ophthalmic suspension low dose|
11516456|NCT01239069|Placebo Comparator|Placebo|
11516457|NCT01239056||Pancreatic Pseudocysts|All adult patients who have a clinical indication to undergo an endoscopic drainage of a pancreatic pseudocyst.
11516458|NCT01239043|Experimental|Menomune® vaccine group|Participants received Menomune® vaccine in MTA29 (NCT00874549)
11516459|NCT01239043|Experimental|Menactra® vaccine group|Participants received Menactra® vaccine in trial MTA29 (NCT00874549)
11516460|NCT01239030|Active Comparator|10 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 10 mg
11516461|NCT01239030|Active Comparator|15 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 15 mg
11516462|NCT01239030|Active Comparator|20 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 20 mg
11516463|NCT01239030|Active Comparator|40 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 40 mg
11516464|NCT01239030|Placebo Comparator|Placebo|Placebo Capsules
11516465|NCT01239017|Experimental|Dose 1|SC REGN475 Dose 1 and IV Placebo
11516466|NCT01239017|Experimental|Dose 2|SC REGN475 Dose 2 and IV Placebo
11516467|NCT01239017|Experimental|Dose 3|SC REGN475 Dose 3 and IV Placebo
11516468|NCT01239017|Experimental|Dose 4|SC Placebo and IV REGN475 Dose 4
11516469|NCT01239017|Placebo Comparator|Dose 5|SC Placebo and IV Placebo
11516470|NCT01239004|Placebo Comparator|Placebo|
11516471|NCT01239004|Experimental|Colesevelam|
11516472|NCT01238991|Experimental|ACC-001 (3 micrograms) + QS-21|Active vaccine dose of 3 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
11516473|NCT01238991|Experimental|ACC-001 (10 micrograms) + QS-21|Active vaccine dose of 10 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
11516474|NCT01238991|Experimental|ACC-001 (30 micrograms) + QS-21|Active vaccine dose of 30 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
11516475|NCT01238978|Experimental|Vildagliptin|
11516476|NCT01238978|Active Comparator|other Oral Antidiabetic Drug in a different therapeutic class|
11516477|NCT01238965|Experimental|Arm I|Patients receive oral panobinostat 3 times a week. Patients also receive leucovorin calcium IV over 2 hours on days 1 and 15 followed by fluorouracil IV continuously over 46 hours on days 1-2 and 15-16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11516478|NCT01238939|Experimental|Treatment|
11516479|NCT01238926|Experimental|PD vitamin supplementation|
11516480|NCT01238926|Experimental|PD exercise intervention|
11516481|NCT01238926|Experimental|PD vitamin + exercise|
11516482|NCT01238926|No Intervention|PD control|
11516483|NCT01238913||benign esophageal lesions|All patients who have a benign esophageal lesion where it is medically indicated that they receive a stent.
11516484|NCT01238900||benign biliary strictures|All patients who have a medical indication for an ERCP to place a stent in their benign biliary strictures
11516485|NCT01238887|Placebo Comparator|microcrystalline cellulose|
11516486|NCT01238887|Active Comparator|Hydroxycitric acid|2800 mg divided in three doses per day
11516487|NCT01238887|Active Comparator|Hydroxycitric Acid|5400 mg divided into three doses per day
11516488|NCT01238874|No Intervention|No intervention|Mostly observational study with 1 patient global assessment.
11516489|NCT01238861|Placebo Comparator|Eosinophilic phenotype (EOS+) Placebo|EOS+ (defined as ELEN Index [proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent] positive and/or FeNO [fraction of exhaled nitric oxide] greater than or equal to [>=] 50 parts per billion [ppb]) participants received matching placebo injections subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
11516490|NCT01238861|Experimental|EOS+ Benralizumab (2 mg)|EOS+ participants received single benralizumab 2 milligram (mg) injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
11516491|NCT01238861|Experimental|EOS+ Benralizumab (20 mg)|EOS+ participants received single benralizumab 20 mg injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
11516492|NCT01238861|Experimental|EOS+ Benralizumab (100 mg)|EOS+ participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
11516493|NCT01238861|Placebo Comparator|Non-eosinophil phenotype (EOS-) Placebo|EOS- (defined as ELEN Index negative and FeNO <50 ppb) participants received matching placebo subcutaneous every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
11516494|NCT01238861|Experimental|EOS- Benralizumab (100 mg)|EOS- participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
11516495|NCT01238848|Experimental|Hypertonic|Nebulized hypertonic saline (sodium chloride 3%) + albuterol
11516496|NCT01238848|Active Comparator|Normal|Normal saline (sodium chloride 0.9%) + albuterol
11516497|NCT01238835|Experimental|TAVR-TA|Transcatheter valve replacement with transapical access
11516498|NCT01238822|Placebo Comparator|Placebo|
11516499|NCT01238822|Active Comparator|Low Dose Methylphenidate|Low dose: 18 mg methylphenidate
11516500|NCT01238822|Active Comparator|Medium Dose Methylphenidate|Medium Dosage: 36 mg if more than 50 kg and 27 mg if less than 50 kg
11516501|NCT01238822|Active Comparator|High Dose Methylphenidate|54 mg if more than 50 kg and 36 mg if less than 50 kg
11516502|NCT01238809||1|
11516503|NCT01238796|Experimental|Normal renal function|Subjects with normal renal function
11516504|NCT01238796|Experimental|Severe renal impairment|Subjects with severe renal impairment
11516505|NCT01238796|Experimental|End stage renal disease|Subjects with end stage renal disease
11516506|NCT01238783|Experimental|AL-15469A 0.5% and AL-65150.3% Ophthalmic Suspension|
11516507|NCT01238783|Experimental|AL-15469A 0.5%|
11516508|NCT01238783|Experimental|AL-6515 0.3%|
11516509|NCT01238783|Placebo Comparator|Vehicle|
11516510|NCT01238770|Experimental|Cyclophosphamid + Pazopanib|Cyclophosphamid + Pazopanib
11516511|NCT01238757|Active Comparator|Non-Invasive Pressure support|"in this arm, non-invasive pressure support will be recorded under 3 conditions:
~with the initial Expiratory Trigger Setting (ETS) with ETS +15% with ETS -15%"
11516512|NCT01238757|Active Comparator|NAVA|"Neurally Adjusted ventilatory Assist is a ventilation mode where the ventilator is piloted by the electrical activity of the diaphragm. Ventilation is triggered and cycled off by the electrical activity of the diaphragm, the pressure delivered being proportional to this activity.
~The proportion named gain is chosen to obtain under NAVA the same peak pressure than during Presure Support"
11516513|NCT01238744|Placebo Comparator|Study I: control drink|
11516514|NCT01238744|Experimental|Study I: flaxseed drink|
11516515|NCT01238744|Active Comparator|Study II: flaxseed drink|
11516516|NCT01238744|Experimental|Study II: flaxseed tablets|
11516517|NCT01238731||Valve replacement|Patients undergoing valve replacement for severe valve disease will be screened for study entry
11516518|NCT01238718|Active Comparator|lidocaine|
11516519|NCT01238718|Placebo Comparator|normal saline|
11516520|NCT01238705|Active Comparator|Felodipine,Irbesartan,Sexual Dysfunction|
11516521|NCT01238705|Active Comparator|Felodipine,Metoprolol,Sexual Dysfunction|
11516522|NCT01238692|Experimental|LBH589|
11516523|NCT01238692|Experimental|LBH589 plus Rituximab|
11516524|NCT01238679|Experimental|Cohort 1|Participants received an oral solution of 0.03 milligrams (mg) of PF-04958242, every 12 hours for 14 days.
11516525|NCT01238679|Experimental|Cohort 2|Participants received an oral solution of 0.05 mg of PF-04958242, every 24 hours for 14 days.
11516526|NCT01238679|Experimental|Cohort 3|Participants received an oral solution of 0.10 mg of PF-04958242, every 24 hours for 14 days.
11516527|NCT01238679|Experimental|Cohort 4|Participants received an oral solution of 0.15 mg of PF-04958242, every 24 hours for 14 days.
11516528|NCT01238679|Experimental|Cohort 5|Participants received an oral solution of 0.20 mg of PF-04958242, every 24 hours for 14 days.
11516529|NCT01238679|Experimental|Cohort 6|Participants received an oral solution of 0.25 mg of PF-04958242, every 24 hours for 14 days.
11516530|NCT01238679|Placebo Comparator|Matching Placebo|Participants received an oral solution of matching placebo, every 12 or 24 hours for 14 days.
11516531|NCT01238640|Experimental|Code STD|"An experimental 2 mg nicotine product coded STD"
11516532|NCT01238640|Experimental|Code STE|"An experimental 2 mg nicotine product coded STE"
11516533|NCT01238640|Active Comparator|Nicorette Microtab|A comparative 2 mg marketed nicotine product called Nicorette Microtab
11516534|NCT01238627|Experimental|Nicotine Sublingual Tablet Mint (NSTM)-2|Experimental 2 mg NSTM
11516535|NCT01238627|Active Comparator|Microtab-2|2 mg Nicotine tablet
11516536|NCT01238627|Experimental|NSTM-4|Experimental 4 mg Nicotine Sublingual Tablet Mint
11516538|NCT01238614|Experimental|PSF-JIT|Mothers in this arm receive prescreening questions and clinicians receive just-in-time handouts to aid in diagnosis.
11516539|NCT01238614|Experimental|PSF|Mothers in this arm receive screening questions on the prescreener form
11516540|NCT01238614|Placebo Comparator|Control|Mothers in this arm receive no maternal depression CHICA additional care
11516541|NCT01238588|Other|Sevelamer Carbonate (Renvela)|Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
11516542|NCT01238575|Experimental|Extended-release guanfacine|
11516543|NCT01238575|Placebo Comparator|Inactive placebo|
11516544|NCT01238562|Experimental|YPEG-Filgrastim, 10mcg/kg|
11516545|NCT01238562|Experimental|YPEG-Filgrastim, 20mcg/kg|
11516546|NCT01238562|Experimental|YPEG-Filgrastim, 30mcg/kg|
11516547|NCT01238562|Experimental|YPEG-Filgrastim, 45mcg/kg|
11516548|NCT01238562|Experimental|YPEG-Filgrastim, 60mcg/kg|
11516549|NCT01238549||Spinal Cord Injury|Participants with SCI
11516550|NCT01238536|Experimental|Epidural Steroid injection|"Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
~Intervention: Epidural steroid with local anesthetic injection
~2cc of .25 - 1% lidocaine and glucocorticoid (Kenalog 40-120 mg, depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg)"
11516551|NCT01238536|Active Comparator|Epidural local anesthetic injection|Intervention: Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
11516552|NCT01238523|Experimental|Long leg cast in full extension|Long leg cast in full extension with instructions to begin immediate weight bearing as tolerated on the injured extremity
11516553|NCT01238523|Experimental|Long leg cast with 45 degrees of flexion|Long leg cast with 45 degrees of flexion at the knee with instructions not to bear weight on the injured extremity
11516554|NCT01238510|Active Comparator|Provisional fKBT|Stent technique that final kissing balloon technique(fKBT) is performed if side branch flow was aggravated to TIMI0-2 after stent deployment
11516555|NCT01238510|Active Comparator|Routine fKBT|Stent technique that fKBT was mandatory irrespective of side branch flow after stenting.
11516556|NCT01238497||Registry 1 - SOURCE XT|Registry 1: All patients implanted with a SAPIEN XT valve, via Transfemoral access using NovaFlex (for 23mm and 26mm valve), or via Transapical access using Ascendra2 (23mm, 26mm and 29mm valve)
11516557|NCT01238497||Registry 2 - Ascendra+|Registry 2: All patients implanted with a SAPIEN XT Valve, via Transapical or Transaortic access using Ascendra+ delivery system (23mm, 26mm and 29mm valve)
11516558|NCT01238497||Registry 3 - NovaFlex+ 29 mm|Registry 3: All patients implanted with a SAPIEN XT valve, 29mm only, via Transfemoral access using NovaFlex+
11516559|NCT01238484|Active Comparator|Control|Patients in the control group will be treated with the current standard of care including shoe modification and home stretching exercises.
11516560|NCT01238484|Experimental|Experimental|Patients assigned to the experimental group will receive the current standard of care as well as the Ankle Dorsiflexion Dynasplint.
11516561|NCT01238471|Experimental|Propranolol|Oral propranolol for premature infants allocated to this arm by randomization
11516562|NCT01238471|Placebo Comparator|Oral sucrose 5%|Placebo: Oral sucrose 5% for premature infants allocated to control arm by randomization
11516563|NCT01238458|Experimental|[18F]AV-45 PET amyloid binding imaging|
11516564|NCT01238432||Inpatient population|Children with asthma who are admitted to the hospital with an exacerbation.
11516565|NCT01238432||Outpatient population|Children with asthma who have not been admitted to the hospital with an exacerbation.
11516566|NCT01238432||Healthy controls|Children without asthma or any other chronic condition.
11516567|NCT01238419|Experimental|Physiotulle|
11516568|NCT01238419|Placebo Comparator|Urgotul|
11516569|NCT01238406|Experimental|MD-logic Artificial Pancreas (MDLAP) system|Use of the closed loop MD-logic Artificial Pancreas(MDLAP)System
11516570|NCT01238406|Active Comparator|Standard treatment with insulin pump|Standard treatment with sensor augmented pump therapy
11516571|NCT01238393|Experimental|Ranibizumab|('intravitreal ranibizumab' )
11516572|NCT01238380||Diabetes diagnosed under 30 years|Patients currently under 50 years of age diagnosed with diabetes under 30 years.
11516573|NCT01238367|Experimental|recombinant factor VIII (N8)|
11516574|NCT01238354|Active Comparator|Without friend|Being in the weight loss programme without friend or family member
11516575|NCT01238354|Experimental|With friend|Having the friend or family member stay together with the patient for 2-3 days for every 3 week stay at the clinic in the weight loss programme
11516576|NCT01238341||Pancreatobiliary disease|Patients who have altered gastric anatomy who need an ERCP with an overtube for evaluation of pancreatobiliary disease.
11516577|NCT01238328|Experimental|Transplantation|
11516578|NCT01238315|Other|HuCNS-SC|
11516579|NCT01238302|Placebo Comparator|Conventional group|
11516580|NCT01238302|Experimental|PRP group|
11516581|NCT01238289|Placebo Comparator|Control group|This arm continues with standard care at community clinic
11516582|NCT01238289|Experimental|Peer Education|This group receives 8 weeks of peer led self management education classes and subsequent monthly support groups for a total of 10 months
11516583|NCT01238250||Copy Number Variants|Individuals with documented pathogenic or likely pathogenic copy number variants related to autism and other neurodevelopmental disorders.
11516584|NCT01238250||Gene Variants|Individuals with documented pathogenic or likely pathogenic variants in a gene related to autism and other neurodevelopmental disorders.
11516585|NCT01238237|Experimental|Cetuximab|
11516586|NCT01238224|Placebo Comparator|Placebo|A single dose of placebo is administered 30 min before a mixed meal.
11516587|NCT01238224|Active Comparator|Tadalafil|A single dose of tadalafil 20 mg is administered 30 min before a mixed meal.
11516668|NCT01237535|No Intervention|No luteal support|
11516669|NCT01237522|Active Comparator|Homozygote for the A270S wildetype|
11516670|NCT01237522|Active Comparator|Homo- or heterozygote for A270S minor alleles|
11516671|NCT01237509||group1|Patients with T1D
11516588|NCT01238211|Experimental|Treatment (daunorubicin hydrochloride, cytarabine, dasatinib)|"INDUCTION THERAPY (course 1): Patients receive daunorubicin hydrochloride IV on days 1-3, cytarabine IV continuously over 168 hours on days 1-7, and dasatinib PO QD on days 8-21. Patients with responsive disease on day 21 undergo consolidation therapy, and patients with non-responsive disease on day 21 (bone marrow cellularity >= 20% and leukemia blasts >= 5%) receive a second course of induction therapy.
~INDUCTION THERAPY (course 2): Patients receive daunorubicin hydrochloride IV on days 1-3, cytarabine IV continuously over 120 hours on days 1-5, and dasatinib PO QD on days 6-19. Patients achieving complete response receive consolidation therapy.
~CONSOLIDATION THERAPY: Patients receive high-dose cytarabine IV over 3 hours on days 1, 3, and 5, and dasatinib PO QD on days 6-26 or 7-27. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients in complete remission receive continuation therapy."
11516589|NCT01238172|Experimental|Arm A - MEAL Program Intervention|Patients will receive dietary education and telephone counseling sessions over 24 months.
11516590|NCT01238172|Experimental|Arm B - Prostate Cancer Foundation Booklet|Patients receive information about diet, nutrition, exercise and cancer. Patients also receive regularly scheduled newsletters.
11516591|NCT01238159|Experimental|CCRT+MIDLE|Patients who are planned to be treated with CCRT plus MIDLE chemotherapy. CCRT means concurrent chemoradiation, and MIDLE represent systemic chemotherapy.
11516592|NCT01238146|Experimental|Arm I|Patients receive obatoclax mesylate IV over 3 hours on days 1-3, rituximab IV over 4-8 hours on day 1, and bendamustine hydrochloride IV over 30 minutes on days 1-2.
11516593|NCT01238146|Experimental|Arm II|Patients receive rituximab and bendamustine hydrochloride as in arm I.
11516594|NCT01238133|Experimental|Treatment (RO4929097, paclitaxel, carboplatin, surgery)|Patients receive gamma-secretase inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17, paclitaxel IV over 60 minutes on days 1, 8, and 15 (day -1 of course one), and carboplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Within 4 weeks after completion of neoadjuvant therapy, patients undergo definitive breast surgery.
11516595|NCT01238120|Active Comparator|Placebo and Home-Based Exercise|200mg placebo (taken twice a day at least 8 hours apart) for a period of 6 weeks and a progressive walking and resistance band exercise program called Exercise for Cancer Patient (EXCAP) for a period of 6 weeks.
11516596|NCT01238120|Active Comparator|Ibuprofen 200mg BID, Home-Based Exercise|200mg ibuprofen (taken twice a day at least 8 hours apart) and a progressive walking and resistance band exercise program called Exercise for Cancer Patient (EXCAP) for a period of 6 weeks.
11516597|NCT01238120|Placebo Comparator|Placebo|200mg placebo (taken twice a day at least 8 hours apart) for a period of 6 weeks.
11516598|NCT01238120|Active Comparator|Ibuprofen 200 mg BID|200mg ibuprofen (taken twice a day at least 8 hours apart) for a period of 6 weeks.
11516599|NCT01238107|Experimental|High dose|
11516600|NCT01238107|Experimental|Low dose|
11516601|NCT01238107|Placebo Comparator|Placebo|
11516602|NCT01238094|Experimental|FOLFIRI or XELIRI/simvastatin|FOLFIRI or XELIRI/simvastatin
11516603|NCT01238068|Active Comparator|Gamma nail, fracture stabilization, better walking|
11516604|NCT01238055|Experimental|Docetaxel + Sunitinib|Docetaxel and Sunitinib
11516605|NCT01238055|Active Comparator|Docetaxel|Docetaxel only
11516606|NCT01238042|Experimental|Light Dose Escalation|Light Dose escalated from 150 joules/cm to 200 joules/cm
11516607|NCT01238029|Experimental|Capecitabine, Lapatinib, Vinorelbine|
11516608|NCT01238016|Other|device|Device implant and EEG recording
11516609|NCT01238003||Hospitalized patients|
11516610|NCT01237977|Experimental|Botulinum toxin type A(Meditoxin®)|
11516611|NCT01237977|Active Comparator|Botulinum toxin type A(Botox®)|
11516612|NCT01237964|Experimental|Xiaflex ( Collagenase use)|all 10 patients will be selected from out burn's clinic pool and will be injected using collagenase
11516613|NCT01237951|Experimental|GemBuMel|"Gemcitabine 1875 mg/m^2 IV (75 mg/ m2 bolus followed by 1800 mg/m^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.
~Busulfan 32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.
~Busulfan area under curve (AUC) 4,000 by vein on Days -8 to -5 as an outpatient or inpatient.
~Melphalan 60 mg/m^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.
~Palifermin 60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.
~Palifermin 60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient.
~Dexamethasone 8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
~Stem Cell Transplant: On Day 0, stem cells returned to body by vein over 30-60 minutes."
11516614|NCT01237938|Experimental|Low Glycemic Diet|
11516615|NCT01237925|Experimental|Dexchlorpheniramine 1% gel|
11516616|NCT01237925|Active Comparator|Dexchlorpheniramine 1% cream|
11516617|NCT01237899|Experimental|1 mg LY2623091|Daily by mouth for 7 days.
11516618|NCT01237899|Experimental|10 mg LY2623091|Daily by mouth for 7 days.
11516619|NCT01237899|Experimental|25 mg LY2623091|The anticipated dose of LY2623091 was revised down from the original proposed dose level of 100 mg based on safety and tolerability data. The 25 mg LY2623091 was administered daily by mouth for 7 days.
11516620|NCT01237899|Experimental|0.3 mg LY2623091|The anticipated dose of LY2623091 was revised down from the original proposed dose level of up to 200 mg. The 0.3 mg LY2623091 was determined based on an interim analysis after the third dose level and was administered daily by mouth for 7 days.
11516621|NCT01237899|Placebo Comparator|Placebo|Daily by mouth for 7 days.
11516622|NCT01237899|Active Comparator|50 mg Eplerenone|Daily by mouth for 7 days.
11516623|NCT01237873|Experimental|Ali/Amlo|Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg
11516624|NCT01237847|Other|Wait List|
11516625|NCT01237847|Experimental|2 phone sessions|
11516626|NCT01237847|Experimental|4 phone sessions|
11516627|NCT01237834||Heavy smokers, 15 or more cigarettes/day|Nicotine dependent.
11516628|NCT01237834||Light smokers (chippers)|Less than 2 cigarettes/day, at least 2 days/week. Non nicotine-dependent.
11516629|NCT01237834||Non smokers|
11516672|NCT01237496|Experimental|1|
11516944|NCT01235871|Placebo Comparator|Placebo|
11516630|NCT01237821|Active Comparator|BenzaClin|Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with > or equal to 15 inflammatory lesions, > or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments
11516631|NCT01237821|Active Comparator|effaclar|Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with > or equal to 15 inflammatory lesions, > or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments
11516632|NCT01237808|Active Comparator|Standard arm|6 cycles of chemotherapy (low-dose cytarabine and etoposide) without ATRA
11516633|NCT01237808|Experimental|Investigational arm|6 cycles of chemotherapy (low-dose cytarabine and etoposide) with ATRA (All-trans-Retinoic acid)
11516634|NCT01237795|Experimental|0.01% fluorosurfactant|An experimental formula for denture hygiene containing 0.01% fluorosurfactant.
11516635|NCT01237795|Experimental|1.0% chloramine T|An experimental formula for denture hygiene containing 1.0% chloramine T.
11516636|NCT01237795|Experimental|0.2% chloramine T|An experimental formula for denture hygiene containing 0.2% chloramine T.
11516637|NCT01237795|Active Comparator|Proprietary dentifrice.|A proprietary denture-specific dentifrice.
11516638|NCT01237782|Experimental|Propolis solution|A proprietary denture cleanser with propolis as the active agent.
11516639|NCT01237782|Placebo Comparator|Saline solultion|Physiologic saline solution.
11516640|NCT01237769|Active Comparator|Vitamin D|All patients will be instructed to exercise and lose weight according to the NCEP-ATP III diet. The participants will be randomized in an open manner into one of the following 2 treatment groups: a) cholecalciferol (VitD3) (2200 IU/day) plus lifestyle measures or b) only lifestyle measures. Recruitment will be completed within one year. The reassessment of the patients will be done 3 months after starting of treatment.
11516641|NCT01237769|Active Comparator|Lifestyle measures|
11516642|NCT01237756|Experimental|pediatric|
11516643|NCT01237730|Active Comparator|Cefuroxime group|Use the cefuroxime as prophylactic antiobiotics, according to the clinical guideline.
11516644|NCT01237730|Experimental|Tailored antibiotics group|Tailored antibiotic is selected according to the patient's oropharyngeal microorganisms.
11516645|NCT01237717||normotensive subjects|subjects without hypertension, and without diabetes, ischemic heart disease, major arrhythmia, heart failure, secondary hypertension, high grade renal disease,
11516646|NCT01237717||Hypertensive subjects|"subjects with hypertension,
~currently not treated at least within 6 months
~without diabetes, ischemic heart disease, major arrhythmia, heart failure, secondary hypertension, high grade renal disease,"
11516647|NCT01237704|Active Comparator|Traditional rehabilitation (TR)|
11516648|NCT01237704|Active Comparator|Transcutaneous electrical stimulation (ES)|
11516649|NCT01237691|Experimental|HOPE supervision|Parolee supervised under California's new HOPE parole model.
11516650|NCT01237691|Active Comparator|Parole-as-usual|Parolees supervised under California parole-as-usual.
11516651|NCT01237678|Experimental|IMGN901 with carboplatin and etoposide|Patients will receive IMGN901 along with carboplatin and etoposide for up to 6 cycles and then be able to continue on IMGN901 alone until no further benefit or toxicity.
11516652|NCT01237678|Active Comparator|Carboplatin and Etoposide|Patients will receive Carboplatin and etoposide for up to 6 cycles.
11516653|NCT01237665|Experimental|IXO regimen|single-group
11516654|NCT01237652||ISH and normotensive|This is a prospective cohort study to compare the incidence of perioperative myocardial ischemia between ISH and normotensive patients admitted for elective non-cardiac surgery. To reduce the number of confounding factors for perioperative myocardial ischemia, RCRI Class I or II patients will be recruited.
11516655|NCT01237652||ISH, Normotensive|This is a prospective cohort study to compare the incidence of perioperative myocardial ischemia between ISH and normotensive patients admitted for elective non-cardiac surgery. To reduce the number of confounding factors for perioperative myocardial ischemia, RCRI Class I or II patients will be recruited.
11516656|NCT01237639|Experimental|Restrictive Red blood cell Transfusion|Transfusion Trigger of 70g/L with an aim to maintain Hemoglobin between 80-90g/L
11516657|NCT01237639|Active Comparator|Liberal Red blood Cell Transfusion|Transfusion Trigger of 90g/L with an aim to maintain Hemoglobin between 100-110g/L
11516658|NCT01237613|Experimental|Artelon|This is an open, prospective study with an anticipated enrollment of 10 patients with chronic or repeat Achilles tendon rupture undergoing surgical repair augmented with Artelon® Tissue Reinforcement.
11516659|NCT01237600|Experimental|Cultivated limbal transplantation|
11516660|NCT01237587|Experimental|Duloxetine|"Blinded treatment period: 30mg or 60mg once daily for 13 weeks
~Open label extension: 30mg or 60mg Duloxetine once daily for 26 weeks
~Taper period: 30mg Duloxetine or placebo once daily for 1 week."
11516661|NCT01237587|Placebo Comparator|Placebo|"Blinded treatment period:Placebo once daily for 13 weeks
~Open label extension: 30mg or 60mg Duloxetine once daily for 26 weeks
~Taper period: 30mg Duloxetine or placebo once daily for 1 week."
11516662|NCT01237574||Patients|Patients with chronic alcoholic and/or metabolic liver disease
11516663|NCT01237561|Experimental|spirometry, patient activation tool|"Receive Portable Spirometer
~Spirometry training of staff
~Provide clinician with web-based COPD interactive guideline tool
~Provide clinician with patient activation tool
~Train clinicians (tools, integration into workflow)
~Academic Detailing"
11516664|NCT01237561|No Intervention|Usual Care|Spirometer and spirometry training of staff
11516665|NCT01237548||All participants|Normal People who have smoked Water-pipe, at least once before.
11516666|NCT01237535|Experimental|Luteal support with progesterone only|Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel)Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.
11516667|NCT01237535|Experimental|Luteal support with estrogen + progesterone|Luteal support with estrogen + progesterone [(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg].
11516673|NCT01237483|Other|Erbitux Radiotherapy|Radiotherapy during 5 weeks and concurrent Erbitux once a week.
11516674|NCT01237470|Experimental|Desarda group|Patients with primary inguinal hernia operated using the Desarda technique
11516675|NCT01237470|Experimental|Lichtenstein group|Patients with primary inguinal hernia operated using the Lichtenstein technique.
11516676|NCT01237457|Experimental|Treatment|
11516677|NCT01237444|Experimental|lopinavir/ritonavir plus lamivudine|"ARM 1:
~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"
11516678|NCT01237444|Active Comparator|lopinavir/ritonavir plus two nucleosides|"ARM 2:
~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype"
11516679|NCT01237431|Experimental|liver transplanted patients|Target group to confirm the hypothesis. Transplantation has to be between 6 an 24 Month before participation.
11516680|NCT01237431|Active Comparator|kidney transplanted patients|Control group, age, gender and medication matched. Transplantation has to be between 6 an 24 Month before participation.
11516681|NCT01237418||Myocardial Infarction|Any patient over 18 years admitted for myocardial infarction (MI) of less than 48 hours, characterized by the typical rise and fall of troponin or CPKMb
11516682|NCT01237405||Knee Osteoarthritis|"Unilateral or bilateral knee osteoarthritis on radiograph associated with knee pain on most days of any one-month in the last year in at least one knee.
~Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi)."
11516683|NCT01237392|Active Comparator|Contact Ultrasonic Debridement Device|
11516684|NCT01237392|Active Comparator|Standard Sharp Debridement|
11516685|NCT01237379||Health Controls|
11516686|NCT01237379||Bipolar Patients with High-Risk of Mania|
11516687|NCT01237379||Bipolar Patients with Ultra-High Risk|
11516688|NCT01237379||First Manic Episode Bipolar Youth|
11516689|NCT01237366|Experimental|Reslient Affective Processing Therapy (RAPT)|
11516690|NCT01237366|No Intervention|Attention-Control|Participants will complete 7 sessions where they will be asked to write about neutral topics and complete psychological measures for the purposes of matching for attention and reimbursement.
11516691|NCT01237353|Experimental|betaine hydrochloride and rabeprazole|
11516692|NCT01237340|Experimental|Saizen®|
11516693|NCT01237327|Active Comparator|1|
11516694|NCT01237327|Experimental|2|
11516695|NCT01237314||Glargine Group|After baseline titration of metformin, this group will take glargine along with metformin.
11516696|NCT01237314||Exenatide Group|After baseline titration of metformin, this group will take exenatide along with metformin.
11516697|NCT01237314||Glargine and Exenatide Group|After baseline titration of metformin, this group will take glargine and exenatide along with metformin.
11516698|NCT01237301|Experimental|CGM Group|Wear an unblinded CGM for 16 weeks. Subjects continued previously started medication regiments for their diabetes. Subjects in this arm were randomized to use real time continuous glucose monitoring (rt CGM).
11516699|NCT01237301|Active Comparator|SMBG Group|Use SMBG 4 to 7 times a day for 16 weeks. Subjects continued previously started medication regiments for their diabetes. Subjects in this arm were randomized to use structured self monitoring blood glucose (stSMBG) and periodic, blinded continuous glucose monitoring (CGM).
11516700|NCT01237288|Experimental|Z-521|
11516701|NCT01237275|Experimental|SSRI treated group|SSRI treated group are depressive patients treated with fluoxetine, paroxetine or sertraline
11516702|NCT01237262|Active Comparator|TNF alfa inhibitors|Male and female adult patients with a diagnosis of moderate to severe psoriasis (when PASI score is > 10 and BSA is > 10%). The overall study enrolment plan is 20 patients. Patients will be screened before the beginning of clinical trial by blood sample in order to exclude major contraindications to use of anti TNF α drugs.
11516703|NCT01237249|Active Comparator|MPV followed by Revlimid/Low Dose Dexamethasone (Rd)|Melphalan/Prednisone/Velcade (MPV) followed by Revlimid/Low Dose Dexamethasone (Rd)
11516704|NCT01237249|Experimental|Alternating MPV with Revlimid/Low Dose Dexamethasone|Alternating Velcade/Melphalan/Prednisone (MPV) with Revlimid/Low Dose Dexamethasone (Rd)
11516705|NCT01237236|Experimental|LEE011|
11516706|NCT01237223|Placebo Comparator|Placebo|In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In single blind run-in (4 weeks) and double blind treatment period (8 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily.
11516707|NCT01237223|Active Comparator|Aliskiren 150 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.
~Patients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."
11516708|NCT01237223|Active Comparator|Amlodipine 2.5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.
~Patients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."
11516709|NCT01237223|Active Comparator|Amlodipine 5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.
~Patients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."
11516710|NCT01237223|Experimental|Aliskiren/amlodipine 150/2.5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.
~Patients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period."
11516945|NCT01235858|Other|Gown group|Anesthesiologists wearing sterile gown for epidural insertion
11516711|NCT01237223|Experimental|Aliskiren/amlodipine 150/5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.
~Patients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."
11516712|NCT01237197|Experimental|Exenatide, then Open-Label Exenatide|Exenatide 5 micrograms (mcg): administered with injection twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study (5 months)
11516713|NCT01237197|Placebo Comparator|Placebo, then Open Label Exenatide|Placebo injection twice a day for three months; Exenatide open label 5mcg twice a day for one month and up-titrated to 10mcg twice a day for remaining two months of study.
11516714|NCT01237184||biocortical fixation|Bi-cortically fixed implants intentionally engaging sinus floor beyond up to 1-2mm without graft but using stopper drill and self-threading concept
11516715|NCT01237184||unicortical fixation|Short implants placed in proximity of the sinus without sinus floor involvement
11516716|NCT01237184||indirect sinus lift|implants engaging both crest and sinus floor but with green stick fracture
11516717|NCT01237171||Sub-lobar resection with Cesium-131|All enrolled patients will undergo sub-lobar resection and brachytherapy implant with Cesium-131 in an effort to study and quantify recurrence/control patterns.
11516718|NCT01237158||healthy controls|
11516719|NCT01237158||bipolar disorder type I|
11516720|NCT01237145||non-EAA, pigeon|subject with BAL because of diseases not suspected to be EAA
11516721|NCT01237145||EAA, pigeon|Bird fanciers with a typical clinical presentation suspected for pigeon induced EAA
11516722|NCT01237119|Experimental|Liraglutide|A once-daily glucagon-like peptide 1 (GLP-1) analogue. Currently has regulation approval for use in type 2 diabetics (ref: guidelines)
11516723|NCT01237119|Placebo Comparator|Placebo|Liraglutide-Placebo manufactured by Novo Nordisk.
11516724|NCT01237106|Experimental|In Vitro Maturation (IVM)|
11516725|NCT01237093|Experimental|1. Meat, no fish or soda|weight maintaining diet with meat but no fish or soda for 12 weeks
11516726|NCT01237093|Experimental|2. Meat and soda, no fish|weight maintaining diet with meat and soda but no fish for 12 weeks
11516727|NCT01237093|Experimental|4. Meat and fish and soda|weight maintaining diet with meat, fish, and soda for 12 weeks
11516728|NCT01237093|Experimental|5. Fish, no meat or soda|weight maintaining diet with meat, fish, and soda for 12 weeks
11516729|NCT01237093|Experimental|6. Fish and soda, no meat|weight maintaining diet with fish and soda but no meat for 12 weeks
11516730|NCT01237093|Experimental|7. No meat, fish, or soda|no fish, and no soda (vegetarian) for 12 weeks
11516731|NCT01237093|Experimental|8. Soda, no meart or fish|weight maintaining diet with soda but no meat or fish (vegetarian + soda) for 12 weeks
11516732|NCT01237093|Experimental|Meat and fish, no soda|weight maintaining diet with meat and fish but no soda for 12 weeks
11516733|NCT01237080|Experimental|Fastrach|50 persons beeing intubated using the Fastrach.
11516734|NCT01237080|Experimental|GlideScope|50 persons beeing intubated using the GlideScope.
11516735|NCT01237067|Experimental|Group 1|Dose esc: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis
11516736|NCT01237067|Experimental|Group 2A|Randomized: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
11516737|NCT01237067|Experimental|Group 2B|Randomized: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
11516738|NCT01237054|Experimental|Imaging in MGUS, SMM, and MM|Participants will have three imaging studies on separate days: a standard positron emission tomography/computed tomography scan (18-FDG PET/CT), a PET/CT scan with an experimental sodium fluoride-based drug (18-NaF PET/CT), and magnetic resonance imaging (DCE-MRI).
11516739|NCT01237041|Experimental|Niacin First|Subjects receive niacin 500mg hourly for 4 hours on day 1 (at 7:30am, 8:30am, 9:30am, and 10:30am) then cross over to receive placebo hourly for 4 hours on day 2 at (7:30am, 8:30am, 9:30am, and 10:30am).
11516740|NCT01237041|Experimental|Placebo First|Subjects receive placebo hourly for 4 hours on day 1 (at 7:30am, 8:30am, 9:30am, and 10:30am) then cross over to receive niacin hourly for 4 hours on day 2 (at 7:30am, 8:30am, 9:30am, and 10:30am).
11516741|NCT01237041|Experimental|Dose-Establishing Study 1 Niacin 250mg|Subjects received Niacin 250 mg every 2 hours for 3 doses (at 6am, 8am, and 10am).
11516742|NCT01237041|Experimental|Dose-Establishing Study 1 Niacin 500mg|Subjects received Niacin 500 mg every 2 hours for 3 doses (at 6am, 8am, and 10am).
11516743|NCT01237041|Experimental|Dose-Establishing Study 2 Niacin 500mg|Subjects received Niacin 500 mg hourly for 4 doses (administered at 7:30am, 8:30am, 9:30am, and 10:30am).
11516744|NCT01237028|Experimental|oral calcitriol|Calcio®
11516745|NCT01237028|No Intervention|placebo|
11516746|NCT01237002||Group 1|117 patients with cumulative clamping time between 60 and 120 minutes
11516747|NCT01237002||Group 2|72 patients with cumulative clamping time longer than 120 minutes
11516748|NCT01236989|Experimental|Anatomical resection|
11516749|NCT01236989|Active Comparator|Non-anatomical resection|
11516790|NCT01236703||ICU patients|ICU patients (post-operative and none operative patients) will be enrolled in the study. They are followed up until the end of ICU stay or, for a maximum of 60 days.
11516946|NCT01235858|Other|No Gown group|Anesthesiologists not wearing gown for epidural insertion
11516750|NCT01236976|Experimental|Intervention Group|"Participants in Group A will receive a triad of interventions comprising body weight supported treadmill training (BWSTT), functional electrical stimulation (FES)-assisted cycling, and trunk and upper and lower extremity exercise. These interventions will be provided at the spinal unit.
~It is neither feasible nor desirable that every participant receives identical intervention because of the expected differences in impairments and activity limitations that he/she experiences. Project staff will use their clinical judgment to select exercises suitable for each participant and to progress them as appropriate. All exercises selected will be documented in the participant source notes."
11516751|NCT01236976|Other|Control Group|"Participants in Group B will receive an upper body strength and fitness program. This program may be provided at the spinal unit, or an appropriately equipped gymnasium as approved by the SCIPA Full-On Project Committee. It will be based on the Burn Rubber Burn (BRB) exercise program already established in Sydney. BRB is a circuit-based exercise program incorporating resistance and cardiovascular training. For this protocol, the circuit will comprise several stations using different pieces of equipment.
~The participants will be supervised by a therapist and/or clinical exercise instructor and exercises will be progressed as appropriate to build strength and endurance. Guidelines for the content and delivery of exercises will be clearly outlined in a handbook to ensure standardisation across sites."
11516752|NCT01236963|Experimental|Essential oils mouthrinse|Subjects use the essential oils mouthrinse
11516753|NCT01236963|Active Comparator|Dental floss|Subjects use dental floss
11516754|NCT01236950|Experimental|Delmopinol mouthrinse|Subjects use the delmopinol mouthrinse
11516755|NCT01236950|No Intervention|Control|Subjects with no use of mouthrinse
11516756|NCT01236950|Experimental|Essential oils mouthrinse|Subjects using the essential oils mouthrinse
11516757|NCT01236937|Active Comparator|Bellows-based breath hold biopsy|CT guided biopsy is preformed with the use a bellows-based breath
11516758|NCT01236937|No Intervention|No Bellows-based breath hold.|CT guided biopsy is preformed without the use a bellows-based breath
11516759|NCT01236924|Experimental|Lifestyle counseling|
11516760|NCT01236911||Calcium after moderate-severe TBI|Patients with moderate -severe TBI with less as 24 hrs , admitted in emergency. We will measure seric calcium to compare the differences between both groups
11516761|NCT01236898|Experimental|NPC-09|Period 1: NPC-09 800mg single oral dosing NPC-09 800mg three times oral dosing a day Period 2: NPC-09 800mg three times oral dosing a day for 5 consecutive days
11516762|NCT01236885|Experimental|Supportive care (Glucommander)|Patients receive blood glucose management with IV insulin using Glucommander.
11516763|NCT01236872|Experimental|Beetroot juice|250ml beetroot juice ingestion
11516764|NCT01236872|Placebo Comparator|Water|250ml low-nitrate water placebo
11516765|NCT01236859|Placebo Comparator|placebo|The patients in the placebo group received equal numbers of identical looking placebo 2 h before operation
11516766|NCT01236859|Active Comparator|gabapentin|Patients in the gabapentin group received two capsules of gabapentin 300 mg (Neurontin®, Pfizer) at 2 h before operation.
11516767|NCT01236846|Placebo Comparator|Plain Yogurt Drink|Daily intake of unfortified yogurt drink(500 ml) for 12 weeks
11516768|NCT01236846|Experimental|VDR Genotype (aa)|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
11516769|NCT01236846|Experimental|VDR Genotype (AA)|Daily intake of yogurt drink fortified (500 ml) with 1000 IU vitamin D for 12 weeks
11516770|NCT01236846|Experimental|VDR genotype (Aa)|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
11516771|NCT01236833|No Intervention|Fasting|
11516772|NCT01236833|Active Comparator|Lactated Ringer's Solution|
11516773|NCT01236820||Normal|Healthy population
11516774|NCT01236820||CKD Patients|Chronic Kidney Disease, in Stage III-V
11516775|NCT01236820||HD patients|End-stage renal disease patients undergoing hemodialysis
11516776|NCT01236807|Active Comparator|MR Inform|Management guided by the result of the MR perfusion scan. Possible intervention: coronary artery revascularization.
11516777|NCT01236807|Active Comparator|FFR Inform|Management guided by the result of FFR measurement. Possible intervention: coronary artery revascularization.
11516778|NCT01236794|Experimental|Lifestyle and Exercise Intervention|
11516779|NCT01236781|Experimental|Group A: Screening|Group A comprises 500 asymptomatic women with no history of breast cancer who are scheduled for routine screening of the breasts with FFDM.
11516780|NCT01236781|Experimental|Group B: Diagnostic Enriched Population|Approximately 50 asymptomatic women with no history of breast cancer who have been informed of positive (abnormal) findings from a recent (within 30 days) FFDM screening will be recruited to Group B prior to their diagnostic imaging (e.g., diagnostic FFDM and/or ultrasound and/or other).
11516781|NCT01236768|Experimental|AG200-15|Thin transdermal contraceptive delivery system (TCDS) that gives systemic exposure of levonorgestrel (LNG) and ethinyl estradiol (EE)
11516782|NCT01236768|Active Comparator|Levora|oral contraceptive containing 150mcg of LNG and 30mcg of EE
11516783|NCT01236755|Experimental|ortho-k lenses|Children were switched to wear ortho-k lenses for 7 months after wearing single-vision glasses for 7 months
11516784|NCT01236742|Experimental|single-vision glasses and ortho-k lenses|Children who are currently wearing ortho-k lenses at night for correction of refractive errors will be switched to wear single-vision glasses for the first 7 months and then switched back to ortho-k lenses for the next 7 months
11516785|NCT01236742|Active Comparator|ortho-k lenses|Children who are currently wearing ortho-k lenses at night for the correction of refractive errors will continue with the current treatment and serve as the first control group
11516786|NCT01236742|Other|single-vision glasses|Children who are currently wearing single-vision spectacles in the daytime for correcting their refractive errors will continue with the current treatment and serve as the second control group
11516787|NCT01236729||Knee replacement recipients|Patients (aged 75 years or over) with late-stage arthritis who have undergone or are undergoing primary knee replacement
11516788|NCT01236716|Experimental|Albumin paclitaxel plus carboplatin|Treatment of Albumin paclitaxel plus carboplatin
11516789|NCT01236716|Active Comparator|Gemcitabine plus carboplatin|Treatment of Gemcitabine plus carboplatin
11516852|NCT01236508|Experimental|Nuclear imaging|PET/CT imaging with F-18 fluorodeoxyglucose
11516853|NCT01236482|Active Comparator|Oxytocin|
11516791|NCT01236677||Community acquired pneumonia,age≥14 ys|Patients with community acquired pneumonia,age≥14 ys and less than one week after the onset of symptoms, without pregnancy,breast-feeding,HIV infection,recent 90-day hospitalized history and in nursing homes or rehabilitation hospitals
11516792|NCT01236664|Experimental|Memory Training|
11516793|NCT01236664|Active Comparator|Control workshop|
11516794|NCT01236651|Experimental|meperidine and duration of 1st stage of labor|meperidine 100mg i.v in 1st stage of labor and calculate the duration of the 1st stage of labor
11516795|NCT01236651|Experimental|drotaverine and duration of 1st stage of labor|drotaverine 40mg i.v in 1st stage of labor and calculate the duration of the 1st stage of labor
11516796|NCT01236638|Experimental|Momelotinib|
11516797|NCT01236599|No Intervention|traditional care|Preterm Infants were placed under a radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel), dried off and wrapped up in a sterile preheated field
11516798|NCT01236599|Experimental|Polyethylene bag with previous drying|infants were placed under the radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel), dried off, and wrapped up in a polyethylene bag, leaving their faces discovered as well as the access at umbilical catheters or veined access.
11516799|NCT01236599|Experimental|Polyethylene bag without previous drying|Preterm infants were placed under a radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel) and without previous body drying (only the head was dried), were wrapped up with the polyethylene bag, leaving their faces discovered as well as the access to umbilical catheters or veined access
11516800|NCT01236534|Active Comparator|Lubiprostone|
11516801|NCT01236534|Placebo Comparator|Sugar pill|
11516802|NCT01236495|Experimental|spinal morphine 0.2 mg|spinal morphine 0.2 mg
11516803|NCT01236495|Active Comparator|spinal morphine 0.3 mg|spinal morphine 0.3 mg
11516804|NCT01236443|Experimental|HPPH|3 mg/m2
11516805|NCT01236404|Experimental|PB1023 Injection|Subcutaneous injection PB1023
11516806|NCT01236404|Placebo Comparator|Placebo (0.9% Sodium Chloride Injection)|Subcutaneous Injection Placebo
11516807|NCT01236391|Experimental|Participants received PCI-32765 560 mg daily|Participants were enrolled and received 560 mg/day dose, stratified into 2 groups based on prior bortezomib exposure.
11516808|NCT01236365|Experimental|Atorvastatin|
11516809|NCT01236365|Placebo Comparator|Placebo|
11516810|NCT01236339|Experimental|TIPS|TIPS with GORE® VIATORR® TIPS Endoprosthesis
11516811|NCT01236339|Active Comparator|LVP|"Large Volume Paracentesis
~*A subject may be crossed-over from large volume paracentesis to TIPS with GORE® VIATORR® TIPS Endoprosthesis if the subject has completed their six month study visit and has met the criteria for cross-over (LVP failure)."
11516812|NCT01236144|Experimental|AC220 Intervention|
11516813|NCT01236144|Experimental|Plerixafor Intervention|
11516814|NCT01236144|Experimental|Ganetespib|
11516815|NCT01235936|Experimental|AKB-6548|
11516816|NCT01235923|Active Comparator|three times weekly Epo|Epo 400 units/kg three times weekly given subcutaneously for 4 weeks
11516817|NCT01235923|Active Comparator|weekly Epo|1,200 units/kg given once a week subcutaneously for 4 weeks
11516818|NCT01235832|Active Comparator|Lower-Fat Diet|The Lower-Fat diet will provide ~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.
11516819|NCT01235832|Active Comparator|Moderate Fat Diet|This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
11516820|NCT01235832|Experimental|Avocado Diet|The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
11516821|NCT01235819|Active Comparator|Insulin alone|Type 1 DM only on Insulin
11516822|NCT01235819|Active Comparator|Insulin and Exenatide|Newly detected Type 1 DM on Insulin and exenatide
11516823|NCT01235819|Active Comparator|Insulin and Sitagliptin|Newly detected Type 1 DM using Insulin and Sitagliptin
11516824|NCT01235793|Experimental|DRBEAT Regimen|
11516825|NCT01236625||No adhesiolysis|All patient undergoing elective laparotomy or laparoscopy with no need for adhesiolysis during the procedure.
11516826|NCT01236625||Adhesiolysis|All patient undergoing elective laparotomy or laparoscopy requiring adhesiolysis during the procedure.
11516827|NCT01236612|Experimental|Immunization + bloodstage challenge|
11516828|NCT01236612|Active Comparator|Immunization + mosquito challenge|
11516829|NCT01236612|Placebo Comparator|Control - Bloodstage challenge|
11516830|NCT01236612|Placebo Comparator|Control - Mosquito challenge|
11516831|NCT01236573|Experimental|Group 1 - CD8 + TIL expressing IL-12 1x10^6|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of interleukin-12 (IL-12) gene-transduced tumor infiltrating lymphocytes (TIL).
11516832|NCT01236573|Experimental|Group 2 - CD8 + TIL expressing IL-12 3x10^6|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
11516833|NCT01236573|Experimental|Group 3 - CD8 + TIL expressing IL-12 1x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
11516834|NCT01236573|Experimental|Group 4- CD8+TIL expressing IL-12 3x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
11516854|NCT01236482|Experimental|Oxytocin - ergometrine|
11516947|NCT01235845|Experimental|DC-DCIK|
11516835|NCT01236573|Experimental|Group 5 - Bulk TIL expressing IL-12 1x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
11516836|NCT01236573|Experimental|Group 6 - Bulk TIL expressing IL-12 3x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
11516837|NCT01236573|Experimental|Group 7- Bulk TIL expressing IL-12 1x10^8|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
11516838|NCT01236573|Experimental|Group 8 - Bulk TIL expressing IL-12 3x10^8|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
11516839|NCT01236573|Experimental|Group 9 - Bulk TIL expressing IL-12 1x10^9|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
11516840|NCT01236573|Experimental|Group 10- Bulk TIL expressing IL12 3x10^9|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
11516841|NCT01236573|Experimental|Group 11 - Bulk TIL expressing MTD 1x10^9 (Phase 2)|Maximum tolerated dose (MTD). Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
11516842|NCT01236560|Experimental|Arm I (vorinostat, Phase II Arm A)|Patients undergo RT 5 days a week for 6 weeks and receive vorinostat at the maximum-tolerated dose determined in the feasibility study. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
11516843|NCT01236560|Experimental|Arm II (temozolomide, Phase II Arm B)|Patients undergo RT as in the feasibility arm and receive temozolomide PO once daily for 42 days by day 5 of RT. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
11516844|NCT01236560|Experimental|Arm III (Bevacizumab, Phase II Arm)|Patients undergo RT as in the feasibility arm and receive bevacizumab IV over 30-90 minutes on days 22 and 36. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
11516845|NCT01236560|Experimental|Arm IV (temozolomide, Phase 3 Arm B)|Patients undergo RT as in the Arm II and receive temozolomide PO once daily for 42 days beginning on day 5 of RT. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
11516846|NCT01236560|Experimental|Arm V (vorinostat/bevacizumab, Phase 3, Chemoradiotherapy)|Patients receive treatment as in phase II, arm I or phase II, arm III, whichever was established as superior in phase II. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
11516847|NCT01236560|Experimental|Feasibility (vorinostat)|Patients undergo RT 5 days a week for 6 weeks and receive vorinostat at 230 mg/m2/day. In the event of 2 or more DLTs, participants will de-escalate to vorinostat at 180 mg/m2/day. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
11516848|NCT01236547|Experimental|Arm I (paclitaxel, pazopanib hydrochloride, IMRT)|Patients receive paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD for 2-3 weeks. Patients then receive concurrent paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD for 6-7 weeks (or until radiation treatment is completed) and IMRT 5 days per week for 6.5 weeks (total of 66 Gy in 33 fractions). Beginning 25-31 days after the completion of IMRT, patients receive paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD. Treatment repeats every 3 weeks for 4 cycles (for patients with no measurable disease) or continues in the absence of disease progression or unacceptable toxicity (for patients with measurable disease).
11516849|NCT01236547|Active Comparator|Arm II (paclitaxel, placebo, IMRT)|Patients receive paclitaxel IV over 1 hour once weekly and placebo PO QD for 2-3 weeks. Patients then receive concurrent paclitaxel IV over 1 hour once weekly and placebo PO QD for 6-7 weeks (or until radiation treatment is completed) and IMRT 5 days per week for 6.5 weeks (total of 66 Gy in 33 fractions). Beginning 25-31 days after the completion of IMRT, patients receive paclitaxel IV over 1 hour once weekly and placebo PO QD. Treatment repeats every 3 weeks for 4 cycles (for patients with no measurable disease) or continues in the absence of disease progression or unacceptable toxicity (for patients with measurable disease).
11516850|NCT01236521|Experimental|Arm 1: Pharmacological (PHARM)|Subjects in the Pharmacological (PHARM) arm will receive at least 8 contacts with the nurse care managers (NCM) over the trial period. Participants will have an initial visit at baseline to assess their current and past treatments for chronic lower back pain, pain intensity, and pain-related limitations. Patients' opioids will be adjusted and/or co-analgesics (or adjuvants) will be initiated. During follow-up calls, patients' pain severity, response to treatment, adherence, adverse effects, and desire to change current treatment will be assessed. Follow-up NCM telephone contacts will occur at 2 and 4 weeks after baseline, and months 2, 3, 4, 6, and 9 months. On average, these calls last between 10 to 20 minutes. Detailed logs will be kept of the timing and content of patient contacts.
11516851|NCT01236521|Experimental|Arm 2: Behavioral treatment (BEH)|Veterans randomized to behavioral treatment arm (BEH) will receive a series of 8 pain self-management/coping skills training sessions delivered by one of three primary-care based clinical psychologists. Since optimal application of non-pharmacological interventions for pain involves tailoring to patient needs, participants will be introduced to a menu of self-management and coping skills rather than receive a prescribed program. Delivery of the behavioral intervention will employ a flexible approach that is easily adapted to individual preferences and perceived need for learning specific pain coping skills. Tailoring will include the selection of relevant content and skills and assessment of readiness to change behaviors.
11516855|NCT01236469||Retrospective Patients|Pediatric (21 years of age or younger) patients who received a CryoValve SG Aortic Valve distributed during the 2000 to 2003 period as an aortic valve replacement.
11516856|NCT01236430|Active Comparator|Ezetimibe 10mg and Atorvastatin 10mg|Ezetimibe 10mg tablet and Atorvastatin 10mg tablet coadministered
11516857|NCT01236430|Experimental|10mg Ezetimibe/10mg Atorvastatin|10mg Ezetimibe/10mg atorvastatin combination tablet
11516858|NCT01236430|Active Comparator|Ezetimibe 10mg and Atorvastatin 80mg|Ezetimibe 10mg tablet and Atorvastatin 80mg tablet coadministered
11516859|NCT01236430|Experimental|10mg Ezetimibe/80mg Atorvastatin|Ezetimibe/atorvastatin 10mg/80mg combination tablet
11516860|NCT01236417|Experimental|Exercise|Subjects will be participating in a home-based flexibility and exercise program
11516861|NCT01236378|Experimental|sirolimus|Subjects must be taking sirolimus (1 mg tablet formulation) with or without concomitant medications, unless specifically excluded below, for prophylaxis of renal rejection.
11516862|NCT01236352|Experimental|Phase 1 (Cohort 1): BMS-911543 (5 mg)|BMS-911543 5 mg capsule by mouth twice daily for 12 months or greater depending on response
11516863|NCT01236352|Experimental|Phase 1 (Cohort 2): BMS-911543 (10 mg)|BMS-911543 10 mg capsule by mouth twice daily for 12 months or greater depending on response
11516864|NCT01236352|Experimental|Phase 1 (Cohort 3): BMS-911543 (20 mg)|BMS-911543 20 mg capsule by mouth twice daily for 12 months or greater depending on response
11516865|NCT01236352|Experimental|Phase 1 (Cohort 4): BMS-911543 (40 mg)|BMS-911543 40 mg capsule by mouth twice daily for 12 months or greater depending on response
11516866|NCT01236352|Experimental|Phase 1 (Cohort 5): BMS-911543 (80 mg)|BMS-911543 80 mg capsule by mouth twice daily for 12 months or greater depending on response
11516867|NCT01236352|Experimental|Phase 1 (Cohort 6): BMS-911543 (120 mg)|BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response
11516868|NCT01236352|Experimental|Phase 1 (Cohort 7): BMS-911543 (160 mg)|BMS-911543 160 mg capsule by mouth twice daily for 12 months or greater depending on response
11516869|NCT01236352|Experimental|Phase 1 (Cohort 8): BMS-911543 (200 mg)|BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response
11516870|NCT01236352|Experimental|Phase 1 (Cohort 9): BMS-911543 (240 mg)|BMS-911543 240 mg capsule by mouth twice daily for 12 months or greater depending on response
11516871|NCT01236352|Experimental|Phase 1 (Cohort 10): BMS-911543 (320 mg)|BMS-911543 320 mg capsule by mouth twice daily for 12 months or greater depending on response
11516872|NCT01236352|Experimental|Phase 2 (Cohort 11): BMS-911543 (120 mg)|BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response
11516873|NCT01236352|Experimental|Phase 2 (Cohort 12): BMS-911543 (200 mg)|BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response
11516874|NCT01236326|Active Comparator|LESS-DN|
11516875|NCT01236326|Active Comparator|Conventional LDN|
11516876|NCT01236313||TEE report|Cardiac surgery patients requiring TEE
11516877|NCT01236300|Experimental|Cellvizio system|
11516878|NCT01236274||Antipsychotic agents AND MI|In the self-controlled case series study, patients who experienced a myocardial infarction and received an antipsychotic agent during up to standard (UTS) follow-up in the GPRD will be included and will act as their own control.
11516879|NCT01236274||Myocardial Infarction|In the case-control study, all cases with a first recorded occurrence of MI during up to standard (UTS) follow-up in the GPRD will be identified
11516880|NCT01236274||No Myocardial Infarction|In the case-control study, a control group with subjects who never experienced a myocardial infarction will be matched to cases (5:1) by age, gender, General Practitioner and registration in the GPRD on the date of MI of the case
11516881|NCT01236261||Fungemia|Patients with a fungal isolate from a blood culture
11516882|NCT01236248|Experimental|Prevention Program|Girls and their mothers who are assigned to participate in a tobacco, alcohol, and other drug use prevention program aimed at young girls.
11516883|NCT01236248|No Intervention|No Prevention Program|Girls and their mothers who are assigned to participate in questionnaires only.
11516884|NCT01236235||ARV-naïve HIV patients initiated on ATV/RTV-based therapy|"Anti-retroviral (ARV)-naïve HIV patients initiated on ATV/RTV-based therapy between 2008-2010
~One cohort being observed for 3 different countries"
11516885|NCT01236222|No Intervention|Control group|
11516886|NCT01236222|Experimental|Cycling to school|
11516887|NCT01236209|Active Comparator|web page|"Control group:
~Information web page with some mindfulness exercises"
11516888|NCT01236209|Experimental|Webpage and situational feedback|"Intervention group:
~have access to the same web-page with information about coping with pain and relaxation and are completing 3 diaries and receiving personalized feedback for 4 weeks at home through a smartphone."
11516889|NCT01236196|Experimental|Arm 1 - Telephone CBT|telephone cognitive behavior therapy for pain management
11516890|NCT01236196|Active Comparator|Arm 2 - telephone education|telephone pain education
11516891|NCT01236170||Group 1|Veterans with spinal cord injury or amputated limbs who use a wheelchair as their primary source of mobility
11516892|NCT01236157||Chest Pain|All patients that call to the SAMU-ACS because of chest pain are included
11516893|NCT01236131||Endometrial biospy samples|The Endometrial Biopsy samples will be provided by women enrolled in the University of Pittsburgh IRB PRO10010112 and PRO10010159
11516894|NCT01236118|Experimental|30 milligrams (mg) LY2439821|Participants will start receiving LY2439821 30 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).
11516895|NCT01236118|Experimental|80 mg LY2439821|Participants will start receiving LY2439821 80 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).
11516896|NCT01236118|Experimental|160 mg LY2439821|Participants will start receiving LY2439821 160 mg once every 2 weeks for the first 3 doses and then once every 4 weeks until Week 44.
11516941|NCT01235884|Active Comparator|Lactobacillus reuteri|Dietary Supplement
11516942|NCT01235884|Placebo Comparator|Placebo|Dietary Supplement
11516897|NCT01236105|Experimental|6 mg LY2624803 Alone Morning Dosing|Participants received 6 milligrams (mg) LY2624803 alone orally (po) at approximately 0800 hours following an overnight fast.
11516898|NCT01236105|Experimental|6 mg LY2624803 Morning Dosing + Activated Charcoal|Participants received 6 mg LY2624803 po at approximately 0800 hours following an overnight fast, followed 1 hour later by a single po dose of 1 gram per kilogram (g/kg) body weight of activated charcoal, mixed with caffeine-free diet cola.
11516899|NCT01236105|Experimental|6 mg LY2624803 Alone Evening Dosing|Participants received 6 mg LY2624803 alone po at approximately 2200 hours following a 4-hour fast.
11516900|NCT01236079|Experimental|Assisted Referral & IVR|
11516901|NCT01236079|No Intervention|Usual Care|
11516902|NCT01236066||Study Group|Australian children aged < 5 years who have been vaccinated with RotaTeq or Rotarix from 2007 to 2009 as well as all children aged < 5 years hospitalised for all-cause gastroenteritis, rotavirus gastroenteritis or bronchiolitis.
11516903|NCT01236053||UK GPRD 1993-2008|The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993. Subjects are excluded from the GPRD cohort if they have a cancer diagnosis or a history of cancer prior to the cohort entry date.
11516904|NCT01236040|Experimental|Group A|Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval.
11516905|NCT01236040|Experimental|Group B|Subjects will receive 2 doses of a formulation of GSK2592984A vaccine at a 21-day interval.
11516906|NCT01236040|Placebo Comparator|Group C|Subjects will receive 2 doses of a placebo at a 21-day interval.
11516907|NCT01236040|Experimental|Group D|Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval.
11516908|NCT01236040|Experimental|Group E|Subjects will receive 2 doses of a formulation of GSK2340274A vaccine at a 21-day interval.
11516909|NCT01236040|Experimental|Group F|Subjects will receive 2 doses of a formulation of GSK2340273A vaccine at a 21-day interval.
11516910|NCT01236027||HIV-negative women|HIV-negative women who agree to have specimens collected for validation of laboratory procedures
11516911|NCT01236014||Eltrombopag & standard of care|
11516912|NCT01236014||Romiplostim & standard of care|
11516913|NCT01236014||Standard of care|
11516914|NCT01236001||Vimpat® treatment|Patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® on/after enrollment.
11516915|NCT01235988||Eltrombopag & standard of care|
11516916|NCT01235988||Standard of care|
11516917|NCT01235975|Experimental|Group A|
11516918|NCT01235975|Active Comparator|Group B|
11516919|NCT01235962|Experimental|pazopanib|Pazopanib oral agent, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.
11516920|NCT01235962|Placebo Comparator|placebo|placebo matching pazopanib 200 mg tablets, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.
11516921|NCT01235949|Experimental|Group IIBU|Immediate ibuprofen group: subjects receiving immediate ibuprofen treatment after each primary vaccine dose
11516922|NCT01235949|Active Comparator|Group DIBU|Delayed ibuprofen group: subjects receiving delayed ibuprofen treatment after each primary vaccine dose
11516923|NCT01235949|Active Comparator|Group NIBU|No ibuprofen group: subjects receiving no prophylactic ibuprofen treatment after each primary vaccine dose
11516924|NCT01235949|Experimental|Group IPARA|Immediate paracetamol group: subjects receiving immediate paracetamol treatment after each primary vaccine dose
11516925|NCT01235949|Experimental|Group DPARA|Delayed paracetamol group: subjects receiving delayed paracetamol treatment after each primary vaccine dose
11516926|NCT01235949|Active Comparator|Group NPARA|No paracetamol group: subjects receiving no prophylactic paracetamol treatment after each primary vaccine dose
11516927|NCT01235949|Experimental|Group IIBU-IIBU|1/3 of the subjects from the primary IIBU group receiving immediate ibuprofen treatment after booster vaccination
11516928|NCT01235949|Experimental|Group IIBU-DIBU|1/3 of the subjects from the primary IIBU group receiving delayed ibuprofen treatment after booster vaccination
11516929|NCT01235949|Experimental|Group IIBU-NIBU|1/3 of the subjects from the primary IIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
11516930|NCT01235949|Experimental|Group DIBU-IIBU|1/3 of the subjects from the primary DIBU group receiving immediate ibuprofen treatment after booster vaccination
11516931|NCT01235949|Experimental|Group DIBU-DIBU|1/3 of the subjects from the primary DIBU group receiving delayed ibuprofen treatment after booster vaccination
11516932|NCT01235949|Experimental|Group DIBU-NIBU|1/3 of the subjects from the primary DIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
11516933|NCT01235949|Experimental|Group NIBU-IIBU|1/3 of the subjects from the primary NIBU group receiving immediate ibuprofen treatment after booster vaccination
11516934|NCT01235949|Experimental|Group NIBU-DIBU|1/3 of the subjects from the primary NIBU group receiving delayed ibuprofen treatment after booster vaccination
11516935|NCT01235949|Active Comparator|Group NIBU-NIBU|1/3 of the subjects from the primary NIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
11516936|NCT01235949|Experimental|Group IPARA-NPARA|subjects from the primary IPARA group receiving no paracetamol treatment after booster vaccination
11516937|NCT01235949|Experimental|Group DPARA-IPARA|subjects from the primary DPARA group receiving immediate paracetamol treatment after booster vaccination
11516938|NCT01235949|Experimental|Group NPARA-IPARA|subjects from the primary NPARA group receiving immediate paracetamol treatment after booster vaccination
11516939|NCT01235910|Other|1|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
11516940|NCT01235897|Experimental|Maximum tolerated dose|
11516948|NCT01235806|Other|MRI|MRI of the scaphoid bone fracture suspicion
11516949|NCT01235767|Experimental|ASF supplement pre-pregnancy to term|Supplement of animal-source foods rich in iron, zinc, vitamin A, and vitamin B12
11516950|NCT01235767|Experimental|ASF Supplement mid-gestation to term|Supplement of animal-source foods rich in iron, zinc, vitamin A, and vitamin B12
11516951|NCT01235767|No Intervention|Routine prenatal care|Nutrition education and iron-folate supplements during pregnancy
11516952|NCT01235754|Placebo Comparator|placebo gel|placebo transdermal gel
11516953|NCT01235754|Experimental|testosterone gel|transdermal testosterone gel
11516954|NCT01235741|Experimental|Group A|Pramlintide+Metreleptin
11516955|NCT01235741|Placebo Comparator|Group B|Placebo
11516956|NCT01235728|Experimental|Treatment Sequence 1|Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D.
11516957|NCT01235728|Experimental|Treatment Sequence 2|Participants were randomized to received MK-0873 on lower lesion A and vehicle on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D.
11516958|NCT01235728|Experimental|Treatment Sequence 3|Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D.
11516959|NCT01235728|Experimental|Treatment Sequence 4|Participants were randomized to receive MK-0873 on lower lesion A and vehicle on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D.
11516960|NCT01235728|Experimental|Treatment Sequence 5|Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D.
11516961|NCT01235728|Experimental|Treatment Sequence 6|Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D.
11516962|NCT01235728|Experimental|Treatment Sequence 7|Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D.
11516963|NCT01235728|Experimental|Treatment Sequence 8|Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D.
11516964|NCT01235715|Active Comparator|Evicel|Evicel is a fibrin sealant used for hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical. It has been shown to stop bleeding in 2 minutes or less. Evicel is a combination of a biologic activated component containing human fibrinogen and topical thrombin that functions on wet, actively bleeding tissue. It is a bioresorbable and biocompatible agent.
11516965|NCT01235715|No Intervention|no evicel|Patients will receive standard treatment for bleeding as practiced at the Hospital for Special Surgery.
11516966|NCT01235689|Experimental|Tight Control Management|"Participants randomized to receive management of disease activity using criteria based on Crohn's Disease Activity Index (CDAI), high sensitivity C-reactive protein (hs-CRP), fecal calprotectin, and corticosteroid use.
~Participants received customized therapy that could include prednisone, adalimumab, and azathioprine. Participants who randomized at Week 9 meeting success criteria started with no therapy; participants who randomized prior to Week 9 or who randomized at Week 9 but did not meet the success criteria began treatment with adalimumab.
~Therapy was escalated according to pre-specified tight control criteria: At Key Visit 1 the success criteria were CDAI < 150, hs-CRP, < 5 mg/L, fecal calprotectin < 250 μg/g, and absence of prednisone use. At Key Visits 3, 4, and 5 (every 12 weeks after Key visit 1), the criteria were CDAI < 150, hs-CRP < 5 mg/L, fecal calprotectin < 250 μg/g, and absence of prednisone during the preceding week."
11516967|NCT01235689|Active Comparator|Clinically Driven Management|"Participants randomized to receive management of disease activity using criteria based on Crohn's Disease Activity Index (CDAI) and corticosteroid use.
~Participants received customized therapy that could include prednisone, adalimumab, and azathioprine.
~Participants who randomized at Week 9 meeting success criteria started with no therapy; participants who randomized prior to Week 9 or who randomized at Week 9 but did not meet the success criteria began treatment with adalimumab.
~Therapy was escalated according to pre-specified failure criteria using less stringent criteria:
~At Key Visit 1 the criteria for management of disease activity were a CDAI decrease ≥ 70 (CR-70) compared to Baseline or CDAI < 200 at 1 week prior to the visit. At Key Visits 3, 4, and 5 (every 12 weeks after Key visit 1), the criteria for a change in treatment were a CDAI decrease of ≥ 100 (CR-100) compared to Baseline or CDAI < 200, and absence of prednisone during the preceding week."
11516968|NCT01235676|Experimental|Diet|Calorie restriction to reduce weight gain
11516969|NCT01235676|Experimental|Exercise|Exercise to reduce weight gain
11516970|NCT01235663|Experimental|advisory support|advisory support for six months to prolong the breast-feeding period
11516971|NCT01235650||Spinal fusion|Patients who underwent complex surgical procedures (spinal fusions) which necessitated arterial line placement and intermittent arterial blood gas analysis
11516972|NCT01235637|Active Comparator|Alfentanil|
11516973|NCT01235637|Sham Comparator|Sufentanil|
11516974|NCT01235624|Other|patient|Patient suffering of adRP that accept to participate at this study have a blood prelevement for genetic analysis (intervention)
11516975|NCT01235598|Other|Placebo followed by Certolizumab Pegol (CZP)|Placebo, saline solution for sc injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
11516976|NCT01235598|Experimental|Certolizumab Pegol (CZP)|Certolizumab Pegol (CZP) 400 mg for subcutaneous injection at Weeks 0, 2 and 4 followed by 200 mg 2-weekly from Week 6 to Week 40
11516977|NCT01235585|Experimental|Bitopertin oral dose level 1|
11516978|NCT01235585|Experimental|Bitopertin oral dose level 2|
11516979|NCT01235585|Placebo Comparator|Placebo|
11516980|NCT01235572|Experimental|Health services research (early discharge, outpatient care)|Patients are discharged within 72 hours after completion of chemotherapy and undergo standard outpatient care by a RN, PA, or resident/fellow at a local facility or the study center approximately 3 times per week, as clinically indicated for up to 45 days.
11516981|NCT01235559|Placebo Comparator|Placebo|
11516982|NCT01235559|Experimental|bitopertin [RO4917838] 1|
11516983|NCT01235559|Experimental|bitopertin [RO4917838] 2|
11517326|NCT01233232|Experimental|2|Treatment arm AZD5069 50mg
11516984|NCT01235546|Placebo Comparator|Placebo and standard of care|250 cc normal saline
11516985|NCT01235546|Experimental|Azithromycin and Standard of care|500 mg Azithromycin in 250 cc normal saline
11516986|NCT01235533|Experimental|N-3 fatty acids|Participants in this arm were received three capsules of n-3 fatty acids. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g。
11516987|NCT01235533|Placebo Comparator|Placebo|Participants in this arm were received three identical capsules per day. All capsules included olive oil.
11516988|NCT01235520|Experimental|1|
11516989|NCT01235520|Experimental|2|
11516990|NCT01235520|Placebo Comparator|3|
11516991|NCT01235507|Experimental|Single Arm|
11516992|NCT01235494|Experimental|polarised 3 helium|inhaled gas
11516993|NCT01235481|Experimental|Exercise DVD|Exercise DVD to be used by participants 30-60 minutes, once daily to facilitate maintenance exercise training
11516994|NCT01235481|Other|Usual Care|Participants advised to perform maintenance exercise training 30-60 minutes, once daily without benefit of exercise DVD
11516995|NCT01235468|Experimental|CB expnasion|ex-vivo expansion of cord blood for transplantation
11516996|NCT01235455||Group 1|
11516997|NCT01235442|Experimental|etanercept and clobetasol|Etanercept 50 mg twice weekly x 12 weeks + clobetasol propionate foam (weeks 11 and 12) then Etanercept 50 mg once weekly x 12 weeks + clobetasol propionate foam (weeks 23 and 24)
11516998|NCT01235442|Experimental|etanercept|Etanercept 50 mg twice weekly x 12 weeks then Etanercept 50 mg once weekly x 12 weeks
11516999|NCT01235429|Experimental|Educational|Participants will receive 12 diabetes self-management educational lessons in a small group setting located within the participating communities and delivered by trained community health workers.
11517000|NCT01235429|Active Comparator|Delayed education|The delayed education group will receive the same intervention after the intervention group has completed the educational lessons and all participants have completed the follow-up assessments.
11517001|NCT01235416|Active Comparator|AMG 706 50mg|50 mg, once daily. (Cohort 1)
11517002|NCT01235416|Active Comparator|AMG 706 75mg|75 mg, twice daily. (Cohort 2)
11517003|NCT01235416|Active Comparator|AMG 706 125mg|125 mg, once daily. (Cohort 3)
11517004|NCT01235403|Experimental|Lacosamide|Flexible dosing between 200mg/day and 400mg/day
11517005|NCT01235390|Experimental|5 g of walnuts|
11517006|NCT01235390|Experimental|40 g of walnuts|
11517007|NCT01235377|Active Comparator|Favor Chlorthalidone|Providers randomized to Favor Chlorthalidone will have agreed to prescribe chlorthalidone for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. This cluster designation applies only for patients for whom there is equipoise; providers are expected to deviate if medically indicated for individual patients
11517008|NCT01235377|Active Comparator|Favor Hydrochlorothiazide|Providers randomized to Favor Hydrochlorothiazide will have agreed to prescribe hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. This cluster designation applies only for patients for whom there is equipoise; providers are expected to deviate if medically indicated for individual patients
11517009|NCT01235364|Experimental|Digital|The patient was randomized to digital insertion of the Foley catheter
11517010|NCT01235364|Experimental|Speculum|
11517011|NCT01235351|Active Comparator|Clopidogrel - for CYP2C19*2 carriers|Clopidogrel for CYP2C19*2 gene carriers
11517012|NCT01235351|Active Comparator|Clopidogrel - for CYP2C19*2 non-carriers|Clopidogrel for CYP2C19*2 gene NON-carriers
11517013|NCT01235338|Experimental|LDX (SPD489) + Venlafaxine XR (Effexor XR)|
11517014|NCT01235338|Experimental|Venlafaxine XR + LDX|
11517015|NCT01235325|Placebo Comparator|Placebo oil capsule|Banner Pharmacaps Europe
11517016|NCT01235325|Experimental|phylloquinone (1000 mcg)|Banner Pharmacaps Europe
11517017|NCT01235312||Healthy subjects|
11517018|NCT01235312||Patients suffering from Diabetes mellitus|
11517019|NCT01235312||Patients suffering from peripheral arterial occlusive disease|
11517020|NCT01235299||Healthy subjects|
11517021|NCT01235299||Subjects suffering from Diabetes mellitus|
11517022|NCT01235299||Subjects suffering from peripheral arterial occlusive disease|
11517023|NCT01235286|Experimental|remote ischemic preconditioning|
11517024|NCT01235273|Experimental|GH replacement therapy|
11517025|NCT01235273|Placebo Comparator|Placebo|
11517026|NCT01235260||001|Becaplermin users A cohort of becaplermin users (ie patients with diabetes treated with becaplermin)
11517027|NCT01235260||002|Becaplermin nonusers A cohort of becaplermin nonusers (ie patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
11517028|NCT01235247|Experimental|reminders, no reminder|
11517029|NCT01235234|Experimental|CF101 0.1 mg|
11517030|NCT01235234|Experimental|CF101 1 mg|
11517031|NCT01235234|Placebo Comparator|Placebo|
11517032|NCT01235221|Experimental|BIIB041 (Fampridine-SR)|Participants take 10 mg sustained-release tablets of fampridine twice daily for up to 27 months or until the product is commercially available.
11517033|NCT01235208|Experimental|Eurodiet treatment|
11517034|NCT01235195|Active Comparator|Sertraline 50 mg capsules|
11517035|NCT01235195|Active Comparator|Sertraline 50 mg tablet|
11517036|NCT01235182||acute dyspnea, field, diagnostic|All patients with shortness of breath as the primary complaint (defined as eitherthe sudden onset of dyspnea without history of chronic dyspnea or an increase in the severity of chronic dyspnea and were age >18 years.
11517037|NCT01235169|Experimental|Proximal Femoral Nail Antirotation|Proximal Femoral Nail Antirotation(PFNA) with cement augmentation
11517038|NCT01235143|Experimental|desflurane anesthesia|maintenance anesthesia with desflurane
11517039|NCT01235143|Active Comparator|sevoflurane|maintenance anesthesia with sevoflurane
11517040|NCT01235130|Active Comparator|OMEGA-3|Long-Chain N-3 polyunsaturated fatty acids (OMEGA-3)
11517041|NCT01235130|Placebo Comparator|Placebo|Placebo soybean oil
11517042|NCT01235104||Total nephrectomy|
11517043|NCT01235091|Other|Standard|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing
11517044|NCT01235091|Experimental|SI/WWE|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing along with Well-Woman Exam
11517045|NCT01235091|Experimental|SI/WWE/PD|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing along with Well-Woman Exam and Peer-delivered Enhanced Intervention
11517046|NCT01235078||Intraosseous vascular access|subjects with urgent vascular access needs in whom intraosseous vascular access has been attempted and/or established.
11517047|NCT01235065|Active Comparator|direct laryngoscope|emergency intubation with direct laryngoscopy technique
11517048|NCT01235065|Active Comparator|video laryngoscope|emergency intubation with video laryngoscopy technique
11517049|NCT01235052|Experimental|TEP with 18F-FMISO|TEP with 18F-FMISO
11517050|NCT01235039|Experimental|Formulation A|VIAject®25 for subcutaneous application
11517051|NCT01235039|Experimental|Formulation B|VIAject®7 for subcutaneous application
11517052|NCT01235039|Experimental|Formulation C|Insulin Lispro for subcutaneous application
11517053|NCT01235026|Experimental|Synbiotic|"Dietary Supplement: Synbiotic: combination of the prebiotic Oligofructose with the probiotic Bifidobacterium animalis subsp. lactis Bb12"
11517054|NCT01235026|Placebo Comparator|Placebo|Dietary supplement: placebo: maltodextrin
11517055|NCT01235013|Experimental|Maraviroc|
11517056|NCT01235013|No Intervention|Control|Patients continue with their usual treatment
11517057|NCT01235000||2010-11 influenza vaccine recipients|Participants of an earlier clinical trial (TITRE II) to evaluate prime-boost response across B lineages in 2009-10
11517058|NCT01234987||Breast cancer|
11517059|NCT01234987||Colon cancer|
11517060|NCT01234987||Lung Cancer|
11517061|NCT01234974|Experimental|Pasireotide|Pasireotide 60 mg day 1 every 28 days
11517062|NCT01234961|Experimental|Redesigning Daily Occupations|The ReDO intervention focuses on how people compose their everyday lives. Supporting people in how to change and modify their patterns of daily occupations is a new intervention method for people with stress-related disorders, but it has been shown to be effective in improving quality of life and self-rated health in other target groups. The basic idea is that re-structuring of an individual's lifestyle and pattern of daily occupations will lead to a healthier balance between the occupations of everyday life, and that this balance will promote wellness and improved work capacity. The program is group based and comprises 16 weeks, with sessions 2 x 2 hours per week, followed by 3-4 booster sessions.
11517063|NCT01234961|Active Comparator|Care as usual|Standard rehabilitation provided by the Social Insurance Office, such as stress management, physical therapy, mindfulness training.
11517064|NCT01234948||Chronic periodontitis patients|Chronic periodontitis patients had at least one site per quadrant with clinical probing depth (CPD) > 5mm and radiographic evidence of bone loss
11517065|NCT01234948||Generalised chronic gingivitis patients|Generalised chronic gingivitis patients presented with bleeding on probing (BOP) at > 30% of sites, CPDs < 4mm and no evidence of bone loss
11517066|NCT01234948||Periodontally healthy subjects|Healthy subjects had < 10% sites with BOP and no sites with CPD > 3mm
11517067|NCT01234935|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11517068|NCT01234935|Experimental|Arm II|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15 and oral dasatinib once daily on days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity. NOTE: *Courses with dasatinib repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.
11517069|NCT01234922|Experimental|Arm I|Patients receive oral benazepril hydrochloride once daily on days 1-7.
11517070|NCT01234922|Experimental|Arm II|Patients receive oral lisinopril once daily on days 1-7.
11517071|NCT01234922|Experimental|Arm III|Patients receive oral ramipril twice daily on days 1-7.
11517072|NCT01234922|Experimental|Arm IV|Patients receive oral losartan potassium once daily on days 1-7.
11517073|NCT01234909||Atopic dermatitis|Pediatric patients ages 1-18 years old with atopic dermatitis
11517074|NCT01234896|Experimental|Nicotine Gum 6|6 mg Nicotine medicated gum
11517075|NCT01234896|Active Comparator|Nicotine Gum 4|4 mg Nicotine Gum
11517076|NCT01234896|Active Comparator|Nicotine Gum 2|2 mg Nicotine Gum
11517077|NCT01234896|Active Comparator|Nicotine Lozenge|4 mg Nicotine Lozenge
11517078|NCT01234883|Experimental|multiple electrolyte solution|Subjects were randomized to receive either multiple electrolyte solution or saline. These solutions were administered IV at 10-20 mL/kg until the subject appeared clinically rehydrated as assessed by the clinician. The selected dose for these solutions is considered standard of care when treating clinical dehydration in children and is consistent with product labeling.
11517079|NCT01234883|Active Comparator|saline|Subjects were randomized to receive either multiple electrolyte solution or saline. These solutions were administered IV at 10-20 mL/kg until the subject appeared clinically rehydrated as assessed by the clinician. The selected dose for these solutions is considered standard of care when treating clinical dehydration in children and is consistent with product labeling.
11517080|NCT01234870|Experimental|Ischemic heart disease patients|Patients with suspected ischemic heart disease prospectively recruited for first pass myocardial perfusion MRI. All subject to receive Gadolinium infusion of 0.075 mmol/kg at rate of 4 ml/sec. Adenosine administered at a rate of 0.14 mg/kg/min for a duration of 4 minutes to induce stress.
11517081|NCT01234857|Experimental|Part A: ridaforolimus + dalotuzumab|Approximately 15 patients will be enrolled to the ridaforolimus-dalotuzumab combination treatment arm. Subsequent Patients are randomly assigned in a 1:1 ratio to treatment with the ridaforolimus (20 mg daily five days a week)/dalotuzumab (intravenous infusion 10 mg/kg once weekly) combination therapy or cross-over to exemestane single-therapy treatment.
11517082|NCT01234857|Active Comparator|Part A: exemestane|Exemestane 25 mg daily; single-agent therapy.
11517083|NCT01234857|Experimental|Part B: ridaforolimus + dalotuzumab|Patients are randomly assigned in a 1:1 ratio to treatment with the ridaforolimus (20 mg daily five days a week)/dalotuzumab (intravenous infusion 10 mg/kg once weekly) combination therapy or cross-over to one of two single-therapy treatments (ridaforolimus alone or dalotuzumab alone). With the implementation of Amendment 3, this study arm will not be opened.
11517327|NCT01233232|Experimental|3|Treatment arm AZD5069 80mg
11517084|NCT01234857|Experimental|Part B: ridaforolimus|Ridaforolimus; 40 mg daily five days a week, single-agent therapy. With the implementation of Amendment 3, this study arm will not be opened.
11517085|NCT01234857|Experimental|Part B: dalotuzumab|Dalotuzumab intravenous infusion 10 mg/kg weekly; single-agent therapy. With the implementation of Amendment 3, this study arm will not be opened.
11517086|NCT01234844|Other|care of guinea pigs|"Each patient serves as own control receiving pet therapy and usual occupational therapy on alternate days."
11517087|NCT01234831|Other|Active Screening|Patients randomized to active screening will have two nasal swabs collected daily for 3 days, for both nucleic acid amplification and culture (CHROMagar)assays.
11517088|NCT01234831|Other|Passive Screening|Patients randomized to passive screening will not actively be identified for testing but may be tested using culture-based algorithm by care team.
11517089|NCT01234818|Experimental|LNG-IUS, endometrial hyperplasia|
11517090|NCT01234805|Experimental|Supportive care (yoga therapy)|Patients participate in yoga classes comprising postures, deep relaxation, breathing practices, and meditation twice weekly for 75 minutes during weeks 1-6. Patients then practice yoga at home twice weekly for 45 minutes during weeks 7-12.
11517091|NCT01234792|Experimental|NIC-6|6 mg Experimental nicotine gum
11517092|NCT01234792|Active Comparator|NIC-4|4 mg Nicotine Gum
11517093|NCT01234792|Active Comparator|NIC-2|2 mg Nicotine Gum
11517094|NCT01234779|Experimental|A|
11517095|NCT01234779|Experimental|B|
11517096|NCT01234779|Active Comparator|C|
11517097|NCT01234779|Placebo Comparator|D|
11517098|NCT01234766|Experimental|Single Arm|Subjects will receive bendamustine and rituximab, followed by 90-yttrium (Y) Ibritumomab Tiuxetan
11517099|NCT01234753|No Intervention|Usulal care|Usual care by a visit to physician at the hospital out-patient clinic
11517100|NCT01234740|Experimental|Arm I|Patients undergo intracerebral microdialysis during debulking craniotomy or stereotactic biopsy. Beginning 24 hours later, patients receive oral bafetinib twice daily for 1 day. Beginning at least 2 weeks after surgery, patients continue to receive oral bafetinib twice daily in the absence of disease progression or unacceptable toxicity.
11517101|NCT01234727||Diabetes|Patients with Type 1 or Type 2 diabetes requiring insulin.
11517102|NCT01234714||Major liver resection|This single Cohort/Group will include all consecutive patients that received pre-operative Magnetic Resonant Imaging (MRI) and underwent major liver resection (>=3 segments).
11517103|NCT01234701||Primary liver tumors, non-cirrhotic|This single Cohort/Group will include all consecutive patients that received pre-operative Magnetic Resonance Imaging (MRI) and underwent resection for primary liver tumors.
11517104|NCT01234688|Experimental|Exercise training|Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
11517105|NCT01234688|No Intervention|Control|Patients allocated to the control group remained in regular dialysis treatment during the same timeframe.
11517106|NCT01234675|Experimental|milnacipran|Drug: milnacipran 7-day dose escalation, 28- day treatment with milnacipran 50 mg and 7-day taper period before or after crossover to placebo
11517107|NCT01234675|Placebo Comparator|placebo|Drug: placebo 45-day placebo treatment before or after crossover to milnacipran
11517108|NCT01234662|Active Comparator|Group 1|Spinal anesthesia + intrathecal opioid bolus (SPA)
11517109|NCT01234662|Active Comparator|Group 2|CSE + epidural opioid bolus (CSE)
11517110|NCT01234662|Experimental|Group 3|CSE + continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs (CSEPCEA)
11517111|NCT01234649|Experimental|Metformin XR plus liraglutide|Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated
11517112|NCT01234649|Active Comparator|Metformin XR plus placebo|Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
11517113|NCT01234636|Active Comparator|cis9,trans 11 CLA oil|50 volunteers on cross over design , receiving 4g/day of cis9,trans11 CLA
11517114|NCT01234636|Placebo Comparator|Placebo oil|50 volunteers cross over design, placebo oil 4g/day
11517115|NCT01234623||UCB eyedrops, single arm|One-centre pilot study, open, non randomized.
11517116|NCT01234610|Experimental|Exercise|Exercise
11517117|NCT01234610|No Intervention|Control|No exercise
11517118|NCT01234597|Active Comparator|Arm A: Without Continous Glucose Monitoring (CGM) sensor|"Run-in phase: insulin glargine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer .
~Treatment phase: insulin glulisine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer. Then, adjustment of the dosage is performed by the treating physician"
11517119|NCT01234597|Experimental|Arm B: Continous Glucose Monitoring (CGM) sensor|"Run-in phase: insulin glargine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer .
~Treatment phase: the patients are connected to a CGM sensor. Insulin glulisine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer. Then, adjustment of the dosage is performed by the national coordinator based on the data collected in the past previous days of CGM sensor monitoring."
11517120|NCT01234584|Experimental|Group A|23 implants using SPK Abutments
11517121|NCT01234584|Active Comparator|Group B|implants using CPK Abutments
11517122|NCT01234558|Placebo Comparator|Normal Saline|IV placebo
11517123|NCT01234558|Experimental|GLYX-13, 1 mg/kg|
11517124|NCT01234558|Experimental|GLYX-13, 5 mg/kg|
11517125|NCT01234558|Experimental|GLYX-13, 10 mg/kg|
11517126|NCT01234545||A|
11517127|NCT01234532|Experimental|entinostat & anastrozole neoadjuvant|"Neoadjuvant entinostat daily on days 1, 8, 15, 22, and 29 + anastrozole daily on days 4-29 followed by surgery ie either lumpectomy or mastectomy.
~Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.
~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery."
11517128|NCT01234519|Experimental|Phase 1 - Cohort 1|"Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
~Patients will be enrolled in cohorts of 3 at a specified AEZS-108 dose beginning with 160mg/m^2. Enrollment will be suspended until all members of a cohort have been observed for dose limiting toxicities (DLT) for a period of 3 weeks (1 cycle of AEZS-108) from initial treatment with AEZS-108. Dose escalation will proceed within each cohort according to a specific scheme where DLT is defined."
11517129|NCT01234519|Experimental|Phase 1 - Cohort 2|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
11517130|NCT01234519|Experimental|Phase 1 - Cohort 3|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
11517131|NCT01234519|Experimental|Phase 1 - Cohort 4|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
11517132|NCT01234519|Experimental|Phase 2|AEZS-108 at MTD to determine efficacy in up to 40 patients.
11517133|NCT01234506|Active Comparator|secoisolariciresinol diglucoside|Secoisolariciresinol diglucoside (SDG) supplementation as 0.8g/day of BeneFlax containing 300 mg SDG. 1000 IU vitamin D as standard of care.
11517134|NCT01234506|Placebo Comparator|Placebo|An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
11517135|NCT01234493|Active Comparator|fixation|Syndesmosis fixation with one 3.5mm fully threaded screw
11517136|NCT01234493|Active Comparator|no fixation|No syndesmosis fixation
11517137|NCT01234467|Experimental|Bendamustine, Rituximab|This is a single arm intervention where patients will receive bendamustine at a dose of 120 mg/m^2 infused over 60 minutes in days 1 and 2 of each 21 day cycle along with rituximab 375 mg/m^2 after bendamustine on day 1 of each cycle. Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 3 at baseline were allowed to receive bendamustine at a dose of 90 mg/m^2 daily with a dose increase to 120 mg/m^2 daily if their ECOG improved.
11517138|NCT01234454|Experimental|Risperidone Treatment Group|A two-week cross-titration phase followed randomization when patients started treatment with Risperidone in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose was 6mg/day or highest dose tolerated.
11517139|NCT01234454|Experimental|Olanzapine Treatment Group|A two-week cross-titration phase followed randomization when patients started treatment with Olanzapine in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose 20mg/day (or the highest dose tolerated) for 8 weeks, following 4 weeks of baseline Thiothixene.
11517140|NCT01234454|No Intervention|Thiothixene|Subjects were first stabilized on open-label Thiothixene for four weeks, target dose 25 mg per day. Patients were then randomized to either Risperidone or Olanzapine treatment for 8 weeks.
11517141|NCT01234441|Sham Comparator|Control|This group of patients will receive a non-nutritive beverage, and no exercise.
11517142|NCT01234441|Active Comparator|Protein|This group of patients will ingest 30 grams of a liquid whey protein supplement during the first hour of their dialysis session
11517143|NCT01234441|Active Comparator|Protein + Exercise|This group will ingest 30 grams of a liquid whey protein supplement as well as exercise for 30-45 minutes during their dialysis treatment
11517144|NCT01234428|Other|surgery|
11517145|NCT01234415|Experimental|Patient|
11517146|NCT01234402|Experimental|Ramucirumab DP + Capecitabine|Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
11517147|NCT01234402|Experimental|Icrucumab + Capecitabine|Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
11517148|NCT01234402|Active Comparator|Capecitabine*|"Crossover Study:
~* At the discretion of the investigator, participants will be eligible to receive either ramucirumab DP or Icrucumab (IMC-18F1) in combination with capecitabine, after radiographic disease progression while on capecitabine. The investigator will decide which investigational product will be given.
~Cycles repeat every 21 days until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant."
11517149|NCT01234389|Other|H. pylori positive patients|
11517150|NCT01234389|Other|H. pylori negative patients|
11517151|NCT01234376||Control patients|
11517152|NCT01234376||Patients with eosinophilic esophagitis|
11517153|NCT01234363|Experimental|Magnetic Resonance Elastography, Supersonic Shear Imaging|Magnetic Resonance Elastography and Supersonic Shear Imaging
11517154|NCT01234350||FIRMAGON|
11517155|NCT01234350||GnRH Agonist|
11517156|NCT01234337|Experimental|Sorafenib (Nexavar, BAY43-9006) + Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
11517157|NCT01234337|Placebo Comparator|Placebo + Capecitabine|Capecitabine was administered orally at a dose of 1,000 mg/m^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
11517158|NCT01234324|Experimental|Arm 1: ECX + Panitumumab|
11517159|NCT01234324|Active Comparator|Arm 2: EXC alone|
11517160|NCT01234311|Placebo Comparator|placebo|Matching placebo
11517161|NCT01234311|Experimental|tasquinimod|Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
11517162|NCT01234298|Experimental|SPD489 Low-Dose|
11517163|NCT01234298|Experimental|SPD489 High-Dose|
11517164|NCT01234298|Placebo Comparator|Placebo|
11517165|NCT01234285|Experimental|intravenous heparin aPTT 40-50 seconds|Patients 11-15: IV heparin, target aPTT range 40-50 seconds
11517166|NCT01234285|Experimental|intravenous heparin|Patients 26-40: IV heparin, target range aPTT 50-60 seconds
11517167|NCT01234285|Experimental|Intravenous heparin|Patients 41-55 IV heparin, target aPTT range 60-70 seconds
11517168|NCT01234285|Active Comparator|sq heparin three times a day|Patients 1-10 will receive subcutaneous heparin three times a day
11517169|NCT01234272|Experimental|ITM-IVPCA|ITM-IVPCA:intrathecal morphine and IV-fentanyl patient controlled analgesia
11517170|NCT01234272|Active Comparator|PCEA|PCEA:epidural PCA(patient controlled analgesia)
11517171|NCT01234259|Experimental|Study group|Device: Venus Freeze (MP)2 V2 system
11517172|NCT01234259|Sham Comparator|control group:|Sham comparator
11517173|NCT01234246||Patients with colorectal cancer|Patients with colorectal cancer are included
11517174|NCT01234246||Partners|Partners of patients with colorectal cancer are included
11517175|NCT01234233|No Intervention|Group 1|Control group - no intervention: no preoperative warming
11517176|NCT01234233|Active Comparator|Group 2 - 10 min prewarming|10 min prewarming preoperatively
11517177|NCT01234233|Active Comparator|Group 3 - 20 min prewarming|20 min prewarming preoperatively
11517178|NCT01234233|Active Comparator|Group 4 - 30 min prewarming|30 min prewarming preoperatively
11517179|NCT01234220||Adrenal Venous Sampling (AVS)|Patients with Primary Aldosteronism (PA) undergoing AVS to discriminate PA forms with unilateral from bilateral excess aldosterone production.
11517180|NCT01234207|Active Comparator|Randomized Order of Interventions 1|Randomized to first wear standard, non-free-form, non-customized PAL spectacles, then second, crossover to wear individually customized free-form surfaced PAL spectacles
11517181|NCT01234207|Active Comparator|Randomized Order of Interventions 2|Randomized to first wear individually customized free-form surfaced PAL spectacles, then second, crossover to wear standard, non-free-form, non-customized PAL spectacles
11517182|NCT01234194|Active Comparator|Group 1|
11517183|NCT01234194|Active Comparator|Group 2|
11517184|NCT01234181|Experimental|BMSCs transplantation|
11517185|NCT01234181|Sham Comparator|No BMSCs transplantation|
11517186|NCT01234155|No Intervention|Control|
11517187|NCT01234155|Experimental|Exercise - Continuous Walking|
11517188|NCT01234155|Experimental|Exercise - Interval Walking|
11517189|NCT01234142|Experimental|Cohort 1|
11517190|NCT01234142|Experimental|Cohort 2|
11517191|NCT01234142|Experimental|Cohort 3|
11517192|NCT01234142|Experimental|Cohort 4|
11517193|NCT01234129||zoledronic acid or not zoledronic acid|patients with multiple myeloma will be treated with cytoreductive therapy following by zoledronic acid or not.
11517194|NCT01234129||zoledronic acid or not zoledronic acid|patients with multiple myeloma will be treated with cytoreductive therapy following by stem cell transplant and did not received zoledronic acid
11517195|NCT01234129||zoledronic acid|Patients with multiple treated with cytoreductive therapy following by stem cell transplant will be planned to received zoledronic acid
11517196|NCT01234116|Active Comparator|Kaletra|Arm 1: Kaletra two tabs twice a day + Truvada one pill once a day.
11517197|NCT01234116|Active Comparator|Raltegravir|Arm 2: Raltegravir 400 mg, one pill twice a day + Truvada one pill once a day.
11517198|NCT01234103|Experimental|Preventing sexual health risks|The over goal is to prevent STIs, unintended pregnancies, and related behaviors including sexual risk, alcohol and other substance misuse
11517199|NCT01234103|Other|Improving nutrition, fitness and injury prevention|The goals are: (1) maintain and improve nutrition and physical fitness through healthier lifestyle and food choices; (2) reduce the risk of sports or physical training injuries and learning how to treat injuries; and (3) Learn to recognize stress and the steps you can take to reduce stress
11517200|NCT01234090||Persons with Aphasia|
11517201|NCT01234077|No Intervention|ECG recording|In-laboratory vs. in-home recordings
11517202|NCT01234064|Active Comparator|Graduated Compression Stockings|
11517203|NCT01234064|Other|No Graduated Compression Stockings|
11517204|NCT01234051|Experimental|Docetaxel, oxaliplatin, palliative chemotherapy|
11517205|NCT01234038|Experimental|Part 1 Cohort 1|
11517206|NCT01234038|Experimental|Part 1 Cohort 2|
11517207|NCT01234038|Experimental|Part 2 Arm A|
11517208|NCT01234038|Experimental|Part 2 Arm B|
11517209|NCT01234025|Experimental|Part 1 Cohort 1|
11517210|NCT01234025|Experimental|Part 1 Cohort 2|
11517211|NCT01234025|Experimental|Part 2 Arm A|
11517212|NCT01234025|Experimental|Part 2 Arm B|
11517213|NCT01234012|Experimental|Treatment: IMF-001|100 or 200 mcg will be administered to patients subcutaneously every 2 weeks for 6 injections.
11517214|NCT01233999|Placebo Comparator|Botox|single-drug dosage comparison cross-over study
11517215|NCT01233986||Case group - Large artery atherosclerosis|
11517216|NCT01233986||Control group-Small vessel occlusion|
11517217|NCT01233973|No Intervention|control subjects|verbal narrative of advance care planning
11517218|NCT01233973|Experimental|intervention group|video decision aid viewed by subjects
11517219|NCT01233960|Experimental|Prochymal|Infusions of Prochymal on days 42-45, 84-87, and 126-129 after first infusion in Protocol 603. Each infusion of PROCHYMAL (remestemcel-L) will contain 200 million cells.
11517220|NCT01233947|Experimental|AFP464|74 mg/m2 AFP464 administered as a 3 hour IV infusion on Days 1 and 8 of a 21-day cycle.
11517221|NCT01233947|Experimental|AFP464 + Faslodex|AFP464 administered as a 3 hour IV infusion on Days 1 and 8 of a 21-day cycles and Faslodex administered per package label.
11517222|NCT01233934|Active Comparator|Dexchlorpheniramine 1% Cream|
11517223|NCT01233934|Experimental|Dexchlorpheniramine 1% Gel|
11517224|NCT01233921|Experimental|Arm I (palifermin)|Patients receive palifermin IV on days 1-3 in the absence of unacceptable toxicity.
11517225|NCT01233921|Active Comparator|Arm II (no palifermin)|Patients do not receive palifermin.
11517226|NCT01233908||PTSD|Patients which underwent surgical repair for primary rhegmatogenous retinal detachment and developed an associated posttraumatic stress disorder
11517227|NCT01233908||PTSD - negative|Patients which underwent surgical repair for primary rhegmatogenous retinal detachment and did not develope an associated posttraumatic stress disorder
11517228|NCT01233895|Experimental|AVE1642/ AVE1642 with Velcade|
11517229|NCT01233882|Experimental|Healthy Volunteers|
11517230|NCT01233882|Experimental|Mild Renal Impairment|
11517231|NCT01233882|Experimental|Moderate Renal Impairment|
11517232|NCT01233882|Experimental|Severe Renal Impairment|
11517233|NCT01233869|Experimental|Cohort A|
11517234|NCT01233869|Experimental|Cohort B|
11517235|NCT01233869|Placebo Comparator|Cohort C|
11517236|NCT01233843|Other|Drug and radiation|Radiotherapy : 70 grays , fractionization : 2Gy/day, 5 days / week, for 7 weeks . Concurrent administration of Carboplatin: 70 mg/m2/day (day 1 until day 4)and 5FU 600 mg/m2/day (day 1 until day 4). Weeks 1; 4; 7.
11517237|NCT01233843|Experimental|drug and radiation|"Induction chemotherapy by Docetaxel 100mg/m2, day 1; cisplatin 100mg/m2, day 1; 5-Fluorouracil 1000mg/m2 (from day 1 to day 5), for a total of three cycles .Those cycles are administrated at day 1; day 22, day43.
~This induction chemotherapy is followed ( for responders or stable disease patients)by radiotherapy (70 grays for 7 weeks) and concurrent Erbitux( weekly administration)."
11517238|NCT01233830|Experimental|1|
11517239|NCT01233830|Placebo Comparator|2|
11517240|NCT01233817|Experimental|Spinal muscular atrophy|Children and adolescents with diagnosis of SMA type II or III. The intervention group (the only arm/group in this pilot study) receives a home-based, supervised, 12-week progressive strength-training program.
11517241|NCT01233804|No Intervention|Opting in|Currently, pregnant women have to sign a consent stating that they want the influenza vaccine (at the clinics where the study is being conducted). Therefore, this group is the same as usual care. However, women will then be asked if they would like to take part in parts 2 and 3 of the study.
11517242|NCT01233804|Experimental|Opting Out|Women will sign a consent form only if they do not want to receive the flu vaccine.
11517243|NCT01233791|Experimental|Vaginal Diazepam Suppository|Patients in this arm will be asked to use one vaginal suppository every night for 28 days
11517244|NCT01233791|Placebo Comparator|Vaginal Placebo Suppository|Patients will be asked to use one vaginal suppository every night for 28 days
11517245|NCT01233778|Experimental|Canola Oil|
11517246|NCT01233778|Experimental|High Oleic Acid Canola + DHA|
11517247|NCT01233778|Experimental|High Oleic Canola Oil|
11517248|NCT01233778|Experimental|Flax & Safflower Oil (60:40)|
11517249|NCT01233778|Experimental|Safflower & Corn Oil (75:25)|
11517250|NCT01233765||Control volunteers with periodontal health|Control volunteers with periodontal health
11517251|NCT01233765||Patient volunteers with chronic periodontitis|Patient volunteers with chronic periodontitis
11517252|NCT01233752||Group A|Homozygous patients,using PCA administration with morphine chlorhydrate for postoperative analgesia, for the more frequent allele of the polymorphism A118G of OPRM1 gene
11517253|NCT01233752||Group B|Both homozygous and heterozygous patients,using PCA administration with morphine chlorhydrate for postoperative analgesia, for the less frequent allele of the polymorphism A118G of OPRM1 gene
11517254|NCT01233739|Placebo Comparator|Placebo|
11517255|NCT01233739|Experimental|Chondroitin sulfate|Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
11517256|NCT01233726|Experimental|T-DIET PLUS DIABET IR|Patients of this group will receive T-Diet plus Diabet IR as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
11517257|NCT01233726|Active Comparator|ISOSOURCE PROTEIN FIBRE|Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
11517258|NCT01233726|Active Comparator|GLUCERNA SELECT|Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
11517259|NCT01233713|Active Comparator|Primary anastomosis|Primary anastomosis refers to a colonic resection with primary anastomosis and covering ileostomy, followed by a stoma reversal operation.
11517260|NCT01233713|Active Comparator|Hartmann's operation|Hartmann's operation is the surgical resection of the rectosigmoid colon with closure of the rectal stump and end colostomy, followed by a stoma reversal operation.
11517261|NCT01233700|Experimental|Motivational Interviewing|Subjects will receive two, individual telephone sessions with an interventionist, each lasting approximately 30-45 minutes. The sessions will focus on assisting subjects to delineate their reasons for or against proceeding with living organ donation and assisting subjects to resolve any lingering concerns about their decisions regarding donation.
11517262|NCT01233700|Active Comparator|Enhanced Standard Care|Subjects will receive two individual telephone sessions with an interventionist, each lasting approximately 30-45 minutes. The sessions will focus on providing educational information to subjects regarding healthy lifestyle issues (healthy eating, diet, exercise, quitting smoking).
11517263|NCT01233700|No Intervention|Standard Care|Subjects will receive the standard care and education provided by the Living Donor Program at their medical center.
11517264|NCT01233687|Experimental|AMG 102 and erlotinib|Combination of AMG 102 and erlotinib
11517265|NCT01233674||patients referred for standard of care MRI|
11517266|NCT01233661|Experimental|short AVD pacing|short AVD pacing
11517267|NCT01233661|No Intervention|prior (stable) programming|prior (stable) programming
11517268|NCT01233648|Active Comparator|AF|
11517269|NCT01233648|Active Comparator|SR|
11517270|NCT01233635|Experimental|A Group 1 no drug|Patients who have not taken ACE/ARB, randomized to no drug.
11517271|NCT01233635|Experimental|A Group 2|Patients who have not taken ACE/ARB, randomized to take cozaar.
11517272|NCT01233635|Experimental|B|Patients currently taking ACE/ARB will have their prescription changed to cozaar.
11517273|NCT01233622|Experimental|Vildagliptin (metformin + glimepiride)|
11517274|NCT01233622|Placebo Comparator|Placebo (metformin + glimepiride)|
11517275|NCT01233609|Active Comparator|Valproic Acid|Subjects who receive valproic acid
11517276|NCT01233609|Placebo Comparator|Placebo|Subjects who receive placebo
11517277|NCT01233596|Active Comparator|Monocanalicular intubation|Monocanalicular intubations (MCI; n=35 eyes) through the inferior canaliculus intubations performed under general anaeshesia in children between 10 and 36 months of age suffering from congenital nasolacrimal duct obstruction (CNLDO).
11517278|NCT01233596|Active Comparator|Bicanalicular intubation|Bicanalicular intubation (BCI; n=35 eyes) performed under general anaeshesia in children between 10 and 36 months of age suffering from congenital nasolacrimal duct obstruction (CNLDO).
11517279|NCT01233583||Betamethasone/Calcipotriol (Dovobet)|patients in whom decision to treat with Dovobet by their dermatologist
11517280|NCT01233583||Acitretin (neotigason)|patients in whom decision to treat with neotigason by their dermatologist
11517281|NCT01233583||narrow-band UVB|patients in whom decision to treat with narrow band UVB by their dermatologist
11517282|NCT01233583||Anti TNF-alpha|patients in whom decision to treat with anti TNF-alpha(adalimumab-etanercept-infliximab) by their dermatologist
11517283|NCT01233570|Experimental|Topical tacrolimus|Once daily topical application
11517284|NCT01233557||Bone Metastases|
11517285|NCT01233544|Experimental|Stereotactic body radiation therapy|Colorectal liver metastases treated by SBRT
11517286|NCT01233544|Active Comparator|Radiofrequency ablation|Colorectal liver metastases treated by RFA
11517287|NCT01233531|Other|A--Monthly cash transfers|Monthly cash transfer payments
11517288|NCT01233531|Other|B--No cash transfers|No cash transfers.
11517289|NCT01233518|Active Comparator|Single arm study|Patients will receive cCTA, ICA, FFR, and cFFR per protocol.
11517290|NCT01233505|Experimental|Treatment (veliparib, capecitabine, oxaliplatin)|Patients receive veliparib PO twice daily and capecitabine PO twice daily on 1-7 and 15-21, and oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11517291|NCT01233453|Active Comparator|the everolimus eluting ® stent|the everolimus eluting XIENCE-V®, XIENCE-Prime® or PROMUS® stent
11517292|NCT01233453|Active Comparator|Biolimus A9 stent|the Biolimus A9 eluting NOBORI® stent
11517293|NCT01233440|Experimental|Cohort 1|25 IU/kg dose
11517294|NCT01233440|Experimental|Cohort 2|50 IU/kg dose
11517295|NCT01233440|Experimental|Cohort 3|75 IU/kg dose
11517296|NCT01233414|Experimental|Parent Training|
11517297|NCT01233414|Active Comparator|Psychoeducation|
11517298|NCT01233401||Mothers|
11517299|NCT01233401||Other Infant Caregivers|Includes fathers, grandparents, and other adults who are infant caregivers
11517300|NCT01233388||Text message surveillance|enroll for text message surveillance
11517301|NCT01233375|Experimental|CO-1.01|
11517302|NCT01233362|Active Comparator|Arm 1: Adults; 14 days interval|89 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
11517303|NCT01233362|Active Comparator|Arm 2: Adults; 28 days interval|89 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
11517304|NCT01233362|Active Comparator|Arm 3: children; 14 days interval|89 children (1-17 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
11517305|NCT01233362|Active Comparator|Arm 4: children; 28 days interval|89 children (1-17 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
11517306|NCT01233362|Active Comparator|Arm 5: Adults; 14 days Interval|15 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
11517307|NCT01233362|Active Comparator|Arm 6: Adults; 28 days interval|15 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
11517308|NCT01233349|Experimental|Litramine|
11517309|NCT01233349|Placebo Comparator|Placebo|
11517310|NCT01233323||All study patients (single arm study)|All eligible patients will be included in the only study arm and will undergo study testing.
11517311|NCT01233297|Active Comparator|Antibiotics|Azithromycin (10 mg/kg once a day for 3 days)
11517312|NCT01233297|Placebo Comparator|Placebo|Placebo mixture (once a day for 3 days)
11517313|NCT01233284|Experimental|tiotropium low dose once daily|once daily, delivered by the Respimat® inhaler
11517314|NCT01233284|Experimental|tiotropium medium dose once daily|once daily, delivered by the Respimat® inhaler
11517315|NCT01233284|Experimental|tiotropium high dose once daily|once daily, delivered by the Respimat® inhaler
11517316|NCT01233284|Placebo Comparator|Placebo once daily|once daily, delivered by the Respimat® inhaler
11517317|NCT01233271|Experimental|1|Space TGC system with incorporated eMPC advised insulin titration to establish glycaemic control
11517318|NCT01233258|Experimental|Arm 1: rFVIII on demand first CS/EP then CS/ADJ|Participants received on-demand treatment with recombinant factor VIII (rFVIII, BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months, followed by cross-over to study drug assayed by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months.
11517319|NCT01233258|Experimental|Arm 2: rFVIII on demand first CS/ADJ then CS/EP|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/ADJ for 6 months, followed by cross-over to study drug assayed by CS/EP for 6 months.
11517320|NCT01233258|Experimental|Arm 3: rFVIII prophylaxis low-dose first CS/EP then CS/ADJ|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII(BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
11517321|NCT01233258|Experimental|Arm 4: rFVIII prophylaxis low-dose first CS/ADJ then CS/EP|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.
11517322|NCT01233258|Experimental|Arm 5: rFVIII prophylaxis high-dose first CS/EP then CS/ADJ|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
11517323|NCT01233258|Experimental|Arm 6: rFVIII prophylaxis high-dose first CS/ADJ then CS/EP|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII(BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.
11517324|NCT01233245||Group 1|
11517325|NCT01233232|Placebo Comparator|1|Placebo dose
11517328|NCT01233219||Group A|Homozygous patients for the more frequent allele of the polymorphism A118G of OPRM1 gene
11517329|NCT01233219||Group B|Both homozygous and heterozygous patients for the less frequent allele of the polymorphism A118G of OPRM1 gene
11517330|NCT01233206|Experimental|Experimental group|Patients receiving metformin pretreatment and co-administration
11517331|NCT01233206|Placebo Comparator|Control group|Placebo
11517332|NCT01233193|Experimental|Intervention|The intervention group receive an pharmacist intervention (health education, Home Blood Pressure Monitoring and Referral to physician as needed) This group will be followed for 6 months
11517333|NCT01233193|No Intervention|Control|The control group receive usual care in the community pharmacy
11517334|NCT01233180|Active Comparator|Gua Sha|Single Gua Sha treatment of the neck and shoulder region.
11517335|NCT01233180|Active Comparator|Thermotherapy|Single use of a mud heat pad on the neck and shoulder region.
11517336|NCT01233167|Experimental|clopidogrel|
11517337|NCT01233167|Placebo Comparator|placebo|
11517338|NCT01233167|Experimental|steply discontinued clopidogrel|
11517339|NCT01233154|Experimental|L. paracasei|L. paracasei
11517340|NCT01233154|Experimental|L. acidophilus + B. lactis|L. acidophilus + B. lactis
11517341|NCT01233141||one group only|all participants
11517342|NCT01233128||polypoidal choroidal vasculopathy|patients who were treated for polypoidal choroidal vasculopathy with intravitreal injections of 0.5 mg of ranibizumab monthly for 3 months
11517343|NCT01233115||polypoidal choroidal vasculopathy|patients who were treated for polypoidal choroidal vasculopathy with combined photodynamic therapy and intravitreal bevacizumab injections
11517344|NCT01233102|Active Comparator|Conserved Therapy|Conserved Therapy
11517345|NCT01233102|Experimental|Interventional Therapy|"Patients with liver cirrhosis will be randomly divided into three groups.
~1. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group.2. Umbilical cord MSCs will be infused to patients intravenously for another group. The control group will receive conserved therapy. The efficacy of different interventional therapies will be compared."
11517346|NCT01233089|Experimental|CARE|Investigational single-vision contact lenses worn bilaterally on a daily wear basis and replaced monthly
11517347|NCT01233089|Active Comparator|AIR OPTIX AQUA|Commercially available single-vision contact lenses worn bilaterally on a daily wear basis and replaced monthly
11517348|NCT01233089|Active Comparator|AIR OPTIX AQUA MULTIFOCAL|Commercially available multifocal contact lenses worn bilaterally on a daily wear basis and replaced monthly
11517349|NCT01233076|Other|Nelfilcon A / Narafilcon B|Nelfilcon A worn first, with narafilcon B worn second. Each product worn bilaterally in a daily wear, daily disposable basis for one week.
11517350|NCT01233076|Other|Narafilcon B / Nelfilcon A|Narafilcon B worn first, with nelfilcon A worn second. Each product worn bilaterally in a daily wear, daily disposable basis for one week.
11517351|NCT01233063|Experimental|Alive2|Lifestyle Intervention delivered via email and web
11517352|NCT01233063|Experimental|Alive2 plus automated phone/print|All of Arm 1 components, plus biweekly tailored automated phone coaching plus monthly tailored automated print materials.
11517353|NCT01233063|Placebo Comparator|Control|Monthly emailed newsletter on other aspects of wellness, excluding diet and physical activity
11517354|NCT01233050|Active Comparator|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative Skin Antisepsis Preparation
11517355|NCT01233050|Active Comparator|Iodine Povacrylex/74% Isopropyl Alcohol|Preoperative Skin Antisepsis Preparation
11517356|NCT01233024|Placebo Comparator|Low fiber control|no treatment dinner bar, no treatment breakfast bar
11517357|NCT01233024|Experimental|Promitor soluble corn fiber|12g in dinner bar, 11g in breakfast bar
11517358|NCT01233024|Experimental|FiberSym resistant starch|12g in dinner bar, 11g breakfast bar
11517359|NCT01233024|Experimental|Orafti P95 fructooligosaccharide|12g in dinner bar, 11g in breakfast bar
11517360|NCT01233024|Experimental|Orafti HPX inulin|12g in dinner bar, 11g in breakfast bar
11517361|NCT01232998||Patient Satisfaction with nursing care|
11517362|NCT01232998||satisfaction of waiting time for first time visit|
11517363|NCT01232998||patient satisfaction|
11517364|NCT01232985|Experimental|RD047-26|Study Device
11517365|NCT01232972|Experimental|oocyte freezing|includes any women who elects to preserve her fertility by vitrifying her unfertilized eggs.
11517366|NCT01232959|Experimental|Transvaginal Surgery|Gallbladder will be removed through the vagina
11517367|NCT01232946|Experimental|Iiraglutide|Type 2 diabetic subjects will be assigned to 3 months of treatment with 1.8mg liraglutide administered once daily in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
11517368|NCT01232946|Experimental|insulin detemir|Type 2 diabetic subjects will be assigned to 3 months of treatment with insulin detemir administered twice daily in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
11517369|NCT01232946|Experimental|Liraglutide plus insulin detemir|Type 2 diabetic subjects will be assigned to 3 months of treatment with a combination of liraglutide and insulin detemir in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
11517370|NCT01232933|Experimental|VPS System|Use of navigational VPS system to place catheter
11517371|NCT01232920|Active Comparator|Methotrexate|
11517372|NCT01232920|Active Comparator|Mycophenolate mofetil|
11517373|NCT01232907|Experimental|L-Carnitine|This study has a single subject design. Each subject acts as its own control. All subjects will go through intervention phase (treatment with L-Carnitine).
11517374|NCT01232894|Experimental|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
11517375|NCT01232894|Active Comparator|Long-acting beta2-agonist|Participants' current long-acting beta2-agonist (LABA) bronchodilator therapy
11517376|NCT01232881||Tumor and Serum Collection|"Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.
~Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib."
11517377|NCT01232868|Other|Age 25-40|Trivalent Influenza vaccine given to age 25-40
11517378|NCT01232868|Other|Age ≥65|Trivalent Influenza vaccine given to age≥65
11517379|NCT01232829|Experimental|Treatment (RO4929097)|"Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
~Patients may undergo tumor biopsy at baseline and on days 16 or 17 of course one for biomarker and other correlative studies. Blood samples may also collected at baseline and periodically during study for pharmacokinetic and angiogenesis marker studies."
11517380|NCT01232816||Delayed graft function|These are patients in whom dialysis is required following transplantation.
11517381|NCT01232816||Immediate function|These are patients in whom no dialysis is required and creatinine declines by >20% in the first 24 hours following transplantation.
11517382|NCT01232803|Active Comparator|2% N-9 gel|Rectal application of 2% N-9 gel
11517383|NCT01232803|Placebo Comparator|HEC placebo gel|Rectal application of HEC placebo gel
11517384|NCT01232803|No Intervention|no-treatment arm|no intervention
11517385|NCT01232803|Experimental|Tenofovir 1% gel|rectal application of Tenofovir 1% gel
11517386|NCT01232790|Experimental|Group A: Intervention/Placebo|Group A first receives the commercially available sustained release form of N-acetylcysteine, then the matching placebo capsules both administered at 1200mg twice a day for 3 full days, along with 1200mg once on the evening prior to and once on the morning following the 3 days (8 total doses over 5 days).
11517387|NCT01232790|Placebo Comparator|Group B: Placebo/Intervention|Group B first receives the placebo and then receives a commercially available sustained release form of N-Acetylcysteine. In each arm, the capsules are both administered at 1200mg twice a day for 3 full days, along with 1200mg once on the evening prior to and once on the morning following the 3 days (8 total doses over 5 days).
11517388|NCT01232777|Active Comparator|Bevacizumab (Avastin) 0.75mg/0.03cc|1/3 of study participants will be randomized to this treatment in one eye (study eye) and the other eye will receive laser (fellow eye)
11517389|NCT01232777|Active Comparator|Bevacizumab (Avastin) 0.625mg/0.025cc|1/3 of patients will be randomized to this treatment in 1 eye (study eye) and the other eye will receive laser (fellow eye).
11517390|NCT01232777|Active Comparator|Laser ablation|1/3 of study participants will be randomized to this treatment in both eyes (study eye and fellow eye)
11517391|NCT01232764|Experimental|Multi-disciplinary wound care team|Stepped wedge study design i.e. start date of exposure is randomized.
11517392|NCT01232738|Experimental|rasagiline|Treated for 12 months with rasagiline 2mg orally, once daily.
11517393|NCT01232725|Experimental|Donor Human Milk|VLBW infants randomized to be fed donor human milk, fortified as appropriate, for all feedings for which maternal milk is not available, including infants who receive no maternal milk
11517394|NCT01232725|Experimental|Preterm Formula|VLBW infants randomized to receive preterm infant formula for any feedings for which maternal milk is unavailable, including infants receiving no maternal milk
11517395|NCT01232712|Experimental|ImMucin|Treatment with ImMucin and rhGMCSF (recombinant human granulocyte-monocyte colony stimulating factor)
11517396|NCT01232699|Active Comparator|Internet Obesity Treatment|Participants will attend weekly class sessions on line and track food and exercise in an on-line journal.
11517397|NCT01232699|Experimental|Internet Obesity Treatment with MI|Participants will attend weekly classes on line, record food and exercise in an on-line journal, and will have no more than 6 individual motivational interviewing sessions.
11517398|NCT01232699|Experimental|Contingent MI|Intervention is the same as for the MI arm, however participants will only receive MI if meeting certain treatment participation conditions.
11517399|NCT01232686|No Intervention|Control area|In the control areas we will monitor the prevalence and treatment of communicable diseases without giving the participants online access to disease surveillance information
11517400|NCT01232686|Experimental|Intervention area|In these areas we will give study participants online access to epidemiological data for communicable diseases
11517401|NCT01232673|Experimental|BMAC treatment active group|Collection of 240ml from both illiac crests, followed by gradient density centrifugation, resulting in obtaining 40ml of BMAC. This ammount is applied by one ml per injection into the critical limb ischemia along the calf vessels.
11517402|NCT01232673|No Intervention|Control Study Group|Standard treatment group of patients with CLI after surgical or interventional revascularisation will serve as control.
11517403|NCT01232660|Active Comparator|Delayed|Delayed addition of hydroxychloroquine in patients with discordant CD4+ cell responses to suppressive HAART
11517404|NCT01232660|Experimental|Immediate|Immediate addition of hydroxychloroquine in patients with discordant CD4+ cell responses to suppressive HAART
11517405|NCT01232647|Active Comparator|Vitamin k1|1.0 mg of vitamin K1 (phylloquinone) and placebo MK4 will be given to one of the treatment arm for 18 months
11517406|NCT01232647|Placebo Comparator|placebo vitamin K1 and MK4|placebo pill of both vitamin K1 and MK4 given for 18 months to the control arm
11517407|NCT01232647|Active Comparator|Menatetrenone MK4|45 mg MK4 given daily and placebo vitamin K1 will be given to one of treatment arm for 18 months
11517408|NCT01232634||All Subjects|
11517409|NCT01232621|Experimental|Physician introduction|Physicians will introduce Research Coordinators (RCs) by name to SDMs and acknowledge patient eligibility to participate in a study using a standardized script.
11517410|NCT01232621|Active Comparator|Non-physician introduction (usual approach)|RCs will either introduce themselves or be introduced by a non-physician member of the health care team.
11517411|NCT01232608|Experimental|Exercise|12 months of exercise training
11517412|NCT01232608|No Intervention|Control|Normal follow-up by primary physician
11517413|NCT01232595|Experimental|LFF571 (POC)|
11517414|NCT01232595|Active Comparator|Vancomycin (POC)|
11517415|NCT01232595|Experimental|LFF571 Dose level 1 (cohort 2)|
11517416|NCT01232595|Experimental|LFF571 Dose level 2 (cohort 2)|
11517417|NCT01232595|Experimental|LFF571 Dose level 3 (cohort 2)|
11517418|NCT01232595|Experimental|LFF571 Dose level 4 (cohort 2)|
11517419|NCT01232569|Experimental|Tocilizumab 162 mg sc|Patients will receive tocilizumab 162 mg subcutaneously (sc) every 2 weeks for 24 weeks.
11517420|NCT01232569|Placebo Comparator|Placebo sc|Patients will receive placebo subcutaneously (sc) every 2 weeks for 24 weeks.
11517421|NCT01232556|Experimental|1|Inotuzumab ozogamicin+rituximab
11517422|NCT01232556|Active Comparator|2|Investigator's choice of (1) rituximab+gemcitabine, or (2) rituximab+bendamustine
11517423|NCT01232543|Experimental|Product 0405|Topical Active Investigational Product 0405
11517424|NCT01232530||Safety Active Surveillance Group|For the active surveillance, all age groups, including children less than 5 years of age, will be identified from the census database and encouraged to attend the health facility whenever sick. Those with a diagnosis of malaria and treated with an antimalarial drug will be actively monitored for AEs.
11517425|NCT01232530||Safety Passive Surveillance Group|For the people under passive surveillance, sick subjects attending the health facilities, diagnosed with malaria and treated with an antimalarial drug will be identified from the census database. The treatment administered will be recorded in a drug exposure log book and the patients will be encouraged to report passively any AE/ADR.
11517426|NCT01232530||Early Pregnancy Exposure to ACTs Group|All the pregnant women identified during the repeat surveys will be included in a pregnancy cohort. At the time the pregnant woman is identified, her possible exposure to ACTs will be extracted from the drug exposure log book or elicited by history. Births identified through the repeat surveys or any other outcome of pregnancy will be retrospectively matched with antimalarial treatment exposure, particularly during the first trimester of the pregnancy.
11517427|NCT01232530||ACT Effectiveness Monitoring Group|"Besides monitoring AEs and ADRs, data on the effectiveness of ACTs when used in real life conditions and on a large scale will be collected in the active surveillance area. For patients with a microscopically confirmed diagnosis of malaria, clinical symptoms and a blood sample for thick and thin blood smears, will be collected before antimalarial treatment, at day 28 after treatment and at any unscheduled visit. Treatment administration will not be supervised."
11517428|NCT01232504|Experimental|rhGM-CSF group|subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) once daily
11517429|NCT01232504|Active Comparator|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) and 2-3μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) each
11517430|NCT01232504|Active Comparator|rhG-CSF group|subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) once daily
11517431|NCT01232491|Active Comparator|Control|Insulin detemir (Levemir®) 100 U/mL, was injected subcutaneously once daily with the evening meal or at bedtime as add-on to subject's pre-trial treatment of metformin for 26 weeks. Subjects did not receive dietary consultation except for basic dietary advice at baseline. Insulin doses were individually adjusted.
11517432|NCT01232491|Experimental|Dietician|Insulin detemir (Levemir®) 100 U/mL, was injected subcutaneously once daily with the evening meal or at bedtime as add-on to subject's pre-trial treatment of metformin for 26 weeks. Subjects received dietary consultation according to local standard during 3 face-to-face meetings and 3 phone contacts. Insulin doses were individually adjusted.
11517433|NCT01232478|Experimental|Comprehensive Adherence Program (CAP)|The comprehensive adherence program emphasizes the patient's active, collaborative role in identifying adherence barriers and solving them to improve adherence to prescribed treatment regimens. Problem-solving sessions will be used to address barriers to adherence that are identified by the adolescent. The intervention also includes provision of a written, Prescribed Treatment Plan, assessment and remediation of gaps in Knowledge of Disease Management, and evaluation and re-instruction/re-training of skills needed to perform daily treatments.
11517434|NCT01232478|Experimental|Standard Care (SC)|Standard care (SC) for adolescents and young adults seen in outpatient CF clinics in Year 1 of the Study. CAP intervention during Year 2 of the Study.
11517435|NCT01232465||IVF|those individuals undergoing conventional IVF to inseminate their retrieved eggs
11517436|NCT01232465||ICSI|those individuals whose eggs were fertilized via intracytoplasmic sperm injection (ICSI)
11517437|NCT01232452|Experimental|Pemetrexed + Cisplatin + Cixutumumab|"Induction Treatment: Pemetrexed 500 mg/m^2 plus cisplatin 75 mg/m^2 plus cixutumumab 20 mg/kg given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for patients with significant tumor size reduction, after sponsor approval.
~Maintenance Therapy: Pemetrexed 500 mg/m^2 plus cixutumumab 20 mg/kg given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met."
11517438|NCT01232452|Active Comparator|Pemetrexed + Cisplatin|"Induction Treatment: Pemetrexed 500 mg/m^2 plus cisplatin 75 mg/m^2 given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for patients with significant tumor size reduction, after sponsor approval.
~Maintenance Therapy: Pemetrexed 500 mg/m^2 given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met."
11517439|NCT01232439|Experimental|opioid receptor kappa antagonist|
11517440|NCT01232426|Experimental|Operative|operative treatment of a Mallet fracture with a biodegradable Meniscus Arrow®
11517441|NCT01232426|Active Comparator|Conservative|Conservative treatment of a Mallet fracture with a Mallet splint
11517442|NCT01232413|Placebo Comparator|Treatment A|Placebo
11517443|NCT01232413|Experimental|Treatment B|ASP1941 low dose
11517444|NCT01232413|Experimental|Treatment C|ASP1941 high dose
11517445|NCT01232413|Active Comparator|Treatment D|Moxifloxacin
11517446|NCT01232400|Experimental|esmolol|Esmolol will be used preferentially to control hypertension.
11517447|NCT01232400|No Intervention|Standard care|Standard care for SAH includes other hypertensives such as nicardipine.
11517448|NCT01232387||Fetomaternal hemorrhage - Mothers|Mothers in Mother-baby pairs in which the testing for fetomaternal hemorrhage on the mother's blood demonstrates the presence of fetal cells.
11517449|NCT01232387||Fetomaternal hemorrhage - Babies|Babies in Mother-baby pairs in which the testing for fetomaternal hemorrhage on the mother's blood demonstrates the presence of fetal cells.
11517450|NCT01232374|Experimental|Nimotuzumab plus chemo-irradiation|Nimotuzumab，chemotherapy(cisplatin )，radiotherapy
11517451|NCT01232374|Placebo Comparator|Placebo plus chemo-irradiation|Placebo，chemotherapy(cisplatin)，radiotherapy
11517574|NCT01231594|Experimental|Cohort A|Subjects who have received </= 8 weeks of GSK2118436 monotherapy in the parent study
11517575|NCT01231594|Experimental|Cohort B|Subjects who have received >8 weeks of continuous treatment with GSK2118436 either as monotherapy or combination therapy with another approved anti-cancer agent
11517452|NCT01232361||Methylphenidate|"Subjects will be stratified by medication, HIV status and HIV antiretroviral therapy as follows:
~Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant (prescribed) efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a (prescribed) protease inhibitor (PI)* with concomitant ritonavir (at boosting doses) or lopinavir/ritonavir.
~*PI may be any of the following: atazanavir, darunavir, fosamprenavir, indinavir, saquinavir or tipranavir"
11517453|NCT01232361||Amphetamine / dextroamphetamine|"Subjects will be stratified by medication, HIV status and HIV antiretroviral therapy as follows:
~Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant (prescribed) efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a (prescribed) protease inhibitor (PI)* with concomitant ritonavir (at boosting doses) or lopinavir/ritonavir.
~*PI may be any of the following: atazanavir, darunavir, fosamprenavir, indinavir, saquinavir or tipranavir"
11517454|NCT01232348||Symbicort|Those with an exposure
11517455|NCT01232322||Pulmicort Respules|Those with an exposure
11517456|NCT01232309|Active Comparator|High Dose Chitin-Glucan|Daily oral dose of 4.5 g of chitin-glucan
11517457|NCT01232309|Active Comparator|Low Dose Chitin-Glucan|Daily oral dose of 1.5 g chitin-glucan
11517458|NCT01232309|Experimental|Low Dose Chitin-Glucan + Olive Extract|Daily oral dose of 1.5 g chitin-glucan + 135 mg olive extract
11517459|NCT01232309|Placebo Comparator|Placebo|Placebo (Rice Flour)
11517460|NCT01232296|Experimental|TKI258|capsule
11517461|NCT01232296|Experimental|Sorafenib|tablet
11517462|NCT01232283|Experimental|Apremilast|Participants were initially randomized 2:1 and received apremilast 30 mg twice a day (BID). Participants maintained dosing through Week 32. At Week 32, responders, those with a Psoriasis Area Severity Index response -≥75 (PASI-75) and partial responders (≥PASI-50) were re-randomized 1:1 to apremilast 30 mg BID or matching placebo (treatment withdrawal). Participants could resume apremilast 30 mg BID at the time of loss of 50% of improvement in PASI score response which was observed at Week 32 compared to baseline), and no later than Week 52. At Week 52, the non-responders (<PASI-50) had the option of adding topical therapies and/or phototherapy to their treatment regimen. Those re-randomized to apremilast 30 mg BID continued dosing through Week 52. At Week 52, participants continued treatment with apremilast 30 mg BID.
11517463|NCT01232283|Placebo Comparator|Placebo|Participants will be initially randomized to placebo, identically matching during Weeks 0-16. At Week 16, Placebo participants will be switched to receive apremilast 30 mg BID. All participants will maintain Apremilast dosing through Week 32. At Week 32, participants originally randomized to placebo at baseline (Week 0) and are considered non-responders i( < PASI-50) will have the option of adding topical therapies and/or phototherapy to their Apremilast treatment regimen. At Week 52, all participants will continue treatment with apremilast 30 mg BID. Participants will be followed and evaluated for safety and efficacy for up to an additional 4 years (years 2 through 5).
11517464|NCT01232270|Active Comparator|fentanyl|
11517465|NCT01232270|Placebo Comparator|saline|
11517466|NCT01232257|Experimental|Healthy volunteers|
11517467|NCT01232257|Experimental|CKD patients|Patients with CKD stage 3-4 (GFR 15-60 ml/min)
11517468|NCT01232257|Experimental|Hemodialysis patients|
11517469|NCT01232257|Experimental|Peritoneal dialysis patients|
11517470|NCT01232244||Healthy young males|
11517471|NCT01232231|Active Comparator|decolonization treatment|topical antiseptic, intranasal antimicrobial, and oral antimicrobial that have activity against MRSA in addition to education regarding personal hygiene and environmental cleaning
11517472|NCT01232231|Other|education|No decolonization treatment in addition to education regarding personal hygiene and environmental cleaning
11517473|NCT01232218|Active Comparator|Current Standard Treatment|Current standard treatment for hemiplegic shoulder pain will be provided to this group.
11517474|NCT01232218|Experimental|Standard treatment + study technique|Participants will receive current standard treatment for hemiplegic shoulder pain PLUS an additional stretching/strengthening technique. Both groups will be allotted the same treatment time.
11517475|NCT01232205|Active Comparator|micronutrient antioxidant|Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium
11517476|NCT01232205|Placebo Comparator|Control|
11517477|NCT01232192|No Intervention|Antenatal model|
11517478|NCT01232192|Experimental|Antenatal Model|
11517479|NCT01232179|Active Comparator|conventional prp|
11517480|NCT01232179|Active Comparator|targeted PRP|
11517481|NCT01232166|Experimental|Endobronchial Intubation, Auscultation|In this arm, the endotracheal tube will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. The study anesthesiologists will then perform bilateral auscultation of the lungs only, with the patient's thorax and head covered with blankets to blind participants to thorax movements and ETT insertion depth (Group Auscultation, n=20)
11517482|NCT01232166|Active Comparator|Endobronchial Intubation, Observation|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform observation and palpation of symmetric chest movements without auscultation of the lungs, with the patient's head covered with blankets to blind participants to ETT insertion depth (Group Observation, n=20);
11517483|NCT01232166|Active Comparator|Endobronchial intubation, tube depth|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then estimate ETT position by observing the ETT cm scale without lung auscultation, with the patient's thorax covered by blankets to blind participants to thorax movements (Group Tube Depth, n=20)
11517484|NCT01232166|Active Comparator|Endobronchial intubation, all three|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform a combination of auscultation, observation and tube depth
11517576|NCT01231594|Experimental|Cohort C|Subjects who have received >8 weeks of continuous treatment with GSK2118436 in combination with a MEK inhibitor, GSK1120212
11517577|NCT01231581|Experimental|GSK1120212 plus Gemcitabine|GSK1120212 administered orally plus gemcitabine IV
11517485|NCT01232166|Experimental|Endotracheal Intubation, Auscultation|In this arm, the endotracheal tube will be positioned in the trachea, 2,5-4cm above the carina under direct visualization through a fiberoptic bronchoscope. The study anesthesiologists will then perform bilateral auscultation of the lungs only, with the patient's thorax and head covered with blankets to blind participants to thorax movements and ETT insertion depth (Group Auscultation, n=20)
11517486|NCT01232166|Active Comparator|Endotracheal Intubation, observation|In this arm, the endotracheal tube (ETT) will be positioned in the trachea, 2,5-3cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform observation and palpation of symmetric chest movements without auscultation of the lungs, with the patient's head covered with blankets to blind participants to ETT insertion depth (Group Observation, n=20);
11517487|NCT01232166|Active Comparator|Endotracheal intubation, tube depth|In this arm, the endotracheal tube (ETT) will be positioned in the trachea, 2,5 - 4 cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then estimate ETT position by observing the ETT cm scale without lung auscultation, with the patient's thorax covered by blankets to blind participants to thorax movements (Group Tube Depth, n=20)
11517488|NCT01232166|Active Comparator|Endotracheal intubation, all three|In this arm, the endotracheal tube (ETT) will be positioned 2,5-4cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform a combination of auscultation, observation and tube depth
11517489|NCT01232153|Active Comparator|NIV preoxygenation|
11517490|NCT01232153|No Intervention|Classical preoxygenation|
11517491|NCT01232140|Experimental|CRP-guided antibiotic treatment|If CRP> 50 mg/l a patient receive antibiotic treatment, whereas in those patients with CRP =< 50 mg/l antibiotic treatment is withheld.
11517492|NCT01232140|Other|GOLD strategy-antibiotic treatment|According to the GOLD strategy a patient with an AECOPD should prescribed antibiotic treatment if a patient has symptoms of increased dyspnea, increased sputum production and change of sputum color. Two of these three criteria should be present, however change in sputum production is obligatory.
11517493|NCT01232127|Other|Atazanavir/ritonavir (300/100 mg) + TDF + ≥ 1 NRTI|The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
11517494|NCT01232127|Other|Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (20)|FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
11517495|NCT01232127|Other|Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (40)|FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
11517496|NCT01232101|Active Comparator|covered self expandable metallic stents|Patients with bile malignant bile duct strictures are randomized to covered or uncovered stent
11517497|NCT01232101|Active Comparator|Uncovered self expandable metallic stent|
11517498|NCT01232088||Data collection group: ICU physicians|Online survey for ICU physicians (members of the European Society of Intensive Care Medicine (ESICM)).
11517499|NCT01232075|Experimental|Extended letrozole regimen|
11517500|NCT01232075|Active Comparator|Clomiphene citrate regimen|
11517501|NCT01232049|Experimental|A|Pitavastatin 4mg
11517502|NCT01232049|Experimental|B|Valsartan 320mg
11517503|NCT01232049|Experimental|C|Pitavastatin 4mg + Valsartan 320mg
11517504|NCT01232036|Active Comparator|A|Reference
11517505|NCT01232036|Experimental|B|Test
11517506|NCT01232036|Placebo Comparator|C|Placebo
11517507|NCT01232023|Experimental|100mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
11517508|NCT01232023|Experimental|200mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
11517509|NCT01232023|Experimental|400mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
11517510|NCT01232023|Experimental|800mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
11517511|NCT01232010|Experimental|Healthy Volunteers|
11517512|NCT01232010|Experimental|Patients with severe renal impairment|
11517513|NCT01231997|Experimental|Healthy Volunteers|
11517514|NCT01231997|Experimental|Patients with mild renal impairment|
11517515|NCT01231997|Experimental|Patients with moderate renal impairment|
11517516|NCT01231997|Experimental|Patients with severe renal impairment|
11517517|NCT01231984|Experimental|4 mm vs. 8 mm|Subjects randomized to this study arm first used either the 4 mm x 32G Pen Needle or the 8mm x 31G Pen Needle for 12 weeks (Period 1), then switched to the alternate pen needle (PN) for another 12 weeks (Period 2). Order of PN use was randomly determined.
11517518|NCT01231984|Experimental|4 mm vs. 12.7 mm|Subjects randomized to this study arm first used either the 4 mm x 32G Pen Needle or the 12.7mm x 29G Pen Needle (PN) for 12 weeks (Period 1), then switched to the alternate PN for another 12 weeks (Period 2). Order of PN use was randomly determined.
11517519|NCT01231971||Cognitively Normal (CN)|150 newly enrolled participants with no apparent memory problems, and CN participants followed from the ADNI1 study
11517520|NCT01231971||Early Mild Cognitive Impairment (EMCI)|100 newly enrolled early amnestic MCI participants, and approximately 200 EMCI participants will be followed from the ADNI-GO study
11517521|NCT01231971||Late Mild Cognitive Impairment (LMCI)|150 newly enrolled late MCI participants, and LMCI participants followed from the ADNI1 study
11517522|NCT01231971||Alzheimer's Disease (AD)|150 newly enrolled mild AD participants
11517523|NCT01231971||Significant Memory Concern (SMC)|100 newly enrolled participants with Significant Memory Concern (SMC)
11517524|NCT01231932||Cancer survivors|Individuals recently completed primary treatment for cancer
11517525|NCT01231932||Individuals receiving cancer treatment|Individuals receiving cancer treatment
11517526|NCT01231932||Individuals with cancer|Individuals with cancer
11517527|NCT01231919|Experimental|Treatment (Akt inhibitor)|Patients receive oral Akt inhibitor MK2206 every other day (schedule 1) OR once weekly (schedule 2) on days 1-28. Treatment repeats every 28 days for up 12 courses (1 year) in the absence of disease progression or unacceptable toxicity.
11517578|NCT01231581|Active Comparator|Placebo plus Gemcitabine|Placebo administered orally plus gemcitabine IV
11517783|NCT01230203|Other|Computed tomography scan versus color duplex ultrasound|
11517528|NCT01231906|Experimental|Arm I (combination chemotherapy)|"INDUCTION THERAPY: Patients receive vincristine sulfate (IV) on day 1 in weeks 1, 2, 5, 6, 9, and 10; doxorubicin hydrochloride IV on days 1 and 2 and cyclophosphamide IV over 30-60 minutes on day 1 in weeks 1, 5, and 9; and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 in weeks 3, 7, and 11.
~CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 7, 8, 9, 10, 13, 14, 17, 18, 21, and 22; doxorubicin hydrochloride IV on days 1 and 2 in weeks 1 and 9; cyclophosphamide IV over 30-60 minutes on day 1 in weeks 1, 7, 9, 13, 17, and 21; and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 in weeks 3, 5, 11, 15, and 19."
11517529|NCT01231906|Experimental|Arm II (combination chemotherapy, topotecan hydrochloride)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 5, 6, 9, 10, 11 and 12; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 9; cyclophosphamide IV over 15-60 minutes on days 1-5 in weeks 1 and 9, and on day 1 of weeks 5 and 11; ifosfamide and etoposide as in arm I; and doxorubicin hydrochloride IV on days 1 and 2 in weeks 5 and 11.
~CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 7-10, 13-16, 19, and 20; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1, 7, and 15; cyclophosphamide IV over 15-60 minutes on days 1-5 in weeks 1, 7, and 15, and on day 1 in weeks 9, 13, and 19; ifosfamide IV over 1 hour and etoposide IV over 1- 2 hours on days 1-5 in weeks 3, 5, 11, 17, and 21; and doxorubicin hydrochloride IV on days 1 and 2 in weeks 9,13, and 19."
11517530|NCT01231893|Experimental|olfactory ensheathing cell recipient|
11517531|NCT01231893|Active Comparator|control|
11517532|NCT01231880|Experimental|Four monthly IPT|IPT give once a school term (every four months)
11517533|NCT01231880|Experimental|Monthly IPT|IPT given every month
11517534|NCT01231880|Placebo Comparator|Placebo|No active drug in the placebo
11517535|NCT01231854|Active Comparator|Ciclosporingroup|
11517536|NCT01231854|Active Comparator|Alitretinoingroup|
11517537|NCT01231841|Experimental|rATG + Cyclosporine|Patients receive anti-thymocyte globulin IV daily over 4-24 hours on days 1-5. Beginning on day 6, patients receive oral cyclosporine twice daily for 6 months followed by a taper. Treatment continues in the absence of disease progression or unacceptable toxicity
11517538|NCT01231828|Experimental|Carnitine|Versus placebo.
11517539|NCT01231828|Experimental|Lactulose|Versus placebo
11517540|NCT01231815|Experimental|PET|15O-H2O PET
11517541|NCT01231815|Experimental|MRI|MRI
11517542|NCT01231802|Experimental|Arm 1: Eniluracil/5-FU/Leucovorin|Arm 1: (weekly, 28-day cycle): Approximately eighty subjects will orally self-administer eniluracil approximately 13 hr (range of 11-16 hr) before receiving 5 FU and leucovorin. The next day they will orally self-administer 5-FU and leucovorin. On the third day, they will orally self-administer leucovorin. The regimen is taken once per week for three consecutive weeks followed by one-week off-treatment.
11517543|NCT01231802|Active Comparator|Arm 2: Capecitabine|Arm 2: (bid daily, 21-day cycle): Approximately sixty subjects will self-administer oral capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
11517544|NCT01231789|Sham Comparator|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min.
11517545|NCT01231789|Experimental|RIPC treatment|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
11517546|NCT01231776|No Intervention|control group|
11517547|NCT01231776|Active Comparator|acupuncture preoperative|acupuncture before operation for one week
11517548|NCT01231776|Active Comparator|acupuncture in hospital|acupuncture all the time in hospital
11517549|NCT01231763||Healthy volunteers|
11517550|NCT01231750|Active Comparator|0.1% Capsaicin Cream|0.1% capsaicin cream spread 8cm x 15cm on abdomen, once, 45 minutes prior to exercise
11517551|NCT01231750|Placebo Comparator|Placebo Cream|Inactive cream, 4cm spread 8cm x 15cm on the abdomen, once, 45 minutes prior to exercise
11517552|NCT01231737|Active Comparator|Prulifloxacin|
11517553|NCT01231724|Active Comparator|Allstate Nasal Spray|
11517554|NCT01231724|Placebo Comparator|Placebo Nasal Spray|
11517555|NCT01231711|Experimental|Vets Prevail|N=50. Participants were recent veterans (deployed after September 11, 2001) of operations in Iraq and Afghanistan who were experiencing depression/distress symptoms at the time of screening (CES-D > 8) but who were not considered to be inappropriate for a health promotion intervention (CES-D > 35 indicating severe depressed mood or exhibiting self-harm risk).
11517556|NCT01231698|Experimental|esmolol|
11517557|NCT01231698|Other|control|
11517558|NCT01231685|Active Comparator|ritonavir-boosted protease inhibitor|
11517559|NCT01231685|Experimental|Raltegravir|
11517560|NCT01231672||Septic shock patients|
11517561|NCT01231659|Experimental|Everolimus + Letrozole|Everolimus 10 mg + Letrozole 2.5 mg
11517562|NCT01231646||Lamotrigine|No intervention
11517563|NCT01231646||Valproate|No intervention
11517564|NCT01231633|Experimental|Group 1|Subjects randomized to this arm will receive one initial treatment with Ozurdex then treated with Avastin if needed.
11517565|NCT01231633|Active Comparator|Group 2|Subjects randomized to this arm will receive one initial treatment with Avastin then treated with Avastin if needed.
11517566|NCT01231620|Experimental|Intravenous (IV) Zanamivir 300mg Twice Daily|300mg of IV zanamivir infusion twice daily plus oral oseltamivir placebo twice daily
11517567|NCT01231620|Experimental|Intravenous (IV) Zanamivir 600mg Twice Daily|600mg of IV zanamivir infusion twice daily plus oral oseltamivir placebo twice daily
11517568|NCT01231620|Active Comparator|Oral Oseltamivir 75mg Twice Daily|75mg oral oseltamivir twice daily plus intravenous placebo zanamivir twice daily
11517569|NCT01231607|Active Comparator|1mg Finasteride|1mg finasteride active plus dutasteride placebo, by mouth once daily
11517570|NCT01231607|Active Comparator|0.02mg Dutasteride|0.02mg dutasteride active plus finasteride placebo, by mouth once daily
11517571|NCT01231607|Active Comparator|0.1mg Dutasteride|0.1mg dutasteride active plus finasteride placebo, by mouth once daily
11517572|NCT01231607|Active Comparator|0.5mg Dutasteride|0.5mg dutasteride active plus finasteride placebo, by mouth once daily
11517573|NCT01231607|Placebo Comparator|Placebo|1mg finasteride placebo plus dutasteride placebo, by mouth once daily
11517579|NCT01231568|Experimental|Cohort 1 Treatment Sequence 1|Subjects will receive two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 1 and two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
11517580|NCT01231568|Experimental|Cohort 1 Treatment Sequence 2|Subjects will receive two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 1 and two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
11517581|NCT01231568|Experimental|Cohort 2 Treatment Sequence 1|Subjects will receive two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 1 and two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
11517582|NCT01231568|Experimental|Cohort 2 Treatment Sequence 2|Subjects will receive two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 1 and two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
11517583|NCT01231555|Experimental|GSK2248761 100 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
11517584|NCT01231555|Experimental|GSK2248761 200 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
11517585|NCT01231555|Active Comparator|Efavirenz 600 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
11517586|NCT01231542|Experimental|Arm 1|Subjects will have a screening visit within 30 days prior to the first dose of study drug, three treatment periods, and a follow-up visit 7-14 days after the last dose of study drug. Subjects enrolled in Arm 1 will receive GSK1349572 50 mg once daily for 7 days, GSK1348572 50 mg twice daily for 7 days, and GSK1349572 50 mg twice daily in combination with rifampin 600 mg once daily for 14 days.
11517587|NCT01231542|Experimental|Arm 2|Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug. Subjects in Arm 2 will receive GSK1349572 50 mg once daily for 7 days and GSK1349572 50 mg once daily in combination with rifabutin 300 mg once daily for 14 days.
11517588|NCT01231529|Experimental|Part 1 Cohort 1|8 subjects with moderate hepatic impairment defined by a Child-Pugh score of 7 to 9 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug.
11517589|NCT01231529|Experimental|Part 1 Cohort 2|8 healthy subjects matched by gender, age and BMI to the subjects in Cohort 1 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug.
11517590|NCT01231529|Experimental|Part 2 Cohort 3|8 subjects with mild hepatic impairment defined by a Child-Pugh score of 5 to 6 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug. This cohort will only be done if the AUC from Cohort 1 is greater than or equal to 2 times the AUC from Cohort 2.
11517591|NCT01231529|Experimental|Part 2 Cohort 4|8 healthy subjects matched by gender, age and BMI to the subjects in Cohort 3 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug. This cohort will only be done if the AUC from Cohort 1 is greater than or equal to 2 times the AUC from Cohort 2.
11517592|NCT01231516|Experimental|GSK1349572 + Raltegravir Placebo|Subjects will receive GSK1349572 50mg once daily plus raltegravir placebo twice daily.
11517593|NCT01231516|Active Comparator|Raltegravir + GSK1349572 Placebo|Subjects will receive raltegravir 400mg twice daily plus GSK1349572 placebo once daily.
11517594|NCT01231503|Experimental|RTS,S Neo-10-14 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) when ≤ 7 days of age and at 10 and 14 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
11517595|NCT01231503|Experimental|RTS,S Neo-10-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) when ≤ 7 days of age and at 10 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanri xHepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
11517596|NCT01231503|Experimental|RTS,S 6-10-14 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 14 weeks of age In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
11517698|NCT01230853|Placebo Comparator|Placebo Comparator A|
11517699|NCT01230853|Active Comparator|Active Comparator: B|
11517700|NCT01230853|Placebo Comparator|Placebo Comparator B|
11517597|NCT01231503|Experimental|RTS,S 6-10-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
11517598|NCT01231503|Experimental|Engerix-B Neo/RTS,S 6-10-26 Group|Subjects received one dose of Engerix-B (HBV) when ≤ 7 days of age followed by 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 26 weeks of age In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E and HBV vaccines were administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
11517599|NCT01231503|Experimental|RTS,S 10-14-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 10, 14 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
11517600|NCT01231503|Experimental|RTS,S 14-26-9M Group|Subjects received 3 doses of RTS,S/AS01E (or GSK257049) at 14 and 26 weeks of age and at 9 months of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when below ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
11517601|NCT01231503|Active Comparator|Engerix-B Neo Group|Subjects in this group received one dose of Engerix-B (HBV) ≤ 7 days of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when below ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The HBV vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
11517602|NCT01231490|Experimental|Active|
11517603|NCT01231490|Placebo Comparator|Placebo|
11517604|NCT01231477||Volunteers|Healthy volunteers not submitted to anesthesia nor surgery.
11517605|NCT01231477||Sevoflurane Group|This group was submitted to inhalational anesthesia with sevoflurane and otorhinolaryngological surgery.
11517606|NCT01231464|Placebo Comparator|placebo|vehicle placebo nasal spray
11517607|NCT01231464|Experimental|FFNS|fluticasone furoate nasal spray
11517608|NCT01231451|Experimental|All Subjects|All Subjects will receive the same intervention
11517609|NCT01231438|Experimental|Renvela|Treatment for 2 weeks
11517610|NCT01231438|Experimental|Etalpha|Vit D Treatment for 2 weeks
11517611|NCT01231425||With usual concomitant treatment|Two observational cohorts of patients will be evaluated: with and without concomitant analgesic/ antiinflammatory drugs. The objective is evaluate that both therapies (drugs and acupuncture) could be used as adjunctive therapy in order to maximize the analgesia that could be reached
11517612|NCT01231425||Without usual concomitant treatment|This group include patients that are not been treated with analgesic drugs at the beginning of the study. As an observational and naturalistic study any indicated treatment is allowed in any time
11517613|NCT01231412|Active Comparator|Arm I (MMF and CSP)|Patients receive FLU IV over 30 minutes on days -4 to -2. Patients also receive CSP PO BID on days -3 to 96 with taper to day 150 and MMF PO TID daily on days 0-29 and then BID on days 30-150 with taper to day 180. Patients undergo allogeneic PBSCT on day 0 following the TBI.
11517614|NCT01231412|Experimental|Arm II (MMF, CSP, and Sirolimus)|Patients receive FLU and CSP as in Arm I and sirolimus PO QD on days -3 to 150 with taper to day 180. Patients also receive MMF PO TID on days 0-29 and then BID on days 30-40. MMF will then be discontinued without taper unless GVHD or disease relapse/progression occurs. Patients undergo allogeneic PBSCT on day 0 following the TBI.
11517615|NCT01231412|Experimental|Arm 0 (CSP and Sirolimus)|Patients receive CSP orally (PO) twice daily (BID) on days -3 to 96 with taper to day 150 and and sirolimus PO once daily (QD) on days -3 to 150 with taper to day 180. Arm removed as of 14-Sep-2011
11517616|NCT01231399|Experimental|Arm I|Patients receive fluorouracil IV continuously over 46 hours, leucovorin calcium IV over 2 hours, and oxaliplatin IV over 2 hours on day 1. Patients also receive oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11517617|NCT01231373|Experimental|polidocanol injectable foam, 0.125%|
11517618|NCT01231373|Experimental|polidocanol injectable foam, 0.5%|
11517619|NCT01231373|Experimental|polidocanol injectable foam, 1.0%|
11517620|NCT01231373|Placebo Comparator|Vehicle|
11517701|NCT01230840|Placebo Comparator|placebo|Control cookies will contain no wheat dextrin and will be taken 3 times daily for 2 weeks.
11517782|NCT01230216|Active Comparator|standard blood pressure control|systolic blood pressure less than 140 mmHg
11517621|NCT01231360|Active Comparator|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
11517622|NCT01231360|Active Comparator|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
11517623|NCT01231347|Active Comparator|AMG 479 12 mg/kg dose + gemcitabine|Arm 2: AMG 479 12 mg/kg IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
11517624|NCT01231347|Placebo Comparator|Placebo + gemcitabine|Arm 1: AMG 479-placebo IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
11517625|NCT01231347|Active Comparator|AMG 479 20 mg/kg + gemcitabine|Arm 3: AMG 479 20 mg/kg IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
11517626|NCT01231334|Active Comparator|Aczone® Gel 5% plus Differin® 0.3% Gel|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
11517627|NCT01231334|Active Comparator|Duac® Topical Gel plus Differin® 0.3% Gel|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks.
11517628|NCT01231321|Experimental|adalimumab|Adalimumab / pre-filled syringe 40 mg/0.8 ml
11517629|NCT01231308|Active Comparator|Lifestyle modification|Intensive nutritional/exercise counseling for weight loss by lifestyle modification in addition to optimum medical treatment.
11517630|NCT01231308|Experimental|Roux-en-Y-Gastric Bypass|A laparoscopic gastric bypass will be performed in the treatment of type 2 diabetes in Overweight-to-Moderately Obese Patients
11517631|NCT01231295||Memory problems|Group with clinically validated memory problems
11517632|NCT01231295||Reference group|Group without memory problems
11517633|NCT01231282|Experimental|diffusion-weighted MRI|MRI
11517634|NCT01231269|Experimental|MRI|diffusion-weighted MRI
11517635|NCT01231256|Experimental|preventive health consultation|Half participants randomized to a one hour preventive health consultation with their own general practitioner and a follow up consultation 3 months later
11517636|NCT01231256|No Intervention|Control|Controls are not offered preventive health consultations, but had questionnaires as the intervention arm
11517637|NCT01231243|Active Comparator|35% hydrogen peroxide control|The tooth bleaching will be performed using a high hydrogen peroxide concentration (35%) without light-activation with LED/light device
11517638|NCT01231243|Active Comparator|20% hydrogen peroxide|The tooth bleaching will be performed with a low hydrogen peroxide concentration (20%) without light activation with a LED/laser device
11517639|NCT01231243|Experimental|35% hydrogen peroxide + light|The tooth bleaching will be performed with a high hydrogen peroxide concentration (35%) associated with LED/laser light activation
11517640|NCT01231243|Experimental|20% hydrogen peroxide + light|The tooth bleaching will be performed with a low hydrogen peroxide concentration (20%) associated with LED/laser light activation
11517641|NCT01231230|Experimental|fluticasone/salmeterol|participants were treated fluticasone/salmeterol,
11517642|NCT01231230|Experimental|salmeterol|participants were treated with salmeterol
11517643|NCT01231230|Experimental|fluticasone|participants were treated with fluticasone
11517644|NCT01231230|Placebo Comparator|placebo inhalation|participants were treated with placebo
11517645|NCT01231217|Other|green (or white) tea|Patients are recommended to drink green (or white) tea but are not allowed to consume any coffee
11517646|NCT01231217|Other|coffee|Patients are recommended to drink coffee but are not allowed to consume any tea
11517647|NCT01231204|Placebo Comparator|Placebo Infusion|Patients will be randomized to receive a continuous infusion of Normal Saline via a Paravertebral Nerve Block.
11517648|NCT01231204|Active Comparator|Ropivicaine 0.4% Infusion|Patients will be randomized to receive a continuous infusion of 0.4% Ropivicaine via a Paravertebral Nerve Block.
11517649|NCT01231191|Active Comparator|IV Acetaminophen|Intraoperative IV acetaminophen administered
11517650|NCT01231191|Placebo Comparator|IV Placebo|Intraoperative IV normal saline administered
11517651|NCT01231178|Active Comparator|Alginate based beverage|
11517652|NCT01231178|Placebo Comparator|Control beverage|
11517653|NCT01231165|Experimental|Amiloride,nitrates,clopidogrel,aspirin,statins|Comparative Efficacious Research
11517654|NCT01231165|Active Comparator|Nitrates, clopidogrel, aspirin, statins|Comparative Efficacious Research
11517655|NCT01231139|Experimental|Paracetamol|Paracetamol dissolved in 0.9% Sodium Chloride
11517656|NCT01231139|Placebo Comparator|0.9% Sodium Chloride|0.9% Sodium Chloride
11517657|NCT01231126|Placebo Comparator|spontaneous vaginal deliveries|
11517658|NCT01231126|Placebo Comparator|elective caesarians|
11517659|NCT01231126|Experimental|induced vaginal delivery by misoprostol|
11517660|NCT01231126|Experimental|caesarians section with induction attempt|
11517661|NCT01231113|Active Comparator|artesunate-amodiaquine arm|A co-blistered pack of amodiaquine and artesunate.The 452 pregnant women in this arm will receive artesunate-amodiaquine tablets(artesunate 4mg/kg and amodiaquine 10mg/kg in twelve hourly doses over 3 days
11517662|NCT01231113|Experimental|Dihydroartemisinin-piperaquine arm|a fixed-dose combination to be administered to the other 452 pregnant women in this arm at an estimated total dosing of 6.75mg/kg dihydroartemisinin and 55mg/kg piperaquine over 3 days
11517663|NCT01231100|Experimental|HCUE-guided care|Hand-carried ultrasound echocardiography
11517664|NCT01231100|No Intervention|Standard care|
11517781|NCT01230216|Active Comparator|intensive blood pressure control|systolic blood pressure less than 120 mmHg
11517665|NCT01231074|Experimental|Psychotropic/metformin (PIW)|"Inclusion Criteria:Psychotropic/metformin (PIW) Cohort: Children aged 10-17 years on psychotropic* medication with reported weight gain defined by 1 of the following: 1. >5% weight increase from the start of medication to 3 months on medication 2. Crossing into the 95th percentile for BMI 3. Crossing into the 85-95th percentile plus one obesity related complication
~The subject will have to be on one of these medications in addition to the criteria above to be eligible for the study: haloperidol, perphenazine, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, thioridazine, fluphenazine, loxapine, mesoridazine, thiothixene or trifluoperazine"
11517666|NCT01231074|Experimental|Obese/metformin (OME)|Obese/metformin (OME) cohort: Children 10-17 years old with BMI >95th percentile and fasting insulin level>21.7U/L
11517667|NCT01231061|Experimental|Arm A: SBRT|
11517668|NCT01231061|Experimental|Arm B: Radiosurgery|
11517669|NCT01231009|Active Comparator|Corticosteroids|Patients receive for 7 days intravenous corticosteroids, dexamethasone, and they continue receiving for 7 days corticosteroids per os
11517670|NCT01231009|Placebo Comparator|Vestibular exercises|Patients perform for 15 days certain vestibular exercises under suspicion of an expert physiotherapist
11517671|NCT01230996|Experimental|Dose escalation study|This is a dose escalation study of IMRT for women with locally advanced cervical cancer. Three dose levels will be investigated, (although, the first dose level is considered to be the equivalent to a standard pelvic dose with parametrial boost). Before moving to the next dose level it must be confirmed by the Chief Investigator that the Maximum Administrable Dose (MAD) has not been met in the previous dose level (see section 6.3). If MAD is reached before dose level 3 the study will stop. All patients enrolled on the study will undergo the same procedures at the same time points, regardless of the dose level they are being given (see section 5).
11517672|NCT01230983|Experimental|Treatment 1: (No HD MTX / No Zinecard)|Closed 09/2000 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), methotrexate/cytarabine), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, IT methotrexate /cytarabine radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), IT methotrexate/cytarabine)
11517673|NCT01230983|Active Comparator|Treatment 2: (No HD MTX / Zinecard)|Closed 09/2000 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), methotrexate/cytarabine, dexrazoxane hydrochloride (Zinecard or DZR)), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, dexrazoxane hydrochloride (Zinecard or DZR), IT methotrexate /cytarabine, radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), IT methotrexate/cytarabine)
11517674|NCT01230983|Active Comparator|Treatment 3: (HD MTX / No Zinecard)|Closed 09/2001 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), leucovorin calcium (LCV), HD methotrexate/cytarabine), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, leucovorin calcium (LCV), HD methotrexate /cytarabine radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), HD methotrexate/cytarabine)
11517675|NCT01230983|Active Comparator|Treatment 4: (HD MTX / Zinecard)|Closed 09/2001 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), leucovorin calcium (LCV), HD methotrexate/cytarabine, dexrazoxane hydrochloride (Zinecard or DZR)), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, HD methotrexate /cytarabine, dexrazoxane hydrochloride (Zinecard or DZR), radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), HD methotrexate/cytarabine)
11517676|NCT01230970|Experimental|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
11517677|NCT01230957|Experimental|Group 1|Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
11517678|NCT01230957|Experimental|Group 2|Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
11517679|NCT01230957|Experimental|Group 3|Participants will receive a dose High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
11517680|NCT01230957|Experimental|Group 4|Participants will receive a dose High-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
11517681|NCT01230957|Placebo Comparator|Group 5|Participants will receive a dose Placebo (0.9% normal saline) on Day 0, 7, and 30, respectively.
11517682|NCT01230957|Experimental|Group 6|Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 180, respectively.
11517683|NCT01230957|Experimental|Group 7|Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 30, and 180, respectively.
11517684|NCT01230944|Active Comparator|Laparoscopic Nissen|Laparoscopic Nissen fundoplication
11517685|NCT01230944|Active Comparator|Open Nissen|Open (conventional) Nissen fundoplication
11517686|NCT01230931|Experimental|Vitagel and Standard of Care|This group of patients will receive the vitagel topical surgical hemostat spray intra-operatively, along with all the other standards of care.
11517687|NCT01230931|Active Comparator|Standard of Care|This group of patients will receive the standard of care for hemostasis in acetabular surgery (electrocautery/ligation of bleeding vessels, fracture reduction and stabilization, cell-saver, lap packing). They will not receive the vitagel product.
11517688|NCT01230918|Experimental|Diagnostic Imaging|A single dose of 800 to 1100 mBq of 99mTc-NC100692 radiopharmaceutical will be injected. Serial cardiac nuclear imaging will be done over a 3 hour period.
11517689|NCT01230905|Other|MPI nuclear scan|Nuclear MPI for CAD for prostate cancer subjects undergoing treatment and development of normal comparison.
11517690|NCT01230892|Active Comparator|Nebivolol|
11517691|NCT01230892|Active Comparator|Atenolol|
11517692|NCT01230879|Experimental|60 - 70 years old|EFR and TDM
11517693|NCT01230879|Experimental|71 - 80 years old|EFR and TDM
11517694|NCT01230879|Experimental|81 - 95 years old|EFR and TDM
11517695|NCT01230866|Other|Proton Radiation Hypofractionation|5 fractions (7.6 Gy(RBE) x 5)
11517696|NCT01230866|Active Comparator|Proton Radiation Standard Fractionation|44 fractions (1.8 Gy(RBE) x 44)
11517697|NCT01230853|Active Comparator|Active Comparator: A|
11517702|NCT01230840|Experimental|wheat dextrin|wheat dextrin (formulated according to the supporter's established method), will be baked in cookies providing three doses per day (≈5 gram of wheat dextrin in each dose)for 2 weeks.
11517703|NCT01230827|Experimental|CNTO 148 (Golimumab)|All patients will receive golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 12. Patients who have a clinical response at Week 16 and who are randomly allocated to golimumab, will receive 30 mg per square meter every 4 weeks through Week 48. Patients will continue to receive golimumab 30 mg per square meter after Week 48 in a long-term extension until Week 248. All patients will receive their fixed dose of commercial methotrexate throughout the study duration.
11517704|NCT01230827|Placebo Comparator|Placebo|All patients will receive golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 12. Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive placebo every 4 weeks through Week 48. However, patients receiving placebo and who will have lack/loss of clinical response will be eligible to receive golimumab 30 mg per square meter every 4 weeks through Week 48. At Week 48, patients do not have a clinical response will begin to receive golimumab 30 mg per square meter in a long-term extension until Week 248 and patients who have a clinical response will be discontinued from the study. All patients will receive their fixed dose of commercial methotrexate throughout the study duration.
11517705|NCT01230814|Experimental|Arm 1|Intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) nightly for 5 consecutive nights each month; 117 Subjects.
11517706|NCT01230814|Placebo Comparator|Arm 2|Placebo suppositories nightly for five consecutive nights each month; 117 Subjects.
11517707|NCT01230801|Experimental|BMN 701|IV infusion
11517708|NCT01230788|Experimental|rituximab|study drug given
11517709|NCT01230775|Experimental|Anagrelide retard|"Week 1:
~1x1 tablet/d of Anagrelide retard (1 tablet = 2mg; total dose = 2mg/d will be administered in week 1.
~Week 2 Anagrelide retard: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.
~Week 3 - Week 4 Anagrelide retard In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.
~Maintenance Phase Anagrelide retard During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range.
~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/d"
11517710|NCT01230775|Placebo Comparator|Placebo|"Week 1:
~x1 tablet/d of Placebo will be administered in week 1.
~Placebo:
~x1 tablet/d of placebo will be administered in week 2.
~Placebo:
~In week 3 and week 4 the maximum dose is 4 tablets per day.
~Placebo:
~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:
~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/d"
11517711|NCT01230762|Experimental|001|dapoxetine 60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
11517712|NCT01230749|Experimental|JNJ-41443532 250 mg|Participants will receive JNJ-41443532 250 mg in morning and evening for 28 days.
11517713|NCT01230749|Experimental|JNJ-41443532 1000 mg|Participants will receive JNJ-41443532 1000 mg (4 X 250 mg) in morning and evening for 28 days.
11517714|NCT01230749|Active Comparator|Pioglitazone|Participants will receive pioglitazone 30 mg in morning for 28 days.
11517715|NCT01230749|Placebo Comparator|Placebo|Participants will receive matching placebo for JNJ-41443532 and pioglitazone for 28 days.
11517716|NCT01230736|Experimental|DuoTrav|One drop in study eye(s) once daily for 8 weeks
11517717|NCT01230723|Active Comparator|Arm 1|Everolimus-Eluting Stent
11517718|NCT01230723|Active Comparator|Arm 2|Zotarolimus-Eluting-Stent
11517719|NCT01230710|Experimental|Erlotinib|Participants received erlotinib 150 mg orally once a day for 48 weeks.
11517720|NCT01230697||Sofanenib and Hypophosphatemia|Patients with advanced renal cells carcinoma and hepatocarcinoma in treatment with Sorafenib
11517721|NCT01230684|Other|Endoleak imaging|In the single arm all participants are recieving both imaging techniques; CEUS and CTA
11517722|NCT01230671|Experimental|Yoga|Patients in this arm will receive yoga therapy
11517723|NCT01230671|Placebo Comparator|No yoga|Patients will not have yoga in this arm
11517724|NCT01230645|Experimental|RV568 treatment group|
11517725|NCT01230645|Placebo Comparator|Placebo treatment group|
11517726|NCT01230632|Experimental|Dietary Supplement|3 days high fat food
11517727|NCT01230619|Experimental|RV568 treatment group|
11517728|NCT01230619|Placebo Comparator|Placebo treatment group|
11517729|NCT01230606||overnight|Subjects that stay overnight at the hospital.
11517730|NCT01230606||Next Day Discharge|Subjects that are discharged on the same day of the procedure.
11517731|NCT01230593|Active Comparator|Hot Compress|"Hot Compress"
11517732|NCT01230593|Active Comparator|Tobrex|"Hot Compress, Tobrex Drops, Tobrex Ointment"
11517733|NCT01230593|Active Comparator|Tobradex|"Hot Compress, Tobradex Drops, Tobradex Ointment"
11517734|NCT01230580|Experimental|Protease Inhibitor Monotherapy|Ritonavir-boosted protease inhibitor
11517735|NCT01230580|Active Comparator|Control|Standard-of-care triple-therapy regimen
11517736|NCT01230554|Experimental|Prism I|Bausch & Lomb daily disposable cosmetic tint contact lens
11517737|NCT01230541|Placebo Comparator|Placebo|Placebo
11517738|NCT01230541|Active Comparator|Udenafil|Udenafil daily tablet
11517739|NCT01230515||Caregiver|Family members will be asked to complete a demographic survey, an assessment of the patient's current pain, and a series of questionnaires including: Caregiver Pain Medicine Questionnaire, the Stressful Caregiving Adult Reactions To Experiences of Dying Scale, and the Caregivers' Self Efficacy in Pain Management Questionnaire. Upon completion of the questionnaires, patients and caregivers will be interviewed separately.
11517740|NCT01230515||Hospice staff|Hospice staff will be asked to complete the Pain Knowledge and Attitudes survey. They will also complete the Technology Acceptance Model (TAM) questionnaire to assess the perceived utility of an opioid titration order sheet to help manage pain control. A demographic survey will also be completed.
11517741|NCT01230515||Referring physician|Referring physicians will be asked to complete the Pain Knowledge and Attitudes survey as well as the TAM questionnaire and Demographic Survey.
11517742|NCT01230515||Patient|Demographic information includes education, marital status, number in household, and employment status will be obtained from patient. Clinical data will be obtained from the patient's medical records. Information to be obtained will include information about the type of cancer, stage of disease, time since diagnosis, current treatment for cancer, type of pain, time since onset of pain, and time of first opioid prescription. The patient will also take a pain assessment survey.
11517743|NCT01230502|Active Comparator|Group 3: Donor Specific Regulation (DSR) -, standard of care|Subjects who test Donor Specific Regulation (DSR) negative will not be randomized to possible tacrolimus withdrawal, and will remain on standard of care immunosuppression.
11517744|NCT01230502|Active Comparator|Group 2 Donor Specific Regulation (DSR) +; standard of care|Subjects that are Donor Specific Regulation (DSR) positive and randomized (1:1) to Group 2 will remain on standard of care immunosuppression.
11517745|NCT01230502|Experimental|Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy|"Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy:
~Subjects that are Donor Specific Regulation (DSR) positive and randomized (1:1) to Group 1 will begin a taper off tacrolimus for 6 months, after repeat DSR testing at 6 months subject will either discontinue tacrolimus if they remain DSR negative or remain at reduced dose if converted to DSR positive"
11517746|NCT01230489|No Intervention|Standard Care|This group will undergo the current standard of care for post operative exit sites at the involved institutions. This group will act as the control or the group to which the interventional group will be compared too.
11517747|NCT01230489|Experimental|MediHoney|This study group will have the dry 2 x 2 dressing replaced with a honey 2 x 2 dressing. Additionally all indentations in the exit site wound will be filled with honey ointment prior to the application of the dressing.
11517748|NCT01230476|Experimental|Cetuximab and chemotherapy|2 cycles of neoadjuvant cisplatin and 5FU (3 weekly), given with weekly cetuximab, followed by 7 doses of weekly cisplatin and cetuximab concurrent with radiotherapy
11517749|NCT01230463|Active Comparator|15 mg ketorolac IV|
11517750|NCT01230463|Active Comparator|30 mg ketorolac IV|
11517751|NCT01230450|Experimental|Single-incision Mini-slings (SIMS- Ajust)|AjustTM has polypropylene fixing anchors (one is fixed and the other adjustable) which are anchored onto the obturator membrane. The pulley like system enables adjustment of the tension once the arms have been anchored. Once in place, the anchors rest at right angles to insertion which is claimed to reduce the chances of anchor dislodgment
11517752|NCT01230450|Other|standared med urethral sling (SMUS)|standard med urethral sling (SMUS)TVT-O, was done as originally described by Deleval et al.
11517753|NCT01230437||asthmatic patients taking montelukast|asthma with or without rhinitis
11517754|NCT01230424|Experimental|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
11517755|NCT01230424|Placebo Comparator|Sodium Chloride|0.9% Sodium chloride injection as Placebo will be given into the study knee once every 12 weeks for a total of 8 injections.
11517756|NCT01230411|Placebo Comparator|placebo|IV saline administration as placebo
11517757|NCT01230411|Experimental|Ibuprofen|IV ibuprofen
11517758|NCT01230385|Experimental|Lersivirine 500 mg QD fasted (wet granulated tablet)|
11517759|NCT01230385|Experimental|Lersivirine 500 mg QD fed (wet granulated tablet)|
11517760|NCT01230385|Experimental|Lersivirine 750 mg QD fasted (wet granulated tablet)|
11517761|NCT01230385|Experimental|Lersivirine 750 mg QD fed (wet granulated tablet)|
11517762|NCT01230385|Active Comparator|Lersivirine 500 mg QD fasted (dry granulated tablet)|
11517763|NCT01230359|Experimental|Vitamin B6 and magnesium|
11517764|NCT01230359|Placebo Comparator|Tang powder group|
11517765|NCT01230346|Experimental|Arm I|Patients receive a culturally-informed adapted motivational interviewing telephone call.
11517766|NCT01230346|Experimental|Arm II|Patients participate in a controlled condition comprising a health habits intervention group.
11517767|NCT01230346|Active Comparator|Arm III|Patients receive usual care comprising a standard scheduling phone call and proceed with normal GCRA process.
11517768|NCT01230320|Experimental|Simplified (S) technique|"Complete dentures fabricated according to a simplified technique, divided into the following four sessions:
~Maxillary and mandibular casts will be obtained from irreversible hydrocolloid impressions made in stock trays.
~Record bases will be adjusted according to vertical dimension and centric relation measurements, without facebow transfer. Casts will be mounted in a semi-adjustable articulator using standardized measures and artificial teeth will be selected.
~Trial dentures will be evaluated for esthetics and maxillomandibular relationships.
~Insertion of finished dentures."
11517769|NCT01230320|Active Comparator|Conventional (C) technique|"Complete dentures fabricated according to a conventional technique:
~Initial impression and the obtainment of custom trays;
~Final impression with border molding using compound;
~Facebow transfer;
~Determination of maxillomandibular relationship;
~Try-in of anterior teeth;
~Try-in of posterior teeth;
~Insertion of finished dentures."
11517770|NCT01230307|Active Comparator|Vitamin D|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
11517771|NCT01230307|Placebo Comparator|Placebo|A placebo loading dose will be given followed by two placebo tablets daily for 6 months.
11517772|NCT01230294||control|participants without structural heart disease
11517773|NCT01230294||CHF|patients with chronic heart failure of the left ventricle affecting the right heart
11517774|NCT01230294||PAH|patients with pulmonary arterial hypertension without left ventricular dysfunction
11517775|NCT01230281|Experimental|Black bean seed coat extract|Daily 1000 mg oral Black bean seed coat extract is given to each subject for 2 weeks from Day2 after measuring antioxidative marker without intervention on Day1.
11517776|NCT01230268|Experimental|Mulberry fruit extract|Daily 1000 mg oral Mulberry fruit extract is given to each subject for 2 weeks from Day2 after measuring antioxidative marker without intervention on Day1.
11517777|NCT01230255|Experimental|Percutaneous catheter decompression|Ultrasound guided percutaneous catheter drainage of free intra-peritoneal fluid or blood
11517778|NCT01230255|Active Comparator|Open abdominal decompression|Surgical treatment of elevated intra-abdominal pressure through traditional open abdominal decompression
11517779|NCT01230229|Active Comparator|Stenting|Active treatment group
11517780|NCT01230229|Placebo Comparator|Conservative treatment|Best medical treatment
11517784|NCT01230190|Active Comparator|Probiotic mixture|participants daily ingest a selected probiotic mixture for a period of 3 months
11517785|NCT01230190|Placebo Comparator|Placebo mixture|controls daily ingest a placebo mixture for a period of 3 months.
11517786|NCT01230177||Etanercept (genetical recombination)|Among the patients with rheumatoid arthritis (only for patients with an inadequate response to prior conventional therapy), the patients who will have changed regimen from 10 mg twice a week administration to 25 mg once a week administration.
11517787|NCT01230151|Active Comparator|Clinical|Stimulation settings predetermined clinically (Clinical)
11517788|NCT01230151|Experimental|Model|stimulation settings derived from a patient-specific computer-based model (Model)
11517789|NCT01230138|Experimental|FP187 - TID|FP187 250mg TID (total daily dose of 750mg)
11517790|NCT01230138|Experimental|FP187- BID|FP187 375mg BID (total daily dose of 750mg)of 750mg administered as 375mg BID
11517791|NCT01230138|Experimental|FP187-LD-BID|FP187 250mg BID (total daily dose of 500mg)
11517792|NCT01230138|Placebo Comparator|Placebo|Placebo treatment
11517793|NCT01230138|Experimental|Open, flexible dosing treatment arm|Open treatment using a flexible dosing schedule for 8 weeks with maximum dose of 750mg FP187 and with a total dosing of 20 weeks. All investigations following same schedule.
11517794|NCT01230125|Experimental|Mapracorat|Ophthalmic suspension 3%
11517795|NCT01230125|Placebo Comparator|Vehicle|Vehicle of mapracorat ophthalmic suspension
11517796|NCT01230099|Experimental|Supportive Information Team Group|Protocolized information and support meetings led by palliative care clinicians
11517797|NCT01230099|No Intervention|Usual Care Group|
11517798|NCT01230086|Active Comparator|ICD implantation only|ICD Implantation without testing of defibrillation threshold testing
11517799|NCT01230086|Active Comparator|Modified upper limit of vulnerability testing|"Modified testing of upper limit of vulnerability"
11517800|NCT01230086|Active Comparator|VF-Induction|traditional VF-induction with T-Wave shock
11517801|NCT01230073|Active Comparator|ICD traditional follow-up|ICD with traditional follow-up in the outpatient clinic
11517802|NCT01230073|Active Comparator|Home-Monitoring|Home-Monitoring
11517803|NCT01230060|Experimental|enVista|enVista One-Piece Hydrophobic Acrylic Intraocular Lens
11517804|NCT01230047|Experimental|Psychoeducational Course|In this arm, clients receive the psychoeducational course.
11517805|NCT01230047|No Intervention|Treatment-as-usual/Waiting list|Clients assigned to this condition will receive treatment-as-usual (TAU) and be placed on a waiting list.
11517806|NCT01230034|Experimental|Imidapril|10 and 20 mg/day, pill
11517807|NCT01230034|Active Comparator|Ramipril|5 and 10 mg/day, pill
11517808|NCT01230021|Experimental|recombinant factor XIII|
11517809|NCT01230008||Radiotherapy in mediastinal lymphoma|Adjuvant radiotherapy or not (control group) in patients treated with R-CHOP
11517810|NCT01230008||Radiotherapy in mediastinal lymphoma|Radiotherapy will no be administered in patients treated with R-CHOP
11517811|NCT01230008||Radiotherapy in primary mediastinal lymphoma|Patients with primary mediastinal lymphoma will be treated with R-CHOP as induction therapy, if complete response is achieved, they were allocated to received or no (control group) adjuvatn radiotherapy, 3.5 G to mediastinal site.
11517812|NCT01229995|Active Comparator|Prefabricated Abutment|
11517813|NCT01229982|Experimental|L-PPDS|
11517814|NCT01229969|Experimental|NeuroCom EquiTest® System|Measure balance assessment (test for Sensory Organization Test (SOT) and Limit of Stability (LOS).
11517815|NCT01229969|Experimental|Wii Fit|Determine if the Wii Fit is valid and feasible in detecting balance problems in older adults
11517816|NCT01229943|Experimental|Arm I (octreotide acetate and everolimus)|Patients receive 28-day cycles until progression or unacceptable toxicity consisting of: everolimus 10 mg PO QD on days 1-28 and octreotide acetate 20 mg IM on day 1.
11517817|NCT01229943|Experimental|Arm II (octreotide acetate, everolimus, and bevacizumab)|Patients receive 28-day cycles until progression or unacceptable toxicity consisting of: everolimus 10 mg PO QD on days 1-28, octreotide acetate 20 mg IM on day 1 and bevacizumab 10 mg/kg IV on days 1 and 15.
11517818|NCT01229904|Experimental|Arm 1|patients with PTSD are randomized to either entering immediately a 6 week treatment with music therapy, or being in the delay group that enters the treatment arm after 6 weeks. This is a delayed entry RCT.
11517819|NCT01229891|Placebo Comparator|Plain yogurt drink|daily intake of two bottle (250 mL) plain yogurt drink
11517820|NCT01229891|Experimental|vitamin D-fortified yogurt drink|daily intake of two bottle yogurt drink fortified with 500 IU vitamin D/250 mL
11517821|NCT01229891|Experimental|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 mL
11517822|NCT01229878|Active Comparator|Arm 1|Hemodialysis Patients randomized to take Vitamin D supplements
11517823|NCT01229878|Placebo Comparator|Arm 2|Hemodialysis Patients randomized to take placebo pills
11517824|NCT01229865|Experimental|VB-111|antiangiogenic and vascular disruptive agent
11517825|NCT01229852|Experimental|Active DSF-rTMS|Active rTMS treatment.
11517826|NCT01229839|Experimental|infusion group|Infusion of anticancer agent followed by Embolization
11517827|NCT01229839|Experimental|lipiodol chemotherapy group|Infusion of mixture of anticancer agent and lipiodol followed by Embolization
11517828|NCT01229813|Active Comparator|bevacizumab and erlotinib (KRAS WT)|
11517829|NCT01229813|Active Comparator|bevacizumab (KRAS WT)|
11517830|NCT01229813|Active Comparator|bevacizumab (KRAS mutated)|
11517831|NCT01229813|Active Comparator|low dose capecitabine (KRAS mutated)|
11517832|NCT01229800|Active Comparator|Split dose PEG|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes.
11517873|NCT01229527|Experimental|Remifentanil RS1|
11517874|NCT01229527|Experimental|Remifentanil RS2|
11517875|NCT01229527|Active Comparator|Meperidine|
11517876|NCT01229514||Exposure to anesthesia|
11517877|NCT01229514||Normal controls|
11517833|NCT01229800|Active Comparator|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
11517834|NCT01229774|Experimental|Etoricoxib|
11517835|NCT01229774|Active Comparator|Diclofenac|
11517836|NCT01229761|Active Comparator|infant cotrimoxazole|
11517837|NCT01229761|Placebo Comparator|infant placebo|
11517838|NCT01229761|Active Comparator|exclusive breastfeeding for 6 months|
11517839|NCT01229761|Active Comparator|exclusive breastfeeding for 12 months|
11517840|NCT01229748|Experimental|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth.(Liddle, 2002) considered in the U.S. and abroad as an empirically supported Best Practice treatment for teen substance abuse and delinquency (USDHHS 2002; Drug Strategies 2003; NIDA 1999; Rigter et al 2004).
11517841|NCT01229748|Experimental|Family Motivational Interviewing|Motivational Interviewing (MI; Miller 1983; Miller & Rollnick 1991), is a client-centered treatment designed to strengthen clients' commitment and empower them to change their substance use behavior (Miller & Rollnick 2002).
11517842|NCT01229748|Other|Standard Care|The standard care condition will represent typical services for teens with alcohol problems in the community: assessment and referral for treatment
11517843|NCT01229735|Experimental|Levetiracetam|250 mg and 500 mg levetiracetam tablet; titration from 1000 mg/day (500 mg bid) to 3000 mg/day (1500 mg bid) levetiracetam with treatment duration up to 52 weeks
11517844|NCT01229735|Active Comparator|Topiramate|25 mg and 100 mg topiramate tablet; titration from 100 mg/day (50 mg bid) to 400 mg/day (200 mg bid) topiramate with treatment duration up to 52 weeks
11517845|NCT01229722|Active Comparator|Beeper|Patients randomized to the control arm (Beeper) will receive the standard of care at each clinic visit. The subjects will bring their HIV medications every 3 weeks (MEMS measure, pill count) and questioned on their adherence to antiretroviral therapy (ART) in the past 7 days. They will not receive any text messages addressing their adherence to ART between each study visit. Their providers will not be receiving any adherence reports but will be asked to assess their adherence at at the start of the trial (Time 1 or T1) and at subsequent clinic visit scheduled according to a frequency defined by standard of care.
11517846|NCT01229722|Experimental|Cell Phone|Participants will receive a text message reminder via ARemind at scheduled intervals, with varying frequency. They will also be subject to a remote adherence assessment, over text messages, interactive voice response (IVR), or a remote pill count with assistance over the phone from a counselor. Those who demonstrate lower adherence rates may receive a call from a counselor.
11517847|NCT01229709|Experimental|Mindfulness Based Tinnitus Reduction|
11517848|NCT01229709|No Intervention|Tinnitus Counseling Only Control|Control group subjects will have had treatment as usual (TAU) care from the UCSF Audiology Clinic which includes Tinnitus Counseling (TC) at least three-months prior to enty into the study.
11517849|NCT01229696|Active Comparator|At Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.
11517850|NCT01229696|Active Comparator|5cm Above Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
11517851|NCT01229683||Shoulder Surgery|Patients will be given an interscalene nerve block and then strength and sensation of the hand and forearm will be tested to determine if the block is helping to anesthetize these areas.
11517852|NCT01229670|Experimental|aerobic intermittent group|aerobic intermittent group
11517853|NCT01229670|Experimental|aerobic continuous group|aerobic continuous group
11517854|NCT01229670|No Intervention|control|home exercise group
11517855|NCT01229644|Experimental|Cohort A|Adult newly diagnosed glioma (both low and high grade) patients, who are able to to take Crenolanib (CP-868,596) for at least 3 days prior to surgical resection.
11517856|NCT01229644|Experimental|Cohort B|Adult patients with recurrent high grade glioma, including patients treated with bevacizumab. Patients are treated with Crenolanib (CP-868,596) continuously until they fulfill one of the criteria for study discontinuation.
11517857|NCT01229644|Experimental|Cohort C|Adult patients with biopsy proven low grade glioma who have residual measurable disease. Patients are treated with Crenolanib (CP-868,596) continuously until they fulfill one of the criteria for study discontinuation.
11517858|NCT01229631|Placebo Comparator|Supplementation with non-active|Subjects will be supplemented with placebo capsules (3 capsules am & 3 capsules pm)
11517859|NCT01229631|Active Comparator|Dietary supplementation with Juice plus+|Subjects will be supplemented with Juice plus+ capsules (3 capsules am & 3 capsules pm)
11517860|NCT01229618|Experimental|1|0.14 ml/kg bw - hyperpolarized pyruvate
11517861|NCT01229618|Experimental|2|0.28 ml/kg bw - hyperpolarized pyruvate
11517862|NCT01229618|Experimental|3|0.43 ml/kg bw - hyperpolarized pyruvate
11517863|NCT01229605|Experimental|Single Arm|Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
11517864|NCT01229592|Experimental|Ethanol|Every three day lock using Ethanol in all the lumen of the Catheter
11517865|NCT01229592|Active Comparator|Heparine|Every three day lock using Heparine in all the lumen of the Catheter
11517866|NCT01229579|Experimental|Zinc Supplement|2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc
11517867|NCT01229579|No Intervention|Placebo|2.5 ml supplement syrup daily without elemental zinc
11517868|NCT01229566|Active Comparator|Active Comparator|Active comparator
11517869|NCT01229566|Placebo Comparator|Placebo|Placebo control
11517870|NCT01229566|Experimental|AKR-963|Investigational drug
11517871|NCT01229553|Experimental|Decolonization group|The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
11517872|NCT01229540|No Intervention|Lifestyle counseling|
11517878|NCT01229488|No Intervention|No Arms|Project was withdrawn before starting
11517879|NCT01229475|Active Comparator|Stepwise approach|Stepwise approach for repeat AF ablation
11517880|NCT01229475|Active Comparator|Linear ablation|Linear ablation for repeat procedure in patients with recurrent atrial fibrillation
11517881|NCT01229462|Other|Combigan®|One drop of brimonidine tartrate/timolol combination ophthalmic solution (Combigan®) and one drop of brimonidine tartrate/timolol fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
11517882|NCT01229462|Active Comparator|Alphagan® and Timolol Concurrent|One drop of brimonidine tartrate ophthalmic solution (Alphagan®) and one drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
11517883|NCT01229449|Experimental|Ibuprofen/acetaminophen (lower dose)|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet
11517884|NCT01229449|Experimental|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg
11517885|NCT01229449|Active Comparator|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®)
11517886|NCT01229449|Active Comparator|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra)
11517887|NCT01229449|Placebo Comparator|Placebo|Two placebo tablets
11517888|NCT01229436|Experimental|Xiapex Injection|
11517889|NCT01229423|Experimental|LATISSE®|bimatoprost 0.03% (LATISSE®)
11517890|NCT01229410|Experimental|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
11517891|NCT01229410|Experimental|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
11517892|NCT01229397|Active Comparator|Inflexal V 0.25 mL x 2|
11517893|NCT01229397|Experimental|Inflexal V 0.5 mL x 1|
11517894|NCT01229384|Experimental|Positive Airway Pressure Nebulization|Will administer nebulized medications using Positive Airway Pressure Nebulization
11517895|NCT01229384|Active Comparator|Standard Nebulization|Current standard of administering nebulized medications without positive airway pressure
11517896|NCT01229371|Active Comparator|Subjects ≥18 to ≤60 Years - CSL HA Antigen|Inflexal V influenza vaccine (CSL HA Antigen) 2010 Group A will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011 containing per 0.5 mL i.m. dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
11517897|NCT01229371|Active Comparator|Subjects >60 Years - CSL HA Antigen|Inflexal V influenza vaccine (CSL HA Antigen) 2010 Group B will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011 containing per 0.5 mL i.m. dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
11517898|NCT01229371|Experimental|Subjects ≥18 to ≤60 Years - AdImmune HA Antigen|Inflexal V influenza vaccine (AdImmune HA Antigen) 2010/2011 Group C will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 containing per 0.5 mL i.m.dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
11517899|NCT01229371|Experimental|Subjects >60 Years - AdImmune HA Antigen|Inflexal V influenza vaccine (AdImmune HA Antigen) 2010/2011 Group D will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 containing per 0.5 mL i.m.dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
11517900|NCT01229358|Experimental|Silver Eluting Dressing|Acticoat Absorbant™ applied as post-operative dressing
11517901|NCT01229358|Active Comparator|Standard Guaze|Standard dry gauze applied as post-operative dressing
11517902|NCT01229345|Experimental|Breakfast & exercise|
11517903|NCT01229345|Experimental|Breakfast & no exercise|
11517904|NCT01229345|Experimental|No breakfast & exercise|
11517905|NCT01229345|No Intervention|No breakfast & no exercise|
11517906|NCT01229332|Placebo Comparator|Carbidopa|
11517907|NCT01229332|Placebo Comparator|Placebo|
11517908|NCT01229319|Experimental|cryo + imiquimod to Left|Cryotherapy alone to Right arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Left arm
11517909|NCT01229319|Experimental|Cryo + imiquimod to Right|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
11517910|NCT01229306|Experimental|reisolation of all PV and additional anterior line|
11517911|NCT01229306|Placebo Comparator|reisolation of all pulmonary veins|
11517912|NCT01229293|Experimental|Resurfacing Total Hip Arthroplasty|A hip replacement that leaves most of the underlying bone intact and mimics the natural biomechanical features of the hip joint. Articular surface replacement ASR, DePuy posterolateral approach used (RTHA)
11517913|NCT01229293|Active Comparator|Standard Total Hip Arthroplasty (THA)|A standard 28 mm head uncemented THA
11517914|NCT01229280|Experimental|Darisec(R) 7.5 mg|
11517915|NCT01229280|Active Comparator|Enablex(R) 7.5 mg|
11517916|NCT01229267|Experimental|V212 Consistency Lot 1|Participants randomized to receive V212 consistency Lot 1 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
11517917|NCT01229267|Experimental|V212 Consistency Lot 2|Participants randomized to receive V212 consistency Lot 2 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
11517918|NCT01229267|Experimental|V212 Consistency Lot 3|Participants randomized to receive V212 consistency Lot 3 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
11517919|NCT01229267|Experimental|V212 High Antigen Lot|Participants randomized to receive V212 High Antigen Lot given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
11517920|NCT01229267|Placebo Comparator|Placebo|Participants randomized to receive matching placebo given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
11517921|NCT01229254|Experimental|Amiodarone|Participants on betrixaban 30 mg and concomitant baseline amiodarone
11517922|NCT01229254|Experimental|Betrixaban 60 mg|Participants with lower weights
11517923|NCT01229254|Experimental|Betrixaban 90 mg|Participants with higher weights
11517924|NCT01229241|Other|levobupivacaine|
11517925|NCT01229241|Other|ropivacaine|
11517926|NCT01229228|Experimental|Naproxen Test (lower dose)|200-mg
11517927|NCT01229228|Experimental|Naproxen Test (upper dose)|400-mg (2 x 200-mg)
11517928|NCT01229228|Active Comparator|Naprosyn 250 mg|
11517929|NCT01229228|Active Comparator|Naprosyn 500 mg|
11517930|NCT01229228|Placebo Comparator|Placebo|
11517931|NCT01229215|Experimental|FCFD4514S|
11517932|NCT01229215|Sham Comparator|sham|
11517933|NCT01229202|Active Comparator|standard of care|standard of care for trabeculectomy surgery
11517934|NCT01229202|Active Comparator|bevacizumab arm|
11517935|NCT01229189|Experimental|Maternal and Neonatal Intervention Arm|Pregnant women will be individually randomized; a daily dose of vitamin D in 4000 IU will be given to Intervention group, started at 20-22 weeks of pregnancy till the time of delivery. The infants of this group will further stratify into two groups, one group will receive 400 IU of Vitamin D for 6 months as Intervention.
11517936|NCT01229189|Placebo Comparator|Maternal and Neonatal Control Arm|
11517937|NCT01229176|Experimental|Vi-CRM, Adults|Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine
11517938|NCT01229176|Active Comparator|Vi-PS, Adults|Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine
11517939|NCT01229176|Experimental|Vi-CRM, Children|Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
11517940|NCT01229176|Active Comparator|Vi-PS, Children|Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine
11517941|NCT01229176|Experimental|Vi-CRM, Older infants|Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
11517942|NCT01229176|Active Comparator|PNC13, Older infants|Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
11517943|NCT01229176|Experimental|Vi-CRM, Infants|Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
11517944|NCT01229176|Active Comparator|PNC13, Infants|Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine
11517945|NCT01229150|Active Comparator|KRAS Mut 2|KRAS Mutant patients randomized to combination therapy arm
11517946|NCT01229150|Active Comparator|KRAS Mut 1|KRAS Mutant patients randomized to monotherapy arm
11517947|NCT01229150|Active Comparator|WT KRAS 1|Wild-Type KRAS patients randomized to monotherapy arm
11517948|NCT01229150|Active Comparator|WT KRAS 2|Wild-Type KRAS patients randomized to combination therapy arm
11517949|NCT01229137||Right Ventricular Cohort|Right Ventricle wtih SRD-1 conversion
11517950|NCT01229137||Left Ventricular Cohort|Left Ventricle with SRD-1 conversion
11517951|NCT01229137||Right Atrium Cohart|Right atrium cohort with SRD-1 conversion
11517952|NCT01229111|Experimental|Treatment (cediranib maleate and modified FOLFOX)|Patients receive cediranib maleate PO QD on days 1-14 and modified FOLFOX6 comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1.
11517953|NCT01229098|Experimental|LEO 80185|
11517954|NCT01229085|Experimental|Test|mometasone 0,1% + salicylic acid 5%
11517955|NCT01229072|Experimental|1|Heparin Blausiegel
11517956|NCT01229072|Active Comparator|2|Liquemine
11517957|NCT01229059||lipid infusion in untrained humans|healthy lean humans before and after lipid infusion
11517958|NCT01229059||lipid infusion in athletes|endurance trained atheletes
11517959|NCT01229046|Active Comparator|ticarcillin-clavulanate|5 doses of IV ticarcillin-clavulanate infants < 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
11517960|NCT01229033|Active Comparator|Ablation|Ablation of atrial tachycardia
11517961|NCT01229033|Active Comparator|Cardioversion|Cardioversion of atrial tachycardia
11517962|NCT01229020||COPD patients|Patients diagnosed with COPD, by the pulmonologist at the institute,who are referred to undergo ventilation/perfusion scans.
11517963|NCT01229007|Experimental|Biostate|
11517964|NCT01228994|Active Comparator|Baclofen 30 mg/day|Baclofen medication
11517965|NCT01228994|Placebo Comparator|Placebo pill|placebo pill
11517966|NCT01228994|Active Comparator|Baclofen 60 mg/day|Baclofen medication high dose
11517967|NCT01228981||Type-2 Diabetic Retinopathy|
11517968|NCT01228968||Volunteers|Volunteers will have a range of body mass index from 19 - 45 kilogram per square meter. In order to fit in the magnetic resonance scanner subjects must weigh less than 300 pounds.
11517969|NCT01228955||Yoga Group|Group will enter a 10 week yoga class
11517970|NCT01228942|Other|Platinum Sensitive|Treatment with platinum-based therapy; COXEN prediction model chooses secondary agent if doublet
11517971|NCT01228942|Other|Platinum resistent|single agent based on Coxen prediction model
11517972|NCT01228929|Experimental|Normal|Subjects with no clinical diagnosis or symptoms of dry eye.
11517973|NCT01228929|Experimental|Aqueous Deficiency Dry Eye (ADDE)|Subjects with low tear volume measured by Schirmer's test less than 10 mm.
11517974|NCT01228929|Experimental|Meibomian Gland Dysfunction (MGD)|Subjects having mild to moderate Meibomian Gland Dysfunction by slit lamp evaluation.
11517975|NCT01228916|Experimental|Tobacco Cessation and Secondhand Smoke Reduction|Community based interventions to raise awareness regarding secondhand smoke exposure, clean indoor air laws, smokefree homes, risks of tobacco use and benefits of cessation; include talks, healthcare provider training, radio public service announcements and talk shows, tleevision interviews, cessation classes and individual sessions, health fairs, community marches for smokefree spaces, materials and resources for assisting in tobacco use cessation, estsablishing smokefree homes, adhering to smokefree laws
11517976|NCT01228916|No Intervention|Delayed Intervention Control|Assessment only during comparison period (no interventions will be provided over and above any secular trends in communities); delayed intervention will be provided at end of 1 year comparison period
11518256|NCT01227044|Placebo Comparator|Placebo + MM/MC|Placebo plus Medical Management/Medication Coaching
11517977|NCT01228903|Placebo Comparator|Control|Patients who are randomized to this group will received placebo tablets. Placebo tables do not contain an active ingredient. This group will be used as a baseline group to compare the effects of lowering uric acid on vascular function.
11517978|NCT01228903|Active Comparator|Allopurinol|Patients who are randomized to this group will receive allopurinol tablets. Allopurinol is a medicine that lowers uric acid levels. The effects of lowering uric acid on vascular function outcomes will be assessed and compared to the control group.
11517979|NCT01228890|Experimental|CATCH-IT 2-R Arm|Primary care/Internet based depression prevention intervention (CATCH-IT 2-R) with a family component.
11517980|NCT01228890|Active Comparator|Attention Monitoring Psycho-education (AMPE) Arm|
11517981|NCT01228877|Experimental|Exercise|Adduction, Abduction and Squat exercise three times a week for 16 weeks
11517982|NCT01228864|Experimental|Brody Belt|
11517983|NCT01228864|Active Comparator|Conventional Urinary Drainage bag|
11517984|NCT01228851|Experimental|Balance Training|Balance training using Wii Fit Balance Board
11517985|NCT01228838|Experimental|NGX-1998, 10% w/w capsaicin|
11517986|NCT01228838|Experimental|NGX-1998, 20% w/w capsaicin|
11517987|NCT01228838|Placebo Comparator|Placebo liquid|
11517988|NCT01228825||CABG without CPB|Patients undergoing coronary artery bypass graft (CABG) without Cardiopulmonary bypass ( CPB)
11517989|NCT01228825||CABG with CPB|Patients undergoing coronary artery bypass graft (CABG) with cardiopulmonary bypass (CPB)
11517990|NCT01228812||RA patients|Patients with Rheumatoid Arthritis
11517991|NCT01228812||Healthy subjects|Healthy subjects matched for age and sex
11517992|NCT01228799|Active Comparator|Trabeculectomy|Trabeculectomy with Mitomycin C
11517993|NCT01228799|Active Comparator|Canaloplasty|Canaloplasty with implant of suture
11517994|NCT01228786||Group A|~ 20 sporadic PHPT patients
11517995|NCT01228786||Group B|~10 normocalcemic euthyroid patients (control tissue)
11517996|NCT01228773|Experimental|A|"Providing tailored web-based care program(Health Navigation®), which provides various information related to the CRF.
~Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue etc."
11517997|NCT01228773|Other|B|Attention control arm: Providing usual care for CRF. Three months later, as attention control, they will be provided tailored web-based care program(Health Navigation®), which provides various information related to the CRF.
11517998|NCT01228760|Experimental|Dose level 1|
11517999|NCT01228760|Experimental|Dose level 2|
11518000|NCT01228760|Experimental|Dose level 3|
11518001|NCT01228760|Experimental|Dose level 4|
11518002|NCT01228760|Experimental|Dose level 5|
11518003|NCT01228760|Experimental|Dose level 5A|
11518004|NCT01228760|Experimental|Dose level 6|
11518005|NCT01228760|Experimental|Dose level 7|
11518006|NCT01228760|Experimental|Dose level 8|
11518007|NCT01228760|Experimental|Dose level 9|
11518008|NCT01228760|Experimental|Chemotherapy-naïve subjects|
11518009|NCT01228760|Experimental|Chemotherapy exposed subjects|
11518010|NCT01228747|Placebo Comparator|Placebo|Matching placebo for 28 weeks
11518011|NCT01228747|Experimental|Levetiracetam|Levetiracetam treatment with flexible dosing of 1000 mg/day or 2000 mg/day or 3000 mg/day for 28 weeks
11518012|NCT01228734|Experimental|Cetuximab + FOLFOX-4|Subjects received cetuximab in combination with FOLFOX-4 chemotherapy regimen. FOLFOX-4 chemotherapy regimen consists of a combination of oxaliplatin with 5-fluorouracil (5-FU)/folinic acid (FA). Cetuximab was always administered every 7 days with an initial dose of 400 milligram per square meter (mg/m^2) at 5 milligram per minute (mg/min) and 250 mg/m^2 at 10 mg/min for subsequent infusions, followed by oxaliplatin 85 mg/m^2 infused over 120 minutes at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin, FA was administered at a dose of 200 mg/m^2 infused over 120 minutes, on Day 1, Day 2, and every 2 weeks and then 5- FU was administered as a bolus of 400 mg/m^2/day intravenously over 2-4 minutes followed by 600 mg/m^2/day infused over 22 hours, on Day 1, Day 2, and every 2 weeks. All subjects received treatment until progression of disease, withdrawal of consent, or unacceptable toxicity.
11518013|NCT01228734|Active Comparator|FOLFOX-4|Subjects received FOLFOX-4 chemotherapy regimen that consists of a combination of oxaliplatin with 5-FU/FA. Oxaliplatin 85 mg/m^2 infused over 120 minutes was administered first or simultaneously with FA at a dose of 200 mg/m^2 infused over 120 minutes on Day 1, Day 2, and every 2 weeks and then 5-FU was administered as a bolus of 400 mg/m^2/day intravenously over 2-4 minutes followed by 600 mg/m^2/day infused over 22 hours on Day 1, Day 2, and every 2 weeks. All subjects received treatment until progression of disease, withdrawal of consent, or unacceptable toxicity.
11518014|NCT01228708|Active Comparator|Intervention|Patients from half the GP practices in Ringkoebing-Skjern municipality that participates in an active implementation of a guideline for COPD
11518015|NCT01228708|No Intervention|Control group|Patients from the half of the GP practice in Ringkoebing-Skjern that do not participate in the active implementation of a guideline for COPD. The GPs are however in postgraduate training groups with intervention groups GPs
11518016|NCT01228708|No Intervention|External control|Patients with GP practice in neighboring county Ikast-Brande where there have been no information or contact at all from the investigators
11518017|NCT01228695||steroid treatment|
11518018|NCT01228682||Patients who are treated with Samsca.|
11518019|NCT01228669|Experimental|A|
11518020|NCT01228669|Experimental|B|
11518021|NCT01228669|Placebo Comparator|C|
11518022|NCT01228656|Experimental|-mometasone furoate associated with salicylic acid|
11518023|NCT01228656|Active Comparator|-mometasone furoate|
11518024|NCT01228643|Experimental|Norzyme®|
11518025|NCT01228643|Active Comparator|Creon®|
11518304|NCT01226706|Experimental|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
11518026|NCT01228630|Experimental|Cloratadd-D|Loratadine 5 mg + 120 mg of sulfate pseudoephedrina and coated tablet of placebo (identical to comparator drug). The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
11518027|NCT01228630|Active Comparator|Allegra-D|Loratadine 5 mg + 120 mg of sulfate pseudoephedrina and coated tablet of placebo (identical to test drug). The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
11518028|NCT01228617|Experimental|A1 Short, no buffer|Nicotine / not yet marketed
11518029|NCT01228617|Experimental|A2 Short, low buffer|Nicotine / not yet marketed
11518030|NCT01228617|Experimental|A3 Short, high buffer|Nicotine / not yet marketed
11518031|NCT01228617|Experimental|B1 Long, no buffer|Nicotine / not yet marketed
11518032|NCT01228617|Experimental|B2 Long, low buffer|Nicotine / not yet marketed
11518033|NCT01228617|Experimental|B3 Long, high buffer|Nicotine / not yet marketed
11518034|NCT01228617|Active Comparator|R = Nicotine Gum|Nicorette® Gum
11518035|NCT01228604|Experimental|Methylphenidate|
11518036|NCT01228591|Other|Acuvue Advance Plus/ Acuvue Advance|Acuvue Advance Plus contact lenses worn first period and Acuvue Advance contact lenses worn second.
11518037|NCT01228591|Other|Acuvue Advance/Acuvue Advance Plus|Acuvue Advance contact lenses worn first period and Acuvue Advance Plus contact lenses worn second.
11518038|NCT01228578|Experimental|Multivitamins (B,C,E)|
11518039|NCT01228578|Placebo Comparator|Placebo|
11518040|NCT01228565|Placebo Comparator|Placebo|Radiotherapy+Erbitux+Placebo
11518041|NCT01228565|Experimental|OTD70DERM|Radiotherapy+Erbitux+OTD70DERM®
11518042|NCT01228552|Active Comparator|Topical, intra-oral ketoprofen gel|
11518043|NCT01228552|Placebo Comparator|Placebo gel|
11518044|NCT01228539|Experimental|TARGET|Affect regulation psychotherapy for PTSD
11518045|NCT01228539|Active Comparator|Prolonged Exposure|Cognitive behavioral therapy for PTSD with trauma memory exposure
11518046|NCT01228513|Active Comparator|0.01% ointment|Lowest concentration
11518047|NCT01228513|Active Comparator|0.03% ointment|Middle concentration
11518048|NCT01228513|Active Comparator|0.1% ointment|Highest concentration
11518049|NCT01228513|Placebo Comparator|Placebo (vehicle without active)|No active ingredient
11518050|NCT01228500|Experimental|Experimental Arm (Internal Control)|"One-half of ulcer receives negative pressure wound therapy
~One-half of ulcer receives a fetal bovine collagen bioscaffold (PriMatrix, TEI Biosciences, Boston, MA) in addition to the same negative pressure wound therapy"
11518051|NCT01228487||Acute knee pain|Patients with a history of knee pain < 6 months. The radiologic and arthroscopic OA stadium is less or equal II°. n=20.
11518052|NCT01228487||Chronic knee pain|Clinical manifestation of knee joint OA, radiological and arthroscopic III° or more. n=20
11518053|NCT01228487||Control group|Patients coming for post- primary repair of the cruciate ligament, having no inflammation and no sign of OA. n=10
11518054|NCT01228474|Experimental|SET|Single embryo transfer
11518055|NCT01228474|Active Comparator|DET|Double embryo transfer
11518056|NCT01228461||AYA with Fatigue and Hodgkin Lymphoma|
11518057|NCT01228448|Experimental|Participants 1-39|PET Scan done right after one radiation treatment is complete and will take 15-20 minutes. After undergoing their first PET scan, participants will have the option to undergo 1-2 additional scans throughout radiation treatment in the same manner as the first scan.
11518058|NCT01228435|Experimental|ALK-inhibitor naive|No prior exposure to ALK-inhibitor
11518059|NCT01228435|Experimental|ALK-inhibitor pre-treated|Prior exposure to ALK inhibitor
11518060|NCT01228422||1|test interferon - blausiegel
11518061|NCT01228422||2|reference interferon - Roferon A (Roche)
11518062|NCT01228409|Other|Low dose Acitretin (17.5 mg)|
11518063|NCT01228383|Experimental|CL184+PVRV|CL184 with rabies vaccine (PVRV)
11518064|NCT01228383|Active Comparator|HRIG+PVRV|HRIG with rabies vaccine
11518065|NCT01228383|Placebo Comparator|Placebo+PVRV|Placebo with rabies vaccine (PVRV)
11518066|NCT01228383|Experimental|CL184+HDCV|CL184 with rabies vaccine (HDCV)
11518067|NCT01228383|Placebo Comparator|Placebo+HDCV|Placebo with rabies vaccine (HDCV)
11518068|NCT01228370|Experimental|Silodosin|Silodosin 8mg once a day for 12 weeks
11518069|NCT01228357|Experimental|SSRI treated group|SSRI treated group is patients treated with fluoxetine, paroxetine, or sertraline
11518070|NCT01228357|Active Comparator|non-SSRI treated group|non-SSRI treated group is patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine
11518071|NCT01228344||Artemether-lumefantrine|
11518072|NCT01228331|Active Comparator|Arm I intensification (cytarabine)|"LR-S patients receive HD cytarabine IV 4 x 3 g over 12 hours daily on days 29-31 and pegaspargase IV over 2 hours on days 31, 52, and 80.
~LR-I and precursor B-cell ALL HR-S and HR-I patients receive HD cytarabine IV 2.500 over 3 hours twice daily on days 29-31 and 106-108 and pegaspargase IV over 2 hours on days 31, 53, 67, and 108.
~Followed by standard consolidation therapy regarding to stratification containing:
~methotrexate, cyclophosphamide, thioguanin, mercaptopurine, etoposide phosphate, amsacrine, cytarabine, methylprednisolone, dexamethasone, vincristine sulfate; whole-brain radiation therapy only if indicated in patients with cns involvement or T-cell ALL"
11518073|NCT01228331|Active Comparator|Arm II intensification (clofarabine)|"LR-S patients receive clofarabine* IV 5 x 40 mg over 2 hours every day on days 29-33 and pegaspargase IV over 2 hours on days 33, 52, and 80.
~LR-I and precursor B-cell ALL HR-S and HR-I patients receive clofarabine* IV over 2 hours on days 29-33 and pegaspargase IV over 2 hours on days 33, 53, 67, and 108.
~Followed by standard consolidation therapy regarding to stratification containing:
~methotrexate, cyclophosphamide, thioguanin, mercaptopurine, etoposide phosphate, amsacrine, cytarabine, methylprednisolone, dexamethasone, vincristine sulfate; whole-brain radiation therapy only if indicated in patients with cns involvement or T-cell ALL"
11518074|NCT01228331|Active Comparator|Arm III reinduct.(doxorubicin hydrochl.)|"LR-S patients receive doxorubicin hydrochloride IV 30 mg/m2 over 24 hours on days 1 and 8.
~LR-I, HR-S and HR-I Patients receive doxorubicin hydrochloride IV 30 mg/m2 over 24 hours on days 1, 8, 22, and 29.
~Followed by standard reinduction and maintenance therapy containing:
~cyclophophamide, cytarabine, thioguanine, mercaptopurine, methotrexate and pegaspargase, dexamethasone, vincristine sulfate"
11518305|NCT01226693|Experimental|Sequence 1|
11518075|NCT01228331|Active Comparator|Arm IV reinduct.(daunorubicin hydrochl.)|"LR-S patients receive daunorubicin hydrochloride IV 36 mg/m2 over 24 hours on days 1 and 8.
~LR-I, HR-S and HR-I Patients receive daunorubicin hydrochloride IV 36 mg/m2 over 24 hours on days 1, 8, 22, and 29.
~Followed by standard reinduction and maintenance therapy containing:
~cyclophophamide, cytarabine, thioguanine, mercaptopurine, methotrexate and pegaspargase, dexamethasone, vincristine sulfate"
11518076|NCT01228318|Experimental|Zoledronic acid|Subjects in this arm will receive 5 milligram (mg) per 100 milliliter (mL) solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.
11518077|NCT01228318|Placebo Comparator|Placebo|Subjects in the placebo arm will receive placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered iv over 15-30 minutes under the supervision of study personnel.
11518078|NCT01228305|Experimental|Acetaminophen|Subjects will be randomly assigned to treatment using a permuted-block randomization algorithm. Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children >=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to <2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
11518079|NCT01228305|Placebo Comparator|Placebo|Subjects will be randomly assigned to treatment using a permuted-block randomization algorithm. Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children >=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to <2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
11518080|NCT01228292|Active Comparator|Standard Anticoagulation|Hemodialysis is performed using standard anticoagulation using unfractionated heparin if no contra-indications for the use of heparin exist. If contra-indications for heparin exist a heparin coated hemofilter (Evodial) will be used. The use of unfractionated heparin or no heparin (with coated hemofilter) is a decision to be taken before every hemodialysis.
11518081|NCT01228292|Experimental|Citrasate|Hemodialysis is performed with Citrasate
11518082|NCT01228279|Active Comparator|DIANEAL|One group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with the same type of solution for another 12 weeks.
11518083|NCT01228279|Active Comparator|EXTRANEAL|The other group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with DIANEAL solution during the day and the non-glucose-based solution, EXTRANEAL, during the night
11518084|NCT01228266|Experimental|autologous mesenchymal stem cell|A single infusion of up to 2 million cells per Kg of autologous mesenchymal stem cells vs suspension media. The treatment will be reversed at 6 months
11518085|NCT01228253|No Intervention|1|Safe voluntary.
11518086|NCT01228253|No Intervention|2|patient with psychotrauma but without PSTD and without any psychiatric trouble at the time of inclusion
11518087|NCT01228253|No Intervention|3|patient with psychotrauma and PTSD (post-traumatic stress disorder) and in full remission at the time of inclusion
11518088|NCT01228253|No Intervention|4.3|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
11518089|NCT01228253|Sham Comparator|4.2|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
11518090|NCT01228253|Experimental|4.1|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
11518091|NCT01228240|Experimental|Metformin, Apo-metformin|
11518092|NCT01228227|Active Comparator|ROSUVASTATIN|
11518093|NCT01228227|Experimental|ATORVASTATIN|
11518094|NCT01228214|Experimental|Amiloride,nitrates,clopidogrel,aspirin|Comparative Efficacious Research
11518095|NCT01228214|Placebo Comparator|Placebo,nitrates,clopidogrel,aspirin|Comparative Efficacious Research
11518096|NCT01228201|Experimental|Aerboic interval training|
11518097|NCT01228201|Active Comparator|Moderate continuous training|
11518098|NCT01228188|Experimental|Idiopathic Full Thickness Macular Hole|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole occurs with a minimum diameter exceeding 400 um.
11518099|NCT01228175|Active Comparator|Varenicline|Varenicline
11518100|NCT01228175|Placebo Comparator|Microcrystal Cellulose|Microcrystal cellulose placebo
11518101|NCT01228162|Experimental|general anaesthesia|patients receiving general anaesthesia and rocuronium bromide for muscle relaxation
11518102|NCT01228162|Active Comparator|spinal anaesthesia|patients receiving spinal anaesthesia without muscle relaxation
11518103|NCT01228149|Active Comparator|Diamox/DexaEDO|Patients receive Diamox (oral acetazolamide) starting 28 days Prior to trabeculectomy. 7 days preoperatively DexaEDO (dexamethasone) eyedrops without preservatives are applied additionally. Patient will undergo trabeculectomy.
11518104|NCT01228149|Experimental|Cosopt S|Patients receive Cosopt S (dorzolamide/timolol) eye drops starting 28 days before trabeculectomy.
11518105|NCT01228136|Active Comparator|Tranexamic acid|
11518106|NCT01228136|Placebo Comparator|Placebo|
11518107|NCT01228123|Active Comparator|CVVH arm|
11518108|NCT01228123|Active Comparator|IHD arm|
11518109|NCT01228110|Active Comparator|Corticosteroid group|This group was entitled to receive hydrocortisone 200 mg loading bolus followed by an intravenous infusion (300 mg in 500 ml 0.9% saline) at a rate of 12.5 mg/hour for 7 days
11518110|NCT01228110|Placebo Comparator|Placebo group|This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug).
11518111|NCT01228097||Gastric Bypass|Participants who receive gastric bypass surgery.
11518112|NCT01228097||Principally Restrictive Surgery|Participants who receive gastric banding or sleeve gastrectomy surgery.
11518113|NCT01228097||Weight Stable|Participants who remain weight stable.
11518114|NCT01228084|Experimental|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
11518115|NCT01228071|Experimental|40 mg daily dose of testosterone gel 2%|testosterone gel 2%
11518306|NCT01226693|Experimental|Sequence 2|
11518307|NCT01226693|Experimental|Sequence 3|
11518116|NCT01228058||Adult trauma patients|Patients admitted to the emergency department (ED) as the highest level of acuity following a traumatic injury at three Level 1 trauma centers in the United States (UT Houston, UC San Francisco, Oregon Health Center).
11518117|NCT01228045|Experimental|Trastuzumab in Combination with TS-ONE and cisplatin|The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
11518118|NCT01228032|Experimental|Intervention|
11518119|NCT01228032|No Intervention|Control|referral only
11518120|NCT01228019||All participants|Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)
11518121|NCT01228006|Experimental|Treatment|NatusGerin
11518122|NCT01228006|Placebo Comparator|Control|Gelatin capsules identical to drug test
11518123|NCT01227993|Experimental|Finasteride|Participants are treated with 5 mg oral finasteride daily when they have clinically significant subretinal fluid accumulation, defined as any subretinal fluid in the macula with a volume of at least 0.1 microliter and causing visual change such as reduced acuity, metamorphopsia, or microperimetry deficits.
11518124|NCT01227980|Active Comparator|Pexacerfont|Pexacerfont was given orally as a loading dose of 300 mg/day for 1 week, followed by 100mg/day for 16-20 days
11518125|NCT01227980|Placebo Comparator|Placebo|Oral placebo was given during the 1-week loading dose phase, and during the next 16-20 days
11518126|NCT01227967|Experimental|Combination Therapy|Amantadine, Ribavirin, Oseltamivir
11518127|NCT01227967|Active Comparator|Oseltamivir monotherapy|Oseltamivir
11518128|NCT01227954|Other|WBRT with Hippocampal Avoidance|Whole brain radiotherapy (WBRT) with hippocampal avoidance using intensity-modulated radiation therapy (IMRT)
11518129|NCT01227941|Experimental|Part A: MK-4827 + pegylated liposomal doxorubicin|MK-4827 and pegylated liposomal doxorubicin combination. Dose escalation/confirmation in participants with advanced solid tumors
11518130|NCT01227941|Experimental|Part B: MK-4827 + pegylated liposomal doxorubicin|MK-4827 and pegylated liposomal doxorubicin combination at 1 or 2 dose levels of MK-4827 to be determined from the results of Part A. Ovarian Cancer Cohort
11518131|NCT01227928|Experimental|pazopanib|experimental medication
11518132|NCT01227928|Placebo Comparator|placebo|placebo comparator
11518133|NCT01227915|Experimental|Test|tobramycin 0.3% + dexamethasone 1% - União Química Lab
11518134|NCT01227915|Active Comparator|Comparator|tobramycin 0.3% + dexamethasone 1% - Alcon Lab
11518135|NCT01227902|Experimental|Retigabine IR|Open Label flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
11518136|NCT01227889|Experimental|GSK2118436|Subjects in this arm will receive GSK2118436 150 mg twice daily.
11518137|NCT01227889|Active Comparator|Dacarbazine (DTIC)|Subjects will receive intravenous dacarbazine (DTIC) 1000 mg/m2 every 3 weeks
11518138|NCT01227889|Experimental|Crossover|Subjects who initially receive DTIC will be allowed to receive GSK2118436 after initial progression.
11518139|NCT01227876|Experimental|Test|Ster ® (prednisolone 1% ophthalmic suspension - União Química)
11518140|NCT01227876|Active Comparator|Comparator|Pred Fort ® (prednisolone 1% ophthalmic suspension - Allergan)
11518141|NCT01227863|Experimental|Test|Dexamethasone + neomycyn + polimixyn B
11518142|NCT01227863|Active Comparator|Comparator|Dexamethasone + neomycyn + polimixy B
11518143|NCT01227850||Parenteral nutrition patients.|
11518144|NCT01227837|Sham Comparator|placebo|use of placebo in control group
11518145|NCT01227837|Experimental|omega 3|use of omega 3 2 gr/day for 6 months
11518146|NCT01227824|Experimental|GSK1349572 (N=~394)|GSK1349572 50mg once daily + raltegravir placebo twice daily + NRTI background therapy once daily
11518147|NCT01227824|Active Comparator|raltegravir (N=~394)|raltegravir 400mg twice daily + GSK1349572 placebo once daily + NRTI background therapy once daily
11518148|NCT01227811|Active Comparator|Enablex(R) 15 mg , single dose|
11518149|NCT01227811|Experimental|Darifenacin 15 mg tablets, single dose|
11518150|NCT01227798|Placebo Comparator|Placebo|100 mM sodium Chloride and 25 mM sodium phosphate at pH 7.0 +/- 0.2
11518151|NCT01227798|Active Comparator|Infergen|15mcg subcutaneous injection at fill volume of 0.5mL
11518152|NCT01227785||INCEPTA ICD and CRT-D|ICD and CRT-D indicated patients were included in the study. Overall patient population, CRT-D or ICD populations, and patients experiencing or not experiencing a protocol-defined heart failure event were included (dependent on outcomes measured).
11518153|NCT01227772|Experimental|Weekly Cohort|The gastric cancer vaccine (OTSGC-A24) will be administered at a dose of 1 mg once a week
11518154|NCT01227772|Experimental|2-weekly cohort|The gastric cancer vaccine (OTSGC-A24) will be administered at the dose of 1 mg every 2 weeks.
11518155|NCT01227772|Experimental|3-weekly cohort|The gastric cancer vaccine (OTSGC-A24)will be administered at 1 mg very 3 weeks
11518156|NCT01227759|Experimental|Verum|
11518157|NCT01227759|No Intervention|Untreated|
11518158|NCT01227759|Placebo Comparator|Vehicle|
11518159|NCT01227746||Tumor biopsies|
11518160|NCT01227733||Breast Tumor|Breast Tumor Blocks
11518161|NCT01227720|Experimental|A NSL2L|Experimental Nicotine Replacement Therapy (NRT)(L) 2 mg
11518162|NCT01227720|Active Comparator|B Lozenge|Marketed Nicotine Lozenge 2 mg
11518163|NCT01227720|Experimental|C NSL4M|Experimental NRT (M) 4 mg
11518164|NCT01227720|Active Comparator|D Lozenge|Marketed Nicotine Lozenge 4 mg
11518165|NCT01227720|Experimental|E NSL4L|Experimental NRT (L) 4 mg
11518166|NCT01227720|Experimental|F NSL4H|Experimental NRT (H) 4 mg
11518167|NCT01227707|Experimental|Single Arm|
11518257|NCT01227018|Experimental|STA-9090|Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11518258|NCT01227005|Active Comparator|Whole Blood|Whole Blood plus pooled platelets
11518168|NCT01227694|Experimental|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias Avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
11518169|NCT01227681|Experimental|high dose G-CSF|high dose group: 3.3ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
11518170|NCT01227681|Active Comparator|low dose G-CSF|low dose group: 1.65ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
11518171|NCT01227681|Placebo Comparator|placebo|Sodium Chloride (NaCl) 0.9 %
11518172|NCT01227668|Experimental|Aripiprazole|
11518173|NCT01227668|Placebo Comparator|Placebo|
11518174|NCT01227655|Experimental|BIA 9-1067 25 mg once daily (QD).|BIA 9-1067, OPC, Opicapone 25 mg once daily (QD).
11518175|NCT01227655|Experimental|BIA 9-1067 50 mg once daily (QD).|BIA 9-1067, OPC, Opicapone 50 mg once daily (QD).
11518176|NCT01227655|Placebo Comparator|Placebo|PLC, Placebo
11518177|NCT01227642|Experimental|pre-implant transrectal ultrasound images and planning|Transrectal ultrasound session will be performed at a separate session prior to the implant.
11518178|NCT01227629|Experimental|dabigatran 50 mg twice daily (bid)|Dabigatran: one capsule in the morning and 1 capsule in the evening. Twice daily (bis in die = bid).
11518179|NCT01227629|Experimental|dabigatran 50 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. Acetylsalicylic acid (ASA) once daily (quaque dies = qd) in the morning.
11518180|NCT01227629|Experimental|dabigatran 50 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
11518181|NCT01227629|Experimental|dabigatran 150 mg bid|Dabigatran: one capsule in the morning and 1 capsule in the evening
11518182|NCT01227629|Experimental|dabigatran 150 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
11518183|NCT01227629|Experimental|dabigatran 150 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
11518184|NCT01227629|Experimental|dabigatran 300 mg bid|Dabigatran: one capsule in the morning and 1 capsule in the evening
11518185|NCT01227629|Experimental|dabigatran 300 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
11518186|NCT01227629|Experimental|dabigatran 300 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
11518187|NCT01227629|Active Comparator|warfarin|once daily, dosed to target International Normalised Ratio (INR) 2.0 to 3.0
11518188|NCT01227616|Experimental|Ferumoxytol|Intravenous (IV) iron
11518189|NCT01227616|Active Comparator|IV Iron Sucrose|Intravenous (IV) iron
11518190|NCT01227603|Experimental|Nifedipine-candesartan FDC|Each subject received single fixed dose combination of 60 mg nifedipine and 32 mg candesartan orally.
11518191|NCT01227603|Active Comparator|Nifedipine and candesartan|Each subject received one dose of nifedipine GITS 60 mg and candesartan 32 mg (2 x 16 mg tablet) as loose combination, orally.
11518192|NCT01227603|Active Comparator|Nifedipine|Each subject received one dose of nifedipine GITS 60 mg orally.
11518193|NCT01227603|Active Comparator|Candesartan|Each subject received one dose of candesartan 32 mg (2 x 16 mg tablet), orally.
11518194|NCT01227590|Experimental|Pharmacokinetics single-arm|The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
11518195|NCT01227577|Experimental|Nilotinib|Participants received 300 mg twice daily (b.i.d.). Dose increases to 400 b.i.d. were permitted, per Investigator's discretion.
11518196|NCT01227564|Experimental|ACC-001 3 μg/ QS-21 50 μg|
11518197|NCT01227564|Experimental|ACC-001 10 μg/ QS-21 50 μg|
11518198|NCT01227564|Placebo Comparator|Placebo- Phosphate buffered saline (PBS)|
11518199|NCT01227551|Experimental|Intratumoral injection|Each patient will receive 4 separate Coxsackievirus A21 (CVA21) administrations in the first 8 days on trial (Days 1, 3, 5 and 8), followed by a fifth dose 2 weeks later (Day 22) and further administrations at 3 weekly intervals (Days 43, 64, 85, 106 and 127, up to a maximum of 10 sets of injections) until confirmed disease progression or development of excessive toxicity. Subjects with stable disease or better at Day 127 were eligible to receive up 9 more sets of CVA21 administrations under an extension protocol (VLA-008).
11518200|NCT01227538||Stimulated urinary C peptide|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
11518201|NCT01227512|Experimental|Tolvaptan 15-60mg|Oral tablet without fluid restriction. After the initial dose, daily dose may be titrated based on response.
11518202|NCT01227512|Active Comparator|Fluid Restriction|Placebo tablet with prescribed fluid restriction. After the initial dose, level of fluid restriction may titrated based response.
11518203|NCT01227486||Obese patients for planned surgery and endotracheal intubation|
11518204|NCT01227473|Experimental|mindfulness prediabetes education group|The mindfulness-based diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the mindfulness-based diabetes prevention group, the instruction will be enhanced with instruction in mindfulness.
11518205|NCT01227473|Active Comparator|conventional prediabetes education group|The conventional diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the conventional diabetes prevention group, the instruction will be enhanced with group exercises and discussions.
11518206|NCT01227460|Experimental|Sitagliptin|
11518207|NCT01227460|Placebo Comparator|Sugar Pill|
11518259|NCT01227005|Active Comparator|Component Therapy|Red blood cells, plasma, platelets
11518308|NCT01226693|Experimental|Sequence 4|
11518309|NCT01226693|Experimental|Sequence 5|oral, 6mg, single dose
11518208|NCT01227434|Experimental|Surgical Group|PD 0332991 125 mg daily for 7 days prior to an indicated, intended surgical resection as clinical care for progression, and then resume drug at the same dose after recovery from surgery on a repeating schedule of 21 consecutive days of drug followed by a 7 day break off therapy (cycle length is 28 days). Treatment will be repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients will be given the option to continue on study past 12 cycles, up to a maximum of 24 cycles.
11518209|NCT01227434|Experimental|Non-surgical group|Patients not in need of surgery treated with PD 0332991 125 mg daily for 21 consecutive days followed by a 7 day break off therapy (cycle length is 28 days). Treatment will be repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients will be given the option to continue on study past 12 cycles, up to a maximum of 24 cycles.
11518210|NCT01227421|Active Comparator|Nitazoxanide, Placebo|300 mg nitazoxanide tablet and 1 placebo tablet twice daily for 5 days
11518211|NCT01227421|Active Comparator|Nitazoxanide, Nitazoxanide|Two 300 mg nitazoxanide tablets(600mg) twice daily for 5 days
11518212|NCT01227421|Placebo Comparator|Placebo|2 placebo tablets twice daily for 5 days
11518213|NCT01227408|Experimental|Metronomic Chemotherapy|Doxorubicin will be administered as an intravenous bolus, careful intravenous injection. PPX will be administerd as an intravenous 10 mins. infusion. Capecitabine and methotrexate will be taken orally twice a day. Cyclophosphamide will be taken orally once a day.
11518214|NCT01227395||Azithromycin|Patients taking Azithromycin.
11518215|NCT01227382|Other|ERCP with Cholangiopancreatoscopy|The subjects who have been scheduled for an Endoscopic Retrograde Cholangiopancreatography (ERCP) with Cholangiopancreatoscopy for evaluation of a bile duct or pancreatic duct stricture sampling.
11518216|NCT01227369||Bisphosphonates|Korean postmenopausal osteoporosis patients with bisphosphonate treatment
11518217|NCT01227356|Experimental|imatinb + pegIntron|
11518218|NCT01227343||Female Smokers|Healthy females who smoke 10-30 cigarettes per day for the past 2 years and meet criteria for nicotine dependence.
11518219|NCT01227343||Female Non-smokers|Healthy females who do not currently smoke cigarettes.
11518220|NCT01227343||Male Smokers|Healthy males who smoke 10-30 cigarettes per day for the past 2 years and who meet criteria for nicotine dependence.
11518221|NCT01227343||Male - Non-Smokers CLOSED|WE ARE NO LONGER RECRUITING MALE NON-SMOKERS
11518222|NCT01227330|Experimental|Medication adherence intervention|Receives 12-week behavioral feedback intervention to improve adherence to statin medication
11518223|NCT01227330|No Intervention|Control|No intervention
11518224|NCT01227330|Active Comparator|Attention-control|Receives visits on the same schedule as the intervention group, with health education that is unrelated to medications or cholesterol
11518225|NCT01227317||Acute dyspnea in ED|Acute severe shortness of breath (SOB) in emergency Department (ED) with suspicion of acute heart failure (AHF) or Pulmonary Embolism (PE)or Community-acquired pneumonia (CAP) or acute Exacerbation of chronic obstructive pulmonary disease (AE COPD)
11518226|NCT01227304|Experimental|Test of volume responsiveness using crystalloids|
11518227|NCT01227291|Experimental|SYL040012|SYL040012 Ophthalmic drop administration
11518228|NCT01227278|Placebo Comparator|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
11518229|NCT01227278|Experimental|Benralizumab 100 mg|Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
11518230|NCT01227265|Experimental|Preladenant 2 mg|Participants received 2 mg as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extension trial or return for a follow-up visit two (2) weeks later.
11518231|NCT01227265|Experimental|Preladenant 5 mg|Participants received 5 mg as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extension trial or return for a follow-up visit two (2) weeks later.
11518232|NCT01227265|Placebo Comparator|Placebo|Participants received preladenant-matching placebo as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extention trial or return for a follow-up visit two (2) weeks later.
11518233|NCT01227252|Experimental|LY2886721|
11518234|NCT01227252|Placebo Comparator|Placebo|
11518235|NCT01227239|Experimental|1|
11518236|NCT01227226|Active Comparator|Refresh tears|Allergan's Refresh tears artificial tear
11518237|NCT01227226|Active Comparator|Systane Ultra|Alcon's Systane Ultra artificial tear
11518238|NCT01227226|Active Comparator|Visine|Visine artificial tear
11518239|NCT01227226|Active Comparator|Blink tears|AMO's blink tears artificial tear
11518240|NCT01227187|Experimental|Xigris|Xigris used as anticoagulant in patients treated with hemodialysis.
11518241|NCT01227174|Experimental|Propofol sedation|Patients will be undergo procedural sedation using propofol.
11518242|NCT01227161||ultrasonography children|American Society of Anesthesiologists (ASA) I-II children between the age 0-7, undergoing elective urological surgery, such as inguinal hernia repair, orchiopexy, ureteroneocystostomy
11518243|NCT01227148|Experimental|Tightly glucose conntrol|
11518244|NCT01227148|Active Comparator|Conventional glucose control|
11518245|NCT01227109||With infection|This group consist of cancer patients with a bacterial infection
11518246|NCT01227109||Without infection|This is a group of cancer patients without infection
11518247|NCT01227096||Electro-acupuncture, Control|
11518248|NCT01227096||Preconditioning, No preconditioning|
11518249|NCT01227083||1|Asthma control test check AQLQ(Asthma Quality of Life Questionnaire)after being cAQOL(Computerized Asthma specific quality of life)
11518250|NCT01227083||2|Asthma control test check cAQOL(Computerized Asthma specific quality of life)after being AQLQ(Asthma Quality of Life Questionnaire)
11518251|NCT01227070||Asthmatic|
11518252|NCT01227070||Healthy Control|
11518253|NCT01227057|Experimental|Arm 1: Cognitive Rehabilitation|Cognitive rehabilitation and exposure therapy for hoarding
11518254|NCT01227057|Active Comparator|Arm 2: Case Management|Case management
11518255|NCT01227044|Active Comparator|NTX + MM/MC|Naltrexone + Medical Management/Medication Coaching
11518260|NCT01226992|Experimental|Fecal Transplant|2 weeks of oral vancomycin pre-treatment followed by single dose fecal transplant administered by rectal enema. Fecal transplant (slurry) consists of 50 grams healthy donor stool blended in 500ml of Normal Saline.
11518261|NCT01226992|Active Comparator|Oral Vancomycin Taper|2 weeks of oral vancomycin pre-treatment followed by 6-week taper of oral vancomycin
11518262|NCT01226979|Experimental|HDRBT (High Dose Rectal Brachytherapy)|Radiation: High-dose endorectal brachytherapy The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer. A daily dose of 6.5 Gy over four consecutive days
11518263|NCT01226966||A|
11518264|NCT01226953|Active Comparator|Arm 1|
11518265|NCT01226953|Active Comparator|Arm 2|
11518266|NCT01226927|Active Comparator|Continuous infusion rate|Patients received a continuous infusion of 0.2% ropivacaine at 10.1 mL/hr via their femoral nerve catheter.
11518267|NCT01226914|Placebo Comparator|Placebo|For subjects in the placebo group, saline was drawn into the applicator and aerosolized in a similar fashion; it was allowed to remain in the wound during closure.
11518268|NCT01226914|Experimental|Evicel|For subjects in the treatment group, Evicel was applied in the usual manner by study personnel, with 5mL of each component drawn into a two-barrel syringe device and aerosolized using a pedal-controlled inert gas supply.
11518269|NCT01226901|Experimental|MK-4827 once daily|MK-4827
11518270|NCT01226875|Active Comparator|A (Narrow focus, LP)|A (Narrow focus): stone is in lower pole of kidney and SWL using narrow focus on lithotripter
11518271|NCT01226875|Active Comparator|B (Wide focus, LP)|B: stone is in lower pole of kidney and SWL using wide focus on lithotripter
11518272|NCT01226875|Active Comparator|C (Narrow focus, no LP)|C: stone is in no-lower pole of kidney and SWL using narrow focus on lithotripter
11518273|NCT01226875|Active Comparator|D (Wide focus, no LP)|D: stone is in no-lower pole of kidney and SWL using wide focus on lithotripter
11518274|NCT01226862||Hub Hospital|Hub Hospital Cohort: Joint Commission-certified Primary Stroke Centers where patients are treated using hospital-based stroke teams and pathways; these hospital personnel also provide telemedicine consultation to satellite hospitals.
11518275|NCT01226862||Spoke Hospital|Spoke Hospital Cohort: non-stroke center certified sites, where patients are treated at an in-network telestroke community hospital using telemedicine technology with consultation provided by physicians from a hub hospital.
11518276|NCT01226862||Control Hospital|Control Hospital Cohort: non-stroke center certified sites with no telemedicine services.
11518277|NCT01226849|Experimental|Single Arm|"bortezomib, rituximab, ifosphamide, etoposide, carboplatin
~Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended"
11518278|NCT01226836|Experimental|Living Well with COPD for Pulmonary Rehabilitation|
11518279|NCT01226823|Placebo Comparator|Placebo|obstetrical monitoring plus placebo
11518280|NCT01226823|Experimental|Ursodeoxycholic acid|obstetrical monitoring plus active drug
11518281|NCT01226797|Placebo Comparator|Placebo|
11518282|NCT01226797|Active Comparator|PF-04136309|
11518283|NCT01226784|Active Comparator|Physcial exercise|15 weeks of progressive resistance group exercise, twice/week supervised by physical therapist
11518284|NCT01226784|Active Comparator|Relaxation exercise|15 weeks of relaxation exercise, twice/week supervised by physical therapist
11518285|NCT01226771|Experimental|"Group A (Loading)"|PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
11518286|NCT01226771|Experimental|"Group B (Priming)"|Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
11518287|NCT01226771|Active Comparator|"Group C (Standard-of-Care)"|PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
11518288|NCT01226758|Experimental|FLU-v with adjuvant|
11518289|NCT01226758|Placebo Comparator|Placebo|Adjuvant only placebo
11518290|NCT01226745|Experimental|ONO-4641 0.15 milligram (mg) - 0.15 mg|
11518291|NCT01226745|Experimental|ONO-4641 0.10 mg - 0.10 mg|
11518292|NCT01226745|Experimental|ONO-4641 0.05 mg - 0.05 mg|
11518293|NCT01226745|Experimental|Placebo - ONO4641 0.15 mg|
11518294|NCT01226745|Experimental|Placebo - ONO4641 0.10 mg|
11518295|NCT01226745|Experimental|Placebo - ONO4641 0.05 mg|
11518296|NCT01226732|Experimental|Dose Level 1|Hsp90 Inhibitor AUY922: 22mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
11518297|NCT01226732|Experimental|Dose Level 2|Hsp90 Inhibitor AUY922: 28mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
11518298|NCT01226732|Experimental|Dose Level 3|Hsp90 Inhibitor AUY922: 40mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
11518299|NCT01226732|Experimental|Dose Level 4|Hsp90 Inhibitor AUY922: 55mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
11518300|NCT01226732|Experimental|Dose Level 5|Hsp90 Inhibitor AUY922: 70mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
11518301|NCT01226732|Experimental|Dose Level 6|Hsp90 Inhibitor AUY922: 70mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1250mg/m2 PO BID d 1-14 of 21-day cycles
11518302|NCT01226719|Experimental|FOLFOXIRI+panitumumab regimen|"All patients will receive the FOLFOXIRI/panitumumab regimen, with drugs administered in the following order:
~Panitumumab
~Oxaliplatin
~Irinotecan
~Leucovorin
~5-Fluorouracil"
11518303|NCT01226706|Placebo Comparator|Placebos|Placebo injected into the detrusor at Day 1,
11518310|NCT01226693|Experimental|Sequence 6|oral, 6mg, single dose
11518311|NCT01226680|Experimental|Tasocitinib 0.005% QD|
11518312|NCT01226680|Experimental|Tasocitinib 0.003% QD|
11518313|NCT01226680|Placebo Comparator|Vehicle for Tasocitinib|
11518314|NCT01226667|Active Comparator|Flexible Dose|flexibly dosed pregabalin given BID (75-300 mg/d) increased gradually over 4 weeks then maintained at that same dosing for 4 weeks
11518315|NCT01226667|Active Comparator|Fixed Dosing|75 mg BID for one week and increased to 150 mg BID for 7 weeks
11518316|NCT01226654|Other|MS Patients|All subjects enrolled in this study will undergo MRI studies. A computerized neuropsychological battery of tests will be administered.
11518317|NCT01226654|Other|Healthy Patients|Patients enrolled in this study will undergo MRI studies. A computerized neuropsychological battery of tests will be administered.
11518318|NCT01226641|Experimental|Telemedecine|CPAP treatment with telemedicine system
11518319|NCT01226641|Active Comparator|Standard Care|Standard care, including CPAP
11518320|NCT01226628|Experimental|Cohort A|Phase 1: 3 patients will receive 60,000 human umbilical tissue-derived cells (hUTC)
11518321|NCT01226628|Experimental|Cohort B|Phase 1: 3 patients will receive 120,000 hUTC
11518322|NCT01226628|Experimental|Cohort C|Phase 1: 3 patients will receive 300,000 hUTC
11518323|NCT01226628|Experimental|Cohort D|Phase 1: 3 patients will receive 560,000 hUTC
11518324|NCT01226628|Experimental|Cohort E|Phase 1: 6 patients will receive 300,000 hUTC
11518325|NCT01226628|Experimental|Cohort F|Phase 1: 6 patients will receive either 60,000 or 300,000 hUTC
11518326|NCT01226628|Experimental|Cohort G|Phase 1: 6 patients will receive either 60,000 or 300,000 hUTC
11518327|NCT01226628|Experimental|Phase 2a|Up to 38 patients will receive one of two optimal doses as selected from the Phase 1 portion of the study
11518328|NCT01226615|Experimental|1|Chondroitin sulphate
11518329|NCT01226615|Placebo Comparator|2|Placebo
11518330|NCT01226602|Experimental|1|Adenosinladder; Ticagrelor (180 mg), Adenosinladder ; Theophylline (5 mg/kg), Adenosinladder
11518331|NCT01226602|Placebo Comparator|2|Adenosinladder; Placebo, Adenosinladder; Theophylline (5 mg/kg), Adenosinladder
11518332|NCT01226576|Experimental|Treatment|ExAblate Treatment Arm
11518333|NCT01226563|Experimental|IK-5001|IK-5001 Sodium Alginate Calcium Gluconate intracoronary injection
11518334|NCT01226563|Placebo Comparator|Saline Solution|Saline Solution intracoronary injection
11518335|NCT01226550|Experimental|cytoreductive surgery and HIPEC|
11518336|NCT01226537|Active Comparator|Diabetes Mellitus type 1 taurine|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
11518337|NCT01226537|Placebo Comparator|Diabetes mellitus type 1 placebo|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
11518338|NCT01226537|Active Comparator|Diabetes type 2 taurine|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
11518339|NCT01226537|Placebo Comparator|Diabetes type 2 placebo|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
11518340|NCT01226524|Experimental|Traditional Chinese Medicine|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulations, i.e. Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan
11518341|NCT01226511|Experimental|Duloxetine|30-120 mg flexible dosing once daily for 10 weeks. At the end of the 10 week blinded treatment period, participants may participate in an 18 week extension
11518342|NCT01226511|Placebo Comparator|Placebo|Administered once daily for 10 weeks. At the end of the 10 week blinded treatment period, placebo participants receive duloxetine in the 18 week extension
11518343|NCT01226498|Experimental|Fresh blood auto-transfusion|
11518344|NCT01226498|Experimental|Old blood auto-transfusion|
11518345|NCT01226485|Experimental|Taladegib|"Part A Cohort 1: 50 milligram (mg) taladegib administered orally QD on a 28-day cycle.
~Part A Cohort 2: 100 mg taladegib administered orally QD on a 28-day cycle.
~Part A Cohort 3: 200 mg taladegib administered orally QD on a 28-day cycle.
~Part A Cohort 4: 400 mg taladegib administered orally QD on a 28-day cycle.
~Part A Cohort 5: 600 mg taladegib administered orally QD on a 28-day cycle.
~Part C: 400 mg taladegib administered orally QD. Participants with advanced solid tumors.
~Part D: 400 mg taladegib administered orally QD. Participants with advanced basal cell carcinoma (BCC)."
11518346|NCT01226472|Experimental|KW-0761|
11518347|NCT01226459|Experimental|Minoxidil Foam|5% Minoxidil Topical Foam
11518348|NCT01226459|Placebo Comparator|Vehicle Foam|Vehicle Topical Foam
11518349|NCT01226446|Experimental|Addition of Vitamin D to Peg-interferon plus Ribavirin|
11518350|NCT01226420|Experimental|Alefacept|Alefacept iv
11518351|NCT01226407|Experimental|Single Arm for CG200745|any progrossive solid cancer
11518352|NCT01226394|No Intervention|surveillance|
11518353|NCT01226394|Experimental|laparotomy plus HIPEC.|
11518354|NCT01226355|Experimental|NOYA|implant NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stents Intervention: Device: stent
11518355|NCT01226355|Active Comparator|Firebird2|implant Firebird2 drug-eluting stents Intervention: Device: stent
11518356|NCT01226342|Experimental|TCEMS|Patients who will receive transcutaneous electrical muscle stimulation
11518357|NCT01226329|Experimental|RQP-MH|Participants in the intervention arm will receive three Patient Activation and Self-Management education sessions, plus a fourth booster session if they show difficulty mastering the content of the first three trainings.
11518570|NCT01224886|No Intervention|Athletes|
11518358|NCT01226329|Active Comparator|Comparison Group|"Participants in this arm will receive a pamphlet in either Spanish or English called Managing Your Mental Health Care."
11518359|NCT01226316|Experimental|Part A and B Schedule 1, Continuous dosing|Part A: Ascending doses of AZD5363 administered orally, every day to define the maximum tolerated dose. Part B: Dose expansion phase, at the defined maximum tolerated dose or recommended dose from Part A.
11518360|NCT01226316|Experimental|Parts A,B,C,D Schedule 2, Intermittent dosing|Part A: Ascending doses of AZD5363 administered orally, twice daily, on a 7-day repeating regimen (4 days on, 3 days off and 2 days on, 5 days off), to define the maximum tolerated dose. Part B: Dose expansion phase, at the defined maximum tolerated dose or recommended dose from Part A (4 days on, 3 days off and 2 days on, 5 days off). Part C and D: AZD5363 orally, twice daily on an intermittent regimen (4 days on, 3 days off).
11518361|NCT01226316|Experimental|Parts A and B Schedule 3, Intermittent dosing.|"Part A: Ascending doses of AZD5363 administered orally, twice daily, on an alternative weekly regimen. Initiation of Schedule 3 is dependant on emerging clinical data.
~Part B: Dose expansion phase, at the defined maximum tolerated dose or recommended dose from Part A"
11518362|NCT01226316|Experimental|Parts E and F, Intermittent dosing with Fulvestrant|Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment to cessation of therapy combined with background therapy of fulvestrant at its licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter to cessation of therapy.
11518363|NCT01226303|Experimental|standard risk|are defined as those patients with a WBC less than 10x10 9 /L at presentation
11518364|NCT01226303|Active Comparator|high risk|are defined as those patients whose highest treatment WBC is equal to or greater than 10x10 9 /L at presentation
11518365|NCT01226290|Experimental|VizAblate treatment|VizAblate System: subject acts as her own control
11518366|NCT01226277|Experimental|A|
11518367|NCT01226251||Healthy adults|Subjects consulting a bad breath clinic at the Department of Periodontology, KULeuven
11518368|NCT01226238|Experimental|Online self-help|Provision of online self-help while waiting for psychotherapy
11518369|NCT01226238|No Intervention|Waiting list alone|Waiting for psychotherapy alone
11518370|NCT01226225|Experimental|Aerobic interval training|
11518371|NCT01226225|Active Comparator|Moderate endurance training|
11518372|NCT01226212|Experimental|Synbiotic|Synbiotic (Synergy 1/B. longum)
11518373|NCT01226212|Placebo Comparator|Placebo|maltodextrose
11518374|NCT01226186|Active Comparator|Nurse dispensed oral morphine solution.|
11518375|NCT01226186|Active Comparator|Self medicated oral morphine solution.|
11518376|NCT01226160|Experimental|Face-down posturing group|Postoperative face-down positioning for 10 days after surgery.
11518377|NCT01226160|Active Comparator|Non-posturing group|avoid a face-up position for 10 days after surgery
11518378|NCT01226134|Experimental|1.Itopride Group|The itopride group will receive itopride 150mg per day(50mg TDS)for four weeks
11518379|NCT01226134|Placebo Comparator|2.Control placebo group|The control group will receive placebo tablets for four weeks
11518380|NCT01226121|Active Comparator|Day 1 manipulation|Finger manipulation one day following Clostridial collagenase injectable
11518381|NCT01226121|Active Comparator|Day 2 manipulation|Finger manipulation two days following Clostridial collagenase injectable
11518382|NCT01226121|Active Comparator|Day 4 manipulation|Finger manipulation four days following Clostridial collagenase injectable
11518383|NCT01226108|Active Comparator|antinitus patch|One patch per day, Duration: three weeks, Administration: behind the ear
11518384|NCT01226095||Osteoarthritic patients|Patients male or female, age ≥ 18 having clinical or radiological evidence of osteoarthritis
11518385|NCT01226082|Experimental|Transcranial Direct Current Stimulation|
11518386|NCT01226069|Active Comparator|Glycerine Magnesium Sulphate paste|
11518387|NCT01226069|Active Comparator|Hirudoid cream|Topical Mucopolysaccharide polysulphate
11518388|NCT01226069|Experimental|No application|Patient will not receive any topical application to apply on the phlebitis site. The outcome assessor will monitor regularly at pre-determined schedule as patients in other active arms.
11518389|NCT01226056|Experimental|RAD001 in combination with sorafenib|
11518390|NCT01226043|Experimental|Lantus (insulin glargine) vial & syringe|10 mL vial, 1000 U per vial for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.
11518391|NCT01226043|Experimental|Lantus (insulin glargine) SoloSTAR pen|3 mL SoloSTAR pre-filled disposable insulin delivery device (pen), 300 U per device for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.
11518392|NCT01226030|Experimental|M2ES 7.5mg|M2ES 7.5mg
11518393|NCT01226030|Experimental|M2ES 15mg|M2ES 15mg
11518394|NCT01226030|Experimental|M2ES 30mg|M2ES 30mg
11518395|NCT01226030|Experimental|M2ES 60mg|M2ES 60mg
11518396|NCT01225991|Experimental|Milnacipran, active drug, open-label|All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day, or to their maximum tolerated dose in the course of the first week. The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day). Final efficacy assessments will be made at the termination visit, and the study medication will be tapered down following 12 weeks of drug treatment.
11518397|NCT01225978||GeneInsight Clinic (GIC)|The Group/Cohort in this study are geneticists, physicians, and genetic counselors who are using the GeneInsight Clinic (previously known as Patient Genome Explorer) to receive and store genetic test reports and variant update information.
11518398|NCT01225965|Experimental|EIL05, Inhalation|
11518399|NCT01225965|Placebo Comparator|Placebo, 0,9% NaCl|
11518400|NCT01225952|Experimental|Crystalens AO|Bausch & Lomb silicone multi-piece accommodating IOL is a modified plate haptic lens
11518401|NCT01225952|Active Comparator|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
11518402|NCT01225952|Active Comparator|AMO Tecnis Multifocal|A foldable hydrophobic acrylic IOL,(Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL
11518403|NCT01225939|Experimental|1|Single Oral dose AZD8329 tablet (fasting)
11518404|NCT01225939|Experimental|2|Single Oral dose AZD8329 solution (fasting)
11518405|NCT01225939|Experimental|3|Single Oral dose AZD8329 tablet (Fed)
11518406|NCT01225926|Experimental|Toric T3 - T9|AcrySof IQ Toric IOL surgically implanted in the capsular bag of the eye following cataract removal. Both eyes were implanted, with the second eye implanted at least 1 week after and within 1 month of the first eye.
11518407|NCT01225926|Active Comparator|IQ SN60WF|AcrySof IQ IOL surgically implanted in the capsular bag of the eye following cataract removal. Both eyes were implanted, with the second eye implanted at least 1 week after and within 1 month of the first eye.
11518408|NCT01225913|Other|Asthma observational study arm|Asthmatics in this arm may be on varying dose of inhaled fluticasone 100-500mcg/salmeterol 50mcg bid via Advair MDI or equivalent dose via Diskus bid or Symbicort (budesonide 80-160mcg/formoterol 4.5mcg bid)or Dulera 100-200mcg mometasone/5 mcg formoterol bid, tiotropium 18mcg capsule daily. This is an observational study and additional pharmacologic intervention may include antibiotic and tapering doses of corticosteroids.
11518409|NCT01225887|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11518410|NCT01225874|Experimental|Stratum 3|Patients receive oral dexamethasone twice daily on days 1-28; vincristine sulfate IV on days 1, 8, 15, and 22; pegaspargase intramuscularly (IM) on day 4, 5, or 6; cytarabine intrathecally (IT) on day 1; and methotrexate IT on day 8 (some patients also receive methotrexate IT on days 15 and 22).
11518411|NCT01225874|Experimental|Stratum 4|Patients receive oral prednisone twice daily on days 1-28; vincristine sulfate IV on days 1, 8, 15, and 22; IM SC-PEG E. coli asparaginase on days 2, 5, 8, 12, 15, and 19; daunorubicin hydrochloride IV over 15-20 minutes on days 8, 15, and 22; and methotrexate IT on days 1 and 8 (some patients also receive methotrexate IT on days 15 and 22).
11518412|NCT01225835|Experimental|Menotrophin|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met. Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.
11518413|NCT01225835|Active Comparator|Follitrophin Alpha|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met. Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.
11518414|NCT01225822|Experimental|BIBR 1048 50 mg bis in die(b.i.d)|BIBR 1048 50 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus one placebo matching enoxaparin 0 mg once a day for the treatment period
11518415|NCT01225822|Experimental|BIBR 1048 150 mg b.i.d|BIBR 1048 150 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
11518416|NCT01225822|Experimental|BIBR 1048 225 mg b.i.d|BIBR 1048 225 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
11518417|NCT01225822|Experimental|BIBR 1048 300 mg quaque die(q.d)|BIBR 1048 150 mg q.d once a day plus placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
11518418|NCT01225822|Active Comparator|Enoxaparin 40 mg subcutaneous(s.c)|placebo matching BIBR 1048 0 mg twice a day plus enoxaparin 40 mg s.c once a day for the treatment period
11518419|NCT01225809||AD01with or without adjuvant|Patients who have received at least one immunization of AD01 with or without adjuvant during AFF001
11518420|NCT01225796|Experimental|Sodium bicarbonate|This group will receive oral sodium bicarbonate 650mg three times daily for 6 months.
11518421|NCT01225796|No Intervention|Control|This group will not receive any sodium bicarbonate.
11518422|NCT01225770|Experimental|Green tea|Gargling with green tea
11518423|NCT01225770|Active Comparator|water|Gargling with water
11518424|NCT01225757|Experimental|Echocardiography|These patients will have echocardiography guided fluid management
11518425|NCT01225757|Active Comparator|Traditional fluid management|Fluid management will be guided by monitoring of central venous pressure and urine output.
11518426|NCT01225744|Experimental|Cetuximab plus Irinotecan, Oxaliplatin and UFT|Cetuximab plus Irinotecan, Oxaliplatin, UFToral
11518427|NCT01225731|Experimental|Part 1: Tildrakizumab 5 mg|Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4
11518428|NCT01225731|Experimental|Part 1: Tildrakizumab 25 mg|Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4
11518429|NCT01225731|Experimental|Part 1: Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4
11518430|NCT01225731|Experimental|Part 1: Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4
11518431|NCT01225731|Placebo Comparator|Part 1: Placebo|Participants receive placebo, SC, at Weeks 0 and 4
11518432|NCT01225731|Experimental|Part 2: Tildrakizumab 5 mg|Participants receive tildrakizumab 5 mg, SC, every 12 weeks for up to 36 weeks
11518433|NCT01225731|Experimental|Part 2: Tildrakizumab 25 mg|Participants receive tildrakizumab 25 mg, SC, every 12 weeks for up to 36 weeks
11518434|NCT01225731|Experimental|Part 2: Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg, SC, every 12 weeks for up to 36 weeks
11518435|NCT01225731|Experimental|Part 2: Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg, SC, every 12 weeks for up to 36 weeks
11518436|NCT01225731|No Intervention|Part 3: Tildrakizumab 5 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
11518437|NCT01225731|No Intervention|Part 3: Tildrakizumab 25 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
11518438|NCT01225731|No Intervention|Part 3: Tildrakizumab 100 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
11518439|NCT01225731|No Intervention|Part 3: Tildrakizumab 200 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
11518440|NCT01225731|No Intervention|Part 3: Placebo Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
11518441|NCT01225705|Experimental|Raltegravir|45 patients will receive open label raltegravir, in addition to the common backbone tenofovir and emtricitabine
11518442|NCT01225705|Active Comparator|Atazanavir/ritonavir|45 patients will receive open label atazanavir/ritonavir
11518443|NCT01225679||polysomnography|Overnight supervised polysomnography (Embla System®) was performed in a sleep laboratory, which included capnometry. Arterial blood gas analysis was performed by radial arterial puncture. Ventilatory response to progressive hypercapnia was measured using the Read breathing technique. Briefly, subjects rebreathed into an air tight 5-L bag containing a mixture of 8% carbon dioxide (CO2) and 40% oxygen (O2). The spirometer technology used to monitor ventilation was based on a bi-directional rotating vane principle (flow sensitive). A continuous record of CO2 concentration in the expired gas was obtained by a CO2 analyzer within the circuit. The ventilatory hypercapnic drive was calculated from the slope produced by changes in ventilation (L. min-1) and changes in end-tidal PCO2.
11518444|NCT01225666|Experimental|Weekly low dose|MOD-4023
11518445|NCT01225666|Experimental|Weekly middle dose|MOD-4023
11518446|NCT01225666|Experimental|Weekly high dose|MOD-4023
11518447|NCT01225666|Experimental|Every-other week dose|MOD-4023
11518448|NCT01225653|Experimental|Latanoprost|Topical treatment with latanoprost
11518449|NCT01225653|Placebo Comparator|Placebo|Placebo arm
11518450|NCT01225640|Experimental|PNU-100480 600 mg BID|
11518451|NCT01225640|Experimental|PNU-100480 1200 mg QD|
11518452|NCT01225640|Active Comparator|RHZE|conjugated tablet with 4 drug combination of RHZE, Rifafour® e275 will be used in countries where can be sourced locally
11518453|NCT01225627|Experimental|Coordinated discharge|Patients will receive support by discharge coordinator for activities associated with discharge and immediate post-discharge care.
11518454|NCT01225627|Placebo Comparator|Control|Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
11518455|NCT01225614|Experimental|bipap ventilation|
11518456|NCT01225614|Active Comparator|Standard care|Standard care and ventilation if occurrence of absolute criteria of ventilation (cf infra).
11518457|NCT01225601||Histocytosis|Adult with isolated pulmonary Langerhans cell histiocytosis (pulmonary LCH)
11518458|NCT01225575|Active Comparator|co.don chondrosphere®, 3-7 spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.
~The dose in group A is 3-7 spheroids/cm2 defect"
11518459|NCT01225575|Active Comparator|co.don chondrosphere®,10-30spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.
~The dose in group B is 10-30 spheroids/cm2 defect"
11518460|NCT01225575|Active Comparator|co.don chondrosphere®,40-70spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.
~The dose in group C is 40-70 Spheroids/cm2 defect"
11518461|NCT01225562|Experimental|1|Oral Treatment
11518462|NCT01225562|Experimental|2|Oral Treatment
11518463|NCT01225562|Placebo Comparator|3|Oral Treatment
11518464|NCT01225549|Experimental|1|AZD5423 75ug
11518465|NCT01225549|Experimental|2|AZD5423 300ug
11518466|NCT01225549|Active Comparator|3|Budesonide 200 microgram
11518467|NCT01225549|Placebo Comparator|4|Placebo
11518468|NCT01225536|Experimental|ARQ 736|
11518469|NCT01225523|Active Comparator|Preoperative chemotherapy followed by surgery|
11518470|NCT01225523|Active Comparator|Perioperative chemotherapy with surgery|
11518471|NCT01225510|Experimental|Primary Cohort|
11518472|NCT01225510|Experimental|Exploratory Cohort|
11518473|NCT01225497|Active Comparator|Standard eccentric exercise|Participants randomised to this group shall complete 180 repetitions a day of Alfredsons heel drop protocol. This has been accepted as standard management for mid-portion Achilles pain in the first instance.
11518474|NCT01225497|Experimental|Eccentric exercise as able|Participants randomised to this group shall carry out exactly the same eccentric exercises as per Alfredsons heel drop protocol. However, these individuals will be instructed to do what they can.
11518475|NCT01225484|Active Comparator|CFNB, periarticular infiltration|
11518476|NCT01225484|Active Comparator|Intraarticular catheter, periarticular infiltration|
11518477|NCT01225458|Placebo Comparator|exclusive nephrology follow-up|"250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring."
11518478|NCT01225458|Experimental|geriatric follow-up|"250 patients will be included and randomized in the geriatric follow-up arm. They will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients.
~About geriatric evaluation Patients randomized in this arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status."
11518479|NCT01225445|Experimental|Treatment|ramipril 2.5 mg daily
11518480|NCT01225445|No Intervention|Control|
11518481|NCT01225432|Experimental|Gait Training|
11518482|NCT01225406||third line naive|Children on second line or other regimen who switch or start third line regimen
11518483|NCT01225406||third line experienced|children who are on third line regimen
11518484|NCT01225393|Experimental|A|
11518485|NCT01225393|Active Comparator|B|
11518486|NCT01225393|Placebo Comparator|C|
11518487|NCT01225380|Experimental|Arm 1|GS-9190 and GS-9256 in combination with Pegasys® and Copegus® for 16 or 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
11518488|NCT01225380|Experimental|Arm 2|GS-9256 (active) and placebo matching GS-9190 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
11518489|NCT01225380|Placebo Comparator|Arm 3|Placebo matching GS-9190 and placebo matching GS-9256 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® will be continued for up to 48 weeks total duration
11518490|NCT01225367||pulmonary doppler|
11518491|NCT01225354|Experimental|Calcium hydroxylapatite|Subject will be treated at baseline and, if needed, at 2 weeks.
11518492|NCT01225341|Experimental|onabotulinumtoxinA/placebo|Patients will be injected every 3 months with onabotulinumtoxinA for a period of 12 months. At the 12 month visit, patients will receive injections of saline.
11518493|NCT01225341|Placebo Comparator|Bacteriostatic normal saline/ onabotulnimtoxinA|Patients will be injected every 3 months with saline for a period of 12 months. At the 12 month visit, patients will receive injections of onabotulnimtoxinA.
11518494|NCT01225328|Experimental|Intervention|Telephone-delivered Behavioral Activation/Problem Solving (BA/PS) intervention
11518495|NCT01225315|Experimental|Setipiprant - Dose 1|100 mg b.i.d.
11518496|NCT01225315|Experimental|Setipiprant - Dose 2|500 mg b.i.d.
11518497|NCT01225315|Experimental|Setipiprant - Dose 3|1,000 mg b.i.d
11518498|NCT01225315|Placebo Comparator|Matching Placebo|Oral placebo
11518499|NCT01225302|Experimental|Arm A|
11518500|NCT01225302|Experimental|Arm B|
11518501|NCT01225289|Active Comparator|with Multiple Sclerosis/ vitamin A|Patients with MS confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A
11518502|NCT01225289|Placebo Comparator|with Multiple Sclerosis/ placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo per day
11518503|NCT01225276|Experimental|Dosage Arm 1|NewGam 10% 0.4 g/kg
11518504|NCT01225276|Experimental|Dosage Arm 2|NewGam 10% 1.0 g/kg
11518505|NCT01225276|Experimental|Dosage Arm 3|NewGam 10% 2.0 g/kg
11518506|NCT01225276|Placebo Comparator|Dosage Arm 4|Placebo 0.9% Saline
11518507|NCT01225263|Experimental|Simvastatin and vitamin D|Participants in this arm will receive simvastatin + vitamin D.
11518508|NCT01225263|Placebo Comparator|"Placebo Sugar Pill"|"Participants in this arm will take placebo pills, which look like the simvastatin and vitamin D. A placebo pill has no active medication in it, and is like taking a sugar pill."
11518509|NCT01225250|Experimental|Polydioxanone (PDS) plates|15 subjects will be randomized to receive a caudal septal extension graft using a PDS plated cartilagenous graft
11518510|NCT01225250|Other|Non-plated cartilagenous graft|15 subjects will be randomized to receive a cartilagenous caudal septal extension fgraft
11518511|NCT01225237|Experimental|ramosetron group|
11518512|NCT01225237|Placebo Comparator|Placebo group|
11518513|NCT01225224|Experimental|ASP015K Single Japanese Group|Participants will be administered a single dose of ASP015K in three stages, each stage corresponding to a different dosage level.
11518514|NCT01225224|Experimental|ASP015K Single Caucasian Group|Participants will be administered a single dose of ASP015K in three stages, each stage corresponding to a different dosage level.
11518515|NCT01225224|Placebo Comparator|Placebo Single Japanese Group|Participants will be administered a single dose of placebo in three stages, each stage corresponding to a different dosage level.
11518516|NCT01225224|Placebo Comparator|Placebo Single Caucasian Group|Participants will be administered a single dose of placebo in three stages, each stage corresponding to a different dosage level.
11518517|NCT01225224|Experimental|ASP015K Multiple Group|Participants will receive ASP015K in three stages, each stage corresponding to a different dosage level. ASP015K will be administered at 12-hour intervals after breakfast and dinner for seven days.
11518518|NCT01225224|Placebo Comparator|Placebo Multiple Group|Participants will receive placebo in three stages, each stage corresponding to a different dosage level. Placebo will be administered at 12-hour intervals after breakfast and dinner for seven days.
11518519|NCT01225211|Placebo Comparator|Cohort 1: Placebo|Participants homozygous (HO) for the F508del-CF transmembrane conductance regulator gene (CFTR) mutation received lumacaftor matched placebo once daily (qd) (Day 1 through Day 14), followed by lumacaftor matched placebo qd in combination with ivacaftor matched placebo every 12 hours (q12h) (Day 15 through Day 21).
11518520|NCT01225211|Experimental|Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 150 mg q12h|Participants homozygous for the F508del-CFTR mutation received 200 milligram (mg) of lumacaftor (LUM) qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 150 mg of ivacaftor (IVA) q12h (Day 15 through Day 21).
11518521|NCT01225211|Experimental|Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h|Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 15 through Day 21).
11518522|NCT01225211|Placebo Comparator|Cohort 2 and 3: Placebo (HO and HE)|Participants homozygous or heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo qd (Day 1 through Day 28), followed by lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 29 through Day 56).
11518523|NCT01225211|Experimental|Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
11518524|NCT01225211|Experimental|Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 400 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
11518525|NCT01225211|Experimental|Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO&HE)|Participants homozygous or heterozygous for the F508del-CFTR mutation received 600 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 600 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
11518526|NCT01225211|Experimental|Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone q12h (Day 1 through Day 28), followed by 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
11518527|NCT01225211|Placebo Comparator|Cohort 4: Placebo|Participants heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 1 through Day 56).
11518571|NCT01224860|Experimental|Telmisartan|
11518528|NCT01225211|Experimental|Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h|Participants heterozygous for the F508del-CFTR mutation received 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 1 through Day 56).
11518529|NCT01225198|Placebo Comparator|Placebo Group|Liquid placebo with identical packaging and flavoring to the real supplement.
11518530|NCT01225198|Experimental|Vitamin/Mineral Supplement Group|Multi-vitamin/mineral supplement designed for this study for children and adults with autism spectrum disorders.
11518531|NCT01225185||Patients undergoing shoulder surgery|"This observational study will compare cerebral blood flow autoregulation in patients undergoing surgery in either the supine lateral position or the semi-recumbent or beach chair position. The choice of patient positioning is not randomized but based on usual surgical considerations."
11518532|NCT01225172|Experimental|BMS-754807|
11518533|NCT01225172|Experimental|BMS-754807 + letrozole|
11518534|NCT01225159|Experimental|Tight glycaemic control (TGC)|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
11518535|NCT01225159|Placebo Comparator|Conventional glycaemic control (Control)|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
11518536|NCT01225146|Active Comparator|Treatment Experienced (Cohort 1|"Previously treated with 6 or more intravitreal ranibizumab with persistent edema followed in RAVE 1 (FVF3348s).
~Cohort 1 patients will receive 1 dose of ranibizumab 2.0 mg, followed by PRN based on pre-defined retreatment criteria"
11518537|NCT01225146|Active Comparator|Treatment Naive (Cohort 2)|Treatment naïve. Cohort 2 patients will receive 6 doses of ranibizumab 2.0 mg, followed by PRN based on pre-defined re-treatment criteria.
11518538|NCT01225133|Active Comparator|Complex Ayurvedic Treatment|In the Āyurveda arm treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
11518539|NCT01225133|Active Comparator|Conventional Care|Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
11518540|NCT01225120|Experimental|Gait Training|
11518541|NCT01225107|Placebo Comparator|Inert Placebo Capsule|
11518542|NCT01225107|Experimental|Cranberry Extract|
11518543|NCT01225094|Experimental|curcumin|Patients will take the study medication (500 mg x 4 capsules, twice daily [BID]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg., and then another 2000 mg dose 6 hours after the repair. Final dose (2000 mg)is administered morning after repair.
11518544|NCT01225094|Placebo Comparator|placebo|The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.
11518545|NCT01225081|Experimental|ASP group|ASP1941 and pioglitazone
11518546|NCT01225081|Placebo Comparator|Placebo group|placebo and pioglitazone
11518547|NCT01225068|Experimental|Milnacipran|milnacipran 50 mg bid; can be increased to 100 mg bid
11518548|NCT01225068|Placebo Comparator|Placebo|Placebo
11518549|NCT01225055|Experimental|Teriparatide|Teriparatide alone with sham vibration
11518550|NCT01225055|Experimental|Vibration|Vibration alone with placebo-teriparatide
11518551|NCT01225055|Experimental|Teriparatide and vibration|Teriparatide with vibration applied in conjuction
11518552|NCT01225042|Experimental|probiotics|Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks
11518553|NCT01225042|Placebo Comparator|placebo|Carrier material powder of identical appearance
11518554|NCT01225029|No Intervention|Standard Fluids|Term neonates receive total fluids of 60 mL/kg/day on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
11518555|NCT01225029|Experimental|Restricted Fluids|Term neonates receive total fluids of 40 mL/kg/day on day of life (DOL) 1. Preterm neonates receive total fluids of 60 mL/kg/day on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved
11518556|NCT01224977|Other|azithromycin|
11518557|NCT01224964|Active Comparator|Montelukast|
11518558|NCT01224964|Active Comparator|long-acting beta2-mimetic|
11518559|NCT01224951|Active Comparator|Qvar 100|"Patients will be randomized to receive either the active arm (3/4) or a SABA as rescue medication (1/4). The patient will be asked to take Qvar 100 (2puffs) in the morning and in the evening.
~Daily dose (400 microgram)."
11518560|NCT01224951|No Intervention|Control|Patients are allowed to use their SABA as rescue medication only. During the last 4 weeks, the patients will receive 400 microgram of Qvar.
11518561|NCT01224938||Asthma patients|Asthmatics of all classes of severity will be included.
11518562|NCT01224938||Healthy control population|A healthy control population will be included to compare with the asthmatics.
11518563|NCT01224925|Active Comparator|Capping over carious exposure with Dycal|Total caries removal. In case of pulp exposure Direct Pulp capping with (Dycal®, Dentsply DeTrey GmbH, Konstanz, Germany)
11518564|NCT01224925|Experimental|Capping over carious exposure with WMTA|Total caries removal. In case of pulp exposure Direct Pulp capping with Mineral Trioxide Aggregate White ProRoot® (WMTA) (DENTSPLY, Tulsa Dental, Tulsa, OK, USA)
11518565|NCT01224912|Experimental|Internet Deliviered CBT for Insomnia|Cognitive behavioral self-help method for insomnia via the Internet
11518566|NCT01224899|Experimental|Surgery|
11518567|NCT01224899|No Intervention|Control|
11518568|NCT01224886|Experimental|Sedentary obese|
11518569|NCT01224886|Experimental|Sedentary normal weight|
11518573|NCT01224847|Active Comparator|Tetracaine gtt|Pre-Intravitreal injection - 1 gtt Tetracaine topically
11518574|NCT01224847|Active Comparator|Tetraciane gtt + Lidocaine pledget|1 gtt Tetracaine pre-IVT injection + application Lidocaine pledget to injection site
11518575|NCT01224847|Active Comparator|Cocaine gtt alone|1 gtt pre-IVT injection
11518576|NCT01224834|Placebo Comparator|1|
11518577|NCT01224834|Experimental|2|
11518578|NCT01224821|Experimental|Tositumomab and Iodine I-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
11518579|NCT01224808|Experimental|Experimental|
11518580|NCT01224795|Experimental|Peramivir|Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to < 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
11518581|NCT01224795|Placebo Comparator|Placebo|Placebo Peramivir, administered intravenously.
11518582|NCT01224782||Chronic Kidney Disease, Secondary Hyperparathyroidism|All eligible participants with chronic kidney disease stage 3 and 4 and secondary hyperparathyroidism treated with Zemplar (paricalcitol) capsules according to the local marketing authorization
11518583|NCT01224769||bendamustine +/- rituximab|
11518584|NCT01224756|Experimental|Tinoridine HCl 100 mg (2 capsules) TID|
11518585|NCT01224756|Placebo Comparator|Placebo TID|
11518586|NCT01224743|Placebo Comparator|Placebo|Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.
11518587|NCT01224743|Experimental|Blend 2|Blend 2 - combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends
11518588|NCT01224743|Experimental|Blend 1|Blend 1 - combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends
11518589|NCT01224730|Experimental|Perifosine 100 mg|Perifosine 100 mg orally daily under Fed and Fasted conditions
11518590|NCT01224717|Experimental|PTH134|
11518591|NCT01224717|Placebo Comparator|Placebo|
11518592|NCT01224717|Active Comparator|Forsteo|
11518593|NCT01224704|Experimental|Lean: hypertonic first|Lean: Hypertonic solution at day 6 and water deprivation at day 10
11518594|NCT01224704|Experimental|Lean: water deprivation first|Lean: Water deprivation at day 6 and hypertonic solution at day 10
11518595|NCT01224704|Experimental|Obese: hypertonic first|Obese: Hypertonic solution at day 6 and water deprivation at day 10
11518596|NCT01224704|Experimental|Obese: water deprivation first|Obese: Water deprivation at day 6 and hypertonic solution at day 10
11518597|NCT01224691||Asmathics|Asmathics
11518598|NCT01224691||Non-Asmathics|Non-Asmathics
11518599|NCT01224678|Placebo Comparator|Placebo|Patients receive oral placebo once daily for 12 months.
11518600|NCT01224678|Experimental|Vitamin D|Patients receive oral vitamin D (2000 IU) once daily for 12 months.
11518601|NCT01224665|Active Comparator|Arm I|therapeutic conventional surgery therapeutic standard lymphadenectomy
11518602|NCT01224665|Experimental|Arm II|therapeutic conventional surgery therapeutic extended lymphadenectomy
11518603|NCT01224652|Experimental|paclitaxel|Paclitaxel 70 mg/m2 on Days 1, 8 and 15 of a 28-day cycle
11518604|NCT01224652|Experimental|irinotecan|irinotecan 150 mg/m2 on Days 1 and 15 of a 28-day cycle
11518605|NCT01224639|Experimental|Group 1: Low Dose; SC|TDV-1: 8 x 10^3 Plaque Forming Units (PFU), TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, TDV-4: 2 x 10^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.
11518606|NCT01224639|Experimental|Group 2: Low Dose; ID|TDV-1: 8 x 10^3 PFU, TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, TDV-4: 2 x 10^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.
11518607|NCT01224639|Experimental|Group 3: High Dose; SC|TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, TDV-4: 3 x 10^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.
11518608|NCT01224639|Experimental|Group 4: High Dose; ID|TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, TDV-4: 3 x 10^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.
11518609|NCT01224639|Placebo Comparator|Placebo (SC)|Phosphate buffered saline administered subcutaneously in a volume of 0.5 mL.
11518610|NCT01224639|Placebo Comparator|Placebo (ID)|Phosphate buffered saline administered intradermally in a dose volume of 0.1 mL.
11518611|NCT01224626||Zyvox (linezolid)|Patients who have been treated with Zyvox (linezolid).
11518612|NCT01224613|Active Comparator|Intanza - self-administered|Self-administered intradermal influenza vaccine
11518613|NCT01224613|Active Comparator|Intanza - nurse-administered|Nurse-administered intradermal influenza vaccine
11518614|NCT01224600||1|patient with newly diagnosed PAD (< 1 year)
11518615|NCT01224587|Experimental|1|D1000078 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172),AstraZeneca,Mölndal, Sweden , under fasting condition
11518616|NCT01224587|Experimental|2|D1000082 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fasting condition
11518617|NCT01224587|Experimental|3|D1000083 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden ,under fasting condition
11518618|NCT01224587|Experimental|4|D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden , under fasting condition
11518619|NCT01224587|Experimental|5|D100083 marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fed condition
11518620|NCT01224587|Experimental|6|D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca, Mölndal, Sweden , under fed condition
11518621|NCT01224561||Constitutional thinness|Women with a a body mass index of less than 16.5 kg/m2
11518622|NCT01224561||Healthy Volonteer|Women with a body mass index between 20 and 25 kg/m2
11518623|NCT01224548|Experimental|vegan group|participants from sites of this group will receive vegan nutritional intervention starting from Feb 2011
11518624|NCT01224548|No Intervention|control group|participants from sites of the control group will not receive the same nutritional information until June 2011
11518625|NCT01224535|Experimental|Maize porridge with Amaranth|Maize porridge enriched with amaranth grain flour at 70:30 maize/amaranth ratio (80g/day)
11518626|NCT01224535|Active Comparator|Maize flour with multiple micronutrients|Maize porridge fortified with a multiple micronutrient powder (MixMe™)
11518627|NCT01224535|Placebo Comparator|Maize Porridge|Plain maize porridge group
11518628|NCT01224522|Experimental|Visionaire|the group who will be operated by the use of Visionaire patient matched cutting blocks
11518629|NCT01224522|Active Comparator|Standard Surgical technique|The group who will be operated by means fo standard surgical technique
11518630|NCT01224509|Experimental|Mifepristone|
11518631|NCT01224509|Active Comparator|Non-treatment|
11518632|NCT01224496|Experimental|Treatment with Chinese herbal concoction|"Patients must have a marrow study to confirm diagnosis of MDS, AA or MF. MDS is classified according to the WHO criteria and scored according to IPSS. The AA group is further classified into AA, SAA or VSAA . MF is defined by the Italian criteria and risk stratified by the Lilles Scoring system. Diagnosis of thal intermedia and major is based on previously done Hb electrophoresis and severity of disease is assessed by degree of anaemia.and frequency of blood transfusions
~TCM diagnosis: Syndrome differentiation according to TCM theory will be assessed as a baseline by experienced TCM collaborators and classified into one of the few defined syndromes as follows
~Yin deficiency of spleen and kidney
~Yang deficiency of spleen and kidney
~Deficiency of both Yin and Yang
~Stagnation of dampness and poison in the blood
~Excessive heat and poison"
11518633|NCT01224470|Active Comparator|bupivacaine|0.5% bupivacaine 1.2 mL + normal saline 0.8 mL = total 2 mL
11518634|NCT01224470|Placebo Comparator|saline|
11518635|NCT01224444||All adenomatous polyps|Standard polypectomy snare of adenomatous polyps (included serrated adenomas) from ≤5mm to ≤20mm.
11518636|NCT01224431|Experimental|Buffered lidocaine J-tip|Needleless injection of buffered lidocaine prior to lumbar puncture versus placebo (Normal saline)
11518637|NCT01224431|Placebo Comparator|Normal saline J-tip|Needleless injection of normal saline (placebo) prior to lumbar puncture versus use of buffered lidocaine
11518638|NCT01224418|Experimental|Tacrolimus group|
11518639|NCT01224405|Active Comparator|Treatment arm|ten docetaxel cycles + maintenance androgen deprivation.
11518640|NCT01224405|Experimental|suspension arm|Ten Docetaxel cycles + stop androgen deprivation therapy
11518641|NCT01224405|Experimental|intermittent arm|Intermittent Docetaxel
11518642|NCT01224405|Active Comparator|Continuous arm|Continuous Docetaxel
11518643|NCT01224392|Active Comparator|Concomitant chemoradiotherapy|Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends
11518644|NCT01224392|Experimental|Radiotherapy with boost|Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor
11518645|NCT01224379|Other|"Arm1: topping off system"|"The intervention group will receive a topping off system (PLIF -posterior intervertebral fusion- connected with a flexible pedicle screw system above the fusion)."
11518646|NCT01224379|Other|Arm 2: monosegmental PLIF|The control group receives a monosegmental PLIF. This is the current standard therapy for many pathologies in the lumbar spine (e.g. Spondylolisthesis)
11518647|NCT01224366|Experimental|Vildagliptin|
11518648|NCT01224366|Placebo Comparator|Placebo|
11518649|NCT01224353|Placebo Comparator|Thioctacid Oral Placebo Tablet|
11518650|NCT01224353|Active Comparator|Thioctacid Oral Tablet|
11518651|NCT01224340|Experimental|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
11518652|NCT01224340|Experimental|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path. The player got points for collected fishes but also credits for time of flying and speed.
11518653|NCT01224340|Experimental|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
11518654|NCT01224327|Experimental|umbilical cord mesenchymal stem cells|Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
11518655|NCT01224327|Active Comparator|Conserved therapy|Patients received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
11518656|NCT01224314|Active Comparator|dialysis fluid potassium high|potassium concentration in the dialysis fluid 1 mmol/L higher than usual
11518657|NCT01224314|Active Comparator|dialysis fluid potassium low|potassium concentration in the dialysis fluid 1 mmol/L lower than usual
11518658|NCT01224301|Experimental|School based flu vaccine: High intensity|Interventions: Parents in high intensity schools have access to school-based flu vaccine clinics and 3 or more communications from schools about influenza illness, influenza vaccine, and school based clinics.
11518659|NCT01224301|Experimental|School based flu vaccine: Low intensity|Interventions: Parents in low intensity schools have access to school-based flu vaccine clinics and less than 3 communications from schools about influenza illness, influenza vaccine, and school based clinics.
11518660|NCT01224301|No Intervention|Standard of Care|Control Schools did not have any in school seasonal influenza vaccine clinics. Parents of children in control schools got no notification from the schools and sought seasonal influenza vaccines for their children as they normally would.
11518661|NCT01224288|Experimental|DCE-CT Scans|DCE-CT = Dynamic contrast enhanced CT - DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
11518662|NCT01224275|Experimental|Group antenatal care|The first arm is midwife which allocated to group based antenatal care. They have education in this model of care and follow up meeting to secure the intervention
11518663|NCT01224275|No Intervention|Individual antenaal care|the second arm include midwife which allocated to traditional care as control group.
11518664|NCT01224262|Experimental|Fluzone + 0.45 mg LIQ001|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (0.45mg)
11518665|NCT01224262|Experimental|Fluzone + 1.8 mg LIQ001|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (1.8mg)
11518666|NCT01224262|Active Comparator|Fluzone|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)
11518667|NCT01224249|Active Comparator|Fish and shellfish|
11518668|NCT01224249|No Intervention|Control|Assessment only
11518669|NCT01224236|Experimental|iron supplementation|2 mg/kg/day of elemental iron as a multivitamin with iron solution
11518670|NCT01224236|Sham Comparator|control|multivitamin solution without iron
11518671|NCT01224223||acute asthma exaecerbtion patients|Patients experiencing acute exacerbation of their asthma
11518672|NCT01224223||chronic asthma group|Two groups are being enrolled. The first group is chronic asthma patients with FEV1 below 80% and FEV1/FVC ratio reduced by 5%
11518673|NCT01224210|Other|Ambrisentan|Open Label Ambrisentan
11518674|NCT01224197|Experimental|001|TMC435 100 or 200 mg capsule one single dose
11518675|NCT01224197|Experimental|002|TMC435 100 or 200 mg capsule once daily for 5 days
11518676|NCT01224184|Active Comparator|Nutrition|Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
11518677|NCT01224184|Experimental|Young Women's|Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (Principal Investigator (PI): Dr. Wendee M. Wechsberg).
11518678|NCT01224171|Placebo Comparator|Placebo|Participants received placebo intravenous infusion at Weeks 0, 2 and 6.
11518679|NCT01224171|Experimental|Vedolizumab|Participants received 300 mg intravenous vedolizumab at Weeks 0, 2, and 6.
11518680|NCT01224158|Experimental|PR-009577 Toothbrush|Experimental Power Toothbrush
11518681|NCT01224158|Active Comparator|PR-000172 Toothbrush|Flat trimmed Manual Toothbrush
11518682|NCT01224145|Experimental|Drug: Bupivacaine Collagen Sponge|bupivacaine collagen sponges
11518683|NCT01224132|No Intervention|Probiotics|
11518684|NCT01224132|No Intervention|skim milk powder, dextrose|
11518685|NCT01224119|Experimental|Amplex (synthetic bone graft)|
11518686|NCT01224119|Active Comparator|Autograft bone|
11518687|NCT01224106|Experimental|Gantenerumab 105 mg (Parts 1 and 2)|Participants with Alzheimer's disease will receive gantenerumab 105 milligrams (mg) by SC injection every 4 weeks (q4w) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who complete the Week 104 visit will be given an option to continue the treatment received during Part 1 for 2 additional years in Part 2.
11518688|NCT01224106|Experimental|Gantenerumab 225 mg (Parts 1 and 2)|Participants with Alzheimer's disease will receive gantenerumab 225 mg by SC injection q4w for 104 weeks or approximately 2 years during Part 1 of the study. Participants who complete the Week 104 visit will be given an option to continue the treatment received during Part 1 for 2 additional years in Part 2.
11518689|NCT01224106|Placebo Comparator|Placebo (Parts 1 and 2)|Participants with Alzheimer's disease will receive placebo SC injection q4w for 104 weeks or approximately 2 years during Part 1 of the study. Participants who complete the Week 104 visit will be given an option to continue the treatment received during Part 1 for 2 additional years in Part 2.
11518690|NCT01224106|Experimental|Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])|Participants with Alzheimer's disease that participated in Part 1 or Part 2 will receive open-label gantenerumab by SC injection at doses up to 1200 mg q4w for 3 additional years.
11518691|NCT01224093||First line|
11518692|NCT01224093||Relapsed/refractory|
11518693|NCT01224080|Experimental|Adiana Device|All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
11518694|NCT01224067|Active Comparator|Quetiapine|Quetiapine (dosage 50mg to 300mg + sertraline)Experimental
11518695|NCT01224067|Placebo Comparator|Placebo|Participant will receive placebo for 8 weeks.
11518696|NCT01224054||Bypass gastric|The mixed surgery which combine the gastric reduction with some degree of disabsorption
11518697|NCT01224054||Biliopancreatic diversion|The mal-absorptive surgery which reduce the intestinal absorption of food
11518698|NCT01224054||Duodenal exclusion|This surgery provides disabsortion by duodenal derivation maintaining an intact stomach
11518699|NCT01224041|Experimental|Tacrolimus group|
11518700|NCT01224028|Experimental|Tacrolimus group|
11518701|NCT01224028|Placebo Comparator|Placebo|
11518702|NCT01224015|Other|onabotulinumtoxinA 24U|24 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
11518703|NCT01224015|Placebo Comparator|placebo (normal saline)|Normal Saline (placebo) injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
11518704|NCT01224015|Experimental|onabotulinumtoxinA 44U|44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
11518705|NCT01223989|Experimental|group bread|group who received an hypocaloric balanced diet including bread
11518706|NCT01223989|Active Comparator|group without bread|group who received a hypocaloric balanced diet with exclusion of bread
11518707|NCT01223963||Macrolane|Women that have had breast enhancement with Macrolane Volume Restoration Factor.
11518708|NCT01223937|Experimental|Desmopressin 25 μg|Participants took 1 orally disintegrating tablet of desmopressin 25 μg every night approximately 1 hour before bedtime for the entire duration of the 3-month treatment period.
11518709|NCT01223937|Placebo Comparator|Placebo|Participants took 1 orally disintegrating tablet of placebo every night approximately 1 hour before bedtime for the entire duration of the 3-month treatment period.
11518710|NCT01223924|Experimental|M2ES 7.5-90mg|M2ES dose escalating
11518711|NCT01223924|Placebo Comparator|Placebo|placebo contract
11518712|NCT01223911|Experimental|A|
11518715|NCT01223885|Experimental|Camel's milk, Cow's milk allergy|
11518716|NCT01223872||Routine Patient Care|
11518717|NCT01223872||Previously-enrolled REACH Clinic Patients|
11518718|NCT01223872||New REACH Clinic Patients|
11518719|NCT01223859|Experimental|intervention|Interstitial soft palate RF surgery
11518720|NCT01223833||tamoxifen|100 postmenopausal women with early breast cancer treated with tamoxifen in the adjuvant setting
11518721|NCT01223833||aromatase inhibitors|200 postmenopausal women with early breast cancer treated with an aromatase inhibitor in the adjuvant setting
11518722|NCT01223820|Experimental|Capsaicin|
11518723|NCT01223807|No Intervention|Control Group|The control group will receive only usual care.
11518724|NCT01223807|Experimental|Diaphragmatic breathing training|The training group will be submitted to a diaphragmatic breathing training program of 4 weeks.
11518725|NCT01223794||Experimental Group|Fall in higher risk
11518726|NCT01223794||Control Group|Fall in lower risk
11518727|NCT01223781|Experimental|Feedforward stimulation|Prior to any gait condition likely to invoke freez, auditory stimulation is presented
11518728|NCT01223781|Experimental|Feedback stimulation|Once a device identifies freezing, a auditory stimulation is triggered
11518729|NCT01223768|Experimental|Acetyl-L-carnitine|
11518730|NCT01223768|Placebo Comparator|placebo|
11518731|NCT01223755|Experimental|Sirolimus|
11518732|NCT01223755|Active Comparator|conventional therapy|
11518733|NCT01223742|Experimental|ACETYL-L-CARNITINE|
11518734|NCT01223742|Placebo Comparator|placebo|
11518735|NCT01223729|Experimental|Acetyl-L-Carnitine|
11518736|NCT01223729|Placebo Comparator|placebo|
11518737|NCT01223716|Experimental|Perceptual learning|
11518738|NCT01223716|Experimental|Video Game|
11518739|NCT01223716|Experimental|Occlusion Therapy|
11518740|NCT01223703|Active Comparator|n-3 PUFAs|
11518741|NCT01223703|Placebo Comparator|Placebo|
11518742|NCT01223690|Placebo Comparator|Placebo|250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
11518743|NCT01223690|Active Comparator|Clarithromycin|1000 mg of clarithromycin diluted in 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
11518744|NCT01223677|Active Comparator|rumination focused CBT|RFCBT-group. This group training is based on research showing that dysfunctional forms of rumination are characterized by an abstract evaluative style of processing, whereas functional forms of of processing are more concrete and process-focused. The training uses psycho-education, functional analysis, group discussion, experiential exercises and behavioral experiments to facilitate the shift from dysfunctional ruminative thinking to a more helpful concrete thinking style.
11518745|NCT01223677|Active Comparator|rumination focused CBT (online)|The online training is based on research showing that dysfunctional forms of rumination are characterized by an abstract evaluative style of processing, whereas functional forms of of processing are more concrete and process-focused. The training uses psycho-education, functional analysis, experiential exercises and behavioral experiments to facilitate the shift from dysfunctional ruminative thinking to a more helpful concrete thinking style.
11518746|NCT01223677|No Intervention|No training control group|No training control group. Participants within this condition received no treatment, but only filled out the outcome measures at each measurement period.
11518747|NCT01223664|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
11518748|NCT01223664|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation
11518749|NCT01223651|Active Comparator|CGMS at sea level.|To assess reliability of continuous glucose monitoring system at sea level whilst subject undergo's a hyperinsulinaemic glucose clamp study.
11518750|NCT01223651|Active Comparator|CGMS reliability at simulated 8000 feet.|To assess reliability of continuous glucose monitoring system at a simulated altitude of 8,000 feet whilst the participant undergo's a hyperinsulinaemic glucose clamp study.
11518751|NCT01223638||Congenital hypothyroidism|Patient which were diagnosed with congenital hypothyroidism
11518752|NCT01223638||Controls|Patients without any endocrine or hearing problems
11518753|NCT01223625|Active Comparator|Rosuvastatin 5mg/day|Rosuvastatin 5mg/day
11518754|NCT01223625|Active Comparator|Rosuvastatin 40mg/day|Rosuvastatin 40mg/day
11518755|NCT01223612|Experimental|Ranibizumab|Intravitreal injection of ranibizumab
11518756|NCT01223612|Active Comparator|Laser|Modified ETDRS laser
11518757|NCT01223586||Regression|Patients with regression of plaque volume by statin
11518758|NCT01223586||Non regression|Patients without regression of plaque volume by statin
11518759|NCT01223547|No Intervention|Control group|Participants in this arm continues their usual insulin therapy
11518760|NCT01223547|Active Comparator|Carb counting|Participants in this arm are taught carb counting
11518761|NCT01223547|Active Comparator|Carb counting and bolus calculator|Participants in this arm are taught carb counting and are provided with an integrated glucose meter and bolus calculator.
11518762|NCT01223534|Active Comparator|Arm A, Standard practice, TST|Participants allocated to screening as stablished by current practice (TST)
11518763|NCT01223534|Experimental|Arm B, Experimental, TST plus QFT-IT|Participants allocated to screening with TST, and if positive, followed by QFT-IT to confirm tuberculosis infection.
11518764|NCT01223521|Experimental|Immediate intrauterine contraception|IUD (either Cu-IUD or LNG-IUS) inserted immediately after abortion.
11518765|NCT01223521|No Intervention|Control group|Post-abortal contraception is prescribed by the hospital but on the responsibility of the patient.
11518766|NCT01223482||Miscarriage with genetic testing|This is a study population of women that have had a miscarriage and had genetic testing performed. The investigators would like to know what their experiences were following their miscarriage and testing.
11518767|NCT01223482||Miscarriage without genetic testing|This cohort is considered the control group. These women have not had genetic testing done, but are asked questions regarding their miscarriage experience.
11518768|NCT01223469|Experimental|Atrial Fibrillation|
11518769|NCT01223469|Experimental|Right-sided Supraventricular Tachycardia|
11518770|NCT01223443|Experimental|PCI-stenting|Stenting the moderate SVG lesion with the paclitaxel stent
11518771|NCT01223443|No Intervention|Standard medical treatment|
11518772|NCT01223430|Experimental|Si-Ni-Tang|
11518773|NCT01223430|Placebo Comparator|Placebo|
11518774|NCT01223404|Experimental|Placebo, Nicotine, Mecamylamine|"Participants undergo 3 test sessions:
~In the first session (placebo), a placebo patch and a placebo capsule is administered.
~In the second session (nicotine), a nicotine patch (7 mg/24 hrs) and a placebo capsule is administered.
~In the third session (mecamylamine), a placebo patch and a mecamylamine capsule is administered."
11518775|NCT01223404|Experimental|Nicotine, Placebo, Mecamylamine|"Participants undergo 3 test sessions:
~In the first session (nicotine), a nicotine patch and a placebo capsule is administered.
~In the second session (placebo), a placebo patch (7 mg/24 hrs) and a placebo capsule is administered.
~In the third session (mecamylamine), a placebo patch and a mecamylamine capsule is administered."
11518776|NCT01223404|Experimental|Placebo, Mecamylamine, Nicotine|"Participants undergo 3 test sessions:
~In the first session (placebo), a placebo patch and a placebo capsule is administered.
~In the second session (mecamylamine), a placebo patch (7 mg/24 hrs) and a mecamylamine capsule is administered.
~In the third session (nicotine), a nicotine patch and a placebo capsule is administered."
11518777|NCT01223404|Experimental|Nicotine, Mecamylamine, Placebo|"Participants undergo 3 test sessions:
~In the first session (nicotine), a nicotine patch and a placebo capsule is administered.
~In the second session (mecamylamine), a placebo patch (7 mg/24 hrs) and a mecamylamine capsule is administered.
~In the third session (placebo), a placebo patch and a placebo capsule is administered."
11518778|NCT01223404|Experimental|Mecamylamine, Placebo, Nicotine|"Participants undergo 3 test sessions:
~In the first session (mecamylamine), a placebo patch and a mecamylamine capsule is administered.
~In the second session (placebo), a placebo patch (7 mg/24 hrs) and a placebo capsule is administered.
~In the third session (nicotine), a nicotine patch and a placebo capsule is administered."
11518779|NCT01223404|Experimental|Mecamylamine, Nicotine, Placebo|"Participants undergo 3 test sessions:
~In the first session (mecamylamine), a placebo patch and a mecamylamine capsule is administered.
~In the second session (nicotine), a nicotine patch (7 mg/24 hrs) and a placebo capsule is administered.
~In the third session (placebo), a placebo patch and a placebo capsule is administered."
11518780|NCT01223391|Experimental|Abdominal binder|Standing with abdominal compression using elastic vs. non-elastic abdominal binders.
11518781|NCT01223391|Placebo Comparator|No abdominal binder|Standing without abdominal compression
11518782|NCT01223378|Experimental|BOL-303259-X|ophthalmic solution
11518783|NCT01223378|Active Comparator|Latanoprost|ophthalmic solution
11518784|NCT01223365|Experimental|Hydrocodone ER|Participants were titrated (or re-titrated for roll-over participants) at escalating dosages of extended-release hydrocodone tablets at dosages of 15, 30, 45, 60, or 90 mg orally every 12 hours until deemed successful for managing their pain during the open-label titration period. Once a successful dose was identified, participants entered the 52 week open-label treatment period in which hydrocodone ER was administered at the successful dose (15, 30, 45, 60, or 90 mg) every 12 hours.
11518785|NCT01223352|Experimental|Bosentan 2 mg/Kg t.i.d.|2 mg/kg bosentan administered three times a day (morning, afternoon, evening) for a planned duration of 24 weeks
11518786|NCT01223352|Experimental|Bosentan 2 mg/Kg b.i.d.|2 mg/kg bosentan administered twice daily (morning and evening) for a planned duration of 24 weeks
11518787|NCT01223339|Experimental|Single Dose Japanese Cohort|This will be a single dose Cohort in which Japanese healthy participants will receive 3 ascending single doses (1 mg, 5 mg, and 25 mg) of ertugliflozin or placebo through 3 dosing periods. A minimum wash out period of 7-days will be set between each dose administration.
11518788|NCT01223339|Experimental|Single dose Western cohort|This will be a single dose Cohort in which Western healthy participants will receive 3 ascending single doses (1 mg, 5 mg, and 25 mg) of ertugliflozin through 3 dosing periods. A minimum wash out period of 7-days will be set between each dose administration.
11518789|NCT01223339|Experimental|Multiple Dose Japanese Cohort|This will be a multiple dose Cohort in which Japanese healthy participants will receive once-daily 25 mg ertugliflozin or placebo for 7 days.
11518790|NCT01223326|Experimental|N-acetylcysteine|Intravenous N-acetylcysteine
11518791|NCT01223326|Placebo Comparator|Placebo|Placebo
11518792|NCT01223313|Experimental|Woman's Condom|The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
11518793|NCT01223300||Osteoporosis|
11518794|NCT01223274|Experimental|CPAP/PEEP Intervention|Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
11518795|NCT01223274|Active Comparator|Control|Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
11518796|NCT01223248|Experimental|stereotactic IGIMRT using a single dose of 24 Gy|This is a phase III, multicenter, randomized, study comparing two dosing schedules for hypofractionated image-guided radiation therapy to bone, spine, soft tissue, and lymph nodes in patients with metastatic disease
11518797|NCT01223248|Experimental|stereotactic IGIMRT 27 Gy in 3 fractions|This is a phase III, multicenter, randomized, study comparing two dosing schedules for hypofractionated image-guided radiation therapy to bone, spine, soft tissue, and lymph nodes in patients with metastatic disease
11519266|NCT01219946||1|Patients with Chronic Obstructive Pulmonary Disease
11519267|NCT01219933|Experimental|1|
11518798|NCT01223235|Experimental|bevacizumab & polyvalent vaccine-KLH conjugate + OPT-821|This is a single institution, open label, pilot study of bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
11518799|NCT01223222|Placebo Comparator|1% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
11518800|NCT01223222|Active Comparator|2% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
11518801|NCT01223222|Active Comparator|5% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
11518802|NCT01223209|Experimental|LTX-315|The dose range of 0,25-2.0 mg/ML LTX-315 will be used. In combination with a fixed dose of GV-1001.
11518803|NCT01223196|Placebo Comparator|Placebo|One arm of the study subjects will be treated with Placebo only, once a day, for 6 months
11518804|NCT01223196|Active Comparator|Pioglitazone|One arm of the study subjects will be treated with Pioglitazone, 15mg, once a day, for 6 months
11518805|NCT01223183|Active Comparator|isotonic saline then hypertonic saline|Subjects inhaled nebulized isotonic saline on study day 1, and then after a 5-24 day washout period, subjects inhaled nebulized 7% hypertonic saline on study day 2.
11518806|NCT01223183|Active Comparator|hypertonic saline then isotonic saline|Subjects inhaled nebulized 7% hypertonic saline on study day 1, and then after a 5-24 day washout period, subjects inhaled nebulized isotonic saline on study day 2.
11518807|NCT01223170|Experimental|Enhanced Internet-based intervention|Behavioral: Tailored content Behavioral: Generic Internet-based information Behavioral: Discussion forum Behavioral: Behavioral monitoring
11518808|NCT01223170|Placebo Comparator|Control|Behavioral: Generic Internet-based information Behavioral: Discussion forum
11518809|NCT01223157|Experimental|Obese patients|
11518810|NCT01223157|Experimental|Normal weight subjects|
11518811|NCT01223144|Experimental|Patients with essential tremor|Patients with essential tremor
11518812|NCT01223144|Active Comparator|age- and sex-matched control subjects|age- and sex-matched control subjects
11518813|NCT01223131|Experimental|Insulin glargine|injection once daily at bedtime
11518814|NCT01223131|Active Comparator|NPH insulin|injection once daily at bedtime or twice daily in the morning and at bedtime
11518815|NCT01223118|Experimental|Oocyte Vitrification|Each patient will have oocytes randomized into two groups immediately after retrieval. Half of oocytes will be vitrified, thawed and inseminated. The other half will be inseminated only. All embryos will be biopsied for PGD prior to transfer and one embryo from each group will be transferred (vitrification and control groups). Following delivery, buccal swabs will be collected on all infants.
11518816|NCT01223105|Experimental|Slow Freezing|oocytes will be frozen by slow freeze/ rapid thaw
11518817|NCT01223105|Experimental|Vitrification|oocytes will be frozen using rapid freezing/rapid thaw
11518818|NCT01223092||Patients undegoing infertility treatment|Male and female patients undergoing infertility treatment
11518819|NCT01223079|Other|r-hFSH (Gonal F)|Patients will be treated with r-hFSH throughout the stimulation phase of their first cycle until r-hCG administration.
11518820|NCT01223079|Other|r-hFSH (Gonal F) and r-hLH (Luveris)|Patients will be treated with r-hFSH only until they have 2 follicles greater than or equal to 14mm. Patients will then bring 300IU/day of r-hLH until r-hCG administration.
11518821|NCT01223066||Women treated with Macrolane in the breasts|
11518822|NCT01223053|Active Comparator|Active|Topical ketoprofen 10% Cream
11518823|NCT01223053|Placebo Comparator|Placebo Cream|Placebo Cream
11518824|NCT01223040|Experimental|SYSTANE® Balance Lubricant Eye Drops|SYSTANE Balance Lubricant Eye Drops dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
11518825|NCT01223027|Experimental|Dovitinib + best supportive care (BSC)|Patients randomized to the dovitinib treatment arm received 500 mg of dovitinib orally on 5 days on/2 days off dosing schedule.
11518826|NCT01223027|Active Comparator|Sorafenib + BSC|Patients in the sorafenib control arm received400 mg of sorafenib (2 x 200 mg tablets) orally taken twice daily.
11518827|NCT01223014||1|Single cohort of 6 subjects
11518828|NCT01223001|Active Comparator|Duloxetine|Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
11518829|NCT01223001|Placebo Comparator|Sugar pill|Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
11518830|NCT01222988|Other|very low calorie diet program|
11518831|NCT01222975|Experimental|1|Risperidone orally disintegrating tablets of Ranbaxy Laboratories, Ltd
11518832|NCT01222975|Active Comparator|2|Risperdal® M-Tab of Janssen Pharmaceutica Products L.P.
11518833|NCT01222962|Experimental|fed treatment|18 healthy volunteers administered with a single dose of Eurartesim
11518834|NCT01222962|Experimental|Fasted Treatment|18 healthy volunteers treated with a single dose of Eurartesim
11518835|NCT01222949|Experimental|Asian Healthy Volunteers|Asian males with a body weight ≤ 65 kg (12 subjects) Asian females with a body weight ≤ 65 kg (12 subjects)
11518836|NCT01222949|Experimental|Caucasian Healthy Volunteers|Caucasian males with a body weight ≤ 65 kg (12 subjects) Caucasian females with a body weight ≤ 65 kg (12 subjects) Caucasian males with a body weight > 65 kg (24 subjects)
11518837|NCT01222923|Active Comparator|2|Risperdal® M-Tab of Janssen Pharmaceutica Products L.P.
11518838|NCT01222923|Experimental|1|Risperidone 1 mg ODT tablets of Ranbaxy Laboratories, Ltd
11518839|NCT01222910|Experimental|Test|Valacyclovir hydrochloride tablets 1 gm of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
11518840|NCT01222910|Active Comparator|Reference|VALTREX® (valacyclovir HCl) caplets 1 gm of GlaxoSmithKline Research Triangle Park, NC 27709
11518841|NCT01222897|Experimental|Test|Valacyclovir hydrochloride tablets 1 gm of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
11518842|NCT01222897|Active Comparator|Reference|VALTREX® (valacyclovir HCl) caplets 1 gm of GlaxoSmithKline Research Triangle Park, NC 27709
11518843|NCT01222884|Active Comparator|Iron isomaltoside 1000|Iron isomaltoside 1000 (Monofer)administered as 500 mg intravenous single bolus injections OR administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
11518844|NCT01222884|Active Comparator|Iron sucrose|Iron sucrose administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
11518845|NCT01222871|Experimental|Triamcinolone|Triamcinolone soaked nasopore dressing
11518846|NCT01222871|Placebo Comparator|Control Group|Saline soaked sponge
11518847|NCT01222858|Active Comparator|Internet Education Program|Participants receive 12 weekly Internet-based weight loss lessons containing information for modification of diet and activity behaviors.
11518848|NCT01222858|Experimental|Innovative Technology Intervention|Participants receive a 12-week Internet-based eating and activity intervention including multimedia lessons and enhanced self-monitoring of weight loss behaviors with automated feedback.
11518849|NCT01222845|Experimental|Pinhead oat porridge|
11518850|NCT01222845|Experimental|Rolled oat porridge|
11518851|NCT01222832|Experimental|Bacitracin|Nasopore sponge soaked in Bacitracin, no oral antibiotics
11518852|NCT01222832|No Intervention|Saline|Nasopore sponge soaked in saline, routine oral antibiotics
11518853|NCT01222819|Experimental|IV filgrastim|as a single daily dose of 5 mcg/kg (rounded to 300 mcg or 480 mcg) in bolus IV injection, as per manufacturer's recommendations.
11518854|NCT01222819|Active Comparator|SC filgrastim|given as a single daily dose of 5 mcg/kg (rounded to 300 mcg or 480 mcg)
11518855|NCT01222780|Experimental|Marqibo|"Marqibo® (Vincristine sulfate liposomal) will be administered intravenously over 60 minutes (±10 minutes) every 7 days (±3 days) (Days 1, 8, 15, 22) for four doses (1 cycle). Cycles may be repeated every 28 days for a maximum of 6 cycles; additional cycles may be offered with evidence of acceptable toxicity and clinical benefit.
~The trial follows a rolling phase I design with 2 to 6 subjects per dose level and standard definitions of MTD and DLT. At the MTD, a total of 6 additional subjects with relapsed or refractory ALL will be evaluated.
~Detailed pharmacokinetic studies will be performed during the first treatment cycle"
11518856|NCT01222767|Experimental|Arm 1|
11518857|NCT01222754|Experimental|1|Radiation with Lenalidomide
11518858|NCT01222741||Healthy Voluntary|Healthy Voluntary
11518859|NCT01222741||Patients|affected patient
11518860|NCT01222741||relatives|family member to patient
11518861|NCT01222715|Experimental|Arm I (vinorelbine tartrate, cyclophosphamide, bevacizumab)|Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1 and 8 and cyclophosphamide IV over 30-60 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1.
11518862|NCT01222715|Experimental|Arm II (vinorelbine tartrate, cyclophosphamide, temsirolimus)|Patients receive vinorelbine tartrate and cyclophosphamide as in arm I. Patients also receive temsirolimus IV over 30-60 minutes on days 1, 8, and 15.
11518863|NCT01222702|Experimental|Cadazolid 250 mg|Subjects received 250 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
11518864|NCT01222702|Experimental|Cadazolid 500 mg|Subjects received 500 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
11518865|NCT01222702|Experimental|Cadazolid 1000 mg|Subjects received 1000 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
11518866|NCT01222702|Active Comparator|Vancomycin 125 mg|Subjects received one vancomycin capsule (125 mg) four times daily and reconstituted placebo-matching cadazolid suspension twice daily for 10 days
11518867|NCT01222689|Experimental|Treatment (erlotinib hydrochloride, selumetinib)|Patients receive selumetinib PO QD and erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11518868|NCT01222663|Other|Standard therapy|Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate
11518869|NCT01222663|Experimental|Hemoperfusion|standard therapy + 2 sessions of hemoperfusion within the first 24 hours
11518870|NCT01222650|Experimental|KSO-0400 Low Dose|
11518871|NCT01222650|Experimental|KSO-0400 High Dose|
11518872|NCT01222650|Experimental|Silodosin|
11518873|NCT01222650|Placebo Comparator|Placebo|
11518874|NCT01222637|Experimental|CetuGEX™, 3-weekly|application q3w
11518875|NCT01222637|Experimental|CetuGEX™ 2-weekly|application q2w
11518876|NCT01222624|Experimental|PankoMab-GEX™, 3-weekly|application, q3w
11518877|NCT01222624|Experimental|Experimental: PankoMab-GEX™, 2-weekly|application q2w
11518878|NCT01222624|Experimental|PankoMab-GEX™, weekly|application q1w
11518879|NCT01222611|No Intervention|Standard HAART|ART with 3 drugs including 2 NRTIs plus a ritonavir boosted PI (different to FPV) or a NNRTI
11518880|NCT01222611|Experimental|HAART inlcuding Fos APV/r|ART with 3 drugs including 2 NRTIs plus ritonavir boosted fosamprenavir
11518881|NCT01222585|Experimental|Treatment|Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours
11518882|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 1)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 54 Gy; Stereotactic Boost to Primary: 10 Gy; Total Dose to Primary: 64 Gy
~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
11518921|NCT01222338|Active Comparator|Immunomodulator intervention|Two cohorts or arms of at least 60 subjects each (total 120) with pulmonary TB positive for sputum AFB smear will be randomized in a 1:1 ratio to receive once-daily, tablet of V-5 immunitor in combination with standard ATT for 2 months followed by ATT outside of trial for next 4 months or however long it needs to be.
11519018|NCT01221701|No Intervention|typical home visitation|Standard of care in home visitation in which mothers can receive treatment in the community if they choose.
11519374|NCT01219205|Active Comparator|major branched retinal venous occlusion|
11518883|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 2)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 50 Gy; Stereotactic Boost to Primary: 15 Gy; Total Dose to Primary: 65 Gy
~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
11518884|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 3)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 46 Gy; Stereotactic Boost to Primary: 20 Gy; Total Dose to Primary: 66 Gy
~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
11518885|NCT01222559|Experimental|co.don chondrosphere®|co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
11518886|NCT01222559|Active Comparator|Micofracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
11518887|NCT01222546|Experimental|CH5132799|
11518888|NCT01222533|Experimental|Tiotropium low|Tiotropium inhalation solution low dose
11518889|NCT01222533|Experimental|Tiotropium medium|Tiotropium inhalation solution medium dose
11518890|NCT01222533|Experimental|Tiotropium high|Tiotropium inhalation solution high dose
11518891|NCT01222533|Active Comparator|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
11518892|NCT01222533|Placebo Comparator|Tiotropium placebo|Placebo inhalation solution
11518893|NCT01222520|Experimental|Telmisartan and amlodipine FDC|once a daily
11518894|NCT01222520|Active Comparator|Telmisartan monotherapy|once a daily
11518895|NCT01222507||Brain Speed Test|60 subjects who complete 60 Second Brain Game and Brain Speed Test
11518896|NCT01222494|Placebo Comparator|Antipsychotic Treated Educational Cntrl|Antipsychotic treated participants randomized to this arm will receive diet and exercise education at monthly intervals with a study clinician or coordinator.
11518897|NCT01222494|Experimental|Antipsychotic Treated Weekly BWL|Antipsychotic treated participants randomized to this arm will engage in an evidence-based, 16 week manualized behavioral weight loss intervention that includes weekly meetings and phone check-ins with a trained study therapist.
11518898|NCT01222494|Active Comparator|Non-antipsychotic Treated Weekly BWL|Participants assigned to this arm will engage in an evidence-based, 16 week manualized behavioral weight loss intervention that includes weekly meetings and phone check-ins with a trained study therapist.
11518899|NCT01222481||Newly-diagnosed Head and Neck Cancer|
11518900|NCT01222468|Active Comparator|nabilone|nabilone 0.5 mg tablets dose-titrated over an 11-week period to a maximum of 3mg po daily. Subjects are allowed to drop back to the previous dose following a dose increase once if required
11518901|NCT01222468|Placebo Comparator|placebo|look-alike 0.5 mg placebo tablets titrated to a maximum daily dose of 3.0 mg daily over an 11-week phase. Subjects are allowed to drop back to the previous dose following a dose increase once during the 11-week phase if required
11518902|NCT01222455|Experimental|1|Mild hepatic impairment
11518903|NCT01222455|Experimental|2|Moderate hepatic impairment
11518904|NCT01222455|Experimental|3|Severe hepatic impairment
11518905|NCT01222455|Experimental|4|Matched healthy volunteers with normal hepatic function
11518906|NCT01222442|Experimental|1|400 µg AZD3199 + moxifloxacin placebo
11518907|NCT01222442|Experimental|2|1200 µg AZD3199 + moxifloxacin placebo
11518908|NCT01222442|Active Comparator|3|AZD3199 placebo + moxifloxacin 400 mg
11518909|NCT01222442|Placebo Comparator|4|AZD3199 placebo + moxifloxacin placebo
11518910|NCT01222429|Active Comparator|diet following American Diabetes Association guidelines|Participants will follow diets based on ADA guidelines. This group will also receive weekly nutrition classes.
11518911|NCT01222429|Experimental|vegan diet|Participants in the intervention group will follow a low-fat, vegan diet for 20 weeks, and will attend nutrition classes in the form of a weekly support group.
11518912|NCT01222416|Experimental|fluorodeoxyglucose PET/CT (FDG-PET/CT)|A PET/CT scan prior to the initiation of therapy, and then two additional scans following the initiation of therapy. Each patient will have up to three scans in a 6 month time frame.
11518913|NCT01222416|Experimental|fluorodeoxythymidine PET/CT (FLT-PET/CT)|A PET/CT scan prior to the initiation of therapy, and then two additional scans following the initiation of therapy. Each patient will have up to three scans in a 6 month time frame.
11518914|NCT01222403|Experimental|Fluad|Subjects aged >65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).
11518915|NCT01222403|Experimental|Vantaflu_aTIV|Subjects aged >65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).
11518916|NCT01222390|Experimental|Contour Profile Tissue Exander|Patients undergoing breast reconstruction using a Contour Profile Tissue Expander (CPX3).
11518917|NCT01222377|Experimental|Arm I|Patients undergo endoscopic breast surgery.
11518918|NCT01222364|Active Comparator|Standard Cord Clamping|
11518919|NCT01222364|Experimental|Delayed Cord Clamping|
11518920|NCT01222351|Experimental|BAY 94-9172|BAY 94-9172 PET/CT
11519013|NCT01221714||Active/Placebo|ACTIVE VITAMIN; PLACEBO OMEGA MAX
11519014|NCT01221714||Active/Active|ACTIVE VITAMIN; ACTIVE OMEGA MAX
11519015|NCT01221714||Placebo/Active|PLACEBO VITAMIN; ACTIVE OMEGA MAX
11518922|NCT01222338|Placebo Comparator|placebo|Control Cohort 1 (60 subjects) will receive standard first-line ATT regimen: (daily Isoniazide (H) 150mg, Rifampicin (R) 300mg, Ethambutol (E) 400mg, and Pyrazinamide (Z) 400mg during first 2 months, followed by H/R three times per week for the next 4 months. Patients also will receive placebo preparation, appearing identical to V-5 immunitor, taken once daily 30 minutes prior or after meal for 2 months
11518923|NCT01222325|Active Comparator|swl 3000 impulses- 60 imp/min|patients in this group were submitted to extracorporeal shockwave lithotripsy (SWL) 3000 impulses at 60 impulses per minute under general anesthesia. Unique session
11518924|NCT01222325|Active Comparator|swl- 4000 impulses - 90 impulses /min|patients in this group were submitted extracorporeal shockwave lithotripsy (swl) to 4000 impulses at 90 impulses per minute under general anesthesia- unique session
11518925|NCT01222312|Active Comparator|Arm A cisplatin|Cisplatin 75 mg/m2, d1 Docetaxel 75 mg/m2, d1 every 3 weeks (d22) max. 6 cycles
11518926|NCT01222312|Experimental|Arm B oxaliplatin|Oxaliplatin 85 mg/m², d1 Docetaxel 50mg/m2, d1 every 2 weeks (d15) max. 8 cycles
11518927|NCT01222299|Experimental|Arm 1 - Low Dose|bepotastine besilate nasal product - low dose
11518928|NCT01222299|Experimental|Arm 2 - Medium Dose|bepotastine besilate nasal product - medium dose
11518929|NCT01222299|Experimental|Arm 3 - High Dose|bepotastine besilate nasal product - high dose
11518930|NCT01222299|Placebo Comparator|Arm 4 - Placebo|placebo comparator nasal product
11518931|NCT01222286|Experimental|IPH2101 0.2 mg/kg|0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
11518932|NCT01222286|Experimental|IPH2101 2 mg/kg|2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
11518933|NCT01222273|Other|Open label|open label Vitamin D
11518934|NCT01222260|Experimental|Treatment Arm|Subjects with AL will receive Bendamustine and Dexamethasone
11518935|NCT01222247|Active Comparator|Betamethasone|A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart
11518936|NCT01222247|Placebo Comparator|Placebo|A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
11518937|NCT01222234|Experimental|Group 1: Cholecalciferol - CKD|Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.
11518938|NCT01222234|Experimental|Group 2: Calcitriol - CKD|Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). They will be administered calcitriol 0.25mcg daily for 8 weeks.
11518939|NCT01222234|Experimental|Group 3: Cholecalciferol - non-CKD|Patients in this arm have low vitamin D levels and normal kidney function. They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.
11518940|NCT01222208|Active Comparator|Oral Nutrition|Subjects will receive an oral nutrition regimen comprised of 50% of their Resting Energy Expenditure (REE) as dextrose and 20% of their REE as pressurized whey protein
11518941|NCT01222208|Placebo Comparator|Peripheral Parenteral Nutrition|Subjects will receive a peripheral parenteral nutrition (PPN) regimen comprised of 50% of their Resting Energy Expenditure (REE) as dextrose and 20% of their REE as amino acids.
11518942|NCT01222195|Experimental|Lenalidomide + Darbepoetin alfa|Lenalidomide 10 mg/day orally days 1-21 and Darbepoetin alfa 200 mcg subcutaneously every 2 weeks of 28 day cycle
11518943|NCT01222182||Eligible plan beneficiaries on atorvastatin|A group of 225 eligible patients would no longer have atorvastatin covered by their prescription plan and would need to be changed to another equivalent anti-hyperlipidemic agent.
11518944|NCT01222169|Experimental|larynx assessment under stimulation|
11518945|NCT01222169|Placebo Comparator|Larynx assessment under stimulation|
11518946|NCT01222156|Experimental|CGCI navigation|Subjects with CGCI navigation to specific target intracardiac anatomical sites
11518947|NCT01222143|Experimental|NOVE-HiDAC and Nilotinib|All patients will be receiving nilotinib combined with mitoxantrone, etoposide and high-dose cytarabine reinduction therapy. Patients achieving complete remission will receive consolidation therapy with nilotinib combined with high-dose cytarabine and mitoxantrone.
11518948|NCT01222117|Experimental|Plasmin Open-label Treatment Group A|Open-label 150 mg Plasmin administered without initial proximal pulse; 5-hour infusion using 10 mL/hour infusion rate.
11518949|NCT01222117|Experimental|Plasmin Open-label Treatment Group B|Open-label 150 mg Plasmin administered with initial proximal pulse; 5-hour infusion using 15 mL/hour infusion rate
11518950|NCT01222117|Experimental|Plasmin Open-label Treatment Group C|Open-label 150 mg Plasmin administered with proximal pulse; 5 hour infusion using 30 mL/hour infusion rate.
11518951|NCT01222117|Experimental|Plasmin Open-label Treatment Group D|Open-label 150 mg Plasmin administered with proximal pulse; 2-hour infusion using 35 mL/hour infusion rate
11518952|NCT01222117|Active Comparator|Plasminogen Activator Blinded Group E|PA administered for five hours at a dose and volume according to the Investigator's clinical judgement/standard practice
11518953|NCT01222117|Placebo Comparator|PA Placebo Blinded Treatment Arm F|PA placebo (normal saline for injection) administered for five hours at a dose and volume according to the Investigator's clinical judgement/standard practice for PA administration
11518954|NCT01222117|Experimental|Plasmin Open-label Treatment Group G|Open-label 150 mg Plasmin administered without pulsing; 5-hour infusion using 60 mL/hour infusion rate
11518955|NCT01222117|Experimental|Plasmin Open-label Treatment Group H|Open-label 150 mg Plasmin administered without pulsing; 2-hour infusion using 75 mL/hour infusion rate
11518956|NCT01222117|Experimental|Plasmin Open-label Treatment Group I|Open-label 150 mg Plasmin administered without pulsing; 5-hour infusion using 30 mL/hour infusion rate with balloon occlusion catheter
11518957|NCT01222117|Experimental|Plasmin Open-label Treatment Group J|Open-label 150 mg Plasmin administered without pulsing; 2-hour infusion using 35 mL/hour infusion rate with balloon occlusion catheter
11518958|NCT01222117|Experimental|Plasmin Open-label Treatment Group M|Open-label 250 mg Plasmin administered without pulsing; 5-hour infusion using 30 mL/hour infusion rate with balloon occlusion catheter
11518959|NCT01222104||Angio-Seal|Angio-Seal attempted and/or deployed
11518960|NCT01222104||Not deployed|Other method of closure
11519016|NCT01221714||Placebo/Placebo|PLACEBO VITAMIN; PLACEBO OMEGA MAX
11519017|NCT01221701|Experimental|In-Home Cognitive Behavioral Therapy|Mothers will receive 15 weekly sessions of IH-CBT plus one booster session scheduled 1 month later.
11518961|NCT01222091|Active Comparator|Propranolol, Then Placebo|Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
11518962|NCT01222091|Placebo Comparator|Placebo, Then Propranolol|Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
11518963|NCT01222078|Experimental|otelixizumab|otelixizumab
11518964|NCT01222065||Glaucoma/Normal|Two groups will be studies: patients with glaucomatous visual field loss and age and gender matched normal patients without visual field loss
11518965|NCT01222052|Experimental|Arm A Taxane-containing|3 courses FEC q3weeks followed by 3 courses Docetaxel q3weeks
11518966|NCT01222052|Active Comparator|Arm B standard anthracyclin|6 courses of FEC q3weeks
11518967|NCT01222052|No Intervention|Observation|
11518968|NCT01222039|Experimental|Conventional treatment plus high dose: 3x10e6 cells / Kg.|Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
11518969|NCT01222039|Experimental|Conventional treatment plus low dose: 1x10e6 cells / Kg|Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
11518970|NCT01222026|Active Comparator|Strontium Ranelate|Receiving Strontium Ranelate + Ca/Vitamin-D
11518971|NCT01222026|Placebo Comparator|Placebo|Receiving Placebo + Ca/Vitamin D
11518972|NCT01222013|Experimental|Imatinib Mesylate|
11518973|NCT01222000|Experimental|right controlled against moisturizing cream|
11518974|NCT01222000|Experimental|left controlled against moisturizing cream|
11518975|NCT01221987||Cohort A|Females > 21 years of age, diagnosed with invasive cervical cancer
11518976|NCT01221987||Cohort B|Females > 21 years of age, diagnosed with moderate or severe cervical intraepithelial neoplasia
11518977|NCT01221974|Experimental|Essure,Hydrosalpinx, Infertility|
11518978|NCT01221948|Experimental|Deep Brain Stimulation|Rechargeable Deep Brain Stimulation System
11518979|NCT01221935||Patients initiated on Pristiq as a first line treatment|
11518980|NCT01221935||Patients initiated on Pristiq as a 2nd-line treatment|
11518981|NCT01221935||Patients initiated on a SNRI or SSRI as a first-line treatment|
11518982|NCT01221935||Patients initiated on a SNRI or SSRI as a 2nd-line treatment|
11518983|NCT01221922|Experimental|Acne treatment|Treatment of acne scars
11518984|NCT01221909|Experimental|Tranexamic acid single dose of 500mg|
11518985|NCT01221909|Placebo Comparator|Saline|
11518986|NCT01221896||Hyperparathyroidism|Patients with hyperparathyroidism, prior to surgery.
11518987|NCT01221883|Placebo Comparator|Placebo|Placebo capsule in ER, identical follow up like those in the active arm.
11518988|NCT01221883|Experimental|Diazepam|10 mg of Diazepam mg orally at ER only (a single administration)
11518989|NCT01221870|Experimental|Tesetaxel once every 3 weeks|Tesetaxel 27 mg/m2 orally once every 21 days for up to 12 months
11518990|NCT01221870|Experimental|Tesetaxel once weekly|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks in a 28-day cycle for up to 12 months
11518991|NCT01221857|Experimental|NiCord|
11518992|NCT01221844|Experimental|Lactoferrin treatment in HT pregnacies|Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of one capsule of 100 mg of bLf (Lattoglobina, Grunenthal, Italy) twice a day before meals. In twin pregnancies or in severe anemia, HT pregnant women are treated until delivery with two capsules of 100 mg of bLf twice a day, before meals.
11518993|NCT01221844|Active Comparator|Ferrous sulfate in HT pregnancies|Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of 520 mg of ferrous sulfate (Ferro-Grad, Abbott Laboratories, USA), once a day during meal.
11518994|NCT01221831|Experimental|estetrol dose 1 / P1|
11518995|NCT01221831|Experimental|estetrol dose 1 / P2|
11518996|NCT01221831|Active Comparator|estradiol valerate/dienogest pill|
11518997|NCT01221831|Experimental|estetrol dose 2 / P1|
11518998|NCT01221831|Experimental|estetrol dose 2 / P2|
11518999|NCT01221818|Experimental|1|
11519000|NCT01221818|Experimental|2|
11519001|NCT01221818|Experimental|3|
11519002|NCT01221818|Experimental|4|
11519003|NCT01221818|Experimental|5|
11519004|NCT01221818|Experimental|6|
11519005|NCT01221792|Active Comparator|carvedilol|Patients randomized to carvedilol will be administered doses ranging from 6.25 to 15.625 mg/day using a flexible-dosing model. After a 1 week titration, investigators my increase daily dose by 6.25 mg/day at weeks 1 and 2 for a maximum dose of 15.625 mg/day. Weeks 3-4 will patients will remain on a stable, tolerable dose. At week 5 patients will have a 1 week taper.
11519006|NCT01221792|Placebo Comparator|Sugar Pill|Patients randomized to placebo will follow same dosing guidelines as if they were in the active comparator arm, carvedilol.
11519007|NCT01221779|Placebo Comparator|sham tDCS|
11519008|NCT01221779|Experimental|anodal tDCS|
11519009|NCT01221753|Experimental|TPF Induction Chemotherapy followed by Chemoradiotherapy|Patients received 3 cycles (21 days each) of TPF induction chemotherapy: docetaxel 75 mg/m2 IV day 1; cisplatin 100 mg/m2 IV day 1 (carboplatin substitute permitted); 5-FU 1000 mg/m2/day IV pump continuous days 1-4. Concurrent chemoradiotherapy followed 4-6 weeks after day 1 of cycle 3 TPF induction: cetuximab 400 mg/m2 IV loading dose 1 week prior and 250 mg/m2 IV weekly (panitumumab substitute permitted); carboplatin AUC 1.5 (Calvert formula) IV weekly; Intensity modulated radiation therapy (IMRT)-response based dosing for 6-7 weeks.
11519010|NCT01221740|Experimental|Milnacipran|"The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period.
~12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8"
11519011|NCT01221727|Other|Midazolam|All 27 subjects will receive midazolam.
11519012|NCT01221727|Active Comparator|Denosumab|Eighteen (18) subjects will receive denosumab.
11519019|NCT01221688|Other|group 2|patients without proven axillary involved nodes will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
11519020|NCT01221688|Experimental|group 1|group 1 : patients with proven involved axillary nodes will undergo SLNB and complete level I-II axillary lymphadenectomy.
11519021|NCT01221636|Other|Low Metal Abatacept|Reference
11519022|NCT01221636|Experimental|High Metal Abatacept|
11519023|NCT01221623|Experimental|AA4500|collagenase clostridium histolyticum
11519024|NCT01221623|Placebo Comparator|Placebo|Placebo
11519025|NCT01221610|Experimental|Drug Releasing Balloon|Passeo-18 Lux Drug Releasing Balloon catheter
11519026|NCT01221610|Active Comparator|Standard PT A (POBA)|Uncoated Passeo-18 PTA catheter
11519027|NCT01221597|Experimental|AA4500|collagenase clostridium histolyticum
11519028|NCT01221597|Placebo Comparator|Placebo|placebo
11519029|NCT01221584||1|Subject 18 years of age or older on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks..
11519030|NCT01221571|Experimental|AFM13|IV (intravenous) infusion, dose escalation
11519031|NCT01221558|Experimental|6mg lycopene|
11519032|NCT01221558|Experimental|15mg lycopene|
11519033|NCT01221558|Placebo Comparator|placebo|
11519034|NCT01221545|Experimental|A - AZD1656|AZD1656
11519035|NCT01221545|Placebo Comparator|B - Placebo|Placebo
11519036|NCT01221532|Experimental|SHHE Peridischarge intervention|Patients receive the Support from Hospital to Home (SHHE) Peridischarge Intervention plus usual care
11519037|NCT01221532|No Intervention|Usual Care|
11519038|NCT01221519|Experimental|1|AZD1656
11519039|NCT01221519|Experimental|2|AZD1656
11519040|NCT01221519|Experimental|3|AZD1656
11519041|NCT01221493|Experimental|Cryo biospy|
11519042|NCT01221480||Beta Blocker Use|
11519043|NCT01221480||No beta blocker use|
11519044|NCT01221467|Active Comparator|Overnight closed-loop combined with real-time CGM|
11519045|NCT01221467|Active Comparator|Real-time CGM alone|
11519046|NCT01221454|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
11519047|NCT01221454|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation
11519048|NCT01221441|Experimental|TissueGene-C|TissueGene-C at 3 x 10e7 cells per injection (intraarticular)
11519049|NCT01221441|Placebo Comparator|Placebo Control|Normal Saline injection
11519050|NCT01221428|Experimental|umbilical cord mesenchymal stem cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells,one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery.
11519051|NCT01221415||Interscalene Ultrasound|Subjects having orthopedic surgery requiring an interscalene peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
11519052|NCT01221415||Interscalene Nerve Stimulator|Subjects having orthopedic surgery requiring an interscalene peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
11519053|NCT01221415||Popliteal Ultrasound|Subjects having orthopedic surgery requiring an popliteal peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
11519054|NCT01221415||Popliteal Nerve Stimulator|Subjects having orthopedic surgery requiring an popliteal peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
11519055|NCT01221415||Femoral Ultrasound|Subjects having orthopedic surgery requiring an femoral peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
11519056|NCT01221415||Femoral Nerve Stimulator|Subjects having orthopedic surgery requiring an femoral peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
11519057|NCT01221402|Experimental|Extended-release niacin|
11519058|NCT01221402|Placebo Comparator|Placebo|
11519059|NCT01221389|Active Comparator|Colloid Control|Patients will receive 2 units of 250 ml of hydroxyethylated starch solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
11519060|NCT01221389|Active Comparator|Plasma|Patients will receive 2 units of AB+ plasma once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
11519061|NCT01221376|Experimental|Imatinib Mesylate|
11519062|NCT01221363|Active Comparator|Lifestyle counselling|Theory based individually tailored lifestyle counselling aimed at reduction of sitting time during leisure time and at work. Four individual sessions over a six months period.
11519063|NCT01221363|No Intervention|Control group|No intervention control group
11519064|NCT01221350|Experimental|Lipoic acid|Lipoic acid 600 mg oral dose (two 300 mg capsules) once daily in the morning during 60 days
11519065|NCT01221350|Placebo Comparator|Placebo|Placebo (two placebo capsules) orally once daily in the morning during 60 days
11519066|NCT01221337|Other|haemodialyzer EVODIAL-haemodialyzer VIE|"Equal number of patients will start either with the haemodialyzer VIE 2,1 or EVODIAL 2,2 followed by a wash out period, before starting the other haemodialyzer."
11519067|NCT01221337|Other|haemodialyzer VIE-haemodialyzer Evodial|"Equal number of patients will start either with the haemodialyzer VIE 2,1 or EVODIAL 2,2 followed by a wash out period, before starting the other haemodialyzer."
11519068|NCT01221324||Patients after open resection of colorectal cancer|
11519069|NCT01221311|Experimental|Fully Covered Metallic Stent|Among patients randomized to the covered, self-expandable metallic stent (cSEMS) group, the endoscopist will deploy a cSEMS of sufficient length to traverse the papilla. Dilation will not be performed unless the cSEMS deployment catheter cannot be advanced over a guidewire beyond the stricture. A biliary sphincterotomy may be performed at the discretion of the treating endoscopist.
11519099|NCT01221077|Placebo Comparator|Arm B: Erlotinib plus Placebo|As of 01 March 2013, the matching placebo is no longer being administered
11519070|NCT01221311|Active Comparator|Plastic Stent|Patients randomized to the plastic stent (PS) group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and multiple (as many as technically feasible) PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing endoscopic retrograde cholangiopancreatography (ERCP), until the stricture has been obliterated using clinical and fluoroscopic criteria (details below).
11519071|NCT01221298|Experimental|ABT-450/r and ABT-072, plus ribavirin (RBV)|ABT-450/r (150/100 mg) once daily (QD) and ABT-072 (400 mg) QD plus weight-based RBV divided twice daily (BID) for 12 weeks.
11519072|NCT01221285|Experimental|German cockroach allergenic extract|Participants will receive weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
11519073|NCT01221272|Experimental|Ranolazine/Placebo|Participants received ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.
11519074|NCT01221272|Experimental|Placebo/Ranolazine|Participants received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.
11519075|NCT01221259|Experimental|Drug E2212|
11519076|NCT01221259|Placebo Comparator|Placebo|
11519077|NCT01221246|Experimental|GM602|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
11519078|NCT01221246|Placebo Comparator|Placebo Comparator|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio; then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients receive Placebo.
11519079|NCT01221233|Experimental|NMES AND Stabilization Exercises|Neuromuscular Electrical Stimulation and Lumbar Stabilization Exercises
11519080|NCT01221233|Active Comparator|Moist Heat AND Stabilization Exercises|Moist Heat and Lumbar Stabilization Exercises
11519081|NCT01221220|Active Comparator|Behavioral Treatment|Six-month, family-based, group, behavioral weight control program
11519082|NCT01221220|Experimental|Behavioral Treatment plus Environmental Strategies|Six-month, family-based, group, behavioral weight control program plus home-based environmental intervention
11519083|NCT01221207|Active Comparator|Device - Total Contact Cast (TCC)|A total contact cast (TCC) is a special cast technique that is used to take the pressure and shear stress off the ulcer to assist in the healing.
11519084|NCT01221207|Active Comparator|Removable Cast Walker (RCW)|The removable cast walker (RCW) is a commercial product that is similar to a cast. It is secured with Velcro straps around the foot and leg and it is also effective at removing the pressure and shear stress on the foot.
11519085|NCT01221207|Active Comparator|Instant Total Contact Cast (ITCC)|The instant total contact cast (ITCC) is a technique that uses the removable cast walker, but secures it so it cannot be removed between clinic visits and evaluation by the subject or the physician.
11519086|NCT01221194|Active Comparator|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
11519087|NCT01221194|Active Comparator|PFC Stockings|The stocking therapy group will be given PFC shear reducing stockings to wear.
11519088|NCT01221181|Experimental|Eculizumab|Patients will receive Eculizumab and be observed for 60 minutes after the first 5 infusions, then 30 minutes after all subsequent infusions. Patients will not be allowed to take other immunomodulatory therapies during the study period but will continue on their other non-immunomodulatory therapies (e.g. ACE inhibitors, -statins, aspirin) without modifications unless clinically indicated. All patients, if unvaccinated, will be given N. meningitides vaccine at least two weeks prior to first eculizumab exposure. All female patients of childbearing potential will be asked to use adequate contraception methods during treatment and up to 5 months following discontinuation of eculizumab treatment.
11519089|NCT01221168||Men with or without Prostate Cancer|"Men with a histological confirmed prostate cancer, and their family members in case of hereditary prostate cancer.
~Men with no prostate cancer after a screening procedure for this disease, so that their biological samples can be compared to those of men with prostate cancer."
11519090|NCT01221142|Experimental|Hypothermia|Device: Cincinnati Sub-Zero Hyper-Hypothermia to core temperature of 34C for 24 hours, rewarming rate 0,5/2h until the patient reaches 36,5C
11519091|NCT01221129||Dietary Restriction|
11519092|NCT01221116|No Intervention|1: Type of surgery|Two types of patients are compared (placebo vs levosimendan): CABG - coronary artery bypass grafting and AVR - aortic valve replacement (either with or without CABG - coronary artery bypass grafting)
11519093|NCT01221103|Experimental|DOT|Combination of dexamethasone, ofatumumab and bendamustine
11519094|NCT01221090|Experimental|Personal Digital Assistant|Individuals in this arm were taught to use a diabetes self-care software, Diabetes Pilot™ (Digital Altitudes, Arlington Heights, IL), developed for PalmOS® (Palm, Sunnyvale, CA) which was loaded on to compatible PDAs, the Tungsten™ E2 handheld device. The Diabetes Pilot allowed participants to monitor their blood glucose, blood pressure, medication usage, physical activity, and dietary intake by tracking these measures in an electronic diary.
11519095|NCT01221090|Active Comparator|CDSMP|6-week, classroom-based program for diabetes self-management. The CDSMP, developed by Stanford University, equipped participants with the education and skill sets needed to take a more proactive approach in managing their chronic condition(s) and related symptoms.
11519096|NCT01221090|Active Comparator|PDA/CDSMP|Combined intervention
11519097|NCT01221090|No Intervention|Control|Usual Care
11519098|NCT01221077|Experimental|Arm A: Erlotinib plus OSI-906|As of 01 March 2013, OSI-906 is no longer being administered
11519100|NCT01221064|Other|Early drainage removal|Patients randomised to early drainage removal arm will have the drain removed in postoperative day 1. Lymph will be punctured on a regular basis
11519101|NCT01221064|Other|Late drainage removal|Patients randomised to late drainage removal arm will have the drains kept until total daily drainage is 30ml and then removed
11519102|NCT01221051|Active Comparator|oxytocin|early cord clamping, administration of oxytocin 10 IU i.v, controlled cord traction, uterine massage after placenta expulsion
11519103|NCT01221051|Placebo Comparator|saline solution|early cord clamping, wait for signs of placenta detachment, encourage the woman to push out placenta by her own effort, uterine massage after placenta expulsion
11519104|NCT01221038||group 1|young women not using OC
11519105|NCT01221038||group 2|young women using OC
11519106|NCT01221038||group 3|young men (database)
11519107|NCT01221025|Experimental|parecoxib|Parecoxib, a water-soluble prodrug of valdecoxib, is a high-selective COX-2 inhibitor that is first available for intravenous administration.
11519108|NCT01221012||men wearing Semipermeable garment|
11519109|NCT01221012||air permeable garment type BP2|
11519110|NCT01221012||air permeable garment type BP3|
11519111|NCT01221012||air permeable garment type MO|
11519112|NCT01221012||air permeable garment type BP1|
11519113|NCT01220999|Experimental|Cohort 1|Subjects received an initial loading dose of 111^In-CS-1008 (0.2 mg/kg) on Day 1, CS-1008 (6 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
11519114|NCT01220999|Experimental|Cohort 2|Subjects received an initial loading dose of 111^In-CS-1008 (1 mg/kg) on Day 1, CS-1008 (6 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
11519115|NCT01220999|Experimental|Cohort 3|Subjects received an initial loading dose of 111^In-CS-1008 (2 mg/kg) on Day 1, CS-1008 (6 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
11519116|NCT01220999|Experimental|Cohort 4|Subjects received an initial loading dose of 111^In-CS-1008 (4 mg/kg) on Day 1, CS-1008 (4 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
11519117|NCT01220999|Experimental|Cohort 5|Subjects received an initial loading dose of 111^In-CS-1008 (6 mg/kg) on Day 1, CS-1008 (2 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
11519118|NCT01220986||Right hepatectomy|Intervals from inflow division.
11519119|NCT01220973|Experimental|Atorvastatin and Celecoxib|
11519120|NCT01220960|Experimental|Art Therapy intervention group|For participants who will be part of the art therapy intervention, the art therapy group will be a closed group for eight women with breast cancer who are in treatment and recently have had surgery. The group will meet once a week for two hours over a period of 8 weeks, and will focus on exploring the expressive capabilities of art making in a supportive group. This group will be held in the conference room at the Cedars Breast Clinic. Each week will revolve around a theme that pertains to the experience of women living with breast cancer, and will be guided by the women's needs in the group. A broad range of art materials will be made available and various art techniques explored. No art experience is necessary. The intervention group will also need to fill out simple questionnaires before the art therapy groups starts and after the group finishes
11519121|NCT01220960|No Intervention|Control Group|The group not assigned to the intervention group will be asked to fill out questionnaires at two separate times (before and after the intervention group is run). The Control group will be offered the opportunity to join an open art therapy group upon completing the questionnaires.
11519122|NCT01220947|Experimental|Group A|Danoprevir 200 mg twice a day (BID) + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
11519123|NCT01220947|Experimental|Group B|Danoprevir 100 mg BID + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
11519124|NCT01220947|Experimental|Group C|Danoprevir 50 mg BID + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
11519125|NCT01220947|Experimental|Group D|Danoprevir 100 mg BID + ritonavir 100 mg + Pegasys 180 μg sc qw + Copegus 1000 mg or 1200 mg po daily for 12 weeks or 24 weeks
11519126|NCT01220947|Active Comparator|Group E|Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 48 weeks
11519127|NCT01220934||Cohort|
11519128|NCT01220921|Experimental|Lumbar Microdiscectomy|Patients aged 18-80 with symptomatic lumbar disc herniation resulting in single nerve root compression recalcitrant to non-invasive therapies for at least 6 weeks
11519129|NCT01220921|Experimental|Single-Level Lumbar Fusion|Patients aged 18-80 with symptomatic grade I degenerative or isthmic spondylolisthesis with mechanical back pain with or without radiculopathy recalcitrant to non-invasive therapies for at least 3 months
11519130|NCT01220908|Experimental|permanent Coil(s) implant, QOL measure|Coil implantation as treatment. Treatment is permanent implant.
11519131|NCT01220895|Experimental|ACT (mutlimer selection) plus standard therapy|Adoptive Cellular Therapy prepared using Multimer Selection in combination with standard best available antiviral drug therapy
11519132|NCT01220895|Active Comparator|Best available antiviral drug therapy|
11519133|NCT01220882|No Intervention|Radiographic skeletal age assessment|Participant group studied will include all pediatric patients presenting to our institution with a unilateral or bilateral SCFE. Patients with metabolic and endocrine conditions will be included.
11519134|NCT01220869|Experimental|Degarelix|
11519135|NCT01220856|Experimental|Reparixin|Reparixin + Immunosuppression
11519136|NCT01220856|No Intervention|No experimental intervention|Immunosuppression only
11519137|NCT01220843|Placebo Comparator|Placebo|DOuble blinded, same labels than the active drug same dosage (2 tablets 3 times per day) during the meal
11519138|NCT01220843|Experimental|Sevelamer carbonate|DOuble blinded, dosage 2 tablets 3 times per day corresponding to 4.8/d to taken during meals
11519139|NCT01220830|Experimental|RFQMR on Multiple Sclerosis lesions|
11519140|NCT01220817|Active Comparator|1 POMx capsule|1 POMx capsule daily
11519141|NCT01220817|Experimental|3 POMx capsules daily|
11519142|NCT01220804||NPDR|Type 2 diabetic patients with nonproliferative diabetic retinopathy (NPDR)
11519143|NCT01220804||Control Population|Healthy volunteers
11519144|NCT01220791|Active Comparator|Follicular Medrol|In an Antagonist protocol for IVF patients will also receive 4mg tabl. Methylprednisolone twice a day from the day 2 of ovarian stimulation and until the day of the pregnancy test on luteal day-14 post oocyte retrieval
11519145|NCT01220791|Placebo Comparator|No medrol group|Patients will receive only Antagonist protocol for IVF as usual
11519146|NCT01220778|Experimental|Exercise|
11519147|NCT01220778|No Intervention|Control|
11519148|NCT01220765|No Intervention|Standard care|Patients randomized to the standard care group receive standard of care using pulse oximetry
11519149|NCT01220765|Experimental|Capnography|In the intervention group capnography is measured using a cannula under the nose connected to the capnograph. The capnographic device displays respiratory rate, end-tidal carbon dioxide (ETCO2) levels, and continuous waveforms.
11519150|NCT01220752|Experimental|IMRT + carbon ion boost|(8 x 3 GyE) carbon ion therapy followed by 50 Gy IMRT (2 Gy/ Fx)corresponding to a total dose of approximately 74 GyE.
11519151|NCT01220739|Sham Comparator|IV tPA + Sham Transcranial Laser Therapy|Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by sham transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset.
11519152|NCT01220739|Active Comparator|IV tPA +Transcranial Laser Therapy|Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset.
11519153|NCT01220726|Active Comparator|Botox|200U onabotulinumtoxinA (botox)
11519154|NCT01220726|Placebo Comparator|Placebo|200U Saline
11519155|NCT01220713|Experimental|Treatment 1--1.5 atm abs|
11519156|NCT01220713|Experimental|Treatment 2--2.0 atm abs|
11519157|NCT01220713|Sham Comparator|Placebo--equivalent to breathing air|
11519158|NCT01220700|Experimental|Triclosane|triclosan coated suture material
11519159|NCT01220700|Active Comparator|Control|ordinary suture material
11519160|NCT01220687|Placebo Comparator|Placebo 20ppm|Nitrogen at 20 ppm at the beginning of study start with gradual taper at 10 minutes of the study and completely off by 17 minutes of the study
11519161|NCT01220687|Experimental|Inhaled Nitric Oxide (iNO) 20 ppm|Inhaled Nitric Oxide 20 ppm at the beginning of study start with gradual taper at 10 minutes of the study and completely off by 17 minutes of the study
11519162|NCT01220674||community dwelling older adults, normal controls|men and women 55 years of age or older who are cognitively intact.
11519163|NCT01220674||community dwelling older adults, mild cognitive impairment|men and women 55 years of age or older who have minimal cognitive decline (MMSE 20-24).
11519164|NCT01220661|Experimental|One dose|One dose prophylactic antibiotic
11519165|NCT01220648|Experimental|Nilotinib in conjunction with low dose interferon alfa|
11519166|NCT01220635|Experimental|Skill Group Program|Positive Thoughts and Actions Program
11519167|NCT01220635|Active Comparator|Individual Support Program|Measure of Adolescent Potential for Suicide (MAPS) - modified
11519168|NCT01220622|Active Comparator|Nimodipine|
11519169|NCT01220622|Placebo Comparator|Placebo|
11519170|NCT01220609|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11519171|NCT01220596|Experimental|Sequential therapy|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
11519172|NCT01220596|Active Comparator|Peginterferon alfa-2a monotherapy|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
11519173|NCT01220583|Experimental|Arm I|Patients undergo 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) 5 days a week for 6-6.5 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiotherapy.
11519174|NCT01220583|Experimental|Arm II|Patients undergo 3D-CRT or IMRT as in arm I.
11519175|NCT01220570|Experimental|Ridaforolimus + Dalotuzumab|Ridaforolimus (MK-8669) + Dalotuzumab (MK-0646)
11519176|NCT01220570|Experimental|Ridaforolimus|Ridaforolimus (MK-8669)
11519177|NCT01220570|Experimental|Dalotuzumab|Dalotuzumab (MK-0646)
11519178|NCT01220557|Experimental|PRIMAS group|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
11519179|NCT01220557|Active Comparator|Control group|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
11519180|NCT01220544|Experimental|HaploTransplant with NK cells|Haploidentical transplantation of mega-dose CD34+ hematopoetic stem cells with transfer of CD56+CD3-NK cells at day +2
11519181|NCT01220518|Active Comparator|CT-P13|infliximab
11519182|NCT01220518|Active Comparator|Remicade|infliximab
11519183|NCT01220492|Experimental|conventional plus MSC treatment|participants will receive conventional treatment plus a dose of MSC from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.
11519184|NCT01220492|Experimental|conventional plus placebo treatment|participants will receive conventional plus placebo treatment from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.
11519185|NCT01220479|No Intervention|Control Healthy|
11519186|NCT01220479|No Intervention|Control Diabetic|
11519187|NCT01220479|Experimental|Exercise Diabetic|
11519188|NCT01220479|Experimental|Exercise Healthy|
11519189|NCT01220466|Experimental|Refractive Error|
11519190|NCT01220440|Experimental|Methylphenidate, Dexamphetamine, Placebo|The 36 participants received each of the three medications for two weeks. Six different medication sequences are possible. The participants are randomly chosen for each of the six sequences in a way that allow six participants into each of the six sequences to balance the sequences.
11519191|NCT01220427||Clinical high-risk prostate cancer, radical prostatectomy|
11519192|NCT01220414|Active Comparator|Men|
11519193|NCT01220414|Active Comparator|Women|
11519194|NCT01220401|Experimental|ERRT-M|Exposure, Relaxation, and Rescripting Therapy for military populations. 4 sessions.
11519195|NCT01220388|Experimental|L-lysine|11 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
11519196|NCT01220388|Placebo Comparator|placebo|11 days treatment with study drug, order of periods (L-lysine or placebo) being sorted out.
11519197|NCT01220375|Experimental|1|Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell release from bone marrow and HSC movement into the peripheral circulation.
11519198|NCT01220362|Other|Group 1|Bupivacaine 0.125%
11519199|NCT01220362|Other|Group 2|Bupivacaine 0.125%/Fentanyl 2mcg/ml
11519200|NCT01220349|Experimental|Echocardiographic 2D strain analysis|
11519201|NCT01220336|Experimental|Health Coaching|
11519202|NCT01220323|Active Comparator|direct current stimulation|The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm.
11519203|NCT01220323|Sham Comparator|sham stimulation|
11519204|NCT01220310|Experimental|Intervention|Online diabetes workshop observation and learning sessions
11519205|NCT01220297|Experimental|Carmustine Etoposide Cyclophosphamide|Carmustine + Etoposide + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.
11519206|NCT01220297|Experimental|FTBI + Cyclophosphamide|FTBI + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.
11519207|NCT01220284|Experimental|Satraplatin in combo with vinorelbine|"Escalating doses of satraplatin and oral vinorelbine in subsequent cohorts of 3-6 patients according to the type and severity grade of acute toxicities observed during cycle 1.
~The dose escalation process will be discontinued once the MTD is achieved."
11519208|NCT01220271|Experimental|Phase 1: 160 mg LY2157299|"During Radiation therapy:
~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.
~LY2157299: 80 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.
~Temozolomide: 75 mg/m2 taken daily for 6 weeks.
~After Radiation Therapy:
~LY2157299: 80 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.
~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
11519209|NCT01220271|Experimental|Phase 1: 300 mg LY2157299|"During Radiation therapy:
~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.
~LY2157299: 150 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.
~Temozolomide: 75 mg/m2 taken daily for 6 weeks.
~After Radiation Therapy:
~LY2157299: 150 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.
~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
11519210|NCT01220271|Experimental|Phase 2: Established dose LY2157299|"During Radiation therapy:
~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.
~LY2157299: Phase 1 established dose taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.
~Temozolomide: 75 mg/m2 taken daily for 6 weeks.
~After Radiation Therapy:
~LY2157299: Phase 1 established dose taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.
~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
11519211|NCT01220271|Experimental|Phase 2: no LY2157299 (control)|"During Radiation therapy:
~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.
~Temozolomide: 75 mg/m2 taken daily for 6 weeks.
~After Radiation Therapy:
~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
11519212|NCT01220258|Experimental|Azithromycin ophthalmic solution, 1%|
11519213|NCT01220245|Experimental|Heparin-bonded endoluminal fempop bypass|Heparin-bonded ePTFE endoluminal femoro-popliteal bypass versus surgical femoro-popliteal bypass
11519214|NCT01220245|Active Comparator|Surgical femoro-popliteal bypass|Surgical femoro-popliteal bypass.
11519215|NCT01220232|Active Comparator|Abacavir/Lamivudine|
11519216|NCT01220232|Experimental|Lersivirine + Abacavir/Lamivudine|
11519217|NCT01220219|Experimental|Pregabalin controlled release, 82.5 mg|
11519218|NCT01220219|Experimental|Pregabalin controlled release, 165 mg|
11519219|NCT01220219|Other|Pregabalin immediate release, 75mg|Reference Treatment
11519220|NCT01220206|Placebo Comparator|Placebo|2 placebo capsules daily
11519221|NCT01220206|Experimental|one POMx capsule|One POMx capsule, one placebo capsule daily
11519222|NCT01220206|Experimental|2 POMx Capsules|2 POMx Capsules daily
11519223|NCT01220193||Normal cornea|
11519224|NCT01220193||Post laser refractive surgery|
11519225|NCT01220193||Cornea pathology|
11519226|NCT01220193||Cataract surgery|
11519227|NCT01220180||Epilepsy|
11519228|NCT01220180||Neuropathic Pain|
11519229|NCT01220180||Fibromyalgia|
11519263|NCT01219972||Allografted patients|"All consecutive patients who underwent an allogeneic blood stem cells transplantation performed at saint Louis hospital during the study recruitment period
~if alive at 100 days post-transplant
~and who gave informed consent"
11519230|NCT01220167|Experimental|Sequence ABC|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
11519231|NCT01220167|Experimental|Sequence BCA|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
11519232|NCT01220167|Experimental|Sequence CAB|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
11519233|NCT01220154|Experimental|Carboplatin Paclitaxel & Bevacizumab|Intraperitoneal carboplatin with weekly intravenous paclitaxel and intravenous bevacizumab
11519234|NCT01220141||A|
11519235|NCT01220128|Experimental|Cohort A-WT1 Group|This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of WT1 ASCI according to the treatment schedule.
11519236|NCT01220128|Placebo Comparator|Cohort A-Placebo Group|This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
11519237|NCT01220128|Experimental|Cohort B-WT1 Group|This group included breast cancer patients who received WT1 ASCI, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
11519238|NCT01220128|Placebo Comparator|Cohort B-Placebo Group|This group included breast cancer patients who received placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
11519239|NCT01220128|Experimental|Cohort C-WT1 Group|This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of WT1 ASCI, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
11519240|NCT01220128|Placebo Comparator|Cohort C-Placebo Group|This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of placebo, 5-Fluorouracil, Carboplatin AUC, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
11519241|NCT01220128|Experimental|Cohort D-WT1 Group|This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer, who received WT1 ASCI, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
11519242|NCT01220128|Experimental|Cohort E-WT1 Group|This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer who were to receive WT1 ASCI, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule. Enrolment in this group was to take place in case of absence of a safety signal and of an adequate induction of an immune response by WT1 ASCI in Cohort D.
11519243|NCT01220128|Placebo Comparator|Cohort E-Placebo Group|This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer who were to receive placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule. Enrolment in this group will take place in case of absence of a safety signal and of an adequate induction of an immune response by WT1 ASCI in Cohort D.
11519244|NCT01220115||No treatment|Patients aged 2 to less than 12
11519245|NCT01220115||No treatment patients aged 12 to less than 18|Patients aged 12 to less than 18
11519246|NCT01220115||No treatment Patients greater than 18 years|patients greater than 18 years
11519247|NCT01220089|Active Comparator|Standard maintenance|During months 7 to 18, individuals in the Standard Maintenance condition will receive informational handouts by mail (or e-mail) regarding weight maintenance.
11519248|NCT01220089|Active Comparator|Intensified Maintenance|"During months 7 to 18, individuals in the Intensified Maintenance condition will continue to have monthly in-person visits with the weight loss counselor (Weight Coach)."
11519249|NCT01220076|Experimental|Tamoxifene|
11519250|NCT01220063|Other|Radiation + Irinotecan|"Irinotecan will be administered :
~- 40 mg/m² in serum physiologique during 30 to 90 min at D1 and D8 of radiotherapy
~Radiotherapy (RSHF) will be administered :
~at D1, D3, D8 and D10
~48 Gy, 12 Gy by fractions twice a week"
11519251|NCT01220050|Experimental|Paricalcitol|
11519252|NCT01220050|Active Comparator|Standard therapy|
11519253|NCT01220037|Experimental|Young regular diet|During the time of the study this group will adhere to a standardized regular diet.
11519254|NCT01220037|Experimental|Young low protein diet|During the time of the study this group will adhere to a standardized low protein diet.
11519255|NCT01220037|Experimental|Young high protein|During the time of the study this group will adhere to a standardized high protein diet.
11519256|NCT01220037|Experimental|Elderly|During the time of the study this group will adhere to a standardized high protein diet
11519257|NCT01220024|Experimental|2, 5x5cm bupivacaine collagen sponges|
11519258|NCT01220024|Placebo Comparator|2, Placebo collagen sponges|
11519259|NCT01220011|Experimental|NO INTERVENTION|
11519260|NCT01220011|Active Comparator|fetoscopic laser|
11519261|NCT01219998||NGAL Kinetics in neonates|to describe postoperative kinetics of urinary NGAL in neonates and to identify the threshold for accurate prediction of severe AKI requiring RRT in neonates and infants undergoing cardiac surgery with cardiopulmonary bypass
11519262|NCT01219985|Experimental|Investigation arm|"standard and respiratory-gated PET acquisitions  for patients included in the trial."
11519264|NCT01219959|Active Comparator|Non-glucose Sparing|Dianeal only
11519265|NCT01219959|Experimental|Glucose Sparing|Dianeal, Extraneal, Nutrineal
11519268|NCT01219920|Active Comparator|FOLFIRI|Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
11519269|NCT01219920|Experimental|FOLFOXIRI|Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
11519270|NCT01219907|Experimental|Arm I|"VACCINE THERAPY: Patients receive HER2 peptide vaccine intradermally once weekly for 3 weeks.
~CHEMOTHERAPY: Patients receive cyclophosphamide IV on day -1.
~IMMUNOTHERAPY: Patients receive ex vivo-expanded HER2 specific T-cell IV over 30 minutes on days 1, 10, and 20."
11519271|NCT01219894||RUTTS Score <30%|Patients with evidence of complete healing of stent at 3 months
11519272|NCT01219894||RUTTS<30%|Group with evidence of incomplete healing of the stent
11519273|NCT01219881|Active Comparator|Desflurane|Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Desflurane.
11519274|NCT01219881|Active Comparator|Sevoflurane|Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Sevoflurane.
11519275|NCT01219868|Experimental|Physician-nurse team|
11519276|NCT01219855|Experimental|Cohort 1: CTAP101 Capsules 60µg|
11519277|NCT01219855|Experimental|Cohort 1: CTAP101 Capsules 90µg|
11519278|NCT01219855|Placebo Comparator|Cohort 1: Sugar Capsule|
11519279|NCT01219855|Experimental|Cohort 2: CTAP101 Capsules 30µg|
11519280|NCT01219855|Placebo Comparator|Cohort 2: Sugar Capsule|
11519281|NCT01219842|Active Comparator|INVASIVE (INV) group|Modern endovascular and/or open revascularization according to the recommendations in the TASC II document.
11519282|NCT01219842|Active Comparator|NON-INVASIVE (NON) group|Patients receiving only best medical treatment (BMT).
11519283|NCT01219829||Family History patients|Patients with a strong family history of pancreatic cancer or with a genetic syndrome that puts them at risk for pancreas cancer.
11519284|NCT01219829||Recurrence patients|Patients who underwent surgery for pancreatic cancer and developed tumor recurrence after surgery
11519285|NCT01219816|Experimental|Patients under 60 years|Hyper CVAD regimen + Epratuzumab (Cyclophosphamide Vincristine Doxorubicin Dexamethasone)
11519286|NCT01219816|Experimental|Patients older than 60 years or < =60 years|Vincristine + Aracytine + Dexamethasone
11519287|NCT01219803|Experimental|High dose GGQL Decoction|
11519288|NCT01219803|Experimental|Mild dose GGQL Decoction|
11519289|NCT01219803|Experimental|Low dose GGQL Decoction|
11519290|NCT01219803|Placebo Comparator|Placebo|
11519291|NCT01219790|Experimental|irradiation + zometa|
11519292|NCT01219777|Experimental|Carboplatin|AUC 5.0 or 6.0
11519293|NCT01219777|Experimental|Bevacizumab|15 mg/kg
11519294|NCT01219777|Experimental|Paclitaxel|60-80 mg/m2
11519295|NCT01219764|Active Comparator|Full Dose|Full dose of Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.
11519296|NCT01219764|Experimental|Half dose|Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days.
11519297|NCT01219751|Experimental|Sunitinib|Sunitinib 50 mg D1-D28 every 6 weeks
11519298|NCT01219738|Experimental|budesonide 360ug|asthmatic subject received different doses of inhaled budesonide in random other
11519299|NCT01219738|Experimental|budesonide 720ug|asthmatic subject received different doses of inhaled budesonide in random other
11519300|NCT01219738|Experimental|budesonide 1440ug|asthmatic subject received different doses of inhaled budesonide in random other
11519301|NCT01219738|Placebo Comparator|placebo|asthmatic subject received inhaled placebo
11519302|NCT01219738|Experimental|Budesonide720ug 4 times|asthmatic subject received 720ug of inhaled budesonide 4 times separated by 30 minutes.
11519303|NCT01219712|Active Comparator|Preoperative Optimization|"Patients with proximal femur fracture who are > 65 yrs old and have an increased NT-proBNP would be randomized to either Standard Management or Optimized Management.
~The main aim of optimization is to achieve a normal oxygen delivery to the tissues preoperatively.
~Hb would be optimized to > 90 g/l
~SaO2 > 96%
~Stroke volume index (SVI) > 30
~Heart rate should ideally be < 80
~Stroke volume index (SVI) > 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is < 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal."
11519304|NCT01219712|No Intervention|Standard treatment|Patients who are randomized to this group would be managed according to existing routines within the hospital. Consequently, these patients would be transferred to the Orthopaedic ward after initial management in the Emergency Department, including fluid therapy, oxygen and pain management. Since these patients have a significantly high NT-proBNP, a Cardiologist would be consulted and a decision for optimization taken together with the attending Anaesthesiologist and Orthopaedic Surgeon prior to surgery.
11519305|NCT01219699|Experimental|BYL719|In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene, and in patients whose tumors are have wild-type PIK3CA gene
11519306|NCT01219699|Experimental|BYL719 + fulvestrant|In post-menopausal patients with estrogen receptor positive locally advanced or metastatic breast cancer whose tumors have an alteration of the PIK3CA gene, and in patients whose tumors are have wild-type PIK3CA gene
11519307|NCT01219686|Experimental|escitalopram 20mg + pindolol 15mg|Days 1-2: escitalopram 10 mg + placebo, days 3-42: escitalopram 20mg + placebo Days 1-14: pindolol 15 mg, days 15-17: pindolol 7.5 mg
11519308|NCT01219686|Active Comparator|Escitalopram 30 mg|Days 1-2: escitalopram 10 mg+ placebo, days 3-4 escitalopram 20 mg + placebo, days 5-42: escitalopram 30mg+ placebo
11519309|NCT01219686|Active Comparator|escitalopram 20 mg|days 1-2: escitalopram 10 mg+ placebo, days 3-42: escitalopram 20 mg + placebo
11519310|NCT01219673|Placebo Comparator|Placebo|Placebo by mouth 2 times every day.
11519311|NCT01219673|Experimental|Armodafinil|Armodafinil 150 mg by mouth once a day.
11519312|NCT01219673|Experimental|Minocycline|Minocycline 100 mg by muth two times a day.
11519313|NCT01219673|Experimental|Bupropion|Bupropion 100 mg by mouth two times a day.
11519314|NCT01219673|Experimental|Armodafinil + Minocycline|"Armodafinil 150 mg by mouth once a day.
~Minocycline 100 mg by mouth two times a day."
11519315|NCT01219673|Experimental|Armodafinil + Bupropion|"Armodafinil 150 mg by mouth once a day.
~Bupropion 100 mg by mouth two times a day."
11519316|NCT01219673|Experimental|Minocycline + Bupropion|"Minocycline 100 mg by muth two times a day.
~Bupropion 100 mg by mouth two times a day."
11519317|NCT01219673|Experimental|Armodafinil + Minocycline + Bupropion|"Armodafinil 150 mg by mouth once a day.
~Minocycline 100 mg by muth two times a day.
~Bupropion 100 mg by mouth two times a day."
11519318|NCT01219647|Experimental|aerobic exercise|Subjects will train on a recumbent cross trainer 20-30 minutes/session for three times/week for six months under supervision of a fitness specialist
11519319|NCT01219647|Active Comparator|stretching|Subjects will particiate in supervised stretching at same frauency, duration and intensity of aerobic exericse arm
11519320|NCT01219621|Active Comparator|DDD Long AVD|
11519321|NCT01219621|Experimental|safeR|
11519322|NCT01219608|Active Comparator|Glutamine 0.5 g/kg/day|
11519323|NCT01219608|Active Comparator|Glutamine 1 g/kg/day|
11519324|NCT01219608|Placebo Comparator|Enteral Nutrition|
11519325|NCT01219595|Active Comparator|Part 1|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.
11519326|NCT01219595|Other|No treatment|20 non-UTI susceptible women will be enrolled to collect data on the types of E. coli flora present in non-UTI women.
11519327|NCT01219595|Active Comparator|Part 2A|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
11519328|NCT01219595|Placebo Comparator|Part 2B|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
11519329|NCT01219595|Active Comparator|Part 3A|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.
11519330|NCT01219595|Placebo Comparator|Part 3B|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for one 4-week period.
11519331|NCT01219582||Group 1|
11519332|NCT01219569||2. Sevoflurane|Subjects will receive sevoflurane at 1.5% and 2.5% end tidal after steady state maintenance has been achieved and have pupillometry readings taken and every 10 minutes for 30 minute at each drug dose.
11519333|NCT01219569||1.Propofol|1.Subjects will receive propofol infusion and have pupillometry readings taken in both eyes after induction, after steady state maintenance has been achieved and at 30 minutes
11519334|NCT01219556||Group 1|
11519335|NCT01219543|Experimental|Part A|Daily dosing of AZD1480 to the patients with solid tumours excluding HCC
11519336|NCT01219543|Experimental|Part B|BID dosing of AZD1480 to the patients with advanced HCC (Child-Pugh A to B7)
11519337|NCT01219543|Experimental|Part C|BID dosing of AZD1480 to the patients with solid tumours excluding HCC
11519338|NCT01219543|Experimental|Expansion|BID dosing of AZD1480 to the patients with EGFR or ROS mutant NSCLC and non-smokers with lung metastasis and gastric cancer and solid tumour with biopsy available.
11519339|NCT01219530||Gestational Carriers|
11519340|NCT01219530||Intended Parents|
11519341|NCT01219517|Experimental|Study Group|All patients in the study receive the same treatment. All will have 2 polar body biopsies and all embryos biopsied prior to transfer.
11519342|NCT01219491||Egg donor recipients|
11519343|NCT01219478||control|0 metabloil risk
11519344|NCT01219478||1|1 metabloil risk
11519345|NCT01219478||2|2 metabloil risk
11519346|NCT01219478||3|3 metabloil risk
11519347|NCT01219465|Experimental|umbilical cord mesenchymal stem cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells
11519348|NCT01219452|Experimental|umbilical cord mesenchymal stem cells|intramuscular injection of umbilical cord mesenchymal stem cell
11519349|NCT01219426||students from the University of Nantes|To be more than 18 years old (the legal age to gamble in France)
11519350|NCT01219426||pathological gamblers seeking treatment|To be more than 18 years old (the legal age to gamble in France)and pathological gambler
11519351|NCT01219413|Experimental|aliskiren, placebo, perindopril|
11519352|NCT01219413|Experimental|perindopril, placebo, aliskiren|
11519353|NCT01219400|Experimental|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
11519354|NCT01219374||egg donors|anonymous egg donors
11519355|NCT01219348|Experimental|Indeolamine 2,3 deoxygenase|To inhibit immune suppression and tolerance, by blocking the IDO enzyme with vaccination against IDO.
11519356|NCT01219322|Experimental|intravenous bicarbonate|Intravenous bicarbonate(05meq/cc ) 50 cc will be injected.
11519357|NCT01219322|Placebo Comparator|Intravenous injection of 50 cc normal saline|Injection of volume equivalent of normal saline to compare the establish the effect of same volume as the experimental drug
11519358|NCT01219309|Active Comparator|Omega 3/6 treatment|
11519359|NCT01219309|Placebo Comparator|Placebo|
11519360|NCT01219283||Control (no PGD)|Receive their planned IVF treatment without PGD. 2 morphologically best embryos are transferred.
11519361|NCT01219283||Case (PGD)|Receive PGD in addition to their planned IVF Cycle. 2 morphologically best PGD normal embryos are transferred.
11519362|NCT01219270||GFR >= 60|MDRD eGFR 60 or more
11519363|NCT01219270||GFR <60|Under MDRD eGFR 60
11519364|NCT01219257||SpA patients|The patients may be included when their rheumatologist has decided that the patient are going to start biological medication.
11519365|NCT01219244|Experimental|Caloric restriction|
11519366|NCT01219244|Experimental|omega-3 supplementation|
11519367|NCT01219244|Experimental|resveratrol supplementation|
11519368|NCT01219244|Placebo Comparator|placebo|
11519369|NCT01219244|Experimental|2nd step: intervention + physical /cognitive training|most effective dietary intervention plus physical and cognitive training
11519370|NCT01219244|Placebo Comparator|2nd step: most effective dietary intervention plus control|most effective dietary intervention plus control
11519371|NCT01219231|Experimental|Exercise|
11519372|NCT01219231|Placebo Comparator|Placebo|
11519373|NCT01219218|Experimental|A|Treatment group. Patients in this group receive actual shockwave therapy.
11519375|NCT01219205|Active Comparator|macular branched retinal venous occlusion|
11519376|NCT01219192|Experimental|M2ES 15mg|
11519377|NCT01219192|Experimental|M2ES 30mg|
11519378|NCT01219192|Experimental|M2ES 45mg|
11519379|NCT01219192|Experimental|M2ES 60mg|
11519380|NCT01219179|Experimental|sterile water|Intervention group received sterile water if their sodium value was greater or equal to 150 mEq/liter
11519381|NCT01219166||laparoscopic Roux-en-Y-gastric-bypass without cholecystectomy|
11519382|NCT01219166||laparoscopic Roux-en-Y-gastric baypass with cholecystectomy|
11519383|NCT01219153|Experimental|Extended high dose letrozole regimen /GnRH antagonist|
11519384|NCT01219153|Active Comparator|Short low dose letrozole regimen /GnRH antagonist|
11519385|NCT01219140|Experimental|2 POMx Capsules|2 POMx Capsules daily
11519386|NCT01219140|Placebo Comparator|2 placebo Capsules|2 placebo Capsules daily
11519387|NCT01219127|Experimental|Derma-PACE|Pre-treatment evaluations include complete history and physical examination, chemistry and coagulation profiles, detailed past surgical and medical treatments. The local findings of the ulcer are quantitatively assessed using the S(AD) SAD classification (6) including photo-documentation for the size, shape and configuration of the ulcer
11519388|NCT01219114||1|
11519389|NCT01219101|Experimental|clomiphene citrate and ethinyl estradiol|Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
11519390|NCT01219101|Active Comparator|clomiphene citrate and placebo|Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
11519391|NCT01219088|No Intervention|Controlled group|Spinal anesthesia with 0.5% bupivacaine alone
11519392|NCT01219088|Active Comparator|Femoral nerve block|Spinal anesthesia plus femoral nerve block with 20 mL of 0.25% bupivacaine
11519393|NCT01219088|Active Comparator|Intrathecal morphine|Spinal anesthesia plus 0.1 mg of intrathecal morphine
11519394|NCT01219088|Active Comparator|Periarticular bupivacaine infiltration|Spinal anesthesia plus periarticular infiltration with 20 mL of 0.25% bupivacaine
11519395|NCT01219075|Experimental|Arm I|Patients receive oral soy isoflavones supplement once daily for 12 months in the absence of disease progression.
11519396|NCT01219075|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 12 months in the absence of disease progression.
11519397|NCT01219062|Placebo Comparator|control|The patient will be performed spinal anesthesia alone, with postoperative PCA
11519398|NCT01219062|Active Comparator|Morphine|The patient will received intrathecal Morphine for 0.1 mg. in Isobaric bupivacaine in spinal anesthesia and postoperative PCA
11519399|NCT01219062|Active Comparator|bupivacaine|the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
11519400|NCT01219049|Experimental|Tyrosine 1000 mg / day|Patients receive 1000 mg tyrosine per day.
11519401|NCT01219049|Experimental|Tyrosine 2000 mg / day|Patients receive 2000 mg tyrosine per day.
11519402|NCT01219049|Placebo Comparator|Placebo|Patients receive placebo daily.
11519403|NCT01219036|Other|Non-adherent|
11519404|NCT01219036|Other|Adherent|
11519405|NCT01219010|Experimental|001|Siltuximab 15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
11519406|NCT01218997|Experimental|Medisorb naltrexone 380 mg (VIVITROL)|
11519407|NCT01218997|Active Comparator|Oral naltrexone 50 mg|
11519408|NCT01218984|Experimental|Medisorb naltrexone 75 mg|
11519409|NCT01218984|Experimental|Medisorb naltrexone 150 mg|
11519410|NCT01218984|Experimental|Medisorb naltrexone 300 mg|
11519411|NCT01218971|Experimental|Medisorb naltrexone 380 mg|Intramuscular (IM) injection administered once every 4 weeks for up to 48 weeks.
11519412|NCT01218971|Experimental|Medisorb naltrexone 190 mg|IM injection administered once every 4 weeks for up to 48 weeks.
11519413|NCT01218958|Experimental|Medisorb naltrexone 190 mg|
11519414|NCT01218958|Experimental|Medisorb naltrexone 380 mg|
11519415|NCT01218958|Placebo Comparator|Placebo for Medisorb naltrexone 190 mg|
11519416|NCT01218958|Placebo Comparator|Placebo for Medisorb naltrexone 380 mg|
11519417|NCT01218945||Fat Removal|Patients undergoing surgical fat removal
11519418|NCT01218932|Experimental|A|Primaquine only, followed by chloroquine/primaquine, followed by chloroquine only
11519419|NCT01218932|Active Comparator|B|Primaquine alone, followed by chloroquine, followed by chloroquine/primaquine
11519420|NCT01218919||Brio DBS System|Eligible subjects in this study will be screened to confirm that they meet the strict guidelines for advanced, levodopa-responsive Parkinson's disease that are not adequately controlled with medication followed by bilateral surgery to implant the Brio™ deep brain stimulation system
11519421|NCT01218906||Cohort Population (Case )|Participants will be examined for febrile illness to diagnose dengue and to identify common causes of fever.
11519422|NCT01218893|Active Comparator|15-15-15|This group will receive three times 15 infected mosquito bites under chloroquine prophylaxis, as we know that this dose is protective.
11519423|NCT01218893|Experimental|10-10-10|This group will receive three times 10 infected and 5 uninfected mosquito bites under chloroquine prophylaxis.
11519424|NCT01218893|Experimental|5-5-5|This group will receive three times 5 infected and 10 uninfected mosquitobites under chloroquine prophylaxis.
11519425|NCT01218893|Placebo Comparator|0-0-0|This group will receive three times 15 uninfected mosquitobites under prophylaxis.
11519426|NCT01218880|Experimental|M2ES-A|
11519427|NCT01218880|Experimental|M2ES-B|
11519428|NCT01218880|Experimental|M2ES-C|
11519429|NCT01218880|Experimental|M2ES-D|
11519430|NCT01218867|Experimental|Cohort 1 (1x10(6) cells (high dose IL-2)|Patients will receive (1x10(6) cells plus high dose aldesleukin
11519431|NCT01218867|Experimental|Cohort 2 (3x10(6) cells (high dose IL-2)|Patients will receive (3x10(6) cells plus high dose aldesleukin
11519432|NCT01218867|Experimental|Cohort 3 (1x10(7) cells (high dose IL-2)|Patients will receive (1x10(7) cells plus high dose aldesleukin
11519789|NCT01216527|Active Comparator|control group|only Surgery
11519433|NCT01218867|Experimental|Cohort 4 (3x10(7) cells (high dose IL-2)|Patients will receive (3x10(7) cells plus high dose aldesleukin
11519434|NCT01218867|Experimental|Cohort 5 (1x10(8) cells (high dose IL-2)|Patients will receive (1x10(8) cells plus high dose aldesleukin
11519435|NCT01218867|Experimental|Cohort 6 (3x10(8) cells (high dose IL-2)|Patients will receive (3x10(8) cells plus high dose aldesleukin
11519436|NCT01218867|Experimental|Cohort 7 (1x10(9) cells (high dose IL-2)|Patients will receive (1x10(9) cells plus high dose aldesleukin
11519437|NCT01218867|Experimental|Cohort 8 (1x10(9) cells (low dose IL-2)|Patients will receive (1x10(9) cells plus low dose aldesleukin
11519438|NCT01218867|Experimental|Cohort 9 (3x10(9) cells (low dose IL-2)|Patients will receive (3x10(9) cells plus low dose aldesleukin
11519439|NCT01218867|Experimental|Cohort10(1x10(10) cells (low dose IL-2)|Patients will receive (1x10(10) cells plus low dose aldesleukin
11519440|NCT01218867|Experimental|Cohort11(3x10(10) cells (low dose IL-2)|Patients will receive (3x10(10) cells plus low dose aldesleukin
11519441|NCT01218854|Experimental|B-NASS|Block assisted needle angle selection system
11519442|NCT01218854|Experimental|L-NASS|Laser assisted needle angle selection system
11519443|NCT01218854|Experimental|MD-NASS|mobile-device assisted needle angle selection system
11519444|NCT01218841|Experimental|Fish oil lipid emulsion|Parenteral lipid emulsion composed by fish oil which is rich in the omega-3 polyunsaturated fatty acids eicosapentanoic and docosahexanoic.
11519445|NCT01218841|Active Comparator|MCT/LCT lipid emulsion|Parenteral lipid emulsion containing 50% of medium-chain triglycerides and 50% of soybean oil
11519446|NCT01218828|Active Comparator|Standard therapy|Hydration with 0.9% saline per a standard protocol (control group)
11519447|NCT01218828|Experimental|LVEDP-based hydration strategy|LVEDP guided hydration with 0.9% saline (treatment group)
11519448|NCT01218815|Experimental|Culprit lesion IRA Revascularization|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
11519449|NCT01218815|Active Comparator|Complete IRA revascularization|Primary PCI of culprit lesion in IRA with DES stent
11519450|NCT01218802|Active Comparator|Rosuvastatin|Participants will take Rosuvastatin 10 mg. daily for 96 weeks
11519451|NCT01218802|Placebo Comparator|Sugar Pill placebo|Participants will take a placebo that appears on the exterior to be the same as active drug. They will take one capsule daily.
11519452|NCT01218789|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 1 year
11519453|NCT01218776||Male, Female, Kidney Disease, Elderly|Non-interventional patient registry
11519454|NCT01218763||ICD patients|Candidates may come from the investigator's general population, who require DR ICD or CRT-D therapy for primary or secondary ICD indication and meet all study eligibility criteria
11519455|NCT01218750|Experimental|edematous tractional epimacular membrane|Diabatic maculopathy comes to the edematous or tractional form. It is believed that epiretinal membranes are comprised from glial components. The processes of these cells may invade through the internal limiting membrane of the retina to the vitreous causing the vitreoretinal adhesion and anomalous posterior detachment of vitreous (APVD). In the macula, APVD causes vitreo-macular traction syndrome, which results in diffuse diabetic macular edema. If vitreoschisis is present, a place of dissection is crucial. If break occurs in front of the hyalocytes remaining on the retinal surface, the vitreous layer is thick and easily shrinks concentrically, which results in the formation of epimacular membrane.
11519456|NCT01218737|Experimental|Association|0.3% gatifloxacin and 1.0% prednisolone acetate association in eye drops plus placebo
11519457|NCT01218737|Active Comparator|Isolated ingredients|0.3% gatifloxacin and 1.0% prednisolone acetate isolated eye drops formulations
11519458|NCT01218685||Health adults|
11519459|NCT01218685||Health children|
11519460|NCT01218685||Pregnants|
11519461|NCT01218685||Elderly over 65 years old|
11519462|NCT01218685||HIV patients|
11519463|NCT01218685||Kidney transplant|
11519464|NCT01218685||Oncologic patients|
11519465|NCT01218685||Rheumatologic adult patients|
11519466|NCT01218685||Rheumatologic children patients|
11519467|NCT01218672|Experimental|GreenLight XPS|Photoselective vaporization of the prostate using GreenLight XPS laser system.
11519468|NCT01218672|Active Comparator|Transurethral Resection of the Prostate|Monopolar and bipolar Transuretheral resection of the prostate (TURP)
11519469|NCT01218659|Experimental|Migalastat|Participants received 150 mg migalastat orally QOD during the 18-month randomized treatment period and the optional 12-month OLE period. Participants received an inactive reminder capsule on alternate days during both treatment periods.
11519470|NCT01218659|Active Comparator|ERT|Participants received ERT (either agalsidase alfa or agalsidase beta) as prescribed by the participant's treating physician and administered in accordance with the approved prescribing information during the 18-month randomized treatment period. Participants were required to be given >80% of the currently labeled dose and regimen during the 18-month randomized treatment period. During the optional 12-month OLE period, participants received 150 mg migalastat orally QOD. Participants received an inactive reminder capsule on alternate days during the OLE.
11519471|NCT01218646|Experimental|Group 1: Investigational Quadrivalent Influenza Vaccine|Participants will receive a dose of Investigational Quadrivalent Inactivated Influenza Vaccine
11519472|NCT01218646|Experimental|Group 2: Investigational Trivalent Influenza Vaccine|Participants will receive a dose of Investigational Trivalent Inactivated Influenza Vaccine
11519473|NCT01218646|Active Comparator|Group 3: Licensed 2010-2011 Trivalent Influenza Vaccine|Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
11519474|NCT01218646|Active Comparator|Group 4: Licensed 2010-2011 Trivalent Influenza Vaccine|Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
11519475|NCT01218633|Placebo Comparator|Saline|
11519476|NCT01218633|Active Comparator|GLP-1-(9,36)-amide|
11519477|NCT01218633|Active Comparator|Exendin-9,39 @30pmol/kg/min|
11519478|NCT01218633|Active Comparator|Exendin-9,39 @300pmol/kg/min|
11519541|NCT01218204|Experimental|Part A Co-Dosing 800mg GSK1292263|Dosing for 14 days
11519542|NCT01218204|Other|Part B Washout|Washout for 4 weeks
11519543|NCT01218204|Active Comparator|Part B Run-in 10mg atorvastatin|Dosing for 4 weeks
11519479|NCT01218620|Experimental|Regimen I (Arm I)|"Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.
~Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral ketoconazole once daily on days 1-10 for course 2 only."
11519480|NCT01218620|Experimental|Regimen I (Arm II)|"Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.
~Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral rifampin once daily on days 1-10 for course 2 only."
11519481|NCT01218620|Experimental|Regimen II (Arm I)|"Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.
~Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral ketoconazole once daily on days 1-10 for course 2 only."
11519482|NCT01218620|Experimental|Regimen II (Arm II)|"Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.
~Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral rifampin once daily on days 1-10 for course 2 only."
11519483|NCT01218607|Placebo Comparator|Placebo|
11519484|NCT01218607|Active Comparator|Active|
11519485|NCT01218594|Experimental|Endostatin combine CCRT|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
11519486|NCT01218581|Active Comparator|group A|Group A received oral letrozole (2.5 mg/day, Femara, Novartis PharmaServices, Basel, Switzerland)
11519487|NCT01218581|Active Comparator|group B|group B received goserelin subcutaneosly (3.6 mg/month, Zoladex@, Zeneka Pharma International, UK)
11519488|NCT01218568|Experimental|Rifaximin plus lactulose|
11519489|NCT01218568|Active Comparator|lactulose|30-60ml/day
11519490|NCT01218555|Experimental|Lenalidomide combination with everolimus|Non-randomized study of escalating doses of daily, orally administered lenalidomide in combination with standard doses of everolimus, an orally available mammalian target of rapamycin (mTOR) inhibitor.
11519491|NCT01218542|Experimental|Volumetric modulated arc therapy|Single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.
11519492|NCT01218529|Experimental|Whole Brain Radiation Therapy (WBRT) + lapatinib|Whole Brain Radiation Therapy (30Gy in 10 fractions) and lapatinib 1250mg once daily for 2 weeks followed by lapatinib treatment 1500mg once daily for 4 weeks.
11519493|NCT01218516|Active Comparator|Farletuzumab plus Chemotherapy|During Combination Therapy, farletuzumab will be given with a protocol-approved platinum doublet (either carboplatin/paclitaxel, carboplatin/pemetrexed, or cisplatin/pemetrexed) for at least 4, but not more than 6, cycles. Participants who experience clinical benefit from the Combination Therapy will enter the Monotherapy Phase and receive farletuzumab as monotherapy until disease progression.
11519494|NCT01218516|Placebo Comparator|Placebo plus Chemotherapy|During Combination Therapy, placebo will be given with a protocol-approved platinum doublet (either carboplatin/paclitaxel, carboplatin/pemetrexed, or cisplatin/pemetrexed) for at least 4, but not more than 6 cycles. Participants who experience clinical benefit from the Combination Therapy will enter the Monotherapy Phase and receive placebo as monotherapy until disease progression.
11519495|NCT01218503|Experimental|CHOICES - obese|behavioral weight loss treatment - overweight/obese females
11519496|NCT01218490|Experimental|lymphadenectomy|after surgery of the ovarian cancer, patient will have Pelvis and aortic-cava lymphadenectomy
11519497|NCT01218490|No Intervention|no lymphadectomy|after surgery, the patient will not have pelvic and aortic-cave lymphadenectomy
11519498|NCT01218477|Experimental|Dasatinib, 100/140 mg QD|Participants received dasatinib, 100/140 mg once daily (QD), depending on cohort (100 mg for those with chronic myeloid leukemia [CML]-chronic phase; 140 mg for those with CML-advanced phase)
11519499|NCT01218477|Experimental|Dasatinib, 100/140 mg QD + BMS-833923, 50 mg QD|Participants received dasatinib, 100/140 mg once daily (QD), depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase) plus BMS-833923, 50 mg, QD
11519500|NCT01218477|Experimental|Dasatinib, 100/140 mg QD + BMS-833923, 100 mg BID/QD|Participants received BMS-833923, 100 mg twice daily (BID) for 7 days then once daily (QD) + dasatinib, 100/140 mg QD, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
11519501|NCT01218477|Experimental|Dasatinib, 100 /140 mg QD+ BMS-833923, 200 mg BID/QD|Participants received BMS-833923, 200 mg twice daily (BID) for 7 days then 200 mg once daily (QD) plus dasatinib, 100 /140 mg QD), depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
11519502|NCT01218464|Experimental|Conventional plus MSC treatment|Participants will receive conventional treatment plus a dose of MSC from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit
11519503|NCT01218464|Experimental|Conventional plus pacebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit
11519504|NCT01218451|Experimental|Group 1|Single dose of NeisVac-C vaccine at 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
11519505|NCT01218451|Experimental|Group 2|Single dose of NeisVac-C vaccine at 6 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
11519506|NCT01218451|Active Comparator|Group 3|Two doses of NeisVac-C vaccine at 2 and 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
11519544|NCT01218204|Active Comparator|Part B Run-in 80mg atorvastatin|Dosing for 4 weeks
11519507|NCT01218438|Experimental|Study Epochs 1-4|"Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.
~Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.
~Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.
~Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion."
11519508|NCT01218425|Experimental|Medication|In this study, a crossover design is applied. All participants receive all three treatments in randomized order on separate days.
11519509|NCT01218412|Experimental|Web-based, Mi=Based Intervention|4 session web-based, MI-based intervention.
11519510|NCT01218399|Active Comparator|Budesonide|"Combination of budesonide and formoterol. Medications are given according to the package insert and manufacturer's instructions.
~Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Symbicort study arm."
11519511|NCT01218399|Placebo Comparator|Placebo Comparator: Budesonide|"Control of budesonide alone. Medication was given according to the package insert and manufacturer's instructions.
~Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Budesonide study arm."
11519512|NCT01218386|Experimental|Study Group|"Start with estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.
~If day 25 is Monday: 6 days Tuesday: 10 days Wednesday: 9 days Thursday: 8 days Friday: 7 days Saturday: 6 days Sunday: 6 days of Progynova, 2x2 mg per day After this pretreatment: Standard GnRH antagonist treatment protocol with start rFSH (Puregon®) at a dose of 150 IU From day 2 of the cycle onwards; GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation"
11519513|NCT01218386|Active Comparator|Control group|Standard GnRH antagonist treatment protocol with start rFSH (Puregon®) at a dose of 150 IU From day 2 of the cycle onwards; GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation
11519514|NCT01218373|Active Comparator|Intervention Group: HOMESWEETHOME services|Monitoring and alarm handling services. eInclusion services. Domotica services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.
11519515|NCT01218373|Placebo Comparator|Control Group: No HOMESWEETHOME services|Normal care.
11519516|NCT01218360||Participants|All participants enrolled
11519517|NCT01218347|Experimental|Rosuvastatin|rosuvastatin treatment
11519518|NCT01218334||1|Cardiac Inpatient
11519519|NCT01218334||2|Cardiac Outpatient
11519520|NCT01218334||3|Cardiac Clinic Patient
11519521|NCT01218321||Antiepileptic treatment group|Group of patients treated by antiepileptic medications
11519522|NCT01218308|Experimental|FluLaval® Quadrivalent Group|Subjects between 3 and 8 years of age at the time of first vaccination received, if primed, 1 dose of FluLaval® Quadrivalent vaccine at Day 0 and, if unprimed, 2 doses of FluLaval® Quadrivalent vaccine at Days 0 and 28. The vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
11519523|NCT01218308|Active Comparator|Havrix Group|Subjects between 3 and 8 years of age at the time of first vaccination received, if primed, 1 dose of Havrix™ vaccine at Day 0 and, if unprimed, 2 doses of Havrix™ vaccine at Days 0 and 28. The vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
11519524|NCT01218295|Experimental|Respiratory muscle training|Patients assigned to this arm train the respiratory muscles by means of normocapnic hyperpnea.
11519525|NCT01218282|Experimental|Home Exercise Training Group A1|Patients assigned to this arm maintain the prescribed walking speed during the training with a metronome
11519526|NCT01218282|Experimental|Home Exercise Training Group A2|Patients assigned to this arm cover a fixed distance in a given period of time.
11519527|NCT01218282|No Intervention|Control|
11519528|NCT01218269|Other|no arms|all patients will receive the treatment - there is only one arms
11519529|NCT01218256|Active Comparator|Hypertrophy resistance training|Aerobic endurance training combined with hypertrophy resistance training in type 2 diabetes mellitus.
11519530|NCT01218256|Active Comparator|Endurance resistance training|Aerobic endurance training combined with hypertrophy resistance training in type 2 diabetes mellitus.
11519531|NCT01218243|Experimental|acupoint|Needle at bilateral BL33 60-80 mm with a 45°angle.A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd)is put on with Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. There are 5 sessions in the first two weeks and 3 sessions in the last two weeks, 30 min/session.
11519532|NCT01218243|Sham Comparator|non-acupoint|Take the place 2 cun far from BL33 on the outside horizontally as the non-point. Needle on the non-point for 60-80mm with a 45°angle. A feeling of soreness and distension will be felt .Needle with a 100-125mm long needle without lifting, thrusting or rotating.Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.
11519533|NCT01218230|Active Comparator|Intravitreal Pegaptanib|
11519534|NCT01218217|Experimental|SQ109 75 mg|75 mg SQ109 monotherapy daily
11519535|NCT01218217|Experimental|SQ109 150 mg|150 mg SQ109 daily
11519536|NCT01218217|Experimental|SQ109 300 mg|300 mg SQ109 daily
11519537|NCT01218217|Experimental|SQ109 150 mg + RIF|150 mg SQ109 + RIF standard dose daily
11519538|NCT01218217|Experimental|SQ109 300 mg + RIF|300 mg SQ109 + RIF standard dose daily
11519539|NCT01218217|Active Comparator|RIF Mono|Standard dose Rifampicin monotherapy daily
11519540|NCT01218204|Other|Part A Run-in|Subjects on stable 40mg atorvastatin > 4 weeks may raise their dose to 80mg for 2 weeks in order to qualify for Part A.
11519545|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 100mg GSK1292263|Dosing for 14 days
11519546|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 300mg GSK1292263|Dosing for 14 days
11519547|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 800mg GSK1292263|Dosing for 14 days
11519548|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 10mg ezetimibe|Dosing for 14 days
11519549|NCT01218204|Experimental|Part B Dosing 100mg GSK1292263|Dosing for 14 days
11519550|NCT01218204|Experimental|Part B Dosing 300mg GSK1292263|Dosing for 14 days
11519551|NCT01218204|Experimental|Part B Dosing 800mg GSK1292263|Dosing for 14 days
11519552|NCT01218204|Experimental|Part B Dosing Placebo GSK1292263|Dosing for 14 days
11519553|NCT01218204|Experimental|Part B Co-Dosing 80mg atorvastatin + 800mg GSK1292263|Dosing for 14 days
11519554|NCT01218204|Experimental|Part B Co-dosing 80mg atorvastatin + Placebo (GSK1292263)|Dosing for 14 days
11519555|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + Placebo (GSK1292263)|Dosing for 14 days
11519556|NCT01218191||Subarachnoid hemorrhage|Patients presenting a SAH
11519557|NCT01218178||Sodium bicarbonate plus NAC|Sodium bicarbonate plus NAC
11519558|NCT01218178||Saline hydration plus NAC|Saline hydration plus NAC
11519559|NCT01218165|No Intervention|Control Group|without intervention
11519560|NCT01218165|Experimental|Intervention Group|This group receives a probiotic drink daily for 6 week.
11519561|NCT01218152||cancer patients|patients who are seen by oncologists and who are willing to donate an extra blood sample when blood is taken routinely
11519562|NCT01218152||NF1 patients|patients, who have neurofibromatosis type 1 and who have developped an MPNST,donating a blood sample
11519563|NCT01218126|Experimental|losmapimod 2.5 mg|losmapimod 2.5 mg
11519564|NCT01218126|Placebo Comparator|placebo|
11519565|NCT01218126|Experimental|losmapimod 7.5 mg|losmapimod 7.5 mg
11519566|NCT01218126|Experimental|losmapimod 15 mg|losmapimod 15 mg
11519567|NCT01218113|Experimental|3D_HIV Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 3 doses of the HIV Vaccine 732462 at Weeks 0, 4 and 28, administered intramuscularly in the deltoid of the non-dominant arm.
11519568|NCT01218113|Experimental|2D_HIV Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 2 doses of the HIV Vaccine 732462 at Weeks 0 and 4 and one dose of placebo (saline solution) at Week 28, administered intramuscularly in the deltoid of the non-dominant arm.
11519569|NCT01218113|Placebo Comparator|Control Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 3 doses of placebo (saline solution) at Weeks 0, 4 and 28, administered intramuscularly in the deltoid of the non-dominant arm.
11519570|NCT01218100|Experimental|1|Combination group - starting dose level nebivolol 5mg and lisinopril 10mg
11519571|NCT01218100|Active Comparator|2|Nebivolol monotherapy group - starting dose level nebivolol 5mg
11519572|NCT01218100|Active Comparator|3|Lisinopril monotherapy group - starting dose level lisinopril 10mg
11519573|NCT01218100|Placebo Comparator|4|Placebo group - starting dose is placebo
11519574|NCT01218087|Experimental|Cranial cup device and Moldable positioner device|The cranial cup for 12/24 hours and the moldable positioner device was used for positioning infants the remainder of the 24 hours
11519575|NCT01218087|Active Comparator|Moldable positioner device|Moldable positioner device was used for positioning infants for 24/24 hours
11519576|NCT01218074|Active Comparator|Thromboelastography alone|Patients undergo standard of care Thromboelastography to evaluate overall coagulation performances.
11519577|NCT01218074|Experimental|Aggregometry+Tromboelastography|Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
11519578|NCT01218048|Experimental|Neo-Adjuvant Cetuximab|"Neo-Adjuvant Cetuximab + Surgery + Post-Surgical Radiation + Cisplatin (or Carboplatin)
~NOTE: Based the results of surgery if the treating physician feels patient is not a candidate for chemotherapy, radiation can be given alone or with cetuximab."
11519579|NCT01218009|Experimental|Albuterol Spiromax|Albuterol multi-dose dry powder inhaler (Spiromax) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for the 12 week double-blind period. Participants then continue into the 40 week open-label period in which they take albuterol multi-dose dry powder inhaler (Spiromax) inhalations of 90 mcg /inhalation as required (PRN).
11519580|NCT01218009|Placebo Comparator|Placebo Spiromax|Placebo delivered using a multi-dose dry powder inhaler (Spiromax) as 2 inhalations four times a day for the 12 week double-blind period. Participants then continue into the 40 week open-label period in which they administer albuterol multi-dose dry powder inhaler (Spiromax) inhalations of 90 mcg /inhalation as required (PRN).
11519581|NCT01217996|Other|Intervention Group|Children treated for a brain tumor (BT) or acute lymphoblastic leukemia (ALL) will complete the computerized working memory training program (intervention).
11519582|NCT01217996|Other|Control Group|Children treated for a brain tumor (BT) or acute lymphoblastic leukemia (ALL) will complete the computerized working memory training program (control).
11519583|NCT01217970|Active Comparator|Ibudilast 20mg BID|Ibudilast 20mg oral BID 7 days
11519584|NCT01217970|Active Comparator|Ibudilast 50mg BID|Ibudilast 50mg oral BID 7 days
11519585|NCT01217970|Placebo Comparator|Placebo|Placebo oral BID 7 days (0mg ibudilast)
11519586|NCT01217957|Experimental|Phase 1: Ixazomib 1.68 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 1.68 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 1.68 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
11519627|NCT01217762|Experimental|24 Gy IRay|Day 0 Lucentis followed by 24 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 19)
11519628|NCT01217749|Experimental|Group 1|In Group 1, PCI-32765 420 mg PO was administered daily for 1 cycle (28 days) before the start of ofatumumab IV dosing
11519790|NCT01216488|Active Comparator|40 ml of Xylocaine|
11519587|NCT01217957|Experimental|Phase 1: Ixazomib 2.23 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 2.23 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 2.23 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
11519588|NCT01217957|Experimental|Phase 1: Ixazomib 2.97 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 2.97 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 2.97 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
11519589|NCT01217957|Experimental|Phase 1: Ixazomib 3.95 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 3.95 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 3.95 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
11519590|NCT01217957|Experimental|Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone|In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 4.0 mg fixed dose, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
11519591|NCT01217944|Experimental|Ranibizumab driven by disease activity|Participants received active ranibizumab on day 1. Thereafter they received ranibizumab treatment based on disease activity criteria
11519592|NCT01217944|Experimental|Ranibizumab driven by stabilization criteria|Participants received ranibizumab on day 1 and month 1. Thereafter they received ranibizumab based on stabilization criteria for visual acuity
11519593|NCT01217944|Active Comparator|Verteporfin PDT|Participants received active vPDT on day 1. From month 3 onwards participants could receive ranibizumab, vPDT or a combination of the two if needed.
11519594|NCT01217931|Experimental|Group 1|Pazopanib + possible Bevacizumab
11519595|NCT01217931|Experimental|Group 2|Pazopanib + possible Everolimus
11519596|NCT01217931|Experimental|Group 3|Everolimus + possible Bevacizumab
11519597|NCT01217931|Experimental|Group 4|Everolimus + possible Pazopanib
11519598|NCT01217931|Experimental|Group 5|Bevacizumab + possible Pazopanib
11519599|NCT01217931|Experimental|Group 6|Bevacizumab + possible Everolimus
11519600|NCT01217918|Experimental|Cohort 1|PH-797804
11519601|NCT01217918|Experimental|Cohort 2|PH-797804
11519602|NCT01217918|Experimental|Cohotr 3|PH-797804
11519603|NCT01217905|Experimental|1|
11519604|NCT01217892|Experimental|1|Dapagliflozin 2.5 mg twice-daily plus open-label metformin
11519605|NCT01217892|Experimental|2|Dapagliflozin 5.0 mg twice-daily plus open-label metformin
11519606|NCT01217892|Experimental|3|Dapagliflozin 10 mg once-daily plus open-label metformin
11519607|NCT01217892|Placebo Comparator|4|Placebo plus open-label metformin
11519608|NCT01217879||Group 1|
11519609|NCT01217866||LAVH, techniques|Women aged 35-75 who underwent laparoscopic assisted vaginal hysterectomy via either suture technique vaginally or Enseal coagulation cutting device vaginally
11519610|NCT01217853||SENSIMED Triggerfish|
11519611|NCT01217840|Experimental|vitamin D|"Subjects were assigned to receive two observed doses of vitamin D2 (150,000 IU ergocalciferol, Barr Laboratories and Winthrop (Sanofi-Aventis)), given at baseline and 12 weeks. Capsules were packaged by the hospital's clinical trial pharmacist and were administered by study staff blinded to group assignments.
~Intervention: Height, weight, and BMI were obtained at baseline, 12 weeks and 24 weeks"
11519612|NCT01217840|Placebo Comparator|Placebo|Subjects were assigned to receive two observed doses of placebo, given at baseline and 12 weeks. Capsules were packaged by the hospital's clinical trial pharmacist and were administered by study staff blinded to group assignments. Height, weight, and BMI were obtained at baseline, 12 weeks and 24 weeks
11519613|NCT01217827|Experimental|Clinical Reminder|Reminder of potential candidacy for an implantable cardioverter defibrillator. The reminder is placed in the medical record with copy to the primary provider and any cardiologist managing the patient.
11519614|NCT01217827|No Intervention|Control|This group does not receive an intervention.
11519615|NCT01217814|Placebo Comparator|Placebo|Placebo 2 mL to match sarilumab once a week (qw) and 0.5 mL to match golimumab every 4 weeks (q4w) on top of MTX (15-25 mg) qw for 12 weeks.
11519616|NCT01217814|Active Comparator|Golimumab 50 mg|Golimumab 50 mg q4w and placebo (matched to sarilumab) qw on top of MTX (15-25 mg) qw for 12 weeks.
11519617|NCT01217814|Experimental|Sarilumab 150 mg|Sarilumab 150 mg qw and placebo (matched to golimumab) q4w on top of MTX (15-25 mg) qw for 12 weeks.
11519618|NCT01217801|Experimental|Ondansetron (ODFS)|single dose of Ondansetron Orally Dissolving Filmstrip 8 mg
11519619|NCT01217801|Active Comparator|Zofran (ODT)|Single dose of Zofran (Ondansetron) ODT Orally Disintegrating Tablets 8 mg
11519620|NCT01217788|Experimental|PH94B intranasal spray|
11519621|NCT01217788|Placebo Comparator|Placebo intranasal spray|
11519622|NCT01217775|Experimental|PH80 intranasal spray|Start using study medication on 14th of the cycle, or the day symptoms start to bother, or if no symptoms on day 21st of the cycle but no later than day 21st of the cycle, up to 6-times per day, and continuing until day 2-3 of the menses
11519623|NCT01217775|Placebo Comparator|Placebo intranasal spray|Start using study medication on 14th of the cycle, or the day symptoms start to bother, or if no symptoms on day 21st of the cycle but no later than day 21st of the cycle, up to 6-times per day, and continuing until day 2-3 of the menses
11519624|NCT01217762|Experimental|11 Gy IRay|Day 0 Lucentis followed by 11 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 2)
11519625|NCT01217762|Experimental|16 Gy IRay|Day 0 Lucentis followed by 16 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 27)
11519626|NCT01217762|Experimental|16 Gy IRay - Radiation First|16 Gy IRay and Lucentis PRN (N = 13)
11519791|NCT01216488|Experimental|25 ml of Xylocaine|
11519629|NCT01217749|Experimental|Group 2|In Group 2, PCI-32765 420 mg PO daily was initiated concomitantly with ofatumumab IV (PCI-32765 initiated on Day 2 of Cycle 1)
11519630|NCT01217749|Experimental|Group 3|In Group 3, two cycles of ofatumumab IV were administered prior to the start of PCI-32765 420 mg PO daily
11519631|NCT01217736|Experimental|VTP-27999|
11519632|NCT01217736|Active Comparator|aliskiren|
11519633|NCT01217736|Placebo Comparator|placebo|
11519634|NCT01217723|Experimental|Thymoglobulin|Thymoglobulin will be administered on Days -2, -1 prior to the transplant and on the day of transplant.
11519635|NCT01217723|Other|No Thymoglobulin|Patients will receive a standard preparative regimen. (i.e. one that does not normally contain Thymoglobulin.)
11519636|NCT01217671|Experimental|Alpha-1 Antitrypsin|
11519637|NCT01217671|Placebo Comparator|Placebo|
11519638|NCT01217658|Experimental|The Happiest Baby on The Block|"Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block."
11519639|NCT01217658|Active Comparator|AAP Education|Those receiving the control group allocation will be counseled in the American Academy of Pediatrics guidelines regarding Infant Colic (AAP Infant Colic counseling).
11519640|NCT01217645|Experimental|150 mg [14C] AZD6765|
11519641|NCT01217632|Placebo Comparator|FG-3019 Placebo|Placebo will be administered at 15-45 mg/kg every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
11519642|NCT01217632|Experimental|FG-3019|FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
11519643|NCT01217619|Experimental|Erlotinib|Single-arm
11519644|NCT01217606|Experimental|Triple Combination Therapy|Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
11519645|NCT01217606|Active Comparator|Combigan®|Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
11519646|NCT01217593|Experimental|ultrasound|Ultrasound guidance will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
11519647|NCT01217593|Active Comparator|predetermined distance|The predetermined distance technique will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
11519648|NCT01217580|Experimental|20 ml per side of 0.5% ropivacaine|Ultrasound guided TAP blocks will be performed once patient is in the recovery area. Patients will be placed on their back with their hands resting comfortably above their head. Using an ultrasound guided technique, the ultrasound probe will be positioned on abdominal until the three lateral abdominal wall muscles and TAP are clearly imaged. A two or four inch, 20 gauge needle will be advanced using an in-plane technique. After visual confirmation that the needle tip is in the TAP, 1 ml of preservative free 0.9% sodium chloride will be injected to reconfirm correct placement in the TAP. Then 20 ml of 0.5% ropivacaine will be injected. The procedure will be repeated on the other side.
11519649|NCT01217580|Placebo Comparator|20 ml per side of 0.9% sodium chloride|Ultrasound guided TAP blocks will be performed once patient is in the recovery area. Patients will be placed on their back with their hands resting comfortably above their head. Using an ultrasound guided technique, the ultrasound probe will be positioned on abdominal until the three lateral abdominal wall muscles and TAP are clearly imaged. A two or four inch, 20 gauge needle will be advanced using an in-plane technique. After visual confirmation that the needle tip is in the TAP, 1 ml of preservative free 0.9% sodium chloride will be injected to reconfirm correct placement in the TAP. Then 20 ml of 0.9% preservative free sodium chloride will be injected. The procedure will be repeated on the other side.
11519650|NCT01217567|Experimental|1st c-section, no previous lower abdominal surgery - s.l.|
11519651|NCT01217567|Experimental|Woman with previous ceasarean section - staples left|
11519652|NCT01217567|Experimental|1st c-section, no previous lower abdominal surgery|
11519653|NCT01217567|Experimental|Woman with previous ceasarean section|
11519654|NCT01217554||age-matched healthy male participants|age-matched healthy male participants without LBP
11519655|NCT01217554||participants with non specific chronic LBP|male participants with non specific chronic LBP
11519656|NCT01217541|Other|Education and supervision|Personnel in nursing home units get intervention in form of education and supervision
11519657|NCT01217541|No Intervention|Control|Only registering of patient and personnel data in the beginning and the end of the study without any form of intervention.
11519658|NCT01217528|Active Comparator|Group A|"Group A:
~VT zone: 350ms
~VF zone: 280ms"
11519659|NCT01217528|Experimental|Group B|"Group B:
~VT zone: 320ms
~VF zone: 250ms"
11519660|NCT01217515|Experimental|Diltiazem hydrochloride 4% cream|2.5 cm Diltiazem hydrochloride 4% cream applied peri-anally three times daily for eight weeks.
11519661|NCT01217515|Experimental|Diltiazem hydrochloride 2% cream|2.5 cm of Diltiazem hydrochloride 2% cream applied peri-anally three times daily for eight weeks.
11519662|NCT01217515|Placebo Comparator|Placebo cream|2.5 cm placebo cream applied peri-anally three times daily for eight weeks.
11519663|NCT01217502|Experimental|Self management|
11519664|NCT01217489||Attendees to symptomatic breast clinic|
11519665|NCT01217476|Active Comparator|Trafermin 0.01% spray|
11519666|NCT01217476|Placebo Comparator|Matching placebo spray|
11519667|NCT01217463|Active Comparator|Trafermin 0.01% spray|
11519668|NCT01217463|Placebo Comparator|Matching placebo spray|
11519669|NCT01217450|Experimental|Treatment (selumetinib, cetuximab)|Patients receive oral MEK inhibitor AZD6244 once or twice daily on days 1-28 and cetuximab IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11519670|NCT01217437|Experimental|Arm I (temozolomide, irinotecan hydrochloride)|Patients receive temozolomide PO and irinotecan hydrochloride IV over 90 minutes on days 1-5.
11519671|NCT01217437|Experimental|Arm II (temozolomide, irinotecan hydrochloride, bevacizumab)|Patients receive temozolomide PO and irinotecan hydrochloride IV as in arm I and bevacizumab IV over 30-90 minutes on days 1 and 15.
11519783|NCT01216579|Active Comparator|Mannitol managed arm|Group of asthmatic patients managed according to their mannitol challenge.
11519672|NCT01217411|Active Comparator|Arm I (WBRT or SRS)|Patients with >= 4 brain lesions undergo WBRT as in phase I and patients with =< 3 brain lesions undergo SRS as in phase I.
11519673|NCT01217411|Experimental|Arm II (WBRT or SRS and RO4929097)|Patients with >= 4 brain lesions receive RO4929097 and undergo WBRT as in phase I and patients with =< 3 brain lesions receive RO4929097 and undergo SRS as in phase I.
11519674|NCT01217385|Experimental|DOSI Pre-Surgery|Participants undergo approximately four assessments of breast health using the DOSI technology during treatment and prior to surgery for breast cancer.
11519675|NCT01217372|Experimental|Lemon supplementation YES|60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
11519676|NCT01217372|No Intervention|Lemon supplementation NO|No lemon supplementation
11519677|NCT01217359|Experimental|Interferon Alfa-2b|Patients will receive a single dose of interferon
11519678|NCT01217346||cardiac syndrome X|subjects fulfilling the clinical triad of cardiac syndrome X
11519679|NCT01217333|Active Comparator|In-person|Participants in this arm have been randomized to receive Consultation Planning in-person
11519680|NCT01217333|Active Comparator|Telephone|Participants in this arm have been randomized to receive Consultation Planning by telephone.
11519681|NCT01217320|Experimental|creatine supplementation|will receive 5g/d of creatine monohydrate throughout the trial
11519682|NCT01217320|Placebo Comparator|placebo|will receive 5g/d of placebo (dextrose) throughout the trial
11519683|NCT01217307|Experimental|Metformin|metformin 500mg twice daily during 4 months
11519684|NCT01217307|Placebo Comparator|Placebo|Placebo twice daily during 4 months
11519685|NCT01217294|Sham Comparator|spinal morphine, sham block|"Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as specified by the anaesthetist performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham ultrasound guided fascia iliaca plane block with saline.
~Post-operative analgesia with Paracetamol 1g four times daily, and patient controlled analgesia (PCA) with morphine (1mg bolus, 5 minute lockout period)"
11519686|NCT01217294|Active Comparator|ultrasound guided fascia iliaca block|"Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.
~Post-operative analgesia with Paracetamol 1g four times daily, and patient controlled analgesia (PCA) with morphine (1mg bolus, 5 minute lockout period)"
11519687|NCT01217281|No Intervention|Control|"Full mouth supra-gingival debridement using hand instruments and ultrasonic scalers, in one session. Patient motivation and oral hygiene instructions Review and prophylaxis at 1 month, 3 months and 6 months after initial treatment session.
~Full mouth periodontal therapy provided at the end of the 6month period (supra and sub- gingival full mouth scaling)"
11519688|NCT01217281|Active Comparator|Test/ Non-surgical Periodontal Therapy|"Full mouth periodontal therapy (sub and supra- gingival debridement) provided under local anaesthesia in two half-mouth sessions.
~Review and prophylaxis 1 month, 3 months and 6 months after the end of the initial therapy."
11519689|NCT01217268|Experimental|Training and supervision of staff|Staff members get training in person centered care by supervision using video-conference kit
11519690|NCT01217255||Brazilian Subject's|Subject's will be recruited from the Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paolo (HCFMUSP); Universidade Estadual de Campinas (UNICAMP); Universidade Federal de São Paulo (UNIFESP)
11519691|NCT01217255||Canadian Subject's|Recruited from The Hospital for Sick Children
11519692|NCT01217242||Children with cerebral palsy (CP)|ages 2 to < 10 years who are able to walk with or without an assistive device
11519693|NCT01217229|Experimental|PLX3397|
11519694|NCT01217216|Active Comparator|Group-based Intervention|We randomly assigned 30 individuals to a group-based intervention to promote weight loss through dietary restriction and physical activity.
11519695|NCT01217216|Active Comparator|Telephone-based Intervention|We randomly assigned 22 individuals to the telephone-based intervention to promote weight loss through dietary restriction and physical activity.
11519696|NCT01217203|Experimental|IPH2101 and lenalinomide|
11519697|NCT01217190|Experimental|Ondansetron ODFS then Zofran ODT|Single dose of Ondansetron Orally Dissolving Film Strip 8 mg followed by single dose of Zofran ODT® Orally Disintegrating Tablet containing Ondansetron 8 mg with 7 days washout between the 2 periods
11519698|NCT01217190|Experimental|Zofran ODT then Ondansetron ODFS|Single dose of Zofran ODT® Orally Disintegrating Tablet containing Ondansetron 8 mg followed by single dose of Ondansetron Orally Dissolving Film Strip 8 mg with 7 days washout between the 2 periods
11519699|NCT01217177|Experimental|2.5 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (2.5mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
11519700|NCT01217177|Experimental|5.0 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (5.0mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
11519701|NCT01217177|Experimental|10 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (10mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
11519702|NCT01217164|No Intervention|higher protein|
11519703|NCT01217151|Sham Comparator|Usual treatment|The hemodynamic management will be performed according to the institution's standard of care, using fluids at the discretion of the anesthesiologist and the ICU specialist.
11519704|NCT01217151|Active Comparator|NICOM|"For volume replacement, crystalloids will be used following the standard procedure according to the anesthesiologist or ICU specialist. Mean arterial pressure and cardiac index will be assessed every 5 minutes, and a volume bolus (250 mL colloid in 10 minutes) will be used to achieve a:
~Mean arterial pressure ≥ 65 mmHg (intra and postoperatively), AND
~Cardiac index ≥ 2.5 L/min/m2 (intra and postoperatively).
~If these cardiovascular parameters are not met after the first colloid infusion, a supplementary bolus will be added. In case of not achieving the target, additional colloid boluses and/or pharmacologic support (norepinephrine in case of persistent hypotension, dobutamine in case of low cardiac output) will be provided according to the protocol"
11519705|NCT01217138|Other|Original epinephrine autoinjector group|Participants were given original epinephrine autoinjector trainer wrapped by a gray sticky paper.
11519706|NCT01217138|Active Comparator|Modified epinephrine autoinjector group|Participants were given the same epinephrine autoinjector trainer wrapped by a gray sticky paper which was modified by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.
11519707|NCT01217112|Active Comparator|GWP42004 and placebo|Contains GWP42004 5 mg and placebo (excipients only)
11519708|NCT01217112|Active Comparator|1:1 GWP42003 : GWP42004|Contains 5 mg each of GWP42003 and GWP42004
11519709|NCT01217112|Active Comparator|20:1 GWP42003 : GWP42004|Contains 100 mg GWP42003 and 5 mg GWP42004
11519710|NCT01217112|Placebo Comparator|Placebo|Contains excipients only
11519711|NCT01217112|Active Comparator|GWP42003 and placebo|Contains 100 mg GWP42003 and placebo (excipients only)
11519712|NCT01217099|No Intervention|methylprednisolone|methylprednisolone pulse azithromycin
11519713|NCT01217099|No Intervention|azithromycin|azithromycin
11519714|NCT01217086|Active Comparator|CT-P13|
11519715|NCT01217086|Active Comparator|Remicade|
11519716|NCT01217073|Experimental|Omarigliptin 0.25 mg (Base)|Omarigliptin 0.25 mg administered once weekly for 12 weeks (Base)
11519717|NCT01217073|Experimental|Omarigliptin 1 mg (Base)|Omarigliptin 1 mg administered once weekly for 12 weeks (Base)
11519718|NCT01217073|Experimental|Omarigliptin 3 mg (Base)|Omarigliptin 3 mg administered once weekly for 12 weeks (Base)
11519719|NCT01217073|Experimental|Omarigliptin 10 mg (Base)|Omarigliptin 10 mg administered once weekly for 12 weeks (Base)
11519720|NCT01217073|Experimental|Omarigliptin 25 mg (Base)|Omarigliptin 25 mg administered once weekly for 12 weeks (Base)
11519721|NCT01217073|Placebo Comparator|Placebo (Base)|Matching placebo to omarigliptin administered once weekly for 12 weeks (Base)
11519722|NCT01217073|Experimental|Pooled omarigliptin (Extension)|Participants who received omarigliptin during the base study, received omarigliptin 25 mg once weekly and placebo to metformin once daily for 66 weeks (Extension).
11519723|NCT01217073|Active Comparator|Placebo/Metformin|Participants who received matching placebo to omarigliptin during the base period, received pioglitazone administered once daily and matching placebo to omarigliptin once weekly for 66 weeks (extension period). Note: A protocol amendment removed pioglitazone during the extension period. Participants discontinued pioglitazone and switched to blinded metformin. Participants who were previously rescued with open-label metformin during the base period continued in the extension period on open-label metformin.
11519724|NCT01217060|Experimental|Docetaxel + 5-FU + Radiation + Surgery|Docetaxel 20 mg/m2 given by vein (IV) once a week up to 5 1/2 weeks. Dexamethasone 10 mg IV 30 minutes prior to weekly Docetaxel. 5-FU 300 mg/m2 IV, continuously for 96 hours 5 days a week for about 5 1/2 weeks. Radiation 50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks. Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
11519725|NCT01217047|Experimental|Group A|For 3 weeks, you will need to come to the International Center for Spinal Cord Injury at Kennedy Krieger Institute (ICSCI) one (1) time per week during which you will perform FES cycling for 1 hour each.
11519726|NCT01217047|Experimental|Group B|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform FES cycling for 1 hour each.
11519727|NCT01217047|Experimental|Group C|For 3 weeks, you will need to come to the ICSCI five (5) times per week during which you will perform FES cycling for 1 hour each.
11519728|NCT01217047|Experimental|Group D|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform cycling without FES for 1 hour each.
11519729|NCT01217034|Experimental|TACE with sorafenib|TACE(on demand) with sorafenib till untreatable progression
11519730|NCT01217034|Active Comparator|TACE alone|TACE(on demand) till unreatable progression
11519731|NCT01217021|Experimental|Assess [18F] MNI-558 and PET imaging|
11519732|NCT01217008|Experimental|GRNOPC1|Subjects who receive an injection of GRNOPC1
11519733|NCT01216995|Active Comparator|Dose A|Dose A
11519734|NCT01216995|Placebo Comparator|Placebo|Placebo
11519735|NCT01216982|Active Comparator|Lovaza, omega-3 fatty acid ethyl ester|
11519736|NCT01216982|Placebo Comparator|Placebo|one gram corn oil in a soft gelatin capsule
11519737|NCT01216956|Experimental|Extended release nicotinic acid|
11519738|NCT01216956|Placebo Comparator|Placebo|
11519739|NCT01216943|Experimental|Triple Combination Therapy|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
11519740|NCT01216930||All colorectal cancer patients|
11519741|NCT01216917||Fitness|
11519742|NCT01216917||Whole-body vibration|
11519743|NCT01216917||Control|
11519744|NCT01216904|Placebo Comparator|Placebo patch|
11519745|NCT01216904|Active Comparator|Nicotine patch|
11519746|NCT01216891|Experimental|Team-based treatment|
11519747|NCT01216865|Experimental|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
11519748|NCT01216865|Active Comparator|Standard Therapy|Any therapy for diabetic foot which is routinely practiced and accepted in China
11519749|NCT01216839|Experimental|Everolimus|
11519750|NCT01216826|Experimental|Everolimus|
11519751|NCT01216787|Experimental|Treatment (gamma-secretase inhibitor RO4929097, surgery)|Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Within 35-56 days after completion of therapy, patients with stable or responsive disease undergo surgery. Patients may continue RO4929097 for 28 days after surgery in the absence of disease progression or unacceptable toxicity.
11519752|NCT01216774|Experimental|Low load + fatigue|
11519753|NCT01216774|Active Comparator|High load|
11519754|NCT01216774|Placebo Comparator|Low load|
11519784|NCT01216566|Experimental|I. Patients with chronic neck pain|
11519785|NCT01216553|Active Comparator|hypertonic inhalation + O2|oxygen for 30 minuets after inhalation of 3% saline 4 times daily
11519786|NCT01216553|Active Comparator|Epinephrine & bromhexine nebulized + O2|oxygen for 30 minuets after inhalation of racemic epinephrine with bromhexine 4 times daily
11519787|NCT01216540||Patients receiving vancomycin|
11519788|NCT01216527|Experimental|experimental group|Neo-adjuvant Chemoradiotherapy followed by Surgery
11519755|NCT01216761|Active Comparator|CHG then PI then IT|"Skin antisepsis prior to any peripheral blood culture collection on Floor A was performed with CHG for 3 months, followed by PI for 3 months, followed by IT for 3 months. Each 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.
~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG
~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI
~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT"
11519756|NCT01216761|Active Comparator|IT then CHG then PI|"Skin antisepsis prior to any peripheral blood culture collection on Floor B was performed with iodine tincture for 3 months, followed by Chlorhexidine gluconate for 3 months, followed by povidone iodine for 3 months. Each 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.
~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT
~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG
~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI"
11519757|NCT01216761|Active Comparator|PI then IT then CHG|"Skin antisepsis prior to any peripheral blood culture collection on Floor C was performed with povidone iodine for 3 months, followed by iodine tincture for 3 months, followed by chlorhexidine gluconate for 3 months. Each 3 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.
~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI
~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT
~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG"
11519758|NCT01216748|Experimental|health life-time non smokers|health lifetime non-smokers will be challenged with 4 respiratory maneuvers:quiet breathing, hypocapnic hyperventilation, hypercapnic hyperventilation, and eucapnic hyperventilation
11519759|NCT01216735|Active Comparator|smokers, Fluticasone first, then Placebo|The current smokers will be given a 3-week treatment course of inhaled fluticasone (220 ug fluticasone twice a day administered as a MDI) . The subjects and the investigators will be blinded to the random choice of inhaler.
11519760|NCT01216735|Placebo Comparator|smokers Placebo first, then Fluticasone|The current smokers will be given a 3-week treatment course of inhaled placebo MDI. The subjects and the investigators will be blinded to the random choice of inhaler.
11519761|NCT01216735|No Intervention|health non-smokers|The healthy non-smokers will have only visit 1 and no intervention.
11519762|NCT01216722|Experimental|Resistance Strengthening|Body weight antigravity positioning and elastic resistance bands are used to provide resistance for strengthening in supine, sitting, and standing in subjects post liver transplant.
11519763|NCT01216722|No Intervention|Usual Care Control|Subjects perform the usual care of progressive ambulation and increased activity post liver transplant
11519764|NCT01216709|Experimental|iron drops|
11519765|NCT01216709|Experimental|iron-fortified formula (2.3 mg iron/L)|
11519766|NCT01216709|Experimental|iron-fortified formula (12.4 mg iron /L)|
11519767|NCT01216696|Experimental|Intervention|"Intervention Details:
~Drug: ipilimumab
~Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first."
11519768|NCT01216683|Experimental|Arm I|Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of induction therapy, patients receive rituximab IV on day 1. Treatment repeats every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
11519769|NCT01216683|Experimental|Arm II|Patients receive rituximab IV on day 1, bortezomib IV on days 1, 4, 8, and 11, and bendamustine hydrochloride IV over 1 hour on days 1 and 4. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of induction therapy, patients receive rituximab as in arm I.
11519770|NCT01216683|Experimental|Arm III|Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 1 hour on days 1 and 2. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Immediately after completing induction therapy, patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for 13 courses in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of induction therapy, patients receive rituximab IV on day 1. Treatment repeats every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
11519771|NCT01216657|Experimental|sunitinib|50 mg Sunitinib daily for 4 weeks, then 2 weeks without treatment
11519772|NCT01216644|Experimental|FLOT|Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP
11519773|NCT01216644|Active Comparator|ECF|Epirubicin 50 mg/m2, d1 Cisplatin 60 mg/m², d1 5-FU 200 mg/m², d1-d21 every 3 weeks (q3w) 3 cycles (9 weeks) pre-OP and 3 cycles (9 weeks) post-OP
11519774|NCT01216631|Active Comparator|IA steroid|Intra-articular injection of steroid (80mg depomedrone)
11519775|NCT01216631|Experimental|IA infliximab|intra-articular injection of 100mg infliximab
11519776|NCT01216631|Experimental|IV infliximab|intravenous infusions of infliximab given at 0, 2, 6 and 14 weeks at a dose of 5mg/kg (patient body weight)
11519777|NCT01216618|Experimental|Device|Subject starts with two clamps including device use follows by a clamp without device use
11519778|NCT01216618|No Intervention|Control|Subject starts with clamps without device
11519779|NCT01216605|Active Comparator|Oxytocin|
11519780|NCT01216605|Placebo Comparator|Placebo|
11519781|NCT01216592||COPD|
11519782|NCT01216579|Placebo Comparator|Reference arm|Asthmatic patients managed as per British Thoracic Society guidelines by symptoms and lung function.
11519792|NCT01216475|Active Comparator|Femtosecond LASIK|2 lasers refractive procedure
11519793|NCT01216475|Experimental|SMILE|Small incision lenticule extraction (SMILE)
11519794|NCT01216449|Experimental|Intravenous Citalopram|
11519795|NCT01216449|Placebo Comparator|Normal Saline|250mL of 0.9% Sodium Chloride Solution
11519796|NCT01216436|Experimental|Vaccine plus untransfected DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm A), each subject will be coinjected with additional mature autologous dendritic cells that are not transfected with RNA.
11519797|NCT01216436|Experimental|Vaccine plus GITRL RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm B), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding the immune modulator GITR-L.
11519798|NCT01216436|Experimental|Vaccine plus antiCTLA4 RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm C), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding immune modulator anti-CTLA4 mAb.
11519799|NCT01216436|Experimental|Vaccine plus GITRL/ antiCTLA4 RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm D), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding both GITR-L and anti-CTLA4 mAb immune modulators.
11519800|NCT01216423||Incidence of recent stroke in patients with PFO|
11519801|NCT01216423||Incidence of recent stroke in patients without PFO|
11519802|NCT01216410|Active Comparator|Metoclopramide|Prophylaxis with metoclopramide and phenylephrine infusion.
11519803|NCT01216410|Placebo Comparator|Phenylephrine infusion|Prophylactic phenylephrine infusion and placebo antiemetics
11519804|NCT01216410|Active Comparator|Combination Group|Metoclopramide and Ondansetron prophylaxis with phenylephrine infusion
11519805|NCT01216397|Experimental|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
11519806|NCT01216397|Experimental|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
11519807|NCT01216384|Experimental|BI 671800 active|SRD part: 3 dose groups each consisting of 12 subjects (9 active, 3 placebo), subjects receive single dose. MRD part: 3 dose groups each consisting of 12 subjects (9 active, 3 placebo), subjects receive single dose followed by multiple doses with a PK sampling interval in between.
11519808|NCT01216384|Placebo Comparator|Placebo|3 subjects will receive placebo in each of the 3 doses in the SRD part and 3 doses in the MRD part
11519809|NCT01216371|Active Comparator|Sunitinib|one year adjuvant treatment with sunitinib
11519810|NCT01216371|Placebo Comparator|Placebo|one year treatment with placebo
11519811|NCT01216358||Arm 1: Combined contraceptive|Initiating an estrogen/progesterone contraceptive
11519812|NCT01216358||Arm 2: Progesterone only contraceptive|Initiating a progesterone-only contraceptive
11519813|NCT01216358||Arm 3 (control): Non-hormonal contraceptive|Initiating or using non-hormonal contraception or not using contraception
11519814|NCT01216332|Experimental|High-Dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
11519815|NCT01216332|Active Comparator|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
11519816|NCT01216319|Experimental|Nipple Reconstruction Cylinder|
11519817|NCT01216306|Experimental|Television reduction curriculum|Students are taught the television reduction curriculum during the school day and parents are invited to attend after-school meetings to discuss reducing their children's television viewing.
11519818|NCT01216306|No Intervention|Control|Students will be taught the standard preschool curriculum.
11519819|NCT01216293|Experimental|Dexlansoprazole 60 mg QD|
11519820|NCT01216293|Active Comparator|Esomeprazole 40mg QD|
11519821|NCT01216293|Placebo Comparator|Placebo QD|
11519822|NCT01216280|Placebo Comparator|2 x 10 mg placebo capsule|2 x 10 mg placebo capsules, administered orally with water, b.i.d.
11519823|NCT01216280|Experimental|10mg Natura-alpha + 10 mg placebo|10 mg Natura-alpha capsule + 10 mg placebo capsule administered orally with water, b.i.d.
11519824|NCT01216280|Experimental|2 x 10 mg Natura-alpha capsules|2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
11519825|NCT01216267|Active Comparator|lansoprazole|lansoprazole for 7 days
11519826|NCT01216254|Active Comparator|Classic electrocoagulation|Arm of the study where the classic low-frequency electrocoagulation is used during the operation
11519827|NCT01216254|Experimental|High Frequency electrocoagulation|Arm of the study where the tested high-frequency electrocoagulation is used during the operation
11519828|NCT01216241|Active Comparator|Daptomycin|Daptomycin intravenous 8mg/kg once per day 5-10 days.
11519829|NCT01216241|Placebo Comparator|Saline Placebo|Saline solution
11519830|NCT01216215||Asthmatic sporadic and familial|
11519831|NCT01216215||Control subjects spradic and familial|
11519832|NCT01216176|Experimental|Phase 1 - Cohort A|Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 (saracatinib) 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer
11519833|NCT01216176|Active Comparator|Phase 2 - Cohort B [Anastrozole + AZD0530]|Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 (saracatinib) 175 mg orally once daily, or as specified per protocol, until disease progression or 4-6 months of treatment completed.
11519834|NCT01216176|Placebo Comparator|Phase 2 - Cohort B [Anastrozole + Placebo]|Dual treatment with 1 mg anastrozole orally once daily together with Placebo orally once daily, or as specified per protocol, until disease progression or4-6 months of treatment completed.
11519835|NCT01216163|Experimental|Treatment A|
11519836|NCT01216163|Active Comparator|Treatment B|
11519837|NCT01216163|Placebo Comparator|Treatment C|
11519838|NCT01216150||aspirin|group treated with aspirin alone
11519839|NCT01216150||aspirin clopidogrel|Goup treated with aspirin and clopidogrel
11519840|NCT01216137|Experimental|Exercise: Vestibular Rehabilitation|Balance and eye movement training
11519841|NCT01216137|Active Comparator|Exercise Control|Bicycle ergometry and stretching
11519842|NCT01216137|No Intervention|Wait-listed Control|Wait-listed Control
11519843|NCT01216111|Experimental|6 cycles of PC adjuvant chemotherapy|paclitaxel 80 mg/m2 and carboplatin (area under the curve [AUC]= 2) on day 1, 8, 15 every 28 days for six cycles
11519844|NCT01216111|Active Comparator|3 cycles of FEC followed by 3 cycles of Docetaxel|fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously
11519845|NCT01216098|Experimental|Experimental arm - D|Experimental arm - Women randomized to this arm will receive doula support alongside standard care.
11519846|NCT01216098|No Intervention|No intervention - ND|No intervention - Women randomized to this arm will receive standard care alone.
11519847|NCT01216085|Experimental|imatinib|Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
11519848|NCT01216072|Experimental|Fingolimod|Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period .
11519849|NCT01216072|Active Comparator|Multiple Sclerosis Disease Modifying Treatments (MS DMTs)|Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months. An open-label extension of up to 3 months of treatment with fingolimod was to be available for patients in the DMT arm who successfully completed all study visits.
11519850|NCT01216059|Experimental|Intervention group|Subjects will receive daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study.
11519851|NCT01216059|No Intervention|Control Group|Subjects will receive a weekly text message reminder about pop-culture, sports or weather.
11519852|NCT01216046|Experimental|Treatment Arm|Subjects randomized to study drug will take VX-809 for 14 days followed by a 14 day washout. Next subjects will take VX-770 for 14 days followed by a 14 day washout. Lastly, subjects will take both VX-809 and VX-770 for 14 days.
11519853|NCT01216046|Placebo Comparator|Placebo Arm|Subjects randomized to placebo will take VX-809 placebo for 14 days followed by a 14 day washout. Next subjects will take VX-770 placebo for 14 days followed by a 14 day washout. Lastly, subjects will take both VX-809 and VX-770 placebo for 14 days.
11519854|NCT01216020|Experimental|cetuximab plus radiotherapy|Cetuximab given one week before radiotherapy (loading dose, 400 mg/m2) plus weekly (250 mg/m2), concomitant with radiotherapy (7O Gy on clinically involved sites).
11519855|NCT01216020|Active Comparator|cisplatin plus radiotherapy|CDDP 40 mg/mq in a single weekly 1-hour infusion concomitant to radiotherapy: (70 Gy to clinically involved sites)
11519856|NCT01216007|Active Comparator|TIVA|TIVA
11519857|NCT01216007|Active Comparator|Inhalational|Inhalational/volatile general anesthetic
11519858|NCT01215981|Active Comparator|Participants Receiving 1 Dose of Vaccine|"Control group participants (healthy volunteers):
~Age 18 to 50 years
~No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome
~No flu vaccine in previous 4 months
~and/or HSCT recipients who are greater than 60 days post transplant."
11519859|NCT01215981|Active Comparator|Participants Receiving 2 Doses of Vaccine|Hematopoietic stem cell transplant (HSCT) recipients who are greater than 60 days post transplant.
11519860|NCT01215968|Placebo Comparator|Placebo|"Each participant will receive placebo on Week 1. Participants randomized to placebo will receive once-weekly doses of placebo on Weeks 2 to 5.
~Placebo will be administered by single subcutaneous injection into the skin of the abdominal wall.
~Participants regularly taking metformin will continue their normal dosing regimen throughout the study."
11519861|NCT01215968|Experimental|LY2189265|"Participants randomized to LY2189265 will receive once-weekly doses of LY2189265 on Weeks 2 to 5.
~1.5 milligram (mg) LY2189265 will be administered by single subcutaneous injection into the skin of the abdominal wall.
~Participants regularly taking metformin will continue their normal dosing regimen throughout the study."
11519862|NCT01215955|Experimental|3 Day Algorithm|"Basal insulin glargine plus mealtime bolus insulin lispro titrated based on blood glucose readings from the past three days.
~(Sites were assigned to Study A and Study B according to an allocation plan that was pre-specified before initiation of Study A and Study B)"
11519863|NCT01215955|Experimental|Daily Algorithm|"Basal insulin glargine plus mealtime bolus insulin lispro titrated based on blood glucose readings from the previous day.
~(Sites were assigned to Study A and Study B according to an allocation plan that was pre-specified before initiation of Study A and Study B)"
11519864|NCT01215942|Experimental|120 milligrams (mg) of LY2127399|"Given every 4 weeks for 240 weeks for those participants from Study BCDO or Study BCDV. Participants who had been receiving placebo immediately prior to enrollment will receive a 240 mg loading dose when initiating treatment.
~Or
~Given every 4 weeks for 168 weeks for those participants from Study BCDM."
11519865|NCT01215942|Experimental|90 mg LY2127399|"Given every 2 weeks for 240 weeks for those participants from Study BCDO or Study BCDV. Participants who had been receiving placebo immediately prior to enrollment will receive a 180 mg loading dose when initiating treatment.
~Or
~Given every 2 weeks for 168 weeks for those participants from Study BCDM."
11519866|NCT01215929|Active Comparator|Dextroamphetamine|
11519867|NCT01215929|Placebo Comparator|Placebo|
11519868|NCT01215916|Experimental|Experimental: Pemetrexed followed by LY573636|Pemetrexed on Day 1 followed by LY573636 on Day 4
11519869|NCT01215916|Experimental|Experimental: LY573636 followed by Pemetrexed|LY573636 on Day 1, pemetrexed on Day 4
11519870|NCT01215916|Experimental|Experimental: LY573636 and Pemetrexed on Day 1|LY573636 and Pemetrexed on Day 1
11519871|NCT01215903|Experimental|Fish gelatin and omega-3|
11519872|NCT01215903|Experimental|Omega-3|
11519873|NCT01215890|Active Comparator|risedronate plus calcium and viamin D|
11519874|NCT01215890|Placebo Comparator|placebo plus clacium and vitamin D|
11519875|NCT01215864|Experimental|TCD-717|
11519917|NCT01215617|Other|Control|Patients will receive standard medical treatment at the University Hospital lung department.
11519876|NCT01215851|Experimental|TMC207|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus pyrazinamide placebo administered once daily
11519877|NCT01215851|Experimental|TMC207 and pyrazinamide|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: < or = 55kg received 2 tablets/day; >55kg to 75kg received 3 tablets/day; >75kg received 4 tablets/day
11519878|NCT01215851|Experimental|PA-824 and pyrazinamide|PA-824 administered once daily as 200mg tablets and pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: < or = 55kg received 2 tablets/day; >55kg to 75kg received 3 tablets/day; >75kg received 4 tablets/day and moxifloxacin placebo (matched to moxifloxacin tablets) administered once daily
11519879|NCT01215851|Experimental|PA-824 and moxifloxacin and pyrazinamide|PA-824 administered once daily as 200mg tablets and pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: < or = 55kg received 2 tablets/day; >55kg to 75kg received 3 tablets/day; >75kg received 4 tablets/day and moxifloxacin administered once daily as 400mg tablets
11519880|NCT01215851|Active Comparator|Rifafour e-275 mg|Rifafour e-275 administered once daily with each tablet containing 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, and 275mg ethambutol and dose by weight as follows: 30kg-37kg received 2 tablets/day; 38kg-54kg received 3 tablets/days; 55kg-70kg received 4 tablets/day; > or = 71kg received 5 tablets/day
11519881|NCT01215851|Experimental|TMC207 and PA-824|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus PA-824 administered once daily as 200mg tablets
11519882|NCT01215825||HD, LD, NIL|HD: the highest daily dose of steroids receiving more than 60 mg/day LD: the highest daily dose of steroids receiving less or equal to 60 mg/day NIL: no steroid use
11519883|NCT01215799|Experimental|Bafetinib|
11519884|NCT01215786|Other|AGN-207281 ophthalmic solution|AGN-207281 0.1% ophthalmic solution on Days 1-7 and AGN-207281 0.3% ophthalmic solution on Days 8-14
11519885|NCT01215786|Active Comparator|Timolol ophthalmic solution 0.5%|timolol ophthalmic solution 0.5%
11519886|NCT01215786|Placebo Comparator|Placebo|AGN-207281 vehicle ophthalmic solution (Placebo)
11519887|NCT01215773|Experimental|BI 671800 HEA medium dose|Tablet, oral administration with 240 mL of water for each treatment
11519888|NCT01215773|Experimental|BI 671800 HEA high dose|2 Tablets, oral administration with 240 mL of water for each treatment
11519889|NCT01215773|Placebo Comparator|Placebo|Matching to HEA 200 mg tablets, oral administration
11519890|NCT01215760|Active Comparator|MIRROR|Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
11519891|NCT01215760|Active Comparator|Home program|The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
11519892|NCT01215747|Experimental|Kiacta (eprodisate disodium)|
11519893|NCT01215747|Placebo Comparator|Placebo|
11519894|NCT01215734|Active Comparator|High-Dose Trivalent Inactivated Influenza Vaccine|Forty adult hematopoetic stem cell transplant recipients at least 6 months post transplant will receive high dose trivalent influenza vaccine
11519895|NCT01215734|Active Comparator|Standard dose Trivalent Inactivated Flu Vaccine|Twenty Adult stem cell transplant recipients at least 6 months post transplant will receive standard dose trivalent influenza vaccine.
11519896|NCT01215721|Experimental|Vesicare|Vesicare 5mg daily for 90 days was prescribed for men presenting with post-Robotic Assisted Radical Prostatectomy (RARP) severe incontinence.
11519897|NCT01215708|Active Comparator|Nifedipine|nifedipine retard 20mg daily
11519898|NCT01215708|Active Comparator|tamsulosin|tamsulosin 0,4mg
11519899|NCT01215708|Placebo Comparator|placebo|placebo capsule
11519900|NCT01215695|Active Comparator|Control|Patients will be randomly assigned to having their ETT placed with use of a pre-formed stylet provided by the manufacturer of the GVL (control group)
11519901|NCT01215695|Experimental|Intervention|Patients will be randomly assigned to either having their ETT placed with use of flexible, disposable tracheoscope (aScope, Ambu, Denmark) (intervention group).
11519902|NCT01215682|Active Comparator|vit D|
11519903|NCT01215682|Placebo Comparator|placebo|
11519904|NCT01215669|Experimental|Group 1: Adult Intradermal (ID) Vaccine|Participants aged 18 to 59 years will be vaccinated with IDflu™ influenza vaccine
11519905|NCT01215669|Active Comparator|Group 2: Adult Intramuscular (IM) Vaccine|Participants aged 18 to 59 years will be vaccinated with Vaxigrip® Influenza vaccine
11519906|NCT01215669|Experimental|Group 3: Elderly Intradermal (ID) Vaccine|Participants aged 60 years or older will be vaccinated with IDflu™ Influenza vaccine
11519907|NCT01215669|Active Comparator|Group 4: Elderly Intramuscular (IM) Vaccine|Participants aged 60 years or older will be vaccinated with Vaxigrip® Influenza vaccine
11519908|NCT01215656|Experimental|Probiotic|follow on formula with the probiotic Lactobacillus fermentum
11519909|NCT01215656|Active Comparator|Control|follow on formula without probiotics
11519910|NCT01215643|Experimental|ALV 1000 mg|Alisporivir (ALV) 600 mg twice daily (BID) for 1 week, followed by ALV 1000 mg once daily (QD) during Weeks 2 to 24.
11519911|NCT01215643|Experimental|ALV 600 mg+RBV|Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with ribavirin (RBV) during Weeks 2 to 24.
11519912|NCT01215643|Experimental|ALV 800 mg+RBV|Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
11519913|NCT01215643|Experimental|ALV 600 mg+PEG|Alisporivir (ALV) 600 mg BID with Peginterferon alfa-2a (PEG) for 1 week, followed by ALV 600 mg QD with PEG once weekly during Weeks 2 to 24.
11519914|NCT01215643|Active Comparator|PEG+RBV|Peginterferon alfa-2a (PEG) and RBV during Weeks 1 to 24.
11519915|NCT01215630||Healthy subjects|Men Women Age; 18-75
11519916|NCT01215617|Experimental|Aerobic Interval Training|Patients randomized to training will meet for supervised aerobic interval training three times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate
11519918|NCT01215591|Active Comparator|Gradual wean from Nasal CPAP|Nasal CPAP for gradual wean group it was cycled off for 3 hours alternating with 3 hours on for first 48 hours, if successful the cycle was extended to 6 hours off and 3 hours on for the next 48 hours. If the baby tolerated this regime the prongs were removed and CPAP was kept off.
11519919|NCT01215591|No Intervention|Sudden wean from Nasal CPAP|Usual practice to wean the preterm neonates from nasal CPAP
11519920|NCT01215578|Experimental|patient treated|patient who receive sunitinib (SUTENT)
11519921|NCT01215565|Experimental|patient treated|patient who receive sunitinib
11519922|NCT01215552|Experimental|HT-0712|
11519923|NCT01215539|Experimental|Panitumumab,capecitabine,oxaliplatin|"Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg.
~Oxaliplatin 130 mg/m2 IV infusion over 2 hours on Day 1 Capecitabine 2000 mg/m2 divided in two doses, orally, on Days 1 - 14"
11519924|NCT01215513|Experimental|Degarelix|
11519925|NCT01215500|Experimental|Radiation therapy|
11519926|NCT01215487||1 - Chronic Myelogenous Leukemia Patients|Patients will be selected from patients referred to the primary hospital site for treatment and assessment. The patients will be approached by the physicians and or the study research nurse to consider participation in the study. Patients may be selected by participating off-site hospital centres and may be enrolled at those collaborating centres.
11519927|NCT01215474||NSCLC Stadium III-IV|
11519928|NCT01215448|No Intervention|Lifestyle changes|Lifestyle changes(booklet and audio cassette of recommended diet, physical activity and breathing exercises)
11519929|NCT01215448|Experimental|Wheatgrass juice & lifestyle changes|Wheatgrass juice & lifestyle changes
11519930|NCT01215435|Experimental|Pre-breakfast BIAsp 30|
11519931|NCT01215435|Experimental|Pre-dinner BIAsp 30|
11519932|NCT01215422||children intubated with Glidescope|children intubated with Glidescope
11519933|NCT01215422||children intubated with DCI|children intubated with DCI
11519934|NCT01215409||Group 1|
11519935|NCT01215396|Placebo Comparator|Carbohydrate Placebo|
11519936|NCT01215396|Active Comparator|Single Dose|"The Amino Vital Focus Zone is a dietary supplement of amino acid mixture, which also contains some minerals, vitamin C, flavour, and sweetener, and its appearance is clear to slightly opaque powder. The Amino Vital Focus Zone contains the five kind of amino acid (L-Leucine, L-Isoleucine, L-Valine, L-Arginine, and L-Glutamine), Citric acid, Vitamin C, some mineral, and sweetener.
~Powdered treatments will be dissolved in water and administered orally. This treatment will contain 0.96 g of amino acids."
11519937|NCT01215396|Active Comparator|Double Dose|"The Amino Vital Focus Zone is a dietary supplement of amino acid mixture, which also contains some minerals, vitamin C, flavour, and sweetener, and its appearance is clear to slightly opaque powder. The Amino Vital Focus Zone contains the five kind of amino acid (L-Leucine, L-Isoleucine, L-Valine, L-Arginine, and L-Glutamine), Citric acid, Vitamin C, some mineral, and sweetener.
~Powdered treatments will be dissolved in water and administered orally. This treatment will contain 1.92 g of amino acids."
11519938|NCT01215383||psychiatric patients|20 in patients and outpatients with schizophrenia, schizoaffective and bipolar disorder based on psychiatrist diagnostic evaluation using DSM-IV criteria, before and at least two months after antipsychotic therapy will be enrolled.
11519939|NCT01215383||healthy volunteers|"Ten healthy volunteers will be checked as controls:
~Employee from the hospital staff with no metabolic disease (Diabetes mellitus, hypertension or dyslipidemia) and non-smokers."
11519940|NCT01215357|Experimental|Ecopipam|Ecopipam is a selective antagonist of one the classes of dopamine receptor.
11519941|NCT01215344|Experimental|VRD|VELCADE, Lenalidomide, Dexamethasone
11519942|NCT01215344|Experimental|VDD|VELCADE, liposomal doxorubicin, dexamethasone
11519943|NCT01215331|Active Comparator|Insulin|Rapid acting insulin and long acting insulin
11519944|NCT01215331|Experimental|Oral Hypoglycemic Agents|Metformin + glyburide + insulin if needed
11519945|NCT01215318|Experimental|Modified vaginal tampons|Patients using modified vaginal tampons during FDG PET/CT
11519946|NCT01215318|Placebo Comparator|Unmodified vaginal tampons|Patients using unmodified vaginal tampons during FDG PET/CT
11519947|NCT01215305||Visiting outpatient departments, if symtoms|patients with upper GI symptoms, visiting the outpatient departments of peripheral hospitals in Greece
11519948|NCT01215292|Placebo Comparator|Acyline & T Gel & Placebo Ketoconazole|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel (T gel) 5 gm daily Days 1-10, + placebo tab PO 1x daily, Day 3-10
11519949|NCT01215292|Experimental|Acyline & T Gel & Ketoconazole 400|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Days 1-10, + ketoconazole 400mg PO 1x daily, Days 3-10
11519950|NCT01215292|Experimental|Acyline & T gel & Ketoconazole 800|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + ketoconazole 800mg PO 1x daily, Days 3-10
11519951|NCT01215292|Experimental|Acyline & T gel & Dutasteride|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + dutasteride 2.5 mg PO 1x daily, Days 3-10
11519952|NCT01215292|Experimental|Group 5: anastrazole|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + anastrazole 1 mg PO 1x daily, Days 3-10
11519953|NCT01215279|Experimental|AZD2423|AZD2423 Oral Treatment for 28 days
11519954|NCT01215279|Placebo Comparator|Placebo|Oral treatment for 28 days
11519955|NCT01215266|Active Comparator|Sorafenib|
11519956|NCT01215266|Placebo Comparator|Placebo|
11519957|NCT01215253|Active Comparator|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at end of first week. For patients on anti-arrhythmic therapy at the time of randomization, their ECG will be checked at end of first week on 500 mg dose and again at end of second week on 1000 mg dose. For patients with CrCl <60ml/min prior to randomization, their CrCl will be checked again at 2 weeks and study drug discontinued if <30ml/min. For patients with CrCl <60ml/min at 2 weeks, their CrCl will be checked again at 4 weeks and study drug discontinued if <30ml/min.
11519992|NCT01215136|Active Comparator|Cohort 2|Everolimus plus paclitaxel (enrollment limited to patients with creatinine clearance < 60 ml/min OR Karnofsky performance status of 60-70%)
11520048|NCT01214746|Active Comparator|Atorvastatin|
11520049|NCT01214733|Experimental|1|
11520050|NCT01214720|Experimental|1|
11519958|NCT01215253|Placebo Comparator|Placebo|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at end of first week. For patients on anti-arrhythmic therapy at the time of randomization, their ECG will be checked at end of first week on 500 mg dose and again at end of second week on 1000 mg dose. For patients with CrCl <60ml/min prior to randomization, their CrCl will be checked again at 2 weeks and study drug discontinued if <30ml/min. For patients with CrCl <60ml/min at 2 weeks, their CrCl will be checked again at 4 weeks and study drug discontinued if <30ml/min.
11519959|NCT01215240|Experimental|Prophylactic peritoneal dialysis|Prophylactic peritoneal dialysis
11519960|NCT01215240|No Intervention|Standard care without PDC|
11519961|NCT01215227|Experimental|Preladenant 2 mg|Participants who received preladenant 2 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 2 mg in this extension study. Participants will receive preladenant 2 mg taken orally twice daily (BID): one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
11519962|NCT01215227|Experimental|Preladenant 5 mg|Participants who received preladenant 5 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 5 mg in this extension study. Participants will receive preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
11519963|NCT01215227|Experimental|Preladenant 5 mg (on placebo in parent study)|Participants who received placebo to preladenant tablet in parent study NCT01155466 or NCT01227265 will receive preladenant 5 mg in this extension study. Participants will receive preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
11519964|NCT01215227|Experimental|Preladenant 10 mg|Participants who received preladenant 10 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 10 mg in this extension study. Participants will receive preladenant 10 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
11519965|NCT01215227|Active Comparator|Rasagiline 1 mg|Participants who received rasagiline 1 mg in parent study NCT01155466 or NCT01227265 will continue to receive rasagiline 1 mg in this extension study. Participants will receive rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.
11519966|NCT01215227|Active Comparator|Rasagiline 1 mg (on placebo in parent study)|Participants who received placebo to rasagiline capsule in parent study NCT01155466 or NCT01227265 will receive rasagiline 1 mg in this extension study. Participants will receive rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.
11519967|NCT01215214|Experimental|midazolam|period 1: midazolam administration alone period 2: ketoconazole 400 mg PO for 4 days administration, midazolam iv single administration period 3: rifampicin 600 mg PO for 9 days administration, midazolam iv single administration
11519968|NCT01215201|Other|Scaling and Root Planing Alone|Control group
11519969|NCT01215201|Experimental|Diode Laser plus Scaling and Root Planing|Diode Laser is used in addition to Scaling and root planing procedure.
11519970|NCT01215188|Experimental|V114 Aluminum-adjuvanted|Four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.
11519971|NCT01215188|Experimental|V114 Non-adjuvanted|Four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.
11519972|NCT01215188|Active Comparator|Prevnar 13®|Four IM doses at 0.5 mL of Prevnar 13® at 2, 4, 6, and 12 to 15 months of age.
11519973|NCT01215175|Active Comparator|Prevnar™ - Adult Cohort|Healthy adult participants received a single 0.5 mL intramuscular injection of Prevnar™ on Day 1.
11519974|NCT01215175|Experimental|V114 Adjuvanted -Toddler Cohort|Healthy toddler (12-15 months of age) participants who had completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
11519975|NCT01215175|Experimental|V114 Nonadjuvanted-Toddler Cohort|Healthy toddlers (12-15 months of age) participants who completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of non-adjuvanted V114 on Day 1.
11519976|NCT01215175|Active Comparator|Prevnar™- Toddler Cohort|Healthy toddlers (12-15 months of age) participants who had previously completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of Prevnar™ on Day 1.
11519977|NCT01215175|Experimental|V114 Adjuvanted -Adult Cohort|Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
11519978|NCT01215162|Experimental|Single arm study|Patients with stage T1/T2No breast cancer receiving breast conserving treatment
11519979|NCT01215149|Experimental|Group A|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 6. Vaccine:Placebo=10:3
11519980|NCT01215149|Experimental|Group B|Ad35-ENVA at Month 0 followed by Ad26.ENVA.01 at Month 6. Vaccine:Placebo=10:3
11519981|NCT01215149|Experimental|Group C|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=10:3
11519982|NCT01215149|Experimental|Group D|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=10:3
11519983|NCT01215149|Experimental|Group E|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
11519984|NCT01215149|Experimental|Group F|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
11519985|NCT01215149|Experimental|Group G|Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
11519986|NCT01215149|Experimental|Group H|Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
11519987|NCT01215149|Experimental|Group I|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
11519988|NCT01215149|Experimental|Group J|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
11519989|NCT01215149|Experimental|Group K|Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
11519990|NCT01215149|Experimental|Group L|Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
11519991|NCT01215136|Active Comparator|Cohort 1|Single-agent everolimus (enrollment limited to patients with patients with creatinine clearance < 60 ml/min AND Karnofsky performance status of 60-70%)
11519993|NCT01215123||Bevacizumab|Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
11519994|NCT01215110|Experimental|TMC207 700/500/400|TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14
11519995|NCT01215110|Experimental|TMC207 500/400/300|TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.
11519996|NCT01215110|Experimental|TMC207 400/300/200|TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14
11519997|NCT01215110|Experimental|TMC207 200/100|TMC207- 200 mg Day 1 and 100 mg Days 2-14
11519998|NCT01215110|Active Comparator|Rifafour e-275 mg|Rifafour e-275 mg
11519999|NCT01215097|Experimental|Linagliptin|once a day
11520000|NCT01215097|Placebo Comparator|placebo|once a day
11520001|NCT01215084|Experimental|Chinese Subpopulation: Fampridine-PR 10 mg|Chinese ethnic participants were administered a single dose of Fampridine-PR 10 mgs
11520002|NCT01215084|Experimental|Japanese Subpopulation: Fampridine-PR 10mg|Japanese ethnic participants were administered a single dose of Fampridine-PR 10 mgs
11520003|NCT01215084|Experimental|Caucasian Subpopulation: Fampridine-PR 10mg|Caucasian ethnic participants were administered a single dose of Fampridine-PR 10 mgs
11520004|NCT01215071|Experimental|limited lymphadenectomy|Fields 5, 7, 9, 11, 13, 14 are removed
11520005|NCT01215071|Experimental|extended lymphadenectomy|Fields 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 are removed
11520006|NCT01215058||1|
11520007|NCT01215045||ReSTOR +4|AcrySof ReSTOR Aspheric +4
11520008|NCT01215032|Experimental|Metformin|This is the only arm of this phase 2 open label study
11520009|NCT01215019|Active Comparator|Arm 1|20% Mannitol
11520010|NCT01215019|Active Comparator|Arm 2|3% sodium chloride
11520011|NCT01214993|Experimental|Treatment A|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive GSK1349572 50mg (two 25mg tablets) q24h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
11520012|NCT01214993|Experimental|Treatment B|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive GSK1349572 50mg (two 25mg tablets) q12h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
11520013|NCT01214993|Placebo Comparator|Treatment C|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive placebo q24h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
11520014|NCT01214980|Experimental|MIST Therapy in conjunction with SOC|Low-frequency, non-contact ultrasound administered in conjunction with standard of care treatment
11520015|NCT01214980|Active Comparator|Control arm|Standard of care treatment
11520016|NCT01214967|Experimental|1|Problem Solving Education, a psycho-educational intervention
11520017|NCT01214967|No Intervention|2|Usual care
11520018|NCT01214954|Active Comparator|Control group|Standard rehabilitation
11520019|NCT01214954|Experimental|Resistance training|10 weeks of supervised progressive resistance training initiated within the first week after total hip replacement.
11520020|NCT01214941|Placebo Comparator|Placebo|
11520021|NCT01214941|Active Comparator|Ticlopidine|
11520022|NCT01214941|Active Comparator|Ticlopidine and itraconazole|
11520023|NCT01214928|Active Comparator|Cholecalciferol|Cholecalciferol 50,000IU po once weekly for 12 continuous weeks.
11520024|NCT01214928|Placebo Comparator|Placebo|Matching placebo po once weekly for 12 continuous weeks
11520025|NCT01214915|Experimental|Anagrelide Hydrochloride|
11520026|NCT01214902|Experimental|Experimental CIMT|Two month home program that includes restricting the non hemiplegic hand an hour a day during play
11520027|NCT01214902|Active Comparator|Active Play|Two month home program that includes active use of hemiplegic hand during play one hour a day
11520028|NCT01214889|Experimental|Study Group A|Participants will receive a single dose of DTacP-IPV//PRP T combined vaccine (PENTAXIM™) at age 2, 4 and 6 months.
11520029|NCT01214889|Active Comparator|Study Group B|Participants will receive a dose of DTacP IPV combined vaccine (TETRAXIM™) and PRP-T vaccine (ActHIB™) at 2, 4, and 6 months of age.
11520030|NCT01214876||Children 1-5 years old|
11520031|NCT01214876||Children 6-10 years old|
11520032|NCT01214876||Adults 25 years and above|
11520033|NCT01214863||T3|Model SN60T3 assigned by AcrySof Toric calculator
11520034|NCT01214863||T4|Model SN60T4 assigned by AcrySof Toric calculator
11520035|NCT01214863||T5|Model SN60T5 assigned by AcrySof Toric calculator
11520036|NCT01214850|Experimental|rMenB+OMV|Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart
11520037|NCT01214850|Experimental|MenACWY|Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart
11520038|NCT01214850|Active Comparator|Control|Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart
11520039|NCT01214837|Experimental|MenACWY3|Subjects received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
11520040|NCT01214837|Experimental|MenACWY4|All the subjects received a 3-dose primary series at 2, 4 and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
11520041|NCT01214837|Placebo Comparator|Routine Vaccines|Subjects received routine vaccines only, including PCV-13, at 2, 4 and 6 months of age and a toddler dose at 12 months of age.
11520042|NCT01214811|Other|Mepilex Border Ag|Non comparative study with one active arm - Mepilex Border Ag
11520043|NCT01214785|Active Comparator|Sanitation intervention|
11520044|NCT01214785|No Intervention|Control|
11520045|NCT01214772|Experimental|heparin,pregnancy,IVF failure|Women in the heparin arm are administered 5000 IU twice a day on the day of embryo transfer
11520046|NCT01214759|Other|Truvada and Raltegravir|Single arm
11520047|NCT01214746|Placebo Comparator|Placebo|
11520051|NCT01214707||Exercise protocol|No arms are required for this study as all subjects complete the entire protocol
11520052|NCT01214694|Experimental|Active Comparator: Internet Resources Comparison (IRC)|Participants will receive the Internet resource comparison group treatment
11520053|NCT01214694|Experimental|I-InTERACT|Participants will receive a 24 week, 27 session internet-based parenting skills program
11520054|NCT01214694|Experimental|I-InTERACT Express|Participants will receive an abbreviated 7 week, 14 session version of the I-InTERACT parenting skills program.
11520055|NCT01214681|Placebo Comparator|Placebo|
11520056|NCT01214681|Experimental|Hi-maize 260|
11520057|NCT01214681|Experimental|Polydextrose|
11520058|NCT01214681|Active Comparator|Hi-maize 260 and polydextrose|
11520059|NCT01214668|Experimental|LY573636 + Liposomal Doxorubicin|
11520060|NCT01214655|Experimental|LY2523355 on Days 1, 2, and 3|Starting dose was 2 milligrams per meter squared (mg/m^2) administered by a 1-hour intravenous (IV) infusion on Days 1, 2, and 3 of every 21-day Cycle.
11520061|NCT01214655|Experimental|LY2523355 on Days 1, 5, and 9|Starting dose was 8 milligrams per meter squared (mg/m^2) administered by a 1-hour IV infusion over 1 hour on Days 1, 5, and 9 of every 21-day Cycle.
11520062|NCT01214642|Experimental|LY2523355 Days 1, 5, 9|LY2523355 administered intravenously on Days 1, 5 and 9, starting dose is 2 milligrams per meter squared (mg/m^2) for 2 planned 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
11520063|NCT01214642|Experimental|LY2523355 Days 1, 8|LY2523355 administered intravenously on Days 1 and 8, starting dose is 8 mg/m^2 for 2 planned 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
11520064|NCT01214642|Experimental|LY2523355 Days 1, 5 + pegfilgrastim|LY2523355 administered intravenously on Days 1 and 5, starting dose is 8 mg/m^2 for 2 planned 21-day cycles and 6 mg pegfilgrastim administered subcutaneously on Day 6 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
11520065|NCT01214642|Experimental|LY2523355 Days 1, 4 + pegfilgrastim|LY2523355 administered on Days 1 and 4, starting dose is 12 mg/m^2 for 2 planned 21-day cycles and 6 mg pegfilgrastim administered subcutaneously on Day 5 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
11520066|NCT01214629|Experimental|LY2523355|
11520067|NCT01214629|Experimental|LY2523355 + pegfilgrastim|
11520068|NCT01214616|Experimental|afatinib and vinorelbine IV|patient to receive 20mg or 40mg of po daily afatinib in combination with vinorelbine IV
11520069|NCT01214603|Experimental|LY2090314|"Cohort 1: 40 milligrams (mg) LY2090314 administered on Days 1, 8, and 15 of a 28-day cycle for at least two (2) 28-day cycles. Participants experiencing clinical benefit may continue treatment until after the discontinuation criteria are met.
~Due to a protocol amendment on September 2010, the study added 2 additional treatment schedules/cohorts. Cohort 2: 40 mg dose given on Days 1, 5, and 9 of a 21-day cycle. Cohort 3: 40 mg dose given on Days 1, 5, 9, and 12 of a 21-day cycle. Participants experiencing clinical benefit may continue treatment until after the discontinuation criteria are met."
11520070|NCT01214590|Experimental|VascuActive Treatment|
11520071|NCT01214577|Experimental|1|Up to three days of treatment
11520072|NCT01214564|Experimental|1|Up to three days of treatment
11520073|NCT01214538||Control group - culture negative|50 children with pneumococcal culture-negative Acute Otitis Media
11520074|NCT01214538||study group- culture positive|50 children with pneumococcal culture-positive Acute Otitis Media
11520075|NCT01214525||Meatotomy|Toilet trained children scheduled for urethral meatotomy for the treatment of urethral meatal stenosis.
11520076|NCT01214499|Active Comparator|Treatment Control|Transmyocardial revascularization (TMR) with Holmium YAG (yttrium aluminium garnet) laser, according to habitual clinical practice in the Department of Cardiovascular Surgery.
11520077|NCT01214499|Experimental|Experimental Treatment|Transmyocardial revascularization (TMR) with Holmium YAG laser plus the patient's own stem cells extracted from bone marrow.
11520078|NCT01214486|Experimental|Raltegravir|
11520079|NCT01214473|Experimental|Probiotic group|Once daily oral administration of a probiotic preparation (1 billion cells of Lactobacillus plantarum and 150 mg of fructooligosaccharides) for one week to newborn infants
11520080|NCT01214473|Placebo Comparator|Placebo|Once daily oral administration of maltodextrin for one week to newborn infants
11520081|NCT01214460||All MET calls|We make an Utstein type analyze to all MET calls
11520082|NCT01214460||All EMS calls|We make an Utstein type analyze to all EMS calls during June 2015
11520083|NCT01214460||All patient in the emergency department|We make an Utstein type analyze to all Emergency visits during June 2015
11520084|NCT01214447||Low - OSND less than 22|
11520085|NCT01214447||Moderate - OSND score 23-27|
11520086|NCT01214447||Normal - OSND score 28-32|
11520087|NCT01214434|Experimental|Promiseb Topical Cream|
11520088|NCT01214434|Sham Comparator|Bland emollient|
11520089|NCT01214421|Experimental|251 Prior Tolvaptan|"Tolvaptan tablets (as multiples of 15 or 30 mg) will be given orally twice daily until the last subject originating from the 156-04-251 trial who is eligible for efficacy analysis has completed the Month 24 visit. Dosing should occur on waking and approximately 9 hours later, irrespective of meals. Exact timing of dosing may be adjusted based on wake/sleep habits (eg, standard 8 AM and 5 PM may be switched to 10 PM and 7 AM if working a night shift). However, dosing times should be consistent for each individual's daily dose to maximize receptor suppression.Subjects should be titrated to the highest dose tolerated unless an equivalent dose was not tolerated and was associated with a significant adverse event in a prior trial. For example, the following titration schedule could be followed:
~Day 0 - 45/15 mg split-dose regimen assigned Week 1 - tolerated dose, up-titrate to 60/30 mg Week 2 - tolerated dose, up-titrate to 90/30 mg Week 3 - tolerated dose, 90/30 mg continued."
11520090|NCT01214421|Experimental|251 Prior Placebo|Subjects on Placebo from a previous open-label trial and not on tolvaptan at the baseline visit, initial dosing will commence with the lowest dose regimen and up-titrated to the last tolerated dosing regimen (as explained above).
11520091|NCT01214421|Experimental|Other Prior Study|For subjects enrolling from a previous open-label trial and are on tolvaptan at the baseline visit, initial dose assignment will remain consistent with the dose regimen the subject is currently on. Should a subject enroll from a previous open-label trial and not be on tolvaptan at the baseline visit, initial dosing will commence with the lowest dose regimen and up-titrated to the last tolerated dosing regimen (as explained above).
11520092|NCT01214408|Experimental|GRP-A|
11520093|NCT01214408|Experimental|GRP-B|
11520094|NCT01214382|Experimental|Sertraline|
11520095|NCT01214369|Active Comparator|X-tip intraosseous injection|
11520096|NCT01214369|Active Comparator|PDL injection|
11520097|NCT01214356|Placebo Comparator|Lower Dose Vitamin D|Vitamin D3 supplementation of 400 IU/D or 4000 IU/D with combined calcium carbonate supplementation of 1000 mg/day
11520098|NCT01214356|Active Comparator|Higher Dose Vitamin D|Vitamin D3 supplementation of 4000 IU/D or 4000 IU/D with combined calcium carbonate supplementation of 1000 mg/day
11520099|NCT01214343|Experimental|Sorafenib with Low-dose FP|
11520100|NCT01214343|Active Comparator|Sorafenib|
11520101|NCT01214330|Experimental|Patient-Collected Cervical Pap Smear|women will receive a self Papanicolaou Smear test (SoloPap) in addition to their physician-collected Papanicolaou Smear
11520102|NCT01214317|Active Comparator|mitoxantrone and plasmapheresis|Monthly Plasmapheresis (plasma exchange machine: Haemonetics, model TCS2, USA) 25 ml/kg for 5 cycles, with replacement of 0.9% saline and 5% human serum albumin followed by monthly IV infusion of 12 mg/m2 mitoxantrone (EBEWE Pharma, Amsterdam, The Netherlands) at the end of each Plasmapheresis course for three successive months. Then, treatment is continued by adding two more 6 mg/m2 doses of mitoxantrone in 3-month intervals.
11520103|NCT01214317|No Intervention|mitoxantrone|Monthly IV infusion of 12 mg/m2 mitoxantrone (EBEWE Pharma, Amsterdam, The Netherlands) for three successive months. Then, treatment is continued by adding two more 6 mg/m2 doses of mitoxantrone in 3-month intervals.
11520104|NCT01214304|Placebo Comparator|Lavender Scent|Patients will receive aromatherapy with a fake lavender scent (placebo) which will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure.
11520105|NCT01214304|Experimental|Essential Lavender Oil|Patients will receive essential Lavender Oil which will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure.
11520106|NCT01214278|Experimental|Supplement 1|EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil uncoated capsules
11520107|NCT01214278|Experimental|Supplement 2|EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG)
11520108|NCT01214278|Experimental|Supplement 3|EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules
11520109|NCT01214278|Experimental|Supplement 4|DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL)
11520110|NCT01214252||Permacol Patients|Patients who have undergone surgical repair of their abdominal wall defect with Permacol Surgical Implants with at least 12 months follow up.
11520111|NCT01214239|Experimental|Linagliptin|once a day
11520112|NCT01214239|Placebo Comparator|Placebo|once a day
11520113|NCT01214226|Active Comparator|Pentoxifylline + Prednisolone|"Pentoxifylline 400 mg prolonged-released tablets 3 time a day [1200 mg/day]
~+ Prednisolone 2 ORODISPERSIBLE TABLETS OF 20 MG 1 TIME PER DAY [40 mg/day]"
11520114|NCT01214226|Placebo Comparator|Placebo + Prednisolone|"Placebo prolonged-release tabled 3 time a day
~+ Prednisolone 2 ORODISPERSIBLE TABLETS OF 20 MG 1 TIME PER DAY [40 mg/day]"
11520115|NCT01214200|Experimental|High Intensity Non Invasive Pos.Pressure|The High Intensity Non-invasive Pos.Pressure trial is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation (HINPPV) for 90 days. Participants will receive HINPPV via bilevel positive airway pressure (BiPAP Synchrony) if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O (centimeters of water); or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
11520116|NCT01214187|Experimental|carbon monoxide inhalation|The primary intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
11520117|NCT01214187|Placebo Comparator|Oxygen 21%|
11520118|NCT01214174|Experimental|Dose 1|513ug
11520119|NCT01214174|Experimental|Dose 2|776ug
11520120|NCT01214174|Experimental|Dose 3|1046ug
11520121|NCT01214161|Experimental|lidocaine gel|This group will be those randomized to receiving the intervention with 2% lidocaine gel.
11520122|NCT01214161|Placebo Comparator|placebo gel (surgilube)|This group will be randomized to having the intervention with the placebo surgilube gel.
11520123|NCT01214148|Other|ORSIRO|
11520124|NCT01214135||1|Patients with a diagnosis of schizophrenia who have been hospitalized and received at least one dose of Seroquel XR or Seroquel IR during the study period (1st of July 2009 - 30th of September 2010).
11520125|NCT01214122|Experimental|Treatment A|AZD9668 - 2 x30mg tablets
11520126|NCT01214122|Experimental|Treatment B|Warfarin - 10 x2.5 mg tablets
11520127|NCT01214109|Experimental|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
11520128|NCT01214109|Active Comparator|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
11520129|NCT01214096|Placebo Comparator|placebo|
11520130|NCT01214096|Experimental|rhNRG-1|recombinant human neuregulin-1
11520131|NCT01214083|Experimental|Arm 1|N-acetylcysteine + high-dose naltrexone (150 mg)
11520132|NCT01214083|Experimental|Arm 2|High-dose naltrexone (150 mg) alone
11520133|NCT01214083|Active Comparator|Arm 3|Low-dose naltrexone (50 mg) alone
11520134|NCT01214070|Active Comparator|Arm 1|Group 1 - Combination Treatment
11520135|NCT01214070|Active Comparator|Arm 2|Group 2 - Combination Treatment
11520136|NCT01214070|Active Comparator|Arm 3|Group 3 - Combination Treatment
11520137|NCT01214070|Active Comparator|Arm 4|Group 4 - Combination Treatment
11520138|NCT01214070|Active Comparator|Arm 5|Group 5 - Monotherapy Treatment
11520139|NCT01214070|Active Comparator|Arm 6|Group 6 - Monotherapy Treatment
11520140|NCT01214070|Active Comparator|Arm 7|Group 7 - Monotherapy Treatment
11520141|NCT01214057|Experimental|Total Intravenous Anesthesia|Total Intravenous Anesthesia (TIVA) with propofol and remifentanyl
11520142|NCT01214057|Active Comparator|Inhaled Anesthesia|Inhaled anesthesia with sevoflurane and remifentanyl.
11520143|NCT01214044|Experimental|Study Drug|Subjects will have a total of 12 visits to Oregon Clinical & Translational Research Institute at Oregon Health & Science University over the 14-16 weeks of study. Subjects will first undergo an initial screening visit to determine eligibility. Subjects who meet criteria and agree to participate will then stop taking their current antidepressant medication (if applicable), during which time the study doctor and staff will conduct weekly mood assessments to ensure safety. Subjects will then have a study initiation/materials visit followed by 9 visits during treatment with placebo or escitalopram. A final post-study follow-up safety visit will be scheduled at the end of treatment.
11520144|NCT01214031|Other|Confocal Laser Endomicroscopy Arm|Confocal laser endomicroscopy (CLE) is another novel imaging tool for enabling histopathologic diagnosis in vivo during endoscopy. Specially designed confocal endoscopes have the confocal laser microscope integrated to the distal tip of the conventional endoscope. This provide images at a cellular level that have been shown to have a high sensitivity, specificity and accuracy.
11520145|NCT01214018||Reference|Nearest relatives of brain-dead patients who donated organs
11520146|NCT01214018||Opposition|Nearest relatives of brain-dead patients opposed to organ donation
11520147|NCT01214018||Medical/Legal|Nearest relatives of brain-dead patients for whom organ donation was not an option because of medical or legal reasons
11520148|NCT01214005|Experimental|schizophrenia|Smokers with schizophrenia or schizoaffective disorder
11520149|NCT01214005|Other|non-psychiatric|smokers without psychiatric illness
11520150|NCT01213992|Active Comparator|Monofer® 500 mg|500 mg iron isomaltoside 1000
11520151|NCT01213992|Active Comparator|Monofer® 1000 mg|1000 mg iron isomaltoside 1000
11520152|NCT01213979|Active Comparator|1000 mg iron isomaltoside 1000 as intravenous infusion|
11520153|NCT01213979|Active Comparator|500 mg iron isomaltoside 1000 as bolus injection|
11520154|NCT01213966|Experimental|800 mg OZ439 po single dose|800 mg OZ439 po single dose
11520155|NCT01213966|Experimental|400 mg OZ439 p.o. single dose|400 mg OZ439 p.o. single dose
11520156|NCT01213966|Experimental|200mg OZ439 p.o. single dose|200mg OZ439 p.o. single dose
11520157|NCT01213966|Experimental|1200 mg OZ439 po single dose|1200 mg OZ439 po single dose
11520158|NCT01213940|Other|baratric surgery|surgery vs.weight loss program 6 months prior to bariatric surgery
11520159|NCT01213940|Other|pre-bariatric weight loss program|weight loss program prior to bariatric surgery
11520160|NCT01213914|Experimental|High-volume hemofiltration at 70ml/kg/hr|Paired randomization into four groups via central randomization center. Group 1: age 18-65 and <40%TBSA Group 2: age 18-65 and >40%TBSA Group 3: age >65 and <40%TBSA Group 4: age >65 and >40%TBSA
11520161|NCT01213914|Active Comparator|Control group|Contemporary care via consideration of the Burn-Specific Sepsis Bundle adapted form the most recent Surviving Sepsis campaign recommendations and specifically modified to our patient population.
11520162|NCT01213901|Experimental|1|"Each patient will receive 2 insulin injections in the abdomen: Once using a pinch method and once using a spread method.
~Injections will be given in a random order and the technician will be blinded to the injection.
~Each patient will evaluate the comfort of the injection by completing a visual analog scale."
11520163|NCT01213888|Experimental|Arm II|
11520164|NCT01213888|Placebo Comparator|Arm I. Placebo + Pan-Retinal Photocoagulation|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
11520165|NCT01213875|Experimental|Experimental: Intervention and control|"I: Experimental Routine monitoring by health team in the reference institution, four home visits and four telephone contacts with trained nurses.
~II: Control Routine monitoring by health team in the reference institution."
11520166|NCT01213875|No Intervention|Control|
11520167|NCT01213862|Experimental|intervention and control|"Group I - Intervention: Routine follow-up in a reference health institution with four home visits and four telephone contacts with specialist nurses.
~Group II - Control: Routine follow-up with the health team in the reference institution."
11520168|NCT01213849|Experimental|200/100 mcg fluticasone furoate/vilanterol|4 inhalations of 50/25 mcg fluticasone furoate/vilanterol
11520169|NCT01213849|Experimental|400/100 mcg fluticasone furoate/vilanterol|4 inhalations of 100/25 mcg fluticasone furoate/vilanterol
11520170|NCT01213849|Experimental|800/100 mcg fluticasone furoate/vilanterol|4 inhalations of 200/25 mcg fluticasone furoate/vilanterol
11520171|NCT01213836|Active Comparator|First Seroquel XR then Seroquel IR|Patients randomised to Seroquel XR will have treatment for 10-16 days and after that cross-over to treatment with Seroquel IR for 10-16 days
11520172|NCT01213836|Active Comparator|First Seroquel IR then Seroquel XR|Patients randomised to Seroquel IR will have treatment for 10-16 days and after that cross-over to treatment with Seroquel XR for 10-16 days
11520173|NCT01213823||Cases|Potential cases were defined as patients with a diagnosis of severe hepatic injury identified in the acute-care inpatient cohort using ICD-9 codes associated with the case definition of severe liver injury. Case status was validated by a Consultant Gastroenterologist blinded to study drug exposure via medical record review using an apriori algorithm. Only validated cases were included in the analysis (N=69)
11520174|NCT01213823||Controls|Controls were defined as patients without a diagnosis of severe hepatic injury (i.e. with no ICD-9 codes associated with the case definition of severe liver injury) selected at random from the same acute-care inpatient cohort as cases (N=467)
11520175|NCT01213797||Suicide attempter and its entourage|"Suicide attempter and its close relatives (who are living under the same roof)
~Comparison of the population of the close relations of committing suicide with the data of the Research Institute and Documentation in Economy of Health (IRDES) on the French population (sample of 20.000 people, representative of 95% of the French households)."
11520176|NCT01213784|Experimental|optimized diabetic control|each participant will be assigned to be optimized in a dedicated diabetic clinic
11520177|NCT01213784|No Intervention|control|participants will be assigned to follow what ever control they were in before the study and not to change any antidiabetic treatment during the interventions period.
11520178|NCT01213771|No Intervention|Preoperative care 2009|Patients are receiving the usual care
11520179|NCT01213758||Liver tumors|Patients where stereotactic body radiation therapy is planned for primary or metastatic liver tumors.
11520180|NCT01213745|Experimental|Intervention|
11520181|NCT01213745|Experimental|Attention|
11520182|NCT01213745|Active Comparator|Control|
11520183|NCT01213732|Experimental|L19TNFα plus melphalan|Subjects will be sequentially assigned to one of 2 dose levels of L19TNFα: 325 µg or 650 µg. All subjects will receive a single dose of L19TNFα and Melfalan (10mg/ L Limb volume).
11520184|NCT01213719|Experimental|creatine|will receive creatine monohydrate (20g/d) throughout 10 days
11520185|NCT01213719|Experimental|betaine|will receive betaine (2g/d) throughout 10 days
11520186|NCT01213719|Placebo Comparator|placebo (dextrose)|will receive dextrose(20g/d)throughout 10 days.
11520187|NCT01213719|Active Comparator|creatine plus betaine|will receive creatine (20g/d) plus betaine (2g/d) throughout 10 days
11520188|NCT01213706|Experimental|Whole Body Periodic Acceleration (WBPA)|All subjects will be performing this procedure. WBPA in spinal axis (pGz) will be administered with a platform that resembles a bed. The platform moves in a repetitive head-to-foot direction at 140 times a minute, producing 0.22 g.
11520189|NCT01213706|Experimental|Sham WBPA|"Sham WBPA :
~All subjects will be performing this procedure before the WBPA. The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge."
11520190|NCT01213693|Experimental|ICS/LABA group|Patients assigned to this arm will take bid 50/500 mcg fluticasone/salmeterol combination
11520191|NCT01213693|Active Comparator|LABA group|Patients assigned to this arm will take bid 50 mcg salmeterol
11520192|NCT01213680|Active Comparator|1000 mg iron isomaltoside as intravenous infusion|
11520193|NCT01213680|Active Comparator|500 mg iron isomaltoside 1000 as bolus injection|
11520194|NCT01213667|Other|ranibizumab as needed|
11520195|NCT01213628|Experimental|Standard heating|Standard intraoperative warming measures including heated sheets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
11520196|NCT01213615||all patients eligible for implantation of a Hancock II Ultra|
11520197|NCT01213602||Femoral block preoperative|In one group (T1) with performance of femoral block before general anesthesia and administration of bolus of local anesthetic through stimulating catheter (combined anesthesia)
11520198|NCT01213602||Femoral block postoperative|In second group (T2) with a administration of local anesthetic through stimulating femoral catheter until awareness of patient (balanced anesthesia).
11520199|NCT01213589||Descending thoracic aortic dissection|Patients diagnosed with a descending thoracic aortic dissection and who are amenable to stent-graft operation. The patient had an indication for treatment by either endovascular stent graft implantation for either an acute, sub-acute or chronic Type B dissection.
11520200|NCT01213576|Active Comparator|albendazole 400mg and ivermectin 200mcg/kg|Annual treatment
11520201|NCT01213576|Active Comparator|Albendazole 800mg and ivermectin 400mcg/kg|Annual treatment
11520202|NCT01213576|Active Comparator|Albendazole 400mg and ivermectin 200mcg/kg|albendazole 400mg and ivermectin 200mcg/kg given twice a year
11520203|NCT01213576|Active Comparator|Albendazole 800mg and ivermectin 400mcg /kg bi-annually|Albendazole 800mg and ivermectin 400mcg/kg given twice a year
11520204|NCT01213563|Experimental|Actrapid insulin|Intensive glycaemic control Intervention: Actrapid insulin
11520205|NCT01213563|Active Comparator|Actrapid insulin+Gloucose|conventional glycaemic control Intervention: Actrapid insulin+Glucose
11520206|NCT01213550|Experimental|Chlorhexidine|
11520207|NCT01213550|Placebo Comparator|Placebo mouthrinse|
11520208|NCT01213537||Patients undergoing clinically indicated CRT implantation|"Patients may be included in the study if they fulfil the following;
~Age ≥18 years old
~Fulfil the current guidance for the implantation of a CRT device; optimal medical treatment for heart failure, broad QRS complex on electrocardiogram with or without evidence of cardiac dyssynchrony as appropriate, LVEF <35%, functional impairment as defined by an NYHA class of III-IV
~Clinically stable with no unplanned admission to hospital for preceding 4 weeks
~No changes in medications for heart failure in preceding 4 weeks
~Able to read and understand patient information sheet and give informed consent
~Patients must be excluded from the study if they fulfil they the following;
~On positive pressure treatment for known sleep disordered breathing at the time of inclusion
~Other known condition (untreated) likely to significantly disturb sleep eg. Restless legs syndrome, pain from any cause etc.
~Pregnancy"
11520209|NCT01213524|Active Comparator|Active nicotine replacement (NRT) + denicotinized cigarettes|42 mg nicotine replacement plus sensorimotor replacement
11520210|NCT01213524|Active Comparator|Placebo NRT + denicotinized cigarettes|inactive transdermal patches plus sensorimotor replacement
11520211|NCT01213524|Active Comparator|Active NRT + no cigarettes|42 mg nicotine replacement with no sensorimotor replacement
11520212|NCT01213524|Placebo Comparator|Placebo NRT + No cigarettes|Double placebo: No nicotine or sensorimotor replacement
11520213|NCT01213524|Active Comparator|usual brand smoking|positive control: usual brand smoking
11520214|NCT01213511|Active Comparator|MECC Group|Patients operated for elective coronary artery bypass grafting with the use of minimal extracorporeal circulation.
11520215|NCT01213511|Active Comparator|CECC Group|Group of patients undergoing elective coronary bypass grafting with the use of conventional extracorporeal circulation.
11520216|NCT01213498|Active Comparator|Atorvastatin|
11520217|NCT01213498|Placebo Comparator|Unikalk|
11520218|NCT01213485||Cohort|
11520219|NCT01213472|Experimental|NY-ESO 1 Group|Patients with non-operable and progressing metastatic cutaneous melanoma, received up to 24 doses of GSK2241658A Cancer Immunotherapeutic, provided that at each tumor evaluation time point, the clinical criteria to continue the treatment were met, including patients having a clinical response.
11520220|NCT01213459||Cohort A|Women ≥15 years of age attending out-patient departments for routine cervical screening in the Kingdom of Saudi Arabia.
11520221|NCT01213446|Experimental|Biostate|
11520222|NCT01213433|Experimental|Amodiaquine+Artesunate|
11520223|NCT01213420|Experimental|Aloë Vera FORMULA F-BC-096|
11520224|NCT01213420|Active Comparator|Aloë Vera FORMULA F-BC-096 with modified preservative|
11520225|NCT01213420|Active Comparator|Eucerin Calming cream|
11520226|NCT01213420|Active Comparator|Nivea Cream|
11520227|NCT01213407|Experimental|Standard therapy plus Trivax|Standard therapy with Surgery, Temozolomide, and Radiotherapy; plus Trivax, 5x10e6 autologous interleukine-12 secreting dendritic cells charged with autologous tumour lysate.
11520228|NCT01213407|Active Comparator|Standard therapy|Surgery, Temozolomide, Radiotherapy
11520229|NCT01213394|Experimental|CellCept optimization|
11520230|NCT01213394|Active Comparator|Control|
11520231|NCT01213381|Experimental|SAR240550|"single cohort: SAR240550
~combination cohort: SAR240550 in combination with Gemcitabine and Carboplatin"
11520232|NCT01213368|Experimental|dronedarone 300 mg|Dronedarone, 100mg + 200mg tablets twice daily, administered with food.
11520233|NCT01213368|Experimental|dronedarone 400 mg|Dronedarone, 400mg tablets twice daily, administered with food.
11520234|NCT01213368|Experimental|dronedarone 600 mg|Dronedarone, 400mg + 200mg tablets twice daily, administered with food.
11520235|NCT01213368|Placebo Comparator|placebo|Matching placebo tablets twice daily, administered with food.
11520236|NCT01213355|Experimental|Placebo|placebo, plus scopolamine 0.5 mg
11520237|NCT01213355|Experimental|PF-05212377 5 mg, plus scopolamine 0.5 mg;|
11520238|NCT01213355|Experimental|PF-05212377 20 mg, plus scopolamine 0.5 mg;|
11520239|NCT01213355|Experimental|PF-05212377 60 mg, plus scopolamine 0.5 mg;|
11520240|NCT01213355|Active Comparator|donepezil 10 mg, plus scopolamine 0.5 mg.|
11520241|NCT01213342|Experimental|Treatment Group|This group will receive Omega-3 EFA supplements for 8 weeks. They will take 4 capsules/day.
11520242|NCT01213342|Placebo Comparator|Placebo Group|This group will receive placebo supplements for 8 weeks. They will take 4 capsules a day.
11520243|NCT01213329|Experimental|Phase I: Alemtuzumab|During Phase I Portion: Each kidney transplant recipient received one 30mg dose (IV push)of Alemtuzmab in the operating room per Standard of Care.
11520244|NCT01213316||Overall Participants|HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks (Initial Cohort), 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.
11520245|NCT01213316||Aging Participants|"HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.
~Includes newly enrolled participants ≥ 50 years of age (Amendment Cohort), plus participants from the Initial Cohort who were ≥ 50 years of age at time of recruitment and who completed 48 weeks of treatment (Prolonged Cohort)."
11520246|NCT01213303||Blood donors|Evaluation of cardiovascular risk factors, oxidative stress and fatty acid metabolism in a cohort of blood donors
11520247|NCT01213290|Active Comparator|EUS-FNA with stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
11520248|NCT01213290|Active Comparator|EUS-FNA without stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
11520249|NCT01213277|Active Comparator|Fast Glycator|The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators
11520250|NCT01213277|Active Comparator|Control|These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients
11520251|NCT01213264||Spontaneous NMB reversal|Participants whose reversal from NMB is spontaneous (no reversal agent used)
11520252|NCT01213264||NMB reversal with sugammadex|Participants who are administered sugammadex for NMB reversal in accordance with routine anesthesiology practice, and labeling guidelines
11520253|NCT01213264||NMB reversal with other agents|Participants who are administered any other agent (other than sugammadex) for NMB reversal in accordance with routine anesthesiology practice, and labeling guidelines
11520254|NCT01213251|Experimental|Single Site Pacing|
11520255|NCT01213251|Experimental|Dual Site Pacing|
11520256|NCT01213251|No Intervention|Control|
11520257|NCT01213238|Experimental|Oxaliplatin + Capecitabine + Bevacizumab|Oxaliplatin 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle. Capecitabine starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle. Bevacizumab 10 mg/kg by vein on day 1 of a 21 day cycle.
11520258|NCT01213238|Experimental|Oxaliplatin + Capecitabine|Oxaliplatin 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle. Capecitabine starting dose of 500 mg/m2 by mouth twice daily, on days 1 -14 of a 21 day cycle.
11520259|NCT01213212|Experimental|Caloric restriction|Caloric restriction
11520260|NCT01213212|Sham Comparator|"Diet ad libitum"|"Diet ad libitum"
11520261|NCT01213199|Experimental|Differin 0.3%|"Differin® 0.3% Gel
~Adapalene 0.3%
~Topical to the face, once daily application in the evening for the first four weeks and twice daily application in the morning and in the evening for the following 20 weeks."
11520262|NCT01213186|Experimental|Drug: high dose of MSC treatment|Participants will receive high dose of MSC from Day 0 through the Week 48 study visit. Participants will then be followed until the Week 48 study visit.
11520263|NCT01213186|Experimental|low dose of MSC treatment|Participants will receive a low dose of MSC treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks.
11520264|NCT01213186|Placebo Comparator|low dose of MSC|Participants will receive a saline placebo treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks.
11520265|NCT01213173|Active Comparator|1|
11520266|NCT01213173|Experimental|2|
11520267|NCT01213160|Experimental|AZD4547|
11520268|NCT01213147|Experimental|clomiphene citrate,pregnancy,poor responders|Woman in clomiphene citrate arm are administered 100mg/day oral from day 3 of menstrual cycle until day 7 of cycle
11520269|NCT01213147|Active Comparator|buserelin,pregnancy,poor responder|women in control arm are administered Buserelin buserelin 50 µg SC twice a day from cycle day 2 of menstrual cycle
11520270|NCT01213121|Experimental|bipolar depression|unmedicated patients with bipolar depression receiving quetiapine treatment
11520271|NCT01213121|No Intervention|Control|healthy controls matched for age, gender, and body mass index
11520272|NCT01213108|Experimental|Örebro prevention program|
11520273|NCT01213108|Active Comparator|Control|Business as usual
11520274|NCT01213095|Experimental|Rituximab|rituximab 375mg/m2, every 8 weeks, 12 times
11520275|NCT01213082|Experimental|24GyE + anti-VEGF|
11520276|NCT01213082|Experimental|16GyE + anti-VEGF|
11520277|NCT01213082|Sham Comparator|Sham Irradiation + anti-VEGF|
11520278|NCT01213069||all 5000 subjects|this is a purely descriptive study with one group
11520279|NCT01213056|Active Comparator|Mindfulness Based Cognitive Therapy * (MBCT)|Mindfulness based cognitive therapy aimed to improve coping with, and managing chronic headache pain.
11520280|NCT01213056|No Intervention|Delayed Treatment Control * (DT)|
11520281|NCT01213043|Active Comparator|Prolastin-C, 60 mg/kg|60 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 60 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).
11520282|NCT01213043|Experimental|Prolastin-C, 120 mg/kg|120 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 120 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).
11520283|NCT01213030|Active Comparator|10 mCi HX4|Patient will be injected with [F-18] FMISO
11520284|NCT01213030|Active Comparator|10 mCi FMISO|Patient will be injected with [F-18] HX4
11520285|NCT01213017|Experimental|Certolizumab pegol|
11520286|NCT01213004|Experimental|thoracic (study group 1) malignancies|On the same day as the CBCT scans and treatment session, patients will receive a research-only respiration correlated CT (RCCT scan), for calculating motion-corrected CBCT. The localization accuracy of motion-corrected CBCT using same-day RCCT will be compared to that using the standard RCCT from simulation.
11520287|NCT01213004|Experimental|abdominal (study group 2) malignancies|On the same day as the CBCT scans and treatment session, patients will receive a research-only respiration correlated CT (RCCT scan), for calculating motion-corrected CBCT. The localization accuracy of motion-corrected CBCT using same-day RCCT will be compared to that using the standard RCCT from simulation.
11520288|NCT01212991|Experimental|Enzalutamide|
11520289|NCT01212991|Placebo Comparator|Placebo|
11520290|NCT01212978|No Intervention|Delayed Intervention|These subjects will neither receive a pedometer or access to the motivational software until completion of the study.
11520291|NCT01212978|Active Comparator|Pedometer only|Participants in the this arm will receive a pedometer with instructions to reach a goal of 10,000 steps/day but will not receive access to the motivational software.
11520292|NCT01212978|Experimental|Pedometer + Motivational Software|In this arm, subjects will receive access to both a pedometer and motivational software
11520293|NCT01212952|Experimental|Arm I|Patients receive oral pomalidomide on days 1-21; bortezomib IV on days 1, 8, 15, 22; and oral dexamethasone on days 1, 8, 15, 22. Treatment repeats every 28 days for 8 courses. Patients then receive maintenance therapy comprising oral pomalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11520294|NCT01212926|Experimental|analysis of myocardial deformation in 2D strain|
11520295|NCT01212913|Experimental|group 1: Basal plus|Insulin glargine with dosage adjustment determined according to the mean value of the last three days Fasting Blood Glucose (FBG) Insulin glulisine, at initial dosing of 4IU, then weekly adjusted according to the mean value of the last three days PostPrandial Blood Glucose (PPBG)
11520296|NCT01212913|Active Comparator|group 2: Biphasic insulin|Insulin aspart/insulin aspart protamine 30/70 (novomix 30) given twice daily and titrated weekly (before breakfast and dinner) according to the lowest of three previous days' pre-meal levels (both breakfast and dinner). Target is 70 mg/dL < Pre-meal blood glucose (dinner and breakfast).
11520297|NCT01212900|Experimental|Imaging|Lipid targets assigned according to the severity of atherosclerotic plaque measured as wall volume in the common and internal carotid arteries by MRI
11520298|NCT01212900|Active Comparator|Standard|Standardized statin therapy based on NCEP ATP IIIR guidelines, including clinical risk factors and blood lipid levels.
11520299|NCT01212874|Active Comparator|Nitroglycerin|nitroglycerin titrated to control hypertension between anesthesia induction and initiation of cardiopulmonary bypass
11520300|NCT01212874|Active Comparator|Esmolol|esmolol titrated to control hypertension between anesthesia induction and initiation of cardiopulmonary bypass
11520301|NCT01212861|Experimental|Suprachoroidal Dissection Instrument|
11520302|NCT01212848|Experimental|TMS|
11520303|NCT01212848|Sham Comparator|Sham|
11520304|NCT01212835|Sham Comparator|no ring|Patients at this group will have RING REMOVED AT THE END OF SURGERY.
11520305|NCT01212835|Active Comparator|RYGBP-Ring|Open Roux-en-Y gastric bypass with a silastic ring which is performed with linear cut stapler 100 mm and a biliopancreatic limb of 60 cm long and a alimentary limb of 100 cm long. All patients will have a 6.5 cm silastic ring located at the middle of the pouch above of the gastroenteroanastomosis.
11520335|NCT01212588|Experimental|Mifepristone|Mifepristone 600mg once daily x 7 days
11520336|NCT01212588|Placebo Comparator|Placebo|Matching placebo tablets one daily
11520337|NCT01212575||300 patients|Female or male aged 18-65 years with a diagnosis of schizophrenia having received at least one dose of Seroquel XR or Seroquel IR during January - March 2010
11520338|NCT01212562||Immunocryosurgery|2 weeks daily imiquimod application prior to a session of cryosurgery and subsequently 3 weeks continued daily imiquimod application
11520339|NCT01212549|Active Comparator|Immunocryosurgery|2 weeks imiquimod, cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 3 weeks imiquimod
11520673|NCT01210170|Experimental|mometasone 400 mcg - 60 min|randomly assigned intervention
11520306|NCT01212822|Experimental|Treatment (bevacizumab, FOLFOX)|"NEOADJUVANT THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive FOLFOX chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46 hours on days 1-2. Treatment with bevacizumab repeats every 2 weeks for 4 courses and treatment with FOLFOX repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
~SURGERY: Patients then undergo planned surgical resection 4-6 weeks after 6 courses of chemotherapy and at least 8 weeks since the last dose of bevacizumab.
~ADJUVANT THERAPY: Beginning 8-10 weeks after surgery, patients receive bevacizumab IV, oxaliplatin IV, leucovorin calcium IV, and fluorouracil IV as in neoadjuvant therapy. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity."
11520307|NCT01212809|Active Comparator|Juvéderm Ultra|Juvéderm Ultra injection
11520308|NCT01212809|Active Comparator|Cosmoderm 1|Cosmoderm 1 injection
11520309|NCT01212783|Active Comparator|Present-Centered Therapy|Mothers will receive 15 weekly sessions of PCT plus two monthly booster sessions following the 15th session.
11520310|NCT01212783|Experimental|In-Home Cognitive Behavioral Therapy|Mothers will receive 15 weekly sessions of IH-CBT plus two booster sessions scheduled monthly following the 15th session.
11520311|NCT01212770|Experimental|Apremilast 20 mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
11520312|NCT01212770|Experimental|Apremilast 30 mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
11520313|NCT01212770|Placebo Comparator|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
11520314|NCT01212770|Placebo Comparator|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
11520315|NCT01212757|Experimental|Apremilast 20mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
11520316|NCT01212757|Experimental|Apremilast 30mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
11520317|NCT01212757|Placebo Comparator|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
11520318|NCT01212757|Placebo Comparator|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
11520319|NCT01212744|Experimental|rAvPAL-PEG|rAvPAL-PEG in varying doses
11520320|NCT01212731||Cohort 1|Subjects with a histological diagnosis of malignancy of the base of skull necessitating irradiation to a minimum of 60 Gy, ECOG PS 0-1 with no evidence of metastatic disease and an estimate life expectancy of at least 1 year and who is able to provide informed consent. Subjects will undergo standard CT simulation and radiotherapy treatment planning.
11520321|NCT01212731||Cohort 2|Subjects with a histological diagnosis of low grade glioma requiring radiotherapy. ECOG PS 0-1 with no evidence of metastatic disease and an estimated life expectancy of at least 1 year and who is able to provide informed consent. Subjects will undergo standard CT simulation and radiotherapy treatment planning.
11520322|NCT01212718|Active Comparator|5-FU|FUFA 5-flurouracil and folinic acid control
11520323|NCT01212718|Active Comparator|Folfiri|5-fluouracil and folinic acid in combination with irinotecan (Folfiri) systemic chemotherapy intensified treatment arm
11520324|NCT01212705|Experimental|ASV|
11520325|NCT01212692|Experimental|Mentally stimulating activities|
11520326|NCT01212692|Active Comparator|Mentally stimulating activities- other|
11520327|NCT01212679|Experimental|nerve growth factor|Patients who underwent TBI will be chosen to receive NGF randomly.
11520328|NCT01212679|Placebo Comparator|Control|Patients who underwent TBI will be chosen to receive nomral saline randomly.
11520329|NCT01212666|Experimental|Adductor-Canal-Block, Ropivacain|25 patients. ACB. 30 mL Ropivacain 7,5 mg/mL. Ultrasound-guided application.
11520330|NCT01212666|Placebo Comparator|Adductor Canal Block, Placebo (saline)|25 patients. ACB. 30 mL Saline. Ultrasound-guided application.
11520331|NCT01212653|Active Comparator|Golimumab|"In this 52-week, randomized, placebo-controlled study, patients will be randomized to receive either golimumab 50 mg monthly or matching placebo for 12 months using a 1:1 randomization procedure.
~The doctors and patients and the nurse who administer the study medication (Golimumab) will be blinded. There will be one unblinded nurse to prepare the study medication."
11520332|NCT01212653|Placebo Comparator|Pacebo-controlled|"In this 52-week, randomized, placebo-controlled study, patients will be randomized to receive either Golimumab 50 mg monthly or matching placebo for 12 months using a 1:1 randomization procedure.
~The doctors and patients and the nurse who administer the study medication (Golimumab) will be blinded. There will be one unblinded nurse to prepare the study medication."
11520333|NCT01212627|Experimental|Ridaforolimus,|Ridaforolimus: 20mg Daily, 5 days each week, on a 28 day cycle until progression
11520334|NCT01212601||1|
11520340|NCT01212549|Active Comparator|Cryoimmunotherapy|Cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 5 weeks imiquimod
11520341|NCT01212536|No Intervention|Conventional|conventional laryngoscopy for intubation
11520342|NCT01212536|Experimental|Airtraq|laryngoscopy with Airtraq for intubation
11520343|NCT01212510|Other|Tumor markers|measurement of tumor markers ( blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA )
11520344|NCT01212497|Experimental|Mindfulness meditation coaching|Assess effectiveness of using a virtual computer coach to train mindfulness meditation
11520345|NCT01212484|Experimental|Placebo (first), Carbidopa (second)|Crossover design Placebo first followed by carbidopa
11520346|NCT01212484|Experimental|Carbidopa (first), Placebo (second)|Crossover design carbidopa first followed by placebo
11520347|NCT01212471|Experimental|Bromfenac Ophthalmic Solution A|Bromfenac ophthalmic solution A
11520348|NCT01212471|Experimental|Bromfenac Ophthalmic Solution B|Bromfenac ophthalmic solution B
11520349|NCT01212471|Placebo Comparator|Placebo Comparator|Placebo Comparator
11520350|NCT01212445|Experimental|PEG + E, 13.125 g|Single sachet of PEG+E (13.125 g) dissolved in 125 mL of non-carbonated water ingested orally with entire volume taken at one time
11520351|NCT01212445|Experimental|PEG + E, 26.25 g|Two sachets of PEG+E (26.25 g) dissolved in 250 mL of non-carbonated water ingested orally with entire volume taken at one time
11520352|NCT01212445|Experimental|PEG + E, 39.375 g|Three sachets of PEG+E (39.375 g) dissolved in 375 mL of non-carbonated water ingested orally with entire volume taken at one time
11520353|NCT01212406|Placebo Comparator|Placebo|Olive oil
11520354|NCT01212406|Experimental|Vitamin D|Addition of D-cure (100.000U) to standard care
11520355|NCT01212393||Intervention group|reminders
11520356|NCT01212393||current practice group|no intervention
11520357|NCT01212380|Experimental|Arm 1|Patients receive carfilzomib IV over 30 minutes once daily on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.Performance of pharmacology, pharmacodynamic and pharmacogenomic studies allow assessment of carfilzomib mechanism of action and also to understand how the variability of these different features correlate with clinical benefit/response and also toxicity.
11520358|NCT01212367|Experimental|Dose Level 1|
11520359|NCT01212367|Experimental|Dose Level 2|This is a dose de escalation.
11520360|NCT01212354|Experimental|A - experimental|7 weeks Radiotherapy Intervention with with 5x2.3 Gy per week up to a total dose of 80.5 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.
11520361|NCT01212354|Active Comparator|B - control|7 weeks Radiotherapy Intervention with 5x2.0 Gy per week up to a total dose of 70 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.
11520362|NCT01212341|Experimental|Singe-dose infusion|Cohort 1: 1x10^6 cells/kg Cohort 2: 1x10^7 cells/kg
11520363|NCT01212341|Experimental|Repeated dose infusion|Cohort 3: 1x10^6 cells/kg Cohort 4: 3x10^6 cells/kg Cohort 5: 1x10^7 cells/kg Cohort 6: 3x10^7 cells/kg
11520364|NCT01212328|Experimental|Care coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
11520365|NCT01212328|Active Comparator|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
11520366|NCT01212315|No Intervention|Control group|Ordinary sutures (Vicryl / Monocryl) is used for wound closure
11520367|NCT01212315|Active Comparator|Group A|Triclosan coated sutures (Vicryl Plus / Monocryl Plus) is used for wound closure
11520368|NCT01212302|Experimental|aspirin, clopidogrel|If the treatment with aspirin and/or clopidogrel is insufficient (platelet function testing) the dose was increased or the drug was changed (clopidogrel to ticlopidine or prasugrel)
11520369|NCT01212289||Primary cardiac surgery|Pediatric patients receiving primary cardiac surgery
11520370|NCT01212289||Reoperation|Pediatric patients receiving cardiac surgery reoperation
11520371|NCT01212276|Experimental|Cohort 1|MORAb-028 0.1 mg/kg intravenous
11520372|NCT01212276|Experimental|Cohort 2|MORAb-028 0.2 mg/kg intravenous
11520373|NCT01212276|Experimental|Cohort 3|MORAb-028 0.5 mg/kg intravenous
11520374|NCT01212276|Experimental|Cohort 4|MORAb-028 1.0 mg/kg intravenous
11520375|NCT01212263|Experimental|Clomiphene Citrate plus HP uFSH|Starting from the 2nd day of the cycle Clomiphene Citrate( CC)50 mg tablets are given in 100 mg daily dose for 5 days together with an low dose HP uFSH (half ampoule: 37.5 IU) given im daily for 8-10 days.
11520376|NCT01212263|Active Comparator|Step-up HP uFSH|HP uFSH started in doses of half ampole (37.5 )IU daily from the 2nd day of cycle for 7 days ,then dose is stepped-up to one ampoule ( 75 IU) for 7 days then the one and a half amps (112.5) IU /day until follicular diameter reaches 18 mm mean diameter
11520377|NCT01212250|Experimental|Carvedilol|Tablet 6.25 mg BD
11520378|NCT01212250|Placebo Comparator|placebo|Placebo tablets 2 BD
11520379|NCT01212237||fMRI Evaluation|"All patients will undergo the following standard imaging and radiotherapy procedures will be performed for each patient:
~Standard MRI for radiotherapy treatment planning which takes about 60 minutes.
~Radiotherapy treatment simulation with CT.
~Radiotherapy treatment planning
~Radiotherapy treatment
~Routine follow-up every 3 months after the radiotherapy.
~Special Procedures.
~The following special imaging and radiotherapy procedures will be performed for each patient:
~fMRI (30 minutes)
~The 3MS examination, administered every 3 months during routine follow-up for one year after the completion of the radiotherapy."
11520380|NCT01212211|Experimental|change in drug therapy|Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
11520381|NCT01212211|No Intervention|reference|drug treatment of ten patients will remain unchanged during the three months of inclusion
11520382|NCT01212198||Korean type 2 diabetic patients|
11520383|NCT01212198||Koreans at high risk for diabetes|
11520384|NCT01212198||Korean gestational diabetic patients|
11520385|NCT01212185|Placebo Comparator|intranasal spray without oxytocin|Twice daily intranasal spray without oxytocin.
11520386|NCT01212185|Experimental|intranasal oxytocin spray|Twice daily intranasal oxytocin spray
11520387|NCT01212172|Active Comparator|Soprano/SHR|Alma Soprano/SHR 810 nm Diode Laser
11520388|NCT01212172|Active Comparator|LightSheer|LightSheer Duet 810 nm diode laser
11520389|NCT01212159|No Intervention|No self monitoring device|Standard or usual care of high LDL including lab lipid profiles after treatment with statin therapy. No device or telemedicine education will be provided
11520390|NCT01212159|Experimental|Self Monitoring Lipid Analyzer|Self measured blood lipids using a home lipidometer, and telephone reporting of data to the clinical center.
11520391|NCT01212146|Experimental|Probiotic-enriched Artichokes|Artichokes containing approximately 1.20 x 10^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme
11520392|NCT01212146|Active Comparator|Ordinary artichokes|Ordinary artichokes (probiotic free) of identical shape, texture, and appearance of probiotic-enriched artichokes
11520393|NCT01212133||A|
11520394|NCT01212120||All patients|All patients
11520395|NCT01212107|Experimental|Part A: 2 mg FGF Receptor QD|"Part A: Dose escalation
~2 milligrams (mg) FGF receptor given orally once daily (QD) for a minimum of (1) 28 day cycle.
~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
11520396|NCT01212107|Experimental|Part A: 4 mg FGF Receptor QD|"Part A: Dose escalation
~4 mg FGF receptor given orally QD for a minimum of (1) 28 day cycle.
~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
11520397|NCT01212107|Experimental|Part A: 10 mg FGF Receptor QD|"Part A: Dose escalation
~10 mg FGF receptor given orally QD for a minimum of (1) 28 day cycle.
~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
11520398|NCT01212107|Experimental|Part A: 10 mg FGF Receptor QD + Phosphate Binders|"Part A: Dose escalation
~10 mg FGF receptor + phosphate binders given QD for a minimum of (1) 28 day cycle.
~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
11520399|NCT01212107|Experimental|Part A: 8 mg FGF Receptor BID|"Part A: Dose escalation
~8 mg of FGF receptor given orally twice a day (BID) for a minimum of (1) 28 day cycle.
~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
11520400|NCT01212107|Experimental|Part A: 10 mg FGF Receptor BID|"Part A: Dose escalation
~10 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.
~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
11520401|NCT01212107|Experimental|Part A: 14 mg FGF Receptor BID|"Part A: Dose escalation
~14 FGF receptor given orally BID for a minimum of (1) 28 day cycle.
~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
11520402|NCT01212107|Experimental|Part A: 18 mg FGF Receptor BID|"Part A: Dose escalation
~18 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.
~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
11520403|NCT01212107|Experimental|Part A: 24 mg FGF Receptor BID|"Part A: Dose escalation
~24 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.
~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
11520404|NCT01212107|Experimental|Part A: 18 mg FGF Receptor BID Extension|"Part A: Dose escalation
~18 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.
~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
11520405|NCT01212107|Experimental|Part A: 16 mg FGF Receptor BID|"Part A: Dose escalation
~16 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.
~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
11520406|NCT01212107|Experimental|Part B: 16 mg FGF Receptor BID|"Part B: Dose determined by part a dose escalation
~16 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.
~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
11520407|NCT01212094|Experimental|Rituximab|Patients received 25mg of rituximab into the CSF and 200mg of rituximab intravenously at Month 0, followed by additional 200mg of rituximab intravenously at Month 0.5 and another 25mg of rituximab into CSF at months 1.5 and 12.
11520408|NCT01212094|Placebo Comparator|Placebo|Patients received normal saline into the CSF and intravenously at Month 0, followed by additional normal saline intravenously at Month 0.5 and another dose of normal saline into CSF at months 1.5 and 12.
11520409|NCT01212094|No Intervention|Baseline|Patients in their first year baseline prior to study drug phase
11520410|NCT01212055||Cohort 1|Patients with DOCK8 deficiency, LAD-1, or GATA2 Deficiency
11520411|NCT01212029|Experimental|1/All Subjects|Imaging studies related to functional brain activation
11520412|NCT01212003||Active TB|subjects with active TB as determined by smear, culture, or biopsy or have appropriately documented clinically suspicious active TB without definitive microbiology confirmation
11520413|NCT01212003||Latent TB|subjects with documented evidence of a positive PPD skin test or Interferon Gamma Release Assays (IGRA) test meeting American Thoracic Society (ATS)/CDC guidelines for latent TB
11520414|NCT01211964|Experimental|LEO 22811 oral solution 1.5 mg (fasted state)|
11520415|NCT01211964|Experimental|LEO 22811 single tablet 1.5 mg (fasted state)|
11520416|NCT01211964|Experimental|LEO 22811 single tablet 1.5 (fed state)|
11520417|NCT01211951|Experimental|KCT-0809 ophthalmic solution, low dose|
11520418|NCT01211951|Experimental|KCT-0809 ophthalmic solution, medium dose|
11520419|NCT01211951|Experimental|KCT-0809 ophthalmic solution, high dose|
11520420|NCT01211951|Placebo Comparator|Placebo|
11520421|NCT01211938|Active Comparator|single-fraction radiotherapy with concomitant 5FU and Hydrea|six 5-day cycles with a 9-day rest period between each cycle (split course). Each cycle includes : a single-fraction at a dose of 2 Gy per session for 5 sessions, combined with 5FU (800 mg/m2/day) and Hydrea (500 mg x 3/day) over the 5 days of the cycle. The total dose of radiotherapy is therefore 60 Gy delivered over 11 weeks.
11520422|NCT01211938|Experimental|hyperfractionated radiotherapy with concomitant Cetuximab|Bifractionated radiotherapy at a dose of 1.2 Gy per session at a rate of 2 sessions per day, at least 6h apart, 5 days per week over 5 weeks, without a split course, combined with Cetuximab. The total dose of radiotherapy is 60 Gy delivered over 5 weeks. Cetuximab (ErbituxÒ) is to be administered in a 2-hour IV infusion at a dose of 400 mg/m2, 8 days before the start of radiotherapy, then in a 1-hour infusion at a dose of 250 mg/m2 on days 1, 8, 15, 22 and 29 of radiotherapy.
11520423|NCT01211925|Experimental|critical ischemia|
11520424|NCT01211925|No Intervention|Control|Best medical treatment
11520425|NCT01211912|Experimental|Arm 1 (20 patients)|Pregnant women will be given a single dose of 1000 mg of acetaminophen orally after a baseline ultrasound and 60 minutes before a repeat ultrasound.
11520426|NCT01211912|Experimental|Arm 2 (34 patients)|Pregnant women will be given a single dose of 1000 mg of acetaminophen orally 30 minutes to 24 hours before a scheduled cesarean section.
11520427|NCT01211873|Experimental|Dotarem (gadoterate meglumine )|Dotarem and Magnevist were randomised as 2:1 ratio for adult patients.
11520428|NCT01211873|Active Comparator|Magnevist (gadopentetate dimeglumine)|Dotarem and Magnevist were randomised as 2:1 ratio
11520429|NCT01211873|Experimental|Dotarem 2 (gadoterate meglumine )|Pediatric patients were assigned to Dotarem group only.
11520430|NCT01211860|Experimental|DCCR Treatment|DCCR Treatment 290 mg diazoxide choline
11520431|NCT01211847|Experimental|DCCR|DCCR Treatment with 290 mg Diazoxide Choline
11520432|NCT01211847|Placebo Comparator|Placebo|Placebo matching DCCR
11520433|NCT01211834|Experimental|Tocilizumab 8mg/kg+DMARDs|
11520434|NCT01211834|Placebo Comparator|Placebo+DMARDs|
11520435|NCT01211821|Other|metoprolol|Treatment A
11520436|NCT01211821|Experimental|BMS-914392 + metoprolol|Treatment B
11520437|NCT01211808|Experimental|Treatment A (BMS-914832)|
11520438|NCT01211808|Experimental|Treatment B (BMS-914832 + diltiazem)|
11520439|NCT01211795|Active Comparator|Topical Ketoprofen gel|
11520440|NCT01211795|Placebo Comparator|Placebo gel|
11520441|NCT01211782|Experimental|AC-1204|
11520442|NCT01211782|Placebo Comparator|Placebo|
11520443|NCT01211769|Experimental|PUFAs|Polyunsaturated fatty acids (PUFAs): borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram; along with 1 gram of fish oil - rich in omega 3 PUFA;
11520444|NCT01211769|Active Comparator|Naltrexone|Naltrexone chlorhydrate 50 mg
11520445|NCT01211769|Placebo Comparator|Placebo|"Naltrexone Placebo: pill with 50mg of talcum powder, identical to the pill of naltrexone;
~Polyunsaturated fatty acids Placebo (PUFAs Placebo): yellow liquid paraffin identical to the pills of borage seed and fish oil."
11520446|NCT01211769|Other|Naltrexone + PUFAs|"Polyunsaturated fatty acids (PUFAs): borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram; along with 1 gram of fish oil - rich in omega 3 PUFA;
~Naltrexone chlorhydrate 50 mg"
11520447|NCT01211756|Experimental|Oxytocin|20 IU of intranasal oxytocin twice per day for the first week, 40 IU of intranasal oxytocin twice per day for the following 3 weeks, one week wash out, 4 week placebo trial.
11520448|NCT01211756|Placebo Comparator|Placebo|Four week placebo trial, one week wash out, 20 IU of intranasal oxytocin twice per day for one week, 40 IU of intranasal oxytocin twice per day for 3 weeks.
11520449|NCT01211743|Active Comparator|Lap Group|Patients in this group are operated for uncomplicated cholelithiasis with standard 4 port laparoscopic cholecystectomy
11520450|NCT01211743|Active Comparator|SILS group|Patients in this group are operated for uncomplicated cholelithiasis with Single Incision Laparoscopic Cholecystectomy
11520451|NCT01211730|Active Comparator|140 Group|Insulin treatment to target blood glucose at 140 mg/dl
11520452|NCT01211730|Active Comparator|180 Group|Insulin treatment to target blood glucose at 180 mg/dl
11520453|NCT01211717|Experimental|Branched Chained Amino Acids|
11520454|NCT01211717|Placebo Comparator|Cellulose mix|
11520455|NCT01211704|Placebo Comparator|Placebo, Counceling|Placebo
11520456|NCT01211704|Experimental|Paliperidone Palmitate|Paliperidone Palmitate
11520457|NCT01211691|Experimental|Phase 1 dose levels: KB004|"IV infusion 1x Weekly for a 21 day dosing cycle
~Subjects with heme malignancies will be assigned to one of 11 planned KB004 (dose levels (20mg, 40mg, 70mg, 100mg, 140mg, 190mg, 250mg, 330mg)"
11520458|NCT01211691|Experimental|Phase 2 dose levels: KB004|"IV infusion 1x Weekly for a 21 day dosing cycle
~Subjects will be assigned to the recommended Phase 2 dose of 250 mg"
11520459|NCT01211665|Experimental|Pulsed IVMP|Intravenous methylprednisolone (IVMP) 1 g/day administered the first 3 days of each weekly cycle, and repeated for 3 additional cycles (totaling 4 cycles). If necessary, 2 additional weekly cycles of 1 g IVMP daily for 3 days can be administered at the discretion of the investigator.
11520460|NCT01211665|Experimental|IVMP with oral prednisolone taper|Intravenous methylprednisolone (IVMP) 1g/day for 6 days followed by an oral taper of prednisolone over 2 months (suggested dosages starting at 80 mg and tapering to 5 mg). If necessary, additional cycles of 1 g IVMP daily for 3 to 5 days can be administered at any time.
11520461|NCT01211652||1|
11520462|NCT01211626|Active Comparator|Part A, Group 1 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 200 mg of ANA773 (n=6) or placebo (n=2)
11520463|NCT01211626|Active Comparator|Part A, Group 2 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 400 mg of ANA773 (n=6) or placebo (n=2)
11520464|NCT01211626|Active Comparator|Part A, Group 3 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 800 mg of ANA773 (n=6) or placebo (n=2)
11520465|NCT01211626|Active Comparator|Part A, Group 4 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 1200 mg of ANA773 (n=6) or placebo (n=2)
11520466|NCT01211626|Active Comparator|Part A, Group 5 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 1600 mg of ANA773 (n=6) or placebo (n=2)
11520467|NCT01211626|Active Comparator|Part B, Group 6 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 2000 mg of ANA773 (n=6) or placebo (n=2)
11522239|NCT01199289|Experimental|AMG 827 210 mg|210 mg AMG 827
11520468|NCT01211626|Active Comparator|Part B, Group 7 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 1200 mg of ANA773 (n=6) or placebo (n=2)
11520469|NCT01211626|Active Comparator|Part B, Group 8 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 1600 mg of ANA773 (n=6) or placebo (n=2)
11520470|NCT01211626|Active Comparator|Part B, Group 9 HCV Infected Patient|multiple oral doses(5 administrations) every other day of 2000 mg of ANA773 (n=8) or placebo (n=2)
11520471|NCT01211613|Experimental|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
11520472|NCT01211613|Experimental|Mechanical Manipulation|Doctor of chiropractic will apply a mechanically-assisted thrust to the lumbar spine of research participants using the Activator IV Instrument.
11520473|NCT01211613|Active Comparator|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
11520474|NCT01211600|Active Comparator|Staples|Interrupted Ethicon Staples
11520475|NCT01211600|Active Comparator|Suture|Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
11520476|NCT01211587|Experimental|100mg safinamide|Two 50mg tablets of safinamide once per day for 12 weeks (weeks 1-12) Open Label part: Two 50mg tablets of safinamide once per day for 12 weeks (week 13-24)
11520477|NCT01211587|Placebo Comparator|Placebo|Two 50mg tablets of placebo once per day for 12 weeks (weeks 1-12) Open Label part: Two 50mg tablets of safinamide once per day for 12 weeks (week 13-24)
11520478|NCT01211574|Experimental|peer coach|Participants will be coached by a peer between treatment visits.
11520479|NCT01211574|Experimental|mentor|Participants will be coached by a mentor between treatment visits
11520480|NCT01211574|Experimental|Professional|Participants will be coached by an interventionist between treatment visits
11520481|NCT01211561|Experimental|Selenium, selenomethionine|
11520482|NCT01211561|Active Comparator|placebo|
11520483|NCT01211548||contrast CTA of the CAP|All patients being considered for a complex aortic surgery and undergoing medically indicated contrast enhanced CT aortic angiography of the chest abdomen and pelvis will be includedRaw data from CT coronary angiography will be available from all patients.
11520484|NCT01211535|Experimental|OPTI-FREE RepleniSH|OPTI-FREE RepleniSH multipurpose solution used with study contact lenses on a daily wear basis for 14 days
11520485|NCT01211535|Active Comparator|ReNu Biotrue|ReNu Biotrue multipurpose solution used with study contact lenses on a daily wear basis for 14 days
11520486|NCT01211522|Experimental|Haloperidol|Haloperidol
11520487|NCT01211522|Experimental|Ziprasidone|Ziprasidone
11520488|NCT01211522|Placebo Comparator|Placebo|Placebo
11520489|NCT01211509|Experimental|montelukast sodium|Daily treatment with 10 mg montelukast after diagnosis of fibroproliferative BOS (fBOS) which is the low neutrophilic phenotype within BOS
11520490|NCT01211509|Placebo Comparator|placebo|Lactose monohydricum Ph.Eur.
11520491|NCT01211496|Active Comparator|High-speed power training|Volunteers randomized into High-speed power training (HSPT) will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength for leg press (LP) and seated knee extension (KE) exercises.
11520492|NCT01211496|Active Comparator|Slow-speed strength training|Volunteers randomized into Slow-speed strength training (SSST) will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength for LP and KE exercises.
11520493|NCT01211496|No Intervention|placebo exercise (control group)|Volunteers randomized into the control group (CON) will undergo a placebo exercise intervention consisting of lower extremity range of motion and flexibility exercises performed 2 times per week with the assistance of the research staff.
11520494|NCT01211483|Experimental|Part A: U3-1287 (high dose) + Erlotinib|U3-1287 (high dose) intravenously (IV) every three weeks (Q3W) + Erlotinib 150 mg/day orally (PO) until cancer gets worse, side effects become unacceptable or participant withdraws consent
11520495|NCT01211483|Experimental|Part B: U3-1287 (low dose) + Erlotinib|U3-1287 (low dose) IV Q3W + Erlotinib 150 mg/day PO until cancer gets worse, side effects become unacceptable or participant withdraws consent
11520496|NCT01211483|Placebo Comparator|Part B: Placebo + Erlotinib|Placebo matching U3-1287 IV Q3W + Erlotinib150 mg/day PO until cancer gets worse, side effects become unacceptable or participant withdraws consent
11520497|NCT01211470|Experimental|PMX-30063|3 arms of PMX-300063
11520498|NCT01211470|Active Comparator|Daptomycin.|Daptomycin will be administered according to the approved product monograph information for ABSSSI.
11520499|NCT01211457|Experimental|Sapacitabine/decitabine (Part 1 - completed)|decitabine will be administered in alternating cycles with sapacitabine
11520500|NCT01211457|Experimental|sapacitabine/venetoclax (Part 2 - recruiting)|sapacitabine will be administered concomitantly with venetoclax
11520501|NCT01211444|Experimental|HGNS System|
11520502|NCT01211431|Active Comparator|Reference|Intrathécale morphine is used for post-cesarean pain control
11520503|NCT01211431|Experimental|Experimental|A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
11520504|NCT01211418|Experimental|Integrative Meditation|
11520505|NCT01211418|Active Comparator|Nondirective Therapy|
11520506|NCT01211405|Active Comparator|Low dose MDMA|Participants will receive 30 mg MDMA during each of two blinded experimental sessions.
11520507|NCT01211405|Active Comparator|Medium dose MDMA|Participants will receive 75 mg MDMA on each of two blinded experimental sessions
11520508|NCT01211405|Experimental|Full dose MDMA|Participants will receive 125 mg MDMA during each of two blinded experimental sessions, followed by a third open label session.
11520509|NCT01211379|No Intervention|FLU-Only Arm|In this arm, primary care patients who got flu shots were only provided with FOBT if the doctor decided to order it.
11520510|NCT01211379|Experimental|FLU-FOBT Arm|In this arm, patients who came in for primary care got a flu shot and were assessed by nurses for eligibility for colorectal cancer screening. Eligible patients were provided with home FOBT.
11520511|NCT01211366|Active Comparator|Conventional Transfusion|Infants will receive PRBCs, crystalloid, and colloid for hemodynamic instability per the usual routine at the discretion of the attending intensive care physician
11520512|NCT01211366|Experimental|Cell Saver|Infants will receive washed cell-saver RBCs for hemodynamic instability in the first 24 hours post-operative period as long as Hgb is < 13 gm/dL and cell-saver is available.
11520513|NCT01211353|Experimental|Personalized Drinking Feedback|Personalized feedback on drinking behaviors
11520514|NCT01211353|Active Comparator|Education-Only|Educational information about alcohol
11520515|NCT01211340|No Intervention|Usual Care|Usual hospice care- there is no intervention in this arm
11520516|NCT01211340|Experimental|ACTIVE|Behavioral intervention using web conferencing
11520517|NCT01211327|Experimental|Cyclosporine A|Cyclosporine A (CsA) 2% eye drops
11520518|NCT01211327|Active Comparator|Dexamethasone|Dexamethasone 0,1% eye drops
11520519|NCT01211314|Experimental|lercanidipine-enalapril fixed combination|uncontrolled hypertensive patients will receive fixed combination therapy
11520520|NCT01211301|Active Comparator|Food-based, Reduced Energy Diet Plan|
11520521|NCT01211301|Experimental|Medifast 5 & 1 Plan|
11520522|NCT01211288|Active Comparator|HIV negative group|This group contains participants consented to receive implants and identified as negative for HIV
11520523|NCT01211288|Experimental|HIV positive group|This group contains participants consented to receive implants and identified as positive for HIV
11520524|NCT01211275|Experimental|arm 2|axitinib + cisplatin + premetrexed
11520525|NCT01211275|Active Comparator|arm 1|cisplatin + premetrexed
11520526|NCT01211262|Experimental|IMCgp100 weekly dosing regimen|Weekly intravenous (IV) infusions of IMCgp100 over treatment cycles of 8 weeks each.
11520527|NCT01211262|Experimental|IMCgp100 daily dosing regimen|Daily IV infusions of IMCgp100 administered on days 1 to 4 and days 22 to 25 of a six-week treatment cycle.
11520528|NCT01211249|Experimental|GLPG0259 (Part A)|
11520529|NCT01211249|Placebo Comparator|Placebo (Part A)|
11520530|NCT01211249|Experimental|GLPG0259 (Part B)|
11520531|NCT01211249|Placebo Comparator|Placebo (Part B)|
11520532|NCT01211236|Experimental|Maggot Debridement Therapy|
11520533|NCT01211236|Active Comparator|control|
11520534|NCT01211223|Experimental|Scaling and root planning + placebo + antibiotics|"Scaling and root planning + placebo
~Scaling and root planning + metronidazole plus amoxicillin
~Metronidazole plus amoxicillin + scaling and root planning"
11520535|NCT01211210|Active Comparator|A: 5Fu with Radiation|Patients receive fluorouracil IV continuously and undergo radiotherapy once daily 5 days a week for 5-6 weeks.
11520536|NCT01211210|Experimental|B: FOLFOX with radiation|Patients receive FOLFOX for 5 cycles and undergo radiotherapy as in arm I from the second cycle of FOLFOX
11520537|NCT01211210|Experimental|C: FOLFOX alone|Patients receive FOLFOX for 4 cycles
11520538|NCT01211197|Experimental|A|3 treatments will be investigated in randomized order
11520539|NCT01211197|Experimental|B|3 treatments will be investigated in randomized order
11520540|NCT01211197|Experimental|C|3 treatments will be investigated in randomized order
11520541|NCT01211184|Placebo Comparator|Fasting|patients undergo surgery in the fasting state
11520542|NCT01211184|Active Comparator|Water administration|Patients undergo hip surgery after receiving 800 ml water by mouth the morning 2 hours before surgery
11520543|NCT01211184|Active Comparator|carbohydrate drink|Patients undergo hip surgery after receiving 800 ml carbohydrate drink by mouth
11520544|NCT01211171||Group 1|
11520545|NCT01211158|Active Comparator|Propofol alone|Patients receiving propofol alone.
11520546|NCT01211158|Active Comparator|Ketofol|0.375 mg/kg each of ketamine and propofol (mixed in the same syringe) as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
11520547|NCT01211145|Placebo Comparator|1|Placebo
11520548|NCT01211145|Experimental|2|ZOMIG 0.5 mg
11520549|NCT01211145|Experimental|3|ZOMIG 2.5 mg
11520550|NCT01211145|Experimental|4|ZOMIG 5.0 mg
11520551|NCT01211132|Active Comparator|Cap arm|
11520552|NCT01211132|Active Comparator|Standard arm|
11520553|NCT01211119|Experimental|platelet-rich fibrin, PRF|
11520554|NCT01211106|Experimental|Arm 1: Integrated Conditions|Motivational enhancement therapy for addiction is combined with Prolonged exposure therapy for PTSD from the beginning of treatment. Both are delivered by the same provider throughout treatment.
11520555|NCT01211106|Experimental|Arm 2 Sequential therapy|Motivational enhancement therapy for addiction is delivered in the first 4 weeks and only after the addiction is addressed is the Prolonged exposure therapy for PTSD started.
11520556|NCT01211093|Experimental|High frequency whole body vibration|This group will receive a single 10-minute session of WBV therapy. The frequency of the vibration signals will be set at 30Hz.
11520557|NCT01211093|Active Comparator|low frequency whole body vibration|This group will receive a single 10-minute session of WBV. The frequency of the vibration signals will be set at 20 Hz.
11520558|NCT01211093|Active Comparator|Control|This group will stand on the same vibration platform for 10 minutes, but no vibration will be given.
11520559|NCT01211080||Threatening hemangioma|The group with cosmetically threatening of functionally threatening hemangiomas warranting active treatment according to our usual criteria (location face, hands, feet with a strong growth tendency and below age of 8 months)
11520560|NCT01211067||Patients age: 15 - 40 years-old|Patients within the 15 to 40 years-old age-group
11520561|NCT01211067||Patients age: 41 to 60 years-old|Patients within the group-age from 41 to 60 years-old
11520562|NCT01211067||Patients age: older than 61 years-old|Patients within the group-age from 61 years-old and older
11520563|NCT01211028|Other|Autologous ASCs|Expanded autologous ASCs (Adipose Stroma/Stem Cells) Intramuscular dose of 100 million expanded cells.
11520564|NCT01211015||Control group|healthy control group
11520565|NCT01211015||Disease group|asthma, COPD, ILD, lung malignancy
11520566|NCT01211002|Active Comparator|radiotherapy combined with EP|the dose of radiotherapy is 60-66 Gy / 30-33f.The combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
11520567|NCT01211002|Experimental|adiotherapy / EP /recombinant human endostatin|recombinant human endostatin: The number of courses is 3 ~ 4 and each course last for 28 days.dose:15mg，d1-14, intravenous injection.
11520568|NCT01210989|Active Comparator|Hepaguard|
11520569|NCT01210989|Placebo Comparator|Placebo|
11520570|NCT01210976|Experimental|levosimendan|
11520571|NCT01210976|Placebo Comparator|placebo|
11520572|NCT01210963||SENSIMED Triggerfish|
11520573|NCT01210950|Experimental|cell and RPR recepients|mesenchymal cells and plasma reach protein are injected to the callus center of short limb
11520574|NCT01210937|Experimental|CEA and TCD monitoring|CEA involves a neck incision and physical removal of the plaque from the inside of the artery.During the surgery, the patient will be monitored by TCD.
11520575|NCT01210924||Pediatric ART patients|
11520576|NCT01210911|Experimental|Gemcitabine, erlotinib and metformin|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine. Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food. Metformin will be administered at a dose of 500 mg twice daily. If well tolerated the dose will be increased to 1000 mg twice daily in the second week.
11520577|NCT01210911|Placebo Comparator|Gemcitabine, erlotinib and placebo|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine. Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food. PLacebo will be administered at a dose of 500 mg twice daily. If well tolerated the dose will be increased to 1000 mg twice daily in the second week.
11520578|NCT01210898|Experimental|Group 1|
11520579|NCT01210898|Experimental|Group 2|
11520580|NCT01210898|Experimental|Group 3|
11520581|NCT01210898|Experimental|Group 4|
11520582|NCT01210898|Experimental|Group 5|
11520583|NCT01210898|Experimental|Group 6|
11520584|NCT01210898|Experimental|Group 7|
11520585|NCT01210898|Experimental|Group 8|
11520586|NCT01210898|Experimental|Group 9|
11520587|NCT01210898|Experimental|Group 10|
11520588|NCT01210898|Experimental|Group 11|
11520589|NCT01210898|Experimental|Group 12|
11520590|NCT01210898|Experimental|Group 13|
11520591|NCT01210885|Experimental|Group I: Investigational MenABCWY Formulation 1|
11520592|NCT01210885|Experimental|Group II: Investigational MenABCWY Formulation 2|
11520593|NCT01210885|Experimental|Group III: Investigational MenABCWY Formulation 3|
11520594|NCT01210885|Experimental|Group IV: Investigational MenABCWY Formulation 4|
11520595|NCT01210885|Active Comparator|Group V: Active comparator investigational MenB|
11520596|NCT01210885|Active Comparator|Group VI: Active comparator MenACWY|
11520597|NCT01210859||Ureteral stents Detrusitol treatment Lyfestyle outcome|Ureteral stents Detrusitol treatment Lyfestyle outcome
11520598|NCT01210846|Experimental|tivozanib|
11520599|NCT01210833|Active Comparator|Healthy participants|Healthy participants aged from 18 to 60 with no history of hand injuries recruited by convenience sampling.
11520600|NCT01210833|Experimental|Hand Injured participants|Participants with hand injuries aged from 18 to 60 recruited from the outpatients attending the occupational therapy clinic.
11520601|NCT01210820|Experimental|Natural Astigmatism|Subjects with refractive astigmatism and no prior history of ophthalmic surgery. May include subjects with cataracts.
11520602|NCT01210820|Experimental|Post cataract with residual astigmatism|Subjects who have had cataract removal surgery but have residual astigmatism.
11520603|NCT01210807|Experimental|Multifocal Intraocular Lens|ZMB00 multifocal intraocular lens
11520604|NCT01210807|Active Comparator|Monofocal Intraocular Lens|ZCB00 monofocal intraocular lens
11520605|NCT01210768|Active Comparator|EC|Cyclophosphamide,600 mg/m2 q3wk and Epirubicin,90 mg/m2 q3wk
11520606|NCT01210768|Experimental|LC|liposomal doxorubicin, 37.5 mg/m2 q3wk, and Cyclophosphamide,600 mg/m2 q3wk
11520607|NCT01210755|Experimental|Rivaroxaban then Dabigatran|Cross-over study with 15 days between administration of Rivaroxaban and Dabigatran
11520608|NCT01210755|Experimental|Dabigatran then Rivaroxaban|Cross-over study with 15 days between administration of Dabigatran and Rivaroxaban
11520609|NCT01210742|Experimental|Viscosupplementation with routine management|
11520610|NCT01210742|Active Comparator|Routine management|Routine management for knee OA (NICE guidelines)
11520611|NCT01210716|Experimental|AMICUS Therapeutic plasma exchange, TPE|Patients are randomized to either TPE on AMICUS or Spectra.
11520612|NCT01210716|Active Comparator|Spectra Therapeutic plasma exchange, TPE|Patients are randomized to either TPE on AMICUS or Spectra.
11520613|NCT01210690||Patients, 1 - 11 months old, prescribed Keppra® oral solution|Epileptic patients who have been prescribed Keppra® (Levetiracetam) oral solution and who are between 1 and 11 months old. The patients will be followed as per current clinical practices for their condition. The choice of medical treatment, including the concomitant use of other antiepileptic drugs, is made independently by the physician in the regular course of practice and is not influenced by the study protocol.
11520614|NCT01210677|Active Comparator|Prednisone|Prednisone 0.5 mg/Kg per day orally for 3 months
11520615|NCT01210677|Placebo Comparator|Placebo|Matching placebo tablets(s) taken orally per day
11520616|NCT01210664|Experimental|Polyclonal Regulatory T Cells|Patients with Type 1 Diabetes Mellitus will have their regulatory T cells (Tregs) isolated by researchers and receive Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells by infusion
11520617|NCT01210651|Experimental|Hatha Yoga Practice Group|Participants in this group practiced 90-minute sessions of hatha yoga exercises twice weekly for a total of 8 weeks.
11520618|NCT01210651|Active Comparator|Attention Control Education Group|Participants in this group attended 90-minute educational seminars on yoga history twice weekly for a total of 8 weeks.
11520619|NCT01210638|Active Comparator|Oxymorphone Hydrochloride|Tablet
11520620|NCT01210638|Active Comparator|Opana|Tablet
11520621|NCT01210625|Active Comparator|Psyllium|Subjects will take 4 capsules containing 1 gram psyllium fiber 3 times a day (12g total per day)
11520622|NCT01210625|Experimental|Nutrabiotix 9g|Subjects take a total of 9g of Nutrabiotix a day (3 capsules of 1g Nutrabiotix 3 times a day)
11520623|NCT01210625|Experimental|Nutrabiotix 12g|Subjects take a total of 12g of Nutrabiotix a day (4 capsules of 1g Nutrabiotix 3 times a day)
11520624|NCT01210612|Active Comparator|Without Unilateral CAI|
11520625|NCT01210612|Active Comparator|With Unilateral CAI|
11520626|NCT01210599|Experimental|IV infusion of pamidronate vs placebo|
11520627|NCT01210586|Active Comparator|Nicotine Patch|Nicotine Patch for Smoking Cessation
11520628|NCT01210586|Placebo Comparator|Placebo Patch|
11520629|NCT01210573||Device adjustment|Advanced or suspected advanced heart failure. Most are anticipated to have severely depressed ejection fraction (<30% and typically <20%), but patients with preserved ejection fraction and either hypertrophy or restrictive cardiomyopathy will also be eligible. Patients pulmonary hypertension, on any therapy (other than diuretics alone), are also felt to be at high risk of developing right heart failure and may also be included. Patients who have already undergone LVAD or cardiac transplant are also considered to have advanced heart failure and are eligible to participate, regardless of the severity of their symptoms at the time of enrollment.
11520630|NCT01210560|Experimental|20 mg MR|
11520631|NCT01210560|Experimental|40 mg MR|
11520632|NCT01210560|Experimental|60 mg MR|
11520633|NCT01210560|Experimental|120 mg MR|
11520634|NCT01210560|Experimental|120 mg IR|
11520635|NCT01210521|No Intervention|Prior to intervention with Vitamin D|Patients will be analyzed for clinical, serological and immunological parameters before starting the interventional drug, Vitamin D.
11520636|NCT01210521|Active Comparator|Vitamin D Intervention|Patients will be analyzed for clinical, serological and immunological parameters after one month taking Vitamin D.
11520637|NCT01210495|Experimental|A|Participants in this group received axitinib + best supportive care. Participants with Child-Pugh Class A disease (score 5 or 6) were enrolled into the randomized portion at a starting axitinib dose of 5 mg BID orally. Participants with Child-Pugh Class B disease (score 7) were to begin enrollment into the randomized portion of the study following determination of the recommended axitinib starting dose in the non-randomized portion. Study treatment was administered in cycles of 4 weeks in duration
11520638|NCT01210495|Placebo Comparator|B|Participants in this group received placebo + best supportive care. Treatment was administered in cycles of 4 weeks in duration. The starting dose of placebo for participants with Child Pugh Class A disease (score 5 or 6) was chosen as 5 mg BID. Participants with Child-Pugh Class B, score 7 received placebo that was determined from the non-randomized portion of the study until the recommended starting dose was determined, participants with Child-Pugh Class B, score 7, were not permitted to enter the randomized portion of the study
11520639|NCT01210482||Temsirolimus|Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma)
11520640|NCT01210469|Experimental|Strengthening Group|Performed balance training with lower limbs muscle strengthening.
11520641|NCT01210469|Experimental|Stretching Group|Performed balance training with stretching
11520642|NCT01210469|No Intervention|Control Group|
11520643|NCT01210456|Active Comparator|Physiological Saline and N-Acetylcysteine|
11520644|NCT01210456|Active Comparator|Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|
11520645|NCT01210443|Experimental|Sitaxentan treatment|
11520646|NCT01210430|Active Comparator|Losartan|
11520647|NCT01210430|Active Comparator|Ascorbic Acid (VItamin C)|
11520648|NCT01210430|Placebo Comparator|Normal Saline|
11520649|NCT01210417||Trauma victims|All prehospital traumatic patients enrolled by our Helicopter Emergency Medical System (HEMS)
11520650|NCT01210404|Experimental|1.0|
11520651|NCT01210391|Experimental|New hydrolyzed infant formula|New, extensively hydrolyzed infant formula
11520652|NCT01210391|Active Comparator|Commercially available infant formula|Commercially available, extensively hydrolyzed infant formula.
11520653|NCT01210378|Experimental|Nitroglycerin|
11520654|NCT01210365|Experimental|furosemide (40 mg) +amiloride (10 mg)|One group of patients will receive furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow the tablet in whole form on an empty stomach with some liquid.
11520655|NCT01210365|Active Comparator|Lasix ®|One group of patients will receive Lasix® (furosemide 40 mg). For treatment, the patient will swallow the tablet in whole form on an empty stomach with some liquid.
11520656|NCT01210352|Experimental|CII Drug|Open Label
11520657|NCT01210339|Experimental|1|Treatment A (Clopidogrel 9 days), at least 14 days wash-out, Treatment B (Clopidogrel 4 days followed by Clopidogrel + Esomeprazole/ASA 5 days)
11520658|NCT01210339|Experimental|2|Treatment B (Clopidogrel 4 days followed by Clopidogrel + Esomeprazole/ASA 5 days), at least 14 days wash-out, Treatment A (Clopidogrel 9 days)
11520659|NCT01210326|Experimental|aspiration|90 patients with non-obstructive azoospermi undergo testicular sperm aspiration
11520660|NCT01210326|Experimental|extraction|90 patients with non-obstructive azoospermi undergo testicular sperm extraction
11520661|NCT01210313||no treatment|
11520662|NCT01210287|No Intervention|Observation|Observation of the HBV reactivation in HBsAg negative/HBcAg positive patients receiving RCHOP without prophylactic anti-HBV treatment.
11520663|NCT01210261|Active Comparator|Autoset S8|Single night auto-titrating CPAP treatment using the reference device (Resmed Autoset S8) with polysomnographic monitoring
11520664|NCT01210261|Experimental|Somnilink SPAP|Single night auto-titrating CPAP treatment using the test device with polysomnographic monitoring
11520665|NCT01210235|Experimental|FLU-FIT Arm|In this arm, eligible patients aged 50-75 will be offered a FIT kit
11520666|NCT01210235|No Intervention|FLU-Only Arm|In this arm, patients will receive flu shots as usual, without the FLU-FIT intervention.
11520667|NCT01210222|Experimental|Treatment (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11520668|NCT01210196||mild affected Fabry patients|
11520669|NCT01210170|Experimental|mometasone 400 mcg - 30 min|randomly assigned intervention
11520670|NCT01210170|Experimental|mometasone 400 mcg simultaneous|randomly assigned intervention
11520671|NCT01210170|Placebo Comparator|placebo- 30 min|randomly assigned intervention
11520672|NCT01210170|Placebo Comparator|placebo simultaneous|randomly assigned intervention
11520674|NCT01210170|Placebo Comparator|placebo- 60 min|randomly assigned intervention
11520675|NCT01210170|Experimental|mometasone 200 mcg - 30 min|randomly assigned intervention
11520676|NCT01210170|Experimental|mometasone 200 mcg - 60 min|randomly assigned intervention
11520677|NCT01210170|Experimental|mometasone 200 mcg simultaneous|randomly assigned intervention
11520678|NCT01210157||I Ischemic CMP|Patients with impaired ventricular function caused by coronary artery disease.
11520679|NCT01210157||II CMP|Patients with impaired ventricular function which is not caused by coronary artery disease. Subgroups based on etiology (familial cardiomyopathy, toxic cardiomyopathy, etc.)
11520680|NCT01210144|Experimental|Gonal-f® + Ovitrelle® + Long Agonist Protocol|
11520681|NCT01210144|Experimental|Gonal-f® + Ovitrelle® + Multi-dose Antagonist Protocol|
11520682|NCT01210131|Experimental|[18F]HX4|
11520683|NCT01210118|Experimental|High intensity intervention|"Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the 5 Αs (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided."
11520684|NCT01210118|Other|Low intensity intervention|Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
11520685|NCT01210105||Macintosh #3 Laryngoscope|
11520686|NCT01210105||Glidescope|
11520687|NCT01210105||Ambu Pentax AWS|
11520688|NCT01210105||McGrath|
11520689|NCT01210105||Airtraq|
11520690|NCT01210105||Storz C-MAC|
11520691|NCT01210092||Macintosh #3 Laryngoscope|
11520692|NCT01210092||Glidescope|
11520693|NCT01210092||Ambu Pentax AWS|
11520694|NCT01210092||McGrath|
11520695|NCT01210092||Airtraq|
11520696|NCT01210092||Storz C-MAC|
11520697|NCT01210079|Experimental|Gabapentin|
11520698|NCT01210079|Placebo Comparator|Placebo|
11520699|NCT01210066|Active Comparator|Pain Challenge|Cold pressor test
11520700|NCT01210066|Active Comparator|Pain + Opioid Challenge|IV fentanyl 1mcg/kg followed by cold pressor test
11520701|NCT01210066|Active Comparator|Opioid Challenge|Administration of fentanyl 1mcg/kg of subject weight
11520702|NCT01210053|Experimental|Single arm|Patients receive oral sunitinib malate 25 mg daily in the absence of disease progression or unacceptable toxicity.
11520703|NCT01210040|Active Comparator|Folic Acid|2.8mg of Folic Acid given weekly
11520704|NCT01210040|Experimental|Folic Acid and Iron|2.8mg Folic Acid and 60mg Iron given weekly
11520705|NCT01210014|Placebo Comparator|A|Patients with Recurrent aphthous stomatitis
11520706|NCT01210014|Active Comparator|B|Patients with Recurrent aphthous stomatitis
11520707|NCT01210001|Experimental|BI 10773 low dose|BI 10773 tablets once daily
11520708|NCT01210001|Experimental|BI 10773 high dose|BI 10773 tablets once daily
11520709|NCT01210001|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
11520710|NCT01209988|Experimental|Tamsulosin 0.4mg|Perioperative tamsulosin 0.4mg daily
11520711|NCT01209988|Placebo Comparator|Control|No medication
11520712|NCT01209975||untreated glaucoma patients|We will evaluate the blood flow before and after Selective Laser Trabeculoplasty in patients with primary open angel glaucoma.
11520713|NCT01209962||Cohort|"The majority of recruited patients will be treated on protocol HUM00004531 A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin with Radiation Therapy in Patients with Pancreatic Cancer."
11520714|NCT01209949|Other|Adapalene 0.1% and Benzoyl Peroxide 2.5% gel|
11520715|NCT01209936|Experimental|deuterium oxide and BC3|Testing of total body water on the BC3 compared to total body water measured by deuterium oxide.
11520716|NCT01209923|Experimental|Body composition testing|Body composition tested using bioelectrical impedance and the DEXA or hydrostatic weighing methods.
11520717|NCT01209910|Experimental|free water|The subjects in this arm will be able to drink water followings study rules.
11520718|NCT01209910|No Intervention|Control|These subjects will be observed during the study.
11520719|NCT01209897|Active Comparator|Stage of Change|
11520720|NCT01209897|Experimental|Common Sense Model|
11520721|NCT01209897|Active Comparator|Action Model|
11520722|NCT01209884||Healthy Elderly sub-group|Healthy males between the age of 80-85 years old who have not experienced chronic disease during their lifetime.
11520723|NCT01209871|Experimental|Treatment (vaccine therapy)|Patients receive autologous lymphoma immunoglobulin-derived scFV-chemokine DNA vaccine ID at 0, 4, and 8 weeks.
11520724|NCT01209858|Experimental|Experimental 1|
11520725|NCT01209858|Experimental|Experimental 2|
11520726|NCT01209845|Experimental|Ketamine|Patients were administered a single sub-anaesthetic i.v. bolus of ketamine (0.2 mg/kg over 1-2 min) in the ED, with continuous monitoring of vital signs, adverse events and psychotomimetic side-effects for 4 h post-administration.
11520727|NCT01209832|Experimental|Drug Interaction arm|
11520728|NCT01209806|Active Comparator|simethicone|
11520729|NCT01209806|No Intervention|no simethicone|
11520730|NCT01209793|Experimental|Dose 1|(3:1, active: placebo)
11520731|NCT01209793|Experimental|Dose 2|(3:1, active: placebo)
11520732|NCT01209793|Experimental|Dose 3|(3:1, active: placebo)
11520733|NCT01209793|Experimental|Dose 4|(3:1, active: placebo)
11520734|NCT01209793|Experimental|Dose 5|(3:1, active: placebo)
11520735|NCT01209780|Experimental|TIV (3-8 years)|Non-Naive subjects received one dose and naive subjects received two doses, administered 4 weeks apart, of investigational trivalent influenza vaccine (TIV)
11520736|NCT01209780|Active Comparator|Control TIV (3-8 years)|Non-Naive subjects received one dose and Naive subjects received two doses, administered 4 weeks apart, of control vaccine. Subjects aged 3 to <4 years and subjects aged 4 to 8 years received different control TIV.
11520737|NCT01209780|Experimental|TIV ( 9-17 years)|All subjects received one dose of investigational TIV. The subjects in this cohort were included only for safety analysis.
11520738|NCT01209780|Active Comparator|Control TIV ( (9-17 years)|All subjects received one dose of the control vaccine. The subjects from this cohort were included only for safety analysis.
11520739|NCT01209767|Experimental|cryolipolysis|
11520740|NCT01209767|Active Comparator|subcision|
11520741|NCT01209767|Active Comparator|Control|Areas with cellulite that had no treatment performed were considered the control arm.
11520742|NCT01209754||Pregnant Women|Pregnant women exposed to an HIV prevention study agent during pregnancy
11520743|NCT01209754||Infant|Infants resulting from pregnancies where there exists maternal HIV prevention agent exposure
11520744|NCT01209741|Active Comparator|1|MK-0974 12MoRT
11520745|NCT01209741|Active Comparator|2|MK-0974 5Mo5C
11520746|NCT01209741|Active Comparator|3|MK-0974 12Mo5C
11520747|NCT01209728|Experimental|Primary insomnia patients and healthy subjects|Elderly participants, including primary insomnia patients and healthy subjects
11520748|NCT01209715|Placebo Comparator|Matching Placebo|Participants will be treated with placebo twice a day for 3 weeks.
11520749|NCT01209715|Active Comparator|Fluticasone/salmeterol|Participants will be assigned to inhaled fluticasone/salmeterol twice a day for 3 weeks.
11520750|NCT01209702|Placebo Comparator|Part 1: Placebo|Participants received intravenous infusions of placebo once every 4 weeks until Week 12. Following the Week 12 visit, participants who completed Part 1 of the study received open-label 8 mg/kg tocilizumab through Week 208.
11520751|NCT01209702|Experimental|Part 1: Tocilizumab|Participants received intravenous infusions of 8 mg/kg tocilizumab once every 4 weeks until Week 12. Following the Week 12 visit, participants who completed Part 1 of the study received open-label 8 mg/kg tocilizumab through Week 208.
11520752|NCT01209702|Placebo Comparator|Part 2: Placebo|Participants received intravenous infusions of placebo once every 4 weeks until Week 24. Participants who did not attain an ASsessment in Ankylosing Spondylitis-20 (ASAS20) response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
11520753|NCT01209702|Experimental|Part 2: Tocilizumab 4 mg/kg|Participants received intravenous infusions of 4 mg/kg tocilizumab once every 4 weeks until Week 24. Participants who did not attain an ASAS20 response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
11520754|NCT01209702|Experimental|Part 2: Tocilizumab 8 mg/kg|Participants received intravenous infusions of 8 mg/kg tocilizumab once every 4 weeks until Week 24. Participants who did not attain an ASAS20 response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
11520755|NCT01209689|Experimental|Tocilizumab 4 mg/kg|Patients received tocilizumab 4 mg/kg intravenously every 4 weeks for 24 weeks.
11520756|NCT01209689|Experimental|Tocilizumab 8 mg/kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks for 24 weeks.
11520757|NCT01209689|Placebo Comparator|Placebo|Patients received placebo to tocilizumab intravenously every 4 weeks for 24 weeks.
11520758|NCT01209676|Experimental|IMCgp100|IMCgp100 will be injected cutaneously or subcutaneously into the metastasis, and peritumoral area if applicable
11520759|NCT01209663|Active Comparator|Ward Care|Protocol based discharge to the surgery ward. Observation and treatment is conducted by ward nurses and general surgeons (current treatment).
11520760|NCT01209663|Experimental|Intermediate Care|Observation and treatment in an intermediate care bed in a minimum of 48 hours after randomization. Daily rounds will be carried out by both general surgeons and intensive care physicians.
11520761|NCT01209637|No Intervention|control|standard care of coronary artery diseases incl. recommended home based exercise 3x/week
11520762|NCT01209637|Active Comparator|Exercise training|exercise training for 4 weeks at 70% of ischemia free individual threshold within a rehabilitation care center
11520763|NCT01209637|Active Comparator|intensive exercise training|intensive exercise training incl. interval training
11520764|NCT01209611|Experimental|Autologous bone marrow mononuclear cells|Patients received autologous MNC transplantation. Bone marrow aspirates are harvested from the anterior iliac crest of the patients under general or local anesthesia. MNCs are isolated by density gradient centrifugation. The cell suspension was adjusted to a final volume of 6-20 ml with saline. The cell suspension was injected into expanded skin intradermally via a 27-gauge needle (approximately 0.5-1×10^6 cells/cm2).
11520765|NCT01209611|Placebo Comparator|Saline|Patient has intradermally and subcutaneously injection of saline.
11520766|NCT01209598|Experimental|Palbociclib 200mg|This is a phase II study of Palbociclib in patients with advanced / metastatic liposarcoma. A one-stage design is used to determine whether patients treated with Palbociclib achieved a PFS rate of ≥ 40% at 12 weeks.
11520767|NCT01209598|Experimental|Palbociclib 125mg|This is a phase II study of Palbociclib in patients with advanced / metastatic liposarcoma. A one-stage design is used to determine whether patients treated with Palbociclib achieved a PFS rate of ≥ 40% at 12 weeks.
11520768|NCT01209585||Rheumatoid Arthritis|Subject must have RA with inflamed joint
11520769|NCT01209585||Osteoarthritis|Subjects must have OA of the knee
11520770|NCT01209585||Pseudo gout|Subjects must have peusdo-gout of knee
11520771|NCT01209572|Experimental|calorimetric chamber|
11520772|NCT01209572|Experimental|Free living conditions|
11520773|NCT01209559||air-Q Intubating Laryngeal Airway|
11520774|NCT01209559||LMA FastrachTM or ILMA|
11520775|NCT01209546|Active Comparator|Flutter group|In Flutter group the exercise used the Flutter ®VRP1 (VarioRaw SA, Switzerland).
11520776|NCT01209546|Active Comparator|PEP group|In PEP group the exercise used the Flutter ®VRP1 (VarioRaw SA, Switzerland) without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1.
11520777|NCT01209546|Placebo Comparator|control group|In placebo patients were assessed as pulmonary function, respiratory muscle strength and transport properties of respiratory secretions
11520778|NCT01209546|Sham Comparator|Group Sham|Exercise with Flutter®VRP1 without the ball inside
11520779|NCT01209520|Experimental|Adjuvant Chemotherapy + Vidaza|
11520780|NCT01209507||Chemotherapy every 3 weeks|One treatment of chemotherapy every 3 weeks. Chemotherapy will either be 2 doses of 20 mg orally (PO) (12 hrs prior and immediately before treatment) or 1 dose via IV. The total dose per cycle is 20-40 mg every 3 weeks for 18 weeks.
11520781|NCT01209507||Weekly chemotherapy|Chemotherapy will be given three times in a three week cycle. Chemotherapy will be given either Day 1, 8, and day 15 or Day 1,2 and day 8). Chemotherapy will either be 2 doses of 20 mg PO (12 hrs priors and immediately before treatment) or 1 dose via IV. The total dose per cycle will be 20-40 mg approximately for 18 weeks.
11520782|NCT01209494||Invasive EP Study Group|200 patients are studied before clinically indicated (according to AHA/ACC/ESC guidelines) first ICD implantation or ICD exchange. Invasive EP study is performed to test inducibility of malignant arrhythmia. In addition MAP recordings are performed for measurements of restitution properties. Pacing is done for 12-lead ECG and MAP recordings for analysis of BVR and TWA, if applicable.
11520783|NCT01209494||Noninvasive EP Study Group|"The assignment of patients to the invasive and noninvasive EP groups does not occur by randomization or for intervention.
~In the noninvasive EP study group, 500 patients with chronically implanted ICD (>3 month after implantation) are investigated using non-invasive EP study via ICD programmer. Programmed electrical stimulation is performed to test for inducibility of malignant arrhythmia. In addition pacing is done for measurements of BVR from the 12-lead ECG."
11520784|NCT01209481|Experimental|Nutritional education|
11520785|NCT01209481|No Intervention|control|
11520786|NCT01209468|Active Comparator|oral appliance 2|Patients in treatment arm/group B will have a customized twinblock OA constructed for them individually. They will undergo an appliance acclimatization period of 4-5 weeks. Three months after baseline assessments - T1 (6 weeks of 'active' treatment), physiological measurements will be evaluated, clinical oral examinations conducted, quality of life and compliance assessed. Following this, a customized monobloc OA will be constructed for subjects individually and they will acclimatize to it for 4-5 weeks (so that the mandible is protruded to the maximum position they feel comfortable with when the appliance is worn). Prior to the active treatment phase, patients will not wear the monobloc OA for 1 week (washout phase). Three months later - T2 (6 weeks of 'active' treatment), all the previous measurements will be conducted again.
11520787|NCT01209468|Experimental|oral appliance 1|Patients in treatment arm/group A will have a customized monobloc OA constructed for them individually. They will undergo an appliance acclimatization period of 4-5 weeks. Three months after baseline assessments - T1 (6 weeks of 'active' treatment), physiological measurements will be evaluated, clinical oral examinations conducted, quality of life and compliance assessed. Following this, a customized twin-bloc OA will be constructed for subjects individually and they will acclimatize to it for 4-5 weeks (so that the mandible is protruded to the maximum position they feel comfortable with when the appliance is worn). Prior to the active treatment phase, patients will not wear the twin-bloc OA for 1 week (washout phase). Three months later - T2 (6 weeks of 'active' treatment), all the previous measurements will be conducted again.
11520788|NCT01209455|No Intervention|Saline|Volunteers will receive an incremental rising dose infusion of IA NAC (6 doses) together with a co-infusion of normal saline to determine a dose response curve for arterial vasodilatation in the forearm.
11520789|NCT01209455|Active Comparator|Histamine antagonists|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of histamine antagonists (H1 and H2 antagonists) to determine vasodilatation in response to NAC in the presence of histamine antagonists.
11520790|NCT01209455|Active Comparator|Low dose paracetamol|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of low dose paracetamol to determine whether the vasodilatory response to NAC is inhibited.
11520791|NCT01209455|Active Comparator|High dose paracetamol|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of higher dose paracetamol to determine whether the vasodilatory response to NAC is inhibited.
11520792|NCT01209442|Experimental|RT with Temozolomide and Bevacizumab|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily TMZ at 75 mg/m2 qd concurrent with IMRT (including weekends and holidays). Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Day 1 and the 1st Fx of IMRT must start on the same day. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab therapy, patients will have a brain MRI and if there is no evidence of disease progression, patients will receive 6 cycles of Bevacizumab and TMZ. Beginning a minimum of 28 days after the last radiation treatment the bevacizumab will be dosed at 10 mg/kg on day 1 and day 15 of each cycle. TMZ will be given at 150-200 mg/m2 qd on days 1-5 of each cycle. Each cycle is 28 days.
11520793|NCT01209429|Experimental|42 hour fast/GH infusion|
11520794|NCT01209429|Experimental|42 hour fast/Placebo infusion|
11520795|NCT01209429|Experimental|12 hour fast/GH infusion|
11520796|NCT01209429|Placebo Comparator|12 hour fast/Placebo infusion|
11520797|NCT01209416|Active Comparator|Ghrelin / Acipimox|Ghrelin infusion and tablet acipimox
11520798|NCT01209416|Active Comparator|Ghrelin / placebo|Ghrelin infusion and placebo tablets
11520799|NCT01209416|Active Comparator|Placebo / Acipimox|saline infusion and tablet Acipimox
11520800|NCT01209416|Placebo Comparator|Placebo / placebo|saline infusion and placebo tablets
11520801|NCT01209403|No Intervention|No treatment|
11520802|NCT01209403|Active Comparator|Glukose-infusion|Glucose-infusion during hemodialysis
11520803|NCT01209403|Active Comparator|Glucose-insulin infusion|Glucose-insulin infusion during hemodialysis
11520804|NCT01209390||Osteochondral lesions|Patients with osteochondral lesions in the knee, the ankle, or other joint
11520805|NCT01209377|Experimental|standard|EMDR treatment with bilateral stimulation via eye movement
11520806|NCT01209377|Experimental|fixed|EMDR treatment with eyes fixed
11520807|NCT01209377|Experimental|no focus|trauma exposition without external stimulus
11520808|NCT01209364|Experimental|Durolane|intraarticular hyaluronic acid
11520809|NCT01209364|Active Comparator|methylprednisolone|intraarticular injection
11520810|NCT01209351|Placebo Comparator|Placebo|Placebo
11520811|NCT01209351|Experimental|teduglutide|
11520812|NCT01209338|Active Comparator|sensitized group|One arm will be a sensitized group which would have received cancer health awareness sessions and / or screening earlier at least once in the past.
11520813|NCT01209338|No Intervention|non-sensitized group|The second arm will belong to an area which has never been exposed to any form of cancer awareness or screening activities thus this group is a completely non-sensitized group.
11520814|NCT01209325|Experimental|Vaccination|Gardasil (quadrivalent HPV types 6, 11, 16, 18) vaccination at weeks 0, 8, 24.
11520815|NCT01209312|Experimental|full bolus -20|Will administer full insulin bolus 20 minutes prior to meal
11520816|NCT01209312|Experimental|Full bolus, T0|Will administer full meal bolus at the start of the meal
11520817|NCT01209312|Experimental|1/2 bolus, T-20|Will only give half the insulin dose 20 minutes before meal
11520818|NCT01209312|Experimental|1/2 bolus T0|Will give half the amount of insulin at the time of the meal
11520819|NCT01209286|Experimental|Blinatumomab 15 μg|Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.
11520820|NCT01209286|Experimental|Blinatumomab 5/15 μg|Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, followed by 15 μg/m²/day starting from Week 2 of treatment.
11520821|NCT01209286|Experimental|Blinatumomab 5/15/30 μg|Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, a dose of 15 μg/m²/day in the subsequent 7 days, followed by 30 μg/m²/day starting from Week 3 of treatment.
11520822|NCT01209273||APD group|which can be 3 to 5 exchanges daily, and up to 20 liters daily( including up to two daytime exchanges)
11520823|NCT01209273||CAPD group|which can be 1 to 4 exchanges daily and up to 16 liters daily(including up to two daytime exchanges)
11520824|NCT01209260|Experimental|Radiofrequency energy needle|Radiofrequency energy needle for transseptal access
11520825|NCT01209260|Active Comparator|Mechanical needle|Mechanical (Brockenbrough) needle for transseptal access
11520826|NCT01209247|Active Comparator|patient treated by fluoroquinolone|patient treated by fluoroquinolone. Nasal, rectal and pharyngeal swabs
11520827|NCT01209247|Placebo Comparator|patient not receiving FQ treatment|reference group of patients not receiving FQ treatment, but hospitalized in the same wards at the same time
11520828|NCT01209234|Active Comparator|MRSA Decolonization|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
11520829|NCT01209234|Active Comparator|Education Arm|Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home. In addition, educational material on hygiene practices to prevent MRSA infection will be provided.
11520830|NCT01209221|Experimental|1|
11520831|NCT01209221|Experimental|2|
11520832|NCT01209221|Placebo Comparator|3|
11520833|NCT01209221|Placebo Comparator|4|
11520834|NCT01209208|Experimental|A|Budesonide
11520835|NCT01209208|Experimental|B|Mesalazine
11520836|NCT01209208|Placebo Comparator|C|
11520837|NCT01209195|Experimental|MM-121 + Paclitaxel|Escalating doses of MM-121 given IV QW in combination with paclitaxel at standard dose of 80 mg/m2 IV QW
11520838|NCT01209182|Experimental|Device image reading|Tissue images generated by the device are read by surgeons to determine if the tissue area under test has abnormal component or not. When Images generated by the device are read by surgeons as abnormal an additional margin of tissue is removed. The new margin is also imaged by the device to ensure complete tumor excision.
11520839|NCT01209156|Experimental|Assess [18F] PBR111 and PET imaging|Evaluation of PET imaging with [18F]PBR111 in HV and AD subjects (Proof of Mechanism)
11520840|NCT01209143|Experimental|Vismodegib + rosiglitazone|Participants received rosiglitazone 4 mg orally on Days 1 and 8 of the study. Participants also received vismodegib 150 mg orally once a day beginning on Day 2 until one of the following occurred; disease progression, intolerable toxicity, most probably attributable to vismodegib, or patient withdrawal of consent.
11520841|NCT01209143|Experimental|Vismodegib + oral contraceptive|Participants received the oral contraceptive norethindrone 1 mg/ethinyl estradiol 35 µg (Ortho-Novum 1/35®) orally on Days 1 and 8 of the study. Participants also received vismodegib 150 mg orally once a day beginning on Day 2 until one of the following occurred; disease progression, intolerable toxicity, most probably attributable to vismodegib, or patient withdrawal of consent.
11520842|NCT01209130|Experimental|A|
11520843|NCT01209130|Experimental|B|
11520844|NCT01209117|Experimental|Periods 1 - 4|Subjects will be randomized in a cross over fashion to receive the GSK2248761 WBM capsule formulation or one of three WBM tablet formulations in one of four sequences.
11520845|NCT01209117|Experimental|Period 5|Subjects in Part B will receive a formulation of GSK2248761 200mg WBM Tablet chosen from Periods 1 - 4 in part A in the fed state (moderate fat meal).
11520846|NCT01209104|Experimental|Cohort 1-PK and and safety of GSK1325756 in subjects 40-64y|This arm assesses the pharmacokinetics and safety of a single oral ose of 100mg of GSK1325756 administered to subjects in the age range 40y-64y when administered in the fasted state, in the presence of a high-fat meal and in the presence of a proton-pump inhibitor.
11520847|NCT01209104|Experimental|Cohort 2- PK and safety of GSK1325756 in subjects aged 65y-80y|This arm assesses the pharmacokinetics and safety of a single dose of 100mg of GSK1325756 administered to a group of subjects in the 64y-80y age range in the fasted state
11520848|NCT01209091||No treatment|
11520849|NCT01209078|Experimental|Regimen 1|GSK1322322 1500mg and Placebo Linezolid given twice a day (BID) for 10 days
11520850|NCT01209078|Active Comparator|Regimen 2|Linezolid 600mg and placebo GSK1322322 given BID for 10 days
11520851|NCT01209065|Experimental|Part A|Approximately 12 subjects will be enrolled. In the first treatment period, all subjects will receive GSK1349572 50 mg every 24 hours for 5 days. In Period 2, subjects will receive GSK1349572 50 mg every 24 hours in combination with fosamprenavir 700 mg plus ritonavir 100 mg every 12 hours for 10 days. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
11520852|NCT01209065|Experimental|Part B|Approximately 15 subjects will be enrolled and receive three single doses of GSK1349572 approximately one week apart. One will be the current tablet formulation containing micronized drug substance and 2 will be new tablet versions, one containing unmicronized drug substance and one containing an intermediate particle size drug substance. Subjects will have a screening visit within 30 days prior to the first dose of study drug, three treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
11520853|NCT01209052|Experimental|COHORT 1|Interlocking design with Cohort 2. Single dose; treatment period over 2 days such that two subjects will receive GSK1325756 and at least one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK1325756 from 10mg, to 50mg, and 200mg, will be administered over the 6 week long treatment period allowing adequate washout period between doses.
11520854|NCT01209052|Experimental|COHORT 2|Interlocking design with Cohort 1. Single dose; treatment period over 2 days such that two subjects will receive GSK1325756 and at least one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK1325756 from 25mg, to 100mg, and 400mg, will be administered over the 6 week long treatment period allowing adequate washout period between doses.
11520855|NCT01209052|Experimental|COHORT 3|Placebo controlled, 14-day, once daily, repeat-dose evaluation with one selected dose of GSK1325756 in 14 subjects. Dose selection based on review of safety and tolerability data from cohorts 1 and 2.
11520856|NCT01209052|Experimental|COHORT 4|Placebo controlled, 14-day, once daily, repeat-dose evaluation with a higher selected dose of GSK1325756 in 14 subjects. Dose selection based on review of safety and tolerability data from cohort 3.
11520857|NCT01209039|Experimental|Part A, cohort 1 and 2|Part A, Cohorts 1 and 2, will investigate escalating multiple daily doses of GSK1144814 in 19 subjects
11520858|NCT01209039|Experimental|Part A, cohort 3|Cohort 3 will investigate safety, tolerability and PK of a dose of GSK1144814 over a repeat treatment period of 28 days in 18 subjects and a potential drug drug interaction between GSK1144814 and the CYP3A4 sensitive substrate midazolam (in 15 subjects).
11520859|NCT01209039|Experimental|Part B|Part B will assess NK1 receptor occupancy following repeated administration of GSK1144814 given once daily until steady state is obtained
11520860|NCT01209026|Experimental|FF/GW642444M (200/25mcg)|Inhaled fluticasone furoate (200mcg) /GW642444M (25mcg) combination Days 1- 7; placebo tablet taken orally single dose (po SD) on Day 7.
11520861|NCT01209026|Experimental|FF/GW642444M (800/100 mcg)|Inhaled fluticasone furoate (800mcg) /GW642444M (100mcg) combination Days 1- 7; placebo tablet (po SD) on Day 7.
11520862|NCT01209026|Active Comparator|Moxifloxacin|Inhaled placebo on Days 1-7; moxifloxacin (400mg po SD) on Day 7
11520863|NCT01209026|Placebo Comparator|Placebo|Inhaled placebo on Days 1-7; placebo tablet (po SD) on Day 7.
11520864|NCT01209013|Experimental|Medlight PDT Balloon|
11520865|NCT01209000||FSGS/MCD Cohort (Cohort A)|"Focal Segmental Glomerulosclerosis/Minimal Change Disease (FSGS/MCD) Cohort
~Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for FSGS or MCD.
~Eligible participants must be scheduled for a clinically indicated renal biopsy."
11520866|NCT01209000||MN Cohort (Cohort A)|"Membranous Nephropathy (MN) Cohort
~Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for MN.
~Eligible participants must be scheduled for a clinically indicated renal biopsy."
11520867|NCT01209000||Other glomerulopathies cohort|"Participants enrolled in NEPTUNE and determined to not have FSGS/MCD or MN will be followed in a third group.
~Eligible participants must be scheduled for a clinically indicated renal biopsy."
11520868|NCT01209000||cNEPTUNE (Cohort B)|Participants < 19 years of age, with < 30 days exposure to immunosuppression therapy who are not scheduled for renal biopsy.
11520869|NCT01208987|Experimental|Intervention (with Medication History)|these patient visits generated a medication history
11520870|NCT01208974|Experimental|Phase 1 MTD NAC RT|"Participants will undergo a Nipple-Areolar Complex (NAC)-sparing mastectomy with immediate reconstruction and axillary surgery, if indicated, on Week 1. Anytime between Weeks 5-8, participants will undergo a dose-escalation/de-escalation of prophylactic NAC radiation treatment (RT) twice daily (minimum of 4 hours apart) for 5 days. Dose escalation/de-escalation design are as follows:
~Dose Level I - 10 fractions of 2.0 Gy for a total of 20 Gy
~Dose Level II - 10 fractions of 2.5 Gy for a total of 25 Gy
~Dose Level III - 10 fractions of 3.0 Gy for a total of 30 Gy
~Dose Level IV - 10 fractions of 3.5 Gy for a total of 35 Gy
~Participants will be treated between cohorts of 2-6 patients per dose level starting at dose level II. Dose escalation stops when 2 out of 2-6 participants encounter Dose Limiting Toxicities (DLT).
~Standard of care chemotherapy, at treating physician's discretion, can be initiated 2 weeks after RT."
11520871|NCT01208961|Active Comparator|Epanova-Lovaza-Epanova-Lovaza|
11520872|NCT01208961|Active Comparator|Lovaza-Epanova-Lovaza-Epanova|
11520873|NCT01208948|Active Comparator|Alpha lipoic acid 600 mg|
11520874|NCT01208948|Placebo Comparator|placebo pill|
11520875|NCT01208922|Experimental|Group A|Rifamycin SV-MMX® 200 mg tablets
11520876|NCT01208922|Active Comparator|Group B|Ciprofloxacin 500 mg capsules
11520877|NCT01208896|Experimental|Rituximab|
11520878|NCT01208883|Experimental|repetitive per-treatment [18F]FDG-PET for treatment adaptation|
11520879|NCT01208870|Experimental|Variety Group|Traditional family based weight control treatment program with components to reduce variety of high energy dense foods incorporated into the treatment. Families meet weekly for 12 weeks, then by-weekly for 1 month and 1 monthly session for a total of 15 behavioral intervention sessions.
11522240|NCT01199276|Experimental|Xenon|60%(1MAC)in oxygen (FiO2 = 0.35-0.45)
11520880|NCT01208870|Experimental|Nutrition Education Control|Traditional family based weight control treatment program, without components from habituation theory incorporated into the treatment. Families meet weekly for 12 weeks, then by-weekly for 1 month and 1 monthly session for a total of 15 behavioral intervention sessions.
11520881|NCT01208844||Posttraumatic Stress|
11520882|NCT01208844||Depression|
11520883|NCT01208844||Healthy|
11520884|NCT01208831|Experimental|LDE225|
11520885|NCT01208818|Active Comparator|BD|
11520886|NCT01208818|Experimental|C-BD|
11520887|NCT01208818|Experimental|HCO|
11520888|NCT01208818|Active Comparator|Control HD|
11520889|NCT01208805||Candidates for dorsal column stimulation|
11520890|NCT01208792|Experimental|Disease group|Two hundred patients with PAH will be included: 50 patients with idiopathic PAH (iPAH), 20 with PAH associated with HIV infection, 20 with porto-pulmonary hypertension, 20 with PAH secondary to congenital heart disorders, 40 with SSc, 20 with SLE, 20 with MCTD and 10 with a PAH associated with a Sjögren's syndrome. Two hundred patients without PAH will also be included: 80 patients with SSc and 20 in each of the following groups: HIV infection, porto-pulmonary hypertension, SLE, congenital heart disorders, MCTD and with Sjögren's syndrome.
11520891|NCT01208792|Other|Control group 1|Two hundred healthy blood donors age and sex-matched with patients with PAH, will be included as controls.
11520892|NCT01208792|Other|Control group 2|Twenty patients with proximal chronic thromboembolic pulmonary hypertension (CTPH) will also be included in a control arm of the study.
11520893|NCT01208779||1|Women with estrogen receptor positive breast cancer already receiving treatment with an aromatase inhibitor (AI) will be enrolled in the study
11520894|NCT01208766|Active Comparator|R1: 4 cycles Bortezomib, Melphalan, Prednisone (VMP)|All patients randomized to VMP treatment, will be treated with Bortezomib, Melphalan, Prednisone(VMP, 4 cycles) and will start intensification with VMP between 4 and 6 weeks after stem cell collection.
11520895|NCT01208766|Experimental|R1: 1 (2) cycle(s) HDM|All patients randomized to intensification with High Dose Melphalan will start intensification with HDM (in hospitals with a policy of double intensification, patients will be randomized between VMP, 1 HDM and 2 HDM) between 4 and 6 weeks after stem cell collection.
11520896|NCT01208766|No Intervention|R2: none|No consolidation, patients will continue to Lenalidomide maintenance.
11520897|NCT01208766|Experimental|R2: 2 cycles of VRD|In patients randomized to consolidation treatment, 2 cycles of Bortezomib, Lenalidomide,Dexamethasone (VRD) will start at 8 weeks after the end of the last course of VMP or HDM.
11520898|NCT01208753|Experimental|Aqueous formulations for formulation selection|50 mg once daily for 3 days of two different aqueous suspensions, with four day wash-out between formulation
11520899|NCT01208753|Experimental|GLPG0555 ascending doses|multiple ascending doses for 13 days, ranging from 100 mg once daily upto a maximum to be determined during escalation (given as once or twice daily)
11520900|NCT01208753|Placebo Comparator|3|once or twice daily for 13 days, matching the scheme of the multiple ascending dose.
11520901|NCT01208740|Experimental|Metformin|Metformin pre-treatment and co-administration
11520902|NCT01208740|Placebo Comparator|Placebo|Placebo pre-treatment and co-administration
11520903|NCT01208727|No Intervention|Control|22 controls patients without post conditionment
11520904|NCT01208727|Experimental|Intervention|22 posconditioned patients
11520905|NCT01208714|Active Comparator|revascularization|The patients randomized to this treatment will undergo PTA with stenting of the renal artery.
11520906|NCT01208714|Active Comparator|medical therapy|The patients randomized to this treatment will undergo optimal medical therapy
11520907|NCT01208701|Active Comparator|Atorvastatin|
11520908|NCT01208701|Placebo Comparator|Placebo|
11520909|NCT01208688|Experimental|FES Therapy|FES Therapy
11520910|NCT01208688|Active Comparator|Conventional Occupational Therapy|The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
11520911|NCT01208675||Mild cognitive impairment|550 patients with mild cognitive impairment or subjective cognitive symptoms at baseline.
11520912|NCT01208675||Healthy elderly subjects|400 elderly subjects, who are cognitively healthy at baseline.
11520913|NCT01208662|Active Comparator|High Dose Treatment|Lenalidomide, bortezomib, dexamethasone. Stem cell collection. Maintenance Lenalidomide.
11520914|NCT01208662|Experimental|High Dose Treatment with SCT|Lenalidomide, bortezomib, dexamethasone. Stem cell collection. Autologous Stem Cell Transplant. Maintenance Lenalidomide.
11520915|NCT01208649|Active Comparator|Exenatide|Drug (including placebo)
11520916|NCT01208649|Placebo Comparator|Placebo|
11520917|NCT01208636||Sun exposed people|Sun exposure >3 hours daily for at least 5 days weekly for the last 3 months.
11520918|NCT01208623||2D|2D digital venography images alone
11520919|NCT01208623||3D|3D rotational venography
11520920|NCT01208623||Combine|combined MDCT angiography/venography
11520921|NCT01208584||Chronic posttraumatic paraplegia|Paraplegic patients (Thoracic level of lesion Th1-Th12), ASIA A, spinal cord injury (SCI) 12-24 months
11520922|NCT01208584||Acute posttraumatic paraplegia|Paraplegic patients (Thoracic level of lesion Th1-Th12), ASIA A,SCI 2-6 months,
11520923|NCT01208584||Myelomeningocele patients|Myelomeningocele patients (congenital paraplegia, thoracic level of lesion Th1-Th12) ASIA A
11520924|NCT01208584||Volunteers|Volunteers without any neurological deficits
11520925|NCT01208571|Experimental|Lifestyle counseling|
11520926|NCT01208571|No Intervention|Treatment as usual|
11520956|NCT01208363|Active Comparator|Fortified Cowpea|Study subjects will receive 3 times per week, as part of the school feeding programme 66g of raw fortified cowpea (with added 10mg Fe as NaFeEDTA)in form of Toubani (a cowpea based snack).
11520927|NCT01208558|Active Comparator|Diet A and physiotherapy|"Behavioral: Diet A Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people, i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid junk food and juice. In order to match carbohydrate intake between the arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.
~Behavioral: Physiotherapy Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end."
11520928|NCT01208558|Active Comparator|Diet B and physiotherapy|"Behavioral: Diet B Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A.
~Other Name: Whole grains Behavioral: Physiotherapy Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end.
~Other Name: Exercise"
11520929|NCT01208558|Active Comparator|Diet A only|"Behavioral: Diet A Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains as much as possible. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. In order to match carbohydrate intake between the intervention arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.
~Other Name: No grains"
11520930|NCT01208558|Active Comparator|Diet B only|"Behavioral: Diet B Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A. The goal is that carbohydrate intake, as a proportion of total energy intake, should not differ between the groups.
~Other Name: Whole grains"
11520931|NCT01208558|No Intervention|Control|Only follow-up. No intervention.
11520932|NCT01208519||Case Control Study 1|To define the impact of antibiotics on new acquisition of MRSA and ESBL-producing gram negative bacteria, a matched case-control study will be done (ratio 1:4). The control group will be selected among patients not receiving antibiotics, admitted in the same ward on the day of the corresponding case, with negative cultures at hospital admission. Matching criteria will include: age (±5 years), sex, and total length of hospitalization.
11520933|NCT01208519||Case control study 2|To define individual level of risk related to specific antibiotics, patients acquiring MRSA and ESBL-producing gram negative bacteria will be compared with patients not acquiring antibiotic-resistant strains after starting antibiotic therapy (ratio 1:4). Previously known risk factors or clinically relevant significant variables from the univariate analysis will be considered for inclusion in multivariate logistic regression analysis.
11520934|NCT01208506|Experimental|Dose level 1|
11520935|NCT01208506|Experimental|Dose level 2|
11520936|NCT01208506|Experimental|Dose level 3|
11520937|NCT01208506|Experimental|Dose level 4|
11520938|NCT01208506|Experimental|Dose level 5|
11520939|NCT01208506|Experimental|Dose level 6|
11520940|NCT01208506|Experimental|Dose level 7|
11520941|NCT01208506|Experimental|Dose level 8|
11520942|NCT01208493|Experimental|high protein preterm infant formula|preterm infant formula with high protein levels
11520943|NCT01208493|Active Comparator|control preterm formula|
11520944|NCT01208467||Basic science (DNA analysis)|DNA extracted from previously collected tumor samples is analyzed to validate the clinicopathologic associations and prognostic significance of ATR mutation.
11520945|NCT01208454|Experimental|Treatment (isotretinoin and vorinostat)|"Patients receive isotretinoin PO BID on days 1-14, PO suspension* of vorinostat QD on days 1-4 of course 1, and capsules of vorinostat PO QD on days 1-4 and 8-11 of course 2 and subsequent courses. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
~EXPANSION COHORT 1 (=< 21 years of age): Once the MTD has been determined, patients are treated at that dose level as above.
~EXPANSION COHORT 2 (22-30 years of age): Patients receive isotretinoin as above and vorinostat at the MTD on days 1-3 and 8-10."
11520946|NCT01208441|Experimental|Arm I|"Patients receive oral letrozole once daily on days 1-21. Beginning in course 2, patients also receive oral RO4929097 on days 1-3, 8-10, and 15-18. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~Beginning 1 week after completion of neoadjuvant therapy, patients undergo surgery or tumor biopsy. Patients continue to receive oral letrozole once daily during surgery and for an additional 4 weeks."
11520947|NCT01208428|Active Comparator|Conventional cognitive behavioral therapy|Subjects randomized to this arm will receive conventional cognitive behavioral therapy for the treatment of major depression
11520948|NCT01208428|Experimental|Religious cognitive behavioral therapy|Subjects randomized to this arm will receive conventional cognitive behavioral therapy, but their religious beliefs will be utilized as a resource in the therapy
11520949|NCT01208415|Experimental|Device Implant|
11520950|NCT01208402|Active Comparator|oral long acting beta blocker|oral administration of long acting beta blocker as standard of care on the day of surgery
11520951|NCT01208402|Experimental|Esmolol infusion|given 30 minutes prior to induction up to 12 hours post-op
11520952|NCT01208389|Experimental|voretigene neparvovec-rzyl (AAV2-hRPE65v2)|Administration of study agent (AAV2-hRPE65v2) to the previously, uninjected contralateral eye:
11520953|NCT01208376||unexplained chronic ALT elevation|Case patients: HIV-infected, unexplained chronic alanine aminotransferase (ALT) elevation
11520954|NCT01208376||always normal ALT|Control patients: HIV-infected, always normal ALT values
11520955|NCT01208363|No Intervention|Unfortified Toubani|Children in the school will receive, 3 times per week 66g of raw unfortified (no added Fe) cowpea in form of Toubani (a cowpea based snack).
11520957|NCT01208350|Experimental|1|
11520958|NCT01208350|Experimental|2|
11520960|NCT01208337|Other|Alemtuzumab induction|Intestine transplant recipients who receive induction with alemtuzumab prior to transplantation.
11520961|NCT01208324|Active Comparator|Estrogen patch|Vivelle Dot® 0.10 - 0.15 mg/day for 8 weeks
11520962|NCT01208324|Active Comparator|Amino Acids|L-Isoleucine (4.2 g), L-Leucine (6.6 g), L-Lysine (4.8 g), L-Methionine (1.5 g), L-Phenylalanine (6.6 g), L-Threonine (3.0 g), L-Valine (4.8 g)
11520963|NCT01208324|Placebo Comparator|Placebo Patch|Placebo
11520964|NCT01208324|Placebo Comparator|Placebo pills|31.5 g of lactose or microcellulose
11520965|NCT01208311||Patients with Hepatitis C Cirrhosis|Patients with Hepatitis C Cirrhosis
11520966|NCT01208298|Experimental|# 1727|Cold sore Patch
11520967|NCT01208285|Experimental|Group A|approximately 12 male and female subjects with moderate hepatic impairment
11520968|NCT01208285|Experimental|Group B|approximately 12 healthy male and female subjects
11520969|NCT01208272|Experimental|Binge Eating Disorder/Therapy|
11520970|NCT01208259|Experimental|Binge Eating Disorder/Therapy|
11520971|NCT01208233|Experimental|1 mg PF-03049423|
11520972|NCT01208233|Experimental|3 mg of PF-03049423|
11520973|NCT01208233|Experimental|6 mg of PF-03049423|
11520974|NCT01208233|Placebo Comparator|Placebo|
11520975|NCT01208220|Active Comparator|Negative pressure wound therapy|NPWT changed TIW
11520976|NCT01208220|Experimental|NPWT plus Collagenase Ointment|Collagenase applied TIW with NPWT
11520977|NCT01208207|Experimental|etoricoxib 60 mg/etoricoxib 60 mg|The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg in Part I and Part II
11520978|NCT01208207|Experimental|etoricoxib 60 mg/etoricoxib 90 mg|The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg in Part I and etoricoxib 90 mg in Part II
11520979|NCT01208207|Experimental|etoricoxib 90 mg/etoricoxib 90 mg|The etoricoxib 90 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg in Part I and Part II
11520980|NCT01208207|Active Comparator|naproxen 1000 mg/naproxen 1000 mg|The naproxen 1000 mg/naproxen 1000 mg treatment sequence will receive naproxen 1000 mg in Part I and Part II
11520981|NCT01208194|Experimental|MGN1703|Study medication
11520982|NCT01208194|Placebo Comparator|Placebo|
11520983|NCT01208181|Experimental|Etoricoxib 60 mg/Etoricoxib 60 mg|The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and Part 2 of the study.
11520984|NCT01208181|Experimental|Etoricoxib 60 mg/Etoricoxib 90 mg|The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 2 of the study.
11520985|NCT01208181|Experimental|Etoricoxib 90 mg|The etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.
11520986|NCT01208181|Placebo Comparator|Placebo|The placebo treatment sequence will receive matching placebo to etoricoxib tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.
11520987|NCT01208168|Experimental|Active drug|
11520988|NCT01208168|Placebo Comparator|Vehicle alone|
11520989|NCT01208155|Experimental|1|Fostamatinib 50 mg tablet x 2
11520990|NCT01208155|Experimental|2|Fostamatinib 100 mg tablet (batch 1)
11520991|NCT01208155|Experimental|3|Fostamatinib 100 mg tablet (batch 2)
11520992|NCT01208155|Experimental|4|Fostamatinib 100 mg tablet (batch 4)
11520993|NCT01208142|Active Comparator|Standard of care|25 Control subjects will only receive SOC (a weekly standardized physical therapy and daily wear of an AFO).
11520994|NCT01208142|Experimental|Dynasplint|25 Patients will receive the standard of care as well as an Ankle Flexion Dynasplint
11520995|NCT01208129|Experimental|Active drug|
11520996|NCT01208129|Placebo Comparator|Vehicle alone|
11520997|NCT01208116||Subgroups|According to the demographic features, subjects may be divided into some subgroups.
11520998|NCT01208103|Experimental|Treatment (oxaliplatin, bevacizumab, capecitabine)|Participants receive oxaliplatin via CVC over 2 hours and bevacizumab IV over 30-90 minutes on day 1. Participants also receive capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11520999|NCT01208090|Experimental|Investigational drug - Dose 1|
11521000|NCT01208090|Experimental|Investigational drug - Dose 2|
11521001|NCT01208090|Placebo Comparator|Matching placebo|
11521002|NCT01208077||Acute CHF|"Recurrent or worsening (within 3 days) shortness of breath as the primary presenting ED complaint
~Initial treating ED physician impression that the worsening dyspnea is most likely caused by decompensated CHF
~Known history of physician diagnosed CHF
~Natriuretic peptide (BNP, MR-pro ANP, NT pro BNP) level will be ordered by the treating physician as part of the patient's work up"
11521003|NCT01208077||Acute Stroke Syndrome|"Onset of abnormal neurological symptoms consistent with possible stroke, within the prior 24 hours, as the primary ED complaint
~Initial treating ED physician impression that the abnormal neurological symptoms/signs are most likely caused by an acute stroke syndrome
~Non contrast head CT will be ordered by the treating physician as part of the patient's work up"
11521004|NCT01208077||Acute Systemic Infection|"Any combinations of acute (within 3 days) symptoms and signs that the treating ED physician, after initial history and physical examination, attributes to a systemic infection
~Blood cultures and/or a blood lactate will be ordered by the treating physician as part of the patient's work up"
11521005|NCT01208064|Experimental|Pazopanib|2 weeks at 600mg and then maintenance at 800mg
11521006|NCT01208064|Placebo Comparator|Placebo|placebo match 2 weeks at 600mg and then maintenance at 800mg
11521007|NCT01208051|Experimental|Arm A (cediranib maleate)|Patients receive cediranib maleate PO QD on days 1-28. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11521008|NCT01208051|Experimental|Arm B (cediranib maleate)|Patients receive cediranib maleate PO and lenalidomide PO as in Phase I. NOTE: As of April 10, 2015, patients assigned to this arm are to discontinue lenalidomide and may continue on cediranib alone.
11521009|NCT01208038|Experimental|Testosterone|Testosterone transdermal patch 300micrograms, twice weekly for 12 weeks
11521010|NCT01208025||symptomatic carotid stenosis 30-69%|Patients with neurological symptoms due to ischemia in the carotid artery territory and with a carotid stenosis between 30% and 69% according to the European Carotid Surgery Trial (ECST) criteria.
11521011|NCT01208012|No Intervention|Metformin|Patients taking Metformin at individual dose
11521012|NCT01208012|Experimental|Metformin and Liraglutide|Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks.
11521013|NCT01207999||Group A|Subjects diagnosed with invasive cervical cancer
11521014|NCT01207986|Other|CT screening|CT interpretations and lung biopsies are guided by a suggested workup algorithm, which is not imposed in each HIV-caring centre
11521015|NCT01207973|Experimental|BI 113823|5 dose-groups of multiple oral doses of BI 113823
11521016|NCT01207960|Active Comparator|EMDR|Eye Movement Desensitization and Reprocessing
11521017|NCT01207960|No Intervention|WLC|Wait-list control group. EMDR treatment takes place after 4 weeks of no treatment which represents the wait-list comparison interval.
11521018|NCT01207947||Group 1|
11521019|NCT01207934|Placebo Comparator|placebo|saline placebo for fourteen days
11521020|NCT01207934|Experimental|low-dose leptin|30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
11521021|NCT01207934|Experimental|high-dose leptin|80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
11521022|NCT01207921|Experimental|Arm 1|"Lenalidomide 15 mg/day Cycle 1 (28 days).
~If no unacceptable side effects Cycle 2 (28 days) will be lenalidomide 20 mg/day.
~If no unacceptable side effects Cycles 3 thru 18 (28 days for each cycle) will be lenalidomide 25 mg/day."
11521023|NCT01207908|Experimental|IGF-1|IGF-1 plus standard steroid treatment
11521024|NCT01207908|No Intervention|Standard steroid treatment alone|
11521025|NCT01207895|Experimental|[18F]-FLT PET scans|
11521026|NCT01207869|Experimental|Mesenchymal stem cells|the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
11521027|NCT01207869|Placebo Comparator|Control|Normal saline
11521028|NCT01207856|Active Comparator|group A|specific cognitive rehabilitation
11521029|NCT01207856|Active Comparator|Groupe B : non specific rehabilitation|
11521030|NCT01207856|Other|group C|group C for MRI, neuropsychological and ecological assessments
11521031|NCT01207830|Experimental|Endo Bypass|Subjects implanted with the investigational ValenTx Endo Bypass System
11521032|NCT01207817||no condition|no condition - healthy volunteers
11521033|NCT01207804|Experimental|Device|
11521034|NCT01207791|Other|Minimal screening only (MSO)|Minimal screening
11521035|NCT01207791|Active Comparator|Screening, assessment, and referral (SAR)|
11521036|NCT01207791|Experimental|Brief intervention plus telephone boosters (BI-B)|
11521037|NCT01207778||preterm ESA recipients|infants 500-1250 grams who received erythropoietin (400 units/kg 3x/week) or darbepoetin (10 micrograms/kg 1x/week), from the first week of life through 35 weeks corrected gestation
11521038|NCT01207778||preterm controls|preterm infants 500-1250 grams who received placebo (sham dosing), from first week of life through 35 weeks corrected gestation
11521039|NCT01207778||term controls|Term infants with normal delivery
11521040|NCT01207765|Experimental|Zevalin|1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging on study day +1. 90Y Zevalin will be administered seven to nine days after 111In Zevalin administration. The dose of 90Y Zevalin will be 0.4 mCi/kg, capped at a maximum dose of 32 mCi.
11521041|NCT01207752|Experimental|Systane Balance|Artificial tear emulsion
11521042|NCT01207752|Active Comparator|Optive Lubricant Eye Drops|Artificial tear
11521043|NCT01207739|Active Comparator|Doxycycline|
11521044|NCT01207739|Active Comparator|Clarithromycin and hydroxychloroquine|
11521045|NCT01207739|Placebo Comparator|Placebo|
11521046|NCT01207726|Experimental|Arm I (azacitidine, entinostat)|Patients receive azacitidine SC on days 1-5 and 8-10 and entinostat PO QD on days 3 and 10. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11521047|NCT01207726|No Intervention|Arm II (standard of care)|Patients receive standard of care.
11521048|NCT01207700|Experimental|CHW based intervention post ACS|CHW trained and supervised for intervening upon post ACS patients to improve adherence to evidence based care
11521049|NCT01207700|No Intervention|Standard Care|Patients will be followed upto 12 months without a community health worker intervention as per standard practices of the hospital
11521050|NCT01207687|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes once every 3 weeks. Courses repeat every 6 weeks for up to 48 weeks in the absence of disease progression or unacceptable toxicity.
11521051|NCT01207661|Experimental|Mesenchymal Injection|Intra Articular injection in Patients with osteoarthritis of knee joint
11521052|NCT01207648||Retrospective Cohort|Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events were observed in this retrospective cohort study. In this study, medical records of participants evaluated between 1997 to 2009 were reviewed. The observation period started with the first medical record available on site till last medical record available on site or the end of the observation period (31 December 2009), whichever occurred first.
11521053|NCT01207635||Breast Cancer Patients|
11521054|NCT01207622|Active Comparator|Atomoxetine|
11521055|NCT01207622|Placebo Comparator|Placebo|
11521056|NCT01207609|Experimental|Laparoscopic Gastric Plication|Collect data prospectively on the safety and efficacy of the Laparoscopic Gastric Plication operation for 50 patients with Severe or Morbid Obesity
11521057|NCT01207596|Active Comparator|Hydromorphone|
11521058|NCT01207583||healthy children after vaccination|healthy children after vaccination
11521059|NCT01207570|Experimental|Endermotherapy|The subjects in the experimental group will receive a single session (5 minutes) of endermotherapy) applied to the gastrocnemius/soleus muscle group in the more affected side. The treatment will b e carried out by a qualified physiotherapist.
11521127|NCT01207128|No Intervention|Voriconazole+Micafungin or Voriconazole+Placebo|Voriconazole+Micafungin or Voriconazole+Placebo
11521060|NCT01207570|Active Comparator|Passive stretching|The subjects in this group will receive a single session of passive stretching of the gastrocnemius/soleus muscle for 5 minutes.
11521061|NCT01207557|Active Comparator|Standard education only|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
11521062|NCT01207557|Active Comparator|Standard Education plus OIDA|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials plus the Ottawa Influenza Decision Aid and tested on their confidence with their immunization decision
11521063|NCT01207544|Experimental|fitball program|This group will undergo the fitball program consisting of a supervised exercise session once per week for 8 weeks, supplemented by home exercises. The exercise session will be conducted by a qualified physiotherapist.
11521064|NCT01207544|Active Comparator|Task-oriented program|This group will undergo the task-oriented motor training program consisting of a supervised exercise session once per week for 8 weeks, supplemented by home exercises. The exercise session will be conducted by a qualified physiotherapist.
11521065|NCT01207531||Survival Group|
11521066|NCT01207531||Death group|
11521067|NCT01207518|Experimental|Intervention Group|For the intervention group, there will be a Guide facilitator provided by the project team, normally the Project Manager or their delegate. The role of the Guide facilitator will be to provide basic information about the Guide and to facilitate the use of the web-based tools.
11521068|NCT01207518|Active Comparator|Control Group|The Control Group will be asked to provide immunization rates for the base year and two years of the study, and will be asked about their influenza immunization campaign activities to use as a comparator. They will receive the Guide and web-based tools following completion of the study.
11521069|NCT01207505|Experimental|Enchancing Emotion Regulation|12 week group 3 week modules: 1) Mindfulness 2) Emotion Regulation 3) Distress Tolerance
11521070|NCT01207492|Experimental|Nilotinib|Nilotinib 200 mg taken as 400 mg twice daily, continuously
11521071|NCT01207479|Experimental|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
11521072|NCT01207466|Other|Nelfilcon A invest'l / nelfilconA comm'l|Nelfilcon A investigational toric contact lenses worn first, with nelfilcon A commercial toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week.
11521073|NCT01207466|Other|Nelfilcon A comm'l / nelfilconA invest'l|Nelfilcon A commercial toric contact lenses worn first, with nelfilcon A investigational toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week.
11521074|NCT01207453|Other|Milnacipran then placebo|This arm of the study will contain half the study population after randomization. The participants in this arm will receive milnacipran for 6 weeks. They will undergo a one-week taper and a two week washout period and then crossover to a placebo for 6 weeks.
11521075|NCT01207453|Other|Placebo then milnacipran|"This arm of the study will contain half the study population after randomization. The participants in this arm will receive placebo for 6 weeks. They will undergo a one-week taper and a two week washout period and then crossover to milnacipran for 6 weeks."
11521076|NCT01207440|Experimental|Cohort A: CP-CML R-I|CP-CML participants R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
11521077|NCT01207440|Experimental|Cohort B: CP-CML with T315I Mutation|CP-CML participants who had T315I mutation of breakpoint cluster region-Abelson complex (BCR-ABL) were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
11521078|NCT01207440|Experimental|Cohort C: Accelerated Phase (AP)-CML R-I|AP-CML R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
11521079|NCT01207440|Experimental|Cohort D: AP-CML with T315I Mutation|AP-CML participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
11521080|NCT01207440|Experimental|Cohort E: Blast Phase (BP)-CML/Ph+ ALL R-I|BP-CML or Ph+ ALL R-I to dasatinib or nilotinib or Ph+ ALL R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
11521081|NCT01207440|Experimental|Cohort F: BP-CML or Ph+ ALL with T315I Mutation|BP-CML or Ph+ ALL participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
11521082|NCT01207440|Experimental|Unassigned to Cohorts A-F|Participants who were not assigned to any of the cohorts and have no T315I mutation at study entry and were not R-I to dasatinib or nilotinib, administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
11521083|NCT01207427|Placebo Comparator|Placebo|Each participant received 1 placebo capsule orally twice daily (BID) during the Run-in Placebo Period (1 week), the Double-blind Treatment Period (4 weeks), and the Run-out Placebo Period (1 week).
11521084|NCT01207427|Experimental|ADL5945 0.1 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally BID for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.1-milligrams (mg) ADL5945 capsule orally BID for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally BID for 1 week.
11521085|NCT01207427|Experimental|ADL5945 0.25 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally BID for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.25-mg ADL5945 capsule orally BID for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally BID for 1 week.
11522562|NCT01196884||Asymptomatic ITP patients|
11521086|NCT01207414|Experimental|iloperidone gradual switch|"Participants taking risperidone, olanzapine or aripiprazole gradually decreased the dose they were taking: 50% of original dose on Day 1, 25% of original dose after the first week and the total discontinuation of the drug after the second week.
~On Day 1 participants began taking iloperidone orally twice a day (bid) in the morning and in the evening beginning at a dose of 1 mg and increasing to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg bid on consecutive days over a 7-day period to achieve a total dose of 12-24 mg/day for 12 weeks."
11521087|NCT01207414|Experimental|iloperidone immediate switch|"Participants taking risperidone, olanzapine or aripiprazole discontinued the drug immediately.
~On Day 1 participants began taking iloperidone orally twice a day (bid) in the morning and in the evening beginning at a dose of 1 mg and increasing to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg bid on consecutive days over a 7-day period to achieve a total dose of 12-24 mg/day for 12 weeks."
11521088|NCT01207401|Experimental|Paracervical Block|
11521089|NCT01207401|No Intervention|No Paracervical Block|
11521090|NCT01207388|Experimental|Blinatumomab|Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.
11521091|NCT01207375|Experimental|experimental group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
11521092|NCT01207375|Placebo Comparator|Placebo control group|The placebo control group will receive placebo memory exercises administered on a laptop computer twice a week for five weeks (10 placebo control sessions).
11521093|NCT01207362||Young adult|
11521094|NCT01207362||Older adult|
11521095|NCT01207349||close follow-up by nurse|close follow-up by nurse : patients were visited each tree months
11521096|NCT01207349||standard follow up|stantdard follow up at one year
11521097|NCT01207323|Experimental|Dose Escalation (MEHD7945A)|Participants will receive intravenous (IV) infusion of MEHD7945A in escalating doses Q2W until MTD is reached or up to disease progression as determined by the investigator, intolerable toxicity, withdrawal of consent, or death, whichever occurs first. Approximately 5 dose levels between 1 and 30 mg/kg will be evaluated.
11521098|NCT01207323|Experimental|Dose Expansion (MEHD7945A)|Participants will receive IV infusion of MEHD7945A Q2W at or below the MTD (decided from dose escalation part) up to disease progression as determined by the investigator, intolerable toxicity, withdrawal of consent, or death, whichever occurs first.
11521099|NCT01207310|Experimental|Pager Arm|Participants in the Pager Arm will be provided with alphanumeric pagers and will receive therapeutic messages on these pagers for 3 months in addition to individual smoking cessation counseling and nicotine patches.
11521100|NCT01207310|Active Comparator|Control Arm|Participants in the Control Arm will receive individual smoking cessation counseling and nicotine patches.
11521101|NCT01207297|Active Comparator|TAC group|Oral tacrolimus (0.04-0.08 mg/kg/d) and prednisone for 12 months.
11521102|NCT01207297|Active Comparator|CYC group|Pulse cyclophosphamide (750mg/m2 per month for six months) and prednisone followed by azathioprine (50mg/day）for 6 months.
11521103|NCT01207284|Experimental|Physical Therapy|Foot and ankle passive and active stretching, muscle strengthening, proprioception training and gait training.
11521104|NCT01207284|No Intervention|Control|
11521105|NCT01207271|Experimental|Cognitive Therapy|
11521106|NCT01207271|Experimental|Dynamic Therapy|
11521107|NCT01207258|Experimental|Brief Intervention Group|Participants randomly assigned to this group receive a brief motivational enhancement therapy intervention group and are assessed at baseline, weekly for 12 weeks, and at 3, 6 and 12 months.
11521108|NCT01207258|No Intervention|Assessed Control Group|This group does not receive the intervention and is assessed at baseline, weekly for 12 weeks, and at 3, 6 and 12 months.
11521109|NCT01207258|No Intervention|No Contact Control Group|This group does not receive the intervention and is assessed only at 3 months.
11521110|NCT01207245|Active Comparator|Morning dose of tobramycin|Administration of tobramycin once daily dose in the morning
11521111|NCT01207245|Active Comparator|Evening tobramycin|Evening dose of tobramycin once daily
11521112|NCT01207232|Experimental|Time Plan Condition|A basic reminder mailing prompted each subject to write down a planned date and time for getting their flu shot.
11521113|NCT01207232|Experimental|Date Plan Condition|A basic reminder mailing prompted each subject to write down a planned date for getting their flu shot.
11521114|NCT01207232|Active Comparator|Control Condition|A basic reminder mailing prompted each subject to receive a flu shot.
11521115|NCT01207219|Experimental|Yoga therapy|Hatha yoga including breathing control (10 minutes), body posture(40-45minutes), and relaxation (5 minutes).
11521116|NCT01207219|Experimental|Aerobic exercise|Aerobic exercise includes walking on the treadmill for 15-20 minutes and stationary cycling for 25-30 minutes.
11521117|NCT01207219|No Intervention|Waitlist group|Patients in waiting list will be treated as usual and acted as control group.
11521118|NCT01207193|Experimental|bone cyst|Patients with bone cyst defect are injected with mesenchymal cells.
11521119|NCT01207180|Experimental|Follow-up phone call from Nurse|Patients in this are will receive a phone call follow-up from a nurse 1-3 days after their discharge from the ED.
11521120|NCT01207180|Placebo Comparator|Satisfaction survey|This group of patients will receive a phone call from a student who will conduct a brief satisfaction survey of the patient's experience in the ED.
11521121|NCT01207180|Placebo Comparator|Control group|Patients in this group will receive no phone call at 1-3 days.
11521122|NCT01207154||BIS guidance|Sedation guided according to a predetermined BIS level
11521123|NCT01207154||Clinical sign guided|Sedation guided by clinical signs
11521124|NCT01207141||rATG induction|Liver transplant recipients who receive induction with rATG prior to transplantation.
11521125|NCT01207141||no rATG induction|Liver transplant recipients who do not receive rATG induction therapy prior to transplantation.
11521126|NCT01207128|Active Comparator|Voriconazole, Micafungin|Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV) Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
11521128|NCT01207115|Experimental|ABT-652 high dose|ABT-652 capsules- twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm.
11521129|NCT01207115|Experimental|ABT-652 low dose|ABT-652 capsules - twice daily for 8 weeks. The dose ABT-652 will depend on the Arm
11521130|NCT01207115|Active Comparator|Naproxen|Naproxen capsules- twice daily for 8 weeks
11521131|NCT01207115|Placebo Comparator|Placebo|Placebo capsules- twice daily for 8 weeks
11521132|NCT01207102|Experimental|Abraxane, Carboplatin|Abraxane 100mg/m2 IV days 1, 8 and 15 of a 28 day cycle Carboplatin area under the concentration curve, (AUC)2 IV days 1,8, and 15 of a 28 day Cycle
11521133|NCT01207089|Placebo Comparator|1|
11521134|NCT01207089|Experimental|2|AZD8329
11521135|NCT01207076|Experimental|receiving AHN-12 and 90Y-AHN-12|Patients receiving nonradiolabeled cold AHN-12 (.20 mg/kg to 1.0 mg/kg) of at least one dose and up to a total of 3 dosimetry infusions (intervals no sooner than 8 days and up to 21 days).
11521136|NCT01207063|Experimental|Radiotherapy|
11521137|NCT01207050|Experimental|Rozerem (Ramelteon)|The primary drug of interest is a melatonin agonist for the treatment of insomnia.
11521138|NCT01207050|Placebo Comparator|Sugar pill|Control condition.
11521139|NCT01207037|Other|Intervention|
11521140|NCT01207024||knee MRI|knee MRI for all patients undergoing bariatric surgery as usual care
11521141|NCT01207011|Experimental|1 AMR|
11521142|NCT01207011|Active Comparator|2 DOC|
11521143|NCT01206998|Experimental|Vaginal progesterone gel|
11521144|NCT01206998|Placebo Comparator|Placebo vaginal gel|
11521145|NCT01206972|Experimental|Arm 1|
11521146|NCT01206972|Experimental|Arm 2|
11521147|NCT01206972|Experimental|Arm 3|
11521148|NCT01206972|Active Comparator|Arm 4|
11521149|NCT01206959||monitor method|"blood pressure monitor Cuff circumference:22cm-48cm
~stethoscopy Cuff circumference: 22cm-48cm"
11521150|NCT01206946|Experimental|Antenatal steroids|
11521151|NCT01206946|Placebo Comparator|Normal saline|
11521152|NCT01206933||Detectable HIV RNA and HCV RNA|HIV and HCV co-infected with detectable HIV RNA and HCV RNA
11521153|NCT01206933||Undetectable HIV and Detectable HCV|HIV and HCV infected, HIV RNA Undetectable(treated) and Detectable HCV RNA.
11521154|NCT01206933||Undetectable HIV and HCV|HIV and HCV infected, Undetectable HIV RNA and HCV RNA
11521155|NCT01206933||Undetectable HCV|HCV(mono-infected,) HCV RNA undetectable
11521156|NCT01206933||Detectable HCV RNA|Monoinfected HCV, detectable RNA
11521157|NCT01206933||Detectable HIV RNA|Monoinfected HIV, Detectable RNA
11521158|NCT01206868|Active Comparator|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
11521159|NCT01206868|Sham Comparator|Control|Standard kidney transplantation
11521160|NCT01206855|Active Comparator|SOC Treated Side of Incision|One side of the incision will be treated with surgeon's standard postoperative care including cleansing, creams, dressings
11521161|NCT01206855|Active Comparator|MIST Treated Side of Incision|One half of the incision will receive MIST Therapy treatments 3 times per week for 2 weeks
11521162|NCT01206842|Experimental|social cognition training|
11521163|NCT01206842|No Intervention|treatment as usual|
11521164|NCT01206829|Active Comparator|Audiological rehabilitation|16 hours of psychosocial rehabilitation course
11521165|NCT01206816|Experimental|two experimental arms|patients receive increasing doses of BI 6727 in combination with increasing doses of BIBW 2992
11521166|NCT01206790|Experimental|Narrative Exposure Therapy (NET)|
11521167|NCT01206790|No Intervention|Waitinglist Control Group|
11521168|NCT01206777|Experimental|Rituximab|
11521169|NCT01206764|Experimental|RAD001|
11521170|NCT01206738|Experimental|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
11521171|NCT01206738|Experimental|Alternative intervention|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
11521172|NCT01206738|Active Comparator|General information|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
11521173|NCT01206725|Other|. Moderate Intensity Exercise Group|Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.
11521174|NCT01206725|Other|Aerobic interval training|Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min.
11521175|NCT01206712||T2DM patients treated with LANTUS + MET|T2DM patients treated with LANTUS + Metformin(MET) in their routine antidiabetic therapy. These patients do not receive any study specific medication.
11521176|NCT01206712||T2DM patients treated with SU + MET|T2DM patients treated with Sulfonylurea (SU) + Metformin(MET)in their routine antidiabetic therapy. These patients do not receive any study specific medication.
11521177|NCT01206712||T2DM patients treated with DPP-4 + MET|T2DM patients treated with Dipeptidylpeptidase 4 inhibitors (DPP-4) + Metformin(MET) in their routine antidiabetic therapy. These patients do not receive any study specific medication.
11521178|NCT01206712||Healthy subjects|healthy volunteres who do not receive any antidiabetic medication in their routine therapie.
11521179|NCT01206699|Experimental|corticoid|Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
11521180|NCT01206699|Placebo Comparator|physiological solution|Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
11521181|NCT01206686|Experimental|1 Hour Planning Prompt|
11521182|NCT01206686|Experimental|2 Hour Planning Prompt|
11521183|NCT01206686|Experimental|1 Day Planning Prompt|
11521184|NCT01206686|Experimental|Default Planning Prompt|
11521185|NCT01206686|Active Comparator|Control|
11522563|NCT01196884||ITP patients treated with Rituximab|
11521186|NCT01206660|Experimental|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
11521187|NCT01206660|Placebo Comparator|placebo|Placebo administered to affected area twice a day for 28 days
11521188|NCT01206647|No Intervention|Control arm|The patients randomized to the control arm will continue their current therapy, as individually prescribed. Insulin will be administered via subcutaneous injection and OADs (if applicable) will be administered orally, as individually prescribed.
11521189|NCT01206647|Experimental|Saxagliptin & metformin|Saxagliptin and metformin tablets will be administered orally. Pioglitazione (Rescue medication) tablets will be administered orally. Insulin glargine (Rescue medication) will be administered via subcutaneous injection as individually prescribed.
11521190|NCT01206634|Experimental|Regenerative injection therapy|
11521191|NCT01206634|Active Comparator|Exercise|
11521192|NCT01206621||ED patients presenting with dyspnea|
11521193|NCT01206608|Active Comparator|Low-dose SKY0402 + bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
11521194|NCT01206608|Active Comparator|Mid-dose SKY0402 + bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
11521195|NCT01206595|Active Comparator|SKY0402|Low-dose, low-mid dose, and mid-dose
11521196|NCT01206595|Active Comparator|Bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
11521197|NCT01206582|Active Comparator|Hemin|Panhematin®, Ovation Pharmaceuticals, Deerfield, Illinois (IL). Hemin was diluted in 25% albumin to obtain a concentration of 2.4 mg/mL and administered at a dose of 1.25 mL/Kg and at a rate of 60 mL/hour. 10 iv infusions for 8 weeks
11521198|NCT01206582|Placebo Comparator|Albumin|10 iv infusions for 8 weeks
11521199|NCT01206569|Experimental|advagraf|Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
11521200|NCT01206543|Experimental|Intraoperative imaging|
11521201|NCT01206517|Experimental|Cohort 1|Participants 10 or 11 years of age
11521202|NCT01206517|Experimental|Cohort 2|Participants 10 or 11 years of age
11521203|NCT01206517|Experimental|Cohort 3a-d|"Cohort 3a: Participants 10 or 11 years of age
~Cohort 3b: Participants 12 or 13 years of age
~Cohort 3c: Participants 14 or 15 years of age
~Cohort 3d: Participants 16 or 17 years of age"
11521204|NCT01206478|Experimental|Amitriptyline plus Megestrol|Amitriptyline once daily at bedtime plus megestrol starting at visit 2
11521205|NCT01206478|Active Comparator|Placebo plus Megestrol|Matching placebo once daily at bedtime plus megestrol starting at visit 2
11521206|NCT01206465|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive pralatrexate IV over 5 minutes on day 1 and fluorouracil IV continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11521207|NCT01206452|Experimental|Ablation plus prednisone|Participants undergo ablation procedure and receive predinisone at protocol determined times.
11521208|NCT01206452|Placebo Comparator|Ablation plus placebo|Participants undergo ablation procedure and receive placebo at protocol determined times.
11521209|NCT01206439|Experimental|Nebivolol 5 or 10 mg, oral, daily|Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.
11521210|NCT01206413|Experimental|LGI|Low glycemic index
11521211|NCT01206413|Active Comparator|HGI|High glycemic index
11521212|NCT01206413|Experimental|HB|Home-based exercise
11521213|NCT01206413|Active Comparator|CONTROL|Non-exercisers
11521214|NCT01206400||pioglitazone vs placebo|15 patients in pioglitazone group and 15 in placebo group
11521215|NCT01206387|Experimental|active product|Desoximetasone Spray 0.25%
11521216|NCT01206387|Placebo Comparator|placebo comparator|vehicle
11521217|NCT01206361||fixed dose prostaglandin combination|
11521218|NCT01206348|Experimental|Open Label Combination|Solodyn, Ziana, Triaz FC
11521219|NCT01206335|Experimental|OHR/AVR118|Experimental Drug
11521220|NCT01206322|Experimental|Insulin vs. placebo|Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.
11521221|NCT01206322|Other|Healthy vs. Diabetic|Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.
11521222|NCT01206309||Controls|Never develop an immune mediated disorder
11521223|NCT01206309||Immune Mediated Disorder|Develop an immune mediated disorder
11521224|NCT01206296|Experimental|Intraperitoneal Gemcitabine|Intraperitoneal Gemcitabine
11521225|NCT01206283|Active Comparator|Cerebral perfusion pressure-targeted|15 comatose operated patients after aneurysmal subarachnoid haemorrhage and severe traumatic brain injury respectively were managed postoperatively using cerebral perfusion pressure-targeted therapy according to the American Associations of Neurological Surgeons. Results were categorised into different Glasgow Outcome Scores.
11521226|NCT01206283|Active Comparator|Intracranial pressure-targeted therapy|
11521227|NCT01206270|Experimental|Testosterone|Testosterone undecanoate 1000mg injection at baseline (0-week), 6-week, 18-week, 30-week
11521228|NCT01206270|Placebo Comparator|Placebo|Injection 4 ml of castor oil at baseline (week-0), week-6, week-18, week-30
11521229|NCT01206257||Group 1|
11521230|NCT01206244||Normal|Normal subjects
11521231|NCT01206244||Dry eye|clinically diagnosed dry eye with aqueous tear deficiency
11521232|NCT01206231||1|Patients with hypercholesterolemia
11521233|NCT01206218|Active Comparator|Group A|FLOT Regimen
11521234|NCT01206218|Experimental|Group B|FLO Regimen or FLOT Regimen
11521235|NCT01206205|Experimental|Lenalidomide, Bortezomib|"3 induction cycles of bortezomib, lenalidomide and dexamethasone (VRD) followed by high dose melphalan and autologous stem cell transplantation.
~Two months after haematological recovery, patients will receive 2 consolidation cycles of VRD and maintenance therapy for 1 year with lenalidomide."
11521236|NCT01206192||Abused Chinese women|
11521237|NCT01206179|Experimental|non union|Patients with nonunion fracture of long bones
11521238|NCT01206166|Experimental|Enteral Nutrition + Parenteral Nutrition|Enteral nutrition with the addition of parenteral supplementation (Olimel 5.7%E/N9E).
11521239|NCT01206166|No Intervention|Enteral Nutrition Only|Enteral nutrition only - no intervention
11521240|NCT01206153|Experimental|metformin|
11521241|NCT01206140|Experimental|Arm I (selumetinib and temsirolimus)|Patients receive selumetinib PO twice daily on days 1-28 and temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22.
11521242|NCT01206140|Experimental|Arm II (selumetinib)|Patients receive selumetinib as in arm I. Patients who experience disease progression may cross over to arm I.
11521243|NCT01206127|Other|Postoperative positioning: Bed rest|Patients in this group must be lying down facing up 2 hours postoperatively
11521244|NCT01206127|Other|Postoperative positioning: Sitting up|Patients in this group should be sitting up in a chair 2 hours postoperatively
11521245|NCT01206114||Vaccinated persons|The participants have taken one or more doses of 2009 H1N1 vaccine, either as a monovalent vaccine or as a part of a trivalent seasonal 2010-2011 influenza vaccine
11521246|NCT01206114||Not (yet) vaccinated persons|The participants do not want to take any 2009 H1N1 vaccine or have not received any yet
11521247|NCT01206101|Experimental|Liraglutide|
11521248|NCT01206101|Placebo Comparator|Liraglutide placebo|
11521249|NCT01206088|Experimental|nilotinib|
11521250|NCT01206075|Other|Mozobil + G-CSF - 001|Up to four patients (splenectomized and non-splenectomized) previously mobilized with G-CSF (previous study), who failed to yield by 2 leukaphereses sufficient CD34+ cells for a future gene therapy procedure, will receive the combination of G-CSF+Mozobil
11521251|NCT01206075|Other|Mozobil|Sixteen or more patients (non-splenectomized and splenectomized) who were not previously mobilized will receive Mozobil alone.
11521252|NCT01206075|Other|Mozobil + G-CSF - 002|Patients who, in this study, fail to mobilize sufficient yields of blood stem cells with Mozobil alone will be invited to be re-mobilized with the combination of Mozobil plus G-CSF.
11521253|NCT01206062|Experimental|Intensive Control of SBP|"Participants randomized into the Intensive BP arm will have a goal of SBP <120 mm Hg. 2-drug therapy initiated in most Intensive participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP <120 mm Hg; at periodic milepost visits: addition of another drug required if not at goal."
11521254|NCT01206062|Active Comparator|Standard Control of SBP|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP <130 mm Hg @ 1 visit; <135 mm Hg @ 2 consecutive visits
11521255|NCT01206049|Experimental|Combination chemotherapy + panitumumab|
11521256|NCT01206049|Experimental|Combination chemotherapy + bevacizumab|
11521257|NCT01206023||Multiple Sclerosis|Multiple Sclerosis patients
11521258|NCT01206023||Healthy controls|healthy individuals
11521259|NCT01206010|Experimental|Varenicline + Active Tailored Dose|
11521260|NCT01206010|Placebo Comparator|Varenicline + Placebo Tailored Dose|
11521261|NCT01205997|Active Comparator|fentanyl|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
11521262|NCT01205997|Placebo Comparator|placebo|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
11521263|NCT01205997|Active Comparator|magnesium sulphate|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
11521264|NCT01205984|Active Comparator|oral methylprednisolone|
11521265|NCT01205984|Placebo Comparator|placebo|
11521266|NCT01205971|Experimental|Motivational Interviewing|Motivational Interviewing to reduce caregiver risk factors for early childhood caries in their children is delivered by Dental Health Advocates (trained public housing residents) in combination with fluoride varnish applications, oral health assessments and referrals for children.
11521267|NCT01205971|Active Comparator|Dental Preventive Services|Fluoride varnish applications, written oral health educational materials regarding early childhood caries prevention, oral health assessments and referrals.
11521268|NCT01205958|Active Comparator|medication(Zaltoprofen)|
11521269|NCT01205958|Active Comparator|Acupuncture|
11521270|NCT01205958|Active Comparator|Zalprofen plus Acupuncture|
11521271|NCT01205932|Experimental|Arm 1|
11521272|NCT01205932|Experimental|Arm 2|
11521273|NCT01205932|Experimental|Arm 3|
11521274|NCT01205932|Active Comparator|Arm 4|
11521311|NCT01205607|Experimental|ITPR -5 & then _9 mm HG|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
11521312|NCT01205594|Experimental|ITPR device|the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
11521313|NCT01205581|Active Comparator|Leukemia-HD|Subjects with a diagnosis of leukemia will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
11521275|NCT01205919|Experimental|Internet-based self-help|This self-help training is exclusively provided via Internet over a period of 10 weeks. The treatment is based on the cognitive-behavioral approach and consists of 18 modules with helpful strategies to cope with tinnitus (e.g., applied relaxation, positive imagery, attention shift exercises, cognitive restructuring, sleep management, concentration management,). All modules include an information text, detailed practice instructions, worksheets and homework assignments. At the end of each treatment week, there is an e-mail contact between the participants and their therapist. The participants report on their work with the modules and if they had encountered any problems. The therapist provides feedback, support and recommendations on how to proceed.
11521276|NCT01205919|Active Comparator|Discussion forum group|To the participants of the control group the internet-based self-help after waiting time of 10 weeks is offered. During the waiting period participants receive access to a tinnitus online discussion forum.
11521277|NCT01205906|Experimental|Internet-based guided self-help|This self-help training is exclusively provided via Internet over a period of 10 weeks. The treatment is based on the cognitive-behavioral approach and consists of 18 modules with helpful strategies to cope with tinnitus (e.g., applied relaxation, positive imagery, attention shift exercises, cognitive restructuring, sleep management, concentration management,). All modules include an information text, detailed practice instructions, worksheets and homework assignments. At the end of each treatment week, there is an e-mail contact between the participants and their therapist. The participants report on their work with the modules and if they had encountered any problems. The therapist provides feedback, support and recommendations on how to proceed.
11521278|NCT01205906|Experimental|Cognitive-behavior group therapy|This well-established, cognitive-behavior group therapy was developed by Hiller and Haerkötter (2005) and consists of 10 weekly group sessions of 90 minutes. The strictly manualized program includes the following components focusing on the special needs of chronic tinnitus patients: Education, relaxation techniques, cognitive restructuring, the role of attentional processes for tinnitus perception, analysis of avoidance behaviors, tinnitus and the health care system as well as relapse prevention. For each session participants receive written materials, exercises and homework assignments to enhance understanding and to transfer the new information into the daily routine.
11521279|NCT01205906|Active Comparator|Discussion forum group|To the participants of the control group the group therapy or the internet-based self-help after waiting time of 10 weeks is offered. During the waiting period participants receive access to a tinnitus online discussion forum.
11521280|NCT01205893|Experimental|Reducer|Implant Reducer
11521281|NCT01205893|Sham Comparator|Control|No treatment
11521282|NCT01205880|Active Comparator|vectical ointment and clobex spray|patients were assigned to apply vectical ointment first then clobex spray on one target lesion and also apply clobex spray first then vectical ointment on a different target lesion on the opposite side of the body.
11521283|NCT01205867|Experimental|1|AZD8848 given to BChE deficient subjects and age & gender matched control subjects
11521284|NCT01205854|No Intervention|Conventional clinical and laboratory assessment|
11521285|NCT01205854|Experimental|Conventional assessment plus ultrasonography|
11521286|NCT01205841|Experimental|Adults|Patients from 16 years of age onwards
11521287|NCT01205841|Experimental|Children|Patients aged 5 to 15 years
11521288|NCT01205828|Experimental|Temozolomide and ABT-888 in HCC patients|Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days ABT-888 40 mg BID PO Days 1-7 every 28 days
11521289|NCT01205802|Active Comparator|PTFE group|MHV reconstruction with ringed Goretex
11521290|NCT01205802|Placebo Comparator|Homograft group|MHV reconstruction with homograft
11521291|NCT01205789||Universal Registry|Subjects who are either not eligible for randomization or for other reasons are not randomized will be consented for the Universal Registry
11521292|NCT01205776|Active Comparator|Percutaneous Coronary Intervention|Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
11521293|NCT01205776|Active Comparator|Coronary Artery Bypass Graft|Those patients receiving CABG
11521294|NCT01205750|Experimental|Glucose clamp|
11521295|NCT01205737|Experimental|TL011|
11521296|NCT01205737|Active Comparator|MabThera®|
11521297|NCT01205724|Experimental|A|
11521298|NCT01205724|Experimental|B|
11521299|NCT01205724|Experimental|C|
11521300|NCT01205698|Placebo Comparator|Group 1 - Control A|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
11521301|NCT01205698|Experimental|Group 2 - Experimental A|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
11521302|NCT01205698|Placebo Comparator|Group 3 - Control B|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
11521303|NCT01205698|Experimental|Group 4 - Experimental B|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
11521304|NCT01205685|Experimental|OSI-906 + Erlotinib + Letrozole + Goserelin|"OSI-906 in a pill form, by mouth, twice a day (12 hours a part)
~Erlotinib in a pill form, by mouth, once a day
~Letrozole in a pill form, by mouth, once a day
~Goserelin, by injection once per month for women who are pre-menopausal"
11521305|NCT01205672|Experimental|Metformin|Metformin 850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
11521306|NCT01205646|Experimental|Zometa & PET Scans|Zoledronate therapy & PET scan ;2 scans [about 1-2 weeks apart] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility, Bone scan (within 4 weeks prior to registration), bone turnover markers, and PSA will be obtained pretherapy. After that, Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration.
11521307|NCT01205633||CNS draining vein abnormalities|
11521308|NCT01205620|Experimental|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
11521309|NCT01205620|No Intervention|No intervention|No intervention will be performed in this control group
11521310|NCT01205607|Experimental|ITPR -9 & then -5 mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
11521443|NCT01204762|Experimental|Part B: pegIFN lambda + Entecavir|
11522564|NCT01196884||ITP patients treated with steroids|
11521314|NCT01205581|Active Comparator|Leukemia-SD|Subjects with a diagnosis of leukemia will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
11521315|NCT01205581|Active Comparator|Solid Tumor-HD|Subjects with a diagnosis of solid tumor will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
11521316|NCT01205581|Active Comparator|Solid Tumor-SD|Subjects with a diagnosis of solid tumor will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
11521317|NCT01205581|Active Comparator|HIV-HD|Subjects with a diagnosis of human immunodeficiency virus (HIV) will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
11521318|NCT01205581|Active Comparator|HIV-SD|Subjects with a diagnosis of human immunodeficiency virus (HIV) will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
11521319|NCT01205568|Experimental|Patients with Resistant Pulmonary Artery Stenosis|Vessels with resistant PA stenosis were identified during catheterization and eligible vessels were randomized to Cutting Balloon or High Pressure Balloon Dilation
11521320|NCT01205555|No Intervention|ultrasound alone group|Patients in the control group will have a standard ultrasound monitoring with HCG administered when the leading follicle reaches 18 mm, and IUI 36 h afterward.
11521321|NCT01205555|Experimental|LH testing combined with ultrasound monitoring|
11521322|NCT01205542|Experimental|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
11521323|NCT01205542|Active Comparator|Reference|Health check and advice to continue ordinary physical activity
11521324|NCT01205529|Other|AF with ST changes on ECG|Those patients with ST segment or J Point elevation on electrocardiogram. Can be on initial screening electrocardiogram or on electrocardiograms during procainamide infusion. These subjects will harbor cardiac sodium channel gene variants.
11521325|NCT01205516|Experimental|Methadone|
11521326|NCT01205516|Active Comparator|Controlled Release Morphine|Controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
11521327|NCT01205503|Other|Cycle 1 Saline; Cycle 2 Mesna|Saline infused over 15 minutes administered prior to and 3 hours post doxorubicin infusion (over 15 minutes) with following Cyclophosphamide 6 hours post doxorubicin during 1st cycle, then Mesna administered (infused over 15 minutes, 360 mg/m2) prior to and 3 hours post doxorubicin infusion with following Cyclophosphamide 6 hours post doxorubicin during 2nd cycle
11521328|NCT01205503|Other|Cycle 1 Mesna; Cycle 2 Saline|Mesna administered (infused over 15 minutes, 360 mg/m2) prior to and 3 hours post doxorubicin infusion with following Cyclophosphamide 6 hours post doxorubicin during 1st cycle, then Saline administered prior to and 3 hours post doxorubicin infusion (over 15 minutes) with following Cyclophosphamide 6 hours post doxorubicin during 2nd cycle
11521329|NCT01205477|Experimental|Methylprednisolone|Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine
11521330|NCT01205477|Placebo Comparator|Placebo|Infiltration of 1 mL of xylocaine
11521331|NCT01205464|Active Comparator|Doxycycline|Treatment with Capsule Doxycycline 200 mg, once daily, for 21 days.
11521332|NCT01205464|Placebo Comparator|Sugar pill|Capsule Placebo, 200 mg, once daily, for 21 days.
11521333|NCT01205451|Experimental|BTX-A|Botulinum toxin type A
11521334|NCT01205438|Experimental|LY2127399 every 2 weeks|
11521335|NCT01205438|Experimental|LY2127399 every 4 weeks|During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
11521336|NCT01205438|Placebo Comparator|Placebo|
11521337|NCT01205425|Experimental|CT|Procedure of stent implantation will be planed on the basis of both angiography and computed tomography results.
11521338|NCT01205425|Active Comparator|Angio|Procedure of stent implantation will be planned only on the basis of diagnostic coronary angiography.
11521339|NCT01205412||Assessed Cohort|Subjects attending out-patient health services for routine cervical screening or presenting for post-natal check up
11521340|NCT01205399||AlloMax Surgical Graft Group|
11521341|NCT01205386||CROSSER|
11521342|NCT01205373|Experimental|BI 671800 high dose|Oral drinking solution
11521343|NCT01205360|Active Comparator|Bupivacaine-Fentanyl (3-15)|Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.
11521344|NCT01205360|Experimental|Bupivacaine-Fentanyl (4-20)|Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
11521345|NCT01205360|Experimental|Bupivacaine-Fentanyl (6-30)|Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
11521346|NCT01205347|Experimental|Simvastatin 80mg|Simvastatin 80mg once a day
11521347|NCT01205347|Active Comparator|Simvastatin 10mg|Simvastatin 10mg once a day
11521348|NCT01205334|Experimental|Autologous CMV-specific CTL|"The patient will receive one of the following doses:
~1.5x10^7 cells/m2
~4.5x10^7 cells/m2
~1.5x10^8 cells/m2"
11521349|NCT01205321|Experimental|Arm 1|
11521350|NCT01205321|Experimental|Arm 2|
11521351|NCT01205308|Active Comparator|Stanol ester spread|Vegetable oil based margarine with stanol ester enrichment
11521352|NCT01205308|Placebo Comparator|control spread|Vegetable oil based margarine without stanol ester enrichment
11521353|NCT01205295||Mental disorders|Preoperative and postoperative screening of mental disorders and efficacy of treatment in hip and shoulder patient.
11521354|NCT01205282|Experimental|Pioglitazone|A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). There will be 14 weeks of active treatment.
11521355|NCT01205282|Placebo Comparator|Placebo|
11521356|NCT01205269|Experimental|First 50 mcg, then 200 mcg, then placebo|period 1: AZD8683 50 mcg, period 2: washout, period 3: AZD8683 200 mcg, period 4:washout, period5: placebo
11521357|NCT01205269|Experimental|First 50 mcg, then placebo, then 200 mcg|period 1: AZD8683 50 mcg, period 2: washout, period 3: placebo, period 4: washout, period5:AZD8683 200 mcg
11521358|NCT01205269|Experimental|First 200 mcg, then placebo, then 50 mcg|period 1: AZD8683 200 mcg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD8683 50 mcg
11521359|NCT01205269|Experimental|First 200 mcg, then 50 mcg, then placebo|period 1: AZD8683 200 mcg, period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period 5: placebo
11521360|NCT01205269|Experimental|First placebo, then 200 mcg, then 50 mcg|period 1: placebo , period 2: washout, period 3: AZD8683 200 mcg, period 4: washout, period5: AZD8683 50 mcg
11521361|NCT01205269|Experimental|First placebo, then 50 mcg, then 200 mcg|period 1: placebo , period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period5: AZD8683 200 mcg
11521362|NCT01205256|Experimental|Methadone|0.25mg/kg IV of racemic methadone at the induction of anesthesia.
11521363|NCT01205243||ZIAGEN®|Patients administrated ZIAGEN® at the site
11521364|NCT01205230|Experimental|Pazonib+ketoconazole|Administration of oral pazopanib 400mg (2 200-mg tablets) once-daily each morning for at least 7 consecutive doses during Period 1. Then administration of oral ketoconazole 400 mg (2 - 200 mg tablets) followed immediately by pazopanib 400 mg (2 -200 mg tablets) once-daily each morning for a total of 5 consecutive doses during Period 2.
11521365|NCT01205230|Experimental|Pazonib+esomeprazole|Subjects will receive orally administered pazopanib 800mg (4 - 200mg tablets) once-daily each morning for at least 7 consecutive doses in Period 1. In the evening on the last day of Period 1, subjects will take their initial dose of esomeprazole 40 mg (1 - 40 mg capsule) approximately 3 hours after the evening meal. Subjects will continue to receive pazopanib (each morning) and esomeprazole each evening once-daily for a total of 5 consecutive doses.
11521366|NCT01205217|Experimental|Arm A|"Lapatinib in combination with epirubicin and cyclophosphamide followed by paclitaxel and lapatinib.
~Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days Lapatinib 1000 mg orally once daily continuously Loperamide as required for the proactive management of diarrhoea
~Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week Lapatinib 1000 mg orally once daily continuously Loperamide as required for the proactive management of diarrhoea"
11521367|NCT01205217|Active Comparator|Arm B|"Epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab.
~Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days
~Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week"
11521368|NCT01205204|Active Comparator|BF25 (Control)|GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
11521369|NCT01205204|Experimental|BC15(Study 1)|GROUP BC15 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
11521370|NCT01205204|Experimental|BC30(Study 2)|GROUP BC30 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
11521371|NCT01205204|Experimental|BC60 (Study 3)|GROUP BC60 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
11521372|NCT01205191|Experimental|CBT-ubiquitous|
11521373|NCT01205191|Placebo Comparator|CBT-placebo|Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management
11521374|NCT01205191|Active Comparator|CBT-TAU|Cognitive behavioural Therapy provided 'As Usual'
11521375|NCT01205178|Active Comparator|Tafenoquine|Tafenoquine, TQ is an 8-aminoquinoline (8-AQ) antimalarial drug being developed for the radical cure of acute P. vivax malaria. Chloroquine will be given for the first 3 days in second and third part of this study to treat Malaria.
11521376|NCT01205178|Active Comparator|Chloroquine|Dose for first 3 days for Part B & C of the study
11521377|NCT01205178|Active Comparator|Primaquine|once daily for first 14 days
11521378|NCT01205165|Experimental|Adefovir Dipivoxil 10mg|All enrolled subject were enrolled to adefovir dipivoxil 10mg arm.
11521379|NCT01205152|Experimental|asfotase alfa|An initial single intravenous (IV) infusion of 2 mg/kg asfotase alfa, followed by subcutaneous (SC) injections of 1 mg/kg asfotase alfa 3 times per week
11521380|NCT01205139|Experimental|001|TMC435 150 mg capsule once daily for 11 days
11521381|NCT01205139|Experimental|002|TMC278 25 mg tablet once daily for 11 days
11521382|NCT01205139|Experimental|003|TMC435 + TMC278 150 mg TMC435 capsule + 25 mg TMC278 tablet once daily for 11 days
11521383|NCT01205139|Experimental|004|TMC435 150 mg capsule once daily for 7 days
11521384|NCT01205139|Experimental|005|TDF 300 mg tablet once daily for 7 days
11521385|NCT01205139|Experimental|006|TMC435 + TDF 150 mg TMC435 capsule + 300 mg TDF tablet once daily for 7 days
11521386|NCT01205126|Experimental|OROS Hydromorphone hydrochloride (HCl)|OROS Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of titrationphase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
11521387|NCT01205126|Active Comparator|Oxycodone HCl Controlled release (CR)|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titrationphase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
11521388|NCT01205100|Active Comparator|Biofeedback|Patients will be taught to control abdominal and diaphragmatic muscles by bio-feedback using EMG recordings.
11521389|NCT01205100|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patients will take a pill of placebo.
11521390|NCT01205087|Placebo Comparator|Placebo|
11521391|NCT01205087|Active Comparator|OKT3 - 0.2|
11521392|NCT01205087|Active Comparator|OKT3 - 1|
11521393|NCT01205087|Active Comparator|OKT3 - 5|
11521394|NCT01205074|Experimental|Repeatability|
11521395|NCT01205074|Experimental|COPD|
11521396|NCT01205074|Experimental|Smokers|
11521397|NCT01205074|Experimental|CYP450 1A2 Inhibitors|
11521398|NCT01205074|Experimental|Cirrhosis Beta Blockers|
11521399|NCT01205074|Experimental|Alcohol|
11521400|NCT01205061|Experimental|Emervel Deep Lidocaine|Emervel Deep Lidocaine injected into left nasolabial fold. Juvederm® Ultra Plus injected into right nasolabial fold.
11521401|NCT01205061|Active Comparator|Juvederm® Ultra Plus|Juvederm® Ultra Plus injected into left nasolabial fold. Emervel Deep Lidocaine injected into the right nasolabial fold.
11521444|NCT01204749|Experimental|AMG 386|Arm A: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 15mg/kg IV QW
11521402|NCT01205048|Experimental|Emervel Classic Lidocaine|Emervel Classic Lidocaine injected into left nasolabial fold. Juvederm® Ultra injected into right nasolabial fold.
11521403|NCT01205048|Active Comparator|Juvederm® Ultra|Juvederm® Ultra injected into left nasolabial fold. Emervel Classic Lidocaine injected into right nasolabial fold.
11521404|NCT01205035|No Intervention|Observation|Observation; No treatment given
11521405|NCT01205035|Experimental|Intravitreal ranibizumab 2.0mg|Initial dose 2.0mg switched to 1.0mg at near conclusion of study.
11521406|NCT01205022|Experimental|Arm I|Patients receive irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes once every 2 weeks. Patients also receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV over 25 minutes once in weeks 3 and 9.Treatment continues in the absence of disease progression or unacceptable toxicity.
11521407|NCT01205009|Active Comparator|Ovitrelle supplemantation|The women will be given 250 mcg of Ovitrelle prior to their IVF cycle
11521408|NCT01205009|No Intervention|no Ovitrelle supplementation|
11521409|NCT01204996|Experimental|1|CNTO888 + docetaxel 15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
11521410|NCT01204996|Experimental|2|CNTO888 + gemcitabine 15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
11521411|NCT01204996|Experimental|3|CNTO888 + Paclitaxel and carboplatin 15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
11521412|NCT01204996|Experimental|4|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection 10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
11521413|NCT01204983||Observational|"This is a quality improvement project to evaluate the current standard of care of nutritional management for very low birth weight infants receiving donor human milk products in the NICU at Texas Children's Hospital.
~There is no randomization, there are no control subjects, and therefore there is no probability of group assignment."
11521414|NCT01204970||COPD|COPD Gold class 1-4
11521415|NCT01204970||Transplant|Lung transplant recipients
11521416|NCT01204970||Control|Patients with normal spirometric data
11521417|NCT01204957|Experimental|Arm 1 Seaweed and Soy Protein|Arm 1 5 g/d Seaweed for 6 wk, then 5 g/d Seaweed and Soy Protein for 1 wk
11521418|NCT01204957|Experimental|Arm 2 Placebo and soy protein|Arm 2 5 g/d Placebo for 6 wk, then 5 g/d Placebo and Soy Protein for 1 wk
11521419|NCT01204931||Gastroesophageal Reflux Disease (GERD) Cases|"Erosive disease - presence of esophageal mucosal injuries documented endoscopically.
~Non-erosive disease - normal esophagogastroduodenoscopy with symptoms"
11521420|NCT01204931||Control Group|normal subjects without symptoms of gastroesophageal reflux disease (GERD)
11521421|NCT01204918|Experimental|Riluzole addition to SSRI antidepressant|Riluzole 100mg added to ongoing SSRI or SNRI antidepressant for 8 weeks
11521422|NCT01204918|Placebo Comparator|Placebo addition to standard SSRI antidepressant|Placebo will be added to ongoing SSRI or SNRI antidepressant treatment for 8 weeks
11521423|NCT01204918|Experimental|Riluzole/Placebo addition to SSRI antidepressant|Riluzole 100mg added to ongoing SSRI or SNRI antidepressant for 4 weeks and placebo will added to ongoing SSRI or SNRI antidepressant treatment for 4 weeks
11521424|NCT01204905|Experimental|Open Label ART|Patients received raltegravir 400 mg PO BID and maraviroc 300 mg PO BID in combination for 48 weeks.
11521425|NCT01204892|Active Comparator|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
11521426|NCT01204892|Active Comparator|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
11521427|NCT01204879|Active Comparator|CM for general activities|Standard care plus individual contingency management session for general activities
11521428|NCT01204879|Experimental|CM for exercise-related activities|Standard care plus individual contingency management session for physical activities
11521429|NCT01204866|Experimental|Stage I|Three (3) healthy male or female volunteers aged 18-59 years, not previously exposed to Valortim and who do not have pre-existing allergies
11521430|NCT01204866|Experimental|Stage II|Up to 4 healthy male or female volunteers aged 18-59 previously exposed to intravenous (IV) Valortim in PharmAthene Study #0036-08-05
11521431|NCT01204853|Experimental|Sitaxentan treatment|
11521432|NCT01204840|Active Comparator|Group A - Control group|"Group A (n=10; control group) will receive the patch protocol consisting of the 100ug estrogen patch (Estradot), a Gonadotropin Releasing Hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), and gonadotropin stimulation with 412 IU of recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris)."
11521433|NCT01204840|Experimental|Group B - treatment group|"Group B will consist of 30 subjects. In addition to the same hormone stimulation patch protocol as Group A, subjects will be treated with growth hormone 10 IU (3.33mg) per day by subcutaneous injection starting day 1 of the last menstrual period in the month prior to gonadotropin stimulation, and will continue daily until the day of human chorionic gonadotropin (hCG) injection."
11521434|NCT01204827|Experimental|CHBV Sebivo|
11521435|NCT01204801|Experimental|Thermochemotherapy|Preoperative Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy.
11521436|NCT01204801|Active Comparator|Chemotherapy (control)|Preoperative Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs
11521437|NCT01204788|Experimental|Arm 1 (Prophylactic Arm)|Prophylactic Treatment (standard of care prophylactic antibiotics) + Prophylactic White Cell Transfusion
11521438|NCT01204788|Experimental|Arm 2 (Therapeutic Arm)|Prophylactic Treatment (standard of care prophylactic antibiotics) + Therapeutic White Cell Transfusion
11521439|NCT01204775|Experimental|Saxagliptin|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
11521440|NCT01204775|Placebo Comparator|Placebo|Placebo matching saxagliptin tablet
11521441|NCT01204762|Experimental|Part A Arm 1: pegIFN (180 μg)|
11521442|NCT01204762|Active Comparator|Part A Arm 2: pegIFNα-2a|
11521445|NCT01204749|Placebo Comparator|AMG 386 Placebo|Arm B: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 Placebo IV QW
11521446|NCT01204736||Group 1|Subjects with posterior deltoid-to-triceps tendon transfers
11521447|NCT01204736||Group 2|Subjects with biceps-to-triceps tendon transfers
11521448|NCT01204736||Group 3|Subjects with cervical SCI who have not had tendon transfers
11521449|NCT01204736||Group 4|Unimpaired control subjects
11521450|NCT01204723|Experimental|Behavioral Condition 1|Nicotine patch (21 mg) plus placebo oral cannabis (0 mg; 3 times a day on days 2-4, given once on day 5)
11521451|NCT01204723|Experimental|Behavioral Condition 2|Placebo nicotine patch (0 mg) plus oral cannabis (10 mg, 3 times each day, days 2-4, day 5 given once)
11521452|NCT01204723|Experimental|Behavioral Condition 3|Placebo nicotine patch (0 mg) plus placebo oral cannabis (0 mg, 3 times each day days 2-4, day 5 given once)
11521453|NCT01204710|Experimental|Olaratumab + Mitoxantrone|1 cycle = 3 weeks (21 days)
11521454|NCT01204710|Active Comparator|Mitoxantrone: Optional Olaratumab Monotherapy|"1 cycle = 3 weeks (21 days)
~Participants who experience progressive disease (PD) have the option to receive olaratumab monotherapy treatment."
11521455|NCT01204697|Experimental|A|
11521456|NCT01204697|Experimental|B|
11521457|NCT01204684|Experimental|Tumor Lysate-pulsed DC vaccination|Cohort #1 will receive autologous tumor lysate-pulsed DC vaccination together with a placebo cream or intramuscular injection of saline.
11521458|NCT01204684|Experimental|Tumor lysate-pulsed DC vaccination+0.2% resiquimod.|Cohort #2 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant 0.2% resiquimod.
11521459|NCT01204684|Experimental|Tumor-lysate pulsed DC vaccination +adjuvant polyICLC.|Cohort #3 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant poly ICLC (TLR3 agonist).
11521460|NCT01204671|Experimental|GSK2321138A Lot 1 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
11521461|NCT01204671|Experimental|GSK2321138A Lot 2 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
11521462|NCT01204671|Experimental|GSK2321138A Lot 3 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
11521463|NCT01204671|Active Comparator|Fluarix Group|Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
11521464|NCT01204671|Active Comparator|GSK2604409A Group|Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
11521465|NCT01204658|Experimental|10PP-LD/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of the GSK 2189242A (or 10PP) vaccine combined with low doses (LD) of pneumococcal pneumolysin toxoid proteins (dPly) and pneumococcal histidine protein D (PhtD) co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of the 10PP and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for the 10PP vaccine and on the right side for Infanrix hexa™.
11521466|NCT01204658|Experimental|10PP-HD/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of the GSK 2189242A (or 10PP) vaccine combined with high doses (HD) of pneumococcal pneumolysin toxoid proteins (dPly) and pneumococcal histidine protein D (PhtD), co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of the 10PP and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for the 10PP vaccine and on the right side for Infanrix hexa™.
11521467|NCT01204658|Active Comparator|Synflorix/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of Synflorix™ vaccine, co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of Synflorix™ and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for Synflorix™ and on the right side for Infanrix hexa™.
11521468|NCT01204658|Active Comparator|Prevnar 13/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of Prevnar 13™ vaccine, co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of Prevnar 13™ and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for Prevnar 13™ and on the right side for Infanrix hexa™.
11521469|NCT01204645||Acute Coronary Syndrome (ACS)|Continuous inclusion at emergency hospitals of patients with acute coronary syndrome (according to ESC/AHA definitions)
11521470|NCT01204645||Follow up|Patients included at 6 or 12 months follow-up visit after an acute coronary event.
11521471|NCT01204645||Coronary|Patients included when undergoing an coronary angiography for suspected or confirmed coronary heart disease
11521472|NCT01204619|No Intervention|Conventional training group|in-center conventional training programs + two home visits
11521473|NCT01204619|Experimental|Intensive training group|in-center conventional training programs + an extra structured patient home visits repeatedly and regularly
11521474|NCT01204606|Experimental|MMA group|
11521475|NCT01204606|Placebo Comparator|Control group|
11522565|NCT01196871|Experimental|Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg)|
11521476|NCT01204593|Experimental|Insulin glargine + insulin glulisine|"Insulin glargine dosage will be individually titrated once a week to obtain FPG 80-120 mg/dL (4.5-6.7 mmol/L).
~Insulin glulisine dosage will be individually titrated once a week to obtain a 2-hour postprandial plasma glucose (PPG) < 180 mg/dL (<10.0 mmol/L) and ideally around 140 mg/dL."
11521477|NCT01204580|Experimental|Amaryl-M (Glimepiride + Metformin)|"Glimepiride 1 mg and metformin 250 mg are the active ingredients of Amaryl-M 1/250 mg film coated tablets.
~Starting dosage is 1 tablet per day, then dosage titration will be based on the result of patient FBG test."
11521478|NCT01204567|Active Comparator|Training follow-up after discharge|Aerobic training Home-program
11521479|NCT01204541||AMD|
11521480|NCT01204541||Young normals|
11521481|NCT01204541||Older normals|
11521482|NCT01204528|Active Comparator|Paricalcitol 2 microgram/d|
11521483|NCT01204528|Active Comparator|Paricalcitol 1 microgram/d|
11521484|NCT01204528|Placebo Comparator|Placebo|
11521485|NCT01204515||Girls with IBS|Girls ages 7-12 years who meet Rome III criteria for IBS
11521486|NCT01204515||Healthy Girls (controls)|Girls ages 7-12 years who are otherwise healthy and have no complaints of stomach pain
11521487|NCT01204502|Experimental|HSVTK retrovirally-transduced donor T lymphocytes|"HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD
~dose 1 5x104 cells/kg
~dose 2 5x105 cells/kg"
11521488|NCT01204489|Experimental|Intensified dietary counseling|The dietary intervention consists of tailored dietary counseling, information leaflets and self-evaluation cards given to the families.
11521489|NCT01204489|Active Comparator|Normal dietary counseling|Public health nurses continue their usual dietary counseling.
11521490|NCT01204476|Experimental|Treatment (cixutumumab, octreotide acetate, everolimus)|Patients receive cixutumumab IV over 60-90 minutes and octreotide acetate IM on day 1 and everolimus PO QD on days 1-21. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
11521491|NCT01204450|Other|Single Arm Temsirolimus + Valproic Acid|"Drug: temsirolimus 60-230mg/m2 weekly during each 28 day course, for up to 12 courses
~Drug: valproic acid (VPA) All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses"
11521492|NCT01204437|Active Comparator|EC standard chemotherapy 4 cycles|
11521493|NCT01204437|Active Comparator|CMF standard chemotherapy 6 cycles|
11521494|NCT01204437|Experimental|Nab-Paclitaxel + Capecitabine 6 cycles|6 cycles of weekly nab-Paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
11521495|NCT01204398|Experimental|eligible hypertension patient|Patients will be given placebo for 2 weeks for wash-out, then qualified patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
11521496|NCT01204385||Study Group|
11521497|NCT01204372|Experimental|Treatment|Gemcitabine - Trastuzumab - Erlotinib
11521498|NCT01204359|No Intervention|follow-up|
11521499|NCT01204346|Experimental|MBT group|mentalization based treatment program
11521500|NCT01204346|Active Comparator|Treatment as usual group|treatment as usual group
11521501|NCT01204333|Experimental|Endovascular thrombolysis|
11521502|NCT01204333|Active Comparator|Standard treatment|
11521503|NCT01204320|Experimental|Paclitaxel-coated Balloon|Paclitaxel-coated Balloon Angioplasty
11521504|NCT01204320|Active Comparator|Paclitaxel-eluting Stent|Paclitaxel-eluting Stent Implantation
11521505|NCT01204307|Experimental|docetaxel/cisplatin|The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
11521506|NCT01204307|Active Comparator|Pemetrexed/cisplatin|The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
11521507|NCT01204294|Experimental|Bigu+Lina|biguanide plus linagliptin
11521508|NCT01204294|Experimental|Glin+Lina|glinide plus linagliptin
11521509|NCT01204294|Experimental|Glit+Lina|glitazone plus linagliptin
11521510|NCT01204294|Experimental|SU+Lina|sulfonylurea plus linagliptin
11521511|NCT01204294|Experimental|A-GI+Lina|alpha-glucosidase inhibitor plus linagliptin
11521512|NCT01204294|Active Comparator|SU+Met|sulfonylurea plus metformin
11521513|NCT01204294|Active Comparator|A-GI+Met|alpha-glucosidase inhibitor plus metformin
11521514|NCT01204281|Experimental|High assistance PAV+|Ventilatory support performed by PAV at 80% assistance (PB 840-plus) FiO2 and PEEP according to routine practice
11521515|NCT01204281|Active Comparator|Assist-control ventilation|Tidal volume, FiO2 and PEEP set according to routine practice
11521516|NCT01204268|No Intervention|Propofol group|Patients will receive the total intravenous anesthesia with propofol infusion during the surgery.
11521517|NCT01204268|Active Comparator|Sevo-C group|Patients will receive the anesthesia with continuous inhalation of sevoflurane.
11521518|NCT01204268|Experimental|Sevo-I group|Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.
11521519|NCT01204255|Experimental|Arm I|Patients apply lorazepam, diphenhydramine hydrochloride, and haloperidol gel topically over 2 minutes.
11521520|NCT01204242|Placebo Comparator|Placebo|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.
~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
11521603|NCT01203644|Active Comparator|Bupivacaine HCl|(e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
11521521|NCT01204242|Experimental|Lidocaine|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.
~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
11521522|NCT01204229|Experimental|MCID|
11521523|NCT01204229|Experimental|BMI|
11521524|NCT01204216|Active Comparator|Aim 1|Subjects in this arm will be 10 people without diabetes as well as 10 people with diabetes and stable glycemic control. Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
11521525|NCT01204216|Active Comparator|Aim 2|For Aim 2, 10 additional subjects with diabetes in poor glycemic control will be studied initially and then again in improved glycemic control after at least 8 months (with up to 5 additional subjects entered as needed to ensure 10 completed paired studies) to assess the potential role of MRBC variation in the discordances seen between HbA1c and blood glucose testing. Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
11521526|NCT01204203|Experimental|Zometa|Zometa (zoledronic acid) will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles. This will continue until progression of disease and/or intolerable toxicity.
11521527|NCT01204190|Experimental|Arm 1|
11521528|NCT01204190|Experimental|Arm 2|
11521529|NCT01204190|Experimental|Arm 3|
11521530|NCT01204177|Experimental|Arm 1|
11521531|NCT01204164|Experimental|TG02 in AL|Single agent TG02 citrate in acute leukemia patients
11521532|NCT01204164|Experimental|TG02 in MM|Single Agent TG02 citrate in multiple myeloma patients
11521533|NCT01204164|Experimental|TG02 + CFZ in MM|TG02 in combination with carfilzomib and dexamethasone in multiple myeloma patients
11521534|NCT01204164|Experimental|TG02 + CFZ + DEX in CFZ refractory MM|TG02 in combination with carfilzomib and dexamethasone in carfilzomib refractory multiple myeloma patients
11521535|NCT01204151|Experimental|Math intervention|
11521536|NCT01204138|Placebo Comparator|placebo|Patient randomized to one of two arms, either placebo, or Apremilast
11521537|NCT01204138|Active Comparator|Apremilast|Patients randomized to either placebo or apremilast
11521538|NCT01204125|Experimental|SAR240550 twice weekly/ paclitaxel weekly|SAR240550 will be administered at the dose of 5.6mg/kg as a 60-min intravenous (IV) infusion. Patients will receive SAR240550 infusions twice weekly (day 1 and day 4; total dose of 11.2mg/kg per week) and paclitaxel weekly as a 60-min IV infusion (day 1; dose of 80mg/m2).
11521539|NCT01204125|Experimental|SAR240550 weekly/ paclitaxel weekly|SAR240550 will be administered at the dose of 11.2 mg/kg as a 60-min intravenous (IV) infusion. Patients will receive SAR240550 infusions once weekly (day 1; total dose of 11.2mg/kg per week) and paclitaxel weekly as a 60-min IV infusion (day 1; dose of 80mg/m2).
11521540|NCT01204125|Active Comparator|Paclitaxel alone|Paclitaxel will be administered at the dose of 80mg/m2 as a 60-min IV infusion. Patients will receive weekly (day 1) paclitaxel infusions.
11521541|NCT01204112|Experimental|Tasocitinib (CP-690,550) plus Rifampin|
11521542|NCT01204099|Active Comparator|Docetaxel (NSCLC)|IV docetaxel administered once every three weeks as per standard of care. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
11521543|NCT01204099|Experimental|PX-866 (NSCLC)|Oral PX-866 administered daily at the RD in combination with IV docetaxel administered once every three weeks on a 21 day cycle. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
11521544|NCT01204099|Active Comparator|Docetaxel (SCCHN)|IV docetaxel administered once every three weeks as per standard of care. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
11521545|NCT01204099|Experimental|PX-866 (SCCHN)|Oral PX-866, administered daily at the RD in combination with IV docetaxel administered once every three weeks on a 21 day cycle. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
11521546|NCT01204086|Experimental|venlafaxine|
11521547|NCT01204086|Experimental|fluoxetine|
11521548|NCT01204073|Experimental|TAK-441|
11521549|NCT01204060|Active Comparator|Nasal allergen challenge|
11521550|NCT01204060|Placebo Comparator|Nasal placebo challenge|
11521551|NCT01204034|Other|Inuvair|
11521552|NCT01204021|Experimental|Tai Chi Chih|12 weeks of physical exercise in the form of Tai Chi Chih
11521553|NCT01204021|Active Comparator|Stress Education Control|Stress management education
11521554|NCT01204008|Experimental|CS|conservative discectomy
11521555|NCT01204008|Active Comparator|AS|
11521556|NCT01203995|No Intervention|Usual Care|
11521557|NCT01203995|Experimental|brief nutrition education|
11521558|NCT01203995|Active Comparator|In Center training|
11521559|NCT01203995|Experimental|Video Conference training|
11521560|NCT01203982|Active Comparator|Rosuvastatin 5mg|Rosuvastatin 5mg/day
11521561|NCT01203982|Active Comparator|Rosuvastatin 40mg|Rosuvastatin 40mg/day
11521562|NCT01203969|Experimental|Single port laparoscopic surgery|
11521563|NCT01203969|Active Comparator|Conventional laparoscopic surgery|
11521564|NCT01203956|Experimental|SmartFlex|Use Continuous Airway Pressure device with SmartFlex engaged
11521565|NCT01203956|Active Comparator|Standard|Use Continuous Airway Pressure device without SmartFlex engaged
11521566|NCT01203943|Experimental|Cohort 1|• Cohort 1: CC-930 50 mg PO daily (two 25 mg capsules once per day PO) beginning on Day 1 in the AM.
11521567|NCT01203943|Experimental|Cohort 2|• Cohort 2: CC-930 100 mg PO daily (one 100 mg capsule once per day PO) beginning on Day 1 in the AM
11521568|NCT01203943|Experimental|Cohort 3|• Cohort 3: CC-930 100 mg twice daily approximately 12 hours apart (one 100 mg capsule twice per day PO) beginning on Day 1.
11521569|NCT01203943|Placebo Comparator|Placebo|Placebo
11521604|NCT01203644|Active Comparator|SKY0402|Low dose, low-mid dose, mid-dose, and high dose
11521605|NCT01203631|Experimental|NNC 0142-0000-0002|
11521606|NCT01203631|Placebo Comparator|Placebo|
11522883|NCT01194700|Experimental|Synchro-Breathe|
11521570|NCT01203930|Experimental|Idelalisib|This arm consists of 2 cohorts. Participants in Cohort 1 will receive idelalisib for up to twelve 28-day cycles (or development of unacceptable toxicity) plus rituximab (8 doses through the end of Cycle 2). Upon completion of twelve 28-cycles, participants are eligible to remain on idelalisib in a continuation protocol. Participants in Cohort 2 will receive idelalisib until disease progression or development of unacceptable toxicity.
11521571|NCT01203917|Other|1|gefitinib 250mg tablet
11521572|NCT01203904||Pulmicort|
11521573|NCT01203891||Healthy brain subjects|The study seeks to recruit 100 normal, healthy brain subjects between ages 10 and 90 for SPECT brain imaging.
11521574|NCT01203878|Experimental|Imiquimod & photodynamic therapy|Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by one session of photodynamic therapy of the entire face with aminolevulinic acid and blue light
11521575|NCT01203878|Active Comparator|Imiquimod|Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by observation
11521576|NCT01203852|Experimental|Metoprolol + Chlorthalidone|Study participants in this group had their current hypertension treatment withdrawn, baseline labs drawn and hypertension documented. Participants were initiated on metoprolol tartrate 50 mg twice daily for two weeks, followed by dose titration to 100 mg twice daily for six additional weeks if blood pressure (BP) > 120/70 mmHg. BP measures were again recorded. Participants entered a washout where metoprolol was titrated, then discontinued, and the patient's hypertension was re-established. After another set of identical baseline labs, study participants were initiated on chlorthalidone 25 mg four days per week (Monday, Wednesday, Thursday, Saturday) 15 mg daily for two weeks, followed by 25 mg daily for an additional six weeks.
11521577|NCT01203839|Experimental|Radiation treatment|This is a Phase II single-arm study of PBI with external-beam radiation therapy in which a group of select women with early-stage invasive and noninvasive breast cancer will be given radiation to the partial breast.
11521578|NCT01203826|Experimental|asfotase alfa|asfotase alfa starting dose 3 mg/kg/week SC injection, increased to 6 mg/kg/week SC injection
11521579|NCT01203813|Experimental|Physician Intervention|"Physicians randomized to the intervention will receive:
~Electronic alerts during office visits for patients with chronic kidney disease
~Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program"
11521580|NCT01203813|No Intervention|Physician Control|Physicians randomized to the control arm will continue to manage their patients with chronic kidney disease according to routine primary care standards.
11521581|NCT01203787|Active Comparator|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg (2 tablets of 200 mg) twice daily until end of treatment or week 24
11521582|NCT01203787|Experimental|Sorafenib Ramp-Up Regimen|200 mg daily from Day 0-Day 13 200 mg twice daily from Day 14-Day 20 600 mg daily from Day 21-Day 27 400 mg twice daily beginning Day 28 until end of treatment or Week 24
11521583|NCT01203774|Active Comparator|Pen-administered vs syringe-admnistered Glargine|SoloSTAR pen-administered Glargine insulin then syringe-administered Glargine insulin
11521584|NCT01203774|Active Comparator|Syringe-administered vs pen-administered Glargine|Syringe-administered Glargine insulin and then pen-administered Glargine insulin
11521585|NCT01203761||Preoperative patients|ENT surgical patients, approximately 1 day before their procedure undertaken
11521586|NCT01203761||Postoperative patients|ENT surgical patients during their postoperative hospitalization
11521587|NCT01203761||Family members|Family members of ENT surgical patients, during the perioperative period
11521588|NCT01203748|Experimental|PVI + Lines Ablation|
11521589|NCT01203748|Active Comparator|PVI Ablation|
11521590|NCT01203748|Experimental|PVI + CFE|
11521591|NCT01203735|Other|Valproic acid, Chemoradiotherapy|
11521592|NCT01203722|Active Comparator|REGIMEN B|"Pre-BMT :
~Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV
~Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV
~Day -1: 400 cGy total body irradiation (TBI) administered in a single fraction
~Day 0: Allogeneic blood or marrow transplantation (BMT)
~Post-Transplantation Immunosuppression Consisting of:
~Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV
~Day 5: Sirolimus loading dose 6 mg PO once
~Day 5 thru Day 35: Mycophenolate Mofetil (MMF) 15 mg/kg PO TID (maximum daily dose 3 g/day)
~Day 6 thru Day 180: Sirolimus maintenance dose 2 mg PO QD with dose adjustments to maintain trough of 3 - 12 ng/mL"
11521593|NCT01203722|Active Comparator|REGIMEN C|"Pre-BMT:
~Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV
~Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV
~Day -1: 400 cGy TBI administered in a single fraction
~Day 0: BMT
~Post-Transplantation Immunosuppression Consisting of:
~Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV
~Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day)
~Day 5 thru Day 180: Tacrolimus 1 mg administered IV QD"
11521594|NCT01203722|Active Comparator|REGIMEN B2|"Pre-PBSCT:
~Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV
~Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV
~Day -1: 400 cGy TBI administered in a single fraction
~Day 0: Peripheral Blood Stem Cell Transplant (PBSCT)
~Post-Transplantation Immunosuppression Consisting of:
~Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV
~Day 5: Sirolimus loading dose 6 mg PO once
~Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day)
~Day 6 thru Day 180: Sirolimus maintenance dose 2 mg PO QD with dose adjustments to maintain trough of 3 - 12 ng/mL"
11521595|NCT01203709|Experimental|Combination treatment|treatment arm
11521596|NCT01203696|Active Comparator|non-amlodipine|For patient with suboptimal angina control: anti-anginal agent excluding calcium channel blocker
11521597|NCT01203696|Active Comparator|non - amlodipine|For patient with suboptimal BP control: anti-hypertensive agent excluding calcium channel blocker
11521598|NCT01203683|Experimental|Active Computer-Based Program|Putatively therapeutic computer program.
11521599|NCT01203683|Placebo Comparator|Placebo computer-based program|Inert computer program.
11521600|NCT01203670|Experimental|Soft capsules of Phytalgic|Phytalgic is a food supplement. Its galenic form is soft capsule.
11521601|NCT01203657|Experimental|Tai Chi|Tai Chi instruction, 2x week in a community senior center setting
11521602|NCT01203657|No Intervention|Wait List Control|This is a wait list control group. There is no active or placebo intervention.
11521607|NCT01203605||In-patient adult non-cardiac surgery|Consecutive patients admitted to participating centres undergoing elective and non-elective non-cardiac surgery commencing during the seven day study period with a planned overnight stay. All eligible patients undergoing surgery within the seven day study period will be recruited wherever possible.
11521608|NCT01203592|Experimental|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
11521609|NCT01203566|Active Comparator|Conventional 3-port laparoscopic appendectomy|Laparoscopic appendectomy will be performed with the standard 3-port technique. The laparoscope is introduced via a 10mm subumbilical port. Dissection will be performed with a 5mm LLQ port and a 5mm RLQ port. Exploratory laparoscopy was first carried out to locate the appendix and to rule out other pathologies. The mesoappendix will be divided with the ultrasonic dissector (Sonosurg, Olympus surgical, Tokyo, Japan). The appendix will be ligated between two polydioxanone suture loops. The specimen will be delivered within a plastic bag via the subumbilical port. Purulent fluid will be irrigated and suctioned from the subhepatic space, right lower quadrant and the pelvis if present. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O absorbable subcuticular sutures. A pelvic drain (12Fr) will be inserted in cases of abscesses or gangrene.
11521610|NCT01203566|Active Comparator|LESS appendectomy|Two 5 mm ports and a 10mm port will be inserted through a 13mm transumbilical incision. Exploratory laparoscopy was first carried out to locate the appendix and to rule out other pathologies. Retraction of the appendix would be performed with a flexible curved forceps. The mesoappendix will be divided with the ultrasonic dissector (Sonosurg, Olympus surgical, Tokyo, Japan). The appendix will be ligated between two polydioxanone suture loops. The specimen will be delivered within a plastic bag via the subumbilical port. Purulent fluid will be irrigated and suctioned from the subhepatic space, right lower quadrant and the pelvis if present. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O absorbable subcuticular sutures. A pelvic drain (12Fr) will be inserted in cases of abscesses or gangrene.
11521611|NCT01203553||Control Group|The main operation will be performed as planned. For the closure of the abdominal wall, a standard technique will be applied using a running suture of PDS 1 loop. The distance of the sutures to the fascial border is 1cm and the distance between two stitches is not more than 1cm. The total length of suture is at least 4 times the total length of the abdominal incision
11521612|NCT01203553||Treatment Group|The main operation will be performed as planned. Prior to the closure of the abdominal wall a mesh will be implanted in a standardized fashion: A Dynamesh IPOM mesh will be used for the present study. The mesh has a width of 15cm and is tailored to overlap lateral and cranial boarders at least 5cm. The mesh will be placed intra-abdominally and fixed using intra-abdominal stitches using Prolene 2/0 in all four corners. After the initial fixation of the mesh in all quadrants, the boarders of the mesh will be adapted using Prolene 2/0 running sutures. The fixation aims to prevent any intestinal structures to herniate onto the mesh. Afterwards, the abdominal wall is closed as described in the control group.
11521613|NCT01203540|Experimental|Naaga in ABAK system|
11521614|NCT01203540|Placebo Comparator|Saline solution|
11521615|NCT01203527||Tamiflu use during first trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the first trimester of their pregnancy.
11521616|NCT01203527||Tamiflu use during second trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the second trimester of their pregnancy.
11521617|NCT01203527||Tamiflu use during third trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the first trimester of their pregnancy.
11521618|NCT01203527||Tamiflu use in non-pregnant women|This group will consist of twenty-five non-pregnant healthy female volunteers who are being treated with Oseltamivir.
11521619|NCT01203514|Experimental|Trial 1 Experimental|Infants 401-1,000g birthweight
11521620|NCT01203514|Sham Comparator|Trial 1: Sham Comparator|Infants 401-1,000g birthweight
11521621|NCT01203514|Experimental|Trial 2: Experimental|Infants 1,001-1,250g birth weight
11521622|NCT01203514|Sham Comparator|Trial 2: Sham Comparator|Infants 1,001-1,250g birth weight
11521623|NCT01203488|Experimental|Experimental|Vitamin A group.
11521624|NCT01203488|Sham Comparator|Control|Sham procedure Control group.
11521625|NCT01203462|Experimental|Bifidobacterium supplemented yogurt|Bifidobacterium supplemented (minimum dosage of 1E+10cfu/serving) vanilla flavored yogurt containing starter cultures: Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus
11521626|NCT01203462|Placebo Comparator|Placebo Yogurt|Vanilla flavored yogurt containing starter cultures Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus
11521627|NCT01203436|Experimental|Supplemental Oxygen|Supplemental oxygen to achieve a pulse oximetry target range of 96% to 99%.
11521628|NCT01203436|Active Comparator|Conventional Oxygen|Conventional oxygenation at a pulse oximetry target of 89% to 94%.
11521629|NCT01203410||Cohort 1|Term infants >2500g birthweight.
11521630|NCT01203397|Active Comparator|GROUP 2|
11521631|NCT01203397|Experimental|GROUP 1|
11521632|NCT01203384|Experimental|CHF5074 1x|oral tablet, multidose
11521633|NCT01203384|Experimental|CHF5074 2x|oral tablet, multidose
11521634|NCT01203384|Experimental|CHF5074 3x|oral tablet, multidose
11521635|NCT01203384|Placebo Comparator|Placebo|placebo, oral tablet, multidose
11521636|NCT01203371|Experimental|Naftopidil|0,25 mg (2 weeks) and 0,50 mg (10 weeks)
11521637|NCT01203371|Active Comparator|Tamsusolin|0,4 mg/day
11521638|NCT01203358|Active Comparator|Surfactant 1|Exosurf Neonatal (Burroughs Wellcome Co.)
11521639|NCT01203358|Active Comparator|Surfactant 2|Survanta (Ross Laboratories)
11521640|NCT01203345|Active Comparator|Immune globulin|Lyophilized human immune globulin product
11521641|NCT01203345|Placebo Comparator|Albumin solution|
11521642|NCT01203332||Alternative Venue Testing (AVT)|Participants recruited for testing through the AVT recruitment method.
11521643|NCT01203332||SSNIT - Index Recruiter|Participants recruited for HIV testing and to bring members of their social and sexual network to the study.
11521782|NCT01202370|Experimental|AR-67|Phase 1 study
11521783|NCT01202357|Experimental|Case Management (1 year)|
11521644|NCT01203332||SSNIT - Network Member|Participants recruited by someone in their social or sexual network to participate in the study, including HIV testing.
11521645|NCT01203319|Experimental|60mcg/1.0ml recombinant hepatitis B vaccine|600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 60mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
11521646|NCT01203319|Experimental|30mcg/1.0ml recombinant hepatitis B vaccine|600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
11521647|NCT01203319|Placebo Comparator|10mcg/1.0ml recombinant hepatitis B vaccine|300 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
11521648|NCT01203306|Experimental|Drugs: bevacizumab + octreotide LAR + capecitabine|bevacizumab + octreotide + metronomic capecitabine
11521649|NCT01203293|Experimental|Cognitive Behavior Therapy|
11521650|NCT01203293|Active Comparator|Treatment as usual|
11521651|NCT01203280|Experimental|balance, neck isometric strength and range of motion|
11521652|NCT01203267|Experimental|paclitaxel plus carboplatin (PCb) Arm|4 cycles of neoadjuvant paclitaxel plus carboplatin
11521653|NCT01203254|Placebo Comparator|Placebo|
11521654|NCT01203254|Active Comparator|Cholestagel|
11521655|NCT01203241|Active Comparator|Conventional ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum
11521656|NCT01203241|Active Comparator|Conventional ablation plus left atrial roof ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum plus creation of a radiofrequency line joining contralateral superior pulmonary veins throughout the left atrial roof.
11521657|NCT01203228|Active Comparator|A|Myeloablative conditioning
11521658|NCT01203228|Experimental|B|Reduced Intensity Conditioning
11521659|NCT01203215|Experimental|JumpStart|
11521660|NCT01203215|Experimental|Choose to Move|
11521661|NCT01203215|Active Comparator|Wellness|
11521662|NCT01203202|Placebo Comparator|PED 0|placebo
11521663|NCT01203202|Experimental|PED 1|PED-1 (clomipramine 15mg)
11521664|NCT01203202|Experimental|PED-2|PED-2 (Clomipramine 30mg)
11521665|NCT01203189|Active Comparator|Shampoo Group|Subjects in the S group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.
11521666|NCT01203189|Active Comparator|Foam group|Subjects in the F group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.
11521667|NCT01203189|Active Comparator|Cross Over Group|apply ketoconazole 2% foam to scalp twice daily for four weeks. Subjects in the Shampoo group will be able to cross over into the Foam group if the TDSS score does not improve by 60% at the end of the four week treatment period using shampoo.
11521668|NCT01203176|Active Comparator|Post-menopausal symptomatic women|
11521669|NCT01203176|Experimental|Post-menopausal asymptomatic women|
11521670|NCT01203163||PDT with porfimer sodium|
11521671|NCT01203150|Experimental|Supplement|Participants randomized to the 'supplement' arm will consume a blended drink containing 48g of ionexchange, hydrolyzed vanilla-flavored whey protein (Whey to Go, Solgar Vitamin and Herb, Leonia, NJ; 3g CH2O, < 3g Total Fat). The drink will be given in split doses immediately before and after each training session, which represents a timing schedule that best stimulates muscle anabolism in persons undergoing exercise training.
11521672|NCT01203150|Placebo Comparator|Placebo|As ingestion of the protein supplement is critically influenced by time of administration, participants assigned to the 'placebo' study arm will consume the identical supplement and dose on days during which training is not performed. This strategy will allow the groups to be isocaloric and equal in protein supplementation.
11521673|NCT01203137||tricuspid regurgitation, severe|To be included in the present study, the following 3 criteria for severe TR should be met based on the preoperative echocardiography: (1) TR jet > 30% of right atrial area, (2) inadequate cusp coaptation, and (3) systolic flow reversal in the hepatic vein.
11521674|NCT01203124|Placebo Comparator|1|Placebo given once daily on 7 days
11521675|NCT01203124|Experimental|2|Active treatment at Day 1 and Day 7. Placebo on Day 2, 3, 4, 5 and 6
11521676|NCT01203124|Experimental|3|Active treatment at Day 1, 4 and 7. Placebo on Day 2, 3, 5 and 6.
11521677|NCT01203124|Experimental|4|Active treatment at Day 1, 3, 5 and 7. Placebo on Day 2, 4 and 6.
11521678|NCT01203124|Experimental|5|Active treatment once daily on 7 days
11521679|NCT01203111|Experimental|Intensive insulin regimen|Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: + insulin glulisine if HbA1c ≥7% at week 12 (end of treatment period 1)
11521680|NCT01203111|Experimental|insulin regimen|Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: no change, if HbA1c <7% at week 12 (end of treatment period 1)
11521681|NCT01203098|Experimental|DU-176b 30mg once daily|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery
11521682|NCT01203098|Active Comparator|Enoxaparin sodium twice daily|Enoxaparin sodium 20mg (=2000IU) / 0.2mL twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery
11521683|NCT01203098|Experimental|DU-176b 15mg once daily|DU-176b 15mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery
11521684|NCT01203085||Pediatric patients|All patients 21 years of age and under who are enrolled in the 6601 study and have undergone the pediatric scale tests.
11521685|NCT01203072|Experimental|DU-176b 5 mg|
11521686|NCT01203072|Experimental|DU-176b 15 mg|
11521687|NCT01203072|Experimental|DU-176b 30 mg|
11521688|NCT01203072|Experimental|DU-176b 60 mg|
11521689|NCT01203072|Placebo Comparator|Placebo|
11521690|NCT01203046|Active Comparator|GROUP A: 7 DAYS ANTIBIOTIC THERAPY|Ertapenem will be administrated within the first 2 hours of Hospital´s admission and the during the next 7 days after surgery.
11521691|NCT01203046|Experimental|GROUP B - 3 DAYS ANTIBIOTIC THERAPY|Ertapenem will be administrated within the first 2 hours of Hospital´s admission and during the next 3 days after surgery.
11521692|NCT01203033||AML patients|newly diagnosed or relapsed AML patients
11521693|NCT01203020|Experimental|Allogeneic hematopoietic progenitor cell transplant|Intravenous busulfex 130mg/m2 on days -6 to -3 before transplant
11521694|NCT01203007|Experimental|Tailored diet|Tailored diet according to demonstrated food sensitivity
11521695|NCT01203007|Experimental|Low-antigen content (LAC) diet|Low-antigen content diet
11521696|NCT01202994|Experimental|Flute|Flutemetamol PET scan.
11521697|NCT01202981||Group 1|Patients who had cataract surgery by the Investigators between July 1, 2007 and June 30, 2008.
11521698|NCT01202981||Group 2|Patients who had cataract surgery by the Investigators between July 1, 2008 and July 1, 2009.
11521699|NCT01202955|Active Comparator|Tolcapone|Tolcapone
11521700|NCT01202955|Placebo Comparator|Placebo|Placebo
11521701|NCT01202942|Experimental|Quest|Participants smoke Quest cigarettes level 1 for 10 days, followed by level 2 for 10 days, and finally by level 3 for 10 days.
11521702|NCT01202942|No Intervention|Preferred brand|Participants smoke their preferred brand of cigarettes for the duration of the study.
11521703|NCT01202929||Type I achalasia|classic achalasia: complete esophageal motor failure
11521704|NCT01202929||Type II achalasia|compression achalasia: simultaneous panesophageal pressurization with aperistalsis
11521705|NCT01202929||Type III achalasia|spastic achalasia with aperistalsis: 100% spasm
11521706|NCT01202916||Congenital Heart Disease|
11521707|NCT01202916||Healthy children|
11521708|NCT01202903|Experimental|Omalizumab|Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 mL vial that was designed to deliver 150 mg of omalizumab for subcutaneous administration upon reconstitution with 1.4 mL sterile water for injection. The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
11521709|NCT01202903|Placebo Comparator|Placebo|The placebo was the same mixture of inactive excipients, in quality and quantity, as those used for the drug product. The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
11521710|NCT01202890|Experimental|Arm 1|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
11521711|NCT01202877|Experimental|5-azacytidine + PKC412|5-azacytidine 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
11521712|NCT01202864||Cases|3000 Cases
11521713|NCT01202864||Controls|3000 Controls
11521714|NCT01202851|Experimental|Relaxation Group 1|Simple stretching exercises, specific breathing skills, and guided relaxation for 3 sessions, 3 times a week for 6 weeks. Each session should last about 60 minutes. Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
11521715|NCT01202851|Experimental|Relaxation Group 2|Simple stretching exercises, specific breathing skills, and guided relaxation for 3 sessions, 3 times a week for 6 weeks. Each session should last about 60 minutes. Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
11521716|NCT01202851|Other|Waitlist Control Group (WLC)|Participants in this group given the option to take part in one of the two forms of relaxation (off study) after they finish their last questionnaire packet. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
11521717|NCT01202838||Composite Implant|Subject receiving composite implant
11521718|NCT01202825|Experimental|001|
11521719|NCT01202825|Placebo Comparator|008|
11521720|NCT01202825|Placebo Comparator|002|
11521721|NCT01202825|Experimental|009|
11521722|NCT01202825|Experimental|003|
11521723|NCT01202825|Placebo Comparator|004|
11521724|NCT01202825|Experimental|005|
11521725|NCT01202825|Experimental|010|
11521726|NCT01202825|Placebo Comparator|006|
11521727|NCT01202825|Experimental|007|
11521728|NCT01202812|Experimental|LOVAZA|
11521729|NCT01202812|Placebo Comparator|Placebo capsule|
11521730|NCT01202799|Experimental|Treatment A|2% w/w diclofenac sodium topical gel
11521731|NCT01202799|Active Comparator|Treatment B|
11521732|NCT01202799|Active Comparator|Treatment C|
11521733|NCT01202786||miRview mets Disclosed|Patients of group 1 will be submitted to the standard conventional work-up (see below) as well as miRview™ mets assay. Their physician will treat the patient based upon both results
11521734|NCT01202786||Control|Patients of group 2 will be submitted to the standard conventional work-up. miRview™ mets assay will be performed but will remain blinded for both the patient and referring physician. Treatment will be decided based on standard work-up results
11521735|NCT01202773|Experimental|120 milligrams (mg) LY2127399|"Given every 4 weeks (Q4W) for 24 weeks. Participants receive a 240-mg loading dose when initiating treatment.
~During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks (Q2W).
~At Week 16, responders will receive 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period.
~At Week 16, non-responders (NR) will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
11521784|NCT01202357|No Intervention|Standard Care (1 year)|
11521785|NCT01202344|Other|Restenosis|Patients who have restinosis immediately following angioplasty.
11521736|NCT01202773|Experimental|90 mg LY2127399|"Given Q2W for 24 weeks. Participants receive a 180-mg loading dose when initiating treatment.
~At Week 16, both responders and NR will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
11521737|NCT01202773|Placebo Comparator|Placebo|"Given Q2W for 24 weeks. Participants receive 2 injections of placebo when initiating treatment.
~At Week 16, responders will receive 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.
~At Week 16, NR will receive a 180-mg loading dose of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
11521738|NCT01202760|Experimental|120 mg LY2127399|"LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240-mg (2 SC injections of 120 mg each) loading dose of LY2127399 when initiating treatment.
~During the Treatment Period, for blinding purposes, participants alternated injections of LY2127399 and injections of Placebo every 2 weeks.
~After 16 weeks, non-responders received 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
11521739|NCT01202760|Experimental|90 mg LY2127399|"LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180-mg (2 SC injections of 90 mg each) loading dose of LY2127399 when initiating treatment.
~After 16 weeks, non-responders continued to receive 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
11521740|NCT01202760|Placebo Comparator|Placebo|"Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections of Placebo when initiating treatment.
~After 16 weeks, non-responders received 90 milligrams (mg) of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
11521741|NCT01202747|Experimental|LipiFlow Treatment|Treatment with LipiFlow device
11521742|NCT01202734|Experimental|001|Methylphenidate HCl Period 1: One tablet oral 36 mg once daily single-dose on Day 1 Period 2: Three tablets oral 18 mg once daily single-dose on Day 1 Period 3: Two tablets oral 36 mg once daily single-dose on Day 1. (Each treatment period will be separated by 3-7 days)
11521743|NCT01202721|Experimental|Atenolol|Atenolol or matching placebo 25 mg up-titrated to 100 mg.
11521744|NCT01202721|Experimental|Telmisartan|Telmisartan or matching placebo 40 mg up-titrated to 80mg
11521745|NCT01202695|Experimental|AVP-21D9|
11521746|NCT01202695|Placebo Comparator|Placebo|
11521747|NCT01202669||Epilepsy patients, EMU stay|
11521748|NCT01202656|Experimental|G-CSF then Saline|G-CSF (Granulocyte colony stimulating factor)
11521749|NCT01202656|Placebo Comparator|Saline then G-CSF|Normal Saline
11521750|NCT01202643|Experimental|G-CSF|G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation
11521751|NCT01202643|Placebo Comparator|Saline|Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation
11521752|NCT01202630|Experimental|Probiotic|BIO-K+ CL1285
11521753|NCT01202630|Placebo Comparator|Placebo|Placebo
11521754|NCT01202617||Schizophrenic outpatients between 18 & 70 years of age|
11521755|NCT01202604||Outpatients with bipolar disorder I or II (as per DSM-IV)|The percentage of patients who experience a relapse episode during the first 9 months after a mood event (manic or depressive).
11521756|NCT01202591|Experimental|AZD4547 + exemestane|Safety run-in: AZD4547 plus exemestane
11521757|NCT01202591|Experimental|AZD4547 + fulvestrant|A Randomised phase IIa: AZD4547 plus fulvestrant
11521758|NCT01202591|Placebo Comparator|Placebo + fulvestrant|Randomised phase IIa: Matching placebo plus fulvestrant
11521759|NCT01202578|Experimental|tympanostomy tube|performance and safety of tympanostomy tube delivery system
11521760|NCT01202565||Adalimumab|Participants with moderate to severe plaque psoriasis received adalimumab (Humira®) therapy according to the local product label and prescription/reimbursement guidelines.
11521761|NCT01202552|Experimental|group 1|receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain
11521762|NCT01202552|Experimental|group 2|receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site
11521763|NCT01202552|Experimental|group 3|receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
11521764|NCT01202526||RYGB patients with type 2 diabetes|Morbid obese patients with type 2 diabetes undergoing gastric bypass surgery
11521765|NCT01202526||RYGB patients without type 2 diabetes|Morbid obese patients with normal glucose tolerance undergoing gastric bypass surgery
11521766|NCT01202513|Experimental|Bimatoprost application|
11521767|NCT01202500|Other|12 months|
11521768|NCT01202500|Experimental|3 months|
11521769|NCT01202487|Experimental|Pre-treatment with LET|Pre-treatment with Lidocaine Epinephrine Tetracaine solution at least 45 minutes prior to laceration repair with tissue adhesive
11521770|NCT01202487|Placebo Comparator|Pre-treatment with Placebo|Pre-treatment with Placebo solution at least 45 minutes prior to laceration repair with tissue adhesive
11521771|NCT01202474|Experimental|insulin glulisine and insulin glargine|insulin glulisine and insulin glargine basal/bolus regimen in accordance with the summary of product characteristics and titrated to Plasma glucose target as defined by American Diabetes Association (ADA) recommendations age-specific goals (12)
11521772|NCT01202448|Active Comparator|DLBCL with risk factor|Patients have any of risk factors for secondary CNS involvement
11521773|NCT01202435|Experimental|Pregabalin controlled release, 82.5 mg|
11521774|NCT01202435|Other|Pregabalin immediate release, 25 mg|Reference Treatment
11521775|NCT01202422|Experimental|Pregabalin controlled release, 165 mg|
11521776|NCT01202422|Experimental|Pregabalin controlled release, 330 mg|
11521777|NCT01202422|Other|Pregabalin immediate release, 150 mg|Reference Treatment
11521778|NCT01202409|Experimental|Panitumumab|Starting Dose of Panitumumab: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
11521779|NCT01202396||ulcerative colitis patients with a pouch|"ulcerative colitis patients undergoing proctocolectomy with an ileal pouch anal anastomosis
~comparing patients with versus those without pouchitis
~no intervention"
11521780|NCT01202383|Active Comparator|NADCC tablets|
11521781|NCT01202383|Placebo Comparator|Placebo tablets|
11521786|NCT01202344|Other|No Restenosis|Patients who do not have restinosis immediately following angioplasty.
11521787|NCT01202331|No Intervention|J|Stop Annual Treatment
11521788|NCT01202331|No Intervention|K|Stop Biannual Treatment
11521789|NCT01202331|Other|L|Continue Annual Treatment
11521790|NCT01202331|Other|M|Continue Biannual Treatment
11521791|NCT01202331|Experimental|N|Targeted Treatment by Age
11521792|NCT01202331|Experimental|O|Targeted Treatment by Clinical Exam
11521793|NCT01202305||HIV negative|
11521794|NCT01202305||HIV positive|
11521795|NCT01202292|Experimental|Lifestyle counseling|
11521796|NCT01202279|Active Comparator|Mucinex D|Mucinex D (1200 mg guaifenesin and 120 mg pseudoephedrine HCl) extended release bilayer tablet twice a day (bid) with a full glass of water for 7 days
11521797|NCT01202279|Placebo Comparator|Placebo|Placebo given bid with a full glass of water for 7 days
11521798|NCT01202266|Experimental|5 mg PF-05161704 or Placebo|
11521799|NCT01202266|Experimental|15 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
11521800|NCT01202266|Experimental|50 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
11521801|NCT01202266|Experimental|150 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
11521802|NCT01202266|Experimental|xx mg PF-05161704 or Placebo|Planned dose and dosing regimen will be determined based on emerging PK and safety data.
11521803|NCT01202266|Experimental|xxx mg PF-05161704 or Placebo|Dose will be determined based on data from previous 5 arms.
11521804|NCT01202266|Experimental|yy mg PF-05161704 or Placebo|Dose will be determined based on data from previous 6 arms
11521805|NCT01202266|Experimental|yyy mg PF-05161704 or Placebo|Dose will be determined based on data from previous 7 arms.
11521806|NCT01202253||Anidulafungin|
11521807|NCT01202240|Experimental|Tasocitinib (CP-690,550) plus Ketoconazole|
11521808|NCT01202227|Experimental|Pregabalin|Flexible dosing in 4 weeks followed by 48 weeks maintenance and one week taper period
11521809|NCT01202214|Experimental|Active drug|
11521810|NCT01202214|Placebo Comparator|Placebo|
11521811|NCT01202201||Study Cohort|Subjects hospitalized with acute gastroenteritis or rotavirus gastroenteritis
11521812|NCT01202188|Experimental|indacaterol and glycopyrronium (QVA149)|QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
11521813|NCT01202188|Active Comparator|glycopyrronium (NVA237)|NVA237 50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
11521814|NCT01202188|Active Comparator|indacaterol (QAB149)|QAB149 150 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
11521815|NCT01202188|Active Comparator|tiotropium|Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
11521816|NCT01202188|Placebo Comparator|Placebo|Matching placebo capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
11521817|NCT01202175|Experimental|Nebivolol|
11521818|NCT01202175|Placebo Comparator|Sugar pill|
11521819|NCT01202162|Active Comparator|Desflurane|Administration of Desflurane
11521820|NCT01202162|Active Comparator|Sevoflurane|Administration of Sevoflurane
11521821|NCT01202149|Active Comparator|Elidel Right Side, Hylatopic Plus Left Side|Elidel applied topically on Right Side of body twice a day and Hylatopic plus emollient foam applied topically on Left Side of body three times a day
11521822|NCT01202149|Active Comparator|Elidel Left Side Hylatopic Plus Right Side|Elidel applied topically on Left Side of body twice a day and Hylatopic plus emollient foam applied topically on Right Side of body three times a day
11521823|NCT01202136||Pancreatic cysts|patients referred to Johns Hopkins Hospital for evaluation and or treatment for 1 or more pancreatic cysts
11521824|NCT01202110|Experimental|Propranolol|Propranolol 1mg iv
11521825|NCT01202110|No Intervention|Control|Routine care
11521826|NCT01202097|Experimental|Salmeterol/Fluticasone|
11521827|NCT01202097|Active Comparator|Seretide|
11521828|NCT01202084|Experimental|Formoterol/Fluticasone Eurofarma|formoterol + fluticasone (12/250 mcg) twice a day per 12 weeks
11521829|NCT01202084|Active Comparator|Foraseq®|formoterol + budedonide (12/400 mcg) twice a day per 12 weeks
11521830|NCT01202084|Active Comparator|Fluticasone|fluticasone (500 mcg) twice a day per 12 weeks
11521831|NCT01202071|Experimental|Rabeprazole sodium Tablets, 5 mg|
11521832|NCT01202071|Experimental|Rabeprazole sodium Tablets, 10 mg|
11521833|NCT01202071|Experimental|Rabeprazole sodium Tablets, 20 mg|
11521834|NCT01202071|Experimental|Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets)|
11521835|NCT01202058|Experimental|NEVO™ SES|"Design Protocol Am3.0 - safety follow-up:
~The study population consists of 103 subjects with atherosclerotic coronary artery disease treated with the NEVO™ SES. Candidates for the initial NEVO II Study must have met ALL inclusion criteria and NO exclusion criteria.
~Design Original Protocol
~Subjects randomized to treatment with the NEVO™ Sirolimus-eluting Coronary Stent System."
11521836|NCT01202058|Active Comparator|XIENCE V®/XIENCE PRIME™/PROMUS®|Subjects randomized to treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System
11521837|NCT01202045||systemic sclerosis patients|Every patient will have a rest echocardiography, a stress echocardiography, a right heart catheterization, a blood specimen, and a pulmonary function test.
11522566|NCT01196871|Experimental|Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg)|
11521838|NCT01202019|Experimental|Supplement|Participants randomized to the 'supplement' arm will consume a blended drink containing 48g of ionexchange, hydrolyzed vanilla-flavored whey protein (Whey to Go, Solgar Vitamin and Herb, Leonia, NJ; 3g CH2O, < 3g Total Fat). The drink will be given in split doses immediately before and after each training session, which represents a timing schedule that best stimulates muscle anabolism in persons undergoing exercise training.
11521839|NCT01202019|Placebo Comparator|Placebo|As ingestion of the protein supplement is critically influenced by time of administration, participants assigned to the 'placebo' study arm will consume the identical supplement and dose on days during which training is not performed. This strategy will allow the groups to be isocaloric and equal in protein supplementation.
11521840|NCT01202006|Experimental|Intervention|General practitioners of patients in the intervention group will receive detailed instructions on uptitration of ACE-inhibitors and beta-blockers before the inclusion of participants.
11521841|NCT01202006|No Intervention|Control|Patients in the control group receive care-as-usual. Their general practitioner will not be trained in applying the uptitration protocol.
11521842|NCT01201980||1|Subject population with essential arterial hypertension currently receiving treatment with a calcium antagonist
11521843|NCT01201967|Experimental|Collaborative care|Study care manager provides education and coordinates treatment between study psychiatrist, patient, and primary medical physician. This occurs in the hospital and by phone after discharge. Care manager may also provide phone-based therapy.
11521844|NCT01201967|Placebo Comparator|Usual care|Patient's physicians are informed of diagnosis of depression/anxiety disorder
11521845|NCT01201954|Active Comparator|sucrose|0,5 ml/kg of sucrose administered 2 minutes prior the procedure
11521846|NCT01201954|Placebo Comparator|sterile water|0,5 ml/kg of sterile water administered 2 minutes prior the procedure
11521847|NCT01201941||Intervention group|"During the first part of the study, the intervention group will not have access to the e-Chasqui system.
~During the second part of the study, the intervention group will have access to the e-Chasqui system."
11521848|NCT01201941||Simultaneous/historical control group|"During the first part of the study, the intervention group will not have access to the e-Chasqui system.
~During the second part of the study, the intervention group will not have access to the e-Chasqui system."
11521849|NCT01201928||Technosphere Insulin Inhalation Powder|
11521850|NCT01201928||Comparator|Based on parent trial
11521851|NCT01201915|Experimental|Cohort 1: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 12 weeks.
11521852|NCT01201915|Experimental|Cohort 2: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 12 weeks.
11521853|NCT01201915|Experimental|Cohort 3: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 8 weeks, followed by 4 weeks with no treatment, followed by a second 8-week vismodegib treatment period.
11521854|NCT01201902|Experimental|Group 1 : Low dose with adjuvant|Group 1: 18 ~ 64 years old subjects
11521855|NCT01201902|Experimental|Group 1: High dose with adjuvant|Group 1: 18 ~ 64 years old subjects
11521856|NCT01201902|Active Comparator|Group1 : Plain vaccine|Group 1: 18 ~ 64 years old subjects
11521857|NCT01201902|Experimental|Group 2 : Low dose with adjuvant|Group 2: greater than or equal to 65 years of age
11521858|NCT01201902|Experimental|Group 2 : high dose with adjuvant|Group 2: greater than or equal to 65 years of age
11521859|NCT01201863|Experimental|Intervention - Treatment|Men with TBI meeting study criteria with Low Testosterone levels will be randomly assigned to either a treatment or placebo group. They will participate in blood assays at baseline and every other week for 12 weeks during inpatient rehabilitation hospitalization. They will also be scored on the FIM (primary outcome measure) and the NIH Toolbox (Secondary Outcome Measure.
11521860|NCT01201863|Placebo Comparator|Intervention Placebo|Men with TBI meeting study criteria with Low Testosterone levels will be randomly assigned to either a treatment or placebo group. They will participate in blood assays at baseline and every other week for 12 weeks during inpatient rehabilitation hospitalization. They will also be scored on the FIM (primary outcome measure) and the NIH Toolbox (Secondary Outcome Measure.
11521861|NCT01201850|Experimental|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses.
11521862|NCT01201837|Placebo Comparator|Placebo|
11521863|NCT01201837|Experimental|Low Dose|CER-001 Low Dose
11521864|NCT01201837|Experimental|Mid Dose|CER-001 Mid Dose
11521865|NCT01201837|Experimental|High Dose|CER-001 High Dose
11521866|NCT01201824|Other|1|
11521867|NCT01201811|Experimental|Single-Arm|Azacitidine 75 mg/m^2/day Subcutaneous for 7 days Day every 28 days for up to 6 cycles
11521868|NCT01201798|Experimental|Durezol|Difluprednate 0.05% ophthalmic emulsion, 1 drop in study eye, 4 times a day for 14 days, followed by a 14-day tapering period
11521869|NCT01201798|Active Comparator|Pred Forte|Prednisolone acetate 1.0% ophthalmic suspension, 1 drop in study eye, 8 times a day for 14 days, followed by a 14-day tapering period
11521870|NCT01201785|Experimental|Aspirin dose range|
11521871|NCT01201772|Active Comparator|Prasugrel 60mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
11521872|NCT01201772|Active Comparator|Prasugrel 30mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
11521873|NCT01201772|No Intervention|Prasugrel 10mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
11521874|NCT01201759|Experimental|Placebo to Salsalate 2gr BID|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.
11521875|NCT01201759|Experimental|Salsalate 2gr BID to placebo|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days.
11521876|NCT01201746|Experimental|Periodontal Therapy|Scaling Root planing and oral hygiene instructions
11521877|NCT01201746|Placebo Comparator|Delayed treatment|Scaling Root planing and oral hygiene instructions
11521878|NCT01201733|Experimental|Traditional Thai massage|The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region
11521879|NCT01201733|Active Comparator|Ultrasound therapy and hot pack|The participants will receive a thirty minutes session of Ultrasound therapy and hot pack
11521880|NCT01201720|Other|Albumin|Albumin solution for infusion 5%. dosage: 43,5 millimole intravenouse use , 6 plasma exchange with albumin in 11 days and administration of polyclonal gamma globulin.6 sessions
11521881|NCT01201707|Experimental|Treatment of CCSVI with Angioplasty|At the time of venography, these patients will have had a significant lesion (blockage) in the internal jugular and/or the azygos vein that will be treated with angioplasty.
11521882|NCT01201707|Sham Comparator|Observation of CCSVI|At the time of venography, these patients will have had a significant lesion (blockage) in the internal jugular and/or the azygos vein that will not be treated with angioplasty. These patients will be observed after treatment and compared to those patients who received treatment.
11521883|NCT01201694|Experimental|Surface-Controlled Water Soluble Curcumin Group|Starting dose 100 mg by mouth two times a day of a 28 day cycle.
11521884|NCT01201694|Experimental|Surface-Controlled Water Soluble Curcumin Expansion|Following finding of MTD surface-controlled water soluble curcumin, escalating dose levels
11521885|NCT01201681||Post-operativeTooth Pain|
11521886|NCT01201668||Persistent Tooth Pain|
11521887|NCT01201642|Experimental|Prednisolone|Prednisolone as 5 mg tablets will be given within 72 h after onset of Bell's palsy as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
11521888|NCT01201642|Experimental|Acute stage acupuncture|Accept acupuncture therapy within 10days after onset of Bell's palsy, do not accept prednisolone therapy. The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints within 72 h after onset of Bell's palsy. Yifeng (TE17), Hegu (LI4) are punctured 0.5-1.0 cun, the others are punctured 0.1-0.3 cun. and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
11521889|NCT01201642|Experimental|Prednisolone + acute stage acupuncture|Accept prednisolone and acupuncture therapy within 10days after onset of Bwll's palsy. Prednisolone used as same as the Arm of Prednisolone. The acupuncture points used as same as the Arm of Acute stage acupuncture.
11521890|NCT01201642|Experimental|Resting stage acupuncture|Accepted acupuncture therapy after 10 days of the onset of Bell's palsy. The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. Penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints 7 d after enrolment. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
11521891|NCT01201642|Experimental|Prednisolone + resting stage acupuncture|Accept prednisolone and acupuncture therapy more than 10days after onset of Bwll's palsy. Prednisolone used as same as the Arm of Prednisolone. The acupuncture points used as same as the Arm of Resting stage acupuncture.
11521892|NCT01201642|Other|Other treatment|Do not accept neither prednisolone nor acupuncture therapy. The therapy accepted is different from the five Arms Previously.
11521893|NCT01201629|Sham Comparator|t DC stimulation|Sham transcranial direct current stimulation tDCS induces slight short-lasting tingling with onset of the stimulation. These sensations usually fade away in seconds. Sham interventions are essential to blind the subject and the assessor in order to obtain unbiased assessment of intervention effects
11521894|NCT01201629|Experimental|tDC stimulation|Actual DC stimulation
11521895|NCT01201616|Experimental|High fat, low carbohydrate diet|Fats intake 55% , Protein 17% and carbohydrate 28% of total energy
11521896|NCT01201616|Active Comparator|Low fat, high carbohydrate diet|Fat intake 20%, Protein 17% and carbohydrate 63% of total energy intake
11521897|NCT01201603|Experimental|Orange Juice|Orange Juice reconstituted from frozen concerntrate
11521898|NCT01201603|Placebo Comparator|Orange drink|Sugars matched orange drink
11521899|NCT01201590|Experimental|High Flavanol Cocoa|609mg cocoa flavanols per 24g serving
11521900|NCT01201590|Placebo Comparator|Low flavanol cocoa|13mg cocoa flavanols per 24g serving
11521901|NCT01201577|Active Comparator|Placebo/Probiotic|
11521902|NCT01201577|Active Comparator|Placebo/Prebiotic|
11521903|NCT01201577|Active Comparator|Prebiotic/Probiotic|
11521904|NCT01201577|Placebo Comparator|Placebo/Placebo|
11521905|NCT01201564|Active Comparator|intraperitoneal onlay mesh repair|
11521906|NCT01201564|Active Comparator|sublay mesh repair|
11521907|NCT01201551|Active Comparator|healthy subjects without PVD|healthy subjects without primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo
11521908|NCT01201551|Active Comparator|healthy subjects with PVD|healthy subjects with primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo
11521909|NCT01201538|Experimental|Single arm|
11521910|NCT01201525|Experimental|Surgical scar - part 1|Surgical scar - part 1
11521911|NCT01201525|Placebo Comparator|Surgical scar - part 2|Surgical scar - part 2
11521912|NCT01201512||Temporomandibular disorders|
11521913|NCT01201499|Active Comparator|Intrathecal morphine|A single shot of intrathecal morphine given before the induction of general anesthesia. Followed by postoperative IV patient-controlled morphine analgesia.
11521914|NCT01201499|Active Comparator|Continuous IV remifentanil|Continuous administration of IV remifentanil during surgery, supported by a single bolus of IV morphine at the end of surgery. Followed by postoperative IV patient-controlled morphine analgesia.
11521915|NCT01201486||Pregnant women|Pregnant females in the 2nd trimester.
11521916|NCT01201473||Measure impact of research participation|
11521917|NCT01201460||Glucose testing|Patients participating in this study may be alerted to possible presence of (DM) or pre-(DM) or to inadequate glycemic control. In such a case, they were advised to follow-up with their physician for definitive diagnosis and treatment. Early diagnosis and improved glycemic control may be of significant benefit to the patients' health.
11521918|NCT01201447||Questionable occlusal lesions|
11521919|NCT01201434|Experimental|Probiotics, Treatment, Food Additive|
11521920|NCT01201408||Dental Caries assessment|
11521921|NCT01201395||Dental caries assessment|
11521922|NCT01201382|Experimental|IPT-AST|Interpersonal Psychotherapy-Adolescent Skills Training
11521923|NCT01201382|Active Comparator|Group Counseling|Group Counseling
11521924|NCT01201369|Active Comparator|Cypher™ Stent|Participants in the Cypher arm will be randomised to receive a Cypher™ (Cordis, Miami Lake, USA) coronary stent
11521925|NCT01201369|Active Comparator|Xience™ Stent|Patients in the Xience™ arm will receive a Xience™ Stent(Abbott Vascular, Santa Clara, USA.
11521926|NCT01201356|Experimental|Fingolimod 0.5 mg/day|Open-label fingolimod 0.5 mg, taken orally once daily
11521927|NCT01201330||ONJ sufferers|history of jaw osteonecrosis
11521928|NCT01201330||Bisphosphonate exposure|patients with exposure to bisphosphonates
11521929|NCT01201317|Experimental|AZD2423, 150 mg|Tablets, 150 mg once daily in the morning.
11521930|NCT01201317|Experimental|AZD2423, 20 mg|Tablets, 20 mg once daily in the morning.
11521931|NCT01201317|Placebo Comparator|Placebo|Tablets, placebo, once daily in the morning.
11521932|NCT01201304|Experimental|Interoceptive exposure|Repeated trials of voluntary hyperventilation intended to reduce fears of arousal-related body sensations.
11521933|NCT01201304|Placebo Comparator|Expressive writing|Expectancy control intervention.
11521934|NCT01201291|Active Comparator|Fraction of inspired oxygen of 0.4|Fraction of inspired normobaric oxygen of 0.4 (low oxygen group)
11521935|NCT01201291|Active Comparator|Fraction of inspired oxygen of 0.7|Fraction of inspired normobaric oxygen of 0.7 (high oxygen group)
11521936|NCT01201278|Experimental|Nasal insulin 8 IU|Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
11521937|NCT01201278|Experimental|Nasal insulin 16 IU|Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
11521938|NCT01201278|Active Comparator|Subcutaneous insulin lispro 8 U|Subcutaneous insulin lispro (Humalog®) 8 U
11521939|NCT01201265|Experimental|Overall Participants|Participants received a combination therapy of bevacizumab with gemcitabine plus carboplatin.
11521940|NCT01201252||Acute gastroenteritis Group|Suspected/confirmed cases of rotavirus gastroenteritis in children < 5 years of age
11521941|NCT01201239|Experimental|raltegravir|HIV-infected patients aged over 18 who have failed previous antiretroviral treatment with multi-drug resistant or with multi-drug intolerance are to accept Ral plus OBT.
11521942|NCT01201226|No Intervention|Patients|Perimenopausal women, who will undergo oelvic organ surgery, and will allow harvest of about half an oary for the study purpose
11521943|NCT01201213|Active Comparator|Extradural bupivacaine|Local anesthetic
11521944|NCT01201213|Active Comparator|Extradural levobupivacaine|local anaesthetic
11521945|NCT01201213|Active Comparator|Extradural ropivacaine|local anaesthetic
11521946|NCT01201213|Active Comparator|Intrathecal bupivacaine|local anaesthetic
11521947|NCT01201213|Active Comparator|Intrathecal levobupivacaine|local anaesthetic
11521948|NCT01201213|Active Comparator|Intrathecal ropivacaine|local anesthetic
11521949|NCT01201200||Group 1 - Obstructive Sleep Apnea (OSA)|Fifty-six patients with Obstructive Sleep Apnea
11521950|NCT01201200||Group 2 - Non-OSA Controls|Fifty individuals without OSA with similar age, gender and body mass index (BMI)
11521951|NCT01201200||Group 3 - Treatment|Fifteen patients with moderate and severe sleep apnea from group 1 underwent treatment with continuous positive airway pressure
11521952|NCT01201200||Group 4 - Placebo|Fifteen patients with moderate/severe sleep apnea underwent to placebo
11521953|NCT01201187|Experimental|YY-162|YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
11521954|NCT01201187|Placebo Comparator|Placebo|Placebo 1T/twice a day(bid) for 8weeks, po medication
11521955|NCT01201174|No Intervention|Patients with Hereditary Spherocytosis|All patients should have clinical and laboratory findings, consistent with mild to severe HS, diagnosed on the basis of spherocyte morphology, elevated MCHC (33-38 g/dl), with a mean value of (35.47 g/dl), increased osmotic fragility , splenomegaly and non-immune mediated hemolysis.
11521956|NCT01201161|Experimental|RANI/PPV|Preoperative intravitreal ranibizumab and pars plana vitrectomy
11521957|NCT01201161|Placebo Comparator|PPV|Sham injection and pars plana vitrectomy
11521958|NCT01201148|Experimental|Oscillating or intermittent tDCS|
11521959|NCT01201135||Sickle cell disease|
11521960|NCT01201135||hereditary spherocytosis.|
11521961|NCT01201122|Experimental|Weight based Mesalamine: Once daily|
11521962|NCT01201122|Experimental|Weight based Mesalamine: Twice daily|
11521963|NCT01201109||Diabetics|Diabetic patients operated for carpal tunnel syndrome
11521964|NCT01201109||Non-diabetics|Non-diabetic patients operated for carpal tunnel syndrome
11521965|NCT01201096||peptide radioreceptor therapy and liver transplantation|
11521966|NCT01201083||HIV-|This study measured how transmission risks and partnership dynamics change over time among recently HIV-infected individuals and their partners comparing their behavioral patterns with those with chronic HIV infection, no HIV infection, and HIV negative testers. Of special focus was the role of drug use, especially methamphetamine, in affecting behaviors over time, and how partnership dynamics interact with drug use to allow for HIV transmission. The study compared behaviors of recently HIV infected men to those with long-term HIV infection and no HIV infection. We looked at how different types of sex partners affected one's drug use and consequently HIV transmission risks including having a prevalent sexually transmitted infection (STI). The study enrolled 105 HIV- recently tested men who have sex with men (MSM) and followed them for a year.
11521967|NCT01201083||HIV+ Acutely Infected|This study enrolled and followed 125 acutely infected HIV+ men. It measured how transmission risks and partnership dynamics change over time among recently HIV-infected individuals and their partners comparing their behavioral patterns with those with chronic HIV infection, no HIV infection, and HIV negative testers. Of special focus was the role of drug use, especially methamphetamine, in affecting behaviors over time, and how partnership dynamics interact with drug use to allow for HIV transmission. The study compared behaviors of recently HIV infected men to those with long-term HIV infection and no HIV infection. We looked at how different types of sex partners affected one's drug use and consequently HIV transmission risks including having a prevalent sexually transmitted infection (STI). The study enrolled 321 recently tested men who have sex with men (MSM) and followed them for a year.
11522002|NCT01200862|Experimental|BGS649 (Part 2)|0.3 or 0.1mg hard gelatin capsules of BGS649 given orally. 0.3mg on Day 1 and 0.1 on all other treatment visits (week 1 to 11).
11522567|NCT01196871|Experimental|Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg)|
11521968|NCT01201083||HIV+ Chronically Infected|This study enrolled and followed 91chronicially infected HIV+ men. It measured how transmission risks and partnership dynamics change over time among recently HIV-infected individuals and their partners comparing their behavioral patterns with those with chronic HIV infection, no HIV infection, and HIV negative testers. Of special focus was the role of drug use, especially methamphetamine, in affecting behaviors over time, and how partnership dynamics interact with drug use to allow for HIV transmission. The study compared behaviors of recently HIV infected men to those with long-term HIV infection and no HIV infection. We looked at how different types of sex partners affected one's drug use and consequently HIV transmission risks including having a prevalent sexually transmitted infection (STI). The study enrolled 321 recently tested men who have sex with men (MSM) and followed them for a year.
11521969|NCT01201070|No Intervention|control group|
11521970|NCT01201070|No Intervention|no treatment|
11521971|NCT01201070|Active Comparator|TREATMENT WITH ANTITHROMBIN|3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
11521972|NCT01201057|Experimental|0.5% SPL7013 Gel|
11521973|NCT01201057|Experimental|1.0% SPL7013 Gel|
11521974|NCT01201057|Experimental|3.0% SPL7013 Gel|
11521975|NCT01201057|Placebo Comparator|Placebo Gel|
11521976|NCT01201044|Experimental|Gemcitabine, Nedaplatin,BAI plus 3DCRT|"Gemcitabine(1000mg/m2)，Nedaplatin(60mg/m2),BAI, Day 1/4weeks. 4weeks per cycle. Tumor assessment will be perforemd after 2 cycles. if no PD, patient will be treated with 3DCRTfor 1 month. for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin.
~then patient will be followed for 1 year.."
11521977|NCT01201044|Other|Gemcitabine, Nedaplatin, IV Plus 3DCRT|"Gemcitabine 100mg/m2, D1 & D8 every 4 weeks Nedaplatin 75mg/m2, D1 every 4 weeks. every 4 weeks per cycle. Tumor assessment will be performed after 2 cycles. if no PD, patient will be treated with 3DCRT for 1 month.
~for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin.
~then patient will be followed for 1 year."
11521978|NCT01201018|Experimental|Oshadi DR|
11521979|NCT01201005|Active Comparator|Hydroxycobalamin|"Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma) is given as a singel intramuscular injection.
~The syringe is covered so it is impossible to see whether it contains any substance"
11521980|NCT01201005|Sham Comparator|needle injection|"The controls receive an intramuscular injection: which is merely an introduction of the needle into the muscle whithout any injection. The syringe is covered so it is not possible to see whether the syringe contains any substance"
11521981|NCT01200992|Experimental|EN3348|8 mg mixed with sterile water for injection for a total volume of 50mL
11521982|NCT01200992|Active Comparator|Mitomycin C|40 mg powder will be reconstituted with sterile water for injection to a total volume of 40 mL
11521983|NCT01200979||pregnant flu vaccinated|pregnant women that choose to receive the seasonal flu vaccine
11521984|NCT01200979||pregnant non-flu vaccinated|pregnant women that do not receive the flu vaccine
11521985|NCT01200953||Confirmed or suspected exposure|Confirmed or suspected exposure to biodefense select agent, to agent of bioterrorism concern, to naturally-occurring pathogen in the environment, to EID agent, or to an individual
11521986|NCT01200953||Confirmed or suspected infection|Confirmed or suspected infection by biodefense select agent, by agent of bioterrorism concern, by naturally-occurring pathogen in the environment, or by emerging infectious disease agent
11521987|NCT01200953||Healthcare worker or healthy volunteer|Healthcare worker or healthy volunteer involved in simulation drills or exercises evaluating the Clinical Center admission, care, and infection control processes
11521988|NCT01200953||Healthcare worker surveillance|Healthcare worker surveillance of medical staff involved in the medical care of patients in the above 2 categories
11521989|NCT01200940|Experimental|Phase I - Low-dose sweetener|68 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
11521990|NCT01200940|Experimental|Phase I - Medium-dose sweetener|170 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
11521991|NCT01200940|Placebo Comparator|Phase I Control Condition|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
11521992|NCT01200940|Experimental|Phase I- High-dose sweetener|250 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test.
11521993|NCT01200940|Placebo Comparator|Phase II - Control Condition|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
11521994|NCT01200940|Experimental|Phase II - Diet Soda 1|less than or equal to 5mg/kg sucralose, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
11521995|NCT01200940|Experimental|Phase II - Diet Soda 2|less than or equal to 5 mg/kg sucralose, less than or equal to 50 mg/kg aspartame, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
11521996|NCT01200940|Experimental|Phase II - Water with sucralose and acesulfame-potassium|less than or equal to 5mg/kg sucralose, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
11521997|NCT01200914|Active Comparator|'PTA without use of the GORE VIABAHN'|Subjects randomized to 'PTA alone without use of the GORE VIABAHN' will receive the standard of care treatment which is Percutaneous Transluminal Angioplasty without the use of the 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
11521998|NCT01200914|Experimental|PTA with covered stent|Subjects randomized to PTA with covered stent will receive Percutaneous Transluminal Angioplasty followed by the delivery of a 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' .
11521999|NCT01200901|Experimental|Melancolic depression patients|Patients with major depression will be recruited for the 8-week clinical trial of quetiapine XR 100 - 300 mg (flexible dosing).
11522000|NCT01200862|Experimental|BGS649 (Part 1)|BGS649 1mg and 0.1mg in hard gelatin capsules. In part 1 there was individualised dosing to titrate the subject's testosterone into the normal range. If the dose was lower than 0.1mg then specific instructions for dilution of an oral solution of BGS649 were provided.
11522001|NCT01200862|Placebo Comparator|Placebo to BGS649 (Part 2)|Matching placebo to BGS649 (0.3 and 0.1mg). 0.3mg placebo capsule given on Day 1 and 0.1mg placebo capsule on other treatment visits (week 1 to 11).
11522003|NCT01200849|Experimental|Enhanced Label|Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
11522004|NCT01200849|No Intervention|Standard Label|Subjects in this arm will receive their prescriptions labeled with a standard label.
11522005|NCT01200810|Placebo Comparator|Arm I|"Patients receive oral placebo once daily on days 1-3, 8-10, and 15-17. Treatment repeats every 21 days for 18 courses in the absence of PSA progression.
~COMBINATION PHASE: All patients then receive oral bicalutamide once daily on days 1-21 and oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity."
11522006|NCT01200810|Experimental|Arm II|"Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Treatment repeats every 21 days for 18 courses in the absence of PSA progression.
~COMBINATION PHASE: All patients then receive oral bicalutamide once daily on days 1-21 and oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity."
11522007|NCT01200797|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11522008|NCT01200784|Experimental|250 mg/d modified release Nicotinamide|
11522009|NCT01200784|Experimental|500 mg/d modified release Nicotinamide|
11522010|NCT01200784|Experimental|750 mg/d modified release Nicotinamide|
11522011|NCT01200784|Experimental|1000 mg/d modified release Nicotinamide|
11522012|NCT01200784|Active Comparator|1000 mg/d immidiate release Nicotinamide|
11522013|NCT01200758|Active Comparator|Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)|Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) in combination with up to 8 cycles of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) or cyclophosphamide, vincristine, prednisolone (CVP) chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.
11522014|NCT01200758|Experimental|Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)|First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
11522015|NCT01200745|Active Comparator|capsaicin patch|
11522016|NCT01200745|Placebo Comparator|Hydrogel patch|
11522017|NCT01200732|Active Comparator|Tadalafil|
11522018|NCT01200732|Placebo Comparator|placebo|
11522019|NCT01200719|Experimental|tACS group|
11522020|NCT01200719|No Intervention|Control group|Patients in the control group followed exactly the same protocol but without receiving the transcranial alternating current stimulation .
11522021|NCT01200706|Active Comparator|Amoxicillin given twice a day|
11522022|NCT01200706|Active Comparator|Amoxicillin given three times a day|
11522023|NCT01200693|Active Comparator|ZES|Patients with coronary bifurcation lesions treated by Zotarolimus eluting stent
11522024|NCT01200693|Active Comparator|SES|Patients with coronary bifurcation lesions treated by Sirolimus eluting stent
11522025|NCT01200693|Active Comparator|EES|Patients with coronary bifurcation lesions treated by Everolimus eluting stent
11522026|NCT01200680||chordoma cohort|Chordoma patients
11522027|NCT01200654|Experimental|MRSA Infections|Methicillin-Resistant Staphylococcus aureus Infections
11522028|NCT01200641|Active Comparator|melatonin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6
~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
11522029|NCT01200641|Active Comparator|gabapentin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6
~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
11522030|NCT01200641|Placebo Comparator|placebo|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6
~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
11522031|NCT01200628||Road traffic accident victims|Cohort of patients hospitalized in surgical department after a motor vehicle accident less than 2 weeks
11522032|NCT01200615|Other|Explanation about common side effects|50 patients started on SSRI's will be updated about its common side effects
11522033|NCT01200615|Other|Explaning side effects and the nocebo effect|subjects started on SSRI's will be updated about its common side effects and the nocebo effect
11522034|NCT01200615|Other|explanation about the nocebo effect|3. 50 patients started on SSRI's will receive an explenation on the nocebo effect, but will not be updated about common side-effects. Nonetheless, they will be informed of severe side-effects.
11522035|NCT01200602|Experimental|Arm A|Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.
11522036|NCT01200602|Active Comparator|Arm B|Patients have clinical observation for weight loss and gain for 4 weeks.
11522037|NCT01200589|Experimental|Arm A: Ofatumumab|Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.
11522038|NCT01200589|Active Comparator|Arm B: Rituximab|Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.
11522039|NCT01200576||1|healthy volunteers
11522040|NCT01200563|Active Comparator|Group 1|Subjects assigned to receive MIST Therapy will be treated 3 times per week. The duration of each MIST treatment will be dependent on the wound's area measured at baseline and at each weekly assessment.
11522041|NCT01200563|Active Comparator|Group 2|Subjects assigned to receive Negative Pressure Wound Therapy will be treated with the Vacuum Assisted Closure system. For administration of this study treatment, e.g., treatment cycle, target pressure and dressing changes, the manufacturer's recommended guidelines will be followed.
11522042|NCT01200563|Active Comparator|Group 3|Subjects assigned to this group will receive MIST Therapy treatments and Negative Pressure Wound Therapy.
11522043|NCT01200550||1|
11522044|NCT01200537|Active Comparator|Estradiol Patch|This group of patients will receive estradiol patches prior to the IVF cycle.
11522045|NCT01200537|Active Comparator|Oral Contraceptive Pills (OCP)|This group of patients will receive OCP's prior to the IVF cycle.
11522046|NCT01200524|Experimental|AZD2423, 20mg|
11522047|NCT01200524|Experimental|AZD2423, 150 mg|
11522048|NCT01200524|Placebo Comparator|Placebo|Tablet to match the 20 mg and 50 mg AZD2423 active tablet
11522049|NCT01200511|Experimental|ReSTOR +3.0|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
11522050|NCT01200498|Experimental|SB939|SB939 starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
11522051|NCT01200485|Experimental|Rasburicase Alone|Rasburicase by vein on Day 1 (0.15 mg/kg or a flat dose of 3 mg) as a single dose, plus as needed dosing (until day 5), during cycle 1 (21 day cycle).
11522052|NCT01200485|Experimental|Arm A (Rasburicase)|Participants randomized to Rasburicase (0.15 mg/kg) by vein on day 1 plus as needed dosing (until day 5) during Cycle 2.
11522053|NCT01200485|Experimental|Arm B (Allopurinol)|Participants randomized to Allopurinol (300 mg/day) by vein each day on Days 1-5 of Cycle 2.
11522054|NCT01200472|Experimental|Apremilast capsules|Apremilast in 10 mg capsules
11522055|NCT01200472|Placebo Comparator|Placebo|
11522056|NCT01200459|Experimental|Social/Mobile Intervention|Theory-based intervention to promote weight loss utilizing web, mobile phone and social media.
11522057|NCT01200459|No Intervention|Control|"Participants randomized to this group will have access to usual care health information via the SMART study website. This arm will be compared to our intervention group."
11522058|NCT01200446|Placebo Comparator|Placebo Docosahexaenoic Acid (DHA)|Eight subjects will take 8 placebo DHA capsules per day for 3 weeks.
11522059|NCT01200446|Experimental|Active Docosahexaenoic Acid (DHA)|Eight subjects will take 8 active DHA capsules per day for 3 weeks.
11522060|NCT01200433|Active Comparator|propofol|Subjects will be sedated with propofol.
11522061|NCT01200433|Active Comparator|dexmedetomidine|Subjects will be sedated with dexmedetomidine.
11522062|NCT01200420|Experimental|miravirsen|Dose escalation study with review of safety data following each cohort.
11522063|NCT01200420|Placebo Comparator|saline|Dose escalation study with review of safety data following each cohort.
11522064|NCT01200407||Filipino Hypertensive patients|Male and Female, 18 to 65 year old Filipino hypertensive patients prescribed by their doctors with Normetec
11522065|NCT01200394|Experimental|PF-00489791|
11522066|NCT01200394|Placebo Comparator|Placebo|
11522067|NCT01200381|Active Comparator|Group A|Automatic anonymous ICD/CRTD follow up (quarterly remote follow ups)
11522068|NCT01200381|Active Comparator|Group B1|Personal ICD/CRTD follow up (phone calls + quarterly remote follow ups)
11522069|NCT01200381|Active Comparator|Group B2|Personal ICD/CRTD follow up (Quarterly visits)
11522070|NCT01200368|Experimental|1|Experimental
11522071|NCT01200368|Active Comparator|2|Active comparator
11522072|NCT01200368|Active Comparator|3|Active comparator
11522073|NCT01200355|Experimental|micafungin|This is a single institution (MSKCC), randomized, open-label comparative trial of micafungin and posaconazole administered as prophylaxis against fungal infections during neutropenia following induction chemotherapy for myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS).
11522074|NCT01200355|Experimental|posaconazole|This is a single institution (MSKCC), randomized, open-label comparative trial of micafungin and posaconazole administered as prophylaxis against fungal infections during neutropenia following induction chemotherapy for myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS).
11522075|NCT01200342|Experimental|Genasense + Paclitaxel + Carboplatin|Genasense 900 mg intravenous (IV) on a fixed-dose as a 1-hour infusion on Days 1, 3, and 5 of a 21 day cycle; Paclitaxel 175 mg/m^2 IV over 3 hours Day 3 after Genasense; Carboplatin dose in mg (target area under the concentration [AUC)]=6) administered over 30 minutes IV Piggyback (IVPB) on Day 3 after Paclitaxel.
11522076|NCT01200329|Experimental|Gemcitabine + Busulfan + Melphalan|Gemcitabine 2775 mg/m2 by vein over about 3 hours on days -8 and -3. Busulfan 32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient. AUC 4,000 by vein over about 3 hours on days -8 to -5. Melphalan 60 mg/m2 by vein over about 30 minutes on days -3 and -2. Palifermin 60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2. Infusion of stem cells on Day 0.
11522077|NCT01200316|Experimental|Standard of Care Group|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
11522078|NCT01200316|Experimental|Rocking Motion Group|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
11522079|NCT01200303|Active Comparator|non-cathartic CTC and OC|This is a single arm, open label, prospective test comparison of non-cathartic, CAD-assisted CTC to segmentally unblinded optical colonoscopy (OC). All study subjects receive both tests, starting with CTC, followed by OC within 5 weeks. CTC results are recorded and revealed to endoscopist on a segment-by-segment basis after initial (blinded) OC evaluation; endoscopist can double check / confirm lesion presence after unblinding and this second read serves as reference standard.
11522080|NCT01200290|Experimental|LY2127399|
11522081|NCT01200277|Experimental|vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
11522125|NCT01199952|Experimental|Intervention|Intervention arm receives a counseling phone call 3 to 4 weeks after enrollment. The call is from a health educator intended to assist with contraception.
11522126|NCT01199939|Experimental|ETR + DRV/rtv|Darunavir 800mg once daily orally for 48 weeks,Etravirine 400mg once daily orally for 48 weeks,Ritonavir 100mg once daily orally for 48 weeks
11522082|NCT01200277|Sham Comparator|sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the bone cement is prepared to simulate the odor associated with mixing of polymethacrylate , but the needle is not placed and cement is not injected.
11522083|NCT01200264|Experimental|apremilast for all subjects|
11522084|NCT01200251|Experimental|Bimatoprost treated eyelid|one eyelid of the patient was randomized to the treatment arm and given the gel to use
11522085|NCT01200251|No Intervention|control arm - no gel|the other fellow eyelid of the patient did not receive any treatment until month 4 and the patient crossed over to treating both eyelids
11522086|NCT01200238|Experimental|STA-9090: Cohort A|"Cohort A participants received STA-9090 200 mg/m2 given intravenously (IV) over 1 hour once weekly (d1, 8, 15 of a 28 day cycle).
~Participants were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal."
11522087|NCT01200238|Experimental|STA-9090: Cohort B|"Cohort B participants received STA-9090 150 mg/m2 given intravenously over 1 hour (IV) twice weekly (d1, 4, 8, 11, 15, 18 of a 28 day cycle).
~Participants were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal."
11522088|NCT01200225||Cohort|
11522089|NCT01200212|Experimental|A|A Taxane (80mg/m2 Paclitaxel weekly or 75mg/m2 Docetaxel day1 q22) + 15mg/kg Bevacizumab day1 q22 + 1800 mg/m2 Capecitabine day 1-14 q22
11522090|NCT01200212|Active Comparator|B|A Taxane (80mg/m2 Paclitaxel weekly or 75mg/m2 Docetaxel day1 q22) + 15mg/kg Bevacizumab day1 q22
11522091|NCT01200199||Varicose veins|
11522092|NCT01200186||Group 1|
11522093|NCT01200186||Group 2|
11522094|NCT01200173|Active Comparator|1 = Tested product|
11522095|NCT01200173|Sham Comparator|2 = Control product|
11522096|NCT01200160||Lipid abnormalities|Niacin
11522097|NCT01200147|Active Comparator|Biopsy Arm|
11522098|NCT01200147|Active Comparator|Dilation Arm|
11522099|NCT01200134|Experimental|18F-FMISO PET-scanning|Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
11522100|NCT01200121|Experimental|Arm A Bevacizumab|48 patients randomized into arm A will receive repeated intra¬peritoneal application of Bevacizumab
11522101|NCT01200121|Placebo Comparator|Arm B Placebo|26 patients randomized into arm B will receive repeated intra¬peritoneal application of Placebo
11522102|NCT01200108|Experimental|Budesonide high dose via AKITA (1mg/2ml)|
11522103|NCT01200108|Experimental|Budesonide low dose via AKITA (0.5mg/2ml)|
11522104|NCT01200108|Active Comparator|Budesonide high dose via conventional nebulizer (1mg/2ml)|
11522105|NCT01200108|No Intervention|Placebo via AKITA|
11522106|NCT01200082||Healthy Controls|Male or female, age 19-65, no apparent signs of hepatobiliary diseases
11522107|NCT01200082||Patients with hepatobiliary diseases|Male or female, age 19-65, visiting the UNMC hepatology clinic for treatment from hepatobiliary diseases
11522108|NCT01200069|Placebo Comparator|Sugar water|500 milliliters of intravenous ringers lactate administered over 30 minutes prior to ECT for treatments 1,2 and 3
11522109|NCT01200069|Active Comparator|Ibuprofen|300mg/8milliliters of intravenous ibuprofen/caldolor over 30 min in 500mL of ringers lactate to be administered prior to ECT for treatments # 1, 2 and 3
11522110|NCT01200056|Active Comparator|Atorvastatin 10mg low dose|Atorvastatin 10mg daily for 6 months and compared to atorvastatin 40mg daily in the other arm. The primary endpoint of 6 months VH-IVUS findings and clinical outcomes would be monitored and compared.
11522111|NCT01200056|Active Comparator|Atorvastatin 40mg moderate dose|Atorvastatin 40mg daily for 6 months and compared to atorvastatin 10mg daily in the other arm. The primary endpoint of 6 months VH-IVUS findings and clinical outcomes would be monitored and compared.
11522112|NCT01200043|Experimental|fructose restriction|Isocaloric fructose restricted diet for 10 days
11522113|NCT01200030|Experimental|electrical stimulation with exercises|The TENS + TRTT group received TENS simultaneously with the TRTT at home under the instruction of a physical therapist.
11522114|NCT01200030|Placebo Comparator|placebo stimulation with exercises|The TENS + TRTT group received placebo-simultaneously with the TRTT at home under the instruction of a physical therapist.
11522115|NCT01200030|No Intervention|Control|Subjects in this group did not receive any active training. Home safety advice and health education including diet control and blood pressure monitoring were given to the subjects during the home-visit and telephone follow-up.
11522116|NCT01200004|Experimental|Azacitidine + Lenalidomide|Azacitidine 75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle. Lenalidomide starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
11522117|NCT01200004|Experimental|Azacitidine + Lenalidomide + Grifola Frondosa|Once Lenalidomide MTD identified in combination with azacitidine, Grifola frondosa added. Cycle 1, azacitidine on day 1, lenalidomide on day 2 and Grifola frondosa on day 3. Azacitidine daily for 5 days every 28 days while lenalidomide and Grifola frondosa on days 1-21 of subsequent cycles.
11522118|NCT01200004|Experimental|Expansion Group A|Azacitidine + Lenalidomide MTD, then 2 weeks later Grifola frondosa
11522119|NCT01200004|Experimental|Expansion Group B|Azacitidine + Grifola Frondosa, then 2 weeks later Lenalidomide
11522120|NCT01199991||Normative database|
11522121|NCT01199978|Other|Fractionated Proton Radiation|Single arm study, delivering fractionated radiation with a technique (proton therapy) that may be associated with reduced side effects
11522122|NCT01199965|Other|IV DHE then MAP0004|Smokers and non-smokers received Intravenous Dihydroergotamine Mesylate (IV DHE) at Visit 2 followed by MAP0004 7-11 days later at Visit 3.
11522123|NCT01199965|Other|MAP0004 then IV DHE|Smokers and non-smokers received MAP0004 at Visit 2 followed by Intravenous Dihydroergotamine Mesylate (IV DHE) 7-11 days later at Visit 3.
11522124|NCT01199952|No Intervention|Control|The control group will not receive a counseling phone call one month after enrollment.
11522236|NCT01199289|Experimental|AMG 827 280 mg|280 mg AMG 827
11522127|NCT01199926|Experimental|Vitamin D|Participants in this arm consumed a 4000 IU vitamin D supplement daily for 12 weeks while participating in a resistance exercise training program.
11522128|NCT01199926|Placebo Comparator|Placebo|Participants in this arm consumed a placebo (microcrystalline cellulose) daily for 12 weeks while participating in a resistance exercise training program.
11522129|NCT01199913||desflurane and sevoflurane|Subjects will be randomized to either desflurane or sevoflurane. They will be given the Mini Mental State exam at 1, 6 and 24 hours after the end of anesthesia.
11522130|NCT01199900|Experimental|(Part 1) 25 mg PF-04171327 predosed at -8 hours prior to OGTT|
11522131|NCT01199900|Experimental|(Part 1) 25 mg PF-04171327 predosed at -12 hours prior to OGTT|
11522132|NCT01199900|Active Comparator|(Part 1) 5 mg Prednisone|5 mg prednisone tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
11522133|NCT01199900|Experimental|(Part 2) 3 mg PF-04171327|
11522134|NCT01199900|Experimental|(Part 2) 10 mg PF-04171327|
11522135|NCT01199900|Active Comparator|(Part 2) 5 mg Prednisone|
11522136|NCT01199900|Active Comparator|(Part 2) 20 mg Prednisone|
11522137|NCT01199887|Experimental|IW001|Three dose cohorts, 0.1 mg, 0.5 mg, 1.0 mg
11522138|NCT01199874|Active Comparator|Primary 1: Rotavirus vaccine 6 and 10 weeks|EPI vaccines + rotavirus vaccine at 6 and 10 weeks
11522139|NCT01199874|Experimental|Primary 1: Rotavirus vaccine 6, 10 and 14 weeks|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks
11522140|NCT01199874|Experimental|Primary 1: Rotavirus vaccine 10 and 14 weeks|EPI vaccines + rotavirus vaccine at 10 and 14 weeks
11522141|NCT01199874|Experimental|Primary 2: Rotavirus vaccine withholding breast feeding|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks withholding breastfeeding
11522142|NCT01199874|Experimental|Primary 2: Rotavirus vaccine with immediate breast feeding|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks with immediate breastfeeding
11522143|NCT01199874|No Intervention|Baseline seroconversion for rotavirus|EPI vaccines
11522144|NCT01199861|Experimental|Fingolimod|Participants received Fingolimod 0.5 mg capsules orally once daily for 12 weeks. At Week 6 of study treatment participants received a seasonal influenza vaccination and a tetanus booster vaccination.
11522145|NCT01199861|Placebo Comparator|Placebo|Participants received placebo tablets orally once daily for 12 weeks. At Week 6 of study treatment participants received a seasonal influenza vaccination and a tetanus booster vaccination.
11522146|NCT01199848|Placebo Comparator|Placebo|Pbo
11522147|NCT01199848|Experimental|10G STRB powder|Dose 1
11522148|NCT01199848|Experimental|20G STRB powder|Dose 2
11522149|NCT01199848|Experimental|40G STRB powder|Dose 3
11522150|NCT01199848|Placebo Comparator|PlacebonoFiber|Placebo without fiber
11522151|NCT01199835|Experimental|high calcium|Dietary intake of calcium ~ 1500 mg/ d, including ~1200 mg/d from dairy products
11522152|NCT01199835|Active Comparator|Low calcium|Low dietary intake of calcium, i.e. ~ <600 mg/d, including 0-1 portion of dairy products
11522153|NCT01199822|Experimental|Olaratumab|
11522154|NCT01199809|Experimental|1|
11522155|NCT01199809|Placebo Comparator|2|
11522156|NCT01199783|Experimental|Daptomycin|Infusion of Daptomycin (6 mg/kg bodyweight) once daily
11522157|NCT01199783|Active Comparator|Vancomycin|Vancomycin once daily (effective blood-plasma concentration of 15 mg/l)
11522158|NCT01199770|Experimental|experimental pasta B, small|small portion experimental pasta B
11522159|NCT01199770|Experimental|experimental pasta C, small portion|small portion experimental pasta C
11522160|NCT01199770|Placebo Comparator|Control pasta, small|small portion Control pasta
11522161|NCT01199770|Other|No Load|Only water
11522162|NCT01199770|Active Comparator|Control pasta, medium|medium portion Control pasta
11522163|NCT01199770|Experimental|experimental pasta B, medium portion|medium portion experimental pasta B
11522164|NCT01199770|Experimental|experimental pasta C, medium portion|medium portion experimental pasta B
11522165|NCT01199757||FF|Cohort of patients receiving fluticasome furoate
11522166|NCT01199757||MF|cohort of patients on mometasone furoate
11522167|NCT01199757||FP|cohort of patients receiving fluticasone propionate
11522168|NCT01199744||Influenza virus infection patients exposed to zanamivir|Safety of Influenza virus infection patients exposed to zanamivir
11522169|NCT01199731|Experimental|GSK2248761 100mg OAD|In combination with darunavir/ritonavir BID and raltegravir BID
11522170|NCT01199731|Experimental|GSK2248761 200mg OAD|In combination with darunavir/ritonavir BID and raltegravir BID
11522171|NCT01199731|Active Comparator|Etravirine|In combination with darunavir/ritonavir BID and raltegravir BID
11522172|NCT01199718|Experimental|CX-4945|CX-4945 oral formulation
11522173|NCT01199705|Experimental|IgPro20|
11522174|NCT01199692||Age|
11522175|NCT01199692||Gender|
11522176|NCT01199692||Ethnicity|
11522177|NCT01199692||Body Mass Distribution|
11522178|NCT01199692||Dietary Habits|
11522179|NCT01199692||Exercise Habits|
11522180|NCT01199692||Medication Requirements|
11522181|NCT01199692||Disease State Burden|
11522182|NCT01199679|Experimental|Endoscopic Mucosal Resection (EMR) Group|
11522183|NCT01199679|Experimental|Banding Group|
11522184|NCT01199666|Experimental|Text message reminders|
11522185|NCT01199666|Active Comparator|standard of care for MMR, letter reminder for Hep A|MMR: automated phone call appointment reminder Hep A: recall letter, automated phone call appointment reminder
11522186|NCT01199653|Active Comparator|Non-operative treatment|Non-operative (conservative) treatment of the clavicle fracture
11522187|NCT01199653|Active Comparator|Operative treatment|Operative stabilization (i.e. ORIF) of the fracture with a plate and screws.
11522188|NCT01199640|Experimental|MLN1202|
11522189|NCT01199627|Experimental|A|"Group A: 1st dose 15mg/kg of TXA (tranexamic acid) in 100ml saline 0.9% after the completion of regional anesthesia, and before the start of surgery.
~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
11522237|NCT01199289|Placebo Comparator|Placebo|Placebo
11522238|NCT01199289|Experimental|AMG 827 140 mg|140 mg AMG 827
11522190|NCT01199627|Experimental|B|"Group B: 1st dose: 10mg/kg of TXA (tranexamic acid) in 100ml 0.9% saline after the completion of regional anesthesia, and before the start of surgery.
~2nd dose: intravenous infusion over 10 minutes of 10mg/kg of TXA in 100ml saline 0.9% at three hours after the first administration."
11522191|NCT01199627|Placebo Comparator|C|Placebo
11522192|NCT01199614|Experimental|open-label PTH(1-84)|open-label PTH(1-84) / variable dosing: 25mcg every other day, 25mcg every day, 50mcg every day, 75mcg every day, 100mcg every day
11522193|NCT01199601|Experimental|Concentrated postpartum counseling|Women randomized to receiving concentrated postpartum counseling from the retrained provider.
11522194|NCT01199601|No Intervention|Routine postpartum counseling|Women receiving intra-partum testing and post-partum counseling from existing cadres of hospital providers at standard of care.
11522195|NCT01199588|Experimental|Nexagon® High Dose|Weekly applications of Nexagon® high dose in addition to compression dressings.
11522196|NCT01199588|Placebo Comparator|Nexagon® Vehicle|Weekly applications of Nexagon® Vehicle in addition to compression dressings.
11522197|NCT01199588|No Intervention|No Investigational Product|Weekly application of compression dressings.
11522198|NCT01199588|Experimental|Nexagon® Low Dose|Weekly applications of Nexagon® low dose in addition to compression dressings.
11522199|NCT01199575|Experimental|Revlimid + Rituximab|"A: Lenalidomide starting at a low dose 2.5 or 5 mg, 21 days/cycle escalated based on patient tolerability. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles (3-7). Each patient may receive up to 7 cycles of treatment with the combination lenalidomide/rituximab if no progressive disease or significant toxicity. Patients with residual disease can elect to receive 6 additional cycles of single agent Revlimid as consolidation.
~Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity."
11522200|NCT01199562||Arm I|Patients receive standard antiviral infection prophylaxis and management comprising ganciclovir, valganciclovir, or foscarnet sodium for 2 weeks or until the plasma CMV DNA Q-PCR is negative. Patients may receive additional courses based on subsequent CMV reactivations.
11522201|NCT01199549||Lycopene group|Mixed age and gender group of healthy volunteers for testing bio-availability of Lycopene containing supplement
11522202|NCT01199549||Resveratrol group|Mixed age and gender group of healthy volunteers for testing bio-availability of Resveratrol containing supplement
11522203|NCT01199549||Laflavon group|Mixed age and gender group of healthy volunteers for testing bio-availability of Soy Isoflavones containing supplement
11522204|NCT01199536||1|patients with Helicobacter-positive duodenal ulcer
11522205|NCT01199523|Placebo Comparator|Placebo|
11522206|NCT01199523|Experimental|mirabegron high dose|
11522207|NCT01199523|Experimental|mirabegron medium dose|
11522208|NCT01199523|Experimental|mirabegron low dose|
11522209|NCT01199523|Active Comparator|moxifloxacin|
11522210|NCT01199510|Experimental|Standard of Care plus FID 112903|SYSTANE® ULTRA Lubricant Eye Drops dosed 4 times daily
11522211|NCT01199510|Active Comparator|Standard of Care only|Post Cataract Standard of Care Regimen
11522212|NCT01199497|Experimental|Group 1|Fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
11522213|NCT01199497|Placebo Comparator|Group 2|Placebo
11522214|NCT01199471||Chinese Patients Requiring Surgery with Anesthesia|Chinese patients 18 to 70 years of age, meeting the American Society of Anesthesiologists (ASA) Physical Status Class 1 (normal healthy), Class 2 (mild systemic disease), or Class 3 (severe systemic disease), who underwent surgery requiring general anesthesia (sevoflurane) administered per local Prescribing Information and endotracheal intubation or laryngeal mask airway (LMA).
11522215|NCT01199458|Active Comparator|opioid|Preoxygenation for 5 min. Injection of opioid (alfentanil 20 mikrogr/kg iv) after 2 min:Injection of induction drug(propofol 2-2.5mg/kg) after anesthesia induction: Application of cricoid pressure for 15 sec.
11522216|NCT01199458|Placebo Comparator|placebo|Preoxygenation for 5 min. Injection of saline iv. after 2 min:Injection of induction drug(propofol 2-2.5mg/kg) after anesthesia induction: Application of cricoid pressure for 15 sec.
11522217|NCT01199445|Experimental|triple fortified extruded rice|
11522218|NCT01199445|Other|regular meal|regular vitamin A meal
11522219|NCT01199432|Experimental|Group B(CEF)|
11522220|NCT01199432|Experimental|Group A(CEFci)|
11522221|NCT01199432|Active Comparator|Group C(EC)|
11522222|NCT01199419||PCI|
11522223|NCT01199419||CABG|
11522224|NCT01199406|Placebo Comparator|normal saline|80 mL 0.9% NaCl
11522225|NCT01199406|Experimental|Levobupivacaine|80mL 0.125% levobupivacaine
11522226|NCT01199380|Active Comparator|Standard Treatment (ST)|Participants will receive a standard, group smoking cessation treatment equated for contact time, based on the most recent clinical practice guideline for treating tobacco. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will complete between group exercises and will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events. Participants will also receive 8 weeks of the transdermal nicotine patch.
11522227|NCT01199380|Experimental|Behavioral Activation for Smoking|Behavioral Activation Treatment for Smoking (BATS) includes standard smoking cessation strategies and identifying life areas, values, and daily activities to help manage mood. Participants will complete between group exercises and will also monitor and plan daily activities in line with their values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Participants will also receive 8 weeks of the transdermal nicotine patch.
11522228|NCT01199367|Experimental|Dose escallation|
11522229|NCT01199341|Experimental|Treatment A|AZD1981, low dose, + Warfarin
11522230|NCT01199341|Experimental|Treatment B|AZD1981, high dose, + Warfarin
11522231|NCT01199328|Active Comparator|1|Aspirin 81 mg
11522232|NCT01199328|Active Comparator|2|Esomeprazole 20mg/aspirin 81mg
11522233|NCT01199315|Experimental|1|Oral capsule. Dose single and followed by 5-day repeated dosing. Specific doses depend on panel.
11522234|NCT01199315|Placebo Comparator|2|Oral capsule. Dose single and followed by 5-day repeated dosing.
11522235|NCT01199302|Experimental|350 mg|
11522241|NCT01199276|Active Comparator|Sevoflurane|1.1-1.4% (1 MAC) in oxygen (FiO2 = 0.35-0.45) and medical air
11522242|NCT01199263|Experimental|Arm I (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
11522243|NCT01199263|Experimental|Arm II (paclitaxel and wild-type reovirus)|Patients receive paclitaxel as in arm I and wild-type reovirus IV over 1 hour on days 1-5.
11522244|NCT01199250||Basic science (biomarker analysis)|Previously collected samples are analyzed for biomarker and other laboratory analyses.
11522245|NCT01199237|Active Comparator|Sevoflurane|Patients receive sevoflurane, rocuronium with neostigmine + glycopyrrolate reversal (70 and 14 ug/kg)
11522246|NCT01199237|Active Comparator|Desflurane|Patients receive Desflurane, rocuronium with neostigmine + glycopyrrolate reversal (70 and 14 ug/kg)
11522247|NCT01199224|Experimental|Arm A|
11522248|NCT01199224|Experimental|Arm B|
11522249|NCT01199224|Experimental|Arm C|
11522250|NCT01199224|Experimental|Arm D|
11522251|NCT01199211||Exercise training, women, marathon.|Other: prospective study with no intervention
11522252|NCT01199198|Experimental|Tolvaptan Group|Tolvaptan Group: Starting dose 15 mg by mouth once a day for 14 days.
11522253|NCT01199198|Placebo Comparator|Placebo Group|Placebo Group: Placebo by mouth once a day for 14 days.
11522254|NCT01199185|Active Comparator|Tobacco Quitline Group|
11522255|NCT01199185|Experimental|Tobacco Quitline plus Interactive Technology Group|
11522256|NCT01199172|No Intervention|Control|
11522257|NCT01199172|Experimental|voice hygiene|Subjects will receive training in voice hygiene
11522258|NCT01199172|Experimental|VH + VP|
11522259|NCT01199159|Active Comparator|preoperative misoprostol|400mcg misoprostol given preoperatively
11522260|NCT01199159|Placebo Comparator|Placebo|
11522261|NCT01199146|Experimental|Abiraterone acetate|
11522262|NCT01199133|Active Comparator|Dpte and Dfar Allergen Extract|
11522263|NCT01199133|Placebo Comparator|Placebo tablets|
11522264|NCT01199120|Experimental|Omega 3|
11522265|NCT01199107|Experimental|Prolonged Exposure + Exercise|
11522266|NCT01199107|Active Comparator|Prolonged Exposure + Wellness Intervention|
11522267|NCT01199094||Patients with mutation in the Lrp5 gene|Patients known to have a mutation in Lrp5 known to be causing a high bone mass phenotype
11522268|NCT01199081|Experimental|Group A|"Dronedarone 400 mg twice daily for 8 weeks starting from randomization.
~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
11522269|NCT01199081|Experimental|Group B|"Dronedarone 400 mg twice daily for 6 weeks starting 2 weeks after randomization.
~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
11522270|NCT01199081|Experimental|Group C|"Dronedarone 400 mg twice daily for 4 weeks starting 4 weeks after randomization.
~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
11522271|NCT01199068|Experimental|CS-7017+Erlotinib|Drug: CS-7017 from 0.25 mg to 0.50 mg twice a daily Drug: Erlotinib 150 mg once daily
11522272|NCT01199055|Experimental|CS-7017+Carboplatin/Paclitaxel|"Drug: CS-7017 from 0.25 mg twice a day (BID) to 0.50 mg BID for up to 4~6 cycles (1 cycle: 3 weeks)
~Drug: Carboplatin IV, Area under the curve (AUC) of 6 mg/mL*min, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)
~Drug: Paclitaxel IV, 200mg/m^2, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)"
11522273|NCT01199042|Other|BiPAP autoSV Advanced Device|Positive airway pressure device
11522274|NCT01199029|Experimental|(Part 1) 10 mg PF-04308515 (8hrs)|
11522275|NCT01199029|Experimental|(Part 1) 10 mg PF-04308515 (12hrs)|
11522276|NCT01199029|Active Comparator|(Part 1) 5 mg Prednisone|
11522277|NCT01199029|Experimental|(Part 2) X mg PF-04308515|
11522278|NCT01199029|Experimental|(Part 2) Y mg PF-04308515|
11522279|NCT01199029|Active Comparator|(Part 2) 5 mg Prednisone|
11522280|NCT01199029|Active Comparator|(Part 2) 20 mg Prednisone|
11522281|NCT01199016||1|
11522282|NCT01198990|Experimental|Group 1|"Subjects in will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.
~eating/physical activity/positive affect/self-affirmation group."
11522283|NCT01198990|Experimental|Group 2|"Subjects will be randomized to the small change eating strategy and a physical activity goal.
~eating/physical activity group. No intervention, just the eating strategy and physical activity components."
11522284|NCT01198977|Active Comparator|Brief telephone-based counseling|Telephone based counseling and instructional video
11522285|NCT01198977|Placebo Comparator|Education Counseling|Mailed Physical Activity information and instructional video only
11522286|NCT01198964||Epileptic Patients|The population of patients with medically refractory epilepsy will already have been recommended clinically for electrode grid placement on the brain and high-level stimulation to map brain function.
11522287|NCT01198938|Active Comparator|Melatonin|
11522288|NCT01198925|Active Comparator|extended infusion|
11522289|NCT01198925|Experimental|continuous infusion|
11522290|NCT01198912|Placebo Comparator|placebo|
11522291|NCT01198912|Experimental|doxycycline 100 mg|
11522292|NCT01198899||left ventricular hypertrophy|Patients with left ventricular hypertrophy will be used.
11522293|NCT01198886|Placebo Comparator|Successful Aging Program|
11522294|NCT01198886|Experimental|Exercise-Nutrition Program|
11522295|NCT01198873|Experimental|Dronedarone|Dronedarone 400 mg twice a day
11522296|NCT01198873|Placebo Comparator|Placebo|Placebo (for Dronedarone) twice a day
11522297|NCT01198847|Active Comparator|Low intensity arm|Written information about a healthy lifestyle
11522298|NCT01198847|Experimental|High intensity arm|Lifestyle support (PA, sleep, food intake) using MI
11522299|NCT01198834|Placebo Comparator|Placebo Patch|Treatment with Placebo Patch
11522300|NCT01198834|Experimental|MRX-7EAT Patch|Treatment with MRX-7EAT Patch
11522301|NCT01198834|Experimental|Lidocaine Patch|Treatment with Lidocaine Patch
11522302|NCT01198834|Experimental|Etodolac Patch|Treatment with Etodolac Patch
11522303|NCT01198821|Experimental|Oral sodium bicarbonate and Gemcitabine|
11522884|NCT01194674|Experimental|Microplasmin|
11522304|NCT01198795|Experimental|1|Flexible-dose 10mg-20mg once-daily oral (10mg tablets) dose of escitalopram
11522305|NCT01198782|Experimental|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|SYSTANE® ULTRA Lubricant Eye Drops dosed 4 times daily
11522306|NCT01198769|Experimental|Rotarix Group|subjects received 2 oral doses of Rotarix™ vaccine at 2 and 4 months of age.
11522307|NCT01198756|Experimental|GSK2282512A 1 Group|Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11522308|NCT01198756|Active Comparator|Victoria strain Fluarix Group|Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11522309|NCT01198756|Active Comparator|Yamagata strain Fluarix Group|Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11522310|NCT01198756|Experimental|GSK2282512A 2 Group|Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants <12 months of age.
11522311|NCT01198704||HCC patients|Patients notified on the national waiting list for hepatic transplant
11522312|NCT01198691|Placebo Comparator|Control Group|This group will receive the standard metallic staples to close their incision.
11522313|NCT01198691|Experimental|Case Group|This group will receive the Insorb absorbable staples to close their incision.
11522314|NCT01198665|Experimental|RAD001-CHOP|Prospective multicenter open-label phase I/II study Phase I: RAD001 2.5 - 10 mg PO daily D1-14 + CHOP every 3 weeks Phase II: Determined dosage of RAD001 + CHOP every 3 weeks Treatment will be continued until planned 6 cycles or disease progression
11522315|NCT01198652||Belfort-Dildy Obstetric Tamponade Tx|Patients treated with Belfort-Dildy Obstetric Tamponade System are eligible for inclusion in the cohort.
11522316|NCT01198639|Active Comparator|manual administration of iv anesthetics|
11522317|NCT01198639|Experimental|closed-loop administration of iv anesthetics|
11522318|NCT01198626|Experimental|JNJ-32729463|
11522319|NCT01198626|Active Comparator|moxifloxacin|
11522320|NCT01198626|Experimental|JNJ-32729463 Open-Label|subjects with suspected or confirmed S. aureus CABP may be entered into an open-label JNJ 32729463 treatment group at selected study sites
11522321|NCT01198613|Placebo Comparator|Placebo|
11522322|NCT01198613|Experimental|ToleroMune Ragweed Regimen 1|
11522323|NCT01198613|Experimental|ToleroMune Ragweed Regimen 2|
11522324|NCT01198613|Experimental|ToleroMune Ragweed Regimen 3|
11522325|NCT01198613|Experimental|ToleroMune Ragweed Regimen 4|
11522326|NCT01198600|Other|Phase 1: Habitual no Replacement, then Habitual Replacement|Contact lenses per participant's habitual prescription worn for 30 days with no replacement, followed by contact lenses per habitual prescription worn for 30 days with a replacement pair dispensed at Day 28.
11522327|NCT01198600|Other|Phase 1: Habitual Replacement, then Habitual no Replacement|Contact lenses per participant's habitual prescription worn for 30 days with replacement pair dispensed at Day 28, followed by contact lenses per habitual prescription worn for 30 days with no replacement.
11522328|NCT01198600|Other|Phase 2: Lotrafilcon B Replacement|Contact lenses worn for 56 days with replacement pair dispensed at Day 28.
11522329|NCT01198600|Other|Phase 3: Lotrafilcon B Replacement Replacement|Contact lenses worn for 43 days with replacement pair dispensed at Day 1 and Day 28.
11522330|NCT01198587|Experimental|Outpatient Zinc Sulfate|Zinc Sulfate
11522331|NCT01198587|Experimental|Inpatient Zinc Sulfate|Zinc Sulfate
11522332|NCT01198587|Placebo Comparator|Outpatient Placebo|Placebo oral capsule
11522333|NCT01198587|Placebo Comparator|Inpatient Placebo|Placebo oral capsule
11522334|NCT01198574|Experimental|Iron group|
11522335|NCT01198574|Experimental|Vitamin A group|Vitamin A group
11522336|NCT01198574|Experimental|Iron and Vitamin A group|Iron and Vitamin A group
11522337|NCT01198574|Experimental|Placebo group|Placebo group with folic acid
11522338|NCT01198561||repetitive Transcranial Magnetic Stimulation|repetitive Transcranial Magnetic Stimulation is a depressive patient group treated with rTMS
11522339|NCT01198548|Experimental|Treatment (FOLXFOX, bevacizumab, cholecalciferol)|Patients receive high-dose cholecalciferol once daily. Patients also receive bevacizumab IV over 10 minutes, leucovorin calcium IV over 2 hours, oxaliplatin* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *Treatment with oxaliplatin is discontinued after course 8
11522340|NCT01198535|Experimental|Arm A (RO4929097, cetuximab)|Patients in Arm A will receive cetuximab at the standard dose: 400 mg/m2 IV loading dose on Day 1 followed by cetuximab 250 mg/m2 IV weekly. The RO4929097 will be dose escalated starting at 20 mg given daily 3 days on, 4 days off, weekly. The dose levels of RO4929097 to be explored will be 20 mg, 30 mg, 45 mg, 90 mg, 140 mg given days 1-3 weekly. No intrapatient dose escalation will be allowed.
11522341|NCT01198535|Experimental|Arm B (RO4929097, cetuximab)|Patients in Arm B will receive cetuximab 200 mg/m2 IV weekly without a loading dose. The RO4929097 will be dose escalated starting at 20 mg given daily 3 days on, 4 days off, weekly. The dose levels of RO4929097 to be explored will be 20 mg, 30 mg, 45 mg, 90 mg, 140 mg given days 1-3 weekly. No intrapatient dose escalation will be allowed.
11522342|NCT01198522|Other|Therapy of L19IL2 and Gemcitabine|Dose escalation study. Part A) Gemcitabine dose escalation. Part B) L19IL2 dose escalation.
11522343|NCT01198509|Active Comparator|Rheumatoid Arthritis (RA) - doxycycline|Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive doxycycline, 100 mg twice a day, for 2 months.
11522344|NCT01198509|Active Comparator|Rheumatoid Arthritis (RA) - vancomycin|Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive vancomycin, 250 mg four times a day, for 2 weeks
11522345|NCT01198509|No Intervention|RA, PsA, healthy|"Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive no antibiotic treatment for comparison with Doxycycline- and Vancomycin-treated patients.
~Patients with psoriatic arthritis (PsA), to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.
~Healthy individuals with no history of arthritis, to provide baseline samples of oral and intestinal microbiota for comparison with RA patients."
11522346|NCT01198496|Experimental|Blood pressure|"The incidence of recurrent stroke will be lower in a strict BP control group having lower BP target: less than 120/80 mmHg* than in a standard BP control group having BP target less than 140/90 mmHg or less than 130/80 mmHg for current DM/CKD/old MI in patients with hypertension.
~This study uses BP target: less than 120/80 mmHg that is sat up for this study rather than the BP target recommended in the Guidelines for the management of hypertension, Japanese Society of Hypertension 2009.
~BP management is strongly recommended in patients with hypertension, DM, and/or CKD for prevention of recurrent stroke in the Japanese guidelines for the management of stroke 2009."
11522347|NCT01198483|Active Comparator|Micro|Microincision cataract surgery
11522348|NCT01198483|Active Comparator|Small|Smallincision cataract surgery
11522349|NCT01198470|Experimental|TRIUMPH® Artificial Disc|Treatment of degenerative disc disease with the TRIUMPH Lumbar Artificial Disc. This is a non-randomized pilot study with only one arm (no control).
11522350|NCT01198457||Group 1|
11522351|NCT01198444||Group 1|
11522352|NCT01198431|Experimental|Sleep restriction|Each participant will be engaged in three consecutive nights of 4 hours of sleep per night (from 3.00 a.m. to 7.00 a.m.)
11522353|NCT01198431|Placebo Comparator|Normal sleep duration|Each participant will be engaged in three consecutive nights of 9 hours of sleep per night (from 10.00 p.m. to 7.00 a.m.)
11522354|NCT01198418|Experimental|Internet-based counseling|Completes surveys monthly about their sexual and drug use behaviors as well as receives information designed to help reduce the chances of getting an STI.
11522355|NCT01198418|No Intervention|Survey Alone|Completes surveys monthly about their sexual and drug use behaviors
11522356|NCT01198405|Experimental|Enhanced External Counterpulsation|Treatment of Enhanced External Counterpulsation (EECP) with a prespecified protocol on top of guideline-driven standard medical therapy.
11522357|NCT01198405|Active Comparator|Control|Guideline-driven standard medical therapy.
11522358|NCT01198392|Experimental|S-1 plus cisplatin|S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks.Number of Cycles: until progression or unacceptable toxicity develops.
11522359|NCT01198392|Active Comparator|5-Fu plus cisplatin|5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.Number of Cycles: until progression or unacceptable toxicity develops.
11522360|NCT01198379|Experimental|Aspirin|
11522361|NCT01198379|Placebo Comparator|Sugar pills|Hemodialysis (HD) patients receive placebo not containing aspirin in this study.
11522362|NCT01198366|Placebo Comparator|Dose Finding Gr 1 placebo x 2|Subjects received two doses (x2) of placebo (sterile buffer) on study days 0 and 28.
11522363|NCT01198366|Experimental|Dose Finding Gr 2 AERAS-402 (1.5 x 10^10 vp) x2|Subjects received two doses (x2) of AERAS-402 (1.5 x 10^10 vp) on study days 0 and 28.
11522364|NCT01198366|Experimental|Dose Finding Gr 3 AERAS-402 (3.0 x 10^10 vp) x 2|Subjects received two doses (x2) of AERAS-402 (3.0 x 10^10 vp) on study days 0 and 28.
11522365|NCT01198366|Experimental|Dose Finding Gr 4 AERAS-402 (1.0 x 10^11 vp) x 2|Subjects received two doses (x2) of AERAS-402 (1.0 x 10^11 vp) on study days 0 and 28.
11522366|NCT01198366|Experimental|Expanded Safety Phase Gr 5 AERAS-402 (1.0 X 10^11 vp) x 3|Subjects received 3 doses (x3) of AERAS-402 (1.0 X 10^11 vp) on days 0, 28 and 280.
11522367|NCT01198366|Placebo Comparator|Expanded Safety Phase Gr 5 Placebo x3|Subjects received 3 doses (x3) of placebo (sterile buffer) on days 0, 28 and 280.
11522368|NCT01198353|Experimental|Ziprasidone|During the 12-week study period, patients were prescribed ziprasidone at 20 to 160 mg/day flexibly based on their effectiveness and tolerability. Fifty to one hundred percent of the past antipsychotic dose was maintained in the first week; during next 3 weeks, flexible dosing of 0-100% was used; then, ziprasidone was discontinued. This study included four visits: baseline, week 4, week 8, and week 12. Concomitant benzodiazepines (oral formula or injection) were allowed up to a dose of 4 mg of lorazepam-equivalents per day for anxiety and agitation.
11522369|NCT01198340|Active Comparator|With basal local anesthetics|
11522370|NCT01198340|Experimental|Without basal local anesthetics|
11522371|NCT01198327|Experimental|Ranibizumab as needed|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart; with optional peripheral laser to areas of non-perfusion.
11522372|NCT01198314|Experimental|LT, withdrawal of immunosuppression|
11522373|NCT01198314|Active Comparator|LT, maintenance of immunosuppression|
11522374|NCT01198288|Active Comparator|Standard Care|"Drugs for COPD (as prescribed), oxygen therapy if needed*, check-up by the general practitioner and/or respirologist as usual.
~Educational leaflet regarding optimization of oxygen therapy and drugs; Benefits of physical activity and proposal of a programme of exercise training; Energy conservation techniques; Nutritional counselling; Activity of daily Living (ADL) diary; Prevention and management of acute exacerbation
~Monthly phone call with the aim of verifying:
~the patients' clinical conditions;
~the patient's adherence to the pharmacological treatments prescribed
~the patient's compliance in filling out the clinical diary and the ADL diary"
11522375|NCT01198288|Experimental|domiciliary rehabilitation|"Same as the standard care group plus 10 (ten) home-based visits supervised by a specifically trained respiratory therapist (education+exercise training) Autonomous home-based programme: The patients will be given instructions and training in order to continue the exercise training programme on the days the respiratory therapist is not visiting them.
~Counselling addressed at the outdoor activities."
11522376|NCT01198275|Active Comparator|n-3 PUFAs|
11522377|NCT01198275|Placebo Comparator|placebo|
11522378|NCT01198249|Experimental|amlodipine monotherapy|
11522379|NCT01198249|Experimental|losartan monotherapy|
11522380|NCT01198249|Experimental|HCTZ|
11522381|NCT01198249|Experimental|mlodipine and Losartan and HCTZ|
11522405|NCT01197989|Placebo Comparator|Standard socks|This arm include all patients sides (left or right) treated with standard cotton socks.
11522568|NCT01196871|Experimental|Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg)|
11522382|NCT01198223|Other|drug: garlic extract, nystatin|Drug: garlic extract 40mg/dl or nystatin suspension 100000 iu/ml tid for one month Patients had been clinically with denture stomatitis and confirmed by oral medicine specialist were selected for the study. Gender, age, medical history, erythema types, size, and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received garlic extract and second group used nystatin suspension for 1 month. Each patients was examined at the beginning of the therapy ,and then every 1 weeks up to 1 months .
11522383|NCT01198210|Placebo Comparator|saline|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
11522384|NCT01198210|Active Comparator|ketamine|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
11522385|NCT01198210|Active Comparator|dexamethasone|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
11522386|NCT01198210|Active Comparator|dexamethasone-ketamine|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
11522387|NCT01198184|Experimental|Treatment (temsirolimus and RO4929097)|Patients receive temsirolimus IV over 30 minutes on day -6 (course 1 only). Patients then receive temsirolimus IV or PO on days 1, 8, and 15 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11522388|NCT01198171||Basic science (DNA analysis)|DNA from archived frozen normal tissue samples is genotyped for the ancestry informative markers. Clinicopathological and demographic characteristics associated with each sample are also collected.
11522389|NCT01198158|Active Comparator|Arm I (everolimus)|Patients receive everolimus PO QD on days 1-28.
11522390|NCT01198158|Experimental|Arm II (everolimus with bevacizumab)|Patients receive everolimus PO QD on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 15.
11522391|NCT01198145|Experimental|Arm I: Sulfasalazine|Patients receive oral sulfasalazine twice daily during radiotherapy and for 4 weeks after completion of radiotherapy.
11522392|NCT01198145|Placebo Comparator|Arm II: Placebo|Patients receive oral placebo twice daily during radiotherapy and for 4 weeks after completion of radiotherapy.
11522393|NCT01198132|Experimental|Cholecalciferol|Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 3 times a week.
11522394|NCT01198132|Placebo Comparator|Placebo|Subjects receive matching placebo to Cholecalciferol once every two weeks along with subcutaneous injection of Rebif 3 times weekly.
11522395|NCT01198119|Experimental|Patient with oral cavity cancer|Patient treated by surgery for the oral cavity cancer
11522396|NCT01198080|Experimental|femoral osteonecrosis patients|patientswith femoral head osteonecrosis
11522397|NCT01198067|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO on days 1-28 or 1-21. Courses repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
11522398|NCT01198054|Experimental|Lenalidomine|Post-induction lenalidomide in patients with de novo AML with deletion 5q cytogenetic abnormality (del (5q)) or monosomy 5 (-5)
11522399|NCT01198028|Experimental|Treatment (erlotinib)|Participants receive erlotinib PO QD in the absence of disease progression or unacceptable toxicity.
11522400|NCT01198015||Rett syndrome girls|The study population (identical to the population in the preliminary research project) consists of a well-defined group of thirteen Dutch RTT girls with complete clinical, molecular, neurophysiological and metabolic work-up.
11522401|NCT01198002|Experimental|120 milligrams (mg) LY2127399|"Given every 4 weeks (Q4W) for 100 weeks. Participants receive a 240 mg loading dose when initiating treatment. During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks (Q2W).
~At Weeks 16 and 52, responders will receive 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 100-week treatment period.
~At Week 16, non-responders (NR) will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
11522402|NCT01198002|Experimental|90 mg LY2127399|"Given Q2W for 100 weeks. Participants receive a 180 mg loading dose when initiating treatment.
~At Weeks 16 and 52, responders will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q4W for the rest of the 100-week treatment period.
~At Week 16, NR will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
11522403|NCT01198002|Placebo Comparator|Placebo|"Given Q2W for 52 weeks. At Week 16, responders will receive 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 52 weeks.
~At Week 52, responders are randomized to receive 1 of the 2 doses of LY2127399, with loading dose of 240 mg or 180 mg of LY2127399, followed by 120 mg of LY2127399 Q4W or 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.
~At Week 16, NR will receive a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
11522404|NCT01197989|Experimental|TEPSO socks|This arm include all patients sides (left or right) treated with TEPSO socks.
11522406|NCT01197976|Experimental|TEPSO socks|This arm include all patients sides (left or right) treated with TEPSO socks.
11522407|NCT01197976|Placebo Comparator|Standard socks|This arm include all patients sides (left or right) treated with standard cotton socks.
11522408|NCT01197963|Other|Surgical treatment|Surgical treatment of one arm of the patient population.
11522409|NCT01197963|Other|Medically controlled group|Managed by endocrinologists using current medical therapy such as pills, injections and life style medication.
11522410|NCT01197950|Active Comparator|Manual Acupuncture|Manual stimulation
11522411|NCT01197950|Experimental|Electro Acupuncture|Electrical and manual stimulation
11522412|NCT01197950|No Intervention|Standard care|No acupunture
11522413|NCT01197924||healthy volonteer children|paired for the sex and the age
11522414|NCT01197924||older children followed for a médulloblastome cérébelleux|children followed for a médulloblastome treaty by surgery, radiotherapy and chemotherapy
11522415|NCT01197911|Experimental|Mild impairment|
11522416|NCT01197911|Experimental|Moderate impairment|
11522417|NCT01197911|Experimental|Normal HF|
11522418|NCT01197898|Experimental|Collagenase Santyl|Ointment applied once daily
11522419|NCT01197898|Placebo Comparator|Vehicle Base|Applied once daily
11522420|NCT01197885|Experimental|IMAB362|Two different doses (antibody / body surface area) of IMAB362 will be administered sequentially.
11522421|NCT01197859|Active Comparator|Contamac 74% silicone hydrogel contact lens|Definitive Contact Lens
11522422|NCT01197859|Placebo Comparator|Cooper Vision Biofinity|Biofinity Contact Lens
11522423|NCT01197846|Experimental|Quetiapine|Quetiapine 300 mg or 600 mg
11522424|NCT01197846|Placebo Comparator|Placebo|
11522425|NCT01197833|Experimental|Endovenous ablation+polidocanol injectable microfoam 0.125%|Endovenous ablation followed by an injection of polidocanol injectable microfoam 0.125% to target vein
11522426|NCT01197833|Experimental|Endovenous ablation+polidocanol injectable micrfoam, 1.0%|Endovenous ablation followed by injection of polidocanol injectable microfoam, 1.0% to the target vein
11522427|NCT01197833|Active Comparator|endovenous ablation+vehicle (placebo)|endovenous ablation followed by injection of vehicle (placebo) to target vein
11522428|NCT01197820|Experimental|Arm 1|30 patients with liver tumour and 15 patients with kidney tumour will be enrolled.
11522429|NCT01197807|Active Comparator|Bulb suctioning|Bulb suctioning of mouth and nose immediately after delivery
11522430|NCT01197807|Active Comparator|Wiping|Gentle wiping of mouth then nose with soft cloth
11522431|NCT01197794|Experimental|AZD1981 10 mg|AZD1981 10 mg
11522432|NCT01197794|Experimental|AZD1981 40 mg|AZD1981 40 mg
11522433|NCT01197794|Experimental|AZD1981 100 mg|AZD1981 100 mg
11522434|NCT01197794|Experimental|AZD1981 400 mg|AZD1981 400 mg
11522435|NCT01197794|Experimental|AZD1981 80 mg|AZD1981 80 mg
11522436|NCT01197794|Experimental|AZD1981 200 mg|AZD1981 200 mg
11522437|NCT01197794|Placebo Comparator|Placebo|
11522438|NCT01197781|Experimental|Period 1|
11522439|NCT01197781|Experimental|Period 2|
11522440|NCT01197768|Experimental|Nutrition Intervention|The intervention group will receive a full nutrition assessment and a nutrition intervention.
11522441|NCT01197768|No Intervention|Control|This group will receive the nutrition assessment but no intervention from a Registered Dietician. If participant appears to be in danger due to BMI or Caloric intake status, their primary care physician will be notified.
11522442|NCT01197755|Experimental|Dosing Regimen A|Oral Treatment
11522443|NCT01197755|Experimental|Dosing Regimen B|Oral Treatment
11522444|NCT01197755|Placebo Comparator|Dosing Regimen C|Oral Treatment
11522445|NCT01197729||STEMI|(ST-Elevation myocardial infarction)
11522446|NCT01197729||NSTEMI|Non-ST-Elevation myocardial infarction
11522447|NCT01197664|Experimental|Arm I (paricalcitol and chemoradiotherapy)|Patients receive paricalcitol PO daily. Patients also receive standard care chemoradiotherapy with fluorouracil PO.
11522448|NCT01197664|Active Comparator|Arm II (chemoradiotherapy)|Patients receive standard care chemoradiotherapy as in Arm I.
11522449|NCT01197625|Experimental|DC-vaccine|
11522450|NCT01197612|Other|Single Arm; nostrils as experimental and comparator|each subject serves as their own control with one nostril being treated with pulmicort and one not
11522451|NCT01197599||Spinal Cord Injury|
11522452|NCT01197599||Able-Bodied Control|
11522453|NCT01197573|Active Comparator|Standard DCD liver transplant|Standard method of liver transplant utilizing a DCD organ
11522454|NCT01197573|Active Comparator|rTPA Treatment Liver Transplant|Ex-vivo treatment of liver donated after cardiac death (DCD) with rTPA
11522455|NCT01197573|Active Comparator|Standard DCD kidney transplant|Standard method of kidney transplant utilizing a DCD organ
11522456|NCT01197573|Active Comparator|rTPA Treatment Kidney Transplant|Ex-vivo treatment of kidney donated after cardiac death (DCD) with rTPA
11522457|NCT01197560|Experimental|Lenalidomide|Lenalidomide 25 mg capsules by mouth on days 1-21 of each 28 day cycle. For patients with Creatinine Clearance ≥ 30 mL/min but < 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
11522458|NCT01197560|Active Comparator|Investigators Choice|"One of the following:
~Gemcitabine, Oxaliplatin, Rituximab, or Etoposide"
11522459|NCT01197547|Other|Genesys HTA|Genesys HTA Endometrial Ablation
11522460|NCT01197534|Experimental|Dosing Regimen A|Oral Treatment
11522461|NCT01197534|Experimental|Dosing Regimen B|Oral Treatment
11522462|NCT01197534|Placebo Comparator|Dosing Regimen C|Oral Treatment
11522463|NCT01197521|Experimental|Dosing Regimen A|Oral Treatment
11522464|NCT01197521|Experimental|Dosing Regimen B|Oral Treatment
11522465|NCT01197521|Placebo Comparator|Dosing Regimen C|Oral Treatment
11522466|NCT01197508|Experimental|0.1 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 0.1 mg BID
11522467|NCT01197508|Experimental|1 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1 mg BID
11522468|NCT01197508|Experimental|4 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 4 mg BID
11522469|NCT01197508|Placebo Comparator|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
11522470|NCT01197495|Experimental|Treatment|Juvederm(R) Ultra XC Injectable Gel
11522471|NCT01197495|Experimental|Control|No treatment for 3 months followed by Juvederm(R) Ultra XC Injectable Gel at Month 3.
11522472|NCT01197469|Placebo Comparator|Placebo|Placebo
11522473|NCT01197469|Active Comparator|Tadalafil|
11522474|NCT01197456||Exposed/chemotherapy|Breast cancer patients who will undergo chemotherapy
11522475|NCT01197456||Unexposed|Breast cancer patients who will not undergo chemotherapy
11522476|NCT01197443|Experimental|Parent-only Group|Treatment will be administered to parents of the overweight child. Parent-only group treatment will include all of the same skills and techniques to promote weight loss, but the information will be delivered only to the parent. Participation of the children assigned to the parent-only treatment arm will be limited to the baseline and follow-up assessments.
11522477|NCT01197443|Active Comparator|Parent + child Group|The treatment for participants in the parent + child arm will be administered in two separate groups, one for the parents and one for the child.
11522478|NCT01197417|Experimental|Magnesium group|Intravenous Magnesium Sulfate
11522479|NCT01197417|Placebo Comparator|Placebo group|Normal Saline placebo
11522480|NCT01197404|Active Comparator|General Health Promotion|
11522481|NCT01197404|Experimental|Affect Management|
11522482|NCT01197391|Experimental|Cohort 1|Dose 1 versus placebo
11522483|NCT01197391|Experimental|Cohort 2|Dose 2 versus placebo
11522484|NCT01197378|Experimental|Cysteamine Bitartrate|Cysteamine bitartrate delayed-release capsules were administered twice daily for up to 96 months.
11522485|NCT01197365|Experimental|STUDY GROUP|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.
~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae"
11522486|NCT01197365|Other|CONTROL GROUP|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients
11522487|NCT01197352|Experimental|Text message queries with feedback|Weekly prompted queries about drinking behavior with personalized feedback.
11522488|NCT01197352|Active Comparator|Text message queries|Weekly prompted queries about drinking behavior
11522489|NCT01197352|No Intervention|Control|Weekly text reminders to complete final (12 week) instruments
11522490|NCT01197339|Experimental|treatment|
11522491|NCT01197339|Sham Comparator|Controls|
11522492|NCT01197326||Group 1|Patients who triggered MET/RRT calls prior to the use of the MP5 EWS patient monitor.
11522493|NCT01197326||Group 2|Patients who triggered MET/RRT calls after the use of the MP5 EWS patient monitor.
11522494|NCT01197313|Experimental|Exercise|
11522495|NCT01197300|Experimental|Zoledronic acid|Twice yearly 0.05 mg/kg (max 5 mg) i.v infusion (at least 30 minutes) of zoledronic acid
11522496|NCT01197287|Experimental|QAK423A Arm A|
11522497|NCT01197287|Experimental|QAK423A Arm B|
11522498|NCT01197287|Experimental|QAK423A Arm C|
11522499|NCT01197274||Mite-sensitized person|
11522500|NCT01197261|Active Comparator|OXN PR|Oxycodone Naloxone tablets
11522501|NCT01197261|Placebo Comparator|PLA|
11522502|NCT01197248|Active Comparator|Cystocele Plication|Placement of sutures over the pubocervical fascia during cystocele repair.
11522503|NCT01197248|Experimental|No Plication|Avoid sutures over pubocervical fascia during cystocele repair
11522504|NCT01197235|Experimental|darbepoetin-α|Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
11522505|NCT01197235|Placebo Comparator|isotonic saline|Infusion of isotonic saline will be performed 1 hour before angiography
11522506|NCT01197222|Active Comparator|EndoClear used|The EndoClear device is used during a laparoscopic abdominal surgery.
11522507|NCT01197222|No Intervention|Control|EndoClear Lens Cleaning Device not used during a laparoscopic abdominal surgery.
11522508|NCT01197209|Experimental|Ad-REIC/Dkk-3 Arm|Active arm on Ad-REIC/Dkk-3
11522509|NCT01197196|Experimental|Behavioral weight loss|
11522510|NCT01197196|Active Comparator|Migraine Education|
11522511|NCT01197170|Experimental|Anastrozole|1 mg PO (by mouth) daily for 28 days.
11522512|NCT01197170|Experimental|Anastrozole + Bevacizumab|Anastrozole 1 mg PO daily and Bevacizumab starting dose 10 mg IV Day 1 of 21 day cycle. Expansion group added when MTD dose of Anastrozole + Bevacizumab found.
11522513|NCT01197170|Experimental|Anastrozole + Everolimus|Anastrozole 1 mg PO daily and Everolimus starting dose 5 mg PO daily for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Everolimus found.
11522514|NCT01197170|Experimental|Anastrozole + Sorafenib|Anastrozole 1 mg PO daily and Sorafenib starting dose 200 mg PO twice a day for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Sorafenib found.
11522515|NCT01197170|Experimental|Anastrozole + Erlotinib|Anastrozole 1 mg PO daily and Erlotinib starting dose 75 mg PO daily for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Erlotinib found.
11522516|NCT01197157|Placebo Comparator|placebo|"• Group A: comprises 100 chronic hepatitis patients who will receive placebo twice daily orally with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.
~All patients in this group will have an HCV RNA within 3 months before initiation of therapy, in addition to ALT levels, CBC and other routine liver function tests."
11522517|NCT01197157|Experimental|Nitazoxanide|"• Group B: comprises 100 CHC patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.
~All patients in this group will have an HCV RNA within 3 months before initiation of therapy, in addition to ALT levels, CBC and other routine liver function tests."
11522518|NCT01197144|Active Comparator|Adalimumab|Treatment with adalimumab 40 mg sc eow for 4 weeks
11522519|NCT01197144|Placebo Comparator|Placebo|Treatment with placebo s c eow for 4 weeks
11522520|NCT01197144|No Intervention|Healthy Controls|"Healthy volunteers, age ≥18. Will perform all the same pain assessments, blood sampling and baseline fMRI as RA patients
~Exclusion criteria:
~For fMRI - left handedness and all forms of metallic implants.
~Fulfilling ACR criteria for fibromyalgia.
~Severe ischemic heart disease.
~Concurrent treatment for depression/anxiety with antidepressant drugs.
~Concurrent neurological disease.
~Other reason as evaluated by the P.I."
11522521|NCT01197131||autistic boys|Boys with autism spectrum disorder, age 5-15 years, diagnosis meets DSM-IV criteria ascertained by ADI-R or ADOS schedule or specialised paediatrician
11522522|NCT01197131||autistic girls|Girls with autism spectrum disorder, age 5-15 years, diagnosis meets DSM-IV criteria ascertained by ADI-R or ADOS schedule or specialised paediatrician.
11522523|NCT01197131||control boys|"Healthy boys, age 5-15 years, mental status assessed by Marburger Beurteilungsskala zum Asperger-Syndrome (MBAS)."
11522524|NCT01197131||control girls|"Healthy girls, age 5-15 years, mental status assessed by Marburger Beurteilungsskala zum Asperger Syndrome (MBAS)."
11522525|NCT01197118|Active Comparator|2|chemotherapy alone following radical resection
11522526|NCT01197118|Experimental|1|sequence chemoradiotherapy following radical resection
11522527|NCT01197105|Experimental|Aroeira|
11522528|NCT01197092|Active Comparator|Verum|
11522529|NCT01197092|Experimental|Control|
11522530|NCT01197079||MSM|Young men (under 26 years of age) who have sex with men
11522531|NCT01197079||Parents|Parents of Boys aged 9 to 18 years
11522532|NCT01197066|Other|Certolizumab Pegol|Single Arm
11522533|NCT01197053|Experimental|100 mcg DBV712 (active)|100 mcg DBV712 administered epicutaneously every 24 hours.
11522534|NCT01197053|Placebo Comparator|Placebo|Placebo will be administered epicutaneously every 24 hours
11522535|NCT01197040|Experimental|B-Experimental|Experimental
11522536|NCT01197040|Active Comparator|A-Active Comparator|Active Comparator
11522537|NCT01197027|Experimental|Enhanced counseling|5 intensive counseling sessions following acute HIV infection
11522538|NCT01197027|Active Comparator|Standard counseling|Standard HIV counseling following acute HIV infection
11522539|NCT01197014|Experimental|Amlodipine plus Losartan|
11522540|NCT01197014|Active Comparator|Amlodipine, Losartan|
11522541|NCT01197001|Experimental|Amlodipine plus Losartan|
11522542|NCT01197001|Active Comparator|Amlodipine, Losartan|
11522543|NCT01196988|Experimental|GSK2321138A 1 Group|Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
11522544|NCT01196988|Active Comparator|Fluarix Group|Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
11522545|NCT01196988|Active Comparator|GSK2604409A Group|Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
11522546|NCT01196988|Experimental|GSK2321138A 2 Group|Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
11522547|NCT01196975|Experimental|GSK2282512A 1 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11522548|NCT01196975|Experimental|GSK2282512A 2 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11522549|NCT01196975|Experimental|GSK2282512A 3 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11522550|NCT01196975|Active Comparator|Victoria Strain FluLaval Group|Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11522551|NCT01196975|Active Comparator|Yamagata Strain FluLaval Group|Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11522552|NCT01196962|Experimental|Internal jugular vein|
11522553|NCT01196949|Active Comparator|Manipulative and Rehabilitative Therapy|
11522554|NCT01196949|Active Comparator|Rehabilitative Therapy|
11522555|NCT01196936|Experimental|Arm I (tamoxifen citrate)|Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
11522556|NCT01196936|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
11522557|NCT01196923|Experimental|HeartLight Ablation|
11522558|NCT01196910|Active Comparator|Stimulation over the left dorsolateral prefrontal cortex|Group A (fifteen subjects) - treatment by HLPFC coil high-frequency stimulation over the left dorsolateral prefrontal cortex (DLPFC).
11522559|NCT01196910|Active Comparator|stimulation over the right DLPFC|Group B (fifteen subjects) - Treatment by HLPFC coil high-frequency stimulation over the right DLPFC.
11522560|NCT01196910|Placebo Comparator|Treatment with HLPFC coil simulator mode|Group C (fifteen subjects) - Treatment with HLPFC coil simulator mode (sham).
11522561|NCT01196897|Experimental|Implantable device|WATCHMAN LAA Closure Technology (Gen 4.0)
11522569|NCT01196871|Experimental|Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg)|
11522570|NCT01196871|Experimental|Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg)|
11522571|NCT01196845|Other|obese + cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
11522572|NCT01196845|Other|obese + Sham cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
11522573|NCT01196845|Other|non-obese + cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
11522574|NCT01196845|Other|non-obese + Sham cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
11522575|NCT01196832||Chronic obstructive pulmonary disease patients|"COPD patients with exacerbation will be recruited during hospitalization in Intensive care unit or as outpatients in the clinical investigation centre of the CHU de Bordeaux.
~Inclusion visit: blood sample for fibrocytes analysis. Second visit 2 months ± 7 days after the exacerbation: clinical and functional evaluation (plethysmography, TLCO, arterial gaz), blood sample for fibrocytes analysis."
11522576|NCT01196832||Control group|Subjects without any history of lung disease and with normal lung function testing
11522577|NCT01196819|Active Comparator|Xience V|Implantation of Xience V drug eluting stent
11522578|NCT01196819|Experimental|Firehawk|Implantation of Firehawk drug eluting stent
11522579|NCT01196793||febrile children, age 3 m to 5 y|
11522580|NCT01196780||Cohort|
11522581|NCT01196767|Experimental|ropivacaine|
11522582|NCT01196767|Other|normal saline|
11522583|NCT01196754|Other|sevoflurane|
11522584|NCT01196741|Active Comparator|Saracatinib plus weekly paclitaxel|
11522585|NCT01196741|Placebo Comparator|Placebo plus weekly paclitaxel|
11522586|NCT01196728|Experimental|CM3.1-AC100 dose A|Compound CM3.1-AC100 s.c.
11522587|NCT01196728|Experimental|CM3.1-AC100 dose B|Compound CM3.1-AC100 s.c.
11522588|NCT01196728|Experimental|CM3.1-AC100 dose C|Compound CM3.1-AC100 s.c.
11522589|NCT01196728|Placebo Comparator|Placebo|Placebo for compound CM3.1-AC100 s.c.
11522590|NCT01196715|Active Comparator|Darbepoetin Alfa|
11522591|NCT01196715|Active Comparator|G-CSF|
11522592|NCT01196715|Active Comparator|Best Supportive Care|Red cell transfusion support to achieve a predicted post-transfusion haemoglobin of 11.0 to 12.0 g/dl at a quantity and frequency such that the minimum haemoglobin is never below 8.0 g/dl
11522593|NCT01196702||CVID|Patients with common variable immunodeficiency
11522594|NCT01196702||CVID and granulomatous disease|Patients with CVID complicated with granulomatous inflammation
11522595|NCT01196702||CVID and bronchiectasis|Patients with CVID complicated by bronchiectasis
11522596|NCT01196702||Control on Immunoglobulin|Patients on immunoglobulin long-term who do not have an immunodeficiency
11522597|NCT01196702||Control bronchiectasis|Controls with bronchiectasis not caused by a known immunodeficiency
11522598|NCT01196702||Control with granulomatous disease|Control patients with Crohn's Disease as this is a disease that causes granulomatous inflammation.
11522599|NCT01196702||Healthy Controls|
11522600|NCT01196689|Experimental|1|AZD1981 100 mg twice daily for 6 ½ days
11522601|NCT01196676|Experimental|1|AZD4451
11522602|NCT01196676|Placebo Comparator|2|Placebo
11522603|NCT01196650|Active Comparator|1|IN 10 003 formulation A
11522604|NCT01196650|Active Comparator|2|IN 10 003 formulation B
11522605|NCT01196650|Placebo Comparator|3|Placebo capsules
11522606|NCT01196637||Thoracic outlet syndrome|These patients have documented thoracic outlet syndrome
11522607|NCT01196637||Normal Subjects|These patients have no thoracic outlet syndrome
11522608|NCT01196624|Active Comparator|TMS TO RT DLPF WITH EXPOSURE|TMS TO RIGHT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE
11522609|NCT01196624|Active Comparator|TMS TO RIGHT DLPF BRAIN AREA WITHOUT EXPOSURE|TMS TO RIGHT DLPF BRAIN AREA WITHOUT EXPOSURE
11522610|NCT01196624|Active Comparator|TMS TO LEFT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE|TMS TO LEFT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE
11522611|NCT01196624|Active Comparator|TMS TO LEFT DLPF BRAIN AREA WITHOUT EXPOSURE|TMS TO LEFT DLPF BRAIN AREA WITHOUT EXPOSURE
11522612|NCT01196611|Experimental|Function Voice Exercises|Behavioral: Function Voice Exercises Patients will receive 6 sessions of therapy over a course of 6 weeks, with one session per week.
11522613|NCT01196611|Experimental|Voice amplification|Behavioral: Voice amplification Patients will use VA over a course of 6 weeks.
11522614|NCT01196598|Active Comparator|PFMT group|Women who undergo to three months of a pelvic floor muscle training program.
11522615|NCT01196598|Active Comparator|HE + PFM group|Women who undergo to three months of a hypopressive exercises plus pelvic floor muscle contraction program.
11522616|NCT01196598|Active Comparator|HE group|Women who undergo to three months of a hypopressive exercises program.
11522617|NCT01196598|Active Comparator|Control|Women who undergo to a session for lifestyle advice.
11522618|NCT01196585|Experimental|Patients under CT- guided pleural biopsy|Arm A: Patients who go under CT-guided pleural needle biopsy for pleural diseases
11522619|NCT01196585|Experimental|Patients under ultrasonography guided needle biopsy|Arm B: Patients who go under ultrasonography guided cutting needle pleural biopsy for pleural diseases
11522620|NCT01196572|Experimental|Laser IU|Urethral stricture incised by Holmium laser
11522621|NCT01196572|Active Comparator|Cold knife IU|Urethral stricture incised by knife
11522622|NCT01196559|Experimental|Vinorelbine and Gemcitabine|Vinorelbine 25 ㎎/㎡ and Gemcibine1000㎎/㎡ D1, D8 every 3weeks
11522623|NCT01196546|Experimental|Vildagliptin/metformin|
11522624|NCT01196533|Experimental|Non Invasive Monitoring|Intervention: Device: Non invasive peripheral blood monitoring
11522625|NCT01196520||BL Cases|Children from East Africa diagnosed with BL
11522626|NCT01196520||HCII Controls|Matched controls from the local health clinics
11522627|NCT01196520||Population Controls|Matched controls from the geographic region
11522628|NCT01196507|Experimental|Carvedilol|Tablet Carvedilol 12.5 mg BD or maximum tolerated dose
11522629|NCT01196507|Placebo Comparator|Placebo|Placebo tablets 2 to 4 BD
11522630|NCT01196494|Experimental|intraoperative colon lavage|
11522631|NCT01196494|Active Comparator|stent and deferred surgery|
11522632|NCT01196481|Experimental|Carvedilol+VSL#3|Tablet Carvedilol 6.25 mg BD + VSL#3
11522633|NCT01196481|Active Comparator|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3-4 weeks till variceal ligation
11522634|NCT01196468||Anal/cervical dyplasia|Any patient presenting for care with any degree of anal or cervical dysplasia
11522635|NCT01196468||STI|Any patient presenting for care with any non-HIV sexually transmitted infection
11522636|NCT01196468||Lymphoma|Any patient presenting for care with malignant lymphoma of any histological type
11522637|NCT01196468||Seborrhoeic dermatitis/exanthema|Any patient presenting for care with seborrhoeic dermatitis/exanthema
11522638|NCT01196468||Thromobocytopaenia/Leucopaenia, or hypergammaglobulinaemia|Any patient presenting for care with unexplained thromobocytopaenia/leucopaenia of more than four weeks duration, or with hypergammaglobulinaemia
11522639|NCT01196442|Experimental|Arm I electric stimulation pain therapy|Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
11522640|NCT01196429|Experimental|Treatment (paclitaxel, carboplatin, temsirolimus, docetaxel)|"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus IV on days 1 and 8. Treatment repeats every 3 weeks for 6 courses. Patients then receive consolidation therapy comprising temsirolimus IV on days 1, 8, and 15. Treatment repeats every 3 weeks for 11 courses in the absence of disease progression or unacceptable toxicity.
~NOTE: * For circumstances in which docetaxel should be substituted for paclitaxel, docetaxel is given IV over 1 hour."
11522641|NCT01196416|Experimental|Treatment (RO4929097, cisplatin, vinblastine, temozolomide)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21, cisplatin IV over 30 minutes and vinblastine IV over 30 minutes on days 1-3, and temozolomide PO QD on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without progressive disease continue to receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 and temozolomide as above in the absence of disease progression or unacceptable toxicity.
11522642|NCT01196390|Experimental|Arm I (radiotherapy, chemotherapy, trastuzumab)|Patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Patients also receive trastuzumab IV over 30-90 minutes on days 1, 8, 15, 22, 29, 36, and 57 and paclitaxel intravenously IV over 60 minutes and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Beginning 21-56 days after surgery, patients receive trastuzumab IV over 30-90 minutes. Treatment repeats every 21 days for 13 courses in the absence of disease progression or unacceptable toxicity.
11522643|NCT01196390|Experimental|Arm II (radiotherapy and chemotherapy)|Patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Patients also receive paclitaxel IV over 60 minutes and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
11522644|NCT01196377|Active Comparator|Nebulized albuterol 10mg/hr continuous|Active control arm, 10mg/hr continuous.
11522645|NCT01196377|Experimental|10mg/hr pulsed|Experimental 10mg/hr pulsed albuterol regimen.
11522646|NCT01196377|Experimental|25mg/hr continuous|Experimental 25mg/hr continuous albuterol.
11522647|NCT01196377|Experimental|25mg/hr pulsed|Experimental 25mg/hr pulsed albuterol
11522648|NCT01196364|Experimental|Sedentary activity, noncaloric beverage|
11522649|NCT01196364|Experimental|Sedentary activity, glucose beverage|
11522650|NCT01196364|Experimental|Exercise activity, noncaloric beverage|
11522651|NCT01196364|Experimental|Exercise activity, glucose beverage|
11522652|NCT01196351|Experimental|Sedentary activity, noncaloric beverage|
11522653|NCT01196351|Experimental|Sedentary activity, glucose beverage|
11522654|NCT01196351|Experimental|Exercise activity, noncaloric beverage|
11522655|NCT01196351|Experimental|Exercise activity, glucose beverage|
11522656|NCT01196338|Active Comparator|Non-weightbearing no ROM|"Patients will be placed in a back slab post-op and will remain non-weight bearing with crutches with no range of motion for a total of 6 weeks.
~After 6 weeks post-op, they will be placed in a boot orthosis and permitted to weight-bear as tolerated."
11522657|NCT01196338|Experimental|Early weight-bearing and ROM|"Patients will be placed in a back slab post-operatively. At 2 weeks post op they will have the back slab removed and placed in a boot orthosis. At this time they will be permitted to weight-bear as tolerated and perform limited ankle range of motion exercises.
~After 6 weeks post op they will start to wean from the boot orthosis."
11522658|NCT01196325||Laser Group|Patients who are clinically indicated for the laser treatment
11522659|NCT01196325||Anti-VEGF Group (Bevacizumab)|Patients who are clinically indicated for the intravitreal injection of Bevacizumab
11522660|NCT01196325||Anti-VEGF Group (Ranibizumab)|Patients who are clinically indicated for intravitreal injection of Ranibizumab
11522661|NCT01196325||Age-matched controls|Group of non-diabetic participants who will be age and gender matched
11522662|NCT01196299||Severe Traumatic Brain Injury Group|The severe traumatic brain injury group are patients admitted to the study with an admission GCS between 3 and 8.
11522663|NCT01196299||Moderate Head Injury Group|The moderate head injury group are patients admitted to the study with an admission GCS from 9 to 12.
11522664|NCT01196299||Mild Head Injury Group|The mild head injury group are patients admitted to the study with an admission GCS from 13 to 15.
11522665|NCT01196299||Healthy Volunteer Group|Healthy volunteers will be selected to match the age distribution of the TBI groups. They must be absent of any abnormal radiological findings.
11522666|NCT01196286|Experimental|MFG and CR|Subjects provided with both multifamily psychoeducation (MFG) and cognitive remediation (CR)
11522667|NCT01196286|Active Comparator|MFG|Subjects provided with only multifamily group psychoeducation (MFG)
11522668|NCT01196273||Regional Ruhrgebiets Cohort|
11522669|NCT01196260|Experimental|5-fluorouracil plus oxaliplatin|patients will be randomized assigned to receive 5-fluorouracil plus oxaliplatin
11522670|NCT01196234|Experimental|Paclitaxel/Carboplatin/Gefitinib|Paclitaxel/Carboplatin/Gefitinib
11522671|NCT01196234|Active Comparator|Paclitaxel/Carboplatin|Paclitaxel/Carboplatin
11522672|NCT01196221||Patients with 30 to 70% carotid artery stenosis|
11522673|NCT01196195|Experimental|QD kaletra|Once daily kaletra
11522674|NCT01196195|Active Comparator|BID kaletra|twice daily dose of kaletra
11522675|NCT01196169|Experimental|Daptomycin|Half of patients anticipated to be enrolled will receive daptomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.
11522676|NCT01196169|Active Comparator|Vancomycin|Half of patients anticipated to be enrolled will receive vancomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.
11522677|NCT01196130||Biomarker Assessment|Leftover sample of tumor tissue from a previous procedure used for biomarker testing. Blood drawn for biomarker testing, to check for levels of cytokines, and to check the circulating tumor cells (CTCs). Cancer Symptom Questionnaire completion about cancer symptoms.
11522678|NCT01196117|Placebo Comparator|14 days of Placebo therapy, then CPAP|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
11522679|NCT01196117|Active Comparator|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
11522680|NCT01196104|Experimental|Technosphere® Insulin Inhalation Powder (TI)|Insulin Glargine and Technosphere® Insulin Inhalation Powder
11522681|NCT01196104|Active Comparator|Comparator|Insulin Glargine and Insulin Aspart
11522682|NCT01196091|Experimental|LY2127399 every 2 weeks|Administered SC
11522683|NCT01196091|Experimental|LY2127399 every 4 wks|During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
11522684|NCT01196091|Placebo Comparator|Placebo|Administered SC
11522685|NCT01196078|Experimental|1|
11522686|NCT01196078|Active Comparator|2|
11522687|NCT01196065|Experimental|Single Arm|
11522688|NCT01196052|Experimental|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg was administered intravenously on Day 1 of each 3-week treatment cycle up to a maximum of 17 cycles.
11522689|NCT01196039|Experimental|A|
11522690|NCT01196039|Placebo Comparator|B|
11522691|NCT01196026|Experimental|Fluarix 6-11 months Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
11522692|NCT01196026|Experimental|Fluarix 12-35 months Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
11522693|NCT01196026|Experimental|Fluarix 3-9 years Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
11522694|NCT01196026|Active Comparator|Havrix Junior 6-11 months Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
11522695|NCT01196026|Active Comparator|Havrix Junior 12-35 months Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
11522696|NCT01196026|Active Comparator|Havrix Junior 3-9 years Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
11522697|NCT01196013|Experimental|Clofarabine|
11522698|NCT01196000|Active Comparator|Arm I|Patients undergo standard conventional laparoscopic resection.
11522699|NCT01196000|Experimental|Arm II|Patients undergo robotic-assisted laparoscopic resection.
11522700|NCT01195987||Hepatitis C with Arthritis|
11522701|NCT01195987||Hepatitis C without Arthritis|
11522702|NCT01195974|Experimental|Period 1|YASMIN + 200 mg GSK2248761 or Placebo
11522703|NCT01195974|Experimental|Period 2|YASMIN + 200 mg GSK2248761 or Placebo
11522704|NCT01195974|Other|Run In Period|YASMIN
11522705|NCT01195948|Experimental|B27PD 1 mg|Participants randomly assigned to the B27PD 1 mg arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
11522706|NCT01195948|Experimental|B27PD 4 mg|Participants randomly assigned to the B27PD 4 mg arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
11522707|NCT01195948|Placebo Comparator|Placebo|Participants randomly assigned to the placebo arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
11522708|NCT01195922|Experimental|Sirolimus|Subjects will be treated with sirolimus 21 days
11522709|NCT01195883|Active Comparator|Crystalloid|Lactated Ringers solution will be used for fluid replacement.
11522710|NCT01195883|Active Comparator|Colloid|Low-molecular weight colloid HES 130/0.4 (Voluven) will be used for fluid replacement
11522711|NCT01195844||Brazilian Children With Rotavirus Gastroenteritis|Brazilian children under 5 years of age who have diarrhea attributed to rotavirus located in 4 hospitals from 4 different Brazilian regions
11522712|NCT01195831|Experimental|Xamiol® gel|Calcipotriol (as hydrate) 50mcg/g plus betamethasone 0.5mg/g (dipropionate)
11522713|NCT01195831|Active Comparator|Calcipotriol scalp solution|Calcipotriol (as hydrate) 50 mcg/ml
11522714|NCT01195818|Experimental|RAS Inhibitors|RAS Inhibitors
11522715|NCT01195805|Active Comparator|Amiloride|
11522716|NCT01195805|Active Comparator|Spironolactone|
11522717|NCT01195805|Placebo Comparator|Placebo|1 tablet twice a day for 28 days
11522718|NCT01195792|Experimental|2 mg GSK1521498|Approximately 20 subjects will be randomised to receive 2 mg GSK1521498. The drug is being developed for the treatment of obesity due to excessive consumption of high calorie foods
11522719|NCT01195792|Experimental|5 mg GSK1521498|Approximately 20 subjects will be randomised to receive 5 mg GSK1521498. The drug is being developed for the treatment of obesity due to excessive consumption of high calorie foods
11522720|NCT01195792|Placebo Comparator|Placebo|Approximately 20 subjects will be randomised to receive matching placebo.
11522721|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A1 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.
11522722|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A1 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.
11522723|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A2 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.
11522724|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A2 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.
11522725|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A3 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.
11522726|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A3 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.
11522727|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B1 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.
11522728|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B1 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.
11522729|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B2 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.
11522730|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B2 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.
11522731|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B3 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.
11522732|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B3 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.
11522733|NCT01195779|Experimental|GSK2321138A vaccine Group|Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).
11522734|NCT01195779|Active Comparator|Fluarix Group|Subjects received 2 doses of Fluarix Vaccine.
11522735|NCT01195766|Experimental|Ofatumumab|Ofatumumab in addition to ESHAP therapy
11522736|NCT01195753|Experimental|Liver Cell Infusion|
11522737|NCT01195740|Experimental|Attachment Based Family Therapy|
11522738|NCT01195740|Active Comparator|Enhanced Usual Care|
11522739|NCT01195727|Experimental|Group 5A - Apixaban (Low Dose)|"Group 5: 12 years to <18 years;
~0.66 mg/m² Oral solution, Oral, Twice A Day (BID), 10 days"
11522740|NCT01195727|Experimental|Group 5B - Apixaban (High Dose)|"Group 5: 12 years to <18 years;
~1.32 mg/m² Oral solution, Oral, Twice A Day (BID), 10 days"
11522741|NCT01195714|Experimental|Ofatumumab|
11522742|NCT01195701||Anorgasmia (cases)|Women with difficulty or inability to reach sexual climax will be the cases in this study.
11522743|NCT01195701||Normal orgasmic function|Women who report that they usually or always achieve sexual climax will be the controls in this study.
11522744|NCT01195688|Experimental|BI 638683|1 single dose per subject as oral solution
11522745|NCT01195688|Placebo Comparator|Placebo solution|1 single dose per subject as oral solution
11522746|NCT01195675|Experimental|BI 10773|single oral (high and low) dose per subject
11522747|NCT01195675|Placebo Comparator|Placebo|2 single oral doses per subject
11522748|NCT01195675|Active Comparator|Moxifloxacin|single oral dose per subject
11522749|NCT01195662|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg tablets
11522750|NCT01195662|Placebo Comparator|Placebo matching Dapagliflozin|Placebo tablets matching dapagliflozin tablets
11522751|NCT01195649||Group 1|
11522752|NCT01195636|Experimental|XPF-002|
11522753|NCT01195636|Placebo Comparator|Placebo|
11522754|NCT01195623|Active Comparator|varicose vein surgery with preop duplex|The surgeon has planned surgery for varicose veins from a clinical examination and has then the extra information available from a preoperative duplex examination to plan surgery more in detail
11522755|NCT01195623|No Intervention|varicose vein surgery no preop duplex|The surgeon has planned surgery for varicose veins from a clinical examination only
11522756|NCT01195610|Experimental|New Nordic Diet|New Nordic Diet
11522757|NCT01195610|Experimental|Average Danish Diet|Average Danish Diet
11522758|NCT01195597|Experimental|E-Cigarette 7.2 mg nicotine|Well characterized group of 40 regular smokers not intending to quit experimenting the E-Cigarette with 7.2 mg nicotine cartridges.
11522759|NCT01195584||BMI < 25|Body Mass Index (WHO) established by WHO. BMI < 25 has been defined as 'normal weight'.
11522760|NCT01195584||25 >= BMI < 30|Body Mass Index (WHO) established by WHO. BMI >= 25 and < 30 has been defined as 'overweight'.
11522761|NCT01195584||BMI >= 30|Body Mass Index (WHO) established by WHO. BMI > 30 has been defined as 'obese'.
11522762|NCT01195571|No Intervention|vaccine administration|Each subject will receive on of four chimera CMV vaccines
11522763|NCT01195558||Blind with sleep problems|Blind individuals with no light perception and with sleep-related problems who may suffer from Non-24
11522764|NCT01195545|Experimental|Veritas Mesh in Hernia Repair|Subjects undergoing laparoscopic paraesophageal hiatal hernia repair using a bovine pericardium mesh (BP) (Veritas® Collagen Matrix, Synovis ®, St. Paul MN) as a reinforcing material during repair.
11522765|NCT01195532||Gliclazide/2|60 mg*1 for T 30 mg*2 For R
11522766|NCT01195532||Reference and test drug|Reference: 30 mg *2 Test: 60 mg *1
11522767|NCT01195519||peritoneal dialysis and hemodialysis patients|peritoneal dialysis and hemodialysis patients
11522768|NCT01195493|Experimental|test mouthrinse|
11522769|NCT01195493|Active Comparator|control group|
11522770|NCT01195480|Experimental|Prophylaxis arm|Patients who have relapsed in the bone marrow after previous myeloablative HSCT and achieve remission after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells after a second HSCT with reduced intensity conditioning.
11522806|NCT01195207|Experimental|005|CNTO 3157 or placebo 0.3 mg/kg CNTO 3157 or placebo infusion
11523466|NCT01190592|Placebo Comparator|Water|
11522771|NCT01195480|Experimental|Pre-emptive arm|In this arm, patients identified at high (> 50%) risk of relapse will be eligible for generation of donor-derived EBV CTL immediately prior to HSCT. These patients will be monitored for evidence of MRD in regular bone marrow aspirates for the first year post-HSCT. MRD positivity post-HSCT is highly predictive of subsequent relapse. In those patients who become MRD+ in the marrow at a level of minimum 5 x 10-4, cryopreserved CTL that have been transduced with a retroviral vector carrying the CD19-zeta transgene will be thawed and administered to the patient pre-emptively.
11522772|NCT01195467|Experimental|All Subjects Truvada/Raltegravir|All Subjects will receive the same intervention, Truvada/Raltegravir
11522773|NCT01195454|Experimental|Insulin glargine / New insulin glargine formulation|"Period 1: Insulin glargine
~Period 2: New insulin glargine formulation
~Period 3: New insulin glargine formulation
~Period 4: New insulin glargine formulation
~Duration of treatment: 1 day at each period"
11522774|NCT01195428|Active Comparator|Simvastatin|Simvastatin 40 mg daily.
11522775|NCT01195428|Placebo Comparator|Placebo|Placebo
11522776|NCT01195415|Experimental|Treatment (vismodegib, gemcitabine hydrochloride)|Patients receive vismodegib PO QD on days 1-28 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 (beginning in course 2). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11522777|NCT01195402|No Intervention|Control|Subjects do not receive any kind of active intervention.
11522778|NCT01195402|Active Comparator|pulmonary outpatient rehabilitation|Subjects participate in an outpatient pulmonary rehabilitation program
11522779|NCT01195389|Active Comparator|Resonator|Treatment with active Resonator device using low level magnetic fields
11522780|NCT01195389|Placebo Comparator|Placebo treatment|
11522781|NCT01195376|Experimental|BEZ235 Dose Escalation once daily|oral BEZ235 once daily (q.d.)
11522782|NCT01195376|Experimental|BEZ Dose escalation twice daily|oral BEZ235 twice daily (b.i.d.)
11522783|NCT01195363|Active Comparator|quetiapine SR|quetiapine SR, 200-600mg, po, qd
11522784|NCT01195363|Placebo Comparator|quetiapine sr Placebo|quetiapine SR placebo, 200-600mg, po qd
11522785|NCT01195350||stroke|
11522786|NCT01195337||Study Group|Newsletters, Physical Activity (PA) Prescription Plan, Pedometer
11522787|NCT01195324|Experimental|001|Canagliflozin/Warfarin Treatment A: Tablets oral canagliflozin 300 mg once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg single dose on Day 6 followed 14 days later by Treatment B: Tablets oral warfarin 30 mg single dose on Day 1
11522788|NCT01195324|Experimental|002|Canagliflozin/Warfarin Treatment B: Tablets oral warfarin 30 mg single dose on Day 1 followed 14 days later by Treatment A: Tablets oral canagliflozin 300 mg once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg single dose on Day 6
11522789|NCT01195311|Experimental|INCB024360|
11522790|NCT01195285|Active Comparator|Single-Incision Laparoscopic Cholecsytectomy (SILS)|
11522791|NCT01195285|Active Comparator|Traditional Laparoscopic Cholecystectomy (TLC)|
11522792|NCT01195272|Experimental|Single Arm|
11522793|NCT01195259||metformin|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
11522794|NCT01195259||rosiglitazone|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
11522795|NCT01195246|Experimental|HEPLISAV|0.5 mL HEPLISAV
11522796|NCT01195246|Active Comparator|Engerix-B|2.0 mL Engerix-B
11522797|NCT01195246|Active Comparator|Fendrix|0.5 mL Fendrix
11522798|NCT01195233|Other|bioxtra spray and mouth rinse|Drug: BioXtra spray or mouth rinse Patients had been xerostomia due to radiation of head and neck were selected for the study. Gender, age, medical history, VAS, dichotomous questionnaire of xerostomia , and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received BioXtra spray and second group used BioXtra mouth rinse for 2 weeks and then 1 weeks wash -out period and for other 2 weeks drugs is switched . Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and 35 days after first visit.
11522799|NCT01195220|Active Comparator|HIV-T|"Group 1, the control, will be the current standard of care, consenting video and testing for HIV alone (HIV-T).
~This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test"
11522800|NCT01195220|Experimental|STI/HIV-T|"Group 2 will add routine STI testing for CT and GC, (STI/HIV-T).
~This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED."
11522801|NCT01195220|Experimental|STI/HIV-Plus|"Group 3, in addition to combined STI/HIV testing, will add a behavioral video encouraging safer sex, which is chosen for participants based on their answers to a brief measure on stage of change (STI/HIV-PLUS).
~This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes"
11522802|NCT01195207|Experimental|001|CNTO 3157 or placebo 0.003 mg/kg CNTO 3157 or placebo infusion
11522803|NCT01195207|Experimental|002|CNTO 3157 or placebo 0.01 mg/kg CNTO 3157 or placebo infusion
11522804|NCT01195207|Experimental|003|CNTO 3157 or placebo 0.03 mg/kg CNTO 3157 or placebo infusion
11522805|NCT01195207|Experimental|004|CNTO 3157 or placebo 0.1 mg/kg CNTO 3157 or placebo infusion
11522807|NCT01195207|Experimental|006|CNTO 3157 or placebo 1 mg/kg CNTO 3157 or placebo infusion
11522808|NCT01195207|Experimental|007|CNTO 3157 or placebo 3 mg/kg CNTO 3157 or placebo infusion
11522809|NCT01195207|Experimental|008|CNTO 3157 or placebo 10 mg/kg CNTO 3157 or placebo infusion
11522810|NCT01195194|Experimental|A- negative pre-transplant ELISPOT|Sirolimus: Start at 5 mg/day as soon as treatment allocation arrives to obtain targeting levels to 8 -15 ng/ml (immunoassay) in the first 3 months, followed by trough levels of 5-10 ng/ml.
11522811|NCT01195194|Experimental|B- Positive pre-transplant ELISPOT|Tacrolimus 0.1 mg/kg/12h starting as soon as treatment allocation arrives to obtain targeting troughs levels of 8-15 ng/ml the first 3 months, followed by trough levels of 5-10 ng/ml until the end of the study.
11522812|NCT01195181|Active Comparator|peginterferon alfa-2a plus ribavirin|patients will receive a fixed dose of 180ug/week of peginterferon alfa-2a plus ribavirin at 15mg/kg/daily.
11522813|NCT01195181|Active Comparator|peginterferon alfa-2b plus ribavirin|patients will receive a weight adjusted dose (1,5ug/kg) from 50 to 150ug/week of peginterferon alfa-2b (standard dose) or a lower dose (1,0ug/kg) at physician discretion (randomization list available only for 100 cases) plus ribavirin at 15mg/kg/daily.
11522814|NCT01195168||PCOS cohort|Women with PCOS as diagnosed by the NIH criteria
11522815|NCT01195168||Control cohort|Women without PCOS
11522816|NCT01195155|Active Comparator|LC n-3 PUFA|Supplementation with 4 x 1g fish oil capsules (Seven Seas, Ireland) containing 1.9g combined EPA and DHA daily for 6 weeks.
11522817|NCT01195155|Placebo Comparator|Placebo (olive oil) supplement|4 x 1g olive oil capsules (Millas Inc) were given daily for 6 weeks.
11522818|NCT01195155|No Intervention|Wash out period|A 6 week wash out period separated the LC n-3 PUFA and the Placebo (olive oil) arms. During this period the subjects took no supplements. This arm was designed to minimise a cross-over effect.
11522819|NCT01195142||PCOS-CSAT|Women with PCOS
11522820|NCT01195142||Control-CSAT|Control population consisting of women without PCOS, matched for age and BMI with the PCOS cohort
11522821|NCT01195129|Other|MicroVention Hydrogel Coils|FDA approved and in common use for cerebral aneurysm treatment.
11522822|NCT01195129|Active Comparator|Non-hydrogel coils|Cerecyte or bare platinum coils (FDA approved and in common use for treatment of cerebral aneurysm).
11522823|NCT01195116|Active Comparator|Dexmedetomidine|Dexmedetomidine is a FDA-approved medication that is a highly selective, short acting, alpha-2 adrenoreceptor agonist. To date, its safety and efficacy is well studied and established.It produces sedative, anxiolytic, and analgesic effects when used while patients undergo procedures and surgical operations.Interstitial Cystitis, as a chronic visceral pain syndrome, has the potential to have a neuropathic component for which an alpha-2 adrenergic agonist may be more effective than other classes, including opioids or NSAIDs.
11522824|NCT01195116|Placebo Comparator|Normal Saline|
11522825|NCT01195103|Experimental|10 mg/kg Lusedra|10 mg/kg Lusedra initial bolus.
11522826|NCT01195103|Active Comparator|6.5 mg/kg Lusedra|6.5 mg/kg Lusedra initial bolus.
11522827|NCT01195103|Active Comparator|Placebo + Midazolam|Placebo initial bolus with dose of midazolam based on patient's weight
11522828|NCT01195090|Active Comparator|sitagliptin|add sitagliptin100mg/d to pre-study OADs
11522829|NCT01195090|Active Comparator|pioglitazone|add pioglitazone 30mg/d to pre-study OADs
11522830|NCT01195077|Experimental|Seaweed, Spirulina, Seaweed + Spirulina|"Randomized to:
~Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day.
~Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.
~Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day."
11522831|NCT01195064||COPD+ OSAS- patients|Patients with chronic obstructive pulmonary disease (COPD) and without obstructive sleep apnea syndrome (OSAS), before planned cardiovascular surgery
11522832|NCT01195064||COPD- OSAS+ patients|Patients with obstructive sleep apnea syndrome (OSAS) and without chronic obstructive pulmonary disease (COPD), before planned cardiovascular surgery
11522833|NCT01195064||COPD+ OSAS+ patients|Patients with chronic obstructive pulmonary disease (COPD) and with obstructive sleep apnea syndrome (OSAS), with planned cardiovascular surgery
11522834|NCT01195064||COPD- OSAS- patients|Patients without chronic obstructive pulmonary disease (COPD) and without obstructive sleep apnea syndrome (OSAS), before planned cardiovascular surgery
11522835|NCT01195051|Experimental|Electronic medication reconciliation|Providers have access to a new, computer-based application to facilitate documentation and prescribing of outpatient medications in the inpatient setting.
11522836|NCT01195051|No Intervention|Control|
11522837|NCT01195025|Other|A.acetatedRingers, B.colloid & C.colloid+acetatedRingers|"First intervention: A. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by 150 minutes of equilibration, when blood samples were collected.
~Washout >7 days
~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.
~Washout > 7 Days
~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples."
11522838|NCT01195025|Other|A.colloid, B.colloid+acetatedRinger & C.acetatedRingers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.
~Washout >7 days
~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.
~Washout > 7 Days
~Third intervention: C. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected."
11522839|NCT01195025|Other|A.acetatedRingers, B.acetatedRingers+colloid & C.colloid|"First intervention: A. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.
~Washout >7 days
~Second intervention: B.Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.
~Washout > 7 Days
~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples."
11522840|NCT01195025|Other|A.colloid, B.acetatedRingers & C.colloid+acetatedRingers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.
~Washout >7 days
~Second intervention: B. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.
~Washout > 7 Days
~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples."
11522841|NCT01195025|Other|A.colloid+acetatedRingers, B.colloid & C.acetated Ringers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.
~Washout >7 days
~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.
~Washout > 7 Days
~Third intervention: C. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected."
11522842|NCT01195012|Other|wait-list control arm|Participants wait-listed to start the behavioral obesity treatment program (Helping HAND) after time two data collection (7 months after baseline).
11522843|NCT01195012|Experimental|Intervention arm|see intervention description
11522844|NCT01194999|Experimental|Pubovaginal sling procedure|Patients undergoing pubovaginal slings for stress urinary incontinence.
11522845|NCT01194986|Experimental|Pilot panel|[11C]AZ12807110 distribution and kinetics
11522846|NCT01194986|Experimental|Main panel|Histamine receptor occupancy reached by AZD5213
11522847|NCT01194973|Experimental|Eculizumab|
11522848|NCT01194960|Active Comparator|Docetaxel Alone|Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
11522849|NCT01194960|Experimental|TroVax plus Docetaxel|Subjects will receive both TroVax plus 10 cycles of Docetaxel.
11522850|NCT01194947||Study participants|patients 18 or older presenting to the Sheba Medical Center pigmented lesion clinic for skin cancer surveillance. Patients routinely undergo total skin examination that includes clinical and dermoscopic evaluation of skin lesions. Patients also routinely undergo annual total body digital photography that allows identification of new or changing lesions.
11522851|NCT01194934|Experimental|Group A|Group A: 2.0 mg/kg NOX-A12 IV every day for 5 days
11522852|NCT01194934|Experimental|Group B|Group B: 4.0 mg/kg NOX-A12 IV every day for 5 days
11522853|NCT01194934|Active Comparator|Group C|"The treatment groups will enter the study sequentially. The decision on starting groups C and D will be made after groups A and B have been completed and data are available.
~Group C: 5 µg/kg filgrastim SC every day for 5 days"
11522854|NCT01194934|Experimental|Group D|"The treatment groups will enter the study sequentially. The decision on starting groups C and D will be made after groups A and B have been completed and data are available.
~Group D: Safe and efficacious dose of NOX-A12 IV in combination with filgrastim SC for 5 days"
11522855|NCT01194908|Experimental|Arm A|Patients treated with decitabine and LBH589
11522856|NCT01194895|Experimental|protective ventilation|
11522857|NCT01194895|Active Comparator|conventional ventilation|
11522858|NCT01194882|Experimental|Insuman Implantable|Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.
11522859|NCT01194882|Active Comparator|Insuplant|Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.
11522860|NCT01194869|Experimental|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
11522861|NCT01194856|Active Comparator|Efavirenz 600 mg|Serving as the Control Arm - patients will maintain EFV-containing antiretroviral regimen
11522862|NCT01194856|Experimental|Arm B - Atazanavir/Ritonavir|Atazanavir 300 mg orally with Ritonavir 100 mg orally once daily for 96 wks
11522863|NCT01194843|Experimental|Ropivacaine|Ropivacaine administration by local per and post surgery infiltration
11522864|NCT01194843|Active Comparator|Physiological serum|Administration of physiological serum by local per and post surgery infiltration
11522865|NCT01194830|Active Comparator|Linagliptin|1 Tablet PO QD
11522866|NCT01194830|Placebo Comparator|Placebo|1 Tablet PO QD
11522867|NCT01194817|Other|Cemented fixation|Nexgen High-Flexion Knee Replacement System using Cemented Fixation
11522868|NCT01194817|Other|Cementless fixation|Nexgen High-Flexion Knee Replacement System using Cementless Fixation
11522869|NCT01194804|Experimental|Eculizumab|Treatment with eculizumab for patients with PNH who have successfully completed the C07-001 protocol
11522870|NCT01194791|Experimental|Lenalidomide, Cyclophosphamide and Dexamenthasone|
11522871|NCT01194778|Placebo Comparator|placebo|The participants of the placebo group will receive daily 1 placebo sachet containing only sucrose
11522872|NCT01194778|Active Comparator|vitamin K1|The participants of this group will receive daily 1 sachet containing 15 µg vitamin K1.
11522873|NCT01194778|Active Comparator|vitamin K2 - 15 µg|The participants of this group will receive daily 1 sachet containing 15 µg vitamin K2
11522874|NCT01194778|Active Comparator|vitamin K2 - 30 µg|The participants of this group will receive daily 1 sachet containing 30 µg vitamin K2
11522875|NCT01194778|Active Comparator|vitamin K2 - 45 µg|The participants of this group will receive daily 1 sachet containing 45 µg vitamin K2.
11522876|NCT01194765|Experimental|Cognitive Behavioural Therapy|
11522877|NCT01194765|No Intervention|Waiting List|
11522878|NCT01194713|Active Comparator|Sleep deprivation|"13 subjects will undergo full sleep deprivation
~these subjects are blind to allocation ntil they enter the study center"
11522879|NCT01194713|No Intervention|Control night|control night of unrestricted sleep in 13 other subjects
11522880|NCT01194700|Experimental|Evohaler|
11522881|NCT01194700|Experimental|Volumatic spacer|
11522882|NCT01194700|Experimental|Aerochamber Plus|
11522885|NCT01194648|Other|High Intensity Focused Ultrasound|HIFU, the Intervention
11522886|NCT01194622|Experimental|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
11522887|NCT01194622|Active Comparator|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
11522888|NCT01194622|Active Comparator|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
11522889|NCT01194609|Experimental|Low dose radiation, Immune cell therapy|Combination treatment of low-dose radiation 20cGy every 3 weeks three times and autologous immune cell therapy 2 consecutive weeks 3 times every 3 weeks
11522890|NCT01194596|Experimental|Spirometry and lifestyle counseling|Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
11522891|NCT01194596|No Intervention|Lifestyle counseling|No intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
11522892|NCT01194583||NO NICOTINE|Well characterized group of 100 regular smokers experimenting the E-Cigarette without nicotine cartridges (NO nicotine group).
11522893|NCT01194570|Experimental|Placebo|Participants with primary progressive multiple sclerosis (PPMS) received placebo matched to ocrelizumab at a schedule interval of 24 weeks up to at least 120 weeks.
11522894|NCT01194570|Placebo Comparator|Ocrelizumab 600 mg|Participants with PPMS received ocrelizumab as two IV infusions of 300 mg separated by 14 days at a scheduled interval of every 24 weeks up to at least 120 weeks.
11522895|NCT01194557|Active Comparator|rapid diagnostic test|Treatment and diagnosis of malaria in drugs hops using rapid diagnostic tests
11522896|NCT01194557|No Intervention|Presumptive malaria treatment|Presumptive treatment for malaria in drug shops
11522897|NCT01194544||population undergoing EGD in health examination.|
11522898|NCT01194531|No Intervention|CONTROL arm|Subjects assigned to this arm of the study will receive no PGS testing.
11522899|NCT01194531|Other|TEST arm|Subjects assigned to this arm of the study will receive PGS testing.
11522900|NCT01194518|Experimental|Lifestyle Intervention Program|
11522901|NCT01194505|Active Comparator|ACL, sciatic, femoral, obturator|ACL reconstruction surgery under ultrasound guided sciatic nerve block plus femoral nerve block plus obturator nerve block
11522902|NCT01194505|Active Comparator|ACL, sciatic nerve block, posterior lumbar plexus block|ACL reconstruction surgery under ultrasound guided sciatic nerve block plus posterior lumbar plexus block
11522903|NCT01194492|Other|Albumin kinetics|
11522904|NCT01194479|Active Comparator|Type 1 Diabetics|The active group were participants with type 1 diabetes.
11522905|NCT01194479|Other|Healthy Volunteers|The control group were participants without diabetes, matched by sex, age and BMI to the active comparator group.
11522906|NCT01194466|Active Comparator|Active TENS|Active high frequency TENS will be use for Active TENS.
11522907|NCT01194466|Experimental|Placebo (low intensity) TENS|Placebo TENS will be applied for one arm of the study
11522908|NCT01194466|Sham Comparator|No Treatment|TENS unit in place but not turned on
11522909|NCT01194453|Experimental|Group A|
11522910|NCT01194453|Active Comparator|Group B|
11522911|NCT01194440|Experimental|Arm I - IV Zoledronic Acid Prophylaxis|Patients receive zoledronic acid IV at months 1 and 6. Beginning 14 days after first zoledronic acid infusion, patients receive oral letrozole once daily for 12 months in the absence of disease progression or unacceptable toxicity.
11522912|NCT01194427|Experimental|Vorinostat and Tamoxifen|Vorinostat and tamoxifen are taken for about 14 days prior to definitive surgery.
11522913|NCT01194414|Experimental|Tocilizumab SC|"Participants received tocilizumab 162 mg subcutaneous (SC) injection weekly plus placebo to tocilizumab intravenous (IV) infusion every 4 weeks for a total of 24 weeks in the double-blind period. Participants continued to receive tocilizumab 162 mg SC injection weekly for a total of 72 weeks in open label extension period.
~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
11522914|NCT01194414|Experimental|Tocilizumab IV|"Participants received tocilizumab 8 mg/kg infusion (IV) every 4 weeks plus placebo to tocilizumab SC injection weekly for a total of 24 weeks in the double-blind period. Participants continued to receive tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 72 weeks in open label extension period.
~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
11522915|NCT01194414|Experimental|Tocilizumab SC Then Tocilizumab IV|"Participants who received tocilizumab 162 mg subcutaneous (SC) injection weekly plus placebo to tocilizumab IV infusion every 4 weeks for 24 weeks in double blind treatment period switched to tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 72 weeks in open label extension period.
~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
11522916|NCT01194414|Experimental|Tocilizumab IV Then Tocilizumab SC|"Participants who received tocilizumab 8 mg/kg infusion (IV) every 4 weeks plus placebo to tocilizumab SC injection weekly in double blind treatment period switched to tocilizumab 162 mg SC injection weekly for a total of 72 weeks in open label extension period.
~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose will be continued throughout the study."
11522917|NCT01194401||Cohort|
11522918|NCT01194388||MicroFx™ PGLA Treated Subjects|
11522919|NCT01194375|Experimental|Low Strength IDP-107|
11522920|NCT01194375|Experimental|High Strength IDP-107|
11522921|NCT01194375|Placebo Comparator|Placebo|
11522922|NCT01194362||45 specimens collected from BAV patients|
11522923|NCT01194362||45 specimens collected from TAV patients|
11522924|NCT01194362||15 specimens collected from CABG pts|
11522925|NCT01194336||Huperzine A: 100 ug|
11522926|NCT01194336||Huperzine A: 200 ug|
11522927|NCT01194336||Donepezil: 2.5 mg|
11522928|NCT01194336||Donepezil: 5 mg|
11522929|NCT01194336||Galantamine: 4 mg|
11522930|NCT01194336||Galantamine: 8 mg|
11522931|NCT01194336||Placebo|
11522932|NCT01194323||Controls|No complaints or history of heartburn or acid regurgitation; no erosion at EGD; and normal pH monitoring
11522933|NCT01194323||GERD Cases|Patients with esophageal erosion at EGD and abnormal pH monitoring.
11522934|NCT01194310||phaco alone|patients w/ diagnosis of open angle glaucoma underwent phaco alone
11522935|NCT01194310||phaco-ELT|patients w/ diagnosis of open angle glaucoma underwent combined phaco plus ELT
11522936|NCT01194310||phaco-Trabectome|patients w/ diagnosis of open angle glaucoma underwent combined phaco plus Trabectome
11522937|NCT01194297|Experimental|Live attenuated influenza vaccine|One dose of live attenuated influenza vaccine, according to routine immunization recommendations
11522938|NCT01194297|Active Comparator|Inactivated influenza vaccine|One dose of inactivated influenza vaccine, according to routine immunization recommendations
11522939|NCT01194284||High-grade osteosarcoma patients|
11522940|NCT01194271|Experimental|Neoadjuvant Ipilimumab|Leuprolide Acetate 22.5 mg administered as a single intramuscular 3 month depot + Ipilimumab 10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy + Radical Prostatectomy Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
11522941|NCT01194258|Experimental|Lispro-PH20/Insulin lispro|"All enrolled participants underwent a titration period of 4 to 6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.
~Next, participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.
~Lispro-PH20 (Treatment A): 100 U/mL insulin lispro with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (combined: Lispro-PH20), injected SC, pre-meals, with doses titrated to each participant individually.
~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually.
~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
11522942|NCT01194258|Experimental|Aspart-PH20/Insulin Lispro|"All enrolled participants underwent a titration period of 4 to 6 weeks in which they received 100 U/mL insulin glulisine, injected SC, pre-meals, with doses titrated to each participant individually.
~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.
~Aspart-PH20 (Treatment A): 100 U/mL insulin aspart with 5.0 µg/mL rHuPH20 (combined: Aspart-PH20), injected SC, pre-meals, with doses titrated to each participant individually.
~Insulin lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually.
~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
11522943|NCT01194245|Experimental|Lispro-PH20 / Insulin Lispro|"All enrolled participants underwent a titration period of 4-6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.
~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle with no washout period.
~Lispro-PH20 (Treatment A): 100 U/mL insulin lispro with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, with doses titrated to each participant individually
~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually
~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
11522944|NCT01194245|Experimental|Aspart-PH20 / Insulin Lispro|"All enrolled participants underwent a titration period of 4-6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.
~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle with no washout period.
~Aspart-PH20 (Treatment A): 100 U/mL insulin aspart with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, with doses titrated to each participant individually
~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually
~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
11522945|NCT01194232|Experimental|Sildenafil|15 subjects will receive 8 week course of Sildenafil administered at a dose of 20 mg per dose three times per day.
11522946|NCT01194219|Active Comparator|Apremilast|Subjects initially randomized to apremilast 30 mg twice a day, and who demonstrate a PASI 75 response at Week 32 will be randomized (1 to 1) to either continue to receive apremilast 30 mg ) BID or to receive placebo (until effect is lost). At the time effect is lost, subjects will be treated with apremilast 30 mg twice a day for the duration of their participation in the study.
11522947|NCT01194219|Placebo Comparator|Placebo|Subjects initially randomized to placebo, are assigned to apremilast 30 mg twice a day beginning at Week 16 for the duration of the subject's participation in the study.
11522948|NCT01194219|Active Comparator|Apremilast 30 mg|Apremilast 30 mg by mouth (PO) twice a day (BID). Participants initially randomized to apremilast 30 mg BID, and who were able to demonstrate a Psoriasis Area Severity Index (PASI) -75 response at week 32 were randomized (1 to 1) to either apremilast 30 mg BID or oral placebo (until effect is lost). At relapse/loss of response to therapy prior to Week 52 (the time at which 75% improvement in PASI score compared to baseline was lost) or at Week 52, participants were re-treated with apremilast 30 mg BID for the duration of their participation in the study. Non-responders or partial responders (PASI response <75) received additional topical therapies or phototherapy beginning at Week 32.
11522949|NCT01194206|Experimental|Arm I|Patients undergo 3 fractions of stereotactic body radiation therapy in 3 fractions delivered within 14 days in the absence of disease progression or unacceptable toxicity.
11522950|NCT01194193|Experimental|1|
11522951|NCT01194180|Experimental|Group A|"BCG-naive subjects receiving intradermal challenge injection of BCG and challenge site punch biopsy"
11522952|NCT01194180|Experimental|Group B|"BCG-naïve subjects receiving intradermal injection of MVA85A followed by intradermal challenge injection of BCG and challenge site punch biopsy"
11522953|NCT01194180|Experimental|Group C|"BCG-experienced subjects receiving intradermal challenge injection of BCG and challenge site punch biopsy"
11522954|NCT01194180|Experimental|Group D|"BCG-experienced subjects receiving intradermal injection of MVA85A followed by intradermal challenge injection of BCG and challenge site punch biopsy"
11522955|NCT01194167|Experimental|Eltrombopag|Eltrombopag 75 mg per day. Possible escalation to 150 mg per day after day 15 lab results. Possible escalation to 300 mg per day after day 29 lab results.
11522956|NCT01194154|Experimental|Mircera|
11522957|NCT01194154|Placebo Comparator|Placebo|
11522958|NCT01194141|Experimental|Exercise training|Aerobic exercise training 45-60 min/3x/week/12 weeks
11522959|NCT01194128|Experimental|Psychoeducatioinal Support|The intervention is comprised of three modules (see Table 6), each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.
11522960|NCT01194128|Active Comparator|INformation only control group|"Participants in the control group will receive a portion of the standardized packet of written information that is also provided to the treatment group. This packet will contain several fact sheets from a nationally-recognized expert source in caregiving (the Family Caregiver Alliance's National Center on Caregiving) and a national information and advocacy group (the National Citizens' Coalition for Nursing Home Reform). The fact sheets are relevant to the placement of a family member into a nursing home and are linked to the content areas covered in the intervention. Documents in this packet include Caregiving and Depression, End of Life Decision Making, and Taking Care of You: Self-Care for Family Caregivers from the Family Caregiver Alliance; and Family Involvement in Nursing Home Care, Problem Solving, and Residents' Rights from the National Citizen's Coalition."
11522961|NCT01194115|Experimental|Cephalexin and metronidazole|500 mg cephalexin per oral every 8 hours for total of 6 doses; 500 mg metronidazole per oral every 8 hours for total of 6 doses
11522962|NCT01194115|Placebo Comparator|Placebo/standard of care|Placebo pills per oral every 8 hours for total of 6 doses
11522963|NCT01194102|Experimental|Stroke Community Wellness Program|"Participants with stroke will attend a 12 week Community Wellness Program. The program consists of a Community Based Exercise Program at the YMCA (2x 1 hour exercise sessions per week with specially trained fitness instructors). They will also attend a 1 hour long Living with Stroke education session one time per week and an independent exercise session in the fitness centre one time per week."
11522964|NCT01194102|Active Comparator|Regular YMCA membership|"The control group will have access to YMCA facilities to use at their discretion but will not attend the Community Based Exercise Program for stroke survivors or the Living with Stroke education program. YMCA staff working with the control group will not receive specialized training in exercise and education for stroke survivors but will be trained on important safety precautions and contraindications to exercise after stroke."
11522965|NCT01194089|Active Comparator|Nasal Nicotine Spray|3 mg of nasal nicotine will be administered postoperatively.
11522966|NCT01194089|Placebo Comparator|Nasal Normal Saline Spray|1 ml of nasal normal saline spray will be administered postoperatively.
11522967|NCT01194076|Experimental|5day intensive treatment|
11522968|NCT01194063|Experimental|Omegaven|Administration of intravenous Omega-3 fish oil lipid emulsion 1 g/kg continuous infusion over 12-24 hrs
11522969|NCT01194050||Cohort|
11522970|NCT01194037|Experimental|Hanferon (low dose) sc weekly + RBV oral daily|
11522971|NCT01194037|Experimental|Hanferon (high dose) sc weekly + RBV oral daily|
11522972|NCT01194037|Active Comparator|Pegasys 180 ug sc weekly + RBV oral daily|
11522973|NCT01194024||Intubated within 24hrs of admission|All patients that are admitted to a participating burn center and intubated within 24 hours
11522974|NCT01193998|Active Comparator|Clinician exposed to Model result|
11522975|NCT01193998|Experimental|Clinician blinded to Model result|
11522976|NCT01193985|Experimental|Intervention|
11522977|NCT01193946||Single-arm design|There is currently considerable debate regarding the accuracy of the estimated average requirement (EAR) and the recommended dietary allowance (RDA) for older people. Very limited data obtained from older individuals are available to support the assumption that age does not affect protein requirement. Existing method like nitrogen balance has inherent limitations that diminish it from being considered a reference method. Indicator amino acid oxidation technique is emerging as an alternative method to measure dietary protein requirement. It is more accurate and less demanding. The current study will be the first time this technique is used with elderly adults and will provide an important foundation for geriatric nutrition research
11522978|NCT01193920|Experimental|1: GBS Trivalent Vaccine with aluminium - 20/20/20 μg|Non-pregnant women who received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
11522979|NCT01193920|Placebo Comparator|2: Placebo - Sterile saline|Non-Pregnant Women who received two injection of saline solution.
11522980|NCT01193920|Experimental|3: GBS Trivalent Vaccine - 0.5/0.5/0.5 µg|Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
11522981|NCT01193920|Experimental|4: GBS Trivalent Vaccine - 2.5/2.5/2.5 µg|Pregnant Women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
11522982|NCT01193920|Experimental|5: GBS Trivalent Vaccine - 5/5/5 µg|Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
11522983|NCT01193920|Placebo Comparator|6: Placebo - Sterile saline|Pregnant Women who received one injection of saline solution.
11522984|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 12.5 mcg|1 dose of 0.5 mL containing 12.5 mcg of Vi-CRM
11522985|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 5 mcg|1 dose of 0.5 mL containing 5 mcg of Vi-CRM
11522986|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 1.25 mcg|1 dose of 0.5 mL containing 1.25 mcg of Vi-CRM
11522987|NCT01193907|Active Comparator|Typherix|1 dose of 0.5 mL containing 25 mcg of Vi-polysaccharide
11522988|NCT01193894|Experimental|Profermin|
11522989|NCT01193894|Active Comparator|Fresubin|
11522990|NCT01193881|Experimental|Treatment (erlotinib, RO4929097)|Patients receive erlotinib hydrochloride PO QD on days 1-21 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11522991|NCT01193868|Experimental|RO4929097|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Blood and tumor tissue samples are collected for pharmacogenetic, pharmacodynamic, and biomarker studies by IHC, FISH, and TUNEL assay."
11522992|NCT01193842|Experimental|Arm A (VR-DA-EPOCH)|Patients receive vorinostat PO QD on days 1-5; rituximab IV on day 1; etoposide IV over 24 hours, doxorubicin hydrochloride IV over 24 hours, and vincristine sulfate IV over 24 hours on days 1-4; prednisone PO daily on days 1-5; and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11522993|NCT01193842|Experimental|ARM B (DA-R-EPOCH)|Patients receive rituximab, etoposide, doxorubicin hydrochloride, vincristine sulfate, prednisone, and cyclophosphamide as in Arm A. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11522994|NCT01193829||NSCLC patients|
11522995|NCT01193816|Experimental|loxapine|loxapine
11522996|NCT01193816|Placebo Comparator|Placebo|Placebo
11522997|NCT01193803||Spondylodiscitis control group|Patients needing vertebral biopsy looking for tumoral etiology
11522998|NCT01193803||Prosthetic Joint Infection control group|Patients with primary prosthetic arthrosis surgery
11522999|NCT01193803||Septic arthritis control group|Arthrosic patients needing evacuating articular punction with leucocytes infiltration less than 1000 /mm3
11523000|NCT01193803||Spondylodiscitis case group|Patients suspected of Discitis and/or Vertebral Osteomyelitis is defined by the need of spinal biopsy in infectious context.
11523001|NCT01193803||Prosthetic Joint Infection case group|Patients suspected of Prosthetic Joint Infection defined by the need of surgical revision for diagnostic or therapeutic aiming in infectious context.
11523002|NCT01193803||Septic arthritis case group|Patients suspected of Septic arthritis without prosthesis were defined by the need of synovial punction and/or biopsy
11523003|NCT01193790|Experimental|Coblation|
11523004|NCT01193777|Placebo Comparator|Saline|
11523005|NCT01193777|Experimental|L-Carnitine|
11523006|NCT01193764|Experimental|cocoa|unsweetened 100% cocoa (Ghirardelli)
11523007|NCT01193764|Placebo Comparator|placebo|hydrolyzed gelatin powder (Gelita)
11523008|NCT01193751||asphyxiated newborns > 37 weeks of gestation|
11523009|NCT01193738|Active Comparator|active osteopathic compression|osteopathic compression of Pterygopalatine node
11523010|NCT01193738|Placebo Comparator|placebo osteopathic compression|placebo osteopathic compression
11523011|NCT01193725|Active Comparator|Prolonged Exposure Therapy (PE)|The PE protocol is based on manualized procedures, which are derived from the theory that effective treatment for PTSD requires that the underlying pathological fear structure be activated and paired with new information that is incompatible with the fear structure. PE involves imaginal exposure and in vivo exposure as the two primary strategies to elicit repeated confrontation of feared but objectively safe thoughts, feelings, situations and events.
11523012|NCT01193725|Experimental|Virtual Reality Exposure Therapy (VRET)|The VRET protocol follows the same procedures as the PE protocol with the primary exception being that all instances of imaginal exposure will be augmented by immersion into Virtual Iraq environments, thus creating a situation known as immersive exposure.
11523013|NCT01193725|Placebo Comparator|Waitlist|The waitlist (WL) participants will be asked to refrain from psychotherapy during the 5 weeks of study participation.
11523014|NCT01193712|Other|on-table non-responder|patients who do not show an improvement of more than or equal to 15% in LV dP/dtmax measured immediately after implantation of a cardiac resynchronization therapy device
11523015|NCT01193712|No Intervention|on-table responders|patients who do show an improvement of more than or equal to 15% in LV dP/dtmax measured immediately after implantation of a cardiac resynchronization therapy device
11523016|NCT01193699|Experimental|P1101|
11523017|NCT01193686|Experimental|Peer Visitation Training (Peer Mentor)|Veteran Peer Visitors participated in a 2-day training program and then provide at 1-5 visits to at least 2 recipients.
11523018|NCT01193686|Experimental|Peer Visitation|Veterans who received at least one visit from a Veteran Peer Visitor.
11523019|NCT01193660|Experimental|Umbilical Cord Blood & Erythropoietin & Rehabilitation|Allogenic umbilical cord blood infusion, erythropoietin injection & active rehabilitation
11523020|NCT01193660|Active Comparator|Erythropoietin & Rehabilitation|Erythropoietin injection, active rehabilitation
11523021|NCT01193660|Placebo Comparator|Only Rehabilitation|Active rehabilitation
11523022|NCT01193634|Experimental|Paradym RF ICD|Active implantable defibrillators range
11523023|NCT01193621|Active Comparator|haloperidol|"0.5, 1, 3 mg of haloperidol will be administered orally every 24 hours for 7 days to 4 healthy subjects in each dose level (a total of 12 subjects).
~Dose groups are as follows; D2-receptor occupancy study Group Single Oral Dose No. of subjects
~0.5 mg 4
~1 mg 4
~5 mg 4"
11523024|NCT01193608|Experimental|0.5 mg/kg AAB-003|
11523025|NCT01193608|Experimental|1 mg/kg AAB-003|
11523026|NCT01193608|Experimental|2 mg/kg AAB-003|
11523027|NCT01193608|Experimental|4 mg/kg AAB-003|
11523028|NCT01193608|Experimental|8 mg/kg AAB-003|
11523029|NCT01193608|Placebo Comparator|Placebo|
11523030|NCT01193595|Experimental|AVE8062/ bevacizumab|The combination of ombrabulin and bevacizumab will be administered every 3 weeks according to the following schedule: One day 1, ombrabulin will be administered as a 30 minutes intravenous (i.v) infusion. Bevacizumab will be administered as a 30-90 minutes i.v. infusion 24 hours after the end of ombrabulin infusion on day 2.
11523031|NCT01193582|Experimental|Group 1|
11523032|NCT01193582|Experimental|Group 2|
11523033|NCT01193582|Experimental|Group 3|
11523034|NCT01193582|Experimental|Group 4|
11523035|NCT01193569||Standard of Care|Standard of Care for stroke except mechanical therapy
11523036|NCT01193556|Active Comparator|Standard of Care|Traditional electrosurgery will be used for the tonsillectomy.
11523037|NCT01193556|Experimental|PlasmaBlade|The PEAK PlasmaBlade will be used for the tonsillectomy.
11523038|NCT01193543|Experimental|calanus oil|calanus oil 1 gram twice daily
11523039|NCT01193543|Placebo Comparator|olive oil|olive oil 1 gram twice daily
11523040|NCT01193530|Experimental|Bright Light Therapy|Daily Bright Light Therapy using Bright Light Litebook device for two 14 day periods.
11523041|NCT01193530|Placebo Comparator|Dim Red Light Therapy|Daily Dim Red Light Therapy (placebo) using control Red Light Litebook device for 14 days then proceed to the open label phase and receive daily bright light for 14 days.
11523042|NCT01193517|Experimental|Phase I|Dose Escalation of Azacitidine + CAPOX (Capecitabine, Oxaliplatin)
11523043|NCT01193517|Experimental|Phase II|MTD of Azacitidine + CAPOX
11523044|NCT01193504|Active Comparator|Pred Forte|Patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Pred Forte BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
11523045|NCT01193504|Active Comparator|Lotemax|patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Lotemax BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
11523046|NCT01193491|Experimental|IPI-493|
11523047|NCT01193478|Active Comparator|Cohort 1|GS-5885 (3 mg), once daily or matching placebo, once daily
11523048|NCT01193478|Active Comparator|Cohort 2|GS-5885 (10 mg), once daily or matching placebo, once daily
11523049|NCT01193478|Active Comparator|Cohort 3|GS-5885 (30 mg), once daily or matching placebo, once daily
11523050|NCT01193478|Active Comparator|Cohort 4|GS-5885 ( up to 90 mg), once daily or matching placebo, once daily
11523051|NCT01193478|Active Comparator|Cohort 5|GS-5885 (up to 90 mg), once daily or matching placebo, once daily
11523052|NCT01193478|Active Comparator|Cohort 6 (optional)|GS-5885 (up to 90 mg), once daily or matching placebo, once daily
11523053|NCT01193465|Experimental|humidity|
11523054|NCT01193452|Experimental|S-1/LV|S-1 combined with Leucovorin
11523055|NCT01193452|Active Comparator|sLV5FU2|5-FU/LV infusion
11523056|NCT01193439||Patients with high risk|
11523057|NCT01193439||Patients in normal conditions|
11523058|NCT01193426||Cirrhosis patient|All consecutive patients with cirrhosis admitted to the five participating center Patients were hospitalized or treated in an ambulatory setting for treatment of ascites or complications of cirrhosis. Ascitic fluid was obtained by paracentesis according to the usual clinical management for these patients.
11523059|NCT01193413||Non-infected necrosis group|There is no necrosis infection in severe acute pancreatitis.
11523060|NCT01193413||Single drainage group|The patients with necrosis infection in severe acue pancreatitis were cured by single drainage.
11523061|NCT01193413||Combined surgery group|If there was no clinical improvement after single drainage about 7 days, an open necrosectomy was performed in the patients with necrosis infection.
11523062|NCT01193400|Experimental|Clofarabine-Cytarabine|Induction therapy with a combination of clofarabine and low-dose cytarabine followed by consolidation therapy with clofarabine and low-dose cytarabine
11523063|NCT01193387|Experimental|IDeg (M) IM1|
11523064|NCT01193387|Experimental|IDeg (M) IM2|
11523065|NCT01193374|Experimental|Parent/child tailored mailed materials|Family provided newsletters tailored to issues and readiness to change. Family receives educational nutrition DVD, pedometers for family activities and child nutrition/physical activity games
11523066|NCT01193374|Active Comparator|Basic information at single time|Family provided with high quality booklet from American Dietetic Association providing the same information that intervention arm received but not tailored.
11523067|NCT01193361|Experimental|Arm 1 - BMS-791325 plus peg-interferon alfa-2a and ribavirin|
11523068|NCT01193361|Experimental|Arm 2 - BMS-791325 plus peg-interferon alfa-2a and ribavirin|
11523069|NCT01193361|Placebo Comparator|Arm 3 - Placebo plus peg-interferon alfa-2a and ribavirin|
11523070|NCT01193348|Experimental|Eculizumab|
11523071|NCT01193335|Active Comparator|Group 1: Preterm infants|Infant born at < 37 weeks of gestation.
11523072|NCT01193335|Active Comparator|Group 2: Term infants|Infants born at ≥ 37 weeks of gestation
11523073|NCT01193296|Experimental|Vildagliptin|
11523074|NCT01193296|Active Comparator|Sitagliptin|
11523075|NCT01193283|Experimental|SAA hematologic response|Treatment-naive severe aplastic anemia patients will receive a low dose of cyclophosphamide (120mg/kg) and low dose cyclosporine ( target therapeutic level of 100-200 micrograms per liter). Cyclophosphamide will be given once daily for 4 doses. Cyclosporine will be started after cyclophosphamide completion, cyclosporine will be given twice daily. The dosing will be modified to attain the therapeutic level.
11523076|NCT01193270|Experimental|Vitamin E|A single intragastric dose of dl-α-tocopheryl acetate (Aquasol E®) 50 IU/kg.
11523077|NCT01193270|Placebo Comparator|Placebo|Sterile water in volume equal to that of the comparator drug.
11523078|NCT01193257|Experimental|Orteronel + prednisone|
11523079|NCT01193257|Placebo Comparator|Placebo + prednisone|
11523080|NCT01193244|Experimental|Orteronel + prednisone|
11523081|NCT01193244|Placebo Comparator|Placebo + prednisone|
11523082|NCT01193231||Acuvail 0.45%|Each subject will be randomized to the eye that they will use Acuvail in for 3 days after PRK
11523083|NCT01193231||Systane Ultra Preservative Free Tears|Each subject's contralateral eye (other eye) will use Sytane for 3 days after PRK surgery.
11523084|NCT01193218|Experimental|BI 10773 low dose QD|BI 10773 tablets low dose once a day
11523085|NCT01193218|Experimental|BI 10773 mid-low dose QD|BI 10773 tablets mid-low dose once a day
11523086|NCT01193218|Experimental|BI 10773 mid-high dose QD|BI 10773 tablets mid-high dose once a day
11523087|NCT01193218|Experimental|BI 10773 high dose QD|BI 10773 tablets high dose once a day
11523088|NCT01193218|Placebo Comparator|Placebo|Placebo tablets once a day
11523089|NCT01193205|Experimental|20 weeks skills group|Participants receive 20 weeks of Dialectical Behaviour Therapy Skills training, covering 5 modules: mindfulness, interpersonal effectiveness, emotional regulation, distress tolerance, dialectics.
11523214|NCT01192321|Experimental|Toric T3 - T9|Bilateral implantation of a Toric intraocular lens (IOL) models T3, T4, T5, T6, T7, T8 or T9
11523090|NCT01193205|No Intervention|Waitlist|Participants on the waitlist condition will be assessed at baseline and symptoms monitored at 10 weeks, 20 weeks and 8 months following baseline assessment. They will then be offered the active treatment.
11523091|NCT01193192||Arm #1 (Test Group)|100 subject administered Neevo® or NeevoDHA® daily
11523092|NCT01193192||Arm #2 (Control group)|100 subject administered a prenatal vitamin daily
11523093|NCT01193179|Experimental|OPC-262|
11523094|NCT01193166|Experimental|001|paliperidone palmitate 78 117 156 or 234 mg monthly injection for 12 months
11523095|NCT01193166|Active Comparator|002|olanzapine flexible dosing as prescribed by the study doctor for 12 months
11523096|NCT01193166|Active Comparator|003|paliperidone flexible dosing as prescribed by the study doctor for 12 months
11523097|NCT01193166|Active Comparator|004|aripiprazole flexible dosing as prescribed by the study doctor for 12 months
11523098|NCT01193166|Active Comparator|005|haloperidole flexible dosing as prescribed by the study doctor for 12 months
11523099|NCT01193166|Active Comparator|006|perphenazine flexible dosing as prescribed by the study doctor for 12 months
11523100|NCT01193166|Active Comparator|007|quetiapine flexible dosing as prescribed by the study doctor for 12 months
11523101|NCT01193166|Active Comparator|008|risperidone flexible dosing as prescribed by the study doctor for 12 months
11523102|NCT01193153|Experimental|001|paliperidone palmitate 78 117 156 234 mg (50 75 100 or 150 mg eq.) monthly by i.m. injection for 15 months
11523103|NCT01193153|Placebo Comparator|002|Placebo monthly by i.m. injection for 15 months
11523104|NCT01193140|Experimental|Arm A|
11523105|NCT01193127|Experimental|OMS302 Solution|OMS302 Solution
11523106|NCT01193127|Experimental|OMS302 Mydriatic Solution|OMS302 Mydriatic Solution
11523107|NCT01193127|Experimental|OMS302 Anti-inflammatory Solution|OMS302 Anti-inflammatory Solution
11523108|NCT01193127|Placebo Comparator|Balanced Salt Solution (BSS) Solution|Balanced Salt Solution (BSS) Solution
11523109|NCT01193114|Experimental|Ecologically-Based Behavioral Treatment|Ecologically-Based Treatment was provided over a period of 6 months. The treatment integrated independent housing, case management services and substance abuse counseling. Specifically, the mothers were housed in an apartment of their choice and received three months of utility and rental assistance of up to $600 per month.
11523110|NCT01193114|Active Comparator|Treatment as Usual|The Mothers were offered services provided through the family shelter.
11523111|NCT01193101|Experimental|LCZ696 100 mg|LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.
11523112|NCT01193101|Experimental|LCZ696 200 mg|LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.
11523113|NCT01193101|Experimental|LCZ696 400 mg|LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.
11523114|NCT01193101|Placebo Comparator|Placebo|Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.
11523115|NCT01193088||CMT1A|Families/people with genetically defined CMT1A
11523116|NCT01193088||Genetically undefined CMT|Families/people with genetically undefined CMT with common causes ruled out.
11523117|NCT01193075||CMT1B|Families/patients with genetically confirmed CMT1B
11523118|NCT01193075||CMT2A|Families/patients with genetically confirmed CMT2A
11523119|NCT01193075||CMT4A|Families/patients with genetically confirmed CMT4A
11523120|NCT01193075||CMT4C|Families/patients with genetically confirmed CMT4C
11523121|NCT01193075||All other CMT|Families/patients with all other forms of CMT or CMT that has not yet been genetically identified
11523122|NCT01193062|Experimental|Cohort 1|Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
11523123|NCT01193062|Experimental|Cohort 2|Subjects will be receive single oral doses of PF-04995274 not exceeding 15mg or a placebo
11523124|NCT01193049|Experimental|Prednisone, then Placebo|Prednisone in the first crossover treatment period and placebo in the second crossover treatment period
11523125|NCT01193049|Experimental|Placebo, then Prednisone|Placebo in the first crossover treatment period and prednisone in the second crossover treatment period
11523126|NCT01193036||Interview|
11523127|NCT01193036||Symptom Inventory Assessment|
11523128|NCT01193023|Active Comparator|Pressure support|"in this arm, pressure support will be recorded under 3 conditions:
~with the initial Expiratory Trigger Setting (ETS)
~with ETS +10%
~with ETS -10%"
11523129|NCT01193023|Experimental|NAVA|Neurally Adjusted ventilatory Assist is a ventilation mode where the ventilator is piloted by the electrical activity of the diaphragm Ventilation is triggered and cycled off by the electrical activity of the diaphragm, the pressure delivered being proportional to this activity.
11523130|NCT01193010|Active Comparator|Control|Surgery without computer-assisted planning.
11523131|NCT01193010|Experimental|Computer-Assisted Surgical Planning|
11523132|NCT01192997|Active Comparator|Menveo-Meningitec|Subjects who were primed with Meningitec who will receive Novartis Menveo
11523133|NCT01192997|Active Comparator|MenACWY-TT-Meningitec|Subjects who were primed with Meningitec who will receive GSK MenACWY-TT
11523134|NCT01192997|Active Comparator|Menveo-Menjugate|Subjects who were primed with Menjugate who will receive Novartis Menveo
11523135|NCT01192997|Active Comparator|MenACWY-TT-Menjugate|Subjects who were primed with Menjugate who will receive GSK MenACWY-TT vaccine.
11523136|NCT01192997|Active Comparator|Menveo-NeisVac-C|Subjects who were primed with NeisVac-C who will receive Novartis Menveo
11523137|NCT01192997|Active Comparator|MenACWY-TT-NeisVac-C|Subjects who were primed with NeisVac-C who will receive GSK MenACWY-TT vaccine
11523138|NCT01192984|Experimental|KW-0761|
11523139|NCT01192971|Experimental|A 850|Arm 850: Experimental apatinib 850 mg qd, and it should be continued until disease progression or intolerable toxicity or patient withdrawal of consent
11523140|NCT01192971|Experimental|B750|B750: apatinib 750 qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11523215|NCT01192321|Active Comparator|Monofocal|Bilateral implantation of a monofocal intraocular lens (IOL) model with no toric component.
11523141|NCT01192932||COPD|COPD patients aged 40 or more, with a smoking history of > 10 pack-years, a post-bronchodilator FEV1/VC < 0.7 and an optimal treatment according to GOLD guidelines will be included. Exclusion criteria are: COPD exacerbation or respiratory infection in the 4 weeks before the begin of the study, concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active malignancy or malignancy of any organ system within the past 5 years.
11523142|NCT01192919||Patients with lung cancer|Patients with lung cancer requiring therapy
11523143|NCT01192906|Experimental|1|
11523144|NCT01192906|Experimental|2|
11523145|NCT01192906|Placebo Comparator|3|
11523146|NCT01192893||OPUS|OPUS is a prospective study of postmenopausal women recruited in the general population between April 1999 and April 2001 from five European centers (Aberdeen (UK), Berlin (Germany), Kiel (Germany), Paris (Hospital Cochin, France), and Sheffield (UK)). Investigations were approved at each institution according to the Declaration of Helsinki. Written consent was obtained from all subjects. Each center recruited approximately 500 postmenopausal women comprising 100 individuals in each 5-yr age band between 55 and 79. Ninety-nine percent of subjects were of white ethnicity.
11523147|NCT01192880|Experimental|Bitopertin 10 mg + Antipsychotics|Treatment Period 1: Participants will receive bitopertin 10 milligrams (mg) tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin 10 mg tablet orally once daily for 28 weeks (up to Study Week 52). After Week 52 there will be a 4-week washout period for at least 50 percent (%) of participants (up to Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and continue to receive bitopertin 10 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
11523148|NCT01192880|Experimental|Bitopertin 20 mg + Antipsychotics|Treatment Period 1: Participants will receive bitopertin 20 mg tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin 20 mg tablet orally once daily for 28 weeks (up to Study Week 52). After Week 52 there will be a 4-week washout period for at least 50% of participants (up to Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and continue to receive bitopertin 20 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
11523149|NCT01192880|Placebo Comparator|Placebo|Treatment Period 1: Participants will receive bitopertin matching placebo tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin matching placebo tablet orally once daily for 32 weeks (up to Study Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and will be switched to (in blinded manner) bitopertin 10 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
11523150|NCT01192867|Experimental|RO4917838 20 milligrams (mg)|Participants, on stable antipsychotics, will receive RO4917838 orally at 20 mg once daily (QD) up to 56 weeks followed by an optional treatment extension for up to 3 years.
11523151|NCT01192867|Experimental|RO4917838 10 mg|Participants, on stable antipsychotics, will receive RO4917838 orally at 10 mg QD up to 56 weeks followed by an optional treatment extension for up to 3 years.
11523152|NCT01192867|Placebo Comparator|Placebo|Participants, on stable antipsychotics, will receive RO4917838 matching placebo orally QD up to 56 weeks.
11523153|NCT01192854|Experimental|1|
11523154|NCT01192854|Active Comparator|2|
11523155|NCT01192841|No Intervention|White coat group|Participants continued their regular practice of wearing their physician white coat.
11523156|NCT01192841|Experimental|Uniform group|Participants were given a clean uniform (scrubs) at the beginning of the day.
11523157|NCT01192828|Experimental|Taurine|Treatment with Taurine
11523158|NCT01192815|Experimental|Arm I|Patients receive erlotinib hydrochloride orally or via gastrostomy tube once daily in weeks 1-9 and then for 2 years following completion of radiation therapy. Beginning on day 1 of week 2, patients undergo radiation therapy once daily, 5 times a week, for 5-7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
11523159|NCT01192802|Active Comparator|1 dose, Albendazole , tablet|
11523160|NCT01192802|Active Comparator|2 doses, albendazole, tablet|1 tablet of 400 mg of albendazole per day for two consecutive days
11523161|NCT01192802|Active Comparator|3 doses albendazole, 400mg, tablet|
11523162|NCT01192789|Other|Intervention|Severe Pneumonia Treatment by LHWs with Amoxicillin at 90mg/kg/day for severe pneumonia
11523163|NCT01192789|Other|Control|LHWs refer the severe pneumonia case to local health facility or private practitioner.
11523164|NCT01192776|Active Comparator|33.5°C for 72 hours|Target Temp: 33.5°C Duration: 72 hrs
11523165|NCT01192776|Experimental|33.5°C for 120 hours|Target Temp: 33.5°C Duration: 120 hrs
11523166|NCT01192776|Experimental|32.0°C for 72 hours|Target Temp: 32.0°C Duration: 72 hrs
11523167|NCT01192776|Experimental|32.0°C for 120 hours|Target Temp: 32.0°C Duration:120 hrs
11523168|NCT01192763|Experimental|Arm I|Patients receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10 in the absence of disease progression or unacceptable toxicity. Beginning 7 days after completion of gamma-secretase inhibitor RO4929097, patients undergo complete resection comprising pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy based on the anatomic location of the cancer. Tumor tissue from biopsy and surgery and blood samples are collected periodically for pharmacodynamic studies.
11523169|NCT01192724|Active Comparator|Triple antiplatelet therapy (TAPT) group|3-month use of cilostazol in addition to dual antiplatelet agent
11523170|NCT01192724|Active Comparator|Dual antiplatelet therapy (DAPT) group|Aspirin and clopidogrel (dual antiplatelet therapy, DAPT) for 1 year
11523171|NCT01192711|Experimental|insulin + DID|Three prandial (before or at the end of meal administration, based on doctor counselling and patient decision) injections per day of insulin glulisine associated with basal insulin glargine; the DID will be used to estimate the CHO content of the food intended to eat. Insulin doses in this group will be adjusted based on DID calculations and pre-meal BG values.
11523216|NCT01192308|Experimental|40mg QD dose intervention|40mg QD dose intervention during 4 weeks in patients with CYP2D6 variant allele or using CYP2D6 inhibitor.
11523467|NCT01190553|Experimental|Treatment|IV amantadine treatment
11523172|NCT01192711|No Intervention|insulin + usual care|Three prandial (before or at the end of meal administration, based on doctor counselling and patient decision) injections of insulin glulisine associated with basal insulin glargine. Insulin doses in group B will be adjusted based on SMBG values reviewed during the doctor office visit.
11523173|NCT01192698|Experimental|IV interferon|IV interferon oral ribavirin
11523174|NCT01192698|No Intervention|Standard of care|standard of care
11523175|NCT01192685|Other|Depressed outpatients treated with TMS|This a 12- week study (1-4 week screening, 6 weeks treatment, 2 weeks follow-up) outpatient open label clinical trial. Twenty-five subjects diagnosed with depression with a Montgomery Asberg Depression Rating Scale (MADRAS) score of 26 or higher, will be enrolled into this trial, up to fifty subjects will be consented. Transcranial Magnetic Stimulation (TMS) will be administered to subjects 5 days a week for 6 weeks. Near infrared spectroscopy (NIRS), a spectroscopic method that uses the near infrared region of the electromagnetic spectrum (from about 700 nm to 2500 nm), will be used to assess blood flow in the brain.
11523176|NCT01192672|Experimental|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
11523177|NCT01192672|Active Comparator|Control Writing|The participants were instructed to write for 30-minute intervals for 4 consecutive days about all of the actions they performed that day for a 24 hour period. The subjects were asked not to write about their feelings or thoughts related to these actions.
11523178|NCT01192672|No Intervention|Usual Care|Subjects in this group did not receive an intervention. They filled out measures at baseline, 1 month, and 3 month follow-up time periods.
11523179|NCT01192659||Patients treated with saxagliptin or placebo|Patients will be treated with saxagliptin or placebo, on top of whatever baseline treatment for diabetes the patient is already receiving.
11523180|NCT01192659||Patients currently or previously on treatment|Patients currently or previously on (within 6 months) treatment with DPP4 inhibitors and/or GLP-1 mimetics are excluded.
11523181|NCT01192646|Active Comparator|Home based life saving skills training|Home based life saving skills will done in one the study group and in the control group no training will be done
11523182|NCT01192646|No Intervention|NO HBLSS|No intervention will be given to the control clusters
11523183|NCT01192594|Experimental|MAPP Trained Case Managers|Consumers assigned to case managers who receive training in the Milestones of Adjustment Post-Psychosis Recovery Model
11523184|NCT01192594|Active Comparator|Non-MAPP trained case managers|Consumers of case managers not trained in the Milestones of Adjustment Post-Psychosis Recovery Model
11523185|NCT01192581|No Intervention|control|routine treatment for brain hypoperfusion
11523186|NCT01192581|Experimental|Vuloven1|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
11523187|NCT01192581|Experimental|Vuloven2|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
11523188|NCT01192581|Experimental|Vuloven3|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
11523189|NCT01192568|Experimental|Oxybutynin Chloride|
11523190|NCT01192555|Experimental|Treatment Plan|Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells) and Cytoxan (Cyclophosphamide)
11523191|NCT01192542|Other|galyfilcon A prototype lens/enfilcon A lens|galyfilcon A prototype contact lens worn daily for 6-8 days first then enfilcon A contact lens worn daily for 6-8 days second.
11523192|NCT01192542|Other|enfilcon A lens/galyfilcon A prototype lens|enfilcon A contact lens worn daily for 6-8 days first then galyfilcon A prototype contact lens worn daily for 6-8 days second.
11523193|NCT01192529|Experimental|Experimental Group|"In addition to their daily diet, patients of this group will receive 400 ml per day of Supressi nutritional supplement"
11523194|NCT01192529|Active Comparator|Control Group|"In addition to their daily diet, patients of this group will receive 400 ml per day of T-Diet plus High Protein product"
11523195|NCT01192516|Experimental|Arm 1|Tailored activity pacing
11523196|NCT01192516|Experimental|Arm 2|General activity pacing and symptom management (Occupational therapy)
11523197|NCT01192516|No Intervention|Arm 3|Usual care group
11523198|NCT01192503|Active Comparator|rasagiline|
11523199|NCT01192503|Placebo Comparator|placebo (sugar pill)|
11523200|NCT01192490|Experimental|Lidocaine Arm|This arm will receive intracervical and cervical lidocaine prior to placement of a Mirena.
11523201|NCT01192490|Placebo Comparator|Lubricant|Subjects in this arm will receive KY gel intracervically and on the cervix prior to placement of a Mirena.
11523202|NCT01192477|Experimental|Ozone 0.1 ppm|
11523203|NCT01192477|Experimental|Ozone 0.2 ppm|
11523204|NCT01192477|Sham Comparator|Filtered air|
11523205|NCT01192464|Experimental|autologous CAR.CD30 EBV specific-CTLs|"Group One Dose (CTLs CAR.CD30) at Day 0: 2x10^7 cells/m2
~Group Two Dose (CTLs CAR.CD30) at Day 0: 5x10^7 cells/m2
~Group Three Dose (CTLs CAR.CD30) at Day 0: 1x10^8 cells/m2"
11523206|NCT01192438|Experimental|Procedure/surgery|
11523207|NCT01192412|Active Comparator|'Less tight' control.|The diastolic blood pressure (dBP) treatment goal is 100 mmHg.
11523208|NCT01192412|Active Comparator|'Tight' control.|The diastolic blood pressure (dBP) treatment goal is 85 mmHg.
11523209|NCT01192399|Experimental|Eculizumab|Eculizumab intravenous infusions every week x 4 doses, then 900 mg 1 week later for 1 dose, then 900 mg every 2 weeks for 4 doses
11523210|NCT01192373|Experimental|High circulating free fatty acids|using Heparin af intralipid infusion for 8 hours
11523211|NCT01192373|Active Comparator|Low circulation free fatty acids|using hyperinsulinaemic euglycemic clamp for 8 hours
11523212|NCT01192360|Experimental|Cardiac Patients|In addition to the routine clinical MRI, we will conduct the DCE MR perfusion imaging research component. For this, we will measure native pre-contrast T1 and then inject a tight bolus of gadolinium (0.1mmol/kg) while acquiring high temporal resolution T1-weighted 3D contrast dynamics information over the whole thorax while the patient is holding his / her breath. Overall, the research component will prolong the clinical study by approximately 5 minutes.
11523213|NCT01192360|Experimental|Pulmonary Patients|Patients in this group will receive a full cardiac and pulmonary MRI assessment, with the DCE pulmonary perfusion scan added as described above. Overall, the investigation will take approximately 45 minutes
11523217|NCT01192295|Experimental|Oxycodone HCl controlled-release|Oxycodone hydrochloride (HCl) controlled-release (CR)
11523218|NCT01192282||Genital Warts|All female patients with Genital Warts presenting to Groote Schuur Hospital
11523219|NCT01192269|Experimental|Docosahexaenoic Acid Supplement|"DHA supplement: Experimental
~1 x 950 mg capsules per day orally, each capsule providing ~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric)."
11523220|NCT01192217|Active Comparator|VATS group|
11523221|NCT01192217|Active Comparator|Mini-thoracotomy group|
11523222|NCT01192204|Active Comparator|10% FBR containing bioadhesive gel|Drug consisting of 10% FBR containing bioadhesive gel. Participants instructed to apply 0.5 gm of 10% FBR containing bioadhesive gel four times a day to lesional site
11523223|NCT01192204|Placebo Comparator|Placebo Gel|Color/consistency matched placebo (no black raspberry) gel
11523224|NCT01192191|Experimental|Fluticasone Furoate/GW642444 100/25mcg|Combination inhaled corticosteroid and long-acting beta2-agonist
11523225|NCT01192191|Experimental|Fluticasone Furoate/GW642444 200/25mcg|Combination inhaled corticosteroid and long-acting beta2-agonist
11523226|NCT01192178|Active Comparator|FLOVENT™ DISKUS™ 100 mcg|FLOVENT™ DISKUS™ 100 mcg is an inhaled corticosteroid indicated in the US for maintenance treatment of asthma as prophylactic therapy in patients 4 years and older.
11523227|NCT01192178|Experimental|ADVAIR™ DISKUS™ 100/50 mcg|ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a corticosteroid and a long acting beta2 adrenergic agonist indicated for; maintenance treatment of asthma in patients 4 years of age and older.
11523228|NCT01192165|Experimental|Treatment Group 1|Trametinib plus Docetaxel
11523229|NCT01192165|Experimental|Treatment Group 2|Trametinib plus Erlotinib
11523230|NCT01192165|Experimental|Treatment Group 3|Trametinib plus Pemetrexed
11523231|NCT01192165|Experimental|Treatment Group 4|Trametinib plus Pemetrexed and Carboplatin
11523232|NCT01192165|Experimental|Treatment Group 5|Trametinib plus nab-Paclitaxel
11523233|NCT01192165|Experimental|Treatment Group 6|Trametinib plus Pemetrexed and Cisplatin
11523234|NCT01192152|Experimental|5 mg saxagliptin + 2 Glucophage XR 500 mg tablet|
11523235|NCT01192152|Experimental|FDC tablet (5 mg saxa + 1000 mg metformin XR) (single dose)|under fed state, single dose
11523236|NCT01192152|Experimental|FDC tablet (5 mg saxa + 1000 mg metformin XR) (4 days)|under fed state, 4 days
11523237|NCT01192139|Experimental|5 mg saxagliptin + a single 500 mg metformin XR tablet|
11523238|NCT01192139|Experimental|FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fed)|under fed state
11523239|NCT01192139|Experimental|FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fasting)|under fasted state
11523240|NCT01192126|Experimental|Bausch & Lomb new daily disposable|New daily disposable contact lenses
11523241|NCT01192126|Active Comparator|Johnson & Johnson Acuvue Moist|Contact lenses
11523242|NCT01192113|Experimental|Group A: Diabetic Peripheral Neuropathy (IV)|
11523243|NCT01192113|Experimental|Group B: Diabetic Peripheral Neuropathy (IM)|
11523244|NCT01192113|Experimental|Group C: Idiopathic Peripheral Neuropathy|
11523245|NCT01192113|Experimental|Group D: Nutritional & Metabolic Peripheral Neuropathy|
11523246|NCT01192113|Experimental|Group E: Compression Peripheral Neuropathy|
11523247|NCT01192100|Experimental|Breakfast Skipping|Breakfast skipping serves as the baseline/control arm since the participants habitually skip breakfast (i.e., skip breakfast at least 5 times/week). Thus, during the week prior to and including the testing day, the participants will continue to skip breakfast each morning.
11523248|NCT01192100|Experimental|Normal Protein Breakfast Meals|For 7 days, the participants will consume normal protein breakfast meals each morning. These meals will consist of cereal-based foods and will be 350 kcal, which is approximately 18% of daily energy intake for overweight and obese adolescents ages 9-18 y. The macronutrient composition of these meals will contain 15% protein (13 g of dietary protein), 65% CHO, and 20% fat.
11523249|NCT01192100|Experimental|Protein-rich Breakfast Meals|For 7 days, the participants will consume protein-rich breakfast meals each morning. These meals will consist of home-cooked foods and will be 350 kcal, which is approximately 18% of daily energy intake for overweight and obese adolescents ages 9-18 y. The macronutrient composition of these meals will contain 40% protein (35 g of protein), 40% CHO, and 20% fat.
11523250|NCT01192087|Experimental|Cetuximab arm|patients receive weekly cetuximab in combination with IMRT and carbon ion boost
11523251|NCT01192074||Ultrasound of the spine|Pregnant women receiving labor epidural analgesia or spinal anesthesia for cesarean delivery
11523252|NCT01192061||Normal tension glaucoma group|
11523253|NCT01192061||Control group|
11523254|NCT01192048||Study Subjects|Individuals with Congenital Heart Disease and family members with or without Congenital Heart Disease. A blood sample collection will be required for all study participants.
11523255|NCT01192035|Active Comparator|NNRTI|
11523256|NCT01192035|Active Comparator|Protease inhibitor|
11523257|NCT01192022|Active Comparator|TachoSil®|TachoSil® absorbable patches, applied topically, once, intraoperatively to stop bleeding. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
11523258|NCT01192022|Active Comparator|Surgicel® Original|Surgicel® Original absorbable patches, applied topically, once, intraoperatively to stop bleeding. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
11523259|NCT01192009|Experimental|Immobilization and Leucine|
11523260|NCT01192009|Placebo Comparator|Immobilization and Placebo|
11523261|NCT01191996|Experimental|MIS416|MIS416, immunomodulating microparticle, given intravenously weekly
11523262|NCT01191983|Experimental|Methoxy polyethylene glycol-epoetin beta|Participants will receive 1.2 mcg/kg methoxy polyethylene glycol-epoetin beta given in monthly doses at each visit. Dose will be measured on the basis of the participants Hb level during the study period. The dose administration will be the nearest possible dose using the prefilled syringes containing 50, 75 and 100 mcg/kg Q4W.
11524152|NCT01185847|Active Comparator|B non-squamous|
11523263|NCT01191970||Epidural recipients|Subjects who received epidural analgesia during labor
11523264|NCT01191970||Non-epidural recipients|Subjects who did not receive epidural analgesia during labor
11523265|NCT01191957|Active Comparator|I. V. Busulphan plus Cyclophosphamide|Conventional conditioning regimen with intravenous (i.v.) Busulphan (Busilvex), 12.8 mg/kg followed by Cyclophosphamide, 120 mg/kg iv.
11523266|NCT01191957|Experimental|I. V. Busulphan plus Fludarabine|Reduced toxicity conditioning regimen with intravenous (i.v.)Busulphan (Busilvex), 12.8 mg/kg plus Fludarabine, 4 x 40 mg/m².
11523267|NCT01191944|Experimental|pramipexole Extended release|subjects will receive 0.375mg once a day to 4.5mg once a day depending on investigator's judgement
11523268|NCT01191944|Active Comparator|pramipexole Immediate release|subjects will receive 0.125mg three times a day to 1.0mg three times a day depending on investigator's judgement
11523269|NCT01191931||prostate cancer|Patients with histologically proven prostate cancer (positive biopsy) and who are planned to undergo radical prostatectomy.
11523270|NCT01191918|Experimental|donepezil|donepezil plus Lithium
11523271|NCT01191918|Placebo Comparator|Control|Placebo plus Lithium
11523272|NCT01191905|Experimental|High dose CRRT|Clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
11523273|NCT01191905|Active Comparator|Conventional dose CRRT|clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
11523274|NCT01191892|Placebo Comparator|Placebo|Carboplatin, Gemcitabine and Placebo
11523275|NCT01191892|Experimental|vandetanib|Carboplatin, Gemcitabine and vandetanib
11523276|NCT01191879||acute MI group|Patients presenting with acute ST elevation myocardial infarction, admitted to the intensive cardiac care unit and that are planned for emergency primary PCI
11523277|NCT01191879||Controls|Patients undergoing a non-invasive evaluation of possible myocardial ischemia.
11523278|NCT01191866||Diabetes mellitus|All children and adolescents with type 1 diabetes mellitus attending Assaf Harofeh Pediatric Diabetes Clinic
11523279|NCT01191853||Healthy volunteers|Healthy volunteers will have blood drawn before and after seasonal flu vaccination
11523280|NCT01191840|Experimental|Algorithm-determined therapy|
11523281|NCT01191840|Active Comparator|Standard of Care|
11523282|NCT01191827||risperidone|
11523283|NCT01191827||clozapine|Patients with schizophrenia treated with clozapine
11523284|NCT01191814|Active Comparator|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
11523285|NCT01191814|Active Comparator|Plastic Stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a plastic stent
11523286|NCT01191801|Experimental|Group A: vosaroxin + cytarabine|vosaroxin (short IV infusion within 10 minutes) on days 1 and 4: cytarabine on days 1 through 5; a maximum of 2 cycles of Induction and 2 cycles for Consolidation
11523287|NCT01191801|Placebo Comparator|Group B: placebo + cytarabine|placebo (short IV infusion within 10 minutes and volume matched to vosaroxin) on days 1 and 4: cytarabine on days 1 through 5; a maximum of 2 cycles of Induction and 2 cycles for Consolidation
11523288|NCT01191788|Experimental|Group CBT|Clients received up to 16 sessions of group CBT for depression
11523289|NCT01191788|Active Comparator|Comparison|Treatment as Usual comparison condition
11523290|NCT01191775|Experimental|PNT2258|PNT2258 is composed of PNT100, a 24-mer oligonucleotide, the active drug substance encapsulated in a liposome.
11523291|NCT01191762|Active Comparator|sevelamer carbonate|2400 mg (3 pills) with each meal
11523292|NCT01191762|Placebo Comparator|placebo control|3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.
11523293|NCT01191749|Experimental|Alemtuzumab|Alemtuzumab 10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
11523294|NCT01191736|Experimental|No training, assessed within 60 mins|Subjects receive no training
11523295|NCT01191736|Experimental|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
11523296|NCT01191736|Experimental|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
11523297|NCT01191736|Experimental|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
11523298|NCT01191736|Experimental|Ultra-brief video; assessed at 2 months|
11523299|NCT01191736|Experimental|Brief video; assessed 2 months later|
11523300|NCT01191736|Experimental|Brief video + hands-on; ass'd 2 ms later|
11523301|NCT01191723|Other|Treatment A, then Treatment B, then Treatment C|"There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.
~Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
11523302|NCT01191723|Other|Treatment A, then Treatment C, then Treatment B|"There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.
~Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
11523303|NCT01191723|Other|Treatment B, then Treatment A, then Treatment C|"There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.
~Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
11523304|NCT01191723|Other|Treatment B, then Treatment C, then Treatment A|"There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.
~Tablets were orally administered after oral inhalation dosing."
11523305|NCT01191723|Other|Treatment C, then Treatment A, then Treatment B|"There was 48 hour wash-out between treatment visits. Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.
~Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
11523510|NCT01190254|Experimental|Asenapine 2.5 mg BID|Participants receive active asenapine 2.5 mg tablets sublingually BID for 8 weeks.
11523306|NCT01191723|Other|Treatment C, then Treatment B, then Treatment A|"There was 48 hour wash-out between treatment visits.
~Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.
~Tablets were orally administered after oral inhalation dosing."
11523307|NCT01191710|Experimental|Antagonist group|Antagonist protocol for IVF
11523308|NCT01191710|Active Comparator|Agonist group|Long Agonist protocol for IVF
11523309|NCT01191697|Experimental|Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine|"Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine for patients with HER2-positive metastatic esophagogastric cancer. Each cycle is 21 days.
~Cycle 1, Day 1 Trastuzumab (loading dose) 4mg/kg IV
~Cycle 2, Day 1 and all Subsequent Cycles Bevacizumab (7.5mg/kg) IV Trastuzumab (6mg/kg) IV Oxaliplatin (130mg/m2) IV Capecitabine (1200mg/m2) PO (taken Days 1-14 of each cycle)
~Patients remained on treatment until disease progression, intercurrent illness that prevented further administration of treatment, unacceptable adverse events, participant decision to withdraw consent or general or specific changes in the participant's condition that rendered the participant unacceptable for further treatment."
11523310|NCT01191684|Experimental|Treatment (vaccine therapy)|Patients receive MVAp53 subcutaneously on days 0, 21, and 42 in the absence of unacceptable toxicity.
11523311|NCT01191645|Experimental|Primperan|
11523312|NCT01191645|Active Comparator|Naloxon|
11523313|NCT01191645|Placebo Comparator|Natriumklorid|
11523314|NCT01191645|Experimental|Ultiva|
11523315|NCT01191632|Active Comparator|Radiation 0,5Gy|"Radiation: one time Radiation with an intensity of 0.5 Gy Group A
~Beginning on a weekday 48 hours before surgery"
11523316|NCT01191632|Active Comparator|No radiation|Control group with 0Gy radiation
11523317|NCT01191632|Active Comparator|Radiation 2Gy|"Radiation: one time Radiation with an intensity of
~2.0 Gy Group B
~Beginning on a weekday 48 hours before surgery"
11523318|NCT01191632|Active Comparator|Radiation 5Gy|"Radiation: one time Radiation with an intensity of
~5 Gy Group C Beginning on a weekday 48 hours before surgery"
11523319|NCT01191619|Experimental|McIvor group|groups in which proseal laryngeal mask airway is inserted with McIvor retractor.
11523320|NCT01191606|Active Comparator|Group A|the exchange of ventilatory mode from volume controlled ventilation to pressure controlled ventilation
11523321|NCT01191606|Active Comparator|Group B|the exchange of ventilatory mode from pressure controlled ventilation to volume controlled ventilation
11523322|NCT01191593|Experimental|Adductor-Canal-Blockade with ropivacaine|
11523323|NCT01191593|Placebo Comparator|Adductor-Canal-blockade with saline|
11523324|NCT01191580|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy is a brief, manualized therapy that has shown efficacy in treating major depression in several controlled trials including a large trial for depressed HIV-infected individuals and other randomized trials in depressed individuals with other comorbid medical illnesses. Research shows that Interpersonal Psychotherapy improves social skills and functioning. Interpersonal Psychotherapy has shown remarkable flexibility and efficacy across age ranges, cultures, formats, and modes of delivery. We recently obtained promising pilot data in a small open trial on the acceptability and efficacy of individual IPT for depressed breast cancer patients of diverse ethnic background, socioeconomic status, and cancer progression stage.
11523325|NCT01191580|Experimental|Problem-Solving Therapy|Problem-Solving Therapy is a brief, manualized form of cognitive-behavioral therapy (CBT) that has been adapted to treat depression in cancer patients, and has shown highly promising results.
11523326|NCT01191580|Active Comparator|Brief Supportive Psychotherapy|Brief Supportive Psychotherapy, a relatively unstructured psychotherapy commonly used in clinical practice, focuses on the patient's affect. It builds a strong therapeutic alliance through careful, empathic listening and validating and encouraging toleration of the patient's emotions. It has shown promising results in depressed individuals with cancer and other medical illnesses.
11523327|NCT01191567|Active Comparator|Conventional treatment|
11523328|NCT01191567|Experimental|VAC treatment|
11523329|NCT01191554|Experimental|High dosage|A loading dose of 30 mg/kg and a maintenance infusion of 16 mg/kg through out the operation, and 2 mg/kg into the cardiopulmonary bypass (CPB) prime volume.
11523330|NCT01191554|Experimental|Low dosage|A loading dose of 10 mg/kg and a maintenance infusion of 1 mg/kg through out the operation, and 1 mg/kg into the cardiopulmonary bypass (CPB) prime volume.
11523331|NCT01191541|Other|DNR+Ara-c,DNR|one group treated with DNR+Ara-C one group treated with DNR
11523332|NCT01191515||Near visual outcomes with Monofocal IOL|Evaluation of intermediate visual outcomes of patients undergoing routine cataract surgery with phacoemulsification and monofocal IOl placement in the capsular bag in at least one eye.
11523333|NCT01191515||Intermediate Visual outcomes|Evaluation of intermediate visual outcomes of patients undergoing routine cataract surgery with phacoemulsification and monofocal IOl placement in the capsular bag in at least one eye.
11523334|NCT01191502||TECNIS MULTIFOCAL (TMF) INTRAOCULAR LENS|
11523335|NCT01191502||CRYSTALENS HD (CHD) INTRAOCULAR LENS|
11523336|NCT01191489|Experimental|High Flow Conditioned Oxygen Therapy in high risk patients|
11523337|NCT01191489|Active Comparator|Non-invasive mechanical ventilation in High Risk Patients|
11523338|NCT01191489|Experimental|High Flow Conditioned Oxygen Therapy in Low Risk Patients|
11523339|NCT01191489|Active Comparator|Conventional Oxygen Therapy in Low Risk Patients|
11523340|NCT01191476|Active Comparator|Sevoflurane|Subjects received sevoflurane, a inhalational (volatile) anesthetic, which was administered for induction and maintenance of general anesthesia. Inhalational induction was induced via vital capacity induction at 8% and maintained at 0.8-1.5 minimum alveolar concentration (MAC).
11523341|NCT01191476|Active Comparator|Propofol|Subjects received propofol, an intravenous (IV) anesthetic, which was administered for induction and maintenance of general anesthesia.
11523342|NCT01191476|Active Comparator|Propofol Induction and Sevoflurane Maintenance|Subjects received a bolus dose of propofol of 1.5 mg/kg administered for IV induction followed by sevoflurane at 0.8-1.5 MAC for maintenance anesthesia.
11523343|NCT01191463|Experimental|Mung Bean Meals and Guava fruit|Subject in this group will receive, a lunch meal based on 50g of Mung beans together with a local, Vitamin C rich fruit (Guava)
11523635|NCT01189292|Placebo Comparator|Placebo (NaCl 0.9%)|
11523344|NCT01191463|Active Comparator|Mung Bean|Subjects in this group will receive a lunch meal based on 50g mung beans but without any vitamin C source.
11523345|NCT01191463|No Intervention|School feeding program|Subjects in this arm, will receive the regular school feeding program as provided by the school authorities
11523346|NCT01191450|Active Comparator|Higroton®|Chlorthalidone 25mg - one oral tablet a day in the morning
11523347|NCT01191450|Experimental|Diupress®|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning
11523348|NCT01191424|Experimental|CHF1535 NEXT DPI|Male and female adolescents and adult patients (≥ 12 years old) treated with CHF1535 NEXT DPI
11523349|NCT01191424|Active Comparator|Free combination BDP and FF|Male and female adolescents and adult patients (≥ 12 years old) treated with a free combination of licenced BDP and FF
11523350|NCT01191411|Active Comparator|Mailed invitations for FIT test kits|"Fecal Immunochemical Tests (FIT) kits from Polymedco Incorporated are mailed to patients' homes for free colorectal cancer screening.
~Intervention: Screening for colorectal cancer using a Polymedco home FIT kit. Mailed invitation to complete a free one sample home FIT kit. Automated and live phone call reminders to promote screening completion, plus usual medical care.
~Patients with abnormal FIT results are navigated to complete a diagnostic colonoscopy."
11523351|NCT01191411|Active Comparator|Mailed invitations for a colonoscopy|"Invitation to schedule a colonoscopy are mailed to patients' homes for free colorectal cancer screening.
~Intervention: Screening for colorectal cancer with colonoscopy. Mailed invitation to complete one free colonoscopy. Automated and live phone reminders to promote screening completion, plus usual medical care.
~Patients with abnormal polyps or adenomas will follow standard clinical protocol after their procedure."
11523352|NCT01191411|Active Comparator|Visit Based Care|"No invitation to complete colorectal cancer screening.
~Intervention: Usual medical care. Patients will continue to see their regular physician, and follow their physician's regular standard of care."
11523353|NCT01191398|Placebo Comparator|Placebo and Ketamine|Normal Saline 0.9% will act as a placebo. Two ml of normal saline 0.9% will be administered intravenously 30 minutes prior to the administration of the ketamine.
11523354|NCT01191398|Active Comparator|Atropine and Ketamine|Atropine will be administered as a single dose of 0.01 mg/kg, with a minimum of dosage of 0.1 mg and a maximum dosage of 0.4 mg, intravenously 30 minutes before the administration of the ketamine.
11523355|NCT01191398|Active Comparator|Glycopyrrolate and Ketamine|Glycopyrrolate will be administered as a single dose of 0.01 mg/kg, with no minimum dosage and a maximum dose of 0.4 mg, intravenously 30 minutes before the administration of the ketamine.
11523356|NCT01191385||Group 1|
11523357|NCT01191372|Placebo Comparator|saline for injection|
11523358|NCT01191372|Experimental|ARC19499 Low Dose|
11523359|NCT01191372|Experimental|ARC19499 Mid Dose|
11523360|NCT01191372|Experimental|ARC19499 High Dose|
11523361|NCT01191359|Active Comparator|sublingual administration|oral immunotherapy with drops applied once daily by single dose containers (200 STU per dose)
11523362|NCT01191359|Active Comparator|vestibular administration|oral immunotherapy with drops applied by single dose containers (200 STU per dose)
11523363|NCT01191346||3T MRI|Patients receiving 3T MRI
11523364|NCT01191333|Experimental|Active rTMS|Those receiving experimental treatment will receive 20 to 30 sessions of rTMS in blocks of 5 sessions. The treatment will be delivered by trained medical personnel.
11523365|NCT01191333|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 to 30 sessions of sham rTMS in blocks of 5 sessions. The treatment will be delivered by trained medical personnel.
11523366|NCT01191320|Placebo Comparator|Placebo|Placebo
11523367|NCT01191320|Experimental|Androxal 12.5 mg|12.5 mg/day
11523368|NCT01191320|Experimental|Androxal 25 mg|25 mg/day
11523369|NCT01191307||Shunt Implant|hydropcephalus cohort
11523370|NCT01191307||Cochlear Implant|hearing impaired cohort
11523371|NCT01191307||Spinal Cord Stiumulation|spinal cord injury cohort
11523372|NCT01191307||Vagus Nerve Stimulation|epilepsy cohort
11523373|NCT01191307||Deep Brain Stimulation|dystonia cohort
11523374|NCT01191294|Experimental|Medical Students|3rd year medical students during their primary care clerkship
11523375|NCT01191281|Experimental|Diet/nutrition counsel+food aid|Intervention. Patients enrolled in the intervention group will receive a multi-component intervention that includes dietary and nutritional counseling and food assistance (food aid basket)
11523376|NCT01191281|Active Comparator|dietary/nutritional counseling|Patients enrolled in the comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
11523377|NCT01191268|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
11523378|NCT01191268|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
11523379|NCT01191268|Active Comparator|Insulin Glargine|"Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks
~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
11523380|NCT01191255|Active Comparator|Active Control|PhosLo (calcium acetate) Renvela (sevelamer carbonate)
11523381|NCT01191255|Placebo Comparator|Placebo|Placebo
11523382|NCT01191255|Experimental|KRX-0502 (Ferric Citrate)|ferric citrate
11523383|NCT01191229|No Intervention|Tecnis One-Piece MF IOL|It is planned that about 25 people who are at least 18 years old who are scheduled to have the Tecnis One-Piece Multifocal Intraocular Lenses placed into their eyes after cataract surgery
11523384|NCT01191229|No Intervention|Crystalens AO|It is planned that about 25 people who are at least 18 years old and have been implanted with Crystalens AO
11523385|NCT01191216|Experimental|Arm I|Patients receive oral 1-methyl-d-tryptophan twice daily on days 1-21 and docetaxel IV over 1 hour on day 1 (in course one patients receive 1-methyl-d-tryptophan once daily on days 1 and 3-21).
11523386|NCT01191203|Active Comparator|Depo Medroxyprogesterone Acetate|
11523387|NCT01191203|Active Comparator|Copper IUD (CuT360)|
11523388|NCT01191190|Experimental|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.
~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered.
~Each patient may receive 3 cycles of treatment in the absence of progressive disease or significant toxicity."
11523389|NCT01191177|Experimental|Lovaza group|Patients randomized to this group will receive Lovaza 1gram per kilogram of body weight, not exceeding 4grams a day
11523390|NCT01191177|Placebo Comparator|Placebo group|Patients randomized to this group will receive corn oil supplement 1gram per kilogram of body weight, not exceeding 4grams per day
11523391|NCT01191164|Experimental|Study Arm|
11523392|NCT01191151||Orthopedic injury, osteoarthritis|All eligible patients receiving orthopedic, sports medicine, arthroscopy and related surgery or nonoperative treatment
11523393|NCT01191138|Other|Infracolic Anastamosis|The gastrojejunal anastamosis is done in the infracolic compartment
11523394|NCT01191138|Other|Supracolic Anastamosis|The gastrojejunal anastamosis is done in the supracolic compartment
11523395|NCT01191125|Experimental|medical food with AN777|
11523396|NCT01191125|Active Comparator|oral nutritional formula|
11523397|NCT01191112|Experimental|Peptide Based enteral formula|
11523398|NCT01191086|Experimental|Open-label USL255|Topiramate extended-release capsules (USL255) up to a maximum of 400 mg per day
11523399|NCT01191073|Experimental|CAD/CAM fabricated dentures|group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)
11523400|NCT01191073|Active Comparator|traditional fabricated dentures|group receiving traditional fabricated dentures (double blind)
11523401|NCT01191060|Experimental|lenalidomide, bortezomib with ASCT|"RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent)
~Autologous stem cell transplant:
~Melphalan: infused over two days (day -2 and day -1) or as a single infusion (day-2) according to institutional practice Re-infusion of PBSCs RVD q 21 days (2 cycles) Maintenance Lenalidomide q28 days (12 months)"
11523402|NCT01191060|Experimental|lenalidomide, bortezomib without ASCT|RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent) RVD q 21 days (5 cycles) Maintenance Lenalidomide q28 days (12 months)
11523403|NCT01191021|Other|Propofol|Volunteers will receive propofol anesthesia on the study day.
11523404|NCT01191008||Latan-timolol maleate fixed comb ophthalmic solution|
11523405|NCT01190995|Experimental|Sucrose|The enrolled neonates will be administered a sterile solution of 24 % sucrose orally for a period of 7 days from enrollment The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure.
11523406|NCT01190995|Placebo Comparator|Placebo|The enrolled neonates will be administered double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
11523407|NCT01190982|Experimental|LEP-ETU|All patient will have baseline to confirm disease status. The disease progression/response is assessed inaccordance to the RECIST guidelines
11523408|NCT01190943||Ancillary-Correlative (biomarker sampling and analysis)|Archived tumor tissue and peripheral blood DNA specimens are analyzed for DNA copy number profiling, gene expression profiling, DNA methylation profiling, microRNA profiling, and genomic resequencing. Clinical data including demographics; date of diagnosis, surgery, chemotherapy, recurrence, progression, and death; imaging; toxicity; and pathologic data elements associated with the specimens are also collected and analyzed.
11523409|NCT01190930|Experimental|Arm A (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; dexamethasone PO BID on days 1-5, 29-33, and 57-61; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
11523410|NCT01190930|Experimental|Arm B (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; dexamethasone PO BID on days 1-5, 29-33, and 57-61; higher-dose methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
11523411|NCT01190930|Experimental|Arm B-LLy (4-week cycle maintenance)|See Detailed Description.
11523412|NCT01190930|Experimental|Arm C (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on day 1; dexamethasone PO BID on days 1-5; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
11523413|NCT01190930|Experimental|Arm D (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on day 1; dexamethasone PO BID on days 1-5; higher-dose methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
11523414|NCT01190930|Experimental|Arm LR-C (risk-adapted chemotherapy)|Patients receive consolidation, interim maintenance I, delayed intensification, interim maintenance II, and maintenance therapy. See detailed description.
11523415|NCT01190930|Experimental|Arm LR-M (risk-adapted chemotherapy)|Patients receive consolidation and maintenance therapy. See detailed description.
11523416|NCT01190930|Experimental|Arm SR DS (12-week cycle maintenance)|See Detailed Description
11523417|NCT01190917|Active Comparator|Cognitive Behavioral Therapy Group|
11523418|NCT01190917|Active Comparator|Social Play Group|
11523419|NCT01190904||Coronary Artery Disease (≥50%) with or without PCI|We propose to investigate four specific aims using 1,143 diabetic men who have CAD (≥50%) lesion in at least one major epicardial vessel with or without PCI.
11523463|NCT01190631|Experimental|Acrysof IQ (SN60WF) IOL|AcrySof IQ SN60WF intraocular lens (IOL) implanted in one eye only during cataract surgery.
11523464|NCT01190592|Experimental|Milk|
11523465|NCT01190592|Experimental|Juice|
11523420|NCT01190891|Active Comparator|Manual Physical Therapy|The orthopaedic manual physical therapy (OMPT) intervention approach used in this study will be based on an impairment model. The physical therapist providing the intervention will address the impairments found in the shoulder joints to include the acromioclavicular joint, glenohumeral joint, and scapular-thoracic joints, and cervical/thoracic spine. Patients will receive procedures tailored to their specific impairments. Procedures will include mobilizations and manipulations of the joint and soft-tissues.
11523421|NCT01190891|Active Comparator|Corticosteroid Injection (Subacromial)|Location: Subacromial space; Syringe: 10mL; Needle: 25 gauge, 1.5 inch; Anesthetic: 6 mL of 1% lidocaine or marcaine; Corticosteroid: 1.0 mL Triamcinolone Acetonide (Kenalog), 40 mg/mL
11523422|NCT01190878|Experimental|ISV-303 BID|
11523423|NCT01190878|Experimental|ISV-303 QD|
11523424|NCT01190878|Active Comparator|Xibrom BID|
11523425|NCT01190878|Placebo Comparator|DuraSite Vehicle BID|
11523426|NCT01190865|Other|HP802-247|Assessment Duration = 8 days Assessment Duration = 15 days Assessment Duration = 22 days Assessment Duration = 29 days Assessment Duration = 31 days Assessment Duration = 43 days Assessment Duration = 50 days Assessment Duration = 57 days
11523427|NCT01190852|Experimental|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
11523428|NCT01190852|Active Comparator|Azelastine mono|REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)
11523429|NCT01190852|Active Comparator|Azelastine|COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
11523430|NCT01190839|Experimental|Infliximab|Infliximab Type=equal unit=mg number=5 form=intravenous infusion route=intravenous use once every 8 weeks
11523431|NCT01190839|Placebo Comparator|Placebo|Placebo Type=equal unit=mg number=5 form=intravenous infusion route=intravenous use once every 8 weeks
11523432|NCT01190826|Experimental|ASM-024 10 mg|ASM-024 administered once by inhalation at a target dose of 10 mg
11523433|NCT01190826|Experimental|ASM-024 100 mg|ASM-024 administered once at a target dose of 100 mg
11523434|NCT01190826|Placebo Comparator|Placebo|Placebo administered once by inhalation
11523435|NCT01190813|Active Comparator|Levodopa/Carbidopa|Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
11523436|NCT01190813|Placebo Comparator|Placebo|Oral placebo tid
11523437|NCT01190787|Experimental|VMP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.
~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
11523438|NCT01190787|Experimental|VCP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.
~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.
~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
11523439|NCT01190787|Experimental|VP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.
~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
11523440|NCT01190774|Experimental|Dentist behaviour|Patient completes the MDAS which is handed to receptionist who then gives the information to the dentist with patient knowledge
11523441|NCT01190774|Experimental|Dentist behaviour and patient expectancy|Patient completes the MDAS and hands to the dentist
11523442|NCT01190761|Experimental|A|Galantamine 4 mg Tablet, single dose
11523443|NCT01190761|Active Comparator|B|Reminyl 4 mg Tablet, single dose
11523444|NCT01190748|Experimental|A|Galantamine 4 mg Tablet, single dose
11523445|NCT01190748|Active Comparator|B|Reminyl 4 mg Tablet, single dose
11523446|NCT01190735|Experimental|Caffeine|Each patient will take pills twice per day containing 100-200 mg of caffeine (as synthetic caffeine alkaloid). Patients will be instructed to take whatever caffeine-containing beverages they are accustomed to taking, without changing their habitual schedule (note that all will be taking <200 mg per day). Caffeine intake will be assessed at each visit. Patients will continue their usual PD medications, without change in dose or timing for the entire duration of the study. Medication will be provided in pre-packaged dosettes.
11523447|NCT01190722|Experimental|etoricoxib|active study drug, coxib
11523448|NCT01190722|Active Comparator|diclofenac|active traditional NSAID control
11523449|NCT01190709|Other|unreamed Intramedullary Nailing|tibial fracture fixed with unreamed Intramedullary Nailing
11523450|NCT01190709|Other|Dynamic Compression Plate|tibial fracture fixed with Dynamic Compression Plate
11523451|NCT01190696|Other|hip spica casting|Patients in the spica cast group treated with skeletal traction and spica cast applied for them
11523452|NCT01190696|Other|titanium elasting nailing|For patients in the Titanium Elasting Nailing group, the nail applied retrogradely in femoral shaft fracture
11523453|NCT01190683|Active Comparator|cholecalciferol|cholecalciferol 60,000IU/week for first eight weeks followed by 60,000 IU every 15 days for four months along with calcium placebo
11523454|NCT01190683|Active Comparator|Calcium carbonate|two tablets of calcium carbonate daily equivalent to 1 gm of elemental calcium for six months along with vitamin D placebo
11523455|NCT01190683|Active Comparator|oral calcium and cholecalciferol|60,000 IU of cholecalciferol every week for ist eight week and then 60,000IU every 15 days for next four months along with 1 gm of elemental calcium ever day for six months
11523456|NCT01190683|Placebo Comparator|lactose|identical placebos
11523457|NCT01190670|Experimental|Part 1, Group 1|ASP015K, low dose followed by high dose, with oral tacrolimus
11523458|NCT01190670|Experimental|Part 1, Group 2|ASP015K, high dose followed by low dose, with oral tacrolimus
11523459|NCT01190670|Experimental|Part 2|ASP015K high dose with intravenous tacrolimus
11523460|NCT01190657|Experimental|Selbex 50mg (14 days)|
11523461|NCT01190657|Experimental|Selbex 50mg (56 days)|
11523462|NCT01190644|Experimental|ACE 011 (Sotatercept)|35mg dose of ACE 011 will be given by subcutaneous injection on Day 1. Up to two additional doses of ACE 011 will be given every 42 days during the treatment period (Day 43 and Day 85)
11523468|NCT01190540|Active Comparator|OSS Phase 1|Thirty-six sites will receive the On Site Support service (OSS) activities for nine to 15 months; 18 will be randomly assigned to receive the OSS in phase 1
11523469|NCT01190540|Active Comparator|OSS Phase 2|Thirty-six sites will receive the OSS activities for nine to 15 months; 18 will be randomly assigned to receive the OSS in phase 2 that will serve as a control group in phase 1 and receive OSS nine months later.
11523470|NCT01190527|Other|FDG-PET|All subjects will have the same course of treatment, the study treatment.
11523471|NCT01190514|Experimental|Bioequivalence and Food effect|
11523472|NCT01190501|Experimental|complier device|
11523473|NCT01190488|Experimental|Intervention - Decision Aid|In addition to usual care, patients assigned to the intervention group will also be asked to view and/or read the EOL-PtDA during their hospitalization. The EOL-PtDA can be utilized anytime in the course of their hospitalization (all hospital rooms at UCH have a DVD player). This could be before, during, or after the palliative care team consultation.
11523474|NCT01190488|Active Comparator|Active comparison|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
11523475|NCT01190475|Experimental|BGS649 high dose|1 BGS649 1.0mg capsule with three 0.1 mg placebo capsules.
11523476|NCT01190475|Experimental|BGS649 low dose|1 BGS649 1.0 mg placebo capsule and 3 BGS649 0.1 mg capsules
11523477|NCT01190475|Placebo Comparator|Placebo to BGS649|1 matching placebo 1.0mg matching and three matching 0.1 mg placebo capsules
11523478|NCT01190449|Experimental|Arm I|Patients receive high-dose ofatumumab IV over 2-8 hours on days 1, 8, 15, and 22 and then once monthly in months 3-9.
11523479|NCT01190449|Experimental|Arm II|Patients receive a lower dose of ofatumumab IV over 2-8 hours on days 1, 8, 15, and 22 and then once monthly in months 3-9.
11523480|NCT01190436|Experimental|Bisoprolol|
11523481|NCT01190423|Experimental|Family Based therapy for young adults|
11523482|NCT01190410|Experimental|Certolizumab pegol: high-dose group|400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
11523483|NCT01190410|Experimental|Certolizumab pegol: low-dose group (weight adjusted)|200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to < 40 kg
11523484|NCT01190397|Experimental|Blephasteam Arm|
11523485|NCT01190397|Active Comparator|warm and moist compresses arm|
11523486|NCT01190384|Experimental|Bean Soup|Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
11523487|NCT01190384|Active Comparator|Couscous plus Fiber|Soup with added fiber; has a low ORAC value. Subject serving is isocaloric to the experimental Bean soup.
11523488|NCT01190384|Active Comparator|Couscous plus Grape Seed Extract|Control for ORAC value of the Bean soup; for examining the effect of fiber in the bean soup.
11523489|NCT01190371|Other|Artesunate|Confirmation of artemisinin tolerance
11523490|NCT01190358|Placebo Comparator|Placebo|Sugar pill
11523491|NCT01190358|Active Comparator|Grape seed extract|300mg of grape seed extract.
11523492|NCT01190345|Experimental|WITH bevacizumab|"bevacizumab 15 mg/kg on day 1 of each cycle : 4 cycles of 5-fluorouracil 500 mg/m² IV + epirubicin 100 mg/m² IV + cyclophosphamide 500 mg/m² IV (FEC100) every 21 days and 4 cycles of docetaxel 100 mg/m² IV every 21 days.
~Patients with HER2+ disease will receive trastuzumab (8 mg/kg (IV then 6 mg/kg, every 21 days), which will be started with docetaxel and administered for a total duration of 54 weeks, 18 injections."
11523493|NCT01190345|Active Comparator|without bevacizumab|"4 cycles 5-fluorouracil 500 mg/m² IV + epirubicin 100 mg/m² IV + cyclophosphamide 500 mg/m² IV of (FEC100) every 21 days and 4 cycles of docetaxel 100 mg/m² IV every 21 days.
~Patients with HER2+ disease will receive trastuzumab (8 mg/kg (IV then 6 mg/kg, every 21 days), which will be started with docetaxel and administered for a total duration of 54 weeks, 18 injections."
11523494|NCT01190332|Placebo Comparator|conventional technique of ERCP|
11523495|NCT01190332|Active Comparator|Rendezvous technique|
11523496|NCT01190319|Placebo Comparator|Placebo Beverage|The placebo beverage is matched in energy, macronutrient composition and sensory properties to the active beverage, but is devoid of strawberry polyphenols.
11523497|NCT01190319|Experimental|Strawberry Beverage|The strawberry beverage is matched in energy, macronutrient composition and sensory properties to the placebo beverage, but contains strawberry polyphenols.
11523498|NCT01190306|Experimental|CXL Treatment|Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light.
11523499|NCT01190306|Active Comparator|Sham Control|Eyes in the control group will be treated with riboflavin only.
11523500|NCT01190293|Experimental|All subjects|All Subjects will receive the same intervention.
11523501|NCT01190280||AC - operation|Patients admitted with acute cholecystitis randomized to operation
11523502|NCT01190280||AC - observation|Patients admitted with acute cholecystitis randomized to observation
11523503|NCT01190280||SGBS - operation|Patients admitted with uncomplicated gallstone disease randomized to operation
11523504|NCT01190280||SGBS - observation|Patients admitted with uncomplicated gallstone disease randomized to observation
11523505|NCT01190280||1983 - stones|Patients that in 1983 were diagnosed with gallstones in a population screening
11523506|NCT01190280||1983 - operation|Patients that were operated for gallstone disease at Haukeland University Hospital, Bergen, Norway, in 1983
11523507|NCT01190280||1983 - controls|Patients that were shown not to have gallstones in a 1983 population screening
11523508|NCT01190280||Gallstone patients|Patients with symptoms from gallstone disease
11523509|NCT01190267|Experimental|Asenapine|All enrolled participants receive open-label asenapine 2.5 mg twice daily (BID) on Day 1-3, which is increased to 5.0 mg BID on Day 4 (dose can be increased earlier at the investigator's discretion). Asenapine dosing is flexible for the remainder of the 26-week open-label drug administration period, and can be adjusted to either 2.5 mg or 5.0 mg BID at the investigator's discretion, based on tolerability and/or symptomatology.
11523511|NCT01190254|Experimental|Asenapine 5.0 mg BID|Participants receive active asenapine 2.5 mg tablets sublingually BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive active asenapine 5.0 mg tablets sublingually BID for the remainder of the 8-week treatment period.
11523512|NCT01190254|Placebo Comparator|Placebo|Participants receive placebo asenapine tablets sublingually BID for 8 weeks.
11523513|NCT01190241|Experimental|Targeted treatment|Targeted treatment with desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib
11523514|NCT01190228|Experimental|Group 1: JE-CV Vaccine Booster|Participants previously vaccinated with JE-CV vaccine will receive a booster dose of JE-CV vaccine on Day 0.
11523515|NCT01190228|Experimental|Group 2: JE-CV Vaccine First Dose|JE-CV vaccine naïve participants will receive a single dose of JE-CV vaccine on Day 0.
11523516|NCT01190228|Active Comparator|Group 3: Varicella Vaccine|JE-CV vaccine naïve participants will receive one dose of Varicella vaccine on Day 0.
11523517|NCT01190215|Experimental|Fluarix Group|Subjects previously vaccinated with Pandemrix vaccine received 1 dose of Fluarix vaccine. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.
11523518|NCT01190215|Active Comparator|Havrix Group|Subjects previously vaccinated with Pandemrix vaccine received 1 first dose of Havrix vaccine (subjects aged above 15 years) or Havrix-Junior vaccine (subjects aged 15 years and below). A second dose was given outside the study setting, at Month 6. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.
11523519|NCT01190202|Experimental|Overall Study Group (Survey 1)|Subjects at least 6 months of age at the time of Survey 1, conducted at Year 1 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
11523520|NCT01190202|Experimental|Overall Study Group (Survey 2)|Subjects at least 6 months of age at the time of Survey 2, conducted at Year 2 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
11523521|NCT01190202|Experimental|Overall Study Group (Survey 3)|Subjects at least 6 months of age at the time of Survey 3, conducted at Year 3 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
11523522|NCT01190202|Experimental|Overall Study Group (Survey 4)|Subjects at least 6 months of age at the time of Survey 4, conducted at Year 4 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
11523523|NCT01190189|Experimental|Cervarix Group|Healthy female subjects who received control vaccine in the primary study HPV-015 (NCT00294047), were administered three doses of Cervarix vaccine intramuscularly, according to a 0,1,6-month schedule.
11523524|NCT01190176|Experimental|HPV-062 study subjects Group|HPV-015 (NCT00294047) study subjects who had normal cervical cytology, but tested positive for oncogenic HPV infection at their concluding HPV-015 (NCT00294047) study visit or were pregnant, so that no cervical sample could be collected at their concluding HPV-015 (NCT00294047) study visit.
11523525|NCT01190163|Experimental|A|
11523526|NCT01190163|Active Comparator|B|
11523527|NCT01190150|Experimental|0.65 g / 1.3 g tranexamic acid|Participants received a single dose of 0.65 g tranexamic acid on Day 1 and a single dose of 1.3 g tranexamic acid on Day 8.
11523528|NCT01190150|Experimental|1.3 g / 0.65 g tranexamic acid|Participants received a single dose of 1.3 g tranexamic acid on Day 1 and a single dose of 0.65 g tranexamic acid on Day 8.
11523529|NCT01190137|Active Comparator|400 IU Vitamin D3|
11523530|NCT01190137|Experimental|400 IU Vitamin D2|
11523531|NCT01190124||CohortHIV|Adult multiple-experienced HIV infected patients who needed to change their antiretroviral therapy and initiated raltegravir + optimized background therapy under the Early Access Program.
11523532|NCT01190111|Experimental|CYT107 (r-hIL-7)|
11523533|NCT01190098|Experimental|Lacosamide|
11523534|NCT01190098|Placebo Comparator|Sugar pill|
11523535|NCT01190085|Active Comparator|Ghrelin (1 microg/kg)|A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
11523536|NCT01190085|Active Comparator|Ghrelin (3 microg/kg)|A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
11523537|NCT01190085|Placebo Comparator|Saline Solution|Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
11523538|NCT01190059|Experimental|EVLP Group|EVLP Group are those recipient lung transplant patients that received donor lungs that had been placed on the ex vivo lung perfusion system with Steen Solution™ .
11523539|NCT01190046|Other|Resistance exercise training|Exercise is being used as an experimental tool to determine if remediation of muscle disuse counteracts cellular/molecular defects in muscle structure/function.
11523540|NCT01190033|Active Comparator|Neurolysis|In this intervention the neurotome will be connected
11523541|NCT01190033|Placebo Comparator|Neurotome OFF|neurotome not raised
11523542|NCT01190020|Active Comparator|Lubiprostone|24mcg BID for 4 weeks, oral medication
11523543|NCT01190020|Placebo Comparator|Placebo|24mcg BID for 4 weeks (placebo), oral medication
11523544|NCT01190007|Experimental|Caduet|
11523545|NCT01189994|Experimental|Acupuncture|Patients will receive acupuncture treatment in addition to standard care, coming to twelve weekly acupuncture sessions
11523721|NCT01188785|Experimental|1 arm|SOC + siG12D LODER
11523546|NCT01189994|Active Comparator|Orientation|Patients will receive standard care only, coming to three monthly orientation sessions
11523547|NCT01189981|Experimental|eHealth intervention|Standard lifestyle counseling. Short Message Service (SMS) encouragements for physical activity,
11523548|NCT01189981|Active Comparator|Lifestyle counseling|Standard lifestyle counseling. No Short Message Service (SMS) encouragements for physical activity.
11523549|NCT01189968|Experimental|Carboplatin and Pemetrexed plus demcizumab|Carboplatin and Pemetrexed plus demcizumab
11523550|NCT01189968|Experimental|Pemetrexed plus demcizumab|Pemetrexed plus demcizumab
11523551|NCT01189955|Active Comparator|HS total thyroidectomy|In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.
11523552|NCT01189955|Active Comparator|conventional total thyroidectomy|A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
11523553|NCT01189929|Experimental|Gemcitabine and demcizumab With or Without Abraxane®|Gemcitabine and demcizumab With or Without Abraxane®
11523554|NCT01189916|Experimental|Transrectal NOTES appendectomy|These patients will undergo an experimental surgical procedure that uses flexible endoscopic instruments (i.e., inserted through the rectum).
11523555|NCT01189890|Experimental|Sitagliptin|Sitagliptin phosphate 100 mg or 50 mg once daily (QD)
11523556|NCT01189890|Active Comparator|Glimepiride|Glimepiride 1-6 mg QD
11523557|NCT01189877|Experimental|pO2 measurements|In patients meeting eligibility requirements outlined below, comparisons will be made between direct pO2 measurements using a tissue hypoximeter and IHC-assessed expression of hypoxia related proteins (HIF-1α, VEGF, CA IX and GLUT-1) in both normal and tumor tissue.
11523558|NCT01189864||Ciprofloxicin or Vigamox or other.|
11523559|NCT01189864||Nonsteroidal (Acular, Voltaren Xibrom, etc)|
11523560|NCT01189864||Steroid (FML, Pred Forte, Flarex, etc.)|
11523561|NCT01189851|Other|IORT|Treated with Intraoperative Radiation Therapy
11523562|NCT01189838||Low Cyr61|Low Cyr61 immunohistochemical stain in patients' TCC tumor
11523563|NCT01189838||High Cyr61|High Cyr61 immunohistochemical stain in patients' TCC tumor
11523564|NCT01189825|Experimental|Exercise|
11523565|NCT01189812|Placebo Comparator|sugar pill|
11523566|NCT01189812|Active Comparator|Lithium|
11523567|NCT01189799|Experimental|Motivational Therapy Aftercare|
11523568|NCT01189799|Other|Dual Recovery Anonymous|Aftercare Treatment as Usual
11523569|NCT01189786|Experimental|Cohort 2: CD34+ cells as a top off|"Cohort 2 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD34 Reagent system' as a topoff without the need for additional conditioning prior to the infusion. These patients who have already received SCT and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse."
11523570|NCT01189786|Experimental|Cohort 1: CD34+ Cells for transplant|Cohort 1 consists of patients receiving CD34+ selected peripheral blood stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The stem cells will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory.
11523571|NCT01189773|Experimental|1|Ibuprofen given orally (10 mg/kg, max = 600 mg) and codeine given orally (1 mg/kg, max = 60 mg).
11523572|NCT01189773|Placebo Comparator|2|Ibuprofen given orally (10 mg/kg, max = 600 mg) and placebo given orally ( identical in taste color to codeine preparation).
11523573|NCT01189760|Experimental|onabotulinumtoxinA 44U|44 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
11523574|NCT01189760|Other|onabotulinumtoxinA 24U|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo (normal saline) injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
11523575|NCT01189760|Placebo Comparator|placebo (normal saline)|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
11523576|NCT01189747|Experimental|onabotulinumtoxinA|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1.
11523577|NCT01189747|Placebo Comparator|placebo (normal saline)|normal saline injected into bilateral Crow's Feet Line areas on Day 1.
11523578|NCT01189734|Placebo Comparator|laparoscopic common bile duct exploration|
11523579|NCT01189734|Active Comparator|laparoscopic cholecystectomy with intraoperative ES|
11523580|NCT01189721|Active Comparator|sevoflurane|Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min. patients who are in this group will be infused propofol intraoperatively.
11523581|NCT01189721|Experimental|propofol|Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min. patients included this group will be inhaled sevoflurane intraoperatively.
11523582|NCT01189708|Experimental|Mesh implantation|Ultrapro® Mesh implantation
11523583|NCT01189708|Active Comparator|Standard wound closure without a mesh|Standard wound closure
11523584|NCT01189695|Experimental|Boosted lopinavir monotherapy|
11523585|NCT01189695|Active Comparator|boosted lopinavir + optimized background regimens (OBRs)|
11523586|NCT01189682|Active Comparator|Tegaderm HP|
11523587|NCT01189682|Placebo Comparator|Tegaderm|
11523588|NCT01189682|Active Comparator|Tegaderm CHG|
11523589|NCT01189669|Active Comparator|LC n-3 PUFA|Supplementation with 4 x 1g fish oil capsules (Seven Seas, Ireland) containing 1.9g combined EPA and DHA daily for 6 weeks.
11523590|NCT01189669|Placebo Comparator|Placebo (olive oil) supplement|4 x 1g olive oil capsules (Millas Inc) were given daily for 6 weeks.
11523591|NCT01189669|No Intervention|Wash out period|A 6 week wash out period separated the LC n-3 PUFA and the Placebo (olive oil) arms. During this period the subjects took no supplements. This arm was designed to minimise a cross-over effect.
11523592|NCT01189656|Experimental|Vaccine+Lamivudine group|Subjects assigned into the experimental and the controlled groups with randomization and double-blindness by a ratio of 2:1
11523593|NCT01189656|Placebo Comparator|Placebo+Lamivudine group|
11523594|NCT01189643|Experimental|Chemotherapy|This is a pilot study to evaluate the acute toxicities and activity of irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator based therapy in newly diagnosed patients with DSRCT.
11523595|NCT01189617|Experimental|Formula PD-F-7619|At least twice per week for one week, massage about a dime-sized amount of the PD-F-7619 personal lubricant product to the application site as directed.
11523596|NCT01189604|Placebo Comparator|Arm1 - Placebo|
11523597|NCT01189604|Active Comparator|Arm 2 - ICI35,868 (propofol)|
11523598|NCT01189604|Active Comparator|Arm 3 - ICI35,868 (propofol)|
11523599|NCT01189604|Active Comparator|Arm 4 - ICI35,868 (propofol)|
11523600|NCT01189604|Active Comparator|Arm 5 - ICI35,868 (propofol)|
11523601|NCT01189604|Active Comparator|Arm 6 - ICI35,868 (propofol)|
11523602|NCT01189604|Active Comparator|Arm 7 - ICI35,868 (propofol)|
11523603|NCT01189591|Experimental|Sleep deprivation|Slow-wave sleep deprivation for one night as an experimental treatment for major depressive disorder
11523604|NCT01189578||Recreational cocaine users|Individuals who have used cocaine in the past 3 months, but do not meet DSM-IV-TR diagnostic criteria for Cocaine Dependence.
11523605|NCT01189565||Joint Replacement Patients|
11523606|NCT01189552|Active Comparator|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001). LETS ACT is based on the belief that the best way to improve mood, remain sober, and to make long-term life changes is by changing and increasing one's activity level. It has been modified to accommodate the needs of a substance using population currently receiving inpatient substance use treatment. Treatment is provided over a 4-week period and is provided in small group format, with each group consisting of 3-5 patients.
11523607|NCT01189552|Placebo Comparator|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Treatment is provided over a 4-week period and is provided in small group format, with each group consisting of 3-5 patients.
11523608|NCT01189526|Experimental|IVRI|IVRI : intravitreal ranibizumab (0.5mg) injection
11523609|NCT01189526|Active Comparator|Laser|Laser : macular laser photocoagulation
11523610|NCT01189513|Experimental|SCH 900105|10 mg/kg intravenous Days 1, 8 and 15 of 30 day cycle.
11523611|NCT01189500|Experimental|Tamoxifen and Desvenlafaxine SR|
11523612|NCT01189487|Experimental|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium 12g/day (3 g four times a day) IV
11523613|NCT01189461|Experimental|pegaptanib sodium arm|all patients will receive pegaptanib sodium
11523614|NCT01189448|Active Comparator|Pyrimethamine/Sulfadiazine|Women who are enrolled and randomised in Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.
11523615|NCT01189448|Active Comparator|Spiramycine|Spiramycin group : spiramycin 1g tid orally
11523616|NCT01189435|Experimental|erlotinib|This will be a single institution, single-arm, two-stage, open-label study of erlotinib in the treatment of patients with recurrent EGFR-mutant lung cancer following completion of adjuvant erlotinib or gefitinib therapy.
11523617|NCT01189422|Experimental|Segment 1: 3 Arms|
11523618|NCT01189422|Experimental|Segment 2: 4 Arms|
11523619|NCT01189409|Experimental|PEG then Senna|PEG in stepped bowel protocol
11523620|NCT01189409|Experimental|Senna then PEG|Stepped bowel protocol with Senna then PEG
11523621|NCT01189396|Experimental|T|Four doses of A006 taken in 30 minute intervals. Doses will have an escalating number of inhalations (1, 1, 2, and 4 inhalations). Total cumulative Albuterol dose at 90 minutes is 1440 mcg.
11523622|NCT01189396|Active Comparator|R|Four doses of Proventil-HFA taken in 30 minute intervals. Doses will have an escalating number of inhalations (2, 2, 4, and 8 inhalations). Total cumulative Albuterol dose at 90 minutes is 1440 mcg.
11523623|NCT01189396|Placebo Comparator|P|Four doses of Placebo DPI taken in 30 minute intervals. Doses will have an escalating number of inhalations (1, 1, 2, and 4 inhalations). Total cumulative Albuterol dose at 90 minutes is 0 mcg.
11523624|NCT01189383|Experimental|IL15-DC Vaccine|Approximately 9 x 10^6 DCs will be injected (subcutaneously)total per vaccination visit. Patients will receive four vaccinations at weeks 0, 4, 8 and 12.At each scheduled vaccination the patient will receive a total of 3 injections, i.e., 3 mL injections at each of 3 anatomical locations.Injection sites are in upper and lower extremities. Subsequent DC injections will be rotated to different locations on the upper and lower extremities.
11523625|NCT01189370|Experimental|Intra-Patient Dose Escalation: Sorafenib|All patients will receive a starting dose of sorafenib 400 mg by mouth twice daily. At four weeks, all patients who have not experienced Grade 3 or 4 toxicity will undergo dose escalation using a treatment schedule of days 1-5 days of each week. Doses will continue to be escalated every 4 weeks depending on tolerability and tumor response.
11523626|NCT01189357||failed meniscal transplantation|
11523627|NCT01189344|Experimental|Not surgical group|The Nos surgical (NS) group includes 15 patients for whom bariatric surgery is planned. Body mass index (BMI) of this group of patients is ≥40 Kg/m2.
11523628|NCT01189344|Experimental|Surgical group|The Surgical (S) group includes 15 patients who had undergone Roux-en-Y bariatric surgery 2 to 3 months before inclusion in the study
11523629|NCT01189331|No Intervention|CT and FFR|
11523630|NCT01189318|Experimental|Seroquel XR|Patients with MDD receives Seroquel XR.
11523631|NCT01189318|No Intervention|healthy control|
11523632|NCT01189305|Experimental|Behavioral Couples Therapy|
11523633|NCT01189305|Experimental|Individual Drug Counseling|
11523634|NCT01189292|Active Comparator|Dexamethasone injection|Administration of 8mg(2ml) intravenous Dexamethasone (Mephameson®)
11523636|NCT01189279|Experimental|Part 1: bimatoprost Formulation A|bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
11523637|NCT01189279|Experimental|Part 1: bimatoprost Formulation B|bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
11523638|NCT01189279|Experimental|Part 2: bimatoprost Formulation C|bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
11523639|NCT01189266|Experimental|Arm 1 Phase I Vorinostat 180 mg/m^2|Patients in phase I received vorinostat at 180 mg/m^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m^2/day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11523640|NCT01189266|Experimental|Arm 2 Phase 1 Vorinostat 230 mg/m^2|Patients received a higher dose of vorinostat at 230 mg/m^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m^2/day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11523641|NCT01189266|Experimental|Arm 3 Phase II Evaluation Vorinostat 230 mg/m^2|Patients received a higher dose of vorinostat at 230 mg/m^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m^2/ day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11523642|NCT01189253|Active Comparator|Doxorubicin 75 mg/m² every 3 weeks|Doxorubicin administered on day 1 every 3 weeks for a maximum of 6 cycles
11523643|NCT01189253|Experimental|Trabectedin IV 3 hours|Trabectedin administered on day 1 every 3 weeks at the dose of 1.3 mg/m² until progression
11523644|NCT01189253|Experimental|Trabectedin IV 24 hours every 3 weeks|Trabectedin administered on day 1 every 3 weeks at the dose of 1.5 mg/m² over 24 hours until progression
11523645|NCT01189240|Experimental|Phase I Dose Finding|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
11523646|NCT01189240|Experimental|Phase II Stage I|"Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15.Other: laboratory biomarker analysis: correlative studies.
~Phase 2 - not implemented due to drug supply from company"
11523647|NCT01189240|Experimental|Phase II Stage II Arm 1|"Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: laboratory biomarker analysis: correlative studies.
~Phase 2 - not implemented due to drug supply from company"
11523648|NCT01189240|Active Comparator|Phase II Stage II Arm 2|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Other: laboratory biomarker analysis: correlative studies.
~Phase 2 - not implemented due to drug supply from company"
11523649|NCT01189240|Experimental|Phase I Dose Finding - Level 1 5mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 5mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
11523650|NCT01189240|Experimental|Phase I Dose Finding - Level 2 10mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 10mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
11523651|NCT01189240|Experimental|Phase I Dose Finding - Level 3 20mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 20mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
11523652|NCT01189227|Experimental|Arm 1: Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
11523653|NCT01189227|Experimental|Arm 2: Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
11523654|NCT01189214|Experimental|Memantine|
11523655|NCT01189201|Experimental|BI 10773/linagliptin FDC SID|medium single dose ofBI 10773/linagliptin FDC (Formulation A1)
11523656|NCT01189201|Experimental|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
11523657|NCT01189201|Experimental|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
11523658|NCT01189201|Experimental|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
11523659|NCT01189188|Experimental|With ultrasound guidance|In this group of patients, ultrasound guidance will be used when drawing blood from the radial artery.
11523660|NCT01189188|Active Comparator|Without ultrasound guidance|In this group of patients, no ultrasound guidance will be used when drawing blood from the radial artery.
11523661|NCT01189175|Experimental|BI 113823|single oral dose per subject
11523662|NCT01189175|Experimental|BI 113823 + Ketokonazole|after wash-out 5 days ketokonazole with BI 113823 on day 3
11523663|NCT01189162|Experimental|NIMV- nasal respiratory support|Infants with RDS will be treateg with nasal intermittent mandatory ventilation
11523664|NCT01189162|Experimental|HFNC- nasal respiratory support with HFNC|Infants with RDS will be treated with nasal respiratory support with high flow nasal canulla
11523665|NCT01189149|Experimental|IV fluids|Infants will get IV fluids whem indicated until able to tolerate full oral feedings
11523666|NCT01189149|Experimental|Oro/naso gastric tube feeding|Infants will get oro/naso gastric tube feeding whem indicated until able to tolerate full oral feedings
11523667|NCT01189136|Sham Comparator|Sham treatment|34 gauge needle inserted 3cm above the medial ankle, but nonconductive cables are connected, so that no electrical stimulation is applied, over a 30-minute treatment period
11523668|NCT01189136|Experimental|PTNS Active Treatment|34 gauge needle inserted 3cm above the medial ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
11523669|NCT01189123|Active Comparator|Standard dose influenza vaccine|Fluzone (Sanofi Pasteur)
11523670|NCT01189123|Active Comparator|High Dose Vaccine|High Dose Fluzone by sanofi pasteur
11523671|NCT01189110|Active Comparator|Arm 1|Stimulation of auriculotherapy points on both ears with functioning Stim Flex 400A TENS unit once a week for 5 weeks.
11523672|NCT01189110|Placebo Comparator|Arm 2|Stimulation of auriculotherapy points on both ears with disabled Stim Flex 400A TENS unit once a week for 5 weeks.
11523673|NCT01189097|Experimental|dextromethorphan|
11523674|NCT01189084||Observational immunotherapy follow-up|
11523675|NCT01189071|Active Comparator|Darifenacin|3 days of preoperative darifenacin anticholinergic medication
11523676|NCT01189071|No Intervention|no pill|The control group will have the standard of care which is no preoperative anticholinegic medication.
11523677|NCT01189058|Experimental|rTMS and CIMT|This group will receive both rTMS and CIMT.
11523678|NCT01189058|Experimental|rTMS and no CIMT|This group will receive rTMS only.
11523679|NCT01189058|Experimental|Sham and CIMT|This group will receive CIMT and sham rTMS.
11523680|NCT01189058|No Intervention|Sham and no CIMT|This group will receive sham rTMS and no CIMT.
11523681|NCT01189045|Experimental|Aerobic Program|The Aerobic Program will be the Experimental arm of this trial, where a structured, progressive aerobic exercise will be conducted in a class format
11523682|NCT01189045|Active Comparator|Balance and Flexibility Program|The Balance and Flexibility Program will be a non-aerobic intervention that will act as an Active Comparator. Stretching, balance exercises, yoga- or Tai Chi-style classes will be conducted.
11523683|NCT01189032|Experimental|High concentration|
11523684|NCT01189032|Experimental|Low concentration|
11523685|NCT01189032|Placebo Comparator|Placebo|
11523686|NCT01189019|Experimental|Group 1 - 2mg ranibizumab monthly|2mg ranibizumab monthly
11523687|NCT01189019|Active Comparator|Group 2 - 2mg x 3 then PRN|
11523688|NCT01189006|Experimental|dextromethorphan|Research clinical trial of double-blind, stratified randomized, parallel group, double-centre study
11523689|NCT01188993|Active Comparator|septic shock TPT then TEE|Group 1: Each patient will be assessed by both the transpulmonary thermodilution technique and transesophageal echocardiography (TEE)..
11523690|NCT01188993|Active Comparator|septic shock TEE then TPT|Goup 2: Each patient will be assessed by both transesophageal echocardiography (TEE) and the transpulmonary thermodilution technique.
11523691|NCT01188980||NoBE (control)|
11523692|NCT01188980||BE without dysplasia|
11523693|NCT01188980||BE with dysplasia|
11523694|NCT01188967|Experimental|GSK598809|Active medication
11523695|NCT01188967|Placebo Comparator|Placebo|Placebo
11523696|NCT01188954|Active Comparator|Doxycycline|Doxycyline, family of tetracycline antibiotics, used to scleroses the lymphatic vessels that may have transected during dissection.
11523697|NCT01188954|Placebo Comparator|Normal Saline/Water|The standard care is wetting and suctioning fluids followed with suturing of the groin.
11523698|NCT01188941|No Intervention|Standard of Care|
11523699|NCT01188941|Experimental|Assigned a Health System Navigator|
11523700|NCT01188928|Experimental|LEO 80185|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension
11523701|NCT01188928|Active Comparator|Betamethasone|Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle
11523702|NCT01188928|Active Comparator|Calcipotriol|Calcipotriol 50 mcg/g in the topical suspension vehicle
11523703|NCT01188928|Placebo Comparator|Topical suspension vehicle|The topical suspension vehicle alone
11523704|NCT01188915|Experimental|intensive screening|annual breast cancer detection based on mammography, echography and RMI.
11523705|NCT01188902|Experimental|walnut|western type diet with 48 g walnut per day
11523706|NCT01188902|No Intervention|control|
11523707|NCT01188876|Experimental|Carboplatin/Pralatrexate|
11523708|NCT01188863|Experimental|Solid Oral Dose - 150 mg tablets|
11523709|NCT01188863|Experimental|Solid Oral Dose - 50 mg tablets|
11523710|NCT01188863|Experimental|Liquid Oral Dose|
11523711|NCT01188850|Experimental|6mg of DNA/dose|Subjects who have previously received a 3 dose series of VGX-3100 containing either 0.6, 2 or 6mg DNA/dose will receive a fourth dose of VGX-3100 containing 6mg of DNA/dose administered via IM injection + electroporation at Day 0
11523712|NCT01188837|Active Comparator|Full Kinetic Chain Manipulative Therapy|
11523713|NCT01188837|Active Comparator|Full Kinetic Chain Rehabilitation|
11523714|NCT01188837|Active Comparator|Full Kinetic Chain Manipulative Therapy with Rehabilitation|
11523715|NCT01188824|Active Comparator|Cilostazol|Pletaal® (Cilostazol) 100 mg, bid p.o.
11523716|NCT01188824|Placebo Comparator|placebo|"Placebo
~1 tablet, bid p.o."
11523717|NCT01188811|Experimental|Arm 1: lipoic acid|28 subjects receive oral lipoic acid 1200mg daily
11523718|NCT01188811|Placebo Comparator|Arm 2: placebo|28 subjects receive placebo daily
11523719|NCT01188798|Experimental|Transplant recipients receiving Methotrexate|Participants will be biologically stratified according to disease, donor, and KIR match. In addition to a standard backbone of 2 GVHD prophylactics, a computer generated randomization procedure will assign participants to a third GVHD prophylactic medication (MTX or pentostatin)
11523720|NCT01188798|Experimental|Transplant recipients receiving Pentostatin|Participants will be biologically stratified according to disease, donor, and KIR match.between donor and host.In addition to a standard backbone of 2 GVHD prophylactics, a computer generated randomization procedure will assign participants to a third GVHD prophylactic medication (MTX or pentostatin)
11523722|NCT01188772|Experimental|Sofosbuvir 200 mg (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive sofosbuvir 200 mg (2 x 100 mg tablets)+placebo to match sofosbuvir (2 tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
11523723|NCT01188772|Experimental|Sofosbuvir 400 mg (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive sofosbuvir 400 mg (4 x 100 mg tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
11523724|NCT01188772|Active Comparator|Placebo (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive placebo to match sofosbuvir (4 tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
11523725|NCT01188772|Experimental|Sofosbuvir 400 mg (Genotype 2/3)|Participants with genotype 2 or 3 HCV infection received sofosbuvir 400 mg (4 x 100 mg tablets)+PEG+RBV for 12 weeks.
11523726|NCT01188759|Experimental|Voriconazole and Anidulafungin Combination|Subjects in the combination arm will receive voriconazole and anidulafungin in combination for 2-4 weeks followed by voriconazole monotherapy to complete 6-12 weeks of therapy.
11523727|NCT01188759|Active Comparator|Voriconazole Monotherapy|Subjects in the monotherapy arm will receive voriconazole monotherapy for 6-12 weeks of therapy.
11523728|NCT01188746|Experimental|Questionnaire or interview|A pre-experimental design was chosen to examine changes in QoL following a palliative intervention.
11523729|NCT01188733|Experimental|Sandostatin LAR 10mg|Sandostatin LAR ( long-acting octreotide) administered every 28 days in a dose of 10mg
11523730|NCT01188733|Experimental|Sandostatin LAR 30mg|Comparison of drug doses
11523731|NCT01188733|Placebo Comparator|Saline|Saline control
11523732|NCT01188720|No Intervention|Baseline|Assessment only baseline
11523733|NCT01188720|Experimental|Acute exercise|Exercise immediately before sexual activity, three times per week.
11523734|NCT01188720|Active Comparator|General exercise|Exercise not immediately before sexual activity, three times per week.
11523735|NCT01188707|Experimental|Belinostat, Erlotinib, NSCLC|
11523736|NCT01188694|Experimental|Psychotherapy plus Methylene Blue, USP|
11523737|NCT01188694|Placebo Comparator|Psychotherapy Plus Placebo|
11523738|NCT01188694|Other|Delayed Psychotherapy|
11523739|NCT01188681|Experimental|Phase 1: 15 mg/kg TRU-016 + Bendamustine|TRU-016 (15 mg/kg) and bendamustine (70 mg/m2), n = 6 patients
11523740|NCT01188681|Experimental|Phase 1: 20 mg/kg TRU-016 + Bendamustine|TRU-016 (20 mg/kg) and bendamustine (70 mg/m2), n = 6 patients
11523741|NCT01188681|Experimental|Phase 2: TRU-016 and bendamustine|TRU-016 (20 mg/kg) and bendamustine (70 mg/m2), n = 32 patients
11523742|NCT01188681|Active Comparator|Phase 2: Bendamustine|Bendamustine (70 mg/m2), n = 33 patients
11523743|NCT01188668|Experimental|Aripiprazole + Desvenlafaxine SR|
11523744|NCT01188655||Treatment Group Enbrel|
11523745|NCT01188629|Placebo Comparator|Safety Training|
11523746|NCT01188629|Experimental|Personal Health Partner and Counseling (PHP+C)|
11523747|NCT01188603|Experimental|flibanserin|flibanserin 100 mg dose every evening
11523748|NCT01188590||Patients undergoing heart surgery|
11523749|NCT01188577|Experimental|Epinephrine Inhalation Aerosol, HFA|Experimental treatment of 10 inhalations of 125 mcg epinephrine base propelled by HFA 134a
11523750|NCT01188577|Active Comparator|Epinephrine Inhalation Aerosol, CFC|Epinephrine Inhalation Aerosol, CFC propelled, 220 mcg/inhalation , 10 inhalations
11523751|NCT01188564|Experimental|rhC1INH|
11523752|NCT01188564|Placebo Comparator|Placebo (Saline)|
11523753|NCT01188551|Experimental|dexmedetomidine w/ midazolam|Midazolam 0.5 mg/kg given orally pre-op and 1 dose of dexmedetomidine 1mcg/kg given intranasally in OR.
11523754|NCT01188551|Active Comparator|fentanyl w/ midazolam|Midazolam 0.5 mg/kg given orally pre-op and 1 dose of fentanyl 2mcg/kg given intranasally in OR.
11523755|NCT01188551|Experimental|dexmedetomidine w/o midazolam|1 dose of dexmedetomidine 1mcg/kg given intranasally in OR without any pre-medication.
11523756|NCT01188551|Active Comparator|fentanyl w/o midazolam|1 dose of fentanyl 2mcg/kg given intranasally in the OR without any pre-medication.
11523757|NCT01188538|Experimental|Epiduo gel|"Dose or Concentration:Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel.
~Mode and Frequency of Administration:Topical to the face, once daily application in the evening.
~Duration of Treatment:12 weeks"
11523758|NCT01188538|Active Comparator|BPO gel|"Dose or Concentration:Adapalene 0% / Benzoyl Peroxide 2.5% Gel.
~Mode and Frequency of Administration:Topical to the face, once daily application in the evening.
~Duration of Treatment:12 weeks"
11523759|NCT01188512|Experimental|BPZE1 - Low dose|1,000 colony forming units (cfu) of BPZE1
11523760|NCT01188512|Experimental|BPZE1- middle dose|100,000 colony forming units (cfu) of BPZE1
11523761|NCT01188512|Experimental|BPZE1 - High dose|10,000,000 colony forming units (cfu) of BPZE1
11523762|NCT01188512|Placebo Comparator|Placebo|Formulation buffer
11523763|NCT01188499|Experimental|Carboplatin/Paclitaxel + Birinapant|Carboplatin (AUC 6/Paclitaxel (175 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
11523764|NCT01188499|Experimental|Irinotecan + Birinapant|Irinotecan (350 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
11523765|NCT01188499|Experimental|Docetaxel + Birinapant|Docetaxel (75 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
11523766|NCT01188499|Experimental|Gemcitabine + Birinapant|Gemcitabine (1000 mg/m2/IV) once weekly (7 days +/- 2 days) for 3 consecutive weeks followed by 1 week off + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 2 week off for each cycle (4 weeks per cycle).
11523767|NCT01188499|Experimental|Liposomal Doxorubicin + Birinapant|Liposomal doxorubicin (40 mg/m2/IV) every 4 weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 2 weeks off for each cycle (4 weeks per cycle).
11523768|NCT01188486|Experimental|pulmonary interstitial lymphography|stereotactic body radiation therapy & pulmonary interstitial lymphography
11523844|NCT01187901|Active Comparator|Erlotinib and Sulindac|Erlotinib 75 mg per day in combination with sulindac 150 mg twice daily for 6 months.
11523769|NCT01188473|Experimental|NPPV plus standard of care|NPPV initiated early and for a prolonged period of time in addition to standard of care in the management of children admitted to the hospital with status asthmaticus
11523770|NCT01188473|No Intervention|Control: standard of care alone|standard of care in the management of children admitted to the hospital with status asthmaticus
11523771|NCT01188460|Placebo Comparator|Control Group|Receive one weekly telephone follow-up call per week to monitor sleep progress, complete 7 weeks of sleep diaries only (sleep diary measures Total Sleep Time in hours, Time to Fall Asleep in minutes, Number of Nocturnal Awakenings, Sleep Efficiency as a percentage, and Sleep Quality as units on a scale), complete questionnaires at three study timepoints
11523772|NCT01188460|Experimental|Experimental Group|Receive one weekly telephone call to monitor sleep progress, complete 7 weeks of sleep diaries (sleep diary measures Total Sleep Time in hours, Time to Fall Asleep in minutes, Number of Nocturnal Awakenings, Sleep Efficiency as a percentage, and Sleep Quality as units on a scale), implement one chapter per week of self-help manual for insomnia over 7 weeks at home, complete questionnaires at three study timepoints
11523773|NCT01188447|Experimental|Eligible low-risk trauma patients|Paramedics will use the Canadian C-Spine Rule to evaluate low-risk trauma patients meeting the study inclusion criteria in order to determine the need for spinal immobilization for transport to the hospital.
11523774|NCT01188434|Experimental|Integrated Behavioral Treatment|Combined substance abuse, parenting skills, and basic needs intervention
11523775|NCT01188434|Active Comparator|casework treatment as usual|services as usual as referred by child welfare
11523776|NCT01188421|Active Comparator|buprenorphine|Sublingual buprenorphine/naloxone tablets (or placebo)
11523777|NCT01188421|Active Comparator|clonidine|Oral clonidine tablets (or placebo)
11523778|NCT01188421|Experimental|tramadol ER|Oral tramadol tablets (or placebo)
11523779|NCT01188408|Experimental|Liposome Entrapped Docetaxel (LE-DT)|Disease status and tumor responses/progression is assessed in accordance to the RECIST guideline
11523780|NCT01188395||subtypes of bipolar disorders|Bipolar I Disorder with alcoholism Bipolar I Disorder without alcoholism Bipolar II Disorder with alcoholism Bipolar II Disorder without alcoholism
11523781|NCT01188382||Healthy elderly|Healthy elderly 60-82 years; Normal MRI; No psychiatric or neurological disorder and without signs of advanced atherosclerotic disease
11523782|NCT01188369|Experimental|levosimendan|infusion 0,1ug/kg/min for duration of ca. 4 hours prior to operation and until the end of operation
11523783|NCT01188369|Placebo Comparator|Placebo|Identical placebo
11523784|NCT01188343|Experimental|Group 1|Participants will receive the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 0 and Measles, mumps, and rubella live attenuated virus vaccine (MMR) on Day 42
11523785|NCT01188343|Experimental|Group 2|Participants will receive Measles, mumps, and rubella live attenuated virus vaccine (MMR) on Day 0, and the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 42.
11523786|NCT01188343|Experimental|Group 3|Participants will receive the Measles, mumps, and rubella live attenuated virus vaccine (MMR) and the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 0
11523787|NCT01188330|Experimental|WITH Comprehensive Geriatric assessment|Conventional haematological management of patients and Comprehensive Geriatric assessment (CGA) at diagnosis followed by interventions according to disabilities detected and planned monthly follow up by a nurse practitioner during 6 months.
11523788|NCT01188330|Active Comparator|Conventional|Conventional haematological management of patients
11523789|NCT01188317|Experimental|1|
11523790|NCT01188317|Placebo Comparator|2|
11523791|NCT01188304|Experimental|1|
11523792|NCT01188304|Placebo Comparator|2|
11523793|NCT01188291||Sleep Apnea / Hypopnea syndrome|Study group composed of patients with Obstructive Sleep Apnea / Hypopnea syndrome
11523794|NCT01188278||Patients in CP-CML treated with 2G TKI|Patients in CP-CML treated with 2G TKI (nilotinib or dasatinib) post imatinib failure
11523795|NCT01188265|Experimental|Valproate & dextromethorphan 30 mg|Valproate and dextromethorphan 30 mg per day
11523796|NCT01188265|Experimental|VPA & dextromethorphan 60 mg|VPA & dextromethorphan 60 mg per day
11523797|NCT01188265|Active Comparator|VPA & Placebo|VPA & placebo
11523798|NCT01188252|Experimental|Roniciclib|
11523799|NCT01188239||HIGH 6wks LOW 6wks NICOTINE|"Well characterized group of 100 regular smokers experimenting the E-Cigarette loaded with ORIGINAL 7.4 mg nicotine cartridges for 6 weeks followed by CATEGORIA 5.2 mg nicotine cartridges for a further 6 weeks (high and low nicotine group)."
11523800|NCT01188226|Experimental|Nano Hybrid Composite Denture teeth|Denture teeth are made of nano hybrid composite material
11523801|NCT01188213|Experimental|Purified MSM|
11523802|NCT01188200|Experimental|Nutritional Formula #M979|nutritional formula
11523803|NCT01188200|Active Comparator|Regular standard meal|standard meal
11523804|NCT01188187|Experimental|Custirsen, Docetaxel, Prednisone|"Three doses of 640 mg custirsen administered intravenously (IV) as a loading dose between Days -9 to -1. Custirsen, 640 mg, given IV weekly on Days 1, 8, and 15 of each 21-day cycle. Docetaxel (75 mg/M^2 via intravenous injection) on Day 1 of every 21 days plus prednisone (5 mg tablets taken by mouth) twice each day and dexamethasone (8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration).
~Treatment continues for 10 cycles or until unacceptable toxicity or disease progression."
11523805|NCT01188187|Active Comparator|Docetaxel, Prednisone|"Docetaxel (75 mg/M^2 via intravenous injection) on Day 1 of every 21 days plus prednisone (5 mg tablets taken by mouth) twice each day and dexamethasone (8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration).
~Treatment continues for 10 cycles or until unacceptable toxicity or disease progression."
11523806|NCT01188174|Experimental|Clofarabine|
11523807|NCT01188161||Normal subjects|Volunteers without a history of dizzyness or vertigo
11523808|NCT01188148|Active Comparator|VPA & Placebo|VPA & Placebo
11523809|NCT01188148|Experimental|VPA & memantine|
11523845|NCT01187901|Placebo Comparator|Placebo A and Placebo B|Placebo capsules matching erlotinib active comparator (Placebo A) once daily and placebo capsules matching sulindac active comparator (Placebo B) twice daily for 6 months
11523846|NCT01187888|Active Comparator|Rasagiline|
11523847|NCT01187888|Placebo Comparator|Sugar pill|
11523848|NCT01187875|Placebo Comparator|Control|Dextrin Control
11523810|NCT01188135|Experimental|Interactive Voice messaging|"Participants will receive three kinds of interventions calls from the IVR phone system. (1) The first call is to orient the participant to the IVR system, ask permission to leave detailed messages in the future, and to encourage adherence in this initial period of great risk for premature discontinuation. (2) The Refill Reminder Call is to remind patients that a refill their antidepressant medications and occurs approximately 6 days before the prior dispense of medication is due to run out. (3) The Tardy Refill Call is made to participants for whom EMR records indicate that a scheduled refill was missed"
11523811|NCT01188135|No Intervention|Usual care arm|usual care treatment with no interactive phone reminder calls phone
11523812|NCT01188135|Experimental|IVR messaging w/ Psycho-ed. materials|"Participants will receive three kinds of interventions calls from the IVR phone system. (1) The first call is to orient the participant to the IVR system, ask permission to leave detailed messages in the future, and to encourage adherence in this initial period of great risk for premature discontinuation. (2) The Refill Reminder Call is to remind patients that a refill their antidepressant medications and occurs approximately 6 days before the prior dispense of medication is due to run out. (3) The Tardy Refill Call is made to participants for whom EMR records indicate that a scheduled refill was missed. In addition, participants will receive educational material about antidepressant medication."
11523813|NCT01188122|Experimental|AnapnoGuard|
11523814|NCT01188109|Experimental|Gemcitabine / Cisplatin|Single arm study. All patients will receive gemcitabine and cisplatin as adjuvant therapy.
11523815|NCT01188096|Experimental|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
11523816|NCT01188083|Experimental|Fructose Drink|Subject will drink 3-8oz drinks per day for 4 weeks
11523817|NCT01188083|Experimental|Glucose Drink|Subject will drink 3-8oz drinks per day for 4 weeks
11523818|NCT01188070|Sham Comparator|Usual Care Attention Control|Provision of printed educational material and attendance at one group session. This session will focus on nutrition education and flexibility and stretching.
11523819|NCT01188070|Experimental|Psychoeducation plus exercise|Psychoeducation intervention plus an individualized exercise program which will include monitored, individually-prescribed aerobic and resistance exercise.
11523820|NCT01188070|Active Comparator|Psychoeducation|Psychoeducational program to involve group sessions over consecutive weeks. The sessions will use the principles of adult learning, emphasizing active learning, group exercises and discussion, and coaching as well as brief talks to provide content. The curriculum will focus on the strengthening of caregiver self-efficacy through enhancement of knowledge and understanding, the acquisition, strengthening, and practice of caregiving skills, and the development of a more clinical or strategic outlook on the caregiving role.
11523821|NCT01188057|Experimental|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, single dose
11523822|NCT01188057|Active Comparator|NIRAVAM TM|NIRAVAM TM 2 mg orally disintegrating tablets, single dose
11523823|NCT01188044||Study group|Healthy children
11523824|NCT01188031|Experimental|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, single dose
11523825|NCT01188031|Active Comparator|NIRAVAM TM|NIRAVAM TM 2 mg orally disintegrating tablets, single dose
11523826|NCT01188018|Active Comparator|Brief Advice|
11523827|NCT01188018|Experimental|Motivational Interviewing|
11523828|NCT01188018|Active Comparator|Health Education|
11523829|NCT01188005|Experimental|OSAS patients|This arm includes the OSAS diagnosed cohort that has been planned to undergo four polysomnographic studies. One standard, one with oxygen supplementation, one with n-CPAP device and one post antioxidants administration
11523830|NCT01188005|No Intervention|Control Group|This group is scheduled to undergo a plain polysomnographic study, whilst plasma cytokine levels will be measured. It will comprise of healthy, non-OSAS volunteers.
11523831|NCT01187992|Experimental|Full-dose atorovastatin (80 mg/d)|For patients randomised to this arm, atorvastatin in the fixed dose of 80 mg/ day was started immediately after randomisation.
11523832|NCT01187992|No Intervention|Conventional medical treatment|For patients randomised to this arm, adherence to the National Cholesterol Education Program, Adult Treatment Panel III guidelines was required. In particular, in these patients,atorvastatin was started at the initial dosage of 20 mg/day immediately after randomisation. Subsequently, atorvastatin dosage was titrated in order to attain low-density lipoprotein cholesterol (LDL-C) levels <100 mg/dL (2.5 mmol/L).
11523833|NCT01187979|Active Comparator|Control|All eligibly enrolled learners in the intervention schools will receive a prevention program delivered by MIET Africa and the KwaZulu-Natal Department of Education. No cash incentives will be paid for meeting milestones
11523834|NCT01187979|Experimental|Cash incentive|All eligibly enrolled learners in the intervention schools will receive a cash incentivised prevention program delivered by MIET Africa and the KwaZulu-Natal Department of Education
11523835|NCT01187966|Placebo Comparator|Placebo|Drug: Placebo
11523836|NCT01187966|Experimental|High Dose (100mg/day)|
11523837|NCT01187966|Experimental|Low dose (50mg/day)|
11523838|NCT01187953|Experimental|LCP-Tacro|The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
11523839|NCT01187953|Experimental|Prograf (tacrolimus)|Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Doses will be adjusted according to whole blood tacrolimus trough levels. In the initial post-transplant period, plasma trough levels will be measured at 24 and 48 hours. Study drugs will be adjusted to maintain the whole blood pre-dose (trough) concentration of tacrolimus in the target range of 6 - 11 ng/mL for the first 30 days, then 4 - 11 ng/mL for the remainder of the study.
11523840|NCT01187940|Experimental|PEGASUS|PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
11523841|NCT01187940|No Intervention|Placebo|Will receive managment as usual from their local educational and NHS services
11523842|NCT01187927||Female subjects|Subjects received Cervarix® as per routine practice
11523843|NCT01187914||Open Irrigation|Those individuals who had an ablation using open irrigation cooled-tip RF ablation.
11523849|NCT01187875|Experimental|Hi-maize resistant starch 9g|Hi-maize resistant starch 9g
11523850|NCT01187875|Experimental|Novalose 330 resistant starch 9g|Novalose 330 resistant starch 9g
11523851|NCT01187875|Experimental|4.5g Hi-maize and 4.5g Novalose 330|4.5g Hi-maize and 4.5g Novalose 330
11523852|NCT01187862|Other|Basel cocktail|
11523853|NCT01187849|Active Comparator|Metformin|
11523854|NCT01187849|Placebo Comparator|Placebo|
11523855|NCT01187836|Experimental|TRV120027|
11523856|NCT01187836|Placebo Comparator|Placebo|
11523857|NCT01187823|Active Comparator|Nocturnal oxygen therapy|
11523858|NCT01187823|Active Comparator|Adaptive servo ventilation|Bipap® auto SV Advanced
11523859|NCT01187810|Experimental|Combination of Fenretinide, Cytarabine, and Methotrexate|IV for 7 days for each 21 day cycle
11523860|NCT01187797|Experimental|Intervention|
11523861|NCT01187784|Active Comparator|CBT|Coping Cat cognitive-behavioral therapy protocol
11523862|NCT01187784|No Intervention|Waitlist Control|Treatment as usual
11523863|NCT01187771|Active Comparator|Laparoscopic Gastric Banding|
11523864|NCT01187771|Active Comparator|Continuous Positive Airway Pressure|
11523865|NCT01187758|Experimental|Educational intervention|Multifacet educational intervention that includes workshops, seminars and focus group meetings
11523866|NCT01187758|No Intervention|Control - no intervention|This group did not have any intervention, but their population was screened for carriage of antibiotic resistant bacteria
11523867|NCT01187745||suspect kidney stones|Patients presenting with flank abdominal pain
11523868|NCT01187732|Experimental|Washing without water|The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
11523869|NCT01187732|Active Comparator|Traditional soap and water bath|The control intervention is the traditional bathing assistance as performed in care dependent patients by using tap water, a bowl, towels, washcloths and soap.
11523870|NCT01187719|No Intervention|Control|ARV prophylaxis for PMTCT follows national guidelines.
11523871|NCT01187719|Experimental|phenytoin interaction|ARV prophylaxis for PMTCT follows national guidelines + start phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
11523872|NCT01187706||gynecological cancer survivors|"Criteria for including: (1)Been diagnosed as cervical cancer, ovarian cancer or endometrial cancer, and has completed six months after the relevant treatment. (2)Age from 20 - 70 years old. (3) Agreed to participate in this study.
~Criteria for exclusion: Combined with other non-gynecologic cancer (cervical cancer, ovarian cancer or endometrial cancer) patients."
11523873|NCT01187706||healthy controls|Criteria for including: (1)Not those who suffer from cancer.(2)20-70 years old.(3)Agreed to participate in this study.Criteria for exclusion:Had undergone gynecologic surgical removal of ovaries or uterus were.
11523874|NCT01187693|Other|Shoe lift|
11523875|NCT01187680|Experimental|Spraygel|
11523876|NCT01187680|Active Comparator|Control|
11523877|NCT01187667||Haloperidol prevention group|ICU patients with a high risk for delirium who are treated with haloperidol for preventive reason.
11523878|NCT01187667||Control group|Historical cohort group of patients (2008-2009)with a determined risk of 50% or more for delirium who were not treated with haloperidol for preventive reason.
11523879|NCT01187654|Experimental|AC133 recipients|intra coronary injection of bone marrow derived AC133+ cells
11523880|NCT01187654|Experimental|MNC recipients|intra coronary injection of bone marrow derived MNC
11523881|NCT01187654|Active Comparator|control|injection of autologous serum
11523882|NCT01187641||colon cancer|patients undergoing treatment for colon cancer
11523883|NCT01187628|Experimental|Arm 1|
11523884|NCT01187615|Experimental|Arm 1|
11523885|NCT01187615|Experimental|Arm 2|
11523886|NCT01187602||Women at average risk for ovarian cancer|Women at average risk for ovarian cancer (no first degree relatives with breast or ovarian cancer) undergoing gynecologic evaluation at UVA for non-malignant or routine indications.
11523887|NCT01187602||Women with ovarian cancer|Women with known or suspected ovarian cancer who are undergoing evaluation and/or treatment at UVA Cancer Center
11523888|NCT01187602||Increased risk for ovarian cancer|Women at increased risk of ovarian cancer based on family history, personal history, or genetic factors defined as either BRCA1 or BRCA2 mutations who still retain both fallopian tubes and both ovaries.
11523889|NCT01187589|Experimental|Pulsehaler|Fully operational Pulsehaler, with protocol enabled
11523890|NCT01187589|Active Comparator|Nebulizer|Deactivated Pulsehaler (protocol disabled), so only the nebulizer is active
11523891|NCT01187576|Experimental|Intervention|Multi-professional team intervention with PAR, lifestyle brochure
11523892|NCT01187576|Active Comparator|Conventional treatment|Ordinary recommendations on health behaviours, lifestyle brochure
11523893|NCT01187576|No Intervention|retrospective med history comparison|Treatment as usual (retrospective data collection)
11523894|NCT01187537|Experimental|Continuous Femoral Nerve Block|
11523895|NCT01187537|Active Comparator|Single-Inj Nerve Block with IV PCA|
11523896|NCT01187537|Active Comparator|IV PCA|
11523897|NCT01187511|Active Comparator|GSK561679|GSK561679 was given orally, once a day in the evening, for 21 days, at a dose of 350mg, administered as four tablets consisting of 3 x 100mg tablets plus 1 x 50mg tablet.
11523898|NCT01187511|Placebo Comparator|Placebo|Placebo was given orally, once a day in the evening, for 21 days, in the form of four tablets that matched those of GSK561679
11523899|NCT01187498|Experimental|Behavioral Training|Behavioral training using delayed voiding, urge suppression techniques, and pelvic floor muscle training
11523900|NCT01187498|Active Comparator|Drug Therapy|Oxybutynin chloride, extended-release, individually-titrated, 5-30 mg
11523901|NCT01187485|Experimental|Androderm® 2.5mg|Study subjects will be randomized to one of the study arms: 2.5 mg of Androderm®.
11523902|NCT01187485|Experimental|Androderm® 5.0 mg|Study subjects will be randomized to one of the study arms: 5.0 mg of Androderm®.
11523903|NCT01187485|Experimental|Androderm® 7.5mg|Study subjects will be randomized to one of the study arms: 7.5 mg of Androderm®.
11523904|NCT01187472||Treated subjects|Subjects treated on a previous study of locally advanced head and neck cancer
11523905|NCT01187459|Experimental|10 ug/day|
11523907|NCT01187446|Experimental|TSEBT & Vorinostat|"Total skin electron beam therapy (TSEBT) will be performed per institution guidelines.
~Vorinostat will be administered at a dose of 400 mg/day, starting one day prior to the initiation of TSEBT. During TSEBT, vorinostat should be taken in the morning and preferably prior to TSEBT."
11523908|NCT01187446|Active Comparator|TSEBT only|"Total skin electron beam therapy (TSEBT) will be administered according to the Stanford 6-field technique or equivalent technique per institutional standards. Patients will receive a planned total skin dose of 12 grey (Gy) fractionated at 2 Gy/cycle (each cycle requiring 2 days of treatment); 4 days each week; for a total of 3 weeks. Supplements will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions (1-2 Gy fractions to a total dose of 12 Gy). Discrete tumors may receive additional boost treatment not to exceed 12 Gy."
11523909|NCT01187433|Experimental|Dengue Vaccine Group|Participants will receive Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus vaccine
11523910|NCT01187433|Placebo Comparator|Control Group|Participants will receive a placebo, NaCl 0.9%.
11523911|NCT01187420||EEG and Cerebral Vasospasm|Cerebral Vasospasm and role of BIS vista monitor in Subarachnoid Hemorrhage (SAH) patients
11523912|NCT01187407|Experimental|12 or 18 mg flexible dose LY2216684 + SSRI|"LY2216684: flexible dose of 12 or 18 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to a 12 or 18 mg flexible dose of LY2216684.
~During the AT Phase, participants first received 6 mg LY2216684 QD for 3 days, followed by 12 mg QD for the next 11 days. Then, based on efficacy and tolerability, dosage could be increased to 18 mg QD over the next 6 weeks. Participants on 18 mg QD could have had their dose decreased back to 12 mg QD. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.
~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
11523913|NCT01187407|Experimental|6 mg fixed dose LY2216684 + SSRI|"LY2216684: fixed dose of 6 mg, administered orally, QD for 8 weeks, adjunctive to an SSRI
~Prior to entering the AT Phase, participants completed a 3-week CF Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to 6 mg fixed dose of LY2216684.
~During the AT Phase, participants received a 6 mg fixed dose of LY2216684 adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the DC Phase.
~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
11523914|NCT01187407|Placebo Comparator|Placebo + SSRI|"Placebo: administered orally, QD for 8 weeks, adjunctive to an SSRI
~Prior to entering the AT Phase, participants completed a 3-week CF Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to placebo.
~During the AT Phase, participants received placebo (administered orally, QD) adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the DC Phase.
~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
11523915|NCT01187381||Participants with Breast Cancer|Participants with early or metastatic HER2-positive breast cancer who were receiving treatment with trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines, will be observed. Dosing and treatment duration of the trastuzumab will be at the discretion of the treating physician.
11523916|NCT01187368|Experimental|Evaheart LVAS (EVA2)|The objective of the study is to evaluate the safety and effectiveness of the EVA2 by demonstrating non-inferiority to commercially approved LVADs when used for the treatment of refractory NYHA Class IV heart failure.
11523917|NCT01187368|Active Comparator|HeartMate 3|The objective of the study is to evaluate the safety and effectiveness of the EVA2 by demonstrating non-inferiority to commercially approved LVADs when used for the treatment of refractory NYHA Class IV heart failure.
11523918|NCT01187355|Experimental|Alcon MPDS|MPDS used for 30 days as specified in protocol for contact lens care.
11523919|NCT01187355|Active Comparator|renu fresh MPS|MPS used for 30 days as indicated for contact lens care.
11523920|NCT01187342||Non-striatal lesion group|acute ischemic Stroke in MCA territory of 10-100 cm³ with sparing of striatocapsular structures
11523921|NCT01187342||Striatal lesion group|acute ischemic stroke in MCA/AchA territory with involvement of at least 125 mm³ of striatocapsular structures
11523922|NCT01187329|Experimental|hyperinsulinemic normoglycemic clamp (HNC)|Patients will be randomized to receive treatment with HNC during cardiac surgery.
11523923|NCT01187329|Placebo Comparator|standard glucose management|Patients will be randomized to receive treatment with standard glucose management during cardiac surgery.
11523924|NCT01187316|Experimental|TENS|
11523925|NCT01187316|Active Comparator|Massage therapy and muscle stretching|
11523926|NCT01187290|No Intervention|neoadjuvant chemotherapy|Chemotherapy Docetaxel 75 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
11523927|NCT01187290|Experimental|neoadjuvant chemoradiotherapy|Docetaxel 75 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
11523928|NCT01187277|Experimental|Group A|Group A = conventional therapy means: 50 min individual physiotherapy and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
11523929|NCT01187277|Active Comparator|Group B|Group B = conventional therapy plus robot-assisted means: 30 min individual physiotherapy plus 20 min robot-assisted gait training and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
11523930|NCT01187264|Active Comparator|methotrexate 10 mg|oral methotrexate 10 mg once weekly
11523931|NCT01187264|Active Comparator|methotrexate 25mg|oral methotrexate 25 mg once weekly
11523932|NCT01187251||Group 1 - mp3 users|Subjects who have been using mp3 players for at least 1 hour per day for at least 1 year
11523933|NCT01187251||Group 2 - mp3 non-users|Subjects who does not listen regularly to mp3 music
11523934|NCT01187238|No Intervention|Arm1-radical radiotherapy alone group|Arm1-radical radiotherapy alone group, the eligibility patients will received radical intensity-modulated radiotherapy alone
11523935|NCT01187238|Experimental|Arm2-concurrent chemoradiotherapy group|Arm2-concurrent chemoradiotherapy group, the eligibility patients will received radiotherapy the same as radical radiotherapy arm,and also will received the concurrent chemotherapy wiht the regimen consist of cisplatin 40mg/m2, weekly for 7weeks.
11523936|NCT01187225|Active Comparator|Fibrinogen concentrate|
11523937|NCT01187225|Active Comparator|Cryoprecipitate|
11523938|NCT01187212|Active Comparator|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day (D) 1
11523939|NCT01187212|Experimental|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
11523940|NCT01187199|Experimental|Carboplatin Group|Carboplatin: Starting dose AUC 2 by vein on day 1 of a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
11523941|NCT01187199|Experimental|Paclitaxel Group|Paclitaxel: Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
11523942|NCT01187199|Experimental|Sorafenib Group|Sorafenib: Starting dose 200 mg by mouth daily for a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
11523943|NCT01187186|Experimental|Moderate Hepatic Impairment|Subjects with Moderate Hepatic Impairment
11523944|NCT01187186|Experimental|Normal Hepatic Function|Subjects with Normal Hepatic Function
11523945|NCT01187160|Experimental|Transoral robotic surgery (TORS)|da Vinci® Robotic Surgical System
11523946|NCT01187147|Experimental|Green Tea|Recruited subjects will be asked to take green tea capsules for 3 months and then stopped for another 3 months.
11523947|NCT01187134|Active Comparator|Intervention group|
11523948|NCT01187134|No Intervention|Conventional CME|Hospitals receive conventional continuing medical education in lecture style twice a year. They receive current publications and recommendations for national and international meetings regarding diagnosis and therapy of sepsis.
11523949|NCT01187121||Experimental|Those persons randomized to the Decide Your Time program.
11523950|NCT01187121||Standard Pracitice|Those persons randomized to the standard probationary practice condition.
11523951|NCT01187108|Placebo Comparator|Placebo pills|
11523952|NCT01187108|Active Comparator|Acetazolamide alone|
11523953|NCT01187108|Active Comparator|N-acetylcysteine alone|
11523954|NCT01187108|Active Comparator|Combination of N-acetylcysteine and acetazolamide|
11523955|NCT01187095|Experimental|counselling|Does couples in IVF treatment benefit from emotional disclosure
11523956|NCT01187095|Active Comparator|Control|Neutral writing exercise
11523957|NCT01187082|Experimental|bladdertraining group|Cognitive training in groups at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
11523958|NCT01187082|Active Comparator|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
11523959|NCT01187069|Experimental|Training course for practice nurses in autonomy support|
11523960|NCT01187069|No Intervention|Control|Control practices were randomly drawn from among intervention practice applicants and were informed by mail about their status as control practice.
11523961|NCT01187056|Experimental|Training, decision making|General practitioners receive training in shared decision-making and risk communication, and use their newly acquired skills in real-life consultations with 7 patients with high cholesterol.
11523962|NCT01187056|Active Comparator|Training, usual practice|The control group GPs will receive 2 hours of training in the primary care guideline for prevention of cardiovascular disease
11523963|NCT01187043|Experimental|ARM 1|1 mg Proellex
11523964|NCT01187043|Experimental|ARM 2|3 mg Proellex
11523965|NCT01187043|Experimental|ARM 3|6 mg Proellex
11523966|NCT01187043|Experimental|ARM 4|9 mg Proellex
11523967|NCT01187043|Experimental|ARM 5|12 mg proellex
11523968|NCT01187017|Experimental|Flu/Cy Response at 6 months|The primary objective is to assess Fludarabine/ Cyclophosphamide (Flu/Cy) hematological response in SAA.The primary endpoint will be response at six months.
11523969|NCT01187004||Acute Lung Injury (ALI)|patients who might develop acute lung injury (ALI) after cardiac surgery with cardiopulmonary by pass
11523970|NCT01186991|Experimental|Onartuzumab + Bevacizumab + Paclitaxel|Participants will receive treatment with onartuzumab, bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable drug-related toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
11523971|NCT01186991|Experimental|Onartuzumab + Placebo + Paclitaxel|Participants will receive treatment with onartuzumab, placebo matching to bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
11523972|NCT01186991|Active Comparator|Placebo + Bevacizumab + Paclitaxel|Participants will receive treatment with placebo matching to onartuzumab, bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
11523973|NCT01186978|Other|Single arm|This phase II study will evaluate whether a reduction in the RT dose, concomitant with a decrease in the RT field size, in patients that achieve CR and have a negative post-chemotherapy PET scan following 4 to 6 cycles of rituximab containing chemotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity.
11523974|NCT01186952|No Intervention|Optimized usual care|participants will attend one visit with the dietician (30mn) and the physical activity specialist (30mn) when they will be given Canadian guidelines pamphlets for physical activity and food consumption. They will also receive a phone call once a month to discuss about issues in guidelines following.
11523975|NCT01186952|Active Comparator|Diet intervention alone|Participants will attend one visit with the physical activity specialist (30mn) when they will receive the physical activity guidelines. Monthly phone call will be make to discuss about issues in physical activity guidelines following.These individuals will also be enrolled in a supervised caloric restriction program. They will have to visit the dietician once a week for the first months and then twice a month for 3 months. The diet intervention will focus on a low fat diet. At each session participants will be weighed and taken the blood pressure.
11523976|NCT01186952|Active Comparator|diet intervention and exercise program|"Participants will attend diet intervention as described for group 2. They will also follow a supervised exercise program three days per week for 4 months. The exercise training is an interval high intensity aerobic (85-90% heart rate reserve) program with resistance exercises (15RM, 2-3 repetitions). Each session will last one hour. At the end of month 1, 2, and 3, all participants will receive the SWA armband for 7 days to record physical activity and estimate energy expenditure.
~At the end of Month 4, all participants will attend a study visit for repeat baseline testing."
11523977|NCT01186939|Experimental|Azacitidine|Azacitidine (study drug) plus best supportive care.
11523978|NCT01186926|Experimental|HGNS Treatment|
11523979|NCT01186913||Stratum A: Typical SCID +HCT|"Stratum A: Typical Severe Combined Immunodeficiency (SCID) treated with HCT therapy.
~Participants with typical (formerly referred to as classic) SCID + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol."
11523980|NCT01186913||Stratum B: Atypical SCID +HCT|"Stratum B: Atypical Severe Combined Immunodeficiency (SCID) treated with HCT therapy.
~Participants with leaky SCID, Omenn syndrome, or Reticular Dysgenesis (RS) + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol."
11523981|NCT01186913||Stratum C:SCID +Non-HCT|"Stratum C: Severe Combined Immunodeficiency (SCID) who receive alternative therapy per standard of care, non-standard care and/or investigational. This stratum includes:
~Adenosine Deaminase-Deficient SCID (ADA Deficient SCID) with intention to treat with Polyethylene Glycol -Adenosine Deaminase Enzyme Replacement Therapy (PEG-ADA ERT)
~ADA Deficient SCID with intention to treat with gene therapy
~X-linked SCID (XSCID) with intention to treat with gene therapy
~Any individual with SCID previously treated with a thymus transplant (includes intention to treat with HCT, as well as PEG-ADA ERT or gene therapy)"
11523982|NCT01186900|Experimental|Ultrasound-guided needle aspiration|One arm is ultrasound-guided needle aspiration, the other active comparison is traditional open incision and drainage of skin abscess
11523983|NCT01186900|Active Comparator|open incision and drainage|
11523984|NCT01186887|Placebo Comparator|Celecoxib|
11523985|NCT01186887|Placebo Comparator|Placebo|
11523986|NCT01186861|Experimental|Arm A: OSI-906 plus erlotinib|OSI-906 150 mg twice daily (BID) starting on Day 1; erlotinib 150 mg once daily (QD) starting on Day 1
11523987|NCT01186861|Placebo Comparator|Arm B: placebo plus erlotinib|placebo BID starting on Day 1: erlotinib 150 mg QD starting on Day 1
11523988|NCT01186848|Active Comparator|1550-nm erbium-doped fractionated laser|
11523989|NCT01186848|Active Comparator|Combination treatment|"micro-focused ultrasound and 1550nm-fractionated laser"
11523990|NCT01186835|Experimental|Combination Botulinum Toxin A and Hyaluronic Acid|One side of face treated with the combination of Botulinum Toxin A and Hyaluronic Acid injections.
11523991|NCT01186835|Active Comparator|Botulinum Toxin A alone|Other side of face treated with =Botulinum Toxin A injection alone.
11523992|NCT01186822|Experimental|Lung Flute for BHT|The Lung Flute arm participants were instructed to blow twice in to the Lung Flute device vigorously enough to make the reed oscillate, followed by 5 normal breaths. This was repeated 10 times, followed by 3 huff coughs to complete 1 cycle. Two such cycles were recommended twice a day. One of these cycles was performed under supervision of the study personnel at the time of enrollment and at each subsequent study visit. Baseline COPD medication regimen was continued in all participants, although the primary physicians of the participants could make medically necessary changes. Chest physical therapy, additional breathing exercises and formal pulmonary rehabilitation programs were not prescribed to any of the participants during the study.
11523993|NCT01186822|No Intervention|No intervenstion|No intervention. Same population.
11523994|NCT01186809|Experimental|Cytokine Induced Killer|Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)
11523995|NCT01186796|Experimental|Fulvestrant|
11523996|NCT01186783|No Intervention|standard treatment|All patients receive established medical therapy according to current guidelines and therapeutic standards.
11523997|NCT01186783|Active Comparator|ivabradine (add-on)|Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.
11523998|NCT01186770|Experimental|MNTX 150 mg|Participants will receive methylnaltrexone (MNTX) 150 milligrams (mg) (1 tablet of MNTX 150 mg and 2 matching placebo tablets) orally once daily (QD) for 28 days (4 weeks), then MNTX tablets at a dose as needed (PRN) for remaining 56 days (8 weeks).
11523999|NCT01186770|Experimental|MNTX 300 mg|Participants will receive MNTX 300 mg (2 tablets of MNTX 150 mg each and 1 matching placebo tablet) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).
11524000|NCT01186770|Experimental|MNTX 450 mg|Participants will receive MNTX 450 mg (3 tablets of MNTX 150 mg each) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).
11524001|NCT01186770|Placebo Comparator|Placebo|Participants will receive 3 tablets of placebo matched to MNTX orally QD for 84 days (12 weeks).
11524002|NCT01186757|Active Comparator|PF-03715455 1.6mg BID|
11524003|NCT01186757|Active Comparator|PF-03715455 4 mg BID|
11524004|NCT01186757|Active Comparator|PF-03715455 10 mg BID|
11524005|NCT01186757|Placebo Comparator|Placebo|
11524006|NCT01186744|Experimental|Active Treatment (10 mg) BID / Placebo BID|Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
11524007|NCT01186744|Experimental|Active Treatment (10 mg) BID|Continuous active treatment (CP-690,550) for 56 weeks
11524008|NCT01186744|Experimental|Active Treatment (5 mg) BID / Placebo BID|Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
11524009|NCT01186744|Experimental|Active Treatment (5 mg) BID|Continuous active treatment (CP-690,550) for 56 weeks
11524010|NCT01186731|Experimental|Liposome Entrapped Docetaxel (LE-DT)|
11524011|NCT01186718||Control Group|Control group = functional symmetric cervical motion.
11524012|NCT01186718||Experimental subject group|Experimental subject group = asymmetric cervical motion
11524013|NCT01186705|Experimental|MK-2206|This will be a single-arm, phase II study of the AKT inhibitor MK-2206 in patients with KRAS-wild-type, PIK3CA-mutated, colorectal cancer whose tumors have progressed through standard chemotherapy regimens.
11524014|NCT01186692|Experimental|Melody TPV Implant|Melody® Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.
11524015|NCT01186679|Experimental|Intralesional|"Surgical transplantation into the lesion site in chronic patients
~Direct intrathecal implantation in acute and subacute patients"
11524016|NCT01186679|Experimental|intrathecal|direct into the CSF through lumbar puncture
11524017|NCT01186666|Experimental|Non ST-elevation acute coronary syndrome|"Coronary intervention using IVUS-VH & FDG PET-MDCT:
~All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers."
11524018|NCT01186666|Experimental|Stable coronary artery disease|"Coronary intervention using IVUS-VH & FDG PET-MDCT:
~All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers."
11524019|NCT01186653|Experimental|Symbicort|Symbicort® (budesonide / formoterol, 400 micrograms/9 micrograms one puff bd, dose as per NICE guidelines
11524020|NCT01186653|Active Comparator|Seretide|fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
11524021|NCT01186640|Experimental|FCM-A followed by A-maintenance|First treatment phase: Chemoimmunotherapy A-FMC maximum 4 cycles. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c.
11524022|NCT01186614|Experimental|Novel treatment paradigm|treatment protocol including - mechanical CPR, therapeutic hypothermia, ECMO, coronary intervention
11524023|NCT01186601|Experimental|Arm 1|
11524024|NCT01186588|Experimental|001|Canagliflozin One 300-mg dose of canagliflozin on Day 1
11524025|NCT01186575|Experimental|Text Message|Context-sensitive text messages are sent to men after undergoing circumcision
11524026|NCT01186575|No Intervention|Usual Care|Usual care after adult male circumcision (no text messages)
11524027|NCT01186562|Active Comparator|Sitagliptin|
11524028|NCT01186562|Placebo Comparator|Placebo|
11524029|NCT01186549|Active Comparator|ephedrine 30 microgram/kg|"Patients were randomly allocated to one of 5
~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
11524030|NCT01186549|Active Comparator|ephedrine 70 microgram/kg|"Patients were randomly allocated to one of 5
~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
11524031|NCT01186549|Active Comparator|lidocaine0.5mg/kg -ephedrine30 micrograms/kg|"Patients were randomly allocated to one of 5
~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
11524032|NCT01186549|Active Comparator|lidocaine 0.5mg/kg|"Patients were randomly allocated to one of 5
~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
11524033|NCT01186549|Placebo Comparator|normal saline 2ml|"Patients were randomly allocated to one of 5
~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
11524034|NCT01186536|Experimental|Whey protein supplementation|Daily whey protein supplementation
11524035|NCT01186536|Experimental|Soy Protein supplementation|Daily soy protein supplementation
11524036|NCT01186536|Experimental|Placebo|Daily carbohydrate placebo supplementation
11524037|NCT01186523|Experimental|400 kcal of exercise/session|400 kcal of exercise/session
11524038|NCT01186523|Experimental|600 Kcal of exercise/session|600 Kcal of exercise/session
11524039|NCT01186523|Experimental|Control, no exercise|No exercise control group
11524040|NCT01186510|Experimental|Lung perfusion|
11524041|NCT01186510|Active Comparator|no lung perfusion|
11524042|NCT01186497|Experimental|Treatment sequence AEBDC|
11524043|NCT01186497|Experimental|Treatment sequence BACED|
11524044|NCT01186497|Experimental|Treatment sequence CBDAE|
11524045|NCT01186497|Experimental|Treatment sequence DCEBA|
11524046|NCT01186497|Experimental|Treatment sequence EDACB|
11524047|NCT01186484|Experimental|001|JNJ-212082 250 mg 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
11524048|NCT01186471|Experimental|001|A643 (nicotine) 1mg oromucosal nicotine spray- three times daily during each treatment period
11524049|NCT01186471|Experimental|002|A643 (nicotine) 2mg oromucosal nicotine spray- three times daily during each treatment period
11524050|NCT01186471|Placebo Comparator|003|placebo placebo - three times daily during each treatment period
11524051|NCT01186458|Experimental|Fludarabine, Velcade and Rituximab|Fludarabine, Velcade and Rituximab
11524052|NCT01186445|Experimental|Morphine chlorhydrate|Intracoronary injection of morphine chlorhydrate during reperfusion
11524053|NCT01186445|Placebo Comparator|Saline solution|Intracoronary injection of saline solution during reperfusion
11524054|NCT01186432|Experimental|Active|ranibizumab sustained delivery implant
11524055|NCT01186419|Experimental|SPD602 (16mg)|
11524056|NCT01186419|Experimental|SPD602 (32mg)|
11524057|NCT01186406|Experimental|Gliadel, Radiation Therapy, Avastin, Temodar|Single arm study where patients with newly diagnosed Grade IV malignant glioma will receive Gliadel at the time of resection, followed by radiation therapy (XRT), Avastin, and Temodar for approximately 6 1/2 weeks, followed by Avastin and Temodar post-radiation
11524058|NCT01186393|Experimental|Control|Arm includes dietary manipulation in the free-living setting to include potatoes/potato products frequently in the diet (5-7 days / week). Control diet will be prescribed for weight maintenance.
11524059|NCT01186393|Experimental|Low Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
11524060|NCT01186393|Experimental|High Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on High Glycemic Index foods.
11524061|NCT01186380||TEE Procedure|patients requiring TEE procedure by their physician
11524062|NCT01186367|Experimental|Linear Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training, at 60% to 75 % of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at baseline.
11524063|NCT01186367|Experimental|Nonlinear Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at Baseline and and as well as the CPET performed at Week 8.
11524064|NCT01186367|Experimental|Progressive Stretching Group (Attention control)|The ultimate goal for the progressive stretching program is 3 to 4 individual stretching sessions/week for 10 to 50 minutes per session (+/- 10 minutes).
11524065|NCT01186354|Experimental|Receiving results via web-based program|participants will receive genetic risk results for Type 2 diabetes via a web-based program that they access on their own
11524066|NCT01186341||Chronic Pain|New or existing patients of the center who are seeking their initial treatment at the Integrative Medicine center for chronic pain (chronic > 3 months) who report their average pain level over the past month to be at least a 4 of 10 on the Visual Analog Scale.
11524067|NCT01186328|Experimental|Single Arm|Patients will receive 2 doses of EZN-3042 (and intrathecal cytarabine, conditionally) prior to initiating systemic therapy with vincristine, doxorubicin, prednisone and PEG-asparaginase. Patients with CNS 1 or 2 will also receive intrathecal methotrexate, and patients with CNS 3 will also receive triple intrathecal therapy (methotrexate, hydrocortisone, and cytarabine).
11524068|NCT01186315|Active Comparator|Prolonged Exposure therapy|These treatments include repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories.
11524069|NCT01186315|Experimental|Exposure therapy + VR/ER|prolonged exposure therapy plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
11524070|NCT01186302|Other|Midlevel provider|Patients were assigned to a midlevel provider (arm 1) or to a physician (arm 2) for their abortion.
11524071|NCT01186302|Other|Physician arm|Patients were assigned to a midlevel provider (arm 1) or to a physician (arm 2) for their abortion.
11524072|NCT01186289|Experimental|atorvastatin|high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
11524073|NCT01186289|Placebo Comparator|placebo|
11524074|NCT01186276|Placebo Comparator|Corn Starch|Corn starch will serve as the control arm.
11524075|NCT01186276|Experimental|Fiber|Fiber will serve as the intervention.
11524076|NCT01186263|Experimental|99mTc- labeled albumin macroaggregates (MAA)|Diagnostic MAA- SPECT- imaging.
11524077|NCT01186263|Experimental|99mTc- labeled albumin microspheres (B20)|Diagnostic B20- SPECT- imaging.
11524078|NCT01186250|Active Comparator|Pioglitazone|Pioglitazone
11524079|NCT01186250|Placebo Comparator|Placebo|Placebo
11524080|NCT01186211||Patients presenting for elective TKA|Patients will be advised preoperatively about an accelerated path while in hospital that will share many attributes of the standard TOH care map but with several additions, chosen to help reduce pain and hemarthrosis, both felt to be the major impediments to faster recuperation.
11524081|NCT01186198||MINI TREK RX 1.20 mm Coronary Dilatation Catheter|
11524082|NCT01186185|Experimental|Fludrocortisone|
11524083|NCT01186172|Experimental|Ethanol-lock|Treatment with a combination of ethanol-lock and parenteral therapy
11524084|NCT01186172|Active Comparator|Antibiotic lock|Treatment with a combination of antibiotic-lock and parenteral therapy
11524085|NCT01186159|Experimental|Normal Saline|
11524086|NCT01186146|Active Comparator|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
11524087|NCT01186146|Experimental|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
11524088|NCT01186133||DESSIAN|consecutive patients receiving CYPHER stent
11524089|NCT01186133||K-XIENCE|consecutive patients receiving Xience stent
11524090|NCT01186133||GENOUS|consecutive patients receiving GENOUS stent
11524091|NCT01186133||ELEMENT|consecutive patients receiving PROMUS-ELEMENT stent
11524092|NCT01186133||PRIME|consecutive patients receiving XIENCE-PRIME stent
11524093|NCT01186133||NOBORI|consecutive patients receiving NOBORI stent
11524094|NCT01186133||INTEGRITY|consecutive patients receiving RESOLUTE-INTEGRITY stent
11524095|NCT01186133||XPEDITION|consecutive patients receiving XIENCE-XPEDITION stent
11524096|NCT01186133||BIOMATRIX|consecutive patients receiving BIOMATRIX stent
11524097|NCT01186133||CILOTAX|consecutive patients receiving CILOTAX stent
11524098|NCT01186133||DEB|consecutive patients receiving Drug eluting balloon
11524099|NCT01186133||DESYNE|consecutive patients receiving DESYNE stent
11524100|NCT01186133||PREMIER|consecutive patients receiving PROMUS-PREMIER stent
11524101|NCT01186133||ORSIRO|consecutive patients receiving ORSIRO stent
11524102|NCT01186133||ONYX|consecutive patients receiving ONYX stent
11524103|NCT01186133||BVS|consecutive patients receiving Bioresorbable Vascular Scaffold
11524104|NCT01186133||BVS AMI|consecutive acute myocardial infarction patients receiving Bioresorbable Vascular Scaffold
11524105|NCT01186133||Ultimaster|consecutive patients receiving Ultimaster stent
11524106|NCT01186133||Synergy|consecutive patients receiving Synergy stent
11524107|NCT01186133||Biofreedom|consecutive patients receiving Biofreedom stent
11524108|NCT01186133||Firehawk|consecutive patients receiving Firehawk stent
11524109|NCT01186133||DESyne X2|consecutive patients receiving DESyne X2 stent
11524110|NCT01186133||Sierra|consecutive patients receiving Sierra stent
11524111|NCT01186120|Experimental|Biolimus A9-eluting stent|NOBORI stent
11524112|NCT01186120|Active Comparator|Everolimus-eluting stent|PROMUS ELEMENTE stent
11524113|NCT01186107|Experimental|Endeavor Resolute stent|zotarolimus-eluting stent
11524114|NCT01186107|Active Comparator|Cypher stent|sirolimus-eluting stent
11524115|NCT01186094|Active Comparator|Cypher|Sirolimus-eluting stent
11524116|NCT01186094|Active Comparator|Endeavor Resolute|Zotarolimus-eluting Stent
11524117|NCT01186081|Experimental|Preoperative chemoradiotherapy|Preoperative chemoradiotherapy with conventional radiation schedule and oral fluoropyrimidine (capecitabine)
11524118|NCT01186081|Active Comparator|Postoperative chemoradiotherapy|Postoperative chemoradiotherapy with conventional radiation schedule and oral fluoropyrimidine (capecitabine)
11524119|NCT01186068|Experimental|V-101 Cream 0.01% Concentration|Low dose
11524120|NCT01186068|Experimental|V-101 Cream 0.06% Concentration|Mid-dose
11524121|NCT01186068|Experimental|V-101 Cream 0.1% Concentration|Mid-dose
11524122|NCT01186068|Experimental|V-101 Cream 0.15% Concentration|High dose
11524123|NCT01186068|Placebo Comparator|Vehicle|Cream without an active ingredient
11524124|NCT01186055||Smoking Cessation Counseling|Individuals will receive individual and group counseling for 8 weeks (6 visits) while they quit smoking.
11524125|NCT01186042||Aging in HIV|20-40 years of age or older than 50
11524126|NCT01186016|Experimental|Genetic Education Session (GES)|The objectives are to: discuss the impact of the human genome project; define basic genetic concepts and terminology; distinguish between single-gene and multifactorial genetic diseases/conditions; describe genetic counseling/testing; identify uses of pharmacogenetics; discuss psychological and legal/ethical implications of genetic discoveries; smoking as a multifactorial behavior; findings of epidemiological studies about smoking heritability; research about candidate genotypes DRD2 and CYP2A6; and potential use of genotyping to tailor smoking cessation treatment.
11524127|NCT01186016|Active Comparator|Nutrition Education Session (NES)|
11524128|NCT01186003|No Intervention|Standard insulin drip therapy|
11524129|NCT01186003|Active Comparator|Insulin drip and Detemir|Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
11524130|NCT01185990||Tinnitus subjects|Subjects with chronic, moderate to severe unilateral tinnitus.
11524131|NCT01185990||Healthy control subjects|
11524132|NCT01185977|Active Comparator|Fluoxetine|1 week single-blinded placebo lead-in and double-blinded FLX treatment for 8 weeks
11524133|NCT01185977|Placebo Comparator|Placebo (PBO)|Placebo treatment for 9 weeks of study
11524134|NCT01185964|Experimental|Phase 1b: Olaratumab + doxorubicin|"All cycles are 21 days.
~Cycles 1-8: Olaratumab 15 mg/kg on days 1+8, and doxorubicin 75 mg/m2 on day 1
~All subsequent cycles until progression: Olaratumab 15 mg/kg on days 1+8"
11524135|NCT01185964|Experimental|Phase 2: Olaratumab and doxorubicin|"All cycles are 21 days.
~Cycles 1-8: Olaratumab 15 mg/kg on days 1+8, and doxorubicin 75 mg/m2 on day 1
~All subsequent cycles until progression: Olaratumab 15 mg/kg on days 1+8"
11524136|NCT01185964|Active Comparator|Phase 2: Doxorubicin: Optional Olaratumab After Progression|"All cycles are 21 days.
~Cycles 1-8: doxorubicin 75 mg/m2 on day 1 until disease progression.
~At disease progression: optional Olaratumab 15 mg/kg on days 1+8 until further progression."
11524137|NCT01185951|Active Comparator|Achilles tendinopathy|Patients suffering both, insertional and midportion Achilles tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
11524138|NCT01185951|Active Comparator|Patella tendinopathy|Patients suffering patella tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
11524139|NCT01185951|Active Comparator|Epikondylitis|Patients suffering both, lateral (tennis elbow) or medial (golfers' elbow) elbow tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
11524140|NCT01185938|Active Comparator|Rosuvastatin|
11524141|NCT01185938|No Intervention|Control|
11524142|NCT01185925|Placebo Comparator|Placebo|Control Group
11524143|NCT01185925|Active Comparator|sildenafil, pde5 inhibitor|treatment group; sildenafil 50 mg three times a day for 1 year
11524144|NCT01185912||Cardiomyocyte apoptosis|Elective aortic valve replacement patience
11524145|NCT01185899||Suspected ACS patients|Patients presenting with chest pain to the Emergency Department, who are suspected of having ACS, will be asked to participate in the study.
11524146|NCT01185873|Experimental|1|
11524147|NCT01185860|Active Comparator|A|
11524148|NCT01185860|Experimental|B|
11524149|NCT01185860|Placebo Comparator|C|
11524150|NCT01185847|Experimental|A non-squamous|
11524153|NCT01185847|Active Comparator|B squamous|
11524154|NCT01185821|Experimental|BAF312 10 mg/2 mg|10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
11524155|NCT01185821|Experimental|BAF312 2 mg/2 mg|2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
11524156|NCT01185821|Experimental|BAF312 1.25 mg/2 mg|1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
11524157|NCT01185821|Experimental|BAF312 .5 mg/2 mg|.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
11524158|NCT01185821|Experimental|BAF312 .25 mg/2 mg|.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
11524159|NCT01185808|Active Comparator|Vitamin D|Vitamin D 5,000IU/day for 6 weeks
11524160|NCT01185808|Placebo Comparator|Placebo|Placebo for 6 weeks.
11524161|NCT01185795|Experimental|Cardioviva™ yogurt|
11524162|NCT01185795|Placebo Comparator|Placebo yogurt|
11524163|NCT01185782|Experimental|SJ-0021 group|
11524164|NCT01185782|Active Comparator|Purified pituitary gonadotropin group|
11524165|NCT01185769|Experimental|High fat|500 mg of tocotrienol will be administered at single dose after consumption of high fat diet
11524166|NCT01185769|Experimental|Low fat|500 mg of tocotrienol will be administered at single dose after consumption of low fat diet
11524167|NCT01185756|Experimental|ICD implantation|"MIBG for diagnostic purpose:
~MIBG scintigraphy for diagnostic purpose"
11524168|NCT01185743|Active Comparator|olanzapine|olanzapine
11524169|NCT01185743|Active Comparator|ziprasidone|ziprasidone
11524170|NCT01185743|Placebo Comparator|Sugar pill|Sugar pill
11524171|NCT01185730|Experimental|pulmonary hypertension|cohort of patients with pulmonary hypertension
11524172|NCT01185704|Experimental|Day 1 protocol|
11524173|NCT01185704|Experimental|Day 7 protocol|
11524174|NCT01185678||Group1|
11524175|NCT01185665|Active Comparator|TENS|FBSS patients treated with TENS
11524176|NCT01185665|Placebo Comparator|Sham-TENS|patients treated with Sham-Tens
11524177|NCT01185639|Experimental|SBRT for metastatic NSCLC|SBRT for lung lesions, liver lesions, adrenal lesions, spinal lesions
11524178|NCT01185626|No Intervention|Usual care|The gynaecological oncologist (GO) provides care as usual. Currently, hospitals provide follow-up following the Dutch guidelines, meaning that they see their patients on given time points based on the number of years after diagnosis. Most hospitals give their patients leaflets regarding the diagnosis and treatment they receive, however none of them provide personalized information. All information is given during the initial treatment phase, but none of the GOs give additional information during follow-up. None of the GOs is actively screening on psychosocial needs. As this might change in time, we will ask the providers and patients about the type of information they provide, respectively, receive.
11524179|NCT01185626|Experimental|SCP care|After initial treatment, the GO provides the patient with a paper SCP and takes time to discuss all items in the SCP. Each time during follow-up meetings between patient and GO, the patient will receive an updated SCP if applicable. The paper SCP is extracted from the online registration system 'ROGY' (Registrationsystem Oncological GYnaecology) and combines personal patient and disease data with tailored information that is related to the specific situation of this patient. Recurrences, toxicities or additionally involved specialists will be registered in ROGY and automatically updated in the personal SCP.
11524180|NCT01185613|Experimental|Therapy™ Cool Flex Ablation Catheter|
11524181|NCT01185600|Active Comparator|Transfusion with washed RBC|Subject assigned to this arm will be transfused with washed RBC
11524182|NCT01185600|Active Comparator|Transfusion with unwashed RBC|Subjects assigned to this arm will be transfused with unwashed RBC
11524183|NCT01185587||healthy patients with a normal heart|
11524184|NCT01185587||patients with HF without an lCD|
11524185|NCT01185587||patients with HF and an ICD without shock|
11524186|NCT01185587||patients with HF and an ICD with shock|
11524187|NCT01185574|Experimental|Vitamin D supplementation|The study medication (a capsule of 50,000 IU of vitamin D2) will be administered once a week for six months.
11524188|NCT01185561|No Intervention|Usual medical care|Participants assigned to this arm represent the control group and will receive usual medical care only.
11524189|NCT01185561|Experimental|Psychoeducational intervention|Participants assigned to this arm represent the experimental group and will receive group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes
11524190|NCT01185548|Experimental|Tasisulam and Tolbutamide|"Three study periods and continued access to tasisulam every 28 days (except Period 1 which was tolbutamide only and lasted 4 days) until disease progression:
~Period 1: 500 milligram (mg) tolbutamide administered on Day 1.
~Period 2: 500 mg of tolbutamide and individualized tasisulam dose [based on area under the curve albumin-corrected threshold (AUCalb)]. The AUCalb is a surrogate marker for unbound tasisulam, and this dosing approach represents the maximum level of unbound tasisulam which may be achieved clinically, administered on Day 1.
~Period 3: Individualized tasisulam dose (based on AUCalb) administered on Day 1 and 500 mg tolbutamide administered on Day 4."
11524191|NCT01185535|Active Comparator|2 times topical anesthesia for glottis|
11524192|NCT01185535|Active Comparator|3 times topical anesthesia for glottis|
11524193|NCT01185535|Active Comparator|4 times topical anesthesia for glottis|
11524194|NCT01185522||Tocilizumab|Eligible participants receiving tocilizumab according to summary of product characteristics in a real life setting will be observed for 4 months
11524195|NCT01185509|Experimental|Trastuzumab and Vinorelbine - Cohort A|Cycle 1: Patients received trastuzumab 8 mg/kg intravenously (IV) on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Cycles 2+: Patients received trastuzumab 6 mg/kg IV on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Patients were treated until disease progression or unacceptable toxicity. Eligibility required patients to have HER2 amplification by fluorescence in situ hybridization (FISH) (mean ratio > 2.0). The CTC tests of the first 11 patients were done at DFCI. The study team then decided to proceed with a different CTC test performed outside of DFCI. Because the method of CTC isolation was different from that performed by DFCI, the first 11 patients were placed into a separate cohort (Cohort A) and the remaining 20 patients represented the main cohort.
11524265|NCT01185028|Experimental|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
11524196|NCT01185509|Experimental|Trastuzumab and Vinorelbine - Main Cohort|Cycle 1: Patients received trastuzumab 8 mg/kg intravenously (IV) on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Cycles 2+: Patients received trastuzumab 6 mg/kg IV on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Patients were treated until disease progression or unacceptable toxicity. Eligibility required patients to have HER2 amplification by FISH (mean ratio > 2.0). The CTC tests of the first 11 patients were done at DFCI. The study team then decided to proceed with a different CTC test performed outside of DFCI. Because the method of CTC isolation was different from that performed by DFCI, the first 11 patients were placed into a separate cohort (Cohort A) and the remaining 20 patients represented the main cohort.
11524197|NCT01185496||CGM|Blinded/Unblinded CGM wear in adjunct with SMBG meter diabetes management
11524198|NCT01185470|Experimental|Subjects with Implantable pump|Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo study device implantation .
11524199|NCT01185457||Left interscalene block|Left shoulder surgery under left interscalene block and HRV
11524200|NCT01185457||Right interscalene block|Right shoulder surgery under right interscalene block and HRV
11524201|NCT01185444|Experimental|Hya-Joint|The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.
11524202|NCT01185444|Active Comparator|Hyalgan|the control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.
11524203|NCT01185431|Experimental|Ficus carica (Fig paste)|
11524204|NCT01185431|Placebo Comparator|Control (Placebo paste)|
11524205|NCT01185418||risperidone|
11524206|NCT01185418||aripiprazole|
11524207|NCT01185418||haloperidol|
11524208|NCT01185418||amisulpride|
11524209|NCT01185418||lactose|
11524210|NCT01185405|Experimental|EA group|Voriconazole dosage adjustment according to the each measurements of voriconazole levels from day 1, using NONMEM program
11524211|NCT01185405|Active Comparator|CA group|Voriconazole dosage adjustment according to the levels from day 5, using predefined protocol
11524212|NCT01185379|Active Comparator|Efalex Active 50+|
11524213|NCT01185379|Active Comparator|DHA-rich fish oil|
11524214|NCT01185379|Placebo Comparator|Placebo|
11524215|NCT01185366|Experimental|Everolimus Group 1|Everolimus 10 mg by mouth once a day.
11524216|NCT01185366|Active Comparator|Sunitinib Group 2|Sunitinib 50 mg by mouth daily for 4 weeks on / 2 weeks off.
11524217|NCT01185353|Experimental|1 mg LY3009104 once daily|Administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
11524218|NCT01185353|Experimental|2 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
11524219|NCT01185353|Experimental|4 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
11524220|NCT01185353|Experimental|8 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
11524221|NCT01185353|Placebo Comparator|Placebo once daily|Placebo administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
11524222|NCT01185353|Experimental|2 mg LY3009104 twice daily|(Not utilized in Part A) After 12 weeks treatment with 1 mg LY3009104 once daily or Placebo once daily in Part A, administered orally twice daily for 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
11524223|NCT01185340|Experimental|LY2216684 + SSRI|"LY2216684: flexible dose of 12 or 18 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to the LY2216684 treatment arm.
~For the first 2 weeks of the AT Phase, participants received a starting dose of 12 mg QD. Then, based on efficacy and tolerability, the dose could be increased to 18 mg QD over the next 6 weeks. Participants who had their dose increased to 18 mg QD could have had their dose decreased to 12 mg QD. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.
~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
11524224|NCT01185340|Placebo Comparator|Placebo + SSRI|"Placebo: Administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to the placebo treatment arm.
~During the AT Phase, participants received placebo (administered orally, QD) adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.
~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
11524225|NCT01185327||Study|Infants to Israeli Ethiopian-origin Mothers
11524226|NCT01185327||Control|Infants to Israeli non-Ethiopian-origin mothers
11524227|NCT01185314|Other|1|EGFR mutation testing
11524228|NCT01185301|Active Comparator|ADA + 2.5 mg MTX|2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks
11524229|NCT01185301|Active Comparator|ADA + 5 mg MTX|5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
11524230|NCT01185301|Active Comparator|ADA + 10 mg MTX|10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
11524231|NCT01185301|Active Comparator|ADA + 20 mg MTX|MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks
11524232|NCT01185288|Experimental|Adalimumab + Low Dose Methotrexate|Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, low dose methotrexate (7.5 mg orally once weekly).
11524233|NCT01185288|Active Comparator|Adalimumab + High Dose Methotrexate|Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, high dose methotrexate (20 mg orally once weekly).
11524234|NCT01185275||Severe Asthma Patients|Severe asthma patients symptomatic despite high dose inhaled corticosteroid and long acting beta-agonist
11524235|NCT01185262|Experimental|Lenalidomida, Rituximab|Phase I: Lenalidomide will be administered from day 1 to 21 of 28 days cycles, escalating doses (from 2,5mg to 25 mg).Rituximab dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).
11524236|NCT01185249|Experimental|Body weight taken in a standing position|Subjects will be weighed in the early morning, as standard of care dictates. They will also be weighed after evening medications are given, around 9pm. The evening weight is not standard, therefore considered the study intervention.
11524237|NCT01185236|Experimental|simvastatin/ezetimibe (vytorin) group|vytorin 10/20mg po once daily for 12weeks
11524238|NCT01185236|Active Comparator|atorvastatin group|atorvastatin 20mg po once daily for 12weeks
11524239|NCT01185223|Other|Valganciclovir|
11524240|NCT01185223|Active Comparator|Ganciclovir|
11524241|NCT01185210|Placebo Comparator|Placebo|Subjects will receive placebo (mix of sugar and salt).
11524242|NCT01185210|Experimental|Alanine - 12.5|Subjects will receive 12.5 grams of alanine
11524243|NCT01185210|Experimental|Alanine - 25|Subjects will receive 25 grams of alanine.
11524244|NCT01185197|Experimental|Myfortic plus low-dose steroid|Not necessary
11524245|NCT01185197|Active Comparator|Standard-dose steroid|Not necessary
11524246|NCT01185184|Experimental|1|Subjects will receive in random order, the immediate release tablet containing 10 mg of CP-690,550 and two different controlled-release capsules containing 20 mg of CP-690,550.
11524247|NCT01185171|Experimental|ZD1839 500mg by mouth (po) daily|Single arm, two-stage, phase II trial of induction therapy with carboplatin and paclitaxel, followed by ZD1839, 5-FU, hydroxyurea, and hyperfractionated radiotherapy, followed by adjuvant ZD1839 alone.
11524248|NCT01185158|Experimental|ZD1839 (IRESSA) 250mg|ZD1839(IRESSA) 250mg orally (po) daily
11524249|NCT01185145|Experimental|Mammosite|Accelerated Partial Breast Irradiation using Mammosite RTS
11524250|NCT01185145|Experimental|IMRT|Accelerated partial breast irradiation using IMRT planning technique of external beam radiotherapy
11524251|NCT01185132|Experimental|IMRT|Intensity modulated radiotherapy, 38.5 Gy, 10 fractions over 5 days
11524252|NCT01185132|Active Comparator|3D-CRT|Three dimensional conformal external radiotherapy, 38.5 Gy, 10 fractions over 5 days
11524253|NCT01185119|Active Comparator|GLP-1|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
11524254|NCT01185119|Placebo Comparator|placebo|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
11524255|NCT01185093||Fourth grade students|Each participant will attend two presentations and six hands-on activities led by St. Jude faculty and research staff on topics within their expertise, such as cells and cancer, and healthy living. The pre-test will take place within 7±1 days before the program presentations and before students receive copies of the printed material. Two post-tests will take place. The first post-test will be administered within 7±1 days after the final scheduled program presentation and will be a measure of knowledge acquisition. The second post-test will take place 90±7 days post-intervention and will be a measure of knowledge retention.
11524256|NCT01185080|Experimental|1. AZD8848|20 μg AZD8848 three times weekly
11524257|NCT01185080|Placebo Comparator|2. Placebo|Placebo three times weekly
11524258|NCT01185080|Experimental|3. AZD8848 and placebo|60 μg AZD8848 once weekly and placebo twice weekly
11524259|NCT01185067|Active Comparator|grape seed extract capsule|Grape seed extract (MegaNatural BP, Polyphenolics, Inc.) 300 milligram capsules twice daily for six weeks
11524260|NCT01185067|Placebo Comparator|maltodextrin capsule|Maltodextrin capsules (matched for appearance and taste to grape seed extract capsules) twice daily for six weeks
11524261|NCT01185054|Experimental|Fluids as Tolerated (FAT) Group|The FAT group will receive ½ strength apple juice and will form the experimental group in this study.
11524262|NCT01185054|Active Comparator|Electrolyte Maintenance Solution (EMS)|The EMS group will form the control group as solutions such as Pediatric Electrolyte® are routinely recommended for use in children with gastroenteritis.
11524263|NCT01185041|Placebo Comparator|Maltodextrin|6g/day of placebo (maltodextrin)
11524264|NCT01185041|Experimental|Watermelon|(6g per day)containing L-citrulline/L-arginine (4/2 g)
11524312|NCT01184651||Girls|Girls with 21-hydroxylase deficiency (21-OHD) congenital adrenal hyperplasia (CAH) ages 10-13
11524266|NCT01185002|Experimental|MgC boosts|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.
~In this arm the subjects will be administered MgC boosts."
11524267|NCT01185002|Experimental|Suprep boosts|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.
~In this arm the subjects will be administered Suprep boosts"
11524268|NCT01185002|Experimental|Suprep boosts - Reduced dose|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.
~In this arm the subjects will be administered a reduced dose of Suprep boosts"
11524269|NCT01184989|Other|Dabigatran etexilate|open label, once daily dose approved by EMEA and Health Canada
11524270|NCT01184976|Experimental|0.6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 0.6mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
11524271|NCT01184976|Experimental|2mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 2mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
11524272|NCT01184976|Experimental|6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
11524273|NCT01184963|Other|Controls|Women in reproductive age regular ovulatory cycles
11524274|NCT01184963|Other|PCOS patients|Patients with anovulatory cycles, hyperandrogenism with or without polycystic ovarian appearance
11524275|NCT01184950|Experimental|Trainer Curriculum|
11524276|NCT01184950|No Intervention|No Curriculum|
11524277|NCT01184937|Experimental|Patient education program|
11524278|NCT01184937|No Intervention|Standard care|
11524279|NCT01184924|No Intervention|Control|Usual Care only. Usual care is defined as the care these subjects would like to seek from any health care practitioner or other program they may seek for healthy living. The subjects in this arm will be offered the AF Tai Chi intervention after an 8 week followup data collection
11524280|NCT01184924|Experimental|Tai Chi|Usual care plus Tai Chi. These subjects will be allowed to seek care from any health practitioner or any other programs and will receive the AF Tai Chi program for 8 weeks.
11524281|NCT01184911|Experimental|SP|Asymptomatic parasitemic pregnant women who receive the standard dose of sulfadoxine-pyrimethamine for prevention of placental malaria
11524282|NCT01184898|Experimental|Sirolimus and MEC|Sirolimus and MEC (Mitoxantrone, Etoposide, and Cytarabine)
11524283|NCT01184885|Experimental|Hyper-CVAD and Sirolimus|Hyper-CVAD and Sirolimus
11524284|NCT01184872|Experimental|Daptomycin|"Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.
~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days."
11524285|NCT01184872|Active Comparator|Vancomycin or Semi-Synthetic Penicillins (SSPs)|"Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.
~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days."
11524286|NCT01184859|Experimental|Desmopressin 10µg|Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.
11524287|NCT01184859|Experimental|Desmopressin 25µg|Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.
11524288|NCT01184859|Experimental|Desmopressin 50µg|Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.
11524289|NCT01184859|Experimental|Desmopressin 100µg|Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.
11524290|NCT01184859|Placebo Comparator|Placebo|Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.
11524291|NCT01184846|Experimental|IgPro10|10% liquid formulation of human immunoglobulin (IgPro10). IgPro10 will be administered by IV infusion as one induction dose of 2 g/kg body weight (bw), followed by seven 3-weekly maintenance doses of 1 g/kg bw.
11524292|NCT01184833||Group 1|
11524293|NCT01184820|Experimental|Arm 1|
11524294|NCT01184820|Experimental|Arm 2|
11524295|NCT01184807|Other|OPB-51602|
11524296|NCT01184794|Placebo Comparator|Saline|Placebo solution
11524297|NCT01184794|Experimental|levobupivacaine, analgesia|Active drug
11524298|NCT01184781|Other|A|On the same patient, we compare both methods (video-colonoscopy vs capsule endoscopy)
11524299|NCT01184768||participants in the 6th tromsø study|
11524300|NCT01184755|Experimental|Resperate device used for 8 weeks|Participants to use Resperate device to guide breathing for 8 weeks. After the primary 8-week trial, this group is divided into two subgroups to examine 16-week data: one subgroup that stops using the device after 8 weeks, and one asked to continue to use the device for the full 16 weeks.
11524301|NCT01184755|Active Comparator|Relaxation control device|Participants use modified device to pace breathing in the 13/minute range for daily practice for 8 weeks and no device thereafter
11524302|NCT01184755|No Intervention|Usual Care|Participants continue their usual medication and other management for their hypertension. All participants (including UC) are given a home BP monitor and asked to take their BP in morning and evening 3 days/week.
11524303|NCT01184729||Spinal Cord Injury|
11524304|NCT01184716|Active Comparator|Vitamin D fortified bread and milk|
11524305|NCT01184716|No Intervention|Non-fortified bread and milk|
11524306|NCT01184690|Active Comparator|Single-operator DBE|Single-operator double-balloon endoscopy
11524307|NCT01184690|Active Comparator|Dual-operator DBE|Dual-operator double-balloon endoscopy
11524308|NCT01184677|Placebo Comparator|Group size 4|
11524309|NCT01184677|Experimental|Group size 3|ProSeal LMA size 3 is inserted to the patients of Group size 3.
11524310|NCT01184664|Experimental|Varenicline + Active Patch|Participants will use varenicline (1mg BD) + an active, 15mg/16hr Nicotine Patch
11524311|NCT01184664|Placebo Comparator|Varenicline + Placebo Patch|Participants will use varenicline (1mg BD) + a Placebo Nicotine Patch
11524392|NCT01184092|Experimental|Sequence 1|
11524313|NCT01184651||Parents|Parent, guardian, or significant caretaker of girls with CAH
11524314|NCT01184638|No Intervention|Local anesthesia|Patients received local anesthesia without any intervention of general anesthetics
11524315|NCT01184638|Active Comparator|Inhalational anesthesia|Patients received sevoflurane anesthesia during general anesthesia
11524316|NCT01184638|Active Comparator|Intravenous anesthesia|Patients received intravenous anesthetic (Propofol) during general anesthesia
11524317|NCT01184625|Experimental|Exercise|
11524318|NCT01184625|No Intervention|No intervention|12 weeks of stable physical exercise level.
11524319|NCT01184612|Active Comparator|(BSF) MI sessions|5 semi-structured manualised MI sessions was conducted by existing prison staff having undergone 3 days of Motivational Interviewing workshop training and 2 days of training with the BSF manual.
11524320|NCT01184612|Active Comparator|(BSF+) MI sessions with supervision|5 semi-structured manualised MI sessions was conducted by ordinary prison staff having undergone 3 days of Motivational Interviewing workshop training and 2 days of training with the BSF manual, followed by ongoing Motivational Interviewing training with feedback based on audio taped sessions in peer supervision groups.
11524321|NCT01184612|Active Comparator|(UPI) Usual Planning Interview|5 sessions was conducted by prison staff according to usual working practices, with the exception that content was structured into 5 sessions and audio recorded. The provision of a government decree served as a basis for the intervention, covering planning of prison activities and post release arrangements including strategies for drug use cessation.
11524322|NCT01184586|Active Comparator|Intervention arm - ESWT Storz Duolith high energy|Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (STORZ DUOLITH, 1000 impulses, 0.55-0,8mJ/mm2)
11524323|NCT01184586|Sham Comparator|Control - SHAM ESWT STORZ DUOLITH [0.01mJ/mm2]|Three weekly sessions of sham extracorporeal shock wave with modified probe without shockwave transduction (1000 impulses)
11524324|NCT01184573||Mild to Moderate CP|Subjects must have a history compatible with chronic pancreatitis.
11524325|NCT01184573||Healthy Controls|Subjects must be in good health of greater than 18 years of age.
11524326|NCT01184560|Experimental|Sibutramine + Orlistat|"A lipase inhibitor used for weight loss. Lipase is an enzyme found in the bowel that assists in lipid absorption by the body. Orlistat blocks this enzyme, reducing the amount of fat the body absorbs by about 30%. It is known as a fat blocker. Because more oily fat is left in the bowel to be excreted, Orlistat can cause an oily anal leakage and fecal incontinence"
11524327|NCT01184560|Placebo Comparator|Sibutramine + Orlistat(Placebo)|"Sibutramine : one of components included into Diet Pills. This reduces appetite, normalizes amount of cholesterol in blood, and reduces abdominal fat.
~Orlistat : A lipase inhibitor used for weight loss. Lipase is an enzyme found in the bowel that assists in lipid absorption by the body. Orlistat blocks this enzyme, reducing the amount of fat the body absorbs by about 30%. It is known as a fat blocker. Because more oily fat is left in the bowel to be excreted, Orlistat can cause an oily anal leakage and fecal incontinence."
11524328|NCT01184547|Experimental|COMBEX|Community Based Exercise Program or exercise group and quality of life Intervention- The community-based exercise program consisted of 12 weeks of exercise with a community-based trainer after hospital discharge.
11524329|NCT01184547|Active Comparator|Standard Of Care|Standard of Care group, group with no exercise and quality of life. Intervention- No exercise training received.
11524330|NCT01184534||Questionnaires + Video|
11524331|NCT01184534||Questionnaires|
11524332|NCT01184521||pulse CO-oximeter|
11524333|NCT01184508|Experimental|LY2300559|
11524334|NCT01184508|Placebo Comparator|Placebo|
11524335|NCT01184495|Experimental|Epoetin Bio-Manguinhos|
11524336|NCT01184495|Active Comparator|EPO-BioSimilar|Subcutaneous administration of EPO-BioSimilar
11524337|NCT01184482|Experimental|Cetuximab and lapatinib|All patients will receive cetuximab by IB weekly and daily doses of lapatinib orally in 3 week cycles with response assessed every 2 cycles.
11524338|NCT01184469||Fresh embryo transfers|Patients who received fresh blastocyst transfer
11524339|NCT01184469||Thawed embryo transfers|Patients who received transfers of frozen/thawed embryos
11524340|NCT01184456|Experimental|GanedenBC30, GBI-30, PTA-6086|
11524341|NCT01184456|Placebo Comparator|Placebo|
11524342|NCT01184443|Experimental|Olanzapine|Those who choose to take olanzapine as part of their treatment (standard practice plus medication).
11524343|NCT01184443|No Intervention|Comparison|Those who choose not to take olanzapine as part of their treatment (standard practice).
11524344|NCT01184430|Active Comparator|advanced hemodynamic monitoring|advanced hemodynamic monitoring with pulse contour analysis ( LiDCO rapid) and goal-directed therapy
11524345|NCT01184430|No Intervention|standard monitoring|hemodynamic monitoring based on the standard operating procedures of our clinic
11524346|NCT01184417|Active Comparator|Phenobarbital group|10 mg/kg IV phenobarbital in 100 ml saline
11524347|NCT01184417|Placebo Comparator|Placebo group|100 ml saline
11524348|NCT01184404|Experimental|Treatment|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
11524349|NCT01184404|No Intervention|Control|
11524350|NCT01184391|Experimental|Test: Divalproex Sodium|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
11524351|NCT01184391|Active Comparator|Reference: Depakote Tablets|DEPAKOTE® Tablets, 500 MG Abbott Laboratories
11524352|NCT01184378|Placebo Comparator|control formula|formula containing only vegetable fats
11524353|NCT01184378|Experimental|new formula|new formula with dairy lipids and soluble milk proteins
11524354|NCT01184365|Experimental|EnMP-1|The goal of the EnMP-1 is to enable participants, through a behavioural, psycho-educational intervention, to better manage and understand their fatigue. This program is provided in four, two-hour sessions held weekly.
11524355|NCT01184365|Active Comparator|EnMP-2|The goal of the EnMP-2 is to control for group effects
11524356|NCT01184352||PCI patients treated with Glider Device|
11524357|NCT01184339||Standard of Care|Current practice methods for the determination of bacteremia, specific to site practice.
11524393|NCT01184092|Experimental|Sequence 2|
11524394|NCT01184092|Experimental|Sequence 3|
11524395|NCT01184092|Experimental|Sequence 4|
11524358|NCT01184339||Gold Standard ID/AST|"Identification of S. aureus: coagulase positive, catalase positive, Staphaurex positive, and PYR negative, if performed).
~Determination of MRSA:S. aureus gold standard and </=11mm OXA DD or </=21mm CFX DD.
~Determination of MSSA: S. aureus gold standard and >/=13mm OXA DD or >/=22mm CFX DD."
11524359|NCT01184326|Experimental|Dose Level 0: Everolimus 5mg + Pazopanib 600 mg|Everolimus 5mg + Pazopanib 600 mg once daily for 28 days each cycle Participants were treated until disease progression, unacceptable toxicity or patient withdrawal.
11524360|NCT01184326|Experimental|Dose Level -1: Everolimus 5mg + Pazopanib 400 mg|Everolimus 5mg + Pazopanib 400 mg once daily for 28 days each cycle Participants were treated until disease progression, unacceptable toxicity or patient withdrawal.
11524361|NCT01184326|Experimental|All Phase I Dose Expansion Participants|All phase I dose expansion participants received Everolimus 5mg and Pazopanib at the maximum tolerated dose established in the dose finding part of the study.
11524362|NCT01184326|Experimental|All Phase I Participants|All phase I participants received Everolimus 5mg and Pazopanib according to the established dose escalation schedule or the maximum tolerated dose established in the dose finding part of the study.
11524363|NCT01184313||aortic valve surgery|
11524364|NCT01184300|Experimental|Rapid Genotyping|Patients randomized to the Rapid Genotyping arm will have their CYP2C19*2 carrier status determined at the time of percutaneous coronary intervention with subsequent alteration in anti-platelet therapy for *2 carriers.
11524365|NCT01184300|No Intervention|Standard Therapy|Patients randomized to the Standard Therapy arm will not undergo genotyping at the time of percutaneous coronary intervention. All patients will receive clopidogrel 75 mg daily for 1 week. At the end of the 1 week period, their CYP2C19*2 carrier status will be verified.
11524366|NCT01184287|Experimental|ranpirnase|All patients who do not progress after two cycles of pemetrexed-carboplatin will receive the study drug, ranpirnase
11524367|NCT01184274|Experimental|SB939|
11524368|NCT01184261|Experimental|Arm I|Patients attend behavioral sessions for smoking and binge drinking cessation over 30 minutes once weekly in weeks 1-6.
11524369|NCT01184261|Experimental|Arm II|Patients attend behavioral sessions for smoking cessation over 30 minutes once weekly in weeks 1-6.
11524370|NCT01184235||Autism Spectrum Disorders|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is Autism Spectrum Disorder
11524371|NCT01184235||Attention Deficit Hyperactivity Disorder|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is Attention Deficit Hyperactivity Disorder.
11524372|NCT01184235||Unaffected 1st Degree Relatives|This group will include unaffected, non treated first degree relatives of this study's subjects receiving or anticipating receiving pharmacological intervention.
11524373|NCT01184235||Mood Disorders|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is mood disorder.
11524374|NCT01184222|Active Comparator|Arm Active SENGO|The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.
11524375|NCT01184222|Placebo Comparator|Arm sham SENGO|The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted.
11524376|NCT01184196|Active Comparator|Arm 1|Subjects randomized to Arm 1 will receive Betadine surgical scrub at the time of primary total knee arthroplasty.
11524377|NCT01184196|Active Comparator|Arm 2|Subjects in Arm 2 will receive ChloraPrep surgical scrub prior to elective primary total knee arthroplasty.
11524378|NCT01184183||Accuseal patch|
11524379|NCT01184183||Bovine Pericardial patch|
11524380|NCT01184170|Experimental|Metabolically Normal|"Subjects in this group are metabolically normal. They have low liver fat defined as less than five percent as determined by magnetic resonance spectroscopy.
~Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits."
11524381|NCT01184170|Experimental|Metabolically Abnormal|"Subjects in this group are metabolically abnormal. They have high liver fat defined as at least ten percent as determined by magnetic resonance spectroscopy.
~Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits."
11524382|NCT01184157|Experimental|Home|Home-based STI screening using self-obtained vaginal swabs and postal return of samples.
11524383|NCT01184157|Active Comparator|Clinic|Receive STI screening in a clinical setting such as a private physician or clinic.
11524384|NCT01184144|Experimental|pioglitazone|Pioglitazone study drug
11524385|NCT01184144|No Intervention|No drug|"Placebo like comparitor"
11524386|NCT01184131|Experimental|Mentor Training|The group that is randomized into the intervention group to attend Mentor Training Sessions.
11524387|NCT01184131|No Intervention|No Mentor Training|
11524388|NCT01184118|No Intervention|FP Discontinued|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
11524389|NCT01184118|Active Comparator|FP 220 mcg 2 puffs BID|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
11524390|NCT01184105|Experimental|Cohort 1 (pre)|Active treatment or placebo
11524391|NCT01184105|Experimental|Cohort 2 (post)|Active treatment or placebo
11524398|NCT01184079|Experimental|12 months|Administration of 3rd dose at 12 months quadrivalent human papillomavirus vaccine
11524399|NCT01184079|Active Comparator|6 month|Administration of 3rd dose at 6 months quadrivalent human papillomavirus vaccine
11524400|NCT01184066|Experimental|ACTS Intervention|The intervention arm are the women who received the ACTS Intervention. It is a 45 minute intervention provided by a breast cancer survivor. The intervention includes a discussion of the patient's attitudes towards chemotherapy, communication strategies with providers, the recommended treatment in accordance with tumor size and tumor characteristics
11524401|NCT01184066|Active Comparator|Usual Care|This group receives care as usual.
11524402|NCT01184053|Experimental|Trisenox treatment|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
11524403|NCT01184040|No Intervention|(A) Non-contingent control|Participants assigned to the control condition will be told to wear the pedometer daily and select a twice-weekly meeting schedule with research staff for 12 weeks (study weeks 4-15). On days randomly selected as meeting days, participants will be asked to bring in their pedometers. Participants who attend their scheduled meetings will receive a $5 gift card just for attending and bringing the pedometer, so long as it has registered steps walked in at least the past 4 days. They will be congratulated if they walked 10,000 steps or more on the prior 4 days, and encouraged to walk 10,000 steps or more per day on subsequent days.
11524404|NCT01184040|Experimental|VIP CM|Participants assigned to Increasing Variable Interval Prize (VIP) Reinforcement group will be scheduled for the same study visits as those in the Control group, but will also earn chances to win prizes if they have walked more than 10,000 steps in the past 4 days.
11524405|NCT01184027||G-tube/swallowing intervention|patients will receive G-tube/nutritional and swallowing intervention. As per patient needs
11524406|NCT01184027||G-tube/swallowing counseling|G-tube/ad lib dietary and swallowing counseling. Current standard of care.
11524407|NCT01184027||nutrition/swallowing intervention|Patients will receive active nutrition and swallowing intervention based on patients caloric and swallowing needs.
11524408|NCT01184027||nutrition/swallowing counseling|Patients will have ad lib dietary intake with general nutrition and swallowing counseling.
11524409|NCT01184014|Experimental|Experimental group|a study-specific steroid (NPH) dosing algorithm plus standard recommended care. The intervention is Neutral Protamine Hagedorn (NPH) insulin plus complete insulin orders (CIO).
11524410|NCT01184014|Active Comparator|Control group|the standard recommended care (Methodist Hospital Complete Insulin Orders)
11524411|NCT01184001|Experimental|Sequence 1|
11524412|NCT01184001|Experimental|Sequence 2|
11524413|NCT01183975||Patients treated with SAGB by solicited teams|Patients treated with SAGB by solicited teams. No selection criteria at cohort inclusion applied to the 500 (+50) first patients treated in order to ensure consecutive and exhaustive recruitment in the concerned centers over the inclusion period.
11524414|NCT01183962|Other|Vitamin D|Subject receives daily dose of Vitamin D
11524415|NCT01183962|Other|No medicine|Subject does not receive medication
11524416|NCT01183949|Experimental|Treatment|Patients will be enrolled into 3 groups which will run sequentially. Groups A and B will receive AT7519M only, whereas Group C will receive AT7519M in combination with Bortezomib.
11524417|NCT01183936|Active Comparator|2 cm margin of excision|Patients with CMM >2 mm treated with an excision of 2-cm.
11524418|NCT01183936|Active Comparator|4 cm margin of excision|Patients with CMM >2 mm treated with an excision of 4-cm.
11524419|NCT01183923|Experimental|Broccoli Sprouts, then Alfalfa Sprouts|Broccoli Sprout sandwich/wrap will be eaten daily for 7 consecutive days followed by alfalfa sprouts after washout.
11524420|NCT01183923|Experimental|Alfalfa Sprouts, then Broccoli Sprouts|Alfalfa Sprout sandwich/wrap will be eaten daily for 7 consecutive days followed by broccoli sprouts after washout.
11524421|NCT01183910|Placebo Comparator|Calcium carbonate placebo pill|Placebo medication to treat the appearance of the skin in patients with senile purpura
11524422|NCT01183910|Active Comparator|Nutraceutical|Patients take a novel, natural nutraceutical product to improve the appearance of the skin of patients with senile purpura
11524423|NCT01183897|Experimental|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|This phase II study of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response in of primary refractory neuroblastoma in bone marrow (i.e., incomplete response to standard treatment).
11524424|NCT01183884|Experimental|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles.
11524425|NCT01183871|Active Comparator|good pulmonary functions (group 1)|FVC and/or FEV1 of 80% of predicted or more
11524426|NCT01183871|Active Comparator|mild pulmonary dysfunction (group 2)|FVC and/or FEV1 of 70%-79% of predicted
11524427|NCT01183871|Active Comparator|moderate pulmonary dysfunction (group 3)|FVC and/or FEV1 of 60%-69% of predicted
11524428|NCT01183871|Active Comparator|severe pulmonary dysfunction (group 4)|FVC and/or FEV1 of 50%-59% of predicted
11524429|NCT01183858|Experimental|Erlotinib 150 mg|Erlotinib 150 mg single daily oral dose until disease progression.
11524430|NCT01183858|Experimental|Erlotinib 300 mg|Erlotinib 300 mg single daily oral dose until disease progression.
11524431|NCT01183845|Experimental|Exam with colon capsule|Colon Capsule Endoscopy
11524432|NCT01183832||Concomitant|In this group, anastrazole is concomitant to the radiotherapy
11524433|NCT01183832||Sequential|In this group, anastrazole is sequential to the radiotherapy (start after the end of radiotherapy)
11524434|NCT01183819|Experimental|Space Fortress and Exercise|Participants engage in aerobic exercise 4 times week and Space Fortress sessions 3 times a week for a total of 12 weeks.
11524435|NCT01183819|Active Comparator|Control Games and Exercise|Participants engage in aerobic exercise 4 times a week and control game sessions 3 times a week for a total of 12 weeks.
11524436|NCT01183819|Active Comparator|Control Games and Stretching|Participants engage in stretching/toning exercises 4 times a week and control game sessions 3 times a week for a total of 12 weeks.
11524437|NCT01183806|Experimental|Rivastigmine and exercise program|Experimental group: Rivastigmine and exercise program: All patients will monthly receive Rivastigmine (Exelon patch). The exercise training program consists of two 40-minute sessions per week for six months and includes aerobic, strength, flexibility and balance training
11524438|NCT01183806|Active Comparator|Rivastigmine|Control group : Rivastigmine All patients will monthly receive Rivastigmine (Exelon patch)
11524439|NCT01183793|Other|Bras pair|MR-enterography then barium follow through
11524440|NCT01183793|Other|Bras impair|Barium follow-through then MR-enterography
11524441|NCT01183780|Experimental|FOLFIRI + Ramucirumab|
11524442|NCT01183780|Placebo Comparator|FOLFIRI + Placebo|
11524443|NCT01183767|Active Comparator|EGCG|Epigallocatechin-Gallate (EGCG)
11524444|NCT01183767|Placebo Comparator|Placebo|
11524445|NCT01183754||patients receiving drug-eluting stents|
11524446|NCT01183728|Experimental|MSV autologous transplantation|Bone marrow collected from patient will be used for mesenchymal stem cells isolation and expansion under GMP conditions at IBGM-Valladolid (MSV). Autologous MSV implanted in knee by articular injection
11524447|NCT01183715|Experimental|Cohort 1|Subjects in Cohort 1 will receive 2 single doses of PF-05161704 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-05161704 will be administered in Period 4 in the fasted state.
11524448|NCT01183715|Experimental|Cohort 2|Subjects in Cohort 2 will receive 2 single doses of PF-05161704 and 1 placebo dose in random order in Periods 1-3
11524449|NCT01183702|Active Comparator|non-LASIK|These participants have NOT had LASIK surgery.
11524450|NCT01183702|Active Comparator|LASIK|These participants have had LASIK surgery.
11524451|NCT01183689|No Intervention|Control Group|"Self-Guided Behavior Changes. This group will be used to determine average rate of weight gain over 3 years with little intervention. Participants randomized to this group will receive one face-to-face session that will provide general education of self-weighing and information about both the small and large changes approach. Participants will also be provided with quarterly newsletters describing study events and very limited information on health eating."
11524452|NCT01183689|Experimental|Small behavior changes|Participants randomized to this group will be taught to self-weigh daily and report weights regularly. They will be reinforced for maintaining weight below randomization weight and taught that if weight exceeds randomization weight, they should reinstate small changes (e.g., modify diet by approximately 100 kcal, decrease portion sizes or change types of food, increase activity by 2000 steps/day).
11524453|NCT01183689|Experimental|Large behavior changes|Participants randomized to this group will be taught to self-weigh daily and report weights regularly. They will be reinforced for maintaining weight below randomization weight and taught that if weight exceeds randomization weight, they should reinstate large changes (e.g., modify diet to 1200-1500 or 1500-1800 kcal/day with < 30% fat, increase exercise to 250 minutes/week of moderate intensity activity).
11524454|NCT01183676|Experimental|Divalproex Sodium|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG - Mylan Pharmaceuticals Inc
11524455|NCT01183676|Active Comparator|Depakote Tablets|DEPAKOTE® Tablets, 500 MG Abbott Laboratories
11524456|NCT01183663|Experimental|Lenalidomide + Bevacizumab|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Bevacizumab starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
11524457|NCT01183663|Experimental|Lenalidomide + Sorafenib|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Sorafenib starting dose: 200 mg by mouth daily for 28 a day cycle.
11524458|NCT01183663|Experimental|Lenalidomide + Temsirolimus|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Temsirolimus starting dose: 15 mg by vein every week for a 28 day cycle.
11524459|NCT01183663|Experimental|Lenalidomide + Oxaliplatin + Leucovorin + 5-fluorouracil|Lenalidomide starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle. Oxaliplatin starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle. Leucovorin 400 mg/m2 by vein on day 1 of a 21 day cycle. 5-fluorouracil 400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.
11524460|NCT01183650|Experimental|Tadalafil|5 mg, administered orally, daily for 10 days
11524461|NCT01183637|Experimental|Treatment|Patients assigned to the treatment arm will receive treatment with the Kensey Nash Corp. Cartilage Repair Device.
11524462|NCT01183637|Active Comparator|Control|Patients assigned to the Control Arm will receive treatment with the standard surgical technique known as microfracture.
11524463|NCT01183624|Experimental|Experimental Patch|Herbal Patch
11524464|NCT01183624|Placebo Comparator|Control Patch|Placebo Patch
11524465|NCT01183611|Experimental|A1|health neonates born to mother with positive for both HBsAg and e antigen
11524466|NCT01183611|Active Comparator|A2|health neonates born to mother with positive for both HBsAg and e antigen
11524467|NCT01183611|Experimental|B1|health neonates born to a mother positive for HBsAg, negative for the hepatitis B e antigen
11524468|NCT01183611|Active Comparator|B2|health neonates born to a mother positive for HBsAg, negative for the hepatitis B e antigen
11524469|NCT01183611|Experimental|C1|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
11524470|NCT01183611|Active Comparator|C2|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
11524471|NCT01183611|Placebo Comparator|C3|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
11524472|NCT01183598|Experimental|Single Arm|
11524473|NCT01183585|Experimental|1|
11524474|NCT01183572|Active Comparator|Folic Acid and Iron|0.4mg of folic acid and 30 mg elemental iron taken daily for 6 months
11524475|NCT01183572|Placebo Comparator|Folic Acid|0.4mg of folic acid taken daily for 6 months
11524476|NCT01183572|Active Comparator|Multivitamins, Folic Acid, and Iron|A multivitamin and micronutrient supplement that constitutes 1 RDA of Vitamins A (2500 IU), B1 (1.4 mg), B2 (1.4 mg), B6 (1.9 mg), B12 (2.6 ug), niacin (18 mg), C (70 mg), E (10 mg), and folic acid (0.4 mg)along with 30 mg of elemental iron taken daily for 6 months.
11524477|NCT01183546||Wheelchair Users with Spinal Cord Injury|wheelchair users with spinal cord injury
11524478|NCT01183533|Experimental|off label rt-PA used|off label rt-PA used on all subject enrolled within 3 hours of waking with stroke symptoms at the standard of care dose.
11524566|NCT01182870|Experimental|cholecalciferol|cholecalciferol in doses 800-6000 IU per day
11524479|NCT01183520|Active Comparator|90 grams of Salmon|Subjects will consume 90 grams of salmon twice a week for 4 weeks
11524480|NCT01183520|Active Comparator|180 grams of salmon|Subjects will consume 180 grams of salmon twice a week for 4 weeks
11524481|NCT01183520|Active Comparator|270 Grams of Salmon|Subjects will consume 270 grams of salmon twice a week for 4 weeks
11524482|NCT01183507|Active Comparator|NIA intervention|
11524483|NCT01183507|Experimental|TSE intervention|
11524484|NCT01183494|Experimental|UGT1A1*1/*1|Participants with UGT1A1*/*1 genotype will receive escalating doses of FOLFIRI (folinic acid+fluorouracil+irinotecan) and bevacizumab. The initial dose of irinotecan will be 260 mg/m2 administered as a 120 min intravenous infusion every two weeks. The dosage of irinotecan will be increased to 310, 370, and 420 mg/m2, and further irinotecan doses will be increased by 14%. 5-FU will be administered as a 400 mg/m2 bolus right after the end of the irinotecan infusion, followed by 2,400 mg/m2 over a 46 h continuous infusion plus LV 200 mg/m2 every two weeks. Bevacizumab will be administered at a dose of 5 mg/kg over 15-30 min IV (after an initial 90 min infusion without a reaction) every two weeks. The first dose will be administrated on day 2 (48 hours after the first irinotecan administration), while the second dose on day 14 (the same day as the second irinotecan administration). No dose escalation will be performed for 5-FU, LV or bevacizumab.
11524485|NCT01183494|Experimental|UGT1A1*1/*28|Participants with UGT1A1*1/*28 genotype will receive escalating doses of FOLFIRI (folinic acid+fluorouracil+irinotecan) and bevacizumab. The initial dose of irinotecan will be 260 mg/m2 administered as a 120 min intravenous infusion every two weeks. The dosage of irinotecan will be increased to 310, 370, and 420 mg/m2, and further irinotecan doses will be increased by 14%. 5-FU will be administered as a 400 mg/m2 bolus right after the end of the irinotecan infusion, followed by 2,400 mg/m2 over a 46 h continuous infusion plus LV 200 mg/m2 every two weeks. Bevacizumab will be administered at a dose of 5 mg/kg over 15-30 min IV (after an initial 90 min infusion without a reaction) every two weeks. The first dose will be administrated on day 2 (48 hours after the first irinotecan administration), while the second dose on day 14 (the same day as the second irinotecan administration). No dose escalation will be performed for 5-FU, LV or bevacizumab.
11524486|NCT01183481|Experimental|Aprepitant and Granisetron|Patients will be given a single dose of Granisetron 2 mg orally and Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the Palliative radiation therapy.
11524487|NCT01183468|Experimental|Part 1a(Aralast NP)-Subjects Aged 16-35 Yrs|Subjects aged 16-35 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by intravenous (IV) infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
11524488|NCT01183468|Experimental|Part 1a (Aralast NP)-Subjects 8-15 Yrs|Subjects aged 8-15 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
11524489|NCT01183468|Experimental|Part 1b (Aralast NP)--Subjects Aged 18-35 Yrs|Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.
11524490|NCT01183468|Experimental|Part 1b (Aralast NP)-Subjects 8-17 Yrs|Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.
11524491|NCT01183455|Experimental|Aralast NP|Participants will receive Aralast NP (90mg/kg) intravenously once a week for 12 weeks.
11524492|NCT01183455|Placebo Comparator|Placebo|Participants will receive placebo intravenously once a week for 12 weeks.
11524493|NCT01183442|Active Comparator|vitamin D (Oleovit®)|vitamin D drops
11524494|NCT01183442|Placebo Comparator|Placebo|placebo drops
11524495|NCT01183429|Experimental|3F8 and 13-cis-retinoic acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(8), patients no longer receive high dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles.
11524496|NCT01183416|Experimental|3F8 monoclonal antibody and 13-cis-Retinoic Acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. The patients are post-transplant and in 1st complete/very good partial remission (CR/VGPR),89 with no evidence of NB by standard studies, but are at high risk for relapse.
11524497|NCT01183390|Experimental|Investigational Test Product|Anastrozole 1 mg Tablets
11524498|NCT01183390|Active Comparator|Reference Listed Drug|Arimidex® 1 mg Tablets
11524499|NCT01183377||1|Female athlete Triad syndrom was based on menstrual disorder,Eating Disorder and bone loss
11524500|NCT01183364|Experimental|STA-9090 and Docetaxel|STA-9090 (ganetespib) and Docetaxel
11524501|NCT01183351|Experimental|Psychosocial intervention|This is a single-group pilot-study
11524502|NCT01183325|Experimental|Proceed Ventral Patch placement|Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
11524503|NCT01183312|Experimental|Placebo, then Flumazenil|Subjects in this arm will first receive a day of placebo, then a day of sublingual flumazenil
11524504|NCT01183312|Experimental|Flumazenil, then Placebo|Subjects in this group will first receive a day of sublingual flumazenil, then a day of placebo.
11524505|NCT01183299|Active Comparator|High salt intake|
11524506|NCT01183299|Placebo Comparator|Low salt intake|
11524507|NCT01183286|Active Comparator|CFFONE|
11524508|NCT01183286|Placebo Comparator|CF website|
11524509|NCT01183273|Active Comparator|Micro-laparoscopic bypass|
11524510|NCT01183273|Active Comparator|Laparoscopic gastric bypass|
11524511|NCT01183260|Experimental|Trabecular Metal Revision Cup|Patients randomized to this arm will receive a trabecular metal revision component which does not have a titanium inner surface and requires a cemented highly crosslinked polyethylene liner.
11524512|NCT01183260|Active Comparator|Trabecular Metal Modular Cup|Patients randomized to this arm will receive a trabecular metal modular component which has a titanium inner surface and requires a non-cemented highly crosslinked polyethylene liner.
11524513|NCT01183247|Active Comparator|Rapamycin|Rapamycin-MMF-tacrolimus
11524514|NCT01183247|Active Comparator|Everolimus|Everolimus - tacrolimus - MMF
11524515|NCT01183247|Active Comparator|Prednisone|tacrolimus - MMF -prednisone
11524516|NCT01183234|Experimental|SPD544 (Equasym XL)|
11524517|NCT01183234|Experimental|Methylphenidate hydrochloride (Metadate CD )|
11524518|NCT01183221|Experimental|placebo spray|
11524519|NCT01183208|Experimental|Cohort 1 active treatment and placebo|Active treatment and placebo
11524520|NCT01183208|Experimental|Cohort 2 - Active treatment and placebo|Active treatment and placebo
11524521|NCT01183208|Experimental|Cohort 3 Active Treatment and placebo|Active treatment and placebo
11524522|NCT01183182|Experimental|Needle Guidance|Lung biopsies performed with the needle guidance system.
11524523|NCT01183169|Experimental|Treatment A: ALV 600 mg QD|Alisporivir (ALV) 600 mg once daily (QD) with Peginterferon alfa-2a (PEG) and Ribavirin (RBV) for up to 48 weeks
11524524|NCT01183169|Experimental|Treatment B: ALV 800 mg QD|Alisporivir (ALV) 800 mg QD with PEG and RBV for up to 48 weeks
11524525|NCT01183169|Experimental|Treatment C1: ALV Placebo - 600 mg QD|ALV Placebo with PEG and RBV for up to 48 weeks; participants not achieving complete early virologic response (cEVR) after 12 weeks of treatment may switch to active ALV 600 mg QD with PEG and RBV.
11524526|NCT01183169|Experimental|Treatment C2: ALV Placebo - 400 mg BID|ALV Placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR after 12 weeks of treatment may switch to active ALV 400 mg twice daily (BID) with PEG and RBV.
11524527|NCT01183169|Experimental|Treatment D: ALV 400 mg BID|Alisporivir (ALV) 400 mg twice daily BID with PEG and RBV for up to 48 weeks
11524528|NCT01183156|Active Comparator|Re-invitation letter|
11524529|NCT01183156|Active Comparator|Educational Meeting|
11524530|NCT01183143|Experimental|GONAL-f®|
11524531|NCT01183130|Experimental|Compliance monitoring in real time|Patients get their opioid substitution medications in electronic compliance monitoring devices and send information of their medication intakes with mobile phone to the clinic every day during the two month study period.
11524532|NCT01183130|Active Comparator|Compliance monitoring|Patients get their opioid substitution medications in electronic compliance monitoring devices. Information of their medication intakes will be reviewed during the weekly visits to the clinic.
11524533|NCT01183117|Experimental|SM-01|
11524534|NCT01183117|Active Comparator|PTA|
11524535|NCT01183104|Experimental|Sitagliptin|
11524536|NCT01183104|Active Comparator|Glimepiride|
11524537|NCT01183091||First AF ablation|Description of the patients experiencing an AF ablation
11524538|NCT01183078|Other|Free-hand technique|Free-hand technique utilized to find screw holes.
11524539|NCT01183078|Other|Wand technique|Wand technique is utilized to find screw holes.
11524540|NCT01183065|Experimental|pralatrexate and vitamin supplementation|This will be an open-label, single arm, Simon optimal two-stage design phase II study.
11524541|NCT01183052|Other|Training|20 sessions of training
11524542|NCT01183039|Active Comparator|Ventilatory threshold|Training at the ventilatory threshold
11524543|NCT01183039|Active Comparator|Metabolic threshold|Training at the metabolic threshold
11524544|NCT01183013|Active Comparator|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily
11524545|NCT01183013|Active Comparator|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily
11524546|NCT01183013|Active Comparator|Pioglitazone 45 mg|Pioglitazone Capsules 45 mg once daily
11524547|NCT01183013|Active Comparator|Linagliptin 5mg|Linagliptin 5mg Tablets once daily
11524548|NCT01183013|Experimental|Linagliptin 5mg / Pioglitazone 15 mg|Linagliptin 5mg / Pioglitazone 15 mg Tablets once daily
11524549|NCT01183013|Experimental|Linagliptin 5mg / Pioglitazone 30 mg|Linagliptin 5mg / Pioglitazone 30 mg Tablets once daily
11524550|NCT01183013|Experimental|Linagliptin 5mg / Pioglitazone 45 mg|Linagliptin 5mg / Pioglitazone 45 mg Tablets once daily
11524551|NCT01183000|Active Comparator|peritoneal closure|
11524552|NCT01183000|No Intervention|Non closure of the peritoneum|
11524553|NCT01182987|Active Comparator|Dementia care management|Patients and family caregivers will be offered dementia care management, which includes detailed comprehensive assessment, education, counseling, referrals to community agencies, collaboration with medical providers and frequent telephone follow-up
11524554|NCT01182987|No Intervention|Usual care|Patients and care family care givers will receive usual support and medical care offered by the health plan.
11524555|NCT01182974|Active Comparator|paracetamol treatment|
11524556|NCT01182974|Active Comparator|control- dypirone treatment|
11524557|NCT01182961|Experimental|Treadmill +virtual reality training|
11524558|NCT01182961|Active Comparator|Treadmill alone|
11524559|NCT01182961|Active Comparator|standard of care exercise group|
11524560|NCT01182948|Experimental|Aerobic Exercise|The aerobic training group will use cardiovascular training devices.
11524561|NCT01182948|Experimental|Resistance Exercise|The resistance training group will perform exercises on weight machines and free weights.
11524562|NCT01182935||participants in the 4th Tromsø study|
11524563|NCT01182922|Active Comparator|Doctor's Information Invitation|Standard invitation with additional leaflet containing information concerning particular doctor performing the examination, that is: his personal data (name, surname, academic title, workplace, picture) and data concerning experience and achievements of the center where he is employed.
11524564|NCT01182922|Active Comparator|Gender Preference Invitation|Standard invitation with additional information about possibility of choosing doctor's gender, mentioned below proposed date of examination
11524565|NCT01182922|Active Comparator|Standard Invitation|Standard invitation without additional information about a doctor or possibility of choosing doctor's gender.
11524567|NCT01182870|Placebo Comparator|placebo|placebo identical looking as cholecalciferol capsules
11524568|NCT01182844|No Intervention|Control|Usual care
11524569|NCT01182844|Experimental|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
11524570|NCT01182831|Active Comparator|percutaneous fluoro guided celiac plexus neurolysis|
11524571|NCT01182831|Active Comparator|EUS guided neurolysis|
11524572|NCT01182818||Observation|all adult patients (18 - 60 years of age) with an acute cerebrovascular event of any etiology
11524573|NCT01182805|Other|Single arm study.|
11524574|NCT01182792|Experimental|Antioxidant|
11524575|NCT01182792|Placebo Comparator|Control|
11524576|NCT01182779|Experimental|A|"Arm A (carbon ion therapy):
~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E."
11524577|NCT01182779|Active Comparator|B|"Arm B (proton therapy):
~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E."
11524578|NCT01182766|Experimental|topiramate|topiramate with brief behavioral enhancement therapy
11524579|NCT01182766|Placebo Comparator|Placebo|Placebo with brief behavioral enhancement therapy
11524580|NCT01182753|Experimental|A|"Arm A (carbon ion therapy):
~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E."
11524581|NCT01182753|Active Comparator|B|"Arm B (proton therapy):
~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E."
11524582|NCT01182740||glidescope|
11524583|NCT01182740||storz c-mac|
11524584|NCT01182740||mcgrath vl|
11524585|NCT01182740||ambu pentax aws|
11524586|NCT01182740||macintosh laryngoscope|
11524587|NCT01182740||others|
11524588|NCT01182727|Experimental|salsalate|Salsalate will be administered in two divided doses of 2grams in the morning and 2 grams in the evening. Salsalate will be administered for 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until a tolerated dose or a minimum dose of 2 grams per day is reached.
11524589|NCT01182714|Other|removal of catheter|
11524590|NCT01182701|Active Comparator|Behavioral intervention|
11524591|NCT01182701|No Intervention|Education support|
11524592|NCT01182675|Experimental|T-cell Graft Permissive SCID|"Patients with SCID with:
~i. NK- phenotype; ii. NK+ phenotype with 10/10 HLA-matched relative or unrelated donor; or iii. NK+ phenotype with maternal engraftment by STR analysis and undergoing haplocompatible HSCT from maternal donor Intervention: Transplant Conditioning with Mobilization Only"
11524593|NCT01182675|Experimental|T-cell Graft Resistant SCID|Patients with SCID with NK+ phenotype with HLA-mismatched donor Intervention: Transplant Conditioning with Mobilization and Alemtuzumab
11524594|NCT01182662|Experimental|Human umbilical cord-derived MSCs and cyclosporin|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated to apply in trimonthly for 2 cycle and CsA 5mg/kg po for 12 months
11524595|NCT01182662|Active Comparator|cyclosporine A|cyclosporine A at a dose of 5 mg CsA/kg
11524596|NCT01182649|Experimental|EES Group|Patients who received an everolimus eluting stent
11524597|NCT01182649|Active Comparator|SES Gruop|Patients who received a sirolimus eluting stent
11524598|NCT01182636|Experimental|Investigational Test Product|Adapalene Topical Gel, 0.1%
11524599|NCT01182636|Active Comparator|Reference Listed Drug|Differin® (adapalene 0.1%) Topical Gel
11524600|NCT01182636|Placebo Comparator|Placebo|Gel base only
11524601|NCT01182623||In vivo diagnosis|Patients undergoing colonoscopy where one or more polyps up to 10mm in size are found.
11524602|NCT01182610|Experimental|Treatment group|"Panitumumab 9mg/kg on Days 1, 22, and 43
~Paclitaxel 200mg/m2 on Days 1 and 22
~Carboplatin AUC=6 on Days 1 and 22
~5FU 225mg/m2/day on Days 1-15 and 22-36"
11524603|NCT01182597|Active Comparator|IV PPI|Pantoprazole 3.3mg/hr for 72hrs
11524604|NCT01182597|Experimental|Oral PPI|Lansoprazole (Takepron OD) 30mg PO q12h
11524605|NCT01182584||Graves' disease|
11524606|NCT01182584||Healthy volunteers|
11524607|NCT01182571||heart transplantation|
11524608|NCT01182558|Other|Activation of Hypothenar Eminence|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
11524609|NCT01182558|Other|Activation of Thenar Eminence|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
11524610|NCT01182558|Other|Activation of Extensor Digitorum Brevis|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
11524611|NCT01182558|Placebo Comparator|Maintain Relaxation of the Opposite Side|While the muscle of the right side is activated periodically and the compound muscle action potential is tested frequently, the muscle on the left side is maintained at rest and the compound muscle action potential is tested infrequently.
11524612|NCT01182545|Placebo Comparator|The normoventilation group|15 minutes prior to CO2 insufflation, the patients' lungs were ventilated with a tidal volume (TV) of about 8 mL.kg-1 and respiratory rate (R.R) owas adjusted to maintain an end-tidal CO2 (ETCO2) of 4.6-6 kPa throughout the procedure.
11524613|NCT01182545|Active Comparator|The hyperventilation group|15 minutes prior to CO2 insufflation, the patients' lungs were ventilated with a TV of 8 mL.kg-1 with the adjustment of the R.R to maintain an ETCO2 of 4-4.6 kPa, until the end of anaesthesia.
11524614|NCT01182532|Active Comparator|Western therapy|
11524615|NCT01182532|Experimental|TCM treatment|
11524616|NCT01182532|Experimental|Western therapy plus TCM treatment|The combination of both western therapy and TCM treatment.
11524617|NCT01182519||Diagnosed with metastatic breast cancer|"The primary objective of this study is to examine the association between urinary PGE-M and the presence or absence of lung metastases in patients with breast cancer. These patients will be subdivided into a set with lung metastases (group 1A; clinically assessed as per guidelines below) versus those with no evidence of lung metastases (group 1B; no known lung metastases). Group #2 (control) will have been treated for early stage breast cancer and will have no known metastases."
11524618|NCT01182519||History of early breast cancer|History of early breast cancer and currently no evidence of disease
11524619|NCT01182506|Experimental|Breast cancer survivors|Participants from both groups will be asked to complete two follow up neurocognitive assessments face to face at MSKCC. The first will be completed within 1-4 weeks after completing the memory training and the second will take place 3-4 months after completing the memory training. Collateral sources will be contacted at these same points to complete their brief assessments as well to test for maintenance of the treatment effect.
11524620|NCT01182506|Experimental|Collateral source|Participants from both groups will be asked to complete two follow up neurocognitive assessments face to face at MSKCC. The first will be completed within 1-4 weeks after completing the memory training and the second will take place 3-4 months after completing the memory training. Collateral sources will be contacted at these same points to complete their brief assessments as well to test for maintenance of the treatment effect.
11524621|NCT01182493|Experimental|Insulin Pump Treatment|Patients will get an insulin pump
11524622|NCT01182493|No Intervention|Insulin treatment with MDI|patients treated with Multiple Daily Injections (MDI); basal/bolus therapy with rapid- and long-acting analogs with at least 3 injections per day
11524623|NCT01182467||Crohn's disease|Patients will receieve Radiation: PET-CT scan
11524624|NCT01182441|Experimental|WATCHMAN|Subjects assigned to receive the WATCHMAN device.
11524625|NCT01182441|Active Comparator|Warfarin|Subjects assigned to warfarin therapy.
11524626|NCT01182428|Experimental|XIENCE V® / XIENCE PRIME™|
11524627|NCT01182428|Active Comparator|CYPHER SELECT|
11524628|NCT01182415|Experimental|High-dose chemotherapy with autologous stem cell transplant|
11524629|NCT01182402|Experimental|Electronic compliance monitoring|Suboxone treated patients in Kuopio city area get their unsupervised Suboxone doses in electronic compliance monitoring devices during the 4 month study.
11524630|NCT01182389|Active Comparator|robotic VT Ablation|Robotic VT ablation by substrate elimination
11524631|NCT01182389|Active Comparator|Conventional therapy|review of ICD programming to ensure that detection and therapy will occur appropriately.
11524632|NCT01182376|Placebo Comparator|Placebo|Half of the patients will be assigned placebo.
11524633|NCT01182376|Experimental|Multaq® (dronedarone)|Half of the patients will be prescribed dronedarone.
11524634|NCT01182363|No Intervention|Control|Usual early intervention services
11524635|NCT01182363|Experimental|Problem Solving Education|
11524636|NCT01182350|Experimental|radiation + bevacizumab|"Cohort 1: MGMT-/EGFR-
~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).
~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy
~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles"
11524637|NCT01182350|Experimental|radiation + bevacizumab + erlotinib|"Cohort 2: MGMT-/EGFR+
~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).
~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy
~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles
~Erlotinib: Administered orally at 85 mg/m2 daily continuously during radiation therapy, through the interim period and for up to 10 maintenance cycles"
11524638|NCT01182350|Experimental|radiation + bevacizumab + temozolomide|"Cohort 3. MGMT+/EGFR-
~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).
~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy
~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles
~Temozolomide: Administered orally at 90 mg/m2/day continuously during radiation therapy, held through the interim period and then 200 mg/m2/day for 5 days for up to 10 maintenance cycles"
11524639|NCT01182350|Experimental|radiation + bevacizumab + erlotinib + temozolomide|"Cohort 4. MGMT+/EGFR+
~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).
~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy
~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles
~Erlotinib: Administered orally at 85 mg/m2 daily continuously during radiation therapy, through the interim period and for up to 10 maintenance cycles"
11524640|NCT01182337|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
11524641|NCT01182337|Placebo Comparator|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
11524642|NCT01182311||Controls|Never received HBV vaccine and never had HBV
11524643|NCT01182311||HIV vaccinated >= 10 years|Well compensated HIV disease, vaccinated HBV >= 10 years ago
11524731|NCT01181700|Experimental|Treatment C|
11524644|NCT01182311||Spontaneously recovered >= 10 years|Spintaneously recovered from acute HBV >= 10 years ago
11524645|NCT01182311||Vaccinated >= 20 years|Vaccinated against HBV >= 20 years ago
11524646|NCT01182311||Vaccinated 10 < 15 years|Vaccinated against HBV 10 < 15 years ago
11524647|NCT01182311||Vaccinated 15 < 20 years|Vaccinated against HBV 15 < 20 years ago
11524648|NCT01182298||Hepatitis C|latino participants with Hepatitis C
11524649|NCT01182285|Experimental|A - Phase I Radioiodine-Resistant|Drug: Valproic Acid Week 1 - 10 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening
11524650|NCT01182285|Active Comparator|B1 - Phase 2 Schedule 1|Drug: Valproic Acid Week 11 - 17 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening Drug: Cytomel (25 micrograms) Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Liothyronine Sodium (Cytomel) for 4 weeks (25 micrograms twice a day)
11524651|NCT01182285|Active Comparator|B2 - Phase 2 Schedule 2|Drug: Valproic Acid Week 11 - 52 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening Weeks 17-52: Patients who show a response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria or have a decreased thyroglobulin level from Day 1 of the treatment (registered as a partial response to the treatment) will continue on valproic acid at their current dose for a total of 52 weeks.
11524652|NCT01182246|Experimental|AXP107-11|
11524653|NCT01182233|Experimental|Total Skeletal Irradiation|Three subjects determined to be eligible for study and agree to participate are assigned to receive 200 cGy of TSI-HT for 5 days. If this dose level is well tolerated in the first 3 subjects, the dose will be increased and given over 5 days. The dose will continue to be increased until the maximum toelrated dose is reached.
11524654|NCT01182220||Ultrasound L5/S1 catheter placement|Pt will have back scanned with Ultrasound and L5/S1 interspace localized for epidural placement.
11524655|NCT01182220||Control Group|Patients will have catheter placed after clinically evaluating the back as is done routinely resulting in mid lumbar catheter placement in general.
11524656|NCT01182207|Experimental|Investigational Test Product|Drospirenone/Ethinyl Estradiol Tablets, 3 mg/0.02 mg
11524657|NCT01182207|Active Comparator|Reference Listed Drug|YAZ® Tablets, 3 mg/0.02 mg
11524658|NCT01182194|Experimental|Investigational Test Product|Drospirenone/Ethinyl Estradiol Tablets, 3 mg/0.02 mg
11524659|NCT01182194|Active Comparator|Reference Listed Drug|YAZ® Tablets, 3 mg/0.02 mg
11524660|NCT01182181|Experimental|Investigational Test Product|Anastrozole Tablets, 1 mg
11524661|NCT01182181|Active Comparator|Reference Listed Drug|Arimidex® Tablets, 1 mg
11524662|NCT01182168|Experimental|gemcitabine and cisplatin plus Everolimus|This is a single-institution phase I study of gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001) in patients with advanced urothelial cancer.
11524663|NCT01182142|Experimental|Capecitabine|All patients will receive capecitabine.
11524664|NCT01182129|Active Comparator|Swedish Snus Type 1|The subject keeps one pouch of snus still between the upper lip and the gum for 30 minutes. Amount of nicotine extracted, plasma nicotine concentration at 30 minutes (C30), Tmax, Cmax, AUCinf and heart rate for each treatment.
11524665|NCT01182129|Active Comparator|Swedish Snus Type 2|The subject keeps one pouch of snus still between the upper lip and the gum for 30 minutes. Amount of nicotine extracted, plasma nicotine concentration at 30 minutes (C30), Tmax, Cmax, AUCinf and heart rate for each treatment.
11524666|NCT01182129|Active Comparator|4 mg Nicorette chewing gum|Nicorette is chewed according to instructions in package insert over 30 minutes.
11524667|NCT01182116|Experimental|J Pouch side to end|Colorectal surgery Function Quality of Life
11524668|NCT01182103||Major depressive patients|
11524669|NCT01182103||Healthy subjects|
11524670|NCT01182090|Active Comparator|Prolapse repair by open approach|Correction of urogenital prolapse by open surgery approach
11524671|NCT01182090|Active Comparator|Prolapse repair by laparoscopic approach|Correction of urogenital prolapse by laparoscopic approach
11524672|NCT01182077|Experimental|Group 1|ASP015K low dose and midazolam followed by ASP015K high dose and midazolam
11524673|NCT01182077|Experimental|Group 2|ASP015K high dose and midazolam followed by ASP015K low dose and midazolam
11524674|NCT01182064||Non infarct|
11524675|NCT01182064||Posttraumatic acute myocardial infarct without coronary injury|
11524676|NCT01182064||Posttraumatic acute myocardial infarct with coronary injury|
11524677|NCT01182051|Experimental|Cognitive behavioral therapy|Key treatment ingredients in CBT include psychoeducation, trigger identification, progressive muscle relaxation training, cognitive restructuring, problem solving, in vivo exposure, and relapse prevention (see Appendix I for an outline of the treatment manual).
11524678|NCT01182051|Active Comparator|Relaxation Training|RT will consist of progressive muscle relaxation training, diaphragmatic breathing, and thermal biofeedback.
11524679|NCT01182038|Experimental|Birth seat group|Randomized to birth on a midwife designed birth seat
11524680|NCT01182038|No Intervention|Non-birth seat group|Randomized to birth in any other position except on the midwife designed birth seat.
11524681|NCT01182025|Active Comparator|Western therapy|
11524682|NCT01182025|Experimental|Xiyanping Injection|
11524683|NCT01182025|Experimental|Xiyanping Injection with western medicine|
11524684|NCT01182012|Experimental|Lifestyle counseling|Adjust drug treatment to control cardiovascular factor risks. A nurse will implement a lifestyle counseling in order to improve compliance of treatment and a healthy lifestyle.
11524685|NCT01181999|Experimental|rituximab|
11524726|NCT01181726|Active Comparator|Reference Listed Drug|Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets
11524727|NCT01181713||No Antibiotic|No prophylactic antibiotic post intravitreal injection
11524728|NCT01181713||Prophylactic Antibiotic|Group treated with 3 day course of prophylactic topic antibiotic, fourth generation fluoroquinolones, after each intravitreal injection
11524729|NCT01181700|Experimental|Treatment A|
11524730|NCT01181700|Experimental|Treatment B|
11524686|NCT01181986|Experimental|Exenatide SC (Sub-study 1)|Study groups will be individuals with recent onset (<3 years) or established (>5 years) T2D. The plan is to achieve 40 complete studies of subcutaneous injection of exenatide BID (Byetta®, 5 or 10 µg) or identically looking Placebo SC for 10 days, separated by 14-day washout period. On the next day after each treatment phase, a single dose of the assigned medication will be injected just before a fat-enriched breakfast meal. A lunch meal of similar caloric and nutrient content will be administered 4 hours following the breakfast meal. Endothelial function will be measured just prior to the injection and every 2 hours during 8-hour post-breakfast period.
11524687|NCT01181986|Experimental|Exenatide IV (Sub-study 2)|Study group will be individuals with recent onset (<1 year) T2D on diet and impaired glucose tolerance. The plan is to achieve 35 complete studies. The intervention will include 3 randomly ordered visits with intravenous infusion of exenatide in the presence (v1) or absence (v2) of GLP-1 receptor inhibitor exendin-9, and a control test with Placebo IV without exendin-9 (v3). Endothelial function will be measured at baseline and 2 hours later during the final 15 minutes of the infusion cocktails. Study participants will remain fasting during the test visit (3 hours total).
11524688|NCT01181973|Active Comparator|Treatment sequence #1|One 1-mL subcutaneous injection at 30 mg/mL in Period 1 and two 1-mL subcutaneous injections at 15 mg/mL each in Period 2
11524689|NCT01181973|Active Comparator|Treatment sequence #2|Two 1-mL subcutaneous injections at 15 mg/mL each in Period 1 and one 1-mL SC injection at 30 mg/mL in Period 2
11524690|NCT01181960||001|Risperidone long acting injectable - New Starts Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
11524691|NCT01181960||002|Risperidone long acting injectable - Continuous Users Patients who have been on Risperidone long acting injectable for at least 6 months before baseline with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
11524692|NCT01181960||003|Paliperidone Palmitate -New and Continuous Users Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
11524693|NCT01181960||004|Other Antipsychotics - New Starts Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
11524694|NCT01181947||patients undergoing TEVAR|Those with a thoracic aortic aneurysm/dissection
11524695|NCT01181934|Experimental|001|A643 (nicotine) 1mg oromucosal nicotine spray- three times daily during each treatment period
11524696|NCT01181934|Experimental|002|A643 (nicotine) 2mg oromucosal nicotine spray- three times daily during each treatment period
11524697|NCT01181934|Placebo Comparator|003|placebo placebo - three times daily during each treatment period
11524698|NCT01181921|Experimental|Galantamine|
11524699|NCT01181908|Experimental|GSK1144814|Subjects will receive either GSK1144814 or placebo at each treatment arm.
11524700|NCT01181908|Placebo Comparator|placebo|Subjects will receive either GSK1144814 or placebo at each treatment arm.
11524701|NCT01181895|Experimental|Vilanterol|Vilanterol inhalation powder once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
11524702|NCT01181895|Active Comparator|Salmeterol|Placebo inhalation powder via NDPI once daily + Salmeterol inhalation powder twice daily for 12 weeks
11524703|NCT01181895|Placebo Comparator|Placebo|Placebo inhalation powder via NDPI once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
11524704|NCT01181882|Experimental|Fish Oil and Aspirin|
11524705|NCT01181869||Oxygen therapy|Database of patients on oxygen
11524706|NCT01181869||ventilation|database of patients on ventilatory support
11524707|NCT01181869||Continuous positive airway pressure|Sleep apnoea patients on CPAP
11524708|NCT01181856|Experimental|Group A|Intramuscular immunisation
11524709|NCT01181856|Experimental|Group B|Intradermal immunisation
11524710|NCT01181843||Cesearean sections receiving duramorph|
11524711|NCT01181830|Active Comparator|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate for 8 weeks
11524712|NCT01181830|Placebo Comparator|placebo|administration of 8.1 mmol bid of placebo for 8 weeks
11524713|NCT01181817|Other|SCS|patients with Failed back Surgery syndrome treated with SCS
11524714|NCT01181804|Experimental|Boceprevir Tablets then Capsules (fed)|Participants will start therapy with a single dose of boceprevir tablets, orally, in fed condition, and then 4 days later will take a single dose of boceprevir capsules, orally, in fed condition.
11524715|NCT01181804|Experimental|Boceprevir Capsules then tablets (fed)|Participants will start therapy with a single dose of boceprevir capsules, orally, in fed condition, and then 4 days later will take a single dose of boceprevir tablets, orally, in fed condition.
11524716|NCT01181804|Experimental|Boceprevir Tablets then Capsules (fasted)|Participants will start therapy with a single dose of boceprevir tablets, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir capsules, orally, following an overnight fast.
11524717|NCT01181804|Experimental|Boceprevir Capsules then Tablets (fasted)|Participants on this study arm will start therapy with a single dose of boceprevir capsules, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir tablets, orally, following an overnight fast.
11524718|NCT01181791|Experimental|probiotic group|Lactobacillus reuteri will be given at a dose of 1x108 colony forming units (CFU)/day
11524719|NCT01181791|Placebo Comparator|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present.
11524720|NCT01181778||All Qualified Participants|All healthy women who consulted their physician for information on contraceptive choices and were eligible for primary and secondary outcome measure analysis, based on the physician's assessment
11524721|NCT01181765|Experimental|Infliximab infusions (5 mg/kg) at weeks 0, 2, 6, 14 and 22|
11524722|NCT01181752||Group A|Baseline/control subjects who are only tested on postoperative day 30
11524723|NCT01181752||Group B|Subjects who will be tested on postoperative day 1 and day 30
11524724|NCT01181752||Group C|"Subjects who cannot proficiently administer the medication on postoperative day 1 will be re-classified as Group C subjects"
11524725|NCT01181726|Experimental|Investigational Test Product|Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg
11524732|NCT01181700|Active Comparator|Treatment D|
11524733|NCT01181700|Active Comparator|Treatment E|
11524734|NCT01181700|Active Comparator|Treatment F|
11524735|NCT01181700|Active Comparator|Treatment G|
11524736|NCT01181674|Experimental|Group 1 (short)|
11524737|NCT01181674|Experimental|Group 2 (long)|
11524738|NCT01181674|Other|Standard care|
11524739|NCT01181661|Experimental|Full Group Contingency|This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
11524740|NCT01181661|Experimental|Mixed Group Contingency|This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
11524741|NCT01181648||oropharynx cancer survivors|This study has two components. First, we will conduct a cross-sectional survey of 200 oropharynx cancer survivors, diagnosed with HPV+ tumors, who are at least 12 months from their last treatment. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis.
11524742|NCT01181635|Experimental|Psychotherapy|Short-term pychotherapy and/or psychoeduchative courses.
11524743|NCT01181622|Experimental|denufosol tetrasodium Inhalation Solution|
11524744|NCT01181622|Placebo Comparator|Placebo|
11524745|NCT01181609|Experimental|1|
11524746|NCT01181596||Arm 1: observational ultrasound|Collection of image data with the ultrasound probe.
11524747|NCT01181583|Experimental|Tailored Internet-delivered CBT|
11524748|NCT01181583|Experimental|Non-tailored Internet-delivered CBT|
11524749|NCT01181583|Active Comparator|Online discussion group|
11524750|NCT01181570|Experimental|Adalimumab|
11524751|NCT01181570|Placebo Comparator|Placebo|
11524752|NCT01181557||rectal cancer with stoma|rectal cancer submitted to rectal anterior resection with stomia (RARS). Differences in QoL between the two groups were analyzed during three time: first preoperative, second postoperative and latter six month after stoma reconversion
11524753|NCT01181557||rectal cancer without stoma|rectal cancer submitted to rectal anterior resection (RAR) Differences in QoL between the two groups were analyzed during three time: first preoperative, second postoperative and latter six month later
11524754|NCT01181557||anterior resection of rectum|patients with rectal cancer submitted to RAR and patients with rectal cancer submitted to RARS
11524755|NCT01181544|Experimental|Heparin dose titration|
11524756|NCT01181531|Active Comparator|Traditional Vitamin D Therapy|
11524757|NCT01181531|Experimental|Cinacalcet|
11524758|NCT01181505|Experimental|Tolterodine|
11524759|NCT01181492||*1/*1|Grouped by CYP3A4*1G polymorphism, wild-type homozygote
11524760|NCT01181492||*1/*1G|Grouped by CYP3A4*1G polymorphism,*1/*1G: mutant heterozygote
11524761|NCT01181492||*1G/*1G|Grouped by CYP3A4*1G polymorphism,*1G/*1G: mutant homozygote
11524762|NCT01181479|Experimental|AG200-15 (cycles 1-13)|AG200-15 containing ethinyl estradiol and levonorgestrel. Type of intervention is drug.
11524763|NCT01181479|Active Comparator|Lessina crossover to AG200-15|Lessina containing ethinyl estradiol and levonorgestrel for 6 cycles followed by AG200-15 for 6 cycles. Type of intervention is drug.
11524764|NCT01181453|Experimental|Dermagraft(R)|Weekly application of Dermagraft(R) with standard care
11524765|NCT01181453|Other|Standard care only|Weekly application of standard care
11524766|NCT01181440|Experimental|Dermagraft(R) and conventional care|
11524767|NCT01181440|Other|Conventional care only|
11524768|NCT01181427|Placebo Comparator|Single Ascending Dose (SAD)|Healthy volunteers, receiving single ascending doses of ABT-267 or placebo.
11524769|NCT01181427|Placebo Comparator|Multiple Ascending Dose (MAD)|Healthy volunteers, receiving multiple ascending doses of ABT-267 or placebo, OR, multiple doses of ABT-267 + single dose of a Cytochrome P450 inhibitor or placebo + single dose of a Cytochrome P450 inhibitor.
11524770|NCT01181427|Active Comparator|Food Effect (FE)|Healthy volunteers, receiving ABT-267, multi-dose, food effect.
11524771|NCT01181427|Placebo Comparator|Antiviral Activity|HCV genotype 1-infected treatment naïve subjects receiving multiple ascending doses of ABT-267 or placebo monotherapy for 3 days.
11524772|NCT01181427|No Intervention|Resistance Monitoring|"HCV genotype 1-infected treatment naïve subjects, receiving at least one dose of ABT-267 or placebo in the Antiviral Activity arm, follow-up to monitor resistance developed to ABT-267, no treatment and only blood samples will be collected"
11524773|NCT01181414|Experimental|Atrioventricular junction ablation|Atrioventricular junction ablation by using radiofrequency energy.
11524774|NCT01181414|Active Comparator|Drug control of ventricular rate|Drug control of ventricular rate.
11524775|NCT01181401|Active Comparator|TPF standard|"TPF version 1 (standard)
~Induction chemotherapy:
~Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 every 21 days for 3 cycles
~Antibody therapy with:
~cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
~RTX: HART (72 Gy), IMRT or 3D-conformal techniques"
11524776|NCT01181401|Experimental|TPF experimental|"TPF version 2 (experimental)
~Induction chemotherapy:
~Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles
~Antibody therapy with:
~cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
~RTX: HART (72 Gy), IMRT or 3D-conformal techniques"
11524777|NCT01181401|Active Comparator|Standard RCT|"Standard RCT:
~HART (72 Gy), IMRT or 3D-conformal techniques
~with concurrent chemotherapy: Cis-platinum 30 mg/m2 once weekly d 1, 8, 15, 22, 29, 36 5-FU 600mg/m² /24h c.i. d 1-5"
11524778|NCT01181388|Active Comparator|intra-guide-catheter infusion of tirofiban|
11524779|NCT01181388|Experimental|intra-thrombus-aspiration-catheter infusion of tirofiban|
11524780|NCT01181375|Experimental|Assays on cervical cancer tissue|
11524781|NCT01181362|Other|Endoscopy|
11524782|NCT01181349||P07535 study participants with a TOF ratio <0.9|Participants enrolled in the P07535 study who are included in the primary outcome measurement, which is defined as the incidence of postoperative residual neuromuscular blockade, who had a TOF ratio <0.9 at PACU arrival.
11525175|NCT01178684||2: HIV-pos on d4T without neuropathy|
11524783|NCT01181349||P07535 study participants with a TOF ratio ≥0.9|Participants enrolled in the P07535 study who are included in the primary outcome measurement, which is defined as the incidence of postoperative residual neuromuscular blockade, who had a TOF ratio ≥0.9 at PACU arrival.
11524784|NCT01181336|Experimental|Group 2|"FLU-v Low Dose with adjuvant. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.
~10 subjects."
11524785|NCT01181336|Experimental|Group 3|"FLU-v High Dose with water for injection. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.
~10 subjects."
11524786|NCT01181336|Experimental|Group 4|High Dose FLU-v with adjuvant FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection. 10 subjects
11524787|NCT01181336|Experimental|Group 1|FLU-v Low Dose with water for injection FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection 10 subjects
11524788|NCT01181336|Placebo Comparator|Control Group|Placebo with adjuvant (4 subjects) or Placebo without adjuvant (4 subjects)
11524789|NCT01181323|Experimental|Group 1: LAIV|0.2 ml of Live attenuated influenza vaccine (LAIV), Flumist® given intranasally (IN) and 0.5 ml of placebo given intramuscularly (IM) injection administered to 120 maternal subjects.
11524790|NCT01181323|Experimental|Group 2: TIV|0.5 ml of Inactivated Trivalent Influenza Vaccine (TIV), Fluzone® given intramuscularly (IM) and 0.2 ml of placebo given intranasally (IN) administered to 120 maternal subjects.
11524791|NCT01181310|Experimental|A, B, D, E, C|Participants received treatment A, B, D, E, C for Periods 1, 2, 3, 4, and 5, respectively.
11524792|NCT01181310|Experimental|B, C, E, A, D|Participants received treatment B, C, E, A, D for Periods 1, 2, 3, 4, and 5, respectively.
11524793|NCT01181310|Experimental|C, D, A, B, E|Participants received treatment C, D, A, B, E for Periods 1, 2, 3, 4, and 5, respectively.
11524794|NCT01181310|Experimental|D, E, B, C, A|Participants received treatment D, E, B, C, A for Periods 1, 2, 3, 4, and 5, respectively.
11524795|NCT01181310|Experimental|E, A, C, D, B|Participants received treatment E, A, C, D, B for Periods 1, 2, 3, 4, and 5, respectively.
11524796|NCT01181310|Experimental|A, C, B, E, D|Participants received treatment A, C, B, E, D for Periods 1, 2, 3, 4, and 5, respectively.
11524797|NCT01181310|Experimental|B, D, C, A, E|Participants received treatment B, D, C, A, E for Periods 1, 2, 3, 4, and 5, respectively.
11524798|NCT01181310|Experimental|C, E, D, B, A|Participants received treatment C, E, D, B, A for Periods 1, 2, 3, 4, and 5, respectively.
11524799|NCT01181310|Experimental|D, A, E, C, B|Participants received treatment D, A, E, C, B for Periods 1, 2, 3, 4, and 5, respectively.
11524800|NCT01181310|Experimental|E, B, A, D, C|Participants received treatment E, B, A, D, C for Periods 1, 2, 3, 4, and 5, respectively.
11524801|NCT01181297|Experimental|Extensively Hydrolyzed Formula with a Probiotic|Extensively Hydrolyzed Formula with a Probiotic
11524802|NCT01181297|Placebo Comparator|Extensively Hydrolyzed Formula without a Probiotic|
11524803|NCT01181284||Lisinopril|Participants will be randomized 2 to 1 to receive drug versus placebo.
11524804|NCT01181271|Experimental|Autologous then Allogeneic transplant|"All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.
~Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.
~Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD)."
11524805|NCT01181258|Experimental|Patients Receiving NK Cell Infusion|Non-Myeloablative Conditioning Using Rituximab, Fludarabine, Cyclophosphamide and Methylprednisolone followed by Interleukin 2-activated Allogeneic Natural Killer Cells infusion for Patients with Refractory NHL and CLL
11524806|NCT01181245|Experimental|FG-3019|All subjects are treated with FG-3019
11524807|NCT01181232|Experimental|MR low-dose group|
11524808|NCT01181232|Experimental|MR high-dose group|
11524809|NCT01181232|Active Comparator|IR group|
11524810|NCT01181219|Experimental|CXL without epithelial removal|Application of Riboflavin and the consequent UV-irradiation with intact corneal epithelium
11524811|NCT01181219|Active Comparator|CXL with epithelial removal|Corneal epithelial removal prior to Riboflavin and the consequent UV-irradiation
11524812|NCT01181206|Active Comparator|Arm 1|
11524813|NCT01181206|Active Comparator|Arm 2|
11524814|NCT01181180|Experimental|balance treatment|
11524815|NCT01181167|Experimental|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery.
11524816|NCT01181167|Active Comparator|enoxaparin sodium|enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery.
11524817|NCT01181154|Placebo Comparator|equivalent volume total (=1000 ml)|Placebo : equivalent volume total (=1000 ml)
11524818|NCT01181154|Experimental|rituximab (Mabthera®)|rituximab (Mabthera®), 1000 mg at day 1 and day 15
11524819|NCT01181141|Experimental|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery
11524820|NCT01181141|Active Comparator|Enoxaparin sodium|Enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery
11524863|NCT01180868||patients with autoimmune dosorders|patients with Rheumatoid arthritis, Crohns's disease, systemic lupus erythematosus.
11524864|NCT01180868||healthy subjects|
11524865|NCT01180855|Placebo Comparator|Placebo|Placebo pills prepared by Takeda Pharmaceutical.
11524866|NCT01180855|Active Comparator|Rozerem|Rozerem 8mg
11524867|NCT01180855|Active Comparator|Rozerem + Multi Component Behavior Therapy|Rozerem 8mg in combination with 4 small group sessions and 2 phone calls of Multi Component Behavior Therapy.
11524868|NCT01180842|Other|Alternative Treatment|The CF Patient Population receiving the specific yoga study treatment
11524869|NCT01180829|No Intervention|Control condition|No interventions text messages sent
11524913|NCT01180556|Experimental|Probiotics supplementation|Supplementation by probiotics for 4 weeks
11524821|NCT01181128|Experimental|Individualized (Tailored) Prophylaxis|"On rFVIIIFc Day 0, all participants underwent pharmacokinetic (PK) analysis with 50 IU/kg rFVIIIFc to estimate their PK parameters and guide the appropriate dose or interval of dosing. A subset of participants (Sequential PK subgroup) also had PK analyses performed with a single dose of 50 IU/kg Advate (Advate Day 0) within 8 weeks prior to rFVIIIFc Day 0. A >= 96 hour washout was performed before the PK dose of Advate or rFVIIIFc was administered. Repeat PK profiling with a single dose of 50 IU/kg rFVIIIFc was conducted at Week 14 or after 12 to 24 weeks of prophylaxis with rFVIIIFc.
~After PK assessments, all participants started twice weekly treatment with 25 IU/kg of rFVIIIFc via intravenous (IV) injection on Day 1 and 50 IU/kg on Day 4, followed by individualized dose and interval modification within the range of 25 to 65 IU/kg every 3 to 5 days, as determined by rFVIIIFc PK analysis, to maintain a trough level of 1% to 3% (or higher, as clinically indicated) FVIII activity."
11524822|NCT01181128|Experimental|Weekly Prophylaxis|65 IU/kg of rFVIIIFc via IV injection every 7 days
11524823|NCT01181128|Experimental|Episodic (On-Demand) Dosing|10 to 50 IU/kg rFVIIIFc via IV injection, as required to treat a bleeding episode
11524824|NCT01181115|Experimental|Active treatment|Interferon treatment for MS
11524825|NCT01181102|Experimental|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery.
11524826|NCT01181102|Active Comparator|enoxaparin sodium|enoxaparin sodium 20mg (=2000IU) 0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery.
11524827|NCT01181076|Experimental|Individualized Nutrition|
11524828|NCT01181076|No Intervention|Control group|The patients in the control group will be nourished after established routine, first by the oral route, later by the PN route. Naso-jejunal tube will not be inserted and enteral nutrition will not be given.
11524829|NCT01181063|Experimental|400/12 μg D94-2BF (60/40) inhaler|
11524830|NCT01181063|Experimental|320/9 μg D94-2BF (20/80) inhaler|
11524831|NCT01181063|Active Comparator|Symbicort 320/9 μg inhaler|
11524832|NCT01181063|Experimental|320/9 μg D94-2F (60/40) inhaler|
11524833|NCT01181063|Experimental|320/9 μg D94-2BF (60/40) inhaler|
11524834|NCT01181050|Experimental|4.0 mg/kg|Subjects received a single dose of 4 mg/kg NNC0142-0002
11524835|NCT01181050|Placebo Comparator|Placebo|Subjects received a single dose of placebo
11524836|NCT01181037||100 patients, displaced subcapital fracture, T.A.N nail.|100 patients sustained a displaced femoral subcapital fracture, that were operated on with closed reduction and internal fixation with TAN nail.
11524837|NCT01181037||100 patients, displaced subcapital fracture, Bipolar H.A..|
11524838|NCT01181024|Experimental|A: HV ascending dose|
11524839|NCT01181024|Experimental|B: HV food effect|
11524840|NCT01181024|Experimental|C: Hepatitis C|
11524841|NCT01181011|Experimental|amlodipine/telmisartan/combination|all patients will be assigned to 6 treatment sequences. cross-over design was adopted to ensure each patient would take amlodipine/telmisartan/combination single dose in randomized order
11524842|NCT01180998|Other|Spherical contact lens users|Habitual spherical contact lens (non-toric lens) users tried one of two toric lenses in a daily wear modality.
11524843|NCT01180998|Other|Contact lens drop-outs|Habitual spectacle users (for vision correction) who have failed contact lens fit and wear, tried one of two toric lenses in a daily wear modality.
11524844|NCT01180998|Other|Habitual Correction with Spectacles (Neophytes)|Habitual spectacle lens wearers (for vision correction) who have never used or been fitted with contact lenses tried one of two toric lenses in a daily wear modality.
11524845|NCT01180985|Other|galyfilcon A prototype/comfilcon A|The galyfilcon A prototype lenses are worn during first period and comfilcon A lenses worn during second period. Each period consists of daily lens wear for one week.
11524846|NCT01180985|Other|comfilcon A/galyfilcon A prototype|The comfilcon A lenses are worn during first period and galyfilcon A prototype lenses worn during second period. Each period consists of daily lens wear for one week.
11524847|NCT01180959|Experimental|Erlotinib + Bevacizumab|Erlotinib 150 mg by mouth once a day. Bevacizumab 10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes.
11524848|NCT01180946|Active Comparator|Ergocalciferol|Weekly ergocalciferol for 16 weeks
11524849|NCT01180946|Placebo Comparator|Placebo|Placebo pill. Note that all subjects in this arm will receive vitamin D repletion at the conclusion of the study.
11524850|NCT01180933|Experimental|fish oil|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 500 mg DHA and 150 eicosapentaenoic acid per day from gestational week 22 until delivery
11524851|NCT01180933|Experimental|folate|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 400 µg folate (methyltetrahydrofolate)per day from gestational week 22 until delivery
11524852|NCT01180933|Experimental|fish oil + folate|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 500 mg DHA, 150 mg eicosapentaenoic acid and 400 µg MTHF per day from gestational week 22 until delivery
11524853|NCT01180933|Placebo Comparator|placebo|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women from gestational week 22 until delivery
11524854|NCT01180920||Periodontal disease|11 patients with periodontal disease, specifically generalized chronic or aggressive periodontitis will be selected. In general, the disease group will be comprised of subjects that need an open flap procedure.
11524855|NCT01180920||Healthy periodontium|11 patients without periodontal disease will be selected. In general, the healthy group will be comprised of subjects that are requiring a gingivectomy or crown lengthening procedure.
11524856|NCT01180907||patients with cancer|
11524857|NCT01180907||patients with autoimmune diseases|
11524858|NCT01180907||healthy subjects|
11524859|NCT01180894|Active Comparator|Iron sucrose|100 mg IV TIW
11524860|NCT01180894|Placebo Comparator|Placebo|Pacebo - Normal Saline
11524861|NCT01180881||Proton Radiation Patients at MGH|Pediatric brain and central nervous system (CNS) tumor patients treated with proton beam radiation therapy
11524862|NCT01180868||patients with cancer|patients with hematological malignancies and solid tumors
11525110|NCT01179178||Older adults (65-81 y)|
11524870|NCT01180829|Experimental|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking
11524871|NCT01180829|Experimental|Consciousness raising text message|A series of 12 text messages, each of which contains text designed to get the person to think about his or her drinking
11524872|NCT01180816|Experimental|Temozolomide (Temodar)|
11524873|NCT01180803|Experimental|oxygen-saving valves|
11524874|NCT01180803|Active Comparator|continuous oxygen supplementation|
11524875|NCT01180790|Experimental|Segment 1: 200 mg ACH-0141625|200 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a and ribavirin for 48 weeks
11524876|NCT01180790|Experimental|Segment 1: 400 mg ACH-0141625|400 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a plus ribavirin for 48 weeks
11524877|NCT01180790|Experimental|Segment 1: 800 mg ACH-0141625|800 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a plus ribavirin for 48 weeks
11524878|NCT01180790|Placebo Comparator|Segment 1: Placebo|Placebo for 28 days plus Peg-IFN alpha-2a plus ribavirin for 48 weeks
11524879|NCT01180790|Experimental|Segment 2: 200 mg ACH-0141625|200 mg ACH-0141625 for 12 weeks plus Peg-IFN and ribavirin for up to a total of 24 or 48 weeks
11524880|NCT01180790|Experimental|Segment 2 : 400 mg ACH-0141625|400 mg ACH-0141625 for 12 weeks plus Peg-IFN and ribavirin for up to a total of 24 or 48 weeks
11524881|NCT01180790|Experimental|Segment 2 : 800 mg ACH-0141625|800 mg ACH-0141625 for 12 weeks plus Peg-IFN and ribavirin for up to a total of 24 or 48 weeks
11524882|NCT01180777|Other|etafilcon A (A)/etafilcon A (B)/etafilcon A (C)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (B) worn second, then printed etafilcon A Lens with PVP (C) worn the last. Each period consisted of approximately one week of daily lens wear.
11524883|NCT01180777|Other|etafilcon A (A)/etafilcon A (C)/etafilcon A (B)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (C) worn second, then printed etafilcon A Lens with PVP (B) worn the last. Each period consisted of approximately one week of daily lens wear.
11524884|NCT01180777|Other|etafilcon A (C)/etafilcon A (A)/etafilcon A (B)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (A) worn second, then printed etafilcon A Lens with PVP (B) worn the last. Each period consisted of approximately one week of daily lens wear.
11524885|NCT01180777|Other|etafilcon A (B)/etafilcon A (C)/etafilcon A (A)|Printed etafilcon A Lens with PVP (B) worn first, then printed etafilcon A Lens with PVP (C) worn second, then printed etafilcon A Lens with PVP (A) worn the last. Each period consisted of approximately one week of daily lens wear.
11524886|NCT01180777|Other|etafilcon A (C)/etafilcon A (B)/etafilcon A (A)|Printed etafilcon A Lens with PVP (C) worn first, then printed etafilcon A Lens with PVP (B) worn second, then printed etafilcon A Lens with PVP (A) worn the last. Each period consisted of approximately one week of daily lens wear.
11524887|NCT01180777|Other|etafilcon A (B)/etafilcon A (A)/etafilcon A (C)|Printed etafilcon A Lens with PVP (C) worn first, then printed etafilcon A Lens with PVP (A) worn second, then printed etafilcon A Lens with PVP (C) worn the last. Each period consisted of approximately one week of daily lens wear.
11524888|NCT01180764|Experimental|Lovaza|Lovaza 4g po qd
11524889|NCT01180764|Placebo Comparator|Placebo|Matching placebo
11524890|NCT01180751|Other|[18F]-Fluorodeoxyglucose|Scanning Procedure: Non-diagnostic Computed Tomography (CT) scan followed by a Diagnostic Positron Emission Tomography (PET) scan.
11524891|NCT01180738|Active Comparator|Body weight supported treadmill training|
11524892|NCT01180738|Active Comparator|Overground walking training|
11524893|NCT01180712|Active Comparator|Blaeberry concentrated caspule|"30 obese male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.
~Volunteers will be given a total daily dose of 1.4 grams of mirtoselect (a concentrated blaeberry extract) a day formulated in hard gelatin capsules (0.47 gram per capsule) administered thrice a day for 21 days.
~Mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/)"
11524894|NCT01180712|Placebo Comparator|Placebo capsules containing lactose|"30 obese male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.
~Volunteers will be given a placebo consisting of lactose formulated in hard gelatin capsules administered thrice a day for 21 days."
11524895|NCT01180699|Experimental|influenza vaccine - intradermal|intradermal versus intramuscular
11524896|NCT01180699|Active Comparator|influenza vaccine - intramuscular|
11524897|NCT01180686|Active Comparator|Multiple thrust Impulse instrument|This instrument automatically delivers 12 thrusts at the same intensity over the joint involved.
11524898|NCT01180686|Active Comparator|Single impulse Activator IV instrument|This is a manual spring loaded device that delivers one thrust to the joint involved
11524899|NCT01180673|Experimental|MINT-TLC|
11524900|NCT01180673|Active Comparator|Control Condition|
11524901|NCT01180660|Active Comparator|Lidocaine|Lidocaine infusion
11524902|NCT01180660|Placebo Comparator|Placebo|Placebo Normal Saline Infusion
11524903|NCT01180647|Active Comparator|Extended-release naltrexone (XR-NTX)|A single 380mg IM depot injection of XR-NTX in the week prior to release from jail. A second 380mg IM injection is offered to persons in the XR-NTX arm post-release and 4 weeks after the initial injection.
11524904|NCT01180647|Placebo Comparator|Motivational Enhancement Counseling Only|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
11524905|NCT01180634|Experimental|1|Inhaled MP-376 (Aeroquin)
11524906|NCT01180634|Placebo Comparator|2|Placebo
11524907|NCT01180621|Experimental|Fluviral|0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
11524908|NCT01180608|Active Comparator|Pregabalin|
11524909|NCT01180608|Placebo Comparator|placebo + pregabalin|
11524910|NCT01180595|Other|Modular|Trabecular Metal Modular Tibial Total Knee Component
11524911|NCT01180595|Other|Monoblock|Trabecular Metal Monoblock Tibial Total Knee Component
11524912|NCT01180569|Experimental|lenalidomide|Eligible patients for this clinical trial will be treated for 6 cycles with lenalidomide at 15 mg daily by mouth on Days1-21 of 28 day cycle, preceded by an escalating schema for safety (5mg daily for 2 weeks; 10 mg daily for 2 weeks; and 15 mg daily for 2 weeks) and then a one week rest).
11524914|NCT01180556|Placebo Comparator|Placebo|Supplementation of placebo for 4 weeks
11524915|NCT01180543|Active Comparator|Active Comparator: Oplon Active Patch|
11524916|NCT01180543|Placebo Comparator|Placebo Comparator: Placebo patch|
11524917|NCT01180530||A|
11524918|NCT01180517|Active Comparator|Drug Eluting Balloon|
11524919|NCT01180517|Active Comparator|Plain Old Balloon Angioplasty (POBA)|
11524920|NCT01180478|Other|Narrow Band Imaging|Narrow Band Imaging (NBI)
11524921|NCT01180478|Other|White Light Trans Urethral Resection|White Light Trans Urethral Resection
11524922|NCT01180465|Experimental|LIPO-102 High|
11524923|NCT01180465|Experimental|LIPO-102, Low|
11524924|NCT01180465|Placebo Comparator|LIPO-102; Placebo|
11524925|NCT01180452|Other|Single group open label|Prospective Cohort
11524926|NCT01180426|Experimental|Tosedostat|
11524927|NCT01180413|Experimental|Vasodilatory|Patients in this arm will receive intensive vasodilatory treatment
11524928|NCT01180400|Experimental|TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1-4 mg BID
11524929|NCT01180400|Placebo Comparator|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
11524930|NCT01180374|Experimental|Active Canabidiol and Active Delta-9-THC|
11524931|NCT01180374|Placebo Comparator|Placebo and Active Delta-9-THC|
11524932|NCT01180374|Experimental|Active Cannabidiol and Placebo|
11524933|NCT01180374|Placebo Comparator|Placebo and Placebo|
11524934|NCT01180361||Active SLE patients|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Fulfill 1982 ACR revised criteria for SLE. SLE activity status designated using the SLEDAI disease activity index. Patients excluded if previous documentation of a connective tissue disorder other than SLE.
11524935|NCT01180361||Psoriatic arthritis|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Diagnosed according to criteria described by McGonagle et al (McGonagle, D., Conaghan, P.G., and Emery, P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 1999; 42: 1080-1086.)
11524936|NCT01180361||Normal controls|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Healthy volunteers. Not on corticosteroids.
11524937|NCT01180361||Active RA patients|Age 18-65, male and female, no methotrexate or statin therapy in prior 3 months. Not on biological therapies. satisfy at least 4 of the 7 revised criteria (1987) for the classification of RA
11524938|NCT01180348|Experimental|Botulift|Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
11524939|NCT01180348|Active Comparator|Botox|Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
11524940|NCT01180335|Active Comparator|Chemotherapy|4 cycles FEC followed by 4 cycles docetaxel
11524941|NCT01180335|Experimental|Genomic driven chemotherapy|High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
11524942|NCT01180322|Active Comparator|Arm A|Standard Therapy
11524943|NCT01180322|Experimental|Arm B|"Investigational Therapy Azacitidine Prior"
11524944|NCT01180322|Experimental|Arm C|"Investigational Therapy Azacitidine Concurrent"
11524945|NCT01180322|Experimental|Arm D|"Investigational Therapy Azacitidine After"
11524946|NCT01180309||lingual frenum alterations|individuals each one with their phonological system complete
11524947|NCT01180296|Experimental|Progesterone Group|Oral Micronized Progesterone
11524948|NCT01180296|Placebo Comparator|Placebo|Identical Placebo Tablet
11524949|NCT01180283|Experimental|lodenafil carbonate (Helleva®)|
11524950|NCT01180270||Cervical dystonia|"patients suffering from cervical dystonia
~under routine botulinum toxin treatment"
11524951|NCT01180270||healthy volunteers|control group
11524952|NCT01180244|Active Comparator|Active treatment|Subjects in this group will receive the noninvasive cortical stimulation signal from the treatment device
11524953|NCT01180244|Placebo Comparator|Placebo group|Subjects in this group will be provided the same experience as those in the active treatment arm, but will not receive the noninvasive cortical stimulation signal from the treatment device
11524954|NCT01180231|Active Comparator|Moxonidine|
11524955|NCT01180231|Active Comparator|Diet|
11524956|NCT01180231|Active Comparator|Moxonidine and diet|Subjects will be asked to take moxonidine and follow dietary plan designed by a qualified nutritionist for 6 months.
11524957|NCT01180231|No Intervention|Control|Subjects will not be asked to take any interventions.
11524958|NCT01180205|Active Comparator|T/A|Telmisartan + Amlopidpine
11524959|NCT01180205|Active Comparator|O/HCT|Olmesartan + Hydrochlorothiazide
11524960|NCT01180192|Experimental|oxygen|
11524961|NCT01180179|Active Comparator|Lansoprazole 30mg once daily|Lansoprazole 30mg once daily
11524962|NCT01180179|Active Comparator|Famotidine 40mg once daily|Famotidine 40mg once daily
11524963|NCT01180166|Experimental|nimotuzumab|Combination of nimotuzumab and capecitabine concurrent chemoradiotherapy is received by patients.
11524964|NCT01180153|Experimental|SOX: advanced BTC or ampullary carcinoma|unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma receive SOX regimen
11524965|NCT01180140|No Intervention|1|without seamguard
11524966|NCT01180140|Experimental|2|with seamguard
11524967|NCT01180127|Active Comparator|exercise, dietary intervention|aerobic training and flavanol containing food product for 12 weeks
11524968|NCT01180127|Active Comparator|no exercise, dietary intervention|wait list control plus flavanol containing food product for 12 weeks
11524969|NCT01180127|Active Comparator|exercise, food product lacking flavanol|aerobic training plus food product without flavanol for 12 weeks
11524970|NCT01180127|Placebo Comparator|wait list control food additive without flavanol|wait list control plus food product without flavanol for 12 weeks
11525111|NCT01179165||Type 2 diabetes age 40-75|Only one diagnostic/observational group
11524971|NCT01180114|Experimental|SUUBI-MAKA|Involves creating and broadening asset ownership opportunities and life options for children (ages 12 to 15 years) orphaned due to AIDS in Uganda.
11524972|NCT01180114|Other|Usual Care|No intervention for asset ownership, development of future planning skills, enhancement of mental health and reduction of risk taking behaviors for children orphaned due to AIDS in Uganda.
11524973|NCT01180101|Active Comparator|Lifestyle modification group|This group will undergo supervised exercise training 5 days per week and follow hypocaloric diet for 12 weeks. All exercise training sessions will be supervised by an Exercise Physiologist or Research Nurse, and will be conducted in the Exercise Physiology Laboratory at the CCF CRU. Exercise training will consist of walking, running on a treadmill, and stationary cycling on a cycle ergometer. Each exercise session will include a brief standardized warm-up and cool-down that include a series of stretching exercises.
11524974|NCT01180101|Active Comparator|Bariatric Surgery Group|This group will include CKD patients who undergo bariatric surgery.
11524975|NCT01180101|No Intervention|CKD Group (control)|This group will not undergo any form of weight loss intervention
11524976|NCT01180088|Experimental|ANTERIOR APPROACH|SURGICAL TECHNIQUE
11524977|NCT01180075||TDF/FTC/EFV Intensive Sampling-Group A|Patients receiving TDF/FTC/EFV who undergo intensive pharmacokinetic sampling over 24 hours
11524978|NCT01180075||TDF/FTC/ATV/r Intensive Sampling Group A|Patients receiving TDF/FTC/ATV/r who undergo intensive pharmacokinetic sampling over 24 hours
11524979|NCT01180075||TDF/FTC/EFV Sparse Sampling Group B|Patients receiving TDF/FTC/EFV who undergo sparse pharmacokinetic sampling on 1 or 2 visits depending on subject's availability
11524980|NCT01180075||TDF/FTC/ATV/r Sparse Sampling Group B|Patients receiving TDF/FTC/ATV/r who undergo sparse pharmacokinetic sampling on 1 or 2 visits depending on subject's availability
11524981|NCT01180062|Active Comparator|Arm 1|Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.
11524982|NCT01180062|Active Comparator|Active Comparator - Arm 2|Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
11524983|NCT01180062|Active Comparator|Active Comparator - Arm 3|Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
11524984|NCT01180049|Active Comparator|temsirolimus (Torisel) 175mg weekly x 3, then 75mg weekly|
11524985|NCT01180049|Active Comparator|temsirolimus (Torisel) 75mg weekly|
11524986|NCT01180036|Active Comparator|Rituximab Treatment Arm|Patients randomized to the RTX arm will receive 1000 mg IV on Days 1 and 15. Patients who achieve complete remission at 6 months will not be retreated. A second course of RTX 1000 mg IV will be administered at study month 6 for individuals who have not achieved a complete remission, but have achieved a minimum of >25% reduction in Time 0 proteinuria. Dosing at study month 6 will be independent of cluster of differentiation (CD) 19+ B cell count.
11524987|NCT01180036|Active Comparator|Cyclosporine Treatment Arm|Patients randomized to the Cyclosporine arm will be started at a dose of CsA = 3.5 mg/kg/day p.o. divided into 2 equal doses given at 12 hour intervals. Target trough CsA blood levels are 125 to 175 ng/ml. Patients will have their doses adjusted according to their blood levels of CSA as monitored every 2 weeks until the target trough level is reached. If a complete remission is achieved by 6 months, CSA will be tapered and discontinued over a three-month period. If after 6 months there has not been a reduction in proteinuria of at least 25% of baseline values, the drug will also be discontinued. If there has been a >25% reduction in baseline proteinuria (but not complete remission) the CSA will be continued for an additional 6 months.
11524988|NCT01180023|Experimental|Sweeping|
11524989|NCT01180023|No Intervention|No sweeping|
11524990|NCT01179997|Active Comparator|Tissue Doppler Imaging (TDI) optimization|Interventricular pacing delay optimized according to Tissue-Doppler echocardiography
11524991|NCT01179997|Active Comparator|Electrocardiographic optimization|Interventricular pacing delay optimized according to QRS width observation in the 12-lead surface electrocardiogram
11524992|NCT01179984|Experimental|PTA and study stent|Bard® LifeStent® Vascular Stent System
11524993|NCT01179971|Experimental|Fish oil|3g/d
11524994|NCT01179971|Experimental|Gamma-linolenic Acid|3g/d gamma-linolenic acid
11524995|NCT01179971|Experimental|Fish oil plus GLA|1.5 g/d DHA + EPA plus 1.5g/d gamma-linolenic acid
11524996|NCT01179971|Sham Comparator|Olive oil|3 g/d olive oil
11524997|NCT01179958|Experimental|aerobic training|24 weeks of aerobic training, 4 times/week
11524998|NCT01179958|Placebo Comparator|stretching/toning|stretching/toning condition, 24 weeks to parallel the active intervention group
11524999|NCT01179945|Experimental|sodium benzoate containing|
11525000|NCT01179945|Active Comparator|non sodium benzoate containing|
11525001|NCT01179932||Anesthesia Record|The nursing and anesthesia records will be examined for accuracy and completeness
11525002|NCT01179919|Experimental|Oseltamivir Dosed Group|Oseltamivir 75 mg by mouth every 12 hours for 9 doses
11525003|NCT01179906|Experimental|Lifestyle intervention-exercise & diet|Subjects trained for 48 weeks with a personal trainer
11525004|NCT01179893|Active Comparator|IVIG|Intravenous Immunoglobulin, 2G/Kg, infused over 2 days in the Medical Day Unit of the University Health Network
11525005|NCT01179893|Experimental|PLEX|Patients received one plasma volume plasma exchanges with 5% albumin replacement fluid. Five plasma exchange procedures occurred every second day with breaks over the weekend allowed. Patients treated in the apheresis units at the University Health Network.
11525006|NCT01179880|Experimental|1|
11525007|NCT01179880|Placebo Comparator|2|
11525008|NCT01179867|Experimental|Electronic Medication Reconciliation|"Electronic medication reconciliation includes:
~Electronic retrieval of the community drug list at admission
~Generation of discharge prescription using the discharge reconciliation module at discharge
~Transfer of information on discontinued and changed medication to respective dispensing pharmacies and prescribing physicians"
11525112|NCT01179152|Active Comparator|Budicort|75 children will receive treatment with Budicort 200 mcg
11525113|NCT01179152|Active Comparator|Symbicort|75 children will receive treatment with Symbicort 160 mcg
11525114|NCT01179152|No Intervention|counselling|75 children who will not treated as their request but will be folowedup
11525115|NCT01179139|Active Comparator|Healthy Control|
11525116|NCT01179139|Experimental|CRS|
11525009|NCT01179867|No Intervention|Usual practice medication reconciliation|Usual practice in dealing with medication reconciliation. This includes viewing the hospital medications through the hospital electronic pharmacy system, and viewing the community drugs in the patient's chart, if it was collected at admission (not always the case). However not all physicians view the community drugs before writing the discharge prescription. The physician will write a paper discharge prescription to be given to the patient, but communications are generally not made directly to the community pharmacist or previous prescribing physicians.
11525010|NCT01179854|Experimental|500 mg|Group of active treatment of Remegal 500 mg
11525011|NCT01179854|Experimental|Remegal 750 mg|Group of active treatment of Remegal 750 mg
11525012|NCT01179854|Experimental|Remegal 1000 mg|Group of active treatment of Remegal 1000 mg
11525013|NCT01179854|Placebo Comparator|Placebo|Placebo
11525014|NCT01179841|Experimental|Playgroup and Parent Training|"One to two-hour individual therapeutic sessions with parent training in the home or clinic, 1x every week over six months;
~parent training/enrichment once a week in our clinic for 20 sessions at 1-2 hours;
~a playgroup session for 1-2 hours 2x week for 6 months in our clinic and
~Community treatment as usual."
11525015|NCT01179841|Active Comparator|Parent Training|"Parent enrichment sessions once a week for 20 sessions (for 1-2 hours)
~Community treatment as usual."
11525016|NCT01179828|Active Comparator|1|Oxycodone 15mg
11525017|NCT01179828|Active Comparator|2|Clobazam 20mg
11525018|NCT01179828|Active Comparator|3|Imipramine 75mg
11525019|NCT01179828|Placebo Comparator|4|Tolterodine 1mg
11525020|NCT01179815||1|Patients with type 1 or type 2 diabetes mellitus, monogenetic diabetes, pancreatogenic diabetes, drug-induced diabetes, other forms
11525021|NCT01179802|Experimental|1|single event of a prolonged strenuous endurance exercise (mountain marathon)
11525022|NCT01179789|Active Comparator|Optimal Diet|Diet advices will receive the Optimal Diet for Elderly
11525023|NCT01179789|Experimental|VSL#3|Diet advices + VSL-3: will receive the Optimal Diet for Elderly + VSL#3® probiotic blend
11525024|NCT01179789|Experimental|AISA-5203-L|Diet advices + 5203-L: will receive the Optimal Diet for Elderly + AISA-5203-L fruit extracted terpene
11525025|NCT01179789|Experimental|Argan oil|Diet advices + Argan oil: will receive the Optimal Diet for Elderly + Argan
11525026|NCT01179776|Experimental|Ilomedin and standard low dose treatment|
11525027|NCT01179776|Placebo Comparator|Placebo|
11525028|NCT01179763||Retinal layer thickness analysis|Optical coherence tomography will be conducted to analyze retinal layer thickness (safe examination)
11525029|NCT01179750|No Intervention|No Ultrasonic Coagulating Shears group|the one arm: operated group without using Ultrasonic coagulation shears during gastrectomy;
11525030|NCT01179750|Experimental|ultrasonic coagulation shears group|the other arm: operated group using ultrasonic coagulation shears during gastrectomy
11525031|NCT01179737|Experimental|Nilotinib|Participants in cohort 1 were assigned to receive nilotinib 50 mg during 14 days, followed by 150 mg during 14 days, followed by 300 mg during 140 days. Participants in cohort 2 were assigned to receive nilotinib 300 mg during 168 days
11525032|NCT01179737|Placebo Comparator|Placebo|Participants were assigned to receive placebo to nilotinib to match 50 mg and 150 mg capsules during 168 days.
11525033|NCT01179724|Experimental|high dose proton pump inhibitor|
11525034|NCT01179724|Active Comparator|H2 receptor antagonist|
11525035|NCT01179711|Other|glasses prescription|At initial visit(of study), the physician will reduce the diopter of hyperopic glasses as much as the patient can maintain their eye alignment (maximum amount 1.5D).
11525036|NCT01179698|Other|Stryker navigation system|
11525037|NCT01179672|Experimental|Duloxetine|
11525038|NCT01179672|Placebo Comparator|Placebo|
11525039|NCT01179659|Active Comparator|Protonix|Protonix 40 mg DR Tablet (Wyeth Pharmaceuticals)
11525040|NCT01179659|Experimental|Pantoprazole 40 mg DR Tablet|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
11525041|NCT01179646|Active Comparator|Protonix|Protonix 40 mg DR Tablet
11525042|NCT01179646|Experimental|Pantoprazole|Pantoprazole 40 mg DR Tablet
11525043|NCT01179633|Active Comparator|Oplon Active Patch|
11525044|NCT01179633|Placebo Comparator|Placebo patch|
11525045|NCT01179620|Experimental|Certoparin|
11525046|NCT01179607|Active Comparator|M0002|"Started at 0.3 mg/day and increased every 3 days (to 1, 3 and 6 mg/day)
~for hyponatraemic subjects: dose was increased until the evening serum level was between 132 mmol/l and 145 mmol/l;
~for normonatraemic subjects the dose was increased until a 500 ml increase in the 24-h urine volume compared with Day-1 was reached.
~Once the required response or max dose was achieved, subjects entered a maintenance phase where they remained on the same dose of M0002 or placebo until 15 days."
11525047|NCT01179607|Placebo Comparator|Placebo|
11525048|NCT01179594|Placebo Comparator|A|
11525049|NCT01179594|Experimental|B|
11525050|NCT01179594|Placebo Comparator|C|
11525051|NCT01179594|Experimental|D|
11525052|NCT01179581|Experimental|1|single ascending doses
11525053|NCT01179581|Placebo Comparator|2|single dose placebo
11525054|NCT01179581|Experimental|3|multiple dose, 10 days, capsules (dosing depends on outcome of single-dose part; can be once or twice daily).
11525055|NCT01179581|Placebo Comparator|4|multiple dose, capsules, 10 days; scheme to match that of Study Arm 3.
11525056|NCT01179568|Active Comparator|CGT with Citalopram|Targeted psychotherapy for complicated grief will be combined with SSRI medication.
11525057|NCT01179568|Active Comparator|Citalopram|Citalopram is an Selective Serotonin Reuptake Inhibitor (SSRI) medication. It will be combined with grief-focused clinical management.
11525058|NCT01179568|Placebo Comparator|Placebo (Sugar pill)|Inactive medication. It will be combined with grief-focused clinical management.
11525059|NCT01179568|Active Comparator|CGT with Placebo|The targeted psychotherapy for complicated grief will be combined with inactive medication.
11525117|NCT01179126|Experimental|complete multivessel revascularization|
11525118|NCT01179126|Active Comparator|stress echo guided revascularization|
11525119|NCT01179113|Placebo Comparator|Placebo|Placebo: Will receive a normal saline bolus during induction, and an infusion of normal saline intraoperatively
11525176|NCT01178684||3: HIV-neg without peripheral neuropathy|
11525060|NCT01179555|Experimental|Pt. 1 Behavioral Activation|"Behavioral Activation (BA) is a behavioral technique to help people overcome avoidant tendencies through goal setting, activity scheduling, and graded task assignment. The key component of BA involves developing an Action Plan, and having the subject document each step of the plan as he or she implements it, reinforcing the steps towards goal attainment. Action Plans are easily applied to diabetes self-care tasks because the latter lend themselves to documentation of simple, step-by-step plans. In this study, a Community Health Educator (CHE) - interventionist will schedule and deliver four 45-60 minute in-home BA sessions within 3 months of randomization (i.e., one session every 2-3 weeks)."
11525061|NCT01179555|Placebo Comparator|Pt. 1 Supportive Therapy|The purpose of Supportive Therapy (ST) is to explore the impact of aging and diabetes on the subject's life. In contrast to the BA intervention, the interventionist does not discuss the importance of dilated eye exams. In subsequent sessions, ST facilitates and deepens knowledge about the subject's life situation in relation to his or her health and other life difficulties. The ST therapist encourages this process and creates an accepting, nondirective, and supportive opportunity for discussion.
11525062|NCT01179542||first trimester|first trimester
11525063|NCT01179542||third trimester|third trimester
11525064|NCT01179542||prgnancies complicated with IUGR|prgnancies complicated with IUGR
11525065|NCT01179542||preeclampsia|preeclampsia
11525066|NCT01179529|Experimental|Omalizumab|
11525067|NCT01179516|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
11525068|NCT01179516|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
11525069|NCT01179516|Experimental|Vortioxetine 15 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 15 mg, encapsulated tablets, orally, once daily for up to 7 weeks.
11525070|NCT01179503|Active Comparator|Calcium only|1200 mg Calcium per day
11525071|NCT01179503|Experimental|Vitamin D plus calcium|2000 IU vitamin D plus 1200 mg calcium per day
11525072|NCT01179490|Experimental|SyB L-0501 + prednisolone|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible. Prednisolone (60 mg/m2/day) will be administered orally for 4 consecutive days and the course will be observed for the next 24 days.
11525073|NCT01179464|Active Comparator|Aminobiphosphonates|Aminobiphosphonates
11525074|NCT01179464|Experimental|Aminobiphosphonates and Statin|Aminobiphosphonates and Statin
11525075|NCT01179451||Post streptococcal reactive arthritis (PSRA)|children who were diagnosed with psra at least one year before the study
11525076|NCT01179425|Active Comparator|non-marijuana dependent controls|
11525077|NCT01179425|Experimental|Marijuana-dependent subjects|
11525078|NCT01179412|Experimental|2% povidone-iodine|
11525079|NCT01179399|Experimental|TAK-960|
11525080|NCT01179386||methylphenidate|30 adolescents who are treated with Methylphenidate will perform the driving simulator and seat pressure mapping tests, in 2 different days : 1. with their regular methylphenidate medication and 2: without the methylphenidate medication after a 4 days washout period. Results will be recorded and statistical test will be performed.
11525081|NCT01179386||no medication|30 adolescents : control group , not suffering from ADHD and without methylphenidate medication will perform the driving simulator and seat pressure mapping tests. Results will be recorded and statistical test will be performed.
11525082|NCT01179373|Active Comparator|TMS, High Frequency|High Frequency TMS with H coil to prefrontal cortex
11525083|NCT01179373|Active Comparator|TMS, Low Frequency|Low Frequency TMS to Prefrontal cortex
11525084|NCT01179373|Placebo Comparator|Sham Stimulation|Sham TMS with H Coil on Prefrontal Cortex
11525085|NCT01179360||Imaging group|
11525086|NCT01179347|Experimental|tiotropium|2 inhalations once daily delivered with Respimat® inhaler
11525087|NCT01179347|Placebo Comparator|placebo|2 inhalations once daily delivered with Respimat® inhaler
11525088|NCT01179334|Experimental|Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks. Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
11525089|NCT01179334|Placebo Comparator|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 12 weeks. Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
11525090|NCT01179321|No Intervention|Control|
11525091|NCT01179321|Experimental|Early nutrition intervention|
11525092|NCT01179308|Active Comparator|General-epidural anesthesia|Epidural and general anesthesia
11525093|NCT01179308|Active Comparator|General anesthesia|General anesthesia alone
11525094|NCT01179295|Experimental|Arm 1|
11525095|NCT01179295|Experimental|Arm 2|
11525096|NCT01179295|Experimental|Arm 3|
11525097|NCT01179295|Experimental|Arm 4|
11525098|NCT01179282|Placebo Comparator|PLACEBO|PLACEBO NASAL SPRAY
11525099|NCT01179282|Active Comparator|DUST MITE ALLERGEN|Subjects will use dust mite Dermatophagoides pteronyssinus (Dp) extract or placebo nasal spray at home for 2 weeks, with a 1 month washout period followed by 2 weeks of the other nasal spray.
11525100|NCT01179269|Experimental|Pazopanib plus Paclitaxel|Pazopanib daily and weekly Paclitaxel IV.
11525101|NCT01179256|Experimental|CURCUMIN|oral supplementation of curcumin 2000mg
11525102|NCT01179256|Placebo Comparator|PLACEBO|oral PLACEBO TABLET
11525103|NCT01179243||intensive care patients|no interventions
11525104|NCT01179230||PET SPECT|Subjects will have both types of imaging performed, PET and SPECT
11525105|NCT01179217|Experimental|L-glutamine|Patients will be randomized to receive investigational product, L-Glutamine.
11525106|NCT01179217|Placebo Comparator|100% maltodextrin|Patients will be randomized to receive Placebo.
11525107|NCT01179204||Patiens operated with TKA|
11525108|NCT01179191|Experimental|morphine sulfate and naltrexone hydrochloride (EMBEDA)|
11525109|NCT01179178||COPD-patients|
11525120|NCT01179113|Active Comparator|Esmolol|Will receive Esmolol Loading: 0.5 mg/kg bolus during induction Infusion: 15 mcg /kg/min, infusion intraoperatively
11525121|NCT01179100|Placebo Comparator|Normal Saline|Normal Saline: Calculated and adjusted to match loading dose and infusion rate of lidocaine equivalent adjusted for weight.
11525122|NCT01179100|Active Comparator|Lidocaine|
11525123|NCT01179074|Active Comparator|Oesophageal stent alone|Patients of inoperable oesophageal cancer in this arm underwent oesophageal stenting with self expandable metal stents
11525124|NCT01179074|Active Comparator|Oesophageal stent followed by EBRT|Patients in this arm underwent oesophageal stenting with self expandable metal stents followed by external beam radiotherapy (30Gy/10#/2weeks)
11525125|NCT01179061|Experimental|Apelin infusion|6 hour infusion of apelin peptide into circulation
11525126|NCT01179061|Placebo Comparator|Placebo|Infusion of saline into systemic circulation
11525127|NCT01179048|Experimental|Liraglutide|
11525128|NCT01179048|Placebo Comparator|Placebo|
11525129|NCT01179035|Active Comparator|Expedited Primary Care|Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
11525130|NCT01179035|Experimental|Transitions Clinic - Parolee Targeted Care|Following randomization, subjects in this arm receive ongoing primary care in a parolee-targeted clinic. Parolee-targeted care includes care from clinicians with a knowledge of the impacts of incarceration on health and experience caring for formerly incarcerated patients, a community health worker that works in medical and social services coordination and chronic disease education, and linkages with community-based organizations serving formerly incarcerated individuals.
11525131|NCT01179009|Experimental|ketamine 100-hour infusion|100-hour infusion of ketamine plus a safener (clonidine)
11525132|NCT01179009|Experimental|ketamine 40-minute infusion|40-minute ketamine infusion following a 100-hours +/- placebo (saline) infusion. Participants will also receive a safener (clonidine)
11525133|NCT01178996|Experimental|Thymosin alpha 1|Patients affected by chronic hepatitis C not responding to a course with approved doses of PEGinterferon alpha plus ribavirin therapy (i.e. at least 1.0 mcg/kg PEGinterferon alpha2b, 180 mcg PEGinterferon alfa2a, 800 mg ribavirin).
11525134|NCT01178996|Placebo Comparator|Placebo|Patients affected by chronic hepatitis C not responding to a course with approved doses of PEGinterferon alpha plus ribavirin therapy (i.e. at least 1.0 mcg/kg PEGinterferon alpha2b, 180 mcg PEGinterferon alfa2a, 800 mg ribavirin).
11525135|NCT01178983|Experimental|telebiofeedback|
11525136|NCT01178983|Active Comparator|biofeedback|
11525137|NCT01178957||Type 1 diabetes|
11525138|NCT01178944|Experimental|Treatment (pralatrexate, oxaliplatin)|Patients receive pralatrexate IV over 3-5 minutes and oxaliplatin IV over 2 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Oxaliplatin will be discontinued after 12 courses.
11525139|NCT01178931|Active Comparator|Oral dydrogesterone|Study group receiving 2x10mg of oral dydrogesterone until a pregnancy test or in the case of pregnancy until 10 week.
11525140|NCT01178931|Active Comparator|Crinone 8% vaginal gel|Control group is receiving vaginal gel, 1x90mg, until a pregnancy test or in the case of pregnancy until 10 week.
11525141|NCT01178918||Healthy volunteers from recipients of H1N1 vaccine|
11525142|NCT01178905|Other|Mother CMV positive|
11525143|NCT01178892|Placebo Comparator|Placebo|
11525144|NCT01178892|Experimental|Omega-3|
11525145|NCT01178892|Experimental|Yoga|
11525146|NCT01178892|Experimental|Exercise|
11525147|NCT01178892|Other|Usual Activity 1|Usual Activity 1 and Usual Activity 2 arms will be compared to the Yoga and Exercise arms.
11525148|NCT01178892|Other|Usual Activity 2|Usual Activity 1 and Usual Activity 2 arms will be compared to the Yoga and Exercise arms.
11525149|NCT01178879|Experimental|Telehealth consultation|Telehealth nurse consultation plus treatment as usual
11525150|NCT01178879|No Intervention|Conventional|Treatment as usual
11525151|NCT01178866||Clinical course|complicated course group (death within 30 days after surgery or ICU stay > 4 days) and uncomplicated course group (ICU stay ≤ 4 days).
11525152|NCT01178853|Experimental|Pitavastatin/Rosuvastatin|
11525153|NCT01178853|Experimental|Rosuvastatin/Pitavastatin|
11525154|NCT01178840|Other|WC then FC2|The couples will use 4 PATH Woman's Condom then 4 FC2 female condom.
11525155|NCT01178840|Other|FC2 then WC|The couples will use 4 FC2 female condom then 4 PATH Woman's Condom.
11525156|NCT01178827|Experimental|Sanctura XR®|Sanctura XR® (trospium chloride), 60mg once daily for 10 days
11525157|NCT01178827|Active Comparator|Oxybutynin IR|Oxybutynin IR (oxybutynin immediate release), 5 mg three times daily for 2 days
11525158|NCT01178827|Placebo Comparator|Oxybutynin IR placebo|Oxybutynin IR placebo three times daily for 2 days
11525159|NCT01178814|Experimental|Revlimid|Revlimid (Lenalidomide) capsule taken orally once a day
11525160|NCT01178801||liver cancer|Clinical data of patients with liver cancer
11525161|NCT01178788|Active Comparator|17 alfa hydroxy Progesterone caproate|Women treated with i.m. 17P injection/weekly (Lentogest, IBSA, Italy)
11525162|NCT01178788|Active Comparator|Micronized Progesterone|micronized P 200 mg per vagina /day (Utrogestan, Besins Healthcare, Belgium)
11525163|NCT01178788|Active Comparator|Control|Routine clinical controls
11525164|NCT01178775|No Intervention|1|control design
11525165|NCT01178775|No Intervention|2|education only group
11525166|NCT01178775|Experimental|3|education and education and walking program design
11525167|NCT01178762|Experimental|Observation|
11525168|NCT01178749||Chronic Hepatitis C Infection|patients Receiving 24-week Interferon-α with Ribavirin Treatments
11525169|NCT01178736||Cancer Screening and Diagnosis|Screening of asymptomatic women for Breast and Cervical cancer in the age group of 35-64 years. Diagnostic assessment of symptomatic women for Ovarian and Endometrial cancer in the age group of 50-64 years.
11525170|NCT01178710|Experimental|treatment|
11525171|NCT01178710|No Intervention|untreated|control
11525172|NCT01178697|Active Comparator|Intravitreal triamcinolone|
11525173|NCT01178697|Active Comparator|Intravitreal bevasizumab|
11525174|NCT01178684||1: HIV-pos on d4T with neuropathy|
11525177|NCT01178684||4 HIV-pos on d4T with asymtomatic neuropathy|
11525178|NCT01178671|Experimental|Sertraline and Mirtazapine|Flexible dose of both medications for up to 24 weeks
11525179|NCT01178671|Active Comparator|Sertraline and Sugar pill|Sertraline and Sugar pill for up to 24 weeks
11525180|NCT01178658|Experimental|BuEAM|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
11525181|NCT01178645|Experimental|BuEAM|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
11525182|NCT01178632|Experimental|Passiflora, Anxiety Disorders|1 tablet Passiflora;Crataegus;Salix; PO;BID
11525183|NCT01178632|Active Comparator|Valeriane, Anxiety Disorder|1 tablet Valeriana officinalis, PO, BID
11525184|NCT01178619||AGA|
11525185|NCT01178619||symmetrical IUGR|
11525186|NCT01178619||asymmetrical IUGR|
11525187|NCT01178593|No Intervention|Standard Medical Therapy (SMT)|standard medical treatment (care as usual) with supportive talks
11525188|NCT01178593|Active Comparator|Gut focused hypnotherapy|weekly sessions of gut focused hypnotherapy in groups (10 sessions within 12 weeks)
11525189|NCT01178554|Active Comparator|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
11525190|NCT01178554|Experimental|Standard Manual Treatment (SMT)|Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
11525191|NCT01178554|Experimental|Modular Maual Treatment (MMT)|Therapists used a modular manual (Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems; Chorpita & Weisz, 2004) to help children with primary problems of anxiety, depression, and conduct.
11525192|NCT01178528|Experimental|Ivabradine|7.5 mg bd
11525193|NCT01178528|Active Comparator|Carvedilol|up to 25 mg bd
11525194|NCT01178528|Experimental|"Drug:Carvedilol and Drug:Ivabradine"|up to 12.5/5 mg bd
11525195|NCT01178515|Sham Comparator|Full fat milk|Full fat milk contain 3% fat
11525196|NCT01178515|Experimental|Partially defatted milk|Partially defatted milk contains 2% of fat
11525197|NCT01178515|Experimental|Defatted milk|Defatted milk contains 1% fat
11525198|NCT01178489||Patients undergoing arthroplasty|Patients undergoing primary, unilateral, total hip or knee arthroplasty under spinal anaesthesia
11525199|NCT01178476|Experimental|Hyposafe Hypoglycemia alarm device|EEG based hypoglycemia detection
11525200|NCT01178476|Active Comparator|Regular glucose control|Regular glucose control group
11525201|NCT01178463||I. Obstructive Azoospermia|
11525202|NCT01178463||II. Non-Obstructive Azoospermia Patients|
11525203|NCT01178450|Active Comparator|Subtotal parathyroidectomy|The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland
11525204|NCT01178450|Experimental|Cinacalcet|Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
11525205|NCT01178424|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of mindfulness skills taught in the program.
11525206|NCT01178424|Active Comparator|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
11525207|NCT01178411|Experimental|ARQ 197 as monotherapy or in combination with other drug (s)|ARQ 197 will be administered twice daily, orally, with meals
11525208|NCT01178385|Experimental|Cognitive-behavioral therapy|Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
11525209|NCT01178385|Active Comparator|Treatment as Usual|Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
11525210|NCT01178372|Active Comparator|lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
11525211|NCT01178372|Active Comparator|probiotics|
11525212|NCT01178346|Experimental|NicVAX|Experimental vaccine
11525213|NCT01178346|Placebo Comparator|Placebo|Placebo vaccine
11525214|NCT01178320||Simvastatin|Participants in the main AIM-HIGH study who are receiving simvastatin.
11525215|NCT01178320||Simvastatin and Extended-Release Niacin|Participants in the main AIM-HIGH study who are receiving simvastatin and extended-release niacin.
11525216|NCT01178307||Part 1|Patient interview and developmental questionnaires
11525217|NCT01178307||Part 2|Content Expert Panel (doctors, nurses) + Patients and Caregivers Questionnaire Development
11525218|NCT01178307||Part 3|Patient MDASI-GIST Questionnaire
11525219|NCT01178294|Experimental|OBI-1|Initial dose: 200 U/kg - additional doses at the discretion of the investigator based on FVIII activity level and clinical assessment of response to treatment (upper limit: 400 U/kg every 2 hours)
11525220|NCT01178281|Experimental|Pomalidomide 0.5 mg|"Participants received pomalidomide 0.5 mg/day by mouth for at least 168 days unless there were unacceptable side effects or disease progression.
~Participants who were RBC-transfusion independent or experienced clinical benefit (defined as a reduction from Baseline of ≥ 50% in RBC-transfusion frequency during the prior 84-day interval) could continue to receive pomalidomide until loss of RBC-transfusion independence response or clinical benefit, or other criteria for treatment discontinuation applied."
11525221|NCT01178281|Placebo Comparator|Placebo|"Participants received placebo taken by mouth once daily for at least 168 days unless there were unacceptable side effects or disease progression.
~Participants who were RBC-transfusion independent or experienced clinical benefit could continue to receive placebo until loss of RBC- transfusion independence response or clinical benefit, or other criteria for treatment discontinuation applied."
11525222|NCT01178281|Experimental|China Extension: Pomalidomide 0.5 mg|"Participants received pomalidomide 0.5 mg/day by mouth for at least 168 days unless there were unacceptable side effects, disease progression, or they received a RBC-transfusion.
~Participants who experienced anemia response could continue treatment until the response was lost or other criteria for treatment discontinuation applied."
11525223|NCT01178268|Active Comparator|XIENCE V EECSS|Patients who will receive this stent.
11525224|NCT01178268|Active Comparator|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
11525225|NCT01178255|Experimental|Group 1|
11525226|NCT01178255|Experimental|Group 2|
11525227|NCT01178255|Experimental|Group 3|
11525228|NCT01178255|Experimental|Group 4|
11525229|NCT01178242|Experimental|Salivary Gland and Labial Mucous Membrane Transplantation|
11525230|NCT01178229|Experimental|Physiotherapy|group of bruxist children that received physiotherapy to change the head posture
11525231|NCT01178229|No Intervention|Control|Group of bruxist children that did not receive treatment
11525232|NCT01178216|Experimental|Rituxan|All study patients will receive Rituxan 1g on day 15 from start of desensitization and either 3M or 6M post transplant depending on the presence of DSA.
11525233|NCT01178190||lung cancer|
11525234|NCT01178177||SOT recipients|solid organ transplant recipients with invasive pulmonary aspergillosis
11525235|NCT01178177||Hematologic disease|Hematologic disease patients with invasive pulmonary aspergillosis
11525236|NCT01178164|Experimental|Diagnosis of Fabry disease|
11525237|NCT01178151|Experimental|afinitor|10mg afinitor daily orally
11525238|NCT01178138|Other|Prazosin effects on methamphetamine|Randomized placebo controlled trial of prazosin effects on methamphetamine
11525239|NCT01178125|Experimental|DR-102|desogestrel/ethinyl estradiol 0.15/0.02 mg for 21 days then ethinyl estradiol 0.01 mg for 7 days
11525240|NCT01178112|Experimental|Trientine + Carboplatin MTD Group|Trientine starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group.
11525241|NCT01178112|Experimental|MTD Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group
11525242|NCT01178112|Experimental|Carboplatin PK Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group. PK testing blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
11525243|NCT01178112|Experimental|Trientine PK Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group. PK testing blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
11525244|NCT01178099|Experimental|Prasugrel|Participants received a single 10 milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants<60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).
11525245|NCT01178086||Participants With CLL|Participants with CLL who are being treated with intravenous (IV) rituximab in combination with chemotherapy, will be observed for 24 months including 6-month treatment period.
11525246|NCT01178073|Active Comparator|Combination ambrisentan + tadalafil|ambrisentan + tadalafil
11525247|NCT01178073|Active Comparator|Monotherapy ambrisentan|ambrisentan
11525248|NCT01178073|Active Comparator|Monotherapy tadalafil|tadalafil
11525249|NCT01178060|Active Comparator|Personalized Risk Information|Patients received personalized stroke and heart attack risk assessment information.
11525250|NCT01178060|Other|Standard Education|Patients received general risk information on heart attack and stroke.
11525251|NCT01178047|Active Comparator|Rasagiline|
11525252|NCT01178047|Placebo Comparator|Placebo|
11525253|NCT01178034|Experimental|pharmacogenetic warfarin dose|Warfarin maintenance dose on the basis of demographic/pharmacogenetic data
11525254|NCT01178021|Active Comparator|Chloroquine|Standard arm
11525255|NCT01178021|Experimental|Chloroquine/Primaquine|Chloroquine combined with primaquine
11525256|NCT01178008|Experimental|Active acupuncture group|Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints.
11525257|NCT01178008|Placebo Comparator|Placebo acupuncture group|Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
11525258|NCT01177995|Experimental|Social Network|Leaders of labor migrant social networks will be trained to disseminate HIV prevention messages to the members of their social networks. The training will sequentially target ways to increase network members' HIV-related knowledge and norms, attitudes, intentions, and confidence in how to avoid risk. Leaders will be encouraged to have these discussions with network members between and after training sessions.
11525259|NCT01177982|Active Comparator|Usual RBT (t-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club
11525260|NCT01177982|Experimental|Reduced RBT (r-RBT)|Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social Club Job Club
11525261|NCT01177982|Experimental|Abbreviated RBT (a-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation
11525262|NCT01177982|Active Comparator|Enhanced RBT (e-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club Recovery housing CAP short term housing admission Recovery sponsor
11525263|NCT01177982|Active Comparator|Early compliant t-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social club Job club
11525264|NCT01177982|Active Comparator|Early non-compliant t-RBT|t-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club e-RBT: Recovery housing CAP short term housing admission Recovery sponsor
11525265|NCT01177982|Experimental|Early compliant r-RBT|a-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation r-RBT: Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
11525266|NCT01177982|Experimental|Early non-compliant r-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social Club Job Club
11525267|NCT01177969|Experimental|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
11525268|NCT01177969|Placebo Comparator|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
11525269|NCT01177956|Experimental|Cetuximab + Cisplatin + 5-Fluorouracil (5-FU)|
11525270|NCT01177943|Experimental|Atomoxetine Oral Solution|
11525271|NCT01177943|Active Comparator|Atomoxetine Capsule Formulation|
11525272|NCT01177930||Feeding with milk with DHA and ARA|
11525273|NCT01177930||Feeding with milk without DHA and ARA|
11525274|NCT01177917|Experimental|Cow milk-based infant formula with prebiotic blend|
11525275|NCT01177917|Placebo Comparator|Marketed Cow milk-based infant formula|
11525276|NCT01177904|Active Comparator|Progesterone 5 Weeks|The study group stop receiving P4 on the day of their first US at 5 weeks pregnancy
11525277|NCT01177904|Other|Control Group : P4 8 weeks|Progesterone will be given until 8 weeks of pregnancy
11525278|NCT01177891||Subject index|Population of familial cases of POF : 20 families with at least two subjects with POF nonsyndromic
11525279|NCT01177891||Population Index Related topics|Women, healthy women, men are potential carriers
11525280|NCT01177891||Population control|100 Caucasian women with normal cycles until at least the age of 40 years and a proven fertility
11525281|NCT01177852|Experimental|Notuss® syrup|Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
11525282|NCT01177852|Active Comparator|Dropropizine + Pseudoephedrine and brompheniramine|Group 2: combined use of dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate.
11525283|NCT01177839||Intussusception cohort|Subjects with Intussusception
11525284|NCT01177826||Group 1|Cases
11525285|NCT01177826||Group 2|Controls
11525286|NCT01177813|Experimental|BI 10773 low dose|Patients receive BI 10773 low dose tablets once daily
11525287|NCT01177813|Experimental|BI 10773 high dose|Patients receive BI 10773 high dose tablets once daily
11525288|NCT01177813|Placebo Comparator|Placebo|Patients receive tablets identical to those containing BI 10773 low dose and high dose and to Sitagliptin
11525289|NCT01177813|Active Comparator|Sitagliptin 100 mg|Patients receive Sitagliptin 100 mg tablets once daily
11525290|NCT01177813|Experimental|BI 10773 high dose open label|Patients receive BI 10773 high dose tablets open label once daily
11525291|NCT01177800|Experimental|Infliximab|5 milligram per kilogram (mg/kg) infusion (a fluid or a medicine delivered into a vein by way of a needle) of infliximab administered intravenously (into a vein) at Week 0, 2 and 6 followed by maintenance regimen of 5 mg/kg infliximab at Week 14 and 22. Placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial infusion), matched to infliximab will be given at Week 10, 12 and 16. Total duration of treatment will be 26 weeks.
11525292|NCT01177800|Experimental|Placebo|Placebo infusion, matched to infliximab will be given intravenously at Week 0, 2 and 6. At Week 10, 12 and 16, participants will receive 5 mg/kg infliximab intravenously. Placebo infusion will be again given at Week 14 and 22. Total duration of treatment will be 26 weeks.
11525293|NCT01177787|Active Comparator|zeltiq|Cryolipolysis had been done for 1 hour on ipsilateral thigh fat through Zeltiq machine.
11525294|NCT01177787|Sham Comparator|electrical stimulation|Lipolysis had been done for 30 minutes on controlateral thigh fat through amplitude modulated frequency.
11525295|NCT01177774||Recent-onset tics that will persist|Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who, when reassessed at 1 year after the first tic began (i.e. 6-12 months after study enrollment) will turn out to meet criteria for a chronic tic disorder (including Tourette syndrome). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).
11525341|NCT01177423|Active Comparator|Quicksleeper intraosseous anesthesia|Pulpal and periapical molar and premolar sedation is managed by Quicksleeper intraosseous anesthesia.
11525296|NCT01177774||Recent-onset tics that will remit|Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who will no longer have tics when reassessed 1 year after the first tic began (6 to 12 months after study enrollment). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).
11525297|NCT01177774||Tic-free control subjects|Children with no current or past tic disorder of similar age, sex and handedness as the children in the recent-onset tics groups.
11525298|NCT01177774||Existing TS/CTD|Children with current tics whose first tics were more than 12 months ago (DSM-5 Tourette's Disorder or Persistent [Chronic] Motor or Phonic Tic Disorder), of similar age, sex and handedness as the children in the recent-onset tics groups.
11525299|NCT01177761|Active Comparator|exercise|endurance,balance, power, resistance type exercise
11525300|NCT01177761|No Intervention|sedentary control|Subjects were instructed to do not relevantly change their lifestyle
11525301|NCT01177748||Patients on the Stroke Unit|
11525302|NCT01177735|Experimental|Pomalidomide|
11525303|NCT01177722|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T (Lot A)|
11525304|NCT01177722|Experimental|Group 2: DTaP-IPV-Hep B-PRP-T (Lot B)|
11525305|NCT01177722|Experimental|Group 3: DTaP-IPV-Hep B-PRP-T (Lot C)|
11525306|NCT01177722|Active Comparator|Group 4: Active Control|
11525307|NCT01177709|Experimental|Metformin|
11525308|NCT01177696|Experimental|psychotherapy|"The study aims to evaluate the effectiveness of an intervention of psychotherapy in improving the mental health of caregivers.
~This intervention is based on theoretical approaches to care adjusted to cognitive theory, in order to be applied in primary health care centres."
11525309|NCT01177696|No Intervention|Control|
11525310|NCT01177683|Experimental|Arm 1|Bendamustine in combination with bortezomib and pegylated liposomal doxorubicin.
11525311|NCT01177657||Gastroenteritis cohort|Children born after 6 March 2006, at least 12 weeks of age and hospitalized for rotavirus severe gastroenteritis
11525312|NCT01177657||Hospital control cohort|Children hospitalized for non gastroenteritis causes
11525313|NCT01177657||Neighbourhood control cohort|Children without any symptoms of gastroenteritis or severe gastroenteritis
11525314|NCT01177644|Experimental|Active|
11525315|NCT01177618||Probands|Severe, early-onset COPD subjects that bring the family into the study
11525316|NCT01177618||Relatives|Relatives of early-onset COPD probands, including first-degree relatives (parents, siblings, and children), second-degree relatives (aunts, uncles, grandparents, half-siblings), spouses, and other affected individuals.
11525317|NCT01177605|Placebo Comparator|Vanilla flavored milk-based beverage containing no prebiotics|Vanilla flavored milk-based beverage containing no prebiotics
11525318|NCT01177605|Experimental|Vanilla flavored milk-based beverage containing prebiotics|Vanilla flavored milk-based beverage containing prebiotics
11525319|NCT01177592|Experimental|Guided Therapy|Subjects on chronic clopidogrel therapy (≥ 5 days maintenance or loading within 4 hours of PCI) will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing
11525320|NCT01177592|No Intervention|Standard Therapy|Patients randomized to the control arm will remain on 75mg clopidogrel arm throughout the study.
11525321|NCT01177579|No Intervention|Aim 1; Biomarkers|Blood concentrations of copper coenzymes will be monitored for 1 year
11525322|NCT01177579|Experimental|Copper supplement Arm|4 mg or 8 mg copper will be compared in a randomized controlled study
11525323|NCT01177579|No Intervention|Normal Controls|Normal subjects will be used to generate reference measures.
11525324|NCT01177566|Active Comparator|pimecrolimus (Elidel)|pimecrolimus twice daily to a chosen target lesion on one side of body
11525325|NCT01177566|Active Comparator|topical medical device cream (Eletone)|topical medical device cream three times daily to a chosen target lesion on one side of the body
11525326|NCT01177553|Active Comparator|Surgery Group|"Patients randomized to surgery will have hospital arrangements (laboratory tests and anesthesia assessment) finalized for a surgery the next day. Patients will sign the informed consent form.
~Patients undergoing surgery will be admitted to Tampa General Hospital and will complete usual hospital admission procedures."
11525327|NCT01177553|Active Comparator|Expectant Management Group|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
11525328|NCT01177540|Experimental|Arm A|
11525329|NCT01177540|Experimental|Arm B|
11525330|NCT01177514|Experimental|GABAPENTIN|Group of patients treated with oral gabapentin
11525331|NCT01177514|Placebo Comparator|PLACEBO|Group given the placebo capsules
11525332|NCT01177501|Experimental|Topotecan|
11525333|NCT01177488|Experimental|BATE-T|Behavioral Activation Therapeutic Exposure done while the patient is at home via videoconferencing technology
11525334|NCT01177488|Active Comparator|BATE-IP|Behavioral Activation Therapeutic Exposure done in the therapist's office
11525335|NCT01177475|Active Comparator|natural milk|
11525336|NCT01177475|Experimental|pasteurized milk|
11525337|NCT01177462||hemineglect stroke patients|Stroke patients with hemineglect
11525338|NCT01177462||Control stroke patients|Stroke patients without hemineglect
11525339|NCT01177462||Normal control|Normal subjects
11525340|NCT01177436|Experimental|Patients treated for prostatic pathology|Patients treated for prostatic pathology (benign or malign)in the hospital department.
11525342|NCT01177423|Active Comparator|Inferior alveolar nerve block|Pulpal and periapical molar and premolar sedation is managed by inferior alveolar nerve block.
11525343|NCT01177410|Placebo Comparator|Placebo|
11525344|NCT01177410|Experimental|Mesalamine Granules 750 mg|
11525345|NCT01177410|Experimental|Mesalamine Granules 1500 mg|
11525346|NCT01177397|Experimental|CC-223|All patients will receive CC-223, but serial patient groups will receive different dose levels in Phase 1. The number of groups will be determined by the number of dose levels required to establish dose-limiting toxicity.
11525347|NCT01177384|Experimental|Sitagliptin|Sitagliptin 100 mg daily (q.d.) + acarbose (continuing the current stable dose of at least 50 mg three times daily [t.i.d.])
11525348|NCT01177384|Placebo Comparator|Placebo|Placebo q.d. + acarbose (continuing the current stable dose of at least 50 mg t.i.d.)
11525349|NCT01177371|Experimental|Arm I|"HIGH-DOSE CHEMOTHERAPY: Patients receive oral busulfan every 6 hours on days -8 to -5 and cyclophosphamide IV over 2 hours on days -4 and -3, or -4 to -2.
~TRANSPLANTATION: Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.
~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine IV over 6 hours on day -1, over 10 hours twice daily on days 0-20, and then orally every 12 hours beginning on day 21 and continuing for 12 months with taper at 9 months. Patients also receive methylprednisolone IV or orally beginning on day 8 and continuing for 7 months with taper at 4 months. Some patients may also receive methotrexate IV on days 1, 3 and 6."
11525350|NCT01177358|Experimental|Botulinum Toxin A injection|"A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.
~5 Units (0.1 mL) of Botulinum Toxin A will be injected at three sites along the incision (midline and 1.5 cm lateral to midline) following a thyroidectomy or parathyroidectomy."
11525351|NCT01177358|Placebo Comparator|Saline|0.1 mL of normal saline in a placebo vial containing 2 mL of normal saline will be injected along the incision (midline and 1.5 cm lateral to midline) following a thyroidectomy or parathyroidectomy.
11525352|NCT01177345||Terminal Disease|Terminal cervical cancer- not treatable
11525353|NCT01177345||Early Disease|Early cervical cancer = meaning treatable with hysterectomy.
11525354|NCT01177345||Advanced Disease|Advanced cervical cancer- treatable with chemotherapy and/or radiation.
11525355|NCT01177332|Experimental|Fasted|Two-hour cycling test, fasted condition
11525356|NCT01177332|Other|Glucose-fed|Two-hour cycling test, glucose-fed condition
11525357|NCT01177306|Experimental|Extended Release Guanfacine|pre and post testing of working memory in subjects whose ADHD has responded to extended release guanfacine. Subjects will be tested before starting study drug and after 6-8 weeks on a stable dose of the study drug.
11525358|NCT01177293|Active Comparator|treatment A - reference w/ water|
11525359|NCT01177293|Experimental|Treatment B - ODT (test) w/o water|
11525360|NCT01177241||CLBP|
11525361|NCT01177241||CLBP OU|
11525362|NCT01177228|Placebo Comparator|Placebo|Vedolizumab-matching placebo, intravenous (IV), infusion on Days 1, 15, 29 and 85.
11525363|NCT01177228|Experimental|Vedolizumab 2 mg/kg|Vedolizumab, 2 mg/kg, IV infusion on Days 1, 15, 29 and 85.
11525364|NCT01177228|Experimental|Vedolizumab 6 mg/kg|Vedolizumab 6 mg/kg, IV infusion on Days 1, 15, 29 and 85.
11525365|NCT01177228|Experimental|Vedolizumab 10 mg/kg|Vedolizumab 10 mg/kg, IV infusion on Days 1, 15, 29 and 85.
11525366|NCT01177215||Digital chest tube|All patients will be treated with the digital chest tube device
11525367|NCT01177202|Experimental|Group A|HAC1 Dose = 15ug; Alum Dose = 0
11525368|NCT01177202|Experimental|Group B|HAC1 Dose = 15ug; Alum Dose = 0.75mg
11525369|NCT01177202|Experimental|Group C|HAC1 Dose = 45ug; Alum Dose = 0
11525370|NCT01177202|Experimental|Group D|HAC1 Dose = 45ug; Alum Dose = 0.75mg
11525371|NCT01177202|Experimental|Group E|HAC1 Dose = 90ug; Alum Dose = 0
11525372|NCT01177202|Experimental|Group F|HAC1 Dose = 90ug; Alum Dose = 0.75mg
11525373|NCT01177202|Placebo Comparator|Group G|Saline
11525374|NCT01177202|Active Comparator|Group H|H1N1
11525375|NCT01177189|Other|Arm 1|Young healthy men and women aged 18-30
11525376|NCT01177189|Other|Arm 2|Older healthy men and women aged >70.
11525377|NCT01177176|Other|Standard Care|Standard tobacco counseling provided to hospital inpatients as part of routine, clinical-guideline compliant care in the study hospital. No post-discharge treatment is offered in this arm.
11525378|NCT01177176|Experimental|Extended Care Management|In addition to Standard Care, subjects in this arm receive Extended Care Management intervention to facilitate the continued use of smoking cessation treatment (counseling and medication use) after hospital discharge. This consists of 3 months of telephone-based contact after discharge.
11525379|NCT01177163|Other|001|Placebo one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
11525380|NCT01177163|Experimental|002|JNJ 28431754 100 mg/placebo one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
11525381|NCT01177163|Experimental|003|JNJ 28431754 300 mg/placebo one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
11525382|NCT01177150|Experimental|001|JNJ-28431754/ Placebo Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses the evening dose will be administered at 10 hours after the morning dose.
11525383|NCT01177150|Experimental|002|JNJ-28431754 Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
11525384|NCT01177137|Experimental|TRT|TRT includes treatment with a conventional sound generator (SG) and directive counseling (DC)
11525385|NCT01177137|Other|Partial TRT|Partial TRT includes treatment with a placebo sound generator (placebo SG) and directive counseling (DC).
11525386|NCT01177137|Other|Standard of Care (SC)|The standard of care arm includes care as typically delivered in US military medical centers
11525387|NCT01177124|Experimental|MBSR 6 Weeks Program|
11525388|NCT01177124|No Intervention|Usual Care (UC)|
11525389|NCT01177111|Experimental|Sunflower seed Oil|
11525390|NCT01177111|Active Comparator|Mustard seed oil|
11525391|NCT01177098|Experimental|bimatoprost/timolol formulation A|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
11525392|NCT01177098|Active Comparator|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
11525393|NCT01177085|Experimental|Mushroom|Mushroom enriched weight loss diet. Participants will be given a personalized diet plan, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
11525394|NCT01177085|Active Comparator|No mushroom diet|Participants will be given a personalized diet plan, without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
11525395|NCT01177072|Experimental|Components-Based Interventions (CBI)|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
11525396|NCT01177072|Experimental|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
11525397|NCT01177072|No Intervention|Wait List Control|Eligible clients will not be provided therapy at enrollment. After the study period has completed, control clients will be re-interviewed. Those that remain eligible due to symptom cutoff scores will be offered therapy. In the interim, controls will receive a phone call once a month; those with indications of possible harm to self or others will be referred to a psychiatrist.
11525398|NCT01177059|Other|Anti-HIV-1 Ribozyme (OZ1) transduced cells|OZ1 transduced cells Long term follow up of previously infused OZ1 transduced cells
11525399|NCT01177033||Best endovascular treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
11525400|NCT01177033||Best surgical treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
11525401|NCT01177020||Placentas after delivery or abortion|
11525402|NCT01177007|Experimental|TheraSphere|
11525403|NCT01176994|Experimental|Skin lesions|Individuals with skin lesions whose lesions are not sent for histology by dermatologists
11525404|NCT01176981|Experimental|HDMTX|This is a single arm study. All subjects enrolled in the study will be in this arm.
11525405|NCT01176968|Experimental|Eplerenone plus standard of care|
11525406|NCT01176968|Placebo Comparator|Placebo plus standard of care|Matching placebo for eplerenone 25mg film coated tablets.
11525407|NCT01176955|Experimental|Internet survey|Subjects will receive a weekly email link to complete an internet survey about their acne and use of the study medication.
11525408|NCT01176955|Placebo Comparator|Control|Subjects will receive standard-of-care treatment with the study medication, without internet surveys.
11525409|NCT01176942|Experimental|Probiotic|
11525410|NCT01176942|Placebo Comparator|Placebo|
11525411|NCT01176929|Experimental|Interventional group|Usual treatment + prevention program of recurrent suicidal acts
11525412|NCT01176929|Active Comparator|Control group|Usual treatment
11525413|NCT01176916|Experimental|A|
11525414|NCT01176903|Experimental|Glyco SD1|Single administration of Glyco pMDI dose level 1
11525415|NCT01176903|Experimental|Glyco SD2|Single administration of Glyco pMDI dose level 2
11525416|NCT01176903|Experimental|Glyco SD3|Single administration of Glyco pMDI dose level 3
11525417|NCT01176903|Experimental|Glyco SD4|Single administration of Glyco pMDI dose level 4
11525418|NCT01176903|Experimental|Glyco SD5|Single administration of Glyco pMDI dose level 5
11525419|NCT01176903|Placebo Comparator|Placebo SP|Single administration of Placebo pMDI
11525420|NCT01176903|Experimental|Glyco MD1|Multiple administration of Glyco pMDI dose level 1
11525421|NCT01176903|Experimental|Glyco MD2|Multiple administration of Glyco pMDI dose level 2
11525422|NCT01176903|Experimental|Glyco MD3|Multiple administration of Glyco pMDI dose level 3
11525423|NCT01176903|Placebo Comparator|Placebo MP|Multiple administration of placebo pMDI
11525424|NCT01176903|Active Comparator|Tiotropium|Multiple administration of tiotropium
11525425|NCT01176890|Experimental|Vago|Truncally vagotomized subjects (due to duodenal ulcer operation)
11525426|NCT01176890|Experimental|Cardia|truncally vagotomized subjects (due to esophagus resection)
11525427|NCT01176890|Experimental|Healthy controls|Healthy control subjects
11525428|NCT01176877|Other|keloid scar|Those with a diagnosis of keloid scar.
11525429|NCT01176864|Active Comparator|Double-balloon enteroscopy|DBE for suspected or known small-bowel bleeding
11525430|NCT01176864|Active Comparator|Single-balloon enteroscopy|SBE for suspected or known small-bowel bleeding
11525431|NCT01176851|Experimental|Glyco pMDI|Glyco pMDI 100 µg
11525432|NCT01176851|Experimental|Glyco pMDI Charcoal|Glyco pMDI 100 µg + charcoal block
11525433|NCT01176851|Active Comparator|Glyco IV injection|Glyco solution for injection 100 µg
11525434|NCT01176825|Experimental|CBT|14-week individual cognitive-behavior therapy
11525435|NCT01176825|No Intervention|Treatment As Usual|14-week waitlist control
11525436|NCT01176812||Dermal Fillers|Facial Wasting
11525437|NCT01176799|Active Comparator|Arm A: Control Arm|"Doxorubicin - 60mg/m2 day 1
~Cyclophosphamide
~-600mg/m2 day1, every 3 weeks x 4 cycles"
11525438|NCT01176799|Experimental|Arm B: Experimental|Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
11525439|NCT01176773|Experimental|Juvéderm® Ultra Lip Injectable Gel|
11526016|NCT01172613||allergic rhinitis patient|
11525440|NCT01176760|Experimental|Vago|Truncally vagotomized subjects (due to duodenal ulcer operation)
11525441|NCT01176760|Experimental|Cardia|Truncally vagotomized subjects (due to cardia resection)
11525442|NCT01176760|Experimental|Ctrl|Healthy matched control subjects
11525443|NCT01176747|Experimental|BDP/formoterol NEXT DPI|Radiolabelled BDP/formoterol 100/6 µg dry powder administered via the NEXT inhaler
11525444|NCT01176734|Experimental|active t-VNS|active t-VNS
11525445|NCT01176721|Active Comparator|t-VNS verum|Active stimulation of the left auricle by t-VNS
11525446|NCT01176721|Placebo Comparator|Sham|Sham-simulation of the left auricle by the t-VNS device.
11525447|NCT01176708|Experimental|Liver transplanted|10 Liver transplanted patients
11525448|NCT01176708|Experimental|Kidney transplanted|10 kidney transplanted individuals
11525449|NCT01176708|Experimental|Healthy controls|10 healthy controls
11525450|NCT01176695|Experimental|1|fish oil containing lipid emulsion
11525451|NCT01176695|Active Comparator|2|MCT/LCT containing lipid emulsion
11525452|NCT01176682||1|Adult patients treated with NSAID therapy for diagnosed OA, RA or AS, and with GI risk factors
11525453|NCT01176669|Experimental|Apatinib|
11525454|NCT01176656||SU|T2DM patients with a prescription for a sulfonylurea but no insulin
11525455|NCT01176656||Antidiabetic without SU|T2DM patients with an oral antidiabetic drug other than an SU, and no insulin
11525456|NCT01176656||Insulin|T2DM patients using insulin, with or without other oral antidiabetics
11525457|NCT01176643|Active Comparator|standard care plus yoga|Participants will be asked to complete two yoga classes weekly over a period of eight weeks.
11525458|NCT01176643|No Intervention|Standard care|
11525459|NCT01176617|No Intervention|Conventional Monitoring Strategy|Subjects will be monitored for 12 months using the conventional strategy which includes wearing a monitor over 3 separate 30-day periods over the first year post-ablation and daily pulse checks.
11525460|NCT01176617|Other|Reveal XT|Subjects will be monitored using the conventional monitoring strategy for the first 6 months post-ablation. During the next 6 months, subjects will be monitored using the data from the Reveal device, transmitted from home every 30 days.
11525461|NCT01176604|Experimental|Treatment (yttrium Y 90 glass microspheres)|Participants receive yttrium Y 90 glass microspheres via a catheter over 5 minutes on day 0. Participants may receive additional treatments at 4-12 week intervals until all tumors in the liver have been treated in the absence of disease progression or unaccepted toxicity.
11525462|NCT01176591|Experimental|Placebo Session 1, Aprepitant Session 2|Participants receive placebo in session 1 and Aprepitant in session 2 of a psychological stressor presentation and receive placebo in session 1 and Aprepitant in session 2 of a physiological stressor presentation. Participants take Aprepitant (80 mg) or placebo tablets for 7 days prior to each session.
11525463|NCT01176591|Placebo Comparator|Placebo Session 1, Placebo Session 2|Participants receive placebo in session 1 and placebo in session 2 of a psychological stressor presentation and receive placebo in session 1 and placebo in session 2 of a physiological stressor presentation. Participants take placebo tablets for 7 days prior to each session. The placebo group is used for analysis purposes in order to control for any order effects found in the Experimental group.
11525464|NCT01176578|Experimental|T2DM|Type 2 Diabetes Mellitus
11525465|NCT01176578|Experimental|IGT|Impaired Glucose Tolerance
11525466|NCT01176578|Active Comparator|NGT|Normal Glucose Tolerance
11525467|NCT01176565|Active Comparator|Standard SBP Reduction Arm|"Intravenous nicardipine hydrochloride will be used as necessary (pro re nata or PRN) as the primary agent in lowering SBP.
~The goal for the standard BP reduction group will be to reduce and maintain SBP < 180 mmHg for 24 hours from randomization. 160 mmHg is the target SBP for this arm.
~For the standard group, SBP below the assigned treatment range is not artificially elevated to stay within the range if lower SBP occurs with nicardipine turned off (no fluid bolus given unless SBP falls below 110 mmHg with nicardipine off and there is risk for hypotension). Euvolemic fluid maintenance is encouraged for all patients according to their medical needs, which may differ."
11525468|NCT01176565|Active Comparator|Intensive SBP Reduction Arm|"Intravenous nicardipine hydrochloride will be used as necessary (pro re nata or PRN) as the primary agent in lowering SBP.
~The goal for the intensive BP reduction group will be to reduce and maintain SBP < 140 mmHg for 24 hours from randomization. 125 mmHg is the target SBP for this arm.
~For the intensive group, SBP falling below 110 mmHg (lower limit of the assigned treatment range) with nicardipine off is treated with normal saline fluid bolus to prevent or remedy hypotension. Euvolemic fluid maintenance is encouraged for all patients according to their medical needs, which may differ."
11525469|NCT01176552|Experimental|Study group: GM-CSF, IFN, IL-2|
11525470|NCT01176539||Sleep Clinic|
11525471|NCT01176513|Experimental|GE 148-002|
11525472|NCT01176487|Experimental|A|A clinical trial using 3-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer
11525473|NCT01176474|Experimental|Nivolumab and Peptide Vaccine|"Cohorts 1 through 3: Participants will receive nivolumab with the peptide vaccine within 8 days after their first apheresis procedure.
~Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG with Escalating Doses of Anti-PD-1 Antibody Nivolumab (BMS-936558). Level 1: 1 mg/kg Nivolumab + peptide vaccine. Level 2: 3 mg/kg Nivolumab + peptide vaccine. Level 3: 10 mg/kg Nivolumab + peptide vaccine."
11525474|NCT01176474|Experimental|Nivolumab and Ipilimumab|Cohorts 4 and 5. Participants will receive their first dose of nivolumab with ipilimumab within 28 days after screening blood draws. Both drugs will be given. Cohort 4: nivolumab 1mg/kg plus ipilimumab 3mg/kg. Cohort 5: nivolumab 3mg/kg plus ipilimumab 1mg/kg.
11525475|NCT01176461|Experimental|A1 - Phase I Dose Escalation|Cohorts 1 through 5. Each treatment cycle is comprised of 6 doses of BMS-936558 and 6 peptide vaccines administered every 2 weeks for 12 weeks (cohort 6 has no peptides) (Cycle 1: Weeks 1, 3, 5, 7, 9, and 11; Cycle 2: Weeks 13, 15, 17, 19, 21, and 23) with tumor response assessments at the end of each cycle (during Weeks 12 and 24).
11525476|NCT01176461|Active Comparator|A2 - BMS-936558 Without Peptide Vaccine|Cohort 6. Each treatment cycle is comprised of 6 doses of BMS-936558 administered every 2 weeks for 12 weeks (cohort 6 has no peptides) (Cycle 1: Weeks 1, 3, 5, 7, 9, and 11; Cycle 2: Weeks 13, 15, 17, 19, 21, and 23) with tumor response assessments at the end of each cycle (during Weeks 12 and 24).
11526214|NCT01171144||Gastroenteritis Group|All children suffering with gastroenteritis
11525477|NCT01176448|Experimental|Fractionated laser|This Arm is the section of scar that will be treated with Fractionated Laser
11525478|NCT01176448|Active Comparator|Dermabrasion|Dermabrasion is the gold standard for scar resurfacing and will be used as the control against which Fractionated Laser is compared.
11525479|NCT01176435|Active Comparator|0.76 mg/kg L-DOPA|Solution taken orally three times a day.
11525480|NCT01176435|Active Comparator|0.51 mg/kg L-DOPA|Solution taken orally three times a day.
11525481|NCT01176435|Placebo Comparator|Placebo|Solution taken orally three times a day.
11525482|NCT01176422||advanced Myelodysplastic Syndrome or acute myeloid leukemia|advanced MDS and AML with/without associated cytogenetic abnormality
11525483|NCT01176409|Experimental|High dose valacyclovir|Valacyclovir 1g po BID
11525484|NCT01176409|Active Comparator|Low dose valacyclovir|Valacyclovir 500mg po BID
11525485|NCT01176409|Placebo Comparator|Placebo|Inert placebo
11525486|NCT01176396|Active Comparator|Caries prevention active intervention|Patients receive CAMBRA related products like CHX, 5000ppm F-toothpaste etc according to their risk level
11525487|NCT01176396|Placebo Comparator|control treatment|Patients receive treatment according to standard of care
11525488|NCT01176383|No Intervention|Control group|The control group will have a standard NHS cessation clinic experience
11525489|NCT01176383|Experimental|Respiragene test and risk score|Subjects will have a buccal swab taken at first attendance for a 12 gene test of SNP variants associated with risk of lung cancer. From the genetic data and clinical data (any history of COPD, family history of lung cancer in a first degree relative and age) a risk score is calculated from which a lifetime risk of lung cancer if the subject continues to smoke can be calculated. This is expected to be a powerful motivator to encourage smoking cessation.
11525490|NCT01176370|Experimental|Implantable Counterpulsation Therapy|The study is a single arm study with up to 20 patients enrolled and implanted with implantable counterpulsation. Patients that meet eligibility will be enrolled and implanted into the treatment arm of the study. There is not a control arm in this feasibility study.
11525491|NCT01176357||1|CABG
11525492|NCT01176357||2|Valve surgery
11525493|NCT01176344|Experimental|Vitamin D supplementation|Participants in the intervention arm will receive 50,000 IU (1.25 mg) cholecalciferol capsules given once monthly
11525494|NCT01176344|Placebo Comparator|Placebo|The control arm will receive identical inert placebo capsules given once monthly.
11525495|NCT01176331||vitrectomy|
11525496|NCT01176318|Experimental|erdosteine|standard care plus erdosteine for 10 days
11525497|NCT01176318|Placebo Comparator|placebo|Standard care for exacerbation of COPD plus placebo
11525498|NCT01176305||Danish Women 15 to 49 years old.|Free of previous VTE and current use of oral contraceptives.
11525499|NCT01176292|Other|Rotating Platform High-Flex Cruciate Substituting TKA|
11525500|NCT01176292|Other|Rotating Platform Cruciate Substituting TKA|
11525501|NCT01176279|Active Comparator|Manual and automated washing of the line|Place in the radial artery the system of invasive monitoring of the blood pressure (BD DTXPlus ™). Insert in line a second 3-way stopcock above the one that has the BD DTXPlus ™; this second 3-way stopcock will be called proximal key. On the distal 3-way stopcock key (the one of TM BD DTXPlus ™), put the needless connector included in the kit to make the extractions of blood. Connect an arterial blood sampling syringe on the proximal 3-way stopcock key. With the assembled system, it is necessary to print a curve of invasive determination of the blood pressure.
11525502|NCT01176279|Experimental|Automated washing of the line|Place in the radial artery the system of invasive monitoring of the blood pressure (BD DTXPlus ™). Insert in line a second 3-way stopcock above the one that has the BD DTXPlus ™; this second 3-way stopcock will be called proximal key. On the distal 3-way stopcock key (the one of BD DTXPlus™), put the needless connector included in the kit to make the extractions of blood. On the proximal 3-way stopcock key put a second identical needless connector: in the intervention group the two 3-way stopcock keys have, each one, a needless connector. With the assembled system, it is necessary to print a curve of invasive determination of the blood pressure.
11525503|NCT01176266|Experimental|Asfotase alfa|A total of 6 mg/kg/week of asfotase alfa administered by SC injection (either 1 mg/kg asfotase alfa 6 times per week, or 2 mg/kg asfotase alfa 3 times per week)
11525504|NCT01176253||25 newly diagnosed Type 1 diabetics|25 newly diagnosed Type 1 diabetics within onset of symptoms
11525505|NCT01176253||25 healthy volunteers|25 healthy volunteers (age & sex matched)
11525506|NCT01176240|Experimental|Droxidopa|droxidopa active drug
11525507|NCT01176240|Placebo Comparator|Placebo|Placebo matched control
11525508|NCT01176227|Placebo Comparator|Kyodophilus matching placebo capsules|
11525509|NCT01176227|Active Comparator|Kyodophilus multi strain probiotic capsules|
11525510|NCT01176214|Experimental|early tracheostomy|see study description
11525511|NCT01176214|Active Comparator|late tracheostomy|"Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails"
11525512|NCT01176201|Experimental|A|400 mg suspension
11525513|NCT01176201|Active Comparator|B|5 x 200 mg immediate release capsule
11525514|NCT01176188|Experimental|Comfort Care|Parental soothing, including tactile and auditory strategies, followed by a quiet period with the application of earmuffs to block auditory stimulation
11525515|NCT01176188|Active Comparator|Usual Care|
11525516|NCT01176175|Experimental|50 mg|Progesterone microspheres injectable suspension 50 mg
11525517|NCT01176175|Experimental|100 mg|Progesterone microspheres injectable suspension 100 mg
11525518|NCT01176175|Experimental|200 mg|Progesterone microspheres injectable suspension 200 mg
11525519|NCT01176175|Experimental|300 mg|Progesterone microspheres injectable suspension 300 mg
11525520|NCT01176162||"Group < 28"|• Gestational Age < 28 weeks
11525521|NCT01176162||"Group 28 - < 33"|• Gestational Age : 28 - < 33 weeks
11525522|NCT01176162||"Group 33- < 37"|Gestational Age : 33- < 37 weeks
11525523|NCT01176162||"Group > 37"|Gestational Age > 37 weeks
11525568|NCT01175824|Active Comparator|Insulin glargine+insulin lispro|Once-daily (bedtime) basal insulin glargine and once-daily (before the main meal with the highest average 2-hour postprandial blood glucose concentration) prandial insulin lispro
11525524|NCT01176149|Experimental|SMBG + intensive education|Patients will receive specific educational interventions to teach them how to perform Self monitoring Blood Glucose (SMBG), how to modify diet and level of physical activity according to blood glucose levels, and the actions to be undertaken in case of abnormal values (hypoglycemia, particularly elevated glucose levels). Patients will be instructed to modify their lifestyle habits (diet, physical activity) in order to reach specific goals (weight reduction, reduction in fat consumption intake, reduction in saturated fat intake, increase in fiber intake, regular physical activity.
11525525|NCT01176149|No Intervention|Usual Care|Usual Care
11525526|NCT01176136|Experimental|HOPS Intervention|Middle school age children who receive the Homework, Organization, and Planning Skills (HOPS) intervention.
11525527|NCT01176136|No Intervention|Treatment As Usual|Middle school age children randomly assigned to receive treatment-as-usual services available through the school and community.
11525528|NCT01176123|Active Comparator|CBT-I in person|Cognitive behavioral therapy for insomnia delivered in person
11525529|NCT01176123|Experimental|CBT-I via telephone therapy|Cognitive behavioral therapy for insomnia delivered by telephone
11525530|NCT01176110|Experimental|thermal management with LMA PerfecTemp™|
11525531|NCT01176110|Active Comparator|no specific thermal management|
11525532|NCT01176097|Experimental|6 - 8 cohorts|6 patients in each cohort will receive AZD5658
11525533|NCT01176097|Placebo Comparator|6 - 8 cohorts|2 patients in each cohort will receive placebo
11525534|NCT01176084|Experimental|low carbohydrate diet|
11525535|NCT01176084|Experimental|diet & exercise|
11525536|NCT01176058|Active Comparator|open label|
11525537|NCT01176045||Pre-surgical treatment|Patients who are pre & post-surgical treated with ocular lubricants.
11525538|NCT01176045||Non-presurgical treatment|Patients who are only post-surgical treated with ocular lubricants
11525539|NCT01176032|Experimental|Aliskiren|"Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks. In addition to the study medication, amlodipine 5mg was given to patients who did not achieve the required blood pressure (<140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication. At week 18 the dose of amlodipine was increased to 10mg if the required level (<140/90 mmHg) was still not achieved.
~HCTZ 12.5mg was prescribed at week 26 if the required values (<140/90 mmHg) had not been reached."
11525540|NCT01176032|Active Comparator|Lostaran|"Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks. In addition to the study medication, amlodipine 5mg was given to patients who did not achieve the required blood pressure (<140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication. At week 18 the dose of amlodipine was increased to 10mg if the required level (<140/90 mmHg) was still not achieved.
~HCTZ 12.5mg was prescribed at week 26 if the required values (<140/90 mmHg) had not been reached."
11525541|NCT01176019|Experimental|Interactive Video|In addition to standard care, the experimental arm will receive an interactive video designed to inform and educate patients about the choices that exist concerning prenatal screening and diagnosis.
11525542|NCT01176019|No Intervention|Control|A control arm will receive standard care, which is the opportunity to meet with a genetic counselor.
11525543|NCT01176006|Active Comparator|Group A|10/10 HLA Matched Related Donor or Unrelated Donor Transplant.
11525544|NCT01176006|Active Comparator|Group B|9/10 HLA Matched Related Donor or Unrelated Donor Transplant.
11525545|NCT01176006|Other|Group C|Donor
11525546|NCT01175993|Active Comparator|Eliptical training|Home base exercise
11525547|NCT01175980|Experimental|Treatment (vorinostat)|Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11525548|NCT01175954|Experimental|Lacosamide Open-Label|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
11525549|NCT01175941|Experimental|NRL001|10 mg NRL001 in a 2 g suppository
11525550|NCT01175941|Placebo Comparator|Placebo|Matched placebo control
11525551|NCT01175928|Experimental|Peristaltic Pulse PCD|Peristaltic Pulse Pneumatic Compression Device (NormaTec PCD)
11525552|NCT01175928|Sham Comparator|Sham Device|Sham Pneumatic Compression Device (looks and sounds like real device, but applies no compression)
11525553|NCT01175915|Active Comparator|Western therapy|
11525554|NCT01175915|Experimental|Reduning Injection|
11525555|NCT01175915|Experimental|Reduning Injection plus western therapy|
11525556|NCT01175902|Active Comparator|Arm 1|Latanoprost first, then Dorzolamide/Timolol Patients first on Latanoprost eyedrops once a day, then on Dorzolamide/Timolol twice a day
11525557|NCT01175902|Active Comparator|Arm 2|Dorzolamide/Timolol first, then Latanoprost Patients first on Dorzolamide/Timolol eyedrops twice a day, then on Latanoprost eyedrops once a day
11525558|NCT01175889|Experimental|one side ACE blade|
11525559|NCT01175889|Active Comparator|one side scalpel|
11525560|NCT01175876|Experimental|1|Device: RIPC RIPC consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins Procedure: Carotid Artery Stenting
11525561|NCT01175876|Sham Comparator|2|Procedure: Carotid Artery Stenting
11525562|NCT01175863|Active Comparator|Intravascular ultrasound|
11525563|NCT01175863|Active Comparator|Fractional flow reserve|
11525564|NCT01175850|Experimental|Drug-Coated Balloon (DCB)|IN.PACT Admiral: Balloon Angioplasty
11525565|NCT01175850|Active Comparator|Standard PTA|Standard Percutaneous Transluminal Angioplasty (PTA) Balloon: Balloon Angioplasty
11525566|NCT01175837|Experimental|Short-term fasting prior to systemic chemotherapy|"COHORT I: Patients fast 24 hours before day 1 of course 2 of chemotherapy. If fast is well tolerated, patients may escalate fasting by 12 hours for each subsequent course of chemotherapy for up to 3 courses in the absence of unacceptable toxicity.
~COHORT II: Patients fast at the longest fasting regimen found to be safe and tolerable in cohort I before day 1 of each course of course of chemotherapy for up to 4 courses in the absence of unacceptable toxicity."
11525567|NCT01175824|Experimental|Insulin lispro low mixture (LM)|Two daily injections (breakfast and dinner) of insulin lispro mix 75/25
11525611|NCT01175486|Experimental|Actos|Actos 30 mg for 6 months
11525612|NCT01175486|Active Comparator|Acarbose|Acarbose 50mg tid for 6 months
11525569|NCT01175811|Experimental|Premixed Insulin|Twice daily (before breakfast and lunch) insulin lispro mix 50 (50% insulin lispro, 50% insulin lispro protamine suspension [LM50]) and once daily (before dinner) insulin lispro mix 25 (25% insulin lispro, 75% insulin lispro protamine suspension [LM25])
11525570|NCT01175811|Active Comparator|Basal-Bolus|Once daily (bedtime) insulin glargine and three pre-meal insulin lispro
11525571|NCT01175798|No Intervention|No treatment (standard of care)|Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
11525572|NCT01175798|Experimental|Vitamin D repletion|Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
11525573|NCT01175785|Experimental|Treatment (chemo, radiation, transplant, GVHD prophylaxis)|Patients receive fludarabine phosphate IV over 1 hour on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI twice daily on days -4 to -1. Patients undergo unmanipulated single- or double-unit umbilical cord blood transplantation on day 0 and receive ex vivo-expanded cord blood progenitor cells IV over 4 hours following the last unmanipulated cord blood infusion. Patients initially receive CSP IV over 1 hour beginning on day -3. CSP may be given PO when the patient can tolerate oral medications and has a normal gastrointestinal transit time. CSP is given until day 100, and may taper on day 101 if there is no graft versus host disease. Patients also receive MMF IV every 8 hours on days 0 to 7 and then may receive MMF PO beginning day 8 to 30. MMF is continued for a minimum of 30 days or until 7 days after blood counts recover whichever is later. If there is no evidence of acute GVHD and donor CD3 engraftment is at least 50% from one donor MMF may be tapered.
11525574|NCT01175772|Experimental|Metronomic Chemoterapy|Maintenance Treatment for Ovary Carcinoma by Metronomic Chemotherapy
11525575|NCT01175759|Experimental|Healthy control group|
11525576|NCT01175759|Experimental|UPRL|
11525577|NCT01175746|Experimental|nicardipine|
11525578|NCT01175746|Active Comparator|remifentanil|
11525579|NCT01175733|Experimental|Panitumumab|
11525580|NCT01175720|Experimental|test and control|The test and control technique will be tested in a split-mouth design.
11525581|NCT01175707|Experimental|Daptomycin|500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted
11525582|NCT01175707|Active Comparator|Vancomycin|Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician
11525583|NCT01175694|Active Comparator|Brachytherapy|Interstitial multicatheter brachytherapy
11525584|NCT01175681|Experimental|treatment|remote ischaemic preconditioning
11525585|NCT01175681|No Intervention|untreated|control
11525586|NCT01175668|Experimental|NMS/Clonidine|
11525587|NCT01175668|Active Comparator|NMS/Phenobarbital|
11525588|NCT01175655|Experimental|MSC|
11525589|NCT01175642|Experimental|Cognitive remediation|Cognitive remediation
11525590|NCT01175642|Active Comparator|Functional Adaptive Skills Training|Functional and social skills group treatment
11525591|NCT01175642|Active Comparator|Combined Treatment|Combined cognitive remediation and functional adaptive skills training
11525592|NCT01175629||Group 1|The Vietnam Era Twin (VET) Registry is a closed cohort composed of 7,369 middle-aged male-male twin pairs both of whom served in the military during the time of the Vietnam conflict (1965-1975). The Registry is a United States Department of Veterans Affairs resource that was originally constructed from military records; the Registry has been in existence for more than 15 years. It is one of the largest national twin registries in the US and currently has subjects living in all 50 states. Initially formed to address questions about the long-term health effects of service in Vietnam the Registry has evolved into a resource for genetic epidemiological studies of mental and physical health conditions. Several waves of mail and telephone surveys have collected a wealth of health-related information on Registry twins. Other data collection efforts have focused on specific sets of twin pairs and conducted detailed clinical or laboratory testing.
11525593|NCT01175616|Experimental|Creatine|Open-Label Active Treatment with Creatine 5 grams daily for 8 weeks.
11525594|NCT01175603|Experimental|Cognitive behavioral intervention|Women in the intervention condition will receive 6 two-hour intervention sessions delivered weekly in a group format by the Study Clinician. Each session contains didactic instruction on core content, as well as activities and group discussion. One of the strengths of embedding the MB Course within home visiting is our ability to have home visitors reinforce the material presented by the Study Clinician. The 6-week curriculum is divided into three modules: (a) pleasant activities, (b) thoughts, and (c) relationships with others. Each module has two sessions. These sessions map onto core cognitive-behavioral concepts.
11525595|NCT01175603|No Intervention|Usual home visiting|Women in the control group will receive usual home visiting services and information on postpartum depression.
11525596|NCT01175590|Experimental|Besivance|besifloxacin ophthalmic suspension 0.6%
11525597|NCT01175590|Placebo Comparator|Vehicle|Vehicle of Besivance
11525598|NCT01175577|Active Comparator|Supplement 1|
11525599|NCT01175577|Active Comparator|Supplement 2|
11525600|NCT01175577|Active Comparator|Food-based Intervention|
11525601|NCT01175577|Placebo Comparator|Placebo|
11525602|NCT01175564|Experimental|Active|Each cohort will have 9 volunteers that will receive TC-5214
11525603|NCT01175564|Placebo Comparator|Placebo|Each cohort will have 3 volunteers that will receive placebo
11525604|NCT01175551||Group 1|women screened at Penn OB/GYN Associates or Helen O. Dickens Center with a documented singleton pregnancy less than 18 weeks gestational age
11525605|NCT01175551||Group 2|Nulliparous pregnant women (no previous pregnancy greater than 15 weeks) screened at Penn OB/GYN Associates or Helen O. Dickens Center less than 18 weeks gestational age
11525606|NCT01175538|Experimental|Lactulose|
11525607|NCT01175525|Placebo Comparator|sugar pill|sugar pill dissolved in water to be given 4 times a day 30 minutes prior to meals
11525608|NCT01175525|Active Comparator|Cromolyn|Cromolyn dose of 200mg(dissolved in water) will be given 4 times a day(30 minutes before a meal)
11525609|NCT01175512|Placebo Comparator|Placebo|
11525610|NCT01175512|Active Comparator|Naltrexone|
11525613|NCT01175473|Experimental|Lixisenatide|1-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 2 weeks, followed by 20 mcg QD for up to Week 4.
11525614|NCT01175473|Active Comparator|Liraglutide|2-step initiation regimen of liraglutide: 0.6 milligram (mg) QD subcutaneously for 1 week, followed by 1.2 mg QD for 1 week, then 1.8 mg QD up to Week 4.
11525615|NCT01175460|Experimental|Chemoradiotherapy|Thoracic radiation 60Gy over 30 fractions.Concurrently, nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 was given on Days 1-14,repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
11525616|NCT01175447|Experimental|Chemoradiotherapy with S-1|radiation 54Gy over 30 fractions,and concurrent with s-1 on days 1-14 and 29-42
11525617|NCT01175434|Experimental|School-Based Medication Group|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse will begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
11525618|NCT01175434|No Intervention|Usual Care Group|Children in the Usual Care group will not receive preventive medications delivered at school. These children will continue to receive all of their asthma care from their parents and primary care physicians.
11525619|NCT01175421||Patients undergoing sleep study|
11525620|NCT01175408|Active Comparator|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
11525621|NCT01175408|Active Comparator|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will send the data to their endocrinologist and receive feedback based on the uploaded glucose data.
11525622|NCT01175408|Active Comparator|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
11525623|NCT01175408|Active Comparator|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
11525624|NCT01175395|Experimental|IBI-20089/Lucentis|Alternate treatment of either 6.9 mg IBI-20089/Lucentis or 13.8 mg IBI-20089/Lucentis
11525625|NCT01175382|Active Comparator|Behavioral Treatment alone|Behavioral treatment is implemented in 4 clinic visits over a period of 6 weeks, followed by 6 weeks of combined behavioral + drug therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and daily bladder diaries, supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
11525626|NCT01175382|Active Comparator|Drug Therapy (Tolterodine + tamsulosin)|Drug therapy for 6 weeks implemented in a clinic visit with telephone follow-up at 3 weeks, followed by 6 weeks of combined drug + behavioral therapy. Participants in the drug group will receive an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
11525627|NCT01175382|Experimental|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
11525628|NCT01175369|No Intervention|Usual Care|Usual asthma care
11525629|NCT01175369|Experimental|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
11525630|NCT01175356|Experimental|Treatment (131I-MIBG, chemotherapy)|See Detailed Description.
11525631|NCT01175343|Experimental|Treatment (RO4929097)|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Blood and tumor tissue samples are collected for correlative studies. Ascitic fluid may also be collected."
11525632|NCT01175330|Placebo Comparator|CABG and intralipid infusion|Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Intralipid Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
11525633|NCT01175330|Active Comparator|CABG and omega-3 fatty acid infusion|Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Omegaven Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
11525634|NCT01175317|Experimental|Goal-directed fluid optimization|Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
11525635|NCT01175317|Other|Regimen based on expertise anaesthesist|Fluid regimen based on expertise anaesthesist
11525636|NCT01175304||Workers in a Barcelona tertiary hospital|Workers attending annual medical checkups
11525637|NCT01175291|Active Comparator|Arm A - FOLFOX 7 + MK-0646|
11525638|NCT01175291|Placebo Comparator|Arm B - FOLFOX 7 + Placebo|
11525768|NCT01174355|Experimental|ND0801|
11525769|NCT01174342||Pregnant women|Healthy pregnant women
11525639|NCT01175278|No Intervention|Observation Arm|Patients who are asymptomatic (no symptoms) will participate in the observational portion of the study.
11525640|NCT01175278|Experimental|Balloon Kypholasty|
11525641|NCT01175278|Active Comparator|Control Arm|Non-surgical Management Treatment Group
11525642|NCT01175265|No Intervention|pulmonary rehabilitation, no breathing retraining|Forty COPD patients (23 females) with a mean (SD) age of 66.0 (6.3) years and a FEV1 of 47.1 (18.9) % predicted were randomized to conventional pulmonary rehabilitation (n=20) and conventional pulmonary rehabilitation plus breathing retraining (n=20).
11525643|NCT01175265|No Intervention|breathing retraining|Forty COPD patients (23 females) with a mean (SD) age of 66.0 (6.3) years and a FEV1 of 47.1 (18.9) % predicted were randomized to conventional pulmonary rehabilitation (n=20) and conventional pulmonary rehabilitation plus breathing retraining (n=20).
11525644|NCT01175252||Gastroenteritis Cohort|All children suffering with gastroenteritis
11525645|NCT01175239|Experimental|Single infusion of autologous CD34+ cells|
11525646|NCT01175226|Experimental|BTA798|
11525647|NCT01175226|Placebo Comparator|Placebo|
11525648|NCT01175213|Experimental|SC/IGSC, 10% with rHuPH20 followed by SC of IGSC, 10% (safety)|Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20) followed by Safety of SC of IGSC, 10% only (safety follow-up)
11525649|NCT01175213|Experimental|SC/IGSC, 10% with rHuPH20 followed by IV of IGSC, 10% (safety|Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20) followed by Safety of intravenous (IV) administration of IGSC, 10% only (safety follow-up)
11525650|NCT01175213|Experimental|IV treatment with IGSC, 10% only|Partial efficacy (trough levels of immunoglobulin G [IgG] only) and safety of intravenous (IV) administration of IGSC, 10% only. This was for participants enrolled in the study who had anti-rHuPH20 andibody titer from study160603
11525651|NCT01175200|Active Comparator|Prasugrel|
11525652|NCT01175200|Active Comparator|Clopidogrel|
11525653|NCT01175200|Active Comparator|Lansoprazole|proton pump inhibitor
11525654|NCT01175200|Placebo Comparator|Placebo|
11525655|NCT01175187||EPIDURAL FEVER|
11525656|NCT01175187||EPIDURAL WITHOUT FEVER|
11525657|NCT01175187||GROUP 1: EPIDURAL FEVER . GROUP 2 EPIDURAL WITHOUT FEVER|
11525658|NCT01175161|Experimental|Immediate postpartum IUD insertion|Women assigned to have the IUD placed 10 minutes to 48 hours postpartum
11525659|NCT01175161|Experimental|6 week postpartum IUD insertion|Women who receive the IUD at the traditional time frame.
11525660|NCT01175148|Experimental|Recipient - Atorvastatin to prevent GVHD|Atorvastatin calcium (Lipitor) will be administered at dose of 40mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning. Patients will receive atorvastatin until +180 days or development of grade 2 GVHD. This is the experimental arm for outcome measures.
11525661|NCT01175148|Other|Donor - Atorvastatin conditioning for donors|Sibling donors will start taking Atorvastatin calcium (Lipitor) orally at 40mg once daily between 14-28 days before the anticipated first day of apheresis or bone marrow harvest.
11525662|NCT01175135|Experimental|PF-02545920 5 mg|
11525663|NCT01175135|Experimental|PF-02545920 15 mg|
11525664|NCT01175135|Placebo Comparator|Placebo|
11525665|NCT01175135|Active Comparator|Risperidone 3 mg|
11525666|NCT01175122|Experimental|H2N3 MO 2003/AA ca Vaccine|Participants will receive a nasal spray administration of the H2N3 MO 2003/AA ca vaccine on Day 0 and Day 28.
11525667|NCT01175109|Experimental|Escalating doses of imatinib and LBH589|"Study will incorporate a 3+3 dose escalation design."
11525668|NCT01175096|Active Comparator|RAD001|2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day Dose level modifications/interruptions must follow guidelines. One treatment cycle consists of 28 days.
11525669|NCT01175083|Experimental|Tritanrix-HepB/Hib+Polio Sabin <6S Group|Children below (<) 6 months of age at time of enrolment, diagnosed with sickle cell disease (S), who received a 3-dose primary vaccination at Study Months 0, 1 and 2 with Synflorix vaccine co-administered with Tritanrix-HepB/Hib and Polio Sabin vaccines, followed by a booster vaccination at Study Month 8.
11525670|NCT01175083|Active Comparator|Tritanrix-HepB/Hib+Polio Sabin <6NS Group|Healthy children, below (<) 6 months of age at time of enrolment, who received a 3-dose primary vaccination at Study Months 0, 1 and 2 with Synflorix vaccine co-administered with Tritanrix-HepB/Hib and Polio Sabin vaccines, followed by a booster vaccination at Study Month 8.
11525671|NCT01175083|Experimental|Synflorix 7-11S Group|Children between 7-11 months of age at time of enrolment, diagnosed with sickle cell disease (S), who received a 2-dose primary vaccination at Study Months 0 and 1 with Synflorix vaccine, followed by a booster vaccination at Study Month 3.
11525672|NCT01175083|Active Comparator|Synflorix 7-11NS Group|Healthy children between 7-11 months of age at time of enrolment, who received a 2-dose primary vaccination at Study Months 0 and 1 with Synflorix vaccine, followed by a booster vaccination at Study Month 3.
11525673|NCT01175083|Experimental|Synflorix 12-23S Group|Children between 12-23 months of age at time of enrolment, diagnosed with sickle cell disease (S), who received a 2-dose vaccination with Synflorix vaccine, at Study Months 0 and 2.
11525674|NCT01175083|Active Comparator|Synflorix 12-23NS Group|Healthy children between 12-23 months of age at time of enrolment, who received a 2-dose vaccination with Synflorix vaccine, at Study Months 0 and 2.
11525675|NCT01175070|Experimental|Pegaptanib|Participants receiving 6-weekly treatment with pegaptanib sodium (Macugen [TM]) for ischaemic diabetic macular oedema over a 30 week period.
11525676|NCT01175057||Group A|10 patients who undergo home monitoring with the MeDiNa Homebox for 4 weeks and then 4 weeks without the MeDina Homebox
11525677|NCT01175057||Group B|Group B starts without the MeDiNa Homebox for 4 weeks and then undergo Homemonitoring with the MeDiNa Homebox for 4 weeks.
11525678|NCT01175044|Active Comparator|Betadine Lavage|dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000ml of sterile saline irrigation
11525679|NCT01175044|Placebo Comparator|Saline Lavage|2000 ml sterile saline lavage alone
11525770|NCT01174329|Experimental|"Patient-regulated neuro-electrostimulation by Saliwell Crown"|"Patient regulated (by a remote control) neuro-electrostimulation by Saliwell Crown"
11525680|NCT01175031|Experimental|REMstar Auto with A-Flex|Manipulation of positive airway pressure (PAP) will occur throughout the night to induce breaking events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced, and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night. Events will be measured with REMstar Auto with A-Flex.
11525681|NCT01175031|Other|Manually Scored Polysomnography (PSG)|Manipulation of positive airway pressure (PAP) will occur throughout the night to induce breaking events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced, and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night. Events will be Manually Scored Polysomnography (PSG).
11525682|NCT01175018|Experimental|Anakinra|Anakinra 100 mg injectable subcutaneously daily
11525683|NCT01175018|Placebo Comparator|Placebo|0.67 ml of sodium chloride (NaCl) 0.9% solution
11525684|NCT01175005||Fever and a central venous catheter|
11525685|NCT01174992|Experimental|Evicel|
11525686|NCT01174992|Other|Sutures only|
11525687|NCT01174979|Experimental|Caroverin|
11525688|NCT01174979|Placebo Comparator|Placebo|
11525689|NCT01174966||Survivor Nonsurvivor|
11525690|NCT01174953|Other|Finasteride plus soy|Finasteride and soy
11525691|NCT01174940|Experimental|Extracorporeal Photopheresis|Patients will receive 2 ECP treatments on day -10 and day -8 and then for two consecutive days every two weeks starting from post engraftment (ANC > 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.
11525692|NCT01174927|Active Comparator|Heroin-dependent patients_1|daily dose of diacetylmorphine (30 mg to 500 mg) in 5 ml
11525693|NCT01174927|Placebo Comparator|Heroin-dependent patients_2|5 ml saline
11525694|NCT01174914|Experimental|Naltrexone Low-dose 3mg capsule|Each person in this arm 1 of the study had never received any ARV drugs and in this study received only one Low-Dose Naltrexone 3mg capsule nightly for 9 months (no placebo).
11525695|NCT01174914|Active Comparator|Naltrexone Low Dose + ARVs|In this Arm 3, Patients were on ARV's plus being given Naltrexone Low-Dose (3mg) once daily at bedtime for 9 months.
11525696|NCT01174914|Placebo Comparator|ARV's (continued,standard) plus Placebo|In this arm 2, patients were started or continued on their standard ARV drugs plus placebo capsule once daily at bedtime; in the 2nd and 3rd arms patients did not know whether they were taking Low-Dose Naltrexone or a placebo.
11525697|NCT01174888|Experimental|GROUP I (Dose levels 1-2):|Patients receive midostaurin orally (PO) twice daily on days 1-14 and bortezomib intravenously (IV) on days 1, 4, 8, and 11. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11525698|NCT01174888|Experimental|GROUP II (Dose levels 3-6)|Patients receive mitoxantrone hydrochloride IV over 10 minutes, etoposide IV over 1 hour, and cytarabine IV over 6 hours on days 1-6. Patients also receive midostaurin PO twice daily on days 8-21 and bortezomib IV on days 8, 11, 15, and 18. Treatment continues in the absence of disease progression or unacceptable toxicity.
11525699|NCT01174875||Pregnant mothers, infants and children|Women in their early pregnancy who are attending the first trimester antenatal ultrasound scan at the public maternity units at KK Women's and Children's Hospital (KKH) and National University Hospital (NUH). Only women age 18 years and above who are Singapore Citizens or Singapore Permanent Residents. Participants have to intend to eventually deliver in NUH or KKH and to reside in Singapore for the next 5 years. Willingness to donate cord, cord blood and placenta. The fetus should be racially homogenous with both sets of grandparents of the same ethnicity. Babies born from these mothers will be followed up until the child is at least 14 years of age.
11525700|NCT01174862||Aspirin responder|Normal aspirin responsiveness in ASPI test (Multiplate)
11525701|NCT01174862||Aspirin non-responder|Reduced aspirin responsiveness in ASPI test (Multiplate)
11525702|NCT01174849|Active Comparator|Synflorix|
11525703|NCT01174849|Active Comparator|Prevenar13|
11525704|NCT01174849|Experimental|COMBO|COMBINATION SCHEDULE of comparator vaccine 1 and comparator vaccine 2 Synflorix at 1,2,4 months then Prevenar13 at 6 months.
11525705|NCT01174823|Experimental|Bepotastine Besilate Ophthalmic Solution|
11525706|NCT01174823|Placebo Comparator|Placebo|
11525707|NCT01174810|No Intervention|Control|
11525708|NCT01174810|Experimental|Exenatide|
11525709|NCT01174797||Patients being evaluated for active ischemia|Subjects with known or suspected CAD who are scheduled to undergo routine exercise MPI or stress echocardiography for the detection of active ischemia are eligible for enrollment.
11525710|NCT01174784|Experimental|Treatment|The Wildcat catheter is a CTO crossing catheter. Subjects will be subjected to crossing with this device.
11525711|NCT01174771||PSP patients|People that have been clinically diagnosed with atypical parkinsonism, i.e., PSP
11525712|NCT01174771||CBD patients|People that have been clinically diagnosed with atypical parkinsonism, i.e., CBD
11525713|NCT01174771||Age-matched healthy controls|People that have not been diagnosed with any kind of neurologic movement disorder.
11525714|NCT01174758||Parkinson's disease|Individuals participating in the study have been diagnosed with idiopathic Parkinson's disease.
11525715|NCT01174732|Experimental|T1|A006 albuterol inhalation powder, 120 mcg/inhalation, 1 inhalation
11525716|NCT01174732|Experimental|T2|A006 albuterol inhalation powder 180 mcg/ inhalation, 1 inhalation
11525717|NCT01174732|Experimental|T3|A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations
11525718|NCT01174732|Experimental|T4|A006 albuterol inhalation powder 180 mcg/inhalation, 2 inhalations
11525719|NCT01174732|Placebo Comparator|P|Placebo, 2 inhalations
11525720|NCT01174732|Active Comparator|R1|Proventil 90 mcg/inhalation, 2 inhalations
11525721|NCT01174732|Active Comparator|R2|Proventil 90 mcg/inhalation, 4 inhalations
11525722|NCT01174719|Active Comparator|Hydroxyethylstarch|
11525723|NCT01174719|Active Comparator|Humanalbumin|
11525724|NCT01174719|Active Comparator|Ringer lactate|
11525725|NCT01174706|Experimental|Usual care arm|Patients randomized to this group will receive usual care. Usual care at the three study sites varies but will be defined as whatever information is usually given to patients regarding the prescription medication or over the counter medicine they were prescribed at emergency department discharge.
11526296|NCT01170546|Experimental|KLC (Kneeling Leg Curl)|plate-loaded kneeling leg curl
11525726|NCT01174706|Experimental|Information prescription|Patients randomized to this arm will receive written information from Medline Plus regarding the prescription or over the counter medicine they have been prescribed at ED discharge plus information on their health condition.
11525727|NCT01174706|Experimental|Informationist|Patients in this arm will receive the same information as patients in group 2 but will also be given contact information for a clinical informationist if they have further questions about their prescription medicine or over the counter medicine prescribed at ED discharge.
11525728|NCT01174706|Experimental|practical assistance|Subjects will be offered practical assistance with obtaining prescription such as location of most convenient pharmacy and hours of operation, programs that offer drugs more cheaply, fax prescription from ED to pharmacy
11525729|NCT01174693|Active Comparator|Clopidogrel|Plavix® 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014
11525730|NCT01174693|Experimental|Triflusal|Disgre® 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014
11525731|NCT01174680|Experimental|patients with stable angina pectoris|stable patients, who have been admitted to one of the participating centres for an elective coronary angiography
11525732|NCT01174667|Experimental|Fascial massage|A specific type of fascial massage to release restricted lumbodorsal fascia.
11525733|NCT01174667|No Intervention|No treatment control|Patient will rest quietly without receiving any instruction.
11525734|NCT01174654|No Intervention|Referral to community resources|
11525735|NCT01174654|Experimental|Contingency Management|
11525736|NCT01174641|Experimental|TMS intervention|Trans-cranial magnetic stimulation will be applied at a 1Hz rate for 20min over the ipsilesional posterior parietal cortex of patients showing left neglect after a right hemisphere stroke
11525737|NCT01174641|Placebo Comparator|Placebo TMS|1 Hz trans-cranial magnetic stimulation will be applied over the vertex
11525738|NCT01174602|Experimental|Exposure Therapy for AN (AN-EX/RP)|Exposure Therapy and Ritual Prevention (AN-EX/RP) includes 12 sessions of confronting feared eating situations without the use of anxiety reducing behaviors.
11525739|NCT01174602|Active Comparator|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT)
11525740|NCT01174589|Other|6 weeks of physical training|The 6 weeks of physical training consists of muscle strength training of both legs, balance and coordination exercises 2 times a week.
11525741|NCT01174589|Other|12 weeks of physical exercise|The 12 weeks of physical training consists of muscle strength training of both legs, balance and coordination exercises 2 times a week.
11525742|NCT01174576|Experimental|caffeinated coffee|200 mL caffeinated coffee with 3 mg caffeine per kg body weight
11525743|NCT01174576|Experimental|decaffeinated coffee|200 mL decaffeinated coffee, same amount as caffeinated coffee
11525744|NCT01174576|Experimental|Water|200 mL, control intervention
11525745|NCT01174563|Experimental|Single Arm|
11525746|NCT01174550|Active Comparator|Functional diagnostic tests|Stress Echocardiogram Nuclear Stress Test Exercise Electrocardiogram
11525747|NCT01174550|Active Comparator|Anatomic diagnostic test|Coronary Angiography
11525748|NCT01174524|Experimental|gestoden and ethinylestradiol|"Gestoden 60 mcg plus ethinylestradiol 15 mcg, once a day, administered in 24∕4 regimen, for three months.
~The use of gestoden and ethinylestradiol can do an improvement of the quality of life before and after the use of the drug.Numerous large clinical trials have shown that this combination is as effective in preventing pregnancies as other oral contraceptives presently on the market. Irregular bleeding and spotting rates appear to be at least as good as older formulations. In general, the incidence of side effects associated with the progestin and estrogen components tends to be low, with very little impact on lipid and carbohydrate metabolism. . For this, the regimen can ameliorate the quality of life of the patients."
11525749|NCT01174511|Experimental|A-1 COOL cream|"A research product - A-1 COOL cream contain herbal medicine plants basically :
~WATER PETROLATUM
~WILD YAM (DIOSCOREA VILLOSA) EXTRACT
~SORBITAN SESQUIOLEATE
~CALENDULA OFFICINALIS EXTRACT
~MINERAL OIL
~ARNICA MONTANA EXTRACT
~MICROCRYSTALLINE WAX
~LICORICE (GLYCYRRHIZA GLABRA) EXTRACT
~DECYL OLEATE
~DICOCOYL PENTAERYTHRITYL DISTEARYL CITRATE
~BEESWAX
~ALUMINUM STEARATES"
11525750|NCT01174511|Placebo Comparator|Vaselin ointment|Using the study as placebo.
11525751|NCT01174498|Active Comparator|t-VNS sytem Vagus stimulation|Subjects experience a transcutaneous vagal stimulation by the t-VNS device
11525752|NCT01174498|Sham Comparator|Sham transcutaneous stimulation|Sham stimulation with an attached t-VNS device
11525753|NCT01174485|Experimental|exercise|exercise plus liposuction
11525754|NCT01174485|No Intervention|sedentary|physical inactivity plus liposuction
11525755|NCT01174472|Active Comparator|Conventional Balloon Angioplasty (COBA)|Patients with lesions treated with conventional balloon angioplasty
11525756|NCT01174472|Experimental|Drug Eluting Balloon Angioplasty (DEB)|Patients with lesions treated with Drug Balloon Angioplasty
11525757|NCT01174459||Patient with Restless Legs Syndrome|
11525758|NCT01174446|Experimental|BAX 326|Recombinant factor IX (rFIX)
11525759|NCT01174446|Active Comparator|BeneFIX|Recombinant Factor IX (rFIX)
11525760|NCT01174433|Experimental|Tryton bifurcation stent system|
11525761|NCT01174420|Experimental|ologen Collagen Matrix|
11525762|NCT01174420|Active Comparator|Mitomycin-C (MMC)|
11525763|NCT01174407||cd35|
11525764|NCT01174394|Experimental|DCEAS|"Body electroacupuncture plus dense cranial electroacupuncture stimulation (DCEAS)
~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
11525765|NCT01174394|Placebo Comparator|n-CEA|"Body electroacupuncture plus non-invasive cranial electroacupuncture (n-CEA)
~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
11525766|NCT01174381|Experimental|Lifestyle modification|Lifestyle modification for behavior change related to NCD prevention
11525767|NCT01174368|Experimental|Cancer macrobeads|Cancer Macrobead placement in abdominal cavity
11525771|NCT01174329|Active Comparator|"Automatic neuro-electrostimulation by Saliwell Crown"|No remote control used
11525772|NCT01174316|Experimental|autotitrating NIV|approximately 24 hours using autotitrating non-invasive ventilation for as many hours as possible whilst an inpatient in hospital
11525773|NCT01174316|Active Comparator|Standard non-invasive ventilation|approximately 24 hours using standard non-invasive ventilation for as many hours as possible whilst an inpatient in hospital.
11525774|NCT01174303|Experimental|IDegAsp - BIAsp|
11525775|NCT01174303|Experimental|BIAsp - IDegAsp|
11525776|NCT01174290|Experimental|Haloperidol 1mg IV q6h|
11525777|NCT01174290|Placebo Comparator|D5W 0.2mL IV q6h|
11525778|NCT01174277||Collection of blood sample|Blood draw
11525779|NCT01174264|Experimental|Arm I (vismodegib on empty stomach)|Patients receive a single dose of vismodegib PO on an empty stomach. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28.
11525780|NCT01174264|Experimental|Arm II (vismodegib after high fat meal)|Patients receive a single dose of vismodegib PO after eating a high fat meal. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28.
11525781|NCT01174264|Experimental|Arm III (vismodegib after low fat meal)|Patients receive a single dose of vismodegib PO after eating a low fat meal. Beginning 7 days later, patients receive vismodegib PO after eating a meal daily on days 1-28.
11525782|NCT01174238|Experimental|Arm A|Patients enrolled in Arm A and Arm B will receive the same treatment with study drugs axitinib, carboplatin, and paclitaxel. Patients enrolled in Arm A and Arm B will have tumor imaging assessments: PET-CT, CT Scan, and/or MRI. In addition patients enrolled in Arm A will also have FLT-PET scans.
11525783|NCT01174238|Experimental|Arm B|Patients enrolled in Arm A and Arm B will receive the same treatment with study drugs axitinib, carboplatin, and paclitaxel. Patients enrolled in Arm A and Arm B will have tumor imaging assessments: PET-CT, CT Scan, and/or MRI. Patients enrolled in Arm B will not have FLT-PET scans.
11525784|NCT01174225|Active Comparator|I|Participants who elect to have an IUD inserted at the time of abortion will be randomized to either Arm I or Arm II. In this arm participants will receive the Flexi T 380(+) IUD. The participant is counseled that she may leave the device in for up to five years. She will be followed for up to five years to determine expulsion rate, discontinuation rate, pregnancy rate, and overall satisfaction with form of contraception.
11525785|NCT01174225|Active Comparator|II|Participants who elect to have an IUD inserted at the time of abortion will be randomized to either Arm I or Arm II. In this arm participants will receive the Nova T IUD. The participant is counseled that she may leave the device in for up to five years. She will be followed for up to five years to determine expulsion rate, discontinuation rate, pregnancy rate, and overall satisfaction with form of contraception.
11525786|NCT01174225|No Intervention|III|"Participants who elect for forms of contraception other than a copper IUD will chose which form of contraception they would like to use and be put into one of the groups specified below based on her contraceptive choice. These participants will be observed throughout the study for overall satisfaction and repeat pregnancy rate.
~Groups - Participants will be in one of the five following groups Group A - Oral contraceptive pill 28day supply provided after abortion Group B - Medroxyprogesterone acetate (Depo-provera)150mg IM provided after abortion, lasts for 3 months Group C - Ethinyl estradiol and etonogestrel (Nuva ring) provided at time of abortion, lasts for 28 days Group D - Condoms provided at time of abortion Group E - Other"
11525787|NCT01174212|Experimental|Experimental|Patients receiving antibiotics approximately 1 hour prior to incision are considered to be in the experimental group of this study.
11525788|NCT01174212|Other|Control|Control group is to receive no antibiotics until the intraoperative cultures have been obtained.
11525789|NCT01174199|Experimental|Arm I|Patients receive oral vorinostat once daily on days 1-14 and temsirolimus IV on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11525790|NCT01174186|Active Comparator|Spondyloarthritis and calprotectin elevated|Spondylitis patients with elevated levels of fecal calprotectin. Patients are treated with adalimumab
11525791|NCT01174186|Active Comparator|Spondyloarthritis and calprotectin normal|Spondylitis patients with normal levels of fecal calprotectin. Patients are treated with adalimumab.
11525792|NCT01174173|Experimental|Ranolazine|1000 mg PO BID
11525793|NCT01174160|Experimental|vernakalant HCl|vernakalant hydrochloride
11525794|NCT01174160|Placebo Comparator|placebo|placebo
11525795|NCT01174147||Hospital Candida Cases|People who developed a positive blood culture for Candida while hospitalized
11525796|NCT01174134|Placebo Comparator|Milk-based beverage w/out DHA|
11525797|NCT01174134|Experimental|Milk-based beverage with DHA|
11525798|NCT01174134|Experimental|Milk-based beverage containing DHA at a higher level|
11525799|NCT01174121|Experimental|1/CD8+ Enriched TIL (CLOSED)|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young CDS+ enriched TIL + high-dose aldesleukin (CLOSED)
11525800|NCT01174121|Experimental|2/Unselected TIL (CLOSED)|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young unselected TIL + high-dose aldesleukin (CLOSED)
11525801|NCT01174121|Experimental|3/Unselected TIL + Pembro Prior to Cells|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young unselected TIL + high-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeks following cell infusion
11525802|NCT01174121|Experimental|4/Unselected TIL + Pembro at POD|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young unselected TIL + high-dose aldesleukin +pembrolizumab within 4 weeks of progressive disease for up to 8 doses every 3 weeks
11525803|NCT01174108|Experimental|1|Target doses: CD34+ cells 8 x 106/kg; CD3+ cells 2 x 107/kg
11525804|NCT01174108|No Intervention|2|Donor
11525805|NCT01174095||Follow-up Group|"Subjects who received AdGVVEGF121cDNA in either IRB protocol #0794-894 entitled Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Diffuse Coronary Artery Disease or IRB protocol #0297-693 entitled Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Diffuse Coronary Artery Disease Via Minimally Invasive Surgery."
11525806|NCT01174082|Experimental|KLH Vaccine (Patient)|After DLI on same day, patients receive vaccine according to donor randomization (the same type of vaccine that their donors received).
11525807|NCT01174082|Experimental|KLH-id Vaccine (Patient)|After DLI on same day, patients receive vaccine according to donor randomization (the same type of vaccine that their donors received).
11525808|NCT01174082|Experimental|KLH Vaccine (Donor)|Donor Group 1: (non-specific vaccination) vaccinated with KLH only vaccine 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.
11525809|NCT01174082|Experimental|Vaccine KLH-id (Donor)|Donor Group 2: (myeloma specific vaccination) vaccinated with KLH-id vaccine 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collections.
11525810|NCT01174069|Experimental|NOTES cholecystectomy|
11525811|NCT01174056|Experimental|Pioglitazone+zileuton placebo|Pioglitazone 45 mg qD for 2 weeks plus Sugar pill q6hr for 5 days
11525812|NCT01174056|Experimental|Zileuton+pioglitazone placebo|Sugar pill qD for 2 weeks plus Zileuton 600 mg q6hr for 5 days
11525813|NCT01174056|Sham Comparator|Pioglitazone placebo+zileuton placebo|Sugar pill qD for 2 weeks plus Sugar pill q6hr for 5 days
11525814|NCT01174043|Experimental|Erlotinib|
11525815|NCT01174030|Experimental|CD07805/47 Gel 0.5% QD|
11525816|NCT01174030|Experimental|CD07805/47 Gel 0.18% QD|
11525817|NCT01174030|Experimental|CD07805/47 Gel 0.18% BID|
11525818|NCT01174030|Placebo Comparator|Vehicle Gel QD|
11525819|NCT01174030|Placebo Comparator|Vehicle Gel BID|
11525820|NCT01174017|Active Comparator|Standard loose Iodine 125 seeds|Prostate brachytherapy implant to be performed with standard format loose Iodine 125 seeds
11525821|NCT01174017|Experimental|AnchorSeed Iodine 125 implant|Prostate brachytherapy implant to be performed with a new design of Iodine 125 seed that has a coating to increase adherence to tissue
11525822|NCT01174004|Experimental|1|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
11525823|NCT01174004|Placebo Comparator|2|placebo, tablet, once daily by mouth for 6 weeks
11525824|NCT01173991|Experimental|Carbohydrate counting|This group received carbohydrate counting training
11525825|NCT01173991|No Intervention|Controls|This group received standard education
11525826|NCT01173978|Experimental|No intervention|Each participant is examined during a normal, active lifestyle, without any intervention: The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl
11525827|NCT01173978|Experimental|Intervention|Each participant is examined during a 12 days intervention.The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl
11525828|NCT01173965|Active Comparator|Endometrial ablation with microwaves|Endometrial ablation with the use of MEA(microwaves endometrial ablation device)
11525829|NCT01173965|Active Comparator|Endometrial ablation with bipolar diathermy|Endometrial ablation with Novasure(bipolar impedence control system)
11525830|NCT01173939|Active Comparator|Active comparator: Standard Pravastatin Group|
11525831|NCT01173939|Active Comparator|Intensive Rosuvastatin Group|
11525832|NCT01173926|Experimental|IAsp|
11525833|NCT01173926|Experimental|IDeg|
11525834|NCT01173926|Experimental|IDegAsp|
11525835|NCT01173913|Experimental|ModraDoc001 10 mg capsules|The optimal dose weekly bi-daily oral docetaxel - ModraDoc001 10 mg in combination with ritonavir will be determined with a classical dose escalation design. Approximately 24 patients will be enrolled depending on required number of dose levels before MTD is reached.
11525836|NCT01173913|Experimental|ModraDoc003 10mg tablets and ModraDoc004 10/50 mg|Both new oral dosage forms, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets will be investigated to see whether these new formulations have comparable pharmacokinetic characteristics, in terms of systemic exposure to docetaxel, as ModraDoc001 10 mg capsule.
11525837|NCT01173913|Experimental|ModraDoc006 10 mg tablet|The optimal dose weekly bi-daily oral docetaxel - ModraDoc006 10 mg in combination with ritonavir will be determined with a classical dose escalation design. Approximately 24 patients will be enrolled depending on required number of dose levels before MTD is reached.
11525838|NCT01173900|Other|Class-based delivery|All girls attending standard 6 in schools selected for class-based vaccine delivery
11525839|NCT01173900|Other|Age-based delivery|All girls born in 1998 attending schools selected for age-based delivery
11525840|NCT01173887|Active Comparator|mLSG15|
11525841|NCT01173887|Experimental|mLSG15 + KW-0761|
11525842|NCT01173874|Experimental|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
11525843|NCT01173874|No Intervention|Cognitive activity control group|This is a non-specific mental activity control condition, conducted two times per week for a total of 30 sessions.
11525844|NCT01173861|Experimental|Physical activity counseling|Group receives face-to-face physical activity counseling.
11525845|NCT01173861|Active Comparator|Manual|Group receives physical activity manual.
11525846|NCT01173848|Active Comparator|Vitamin D2|Patients randomized to take vitamin D2
11525847|NCT01173848|Active Comparator|Vitamin D3|Patient's randomized to take Vitamin D3
11525848|NCT01173822|Experimental|Treatment group|Ultra filtration of residual blood.
11525849|NCT01173822|No Intervention|Control|The current practice in our institution was to displace all the remaining volume in the CPB circuit into a transfer pack by displacing the remaining blood in the CPB circuit with additional Lactated Ringers solution. This transfer pack is then given to the anesthetist for reinfusion into the patient.
11525850|NCT01173809|Active Comparator|Control|Patient will continue taking Amiodarone before, during and after catheter ablation (8 weeks post-ablation).
11525851|NCT01173809|Active Comparator|Study|Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
11525852|NCT01173796|Experimental|PMFL ablation|Radio-frequency catheter ablation of the mitral isthmus only
11525853|NCT01173796|Experimental|Repeat PVAI and triggers ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
11525854|NCT01173770|Experimental|Cohort 1: ADC3680B vs. Placebo|
11525855|NCT01173770|Experimental|Cohort 2: ADC3680B vs. Placebo|
11525856|NCT01173770|Experimental|Cohort 3: ADC3680B vs Placebo|
11525857|NCT01173770|Experimental|Cohort 4: ADC3680B vs. Placebo|
11525858|NCT01173770|Experimental|Cohort 5: ADC3680B vs. Placebo|
11525859|NCT01173770|Experimental|Cohort 6: ADC3680B|
11525860|NCT01173757|Experimental|PF-04995274|
11525861|NCT01173744|Experimental|Gamma-3 Nail|
11525862|NCT01173744|Active Comparator|DHS|
11525863|NCT01173731|Experimental|AFQ056|
11525864|NCT01173718|Experimental|GORE® ACUSEAL Vascular Graft|
11525865|NCT01173705||Normal weight: abdominal surgery|Lean individuals undergoing elective abdominal surgery
11525866|NCT01173705||Obese: abdominal or bariatic surgery|Obese subjects undergoing elective abdominal or bariatric surgery
11525867|NCT01173692|Placebo Comparator|Placebo|Twice Daily Orally
11525868|NCT01173692|Experimental|Minocycline|100 mg Twice Daily Orally
11525869|NCT01173679|Other|dasatinib, rituximab, fludarabine|Single-arm, open-label
11525870|NCT01173666|Placebo Comparator|Drug therapy|Patients will be treated by standard medical therapy.
11525871|NCT01173666|Experimental|Drug therapy + stenting angioplasty|Patients will be treated by standard medical therapy + stenting angioplasty of renal artery.
11525872|NCT01173653|Placebo Comparator|Standard EM Smoking Cessation Info|Patients discharged from ER receive pamphlet re: smoking cessation
11525873|NCT01173653|Active Comparator|Patients contact 1-800-QUIT-NOW before leaving ED|Prior the patient leaving the ED, the PI will assist the patient with contacting 1-800-QUIT-NOW, who will help patient to quit smoking.
11525874|NCT01173640|Experimental|Midazolam Alone|Baseline pharmacokinetics. On Study Visit Day 1, subjects will receive a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
11525875|NCT01173640|Experimental|Single dose resveratrol|On Study Visit Day 8, subjects will receive a 1 g oral dose of resveratrol followed 2 hours later by a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
11525876|NCT01173640|Experimental|Multiple dose resveratrol|Between Study Visit Days 8 and 15, subjects will take a 1 g dose of resveratrol daily. On Study Visit Day 15, subjects will receive a 1 g oral dose of resveratrol followed 2 hours later by a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
11525877|NCT01173627|Experimental|A - Test fentanyl citrate 400 mcg troche|Test fentanyl citrate 400 mcg troche
11525878|NCT01173627|Active Comparator|B - Actiq 400 mcg|Actiq 400 mcg
11525879|NCT01173614||Normal subjects|Subjects with two normal eyes.
11525880|NCT01173601|Experimental|12 milligrams (mg) LY2216684 + SSRI|"LY2216684: 12 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the LY2216684 12-mg treatment arm (AT Phase).
~Participants who completed the AT Phase or discontinued early entered a 2-week Discontinuation (DC) Phase. Participants were randomly assigned to either abrupt DC or tapered DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
11525881|NCT01173601|Experimental|18 milligrams (mg) LY2216684 + SSRI|"LY2216684: 12 milligrams (mg), administered orally, once daily (QD) for 1 week, followed by 18 mg, administered orally, once daily for 7 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the LY2216684 18-mg treatment arm (AT Phase).
~Participants who completed the AT Phase or discontinued early entered a 2-week Discontinuation (DC) Phase. Participants were randomly assigned to either abrupt DC or tapered DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
11525882|NCT01173601|Placebo Comparator|Placebo + SSRI|"Placebo: Tablet equivalent to LY2216684, administered orally, once daily (QD) for 11 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the placebo treatment arm (AT Phase).
~Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase. Participants who had received placebo were assigned to the abrupt DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
11525883|NCT01173588|Experimental|Yogurt+fiber+probiotic|Yogurt YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
11525884|NCT01173588|Placebo Comparator|regular yogurt|yogurt YR had no additional fiber or bifidobacterium
11525885|NCT01173575||Bacterial Infection|All Patients with bacterial infection receiving fosfomycin may be included
11525886|NCT01173562|Experimental|Mebendazole|
11525887|NCT01173549|Experimental|001|no intervention Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
11525888|NCT01173549|Experimental|002|Canagliflozin/Placebo Placebo/Canagliflozin Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).
11525889|NCT01173536|Active Comparator|A|
11525890|NCT01173536|Active Comparator|B|
11525891|NCT01173536|Experimental|C|
11525934|NCT01173224|Experimental|Cohort 3: 30 mg 1 day|Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
11525935|NCT01173224|Experimental|Cohort 1: 20 mg, 1 day|Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg).
11525892|NCT01173523|Experimental|Cohort A: STA-9090|Once weekly IV dosing of STA-9090 200mg/m2 was given weeks 1, 2, and 3 of a 4-week cycle. Participants received treatment until evidence of progressive disease or unacceptable toxicity. Participants were stratified at baseline into 2 distinct prognostic groups. Cohort A participants had relapsed > 60 days following initial chemotherapy completion.
11525893|NCT01173523|Experimental|Cohort B: STA-9090|Once weekly IV dosing of STA-9090 200mg/m2 was given weeks 1, 2, and 3 of a 4-week cycle. Participants received treatment until evidence of progressive disease or unacceptable toxicity. Participants were stratified at baseline into 2 distinct prognostic groups. Cohort B participants had not responded or had relapsed </= 60 days from the completion of initial chemotherapy.
11525894|NCT01173510|Experimental|Raltegravir plus tenofovir/emtricitabine|
11525895|NCT01173510|Active Comparator|Efavirenz/Emtricitabine/Tenofovir|
11525896|NCT01173497|Experimental|INIPARIB, irinotecan|
11525897|NCT01173484||Vomiting-predominant idiopathic gastroparesis|Vomiting with retching and nausea are the most bothersome symptoms
11525898|NCT01173484||Dyspepsia-predominant idiopathic gastroparesis|Unpleasant or troublesome sensation (discomfort or pain) centered in the upper abdomen is the most bothersome symptom; this sensation may be characterized by or associated with upper abdominal fullness, fullness after small meals, bloating, or nausea
11525899|NCT01173484||Regurgitation-predominant idiopathic gastroparesis|Effortless regurgitation of acid or undigested food or heartburn is the most bothersome symptom
11525900|NCT01173471|Experimental|1) AZD4017|Europe: 200 mg AZD4017
11525901|NCT01173471|Placebo Comparator|2) Placebo|Europe: placebo
11525902|NCT01173471|Experimental|3) AZD4017|USA: 800 mg AZD4017
11525903|NCT01173471|Placebo Comparator|4) Placebo|USA: placebo
11525904|NCT01173458||Blood Draw|"Approximately 1 and one-half teaspoons of blood will be drawn at times specified.
~one sample prior to treatment initiation
~one sample after completion of treatment
~one sample every 6 to 8 weeks during follow up visits
~one sample at the time of Relapse"
11525905|NCT01173432|Active Comparator|continuous positive airway pressure|using continuous positive airway pressure (CPAP) device during sleep, for the study period (4 weeks)
11525906|NCT01173432|No Intervention|control|observation for the study period (4 weeks, no CPAP)
11525907|NCT01173419|Active Comparator|VenaCure EVLT NeverTouch|
11525908|NCT01173419|Active Comparator|RF ClosureFAST|
11525909|NCT01173406|Sham Comparator|Standard care (SC)|Standard care
11525910|NCT01173406|Active Comparator|Extended education (ME+SC)|Motivational enhancement education + Standard care
11525911|NCT01173393|No Intervention|Standard Treatment|"For patients randomised to hospital cooling:
~LMA/ Intubation and ventilation with 100% oxygen
~Measure temperature using tympanic probe and record
~Insert IV line and administer drugs as per protocol
~Fluid challenge with standard temperature saline only as per current guideline (suspected hypovolemia)
~Post resuscitation: midazolam 1-5 mg only to maintain LMA/ intubation as needed.
~Pancuronium 8 mg only if intubation unable to be maintained with midazolam.
~After arrival at the Emergency Department, all patients receive standard care."
11525912|NCT01173380|Sham Comparator|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
11525913|NCT01173380|Active Comparator|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
11525914|NCT01173367|Active Comparator|Aggressive Fever Treatment|
11525915|NCT01173367|Active Comparator|Permissive Fever Treatment|
11525916|NCT01173354|Experimental|COPD patients only|Free balanced amino acid mixture or free essential amino acid mixture
11525917|NCT01173341||Subgroup 2|Subgroup2 represents will undergo trastuzumab therapy only
11525918|NCT01173341||Subgroup 1|Subgroup 1 are anthracycline only treated patients.
11525919|NCT01173341||Subgroup 3|Subgroup 3 are patients that will undergo trastuzumab therapy with anthracyclines.
11525920|NCT01173328|Experimental|Pursed-lip Breathing|
11525921|NCT01173315|Experimental|Group MV|Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg
11525922|NCT01173315|Experimental|Group MVB|Group MVB: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg)plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg)
11525923|NCT01173315|Placebo Comparator|Group P|Group P: starch (placebo
11525924|NCT01173302|Experimental|Post vaccination|All the subjects had been vaccinated with antirabies vaccine.
11525925|NCT01173289|Experimental|External Beam Radiotherapy|"Definition of target volume:
~Gross tumor volume (GTV) = gross tumor defined with intravenous bolus contrast administration given CT scan
~Clinical target volume (CTV) = GTV + included volumes of clinical and suspected subclinical involvement (draining lymph nodes)
~Planning target volume (PTV) = CTV + 5-10 mm of lateral, craniocaudal, and anteroposterior margins.
~Radiation dose and planning :
~Total dose 65 Gy for gross tumor, 62.4 Gy for microscopic involved area, 58.5 Gy for high risk lymph node area and 52 Gy for elective lymph node area in 26 fractions during 6 weeks
~Dose prescription: 90% isodose volume of prescribed dose encompassed PTV
~The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the esophagus, lung, contralateral normal thyroid, arytenoids, vocal cord and spinal cord, etc., was calculated."
11525926|NCT01173263|Active Comparator|BIS 70|BIS levels of 70, will be targeted (Anxiolysis/high-frequency EEG activity, beta-augmentation);
11525927|NCT01173263|Active Comparator|BIS 50|BIS levels of 50 will be targeted, (Low frequency EEG activity, theta-delta activity)
11525928|NCT01173263|Active Comparator|BIS 35|BIS levels of 35 will be targeted (low frequency EEG activity)
11525929|NCT01173250|Active Comparator|stapled ileoanal pouch without diverting ileostomy|
11525930|NCT01173250|Placebo Comparator|stapled ileoanal pouch with diverting ileostomy|
11525931|NCT01173237|Active Comparator|Tracheal intubation|Endotracheal tube is a airway device used for ventilation or surfactant administration, in preterm babies with SDR surfactant deficiency.
11525932|NCT01173237|Experimental|Proseal laryngeal mask airway|Laryngeal mask airway is a airway device used for ventilation with self-inflating bag or flow-inflating bag. In this study it will be used for surfactant administration, in preterm babies with SDR surfactant deficiency.
11525933|NCT01173224|Experimental|Cohort 2: 20 mg 10 days|Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg).
11525936|NCT01173211|Experimental|Arm 1: Fluarix®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Fluarix®.
11525937|NCT01173211|Experimental|Arm 3: Fluzone®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Fluzone®.
11525938|NCT01173211|Experimental|Arm 2: Agriflu®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Agriflu®.
11525939|NCT01173198|Active Comparator|WAVEFRONT GUIDED LASIK|
11525940|NCT01173198|Active Comparator|WAVEFRONT OPTIMIZED|
11525941|NCT01173172|Experimental|BNCT, recurrent head and neck cancer|Single arm treated by BNCT only
11525942|NCT01173159|Experimental|Omegaven|Subjects will receive Omegaven at a dose of up to 1 g/kg body weight/day until they no longer require Total Parenteral Nutrition or until their conjugated/direct bilirubin has normalized and their enteral lipid intake is sufficient to discontinue intravenous lipids.
11525943|NCT01173120|Experimental|Abatacept Combination Product (ACP)|Participants from the long-term period of study NCT00559585 who enrolled in the ACP substudy switched to administration of subcutaneous (SC) abatacept via the ACP for the duration of the substudy. Abatacept was administered SC using the ACP by the participant or caregiver on Substudy Day 1 and at weekly intervals thereafter. The ACP was a pre-filled liquid product device delivering 125 mg abatacept/device (125 mg/mL).
11525944|NCT01173107|Experimental|MDRD eGFR 10~50 ml/min/1.73m2|
11525945|NCT01173094|Experimental|PTA|The patients with short-obstruction in the below-knee artery will be included in this group.
11525946|NCT01173094|Experimental|bypass|The patients with long-obstruction in the below-knee artery will be included in this group.
11525947|NCT01173081|Experimental|Teriparatide|Patients randomized into this group will inject 20mcg of teriparatide once daily for 16 weeks or until the study endpoint is achieved. Additionally, patients will take oral calcium (1,000mg) and vitamin D3 (1,000 IU) supplements daily.
11525948|NCT01173081|Placebo Comparator|Placebo Control|Patients randomized into this group will inject a matching dose of placebo once daily for 16 weeks or until the study endpoint is achieved. Additionally, patients will take oral calcium (1,000mg) and vitamin D3 (1,000 IU) supplements daily.
11525949|NCT01173055|Experimental|Milnacipran|Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
11525950|NCT01173055|Experimental|Placebo|Placebo will be given orally twice daily in tablet form at different times during the course of the study.
11525951|NCT01173042|Placebo Comparator|Control|Shake containing heavy whipping cream, glucose and chocolate syrup
11525952|NCT01173042|Experimental|Peanut|Shake containing control (whipping cream, glucose and chocolate syrup) + 3oz of peanuts
11525953|NCT01173042|Experimental|Oil blend|Shake containing control (heavy whipping cream, glucose and chocolate syrup) + oil blend (equivalent to fatty acids provided in 3oz peanuts)
11525954|NCT01173029||Resistant Arterial Hypertension|Subjects with systemic arterial hypertension in whom arterial pressure control was not achieved (24hr ambulatory pressure monitoring: mean 24hr systolic pressure >/=130 mmHg or mean 24hr diastolic pressure >/=80mmHg) by non-investigation specialized hypertensive unit care, in spite of appropriate drug treatment regimen with three or more anti-hypertensive drugs including a diuretic. Anti-hypertensive drug treatment was non-investigational and was prescribed at discretion of the physician who performed primary evaluation.
11525955|NCT01173029||Pseudo-resistant Arterial Hypertension|Subjects with systemic arterial hypertension in whom arterial pressure control was achieved (24hr ambulatory pressure monitoring: mean 24hr systolic pressure <130 mmHg and mean 24hr diastolic pressure <80mmHg) by non-investigation specialized hypertensive unit care, with appropriate drug treatment regimen with three or more anti-hypertensive drugs including a diuretic. Anti-hypertensive drug treatment was non-investigational and was prescribed at discretion of the physician who performed primary evaluation.
11525956|NCT01173016|Experimental|Laronidase After Transplantation|Patients with Mucopolysaccharidosis type IH (MPS I, Hurler syndrome) treated with a prior allogeneic transplant >2 years previously and treated with Laronidase weekly for 2 years after transplant.
11525957|NCT01172990|Experimental|Conventional Group|Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- Percutaneous Coronary Intervention PCI between 24 to 48 hours from randomisation according to local policy and guidelines
11525958|NCT01172990|Active Comparator|Immediate Invasive Group|Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting Percutaneous Coronary Intervention(PCI) will be performed according to local policy and guidelines
11525959|NCT01172977||HbA1c ≤ 7|Stroke patients with mild diabetes mellitus HbA1c ≤ 7
11525960|NCT01172977||HbA1c ≥ 7,5|Stroke patients with severe diabetes mellitus HbA1c ≥ 7,5
11525961|NCT01172964|Experimental|Arm I|Patients undergo debulking craniotomy and receive injections of HB1.F3.CD neural stem cells directly into brain tissue on day 0. Patients then receive oral 5-fluorocytosine every 6 hours on days 4-10 in the absence of disease progression or unacceptable toxicity.
11525962|NCT01172951|Active Comparator|OGTT-OGTT-Physical tests|2 successive Oral Glucose Tolerance Tests followed by a physical tests session
11525963|NCT01172951|Active Comparator|OLTT-OLTT-Physical tests|2 successive Oral Lipid Tolerance Tests followed by a physical test session
11525964|NCT01172951|Active Comparator|OGTT-OLTT-Physical tests|Oral glucose tolerance test followed by an oral lipid tolerance test (or vice-versa) followed by a physical tests session
11525965|NCT01172938|Experimental|Apremilast 20 mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
11525966|NCT01172938|Experimental|Apremilast 30mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
11526013|NCT01172639|Other|Tight Step Up low risk group|"Methotrexate 15mg tablet by mouth, weekly for entire trial
~No oral steroids allowed during the first year of the trial"
11526014|NCT01172626||epileptic patients|epileptic patients receiving treatment with continuous Sodium Valproate
11526015|NCT01172613||healthy subjects no symptoms|
11525967|NCT01172938|Placebo Comparator|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
11525968|NCT01172938|Placebo Comparator|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
11525969|NCT01172925|Experimental|Tiotropium|Inhaler
11525970|NCT01172925|Placebo Comparator|Placebo|Inhaler
11525971|NCT01172899|Experimental|Laparoscopic adjustable gastric band|
11525972|NCT01172899|Active Comparator|Control group|
11525973|NCT01172873|Active Comparator|DCS + Exposure and Response Prevention|Participants in this arm receive 10 twice-weekly 60-minute sessions of Exposure and Response Prevention (E/RP) therapy and 50mg of D-Cycloserine immediately after each therapy session. D-Cycloserine is only administered on days in which therapy sessions are held.
11525974|NCT01172873|Active Comparator|E/RP alone (no DCS administration)|Participants in this arm received twice-weekly 60 minute sessions of E/RP alone for a total of 10 sessions.
11525975|NCT01172860|Experimental|EndoVe treatment|Use of the EndoVe device to safely and effectively ablate rectal tumor tissue
11525976|NCT01172847|Active Comparator|A|
11525977|NCT01172847|Active Comparator|B|
11525978|NCT01172847|Experimental|C|
11525979|NCT01172834|Experimental|Lifestyle counseling|
11525980|NCT01172821|Experimental|tiotropium low dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
11525981|NCT01172821|Experimental|tiotropium high dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
11525982|NCT01172821|Active Comparator|50 mcg salmeterol|Twice daily, delivered with HFA MDI (+ inhalation of placebo Respimat® inhaler once daily)
11525983|NCT01172821|Placebo Comparator|placebo|Once daily, delivered with Respimat® inhaler + twice daily delivered with HFA MDI
11525984|NCT01172808|Experimental|tiotropium low dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
11525985|NCT01172808|Experimental|tiotropium high dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
11525986|NCT01172808|Active Comparator|50 mcg salmeterol|Twice daily, delivered with HFA MDI (+ inhalation of placebo Respimat® inhaler once daily)
11525987|NCT01172808|Placebo Comparator|placebo|Once daily, delivered with Respimat® inhaler + twice daily delivered with HFA MDI
11525988|NCT01172795||healthy controls|
11525989|NCT01172795||chronic whiplash patients|
11525990|NCT01172795||Fibromyalgia patients|
11525991|NCT01172782|Placebo Comparator|control group|control group (CG) received 6 mg of hyperbaric bupivacaine and 0.05 mL of saline.
11525992|NCT01172782|Active Comparator|2.5 ug hydromorphone recieved group|the 2.5 μg hydromorphone group (2.5HG) received 1.2 (6 mg) mL of 0.5% hyperbaric bupivacaine and 2.5 μg of hydromorphone in 0.05 mL of saline
11525993|NCT01172782|Active Comparator|5 μg hydromorphone group|5 μg hydromorphone group received 1.2 mL of 0.5% hyperbaric bupivacaine and 5 μg of hydromorphone in 0.05 mL of saline
11525994|NCT01172782|Active Comparator|the 10 μg hydromorpnone group|the 10 μg hydromorphone group received 1.2 mL of 0.5% hyperbaric bupivacaine and 10 μg of hydromorphone in 0.05 mL of saline.
11525995|NCT01172769|Experimental|Temsirolimus|
11525996|NCT01172756|Experimental|Arm 1|
11525997|NCT01172756|Experimental|Arm 2|
11525998|NCT01172756|Experimental|Arm 3|
11525999|NCT01172756|Placebo Comparator|Arm 4|
11526000|NCT01172743||Diabetes|Individuals with diabetes that fit eligibility criteria.
11526001|NCT01172743||Normal Control|Individuals without history of diabetes.
11526002|NCT01172730||Ultrasound scanning|
11526003|NCT01172717|Experimental|Panitumumab|Single arm study
11526004|NCT01172704|Active Comparator|Care as Usual|Participants randomized to CAU receive the standard care given to patients of the Boston Medical Center who are interested in learning more about HIV/AIDS. Included in this care would be referrals for HIV counseling and testing.
11526005|NCT01172704|Experimental|Skills Building - Motivational Interviewing|Participants randomized to SB-MI will receive three individual sessions and a booster. Content of the sessions are as follows; Session 1: Risk Behavior Feedback & Building Motivation; Session 2: Building Motivation & Skill Selection and Practice; Session 3: Developing Change Plan & Skill Practice and Booster Session(s): Review Change Plan Implementation, Maintaining Motivation & Skill Practice.
11526006|NCT01172691|Experimental|Placebo and Study|
11526007|NCT01172652|Experimental|ziprasidone|
11526008|NCT01172652|Placebo Comparator|Placebo|
11526009|NCT01172639|Other|CoBRA classic high risk group|"Methotrexate 15mg tablet by mouth, weekly for entire trial
~Sulfasalazine 2g tablet by mouth, daily for 40 weeks
~Prednisone tablet by mouth, weekly step down scheme 60 - 40 - 25 - 20 - 15 - 10 mg daily for 6 weeks, followed by 7.5mg daily till week 28, then further tapered down to stop at week 32"
11526010|NCT01172639|Other|CoBRA slim high risk group|"Methotrexate 15mg tablet by mouth, weekly for entire trial
~Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32"
11526011|NCT01172639|Other|CoBRA avant-garde high risk group|"Methotrexate 15mg tablet by mouth, weekly for 40 weeks (continued for entire trial if randomized to Methotrexate monotherapy at week 40)
~Leflunomide 10mg tablet by mouth, daily for 40 weeks (continued for entire trial if randomized to Leflunomide monotherapy at week 40)
~Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32"
11526012|NCT01172639|Other|CoBRA slim low risk group|"Methotrexate 15mg tablet by mouth, weekly for entire trial
~Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32"
11526017|NCT01172600|Active Comparator|Entonox|Patients will receive inhaled Entonox along with the interventional block they are scheduled.
11526018|NCT01172600|Placebo Comparator|Oxygen|Patients will receive inhaled oxygen along with the interventional block they are scheduled.
11526019|NCT01172587|Experimental|Lifestyle Counseling|Couples receive behavioral couples therapy for parental drug use.
11526020|NCT01172574|Experimental|Motor control exercise|Subjects of the exercise group underwent a 3-month (13-week) treatment program directed on 3-weekly 1-hr one-to-one sessions by the researcher who had experience in the specific exercise treatment of the spinal region. During the next 3 months, the subjects were urged to perform the exercises alone at home at least once a day, and compliance was monitored by the activity quota chart given to them at the beginning of each study-month.
11526021|NCT01172574|No Intervention|Control group|The control group underwent treatment throughout a 6-month period, directed by each patient's medical practitioner. This consisted of the patients carrying out regular weekly general exercises (walking and swimming). Three of them regularly attended other treatment providers involving group general exercise programs. Two patients received the application of local pain-relieving methods such as heat, massage, laser and ultrasound and one did nothing except for receiving osteoporotic medication.
11526022|NCT01172561|Active Comparator|Usual Care Group|All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
11526023|NCT01172561|Experimental|Lay Health Advisor Intervention|The Lay Health Advisor education intervention - The intervention consisted of an intensive, reinforced, one on one, interactive ed. program (an initial meeting, then 2 calls and a series of 4 postcards mailed at regular intervals and a 2nd visit. Woman were enrolled for about 12 to 14 months.
11526024|NCT01172548|Experimental|imatinib mesylate|
11526025|NCT01172535|Experimental|Lopinavir/ritonavir|Participants will receive lopinavir/ritonavir in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.
11526026|NCT01172522|Experimental|Fexofenadine left; placebo right|"Topical treatment active versus placebo.
~Double blind randomized placebo controlled split face intrasubject comparison."
11526027|NCT01172522|Experimental|Fexofenadine right; placebo left|Split face double blind
11526028|NCT01172509|Placebo Comparator|sugar pill|placebo administered under double blind conditions
11526029|NCT01172509|Experimental|3 mg of R-baclofen|3 mg of R-Baclofen administered double blind
11526030|NCT01172509|Experimental|10 mg of R-baclofen|10 mg of R-baclofen administered double-blind
11526031|NCT01172509|Experimental|25 mg of R-baclofen|25 mg of R-baclofen administered double blind
11526032|NCT01172509|Placebo Comparator|second sugar pill|the second placebo administered double blind
11526033|NCT01172496|Experimental|1 mg tablet; 1mg solution|
11526034|NCT01172496|Experimental|1mg solution; 1mg tablet|
11526035|NCT01172483|Experimental|multimodal community program|multimodal community program of exercise and education
11526036|NCT01172483|Active Comparator|active control|general practice in primary care and education of chronic disorders
11526037|NCT01172457|Active Comparator|Epiduroscopy with ozone therapy|Patients in this group will receive 30 mL of ozone at a concentration of 30 mcg / ml by epiduroscopy.
11526038|NCT01172457|Placebo Comparator|Epiduroscopy with oxygen therapy|Patients in this group will receive 30 mL of oxygen by epiduroscopy.
11526039|NCT01172444|Experimental|Test|Sandoz Mesalamine 1 g Suppository
11526040|NCT01172444|Active Comparator|Reference|Canasa 1 g Suppository
11526041|NCT01172444|Placebo Comparator|Placebo|Sandoz 1 g Placebo Suppository
11526042|NCT01172431|Experimental|Indapamide|Indapamide SR 1.5mg qd
11526043|NCT01172431|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide 25mg qd
11526044|NCT01172418|Active Comparator|Thymoglobulin and Daclizumab|Group I: Our standard steroid avoidance protocol, i.e., 3 daily doses of 1 mg/kg of Thymoglobulin®, the first to be infused at surgery, accompanied by 2 doses of anti-CD25 humanized monoclonal antibody, the first also to be given at surgery, and the second 2 weeks later. (controls)
11526045|NCT01172418|Experimental|Thymoglobulin and Alemtuzumab|Group II: A new steroid avoidance protocol in which 1 dose of 1 mg/kg of Thymoglobulin® is to be infused at surgery followed by 1 dose of alemtuzumab (Campath-1H) at 0.3 mg/kg within 24 hours. No further antibody therapy will be used.
11526046|NCT01172405|Experimental|Ibuprofen + Caffeine|72 patients treated with one or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
11526047|NCT01172405|Active Comparator|Ibuprofen|72 patients treated with one or two tablets of ibuprofen 400 mg when presenting headache.
11526048|NCT01172392|Experimental|PegIFN + Nucleosidic or Nucleotidic Analog|
11526049|NCT01172392|Active Comparator|Nucleosidic or Nucleotidic Analog|
11526050|NCT01172379|Experimental|Experimental 1|
11526051|NCT01172379|Experimental|Experimental 2|
11526052|NCT01172379|Experimental|Experimental 3|
11526053|NCT01172379|Placebo Comparator|Placebo Comparator|
11526054|NCT01172353|Experimental|sodium bicarbonate|hydration with sodium bicarbonate
11526055|NCT01172353|Active Comparator|saline|hydration with saline 1ml/Kg/h for 6 hours
11526056|NCT01172340|Experimental|Behavioral and support intervention|one individual counseling session with diet and exercise recommendations plus 16 weeks of group sessions, plus 8 weeks of phone followup
11526057|NCT01172340|Placebo Comparator|wait-listed control group|Controls receive individual counseling session and recommendations, mailed health information, and after post-test measures are offered an abbreviated group-based intervention
11526058|NCT01172327|Experimental|Multicomponent exercise|This arm is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks.
11526169|NCT01171469|Experimental|Dose Level 2|10 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
11526059|NCT01172327|Active Comparator|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks.
11526060|NCT01172314|Experimental|EAA+LEU vs total AA|
11526061|NCT01172314|Experimental|Total AA vs EAA+LEU|
11526062|NCT01172301|Experimental|Oral EAA vs total AA supplement|
11526063|NCT01172288|Experimental|N-Acetylcysteine|NAC was titrated up to a maximum dose of 2400 mg over the course of 2 weeks. Subjects were assigned 600 mg twice a day for weeks 1-2, and then were assigned 1200 mg twice a day for the remainder of the 12 week study.
11526064|NCT01172288|Placebo Comparator|Placebo|Placebo: Subjects were assigned to take two capsules twice a day for weeks 1-2, and then were assigned 4 capsules twice a day for the remainder of the 12 week study.
11526065|NCT01172275|Experimental|N-Acetylcysteine|N-Acetylcysteine effervescent tablets. 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
11526066|NCT01172275|Placebo Comparator|Placebo|Placebo effervescent tablets. 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
11526067|NCT01172262||Bothered Tinnitus|Either responds with a Global Tinnitus Scale of Moderately or Severely Bothered. Score >30 on the Tinnitus Handicap Index (THI).
11526068|NCT01172249|Experimental|Glucosamine-Chondroitin Mantecorp|1 capsule three times daily before meals (drug test - glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg - Mantecorp)
11526069|NCT01172249|Active Comparator|Condroflex|1 capsule three times daily before meals (reference medication - glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg - Condroflex ®).
11526070|NCT01172236|Experimental|Lactoferrin|
11526071|NCT01172223|Experimental|LAPADO|Non-pegylated liposomal doxorubicin (NPLD; Myocet, 60 mg/m2 i.v. day 1 q3 weeks), Paclitaxel (175 mg/m2 i.v. day 1 q3 weeks), and Lapatinib (GW572016, Tykerb, 750-1500 mg/d orally daily until the day of the definitive surgery)
11526072|NCT01172210||Bulimia Nervosa|
11526073|NCT01172210||Bulimia Nervosa w/ Alcohol Use Disorder|
11526074|NCT01172210||Healthy Controls|
11526075|NCT01172197|Active Comparator|Ropivacaine|Local anaesthetic bolus and infusion
11526076|NCT01172197|Active Comparator|Levobupivacaine|Local anaesthetic bolus and infusion
11526077|NCT01172184||Severe mitral regurgitation|Patients with severe mitral regurgitation are admitted for pre-operation cardiac catheterization and are willing to participate in this study.
11526078|NCT01172171|Active Comparator|Melatonin|The randomized patients will receive 10 ml 0,1 mg/ml melatonin intracoronarily and 49 mg intravenously.
11526079|NCT01172171|Placebo Comparator|Isotonic saline|The randomized patients will receive 10 ml isotonic saline (NaCl)and 490 ml intravenously.
11526080|NCT01172158||Forgotten ureteral stents|
11526081|NCT01172145|Placebo Comparator|Cholinesterase inhibitor only|
11526082|NCT01172145|Experimental|Cholinesterase Plus Modafinil|
11526083|NCT01172119|Experimental|BioFreedom Standard Dose|
11526084|NCT01172119|Experimental|BioFreedom Low Dose|
11526085|NCT01172119|Active Comparator|Taxus Liberte drug eluting stents|
11526086|NCT01172106|Placebo Comparator|Encouragement on drug compliance|The intervention for the placebo comparator will be encouragement on drug compliance
11526087|NCT01172106|Experimental|Family psychoeducation|The experimental group will receive weekly sessions of psychoeducation for 12 weeks in addition to receiving drug compliance encouragement
11526088|NCT01172080|No Intervention|control|Participants in this group are monitored for adherence to colonoscopy recommendations.
11526089|NCT01172080|Experimental|intervention|Participants to receive a protocol of reminder letters and a phone call regarding due follow up colonoscopy
11526090|NCT01172067|Experimental|Quickopt Group|the QuickOpt Group patients will be optimized by QuickOpt(IEGM);
11526091|NCT01172067|Active Comparator|Echocardiography group|the Echo Group patients will be optimized by Echo.
11526092|NCT01172054|Experimental|VAX128|Novel H1N1 Influenza vaccine
11526093|NCT01172054|Placebo Comparator|Placebo|one IM injection
11526094|NCT01172028|Experimental|Alimta and Taxotere|Alimta and Taxotere given in combination with dose modifications.
11526095|NCT01172015|Experimental|PTI patients|Study NK cells functions, phenotypic changes and transcripts from ITP patients
11526096|NCT01172015|Other|healthy volunteers|Study NK cells functions, phenotypic changes and transcripts from healthy volunteers
11526097|NCT01172002|Experimental|leflunomide group|
11526098|NCT01172002|Active Comparator|Azathioprine group|
11526099|NCT01171989|Experimental|GSK2202083A + SYNFLORIX GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of GSK2202083A and Synflorix™ vaccines in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of GSK2202083A vaccine at Day 0 and of Synflorix™ vaccine at Month 1. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
11526100|NCT01171989|Active Comparator|INFANRIX HEXA/MENJUGATE GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of Infanrix hexa™ vaccine and 2 doses of Menjugate® vaccine in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of Infanrix hexa™ vaccine co-administered with Menjugate® vaccine at Day 0. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
11526101|NCT01171989|Active Comparator|INFANRIX HEXA/NEISVAC-C + SYNFLORIX GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of Infanrix hexa™ vaccine and Synflorix™ vaccines in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of Infanrix hexa™ vaccine co-administered with NeisVac-C® vaccine at Day 0 and 1 dose of Synflorix™ vaccine at Month 1. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
11526213|NCT01171157||Group 1|Subjects with influenza like illness
11526102|NCT01171976|Experimental|TE Ranibizumab 0.5 mg and Laser|On Day 1, all patients received an intravitreal injection with 0.5 mg ranibizumab and subsequently entered Phase A which comprised of monthly injections. Laser therapy was applied at Day 1. It could then be re-administered according to ETDRS criteria at any visit with 0.5 mg ranibizumab treatment if deemed necessary by the Treating Investigator with a minimal treatment interval between laser treatments of 3 months. Laser therapy was administered ≥ 30 minutes prior to the ranibizumab injection.
11526103|NCT01171976|Experimental|TE Ranibizumab 0.5 mg alone|Patients received ranibizumab intravitreal injection therapy only.
11526104|NCT01171976|Active Comparator|PRN Ranibizumab 0.5 mg|Patients received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.
11526105|NCT01171963|Experimental|Rotarix Group|Subjects aged between and including 6 and 16 weeks at the time of first vaccination received 2 doses of Rotarix™ vaccine, liquid formulation, at Day 0 and at Month 1. As part of the routine childhood vaccination according to the Expanded Program of Immunization (EPI) recommendations in China, subjects in this group also received 3 doses of Infanrix™ vaccine and 3 doses of the oral poliovirus vaccine manufactured by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (OPV). The Infanrix™ and the OPV vaccines were administered independently of (Sub-cohort 1) or concomitantly with (Sub-cohort 2) the Rotarix™ vaccine. When administered concomitantly, subjects received the 3 doses of Infanrix™ vaccine at Months 1, 2 and 3, and the 3 doses of the OPV vaccine at Day 0, Month 1 and Month 2. The Rotarix™ and OPV vaccines were administered orally; the Infanrix™ vaccine was administered intramuscularly in the left anterolateral thigh.
11526106|NCT01171963|Placebo Comparator|Placebo Group|Subjects aged between and including 6 and 16 weeks at the time of first vaccination received 2 doses of Placebo at Day 0 and at Month 1. As part of the routine childhood vaccination according to the Expanded Program of Immunization (EPI) recommendations in China, subjects in this group also received 3 doses of Infanrix™ vaccine and 3 doses of the oral poliovirus vaccine manufactured by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (OPV). The Infanrix™ and the OPV vaccine were administered independently of (Sub-cohort 1) or concomitantly with (Sub-cohort 2) the Placebo. When administered concomitantly, subjects received the 3 doses of Infanrix™ vaccine at Months 1, 2 and 3, and the 3 doses of the OPV vaccine at Day 0, Month 1 and Month 2. The Placebo and the OPV vaccine were administered orally; the Infanrix™ vaccine was administered intramuscularly in the left anterolateral thigh.
11526107|NCT01171950|Other|All Patients|All patients meeting the patient selection criteria will be treated with the CentriMag device.
11526108|NCT01171937|Active Comparator|Open-Label Risperidone|Risperidone oral solution (1mg/mL) qd for 8 weeks.
11526109|NCT01171937|Placebo Comparator|Placebo|Placebo
11526110|NCT01171924|Experimental|Arm A: 5 days/week schedule|
11526111|NCT01171924|Experimental|Arm B: 3 days/week schedule|
11526112|NCT01171898|Experimental|Dose Escalation Cohort (Phase 1)|ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily. Once Recommended Phase 2 Dose (RP2D) has been selected, Phase 1 participants being treated at the lower dose levels will be allowed to escalate to the RP2D level at the discretion of the primary investigator.
11526113|NCT01171898|Experimental|Non-metastatic CRPC (Phase 2)|Participants with non-metastatic, treatment-naive Castration-Resistant Prostate Cancer (CRPC) with rapidly rising Prostate Specific Antigen (PSA) will be enrolled. ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
11526114|NCT01171898|Experimental|Treatment-naive metastatic CRPC (Phase 2)|Participants with treatment-naive metastatic CRPC will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.
11526115|NCT01171898|Experimental|Post-abiraterone metastatic CRPC (Phase 2)|Participants with metastatic CRPC that are chemotherapy-naive, but have been previously treated with abiraterone will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.
11526116|NCT01171885|Placebo Comparator|Placebo|Bilateral superficial cervical block.
11526117|NCT01171885|Experimental|Ropivacaine 0.25%|Bilateral superficial cervical block
11526118|NCT01171885|Experimental|Ropivacaine 0.5%|Bilateral superficial cervical block.
11526119|NCT01171872||Unaffected|Individuals who do not have IBD
11526120|NCT01171872||Affected|Individuals who have IBD
11526121|NCT01171859|Experimental|Doxycycline + Tauroursodeoxycholic acid|
11526122|NCT01171846|Active Comparator|Physiotherapy|
11526123|NCT01171846|No Intervention|Control|Women allocated to the Control group will only receive, by post, the same Lifestyle Advice Sheet as the intervention group.
11526124|NCT01171833|Experimental|Group A(Sevoflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.
~Each subgroup has 4 patients.
~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
11526125|NCT01171833|Experimental|Group B(Desflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.
~Each subgroup has 4 patients.
~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
11526126|NCT01171833|Experimental|Group C(Isoflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.
~Each subgroup has 4 patients.
~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
11526127|NCT01171820|Active Comparator|TAXUS® Liberté™|
11526128|NCT01171820|Active Comparator|XIENCE V® EECSS|
11526129|NCT01171807|Active Comparator|Dexamethasone 21-phosphate encapsulated into red cells|
11526130|NCT01171807|Sham Comparator|Placebo|
11526131|NCT01171794|Active Comparator|ibuprofen|600mg ibu TID
11526132|NCT01171794|Placebo Comparator|placebo|visually identical
11526133|NCT01171781|Active Comparator|3 weekly CDDP based CCRT|radiation (conventioal or IMRT) with 3 cycles of 3-weekly cisplatin
11526134|NCT01171781|Experimental|weekly cisplatin based CCRT|radiation (conventional or IMRT) with 7 cycles of weekly cisplatin therapy
11526135|NCT01171768||patients with hemoptysis within 2 weeks|
11526136|NCT01171768||patients without hemoptysis within 2 years|
11526137|NCT01171755|Experimental|Gemcitabine, Ts-1|Gemcitabine : 1000/m2 will be administered on days 1 and 8 at every 3 weeks . TS-1 will be administered orally according to body surface area (BSA) as follows : BSA<1.25 M2, 80 mg/day; 1.25 M2≤BSA<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
11526138|NCT01171742|Experimental|IHIO|Intermittent hepatic inflow occlusion (IHIO) by clamping of the portal triad, minimizes blood loss and operation time during liver resection. In addition, ischemic preconditioning with IHIO has been reported to have protective effects in patients undergoing liver resection. IHIO'll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
11526139|NCT01171742|Sham Comparator|Control|The donor liver parenchyma'll be transected without IHIO.
11526140|NCT01171716|Other|Dietary Protein Intake|LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
11526141|NCT01171703|Experimental|bypass|femoral-popliteal bypass
11526142|NCT01171703|Experimental|stent|
11526143|NCT01171690|Experimental|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
11526144|NCT01171677|Experimental|IntenSati|"IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem."
11526145|NCT01171677|No Intervention|Treatment as Usual|
11526146|NCT01171664|Placebo Comparator|Placebo|Placebo containing no active pharmaceutical ingredients
11526147|NCT01171664|Experimental|STAHIST|STAHIST tablet for the symptomatic treatment of Seasonal Allergic Rhinitis
11526148|NCT01171651|Experimental|JX-594 followed by sorafenib|1e9 pfu (plaque-forming units) total JX-594 dose on each of up to four (4) JX-594 treatment days. Sorafenib is initiated after 3 JX-594 treatments and briefly interrupted if an optional 4th JX-594 treatment is given.
11526149|NCT01171638||Critical Controls|"Critically injured patients with NO severe traumatic lower extremity injuries to provide normative data for the critically injured physiological status upon arrival at study site"
11526150|NCT01171638||Investigational cohort|"Soldiers with severe traumatic lower extremity injuries in stable or critical physiological status presenting to a participating study site within 12 hours of their injury, to provide data on the acute post-injury phase. This cohort will be made up of:
~Patients meeting inclusion criteria for investigational cohort, who have UNILATERAL severe lower extremity injuries
~Patients meeting inclusion criteria for investigational cohort, who have BILATERAL severe lower extremity injuries.
~Patients meeting inclusion criteria for investigational cohort, who have been clinically diagnosed by the treating provider using that treating providers standards for diagnosing ACS and the patient in addition to be diagnosed with ACS undergoes four-compartment leg fasciotomy."
11526151|NCT01171625|Other|CEP Aortic Bioprothesis, model 3300TFX|
11526152|NCT01171612||Coronary Stent|Patients with coronary Bare Metal Stent (BMS) or Drug Eluting Stent (DES) undergoing noncardiac surgery
11526153|NCT01171586|Experimental|SMS Only|"The SMS only group will receive hints, tips, strategies, and questions related to weight loss behaviors, physical activity, nutrition, and motivation. The messages will be pushed to participants (i.e. no response needed) and pulled from participants (i.e. response is needed). The SMS only group will also receive a brief printed or web based outline on weight loss resources and information."
11526154|NCT01171586|Experimental|SMS + Phone Counseling|"This group will receive hints, tips, strategies, and questions related to weight loss behaviors, physical activity, nutrition, and motivation. The messages will be pushed to participants (i.e. no response needed) and pulled from participants (i.e. response is needed). The group will also receive monthly counseling calls from a Health Coach to discuss barriers and solutions and will receive a brief printed or web based outline on weight loss resources and information."
11526155|NCT01171586|No Intervention|Control|The Control group will receive a binder with an attractive set of Standard Print Materials related to weight loss that is comparable to what one would receive from community resources such as libraries, magazines and national non-profit or governmental organizations such as 5-A Day, American Heart Association and the like.
11526156|NCT01171573||Myositis Patients|Cases with myositis PM DM IBM Venepuncture
11526157|NCT01171573||Healthy controls|Control
11526158|NCT01171560|Active Comparator|EZ Blocker|Patients assigned to the EZ group will be intubated using a conventional tube in an adequate size as it is standard of care and single lung ventilation will be provided using the EZ-Blocker.
11526159|NCT01171560|Active Comparator|Double lumen tube|"The patients assigned to the double lume tube group will be intubated using the double lume tube in an adequate size as it is standard of care."
11526160|NCT01171534|Active Comparator|Vessel Loop fasciotomy closure|Fasciotomy closure using vessel loops and staples.
11526161|NCT01171534|Experimental|DermaClose fasciotomy closure|Fasciotomy closure via DermaClose device
11526162|NCT01171521|Experimental|DermaClose Group|DermaClose device applied to complex soft-tissue wound, with or without negative pressure wound therapy, and prospectively followed for primary and secondary outcomes for one year.
11526163|NCT01171508||Breast cancer patients|12 breast cancer patients aged 30-70 years undergoing a lumpectomy at Herlev Hospital. ASA score I-III.
11526164|NCT01171495|Experimental|Ensure Plus + Multivitamin/Counselling|
11526165|NCT01171495|Active Comparator|Multivitamin/Counselling|
11526166|NCT01171482|Experimental|The FM group|Patients in the FM group will be administered 5-FU plus mitomycin
11526167|NCT01171482|Active Comparator|The sorafenib group|Patients in the sorafenib group will be administered sorafenib
11526168|NCT01171469|Experimental|Dose Level 3|15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
11526170|NCT01171469|Experimental|Dose Level 1|5 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
11526171|NCT01171456|Placebo Comparator|Metformin Placebo|
11526172|NCT01171456|Active Comparator|Metformin|
11526173|NCT01171430|Experimental|MRI WHOLE BODY|
11526174|NCT01171417||Cohort 1|1st-line Faslodex 500 mg
11526175|NCT01171417||Cohort 2|2nd-line Faslodex 500 mg
11526176|NCT01171417||Cohort 3|3rd- line Faslodex 500 mg
11526177|NCT01171417||Cohort 4|patients on exemestane
11526178|NCT01171404||1|Patients, older than 18, hospitalized within 24 hours of onset of symptoms and diagnosed with UA, STEMI or NSTEMI
11526179|NCT01171391|Experimental|VA106483 1mg|
11526180|NCT01171391|Experimental|VA106483 2mg|
11526181|NCT01171391|Experimental|VA106483 4mg|
11526182|NCT01171391|Placebo Comparator|Sugar pill|
11526183|NCT01171378|Other|Ofatumumab|Single arm study
11526184|NCT01171365|Active Comparator|Ciclesonide|Ciclesonide 320 microgrammes twice daily
11526185|NCT01171365|Placebo Comparator|Placebo|Placebo 2 inhalations twice daily
11526186|NCT01171352||ICU Dialysis Patients|Any patient 18 years and older who is admitted to the OHSU Hospitals ICUs with ARF, or End Stage Renal Disease (ESRD) for a diagnosis other than hyperkalemia, as the sole determinant for that level of care, will be invited to participate. The patient must have acute or chronic needs for dialytic support during their ICU stay.
11526187|NCT01171339|No Intervention|Control|"Usual care in accordance with recommended standard#
~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
11526188|NCT01171339|Experimental|Intervention arm|"Intervention: Healthcare assistant (HCA) and computer assisted optimization of multi-medication (complex intervention) in accordance with recommended standard#
~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
11526189|NCT01171326|Experimental|Topical Minocycline Foam FXFM244 - 4%|Minocycline Foam FXFM244 - 4%
11526190|NCT01171326|Experimental|Topical Minocycline Foam FXFM244 - 1%|Minocycline Foam FXFM244 - 1%
11526191|NCT01171313|Experimental|Treatment sequence 1|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
11526192|NCT01171313|Experimental|Treatment sequence 2|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
11526193|NCT01171313|Experimental|Treatment sequence 3|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
11526194|NCT01171313|Experimental|Treatment sequence 4|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
11526195|NCT01171287|Experimental|Aircast Walker|Automobile driving with an Aircast Walker applied to each participant's right lower extremity
11526196|NCT01171287|Experimental|Walking cast|Automobile driving with a walking cast applied to each participant's right lower extremity
11526197|NCT01171287|Active Comparator|Running shoe|Automobile driving with a running shoe applied to each participant's right lower extremity
11526198|NCT01171274|Active Comparator|Hatha Yoga|"9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.
~One class of 90 minutes per week, 10 minutes training at home each day."
11526199|NCT01171274|Active Comparator|Exercise information|"9 weeks of exercises practiced at home.
~Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients."
11526200|NCT01171261|Experimental|Jackie Chan Studio Fitness|The Jackie Chan Studio Fitness (J-MAT) cartridge includes four types of activities that use a four panel floor mat made of flexible material that functions as the wireless interface game controller. The celebrity actor and choreographer Jackie Chan is the avatar character in the game that demonstrates and guides users in four types of aerobic and anaerobic game modes.
11526201|NCT01171261|Experimental|XaviX Tennis|XaviX Tennis simulates tennis using a tennis racket controller and an infrared sensor to detect speed and timing of the player's swing of the racquet. The Tennis cartridge includes three playing modes. In Tournament Tour players select from eight different characters with different skills and play opponents in a bracketed tournament. In Exhibition mode players choose a computer opponent or play a tennis match with a friend. The Training Games mode includes a) Serving, b) Target Challenge, c) Serve & Finish, and d) Rally Time.
11526202|NCT01171261|Experimental|XaviX Bowling|XaviX Bowling uses a wireless bowling ball game controller to simulate bowling. The cartridge includes three modes. In Regular Game up to four people can select from 8 preset bowlers with different characteristics. In Tournament Mode up to eight people can play. Challenge Games consists of three games called Against the Clock, Moving Pins, and Panel Crusher.
11526203|NCT01171261|Experimental|XaviX Boxing|XaviX Boxing uses boxing gloves as the game controller and allows players to box against five different computer opponents in Championship and Exhibition modes and to practice boxing skills in Exercise mode. Exercise mode includes Punch Fast, Panel Toucher, Punch the Red Ball, and Combination Training.
11526204|NCT01171248||type 1 diabetes|
11526205|NCT01171248||non-diabetics|
11526206|NCT01171222||veteran soccer players from Saarland County, Germany|
11526207|NCT01171209|Experimental|IFN-alfa|One single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c.
11526208|NCT01171209|Experimental|Interferon-beta|One single injection of IFN-beta followed by blood test for MxA9.12 hours after injection
11526209|NCT01171183|Placebo Comparator|Placebo|
11526210|NCT01171183|Active Comparator|Carvedilol controlled release|controlled release carvedilol (Coreg CR) at 80 mg/day in once daily dosing
11526211|NCT01171170|Active Comparator|carboplatin-paclitaxel-bevacizumab|paclitaxel 200 mg/m2 d1 - carboplatin area under the curve (AUC) 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
11526212|NCT01171170|Experimental|standard treatment plus nitroglycerin|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
11526215|NCT01171131||Chronic TBI Patients - Non-penetrating|"Chronic TBI patients should have a history of head trauma manifesting in one or more of the following:
~Loss of consciousness
~Post-traumatic amnesia
~Focal neurologic deficits, seizure
~Persistent symptoms of increased arousal (e.g. difficulty falling or staying asleep, anger and hypervigilance)
~Impairment in social, occupational, or other important areas of functioning (e.g. problems with work and relationships.) Patients will be excluded from the study if we are unable to obtain informed consent and if they are non-communicative (i.e. in a vegetative state)."
11526216|NCT01171131||Chronic TBI Patients - Blast|"Chronic TBI Blast injury patients should have a history of head trauma manifesting in one or more of the following:
~Loss of consciousness
~Post-traumatic amnesia
~Focal neurologic deficits, seizure
~Persistent symptoms of increased arousal (e.g. difficulty falling or staying asleep, anger and hypervigilance)
~Impairment in social, occupational, or other important areas of functioning (e.g. problems with work and relationships.) Patients will be excluded from the study if we are unable to obtain informed consent and if they are non-communicative (i.e. in a vegetative state)."
11526217|NCT01171131||Healthy Volunteers|"Healthy volunteers include gender, age and race matched volunteers able to provide informed consent who have,
~No significant medical history
~Take no medications (other than birth control pills)
~Fever free
~No history of head trauma or recent injury/infection
~No history of neurological or psychiatric disorders or alcohol or drug dependency."
11526218|NCT01171118|Experimental|Sedation & Physostigmine & Room Air|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
11526219|NCT01171118|Placebo Comparator|Sedation & Placebo & Room Air|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
11526220|NCT01171118|Experimental|Sedation & Physostigmine & Oxygen|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
11526221|NCT01171118|Placebo Comparator|Sedation & Placebo & Oxygen|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
11526222|NCT01171105|Experimental|1|AZD5213 (dose escalating)
11526223|NCT01171105|Placebo Comparator|2|Placebo
11526224|NCT01171092|Experimental|bortezomib and G-CSF|
11526225|NCT01171079|Experimental|Interceed|
11526226|NCT01171053|Placebo Comparator|Attention control|Weekly support from therapist without CBT-interventions
11526227|NCT01171053|Experimental|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support
11526228|NCT01171040||Consecutive patients received echocardiographic examinations|Consecutive patients received echocardiography are willing to participate in this study.
11526229|NCT01171027|Experimental|NOTES(R) Cholecystectomy|Natural Orifice Translumenal Endoscopic Surgery techniques
11526230|NCT01171027|Active Comparator|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
11526231|NCT01171014|Experimental|High dose probiotic|Bifidobacterium lactis HN019, 10 billion cfu/day
11526232|NCT01171014|Experimental|Low dose probiotic|Bifidobacterium lactis HN019, 1 billion cfu/day
11526233|NCT01171014|Placebo Comparator|Placebo|Placebo
11526234|NCT01170988|Other|surgical procedure|T-graft bypass or conventional bypass
11526235|NCT01170975|Other|Treatment sequence 1|Treatment Period 1: Tesetaxel 10 mg in the fed state; Treatment Period 2: Tesetaxel 10 mg in the fasted state
11526236|NCT01170975|Other|Treatment sequence 2|Treatment Period 1: Tesetaxel 10 mg in the fasted state; Treatment Period 2: Tesetaxel 10 mg in the fed state
11526237|NCT01170962|Experimental|Arm 1: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior null responders)
11526238|NCT01170962|Experimental|Arm 2: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior null responders)
11526239|NCT01170962|Experimental|Arm 3: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior partial responders)
11526240|NCT01170962|Experimental|Arm 4: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior partial responders)
11526241|NCT01170962|Experimental|Arm 5: Placebo plus peginterferon alfa-2a and ribavirin|(prior partial responders only)
11526242|NCT01170949|Experimental|Miltefosine|
11526243|NCT01170949|Placebo Comparator|Placebo|
11526244|NCT01170936|Experimental|Canakinumab|
11526245|NCT01170923|Experimental|FDG-PET guided|Chemotherapy regimen will be changed depending on metabolic response.
11526246|NCT01170923|Active Comparator|CT guided|Chemotherapy regimen will be changed depending on CT findings (RECIST).
11526297|NCT01170533|Active Comparator|Omeprazole|prospective, open-label, two-sequence, three-period, randomized crossover study
11526247|NCT01170910|Other|Static incubation|If conservation in static incubation (group 1) is chosen by random selection, the transplant should be carried out while keeping the cold ischemic time (CIT) as short as possible (preferably less than 18 hours). Keep in mind that for reasons of homogeneity for result analysis and for conservation quality, it is recommended that kidneys in group 1 be conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution.
11526248|NCT01170910|Experimental|Pulsatile perfusion|If conservation in a pulsatile perfusion machine (group 2) is chosen by random selection, the kidney will be placed in the perfusion machine within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
11526249|NCT01170897|Other|Maximally Tolerated Dose|To identify the maximally tolerated dose (MTD) of PEGPH20.
11526250|NCT01170884|Active Comparator|Combigan® + Lumigan®|COMBIGAN® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution) adjunctive to LUMIGAN® (bimatoprost 0.03% ophthalmic solution)
11526251|NCT01170884|Active Comparator|Lumigan®|LUMIGAN® (bimatoprost 0.03% ophthalmic solution) plus Gen Teal® Mild (hypromellose 0.2% eye drops) used for masking purposes
11526252|NCT01170871|Experimental|Experimental|Escalating doses of Ixabepilone and Pemetrexed
11526253|NCT01170858|Experimental|Icodextrin group|7.5% icodextrin dialysis solution
11526254|NCT01170858|Active Comparator|glucose solution group|2.5% or 4.25% glucose dialysis solution
11526255|NCT01170845|Placebo Comparator|Control group|Patients in the control group received saline for 7 days starting at the beginning of surgery
11526256|NCT01170845|Active Comparator|S group|Patients in the S group received sivelestat sodium hydrate at a dosage 4.8mg/kg/day for 7 days starting at the beginning of surgery
11526257|NCT01170819|Active Comparator|Dinoprostone Vaginal Insert|
11526258|NCT01170819|Experimental|Double Balloon Catheter|
11526259|NCT01170806|Active Comparator|Orlistat (Lipiblock) treatment|Lipiblock is a new Orlistat formulation, produce by Germed Pharma, Brazil. Capsule 120mg
11526260|NCT01170806|Active Comparator|Orlistat (Xenical) treatment|Xenical is a innovator Orlistat formulation, produced by Roche
11526261|NCT01170793|No Intervention|2|no educative telephone coaching (ETC)
11526262|NCT01170793|Experimental|1|with educative telephone coaching (ETC)
11526263|NCT01170780|Placebo Comparator|Placebo|Saline
11526264|NCT01170780|Active Comparator|Dexamethasone|Corticosteroid (Fortecontin 8 mg)
11526265|NCT01170767|Experimental|Avastin|intravitreal injection of bevacizumab
11526266|NCT01170767|Active Comparator|Lucentis|intravitreal injection of ranibizumab
11526267|NCT01170754|Experimental|PEG-3350 and Gatorade|255 miralax with 64 oz gatorade.
11526268|NCT01170754|Active Comparator|Golytely 4 Liters|Golytely 4 Liters
11526269|NCT01170741|No Intervention|Delayed Control Condition|Participants assigned to the delayed treatment control condition will be offered biological testing and the tailored cue-card intervention upon completion of their 3- month follow-up interview. Use of a delayed treatment control group design will permit us to separate intervention effects on HIV risk behaviors from the general effects of participating in the study and completing a detailed HIV risk assessment.
11526270|NCT01170728||Virtue® Male Sling|Device: Coloplast Virtue® Male Sling
11526271|NCT01170715|Experimental|Experimental Group|Enbrel (etanercept): started with self-injection of 50 mg subcutaneous twice weekly for 12 weeks, followed by self-injection of 50 mg subcutaneous weekly for 40 weeks.
11526272|NCT01170702|Placebo Comparator|Group 1|TAP Block utilizing 15mL of 0.9% normal saline per side
11526273|NCT01170702|Experimental|Group 2|TAP Block utilizing 15ml of 0.2% ropivacaine per side
11526274|NCT01170702|Experimental|Group 3|TAP Block utilizing 15ml of 0.5% ropivacaine per side
11526275|NCT01170702|Experimental|Group 4|TAP Block utilizing 15ml of 0.75% ropivacaine per side
11526276|NCT01170689||Inpatient schizophrenia or schizoaffective disorder|
11526277|NCT01170676|Experimental|Puff City GA|Puff City is an NHLBI-funded (C. Joseph, PI; Henry Ford Health System, Detroit, MI), web-based intervention that targets three key asthma management issues in youth: 1) smoking reduction or cessation in those who are smokers, 2) improving adherence to asthma controller medication use, and 3) improving compliance of carrying a rescue inhaler at all times for use at the first sign of asthma symptoms. Puff City Ga. is a replication study in the rural southeastern United States that adds biological assessments in addition to self-report data.
11526278|NCT01170676|Active Comparator|General Asthma Education|Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
11526279|NCT01170663|Experimental|Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel|Ramucirumab (IMC-1211B) DP and Paclitaxel
11526280|NCT01170663|Placebo Comparator|Placebo and Paclitaxel|Placebo and Paclitaxel
11526281|NCT01170650|Experimental|Arm A|EC145 + Pegylated Liposomal Doxorubicin (PLD)
11526282|NCT01170650|Active Comparator|Arm B|placebo + Pegylated Liposomal Doxorubicin (PLD)
11526283|NCT01170637|Active Comparator|Ibuprofen 200 mg|Oral administration as a fixed dose combination tablet (RhinAdvil(R))
11526284|NCT01170637|Active Comparator|Pseudoephedrine-HCl 30 mg|Oral administration as a fixed dose combination tablet (RhinAdvil(R))
11526285|NCT01170637|Active Comparator|Ibuprofen 200 mg BI|Oral administration as a fixed dose combination tablet (BI product)
11526286|NCT01170637|Active Comparator|Pseudoephedrine-HCl 30 mg BI|Oral administration as a fixed dose combination tablet (BI product)
11526287|NCT01170611|Experimental|AAISAFER alone - AAISAFER+PREVENTIVE ALGORITHM - DDD|
11526288|NCT01170598|Experimental|Exercise|
11526289|NCT01170585|Placebo Comparator|Placebo|randomised to placebo.
11526290|NCT01170585|Active Comparator|Active|randomised to rosuvastatin.
11526291|NCT01170572||Long bone fracture|Patients presenting to accident and emergency during the study period with long bone or clavicle fracture
11526292|NCT01170559|Experimental|Group 1: ILR Group|Group allocated to receiving an ILR in the A&E department.
11526293|NCT01170559|No Intervention|Group 2: Conventional|Group randomised to conventional lines of investigation
11526294|NCT01170546|Experimental|KLCIR|plate-loaded kneeling leg curl with internal rotation
11526295|NCT01170546|Experimental|SP (Squat Press)|plate-loaded squat press
11526298|NCT01170533|Active Comparator|Pantoprazole|prospective, open-label, two-sequence, three-period, randomized crossover study
11526299|NCT01170520|Experimental|rTMS|
11526300|NCT01170507|Active Comparator|vitamin D3 1000 IU|
11526301|NCT01170507|Active Comparator|Vitamin D3 3000 IU|
11526302|NCT01170507|Active Comparator|Vitamin D3 5000 IU|
11526303|NCT01170507|Placebo Comparator|Placebo|
11526304|NCT01170494|Active Comparator|D2 2000 IU daily|
11526305|NCT01170494|Active Comparator|D3 2000 IU daily|
11526306|NCT01170494|Active Comparator|D2 1000 IU + D3 1000 IU daily|
11526307|NCT01170494|Active Comparator|D2 25000 IU Q2wk|
11526308|NCT01170494|Active Comparator|D3 25000 IU Q2wk|
11526309|NCT01170494|Active Comparator|D2 50000 IU Q4wk|
11526310|NCT01170494|Active Comparator|D3 50000 IU Q4wk|
11526311|NCT01170494|Placebo Comparator|placebo daily|
11526312|NCT01170481||papilloedema without glaucoma|
11526313|NCT01170481||papilloedema with glaucoma|
11526314|NCT01170481||glaucoma without papilloedema|
11526315|NCT01170468|Experimental|Vitamin D3|Vitamin D3 5000 IU daily
11526316|NCT01170468|Placebo Comparator|Placebo|Placebo daily
11526317|NCT01170455|Experimental|Blind Intubation Device|
11526318|NCT01170455|Active Comparator|Direct laryngoscope|
11526319|NCT01170442|Experimental|vitamin D3 2000 IU|
11526320|NCT01170442|Experimental|vitamin D3 5000 IU|
11526321|NCT01170442|Placebo Comparator|Placebo|
11526322|NCT01170429|Experimental|I. Procaterol Hydrochloride|Meptin (Procaterol hydrochloride) Tablets, 25µg twice daily orally plus inhaled budesonide 200µg twice daily for eight weeks;
11526323|NCT01170429|Placebo Comparator|II. Procaterol hydrochloride placebo|Meptin placebo (Procaterol hydrochloride) Tablets, 25µg twice daily orally plus inhaled budesonide 200µg twice daily for eight weeks;
11526324|NCT01170416||12-Lead Body Surface Mapping - Focal VT .|Body surface mapping (BSM) will be completed in patients with a defined focal VT site during the EP study.
11526325|NCT01170416||12-Lead BSPM - Scar related VT, exit not identified|Body surface mapping will be competed on patients with scar related VT where the exit cannot be identified
11526326|NCT01170416||12-Lead BSPM - Scar related VT exit identified|Body surface mapping will be competed on patients with scar related VT where the exit is identified
11526327|NCT01170416||12-Lead BSPM - Supraventricular tachycardia|Body surface mapping will be completed on patients requiring an EP study for the treatment of symptoms related to supraventricular tachycardia
11526328|NCT01170403||NGT/IFG/DM, MeS/no-MeS|NGT: normal glucose tolerance IFG: impaired glucose tolerance DM : diabetes mellitus MeS: metabolic syndrome no-MeS: no metabolic syndrome
11526329|NCT01170390|Other|All participants|A low dose oral contraceptive given cyclically (21 days of active pills/cycle with a 7 day hormonal-free interval) for 2 cycles (56 days).
11526330|NCT01170390|Active Comparator|Aviane and Portia|A low dose oral contraceptive given cyclically (30mcg EE component, 21 days of active pills/cycle with a 7 day hormonal-free interval) for two cycles
11526331|NCT01170390|Active Comparator|Aviane & Aviane|A very-low dose oral contraceptive given continuously for 56 days (20mcg EE component, 28 days of active pills/cycle with no hormone free interval)
11526332|NCT01170377||Mental Retardation|Patients receiving valproate or not
11526333|NCT01170364|Experimental|Sibutramine|Participants in this arm receive sibutramine 15mg for one week followed by two weeks of placebo.
11526334|NCT01170364|Experimental|Placebo|Participants are prescribed two weeks of placebo, followed by one week of 15mg sibutramine.
11526335|NCT01170351|Active Comparator|Group-A|Treatment-naive AIH patients consenting to participate
11526336|NCT01170351|Experimental|Group-B|Treatment-naive AIH patients consenting to participate. This group will receive Cyclosporine-A according to a set protocol.
11526337|NCT01170338|Experimental|active Chantix|active drug to help smoking cessation
11526338|NCT01170338|Placebo Comparator|sugar pill|
11526339|NCT01170325|Experimental|Group A|
11526340|NCT01170325|Placebo Comparator|Group B|
11526341|NCT01170312|Active Comparator|Autologous conditioned plasma|
11526342|NCT01170312|Placebo Comparator|Normal saline|
11526343|NCT01170286|Experimental|DBV712 Viaskin|The experimental arm is composed of subjects treated with whole peanut extract on an epicutaneous delivery system (Viaskin patch)
11526344|NCT01170286|Placebo Comparator|Placebo Viaskin|The placebo arm is composed of subjects treated with a placebo formulation on an epicutaneous delivery system (Viaskin patch)
11526345|NCT01170273|Placebo Comparator|Placebo Arm|placebo capsule
11526346|NCT01170273|Experimental|Cholecalciferol 4000 IU|cholecalciferol 4000 IU daily
11526347|NCT01170260|Active Comparator|Info-only sexual risk reduction|Corresponding intervention gives information only on STDs/HIV
11526348|NCT01170260|Experimental|Sex plus alcohol risk reduction|Corresponding intervention gives info focusing on sex and alcohol risk reduction only
11526349|NCT01170260|Experimental|Sex + alcohol + marijuana risk reduction|Corresponding intervention gives info on sex, alcohol, and marijuana risk reduction
11526350|NCT01170247|Experimental|Intranasal Ketamine|
11526351|NCT01170247|Active Comparator|Intramuscular Ketamine|
11526352|NCT01170234||Eosinophilic esophagitis (EoE)|Treatment-naïve EoE patients, age 7 -65
11526353|NCT01170221|Experimental|TR-701 FA|TR0-701 FA 200 mg tablets once a day for six days followed by 4 days of placebo
11526354|NCT01170221|Active Comparator|Linezolid|Linezolid 600 mg tablets oral twice a day for 10 days
11526355|NCT01170208|Other|Group I|Type 1 diabetes treated with basal-bolus insulin therapy, incorporating carbohydrate-counting and insulin dose software.
11526356|NCT01170208|Other|Group II|Type 2 diabetes treated with basal-bolustherapy and insulin dose software.
11526357|NCT01170208|Other|Group III|Type 2 diabetes treated with biphasic insulin and insulin dose software.
11526358|NCT01170182|Experimental|Omeprazole|Omeprazole Delayed Release Capsules of Dr. Reddy's Laboratories Limited
11526359|NCT01170182|Active Comparator|Prilosec|Prilosec® 40 mg Merck & Co. Inc
11526360|NCT01170169|Experimental|Omeprazole|Omeprazole Delayed Release Capsules of Dr. Reddy's laboratories limited
11526361|NCT01170169|Active Comparator|Prilosec|Prilosec® 40 mg of Merck & Co.Inc.
11526362|NCT01170143|Active Comparator|Trastuzumab QW|Arm A: Trastuzumab 2mg/kg, d1; qw (loading dose 4mg/kg wk1) Paclitaxel 80mg/m2,. d1; qw Carboplatin AUC 2 d1, qw
11526363|NCT01170143|Active Comparator|Trastuzumab Q3W|Arm B: Trastuzumab 6mg/kg, d1(loading dose 8mg/kg wk1) Paclitaxel 175mg/m2,. d1, q3w; Carboplatin AUC 6 ,. d1,q3w
11526364|NCT01170130|Experimental|Lidmyd|The same group is used for the first and the second part of the experiment. Initially the patients will be given topical cyclopentolate 1% and Phenylephrine 10% and the pupil diameter will be recorded. In the second part of the experiment lidocaine 1% will be introduced intracamerally and the pupil size will be recorded again. The 2 measurements will be statistically compared/evaluated.
11526365|NCT01170117|Placebo Comparator|Placebo|Control group receiving placebo
11526366|NCT01170117|Experimental|Olanzapine|Group receiving olanzapine
11526367|NCT01170091||Pramipexole|
11526368|NCT01170078|Experimental|Arm A: Epoetin Hospira administered IV for three doses|
11526369|NCT01170078|Active Comparator|Arm B: Epogen administered IV for three doses|
11526370|NCT01170065|Experimental|BIBF 1120 low qd|Low dose BIBF 1120 once daily
11526371|NCT01170065|Experimental|BIBF 1120 low bid|Low dose BIBF 1120 twice daily
11526372|NCT01170065|Experimental|BIBF 1120 medium bid|Intermediate dose BIBF 1120 twice daily
11526373|NCT01170065|Experimental|BIBF 1120 high bid|High dose BIBF 1120 twice daily
11526374|NCT01170039|Active Comparator|Lubiprostone|
11526375|NCT01170039|Placebo Comparator|Placebo|
11526376|NCT01170026|Experimental|Family Check-up/Individual MI|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use plus 2 session Individual Motivational Intervention for the adolescent
11526377|NCT01170026|Active Comparator|Psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors especially substance use
11526378|NCT01170013|Experimental|Family Check-up|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use
11526379|NCT01170013|Active Comparator|Psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors especially substance use
11526380|NCT01169987||Participants Treated with Adalimumab|Participants with chronic plaque psoriasis in whom adalimumab (Humira) treatment is initiated. All medications will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.
11526381|NCT01169974||healthy volunteers|
11526382|NCT01169948||Patients awaiting cardiac surgery|
11526383|NCT01169935|Experimental|Administration of Intra-dermal SPIO|MRI scanning before and after intra-dermal injection of SPIO.
11526384|NCT01169935|Experimental|Mantoux, Venesection, Labelled cells|Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by venesection.
11526385|NCT01169935|Experimental|Mantoux, Apheresis, Labelled cells|Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by apheresis.
11526386|NCT01169935|Experimental|Mantoux, Administration of Endorem|Mantoux test then MRI scanning before and after administration of Endorem.
11526387|NCT01169935|Experimental|Mantoux only|Mantoux test then serial MRI scanning.
11526388|NCT01169922|Experimental|SEXUAL PLUS ALCOHOL RISK REDUCTION|Intervention contains information geared toward sexual risk reduction as well as alcohol risk reduction.
11526389|NCT01169922|Active Comparator|INFORMATION-ONLY SEXUAL RISK REDUCTION|Intervention contains information geared toward sexual risk reduction only.
11526390|NCT01169909|Experimental|Ranibizumab treatment|Patients will receive a sub-tenons injection of Ranibizumab 0.5mg, to be repeated twice with 30 day intervals between each dose.
11526391|NCT01169883|Active Comparator|Attention Control Group|1) Doctor Asthma Messages delivered over a 10 week time period; 2) Asthma Supervision; and 3) Music Tracks.
11526392|NCT01169883|Experimental|Intervention Group|1) Coping Peer Support delivered over a 10 week time period; 2) Coping Peer Asthma Messages delivered over a 10 week time period; 3) Asthma Supervision; and 4) Music Tracks.
11526393|NCT01169870|Experimental|Genexol-PM|Genexol-PM 300mg/m2, diluted with 500ml of 5% dextrose or normal saline, intravenous infusion over 1 hour on day 1, every 3 week cycle.
11526394|NCT01169870|Active Comparator|Paclitaxel|Paclitaxel 175mg/m2, diluted with 500ml of 5% dextrose or normal saline, intravenous infusion over 3 hour on day 1, every 3 week cycle.
11526395|NCT01169857|Experimental|Velcade Therapy|
11526396|NCT01169844|Experimental|AIN457|
11526397|NCT01169831|Experimental|Sedentary Older Adults|
11526398|NCT01169831|Experimental|Older Endurance Athletes|
11526399|NCT01169818|Experimental|Intervention group|Initiation on a fixed dose of insulin glargine, then subjects will self-adjusted their basal insulin dose every 3 days
11526400|NCT01169818|Active Comparator|Usual standard of care group|Initiation on a fixed dose of insulin glargine, then basal insulin dose is adjusted at each visit by a physician
11526401|NCT01169805|Experimental|ONSERAN|
11526402|NCT01169805|Experimental|NASEA|
11526403|NCT01169805|Experimental|ALOXI|
11526404|NCT01169805|Placebo Comparator|normal saline|
11526405|NCT01169792||Breast cancer patients|Breast cancer patients who underwent surgery with or without chemotherapy, endocrine therapy and/or radiation therapy. The patients are categorized according to the genetic polymorphisms or the activity score of the cytochrome P450 metabolism.
11526406|NCT01169779|Experimental|Lixisenatide|1-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 2 weeks, followed by 20 mcg QD up to Week 24.
11526407|NCT01169779|Placebo Comparator|Placebo|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, followed by 20 mcg QD up to Week 24.
11526408|NCT01169753|Placebo Comparator|Placebo|Patients randomized to nonintervention will take a placebo every morning for 2 weeks.
11526409|NCT01169753|Experimental|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
11526410|NCT01169740||Neonatal jaundice|Infants born between July 1st 2010 and July 31st 2010 and admitted to normal newborn nursery
11526411|NCT01169714|Experimental|Dosing Healthy Adult|Ascending Doses in Healthy Adult Volunteers
11526412|NCT01169714|Experimental|Dosing Healthy Elderly|Dosing in Healthy Elderly volunteers
11526413|NCT01169701|Active Comparator|Tacrolimus|Participants continued with the same tacrolimus+Mycophenolic acid (MPA) (Myfortic® or Cell-Cept®) doses that were taken before study initiation (tacrolimus levels 4-7 ng/ml).
11526414|NCT01169701|Experimental|Everolimus|Participants received an initial dose (day 1) of Everolimus (EVL) 2mg at night and tacrolimus (if taking Prograf®, a full dose of Prograf® in the morning and a 50% dose of Prograf® at night; if taking Advagraf®, a 75% dose in the morning. On days 2 and 3, participants took EVL 2 mg twice daily (bid) without tacrolimus. On days 4 and 5, the EVL dose was adjusted and levels maintained between 5-8 ng/mL. Participants also continued with their MPA doses that were taken prior to study initiation.
11526415|NCT01169675|Experimental|BIBW 2992 low dose|patient receives low dose tablet BIBW 2992 po daily plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
11526416|NCT01169675|Experimental|BIBW 2992 medium dose|patient receives medium dose BIBW 2992 po daily plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
11526417|NCT01169675|Experimental|BIBW 2992 high dose|patient receives high dose BIBW 2992 po daily plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
11526418|NCT01169675|Experimental|BIBW 2992 low dose 6 day|patient receives low dose BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
11526419|NCT01169675|Experimental|BIBW 2992 medium dose 6 day|patient receives medium BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
11526420|NCT01169675|Experimental|BIBW 2992 high dose 6 day|patient receives high dose BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
11526421|NCT01169662|Active Comparator|Vegetable/ Fruit juice|450ml active product, 45 ml no added sugar squash (for flavour)
11526422|NCT01169662|Placebo Comparator|Placebo juice|
11526423|NCT01169649|Experimental|islet cell carcinomas and carcinoid tumors|This is an open label phase II study of MK-2206 administered to patients with metastatic neuroendocrine tumors.
11526424|NCT01169636|Experimental|Panobinostat MTD + ICE|Phase 1: Escalating Panobinostat dose with routine ICE Chemotherapy
11526425|NCT01169636|Experimental|ICE Chemotherapy|Phase 2: Routine ICE Chemotherapy (Ifosfamide, Carboplatin, + Etoposide)
11526426|NCT01169636|Experimental|Panobinostat + ICE|Phase 2: Panobinostat with ICE Chemotherapy
11526427|NCT01169623|Experimental|Educational Intervention|55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
11526428|NCT01169623|Placebo Comparator|CONTROL|55 of head nurses who will not participate in educational intervention will be considered as a control arm
11526429|NCT01169610|Experimental|Varenicline|
11526430|NCT01169584|Experimental|Single Arm - JX-594|Intratumoral injection of JX-594
11526431|NCT01169571||Group I - No loading dose|No loading dose to be administered during the loading-dose paradigms
11526432|NCT01169571||Group II - Loading dose over 10 minutes|Loading dose dexmedetomidine 1 mcg/kg administered over 10 minutes during the loading-dose paradigms
11526433|NCT01169571||Group III - Loading dose over 20 minutes|Loading dose dexmedetomidine 1 mcg/kg administered over 20 minutes during the loading-dose paradigms
11526434|NCT01169558|Experimental|Bevacizumab|Bevacizumab will be administered in combination with fluoropyrimidine-based chemotherapy as first line treatment in participants with metastatic cancer of the colon or rectum until disease progression or study completion.
11526435|NCT01169545||Cancer patients over the age of 18|Cancer patients over the age of 18 who are receiving active treatment.
11526436|NCT01169532|Experimental|Treatment (ridaforolimus and vorinostat)|Patients receive ridaforolimus PO once daily on days 1-5 and vorinostat PO twice daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11526437|NCT01169519|Active Comparator|Sildenafil|Pharmacokinetic and hemodynamic evaluation following sildenafil administration
11526438|NCT01169506|Experimental|COPD patients and healthy individuals|
11526439|NCT01169493|Experimental|VVI-40 to RV DDD-40 to Bi-V DDD-40|Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
11526440|NCT01169493|Experimental|VVI-40 to Bi-V DDD-40 to RV DDD-40|Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
11526441|NCT01169493|Experimental|Bi-V DDD-40 to VVI-40 to RV DDD-40|Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
11526442|NCT01169493|Experimental|Bi-V DDD-40 to RV DDD-40 to VVI-40|Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
11526443|NCT01169493|Experimental|RV DDD-40 to VVI-40 to Bi-V DDD-40|Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
11526444|NCT01169493|Experimental|RV DDD-40 to Bi-V DDD-40 to VVI-40|Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
11526445|NCT01169480|Experimental|Massage Giver|Participants in the experimental group will be asked to give one 50-minute Swedish massage to another volunteer.
11526446|NCT01169480|No Intervention|Passive Controls|Participants in this arm will wait in a classroom (as usual) and do nothing out of their ordinary routines.
11526447|NCT01169467|Active Comparator|Standard-of-Care plus Precedex|Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment.
11526448|NCT01169467|Placebo Comparator|Standard-of-Care|Subjects who are treated with the standard of care sedation regiment only.
11526449|NCT01169454||Monitor then drain|Subjects who are treated with intermittent CSF drainage
11526450|NCT01169454||Drain then monitor|Subjects who are treated with continuous CSF drainage at set pressure thresholds
11527267|NCT01163422|Placebo Comparator|Delayed RVRT|RVRT switched on 4 weeks after pacemaker implant
11526451|NCT01169428|Active Comparator|Standard Behavioral Weight-Loss Maintenence|"Attention/Education/Support Control
~Group designed to control for educational content as well as multiple nonspecific treatment factors (e.g., support, time invested, leader attention, positive expectancy)"
11526452|NCT01169428|Active Comparator|Behavioral: Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss.
11526453|NCT01169415|Experimental|Protracted (30 days), Dexamethasone|Participants will receive a protracted course (30 days) of dexamethasone after surgery.
11526454|NCT01169415|Experimental|Abbreviated (14 days), dexamethasone|Participants will receive an abbreviated (14 days) course of dexamethasone after surgery.
11526455|NCT01169402|Experimental|Fluconazole|
11526456|NCT01169389|Active Comparator|Durolane|
11526457|NCT01169389|Placebo Comparator|Bupivacaine|
11526458|NCT01169350|Experimental|Diagnostic (18F FDG and 18F FMISO PET/CT)|Patients undergo 18F FDG and 18F FMISO PET/CT scans before starting neoadjuvant chemotherapy (without or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy.
11526459|NCT01169337|Experimental|Arm A (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11526460|NCT01169337|Active Comparator|Arm B (observation)|Patients undergo observation until progression to symptomatic myeloma.
11526461|NCT01169324|Experimental|DBS on|baseline settings
11526462|NCT01169324|No Intervention|DBS off|DBS off
11526463|NCT01169311|Experimental|HEEA Stapler|hemorrhoidopexy using Covidien EEA Hemorrhoid and Prolapse Stapling Set
11526464|NCT01169298|Experimental|Lenalidomide|Lenalidomide: 25mg daily on day1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort) or 35 mg daily of each 28 days (3rd cohort)
11526465|NCT01169272|Experimental|CRT-SonR 9770|Active implantable defibrillator with ability to cardiac resynchronization therapy
11526466|NCT01169259|Active Comparator|Vitamin D + fish oil|
11526467|NCT01169259|Active Comparator|Vitamin D + fish oil placebo|
11526468|NCT01169259|Active Comparator|Vitamin D placebo + fish oil|
11526469|NCT01169259|Placebo Comparator|Vitamin D placebo + fish oil placebo|
11526470|NCT01169246||Paradym VR, DR and CRT models|
11526471|NCT01169233|Other|Shorter Wavelength (green)|
11526472|NCT01169233|Other|Intermediate Wavelength (white w/ green filter)|
11526473|NCT01169233|Other|Longer Wavelength (red)|Placebo
11526474|NCT01169220|Experimental|Split prep|
11526475|NCT01169220|Active Comparator|Whole prep|
11526476|NCT01169207||Unaffected|Individuals who do not have IBD
11526477|NCT01169207||Affected|Individuals with IBD
11526478|NCT01169194||Affected|Patients with IBD
11526479|NCT01169194||Unaffected|Individuals who do not have IBD
11526480|NCT01169181|Active Comparator|AMES therapy with rTMS|Each subject will participate in 30 therapy sessions over a 10- to 15-week period. A session will last 90 to 120 minutes, which includes 20 minutes of AMES+rTMS, followed by an EMG test. During the hand-opening phase of the AMES therapy, the subjects assigned to the AMES+rTMS treatment group will be subjected to trains of TMS pulses.
11526481|NCT01169181|Active Comparator|AMES therapy with tDCS|Each subject will participate in 30 therapy sessions over a 10- to 15-week period. A session will last 90 to 120 minutes, which includes 20 minutes of AMES+tDCS, followed by an EMG test. A constant current will be applied throughout the entire 20-minute therapy session with the AMES device.
11526482|NCT01169155|Active Comparator|Study 3. Adults 20-49 Years of Age|"Using a randomized, non-blinded, repeated measures, clinical intervention design, our two working hypotheses as stated in Specific Aims 1 and 2 will be tested in a linked study, Study 3, with adult participants 20-49 years of age to ensure that the alarms tested will also work for adults in this age group.
~This arm will use the alarm signal identified in Study 2 that is significantly associated with Electroencephalography (EEG)-defined awakening and successful completion of simulated escape behaviors by children after awakening from slow wave sleep. A lower frequency tone smoke alarm will evaluate the influence of alarm signal frequency on awakening. A conventional residential tone smoke alarm will be used as a reference stimulus. Both a male and a female voice will be used as alarm stimuli. Note that these will be strangers' voices, and not a mother's voice."
11526483|NCT01169155|Active Comparator|Study 4. Older Adults 60-84 Years of Age|Study 4 of this project will take the voice alarm script in Study 2 and compare it with a low-frequency 520 Hz square wave tone smoke alarm in awakening older adults 60-84 years of age from slow wave sleep and prompting their performance of a simulated escape procedure. Note that this will necessarily be a female stranger's voice, and not a mother's voice, in this older age group. As in Studies 1 and 2, a conventional residential tone smoke alarm will be used as a reference stimulus in Study 4. In order to maintain the same experimental design across these studies, a fourth alarm type will be introduced. This fourth alarm will be a hybrid of the low-frequency 520 Hz square wave tone smoke alarm and the voice alarm, i.e., the stimulus will begin with the 520 Hz square wave tone in a T-3 pattern followed by the voice script, with this stimulus being repeated until the subject completes the escape procedure.
11526484|NCT01169155|Active Comparator|Study 1. Maternal Voice Smoke Alarm Characteristics|"Study 1. Identification of Specific Maternal Voice Smoke Alarm Characteristics Associated With Awakening and Escaping.
~Using a randomized, non-blinded, repeated measures, clinical intervention design, Study 1 will identify the critical elements (i.e., use of child's first name and/or behavior commands in message content) in the maternal voice signal that are significantly associated with EEG-defined awakening (and completion of simulated escape behaviors by children after awakening from S4). A conventional residential tone smoke alarm meeting current NFPA 72 National Fire Alarm Code will be used as a reference stimulus to allow comparison of responses to the voice alarm stimuli with responses to a conventional residential tone alarm stimulus."
11526515|NCT01168986|Active Comparator|Exercise|Participants perform an exercise to strengthen the deep neck flexors
11526516|NCT01168986|No Intervention|No intervention|Participants receive/perform no intervention
11526517|NCT01168973|Experimental|Ramucirumab + Docetaxel|
11526518|NCT01168973|Placebo Comparator|Placebo + Docetaxel|
11526519|NCT01168960|Other|Cognitive Behavioral Treatment|A single intervention study
11526520|NCT01168947|Experimental|5% dextrose|5% dextrose rinsing fluid
11526485|NCT01169155|Active Comparator|Study 2. Mother's Versus Stranger's Voice Alarms & Alarm Freq.|"Study 2. Comparison of Mother's Versus Stranger's Voice Smoke Alarms and Alarm Frequency.
~Study 2 will take the voice alarm script that was the most successful in Study 1 in awakening and prompting children to perform the simulated escape behaviors, and will compare mother's voice to a female stranger's voice using this script. This will determine whether mother's voice is a critical factor for success of the voice smoke alarm. In addition, a Temporal-Three (T-3) pattern smoke alarm with dominant tones in lower frequency ranges similar to the human voice range will be included as a stimulus in Study 2 to evaluate the influence of alarm signal frequency on EEG-defined awakening (as well as completion of simulated escape behaviors by children after awakening from S4). As in Study 1, a conventional residential tone smoke alarm will be used as a reference stimulus in Study 2. This conventional residential tone alarm has a higher frequency signal than the other T-3 tone alarm."
11526486|NCT01169155|Active Comparator|Study 5. Male Voice and Hybrid Tone/Voice Alarm for Children|Study 5. Children 5-12 Years of Age (Testing Male Voice and Hybrid Tone/Voice Alarm) Using a randomized, non-blinded, repeated measures, clinical intervention design, our two working hypotheses as stated in Specific Aims 1 and 2 will be tested in Study 5 among children 5-12 years of age using the following 4 alarm stimuli: female stranger's voice, male stranger's voice, hybrid of the low-frequency 520 Hz square wave tone smoke alarm and the voice alarm (from Study 4), and conventional high frequency tone residential alarm. This study arm will allow comparison of a male versus female voice and also evaluate the hybrid low frequency tone/voice alarm among children 5-12 years of age. The same protocol will be used for children in this study arm as was used in Studies 1 and 2.
11526487|NCT01169142|Active Comparator|Immediate Vitamin D3|Will start Vitamin D3 immediately
11526488|NCT01169142|Active Comparator|Three month delay|Half the subjects will be delayed three months (but evaluated) before getting Vitamin D3. (If the level is very low they will start immediately)
11526489|NCT01169129|Active Comparator|surgery+whole-brain irradiation|brain metastases is resected and the patient is submitted to whole-brain irradiation
11526490|NCT01169129|Active Comparator|whole-brain irradiation+radiosurgery|patients will be submitted to whole-brain irradiation and after, they will be submitted to radiosurgery.
11526491|NCT01169103|Experimental|recombinant human growth hormone|Forty subjects will be randomized to receive either recombinant human growth hormone or placebo.
11526492|NCT01169103|Placebo Comparator|Placebo|Forty subjects will be randomized to receive either recombinant human growth hormone or placebo.
11526493|NCT01169090|Experimental|SK-0403 100 mg QD|
11526494|NCT01169090|Experimental|SK-0403 200 mg QD|
11526495|NCT01169090|Experimental|SK-0403 400 mg QD|
11526496|NCT01169090|Experimental|SK-0403 200 mg BID|
11526497|NCT01169090|Sham Comparator|Placebo|
11526498|NCT01169090|Active Comparator|Sitagliptin 100 mg QD|
11526499|NCT01169077|Experimental|Group I: 0.25 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 0.25 mg, on Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
11526500|NCT01169077|Experimental|Group II: 1.0 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 1.0 mg, on Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
11526501|NCT01169077|Experimental|Group III: 4.0 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 4.0 mg, Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
11526502|NCT01169064|Active Comparator|Silver-containing surgical dressing|Self adhesive 4 x 10 dressing impregnated with nanocrystalline silver
11526503|NCT01169064|Active Comparator|Cloth adhesive dressing|Soft cloth adhesive wound dressing
11526504|NCT01169051||Thoracic sugery statins|
11526505|NCT01169051||Thoracic surgery non-statins|
11526506|NCT01169038|Active Comparator|Antibiotics|"Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD
~**Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. **We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway."
11526507|NCT01169025|Experimental|Ketamine|Subjects receive 0.3 mg/kg IV ketamine over 5 minutes and are evaluated every 10 minutes. Residual or recurring pain will be treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, subjects are asked if they need additional pain medication every 10 minutes, unless an earlier, spontaneous request is made by the subject or the provider determines that more is needed. For the potential of rare ketamine side effects (dysphoria, anxiety, or agitation), 2 mg IV midazolam is given every 5 minutes as needed for any of these symptoms. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
11526508|NCT01169025|Active Comparator|Fentanyl|Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
11526509|NCT01169012|Other|Single Arm Trial|Single Arm Trial
11526510|NCT01168999|Active Comparator|spinal manipulation|a spinal manipulation known to be effective in the treatment of low back pain for some individuals
11526511|NCT01168999|Placebo Comparator|sham spinal manipulation|a sham spinal manipulation intended to mimic the studied spinal manipulation
11526512|NCT01168999|No Intervention|natural history|No intervention is provided to participants in this arm of the study
11526513|NCT01168999|Placebo Comparator|Enhanced sham spinal manipulation|"a sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
11526514|NCT01168986|Active Comparator|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
11526521|NCT01168934|Experimental|1|Each subject will receive single oral and IV doses of crizotinib separated by at least 14 days.
11526522|NCT01168921|Experimental|Eltrombopag|Starting dose 75 mg by mouth (PO) daily for 28 day cycle.
11526523|NCT01168908|Experimental|Revatio (sildenafil)|This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
11526524|NCT01168908|Other|Placebo|This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
11526525|NCT01168895|Experimental|Arm 1|
11526526|NCT01168895|Experimental|Arm 2|
11526527|NCT01168869||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
11526528|NCT01168856||Cohort|
11526529|NCT01168843||normal pregnant|
11526530|NCT01168830|Experimental|Investigational device|
11526531|NCT01168817|Experimental|Arm 1|
11526532|NCT01168817|Active Comparator|Arm 2|
11526533|NCT01168817|Placebo Comparator|Arm 3|
11526534|NCT01168804|Experimental|single arm bendamustine bortezomib dexamethasone|single arm combination regimen: bendamustine - bortezomib- dexamethasone
11526535|NCT01168791|Experimental|doxorubicin plus palifosfamide-tris|
11526536|NCT01168791|Active Comparator|doxorubicin plus placebo|
11526537|NCT01168778|No Intervention|Control|
11526538|NCT01168778|Experimental|Intervention|
11526539|NCT01168765|Experimental|Intervention group|This is the promotora plus group that will receive the TSSC newsletter and exposure to the media campaign but will also receive monthly visits by promotoras/lay health workers who will review the monthly newsletter with participants, emphasize role model stories, and discuss physical activity and healthful food choices using motivational interviewing strategies.
11526540|NCT01168765|Other|Control group|TSSC Media Campaign only participants who will receive a newsletter and the same exposure to the media campaign intervention as other community members not enrolled in the behavioral intervention.
11526541|NCT01168752|Experimental|schedule A|"Debio 0932 will be administered orally to sequential escalating dose cohorts, as an every-other-day schedule.
~Each dose level (DL) for each schedule will be determined according to the maximum grade of treatment-related AEs observed during the first 30 days treatment period (DLT period) in the previous DL.
~Dose-escalation could be undertaken only after a minimum of 3 (or 6 in case of DLT) patients have been followed up and evaluated for at least 1 DLT period."
11526542|NCT01168752|Experimental|schedule B|"Debio 0932 will be administered orally to sequential escalating dose cohorts, as a daily schedule.
~Each dose level (DL) for each schedule will be determined according to the maximum grade of treatment-related AEs observed during the first 30 days treatment period (DLT period) in the previous DL.
~Dose-escalation could be undertaken only after a minimum of 3 (or 6 in case of DLT) patients have been followed up and evaluated for at least 1 DLT period."
11526543|NCT01168739|Experimental|Quercetin|not necessary, contained in protocol
11526544|NCT01168739|Placebo Comparator|Placebo|not necessary, contained in protocol
11526545|NCT01168726|Experimental|Protective Behavioral Strategies|Personalized feedback on use of protective behavioral strategies.
11526546|NCT01168726|Experimental|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
11526547|NCT01168726|Active Comparator|Alcohol Education|Educational information about harms associated with heavy drinking.
11526548|NCT01168713|Active Comparator|Levofloxacin|
11526549|NCT01168713|Experimental|CEM-101|
11526550|NCT01168700|Placebo Comparator|Placebo|Placebo 1.2 g per day for 12 weeks, followed by a second treatment period with aged garlic extract during 12 more weeks.
11526551|NCT01168700|Experimental|Aged garlic extract (Kyolic ®)|Aged garlic extract, 1.2 g per day for 12 weeks, followed by a second treatment period with placebo during 12 more weeks.
11526552|NCT01168687|Experimental|Group A|Twenty moderate to heavy social alcohol users will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.
11526553|NCT01168687|Experimental|Group B|Twenty moderate to heavy social alcohol users will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days.
11526554|NCT01168674|Placebo Comparator|Sugar pill|Patients are randomized to a sugar pill (placebo), added to their current medications.
11526555|NCT01168674|Active Comparator|Ziprasidone|Patients are randomized to ziprasidone, added to their current medications.
11526556|NCT01168661|No Intervention|Control arm|Participants in this arm will be recruited from the group who applied to participate in the study and fulfilled the inclusion criteria but for various reasons (such as time constraints) could not participate.
11526557|NCT01168661|Active Comparator|Cognitive psychotherapy arm|In this arm, participants will attend a group meeting to practice cognitive psychotherapy once a week. They will also practice on their own >= 4 times a week.
11526558|NCT01168661|Active Comparator|Mindfulness based cog psychotherapy arm|In this arm, participants will attend a group meeting to practice mindfulness based cognitive psychotherapy once a week. They will also practice on their own >= 4 times a week.
11526559|NCT01168661|Active Comparator|Yoga treatment group|Persons in this arm will practice yoga >= 5 time each week (2 times in a supervised group and the other times on their own).
11526560|NCT01168648|Experimental|Yoga as stress management|The intervention consists of following a program of yoga at least three times a week for three months. The yoga program has been designed to reduce stress.
11526561|NCT01168648|Active Comparator|Control group|The group rests without using any specific program for relaxation at least three times a week for three months.
11526562|NCT01168648|Other|Yoga as stress management fewer tests|Eight persons participated in the same intervention as the experimental arm but did not undergo the full range of tests because they did not meet all the inclusion criteria for the study, most commonly because of medication use or body mass index.
11526563|NCT01168635|Experimental|Intervention|Virtually-delivered spirometry quality improvement program
11526564|NCT01168635|No Intervention|Standard of Care|
11526565|NCT01168609||patients with acute myocardial infarction|Acute myocardial infarction (AMI) was defined using the European Society of Cardiology / American College of Cardiology guidelines. Myocardial infarction was detected by the presence of at least two of the following criteria: chest pain lasting more than 30 minutes, typical electrocardiographic changes, and elevated creatinine kinase-MB fraction. Consecutive patients 18 years of age or older who presented within 12 hours after the onset of symptoms were considered for enrollment. Patients who had ST-segment elevation of 1 mm or more in two or more contiguous leads were classified as ST-segment elevation MI.
11526566|NCT01168596|Placebo Comparator|sugar pill|Placebo tablet, 1 per day, duration is approximately 12 weeks.
11526567|NCT01168596|Active Comparator|rasagiline|Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks.
11526568|NCT01168583||Positive Fluid Balance of 2000ml|
11526569|NCT01168583||Negative Fluid Balance of 2000ml|
11526570|NCT01168570||SAA monitored group|FMF-Amyloidosis patients receiving colchicine with a purpose to normalize SAA levels
11526571|NCT01168570||Historical control group|FMF-Amyloidosis patients receiving colchicine at a dose determined to stop FMF attacks. obtained from the Fibrillex study
11526572|NCT01168557|Experimental|Stress-Echo and EIT|Patients who routinely undergo stress-echocardiography will additionally be measured by EIT using a rubber belt, which will be placed around their chest
11526573|NCT01168544|Experimental|loading dose and 50.000 IU vit D3/month|Loading dose based on body weight and baseline serum 25 (OH)D level + 50.000 IU vit D3/month consolidation
11526574|NCT01168544|Experimental|Loading dose and 25.000 IU vit D3/month|Loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
11526575|NCT01168544|Active Comparator|800 IU vit D3/dag|800 IU vit D3/dag
11526576|NCT01168531|Placebo Comparator|placebo arm|
11526577|NCT01168531|Active Comparator|pregabalin arm|
11526578|NCT01168531|Experimental|dexamethasone with pregabalin arm|
11526579|NCT01168505|No Intervention|no iron supplentation|
11526580|NCT01168505|Experimental|iron supplement|
11526581|NCT01168492|Experimental|ketamine|group with triple sedation (ketamine, midazolam, meperidine)
11526582|NCT01168492|Placebo Comparator|placebo|group with conventional sedation and placebo ( midazolam, meperidine and placebo)
11526583|NCT01168479|Active Comparator|standard arm|The standard arm receives the current gold standard, namely 77Gy to the prostate in 35 fractions of 2.2 Gy, 5 times per week.
11526584|NCT01168479|Experimental|FLAME boost|In the experimental arm patients receive in addition to the current gold standard of 77 Gy to the prostate an integrated boost to the macroscopically visible tumour to reach a total dose of 95 Gy in 35 fractions of 2.7 Gy, 5 times per week.
11526585|NCT01168466|No Intervention|Neurofeedback|Waitlist control group.
11526586|NCT01168466|Experimental|QEEG-based Neurofeedback Training|A randomly selected half of participants waits 15 weeks for the other half to complete treatment, and are then reassessed, serving as controls. They then receive the same treatment as the experimental group.
11526587|NCT01168453||neutral head position|supine with neutral head position
11526588|NCT01168453||head rotation|supine with 30° head rotation
11526589|NCT01168414|Active Comparator|Ganfort|Fixed combination of Bimatoprost and Timolol
11526590|NCT01168414|Active Comparator|Duotrav|Fixed combination of Travoprost and Timolol
11526591|NCT01168401|Experimental|NoV GI.1/GII.4 Bivalent VLP Vaccine|Norovirus Bivalent GI.1 and GII.4 VLP Vaccine, adjuvanted with 50 microgram (mcg) MPL and 500 mcg Al(OH)3, IM, on Days 0 and 28.
11526592|NCT01168401|Placebo Comparator|Saline|
11526593|NCT01168388||Movement disorder|
11526594|NCT01168375|Active Comparator|conventional therapy|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
11526595|NCT01168375|Active Comparator|conventional therapy plus umbilical cord serum eye drop|
11526596|NCT01168362||High risk group|positive cardiovascular risk group
11526597|NCT01168362||Low risk group|negative cardiovascular risk group
11526598|NCT01168349||Cohort|
11526599|NCT01168336|Experimental|betahistine|Betahistine 24 mg tablets
11526600|NCT01168336|Experimental|betahistine XR|betahistine 32 mg tablets
11526601|NCT01168336|Placebo Comparator|placebo|
11526602|NCT01168323|Experimental|Spaced education clinicians - cohort 1|Spaced education clinicians receive four isomorphic cycles of 9 spaced education emails over 36-weeks (0-2 emails per week). Each email contained one question-explanation.
11526603|NCT01168323|No Intervention|Control clinicians - cohort 2|Control clinicians received no intervention
11526604|NCT01168310|Experimental|1|
11526605|NCT01168310|Experimental|2|
11526606|NCT01168310|Experimental|3|
11526607|NCT01168310|Experimental|4|
11526608|NCT01168310|Experimental|5|
11526609|NCT01168310|Active Comparator|6|
11526610|NCT01168310|Placebo Comparator|7|
11526611|NCT01168297||Maycoba residents|Pima and non-Pima Mexicans from the village of Maycoba
11526612|NCT01168271||Children Ages 0-3 years|Children aged 0-3 years in Ouelessebougou
11526613|NCT01168271||Febrile Hospitalized Children|Febrile hospitalized children aged 0-10 years in Ouelessebougou or the Pediatric service of Gabriel Toure Hospital in Bamako
11526614|NCT01168271||Non-Hospitalized Children|Febrile non-hospitalized children aged 0-10 years in Ouelessebougou or the Pediatric service of Gabriel Toure Hospital in Bamako
11526615|NCT01168271||Pregnant Women + Newborns|Pregnant women presenting for antenatal consultations and delivery and their newborns
11526616|NCT01168245|Experimental|NICE-System NeuroAD|Treatment Group
11526617|NCT01168245|Sham Comparator|Sham-TMS|Control Group
11526618|NCT01168232|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11526657|NCT01167868|Experimental|FosD|Four sequential cohorts of Japanese subjects are planned with doses ranging from 50mg once daily to a maximum of 200mg twice daily. One cohort of White subjects is also planned to receive the same dose regimen as the third dose level in Japanese subjects
11526658|NCT01167868|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
11527312|NCT01163045|Experimental|neuromonitoring and neurostimulation|
11526619|NCT01168219|Experimental|Treatment (chemotherapy and transplant)|"REDUCED-INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3, busulfan IV over 45 minutes on days -6 to -3, and anti-thymocyte globulin IV over 4-10 hours on days -6 to -5 (matched sibling donor [MSD]) or -6 to -4 (matched unrelated donor [MUD]).
~TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0 or on days 0-1.
~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus PO or IV on days -2 to 90 with taper on days 150-180. Patients also receive methotrexate IV on days 1, 3, 6 (MSD), and 11 (MUD).
~CONSOLIDATION: Beginning on day 42, patients receive azacitidine SC or IV on days 1."
11526620|NCT01168206|Placebo Comparator|Placebo|
11526621|NCT01168206|Experimental|TK3|1 capsule, 3 times per day.
11526622|NCT01168193|Other|Patients that underwent surgery|Single arm
11526623|NCT01168180|Experimental|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
11526624|NCT01168180|Active Comparator|Ultrasound therapy and hot pack|The participants will receive thirty minutes session of Ultrasound therapy and hot pack for 9 sessions over a period of 3 weeks
11526625|NCT01168167||raltegravir-based cART|Patients who begin cART in regular clinical routine with 2N(t)RTI plus raltegravir (n=10 patients) will be offered to participate in this observation arm, but only if no other antiretroviral drugs and no concomitant drugs with relevant impact on antiretroviral's pharmacokinetics are administered. At time of study inclusion, patients should be characterised by a HIV-1 RNA load of >5,000 copies/mL and CD4-cell count of >200/µL within 12 weeks before cART initiation.
11526626|NCT01168167||standard of care-cART|Patients who begin cART in regular clinical routine with 2N(t)RTI plus either a boosted protease inhibitor or efavirenz (n=10 patients) at standard doses will be offered to participate in this observation arm. They will be offered to participate in this trial only if no other antiretroviral drugs and no concomitant drugs with relevant impact on antiretroviral's pharmacokinetics are administered. At time of study inclusion, patients should be characterised by a HIV-1 RNA load of >5,000 copies/mL and CD4-cell count of >200/µL within 12 weeks before cART initiation.
11526627|NCT01168154|Active Comparator|Lactobacillus Reuterii|
11526628|NCT01168154|Placebo Comparator|Placebo|
11526629|NCT01168128|Experimental|Tailored Action Plan|A Tailored Action Plan is an intervention selected to overcome barriers identified before the design and delivery of the intervention.
11526630|NCT01168063|Experimental|Helicobacter pilory triple treatment|Triple treatment on this arm is based on results of molecular detection of resistance to antibiotics
11526631|NCT01168063|Active Comparator|Helicobacter pilori standard recommended treatment|H.Pylori Eradication rate with empirical treatment
11526632|NCT01168050|Experimental|Nilotinib|
11526633|NCT01168037||Open repair|Open Surgical Repair (aortic replacement with revascularization of visceral arteries)
11526634|NCT01168037||Endovascular (Windows 1)|Endovascular therapy branched or fenestrated stent-graft
11526635|NCT01168037||Endovascular (Windows 3)|Endovascular therapy branched or fenestrated stent-graft (vascutek anaconda)
11526636|NCT01168024|Experimental|CINCOR™ System Treatment|Use of the CINCOR™ System and CCS-1 device during the pericutanous coronary intervention (PCI) procedure plus Standard of Care peri-procedural hydration for the prevention of contrast induced nephropathy (CIN).
11526637|NCT01168024|Other|Standard of Care|The control group will receive a peri and post-procedural hydration rate.
11526638|NCT01168011|Experimental|rigosertib|Doses of rigosertib up to 700 mg twice a day or three times a day every day of 21-day cycles.
11526639|NCT01167985|Experimental|Root canal sealer group+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
11526640|NCT01167985|Experimental|Provisional restoration material+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
11526641|NCT01167985|Experimental|Experimental- Different root canal sealer+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
11526642|NCT01167972||1|
11526643|NCT01167959||obesity diabetes, surgical and dietary|
11526644|NCT01167946|Experimental|Group A|will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks
11526645|NCT01167946|Active Comparator|Group B|will receive 2 consecutive daily pulses every 3 weeks for 24 weeks
11526646|NCT01167946|Active Comparator|Group C|will receive 3 consecutive daily pulses every 3 weeks for 24 weeks.
11526647|NCT01167933|Experimental|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd.
11526648|NCT01167933|Active Comparator|Zocor|Zocor® 80 mg tablets of Merck & Co. Inc., USA
11526649|NCT01167920|Active Comparator|Virtual Hypertension Clinic Group|In the VHC group, patients will be ask to regularly measure blood pressure with the Stabil-o-Graph so that these readings are transmitted to Virtual Hypertension Clinic. The data will be reviewed weekly and the patient will receive feedback and intervention if needed at every 2 week interval to achieve blood pressure goal. Once they reach goal, the feedback will be less intense and given at four week intervals till the end of the study.
11526650|NCT01167920|No Intervention|Usual Care Group|The Usual Care Group (UCG) patients will be told their BP is not in control and encouraged to work with their physician to improve it. There will be no further structured intervention during the rest of the study.
11526651|NCT01167907|Experimental|0.2% ropivacaine|Patients with evidence of sciatic and saphenous nerve block will be randomized to receive a postoperative continuous infusion of either saline (control) or 0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement.
11526652|NCT01167907|Placebo Comparator|Saline|Patients with evidence of sciatic and saphenous nerve block will be randomized to receive a postoperative continuous infusion of either saline (control) or 0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement.
11526653|NCT01167894|Experimental|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd.
11526654|NCT01167894|Active Comparator|Zocor|Zocor® 80 mg tablets of Merck & Co. Inc., USA
11526655|NCT01167881|Experimental|BI 10773 dose plus metformin|Patients receive one BI10773 tablet and one placebo Glimepiride capsule once daily
11526656|NCT01167881|Active Comparator|Glimepiride 1-4 mg plus metformin|Patients receive one glimepiride capsule and one placebo tablet Bi 10773 once daily.
11527313|NCT01163045|Experimental|neurostimulation of recurrent laryngeal nerve|
11526659|NCT01167855|Experimental|Intervention|"Telemedicine asthma education sessions
~Asthma health assessment via telemonitoring
~Provider treatment prompts
~School absenteeism
~Prescription filling profile"
11526660|NCT01167829|Experimental|Acyline and oral testosterone|
11526661|NCT01167816|Experimental|azacitabine|
11526662|NCT01167803|Active Comparator|Reference - desflurane|The patients in this group will undergo anesthesia using remifentanil associated with desflurane.
11526663|NCT01167803|Experimental|Experimental - xenon|The patients in this group will undergo anesthesia using remifentanil associated with xenon
11526664|NCT01167777||male/female|Symtomatic and asymptomatic males and females attending STD, family planning, public health and women's health clinics, or other applicable centers, who are being screened for CT or GC.
11526665|NCT01167764|Active Comparator|tranexamic acid|tranexamic acid 250mg po 3 times/day for 1 months
11526666|NCT01167764|Placebo Comparator|placebo|placebo po 3 times/day for 1 months
11526667|NCT01167751|Experimental|MNC implantation|Implantation of BM derived MNC
11526668|NCT01167751|Experimental|AC 133 implantation|Implantation of BM derived AC 133
11526669|NCT01167751|Placebo Comparator|Control|Injection of cell carrier
11526670|NCT01167738|Experimental|PEXG regimen + metformin|cisplatin and epirubicin at 30 mg/mq on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15, Metformin at 2 g days 1-28
11526671|NCT01167738|Active Comparator|PEXG regimen|cisplatin and epirubicin at 30 mg/mQ on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15
11526672|NCT01167725|Active Comparator|Arm I|Patients receive standard systemic therapy, at the discretion of patients' oncologist, comprising combinations of fluorouracil, leucovorin calcium, irinotecan hydrochloride, oxaliplatin, and/or capecitabine (including FOLFOX4, mFOLFOX6, CapeOx, or FOLFIRI), bevacizumab, or cetuximab. Treatment repeats in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may crossover to arm II.
11526673|NCT01167725|Experimental|Arm II|Patients undergo cytoreduction surgery and hyperthermic intraperitoneal mitomycin C over 45-90 minutes. Beginning 8 weeks after surgery, patients receive standard systemic therapy as in arm I. Treatment with systemic therapy repeats for 6 courses in the absence of disease progression or unacceptable toxicity.
11526674|NCT01167712|Experimental|Arm I (adjuvant chemotherapy suboptimally debulked)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.
11526675|NCT01167712|Experimental|Arm II (neoadjuvant chemotherapy)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive surgery between courses 3 and 4.
11526676|NCT01167686|Experimental|Food supplement|Half of the subjects participating in the trial (91) will recieve four tablets of the food supplement (Gardemont Goldrain Plus) three times a day for seven consecutive days from inclusion.
11526677|NCT01167673|Active Comparator|treatment with study drug|patients receiving study drug for 4 weeks. 3 capsules a day of coltect
11526678|NCT01167673|Placebo Comparator|placebo|patients receiving similar capsules but no active ingredients
11526679|NCT01167660||Healthy newborn babies|Healthy newborn babies immediately after birth.
11526680|NCT01167660||Sick newborn babies|Sick newborn babies whose medical condition indicates performing coagulation tests.
11526681|NCT01167647||bronchoscopy patients|
11526682|NCT01167634|No Intervention|1|
11526683|NCT01167634|Experimental|2|Deposit contract with a 1:1 match
11526684|NCT01167634|Experimental|3|Deposit contract with a 2:1 match
11526685|NCT01167634|Experimental|Experimental 4|Deposit contract with no match
11526686|NCT01167608||People with Parkinson's disease|Individuals diagnosed with Parkinson's disease
11526687|NCT01167595|Experimental|PEP uP Protocol|PEP-uP protocol and treatment algorithm implemented for all patients in ICU.
11526688|NCT01167595|No Intervention|Standard Feeding Protocol|Enteral feeds are guided by a standard feeding protocol specified by pre-printed ICU admission orders. The admitting physician has the option of initiating the enteral feeding protocol or keeping the patient nil per os (NPO).
11526689|NCT01167582|Experimental|Liberal Transfusion Strategy|Patients randomly allocated to the liberal transfusion strategy receive one unit of packed red cells following randomization and receive enough blood to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days. Any transfusion following the initial unit of packed red cells must be preceded by blood test documenting a hemoglobin concentration below 10 g/dL.
11526690|NCT01167582|Experimental|Restrictive transfusion strategy|"Receive a transfusion if they develop symptoms related to anemia. Transfusion is also permitted, but not required, in the absence of symptoms only if the hemoglobin concentration falls below 8 g/dL. Blood is administered one unit at a time and the presence of symptoms is reassessed. Only enough blood is given to relieve symptoms. If the transfusion is given because the hemoglobin concentration falls below 8 g/dL, then only enough blood is given to increase the hemoglobin concentration above 8 g/dL.
~Symptoms of anemia that will be indications for transfusion are: 1) Definite angina requiring treatment with sublingual nitroglycerin or equivalent therapy. 2) Unexplained tachycardia or hypotension."
11526691|NCT01167569|Active Comparator|A-Ascorbic Acid (Vitamin C)|Ascorbic Acid (Vitamin C) 10mg/kg x 2 in the operating room followed by Ascorbic Acid (Vitamin C) 5mg/kg every 4 hours x 48 hours.
11526692|NCT01167569|Placebo Comparator|B-5% Dextrose Water or Normal Saline|5% Dextrose Water or Normal Saline (placebo) x 2 in the operating room followed by 5 % Dextrose Water or NS (placebo) every 4 hours X 48 hours.
11526693|NCT01167556|Experimental|Family Motivational Intervention|An intervention provided to parents consisting of 6 sessions of training in Interactions Skills and 6 sessions training in Motivational Interviewing.
11526694|NCT01167556|Active Comparator|Routine care for parents|Routine care for parents consisting of 2 sessions psycho-education and individual support
11526695|NCT01167543||Pediatric patients with symptoms or diagnosis of GER|
11526696|NCT01167543||Control group of pediatric subjects with no symptoms of GER.|
11526697|NCT01167517|Experimental|Instructional digital video disc (DVD)|Breast milk expression instructions provided by digital video disc at the time of hospital discharge.
11526698|NCT01167517|Placebo Comparator|Instructions in print format|Breast milk expression instructions provided in print format at the time of hospital discharge.
11526699|NCT01167504||Saliva Sample Collection|Saliva collection
11526700|NCT01167491|Other|Disease group|Physiopathology
11526701|NCT01167478|Experimental|Caffeine|
11526702|NCT01167452|Experimental|Sulfamethoxazole/trimethoprim|2 DS tablets of sulfamehtoxazole/trimethoprim (1600 mg/320 mg)
11526703|NCT01167439|No Intervention|Mild dysphagia|
11526704|NCT01167439|Active Comparator|Severe dysphagia|
11526705|NCT01167426|Active Comparator|20 mg/0.5 mL Glatiramer Acetate|Participants received once daily subcutaneous administration of 20 mg glatiramer acetate as 20 mg/1.0 mL utilizing autoject 2 for glass syringe for two weeks (Period 1), followed by 20 mg/0.5 mL utilizing the autoject 2 device for four weeks (Period 2).
11526706|NCT01167413||FIbromyalgia Patients|Patients diagnosed as suffering from Fibromyalgia according to the ACR criteria
11526707|NCT01167400|Experimental|Cybercycling|cybercycling for 3 months
11526708|NCT01167400|Active Comparator|Traditional Stationary Biking|Traditional exercise on a stationary bike for 3 months.
11526709|NCT01167387|Experimental|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrine; 240 mOsm/L) in dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
11526710|NCT01167387|Placebo Comparator|water|The control group will receive plain water with the same volume and timing of treatment.
11526711|NCT01167374|Experimental|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
11526712|NCT01167361||Children with upper or lower respiratory infections|Respiratory Virus infections in children who are symptomatic with either an Upper Respiratory Tract Infections and/or Lower Respiratory Tract Infections is determined by using a novel highly sensitive and rapid assay for RV detection. An aliquot from the leftover sample remaining after clinical diagnostic testing will be used for FilmArrayTM analysis. Specimens collected will include nasopharyngeal washes, nasopharyngeal swabs, tracheal aspirates and bronchoalveolar lavage as ordered by the treating physician. Diagnostic studies on this specimen will be performed as ordered and the results will be available to the treating physicians after reporting.
11526713|NCT01167335|Experimental|BGG492|
11526714|NCT01167335|Placebo Comparator|Placebo|
11526715|NCT01167322|Experimental|NPC-07|Single administration of NPC-07 at a dose of 20mg/kg body weight
11526716|NCT01167309|Active Comparator|Part 1 SAD|four diffferent doses
11526717|NCT01167309|Placebo Comparator|Part 2a MAD|three doses
11526718|NCT01167309|Active Comparator|Part 2b|0.24 mg LEO 27847
11526719|NCT01167309|Active Comparator|Part 2c|0.24 mg LEO 27847
11526720|NCT01167309|Placebo Comparator|Parat 2a MAD|one dose
11526721|NCT01167296|Active Comparator|Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.removed uterine stent was sent for bacterial culture too.
11526722|NCT01167296|Experimental|without Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
11526723|NCT01167283|Active Comparator|Electrostimulation|Neuromuscular electrical stimulation
11526724|NCT01167283|Sham Comparator|Sham stimulation|Sham stimulation
11526725|NCT01167270|Active Comparator|Parenting Insight|Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
11526726|NCT01167270|Placebo Comparator|Child Safety Insights|A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the AAP guidelines and the Academy's guide for health supervision, Bright Futures
11526727|NCT01167257|Experimental|Experimental arm|"Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation
~Liposome encapsulated botulinum toxin A'"
11526728|NCT01167257|Placebo Comparator|Control arm|"Normal saline 50 mL in single intravesical instillation
~Normal saline instillation'"
11526729|NCT01167244|Experimental|BMS-690514|
11526730|NCT01167231||Group 1|
11526731|NCT01167218||verify now assay|subjects who have Myelodysplastic syndrome, immune thrombocytopenia, and myeloproliferative disorders with platelet disorders
11526732|NCT01167192|Experimental|Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation|"Cisplatin 75 mg/m^2 IV every 21 days for 4 cycles or Carboplatin AUC 6 IV every 21 days for 4 cycles.
~Radiation beginning cycle 2 day 1 daily for 5-6 weeks 45-50 Gy.
~Recommended mastectomy
~Recommended adjuvant chemotherapy
~-doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 for 14 days for 4 cycles followed by paclitaxel 175 mg/m2 for 14 days for 4 cycles)"
11526733|NCT01167179|No Intervention|comparison group|Usual care Participants in the comparison group receive the usual care which consists of a 5 year medical routine control schedule based on the national guidelines, and - if appropriate - involvement of the dietician and the speech language therapist.During years one to five the routine control appointments are planned at a minimum of every 2, 3, 4, 6 and 12 months respectively. Most patients who undergo a total laryngectomy have additional contact with an oncology nurse during their 6-8 weekly medical control visits at the outpatient clinic for approximately the first year of follow-up. All other head and neck cancer patients have no structured follow-up contact with an oncology nurse.
11526734|NCT01167179|Experimental|nurse-led consultation|"Interventional care Year 1 follow-up: 2-monthly medical control visit + 30 minute nursing consultation, to a minimum of 6 in year 1. No restrictions with regard to cancer stage, site or treatment modality.
~Intervention consist of standardised nursing consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. Goals: helping patients (and their partners) cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship."
11527314|NCT01163032|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
11526735|NCT01167166|Experimental|rigosertib|Patients will receive 2400 mg dose of rigosertib as a intravenous continuous infusion over 24 hours for 72 to 120 consecutive hours every 2 weeks for the first 4 weeks then will receive oral rigosertib at a 560 mg twice-daily dose as capsules taken continuously.
11526736|NCT01167153|Experimental|Valsartan/amlodipine|Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.
11526737|NCT01167153|Active Comparator|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.
11526738|NCT01167140|Experimental|Cryo-Touch II|
11526739|NCT01167127|No Intervention|Tablet|OXN tablet, oral BID, flexible dose design
11526740|NCT01167114|Experimental|STA-9090|All subjects receive STA-9090
11526741|NCT01167101|Other|Pantoprazole|controls Pantoprazole 40mg qd for 28days
11526742|NCT01167101|Active Comparator|Pantoprazole + Rebamipde|Pantoprazole 40mg qd + Rebamipide 100mg Tid for 28days
11526743|NCT01167088|Experimental|Mitoquinone mesylate tablets (MitoQ)|
11526744|NCT01167088|Placebo Comparator|Matching placebo tablet|
11526745|NCT01167075|Active Comparator|Fresubin Original|
11526746|NCT01167075|Experimental|Intestamin plus Fresubin Original|
11526747|NCT01167062|Placebo Comparator|Placebo|
11526748|NCT01167062|Experimental|Tamsulosin Hydrochloride OCAS 0.4 mg|
11526749|NCT01167049|Experimental|CAPECITABINE|"Single arm:
~Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; repeat three cycles (approximately 3- months);"
11526750|NCT01167036|Experimental|FascialEdge tool|A massage tool used to loosen adhesions in the superficial fascia
11526751|NCT01167036|Placebo Comparator|Placebo|Detuned electric point stimulation over the upper trapezius trigger point
11526752|NCT01167023|Experimental|7.5 mg Prasugrel|Participants were to receive 7.5 milligrams (mg) of prasugrel orally, once daily if they weighed ≥60 kilograms (kg) and if pharmacodynamic (PD) measures indicated that the 5-mg prasugrel dose did not produce a steady-state PD response equivalent to inhibition of platelet activation (IPA) ≥25%. Because these criteria were not met, no participants received 7.5 mg of prasugrel.
11526753|NCT01167023|Placebo Comparator|Placebo|
11526754|NCT01167023|Experimental|5 mg Prasugrel|
11526755|NCT01167010|Experimental|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a day for 12 weeks.
11526756|NCT01167010|Active Comparator|Foraseq|Foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
11526757|NCT01167010|Active Comparator|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
11526758|NCT01166997|Experimental|Ultrasound accelerated thrombolysis|Patients in this arm will receive anti-coagulation (intravenous unfractionated heparin) plus the EkoSonic Endovascular System will be used to deliver a low dose <20mg rt-PA (Actilyse) directly into the occlusive pulmonary thrombus.
11526759|NCT01166997|Active Comparator|Intravenous unfractionated heparin|Patients in this arm will receive the standard of care: intravenous unfractionated heparin used as anti-coagulation treatment.
11526760|NCT01166984|Experimental|AB103 Peptide Antagonist|AB103 Peptide Antagonist given intravenously
11526761|NCT01166984|Placebo Comparator|Placebo|Saline
11526762|NCT01166971|Experimental|ReSTOR +3|Bilateral Implantation of ReSTOR +3 Intraocular lenses after cataract extraction
11526763|NCT01166971|Active Comparator|Tecnis MF|Bilateral Implantation of Tecnis Multifocal Intraocular lenses after cataract extraction
11526764|NCT01166958|Active Comparator|Daily teriparatide (Forteo)|
11526765|NCT01166958|Active Comparator|Monthly cycles of teriparatide followed by raloxifene|
11526766|NCT01166945|Placebo Comparator|Short Course|Short course (5 days) of antimicrobial therapy Amoxicillin-Potassium Clavulanate Combination and placebo for next 9 days.
11526767|NCT01166945|Active Comparator|Long Course|Long course (14 days) of antimicrobial therapy Amoxicillin-Potassium Clavulanate Combination given orally for 14 days.
11526768|NCT01166932|Active Comparator|amoxicillin/clavulanic acid|patients who received amoxicillin/clavulanic acid
11526769|NCT01166932|Active Comparator|ceftriaxone/oxacillin|
11526770|NCT01166919|Experimental|Medical Tool|Matrix Radiofrequency Treatment of Port Wine Stain Birthmarks
11526771|NCT01166893||Burn wound|Modulated Imaging and Laser Speckle Imaging
11526772|NCT01166880||Laser Speckle Imaging|Laser Speckle Imaging Infant Head Blood flow
11526773|NCT01166867||Infant Development|Photo-plethysmography monitoring
11526774|NCT01166854||Muscle weakness|Diffuse Optical Spectroscopy
11526775|NCT01166841|Experimental|PSVC line clamped|Clamping of the percutaneously placed superior vena cava line placed for minimally invasive mitral valve repair/replacement.
11526776|NCT01166841|No Intervention|Unclamped PSVC|Unclamped percutaneously placed superior vena cava line placed for minimally invasive mitral valve repair/replacement.
11526777|NCT01166828|Experimental|1|The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
11526778|NCT01166828|Active Comparator|2|TAC participants will have six phone contacts every other week for three months.
11526779|NCT01166815|Active Comparator|Zinc supplemented|"Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. Bulk boxes will identify the products as A and B."
11526780|NCT01166815|Placebo Comparator|Placebo|"Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. Bulk boxes will identify the products as A and B."
11526781|NCT01166789|Active Comparator|Lubiprostone|Lubiprostone 48ug taken daily for 14 days.
11526782|NCT01166789|Placebo Comparator|Placebo|2 capsules containing a substance with no active ingredient taken daily for 14 days.
11526783|NCT01166776||Umbilical cord|To isolate Umbilical cord Wharton's jelly matrix to be used as a scaffold for tissue regenerative applications, including avascular necrosis.
11526784|NCT01166763|Experimental|high dose vitamin D3 (10,000 IU weekly)|Group/Cohort Label vitamin D3
11526785|NCT01166750|Experimental|CD-ROM-treatment|
11526786|NCT01166750|Active Comparator|Wait-list Control Group|
11526787|NCT01166737|No Intervention|Control Arm - Chemotherapy only|Chemotherapy for platinum-sensitive Ovarian Cancer can be selected on investigators choice
11526788|NCT01166737|Experimental|Procedure/Surgery|Maximum effort cytoreductive surgery
11526789|NCT01166724|Active Comparator|Sirolimus|patients will be switched from Tacrolimus to Sirolimus
11526790|NCT01166724|No Intervention|Tacrolimus|Patient will stay on Tacrolimus
11526791|NCT01166711|Experimental|Bare Metal Stent (BMS) followed by Drug Eluting Balloon (DEB)|
11526792|NCT01166711|Active Comparator|Drug Eluting Stent (DES)|
11526793|NCT01166698|Experimental|AZD9819|Inhaled suspension
11526794|NCT01166698|Placebo Comparator|Placebo|Inhaled suspension
11526795|NCT01166685|Active Comparator|Everolimus-eluting stent|A Xience Prime stent (Everolimus-eluting stent) is implanted in significant coronary lesions.
11526796|NCT01166685|Active Comparator|Bare-metal stent|Implantation of a bare-metal stent
11526797|NCT01166685|Experimental|Biodegradable Polymer-DES|Implantation of a Biodegradable Polymer-DES
11526798|NCT01166659|Experimental|CyPass Micro-Stent|Subjects receive the CyPass Micro-Stent
11526799|NCT01166646|Experimental|Halobetasol Proprionate Lotion 0.05%|Subjects randomized to receive lotion
11526800|NCT01166646|Active Comparator|Halobetasol Proprionate Cream 0.05%|Subjects randomized to receive cream
11526801|NCT01166633|Experimental|Pitavastatin 2 mg|
11526802|NCT01166633|Active Comparator|Atorvastatin 10mg|
11526803|NCT01166620||Patients with rheumatoid arthritis new to abatacept.|
11526804|NCT01166620||Patients with rheumatoid arthritis new to etanercept|
11526805|NCT01166620||Patients with rheumatoid arthritis new to adalimumab|
11526806|NCT01166620||Patients with rheumatoid arthritis new to infliximab|
11526807|NCT01166594|Experimental|Bevacizumab|Tested Drug
11526808|NCT01166594|Placebo Comparator|Control|Control - BSS
11526809|NCT01166568|Experimental|Implantation-Non Randomized|Subjects are not participants in the randomized sub-study. PresView Scleral Implants surgical placed in the eye(s) after enrollment and meeting inclusion/exclusion criteria.
11526810|NCT01166568|Experimental|Implantation-Randomized|Subjects are participants in the randomized sub-study. Subjects were randomized to the Immediate Treatment group. PresView Scleral Implants surgical placed in the eye(s)Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria.
11526811|NCT01166568|No Intervention|Deferred Implantation-Randomized|Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria. Subjects were randomized to the Deferred Treatment group are observed for 6 months. Upon completion of the observation follow-up, subjects can opt to have PresView Scleral Implants surgically placed in the eye(s) and become part of the overall study experimental group.
11526812|NCT01166555|Experimental|1|
11526813|NCT01166542|Active Comparator|REOLYSIN, paclitaxel, carboplatin|
11526814|NCT01166542|Placebo Comparator|placebo, paclitaxel, carboplatin|
11526815|NCT01166529|Experimental|EUS-CPN|
11526816|NCT01166516|Other|Treatment with HUD IBV Valve System|Treatment with HUD IBV Valve System in Post-Approval Study
11526817|NCT01166503||Early Surgery|This group will be made up of subjects whose parents choose to have them undergo corrective surgery at or before age 11 months.
11526818|NCT01166503||Standard Surgery|This group will be made up of subjects who present after age 11 months or whose parents choose to have them undergo corrective surgery between 11-18 months.
11526819|NCT01166490|Experimental|1|ASG-5ME
11526820|NCT01166477|Active Comparator|Triple therapy|The patients who would be allocated to this arm will continue with their triple therapy treatment, based on any protease inhibitor boosted with ritonavir
11526821|NCT01166477|Experimental|Monotherapy|Those patients allocated to this arm will start to take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
11526822|NCT01166464|Experimental|Text Messaging|A text message-based intervention for smoking cessation
11526823|NCT01166464|Placebo Comparator|Control|Individuals in this group will receive generic (non-smoking related) text messages on the same schedule as the intervention arm. This provides a control for staff/program contact time and participant burden.
11526824|NCT01166451|Experimental|Low-iron|Infants randomly assigned at 6 months of age to receive low-iron formula (average 2.3 mg/L, range 1.6 - 2.4 mg/L) until 12 months of age.
11526825|NCT01166451|Experimental|High-iron|Infants randomly assigned at 6 months of age to receive high-iron formula (average 12.7 mg/L) until 12 months of age.
11526826|NCT01166438|Experimental|Botox A|A single intradetrusor injection of 100U botulinum toxin A (Botox A®) plus daily oral placebo tablets
11526827|NCT01166438|Active Comparator|Standardized Anticholinergic Regimen|A standardized 3-step anticholinergic regimen of daily oral solifenacin 5mg, solifenacin 10mg, and/or trospium chloride XR 60mg, as well as a single intradetrusor injection of saline (placebo). All subjects will begin on solifenacin 5 mg for 2 mo. If a subject's symptoms are not adequately controlled at 2 mo, she will be escalated to solifenacin 10mg, and similarly at 4 mo to trospium XR 60mg. If a subject's symptoms are adequately controlled on solifenacin 5 mg, she may continue that study medication for the entirety of the study (6 mo). Additionally, if a subject is dose-escalated to solifenacin 10mg at study mo 2 or 4, and her symptoms are adequately controlled, she may continue the solifenacin 10mg dose for the remainder of the study.
11526828|NCT01166425|Active Comparator|Lithium Carbonate|Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID (three times a day) at visit 1 (total dose 900 mg). Participants weighing < 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID (two times a day) the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose.
11526829|NCT01166425|Placebo Comparator|placebo|Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
11526830|NCT01166412|Active Comparator|Dose level AG1000-6.5|
11526831|NCT01166412|Active Comparator|Dose level AG1000-12.5|
11526874|NCT01166087|Experimental|Fluoxetine Hydrochloride|Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited
11526832|NCT01166399||Primiparous women with an obstetric anal sphincter tear|Subjects in this trial will be primiparous women who underwent anal sphincter repair at the time of a singleton vaginal delivery. Sphincter tears will be clinically characterized at the time of delivery as <50% tear through the anal sphincter (modified WHO 3a), >50% (modified WHO 3b), or complete tear through the anal sphincter (4th degree). Subjects in this study will not have receive study interventions.
11526833|NCT01166386|Experimental|1|Treatment intervention using a 10-session behavioral program
11526834|NCT01166386|Placebo Comparator|2|Patients will spend time with a therapist viewing video discs and standard rehabilitation care
11526835|NCT01166373|Experimental|Enrollment video arm|Arm of subjects that will be shown a standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process.
11526836|NCT01166373|No Intervention|No video intervention arm|This group of subjects will not view a standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process.
11526837|NCT01166373|Experimental|ULS|Uterosacral Ligament Suspension was one of the randomized surgical treatments in the OPTIMAL study
11526838|NCT01166373|Experimental|SSLF|Sacrospinous Ligament Fixation was one of the randomized surgical treatments in the OPTIMAL study.
11526839|NCT01166373|Experimental|PMT|Perioperative Behavioral Therapy/Pelvic Muscle Training was one of the randomized non-surgical (behavioral) interventions in the OPTIMAL study.
11526840|NCT01166373|Other|Usual Care|No Perioperative Behavioral Therapy/Pelvic Muscle Training (i.e., usual care) was one of the randomized non-surgical (behavioral) interventions in the OPTIMAL study.
11526841|NCT01166360||Patients 2009|Patients undergoing cardiac surgery in 2009
11526842|NCT01166360||Patients 2008|Patients undergoing cardiac surgery in 2008
11526843|NCT01166347|Experimental|HeartWare® VAS|Implant of HeartWare® Ventricular Assist System
11526844|NCT01166347|Active Comparator|Control LVAD|Implant of FDA-approved LVADs approved for destination therapy
11526845|NCT01166334|Active Comparator|WebQuit study group|Intervention arm 1 (identity and description withheld to protect integrity of study)
11526846|NCT01166334|Active Comparator|WebQuit control group|Intervention arm 2 (identity and description withheld to protect integrity of study)
11526847|NCT01166321|Experimental|Carbon Ion Radiotherapy Boost|Carbon Ion Boost to the Macroscopic Tumor visible on contrast-enhanced MR-Imaging
11526848|NCT01166308|Experimental|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I Part of the Trial
11526849|NCT01166308|Active Comparator|Standard Treatment: Fractionated Stereotacitc Radiotherapy|Standard Precision Radiotherapy performed as Fractionated Stereotactic Radiotherapy (FSRT) up to 36 Gy in single dosis of 2 Gy
11526850|NCT01166282|Placebo Comparator|Double-blind Placebo EOW|Placebo for adalimumab every other week (eow) for 12 weeks.
11526851|NCT01166282|Experimental|Double-blind Adalimumab EOW|Adalimumab (body surface area dosing 24 mg/m^2 up to a maximum of 40 mg) every other week (eow) for 12 weeks.
11526852|NCT01166282|Experimental|Open-label Adalimumab EOW|Adalimumab (body surface area dosing 24 mg/m^2 up to a maximum of 40 mg) every other week (eow) for up to 192 weeks.
11526853|NCT01166269|Experimental|Grass-Allergen x 6|This arm will receive 6 injections of allergen.
11526854|NCT01166269|Active Comparator|grass-allergen x 3 and placebo x 3|this arm will receive 3 injections of allergen, and 3 injections of placebo.
11526855|NCT01166269|Placebo Comparator|placebo x 6|this arm will receive 6 injections of placebo.
11526856|NCT01166256|Experimental|High-flow nasal cannula|In this arm,patients with acute hypoxemic respiratory failure were treated with high-flow nasal cannula system(Optiflow, Fisher & Paykel, Auckland, New Zealand) to achieve SpO2 >92% or PaO2 >65 mmHg.
11526857|NCT01166256|Active Comparator|Non-invasive ventilation|In this arm, patients with acute hypoxemic respiratory failure is treated with the bi-level positive airways pressure mode (BiPAP Vision, Respironics Inc., Murrysville, PA) S/T mode to achieve SpO2 >92% or PaO2 >65 mmHg.
11526858|NCT01166243|Experimental|Fibrin Pad|Biologic
11526859|NCT01166243|Other|Standard of Care|Procedure
11526860|NCT01166230||Patients with Ta/T1, randomized to white light cystoscopy|Patients with non-invasive papillary bladder cancer (Ta/T1), enrolled in the previously completed pivotal phase III study PC B305/04 who were followed for recurrence.
11526861|NCT01166230||Patients with Ta/T1 randomized to Hexvix cystoscopy|Patients with non-invasive papillary bladder cancer (Ta/T1), enrolled in the previously completed pivotal phase III study PC B305/04 who were followed for recurrence.
11526862|NCT01166217|Experimental|ABCE, ACBD, BACD, BCAE, CABE and CBAD|
11526863|NCT01166204|Experimental|Single group|
11526864|NCT01166191|Experimental|SCLC|
11526865|NCT01166178|Experimental|Zoledronic Acid|Participants received zoledronic acid infusion in addition to calcium and vitamin D
11526866|NCT01166178|Placebo Comparator|Placebo|Participants received placebo to zoledronic acid infusion in addition to calcium and vitamin D
11526867|NCT01166165|Active Comparator|Cholecalciferol|
11526868|NCT01166165|Placebo Comparator|Placebo|
11526869|NCT01166139|Experimental|Nilotinib 400 mg twice daily|
11526870|NCT01166126|Experimental|Treatment (temsirolimus and selumetinib)|"Treatment Phase: This period begins with the first intravenous (through the vein) infusion of TEMSIROLIMUS and the first AZD6244 administration by mouth (visit 2, Week 1) and will continue until Week 8 (Visit 4).
~As many as 38 patients will receive the same dosage of TEMSIROLIMUS injected in the veins once a week for 8 weeks, and the AZD6244 will be given as capsules by mouth twice a day for 8 weeks. That is one cycle. The TEMSIROLIMUS and AZD6244 will be given to participants as an outpatient, unless admission to the hospital was needed for treatment of related side effects or underlying disease. The subsequent cycles of TEMSIROLIMUS and AZD6244 will be given every 8 weeks. The TEMSIROLIMUS will be injected in a vein over 30 minutes.
~The continuation phase begins with visits at weeks 12 in patients who receive at least two cycles of treatments."
11526871|NCT01166113|Experimental|PCP|
11526872|NCT01166100|Experimental|Fluoxetine Hydrochloride|Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited
11526873|NCT01166100|Active Comparator|Prozac ® weekly TM|Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company
11527002|NCT01165242|Active Comparator|Group C|Subjects were vaccinated with Menactra®
11526875|NCT01166087|Active Comparator|Prozac ® weekly|Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company
11526876|NCT01166074||SCIG|
11526877|NCT01166061|Experimental|Cohort 1|Subjects to receive either active or placebo
11526878|NCT01166061|Experimental|Cohort 2|Subjects to receive either active or placebo comparator
11526879|NCT01166061|Experimental|Cohort 3|Subjects to receive either active or placebo comparator
11526880|NCT01166061|Experimental|Cohort 4|Subjects to receive either active or placebo comparator
11526881|NCT01166061|Experimental|Cohort 5|Subjects to receive either active or placebo comparator
11526882|NCT01166048|Placebo Comparator|Milk powder pill|Patients will receive 2 placebo pills per day for a period of 4 weeks.
11526883|NCT01166048|Experimental|Duloxetine|In the experimental arm of the study patients will receive duloxetine, which will be titrated up to a dosage of 120mg over a period of two weeks and continued at this dosage for two weeks.
11526884|NCT01166022|Experimental|Exercise|Muscle strengthening program using weights and resistance bands in combination with a home based cycle ergometry program. The home-based exercise program will be performed up to 5 times weekly.
11526885|NCT01166022|No Intervention|Typical Activity|Subjects in this group will be asked to maintain their typical daily activity. Those assigned to this arm will be given the opportunity to join the intervention arm seven months after their screening visit.
11526886|NCT01165996|Experimental|Arm I: decitabine|INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts &lt; 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
11526887|NCT01165983|Placebo Comparator|Placebo|
11526888|NCT01165983|Experimental|Aliskiren|
11526889|NCT01165970|Active Comparator|Glandosane|After in situ exposition the enamel and dentin samples will demineralize with Glandosane.
11526890|NCT01165970|Experimental|Saliva natura|After in situ exposition the enamel and dentin samples will remineralize with Saliva natura
11526891|NCT01165957||Mobile bearings|Tibial polyethylene inserts retrieved from total knee replacements where the insert is designed to slide or rotate on the metal baseplate.
11526892|NCT01165957||Fixed bearings|Tibial polyethylene inserts retrieved from total knee replacements where the insert is locked to the metal baseplate.
11526893|NCT01165944|No Intervention|Standard diabetes therapy|Standard diabetes therapy with either oral agents or insulin injections
11526894|NCT01165944|Active Comparator|Oral diabetic agents and pramlintide|
11526895|NCT01165944|Active Comparator|Insulin injection with pramlintide|
11526896|NCT01165931|Experimental|Arm 1|
11526897|NCT01165918||Donated embryos|
11526898|NCT01165866|Active Comparator|Treatment 1.|Metoclopramide 0.3 mg/kg max 10 mg in burette and mixed with normal saline to make up 50 cc of medication and normal saline as a single intravenous dose. Complete blood count,serum electrolytes,renal function,HCO3 level will be requested.Oral fluid will be started thereafter and increased gradually until patient discharge.
11526899|NCT01165866|Other|Treatment2.|Ondansetron 0.15 mg/kg max 4 mg in burette and mixed with normal saline to make up 50 cc of medication and normal saline to be given over 10 minutes,then patient will be kept NPO for one hour after completion of the anti emetic infusion and last episode of vomiting . Oral fluid will be started thereafter and increased gradually until fully tolerated and the patient is ready for discharge
11526900|NCT01165853|Other|Glucose|
11526901|NCT01165853|Other|Fructose|
11526902|NCT01165840|Experimental|Dapsone|Dapsone 100 mg PO x 1 dose
11526903|NCT01165827||Patients with aortic valve procedures|"All consecutive patients from participating hospitals with aortic valve defects who have received one of the following therapies:
~surgical aortic valve replacement,
~percutaneous transvascular (retrograde) aortic valve implantation
~percutaneous transapical aortic valve implantation as principal indication. If the aortic valve insufficiency is concurrent with combination procedures (e.g. coronary artery bypass graft, mitral valve surgery) the aortic valve stenosis must fulfil only the criteria for indication according to the German National guidelines (see: detailed study description)."
11526904|NCT01165814|Active Comparator|Tramadol at fixed intervals|
11526905|NCT01165814|Active Comparator|Tramadol on request|
11526906|NCT01165814|Active Comparator|Naproxen at fixed intervals|
11526907|NCT01165814|Active Comparator|Naproxen on request|
11526908|NCT01165801|No Intervention|Control Group (CO)|Fifty-four patients with cataract and non-exudative age-related macular degeneration (AMD) were randomized into an early surgery group (ES=28) with immediate cataract surgery and a control group (CO=26) where surgery was performed after six months.
11526909|NCT01165788||autologous BMT recipients|Lymphoma patients who received an autologous BMT as adults
11526910|NCT01165775||Threatened pre term labor patients|Patients receiving betamethasone to minimize the complications of prematurity will monitor blood glucose levels using the Dexcom Seven Plus Continuous Glucose Monitoring System.
11526911|NCT01165762|Experimental|Immune Tolerance, Kidney transplantation|Induction of immune tolerance in Haplotype matched living donor kidney transplantation.
11526912|NCT01165736|Active Comparator|Intravenous: PF-05186462|
11526913|NCT01165736|Active Comparator|Oral: PF-05186462|
11526914|NCT01165736|Active Comparator|Intravenous: PF-05089771|
11526915|NCT01165736|Active Comparator|Oral: PF-05089771|
11526916|NCT01165736|Active Comparator|Intravenous: PF-05150122|
11526917|NCT01165736|Active Comparator|Oral: PF-05150122|
11526918|NCT01165736|Active Comparator|Intravenous: PF-05241328|
11526919|NCT01165736|Active Comparator|Oral: PF-05241328|
11526920|NCT01165723|Experimental|IV Dose 1: experimental|
11526921|NCT01165723|Experimental|IV Dose 2: experimental|
11526922|NCT01165710||001|Patients with Atrial Fibrillation (AF) Treatment patterns of AF according to patient demographics clinical factors risk stratification and geographic regions.
11526923|NCT01165697||Fabry disease biomarker|Neuro-retinal fluorescein angiography (NRFA) exam will be administered once every 6 months for up to 3 years.
11526924|NCT01165684|Experimental|Step-wise|
11526925|NCT01165684|Active Comparator|Basal-bolus|
11526926|NCT01165671|Experimental|Experimental Arm|Carbon Ion Radiotherapy to the Macroscopic Tumor 6 x 3 Gy E up to 18 Gy E
11526927|NCT01165671|Active Comparator|Standard Arm|Proton Radiotherapy to the Macroscopic Tumor 5 x 2 Gy E up to 10 Gy E (Standard dose) applied after 48-52 Gy photon radiotherapy
11526928|NCT01165658|Experimental|Proton Therapy|The radiation prescription dose ranges from 45 Gy in 3 Gy fractions to 60 Gy in 4 Gy fractions. Patients will be assigned to receive 1 of 3 doses of radiation therapy, based on when they joined the study. The first group of at least 3 participants will receive the lowest total radiation dose. If the first dose is tolerated well by the first group of participants in this study, then the next group of participants will receive the second, higher dose of radiation. If this dose is tolerated, then a third group will be treated at the highest dose.
11526929|NCT01165645|Experimental|Arm I|Patients receive oral lopinavir and ritonavir twice daily for 28 days in the absence of disease progression or unacceptable toxicity.
11526930|NCT01165645|No Intervention|Arm II|Patients receive no therapy.
11526931|NCT01165632|Experimental|Arm I|Beginning at no more than 1 week before biopsy or resection, patients undergo fluorine F 18 fluorodopa-labeled PET/CT scan and pre-operative MRI. Patients then undergo stereotactic craniotomy. Some patients may also undergo radiation therapy.
11526932|NCT01165619||Hypothalamic Amenorrhea|This group is for pre-menopausal women between the aged 18-40 who have been previously diagnosed with Hypothalamic Amenorrhea. They can be currently diagnosed or may have recovered.
11526933|NCT01165619||Healthy Adult Men|This group is men over the age of 18 who do not have any history of reproductive disorders or chronic disease.
11526934|NCT01165619||Healthy Adult Women|This group is pre-menopausal, regularly menstruating women ages 18-40 who do not have a history of reproductive disorders or chronic disease.
11526935|NCT01165619||Idiopathic Hypogonadotropic Hypogonadism|This group is for adult men and women over the age of 18 who have been diagnosed with Idiopathic Hypogonadotropic Hypogonadism with or without anosmia.
11526936|NCT01165606|Experimental|Physiotherpy|
11526937|NCT01165593||Patients with atrial fibrillation|Patients with atrial fibrillation who have received a cardiac CT scan as part of normal care prior to catheter-based treatment of atrial fibrillation.
11526938|NCT01165580|Experimental|Single Arm|
11526939|NCT01165567|Experimental|sarpogrelate 300 mg per day|Patients in the sarpogrelate group receive sarpogrelate 300 mg per day for 24 hours before exposure to contrast agent.
11526940|NCT01165567|No Intervention|No sarpogrelate medication|
11526941|NCT01165554|Experimental|[18F] Flutemetamol|
11526942|NCT01165541|Active Comparator|Quetiapine fumarate extended release (Quetiapine XR)|Quetiapine XR 50-400mg
11526943|NCT01165541|Experimental|Quetiapine XR and Mirtazapine|Quetiapine XR 50-400mg + Mirtazapine 7.5-45mg
11526944|NCT01165528|Active Comparator|Adaptive support ventilation in ARDS|patients of ARDS will be randomized to this arm to receive mechanical ventilation as per ASV protocol
11526945|NCT01165528|Active Comparator|conventional ventilation strategy in ARDS|
11526946|NCT01165515||Healthy young females|20 healthy females, aged between 18 and 35 years
11526947|NCT01165515||Healthy young males|20 healthy males, aged between 18 and 35 years
11526948|NCT01165515||Healthy elderly smokers|20 healthy smokers, aged between 45 and 75 years
11526949|NCT01165515||Healthy elderly non-smokers|20 healthy non-smokers, aged between 45 and 75 years
11526950|NCT01165515||Healthy young female smokers|20 healthy female smokers, aged between 18 and 35 years
11526951|NCT01165515||Healthy young male smokers|20 healthy male smokers, aged between 18 and 35 years
11526952|NCT01165515||Healthy postmenopausal women|20 healthy postmenopausal women
11526953|NCT01165515||Female CMP Patients|20 female patients suffering from cardiomyopathy (ischemic or dilating)
11526954|NCT01165515||Male CMP Patients|20 male patients suffering from cardiomyopathy (ischemic or dilating)
11526955|NCT01165515||Female CHD patients|30 female patients suffering from cardiac heart disease, before aorto-coronary bypass surgery (and after)
11526956|NCT01165515||Male CHD Patients|30 male patients suffering from cardiac heart disease, before aorto-coronary bypass surgery (and after)
11526957|NCT01165515||male athlets|20 male athlets
11526958|NCT01165515||female athlets|20 female athlets
11526959|NCT01165502|Experimental|CM3.1-AC100|Compound CM3.1-AC100 s.c.
11526960|NCT01165502|Placebo Comparator|Placebo|Placebo for compound CM3.1-AC100 s.c.
11526961|NCT01165489||Laryngomalacia|Patients with Laryngomalacia
11526962|NCT01165489||Control Group|Patients without Laryngomalacia
11526963|NCT01165476|Active Comparator|manufacturer #1|treprostinil diethanolamine from manufacturer #1
11526964|NCT01165476|Experimental|manufacturer #2|treprostinil diethanolamine from manufacturer #2
11526965|NCT01165463|Experimental|Clinic-based SOPT basic training|Clinic-based SOPT basic training for 10 hours.
11526966|NCT01165463|Experimental|Home-based SOPT basic training|Home-based SOPT basic training for 10 hours.
11526967|NCT01165463|Active Comparator|Crossword Puzzles Training|Crossword puzzles training for 10 hours in our lab.
11526968|NCT01165463|Experimental|SOPT basic and SOPT booster-training|Clinic-based SOPT basic training and SOPT booster training.
11526969|NCT01165450|Active Comparator|Nexagon|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
11526970|NCT01165450|Placebo Comparator|Vehicle only|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
11526971|NCT01165437||Suspected Arterial Disease|Patients with known or suspected arterial disease and patients screened using AHA/ACC criteria for P.A.D.
11526972|NCT01165424|Experimental|MFNS 50 μg device|"MFNS 50 μg spray device. The dose will be as follows:
~3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.
~12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning."
11526973|NCT01165411||Patients with CVCs and PICC lines placed|This group will have either Standard of Care (control) or Process Improvement infection control changes administered.
11526974|NCT01165398||Residents, PAs, mid level providers|Lehigh Valley Health Network residents, physician assistants, and mid level providers who place central lines and attend the central lines simulation course
11526975|NCT01165385|Experimental|Pazopanib and Cisplatin|"Steady state period:Pazopanib will be given 8 days prior to cisplatin
~Then pazopanib will be given 400 mg, 600 mg or 800 mg/day, daily and cisplatin 60, 75 or 100 mg/m2 , day 1 - 3 weekly, depending of the dose level"
11526976|NCT01165372|Experimental|Artesunate 2mg|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with artesunate 2mg/kg/day for 3 days and followed by DHA-PPQ treatment at doses according to National guidelines for 3 days.
11526977|NCT01165372|Experimental|Artesunate 4mg|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with artesunate 4mg/kg/day for 3 days and followed by DHA-PPQ treatment at doses according to National guidelines for 3 days.
11526978|NCT01165372|Experimental|DHA-piperaquine|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with dihydroartemisinin-piperaquine once daily according to weight for 3 days.
11526979|NCT01165359|Experimental|Part A: ITX 5061|Participants will receive ITX 5061 once a day for 3 days.
11526980|NCT01165359|Placebo Comparator|Part A: Placebo|Participants will receive placebo once a day for 3 days.
11526981|NCT01165359|Experimental|Part B: ITX 5061|Participants will receive ITX 5061 once a day for 14 days.
11526982|NCT01165359|Placebo Comparator|Part B: Placebo|Participants will receive placebo once a day for 14 days.
11526983|NCT01165359|Experimental|Part C: ITX 5061|Participants will receive ITX 5061 once a day for 28 days.
11526984|NCT01165359|Placebo Comparator|Part C: Placebo|Participants will receive placebo once a day for 28 days.
11526985|NCT01165346|Experimental|Stereotaxic radiation by CyberKnife|Implantation of fiducials Stereotaxic radiation by CyberKnife : 3 X 15 Gy over 8 to 10 days
11526986|NCT01165333|Experimental|Dose escalation|In the first part of the trial, a dose-ranging study in ca. 18-21 patients will be done. A standard dose escalation strategy will be used including 3 to 6 patients at each dose level, the first cohort of patients being treated at dose level one Interventions : Cilengitide dose escalation ; Concomitant radiotherapy ; Pharmacokinetic ; Pharmacogenetic
11526987|NCT01165333|Experimental|Cohort extension|An additional 20 patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations Interventions : Cilengitide ; Concomitant radiotherapy ; Pharmacokinetic ; Pharmacogenetic
11526988|NCT01165320|Experimental|Participants with Esophageal Candidiasis|Candida infection is strongly suspected based on clinical symptoms and the participant's clinical course, white moss (plaque) is observed on the esophageal mucosa, and therapy via intravenous infusion is judged to be suitable for the present episode of esophageal candidiasis. MK-0991 therapy as a single loading dose of 70 mg/m^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 7 and 28 days, respectively.
11526989|NCT01165320|Experimental|Participants with Invasive Candidiasis|Candida infection is strongly suspected based on the presence of refractory fever not responding to an antibiotic agent, or clinical symptoms at the site of disease, or the participant's clinical course. In addition, at least 1 of the following criteria must be met: 1) Candida infection is strongly suspected based on radiographic imaging findings and positive serological test for fungus, 2) yeast is observed by direct microscopy or histopathological test of tissue biopsied from the site of disease, or 3) Candida species are observed by culture test of specimens sampled from the site of disease. MK-0991 therapy as a single loading dose of 70 mg/m^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 14 and 56 days, respectively.
11526990|NCT01165320|Experimental|Participants with Aspergillosis|Aspergillus infection is strongly suspected based on clinical symptoms and the participant's clinical course, and characteristic radiographic imaging findings are observed. In addition, at least 1 of the following criteria must be met: 1) risk factors predisposing to an Aspergillus infection, 2) positive serological test for Aspergillus, 3) acute-branching mold with separated hyphae are observed by direct microscopy or histopathological test, or 4) Aspergillus species are observed by culture test. MK-0991 therapy as a single loading dose of 70 mg/m^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 14 and 84 days, respectively.
11526991|NCT01165307|Active Comparator|Medical Therapy|Subjects will be prescribed monthly packets of Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills. Subjects who are unable to tolerate oral contraceptive pills or are unwilling to take oral contraceptive pills will be prescribed naproxen sodium pills. The latter will be administered as follows; 500mg with onset of menses, then 250mg three times daily for the duration of the menses (or maximum of five days).
11526992|NCT01165307|Active Comparator|Radiofrequency Endometrial Ablation|Subjects will undergo NovaSure® radiofrequency endometrial ablation within 4 weeks of randomization. The procedure will occur at any time during the menstrual cycle, without endometrial pre-treatment. Endometrial thinning will be carried out using suction curettage in 50% of the cases included in the ablation group. Random assignment for this treatment will be included in the overall randomization plan.
11526993|NCT01165294|Experimental|001|ketamine An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
11526994|NCT01165294|Experimental|002|Placebo An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
11526995|NCT01165281|Experimental|001|R331333 (referred to as JNS024 ER or CG5503) One 25 mg to 200 mg capsule twice daily for 4 weeks.
11526996|NCT01165281|Active Comparator|002|Oxycodone CR One 5 mg to 40 mg capsule twice daily for 4 weeks.
11526997|NCT01165268|Active Comparator|Dapagliflozin (T2DM)|
11526998|NCT01165268|Active Comparator|Dapagliflozin (Healthy Subjects)|
11526999|NCT01165255||Infants born to women who were exposed to antidepressants|Women ages 12 through 49 (as of delivery date) who were dispensed an antidepressant between 01 January 1995 and 30 September 2004 from the original Bupropion study.
11527000|NCT01165242|Experimental|Group A|Subjects were vaccinated with vaccine GSK134612 Lot A
11527001|NCT01165242|Experimental|Group B|Subjects were vaccinated with vaccine GSK134612 Lot B
11527003|NCT01165229|Experimental|Zoster vaccine group|Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
11527004|NCT01165229|Placebo Comparator|Placebo group|Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
11527005|NCT01165216|Experimental|Dose Level 1: Ipilimumab, 3 mg/kg + Paclitaxel + Carboplatin|Participants received ipilimumab, 3 mg/kg, administered as a single dose intravenously (IV) over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, area under the curve (AUC)=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
11527006|NCT01165216|Experimental|Dose Level 2: Ipilimumab, 10 mg/kg + Paclitaxel + Carboplatin|Participants received ipilimumab, 10 mg/kg, administered as a single dose IV over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, AUC=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
11527007|NCT01165203|Experimental|GSK1437173A Group|Subjects who received three doses of GSK1437173A vaccine (Months 0, 2 and 6), administered intramuscularly, in the deltoid muscle of the non-dominant arm.
11527008|NCT01165203|Placebo Comparator|Placebo Group|Subjects who received three doses of placebo (Months 0, 2 and 6), administered intramuscularly, in the deltoid muscle of the non-dominant arm.
11527009|NCT01165190||Pioglitazone group|
11527010|NCT01165177|Experimental|GSK1437173A group|Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
11527011|NCT01165177|Placebo Comparator|Placebo group|Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
11527012|NCT01165164|Experimental|FID 115958D|Lubricant eye drop
11527013|NCT01165151|Experimental|Small group|10-member groups
11527014|NCT01165151|Active Comparator|Large group|30-member groups
11527015|NCT01165138|Experimental|Fluticasone furoate/Vilanterol (GW642444)|Fluticasone furoate/Vilanterol inhalation powder once daily for 12 weeks
11527016|NCT01165138|Experimental|Fluticasone Furoate|Fluticasone furoate inhalation powder once daily for 12 weeks
11527017|NCT01165138|Placebo Comparator|Placebo|Placebo inhalation powder once daily for 12 weeks
11527018|NCT01165125|Other|FF/GW642444 and keto|Ketoconazole (400mcg) administered on Days 1-11, with co-administration of fFF / GW642444 (200mcg/25mcg) on Days 5-11
11527019|NCT01165125|Other|Ketoconazole Placebo to match & FF/GW642444|ketoconazole placebo to match administered on days 1-11. FF/GW642444 (200mcg/25mcg) co-administered on Days 5-11
11527020|NCT01165112|Experimental|Treatment (chemotherapy and monoclonal antibody therapy)|Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60 minutes on days 1-3, and carboplatin IV over 60 minutes on day 1. Patients with CD20+ T-cell lymphoma disease also receive rituximab IV on day 2 or 3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
11527021|NCT01165099|Experimental|manual acupuncture|Sterile needles were inserted intramuscularly to a depth of 15-20mm until an unusual (De-Qi) sensation developed and remained inserted for 30-60 minutes and were manually manipulated during this time. The following bilateral acupoints on the hands and feet at Hegu (LI 4), Sanyinjiao (Sp 6) Kunlun (BL 60) and Zhiyin (BL 67)were used.
11527022|NCT01165099|Experimental|electro acupuncture|Sterile needles were inserted intramuscularly to a depth of 15-20mm until an unusual (De-Qi) sensation developed and remained inserted for 30-60 minutes and were either electronically simulated withm2 Hz pulses of 0.5 msec duration for 30 minutes sufficient to cause non-painful muscle contractions. The following bilateral acupoints on the hands and feet at Hegu (LI 4), Sanyinjiao (Sp 6) Kunlun (BL 60) and Zhiyin (BL 67)were used.
11527023|NCT01165099|Sham Comparator|Sham manual or electro acupuncture|Sterile needles were inserted adjacent to the specific acupuncture sites identified for the manual and electro groups to a depth of 1-1.5mm only and insufficient to provoke an unusual sensation and left in position for a 30-60 minutes. Those randomised to 'sham-manual' received no stimulation and those randomised to 'sham-electro' were connected to the electrical stimulator but the current not activated.
11527024|NCT01165099|No Intervention|control group|Following randomisation to be control group, no specific treatment was organised at this time.
11527025|NCT01165073|Experimental|Naso-gastric tube feeding|
11527026|NCT01165073|Active Comparator|Oral feeding|
11527027|NCT01165060|Experimental|Bezafibrate|All patients in the trial will use bezafibrate 400 mg once daily until week 12, and subsequently use 800 mg onde daily until week 24.
11527028|NCT01165047|Experimental|Nitric Oxide|80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM
11527029|NCT01165034|No Intervention|Usual care|Best usual practice including general respiratory specialist and primary care
11527030|NCT01165034|Experimental|Breathlessness Support Service|Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
11527031|NCT01165021|Experimental|Pemetrexed + Cisplatin|
11527032|NCT01164995|Experimental|MK-1775 and carboplatin|MK-1775: oral capsules. Carboplatin: intravenous infusion in 30 minutes
11527033|NCT01164969||H. pylori eradication failure|People who are not able to eradicate H. pylori although the appropriate antibiotic therapy taken.
11527034|NCT01164956|Experimental|M-P, P-M, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
11527405|NCT01162460|Active Comparator|Carbamazepine controlled release|
11527035|NCT01164956|Experimental|P-M, P-M, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
11527036|NCT01164956|Experimental|P-M, M-P, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
11527037|NCT01164956|Experimental|M-P, M-P, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
11527038|NCT01164956|Experimental|M-P, P-M, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
11527039|NCT01164956|Experimental|M-P, M-P, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
11527040|NCT01164956|Experimental|P-M, P-M, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
11527041|NCT01164956|Experimental|P-M, M-P, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
11527042|NCT01164943|Active Comparator|Human FSH|
11527043|NCT01164943|Active Comparator|Recombinant FSH|
11527044|NCT01164930|Experimental|Acceptance and Commitment Therapy group|8-week ACT group
11527045|NCT01164930|No Intervention|Wait-list control group|Participants will be offered treatment following wait-list data collection
11527046|NCT01164917|Active Comparator|AMG811|All will receive AMG 811, either on Day 1 or Day 85
11527047|NCT01164917|Placebo Comparator|AMG811 Placebo|All will receive placebo, either on Day 1 or Day 85
11527048|NCT01164904|Experimental|Experimental|Ten escalating dose levels of AMG 181 administered as a single dose SC or IV in healthy volunteers and SC in subjects with mild-to-moderate ulcerative colitis.
11527049|NCT01164891|Experimental|Single Arm|
11527050|NCT01164878||Before|ELBW infants before change of feeding policy
11527051|NCT01164878||After|ELBW infants after change of feeding policy
11527052|NCT01164865|Experimental|OPTI-FREE RepleniSH|OPTI-FREE RepleniSH multipurpose disinfecting solution used with study contact lenses on a daily basis for 2 weeks.
11527053|NCT01164865|Active Comparator|Clear Care|Clear Care contact lens care system used with study contact lenses on a daily basis for 2 weeks.
11527054|NCT01164852|No Intervention|Expectant management|Expectant management: refers to pregnancy prolongation during which time women and fetuses are carefully monitored for indications for delivery.
11527055|NCT01164852|Active Comparator|Interventionist management|Interventionist management: in which blood pressure is stabilized, corticosteroids are given for acceleration of fetal maturity and delivery is planned within 48-72 hours.
11527056|NCT01164826|Experimental|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
11527057|NCT01164826|Active Comparator|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
11527058|NCT01164813|Experimental|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
11527059|NCT01164813|Active Comparator|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
11527060|NCT01164800|Experimental|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
11527061|NCT01164800|Active Comparator|Mavik®|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
11527062|NCT01164787|Experimental|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
11527063|NCT01164787|Active Comparator|Mavik®|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
11527064|NCT01164774|Experimental|Ramipril|Ramipril 10 mg capsules of Dr. Reddy's Laboratories Limited
11527065|NCT01164774|Active Comparator|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
11527066|NCT01164761|Experimental|Ramipril|Ramipril 10 mg capsules of Dr. Reddy's Laboratories Limited
11527067|NCT01164761|Active Comparator|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
11527068|NCT01164748||Sentinel Node Biopsy|All women who has Sentinel Node Biopsy as their primary treatment of the axilla
11527069|NCT01164748||Axillary Lymph Node Dissection|All women who had Axillary Lymph Node Dissection as primary axillary treatment
11527070|NCT01164735||Correlative studies|Archived tumor tissue samples are analyzed for topoisomerase 2-alpha gene alteration and expression and chromosome 17 polysomy by FISH and IHC. Clinical information associated with each endometrial carcinoma sample (e.g., age, race/ethnicity, cell type, histologic grade, disease stage, and regimen type) is also collected.
11527110|NCT01164449|Experimental|1|Space TGC system with incorporated eMPC advised insulin titration to establish glycaemic control
11527071|NCT01164722|Experimental|Arm I: Infrared coagulator treatment|Infrared photocoagulation therapy. The infrared coagulator (IRC) contact tip is placed in direct contact with lesion under high-resolution anoscopy (HRA) guidance. Patients then undergo IRC ablation for 1.5 second pulses. IRC ablation is reapplied until the level of submucosal vessels are reached.
11527072|NCT01164722|Active Comparator|Arm II: Expectant management|Patients receive standard of care and undergo clinical observation. After 12 months, patients may receive IRC ablation to all anal intraepithelial neoplasia lesions despite of their size.
11527073|NCT01164709|Experimental|bortezomib + nelfinavir|escalation 3 by 3 cohorts
11527074|NCT01164696||Group 1|
11527075|NCT01164683|Experimental|Arm 1|Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
11527076|NCT01164683|Active Comparator|Arm 2|Usual care
11527077|NCT01164670||Men|Men over 70 years old.
11527078|NCT01164670||Women|Women over 70 years old.
11527079|NCT01164657|Experimental|study group|Randomized to give birth on a birthing seat
11527080|NCT01164657|No Intervention|control group|Randomized to birth in any other position except the birthing seat
11527081|NCT01164644|Active Comparator|Arnica Montana|The subject will take twelve pills by mouth three times a day over four days.
11527082|NCT01164644|Placebo Comparator|Placebo|The subject will take twelve pills by mouth three times a day over four days.
11527083|NCT01164631|Experimental|Orthodontic treatment|Snoring patients enrolling for tonsil surgery with maxillary constriction, and/or jaw retrognathism
11527084|NCT01164631|No Intervention|Control Group|Patients enrolled for tonsils surgery
11527085|NCT01164618|Experimental|Group 1|The subjects in this arm will begin on the daily remote ischemic preconditioning (RIPC) protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily exercise.
11527086|NCT01164618|Experimental|Group 2|The subjects in this arm will begin on the exercise protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily remote ischemic preconditioning (RIPC).
11527087|NCT01164592|Active Comparator|Therapy with adaptive servo ventilation|optimal medical therapy + adaptive servoventilation
11527088|NCT01164592|No Intervention|Optimal medical therapy according to guidelines|optimal medical therapy
11527089|NCT01164579|Experimental|Tofacitinib (CP 690,550) 10 mg BID plus MTX|
11527090|NCT01164579|Experimental|Tofacitinib (CP-690,550) 10 mg BID, tablet plus placebo MTX|
11527091|NCT01164579|Active Comparator|Placebo tofacitinib (CP-690,55) plus MTX 10 mg/wk to 20 mg/wk|
11527092|NCT01164566|Experimental|Arm I|Patients undergo transnasal esophagoscopy at baseline and 3 months following completion of radiation therapy and/or chemotherapy.
11527093|NCT01164553|Experimental|Group 2, 0.5 mL TIV|Naive cohort participants (n=180) receive 0.25 mLTrivalent Inactivated Vaccine (TIV) in two intramuscular doses 28-42 days apart. Fully Primed cohort participants (previously vaccinated) (n=40) will receive 0.5 mL Trivalent Inactivated Influenza Vaccine (TIV) in one intramuscular dose.
11527094|NCT01164553|Active Comparator|Group 1, 0.25 mL TIV|Naive cohort participants (n=90) receive 0.25 mLTrivalent Inactivated Vaccine (TIV) in two intramuscular doses 28-42 days apart. Fully Primed cohort participants (previously vaccinated) (n=20) will receive 0.25 mL Trivalent Inactivated Influenza Vaccine (TIV) in one intramuscular dose
11527095|NCT01164540|Experimental|1|Oral Treatment
11527096|NCT01164540|Placebo Comparator|2|Oral treatment
11527097|NCT01164514|Active Comparator|Group 1 - vaccine alone|8 subjects to receive vaccine (10 mcg) alone on Days 0, 29 and 59.
11527098|NCT01164514|Experimental|Group 3 - vaccine + CPG 7909 (250 mcg)|8 subjects to receive vaccine (10 mcg) with 250 mcg of adjuvant on Days 0, 29 and 59.
11527099|NCT01164514|Experimental|Group 2 - vaccine + CPG 7909 (500 mcg)|8 subjects to receive vaccine (10 mcg) with 500 mcg of adjuvant on Days 0, 29 and 59.
11527100|NCT01164514|Placebo Comparator|Group 4 - Placebo|4 subjects to receive normal saline (placebo) on Days 0, 29 and 59.
11527101|NCT01164501|Experimental|BI 10773 low dose|BI 10773 tablets once daily
11527102|NCT01164501|Experimental|BI 10773 high dose|BI 10773 tablets once daily
11527103|NCT01164501|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
11527104|NCT01164488|Experimental|1|
11527105|NCT01164475|Experimental|Fixed Dose Plerixafor|10 microgram per kilogram (mcg/kg) granulocyte-colony stimulating factor (G-CSF) subcutaneous (SC) injection once daily in morning from Day 1 through Day 4 (G-CSF mobilization period), followed by 20 milligram (mg) plerixafor SC injection (fixed dose) in evening of Day 4 (10 to 11 hours prior to first apheresis), and then 10 mcg/kg G-CSF SC injection in morning of Day 5 (1 hour prior to first apheresis). Apheresis process and treatment with plerixafor (10 to 11 hours prior to apheresis) and G-CSF (1 hour prior to apheresis) was continued until the target number of cluster of differentiation 34 (CD34+) stem cells (greater than or equal to [>=] 5*10^6 cells/kg) was collected or until a maximum 4 apheresis sessions occurred.
11527106|NCT01164475|Active Comparator|Weight-Based Plerixafor|G-CSF 10 mcg/kg SC injection once daily in morning from Day 1 through Day 4 (G-CSF mobilization period), followed by plerixafor 0.24 milligram per kilogram (mg/kg) SC injection (weight-based dose) in evening of Day 4 (10 to 11 hours before first apheresis), and then G-CSF 10 mcg/kg SC injection in morning of Day 5 (1 hour prior to first apheresis). Apheresis process and treatment with plerixafor (10 to 11 hours prior to apheresis) and G-CSF (1 hour prior to apheresis) was continued until the target number of CD34+ stem cells (>=5*10^6 cells/kg) was collected or until a maximum 4 apheresis sessions occurred.
11527107|NCT01164462|Other|A 2|During the normal opening hours of five testing centers, clients with a rapid finger-stick blood specimen test
11527108|NCT01164462|Other|B group|During evenings and week-ends (i.e. when the centers are closed) only community based with rapid HIV testing
11527109|NCT01164462|Other|A1 group|During the normal opening hours of five testing centers, clients with a conventional test.
11527406|NCT01162460|Experimental|Eslicarbazepine acetate|
11527111|NCT01164423|Experimental|1|Space TGC system with incorporated eMPC advised insulin infusion to establish glycaemic control
11527112|NCT01164410||Pediatric Colonoscopy|Patients undergoing colonoscopy in the Department of Pediatric Gastroenterology at the Cleveland Clinic Children's Hospital in Cleveland, Ohio.
11527113|NCT01164397||Dislipidemic Population|People with high levels of total cholesterol, LDL, C-HDL and triglycerides
11527114|NCT01164371||Initial presentation of coronary disease - Stable angina|Patients whose initial symptomatic presentation of coronary disease is stable angina (either diagnosis or symptoms)
11527115|NCT01164371||Initial presentation of coronary disease - ACS|Patients whose initial symptomatic presentation of coronary disease is acute coronary syndrome (ST-elevation myocardial infarction [STEMI], non-STEMI [nSTEMI] or unstable angina) without prior stable angina or symptoms of stable angina
11527116|NCT01164371||Initial presentation of coronary disease - Coronary death|Patients whose initial symptomatic manifestation of coronary disease is coronary death with no prior diagnosis of stable angina (or symptoms of stable angina) or diagnosis of acute coronary syndrome
11527117|NCT01164371||Initial presentation of coronary disease - None|Patients without symptomatic presentation of coronary disease, either alive or dead from non-coronary cause
11527118|NCT01164358||study arm I|"patients who have been enrolled in the previous study Intrastromal Correction of Ametropia by Femtosecond Laser (study ISCAF), study arm 1, Presbyopia sub-group: treatment pattern 5-Rings"
11527119|NCT01164358||study arm II|"patients who have been enrolled in the previous study Intrastromal Presbyopia Correction by Means of Femtosecond Laser (study # 0905)"
11527120|NCT01164345|Experimental|MOZOBIL|treatment with mozobil for autologous stem cell collection
11527121|NCT01164332|Other|Method A|First experimental detection method
11527122|NCT01164332|Other|Method B|Second experimental detection method
11527123|NCT01164319|Active Comparator|Group 1 (no early recurrence)|Patients without atrial fibrillation recurrences through the implantable cardiac monitors during the 3 months post-ablation period.
11527124|NCT01164319|Active Comparator|Group 2 (early AF recurrence)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period.
11527125|NCT01164319|Active Comparator|Group 3 (early recurrence-no reablation)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period from Group 2 would not receive reablation.
11527126|NCT01164319|Active Comparator|Group 4 (early recurrence-early reablation)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period from Group 2 will receive early reablation based on data stored by implanted monitor.
11527127|NCT01164306|Experimental|LifeSkills training|
11527128|NCT01164306|Active Comparator|Healthy Lifestyle Behaviors|
11527129|NCT01164293|Experimental|Atopy patch test|Atopy patches were applied on food allergy patient's back for 48 hrs then the patches were removed. Reaction was evaluated at 48 and 72 hrs after applying atopy patch test
11527130|NCT01164280|Experimental|Pulse Rate Change|Patients are subjected to different pulse rate settings of their neurostimulator. The effect of pulse rate changes on clinical outcome is measured.
11527131|NCT01164241||1|Eczema
11527132|NCT01164241||2|unaffected relatives
11527133|NCT01164241||3|healthy volunteers
11527134|NCT01164241||4|other allergic phenotypes
11527135|NCT01164228|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 22, and 29 and oral sunitinib malate once daily on days 1-14 and 22-35.
11527136|NCT01164228|Active Comparator|Arm II|Patients receive oral sunitinib malate once daily on days 1-14 and 22-35.
11527137|NCT01164215|Experimental|mFOLFOX6|"Patients will receive cycle 1 of standard dose mFOLFOX6, with the same dose of mFOLFOX6 continued in subsequent cycles, once patient achieves the target AUC.
~mFOLFOX 6 is a regimen comprised of Oxaliplatin + Leucovorin +5-Fluorouracil (FU)"
11527138|NCT01164202|Placebo Comparator|Placebo|placebo 3cps/days 4 weeks over 6 during 1 year
11527139|NCT01164202|Experimental|Sunitinib|sunitinib (SUTENT®) 37,5 mg/d (3 cps of 12,5 mg) orally 4 weeks over 6 (4 weeks of treatment followed by 2 weeks without treatment) during 1 year
11527140|NCT01164189|Other|Temozolomide|Administered orally on day 1-5, 150-200 mg/m(2), repeated every 4 weeks, up to 12 cycles
11527141|NCT01164189|Experimental|Temozolomide + Bevacizumab|"TMZ: Administered orally on day 1-5, 150-200 mg/m(2), repeated every 4 weeks, up to 12 cycles
~Beva: 10 mg/kg bw IV in 90 minutes on day 1 and 14, 4 week cycles."
11527142|NCT01164176|Experimental|RAD001 group|
11527143|NCT01164163|Experimental|Treatment (Ruxolitinib)|
11527144|NCT01164150|Experimental|Arm B|Radiation: 45 Gy / 25 fractions pelvic radiotherapy using intensity modulated radiotherapy (IMRT) followed by 11 Gy / 2 fractions vaginal vault brachytherapy
11527145|NCT01164150|Other|Arm A Control|Radiation: 45 Gy/25 fraction external beam pelvic radiotherapy delivered using a 3-dimensional planned technique followed by 11 Gy / 2 fractions vaginal vault brachytherapy
11527146|NCT01164137|Experimental|Medication Reconciliation Intervention|Participants receiving a pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at identifying and correcting medication discrepancies.
11527147|NCT01164137|No Intervention|Medication Reconciliation Non-Interven.|Participants not receiving a pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at identifying and correcting medication discrepancies.
11527148|NCT01164124|Experimental|Probiotic supplementation|500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter & Gamble.Inc)
11527149|NCT01164124|Placebo Comparator|Routine feedings|
11527150|NCT01164111|Experimental|Preoperative resistance training|preoperative resistance training: Duration 8 weeks. Intensity: 3 sets of 80 % of 1 repetition max (1 RM) in each exercise. Frequency: 2 times/week
11527151|NCT01164111|No Intervention|Control|Standard preoperative track.: No training intervention. Standard preoperative information.
11527152|NCT01164098|Active Comparator|Rituximab|Participants will receive Rituximab post within 24 of Kidney Transplant
11527153|NCT01164098|No Intervention|No rituximab|Participants will not receive Rituximab within 24 hours of Kidney Transplant
11527154|NCT01164085|Experimental|Ketorolac|4mg intravitreal injection of ketorolac
11527266|NCT01163422|Active Comparator|Immediate RVRT|RVRT switched on immediately after pacemaker implant
11527155|NCT01164072||HIGH NICOTINE|Well characterized group of 100 regular smokers experimenting the E-Cigarette loaded with 7.2 mg nicotine cartridges (high nicotine group).
11527156|NCT01164059|Experimental|atypical antipsychotics|Olanzapine, Quetiapine, or Aripiprazole
11527157|NCT01164059|Active Comparator|typical antipsychotics|Haloperidol or Flupentixol
11527158|NCT01164046|Active Comparator|vitamin K antagonists|
11527159|NCT01164046|Active Comparator|Low molecular weight heparin|
11527160|NCT01164033|Active Comparator|A|
11527161|NCT01164033|Experimental|B|
11527162|NCT01164033|Experimental|C|
11527163|NCT01164033|Experimental|D|
11527164|NCT01164020|Placebo Comparator|placebo control|this only receives placebo (dextrose)
11527165|NCT01164020|Experimental|placebo and exercise|this is trained and receives placebo
11527166|NCT01164020|Experimental|creatine supplementation|this is non-exercise trained and receives creatine supplementation
11527167|NCT01164020|Experimental|Creatine and Exercise|this is exercised trained and receives creatine supplementation
11527168|NCT01164007|Experimental|Dacarbazine + Bevacizumab|Participants with unresectable/metastatic melanoma not previously treated with chemotherapy for metastatic disease will receive dacarbazine and bevacizumab until disease progression, unacceptable toxicity, participant withdrawal, or physician decision to discontinue.
11527169|NCT01163994|Active Comparator|MEM-ceftriaxone|
11527170|NCT01163994|Active Comparator|MEM-doxycycline|
11527171|NCT01163994|No Intervention|controls|
11527172|NCT01163994|Active Comparator|EM-doxycycline|
11527173|NCT01163981|No Intervention|Blind cannulation|Cannulation without guidance
11527174|NCT01163981|Experimental|Ultrasound guided cannulation|Ultrasound guided cannulation
11527175|NCT01163968|Experimental|Weight reduction program|MOMENTUM intervention
11527176|NCT01163955|Other|Sitting in a chair|Sitting in a chair with back support and feet flat on the ground
11527177|NCT01163955|Other|Sitting on the Floor|Sitting on the floor without back support, crossed leg style
11527178|NCT01163942|Active Comparator|No G-CSF, No 2nd ATG|Patients randomised not to receive G-CSF (alongside ATG and CSA) and to not receive early retreatment in case of no response.
11527179|NCT01163942|Active Comparator|No G-CSF, yes 2nd ATG|Patients randomised not to receive G-CSF (alongside ATG and CSA) but they do receive early retreatment in case of no response.
11527180|NCT01163942|Active Comparator|Yes G-CSF, No 2nd ATG|Patients randomised to receive G-CSF (alongside ATG and CSA) and to not receive early retreatment in case of no response.
11527181|NCT01163942|Active Comparator|Yes G-CSF, Yes 2nd ATG|Patients randomised to receive G-CSF (alongside ATG and CSA) and to receive early retreatment in case of no response.
11527182|NCT01163929|Experimental|paclitaxel, trastuzumab and everolimus|
11527183|NCT01163916||Patients with RA, PsA and AS|Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) prescribed adalimumab as part of Routine Clinical Care in Russia.
11527184|NCT01163903|Experimental|Pantoprazole and doxorubicin|
11527185|NCT01163890|Experimental|WHI|
11527186|NCT01163890|Active Comparator|Usual Care|
11527187|NCT01163877|Other|Symptomatic malaria infection|
11527188|NCT01163877|Other|Asymptomatic malaria infection|
11527189|NCT01163877|Other|Hookworm infection|
11527190|NCT01163877|Other|Schistosoma haematobium infection|
11527191|NCT01163864|Experimental|affect regulation training|
11527192|NCT01163864|Active Comparator|health and lifestyle|
11527193|NCT01163851|Experimental|PF-04950615 (RN316)|
11527194|NCT01163838|Placebo Comparator|Placebo|
11527195|NCT01163838|Experimental|RN316: 1 mg/kg every 2 weeks|
11527196|NCT01163838|Experimental|RN316: 2 mg/kg every 4 weeks|
11527197|NCT01163838|Experimental|RN316: 4 mg/kg every 4 weeks|
11527198|NCT01163838|Experimental|RN316: 4 mg/kg every 8 weeks|
11527199|NCT01163838|Experimental|RN316: 8 mg/kg every 8 weeks|
11527200|NCT01163838|Experimental|RN316: 12 mg/kg every 8 weeks|
11527201|NCT01163825|Experimental|Nerve Growth Factor|Dose 1
11527202|NCT01163825|Experimental|Nerve Growth Factor 2|Dose 2
11527203|NCT01163812|Experimental|Laparoscopic D2 gastrectomy|
11527204|NCT01163799|Experimental|Alefacept (ASP0485)|Safety and efficacy of alefacept in combination with alemtuzumab induction and calcineurin inhibitor (CNI) and corticosteroid withdrawal.
11527205|NCT01163786|Experimental|Bortezomib|Patients will Receive 2 4week cycles of Bortezomib. Each cycle will consist of weekly bortezomib with a 2 week interval between cycles.
11527206|NCT01163760|Other|etafilcon A / ocufilcon D|etafilcon A contact lens worn first daily disposable , ocufilcon D contact lens worn second daily disposable
11527207|NCT01163760|Other|oculfilcon D / etafilcon A|ocufilcon D contact lens worn first, etafilcon A contact lens worn second
11527208|NCT01163760|Other|ocufilcon D / ocufilcon D|ocufilcon D contact lens worn first and second
11527209|NCT01163760|Other|etafilcon A / etafilcon A|etafilcon A contact lens worn first and second
11527210|NCT01163747|Active Comparator|Methotrexate|Participants continued to receive their standard dose of methotrexate up to Week 8. From Week 8 participants also received 8 mg/kg tocilizumab intravenously every 4 weeks until Week 20. At Week 3 participants received both pneumococcal and tetanus toxoid vaccinations.
11527211|NCT01163747|Experimental|Tocilizumab + Methotrexate|Participants received 8 mg/kg tocilizumab intravenously at Baseline (Day 1) and every 4 weeks up to Week 20, in addition to their standard dose of methotrexate. At Week 3 participants received both pneumococcal and tetanus toxoid vaccinations.
11527212|NCT01163734|Experimental|Ranolazine|
11527213|NCT01163734|Placebo Comparator|Saline 0.9%|Saline 0.9% and placebo tablet
11527214|NCT01163721|Experimental|Ranolazine|Participants were randomized to receive ranolazine for 12 weeks.
11527215|NCT01163721|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match ranolazine for 12 weeks.
11527216|NCT01163708|Active Comparator|Navigation alone|Navigation system alone vs Prophecy technique with Navigation system validation
11527217|NCT01163708|Experimental|Prophecy and Navigation validation|
11527691|NCT01160263|Other|patients with mixed stiffness|
11527218|NCT01163682|Active Comparator|Electro-acupuncture|45 minute sessions scheduled once a week for 12 weeks.
11527219|NCT01163682|Sham Comparator|Sham acupuncture|45 minute sessions scheduled once a week for 12 weeks
11527220|NCT01163669||kidney transplant recipients|
11527221|NCT01163656|Active Comparator|Direct Laryngoscopy|Laryngoscopy will be performed with the randomized device, which will be the Miller Laryngoscope.
11527222|NCT01163656|Active Comparator|Glidescope Cobalt Video Laryngoscopy|Laryngoscopy will be performed with the randomized device, which will be the Glidescope Cobalt Video Laryngoscope.
11527223|NCT01163643|Experimental|0.3% BOL-303242-X ophthalmic suspension|0.3% BOL-303242-X ophthalmic suspension
11527224|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension|2% BOL-303242-X ophthalmic suspension
11527225|NCT01163643|Placebo Comparator|Vehicle|Vehicle twice daily (BID)
11527226|NCT01163643|Experimental|1% BOL-303242-X ophthalmic suspension|1% BOL-303242-X ophthalmic suspension
11527227|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension in the morning|2% BOL-303242-X ophthalmic suspension in the morning (AM) and vehicle in the afternoon (PM)
11527228|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension PM|Vehicle in the AM and 2% BOL-303242-X ophthalmic suspension in the PM.
11527229|NCT01163630|Experimental|1|esomeprazole 20mg/ASA 81 mg FDC after a 10-hour fast
11527230|NCT01163630|Experimental|2|esomeprazole 20mg/ASA 81 mg FDC 30 minutes after start of a high-fat, high-calorie breakfast
11527231|NCT01163617|Experimental|Current/Physiolis Syringe|Self-injection using current syringe at Week 0 (Visit 1), self-injection using Physiolis syringe at Week 2 (Visit 2) (Phase A)
11527232|NCT01163617|Experimental|Physiolis/Current Syringe|Self-injection using Physiolis syringe at Week 0 (Visit 1), self-injection using current syringe at Week 2 (Visit 2) (Phase A)
11527233|NCT01163617|Experimental|Current/Physiolis Autoinjector|Self-injection using current autoinjector at Week 0 (Visit 1), self-injection using Physiolis autoinjector at Week 2 (Visit 2) (Phase A)
11527234|NCT01163617|Experimental|Physiolis/Current Autoinjector|Self-injection using Physiolis autoinjector at Week 0 (Visit 1), self-injection using current autoinjector at Week 2 (Visit 2) (Phase A)
11527235|NCT01163617|Experimental|Physiolis Autoinjector at 2° to 8°C|Injection performed by health care provider at Week 4 (Visit 3) using Physiolis autoinjector at storage temperature (2° to 8°C) (Phase B)
11527236|NCT01163617|Experimental|Current Autoinjector 2° to 8°C|Injection performed by health care provider at Week 4 (Visit 3) using current autoinjector at storage temperature (2° to 8°C) (Phase B)
11527237|NCT01163617|Experimental|Physiolis Autoinjector 20° to 27°C|Injection performed by health care provider at Week 4 (Visit 3) using Physiolis autoinjector at room temperature (20° to 27°C) (Phase B)
11527238|NCT01163617|Experimental|Current Autoinjector 20° to 27°C|Injection performed by health care provider at Week 4 (Visit 3) using current autoinjector at room temperature (20° to 27°C) (Phase B)
11527239|NCT01163604|Experimental|Argatroban group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive continuous infusions of argatroban for 2 days before and 3 days after stenting, with accompanied aspirin and clopidogrel treatment.
11527240|NCT01163604|Experimental|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
11527241|NCT01163591||Case|Patients with overt diabetic nephropathy as evidenced by ACR greater than or equal to 30mg/mmol on urinalysis and eGFR greater than or equal to 15ml/min/1.73m2 and less than 60ml/min/1.73m2
11527242|NCT01163591||Control|Patients without diabetic nephropathy as defined by the absence of albuminuria (defined by a random spot urinary ACR <2.5 mg/mmol in women or ACR<3.5 mg/mmol in men)and eGFR greater or equal to 90 ml/min/1.73m2
11527243|NCT01163565|Active Comparator|Ligasure device|
11527244|NCT01163565|No Intervention|Hand ties|
11527245|NCT01163552|Experimental|Surgical Debulking and Intrathoracic Hyperthermic Chemotherapy|Patients in this trial will undergo surgical debulking followed by intrathoracic hyperthermic chemotherapy perfusion.
11527246|NCT01163526||neuroendocrine metastases|15 patients with neuroendocrine metastases
11527247|NCT01163526||colon cancer metastases|15 patients with colon cancer metastases
11527248|NCT01163526||HCC treated with cyberknife radiation and chemotherapy|15 patients with HCC treated with cyberknife radiation and chemotherapy
11527249|NCT01163526||HCC treated with Sirsphere embolization and chemotherapy|15 patients with HCC treated with Sirsphere embolization and chemotherapy
11527250|NCT01163513||White population|
11527251|NCT01163513||Indian|
11527252|NCT01163513||Pakistani|
11527253|NCT01163513||Bangladeshi|
11527254|NCT01163513||Other|other South Asian
11527255|NCT01163500|Placebo Comparator|Pill|
11527256|NCT01163500|Experimental|Coenzyme Q10|
11527257|NCT01163487|Experimental|Dichloroacetate (DCA)|25 mg/kg/day, 37.5 mg/kg, or 50 mg/kg/day oral DCA.
11527258|NCT01163474|Experimental|Arm 1 - All study participants|Evaluate video clinic visit prior to Face-to-Face usual care visit
11527259|NCT01163461|Experimental|Immediate Treatment|individuals will receive 60 hours of speech therapy
11527260|NCT01163461|Experimental|Delayed Treatment|individuals will receive 60 hours of speech therapy after 6 week delay period
11527261|NCT01163448|Experimental|High-Dose Single-Fraction Image-Guided Radiotherapy|This will assess the feasibility and safety of this approach in men at high-risk for extraprostatic prostate cancer undergoing RP. This initial trial has been designed in a manner intended to emphasize patient comfort and safety.
11527262|NCT01163435|Experimental|high dose dual therapy|group A1 and A2 - high dose dual therapy (rabeprazole 20 mg qid, amoxicillin 750 mg qid for 14 days)
11527263|NCT01163435|Experimental|sequential therapy|group B1 and B2 - sequential therapy (rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days)
11527264|NCT01163435|Active Comparator|clarithromycin-based triple therapy|group C1 - clarithromycin-based triple therapy (rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days)
11527265|NCT01163435|Active Comparator|levofloxacin-based triple therapy|group C2 - levofloxacin-based triple therapy (rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days)
11527268|NCT01163409|Experimental|acupuncture|will be made with classic acupuncture needling in traditional points, surpassing the skin
11527269|NCT01163409|Experimental|sham acupuncture|sham acupuncture will be done through a needle and a plastic device attached to skin in traditional acupuncture points.
11527270|NCT01163409|Experimental|exercise training resistance and aerobic|Aerobic exercise for 1 hour and resistance exercises for major muscle groups.
11527271|NCT01163409|No Intervention|healthy lifestyle|Group 4 - will be the control group who receive follow-up and recommendation for physical activity, but without any intervention supervised.
11527272|NCT01163396|Experimental|FOLFOXIRI plus bevacizumab|BEVACIZUMAB 5 mg/Kg i.v. followed by IRINOTECAN 165 mg/sqm i.v. over 1 hr followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hr concomitantly with l-LV 200 mg/sqm over 2 hrs followed by 5FU 3.200 mg/sqm c.i. over 48 hrs starting on day 1. Cycles repeated every 2 weeks
11527273|NCT01163370|Placebo Comparator|control and exercise|this is trained and receives placebo
11527274|NCT01163370|Experimental|creatine|this is non-exercise trained and receives creatine supplementation
11527275|NCT01163370|Experimental|exercise and creatine|this is exercised trained and receives creatine supplementation
11527276|NCT01163370|Placebo Comparator|placebo|this only receives placebo (dextrose)
11527277|NCT01163357|Experimental|Group I (bortezomib, fludarabine phosphate, TMI, melphalan)|Patients receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. Patients also undergo TMI BID on days -9 to -7. If no DLT is observed in the first cohort, bortezomib IV will be added on days -6 and -3 for subsequent cohorts.
11527278|NCT01163357|Experimental|Group II (bortezomib, fludarabine phosphate, melphalan|Patients receive fludarabine phosphate IV and melphalan IV as in Stratum I. Patients also receive bortezomib IV on days -6, -3, 1, and 4.
11527279|NCT01163344||Dance Therapy Group|This will group will undergo dance therapy once a week for a series of 8 weeks.
11527280|NCT01163344||Physical Therapy Group|This group will undergo physical therapy sessions once a week for a series of 8 weeks
11527281|NCT01163331|Experimental|Singing Therapy Group|Singing Therapy Group
11527282|NCT01163318||Adalimumab 40 mg/0.8 mL syringe for subcutaneous injection|Participants with rheumatoid arthritis who received adalimumab, per approved label
11527283|NCT01163305||metastatic colorectal cancer|
11527284|NCT01163292||Adalimumab|Participants who continued adalimumab treatment after completion of Study NCT00870467 (M06-859)
11527285|NCT01163292||Non-Adalimumab|Participants who discontinued adalimumab treatment after completion of Study NCT00870467(M06-859)
11527286|NCT01163279|Experimental|Cognitive Training|
11527287|NCT01163279|Active Comparator|Psychosocial Education|
11527288|NCT01163266|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 8 weeks.
11527289|NCT01163266|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
11527290|NCT01163266|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week then vortioxetine 20 mg, encapsulated tablets, orally, once daily for up to 7 weeks.
11527291|NCT01163253|Experimental|Active Treatment|"The study is anticipated to continue for up to at least 2 years post First Market Approval (FMA) in a global, major market.
~All subjects will receive 10 mg BID of CP-690,550 for first 3 months of trial. Study has the option for variable dosing with 5 mg or 10 mg BID after first 3-months of treatment based on PI discretion"
11527292|NCT01163240||pediatric|
11527293|NCT01163227|Placebo Comparator|Placebo|
11527294|NCT01163227|Experimental|AQW051 Dose 1|
11527295|NCT01163227|Experimental|AQW051 Dose 2|
11527296|NCT01163227|Experimental|AQW051 Dose 3|
11527297|NCT01163214|Experimental|Nerve Block|Preoperative femoral block with indwelling femoral catheter and a single shot sciatic block.
11527298|NCT01163214|Active Comparator|Periarticular Injection|Injection combination prior to skin closure.
11527299|NCT01163201|Experimental|Treg Plus CD3+Teff Treatment|Includes dose adjustment of T regulatory (Treg) and CD3+ T effector (CD3+ Teff) cells in recipients of double UCB transplantation
11527300|NCT01163188||Proband|Very low birth weight children (< 32 weeks of gestation) and/ or Very preterm children (< 1500 g birthweight) of the Bavarian Longitudinal Study
11527301|NCT01163188||Controls|Term born children of the Bavarian Longitudinal Study
11527302|NCT01163162|Experimental|Paricalcitol|After baseline measurements are complete, pt will receive 2 mcg Paricalcitol (Zemplar) for 7 consecutive days. After this, Kidney function will again be measured. The pt will then be washed off the paricalcitol for 7 days then kidney function will be measured for the last time.
11527303|NCT01163149|Experimental|Cohort 1|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (2.1 mg/kg/week total)
11527304|NCT01163149|Experimental|Cohort 2|Cohort 2: Daily SC injections of 0.5 mg/kg asfotase alfa (3.5 mg/kg/week total)
11527305|NCT01163149|No Intervention|Concurrent Control|Following completion of the Week 24 visit, all patients (including those randomized to the concurrent control cohort) may be eligible to participate in an open-label extension treatment period. In this extension period, all patients will be treated with daily SC injections of 0.5 mg/kg/day asfotase alfa (a total of 3.5 mg/kg/week) for approximately 24 weeks, then subjects will receive 1 mg/kg/day 6 days/week for an additional 48 weeks or until regulatory approval of the drug.
11527306|NCT01163097|Experimental|Palifermin 40 µg/kg and heparin IV infusion|Treatment A: palifermin 40 µg/kg/day for three consecutive days as IV bolus injections and continuous heparin IV infusion
11527307|NCT01163097|Experimental|Palifermin 40 µg/kg|Treatment B: palifermin 40 µg/kg/day for three consecutive days as IV bolus injections
11527308|NCT01163097|No Intervention|Control group without any treatment|Treatment C: control group without any treatment administered.
11527309|NCT01163084|Experimental|Arm I (leuprolide acetate, goserelin acetate, vismodegib)|Patients receive LHRH analogue comprising leuprolide acetate IM or goserelin acetate SC on day 1 and vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.
11527310|NCT01163084|Active Comparator|Arm II (leuprolide acetate, goserelin acetate)|Patients receive LHRH analogue comprising leuprolide acetate or goserelin acetate as in Arm I. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.
11527311|NCT01163071|Experimental|ABI-011|
11527315|NCT01163032|Placebo Comparator|placebo|Placebo capsules, PO daily for 6 months
11527316|NCT01163019||Chest pain|Patients who present to the emergency department with a chief complaint of chest pain and have a moderate pre-test probability for an acute coronary syndrome
11527317|NCT01163006|Experimental|polydextrose|
11527318|NCT01163006|Experimental|soluble glucofibre|
11527319|NCT01163006|Placebo Comparator|isocaloric dietary control|
11527320|NCT01163006|Placebo Comparator|full caloric control|
11527321|NCT01162993|Experimental|Spinal Cord Stimulation|Spinal cord stimulation
11527322|NCT01162993|No Intervention|Treatment as usual|Treatment as usual
11527323|NCT01162967|Active Comparator|Benznidazole|
11527324|NCT01162967|Experimental|Posaconazole, low dose|
11527325|NCT01162967|Experimental|Posaconazole, high dose|
11527326|NCT01162954|Experimental|DA-6034|
11527327|NCT01162954|Placebo Comparator|Placebo|
11527328|NCT01162941|Experimental|Steroid dependant ITP|more than 10 mg of prednisolone per day is required to maintain a platelet count above 20X109/L (minimum follow up duration: 3 months after diagnosis)
11527329|NCT01162928|Experimental|1|3-chamber-bag combined with Oxepa
11527330|NCT01162928|Active Comparator|2|3-chamber-bag combined with Pulmocare
11527331|NCT01162915|Experimental|Safety|Infusion of autologous bone marrow-derived mesenchymal stem cells.
11527332|NCT01162902|Experimental|Diltiazem treated group|Diltiazem 180mg treated group
11527333|NCT01162902|Active Comparator|Bisoprolol treated group|Bisoprolol 5mg treated group
11527334|NCT01162902|Active Comparator|Candesartan treated group|Candesartan 32mg treated group
11527335|NCT01162889|Placebo Comparator|Placebo - SC injection|
11527336|NCT01162889|Experimental|Drug dose level 1 - SC injection|
11527337|NCT01162889|Experimental|Drug dose level 2 - SC injection|
11527338|NCT01162889|Experimental|Drug dose level 3- SC injection|
11527339|NCT01162889|Experimental|Drug dose level 4 - SC injection|
11527340|NCT01162889|Experimental|Drug dose level 5 - SC injection|
11527341|NCT01162889|Experimental|Drug dose level 6 - IV Infusion|
11527342|NCT01162889|Experimental|Drug dose level 7 - IV Infusion|
11527343|NCT01162889|Experimental|Drug dose level 8 - IV infusion|
11527344|NCT01162889|Placebo Comparator|Placebo - IV infusion|
11527345|NCT01162889|Experimental|Drug dose level 9 - IV infusion|
11527346|NCT01162876|Experimental|saxagliptin|5 mg daily for 14days
11527347|NCT01162863|Active Comparator|Lubiprostone 8 mcg BID|
11527348|NCT01162863|Active Comparator|Lubiprostone 24 mcg QD|
11527349|NCT01162863|Placebo Comparator|Placebo|
11527350|NCT01162850|Active Comparator|Polypodium Leucotomos|Oral Polypodium Leucotomos twice daily plus sunscreen SPF 45 for 12 weeks.
11527351|NCT01162850|Placebo Comparator|Placebo|Oral Placebo twice daily plus sunscreen SPF 45 for 12 weeks.
11527352|NCT01162837|Other|All subjects|All subjects are enrolled in this arm and will use the BEAM device on one side of the face and the other side of the face will be the control
11527353|NCT01162824|Other|No endothelial dysfunction|
11527354|NCT01162824|Other|Endothelial Dysfunction|Definition of abnormal epicardial and microvascular vasoreactivity Abnormal epicardial vasoreactivity is defined as a reduction of the baseline coronary diameter ≥75% after glyceryltrinitrate i.c. together with a reproduction of the angina symptoms reported by the patient and/or ischemic ECG-changes. Abnormal microvascular vasoreactivity is defined as the reproduction of the angina symptoms together with ischaemic ECG-changes, but without changes in epicardial vasomotion.
11527355|NCT01162811|No Intervention|Control group|The control group receives conventional care and treatment
11527356|NCT01162811|Experimental|Intervention group|the intervention group receives visualization and relaxation exercises together with structured behavioural attention
11527357|NCT01162798|Active Comparator|Control|commercially available formula
11527358|NCT01162798|Experimental|Test|test formula
11527359|NCT01162785|Experimental|First Dose SCH 721015|Part1: 2 Instillations of intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume
11527360|NCT01162785|Experimental|Second Dose SCH 721015|Part 2: Subjects who have a complete response to treatment at Week 12 in Part 1 receive second regimen of intravesical administration of SCH 721015 with Syn3 on same Day 1 and Day 4 regimen at same dose level.
11527361|NCT01162772||Female Diabetics|female, 25-75 years old, no pregnancy, with/out Hormone replacement therapy T2DM, HbA1c > 7% with metformin mono-therapy
11527362|NCT01162772||Male diabetics|25-75 years, T2DM, HbA1c > 7% with metformin mono-therapy
11527363|NCT01162759|No Intervention|Usual Care|The control group receiving usual care
11527364|NCT01162759|Experimental|Home Blood Pressure Monitoring Group|Intervention group
11527365|NCT01162746|Experimental|Intravitreal dexamethasone and intravitreal ranibizumab|"Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.
~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT."
11527366|NCT01162746|Active Comparator|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
11527367|NCT01162733|Active Comparator|Study Drug 1|Vancomycin 15mg/kg
11527368|NCT01162733|Active Comparator|Study Drug 2|Vancomycin 30mg/kg
11527369|NCT01162720|Experimental|Short duration tourniquet|Patients allocated to this group will have the pneumatic tourniquet applied to the index limb for approximately 20-30 minutes during cement fixation of the prosthesis.
11527407|NCT01162447||PCO|Healthy control subjects and patients with polycystic ovarian syndrome will be recruited for the study.
11527370|NCT01162720|Active Comparator|Long duration tourniquet|Patients randomised to this arm will have the tourniquet applied from commencement of surgery and removed just prior to skin closure.
11527371|NCT01162707|Experimental|Pressure Measurement System|CardioMEMS HF Pressure Measurement System
11527372|NCT01162694|Active Comparator|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
11527373|NCT01162694|Active Comparator|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will send the uploaded data and receive feedback from their endocrinologist every 2 weeks.
11527374|NCT01162681|Experimental|A-623 high dose weekly|
11527375|NCT01162681|Experimental|A-623 low dose weekly|
11527376|NCT01162681|Experimental|A-623 high dose every 4 weeks|
11527377|NCT01162681|Placebo Comparator|Placebo|
11527378|NCT01162655|Experimental|Telehealth|Complete CBT group via telehealth
11527379|NCT01162655|Experimental|Internet|Complete Internet-based CBT program
11527380|NCT01162642|Experimental|Green Tea|4 cups daily of green tea for 6 weeks
11527381|NCT01162642|Placebo Comparator|No Green Tea|4 cups daily of placebo tea for 6 weeks
11527382|NCT01162629||Osteon|Patients requiring dental implants with deficient alveolar bone height
11527383|NCT01162616|Other|Iron absorption|
11527384|NCT01162603|Experimental|TAFLUPROST 0.0015% EYEDROPS|Tafluprost 0.0015% preservative-free ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means of Goldmann and Perkins applanation tonometry.
11527385|NCT01162603|Active Comparator|LATANOPROST 0.005% EYEDROPS|Latanoprost 0.005% preservative-added ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means Goldmann and Perkins applanation tonometry.
11527386|NCT01162590|Experimental|Rotarix Group|Subjects will receive Rotarix™.
11527387|NCT01162590|Placebo Comparator|Placebo Group|Subjects will receive placebo.
11527388|NCT01162577|Experimental|Intervetion|The intervention group received the 5 standard tobacco calls plus 3 weight calls with a weight coach to address weight concerns related to quitting smoking
11527389|NCT01162577|No Intervention|Control|Participants in this arm received only the 5 standard tobacco calls
11527390|NCT01162564||NG-TSM|Patients receiving NG-TSM to repair an abdominal incisional/ventral hernia
11527391|NCT01162551|Experimental|Sirolimus and Methotrexate|"Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.
~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.
~One cycle is 28 days"
11527392|NCT01162525|Experimental|pTNS treatment|
11527393|NCT01162512|Experimental|Physical Activity|Participants will receive 7 weeks of weekly news letters and phone calls. The news letters and phone calls will include information about physical activity and ways to increase physical activity levels. This is in addition the standard medical care.
11527394|NCT01162512|No Intervention|Standard Medical Care|Participants will receive standard medical care
11527395|NCT01162499|Experimental|Exendin-(9-39) first, then Vehicle|"After an overnight fast, an intravenous (IV) infusion of Exendin-(9-39) will be started 1 hour prior to the meal challenge and continued for 5 hours. After the first hour of the infusion, subjects will undergo a mixed meal tolerance test in which Pediasure (10cc/kg) will be consumed by mouth or gastrostomy/nasogastric tube over a period of 15 minutes (for infants under 12 months, Pediasure will be replaced by the infant's formula). Blood samples will be drawn at different time points during the infusion to measure blood glucose, plasma insulin, glucagon and plasma glucagon-like-peptide-1 (GLP-1). The Exendin-(9-39) dose for the first 3 subjects will be 300pmol/kg/min and, if tolerated, the dose will be increased to 500pmol/kg/min for subsequent subjects.
~The next day, all procedures will be repeated except subjects will receive an IV infusion of normal saline (vehicle) over 6 hours."
11527396|NCT01162499|Active Comparator|Vehicle first, then Exendin-(9-39)|"After an overnight fast, an intravenous (IV) infusion of normal saline (vehicle) will be started 1 hour prior to the meal challenge and continued for 5 hours. After the first hour of the infusion, subjects will undergo a mixed meal tolerance test in which Pediasure (10cc/kg) will be consumed by mouth or gastrostomy/nasogastric tube over a period of 15 minutes (for infants under 12 months, Pediasure will be replaced by the infant's formula). Blood samples will be drawn at different time points during the infusion to measure blood glucose, plasma insulin, glucagon and plasma glucagon-like-peptide-1 (GLP-1).
~The next day, all procedures will be repeated except subjects will receive an IV infusion of Exendin-(9-39) which will be started 1 hour prior to the meal challenge and continue for 5 hours. The dose for the first 3 subjects will be 300pmol/kg/min and, if tolerated, the dose will be increased to 500pmol/kg/min for subsequent subjects."
11527397|NCT01162486|Active Comparator|Rifampin control|Rifampin + midazolam
11527398|NCT01162486|Experimental|RPT 1|RPT Cohort 1 - 5 mg/kg
11527399|NCT01162486|Experimental|RPT 2|RPT Cohort 2 - 10 mg/kg
11527400|NCT01162486|Experimental|RPT 3|RPT Cohort 3 - 15 mg/kg
11527401|NCT01162486|Experimental|RPT 4|RPT Cohort 4 - 20 mg/kg
11527402|NCT01162486|Experimental|RPT 5|RPT Cohort 5 - Maximal tolerated dose, if dose limiting toxicities are observed
11527403|NCT01162473|Active Comparator|Delayed Sensitivity|All subjects will undergo a food challenge (week 2). Subjects undergoing delayed desensitization via milk oral immunotherapy with milk protein powder will begin build-up of desensitization during Week 16 and continue thru Week 50. Total active participation will last 51 weeks.
11527404|NCT01162473|Active Comparator|Immediate Sensitivity|All subjects will undergo a food challenge (week 2). Subjects undergoing immediate desensitization via milk oral immunotherapy with milk protein powder will begin build-up of desensitization during Week 3 and continue thru Week 35. Total active participation will last 38 weeks.
11527408|NCT01162434||Patients|Up to 8 patients who have received Deep Brain Stimulation for Treatment Resistant Depression at Frenchay Hospital (UK) will be recruited.
11527409|NCT01162434||Healthy volunteers|Up to 16 healthy volunteers, matched to the DBS patients on age, sex, handedness, and education, will be recruited.
11527410|NCT01162421|Experimental|Early Adalimumab|Participants in the Early Adalimumab arm will receive adalimumab and methotrexate at Baseline and every other week for study duration.
11527411|NCT01162421|Active Comparator|Standard of Care|Participants in the Standard of Care arm will receive methotrexate and other disease modifying antirheumatic drugs as per local treatment guidelines and study doctor's judgement. Adalimumab may be initiated after a minimum of 6 months.
11527412|NCT01162395|Experimental|A|Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD)
11527413|NCT01162382|Experimental|Transcranial Magnetic Stimulation|Open-label transcranial magnetic stimulation
11527414|NCT01162369||Group 1 - Non-Delirius Patients|
11527415|NCT01162369||Group 2 - Delirious Patients|
11527416|NCT01162343||Older Emergency Department Patients|Patients who were 65 years or older from the emergency department were enrolled.
11527417|NCT01162330||Babies referred for further hearing tests|Babies referred for further hearing tests after their neonatal hearing screening tests
11527418|NCT01162317|Active Comparator|Arm 1: sham acupuncture|sham acupuncture
11527419|NCT01162317|Experimental|Arm 2: acupuncture|acupuncture
11527420|NCT01162304|Active Comparator|ER Oxycodone vs IR Oxycodone|"Extended release Oxycodone to assess pain relief adverse effects, treatment satisfaction and impact of treatment on health related quality of life.
~IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every four hours"
11527421|NCT01162291||movement|healthy subjects, randomised to do flexion and extension movements with their left and right elbow joint after intramuscular application of NaCl 2ml in the right musculus biceps brachii, and 1ml in the left musculus biceps brachii
11527422|NCT01162291||rest|healthy subjects are randomised to rest after intramuscular application of NaCl 1ml in the left and 2ml in the right musculus biceps brachii
11527423|NCT01162278|Other|single fraction|Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 35Gy in one fraction. Subsequent cohorts of patients will receive an additional 5Gy per treatment to a maximum planned dose of 50Gy in one fraction.
11527424|NCT01162265||Contacts|Contacts of active cases of tuberculosis
11527425|NCT01162265||new entrants|new entrants from high incidence (>40/100000) countries.
11527426|NCT01162252|Active Comparator|Mindfulness-Based Stress Reduction|
11527427|NCT01162252|Active Comparator|Living Well|
11527428|NCT01162239|Experimental|Extended Brief Contact|Following standard brief treatment, participants have monthly meetings with medical staff.
11527429|NCT01162239|Experimental|Extended Health Education|Following standard treatment, participants receive monthly counseling with content based on a health education model.
11527430|NCT01162239|Experimental|Extended Relapse Prevention plus varenicline|Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model plus access to ongoing medication treatment with varenicline.
11527431|NCT01162239|Experimental|Extended Relapse Prevention|Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model.
11527432|NCT01162226|Experimental|training program|
11527433|NCT01162213|Experimental|100 mg of Lychee fruit extract|
11527434|NCT01162213|Experimental|200 mg of Lychee fruit extract|
11527435|NCT01162213|Experimental|600 mg of Lychee fruit extract|
11527436|NCT01162213|Experimental|2000 mg of Lychee fruit extract|
11527437|NCT01162200|Other|Stereotactic Body Radiation Therapy|SBRT dose per fraction
11527438|NCT01162174|Experimental|100 mg of Oligonol|
11527439|NCT01162174|Experimental|200 mg of Oligonol|
11527440|NCT01162174|Placebo Comparator|0 mg of Oligonol|
11527441|NCT01162161||hydrostatic pulmonary edema|patients with a pulmonary edema caused by chronic heart failure
11527442|NCT01162161||toxic pulmonary edema|patients with a pulmonary edema preceded by pneumonia
11527443|NCT01162161||control group|not ventilated patients without any pulmonary edema receiving a bronchoscopy due to another pulmonary problem (no pneumonia, no heart failure)
11527444|NCT01162148|Experimental|1|conventional
11527445|NCT01162148|Experimental|2|sham IMT
11527446|NCT01162148|Experimental|3|Conventional plus threshold IMT
11527447|NCT01162148|Experimental|4|threshold IMT alone
11527448|NCT01162135|Experimental|Open Label Pilot Study|
11527449|NCT01162122|Experimental|aTIV|Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).
11527450|NCT01162122|Experimental|Licensed TIV|Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).
11527451|NCT01162109|Placebo Comparator|Severe sepsis without zinc|Mechanically ventilated patients with severe sepsis will be randomized to receive IV zinc or placebo
11527452|NCT01162109|Experimental|Zinc in severe sepsis|Mechanically ventilated patients with severe sepsis will be randomized to receive IV zinc or placebo
11527453|NCT01162109|Experimental|Healthy Volunteers receiving zinc|Cohort of healthy volunteers will receive a single dose of 500 mcg/kg IBW IV zinc and pharmacokinetics will be measured for 8 hours. PK in sepsis patients and healthy volunteers will be compared.
11527454|NCT01162096|Experimental|Transplantation|
11527455|NCT01162083||Mitral Valve disease|Patients with mitral valve disease, deemed suitable and ready for elective valve repair or replacement. No significant arrhythmias, other valvular disease or LV dysfunction present. We shall also be recruiting patients undergoing a Mitraclip procedure.
11527456|NCT01162083||COPD|Patients with isolated chronic obstructive pulmonary disease and no cardiac disease.
11527457|NCT01162083||Mixed Lesions|Patients with proven limitation from both cardiac and respiratory disease.
11527458|NCT01162083||CRT|Patients with symptomatic heart failure who have responded to cardiac resynchronisation therapy (biventricular pacemaker).
11527509|NCT01161602|Placebo Comparator|Placebo|
11527459|NCT01162083||Cardiomyopathy|Heart Failure of primarily myopathic origin, without rhythm disturbance, ongoing ischaemia or significant valvular disease.
11527460|NCT01162070|Active Comparator|Free strategy|Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
11527461|NCT01162070|Experimental|Experimental strategy|Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
11527462|NCT01162044|No Intervention|No intervention|Subjects will be assessed, but no active intervention given
11527463|NCT01162044|Experimental|Computer game|Subjects will play with computer game while in the Emergency Room
11527464|NCT01162018|Experimental|Acupuncture Arm|
11527465|NCT01162018|Sham Comparator|Sham Acupuncture|Sham Acupuncture
11527466|NCT01162005|Experimental|Tacrolimus|Tacrobell
11527467|NCT01161979|Experimental|Zonisamide|Zonisamide Capsules 100 mg of Dr.Reddy's laboratories Limited
11527468|NCT01161979|Active Comparator|Zonegran|Zonegran Capsules 100 mg of EISAI INC
11527469|NCT01161966|Experimental|Zonisamide|Zonisamide Capsules 100 mg of Dr.Reddy's laboratories Limited
11527470|NCT01161966|Active Comparator|Zonegran|Zonegran Capsules 100 mg of EISAI INC
11527471|NCT01161940|Experimental|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited
11527472|NCT01161940|Active Comparator|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
11527473|NCT01161927|Experimental|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited
11527474|NCT01161927|Active Comparator|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
11527475|NCT01161914|Active Comparator|Cerezyme®|60 U/kg infusion (every 2 weeks for 24 weeks)
11527476|NCT01161914|Experimental|ISU302|60 U/kg infusion (every 2 weeks for 24 weeks)
11527477|NCT01161901||blood sample|
11527478|NCT01161862|Experimental|Bi-hormonal with meal-priming bolus|The first meal-priming bolus was solely based on weight (0.05 U/kg), after which meal-priming boluses were automatically adapted by the control system online targeting 75% of the anticipated insulin needed in the first four hours after the start of the meal
11527479|NCT01161862|Experimental|Bi-hormonal without meal-priming bolus|The insulin controller was entirely reactive to CGMG; there were no meal priming boluses and no meal announcements
11527480|NCT01161836|Experimental|iniparib|"Segment 1: 400 mg [14C]-iniparib single administration
~Segment 2: Iniparib, 5.6mg/kg, extension treatment with or without additional chemotherapy"
11527481|NCT01161823||Nebivolol|2,5mg or maximum 5mg per day
11527482|NCT01161823||Menoflavon|2 times 1 pill at 40mg Isoflavone per day
11527483|NCT01161810||Post-Burn Rehabilitation|Patients with an acute burn injury who are admitted to the hospital with anticipated length of stay of 5 days or greater
11527484|NCT01161784|Placebo Comparator|Nutrient drink|
11527485|NCT01161784|Experimental|Probiotics|
11527486|NCT01161771||Patients with cataract and corneal astigmatism|Patients with cataract(s) and corneal astigmatism who received surgical treatment (cataract extraction and limbal-relaxing incisions)
11527487|NCT01161758|Active Comparator|Passive cervical mobilisation|Grade III cervical mobilization technique as described by Maitland. Applied to left C5/6 Segment.
11527488|NCT01161758|Placebo Comparator|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique.
11527489|NCT01161758|No Intervention|Non-contact control|Non-contact control, which involved the subject resting in the treatment position without any physical contact between the researcher and the subject.
11527490|NCT01161732|No Intervention|Conventional treatment|In the conventional treatment group, indications for aortic valve replacement surgery are development of symptoms, reduced left ventricular systolic function and an increase in aortic jet velocity > 0.5 m/sec during follow-up.
11527491|NCT01161732|Active Comparator|Early Surgery|Early surgery is performed within 2 months of randomization.
11527492|NCT01161719|Experimental|Videoconference|Parent training through videoconference
11527493|NCT01161719|Active Comparator|Control|Parent training through face to face conference
11527494|NCT01161706|No Intervention|Control|0 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
11527495|NCT01161706|Experimental|8 fluid ounces vegetable juice|8 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
11527496|NCT01161706|Experimental|16 fluid ounces vegetable juice|16 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
11527497|NCT01161693|No Intervention|Standard pillow under head|Control (C) - Standard pillow under head (figure 1) as is the usual practice at BC Women's Hospital
11527498|NCT01161693|Active Comparator|Troop Elevation Pillow in horizontal position-HERP|TROOP® elevation pillow (designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table)
11527499|NCT01161693|Active Comparator|Troop Elevation Pillow in horizontal position-HERP-H|Operating table tilted in Trendelenberg position so angle of Troop pillow is parallel to floor (figure 3) until establishment of adequate block and then the bed levelled to horizontal i.e. to the same position as group (HERP) (figure 2)
11527500|NCT01161641|Experimental|ODSH at 0.125 mg/kg/h|First cohort of 3 subjects to be administered the lowest dose of ODSH.
11527501|NCT01161641|Experimental|ODSH at 0.250 mg/kg/h|Second cohort of 3 subjects to receive the medium dose of ODSH
11527502|NCT01161641|Experimental|ODSH at 0.375 mg/kg/h|Third and last cohort of subject to receive the high dose of ODSH.
11527503|NCT01161628|Experimental|Rituxan|All patients receive Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
11527504|NCT01161615|Placebo Comparator|Placebo|Therapy with placebo
11527505|NCT01161615|Experimental|MRX-7EAT|Therapy with experimental drug
11527506|NCT01161602|Experimental|0.2mg Pumosetrag|
11527507|NCT01161602|Experimental|0.5mg Pumosetrag|
11527508|NCT01161602|Experimental|0.8mg Pumosetrag|
11527510|NCT01161576|Experimental|Group A|The first dose cohort consists of 6 subjects who received AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies (gc) total dose. This is equal to 900,000,000,000 molecules of the drug.
11527511|NCT01161576|Experimental|Group B|The second dose cohort consists of 10 subjects, who will receive AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies (gc) total dose. This is equal to 285,000,000,000 molecules of the drug.
11527512|NCT01161563|Active Comparator|Leuprolide acetate|Polymeric matrix formulation of leuprolide acetate (Eligard 45 mg) injected subcutaneously in upper or mid-abdominal area. Injection occurred either 6 months before or 6 months after injection of triptorelin pamoate suspension (Trelstar 22.5 mg) intramuscularly in the buttock.
11527513|NCT01161563|Active Comparator|Triptorelin pamoate|Triptorelin pamoate suspension (Trelstar 22.5 mg) injected intramuscularly in the buttock. Injection occurred either 6 months before or 6 months after injection of polymeric matrix formulation of leuprolide acetate (Eligard 45 mg) subcutaneously in upper or mid-abdominal area.
11527514|NCT01161550|Experimental|Arm 1|"GCSF 300 mcg SC Days 1-6
~Cladribine 5 mg/m2 IV Days 2-6
~Cytarabine 2 mg/m2 IV Days 2-6
~ATRA 15 mg/m2 PO QD Days 7-20
~Midostaurin 25 mg PO BID Days 7-20"
11527515|NCT01161550|Experimental|Arm 2|"GCSF 300 mcg SC Days 1-6
~Cladribine 5 mg/m2 IV Days 2-6
~Cytarabine 2 mg/m2 IV Days 2-6
~ATRA 15 mg/m2 PO QD Days 7-20
~Midostaurin 50 mg PO BID Days 7-20"
11527516|NCT01161537|Experimental|VX-770|"Part A: Subjects received placebo tablets matched to VX-770 150 milligram (mg) orally twice daily from Day 1 to 14 (Placebo run-in period), followed by VX-770 150 mg tablets orally twice daily from Day 15 to 42 (VX-770 treatment period), and then placebo tablets matched to VX-770 150 mg orally twice daily from Day 43 to 57 (Placebo washout period) during Part A of the study.
~Part B: Subjects received VX-770 150 mg tablets orally twice daily for 48 weeks during Part B of the study. Part B included subjects from Part A and newly enrolled subjects."
11527517|NCT01161524|Experimental|Perampenal (Core Study)|Participants received perampanel 2 mg per day and up-titrated weekly in 2-mg increments to a target dose range of 8 to 12 mg per day.
11527518|NCT01161524|Placebo Comparator|Placebo (Core Study)|Participants received matching placebo tablets once a day (6 tablets of placebo).
11527519|NCT01161524|Experimental|Perampanel (Extension Phase)|During the Extension Phase, participants previously assigned to perampanel arm (Core Study) continued taking study medication at the dose achieved at the end of the Core Study once daily. Participants previously assigned to a placebo arm (Core Study) started perampanel dose at 2 mg/day and up-titrated weekly in 2-mg increments up to a maximum dose of 12 mg/day.
11527520|NCT01161511|Experimental|1|XmAb5574
11527521|NCT01161498|Active Comparator|Radiation/Cisplatin|Participants received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42. Radiation was administered concurrently with cisplatin in 35 fractions over a 7-week period.
11527522|NCT01161498|Experimental|Talimogene Laherparepvec + Radiation/Cisplatin|The first dose of talimogene laherparepvec was up to 8 mL total volume (up to 4 mL per lesion) at 10⁶ plaque-forming units (PFU)/mL, administered into all injectable affected nodes on Day 0. Subsequent doses were up to 8 mL total volume (up to 4 mL per lesion) at 10⁸ PFU/mL on Days 21, 42, and 63. Participants also received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42 and radiation administered concurrently in 35 fractions over a 7-week period.
11527523|NCT01161485|Active Comparator|HIV Testing and Counseling|HIV Testing and Counseling
11527524|NCT01161485|Active Comparator|Contingency Management (CM)|Contingency management is based on Skinner's principles of operant conditioning in behavioral psychology, dating back to the 1930s (Skinner 1938). The basis of this model is that behavior is learned and reinforced by environmental contingencies that reward or punish.
11527525|NCT01161485|Experimental|CM with Strengths-based case management|Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community.
11527526|NCT01161472|Experimental|4mg fesoterodine|
11527527|NCT01161472|Experimental|fesoterodine 8mg|
11527528|NCT01161472|Active Comparator|1mg alprazolam|
11527529|NCT01161472|Placebo Comparator|Placebo|
11527530|NCT01161459|Experimental|Tripterygium wilfordii|120mg/d for 6 months,then decrease to 60mg/d by 30mg/d every month for 12 months
11527531|NCT01161459|Active Comparator|FK506|
11527532|NCT01161446|Experimental|Home Testing|
11527533|NCT01161446|No Intervention|Standard Testing|
11527534|NCT01161433|Experimental|Intervention|Virtually delivered spirometry quality improvement program
11527535|NCT01161433|No Intervention|Standard of Care|
11527536|NCT01161420|Experimental|Inspire Therapy|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
11527537|NCT01161407|Placebo Comparator|Placebo|Placebo control for calcium carbonate, given in same capsule form as the calcium carbonate, 3 times per day with meals.
11527538|NCT01161407|Active Comparator|Calcium Carbonate (Phosphate Binder)|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium.
11527539|NCT01161394|Experimental|Pioglitazone 15mg|8 patient will receive this drug
11527540|NCT01161394|Experimental|pioglitazone 30mg|8 patients will get this drug
11527541|NCT01161394|Placebo Comparator|Placebo|8 patient will get this drug
11527542|NCT01161381||Normal|Subjects that underwent night polysomnography with an observed Apnea-Hypopnea Index (AHI) < 5.
11527543|NCT01161381||OSAHS patients|Subjects that underwent night polysomnography with an observed Apnea-Hypopnea Index (AHI) > 5.
11527544|NCT01161368|Experimental|lapatinib, vinorelbine|"Drug: Lapatinib, Vinorelbine Lapatinib 1250mg orally once daily continuously
~plus
~Vinorelbine 20 mg/m2 intravenously (IV) once weekly [Days 1 and 8] for 2 weeks, followed by a rest week in a 3-week cycle."
11527545|NCT01161355|Experimental|AZD9668|Tablets and intravenous (IV) dose
11527546|NCT01161329|No Intervention|Control group|Participants in the control group are instructed to live their ordinary life.
11529259|NCT01149369|Active Comparator|Aprepitant|Aprepitant 125 mg per day
11527547|NCT01161329|Experimental|Intervention group|Exercising two times/week according to the High-Intensity Functional Exercise Program (HIFE) in groups of 5-7 patients in combination with motivational discussions.
11527548|NCT01161316|Active Comparator|Control|mFOLFOX-6 + cetuximab until disease progression or early withdrawal.
11527549|NCT01161316|Experimental|Experimental|8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.
11527550|NCT01161277|Active Comparator|aripiprazole|
11527551|NCT01161277|Active Comparator|haloperidol|
11527552|NCT01161277|Placebo Comparator|suger pill|
11527553|NCT01161264|Experimental|18-60 YOA|
11527554|NCT01161264|Experimental|≥ 60 YOA|
11527555|NCT01161251||Atrial fibrillation patients|Non-valvular atrial fibrillation (paroxysmal, persistent or permanent)
11527556|NCT01161238||Lower-limb amputee|Subjects with at least one lower limb amputated at the trans-tibial level
11527557|NCT01161225|Experimental|peer-led asthma self-managment program|
11527558|NCT01161225|Active Comparator|Adult-led asthma self-management program|
11527559|NCT01161212|Other|Control group|
11527560|NCT01161212|Other|Intervention group|
11527561|NCT01161199||Untreated non-controllers|
11527562|NCT01161199||Elite controllers|
11527563|NCT01161199||HAART-suppressed|
11527564|NCT01161186|Experimental|Nab-paclitaxel,Gemcitabine, and Capecitabine|
11527565|NCT01161173||Erlotinib|Participants received erlotinib (Tarceva) at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics. The recommended daily dose of erlotinib is 150 mg orally once daily.
11527566|NCT01161160|Experimental|AREPANRIX 1/2 GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 half (1/2) pediatric dose of Arepanrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
11527567|NCT01161160|Experimental|PANDEMRIX 1/2 GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 half (1/2) pediatric dose of Pandemrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
11527568|NCT01161160|Experimental|AREPANRIX GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 pediatric dose of Arepanrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
11527569|NCT01161147|Experimental|Meloxicam|Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited
11527570|NCT01161147|Active Comparator|Mobic|Mobic Tablets 15 mg of Boehringer Ingelheim Pharmaceuticals Inc
11527571|NCT01161134|Experimental|Meloxicam|Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited
11527572|NCT01161134|Active Comparator|Mobic|Mobic Tablets 15 mg of Boehringer Ingelheim Pharmaceuticals Inc
11527573|NCT01161121|Experimental|Adenosine then Regadenoson|Adenosine infusion will be compared to Regadenoson for efficacy and safety/side effects. Arterial blood pressure, coronary pressure, heart rate, oxygen saturation and coronary flow, FFR, and coronary flow velocity will be assessed. Safety will be assessed by monitoring for any side effects such as chest pain, headache, flushing, nausea, or arrhythmias. Adenosine infusion will be administered at 140 mcg/kg for 2 minutes and once mean coronary flow velocity returns to within 15% of pre-dose value, Regadenoson IV bolus 0.4 mg/5 ml will be administered followed by a 5 cc normal saline flush.
11527574|NCT01161108|Active Comparator|Group A: Fast Release Melatonin|"Subjects will be randomized to one of the two treatment arms and to the order of study medication v.s. placebo.
~The subject will undergo the assigned treatment for 7 weeks (3 weeks of study drug, a one week wash-out and 3 weeks of placebo, or vice versa)."
11527575|NCT01161108|Active Comparator|Group B: Timed Release Melatonin|"Subjects will be randomized to one of the two treatment arms and to the order of study medication v.s. placebo.
~The subject will undergo the assigned treatment for 7 weeks (3 weeks of study drug, a one week wash-out and 3 weeks of placebo, or vice versa)."
11527576|NCT01161095|Experimental|Immediate|LNG-IUS insertion within the timeframe of delivery of the placenta to 72 hours postpartum
11527577|NCT01161095|Active Comparator|Interval|LNG-IUS insertion after 6 weeks postpartum
11527578|NCT01161082|Experimental|Group 1 with atorvastatin|Dose 1 versus placebo
11527579|NCT01161082|Experimental|Group 2 with atorvastatin|Dose 1 versus placebo
11527580|NCT01161082|Experimental|Group 3 with atorvastatin|Dose 2 versus placebo
11527581|NCT01161082|Experimental|Group 4 with atorvastatin|Dose 2 versus placebo
11527582|NCT01161082|Experimental|Group 5 with atorvastatin|Dose 3 versus placebo
11527583|NCT01161082|Experimental|Group 6 with atorvastatin|Dose 3 versus placebo
11527584|NCT01161082|Experimental|Group 7 without atorvastatin|Dose 3 versus placebo
11527585|NCT01161082|Experimental|Group 8 with atorvastatin|Dose4 versus placebo
11527586|NCT01161069|Active Comparator|PF-03049423|Cohorts 1 through 3 were healthy young adult volunteers; cohorts 4 and 5 were healthy elderly adult volunteers
11527587|NCT01161069|Placebo Comparator|Drug|Placebo in oral solution, given once daily for 14 days
11527588|NCT01161056||Healthy Control Group|
11527589|NCT01161043|Experimental|Sensor|All subjects that wear sensors (all subjects)
11527590|NCT01161030|Experimental|almonds|1-oz raw almonds: 173 kcal, 4.6 g carbohydrate, 14.6 g fat
11527591|NCT01161030|Placebo Comparator|Control|cheese stick
11527592|NCT01161017|Active Comparator|1 Amitriptyline.|Amitriptyline
11527593|NCT01161017|Active Comparator|2 Topiramate|Topiramate
11527594|NCT01161004|Experimental|Sugammadex - Nacl 9/00|"Sugammadex - Nacl 9/00:
~Patients will first receive sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.
~In case of complete reversal of myorelaxation, total intravenous anesthesia is stopped and patients are allowed to awake.
~In the adverse case, patients wil receive Nacl 9/00 5 minutes after the first bolus of sugammadex.
~The study is finished 5 minutes after this second injection and care is let to the choice of the anesthesiologist in charge."
11527644|NCT01160640|Placebo Comparator|Ceftriaxone/Doxycycline/Placebo Oral Cap|ceftrixone 250mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus placebo oral capsule PO bid x 14 days
11527692|NCT01160237|Experimental|Group A|Subjects previously vaccinated with a vaccine against the pandemic H1N1 strain
11527595|NCT01161004|Experimental|Nacl 9/00 - sugammadex|"Nacl 9/00 - Sugammadex :
~Patients wil first receive Nacl 9/00. In case of complete reversal of myorelaxation, total intravenous anesthesia is stopped and patients are allowed to awake.
~In the adverse case, patients wil receive sugammadex 5 minutes after the first bolus of Nacl 9/00.
~Sugammadex is given as: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.
~The study is finished 5 minutes after the injection of sugammadex and care is let to the choice of the anesthesiologist in charge."
11527596|NCT01160991|Active Comparator|Amisulpride|Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.
11527597|NCT01160991|Experimental|Olanzapine|Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.
11527598|NCT01160991|Placebo Comparator|Placebo|Placebo capsules are given at 8:00 a.m. Procedures are performed as described above.
11527599|NCT01160978|Active Comparator|Simvastatin 80 mg group|The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
11527600|NCT01160978|Experimental|Control Rx|The transplant recipients who have received an organ from non-treated donors.
11527601|NCT01160965|Active Comparator|0.5% levobupivacaine|Participants given 15mls of 0.5% levobupivacaine as the solution for their epidural top-up
11527602|NCT01160965|Active Comparator|0.75% Rpoivacaine|Participants given 15mls of 0.75% ropivacaine as the solution for their epidural top-up.
11527603|NCT01160952|Other|long-term group|long-term group refers to prophylaxis by using itraconazole for up to 90 days
11527604|NCT01160952|Other|short term group|short term group refers to prophylaxis by itraconazole for 30 days
11527605|NCT01160926|Experimental|AZD6244 + capecitabine + radiotherapy|10 days single-agent dosing AZD6244 Then 35 days dosing of AZD6244 in combination with standard chemoradiotherapy
11527606|NCT01160926|Experimental|Cediranib + capecitabine + radiotherapy|10 days single agent dosing with Cediranib (AZD2171) then 35 days dosing of AZD2171 in combination with standard chemoradiotherapy
11527607|NCT01160913|Active Comparator|Continuous wound infusion above the fascia|
11527608|NCT01160913|Active Comparator|Continuous wound infusion below the fascia|
11527609|NCT01160900|Experimental|multivessel revascularization|Complete Revascularization : the Infarcted related artery was opened followed by dilatation of other significantly narrowed arteries during the same procedure
11527610|NCT01160887||Patients with diabetic peripheral neuropathy|
11527611|NCT01160887||Healthy matched controls|
11527612|NCT01160874|Experimental|TDA/H|
11527613|NCT01160874|Other|Sleep apnea patient|
11527614|NCT01160874|Other|Healthy volunteer|
11527615|NCT01160861|Experimental|A|
11527616|NCT01160861|Experimental|B|
11527617|NCT01160861|Experimental|C|
11527618|NCT01160848|Other|Part 1|Three areas will be randomized to either a pre-treatment cleaning using a wipe containing an ethyl alcohol solution(one area) or a cleansing wipe containing saline water (two areas), before application of the Visonac cream. One of the areas cleaned with saline wipe will also be occluded with a transparent dressing (Tegaderm) during the incubation time. In vivo fluorescence spectroscopy will be performed in the three areas before cream application, and at 1h, 1.5h, 2h, 2.5h and 3 h after cream application
11527619|NCT01160848|Other|Part 2|For each patient, 3 areas were randomized to treatment with Visonac for 24 hours (2 areas) or Visonac for 1 hour (1 area)
11527620|NCT01160835|Experimental|Quadriceps-sparing total knee arthroplasty|Quadriceps-sparing arthrotomy with side-cutting instruments
11527621|NCT01160835|Active Comparator|Medial parapatellar total knee arthroplasty|Medial parapatellar arthrotomy with front-cutting instruments
11527622|NCT01160822|Experimental|Part A: Canakinumab|In this ascending dose part, participants received a single intra-articular injection of canakinumab. The beginning dose was 150 mg, escalating to the 300 mg dose and then to 600 mg.
11527623|NCT01160822|Placebo Comparator|Part A: Placebo|Participants received a single intra-articular injection of canakinumab-matching placebo.
11527624|NCT01160822|Experimental|Part B: Canakinumab|Participants received a single intra-articular injection of canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.
11527625|NCT01160822|Placebo Comparator|Part B: Placebo|Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.
11527626|NCT01160822|Active Comparator|Part B: Naproxen|Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.
11527627|NCT01160809|Experimental|Mosquito repellent and LLINs group vs. LLINs group only|This study is based on two population groups: 1) a group of households that use LLINs alone (control) and 2) a group of households that use both mosquito repellent and LLINs (repellent group).
11527628|NCT01160796|Experimental|Lcr35®|
11527629|NCT01160796|Placebo Comparator|placebo|
11527630|NCT01160770|Experimental|Clobazam|
11527631|NCT01160757|Other|ultrasound|
11527632|NCT01160744|Experimental|IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin|IMC-1121B + Pemetrexed + Carboplatin [Area Under the Concentration Time Curve 6 (AUC 6)] or Cisplatin
11527633|NCT01160744|Active Comparator|Pemetrexed + Carboplatin (AUC 6) or Cisplatin|Pemetrexed + Carboplatin (AUC 6) or Cisplatin
11527634|NCT01160744|Experimental|IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin|IMC-1121B + Gemcitabine + Carboplatin [Area Under the Concentration Time Curve 5 (AUC 5)] or Cisplatin
11527635|NCT01160744|Active Comparator|Gemcitabine + Carboplatin (AUC 5) or Cisplatin|Gemcitabine + Carboplatin (AUC 5) or Cisplatin
11527636|NCT01160731|Experimental|Cisplatin, Etoposide & Panobinostat|
11527637|NCT01160718|Active Comparator|Arm A: Fulvestrant / AZD6244|Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days AZD6244 75 mg p.o. bid
11527638|NCT01160718|Placebo Comparator|Arm B: Fulvestrant / Placebo|Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Placebo 3 caps p.o. bid (same appearance as AZD6244)
11527639|NCT01160692|Experimental|Arm 1|
11527640|NCT01160692|Placebo Comparator|Arm 2|
11527641|NCT01160666|Experimental|1: Belilumab|
11527642|NCT01160653|Experimental|1|Gait training and Cognitive Training
11527643|NCT01160653|No Intervention|2|Able Bodied
11527690|NCT01160263|Other|patients with pyramidal stiffness|
11527645|NCT01160640|Active Comparator|Ceftriaxone, Doxycycline, Metronidazole|ceftriaxone 250 mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus metronidazole 500 mg PO bid x 14 days
11527646|NCT01160627|Active Comparator|Standard treatment|Hydration
11527647|NCT01160627|Active Comparator|Combined Acetylcystein and Sodium Bicarbonat|
11527648|NCT01160627|Active Comparator|Sodium Bicarbonate|
11527649|NCT01160627|Active Comparator|Acetylcystein for 2 days|Standard treatment + acetylcystein for 2 days
11527650|NCT01160614|Experimental|ORF Tablets|ORF Tablets
11527651|NCT01160601|Experimental|paclitaxel/carboplatin plus bavituximab|Patients will receive paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve [AUC] 6) on Day 1 of each 21 day cycle for up to 6 cycles, in combination with 3 mg/kg bavituximab administered weekly.
11527652|NCT01160601|Active Comparator|paclitaxel/carboplatin|Patients will receive paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve [AUC] 6) on Day 1 of each 21 day cycle for up to 6 cycles.
11527653|NCT01160588||Sertraline treatment|Participants with Generalized Anxiety Disorder, and/or Social Anxiety Disorder, and/or Separation Anxiety Disorder will undergo MRI scanning, EEG's, and sertraline treatment.
11527654|NCT01160588||Healthy Controls|Healthy control participants will undergo MRI scanning and EEG's.
11527655|NCT01160588||Cognitive Behavioral Therapy|Participants with Generalized Anxiety Disorder, and/or Social Anxiety Disorder, and/or Separation Anxiety Disorder will undergo MRI scanning, EEG's, and talk therapy (CBT).
11527656|NCT01160549||Cases|Women living in rural environments
11527657|NCT01160549||Controls|Women living in more urban environments
11527658|NCT01160510||Women undergoing mammography|women undergoing mammography at the UVM Breast Cancer Surveillance Consortium site
11527659|NCT01160484|Experimental|DVD-R single arm|"Dose schematic of Dexamethasone + Bortezomib + Pegylated Liposomal Doxorubicin + Lenalidomide (DVD-R) Therapy:
~Dexamethasone*- 40 mg IV Bortezomib**- 1.0 mg/m2 IV Push Pegylated Liposomal Doxorubicin*- 4.0 mg/m2 IV Lenalidomide***- 10 mg PO
~Per 28 Day Cycle
~Intravenous infusion (IV) Days 1, 4, 8 and 11 ** Intravenous push (IVP) Days 1, 4, 8 and 11 *** Per Orem (PO) Days 1-14"
11527660|NCT01160471||Healthy Volunteers|Adult men and women without a clinical diagnosis of heart failure
11527661|NCT01160471||Patients|Adult men and women with a clinical diagnosis of heart failure
11527662|NCT01160458|Experimental|IMC-A12 Monotherapy in Patients|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
11527663|NCT01160445|Experimental|HD IL-2 + Zanolimumab - Melanoma|"Patients with metastatic melanoma Zanolimumab 14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.
~Aldesleukin (IL-2) 720,000 IU/kg every 8 hours for a maximum of 15 doses."
11527664|NCT01160445|Experimental|HD IL-2 + Zanolimumab - Renal Cell|"Patients with metastatic renal cancer Zanolimumab 14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.
~Aldesleukin (IL-2) 720,000 IU/kg every 8 hours for a maximum of 15 doses."
11527665|NCT01160432|Experimental|Methadone naloxone combination product 2/0,04 mg/ml|Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml
11527666|NCT01160432|Active Comparator|Methadone 2 mg/ml|Normal treatment except the dilution of methadone solution (5 mg/ml → 2 mg/ml).
11527667|NCT01160419|Other|FLOT|Docetaxel, Oxaliplatin, Folinic acid, 5-FU, q 2 weeks, application of 6 cycles
11527668|NCT01160406||ischemic stroke, no atrial fibrillation|Patients who have suffered ischemic stroke or transient ischemic attack without known atrial fibrillation
11527669|NCT01160393|Other|Miniaturized bypass system|Miniaturized bypass system and the incidence of atrial fibrillation after cardiac surgery
11527670|NCT01160380|Experimental|Armodafinil|The patients receive armodafinil for all 56 days of the study.
11527671|NCT01160380|Placebo Comparator|Placebo-First|These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
11527672|NCT01160367|Active Comparator|standard of care health decision making|Patient-family dyads will receive the standard of care for support of patient and family members health care decision making during a clinic appointment.
11527673|NCT01160367|Experimental|TAILORED intervention|Patients and family members who receive the TAILORED Decision Making Intervention
11527674|NCT01160354|Experimental|Plerixafor 240 mcg/kg + Clofarabine|"Plerixafor 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before hour IV administration of Clofarabine fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).
~Phase II: Plerixafor at the highest dose tolerated in Phase I.
~Plerixafor was dose-escalated in a 3+3 design, starting at 240 mcg/kg, and proceeding to dose levels of 320 mcg/kg, and 400 mcg/kg."
11527675|NCT01160341|Experimental|Testosteron, secondary hypogonadism|
11527676|NCT01160328|No Intervention|Control Group|Participants in this group will not receive any treatment.
11527677|NCT01160328|Experimental|Lupron Group|Participants in this group will receive leuprolide acetate (Lupron) treatment for 7 weeks resulting in temporary decreases in testosterone levels.
11527678|NCT01160328|Other|Lupron & Testosterone Group|Participants in this group will receive 7 weeks of leuprolide acetate (Lupron) treatment with testosterone gel (Androgel).
11527679|NCT01160315|Experimental|Arm A (GnRha arm)|IM injection of Triptorelin -Decapeptyl PR 11.25mg- (every 3 months) and Norethisterone acetate- Primolut-Nor 5 mg- per os continuously until the end of the chemotherapy
11527680|NCT01160315|Active Comparator|Arm B (control Arm)|Norethisterone acetate alone, 5mg par day, (ARM B) until the end of the chemotherapy.
11527681|NCT01160302|Experimental|Microgranular Curcumin|Consume 4g microgranular curcumin (Curcumin C3 Complex) twice per day
11527682|NCT01160289|Experimental|1 milligram (mg) LY2452473 + 5 mg tadalafil|
11527683|NCT01160289|Experimental|5 mg LY2452473 + 5 mg tadalafil|
11527684|NCT01160289|Experimental|5 mg LY2452473 + placebo|
11527685|NCT01160289|Active Comparator|10 mg tadalafil + placebo|
11527686|NCT01160289|Active Comparator|5 mg tadalafil + placebo|
11527687|NCT01160276|Active Comparator|Cyclosporine|The first group is composed of 14 renal graft recipients under cyclosporine
11527688|NCT01160276|Active Comparator|Tacrolimus|The second group is composed of 14 renal graft recipients under tacrolimus
11527689|NCT01160263|Other|patients without stiffness|
11527693|NCT01160237|Experimental|Group B|Subjects previously vaccinated with a vaccine against the pandemic H1N1 strain
11527694|NCT01160237|Active Comparator|Group C|Subjects not previously vaccinated with a vaccine against the pandemic H1N1 strain
11527695|NCT01160224|Active Comparator|GW766944|This is the active drug (GW766944)
11527696|NCT01160224|Placebo Comparator|Placebo|Placebo Arm.
11527697|NCT01160211|Experimental|Lapatinib plus trastuzumab plus aromatase inhibitor|Experimental
11527698|NCT01160211|Active Comparator|trastuzmab plus aromatase inhibitor|Active Comparator
11527699|NCT01160211|Active Comparator|lapatinib plus aromatase inhibitor|Active Comparator
11527700|NCT01160198|Experimental|ferrous bisglycinate chelate 1 OD|ferrous bisglycinate chelate 1 tablet daily
11527701|NCT01160198|Active Comparator|ferrous ascorbate|ferrous ascorbate, 1 tablet daily
11527702|NCT01160198|Experimental|ferrous bisglycinate chelate 2 OD|ferrous bisglycinate chelate 2 tablets daily
11527703|NCT01160185||cisplatin|
11527704|NCT01160185||cisplatin + topotecan|
11527705|NCT01160185||cisplatin + paclitaxel|
11527706|NCT01160172|Experimental|Group A|
11527707|NCT01160172|Experimental|Group B|
11527708|NCT01160172|Experimental|Group C|
11527709|NCT01160172|Experimental|Group D|
11527710|NCT01160172|Placebo Comparator|Group E|
11527711|NCT01160172|Placebo Comparator|Group F|
11527712|NCT01160159||Thrombophilia|
11527713|NCT01160159||Healthy volunteers|
11527714|NCT01160146||Lifestyle counseling|"Clinicians provide lifestyle management counseling regarding healthful lifestyle behaviors and daily physical activity.
~Logging foods for accountability and counting calories
~Close attention to portion control and appropriate serving sizes of foods consumed
~Consumption of appropriate calorie and sugar free beverages
~Good meal distribution and avoidance of meal skipping
~Balance of food groups using the MyPlate concept (USDA Choose My Plate)-inclusion of all food groups with emphasis on fruits, vegetables, whole grains, low-fat dairy products and lean meat/fish/poultry
~Increasing physical activity with reasonable, sustainable exercise or activity. Working toward a goal of at least 30 minutes, 5 days per week"
11527715|NCT01160133|Experimental|Systane|Systane Lubricant Eye Drops
11527716|NCT01160133|Experimental|Refresh Tears|Refresh Tears Lubricant Eye Drops
11527717|NCT01160120|Other|1|Patients can be either treatment-naïve or treatment-experienced when entering this clinical trial. After meeting the inclusion and exclusion criteria, patients will start with generic FDC of TDF/3TC/EFV 1 pill a day at night time. Only patient who are on individual TDF 3TC and EFV will undergo TDM sampling ( 11-13 hours after dosing) at baseline.
11527718|NCT01160107|Experimental|RP followed MPR|
11527719|NCT01160094||Patients|ErbB2+ metastatic breast cancer patients
11527720|NCT01160081||National Health and Nutrition Survey 2006 (ENSANUT 2006)|
11527721|NCT01160068|Experimental|Metformin|Metformin Hydrochloride 1000 mg tablets of Dr. Reddy's Laboratories Limited
11527722|NCT01160068|Active Comparator|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
11527723|NCT01160055||Cohort A|Subjects with a new episode of Acute Otitis Media (<3 days of onset) who have not yet received antibiotic therapy for the episode.
11527724|NCT01160055||Cohort B|Subjects who have had a diagnosis of Acute Otitis Media within 2-3 days prior to study enrolment and received antibiotic therapy, but remain symptomatic.
11527725|NCT01160042|Experimental|Metformin|Metformin Hydrochloride 1000 mg tablets of Dr. Reddy's Laboratories Limited
11527726|NCT01160042|Active Comparator|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
11527727|NCT01160029|Experimental|Nateglinide|Nateglinide Tablets 120 mg of Dr. Reddys Laboratories Limited
11527728|NCT01160029|Active Comparator|Starlix|Starlix Tablets 120 mg of Novartis
11527729|NCT01160003|Experimental|Treatment Period 1|5mg of GW870086X or placebo will be given once daily for 14 days.
11527730|NCT01160003|Experimental|Treatment Period 2|GW870086X (5mg or 8.75mg) or placebo will be given once daily for 14 days. In a randomised dose escalating manor following on from treatment period 1.
11527731|NCT01160003|Experimental|Treatment Period 3|8.75mg of GW870086X or placebo will be given once daily for 14 days.
11527732|NCT01159990|Experimental|Recombinant adenovirus serotype 5 (rAd5) Gag/Pol Env A/B/C|Participants will receive one intramuscular injection of rAd5 Gag/Pol Env A/B/C.
11527733|NCT01159990|Active Comparator|rAd5 gag/pol|Participants will receive one intramuscular injection of rAd5 gag/pol.
11527734|NCT01159977|Experimental|Facilitated small group|Facilitated small groups.
11527735|NCT01159977|Active Comparator|Unstructured protected time|Same time provided as for facilitated small groups, but without structure.
11527736|NCT01159977|Placebo Comparator|Usual practice|No protected time.
11527737|NCT01159964|Experimental|Cohort 1|Subjects will receive investigational dose-level A (different from dose-levels B and C). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
11527738|NCT01159964|Experimental|Cohort 2|Subjects will receive investigational dose-level B (different from dose-levels A and C). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
11527739|NCT01159964|Experimental|Cohort 3|Subjects will receive investigational dose-level C (different from dose-levels A and B). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
11527740|NCT01159951||Hepatitis Cohort|Subjects suffering with hepatitis
11527741|NCT01159938|Experimental|T2DM, albuminuria but normal kidney function|
11527742|NCT01159938|No Intervention|Healthy participants|
11527743|NCT01159938|Experimental|T2DM, normal urinary albumin excretion rate (UAER)|
11527744|NCT01159925||Possible hepatitis A Cohort|Children with an acute disease characterized by discrete onset of symptoms and jaundice
11527745|NCT01159925||Probable hepatitis A Cohort|Children with an increase in serum levels of transaminase 2.5 times higher than the maximum limit of the normal interval
11527746|NCT01159925||Confirmed hepatitis A Cohort|Children presenting a positive result for Immunoglobulin M for hepatitis A virus
11527747|NCT01159912|Experimental|Fluticasone Furoate OD and Placebo BID|Fluticasone furoate inhalation powder once daily and placebo inhalation powder twice daily for 24 weeks
11527846|NCT01159145|Experimental|D961H 10 mg capsule|2 way crossover
11527748|NCT01159912|Active Comparator|Fluticasone Propionate BID and Placebo OD|Fluticasone propionate inhalation powder twice daily and placebo inhalation powder once daily for 24 weeks
11527749|NCT01159912|Placebo Comparator|Placebo only BID|Placebo inhalation powder twice daily for 24 weeks
11527750|NCT01159886|Active Comparator|left lateral|After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus position. Then terminal ileal intubation will be attempted.
11527751|NCT01159886|Active Comparator|supine|After confirmation of cecal intubation, patient will undergo randomization to the supine position. Then terminal ileal intubation will be attempted.
11527752|NCT01159873|Experimental|CEP-37251|
11527753|NCT01159873|Placebo Comparator|Placebo|
11527754|NCT01159860|Active Comparator|Cryosurgery|One lesion on the patients' trunk or proximal extremities will be treated with cryosurgery.
11527755|NCT01159860|Active Comparator|Curettage|One lesion on one side of the patients' trunk or proximal extremities will be treated by curettage.
11527756|NCT01159847|Experimental|Sitagliptin|Patients will receive insulin therapy with sitagliptin.
11527757|NCT01159847|Active Comparator|Insulin|Patients will receive insulin therapy without sitagliptin.
11527758|NCT01159834||Gardasil, HPV infection|
11527759|NCT01159821|Experimental|001|31001074/paroxetine 1 tablet of 31001074 will be administered on Day 1 and Day 13. One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
11527760|NCT01159808|Experimental|INX-08189|
11527761|NCT01159808|Placebo Comparator|Placebo|
11527762|NCT01159782|Other|Asthma, Healthy|Asthmatics or Healthy Volunteers
11527763|NCT01159769|Experimental|Olopatadine 0.2%|1 drop self-administered in each eye once daily in the morning for 7 days
11527764|NCT01159756|Experimental|Travacom|Travacom ophthalmic solution
11527765|NCT01159743||Efavirenz|HIV-infected patients on initial antiretroviral therapy for at least two years with efavirenz (Sustiva®; EFV) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
11527766|NCT01159743||Lopinavir / Ritonavir|HIV-infected patients on initial antiretroviral therapy for at least two years with lopinavir/ritonavir (Kaletra®; LPV/r) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
11527767|NCT01159730|Experimental|Multiple doses of VB-201|
11527768|NCT01159730|Placebo Comparator|Placebo|
11527769|NCT01159704|Experimental|Network plus HIV Counseling&Education|"Social network peer education model plus HIV testing and counseling; the C & E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
11527770|NCT01159704|Active Comparator|HIV Counseling and Education (C&E) only|"HIV testing and counseling C&E; the C & E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
11527771|NCT01159691||Neupro|Routine treatment as per approved label in Europe/ in accordance with the terms of the local marketing authorization for Neupro® transdermal patch.
11527772|NCT01159678|Experimental|online psychoeducation|
11527773|NCT01159665|Experimental|PPV 5-30 minutes after injection|Primary Pars Plana Vitrectomy 5 to 30 minutes after 125µg of ocriplasmin intravitreal injection
11527774|NCT01159665|Experimental|PPV 31-60 minutes after injection|Primary Pars Plana Vitrectomy 31 to 60 minutes after 125µg of ocriplasmin intravitreal injection
11527775|NCT01159665|Experimental|PPV 2-4 hours after injection|Primary Pars Plana Vitrectomy 2 to 4 hours after 125µg of ocriplasmin intravitreal injection
11527776|NCT01159665|Experimental|PPV 24 hours (+2 hours) after injection|Primary Pars Plana Vitrectomy 24 hours (+2 hours)after 125µg of ocriplasmin intravitreal injection
11527777|NCT01159665|Experimental|PPV 7 days (+1 day) after injection|Primary Pars Plana Vitrectomy 7 days (+1 day)after 125µg of ocriplasmin intravitreal injection
11527778|NCT01159665|No Intervention|PPV without injection|Control Arm, no ocriplasmin intravitreal injection
11527779|NCT01159652|Placebo Comparator|Bedtime Placebo|
11527780|NCT01159652|Placebo Comparator|Middle of the Night Placebo|
11527781|NCT01159652|Experimental|Zolpidem|
11527782|NCT01159652|Experimental|Zaleplon|
11527783|NCT01159639|No Intervention|aspirin low responders monotherapy|patients with inappropriate response to aspirin assessed by multiple electrode aggregometry
11527784|NCT01159639|Active Comparator|aspirin low responders dual antiplatelet therapy|patients with inappropriate response to aspirin 300 mg therapy after CABG, randomized to receive clopidogrel 75 mg in addition to aspirin
11527785|NCT01159626|Experimental|Single dose|
11527786|NCT01159626|Experimental|Multiple dose|
11527787|NCT01159613||Non Responders|Non Responders
11527788|NCT01159613||RESPONDERS|
11527789|NCT01159600|Experimental|BI 10773 Arm 2|BI 10773 once daily high dose
11527790|NCT01159600|Placebo Comparator|Placebo|Placebo matching BI 10773
11527791|NCT01159600|Experimental|BI 10773 open-label|BI 10773 once daily high dose open label
11527792|NCT01159600|Experimental|BI 10773 Arm 1|BI 10773 once daily low dose
11527793|NCT01159587||Group 1|
11527794|NCT01159587||Group 2|
11527795|NCT01159574|Experimental|all patients|"ClaPd therapy:
~Dexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.
~Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day."
11527796|NCT01159561|Experimental|Vaccinated|Western Equine Encephalitis Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, administered in 0.5 mL doses subcutaneously in the upper outer aspect of the triceps in a 3-dose primary series (Days 0, 7, and 28) with a mandatory boost (Day 180)
11527797|NCT01159548|No Intervention|Saline|
11527798|NCT01159548|Other|Promethazine 6.25 mg|
11527799|NCT01159548|Other|Promethazine 3 mg|
11527847|NCT01159145|Experimental|Omeprazole 10 mg tablet|2 way crossover
11527848|NCT01159132|Active Comparator|1|RAL 400 mg OD
11527849|NCT01159132|Active Comparator|2|RAL 800 mg OD
11527850|NCT01159119|Experimental|EUR-1066-A|Treatment with Eur-1006-A.
11527851|NCT01159119|Experimental|EUR-1066-B|Treatment with Eur-1066-B
11527800|NCT01159535|Active Comparator|MBRP|The Mindfulness Based Relapse Prevention (MBRP) intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants). Individual sessions will be team-taught by two therapists and will include mindfulness practices targeting craving, Negative affect, and reactivity, as well as discussion about how to implement practice into high-risk situations and in daily life.
11527801|NCT01159535|Active Comparator|Relapse Prevention (RP)|The RP intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants). Individual sessions will be team-taught by two therapists and will include discussions of personal high-risk situations, coping skills assessment, and exercises to evaluate expectancies, self-efficacy, and craving.
11527802|NCT01159535|Active Comparator|Treatment as Usual|All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
11527803|NCT01159522|Experimental|SCB01A|This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
11527804|NCT01159509||Infants ages -13 years that had HPS in infancy|
11527805|NCT01159496|Experimental|Active|
11527806|NCT01159496|Placebo Comparator|Placebo|
11527807|NCT01159483|Experimental|Cohort A|"Period 1: Participants received 0.01 milligrams (mg) of PF-04958242 or matching placebo, once, orally.
~Period 2: Participants received 0.03 mg of PF-04958242 or matching placebo, once, orally.
~Period 3: Participants received 0.1 mg of PF-04958242 or matching placebo, once, orally."
11527808|NCT01159483|Experimental|Cohort B|"Period 1: Participants received 0.3 mg of PF-04958242 or matching placebo, once, orally (fasted).
~Period 2: Participants received 0.6 mg of PF-04958242 or matching placebo, once, orally.
~Period 3: Participants received 1.0 mg of PF-04958242 or matching placebo, once, orally (fed)."
11527809|NCT01159470||bacterial infection|children with fever due to bacterial infection
11527810|NCT01159470||viral infection|children with fever due to viral infection
11527811|NCT01159457|Active Comparator|1|celiac patients who did not respond to initial hepatitis B vaccine series , will receive Sci-B-Vac vaccination series
11527812|NCT01159457|Active Comparator|2|celiac patients who did not respond to initial hepatitis B vaccine series , will receive Engerix 3-dose vaccination series
11527813|NCT01159431|Experimental|Active|
11527814|NCT01159431|Other|Control|
11527815|NCT01159418|Experimental|Panobinostat (LBH589), Carboplatin and Paclitaxel|
11527816|NCT01159405|Experimental|99mTc-GP|99mTc-GP with SPECT/CT imaging & whole body scan.
11527817|NCT01159392||Brain injury plus acute lung injury|Patients with severe brain injury (Glasgow coma score<13) with acute lung injury (PaO2/FiO2 <300 mmHg)
11527818|NCT01159379|Experimental|ertapenem, tolerance tests|Patients with IgE-mediated allergy to beta-lactams
11527819|NCT01159366|Active Comparator|occluded culprit artery|An occluded lesion was defined as a lesion with 100% stenosis or TIMI-flow grade 0 or 1.
11527820|NCT01159366|Active Comparator|non-occluded culprit artery|A non-occluded lesion was defined as a lesion without 100% stenosis or TIMI-flow grade 0 or 1.
11527821|NCT01159353|Experimental|insulin glulisine + insulin aspart|insulin glulisine (1 day) + wash-out (7 days) + insulin aspart (1 day)
11527822|NCT01159353|Experimental|insulin aspart + insulin glulisine|insulin glulisine (1 day) + wash-out (7 days) + insulin aspart (1 day)
11527823|NCT01159327|Experimental|Arm A|Sorafenib maintenance arm
11527824|NCT01159327|No Intervention|Arm B|observation arm
11527825|NCT01159314|Experimental|Arm A - Baerveldt 250 mm2|Patients receiving Baerveldt 250 mm2
11527826|NCT01159314|Experimental|Arm B - Baerveldt 350 mm2|Patients receiving Baerveldt 350 mm2
11527827|NCT01159301|Experimental|Treatment (entinostat, sorafenib tosylate)|Patients receive oral entinostat once daily on days 1 and 15 and oral sorafenib tosylate twice daily on days 1-28 (days 15-28 only of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11527828|NCT01159275|Other|1|First Generic LPV/r 200/50 mg BID, then cross over to Pediatric Aluvia 200/50 mg BID
11527829|NCT01159275|Other|2|First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
11527830|NCT01159262|Experimental|Dexmedetomidine 0.05 mcg/kg|Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
11527831|NCT01159262|Experimental|Dexmedetomidine 0.1 mcg/kg|Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
11527832|NCT01159262|Experimental|Dexmedetomidine 0.2 mcg/kg|Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
11527833|NCT01159249|Other|Open Met add-on vildagliptin|
11527834|NCT01159249|Other|Open TZD add-on vildagliptin|
11527835|NCT01159249|Other|Open α-GI add-on vildagliptin|
11527836|NCT01159249|Other|Glinides add-on vildagliptin|
11527837|NCT01159236|Experimental|Group 1: ER-Positive|"Participants with Estrogen Receptor (ER)-Positive breast cancers receive Standard T/FAC or T/FEC chemotherapy before surgery.
~T/FAC or T/FEC: Combination chemotherapy with sequential paclitaxel (80 mg/m2) weekly x 12 weeks followed by 5-fluorouracil (500 mg/m2), cyclophosphamide (500 mg/m2) and doxorubicin (50 mg/m2) or epirubicin (100 mg/m2) (FAC or FEC) once every 3 weeks for 4 treatments."
11527838|NCT01159236|Experimental|Group 2: ER-Negative|Participants with ER-negative cancers (randomized between Group 2 & Group 3), Standard T/FAC or T/FEC chemotherapy before surgery.
11527839|NCT01159236|Experimental|Group 3: ER-Negative + Bevacizumab|Participants with ER-negative cancers (randomized between Group 2 & Group 3), T/FEC chemotherapy combined with 10 mg Bevacizumab every 2 weeks during first 3 treatments before surgery.
11527840|NCT01159223|Experimental|1|ATV/r 200 mg/100 mg OD
11527841|NCT01159223|Experimental|2|ATV/r 300 mg/100 mg OD
11527842|NCT01159197|Experimental|cognitive behaviorial therapy|
11527843|NCT01159171|Experimental|1|
11527844|NCT01159158|Experimental|Nateglinide|Nateglinide Tablets 120 mg of Dr. Reddys Laboratories Limited
11527845|NCT01159158|Active Comparator|Starlix|Starlix Tablets 120 mg of Novartis
11527852|NCT01159119|Active Comparator|Zenpep|Control Group: Consist of treatment with Zenpep
11527853|NCT01159093|Experimental|Family Decision Support|Families will receive informational vaccine reminder telephone calls.
11527854|NCT01159093|Experimental|Clinical Decision Support|In this treatment arm, clinicians receive the decision support at the point of care within an electronic health record.
11527855|NCT01159093|Experimental|Family DS+ Clinician DS|Families will receive informational vaccine reminder calls and their clinicians will receive electronic health record-based decision support for immunizations.
11527856|NCT01159093|Other|Control|This group will receive regular primary care with no decision support.
11527857|NCT01159080|Active Comparator|routine dose tacrolimus and less myfortic|
11527858|NCT01159080|Experimental|reduced dose tacrolimus and conventional myfortic|
11527859|NCT01159067|Experimental|Arm I|Patients receive oral deferasirox once daily for up to 6 months in the absence of unacceptable toxicity.
11527860|NCT01159054|Experimental|This study has only one arm.|Blood sample and scan results to be compared before and after intervention in each subject.
11527861|NCT01159041|Experimental|Family Focused Treatment (FFT)|15 session family-based treatment emphasizing improving relationship skills to combat depression symptoms and support recovery.
11527862|NCT01159041|Active Comparator|Individual Treatment (IP)|15 session individually-based treatment to assist children in understanding the causes of their symptoms.
11527863|NCT01159028|Experimental|BP1001|Subjects are treated with open-label study drug (BP1001) in a dose-escalation model.
11527864|NCT01159028|Experimental|BP1001 in combination with LDAC|AML subjects are treated with open-label escalating study drug (BP1001) in combination with low dose ara-C (LDAC)
11527865|NCT01159015|Experimental|KetoNaph|KetoNaph Ophthalmic Solution
11527866|NCT01159015|Placebo Comparator|Vehicle|Vehicle of KetoNaph Ophthalmic Solution
11527867|NCT01159002||Critically ill ICU patients|ICU patients with brain injuries who will be receiving a feeding tube.
11527868|NCT01158989||Critically ill|Critically ill subjects were intubated, mechanically ventilated and sedated
11527869|NCT01158989||Ambulatory Group|Subjects were scheduled for an outpatient procedure but were otherwise healthy
11527870|NCT01158976|Experimental|DHA supplementation|
11527871|NCT01158976|Placebo Comparator|Soybean Oil|
11527872|NCT01158950|Experimental|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
11527873|NCT01158950|Placebo Comparator|Placebo|Drug: Placebo for tolcapone administered at study visit
11527874|NCT01158937|Experimental|Extended Meropenem Infusion|Meropenem Infusion over 3 hours
11527875|NCT01158937|Experimental|Bolus Meropenem Infusion|Meropenem infusion over 30 minutes
11527876|NCT01158924|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
11527877|NCT01158911||non-diabetic Chronic Kidney disease|
11527878|NCT01158898|Active Comparator|TPI ASM8 low dose|
11527879|NCT01158898|Active Comparator|TPI ASM8 high dose|
11527880|NCT01158898|Placebo Comparator|Placebo|
11527881|NCT01158885|Experimental|Single Arm|"A maximum of two courses of the following regimen will be administered.
~Clofarabine: 20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.
~Cytarabine intravenous: 1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.
~Methotrexate: to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age.
~Intrathecal (IT) cytarabine: is optional for acute myelogenous leukemia (AML) patients."
11527882|NCT01158859|Experimental|Pregabalin|
11527883|NCT01158859|Placebo Comparator|Placebo|
11527884|NCT01158846|Active Comparator|prasugrel/bivalirudin|60 mg loading dose of prasugrel will be followed by maintenance dose of 10mg (or 5mg according to body weight and age). During primary PCI, Bivalirudin will be used as anticoagulant (bolus plus infusion), on a weight-adjusted dose.
11527885|NCT01158846|Active Comparator|clopidogrel/abciximab|600mg loading dose of clopidogrel will be followed by 75mg maintenance dose. During primary PCI abciximab (bolus plus infusion) will be used as anticoagulant.
11527886|NCT01158833||spastic diplegia due to Cerebral Palsy|
11527887|NCT01158820|Placebo Comparator|Placebo|midazolam load fentanyl load midazolam demand fentanyl demand benadryl demand
11527888|NCT01158820|Active Comparator|dexmedetomidine and ketamine|dexmedetomidine load ketamine load dexmedetomidine maintenance ketamine maintenance midazolam demand fentanyl demand benadryl demand
11527889|NCT01158807||HHT- Brain Arteriovenous Malformation|"Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT and
~Presence of Brain Arteriovenous Malformation"
11527890|NCT01158807||HHT -NO BAVM|1. Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT
11527891|NCT01158794||Study participants|Participants with sickle cell disease and transfusional iron-overload, and non-sickle cell disease (thalassemia major, cancer patients, etc.) and iron overload. Participants with iron overload, defined as too much iron in the body as a consequence of too many blood transfusions.
11527892|NCT01158781|Experimental|gait, balance, arm function, cognition|12 weeks of training for balance, gait, upper limb function, and cognition
11527893|NCT01158768||Violence, Comorbidity|
11527894|NCT01158755|Active Comparator|Standard dose rifampisin|"Subjects in this arm receive 450 mg rifampicin orally.
~In accordance with national TB treatment standard that encourages the use of 4 drugs, all subjects -both in active comparator and experimental arm- will also receive isoniazide 300 mg p.o. and pyrazinamide 1500 mg p.o.
~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
11527969|NCT01158131|No Intervention|Post-gestational diabetes mellitus (GDM) Follow-up Group|Participants in this group will not take part in the intervention.
11528705|NCT01153386|Experimental|2.5 mg treprostinil diethanolamine|2.5 mg treprostinil diethanolamine
11527895|NCT01158755|Experimental|High dose rifampisin|"Subjects in this arm receive 600 mg Rifampisin i.v. for 14 days, and the dosage will be switched to 450 mg Rifampisin p.o afterwards until completion of TB medication (in accordance with National TB Program)
~In accordance with national TB treatment standard that encourages the use of 4 drugs, all subjects -both in active comparator and experimental arm- will also receive isoniazide 300 mg p.o. and pyrazinamide 1500 mg p.o.
~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
11527896|NCT01158742||1|Caucasians who donated a kidney at Mayo Clinic in Rochester, Minnesota (MN)
11527897|NCT01158742||2|Caucasians who donated a kidney at the University of Minnesota
11527898|NCT01158742||3|African-Americans who donated a kidney at the University of Alabama
11527899|NCT01158729|Experimental|ATIII experimental group|30 neonates (4-30 days of age) undergoing surgery requiring cardiopulmonary bypass will receive Antithrombin (Recombinant) prior to initiation of bypass
11527900|NCT01158729|Placebo Comparator|Placebo Controls|30 neonates (4-30 days of age) undergoing surgery requiring cardiopulmonary bypass will receive placebo prior to initiation of bypass
11527901|NCT01158716|Active Comparator|Remote Ischemic Preconditioning|
11527902|NCT01158716|No Intervention|Control|
11527903|NCT01158703|Active Comparator|clopidogrel|aspirin and clopidogrel
11527904|NCT01158703|Placebo Comparator|sugar pill|aspirin and placebo
11527905|NCT01158690|Experimental|resource card group|The intervention group will receive an envelope with a gift voucher and a resource card (wallet size card with on the one side safety measures and on the other side contact details of resources for violence).
11527906|NCT01158690|Active Comparator|control group|The control group will receive the same envelop with a gift voucher and a letter of thanks.
11527907|NCT01158664|Experimental|0.6 mm tread pitch implant|
11527908|NCT01158664|Experimental|0.1 mm tread pitch implant|
11527909|NCT01158651|Experimental|RAD001 (Everolimus) Active Therapy|"If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment course lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).
~You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection."
11527910|NCT01158638|No Intervention|Usual Care|Usual Care
11527911|NCT01158638|Active Comparator|10,000 Steps Group|Each participant randomized to this study arm will receive a pedometer and a generic recommendation to accumulate 10,000 Steps per Day.
11527912|NCT01158638|Experimental|Web Mediated Step Group|Participants randomized to this study arm receive an introduction to the study website. Each person utilizes the website to track their daily physical activity steps. Goals are given on a weekly basis to increase steps by 10% per day per week over baseline values. The website channels each participant through a series of motivational messages designed to increase compliance with recommended physical activity targets
11527913|NCT01158625|No Intervention|Morning dosing of antihypertensive drugs|
11527914|NCT01158625|Active Comparator|Nighttime dosing of antihypertensive drugs|
11527915|NCT01158612|Experimental|Growth hormone|The effect of Growth hormone on the collagen synthesis rate
11527916|NCT01158612|Placebo Comparator|Saline|
11527917|NCT01158599|Other|IXIARO 0,5 ml|IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28
11527918|NCT01158586|Experimental|Levobupivacaine|patient control epidural analgeisa using 0.2% levobupivacaine with 2ug/ml fentanyl
11527919|NCT01158586|Active Comparator|Ropivacaine|patient controlled epidural analgesia using 0.2% ropivacaine with 2ug/ml fentanyl
11527920|NCT01158573||Healthy non-asthmatic obese adults|Healthy non-asthmatic obese adults
11527921|NCT01158573||Healthy non-asthmatic non-obese adults|Healthy non-asthmatic non-obese adults
11527922|NCT01158573||Asthmatic obese adults|Asthmatic obese adults
11527923|NCT01158573||Asthmatic non-obese adults|Asthmatic non-obese adults
11527924|NCT01158560|Experimental|Vitamin D and gargling|Participants will be given a weekly dose of 10,000 IU of vitamin D3 (oral capsule) and asked to gargle with tap water twice daily
11527925|NCT01158560|Experimental|Vitamin D and general health advice|Participants will be given a weekly dose of 10,000 IU of vitamin D3 (oral capsule) and will receive general health advice in place of gargling advice
11527926|NCT01158560|Placebo Comparator|Placebo and general health advice|Participants will be given an aesthetically matched placebo capsule to take once weekly and will be given general health advice in place of gargling advice.
11527927|NCT01158560|Placebo Comparator|Placebo and gargling|Participants will be given an aesthetically matched placebo capsule to take once weekly and will be asked to gargle with tap water twice daily
11527928|NCT01158534|Experimental|Arm I|Patients receive oral celecoxib twice daily and recombinant interferon alpha-2b subcutaneously, once daily, 5 times a week. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11527929|NCT01158521|Experimental|Arm I|Patients receive oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
11527930|NCT01158508|Experimental|Remote Ischemic Preconditioning|Patients with aneurysmal subarachnoid hemorrhage, after aneurysm treatment, will be given prophylactic remote ischemic preconditioning by transient lower limb ischemia.
11527931|NCT01158482||IVC Filter Placement or Removal|Patients undergoing IVC filter placement and/or IVC filter removal at Stanford Medical Center.
11527932|NCT01158456||African Americans|Subjects will be classified as African American if they report themselves, biological parents and both sets of biological grandparents as African American or African descent.
11527933|NCT01158456||European American|Subjects will be classified as European American if they report themselves, biological parents and both sets of biological grandparents as European American or European descent.
11528013|NCT01157767||breast pts who have undergone surgery|This will be a feasibility study designed to evaluate the compliance of an at-home, directed exercise program and its influence on physical measures during post-operative adjuvant chemotherapy and radiation (if applicable).
11527934|NCT01158443|Experimental|Behavioral activation therapy|The Behavioral Activation Program for Energy and Productivity (BA-PEP) is a manualized, 8-session intervention, scheduled to coincide with maintenance armodafinil treatment. It is a structured counseling program with homework, short-term activities and goals, and includes problem-solving, identification of barriers and strategies for their resolution, with an ongoing focus on achieving employment or training.
11527935|NCT01158443|Placebo Comparator|supportive counseling (SC)|Supportive counseling is designed to create an empathic, accepting environment, to direct attention to the patient's feelings and to facilitate acceptance of affective experience using supportive statements, reflective listening and empathic communications.
11527936|NCT01158430|Experimental|ACT group therapy|"Third generation cognitive behavioral therapy
~Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions & 1 booster session 1 month after 9th session, a total of 35.5 hours"
11527937|NCT01158430|No Intervention|Control|Control group assigned to wait list (treatment as usual). After 9 months they are offered ACT group therapy, but not as part of the research project.
11527938|NCT01158417|Placebo Comparator|Placebo|Placebo tablets
11527939|NCT01158417|Experimental|Resveratrol 40 mg oral three times a day|Resveratrol
11527940|NCT01158417|Experimental|resveratrol 500 mg oral once daily.|Resveratrol
11527941|NCT01158404|Experimental|LY900009|"Dose escalation phase: 2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.
~Dose confirmation phase: 30 mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.
~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
11527942|NCT01158391|Experimental|NTrainer® Intervention|NTrainer® Intervention - Infants in the experimental group will receive the NTrainer System patterned synthetic orocutaneous stimulation during the first 30 minutes of a tube (gavage) feeding session. The intervention may be provided up to 4 times daily to achieve an average of 30 sessions distributed over a two week period.
11527943|NCT01158391|Sham Comparator|Control Intervention|Control Intervention - Infants in the Control group will be provided orocutaneous stimulation with a 'quiet pacifier' during the first 30 minutes of a tube (gavage) feeding session. The intervention may be provided up to 4 times daily to achieve an average of 30 sessions distributed over a two week period.
11527944|NCT01158378|Active Comparator|DuraSeal Dural Sealant System|
11527945|NCT01158378|Experimental|Adherus Dural Sealant System|
11527946|NCT01158365|Experimental|Dermacyd (different fragrances)|Day 1 until 30: Investigational Product (Dermacyd) Day 31 until 37: wash-out Day 38 until 67: Glycerine Vegetal Soap Granado Traditional
11527947|NCT01158365|Active Comparator|Glycerine Vegetal Soap Granado Traditional|Day 1 until 30: Glycerine Vegetal Soap Granado Traditional Day 31 until 37: wash-out Day 38 until 67: Investigational Product (Dermacyd)
11527948|NCT01158352|Experimental|Nutritional supplemntation formula|Nutritional supplementation standardized formula (powder added to liquids or food) containing 25% of recommended DRI for calories, high protein (20% of calories) and multi vitamins and mineral(25%-100% of DRI for recommended daily allowance or adequate intake)
11527949|NCT01158352|Placebo Comparator|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
11527950|NCT01158339|Active Comparator|Arm 1: CBGT|Cognitive Behavioural Group Therapy (CBGT)
11527951|NCT01158339|Experimental|Arm 2: CBGT-ISE|Cognitive Behavioural Group Therapy, with in-Session Exposure (CBGT-ISE).
11527952|NCT01158326|Active Comparator|Resfenol Solution oral|Acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride active drug
11527953|NCT01158326|Placebo Comparator|Placebo|Placebo oral solution
11527954|NCT01158313||Thickener|"Patients with history of swallowing difficulties associated with aging and/or neurological diseases including patients with:
~neurodegenerative diseases.
~non-progressive neurological diseases including stroke.
~older patients including nursing home patients."
11527955|NCT01158287|Experimental|Sorafenib 400mg bd, p.o, continuously|
11527956|NCT01158274|Experimental|Treatment|Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11527957|NCT01158261||Vascular Surgery Subjects Treated with EVICEL|
11527958|NCT01158235|Experimental|LTX-109 (Lytixar)|Ascending dose study. Start enrollment to group 1: 1% LTX-109/placebo, then group 2: 2%LTX-109/placebo and finally group 3: 5%LTX-109/placebo dosed in each nostril TID for 3 consecutive days.
11527959|NCT01158222|Experimental|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 42 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
11527960|NCT01158209||Assessed cohort|Subjects attending out-patient health services for gynaecological examination.
11527961|NCT01158196|Experimental|infra-red diode laser|one session, one dose
11527962|NCT01158183||Group 1|No intervention
11527963|NCT01158170|Experimental|prophylactic cranial irradiation|Patients receive Erlotinib or gefitinib until disease progression or intolerable toxicity, and prophylactic cranial irradiation 25GY over 10 fractions.
11527964|NCT01158170|Active Comparator|Conctrol|Patients received Erlotinib or gefitinib until disease progression,or intolerable toxicity
11527965|NCT01158157|Other|Vaccination|This study was a single arm study. All eligible subjects received ACAM2000.
11527966|NCT01158144|Experimental|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
11527967|NCT01158144|Active Comparator|Conctrol|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
11527968|NCT01158131|Experimental|Lifestyle Intervention group|Participants in this group will take part in the lifestyle intervention.
11527970|NCT01158118|Experimental|Arm 1 - Donor|"Days 1-5: Mobilization with 5 mcg/kg/day GM-CSF (first 4 donors were mobilized with 10 mcg/kg GM-CSF then changed to 5 mcg/kg for remaining donors)
~Day 5: Mobilization with 320 mcg/kg plerixafor IV
~Day 5: Leukopheresis
~If PBSC collected are not adequate, then donor will be mobilized with GM-CSF and plerixafor IV on day 6 and have leukopheresis collection on day 6."
11527971|NCT01158118|No Intervention|Arm 2 - Recipient|"Conditioning Regimens
~fludarabine and busulfan +/- thymoglobulin
~fractionated total body irradiation and cyclophosphamide
~busulfan and cyclophosphamide
~single dose total body irradiation and cyclophosphamide
~Day -2 = GvHD prophylaxis
~Day 0 or +1 = PBSC transplant
~Day +7 until neutrophil engraftment = G-CSF 5 ug/kg/day"
11527972|NCT01158105|Experimental|Bortezomib|1.6 mg/m2 intravenous infusion will be administered on days 1, 8, 15, 22 of each 35 day cycle, for up to 6 cycles. Patients who continue to respond during the initial treatment phase with no ongoing significant adverse events will be eligible to receive up to 6 additional cycles. This maintenance dose will be administered on days 1 and 15.
11527973|NCT01158092|Active Comparator|Treatment with SInergy™ System|Lateral branch denervation using the SInergy™ System
11527974|NCT01158092|Active Comparator|Conservative Treatment|Treatment with physical therapy, chiropractic care, and medication
11527975|NCT01158066|No Intervention|CT cardiac|the patient will undergo cardiac CT
11527976|NCT01158040||Insulin pump|Women suffering from pregestational diabetes mellitus and being treated with insulin pump during pregnancy and delivery
11527977|NCT01158040||IV insulin|Women suffering from pregestational diabetes mellitus and being treated with insulin sub-cutan (SC) during pregnancy and IV insulin during delivery
11527978|NCT01158040||Healthy|Healthy women accepted for delivery in our institute
11527979|NCT01158027||children|
11527980|NCT01158014|Experimental|Fibrin Glue, surgery|Conjunctival autograft will be glued using fibrin glue to pterygia bed after removal
11527981|NCT01158014|Active Comparator|Control|Conjunctival autograft will be sutured using 10/0 vicryl sutures to pterygia bed after removal
11527982|NCT01158001|Experimental|Psychotherapy via telemedicine|In this arm, veterans received standard psychotherapy (prolonged exposure therapy) in a novel format - interacting with a therapist via videoconferencing.
11527983|NCT01158001|Active Comparator|Face-to-face (in person) psychotherapy|In this arm, veterans received standard psychotherapy (prolonged exposure therapy) in the traditional format - in person with a therapist.
11527984|NCT01157988|Experimental|ibritumomab tuixetan, response, toxicity|
11527985|NCT01157975|Experimental|Pioglitazone|
11527986|NCT01157975|Experimental|Prednisone|
11527987|NCT01157962|Experimental|Group A Sentinel lymphadenectomy|In group A exclusively sentinel lymphadenectomy is performed
11527988|NCT01157962|Active Comparator|Group B radical pelvine lymphadenectomy|in group B radical systematic pelvic lymphadenectomy is done. In patients with tumor free lymph nodes either radical hysterectomy or, in women seeking parenthood, radical trachelectomy is performed. If lymph nodes are tumor-involved systematic pelvic and paraaortic lymphadenectomy followed by primary chemoradiation is recommended.
11527989|NCT01157949|Active Comparator|Study withdrawn|Study withdrawn
11527990|NCT01157949|Placebo Comparator|Withdrawn|Study withdrawn
11527991|NCT01157936|Active Comparator|Allopurinol treatment|
11527992|NCT01157936|Placebo Comparator|Placebo|
11527993|NCT01157923|Experimental|intervantion group|Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor.
11527994|NCT01157923|No Intervention|control group|Regular treatment, No change will be made in the insulin pump setting during the study(unless there is a medical need or any safety concern).
11527995|NCT01157897|Experimental|Cohort 1: 15 μg VMP001|15ug VMP001 per vaccination on days -1 or 0, 28, and 84. P. vivax sporozoite challenge on day 98.
11527996|NCT01157897|Experimental|Cohort 2: 30 μg VMP001|30ug VMP001 per vaccination on days 14, 42, and 84. P. vivax sporozoite challenge on day 98.
11527997|NCT01157897|Experimental|Cohort 3: 60 μg VMP001|60ug VMP001 per vaccination on days 28, 56, and 84. P. vivax sporozoite challenge on day 98.
11527998|NCT01157897|Other|Control|No Vaccinations given for controls. P. vivax sporozoite challenge on day 98.
11527999|NCT01157884||Kidney Transplantation|
11528000|NCT01157871|Experimental|placebo|4 administrations at 2-week interval of placebo solution
11528001|NCT01157871|Experimental|NV1FGF 16 mg|4 administrations at 2-week interval of 4mg at each administration
11528002|NCT01157871|Experimental|NV1FGF 32 mg|4 administrations at 2-week interval of 8mg at each administration
11528003|NCT01157858|Active Comparator|Everolimus + octreotide LAR|Octreotide LAR combined with everolimus
11528004|NCT01157858|Active Comparator|Octreotide LAR|Octreotide LAR monotherapy
11528005|NCT01157845|Experimental|Laboratory assay|
11528006|NCT01157819|Active Comparator|Ciloxan Ear Drops|Ciloxan (Alcon, Inc.) Sterile Ophthalmic and Ear Drops
11528007|NCT01157819|Experimental|Foam Otic Cipro|Patients randomized to this study arm will receive the experimental product
11528008|NCT01157806|Experimental|radiochemotherapy instead of surgery|
11528009|NCT01157793|Experimental|Group 1|
11528010|NCT01157793|Experimental|Group 2|
11528011|NCT01157780|Experimental|fish oil|When a subject develops PNALD (three consecutive direct bilirubin concentrations > 2 mg/dL), and is able to tolerate at least trophic feeds (1 mL Q12h), the subject will be randomized to either the control group (our current hospital practice including advancement of enteral feeding, ursodiol, and cyclic PN, but not ω3PUFA) or the active treatment group (current hospital practice plus the addition of enteral ω3PUFA supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period). All patients will be started at 1 g/kg/day with a maximum dose of 4 g/day.
11528012|NCT01157780|No Intervention|standard of care|When a subject develops PNALD (three consecutive direct bilirubin concentrations > 2 mg/dL), and is able to tolerate at least trophic feeds (1 mL Q12h), the subject will be randomized to either the control group (our current hospital practice including advancement of enteral feeding, ursodiol, and cyclic PN, but not ω3PUFA) or the active treatment group (current hospital practice plus the addition of enteral ω3PUFA supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period). All patients will be started at 1 g/kg/day with a maximum dose of 4 g/day.
11528014|NCT01157754|Experimental|OCP+GnRH antagonist|Microgynon 14 to 21 tablets starting COH on day 5 post pill, rFSH + GnRH antagonist
11528015|NCT01157754|Active Comparator|long GnRH agonist|daily triptorelin starting day 21st of previous cycle
11528016|NCT01157741|No Intervention|Standard Practice (H-C)|1) Hospital control group (Group H-C): children assigned to this group received the standard hospital-based, outpatient treatment package, which consisted of fortnightly follow-up for growth monitoring, health and nutrition education, and micronutrient supplementation.
11528017|NCT01157741|Experimental|C-C|Community-based follow-up (Group C-C): the standard community-based follow-up package was identical to the one provided to the hospital-based control group, except that the follow-up visits took place at the nearest CNFU rather than the HNFU.
11528018|NCT01157741|Experimental|C-SF|Community-based follow-up plus supplementary food (Group C-SF): children assigned to this group received the same treatment package as those in Group C-C, except that supplementary food (SF) packets and preparation instructions were also provided at the time of each follow-up clinic visit for consumption at home in addition to the children's usual meals.
11528019|NCT01157741|Experimental|C-PS|Community-based follow-up plus psychosocial stimulation (Group C-PS): children assigned to this group received the same treatment package as those in Group C-C, except that they were also provided with psychosocial stimulation (PS).
11528020|NCT01157741|Experimental|C-SF+PS|Community-based follow-up plus SF and PS (Group C-SF+PS): children assigned to this group received the same treatment package as those in the Group C-C, except that they were also provided with both SF and PS, as described above.
11528021|NCT01157728||Relapsing Multiple Sclerosis patients|
11528022|NCT01157728||healthy volunteer|
11528023|NCT01157715|Experimental|0.5 mg cohort|patients will receive monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii. prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .
11528024|NCT01157715|Experimental|2.0 mg cohort|patients will receive monthly intravitreal injections of 2.0 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii. prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .
11528025|NCT01157702|Experimental|Vaccine|Vaccination with one dose (0.5 mL) of inactivated influenza vaccine
11528026|NCT01157689||Coartem, chloroquine, quinine|All children with a positive malaria test will included. Results will be subanalysed acording to treatment given by routine health staff.
11528027|NCT01157676|Active Comparator|Open cystectomy|Open cystectomy performed using an incision made just above or at the level of umbilicus to the pubic symphysis.
11528028|NCT01157676|Active Comparator|Robotic assisted radical cystectomy|Robotic assisted Radical Cystectomy (RARC) is accomplished by a robot assisted laparoscopic approach.
11528029|NCT01157663|Experimental|Adapted Balance Training group|
11528030|NCT01157663|Active Comparator|Standard Balance training group|Balance training with unipedal standing during 8 weeks
11528031|NCT01157650|Experimental|Autologous mesenchymal stem cells|Fistulizing Crohn's disease
11528032|NCT01157624|Active Comparator|oxygen|
11528033|NCT01157624|Placebo Comparator|air supplement|
11528034|NCT01157611|Active Comparator|Mentoring program group|type 1 diabetes patients participating in online base mentoring program
11528035|NCT01157611|No Intervention|Control group|type 1 diabetes patients receiving regular clinic visits
11528036|NCT01157598|Active Comparator|BIS group|
11528037|NCT01157598|Placebo Comparator|non BIS group|
11528038|NCT01157585|Other|drug|
11528039|NCT01157572|Active Comparator|Metoprolol|
11528040|NCT01157572|Placebo Comparator|Placebo|
11528041|NCT01157546|Placebo Comparator|Control|group A (control) will receive a bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side) via both TAP catheters.The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
11528042|NCT01157546|Experimental|TAP|group B (TAP) will receive a bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side) via TAP catheters. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
11528043|NCT01157533|Experimental|Vancomycin Loading|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
11528044|NCT01157520||Cesarean|Women scheduled for elective Cesarean section under spinal anesthesia
11528045|NCT01157507|Active Comparator|Botulinum A toxin|Botulinum A toxin intravesical injection.
11528046|NCT01157507|Sham Comparator|Bladder overdistension|Standard treatment: bladder overdistension
11528047|NCT01157507|Placebo Comparator|Placebo|
11528048|NCT01157494||children with hemiplegia|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
11528049|NCT01157481|Experimental|Conventional therapy plus nifedipine|
11528050|NCT01157481|Active Comparator|Conventional therapy|
11528051|NCT01157468||Cases|"The Case group is constituted with patients with Systemic Lupus Erythematosus from Martinique, divided en 2:
~30 patients with a quiescent lupus
~30 patients with an active lupus"
11528052|NCT01157468||Controles|"The Control group is constituted by people coming to give blood to the French Blood Establishment of Martinique."
11528053|NCT01157442|Experimental|cell phone sms messages|The experimental arm will receive the cell phone SMS text messaging intervention.
11528054|NCT01157442|No Intervention|Control|The control group will receive the standard of care but no SMS text messages.
11528055|NCT01157429|Active Comparator|D-cycloserine plus CBT|Individuals receive 12 sessions of manualized trauma-focused cognitive behavioral therapy plus seven doses of D-cycloserine.
11528056|NCT01157429|Placebo Comparator|Placebo pill|Individuals receive 12 sessions of trauma-focused cognitive behavioral therapy plus seven doses of placebo pill.
11528057|NCT01157416|Active Comparator|D-cycloserine plus CBT|Individuals receive 12 sessions of manualized trauma-focused cognitive behavioral therapy plus seven doses of D-cycloserine.
11528058|NCT01157416|Placebo Comparator|Placebo plus CBT|Individuals receive 12 sessions of trauma-focused cognitive behavioral therapy plus seven doses of placebo pill.
11528059|NCT01157403|Experimental|mesenchymal stem cells|To study the safety and efficacy of autologous transplantation of bone marrow mesenchymal stem cells in treatment of newly diagnosed patients with T1DM.
11528060|NCT01157390|Experimental|Infant formula|The infants will be fed with Wondersun infant formula with high proportion of palmitic acid at the sn-2 position
11528061|NCT01157390|Active Comparator|Breast feeding|Complete breast feed within the first 3 month
11528062|NCT01157377|Experimental|AGN-214868 total dose 500 ng|AGN-214868 injected into the bladder for total dose of 500 ng on Day 1.
11528063|NCT01157377|Experimental|AGN-214868 total dose 1000 ng|AGN-214868 injected into the bladder for total dose of 1000 ng on Day 1.
11528064|NCT01157377|Experimental|AGN-214868 total dose 2000 ng|AGN-214868 injected into the bladder for total dose of 2000 ng on Day 1.
11528065|NCT01157377|Experimental|AGN-214868 total dose 6000 ng|AGN-214868 injected into the bladder for total dose of 6000 ng on Day 1.
11528066|NCT01157377|Experimental|AGN-214868 total dose 18000 ng|AGN-214868 injected into the bladder for total dose of 18000 ng on Day 1.
11528067|NCT01157377|Experimental|AGN-214868 total dose 60000 ng|AGN-214868 injected into the bladder for total dose of 60000 ng on Day 1.
11528068|NCT01157377|Placebo Comparator|Placebo to AGN-214868|Placebo to AGN-214868 injected into the bladder on Day 1.
11528069|NCT01157364|Other|bimatoprost 20 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 20 µg generation 2 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
11528070|NCT01157364|Other|bimatoprost 15 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 15 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
11528071|NCT01157364|Other|bimatoprost 10 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
11528072|NCT01157364|Other|bimatoprost 6 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
11528073|NCT01157364|Other|bimatoprost 15 µg generation 1, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
11528074|NCT01157364|Other|bimatoprost 10 µg generation 1, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
11528075|NCT01157351|Experimental|001|paliperidone palmitate 78 117 156 or 234 mg monthly injection for 15 months
11528076|NCT01157351|Active Comparator|002|aripiprazole flexible dosing as prescribed by the study doctor for 15 months
11528077|NCT01157351|Active Comparator|003|haloperidole flexible dosing as prescribed by the study doctor for 15 months
11528078|NCT01157351|Active Comparator|004|olanzapine flexible dosing as prescribed by the study doctor for 15 months
11528079|NCT01157351|Active Comparator|005|paliperidone flexible dosing as prescribed by the study doctor for 15 months
11528080|NCT01157351|Active Comparator|006|perphenazine flexible dosing as prescribed by the study doctor for 15 months
11528081|NCT01157351|Active Comparator|007|quetiapine flexible dosing as prescribed by the study doctor for 15 months
11528082|NCT01157351|Active Comparator|008|risperidone flexible dosing as prescribed by the study doctor for 15 months
11528083|NCT01157338|Active Comparator|diagnostic cardiac catheterization|patients with diagnostic cardiac catheterization
11528084|NCT01157338|Active Comparator|therapeutic cardiac catheterization|patient with angioplasty
11528085|NCT01157325|Active Comparator|Non-neuraxial analgesia|Parturients will not receive neuraxial analgesia
11528086|NCT01157325|Active Comparator|Neuraxial analgesia|Parturients will receive neuraxial analgesia
11528087|NCT01157312|Experimental|minimal stimulation protocol|5 days of CC (100mg/day) from day 3 followed by 150 IU of highly purified uFSH on cycle day 9 for three treatment cycles
11528088|NCT01157312|Active Comparator|clomiphene citrate(CC)|5 days of CC (100mg/day) from cycle day 3 for three treatment cycles.
11528089|NCT01157299||Hemodynamic instability|Hypotension and/or evidence of end-organ hypoperfusion
11528090|NCT01157299||Hemodynamic stability|"Normotension and end-organ normoperfusion along with
~Vasopressor, vasodilator or inotropic therapy
~Edema and/or evidence of hypervolemia"
11528091|NCT01157299||"Hemodinamically normal"|"Normotension and end-organ normoperfusion along with
~Non vasopressor, vasodilator or inotropic therapy
~Normohydration state
~Non Systemic Inflammatory Response Syndrome
~Spontaneous breathing and PEEP, or CPAP, equal or less than 5 cm H2O"
11528092|NCT01157286||level of apnea|patients will be separated depending on the iah(apnea hypopnea index) in mild, moderate and severe
11528093|NCT01157273||High Anxiety (HA) group|13 participants of both genders, 19-42 years old, with no history of psychiatric disorders and scores above 41 in STAI-Trait
11529471|NCT01147757|Placebo Comparator|saline|Group S (n = 15): saline
11528094|NCT01157273||Low Anxiety (LA) group|11 participants of both genders, 19-42 years old, with no history of psychiatric disorders and scores below 41 in STAI-Trait
11528095|NCT01157260|Experimental|AST-120|AST-120 administration 2g three times a day
11528096|NCT01157260|No Intervention|Control|Control Chronic Kidney disease stage 3,4
11528097|NCT01157247|Other|Group SNI|Insertion of spinal needle with introducer
11528098|NCT01157247|Other|Group SNI+LA|Local infiltration of lidocaine was applied three minutes after insertion of spinal needle with introducer
11528099|NCT01157247|Other|Group SNI+F|Intravenous fentanyl was applied 3 min before insertion of spinal needle with introducer
11528100|NCT01157247|Other|Group SN|Spinal puncture was performed only with spinal needle without introducer, local anesthetic infiltration or intravenous fentanyl before spinal puncture.
11528101|NCT01157234|Active Comparator|Nebivolol|Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of <140/90 and continued until month-12 of the study.
11528102|NCT01157234|Active Comparator|Metoprolol|Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of <140/90 and continued until month-12 of the study.
11528103|NCT01157221|Experimental|intervention group|intervention group: end-range mobilization/scapular mobilization treatment approach group
11528104|NCT01157221|Active Comparator|control|
11528105|NCT01157221|Sham Comparator|control-criteria group|
11528106|NCT01157208|Experimental|Diet A|This diet is high in omega-3 fatty acids, low in trans fatty acids, and low in omega-6 fatty acids. Subjects are encouraged to eat fatty fish daily (e.g., salmon), to limit vegetable oil intake, and to eat fruits, vegetables and whole grains. Specifically formulated and other provided foods for this group will include salmon-salad sandwiches, hummus with olive oil, other bean dips and bean dishes, frozen and canned fish, and blueberry-flax muffins.
11528107|NCT01157208|Experimental|Diet B|This diet is low in trans fatty acids and low in omega-6 fatty acids. Subjects are encouraged to to limit vegetable oil intake, to replace meats and eggs with beans and lean fish/shellfish, and to eat fruits, vegetables and whole grains. Specifically formulated and other provided foods for this group will include hummus with olive oil, other bean dips and bean dishes, lean fish and shellfish,and blueberry muffins.
11528108|NCT01157195|Active Comparator|CI therapy|
11528109|NCT01157195|Experimental|Tele-AutoCITE|AutoCITE stands for Automated Constraint Induced Therapy Extender.
11528110|NCT01157182|Experimental|Investigational Test Product|Estradiol/Norethindrone acetate 1/0.5 mg Tablets
11528111|NCT01157182|Active Comparator|Reference Listed Drug|Activella® 1/0.5 mg Tablets
11528112|NCT01157169|Experimental|Investigational Test Product|Buprenorphine 8 mg Sublingual Tablets
11528113|NCT01157169|Active Comparator|Reference Listed Drug|Subutex® 8 mg Sublingual Tablets
11528114|NCT01157143|Experimental|NV1FGF 500 μg|8 intramuscular injections for a total of 500 μg administered in one single administration 3 to 8 days before major amputation
11528115|NCT01157143|Experimental|NV1FGF 2000 μg|8 intramuscular injections for a total of 2000 μg administered in one single administration 3 to 8 days before major amputation
11528116|NCT01157143|Experimental|NV1FGF 4000 μg|8 intramuscular injections for a total of 4000 μg administered in one single administration 3 to 8 days before major amputation
11528117|NCT01157130|Experimental|Intervention Group|Each patient will have a weekly goal of 2000 calories burned and 18 MET-hours of exercise which can be achieved in 4 to 7 hours of physical activity per week. Resistance training, using weight machines and aerobic training using treadmills, elliptical trainers and stationary bicycles, will be utilized in the intervention group.
11528118|NCT01157130|No Intervention|Control Group|The control group will receive basic information on physical activity but not be instructed.
11528119|NCT01157117|Experimental|Omalizumab/milk OIT|Participants receive blinded omalizumab injections every 2 to 4 weeks through Month 16 and unblinded omalizumab injections thereafter until the Month 28 desensitization oral food challenge (OFC). Participants ingest milk powder daily starting at Month 4 with a dose of 0.07 mg milk protein and escalate for 22 to 40 weeks until reaching the maintenance dose of 3.84 g milk protein (minimum required maintenance dose is 520 mg milk protein). At Month 28, participants complete a 10g milk OFC and discontinue omalizumab injections. If they fail the OFC they permanently discontinue ingestion of the milk powder; if they pass the OFC they continue ingestion of the maintenance dose of milk powder through Month 30 and then discontinue it.
11528120|NCT01157117|Placebo Comparator|Placebo for omalizumab/milk OIT|Participants receive blinded placebo for omalizumab injections every 2 to 4 weeks through Month 16; after unblinding the injections are discontinued. Participants ingest milk powder daily starting at Month 4 with a dose of 0.07 mg milk protein and escalate for 22 to 40 weeks until reaching the maintenance dose of 3.84 g milk protein (minimum required maintenance dose is 520 mg milk protein). At Month 28, participants complete a 10g milk oral food challenge (OFC); if they fail the OFC they permanently discontinue ingestion of the milk powder; if they pass the OFC they continue ingestion of the maintenance dose of milk powder through Month 30 and then discontinue it.
11528121|NCT01157117|No Intervention|Untreated control|Participants did not receive any study intervention but provided regular blood draws at specific study time points to allow mechanistic comparisons with the participants in the other two groups who did receive study intervention.
11528122|NCT01157104|Experimental|IDX320 + PBO → IDX320 + IDX184|400 mg IDX320 and IDX184 matching placebo (PBO) once daily for 7 days; followed by 400 mg IDX320 and 100 mg IDX184 once daily for 7 days
11528123|NCT01157104|Experimental|IDX184 + PBO → IDX184 + IDX320|100 mg IDX184 and IDX320 matching PBO for 7 days; followed by 100 mg IDX184 and 400 mg IDX320 for 7 days
11528124|NCT01157104|Placebo Comparator|IDX320 PBO + IDX184 PBO|IDX320 matching PBO + IDX184 matching PBO for 14 days
11528125|NCT01157091|Experimental|Arm I|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11528126|NCT01157078|Experimental|TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1-4 mg BID
11528127|NCT01157078|Placebo Comparator|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
11528706|NCT01153386|Experimental|1 mg treprostinil diethanolamine|1 mg treprostinil diethanolamine
11528128|NCT01157065|Experimental|AL-78898A|Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up
11528129|NCT01157065|Active Comparator|Lucentis|Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up
11528130|NCT01157052|Active Comparator|Ca2+/Mg2+ pre & post cycle 1|Arm A:Ca2+/Mg2+: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 1
11528131|NCT01157052|Active Comparator|Ca2+/Mg2+pre & post cycle 2|Arm B:Ca2+/Mg2+: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 2
11528132|NCT01157039|Experimental|Dietary Supplement|Arm A: At cycle 2, patients will be randomized to receive for 6 days- Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3
11528133|NCT01157039|Experimental|Dietary supplement|Arm B: At cycle 2, patients will be randomized to receive for 6 days: Glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3.
11528134|NCT01157026|Experimental|Tocotrienol Rich Fraction plus Tamoxifen|
11528135|NCT01157026|Active Comparator|Placebo plus tamoxifen|
11528136|NCT01157013|Experimental|Advanced Hepatocellular Carcinoma|Hepatocellular carcinoma patients not candidates to local and/or curative treatment and an expected overall survival of at least three months and who are susceptible of receiving sorafenib therapy.
11528137|NCT01157000|Experimental|001|Canagliflozin On Day 1 all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
11528138|NCT01156987|Experimental|Healthy Volunteers|Five healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition.
11528139|NCT01156987|Experimental|Breast Cancer Patients|40 breast cancer patients who have suspected breast lesion that will be biopsied will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection and SWIFT acquisition.
11528140|NCT01156974|Experimental|care guide|patients receive education about care goals and work with a care guide to achieve goals
11528141|NCT01156974|Active Comparator|no care guide|patients receive education about care goals and usual care to achieve goals
11528142|NCT01156961|Experimental|Single Arm|
11528143|NCT01156948|Active Comparator|vaginal misoprostol|vaginal misoprostol was administered to this group of nulliparous women
11528144|NCT01156948|Experimental|oral misoprostol|oral misoprostol
11528145|NCT01156935|Experimental|Laugh yoga|experimental laugh yoga
11528146|NCT01156922|Experimental|Rituximab|Rituximab induction two infusions (500 mg/m2, max 1000 mg) two weeks apart, followed by maintenance Rituximab infusions (500 mg/m2, max 1000 mg) after 3, 6, 10 and 15 months.
11528147|NCT01156909|Experimental|Rituximab|Rituximab induction using two infusions (500mg/m2, max 1000 mg) two weeks apart, followed by maintenance Rituximab infusions (500 mg/m2, max 1000 mg) after 3, 6, 10 and 15 months.
11528148|NCT01156896|Experimental|Iron intervention|"All study subjects with malaria and all control subjects will receive an iron intervention (supplement or fortification dose of iron).
~Control subjects will be studied on only one occasion.
~Study subjects with malaria will receive the same iron intervention two weeks later, after the malarial episode has been successfully treated."
11528149|NCT01156870|Experimental|SAR566658|SAR566658 will be administered by intravenous (IV) infusion according to three different schedules
11528150|NCT01156857|Experimental|A|Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
11528151|NCT01156857|Experimental|B|Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of progestin (oral tablets).
11528152|NCT01156844|Experimental|Indacaterol 37.5 µg (twice a day)|"Indacaterol 37.5 µg twice a day (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days.
~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
11528153|NCT01156844|Experimental|Indacaterol 75 µg (once a day)|"Indacaterol 75 µg once a day (qd) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and Placebo to Indacaterol inhaled once daily via Concept1 in the evening for 16 days.
~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
11528154|NCT01156844|Experimental|Indacaterol 150 µg (every other day)|"Indacaterol 150 µg every other day (qod) inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for a total of 16 days. Indacaterol 150 µg inhaled via Concept1, a SDDPI, in the morning and Placebo to Indacaterol inhaled via Concept1 in the evening on odd days; and Placebo to Indacaterol inhaled via Concept1 in the morning and in the evening on even days.
~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
11528155|NCT01156844|Placebo Comparator|Placebo|"Placebo to Indacaterol twice daily (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days.
~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
11528156|NCT01156818||Children|Age 8-21 years
11528157|NCT01156818||Adult|Age 21-80 years
11528158|NCT01156805|Experimental|Educational intervention, Control|Experimental, intervention group has received specific educational training to improve food habits and physical activity during the period of the study.
11528159|NCT01156805|No Intervention|Educational program|No intervention has been made.
11528160|NCT01156792|Experimental|FP 100mcg BID plus GSK2190915 100mg QD (AM)|FP 100mcg BID plus GSK2190915 100mg QD (AM)
11528161|NCT01156792|Experimental|FP 100mcg BID plus GSK2190915 300mg QD (AM)|FP 100mcg BID plus GSK2190915 300mg QD (AM)
11528162|NCT01156792|Active Comparator|FP 100mcg BID plus montelukast 10mg QD (PM)|FP 100mcg BID plus montelukast 10mg QD (PM)
11528163|NCT01156792|Active Comparator|FP 100mcg BID plus placebo BID|FP 100mcg BID plus placebo BID
11528164|NCT01156792|Active Comparator|FP/SAL 100/50mcg BID plus placebo BID|FP/SAL 100/50mcg BID plus placebo BID
11528165|NCT01156779|Experimental|DA-3091|SR-exenatide
11528166|NCT01156779|Placebo Comparator|Placebo of DA-3091|Placebo
11528167|NCT01156753|Experimental|CDX-011|
11528168|NCT01156753|Active Comparator|"Investigator's Choice chemotherapy"|
11528169|NCT01156740|Active Comparator|Intramuscular benzathine Penicillin G|A single dose of intramuscularly administered intramuscular benzathine penicillin G (IM BPG). The dosing was as follows: IM BPG; 600,000 U > 27kg or 1,200,000 U <27 kg
11528170|NCT01156740|Active Comparator|Amoxicillin|A 10-day once daily dose of Amoxicillin was given in an oral form. The first dose was given at the time of randomization, and parents were instructed on giving the remaining doses. Dosing was as follows: 750 mg/QD
11528171|NCT01156727||SURVEY: 6 months post-deployment|Michigan Army National Guard soldiers 6 months post deployment between August 2011 and December 2013
11528172|NCT01156727||SURVEY: 12 months post-deployment|Michigan Army National Guard soldiers 12 months post deployment between August 2011 and December 2013.
11528173|NCT01156727||INTERVIEWS|Michigan Army National Guard soldiers 12-24 months post deployment between October 2011-April 2014. Also key stakeholders from the B2B program.
11528174|NCT01156714|Other|Arm 1: Treadmill Training|Treadmill training with aerobic exercise
11528175|NCT01156714|Other|Arm 2: Memory Training|Memory training with computerized memory program
11528176|NCT01156714|Other|Arm 3: Treadmill and Memory Training|Combination of treadmill training and computerized memory program
11528177|NCT01156701||Cohort1: Prophylaxis with untreated index|"Individuals are eligible to be included in the prophylaxis with untreated index cohort if they are at least 5 years old and have at least 6 months of continuous enrollment, and
~Received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034), and
~Have no diagnosis of influenza (ICD-9 487.xx) on the day of Relenza dispensing or in the 3 preceding days, and
~A household member (index case) with the same family identifier code has had a medical visit (outpatient, inpatient or emergency room (ER) visit) in the 3 days preceding or the day of the Relenza dispensing with a diagnosis of influenza (ICD-9 487.xx), and
~The household member (index case) has not received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
11528178|NCT01156701||Cohort2: Prophylaxis with treated index|"Individuals are eligible to be included in the prophylaxis with treated index cohort if they are at least 5 years old, have 6 months continuous enrollment and
~Received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034), and
~Have no diagnosis of influenza (ICD-9 487.xx) on the day of Relenza dispensing or in the 3 preceding days, and
~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) in the 3 days preceding or the day of the Relenza dispensing with a diagnosis of influenza (ICD-9 487.xx), and
~The household member (index case) has received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
11528179|NCT01156701||Cohort3: No prophylaxis with untreated index|"Individuals are eligible to be included in the no prophylaxis with untreated index cohort if they are at least 5 years old, have 6 months continuous enrollment and
~Have not received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034) within 3 days following the date on which
~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) with a diagnosis of influenza (ICD-9 487.xx), and
~The household member (index case) has not received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
11528180|NCT01156701||Cohort4: No prophylaxis with treated index|"Individuals are eligible to be included in the no prophylaxis with treated index cohort if they are at least 5 years old, have 6 months continuous enrollment and
~Have not received a dispensing of Relenza(HICL=020398 or HCPCS = G9018 or G9034) within 3 days following the date on which
~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) with a diagnosis of influenza (ICD-9 487.xx), and
~The household member (index case) has received zanamivir (Relenza) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza"
11528181|NCT01156688|Active Comparator|Sublingual Misoprostol|
11528182|NCT01156688|Active Comparator|Buccal misoprostol|
11528183|NCT01156675|Experimental|FLEXUS™ Interspinous Spacer|
11528184|NCT01156675|Active Comparator|XSTOP® Interspinous Spacer|
11528185|NCT01156662|Active Comparator|No aspiration|
11528186|NCT01156662|Active Comparator|Thrombus aspiration|
11528187|NCT01156649|Sham Comparator|Sham PAP therapy|Sham PAP will be used with 30 children, and consists of continuous sub-therapeutic levels of air pressure (approximately 1 cm of water) that are delivered through the nasal interface device.
11528188|NCT01156649|Active Comparator|Treatment group|30 children will receive active treatment PAP, which consists of automatically adjusted air pressures that are delivered through the nasal interface device at levels which effectively treats the obstructive events.
11528189|NCT01156636|Active Comparator|Sildenafil|
11528190|NCT01156636|Placebo Comparator|Placebo|
11528191|NCT01156623|Experimental|With EBUS-TBNA group|The patients enrolled in present study are those with non-small lung cancer and receive contrast-enhanced computed tomography (CT) and Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) examination. In this group, further EBUS-TBNA will be arranged if patients agreed it.
11528192|NCT01156623|No Intervention|Without EBUS-TBNA group|The patients enrolled in present study are those with non-small lung cancer and receive contrast-enhanced computed tomography (CT) and Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) examination. In this group, no EBUS-TBNA will be arranged if patients refused it despite we advised it.
11528214|NCT01156428||Renal Disease Subjects|Patients who require a renal biopsy based upon clinical indications such as proteinuria, hematuria, acute renal failure (ARF) of unclear etiology, chronic kidney disease of unclear etiology, nephrotic syndrome, nephritic syndrome, suspected lupus nephritis or any other medically warranted indication for a biopsy.
11528215|NCT01156415|Experimental|Agomelatine (AGO178) 0.5 mg|
11528216|NCT01156415|Experimental|Agomelatine (AGO178) 1 mg|
11528193|NCT01156610|Experimental|Integrated Cessation Counseling|"IVR System: IVR will be used for two purposes: (1) to facilitate access to treatment for low-SES and minority smokers and (2) perform six-month outcome assessment.
~Tobacco Treatment Specialist Calls: A tobacco treatment specialist will make four attempts to contact the patient by phone within 14 days. On contacting the patient, the specialist will screen the patient for readiness to quit, provide brief (10 to 15 minutes) counseling tailored to the patient's readiness to quit, and provide information and support for use of medications that could be or were prescribed and about relevant community resources.
~NRT: Patients who do not have a contraindication and smoke > 10 cigarettes per day, will be offered a free 6-week kit of generic nicotine patches (2 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches). Individuals who smoke 5-10 cigarettes/day will be offered a 6-week course, starting with the 14 mg patch. Those with a contraindication will not get NRT."
11528194|NCT01156610|Active Comparator|Usual Care|"IVR Call: Similar to the initial IVR call for the intervention arms, the initial control arm call will confirm the participant's identify and provide a brief description of the study (obtaining information about health behaviors), with the opportunity for the individual to accept or decline participation. Following this introduction, the IVR script will confirm smoking status. The phone script will collect specific information about current smoking (cigarettes/day), prior quit attempts, and motivation to quit during the next month. No further contact will be made with patients in the control clinics until the outcome assessment call. In the control practices, the IVR machine will also generate a text note documenting the information obtained for the patients' EHR for use by the patient's health care providers as part of their visit-based best practices."
11528195|NCT01156597|Active Comparator|Pioglitazone Group|This is a baseline versus treatment study comparing subjects on pioglitazone to a matched group of subjects treated with either metformin or sulfonylurea with the intent of controlling blood sugar to a comparable level
11528196|NCT01156597|No Intervention|Comparator Group|This group of subjects will be maintained on standard treatment with either metformin or sulfonylurea with the intent of controlling blood sugar to a comparable level as group treated with pioglitazone.
11528197|NCT01156584|Experimental|Single arm|Toca 511 vector/ Toca FC prodrug
11528198|NCT01156571|Experimental|cangrelor|"Cangrelor was administered as a 30 µg/kg bolus followed by a 4.0 µg/kg/min cangrelor IV infusion for a minimum of 2 hours or until conclusion of the index procedure, whichever is longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours.
~Following the discontinuation of the cangrelor infusion, 600mg of clopidogrel was administered."
11528199|NCT01156571|Active Comparator|clopidogrel|"Clopidogrel 300 mg or 600 mg administered pre or post PCI. Selection of dose and timing of dose were per investigator discretion.
~During the PCI a placebo infusion was given to maintain the blinding of the trial. In addition, placebo capsules were administered at the end of the infusion mimic the 600mg post infusion dose provided in the cangrelor arm."
11528200|NCT01156545|Experimental|Treatment arm|BIBW 2992 plus simvastatin arm
11528201|NCT01156545|Active Comparator|control arm|BIBW 2992 arm
11528202|NCT01156532||Adalimumab Treatment in Participants with Psoriasis|Participants with moderate to severe chronic plaque psoriasis defined as Psoriasis Area and Severity Index (PASI) ≥ 10 and body surface area ≥ 10% with or without psoriatic arthritis, who have an adalimumab therapy indication because they are candidates for systemic therapy or phototherapy and other systemic therapies are medically less appropriate.
11528203|NCT01156519|Other|Salivary cortisol|
11528204|NCT01156493|Experimental|Protein Hydrolyzed Formula|Infants assigned to this group will receive HP formula when breast milk not available or indicated to receive formula by the attending physician
11528205|NCT01156493|No Intervention|Control|Infants in this group will receive standard prematrue formula when no breast milk available or indicated by the attending physician
11528206|NCT01156480|Experimental|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via intravenous (IV) route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. Subjects in placebo group will receive equal volume of placebo on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
11528207|NCT01156480|Placebo Comparator|Placebo|Subjects in placebo group will receive equal volume of placebo (as compared to hydrocortisone arm) on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
11528208|NCT01156467|Active Comparator|Control|Infants randomised to this arm will receive a regular nasogastric tube, and the ventilatory care is given as routinely is done.
11528209|NCT01156467|Active Comparator|NAVA|Infants randomised to this arm will receive and Edi-catheter as an oro-/nasogastric tube and the Edi-signal will be monitored and when possible NAVA-ventilation used.
11528210|NCT01156454||Surgery followed by x-ray assessment|After nodes are removed they are taken to radiology to be x-rayed
11528211|NCT01156441|Experimental|surgical mitral valve repair|Non-invasive transesophageal echocardiography will be performed on all study volunteers to determine if the individual has mitral regurgitation and, if so, to what degree. Mitral valve repair will be performed with mitral valve annuloplasty via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia.
11528212|NCT01156441|No Intervention|control: medical management|Clinical observation will be continued without surgery. Non-invasive transesophageal echocardiography will be performed on all study volunteers to determine if the individual has mitral regurgitation and, if so, to what degree.
11528213|NCT01156428||Control Subjects (normal volunteers)|"Control kidney specimens will be obtained from donor transplant kidneys or nephrectomy specimens performed on patients undergoing nephrectomy for the clinical indication of an identified renal mass.
~In the case of donor transplant kidneys, the renal biopsy will be conducted during the act of living donor nephrectomy and transplantation.
~In the case of renal mass nephrectomies, representative normal tissue will be obtained from the nephrectomized kidney at a site distant from the renal mass."
11528217|NCT01156402|Experimental|Active Intervention: Obesity Prevention|
11528218|NCT01156402|Experimental|Alternative Intervention/control: Oral Health|
11528219|NCT01156389|Active Comparator|Ritonavir plus Pyramax arm|Subjects in arm A will take 7 days of ritonavir followed by 3 days of ritonavir plus Pyramax followed by 7 days of ritonavir followed by 33 days follow-up period (40 days since last Pyramax dosing) and a study completion evaluation.
11528220|NCT01156389|Active Comparator|Pyramax arm|Subjects in arm B will take a three day treatment course of Pyramax, followed by a follow up period of 40 days since last Pyramax dosing and a study completion evaluation.
11528221|NCT01156376|Experimental|PO-019|Formula 12027-019 Mouthwash
11528222|NCT01156376|Experimental|PO-020|Formula 12027-020 Mouthwash
11528223|NCT01156376|Active Comparator|PO-116-A|Cool Mint Listerine
11528224|NCT01156363|Experimental|Single Arm|
11528225|NCT01156337||low sodium diet 80 mmol/day|
11528226|NCT01156337||moderate sodium intake 120 mmol/day|
11528227|NCT01156324|Placebo Comparator|Control|Participants of the routine care control group will each receive a $50 gift certificate at the end of each IVF cycle for which they completed the questionnaires.
11528228|NCT01156324|Experimental|Online Stress Management Group (Upliv)|Personalized online stress management program consisting of weekly sessions which each include relaxation exercises, stress management strategies, and lifestyle modification advice. Participants in Upliv will also be given a set of personal care products as part of the program.
11528229|NCT01156311|Experimental|Glatiramer acetate (GA) and dimethyl fumarate|Participants taking a stable dose of GA for at least 12 months prior to the study remain on that dose throughout the study. Dimethyl fumarate is administered at 120 mg three times a day (TID) on Days 1-7, and 240 mg TID on Day 8 until the end of treatment (approximately 6 months).
11528230|NCT01156311|Experimental|Interferon beta (IFNβ) and dimethyl fumarate|Participants taking a stable dose of one of the IFNβ products for at least 12 months prior to the study remain on that product and dose throughout the study. Dimethyl fumarate is administered at 120 mg three times a day (TID) on Days 1-7, and 240 mg TID on Day 8 until the end of treatment (approximately 6 months).
11528231|NCT01156298||Cohort 1|Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS. Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not. Cohort 1 patients will have annual EDSS, self-report EDSS, medication review and relapse recalculation. SF-36 and SDMT assessments will be performed at years 1 and 5 during routine office visits. A MRI will be performed each patient's 15 year anniversary date.
11528232|NCT01156298||Cohort 2|Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS. Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not. Patients will be waiving written informed consent and asked to provide concomitant medication, self-reported EDSS, and SF-36 only.
11528233|NCT01156285||AAU|patient with acute attack of anterior uveitis
11528234|NCT01156272||Replacement aortic heart valve|ATS 3f® Aortic Bioprosthesis, Model 1000, Size 19mm
11528235|NCT01156259|Experimental|30 Gy|
11528236|NCT01156259|Active Comparator|40 Gy|
11528237|NCT01156246|Experimental|1|Dapagliflozin/metformin tablet, high fat, high calorie breakfast day 1, visit 2, 7-14 days wash-out, Dapagliflozin/metformin tablet, fasting conditions day 1, visit 3.
11528238|NCT01156246|Experimental|2|Dapagliflozin/metformin tablet, fasting conditions day 1, visit 2, 7-14 days wash-out, Dapagliflozin/metformin tablet, high fat, high calorie breakfast day 1, visit 3.
11528239|NCT01156233|Experimental|Cuff palpation technique|Cuff palpation by the investigator's finger.
11528240|NCT01156233|Experimental|Withdrawing tube technique|Identification of the tube by withdrawing until good quality breath sounds
11528241|NCT01156220|Experimental|female|"The healthy female volunteers receive furosemide and aminohippurate sodium PAH as single dose randomised on day 1 or day 2."
11528242|NCT01156220|Experimental|male|"The healthy male volunteers receive furosemide and aminohippurate sodium PAH as single dose randomised on day 1 or day 2"
11528243|NCT01156207|Experimental|Aliskiren|
11528244|NCT01156207|Placebo Comparator|placebo|
11528245|NCT01156194|Active Comparator|Homeopathy 1|Arnica montana C6 and Bellis perennis C6
11528246|NCT01156194|Active Comparator|Homeopathy 2|Arnica montana C30 and Bellis perennis C30
11528247|NCT01156194|Placebo Comparator|Placebo|globules identical to true comparators
11528248|NCT01156181|Experimental|Cervical discharge removal|Cervical discharge will be removed using a cotton swab before embryo transfer during ICSI cycles
11528249|NCT01156181|Active Comparator|Control|Embryo transfer without any intervention
11528250|NCT01156155||Participants with Rheumatoid Arthritis|Rheumatoid arthritis patients Digital xray of jaw and teeth Blood draw questionnaires Periodontal Examination Bilateral digital xray of hands
11528251|NCT01156155||Osteoarthritis|Osteoarthritis patients Digital xray of jaw and teeth Blood draw questionnaires Periodontal Examination
11528252|NCT01156142|Experimental|Arm I|Patients receive doxepin hydrochloride oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm II on day 2.
11528253|NCT01156142|Placebo Comparator|Arm II|Patients receive placebo oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm I on day 2.
11528254|NCT01156129|Active Comparator|Arm A: Standard therapy (use of medications)|stool softener
11528255|NCT01156129|Experimental|Arm B: Acupressure bracelets|device - Biobands
11528256|NCT01156129|Experimental|Arm C|Sugar free gum
11528257|NCT01156116|Active Comparator|Continuous positive airway pressure|2 weeks of continuous positive airway pressure (CPAP) treatment which includes wearing the CPAP mask for 8 hours each night
11528258|NCT01156116|Placebo Comparator|Placebo|2 weeks of oral administration of a placebo tablet 30min before bedtime
11528259|NCT01156103|Experimental|SCORES|America SCORES, Bay Area, after-school program
11528260|NCT01156103|No Intervention|Usual care|Standard after-school programming
11528261|NCT01156090||Vectibix|patients who received at least one treatment of Vectibix
11528262|NCT01156077|Experimental|oral TR-701 FA|Single oral dose of 200 mg TR-701
11528263|NCT01156077|Experimental|IV TR-701 FA|Single IV infusion of 200 mg TR-701 FA
11528264|NCT01156064||Case (subjects with digestive diseases)|The investigators cases are subjects with confirmed digestive diseases.
11528265|NCT01156064||Control|Healthy individuals aged between 18 and 90 years who are asymptomatic for digestive diseases.
11528266|NCT01156051|Experimental|Guanfacine Extended-Release Tablets|Guanfacine Extended-Release Tablets 1mg, 2mg, 3mg, and 4mg
11528267|NCT01156051|Placebo Comparator|Placebo comparator|Placebo control
11528268|NCT01156038|Experimental|Atopy patch test|Atopy patches were applied on healthy volunteer's back for 48 hrs then the patches were removed. Reaction was evaluated 48 and 72 hrs after applying atopy patch test
11528269|NCT01156025|Experimental|GV550|(Ganciclovir 1.5 mg/g ophtalmic gel)
11528270|NCT01156025|Placebo Comparator|Placebo|Placebo ophtalmic gel
11528271|NCT01156012|Experimental|T2345|One drop of T2345
11528272|NCT01156012|Active Comparator|Prostaglandin|One drop
11528273|NCT01155999|Experimental|T1225|
11528274|NCT01155999|Active Comparator|Tobramycin|
11528275|NCT01155986|Placebo Comparator|Placebo Plaster|Active Comparator
11528276|NCT01155986|Active Comparator|Lidocaine Plaster|
11528277|NCT01155973|Experimental|EDUCORE intervention|Use of low risk SCORE table. Use of visual impact images. Handing the patient a pamphlet (advice on how to maintain cardiovascular health plus the low risk SCORE table with the patient's current score marked).
11528278|NCT01155973|Active Comparator|control group|Use of low risk SCORE table; verbally informing the patient of his/her CVR. Giving advice/verbal information on risk factors.
11528279|NCT01155960|Active Comparator|Arimidex|Arimidex® Tablets 1 mg
11528280|NCT01155960|Experimental|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
11528281|NCT01155947|Active Comparator|Arimidex|Arimidex® Tablets 1 mg
11528282|NCT01155947|Experimental|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
11528283|NCT01155934|Experimental|Risperidone Orally Disintegrating|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
11528284|NCT01155934|Active Comparator|Risperdal M-TAB|(Risperdal M-TAB) 1 mg risperidone orally disintegrating tablets Janssen Pharmaceutica Products
11528285|NCT01155921|Experimental|Risperidone Orally Disintegrating|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
11528286|NCT01155921|Active Comparator|Risperdal M-TAB|(Risperdal M-TAB) 1 mg risperidone orally disintegrating tablets Janssen Pharmaceutica Products
11528287|NCT01155908|Experimental|Amlodipine Besylate/Benazepril Hydrochloride|10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules of Dr.Reddy's Laboratories Limited
11528288|NCT01155908|Active Comparator|Lotrel|Lotrel® (10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules) of Novartis
11528289|NCT01155895|Experimental|Amlodipine Besylate/Benazepril Hydrochloride|10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules of Dr.Reddy's Laboratories Limited
11528290|NCT01155895|Active Comparator|Lotrel|Lotrel® (10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules) of Novartis
11528291|NCT01155882||Whipple Surgery at the Splenic Artery|Whipple at the Splenic Artery (WATSA) is at resecting tumors with negative microscopic margins (R0) at the resection line on the pancreas and at the tangential posterior, uncinate, and venous margins.
11528292|NCT01155869|Experimental|XR-NTX|Depot naltrexone (Vivitrol) 380 mg. IM monthly
11528293|NCT01155869|Active Comparator|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
11528294|NCT01155856|Experimental|telemedicine|Within 24 hours after admission for exacerbation of COPD, patients in the intervention group are sent home for further treatment (telemedicine based) instead of the conventional treatment at the hospital. Patients in the intervention group will receive the same treatment as the control group and have daily contact with the physician/nurse at the hospital through a videoconference system.
11528295|NCT01155856|No Intervention|control|The control group will receive usual care and treatment at the hospital until discharge(typically between 5-7 days).
11528296|NCT01155843||Asthmatic, chronic stress|
11528297|NCT01155843||Asthmatic, non-stress|
11528298|NCT01155830||Infants with CHD|Infants with Congenital Diaphragmatic Hernia (CHD)
11528299|NCT01155830||Infants with sepsis|Infants who are culture positive for sepsis and require vasopressor support
11528300|NCT01155830||Infants treated with ECMO|Infants suffering cardiopulmonary failure significant enough to require heart/lung bypass treatment with extracorporeal membrane oxygenation (ECMO)
11528301|NCT01155817|Experimental|Nilotinib|
11528302|NCT01155804|Other|Exercice|
11528303|NCT01155804|Other|non-exercice|
11528304|NCT01155791|Experimental|combination sodium selenite and docetaxel|
11528305|NCT01155778|Experimental|10 mg rhHNS|10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months
11528306|NCT01155778|Experimental|45 mg rhHNS|45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months
11528307|NCT01155778|Experimental|90 mg rhHNS|Given IDDD as a 45 mg dose every 14 [±2 days] for a monthly total of 90 mg for 6 months
11528308|NCT01155765|Experimental|Prasugrel|Prasugrel per os 10 mg/day
11528309|NCT01155765|Active Comparator|Clopidogrel|Clopidogrel per os 150 mg/day
11528310|NCT01155752|Experimental|PULMOZYME|active drug
11528311|NCT01155752|Placebo Comparator|placebo|cross over to placebo
11528312|NCT01155739||procalcitonine monitoring|PCT group: antibiotic use is tailored by serum procalcitonin values, determined every 48houres.
11528313|NCT01155739||control group|control group: antibiotic use and length of treatment as defined by guidelines
11528314|NCT01155726|Active Comparator|Nelfilcon A, Masked, Unmasked|Nelfilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (unmasked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
11528315|NCT01155726|Active Comparator|Nelfilcon A, Masked, Partially Masked|Nelfilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (partially masked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
11528354|NCT01155492||Subjects with Parkinson's disease|Male and female subjects with clinically diagnosed Parkinson's disease, Stage I-IV.
11528355|NCT01155492||Control subjects|Age- and gender-matched subjects who do not have Parkinson's disease
11528316|NCT01155726|Active Comparator|Etafilcon A, Masked, Unmasked|Etafilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (unmasked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
11528317|NCT01155726|Active Comparator|Etafilcon A, Masked, Partially Masked|Etafilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (partially masked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
11528318|NCT01155713|Experimental|Arm 1 - TKI258 - bioavailability|
11528319|NCT01155713|Experimental|TKI258 - food effect|
11528320|NCT01155700|Experimental|Omalizumab|Omalizumab treatment
11528321|NCT01155687||Psychosocial counseling|the group received annualized treatment of psychosocial counseling
11528322|NCT01155687||Medication|this group received medical treatment by the local medical doctor
11528323|NCT01155674||Sepsis patients|Patients presenting sepsis
11528324|NCT01155674||SIRS patients|Patients presenting with the systemic inflammatory response syndrome
11528325|NCT01155674||Healthy subjects|Healthy blood donors
11528326|NCT01155661|Experimental|LY2216684 (edivoxetine) + SSRI|
11528327|NCT01155648|Experimental|PSV group.|Chest wall compression plus increase of 10 cmH2O of PSV.
11528328|NCT01155648|Active Comparator|chest wall compression group|Chest wall compression
11528329|NCT01155635|Active Comparator|Beta-blocker|Use of Carvedilol with any dose
11528330|NCT01155635|Active Comparator|Non Beta-blocker|No use of Carvedilol
11528331|NCT01155622|Active Comparator|32º Celsius|Endovascular Cooling was set at a target temperature of 32°C
11528332|NCT01155622|Active Comparator|34º Celsius|Endovascular Cooling was set at a target temperature of 32°C
11528333|NCT01155609|Experimental|Supportive care (oral complications management)|Patients receive L-Lysine PO QD until completion of radiotherapy and resolution of mucositis in the absence of disease progression or unacceptable toxicity.
11528334|NCT01155596|No Intervention|Control group|Base on positive pressure ventilation with intubation and mechanical ventilator, weaning processes will undergo by Pulmonologists.
11528335|NCT01155596|Experimental|Experimental group|Experimental group is weaning with the support of negative pressure ventilator.
11528336|NCT01155583|Experimental|Arm A - Azacitidine/Lenalidomide/Dexamethasone|"Dose Level (DL) 1 - Azacitidine 30mg/m2 1x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week
~DL 2 - Azacitidine 40mg/m2 1x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week
~DL 3 - Azacitidine 30mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week
~DL 4 - Azacitidine 40mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week
~DL 5 - Azacitidine 50mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week
~Patients (with GFR > 60 ml/min) receive azacitidine subcutaneously 1 or 2x per weekly and oral Dexamethasone 1x weekly starting on day 1. Patients receive oral lenalidomide 1x daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
11528337|NCT01155583|Experimental|Arm B - Chronic Kidney Disease (CDK) Cohort|"DL (-1) - Azacitidine 30mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week
~DL 1 - Azacitidine 40mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week
~DL 2 - Azacitidine 50mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week
~Patients (with GFR 30-59 ml/min Chronic Kidney Disease (CKD)) receive azacitidine subcutaneously 1 or 2x per weekly and oral dexamethasone 1x weekly starting on day 1. Patients receive oral lenalidomide 1x daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
11528338|NCT01155570||Humira|Humira 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 80 mg.
11528339|NCT01155557|Active Comparator|Specific Strength Training|10 weeks of specific strength training of neck and shoulder muscles using elastic resistance.
11528340|NCT01155557|Active Comparator|Lifestyle Counseling|10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
11528341|NCT01155544|Active Comparator|Aripiprazole|
11528342|NCT01155544|Placebo Comparator|Placebo|
11528343|NCT01155531|Experimental|Telenzepine - Group A|Group A: No Sertraline; 0, 1, 2, 3 mg/day Telenzepine
11528344|NCT01155531|Experimental|Sertraline plus Telenzepine - Group B|Sertraline 50 mg/day; 0, 1, 2, 3 mg/day Telenzepine
11528345|NCT01155531|Experimental|Sertraline plus Telenzepine - Group C|Sertraline 50, 100 mg/day; 0, 1, 2, 3 mg/day Telenzepine
11528346|NCT01155531|Experimental|Sertraline plus Telenzepine - Group D|Sertraline 50, 100, 150 mg/day; 0, 1, 2, 3 mg/day Telenzepine
11528347|NCT01155518|Experimental|testosterone|intramuscular injections every 2 weeks
11528348|NCT01155518|Experimental|clomiphene|oral drug thrice a week
11528349|NCT01155518|Placebo Comparator|placebo for testosterone|placebo for testosterone arm
11528350|NCT01155518|Placebo Comparator|placebo for clomiphene|oral placebo for clomiphene arm
11528351|NCT01155518|No Intervention|eugonadal obese|obese men with normal testosterone level
11528352|NCT01155518|No Intervention|lean|healthy lean men (control)
11528353|NCT01155505|Experimental|CC-5013 in combination with Paclitaxel|"Cohorts of 3 evaluable patients will initially be entered within each dose level, sequentially. In each dose level the second and third patient will enter 2 weeks after the first one. The second and third patient may be treated simultaneously, except if a DLT is reported in the first patient, in which case the second and third patient should be treated sequentially, at least one week apart.
~Dose escalation will be done when all the patients included in each DL will finish the first treatment cycle. Three additional patients will be sequentially entered (separated by one week each other) if one DLT is observed in cycle 1 among the first 3 patients entered within a dose level. If a DLT is observed in a second patient at this dose level, no further dose escalation will be allowed and the dose level will be considered the MTD.
~Once the RD (one level below the MTD) has been defined, additional patients (up to 12) will be treated in order to confirm the safety profile of the combination."
11529642|NCT01146639|Experimental|MDCT and additional DynaCT|
11528356|NCT01155492||Multiple system atrophy.|Men and women with clinically diagnosed multiple system atrophy.
11528357|NCT01155479|Experimental|Preladenant 2 mg|Preladenant 2 mg oral tablet and placebo for rasagiline taken in the morning (AM) followed by preladenant 2 mg oral tablet taken in the evening (PM) for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
11528358|NCT01155479|Experimental|Preladenant 5 mg|Preladenant 5 mg oral tablet and placebo for rasagiline taken in the AM followed by preladenant 5 mg taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
11528359|NCT01155479|Experimental|Preladenant 10 mg|Preladenant 10 mg oral tablet and placebo for rasagiline taken in the AM followed by preladenant 10 mg taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
11528360|NCT01155479|Placebo Comparator|Placebo|Placebo for preladenant and placebo for rasagiline taken in the AM followed by placebo for preladenant taken in the PM for 26 weeks (Part 1); preladenant 5 mg was taken twice daily for 26 weeks (Part 2).
11528361|NCT01155479|Active Comparator|Rasagiline|Rasagiline 1 mg oral capsule and placebo for preladenant taken in the AM followed by placebo for preladenant taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
11528362|NCT01155466|Experimental|Preladenant 2 mg|Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks
11528363|NCT01155466|Experimental|Preladenant 5 mg|Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks
11528364|NCT01155466|Experimental|Preladenant 10 mg|Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks
11528365|NCT01155466|Placebo Comparator|Placebo|Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks
11528366|NCT01155466|Active Comparator|Rasagiline 1 mg|Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks
11528367|NCT01155453|Experimental|BKM120 + GSK1120212 DE|Dose Escalation
11528368|NCT01155453|Experimental|BKM120 + GSK1120212 NSCLC patients|Advanced RAS or BRAF mutant NSCLC patients
11528369|NCT01155453|Experimental|BKM120 + GSK1120212 ovarian cancer patients|Advanced RAS or BRAF mutant ovarian cancer patients
11528370|NCT01155453|Experimental|BKM120 + GSK1120212 pancreatic cancer patients|Advanced RAS or BRAF mutant pancreatic cancer patients
11528371|NCT01155440|Experimental|LIDOCAINE group|Beside general anesthesia, patients will receive intravenous lidocaine bolus 1.5 mg/kg just prior induction and an infusion of lidocaine 2mg/kg/h will be started and maintained during the whole surgical procedure. Entering the recovery room, this infusion will be decreased at the rate of 1mg/kg/hour for the 48 first hours
11528372|NCT01155440|Active Comparator|Epidural group|Beside general anesthesia, patient will receive epidural freezing medication for 48 hours.
11528373|NCT01155427||entecavir|Patients initiating special antiviral treatments for CHB
11528374|NCT01155427||tenofovir|Patients initiating special antiviral treatments for CHB
11528375|NCT01155427||lamivudine|Patients initiating special antiviral treatments for CHB
11528376|NCT01155427||telbivudine|Patients initiating special antiviral treatments for CHB
11528377|NCT01155427||adefovir|Patients initiating special antiviral treatments for CHB
11528378|NCT01155414|Experimental|Investigational infant formula A|Investigational Protein Hydrolysate formula
11528379|NCT01155414|Active Comparator|Hydrolysate based Infant Formula|
11528380|NCT01155414|Experimental|Investigational Infant Formula B|Investigational Protein Hydrolysate Formula
11528381|NCT01155401||1|Patients with acute upper gastrointestinal bleeding
11528382|NCT01155388|Experimental|Ferumoxytol|"Participants will receive 1 of the following 2 ferumoxytol dose regimens:
~Four IV injections of ferumoxytol 3.5 mg Fe/kg (maximum of 255 mg/dose) administered on nonconsecutive days within a 14-day period as follows: Day 1 (dose 1), Days 3* through 10 (dose 2), Days 5 through 12 (dose 3), and Days 7 through 14 (dose 4). *Participants participating in PK sampling received the second dose on Day 4 after the 72-hour PK sample was collected.
~Two IV injections of ferumoxytol 7.0 mg Fe/kg (maximum of 510 mg/dose), the first administered on Day 1 and the second on Days 3 through 9."
11528383|NCT01155388|Active Comparator|Oral Iron|Participants will receive oral iron: 2.5 mg Fe/kg twice daily (maximum of 100 mg/dose) on Days 1 through 35.
11528384|NCT01155375|Experimental|Ferumoxytol|"Participants will receive 1 of the following 2 ferumoxytol dose regimens:
~Four IV injections of ferumoxytol 3.5 mg Fe/kg (maximum of 255 mg/dose) administered on nonconsecutive days within a 14-day period as follows: Day 1 (dose 1), Days 3* through 10 (dose 2), Days 5 through 12 (dose 3), and Days 7 through 14 (dose 4). *Participants participating in PK sampling received the second dose on Day 4 after the 72-hour PK sample was collected.
~Two IV injections of ferumoxytol 7.0 mg Fe/kg (maximum of 510 mg/dose), the first administered on Day 1 and the second on Days 3 through 9."
11528385|NCT01155375|Active Comparator|Oral Iron|Participants will receive oral iron 2.5 mg Fe/kg twice daily (maximum of 100 mg/dose) on Days 1 through 35.
11528386|NCT01155362|Experimental|1 unit Human Placenta-Derived Cells PDA001|1 unit PDA001 in 240 millilters (mL) infused intravenously in one arm on Day 0 and Day 7.
11528387|NCT01155362|Experimental|4 units Human Placenta-Derived Cells PDA001|4 units PDA001 in 240 mL infused intravenously in one arm on Day 0 and Day 7.
11528388|NCT01155362|Placebo Comparator|vehicle control|4 units placebo in 240 mL infused intravenously in one arm on Day 0 and Day 7.
11528389|NCT01155362|Experimental|8 units Human Placenta-Derived Cells PDA001|4 units PDA-001 in 240 mL infused intravenously in each arm on Day 0 and Day 7 or 8 units PDA-001 in 240 mL infused intravenously in one arm on Day 0 and Day 7
11528390|NCT01155349|Experimental|InSight Brain Fitness|
11528391|NCT01155349|Placebo Comparator|No contact-control|
11528392|NCT01155336|Experimental|Lovaza®|Lovaza® is a prescription grade EPA+DHA fish oil supplement. Four capsules (each containing 1 gram of fish oil) were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
11528393|NCT01155336|Placebo Comparator|Corn Oil|The placebo contained 1 gram of corn oil in each capsule. Four capsules were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
11528548|NCT01154387|Experimental|TOL101 (Dose A)|TOL101 induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
11528394|NCT01155323|Active Comparator|etafilcon A/omafilcon A|etafilcon A contact lenses will be worn during the first week and omafilcon A contact lenses will be worn during the second. Lenses were replaced daily
11528395|NCT01155323|Active Comparator|omafilcon A/etafilcon A|omafilcon A contact lenses will be worn during the first week and etafilcon A contact lenses will be worn during the second. Lenses were replaced daily.
11528396|NCT01155310|Experimental|Helium/Oxygen|Helium/Oxygen 78%/22% will be administered for a maximum of 72 hours.
11528397|NCT01155310|Active Comparator|Air/Oxygen|Air/Oxygen will be administered for a maximum of 72 hours.
11528398|NCT01155297|Sham Comparator|Control Group|At the control group, with 34 subjects, will be performed stretching and metabolic exercises. This group will make the assessments before and the reassessments after the end of the program.
11528399|NCT01155297|Active Comparator|Training group|At the training group, with 34 subjects, will be performed stretching, physical training and resistance. This group will make the assessments before and the reassessments after the end of the program.
11528400|NCT01155284|Experimental|Sitagliptin and Lansoprazole|Sitagliptin 50mg co-administered with Lansoprazole 30mg. Subjects age 11-17 years at Visit 2 will take 1 capsule of each once daily Subjects age 18-45 years at Visit 2 will take 2 capsules of each once daily
11528401|NCT01155284|Placebo Comparator|Placebo|Sitagliptin Placebo and Lansoprazole placebo capsules will be administered. Subjects age 11-17 years at Visit 2 will take 1 placebo capsule of each once daily Subjects age 18-45 years at Visit 2 will take 2 placebo capsules of each once daily
11528402|NCT01155271|Active Comparator|ERGO|General endurance training on cycloergometer
11528403|NCT01155271|Active Comparator|ERGONIV/ ERGOSPIRO|General endurance training on cycloergometer using ventilatory assistance (ERGONIV) or additional respiratory muscle training (ERGOSPIRO)
11528404|NCT01155258|Experimental|Arm I|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and vinorelbine ditartrate IV over 5-10 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11528405|NCT01155245||Forteo (teriparatide)|postmenopausal women with osteoporosis
11528406|NCT01155245||Forteo (teriparatide) with AFF|Women with atypical femur fractures
11528407|NCT01155232||Forteo (teriparatide)|postmenopausal women and men with osteoporosis Teriparatide is marketed as Forteo by Eli Lilly Teriparatide is not supplied (observational study)
11528408|NCT01155232||Forteo (teriparatide) in AFF|women who have experienced an atypical femur fracture (AFF) Teriparatide is not supplied (observational study)
11528409|NCT01155219|Experimental|Geltim LP®|Geltim LP® 1 mg/g (0.1 % timolol maleate, without preservative) packaged in single-dose containers (unidoses); one drop in the conjunctival sac of each eye in the morning (84 days).
11528410|NCT01155219|Active Comparator|Xalatan®|Xalatan® (Latanaprost) aqueous eye drop (one drop in the conjunctival sac of each eye in the evening during 84 days.
11528411|NCT01155206|Experimental|high glucagon|For one of the two studies to be performed in random order, the subject will receive an infusion of glucagon at a dose that has been shown to achieve high physiological plasma levels. The IV glucagon will be administered at a rate of 3ng/kg/min.
11528412|NCT01155206|Experimental|low glucagon|For one of the two studies to be performed in random order, the subject will receive an infusion of glucagon at a low rate that is designed to mimic basal plasma glucagon concentration. The IV glucagon will be administered at a rate of 0.65ng/kg/min.
11528413|NCT01155193||Palivizumab|Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season.
11528414|NCT01155180|Experimental|Leptin|We will start the leptin at a dose of 0.08mg/kg fat mass in men and 0.14mg/kg fat mass in women
11528415|NCT01155180|Placebo Comparator|Placebo|We will start the placebo at a dose of 0.08mg/kg fat mass in men and 0.14mg/kg fat mass in women
11528416|NCT01155167|Placebo Comparator|Placebo|
11528417|NCT01155167|Experimental|Topical dilator|
11528418|NCT01155154|Active Comparator|clindamycin|clindamycin 300 mg (two 150 mg capsules) every 6 hours for 7 days
11528419|NCT01155154|Active Comparator|cepahlexin|
11528420|NCT01155154|Placebo Comparator|Placebo|
11528421|NCT01155141|Experimental|No arms|There are no arms to this study. All patients receive drug (H.P. Acthar Gel)
11528422|NCT01155128|Experimental|Lifestyle interventions|After recruitment of the participants and consented to participate those deemed eligible for inclusion completed baseline surveys will be randomly assigned to an intervention group and another control group that will receive the usual care
11528423|NCT01155128|Placebo Comparator|lifestyle interventions|After recruitment of the participants and consented to participate those deemed eligible for inclusion completed baseline surveys will be randomly assigned to an intervention group and another control group that will receive the usual care
11528424|NCT01155115|Experimental|Primary Ciliary Dyskinesia (PCD) Patients|
11528425|NCT01155115|Experimental|Cystic Fibrosis (CF) Patients|
11528426|NCT01155076|Experimental|Vitality product|Proprietary blend of ginseng, cordyceps, and pomegranate
11528427|NCT01155076|Placebo Comparator|Placebo|Placebo
11528428|NCT01155063||Main Group|Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer Who Are Disease-Free After 2-3 Years Of Initial Adjuvant Tamoxifen Therapy
11528429|NCT01155050|Active Comparator|Tele-health Home Monitoring|Participants will use the tele-health monitoring equipment to measure daily weight.
11528430|NCT01155050|No Intervention|Self-Directed Group|Participants will receive information on physical activity recommendations and guidelines on nutrition aimed at promoting weight loss.
11528431|NCT01155050|Active Comparator|TrestleTree Telephone Coaching|Participants will speak to Trestletree health coaches for 15 to 60 minutes each session. During these sessions, the coaches will identify the participant's stage of change and intervene accordingly. The telephone calls will be centered on weight loss.
11528432|NCT01155050|Active Comparator|Home monitoring + telephone coach|System to track stage of change in weight loss.
11528433|NCT01155037|Experimental|3.75 µg of the vaccine on days 0 and 21|Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
11528549|NCT01154387|Experimental|TOL101 (Dose B)|TOL101 induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
11528434|NCT01155037|Experimental|7.5 µg of the vaccine on days 0 and 21|Patients infected with HIV will receive 7.5µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
11528435|NCT01155037|Active Comparator|3.75 µg of the vaccine on day 0|The volunteers in the control group will receive a single application of 3.75 µg dose of the vaccine.
11528436|NCT01155024|Other|Traditional Socket First, then DM Socket|Initial fitting of a traditional diagnostic prosthetic socket in first intervention period and initial fitting of a direct manufactured prosthetic socket in the second intervention period
11528437|NCT01155024|Other|DM Socket First, then Traditional Socket|Initial fitting of a direct manufactured prosthetic socket in first intervention period and initial fitting of a traditional diagnostic prosthetic socket in the second intervention period
11528438|NCT01155011|Experimental|MIPARC intervention|"Eleven Continuing Care Retirement Communities were randomized to either the MIPARC intervention or an attention-control condition. The intervention focused on increasing light to moderate PA.
~The MIPARC study intervenes on four levels: individual (pedometer self monitoring, educational materials and monthly counseling calls, support), interpersonal (monthly group educational sessions and peer mentoring), environment (walking signage prompts, tailored environmental resources, step counts)and policies (review of on-site activity opportunities and walkability, recommendations for policy change and peer led advocacy)to increase the activity levels of residents.
~For the first 3 months, intervention participants will engage in either a group educational session, phone counseling call, or a peer led session, on a rotating basis."
11528439|NCT01155011|Active Comparator|Health Education Control|The control group received an active health education intervention. The education curriculum will involve both lectures and mailed materials. The lectures were delivered to match the MIPARC intervention schedule. Sessions included information on general health and healthy aging. Physical activity was not discussed in these sessions but participants received information on the benefits of PA. Control participants also received health check phone calls to match the individual attention paid to participants in the MIPARC intervention sites.
11528440|NCT01154998||Cases|
11528441|NCT01154998||Controls|
11528442|NCT01154985|Placebo Comparator|Placebo|3x placebo capsules TID
11528443|NCT01154985|Experimental|EPA-E 1800 mg/day|2x EPA-E 300 mg capsules + 1placebo capsule TID
11528444|NCT01154985|Experimental|EPA-E 2700 mg/day|3x EPA-E 300 mg capsules TID
11528445|NCT01154972|Experimental|Single arm study - Sentinel Node Localisation|
11528446|NCT01154959|Experimental|Regimen 1|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 3 months (3RHZEM)
11528447|NCT01154959|Experimental|Regimen 2|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, and moxifloxacin daily for 2 months (2 RHZEM daily / 2 RHM daily)
11528448|NCT01154959|Experimental|Regimen 3|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, and moxifloxacin thrice weekly for 2 months (2 RHZEM daily / 2RHM thrice weekly)
11528449|NCT01154959|Experimental|Regimen 4|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, ethambutol and moxifloxacin thrice weekly for 2 months (2 RHZEM daily / 2 RHEM thrice weekly)
11528450|NCT01154959|Active Comparator|Control Regimen|Rifampicin, isoniazid, pyrazinamide and ethambutol thrice weekly for 2 months followed by rifampicin and isoniazid thrice weekly for 4 months (2 RHZE thrice weekly / 4 RH thrice weekly)
11528451|NCT01154946||DAC group|patients who show detrusor after-contraction during voiding cystometrography (CMG)
11528452|NCT01154933|Experimental|exenatide 5 mcg|exenatide 5 mcg
11528453|NCT01154933|Experimental|exenatide 10 mcg|exenatide 10 mcg
11528454|NCT01154933|Placebo Comparator|placebo|placebo
11528455|NCT01154920|Experimental|PCC Group + RT|Group A: Paclitaxel, Carboplatin and Cetuximab (PCC) Induction + Radiation (RT)
11528456|NCT01154920|Experimental|PCC Group + RT + Chemotherapy|Group A: Paclitaxel, Carboplatin and Cetuximab (PCC) Induction + Radiation (RT) + Chemotherapy
11528457|NCT01154920|Experimental|C-TPF Group + RT|Group B: Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) Induction + Radiation (RT)
11528458|NCT01154920|Experimental|C-TPF Group + RT + Chemotherapy|Group B: Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) Induction + Radiation (RT) + Chemotherapy
11528459|NCT01154907||Girls ages 10-12|"In 18 rural schools in Ugu District, South Africa. Undergoing mass-treatment provided by the Department of Health.
~Praziquantel was administered at 40mg/kg in annual mass-treatment"
11528460|NCT01154907||Young adult women|"In rural schools in three districts, South Africa. Undergoing mass-treatment provided by the Departments of Health.
~Praziquantel was administered at 40mg/kg in annual mass-treatment"
11528461|NCT01154894|Experimental|Placebo-controlled trial|
11528462|NCT01154881|Experimental|IDeg 100U/mL 0.4U/kg|
11528463|NCT01154881|Experimental|IDeg 100U/mL 0.6U/kg|
11528464|NCT01154881|Experimental|IDeg 100U/mL 0.8U/kg|
11528465|NCT01154881|Experimental|IDeg 200U/mL 0.6U/kg|
11528466|NCT01154868|Other|Healos|
11528467|NCT01154855||Periodontitis|"Patients with severe periodontal disease Intervention (Procedure/surgery): Prophylaxis; Gross debridement for diseased patients
~Other Names:
~Teeth cleaning
~1 per patient at 2nd visit lasting approximately 1 hour."
11528468|NCT01154855||Healthy patients|"Patients without periodontal (gum) disease Intervention (Procedure/surgery): Prophylaxis; Gross debridement for diseased patients
~Other Names:
~Teeth cleaning"
11528469|NCT01154842||Hemodialysis|Adult hemodialysis patients (age>18 years)
11528470|NCT01154829|Active Comparator|first choice treatment|Treatment with amisulpride
11528471|NCT01154829|Active Comparator|second choice treatment|treatment with aripiprazole
11528472|NCT01154816|Experimental|Arm I (neuroblastoma- measurable)|Patients with measurable neuroblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11528473|NCT01154816|Experimental|Arm II (Neuroblastoma- MIBG evaluable)|Patients MIBG evaluable neuroblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11528547|NCT01154387|Active Comparator|Anti-Thymocyte Globulin|Anti-Thymocyte Globulin induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
11528474|NCT01154816|Experimental|Arm III (rhabdomyosarcoma)|Patients with rhabdomyosarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11528475|NCT01154816|Experimental|Arm IV (osteosarcoma)|Patients with osteosarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11528476|NCT01154816|Experimental|Arm V (Ewing sarcoma/peripheral PNET)|Patients with Ewing sarcoma/peripheral PNET receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11528477|NCT01154816|Experimental|Arm VI (non-RMS soft tissue sarcoma)|Patients with non-RMS soft tissue sarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11528478|NCT01154816|Experimental|Arm VII (hepatoblastoma)|Patients hepatoblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11528479|NCT01154816|Experimental|Arm VIII (malignant germ cell tumor)|Patients with malignant germ cell tumor receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11528480|NCT01154816|Experimental|Arm IX (Wilms tumor)|Patients with Wilms tumor receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11528481|NCT01154816|Experimental|Arm X (acute lymphoblastic leukemia)|Patients with acute lymphoblastic leukemia receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11528482|NCT01154816|Experimental|Arm XI (acute myelogenous leukemia)|Patients acute myelogenous leukemia receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11528483|NCT01154816|Experimental|Arm XII (rhabdoid malignancy)|Patients with rhabdoid malignancy receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
11528484|NCT01154803|Experimental|Ready to Use Therapeutic Food (RUTF)|500 kcal /day for 2 weeks
11528485|NCT01154803|Experimental|Micronutrient Powder (MNP)|2 x 1 g sachets micronutrients /day for 2 weeks
11528486|NCT01154803|No Intervention|no supplement|no supplementation
11528487|NCT01154790|Experimental|CG100649|By the amount of doses, the groups are classified
11528488|NCT01154790|Active Comparator|Naproxen|By the amount of doses, the groups are classified
11528489|NCT01154790|Placebo Comparator|Placebo|By the amount of doses, the groups are classified
11528490|NCT01154764|Experimental|CG100649|study drug CG100649 (1 mg x 6 capsules) will be administered alone on Day 1, or the combination of CG100649 (1 mg x 6 capsules) and Dongkwang ketoconazole tablets (200 mg x 2 tablets) will be administered together on Day 1, followed by additional Dongkwang ketoconazole tablets (200 mg x 2 tablets) which will be administered once a day for 4 days (Days 2-5), for a total of 5 days.
11528491|NCT01154764|Experimental|CG100649 and ketoconazole|study drug CG100649 (1 mg x 6 capsules) will be administered alone on Day 1, or the combination of CG100649 (1 mg x 6 capsules) and Dongkwang ketoconazole tablets (200 mg x 2 tablets) will be administered together on Day 1, followed by additional Dongkwang ketoconazole tablets (200 mg x 2 tablets) which will be administered once a day for 4 days (Days 2-5), for a total of 5 days.
11528492|NCT01154751|Other|Device SUPERA Stent|SUPERA Interwoven Self-Expanding Nitinol Stent System
11528493|NCT01154738|Experimental|Lidocaine|Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Lidocaine
11528494|NCT01154738|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
11528495|NCT01154725|Other|Habitual stoma care|habitual patient education
11528496|NCT01154725|Experimental|Patient education and rehabilitation|patient education and rehabilitation
11528497|NCT01154712|Active Comparator|Real Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
11528498|NCT01154712|Sham Comparator|Sham Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
11528499|NCT01154699|Experimental|Usual Care first, then Bilevel PAP|"Subjects will begin the study by continuing their usual care for 4 weeks. They will complete questionnaires and breathing tests at the start and end of this 4 week period. After a Washout Period of an additional 4 weeks of usual care, they will then start Bilevel PAP therapy for 4 weeks. Just before and after the Bilevel PAP they will complete questionnaires and breathing tests."
11528500|NCT01154699|Experimental|Bilevel PAP first, then Usual Care|"Subjects will begin the study by starting on Bilevel PAP for 4 weeks. Just before and after the Bilevel PAP they will complete questionnaires and breathing tests. After a 4 week Washout Period of usual care, they will start a Usual Care period for 4 weeks. They will complete questionnaires and breathing tests at the start and end of this 4 week period."
11528501|NCT01154673|Experimental|Intensive HAART|"Patients in this arm will receive the following HAART regimen:
~Raltegravir 400 mg BID + Maraviroc 150mg BID + emtricitabine 200mg /tenofovir 300mg QD + lopinavir 400 mg/ritonavir 100mg BID for 96 weeks"
11528502|NCT01154673|Placebo Comparator|Placebo Arm|Placebo (in place of raltegravir and maraviroc) will be added to standard HAART (Emtricitabine 200mg /tenofovir 300mg QD + Lopinavir 400 mg/ritonavir 100mg BID) for 48 weeks and then offered open label Raltegravir and Maraviroc after 48 weeks
11528503|NCT01154660|Experimental|Neutral|
11528504|NCT01154660|Active Comparator|Trendelenberg|
11528505|NCT01154647|Experimental|selective serotonin reuptake inhibitor|intravenous, acute, 20mg/ml
11528506|NCT01154647|Placebo Comparator|1 ml 0.9 % NaCl|
11528507|NCT01154634|Experimental|First 5 mg, then placebo, then 16 mg, then 40 mg|period 1: AZD2516 5 mg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD2516 16 mg, period 6: washout, period 7: AZD2516 40 mg.
11528508|NCT01154634|Experimental|First 40 mg, then 16 mg, then placebo, then 5 mg|period 1: AZD2516 40 mg, period 2: washout, period 3: AZD2516 16 mg, period 4: washout, period 5: placebo, period 6: washout, period 7: AZD2516 5 mg.
11528550|NCT01154374|Experimental|MEBO Wound Ointment|Topical application twice daily
11528509|NCT01154634|Experimental|First 16 mg, then 5 mg, then 40 mg, then placebo|period 1: AZD2516 16 mg, period 2: washout, period 3: AZD2516 5 mg, period 4: washout, period 5: AZD2516 40 mg, period 6: washout, period 7: placebo.
11528510|NCT01154634|Experimental|First placebo, then 40 mg, then 5 mg, then 16 mg|period 1: placebo, period 2: washout, period 3: AZD2516 40 mg, period 4: washout, period 5: AZD2516 5 mg, period 6: washout, period 7: AZD2516 16 mg
11528511|NCT01154621|Experimental|1|Single dose of 750mg of intravenous AZD9742 in healthy elderly volunteers
11528512|NCT01154621|Placebo Comparator|2|Sterile 5% dextrose solution
11528513|NCT01154608|Experimental|pancreatic enzymes|
11528514|NCT01154608|Placebo Comparator|control|
11528515|NCT01154595|Active Comparator|Food-for-Training component|Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
11528516|NCT01154595|Experimental|Food-for-Training + RUF (Plumpy Doz(r))|"Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
~In addition, a blanket supplementation with 47g RUF (Plumpy Doz(r)) per day per child is provided."
11528517|NCT01154582|Experimental|Egg|
11528518|NCT01154582|Experimental|Cottage cheese|
11528519|NCT01154569|Active Comparator|Post Roux-en-Y gastric bypass|Post-bypass receiving a single dose of azithromycin
11528520|NCT01154569|Active Comparator|Controls|BMI and sex matched. Have not undergone surgery
11528521|NCT01154556||HIV1 positive, NNRTI exposure and failure|
11528522|NCT01154543||HIV positive, gential HSV,Famvir™ 500mg bd, suppressive|
11528523|NCT01154530|Active Comparator|Chlorhexidine mouthwash|Participants randomized to chlorhexidine mouthwash prior to gastroscopy
11528524|NCT01154530|No Intervention|No mouthwash|Mouthwash is not performed prior to gastroscopy as is the standard today.
11528525|NCT01154504|Other|clinical treatment|"Patients with previous diagnosis of decompensated III and IV Heart Failure will be included. The clinical treatment will be optimized.
~Clinical assessment, Adrenomedullin, Angiotensin II, Brain Natriuretic Peptide, oxydative stress, sympathetic nervous system activity will be evaluated at the beginning, at discharge and 90 days after randomization(plus or minus3)."
11528526|NCT01154504|Experimental|ultrafiltration|"ultrafiltration will be done on decompensated patients III and IV acute heart failure on Intensive Care Unit. This patients will have biochemical analysis, adrenomedullin, angiotensin II,Brain Natriuretic Peptide, oxydative stress measurements,sympathetic nervous system activity evaluated and clinical outcome analyzed at the beginning,at discharge and 90 days after randomization(plus or minus 3).
~Diuretic will be withdrawn during ultrafiltration."
11528527|NCT01154504|Experimental|isovolumetric hemofiltration|Patients randomized to this group will have isovolumetric hemofiltration on Intensive Care Unit. They will have biochemical analysis, Adrenomedullin plasmatic level, Brain Natriuretic Peptide Level, Angiotensin II level, Oxydative stress measurement,sympathetic nervous system, and clinical outcome evaluated at the study beginning,at discharge and 90 days after randomization(plus or minus 3).
11528528|NCT01154491|Placebo Comparator|Placebo|Two placebos: placebo for ferric carboxymaltose and placebo for erythropoietin
11528529|NCT01154491|Experimental|FE|Ferric carboxymaltose and placebo for erythropoietin
11528530|NCT01154491|Experimental|EPOFE|Ferric carboxymaltose and erythropoietin
11528531|NCT01154478|Experimental|B group|Diet rich in omega-3 fatty acids
11528532|NCT01154478|Experimental|C group|Diet rich in polyphenols
11528533|NCT01154478|Experimental|D group|Diet rich in polyphenols and in omega-3 fatty acids
11528534|NCT01154478|Placebo Comparator|A group (control group)|diet with low content of omega-3 fatty acids and polyphenols
11528535|NCT01154465|Active Comparator|Anatomical guidance puncture|"The patient is placed supine (with a slight neck extension for jugular punctures).
~The preparation of the CVC installation will follow the procedures for disinfection, for skin preparation of the operator, for installation of sterile fields and for local anaesthesia.
~The veins will be tracked by simple palpation of the carotid pulse.
~The puncture will be made following:
~The anterior Boulanger's incision for the internal jugular vein;
~When venous aspiration is obtained, the catheter is assembled according to the Seldinger method."
11528536|NCT01154465|Experimental|US-guided puncture|"The patient is placed supine (with a slight neck extension for jugular punctures).
~The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed. A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:
~- The anterior Boulanger's incision for the internal jugular vein pathway;"
11528537|NCT01154452|Experimental|Arm I (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.
11528538|NCT01154452|Experimental|Arm II (vismodegib and gamma-secretase inhibitor RO4929097)|Patients receive vismodegib PO and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.
11528539|NCT01154439|Experimental|Everolimus|Everolimus mice-regimen
11528540|NCT01154426|Experimental|Treatment (gemcitabine hydrochloride and ABT-888)|Patients receive oral ABT-888 twice daily on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 21* days in the absence of disease progression or unacceptable toxicity.
11528541|NCT01154413|Experimental|Intensive education of the doctor/nursing team on the protocol|
11528542|NCT01154413|No Intervention|Without intervention in the team|
11528543|NCT01154400|Experimental|Casein protein hydrolysates|15 g casein protein hydrolysates and 15 g maltodextrin
11528544|NCT01154400|Experimental|Whey protein hydrolysates|15 g whey protein hydrolysates and 15 g maltodextrin
11528545|NCT01154400|Experimental|Casein protein hydrolysates + LEU|15 g casein protein hydrolysates + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
11528546|NCT01154400|Experimental|Whey protein hydrolysates + LEU|15 g whey protein hydrolysates + 1.5 g LEU (40% of EAA content) + 15 g maltodextrin
11528551|NCT01154374|Active Comparator|Standard of Care (sterile saline moistened gauze)|Topical application twice daily
11528554|NCT01154348|Experimental|Washout period, S-707106 tablet|14-day washout of metformin, followed by S-707106 once daily for 14 days under fed conditions
11528555|NCT01154348|Placebo Comparator|Washout, placebo|14-day washout of metformin followed by placebo for S-707106 once daily for 14 days under fed conditions
11528556|NCT01154348|Experimental|Maintenance, S-707106 tablet plus metformin|14-day maintenance of metformin, followed by S-707106 once daily plus open-label metformin twice daily for 14 days under fed conditions
11528557|NCT01154348|Placebo Comparator|Maintenance, placebo plus metformin|14-day maintenance of metformin, followed by placebo for S-707106 once daily plus open-label metformin twice daily for 14 days under fed conditions
11528558|NCT01154335|Experimental|Dose Level 1|"combination of OSI-906 and everolimus
~OSI-906: 50 mg Twice a Day, cycle-28 days
~Everolimus: 5mg Daily, cycle-28 days"
11528559|NCT01154335|Experimental|Dose Level 2|"combination of OSI-906 and everolimus
~OSI-906: 100 mg Twice a Day, cycle-28 days
~Everolimus: 10mg Daily, cycle-28 days"
11528560|NCT01154335|Experimental|Dose Level 2a|"combination of OSI-906 and everolimus
~OSI-906: 100 mg Twice a Day, cycle-28 days
~Everolimus: 5mg Daily, cycle-28 days"
11528561|NCT01154322|Experimental|Pediatric mask|
11528562|NCT01154309|Experimental|1|Clients are invited to attend 18 group CBT sessions
11528563|NCT01154309|No Intervention|2|Clients receive usual care
11528564|NCT01154296|Experimental|Rapid HIV Testing w/ Counseling (Group 1)|Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.
11528565|NCT01154296|No Intervention|Rapid HIV Testing & Information Only (Group 2)|Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.
11528566|NCT01154283|Active Comparator|Bi-level, standard, NIPPV|Standard NIPPV with both an inspiratory and expiratory positive airway pressure.
11528567|NCT01154283|Experimental|IPAP-only, NIPPV|NIPPV with only inspiratory positive airway pressure, no expiratory positive airway pressure
11528568|NCT01154270|Experimental|IMRT + C12-boost|(8 x 3 GyE) carbon ion therapy followed by 50 Gy IMRT (2 Gy/ Fx)corresponding to a total dose of approximately 74 GyE.
11528569|NCT01154257|Experimental|Cleaning teeth with toothbrush|Following randomisation one side of the mouth (split mouth study) will be assigned to cleaning teeth with a toothbrush
11528570|NCT01154257|Experimental|Cleaning teeth with foam swab|Following randomisation one side of the mouth (split mouth study) will be assigned to cleaning teeth with a faom swab
11528571|NCT01154244||Drug naive type II DM|Newly diagnosed type II Diabetes Mellitus
11528572|NCT01154231||Nonacog Alfa (Genetical Recombination)|
11528573|NCT01154218|Experimental|1|"All subjects will receive four treatments in one of the indicated orders:
~A-B-C-D, B-D-A-C, C-A-D-B, D-C-B-A"
11528574|NCT01154205||Patients post implantation of ICD or CRTD|
11528575|NCT01154192|Experimental|PCOS group|Intervention: Each subject in the PCOS group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
11528576|NCT01154192|Experimental|Normal group|Intervention: Each subject in the Normal group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
11528577|NCT01154192|Experimental|Oligomenorrhea group|Intervention: Each subject in the Oligomenorrhea group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
11528578|NCT01154179|No Intervention|Normocaloric feeding|This control group will receive energy and protein intakes as recommended by the use of Schofield equations, as is current practice (100% of requirements)
11528579|NCT01154166|Experimental|ReQuip PR|Ropinirole PR tablets of 2.0 mg, 4.0mg and 8.0 mg
11528580|NCT01154166|Placebo Comparator|Placebo|Placebo
11528581|NCT01154153|Placebo Comparator|Placebo|"placebo during the screening phase and
~placebo during the treatment phase.
~All children had the option to take rescue medication, (Claritin®) as needed to relieve symptoms of AR."
11528582|NCT01154153|Experimental|TAA-AQ|"placebo during the screening phase and
~TAA-AQ (Nasacort AQ) during the treatment phase.
~All children had the option to take rescue medication, (Claritin®) as needed to relieve symptoms of AR."
11528583|NCT01154140|Experimental|A|
11528584|NCT01154140|Active Comparator|B|
11528585|NCT01154127|Experimental|NVA237 followed by Placebo|"Period 1: 50 μg NVA237 via NEOHALER inhaler device for 21 days
~Period 2: Matching placebo via NEOHALER inhaler device for 21 days
~The washout period ran for 14 to 28 days between treatment periods. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study.
~Salbutamol (albuterol) was used as rescue medication throughout the study."
11528586|NCT01154127|Experimental|Placebo followed by NVA237|"Period 1: Matching placebo of NVA237 via NEOHALER inhaler device for 21 days
~Period 2: 50 μg NVA237 via NEOHALER inhaler device for 21 days
~The washout period ran for 14 to 28 days between treatment periods. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study.
~Salbutamol (albuterol) was used as rescue medication throughout the study."
11528587|NCT01154114|Experimental|moderate hepatic impaired subjects|Male and female subjects with moderate hepatic impairment defined by a Child-Pugh score of 7-9 will be included. The subjects will be administered 40 mg oral doses of darapladib (SB-480848) enteric-coated tablets daily for 10 consecutive days.
11528588|NCT01154114|Experimental|normal healthy volunteers|Healthy male and female subjects will be included and will be matched as closely as possible to the group of moderate hepatic impairment subjects for gender, age and body mass index. Each subject will receive daily 40 mg oral doses of darapladib (SB-480848) enteric-coated tablets for 10 consecutive days.
11529010|NCT01151215|Placebo Comparator|3|Placebo (bd) plus anastrozole 1mg (od)
11528589|NCT01154101|Active Comparator|Cohort 2 - 500mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).
~Cohort 2 will commence after Cohort 1 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee.
~Cohort 2 will be administered at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff."
11528590|NCT01154101|Active Comparator|Cohort 3 - 1000mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).
~Cohort 3 will commence after Cohort 2 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee.
~Cohort 3 will be administered four SRT2104 capsules at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff."
11528591|NCT01154101|Active Comparator|Cohort 1 - 250mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).
~Cohort 1 will be administered at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff.
~Dosing for Cohort 2 will not commence until Cohort 1 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee."
11528592|NCT01154088|Experimental|Group A|
11528593|NCT01154088|Experimental|Group B|
11528594|NCT01154088|Active Comparator|Group C|
11528595|NCT01154062|Experimental|low dose|Pazopanib tablet
11528596|NCT01154049|Experimental|single arm|3 doses of the vaccine, on days 0, 30 and 60.
11528597|NCT01154036|Experimental|Phase I: ezetimibe (EZ) 10 mg + atorvastatin (Atorva) 10 mg|Co-administration of EZ 10 mg tablet + Atorva 10 mg tablet; once daily for 6 weeks
11528598|NCT01154036|Active Comparator|Phase I: Atorvastatin 20 mg|Atorvastatin 20 mg tablet once daily for 6 weeks
11528599|NCT01154036|Active Comparator|Phase I: Rosuvastatin 10 mg|Rosuvastatin 10 mg tablet once daily for 6 weeks
11528600|NCT01154036|Experimental|Phase II: EZ 10mg+Atorva 10mg|Participants who had previously received EZ 10 mg + Atorva 10 mg in Phase I and continued on EZ 10 mg + Atorva 10 mg once daily for 6 weeks during Phase II regardless of whether or not LDL-C goals were achieved in Phase I
11528601|NCT01154036|Experimental|Phase II: EZ 10mg + Atorva 20mg [A]|Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched to EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II
11528602|NCT01154036|Active Comparator|Phase II: Atorva 40mg|Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched Atorva 40 mg once daily for 6 weeks in Phase II
11528603|NCT01154036|Experimental|Phase II: EZ 10mg + Atorva 20mg [R]|Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and received EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II
11528604|NCT01154036|Active Comparator|Phase II: Rosuvastatin 20mg|Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and were switched to Rosuvastatin 20 mg once daily for 6 weeks in Phase
11528605|NCT01154023|Experimental|stimulus control therapy|Focuses on strengthening the bed and bedroom as cues for sleepiness and sleep, weaken them as cues for arousal, and developing a consistent sleep-wake pattern
11528606|NCT01154023|Experimental|sleep restriction therapy|Sleep restriction therapy consolidates sleep by restricting the amount of time spent in bed and limiting sleep to a specific time period .
11528607|NCT01154023|Experimental|multi-component intervention|Combines stimulus control and sleep restriction: strengthen the bed and bedroom as cues for sleepiness and sleep, weaken them as cues for arousal, develop a consistent sleep-wake pattern, consolidate sleep by restricting the amount of time spent in bed and limit sleep to a specific time period
11528608|NCT01154010|Active Comparator|Active Device|"ActiPatch, a device that emits a low frequency energy called pulsed electromagnetic field (PEMF), will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids."
11528609|NCT01154010|Placebo Comparator|Placebo Device|Patients wear the PEMF placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.
11528610|NCT01153997|Experimental|A|
11528611|NCT01153997|Experimental|B|
11528612|NCT01153997|Placebo Comparator|C|
11528613|NCT01153997|Placebo Comparator|D|
11528614|NCT01153984|Experimental|Erlotinib|Participants will receive 150 milligrams (mg) erlotinib orally daily until disease progression, unacceptable toxicity, withdrawal due to any reason or death.
11528615|NCT01153971|Experimental|1|
11528616|NCT01153958|Experimental|Colposeptine (A)|
11528617|NCT01153958|Active Comparator|Metronidazole (B)|
11528618|NCT01153945||Hypothyroid|
11528619|NCT01153945||Non hypothyroid|
11528620|NCT01153945||Healthy subjects|
11528621|NCT01153932|Experimental|Continuous regimen; 6mg/kg once weekly|Once Weekly
11528622|NCT01153932|Experimental|Intermittent regimen; 6mg/kg twice weekly|Twice weekly on 1st, 3rd and 5th weeks, once weekly on 2nd, 4th and 6th weeks, and no active drug on 7th to 10th week of each 10 week cycle
11528623|NCT01153919|Active Comparator|Arm I|Patients receive romiplostim subcutaneously once weekly for 8 weeks in the absence of disease progression or unacceptable toxicity.
11528624|NCT01153919|Placebo Comparator|Arm II|Patients receive placebo subcutaneously once weekly for 8 weeks. Patients failing to achieve a platelet count of &gt; 100,000/L cross over to arm I.
11528625|NCT01153906||Exposed cohort|Females 9-25 years of age, who received at least one dose of Cervarix® as part of their routine health care.
11528626|NCT01153906||Unexposed cohort|Females 9-25 years of age, who did not receive Cervarix®
11528792|NCT01152775|Experimental|Yes Media Newly Diagnosed Breast Cancer Pts|Sixty participants will be randomized into one of two cohorts: 1. No media 2. Yes media
11528627|NCT01153893|Experimental|Synflorix/Infanrix primed Group|Subjects previously primed with the Synflorix™ vaccine in the primary study 110521 (NCT00678301) received a booster dose of the Synflorix™ vaccine co-administered with a booster dose of the Infanrix™ vaccine at 15-21 months of age. Synflorix™ vaccine was administered intramuscularly in the right thigh or deltoid muscle of the arm. Infanrix™ vaccine was administered intramuscularly in the left thigh or deltoid muscle of the arm.
11528628|NCT01153893|Experimental|Synflorix/Infanrix unprimed Group|Unprimed subjects from the primary study 110521 (NCT00678301), not previously vaccinated with any pneumococcal vaccine, received a 2-dose catch-up vaccination of Synflorix™ vaccine at 15-21 and 17-23 months of age and a booster dose of Infanrix™ vaccine co-administered with the first dose of Synflorix™ vaccine at 15-21 months of age. Synflorix™ vaccine was administered intramuscularly in the right thigh or deltoid muscle of the arm. Infanrix™ vaccine was administered intramuscularly in the left thigh or deltoid muscle of the arm.
11528629|NCT01153880||Age <9 months definitive|Age at time of prescription was <9 months
11528630|NCT01153880||Age <9 months uncertain|Age at time of prescription was uncertain for <9 months
11528631|NCT01153880||9 months to 6 years|Age at time of prescription was 9 months to 6 years
11528632|NCT01153880||7 to 18 years|Age at time of prescription was 7 to 18 years
11528633|NCT01153880||19 to 65 years|Age at time of prescription was 19 to 65 years
11528634|NCT01153880||66 years and older|Age at time of prescription was 66 years and older
11528635|NCT01153867|Experimental|Schema Focused Therapy|Participants will receive Schema Focused Therapy
11528636|NCT01153854|Experimental|ORS-Raceca In hospital Group|This group included 135 dehydrated patients which need an oral rehydration therapy in hospital and were assigned to received oral rehydration solution and racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.
11528637|NCT01153854|Placebo Comparator|ORS-Placebo in hospital group|This group included 135 dehydrated patients which need an oral rehydration therapy in hospital and were assigned to received oral rehydration solution and placebo in double blind assigned.
11528638|NCT01153854|Placebo Comparator|ORS-Placebo ambulatory group|This group included 92 non dehydrated patients which were assigned to received oral rehydration solution and placebo in double blind assigned and ambulatory (in home) bases.
11528639|NCT01153854|Experimental|ORS-Raceca ambulatory group|This group included 92 non dehydrated patients which were assigned to received oral rehydration solution and racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned and ambulatory (in home) bases.
11528640|NCT01153841|Experimental|Synflorix Group|Subjects receiving Synflorix™(GSK 1024850A) co-administered along with Infanrix hexa™.
11528641|NCT01153841|Active Comparator|Control Group|Subjects receiving Infanrix hexa™ vaccine alone.
11528642|NCT01153828||(1) Age <9 months|Age at time of prescription was <9 months
11528643|NCT01153828||(2) 9 months to 6 years|Age at time of prescription was 9 months to 6 years
11528644|NCT01153828||(3) 7 years to 18 years|Age at time of prescription was 7 years to 18 years
11528645|NCT01153828||(4) 19 to 65 years|Age at time of prescription was 19 to 65 years
11528646|NCT01153828||(5) 66 years and older|Age at time of prescription was 66 years and older
11528647|NCT01153815|Placebo Comparator|placebo|Sodium chloride
11528648|NCT01153815|Experimental|GSK1358820(Botulinum Toxin Type A)|"GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)"
11528649|NCT01153802|Experimental|Healthy Male Volunteers|All the 12 subjects enrolled in the study were exposed to at least one dose of GSK1360707 15 mg, 30 mg, 60 mg, 90 mg, 120 mg and 150 mg. All the subjects completed the study. The initial dose, given in the study as a single-dose was 15 mg GSK1360707. The remaining subjects were dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose did not exceed 150 mg per day, the maximum total dose given in the FTIH study.
11528650|NCT01153789|Experimental|Patients orthoptic rehabilitation|Children with vertigo-headache and vergence disorders
11528651|NCT01153789|Other|Control Orthoptic diagnostic|Healthy controls
11528652|NCT01153776|Experimental|64-slice CT angiography|64-slice CT angiography
11528653|NCT01153763|Other|All patients|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
11528654|NCT01153750|Experimental|Glivec and 5-Fluorouracil/Leucovorin|"All patients will receive Glivec® 600 mg once daily without dose escalation. Glivec® will be given on day -4, -3, -2, -1, 1, 2, 3 and 4. There will be no day 0. Patients will also receive 5-FU (2000mg/qm 24hc.i. d1 + d2) and leucovorin (200mg/qm 2h-infusion) qd15."
11528655|NCT01153737|Experimental|manual therapy|
11528656|NCT01153737|Active Comparator|TENS|Electric Nerve Stimulation (TENS)
11528657|NCT01153724|Experimental|Olodaterol|
11528658|NCT01153724|Experimental|Olodaterol + Fluconazole|
11528659|NCT01153711|Experimental|BI 1744 10 mcg|solution for oral inhalation
11528660|NCT01153711|Experimental|Ketoconazole 400 mg|tablet
11528661|NCT01153698||patients after hip or knee replacement|
11528662|NCT01153685|Experimental|Fluviral A Group|Subjects aged between 18 and 60 years who received one dose of Fluviral vaccine at Day 0, administered intramuscularly in the deltoid region of the non-dominant arm.
11528663|NCT01153685|Experimental|Fluviral B Group|Subjects over 60 years of age who received one dose of Fluviral vaccine at Day 0, administered intramuscularly in the deltoid region of the non-dominant arm.
11528664|NCT01153672|Experimental|Treatment (enzyme inhibitor therapy, AI sensitization therapy)|Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD, letrozole PO QD, OR exemestane PO QD for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
11528665|NCT01153659|Experimental|1|
11528666|NCT01153659|Active Comparator|2|
11528667|NCT01153659|Active Comparator|3|
11528668|NCT01153646|Experimental|Cohort 1: 1x10e9 and Cohort 2: 1x10e10 T cells per infusion|Group of patients receiving genetically modified T-cells
11528752|NCT01153009|Experimental|Vortioxetine 15 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 15 mg, encapsulated tablets, orally, once daily for 7 weeks, then placebo-matching capsules, orally, once daily for one week.
11529147|NCT01150149|Experimental|2|No face touch
11528669|NCT01153633|Active Comparator|Prontosan Wound Solution and Gel|Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel. Secondary dressing to be a semi occlusive dressing. Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)
11528670|NCT01153633|Placebo Comparator|Normal Saline and Placebo Gel|Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel. Secondary dressing to be a semi occlusive dressing. Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)
11528671|NCT01153620|Placebo Comparator|Ringer's Solution|
11528672|NCT01153620|Active Comparator|Lavasept 0.04%|
11528673|NCT01153607|Experimental|Arm 1|
11528674|NCT01153607|Experimental|Arm 2|
11528675|NCT01153607|Experimental|Arm 3|
11528676|NCT01153594|Experimental|Recovery Management Checkups (RMC)|Participants in the RMC group are interviewed quarterly. When they were found to be in need of treatment, the participant was transferred from the interviewer to a linkage manager to receive the intervention (described next). They were also able to re-enter treatment on their own and naturally cycle through multiple periods of substance use, treatment, incarceration and recovery.
11528677|NCT01153594|No Intervention|Control Group|Participants in the control group are interviewed quarterly. While they do not receive any active intervention from the research team, they are able to re-enter treatment on their own and naturally cycle through multiple periods of substance use, treatment, incarceration and recovery.
11528678|NCT01153581|Experimental|Ganirelix acetate|Subjects were given 250 μg in 0.5ml normal saline for 16 days. (Organon, Roseland, NJ, USA)
11528679|NCT01153581|Experimental|17β-Oestradiol, E2|The same women added 17β-Oestradiol, E2; 0.2 mg day-1 patch (Vivelle; CIBA Pharmaceuticals, Summit, NJ) for days 4-16.
11528680|NCT01153581|Experimental|Progesterone|The same women added progesterone (P4, 200 mg day-1 Prometrium, oral, Solvay Pharmaceuticals, Marietta, GA, USA) on days 13-16.
11528681|NCT01153568|Placebo Comparator|Placebo|placebo
11528682|NCT01153568|Experimental|Vitamin D 3|Vitamin D3 will be available in doses of 60, 90, 120, and 150 µg
11528683|NCT01153555||Intermediate coronary lesions|"Diagnostic device: FFR
~Diagnostic device: IVUS RF
~At participating centers, FFR and IVUS are standard of care diagnostic procedures for patients with intermediate (40-80% angiographic stenosis by visual estimate). Both modalities were used regularly for such patients whether or not they are participants in this clinical study. In FIRST, the decision to perform percutaneous coronary intervention (PCI) was left to the discretion of the investigator, and was not dictated by the clinical protocol."
11528684|NCT01153542|Experimental|VX-770|
11528685|NCT01153542|Experimental|desipramine|
11528686|NCT01153529||Group 1|OEF/OIF Veterans
11528687|NCT01153503|Active Comparator|Ketorolac 30 mg, IV + TAP block|"Ketorolac 30 mg, IV + Bilateral ultrasound-guided TAP blocks at the end of the surgery
~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine
~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
11528688|NCT01153503|Active Comparator|TAP block|"Intraoperative (at the end of surgery): Bilateral ultrasound-guided TAP block at the end of the surgery
~First 24-h Postoperative: IV-PCA morphine
~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
11528689|NCT01153503|No Intervention|Ketorolac 30 mg|"Intraoperative (at the end of surgery): Ketorolac 30 mg, IV at the end of the surgery.
~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h +IV-PCA morphine.
~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
11528690|NCT01153490|Placebo Comparator|Placebo|
11528691|NCT01153490|Active Comparator|Quetiapine ER|
11528692|NCT01153477|No Intervention|TAU|This group is the control group by which we are comparing our intervention. This group will not receive an intervention from us but will continue to be treated at the Intensive Outpatient facility from which we recruited them.
11528693|NCT01153477|Experimental|Counseling (TMAC-E)|This telephone based intervention includes six factors to improve our extended treatment model: Incentive component; Patient choice; Provision of cell phones to those who need them; Social support and community resources; Positive recovery factors; and Outreach following dropout.
11528694|NCT01153464|No Intervention|Treatment As Usual|In this arm, participants are not provided any intervention through the study, they are just followed for research purposes at 3m, 6m, 9m, and 12m post baseline as the comparison group.
11528695|NCT01153464|Experimental|Recovery Support Counseling|This group is eligible to receive the telephone based recovery support counseling from paraprofessionals based out of the City of Philadelphia's Department of Behavioral Health.
11528696|NCT01153451|No Intervention|Usual Care|Responsible inpatient and ambulatory physicians assigned to usual care will not receive any email(s) of patients' test results generated from the notification system.
11528697|NCT01153451|Other|Email Notification|Responsible inpatient and ambulatory physicians will receive automated email(s) of patients' tests results finalized post-discharge generated from the notification system. Finalized results will be batched such that no provider will receive more than one email per day.
11528698|NCT01153438||Gastric bypass, Gastric banding|
11528699|NCT01153425|Active Comparator|Teriparatide (Forteo)|20 µg of Teriparatide will be self-injected subcutaneously once a day for 12 months and an MRI at 3T ('Virtual Bone Biopsy') will be performed at 0 and 12 months.
11528700|NCT01153425|Active Comparator|Zoledronic Acid (Reclast)|5 mg of zoledronic Acid will be administered intravenously at baseline and 12 months and an MRI at 3T ('Virtual Bone Biopsy) will be performed at 0 and 12 months.
11528701|NCT01153412|No Intervention|Control Group|Control group no intervention
11528702|NCT01153412|Experimental|Osteopathic Manipulative Treatment|Osteopathic Manipulative medicine group
11528703|NCT01153399||1|Patients with Non Small Cell Lung Cancer, visiting hospital oncology clinics
11528704|NCT01153386|Experimental|0.5 mg treprostinil diethanolamine|0.5 mg treprostinil diethanolamine
11529148|NCT01150149|Experimental|3|Surgical face mask
11528707|NCT01153373|Placebo Comparator|Minimal Intervention Control|"All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only. The reports will not be printed or dynamic referrals generated, and all patients will receive treatment-as-usual by their ED providers."
11528708|NCT01153373|Active Comparator|DARSSA Intervention|All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
11528709|NCT01153360|Experimental|T3|triiodothyronine
11528710|NCT01153360|Active Comparator|cyanocobalamin|vitamin B12
11528711|NCT01153347|Experimental|SSRI/Serotonin/SNRI+ TC-5214 0.5 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 0.5 mg BID
11528712|NCT01153347|Experimental|SSRI/Serotonin/SNRI + TC-5214 2 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 2 mg BID
11528713|NCT01153347|Experimental|SSRI/Serotonin/SNRI + TC-5214 4 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 4 mg BID
11528714|NCT01153347|Placebo Comparator|SSRI/Serotonin/SNRI + Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
11528715|NCT01153334|Experimental|Early intensive rosuvastatin therapy|
11528716|NCT01153334|Placebo Comparator|Conventional statin therapy|
11528717|NCT01153321|Experimental|1|Oral treatment
11528718|NCT01153321|Placebo Comparator|2|Oral treatment
11528719|NCT01153308||Bariatric Surgery Patients|Bariatric Surgery patients at UMass Memorial Medical Center
11528720|NCT01153295|Experimental|Positive diagnosis|The diagnosis of IBS is based on the international ROME III criteria, few blod tests, and abscence of danger signals
11528721|NCT01153295|Active Comparator|Diagnosis of exclusion|The diagnosis of IBS is based on normal extended blood tests, screening for celiac sprue and lactose intolerance, stool for ova and parasites and endoscopy with biopsy
11528722|NCT01153269||HIV-infected patients with hepatitis co-infection|HIV-infected patients with co-infections of Hepatitis B or Hepatitis C
11528723|NCT01153256|Experimental|group M|
11528724|NCT01153256|Placebo Comparator|Group R-0.6|
11528725|NCT01153256|Placebo Comparator|Group R-0.9|
11528726|NCT01153243|Active Comparator|Ergocalciferol|The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)
11528727|NCT01153243|Placebo Comparator|Placebo pill|The investigators will give intervention group 12 weeks of placebo pill (in pill every week)
11528728|NCT01153230||poisoned patient|after patients died the pathological findings evaluated with autopsy
11528729|NCT01153217|Experimental|Abacavir|Switch from tenofovir to abacavir
11528730|NCT01153217|No Intervention|tenofovir|Follow same ART regimen
11528731|NCT01153204|Experimental|Group Psychotherapy (GP)|Time-limited group psychotherapy is a technique based on psychodrama, an in-depth method of group psychotherapy. Active methods are used to enable past, present, and future life events to be explored. Sexual issues and their possible solutions are enacted rather than simply discussed. Time-limited group psychotherapy focuses on a central or core issue or a circumscribed area of conflict (psychogenic erectile dysfunction) as the only or major object of intervention efforts.
11528732|NCT01153204|Active Comparator|Sildenafil|Participants took sildenafil citrate 50 mg as needed for sexual activity (on demand), no more than once daily, according to psychiatric prescription. Sildenafil citrate was taken with a glass of water on an empty stomach (at least 2 hours after eating). Participants met with a psychiatrist every month for 30-minutes to report adverse effects and to obtain the following month's dosage of four pills.
11528733|NCT01153204|Active Comparator|Group Psychotherapy (GP) plus Sildenafil|The same as above.
11528734|NCT01153191|Experimental|Pressurized irrigation|first group-After closure of patients abdominal wall fascia, Hydrostatic irrigation with 3 liters of normal saline with Simpulse Solo irrigation system (Davol) at less than 15PSI will be applied to subcutaneous tissues prior to closure
11528735|NCT01153191|Experimental|Sub Q Antibiotic|second group of patients will receive 2mg/lg of gentamicin in 20 ml of sterile saline injected into the superficial tissues above the ABD wall fascia prior to initial incision
11528736|NCT01153165|Experimental|Citalopram|Participants will be commenced on Citalopram 20mgs daily
11528737|NCT01153165|Placebo Comparator|Control|Control group - will receive a matched placebo
11528738|NCT01153139|Experimental|bilateral theta burst stimulation to the DLPFC|intermittent TBS (iTBS) to the left DLPFC continuous TBS (cTBS) to the right DLPFC
11528739|NCT01153139|Placebo Comparator|Sham stimulation|Sham stimulation with a 45° tilted coil
11528740|NCT01153126|No Intervention|No Intervention: Usual Care|A group receiving usual care plus 5 reliable websites
11528741|NCT01153126|Experimental|Intervention|A group using the Comprehensive Health Enhancement Support System (CHESS.)
11528742|NCT01153113|Experimental|Treatment Arm A|• 5x106 cells per infusion administered ID
11528743|NCT01153113|Experimental|Treatment Arm B|• 1x107 cells per infusion administered ID (Treatment arm B).
11528744|NCT01153100|No Intervention|Standard insulin drip therapy|Standard insulin drip therapy
11528745|NCT01153100|Active Comparator|Insulin drip and glargine|Insulin drip and glargine 0.25 units per kg body weight
11528746|NCT01153074|Experimental|Occluder|The patients with bronchopleural fistulas treated with bronchoscopic deployment of the cardiac septal defects occluder.
11528747|NCT01153061|Experimental|Fistula closure with occluder|Patients with benign tracheoesophageal fistulas will be submitted to the correction with the occluder.
11528748|NCT01153048|Experimental|Specific education intervention with peer educators|
11528749|NCT01153048|No Intervention|General education session in the health structure|
11528750|NCT01153035|Other|Surgery followed by RFA|
11528751|NCT01153009|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
11528791|NCT01152775|Placebo Comparator|No Media|Sixty participants will be randomized into one of two cohorts: 1. No media 2. Yes media
11528753|NCT01153009|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 20 mg, encapsulated tablets, orally, once daily for 7 weeks, then placebo-matching capsules, orally, once daily for one week.
11528754|NCT01153009|Active Comparator|Duloxetine 60 mg|Duloxetine 30 mg capsules, orally, once daily for one week then duloxetine 60 mg, capsules, orally, once daily for 7 weeks, then duloxetine 30 mg capsules, once daily, for one week.
11528755|NCT01152996|Experimental|Vortioxetine|Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks.
11528756|NCT01152970||drug-using youth with violent injury|Youth(ages 14-24) who report illicit drug use and who present to an urban ED for an acute violent injury
11528757|NCT01152970||drug-using youth with non-violent injury|Youth(ages 14-24) who report illicit drug use and who present to an urban ED for non-violence related care
11528758|NCT01152957|Experimental|Community Health Worker Model|Care, Attention, Resources, Information, Nutrition and Optimism Project (CARIÑO Project) will provide outreach support services to patients with poorly controlled diabetes, such as health education, lifestyle changes, home visits, follow-up phone calls, support groups, one on one counseling and coaching, and assistance with resource referrals.
11528759|NCT01152957|Active Comparator|Enhanced Usual Care|Usual Care and mailing of 4 health education brochures over the year.
11528760|NCT01152931|Active Comparator|COHORT A= Amodiaquine + Artesunate|Amodiaquine will be administered orally at 10mg/kg daily for 3days. Artesunate 50mg will be administered orally daily for 3days.For subjects >6months< 1 years 4mg/kg daily for 3 days
11528761|NCT01152931|Active Comparator|cohort B= Lumefantrine +Artemether|Artemether 20mg/Lumefantrine 120mg fixed combination administered daily for 3 days
11528762|NCT01152931|Experimental|cohort C = Artesunate + vitamin A|Artesunate 50mg daily for 4days. if >6 months< 1 year 4mg/kg daily for 4days + Vitamin A 5000IU daily for 4days if < 1 year and 10,000IU daily for 4days if > 1 year respectively
11528763|NCT01152931|Experimental|Artesunate, vitamin E oral administration|Artesunate 50mg daily for 4 days.if >6 months< 1 year 4mg/kg daily for 4 days + vitamin E 100mg daily administered orally to the experimental group 4 days.
11528764|NCT01152931|Experimental|cohort E will be given Artesunate and Zinc orally|cohort E will be given Artesunate 50mg daily for 4 days. if > 6 months< 1 year 4mg/kg daily for 4 days + zinc gluconate 50mg orally daily for 4 days. if < 1 year 25 mg daily for 4 days
11528765|NCT01152931|Experimental|cohort F= Artesunate and selenium will be given orally|Artesunate 50mg daily for 4 days. if > 6 months< 1 year 4mg/kg daily for 4 days + selenium 100ug daily for 4 days. if < 1 year 50ug daily for 4 days.
11528766|NCT01152931|Experimental|cohort G = Amodiaqiune and Vitamin A will be given orally|Amodiaquine 10mg/kg daily for 3 days + vitamin A 5000iu daily for 4 days if < 1 year. 10,000 IU daily for 4 days if > 1 year.
11528767|NCT01152931|Experimental|cohort H = amodiaquine and vitamin E administerd orally|Amodiaquine 10mg/kg daily for 4 days + vitamin E 100 mg daily for 4 days
11528768|NCT01152931|Experimental|cohort I = Amodiaquine and Zinc will be given orally|Amodiaquine 10mg/kg daily for 4 days + zinc 50mg daily 4 days. if < 1 year 25 mg daily for 4 days.
11528769|NCT01152931|Experimental|Cohort J = amodiaquine and selenium will be given orally|Amodiaquine 10mg/kg daily for 4 days + selenium 100ug daily for 4 days if > 1 year. 50ug daily for 4 days if < 1 year.
11528770|NCT01152931|Experimental|K= Artesunate+ vitamin A + vitamin E|Tab Artesunate 50mg orally dly x 4 days + Vitamin A, 5000IU orally, dly x 4 days if ≤ 1yr. 10,000IU orally dly x 4days if > 1 yr + vitamin E 100 mg orally dly for 4 days
11528771|NCT01152931|Experimental|L = Artesunate+ Vitamin A + Zinc|Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if < 1 year. 10,000IU daily for 4 days if > 1 year. All administered orally.
11528772|NCT01152931|Experimental|M = Artesunate+ Vitamin A + selenium|Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if < 1 year. 10,000IU orally daily for 4 days if > 1 year.
11528773|NCT01152931|Experimental|N = Artesunate + Vitamin E + Zinc|Artesunate 50mg daily for 4 days. vitamin E 100mg daily for 4 days. Zinc 50 mg daily for 4 days if > 1 year. 25 mg daily for 4 days if < 1 year.
11528774|NCT01152931|Experimental|O = Artesunate+ Vitamin E + Selenium|Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if > 1 year. 50 ug orally daily for 4 days if < 1 year.
11528775|NCT01152918|Experimental|Linkage-to-Care Component: Financial Incentive (FI)|HIV test sites will provide financial incentives to encourage linkage to HIV care.
11528776|NCT01152918|Active Comparator|Linkage-to-Care Component: Standard of Care (SOC)|HIV test sites will provide the standard-of-care to their patients for linkage to HIV care.
11528777|NCT01152918|Experimental|Viral Suppression Component: FI|HIV care sites will provide financial incentives to encourage viral load suppression.
11528778|NCT01152918|Active Comparator|Viral Suppression Component: SOC|HIV care sites will provide the standard-of-care to their patients for viral load suppression.
11528779|NCT01152918|Experimental|Prevention for Positives Component: Counseling and SOC|Participants will take part in a computerized HIV risk reduction counseling program and receive SOC for HIV infection.
11528780|NCT01152918|Active Comparator|Prevention for Positives Component: SOC|Participants will receive SOC for HIV infection.
11528781|NCT01152905||Air/TIVA group|The patients received during the anesthesia a mixture of air with 30% oxygen All patients received total intravenous anesthesia (TIVA) using target controlled infusion of propofol and remifentanil.
11528782|NCT01152905||Nitrous oxide/TIVA group|The patients received nitrous oxide with 30% oxygen.All patients received total intravenous anesthesia (TIVA) using target controlled infusion of propofol and remifentanil.
11528783|NCT01152879||Home Parenteral Nutrition|Patients receiving home parenteral nutrition
11528784|NCT01152853|Experimental|single arm|PF00299804 treatment arm
11528785|NCT01152840|Experimental|RAD001|RAD001 daily po medication
11528786|NCT01152827|Experimental|RAD001|RAD001 10 mg daily po medication
11528787|NCT01152814|Experimental|Arm 1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
11528788|NCT01152801|Experimental|RAD001|
11528789|NCT01152788|Active Comparator|rIL-21|
11528790|NCT01152788|Active Comparator|Dacarbazine|
11528793|NCT01152762|Experimental|Standardized Respiratory Physiotherapy|Standardized Respiratory Physiotherapy is the intervention in all selected patients
11528794|NCT01152749|Experimental|UNG-GC-2|2 mg experimental NRT product
11528795|NCT01152749|Experimental|UNG-GC-4|4 mg experimental NRT product
11528796|NCT01152749|Active Comparator|Nicorette® Gum-2|2 mg Nicorette® Gum
11528797|NCT01152749|Active Comparator|Nicorette® Gum-4|4 mg Nicorette® Gum
11528798|NCT01152736|Experimental|NSC018|Nicotine
11528799|NCT01152736|Active Comparator|Nicotine Gum|Nicorette® Gum
11528800|NCT01152723|Experimental|UNG-GA|New NRT product
11528801|NCT01152723|Experimental|UNG-GB|New NRT product
11528802|NCT01152723|Active Comparator|Nicorette® Gum|Nicorette® Gum
11528803|NCT01152697|Experimental|Patient Noncompliance|There was only one arm for this study.
11528804|NCT01152684||HIV-Positive Latinos living in San Diego or Tijuana|This is an exploratory study of Latinos living with HIV in the San Diego-Tijuana US-Mexico border region.
11528805|NCT01152671|Experimental|Arm 1|
11528806|NCT01152671|Placebo Comparator|Arm 2|
11528807|NCT01152658|Placebo Comparator|Nacl Injection|"Blood samples (4 test tubes) will be extracted from control groups and 8 test tubes for the trial group. The blood of the trial group will be centrifuged and the platelet fraction extracted and counted (only 4 test tubes).
~NACL0.9% solution will be then injected to the control group in sterile conditions under ultrasound control
~double blind procedure
~."
11528808|NCT01152658|Experimental|PRGF|1. Blood samples (4 test tubes) will be extracted from control groups and 8 test tubes for the trial group. The blood of the trial group will be centrifuged and the platelet fraction extracted and counted (only 4 test tubes).2. The enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control.
11528809|NCT01152645|Experimental|ARQ 197|
11528810|NCT01152632|Experimental|specific points of Bladder meridian and Shanjiao meridian|In traditional Chinese acupuncture theory, Bladder meridian and Shanjiao meridian have been considered as the main pathological meridian location of migraine. Meanwhile, specific points on both meridians have been used widely in its treatment for a long time.
11528811|NCT01152632|Experimental|non-specific points of Bladder meridian and Shanjiao meridian|Non-specific points of Shaoyang meridians are also used in cure of migraine. It is conventionally thought to be less effective using non-specific points than specific ones.
11528812|NCT01152632|Active Comparator|specific points of Stomach meridian|Specific points of Stomache meridian for migraine were searched in Chinese ancient data. And this group is set to compare with specific points of Shaoyang meridians for their possible different brain networks.
11528813|NCT01152632|Placebo Comparator|non-acupoints|Three non-acupoints were chosen,two of which were located on the arm and one one the leg.
11528814|NCT01152632|No Intervention|waiting list|
11528815|NCT01152619|Experimental|1|
11528816|NCT01152619|Experimental|2|
11528817|NCT01152619|Placebo Comparator|3|
11528818|NCT01152619|Placebo Comparator|4|
11528819|NCT01152606||Cohort|
11528820|NCT01152593|Experimental|Intranasal Mupirocin|
11528821|NCT01152580|Placebo Comparator|Sugar pill|
11528822|NCT01152580|Active Comparator|melatonin|
11528823|NCT01152567||ACE|Patients treated for hypertension with ACEs without CVD
11528824|NCT01152567||Candesartan|Patients treated for hypertension with candesartan without CVD
11528825|NCT01152554|Experimental|SSRI/Serotonin/SNRI + TC-5214 1-4 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214 1-4 mg BID
11528826|NCT01152554|Placebo Comparator|SSRI/Serotonin/SNRI + placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + placebo BID
11528827|NCT01152541|Active Comparator|Hypotonic Riboflavin|Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
11528828|NCT01152541|Active Comparator|Riboflavin/dextran|Administration of Riboflavin/dextran every 2 minutes for the duration of UV exposure.
11528829|NCT01152515|No Intervention|Control|stopping of propofol and remifentanil infusion
11528830|NCT01152515|Active Comparator|Remifentanil|stopping of propofol and maintenance of remifentanil infusion
11528831|NCT01152489|No Intervention|Standard Care|Immunizations are given with standard care of no pain control
11528832|NCT01152489|Active Comparator|Experimental|Vibrating device with cold pack held to arm proximal to injections within the same dermatome; caretakers offered and instructed in use of distraction cards.
11528833|NCT01152489|Sham Comparator|Sham Device|The device without batteries or cold pack held to arm proximal to injections. No formal distraction.
11528834|NCT01152476|Active Comparator|group SR|
11528835|NCT01152476|Active Comparator|group S|
11528836|NCT01152450|Experimental|Tiotropium daily dose q.d.|two actuations delivered via Respimat® inhaler
11528837|NCT01152450|Experimental|Tiotropium half daily dose b.i.d.|two actuations delivered via Respimat® inhaler
11528838|NCT01152450|Placebo Comparator|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
11528839|NCT01152437|Experimental|BIBW 2992|Patients receive BIBW 2992 tablets once daily
11528840|NCT01152437|Active Comparator|Cetuximab|Patients receive cetuximab intravenously once a week, every week
11528841|NCT01152424||Acute eosinophilic pneumonia|
11528842|NCT01152424||Community acquired pneumonia|
11528843|NCT01152411|Experimental|Autologous bone marrow stem cells|
11528844|NCT01152398|Experimental|MVA-BN-HER2|
11528845|NCT01152385|Experimental|high|AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)
11528846|NCT01152385|Experimental|Middle|AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)
11528847|NCT01152385|Experimental|low|AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)
11528848|NCT01152385|Placebo Comparator|4|
11528849|NCT01152372|Other|Arm 1|Beta cell function by frequently sampled intravenous glucose tolerance test
11528850|NCT01152372|Other|Arm 2|Modified glucose disposal test assessment of insulin sensitivity, endogenous glucose production and insulin secretion
11528851|NCT01152372|Other|Arm 3|Endogenous glucose production and insulin sensitivity by isotope dilution and isoglycemic, heperinsulinemic clamp
11528852|NCT01152359|Experimental|Arm 1|Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.
11528853|NCT01152359|Active Comparator|Arm 2|Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
11528854|NCT01152346|Other|ARM 1|Sequence- Azacitidine followed by Vidaza®
11528855|NCT01152346|Other|ARM 2|Sequence-Vidaza® followed by Azacitidine
11528856|NCT01152333|Active Comparator|Exendin (9-39) Acetate|Exendin (9-39) is a synthetic peptide that acts as an antagonist to the GLP-1 receptor. Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length at 600-750 pM/kg/min.
11528857|NCT01152333|Placebo Comparator|Saline|Saline 0.9% will be used as the control infusion.
11528858|NCT01152320|No Intervention|Standard of Care|
11528859|NCT01152320|Experimental|Intervention|Spirometry Fundamentals™ CD training program
11528860|NCT01152307|Experimental|Decision Aid|Group receiving the decision aid (DVD/booklet)
11528861|NCT01152307|No Intervention|Control|Group not receiving the decision aid (DVD/booklet)
11528862|NCT01152294|No Intervention|Control|Group not receiving the decision aid (DVD and booklet)
11528863|NCT01152294|Experimental|Decision Aid|Group receiving the decision aid (DVD/booklet)
11528864|NCT01152281|Active Comparator|Maximal Control|Basic awareness messages with stories of people living with AIDS
11528865|NCT01152281|Experimental|Instrumental|Instrumental messages with stories of people living with HIV
11528866|NCT01152281|Experimental|Empowering|Empowering messages with stories of people living with HIV
11528867|NCT01152281|Experimental|Instrumental and Empowering|Instrumental and empowering messages with stories of people living with HIV
11528868|NCT01152281|Active Comparator|Minimal Control|Basic awareness messages with stories of people who are not infected with HIV
11528869|NCT01152268||Adolescent Male Participants|"Self-report questionnaire data will be collected one time, between Days 1-7 post initiation of cancer therapy(e.g. Days 2-8 of being on-treatment for cancer) among eligible participants and their families who enroll on the study. Patients who agree to participate will be asked to complete a battery of paper and pencil questionnaires (which will also be available on-line if preferred) that assess risk/protective factors for sperm banking. When the banking recommendation is Yes or further assessment required, the profiling and referral tool will be given to the family and instructions for completion will be provided. The tool will include a list of key items which will be based on the most influential barriers to banking sperm."
11528870|NCT01152255|Experimental|Panel A - MK6186 40 mg|MK6186 40 mg
11528871|NCT01152255|Placebo Comparator|Panel A - Placebo|placebo
11528872|NCT01152255|Experimental|Panel B - MK6186 150 mg|MK6186 150 mg
11528873|NCT01152255|Placebo Comparator|Panel B - Placebo|placebo
11528874|NCT01152255|Experimental|Panel C - MK6186 <=150 mg|MK6186 <=150 mg
11528875|NCT01152255|Placebo Comparator|Panel C - Placebo|placebo
11528876|NCT01152255|Experimental|Panel D - MK6186 <=150 mg|MK6186 <=150 mg
11528877|NCT01152255|Placebo Comparator|Panel D - Placebo|placebo
11528878|NCT01152242|Active Comparator|Part 1|Part I of the trial
11528879|NCT01152242|Active Comparator|Part 2|Part II of the trial
11528880|NCT01152229||nuisance bleeding|
11528881|NCT01152229||alarming bleeding|
11528882|NCT01152229||maintenance therapy|
11528883|NCT01152216|Experimental|Dimebon|
11528884|NCT01152203|Experimental|Bendamustine + Bevacizumab|Bendamustine starting dose of 70 mg/m^2 by vein on Days 1 and 2 of a 28 day cycle. Bevacizumab 10 mg/kg by vein on Days 1 & 15 of every 28 day cycle.
11528885|NCT01152190|Experimental|5 milligrams (mg) Tadalafil|
11528886|NCT01152190|Placebo Comparator|Placebo|
11528887|NCT01152177|Active Comparator|Electronic reminders|Electronic reminders
11528888|NCT01152177|No Intervention|Usual care|usual care
11528889|NCT01152164||rectal cancer patients|
11528890|NCT01152151|Active Comparator|Postal reminders|Postal reminders
11528891|NCT01152151|Active Comparator|Electronic reminders|Electronic reminders
11528892|NCT01152138|Active Comparator|Open Cell Stent|Open cell stent (Driver™ or Integrity™,Medtronic), routinely employed during percutaneous coronary interventions for ST elevation acute myocardial infarction
11528893|NCT01152138|Active Comparator|Closed Cell Stent|Closed cell stent (Presillion Plus™, Cordis), routinely employed during percutaneous coronary interventions for ST elevation acute myocardial infarction
11528894|NCT01152125|Experimental|Autologous bone marrow stem cells|
11528895|NCT01152112|Experimental|Treatment, Office Setting, myomectomy|Myomectomy for uterine polyps and/or fibroids occurring in an office setting
11528896|NCT01152112|Experimental|Treatment, Hospital Setting, myomectomy|Myomectomy for uterine polyps and/or fibroids occurring in a hospital setting
11528922|NCT01151904|Experimental|COMBIGAN® with Latanoprost|Patients on current latanoprost monotherapy that qualify for study entry will have COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) added to the latanoprost for 12 additional weeks.
11528923|NCT01151891||Diabetics|Diabetics in the parish of St. James, Jamaica
11529149|NCT01150149|Experimental|4|Surgical face mask + no face touch
11528897|NCT01152099|Active Comparator|GroupA|"Ambulatory treatment is performed during one month. Specific exercises and prevention measures are taught. Multilayer bandage is applied daily during the first four weeks.
~The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.
~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month,and this time the treatment corresponding to the group B or experimental will be applied."
11528898|NCT01152099|Experimental|GroupB|"Ambulatory treatment is carried out during one month. Specific exercises measures of prevention are taught. MLD is carried out followed by a daily multilayer bandage during the first four weeks. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.
~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month, and this time the treatment corresponding to the group A or Control will be applied."
11528899|NCT01152086|Active Comparator|Hiking first|This group first starts with mountain hiking over 9 weeks followed by a 9 weeks control period.
11528900|NCT01152086|Active Comparator|Control first|This group first starts with the control period (9 weeks) followed by the 9 weeks mountain hiking intervention.
11528901|NCT01152073|Placebo Comparator|Placebo|Study participants whose drink formulation contains no active ingredients but will appear and taste similar to the two other formulations. This will form the control formulation
11528902|NCT01152073|Active Comparator|Second Formulation|Study participants' drink formulation will include Red Yeast Rice 600mg, Niacin 12.5mg, Phytosterol esters 650mg, L-Carnitine 150mg, vitamin C 500mg, and Co-Q-10 25mg.
11528903|NCT01152073|Active Comparator|Third Formulation|The third formulation will be identical to the second, but without the Red Yeast Rice.
11528904|NCT01152060||prednisone|
11528905|NCT01152060||prednisone and anti-virus|
11528906|NCT01152047|Experimental|oxytocin, satiety|Oxytocin is given as infusion to examine if this decreases satiety compared to saline during a drinking test
11528907|NCT01152034|Experimental|Psychoeducation group therapy|The structured group program comprised of an initial block of 12 weekly sessions with three additional monthly booster sessions, designed to support participants in the application of knowledge and skills to everyday life situations. All participants also received standard psychiatric care as well.
11528908|NCT01152034|Placebo Comparator|Treat as Usual|Patients who were assigned to the control group received standard psychiatric care and standard pharmacological treatment without group-based psychosocial intervention. Weekly phone calls to the control group over the initial 12 weeks were controlled for any extra contact time with researchers outside of the structured intervention group.
11528909|NCT01152021|Active Comparator|Dexmedetomidine Group|Dexmedetomidine given as 2mcg/kg bolus over 10 minutes followed by 1.5mcg/kg/hr infusion for duration of scan. The bolus may be repeated up to 2 times at any time during the sedation in the event that adequate sedation conditions (minimum Ramsay Sedation Score of 4) are not achieved. In the event that dexmedetomidine is unable to achieve motionless conditions, after a total of 3 boluses, 0.5 mg/kg IV pentobarbital may be administered at q1 minute intervals up to a maximum of 2 mg/kg, per established protocol.
11528910|NCT01152021|Active Comparator|Propofol Group|Propofol bolus at an initial dose of 1 mg/kg over 1 minute then up to two additional 1 mg/kg boluses may be administered (total 3 mg/kg) - each over a one (1) minute interval, waiting 30 seconds after completion of each bolus to reassess sedation level. Once a minimum Ramsey Sedation Score 4 is achieved, an infusion at 125 mcg/kg/min is initiated. It may be titrated to 300 mcg/kg/min. If there is movement or awakening the patient may be rebolused with no more than 2 doses of Propofol at 1 mg/kg over 1 minute, in the same dosing manner as described above, waiting 30 seconds between doses. If adequate sedation is not achieved, 0.5 mg/kg IV pentobarbital may be administered at q1 minute intervals up to a maximum of 2 mg/kg.
11528911|NCT01152008||healthy volunteers|
11528912|NCT01151995||Remote plus on-site|Subjects will have remote source document verification performed 2-4 weeks prior to study monitors scheduled visit and any variables that were not able to be verified remotely will be verified on-site.
11528913|NCT01151995||On-site monitoring|Traditional source document verification will be performed when study monitor is on site
11528914|NCT01151982|Experimental|Psychosocial Intervention|"The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.
~We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.
~The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.
~The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources."
11528915|NCT01151982|No Intervention|Usual Care|The kind of care that general practitioners usually provide when not knowing the level and risk profile of depression of the patients
11528916|NCT01151969|Experimental|New multicomponent intervention|
11528917|NCT01151969|No Intervention|Usual Care|
11528918|NCT01151956||actinic keratosis patients|patients who see their non-hospital based dermatologist, because of multiple actinic keratoses and who are then routinely treated with topical 5% Imiquimod
11528919|NCT01151943|Experimental|Transversus Abdominis Plane (TAP) Block|Patients will receive a bilateral transversus abdominis plane block
11528920|NCT01151943|Active Comparator|Incisional Infiltration of Local Anesthetic|Patients will receive an incisional infiltration with local anesthetic (continuous administration of levobupivacaïne during 48 hours)
11528921|NCT01151917||Bilio-pancreatic diversion|Each subject is own control
11528924|NCT01151878|Experimental|Glucomannan|glucomannan preparation in sachets: 1 saschet of 1.26g 2 times per day (daily dosage 2,52g); duration of intervention: 4 weeks
11528925|NCT01151878|Placebo Comparator|Placebo|maltodextrin prepared in sachets (1,3 g per sachet); 2 sachets per day; duration of intervention: 4 weeks
11528926|NCT01151865|Active Comparator|Dexmedetomidine|"Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.
~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4."
11528927|NCT01151865|Placebo Comparator|Saline placebo|An identical syringe to that in the intervention arm, but which does not contain dexmedetomidine, will be provided. The initial rate of infusion and subsequent adjustments will be the same as in the dexmedetomidine group.
11528928|NCT01151852|Experimental|Imatinib|Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
11528929|NCT01151852|Placebo Comparator|Placebo|Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
11528930|NCT01151839|Active Comparator|Surgery Alone|
11528931|NCT01151839|Active Comparator|Neoadjuvant chemoradiation followed by surgery|
11528932|NCT01151813|Active Comparator|Varenicline|Varenicline, oral administration for 1 week
11528933|NCT01151813|Placebo Comparator|Placebo|Placebo, oral administration for 1 week
11528934|NCT01151800|Experimental|IVR group|
11528935|NCT01151800|No Intervention|Usual care|
11528936|NCT01151787|Active Comparator|cyclobenzaprine hydrochloride|
11528937|NCT01151787|Placebo Comparator|placebo|
11528938|NCT01151761|Experimental|SBRT, Chemo and Liver Transplantation|The patients received Stereotactic Body Radiotherapy and Chemotherapy followed by a liver transplantation. The chemo could be any combination of the following: Gemcitabine, Cisplatin, Carboplatin, Capecitabine and 5FU
11528939|NCT01151735|Active Comparator|C-1-esterase inhibitor 1000 units|1000 units of C-1-esterase inhibitor given at time of prodromal symptoms
11528940|NCT01151735|Active Comparator|1500 units of C-1-esterase inhibitor|treatment with 1500 units of C-1-esterase inhibitor IV at the time of prodromal symptoms to decrease risk of exacerbation of HAE
11528941|NCT01151735|Placebo Comparator|placebo injection|placebo injection given for prodromal symptoms as double blinded therapy
11528942|NCT01151722|No Intervention|no injection|no bevacizumab
11528943|NCT01151722|Experimental|experimental 2|bevacizumab before vitrectomy
11528944|NCT01151722|Experimental|experimental 3|bevacizumab after vitrectomy
11528945|NCT01151709||physicians|primary care practitioners, both family practice and internal medicine physicians from a random sample of providers nationwide
11528946|NCT01151696|Experimental|hydroxyzine|Patients will receive intravenous hydroxyzine 1mg/kg at the beginning of the morphine titration protocol, and intravenous morphine 0.15 mg/kg then 0.05 mg/kg if necessary, every 5 minutes.
11528947|NCT01151696|Placebo Comparator|Placebo|Patients will receive intravenous placebo at the beginning of the morphine titration protocol, and intravenous morphine 0.15 mg/kg then 0.05 mg/kg if necessary, every 5 minutes.
11528948|NCT01151683|Active Comparator|Magnesium|Magnesium chelate 600 mg per day
11528949|NCT01151683|Placebo Comparator|Placebo|Placebo 4 capsules per day
11528950|NCT01151670|Experimental|Arm I|Pioglitazone 22.5 mg once daily by mouth
11528951|NCT01151670|Experimental|Arm 2|Pioglitazone 45 mg once daily by mouth
11528952|NCT01151657|Placebo Comparator|Placebo|Capsules containing maltodextrin.
11528953|NCT01151657|Experimental|Probiotics|Probiotics containing the 3 strains: Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12 in the dose of 2 x 109 - 10 x 109 CFU/capsule. The patients are to take 2x2 capsules a day.
11528954|NCT01151644|Active Comparator|VACCINATION OF PATIENTS|
11528955|NCT01151644|Active Comparator|VACCINATION OF HEALTHY CONTROLS|
11528956|NCT01151631|Active Comparator|100% occipital nerve stimulation|Stimulation frequency and pulse width will be uniformly held constant at 60 Hz and pulse width at 450 ms. The perception and discomfort amplitude will be defined by increasing the stimulation amplitude in steps of 0.1 V. The amplitude at which the patient starts feeling paraesthesis is called the perception threshold. The threshold at which the patient does not want the voltage to be increased any further because of painful sensations is designated the discomfort threshold. 100% stimulation is defined as stimulation at 90% of the range between perception and discomfort thresholds.
11528957|NCT01151631|Sham Comparator|30% occipital nerve stimulation|30% stimulation means a stimulation level at 30% of the range between perception threshold and 100% stimulation level
11528958|NCT01151618|Experimental|Respironics Synchrony ventilator (Non Invasive Ventilation)|Non Invasive Ventilation using forced oscillation technique (FOT)
11528959|NCT01151605|Experimental|obese|20 obese subjects
11528960|NCT01151605|Active Comparator|lean|20 lean subjects
11528961|NCT01151605|Experimental|type 2 diabetes|20 type 2 diabetes
11528962|NCT01151579|Active Comparator|Levalbuterol 0.63|Patients received an initial dose of levalbuterol 0.63 mg alternating with albuterol 2.5 mg.
11528963|NCT01151579|Active Comparator|Levalbuterol 1.25|Patients received an initial dose of levalbuterol 1.25 mg alternating with albuterol 2.5 mg.
11528964|NCT01151566||Renal Compromise|Those referred for CT scan with identified renal compromise necessitating use of no contrast agent
11528965|NCT01151566||Sensitivity to CT Contrast Agents|Those referred for CT scan with prior demonstration of contrast sensitivity requiring use of no contrast
11528966|NCT01151553|Other|Patients with CHF with CRT Therapy|Patients with CHF with CRT Therapy
11529009|NCT01151215|Experimental|2|AZD8931 20mg (bd) plus anastrozole 1mg (od)
11528967|NCT01151540|Experimental|Rufinamide|Ralfinamide was administered orally twice daily after breakfast and dinner. Participants on placebo in Study 304 were titrated over to rufinamide within 2 weeks during the Conversion Period. As a general rule, the dose of rufinamide at the end of the Conversion Period was maintained throughout the Maintenance Period.
11528968|NCT01151527||Sporadic (idiopathic) or familial interstitial pneumonia|We are recruiting patients with Idiopathic Pulmonary Fibrosis and other types of Idiopathic Interstitial Pneumonias that occur sporadically or familial (2 or more affected individuals in a family). Participation can be done by mail or visiting Duke University Medical Center (Durham, NC)or National Jewish Health (Denver, CO).
11528969|NCT01151514||nrHA-AKI patients|Patients with hospital-acquired acute kidney injury not referred to the nephrologists
11528970|NCT01151514||lrHA-AKI patients|Patients with hospital-acquired acute kidney injury whao are late referred to the nephrologists
11528971|NCT01151501|Experimental|noninvasive positive pressure ventilation|
11528972|NCT01151488|Experimental|Resistance Training|16 weeks of moderate intensity resistance training, 3x/week
11528973|NCT01151449|Experimental|Treatment (gamma-secretase/Notch signalling pathway inhibitor)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11528974|NCT01151436|Experimental|hyaluronic acid|
11528975|NCT01151423|Experimental|Caplacizumab|Caplacizumab 10 mg once daily
11528976|NCT01151423|Placebo Comparator|Placebo|Placebo once daily
11528977|NCT01151410|Experimental|Aliskiren|Patients will receive one of the following doses based on the their weight: Low weight (≥20 to <50 kg) patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg Mid weight (≥50 to <80 kg) patients: Starting dose 75 mg with optional titration to 150 and then 300 mg High weight (≥80 to ≤150 kg) patients: Starting dose 150 mg with optional titration to 300 and then 600 mg
11528978|NCT01151410|Active Comparator|Enalapril|Patients will receive one of the following doses based on their weight: Low weight (≥20 to <50 kg) patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg Mid weight (≥50 to <80 kg) patients: Starting dose 5 mg with optional titration to 10 and then 20 mg High weight (≥80 to ≤150 kg) patients: Starting dose 10 mg with optional titration to 20 and then 40 mg
11528979|NCT01151397|Active Comparator|Peg + Vitamin D + Ribavirin|Peg + Vitamin D + Ribavirin for 3 months
11528980|NCT01151397|Active Comparator|Peg + Ribavirin|Peg + Ribavirin for 6 months
11528981|NCT01151384|Experimental|LE-DT|
11528982|NCT01151371|Experimental|narafilcon B daily disposable 4 weeks|narafilcon B soft contact lenses worn daily on a daily disposable/replacement schedule, for 4 weeks
11528983|NCT01151371|Active Comparator|nelfilcon A daily disponsable 1 week|nelfilcon A soft contact lenses worn daily on a daily disposable/replacement schedule, for 1 week
11528984|NCT01151371|Active Comparator|lotrafilcon B daily wear, monthly replacement, 4-weeks|lotrafilcon B soft contact lenses worn daily on a 1-month replacement schedule, for 4 weeks
11528985|NCT01151345|Experimental|diltiazem|
11528986|NCT01151319|Experimental|Stage 1.|The first stage will start from a low and well tolerated, but likely less immunogenic dose of ChAdV63.HIVconsv (n=2).
11528987|NCT01151319|Experimental|Stage 2|The highest dose of ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0 and 8, respectively (n=8). Followed up at 6,12 and 24 months after last vaccination.
11528988|NCT01151319|Experimental|Stage 3|Three doses of pSG2.HIVconsv DNA followed by boost with high dose ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0,4,8,12 and 20, respectively (n=8). Followed up at 6, 12 and 24 months after last vaccination.
11528989|NCT01151319|Experimental|Stage 4|Three doses of pSG2.HIVconsv DNA followed by boost with MVA.HIVconsv followed by boost with high dose ChAdV63.HIVconsv at weeks at week 0,4,8,12 and 16, respectively (n=8).
11528990|NCT01151319|Placebo Comparator|Stage 2 Placebo|Time-course matched to vaccinations (n=2)
11528991|NCT01151319|Placebo Comparator|Stage 3 placebo|Time-course matched to vaccinations (n=2)
11528992|NCT01151319|Placebo Comparator|Stage 4 placebo|Time-course matched to vaccinations (n=2)
11528993|NCT01151306|Placebo Comparator|Lactose tablet|
11528994|NCT01151306|Active Comparator|Simvastatin 20mg|
11528995|NCT01151280|Experimental|WallFlex Biliary Fully Covered Stent|All eligible patients entered into the study will be treated with a WallFlex Biliary Fully Covered Stent
11528996|NCT01151267|Other|Control Arm|The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation >97% and end tidal CO2 at 35-45mmHg.
11528997|NCT01151267|Active Comparator|HSH Group|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
11528998|NCT01151254|Active Comparator|PA-Intravenous Sedation|Propofol based total intravenous anesthesia and postoperative sedation
11528999|NCT01151254|Active Comparator|Volatile sedation|Total inhalational anesthesia and postoperative sedation with the AnaConda device
11529000|NCT01151241|Experimental|Early discharge|Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.
11529001|NCT01151241|Active Comparator|Normal Discharge|Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
11529002|NCT01151228|Placebo Comparator|Zero volume|Patients will not ingest any apple juice prior to the second ultrasound.
11529003|NCT01151228|Experimental|50 mL|Patients will ingest 50 mL apple juice prior to the second ultrasound.
11529004|NCT01151228|Experimental|100 mL|Patients will ingest 100 mL apple juice prior to the second ultrasound.
11529005|NCT01151228|Experimental|200 mL|Patients will ingest 100 mL apple juice prior to the second ultrasound.
11529006|NCT01151228|Experimental|300 mL|Patients will ingest 300 mL apple juice prior to the second ultrasound.
11529007|NCT01151228|Experimental|400 mL|Patients will ingest 400 mL apple juice prior to the second ultrasound.
11529008|NCT01151215|Experimental|1|AZD8931 40mg (bd) plus anastrozole 1mg (od)
11529011|NCT01151202|Experimental|AG NPP709 syrup|AG NPP709 contains Ivy leaf extract and coptis rhizoma extract
11529012|NCT01151202|Active Comparator|Ivy leaf extract syrup|
11529013|NCT01151189|Placebo Comparator|Placebo|The placebo is a licensed product manufactured by Allermed, Inc. and is used for evaluation of delayed-type of hypersensitivity reactions in adults.
11529014|NCT01151189|Experimental|MVA85A/AERAS-485|MVA85A/AERAS-485 is a recombinant modified vaccinia virus Ankara expressing the M. tuberculosis antigen, Ag85A. Dosage of the study vaccine to be administered will be 1x10^8 pfu.
11529015|NCT01151176|Active Comparator|Insulin|Intensive Insulin Therapy
11529016|NCT01151176|Other|Regular Insulin|Sub Cutaneous Regular Insulin
11529017|NCT01150916|Active Comparator|Heart failure|Patients must fulfill Framingham and/or Boston criteria for heart failure and have systolic or diastolic disfunction in rest echocardiography.
11529018|NCT01150916|Active Comparator|Liver Cirrhosis|Patients must have a biopsy proven diagnosis of liver cirrhosis or the diagnosis established on clinical basis in cases of known etiology of liver disease, peripheral signs of chronic liver disease, esophageal varices at endoscopy and an imaging method with evidence of cirrhosis.
11529019|NCT01150916|Active Comparator|Other causes of ascites|Patients must fulfill stringent diagnostic criteria for the cause of ascites, by clinical criteria, laboratory and imaging tests and histology when appropriate.
11529020|NCT01150916|Active Comparator|Concurrent heart failure and cirrhosis|Patients must fulfill the aforementioned criteria for both conditions.
11529021|NCT01150851|Active Comparator|caloric restriction|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration
11529022|NCT01150851|Active Comparator|aerobic exercise|supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
11529023|NCT01150851|Active Comparator|caloric restriction and aerobic exercise|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration, and supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
11529024|NCT01150851|No Intervention|usual diet and usual activity|usual diet and usual activity
11529025|NCT01150838|Experimental|Propofol administration|"Propofol 2 mg/kg administered to first subject. Dose will be increased by 0.3 mg/kg for the next subject if intubation score is not excellent. Dose will be decreased by 0.3 mg/kg if intubation score is excellent. This dosing scheme will be continued."
11529026|NCT01150747||Risk of positive chlamydia|"current, untreated endocervical C. trachomatis infection
~mucopurulent cervicitis on pelvic examination
~Sexual contact with a male partner recently diagnosed with C. trachomatis, and/or non-gonococcal urethritis"
11529027|NCT01149226|Placebo Comparator|placebo control|
11529028|NCT01149226|Experimental|oral medication chloral hydrate|
11529029|NCT01151137|Experimental|Dronedarone|Dronedarone 400 mg twice a day until the CSED
11529030|NCT01151137|Placebo Comparator|placebo|Placebo (for Dronedarone) twice a day until the CSED
11529031|NCT01151124|Experimental|CTX0E03 DP|human neural stem cell product, once only injection, increasing doses
11529032|NCT01151098|Experimental|BTDS 5, 10 or 20|Buprenorphine transdermal patch
11529033|NCT01151085||Voriconazole|Subjects who are treated with voriconazole
11529034|NCT01151072|Experimental|IDeg i.m. thigh|
11529035|NCT01151072|Experimental|IDeg i.v.|
11529036|NCT01151072|Experimental|IDeg s.c. abdomen|
11529037|NCT01151072|Experimental|IDeg s.c. deltoid|
11529038|NCT01151072|Experimental|IDeg s.c. thigh|
11529039|NCT01151059|Other|Group 1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
11529040|NCT01151046|Experimental|MM-121 (SAR256212) + exemestane|
11529041|NCT01151046|Placebo Comparator|Placebo + exemestane|
11529042|NCT01151033|Experimental|stent implantation|ProNOVA XR Polymer Free Drug Eluting Stent implantation - single arm
11529043|NCT01151020|Experimental|Arm 1|Zenith® TX2® Low Profile TAA Endovascular Graft (Thoracic Aortic Aneurysm)
11529044|NCT01151007||Patients with colorectal carcinoma|Patient with colorectal carcinoma operated in Martinique between January 1st, 2007 and December 31st, 2009
11529045|NCT01150994|No Intervention|Treatment as Usual|
11529046|NCT01150994|No Intervention|Screening Alone|Enhanced screening among ED patients
11529047|NCT01150994|Experimental|Safety Assessment and Follow-up Telephone Intervention|SAFTI: Safety Assessment in the ED combine with a Follow-up Telephone Intervention.
11529048|NCT01150981|Experimental|Rosiglitazone|One 8mg capsule daily for 6 weeks.
11529049|NCT01150981|Placebo Comparator|Placebo|One capsule daily for 6 weeks.
11529050|NCT01150968|Experimental|Internal Medicine Residents|All UCSf Internal Medicine residents for 2009-2010
11529051|NCT01150955|Active Comparator|Resveratrol|Dietary supplement of resveratrol 500 mg three times a day over five weeks.
11529052|NCT01150955|Placebo Comparator|Placebo|
11529053|NCT01150942|Experimental|vero cell-derived JE vaccine|vero cell-derived vaccine group
11529054|NCT01150942|Active Comparator|Mouse brain-derived JE vaccine|Mouse brain-derived JE vaccine group
11529055|NCT01150929|Active Comparator|Fixed bearing|One of the 2 used implants.
11529056|NCT01150929|Active Comparator|Rotating platform|One of the 2 used implants.
11529057|NCT01150903||PDE5 inhibitor prescription|
11529058|NCT01150903||Age-matched Control|
11529059|NCT01150890|Experimental|AMG 827 IV 350 MG|350 mg AMG 827
11529060|NCT01150890|Experimental|AMG 827 IV 700 MG|700 mg AMG 827
11529061|NCT01150890|Placebo Comparator|PLACEBO|Placebo
11529062|NCT01150890|Experimental|AMG 827 IV 210 MG|210 mg AMG 827
11529063|NCT01150877|Experimental|Experimental Dietary Supplement (e.g., vitamins, minerals)|Experimental arm is supplemented with high-dose of vitamin D.
11529064|NCT01150877|No Intervention|No Intervention|
11529065|NCT01150864|Active Comparator|Passive Humidifier|The Passive Humidifier (HME)will changed every 24 hours
11529066|NCT01150864|Active Comparator|Active-Passive humidifier|The Active-Passive Humidifier will be changed every 24 hours
11529067|NCT01150864|Active Comparator|Hot Water Humidifier|Hot water humidifier will be set at 36-37 °C
11529068|NCT01150825||STEMI|Patients with ST segment elevation myocardial infarction, verified by elevated troponin levels
11529069|NCT01150825||NSTEMI|Patients with non-ST segment elevation myocardial infarction, verified by elevated levels of troponin
11529070|NCT01150812|Experimental|1|
11529071|NCT01150786|Experimental|selenium|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
11529072|NCT01150786|Placebo Comparator|placebo capsule|The patients in this arm took one placebo capsule daily for 12 weeks.
11529073|NCT01150760||Alvimopan Users|
11529074|NCT01150760||Matched controls|
11529075|NCT01150721||1/PNMI|Adult patients with Pulmonary Nontuberculous Mycobacterial Infection
11529076|NCT01150721||2/Healthy Volunteers|Healthy Volunteer adults
11529077|NCT01150708||Chiari 1 with syringomyelia|Chiari I malformation with syringomyelia.
11529078|NCT01150708||Chiari 1 without syringomyelia|A Chiari I Malformation without syringomyelia is defined as descent of the cerebellar tonsils > 5 mm below the foramen magnum 79 without associated syringomyelia.
11529079|NCT01150708||Syringomyelia without chiari|A syrinx or syringomyelia is defined as an intramedullary cyst that extends / length > 1spinal segment.
11529080|NCT01150695|Experimental|Group A (DVC-LVS)|Single dose of the Dynport Vaccine Company Live Vaccine Strain (DVC-LVS) product in one arm and normal saline (NS) control in the other arm on Day 0.
11529081|NCT01150695|Experimental|Group B (USAMRIID-LVS)|Single dose of the United States Army Medical Research Institute of Infectious Diseases Live Vaccine Strain (USAMRIID-LVS) product in one arm and normal saline (NS) control in the other arm on Day 0.
11529082|NCT01150669||Observational|Cryopreserved specimens are studied in vitro with lestaurtinib with or without chemotherapy agents. Samples are analyzed for FLT3 protein expression and/or activation; sensitivity to lestaurtinib with or without chemotherapy agents; and activation of STAT, AKT, and RAS-MAPK and other pathways by western blot. The most effective treatment from this study is then validated in vivo in a NOD/SCID xenograft model.
11529083|NCT01150630|Experimental|adjuvant PEXG|cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 6 months
11529084|NCT01150630|Experimental|perioperative PEXG|cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 3 months before surgery and 3 months after surgery
11529085|NCT01150630|Active Comparator|Adjuvant Gemcitabine|Adjuvant Gemcitabine at 1000 mg/mq for 3 weeks every 4 weeks for 6 months
11529086|NCT01150617|Active Comparator|long-acting insulin plus analogues|three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening.
11529087|NCT01150617|Active Comparator|long-acting insulin and oral agents|treatment will be once-daily long-acting insulin and oral antidiabetic agents
11529088|NCT01150604|Experimental|Self-help course|
11529089|NCT01150578||Lexi-Echo pilot|Appropriate patients at University of Arizona Medical Center stress imaging laboratory who have a routine regadenoson SPECT nuclear scan will have simultaneous cardiac echo images obtained.
11529090|NCT01150565|Experimental|LiRIS low dose|The first dose group of approximately 10 patients receive low dose LiRIS on Day 1 to Day 14.
11529091|NCT01150565|Experimental|LiRIS high dose|The second dose group of approximately 10 patients receive high dose LiRIS on Day 1 to Day 14.
11529092|NCT01150552||Poultry exposed individuals|Any individual who had an occupational contact with poultry in the previous five years will be considered exposed. Individuals working on poultry farms, poultry wet markets, or keeping limited numbers of poultry in their backyard, are considered exposed.
11529093|NCT01150552||Non-poultry exposed adult controls|Unexposed individuals must have no occupational exposure to poultry in their lifetime and must also not be exposed to poultry purchased from live bird markets.
11529094|NCT01150539|Experimental|Overweight/obese women with PCOS|10 overweight/obese women with polycystic ovary syndrome
11529095|NCT01150526|Placebo Comparator|Placebo|Oral Placebo capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
11529096|NCT01150526|Experimental|CaHMB Pre|Oral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
11529097|NCT01150526|Experimental|CaHMB Pre and Post|Oral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A CaHMB capsule and placebo gel dosage are are then administered 3 times daily during the remainder of the study.
11529098|NCT01150526|Experimental|HMB Free Acid Gel Pre|Oral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
11529099|NCT01150526|Experimental|HMB Free Acid Gel Pre and Post|Oral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and HMB free acid gel dosage are then administered 3 times daily during the remainder of the study.
11529100|NCT01150513|Active Comparator|EC-T|
11529101|NCT01150513|Experimental|TP|
11529102|NCT01150500|Experimental|Drug Eluting Stent|Up to two lesions in two separate target vessels may be treated under this protocol. The lesions should be amenable to treatment with at least one 2.25 mm stent, a second lesion could be treated with any stent from 2.25 to 3.5 mm.
11529103|NCT01150487|Experimental|Sensitized Renal Allograft Recipients|Patients who have antibodies against their donors in their blood.
11529104|NCT01150474|Experimental|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
11529105|NCT01150474|Placebo Comparator|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
11529106|NCT01150461|Experimental|losartan|Losartan 50 mg b.i.d.
11529107|NCT01150461|Placebo Comparator|placebo|Placebo b.i.d.
11529150|NCT01150136||1|Children with proven CF and known genotype, age 0-17 yr
11529151|NCT01150123|Experimental|5 µg_No Adj|Subjects received either 1 or 2 doses of active vaccine (5 µg) without any adjuvant
11529645|NCT01146613|Active Comparator|Varenicline|Varenicline Tartrate
11529108|NCT01150448|Experimental|001|Paliperidone palmitate Treatment A All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
11529109|NCT01150448|Experimental|002|Paliperidone palmitate Treatment B Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq patients who do not wish to have multiple blood samples collected will also be assigned to Treatment B
11529110|NCT01150435||Maintenance Medication D, S- Methadon|
11529111|NCT01150435||Maintenance Medication S- Methadon|
11529112|NCT01150435||Buprenorphine|
11529113|NCT01150435||Buprenorphine+ Naloxone|
11529114|NCT01150422|No Intervention|Standard of care for post medical abortion follow-up|Standard of care includes a routine hospital visit two weeks after mifepristone administration. At the hospital visit, the woman will undergo a bimanual and vaginal ultrasound examination. In the event the woman fails to return for the follow-up visit, each hospital will follow their standard procedure for contacting women who fail to attend their follow-up visit, i.e. three efforts to contact the woman. Form 2a will document the results of any clinical examinations, any additional medical abortion-related care given and the abortion outcome. At the follow-up visit, women will also be asked about the acceptability of current medical abortion follow-up procedures and their future preferences.
11529115|NCT01150422|Active Comparator|Alternative follow-up|"At their first clinic visit, women will be asked to provide their phone number for contact purposes. Women will also be asked to complete a semi-quantitative pregnancy test in the clinic and the results of the test will be noted on a study form. After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist.
~Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned date two weeks after mifepristone administration. The checklist will indicate that if the woman answers yes to any of the questions, then she should return to the clinic for a follow-up visit. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests."
11529116|NCT01150409|Experimental|hydrocortisone|Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
11529117|NCT01150409|Placebo Comparator|Normal Saline (placebo)|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
11529118|NCT01150383|Active Comparator|group RO (Room air / Oxygen)|RO (Room air / Oxygen): First 6 weeks of exercise training under normoxic conditions (Room air), followed by 6 weeks of exercise training with oxygen supplementation.
11529119|NCT01150383|Active Comparator|group OR (Oxygen / Room air)|OR (Oxygen / Room air): First 6 weeks of exercise training with oxygen supplementation, followed by 6 weeks of exercise training under normoxic conditions (room air).
11529120|NCT01150370|Experimental|Males undergoing circumcision|
11529121|NCT01150357|Experimental|Low Dose Aliskiren|Participants received body-weight stratified dose of aliskiren capsules (6.25/12.5/25 mg) once daily. Participants whose body weight ≥ 20 kilogram (kg) to less than < 50 kg received 6.25 mg; ≥50 kg and < 80 kg received 12.5 mg and ≥ 80 kg and ≤ 150 kg received 25 mg of aliskiren.
11529122|NCT01150357|Experimental|Mid dose|Participants received body-weight stratified dose of aliskiren capsules (37.5/75/150 mg) once daily. Participants whose body weight ≥ 20 kg to < 50 kg received 37.5 mg; ≥50 kg and < 80 kg received 75 mg and ≥ 80 kg and ≤ 150 kg received 150 mg of aliskiren.
11529123|NCT01150357|Experimental|High dose|Participants received body-weight stratified dose of aliskiren capsules (150/300/600 mg) once daily. Participants whose body weight ≥ 20 kg to < 50 kg received 150 mg; ≥50 kg and < 80 kg received 300 mg and ≥ 80 kg and ≤ 150 kg received 600 mg of aliskiren.
11529124|NCT01150344|Active Comparator|Malarone|"Malarone (atovaquone + proguanil combination):
~patients treated with Malarone®"
11529125|NCT01150344|Active Comparator|Riamet|"RIAMET (artemether + LUMEFANTRIN combination):
~patients treated with Riamet®"
11529126|NCT01150331|Experimental|Clonazepam + levetiracetam|Clonazepam IV 1 mg+ levetiracetam IV 2500 mg
11529127|NCT01150331|Active Comparator|Clonazepam + placebo|Clonazepam IV 1 mg + placebo levetiracetam IV
11529128|NCT01150318|Experimental|1|Patients treated by 131 iodine for thyroid cancer
11529129|NCT01150305||1|Patient presenting familial dominant non syndromic hearing loss starting between 4 and 40 years old, over 2 generations
11529130|NCT01150305||2|Healthy volunteer from the same families
11529131|NCT01150292|Experimental|DHA - Sunflower oil|400 mg DHA supplementation by day for 2 weeks then placebo for 2 weeks after a wash out period of 6 to 9 weeks
11529132|NCT01150292|Experimental|Sunflower oil - DHA|Placebo during 2 weeks then 400 mg DHA supplementation by day for 2 weeks after a wash out period for 6 to 9 weeks
11529133|NCT01150266|Experimental|Alteplase|Alteplase 0.9mg/kg (maximum 90mg), 10% IV bolus over 1 minute and the remainder over one hour infusion in patients with ischemic stroke after awaking.
11529134|NCT01150253|Experimental|probiotic fermented milk|
11529135|NCT01150253|Placebo Comparator|placebo|
11529136|NCT01150240||Primary Immunodeficiency Disease|Patients with primary Immunodeficiency disease (PID)
11529137|NCT01150214||DE-MRI|All patients will undergo Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI)to quantify the degree of atrial structural remodeling or fibrosis pre-ablation and DE-MRI will be obtained at 3, 6, and 12 months follow-up to detect and quantify ablation-related scar formation.
11529138|NCT01150201|Experimental|Aliskiren|Aliskiren
11529139|NCT01150201|Active Comparator|Losartan|ARB
11529140|NCT01150188|Active Comparator|Amino acids|Amino acid supplementation between meals for eight weeks
11529141|NCT01150188|Placebo Comparator|Placebo|Supplementation of placebo (inert components) between meals for eight weeks
11529142|NCT01150175|Experimental|Autologous bone marrow cells|
11529143|NCT01150175|Placebo Comparator|Plasma|
11529144|NCT01150162|Experimental|Mucosta and Omeprazole|
11529145|NCT01150162|Active Comparator|Omeperazole|
11529146|NCT01150149|No Intervention|1|
11529152|NCT01150123|Experimental|20 µg_No Adj|Subjects received either 1 or 2 doses of active vaccine (20 µg) without any adjuvant.
11529153|NCT01150123|Experimental|5 µg_Alum|Subjects received either 1 or 2 doses of active vaccine (5 µg) with Alum adjuvant.
11529154|NCT01150123|Experimental|20 µg_Alum|Subjects received either 1 or 2 doses of active vaccine (5 µg) with Alum adjuvant.
11529155|NCT01150123|Experimental|5 µg_MF59-H|Subjects received either 1 or 2 doses of active vaccine (5 µg) adjuvanted with 4.87 mg of MF59
11529156|NCT01150123|Experimental|20 µg_MF59-H|Subjects received either 1 or 2 doses of active vaccine (20 µg) adjuvanted with 4.87 mg of MF59
11529157|NCT01150123|Experimental|5 µg_MF59-F|Subjects received either 1 or 2 doses of active vaccine (5 µg) adjuvanted with 9.75 mg of MF59
11529158|NCT01150123|Experimental|20 µg_MF59-F|Subjects received either 1 or 2 doses of active vaccine (20 µg) adjuvanted with 9.75 mg of MF59
11529159|NCT01150123|Placebo Comparator|Placebo|Subjects received 2 injections of placebo administered 1 month apart
11529160|NCT01150097|Experimental|Everolimus + reduced tacrolimus|Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.
11529161|NCT01150097|Experimental|Tacrolimus elimination|Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.
11529162|NCT01150097|Active Comparator|Tacrolimus control|Participants were maintained on a whole blood trough level of 6 - 10 ng/mL tacrolimus.
11529163|NCT01150084|Experimental|lunchtime walking|
11529164|NCT01150084|Other|waiting-list control|
11529165|NCT01150071||Children born extremely preterm|national cohort of children born before 28 weeks' gestational age or with a birthweight less than 1000 g. 365 eligible survivors
11529166|NCT01150045|Active Comparator|Arm A - FOLFOX and placebo (12 treatments)|Patients receive FOLFOX every 2 weeks plus placebo every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
11529167|NCT01150045|Experimental|Arm B - FOLFOX and celecoxib (12 treatments)|Patients receive FOLFOX every 2 weeks plus celecoxib every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
11529168|NCT01150045|Active Comparator|Arm C - FOLFOX and placebo (6 treatments)|Patients receive FOLFOX every 2 weeks plus placebo every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
11529169|NCT01150045|Experimental|Arm D - FOLFOX and celecoxib (6 treatments)|Patients receive FOLFOX every 2 weeks plus celecoxib every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
11529170|NCT01150032||Osteopenic women|Women with osteopenia: Bone Mineral Density T-score between -1.0 and -2.5 (for whom with clinical factor risk) or -3.0 (for whom without clinical factor risk)
11529171|NCT01150019||Obese Group|
11529172|NCT01150019||Non Obese Group|
11529173|NCT01150006||Healthy male participants|
11529174|NCT01149993|Experimental|pre-transplant immunosuppression|subjects in this arm will receive Myfortic 720mg twice daily for 7 days prior to transplantation. Intra-operatively, the donor kidney will receive an infusion of Thymoglobulin, prior to the transplantation.
11529175|NCT01149993|Experimental|pre-transplant induction|subjects in this arm will not receive any pre-transplant immunosuppression. However, the donor kidney will receive an infusion of Thymoglobulin prior to transplantation.
11529176|NCT01149993|Active Comparator|standard of care|subjects in this arm will not receive any pre-transplant immunosuppression, and the donor kidney will not receive an additional dose of Thymoglobulin prior to transplantation. This is the standard of care protocol for Georgetown University Hospital
11529177|NCT01149980|Experimental|Citalopram|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's
11529178|NCT01149980|Active Comparator|Celexa|Celexa 40 mg Tablets of Forest Labs
11529179|NCT01149967|Experimental|Citalopram|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's
11529180|NCT01149967|Active Comparator|Celexa|Celexa 40 mg Tablets of Forest Labs
11529181|NCT01149954|Experimental|Ibuprofen|Ibuprofen 200 mg gel Capsules of Dr. Reddy's laboratories Limited
11529182|NCT01149954|Active Comparator|Advil|Advil liquigels 200 mg gel capsules of Wyeth Consumer Healthcare
11529183|NCT01149941|Experimental|Ibuprofen|Ibuprofen 200 mg gel Capsules of Dr. Reddy's laboratories Limited
11529184|NCT01149941|Active Comparator|Advil|Advil liquigels 200 mg gel capsules of Wyeth Consumer Healthcare
11529185|NCT01149928||C/S delivered, wet lung|
11529186|NCT01149928||C/S delivered, healthy infants|
11529187|NCT01149889|Experimental|active stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
11529188|NCT01149876|Experimental|Nu Skin Product|
11529189|NCT01149876|Experimental|Nu Skin product with galvanic spa system|
11529190|NCT01149876|Active Comparator|Tretinoin cream 0.05|
11529191|NCT01149876|Placebo Comparator|over the counter moisturizer|
11529192|NCT01149863|Experimental|Plerixafor 17 hours prior to apheresis|Dosing of plerixafor will occur at 3PM (1500 hours).
11529193|NCT01149850|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks and oral temozolomide on days 1-5. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
11529194|NCT01149837||residual blood donor samples|Protocol describes testing an HTLV-I/II antibody reactive population from this cohort using the InnoLIA HTLV I/II Score line immunoassay
11529195|NCT01149824|Other|Dose Escalating|
11529196|NCT01149811||Fipamezole ODT Cohort 1|
11529197|NCT01149811||Fipamezole ODT Cohort 2|
11529198|NCT01149798|Experimental|Abraxane and Cisplatin combination|Abraxane and Cisplatin combination
11529199|NCT01149785|Experimental|1|There should be at least 14-day washout period between treatment A and B.
11529200|NCT01149772|Experimental|ACCESS|Medically ill patients received six-sessions of cognitive behavioral therapy tailored to their unique needs. Patients received 2 core modules and 3 elective modules. Elective modules focused on physical health, cognitive restructuring, behavioral activation, and relaxation. The six session was a wrap up that everyone received. Patients also had the option to receive 2 follow-up booster sessions to aid in maintenance of skills learned.
11529201|NCT01149772|No Intervention|Enhanced Usual Care|Patients in this arm received feedback about their physical and emotional health functioning and were still able to receive usual primary care services.
11529202|NCT01149759|Experimental|Cyclosporine A|5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks.
11529203|NCT01149746|Experimental|Tamsulosin|0.4 mg Capsule
11529204|NCT01149746|Active Comparator|Flomax®|0.4 mg Capsule
11529205|NCT01149733|Experimental|Tamsulosin|0.4 mg Capsule
11529206|NCT01149733|Active Comparator|Flomax®|0.4 mg Capsule
11529207|NCT01149720|Experimental|ARQ 197 Capsule, oral|Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
11529208|NCT01149720|Experimental|ARQ 197 Tablet, oral|Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
11529209|NCT01149720|Experimental|ARQ 197 Capsule D, oral|Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
11529210|NCT01149707|Experimental|PUR 0110 Rectal Enema 250 mg|Active treatment
11529211|NCT01149707|Experimental|PUR 0110 Rectal Enema 500 mg|Active treatment
11529212|NCT01149707|Experimental|PUR 0110 Rectal Enema 1000 mg|Active treatment
11529213|NCT01149707|Placebo Comparator|Placebo Enema|Placebo comparator
11529214|NCT01149694|Other|Cohort 1|
11529215|NCT01149694|Other|Cohort 2|
11529216|NCT01149694|Other|Cohort 3|
11529217|NCT01149694|Other|Cohort 4|
11529218|NCT01149681|Experimental|Arm one|
11529219|NCT01149668|Experimental|PCI-24781|
11529220|NCT01149655|Experimental|Phase 1|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
11529221|NCT01149655|Experimental|Phase 2|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
11529222|NCT01149655|Placebo Comparator|Phase 3|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg) or placebo
11529223|NCT01149642|Experimental|Oral immunomodulatory solution|The oral supplement is a 74g sachet containing 302 kcal and 16.7g proteins as well as immunonutrients such as L-Arginine, ARN and omega-3.
11529224|NCT01149642|Placebo Comparator|Placebo|The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
11529225|NCT01149629|Active Comparator|Fed Dosing|Subjects fed a high calorie, high fat meal prior to receiving 3 x 100mg capsules
11529226|NCT01149629|Active Comparator|Fasted Dosing|Subjects fasted prior to receiving 3 x 100mg capsules
11529227|NCT01149629|Active Comparator|Bioequivalence|Subjects fasted prior to receiving 1x 300mg capsule
11529228|NCT01149629|Active Comparator|TID Dosing|Droxidopa 300 mg given TID
11529229|NCT01149616|Active Comparator|Intervention|Dexamethasone 8mg iv x 1
11529230|NCT01149616|Placebo Comparator|Placebo|placebo
11529231|NCT01149603|Experimental|Implantation of the HeartMate II VAD|Consenting patients who meet the study inclusion and exclusion criteria will be implanted with a HeartMate II ventricular assist device.
11529232|NCT01149590|Experimental|CT Calcium Score & Coronary Angiography|CT Scan
11529233|NCT01149590|No Intervention|No CT Scan|No CT Scan
11529234|NCT01149577|Experimental|Schizophrenia patients|The study population of 25 schizophrenia patients constituted the active arm of the study.
11529235|NCT01149564|Placebo Comparator|IV ibuprofen|The first dose of either oral or IV ibuprofen will be given at the time the patient is randomized.The subsequent doses of indometacin or ibuprofen are also determined according to the echocardiographic PDA flow patterns at intervals of once every 24 hours from the last dose. The dosage of both oral ibuprofen (Ibuprofen suspension, 20 mg/ml, Yung Shing Co., Taiwan) and IV ibuprofen (PedeaR 20 mg/ml, developed by Orphan Europe and approved by the EMEA) are an initial dose of 10 mg/kg and then 5 mg/kg at 24-hour intervals as indicated by PDA flow pattern.
11529236|NCT01149564|Active Comparator|Oral ibuprofen|
11529237|NCT01149551||Group 1|
11529238|NCT01149538|Experimental|Choline Bitartrate|Choline Bitartrate supplementation
11529239|NCT01149538|Placebo Comparator|Placebo|Placebo for choline bitartrate supplementation
11529240|NCT01149525|Experimental|1|oral solution of L-Carnitine, 4g per day
11529241|NCT01149525|Placebo Comparator|2|Similar oral solution without L-Carnitine
11529242|NCT01149512||LAGB patients in Weight Wise Program|All patients seen within the Weight Wise program and selected for surgical management, who have undergone LAGB will be included in this analysis.
11529243|NCT01149499|Experimental|Valacyclovir|Test 1000 mg Valacyclovir Tablet
11529244|NCT01149499|Active Comparator|Valtrex|Reference Listed 1000 mg Valtrex Tablet
11529245|NCT01149486|Experimental|Generic Test Product|Losartan potassium/Hydrochlorothiazide 100/25 mg Tablets
11529246|NCT01149486|Active Comparator|Reference Listed Drug|Hyzaar® 100/25 mg Tablets
11529247|NCT01149473|Experimental|Generic Test Product|Losartan potassium/Hydrochlorothiazide 100/25 mg Tablets
11529248|NCT01149473|Active Comparator|Reference Listed Drug|Hyzaar® 100/25 mg Tablets
11529249|NCT01149460|Experimental|Valacyclovir|Test 1000 mg Tablet
11529250|NCT01149460|Active Comparator|Valtrex|Reference Listed Valacyclovir 1000 mg Tablet
11529251|NCT01149434|Experimental|Pharmacokinetic Arm|Patients going on Pharmacokinetic arm will receive JI-101 & Everolimus (4 patients only)
11529252|NCT01149434|Experimental|Pharmacodynamic arm|Patients going on the Pharmacodynamic study will receive JI-101 only.
11529253|NCT01149421|Experimental|1.5 milligram (mg) LY2189265|LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
11529254|NCT01149421|Experimental|0.75 milligram (mg) LY2189265|LY2189265: 0.75 milligram (mg), subcutaneous (SC), once weekly (QW)
11529255|NCT01149421|Placebo Comparator|Placebo|Placebo: subcutaneous (SC), once weekly (QW)
11529256|NCT01149408|Experimental|All patients|All participants enrolled.
11529257|NCT01149395|Experimental|Dexlansoprazole|
11529258|NCT01149382||islet cell transplant recipients|
11529260|NCT01149369|Placebo Comparator|Aprepitant-placebo|Placebo aprepitant 125mg per day
11529261|NCT01149356|Experimental|Arm I|Patients receive oral exemestane once daily on days 1-21 and oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11529262|NCT01149356|Active Comparator|Arm II|Patients receive exemestane as in arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11529263|NCT01149343|Experimental|GSK2302025A Cohort 1|Male or female patients with histologically proven cutaneous melanoma received the investigational Low-Dose (LD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
11529264|NCT01149343|Experimental|GSK2302025A Cohort 2|Male or female patients with histologically proven cutaneous melanoma received the investigational Middle-Dose (MD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
11529265|NCT01149343|Experimental|GSK2302025A Cohort 3|Male or female patients with histologically proven cutaneous melanoma received the investigational High-Dose (HD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
11529266|NCT01149343|Experimental|GSK2302025A Cohort 4|In Phase 2 of the study subjects received the optimal investigational dose-level identified in Phase 1. Patients received a treatment consisting of 24 injections of the experimental GSK2302025A immunotherapeutic.
11529267|NCT01149330|Experimental|Adapalene-BPO Gel|
11529268|NCT01149317|Experimental|Acupuncture|Weekly acupuncture treatment for up to 14 weeks
11529269|NCT01149304|Experimental|Group A|Medication group with patients receiving the study medication according to the study protocol for 8 weeks after HDR brachytherapy.
11529270|NCT01149304|No Intervention|Group B|Comparison group with patients receiving the standard therapy of HDR brachytherapy without the study specific medication.
11529271|NCT01149291||End stage renal disease patients|
11529272|NCT01149278|Active Comparator|high pressure|
11529273|NCT01149278|Placebo Comparator|normal pressure|
11529274|NCT01149265|Experimental|Online support group|
11529275|NCT01149265|Active Comparator|Expressive writing|
11529276|NCT01149252|Placebo Comparator|Psoralait|
11529277|NCT01149213|Experimental|Transcranial Direct Current Stimulation|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
~The patient will receive tDCS every other week during the first three months, then once a month during the next three months."
11529278|NCT01149200|Experimental|TC-6499|
11529279|NCT01149200|Placebo Comparator|Placebo|
11529280|NCT01149187||IGRA in solitary pulmonary nodules|Inpatients who undergo percutaneous needle biopsy for diagnosis of pulmonary nodules in Seoul National University hospital for six months are going to be included. Patients who are not tolerable for PCNB or do not agree the enrollment of study will be excluded.
11529281|NCT01149174|No Intervention|transurethral resection alone|Patients with non-muscle invasive bladder cancer who underwent transurethral resection alone;
11529282|NCT01149174|Active Comparator|intravesical mitomycin-C|Patients with non-muscle invasive bladder cancer who underwent one intravesical instillation of mitomycin-C immediately after transurethral resection
11529283|NCT01149174|Experimental|electromotive mitomycin-C|Patients with non-muscle invasive bladder cancer who underwent single immediate intravesical instillation of electromotive mitomycin-C immediately before transurethral resection
11529284|NCT01149161|Active Comparator|C group|Routine central neck dissection
11529285|NCT01149161|No Intervention|N group|No central neck node dissection
11529286|NCT01149148|Active Comparator|Intervention INVOS Cerebral Oximetry Monitoring|Intervention will be initiated if rSO2 drops > 20% from baseline or rSO2 declines below 50%.
11529287|NCT01149148|Active Comparator|Standard of Care|Blinded cerebral oximetry monitoring with no intervention in surgical procedures and anesthesia without deviation from standard of care.
11529288|NCT01149135|Active Comparator|Standard light treatment|standard light treatment 5000K; 10 000 lux
11529289|NCT01149135|Experimental|blue enriched light|Blue enriched light with a low intensity (750 lux)
11529290|NCT01149122|Active Comparator|Gemcitabine/Oxaliplatin with Erlotinib|
11529291|NCT01149122|Active Comparator|Gemcitabine/Oxaliplatin without Erlotinib|
11529292|NCT01149109|Experimental|lomustine (CCNU) + temozolomide (TMZ) and radiotherapy|60 Gy standard radiotherapy (RT, 30 x 2 Gy) Six 42-day courses of oral CCNU 100 mg/m2 (day 1) and oral TMZ 100 mg/m2 (day 2-6), first CCNU application during the first week of RT CCNU/TMZ and radiotherapy start 2-5 weeks after diagnosis (day of surgery for glioblastoma (GBM)). In courses 2-6, TMZ dose are adjusted according to the hematotoxicity observed in the previous course and can be increased stepwise up to 200 mg/m2/day
11529293|NCT01149109|Active Comparator|temozolomide and radiotherapy|60 Gy standard radiotherapy (RT, 30 x 2 Gy) and concomitant TMZ therapy (daily TMZ 75 mg/m2) starting with the first day of radiotherapy Six 28-day courses of TMZ (day 1-5) starting 4 weeks after completion of radiotherapy. In the first course TMZ is given at a dose of 150 mg/m2/day, in case no toxicity is observed, the 2nd course is applied at a daily dose of 200 mg/m2
11529643|NCT01146626|Active Comparator|Peg+ Vitamin D+ Ribavirine|Peg+ Vitamin D+ Ribavirine
11529294|NCT01149096|Active Comparator|Arm I (conventional bone marrow harvest)|Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
11529295|NCT01149096|Experimental|Arm II (filgrastim, bone marrow harvest)|Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
11529296|NCT01149083|Experimental|Arm I (veliparib)|Patients receive veliparib PO BID on days 1-21.
11529297|NCT01149083|Experimental|Arm II (veliparib, carboplatin)|Patients receive carboplatin IV over 30 minutes on day 1 and veliparib as in Arm I.
11529298|NCT01149057|Experimental|Single Arm|
11529299|NCT01149044|Active Comparator|Upfront Thrombectomy followed by PCI|Upfront manual aspiration thrombectomy followed by PCI
11529300|NCT01149044|Active Comparator|PCI Alone|PCI without upfront manual aspiration thrombectomy
11529301|NCT01149031|Active Comparator|low level laser therapy, using a probe|"The treatment will be done by using a LLL-probe touching several areas of the vulvar vestibule, according to the selected protocol.
~Every patient will be treated twice weekly for 6 weeks."
11529302|NCT01149031|Placebo Comparator|Placebo|The patients will be treated with placebo-probe, according to the same protocol
11529303|NCT01149018|Experimental|Tetrahydrocannabinol|
11529304|NCT01149018|Placebo Comparator|Placebo|
11529305|NCT01149005|Experimental|insulin|patients who will get insulin with main meals during Intravenous (IV) antibiotic therapy due to pulmonary exacerbation
11529306|NCT01148992|Active Comparator|Lofexidine|
11529307|NCT01148992|Placebo Comparator|Placebo|
11529308|NCT01148979|Experimental|Adjunct Lisdexamfetamine (Vyvanse)|Participants receive Lisdexamfetamine Dimesylate 20-50 mg capsule each morning for 4 weeks. After a washout period of 2 weeks, they receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) capsule) each morning for 4 weeks.
11529309|NCT01148979|Placebo Comparator|Adjunct Placebo|Participants receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) 20-50 mg capsule) each morning for 4 weeks. After a washout period of 2 weeks, they receive Lisdexamfetamine Dimesylate capsule each morning for 4 weeks.
11529310|NCT01148966|Experimental|Treatment (photodynamic therapy)|Patients receive aminolevulinic acid PO 4 hours before undergoing surgery.
11529311|NCT01148953|Active Comparator|ALN-TTR01|
11529312|NCT01148953|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
11529313|NCT01148940||White women with Hb AA|White pregnant and postpartum women with Hb AA
11529314|NCT01148940||Black women with Hb AA|Black pregnant and postpartum women with HbAA
11529315|NCT01148940||Black women with Sickle Trait|Black pregnant and postpartum women with HbAS
11529316|NCT01148927||Adult acute lymphoblastic leukemia patients|
11529317|NCT01148914||Baseline level of biomarkers|
11529318|NCT01148901|Experimental|Remicade|Infliximab 5 mg/kg was administered as specified in the Summary of Product Characteristics for patients with ankylosing spondylitis
11529319|NCT01148888|Experimental|Magnesium Sulfate|The study will be conducted in the 45 minute interval between the completion of spinal instrumentation and the completion of skin closure. Once the spinal instrumentation is complete and the integrity of the spinal cord pathways is confirmed using SEPs and MEPs, magnesium will be administered for the remainder of surgery.
11529320|NCT01148862|Other|Group A|Group A will wear the MiniMed Paradigm® X54 System with the Low Glucose Suspend (LGS) feature activated
11529321|NCT01148862|Other|Group B|Group B will wear the MiniMed Paradigm® X54 System with the Low Glucose Suspend (LGS) feature deactivated
11529322|NCT01148849|Experimental|MGAH22|Anti-HER2 monoclonal antibody (margetuximab)
11529323|NCT01148836|Experimental|Coenzyme Q 10 and Pulmonary Hypertension|PAH subjects to take Co-Q daily for three months
11529324|NCT01148836|Experimental|Coenzyme Q 10 and Normal Controls|Normal controls to take Co-Q daily for three months
11529325|NCT01148823|Experimental|Postoperative day 1|Dressing was removed on the first postoperative day
11529326|NCT01148823|Experimental|Postoperative day 6|Dressing was removed on the 6th postoperative day
11529327|NCT01148810|Placebo Comparator|Placebo|
11529328|NCT01148810|Experimental|BAF312|
11529329|NCT01148797|Experimental|Canakinumab|
11529330|NCT01148784|Active Comparator|Quadrupled Hamstring Allograft|
11529331|NCT01148784|Active Comparator|Doubled Tibialis Anterior Allograft|
11529332|NCT01148771|Experimental|Ertapenem 1 gram intravenous (IV) 5 minute bolus|Participants received ertapenem 1 gram every 24 hours for 3 doses with each dose infused as a 5 minute IV bolus.
11529333|NCT01148771|Active Comparator|Ertapenem 1 gram IV 30 minute infusion|Participants received ertapenem 1 gram every 24 hours for 3 doses with each dose infused as a 30 minute infusion (i.e., the standard dose).
11529334|NCT01148758|Experimental|Single Arm|
11529335|NCT01148745|Other|ferumoxytol|FDA approved drug
11529336|NCT01148732||Patient needed intubation in emergency department|
11529337|NCT01148719|Active Comparator|Index group|Patients in the index group receive the diagnostic triage instrument. This includes echocardiographic, electrocardiographic and spirometric measurements and blood testing.
11529338|NCT01148719|No Intervention|Control|Participants receive care as usual.
11529339|NCT01148706|Experimental|ActiSight Needle Guidance System|
11529340|NCT01148693|Active Comparator|gentamicin|adding 10mg gentamicin to every 10 ml of contrast media
11529341|NCT01148693|Placebo Comparator|Placebo|Identical placebo
11529342|NCT01148680|Experimental|immediate registration on islet graft list|"group 1 'immediate registration on infusion waiting list' : patients who will be immediately registrated on islet cell infusion waiting list after randomization.
~Intervention : Procedure/surgery (islet graft)"
11529343|NCT01148680|Active Comparator|delayed registration on islet graft list|"group 2 'delayed registration on infusion waiting list' : patients who will be registrated 6 months later on islet cell infusion waiting list after randomization.
~Intervention : Procedure/surgery (islet graft)"
11529344|NCT01148667|Active Comparator|Infants drink formula added with LGG|Infants have been randomized (1:1) to get casein hydrolysate with or without LGG
11529345|NCT01148667|Placebo Comparator|Infants drink casein hydrolysate without LGG|Infants get extensively hydrolysed casein formula
11529472|NCT01147757|Experimental|remifentanil 0.3 mcg/kg/min|Group 0.3 (n = 15): remifentanil 0.3 mcg/kg/min
11529346|NCT01148654||1- Preterm Labor 22.0-33.6 weeks gestational age|Pregnant women between 22.0 and 33.6 weeks gestational age presenting to the Hospital of the University of Pennsylvania (HUP) complaining of Preterm labor (PTL), preterm premature rupture of membranes (PPROM), or cervical insufficiency (CI).
11529347|NCT01148654||2- Preterm birth 34-36.6 weeks gestational age|Pregnant women delivering at the University of Pennsylvania between 34.0 and 36.6 weeks gestational age
11529348|NCT01148641||LNS-regular|Lipid-based nutrient supplement, regular (peanut) flavor
11529349|NCT01148641||LNS-cinnamon|Lipid-based nutrient supplement, cinnamon flavor
11529350|NCT01148628|Experimental|RAD 001 in combination with CaelyxTM|"RAD001 will be given p.o. at increasing doses (no intra-patient)and CaelyxTM will be administered i.v. at a fixed dose.
~At each dose level 3 to 6 patients will be entered, according to toxicities observed; the first 3 patients can be treated simultaneously; subsequent patients can be treated after the first 3 have been observed for at least one cycle (4 weeks).
~The dose escalation process will be discontinued once the MTD has been achieved and the RD will be evaluated in a subsequent expansion part of the study."
11529351|NCT01148615|Experimental|Aflibercept/ docetaxel|"Patients with advanced cancer will receive different doses of aflibercept in combination with approved dose of docetaxel.
~Aflibercept 4 or 6mg/kg over 1 hour IV immediately followed by Docetaxel 75mg/m2 IV over 1 hour on Day 1, every 3 weeks"
11529352|NCT01148602|No Intervention|'Off Clock'|"Stopwatch timers will NOT be used for off clock weeks, so patients presenting with hyperacute stroke will be managed normally without the visual timer."
11529353|NCT01148602|Active Comparator|"'On Clock"|"LED stopwatch-clock timers will be posted for all patients presenting during ON clock weeks. All patients presenting with hyperacute stroke will be managed normally with the addition of a visual stopwatch timer."
11529354|NCT01148576|Other|control group|patients only with chronic hepatitis B
11529355|NCT01148576|Active Comparator|model group|patients with chronic hepatitis B and hepatic steatosis
11529356|NCT01148576|Experimental|Essentiale group|patients with chronic hepatitis B and hepatic steatosis
11529357|NCT01148576|Experimental|treatment group 2|patients with chronic hepatitis B and hepatic steatosis
11529358|NCT01148563|No Intervention|Standard Care|The Standard Care group will continue regular LSU HCSD disease management care for heart failure patients with no additional intervention.
11529359|NCT01148563|Active Comparator|Tele-health Monitoring Group|The tele-monitoring intervention group will have the continual standard care from their physician plus the tele-health monitoring. The tele-health monitor will collect the following data: weight, blood pressure, pulse oximetry, pulse rate, & patient responses to disease-specific questions regarding changes in state of health for 6 months.
11529360|NCT01148550||Group 1|Mitochondrial Hepatopathy Disease Group
11529361|NCT01148550||Group 2|Subjects with Suspected Mitochondrial Hepatopathy who do not meet the enrollment criteria for Group 1 Subjects with Suspected Mitochondrial Hepatopathy who do not meet the enrollment criteria for Group 1
11529362|NCT01148537|Experimental|BTDS|Buprenorphine transdermal patches 5, 10, 20, and 2 * 20 mcg/h.
11529363|NCT01148537|Placebo Comparator|Placebo TDS|Matching placebo transdermal patches 5, 10, 20 and 2 * 20.
11529364|NCT01148537|Active Comparator|Moxifloxacin|Moxifloxacin hydrochloride 400 mg tablets
11529365|NCT01148524|Other|rMenB06|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 6 months) and placebo (at 1 and 2 months) in V72P10 study had a blood draw.
11529366|NCT01148524|Other|rMenB0|Subjects who had received 1 dose of rMenB+OMV-NZ (at 0 month) and 3 doses of placebo (at 1, 2 and 6 months) in V72P10 study had a blood draw.
11529367|NCT01148524|Other|rMenB016|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 1 and 6 months) and 1 dose of placebo (at 2 months) in V72P10 study had a blood draw.
11529368|NCT01148524|Other|rMenB01|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 1 month) and placebo (at 2 and 6 months) in V72P10 study had a blood draw.
11529369|NCT01148524|Other|rMenB026|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 2 and 6 months) and 1 dose of placebo (at 1 month) in V72P10 study had a blood draw.
11529370|NCT01148524|Other|rMenB02|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 2 months) and placebo (at 1 and 6 months) in V72P10 study had a blood draw.
11529371|NCT01148524|Other|rMenB012|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 1 and 2 months) and 1 dose of placebo (at 6 months) in V72P10 study had a blood draw.
11529372|NCT01148524|Other|rMenB6|Subjects who had received 1 dose of rMenB+OMV-NZ (at 6 months) and 3 doses of placebo (at 0, 1 and 2 months) in V72P10 study had a blood draw.
11529373|NCT01148524|Other|Naive|An additional study group of naïve subjects that served as a baseline comparator for assessing antibody persistence in the vaccine groups and had blood draw for serological analyses at the time of enrollment.
11529374|NCT01148511|Experimental|Treat and Extend|Patients received ranibizumab 0.5 mg intravitreally (ivt) once a month for 3 months. If the disease was inactive 4 weeks later, the next visit was postponed 2 weeks to 6 weeks later. If the disease was inactive during subsequent visits, the next visit was postponed an additional 2 weeks to 8 weeks later, the maximum interval between visits. If the disease became active at any visit, the patient received ranibizumab 0.5 mg ivt and the follow-up schedule started over.
11529375|NCT01148511|Active Comparator|Treat and Observe|Patients received ranibizumab 0.5 mg intravitreally (ivt) once a month for 3 months. All subsequent visits occurred monthly. If the disease was active, the patient received ranibizumab 0.5 mg ivt. If the disease was inactive, no treatment was administered and the patient was instructed to return 1 month later.
11529376|NCT01148498|Experimental|Group 1|Older adults with mild Dementia Alzheimer's Type (DAT)
11529377|NCT01148498|Experimental|Group 2|Older adult controls with possible Alzheimer's Disease Pathology
11529378|NCT01148498|Experimental|Group 3|Older adult controls with no evidence of Alzheimer's Disease
11529379|NCT01148498|Experimental|Group 4|Younger subjects who are assumed to have no cognitive impairment
11529380|NCT01148472|Experimental|Escitalopram|
11529381|NCT01148472|Active Comparator|Duloxetine|
11529382|NCT01148459|Experimental|Group A|Infants enrolled to this group will receive 3 doses of the experimental vaccine.
11529383|NCT01148459|Active Comparator|Group B|Infants enrolled to this group will receive 3 doses of the rabies comparator vaccine.
11529644|NCT01146626|Experimental|Peg+ Ribavirine|Peg+ Ribavirine
11529384|NCT01148446|Experimental|R-CHOP|R-CHOP (every 21 days) for six courses Cyclophosphamide: 750 mg/m2, IV, day 1 Doxorubicin: 50 mg/m2, IV, day 1 Vincristine: 1.4 (max 2) mg/m2, IV, day 1 Prednisone: 75 mg/m2, IV, days 1-5 Rituximab: 375 mg/m2, IV, day 1 G-CSF: 300 µg tota, SC; days 7-11
11529385|NCT01148446|Experimental|R-mini-CEOP|R-miniCEOP (every 21 days)for six courses Cyclophosphamide: 50 mg/m2, IV, day 1 Epirubicin: 50 mg/m2, IV, day 1 Vinblastine: 5 mg/m2, IV, day 1 Prednisone: 60 mg/m2, IV/PO, days 1-5 Rituximab: 375 mg/m2, IV, day 1 G-CSF: 300 µg tota, SC; days 7-11
11529386|NCT01148433||TESTIM® - drug given by prescription|Male patients with Hypogonadism
11529387|NCT01148420|Experimental|DMPA & MPA|150 mg intramuscularly received DMPA and two 10 mg tablets of MPA every 8 hours for 3 days
11529388|NCT01148394|No Intervention|Traditional|Involves traditional management of patients with preoperative mechanical bowel preparation, no preoperative education, nasogastric tube, delayed feeding and mobilisation, use of drains
11529389|NCT01148394|Active Comparator|Multimodal rehabilitation|Involves preoperative patient education, no preoperative mechanical bowel preparation, no nasogastric tube, early oral feeding and mobilisation, physiotherapy
11529390|NCT01148381||controls|healthy non-smoking, participants with no substance use disorders
11529391|NCT01148381||psychiatric disorders|individuals with other psychiatric disorders
11529392|NCT01148381||smokers|healthy individuals with nicotine use disorder
11529393|NCT01148381||substance use disorders|healthy individuals with other substance use disorders
11529394|NCT01148381||treatment seeking individuals|treatment seeking individuals with substance use disorders
11529395|NCT01148368|Experimental|renal impairment patients|renal impairment patients who eGFR is lower than 30 ml/min/1.73m^2 without hemodialysis
11529396|NCT01148368|Active Comparator|healthy volunteers|healthy volunteers group
11529397|NCT01148329||Single arm observational study|To evaluate real world clinical outcomes data for the PROMUS™ Element™ Coronary Stent System in unselected patients in routine clinical practice
11529398|NCT01148316|Active Comparator|Fluoxetine|drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
11529399|NCT01148316|Active Comparator|Group cognitive-behavioral therapy|weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
11529400|NCT01148303|Experimental|Etoricoxib First|This arm will receive etoricoxib for six days, followed by placebo for eight days.
11529401|NCT01148303|Experimental|Etoricoxib Second|This arm will get placebo for eight days before beginning their fast, followed by etoricoxib for six days.
11529402|NCT01148290|Active Comparator|Tension free vaginal tape|
11529403|NCT01148290|Experimental|Bulking agent injection|
11529404|NCT01148277|Active Comparator|Propofol and Remifentanyl|Propofol, colonoscopies, liver diseases, cirrhosis
11529405|NCT01148277|Active Comparator|midazolam and fentanyl|midazolam and fentanyl, colonoscopies, liver diseases
11529406|NCT01148277|Experimental|control midazolam anf fentanyl|midazolam anf fentanyl
11529407|NCT01148264|Experimental|olanzapine|
11529408|NCT01148264|Active Comparator|metoclopramide|
11529409|NCT01148238||Diabetes type 1 older than 10 years|Blood samples will be taken from 10 patients with diabetes type 1 older than 10 years and 10 healthy age-and sexmatched controls.
11529410|NCT01148238||Newly diagnosed type 1 diabetes|Blood samples will be taken from 10 patients with newly diagnosed type 1 diabetes and 10 healthy age-and sexmatched controls.
11529411|NCT01148238||LADA|Blood samples will be taken from 10 patients with LADA and 10 healthy age-and sexmatched controls.
11529412|NCT01148225|Other|Adalimumab|Participants received open label (OL) adalimumab 40 mg by subcutaneous (SC) injection every other week (eow) until the final visit.
11529413|NCT01148199|Active Comparator|Multiple plastic stents|Multiple plastic stents placement after sphincterotomy and stricutre dilation. ERCP repeated every 3 - 4 months during 1-year
11529414|NCT01148199|Experimental|Self-expandable metalic stent|Self-expandable metalic stent after sphincterotomy. Stent removal scheduled for 6 months
11529415|NCT01148186|Experimental|Educational intervention|Administration of an educational intervention to inform patients of the risks and safe alternatives to their current potentially inappropriate medication. The textual content of this knowledge transfer tool will be divided into three parts: a) presentation of the evidence-based risks associated with the targeted potentially inappropriate medication (e.g. benzodiazepines); b) presentation of evidence-based equally or more effective therapeutic substitutes for the medical condition (e.g. insomnia and anxiety); and c) presentation of evidence based tapering recommendations where applicable.
11529416|NCT01148186|No Intervention|Wait-list group|
11529417|NCT01148173|Experimental|Systemic and intrathecal chemotherapy|
11529418|NCT01148160||1|Patients with hematologic malignancies who were given voriconazole to treat invasive (pulmonary) aspergillosis at Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
11529419|NCT01148147|Placebo Comparator|Placebo|Intracoronary Placebo administration
11529420|NCT01148147|Active Comparator|Adenosine|Intracoronary adenosine administration
11529421|NCT01148134||Bcr-Abl positive ALL|
11529422|NCT01148134||Bcr-Abl negative ALL|
11529423|NCT01148108|Experimental|Mantle Cell Lymphoma|Patients with relapsed or refractory mantle cell lymphoma
11529424|NCT01148108|Experimental|Diffuse Large B Cell Lymphoma|Patients with relapsed or refractory diffuse large B cell lymphoma
11529425|NCT01148108|Experimental|Multiple Myeloma|Patients with relapsed or refractory multiple myeloma
11529426|NCT01148095|Experimental|1|AZD2516 (dose escalating)
11529427|NCT01148095|Placebo Comparator|2|Placebo
11529428|NCT01148069|Experimental|Surgery combined with IMRT-IGRT|
11529429|NCT01148056|Experimental|Short course IMRT|Patients will receive short course IMRT (Intensity Modulated Radiation Therapy) prior to surgery. Dose will be 5 Gy x 5, followed by surgery the week after
11529430|NCT01148043|Placebo Comparator|Placebo|
11529431|NCT01148043|Experimental|Hydroxychloroquine|
11529432|NCT01148030||Single|3M Skin and Nasal Antiseptic
11529473|NCT01147757|Experimental|remifentanil 0.6 mcg/kg/min|Group 0.6 (n = 15): remifentanil 0.6 mcg/kg/min
11529474|NCT01147757|Experimental|remifentanil 0.9 mcg/kg/min|Group 0.9 (n = 15): remifentanil 0.9 mcg/kg/min
11529433|NCT01148017|Experimental|ACWY - 4|Subjects who had previously received 4 doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in the parent study during their first year of life are administered one booster dose of the same vaccine at 60 months of age.
11529434|NCT01148017|Experimental|ACWY - 2|Subjects who had previously received 1 or 2 doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in the parent study during their second year of life, are administered one booster dose of the same vaccine at 60 months of age.
11529435|NCT01148017|Other|Naïve - 40|Control subjects, age-matched with the intervention groups subjects (40 months of age), to receive 1 optional dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
11529436|NCT01148017|Active Comparator|Naïve - 60|Control subjects, age-matched with the intervention groups subjects (60 months of age), are administered one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
11529437|NCT01147978|Experimental|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
11529438|NCT01147978|No Intervention|Usual Procedure|Usual discharge procedure from the ICU
11529439|NCT01147965|Experimental|Ad5 CEA Vaccine|Single arm dose escalation study
11529440|NCT01147952|Experimental|12 week exercise training|
11529441|NCT01147952|No Intervention|Conventional Care|
11529442|NCT01147939|Experimental|Elacytarabine|
11529443|NCT01147939|Active Comparator|Investigator's Choice|
11529444|NCT01147926|Placebo Comparator|Placebo|Placebo
11529445|NCT01147926|Active Comparator|Prucalopride|1 milligram (mg) or 2 mg
11529446|NCT01147913|Experimental|Positive Interpretation Training|Four sessions of positive information-processing training for interpretation of ambiguous scenarios relevant to themes of depression.
11529447|NCT01147913|Sham Comparator|Attention Control Training|"Four sessions of interpretation training for filler or neutral scenarios, unrelated to themes associated with depression."
11529448|NCT01147900|Experimental|Boostrix-REF Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, reference formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
11529449|NCT01147900|Experimental|Boostrix-US Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, United States(US)-marketed formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, US-marketed formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
11529450|NCT01147900|Experimental|Boostrix-INV Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, investigational formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
11529451|NCT01147887|Experimental|001|Drug combination/ 26489112 On Day 1 and on Day 19 a single oral dose of a drug combination consisting of midazolam (2 mg/mL liquid) tolbutamide (a 500 mg tablet) and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21 a single oral dose of two 26489112 tablets will be taken.
11529452|NCT01147874|No Intervention|psoriatic arthritis (PsA) questionnaire|
11529453|NCT01147861|Placebo Comparator|Placebo|Subjects will receive 2 placebo tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
11529454|NCT01147861|Other|5mg BID|Subjects will receive 1 x 5mg tablet and 1 placebo tablet in the morning, and 1 x 5mg tablet and 1 placebo tablet in the evening on Day 1 and Day 2.
11529455|NCT01147861|Other|10mg QD|Subjects will receive 2 x 5mg tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
11529456|NCT01147861|Other|25mg BID|Subjects will receive 1 x 25mg tablet and 1 placebo tablet in the morning, and 1 x 25mg tablet and 1 placebo tablet in the evening on Day 1 and Day 2.
11529457|NCT01147861|Other|50mg QD|Subjects will receive 2 x 25mg tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
11529458|NCT01147848|Experimental|Fluticasone furoate/Vilanterol (GW642444)|Fluticasone furoate/vilanterol inhalation powder once daily + placebo inhalation powder twice daily for 24 weeks
11529459|NCT01147848|Active Comparator|Fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol inhalation powder twice daily + placebo inhalation powder once daily for 24 weeks
11529460|NCT01147835|Placebo Comparator|Placebo Lollipop|The placebo group will ingest the same herbal lollipop formula without the active ingredient.
11529461|NCT01147835|Experimental|Chinese Licorice Root|The experimental group will ingest the herbal lollipop formula with the active ingredient.
11529462|NCT01147822|Experimental|Pazopanib|800 mg administered once daily orally continuous dosing
11529463|NCT01147822|Active Comparator|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment
11529464|NCT01147809|Active Comparator|Eltrombopag|Drug: eltrombopag olamine thrombopoietin receptor agonist
11529465|NCT01147809|Placebo Comparator|Placebo|Other: Placebo Placebo tablets with no active pharmaceutical ingredient
11529466|NCT01147796|Active Comparator|Thrombus|patients with positive TEE (thrombus)
11529467|NCT01147796|Placebo Comparator|No thrombus|patients with negative TEE (no thrombus)
11529468|NCT01147783||SimBaby|
11529469|NCT01147783||Infants (1-12 mo)|
11529470|NCT01147770|Experimental|stop progesterone|
11529520|NCT01147484|Experimental|Foretinib|
11529475|NCT01147744|Experimental|GSK2190915 10mg and placebo|GSK2190915 10mg (1 x 10mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
11529476|NCT01147744|Experimental|GSK2190915 30mg and placebo|GSK2190915 30mg (1 x 30mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
11529477|NCT01147744|Experimental|GSK2190915 100mg QD and placebo|GSK2190915 100mg (1 x 100mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
11529478|NCT01147744|Experimental|GSK2190915 300mg QD and placebo|GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
11529479|NCT01147744|Active Comparator|Fluticasone propionate 100mcg and placebo|Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS and two placebo tablets in the morning and one placebo capsule in the evening
11529480|NCT01147744|Active Comparator|Montelukast 10mg and placebo|Montelukast 10mg (1 x 10mg capsule) once daily in the evening and two placebo tablets in the morning and inhaled placebo twice daily via ACCUHALER/DISKUS
11529481|NCT01147744|Placebo Comparator|Placebo Comparator|Two GSK2190915 placebo tablets once daily in the morning, montelukast placebo capsule once daily in the evening and fluticasone propionate placebo twice daily via ACCUHALER/DISKUS
11529482|NCT01147731|Experimental|warfarin plus albiglutide|A single dose of 25mg warfarin on day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 25mg warfarin on day 45.
11529483|NCT01147718|Experimental|digoxin plus albiglutide|A single dose of 0.5mg digoxin administered on Day 1 followed by 5 weekly subcutaneous injections of albiglutide, followed by a further single dose of 0.5mg digoxin on Day 38.
11529484|NCT01147705|Active Comparator|Allopurinol|Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks.
11529485|NCT01147705|Placebo Comparator|Placebo|Same number of tablets and appearance as active drug.
11529486|NCT01147692|Experimental|simvastatin plus albiglutide|A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
11529487|NCT01147679||bvFTD|This group will include 33 patients who have been diagnosed with behavioral variant frontotemporal dementia by Dr. Mario Mendez. Patients diagnosed elsewhere must have a secondary evaluation at the UCLA FTD Clinic to confirm their diagnosis before study enrollment.
11529488|NCT01147679||Alzheimer's disease|This group will include 33 patients who have been diagnosed with clinically probable Alzheimer's disease by Dr. Mario Mendez. Patients diagnosed elsewhere must have a secondary evaluation at the UCLA FTD Clinic to confirm their diagnosis before study enrollment.
11529489|NCT01147679||Controls|33 health individuals without clinically significant cognitive impairments will be enrolled in this study.
11529490|NCT01147666|Experimental|Population A; Experimental Drug|Patients responding normally to current treatment
11529491|NCT01147666|Active Comparator|Population A; Active Comparator|Patients responding normally to current treatment
11529492|NCT01147666|Experimental|Population B; Experimental Drug|Patients not responding well to current treatment
11529493|NCT01147666|Active Comparator|Population B; Active Comparator|Patients not responding well to current treatment
11529494|NCT01147666|Placebo Comparator|Population B; Placebo Comparator|Patients not responding well to current treatment
11529495|NCT01147653|Active Comparator|Autologous UCB Reinfusion First,Then Placebo|Subjects receive their autologous umbilical cord blood cells at Baseline, than placebo at Year 1.
11529496|NCT01147653|Placebo Comparator|Placebo First, Then Autologous UCB Reinfusion|Subjects receive placebo at Baseline, then autologous umbilical cord blood cell reinfusion at Year 1.
11529497|NCT01147640|Experimental|CXA 101/tazobactam and metronidazole|
11529498|NCT01147640|Active Comparator|meropenem with matching saline placebo|
11529499|NCT01147627|Active Comparator|Exenatide|
11529500|NCT01147627|Active Comparator|Premixed insulin analog|
11529501|NCT01147627|Active Comparator|pioglitazone|
11529502|NCT01147614|Active Comparator|specialty mental health care referral|
11529503|NCT01147614|Experimental|Brief Cognitive Behavioral Therapy|
11529504|NCT01147601|Active Comparator|Topical 0.5% Timolol|Half of the enrolled subjects (intervention group) will receive topical 0.5% Timolol.
11529505|NCT01147601|Placebo Comparator|Placebo|Aqueous placebo, 2-3 drops to cover the hemangioma, twice daily
11529506|NCT01147588|Experimental|1|lansoprazole 60 mg + clopidogrel 300 mg/ 75 mg
11529507|NCT01147588|Experimental|2|omeprazole 80 mg + clopidogrel 300/75 mg
11529508|NCT01147588|Experimental|3|esomeprazole 40 mg + clopidogrel 300/75 mg
11529509|NCT01147588|Experimental|4|clopidogrel 300/75 mg alone
11529510|NCT01147575|Active Comparator|Creatine monohydrate|The patients received orally 200 mg CMH per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH respectively the groups were switched for another 6 months (period 2).
11529511|NCT01147575|Placebo Comparator|Placebo|The patients received orally 200 mg Placebo per kg body weight divided in three doses per day in identically prepared capsules. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without Placebo respectively the groups were switched for another 6 months (period 2).
11529512|NCT01147562|Other|Lung Cancer Patients|Patients with a suspected or confirmed diagnosis of lung cancer, whether or not scheduled for lesion biopsy, thoracentesis or surgical resection of their tumor
11529513|NCT01147549|Experimental|1|[C14]AZD9668
11529514|NCT01147536|Experimental|HSPPC-96 treatment|
11529515|NCT01147523|Experimental|Vitamin E|Vitamin E, capsules 400 mg daily, for 52 weeks
11529516|NCT01147510|Active Comparator|Monotherapy of medium dose ICS|
11529517|NCT01147510|Experimental|Combination of low ICS and montelukast|
11529518|NCT01147497|Experimental|misoprostol|Misoprostol 400mcg taken buccally 2 hours prior to IUD insertion visit
11529519|NCT01147497|Placebo Comparator|placebo|Pill that is identical to the study drug in appearance, taste, and smell, taken buccally 2 hours prior to IUD insertion visit
11529521|NCT01147471|Active Comparator|Operative rib fixation|"Randomized subjects will be operated upon within 72 hours of ventilation (early fixation) to stabilize the stove-in segment. Where all fractured ribs are accessible and the number of fractured ribs is few, stabilization of all fractured ribs would be the goal. However, where fractured ribs are in areas difficult to access, enough ribs, based on surgeon judgment, would be fixed to stabilize the stove-in segment. Post-operatively, the patients would receive the standard of care, similar to what is outlined for the non-operative arm.
~Operative fixation will be accomplished utilizing the MatrixRIB Fixation System (Synthes CMF, West Chester, PA, USA) according to the device's instructions for use. Sites will obtain the product based on their medical center's normal purchasing practices."
11529522|NCT01147471|No Intervention|Non-operative arm|"Randomized subjects to receive standard of care therapy for blunt thoracic trauma (as per each participating institution's own protocols):
~a. Ventilatory support b.Timing of extubation (removal from ventilator): c.Analgesia: institution should provide adequate analgesia utilizing available resources including oral, parenteral, epidural, local nerve blocks etc., d.Chest physical therapy, e.Postural drainage, f.Incentive spirometry - after extubation."
11529523|NCT01147458|Experimental|PF-04191834 followed by placebo|PF-04191834 600 mg BID dose followed by matched placebo plus naproxen placebo.
11529524|NCT01147458|Experimental|Placebo followed by PF-04191834|Placebo followed by 600 mg BID dose of PF-04191834 plus naproxen placebo.
11529525|NCT01147458|Experimental|PF-04191834+Naproxen followed by Naproxen|PF-04191834 600 mg BID + Naproxen 500 mg BID followed by Naproxen 500 mg BID plus PF-04191834 placebo
11529526|NCT01147458|Experimental|Naproxen followed by PF-04191834+Naproxen|Naproxen 500 mg BID followed by PF-04191834 600 mg BID + Naproxen 500 mg BID
11529527|NCT01147445|Experimental|Cohort 1: 5 mcg dmLT|6 subjects to receive 5 micrograms (mcg) of dmLT vaccine.
11529528|NCT01147445|Experimental|Cohort 4: 100 mcg dmLT|6 subjects to receive 100 mcg of dmLT vaccine.
11529529|NCT01147445|Experimental|Cohort 2: 25 mcg dmLT|6 subjects to receive 25 mcg of dmLT vaccine.
11529530|NCT01147445|Experimental|Cohort 3: 50 mcg dmLT|6 subjects to receive 50 mcg of dmLT vaccine.
11529531|NCT01147445|Experimental|Cohort 5: 50 mcg or 100 mcg dmLT|12 subjects randomized, double-blinded, to receive either 50 mcg or 100 mcg of dmLT vaccine.
11529532|NCT01147432|Experimental|PF-04427429|
11529533|NCT01147432|Placebo Comparator|Placebo|
11529534|NCT01147432|Active Comparator|EMLA|
11529535|NCT01147419|Experimental|bypass|Patients presenting with long occlusion of the superficial femoral artery enrolled in bypass arm will undergo suprageniculate femoropopliteal bypass surgery to bypass the occluded superficial femoral artery. And the graft will be artificial blood vessel.
11529536|NCT01147419|Experimental|stent|
11529537|NCT01147406|Experimental|Active|N6022
11529538|NCT01147406|Placebo Comparator|Placebo|Placebo
11529539|NCT01147393|Experimental|All subjects|two weekly infusions of 90Y-epratuzumab tetraxetan in combination with four weekly infusions of 200 mg/m2 veltuzumab.
11529540|NCT01147380|Experimental|Small dose|From the donor liver perfusate, mononuclear cell will be extracted and cultured. Then, the cells will be stimulated with IL-2. The number of inoculation cells( mainly NK cells) is between 10 and 100 million cells. The cells will be given to the liver transplant recipient who had the same donor for liver and liver perfusate. Patient of this arm receive small dose of liver NK cell inoculation as described.
11529541|NCT01147380|Experimental|Large dose|From the donor liver perfusate, mononuclear cell will be extracted and cultured. Then, the cells will be stimulated with IL-2. The number of inoculation cells(mainly NK cells) is between 100 and 1000 million cells. The cells will be given to the liver transplant recipient who had the same donor for liver and liver perfusate.Patient of this arm receive large dose of liver NK cell inoculation as described.
11529542|NCT01147367|No Intervention|Control|no physical activity intervention
11529543|NCT01147367|Experimental|Exercise intervention|3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
11529544|NCT01147354|Experimental|experimental group|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
11529545|NCT01147354|Placebo Comparator|control group|The patients in this arm took one placebo capsule daily for 12 weeks.
11529546|NCT01147341|Placebo Comparator|placebo|Placebo (0.9% sodium chloride) given as 2 subcutaneous (sc) injections at weeks 0, 2, and 4, followed y 1 sc injection given an weeks 6, 8, and 10. At week 12 subjects entered the open label phase. Subjects received 400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 12,14 and 16, followed by 1 sc injection at weeks 18, 20, and 22.
11529547|NCT01147341|Active Comparator|active treatment with Cimzia|400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 0, 2, and 4, followed by 1 sc injection at weeks 6, 8, and 10. At week 12 subjects entered the open label phase. Subjects received 400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 12,14 and 16, followed by 1 sc injection at weeks 18, 20, and 22.
11529548|NCT01147328||1|Patients who did not have their data accessed in the VHR by a provider within 6 months after they consented will be part of the control group
11529549|NCT01147328||2|Patients who had their data accessed in the VHR by a provider within 6 months after they consented will be part of the intervention group
11529550|NCT01147315|Experimental|Hybrid bone substitution|Hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow
11529551|NCT01147302|Experimental|C1 Esterase Inhibitor (Human)|Subjects were to receive C1 esterase inhibitor intravenously at a rate of approximately 1 mL per minute as tolerated. Subjects were to receive a total of 7 doses over a 2-week period: an initial IV infusion of 5000 U (not to exceed 100 U/kg) on Day 1, followed by 2500 U (not to exceed 50 U/kg) IV on Days 3, 5, 7, 9, 11, and 13
11529552|NCT01147302|Placebo Comparator|Normal Saline|placebo infused as above
11529553|NCT01147289|Experimental|dexalgen|Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose for 3 days, at least
11529554|NCT01147289|Active Comparator|Meloxicam|Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose for at least 3 days.
11529555|NCT01147276|Experimental|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
11529556|NCT01147263||Patients diagnosed with Fibromyalgia|
11529557|NCT01147250|Placebo Comparator|Placebo|Placebo matched to lixisenatide once daily (QD) up to end of treatment.
11529558|NCT01147250|Experimental|Lixisenatide|Lixisenatide 10 mcg QD for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to end of treatment.
11529559|NCT01147237|Experimental|Single arm study|
11529560|NCT01147224||ATEM|A prospective one-arm non-interventional study with asthma patients treated with Alvesco.
11529561|NCT01147211|Experimental|MK2206 in combination with Gefitinib|MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
11529562|NCT01147198|Active Comparator|Ready to Use Supplementary Food|Ready to Use Supplementary Food treatment
11529563|NCT01147198|Active Comparator|Premix|Premix Corn Soy Blend-oil treatment
11529564|NCT01147185|Other|Intensive training|Locomotor training using a robotic device of at least 50 minutes
11529565|NCT01147185|Active Comparator|Standard training|Locomotor training using a robotic device of maximally 25 minutes
11529566|NCT01147172|Experimental|Elevess|Gel implant (dermal filler) composed of hyaluronan produced by Streptococcus equi (bacterial fermentation) that is cross-linked and suspended in phosphate buffered saline with 0.3% lidocaine HCl and 0.1% sodium metabisulfite
11529567|NCT01147159|Other|Skin Prick Test|
11529568|NCT01147133|Experimental|Original|Treatment phase with the original formulation of clopidogrel
11529569|NCT01147133|Active Comparator|Generic|Treatment phase with the generic clopidogrel
11529570|NCT01147120|Active Comparator|Progressive Muscle Relaxation|
11529571|NCT01147120|Active Comparator|Clinical Massage Therapy|
11529572|NCT01147107|Experimental|Raltegravir based therapy|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
11529573|NCT01147107|Active Comparator|Efavirenz based therapy|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
11529574|NCT01147081|Experimental|Arm 1|
11529575|NCT01147068|Experimental|PanBlok 135µg No Adjuvant|135µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
11529576|NCT01147068|Experimental|PanBlok 45µg No Adjuvant|45µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
11529577|NCT01147068|Experimental|PanBlok 45µg and GLA 1.0µg, SE 2%|45µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
11529578|NCT01147068|Experimental|PanBlok 15µg and GLA 1.0µg, SE 2%|15µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
11529579|NCT01147068|Experimental|PanBlok 7.5µg and GLA 1.0µg, SE 2%|7.5µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
11529580|NCT01147068|Experimental|PanBlok 3.8µg and GLA 1.0µg, SE 2%|3.8µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
11529581|NCT01147068|Placebo Comparator|Placebo|0.9% Sodium Chloride; Two 0.5 mL IM injections 21 days apart
11529582|NCT01147055|Experimental|1|There should be at least 14-day washout period between treatment A and B.
11529583|NCT01147042|Active Comparator|gp91 CGD with relatively high baseline superoxide|"Patients with X-linked Chronic Granulomatous Disease (CGD) with a missense gp91phox mutation and relatively high baseline superoxide production.
~IFN-gamma was the administered intervention."
11529584|NCT01147042|Active Comparator|Autosomal Recessive CGD with p47|Patients with Autosomal Recessive Chronic Granulomatous Disease (CGD) with p47 phox mutation. IFN-gamma was the administered intervention.
11529585|NCT01147016|Experimental|HER2Bi-armed activated T cells + Neoadjuvant Chemotherapy|"HER2Bi-armed activated T cells - Total of 4 of the T cell infusions IV over a period of 1 month
~Cyclophosphamide, doxorubicin hydrochloride, paclitaxel -As prescribed by physician, standard of care."
11529586|NCT01147003|Experimental|BGG492 low dose|
11529587|NCT01147003|Placebo Comparator|Placebo|
11529588|NCT01147003|Experimental|BGG492 high dose|
11529589|NCT01146990||Infants Born to Mothers in the 17P-ES-003 Study|Infants Born to Mothers Who Participated in the 17P-ES-003 Study and whose mothers consented for them to be followed for this study.
11529590|NCT01146977|Experimental|Autologous HCT|"5.1.3. After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.
~5.1.3.1. If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue."
11529591|NCT01146977|Active Comparator|HDAC chemotherapy|If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.
11529592|NCT01146964|Experimental|Phacoemulsification, Safety, Efficacy|
11529593|NCT01146964|Experimental|MSSICS, Safety, Efficacy|
11529594|NCT01146951|Experimental|Rufinamide (E2080)|
11529595|NCT01146951|Placebo Comparator|Placebo|
11529596|NCT01146938|Experimental|hepatic impairment patients|Hepatic impairment patients group Child-Pugh score A or Child-Pugh score B (not Child-Pugh score C)
11529597|NCT01146938|Active Comparator|Healthy volunteers|healthy volunteers group
11529598|NCT01146925|Experimental|CRMD-001-Deferiprone|
11529599|NCT01146925|Placebo Comparator|Placebo|
11529600|NCT01146912|Experimental|Text message vaccine reminders|Receipt of text message vaccine reminders
11529601|NCT01146912|Active Comparator|automated phone call from clinic|Receipt of automated phone call from clinic
11529602|NCT01146899|Experimental|Provider Alert|Provider receives alert for patient visit
11529603|NCT01146899|No Intervention|No Alert|No alert provided
11529604|NCT01146886|Experimental|BI 135585|1 single dose per subject as oral solution in Part 1, or 3 single doses per subject as oral solution and 2 different tablet formulations in Part 2
11529605|NCT01146886|Placebo Comparator|Placebo to BI 135585|1 single dose per subject as oral solution in Part 1
11529640|NCT01146665|Sham Comparator|Computer-based sham|Standard medical care followed by a computer-based sham.
11529641|NCT01146652|Experimental|Extension study|Sarilumab (SAR153191), Disease Modifying Anti-Rheumatic Drug (DMARD) therapy as required in the initial protocol.
11529606|NCT01146873|Active Comparator|Group 1: Lopinavir/ritonavir (LPV/r)|Participants are assigned to remain on their current LPV/r-based antiretroviral regimen. Ritonavir-boosted lopinavir syrup was given twice per day at 230 mg/m^2 per dose. Children able to swallow tablets were given 1 tablet twice per day (200 mg lopinavir/50 mg ritonavir) if body surface area was less than 0.9m^2 or 2 tablets twice per day if body surface area was 0.9m^2 or higher.
11529607|NCT01146873|Experimental|Group 2: Efavirenz (EFV)|Participants are assigned to switch to an EFV-based antiretroviral regimen. Efavirenz was prescribed once daily in the evening at 200 mg for weights of 10 kg to 13.9 kg (22-30 lb) and 300mg for weights of 14 kg to 24.9 kg (31-55 lb). Efavirenz was available in 50-mg and 200-mg capsules. If children were unable to swallow capsules, caregivers were shown how to open the capsules and dissolve the contents in water.
11529608|NCT01146873|Active Comparator|Group D: Stavudine (D4T)|Children are assigned to remain on their current antiretroviral regimen, which includes D4T. D4T was given at 1 mg/kg twice daily
11529609|NCT01146873|Experimental|Group A: Abacavir (ABC)|Children stop taking D4T and switch to ABC. ABC was given at 8 mg/kg twice daily.
11529610|NCT01146860|Experimental|BNO 1016|sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
11529611|NCT01146860|Placebo Comparator|Placebo|sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration: 15 days
11529612|NCT01146847|Experimental|1|Space TGC system with incorporated eMPC advised insulin titration to establish tight glycaemic control
11529613|NCT01146834|Experimental|Arm A: VELCADE, CYCLOPHOSPHAMIDE, & G-CSF|VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11 in combination with high-dose cyclophosphamide at 2.0 g/m2 on day 4. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.
11529614|NCT01146834|Experimental|Arm B: VELCADE & G-CSF|VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Day 12 start pheresis collection
11529615|NCT01146834|Experimental|Arm C: CYCLOPHOSPHAMIDE & G-CSF|High-dose cyclophosphamide at 2.0 g/m2 on day 1. G-CSF is given for ten (+/- two) consecutive days starting on day 2 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.
11529616|NCT01146834|Experimental|Arm D: PLERIXAFOR & G-CSF|G-CSF is given for ten (+/- two) consecutive days starting on day 1 at a dose of 10 micrograms/kg/day. Plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5. Both G-CSF and plerixafor are continued daily until collection is complete. Pheresis will commence for everyone on Day 5 regardless of ANC status.
11529617|NCT01146834|Experimental|Arm E: PLERIXAFOR, VELCADE, & G-CSF|"Bortezomib at 1.3 mg/m2 IVP on days 1, 4, 8 and 11. G-CSF is given for ten (+/- wo) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day.
~Plerixafor is given on day 12, approximately 11 hours prior to stem cell collection attempt and is continued daily until collection is complete. Pheresis will commence for everyone on Day 13 regardless of ANC status."
11529618|NCT01146821|No Intervention|Standard care|Standard care
11529619|NCT01146821|Active Comparator|standard care + 0.20gm/kg fish oil|standard care + 0.20gm/kg fish oil
11529620|NCT01146821|Active Comparator|standard care + 0.50 gm/kg fish oil|standard care + 0.50 gm/kg fish oil
11529621|NCT01146808|Experimental|ADV plus hepatitis B vaccination|Adefovir dipivoxil and hepatitis B vaccination: All subjects will receive adefovir 10mg po daily, or adjusted for renal function and an option for Hepatitis B vaccination, double dose.
11529622|NCT01146795|Experimental|Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab|Three 21 day cycles of carboplatin, paclitaxel, and bevacizumab
11529623|NCT01146782|Experimental|Treatment|Treatment with the Attune Sleep Apnea System
11529624|NCT01146769|Experimental|Pelvic floor exercise|
11529625|NCT01146769|No Intervention|Control|
11529626|NCT01146756|Experimental|AZD6244 & Thoracic Radiotherapy|AZD6244 in combination with thoracic radiotherapy (RT)- the aim is to determine the recommended phase II dose (RP2D).
11529627|NCT01146743|Active Comparator|EUS-guided|EUS-guided gallbladder drainage in acute cholecystitis with high risk patients
11529628|NCT01146743|Active Comparator|percutaneous transhepatic|percutaneous transhepatic gallbladder drainage in acute cholecystitis with high risk patients
11529629|NCT01146730|Experimental|Workcoping and IPS|CBT based counseling and supported employment
11529630|NCT01146730|Active Comparator|Ordinary care by GP or NAV|Ordinary care by GP or The Norwegian Labour and Welfare Administration (NAV)
11529631|NCT01146717|Experimental|Exercise|
11529632|NCT01146717|Placebo Comparator|Control group|
11529633|NCT01146704|Active Comparator|Standard Diet|Standard protein diet group as control based on 0.5 gram protein per pound of lean body mass with same calories: 15% protein and 55% carbohydrate.
11529634|NCT01146704|Active Comparator|High Protein Diet|High protein diet group based on 1 gram of protein per pound of lean body mass: 30% protein and 40% carbohydrate.
11529635|NCT01146691||Standard staffing model|All patients in participating ICUs during the blocks of time when a single intensivist staffs a participating ICU for a 7 day period. The intensivist will be present during daytime hours, and takes call from home afterwards.
11529636|NCT01146691||24-7 shiftwork staffing model|All patients in participating ICUs during the blocks of time when the 24-7 in-hospital intensivist coverage model is in place. This model is enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am. Call rooms will be provided to allow the night shift intensivist to sleep, if the workload permits.
11529637|NCT01146678|Experimental|Lantus(insulin glargine)/lixisenatide on-site mix|Single dose injection of an on site mix of Lantus U100 and lixisenatide (800µg/mL in Lantus U100) at one peri-umbilical site under fasting conditions
11529638|NCT01146678|Active Comparator|lixisenatide + Lantus (insulin glargine)|Single dose, separate injection simultaneous injections of Lantus U100 and lixisenatide (100µg/mL) at opposite peri-umbilical sites within 1 minute under fasting conditions
11529639|NCT01146665|Experimental|Computer-based PAF|Standard medical care followed by computer-based personalized assessment feedback (PAF).
11529646|NCT01146613|Placebo Comparator|Sugar Pill|
11529647|NCT01146600|Experimental|Random Group A|Subjects will be randomized to group A or group B. The order of presentation of placebo and clarithromycin will be opposite in these two groups, but investigators and subjects will remain blinded to group allocation and order of treatment presentation within the groups.
11529648|NCT01146600|Experimental|Random Group B|Subjects will be randomized to group A or group B. The order of presentation of placebo and clarithromycin will be opposite in these two groups, but investigators and subjects will remain blinded to group allocation and order of treatment presentation within the groups.
11529649|NCT01146587|Experimental|GangTrainer GT1|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo robotic treatment with the Gangtrainer GT1 for 30 minutes of gross therapy time every workday for a 8 weeks period
11529650|NCT01146587|Experimental|Lokomat|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo robotic treatment with the Lokomat for 30 minutes of gross therapy time every workday for a 8 weeks period
11529651|NCT01146587|Active Comparator|Conventional Physiotherapy|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo a conventional physiokinetherapeutic treatment session for 30 minutes of gross therapy time every workday for a 8 weeks period
11529652|NCT01146574|Experimental|0.1mg/kg Sotatercept|Approximately 8 subjects will be randomized to receive either a single 0.1 mg/kg subcutaneous dose of sotatercept or matching placebo in a 3:1 ratio
11529653|NCT01146574|Experimental|0.3mg/kg Sotatercept|Dose Group 1: 0.3 mg/kg sotatercept subcutaneous every 28 days
11529654|NCT01146574|Experimental|0.5mg/kg Sotatercept|Dose Group 2: 0.5 mg/kg sotatercept subcutaneous every 28 days
11529655|NCT01146574|Experimental|0.7mg/kg Sotatercept|Dose Group 3: 0.7 mg/kg sotatercept subcutaneous every 28 days
11529656|NCT01146574|Placebo Comparator|Placebo|The Placebo to Sotatercept ratio is 1:3 meaning for every 1 patient that receives Placebo, 3 patients will receive Sotatercept.
11529657|NCT01146561|Experimental|Tanezumab 20 mg|
11529658|NCT01146561|Placebo Comparator|Placebo|
11529659|NCT01146548|Experimental|the fluoxetine group|Multiple System Atrophy's patients with fluoxétine
11529660|NCT01146548|Placebo Comparator|the placebo group|Multiple System Atrophy's patients with placebo
11529661|NCT01146535|Experimental|Interferon-alpha|"Interferon-alpha
~150 IU lozenges bid for 5 days"
11529662|NCT01146535|Placebo Comparator|maltose|"maltose
~200 mg maltose lozenges bid for 5 days"
11529663|NCT01146522|Experimental|LCQ908|
11529664|NCT01146522|Placebo Comparator|Placebo|
11529665|NCT01146509|Experimental|1|
11529666|NCT01146496|Active Comparator|Storage container|Ultraviolet light resistant plastic in-ground pesticide storage container
11529667|NCT01146496|No Intervention|Control|
11529668|NCT01146483|Active Comparator|Pantoprazole|two-arm study: 2-period, 2-sequence, cross-over study.Volunteers will be administered either sequence 1 or sequence 2 randomly.
11529669|NCT01146483|Placebo Comparator|Placebo|
11529670|NCT01146470|Experimental|RGC 200 mg|
11529671|NCT01146470|Experimental|RGC 400 mg|
11529672|NCT01146470|Placebo Comparator|Placebo|
11529673|NCT01146457|Placebo Comparator|Placebo|
11529674|NCT01146457|Active Comparator|Morphine 25|
11529675|NCT01146457|Active Comparator|Morphine 50|
11529676|NCT01146457|Active Comparator|Morphine 75|
11529677|NCT01146457|Active Comparator|Morphine 100|
11529678|NCT01146444|Experimental|sunscreens with a low, medium, high SPF|sunscreens with a low, medium, and high SPF. UVA and UVB irradiation
11529679|NCT01146444|Experimental|vehicle|Intra-individual application of vehicle in random order; UVA and UVB irradiation
11529680|NCT01146431||Hemodynamic parameters|Hemodynamic parameters will be used as a guide for anesthesia.
11529681|NCT01146431||BIS|Bispectral Index (BIS) will be used as a guide for anesthesia.
11529682|NCT01146418|Experimental|Corifollitropin alfa 150 μg|Participants in Base Study P06029 received a single injection of 150 ug corifollitropin alfa on Stimulation Day 1 and daily injections of placebo-recFSH from Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.
11529683|NCT01146418|Active Comparator|recFSH 300 IU|Participants in the reference group in Base Study P06029 received a single injection of placebo for corifollitropin alfa on Stimulation Day 1 and daily injections of 300 IU recFSH on Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.
11529684|NCT01146392||1|Primary care patients with COPD diagnosis
11529685|NCT01146379|Experimental|Low Movement Dose, 3200 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
11529686|NCT01146379|Experimental|Medium Movement Dose, 6400 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
11529687|NCT01146379|Experimental|High Movement Dose, 9600 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
11529731|NCT01146093|Experimental|Pravastatin Sodium Tablets 80 mg|Dr.Reddy's Laboratories Limited
11529688|NCT01146379|Experimental|Individual Maximum High Movement Dose|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
11529689|NCT01146353||CRRT Patients receiving Peramivir|"Eligible patients are male or female patients ≥18 years of age who are hospitalized, undergoing CVVH or CVVHD, and receiving peramivir.
~Eligible patients will additionally have the following: blood flow rate will be required to be ≥100 mL/ min with an ultrafiltrate +/- dialysis flow rate greater than or equal to 3000mL/hr, and the continuous renal replacement therapy must be scheduled to run for the full duration of the dosing interval (full 24 hours).
~Written informed consent in a form approved by the Northwestern University and the Midwestern University Institutional Review Boards will be granted by the patient."
11529690|NCT01146340|Experimental|SBRT|SBRT 40 Gy in 5 fractions over 29 days delivered using step and shoot IGRT
11529691|NCT01146327|Experimental|PF-04620110|
11529692|NCT01146327|Placebo Comparator|Placebo Comparator|
11529693|NCT01146314|Experimental|Lifestyle intervention|A 6-month 14 session lifestyle intervention led by a psychologist and a dietitian for 90 minutes group sessions. Intervention sessions were help weekly, biweekly, and monthly over the course of 6 months.
11529694|NCT01146301|Active Comparator|300 mg Loading dose clopidogrel|
11529695|NCT01146301|Experimental|600 mg Loading dose of clopidogrel|
11529696|NCT01146288|Experimental|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.
11529697|NCT01146288|Experimental|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.
11529698|NCT01146275|Other|Participants in the Pilot study 31GB0601|"This is an additional safety follow up 7-years post treatment, for subjects enrolled in a pilot study using a previous formulation of Macrolane for breast augmentation.
~Radiological breast examinations - MRI of breast, mammography and ultrasound of breast"
11529699|NCT01146249||1: healthy subject|
11529700|NCT01146249||3: post stroke patients|
11529701|NCT01146249||2: vestibular patients|Vestibular patients with a unique history of peripheric vestibular disorder
11529702|NCT01146249||4: ataxic patients|Patient with proprioception disorder related to peripheral neuropathy
11529703|NCT01146249||5: Old fallers|Old subjects with a history of falls (one or more during the last year)
11529704|NCT01146236|Active Comparator|Sutures|Orthopedic surgical wound closed with sutures
11529705|NCT01146236|Active Comparator|Staples|Orthopedic surgical wound closed with metallic staples
11529706|NCT01146223||Basic science (correlative studies)|Patient mRNA samples from diagnosis are analyzed via quantitative PCR to measure WT1 and VEGF-1 expression.
11529707|NCT01146210||Ancillary-correlative|Previously collected cryopreserved cells are analyzed via western blot to identify patients with Fanconi anemia.
11529708|NCT01146197|Experimental|Amiloride, Indometacin, Eplerenone|Amiloride, indometacin(+Omeprazole), Eplerenone
11529709|NCT01146197|Experimental|Amiloride, Eplerenone, indometacin|Amiloride, Eplerenone, indometacin (+Omeprazole)
11529710|NCT01146197|Experimental|Eplerenone, Amiloride, indometacin|Eplerenone, Amiloride, indometacin (+Omeprazole)
11529711|NCT01146197|Experimental|Eplerenone, Indometacin, Amiloride|Eplerenone, Indometacin, Amiloride
11529712|NCT01146197|Experimental|Indometacin, Eplerenone, Amiloride|Indometacin, Eplerenone, Amiloride
11529713|NCT01146197|Experimental|Indometacin, Amiloride, Eplerenone|Indometacin, Amiloride, Eplerenone
11529714|NCT01146184|Experimental|Single-Incision Cholecystectomy|Extracting the gallbladder laparoscopically is made difficult through a single incision.
11529715|NCT01146171|Experimental|BMS-844203 (CT-322)|
11529716|NCT01146158|Experimental|surgery Axillary dissection|surgery Axillary dissection
11529717|NCT01146145|Experimental|treatment|intravenous morphine titration combined to ketamine
11529718|NCT01146145|Placebo Comparator|placebo|morphine titration alone
11529719|NCT01146132|Other|Luxembourg diet + wine|Luxembourg variant of the mediterranean Diet, physical activity with wine consumption
11529720|NCT01146132|Other|conventional + wine|conventional Diet with red wine
11529721|NCT01146132|Other|conventional|conventional diet without wine
11529722|NCT01146132|Other|Luxembourg diet|Luxembourg variant of the mediterranean Diet, physical activity with wine consumption
11529723|NCT01146119|Experimental|Multimeric-001, Adjuvanted|64 subjects received 2 injections of Adjuvanted Multimeric-001, 500 mcg with an interval of 21 days and then 60 days later were further immunized with a 15% dose of commercial seasonal trivalent vaccine (season 2011).
11529724|NCT01146119|Active Comparator|PBS and TIV 15%|32 subjects received 2 injections of PBS (Phosphate Buffered Saline) with an interval of 21 days and then were further immunized 60 days later with a 15% dose of commercial seasonal trivalent vaccine (season 2011).
11529725|NCT01146119|Placebo Comparator|Placebo, Adjuvanted|32 subjects received Adjuvanted PBS (Placebo) with an interval of 21 days.
11529726|NCT01146119|Experimental|Co-administration M-001 and TIV 15%|24 subjects received 2 injections on the same day, one injection containing Adjuvanted Multimeric-001 500 mcg and the other containing TIV 15%.
11529727|NCT01146119|Experimental|Co administration of M-001 and TIV 50%|24 subjects received 2 injections on the same day, one injection containing Adjuvanted Multimeric-001 500 mcg and the other containing TIV 50%.
11529728|NCT01146119|Active Comparator|Co administration of PBS and TIV 50%|24 subjects received 2 injections on the same day, one injection containing PBS and the other containing TIV 50%.
11529729|NCT01146106|Experimental|Pravastatin Sodium Tablets 80 mg|Dr.Reddy's Laboratories Limited
11529730|NCT01146106|Active Comparator|Pravachol 80 mg Tablets|Bristol Myers Squibb
11530725|NCT01139008|Active Comparator|azelaic acid 15% gel|
11529732|NCT01146093|Active Comparator|Pravachol 80 mg Tablets|Bristol Myers Squibb
11529733|NCT01146080|Experimental|Promus Element|21 consecutive patients with Promus Element implanted to treat coronary artery lesion
11529734|NCT01146080|Active Comparator|Promus|21 consecutive patients with Promus stent implanted to treat coronary artery lesions
11529735|NCT01146067|Experimental|Rivastigmine|Rivastigmine capsules 1.5 mg of Dr.Reddy's Laboratories Limited
11529736|NCT01146067|Active Comparator|Exelon|Exelon 1.5 mg capsules of Novartis
11529737|NCT01146054|Experimental|SBRT and Gemzar|Before stereotactic Body Radiotherapy (SBRT) 3-5 gold fiducials are placed by endoscopic ultrasound or CT guidance. A simulation FDG-PET/CT (Fludeoxyglucose (18F) - Positron emission tomography/Computerized tomography) scan will be used for treatment planning purposes (standard free-breathing CT and respiratory-correlated 4-D (4 dimensional) pancreatic protocol CT). Patients are treated by either respiratory gated (Trilogy, Elekta, Novalis) or by respiratory tracking (CyberKnife). SBRT is delivered in 5 fractions of 6.6 Gy by LINAC-based or CyberKnife based radiotherapy over a five-day period. Gemcitabine, cycles should resume/start up to 4 weeks following SBRT on a 3-week on, 1-week off schedule. Initial follow up is at 4, 6, 9 and 12 months and then for years 2-5 is every 3-6 months.
11529738|NCT01146041|Experimental|Rivastigmine|Rivastigmine capsules 1.5 mg of Dr.Reddy's Laboratories Limited
11529739|NCT01146041|Active Comparator|exelon|Exelon 1.5 mg capsules of Novartis
11529740|NCT01146028|Experimental|Tizanidine HCl 4 mg|Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited
11529741|NCT01146028|Active Comparator|Zanaflex|Zanaflex 4 mg Tablets
11529742|NCT01146015|Experimental|1|
11529743|NCT01146002|Other|Guanfacine treated.|Single arm - all patients treated with study drug. Comparison is against pre-treatment performance.
11529744|NCT01145989|Experimental|AT9283|Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
11529745|NCT01145976|Active Comparator|CY-ATG(Arm1)|"Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.
~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2"
11529746|NCT01145976|Experimental|Flu-ATG(Arm2)|Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
11529747|NCT01145963|Experimental|experimental pasta B|Past B
11529748|NCT01145963|Experimental|experimental pasta C|Pasta C
11529749|NCT01145963|Placebo Comparator|Control pasta|Control
11529750|NCT01145950|Experimental|Group 1|
11529751|NCT01145950|Experimental|Group 2|
11529752|NCT01145937|Experimental|PET|"Partial endothelial trepanation in addition to anterior lamellar keratoplasty.
~The endothelium en Descemet are paracentrally and circular loosened, but some tissue bridges are left in place. This 'island' is able to mould to the healthy donor curvature."
11529753|NCT01145937|Active Comparator|DALK|Conventional DALK grafting procedure where the Big Bubble technique is used according to Anwar et al.
11529754|NCT01145924|Active Comparator|EBUS TBNF|single arm trial, patients with enlarged mediastinal nodes will be examine
11529755|NCT01145911||Glaucoma patients|Glaucoma patients
11529756|NCT01145898||Glaucoma patients|Patients with Glaucoma
11529757|NCT01145885|Experimental|BI 6727|BI 6727 cycles in every 21 days
11529758|NCT01145872|Experimental|Mindfulness Based Cognitive Therapy|
11529759|NCT01145872|Active Comparator|Health Enhancement Program|
11529760|NCT01145859|Experimental|Arm 1|
11529761|NCT01145846|Experimental|Arm I (AI regimen)|Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Idarubicin 12 mg/m2/day iv daily for 3 days (D 1-3)
11529762|NCT01145833|Active Comparator|Immediate treatment group|The immediate treatment group begins the 5-month treatment immediately after baseline assessment.
11529763|NCT01145833|Other|Delayed Treatment Group|The delayed treatment group serves as the control group. This group starts treatment 5 months after the baseline assessment. No intervention is involved during this 5-month waiting period. After 5 months, the delayed group is assessed for the second time and then begins the 5-month treatment.
11529764|NCT01145820|Experimental|Juice Plus|
11529765|NCT01145820|Placebo Comparator|Placebo|
11529766|NCT01145807|Placebo Comparator|Placebo|non Transfersome® placebo
11529767|NCT01145807|Sham Comparator|Transfersome® vehicle|Transfersome® vehicle
11529768|NCT01145807|Experimental|TDT 067|TDT 067
11529769|NCT01145781|Active Comparator|Single-freeze cryotherapy|Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw.
11529770|NCT01145781|Active Comparator|Double-freeze cryotherapy|Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.
11529771|NCT01145768|Experimental|1|Each cohort will have 9 volunteers that will receive TC-5214
11529772|NCT01145768|Placebo Comparator|2|Each cohort will have 3 volunteers that will receive placebo
11529773|NCT01145755|Experimental|AZD2066|
11529774|NCT01145755|Placebo Comparator|Placebo|
11529775|NCT01145755|Active Comparator|Duloxetine|Duloxetine
11529776|NCT01145742|Experimental|self-management support and BP telemonitoring|collaborative intervention involving home BP monitoring, home behavior change counseling to enhance self management, and intensification of treatment by primary care doctors
11529777|NCT01145742|No Intervention|usual care|usual primary care management of BP. lipids, and glucose
11529778|NCT01145729|Active Comparator|Biomarker feedback|Biomarkers of tobacco exposure (laboratory values) delivered to health care provider
11529779|NCT01145729|Placebo Comparator|Usual care (general counseling)|Brochure about pesticides, lead, SHS
11529780|NCT01145716|Other|Surgical exploration|Descriptive
11529781|NCT01145703|Active Comparator|RDA Vitamin D|
11529782|NCT01145703|Experimental|Vit D repletion + 6M Supplementation|
11529783|NCT01145703|Experimental|Vit D repletion + 6M Supplementation +AEX|
11529784|NCT01145703|Experimental|Vit D repletion + 6M Supplementation +RT|
11529785|NCT01145690||Internet-based CBT|All participants in this cohort received Internet-based CBT for social anxiety disorder in 2005. All participants were Swedish adults with a DSM-IV diagnosis of social anxiety disorder.
11529786|NCT01145677|Experimental|Topiramate|
11529787|NCT01145664|Active Comparator|Western therapy|
11529788|NCT01145664|Experimental|Herbal concentrate-granules plus western therapy|
11529789|NCT01145664|Experimental|Reduning Injection plus western therapy|
11529790|NCT01145638|Experimental|iron isomaltoside 1000|Iron isomaltoside intravenously as bolus or infusion
11529791|NCT01145638|Active Comparator|iron sulphate|oral iron sulphate twice a day
11529792|NCT01145625|Experimental|5% MTF|5% Minoxidil Topical Foam
11529793|NCT01145625|Active Comparator|2% MTS|2% Minoxidil Topical Solution
11529794|NCT01145612|Experimental|Losartan|Losartán dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
11529795|NCT01145612|Experimental|Atenolol|Atenolol dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
11529796|NCT01145599||Type-2 diabetes, NPDR|Type-2 diabetic patients with NPDR.
11529797|NCT01145586|Experimental|Lactase EUF|1 oral tablet of the test drug before breakfast, lunch and dinner for 42 consecutive days
11529798|NCT01145586|Active Comparator|Lactase Ref|1 oral tablet of the comparative drug before breakfast, lunch and dinner for 42 consecutive days
11529799|NCT01145573|Placebo Comparator|Placebo|Inactive pill taken daily
11529800|NCT01145573|Active Comparator|Calcium|1000mg of calcium taken daily
11529801|NCT01145560|Experimental|1|AZD9773 250/50 units/kg
11529802|NCT01145560|Experimental|2|AZD9773 500/100 units/kg
11529803|NCT01145560|Placebo Comparator|3|
11529804|NCT01145547|Active Comparator|low glycemic index effect on post-prandial peak|Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a low Glycemic Index.
11529805|NCT01145547|Active Comparator|high glycemic index effect on post-prandial peak|Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a high Glycemic Index.
11529806|NCT01145534|Active Comparator|Glibenclamide|Patients used 5 mg glibenclamide daily for 60 days
11529807|NCT01145534|Experimental|Experimental|Patients ingested the infusion of Cissus verticillata L. prepared as 1 g in 150 mL of hot water for 10 min. This was done daily for 60 days
11529808|NCT01145508|Experimental|Arm A (vaccine therapy and chemotherapy)|Patients receive rilimogene-galvacirepvec SC on day 1 of course 1 and fowlpox-PSA-TRICOM vaccine SC on days 15, 29, 43, and 57 of course 1. Beginning on day 85 (day 1 of course 2), patients receive docetaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment with docetaxel and prednisone repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11529809|NCT01145508|Active Comparator|Arm B (docetaxel, prednisone)|Patients receive docetaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11529810|NCT01145495|Experimental|Treatment (lenalidomide, rituximab)|Patients receive lenalidomide PO QD on days 1-21. Treatment with lenalidomide repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, 15, and 22 and in weeks 13, 21, 29, and 37 in the absence of disease progression or unacceptable toxicity.
11529811|NCT01145482|Experimental|insulin|20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
11529812|NCT01145482|Placebo Comparator|Saline|200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
11529813|NCT01145456|Experimental|Treatment (RO4929097 and gemcitabine hydrochloride)|Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11529814|NCT01145443||Continuous intensivist staffing model|These are the patients admitted to participating Intensive Care Units during the 3 month phases of the study when a single intensivist was the sole attending physician of record for intervals of 2 weeks (or 1/2 month).
11529815|NCT01145443||Discontinuous intensivist staffing model|These are the patients admitted to participating Intensive Care Units during the 3 month phases of the study when, for intervals of 2 weeks (or 1/2 month), there was a single intensivist who was the primary attending of record during Mondays-Fridays, but cross-covering colleagues took over that role during the weekends.
11529816|NCT01145430|Experimental|Treatment (veliparib and liposomal doxorubicin hydrochloride)|Patients receive veliparib PO BID on days 1-14 and pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11529817|NCT01145417|Experimental|Pregabalin (Lyrica)|
11529818|NCT01145404|Experimental|Arm A: Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
11529819|NCT01145404|Experimental|Arm B|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
11529820|NCT01145391|No Intervention|Control|Patients receive usual care.
11529821|NCT01145391|Active Comparator|Intervention|An outreach coordinator raised patient and provider awareness of unmet Blood Pressure goals, arranged Blood Pressure-focused clinic visits, and furnished providers with treatment decision support.
11529822|NCT01145365|Active Comparator|Combination Therapy Group|Patients in this arm will have surgically established drainage of their Crohns perianal fistulas and/or abscesses (exam under anesthesia (EUA)) done BEFORE beginning medical therapy with Cimzia.
11529823|NCT01145365|No Intervention|Control Group|Patients in this group will begin medical therapy with Cimzia regardless of status of surgically established drainage.
11529824|NCT01145352||Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis during registered period (2.5 year).
11529825|NCT01145339|Experimental|Lactase EUF|1 chewable tablet of the test drug 30 minutes before the standard lactose dose (25 g).
11529826|NCT01145339|Active Comparator|Lactase Ref|1 chewable tablet of the comparative drug 30 minutes before the standard lactose dose (25 g).
11529827|NCT01145326|Sham Comparator|Control|Sham-Functional microneedles (no actual microneedles) application, prior to 4% lidocaine gel (LG4) placement.
11529828|NCT01145326|Experimental|Microneedle|Functional microarray (FMA) (microneedles) application, prior to 4% lidocaine gel (LG4) placement.
11529829|NCT01145313||Patients diagnosed with Major Depressive Disorder|Patients diagnosed with MDD who are treated with antidepressants and subsequently augment with atypical antipsychotic therapy.
11529830|NCT01145261||Anxiety|Children with anxiety disorders
11529831|NCT01145261||healthy controls|children without anxiety disorders
11529832|NCT01145248|Experimental|Malignant biliary disease|
11529833|NCT01145248|Experimental|Benign biliary disease|
11529834|NCT01145235||Females previously treated with Macrolane in their breasts.|
11529835|NCT01145222|Experimental|A. Remimazolam (CNS 7056)|"Initial 8 mg iv for sedation induction, and 3 mg iv top-ups for sedation maintenance.
~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses."
11529836|NCT01145222|Experimental|B. Remimazolam (CNS 7056)|"Initial 7 mg iv for sedation induction, and 2 mg iv top-ups for sedation maintenance.
~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses."
11529837|NCT01145222|Experimental|C. Remimazolam (CNS 7056)|"Initial 5 mg iv for sedation induction, and 3 mg iv top-ups for sedation maintenance.
~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses."
11529838|NCT01145222|Active Comparator|D. Midazolam|"Initial 2.5 mg iv for sedation induction, and 1 mg iv top-ups for sedation maintenance.
~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses"
11529839|NCT01145209|Experimental|FO Arm (fludarabine and ofatumumab)|For patients with non-high risk FISH changes
11529840|NCT01145209|Experimental|FCO Arm (fludarabine, cyclophosphamide, and ofatumumab)|For patients with high risk FISH changes
11529841|NCT01145196||Affected|Participants affected by Paquenil induced retinal toxicity
11529842|NCT01145196||Unaffected|control participants without Plaquenil induced retinal toxicity
11529843|NCT01145183|Experimental|Doxazosin|Doxazosin is a long-acting and selective alpha 1-NE blocker, which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system.
11529844|NCT01145183|Placebo Comparator|Placebo|Matched placebo daily dosing.
11529845|NCT01145170|Experimental|Nimotuzumab|The study consists of a single treatment group, which will receive the first-line therapy for the disease. The therapy is the standard radiotherapy and a dose of the investigational product (nimotuzumab) at 150 mg/m2.
11529846|NCT01145157|Experimental|Signature Knee Guide|Total Knee Arthroplasty using the Signature Knee Guide with the Vanguard Knee System
11529847|NCT01145157|Active Comparator|Conventional Instrumentation|Total Knee Arthroplasty will be performed using Conventional Instrumentation with the Vanguard Knee System
11529848|NCT01145157|Active Comparator|Computer Assisted Navigation|Total Knee Arthroplasty will be performed using Computer Assisted Navigation with the Vanguard Knee System
11529849|NCT01145144|Experimental|DHEA supplementation|DHEA was added to induction of ovulation by recombinant FSH and recombinant LH, in IVF long protocol
11529850|NCT01145144|No Intervention|only induction of ovulation by same long protocol without DHEA|
11529851|NCT01145131|Experimental|Beef steak|
11529852|NCT01145131|Experimental|Minced beef|
11529853|NCT01145079|Experimental|Endeavor arm|
11529854|NCT01145079|Active Comparator|Endeavor resolute arm|
11529855|NCT01145079|Active Comparator|Xience arm|
11529856|NCT01145079|Active Comparator|Cypher arm|
11529857|NCT01145066|Experimental|borage and echium oil combination|borage/echium oil combination containing 0.85g/day SDA and 1.7 g/day GLA
11529858|NCT01145066|Active Comparator|fish oil|Croda 18:12 fish oil
11529859|NCT01145066|Placebo Comparator|corn oil|
11529860|NCT01145053||Treatment|
11529861|NCT01145040||Partition 1|Overt primary hypothyroidism
11529862|NCT01145040||Partition 2|"Hypothyroidism with full dose levothyroxine substitution therapy (more than 1.75 µg per kg of body mass)"
11529863|NCT01145040||Partition 3|Overt primary hyperthyroidism
11529864|NCT01145027|No Intervention|Control group|
11529865|NCT01145027|Experimental|Sensorial Stimulus|The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste, in order to trigger the cephalic phase of insulin secretion
11529866|NCT01145014|Experimental|BI 660848 2 mg|oral drinking solution
11529867|NCT01145014|Experimental|BI 660848 10 mg|oral drinking solution
11529868|NCT01145014|Experimental|BI 660848 20 mg|oral drinking solution
11529869|NCT01145014|Experimental|BI 660848 50 mg|oral drinking solution
11529870|NCT01145014|Experimental|BI 660848 100 mg|oral drinking solution
11529871|NCT01145014|Experimental|BI 660848 150 mg|oral drinking solution
11529872|NCT01145014|Experimental|BI 660848 200 mg|oral drinking solution
11529873|NCT01145014|Experimental|BI 660848 400 mg|oral drinking solution
11529874|NCT01145014|Experimental|BI 660848 600 mg|oral drinking solution
11529875|NCT01145014|Experimental|BI 660848 10,0 mg|immediate release tablet
11529876|NCT01145014|Experimental|BI 660848 50,0 mg|immediate release tablet
11529877|NCT01145014|Experimental|Placebo|matching placebo (oral drinking solution and IR tablets)
11529878|NCT01145001|Active Comparator|Active Nicotine Patch and Contingency Management|Subjects in this group will receive Contingency Management and active nicotine patch
11529879|NCT01145001|Active Comparator|Nicotine Patch with no Contingency Management|Subjects in this group will receive active nicotine patch without contingency management for abstinence
11529880|NCT01145001|Placebo Comparator|Placebo patch and Contingency Management|Subjects in this group will receive a placebo transdermal patch and contingency management
11529881|NCT01145001|Placebo Comparator|Placebo Patch and no Contingency Management|Subjects in this group will receive a placebo patch and will not receive contingency management
11529882|NCT01144975|Active Comparator|XOMA 052|
11529883|NCT01144975|Placebo Comparator|Placebo|
11529884|NCT01144962|Sham Comparator|Control group|Patients in the control group will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.
11529885|NCT01144962|Active Comparator|Cohort 1|10x10^6 MSC
11529886|NCT01144962|Active Comparator|Cohort 2|30x10^6 MSC
11529887|NCT01144962|Active Comparator|Cohort 3|90x10^6 MSC
11529888|NCT01144949|Active Comparator|silodsosin|
11529889|NCT01144949|Placebo Comparator|placebo|
11529890|NCT01144936|Experimental|Panel 1: VX-985 Dose 1|
11529891|NCT01144936|Experimental|Panel 2: VX-985 Dose 2|
11529892|NCT01144936|Experimental|Panel 3: VX-985 Dose 3|
11529893|NCT01144923|Active Comparator|Conservative treatment|Pharmacotherapy with nortriptyline and/ or gabapentin, physical therapy (e.g. range of motion, therapeutic massage, strengthening exercises), and possibly others (e.g. acupuncture)
11529894|NCT01144923|Experimental|Epidural Steroids|A series of up to 3 epidural steroid injections (ESI)with depo-methylprednisolone
11529895|NCT01144923|Experimental|Combination Treatment|These patients will receive both treatments. They can have up to 3 epidural steroid injections (ESI) with depo-methylprednisolone, and conservative treatment (i.e. pharmacotherapy with nortriptyline and/ or gabapentin, and physical therapy)
11529896|NCT01144910||BHR non-atopy|Patients from the outpatient Department of Allergy, Pneumology and Cystic fibrosis, children's hospital, Goethe-University, Frankfurt, Germany. Over a time-span of 5 years the investigators will explore the lung function and the bronchial hyperresponsiveness. Bronchial methacholine challenges will be performed at baseline and after 1, 3 and 5 years.
11529897|NCT01144910||BHR atopy|Patients from the outpatient Department of Allergy, Pneumology and Cystic fibrosis, children's hospital, Goethe-University, Frankfurt, Germany. Over a time-span of 5 years the investigators will explore the lung function and the bronchial hyperresponsiveness. Bronchial methacholine challenges will be performed at baseline and after 1, 3 and 5 years.
11529898|NCT01144897|Experimental|PET Acetate Imaging with Docetaxel|"PET-acetate as an intermediate endpoint in the assessment of response of patients undergoing docetaxel for hormone refractory prostate cancer (HRPC).
~Subjects will be treated with docetaxel, 75 mg/m2 every 21 days until disease progression or unacceptable toxicity occurs. Subjects will have two PET acetate scans - one prior to beginning chemotherapy and one approximately 8-9 weeks after chemotherapy has begun."
11529899|NCT01144884|Other|Single arm trial|"Education:To standardize, treatment education will consist of counsel to stay active. Details will be given to subjects verbally & reinforced in the home booklet.
~Posture:Facilitation of proper posture has been show to increase recruitment of the lumbar multifidus & deep neck flexors. Instruction will be given verbally & in writing.
~Stretching:Stretching exercises will be targeted to address these common impairments. Patients will be introduced to proper stretching procedures. Each stretch will be held for 30s & repeated two times,each side as applicable. The following stretches will be performed:
~Upper trap Anterior/medial Scalene Suboccipital Pectoralis
~Muscular Performance: Muscle performance will be trained incorporating components of strength, endurance and motor control. Each of the exercises listed below are outlined based on progressions.
~Isometric Cervical Extension Craniocervical flexion Seated Row Seated T Palms Up Seated Side Arm Raises"
11529900|NCT01144871||Male Parent/Guardians|Male Parent/Guardian of Adolescent 12-17 yo. Health care members of either San Francisco General Hospital or Kaiser Permanente Northern California.
11529901|NCT01144871||Female Parent/Guardian|Female Parent/Guardian of Adolescent 12-17 yo. Health care members of either San Francisco General Hospital or Kaiser Permanente Northern California.
11529902|NCT01144858||patients with persistent atrial fibrillation ablation|
11529903|NCT01144845||Thoracic surgical patients|Patients with pulmonary malignancies
11529904|NCT01144832|Placebo Comparator|placebo capsule|
11529905|NCT01144832|Active Comparator|ebastine|
11529906|NCT01144819||STEMI|Patients with STEMI according to ESC STEMI guidelines: Age above 18 years and able to give written, informed consent to participation in the project.
11529907|NCT01144806|Active Comparator|Group 1|Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
11529908|NCT01144806|Active Comparator|Group 2|Ready to use therapeutic food (RUTF / PlumpyNut)will be provided to parent/care givers of children with severe malnutrition in enrolled in this group
11529909|NCT01144767|Experimental|Computer-generated advisor|Participants receive sessions with a computer-generated adviser who will provide tailored advice and encouragement to engage in physical activity.
11529910|NCT01144767|Active Comparator|Comparison control condition|Participants will receive live, group sessions on health topics unrelated to physical activity.
11529911|NCT01144741||Freeman-Sheldon syndrome Classic Type|"Patients who have all features required by the Stevenson criteria, including: very small mouth (microstomia); whistling-face appearance (pursed lips); H or V shaped chin dimple; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping."
11529912|NCT01144741||Freeman-Sheldon syndrome Craniofacial Type|"Patients who have only the face and skull physical findings required by the Stevenson criteria, including: very small mouth (microstomia), whistling-face appearance (pursed lips), H or V shaped chin dimple, very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases)."
11529913|NCT01144741||Freeman-Sheldon syndrome Mixed Type|Patients who have the face and skull physical findings required by the Stevenson criteria and some but not all required joint problems.
11529914|NCT01144741||Sheldon-Hall syndrome|Patients who have all features required by the Stevenson criteria, including: small mouth (not microstomia); neck webbing (pterygium colli); small but prominent chin; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
11530041|NCT01143870|Other|Hemoglobin A1C|Diabetes control related to patients using standard hemoglobin A1C
11529915|NCT01144741||Distal Arthrogryposis Type 1|Patients with features consistent with this diagnosis, including restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
11529916|NCT01144741||Distal Arthrogryposis Type 3|Patients with features consistent with this diagnosis, including: gap in the roof of the mouth (cleft palate); drooping eyelid (blepharoptosis); and backbones curve problems; and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
11529917|NCT01144728|Experimental|Single arm Glimepiride+metformin|Start and titration based on FBG and tolerance. Titration should be achieved within maximum 4 weeks.
11529918|NCT01144715|Experimental|Hand Mentor Therapy|Use of the Hand Mentor (TM) Stroke Therapy Device at home for 8 weeks
11529919|NCT01144715|Active Comparator|Control|Self administered home therapy program
11529920|NCT01144702|Experimental|artesunate & mefloquine combination|ASMQ will be administered to individuals with uncomplicated malaria by P. falciparum according to the dose regimen for age and weight, standardized (Farmanguinhos, Ministry of Health). For patients in the range of 5 to <18kg (6 months to 5 years old), will be offered treatment in the pediatric presentation of Artesunate+Mefloquine 25 +50 mg (5 to <9 kg = 1 tablet once daily for 3 days, 9 to <18 kg = 2 tablets once daily for 3 days). To study subject aged 18 or more kilos (six years or more years old) will be given the combination of Artesunate + Mefloquine presentation ASMQ 100 +200 mg (18 to 29 kg = 1 tablet once daily for 3 days, 30 kg or more = 2 tablets once daily for 3 days). Clinically and biochemically monitoring will be done for 42 days.
11529921|NCT01144689|Experimental|Mindfulness Training|
11529922|NCT01144689|Active Comparator|Smoking Cessation Therapy|
11529923|NCT01144676|Experimental|Group A1: Dapivirine Vaginal Ring|
11529924|NCT01144676|Placebo Comparator|Group A2: Placebo Vaginal Ring|
11529925|NCT01144676|Experimental|Group B1: Dapivirine Vaginal Ring|
11529926|NCT01144676|Placebo Comparator|Group B2: Placebo Vaginal Ring|
11529927|NCT01144663|Experimental|Nimenrix 3 Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 3 primary doses of Nimenrix™ vaccine at 2, 3 and 4 months of age, followed by a booster dose of Nimenrix™ vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 3, 4 and 12 months of age.
11529928|NCT01144663|Experimental|Nimenrix 2 Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 2 primary doses of Nimenrix™ vaccine at 2 and 4 months of age, followed by a booster dose of Nimenrix™ vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 4 and 12 months of age.
11529929|NCT01144663|Active Comparator|Menjugate Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 2 primary doses of Menjugate® vaccine at 2 and 4 months of age, followed by a booster dose of Menjugate® vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 4 and 12 months of age.
11529930|NCT01144663|Active Comparator|NeisVac-C Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 2 primary doses of NeisVac-C™ vaccine at 2 and 4 months of age, followed by a booster dose of NeisVac-C™ vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 4 and 12 months of age.
11529931|NCT01144650|Placebo Comparator|Placebo|Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
11529932|NCT01144650|Experimental|Dapsone|Patients will receive either a single total dose of 250 mg IV and oral dosage
11529933|NCT01144637|Experimental|Group 1|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
11529934|NCT01144637|Experimental|Group 2|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
11529935|NCT01144637|Experimental|Group 3|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
11529936|NCT01144637|Placebo Comparator|Group 4|Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
11529937|NCT01144624|Experimental|1|"AZD9773 250 units/kg (1 infusion) + 50 units/kg (9 infusions) (Dose Cohort 1):
~AZD9773 500 units/kg (1 infusion) + 100 units/kg (9 infusions) (Dose Cohort 2)"
11529938|NCT01144624|Placebo Comparator|2|
11529939|NCT01144611|Active Comparator|bIAP|intravenous as a bolus of bIAP (alkaline phosphatase, 1000 IU) just prior to surgery followed by a 40 IU/kg bIAP infusion during the first 8 hours post surgery.
11529940|NCT01144611|Placebo Comparator|placebo|intravenous as a bolus just prior to surgery followed by an infusion during the first 8 hours post surgery.
11529941|NCT01144598||Turkish patients with rheumatoid arthritis|
11529942|NCT01144585|Experimental|RIPC|those who receive RIPC and RIPoC before and after CPB
11529943|NCT01144585|Placebo Comparator|Control|this group have same pneumatic cuff around their arm, but it is not inflated.
11529944|NCT01144572||1|Chinese postmenopausal HR(+) EBC patients during adjuvant Aromatase Inhibitors(AIs) treatment
11529945|NCT01144559|Active Comparator|Continuous Infusion|Each subject will have one lower extremity (Right or Left) randomized to receive a perineural catheter with a continuous infusion of local anesthetic and then the outcomes will be measured.
11529946|NCT01144559|Active Comparator|Bolus Administration|The opposite lower extremity (right or left) will be randomized to receive a perineural catheter with the local anesthetic being delivered via a bolus as opposed to continuous as is the case with their other extremity. The outcome measures will then be assessed as described.
11529947|NCT01144546|Experimental|Passive Leg Raising|elevation of both legs to a 45 degrees for about 1-2 minute before anesthesia induction
11529948|NCT01144533|Placebo Comparator|Isotonic saline|
11529949|NCT01144533|Experimental|Steroid|
11529950|NCT01144533|Experimental|Hyaluronate|
11529951|NCT01144533|Experimental|Steroid + Hyaluronate|
11529952|NCT01144520||Normoglycemic|Healthy subjects that do not have diabetes
11529953|NCT01144520||Type II Diabetes (HbA1c <7 or 7%)|Subject that have Type II Diabetes with good glucose control with glycated hemoglobin (HbA1c <7 or 7%)
11530042|NCT01143870|Experimental|Face|Face expressing emotion used to depict diabetes control
11529954|NCT01144520||Type II Diabetes (HbA1c between 7.1-9)|Subjects with Type II Diabetes with moderate glucose control (HbA1c between 7.1-9)
11529955|NCT01144520||Type II Diabetes (HbA1c >9%)|Subjects with Type II Diabetes with poor glucose control (HbA1c >9%)
11529956|NCT01144507||Group A|Approximately 60 subjects with a heterogeneous echo pattern of the liver on abdominal ultrasound (HTG US).
11529957|NCT01144507||Group B|Approximately 680 subjects with a normal echo pattern on abdominal ultrasound (NL US). Of these subjects, approximately 110 will be matched 1:1 with Group A participants and followed for the duration of the study. The remaining unmatched subjects will not be followed beyond their initial visit.
11529958|NCT01144507||Group C|An estimated 30 subjects with cirrhosis pattern on abdominal ultrasound. These subjects will be followed in the study.
11529959|NCT01144507||Group D|An estimated 30 subjects with diffusely homogeneous echogenic pattern at screening ultrasound will be followed in the study.
11529960|NCT01144494|Active Comparator|Intraocular pressure lowering drug|Eyedrops for lowering intraocular pressure
11529961|NCT01144494|Placebo Comparator|Artificial Tears|Lubricated eye drops
11529962|NCT01144481||breast cancer with metastasis|female breast cancer patients with metastases to any site
11529963|NCT01144468||MAP3 Participants|study participants in the MAP.3 study are randomly assigned to either placebo or 25 mg exemestane daily for 5 years. Allocation is blinded. We are following 354 of these study participants and are blinded to treatment allocation.
11529964|NCT01144455|Active Comparator|Gemcitabine|Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle
11529965|NCT01144455|Experimental|240 mg/m2 TH-302 + Gemcitabine|"TH-302: 240 mg/m2 administered IV over 30 minutes Day 1, 8, and 15 of each 28-day cycle
~Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle"
11529966|NCT01144455|Experimental|340 mg/m2 TH-302 + Gemcitabine|"TH-302: 340 mg/m2 of TH-302 be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
~Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle"
11529967|NCT01144442|Experimental|HIPC Treatment|
11529968|NCT01144429|Active Comparator|100 DPP/mL|Concentration of solution fo s.c. injection: 100 DPP/mL
11529969|NCT01144429|Active Comparator|1000 DPP/mL|Concentration of solution fo s.c. injection: 1000 DPP/mL
11529970|NCT01144429|Active Comparator|5000 DPP/mL|Concentration of solution fo s.c. injection: 5000 DPP/mL
11529971|NCT01144429|Active Comparator|10000 DPP/mL|Concentration of solution fo s.c. injection: 10000 DPP/mL
11529972|NCT01144416|Experimental|Single injection of 150 µg SCH 900962 (MK-8962)|Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7
11529973|NCT01144416|Active Comparator|Daily 300 IU recFSH|Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of recFSH from Stimulation Days 1-7
11529974|NCT01144403|Experimental|Rituximab|Rituximab, 375 milligram per meter square (mg/m^2) was given intravenously on Day 1 and then every 28 days (+/-7 days) for 6 cycles, followed by 2 consolidated infusions in responders as rituximab induction therapy. Rituximab infusions were administered concomitantly with prescribed chemotherapy i.e., fludarabine, cyclophosphamide and mitoxantrone (maximum 6 cycles).
11529975|NCT01144390|Experimental|CBT plus MMT|cognitive behavioral therapy for heroin addicts with methadone maintenance treatment
11529976|NCT01144390|Active Comparator|methadone maintenance treatment|methadone maintenance treatment for heroin addicts
11529977|NCT01144377|Experimental|180 mg LY2541546 Q4W + Placebo|"LY2541546: 180 milligrams (mg) administered subcutaneously every 4 weeks (Q4W) for 52 weeks.
~Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks."
11529978|NCT01144377|Experimental|180 mg LY2541546 Q2W|LY2541546: 180 milligrams (mg) administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
11529979|NCT01144377|Experimental|270 mg LY2541546 Q2W|LY2541546: 270 milligrams (mg) LY2541546 administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
11529980|NCT01144377|Experimental|270 mg LY2541546 Q12W + Placebo|"LY2541546: 270 milligrams (mg) administered subcutaneously every 12 weeks (Q12W) for 52 weeks.
~Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks."
11529981|NCT01144377|Placebo Comparator|Placebo Comparator Q2W|Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
11529982|NCT01144364|Experimental|1|
11529983|NCT01144351|Experimental|ELND002|ELND002 sc injection
11529984|NCT01144351|Placebo Comparator|Placebo|placebo injection
11529985|NCT01144338|Experimental|Exenatide Once Weekly|
11529986|NCT01144338|Placebo Comparator|Placebo|
11529987|NCT01144312|Experimental|pharmacokinetics of fentanyl|
11529988|NCT01144299|Experimental|Fluarix Adult Group|Subjects aged 18 to 60 years received one dose of Fluarix™.
11529989|NCT01144299|Experimental|Fluarix Elderly Group|Subjects aged > 60 years received one dose of Fluarix™.
11529990|NCT01144286|Placebo Comparator|placebo|placebo pessary, single dose
11529991|NCT01144286|Experimental|Arasertaconazole nitrate 150 mg|Arasertaconazole nitrate 150 mg pessary, single dose
11529992|NCT01144286|Experimental|arasertaconazole nitrate 300 mg|Arasertaconazole nitrate 300 mg pessary, single dose
11529993|NCT01144286|Experimental|arasertaconazole 600 mg|Arasertaconazole nitrate 600 mg pessary, single dose
11529994|NCT01144273|Active Comparator|0.5% Ropivacaine|group receiving TAP block (0.5% ropivacaine at TAP plane)
11529995|NCT01144273|Placebo Comparator|normal saline|group receiving placebo (saline) at TAP plane
11529996|NCT01144260|Experimental|Bafetinib|
11529997|NCT01144247|Experimental|alloreactive CTL arm|
11529998|NCT01144234|Experimental|Invitation letter to male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
11529999|NCT01144234|Placebo Comparator|Information letter|In this arm the pregnant women got an information letter about antenatal care.
11530000|NCT01144221|Experimental|Stem cell treatment|Patients treated via stem cell injection
11530001|NCT01144182|No Intervention|Current Best Practice (CBP)|CBP received no intervention and only current best practices for inpatient HF care.
11530043|NCT01143870|Experimental|Letter grade|Letter grade used to express diabetes control
11530044|NCT01143857|Active Comparator|Varenicline|
11530002|NCT01144182|Active Comparator|Quality improvement program (QIP)|Comprehensive quality improvement program (QIP) intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
11530003|NCT01144169|Experimental|Hydroxychloroquine (HC)|HC orally for 14 days prior to nephrectomy
11530004|NCT01144143|Experimental|Infliximab|
11530005|NCT01144143|Placebo Comparator|Salt Water|
11530006|NCT01144143|Active Comparator|Methylprednisolone acetate|
11530007|NCT01144117|Experimental|Erythropoietin|Erythropoietin treated patients contra placebo.
11530008|NCT01144104|Experimental|Public Service Announcements|Demographically targeted public service announcement
11530009|NCT01144104|Experimental|Interactive Multi-Media Computer Program|Personally tailored information about seeking care for depression based on respondent characteristics
11530010|NCT01144104|Active Comparator|Attention Control Video|Two-minute video focusing on common sleep disorders.
11530011|NCT01144091|Experimental|pentoxyphylline cardio|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo coronary angiography
11530012|NCT01144091|Placebo Comparator|placebo cardio|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo coronary angiography
11530013|NCT01144091|Experimental|radiology pentoxyphylline|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo computed tomography with contrast
11530014|NCT01144091|Placebo Comparator|radiology placebo|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo computed tomography with contrast
11530015|NCT01144078|Experimental|High Intensity Interval Exercise|This arms receives the High Intensity Interval Exercise intervention
11530016|NCT01144078|Experimental|Traditional Intensity Exercise|This arms receives the Traditional Intensity Exercise intervention
11530017|NCT01144065||Patient with acute MI|Patients with acute MI ( elevated cardiac enzymes + chest pain or typical ECG changes)admitted to the cardiology department at Meir Medical Center
11530018|NCT01144065||Patient with prior cardiovascular disease and/or diabetes|These patients do not have acute coronary syndrome or stroke. Prior cardiovascular disease (CVD) is defined as a history of hospital admission due to acute coronary artery occlusion, percutaneous coronary interventions (PCI), coronary artery bypass grafting, any aortic or peripheral vascular disease that was either symptomatic or required intervention, ischemic or hemorrhagic stroke or transient ischemic attack.
11530019|NCT01144065||Patients without prior cardiovascular disease or diabetes|These patients do not have acute coronary syndrome or stroke Prior cardiovascular disease (CVD) or diabetes
11530020|NCT01144052|Active Comparator|Natalizumab|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.
11530021|NCT01144052|Experimental|Interferon-beta-1b|250 mcg (8 MIU) subcutaneous injections every other day
11530022|NCT01144026|Experimental|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
11530023|NCT01144026|Experimental|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
11530024|NCT01144000|Experimental|Daptomycin|High dose Daptomycin in hip, knee and shoulder prosthesis infections
11530025|NCT01143987|Experimental|Cinacalcet|Oral cinacalcet
11530026|NCT01143974|Experimental|PC Regimen|
11530027|NCT01143961|Experimental|NBL with one-way valve|NBL performed with one-way valve in ventilator circuit during procedure
11530028|NCT01143961|No Intervention|Standard NBL|Performance of standard NBL with recording of changes in regional ventilation by electrical impedance tomography
11530029|NCT01143948|Active Comparator|15 patient sliding scale regular insulin|
11530030|NCT01143948|Active Comparator|15 patient BBI NPH plus regular insulin|
11530031|NCT01143948|Active Comparator|15 patients BBI Glargine plus Glulisine|
11530032|NCT01143935||Live patients|All patients undergoing CT scans of the abdomen for non hepatobiliary conditions
11530033|NCT01143935||Autopsy cases|All autopsy cases with no liver disease or trauma.
11530034|NCT01143922||Patients with gastrointestinal tract malignancies|All patients with GI tract malignancies undergoing surgery will be subjected to intraoperative ultrasound
11530035|NCT01143909|Experimental|No FFP transfusion prior to intervention|Patients with a coagulopathy (INR 1,5-3,0), who are randomized to omitting transfusion of fresh frozen plasma before they undergo an intervention.
11530036|NCT01143909|No Intervention|FFP transfusion prior to intervention|Patients with a coagulopathy (INR 1,5-3,0), who are randomized to transfusion of fresh frozen plasma before they undergo an intervention. This is considered standard care.
11530037|NCT01143896|Experimental|Arm 1: Depression Collaborative Care|Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
11530038|NCT01143896|No Intervention|Arm 2: Usual Care|Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.
11530039|NCT01143883|Experimental|Silverlon Dressing|The Silverlon(Cura Surgical, Geneva, IL) dressing is applied to the surgical wound postoperatively. This dressing is coated with silver nylon.
11530040|NCT01143883|Active Comparator|Standard of Care Dressing|The standard plain gauze is used to dress the wound postoperatively
11530045|NCT01143857|Placebo Comparator|Placebo|
11530046|NCT01143844||Exposed females, ages 11-40|"Prior exposure to alkylating agent chemotherapy and/or radiation therapy
~At least 1 year from completion of chemotherapy and/or radiation therapy
~Uterus and at least one ovary are present
~Not pregnant or breastfeeding in the past 3 months
~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits
~No medical condition (other than cancer) known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
11530047|NCT01143844||Unexposed females, ages 40-50|"Never exposed to chemotherapy or radiation therapy
~Regular menstrual cycle (every 21-35 days)
~Uterus and at least one ovary are present
~Not pregnant or breastfeeding in the past 3 months
~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits
~No medical condition known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
11530048|NCT01143844||Unexposed females, ages 11-35|"Never exposed to chemotherapy or radiation therapy
~Regular menstrual cycle (every 21-35 days)
~Uterus and at least one ovary are present
~Not pregnant or breastfeeding in the past 3 months
~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits
~No medical condition known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
11530049|NCT01143831|Experimental|All study participants|Three blood collections, one at baseline, one two weeks later, and the final blood collection 4 weeks from baseline, after taking Vitamin K orally for 14 days.
11530050|NCT01143818||AndroGel (testosterone gel )1%|AndroGel is topical testosterone gel 1% (1 sachet of 5 g contains 50 mg of testosterone), 1 daily dose.
11530051|NCT01143805|Experimental|Treatment A: Tasocitinib 10 mg oral tablet|
11530052|NCT01143805|Experimental|Treatment B: Tasocitinib 10 mg IV Infusion|
11530053|NCT01143792|Experimental|CRA + HIV prevention|
11530054|NCT01143792|Active Comparator|Case Management + HIV prevention|
11530055|NCT01143792|Active Comparator|MET + HIV prevention|
11530056|NCT01143779|Experimental|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
11530057|NCT01143766|Active Comparator|Standard sedation|Patients will receive combination opiate and benzodiazepine for sedation, the current standard of care.
11530058|NCT01143766|Active Comparator|Gapabentin|Patients will receive gabapentin 900mg PO x 1 dose, one hour prior to the procedure. At the time of ERCP, patients will be sedated in a standard fashion.
11530059|NCT01143753|Experimental|RO5212054: Continuous Dosing Cohort|Participants will receive RO5212054 in escalating dose levels.
11530060|NCT01143753|Experimental|RO5212054: New Formulation (F05) Bridging Cohort|Participants will receive RO5212054 as a single dose of new formulation (F05-150 mg film-coated tablet with different ratios of ingredients than F03 to increase bioavailability) and a single dose of current clinical Formulation (F03-150 mg film-coated tablet) in a cross-over manner. Participants will be alternately assigned to receive either F05 or F03 as their first dose, followed by the opposite Formulation as their second dose. Dose of RO5212054 will be decided based on the results of continuous dosing cohort.
11530061|NCT01143740|Experimental|Single Arm|
11530062|NCT01143727|Active Comparator|A|Santyl
11530063|NCT01143727|Active Comparator|B|Tegaderm Hydrogel
11530064|NCT01143714|Active Comparator|A|
11530065|NCT01143714|Placebo Comparator|B|
11530066|NCT01143701|Experimental|ADHD Collaborative Intervention|The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the American Academy of Pediatrics consensus recommendation for evidence-based ADHD care.
11530067|NCT01143701|No Intervention|Typical ADHD care|Physicians in this group will provide typical ADHD care.
11530068|NCT01143688|Active Comparator|albuterol inhaler|albuterol
11530069|NCT01143688|Placebo Comparator|placebo inhaler|placebo
11530070|NCT01143688|Placebo Comparator|placebo acupuncture|placebo
11530071|NCT01143662|Experimental|Group 1|Ypeginterferon alfa-2b 90mcg per week
11530072|NCT01143662|Experimental|Group 2|Ypeginterferon alfa-2b 135mcg per week
11530073|NCT01143662|Experimental|Group 3|Ypeginterferon alfa-2b 180mcg per week
11530074|NCT01143662|Active Comparator|Group 4|Pegasys 180mcg per week
11530075|NCT01143649|Experimental|active tDCS + CIMT - stroke patients|Participants will receive 5 sessions of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT - 10 consecutive sessions Monday- Friday).
11530076|NCT01143649|Experimental|active tDCS + CIMT - Healthy|Participants will receive one session of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT)
11530077|NCT01143649|Experimental|tACS - Healthy Subjects|The investigators will have 40 healthy subjects who will undergo one session of treatment with active tACS (in which the order in which they receive either sham or active transcranial alternating current stimulation (tACS) stimulation will be randomized).
11530078|NCT01143649|Sham Comparator|sham tDCS + CIMT - stroke patients|Participants will receive 5 sessions of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT - 10 consecutive sessions Monday- Friday). For the sham session, tDCS is turned off after 30seconds.
11530079|NCT01143649|Sham Comparator|sham tDCS + CIMT - Healthy|Participants will receive one session of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT). The sham stimulation consists of 30 seconds of stimulation at the beginning of the 40 min of treatment.
11530080|NCT01143649|Sham Comparator|sham tACS - Healthy Subjects|The investigators will have 40 healthy subjects who will undergo one day of treatment with sham tACS. All participants received active and sham stimulation in a randomized order.
11530302|NCT01142115|Active Comparator|control|SpeediCath coated catheter
11530081|NCT01143636|Sham Comparator|Active tDCS - pelvic pain patients|ACTIVE tDCS: Subjects will receive a total of 10 consecutive sessions of active tDCS over a two-week period (administered Monday - Friday). During each session, the anode electrode will be placed over the primary motor cortex of the predominantly painful side.
11530082|NCT01143636|Experimental|Sham tDCS - pelvic pain patients|SHAM tDCS: Subjects will receive a total of 10 consecutive sessions of sham tDCS over a two-week period (administered Mon-Fri). During each session, the anode will be placed over the primary motor cortex of the predominantly painful side.
11530083|NCT01143636|Experimental|Active tDCS - healthy|The healthy controls will undergo one day of treatment with active tDCS. All participants will receive both active and sham stimulation in a randomized order.
11530084|NCT01143636|Experimental|Sham tDCS - healthy|The healthy controls will undergo one day of treatment with sham tDCS. All participants will receive both active and sham stimulation in a randomized order.
11530085|NCT01143623|Active Comparator|Probiotic|
11530086|NCT01143623|Active Comparator|Probiotic-2|
11530087|NCT01143623|Placebo Comparator|Placebo|
11530088|NCT01143610|Experimental|Newly forming bone|Miller class I or II deep recessions treated by the newly forming bone technique.
11530089|NCT01143610|Active Comparator|Subepithelial connective tissue graft|Miller class I or II deep recessions treated by subepithelial connective tissue graft.
11530090|NCT01143597|Active Comparator|Somatosensory stimulation (SS)|Participants in the SS group receive median nerve electrical stimulation applied to the skin of the wrists.
11530091|NCT01143597|Active Comparator|Massed practice + somatosensory stimulation (MP+SS)|Participants in the MP+SS group receive a combined intervention consisting of SS and a skill-based exercise protocol
11530092|NCT01143597|Active Comparator|Conventional resistance training (CRT)|Participants in the CRT group will participate in a weight-based exercise program
11530093|NCT01143584|Experimental|Rapid escalation|Weekly escalation of cabergoline dose in macroprolactinomas Start with 1 mg/week. increase by 1mg/wk every week till 4 weeks. after 4 weeks Cabergoline dose would be increased @1mg/wk every 4 weekly till normalization of prolactin and >50% decrease in tumor volume from baseline.
11530094|NCT01143584|Active Comparator|Conventional escalation|"Conventional escalation of cabergoline
~In the Conventional escalation group schedule of cabergoline dosing will be 0.5 mg once a week for 4 weeks. Cabergoline will be incrementally dose adjusted on the basis of individual Prolactin values till amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or till primary endpoint."
11530095|NCT01143558|Experimental|1|All cohorts undergo the same intervention with the study device.
11530096|NCT01143545|Experimental|1|Allogeneic tumor cell vaccine + chemotherapy
11530097|NCT01143532||1|Kidney transplant recipient of black African descent.
11530098|NCT01143532||2|Kidney transplant donor of black African descent.
11530099|NCT01143519||FLT1 C-677T|SNP
11530100|NCT01143519||MDM2 rs2279744|SNP
11530101|NCT01143519||p53 rs1042522|SNP
11530102|NCT01143519||RMM1 rs1465952|SNP
11530103|NCT01143519||TLR8 rs3761624|SNP
11530104|NCT01143493||Carrier - Other|
11530105|NCT01143493||Carrier hGR N363S Heterozygote|
11530106|NCT01143493||Carrier hGR N363S Homozygote|
11530107|NCT01143493||Carrier hGR9B A3669G Heterozygote|
11530108|NCT01143493||Carrier hGR9B A3669G Homozygote|
11530109|NCT01143493||Control|
11530110|NCT01143480||ABCA1|SNP or allele of interest
11530111|NCT01143480||APOE|SNP or allele of interest
11530112|NCT01143480||APOL1|SNP or allele of interest
11530113|NCT01143480||CD14|SNP or allele of interest
11530114|NCT01143480||CD44|SNP or allele of interest
11530115|NCT01143480||IRGM|SNP or allele of interest
11530116|NCT01143480||ITIH3|SNP or allele of interest
11530117|NCT01143480||ITIH4|SNP or allele of interest
11530118|NCT01143480||MyD88|SNP or allele of interest
11530119|NCT01143480||TIRAP|SNP or allele of interest
11530120|NCT01143480||TLR4|SNP or allele of interest
11530121|NCT01143480||TLR5|SNP or allele of interest
11530122|NCT01143480||TNFa|SNP or allele of interest
11530123|NCT01143454||1. Adult index cases and relatives|Enrolled with a known or suspected pathology that may be associated w/cardiovascular dysfunction or risk w/suspected atypical presentation, heritable disorder, or genetic predisposition.
11530124|NCT01143454||2. Child index case and child relatives|Children over 1 years of age who is affected with diseases/disorders (index cases), or who is a relative of a person who is affected with diseases/disorders.
11530125|NCT01143454||3. Healthy adult volunteers|Healthy adult volunteers must be 18 years of age or older, and must agree to have blood or tissue samples studied, and potentially stored for future research.
11530126|NCT01143441|Experimental|Cohort A|Long-Term daclizumab cohort
11530127|NCT01143441|Experimental|Cohort B|New Treatment Cohort
11530128|NCT01143441|No Intervention|Cohort C|MS Controls
11530129|NCT01143402|Experimental|Arm I (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who are unable to be treated with temozolomide may be treated with dacarbazine IV every 3 weeks (with approval from the Principal Investigator). Patients who experience disease progression may crossover to arm II.
11530130|NCT01143402|Experimental|Arm II (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11530131|NCT01143389|Active Comparator|Riboflavin 0.1% eyedrops every 5 minutes|The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 5 minutes for this arm).
11530132|NCT01143389|Active Comparator|Riboflavin 0.1% eyedrops every 2 minutes|The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 2 minutes for this arm).
11530133|NCT01143376|Active Comparator|Moderate intensity exercise|Moderate intensity exercise
11530134|NCT01143376|Experimental|High Intensity training|High Intensity intermittent training
11530135|NCT01143376|Experimental|Short springs|short springs training
11530136|NCT01143363|Placebo Comparator|Resting - control|No exercise
11530137|NCT01143363|Experimental|Moderate intensity exercise|Moderate intensity exercise (continuous) 1h after breakfast
11530138|NCT01143363|Experimental|High intensity intermittent training|High intensity intermittent training 1h after breakfast
11530139|NCT01143363|Experimental|Short sprint|Short sprint 1h after breakfast
11530140|NCT01143350|Experimental|EHPAD Training and Stimulation|"EHPAD of the group of Training / Stimulation will benefit:
~after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.
~of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD."
11530141|NCT01143350|Placebo Comparator|2- EHPAD control|EHPAD of the reference group, will have their habitual functioning
11530142|NCT01143337|Experimental|1|dose1
11530143|NCT01143337|Placebo Comparator|2|Placebo
11530144|NCT01143324||MAST™ procedure|
11530145|NCT01143311|Other|ARM A|"4 distinct biopsies will be taken
~in a non UV-exposed area (inner arm)
~in a UV-exposed area (external surface of the forearm)
~in a pretumoral region (actinic keratosis)
~inside the tumor"
11530146|NCT01143298|Experimental|LEO 27847 oral solution 0.1 mg|LEO 27847 oral solution 0.1 mg
11530147|NCT01143298|Experimental|LEO 27847 tablet 0.10 mg|LEO 27847 tablet 0.10 mg
11530148|NCT01143298|Experimental|LEO 27847 tablet 0.01 mg|LEO 27847 tablet 0.01 mg
11530149|NCT01143285|Experimental|I - Early and active nutritional support.|During the initial consultation, the dietician will answer the questions of the patient and their family. Patients will be seen regularly in follow-up for weight measurement, serum albumin assay, a 1 or 3 day food record and an evaluation of appetite level. Nutritional counselling is then adjusted accordingly and:Balanced meals are continued if weight is stable and appetite is undiminished.Protein and energy fortification is recommended if weight loss is observed or if food intake decreases between 2 consultations leading to total food intake of less than 50% of required food intake. When a patient presents with signs of malnutrition according to the criteria set out by the Authority for Health, oral nutritional support (ONS) is set up, in agreement with the department head. Two 200ml bottles of Fortimel Extra are to be taken every day. If this ONS strategy is insufficient to improve the patient's nutritional status, artificial nutrition should be discussed.
11530150|NCT01143285|No Intervention|II - No nutritional support|Should malnutrition develop in a group II patient, ONS will be ordered. It will consist of two 200ml Fortimel Extra* bottles per day in addition to regular meals. Ideally, the ONS should be taken as a snack outside of meal times so as to not spoil the appetite. If this ONS is insufficient to improve the nutritional status of the patient, artificial nutrition (either enteral or parenteral) will be discussed.
11530151|NCT01143272|Active Comparator|Saccharomyces boulardii|Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
11530152|NCT01143272|Placebo Comparator|Microcristallin cellulose|Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
11530153|NCT01143259|Placebo Comparator|300 mg Polyethylene|
11530154|NCT01143259|Active Comparator|Alvimopan|
11530155|NCT01143246|Experimental|Terlipressin|intravenous terlipressin (1 mg) every 6 hours with concomitant albumin
11530156|NCT01143246|Placebo Comparator|Placebo|lyophilized mannitol
11530157|NCT01143233|Active Comparator|control formula group|infants are fed a commercial, hydrolysed formula during the first 4 month of life, according to protocol
11530158|NCT01143233|Experimental|intervention formula 1 group|infants are fed hydrolyzed infant formula with different protein content during the first 4 month of life, according to protocol
11530159|NCT01143233|Experimental|intervention formula 2 group|infants are fed hydrolyzed infant formula with different protein content with pro- and prebiotics during the first 4 month of life, according to protocol
11530160|NCT01143233|Experimental|intervention formula 3 group|infants are fed hydrolyzed instant formula with different protein content with pro- and prebiotics during the first 4 months of life, according to protocol
11530161|NCT01143233|No Intervention|Reference group|infants are breast fed
11530162|NCT01143220||ICD / CRT-D patient|Patients implanted with a single or dual chamber ICD or CRT-D device approved in Japan capable of using the IBP feature.
11530163|NCT01143207|Experimental|Medroxyprogesterone acetate|Single injection of Medroxyprogesterone acetate (hormonal contraceptive)
11530164|NCT01143194|Experimental|oréVida™ 60mg/day|
11530165|NCT01143194|Experimental|oréVida™ 120mg/day (1)|
11530166|NCT01143194|Experimental|oréVida™ 120mg/day (2)|
11530167|NCT01143194|Placebo Comparator|Placebo|
11530168|NCT01143181|Experimental|CMX001|CMX001 administered orally twice weekly
11530169|NCT01143142|Experimental|Tailoring|Individuals assigned to the experimental group will receive a two-page brochure tailored based on their responses to the survey.
11530170|NCT01143142|Active Comparator|Untailored information|Individuals assigned to the control group will receive the CDC vaccine information sheet that is standardly provided.
11530171|NCT01143129|Experimental|dexamethasone|Single dose of dexamethasone (1 mg/kg) at the start of the cardiac surgical procedure
11530172|NCT01143129|Placebo Comparator|Placebo|
11530173|NCT01143103|Experimental|Respiratory therapy with cough assist|
11530174|NCT01143103|Active Comparator|Usual respiratory therapy|
11530175|NCT01143090|Experimental|Open Label|Subjects will continue on treatment with the same dose of lurasidone flexible dosing - 40 mg to 12 mg once daily taken orallay at endpoint of the D1050289 ( NCT01143077) core study.
11530176|NCT01143077|Experimental|Lurasidone Open-Label Arm A|
11530177|NCT01143077|Experimental|Lurasidone Open-Label Arm B|
11530178|NCT01143077|Experimental|Lurasidone Open-Label Arm C|
11530179|NCT01143064|Active Comparator|Progesterone|
11530180|NCT01143064|Placebo Comparator|Lipid emulsion without progestrone|
11530181|NCT01143051|Active Comparator|Treatment C|Active comparator arm utilizing marketed Primatene Mist with CFC propellant at the labeled dose.
11530182|NCT01143051|Experimental|Treatment 1|T1 is HFA propelled epinephrine inhalation aerosol 125 mcg/inhalation
11530183|NCT01143051|Experimental|Treatment 2|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation
11530184|NCT01143038|Experimental|Romiplostim|Participants received romiplostim administered weekly by subcutaneous injection during the 12-month treatment period. The starting dose was 1 μg/kg with weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L.
11530185|NCT01143025|Active Comparator|Ropivacaine 50 mg|Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity
11530186|NCT01143025|Experimental|Ropivacaine 100 mg|Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity
11530187|NCT01143025|Experimental|Ropivacaine 150 mg|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
11530188|NCT01143012|Active Comparator|Group eczema education session|One group will attend a group eczema education session. All subjects will answer quality of life questions two times.
11530189|NCT01143012|Active Comparator|Control group|The other group will not attend the group eczema education session. Both groups will be asked quality of life questions two times.
11530190|NCT01142999|Active Comparator|Intervention (moisturizer group)|One group will be instructed to use a choice of 3 FDA-approved moisturizers and soap substitutes on their newborn infants.
11530191|NCT01142999|Active Comparator|Control group (no moisturizers)|This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.
11530192|NCT01142986|Experimental|Low Threshold Stepped Care (LTSC)|Subjects in this condition will receive low intensity care during the first 3-months (13 weeks) of study participation, and usual counseling care during the final 3-months (13 weeks) of participation.
11530193|NCT01142986|Experimental|Voucher-Based Stepped Care (VBSC)|Subjects in this condition will receive usual counseling care during the entire 6 months of study participation. They will receive voucher reinforcement, and will have the opportunity to earn voucher incentives during the first 3-months of care (13 weeks).
11530194|NCT01142986|No Intervention|Routine Stepped-Care (RSC)|Subjects in this condition will receive usual counseling care during the entire 6-month study (26 weeks).
11530195|NCT01142960|Active Comparator|Placebo|Starch
11530196|NCT01142960|Experimental|Lycium Barbarum|Lycium Barbarum supplement
11530197|NCT01142947|Other|beclomethasone dipropionate (BD)|Patients who meet eligibility criteria will be treated with 6 weeks of beclomethasone dipropionate to assess change in pulmonary function and asthma control. These change will be used as phenotypes in a genetic association study. There is no placebo group.
11530198|NCT01142934|Other|TegaDerm CHG|TegaDerm CHG is the interventional arm to be compared with the control group in which the dressing is TegaDerm (without CHG).
11530199|NCT01142921|Active Comparator|Ordinary Tannenbaum biliary stent|Ordinary Tannenbaum biliary stent
11530200|NCT01142921|Experimental|Anti-reflux Tannenbaum biliary stent|Anti-reflux Tannenbaum biliary stent
11530201|NCT01142908|Experimental|Arm 1|The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
11530202|NCT01142908|No Intervention|Arm 2|The education control group - these participants will receive educational material about CVD reduction.
11530203|NCT01142882|Active Comparator|Traditional Prevention|educator-delivered, small-group HIV & disease prevention education
11530204|NCT01142882|Experimental|Web-based Prevention|self-directed, interactive & customized web-based HIV & disease prevention education
11530205|NCT01142817||HIV Postive Women|Women living with HIV who meet study eligibility criteria
11530206|NCT01142817||Healthy Control Subjects|Women without HIV who meet study eligibility criteria
11530207|NCT01142804|Experimental|Enhanced Usual Care Group|Participants received weekly emailed tips of the week to provide support for walking.
11530208|NCT01142804|Experimental|WalkLink Group|Participants received weekly emailed tips of the week, plus evidence-based online fitness walking program.
11530209|NCT01142804|Experimental|WalkLink+ Group|Participants received weekly emailed tips, plus evidence-based online fitness walking program, plus online/in-person social network intervention.
11530210|NCT01142791|Other|ExAblate treatment|
11530211|NCT01142778|Experimental|Trastuzumab, Docetaxel, and Bevacizumab|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of <70% will receive trastuzumab and docetaxel along with bevacizumab in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the bevacizumab infusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
11530212|NCT01142778|Active Comparator|Trastuzumab and Docetaxel|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of <70% will receive trastuzumab and docetaxel in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the study treatment perfusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
11530213|NCT01142778|Active Comparator|Trastuzumab and Docetaxel (Standard Regimen)|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of >/=70% will receive trastuzumab and docetaxel in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the study treatment perfusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
11530214|NCT01142765|Experimental|Group 1|1 dose of AdCh63 MSP1 and 1 dose MVA MSP1 followed by sporozoite challenge
11530215|NCT01142765|Experimental|Group 2|1 dose of AdCh63 AMA1 and 1 dose MVA AMA1 followed by sporozoite challenge
11530216|NCT01142765|Experimental|Group 3|1 dose of AdCh63 AMA1 and 1 dose AdCh63 MSP1 co-administered into separate arms followed by 1 dose of MVA AMA1 and 1 dose MVA MSP1 co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge
11530303|NCT01142102|Experimental|Arm 1|Radiation Therapy
11530217|NCT01142765|Experimental|Group 4|1 dose of AdCh63 MSP1 and 1 dose AdCh63 ME-TRAP co-administered into separate arms followed by 1 dose of MVA MSP1 and 1 dose MVA ME-TRAP co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge
11530218|NCT01142765|Other|Group 5|Non-vaccinated controls for sporozoite challenge
11530219|NCT01142752||Control|Control group of women with uneventful pregnancy
11530220|NCT01142752||Population at risk with preterm birth|Women medically considered at risk for PTB and actually delivering preterm
11530221|NCT01142752||Population at risk without preterm birth|Women medically considered at risk for PTB but with uneventful pregnancy
11530222|NCT01142739||Parkinson's Disease patient|levodopa-treated parkinson's disease (PD) patients
11530223|NCT01142739||Non Parkinson's disease controls|Non Parkinson's disease controls
11530224|NCT01142726|Active Comparator|Abatacept, 125 mg, plus methotrexate, 2.5 mg|Participants received abatacept, 125 mg subcutaneously, plus methotrexate, 2.5 mg orally as tablets, once weekly, during the 12-month Treatment Period
11530225|NCT01142726|Active Comparator|Methotrexate, 2.5 mg, plus abatacept placebo|Participants received methotrexate, 2.5 mg, orally as tablets, plus abatacept placebo subcutaneously, once weekly during the 12-month Treatment Period
11530226|NCT01142726|Active Comparator|Abatacept, 125 mg, plus methotrexate placebo|Participants received abatacept, 125 mg subcutaneously, plus methotrexate placebo tablets orally, once weekly during the 12-month Treatment Period
11530227|NCT01142700|Experimental|BMS-824393 (10mg)|"Plus Peginterferon Alfa-2a and Ribavirin
~Day 1 - Week 12"
11530228|NCT01142700|Experimental|BMS-824393 (30 mg)|"Plus Peginterferon Alfa-2a and Ribavirin
~Day 1 - Week 12"
11530229|NCT01142700|Experimental|BMS-824393 (100 mg)|"Plus Peginterferon Alfa-2a and Ribavirin
~Day 1 - Week 12"
11530230|NCT01142700|Placebo Comparator|Placebo|"Plus Peginterferon Alfa-2a and Ribavirin
~Day 1 - Week 12"
11530231|NCT01142700|Other|Peginterferon alfa-2a plus Ribavirin|Weeks 13 - 48
11530232|NCT01142687|Active Comparator|dihydrocapsiate 3 mg|• Group 1: 1 Dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner
11530233|NCT01142687|Active Comparator|dihydrocapsiate 9 mg|• Group 2: 3 Dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner
11530234|NCT01142687|Placebo Comparator|Placebo capsule|• Group 3: 3 placebo capsules three times per day within 30 minutes before breakfast, lunch and dinner
11530235|NCT01142661|Experimental|Eribulin mesylate|
11530236|NCT01142622|Experimental|Ropivacaine nebulization|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
11530237|NCT01142622|Active Comparator|Ropivacaine instillation|Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity before surgery
11530238|NCT01142609|Experimental|Internet (eGetgoing)|Subjects will assigned to use an accredited web-based platform (eGetgoingTM, CRC Health Group, Inc.) to deliver routine substance abuse counseling.
11530239|NCT01142609|No Intervention|Routine on-site|Subjects will attend routine face-to-face individual counseling sessions.
11530240|NCT01142596|Experimental|Asenapine 5 mg BID|Participants continue in the same arm they were on in core trial P06124 (except placebo arm starts 5 mg BID at Week 2) and will be re-randomized after Week 6 to asenapine 5 mg BID or asenapine 10 mg BID, administered open-label for 46 weeks. Open label dose can be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
11530241|NCT01142596|Experimental|Asenapine 10 mg BID|Participants continue in the same arm they were on in core trial P06124 (except placebo arm starts 5 mg bid at Week 2) and will be re-randomized after Week 6 to asenapine 5 mg BID or asenapine 10 mg BID, administered open-label for 46 weeks. Open label dose can be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
11530242|NCT01142570|Active Comparator|Group 1|Patients will be receive caloric support as dictated by Hariss-Benedict Formula (Group 1)
11530243|NCT01142570|Active Comparator|Group 2|Patients will be receive caloric support as dictated by Indirect Calorimetry (Group 2)
11530244|NCT01142570|Active Comparator|Group 1A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.
~Patients in the first(Group 1A)group will receive caloric support calculated by the HARISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight."
11530245|NCT01142570|Active Comparator|Group 2A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.
~Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight."
11530246|NCT01142570|Active Comparator|Group 3A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.
~Patients in the third group will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight."
11530247|NCT01142544||Pediatric ALIEN|All children from 1 month to 18 years old meeting the American-European Consensus Conference definition of acute lung injury
11530248|NCT01142531||COPD|COPD patients aged 40 or more, with a smoking history of > 10 PY and a post-bronchodilator FEV1/VC < 0.7 will be included. Exclusion criteria are: COPD exacerbation or respiratory infection in the 4 weeks before the begin of the study, concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active malignancy or malignancy of any organ system within the past 5y.
11530249|NCT01142505|Placebo Comparator|Placebo|Patients in the placebo arm will be given an inactive version of the investigational medical product formed of the excipient mannitol (which is coated with the active drug montelukast in the active comparator arm)
11530250|NCT01142505|Active Comparator|Montelukast|Patients in the active arm will be given an active version of the investigational medical product formed of the inactive excipient mannitol with a coating of active drug montelukast.
11530251|NCT01142479|Placebo Comparator|herbal A|dilute of (TPE-1) decoction.
11530252|NCT01142479|Experimental|herbal B|TPE-1 decoction (100 ml)
11530253|NCT01142466|Experimental|Rebif (3x44 mcg) Group|
11530254|NCT01142466|No Intervention|No treatment Group|
11530255|NCT01142440|Experimental|behavioral intervention|
11530256|NCT01142440|No Intervention|convention dental treatment|
11530257|NCT01142427||Ancillary-Correlative (classification)|Patients undergo blood sample collection and bone marrow biopsies at baseline and during and after induction therapy for immunophenotyping for ALL confirmation and classification, DNA ploidy, genomic variation, and cytogenetic (BCR-ABL, trisomies 4+10, and molecular testing for translocations) analysis by flow cytometry and FISH. Immunophenotype results obtained on this study are used to determine patient's assignment to specific clinical-trial treatments. Some samples (leukemic and germline) may be banked for current and/or future analyses.
11530258|NCT01142401|Experimental|Arm A (fulvestrant)|Patients receive fulvestrant IM on day 1 (days -14, 1, and 15 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may crossover to arm C.
11530259|NCT01142401|Experimental|Arm B (fulvestrant, bortezomib)|Patients receive fulvestrant as in arm A and bortezomib IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11530260|NCT01142401|Experimental|Arm C (fulvestrant, bortezomib)|Patients receive fulvestrant IV on day 1 and bortezomib IM on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11530261|NCT01142388|Experimental|Arm I (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
11530262|NCT01142388|Experimental|Arm II (cixutumumab, paclitaxel)|Patients receive cixutumumab IV over 1 hour on days 1 and 15, and paclitaxel as in Arm I.
11530263|NCT01142362|Experimental|0.6mg of DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 0.6 mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
11530264|NCT01142362|Experimental|2mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 2mg of DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
11530265|NCT01142362|Experimental|6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 6 mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
11530266|NCT01142349|Experimental|Lifestyles A|Cognitive Behavioral Therapy for Pain and Insomnia
11530267|NCT01142349|Experimental|Lifestyle B|Cognitive Behavioral Therapy for Pain
11530268|NCT01142349|Active Comparator|Lifestyles C|Osteoarthritis Education
11530269|NCT01142336|Experimental|Simvastatin|Simvastatin 40mg qHS for 1 year
11530270|NCT01142336|Placebo Comparator|Placebo|Placebo 1 tablet qHS for 1 year
11530271|NCT01142323|Experimental|Fenofibrate|fenofibrate 160 mg po daily
11530272|NCT01142310|Active Comparator|Lamotrigine|Dose titration: begin at Baseline at 25mg PO QD for two weeks. Increase to 50mg PO QD at Week 2 for two weeks. Increase to 100mg PO QD at Week 4. Increase to 150mg PO QD at Week 5. Increase to 200mg PO QD at Week 6. Increase to 250mg PO QD at Week 7. Increase to 300mg PO QD at Week 8. Increase to 350mg PO QD at Week 9. Increase to 400mg PO QD at Week 10. Stay at 400mg PO QD from Week 10 to Week 48.
11530273|NCT01142310|Placebo Comparator|Placebo|Placebo administered the same as the Lamotrigine just described.
11530274|NCT01142297|Other|dental implant|standard SLA surface and chemically modified surface
11530275|NCT01142284|Placebo Comparator|Placebo|Placebo
11530276|NCT01142284|Experimental|Cilostazol|cilostazol
11530277|NCT01142284|Experimental|Probucol|probucol
11530278|NCT01142284|Experimental|Cilostazol + Probucol|cilostazol and probucol
11530279|NCT01142271|Experimental|Billroth-I|Patients in this group should be underwent gastroduodenostomy as reconstruction procedure after standard distal subtotal gastrectomy with lymph node dissection.
11530280|NCT01142271|Experimental|Roux en Y|Patients in this group should be underwent jejunojejunostomy and gastrojejunostomy as reconstruction procedure after standard distal gastrectomy.
11530281|NCT01142258|Experimental|Trazodone|Study group will receive trazodone 50mg
11530282|NCT01142258|Placebo Comparator|Placebo|Inert pill
11530283|NCT01142245|Active Comparator|oral esomeprazole|"Esomeprazole placebo IV loading bolus
~Esomeprazole placebo intravenous infusion for 72 hours
~Oral Esomeprazole: 80 mg/Day on Day 1, 2 and Day 3, and the drug will be given as 40 mg q12h."
11530284|NCT01142245|Active Comparator|Intravenous Esomeprazole|"Esomeprazole IV loading bolus 80mg
~• Esomeprazole intravenous infusion 8mg/hr for 72 hours"
11530285|NCT01142232|Experimental|Melphalan with lenalidomide|Melphalan will be given on Day -2 and Day -1. Lenalidomide will be given from Day -7 to Day +2.
11530286|NCT01142219|Experimental|L-arginine|0.1g/kg/day for 6 months
11530287|NCT01142206|Active Comparator|Physical Activity|A standard behavioral weight loss intervention with a physical activity prescription of 200 minutes of moderate intensity physical activity per week.
11530288|NCT01142206|Experimental|Physical Activity & TV Watching|A standard behavioral weight loss intervention with a physical activity prescription of 200 minutes of moderate intensity physical activity per week and an additional prescription of reducing TV watching to 10 hours per week or less.
11530289|NCT01142193|Experimental|USL255|
11530290|NCT01142193|Placebo Comparator|Placebo|
11530291|NCT01142180|Active Comparator|TAE group|Patients will be undergone TAE after endoscopic hemostasis.
11530292|NCT01142180|Active Comparator|No TAE group|No TAE procedure will be performed after endoscopic treatment.
11530293|NCT01142167|Active Comparator|Standard Colonoscopy|Colonoscopy with standard instrument
11530294|NCT01142167|Experimental|Ultra-thin colonoscopy|New prototype scope
11530295|NCT01142154|Experimental|oral, liquid solution|
11530296|NCT01142141|Other|Manual therapy, kinesiotherapy|
11530297|NCT01142128|Active Comparator|Nexium alone|Nexium alone is given for one month to be compared to a placebo to Nexium, Viokase 16 plus Nexium and Viokase 16 plus a placebo to Nexium
11530298|NCT01142128|Placebo Comparator|Placebo to Nexium, alone|Placebo to Nexium is given instead of Nexium for one month. This will be compared to the Nexium alone, Viokase 16 plus Nexium and Viokase 16 plus placebo to Nexium
11530299|NCT01142128|Active Comparator|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month.
11530300|NCT01142128|Placebo Comparator|Viokase 16 + placebo to Nexium|Viokase 16 is given with a placebo to Nexium for one month to be compared against Viokase 16 plus Nexium, Nexium alone and Placebo to Nexium alone
11530301|NCT01142115|Experimental|Monza|nonCE marked intermittent catheter
11530304|NCT01142089|Placebo Comparator|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours)
11530305|NCT01142089|Experimental|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
11530306|NCT01142076|Placebo Comparator|placebo|Dose treatment group, 10%
11530307|NCT01142076|Active Comparator|Xinju Xiaogao Prescription|treatment group
11530308|NCT01142063||Treatment A (Reference fasted)|Treatment A (Reference fasted): A 40 mg tablet strength neratinib administered as a single dose of 6 x 40 mg under fasted condition.
11530309|NCT01142063||Treatment B (Test fasted)|Treatment B (Test fasted): A 240 mg tablet strength neratinib administered as a single dose of 1 x 240 mg under fasted condition.
11530310|NCT01142063||Treatment C (Reference fed)|Treatment C (Reference fed): A 40 mg tablet strength neratinib administered as a single dose of 6 x 40 mg under fed condition.
11530311|NCT01142063||Treatment D (Test fed)|Treatment D (Test fed): A 240 mg tablet strength neratinib administered as a single dose of 1 x 240 mg under fed condition.
11530312|NCT01142037|Experimental|Furanocoumarin|Includes participants first refraining from eating foods with furanocoumarins for one week, followed by 2 weeks of increasing furanocoumarin consumption. Participants will be asked to consume cooked parsnips and parsley.
11530313|NCT01142024|Placebo Comparator|saline|saline hydration
11530314|NCT01142024|Experimental|Glutathione|
11530315|NCT01142011|Experimental|Belimumab|"The first cycle of Belimumab is a loading cycle of 3 doses over 28 days (days 1, 15, 29).
~After the first cycle, additional cycles of belimumab will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles)."
11530316|NCT01141998|Placebo Comparator|Placebo|
11530317|NCT01141998|Active Comparator|Vitamin D administered orally|
11530318|NCT01141998|Experimental|Vitamin D administered via UVB|
11530319|NCT01141985|Other|Treated|This is a single arm study.
11530320|NCT01141972|Active Comparator|Supplement|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml [≥75 nmol/L]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency
11530321|NCT01141972|Placebo Comparator|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
11530322|NCT01141933|Other|Usual care|Subjects in this group receive the usual treatment only.
11530323|NCT01141933|Experimental|Individual intervention|Consisting in a 12 weekly sessions with a therapist. Each session lasts 1 hour.
11530324|NCT01141933|Experimental|Group intervention|Consisting in a 12 weekly sessions with two therapists. Number of subjects in each group is from 5 to 10. Each session lasts 2 hours.
11530325|NCT01141920|Active Comparator|3-month counseling induction: routine care|Participants assigned to this condition will receive routine stepped-care treatment at ATS. Participants will begin in Step 2 (one counseling session per week), and be advanced to higher intensity care based on missed counseling sessions and drug-positive urine samples. Participants advanced to Step 3 will be scheduled to attend 2 group counseling sessions per week (in addition to individual counseling), and those advanced to Step 4 will be scheduled to attend 8 group counseling sessions per week (in addition to individual counseling). Time of methadone dosing will be based on step of care.
11530326|NCT01141920|Experimental|3-month counseling induction: low threshold|Participants assigned to this treatment arm will receive low threshold counseling. These participants will be scheduled to attend one counseling session per month with their individual counselor for the first 3-months. Participants can attend more counseling sessions if they desire, and they can meet with program supervisors to address crisis situations. They can receive methadone dosing any time during the clinic hours (7:30 am-1:15 pm and 4:00 pm - 6:00 pm)
11530327|NCT01141907|Experimental|Heart Failure Self Care Support|The goal of the Heart Failure Self Care Support Intervention (Navigator Program), delivered by a nurse and community health navigator team over 3 months post discharge from the index hospitalization, was to improve care transitions by providing patients with tools and support that promote knowledge and skills for HF self care as they transition from hospital to home. The multifaceted Navigator Intervention included the following intervention components: HF home automated telemonitoring support, medication and symptom self management, patient-centered record, HF care follow up, and activation of key supporter.
11530328|NCT01141907|Active Comparator|Usual Heart Failure Care|Usual care for HF patients included the following: 1) Referral to HF clinic if the patient has no usual source of HF outpatient care, 2) HF patient education by HF care coordinator (advanced practice nurse), and 3) HF self care guide. All participants were treated by their usual source of HF care in the usual manner.
11530329|NCT01141894|Active Comparator|Routine fluid treatment|Buffered Glucose 25 mg/ml 1ml/kg/h Ringer's Acetate 2 ml/kg/h and additionally as needed Voluven at the attending anaesthetist's discretion Phenylephrine 50 μg for correction of hypotension
11530330|NCT01141894|Experimental|Goal directed haemodynamic treatment|Goal directed haemodynamic treatment Dobutamine 0.2-10 μg/kg/min Buffered Glucose 25 mg/ml 1ml/kg/h Ringer's Acetate 2 ml/kg/h Voluven 3 ml/kg as fluid challenge at the attending anaesthetist's discretion Phenylephrine 50 μg for correction of hypotension
11530331|NCT01141881|Experimental|TPA,IVB,F/U|
11530332|NCT01141868|Experimental|Internet Intervention|
11530333|NCT01141868|Experimental|Delayed Intervention|Receive access to the online Internet intervention after completing post-assessments.
11530334|NCT01141855|Experimental|Champix plus counselling|varenicline tartrate will be initiated whilst subjects are inpatients with the standard MIMS dosing schedule (including period of titration). In combination with Quit SA (5A) telephone counselling service
11530335|NCT01141855|Active Comparator|counselling alone|5A counselling via Quit SA (quitline) telephone counselling service. (maximum 8 phone calls per subject within a 3 month period).
11530336|NCT01141842|Experimental|lung cancer|breath samples of patients with confirmed lung cancer
11530337|NCT01141842|Active Comparator|underlying lung disease|patients with underlying lung disease and impairment in lung function
11530338|NCT01141842|Sham Comparator|healthy individual|healthy individual with no lung disease and no history of cancer including lung cancer
11530339|NCT01141816|Experimental|Contrast-Enhanced Ultrasound|
11530340|NCT01141803|No Intervention|control|
11530341|NCT01141803|Active Comparator|Apples|
11530342|NCT01141803|Active Comparator|Apple pomace|
11530343|NCT01141790|Placebo Comparator|Silence|"The control group listened silence and was evaluated the same things."
11530344|NCT01141777|Active Comparator|Spirulina platensis|
11530345|NCT01141777|Placebo Comparator|Soya bean|
11530346|NCT01141764|Experimental|Study Group|"In our study, patients will be scanned with their DBS electrodes turned on and off.
~Participation involves undergoing 2 separate PET scans on 2 separate days. The MRI and neuropsychological tests will either be performed on the same day as one of the PET scans or on a separate day.
~Procedures performed in this study are not part of the standard management of epilepsy."
11530347|NCT01141738|Experimental|Caregiver Problem-Solving Intervention|The experimental treatment will provide structured information, guided problem-solving, and training in skills for coping with stress and emotional responses (e.g., relaxation, cognitive reframing, changing negative problem orientation, PS skills).
11530348|NCT01141738|Other|Wait List Control|WLC subjects will be offered an intervention after the 6 month assessment. Both groups will receive standard services provided by the rehabilitation team to CGs of stroke survivors.
11530349|NCT01141725|Experimental|Treatment (combination chemotherapy)|Patients receive bendamustine hydrochloride IV on days 1-5 and idarubicin IV on days 1 and 2. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11530350|NCT01141712|Other|Autologous transplant|Patients will receive BCNU 300 mg/m^2 Day -6, Etoposide 100 mg/m^2 BID Days -5 to -2, Cytarabine 100 mg/m^2 BID Days -5 to -2, and Melphalan 140 mg/m^2 Day -1 followed by autologous HCT.
11530351|NCT01141699||female|Women who live in the Shuang Ho Region of Taipei City. Women can read and write chinese language.
11530352|NCT01141660|Experimental|Endotracheal Tube|Children undergoing adenotonsillectomy are randomized to endotracheal tube or laryngeal mask airway.
11530353|NCT01141660|Experimental|Laryngeal Mask Airway|Children undergoing adenotonsillectomy are randomized to endotracheal tube or laryngeal mask airway.
11530354|NCT01141647|Experimental|24-Month Supported Employment|Evidence-Based Supported Employment Vocational Rehabilitation or Other Vocational Services
11530355|NCT01141608|Experimental|Vigorous Intensity High Dose Exercise|Usual Care Augmented with Vigorous Intensity High Dose Exercise
11530356|NCT01141608|Experimental|Health Education Intervention|Health Education Intervention
11530357|NCT01141595|Experimental|Kuvan®|Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
11530358|NCT01141569|Experimental|Treatment (RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11530359|NCT01141556|Placebo Comparator|Placebo|Placebo (NaCl) i.v. intraoperatively, followed by an daily bolus of Placebo (NaCl) i.v. until discharge from ICU (no longer than 13 days)
11530360|NCT01141556|Active Comparator|Selenase|Selenase Bolus 4000 microgram i.v. intraoperatively, followed by an daily bolus of Selenase 1000 microgram i.v. until discharge from ICU (no longer than 13 days)
11530361|NCT01141543||cohort 1|Patients in Cohort 1 will be followed with daily Flowcytometric studies to quantify CXCR4 positive cells.The samples will be obtained before the following doses of FLUDARABINE and BUSULFAN. Eighteen hrs (range 18 -20 hrs) after start of the last dose of FUDARABINE andBUSULFAN and before the first dose of TBI a PB sample as well as bone marrow aspirate and biopsy will be obtained to repeat the studies as conducted prior to the first dose of PLERIXAFOR
11530362|NCT01141543||Cohort 2|Patients in Cohort 2 will receive the second dose of PLERIXAFOR 24 hrs after the first dose. A PB sample for a CBS and Flowcytometry will be drawn prior to the dose. Nine hrs later a further study sample for Flowcytometry will be obtained prior to administration of the second dose of FLUARABINE and BUSULFAN. Flowcytometric studies will be repeated on day 3 and 4. Eighteen hrs (range 18 - 20 hrs) after start of the last dose of FLUDARABINE and BUSULFAN and before the first dose of TBI a PB sample as well as bone marrow aspirate and biopsy will be obtained to repeat the studies as conducted prior to the first dose of PLERIXAFOR.
11530363|NCT01141543||cohort 3|Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN
11530364|NCT01141543||Cohort 4|Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN
11530365|NCT01141530||Tissue Bank Samples|Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study. All samples studied will be obtained through the UAMS Tissue Bank.
11530366|NCT01141504|Placebo Comparator|Placebo|Oral placebo capsules similar in color and size to the intervention
11530367|NCT01141504|Active Comparator|PeakATP 250|Oral supplement capsules containing 250 mg/day of PeakATP
11530368|NCT01141504|Active Comparator|PeakATP 400|Oral supplement capsules containing 400 mg/day of PeakATP
11530369|NCT01141504|Active Comparator|PeakATP 400 plus proprietary blend|Oral supplement capsules containing 400 mg/day of PeakATP plus a proprietary blend
11530370|NCT01141491|Experimental|Arm A|Vaccine plus OPT-821
11530371|NCT01141491|Active Comparator|Arm B - OPT-821 immunologic adjuvant|Patients will be given 10 injections of OPT-821 alone as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
11530372|NCT01141478|Active Comparator|Proton Beam Radiotherapy plus Sorafenib|A combination of radiation therapy (proton) to kill tumor cells as well as Sorafenib which is a study drug administered to patients to stop tumor growth.
11530373|NCT01141478|Active Comparator|Sorafenib|Sorafenib is an oral pill taken daily to inhibit tumor growth at the cellular level.
11530374|NCT01141465||IPDA FP/SAL DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL DPI at ≥twice the equivalent BDP-equivalent dose
11530460|NCT01140971|Active Comparator|Foley|Foley catheter number 14 or 16 was installed intracervical for no more than 48 hours.
11530375|NCT01141465||IPDA FP/SAL MDI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL MDI at ≥twice the equivalent BDP-equivalent dose
11530376|NCT01141465||IPDI FP/SAL DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL DPI at equivalent BDP-equivalent dose
11530377|NCT01141465||IPDI BUD/FOR DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as BUD/FOR DPI at equivalent BDP-equivalent dose
11530378|NCT01141465||IPDI FP/SAL MDI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL MDI at equivalent BDP-equivalent dose
11530379|NCT01141465||IPDA BUD/FOR DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as BUD/FOR DPI at ≥twice the equivalent BDP-equivalent dose
11530380|NCT01141452||IPDA FP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as fluticasone via metered dose inhaler
11530381|NCT01141452||IPDA HFA-BDP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as extra-fine hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
11530382|NCT01141452||IPDA CFC-BDP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as chlorofluorocarbon beclomethasone dipropionate via metered dose inhaler
11530383|NCT01141452||IPDI CFC-BDP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as chlorofluorocarbon beclomethasone dipropionate via metered dose inhaler
11530384|NCT01141452||IPDI HFA-BDP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
11530385|NCT01141452||IPDI FP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as fluticasone propionate via metered dose inhaler
11530386|NCT01141439||IPDI HFA-BDP MDI|Patients who commenced inhaled corticosteroid therapy as HFA-BDP via MDI
11530387|NCT01141439||IPDI FP MDI|Patients who commenced inhaled corticosteroid therapy as FP via MDI
11530388|NCT01141439||IPDA FP MDI|Patients who had a step up in inhaled corticosteroid therapy as FP via MDI
11530389|NCT01141439||IPDA HFA-BDP MDI|Patients who had a step up in inhaled corticosteroid therapy as HFA-BDP via MDI
11530390|NCT01141439||IPDI CFC-BDP MDI|Patients who commenced inhaled corticosteroid therapy as CFC-BDP via MDI
11530391|NCT01141439||IPDA CFC-BDP MDI|Patients who had a step up in inhaled corticosteroid therapy as CFC-BDP via MDI
11530392|NCT01141426|Active Comparator|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
11530393|NCT01141426|Experimental|Intensive Short-Term Dynamic Psychotherapy (ISTDP) Group|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
11530394|NCT01141413||RA patients using Remicade®|
11530395|NCT01141413||RA patients using Orencia®|
11530396|NCT01141400||depression & initial prescription for an antidepressant|A sample of adults with a diagnosis of depression and an initial prescription fill for an antidepressant
11530397|NCT01141387||Patients at the intervention sites|The intervention sites will receive the results of the patient-reported depression severity collected during the phone interviews on a monthly basis. The patients in the intervention arm will be interviewed by phone once per month for 6 months.
11530398|NCT01141387||Patients at the usual care sites|The usual care sites will receive the results of the patient-reported depression severity at the end of the study. Patients in the usual care arm will be interviewed at 3 months and 6 months post study enrollment.
11530399|NCT01141374|No Intervention|control group without treatment|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
11530400|NCT01141374|Experimental|Auriculotherapy by needles|The investigators used 3 points, Shenmen, Kidney, and Brain Stem with semi-permanent needles of 1.8 mm, 1 time per week for 8 sessions.
11530401|NCT01141374|Experimental|Auriculotherapy by seeds|The investigators used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.
11530402|NCT01141361||Peripheral arterial disease patients|Patients with a peripheral arterial disease, defined by an ankle to brachial index below 0.90
11530403|NCT01141348|Experimental|Special Intervention|
11530404|NCT01141348|Experimental|Delayed Intervention|
11530405|NCT01141335|Experimental|PTFE mesh|A Lichtenstein tension-free hernioplasty is performed using PTFE mesh
11530406|NCT01141335|Active Comparator|polypropylene mesh|A Lichtenstein tension-free hernioplasty is performed using polypropylene mesh
11530461|NCT01140945||Males attending in vitro fertilization clinic|
11530407|NCT01141322|Experimental|UDCA treatment|Patients with drug-induced liver injury will be randomly allocated to UDCA treatment group: oral intake ursodeoxycholic acid (UDCA) 13-15 mg/kg BW/day into 3 divided doses after meal till the endpoint or the 8th week. UDCA is 100 mg per tab.
11530408|NCT01141322|Placebo Comparator|Placebo|Patients with drug-induced liver injury will be randomly allocated to placebo group. The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
11530409|NCT01141309|Experimental|sorafenib with everolimus|This is a two-stage phase II study combining sorafenib with everolimus in patients with thyroid cancer.
11530410|NCT01141296|Active Comparator|Fenofibrate|
11530411|NCT01141296|Placebo Comparator|sugar pill|
11530412|NCT01141283|Experimental|BTDS|Buprenorphine transdermal patch
11530413|NCT01141270|Experimental|AFOLIA|225 IU sc
11530414|NCT01141270|Active Comparator|Gonal-f|225 IU sc
11530415|NCT01141257|Experimental|Angiocal®|Angiocal®
11530416|NCT01141244|Experimental|Treatment (temsirolimus, irinotecan, temozolomide)|Patients receive temsirolimus IV over 30 minutes on days 1 and 8 or on days 1, 8, and 15 and temozolomide PO and irinotecan hydrochloride PO on days 1-5. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
11530417|NCT01141218||Never-smokers with lung cancer|
11530418|NCT01141205|Experimental|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
11530419|NCT01141205|Placebo Comparator|Saline|Saline
11530420|NCT01141192|Active Comparator|Vitamin D3 supplement|60,000 IU vitamin D3 oral supplement provided every four weeks at weeks 0, 4, 8, and 12 in the form of one 50,000 and two 5,000 IU vitamin D3 supplements in gelcap form.
11530421|NCT01141192|Placebo Comparator|Sugar Pill|Inactive placebo tablets identical in appearance to the active comparator provided every four weeks at weeks 0,4,8,and 12.
11530422|NCT01141179|Experimental|LEO 27847|
11530423|NCT01141166|Experimental|nutritional and physical rehabilitation plan|
11530424|NCT01141153|Experimental|Oral anticoagulation plus dual antiplatelet therapy|
11530425|NCT01141153|Active Comparator|Dual antiplatelet therapy|
11530426|NCT01141140|Other|M-NO-NR|Men (M) non-obese (NO) and non-restrained (NR).
11530427|NCT01141140|Other|M-NO-R|Men (M) non-obese (NO) and restrained (R).
11530428|NCT01141140|Other|M-O-NR|Men (M) overweight or obese (O) and non-restrained (NR).
11530429|NCT01141140|Other|M-O-R|Men (M) overweight or obese (O) and restrained (R).
11530430|NCT01141140|Other|W-NO-NR|Women (W) non-obese (NO) and non-restrained (NR).
11530431|NCT01141140|Other|W-NO-R|Women (W) non-obese (NO) and restrained (R).
11530432|NCT01141140|Other|W-O-NR|Women (W) overweight or obese (O) and non-restrained (NR).
11530433|NCT01141140|Other|W-O-R|Women (W) overweight or obese (O) and restrained (R).
11530434|NCT01141127|Active Comparator|INTERMITENT ADMINISTRATION|Administration of 10 mg/kg of Tranexamic Acid at the beginning ,the middle and at the end of the intervention
11530435|NCT01141127|Experimental|continuous administration of Tranexamic Acid|Administration of 10 mg /Kg of Tranexamic Acid at the beginning in the priming pump and continuous infusion of 1 mg/KG of Tranexamic Acid until the end of the intervention
11530436|NCT01141114|Experimental|Use of a Patient Navigator|
11530437|NCT01141114|Other|Usual Care|No Intervention - usual care
11530438|NCT01141101||MRSA-exposed|The MRSA-exposed group will include 100 MRSA-colonized mothers and their babies
11530439|NCT01141101||MRSA-unexposed|The MRSA-unexposed group will include 100 MRSA-negative mothers and their babies.
11530440|NCT01141088|Experimental|Bilateral stent-in-stent insertion|The passage of the bilateral metal stent across the stricture, stent-in-stent method.
11530441|NCT01141088|Active Comparator|Bilateral side-by-side insertion|The passage of the bilateral metal stent across the stricture, side-by-side method.
11530442|NCT01141075|Experimental|Ataluren|"Cycle 1: Ataluren treatment will be taken 3 times per day with meals for 28 days at doses of 5 mg/kg (morning), 5 mg/kg (midday), and 10 mg/kg (evening); there will then be an interval of 21 up to 42 days without treatment.
~Cycle 2: Ataluren treatment will be taken 3 times per day with meals for 28 days at doses of 10 mg/kg (morning), 10 mg/kg (midday), and 20 mg/kg (evening); there will then be an interval of 14 days without treatment."
11530443|NCT01141062|Experimental|Treated leiomyomas|Philips MR-guided HIFU
11530444|NCT01141049|Active Comparator|Gabapentin|Gabapentin will be titrated over a 7-day period to the dose target or the maximum tolerated dose. The maximum dose will be 1200mg TID. Participants must be able to tolerate and comply with at least 400 mg daily.
11530445|NCT01141049|Placebo Comparator|Placebo|Placebo capsules will be administered TID.
11530446|NCT01141036|Active Comparator|propofol|propofol
11530447|NCT01141036|Active Comparator|Midazolam|Midazolam
11530448|NCT01141023|Experimental|Datscan SPECT Imaging|Subjects will b injected with 3-5 mCi of dopamine transporter. Within a 4 hour (+/- 30 minutes) window following the injection, subjects will undergo SPECT imaging on the camera.
11530449|NCT01141010|Sham Comparator|Plain language|Conventional plain language will be given without any psychological intervention
11530450|NCT01141010|Active Comparator|Pre-psycho-language|Prior surgery psychological linguistic intervention
11530451|NCT01141010|Active Comparator|Intra-psycho-language|Intraoperative psychological linguistic intervention
11530452|NCT01141010|Active Comparator|Post-psycho-language|Postoperative psychological linguistic intervention
11530453|NCT01141010|Active Comparator|Combined language|Psychological linguistic intervention will be given in a combination of pre-, intra- and post-operatively
11530454|NCT01140997|Experimental|Group 1|Ypeginterferon alfa-2b 90mcg per Week, with Ribavirin 1000-1200mg/d
11530455|NCT01140997|Experimental|Group 2|Ypeginterferon alfa-2b 135mcg per Week, with Ribavirin 1000-1200mg/d
11530456|NCT01140997|Experimental|Group 3|Ypeginterferon alfa-2b 180mcg per Week, with Ribavirin 1000-1200mg/d
11530457|NCT01140997|Active Comparator|Group 4|Pegasys 180mcg per Week, with Ribavirin 1000-1200mg/d
11530458|NCT01140984|Experimental|treatment|
11530459|NCT01140971|Active Comparator|Misoprostol|Use 25 micrograms vaginal every 6 hours (max dosis 200 micrograms in 48 hours)
11530462|NCT01140932|Experimental|Intervention|Medical and behavioural intervention
11530463|NCT01140906|Placebo Comparator|Placebo|
11530464|NCT01140906|Experimental|Vortioxetine: 15 mg|
11530465|NCT01140906|Experimental|Vortioxetine: 20 mg|
11530466|NCT01140906|Other|Duloxetine: 60 mg|Active Reference
11530467|NCT01140893|Experimental|exenatide|55 subjects
11530468|NCT01140893|Placebo Comparator|Placebo|55 subjects
11530469|NCT01140880|Experimental|Contingency Management|"Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for stimulant metabolites. Increasingly valuable incentives will be provided for urine samples that lack metabolites of stimulant drugs.
~Participants reporting recent (i.e., < 48 hours) exposure to HIV viral inoculum will have the opportunity to initiate Truvada (1 pill daily for 28 days)."
11530470|NCT01140880|Sham Comparator|Yoked Contingency Management|"Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for stimulant metabolites. Incentives will be provided to participants independent of stimulant drug use and determined in the same rate and timing as a randomly selected participant in the active CM condition.
~Participants reporting recent (i.e., < 48 hours) exposure to HIV viral inoculum will have the opportunity to initiate Truvada (1 pill daily for 28 days)."
11530471|NCT01140867|Experimental|1|
11530472|NCT01140854||Hypertension (case)|Elderly patients 60 years old or older undergoing simple lumbar spine surgery under general anesthesia will receive neurologic/neuropsychometric examinations.
11530473|NCT01140854||Normotension (control)|Middle-aged patients (40-60 years) undergoing simple lumbar spine surgery under general anesthesia as controls to compare their performance to those patients >60 years - will also receive neurologic/neuropsychometric examinations.
11530474|NCT01140841||Fipamezole ODT|
11530475|NCT01140841||Placebo|
11530476|NCT01140828|Active Comparator|Rabeprazole|Rabeprazole
11530477|NCT01140828|Placebo Comparator|Rabeprazole Placebo|Rabeprazole Placebo
11530478|NCT01140815|Active Comparator|Total|The Smith and Nephew Total Knee System
11530479|NCT01140815|Experimental|Deuce|The Journey Deuce Bicompartmental Knee System
11530480|NCT01140802||IBD patients|Crohn's disease or ulcerative colitis patients
11530481|NCT01140802||Healthy controls (non-IBD)|Patients comprise ethnicity - matched patients undergoing colonoscopy for polyp or colorectal cancer screening, or rectal bleeding
11530482|NCT01140802||Relatives of IBD patients|They will be a first degree relative of a IBD patient.
11530483|NCT01140789||Crohn's disease patients|Diagnosis of Crohn's disease by endoscopy, radiology and histology
11530484|NCT01140789||Ulcerative colitis patients|Diagnosis of ulcerative colitis defined by endoscopy, radiology and histology
11530485|NCT01140789||Non-IBD patients|Ethically, sex and aged-matched controls attending clinics or endoscopy for functional upper gastrointestinal diseases or screening colonoscopy.
11530486|NCT01140776||OSNA Breast Cancer System|"For in vitro diagnostic use only.
~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).
~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required."
11530487|NCT01140763||Sysmex's 5-blade cutter.|
11530488|NCT01140737|Experimental|Axitinib|Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily.
11530489|NCT01140711|Experimental|Gastric bypass|Patients submitted to gastric bypass for treatment of morbid obesity
11530490|NCT01140711|Experimental|Sleeve gastrectomy|Patients submitted to sleeve gastrectomy for treatment of morbid obesity
11530491|NCT01140698||Term and preterm newborn infants|5 infants of each gestational age of 24-42 weeks
11530492|NCT01140672|Experimental|Cohort 1 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 3 mg per day for 14 days. (2 placebo: 8 active)
11530493|NCT01140672|Experimental|Cohort 2 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 3 mg per day for 14 days. (2 placebo: 8 active)
11530494|NCT01140672|Experimental|Cohort 3 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 30 mg per day for 14 days. (2 placebo: 8 active)
11530495|NCT01140672|Experimental|Cohort 4 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 100 mg per day for 14 days. (2 placebo: 8 active)
11530496|NCT01140672|Experimental|Cohort 5 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 300 mg per day for 14 days. (2 placebo: 8 active)
11530497|NCT01140672|Experimental|Cohort 6 (N=10) Optional cohort|Placebo-controlled, multiple doses of PF-04634817 up to 300 mg per day for 14 days. (2 placebo: 8 active)
11530498|NCT01140659|Other|Objective measurement of sweat|"We selected 40 patients from February 2007 to May 2009. All participants were randomized into two groups of 20 patients (G3 and G4) and underwent the sympathectomy, being followed for 12 months. We used an objective method for measuring sweat, checking the TEWL (transepidermal water loss) measured by the VapoMeter, and evaluated the quality of life before and after the operation. Also studied were: incidence and intensity of the compensatory hyperhidrosis."
11530499|NCT01140646|Experimental|Arm I|The first week of the study is a baseline week where data are being collected but study agent is not being taken. Patients then receive oral s-adenosyl-L-methionine, 400 mg, once daily on days 8-14 and twice daily on days 15-49 in the absence of unacceptable toxicity.
11530500|NCT01140620|Experimental|ketamine and risperidone|Oral risperidone pretreatment and intravenous ketamine infusion
11530501|NCT01140620|Active Comparator|ketamine and placebo|Oral placebo risperidone pretreatment and intravenous ketamine infusion
11530502|NCT01140620|Active Comparator|saline and risperidone|Oral risperidone pretreatment and intravenous saline infusion
11530503|NCT01140620|Placebo Comparator|saline and placebo|Oral placebo risperidone pretreatment and intravenous saline infusion
11530765|NCT01138748|Experimental|Radiation therapy|
11530504|NCT01140620|No Intervention|Patients with Schizophrenia|Patients with schizophrenia will not receive study drug and will not undergo randomisation.
11530505|NCT01140607|Experimental|Cohort 1: normal hepatic function: cabazitaxel|"cabazitaxel 25mg/m^2
~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
11530506|NCT01140607|Experimental|Cohort 2: mild hepatic impairment : cabazitaxel|"cabazitaxel 20mg/m^2
~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
11530507|NCT01140607|Experimental|Cohort 3: moderate hepatic impairment: cabazitaxel|"cabazitaxel 10mg/m^2
~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
11530508|NCT01140607|Experimental|Cohort 4: severe hepatic impairment: cabazitaxel|"cabazitaxel 5 mg/m^2 or 10mg/m^2
~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
11530509|NCT01140607|Experimental|Cohort 5: normal hepatic function: cabazitaxel and midazolam|"cabazitaxel 25mg/m^2
~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks).
~Midazolam is given orally in single dosing on day -1 and day 1 (crossover)"
11530510|NCT01140594|Active Comparator|Wavefront-guided PRK|Wavefront-guided PRK
11530511|NCT01140594|Active Comparator|Wavefront-guided LASIK|Wavefront-guided LASIK
11530512|NCT01140581|Experimental|Group A|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks followed by dronedarone 400 mg twice daily for 8 weeks
11530513|NCT01140581|Experimental|Group B|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks. Two weeks wash-out followed by dronedarone 400 mg twice daily for 6 weeks
11530514|NCT01140581|Experimental|Group C|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks. Four weeks wash-out followed by dronedarone 400 mg twice daily for 4 weeks
11530515|NCT01140568|Experimental|nilotinib|Patients will take nilotinib twice daily at the standard dose of 400mg taken by mouth twice a day until disease progression or development of unacceptable side effects.
11530516|NCT01140555|Experimental|GYNECARE GYNOCCLUDE™|GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device
11530517|NCT01140542|Active Comparator|Roflumilast|500µg, once daily
11530518|NCT01140542|Placebo Comparator|Placebo|
11530519|NCT01140529|Experimental|Dexmedetomidine|
11530520|NCT01140529|Active Comparator|Haloperidol|
11530521|NCT01140529|Placebo Comparator|Placebo|
11530522|NCT01140516|Active Comparator|Trimethoprim|Prophylactic Antibiotics
11530523|NCT01140516|Placebo Comparator|Simple syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
11530524|NCT01140503|Experimental|apremilast|apremilast 20mg bid
11530525|NCT01140490|No Intervention|Sub-total Parathyroidectomy|
11530526|NCT01140477|Experimental|Crystalens toric IOL|Toric Accommodating Lens Crystalens toric silicone multi-piece accommodating IOL (Models AT-50T/AT-52T)
11530527|NCT01140477|Active Comparator|Crystalens IOL|Accommodating Lens Crystalens silicone multi-piece accommodating IOL (Models AT-50SE/AT-52SE)
11530528|NCT01140464|Active Comparator|Enhanced Usual Care|Usual care treatment of depression in primary care settings. Usual care considered enhanced as patients and their parents were given screening results and encouraged to seek care from their primary care doctor and behavioral health services.
11530529|NCT01140464|Active Comparator|Collaborative Care|Collaborative care intervention for depression. Involves care management, evidence based treatments in primary care setting, symptom monitoring and stepped care design
11530530|NCT01140451|Experimental|Ataluren/Ataluren|Participants who received double-blind ataluren during Study 009 will continue to receive open-label ataluren 3 times per day TID: 10 milligram (mg)/kilogram (kg) of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total dose 40 mg/kg/day), for up to 96 weeks. Participants will be followed for 4 weeks after treatment.
11530531|NCT01140451|Experimental|Placebo/Ataluren|Participants who received double-blind placebo during Study 009 will receive open-label ataluren TID: 10 mg/kg of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total dose 40 mg/kg/day), for up to 96 weeks. Participants will be followed for 4 weeks after treatment.
11530532|NCT01140438|Active Comparator|Metformin + NPH Insulin|Patients are treated with metformin during the run-in period (3 months) and also after randomization. By randomization insulin treatment will be added in the form of injections of NPH insulin in the evenings.
11530533|NCT01140438|Active Comparator|Metformin + sitagliptin +/-repaglinid|Patients are treated with metformin during the run-in period (3 months) and also after randomization. By randomization sitagliptin tablets will be added.If HbA1c after 6 months of treatment is > 10 % above the upper limit of normal,then treatment with repaglinide tablets tree times daily at mealtimes will be added.
11530534|NCT01140425|Experimental|PF-00232798 supratherapeutic dose|PF-00232798 supratherapeutic dose
11530535|NCT01140425|Experimental|PF-00232798 therapeutic dose|PF-00232798 therapeutic dose
11530536|NCT01140425|Placebo Comparator|Placebo for PF-00232798|Placebo for PF-00232798
11530537|NCT01140425|Active Comparator|Moxifloxacin|Moxifloxacin
11530538|NCT01140412|Experimental|Cohort 1|Twice daily regimen
11530539|NCT01140412|Experimental|Cohort 2|Once daily regimen
11530540|NCT01140399|Active Comparator|Infusional drug treatment|Diuretics or diuretics plus fixed low dose dopamine infusion
11530541|NCT01140399|Experimental|Ultrafiltration|Device: Ultrafiltration appliance Sessions of 8 h UF are conducted on 2 subsequent days in the first 48 hours after randomization; a third session is performed on day 3 in case of persistent congestion
11530542|NCT01140386||hospital pediatric patients 1/1/2000-12/31/2008 documented VTE|Age <18 Hospitalized for greater than or equal to 24 hours VTE documented during hospital admission
11530543|NCT01140373|Experimental|autologous T cells & cyclophosphamide.|This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of engineered autologous T cells targeted to Prostate-Specific Membrane Antigen (PSMA) administered one day after pretreatment with cyclophosphamide.
11530587|NCT01140061|Experimental|Panel A - MK-0873 5.1 mg|In Part I, healthy participants received skin patches containing nothing (plain patch), placebo, and various potencies of MK-0873 cream (0.05%, 0.5%, or 2%; yielding a dose of 5.1 mg of MK- 0873) once daily for 21 days.
11530815|NCT01138397|Experimental|Group 1|Participants at 18 to 59 years of age
11530544|NCT01140360|Experimental|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA > 1.8 m2 or 55 mg/m2 twice daily for patients with BSA < 1.8 m2. For patients with a BSA > 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA < 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
11530545|NCT01140347|Experimental|Ramucirumab DP and BSC|
11530546|NCT01140347|Placebo Comparator|Placebo and BSC|
11530547|NCT01140334|Experimental|Reinforced On-Site Integrated Care (ROIC)|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. In addition, they will be able to earn a voucher incentive for each week of psychiatric compliance.
11530548|NCT01140334|Active Comparator|Standard On-Site Integrated Care (SOIC).|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week.
11530549|NCT01140321|Experimental|Neridronato|Thalassemia Major or Severe Thalassemia Intermedia
11530550|NCT01140321|No Intervention|Placebo|Thalassemia Major or Severe Thalassemia Intermedia
11530551|NCT01140308|Placebo Comparator|Sugar Pill|Simvastatin 20mg + Placebo
11530552|NCT01140308|Active Comparator|Co Q10|Simvastatin 20mg + CoQ10
11530553|NCT01140295|Active Comparator|1, Miralax|Miralax colonoscopy preparation
11530554|NCT01140295|Active Comparator|2, senna|Senna colonoscopy preparation
11530555|NCT01140282|Active Comparator|Arm I (Control)|Patients refrain from increasing physical activity levels for 16 weeks.
11530556|NCT01140282|Experimental|Arm II (Exercise)|Patients participate in supervised exercise sessions over 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30-45 minutes once weekly for 16 weeks.
11530557|NCT01140269|No Intervention|No PCR testing|Control patients will not have PCR testing. This group will have routine testing and treatment as defined by the standard of care.
11530558|NCT01140269|Experimental|PCR testing|PCR will be used in parallel with routine laboratory tests such as culture. Treatment for PCR results will be based on the standard of care. Treatment of the patient will be dependent on the physician's clinical judgment based on existing clinical information including PCR, microbiology, patient physical presentation, and other laboratory results.
11530559|NCT01140256||SGA infants|SGA infants were recruited at birth and zinc stable isotope was administered at birth and at 6 months of age .This was a longitudinal study whereby the growth trajectory and zinc pools were measured.
11530560|NCT01140256||AGA|AGA infants were recruited at birth and zinc stable isotope was administered at birth and at 6 months of age .This was a longitudinal study whereby the growth trajectory and zinc pools were measured.
11530561|NCT01140256||SGA infant|Infants who were born small for gestational age were recruited and zinc stable isotopes were administered at birth and at 6 months.
11530562|NCT01140243|Experimental|test product|Dietary supplement
11530563|NCT01140243|Active Comparator|standart|Dietary supplement
11530564|NCT01140217|Experimental|Active treatment|Norethindrone Acetate Transdermal Delivery System
11530565|NCT01140204|Placebo Comparator|Placebo control|Contrast medium without Paclitaxel
11530566|NCT01140204|Active Comparator|Iopromide Paclitaxel 0.85 mg|Iopromide Paclitaxel 0.85 mg
11530567|NCT01140204|Active Comparator|Iopromide Paclitaxel 4.27 mg|Iopromide Paclitaxel 4.27 mg
11530568|NCT01140204|Active Comparator|Iopromide Paclitaxel 8.54 mg|Iopromide Paclitaxel 8.54 mg
11530569|NCT01140204|Active Comparator|Iopromide Paclitaxel 17.08 mg|Iopromide Paclitaxel 17.08 mg
11530570|NCT01140191|Experimental|WR 279,396|All subjects in this one-arm study will receive topical WR 279,396
11530571|NCT01140178|Experimental|HPPH|a fixed HPPH dose of 4 mg/m2 infused over 1 hour, and 24 hours later light doses escalating from 100 J/cm2 to 125 and 140 J/cm2, respectively.
11530572|NCT01140165|Active Comparator|butter|Danish butter
11530573|NCT01140165|Experimental|cheese|
11530574|NCT01140152||No rejection|Intestinal transplant recipients with no evidence of biopsy proven rejection
11530575|NCT01140152||Rejection|Intestinal transplant recipients who had evidence of biopsy proven rejection
11530576|NCT01140139|Experimental|HIV DNA + Hydroxyurea|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption. The patients also received 500 mg of hydroxyurea daily.
11530577|NCT01140139|Experimental|HIV DNA|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
11530578|NCT01140139|Placebo Comparator|Placebo|PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
11530579|NCT01140126|Experimental|Antibody (UB-421)|
11530580|NCT01140113|No Intervention|Placebo|this group had undergone to routine coronary artery bypass graft surgery
11530581|NCT01140113|Experimental|Modified Ultrafiltration|patients after weaning from bypass were submitted to ultrafiltration
11530582|NCT01140100|Active Comparator|propofol-propofol|
11530583|NCT01140100|Experimental|thiopental-propofol|
11530584|NCT01140087|Experimental|Interventional|Face Transplantation
11530585|NCT01140074|Experimental|Zinc sulfate|Children in active treatment group will be given zinc sulfate 10-20 mg per day orally plus probiotics
11530586|NCT01140074|Placebo Comparator|Placebo|Children will be given placebo plus probiotics
11530588|NCT01140061|Placebo Comparator|Panel A - Placebo|In Part I, healthy participants received skin patches containing nothing (plain patch) or placebo once daily for 10 days.
11530589|NCT01140061|Experimental|Panel B - MK-0873 25 mg|In Part II, healthy participants received skin application of 0.5% MK-0873 cream (yielding a dose of 25 mg of MK- 0873) twice daily for 10 days.
11530590|NCT01140061|Placebo Comparator|Panel B - Placebo|In Part II, healthy participants received skin application of placebo cream twice daily for 10 days.
11530591|NCT01140061|Experimental|Panel C - MK-0873 100 mg|In Part II, healthy participants received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) once daily for 10 days.
11530592|NCT01140061|Placebo Comparator|Panel C - Placebo|In Part II, healthy participants received skin application of placebo cream once daily for 10 days.
11530593|NCT01140061|Experimental|Panel D - MK-0873 200 mg|In Part II, healthy participants received skin application of 2% MK-0873 (yielding a dose of 100 mg of MK-0873) twice daily for 10 days.
11530594|NCT01140061|Placebo Comparator|Panel D - Placebo|In Part II, healthy participants received skin application of placebo cream twice daily for 10 days.
11530595|NCT01140061|Experimental|Panel E and Extension - MK-0873 200 mg|In Part III, participants with mild psoriasis received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) twice daily for up to 28 days.
11530596|NCT01140061|Placebo Comparator|Panel E and Extension - Placebo|In Part III, participants with mild psoriasis received skin application of placebo cream twice daily for up to 28 days.
11530597|NCT01140048||All Enrolled Participants|All participants who completed Protocol 272 and were enrolled in Protocol 374
11530598|NCT01140035|Experimental|Intensive insulin therapy|"Intensive insulin therapy with goal of glucose < 150 mg/dl
~Control group with standard insulin therapy with goal of glucose 180 mg/dl"
11530599|NCT01140022||Female Patients 18-25 yo|Female patients aged 18-25 who have come to one of the ED or urgent care sites for care, regardless of the presence of CT symptoms.
11530600|NCT01140009|Placebo Comparator|Group 1|FLuviral 2010/11Tri-valent Seasonal Influenza Vaccine (TIV)1st; saline placebo 10 days later
11530601|NCT01140009|Placebo Comparator|Group 2|Saline placebo 1st; Fluviral 2010/11 Tri-valent Seasonal Influenza Vaccine (TIV)10 days later
11530602|NCT01139996|Experimental|Transdermal Clonidine/Oral Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of a Clonidine Transdermal system at a dose of 0.3 mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3 mg after 12 hours
11530603|NCT01139996|Placebo Comparator|Comparator|Placebo group will receive a placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final placebo tablet
11530604|NCT01139970|Experimental|Treatment (temozolomide and veliparib)|"Patients receive veliparib PO QD on day 1 and twice daily on days 4-12 and temozolomide PO QD on days 3-9 of course 1.
~Beginning at least 30 days after the start of treatment, patients receive veliparib PO BID on days 1-8 and temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Patients achieving complete remission receive 5 more courses in the absence of disease progression or unacceptable toxicity."
11530605|NCT01139957||Ancillary-correlative|Patients complete the Health Update Questionnaire annually for up to 5 years. The questionnaire focuses specifically on cancer risk, incidence, and mortality. Patients also receive ongoing communication (e.g., periodic newsletters, copies of study-related publications, etc.) to keep them informed regarding study-related research results, new research findings, new research opportunities for which patients may be eligible, and evolving clinical recommendations regarding hereditary breast/ovarian cancer.
11530606|NCT01139944||Group 1|Archived tumor and intrathoracic lymph node tissue samples are analyzed for aberrant DNA methylation (p16/CDKN2A, DAP kinase, H-cadherin, APC, and RASSF1A) by methylation-specific PCR. Analyses are then compared with the preliminary data from the Johns Hopkins institutional study.
11530607|NCT01139918||Cohort A|40 patients with moderate psoriatic arthritis and moderate psoriasis
11530608|NCT01139918||Cohort B|40 patients with mild psoriatic arthritis and moderate psoriasis
11530609|NCT01139918||Cohort C|40 patients with moderate psoriatic arthritis and mild psoriasis
11530610|NCT01139905|Other|1|standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour
11530611|NCT01139892||Surgical management|Surgical clipping will be performed within 6 weeks of randomization, according to standards of practice, and under general anaesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, bypasses, and other flow-redirecting treatments that do not directly clip the aneurysm will not be included.
11530612|NCT01139892||Endovascular management|Endovascular treatment will be performed within 6 weeks of randomization, according to standards of practice, and under general anaesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling or stents, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
11530613|NCT01139879|Experimental|P400 support surface|All patients will receive the P400 mattress
11530614|NCT01139866||Group 1: SABER™-Bupivacaine|Received 5.0 mL SABER™-Bupivacaine in previous C803-017 trial
11530615|NCT01139866||Group 2: SABER™-Placebo|Received 5.0 mL SABER™-Placebo in previous C803-017 trial
11530616|NCT01139853|Active Comparator|Nasogastric Tube|10 French Nasogastric Tube inserted before surgery
11530617|NCT01139853|No Intervention|No Nasogastric Tube|
11530618|NCT01139840|Active Comparator|vitamin D2|
11530619|NCT01139840|Active Comparator|vitamin D3|
11530620|NCT01139827||normal|normal group has no diabetes.
11530621|NCT01139827||IGT|IGT group has impaired fasting glucose or impaired glucose tolerance.
11530622|NCT01139814|Experimental|Catheter Robot|device
11530623|NCT01139801|Active Comparator|Oxytocin|Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.
11530624|NCT01139801|Experimental|Misoprostol|Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
11530625|NCT01139788|Experimental|LY2624587|
11530626|NCT01139775|Experimental|Phase 1: LY2603618 130 to 275 mg|"Cycle 1-2 (21-day cycle):
~Day 1: pemetrexed 500 milligrams per meter square (mg/m^2) + cisplatin 75 mg/m^2
~Day 2: LY2603618 at 130-275 milligrams (mg)
~After 2 cycles, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
11530669|NCT01139437|Experimental|Adults|Adults ages 18 to 49 years of age. Open label.
11530627|NCT01139775|Experimental|Phase 2: Pemetrexed + Cisplatin + LY2603618|"Cycles 1-4 (21-day cycle):
~Before 25 Oct 2012:
~Day 1: pemetrexed 500 mg/m^2 + cisplatin 75 mg/m^2
~Day 2: LY2603618 dose from phase 1 portion of trial
~After 25 Oct 2012:
~Day 1: pemetrexed 500 mg/m^2 + cisplatin 75 mg/m^2
~After 4 cycles, participants may continue on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
~Maintenance Therapy Experimental Arm (every 21 days):
~Before 25 Oct 2012:
~Day 1: pemetrexed 500 mg/m^2
~Day 2: LY2603618 dose determined from phase 1
~After 25 Oct 2012:
~Day 1: pemetrexed 500 mg/m^2
~If, as of 25 Oct 2012, participant was in maintenance therapy and randomized to the experimental arm, the participant is eligible to continue with pemetrexed (Day 1)/LY2603618 (Day 2) therapy if the investigator deems it is in the best interest of the participant and the participant consents."
11530628|NCT01139775|Active Comparator|Phase 2: Pemetrexed + Cisplatin|"Cycle 1-4 (21-day cycle):
~Day 1: pemetrexed 500 mg/m^2 + cisplatin 75 mg/m^2
~After 4 cycles, participants may continue on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
~Maintenance Therapy Comparator Arm: Phase 2 (every 21 days):
~Day 1: pemetrexed 500 mg/m^2"
11530629|NCT01139762|Experimental|Tadalafil|
11530630|NCT01139762|Placebo Comparator|Placebo|
11530631|NCT01139749|Active Comparator|Oral isotretinoin|Subjects from treatment arm will be treated with low-dose oral isotretinoin - 20 mg a day, every other day, for six months
11530632|NCT01139749|Active Comparator|salicylic acid and ciclopirox olamine|Subjects from comparison arm will be treated with topical salicylic acid and ciclopirox olamine shampoo
11530633|NCT01139736|Experimental|Probiotics|IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks. VSL#3 was selected for use in this study because (a) it contains three different Bifidobacteria strains (in addition to lactobacilli and streptococci) and the limited evidence available Bifidobacteria as the most effective probiotics in IBS .
11530634|NCT01139723|Experimental|A|
11530635|NCT01139723|Experimental|B|
11530636|NCT01139697||Patients with systolic heart failure|Patients with systolic heart failure defined as ejection fraction <45%
11530637|NCT01139684|Experimental|Exercise|
11530638|NCT01139658||All comers|
11530639|NCT01139645|Experimental|Proton Pump Inhibitors|patients were started on Proton Pump inhibitors for 3 months (the whole duration of the study)
11530640|NCT01139645|No Intervention|No Proton Pump Inhibitors|patients are not taking any Proton Pump Inhibitor, and they are matched by age to patients in the experimental group.
11530641|NCT01139619||1|Inoperable non small cell lung cancer patients. Diagnosed between 2010-05-31 and 2009-06-01.
11530642|NCT01139606|Experimental|Vibration trainig|
11530643|NCT01139593||morning dose|women undergoing IVF/ICSi taking their gonadotropin dose in the am
11530644|NCT01139593||evening dose|Women undergoing IVF/ICSI taking their gonadotropin in the evening
11530645|NCT01139580|Experimental|Calcipotriene Foam|Calcipotriene Foam 0.005%,
11530646|NCT01139580|Placebo Comparator|Vehicle Foam|Vehicle Foam
11530647|NCT01139567||Standard Care Group|Subjects who will undergo only standard wound care management.
11530648|NCT01139567||Hyperbaric Oxygen Therapy Group|Subjects who are selected for adjunctive hyperbaric oxygen therapy in addition to standard wound care intervention.
11530649|NCT01139541|No Intervention|Control|Participants in the control condition will be asked to refrain from using the WalkStations during the study period.
11530650|NCT01139541|Experimental|Individual|In the individual condition, participants will not be part of a team. They will receive weekly email feedback on their Walkstation performance (e.g. number of time slots they signed up for, and number of times they showed up for the time slot.)
11530651|NCT01139541|Experimental|Pairs|In the pair condition, participants will be randomly assigned to a partner. They will receive the same feedback as those in the individual condition, for both themselves AND their partner.
11530652|NCT01139541|Experimental|Groups|In the group condition, participants will be randomly assigned to a group of 5 people. They will receive the same feedback as those in the individual condition, for both themselves AND each member of their group.
11530653|NCT01139528|Active Comparator|Operative treatment|Closed reduction of the fracture and osteosynthesis with 2-3 intramedullary K-wires (Bouquet method), cast treatment for 7-10 days followed by 5 weeks of buddy-strapping before removal of the K-pins
11530654|NCT01139528|No Intervention|Conservative treatment|No attempt of reduction of the fracture, 7-10 days of cast treatment followed by 5 weeks of buddy-strapping
11530655|NCT01139515|Experimental|Treatment A|1 X 20 mg eletriptan
11530656|NCT01139515|Experimental|Treatment B|1 X 40 mg eletriptan
11530657|NCT01139515|Experimental|Treatment C|2 X 40 mg eletriptan
11530658|NCT01139515|Experimental|Treatment D|1 X 40 mg tablet given 2 hr after initial 1 X 40 mg tablet dose
11530659|NCT01139502|Active Comparator|Work rehab with cognitive therapy|Work rehabilitation based on the cognitive therapeutical model
11530660|NCT01139502|Active Comparator|Work rehab with cognitive training|Work rehabilitation with the addition of weekly training of concentration, memory, and executive function
11530661|NCT01139489|Active Comparator|procalcitonin-guidance|A daily advise to continue or stop antibiotics based on the measurement of the biomarker procalcitonin
11530662|NCT01139489|No Intervention|standard-of-care|standard-of-care treatment of ICU infections based upon consensus guidelines and expert opinion
11530663|NCT01139476||AHS BEEA participants|A subset of 1990 AHS cohort members who are male private pesticide applicators, living and over 50 years of age at the time contact, cancer free, and who completed AHS Phases IIII.
11530664|NCT01139476||Non-AHS BEEA participants|A group of 225 age-, race-, and countymatched, non-AHS controls, who have not lived or worked on a farm as an adult, or held a job applying pesticides.
11530665|NCT01139463||Antipsychotic treatment|Patients were not taking any medications - apart from the prescribed antipsychotic - for a period of 1 month prior to the study with psychotic relapse or newly diagnosed psychotic disorder were recruited from psychiatric inpatient and outpatient clinics of the Split Clinical Hospital.
11530666|NCT01139450|Experimental|Test|Test product that contains the active pharmaceutical ingredient
11530667|NCT01139450|Active Comparator|Reference|Reference product that contains the active pharmaceutical ingredient
11530668|NCT01139450|Placebo Comparator|Vehicle|Placebo that contains no active pharmaceutical ingredient
11530670|NCT01139437|Experimental|Seropositive children - vaccine|Children ages 15 to 59 months of age who already have HPIV2 antibodies receiving the HPIV2 vaccine.
11530671|NCT01139437|Experimental|Seronegative infants and children - low dose vaccine|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a low dose of the HPIV2 vaccine.
11530672|NCT01139437|Experimental|Seronegative infants and children - standard dose vaccine|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a standard dose of the HPIV2 vaccine.
11530673|NCT01139437|Placebo Comparator|Seropositive children - placebo|Children ages 15 to 59 months of age who already have HPIV2 antibodies receiving a placebo.
11530674|NCT01139437|Placebo Comparator|Seronegative infants and children - low dose placebo|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a low dose of placebo.
11530675|NCT01139437|Placebo Comparator|Seronegative infants and children - standard dose placebo|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a standard dose of placebo.
11530676|NCT01139424|Experimental|open label treatment arm|endoscopic suturing
11530677|NCT01139411|Experimental|Behavioral Weight Control with Enhanced Parent Involvement|This treatment arm included periodic dyadic sessions with adolescents and their parents, focusing on weight-related communication combined with standard behavioral weight control.
11530678|NCT01139411|Placebo Comparator|Behavioral Weight Control with Minimal Parent Involvement|This treatment arm included standard behavioral weight control delivered to the adolescent with minimal parent involvement.
11530679|NCT01139385||clipless|laparoscopic cholecystectomy performed by harmonic scalpel with closure and division of the cystic duct only by the device
11530680|NCT01139385||traditional|laparoscopic cholecystectomy performed by harmonic scalpel with closure of the cystic duct only by titanium clip
11530681|NCT01139372|Experimental|FID 115958D|Lubricant eye drop
11530682|NCT01139359|Experimental|Single Arm, darinaparsin and CHOP|open label, single arm, unblinded
11530683|NCT01139346|Experimental|oral darinaparsin|open label, single arm, dose escalation
11530684|NCT01139294|No Intervention|standard IV therapy|control arm of the study
11530685|NCT01139294|Experimental|Hylenex|1ml subcutaneous with initiation of intravenous fluids then every 24 hours with a maximum dose of 3 injections in 72 hours
11530686|NCT01139281|Active Comparator|Study Group|The Study Group(SG) received Ginkgo biloba extract(GBE761)(240mg/day)plus cisplatin(CDDP)
11530687|NCT01139281|Placebo Comparator|Control Group(CG)|The Control Group received Placebo plus CDDP
11530688|NCT01139255|Experimental|Podcasting + mobile media|
11530689|NCT01139255|Active Comparator|Podcasting|
11530690|NCT01139242|Other|Body & Soul nutritional intervention|This is a standardized intervention to increase fruit and vegetable consumption among church members through pastoral and peer counseling and church activities/menus.
11530691|NCT01139242|Experimental|Newsletters/peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening among church members out-of-date according to screening guidelines. For those up-to-date, promotion is of increased physical activity.
11530692|NCT01139229|Other|HE group|
11530693|NCT01139229|Other|HS group|
11530694|NCT01139229|Other|SA group|
11530695|NCT01139216|Experimental|Daikenchuto (TU-100) 7.5g/day|Daikenchuto (TU-100) 2.5g TID (7.5g/day)
11530696|NCT01139216|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID (15g/day)
11530697|NCT01139216|Placebo Comparator|Placebo|Placebo TID
11530698|NCT01139203|Active Comparator|lamivudine|
11530699|NCT01139203|Active Comparator|lamivudine and adefovir|
11530700|NCT01139203|Active Comparator|entecavir|
11530701|NCT01139190|Experimental|PL3100|
11530702|NCT01139190|Active Comparator|Naproxen|
11530703|NCT01139177|Experimental|Stent placement|
11530704|NCT01139164|Experimental|Single Arm, non-randomized study|
11530705|NCT01139151|Experimental|Group 1 - 3 Day Thiarabine|Thiarabine 3 days in a row in each cycle.
11530706|NCT01139151|Experimental|Group 2 - 5 Day Thiarabine|Thiarabine 5 days a row in each cycle.
11530707|NCT01139138|Experimental|Panitumumab + Irinotecan + Everolimus|
11530708|NCT01139125|Experimental|Cystagon, Cysteamine Bitartrate|We are examining the safety and efficacy of this medication on the treatment of schizophrenia patients.
11530709|NCT01139099|Other|Arm|There is no arm in this study.
11530710|NCT01139086||Cardiovascular disease|Diagnosis of cardiomyopathy or ischemic heart disease without heart failure
11530711|NCT01139086||Chronic heart failure|Diagnosis of cardiomyopathy or ischemic heart disease LVEF <40%
11530712|NCT01139086||Control|Age and body built matched with chronic heart failure group
11530713|NCT01139060|Experimental|Intervention Group|18-month organized treatment program focused on outreach and engagement for chronic or recurrent depression
11530714|NCT01139060|No Intervention|Usual Care|
11530715|NCT01139047|Active Comparator|metronidazole 1% gel|
11530716|NCT01139047|Active Comparator|azelaic acid 15% gel|
11530717|NCT01139034|Experimental|shoulder FES treatment|
11530718|NCT01139021|Experimental|B246_12_M12|Subjects assessed one year post administration of rMenB+OMV NZ and MMRV at 12th month after primary vaccination at 2nd ,4th and 6th months of age.
11530719|NCT01139021|Experimental|B246_12M13|Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 13th month after primary vaccination at 2nd ,4th and 6th months of age.
11530720|NCT01139021|Experimental|B13_15_27|Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at 13th and 15th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27 months of age.
11530721|NCT01139021|Experimental|B12_14_26|Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 26 months of age.
11530722|NCT01139021|Experimental|B_24_26|Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.
11530723|NCT01139021|Experimental|B12M13|Subject was randomized in group B13_15_27 but treated as group B12_M13.
11530724|NCT01139008|Active Comparator|metronidazole 1% gel|
11530726|NCT01138995|Active Comparator|Ankle-foot orthosis (AFO) Control Group|"The Control Group will walk with the a usual ankle-foot orthosis (AFO) for 30 weeks."
11530727|NCT01138995|Experimental|Ness L300 Treatment Group|The Original Treatment Group will walk with the Ness L300 for 30 weeks.
11530728|NCT01138982|Experimental|Mentoring program|Mentor and mentee meet at least every second week, for 2-4 h on every occasion, during 1 year (i.e., for a minimum of two school semesters). Meetings take place outside school and work hours, and the pairs choose activities of their own preferences. No monetary incentives exist, and the mentors are laymen volunteers. The program objective is to establish a safe and supportive relationship, by which the youth is assumed to benefit in social, emotional, and academic development, and as a consequence, be less prone to use alcohol and drugs.
11530729|NCT01138982|No Intervention|Control group|No intervention provided, only brief phone calls to control for attention bias
11530730|NCT01138969|Active Comparator|Esomeprazole plus clopidogrel group|esomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months
11530731|NCT01138969|No Intervention|Clopidogrel group|clopidogrel 75 mg qd for 6 months
11530732|NCT01138956|Experimental|Group 1|Pentavalent antimonial, 20mg/kg/day, 28 days, IV, plus N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po.
11530733|NCT01138956|Active Comparator|Group 2|Pentavalent antimonial, 20mg/kg/day, 28 days
11530734|NCT01138943|Active Comparator|Chlorhexidine alcohol-base mouthrinse|
11530735|NCT01138943|Experimental|non alcohol chlorhexidine mouthrinse|
11530736|NCT01138930|Experimental|Berberine|
11530737|NCT01138930|Placebo Comparator|Placebo|
11530738|NCT01138917|Experimental|all participants|All participants will receive both ReCell and split-thickness skin graft
11530739|NCT01138904|Active Comparator|IROX arm: FOLFIRI -> FOLFOX|"IROX arm: FOLFIRI -> FOLFOX
~FOLFOX REGIMEN
~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr
~Every 2 weeks
~FOLFILI REGIMEN
~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr"
11530740|NCT01138904|Active Comparator|OXIR arm: FOLFIRI -> FOLFOX|"OXIR arm: FOLFIRI -> FOLFOX
~FOLFOX REGIMEN
~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr
~Every 2 weeks
~FOLFILI REGIMEN
~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr"
11530741|NCT01138891||Removed breast implants for any reason|
11530742|NCT01138878||Patient pre-study group|A set of all 16-65 yr olds (not know already to be HIV-positive) accessing the healthcare setting prior to the introduction of the HIV testing pilot programme
11530743|NCT01138878||Staff pre-study group|A set of staff working within the healthcare setting prior to the introduction of the HIV screening programme
11530744|NCT01138878||Patient intra-study group|A set of patients, aged 16-65 and known not to be HIV-positive, who access the healthcare setting during the HIV testing pilot programme
11530745|NCT01138878||Post-study staff group|A set of staff who worked within the healthcare setting for the duration of the HIV testing pilot programme
11530746|NCT01138865|Other|1|Device: AutoSet Spirit--Wash--Modified-AutoSet Spirit 3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
11530747|NCT01138865|Other|2|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
11530748|NCT01138852|Experimental|ampicillin-sulbactam|This is the drug used to prevent post-cesarean infection
11530749|NCT01138852|Active Comparator|cefuroxime|This drug was compared to ampicillin sulbactam for prevention of infection
11530750|NCT01138839|Placebo Comparator|sterile water|Pregnant women will receive 2.5 cc of sterile water every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 doses after delivery.
11530751|NCT01138839|Experimental|Dexamethasone|Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.
11530752|NCT01138826|Active Comparator|treatment A - reference w/ water|
11530753|NCT01138826|Experimental|Treatment B - ODT (test) w/ water|
11530754|NCT01138826|Experimental|Treatment C - ODT (test) w/o water|
11530755|NCT01138813||1|Male and female patients aged 18-70 years old with newly diagnosed operable glioma of grade II or higher
11530756|NCT01138787|Active Comparator|Reference spread|"2250 mg PS (as PSE) in spread (30 g)
~50 mg labeled D7-cholesterol,
~30 mg 3,4-13C-cholesterol, iv dosed at same time."
11530757|NCT01138787|Placebo Comparator|Placebo spread|"regular light margarine (30 g)
~50 mg labeled D7-cholesterol,
~30 mg 3,4-13C-cholesterol, iv dosed at same time."
11530758|NCT01138787|Experimental|Test spread|"2250 mg PS in innovatively processed spread (30 g)
~50 mg labeled D7-cholesterol,
~30 mg 3,4-13C-cholesterol, iv dosed at same time."
11530759|NCT01138774|Placebo Comparator|Control group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + placebos supplements
11530760|NCT01138774|Experimental|EPA group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA (1.3 g/day, 3 capsules of 433 mg/day) supplement (EPA Group).
11530761|NCT01138774|Experimental|Lipoic acid group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + LA (300 mg/day, 3 capsules of 100 mg/day) supplement (LA Group)
11530762|NCT01138774|Experimental|EPA+LA group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA/LA (1.3 g /day and 300 mg/day respectively).
11530763|NCT01138761|No Intervention|Physician/resident instruction|This arm is standard of care instruction given to parents/caregivers of children with atopic dermatitis by the dermatologist and/or dermatology resident during a patient visit.
11530764|NCT01138761|Active Comparator|Nurse instruction|Following the usual standard of care instruction by physician/resident (which both the treatment group and the non-treatment group will receive); the dermatology nurse will give enhanced instruction about skin care and medications to the caregivers/parents who were randomized to the treatment group.
11530766|NCT01138735|Active Comparator|adapalene/benzoyl peroxide|Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks
11530767|NCT01138735|Placebo Comparator|Topical Gel Vehicle|Topical Gel Vehicle applied topically once daily for 12 weeks
11530768|NCT01138709|Experimental|Convexity/Vitala|For all enrolled Subjects, STAGE 1 (Days 1 - 14 equals Convex Product Wear Period followed by, for those who successfully complete Stage I, weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 15 to 21), followed by 8 hours of daily wear time per week (Day 22 to 28), followed by 12 hours of daily wear time (Days 29 to 43).
11530769|NCT01138696||Stryker Dacron synthetic graft|
11530770|NCT01138696||Trevira synthetic graft|
11530771|NCT01138683|Active Comparator|ultrafiltration group|
11530772|NCT01138683|Active Comparator|diuretics group|
11530773|NCT01138670||Cardiac device group|
11530774|NCT01138657|Experimental|Adalimumab|Participants received adalimumab 80 mg subcutaneous loading dose at Baseline followed by 40 mg doses every other week (eow) starting at Week 1 for a maximum of 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper until Week 15.
11530775|NCT01138657|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection at Baseline followed by eow dosing starting at Week 1 for up to 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper until Week 15.
11530776|NCT01138631|Active Comparator|Embryoscope|
11530777|NCT01138631|No Intervention|Conventional incubator|
11530778|NCT01138618||CHEMPAQ-venous-CHEMPAQ-venous|The two arms only differ in order of kind of blood samples.
11530779|NCT01138618||Venous-CHEMPAQ-Venous-CHEMPAQ|The two arms only differ in order of kind of blood samples.
11530780|NCT01138605|Experimental|005|Darunavir 400 mg tablet intake of 2 tablets once daily in combination with ritonavir
11530781|NCT01138605|Experimental|006|Ritonavir Liquid formulation 80 mg/ml taken in combination with Darunavir
11530782|NCT01138605|Experimental|007|Ritonavir 100 mg capsule to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
11530783|NCT01138605|Experimental|008|Ritonavir 100 mg tablet to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
11530784|NCT01138605|Experimental|001|Darunavir Oral suspension 100 mg/ml 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
11530785|NCT01138605|Experimental|002|Darunavir 375 mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight between 20 and 30 kg
11530786|NCT01138605|Experimental|003|Darunavir 450 mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight between 30 and 40 kg
11530787|NCT01138605|Experimental|004|Darunavir 600mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight as of 40 kg
11530788|NCT01138605|Experimental|009|Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.
11530789|NCT01138592||Primary Care Patients|Any patient undergoing a telemedicine evaluation involving auscultation of the heart and lungs.
11530790|NCT01138579|Experimental|1|
11530791|NCT01138566||ESBL- and/or AmpC-(+) or (-)|
11530792|NCT01138553|Experimental|Mifepristone|
11530793|NCT01138540|Active Comparator|Semirecumbent position|Semirecumbent position of patients on mechanical ventilation in the bed of the ICU
11530794|NCT01138540|Experimental|lateral-Trendelenburg position|lateral-Trendelenburg position of patients on mechanical ventilation in the bed of the ICU
11530795|NCT01138527||Biopsy-proven prostate cancer|Patients with biopsy-proven prostate cancer, planned for radical prostatectomy
11530796|NCT01138514|Active Comparator|Clindamycin 1%/Benzoyl Peroxide 5%|
11530797|NCT01138514|Active Comparator|Reference Product|
11530798|NCT01138514|Placebo Comparator|Vehicle|
11530799|NCT01138501|Experimental|rFVIII|
11530800|NCT01138488|Experimental|NN5401|
11530801|NCT01138475|Active Comparator|Paricalcitol|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules,cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
11530802|NCT01138475|Active Comparator|cholecalciferol|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules, cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
11530803|NCT01138475|Placebo Comparator|placebo|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules, cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
11530804|NCT01138462|No Intervention|Standard Precautions|control arm, standards precautions for all residents living in the nursing home of control arm, including MRSA carriers
11530805|NCT01138462|Other|Intervention|Intervention arm, standards precautions for all residents living in nursing homes of intervention arm, and topical decolonization for MRSA carriers, including environmental disinfection
11530806|NCT01138449|Experimental|Vitamin A|Vitamin A capsules have retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil
11530807|NCT01138449|Placebo Comparator|Placebo|Placebo capsules contain minute amounts of vitamin E in soybean oil
11530808|NCT01138436|Experimental|MEBO Wound Ointment (MEBO)|Topical application once a day
11530809|NCT01138436|Active Comparator|Standard of Care|Application of Profore multilayer compression bandage system
11530810|NCT01138423|Experimental|Aliskiren|
11530811|NCT01138423|Experimental|Moxonidine|
11530812|NCT01138423|Experimental|Hydrochlorothiazide|
11530813|NCT01138423|Placebo Comparator|Placebo|
11530814|NCT01138410|Experimental|SCIB1|
11530816|NCT01138397|Experimental|Group 2|Participants at 60 years of age or older
11530817|NCT01138384|Experimental|Foretinib and Lapatinib|Patients will receive foretinib as a continuous oral dose, and lapatinib as a continuous oral dose. Lapatinib will commence on Day1, Cycle 1 and foretinib will commence on Day 3, Cycle 1.
11530818|NCT01138371||Familial hypercholesterolemia|"Heterozygous FH with documented CAD and LDL-C ≥ 200 mg/dL (Documented CAD may be represented as: Lesion(s) on coronary angiography, history of myocardial infarction, CABG, PTCA, progressive angina demonstrated by stress testing, history of other revascularization procedure)
~Homozygous FH and LDL-C > 500 mg/dL
~Heterozygous FH and LDL-C ≥ 300 mg/dL
~On stable LDL apheresis therapy for at least 6 months"
11530819|NCT01138345||Treatment w/Surgery|Breast Cancer survivors treated with surgery with or without radiation.
11530820|NCT01138345||Treatment w/endocrine therapy|Breast Cancer survivors treated with surgery with or without radiation plus endocrine therapy.
11530821|NCT01138345||Treatment w/ chemotherapy|Breast Cancer survivors treated with surgery with or without radiation and chemotherapy with or without endocrine therapy.
11530822|NCT01138293|Experimental|motion sensor integrated in a mobile phone|A motion sensor integrated in a mobile phone. The system analyses kind, intensity and duration of physical activity and eating habits.
11530823|NCT01138280|Experimental|Heat disinfection|Experimental arm: Heat disinfection link to RO water treatment system and piping system to dialysis machine
11530824|NCT01138280|No Intervention|Conventional RO water treatment|Placebo arm: conventional chemical disinfection link to RO water treatment system.
11530825|NCT01138254|No Intervention|control group|ESRD patients will not receive FIR therapy in this study.
11530826|NCT01138254|Experimental|Far infrared therapy|Patients will receive far infrared therapy 40 minutes three times weekly (TIW) for 6 months.
11530827|NCT01138241||1|ARV experience (TDF based HAART)
11530828|NCT01138241||2|ARV experience (non TDF based ART)
11530829|NCT01138241||3|ARV Naive
11530830|NCT01138228||Normal vision|This within-subjects design is counter balanced for order. Each operator sees the subject's arm either initially with the normal eye or with the device, then repeats with the second condition (i.e., device or normal vision).
11530831|NCT01138228||Vein Imaging Device|This within-subjects design is counter balanced for order. Each operator sees the subject's arm either initially with the normal eye or with the device, then repeats with the second condition (i.e., device or normal vision).
11530832|NCT01138215|Experimental|1|Receive 1 course of VZV vaccine : 2 doses of vaccines with 3 months apart.
11530833|NCT01138202|Experimental|1|boosted LPV/r 400/100 mg BID + 2 NRTI
11530834|NCT01138202|Experimental|2|boosted LPV/r 600/150 mg BID + 2 NRTI
11530835|NCT01138176|No Intervention|Standard care|
11530836|NCT01138176|Experimental|Cooling|Reduction of rectal temperature to 33.5 C for 72 hours
11530837|NCT01138163|Experimental|Docetaxel plus bavituximab 1 mg/kg|
11530838|NCT01138163|Experimental|Docetaxel plus bavituximab 3 mg/kg|
11530839|NCT01138163|Placebo Comparator|Docetaxel plus placebo|
11530840|NCT01138150|Active Comparator|Treximet|"Fourteen participants randomized to receive Treximet (sumatriptan & naproxen) during an acute migraine attack. Blood drawn for immune & inflammatory markers (adipocytokines,cytokines, sex hormones) at different time points - on presentation with moderate to severe migraine pain; then 30 minutes, 1 hour and 2 hours after administration of study drug (Treximet).
~Participants will be offered a traditional headache rescue medicine at 2 hours after administration of Treximet if participant still reports moderate to severe pain and desires further treatment. Rescue medicine may include the following: prochlorperazine 10 mg IV preceded by diphenhydramine 25 mg IV/PO or metoclopramide 10 mg IV preceded by diphenhydramine 25 mg IV/PO or Toradol 30 mg IV to be determined by the physician."
11530841|NCT01138150|Placebo Comparator|Sugar Pill|"Fourteen participants randomized to receive placebo during an acute migraine attack. Blood is drawn for immune & inflammatory markers (adipocytokines,cytokines), sex hormones at different time points - on presentation with moderate to severe migraine pain, then 30 minutes, 1 hour and 2 hours after administration of placebo.
~Participants will be offered a traditional headache rescue medicine at 2 hours after administration of placebo if participant still reports moderate to severe pain and desires further treatment. Rescue medicine may include the following: prochlorperazine 10 mg IV preceded by diphenhydramine 25 mg IV/PO or metoclopramide 10 mg IV preceded by diphenhydramine 25 mg IV/PO or Toradol 30 mg IV to be determined by the physician."
11530842|NCT01138137|Experimental|All subjects|
11530843|NCT01138124||UK GPRD 1993-2008|The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993.
11530844|NCT01138111|Experimental|Arm 1|
11530845|NCT01138098|Experimental|Infanrix-hexa/Engerix-B Group|Subjects aged 11-12 year old received 3 doses of Infanrix-hexa vaccine in the primary study (217744/031 (NCT01457495)) and a challenge dose of Engerix-B vaccine in this study. Engerix-B was administered as a single dose intramuscularly into the deltoid region of the non-dominant arm.
11530846|NCT01138098|Active Comparator|Infanrix-IPV+Hib/Engerix-B Group|Subjects aged 11-12 year old received 3 doses of Infanrix-IPV+Hib and Engerix-B vaccines in the primary study (217744/031 (NCT01457495)) and a challenge dose of Engerix-B vaccine in this study. Engerix-B was administered as a single dose intramuscularly into the deltoid region of the non-dominant arm.
11530847|NCT01138085|Experimental|Dose Escalation|Dose escalation will proceed until unacceptable toxicity is observed. Dose escalation decisions will take into account all available data, including PK data and the safety profile of prior cohorts and will occur following review of these data by the investigator(s), GSK medical monitor, pharmacokineticist, and statistician.
11530885|NCT01137890|Experimental|Zonisamide|Participants administered blind capsules containing either placebo or zonisamide.
11530886|NCT01137890|Placebo Comparator|Placebo|Participants administered only placebo capsules containing lactose.
11530887|NCT01137877|Active Comparator|Infant Formula #1|Milk-based Infant Formula Powder
11531460|NCT01133899|Experimental|GAA-1|1.2 grams of guanidinoacetic acid
11530848|NCT01138085|Experimental|Expansion Cohorts|"Enrollment into expansion cohort(s) in Part 2A may begin once a recommended dosing regimen(s) is identified in Part 1A utilizing a once daily continuous dosing schedule for both GSK1120212 and GSK2141795. Enrolment to cohorts utilizing this daily dosing schedule may proceed in parallel with enrolment in Part 1B. Expansion cohort(s) will preferentially enroll subjects with treatment-refractory, measurable and biopsiable triple negative breast cancer or BRAF- wild type melanoma. Subjects selected for enrollment into Part 2A or Part 2B will be tested for PTEN deficiency and must agree to provide paired tumor biopsies (at baseline and once while on- treatment). An additional tumor biopsy at the time of disease progression should also be collected if feasible.
~In Part 2A and Part 2B, up to 35 additional subjects per tumor type and schedule (i.e., a total of up to 70 subjects per schedule tested) may be enrolled in a two-stage design to better characterize safety, PK and PD."
11530849|NCT01138072|Experimental|Treatment A|Simvastatin 20mg (single dose) Day 1
11530850|NCT01138072|Experimental|Treatment B|Atorvastain 20 mg (single dose) Day 3
11530851|NCT01138072|Experimental|Treatment C|Rosuvastatin 10mg (single dose) Day 7
11530852|NCT01138072|Experimental|Treatment X|GSK2248761 200mg single dose Day 10-14, Day 16-17, Day 19-21, Day 23-24
11530853|NCT01138072|Experimental|Treatment D|GSK2248761 200mg + simvastatin 20 mg Day 15
11530854|NCT01138072|Experimental|Treatment E|GSK2248761 200mg + atorvastatin 20 mg Day 18
11530855|NCT01138072|Experimental|Treatment F|GSK2248761 200mg + rosuvastatin 20 mg Day 22
11530856|NCT01138059||Acute ischemic stroke patients with unclear onset|
11530857|NCT01138046|Experimental|Lap+weekly Pacli|These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib. Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent.
11530858|NCT01138033|Experimental|Part 1|Part 1 - dose escalation; starting dose 80 mg BID
11530859|NCT01138033|Experimental|Part 2|Part 2 - Dose expansion phase of the study at the maximum tolerated dose and schedule identified in Part 1 in patients with tumors known to over express FAK
11530860|NCT01138033|Experimental|Part 3|Part 3 - Characterize the biologically active dose range by analysis of PD markers in skin, hair and in tumor tissue in subjects with solid tumors amendable to biopsy and know to over express FAK
11530861|NCT01138033|Experimental|Part 4|Part 4 - Explore further the safety, PK, tolerability and anti-tumor activity of GSK2256098 in subjects with relapsed glioblastoma multiforme (GBM).
11530862|NCT01138033|Experimental|Part 5|Part 5 will investigate the time course, the extent of an apparent change in the PK of GSK2256098 following repeated dosing, and screen for potential CYP3A induction as a possible mechanism of reduced systemic exposure of GSK2256098 at Day 15 and later time points.
11530863|NCT01138020|Experimental|Arm 1|Cognitive intervention
11530864|NCT01138020|Active Comparator|Arm 2|Educational intervention
11530865|NCT01138007|Experimental|323U66 SR 150 mg cohort|323U66 SR 150 mg tablet is orally administered once in the morning and 323U66 SR 150 mg placebo tablet is orally administered once in the evening throughout the treatment phase.
11530866|NCT01138007|Experimental|323U66 SR 300 mg cohort|323U66 SR 150 mg tablet is orally administered once in the morning and 323U66 SR 150 mg placebo tablet is orally administered once in the evening during the first week of the treatment phase. At the second week, 323U66 SR 300mg cohort is up-titrated to a daily dose of 323U66 SR 300 mg, administered as 323U66 SR 150 mg tablet twice daily in the morning and in the evening, and the same daily dose is maintained to administer until the end of the treatment phase.
11530867|NCT01138007|Placebo Comparator|Placebo cohort|323U66 SR placebo tablet is orally administered twice daily throughout the treatment phase.
11530868|NCT01137994|Experimental|Lapatinib plus Chemotherapy|Lapatinib (1250mg once daily) in combination with chemotherapy (docetaxel, paclitaxel or vinorelbine) selected at the discretion of the investigator
11530869|NCT01137994|Experimental|Trastuzumab plus Chemotherapy|Trastuzumab (either 6mg/kg q3-weekly or 2mg/kg weekly) in combination with chemotherapy (docetaxel, paclitaxel or vinorelbine) selected at the discretion of the investigator
11530870|NCT01137981||Pregnant, HIV Positive Women|Any pregnant, HIV positive woman exposed to antiretroviral drugs during pregnancy.
11530871|NCT01137968|Experimental|imetelstat plus standard of care|imetelstat plus standard of care (bevacizumab or observation)
11530872|NCT01137968|Other|Standard of care|Bevacizumab or observation
11530873|NCT01137955|Experimental|Rifaximin|Antibiotic
11530874|NCT01137955|Placebo Comparator|Placebo|
11530875|NCT01137942||H. pylori eradication failure|Those who eradicated Helicobacter pylori with appropriate antibiotic therapy and those who did not.
11530876|NCT01137929||With APN, With VUR, With Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will also have VUR by VCUG and a renal scar on follow-up DMSA renal scan.
11530877|NCT01137929||With APN, With VUR, Without Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will also have VUR by VCUG and NO renal scar on follow-up DMSA renal scan.
11530878|NCT01137929||With APN, without VUR, with Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan but who will NOT have VUR by VCUG; however they will have a renal scar on follow-up DMSA renal scan.
11530879|NCT01137929||With APN, Without VUR, Without Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will NOT have VUR by VCUG, NOR will they have a renal scar on follow-up DMSA renal scan.
11530880|NCT01137929||Without APN, With VUR|This group of children who present with a febrile UTI will be found NOT to have APN on DMSA renal scan and will also have VUR by VCUG. They will not undergo a second DMSA scan since the first one is normal.
11530881|NCT01137929||Without APN, Without VUR|This group of children who present with a febrile UTI will be found NOT to have APN on DMSA renal scan and will also NOT have VUR by VCUG, NOR a renal scar on follow-up DMSA renal scan.
11530882|NCT01137916|Experimental|drug|Imatinib 800 mg
11530883|NCT01137903|Other|Patients undergoing medical treatment|"Antibiotic treatment within 90 days with:
~Ciprofloxacin Amoxicillin /Clavulanic acid. Trimethoprim /Sulfamethoxazole."
11530884|NCT01137903|Other|Patients undergoing surgical treatment|Conservative surgical Minor amputation 7 days antibiotic after surgical
11530888|NCT01137877|Experimental|Investigational Infant Formula #1|Investigational Milk-based Infant Formula Powder
11530889|NCT01137877|Experimental|Investigational Infant Formula #2|Investigational Milk based infant formula powder
11530890|NCT01137877|Active Comparator|Human Milk|Reference group
11530891|NCT01137864|Experimental|Infectious disease specialist advice|Patients receiving the intervention (infectious disease specialist advice)
11530892|NCT01137864|No Intervention|Control|Patients not receiving infectious disease specialist advice
11530893|NCT01137851||New to bDMARD|New to bDMARD RA patients with high and low cost share who continue or discontinue treatment
11530894|NCT01137838||Patients with RA and new to abatacept|
11530895|NCT01137838||Patients with RA and new to infliximab|
11530896|NCT01137838||Patients with RA and new to etanercept|
11530897|NCT01137838||Patients with RA and new to adalimumab|
11530898|NCT01137812|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
11530899|NCT01137812|Active Comparator|Sitagliptin 100 mg|Each patient will receive 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
11530900|NCT01137799|Experimental|001|JNJ-39393406 10mg nanosuspension (sort of liquid formulation) once daily (single dose)
11530901|NCT01137799|Experimental|002|JNJ-39393406 30mg nanosuspension (sort of liquid formulation) once daily (single dose)
11530902|NCT01137799|Experimental|003|JNJ-39393406 50mg nanosuspension (sort of liquid formulation) once daily (single dose)
11530903|NCT01137799|Experimental|004|JNJ-39393406 100mg nanosuspension (sort of liquid formulation) once daily (single dose)
11530904|NCT01137799|Experimental|005|JNJ-39393406 200mg nanosuspension (sort of liquid formulation) once daily (single dose)
11530905|NCT01137799|Placebo Comparator|006|placebo Once daily (single dose)
11530906|NCT01137786|Active Comparator|IOPAMIDOL 370|
11530907|NCT01137786|Active Comparator|IODIXANOL 320|
11530908|NCT01137773|Experimental|Intensive IV Insulin|Patients will receive IV insulin to maintain target glucose levels of 80-110 mg/dl
11530909|NCT01137773|Active Comparator|Conventional Insulin Treatment|Patents will receive conventional IV insulin treatment with target glucose levels of 150-170 mg/dl
11530910|NCT01137760|Placebo Comparator|Sugar pill|
11530911|NCT01137760|Experimental|Galactooligosaccharide 2.5 g|
11530912|NCT01137760|Experimental|Galactooligosaccharide 5.0 g|
11530913|NCT01137747|Experimental|Dose Level 0 (starting dose)|"Carfilzomib - 20 mg/m2 days 1 and 2, 27 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 36 mg/m2 for all subsequent doses. If DLT occurs while receiving 36 mg/m2, the dose may be reduced to 27 mg/m2.
~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.
~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
11530914|NCT01137747|Experimental|Dose Level +1|"Carfilzomib - 20 mg/m2 days 1 and 2, 36 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 45 mg/m2 for all subsequent doses. If DLT occurs while receiving 45 mg/m2, the dose may be reduced to 36 mg/m2.
~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.
~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
11530915|NCT01137747|Experimental|Dose Level +2|"Carfilzomib - 20 mg/m2 days 1 and 2, 45 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 56 mg/m2 for all subsequent doses. If DLT occurs while receiving 56 mg/m2, the dose may be reduced to 45 mg/m2.
~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.
~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
11530916|NCT01137721||Pre-Hydroxyurea - subjects with SCD|Patients with a diagnosis of HbSS (sickle cell anemia) or HbS/ß0-thalassemia (beta thalassemia) who will be treated with hydroxyurea therapy.
11530917|NCT01137721||Sibling control|Sibling control with no diagnosis of HbSS or HbS/ß0-thalassemia.
11530918|NCT01137721||Observational - subjects with SCD|Patients with a diagnosis of HbSS or HbS/ß0-thalassemia.
11530919|NCT01137721||Pre-transfusion - subjects with SCD|Patients with a diagnosis of HbSS or HbS/ß0-thalassemia who will be treated with transfusion therapy.
11530920|NCT01137708|Experimental|Treatment Sequence 1|
11530921|NCT01137708|Experimental|Treatment Sequence 2|
11530922|NCT01137695|Active Comparator|Symlin Naive, Usual Dose|Symlin 120 mcg three times daily in patients not previously treated with pramlintide before the study.
11530923|NCT01137695|Experimental|Symlin Naive, Dose Escalation|Escalation of pramlintide dose to 360 mcg three times daily in patients not taking pramlintide prior to study.
11530924|NCT01137695|Active Comparator|Symlin treated, Usual Dose|pramlintide 120 mcg three times daily in patients who have been treated with pramlintide 120 mcg prior to the trial.
11530925|NCT01137695|Experimental|Symlin Treated, Dose Escalation|pramlintide 360 mcg three times daily in patients previously treated with 120 mcg prior to the study.
11530926|NCT01137682|Experimental|Pasireotide LAR 40 mg|Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution)
11530927|NCT01137682|Experimental|Pasireotide LAR 60 mg|Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution)
11530928|NCT01137682|Active Comparator|Control arm (octreotide or lanreotide)|"If a patient is randomized to the open label arm the investigator will either:
~be instructed to contact a Novartis delegate to initiate shipment of either octreotide LAR 30 mg or lanreotide ATG 120 mg from a Novartis or designee depot to the site, or
~continue to dispense either octreotide LAR 30 mg or lanreotide ATG 120 mg available at the institution to the patient if permitted by local regulations."
11530929|NCT01137669|Placebo Comparator|Placebo|10 subjects to receive placebo subcutaneously.
11530930|NCT01137669|Experimental|ZOSTAVAX®|30 subjects to receive 0.65 mL ZOSTAVAX® subcutaneously.
11530931|NCT01137656|Other|Acetylcholine and Blood|This is single arm study. Acetylcholine and blood is infused in brachial artery of non-dominant arm. Blood flow
11530932|NCT01137630|Experimental|K40a|K40a is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
11530933|NCT01137630|Experimental|K40b|K40b is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
11530934|NCT01137630|Placebo Comparator|Placebo|Placebo is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
11530935|NCT01137604|Experimental|Cohort 1|"Cohort 1 assessed participants with recurrent Grade 4 malignant glioma (ie, glioblastoma [GBM]) who were bevacizumab-naive. Participants were planned to be accrued in Cohort 1 and randomized in a 1:1 ratio to receive lenvatinib (experimental) or bevacizumab (active comparator).
~Cohort 1 - Bevacizumab
~Cohort 1 - Lenvatinib"
11530936|NCT01137604|Experimental|Cohort 2|Cohort 2 assessed participants with recurrent Grade 3 malignant glioma who were bevacizumab-naive. Participants in Cohort 2 were planned to be treated with lenvatinib.
11530937|NCT01137604|Experimental|Cohort 3|Cohort 3 assessed participants with recurrent GBM who had disease progression following prior bevacizumab treatment. Participants in Cohort 3 were planned to be treated with lenvatinib.
11530938|NCT01137591|Experimental|APAP and NAC combination|N-acetyl-p-aminophenol and placebo (APAP-NAC) combination pill
11530939|NCT01137591|Placebo Comparator|APAP and Placebo combination|N-acetyl-p-aminophenol and placebo (APAP-placebo) combination pill
11530940|NCT01137578|Other|Cohort A: US, MRI with contrast, MRI without contrast|Subjects with a central venous catheter (CVC) in place and asymptomatic for a CVC-related DVT to have an Ultrasound (US), Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
11530941|NCT01137578|Other|Cohort B: US, MRI with contrast, MRI without contrast|Subjects with a CVC in place either symptomatic for a CVC-related DVT or having an incidental diagnosis of CVC-related DVT by radiographic imaging performed for other clinical reasons to have an Ultrasound, Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
11530942|NCT01137578|Other|Cohort C: US, MRI with contrast, MRI without contrast|Subjects with a CVC in place having an MRI for clinical reasons to have an Ultrasound, Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
11530943|NCT01137565|Experimental|AMG 853|
11530944|NCT01137565|Placebo Comparator|Placebo|
11530945|NCT01137552|Experimental|A|Dose Escalation
11530946|NCT01137552|Experimental|B|Dose Expansion
11530947|NCT01137539|Experimental|Gynecare TVT-SECUR system|All patients enrolled into the study will receive the TVT-SECUR system to treat stress urinary incontinence
11530948|NCT01137526|Experimental|ABT-384 Dose 1|
11530949|NCT01137526|Experimental|ABT-384 Dose 2|
11530950|NCT01137526|Active Comparator|donepezil|
11530951|NCT01137526|Placebo Comparator|placebo|
11530952|NCT01137513||Chest Pain|Acute Myocardial ischemia
11530953|NCT01137487|Other|residual gastric volume|
11530954|NCT01137487|Other|residual gastric volume not monitored|
11530955|NCT01137474|Experimental|Dapagliflozin, 10 mg|Oral tablets administered as 10 mg once daily for up to 12 weeks
11530956|NCT01137474|Placebo Comparator|Placebo-matching dapagliflozin|Oral tablets administered once daily in the morning
11530957|NCT01137474|Experimental|Dapagliflozin, 2. 5 mg|Oral tablets administered as 2.5 mg once daily for up to 12 weeks (Arm discontinued as of Protocol Amendment 8)
11530958|NCT01137474|Experimental|Dapagliflozin, 5 mg|Oral tablets administered as 5 mg once daily for up to 12 weeks (Arm discontinued as of Protocol Amendment 8)
11530959|NCT01137461|Other|abdominal ultrasound|traditional technique
11530960|NCT01137461|Other|transvaginal ultrasound|new technique
11530961|NCT01137448|Experimental|Weight Loss|Subjects will be enrolled in a weight loss program and will receive weight loss and nutritional counseling.
11530962|NCT01137435|Experimental|Study Group|
11530963|NCT01137409||Suspected or Diagnosed with Coronary artery disease|All patients with suspected or previously diagnosed coronary artery disease
11530964|NCT01137396|Experimental|Modafinil|
11530965|NCT01137396|Placebo Comparator|Placebo|
11530966|NCT01137383|Experimental|Treatment group|
11530967|NCT01137370||Patients with TB|
11530968|NCT01137370||People without TB|
11530969|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L.plantarum WCFS1)|
11530970|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L.plantarum NIZO3400)|
11530971|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L. plantarum NIZO2877)|
11530972|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L.plantarum CBS125632)|
11530973|NCT01137357|Active Comparator|Yoghurt with Lactobacillus casei Shirota|
11530974|NCT01137357|Placebo Comparator|Placebo Yoghurt|
11530975|NCT01137331|Experimental|K301|K301 applied topically to the affected area of the scalp once daily during the 4 weeks. Treatment is to be applied before bedtime and can be washed out with the patient's normal shampoo in the morning.
11530976|NCT01137331|Placebo Comparator|Placebo|Placebo applied topically to the affected area of the scalp once daily during the 4 weeks. Treatment is to be applied before bedtime and can be washed out with the patient's normal shampoo in the morning.
11530977|NCT01137318|Experimental|Cognitive remediation and Behavioral Intervention|
11530978|NCT01137318|Placebo Comparator|Low Level Cognitive Remediation and Behavioral Parent Traning|
11530979|NCT01137292||Active Treatment|Patients who are eligible for voriconazole treatment according to their physician decision.
11530980|NCT01137266|Active Comparator|skin resistence|1) the location with the lowest resistance
11530981|NCT01137266|Active Comparator|irradiation|2) the site that causes an irradiation sensation
11530982|NCT01137266|Active Comparator|random|3) a random stimulation site.
11530983|NCT01137253|Experimental|Trimethaphan|Response to intrabrachial vasodilators during autonomic withdrawal
11530984|NCT01137253|Placebo Comparator|Placebo|Response to intrabrachial vasodilators during saline intravenous (IV) infusion
11530985|NCT01137240||Children with mitochondrial disorders|suffering from gastrointestinal dysfunction
11530986|NCT01137227||Description|"2137 studies retrieved in 8 databases (Biomed Central, CINAHL, EMBASE, ERIC, PsycInfo, PUBMED, SCOPUS, SPORTDiscus and uploaded in EndNote Web®.
~332 studies were excluded as duplicates by EndNote Web®.
~1805 titles and abstracts were assessed independently by two researchers (PG/AM): 1541 studies excluded.
~264 studies referred for full-text assessment by two independent investigators (PG/AM)
~225 studies were excluded according to the eligibility criteria (in case of discrepancies in the assessment of the researchers, studies were reviewed in duplicate)
~39 Studies assessed for quality using STROBE
~13 Studies were included in the descriptive synthesis"
11530987|NCT01137214|Active Comparator|CPAP|Continuous Positive Airway Pressure
11530988|NCT01137214|Active Comparator|Adaptive Servo-Ventilator|Non-invasive positive pressure ventilator that applies a constant expiratory pressure, as well as a variable inspiratory pressure.
11530989|NCT01137201|Experimental|Mesenteric defects sutured|Closure of the mesenteric defects using running, non-absorbable suture
11530990|NCT01137201|No Intervention|Mesenteric defects not sutured|Non-closure of the mesenteric defects
11530991|NCT01137188|Experimental|Intervention group|Intensive weight loss program and regular group sessions with clinical dietician. Complete dietary substitution with a low calorie diet containing 800-1000 kcal/day for 8 weeks
11530992|NCT01137188|No Intervention|No intervention|Study subjects will receive routine dietary counseling for 8 weeks and will cross over to intervention upon completion
11530993|NCT01137149|Active Comparator|Treatment as Usual- Psychotherapy|The TAU condition will be implemented consistent with usual and customary clinical practices within the Child Psychiatry Clinic at Seattle Children's Hospital (SCH. Within the SCH system, TAU for a depressed adolescent will typically consist of an individual therapy approach with adjunct family sessions and pharmacotherapy as deemed necessary by the primary therapist. The therapeutic approach typically used is cognitive behavioral but is administered in an eclectic, non-manualized fashion. Therapists for the TAU arm of the study will be care providers currently working within the SCH system. For this phase of the study, we will draw on clinicians whose level of experience is comparable to that of the Behavioral Activation therapists.
11530994|NCT01137149|Experimental|Behavioral Acitivation Therapy|Behavioral activation is a 12 week psychotherapeutic intervention utilizing a semi-structured format. Initial sessions focus on specific areas (Assessment and orientation, Activation, Problem Solving, Goal Setting, Overcoming Barriers, Avoidance) interspersed as needed by sessions that focus on individual issues and applications. In these sessions the therapists maintains the session structure, but can use techniques presented in earlier sessions based on their functional analysis of the particular case. Parents participate in at least two of the ATA sessions but more active parental participation can be included as needed.
11530995|NCT01137136||SMAC (SMc AI user Cohort)|All patients who took the AI (Aromatase inhibitor)will be enrolled
11530996|NCT01137123|Active Comparator|standard two field +follow-up|
11530997|NCT01137123|Experimental|standard two field +adjuvant chemotherapy|
11530998|NCT01137123|Experimental|total two field+follow-up|
11530999|NCT01137123|Experimental|total two field+adjuvant chemotherapy|
11531000|NCT01137123|Experimental|three field+follow-up|
11531001|NCT01137123|Experimental|three field+adjuvant chemotherapy|
11531002|NCT01137110|Other|Brief LEV|Administration of three days of levetiracetam twice daily after SAH
11531003|NCT01137110|Other|Extended LEV|Administration of levetiracetam twice daily after SAH
11531004|NCT01137097|Active Comparator|Lateral sentinel group|Lateral sentinel lymph node biopsy with radioisotope
11531005|NCT01137097|No Intervention|No intervention for lateral neck|No lateral sentinel lymph node biopsy with radioisotope
11531006|NCT01137084|Active Comparator|a steroid immunosuppression protocol|
11531007|NCT01137084|Active Comparator|a steroid-free immunosuppression protocol|without steroid
11531008|NCT01137071|Experimental|Monoclonal antibody hu3S193|Monoclonal antibody hu3S193 will be administered to 51 patients at the dose of 30mg/m2 every other week (total of 12 infusions) for a total of 23 weeks.
11531009|NCT01137058|Experimental|U-healthcare|glucose meter and U-healthcare
11531010|NCT01137058|Active Comparator|SMBG group|Diabetic patients who do self monitoring of blood glucose only were categorized into self monitoring of blood glucose (SMBG) group.
11531011|NCT01137058|No Intervention|control|conventional treatment
11531012|NCT01137045|Active Comparator|SPEEDA with modified TRC-ID regimen|35 healthy volunteers
11531013|NCT01137045|Active Comparator|VERORAB with modified TRC-ID regimen|35 healthy volunteers
11531014|NCT01137045|Active Comparator|SPEEDA with modified TRC-ID regimen plus ERIG|35 healthy volunteers
11531015|NCT01137045|Active Comparator|VERORAB with modified TRC-ID regimen plus ERIG|35 WHO category III patients
11531016|NCT01137045|Active Comparator|SPEEDA with ESSEN IM regimen plus ERIG|35 healthy volunteers
11531017|NCT01137045|Active Comparator|TRCS SPEEDA with modified TRC-ID regimen plus ERIG|35 healthy volunteers
11531018|NCT01137032|Experimental|Pandel Cream 0.1%|Pandel Cream 0.1%
11531019|NCT01137019|Active Comparator|Biolimus-eluting stent|
11531020|NCT01137019|Active Comparator|Everolimus-eluting stent|
11531021|NCT01137006|Experimental|IMC-20D7S (1A-4A Cohorts)|Escalating doses up to 30 milligrams per kilogram (mg/kg) administered intravenously (i.v.) every 2 weeks; includes Cohorts 1A, 2A, 3A, and 4A.
11531022|NCT01137006|Experimental|IMC-20D7S (1B-3B Cohorts)|Escalating doses up to 30 mg/kg administered i.v. every 3 weeks; includes Cohorts 1B, 2B, and 3B.
11531023|NCT01136993||All bi-directional telestroke consultations|
11531024|NCT01136980|Placebo Comparator|Sham placebo procedure|Sham Procedure: SHAM/PPI's An upper GI Endoscopy is performed with a standard endoscope, during 30-45 minutes. The patient is under general anesthesia. EGD explores the esophagus, the stomach, and the GEJ.
11531025|NCT01136980|Active Comparator|TIF Transoral Fundoplication|Intervention: TIF 2.0/Placebo TIF Transoral Incisionless Fundoplication: A fundoplication of 270 degrees and 3cm in length was created. The EsophyX device is introduced over a standard endoscope, through the mouth, into the stomach.
11531026|NCT01136967|Experimental|Cohort 1 (V600E BRAF negative)|Cohort 1 (V600E BRAF negative) enrolled participants not harboring the V600E BRAF mutation with disease progression following up to 2 prior systemic anticancer regimens (excluding anti-VEGF) for unresectable Stage III or Stage IV melanoma.
11531027|NCT01136967|Experimental|Cohort 2 (V600E BRAF positive)|Cohort 2 (V600E BRAF positive) enrolled participants harboring the activating BRAF mutations (mainly the V600E mutation) with disease progression following BRAF V600E-targeted therapy.
11531028|NCT01136954|Experimental|1|
11531029|NCT01136941|Experimental|Treatment|Research participants will be administered Zileuton according to the dose escalation/de-escalation schema provided in the protocol.
11531030|NCT01136928|Experimental|American ginseng and efavirenz|This is a sequential study. Healthy volunteers will receive efavirenz alone for 14 days followed by efavirenz plus American ginseng for an additional 14 days.
11531031|NCT01136915|Active Comparator|IOPAMIDOL injection 370|
11531032|NCT01136915|Active Comparator|Iodixanol 320|
11531033|NCT01136902||Type 2 DM|This group includes subjects diagnosed with type 2 diabetes mellitus with none or minimal diabetic retinopathy.
11531034|NCT01136889|Active Comparator|PFMT plus routine pessary management|"Women allocated to the intervention group will be invited to attend 5 out-patient appointments over a 16 week period with a trained specialist women's health physiotherapist at the study centre. Women will be taught how to contract the muscles, and also how to contract and hold prior to an event that increases intra-abdominal pressure (the Knack). Tailored advice will be given on ways of reducing intra-abdominal pressure, e.g. advice on weight loss, chronic cough, heavy lifting and general exercise. A prolapse specific Lifestyle Advice sheet will also be given to the women by the physiotherapist."
11531035|NCT01136889|Active Comparator|Lifestyle|Women allocated to the control group will be sent a Lifestyle Advice Leaflet only. They will have no planned intervention after their pessary is fitted, other than routine pessary management according to local protocols. The Lifestyle Advice Leaflet gives instructions on seeking advice, where appropriate, about weight loss, constipation, and avoidance of heavy lifting, coughing and high impact exercise, with a view to minimising increases in intra-abdominal pressure which may cause the prolapse to worsen.
11531036|NCT01136876|Active Comparator|Iopamidol|Non-ionic low-osmolar iodinated contrast media
11531037|NCT01136876|Active Comparator|Iodixanol|Non-ionic iso-osmolar iodinated contrast media comparator
11531038|NCT01136863|Active Comparator|felodipine group, active, pill|felodipine and HCTZ treatment group
11531039|NCT01136863|Placebo Comparator|placebo, no treatment, pill|placebo and HCTZ group
11531040|NCT01136850|Active Comparator|SP, chloroquine treatment; bed net|Treatment course of sulphadoxine pyrimethamine and chloroquine on enrolment. Long lasting insecticide treated bed net
11531041|NCT01136850|Experimental|3 x SP plus azithromycin; bed nets|Three x monthly courses of azithromycin and sulphadoxine pyrimethamine plus long lasting insecticide treated bed net.
11531042|NCT01136837||fragmented QRS positive|fQRS at 48 hours after Primary PCI
11531043|NCT01136824||Sarcoma Subjects|Soft tissue sarcoma patients treated with the adjuvant and neoadjuvant chemotherapy protocol of doxorubicin plus ifosfamide (AI)
11531044|NCT01136811|Experimental|Computer assisted surgery|
11531045|NCT01136798|Placebo Comparator|Usual T2 DM med regimen|Subjects will continue on Type 2 DM therapy but will add placebo injected subcutaneously twice daily to their regimen for a total of 6 weeks.
11531046|NCT01136798|Experimental|Usual T2 DM med regimen plus Exenatide|Subjects will continue on Type 2 DM therapy but will add injectable exenatide to their regimen There will be twice daily treatment with subcutaneous injections of 5 µg of Exenatide for 2 weeks followed by 4 weeks of treatment with twice daily subcutaneous injections of 10 µg of Exenatide.
11531047|NCT01136785|Active Comparator|Active CPAP therapy|7 days of treatment in the laboratory with active CPAP therapy.
11531048|NCT01136785|Sham Comparator|Sham CPAP therapy|7 days of sham CPAP therapy in the laboratory.
11531049|NCT01136772|Experimental|Paliperidone palmitate|Intramuscular injections of paliperidone palmitate 39-234 mg every month
11531050|NCT01136772|Active Comparator|Haloperidol decanoate|Intramuscular injections of haloperidol decanoate 25-200 mg every month
11531051|NCT01136759|Placebo Comparator|Pregnancy cohort, placebo|Pregnant women will receive placebo gel.
11531052|NCT01136759|Experimental|Lactation cohort, tenofovir gel|Lactating mothers will receive tenofovir gel.
11531053|NCT01136759|Experimental|Pregnancy cohort, tenofovir gel|Pregnant women will receive tenofovir gel.
11531054|NCT01136746|Active Comparator|Sliding scale regular insulin|
11531055|NCT01136746|Experimental|Basal-bolus therapy|
11531056|NCT01136733|Experimental|Lenvatinib|
11531057|NCT01136733|Experimental|Lenvatinib plus Everolimus|
11531058|NCT01136733|Active Comparator|Everolimus|
11531059|NCT01136720||patients injected with the Halifax produced 18-FDG|
11531060|NCT01136707||Patients with rheumatoid arthritis new to Orencia|
11531061|NCT01136694||RA patients who are new bDMARD users|
11531062|NCT01136694||RA patients who are existing DMARD users|
11531063|NCT01136668|Experimental|Treatment group|
11531064|NCT01136668|Active Comparator|Control Group|
11531065|NCT01136655|Experimental|BUD 160/FM 2.25|2.25 μg formoterol (as 80/2.25 μg Symbicort pMDI × 1 inhalation) + 40 μg budesonide HFA pMDI × 2 inhalations
11531066|NCT01136655|Experimental|BUD 160/FM 4.5|placebo HFA pMDI × 1 inhalation + 4.5 μg formoterol (as 80/2.25 μg Symbicort pMDI × 2 inhalations)
11531067|NCT01136655|Experimental|BUD 160/FM 9.0|placebo HFA pMDI × 1 inhalation + 9 μg formoterol (as 80/4.5 μg Symbicort pMDI × 2 inhalations)
11531068|NCT01136655|Placebo Comparator|BUD 160|placebo HFA pMDI × 1 inhalation + 80 μg budesonide HFA pMDI × 2 inhalations
11531069|NCT01136655|Active Comparator|BUD 160/Foradil 12.0|Foradil Aerolizer 12 μg × 1 inhalation + 80 μg budesonide HFA pMDI × 2 inhalations
11531070|NCT01136629||Subjects with hyper-pigmented spots|Subjects age 21 to 80 year old, who have elected to undergo a plastic surgery will be enrolled. Subjects will be from Chinese, Malay, Indian or Caucasian ancestry. Subjects will be female or male with a hyper-pigmented spots.
11531165|NCT01135940|Experimental|1|2-octylcyanoacrylate (Dermabond) closure
11531166|NCT01135940|Active Comparator|2|Standard staple closure
11531167|NCT01135927|Experimental|A|
11531168|NCT01135927|Active Comparator|B|
11531071|NCT01136616||Nasal Fracture|"67 patients admitted for facial fractures and who undergo routine CT scans of the face are to be studied. CT scans are evaluated to assess the position, comminution and displacement of the 5 said buttresses.
~The buttresses are graded Grade 1 Simple fracture without displacement Grade 2 Simple fracture with displacement Grade 3 Comminuted fracture without displacement Grade 4 Comminuted fracture with minimal displacement Grade 5 Comminuted fractured with displacement
~The septum is graded from Grade 0 Septum is straight Grade 1 Septum is deviated by less than 1 half the distance from the midline to the nasal turbinate Grade 2 Septum is deviated by more than 1 half the distance from the midline to the nasal turbinate Grade 3 Septum is almost touching the nasal turbinate"
11531072|NCT01136603|Experimental|TIGR Mesh|Experimental - TIGR Mesh
11531073|NCT01136603|Active Comparator|Control|Control group - Non absorbable Polypropylene mesh
11531074|NCT01136590|Experimental|tranexamic acid|tranexamic acid will be administered as a bolus (10-mg/kg dose ) or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery
11531075|NCT01136590|Placebo Comparator|placebo|The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
11531076|NCT01136577|Experimental|LEDDYBLOO®|LEDDYBLOO® phototherapy device equipped with 20 at 30 blue and white LEDs
11531077|NCT01136577|Experimental|Double BILITRON®|Double BILITRON® phototherapy corresponding to two small ramps associated together each one equipped of 5 blue LEDS
11531078|NCT01136577|Experimental|Futura®|Future phototherapy device equipped with 8 fluorescent tubes
11531079|NCT01136564|Active Comparator|Paricalcitol|
11531080|NCT01136564|Placebo Comparator|Placebo|
11531081|NCT01136551|Active Comparator|IR formulation|Healthy volunteers will receive imediate release formulation of Huperzine A (0.4mg)
11531082|NCT01136551|Experimental|CR 1|"CR formulation
~Healthy volunteers will receive controlled release formulation 1 of Huperzine A (0.4mg)"
11531083|NCT01136551|Experimental|CR 2|"CR formulation
~Same volunteers will receive controlled release formulation 2 of Huperzine A (0.4mg)"
11531084|NCT01136538|Experimental|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
11531085|NCT01136538|Active Comparator|Valtrex (R)|Valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline
11531086|NCT01136525|Experimental|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
11531087|NCT01136525|Active Comparator|Valtrex (R)|Valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline
11531088|NCT01136512||metformin use|Patients with type 2 diabetes treated with metformin
11531089|NCT01136512||no metformin use|Patients with type 2 diabetes who are not being treated with metformin
11531090|NCT01136499|Experimental|LBH PANOBINOSTAT|40 mg 3 days per week
11531091|NCT01136473||congenital cataract or aphakic glaucoma|children with congenital cataract or aphakic glaucoma
11531092|NCT01136460||Primary congenital glaucoma|Primary congenital glaucoma patients and their immediate relatives
11531093|NCT01136447|Placebo Comparator|Neurostimulation|Block catheter will be introduced using neurostimulation
11531094|NCT01136447|Active Comparator|Ultrasound|Block catheter will be introduced using ultrasound
11531095|NCT01136421|Active Comparator|Ipratropium bromide|Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.
11531096|NCT01136421|Experimental|Magnesium sulfate|Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.
11531097|NCT01136408|Experimental|Dabigatran etexilate 220 mg daily|Dabigatran etexilate 110 mg capsule, twice a day, oral administration
11531098|NCT01136408|Experimental|Dabigatran etexilate 300 mg daily|Dabigatran etexilate 150 mg capsule, twice a day, oral administration
11531099|NCT01136408|Active Comparator|Warfarin|Dose-adjusted warfarin based on target INR values
11531100|NCT01136395|Active Comparator|LD kidney transplantation, ABOi|Living donor (LD) kidney transplantation, ABO incompatible (ABOi); Immunosuppressive treatment: Tacrolimus (Tacr)/ Mycophenolate sodium (MPS), Basiliximab induction, Rtx induction
11531101|NCT01136395|Active Comparator|LD kidney transplantation, ABOc|Living donor (LD) kidney transplantation, ABO compatible (ABOc); Immunosuppressive treatment: Tacr/MPS, Basiliximab induction
11531102|NCT01136395|Active Comparator|DD kidney transplantation|Deceased donor (DD) kidney transplantation, ABO compatible; Immunosuppressive treatment: Tacr/MPS, Basiliximab induction
11531103|NCT01136382|Experimental|1|Budesonide pMDI 160 ug bid (80 ug x 2 inhalations bid)
11531104|NCT01136382|Placebo Comparator|2|Placebo pMDI 2 inhalations bid
11531105|NCT01136369||OSNA Breast Cancer System|
11531106|NCT01136356|Experimental|Morphine, then Buprenorphine|Healthy, out of treatment opioid-dependent residential volunteers (N=7) were randomized to receive morphine (120 mg/day i.m.) administered in four divided doses each day for 9 days (30 mg of morphine four times per day). Participants then underwent an 18-day period of spontaneous opioid withdrawal, during which four double blind i.m. placebo injections were administered daily. After the period of spontaneous withdrawal, participants received buprenorphine (32 mg/day i.m.) administered in four divided doses each day for 9 days (8 mg of buprenorphine four times per day) followed by a second 18-day period of spontaneous withdrawal identical to the withdrawal period described above.
11531169|NCT01135914|Experimental|Combination Therapy|Participants received ranibizumab intravitreal injection and laser photocoagulation treatments
11531170|NCT01135914|Experimental|Ranibizumab Monotherapy|Participants received ranibizumab intravitreal injection therapy only
11531171|NCT01135914|Active Comparator|Laser Monotherapy|Participants received Laser photocoagulation therapy only
11531172|NCT01135901|Experimental|group programme|Group based behaviour change programme
11531107|NCT01136356|Experimental|Buprenorphine, then Morphine|Healthy, out of treatment opioid-dependent residential volunteers (N=7) were randomized to receive buprenorphine (32 mg/day i.m.) administered in four divided doses each day for 9 days (8 mg of buprenorphine four times per day). Participants then underwent an 18-day period of spontaneous withdrawal, during which four double blind i.m. placebo injections were administered daily. After the period of spontaneous withdrawal, participants received morphine (120 mg/day i.m.) administered in four divided doses each day for 9 days (30 mg of morphine four times per day) followed by a second 18-day period of spontaneous withdrawal identical to the withdrawal period described above.
11531108|NCT01136343|Experimental|lifestyle modified project|education, counseling
11531109|NCT01136343|No Intervention|control|waiting list control
11531110|NCT01136317|Experimental|Omeprazole|
11531111|NCT01136317|Experimental|Rabeprazole|
11531112|NCT01136317|Placebo Comparator|Placebo|
11531113|NCT01136304||Adults with Type 1 Gaucher disease (GD1)|Adults with GD1 who are cared for at one of the participating research sites whether treatment naive or treated in past or currently with imiglucerase enzyme replacement treatment.
11531114|NCT01136291|Other|physical exercise|exercise on obese and overweight pregnant women, routine prenatal care and nutritional counseling
11531115|NCT01136291|No Intervention|no exercise|Routine prenatal care and nutritional counseling. No exercise
11531116|NCT01136278|Experimental|clonidine, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
11531117|NCT01136252|Experimental|Adalimumab|
11531118|NCT01136239|Placebo Comparator|Placebo|Placebo (600mg twice daily)
11531119|NCT01136239|Active Comparator|N-acetylcysteine|N-acetylcysteine (600mg twice daily)
11531120|NCT01136226|Other|Eligard (TM)|Eligard (TM) administered 22.5mg
11531121|NCT01136213||Multiple system atrophy|
11531122|NCT01136213||Idiopathic Parkinson Disease|
11531123|NCT01136213||Volunteers without neuropsychiatric disorder (Control)|
11531124|NCT01136200|Experimental|Infectious disease specialist advice|Patients receiving the intervention (infectious disease specialist advice)
11531125|NCT01136200|No Intervention|Control|Patients not receiving infectious disease specialist advice
11531126|NCT01136187|Experimental|Radial approach|Primary percutaneous coronary intervention from the radial approach
11531127|NCT01136187|Active Comparator|Femoral approach|Primary percutaneous coronary intervention from the femoral approach
11531128|NCT01136174|Experimental|BIBF 1120 50 mg|Low dose for cohort 1
11531129|NCT01136174|Experimental|BIBF 1120 100 mg|Middle dose for cohort 2
11531130|NCT01136174|Experimental|BIBF 1120 150 mg|High dose for cohort 3
11531131|NCT01136174|Placebo Comparator|Placebo|Placebo for cohort 1,2,3
11531132|NCT01136161|Experimental|RUTI 5 micrograms of FCMtb in HIV -|n=12
11531133|NCT01136161|Experimental|RUTI 25 micrograms of FCMtb in HIV -|n=12
11531134|NCT01136161|Experimental|RUTI 50 micrograms of FCMtb in HIV -|n=12
11531135|NCT01136161|Placebo Comparator|RUTI Matching Placebo in HIV -|n=12
11531136|NCT01136161|Experimental|RUTI 5 micrograms of FCMtb in HIV +|n=12
11531137|NCT01136161|Experimental|RUTI 25 micrograms of FCMtb in HIV +|n=12
11531138|NCT01136161|Experimental|RUTI 50 micrograms of FCMtb in HIV +|n=12
11531139|NCT01136161|Placebo Comparator|RUTI Matching Placebo in HIV +|n=12
11531140|NCT01136148|Experimental|A Medical and Mental Health Unit|A specialist unit for cognitively impaired older patients admitted as a medical emergency to the acute hospital.
11531141|NCT01136148|Active Comparator|Standard care wards|The standard care provided by the acute hospital for cognitively impaired older patients admitted as a medical emergency.
11531142|NCT01136135||CARDIAC MRI|
11531143|NCT01136122|Active Comparator|CPAP Arm|Receive effective CPAP treatment for one month
11531144|NCT01136122|No Intervention|Control Arm|Receive no treatment for one month
11531145|NCT01136109||Bedside ultrasound only|Bedside ultrasound to determine the dimensions of the inferior vena cava
11531146|NCT01136109||Ultrasound with ventilator changes|Bedside ultrasound to determine the dimensions of the inferior vena cava pre and post ventilator changes.
11531147|NCT01136096|Experimental|Lifestyle counseling|To promote participants' exercise behaviors with individualized home-based exercise program was designed based on the Health Belief Model and Transtheoretical Model
11531148|NCT01136096|Other|Control|Received oral instruction and written general education information without individualized exercise program
11531149|NCT01136083|Experimental|Exercise training|Subjects in exercise group will undergo individualized high aerobic interval training on treadmill for 30 minutes under the supervision of an experienced physical therapist 3 times a week and home exercise twice a week with accelerometer.
11531150|NCT01136083|Active Comparator|Control group|Subjects in control group will not undergo individualized high aerobic interval training on treadmill. They will receive usual care as normally does in hospital.
11531151|NCT01136070||Burn Trauma Patients|
11531152|NCT01136057||Influenza A Exposure|Participants will include people who have recovered from influenza, received a seasonal influenza vaccine, or have both recovered from influenza and received a seasonal influenza vaccine.
11531153|NCT01136031|Experimental|Paclitaxel and irinotecan|
11531154|NCT01136018||intentional lateral caudal approach|
11531155|NCT01136005|Experimental|dexpanthenol 5% cream|dexpanthenol 5% cream
11531156|NCT01136005|Active Comparator|cetomacrogol cream|a vehicle
11531157|NCT01135992|Experimental|IGlar/IDeg|
11531158|NCT01135992|Experimental|IDeg 3TW|
11531159|NCT01135979||Arterio-venous fistulae creation|
11531160|NCT01135966|Active Comparator|Conventional training|
11531161|NCT01135966|Experimental|Whole body vibration training|
11531162|NCT01135953|Experimental|ARM 1 - CONTROL|Subject given tDCS every day of the week (5 sessions) at 2 mA.
11531163|NCT01135953|Experimental|Arm 2 - INCREASING|Subjects given increasing intensity during tDCS across the week (Monday 1mA, Tuesday 1.5mA, Wednesday 1.5 mA, Thursday 2 mA, Friday 2mA).
11531164|NCT01135953|Experimental|ARM 3 - CYCLOSERINE|D-cycloserine (100 mg) given on the Monday and Thursday sessions, administering tDCS at 2 mA.
11531177|NCT01135875||GBM Patients|GBM Patients with a histologically confirmed or suspected diagnosis of glioblastoma multiforme.
11531178|NCT01135875||Normal Controls|Normal Controls will be adult volunteers who identify themselves as not having been diagnosed with a glioblastoma multiforme.
11531179|NCT01135862|Experimental|platelet administered|patients will receive 6 packs of platelets
11531180|NCT01135862|No Intervention|no platelets administered|patients will not receive platelets
11531181|NCT01135836|Experimental|pulmonary recruitment maneuver|a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anestheiologist held the fifth positive pressure inflation for approximately 5 seconds.
11531182|NCT01135836|Experimental|intraperitoneal normal saline|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity
11531183|NCT01135836|Placebo Comparator|Control group|CO2 was removed by passive exsufflation through the port site.
11531184|NCT01135797||Patients from phase I-II studies|
11531185|NCT01135784|Active Comparator|MIGRA-ZEN RELIEF PLUS|Active treatment
11531186|NCT01135784|Placebo Comparator|Placebo for Migra zen plus|Placebo
11531187|NCT01135758|Experimental|ketamine 0.5 mg/kg i.v.|Single administration of ketamine 0.5 mg/kg i.v.
11531188|NCT01135745|Experimental|Deep Brain Stimulation Therapy for OCD|Reclaim® DBS Therapy uses thin wires to deliver electric current (stimulation) to a very specific target in the brain. These wires are implanted surgically. They are attached to internal neurostimulators implanted under the skin of the chest below the collarbone, similar to cardiac pacemakers, or in the abdominal wall. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
11531189|NCT01135732||study group-previous sphincterotomy|
11531190|NCT01135732||control group-not previous sphincterotomy|
11531191|NCT01135719|Active Comparator|Wavefront guided LASIK/PRK|Wavefront-guided LASIK/PRK
11531192|NCT01135719|Active Comparator|Wavefront optimized LASIK/PRK|Wavefornt optimized LASIK/PRK
11531193|NCT01135706||Pulmonary Hypertension|Patients having a right heart catheterization and CT pulmonary angiogram with a diagnosis of Pulmonary Hypertension
11531194|NCT01135706||Non Pulmonary Hypertension|Patients having a right heart catheterization and CT pulmonary angiogram without a diagnosis of Pulmonary Hypertension.
11531195|NCT01135680|Placebo Comparator|Arm 1|"Cohort A: 9 mL HPN-100 or placebo
~Cohort B: 12 mL HPN-100 placebo"
11531196|NCT01135680|Placebo Comparator|Arm 2|"This study requires 4 periods. In each of the periods you will receive one of the dose groups listed below. At the completion of the study you will have participated in all 4 dose groups. The order in which you participate in each dose group will be randomly assigned.
~Dose Group A: 9 mL placebo via oral syringe 3 times daily for 3 days
~Dose Group B: single oral dose of 400 mg moxifloxacin on study Day 3
~Dose Group C: 6 mL HPN-100 and 3 mL placebo via oral syringe 3 times daily for 3 days
~Dose Group D: 9 mL HPN-100 via oral syringe 3 times daily for 3 days"
11531197|NCT01135667|Active Comparator|clopidogrel|clopidogrel 150 mg once daily for 30 days (and then 75 mg for additional 11 months - not study related)
11531198|NCT01135667|Active Comparator|Prasugrel|Prasugrel 10 mg once daily for 30 days (and then clopidogrel 75 mg once daily for additional 11 months - not study related)
11531199|NCT01135654|Experimental|Non-Physician Provider|
11531200|NCT01135654|No Intervention|Control|
11531201|NCT01135654|Active Comparator|Primary Care Provider|In clinics randomized to this arm, we will train (and provide technical assistance to) Primary Care providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment.
11531202|NCT01135641|Experimental|Rituximab, ciclosporine and corticosteroids|As soon as the diagnosis of chronic GVHD requiring systemic immunosuppressive therapy is confirmed, patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.Rituximab should be administered within 14 days of starting prednisone. Follow-up dates for response assessment and laboratory tests relate to the date of Rituximab infusion.Patients having a partial response after the 1st cycle of Rituximab will be eligible to receive a second cycle of 4 infusions during 4 weeks. A delay of 8 weeks (from the first infusion of Rituximab) will be observed between the two cycles of Rituximab therapy.Patients who relapse after an initial treatment with one cycle of 4 infusions of Rituximab will be eligible to receive a second cycle of Rituximab therapy.
11531203|NCT01135628|Active Comparator|MHE and diet plus lactobacillus reuteri|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods and lactobacillus reuteri.
11531204|NCT01135628|Active Comparator|MHE and diet|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods.
11531205|NCT01135628|Active Comparator|MHE and diet plus nitazoxanide|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods and nitazoxanide.
11531206|NCT01135615|Other|Sevelamer|
11531207|NCT01135615|Other|calcium acetate|
11531208|NCT01135602|Experimental|Topiramate|1 group
11531209|NCT01135589|Experimental|HSCT|
11531210|NCT01135576|Placebo Comparator|Placebo juices|Consumption of non-iron fortified fruit juices as part of the usual diet
11531211|NCT01135576|Experimental|Iron fortified fruit juices|Consumption of iron fortified fruit juices as part of the usual diet
11531212|NCT01135563|Experimental|Vinblastine and Sirolimus|The standard 3+3 Phase 1 trial design will be used for the conduct of this study. Three to six patients can be concurrently enrolled onto a dose level. Accrual is suspended when a cohort of three has been enrolled until toxicity data for that cohort have been reported, or when the study endpoints have been met.
11531213|NCT01135550|Active Comparator|Standard Arm|"Subjects scheduled to undergo radiation therapy are enrolled before the therapy is started. Once radiation therapy begins they will complete a daily diary about any headaches or nausea/vomiting they experience.
~If they experience increased headache or vomiting they will be randomized to receive either a high or a low dose of dexamethasone, to control these symptoms."
11531291|NCT01135017|Placebo Comparator|Placebo|Placebo (for Dronedarone) twice a day for 12 weeks
11531292|NCT01135004||Pneumothorax patients|Primary spontaneous pneumothorax patients undergoing thoracoscopic bullectomy
11531293|NCT01134991|Placebo Comparator|Topical Minocycline Foam FXFM244 Placebo|Minocycline Foam FXFM244 Placebo
11531214|NCT01135550|Active Comparator|Control Arm|"Subjects scheduled to undergo radiation therapy are enrolled before the therapy is started. Once radiation therapy begins they will complete a daily diary about any headaches or nausea/vomiting they experience.
~If they experience increased headache or vomiting they will be randomized to receive either a high or a low dose of dexamethasone, to control these symptoms."
11531215|NCT01135537|Experimental|Thymoglobulin|Thymoglobulin 7.5 mg/kg/course prior to HSCT
11531216|NCT01135524|Experimental|BTDS|Buprenorphine transdermal patch
11531217|NCT01135511|Experimental|Treatment 1|
11531218|NCT01135511|Experimental|Treatment 2|
11531219|NCT01135511|Experimental|Treatment 3|
11531220|NCT01135511|Placebo Comparator|Treatment 4|
11531221|NCT01135511|Active Comparator|Treatment 5|
11531222|NCT01135498|Experimental|1|
11531223|NCT01135485||Study group I|Study group I will include children who have undergone stage I palliation employing allograft material for left ventricular outflow tract reconstruction at CHOP during infancy (<1 year of age). Stage I palliation is defined as an operation in which augmentation of the native ascending aorta and aortic arch is performed to bypass atresia or critical obstruction of the left heart structures.
11531224|NCT01135485||Study Group II|Study group II who have undergone stage II palliation in which allograft material is used, but have not undergone antecedent stage I palliation. Stage II palliation is defined as a superior cavopulmonary anastomosis in which the superior vena cava is anastomosed to the ipsilateral pulmonary artery via either the bidirectional Glenn or hemi-Fontan procedures.
11531225|NCT01135485||Control Group|The control group who have undergone palliative or corrective surgery for congenital heart disease during infancy (<1 year of age) not requiring allograft material.
11531226|NCT01135472|Experimental|Nexium|ARM 1: NEXIUM 40MG ONCE DAILY, ARM 2: NEXIUM 40MG TWICE DAILY, ARM 3: NEXIUM 80MG TWICE DAILY
11531227|NCT01135459|Experimental|CEP-33457|200 mcg of CEP-33457
11531228|NCT01135459|Placebo Comparator|Placebo|
11531229|NCT01135446|Experimental|dapagliflozin (0.001 mg)|Cohort 1
11531230|NCT01135446|Experimental|dapagliflozin (0.01 mg)|Cohort 2
11531231|NCT01135446|Experimental|dapagliflozin (0.1 mg)|Cohort 3
11531232|NCT01135446|Experimental|dapagliflozin (0.3 mg)|Cohort 4
11531233|NCT01135446|Experimental|dapagliflozin (1 mg)|Cohort 5
11531234|NCT01135446|Experimental|dapagliflozin (2.5 mg)|Cohort 6
11531235|NCT01135433|Experimental|ASP group|ASP1941 and metformin
11531236|NCT01135433|Placebo Comparator|Placebo group|placebo and metformin
11531237|NCT01135420|Active Comparator|Usual Care|Psychiatry inpatient usual care
11531238|NCT01135420|Experimental|Telephone Monitoring|Patients in the TM condition will receive an in-person session while in treatment, followed by monitoring over the telephone for three months after discharge. The intervention will incorporate motivational interviewing to monitor patients' substance use, facilitate entry into outpatient treatment, and encourage 12-step self-help group participation.
11531239|NCT01135407||group #1|Parkinson's disease patients at a disease's stage characterized by motor complications
11531240|NCT01135407||group #2|Parkinson's disease patients treated by subthalamic nucleus deep brain stimulation.
11531241|NCT01135407||group #3|healthy controls
11531242|NCT01135394|Experimental|Pioglitazone (Actos)|Participants will have metabolism studies to consist of outpatient X-ray and MR measurements of bone density and body composition, metabolic testing (intravenous glucose tolerance test), and muscle and adipose tissue biopsies. Blood will also be drawn for genetic testing and for microarray studies of leukocytes. Upon completion of the above studies, the participant will begin pioglitazone therapy. Every 4 weeks throughout the drug intervention, glycemic control, lipoprotein profile, and weight will be monitored. After 12 weeks of pioglitazone therapy, the X-ray and MR measurements of body composition, the biopsies, microarray studies for leukocytes and the metabolic tests will be repeated.
11531243|NCT01135381|Experimental|CHF patients, IVR-Enhanced Care|Patients with congestive heart failure (CHF) who receive the interactive voice response (IVR) intervention.
11531244|NCT01135381|Experimental|COPD patients, IVR-Enhanced Care|Patients with chronic obstructive pulmonary disease (COPD) who receive the interactive voice response (IVR) intervention.
11531245|NCT01135381|No Intervention|CHF patients, Usual Discharge Care|Patients with congestive heart failure (CHF) who receive usual discharge care (no intervention).
11531246|NCT01135381|No Intervention|COPD patients, Usual Discharge Care|Patients with chronic obstructive pulmonary disease (COPD) who receive usual discharge care (no intervention).
11531247|NCT01135368|Experimental|Lansoprazole|"Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
~Depending on response, dosage could then be decreased to 15 mg, once daily, or increased to 30 mg, twice daily for up to 4 years and 10 months."
11531248|NCT01135342|Experimental|Diet & Exercise plus Sleep Intervention|Diet and exercise instruction to promote weight loss plus cognitive behavioral therapy for insomnia.
11531249|NCT01135342|Sham Comparator|Diet & Exercise plus Passion and Balance|Diet and exercise instruction to promote weight loss plus sessions that are of general interest, but unrelated to diet, exercise, or sleep.
11531250|NCT01135329|Experimental|Transplant|Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.
11531251|NCT01135303|Experimental|VistaO2 device|This device combines the transcutaneous oxyhemoglobin saturation (allowing to compute the oxyhemoglobin desaturation index), the slow variations in heart rate and an index of nocturnal respiratory events calculated by analyzing the movements of the chest performed by chest impedance variations.
11531252|NCT01135290|Other|B|
11531253|NCT01135290|Active Comparator|A|
11531254|NCT01135277||Sepsis|Patients who have been diagnosed with Sepsis within 24 hours of admission
11531255|NCT01135277||Non-Septic|Patients who have not been diagnosed with sepsis within 24 hours of admission
11531294|NCT01134991|Experimental|Topical Minocycline Foam FXFM244, 1%|Minocycline Foam FXFM244, 1%
11531295|NCT01134991|Experimental|Topical Minocycline Foam FXFM244, 4%|Minocycline Foam FXFM244, 4%
11531328|NCT01134731|Experimental|paliperidone|dose escalation , levels 1-5 daily dosing ranged from 1-5mg
11531329|NCT01134731|Active Comparator|lithium|dose escalation, level 1-5 daily dosing 300-1500mg
11531330|NCT01134731|Placebo Comparator|placebo|1-5 placebo capsules
11531256|NCT01135264|Active Comparator|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur & Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
11531257|NCT01135264|Experimental|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
11531258|NCT01135251|Experimental|dimiracetam|Capsules containing 400 mg of dimiracetam will be administered orally, twice a day for 8 weeks in ascending schedule, contingent on tolerability of the previous dose, as follows: 1 capsule for two weeks (800mg/day), two capsules for the next two weeks (1600mg/day)and 4 capsules for the final 4 weeks (3200mg/day).
11531259|NCT01135251|Placebo Comparator|sugar pill|capsules containing 400 mg of inert material will be orally administered twice a day with the same modalities used for the dimiracetam arm: one capsule for 2 weeks, 2 capsules for another 2 weeks and 4 capsules for 4 weeks
11531260|NCT01135225|Active Comparator|PROMUS(TM) Element(TM) Coronary Stent|PROMUS(TM) Element(TM) Everolimus-Eluting Coronary Stent System
11531261|NCT01135225|Experimental|Evolution Coronary Stent A|Evolution Everolimus-Eluting Monorail Coronary Stent System
11531262|NCT01135225|Experimental|Evolution Coronary Stent B|Evolution Everolimus-Eluting Monorail Coronary Stent System
11531263|NCT01135212|Active Comparator|Fimasartan 60mg|Take one tablet of Fimasartan 60mg once a day in the morning
11531264|NCT01135212|Active Comparator|Fimasartan 120mg|Take one tablet of Fimasartan 120mg once a day in the morning
11531265|NCT01135212|Active Comparator|Candesartan 8mg|Take one tablet of Candesartan 8mg once a day in the morning
11531266|NCT01135186|Other|Sapropterin|open label study of sapropterin dihydrochloride
11531267|NCT01135173|Active Comparator|Arm A|Motivational and educational intervention, delivered by a trained physician from the SCTS plus written self-help materials.
11531268|NCT01135173|Experimental|Arm B|"Behavioral counseling intervention conducted by a trained physician at the SCTS cessation clinic. Subjects complete homework before the session to facilitate this process. Subjects are asked to identify high-risk situations and difficulties in previous cessation attempts and are walked through a series of suggestions in the event of a slip. Three brief (approximately 10 minute) phone calls are provided to subjects during the 90 day follow-up period. These calls are used to identify early relapse, encourage participants, and provide support. In addition, they are used to review materials and information provided during the sessions."
11531269|NCT01135160||TKA/THA|All patients receiving TKA/THA meeting inclusion but not exclusion criteria
11531270|NCT01135147|Experimental|Diet|Patients treated with diet and physical therapy for the entire 6 months of the study
11531271|NCT01135147|Active Comparator|Surgery|Patients undergoing adenotonsillectomy at some point of the study period
11531272|NCT01135134|Experimental|Mometasone furoate nasal spray (MFNS) (50 μg spray device)|"The dose will be as follows:
~5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks
~12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks"
11531273|NCT01135134|Placebo Comparator|MF placebo nasal spray|"Administration will be as follows:
~5 to 11 years: one spray per nostril once daily in the morning for 2 weeks
~12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks"
11531274|NCT01135121||Weaning failure|
11531275|NCT01135121||Weaning succes|
11531276|NCT01135108|Placebo Comparator|A1: Placebo|Placebo
11531277|NCT01135108|Experimental|A2: KAI-1678|Experimental
11531278|NCT01135095|Experimental|low-dose imaging|low dose versus standard dose imaging
11531279|NCT01135082|Other|1|Receive valent pneumococcal conjugated vaccine in HIV - infected children
11531280|NCT01135082|Other|2|Receive valent pneumococcal conjugated vaccine in HIV negative children
11531281|NCT01135069|Active Comparator|Generic|treatment of acne for 12 weeks
11531282|NCT01135069|Active Comparator|Brand|Treatment of acne for 12 weeks
11531283|NCT01135069|Placebo Comparator|Placebo|Treatment if acne for 12 weeks as placebo
11531284|NCT01135056|Active Comparator|Sorafenib, Multikinase Inhibitor, Tablet|"Sorafenib tosylate:
~Sorafenib is a multikinase inhibitor that decreases tumor cell proliferation.
~Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, RET, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR- ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of the human hepatocellular carcinoma and renal cell carcinoma, and several other human tumor xenografts in immunocompromised mice. A reduction in tumor angiogenesis and increases in tumor apoptosis was seen in models of human hepatocellular and renal cell carcinoma. Additionally a reduction in tumor cell signaling was seen in a model of human hepatocellular carcinoma."
11531285|NCT01135056|Active Comparator|SIR-Spheres, Microspheres, Device|"SIR-Spheres:
~SIR-Spheres consist of biocompatible resin microspheres containing yttrium-90, with a size between 20 and 60 microns in diameter. Yttrium-90 is a high-energy pure beta-emitting isotope with no primary gamma emission. The half life of yttrium-90 is 64.1 hours. In clinical use which requires the isotope to decay to infinity, 94% of the radiation is delivered in 11 days leaving only background radiation with no therapeutic value.
~SIR-Spheres is implanted into hepatic tumours by delivery via either the common hepatic artery or the right or left hepatic artery using a catheter or implanted port . Once SIR-Spheres is implanted into the liver, it is not metabolised or excreted and it stays permanently in the liver."
11531286|NCT01135043|Experimental|education|educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.
11531287|NCT01135043|Placebo Comparator|control|patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure.
11531288|NCT01135030|Active Comparator|Posterior referencing|
11531289|NCT01135030|Active Comparator|Anterior referencing|
11531290|NCT01135017|Experimental|Dronedarone|Dronedarone 400 mg twice a day for 12 weeks
11531461|NCT01133899|Experimental|GAA-4|4.8 grams of guanidinoacetic acid
11531296|NCT01134978|Experimental|Practice Schedules|Subjects are randomly assigned to either a blocked or random practice schedule when learning three 3-D computer mazes. A blocked practice schedule is created when the tasks to be learned are presented in a predictable order, while a random practice schedule has tasks presented in a nonsequential, unpredictable order. Neural activity and behavioral measures will differ for the two practice schedules. For memory and transfer, it is predicted that random practice will be better than blocked practice.
11531297|NCT01134965|Experimental|Digoxin plus Flibanserin|Flibanserin 100 mg tablets once daily for 7 days plus Digoxin 0.5 mg (2 tables of 0.25 mg) as single dose
11531298|NCT01134965|Experimental|Digoxin|Digoxin 0.5 mg as single dose
11531299|NCT01134952|Experimental|Mycophenolate to sirolimus switch|Liver transplant recipients with Hepatitis C virus switched from mycophenolate mofetil (MMF) to sirolimus (SRL) for 3 months and then switched back to MMF
11531300|NCT01134939||HIV-infected women and men|
11531301|NCT01134926|No Intervention|intra-uterine residua. expectant management|The patients in this arm will not get any treatment and be followed up by US examinations
11531302|NCT01134926|Experimental|Intra-uterine residua. misoprostol|The patients in this arm will be treated with misoprostol at the recruitment day. If there will be sonographic evidence of intra-uterine residua the day after, they'll gat another dose.
11531303|NCT01134900|Experimental|Dashboard|Patients appear on dashboard and are eligible for pharmacy intervention in addition to existing clinical decision support interventions.
11531304|NCT01134900|No Intervention|Control|Patients do not appear on dashboard for pharmacy intervention, but only receive existing clinical decision support interventions.
11531305|NCT01134887|Experimental|Arm 1: Intervention-Veterans|"Veterans enrolled in the Intervention-Veterans arm received a copy of the NIA guide for Talking with Your Doctor [Informational Guide for Patients]. Just prior to their next scheduled visit an educator met with each Veteran in the intervention arm individually for 20-30 minutes to review the material in the pamphlet and develop a plan for enhancing communication about self-management of hypertension with their doctor [Educational Coaching]. To facilitate communication change, the educator assisted the patient in setting a goal to achieve during their visit. The educator also provided telephone follow-up within 24 hours to review satisfaction and effectiveness of the visit and assess barriers and facilitators to communicating about self-management."
11531306|NCT01134887|Active Comparator|Arm 2: Control-Veterans|"Veterans enrolled in the Control-Veterans arm received a copy of the NIA guide for Talking with Your Doctor [Informational Guide for Patients]. This pamphlet was specifically developed for this purpose (updated in 2002). It has pictorials and is written at an 8th grade level."
11531307|NCT01134887|Experimental|Arm 3: Intervention-Physicians|"Primary care providers randomly assigned to the Intervention-Physicians arm of this study received a copy of the Four Habits of Highly Effective Physicians [Monograph for Physicians]. The Four Habits provided practical evidence-based advice for improving patient-physician communication. Second, physicians participated in an audiotaped intensive 30 minute, one-on-one educational intervention with PI Frankel after their first set of visits from their three participating patients [Video-Assisted Coaching], but before seeing them for follow-ups. The main goal of this meeting was to review and discuss the analysis of the physician's videotaped visits using the Four Habits framework, with a particular focus on improving communication about self-management."
11531308|NCT01134887|Active Comparator|Arm 4: Control-Physicians|"Primary care providers randomly assigned to the Control-Physicians arm of the study did not receive coaching or additional resources, and conducted their primary care practice as usual [Control]."
11531309|NCT01134874|Experimental|Standard weight loss intervention|
11531310|NCT01134874|Experimental|Standard weight loss intervention plus technology|
11531311|NCT01134874|Experimental|Technology only|
11531312|NCT01134861|Active Comparator|Arm 1: Sequential ChemoRT|Vinblastine 6 mg/m2 i.v. bolus weekly first 5 weeks Cisplatin 100 mg/m2 i.v. over 30-60 minutes, days 1 & 29 RT: 63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 50
11531313|NCT01134861|Experimental|Arm 2: Concurrent STD RT|Vinblastine 5 mg/m2 i.v. bolus weekly first 5 weeks Cisplatin 100 mg/m2 i.v. over 30-60 minutes, days 1 & 29 RT: 63 GY/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1
11531314|NCT01134861|Experimental|Arm 3: Concurrent HFX RT|Oral VP-16 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40 (76 mg/day if BSA < 1.7m2) Cisplatin 50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36 RT: 69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1
11531315|NCT01134848|Active Comparator|Morphine-neostigmine|
11531316|NCT01134848|Active Comparator|Secretin|
11531317|NCT01134835|Experimental|IMP Pioglitazone|Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
11531318|NCT01134835|Placebo Comparator|Placebo|Placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
11531319|NCT01134822||Idiopathic pulmonary fibrosis (IPF)|
11531320|NCT01134809||Major abdominal surgery|Patients having major abdominal surgery
11531321|NCT01134783|Experimental|Intervention Group|The CHOICES intervention included a 1-credit, academic college course focusing on healthy weight behaviors and participation in a social networking and social support website
11531322|NCT01134783|No Intervention|Control Group|Control group (serving as a comparison group)
11531323|NCT01134770||Prenatal Cocaine|Use of cocaine at anytime during pregnancy. Subjects may also have used other drugs in combination with Cocaine
11531324|NCT01134770||Prenatal Nicotine-Alcohol-Marijuana|Subjects may have used any of these drugs during pregnancy, alone or in combination. This group has not used cocaine during pregnancy.
11531325|NCT01134770||Drug-Free Pregnancy|"Subjects did not use any of the following drugs during pregnancy:
~cocaine, nicotine, alcohol, marijuana."
11531326|NCT01134757|Other|house dust mite and alternaria allergy|As the intervention patients with house dust mite or alternaria allergy will undergo a bronchial allergen challenge with mite or alternaria extract. The early asthmatic response (EAR) and the late asthmatic response (LAR) will be measured before and after one year of allergen specific immunotherapy. Except of the challenge no further interventions are planned.
11531327|NCT01134744||Chest trauma|chest x-ray applied for patients with chest trauma and the manifestations compared with clinical examination
11531331|NCT01134718|Experimental|001|TMC435 (F021) one morning dose of 150 mg
11531332|NCT01134718|Experimental|002|TMC435 (G006) one morning dose of 150 mg
11531333|NCT01134718|Experimental|003|TMC435 (G007) one morning dose of 150 mg
11531334|NCT01134705|Experimental|BDP HFA 320 µg/day|During the 6-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.
11531335|NCT01134705|Placebo Comparator|Placebo|During the 6-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.
11531336|NCT01134692|Placebo Comparator|Propranolol + Placebo|
11531337|NCT01134692|Active Comparator|Propranolol + Norfloxacin|drug
11531338|NCT01134692|Experimental|Propranolol + Probiotic|VSL#3
11531339|NCT01134679|Experimental|Phone calls|Disease management with close patient follow-up, using phone calls.
11531340|NCT01134653|Experimental|Jump stretch|Distraction with early mobilization
11531341|NCT01134653|Active Comparator|RICE|Subject receive standard ankle sprain treatment of Rest Ice compression and elevation for one week. This is followed by traditional strength and range of motion therapy. The subject does not receive distraction treatments.
11531342|NCT01134627|Experimental|Minocycline group|
11531343|NCT01134627|Placebo Comparator|Placebo Group|
11531344|NCT01134614|Experimental|Arm A (ipilimumab and sargramostim)|Patients receive induction therapy comprising ipilimumab IV over 90 minutes on day 1 and sargramostim SC once daily on days 1-14. Treatment repeats every 21 days for 4 cycles. After 12 weeks of induction treatment, anti-tumor response is assessed and patients then receive maintenance therapy comprising ipilimumab IV over 90 minutes on day 1 and sargramostim SC once daily on days 1-14. Treatment with ipilimumab repeats every 12 weeks and treatment with sargramostim repeats every 21 days. After 12 weeks of maintenance therapy, anti-tumor response is reassessed and patients with responsive or stable disease then continue maintenance therapy until disease progression or unacceptable toxicity.
11531345|NCT01134614|Active Comparator|Arm B (ipilimumab)|Patients receive induction therapy comprising ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles. After 12 weeks of induction treatment, anti-tumor response is assessed and patients then receive maintenance therapy of ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 12 weeks. After 12 weeks of maintenance therapy, anti-tumor response is reassessed and cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity
11531346|NCT01134588|Active Comparator|Reference group|This group will fill out paper questionnaires.
11531347|NCT01134588|Experimental|Experimental group|This group will fill out touch-screen questionnaires.
11531348|NCT01134575|Experimental|Period 1: CMC-544 (Inotuzumab Ozogamycin) 1.3mg/m^2|First patients > 16 years and < 16 years receive CMC-544 (Inotuzumab Ozogamycin) at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle. With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
11531349|NCT01134575|Experimental|Period 3: Weekly CMC-544 (Inotuzumab Ozogamycin)|CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2.
11531350|NCT01134575|Experimental|Period 2: CMC-544 (Inotuzumab Ozogamycin) 1.8mg/m^2|First patients > 16 years and < 16 years receive CMC-544 (Inotuzumab Ozogamycin) at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle. With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
11531351|NCT01134562|Placebo Comparator|Placebo|Participants received a single dose of placebo intravenous (IV) injection after hemodialysis.
11531352|NCT01134562|Experimental|Etelcalcetide|Participants received a single dose of etelcalcetide by intravenous (IV) injection after hemodialysis.
11531353|NCT01134549|Placebo Comparator|Placebo|Participants received a single dose of placebo intravenous injection.
11531354|NCT01134549|Experimental|Etelcalcetide|Participants received a single dose of etelcalcetide intravenous injection; the starting dose was 0.5 mg.
11531355|NCT01134536|Experimental|Tapentadol Oral Solution (OS)|
11531356|NCT01134523|Active Comparator|Group A: EC-T regimen|
11531357|NCT01134523|Experimental|Group B: ET regimen|
11531358|NCT01134510|Experimental|C1 esterase inhibitor|10 subjects will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
11531359|NCT01134510|Placebo Comparator|Placebo|10 subjects placebo [normal saline] in addition to standard of care immunosuppressive therapy.
11531360|NCT01134497|Active Comparator|Arm A (control): carboplatin + placebo|The control arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus placebo by mouth on days 1-21 of a 21 day cycle.
11531361|NCT01134497|Experimental|Arm B: carboplatin + ZD4054|The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
11531362|NCT01134484|Experimental|VTD|
11531363|NCT01134484|Active Comparator|TD|
11531364|NCT01134471|No Intervention|Control|
11531365|NCT01134471|Active Comparator|Bonewax|Patients treated with the hemostatic bonewax
11531366|NCT01134471|Active Comparator|Ostene|Patients treated with the hemostatic Ostene
11531367|NCT01134458|No Intervention|Control|Receive primary care and management of CVD according to the discretion of their primary care provider. They will also receive generic educational information concerning CVD at baseline and at study end (at their request). We will collect outcomes at baseline and 3-months.
11531414|NCT01134185|Active Comparator|Group II|Severe hepatic impairment (grade C)
11531415|NCT01134185|Active Comparator|Group III|healthy subjects
11531462|NCT01133899|Placebo Comparator|PLACEBO|cellulose
11531463|NCT01133886|Experimental|Decitabine|
11531368|NCT01134458|Experimental|Web-based Intervention|Given current risk assessment for CVD based on Health Dialog Cardiac Risk Calculator, recommendations for behavior change, and Health Dialog's Living with Coronary Heart Disease. Can change initial patient risk information provided by the Risk Calculator during the initial visit, noting what they are will work on during the study. Sent monthly email reminders to log onto the system to choose that months' behavioral modules. Given a choice of at least 2 health behavior modules per month (smoking cessation, exercise, diet, and weight) to improve their CVD risk. Information on risk, CVD knowledge, medication management and side effects will be provided to all participants. It will also provide tailored information to help the individual initiate and maintain these behaviors.
11531369|NCT01134445|Other|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
11531370|NCT01134432|Experimental|Prednisolone + Rituximab|
11531371|NCT01134432|Active Comparator|Prednisolone|
11531372|NCT01134419|Experimental|Computerized Handoff Tool plus training|Computerized handoff tool implemented together with team training for residents
11531373|NCT01134419|Active Comparator|Team training only|No computerized tool
11531374|NCT01134406|Experimental|Hydros Joint Therapy|Experimental viscosupplement.
11531375|NCT01134406|Experimental|Hydros-TA Joint Therapy|Experimental viscosupplement.
11531376|NCT01134406|Active Comparator|Synvisc-One|Commercial control.
11531377|NCT01134393|Experimental|telmisartan/amlodipine|start low dose and uptitrate to high dose on the basis of blood pressure goal
11531378|NCT01134380||[*1] Genotype - Good responders to Clopidogrel|This group of patients is defined thanks to the DNA extracted from their saliva: [*1] genotype patients are good responders to clopidogrel
11531379|NCT01134380||[*2] genotype with adapted thienopyridine treatment|This group of patients is defined thanks to the DNA extracted from their saliva: [*2] genotype patients are bad responders to clopidogrel and their thienopyridine treatment has been adapted
11531380|NCT01134367||1|Patients with GERD
11531381|NCT01134354||TEFTOM|Patient outcome measure
11531382|NCT01134341|Experimental|Bexarotene (Targretin) & Pralatrexate (Folotyn)|"Bexarotene (Targretin): administered po qd. The initial daily dose of bexarotene will depend on the cohort to which each patient is assigned. Bexarotene will be self-administered except in patients who underwent plasma PK sampling on cycle 1, dose 1 and cycle 1, dose 3, at which time bexarotene was to be administered at the investigational site 1 hour (± 5 minutes) prior to pralatrexate administration.
~Pralatrexate (Folotyn): administered weekly via IV push over a minimum of 30 seconds up to a maximum of 5 minutes. One cycle is 4 weeks in duration consisting of weekly dosing of pralatrexate for 3 weeks followed by 1 week of rest. The initial dose of pralatrexate will depend on the cohort to which each patient is assigned."
11531383|NCT01134328|Experimental|AC-150 Combo|
11531384|NCT01134328|Active Comparator|AC-150A 0.1%|
11531385|NCT01134328|Active Comparator|AC-150B 0.005%|
11531386|NCT01134328|Other|Vehicle|
11531387|NCT01134315||Paricalcitol|Pediatric participants who received paricalcitol capsules to treat secondary hyperparathyroidism (SHPT). Paricalcitol was prescribed by each physician under the usual and customary practice of that physician.
11531388|NCT01134315||Calcitriol|Pediatric participants who received calcitriol to treat secondary hyperparathyroidism (SHPT). Calcitriol was prescribed by each physician under the usual and customary practice of that physician.
11531389|NCT01134302|Active Comparator|Arm 1|Hybrid Management
11531390|NCT01134302|Active Comparator|Arm 2|Norwood Management
11531391|NCT01134289|Active Comparator|lumbar sympathetic block|Unilateral lumbar sympathetic blockade using chirocaine
11531392|NCT01134289|No Intervention|contralateral side|
11531393|NCT01134276|Active Comparator|PTBD|biliary drainage : PTBD procedure for obstructive jaundice in patients with periampullary cancer
11531394|NCT01134276|Active Comparator|ERBD|biliary drainage : ERBD/ENBD procedure for obstructive jaundice in patients with periampullary cancer
11531395|NCT01134263|Experimental|CYD Dengue Vaccine Phase III Lot 1|Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1),Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
11531396|NCT01134263|Experimental|CYD Dengue vaccine - Phase III Lot 2|Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
11531397|NCT01134263|Experimental|CYD Dengue vaccine - Phase III Lot 3|Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
11531398|NCT01134263|Experimental|CYD Dengue vaccine - Phase II Lot|Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
11531399|NCT01134263|Placebo Comparator|Placebo|Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
11531400|NCT01134250|Experimental|F16IL2 in combination with paclitaxel|
11531401|NCT01134237|Active Comparator|Urokinase|arm of interest
11531402|NCT01134237|Placebo Comparator|Control|Normal saline as a placebo for control arm
11531403|NCT01134224|Experimental|NN5401 - low dose|
11531404|NCT01134224|Experimental|NN5401 - medium dose|
11531405|NCT01134224|Experimental|NN5401 - high dose|
11531406|NCT01134224|Active Comparator|biphasic insulin aspart 30 - low dose|
11531407|NCT01134224|Active Comparator|biphasic insulin aspart 30 - medium dose|
11531408|NCT01134224|Active Comparator|biphasic insulin aspart 30 - high dose|
11531409|NCT01134211|Other|nelfilcon A / filcon II 3|Nelfilcon A contact lenses worn first, with filcon II 3 contact lenses worn second. Both products worn in both eyes on a daily wear, daily disposable basis for one week each.
11531410|NCT01134211|Other|filcon II 3 / nelfilcon A|Filcon II 3 contact lenses worn first, with nelfilcon A contact lenses worn second. Both products worn in both eyes on a daily wear, daily disposable basis for one week each.
11531411|NCT01134198|Active Comparator|Mifepristone|Mifepristone 600mg
11531412|NCT01134198|Placebo Comparator|placebo|Placebo
11531413|NCT01134185|Active Comparator|Group I|Moderate hepatic impairment (grade B)
11531464|NCT01133873|Experimental|1|
11531416|NCT01134172||Breast cancer survivors|Women being treated for stage I-III breast cancer who were employed prior to this diagnosis will be recruited in their physicians' offices.
11531417|NCT01134172||Comparison group|Peer controls will be nominated by participants in the breast cancer survivor group or recruited by community outreach and matched for age, language, and ethnicity. This cohort is no longer recruiting.
11531418|NCT01134159||Xience V|Those who have only received a Xience V stent
11531419|NCT01134159||Taxus Liberte|Those who have received only a Taxus Liberte stent
11531420|NCT01134146|Experimental|Intensity Modulated Radiation Therapy (IMRT)|Intensity Modulated Radiation Therapy (IMRT) Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
11531421|NCT01134120|Experimental|LY2784544|
11531422|NCT01134107|Experimental|Insulin Lispro 6 Day (6D)|
11531423|NCT01134107|Active Comparator|Insulin Aspart 6 Day (6D)|
11531424|NCT01134094|Active Comparator|Non-Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
11531425|NCT01134094|Active Comparator|Operative|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
11531426|NCT01134081|Experimental|CelTx™|Living bilayered cell therapy product
11531427|NCT01134081|Active Comparator|Free Gingival Grafts|Harvested tissue from palate
11531428|NCT01134055|Experimental|investigational arm 1|5 mg/mL pazopanib eye drops TID with allowance for as-needed ranibizumab injection
11531429|NCT01134055|Experimental|investigational arm 2|5 mg/mL pazopanib eye drops QID with allowance for as-needed ranibizumab injection
11531430|NCT01134055|Experimental|investigational arm 3|10 mg/mL pazopanib eye drops BID with allowance for as-needed ranibizumab injection
11531431|NCT01134055|Experimental|investigational arm 4|10 mg/mL pazopanib eye drops TID with allowance for as-needed ranibizumab injection
11531432|NCT01134055|Experimental|investigational arm 5|10 mg/mL pazopanib eye drops QID with allowance for as-needed ranibizumab injection
11531433|NCT01134055|Placebo Comparator|placebo control arm|Placebo eye drops QID with allowance for as-needed ranibizumab injection
11531434|NCT01134055|Active Comparator|active open-label control arm|Ranibizumab intravitreal injection every 4 weeks
11531435|NCT01134042|Experimental|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks
11531436|NCT01134042|Active Comparator|Fluticasone Furoate|Fluticasone furoate inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks
11531437|NCT01134042|Active Comparator|Fluticasone Propionate|Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 24 weeks
11531438|NCT01134029|No Intervention|Enhanced Usual Care|Control Group
11531439|NCT01134029|Experimental|Stepped Care|Intervention
11531440|NCT01134016|Experimental|Antroquinonol|"6 dose levels, Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.
~A maximum of 36 patients were planned based on a criteria of a maximum of 6 patients per cohort: 1 to 6 patients were planned for each dose group in the accelerated phase; 3 to 6 patients for each dose group in the standard phase .
~The method of dose escalation in the accelerated titration phase continued to the next higher dose level until a patient experienced MT or a DLT. Standard titration phase start with 3+3 patients. Dose escalation proceeded sequentially between cohorts."
11531441|NCT01133990|Active Comparator|FOLIRI|
11531442|NCT01133990|Experimental|E7820|FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820
11531443|NCT01133990|Experimental|FOLFIRI plus Bevacizumab|
11531444|NCT01133977|Experimental|Lenvatinib + Dacarbazine (Phase 1b)|Participants received 16 mg, 20 mg or 22 mg lenvatinib once daily in combination with dacarbazine
11531445|NCT01133977|Experimental|Lenvatinib + Dacarbazine (Phase 2)|Participants received lenvatinib per the maximum tolerated dose (MTD) as determined in the Phase Ib of the study in combination with dacarbazine
11531446|NCT01133977|Active Comparator|Dacarbazine (Phase 2)|Participants received dacarbazine
11531447|NCT01133964|Experimental|milk|skim milk
11531448|NCT01133964|Experimental|casein drink|
11531449|NCT01133964|Experimental|whey drink|
11531450|NCT01133964|Sham Comparator|water|
11531451|NCT01133951|Experimental|OAC triple therapy|
11531452|NCT01133951|Placebo Comparator|Placebo|
11531453|NCT01133938||Closed reduction < 12 months of age|
11531454|NCT01133938||Open reduction < 12 months of age|
11531455|NCT01133938||Open reduction with concomitant osteotomies > 12 months fo age|
11531456|NCT01133925|Active Comparator|ODESSA|ODESSA trial (NCT 00693030)Patients were randomized (2:2:2:1) to receive multiple TAXUS Libertè™ vs Cypher Select™ vs Endeavor™ vs Libertè BM stents, in overlap. At 6-months follow-up coronary angiography (QCA), IVUS and Optical Coherence Tomography assessments were made. Data reported in J. Am. Coll. Cardiol. Intv. 2010;3;531-539. DOI 10.1016/j.jcin.2010.02.008.
11531457|NCT01133925|Experimental|Resolute Sprint arm|Zotarolimus Eluting stents (Resolute Sprint) implanted in overlap to treat long coronary lesions
11531458|NCT01133912|Experimental|paclitaxel, gemcitabine, lapatinib|paclitaxel 80mg/m2 D1, D8 gemcitabine 1000mg/m2 D1, D8, every 3 weeks, 6 cycle lapatinib(Tykerb®)1000mg every day
11531459|NCT01133899|Experimental|GAA-2|2.4 grams of guanidinoacetic acid
11531466|NCT01133860|Experimental|eltrombopag|
11531467|NCT01133847|Experimental|Intensive Reading Instruction|Specialized phonologically-based reading instruction provided by well-trained tutors either individually (one-on-one) or to groups of two students for 45 minutes, four days per week, for 16 weeks. The instructional approach includes an individualized combination of published programs targeting word reading and decoding; reading fluency; and reading comprehension.
11531468|NCT01133847|Experimental|ADHD Intervention|Carefully-managed medication and behavioral parent training. Medication treatment begins with a four-week titration period, beginning with a trial of methylphenidate. If benefit is insufficient or side effects are intolerable, the physician may initiate a trial of mixed salt amphetamine, followed by either Atomoxetine or Guanfacine. When the optimum medication and dosage is determined the child returns for monthly medication maintenance visits until the end of the 16-week intervention period. Parent training consists of nine group sessions provided by a psychologist addressing ADHD and its treatment, principals of behavior modification, and evidence-supported practices for managing behavior.
11531469|NCT01133847|Experimental|Combined ADHD and Reading Instruction|"All interventions described in Reading Instruction and ADHD treatment arms:
~Phonologically-based reading instruction provided for 45 minutes, four days per week, for 16 weeks. Carefully-managed medication and behavioral parent training. Medication treatment begins with a trial of methylphenidate. If benefit is insufficient or side effects are intolerable, the physician may initiate a trial of mixed salt amphetamine, followed by either Atomoxetine or Guanfacine. When the optimum medication and dosage is determined the child returns for monthly medication maintenance visits until the end of the 16-week intervention period. Parent training consists of nine group sessions on parenting a child with ADHD."
11531470|NCT01133834||patients with meningococcemia|Patients with meningococcemia admitted at the Intensive Care Unit
11531471|NCT01133821|Placebo Comparator|Placebo|Subjects will receive 20 weeks of an experimental psychotherapy called interpersonal and social rhythm therapy (IPSRT) plus placebo (sugar pill). This condition will be called IPSRT-PLA.
11531472|NCT01133821|Experimental|IPSRT plus quetiapine|Subjects will receive 20 weeks of an experimental psychotherapy called interpersonal and social rhythm therapy (IPSRT) plus the FDA approved medication quetiapine (Seroquel). This condition will be called IPSRT-QUE.
11531473|NCT01133795|Experimental|Midodrine, Albumin|Midodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
11531474|NCT01133782|Experimental|Rapid result|Result of diagnostic PCR panel provided the following day
11531475|NCT01133782|No Intervention|Delayed result|Result of dagnostic PCR panel provided within 10+/-2 days at follow-up visit.
11531476|NCT01133769||Surgical vs Non surgical|This is an open, prospective, randomized, dual arm, parallel group clinical study of open reduction and internal fixation (ORIF) or intramedullary nail (IMN) versus non operative treatment for clavicle fracture in polytrauma patients with associated chest injury, with or without additional injuries to the head, abdomen, pelvis and extremities.
11531477|NCT01133756|Experimental|Lenvatinib plus carboplatin + gemcitabine|Phase IB and Phase II
11531478|NCT01133756|Active Comparator|Carboplatin + gemcitabine|Phase II
11531479|NCT01133743|Experimental|Lenalidomide and Dexamethasone|Lenalidomide target dose of 25 mg PO OD continuously (28-day cycle) using an initial dose escalation period. Oral dexamethasone 12 mg daily on days 1-7, 14 and 21 of each cycle.
11531480|NCT01133730|Experimental|Active treatment group|Ultrasound-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine
11531481|NCT01133730|Placebo Comparator|Placebo arm|Ultrasound-guided TFP block with 20ml of 5% dextrose solution
11531482|NCT01133717||Control without Sleep Apnea|
11531483|NCT01133717||Subjects with Sleep Apnea|
11531484|NCT01133704|Active Comparator|sipuleucel-T (APC8015)|
11531485|NCT01133704|Placebo Comparator|Placebo|
11531486|NCT01133691||healthy children aged 6 - 12 years|
11531487|NCT01133678|Experimental|Everolimus|Everolimus 5 mg PO Daily for 2 21-day cycles
11531488|NCT01133678|Experimental|Placebo|Placebo 5 mg PO Daily for 2 21-day cycles
11531489|NCT01133665|Experimental|Sub Group 1|All Subjects Enrolled in the Trial
11531490|NCT01133652|Active Comparator|VeinViewer|The Veinviewer machine will be used to guide intravenous access.
11531491|NCT01133652|Active Comparator|Ultrasound|The Ultrasound will be used to guide intravenous access.
11531492|NCT01133652|Active Comparator|Conventional IV placement|IV will be placed using conventional technique
11531493|NCT01133639|Placebo Comparator|Placebo|Placebo plus standard of care
11531494|NCT01133639|Experimental|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
11531495|NCT01133626|Placebo Comparator|Placebo|Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
11531496|NCT01133626|Experimental|BDP HFA 320 µg/day|Participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning for 6 weeks (42 days). During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
11531497|NCT01133626|Active Comparator|Prednisone|Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a 10/mg a day prednisone capsule.
11531498|NCT01133613|Experimental|Cohort 1|0.03 mg/ml BMP-7 or placebo via intraarticular knee injection
11531499|NCT01133613|Experimental|Cohort 2|0.1 mg/ml BMP-7 or placebo via intraarticular knee injection
11531500|NCT01133613|Experimental|Cohort 3|0.3 mg/ml BMP-7 or placebo via intraarticular knee injection
11531501|NCT01133600|Active Comparator|daptomycin|Dosed at 6mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if creatinine clearance (CrCl)is <30ml/min.
11531502|NCT01133600|Active Comparator|vancomycin|Dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
11531503|NCT01133587|Experimental|admissions contract|"contract regarding patient-guided admissions"
11531504|NCT01133587|Active Comparator|wait list control|1 year on waiting list
11531505|NCT01133574|Experimental|A1|Part A, Parallel design Arm 1
11531506|NCT01133574|Experimental|A2|Part A, Parallel design Arm 2
11531507|NCT01133574|Experimental|A3|Part A, Parallel design Arm 3
11531508|NCT01133574|Experimental|A4|Part A, Parallel design Arm 4
11531509|NCT01133574|Experimental|A5|Part A, Parallel design Arm 5
11531510|NCT01133574|Experimental|A6|Part A, Parallel design Arm 6
11531511|NCT01133574|Experimental|A7|Part A, Parallel design Arm 7
11531512|NCT01133574|Experimental|A8|Part A, Parallel design Arm 8
11531513|NCT01133574|Placebo Comparator|A9|Part A, Parallel design Arm 9
11531514|NCT01133574|Experimental|B1-1|Part B, Cross-over design, Arm 1
11531515|NCT01133574|Experimental|B1-2|Part B, Cross-over design, Arm 2
11531516|NCT01133574|Experimental|B2-1|Part B, Cross-over design, Arm 3
11531517|NCT01133574|Experimental|B2-2|Part B, Cross-over design, Arm 4
11531518|NCT01133574|Placebo Comparator|B3|Part B, Cross-over design, Arm 5
11531519|NCT01133561|Active Comparator|actozone A|Pioglitazone 30 mg tablets daily
11531520|NCT01133561|Placebo Comparator|actozone B|placebo
11531521|NCT01133548|Experimental|1|Testosterone Gel 1.62%
11531522|NCT01133535||Pancreatitis, acute, recurrent|Patients with acute recurrent pancreatitis where the cause is unknown
11531523|NCT01133522|Experimental|Evolocumab|Participants received one of 5 dose levels of evolocumab administered as multiple subcutaneous doses.
11531524|NCT01133522|Placebo Comparator|Placebo|Participants received matching placebo dose regimens by subcutaneous injection.
11531525|NCT01133509|Other|gardisil|gardisil
11531526|NCT01133496|Experimental|Alendronate Sodium|Alendronate Sodium Tablets, 70 mg of Dr. Reddy's
11531527|NCT01133496|Active Comparator|Fosamax|Fosamax Tablets 70 mg of Merck & Company. Inc., USA.
11531528|NCT01133483|Experimental|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories
11531529|NCT01133483|Active Comparator|Allegra-D 24 hour ER Tablets|Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.
11531530|NCT01133470|Experimental|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories
11531531|NCT01133470|Active Comparator|Allegra-D 24 hour ER Tablets|Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.
11531532|NCT01133457|Experimental|Finasteride|Finasteride tablets 1 mg of Dr. Reddy's
11531533|NCT01133457|Active Comparator|Propecia|Propecia 1 mgTablets of Merck & Co.,
11531534|NCT01133444|Experimental|Finasteride|Finasteride tablets 1 mg of Dr. Reddy's
11531535|NCT01133444|Active Comparator|Propecia|Propecia 1 mgTablets of Merck & Co.,
11531536|NCT01133431|Experimental|CKD-501 + Glimepiride -> CKD-501 placebo + Glimepiride|This study is randomized, single-blinded, two-period, 2 treatments, crossover design to assess the pharmacokinetics interaction between CKD-501 and sulfonylurea.
11531537|NCT01133431|Experimental|CKD-501 placebo + Glimepiride -> CKD-501 + Glimepiride|This study is randomized, single-blinded, two-period, 2 treatments, crossover design to assess the pharmacokinetics interaction between CKD-501 and sulfonylurea.
11531538|NCT01133418|Experimental|Cognitive Training|Computerized Progressive Attention Training
11531539|NCT01133418|Sham Comparator|Non-progressive cognitive training|Children in the control condition will participate in the same tasks as children in the Intervention arm. They will experience the same number of blocks and trials of training as the intervention group. Further, their training will be conducted by the same set of trainers and for the same amount of time as the intervention group. However, children in the control group will remain at the lowest level for each CT task throughout training irrespective of performance.
11531540|NCT01133405|Experimental|LY2886721 Part 1: Cohort A/B|Single (7 milligram (mg), 15 mg, 25 mg, 35 mg) doses of LY2886721 administered orally in up to three of three study periods
11531541|NCT01133405|Placebo Comparator|Placebo Part 1: Cohort A/B|Single dose in up to 1 period
11531542|NCT01133405|Experimental|LY2886721 Part 2: Cohort C|Single 10 mg dose of LY2886721, dose determined by Part 1
11531543|NCT01133405|Experimental|LY2886721 Part 2: Cohort D|Single 35 mg dose of LY2886721, dose determined by Part 1
11531544|NCT01133405|Placebo Comparator|Placebo Part 2: Cohort C/D|Single dose
11531545|NCT01133392|Experimental|Insulin Lispro A|20 units (U) subcutaneously (SC)
11531546|NCT01133392|Active Comparator|Insulin lispro B|20 units (U) subcutaneously (SC)
11531547|NCT01133379|Experimental|PO-019|1.40% Potassium Oxalate Sensitive Mouthwash without fluoride (12027-019)
11531548|NCT01133379|Experimental|PO-020|1.40% Potassium Oxalate Sensitive Mouthwash with fluoride (12027-020)
11531549|NCT01133379|Sham Comparator|PO-021|Vehicle Control Mouthrinse (without potassium oxalate and without fluoride) (12027-021)
11531550|NCT01133366|Active Comparator|warfarin alone|
11531551|NCT01133366|Experimental|warfarin with mipomersen|
11531552|NCT01133353|Experimental|Tetrabenazine MR|
11531553|NCT01133353|Placebo Comparator|Placebo|
11531554|NCT01133327|Experimental|Adapt Carotid Stent System|Intervention with Adapt Carotid Stent System with the FilterWire EZ System
11531555|NCT01133301|Active Comparator|Naltrexone-Placebo|In the first three weeks of the study, 50 mg Naltrexone will be administrated, the following three three weeks placebo will be administrated.
11531556|NCT01133301|Placebo Comparator|Placebo-Naltrexone|The first three weeks, placebo will be administrated, the following three weeks 50 mg Naltrexone will be administrated.
11531557|NCT01133275|Experimental|Lenalidomide and Prednisone Therapy|All participants received lenalidomide and prednisone therapy for 6 cycles (24 weeks). Each cycle is 28 days (4 weeks).
11531558|NCT01133249||Total hip|all consented patients receiving total hip arthroplasty
11531559|NCT01133236|Experimental|Salt and Fluid|Intervention: Fluid 800 Ml and Salt 2 g per day Control: FLuid and Salt Free
11531560|NCT01133223|Active Comparator|Thrombectomy|
11531561|NCT01133223|Active Comparator|Usual Care|
11531562|NCT01133210|Experimental|Maraviroc|Subjects will receive 12 weeks of treatment with maraviroc (300 mg po bid).
11531563|NCT01133210|Placebo Comparator|Placebo|Subjects will receive 12 weeks of treatment with placebo
11531564|NCT01133197||controls|No hand arthritis
11531565|NCT01133197||CMC Arthritis|Patients with arthritis
11531983|NCT01129960|Placebo Comparator|Placebo|
11531566|NCT01133171|Experimental|Dashboard Plus Nurse|Patients randomized to this intervention arm were seen twice over six months by a research nurse to collect data on risk factors and received counseling plus a computerized dashboard intervention.
11531567|NCT01133171|Experimental|Nurse Alone|Patients randomized to this intervention arm were seen twice over six months by a research nurse to collect data on risk factors and received counseling.
11531568|NCT01133171|No Intervention|Control|Patients randomized to this group were followed retrospectively to collect data on their primary care visits and laboratory results and past medical history over the 12 month study period. They had no contact with study personnel and did not receive any type of intervention.
11531569|NCT01133158|Experimental|R-BMD|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone Induction: 6 Rituximab, Bendamustine, Mitoxantrone, Dexamethasone cycles Maintenance: Rituximab every 3 months for 2 years
11531570|NCT01133145|Experimental|vascularized transplantation|allogeneic vascularized knee transplantation
11531571|NCT01133132|Placebo Comparator|Control|This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
11531572|NCT01133132|Experimental|Intervention|For those subjects randomized to the Survivorship CHESS condition they will receive a smartphone and access to a web based information system that provides access to clinical information about colon cancer treatment, survivorship, exercise planning and tracking functions to allow these subjects to monitor their self defined exercise goals and objectives.
11531573|NCT01133119|Active Comparator|Treatment Group 1|
11531574|NCT01133119|Experimental|Treatment Group 2|
11531575|NCT01133106|Experimental|In-person behavioral intervention|behavioral counseling plus antidepressant treatment prescribed by participant's own provider; consisted of orientation session plus 6 counseling sessions in person with a psychosocial nurse practitioner
11531576|NCT01133106|Experimental|Telephone behavioral intervention|This arm is identical to the in-person Arm except that the intervention is delivered by telephone instead of in-person.
11531577|NCT01133106|Active Comparator|Standard care|participants have orientation to the study with the same written materials given those in the experimental arms. Keep a medication log and keep appointments with their own post-stroke provider
11531578|NCT01133080|Experimental|Minocycline|
11531579|NCT01133080|Placebo Comparator|Placebo|
11531580|NCT01133054|Experimental|low FFR|FFR<0.75
11531581|NCT01133054|No Intervention|high FFR|FFR > 0.75
11531582|NCT01133041|Experimental|NBI observation|
11531583|NCT01133041|Experimental|i-Scan observation|
11531584|NCT01133028|Experimental|Combined|This represents a combination of the tolerance training and behavioral management interventions together.
11531585|NCT01133028|Active Comparator|Behavioral management|This represents the behavioral contingency management intervention only.
11531586|NCT01133015|Experimental|Intermediate lesion|Intermediate lesion will be evaluated by both IVUS and FFR
11531587|NCT01133002||VTE management registry|Patients receiving enoxaparin, with or without oral anticoagulation, within Day 0-10 after diagnosis of VTE
11531588|NCT01132976|Active Comparator|Goal-based motivational interview|Participants randomised to this group will receive the goal based motivational interview - Personal Concerns Inventory (PCI) in addition to treatment as usual.
11531589|NCT01132976|Other|Treatment as usual|Participants randomly allocated to this group will receive treatment as usual only, ie no specific motivational intervention.
11531590|NCT01132963|Experimental|Outdoor Shoes|Patient will be asked to do balance tests while wearing outdoor shoes.
11531591|NCT01132963|Active Comparator|Pillow Paws Slippers|Patient will be asked to complete balance tests while wearing standard hospital issue 'Pillow Paw' slippers on their feet
11531592|NCT01132950|Active Comparator|Didactic Educational Counseling|
11531593|NCT01132950|Experimental|Motivation Interviewing|Participant will receive two sessions of personalized motivational interviewing.
11531594|NCT01132937||Healthy Controls|Accrual Ceiling: 20. Healthy, uninjured, subjects are used to match to those suspected of head injury. 10 subjects have been enrolled to date in the PET arm
11531595|NCT01132937||Suspected of Head Injury|Accrual Ceiling: 1000. Subjects enrolled with 48hrs of suspected head injury in emergency department of local hospitals, Suburban Hospital Center or Washington Hospital Center
11531596|NCT01132924||EPS Study Participants|Women who participated in the 1982-1986 North Carolina Early Pregnancy Study (EPS)
11531597|NCT01132898||cross-sectional TBI|Participants with a mild, moderate, or severe Traumatic Brain Injury enrolled within 5 years from injury. Seen at only one visit.
11531598|NCT01132898||HV|Healthy Volunteer with no history of TBI
11531599|NCT01132898||Prospective TBI|Participants with a mild, moderate, or severe Traumatic Brain Injury enrolled within 1 year from injury.
11531600|NCT01132898||Select Exposure Group|US government associated personnel experiencing TBI-like symptoms arising after possible exposure to a non-natural energy source
11531601|NCT01132898||Select Exposure Matched Unaffected|A longitudinal control group comprised of unaffected volunteers matched to the Select Exposure group
11531602|NCT01132885||Adults with WS or genetic abnormalities|Adults with Williams syndrome or genetic abnormalities in chromosome 7q11.23
11531603|NCT01132885||Children with WS or genetic abnormalities|children ages 5 17 with Williams Syndrome or genetic abnormalities in chromosome 7q11. 23
11531604|NCT01132885||Parents|Parents of children with 7q11.23 CNV will undergo blood draws
11531605|NCT01132885||Unaffected Siblings|Siblings of children with 7q11.23 CNV
11531606|NCT01132885||Unrelated children|Typically developing children ages ages 5 -17
11531607|NCT01132859||1|Volunteers of 18 years of age or older willing to donate blood and tissue specimens and participate in imaging studies to evaluate the components of the immune system
11531608|NCT01132846|Active Comparator|Low dose Dopamine|"Drug: Dopamine
~Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study"
11531609|NCT01132846|Placebo Comparator|Placebo|Drug: Placebo Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
11531610|NCT01132846|Active Comparator|Low Dose Nesiritide|Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
11531984|NCT01129947|Experimental|DHEA|
11531611|NCT01132820|Experimental|Treatment (cediranib maleate)|Patients receive cediranib maleate PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11531612|NCT01132807|Experimental|Treatment (chemotherapy and F-18 PET/CT)|See Detailed Description
11531613|NCT01132794|Placebo Comparator|Placebo|Intranasal nasal saline
11531614|NCT01132794|Active Comparator|Dexmedetomidine|Intranasal dexmedetomidine
11531615|NCT01132781|Placebo Comparator|Placebo|200mg twice daily of placebo drug
11531616|NCT01132781|Active Comparator|200mg theophylline|200mg twice daily of slow release theophylline
11531617|NCT01132768|Active Comparator|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily.
11531618|NCT01132768|Experimental|Olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily.
11531619|NCT01132755|Experimental|Patients who require diagnostic laparoscopy|Diagnostic peritoneal lavage will be performed at the time of laparoscopy utilizing a Veress needle/Seldinger technique to insert a peritoneal dialysis catheter. This is not a new technique. The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon.
11531620|NCT01132742||hospitalised children|
11531621|NCT01132703|Experimental|RP-1127 (Glyburide for Injection)|
11531622|NCT01132703|Placebo Comparator|Placebo|Placebo (RP-1127 excipients without active)
11531623|NCT01132690|Experimental|30 units/kg|
11531624|NCT01132690|Experimental|60 units/kg|
11531625|NCT01132677|Active Comparator|Hyaluronic Acid (HA) Injection|Patients allocated to the HA group will receive a single IA injection Hylan G-F 20 Synvisc One™ (1 injection of 6cc's). All injections will be administered as outlined on the company label. Aspiration of the knee will not be performed.
11531626|NCT01132677|Active Comparator|Corticosteroid Injection|Patients allocated to the corticosteroid injection will receive a single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label. Aspiration of the knee will not be performed.
11531627|NCT01132664|Experimental|HER2+ metastatic breast cancer|Patients with HER2-overexpressing metastatic breast cancer, with or without PIK3 signaling pathway alteration, who have previously failed trastuzumab
11531628|NCT01132664|Experimental|HER2+ metastatic breast cancer with BM|Patients with HER2-overexpressing metastatic breast cancer and brain metastases, with or without PIK3 signaling pathway alteration, who have previously failed trastuzumab
11531629|NCT01132651|Experimental|Chillow cooling pillow|This group of subjects will follow their current eczema regimen with the addition of using the cooling pillow at night to sleep on.
11531630|NCT01132651|Placebo Comparator|Standard of care (regular pillow at night)|This group of subjects will serve as the control group following a their current eczema care regimen, including sleeping on their normal pillow.
11531631|NCT01132638|Active Comparator|Magnesium Pantoprazole|
11531632|NCT01132638|Active Comparator|Magnesium Esomeprazole|
11531633|NCT01132625|Experimental|AUY922|
11531634|NCT01132612|Experimental|Fixed-time interval regimen|Secukinumab 150 mg subcutaneous (sc) administered at Week 1 (baseline) of the extension study and every 12 weeks thereafter
11531635|NCT01132612|Experimental|Treatment at start of relapse regimen|Placebo administered at Week 1 (baseline) of the extension study and every 12 weeks thereafter. If relapse, then switch to secukinumab 150 mg sc administered every 4 weeks
11531636|NCT01132612|Experimental|Open-label|Secukinumab 150 mg sc administered every 4 weeks
11531637|NCT01132586|Experimental|Treatment (lenalidomide, cytarabine, idarubicin)|"INDUCTION:
~COHORT I: Patients receive lenalidomide PO QD on days 1-21, cytarabine IV continuously over 96 hours on days 5-8, and idarubicin IV over 1 hour on days 5-7.
~COHORT II: Patients receive lenalidomide PO QD on days 1-21, cytarabine IV continuously over 24 hours on days 5-11, and idarubicin as above.
~Patients with residual disease on day 18 undergo a second course of induction therapy.
~CONSOLIDATION:
~COHORT I: Patients receive lenalidomide PO QD on days 1-14, idarubicin IV over 1 hour on days 5-6, cytarabine IV continuously on days 5-7. Treatment continues for 1 course in the absence of disease progression or unacceptable toxicity.
~COHORT II: Patients 2 receive 4 courses of consolidation therapy comprising lenalidomide PO QD on days 1-14 and cytarabine IV every 12 hours on days 5, 7, and 9. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
11531638|NCT01132573|Experimental|Treatment (entinostat and clofarabine)|"Patients receive entinostat PO on days 1 and 8 and clofarabine IV over 2 hours on days 3-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity (only for patients >= 60 years of age with newly diagnosed ALL or ABL who are unable or unwilling to tolerate standard multi-agent chemotherapy and patients with relapsed or refractory ALL or ABL).
~Patients 40-59 years of age with newly diagnosed ALL receive standard multi-agent induction chemotherapy beginning on day 11. Patients >= 21 years of age in their first relapse with sensitive disease begin initiation of allogeneic transplant after one course of entinostat and clofarabine."
11531639|NCT01132547|Experimental|Arm I cyproheptadine hydrochloride|Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.
11531640|NCT01132547|Placebo Comparator|Arm II placebo|Patients receive an oral placebo twice daily for 8 weeks.
11531641|NCT01132534||SE then AFI/NBI|Patients will be randomised to be examined by standard videoendoscopy (SE) then combined AFI/NBI during the esophagogastroduodenoscopy (EGD) examination at same setting.
11531642|NCT01132534||AFI/NBI then SE|Patients will be randomised to be examined by combined AFI/NBI then standard videoendoscopy (SE) during the EGD examination at same setting.
11531643|NCT01132521|Experimental|ulinastatin group|Regular treatments plus ulinastatin. Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
11531644|NCT01132521|Placebo Comparator|placebo group|Regular treatment plus placebo. Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
11531645|NCT01132508||Treatment|
11531646|NCT01132495|Other|Cohort A: PCI plus OMT|PCI plus optimal medical treatment
11531647|NCT01132495|Other|Cohort A: OMT alone|Optimal medical treatment alone
11531648|NCT01132495|Other|Cohort B|FFR > 0.80; treatment according to local practice
11531649|NCT01132482|Experimental|Sildenafil|Subjects will receive escalating doses of sildenafil
11531650|NCT01132482|Placebo Comparator|Placebo|During the placebo arm, subjects receiving placebo will have sham dose escalation to maintain blinding.
11531651|NCT01132469|Experimental|Endoscopic Submucosal Dissection|Single-arm for ESD procedure and retrospective surgical procedure(Laparoscopy, Open surgery)data collection
11531652|NCT01132456|Experimental|Different patient subset|Patients with dual vessel treatment where each vessel has a lesion with length ≤ 27 mm and reference vessel diameters between 2.25 mm and 4.0 mm.
11531653|NCT01132456|Experimental|38 mm Cohort|Patients with at least one lesion amenable to treatment with a 38 mm length Endeavor Resolute stent. Patients may have one or two lesions, if the two lesions are located in separate target vessels.
11531654|NCT01132443|Experimental|Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,|Apply topically once daily; clindamycin (CLN); benzoyl peroxide (BPO); methylparaben-free (MPF)
11531655|NCT01132443|Active Comparator|Duac/ formulation 1|Apply topically once daily, Topical Gel (CLN 1%-BPO 5%), methylparaben-preserved
11531656|NCT01132443|Active Comparator|Duac/ formulation 2|Apply topically once daily, Duac Once Daily Gel (CLN 1%-BPO 5%), MPF
11531657|NCT01132430|Placebo Comparator|Usual care|Standard medical care within 4-6 week period
11531658|NCT01132430|Experimental|Motivational interviewing|Brief MI sessions within 4-6 week period
11531659|NCT01132417||Multidrug resistant (MDR)bacterial strains|
11531660|NCT01132404|Experimental|TAK-448 Dose 1|
11531661|NCT01132404|Experimental|TAK-448 Dose 2|
11531662|NCT01132404|Active Comparator|Leuprorelin|
11531663|NCT01132391|Experimental|1|Endoanal application
11531664|NCT01132391|Experimental|2|Perianal application
11531665|NCT01132378|Active Comparator|Mini-midvastus approach|Mini Midvastus approach with skin incision less than 13 cm long and vastus medialis obliquus dissection not more than 3 cm from the patellar margin was used to perform total knee arthroplasty in 40 patients.
11531666|NCT01132378|Active Comparator|Medial Parapatellar Approach|Mini Medial Parapatellar approach with skin incision less than 13 cm. The extension into quadriceps tendon did not exceed 3 cm.Mini medial parapatellar approach was used to perform total knee arthroplasty.
11531667|NCT01132365||knee arthroplasty|
11531668|NCT01132352|Experimental|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
11531669|NCT01132352|Active Comparator|Keppra®|Keppra® 750 mg Tablets of UCB Pharma Inc.,
11531670|NCT01132339||Enhanced MR (case group)|those with an exposure to gadolinium-based contrast agent
11531671|NCT01132339||Unenhanced MR (control group)|those without an exposure to gadolinium-based contrast agent
11531672|NCT01132339||Unenhanced CT (control group)|those without an exposure to iodine-containing contrast agent
11531673|NCT01132339||Enhanced CT (case group)|those with an exposure to iodine-containing contrast agent
11531674|NCT01132326|Experimental|Droxidopa|Open-Label Droxidopa
11531675|NCT01132313|Experimental|2|4 weeks of high dose TID BI 207127 and QD BI 201335 in combination with RBV, Part 1
11531676|NCT01132313|Experimental|1|4 weeks of low dose three times per day (TID) BI 207127 and once daily (QD) BI 201335 in combination with RBV, Part 1
11531677|NCT01132313|Experimental|3|16 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
11531678|NCT01132313|Experimental|4|28 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
11531679|NCT01132313|Experimental|5|40 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
11531680|NCT01132313|Experimental|6|28 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 2
11531681|NCT01132313|Experimental|7|28 weeks of TID BI 207127 and QD BI 201335 without RBV, Part 2
11531682|NCT01132313|Experimental|8|16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
11531683|NCT01132313|Experimental|9|24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
11531684|NCT01132313|Experimental|10|24 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 3
11531685|NCT01132313|Experimental|11|16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
11531686|NCT01132313|Experimental|12|24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
11531687|NCT01132300|Experimental|Treatment|
11531688|NCT01132287|Experimental|1 FID 112903|FID 112903
11531689|NCT01132287|No Intervention|No Intervention|
11531690|NCT01132274|Active Comparator|Conventional catheter ablation|Radiofrequency catheter ablation through fluoroscopic guidance
11531691|NCT01132274|Experimental|Non-fluoroscopic catheter ablation|Radiofrequency catheter ablation guided by the EnSite NavX (St.Jude Medical, St Paul, MN, USA) mapping-system
11531692|NCT01132261|Active Comparator|1|brain preservation diet
11531693|NCT01132261|No Intervention|2|
11531694|NCT01132248|Experimental|Mefloquine|15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
11531695|NCT01132248|Placebo Comparator|S/P|sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
11531696|NCT01132222|Experimental|Ibuprofen + Psuedoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets
11531697|NCT01132222|Active Comparator|Advil® Cold and Sinus|Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare
11531698|NCT01132209|Active Comparator|Large tissue bites|As control the conventional large bites technique (mass closure) will be applied in with bites widths of 1 cm and inter-suture spacing of 1 cm with the use of PDS plus ll 1-0 double loop suture material with a 48 mm needle.
11531699|NCT01132209|Experimental|small tissue bites|In the other group of 288 patients the small bites technique will be applied with bite widths of 0,5 cm and inter suture spacing of 0,5 cm with the use of PDS plus ll 2-0 single suture material with a 31 mm needle placed in the linea alba. In the small bites technique, twice as many stitches will be placed per sutured cm, with a smaller needle and thinner suture material.
11531700|NCT01132196|Experimental|Divalproex Sodium DR Tablets 500 mg|Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Laboratories Limited
11531701|NCT01132196|Active Comparator|Depakote DR 500 mg Tablets|Depakote DR 500 mg Tablets of Abbott Laboratories PR Ltd.,
11531702|NCT01132183|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
11531703|NCT01132183|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
11531704|NCT01132170|Experimental|Divalproex Sodium DR Tablets 500 mg|Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Laboratories Limited
11531705|NCT01132170|Active Comparator|Depakote DR 500 mg Tablets|Depakote DR 500 mg Tablets of Abbott Laboratories PR Ltd.,
11531706|NCT01132157|Experimental|Propofol group|
11531707|NCT01132157|Active Comparator|Desflurane group|
11531708|NCT01132144|Experimental|Endometrial injury group|Endometrial biopsy was performed once with a pipelle de Cornier® in the month before initiating controlled ovarian stimulation.
11531709|NCT01132144|Sham Comparator|Control group|Introduction of the speculum and wiping of the cervix with gaze for 30 seconds.
11531710|NCT01132131|Active Comparator|Delegation form|
11531711|NCT01132131|Active Comparator|Regular doctor's consultation|
11531712|NCT01132118|Other|Placebo then HCQ|This arm of the study will contain half the study population after randomization. The participants in this arm will receive hydroxychloroquine for 8 weeks and then crossover to a placebo for 8 weeks. Study staff will be blinded to which order they are taking the hydroxychloroquine and placebo in.
11531713|NCT01132118|Other|HCQ then Placebo|This arm of the study will contain half the study population after randomization. The participants in this arm will receive hydroxychloroquine for 8 weeks and then crossover to a placebo for 8 weeks. Study staff will be blinded to which order they are taking the hydroxychloroquine and placebo in.
11531714|NCT01132105||Normal subjects|Adults normal hearing and vestibular function subjects
11531715|NCT01132092||Normal hearing (experimental 1)|76 Normal hearing subjects, male and female, adults, , evaluated by new device
11531716|NCT01132092||Normal hearing (experimental 2)|15 Normal hearing subjects, male and female, adults, , evaluated by new device
11531717|NCT01132092||Hearing loss (experimental 3)|15 hearing loss subjects, male and female, adults, evaluated by new device
11531718|NCT01132092||Gold standard 1|15 Normal hearing subjects, male and female, adults, evaluated by gold standard device
11531719|NCT01132092||Gold Standard 2|15 hearing loss subjects, male and female, adults, evaluated by gold standard device
11531720|NCT01132079|Experimental|Pimecrolimus cream treatment|
11531721|NCT01132079|Active Comparator|Betamethasone valerate cream treatment|
11531722|NCT01132066|Experimental|tDCS|tDCS will provide an increase in cortical excitability. Patients will be randomized to receive tDCS or sham stimulation.
11531723|NCT01132066|Placebo Comparator|sham|Sham stimulation will provide identical subjective sensation as anodal tDCS.
11531724|NCT01132053||PML|These are subjects who have confirmed PML.
11531725|NCT01132053||Control|These are subjects who do not have PML. They may be healthy or immune compromised due to Cancer, Transplant, or HIV.
11531726|NCT01132040|Experimental|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories
11531727|NCT01132040|Active Comparator|Mysoline|Mysoline Tablets of Yamanouchi Pharma Technologies Inc,
11531728|NCT01132027|Experimental|Tacrolimus|Tacrolimus Capsules, 5 mg of Dr.Reddy's Laboratories Limited
11531729|NCT01132027|Active Comparator|Prograf Capsules|Prograf Capsules of Astellas Pharma US, Inc.,
11531730|NCT01131988|Experimental|Tacrolimus|Tacrolimus Capsules, 5 mg of Dr.Reddy's Laboratories Limited
11531731|NCT01131988|Active Comparator|Prograf Capsules|Prograf Capsules of Astellas Pharma US, Inc.,
11531732|NCT01131975|Experimental|Lamotrigine (chewable, dispersible)|Lamotrigine Tablets (chewable, dispersible),25 mg of Dr. Reddy's Laboratories Limited
11531733|NCT01131975|Active Comparator|Lamictal|Lamictal Tablets 25 mg of Glaxo SmithKline
11531734|NCT01131962|Active Comparator|band ligation group|this group will have immediate control of the hematemesis by endoscopic band ligation.
11531735|NCT01131962|Active Comparator|sclerotherapy group|This group will have immediate control of hematemesis by endoscopic sclerotherapy
11531736|NCT01131949|Experimental|Lamotrigine (chewable, dispersible)|Lamotrigine Tablets (chewable, dispersible),25 mg of Dr. Reddy's Laboratories Limited
11531737|NCT01131949|Active Comparator|Lamictal|Lamictal Tablets 25 mg of Glaxo SmithKline
11531738|NCT01131936|Experimental|Amlodipine Tablets, 10 mg|Amlodipine Tablets, 10 mg of Dr. Reddy's Laboratories Limited
11531739|NCT01131936|Active Comparator|Norvasc Tablets, 10 mg|
11531740|NCT01131923|Experimental|Amlodipine Tablets, 10 mg|Amlodipine Tablets, 10 mg of Dr. Reddy's Laboratories Limited
11531741|NCT01131923|Active Comparator|Norvasc Tablets, 10 mg|
11531742|NCT01131910|Experimental|Vaccination against TBE|"Less than 60 years old: Two doses of TBE- vaccine separated by a month and a third dose 12 months after the first dose
~60 years and above: Three doses, given at 0+1+3 months and a 4 th dose 12 months after the first dose"
11531743|NCT01131897|Experimental|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
11531744|NCT01131897|Active Comparator|Keppra®|Keppra® 750 mg Tablets of UCB Pharma Inc.,
11531745|NCT01131884|Active Comparator|Fosamax|Fosamax at 70 mgs q weekly by mouth for the duration of the study.
11531746|NCT01131884|Placebo Comparator|Placebo Sugar Pill|Double blind study using Fosamax versus placebo. Placebo is an inactive drug.
11531747|NCT01131871|Active Comparator|Standard Behavioral Weight Loss Intervention|
11531748|NCT01131871|Experimental|Enhanced Weight Loss Intervention|
11531749|NCT01131858|Placebo Comparator|Placebo|Placebo
11531750|NCT01131858|Active Comparator|Vitamin D|Vigantol (cholecalciferol) 4000 IE/day
11531751|NCT01131845|Experimental|Treprostinil diethanolamine|
11531752|NCT01131832|Experimental|Plant sterol|Plant sterol supplementation, 2 grams per day of plant sterols in a margarine
11531753|NCT01131819|Other|1|The novel intervention we propose to use, the Wii Fit, will be introduced for a period of at least 20 minutes but not greater than 30 minutes per day to all the subjects in the study.
11531754|NCT01131806|Active Comparator|MD Flu/Sal|fluticasone125 mcg/ salmeterol 25 mcg 2puffs (medium dose group) inhaled twice daily; salbutamol evohaler allowed from 100 to 400 mcg for inhalation as needed basis.
11531755|NCT01131806|Experimental|HD Flu/Sal|fluticasone 250 mcg/salmeterol 25 mcg 2puffs (high dose group) inhaled twice daily; salbutamol evohaler allowed from 100 to 400 mcg for inhalation as needed basis.
11531756|NCT01131793|Experimental|RF Guidewire|
11531757|NCT01131780|Experimental|Ibuprofen + Psuedoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets
11531758|NCT01131780|Active Comparator|Advil® Cold and Sinus|Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare
11531759|NCT01131767|Experimental|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.
11531760|NCT01131767|Active Comparator|Aleve Cold and Sinus|Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).
11531761|NCT01131754|Experimental|Heparin sol 100U/L|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
11531762|NCT01131754|Active Comparator|saline|peripheral venous catheter flushing with 3 mL of normal saline from mono-use vials (prepared by the hospital pharmacy) at the end of each drug infusion. Independently of the number of drug infusions, all patients will receive at least two catheter flushes every day.
11531763|NCT01131741|Experimental|Epinephrine|
11531764|NCT01131741|Placebo Comparator|Control|
11531765|NCT01131728|Experimental|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.
11531766|NCT01131728|Active Comparator|Aleve Cold and Sinus|Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).
11531767|NCT01131715||Study group|Patients who are included in the pharmacist follow-up procedure
11531768|NCT01131702|Experimental|Ranitidine Tablets, 300 mg|Ranitidine Tablets, 300 mg of Dr. Reddy's Laboratories Limited
11531769|NCT01131702|Active Comparator|Zantac Tablets, 300 mg|
11531770|NCT01131676|Experimental|BI 10773 low dose|BI 10773 tablets once daily
11531771|NCT01131676|Experimental|BI 10773 high dose|BI 10773 tablets once daily
11531772|NCT01131676|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
11531773|NCT01131650||diabetic retinopathy|
11531774|NCT01131650||diabetica retinopathy prevalence|
11531775|NCT01131637|Experimental|rhNRG-1|recombinant human neuregulin-1
11531776|NCT01131637|Placebo Comparator|placebo|placebo
11531777|NCT01131624|Active Comparator|Ferric carboxymaltose|"Subjects with bw ≥66 kg will receive an infusion of 1,000 mg iron as FCM and after 1 week a further 500 mg iron as FCM, depending on Hb at screening.
~subjects with bw <66 kg, 2-3 infusions of 500 mg iron as FCM will be administered within 2 weeks from baseline, depending on Hb at screening"
11531778|NCT01131624|Active Comparator|Oral Iron|Oral Iron oral iron preparation will be provided at 200 mg iron per day in a convenient dosage schedule.
11531779|NCT01131611|Experimental|CBPT intervention|Standard PT treatment + CBPT
11531780|NCT01131611|Placebo Comparator|Control-Attention|Standard PT treatment + weekly phone calls
11531781|NCT01131585|Experimental|Active laser photocoagulation and ranibizumab|"Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
~Ranibizumab intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment."
11531782|NCT01131585|Active Comparator|Active laser photocoagulation and sham injection|"Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
~Sham intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment."
11531783|NCT01131572|Other|N-acetylcysteine|open label treatment. Each subject receives N-acetylcysteine.
11531784|NCT01131559|Active Comparator|Lisdexamfetamine|Drug
11531785|NCT01131559|Placebo Comparator|Placebo|Drug
11531786|NCT01131546|Experimental|Levamlodipine besylate (2.5mg)|
11531787|NCT01131546|Experimental|Levamlodipine besylate (5mg)|
11531788|NCT01131546|Active Comparator|Amlodipine maleate (5mg)|
11531789|NCT01131533|Experimental|Erythropoietin|patients with chronic macular edema associated with diabetic retinopathy
11531790|NCT01131520|Experimental|Computerized Brief Intervention|Computerized one-session brief intervention for drug use
11531791|NCT01131520|Active Comparator|Counselor delivered brief intervention|This is a brief intervention focused on drug use delivered by a behavioral health counselor and based on motivational interviewing
11531792|NCT01131507|Experimental|EUR-1008 (APT-1008)|
11531793|NCT01131494|Experimental|Swallowing exercises|
11531794|NCT01131481|Other|AcrySof MA50BM,AVS Model X-60|AcrySof MA50BM, AVS Model X-60
11531795|NCT01131468|Experimental|N-acetylcysteine|N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin
11531796|NCT01131468|No Intervention|Controls|Vancomycine and/or amikacin alone
11531797|NCT01131455|Active Comparator|Fusion+ACP+Autograft|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus, external rotation and neutral foot dorsiflexion). The arthrodesis undertaken for all groups will be the standard arthroscopic ankle arthrodesis with portals to the ankle (anterior medial / anterior lateral), skin incision only technique with dissection through the capsule and penetration to the joint. Standard debridement of the gutters, tibia osteophyte, tibia-talor joint resection and autograft preparation will be performed in the joint. Depending on randomization of the subject, (Autologous concentrated Plasma)ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and reduced.
11531798|NCT01131455|Active Comparator|Fusion + ACP +DBM|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus and external rotation and neutral foot dorsiflexion). Depending on the randomization of the subject, (Autologous Concentrated Plasma)ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and then reduced.
11531837|NCT01131104||Cohort 1|Participants with NAION who have used PDE5 inhibitors
11531838|NCT01131091|Other|Group A|Subjects with end stage renal disease (ESRD) who are receiving hemodialysis treatment
11531839|NCT01131091|Other|Group B|Subjects with severe renal impairment
11531840|NCT01131091|Other|Group C|Subjects with moderate renal impairment
11531841|NCT01131091|Other|Group D|Subjects with mild renal impairment
11531842|NCT01131091|Other|Group E|Healthy subjects
11531799|NCT01131455|No Intervention|Standard-Fusion +Autograft only|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus and external rotation and neutral foot dorsiflexion). The arthrodesis undertaken for all groups will be the standard arthroscopic ankle arthrodesis with portals to the ankle (anterior medial / anterior lateral), skin incision only technique with blunt dissection through the capsule and penetration to the joint. Depending on the randomization of the subject, ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and then reduced.
11531800|NCT01131442||The patient group|
11531801|NCT01131442||healthy control group|
11531802|NCT01131429|Experimental|first-line erlotinib|erlotinib in first-line treatment and docetaxel/cisplatin in second-line treatment
11531803|NCT01131429|Active Comparator|second-line erlotinib|docetaxel/cisplatin in first-line treatment and erlotinib in second-line treatment
11531804|NCT01131416|Experimental|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
11531805|NCT01131416|No Intervention|Conventional|Conventional postoperative feeding schedule
11531806|NCT01131403||BW= using baby wipes and CW= using cotton wool|
11531807|NCT01131403||wet wipe, cotton wool|Group 1 (BW),(n= 01-19):Using of wet wipe during the diaper changes Group 2 (CW),(n=20-40):Using a cotton wool cloth, moistened with clear water during the diaper changes.
11531808|NCT01131377|Experimental|Acetazolamide|"If ABGA is pH ≥ 7.43 & HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV.
~If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip."
11531809|NCT01131377|Placebo Comparator|Placebo|This group will be managed with general metabolic alkalosis treatment such as electrolyte correction, hydration except acetazolamide.
11531810|NCT01131364|Experimental|F16IL2 in combination with doxorubicin|
11531811|NCT01131351|Experimental|OPC-67683|Dose Escalation
11531812|NCT01131325|Experimental|Nilotinib|
11531813|NCT01131312|Experimental|Cytology|Referred to colposcopy if cytology is high grade
11531814|NCT01131312|Experimental|Human Papillomavirus (HPV)|Referred to colposcopy if cytology is high grade or HPV +
11531815|NCT01131312|Experimental|Colposcopy|All refer to colposcopy
11531816|NCT01131299|Active Comparator|Alpha cyclodextrin first then placebo|Randomized subjects will receive alpha cyclodextrin 2g orally three times a day for 12-14 weeks. After the one week washout, the subjects will receive 2 tablets orally of placebo (three times a day for 12-14 weeks).
11531817|NCT01131299|Placebo Comparator|Placebo first then Alpha cyclodextrin|Participants will receive 2 tablets orally of placebo (three times a day for 12-14 weeks). The subjects will have a one-week washout. After the washout, the participants will receive alpha cyclodextrin 2g orally three times a day for 12-14 weeks.
11531818|NCT01131273|Active Comparator|Methadone maintenance for 12 weeks|Methadone maintenance for 12 weeks as compared to 12 weeks maintenance on Suboxone.
11531819|NCT01131273|Active Comparator|buprenorphine-naloxone (Suboxone)|12 weeks of maintenance on buprenorphine-naloxone (Suboxone) at daily doses ranging from 8 to 32 mg with counseling
11531820|NCT01131260|Experimental|Open Group|• Fetal STAN monitor electrode inserted and data available to caregivers
11531821|NCT01131260|Other|Masked Group|•Fetal STAN monitor electrode inserted, but data masked to the caregivers
11531822|NCT01131247|Experimental|ofatumumab + bendamustine|
11531823|NCT01131234|Experimental|Treatment (cediranib maleate and RO4929097)|Patients receive gamma-secretase inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17 (days 1-3, 8-10, 15-17 22-24, 29-31, and 36-38 of course 1 only) and cediranib maleate PO QD on days 1-21 (days 22-42 course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
11531824|NCT01131195|Active Comparator|Arm A: bevacizumab and paclitaxel|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Paclitaxel (90 mg/m2) i.v. is given on days 1, 8, and 15 of a 4 week cycle. Both medications are given until PD, unacceptable adverse event, or consent withdrawal. If an unacceptable adverse event to any of the drugs in this treatment arm occurs the remaining tolerated drug is given until PD, consent withdrawal, or unacceptable adverse event according to local investigators opinion.
11531825|NCT01131195|Active Comparator|Arm B: bevacizumab, cyclophosphamide and capecitabine|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Cyclophosphamide (50 mg) and capecitabine (3x 500 mg) p.o. are given daily. All three medications are given until PD, unacceptable adverse event, or consent withdrawal. If an unacceptable adverse event to any of the drugs in this treatment arm occurs the remaining tolerated drug(s) is (are) given until PD, consent withdrawal, or unacceptable adverse event according to local investigators opinion
11531826|NCT01131182|Experimental|Sitagliptin|Sitagliptin 100 mg administered orally daily as monotherapy or in combination with metformin over the Ramadan period.
11531827|NCT01131182|Active Comparator|Sulfonylurea|Sulfonylurea administered orally daily as monotherapy or in combination with metformin over the Ramadan period.
11531828|NCT01131169|Experimental|relapsed multiple myeloma|This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma.
11531829|NCT01131169|Experimental|high-risk multiple myeloma|This is a two arm phase II trial to assess the progression-free and overall survival as well as the safety and efficacy of allogeneic hematopoietic stem cell transplantation using a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with relapsed or high-risk multiple myeloma.
11531830|NCT01131143|Experimental|Treatment Group 1|Patients will receive a pre-visit, post-referral and post-contact phone call using providers voice
11531831|NCT01131143|Experimental|Treatment Group 2|Patients will receive a previsit, post-referral and post-contact call using a generic voice
11531832|NCT01131143|No Intervention|Treatment Group 3|Patients will be provided usual care with no additional phone calls.
11531833|NCT01131130|Experimental|Investigational contact lens|Bausch & Lomb
11531834|NCT01131130|Active Comparator|Acuvue Oasys Contact Lens|Johnson & Johnson Lens
11531835|NCT01131130|Active Comparator|Air Optix Aqua|Ciba Vision
11531843|NCT01131078|Experimental|Bevacizumab + Irinotecan + Capecitabine (1000 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle. Irinotecan was administered as a 240 mg/m^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice daily (Day 2 to 15). Cycle length was 3 weeks consisting of 2 weeks of capecitabine treatment followed by 1 week without treatment up to 6 cycles. After 6 cycles, participants with objective response or SD were treated with bevacizumab alone until unacceptable toxicity, PD, or participant withdrawal.
11531844|NCT01131078|Experimental|Bevacizumab + Capecitabine (1250 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle in combination with capecitabine administered orally at 1250 mg/m^2 twice daily (Day 1 to 14). Cycle length was 3 weeks with 2 weeks of capecitabine treatment followed by 1 week without treatment up to 6 cycles. After 6 cycles, participants with objective response or SD were treated with bevacizumab alone until unacceptable toxicity, PD, or participant withdrawal.
11531845|NCT01131078|Experimental|Bevacizumab + Capecitabine (650 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 Week cycle in combination with capecitabine administered orally at 650 mg/m^2 twice daily (Day 1 to 21). Cycle length was 3 weeks with 3 weeks of capecitabine treatment without interruptions. Participants received the same regimen until unacceptable toxicity, PD, or participant withdrawal.
11531846|NCT01131065|Experimental|Hepatitis B immune globulin|Treatment group (newly liver transplanted subjects due to HBV induced liver disease)
11531847|NCT01131052|Active Comparator|BASAL PLUS|Diabetic subjects receive insulin glargine once daily plus corrective doses of insulin glulisine before meals and bedtime as needed
11531848|NCT01131052|Active Comparator|sliding scale regular insulin (SSRI)|Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed
11531849|NCT01131039|Experimental|Single|
11531850|NCT01131013|Experimental|Treatment Sequence 1|Dosing Period 1 - Placebo; Dosing Period 2 - 375 mg CK-2017357; Dosing Period 3 - 500 mg CK-2017357
11531851|NCT01131013|Experimental|Treatment Sequence 2|Dosing Period 1 - Placebo; Dosing Period 2 - 500 mg CK-2017357; Dosing Period 3 - 375 mg CK-2017357
11531852|NCT01131013|Experimental|Treatment Sequence 3|Dosing Period 1 - 375 mg CK-2017357; Dosing Period 2 - Placebo; Dosing Period 3 - 500 mg CK-2017357
11531853|NCT01131013|Experimental|Treatment Sequence 4|Dosing Period 1 - 375 mg CK-2017357; Dosing Period 2 - 500 mg CK-2017357; Dosing Period 3 - Placebo
11531854|NCT01131013|Experimental|Treatment Sequence 5|Dosing Period 1 - 500 mg CK-2017357; Dosing Period 2 - Placebo; Dosing Period 3 - 375 mg CK-2017357
11531855|NCT01131013|Experimental|Treatment Sequence 6|Dosing Period 1 - 500 mg CK-2017357; Dosing Period 2 - 375 mg CK-2017357; Dosing Period 3 - Placebo
11531856|NCT01131000|Experimental|Ibuprofen|
11531857|NCT01131000|Placebo Comparator|Saline|Normal Saline
11531858|NCT01130987|Experimental|Comprehensive Handoff Program|Introduction of Computerized tool plus team training
11531859|NCT01130974|Experimental|Bausch & Lomb contact lens|Bausch & Lomb daily disposable cosmetic tint contact lens
11531860|NCT01130974|Active Comparator|Marketed daily disposable contact lens|Marketed daily disposable cosmetic tint contact lens
11531861|NCT01130935||1|
11531862|NCT01130922|Experimental|Moxifloxacin IV|
11531863|NCT01130922|Active Comparator|Moxifloxacin oral|
11531864|NCT01130909|Experimental|AZD6765 75 mg|
11531865|NCT01130909|Experimental|AZD6765 150 mg|
11531866|NCT01130909|Active Comparator|Ketamine 0.5 mg/kg|
11531867|NCT01130909|Placebo Comparator|125 mL sterile NaCl 0.9%|
11531868|NCT01130896||MRI and Cardiac Devices|Clinically indicated MRI (all types) in patients with implanted pacemakers and ICD
11531869|NCT01130883||Respiratory Infections|Czech patients with acute tracheitis, acute tracheobronchitis or acute bronchitis; or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid®SR treatment 6 weeks prior to the next Klacid®SR dose or in intervals: 7-week - 3- month, 4- month - 12- month, 13- month - 24- month prior to the next Klacid®SR dose (next Klacid®SR dose = dose administered within this PMOS).
11531870|NCT01130870|Active Comparator|Sensory threshold - Amplitude|Stimulation amplitude set at sensory threshold.
11531871|NCT01130870|Experimental|25% below sensory threshold - Amplitude|Stimulation amplitude 75% of sensory threshold.
11531872|NCT01130870|Experimental|50% below sensory threshold - Amplitude|Stimulation with amplitude set 50% below sensory threshold
11531873|NCT01130844|Experimental|MMX Mesalamine (30mg/kg)|
11531874|NCT01130844|Experimental|MMX Mesalamine (60 mg/kg)|
11531875|NCT01130844|Experimental|MMX Mesalamine (100 mg/kg)|
11531876|NCT01130818|Experimental|1|single ascending doses
11531877|NCT01130818|Placebo Comparator|2|single dose placebo
11531878|NCT01130818|Experimental|3|single dose, oral solution, 50 mg
11531879|NCT01130818|Experimental|4|single dose, capsules (fasting)
11531880|NCT01130818|Experimental|5|single dose, capsules (fed)
11531881|NCT01130805|Experimental|Pazopanib in combination with capecitabine and oxaliplatin|Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks
11531882|NCT01130792|Experimental|Lactobacillus GG|LGG once daily for 4 weeks
11531883|NCT01130792|Placebo Comparator|Inulin|
11531884|NCT01130779|Experimental|tarceva|continuation of tarceva
11531885|NCT01130766|Experimental|stereotactic radiosurgery (SRS)|
11531886|NCT01130766|No Intervention|observation|
11531887|NCT01130740|No Intervention|Arm 1|usual care
11531888|NCT01130740|Experimental|Arm 2|Osteoarthritis Intervention - Primary care providers receive patient-specific osteoarthritis information and treatment recommendations approximately one week prior to the patient's first post-enrollment routine appointment with PCP; patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
11531889|NCT01130727|Active Comparator|green tea extract|
11531890|NCT01130727|Active Comparator|Cocoa extract rich in polyphenols|
11531891|NCT01130727|Placebo Comparator|placebo|
11531892|NCT01130727|Placebo Comparator|cocoa extract with low polyphenol|
11531893|NCT01130714|Experimental|Resistance training|Group assigned to complete resistance training during duration of chemotherapy.
11531894|NCT01130714|No Intervention|Control|Usual care.
11531895|NCT01130688|Experimental|single arm of experimental drug combination|
11531896|NCT01130675|Active Comparator|eight ounces of caffeinated coffee for breakfast and lunch|
11531897|NCT01130675|No Intervention|standard care|
11531898|NCT01130662|Experimental|Decitabine Midostaurin combination|
11531899|NCT01130649||Epilepsy patients, electronic diary|Cohort of epilepsy patient using an electronic diary system to record all seizures, side effects, and medication compliance
11531900|NCT01130649||Epilpesy patient, no electronic diary|Group of epilepsy patients who are followed using the standard of care, which is a paper diary and routine outpatient follow up visits
11531901|NCT01130636|Experimental|Tamiflu|Lactating women (up to 20 subjects) who present with clinical symptoms indicative of influenza will be recruited (a maximum of 6 months period of recruitment) to receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules, provided free of charges for the study) at a standard dose of 75 mg twice daily. These subjects will have a 12 hour pharmacokinetic plasma, urine and breast milk study undertaken after the steady state in oseltamivir concentrations (both active and inactive metabolites will be measured) is reached in blood, i.e. after three days after treatment.
11531902|NCT01130597|Experimental|patiromer|spironolactone + patiromer
11531903|NCT01130584||Cancer patient|
11531904|NCT01130571||Non-Small Cell Lung Cancer|
11531905|NCT01130558|Active Comparator|Ordering template and education|Internal medical residents who were asked to use the insulin order template and received education about basal-bolus insulin ordering.
11531906|NCT01130558|Active Comparator|Education|Internal medical residents who received education about basal-bolus insulin ordering.
11531907|NCT01130545||Volunteers|Volunteers (maybe Volunteers, NIH employee and current NIH protocol participants)
11531908|NCT01130532|Active Comparator|2.5 milligram (mg) titrated to 5 mg Tadalafil|2.5 mg for 4 weeks, followed by 5 mg for 8 weeks with option to continue treatment at 5 mg for an additional 4 weeks
11531909|NCT01130532|Active Comparator|5 mg Tadalafil|5.0 mg for 12 weeks with option to continue treatment for additional 4 weeks
11531910|NCT01130532|Placebo Comparator|Placebo|for 12 weeks
11531911|NCT01130519|Experimental|1|All patient will be receiving fixed starting dose of bevacizumab (10 mg /kg IV every 2 weeks) and erlotinib (150 mg/day PO)
11531912|NCT01130506|Experimental|Treatment (decitabine, vorinostat, cytarabine)|"INDUCTION THERAPY: Patients receive decitabine IV over 1 hour on days 1-10; vorinostat PO on days 5-10; and high-dose cytarabine IV over 2 hours on days 12, 14, and 16 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR proceed to maintenance therapy. Patients who achieve CR with incomplete blood count recovery undergo bone marrow aspiration and biopsy at count recovery or day 42 before proceeding to maintenance therapy.
~MAINTENANCE THERAPY: Patients receive decitabine IV over 1 hour on days 1-5 and vorinostat PO on days 5-10. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity."
11531913|NCT01130493|Other|IPX066-CLE-OLE|Dose conversion from CLE to IPX066, IPX066 (Part 1 Period 1), Open-label IPX066, CLE (Part 1 Period 2), OLE (Part 2)
11531914|NCT01130493|Other|CLE-IPX066-OLE|Dose conversion from CLE to IPX066, CLE (Part 1 Period 1), Open-label IPX066, IPX066 (Part 1 Period 2), OLE (Part 2)
11531915|NCT01130480|Experimental|A|
11531916|NCT01130467||Normal control|
11531917|NCT01130467||pure ADHD|
11531918|NCT01130467||ADHD with comorbidity|
11531919|NCT01130454|Active Comparator|SCIO Test Group|
11531920|NCT01130454|Placebo Comparator|SCIO Placebo Group|
11531921|NCT01130441||self-harming group|
11531922|NCT01130441||non-self-harming group -control group|
11531923|NCT01130428|Experimental|Intervention group|As a mechanical intervention, we will use a vibration platform to administer mechanical stimulation to the forearm of subjects (see Figure 1). All subjects will participate in a single experiment during which they will receive the mechanical intervention a fixed dose of; the duration of an experiment is approximately three hours.
11531924|NCT01130415||Patients treated with sacral neuromodulation|
11531925|NCT01130402||Neck masses|Patients with previously untreated neck masses
11531926|NCT01130376|Experimental|Vaccine and cytokines|"Day 0: Patients receive GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injection.
~Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.
~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC.
~Further vaccine boosters are given on day 42 and day 84. GTU-MultiHIV B clade vaccine 1mg/ml being administered as 10 intradermal injections of 100 µl/injection."
11531927|NCT01130376|Active Comparator|Vaccine alone|"Day 0: Patients are given GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injections.
~Day 42: GTU-MultiHIV B clade vaccine as day 0.
~Day 84: GTU-MultiHIV B clade vaccine as day 0."
11531928|NCT01130376|Active Comparator|Cytokines alone|"Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.
~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC."
11531929|NCT01130363||Fundic Gland Polyps on PPI|Patients found to have fundic gland polyps on endoscopic evaluation that have also been prescribed and regularly take a proton pump inhibitor.
11531930|NCT01130363||Fundic Gland Polyp not on PPI|Patients found to have fundic gland polyps on endoscopic evaluation that have not been prescribed a proton pump inhibitor.
11531931|NCT01130363||Group 3 (Control Group)|Individuals who are prescribed proton pump inhibitor but are not found to have fundic gland polyps on endoscopic evaluation.
11531932|NCT01130337|Experimental|1|
11531933|NCT01130324||VIBATIV treated pregnant women|Women treated with telavancin (any dose or duration) during pregnancy.
11531934|NCT01130311|Experimental|Cholecalciferol (Vitamin D)|Intramuscular injection of VITAMIN D, 600,000 UNITS WILL BE GIVEN TO THE TEST SUBJECTS AT WEEK 0 and at week 4 OF the TRIAL
11531935|NCT01130311|Placebo Comparator|SALINE, INTRAMUSCULAR INJECTION|NORMAL SALINE INJECTION WILL BE GIVEN TO THE CONTROL SUBJECTS at week 0 and week 4 of the trial
11531936|NCT01130298|Experimental|1|
11531937|NCT01130285||Non-Lung Cancer, Heavy Smoker|Subjects will be ≥ 50 years of age and have a ≥ 20 pack year smoking history and will be either healthy volunteers or individuals undergoing diagnostic bronchoscopy, with absence of lung cancer documented at the time of enrollment.
11531938|NCT01130272|Experimental|Eluxadoline 5 mg|Eluxadoline 5 mg tablets, orally, twice daily for up to 12 weeks.
11531939|NCT01130272|Experimental|Eluxadoline 25 mg|Eluxadoline 25 mg tablets, orally, twice daily for up to 12 weeks. .
11531940|NCT01130272|Experimental|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 12 weeks.
11531941|NCT01130272|Experimental|Eluxadoline 200 mg|Eluxadoline 200 mg tablets, orally, twice daily for up to 12 weeks.
11531942|NCT01130272|Placebo Comparator|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 12 weeks.
11531943|NCT01130246|Experimental|A-002 500 mg|Once daily oral administration
11531944|NCT01130246|Placebo Comparator|Matched Placebo|Once daily oral administration
11531945|NCT01130233|Experimental|robotic|robotic assisted rectal resection
11531946|NCT01130233|Active Comparator|laparoscopic|laparoscopic rectal resection
11531947|NCT01130220||Brain Tumor Patient|"A one-time focus group will be held in a quiet room for approximately 30-60 minutes until a saturation of themes has been identified."
11531948|NCT01130220||Health Care Provider|"A one-time focus group will be held in a quiet room for approximately 30-60 minutes until a saturation of themes has been identified."
11531949|NCT01130194|Experimental|Experimental|C-MOPP-R chemotherapy, 6 cycles Peripheral blood stem cell mobilization Radioimmunotherapy Autologous Hematopoietic Stem Cell Transplantation
11531950|NCT01130181|Experimental|Cholecalciferol|
11531951|NCT01130181|Placebo Comparator|Placebo|
11531952|NCT01130168|Experimental|Placebo/ISMN ER/Amlodipine (Sequence 1)|Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.
11531953|NCT01130168|Experimental|ISMN ER/Amlodipine/Placebo (Sequence 2)|Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
11531954|NCT01130168|Experimental|Amlodipine/Placebo/ISMN ER (Sequence 3)|Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
11531955|NCT01130168|Experimental|ISMN ER/Placebo/Amlodipine (Sequence 4)|Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.
11531956|NCT01130168|Experimental|Placebo/Amlodipine/ISMN ER (Sequence 5)|Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
11531957|NCT01130168|Experimental|Amlodipine/ISMN ER/Placebo (Sequence 6)|Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule for 4 weeks during Period, with a 2-week washout between each period.
11531958|NCT01130155||Mwanza Region|Households, and patients presenting at public health facilities in Mwanza Region
11531959|NCT01130155||Mbeya Region|Households, and patients presenting at public health facilities in Mbeya Region
11531960|NCT01130155||Mtwara Region|Households, and patients presenting at public health facilities in Mtwara Region
11531961|NCT01130142|Active Comparator|Arm 1 (Phase 2)|IPI-926 in combination with gemcitabine
11531962|NCT01130142|Placebo Comparator|Arm 2 (Phase 2)|Placebo in combination with gemcitabine
11531963|NCT01130129|Experimental|Ex-vivo treatment of platelets|Ex-vivo treatment of platelets
11531964|NCT01130103|Experimental|Paroxetine|Paroxetine and Prolonged Exposure Therapy
11531965|NCT01130103|Placebo Comparator|Placebo pill|Placebo pill plus Prolonged Exposure Therapy
11531966|NCT01130077|Experimental|HLA Restristed glioma antigen peptides plus Poly ICLC|All subjects will receive vaccine plus Poly ICLC will receive 9 injections ( once every 3 weeks)
11531967|NCT01130064|Experimental|QAX576|QAX576
11531968|NCT01130064|Placebo Comparator|Placebo|Placebo
11531969|NCT01130051|Experimental|Colcrys® 0.6 mg intact tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
11531970|NCT01130051|Experimental|Colcrys® 0.6 mg tablet on applesauce|One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
11531971|NCT01130038||Children with DCD and Typical Development|
11531972|NCT01130038||Children with DCD|2 groups Children with DCD and Typical Development
11531973|NCT01130025|Experimental|Innohep®|Long-term treatment with Innohep® only.
11531974|NCT01130025|Active Comparator|Warfarin|Oral treatment with warfarin in combination with overlapping initial (5 to 10 days) treatment with Innohep®.
11531975|NCT01130012|Other|Lifestyle, follow-up, early care, standard care high/low risk|Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.
11531976|NCT01130012|Other|Close follow-up|Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
11531977|NCT01129999|Experimental|Cognitive-Behavioral Therapy|
11531978|NCT01129999|Experimental|Hypnotherapy|
11531979|NCT01129986|Experimental|Dermastream|
11531980|NCT01129960|Experimental|Eslicarbazepine acetate 800 mg once daily (QD)|
11531981|NCT01129960|Experimental|Eslicarbazepine acetate 1200 mg QD|
11531982|NCT01129960|Experimental|Eslicarbazepine acetate 1600 mg QD|
11531985|NCT01129934|Experimental|Morphine-Promethazine|Pain relief by administration of morphine-promethazine combination
11531986|NCT01129934|Active Comparator|morphine|pain relief by administration of morphine
11531987|NCT01129921|Active Comparator|Decompression with mild® Device Kit|Fluoroscopically guided percutaneous lumbar decompression using the Vertos mild® Device Kit for bone and tissue removal to decompress the targeted stenosed level(s).
11531988|NCT01129921|Sham Comparator|Sham lumbar decompression|Sham procedure of fluoroscopically guided percutaneous placement of mild® Device Kit instrumentation with no removal of bone or tissue.
11531989|NCT01129895|Experimental|Health promotion|5 workshops on the initiation of health prevention projects in each clinic will be organized by the intervention team and than the clinic will be followed by the intervention team for 6 months.
11531990|NCT01129895|No Intervention|Promoting Health|No intervention follow-up only
11531991|NCT01129882|Experimental|Aripiprazole IM depot|Active treatment of monthly doses of aripiprazole IM depot (300 mg or 400 mg)
11531992|NCT01129856|Active Comparator|Ocular Iontophoresis EGP-437, Low Dose|Ocular Iontophoresis with EGP-437 4.0 mA-min at 1.5 mA
11531993|NCT01129856|Active Comparator|Ocular Iontophoresis EGP-437, High Dose|Ocular Iontophoresis with EGP-437 6.5 mA-min at 2.5 mA
11531994|NCT01129856|Placebo Comparator|Ocular Iontophoresis Placebo|Ocular Iontophoresis with Placebo 6.5 mA-min at 2.5 mA
11531995|NCT01129843|Experimental|Directly observed home based daily iron therapy|Village volunteers will provide directly observed home based daily iron supplementation( ferrous sulphate) to enrolled anemic women in the experimental arm
11531996|NCT01129843|Active Comparator|Clinic driven unsupervised daily iron therapy|In the control group of villages, clinic driven unsupervised iron ( ferrous sulphate) supplementation will be offered on monthly basis to anemic women for 3 months
11531997|NCT01129830|Other|Dehydroepiandrosterone|infertile women with low anti mullerian hormone levels
11531998|NCT01129817|Experimental|Cognitive Functional Therapy|
11531999|NCT01129817|Active Comparator|Manual Therapy and Exercise|
11532000|NCT01129804|Experimental|Network Support|Network Support treatment is aimed at helping patients change their social support network so that it supports abstinence. In this treatment patients will be encouraged to attend AA meetings and engage in other activities that would involve non-drinkers. These activities would be determined by the patient, with help from the therapist. Patients would learn about methods of avoiding drinking, making new friends, and getting enjoyment from activities other than drinking. In addition patients will learn specific skills intended to help them make new acquaintances and change their circle of friends.
11532001|NCT01129804|Active Comparator|Packaged Cognitive-Behavioral Treatment|The purpose of Packaged Cognitive-Behavioral Treatment (PCBT) is to train patients in a variety of skills that they can use to keep themselves from drinking.
11532002|NCT01129791|Experimental|Raw Milk first|Organic raw cow's milk
11532003|NCT01129791|Placebo Comparator|Pasteurized milk first|Organic pasteurized cow's milk
11532004|NCT01129791|Placebo Comparator|Non-Dairy Milk first|Unflavored soy milk
11532005|NCT01129778|Experimental|Received Zegerid (Ome-NaBic)|Administered Ome-NaBic 40 mg orally 1 h before breakfast and bedtime
11532006|NCT01129765||Parents of congested children|Parents of children less than six years of age with nasal congestion for which nasal suctioning and salt water irrigation is traditionally recommended.
11532007|NCT01129752||children at risk for depression|children at familial risk for depression
11532008|NCT01129739|Experimental|Human umbilical cord-derived MSCs|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated to apply in trimonthly for 2 cycle
11532009|NCT01129739|Active Comparator|cyclosporine A (CsA)|CsA at a dose of 5 mg CsA/kg
11532010|NCT01129726|Experimental|Intubation|Transillumination-guided Fiberoptic Intubation
11532011|NCT01129713|Active Comparator|Nexium|Comparing 40 mg.once daily in healing erosive esophagitis.
11532012|NCT01129713|Active Comparator|Secretol|Comparing the efficacy of 80/80 Secretol once daily in healing erosive esophagitis.
11532013|NCT01129700|Experimental|short-course CRT-5FU|
11532014|NCT01129687||ANSRS group|Patients qualifying for the study.
11532015|NCT01129674|Active Comparator|Standard of Care|
11532016|NCT01129674|Experimental|LY2140023|"20mg, 40mg or 80mg
~After 104 weeks, patients have the option to continue on treatment until the end of the study"
11532017|NCT01129661|Placebo Comparator|normal saline (0.9%)|
11532018|NCT01129661|Experimental|CSL112|
11532019|NCT01129648|Placebo Comparator|BCX4208 placebo + Allopurinol placebo|Administered daily for 21 days.
11532020|NCT01129648|Active Comparator|BCX4208 placebo + Allopurinol 100mg|Administered daily for 21 days.
11532021|NCT01129648|Active Comparator|BCX4208 placebo + Allopurinol 200 mg|Administered daily for 21 days.
11532022|NCT01129648|Active Comparator|BCX4208 Placebo + Allopurinol 300 mg|Administered daily for 21 days.
11532023|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol Placebo|Administered daily for 21 days.
11532024|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol 100 mg|Administered daily for 21 days.
11532025|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol 200 mg|Administered daily for 21 days.
11532026|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol 300 mg|Administered daily for 21 days.
11532027|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol placebo|Administered daily for 21 days.
11532028|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol 100 mg|Administered daily for 21 days.
11532029|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol 200 mg|Administered daily for 21 days.
11532030|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol 300 mg|Administered daily for 21 days.
11532031|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol Placebo|Administered daily for 21 days.
11532032|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol 100 mg|Administered daily for 21 days.
11532033|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol 200 mg|Administered daily for 21 days.
11532034|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol 300 mg|Administered daily for 21 days.
11532035|NCT01129635|Experimental|CRT Candidate|"Patients with NYHA Class III or IV heart failure; EF ≤ 30% and QRS duration ≥ 120 ms, who are scheduled for CRT surgery.
~Intervention: Cardiac Resynchronization Therapy (CRT) implantation"
11532036|NCT01129622|Experimental|Letrozole, Breast enhancement, Safety|Single arm of healthy postmenopausal women who received baseline diagnostic MRI will receive letrozole of 12.5 mg/day orally for three successive days. A second post treatment breast MRI is done right after receiving the three days of letrozole treatment and within one month after the first MRI .
11532037|NCT01129609||Participants with Successful Secondary Endovascular Treatment|
11532038|NCT01129596||1|
11532039|NCT01129583|Experimental|Botulinum Toxin|100 U injected into biceps, 100 U into brachialis
11532040|NCT01129583|Placebo Comparator|Saline|100 U injected into biceps, 100 U into brachialis
11532041|NCT01129570|Experimental|Siliphos - dose escalation|
11532042|NCT01129557|Active Comparator|Tekturna|Tekturna (Aliskiren), a direct renin inhibitor (DRI) 300 mg by mouth once daily for 9 months
11532043|NCT01129557|Active Comparator|Diovan|Diovan (Valsartan), an angiotensin receptor blocker (ARB) 320 mg by mouth once daily for 9 months
11532044|NCT01129557|Active Comparator|Tekturna & Diovan|Tekturna (Aliskiren), a direct renin inhibitor (DRI) 150 mg by mouth once daily & Diovan (Valsartan), an angiotensin receptor (ARB) 160 mg by mouth once daily for 9 months
11532045|NCT01129544|Experimental|Gene Transfer|open label single arm study
11532046|NCT01129531|Experimental|AGN-214868 3.25 μg|AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 3.25 μg per treatment.
11532047|NCT01129531|Experimental|AGN-214868 16.25 μg|AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 16.25 μg per treatment.
11532048|NCT01129531|Placebo Comparator|Placebo|Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
11532049|NCT01129518|Experimental|Two Dose MenC Group|Two doses of MenC-CRM197 priming at 3 and 4 months of age.
11532050|NCT01129518|Experimental|Single Dose MenC-CRM197 Group|One dose of MenC-CRM197 priming at 3 months of age.
11532051|NCT01129518|Experimental|Single Dose MenC-TT Group|Single dose MenC-TT priming at 3 months of age
11532052|NCT01129518|Experimental|Control Group|Zero dose MenC priming
11532053|NCT01129492|Placebo Comparator|Sham Laser|Ten applications of placebo were performed (twice a week) with the same method and Laser equipment, which has a placebo function available with a red ordinary light indistinguishable of the Laser light.
11532054|NCT01129492|Active Comparator|Active Laser|Ten applications of low-level Laser therapy (twice a week) were performed with a continuous wave diode laser device (830nm, beam area of 0.2827cm2), using the punctual method, continuous emission mode, output power of de 50 mW and fluence of 70J/cm2.
11532055|NCT01129479|Active Comparator|Galantamine|
11532056|NCT01129479|Placebo Comparator|Placebo|
11532057|NCT01129466|Active Comparator|Supplement A followed by supplement B|
11532058|NCT01129466|Active Comparator|Supplement B followed by Supplement A|
11532059|NCT01129453|Experimental|Vaccine-recipients|
11532060|NCT01129453|Placebo Comparator|Placebo|
11532061|NCT01129440|Active Comparator|Fluoride Varnish|Topical fluoride varnish (FV) applications every 6 months
11532062|NCT01129440|Experimental|FV + Glass Ionomer Sealants|Topical fluoride varnish (FV) applications every 6 months, and fluoride-releasing glass ionomer sealants (GIS) placed on primary molars at baseline and annually, as needed
11532063|NCT01129427|Experimental|Group clopidogrel - clopidogrel + pantoprazole|"Period 1:
~Day 1: clopidogrel 300 mg loading dose
~Day 2 to Day 5: clopidogrel 75 mg, once daily
~Period 2:
~Day -7 to Day -1: pantoprazole 80 mg, once daily
~Day 1: clopidogrel 300 mg loading dose + pantoprazole 80 mg concomitantly
~Day 2 to Day 5: clopidogrel 75 mg + pantoprazole 80 mg concomitantly, once daily
~Each intake is under fasted conditions."
11532064|NCT01129427|Placebo Comparator|Group placebo - placebo + pantoprazole|"Period 1:
~Day 1: placebo loading dose
~Day 2 to Day 5: placebo, once daily
~Period 2:
~Day -7 to Day -1: pantoprazole 80 mg, once daily
~Day 1: placebo loading dose + pantoprazole 80 mg concomitantly
~Day 2 to Day 5: placebo + pantoprazole 80 mg concomitantly, once daily
~Each intake is under fasted conditions."
11532065|NCT01129427|Experimental|Group clopidogrel + pantoprazole - clopidogrel|"Period 1:
~Day -7 to Day -1: pantoprazole 80 mg, once daily
~Day 1: clopidogrel 300 mg loading dose + pantoprazole 80 mg concomitantly
~Day 2 to Day 5: clopidogrel 75 mg + pantoprazole 80 mg concomitantly, once daily
~Period 2:
~Day 1: clopidogrel 300 mg loading dose
~Day 2 to Day 5: clopidogrel 75 mg, once daily
~Each intake is under fasted conditions."
11532066|NCT01129427|Placebo Comparator|Group placebo + pantoprazole placebo|"Period 1:
~Day -7 to Day -1: pantoprazole 80 mg, once daily
~Day 1: placebo loading dose + pantoprazole 80 mg concomitantly
~Day 2 to Day 5: placebo + pantoprazole 80 mg concomitantly, once daily
~Period 2:
~Day 1: placebo loading dose
~Day 2 to Day 5: placebo, once daily
~Each intake is under fasted conditions."
11532067|NCT01129414|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:
~Day 1: clopidogrel 600 mg loading dose
~Day 2 to Day 5: clopidogrel 150 mg, once daily
~Period 2:
~Day -5 to Day -1: omeprazole 80 mg, once daily
~Day 1: clopidogrel 600 mg loading dose + omeprazole 80 mg concomitantly
~Day 2 to Day 5: clopidogrel 150 mg + omeprazole 80 mg concomitantly, once daily
~Each intake is under fasted conditions"
11532068|NCT01129414|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:
~Day 1: placebo loading dose
~Day 2 to Day 5: placebo, once daily
~Period 2:
~Day -5 to Day -1: omeprazole 80 mg, once daily
~Day 1: placebo loading dose + omeprazole 80 mg concomitantly
~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily
~Each intake is under fasted conditions"
11532069|NCT01129414|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:
~Day -5 to Day -1: omeprazole 80 mg, once daily
~Day 1: clopidogrel 600 mg loading dose + omeprazole 80 mg concomitantly
~Day 2 to Day 5: clopidogrel 150 mg + omeprazole 80 mg concomitantly, once daily
~Period 2:
~Day 1: clopidogrel 600 mg loading dose
~Day 2 to Day 5: clopidogrel 150 mg, once daily
~Each intake is under fasted conditions"
11532070|NCT01129414|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:
~Day -5 to Day -1: omeprazole 80 mg, once daily
~Day 1: placebo loading dose + omeprazole 80 mg concomitantly
~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily
~Period 2:
~Day 1: placebo loading dose
~Day 2 to Day 5: placebo, once daily
~Each intake is under fasted conditions"
11532071|NCT01129401|Other|Stonewall Project Participants|
11532140|NCT01128972|Experimental|Test Dentifrice + Test Mouth Rinse (MR)|Test fluoride dentifrice and test fluoride MR
11532141|NCT01128972|Experimental|Test Dentifrice + Sterile Water Rinse|Test fluoride dentifrice and sterile water rinse
11532072|NCT01129388|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:
~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions
~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily
~Period 2:
~Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily
~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner
~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily"
11532073|NCT01129388|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:
~Day 1: placebo loading dose in the morning under fasted conditions
~Day 2 to Day 5: placebo in the morning under fasted conditions, once daily
~Period 2:
~Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily
~Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner
~Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily"
11532074|NCT01129388|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:
~Day -5 to Day -1: omeprazole 80 mgin the evening 2 hours after dinner, once daily
~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner
~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily
~Period 2:
~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions
~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily"
11532075|NCT01129388|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:
~Day -5 to Day -1: omeprazole 80 mg, once daily in the evening 2 hours after dinner
~Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner
~Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily
~Period 2:
~Day 1: placebo loading dose in the morning under fasted conditions
~Day 2 to Day 5: placebo in the morning under fasted conditions, once daily"
11532076|NCT01129375|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:
~Day 1: clopidogrel 300 mg loading dose
~Day 2 to Day 5: clopidogrel 75 mg, once daily
~Period 2:
~Day -5 to Day -1: omeprazole 80 mg, once daily
~Day 1: clopidogrel 300 mg loading dose + omeprazole 80 mg concomitantly
~Day 2 to Day 5: clopidogrel 75 mg + omeprazole 80 mg concomitantly, once daily
~Each intake is under fasted conditions"
11532077|NCT01129375|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:
~Day 1: placebo loading dose
~Day 2 to Day 5: placebo, once daily
~Period 2:
~Day -5 to Day -1: omeprazole 80 mg, once daily
~Day 1: placebo loading dose + omeprazole 80 mg concomitantly
~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily
~Each intake is under fasted conditions"
11532078|NCT01129375|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:
~Day -5 to Day -1: omeprazole 80 mg, once daily
~Day 1: clopidogrel 300 mg loading dose + omeprazole 80 mg concomitantly
~Day 2 to Day 5: clopidogrel 75 mg + omeprazole 80 mg concomitantly, once daily
~Period 2:
~Day 1: clopidogrel 300 mg loading dose
~Day 2 to Day 5: clopidogrel 75 mg, once daily
~Each intake is under fasted conditions"
11532079|NCT01129375|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:
~Day -5 to Day -1: omeprazole 80 mg, once daily
~Day 1: placebo loading dose + omeprazole 80 mg concomitantly
~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily
~Period 2:
~Day 1: placebo loading dose
~Day 2 to Day 5: placebo, once daily
~Each intake is under fasted conditions"
11532080|NCT01129362||Group 1|Participants that only received Pentacel® vaccine.
11532081|NCT01129362||Group 2|Participants that only received a single brand of pertussis vaccine other than Pentacel® vaccine.
11532082|NCT01129362||Group 3|Participants that received more than one brand of Pertussis vaccine or one or more doses of an unknown brand.
11532083|NCT01129349|Experimental|Oprozomib|Phase I, Dose Escalation, Single Arm, Open Label
11532084|NCT01129336|Experimental|Patients without bone metastases|Patients with no bone metastasis were randomized into a 1:1 ratio to standard therapy plus zoledronic acid 4mg IV Zoledronic acid administration monthly during Months 1-18.
11532085|NCT01129336|Experimental|Patients with bone metastases|Patients with bone metastasis received standard therapy + zoledronic acid for 18 months (discontinued upon disease progression/secondary malignancy)
11532086|NCT01129323|Experimental|Reduced-Intensity Preparative Regimen for Allogeneic SCT|Patient in this arm will receive maximally tolerated (reduced) doses of cytotoxic therapy with the goals of suppressing the immune system, and ablate host hematopoiesis to ensure engraftment of the donor's hematopoietic system.
11532087|NCT01129297||BMI ≥ 35 kg/m2 and diabetes|BMI (Body Mass Index) ≥ 35 kg/m2 and diabetes defined by a fasting blood glucose ≥ 7 mmol/l and/or ≥ to 11.1 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
11532088|NCT01129297||BMI ≥ 35 kg/m2 with intolerance glucose|BMI (Body Mass Index) ≥ 35 kg/m2 with intolerance glucose defined by a fasting blood glucose> 6 mmol/L and <7 mmol/l and / or> 7.8 mmol/l and <11.1 mmol/l , 120 minutes after ingestion of glucose (oral glucose tolerance test)
11532089|NCT01129297||BMI ≥ 35 kg/m2 without diabetes|BMI (Body Mass Index)≥ 35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
11532090|NCT01129297||BMI <27 kg/m2 without diabetes|BMI (Body Mass Index) <27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
11532091|NCT01129297||27 < BMI < 35 kg/m2 without diabetes|BMI (Body Mass Index) <27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
11532092|NCT01129284|Experimental|Acthar gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
11532093|NCT01129271|Experimental|Group clopidogrel fed - fasting|"Period 1:
~Day 1: clopidogrel 300 mg loading dose with high fat breakfast
~Day 2 to Day 5: clopidogrel 75 mg/day with standard breakfast, once daily
~Period 2:
~Day 1: clopidogrel 300 mg loading dose under fasted conditions
~Day 2 to Day 5: clopidogrel 75 mg/day under fasted conditions, once daily"
11532094|NCT01129271|Placebo Comparator|Group placebo fed - fasting|"Period 1:
~Day 1: placebo loading dose with high fat breakfast
~Day 2 to Day 5: placebo with standard breakfast, once daily
~Period 2:
~Day 1: placebo loading dose under fasted conditions
~Day 2 to Day 5: placebo under fasted conditions, once daily"
11532095|NCT01129271|Experimental|Group clopidogrel fasting - fed|"Period 1:
~Day 1: clopidogrel 300 mg loading dose under fasted conditions
~Day 2 to Day 5: clopidogrel 75 mg/day under fasted conditions, once daily
~Period 2:
~Day 1: clopidogrel 300 mg loading dose with high fat breakfast
~Day 2 to Day 5: clopidogrel 75 mg/day with standard breakfast, once daily"
11532096|NCT01129271|Placebo Comparator|group placebo fasting -fed|"Period 1:
~Day 1: placebo loading dose under fasted conditions
~Day 2 to Day 5: placebo in fasted conditions, once daily
~Period 2:
~Day 1: placebo loading dose with high fat breakfast
~Day 2 to Day 5: placebo with standard breakfast, once daily"
11532097|NCT01129258|Experimental|PF-04991532|
11532098|NCT01129258|Placebo Comparator|Placebo|
11532099|NCT01129245|No Intervention|Control cycle|Control menstrual cycle
11532100|NCT01129245|Experimental|Pre-LH surge celecoxib administration|Pre-LH surge dosing of celecoxib
11532101|NCT01129245|Experimental|Post-LH surge celecoxib administration|Post-LH surge dosing of celecoxib
11532102|NCT01129232|Experimental|GAD-alum|GAD-alum administered at 0 and 1 months after inclusion
11532103|NCT01129232|Placebo Comparator|Placebo|
11532104|NCT01129219|Experimental|Usual care|Subjects in the control group were asked to maintain their current lifestyle. No restrictions were placed on their exercise activities.
11532105|NCT01129206|Experimental|Arm I|Patients receive pralatrexate IV over 3-5 minutes and docetaxel IV on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11532106|NCT01129193|Experimental|Arm I (Hematologic Malignancies)|Patients will receive orally administered AR-42 three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
11532107|NCT01129193|Experimental|Arm II (Solid Tumors)|Patients will receive orally administered AR-42 three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
11532108|NCT01129180|Experimental|Arm I|Patients receive bortezomib IV on days 4, 8, 11, and 15 and azacitidine SC on days 1-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Attempt to collect Correlative studies will be made.
11532109|NCT01129154|Experimental|panitumumab|Patients will receive six infusions of panitumumab every 2 weeks for the first cycle.
11532110|NCT01129141|Experimental|Tele-PTM|Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
11532111|NCT01129141|Other|Wait List Control|Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
11532112|NCT01129128|Active Comparator|Echinacea preparation 1|Commercially available Echinacea purpurea product
11532113|NCT01129128|Active Comparator|Echinacea preparation 2|Commercially available Echinacea purpurea product
11532114|NCT01129128|Placebo Comparator|Placebo|Inert liquid that is similar in appearance and taste to the active Echinacea products
11532115|NCT01129115|Active Comparator|Nonexercise control group|
11532116|NCT01129115|Experimental|Aerobic Exercise Group 1|
11532117|NCT01129115|Experimental|Aerobic Exercise Group 2|
11532118|NCT01129115|Experimental|Aerobic Exercise Group 3|
11532119|NCT01129102|Experimental|NPC-01|Norethisterone 1mg, Ethinyl estradiol 0.02mg
11532120|NCT01129102|Active Comparator|IKH-01|Norethisterone 1mg, Ethinyl estradiol 0.035mg
11532121|NCT01129102|Placebo Comparator|Placebo|Placebo for NPC-01
11532122|NCT01129089|Experimental|LNS-PLW|There will be 48 pregnant or lactating women (PLW) in this arm. They will be randomized to receive cumin flavored LNS-PLW or LNS-PLW with no added flavor on day 2. On day 3, the PLW getting a test-dose of cumin flavored LNS-PLW on day 2 will receive LNS-PLW with no added flavor and the PLW getting a test-dose of LNS-PLW with no added flavor on day 2 will receive cumin flavored LNS-PLW.
11532123|NCT01129089|Experimental|LNS-Child|There will be 48 infant and young children(IYC) in this arm. They will be randomized to receive cardamom flavored LNS-Child or LNS-Child with no added flavor on day 2. On day 3, the IYC getting a test-dose of LNS-Child with no added flavor on day 2 will receive cardamom flavored LNS-Child and the IYC getting a test-dose of cardamom flavored LNS-Child on day 2 will receive LNS-Child with no added flavor.
11532124|NCT01129089|Experimental|MNP-Child|There will be 48 infant and young children(IYC) in this arm. They will receive MNP on day 2 and day 3.
11532125|NCT01129063|Experimental|Sequence clopidogrel 75 / 75 / 300 mg|"Period 1: clopidogrel 75 mg single dose
~Period 2: clopidogrel 75 mg single dose
~Period 3: clopidogrel 300 mg single dose
~Each intake is at around 8:00 AM under fasted conditions."
11532126|NCT01129050|Experimental|Low-dose Flaxseed Oil|2.2 g ALA (alpha-linolenic acid) per day
11532127|NCT01129050|Experimental|High-dose Flaxseed Oil|6.6 g ALA (alpha-linolenic acid) per day
11532128|NCT01129050|Experimental|Low-dose Fish Oil|1.2 g EPA+DHA (700 mg EPA and 500 mg DHA) per day
11532129|NCT01129050|Experimental|High-dose Fish Oil|3.6 g EPA+DHA (2.1 g EPA and 1.5 g DHA) per day
11532130|NCT01129050|Placebo Comparator|Placebo|4 g or 6 g soybean oil per day
11532131|NCT01129037|Other|Goal directed fluid management|
11532132|NCT01129024|Experimental|S-888711 0.5 mg tablet|S-888711 0.5 mg tablet q.d.
11532133|NCT01129011|Experimental|PN400|Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily
11532134|NCT01129011|Active Comparator|Naproxen|Naproxen 500 mg dosed twice daily
11532135|NCT01128998|Experimental|S-1 and Sorafenib|
11532136|NCT01128985|Experimental|001|Canagliflozin 50 mg 50 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
11532137|NCT01128985|Experimental|002|Canagliflozin 100 mg 100 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
11532138|NCT01128985|Experimental|003|Canagliflozin 300 mg 300 mg capsule once daily for 7 consecutive days from Day 1 to Day 7.
11532139|NCT01128985|Placebo Comparator|004|Placebo matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
11532142|NCT01128972|Experimental|Placebo Dentifrice + Test MR|Placebo dentifrice and test fluoride rinse
11532143|NCT01128972|Active Comparator|Reference Dentifrice + Sterile Water Rinse|Marketed fluoride dentifrice with sterile water rinse
11532144|NCT01128972|Placebo Comparator|Placebo Dentifrice + Sterile Water Rinse|Placebo dentifrice and sterile water rinse
11532145|NCT01128959|Experimental|Intravenous Carbamazepine (IV CBZ)|
11532146|NCT01128946|Experimental|Fluoride Toothpaste 1|Fluoride toothpaste containing sodium fluoride (NaF)
11532147|NCT01128946|Experimental|Fluoride Toothpaste 2|Fluoride toothpaste containing stannous fluoride (SnF) and NaF.
11532148|NCT01128946|Experimental|Fluoride Toothpaste 3|Fluoride toothpaste containing sodium monofluorophosphate (NaMFP) and NaF.
11532149|NCT01128946|Active Comparator|Reference Dentifrice|Low fluoride toothpaste containing NaF
11532150|NCT01128933|Experimental|Hypertensive patients|Hypertensive patients with at least moderate renal artery stenosis
11532151|NCT01128920|Experimental|Skin and Needle Hygiene Intervention|
11532152|NCT01128920|Experimental|Assessment-Only Condition|
11532153|NCT01128907||1|Hematological neutropenic patients at high risk of Invasive Aspergillosis with persistent fever and an opportunist infection suspicion.
11532154|NCT01128907||2|Patients without hematological illness and without Invasive Aspergillosis suspicion.
11532155|NCT01128894|Experimental|albiglutide|weekly albiglutide subcutaneous injection
11532156|NCT01128894|Active Comparator|liraglutide|liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
11532157|NCT01128881|Experimental|IMMUNINE|
11532158|NCT01128868|Active Comparator|Proximal femur locking plate|Treatment of reverse oblique intertrochanteric or subtrochanteric fractures with a Proximal Femur Locking Compression Plate (PF-LCP, PF-LCP Hook Plate, PeriLoc)
11532159|NCT01128868|Other|Trochanteric nail|Treatment of reverse oblique intertrochanteric or subtrochanteric fractures with Trochanteric Nails (PFNA, TFN, GN)
11532160|NCT01128855|Experimental|Cohort 1|3 mg/kg GSK2402968 / placebo
11532161|NCT01128855|Experimental|Cohort 2|6 mg/kg GSK2402968 / placebo
11532162|NCT01128855|Experimental|Cohort 3|9 mg/kg GSK2402968 / placebo
11532163|NCT01128855|Experimental|Cohort 4|12 mg/kg GSK2402968 / placebo
11532164|NCT01128842|Experimental|Neratinib + Capecitabine|Neratinib + Capecitabine
11532165|NCT01128829|Experimental|water-sucralose|"Subjects in this group drank water 10 min before drinking a glucose load on their first oral glucose tolerance test (OGTT) and drank sucralose 10 min before drinking a glucose load on their second OGTT. The two OGTT were separated on average by 1 week (i.e. washout was approximately 1 week)."
11532166|NCT01128829|Experimental|sucralose-water|"Subjects in this group drank sucralose 10 min before drinking a glucose load on their first OGTT and drank water 10 min before drinking a glucose load on their second OGTT. The two OGTT were separated on average by 1 week (i.e. washout was approximately 1 week)."
11532167|NCT01128816|No Intervention|Standard HF therapy|Subjects will receive optimal standard therapy for heart failure conforming to national guidelines as determined by the referring cardiologist
11532168|NCT01128816|Active Comparator|Standard therapy for HF + ASV|Subjects will receive treatment with Adaptive Servo Ventilation in addition to optimal standard therapy for heart failure conforming to national guidelines, as determined by the referring cardiologist
11532169|NCT01128790|Experimental|remote ischemic preconditioning|4 cycles of 5 mins upper limb ischemia induced by blood pressure cuff inflation 20mmHg above systolic blood pressure
11532170|NCT01128790|Sham Comparator|Sham control|4 x 5 mins of upper limb blood pressure cuff inflation to 10mmHg (non-occlusive)
11532171|NCT01128777|Experimental|Cognitive behavioral group therapy|Cognitive behavioral group therapy for adolescents and a parallel group for parents
11532172|NCT01128777|Active Comparator|Nondirective supportive group therapy|Nondirective supportive group therapy for adolescents and a parallel group for parents
11532173|NCT01128764|Experimental|CBT for depression and healthy lifestyle plus exercise|CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
11532174|NCT01128764|Active Comparator|CBT for depression|CBT for depression only
11532175|NCT01128751|Active Comparator|Embol-X|Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
11532176|NCT01128751|Active Comparator|DBT dynamic bubble trap|Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
11532177|NCT01128751|No Intervention|Control group|In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
11532178|NCT01128738|Active Comparator|GSK1358820|Onabotulinum toxin type A
11532179|NCT01128738|Placebo Comparator|Placebo|Placebo
11532180|NCT01128725|Other|Group Alzhamyd|"The patients coming in consultation for a mnésique complaint will see each other offering the study. During a consultation, the following balance sheet will be accomplished :clinical Maintenance, collection of records and used treatments
~psycho-behaviour Valuation through Neuropsychiatric Inventory (NPI) and through Inventory Apathy
~Valuation of self-government in the activities of daily life (IADL). Further to this balance sheet, it is habitually offered on the subjects of advice (principally centered on the proposals of use of external helps for instance book memo, agenda and internal assistants medium notes-techniques and associations to keep information) and a new consultation 1 year afterwards including the same balance sheet.
~In a supplementary way in this clinical valuation, a blood sample will be accomplished at the time of inclusion and 12 months afterwards."
11532181|NCT01128712|Other|Group 1|Pregabalin (150mg/day)
11532182|NCT01128712|Other|Group 2|Pregabalin (450mg/day)
11532183|NCT01128699|Experimental|ISA+AVI|injection of intraoperative subconjunctival Avastin as an adjunct to Ahmed valve implant
11532184|NCT01128699|Active Comparator|AVI|Ahmed valve implant
11532185|NCT01128686||CHB patients who started LAM as an initial antiviral treatment|CHB patients who started LAM as an initial antiviral treatment at least 5 years prior to this investigation
11532186|NCT01128673||Body Cooled|Infants undergoing total body cooling for HIE
11532187|NCT01128673||HIE,Selective Head Cooled|Infants undergoing head cooling for HIE
11532188|NCT01128660||RSD-citizens|Residents of Southern Denmark, who filed more than 9 prescriptions during 2009.
11532189|NCT01128634|Other|GSK573719|GSK573719
11532190|NCT01128634|Other|GSK573719/GW642444|GSK573719/GW642444
11532191|NCT01128621|Other|Part A|Part A is open label, in T2DM subjects on established metformin monotherapy. Subjects will receive a single dose of GSK1292263 with food. This will permit a comparison of GSK1292263 exposures in this cohort with those observed in study GPR111598 in which T2DM subjects were drug naïve or washed off prior anti-diabetic medications.
11532192|NCT01128621|Placebo Comparator|Part B - PLA|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
11532193|NCT01128621|Active Comparator|Part B - Active|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
11532194|NCT01128621|Active Comparator|Part B - Sitagliptin|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
11532195|NCT01128608|Active Comparator|Control Group - Healthy Subjects|Healthy volunteers with normal EGD.
11532196|NCT01128608|Active Comparator|NERD Group|Subjects with NERD. Heartburn symp x2 wk for 3 months. Normal EGD and abnormal 24 hour pH.
11532197|NCT01128595|Active Comparator|ICS|
11532198|NCT01128595|Active Comparator|ICS/LABA|
11532199|NCT01128595|Active Comparator|LABA|
11532200|NCT01128595|Placebo Comparator|Placebo|
11532201|NCT01128582|Active Comparator|Rozerem|Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
11532202|NCT01128582|Placebo Comparator|placebo|Comparing the effect of Rozerem vs. placebo on GERD symptomatology
11532203|NCT01128569|Placebo Comparator|Placebo|Placebo Inhaler
11532204|NCT01128569|Active Comparator|inhaled corticosteroid(ICS)/long acting bronchodilator (LABA)|ICS/LABA inhaler
11532205|NCT01128569|Active Comparator|ICS|ICS inhaler
11532206|NCT01128556|Experimental|Bepreve|topical ocular treatment as indicated
11532207|NCT01128543|Active Comparator|lapatinib 1250mg|Patients will receive 1250mg lapatinib once a day for 24 weeks.
11532208|NCT01128543|Active Comparator|Vinorelbine 25mg/sqm|Patients will receive vinorelbine 25mg/sqm IV Day 1 and Day 8, every 3 week for 24 weeks.
11532209|NCT01128530|Experimental|JNJ-32729463|JNJ-32729463 250 mg tablet and matching linezolid placebo twice daily
11532210|NCT01128530|Active Comparator|linezolid|linezolid 600 mg tablet and matching JNJ-32729463 placebo twice daily
11532211|NCT01128517|Experimental|Bahavioral|Education about complementary food given to mothers
11532212|NCT01128478|Other|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
11532213|NCT01128478|No Intervention|Nil-per-mouth regimen|Conventional management
11532214|NCT01128452|Placebo Comparator|Placebo|Placebo
11532215|NCT01128452|Experimental|EVT 101|EVT 101
11532216|NCT01128439||1|
11532217|NCT01128426||1|
11532218|NCT01128413|Experimental|Fluid Optimization (FO)|"Cheetah NICOM® (non-invasive cardiac output monitoring) Passive Leg Raise Testing (PLRT) that demonstrates a >/= 15% change in stroke volume index (SVI) or cardiac index (CI) will receive a 500ml normal saline bolus. NICOM® PLRT with SVI or CI <15% will receive a saline lock. If bolused, NICOM® PLRT will be performed within 10 minutes after the bolus with the decision to re-bolus or saline lock according to repeated NICOM® PLRT measurements. If saline locked, NICOM® PLRT will be performed every 30 minutes with the decision to re-bolus or saline lock according to repeated NICOM® PLRT measurements.
~Additionally, USCOM®, IVC Ultrasound collapsibility, CURVES Questionnaire, and repeat lactate measurements will be performed."
11532219|NCT01128413|Active Comparator|Routine Care (RC)|Patients randomized to receive routine ED care will receive IV fluid administration per the treating clinicians discretion. The Cheetah NICOM®PLRT, USCOM®, IVC Ultrasound collapsibility, and CURVES Questionnaire will be performed and repeat lactate measurements will only be revealed to the routine care arm if they are used as part of the provider's routine care.
11532220|NCT01128400||rs1761667- AA genotype|subjects carrying the CD36 genotype rs1761667, i.e. a Single Nucleotide Polymorphism that significantly reduces CD36 level and has a minor allele frequency of 38-48%.
11532221|NCT01128400||rs1761667-GG genotype|subjects who are homozygous of CD36 genotype rs1761667-G allele.
11532222|NCT01128400||rs1761667-AG genotype|Heterozygous of CD36 gene rs1761667-A genotype.
11532223|NCT01128387|Experimental|Dose Level -1|Panitumumab/Cisplatin/Fluorouracil and Radiation therapy 1.5mg/kg Panitumumab, 60mg/m2 cisplatin, 750mg/m2 5FU (Fluorouracil)
11532224|NCT01128387|Experimental|Dose Level 1|Panitumumab/Cisplatin/Fluorouracil and Radiation therapy 1.5mg/kg Panitumumab, 80mg/m2 cisplatin, 1000mg/m2 5FU (Fluorouracil)
11532225|NCT01128374|Experimental|intervention|Therapy
11532226|NCT01128361|Experimental|Aerobic Exercise|
11532227|NCT01128361|Active Comparator|Stretching|
11532228|NCT01128348|Experimental|patient advocate|"Patient advocate works with patient before, during, and after a visit to asthma doctor.
~Patient receives video of asthma education materials"
11532229|NCT01128348|Active Comparator|asthma education|Patient receives video of asthma education materials
11532230|NCT01128335|Active Comparator|Arm 1|MMF(1000mg bid) + tacrolimus + standard of care medications
11532231|NCT01128335|Experimental|Arm 2|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
11532232|NCT01128335|Experimental|Arm 3|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
11532233|NCT01128335|Experimental|Arm 4|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
11532234|NCT01128322|Experimental|S-Amlodipine 2.5mg + Telmisartan 40mg|
11532235|NCT01128322|Experimental|S-Amlodipine 2.5mg + Telmisartan 80mg|
11532236|NCT01128322|Experimental|S-Amlodipine 5mg + Telmisartan 40mg|
11532237|NCT01128322|Experimental|S-Amlodipine 5mg + Telmisartan 80mg|
11532238|NCT01128322|Active Comparator|S-Amlodipine 2.5mg|
11532239|NCT01128322|Active Comparator|S-Amlodipine 5mg|
11532240|NCT01128322|Active Comparator|Telmisartan 40mg|
11532241|NCT01128322|Active Comparator|Telmisartan 80mg|
11532242|NCT01128322|Placebo Comparator|Placebo|
11532243|NCT01128309|Experimental|Stress Reduction Intervention|Stress Reduction Intervention
11532244|NCT01128309|Active Comparator|Active Control Condition|
11532245|NCT01128296|Experimental|Hydroxychloroquine + Gemcitabine (HcGc)|Hydroxychloroquine orally twice daily in combination with gemcitabine for 31 days prior to surgical resection
11532246|NCT01128283||Sepsis|Patients with severe sepsis
11532247|NCT01128283||Non-infected|ICU patients without evidence of infection
11532248|NCT01128270|Experimental|1A: Chloral Hydrate and DCA: Env|Subjects consume Chloral Hydrate 1.5ug/kg by mouth for 5 nights. On the 6th day they consume DCA 2.5ug/kg by mouth and have blood samples drawn. (Period 1)
11532249|NCT01128270|Experimental|1B: Chloral Hydrate Env dose|Drug Study Subjects are admitted to the clinical research unit and receive 1.5 ug/kg (environmental dose) of Chloral Hydrate for 5 nights. Pharmacokinetics are done on days 1 and day 5. (Period 2)
11532250|NCT01128270|Experimental|2A: Chloral Hydrate and DCA therapeutic|Drug Study Subjects are admitted to the clinical research center and receive a clinical dose of Chloral Hydrate for 5 nights (25mg/kg). On day 6 they are given a clinical dose (25mg/kg)of Dichloroacetate. (Period 3)
11532251|NCT01128270|Experimental|2B: Chloral Hydrate Therapeutic|Subjects are given 25 mg/kg of Chloral Hydrate for five nights. Pharmacokinetics are done on days 1 and 5. (Period 4)
11532252|NCT01128257||1|
11532253|NCT01128257||2|
11532254|NCT01128244|Experimental|Vitamin B6 Effects in OC Users|"All subjects will be given an infusion of labeled serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.
~The results from analysis of vitamin B6 and these amino acids in blood will provide us with specific measurements of the rates of two aspects of metabolism (Primary Outcomes 1 and 2) and specific measurements of vitamin B6 nutritional status (Primary Outcomes 3 and 4)."
11532255|NCT01128218|Experimental|Tumor fluorescence|A single arm in this open-label study where all patients are treated with the study drug - 5-aminolevulinic acid. Areas of the brain that are fluorescent and areas that are not fluorescent are evaluated for presence of tumor cells
11532256|NCT01128205||Diagnosed for 6 months or more|
11532257|NCT01128192|Experimental|Pasireotide 600 µg sc bid|n=19. Pasireotide 600 µg sc bid
11532258|NCT01128192|Experimental|Pasireotide 900 µg sc bid|n=19. Pasireotide 900 µg sc bid
11532259|NCT01128192|Experimental|Pasireotide 1200 µg sc bid|n=7. Due to increased severity of gastro-intestinal side effects, this arm was discontinued. These participants were only included in the safety analysis.
11532260|NCT01128179|Experimental|Lanthanum carbonate|
11532261|NCT01128179|Placebo Comparator|Placebo|
11532262|NCT01128166||Patients implanted with a CRT-D (Cardiac Resynch. Therapy)|
11532263|NCT01128153|Experimental|Saxagliptin 5 mg once daily|
11532264|NCT01128153|Placebo Comparator|Placebo once daily|
11532265|NCT01128140|Experimental|Motivational Enhancement Therapy|
11532266|NCT01128140|Active Comparator|Education|
11532267|NCT01128127|Experimental|Multifaceted intervention 1|psycho-educational workshop + audit-feedback + computer-based clinical decision support system (CCDSS) + usual intervention
11532268|NCT01128127|Experimental|Multifaceted intervention 2|audit-feedback + computer-based clinical decision support system (CCDSS) + usual intervention
11532269|NCT01128127|Active Comparator|Control|usual intervention
11532270|NCT01128114|Experimental|Quetiapine XR|Quetiapine fumarate (Seroquel XR)
11532271|NCT01128101|Experimental|Spironolactone|The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
11532272|NCT01128088||PCA and Volulyte|
11532273|NCT01128088||PCA and Hartmann's|
11532274|NCT01128088||Spinal and Volulyte|
11532275|NCT01128088||Spinal and Hartmann's|
11532276|NCT01128075||naïve subjects|Cohort of RMS patients who initiate disease modifying treatment with Rebif®
11532277|NCT01128075||non-naïve subjects|Cohort of RMS patients who initiate treatment with Rebif® after having failed therapy with other disease modifying drugs on the basis of lack of efficacy, compliance, safety, tolerability or convenience, as per clinical judgment of study investigator
11532278|NCT01128049|Active Comparator|Normal Patient Population|Non-Dry Eye patient population (intervention remains the same across all arms)
11532279|NCT01128049|Active Comparator|MGD Patient Population|Meibomium Gland Dysfunction population(intervention remains the same across all arms)
11532280|NCT01128049|Active Comparator|ADDE Population|Aqueous Deficient Dry Eye population(intervention remains the same across all arms)
11532281|NCT01128036||CHF, cardomyopathy|Patients with signs of poor peripheral perfusion due to cardiomyopathy or congestive heart failure
11532282|NCT01128023||PET Rb-82 perfusion imaging|Patients diagnosed with or suspected coronary artery disease requiring evaluation and/or risk stratification will undergo PET Rb-82 perfusion imaging.
11532283|NCT01128023||SPECT perfusion imaging|Patients diagnosed with or suspected coronary artery disease who have undergone SPECT myocardial perfusion imaging.
11532284|NCT01128010||alcoholic liver disease|alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution
11532285|NCT01128010||controls|Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination
11532286|NCT01127997||study A|post-breakfast meal tolerance test + post-lunch meal tolerance test
11532287|NCT01127997||study B|fasting + post-lunch meal tolerance test
11532288|NCT01127984|Experimental|treatment with tissucol|patients treated with tissucol, local application in the pocket of PM / ICD
11532289|NCT01127984|Active Comparator|vacuum drainage system|patients treated with application of vacuum drainage system.
11534217|NCT01114932||BMI-III|Patients with BMI values between 30-49.9
11532290|NCT01127958|Active Comparator|SeQuent Please|PCI with drug-eluting balloon
11532291|NCT01127958|Active Comparator|Xience Prime|PCI with a drug-eluting stent
11532292|NCT01127945|Experimental|atorvastatin 80mg|
11532293|NCT01127945|Active Comparator|conventional therapy (for heart failure)|
11532294|NCT01127932|Experimental|CBT for suicide|
11532295|NCT01127932|Active Comparator|Enhanced care control group|This group is designed to be an active control which provides detailed information about substance use, suicide risk, and depression without providing any CBT or other specific therapy.
11532296|NCT01127919||Low Commitment|Group 1 participants will take a 1-credit hour course that involves exercise training only.
11532297|NCT01127919||High Commitment|Group 2 participants will take a 3-credit hour course that involves exercise training plus an online cognitive component that provides information on fitness and health topics and includes quizzes and other written course work
11532298|NCT01127919||Non-Exercise|Group 3 participants will take the cognitive component of the formal course but will not partake in the formalized exercise program for a period of 35 weeks.
11532299|NCT01127906|Other|Randomized cross-over sequence|Randomized unbalanced sequence of incomplete block design with replicates within sequence
11532300|NCT01127893|Experimental|Tanezumab 10 mg|
11532301|NCT01127893|Experimental|Tanezumab 5 mg|
11532302|NCT01127893|Experimental|Tanezumab 2.5 mg|
11532303|NCT01127880|Active Comparator|Ancef 1 gm or Clindamycin 300 mg|Group A will receive Ancef 1gm or Clindamycin 300mg if penicillin or bet-lactam allergy exists
11532304|NCT01127880|Placebo Comparator|Placebo|Group B will receive .9% Normal Saline as a placebo.
11532305|NCT01127854||Cases|
11532306|NCT01127854||Controls|
11532307|NCT01127841|Experimental|Rituximab and Bendamustine|
11532308|NCT01127828|Active Comparator|Probiotic yoghurt (Cultura)|Cultura yoghurt containing: L bulgaricus, S thermophilus
11532309|NCT01127828|Placebo Comparator|Yoghurt with no probiotic|
11532310|NCT01127789|Experimental|non-invasive brain stimulation|
11532311|NCT01127776|Experimental|Apos System|
11532312|NCT01127776|Placebo Comparator|CONTROL|
11532313|NCT01127763|Experimental|RAD001+carboplatin|Carboplatin (starting dose was initially AUC 6, later decreased to AUC 5, then AUC 4) every 3 weeks as IV infusion and RAD001 as 5 mg pill each day until disease progression or unacceptable toxicity.
11532314|NCT01127750|Experimental|FTY720|
11532315|NCT01127737|Placebo Comparator|Control|
11532316|NCT01127737|Active Comparator|Intervention|Educational intervention consisting of a mnemonic and a workbook used by kidney transplant recipients (KTRs) to assist with early detection of SCCs.
11532317|NCT01127724|Experimental|group 1- 1000 mcg|Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months
11532318|NCT01127724|Experimental|Group 2- 100 mcg|Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months
11532319|NCT01127724|Experimental|group 3- 2000 mcg|Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
11532320|NCT01127672|Active Comparator|control|corticosteroid injection into the origin of the plantar fascia
11532321|NCT01127672|Active Comparator|experimental|platelet rich plasma injection into the origin of the plantar fascia
11532322|NCT01127659|Active Comparator|diabetes with HH-active|Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.
11532323|NCT01127659|No Intervention|diabetes with normal testosterone|Eugonadal subjects with diabetes. They will not be treated
11532324|NCT01127659|Active Comparator|obese with HH-active|Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.
11532325|NCT01127659|No Intervention|obese with normal testosterone|Eugonadal non-diabetic obese subjects. They will not be treated
11532326|NCT01127659|Placebo Comparator|Diabetes with HH-placebo|Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to placebo.
11532327|NCT01127659|Placebo Comparator|Obese with HH-placebo|Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to placebo.
11532328|NCT01127646|Experimental|Atomoxetine|Participants received 25-80 milligrams (mg) of atomoxetine orally, once daily during the run-in period for up to 7 days. The run-in period was followed by the 4-week on/off period in which participants received 25-80 mg of atomoxetine orally, once daily for 4 weeks, except for the off-days, where participants received 1 or 2 oral once daily placebo doses per week, with 6 nonconsecutive, double-blinded placebo doses in total over the 4-week on/off period. The on/off period was followed by a run-out period in which participants received 25-80 mg of atomoxetine orally, once daily for 1-5 days.
11532329|NCT01127646|Active Comparator|Osmotic-release oral system methylphenidate|Participants received 18-54 mg of osmotic-release oral system (OROS) methylphenidate orally, once daily during the run-in period for up to 7 days. The run-in period was followed by the 4-week on/off period in which participants received 18-54 mg of OROS methylphenidate orally, once daily for 4 weeks, except for the off-days, where participants received 1 or 2 oral once daily placebo doses per week, with 6 nonconsecutive, double-blinded placebo doses in total over the 4-week on/off period. The on/off period was followed by a run-out period in which participants received 18-54 mg of OROS methylphenidate orally, once daily for 1-5 days.
11532330|NCT01127633|Experimental|Solanezumab|
11532331|NCT01127633|Placebo Comparator|Placebo|
11532332|NCT01127620|Experimental|Bilastine|20 mg encapsulated tablets
11532333|NCT01127620|Active Comparator|Cetirizine|10 mg encapsulated tablets
11532334|NCT01127620|Placebo Comparator|Placebo|Encapsulated tablets
11532335|NCT01127607|Experimental|stimulant medication|blinded lisdexamfetamine at the optimal dose for the individual participant as previously determined during the med optimization portion of the study
11532336|NCT01127607|Placebo Comparator|placebo pill|placebo medication identical in appearance to active med
11532337|NCT01127581|Experimental|MVI 200|MVI 200 mcg vaginal insert
11532338|NCT01127581|Active Comparator|Dinoprostone Vaginal Insert (DVI)|10 mg Dinoprostone vaginal insert
11532339|NCT01127568|Experimental|Propranolol|Propranolol is a beta-blocker (blocking beta- adrenergic receptors) that reduces sympathetic activity. It is a well-known drug typically prescribed to individuals suffering from hypertension, tachycardia, cardiac arrhythmia, tremors, thyroid disease, or migraine.
11532340|NCT01127568|Placebo Comparator|Placebo|The placebo is an inactive capsule that will have no medication effect, but looks exactly like the medication.
11532341|NCT01127542|Experimental|Lenalidomide for early stage poor prognosis CLL|
11532342|NCT01127529||Subjects with severe congenital protein C deficiency|Registry subjects will be identified by working with Hemophilia Treatment Centers and Thrombosis Centers known to have subjects with severe congenital protein C deficiency, as well as by working with centers that use Ceprotin in emergency care situations.
11532343|NCT01127503|Experimental|Metyrosine|
11532344|NCT01127503|Placebo Comparator|Placebo|
11532345|NCT01127477|Experimental|1|
11532346|NCT01127464|Experimental|.3 dose level of DCVax -001|.3 dose level of DCVax plus fixed dose of 1.6 ml Poly ICLC
11532347|NCT01127464|Experimental|1 mg dose level of DCVax -001|1 mg dose level of DCVax -001 plus 1.6 ml of poly ICLC
11532348|NCT01127464|Experimental|3 mg dose level of DCVax-001|3 mg dose level of DCVax-001 plus poly ICLC
11532349|NCT01127464|Placebo Comparator|Placebo|sterile saline
11532350|NCT01127464|Experimental|poly-ICLC alone|1.6 mg of poly-ICLC alone
11532351|NCT01127451|Experimental|Denileukin diftitox|12 mcg/kg/day on Days 1 through 4 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks)
11532352|NCT01127438|Active Comparator|fospropofol disodium Subgroup 1 Lower Dose|
11532353|NCT01127438|Active Comparator|: fospropofol disodium Subgroup 1 Approved Dose|
11532354|NCT01127438|Active Comparator|fospropofol disodium Subgroup 2 Lower Dose|
11532355|NCT01127438|Active Comparator|fospropofol disodium Subgroup 2 Approved Dose|
11532356|NCT01127438|Active Comparator|fospropofol disodium Subgroup 3 Lower Dose|
11532357|NCT01127438|Active Comparator|fospropofol disodium Subgroup 3 Approved Dose|
11532358|NCT01127425|Active Comparator|1|Intervention: Surgery: laparoscopic sigmoid resection without fast track postoperative care
11532359|NCT01127425|Active Comparator|2|Intervention: Surgery: conventional (open) sigmoid resection without fast track postoperative care
11532360|NCT01127412|Active Comparator|Physical activity stimulating program|Advices to stimulate motor activity and motor development at the age of two weeks, two months, four months, eight months and eleven months
11532361|NCT01127412|No Intervention|Control|
11532362|NCT01127399||Bariatric, nonasthma|Participants that will have had a bariatric surgery but do not have asthma.
11532363|NCT01127399||Bariatric, asthma|Participants that will have had a bariatric surgery and have been physician diagnosed with asthma prior to the surgery.
11532364|NCT01127399||Control, nonasthma|Healthy participants that who will not be getting a bariatric surgery and who do not have asthma.
11532365|NCT01127399||Control, asthma|Healthy participants that will not be having a bariatric surgery but do have asthma.
11532366|NCT01127386|Experimental|fix dose lenalidomide 25mg, basic cachexia management|dose reduction according to toxicity possible
11532367|NCT01127386|Experimental|CRP-response guided lenalidomide, basic cachexia management|start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
11532368|NCT01127386|Experimental|placebo|to generate data about basic cachexia management, no direct comparator for treatment arms efficacy
11532369|NCT01127373|Experimental|radiation therapy via multi-beam IMRT|This is a single-arm feasibility study of multi-beam IMRT with daily set-up verification in the treatment of women with node-positive breast cancer who will receive radiation to the breast/chest wall and regional lymph nodes, including the internal mammary lymph nodes.
11532370|NCT01127360|Experimental|Bevacizumab|Bevacizumab 1,25 mg, intravitreal injections every 4th to 12th week
11532371|NCT01127360|Active Comparator|Ranibizumab|Ranibizumab 0,5 mg, intravitreal injection, every 4th to 12th week
11532372|NCT01127334||Systolic Heart Failure, Dyssynchrony, CRT-D|Patients with systolic heart failure and dyssynchrony that have a CRT-D that have not been optimized in the past 3 months.
11532373|NCT01127321|Placebo Comparator|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
11532374|NCT01127321|Experimental|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
11532375|NCT01127321|Experimental|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
11532376|NCT01127321|Experimental|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
11532377|NCT01127321|Experimental|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
11532378|NCT01127308|Experimental|[14C]Ertugliflozin|Single dose - oral dosing suspension
11532379|NCT01127295|Other|Tamoxifen, Anastrozole, letrozole, Exemestane|Current hormonotherapy treatment in hormono dependent breast cancer
11532380|NCT01127282|Experimental|Vitamin|Vitamin(vitamin A 15mg,C 500mg,E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics
11532381|NCT01127282|Placebo Comparator|Control|Placebo(digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
11532382|NCT01127269|Experimental|Insulin Glargine|"Patients will receive insulin glargine titrated based on standard of care as recommended by the ADA/EASD Consensus Algorithm. Step 1: insulin glargine initiation regimen for insulin naive patients/ Switch to insulin glargine for patient already treated with basal insulin.
~Step 2: the insulin dosage of patients will be titrated according to the ADA/EASD Consensus Algorithm."
11532383|NCT01127256|Experimental|1|
11532384|NCT01127256|Active Comparator|2|
11532385|NCT01127243|Active Comparator|inpatient LSH|LSH means laparoscopic supracervical hysterectomy
11532386|NCT01127243|Experimental|Day-case LSH|LSH means laparoscopic supracervical hysterectomy
11532387|NCT01127230||Liposuction patients|Patients who already opted and are scheduled for liposuction.
11532388|NCT01127217|Experimental|amlodipine/losartan|
11532389|NCT01127217|Active Comparator|amlodipine|
11532390|NCT01127204|Active Comparator|arm 1 (reference strategy)|AZT-3TC-LPV/r twice a day
11532391|NCT01127204|Experimental|arm 2 (simplification strategy)|ABC-3TC-EFV once a day
11532392|NCT01127191||Military|
11532393|NCT01127178|Experimental|E7016 + TMZ|
11532394|NCT01127165|Experimental|Zonisamide Low Dose Group|
11532395|NCT01127165|Experimental|Zonisamide High Dose group|
11532396|NCT01127152|Active Comparator|Automatic relays|Automatic relays of noradrenalin using intensive basis.
11532397|NCT01127152|Active Comparator|Manual relays|Relays of noradrenalin using manual method
11532398|NCT01127139||Czech patients with essential hypertension|Czech hypertensive patients (women and men) with systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg who can be treated with fixed-combination Tarka®.
11532399|NCT01127126|Active Comparator|Bryophyllum|muscle relaxing substance
11532400|NCT01127126|Placebo Comparator|Placebo|control group postmenopausal women suffering from overactive bladder
11532401|NCT01127113|Active Comparator|SPIO-labelled mononuclear cells|
11532402|NCT01127113|Placebo Comparator|Unlabelled mononuclear cells|
11532403|NCT01127113|Active Comparator|SPIO alone|
11532404|NCT01127100|Experimental|Transdermal fentany matrix|Transdermal fentanyl matrix is second-line medication on the neuropathic pain but gabapentin is the first-line medication. So, transdermal fentanyl matrix is experimental arm and gabapentin is active comparator arm.
11532405|NCT01127100|Active Comparator|gabapentin|Gabapentin is the first-line medication in neuropathic pain. So, gabapentin is active comparator in this study and transdermal fentanyl matrix is experimental.
11532406|NCT01127087|Experimental|RYGB CaOx Stone Formers|"Subjects with enteric hyperoxaluria after Roux-en-Y Gastric Bypass (RYGB).
~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
11532407|NCT01127087|Experimental|Idiopathic Hyperoxaluria CaOx Stone Formers|"Subjects with idiopathic hyperoxaluria.
~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
11532408|NCT01127074|Experimental|KS24.22-vaccination|"The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).
~Immediately before administration, KS24.22 cells were thawed and lethally irradiated. KS24.22 cells were adjusted to 10E7/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites."
11532409|NCT01127061|Experimental|Exercise Training|Participants in the exercise group will undergo 4 months of training, 4-7 days per week with a minimum of 20 minutes per day. The protocol will be custom designed in consultation with an exercise physiologist based on data from the initial cardiopulmonary stress test. Exercise regimen will begin at a low level of intensity then increase in duration and training intensity to a goal of 60 minutes a day and 70% of the heart rate reserve during the 1st month of the study protocol with maintenance of the program thereafter. There is no need to come to a participating site for actually doing the exercise regimen. No strength training or burst activity will be prescribed and all activities will fall well within the recommended national guidelines for recreational exercise.
11532410|NCT01127061|No Intervention|Usual Activity|Participants in this group are not restricted in their activities. They simply are not guided in their physical activities by the study team. At the end of the 4 month study period, they will also receive an individualized exercise prescription for personal use.
11532411|NCT01127048|Experimental|Prospan Hustenzäpfchen|
11532412|NCT01127048|Placebo Comparator|Placebo|
11532413|NCT01127035|Experimental|SLIT|sublingual immunotherapy biologically standardized
11532414|NCT01127035|Placebo Comparator|placebo|same preparation of SLIT without the allergen
11532415|NCT01127022|Active Comparator|480 mg/d choline intake|480 mg/d choline derived from the diet [380 mg choline/d] plus supplemental choline chloride [100 mg choline/d]
11532416|NCT01127022|Experimental|930 mg/d choline intake|930 mg/d choline derived from the diet [380 mg choline/d] plus supplemental choline chloride [550 mg choline/d]
11532417|NCT01127009|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11; and mitoxantrone IV, etoposide IV over 1 hour, and intermediate-dose cytarabine IV over 6 hours on days 1-6. Treatment continues in the absence of disease progression or unacceptable toxicity.
11532418|NCT01126996||MenC vaccinated healthy children|Children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.
11532419|NCT01126983|Experimental|Non-Suture|No suture will be used to secure the leads. Benzoin and Steri-Strips will be used like in the other two arms.
11532420|NCT01126970|Placebo Comparator|Placebos.|Velneperit Placebo q.d.+ Orlistat Placebo t.i.d.
11532421|NCT01126970|Experimental|Velneperit 400 mg|Velneperit 400 mg q.d.
11532422|NCT01126970|Active Comparator|Orlistat 120 mg|Orlistat 120 mg t.i.d.
11532423|NCT01126970|Experimental|Velneperit 400 mg + Orlistat 120 mg|Velneperit 400 mg q.d.and Orlistat 120 mg t.i.d
11532424|NCT01126957|Experimental|Ketamine|Participants received 0.5-1.5 micrograms/kg Fentanyl, followed 0.5 mg/kg Ketamine infusion, followed by propofol to maintain sedation.
11532425|NCT01126957|Placebo Comparator|Placebo|Participants received 0.5-1.5 micrograms/kg Fentanyl, followed by placebo infusion, followed by propofol to maintain sedation.
11532426|NCT01126944|Experimental|system heart mate II|left ventricular assist device
11532427|NCT01126944|No Intervention|normal medical care|Optimal medical treatment for heart failure according to international guidelines
11532428|NCT01126918|Active Comparator|Brochure Condition|Participants in this condition receive an educational brochure about healthy body image via post-mail.
11532429|NCT01126918|Experimental|Group Condition|Participants in this condition attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
11532430|NCT01126892|Experimental|Nilotinib|
11532431|NCT01126879|Experimental|Arm I|Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
11532432|NCT01126879|Placebo Comparator|Arm II|Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
11532433|NCT01126866|Experimental|preoperative chemotherapy|
11533109|NCT01122108|Active Comparator|Cholestyramine 12 grams|Cholestyramine 12 grams
11532434|NCT01126853|Experimental|Vaccination|Receipt of up to 3 series of double dose combination hepatitis A/B vaccine (Twinrix)
11532435|NCT01126840||Questionnaire + Telephone Interview|Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete. The phone interview should take 30-45 minutes to complete.
11532436|NCT01126827|Active Comparator|Supportive Psychotherapy|
11532437|NCT01126827|Active Comparator|Mindfulness-Based Cognitive Behavioral Therapy|
11532438|NCT01126814|Experimental|one|
11532439|NCT01126801|Experimental|Estradiol|
11532440|NCT01126801|Placebo Comparator|Placebo control|
11532441|NCT01126788||PADnet + testing|
11532442|NCT01126788||Parks Flo-lab Test|
11532443|NCT01126775||group non-high-risk|
11532444|NCT01126775||group high risk|
11532445|NCT01126762|Experimental|Dietary advice and grocery store card|Dietary advice to consume low mercury, high DHA fish plus a grocery store gift card to support the purchase of fish
11532446|NCT01126762|Experimental|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
11532447|NCT01126762|Placebo Comparator|Control|General dietary advice not focused on fish intake
11532448|NCT01126749|Experimental|E7389 in combination with gemcitabine plus cisplatin|
11532449|NCT01126749|Experimental|gemcitabine plus cisplatin|
11532450|NCT01126736|Experimental|Low Dose E7389 in Combination with Pemetrexed|
11532451|NCT01126736|Active Comparator|Pemetrexed|
11532452|NCT01126736|Experimental|High Dose E7389 in Cominbation with Pemetrexed|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
11532453|NCT01126723|Experimental|Tai Chi group|
11532454|NCT01126723|Active Comparator|Educational Control group|
11532455|NCT01126697|No Intervention|Enhanced standard of care|
11532456|NCT01126697|Active Comparator|Lisinopril|
11532457|NCT01126697|Active Comparator|Coenzyme Q10|
11532458|NCT01126697|Active Comparator|Coenzyme Q10 and Lisinopril|
11532459|NCT01126684|Active Comparator|Atorvastatin|
11532460|NCT01126684|Placebo Comparator|Placebo|
11532461|NCT01126671|Active Comparator|Low Dose Vitamin D|Subjects are randomized to take 200 IU vitamin D3 daily in this arm.
11532462|NCT01126671|Active Comparator|High Dose Vitamin D|Subjects are randomized to take 1000 IU vitamin D3 daily in this arm.
11532463|NCT01126658||All subjects act as their own contral|
11532464|NCT01126645|Other|local ablation group|Local ablation group: Potentially curative treatment of early HCC includes surgical resection and local ablation (RFA, PEI, BT). Recurrence rates after such approaches are reported to amount to 50% at 3 years and 70% at 5 years. Tumor recurrence may be either due to de novo development of new primary tumors or due to intrahepatic (unrecognized) metastases. Prevention of recurrence after local ablation is an important strategy to improve overall survival. So far, adjuvant chemoembolization and chemotherapy have not proven to be effective in preventing recurrences. There is, however, a strong rationale to assume that sorafenib will be of value in the adjuvant treatment of HCC as sorafenib has a dual mechanism of action (inhibition of tumor proliferation and antiangiogenesis) and has proven efficacy in HCC.
11532465|NCT01126645|Active Comparator|palliative treatment group|"Radioembolization has been reported to be effective in patients with unresectable HCC with preserved liver function from a number of trials. Successful downstaging of disease rendering patients eligible for potentially curative therapies, and even histologically confirmed complete responses of unresectable HCC, have repeatedly been reported providing the rationale to evaluate SIRT+sorafenib in comparison to sorafenib alone.
~The impact of cirrhosis as a concomitant disease in most patients with HCC is that it limits the ability of many patients to tolerate chemotherapy and is an independent cause of death in HCC patients. Thus, the historical difficulty in demonstrating an effect of therapy on survival in patients with advanced-stage, unresectable HCC (the majority). A new therapy that is effective in controlling hepatic disease, is less toxic than traditional chemotherapy, and improves the quality of life for patients in the advanced stages of HCC could represent an alternative."
11532466|NCT01126632||Cap Assisted Colonoscopy|Patients receiving colonoscopies where scope is fitted with cap
11532467|NCT01126632||Standard Colonoscopy|Patients receiving standard colonoscopy without the cap on the scope
11532468|NCT01126619||Anti-TNF|Participants with moderate to severe psoriasis who were prescribed an Anti Tumor Necrosis Factor (anti-TNF) agent prior to enrollment according to national approved indications and reimbursement guidelines.
11532469|NCT01126606|Experimental|Group 1|Dermacyd Silver Frutal followed by Dermacyd Silver Frutal+PH_DESYLSTY_FR followed by wash out followed by Glycerine Vegetal Soap Granado Traditional
11532470|NCT01126606|Experimental|Group 2|Glycerine Vegetal Soap Granado Traditional followed by wash out followed by Dermacyd Silver Floral followed by Dermacyd Silver Floral + PH_DESYLSTY_FR
11532471|NCT01126593|Placebo Comparator|Placebo group|The placebo group will receive the same subacromial infusion catheter as the study group.However, the reservoir will be filled with 200cc of 0.9% normal saline.
11532472|NCT01126593|No Intervention|Control group|The control group patients will receive no continuous infusion catheter.
11532473|NCT01126593|Experimental|Study Group|Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The infusion rate will be 4cc per hour.
11532474|NCT01126580|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks
~Placebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52"
11532475|NCT01126580|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks
~Placebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52"
11532555|NCT01126021|Experimental|Team-based|Teams compete against each other and receive rewards according to relative participation.
11532556|NCT01126008|Experimental|weekly docetaxel and cisplatin|
11532476|NCT01126580|Active Comparator|Metformin|"Metformin: 500 milligrams per day (mg/day), orally, for Week 1; 1000 mg/day, orally, for Week 2; 1500 mg/day, orally, for Week 3; 2000 or at least 1500 mg/day, orally, for Weeks 4 through Week 52
~Placebo: subcutaneously (SC), once weekly for 52 weeks"
11532477|NCT01126567||High Sampling Rate|Samples will be obtained at a high rate
11532478|NCT01126567||Low Sampling Rate|Samples will be obtained at a low rate
11532479|NCT01126554||Critically ill patients|
11532480|NCT01126541|Experimental|A|1000 mg IV rituximab
11532481|NCT01126541|Experimental|B|2 x 1000 mg IV rituximab
11532482|NCT01126528|Experimental|Vitamin D3|Vitamin D3 (cholecalciferol)
11532483|NCT01126528|Placebo Comparator|Control|Placebo control group
11532484|NCT01126515||Hyperbaric oxygen|In this open-label feasibility study, all subjects will receive 60 hyperbaric oxygen sessions (100% oxygen, 1.5 atmospheres absolute (atm abs), for 60 minutes), delivered daily, five days per week.
11532485|NCT01126502|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive alvespimycin hydrochloride IV over 60 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11532486|NCT01126476|Active Comparator|small volume strata|12 in small volume strata
11532487|NCT01126476|Active Comparator|large volume strata|12 in large volume strata
11532488|NCT01126463|Experimental|Rhenium Lipiodol|Hepatic Intra-Arterial Administration of radio-active lipiodol.
11532489|NCT01126450|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-28 and cetuximab IV once weekly over 1-2 hours on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11532490|NCT01126437|Experimental|tiotropium 2.5 mcg and placebo|Patients receive one of the active tiotropium arms daily
11532491|NCT01126437|Active Comparator|tiotropium 18 mcg and placebo|Patients receive one of the active tiotropium arms daily
11532492|NCT01126437|Experimental|tiotropium 5 mcg and placebo|Patients receive one of the active tiotropium arms daily
11532493|NCT01126424|Experimental|Solifenacin|Participants received 21 days of treatment with 5 mg solifenacin, in tablet form once a day.
11532494|NCT01126424|Active Comparator|Oxybutynin|Participants received 21 days of treatment with 10 mg oxybutynin (1 x 5 mg twice daily) in capsule form.
11532495|NCT01126424|Placebo Comparator|Placebo|Participants received 21 days of treatment with placebo.
11532496|NCT01126411|No Intervention|control|control group / no immunoadsorption
11532497|NCT01126411|Active Comparator|immunoadsorption|immunoadsorption
11532498|NCT01126398||Ankle / dist. tibia fracture fixation|
11532499|NCT01126385||Transpedicular stabilization|Patients undergoing transpedicular stabilization of the spine
11532500|NCT01126359|Placebo Comparator|Lidocaine then Placebo-Saline|
11532501|NCT01126359|Active Comparator|Placebo-Saline then Lidocaine|
11532502|NCT01126346|Experimental|Arm I|Patients and their caregiver(s) receive a hyperthermic intraperitoneal chemotherapy (HIPEC) orientation with a Survivorship Navigator (SN) over 90 minutes following their initial surgical consult. Patients then receive telephone calls over 20-30 minutes from the SN once weekly for 3 weeks prior to HIPEC. After HIPEC, patients meet with the SN for 20-30 minutes to discuss adjustments and adaptation to the surgery and hospitalization 3-4 days post-HIPEC, biweekly for two weeks and weekly thereafter until hospital discharge. After hospital discharge, patients receive telephone calls from the SN twice monthly for 1 month.
11532503|NCT01126333||Long term Sirolimus or Tacrolimus|"Ths study cohort will consist of participants who successfully completed two years of the original Spare the Nephron (STN) study, a two year prospective multi-center study where participants were assigned to receive either center-specific CNI regimen (assigned at the time of transplantation) or were switched to replace the CNI with Sirolimus therapy.
~In this current long-term follow-up study, we will approach patients who previously enrolled in the STN study and offer them the opportunity to enroll to be followed-up for another 3 years. There will be no change in immunosuppression unless clinically indicated. The majority of effort is standard care with every 6 month follow-up appointments.Participants will be required to consent to participate in the three year extension study."
11532504|NCT01126320|Experimental|AnapnoGuard 100|Respiratory guard system during mechanical ventilation
11532505|NCT01126320|Active Comparator|Control|routine mechanical ventilator
11532506|NCT01126307|Active Comparator|verapamil|verapamil 80mg tid
11532507|NCT01126307|Placebo Comparator|placebo sugar pill|placebo tid
11532508|NCT01126294|Experimental|Melatonin 5 mg|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
11532509|NCT01126294|Experimental|Melatonin 10 mg|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
11532510|NCT01126294|Placebo Comparator|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
11532511|NCT01126281|Experimental|Floseal use|
11532512|NCT01126268|Experimental|Retapamulin ointment 1%|
11532513|NCT01126255|Active Comparator|1|Clobetasol propionate 0.05%, topical application, once daily about 2 g, during 12 weeks
11532514|NCT01126255|Experimental|2|Progesterone 8%, topical application, once daily about 2 g, during 12 weeks
11532515|NCT01126242|Experimental|tape|Group I will be treated with non-elastic adhesive tape around the affected ankle, applied by the 'van Unen-technique'. This technique is an alternative for the 'Coumans- technique'. The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity. Taping is a treatment that involves no loss of time, requires no crutches and is not attended with any ultimate impairment of function.
11532557|NCT01125995|Active Comparator|late CCRT|radiotherapy start on day one of the third cycle of chemotherapy
11532558|NCT01125995|Experimental|Early CCRT|Radiotherapy start on day 1 of 1st cycle of chemotherapy
11533013|NCT01122680|Experimental|Treatment A|patients inhale 2 puffs (dose of 1.25 mcg) once daily in the evening via Respimat inhaler
11532516|NCT01126242|Active Comparator|Lace-up brace|The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
11532517|NCT01126242|Active Comparator|Semi rigid brace|A semi-rigid brace, the M-step® from Medi®, will be applied. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
11532518|NCT01126229|Placebo Comparator|Placebo|Dietary Supplement: placebo
11532519|NCT01126229|Experimental|300 mg/d Resveratrol|Dietary Supplement: 300 mg/d Resveratrol
11532520|NCT01126229|Experimental|1000 mg/d Resveratrol|Dietary Supplement: 1000 mg/d Resveratrol
11532521|NCT01126216|Experimental|Reduced RT + Pacitaxel/Cisplatin|63,6 Gy accelerated hyperfractionated radiotherapy with Paclitaxel (20mg/m^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m^2/d) on days 1-4 and 29-32, followed by a salvage operation or neck dissection if there is persisting tumor
11532522|NCT01126216|Active Comparator|Standard RT + 5-Fluorouracil/Cisplatin|70,6 Gy accelerated hyperfractionated radiotherapy with 5-Fluorouracil(600mg/m^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m^2/d) on days 1-5 and 29-33, followed by a salvage operation or neck dissection if there is persisting tumor
11532523|NCT01126203|Experimental|selective laser trabeculoplasty (SLT)|
11532524|NCT01126203|Experimental|Argon laser trabeculoplasty (ALT)|
11532525|NCT01126190|Experimental|Neugranin|
11532526|NCT01126190|Active Comparator|Pegfilgrastim|
11532527|NCT01126177|Placebo Comparator|Placebo|Placebo once daily for 14 days
11532528|NCT01126177|Experimental|SNG001|
11532529|NCT01126164|Experimental|parent handbook|parent handbook
11532530|NCT01126164|Experimental|peer basics|peer delivered basics
11532531|NCT01126164|Experimental|parent handbook and peer basics|parent handbook and peer basics
11532532|NCT01126151|Experimental|parent handbook|parent handbook to increase the quantity and quality of communications about alcohol
11532533|NCT01126151|Experimental|parent handbook with boosters|boosters are given to parents at three times (move in, visit weekend; student visits home)
11532534|NCT01126151|Experimental|parent handbook delay|parent handbook is delayed and given after semester has begun
11532535|NCT01126138|Other|Arm A|Vinorelbine plus Capecitabine
11532536|NCT01126138|Other|Arm B|Docetaxel plus Capecitabine
11532537|NCT01126125|Experimental|Iodized oil to mother|400 mg iodine as iodized oil to breastfeeding mother
11532538|NCT01126125|Active Comparator|Iodized oil to infant|100 mg of iodine as iodized oil to infant
11532539|NCT01126112|Experimental|Panitumumab|Panitumumab: 6 mg/Kg Q2W Treatment cycles repeated every 14 days. Subjects will be evaluated for tumour response every 3 cycles (6 wks ± 1 wk) the first 24 weeks and every 8 weeks ± 2 weeks thereafter (per the revised-RECIST 1.1 guideline) until PD or withdrawal from the trial.
11532540|NCT01126099|Experimental|Prazosin|In the double blind phase (12 weeks), study participants will take either prazosin for placebo. For the open label phase (12 weeks), all study participants will take prazosin.
11532541|NCT01126099|Placebo Comparator|Placebo|In the double blind phase (12 weeks), study participants will take either prazosin for placebo. For the open label phase (12 weeks), all study participants will take prazosin.
11532542|NCT01126086|Experimental|Mild impairment|Patients with mild hepatic impairment
11532543|NCT01126086|Experimental|Moderate impairment|Patients with moderate impairment
11532544|NCT01126086|Experimental|Healthy subjects|Matched healthy subjects
11532545|NCT01126073|Placebo Comparator|placebo|
11532546|NCT01126073|Active Comparator|Niacin/Laropiprant 2000mg/40 mg|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will be randomized in the ratio 1:1 to either receive ER niacin/laropiprant or placebo in addition to the statin therapy. Patients in the ER niacin/laropiprant group will receive 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.
11532547|NCT01126060|Active Comparator|Fibrin sealant|usage of fibrin sealant after surgery
11532548|NCT01126060|No Intervention|Control|No usage of fibrin sealant
11532549|NCT01126047|Other|PFT's, eCO, and pulse oximetry|All subjects in the study will undergo complete pulmonary function testing (spirometry, blood collection for carboxyhemoglobin, diffusing capacity); exhaled carbon-monoxide testing, and pulse oximetry.
11532550|NCT01126034|Experimental|intervention|"Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:
~The name and medical record # of the patients involved
~Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy
~A reminder of the adverse effect of long-term metoclopramide therapy
~A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients
~A request that the physician document the discontinuation trial in the electronic medical record"
11532551|NCT01126034|No Intervention|non-intervention|No intervention letters were sent to subjects in this arm
11532552|NCT01126021|Active Comparator|Control|Given access to mental exercises but receives no rewards for use.
11532553|NCT01126021|Experimental|Atomistic|Each individual is awarded for his or her individual participation
11532554|NCT01126021|Experimental|Altruistic|Participants are paired and rewarded according to the other individual's participation.
11534218|NCT01114893|Active Comparator|TRAVATAN|TRAVATAN 0.004% once daily
11532559|NCT01125982|Active Comparator|Desflurane|Patients will receive Desflurane to provide sleep during anaesthesia for laparoscopic cholecystectomy. Analgesia will be provided by remifentanil.
11532560|NCT01125982|Active Comparator|Propofol|Patients will receive Propofol to provide sleep during anaesthesia for laparoscopic cholecystectomy. Analgesia will be provided by remifentanil.
11532561|NCT01125969|Active Comparator|Control|
11532562|NCT01125969|Experimental|Incentive|
11532563|NCT01125969|Experimental|Peer Mentoring|
11532564|NCT01125969|Experimental|Incentives and Peer Mentoring|
11532565|NCT01125956|No Intervention|Control|This group will receive usual diabetes care through their primary care clinicians.
11532566|NCT01125956|Experimental|Peer counseling|A peer counselor will be assigned to each participant who currently has good diabetes control but had poor control in the past 3 years.
11532567|NCT01125956|Experimental|Financial incentives|Patient participants in the financial incentive arm will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
11532568|NCT01125943|Experimental|Acetylcholine|Intra-arterial infusion of acetylcholine in two increasing dosages during 5 minutes each during the intra-arterial infusion of bevacizumab
11532569|NCT01125943|Experimental|Nitroprusside|Infusion of two increasing dosages of nitroprusside during 5 minutes each during the continuous infusion of bevacizumab
11532570|NCT01125930|Placebo Comparator|Vehicle gel|Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
11532571|NCT01125930|Active Comparator|Atralin gel|Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
11532572|NCT01125917|Experimental|BTDS|Buprenorphine transdermal patch
11532573|NCT01125904|Experimental|crizotinib|
11532574|NCT01125891|Experimental|gemcitabine and ON 01910.Na|
11532575|NCT01125878|Active Comparator|Starch Composite B|
11532576|NCT01125878|Active Comparator|Starch Composite C|
11532577|NCT01125878|Active Comparator|Starch Composite D|
11532578|NCT01125878|Placebo Comparator|Placebo|
11532579|NCT01125865|Active Comparator|SEMS|Self-expandable metallic stent will be inserted for the malignant hilar obstruction.
11532580|NCT01125865|Active Comparator|DLS|DoubleLayer plastic stent (Olympus) will be inserted for malignant hilar obstruction.
11532581|NCT01125852|Active Comparator|Intervention group|Patients in this group are treated with usual therapeutic endoscopy including endoscopic combination therapy and 72 hours intravenous proton pump inhibitor. Within 24 hours from the therapeutic endoscopy they receive supplementary angiographic embolization.
11532582|NCT01125852|Active Comparator|Control group|Patients in this arm receive standard treatment including therapeutic endoscopy with endoscopic combination therapy followed by 72 hours intravenous proton pump inhibitor.
11532583|NCT01125839||Spondylitis|Patients who checked spine MRI for back pain
11532584|NCT01125813|Experimental|human cl-rhFVIII|
11532585|NCT01125800|Experimental|LDE225 233mg/m2 daily dose|Pediatric dose.
11532586|NCT01125800|Experimental|LDE225 372mg/m2 daily dose|Pediatric dose.
11532587|NCT01125800|Experimental|LDE225 425 mg/m2 daily dose|Pediatric dose.
11532588|NCT01125800|Experimental|LDE225 680 mg/m2 daily dose|Pediatric dose.
11532589|NCT01125800|Experimental|LDE225 800 mg/m2 daily dose|Adult dose
11532590|NCT01125787|Experimental|ofatumumab + bendamustine|
11532591|NCT01125774|Experimental|Telcagepant|Telcagepant 140 mg was administered once daily at bedtime for 7 consecutive days each month, beginning at the onset of menses, for up to 6 months. Dosing could begin up to 3 days prior to menses onset if prodromal symptoms reliably predicted onset of menses.
11532592|NCT01125774|Placebo Comparator|Placebo|Placebo was administered once daily at bedtime for 7 consecutive days each month, beginning at the onset of menses, for up to 6 months. Dosing could begin up to 3 days prior to menses onset if prodromal symptoms reliably predicted onset of menses.
11532593|NCT01125761|Experimental|dexamethasone 0.5 mg and 1.0 mg clemastine cream|
11532594|NCT01125761|Active Comparator|dexamethasone 0,5 mg cream|
11532595|NCT01125748|Experimental|Omalizumab|Participants received omalizumab subcutaneously at the same dose and dosing interval as administered prior to enrollment in this study. The dose of omalizumab was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.
11532596|NCT01125748|Placebo Comparator|Placebo|Participants received placebo subcutaneously at the same dosing interval as omalizumab was administered prior to enrollment in this study.
11532597|NCT01125735|Experimental|MIST Therapy|MIST Therapy is a low energy, low intensity ultrasound delivered through a saline mist to the wound bed.
11532598|NCT01125735|Other|Standard of Care|Standard of Care with saline rinse using a sham device which is a nebulizer compressor designed to deliver a continuous saline mist to a skin treatment site. The saline mist generated has been designed to be comparable to that delivered by the MIST Therapy System, but without the ultrasound waves.
11532599|NCT01125722|Active Comparator|Investigator Placement Group|
11532600|NCT01125722|Active Comparator|Subject Placement Group|
11532601|NCT01125696|Active Comparator|Standard of Care|
11532602|NCT01125696|Experimental|Tenofovir|
11532603|NCT01125683|Experimental|1|2,5 mg once daily
11532604|NCT01125683|Active Comparator|2|single dose of 5 mg
11532605|NCT01125683|Placebo Comparator|3|
11532606|NCT01125683|Experimental|4|60 mg once daily
11532607|NCT01125683|Experimental|5|60 mg three times daily
11532608|NCT01125670|Experimental|fast-fed sequence group|
11532609|NCT01125670|Experimental|fed-fast sequence group|
11532610|NCT01125657|Experimental|formualation-A to -B sequence group|
11532611|NCT01125657|Experimental|formulation-B to -A sequence group|
11532612|NCT01125644|Experimental|Single Arm|"Patients are males and females between 18 and 75 years of age with proven fungal etiology confirmed by mycological culture test and by hystopathological exam (patients with definite diagnosis), or patients with fungal infection of which is difficult to determine the etiological agent but with diagnosis of deep mycosis based on blood testing for fungal infection and/or clinical radiological examination, and/or endoscopic clinical examination, clinical symptomatology (patients with clinical diagnosis)."
11532613|NCT01125631|Experimental|PF-04360365 8.5 mg/kg|
11532614|NCT01125631|Placebo Comparator|Placebo|
11532615|NCT01125618|Experimental|MVP village|Wealth stratified and randomly selected households residing in a village exposed to the Millennium Villages Project intervention (or health and development intervention package)
11532616|NCT01125618|Active Comparator|Comparison village|Villages receiving routine services through established programs
11532617|NCT01125605||Adults > 12 years|adult patients and patients older than 12 years
11532618|NCT01125605||Children 6-12 years|children between 6 and 12 years
11532619|NCT01125605||Children 1-6 years|children between 1 and 6 years
11532620|NCT01125592|Experimental|Footbath|Participants in this arm of the study will receive 4 30 minutes ionic footbath sessions, one each week for 4 weeks.
11532621|NCT01125579||Children aged 6-12|"Children suffering from nervous restlessness, e.g. in agitated depression (ICD 10, F3 and DSM IV affective disorders), aged 6-12 years"
11532622|NCT01125566|Active Comparator|Arm B: trastuzumab with vinorelbine|patients receive weekly intravenous infusion of trastuzumab and vinorelbine
11532623|NCT01125566|Experimental|Arm A: BIBW 2992 with vinorelbine|patients receive BIBW 2992 tablets once daily combined with weekly intravenous infusion of vinorelbine
11532624|NCT01125553|Experimental|IDegAsp B|
11532625|NCT01125553|Experimental|IDegAsp F|
11532626|NCT01125527|Active Comparator|Arm 1|
11532627|NCT01125527|Active Comparator|Arm 2|
11532628|NCT01125514|Experimental|Furosemide 60 mg|Treatment period 1 (Day 1 to Day 7): All eligible patients received 60 mg furosemide, 150 mg placebo of aliskiren, and 300 mg placebo aliskiren once daily.
11532629|NCT01125514|Experimental|Furosemide 60 mg + Aliskiren 150 mg|Treatment Period 2 (Day 8 to day 17): Patients received 60 mg furosemide, 150 mg aliskiren and 300 mg placebo once daily.
11532630|NCT01125514|Experimental|Furosemide 60 mg + Aliskiren 300 mg|Treatment Period 3 (Day 18 to day 27): Patients received 60 mg furosemide, 300 mg aliskiren and 150 mg placebo of aliskiren once daily.
11532631|NCT01125501|Active Comparator|Protandim|one capsule a day for 30 days of protandim given, followed by a wash out period.
11532632|NCT01125501|Placebo Comparator|Placebo|one capsule a day for 30 days will be given followed by a washout period.
11532633|NCT01125488|Experimental|LNG-IUS|LNG-IUS insertion during conservative surgery and GnRH agonist 6 doses.
11532634|NCT01125488|Active Comparator|GnRH agonist|The second group of patients receive GnRH agonist (triptorelin 3.75 mg, sc q28day) alone for 24 weeks.
11532635|NCT01125462||Subjects previously treated with Gonal-f|Subjects who had undergone at least one treatment cycle with Gonal-f powder and solvent for solution for injection within the past 12 months (equivalent to 75 IU/ml, 450 IU/0.75ml or 1050 IU/1.75 ml)
11532636|NCT01125462||Subjects previously treated with urine-derived FSH|Subjects which had undergone at least one treatment cycle with urine-derived FSH therapy with vials within the past 12 months
11532637|NCT01125449|Other|Intravenous IVC Intervention|Intravenous ascorbic acid, 1.5g/kg at an infusion rate not to exceed 250mg/min.
11532638|NCT01125436|Experimental|Cholecalciferol|Nutritional supplement
11532639|NCT01125436|Placebo Comparator|placebo|
11532640|NCT01125423|Active Comparator|Subjects with Fibromyalgia|Subjects with Fibromyalgia have skin biopsies taken from the dominant trapezius and palm. Subjects will receive an eight week supply of milnacipran to be titrated 12.5 mg x one day, 12.5 mg twice a day x 2 days, 25mg twice daily for 4 days, then 50mg twice a day x 7 weeks.
11532641|NCT01125423|Other|Control subjects without Fibromyalgia|Subjects without Fibromyalgia have skin biopsies taken from the dominant trapezius and palm.
11532642|NCT01125410|Experimental|Dequalinium chloride 10mg|
11532643|NCT01125410|Active Comparator|clindamycin vaginal cream 2%|
11532644|NCT01125397|Experimental|Behavioral Intervention|
11532645|NCT01125397|No Intervention|Control|These participants will be randomized to receive no behavioral intervention prior to bariatric surgery.
11532646|NCT01125384|No Intervention|nurse swabbing|
11532647|NCT01125384|Experimental|"accurate swabbing by a physician"|
11532648|NCT01125371|Experimental|Computerized Brief Alcohol Intervention + IVR|Computer-delivered brief alcohol intervention (CBI) with booster phone calls delivered by IVR+ text messages (TM)
11532649|NCT01125371|Active Comparator|Computerized Brief Alcohol Intervention|Computerized Brief Alcohol Intervention only (CBI)
11532650|NCT01125371|Placebo Comparator|Attention Control|Attention control
11532651|NCT01125358|Experimental|10 mg LY2140023|
11532652|NCT01125358|Experimental|80 mg LY2140023|
11532653|NCT01125358|Experimental|160 mg LY2140023|
11532654|NCT01125358|Placebo Comparator|Placebo|
11532655|NCT01125345|Experimental|Hydrophobic IOL|The single piece Acrysof hydrophobic IOL model- SN60WF
11532656|NCT01125345|Active Comparator|Hydrophilic IOL|Rayner Intraocular Lenses Ltd., England, Model C-flex 570C
11532657|NCT01125345|Active Comparator|Hydrophillic IOL|Bausch and Lomb ltd, model Akreos Adapt
11532658|NCT01125332|Placebo Comparator|group gel KY|
11532659|NCT01125332|Experimental|group gel lidocaine|
11532660|NCT01125319|Other|patients Hemophagocytic lymphohisticytosis group|
11532661|NCT01125319|Other|group control patient|
11532662|NCT01125319|Other|healthy control group|
11532663|NCT01125293|Experimental|single arm|Combination of everolimus & rituximab with bortezomib in patients with relapsed or refractory WM
11532664|NCT01125280|Experimental|SBO score application|Acute strangulated SBO patients will receive a severity score at emergency admission. According to the score, they will be managed either conservatively or surgically. During surgery, the need of small bowel resection will be evaluated. The endpoint will be to correlate the type and success of treatment with the score in order to validate this new tool in SBO assessment.
11534222|NCT01114893|Experimental|Travoprost Group C|Travoprost Group C
11532665|NCT01125267|Experimental|multifamily group-adherence|multifamily group treatment with a focus on improving adherence to antipsychotic medication
11532666|NCT01125267|Active Comparator|multifamily group-standard|multifamily group focused on problems identified by group participants
11532667|NCT01125267|No Intervention|treatment as usual|
11532668|NCT01125254|Experimental|Amlodipine|amlodipine 5mg qd
11532669|NCT01125254|Placebo Comparator|Controls|placebo
11532670|NCT01125241|Experimental|Wuling capsule|
11532671|NCT01125241|Placebo Comparator|Placebo|
11532672|NCT01125228||Arm 1|Zidovudine 200mg by mouth every 4hr
11532673|NCT01125228||Arm 2|-Zidovudine 200mg by mouth every 4hr -Alpha Interferon 1 million units once a day, escalating
11532674|NCT01125228||Arm 3|-Alpha Interferon 1 million units once a day, escalating
11532675|NCT01125215|Placebo Comparator|Placebo|Matched gel base of capsaicin nanoparticle
11532676|NCT01125215|Experimental|Capsaicin|0.075% capsaicin nanoparticle gel
11532677|NCT01125202|Experimental|SCT-based behavioral intervention|Intervention participants continue to receive routine dialysis care, as well as a 16 week dietary counseling intervention based on Social Cognitive Theory. Dietary counseling is paired with Personal Digital Assistant-based dietary self-monitoring.
11532678|NCT01125202|Active Comparator|Attention control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
11532679|NCT01125189|Experimental|Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg)|
11532680|NCT01125189|Experimental|Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg)|
11532681|NCT01125189|Placebo Comparator|Placebo plus peg-interferon alfa-2a and ribavirin|
11532682|NCT01125176|Experimental|All subjects|In Cycle -1, even numbered patients will receive oral lenalidomide daily on days 1-14 and then no treatment on days 15-28. In Cycle -1, odd numbered patients will receive oral thalidomide daily days 1-14 followed by no treatment on days 15-28. Starting with cycle 1, all patients will alternate daily thalidomide (every odd day) with daily lenalidomide (every even day) for days 1-28. Rituximab will be given on days 1, 8, 15, and 22 starting with Cycle 1, and then again every 6th cycle thereafter (cycles 7, 13, 19, etc.)
11532683|NCT01125163|Active Comparator|multivitamin with iron|daily oral multivitamin providing 2mg/kg of iron
11532684|NCT01125163|Placebo Comparator|multivitamin without iron|daily oral multivitamin without iron
11532685|NCT01125137|Experimental|Biopsy|
11532686|NCT01125124|Active Comparator|Silver Nitrate 1|Patients submitted to pleurodesis via pleural catheter using 30ml of 0.5% silver nitrate solution.
11532687|NCT01125124|Experimental|Silver Nitrate 2|Patients submitted to instilation of 30ml 0.3% silver nitrate solution via pleural catheter.
11532688|NCT01125124|Experimental|Silver Nitrate 3|Patients submitted to instilation of 60ml 0.3% silver nitrate solution via pleural catheter.
11532689|NCT01125111||robotic surgery group|
11532690|NCT01125111||laparoscopic surgery group|
11532691|NCT01125098||PRO-CT group: Experimental|COPD patients in the PRO-CT group will continue or discontinue antibiotic therapy depending on PRO-CT values.
11532692|NCT01125098||Standard group: No intervention|COPD patients in the Standard group will continue antibiotic therapy for 10 days according to guidelines recommended treatment plan in case of COPD exacerbations.
11532693|NCT01125085|Other|131I-L19SIP RIT in Combination with WBRT|131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)
11532694|NCT01125072||entire cohort|patients presenting to the emergency department with chest pain and being admitted to rule out acute coronary syndrome
11532695|NCT01125059|Active Comparator|Methadone Group|0.2 mg/kg IV methadone
11532696|NCT01125059|Placebo Comparator|Placebo Group|5 mL saline bolus
11532697|NCT01125046|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months. Patients may then receive bevacizumab IV every 3 weeks for up to 12 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
11532698|NCT01125033|Experimental|Vitamin C & Vitamin E.|The patients in this arm received one tablet of vitamin C (200 mg) and one capsule of vitamin E (400 mg) daily for 8 weeks
11532699|NCT01125033|Experimental|Vitamin C & Placebo|The patients in this arm received one tablet of vitamin C (200 mg) and one placebo capsule daily for 8 weeks.
11532700|NCT01125033|Experimental|Vitamin E & Placebo|The patients in this arm received one capsule of vitamin E (400 mg) and one placebo tablet daily for 8 weeks.
11532701|NCT01125033|Placebo Comparator|Double Placebo|The patients in this arm received one placebo capsule and one placebo tablet daily for 8 weeks.
11532702|NCT01125020|Active Comparator|gemcitabine and oxaliplatin|
11532703|NCT01125020|Active Comparator|doxorubicin, 5-Fu and cisplatin|
11532704|NCT01125007|Active Comparator|toothbrush|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
11532705|NCT01125007|Experimental|medium toothbrush|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
11532706|NCT01124994|Active Comparator|Mucosectomy|Patients in this arm are undergoing mucosctomy after previous confocal laser endomicroscopy.
11532707|NCT01124981|Placebo Comparator|Albumin|
11532708|NCT01124981|Experimental|Haemocomplettan® P|
11532709|NCT01124968|Experimental|eConsulta|Those patients who are offered to use the eConsulta, a web where they can virtually consult with their primary care doctor or nurse.
11532710|NCT01124955|Active Comparator|Intervention Group|Patients receive 5 sessions of real acupuncture. The technique of acupuncture used in this study is Yamamoto New Scalp Acupuncture called YNSA.
11532711|NCT01124955|Placebo Comparator|Non-penetrating acupuncture|The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
11532712|NCT01124942|Experimental|MGuard|MGuard net protective stent, investigational device
11532713|NCT01124942|Active Comparator|BMS plus thrombectomy|Bare-metal stent plus manual thrombectomy device
11532714|NCT01124929|Active Comparator|Arm 1: Category I treatment for 6 months|Anti-tuberculosis drugs
11532715|NCT01124929|Active Comparator|Arm 2: Category I treatment for 9 months|Anti-tuberculosis drugs,
11532716|NCT01124916|Active Comparator|Laparoscopic Abdominal Sacrocolpopexy (LASC)|Women assigned to this cohort will receive standard laparoscopic abdominal sacrocolpopexy (LASC)
11532717|NCT01124916|Experimental|Robotic Assisted Laparoscopic (RASC)|Women assigned to this cohort will receive robotic assisted laparoscopic abdominal sacrocolpopexy (RASC)
11532718|NCT01124903|Experimental|Dehydration|Multiple measures of hydration status were made when subjects were normally hydrated (euhydrated) and when dehydrated. The diagnostic usefulness of the measures was determined.
11532719|NCT01124890|Placebo Comparator|Conservative|no transfer for early percutaneous coronary intervention after thrombolysis
11532720|NCT01124890|Active Comparator|early PCI|transfer for early percutaneous coronary intervention after thrombolysis
11532721|NCT01124877|Other|Open|
11532722|NCT01124864|Experimental|EGFR mutant patients|Patients with EGFR activating mutation tumors (Note: These patients must have progressed on one prior EGFR TKI containing regimen unless they have documented T790M activating mutation). Patients received AUY922 at 70 mg/m^2 weekly infusions.
11532723|NCT01124864|Experimental|Kras mutant patients|Patients with KRAS mutant tumors. Patients received AUY922 at 70 mg/m^2 weekly infusions.
11532724|NCT01124864|Experimental|EGFR and Kras wild type patients|Patients exhibiting both mutations were stratified to the KRAS mutation stratum. Patients received AUY922 at 70 mg/m^2 weekly infusions.
11532725|NCT01124864|Experimental|Patients with EML4-ALK translocation|Patients with NSCLC who have tumors with an inversion in the short arm of chromosome 2 that results in the fusion of the echinoderm microtubule-associated protein-like 4 (EML4) gene with the ALK gene leading to the production of an EML4-ALK fusion tyrosine kinase. ALK is a transmembrane protein, which has a kinase domain and is not usually expressed in the lung. EML4 mediate ligand-independent dimerization, and therefore constitutive activity of the ALK tyrosine kinase domain. Patients received AUY922 at 70 mg/m^2 weekly infusions.
11532726|NCT01124864|Experimental|Modified EGFR mutant patients|The modified EGFR stratum was defined as patients less heavily pretreated who had received one or two lines of prior therapy, with a documented response to a EGFR tyrosine kinase inhibitor (TKI) (complete response (CR), partial response (PR) or stable disease (SD) for ≥ 6 months), unless the patient had de novo resistance to EGFR TKI. Patients received AUY922 at 70 mg/m^2 weekly infusions.
11532727|NCT01124851|Experimental|Arm 1|ABT-652 Dose 1 vs placebo capsules administered orally once daily for 7 days
11532728|NCT01124851|Experimental|Arm 2|ABT-652 Dose 2 vs placebo capsules administered orally once daily for 7 days
11532729|NCT01124851|Experimental|Arm 3|ABT-652 Dose 3 vs placebo capsules administered orally once daily for 7 days
11532730|NCT01124838|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection at Baseline followed by every other week (eow) dosing starting at Week 1 for up to 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 10 to 35 mg/day at study entry followed by a protocol-defined mandatory taper until Week 19.
11532731|NCT01124838|Experimental|Adalimumab|Participants received adalimumab 80 mg subcutaneous loading dose at Baseline followed by 40 mg doses eow starting at Week 1 for a maximum of 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper until Week 19.
11532732|NCT01124825|Active Comparator|IGel|Subjects will receive an IGel(TM) airway induction and maintenance of positive pressure ventilation
11532733|NCT01124825|Active Comparator|King Airway|Subject will receive a KING-LTS-D(TM) for induction and maintenance of positive pressure ventilation
11532734|NCT01124812|Experimental|131I-L19SIP|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy: Treatment dose of 131I-L19SIP RIT is titrated in cohorts of 3 patients.
11532735|NCT01124799|Experimental|001|TMC435 one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening for 9 days
11532736|NCT01124799|Placebo Comparator|002|Placebo placebo dose in the morning at noon and in the evening for 9 days
11532737|NCT01124799|Active Comparator|003|Ciprofloxacin one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg for 9 days
11532738|NCT01124786|Experimental|CO-1.01|
11532739|NCT01124786|Active Comparator|gemcitabine|
11532740|NCT01124773||Previous HT use and cognition|Women who were aged 50-54 at the time of randomization into the WHI hormone trials.
11532741|NCT01124760|Experimental|1|AZD9742
11532742|NCT01124747|Experimental|ASP1585 and 14C-Labeled ASP1585|
11532743|NCT01124734|Experimental|Course 1 Cycle 1 and Cycle 2|"Course 1 Cycle 1: Participants will be given high-dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals.
~Course 1 Cycle 2: Participants will be given high-dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals. On the day after discharge, patients will be given oral temozolomide at 75 mg/m2 daily for 21 days."
11532744|NCT01124721|Experimental|Cogmed cognitive training|Computerized working memory, attention and cognitive tasks
11532745|NCT01124721|Active Comparator|Active placebo|Cognitive training, however the training does not increase in difficulty, or does so to a minimal degree.
11532746|NCT01124708|Placebo Comparator|Placebo|Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
11532747|NCT01124708|Active Comparator|TC-5619|TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, one capsule once daily p.o.
11532748|NCT01124656|Experimental|Pioglitazone-Azilsartan QD|(Dependent on glycosylated hemoglobin level at screening)
11532749|NCT01124643|Experimental|Replagal 0.2 mg/kg EOW|Intravenous, 0.2mg/kg EOW
11532750|NCT01124630|Experimental|CS-1008 with FOLFIRI|Experimental drug CS-1008 in combination with FOLFIRI
11533110|NCT01122108|Active Comparator|Colesevelam HCl|Colesevelam HCl, 4 grams
11532751|NCT01124617|Experimental|Tapentadol|Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
11532752|NCT01124617|Placebo Comparator|Placebo|Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
11532753|NCT01124604|Experimental|Tapentadol Hydrochloride|
11532754|NCT01124604|Placebo Comparator|Placebo|
11532755|NCT01124591|Experimental|Treatment|Assessment and brief intervention
11532756|NCT01124578||Control|Existing used daily change-out device
11532757|NCT01124578||Egret|Extended Use Catheter w/BIOSAFE
11532758|NCT01124565|Experimental|RT001|RT001 (Botulinum Toxin Type A) Topical Gel
11532759|NCT01124552|Experimental|RT001 Botulinum toxin Type A (Dose A)|RT001 (Botulinum toxin Type A)
11532760|NCT01124552|Experimental|RT001 Botulinum toxin type A (Dose B)|RT001 (Botulinum Toxin Type A)
11532761|NCT01124552|Other|Dose C|Vehicle Control
11532762|NCT01124552|Placebo Comparator|Dose D|Placebo
11532763|NCT01124539|Experimental|AR-67|
11532764|NCT01124526|Experimental|Rituximab, Fludarabine, ciclophosphamide|"Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:
~RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2)"
11532765|NCT01124513|Active Comparator|Digital Camera|Digital camera images will be taken of a a 2cm^2 area of sun protected skin.
11532766|NCT01124513|Active Comparator|Spectrophotometer|The probe of the protable reflectance spectrophotometer is lightly applied to the sufance of the skin and a reading is taken.
11532767|NCT01124513|Active Comparator|Videodermoscopy|The instrument is put in contact with sun protected skin and an image is taken of a 2 cm^2 area.
11532768|NCT01124500|Experimental|methylphenidate via transdermal patch compared to placebo|The proposed study is a within-subject, cross-over, randomized and double-blinded pilot trial, designed to evaluate the efficacy and feasibility of sustained-release, long-acting methylphenidate via transdermal patch compared to placebo in fatigued patients with Head and Neck malignancies
11532769|NCT01124487|Experimental|palm olein|
11532770|NCT01124487|Experimental|olive oil|
11532771|NCT01124487|Experimental|lard|
11532772|NCT01124474|No Intervention|Standard fluid management|Standard intraoperative fluid management as determined by usual monitoring and decision making applied by anesthesiology team
11532773|NCT01124474|Other|Vigileo model number MHM1|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV>12%.
11532774|NCT01124461||Brain Tumor|Brain neoplasms, malignant
11532775|NCT01124448|Experimental|Lactobacillus salivarius PS2|Women with mastitis (n=25) receiving Lactobacillus salivarius PS2 (9.5 log per day, 21 days)
11532776|NCT01124448|Active Comparator|Lactobacillus salivarius PS2B|Lactating women without mastitis (n=15)
11532777|NCT01124422|Experimental|fluticasone propionate/salmeterol DISKUS 250/50 + tiotropium|This is the active DISKUS (that is, containing fluticasone propionate/salmeterol combination) + open-label tiotropium
11532778|NCT01124422|Placebo Comparator|placebo DISKUS + tiotropium|This is the DISKUS and excipient minus the active ingredient (which is fluticasone propionate/salmeterol combination) + open-label tiotropium
11532779|NCT01124409|Active Comparator|3DCRT with EPID|this patients randomised to this arm will be planned by 3DCRT and during treatment setup error will be identified and corrected by weekly EPID if error >3mm.Weekly CBCT will be done for this arm to note the setup error but will not be corrected.
11532780|NCT01124409|Active Comparator|IGRT with CBCT|The patients randomised to this arm will be planned by 3DCRT and set up error during RT will be verified by CBCT and error corrected if >3mm.Weekly EPID will be done for setup error documentation but no correction based on EPID in this arm.
11532781|NCT01124396||30 ug|30 ug
11532782|NCT01124396||60 ug|60 ug
11532783|NCT01124396||Placebo|Placebo
11532784|NCT01124383|Active Comparator|General anesthesia|
11532785|NCT01124383|Active Comparator|Local anesthesia with sedation|
11532786|NCT01124370|Experimental|Treatment|All enrolled subjects will undergo attempted system implantation and therapeutic assessment. Subjects' baseline assessment values will serve as control parameters for the therapy evaluation.
11532787|NCT01124357|Active Comparator|novasure|Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
11532788|NCT01124357|Other|thermachoice|ThermachoiceTM III thermal balloon ablation
11532789|NCT01124344|Active Comparator|Placebo or BMS-866949 (3 mg)|Panel 1: Healthy Male Subjects
11532790|NCT01124344|Active Comparator|Placebo or BMS-866949 (10 mg)|Panel 2: Healthy Male Subjects
11532791|NCT01124344|Active Comparator|Placebo or BMS-866949 (30 mg)|Panel 3: Healthy Male Subjects
11532792|NCT01124344|Active Comparator|Placebo or BMS-866949 (45 mg)|Panel 4: Healthy Male Subjects
11532793|NCT01124344|Active Comparator|Placebo or BMS-866949 (60 mg)|Panel 5: Healthy Male Subjects
11532794|NCT01124344|Active Comparator|Placebo or BMS-866949 (90 mg)|Panel 6: Healthy Male Subjects
11532795|NCT01124344|Active Comparator|Placebo or BMS-866949 (3 - 60 mg)|Panel 7: Females
11532796|NCT01124331|Experimental|High Oxygen saturation|Higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter, for durations as specified in each trial protocol.
11532797|NCT01124331|Active Comparator|Lower oxygen saturation|Lower (SpO2 85-89%) functional oxygen saturation target range from birth, or soon thereafter, for durations as specified in each trial protocol.
11532798|NCT01124318|Active Comparator|Lactofiltrum|
11532799|NCT01124318|Placebo Comparator|Placebo|
11532800|NCT01124305|Active Comparator|Traditional Instrumentation|Control group: Cases performed with traditional surgical instruments
11532801|NCT01124305|Experimental|Customized Patient Instrumentation|Experimental group: Cases performed with custom instruments specifically made for each patient using pre-op CT scans.
11532802|NCT01124292|Experimental|Able-bodied subject with piercing|Able-bodied subjects who already have tongue piercing.
11533199|NCT01121419||Neuroblastoma|
11532803|NCT01124292|Experimental|Able-bodied subject without piercing|Able-bodied subjects who willing to receive a tongue piercing for this study.
11532804|NCT01124292|Experimental|Subjects with spinal cord injury|Persons with mobility limitations requiring power wheel chair, able to move tongue, able to follow simple commands, and have some experience with computers. All participants willingly received a mid-line tongue piercing.
11532805|NCT01124279|Experimental|AMG 853|
11532806|NCT01124266|Experimental|endoscopist only|
11532807|NCT01124266|Experimental|nurse participation|
11532808|NCT01124253|Experimental|NP plus recombinant human endostatin|
11532809|NCT01124253|No Intervention|vinorelbine plus cisplatin|
11532810|NCT01124227|Sham Comparator|Standard Care|
11532811|NCT01124227|Active Comparator|2 Icodextrin PD changes / day|
11532812|NCT01124227|Active Comparator|1 Icodextrin PD change/day|
11532813|NCT01124214|No Intervention|High Resolution endoscopy (HRE)|Standard of care, high resolution endoscopy surveillance/ evaluation of BE and or IEN
11532814|NCT01124214|Active Comparator|Endomicroscopy (EM)|Standard of care, high resolution endoscopy surveillance/ evaluation of BE and or IEN and endomicroscopy esophageal evaluation
11532815|NCT01124201|Experimental|Stabilization group|In the Segmental Stabilization group exercises focused on the transversus abdominis and lumbar multifidus muscles.
11532816|NCT01124201|Experimental|Strengthening group|In the Superficial Strengthening group, exercises focused on the rectus abdominis, abdominus obliquus internus, abdominus obliquus externus and erector spinae muscles.
11532817|NCT01124201|Experimental|Stretching group|Stretching group: erector spinae, posterior connective tissues and ischiotibials muscles
11532818|NCT01124188|Experimental|Study Intervention Arm|Higher-dose venlafaxine and Problem Solving Therapy for Depression and Pain (PST-DP)
11532819|NCT01124188|Active Comparator|Active Control|Higher-dose venlafaxine and supportive management (SM)
11532820|NCT01124175|Experimental|Generic Test Product|Losartan 100 mg Tablets
11532821|NCT01124175|Active Comparator|Reference Listed Drug|Cozaar® 100 mg Tablets
11532822|NCT01124162|Experimental|Generic Test Product|Losartan 100mg Tablets
11532823|NCT01124162|Active Comparator|Reference Listed Drug|Cozaar® 100 mg Tablets
11532824|NCT01124149|Experimental|MMX mesalamine/ mesalazine|
11532825|NCT01124136|Experimental|Neurostimulation + Medication management|Investigational nerve stimulator device implanted to heart plus standard medication therapy.
11532826|NCT01124136|Other|Standard of Care (Control)|Standard of Care treatment is medication management only. Heart failure medications control symptoms and comorbidities, i.e. blood thinners, lipid lowering, and diuretics, and manage heart function, i.e. heart rhythm, rate, and pumping strength.
11532827|NCT01124123|Experimental|Bilastine 20 mg|Single dose 20 mg bilastine oral tablet. Test drug
11532828|NCT01124123|Active Comparator|Bilastine 10 mg|Single dose 10 mg Bilastine endovenous. Control drug
11532829|NCT01124110|Other|1-800-QUIT-NOW Telephone Hotline|The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
11532830|NCT01124110|Experimental|Tobacco Tactics Intervention|This intervention contains a website, medications, and nurse counseling.
11532831|NCT01124097|Experimental|Eslicarbazepine acetate 800 mg once daily (QD)|
11532832|NCT01124097|Experimental|Eslicarbazepine acetate 1200 mg QD|
11532833|NCT01124097|Experimental|Eslicarbazepine acetate 1600 mg QD|
11532834|NCT01124097|Placebo Comparator|Placebo|
11532835|NCT01124084||Health Care Providers|
11532836|NCT01124071|Active Comparator|Korean Diet|Provision of 2 Korean meals per day, 6 days per week
11532837|NCT01124071|Active Comparator|Western Diet|Lifestyle counseling, dietary advice, grocery vouchers
11532838|NCT01124058|Experimental|Loading|1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose
11532839|NCT01124058|Active Comparator|Maintenance|Re-start same dose as previously stable on
11532840|NCT01124045|Experimental|DUREZOL|Difluprednate ophthalmic emulsion, 0.05%, 1 drop in the study eye at the end of surgery (Day 0) and 4 times a day beginning on the day after surgery (Day 1) for 14 days, followed by a tapering period of 14 days, dependent upon the Investigator's determination of adequate response to treatment
11532841|NCT01124045|Active Comparator|PRED FORTE|Prednisolone acetate ophthalmic suspension, 1.0%, 1 drop in the study eye at the end of surgery (Day 0) and 4 times a day beginning on the day after surgery (Day 1) for 14 days, followed by a tapering period of 14 days, dependent upon the Investigator's determination of adequate response to treatment
11532842|NCT01124032|Experimental|ADHD adults|
11532843|NCT01124032|Experimental|healthy adults|
11532844|NCT01124019||Random Sample|A random sample of 600 women undergoing screening mammography
11532845|NCT01124019||BIRADS score of 4|An additional 600 women determined to have a Breast Imaging Reporting and Data System (BIRADS) score of 4 as determined by final mammogram results.
11532846|NCT01124006|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
11532847|NCT01124006|Placebo Comparator|Water for injection|Sterile water for injection
11532848|NCT01123993|No Intervention|Lifestyle counselling|
11532849|NCT01123980|Experimental|BIAsp 30|0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride
11532973|NCT01122927|Experimental|Phase 1 and Phase 2|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
11532850|NCT01123980|Active Comparator|Insulin glargine|0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride
11532851|NCT01123967|Experimental|PRO+NRT+TC|Proactive outreach (mailed invitation letter followed by telephone outreach) combined with free nicotine replacement therapy (NRT) and telephone counseling (PRO+NRT+TC)to usual care (UC)
11532852|NCT01123967|Active Comparator|Usual Care (UC)|Usual (standard) care - Smoking cessation products: patch, gum, lozenge, inhaler and nasal spray
11532853|NCT01123954|Other|Arm 1|
11532854|NCT01123941|Experimental|NVGH Vi-CRM197 conjugate vaccine|
11532855|NCT01123941|Active Comparator|Vi-polysaccharide vaccine|
11532856|NCT01123928|Experimental|Counseling|Subjects will be asked to watch a 5-10 min video and participate in a 10-15 min pre-operative counseling session with a trained nurse. Subjects will also participate in a 5 min post-operative counseling session.
11532857|NCT01123928|No Intervention|Non-counseling|
11532858|NCT01123915|Experimental|Opal-HIV-Gag(c)|Opal-HIV-Gag(c) administered ex vivo to separated white blood cells on 4 occasions at 4 weekly intervals.
11532859|NCT01123915|Placebo Comparator|Diluent|Administered ex vivo to separated white blood cells on 4 occasions at 4 weekly intervals.
11532860|NCT01123902|Experimental|hand-held fan|
11532861|NCT01123902|Placebo Comparator|wristband|
11532862|NCT01123889|Active Comparator|control|corticosteroid injection into subacromial space
11532863|NCT01123889|Experimental|experimental|patients will receive an injection of platelet rich plasma into the subacromial space
11532864|NCT01123876|Experimental|Veliparib and FOLFIRI|Veliparib in combination with FOLFIRI regimen.
11532865|NCT01123863||Patient Group|"This study will administer Brigance Preschool Screen -II to 3 year old children with SCD followed at St. Jude Children's Research Hospital
~Intervention: Brigance Preschool Screen -II"
11532866|NCT01123863||control group|"The control group will consist of 3-year-old children attending day care in the Memphis area and serve as a population that come from a similar socioeconomic background as the SCD patient population.
~Intervention: Brigance Preschool Screen -II"
11532867|NCT01123850|Active Comparator|Single ARM - Copios Bone Filler|All subjects will undergo an instrumented, pedicle screw PLF procedure. Autograft or other interbody devices identified by the surgeon to be in the best interest of the patient may be used. Enrolled patients will receive CopiOs BVF sponge soaked with bone marrow aspirate on one side and autologous bone on the other side. All patients will receive both CopiOs BVF and autologous bone. Patients will serve as self-controls in this counter-balanced study.
11532868|NCT01123837|Active Comparator|D5LR|In the treatment group, a 250cc bolus over 2 hrs of D5LR will be initiated prior to the end of surgery and continued in PACU.Blood glucose will be measured at 3 different timepoints using a point of care testing device (Accu-Chek). We will be measuring changes in blood glucose levels associated with PONV and the type and number of rescue medicines given at 30, 60, and 120 minutes after anesthesia and the first postoperative morning
11532869|NCT01123837|Active Comparator|lactated ringers|In the control group, a 250cc bolus over 2 hrs of LR will be initiated prior to the end of surgery and continued in PACU. Blood glucose will be measured at 3 different timepoints using a point of care testing device (Accu-Chek). We will be measuring changes in blood glucose levels associated with PONV and the type and number of rescue medicines given at 30, 60, and 120 minutes after anesthesia and the first postoperative morning.
11532870|NCT01123824|Experimental|Sequence clopidogrel 300/75 mg - 600/150 mg|"Period 1:
~Day 1: clopidogrel, 300 mg loading dose + placebo
~Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily
~Period 2:
~Day 1: clopidogrel, 600 mg loading dose
~Day 2 to Day 5: clopidogrel, 150 mg, once daily
~Each intake is at around 8:00 AM fasted for at least 10 hours"
11532871|NCT01123824|Experimental|Sequence clopidogrel 600/150 mg - 300/75 mg|"Period 1:
~Day 1: clopidogrel, 600 mg loading dose
~Day 2 to Day 5: clopidogrel, 150 mg, once daily
~Period 2:
~Day 1: clopidogrel, 300 mg loading dose + placebo
~Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily
~Each intake is at around 8:00 AM fasted for at least 10 hours"
11532872|NCT01123811|Experimental|Cetuximab IF|Treatment with combination of Cetuximab and Irinotecan 5-FU
11532873|NCT01123798||Stable controls|Uninjured soldiers to provide normative data for stable physiological status
11532874|NCT01123798||Critical controls|"Critically injured soldiers with no lower extremity traumatic injuries (excepting skin abrasions and small/superficial fragmentation wounds) to provide normative data for the shock physiological status."
11532875|NCT01123798||Lower extremity trauma|Soldiers with severe traumatic lower extremity injuries in stable and shock physiologic status. This is the investigational cohort.
11532876|NCT01123785|Placebo Comparator|Control|Matched vehicle-control
11532877|NCT01123785|Experimental|INO-8875|Adenosine agonist eye drop
11532878|NCT01123772|Placebo Comparator|Control|Vehicle control
11532879|NCT01123772|Experimental|INO-8875|Active drug
11532880|NCT01123759|Active Comparator|Tilapia|Subjects are fed 6 oz tilapia once a week for 3 months
11532881|NCT01123759|Active Comparator|Salmon|Subjects fed 6 oz salmon once a week for 3 months
11532882|NCT01123707|Experimental|Aripiprazole/Escitalopram combination therapy|
11532883|NCT01123694||Xeroderma Pigmentosum patients|Xeroderma Pigmentosum patients who attend Camp Sundown, a camp for children with this condition.
11532884|NCT01123681||Ventilator associated pneumonia|
11532885|NCT01123681||No pneumonia|
11532886|NCT01123668||ADHD and non-ADHD Smokers|Those that are defined as regular smokers (10 cigarettes/day or Carbon Monoxide reading of 10 ppm). The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
11532887|NCT01123655|Experimental|Arm 1|"The study will have 3 treatment arms each with 10-12 patients who have demonstrated T cell immunity to CII and have an in vitro response to APL A12 at the screening visit. Patients will be randomized to one of the 2 treatment arms (30 micrograms APL A12 or placebo). Each of the 2 treatments will be given for 16 weeks.
~Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate.
~Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate."
11533014|NCT01122680|Experimental|Treatment C|patients inhale 2 puffs (dose of 5 mcg) once daily in the evening via Respimat inhaler
11534282|NCT01114542|Active Comparator|IGlar 0.4 U/kg|
11532888|NCT01123655|Experimental|Arm 2|"The next group will receive a higher dose (50 micrograms) and/or placebo (Block 2).
~Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate."
11532889|NCT01123655|Experimental|Arm 3|"Block 3 (Arm 3) will include placebo and both doses of APL/A12 to ensure 10-12 patients are enrolled in each arm ( total of approximately 32 subjects) so we will have 24 subjects who complete the 16 weeks of study treatment. Arms 2 and 3 will run simultaneously.
~Intervention: Drug treatment will be stopped or interrupted if indicated."
11532890|NCT01123642||Group 1|Operation Enduring Freedom and Operation Iraqi Freedom Veterans
11532891|NCT01123616|Active Comparator|non-triclosan-coated|Two arms are separeted by computer randomization at abdomial wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
11532892|NCT01123616|Active Comparator|triclosan coated suture|Two arms are separeted by computer randomization at abdomial wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
11532893|NCT01123590||Thymoma|Patients with thymoma
11532894|NCT01123590||Control|Normal controls
11532895|NCT01123577|Experimental|Intervention|
11532896|NCT01123577|No Intervention|Control|Participants receive usual care by providers.
11532897|NCT01123564|Experimental|Lucentis (ranibizumab)|
11532898|NCT01123564|Active Comparator|Laser|
11532899|NCT01123551|Experimental|Nebulized Morphine|After randomization, patients will receive 10 mg of morphine (1ml) diluted in 4 ml normal saline and nebulized with 6 l/mn during 10 min. Nebulization will be repeated systematically 3 times every twenty minutes unless the patient pain was resolved (VAPS 30%). In addition, patients receive a bolus of IV placebo(5 ml normal saline . IV placebo (2 ml) will be repeated every 10 minutes if the objective of analgesia was not reached .
11532900|NCT01123551|Active Comparator|Intravenous morphine|After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS >30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS >30%).
11532901|NCT01123538|Other|Natural progesterone|Combined menopausal treatment containing natural progesterone
11532902|NCT01123538|Active Comparator|Chlormadinone acetate|Combined menopausal treatment containing chlormadinone acetate
11532903|NCT01123525|Experimental|Adenosine cardioplegia|Adenosine cardioplegia
11532904|NCT01123525|Active Comparator|Control|Standard hyperkalemic cardioplegia
11532905|NCT01123512|Experimental|Kiva VCF Treatment System|
11532906|NCT01123512|Active Comparator|Balloon Kyphoplasty|
11532907|NCT01123499||Healthy Volunteers|Any healthy volunteers that are eligible to donate blood.
11532908|NCT01123486|Experimental|hydromorphone|open label single arm pharmacokinetic-pharmacodynamic study
11532909|NCT01123473|Experimental|Lapatinib|Chemotherapy + lapatinib
11532910|NCT01123473|Placebo Comparator|Placebo|Chemotherapy + placebo
11532911|NCT01123447|Active Comparator|Surgery|Isolated ulnar shaft fractures will be treated with open reduction and internal fixation using a limited contact dynamic compression (LC-DC) plate with screws. These will remain at the fracture site for the lifetime of the patient.
11532912|NCT01123447|Active Comparator|Short arm cast|Those individuals randomized to the non-operative treatment group will be treated with a closed reduction and short-arm (below-elbow) cast.
11532913|NCT01123434||1|Localised with one of any high recurrence risk factors, or locally advanced Chinese prostate cancer patients confirmed histologically through radical prostatectomy either with laparoscopy or laparotomy within 1 month after surgery. Before the patient recruitment, the investigator has decided to prescribe immediate postoperative adjuvant hormonal treatment to the patient according to the Chinese routine practice.
11532914|NCT01123421||With osteoporotic fracture|Approximately 100 postmenopausal women that have been enrolled in a population-based case-control study that have experienced a clinically-diagnosed fracture of thoracolumbar spine or distal forearm due to minimal or moderate trauma based on review on their inpatient and outpatient medical records will be enrolled.
11532915|NCT01123421||Without osteoporotic fracture|Approximately 100 control women will have no history of a prior spine, hip, or wrist fracture.
11532916|NCT01123408|Experimental|clozapine|During the first 6 weeks clozapine was gradually increased to 500 mg/day and then continued. For the next period, it could vary from 200-800 mg/day;
11532917|NCT01123408|Experimental|Olanzapine|During the first 6 weeks olanzapine was increased to 20 mg and remained fixed for until the end of six week. During the last 6 weeks olanzapine could vary from 10 to 30 mg/day
11532918|NCT01123408|Active Comparator|Haloperidol|During the first 6 weeks haloperidol was increased to 20 mg and remained fixed for until the end of six week. During the last 6 weeks the dose could vary from 10 to 30 mg/day
11532919|NCT01123395|Experimental|Colcrys® (colchicine USP) 0.6 mg intact tablet|One Colcrys® (colchicine USP) 0.6 mg intact tablet taken by mouth
11532920|NCT01123395|Experimental|Colcrys® 0.6 mg tab in apple juice|One Colcrys® 0.6 mg tablet crushed and dissolved in apple juice
11532921|NCT01123382|Experimental|IM Electrical Stimulation (IM ES)|The IM ES Group will receive electrical stimulation treatment for three weeks (6 hrs daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
11532922|NCT01123382|Active Comparator|Usual Care (UC)|The Usual Care Group will receive outpatient therapy for four weeks, coupled with prescribed daily home exercises.
11532923|NCT01123356|Experimental|Oratumumab and Lenalidomide|"Single arm, non randomized study
~Ofatumumab, Lenalidomide: -Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1.
~Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28.
~Treatment to be administered for up to 6 cycles"
11532924|NCT01123343|Active Comparator|LRI Templates|To evaluate the ability of the TRUEVISION 3D VISUALIZATION AND GUIDANCE SYSTEM FOR MICROSURGERY to provide the ophthalmic surgeon appropriate alignment, orientation and sizing information during cataract or refractive lens exchange surgery compared to the current standard of care (manual markings or heuristic techniques) for LRI.
11532974|NCT01122901|Experimental|Group A (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, 15-17, and 22-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11534283|NCT01114542|Active Comparator|IGlar 0.6 U/kg|
11532925|NCT01123343|Active Comparator|Capsulorhexis Templates|To evaluate the ability of the TRUEVISION 3D VISUALIZATION AND GUIDANCE SYSTEM FOR MICROSURGERY to provide the ophthalmic surgeon appropriate alignment, orientation and sizing information during cataract or refractive lens exchange surgery compared to the current standard of care (manual markings or heuristic techniques) for Capsulorhexis.
11532926|NCT01123330|Experimental|Motivational Interviewing plus DVD|Caregivers watched a 15-minute educational video designed for the project emphasizing the importance of good oral health in children, and how the caregiver can keep children free from tooth decay. The MI interviewer engaged the parent in a discussion of their thoughts and concerns regarding their child's oral health and what changes they wished to make regarding monitoring their child's oral health. Feedback from the child's dental exam was also reviewed. MI+DVD caregivers received a brochure displaying a photo of their child and for those who chose to set specific goals for their child's oral health, those goals were listed on the brochure. Caregivers choosing not to set specific goals were offered a list of 10 project recommendations regarding dietary intake, oral hygiene, and dental check-ups. The session ended with a dialogue regarding possible barriers to implementing the personal plan and how the caregiver planned to overcome those barriers.
11532927|NCT01123330|Active Comparator|DVD only|Caregivers watched the same educational video. At the end of the video, caregivers were given a glossy-printed brochure displaying the project developed recommendations as well as the child's photograph. The brochure was not re-mailed, as it was for the MI+DVD group and caregivers in this condition did not receive any feedback from the dental examination regarding their child's oral health status.
11532928|NCT01123317|Experimental|Oxytocin|Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2
11532929|NCT01123304|Experimental|MORAb 028|
11532930|NCT01123291|Active Comparator|routine follow-up coronary angiography|routine follow-up coronary angiography at 8-12 after discharge for percutaneous coronary intervention
11532931|NCT01123291|Active Comparator|clinical follow-up|no routine follow-up coronary angiography at 8-12 after discharge for percutaneous coronary intervention
11532932|NCT01123278|Experimental|Testosterone gel|Testosterone transdermal gel 50 mg/day
11532933|NCT01123278|Placebo Comparator|Placebo gel|Placebo gel
11532934|NCT01123265||Anti-TNF|
11532935|NCT01123265||Methotrexate|
11532936|NCT01123252|Active Comparator|Seasonal Affective Rhinitis Group 1|Active Comparator Group
11532937|NCT01123252|Placebo Comparator|Seasonal Affective Rhinitis Group 2|Placebo Group
11532938|NCT01123239|Experimental|Coached Care|"Coached Care pairs patients with linguistically and ethnically matched peer coaches who have been trained to promote patient participation in the medical visit. The coaches, who themselves have diabetes, meet with patients immediately before each of their regularly scheduled medical visits to encourage active involvement in information seeking and decision-making."
11532939|NCT01123239|Active Comparator|Standard Diabetes Education|Patients receive one-on-one diabetes education sessions before each medical visit. These sessions are purely informational, and do not include the specific patient activation components of the coached care intervention.
11532940|NCT01123226|Experimental|Diversified HVLA spinal manipulation|
11532941|NCT01123226|Active Comparator|Trigger point pressure release|
11532942|NCT01123200|Other|Brain Computer Interface In-Home Use|
11532943|NCT01123187|Experimental|islet transplantation|Islet transplantation
11532944|NCT01123174|Experimental|ALGOS group|Algorithm of case management over the 6 months following the suicidal gesture (systematic telephone contact, postcards and crisis card)
11532945|NCT01123174|No Intervention|Control group|Treatment as usual (referral back to the general practitioner)
11532946|NCT01123161|Active Comparator|Group1: IV t-PA and normothermia|IV tpa and normothermia
11532947|NCT01123161|Active Comparator|Group 2 : IV t-PA and hypothermia and anti-shivering treatment|IV tpa and hypothermia and anti-shivering treatment
11532948|NCT01123148|Other|Tilt testing|
11532949|NCT01123135|Active Comparator|Vaginal ERT|1gm of estrogen vaginal cream [EVC] at bed time 3 times a week
11532950|NCT01123135|Placebo Comparator|Placebo|1gm of placebo at bed time 3 times a week
11532951|NCT01123122|Active Comparator|Strict glucose control|
11532952|NCT01123122|No Intervention|Standard glucose control|
11532953|NCT01123109|Other|nulliparous females|nulliparous women over the age of 18
11532954|NCT01123096||Stress Urinary Incontinence|Patients with the primary complaint of stress incontinence with minimal or no urge incontinence symptoms. They must be able to read English as the study involves use of validated questionnaires which have only been validated in English.
11532955|NCT01123083|Experimental|otelixizumab|otelixizumab
11532956|NCT01123083|Placebo Comparator|placebo|placebo
11532957|NCT01123070|Experimental|TL011|TL011 infusions
11532958|NCT01123070|Active Comparator|MabThera|MabThera infusions
11532959|NCT01123044|Experimental|corneal stem cell transplant|
11532960|NCT01123044|No Intervention|conservative medical therapy|
11532961|NCT01123031|Active Comparator|lansoprazole|lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
11532962|NCT01123031|Active Comparator|esomeprazole|esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
11532963|NCT01123018||Older Adults|Persons over age 60 Participants will complete the Memtrax memory screening test
11532964|NCT01123005|Experimental|Carbogen arm|
11532965|NCT01123005|Experimental|DCA arm|
11532966|NCT01122979|Experimental|group 1: insulin glargine + insulin glulisine|insulin glargine once daily + glulisine at meal times
11532967|NCT01122979|Active Comparator|group 2 NPH insulin + regular insulin|NPH insulin (isophane insulin) (2 or more divided doses) + regular insulin at meal times
11532968|NCT01122966|Other|trabeculectomy|Subjects who have trabeculectomies with intraocular bevacizumab injection
11532969|NCT01122953|Experimental|Phenytoin|
11532970|NCT01122953|Active Comparator|Epamin|
11532971|NCT01122940|Active Comparator|Epamin: McNeil LA LLC|
11532972|NCT01122940|Experimental|Phenytoin: Laboratorios Pfizer SA DE CV|
11532975|NCT01122901|Experimental|Group B (gamma-secretase inhibitor RO4929097, surgery)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days -6 to -1. Patients undergo surgical resection on day 0. Within 30 days after surgical resection, patients receive gamma-secretase inhibitor RO4929097 as in group A.
11532976|NCT01122888|Experimental|Arm I (course 1)|Patients receive cilengitide IV over 1 hour twice weekly for 2 weeks.
11532977|NCT01122888|Other|Arm II (course 1)|Patients do not receive treatment and undergo a 2-week rest period.
11532978|NCT01122875|Experimental|A|
11532979|NCT01122862|Active Comparator|0.12% Chlorhexidine Mouthrinse|Commercially available 0.12% Chlorhexidine mouthrinse
11532980|NCT01122862|Active Comparator|Cosmetic mouthrinse|Commercially available cosmetic mouthrinse
11532981|NCT01122862|Placebo Comparator|Sterile Water|Sterile Water
11532982|NCT01122849|Experimental|Prototype Nasal Dilator|Prototype Nasal Dilator
11532983|NCT01122849|Active Comparator|Marketed Nasal Strip|Marketed Nasal Strip
11532984|NCT01122849|Placebo Comparator|Placebo Nasal Strip|Placebo
11532985|NCT01122836|Experimental|Massage Dose 1|This arm receives weekly 60-minute massage for 4 weeks after a 4-week period of no treatment.
11532986|NCT01122836|Experimental|Massage - Dose 2|This arm receives weekly 60-minute massage for 4 weeks.
11532987|NCT01122836|Experimental|Massage - Dose 3|This arm receives 2 weekly 30-minute massage for 4 weeks.
11532988|NCT01122836|Experimental|Massage - Dose 4|This arm receives 2 weekly 60-minute massages for 4 weeks.
11532989|NCT01122836|Experimental|Massage - Dose 5|This arm receives 3 weekly 30-minute massages for 4 weeks.
11532990|NCT01122836|Experimental|Massage - Dose 6|This arm receives 3 weekly 60-minute massages for 4 weeks.
11532991|NCT01122823|Experimental|On-line workshop|The online CDSMP is an internet-based program for people with 1 or more chronic conditions. It's built on self-efficacy theory, facilitated by lay leaders, and uses a curriculum emphasizing problem solving, decision making, and confidence building in weekly sessions over six weeks. It addresses generic topics and skills relevant to managing any chronic condition, including: action plans; problem solving; nutrition; exercise; fatigue; breathing; managing medications; managing stress and emotions; working with health care providers. The structure includes: 1) password-protected, interactive web-based instruction; 2) web-based bulletin board discussion groups to enable participatory learning and support; 3) and a reference book that contains the program content and supplemental information.
11532992|NCT01122797||Alcoholic liver disease|Alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution
11532993|NCT01122797||Controls|Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination.
11532994|NCT01122784|Active Comparator|Group 1|160 Volunteers will be vaccinated with 80 mcg rF1V vaccine with adjuvant at Study Days 0, 56 and 182
11532995|NCT01122784|Active Comparator|Group 2|40 Volunteers will be vaccinated with 80 mcg rF1V vaccine without adjuvant at Study Days 0, 56 and 182
11532996|NCT01122784|Active Comparator|Group 3|160 Volunteers will be vaccinated with 80 mcg rF1V vaccine with adjuvant at Study Days 0, 56 and 121
11532997|NCT01122784|Active Comparator|Group 4|40 Volunteers will be vaccinated with 80 mcg rF1V vaccine without adjuvant at Study Days 0, 56 and 121
11532998|NCT01122771|Active Comparator|Ambisome|15mg Ambisome on days 1,3 and 5
11532999|NCT01122771|Experimental|Ambisome + Miltefosine|Ambisome 5mg + miltefosine 10 days
11533000|NCT01122771|Experimental|Ambisome +paromomycin|AmBisome IV infusion (single dose, day 1) + Paromomycin base 11mg/kg/day IM (Gland Pharma, India) for 10 days (days 2-11)
11533001|NCT01122771|Experimental|Miltefosine + paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
11533002|NCT01122758||COPD cohort|"Inclusion criteria:
~Patients ≥ 35 years.
~Diagnosis of COPD (GOLD PBD FEV1/FVC ratio <0.70).
~Being in a stable phase of disease (8 weeks without exacerbation).
~Cummulative smoking ≥ 10 pack-years.
~Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);
~Absence of malignancy or very serious comorbidities that would prevent study completion.
~Exclusion criteria:
~Patients <35 years.
~Recent exacerbation (<8 weeks).
~Not giving written informed consent.
~Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,
~Diffuse bronchiectasis not associated with COPD.
~Presence of malignancy or very serious comorbidities that would prevent study completion.
~Difficulty to perform appropriate follow-up."
11533003|NCT01122758||Control cohort|"Inclusion criteria:
~Patients ≥ 35 years.
~Absence of diagnosis of COPD (GOLD PBD FEV1/FVC ratio >=0.70).
~Cummulative smoking ≥ 10 pack-years.
~Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);
~Absence of malignancy or very serious comorbidities that would prevent study completion.
~Exclusion criteria:
~Patients <35 years.
~Not giving written informed consent.
~Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,
~Diffuse bronchiectasis not associated with COPD.
~Presence of malignancy or very serious comorbidities that would prevent study completion.
~Difficulty to perform appropriate follow-up."
11533004|NCT01122745||Catheter Group|Patient will have continuous interscalene block for pain relief placed preoperatively. They will go home with the portable pump. Pain score will be tracked via phone and compared with the control or single short group.
11533005|NCT01122745||Single shot group|Patient will have single shot interscalene block and will go home. Pain will be tracked using phone. Pain will be compared with the catheter group.
11533006|NCT01122732||US Group|Interscalene catheter will be placed with US guidance without any nerve stimulation guidance.
11533007|NCT01122732||NS Group|Catheter will be placed using nerve stimulation guidance
11533008|NCT01122706|Experimental|Taiji|35 healthy participants will regularly during 12 weeks attend Taiji training classes twice a week for one hour. (Sept. 6th till Nov. 25th 2010).
11533009|NCT01122706|No Intervention|waiting list control group|35 healthy participants are not allowed to attend any Taiji training during the intervention period (Sept. 6th till Nov. 25th 2010).
11533010|NCT01122693|Active Comparator|standard 2D ultrasound images|
11533011|NCT01122693|Experimental|high-quality 2D ultrasound images|
11533012|NCT01122693|Active Comparator|nerve stimulation techniques|
11534284|NCT01114542|Active Comparator|IGlar 0.8 U/kg|
11533015|NCT01122680|Placebo Comparator|Placebo|patients inhale 2 puffs of placebo matching tiotropium once daily in the evening via Respimat inhaler
11533016|NCT01122680|Experimental|Treatment B|patients inhale 2 puffs (dose of 2.5 mcg) once daily in the evening via Respimat inhaler
11533017|NCT01122667|Experimental|Part 1 - Panel A|Subjects with severe renal impairment
11533018|NCT01122667|Experimental|Part 1 - Panel B|Healthy matched control subjects
11533019|NCT01122667|Experimental|Part 2 - Panel C|Subjects with moderate renal impairment
11533020|NCT01122667|Experimental|Part 2 - Panel D|Healthy matched control subjects
11533021|NCT01122667|Experimental|Part 2 - Panel E|Subjects with mild renal impairment
11533022|NCT01122667|Experimental|Part 2 - Panel F|Healthy matched control subjects
11533023|NCT01122654||Control|
11533024|NCT01122654||Experimental 1|
11533025|NCT01122654||Experimental 2|
11533026|NCT01122641|Placebo Comparator|Placebo|
11533027|NCT01122641|Experimental|Vildagliptin|Vildagliptin 50mg bid
11533028|NCT01122628||DVR-A|Patients with a distal radial fracture treated with a DVR-A locking plate
11533029|NCT01122615|Experimental|Sunitinib + Temsirolimus|Sunitinib 12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle. Temsirolimus 6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.
11533030|NCT01122602|Experimental|Arm 1|
11533031|NCT01122602|Active Comparator|Arm 2|
11533032|NCT01122602|Placebo Comparator|Arm 3|
11533033|NCT01122589|Experimental|Motivation Interviewing/CBT|
11533034|NCT01122589|Active Comparator|Control|Receive a smoking cessation pamphlet and watch a series of six weekly 30-45 minutes general wellness videos.
11533035|NCT01122576|Experimental|Crystalens AO|Eligible subjects to undergo small incision cataract surgery and were implanted with the Crystalens AO bilaterally.
11533036|NCT01122576|Active Comparator|ReSTOR|Eligible subjects to undergo small incision cataract surgery and were implanted with the ReSTOR IOL bilaterally.
11533037|NCT01122576|Active Comparator|Tecnis Multifocal IOL|Eligible subjects to undergo small incision cataract surgery and were implanted with the Tecnis Multifocal IOL bilaterally.
11533038|NCT01122524||Chromosomal Abnormality|Fetus affected by chromosomal abnormality
11533039|NCT01122524||No Chromosomal Abnormality|Fetus not affected by chromosomal abnormality
11533040|NCT01122511|Experimental|700 ug dexamethasone and ranibizumab|Intravitreal injection of 700 ug dexamethasone and ranibizumab into study eye
11533041|NCT01122511|Active Comparator|ranibizumab and sham|Intravitreal injection of ranibizumab and Sham into study eye
11533042|NCT01122498|Experimental|1|
11533043|NCT01122498|Experimental|2|
11533044|NCT01122498|Experimental|3|
11533045|NCT01122485|Experimental|Low dose group|two tablets per dose (one tablet of investigational drug and one tablet of placebo)
11533046|NCT01122485|Experimental|High dose group|two tablets per dose (two tablets of investigational drug)
11533047|NCT01122485|Placebo Comparator|Control group|two tablets per dose (two tablets of placebo)
11533048|NCT01122472|Experimental|Lenalidomide|Lenalidomide daily for 3 weeks every 4 weeks for 24 months
11533049|NCT01122472|Placebo Comparator|Placebo|Placebo daily for 3 weeks every 4 weeks for 24 months
11533050|NCT01122459|Active Comparator|Hartmanns|These patients will receive Hartmanns during anaesthesia
11533051|NCT01122459|Active Comparator|Voluven 6%|
11533052|NCT01122446|Placebo Comparator|Placebo comparator|Two doses of placebo day 1 and 30
11533053|NCT01122446|Active Comparator|Alum-GAD (Diamyd)|20 microgram Diamyd day 1 and 30
11533054|NCT01122433|Experimental|C-MAC|After a maximum of three failed intubation attempts using direct laryngoscope the C-MAC video laryngoscope is used as an emergency airway device.
11533055|NCT01122420|Experimental|Goal-Setting Tool|
11533056|NCT01122420|Active Comparator|Health Web Sites|
11533057|NCT01122407|Experimental|trimethaphan|Trimethaphan infusion doses of 4 mg/min
11533058|NCT01122407|Experimental|Trimethaphan plus L-NMMA|Trimethaphan infusion 4 mg/min L-NMMA (L-NG-monomethyl Arginine citrate) infusion 250 mpg/kg/min A small group of arm 1 will receive both drugs.
11533059|NCT01122394|Experimental|Tailored Intervention (TI)|Tailored intervention based on the transtheoretical model
11533060|NCT01122394|Placebo Comparator|Attention Placebo (AP)|Attention Placebo
11533061|NCT01122381|Experimental|Arm 1-ethosuximide|"ethosuximide blinded capsules of 250mg ESX; titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed 30mg/kg/d) vs maximum tolerability"
11533062|NCT01122381|Placebo Comparator|Arm 2-placebo comparator|"placebo same size blinded capsules as the 250mg ESX; similar titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed 30mg/kg/d) vs maximum tolerability"
11533063|NCT01122368|Experimental|1 Micafungin|IV
11533064|NCT01122368|Placebo Comparator|2 Placebo|IV
11533065|NCT01122355|Active Comparator|niacin arm|
11533066|NCT01122355|Active Comparator|fenofibrate arm|
11533067|NCT01122342|Experimental|Vaginal Testosterone|Daily application of vaginal testosterone for 28 days.
11533068|NCT01122329|Placebo Comparator|inactive food packet|
11533069|NCT01122329|Active Comparator|Axona®|
11533070|NCT01122316|Experimental|Metformin|
11533071|NCT01122303||SJS|Stevens-Johnson syndrome patients with dry eye
11533072|NCT01122303||Control|Non-autoimmune dry eye patients
11533073|NCT01122290||negative emotion|Children experienced induction of mild negative emotion through a jigsaw with a missing piece (negative emotion group)
11533074|NCT01122290||neutral emotion|Vs. Same task with No missing piece (neutral emotion).
11533075|NCT01122264|Experimental|Tadalafil on demand|10 milligrams (mg) or 20 mg on demand
11533076|NCT01122264|Experimental|Tadalafil once a day|5 mg or 2.5 mg once a day
11533077|NCT01122264|Active Comparator|Sildenafil Citrate|50 mg, 100 mg, or 25 mg on demand
11533078|NCT01122251|Experimental|Lercanidpine + Valsartan|L10/V80, L20/V80, L10/V160, L20/V160
11533079|NCT01122251|Active Comparator|Lercanidipine or Valsartan|L10, L20, V80, V160
11533080|NCT01122251|Placebo Comparator|Placebo|Placebo comparators of Lercanidipine and Valsartan
11534433|NCT01113528|Experimental|Regenerative therapy|
11533081|NCT01122238|Experimental|1, Nicotine Patch, Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:
~How effective is the following intervention? Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
11533082|NCT01122238|Experimental|2, Nicotine Patch, Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:
~How effective is the following intervention? Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
11533083|NCT01122238|Experimental|3, Nicotine Patch, Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:
~How effective is the following intervention? Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
11533084|NCT01122238|Experimental|4, Nicotine Patch, Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:
~How effective is the following intervention? Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
11533085|NCT01122238|Experimental|5, Nicotine Patch, No Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:
~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
11533086|NCT01122238|Experimental|6, Nicotine Patch, No Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:
~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
11533087|NCT01122238|Experimental|7, Nicotine Patch, No Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:
~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
11533088|NCT01122238|Experimental|8, Nicotine Patch, No Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:
~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
11533089|NCT01122238|Experimental|9, No Nicotine Patch, Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:
~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
11533090|NCT01122238|Experimental|10, No Nicotine Patch, Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:
~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
11533091|NCT01122238|Experimental|11, No Nicotine Patch, Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:
~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
11533092|NCT01122238|Experimental|12, No Nicotine Patch, Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:
~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
11533093|NCT01122238|Experimental|13, No Nicotine Patch, No Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:
~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
11533094|NCT01122238|Experimental|14, No Nicotine Patch, No Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:
~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
11533095|NCT01122238|Experimental|15, No Nicotine Patch, No Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:
~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
11533096|NCT01122238|Experimental|16, No Nicotine Patch, No Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:
~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
11533097|NCT01122225||Septic shock|
11533098|NCT01122199|Experimental|Open Label|RAD001+ AMG479
11533099|NCT01122186|Experimental|Intervention Condition|Eight sessions of Motivational Interviewing and Cognitive Behavioral Skills Training, adapted to target both MA use and medication adherence, as well as sexual risk behaviors and polydrug use.
11533100|NCT01122186|Active Comparator|Education Condition|Eight sessions of education with content designed to mirror the information covered in the intervention condition. The content will be as follows: 3 sessions focusing on medication adherence; 3 sessions focusing on the dangers of methamphetamine use; 1 session addressing sexual risk; and 1 session addressing poly-substance use.
11533101|NCT01122173|Experimental|Robotic catheter manipulation, Ablation|To evaluate the safety and effectiveness of the family of Artisan guide catheters when used to remotely introduce and position commercially available cardiac RF ablation catheters to treat subjects with paroxysmal atrial fibrillation.
11533102|NCT01122160|Placebo Comparator|placebo|Placebo with berries (blackberries + strawberries)
11533103|NCT01122160|Experimental|omeprazole|Prilosec (omeprazole) 20.6 mg tablet with berries (blackberries + strawberries)
11533104|NCT01122147|Active Comparator|chamomilla tincture mouthwash|Chamomile comprises bisaboloids, matricine and chamazulene, flavonoids, and cumarins having therapeutical anti-inflammatory, analgesic, musculotropic, and spasmolytic action
11533105|NCT01122147|Placebo Comparator|placebo mouth wash|placebo mouthwash is produced with the same taste and smell for using in placebo/ control group.
11533106|NCT01122134||20 adults with severe malaria|20 adult patients admitted with severe malaria
11533107|NCT01122121|Experimental|Combined Radiotherapy and Hormone Therapy|Leuprorelin 11.25 milligram (mg) sustained release (SR), injection, subcutaneously, once every 3 months up to 3 years and flutamide 250 mg, tablet, orally, thrice daily for 30 days from the first dose of leuprorelin. Radiotherapy 70 +/- 4 Gray (Gy) in 35 fractions at a rate of 5 fractions of 2 Gy per week up to 3 years. An interval of a maximum of 2 weeks is authorized between radiation of the pelvis with 50 Gy (±4) (5 weeks) and radiation of the prostate with an additional 20 Gy.
11533108|NCT01122121|Active Comparator|Hormone Therapy alone|Leuprorelin 11.25 mg SR, injection, subcutaneously, once every 3 months up to 3 years and flutamide 250 mg, tablet, orally, thrice daily for 30 days from the first dose of leuprorelin.
11534491|NCT01113125|Experimental|Fucicort|
11533111|NCT01122095||Psoriasis|Children with psoriasis Age matched controls without psoriasis or other significant inflammatory disease
11533112|NCT01122095||Control patient|Age matched, without psoriasis or significant inflammatory disease
11533113|NCT01122069||Contrast echocardiography|110 patients with acute non-ST elevation myocardial infarct were examined with contrast echocardiography prior to coronary angiography.
11533114|NCT01122056|Active Comparator|A = Active group|Patients will receive interactive exercise training session from an experienced multiple sclerosis
11533115|NCT01122056|No Intervention|B = Control group (Placebo Comparator)|Patients will receive general advice about benefits/side effects of physical activity in multiple sclerosis.
11533116|NCT01122043||Endoglide|Patients with moderate degrees of corneal decompensation from a variety of disorders which require DSAEK corneal transplantation surgery, with or without concurrent cataract surgery, to restore visual acuity.
11533117|NCT01122030|Experimental|Cohort 1|In this cohort 9 participants received one 0.1 mg naldemedine tablet and 3 participants received matching placebo administered on Day 15 under fasted conditions.
11533118|NCT01122030|Experimental|Cohort 2|In this cohort 9 participants received a single dose of 0.3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
11533119|NCT01122030|Experimental|Cohort 3|In this cohort 9 participants received a single dose of 1 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
11533120|NCT01122030|Experimental|Cohort 4|In this cohort 9 participants received a single dose of 3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
11533121|NCT01122030|Experimental|Cohort 5|In this cohort 9 participants received a single dose of 0.03 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.
11533122|NCT01122030|Experimental|Cohort 6|In this cohort 9 participants received a single dose of 0.01 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.
11533123|NCT01122017|Experimental|Medial Opening-Wedge Osteotomy|Medial Opening-Wedge Osteotomy (MOWO) is an approach for the correction of malalignment of the knee
11533124|NCT01122004|Active Comparator|Gabapentin|
11533125|NCT01122004|Active Comparator|Pregabalin|
11533126|NCT01121978|No Intervention|Conservative treatment group|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole or vision deterioration occurs
11533127|NCT01121978|Experimental|Early vitrectomy|Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine green dye assisted internal limiting membrane peeling
11533128|NCT01121965|No Intervention|Conservative treatment group|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole occurs
11533129|NCT01121965|Experimental|Early vitrectomy|Pars plana vitrectomy with ILM peeling would be employed when visual symptoms occur.
11533130|NCT01121952|Placebo Comparator|Placebo|Single high-velocity, low-amplitude (HVLA) thrust manipulation towards Tibia, not affecting the dysfunctional talo-crural joint
11533131|NCT01121952|Experimental|Treatment|Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation on dysfunctional talo-crural joint
11533132|NCT01121939|Experimental|1|combination of bevacizumab, pertuzumab, and sandostatin for patients with advanced neuroendocrine cancers
11533133|NCT01121926|Experimental|Trazodone HCl OAD|OAD: Once A Day
11533134|NCT01121926|Active Comparator|Trazodone HCl (Apotex Corp.)|
11533135|NCT01121913|Experimental|Trazodone Contramid® OAD (test product 1)|Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)
11533136|NCT01121913|Experimental|Trazodone Contramid® OAD(test product 2)|Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)
11533137|NCT01121913|Active Comparator|Triticco®|
11533138|NCT01121913|Active Comparator|Desyrel®|
11533139|NCT01121900|Experimental|Trazodone HCl OAD|OAD: Once A Day
11533140|NCT01121900|Active Comparator|Trazodone HCl (Apotex Corp.)|
11533141|NCT01121887|Active Comparator|Standard treatment|
11533142|NCT01121887|Experimental|Motivational Interviewing|
11533143|NCT01121874|Active Comparator|LRTI|These patients will undergo ligament reconstruction with tendon interposition (LRTI) surgery. They will serve as a control group, against which to compare the investigational surgical technique.
11533144|NCT01121874|Experimental|Suture fixation system|CMC arthroplasty which reconstructs palmar oblique ligament using a suture fixation system.
11533145|NCT01121874|Experimental|Suture fixation system + 2 week immobilization|CMC arthroplasty which reconstructs palmar oblique ligament using a suture fixation system, and with a decreased immobilization time from 6 to 2 weeks post-surgery.
11533146|NCT01121848|Active Comparator|5-FU & LV|"Day 1: LV 400 mg/m2 (given as a 2-hour infusion)
~Day 1 and 2: 5-FU given as a bolus IV 400 mg/m2 dose on Day 1 followed by 2400 mg/m2 continuous infusion over 46 hours.
~This chemotherapy regimen will be administered each two weeks."
11533147|NCT01121848|Experimental|XELOX or modified FOLFOX-6|"XELOX:
~Day 1: Oxaliplatin 130 mg/m2 (2 hours infusion)
~This chemotherapy regimen will be administered each two weeks.
~OR modified FOLFOX-6:
~Day 1: Oxaliplatin 85 mg/m2 (given as a 2-hour infusion)
~Day 1: LV 400 mg/m2 (given as a 2-hour infusion simultaneous to oxaliplatin)
~Day 1 and 2: 5-FU given as a bolus IV 400 mg/m2 dose on Day 1 followed by 2400 mg/m2 continuous infusion over 46 hours (Day 1 and 2)
~This chemotherapy regimen will be administered each two weeks."
11533148|NCT01121835|Experimental|Insulin glargine|"Administered once a day in the evening, at the same time every day. The starting daily dose is 0.2 U/Kg of body weight or 12 U, at the investigator's decision.
~Insulin glulisine is administered for patients of the insulin glargine group requiring insulin glulisine at week 12 (visit 11).
~Insulin glulisine is administered prior (10-15 min) to the main meal of the day, which is the meal with highest Post-Prandial Plasma Glucose (PPPG) on the 3 profiles performed before week 12.
~Starting dose is of 4 units per day."
11533200|NCT01121406|Experimental|BI 6727|Patients receive BI 6727 infusion every 3 weeks
11533266|NCT01121055|Placebo Comparator|Control|Placebo 1T by mouth (po) at night one day before FB and placebo 1T po 30min before the FB
11533149|NCT01121835|Experimental|Premixed insulin|administered once a day (in the evening at dinner) or twice a day (in the morning before breakfast and in the evening at dinner). Starting daily dose will be 6 U at breakfast and 6 U at dinner, if administered twice a day or 12 U at dinner if administered once a day
11533150|NCT01121822|Experimental|Group 1|Participants at age 18 to 59 years
11533151|NCT01121822|Experimental|Group 2|Participants at age 60 years or older
11533152|NCT01121809|Other|Raltegravir|Raltegravir 400 mg bid
11533153|NCT01121809|Other|Etravirine|Etravirine 200 mg bid
11533154|NCT01121796|Active Comparator|Vitamin D|
11533155|NCT01121796|Placebo Comparator|Placebo|
11533156|NCT01121796|Active Comparator|Unique vehicle for Vitamin D supplementation|
11533157|NCT01121783|Active Comparator|Lactisole-Glucose|
11533158|NCT01121783|Active Comparator|Lactisole-water|
11533159|NCT01121783|Placebo Comparator|Water-Glcuose|
11533160|NCT01121783|Placebo Comparator|Water-Water|
11533161|NCT01121770|Experimental|Arixtra|
11533162|NCT01121757|Experimental|Azacitidine followed by Lenalidomide|"Azacitidine 75 mg/m2 subcutaneously (SC) or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.
~Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1."
11533163|NCT01121757|Experimental|Lenalidomide followed by Azacitidine|"Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.
~Azacitidine 75 mg/m2 subcutaneously (SC) or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a."
11533164|NCT01121731|Experimental|Interferon α-5|
11533165|NCT01121731|Experimental|Interferon α-5 plus Interferon α-2b|
11533166|NCT01121731|Active Comparator|Interferon α-2b (INTRON® A)|
11533167|NCT01121718|Experimental|ICG Intervention|Intraoperative NIR fluorescence imaging was performed after injection of 1.0 ml of 100 µM, 250 µM or 500 µM of ICG:HSA in four quadrants around the primary lesion. (The intervention to be administered is the ICG.)
11533168|NCT01121705|No Intervention|A1. standard duration|Patients were randomly assigned in a 1:1 ratio to two treatment arms. In the standard treatment group (A1), patients were treated for 24 weeks irrespective of the HCV RNA status at week 4 with Peg-interferon alfa-2b at a dose of 1.5 mcg per kilogram of body weight weekly in combination with oral ribavirin administered at a dose of 1000 mg/day for patients with a weight <75 kg or 1200 mg/day for those with a weight of ≥75 kg. Patients enrolled in Arm A1 will be treated for standard 24 weeks duration of treatment with standard dosages of PegInterferon alpha 2b and weight-based dosages of ribavirin.
11533169|NCT01121705|Experimental|B 1 I or II|In the variable treatment group, patients with a virologic response at week 4 will receive treatment for 12 weeks and those without a virologic response at 4 weeks treatment for 36 weeks. Patients without RVR will be treated for 24 or 36 weeks and labelled (B1I) or (B1II, respectively Intervention: different durations of treatment for patients without RVR
11533170|NCT01121692|Experimental|VCT/Women's CoOp|
11533171|NCT01121692|Experimental|Women's CoOp/Men's CoOp|
11533172|NCT01121692|Experimental|Couples CoOp|
11533173|NCT01121679||Patients aged 80 years and older|Patients aged 80 years and older and hospitalized in a cardiology department
11533174|NCT01121666|Active Comparator|Gonal-f® (Follitropin alfa)|
11533175|NCT01121666|Experimental|AFOLIA-150 (Follitropin alfa)|
11533176|NCT01121640|Other|CA125 every screen, HE4 at confirmatory screen.|CA125 will be used at every screen. Women with a parametric empirical Bayes (PEB) longitudinal algorithm score above the 90th percentile will be asked to return for early recall screening. Women with a PEB score above the 95th percentile will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
11533177|NCT01121640|Other|CA125 and HE4 at every screen.|CA125 and HE4 will both be used at every screen. Women with a PEB score above the 95th percentile on either CA125 or HE4 will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
11533178|NCT01121627|Experimental|Computerized cognitive training|A 12 week computerized cognitive training
11533179|NCT01121614|Experimental|LOTUS|LOTUS ultrasonic instrument
11533180|NCT01121614|Experimental|Ethicon Harmonic Scalpel|Ultrasonic instrument
11533181|NCT01121614|Experimental|LigaSure|Bipolar feedback vessel sealing device
11533182|NCT01121601|Experimental|Group COSEAL|
11533183|NCT01121601|Active Comparator|Reference group|
11533184|NCT01121588|Experimental|Crizotinib|
11533185|NCT01121575|Experimental|Arm 1|PF-02341066 AND PF-00299804: Patients will be treated with combined cMET inhibitor (PF-02341066) and panHER inhibitor (PF-00299804).
11533186|NCT01121575|Experimental|Arm 2|PF-00299804 FOLLOWED BY COMBINED PF-02341066 AND PF-00299804: Patients will be treated with single agent panHER inhibitor (PF-00299804) until disease progression and then with the maximum tolerated combined dose of cMET inhibitor (PF-02341066) and panHER inhibitor (PF-00299804).
11533187|NCT01121562|Experimental|Sunitinib arm|
11533188|NCT01121549||Aromasin|All patients included in the study
11533189|NCT01121536|Experimental|Armodafinil 150-200 mg/day|Participants began taking armodafinil at a dosage of 50 mg/day; the dosage was increased by 50 mg/day on days 2 and 4, up to a dosage of 150 mg/day. At the discretion of the investigator, the dosage of armodafinil may be increased to 200 mg/day on day 6 or thereafter, and reduced to 150mg/day if the higher dose is not well tolerated. Treatment was administered for six months.
11533190|NCT01121523|Experimental|Cue-directed tactile stimulation|
11533191|NCT01121523|Active Comparator|Control group|
11533192|NCT01121497|Experimental|Physostigmine|Colonoscopy sedation with or without physostigmine
11533193|NCT01121484|Experimental|desvenlafaxine succinate sustained-release|
11533194|NCT01121484|Placebo Comparator|Placebo|
11533195|NCT01121471|Placebo Comparator|Safflower Oil|8.0 g/day safflower oil
11533196|NCT01121471|Experimental|CLA 6.4g/day|Conjugated linoleic acid at a dose of 6.4g/day in a supplement with a total of 8.0g oil
11533197|NCT01121445|No Intervention|CPAP with heated humidification|Standard of care
11533198|NCT01121432||Mediastinal lymphadenopathy|
11533201|NCT01121406|Active Comparator|Cytotoxic|At the investigator discretion, patient will receive one of the following cytotoxics: topotecan, paclitaxel, gemcitabine or liposomal doxorubicin
11533202|NCT01121393|Experimental|Arm A BIBW 2992|Patients receive a tablet of BIBW 2992 daily until progression or unacceptable toxicity
11533203|NCT01121393|Active Comparator|Arm B Chemotherapy|Patients receive Gemcitabine and Cisplatin, maximum is 6 courses
11533204|NCT01121380|Experimental|Cohort A - 10 mg|
11533205|NCT01121380|Experimental|Cohort B - 20 mg|
11533206|NCT01121380|Experimental|Cohort C - 40 mg|
11533207|NCT01121380|Experimental|Cohort D - 80 mg|
11533208|NCT01121380|Experimental|Cohort E - X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
11533209|NCT01121380|Experimental|Cohort F - 2X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
11533210|NCT01121380|Experimental|Cohort G - 4X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
11533211|NCT01121380|Placebo Comparator|Placebo|In each cohort there is a placebo arm
11533212|NCT01121367||Emphysema-alone|
11533213|NCT01121367||CPFE group|
11533214|NCT01121367||IPF-alone|
11533215|NCT01121367||smokers|
11533216|NCT01121367||nonsmokers|
11533217|NCT01121354|Experimental|Cefazolin 2g (Test)|
11533218|NCT01121354|Active Comparator|Cefazolin 1.5g (Control)|
11533219|NCT01121341|Experimental|EVOH|Procedure: Endoscopic vein with an open CO2 system harvesting
11533220|NCT01121341|Active Comparator|OVH|Procedure: Conventional vein harvesting
11533221|NCT01121328|Experimental|Autologous cord blood transfusion|Collected cord blood at birth will be transfused for the preterm neonate
11533222|NCT01121315||1|Diabetes type II patients, according to medical records, prescriptions or lab results, followed for >6 months after diagnosis.
11533223|NCT01121302|Experimental|1|dose escalating
11533224|NCT01121302|Placebo Comparator|2|placebo
11533225|NCT01121289|Experimental|NN1218, formulation A|
11533226|NCT01121289|Experimental|NN1218, formulation B|
11533227|NCT01121289|Experimental|NN1218, formulation B (high)|
11533228|NCT01121289|Experimental|NN1218, formulation C|
11533229|NCT01121289|Experimental|NN1218, formulation D|
11533230|NCT01121289|Active Comparator|insulin aspart|
11533231|NCT01121276|Experimental|NN1218, formulation A|
11533232|NCT01121276|Experimental|NN1218, formulation B|
11533233|NCT01121276|Experimental|NN1218, formulation C|
11533234|NCT01121276|Experimental|NN1218, formulation D|
11533235|NCT01121276|Active Comparator|insulin aspart|
11533236|NCT01121263||Angiogram Review Group|All consecutive and consenting patients undergoing diagnostic cardiac catheterization in a 3 month period
11533237|NCT01121263||Therapeutic Intervention Group|"Cohort 2 Therapeutic Intervention Group - HCR Patients (including those from the angiogram review group) who undergo Hybrid coronary revascularization (HCR) with minimally invasive LIMA-LAD CABG, OR
~Cohort 2 Therapeutic Intervention Group - PCI Patients (including those from the angiogram review group) who meet the proposed anatomic and clinical eligibility criteria and undergo multivessel Percutaneous Coronary Intervention with Drug Eluting Stents"
11533238|NCT01121250|Experimental|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
11533239|NCT01121250|Active Comparator|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
11533240|NCT01121250|No Intervention|Usual Care|Participants do not receive any services.
11533241|NCT01121237||CKD5, renal anaemia, haemodialysis|CKD5, renal anaemia, haemodialysis receiving recombinant human erythropoietin alfa (biosimilar)
11533242|NCT01121224|Active Comparator|BMS Group|Patients who receive a bare metal stent in the saphenous vein graft target lesion(s).
11533243|NCT01121224|Experimental|DES Group|Patients who receive a drug-eluting stent in the saphenous vein graft target lesion(s).
11533244|NCT01121211|Active Comparator|Testosterone|Testosterone x 24 weeks
11533245|NCT01121211|Placebo Comparator|Placebo|Placebo x 24 weeks
11533246|NCT01121198|Experimental|ASP1941 single arm|
11533247|NCT01121198|Experimental|ASP1941 repeated arm|
11533248|NCT01121198|Placebo Comparator|placebo single arm|
11533249|NCT01121198|Placebo Comparator|placebo repeated arm|
11533250|NCT01121185|Experimental|MBL-HCV1|
11533251|NCT01121185|Placebo Comparator|0.9% sodium chloride|
11533252|NCT01121172||obese|obese subjects according to International Obesity Task Force criteria
11533253|NCT01121172||lean|
11533254|NCT01121159||Preoperatively preformed orbital plates|Reconstruction with MatrixMIDFACE Preformed Orbital Plate (Synthes) or Custom-made orbital implant
11533255|NCT01121159||Non-preformed orbital plates|Reconstruction with Orbital Floor Mesh Plate or SynPOR Titanium Reinforced Fan Sheet (both Synthes)
11533256|NCT01121146|Active Comparator|Crosslinked Marathon polyethylene|
11533257|NCT01121146|Active Comparator|Standard Enduron polyethylene|
11533258|NCT01121133|Experimental|Arm A (navitoclax and rifampin)|
11533259|NCT01121120|Experimental|TXA127|300mcg/kg/day administered subcutaneously up to 28 days
11533260|NCT01121120|Placebo Comparator|Placebo|300mcg/kg/day administered subcutaneously up to 28 days
11533261|NCT01121107|Experimental|Left Atrial Pressure Monitoring System|Left Atrial Pressure (LAP) Monitoring System
11533262|NCT01121107|Active Comparator|Patient Advisor Module|Patient Advisory Module
11533263|NCT01121081|Placebo Comparator|Placebo|sugar pills
11533264|NCT01121081|Experimental|Dunaliella|drug
11533265|NCT01121068||Health care workers|
11533267|NCT01121055|Experimental|Lorazepam|Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB
11533268|NCT01121042|Active Comparator|Ondansetron|Ondansetron oral capsule 8mg daily
11533269|NCT01121042|Placebo Comparator|Placebo|Placebo (100% lactose) matched oral capsule
11533270|NCT01121029|Experimental|Hematopoietic stem cells|
11533271|NCT01121016|Active Comparator|combination therapy|combination therapy with inhaled budesonide and oral montelukast
11533272|NCT01121016|Placebo Comparator|monotherapy|monotherapy with inhaled budesonide and placebo of montelukast
11533273|NCT01121003|Other|Low fructose diet/no exercise|
11533274|NCT01121003|Experimental|high fructose diet/no exercise|
11533275|NCT01121003|Experimental|high fructose diet+exercise|
11533276|NCT01120990|Other|All patients|All eligible patients in the study consist a single group and the same intervention is assigned to all of them.
11533277|NCT01120977||Male|
11533278|NCT01120977||Female|
11533279|NCT01120964|Experimental|Intravenous L-Citrulline|
11533280|NCT01120964|Placebo Comparator|Placebo of Intravenous L-Citrulline|
11533281|NCT01120925|Experimental|MNC|Bone marrow derived MNC
11533282|NCT01120925|Experimental|CD133|CD133 derived from Bone marrow
11533283|NCT01120925|Placebo Comparator|Control|Normal saline with 5% Human Serum Albumin
11533284|NCT01120912|Experimental|Oral insulin and placebo|
11533285|NCT01120899|Experimental|Minocycline|
11533286|NCT01120873|Experimental|Metamin 3D|A randomized, double-blinded and placebo-controlled study
11533287|NCT01120847||Veterans with PTSD|No intervention; this is an observational study.
11533288|NCT01120847||Control group w/out PTSD|No intervention; this is an observational study.
11533289|NCT01120834|Experimental|all subjects|
11533290|NCT01120821|Experimental|Study drug|Gleevec treatment
11533291|NCT01120808|Experimental|All Participants|Participants were registered competitors in RacingThePlanet 6 stage 7 day 155mile (250km) ultramarathon.
11533292|NCT01120795|Experimental|pegylated interferon and ribavirin|Anti hepatitis C agents
11533293|NCT01120782|Active Comparator|etafilcon A toric new lens/etafilcon A toric lens|The lens worn first is a new etafilcon A toric contact lens and the lens worn second is a marketed etafilcon A toric contact lens. Each lens worn for a maximum of 15 minutes bilaterally.
11533294|NCT01120782|Active Comparator|etafilcon A toric lens/etafilcon A toric new lens|The lens worn first is a marketed etafilcon A toric contact lens and the lens worn second is a new etafilcon A toric contact lens. Each lens worn for a maximum of 15 minutes bilaterally.
11533295|NCT01120769|Active Comparator|Acetaminophen|
11533296|NCT01120769|Placebo Comparator|Placebo|
11533297|NCT01120756|Experimental|Goal-oriented attentional self-regulation training|Goal-oriented attentional self-regulation training (GOALS).
11533298|NCT01120756|Active Comparator|Brain Health Education|Brain Health Education (EDU)
11533299|NCT01120730|Active Comparator|HES|Fluid resuscitation with HES
11533300|NCT01120730|Placebo Comparator|ringers lactat|Standard treatment
11533301|NCT01120717|Experimental|QVA149|110µg/50µg capsule for oral inhalation, once daily, delivered by a single dose dry powder inhaler (SDDPI)
11533302|NCT01120717|Placebo Comparator|Placebo|Placebo to match QVA149, capsules for inhalation once daily, delivered by an SDDPI
11533303|NCT01120704|Experimental|1, 26Wks, Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
11533304|NCT01120704|Experimental|2, 26Wks, Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
11533305|NCT01120704|Experimental|3, 26Wks, Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
11533306|NCT01120704|Experimental|4, 26Wks, Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
11533307|NCT01120704|Experimental|5, 26Wks, Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
11533308|NCT01120704|Experimental|6, 26Wks, Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
11533309|NCT01120704|Experimental|7, 26Wks, Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
11533310|NCT01120704|Experimental|8, 26Wks, Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
11533403|NCT01120184|Experimental|Trastuzumab + Taxane (docetaxel or paclitaxel)|
11533404|NCT01120184|Experimental|Trastuzumab emtansine + pertuzumab|
11533405|NCT01120184|Experimental|Trastuzumab emtansine + pertuzumab placebo|
11533311|NCT01120704|Experimental|9, 26Wks, No Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
11533312|NCT01120704|Experimental|10, 26Wks, No Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
11533313|NCT01120704|Experimental|11, 26Wks, No Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
11533314|NCT01120704|Experimental|12, 26Wks, No Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
11533315|NCT01120704|Experimental|13, 26Wks, No Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
11533316|NCT01120704|Experimental|14, 26Wks, No Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
11533317|NCT01120704|Experimental|15, 26Wks, No Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
11533318|NCT01120704|Experimental|16, 26Wks, No Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
11533319|NCT01120704|Experimental|17, 8Wks, Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
11533320|NCT01120704|Experimental|18, 8Wks, Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
11533321|NCT01120704|Experimental|19, 8Wks, Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
11533322|NCT01120704|Experimental|20, 8Wks, Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
11533323|NCT01120704|Experimental|21, 8Wks, Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
11533324|NCT01120704|Experimental|22, 8Wks, Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
11533325|NCT01120704|Experimental|23, 8Wks, Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
11533326|NCT01120704|Experimental|24, 8Wks, Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
11533327|NCT01120704|Experimental|25, 8Wks, No Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
11533328|NCT01120704|Experimental|26, 8Wks, No Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
11533329|NCT01120704|Experimental|27, 8Wks, No Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
11533330|NCT01120704|Experimental|28, 8Wks, No Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
11533331|NCT01120704|Experimental|29, 8Wks, No Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
11533332|NCT01120704|Experimental|30, 8Wks, No Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
11533333|NCT01120704|Experimental|31, 8Wks, No Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
11533334|NCT01120704|Experimental|32, 8Wks, No Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:
~How effective is the following intervention?:
~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
11533335|NCT01120691|Experimental|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
11533336|NCT01120691|Active Comparator|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
11533337|NCT01120691|Active Comparator|open-label tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
11533338|NCT01120678||Neonates assessed for sepsis.|
11533339|NCT01120665|Experimental|PLACEBO-CONTROL|PLACEBO + CONTROL TO EXERCISE
11533340|NCT01120665|Experimental|ESTROGEN THERAPY + CONTROL|ESTROGEN THERAPY (estradiol valerate 1 mg/dia orally) + CONTROL TO EXERCISE
11533341|NCT01120665|Experimental|PLACEBO+AEROBIC TRAINING|PLACEBO + AEROBIC TRAINING (cicle-ergometer, 50 minutes, 3x week)
11533342|NCT01120665|Experimental|ESTROGEN THERAPY + AEROBIC TRAINING|ESTROGEN THERAPY (estradiol valerate 1 mg/dia orally) + AEROBIC TRAINING (cicle-ergometer, 50 minutes, 3x week)
11533343|NCT01120652|Experimental|Mind-Body Skills Training|This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices.
11533344|NCT01120652|Active Comparator|Supportive Counseling|This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice.
11533345|NCT01120639|Experimental|Stereotactic Radiosurgery (25 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) < 60 cm³ vs 60 to 150 cm³.
11533346|NCT01120639|Experimental|Stereotactic Radiosurgery (30 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) < 60 cm³ vs 60 to 150 cm³.
11533347|NCT01120639|Experimental|Stereotactic Radiosurgery (35 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) < 60 cm³ vs 60 to 150 cm³.
11533348|NCT01120639|Experimental|Stereotactic Radiosurgery (40 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) < 60 cm³ vs 60 to 150 cm³.
11533349|NCT01120626|Active Comparator|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
11533350|NCT01120626|Placebo Comparator|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
11533351|NCT01120613|Experimental|chronotherapy|Patients identified with Nocturnal Hypertension, will have one of the blood pressure medications switched from daytime dosing to nighttime dosing
11533352|NCT01120600|Experimental|Odanacatib 50 mg once weekly|Participants will receive one Odanacatib 50 mg tablet once weekly. In addition, they will receive a weekly dose 5600 IU of open-label Vitamin D3 as well as a sufficient supply of open-label calcium carbonate so that their total daily calcium intake from both dietary and supplemental sources is approximately 1200 mg.
11533353|NCT01120600|Placebo Comparator|Placebo once weekly|Participants will receive one Placebo tablet once weekly. In addition, they will receive a weekly dose 5600 IU of open-label Vitamin D3 as well as a sufficient supply of open-label calcium carbonate so that their total daily calcium intake from both dietary and supplemental sources is approximately 1200 mg.
11533354|NCT01120574|No Intervention|1|Oxygen therapy group.
11533355|NCT01120574|Active Comparator|2|Home mechanical ventilation plus oxygen therapy group.
11533356|NCT01120548|Experimental|Rehabilitation + Ventilation Group|Patient Heart Failure with sleep disordered breathing who follows ventilation therapy and physical training.
11533357|NCT01120548|No Intervention|Rehabilitation Only Group|
11533358|NCT01120535|Experimental|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
11533359|NCT01120522|Experimental|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
11533360|NCT01120509|Experimental|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
11533361|NCT01120496|Experimental|hypertonic saline|hypertonic saline (HS)
11533362|NCT01120496|Placebo Comparator|normal saline (NS)|normal saline (NS)
11533406|NCT01120171|Experimental|1|Cyclofosfamide/Liposomal-encapsulated doxorubicin
11533407|NCT01120158|Experimental|1|Paclitaxel/Bevacizumab
11533363|NCT01120470|Experimental|OGX-427 and Prednisone|OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427
11533364|NCT01120470|Active Comparator|Prednisone|"Control Arm:
~Prednisone: 5 mg BID orally starting within 4 days following randomization"
11533365|NCT01120457|Experimental|Arm 1: Dose Escalation and Expansion cohort (AML Patients)|"Dose Escalation: BMS-936564 0.3-10 mg/kg solution, Intravenous, Single 60 minute infusion as monotherapy 7 days/cycle 1 and with chemotherapy for subsequent cycles (28 days/cycle)
~Dose Expansion: BMS-936564 maximum tolerated dose (MTD) based on dose escalation, solution, Intravenous, Single 60 minute infusion as monotherapy 7 days/cycle 1 and with chemotherapy for subsequent cycles (28 days/cycle)"
11533366|NCT01120457|Experimental|Arm 2: Dose Expansion cohort (DLBCL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
11533367|NCT01120457|Experimental|Arm 3: Dose Expansion cohort (CLL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
11533368|NCT01120457|Experimental|Arm 4: Dose Expansion cohort (FL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
11533369|NCT01120444|Active Comparator|Subcutaneous delivery of insulin|A bolus dose of insulin will be given subcutaneously just prior to a standardized meal.
11533370|NCT01120444|Experimental|Intradermal delivery of insulin|A bolus dose of insulin will be given intradermally just prior to a standardized meal
11533371|NCT01120431|Active Comparator|Oral rehydration therapy|
11533372|NCT01120431|Experimental|hylenex-facilitated SC hydration|
11533373|NCT01120418|Experimental|Besifloxacin Ophthalmic Suspension 0.6%|Topical ocular administration three times daily (TID) for 5 days
11533374|NCT01120405|Experimental|Xenon|0.8-1.1 minimum alveolar concentration (MAC) Xenon in 30 % oxygen (Group A)
11533375|NCT01120405|Active Comparator|sevoflurane|0.8-1.1 Minimum Alveolar Concentration (MAC) Sevoflurane in 30 % oxygen (Group B)
11533376|NCT01120392|Experimental|Treatment group - Nintendo wii.|
11533377|NCT01120392|Active Comparator|conventional - Physical Therapy|
11533378|NCT01120379||XV-LTF cohort|
11533379|NCT01120366|Active Comparator|SWITCH|Tocilizumab monotherapy
11533380|NCT01120366|Active Comparator|ADD-ON|Tocilizumab plus methotrexate combination
11533381|NCT01120353||Cancer survivors|Survivors of cancer, diagnosed under 21 years of age, between 1970 and 1999 This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, for an increased risk of late-occurring events associated with excess mortality and morbidity.
11533382|NCT01120353||Sibling Controls|A group of sibling controls will be identified to provide: (1) the ability to make direct comparisons with the survivors, (2) data on outcomes in a non-cancer population, and (3) additional comparison group to determine consistency of findings between data sources.
11533383|NCT01120340|Active Comparator|mesalamine|Posology: mesalamine: 1,6 g/die for ten days every month for 24 months
11533384|NCT01120340|Placebo Comparator|placebo|
11533385|NCT01120327|Experimental|Amlodipine|Amlodipine
11533386|NCT01120327|Placebo Comparator|Placebo|Placebo
11533387|NCT01120314|Experimental|Severe renal impairment population|
11533388|NCT01120314|Experimental|Moderate renal impairment population|
11533389|NCT01120314|Experimental|Mild renal impairment population|
11533390|NCT01120314|Experimental|Healthy population|Healthy matched subjects
11533391|NCT01120301|Experimental|Transcranial Laser Therapy|
11533392|NCT01120301|Sham Comparator|Sham control procedure|
11533393|NCT01120275|Experimental|Treatment (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11533394|NCT01120249|Experimental|Arm I|Patients receive oral everolimus once daily on days 1-42. Treatment repeats every 6 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
11533395|NCT01120249|Placebo Comparator|Arm II|Patients receive oral placebo once daily on days 1-42. Treatment repeats every 6 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
11533396|NCT01120236|Experimental|Arm I (androgen deprivation and cixutumumab)|Patients receive androgen deprivation therapy comprising bicalutamide PO QD on days 1-28 and either goserelin acetate SC or leuprolide acetate IM every 1, 3, 4, 6, or 12 months. Patients also receive cixutumumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for 7 courses in the absence of disease progression or unacceptable toxicity.
11533397|NCT01120236|Active Comparator|Arm II (androgen deprivation therapy)|Patients receive androgen deprivation therapy comprising bicalutamide and either goserelin acetate or leuprolide acetate as in arm I.
11533398|NCT01120223|Experimental|LEO 80185 gel once daily application|
11533399|NCT01120210|Experimental|Part 1 (Main Study)|3 consecutive 1-hour infusions of JNJ-39588146 5, 15, or 30 ng/kg/min or matching placebo
11533400|NCT01120210|Experimental|Part 2 (Extended Infusion Sub-Study)|1 18-hr infusion of JNJ-39588146 of the highest tolerated dose from Part 1 of the study or matching placebo
11533401|NCT01120197|Experimental|Exercise group|"Exercise group with intervention
~Subjects in the intervention group must participate in a training course consisted of 24 sessions over 3 months. The exercises include aerobic, stretching, balance and functional training, i.e. circuit exercises focus been on: the prevention of falls and fractures, improving balance and coordination, improving posture, and informing subjects about risk factors for falls and for osteoporosis and fractures. A 3-hour session of information and supervision will be hold for the intervention group by the same physiotherapist who leads the training sessions. The focus is on body awareness and ergonomic advice in specific, daily-life situations (e.g. lifting/carrying, resting positions)."
11533402|NCT01120197|Other|Control Group|"Control group with no intervention
~Subjects in the control group are asked to maintain their current lifestyle. No restrictions are placed on their exercise activities. The control group is followed for the same duration as the intervention group."
11533408|NCT01120145||Therapeutic efficacy study|Asymptomatic parasitemic pregnant women at 16-26 weeks of gestation will be enrolled into the study and followed weekly for 42 days after the receipt of sulphadoxine-pyrimethamine intermittent preventive treatment in pregnancy to assess the clearance of parasitemia.
11533409|NCT01120145||Birth outcomes study|Women presenting for delivery will be enrolled and assessed for a history of sulphadoxine-pyrimethamine intermittent preventive treatment in pregnancy and evidence of malaria infection by placental histology, maternal peripheral parasitemia, maternal anemia and infant cord blood parasitemia.
11533410|NCT01120145||Characterizing molecular markers of SP resistance|Parasitemic outpatients attending the health facility will be tested for parasite molecular markers of sulphadoxine-pyrimethamine resistance.
11533411|NCT01120132|Experimental|Cyclosporine low dose , Prednisolone Acetate|Administration of a solution of Cyclosporine (low dose) and a suspension of Prednisolone Acetate
11533412|NCT01120132|Experimental|Cyclosporine high dose, Prednisolone Acetate|Administration of a solution of Cyclosporine (high dose) and a suspension of Prednisolone Acetate
11533413|NCT01120132|Experimental|Cyclosporine high dose|Administration of a solution of Cyclosporine (high dose) and Placebo
11533414|NCT01120132|Experimental|Cyclosporine low dose|Administration of a solution of Cyclosporine (low dose) and Placebo
11533415|NCT01120132|Active Comparator|Prednisolone Acetate|Administration of a suspension of Prednisolone Acetate and Placebo
11533416|NCT01120132|Placebo Comparator|Placebo|Administration of Placebo
11533417|NCT01120119|Experimental|Calcitriol|
11533418|NCT01120119|Placebo Comparator|placebo|
11533419|NCT01120106|Active Comparator|levosimendan|levosimendan continuous infusion at a rate of 0.1 mcg/kg<min
11533420|NCT01120106|Placebo Comparator|placebo|saline infusion
11533421|NCT01120093|Experimental|Aclidinium bromide 100 μg bid|Aclidininum bromide 100 μg twice daily by inhalation
11533422|NCT01120093|Experimental|Aclidininum bromide 200 μg bid|Aclidininum bromide 200 μg twice daily by inhalation
11533423|NCT01120093|Experimental|Aclidininum bromide 400 μg bid|Aclidininum bromide 400 μg twice daily by inhalation
11533424|NCT01120093|Placebo Comparator|Placebo|Placebo twice-daily by inhalation
11533425|NCT01120093|Active Comparator|Formoterol 12 μg bid|Formoterol 12 μg twice daily by inhalation
11533426|NCT01120080|Placebo Comparator|Practical Counseling|
11533427|NCT01120080|Active Comparator|Alcohol Intervention Counseling|
11533428|NCT01120067|Experimental|Intensive Treatment|Intensive 3 week treatment for pain and PTSD. This includes elements of Cognitive Processing Therapy and CBT for Chronic Pain
11533429|NCT01120067|Experimental|Treatment as Usual|Treatment as Usual. Participants are eligible for all treatment services as needed except for treatment of pain or PTSD
11533430|NCT01120041|Experimental|Prenatal MI - Postpartum MI|Motivational interviewing counseling given during the prenatal and postpartum phases
11533431|NCT01120041|Experimental|Prenatal MI - Postpartum Health Ed|Motivational interviewing counseling given during the prenatal phase with traditional health education given during the postpartum phase
11533432|NCT01120041|Experimental|Prenatal Health Ed - Postpartum MI|Traditional health education given during the prenatal phase with motivational interviewing counseling given during the postpartum phase
11533433|NCT01120041|Placebo Comparator|Prenatal Health Ed/Postpartum Health Ed|Traditional health education given during the prenatal phase and the postpartum phase
11533434|NCT01120028|Experimental|Alemtuzumab/Sirolimus|"Induction therapy allocation: Alemtuzumab (Campath-1H).
~Maintenance therapy allocation (at 6-months post-transplant): Sirolimus"
11533435|NCT01120028|Experimental|Alemtuzumab/Tacrolimus|"Induction therapy allocation: Alemtuzumab (Campath-1H).
~Maintenance therapy allocation (at 6-months post-transplant): Tacrolimus"
11533436|NCT01120028|Active Comparator|Basiliximab/Tacrolimus|"Induction therapy allocation: Basiliximab.
~Maintenance therapy allocation (at 6-months post-transplant): Tacrolimus"
11533437|NCT01120028|Active Comparator|Basiliximab/Sirolimus|"Induction therapy allocation: Basiliximab.
~Maintenance therapy allocation (at 6-months post-transplant): Sirolimus"
11533438|NCT01120015|Experimental|Diacerein|diacerein 50mg oD first month, 50 mg BD next 2 months
11533439|NCT01120002|Placebo Comparator|Placebo pill|
11533440|NCT01120002|Active Comparator|Tamibarotene|
11533441|NCT01119989|No Intervention|weight maintenance diet|
11533442|NCT01119989|Placebo Comparator|weight maintenance + fructose|
11533443|NCT01119989|Experimental|weight maintenance diet + fructose and amino-acid|
11533444|NCT01119976|Experimental|Group A|Reduced calorie diet and exercise plan that changes with phases of the menstrual cycle
11533445|NCT01119976|Active Comparator|Group B|Different reduced calorie diet and exercise plan based on MyPyramid.gov website
11533446|NCT01119963|Active Comparator|17-alpha hydroxyprogesterone caproate, Makena®|250 mg of 17P, Makena® intramuscular (IM) weekly.
11533447|NCT01119963|Placebo Comparator|Placebo|Castor Oil (Placebo)intramuscular (IM) weekly
11533448|NCT01119950|Experimental|NVA237 12.5 µg q.d.|NVA237 12.5 µg once daily
11533449|NCT01119950|Experimental|NVA237 25.0 µg q.d.|NVA237 25.0 µg once daily
11533450|NCT01119950|Experimental|NVA237 12.5 µg b.i.d.|NVA237 12.5 µg twice daily
11533451|NCT01119950|Experimental|NVA237 50.0 µg q.d.|NVA237 50.0 µg once daily
11533452|NCT01119950|Experimental|NVA237 25.0 µg b.i.d.|NVA237 25.0 µg twice daily
11533453|NCT01119950|Experimental|NVA237 100.0 µg q.d.|NVA237 100.0 µg once daily
11533454|NCT01119950|Experimental|NVA237 50.0 µg b.i.d.|NVA237 50.0 µg twice daily
11533455|NCT01119950|Placebo Comparator|Placebo|Placebo to NVA237 once daily
11533456|NCT01119937|Experimental|NVA237|50µg once daily
11533457|NCT01119937|Experimental|Tiotropium|18µg once daily
11533458|NCT01119924|Active Comparator|Mirtazapine|Mirtazapine 15mg/day or placebo once a day on the fist week, then 30 mg/day or placebo once a day, and then for 7 consecutive weeks
11533459|NCT01119924|Placebo Comparator|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
11533460|NCT01119898|Experimental|PENNSAID Gel|Diclofenac sodium 2.0% w/w
11533461|NCT01119898|Placebo Comparator|Vehicle|The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
11533462|NCT01119885||001|fentanyl matrix Knee osteoarthritis starting with 12mcg/h (flexible dose)
11533463|NCT01119885||002|fentanyl matrix Hip osteoarthritis starting with 12mcg/h (flexible dose)
11533464|NCT01119872|Other|Compliance-guided PEEP group|Positive End-Expiratory Pressure(PEEP) level was set daily, according to the method described by Suter in 1978. Static compliance (Cst) was calculated at different levels of PEEP at a constant tidal ventilation of 6-8 ml/kg of predicted body weight. Cst was determined by dividing tidal volume by the difference between the pressure at the end of inflation hold and the PEEP. The maximum value of Cst in individual patients was considered as the best PEEP.
11533465|NCT01119872|Other|FiO2-driven-PEEP group|"PEEP was set based on the patient fraction of inspired oxygen (FiO2) according to the Positive End-Expiratory Pressure(PEEP) strategy reported in 2000:Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network."
11533466|NCT01119859|Experimental|Tocilizumab 8 mg/kg|Patients received 6 infusions of tocilizumab 8 mg/kg intravenously every 4 weeks and 12 injections of placebo to adalimumab subcutaneously every 2 weeks.
11533467|NCT01119859|Active Comparator|Adalimumab 40 mg|Patients received 12 injections of adalimumab 40 mg subcutaneously every 2 weeks and 6 infusions of placebo to tocilizumab intravenously every 4 weeks.
11533468|NCT01119846|Experimental|Part A|Part A (Cohort 1) is a single-blind, randomized, placebo-controlled, 5-period crossover in which drug naïve T2DM subjects will receive escalating doses of GSK1292263 in each of 3 periods and placebo and open-label sitagliptin in the other 2 periods. The sequence will be randomized, but will maintain the low, medium and high dose order for GSK1292263.
11533469|NCT01119846|Experimental|Part B|Part B (Cohort 2) is a single-blind, randomized, 2-period study in which T2DM subjects will receive a single dose of GSK1292263, fasted or fed.
11533470|NCT01119846|Experimental|Part C|Part C (Cohort 3, optional Cohort 4) is a single-blind, randomized, placebo-controlled, 5-arm study of 14 days of dosing with GSK1292263, placebo or open-label sitagliptin. An optional Cohort 4 may be enrolled to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1292263 when dosed in a BID regimen.
11533471|NCT01119833|Experimental|GMI-1070|
11533472|NCT01119833|Placebo Comparator|Placebo|
11533473|NCT01119820|Experimental|Tissue Donation|This study will involve females over 18 who are scheduled to undergo elective surgery. These patients will be screened for participation in this study, which will only involve the collection of discarded tissue.
11533474|NCT01119807|Experimental|IV|
11533475|NCT01119807|Experimental|Humeral IO|
11533476|NCT01119807|Active Comparator|Tibial IO|
11533477|NCT01119794|Experimental|ofatumumab and bortezomib|Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
11533478|NCT01119781|Experimental|peginterferon beta-1a|Single dose of peginterferon beta-1a at either 63 or 125 mcg in renal impaired Participants and healthy volunteers
11533479|NCT01119768|Active Comparator|Esomeprazole 8 weeks treatment|20 mg q.d. (quaque die) once a day dosing for 8 weeks
11533480|NCT01119768|Active Comparator|Esomeprazole 2 Weeks Treatment|20 mg q.d. (quaque die) once a day dosing for 2 weeks
11533481|NCT01119742|Experimental|Butenafine Hydrochloride 1% A|1
11533482|NCT01119742|Experimental|Butenafine Hydrochloride 1% B|2
11533483|NCT01119742|Active Comparator|Butenafine Hydrochloride 1%|3
11533484|NCT01119742|Placebo Comparator|Vehicle A|4
11533485|NCT01119742|Placebo Comparator|Vehicle B|5
11533486|NCT01119729||HIV-infected Outpatients|
11533487|NCT01119716||All Enrolled Participants|Participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options
11533488|NCT01119703||Arm 1: Healthy, elderly participants|Healthy participants 65 years old and older.
11533489|NCT01119703||Arm 2: Healthy, young, participants|Healthy participants 25 to 40 years old.
11533490|NCT01119690|Active Comparator|Rapeseed oil|
11533491|NCT01119690|Active Comparator|Milk fat|
11533492|NCT01119677|Experimental|Group 1|No dose titration
11533493|NCT01119677|Experimental|Group 2|Fast dose titration
11533494|NCT01119677|Experimental|Group 3|Slow dose titration
11533495|NCT01119664|Experimental|No prior chemotherapy|Intrapleural SCH 721015 (Ad.hIFN-α2b) instilled over 2-5 minutes on Days 1 and 4. Chemotherapy administered for 4 to 6 cycles Subjects with malignant pleural mesothelioma who have been previously untreated with chemotherapy
11533496|NCT01119664|Experimental|Patients with prior Pemetrexed-based chemotherapy|Intrapleural SCH 721015 (Ad.hIFN-α2b) instilled over 2-5 minutes on Days 1 and 4. Chemotherapy administered for 4 to 6 cycles Subjects with malignant pleural mesothelioma who have been previously treated with chemotherapy
11533497|NCT01119651|Experimental|Tazarotene Foam without irradiation|Subjects will be exposed to Tazarotene Foam Patch without irradiation
11533498|NCT01119651|Experimental|Tazarotene Foam with UVA and UVB irradiation|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB irradiation
11533499|NCT01119651|Experimental|Tazarotene Foam & UVA/UVB/visible light|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB and visible light irradiation
11533500|NCT01119651|Placebo Comparator|Vehicle Foam without irradiation,|Subjects will be exposed to Vehicle Foam Patch without irradiation
11533501|NCT01119651|Placebo Comparator|Vehicle Foam with UVA and UVB irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB irradiation
11533502|NCT01119651|Placebo Comparator|Vehicle Foam with UVA & UVB visible light irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB and visible light irradiation
11533503|NCT01119651|Sham Comparator|Blank patch without irradiation|Subjects will be exposed to blank patch without irradiation,
11533504|NCT01119651|Sham Comparator|Blank patch with UVA and UVB irradiation|Subjects will be exposed to blank patch with UVA and UVB irradiation
11533505|NCT01119651|Sham Comparator|Blank Patch with UVA & UVB visible light irradiation|Subjects will be exposed to Blank Patch with UVA and UVB and visible light irradiation
11533506|NCT01119638|Active Comparator|Escitalopram Drug|"Drug:
~Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion."
11533553|NCT01119300|Active Comparator|Standard care|Standard care
11533507|NCT01119638|Active Comparator|Risperidone Drug|Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
11533508|NCT01119625|Experimental|Synflorix™ Commercial-Commercial + Infanrix™-IPV/Hib Group|children primed with 3 doses of commercial lot of Synflorix™ co-administered with Rotarix™ and Infanrix™-hexa in the primary phase of the study (NCT00808444) and boosted with commercial lot of Synflorix™ co-administered with Infanrix™-IPV/Hib. The Synflorix™ vaccine (commercial lots) was administered intramuscularly in the right deltoid or anterolateral thigh and the Infanrix™-IPV/Hib vaccine was administered intramuscularly in the left deltoid or anterolateral thigh.
11533509|NCT01119625|Active Comparator|Synflorix™ Clinical-Commercial + Infanrix™-IPV/Hib Group|children primed with 3 doses of clinical lot of Synflorix™ + Rotarix™ co-administered with Infanrix™-hexa in the primary phase of the study (NCT00808444) and boosted with commercial lot of Synflorix™ co-administered with Infanrix™-IPV/Hib. The Synflorix™ vaccine (clinical and commercial lots) was administered intramuscularly in the right deltoid or anterolateral thigh and the Infanrix™-IPV/Hib vaccine was administered intramuscularly in the left deltoid or anterolateral thigh.
11533510|NCT01119612|Active Comparator|Iron|
11533511|NCT01119612|Placebo Comparator|Placebo|
11533512|NCT01119599|Experimental|Treatment (RO4929097, surgery, radiation therapy)|See Detailed Description.
11533513|NCT01119560||Ancillary-Correlative (Questionnaire, saliva & tissue sample)|The biologic mother of the patient is asked to complete a Diet History Questionnaire about diet during pregnancy, and information on demographics, lifestyle factors, medication used during pregnancy, history of breast feeding, and family history of cancer or birth defects. Parents are given ORAgene saliva collection kits for self-collection. Saliva bio-specimen samples are collected from both biologic parents and the patient. Tissue samples previously stored in a tissue bank are obtained for deceased patients, if available. DNA is extracted from samples, amplified and analyzed using real-time PCR quantitation assay, and genotyped using single nucleotide polymorphisms.
11533514|NCT01119547|Experimental|Home exercise|The patients is training at home during 6 v. with an individual exercise program.
11533515|NCT01119547|Experimental|Exercise in group|The patients is doing their individual exercise program in a group.
11533516|NCT01119534|Experimental|Transpulmin|Suppository composed by guaiacol, eucalyptol, menthol and camphor
11533517|NCT01119534|Active Comparator|Comparator 1|Suppository composed by guaiacol
11533518|NCT01119534|Active Comparator|Comparator 2|Syrup composed by guaifenesin
11533519|NCT01119521|Experimental|Group A: INH; BCG|6 months of Isoniazid (INH) treatment for latent tuberculosis infection (LTBI) (completed within no more than 7 months) followed by intradermal Bacillus Calmette-Guérin (BCG) revaccination.
11533520|NCT01119521|Experimental|Group B: observation; BCG; observation; INH|7 months of observation (run in period) followed by intradermal Bacillus Calmette-Guérin (BCG) revaccination followed after 6 months of observation by 6 months of Isoniazid (INH) treatment for latent tuberculosis infection (LTBI).
11533521|NCT01119508|Experimental|Ipilimumab + Temozolomide|Induction: Ipilimumab 10 mg/kg IV over 90 minutes Day 1 + Temozolomide 200 mg/m2 PO on Days 1 - 4, every 3 weeks for 4 courses over 3 months.
11533522|NCT01119482|Other|Vaccination|Healthy volunteers before and after vaccination
11533523|NCT01119469|Experimental|Cognitive Therapy (CT)|There will be 12 50-minute individual sessions conducted at weekly intervals. Booster sessions will be conducted one, three and six months after treatment. Sessions include psychoeducation, attention training, cognitive restructuring, behavioral experiments, imagery rescripting and relapse prevention.
11533524|NCT01119469|Experimental|Exposure Therapy (ET)|There will be 12 50-minute individual sessions conducted at weekly intervals. Booster sessions will be conducted one, three and six months after treatment. Sessions include change of safety behavior, exposition (in sensu and in vivo), and response prevention.
11533525|NCT01119469|No Intervention|Waiting List (WL)|12 weeks waiting time
11533526|NCT01119456|Experimental|IMC-RON8|A monoclonal antibody to human macrophage-stimulating 1-receptor-8 (RON8).
11533527|NCT01119443|Other|Treatment sequence A|V4: PPX ER 1.5mg x 1 fed, V5: PPX ER 0.375mg x 4 fed, V6:: PPX ER 1.5mg x 1 fasted, V5: PPX ER 0.375mg x 4 fasted
11533528|NCT01119443|Other|Treatment sequence B|V4: PPX ER 0.375mg x 4 fed, V5: PPX ER 1.5mg x 1 fed, V6:: PPX ER 0.375mg x 4 fasted, V5: PPX ER 1.5mg x 1 fasted
11533529|NCT01119430|Placebo Comparator|Fluoxetine plus placebo|
11533530|NCT01119430|Active Comparator|Fluoxetine plus DU125530|
11533531|NCT01119417|Experimental|BQ123|endothelin blocker
11533532|NCT01119417|Placebo Comparator|Saline|IV saline
11533533|NCT01119404||Metabolic Syndrome|120 men with metabolic syndrome
11533534|NCT01119404||Coronary Heart Disease (CHD)|120 men with angiographically verified CHD
11533535|NCT01119404||Control|80 physically active men
11533536|NCT01119391||Patients undergoing IVF|Women undergoing an in vitro fertilization cycle
11533537|NCT01119378|Experimental|Post Menopausal|post menopausal women between the ages 50-70 yrs.
11533538|NCT01119365|Experimental|Light|Bright light
11533539|NCT01119352|Experimental|1|
11533540|NCT01119352|Placebo Comparator|2|
11533541|NCT01119339|Experimental|LAS 41004 dosage 1|
11533542|NCT01119339|Experimental|LAS 41004 dosage 2|
11533543|NCT01119339|Experimental|LAS 41004 dosage 3|
11533544|NCT01119339|Experimental|LAS 41004 dosage 4|
11533545|NCT01119339|Experimental|LAS 41004 dosage 5|
11533546|NCT01119339|Experimental|LAS 41004 dosage 6|
11533547|NCT01119339|Placebo Comparator|Placebo|
11533548|NCT01119339|Active Comparator|Reference|
11533549|NCT01119326|Placebo Comparator|Placebo|Placebo procedure
11533550|NCT01119326|Experimental|Autologous Fat Transfer (AFT) group|Subjects will be registered in the context of either the Early AFT subgroup, or the Delayed AFT subgroup based on the timing of their wound closure: early AFT subgroup will contain subjects who are medically stable such that study sites are amenable to AFT within 2-4 weeks of definitive closure (STSG) or healing (secondary closure) and the delayed AFT subgroup will contain subjects who are medically stable such that study sites are amenable to AFT within 6 months or more of definitive closure (STSG) or healing (secondary closure
11533551|NCT01119313|Experimental|LAS 41002|
11533552|NCT01119313|Active Comparator|Active|
11533777|NCT01117636|Active Comparator|Arm 2|
11533554|NCT01119300|Experimental|Genotype-guided dosing algorithm|Genotyping for CYP2C9*2, CYP2C9*3, and VKORC1 (-1639G→A) was performed with the use of a point-of-care test. For patients assigned to the genotype-guided group, warfarin doses were prescribed according to pharmacogenetic-based algorithms for the first 5 days.
11533555|NCT01119287|Experimental|Maxidex|Dexamethasone 0.1% ophthalmic suspension, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days [Visit 4 through Visit 6 morning only]
11533556|NCT01119287|Experimental|Patanol|Olopatadine hydrochloride 0.1% ophthalmic solution, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days [Visit 4 through Visit 6 morning only]
11533557|NCT01119287|Placebo Comparator|Tears Naturale II|Inactive ingredients, used as placebo, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days [Visit 4 through Visit 6 morning only]
11533558|NCT01119274|Active Comparator|Non-genotype-guided dosing algorithm|
11533559|NCT01119274|Experimental|Genotype-guided dosing algorithm|
11533560|NCT01119261|Active Comparator|Non-genotype-guided dosing algorithm|
11533561|NCT01119261|Experimental|Genotype-guided dosing algorithm|
11533562|NCT01119248||Children undergoing MRI|120 children ages of 6 months and 8 years for MRI and axillary temperature before MRI and after the MRI with MRI compatible device
11533563|NCT01119235|Active Comparator|Cohort 1: PF-04531083|
11533564|NCT01119235|Active Comparator|Cohort 2: PF-04531083|
11533565|NCT01119222|Active Comparator|Gabapentin 1200mg|
11533566|NCT01119222|Active Comparator|Diphenhydramine 50 mg|
11533567|NCT01119222|Active Comparator|Morphine 10 mg|
11533568|NCT01119222|Placebo Comparator|Placebo formulations|
11533569|NCT01119209|Active Comparator|Ropivacaine|
11533570|NCT01119209|Placebo Comparator|Saline|
11533571|NCT01119196|No Intervention|glucose-based dialysate|most frequently used Standard of Care (SOC) dialysate
11533572|NCT01119196|Other|Icodextrin dialysate|alternate SOC dialysate
11533573|NCT01119183|No Intervention|1|
11533574|NCT01119183|Active Comparator|2|
11533575|NCT01119183|Experimental|3|
11533576|NCT01119170|Placebo Comparator|control starter formula|
11533577|NCT01119170|Experimental|D-lactate probiotics|
11533578|NCT01119157|Experimental|humoral and cellular immune response|
11533579|NCT01119157|Experimental|reactogenicity|
11533580|NCT01119144|Experimental|Polycaprolactone / Tricalcium Phosphate|Polycaprolactone / Tricalcium Phosphate group to assess efficacy of new implant
11533581|NCT01119144|Active Comparator|Control|Control group with titanium mesh
11533582|NCT01119131|Active Comparator|Arm 1|Will be on high dose vitamin D3 (10,000 IU daily) and 1000 mg of calcium
11533583|NCT01119131|Placebo Comparator|Arm 2|Will be on placebo and 1000mg of calcium.
11533584|NCT01119118|Experimental|1|ZD4054 + multimodal PET/MRI imaging
11533585|NCT01119105|Experimental|BC-3781 dose 100mg|
11533586|NCT01119105|Experimental|BC-3781 dose 150mg|
11533587|NCT01119105|Active Comparator|Vancomycin|
11533588|NCT01119092|Sham Comparator|Sham intervention plus standard treatment|"This group will receive a laying of hands treatment in addition to standard treatment. The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between."
11533589|NCT01119092|No Intervention|Control Group|This group will be individuals who suffer from the same injury but will be instructed to stretch at home 5 days a week for 2 weeks.
11533590|NCT01119092|Experimental|Grade IV AP joint mobilization plus standard treatment|This group will receive 3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
11533591|NCT01119079|Placebo Comparator|Standard labor epidural protocol|Standard labor epidural protocol
11533592|NCT01119079|Experimental|10ml Normal Saline prior to lidocaine|
11533593|NCT01119066|Experimental|Total Body Irradiation, Thiotepa and Cyclophosphamide|Hyperfractionated total body irradiation to a dose of 1375-1500 cGy (depending on age, stage of disease and requirement of general anesthesia) with lung shielding) Thiotepa (5 mg/kg/day x 2 or 10 mg/kg/day x 1) Cyclophosphamide (60 mg/kg/day x 2) (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)
11533594|NCT01119066|Experimental|Busulfan, Melphalan and Fludarabine|Busulfan (0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified according to pharmacokinetics Melphalan (70mg/m2/day x 2 ) Fludarabine (25mg/m2/ day x 5)
11533595|NCT01119066|Experimental|Clofarabine, Melphalan and Thiotepa|Clofarabine (20mg/m2/ day x 5) (or, for children <18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval), Melphalan (70 mg/m2/day x 2) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)
11533596|NCT01119066|Experimental|Melphalan, Fludarabine and Thiotepa|Melphalan (70 mg/m2/day x 2) Fludarabine (25mg/m2/ day x 5 ) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)
11533597|NCT01119053|Sham Comparator|Arm I|In this branch of study, study participants obtain the VNS therapy after a defined space of time of 12 weeks.
11533598|NCT01119053|Experimental|Arm II|Within this space of time, study participants obtain the VNS therapy at once.
11533599|NCT01119040|Experimental|NOTES PEG Rescue|A new way of performing surgery is called Natural Orifice Translumenal Endoscopic Surgery, or NOTES, for short. NOTES may allow surgeons to perform abdominal surgery without any skin incisions. By using natural openings in the body, like the mouth, surgeons can enter the stomach with a tube instead of the traditional method of making an incision in the skin of the abdomen.
11533600|NCT01119027||Surgeons|Surgeons and trainee surgeons attending laparoscopic colorectal training courses will be recruited to study using different training models to compare each model and correlate outcomes with each model to pre-course experience. .
11533601|NCT01119027||Trainee Surgeons|Surgeon and trainee surgeons attending laparoscopic colorectal training courses will be recruited to study using different training models to compare each model and correlate outcomes with each model to pre-course experience.
11533602|NCT01119014|Experimental|Aripirazole|
11533603|NCT01119014|Experimental|Quetiapine prolong|
11533604|NCT01119001|Experimental|P300 Brain Computer Interface for people with ALS|
11533605|NCT01118988|Experimental|Mentorship|"Subjects randomly assigned to this arm received the specified Mentorship Intervention"
11533606|NCT01118988|No Intervention|Control|Subjects randomly assigned to this control group receive treatment as usual (TAU).
11533607|NCT01118988|No Intervention|Mentors|"Subjects recruited to the Mentor arm of the study are UCLA Pediatric Pain Program patients between the ages of 14 and 18. These mentors are identified by the Principal Investigator as children who have not necessarily eliminated pain, but have learned how to cope with pain and maintain appropriate functioning in daily life. Mentors undergo an in depth training from doctoral level psychologists who are members of the research team. Mentors present pain coping information developed by the research team, provide support, and encourage mentees to attend pain management therapies. They are also monitored by doctoral level psychologists throughout the duration of the study to ensure safety and appropriate contact with mentees via telephone."
11533608|NCT01118975|Experimental|Pilot Phase - Vornistat 200 to 400mg + Lapatinib|lapatinib 1,250 mg continuous daily and escalating doses of vorinistat (200mg run-up, 300mg, and 400mg 4 days on 3 days off)
11533609|NCT01118975|Experimental|Phase II - Vorinistat 400mg + Lapatinib|lapatinib 1,250 mg continuous daily and vorinostat 400 mg 4 days on 3 days
11533610|NCT01118962|Experimental|Lacosamide|"Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949).
~Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses."
11533611|NCT01118949|Experimental|Lacosamide|
11533612|NCT01118936|No Intervention|Washout|
11533613|NCT01118936|Active Comparator|Mablet|
11533614|NCT01118936|Placebo Comparator|Placebo|
11533615|NCT01118923|No Intervention|Washout|
11533616|NCT01118923|Active Comparator|Mablet|
11533617|NCT01118923|Placebo Comparator|Placebo|
11533618|NCT01118910|Experimental|Vusion ointment|
11533619|NCT01118897|Experimental|Neoadjuvant chemoradiation|All patients will receive concurrent chemoradiation. Chemotherapy will consist of Inj. Gemcitabine 300mg/mt2 weekly throughout the course of Radiotherapy. Radiotherapy will be delivered using Tomotherapy to a dose of 57Gy/25# over 5 weeks
11533620|NCT01118884|Experimental|sedation|20 healthy uncooperative children aged 36-96 months were examined in a cross-over study design , each patient served as his/her own control. Each patient was assigned randomly to received 1 of 2 drug regimens for initial sedation session and the other regimen administered at second session which was one week later.
11533621|NCT01118871|Active Comparator|Standard of care|
11533622|NCT01118871|Experimental|NRTI sparing arm|
11533623|NCT01118858||Case|Pediatric patients who have a primary diagnosis of ADHD, combined type, hyperactive impulsive, or inattentive type (ADD).
11533624|NCT01118858||Control|Healthy subjects: Age and gender matched subjects who do not meet any of the exclusion criteria
11533625|NCT01118845|Experimental|SyB L-0501|
11533626|NCT01118819|Experimental|Clostridium novyi-NT spores|
11533627|NCT01118806||medical residents, vit d|vitamin
11533628|NCT01118806||levels of vitamin d|resident
11533629|NCT01118793||double dosing of Clopidogrel|
11533630|NCT01118780|Experimental|Duloxetine 30 milligrams (mg) -120 mg|
11533631|NCT01118780|Placebo Comparator|Placebo|
11533632|NCT01118767|Experimental|Cell phone intervention|Participant receives short text messages
11533633|NCT01118767|No Intervention|Standard of care|Participant receives standard of care support but not short text messages
11533634|NCT01118754|Experimental|DE-101 ophthalmic suspension high dose|
11533635|NCT01118754|Experimental|DE-101 ophthalmic suspension low dose|
11533636|NCT01118754|Placebo Comparator|DE-101 ophthalmic suspension vehicle|
11533637|NCT01118728|Experimental|Sarilumab|Sarilumab 150 mg subcutaneous (SC) injection every week (or every other week in case of safety issue) for 260 weeks, or until commercially available, or until discontinuation of the project, whichever came first.
11533638|NCT01118715|Experimental|Compression glove|Patients in this group have a compression glove incorporated into their splint for 2 weeks post-op, and wear a glove underneath their cast for 3 weeks. The patient then wears the glove at night after cast removal.
11533639|NCT01118715|No Intervention|Control|Patients in this group undergo standard recovery procedures. This includes a splint worn for 2 weeks post-op, followed by a short arm cast worn for the next 3 weeks.
11533640|NCT01118702|Active Comparator|001|Concerta one 54mg tablet once
11533641|NCT01118702|Active Comparator|002|Ritalin-SR 3-20mg tablets once
11533642|NCT01118702|Active Comparator|003|Novo-Methylphenidate ER-C one 54mg tablet once
11533643|NCT01118689|Experimental|MLN0128|
11533644|NCT01118676|Experimental|Cilengitide with standard radiochemotherapy|Cilengitide (4 dose levels are defined :12, 18, 27 et 40 mg /hour) concomitant with radiotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction) and cisplatin and vinorelbine based chemotherapy.
11533645|NCT01118663|Experimental|Acetadote without EDTA|Acetadote EF [Ethylenediaminetetraacetic Acid (EDTA) - Free]
11533646|NCT01118663|Active Comparator|Acetadote|Acetadote [Old formulation containing EDTA]
11533647|NCT01118637|Experimental|Immediate|Assigned immediately after baseline assessment to receive step 1 treatment (web-based self-help)
11533648|NCT01118637|No Intervention|Wait list|Assigned to wait list for 10 weeks before receiving step 1 treatment.
11533649|NCT01118624|Experimental|Pralatrexate, (RS)-10-propargyl-10-deazaaminopterin (Folotyn)|"Intravenous (IV) push administration over 3-5 minutes. Initial dose: 190 mg/m2 Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.
~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
11533650|NCT01118598|Placebo Comparator|placebo arm|this group will receive placebo as per protocol
11533651|NCT01118598|Active Comparator|tredaptive|tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks
11533652|NCT01118585|Other|TIF Procedure|Intervention: Transoral incisionless fundoplication procedure using the EsophyX device. During general anesthesia the EsophyX device is introduced trans orally into the stomach and used to created a 270 degree, 3cm in length, wrap at the distal end of the esophagus to treat GERD.. .
11533653|NCT01118572|Experimental|YM177 group|
11533654|NCT01118572|Active Comparator|etodolac group|
11533655|NCT01118572|Placebo Comparator|placebo group|
11533656|NCT01118559|Experimental|fast-fed sequence group|drug is administered in a fasted condition first, and fed-condition study follows
11533657|NCT01118559|Experimental|fed-fast sequence group|drug is administered in a fed condition first, and fasted-condition study follows
11533658|NCT01118546||controls 2|patient without CAD, not on aspirin and without history of hypersensitivity
11533659|NCT01118546||case of hypersensitivity|patient with CAD on aspirin, with a history of hypersensitivity
11533660|NCT01118546||controls 1|patient with CAD on aspirin, without history of hypersensitivity
11533661|NCT01118533|Experimental|metallic blades|laryngoscope blade material
11533662|NCT01118533|Active Comparator|plastic laryngoscope blades|Laryngoscope Blade Material
11533663|NCT01118520|Active Comparator|perindopril|ACE inhibitor blood pressure lowering agent
11533664|NCT01118520|Active Comparator|amlodipine|calcium channel blocker blood pressure lowering agent
11533665|NCT01118520|Placebo Comparator|placebo|inactive substance identical in appearance to the othe two comparators
11533666|NCT01118507||TRISOMY|mothers of a trisomic fetus 21
11533667|NCT01118507||NORMAL KARYOTYPE|mothers of DISOMIQUE foetus 21
11533668|NCT01118494||CKD patients|People who have been diagnosed with CKD，and been in the stage of 3 or 4.
11533669|NCT01118481||Pressure and flow velocity|
11533670|NCT01118481||Pressure only|
11533671|NCT01118455|Experimental|Vagus Nerve Stimulation (VNS) Therapy|Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
11533672|NCT01118455|Experimental|Anti-Epileptic Drug (AED)|This arm will supply a comparison between VNS and new AEDs which is necessary to determine an overall treatment regimen for the 30% to 40% of patients who fail to respond to 2 AEDs.
11533673|NCT01118429|Experimental|Oxybutynin|Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
11533674|NCT01118429|Placebo Comparator|Placebo|Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
11533675|NCT01118416|Experimental|intervention condition|Participants randomized to the intervention condition will undergo 4 one-hour sessions of motivational interviewing (MI), during which their sexual risk taking and substance use patterns will be discussed with a trained counselor with the goal of reducing instances of unprotected anal sex and substance use.
11533676|NCT01118416|Active Comparator|Education condition|Participants randomized to the education condition will undergo 4 one-hour sessions during which they will view video segments and discuss sexual risk taking and substance use with a health educator, with the goal of reducing instances of unprotected anal sex and substance use by making informed decisions.
11533677|NCT01118403|Experimental|Sultamicillin, Antibiotic Prophylaxis|Sultamicillin, Antibiotic Prophylaxis
11533678|NCT01118403|Placebo Comparator|Placebo|Physiologic Sodium Chloride Solution
11533679|NCT01118390|Experimental|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
11533680|NCT01118390|Active Comparator|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
11533681|NCT01118377|Experimental|Capecitabine + radiation therapy|Participants received 9 weeks of capecitabine 650 mg/m^2 orally (po) twice daily (bid) plus radiation therapy (180 cGy/day 5 days a week, total target dose of 56 Gy) followed by a 2-week rest period. Participants then received 3 cycles of capecitabine 1250 mg/m^2 po bid for 14 days followed by a 7-day rest period without radiation therapy.
11533682|NCT01118364|Experimental|cigarette with cannabis|"a cigarette tobacco trade mark Drum with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)"
11533683|NCT01118364|Other|cigarette without cannabis|"a cigarette tobacco trade mark Drum"
11533684|NCT01118351|Experimental|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
11533685|NCT01118338|Experimental|Redesigned Purevision Contact Lens|Redesigned Bausch & Lomb PureVision contact lens
11533686|NCT01118338|Active Comparator|PureVision Contact Lens|Bausch & Lomb PureVision contact lens
11533687|NCT01118325|Experimental|AZD6140 45 mg bd|
11533688|NCT01118325|Experimental|AZD6140 90 mg bd|
11533689|NCT01118325|Active Comparator|Clopidogrel 75 mg od|
11533690|NCT01118312|Active Comparator|Nasal Steroid|Intranasal mometasone, 1 spray (age < 12 yr) or 2 sprays (age >= 12 yrs) each nostril once a day
11533691|NCT01118312|Placebo Comparator|Placebo|Intranasal placebo, 1 spray (age < 12 yr) or 2 sprays (age >= 12 yrs) each nostril once a day
11533692|NCT01118299|Experimental|Device|AMPLATZER Cardiac Plug
11533693|NCT01118299|Active Comparator|Optimal Medical Therapy (control)|Warfarin Dabigatran
11533694|NCT01118286||Group 1|
11533695|NCT01118273|Experimental|Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|
11533696|NCT01118273|Active Comparator|Naproxen Sodium 440 mg (BAYH6689)|
11533697|NCT01118273|Experimental|Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|
11533698|NCT01118273|Active Comparator|Naproxen Sodium 220 mg (BAYH6689)|
11533699|NCT01118273|Active Comparator|DPH 50mg|
11533700|NCT01118273|Active Comparator|Ibuprofen 400 mg / Diphenhydramine citrate 76 mg|
11533701|NCT01118260|Active Comparator|TIVA|Total intravenous anaesthesia (TIVA) with propofol and remifentanil
11533702|NCT01118260|Active Comparator|Spinal|Spinal anaesthesia with bupivacaine and fentanyl
11533703|NCT01118247|Experimental|pure Ti|Cup and stem partly coated with pure titanium
11533704|NCT01118247|Active Comparator|pure Ti and HA|Cup and stem partly coated with pure titanium, and fully coated with HA.
11533705|NCT01118234|Experimental|Rituximab|Treatment with Rituximab 375 mg/m² every 3 months for 24 months
11533706|NCT01118234|No Intervention|Observation|Observation for 24 months
11533707|NCT01118221|Experimental|Arm 1|enroll in pulmonary rehabilitation program
11533708|NCT01118221|No Intervention|Arm 2|no structured exercise
11533709|NCT01118208|Experimental|Blister Packaging|Patients will receive all prescription medications on blister pack cards.
11533710|NCT01118208|Active Comparator|Dispense as Usual|Patients will receive all prescription medications in standard pill bottles.
11533711|NCT01118195||TBI and Suicidal Behavior|
11533712|NCT01118195||TBI and No Suicidal Behavior|
11533713|NCT01118182||Traumatic Brain Injury (TBI)|Veterans with a positive history of TBI
11533714|NCT01118182||No Traumatic Brain Injury (TBI)|Veterans with a negative history of TBI
11533715|NCT01118169||Veterans|
11533716|NCT01118156||Mental Health Clinicians|MH Clinicians at the Denver and Grand Junction VA Medical Centers
11533717|NCT01118143|Experimental|intervention group|Tailored oral health literacy instruction
11533718|NCT01118143|No Intervention|control group|Oral health instruction not tailored to oral health literacy level
11533719|NCT01118130||Case|MS patients experiencing an adverse drug reaction to an MS immunomodulatory therapy
11533720|NCT01118130||Control|MS patients not experiencing an adverse drug reaction to an MS immunomodulatory therapy
11533721|NCT01118117|Experimental|Misago™ Self-Expanding Stent System|
11533722|NCT01118104|Other|Pulmonary vocational rehabilitation|
11533723|NCT01118091|Active Comparator|Arm 1-Aldesleukin|Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.
11533724|NCT01118091|Experimental|Arm 2 - Adoptive cell therapy|Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10^9 to 2x10^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x10^8) and the administration of high-dose aldesleukin.
11533725|NCT01118078||Biomarker (DNA methylation, gene expression, RT-PCR)|Archived tumor tissue samples are analyzed for DNA copy number determination, gene expression analysis, DNA methylation, and genomic re-sequencing by microarray analysis-based methods, including PCR analysis, DNA methylation analysis-specific RT-PCR, and quantitative RT-PCR (reverse transcriptase-polymerase chain reaction)
11533726|NCT01118052|Experimental|Treatment (EGEN-001)|Patients receive intraperitoneal EGEN-001 on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11533727|NCT01118026|Experimental|ABVD +/- BEACOPP + radiation|"Patients receive ABVD administered by intravenous (IV) infusion on days 1 and 15 of each cycle. A cycle is considered 28 days. Patients receive a total of two cycles.
~Patients undergo a PET scan following two cycles of ABVD. If the PET scan is negative, then the patient will receive four more cycles of ABVD (a total of 6 cycles of ABVD). If the PET scan is positive, then the patient receives four cycles of escalated BEACOPP for 21 days (a total of 4 cycles).
~3-6 weeks after BEACOPP therapy, patients receive radiation therapy for 5 days per week (a total of 3.5 weeks).
~All patients will be followed for a maximum of ten years."
11533728|NCT01118013|Experimental|Treatment|"Matched-unrelated donor: Patients receive antithymocyte globulin, tacrolimus, and methotrexate as in HLA-identical donor regimen. Patients also receive oral mycophenolate mofetil twice daily on days 0 to 60.
~Allogeneic Stem Cell Transplantation: Patients undergo allogeneic peripheral blood stem cell transplantation on days 0 and 1. Patients then receive filgrastim subcutaneously daily beginning on day 7 and continuing until blood counts recover.
~Donor Lymphocyte Infusion (DLI): After day 180 (or day 210 for patients without an HLA-identical donor), patients with stable or progressive disease and no active GVHD may receive up to 3 DLIs every 8 weeks.
~Blood samples are collected at baseline and then periodically during study therapy for pharmacokinetic studies.
~After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for up to 5½ years."
11533729|NCT01118000|Experimental|limb ischemia preconditioning|limb ischemic preconditioning consists of three 5-min cycles of left upper limb ischemia induced by a blood pressure cuff placed on the left upper arm and inflated to 200 mmHg,with an intervention 5-min of reperfusion during which the cuff was deflated.
11533730|NCT01117987|Experimental|Core imatinib|Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.
11533731|NCT01117987|Experimental|Core placebo|Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.
11533732|NCT01117974|Experimental|Liposuction|
11533733|NCT01117961|No Intervention|control|
11533734|NCT01117961|Experimental|Intervention|Lifestyle intervention delivered during pregnancy
11533735|NCT01117948|Experimental|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
11533736|NCT01117948|Placebo Comparator|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
11533737|NCT01117935|Experimental|Arm I|Patients undergo hypofractionated intensity modulated radiotherapy once daily, 5 days a week, for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with intermediate- and high-risk disease may also receive concurrent and adjuvant or long-term androgen deprivation therapy for up to 36 months.
11533738|NCT01117922|Experimental|Intervention|After consent, subjects will be assigned to either a usual care group (no intervention) or an intervention group (targeted interconceptional interventions).
11533739|NCT01117922|Other|Usual Care Group|This group will receive usual care.
11533778|NCT01117636|Placebo Comparator|Arm 3|
11533779|NCT01117623|Experimental|Arm 1|
11533780|NCT01117623|Experimental|Arm 2|
11533781|NCT01117623|Experimental|Arm 3|
11533782|NCT01117623|Experimental|Arm 4|
11533783|NCT01117623|Experimental|Arm 5|
11533740|NCT01117909|Sham Comparator|"Laying of hands plus standard therapy"|Subjects will lie on their back as if they were receiving the joint mobilization treatment and the therapist will place their hands in a position as if to perform the mobilization but no movement will occur. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression
11533741|NCT01117909|Experimental|Standard therapy with joint mobilization|This group will receive three 60-second bouts of posterior joint mobilizations applied to the ankle joint during each treatment session, in addition to standard therapy. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression
11533742|NCT01117896|Experimental|Adult vs Pedi manikin CC quality|"The primary objective is to determine whether chest compression deterioration occurs at the same rate in pediatric and adult manikins. The primary endpoint will be the difference in mean number of effective compressions per minute in each manikin at times 1, 2, 5 and 10 minutes.
~Another objective is to identify the correlation between the anaerobic threshold and the deterioration of compressions in each manikin. The endpoint will be the difference between mean time to ineffective compressions (defined as 10 consecutive compressions that fail to meet AHA guidelines for depth and rate) and mean time to anaerobic threshold in each manikin."
11533743|NCT01117896|Experimental|Stepstool use|A third main objective is to determine the effect of the stepstool use on the quality of chest compressions and metabolic demand. The endpoint will be the difference between mean time to ineffective compressions (defined as 10 consecutive compressions that fail to meet AHA guidelines for depth and rate) and mean time to anaerobic threshold in each experimental group.
11533744|NCT01117870|Placebo Comparator|Placebo|The needle will be continuously stimulated at a low voltage to give a sensation of PRF treatment.
11533745|NCT01117870|Experimental|Pulsed Radiofrequency|PRF will be applied for 120 seconds at 42 degrees celsius.
11533746|NCT01117857|Experimental|Duloxetine|After a one-week placebo lead-in, all eligible subjects will receive Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg Duloxetine per day for 7 weeks.
11533747|NCT01117844|Experimental|Proton radiation|
11533748|NCT01117818|Active Comparator|A: AFFITOPE AD02|
11533749|NCT01117818|Active Comparator|B: AFFITOPE AD02|
11533750|NCT01117818|Active Comparator|C: AFFITOPE AD02|
11533751|NCT01117818|Active Comparator|D: Placebo control|
11533752|NCT01117805|Active Comparator|Intervention|Subjects will be randomized to the program intervention which is a female-specific, culturally relevant, self-regulation based telephone counseling intervention designed for African American women with asthma.
11533753|NCT01117805|No Intervention|usual care|Usual care at the University of Michigan Health System is based on the guidelines as recommended by the National Asthma Education and Prevention Program Expert Panel Report 3 (NAEPP-EPR3): Diagnosis and Treatment of Asthma and is coordinated so that all patients receive the same action plan, educational materials and instructions in use of devices.
11533754|NCT01117792|Experimental|S-ICD System|
11533755|NCT01117779||Kidney lesions amenable to cryoablation|Kidney lesions treated with cryoablation.
11533756|NCT01117766|Active Comparator|Active drug|
11533757|NCT01117766|Placebo Comparator|Placebo|
11533758|NCT01117753|Experimental|OPT-A|OPT-A is an outpatient family-based treatment for co-occurring substance use and internalizing disorders
11533759|NCT01117753|Active Comparator|Treatment as Usual|Treatment as usual in a community based mental health center
11533760|NCT01117740||Thoracoscopy Group|
11533761|NCT01117740||Indwelling Pleural Catheters|
11533762|NCT01117727|Experimental|Pilot Testing|
11533763|NCT01117714|Active Comparator|EUS/EBUS with FNA|EUS/EBUS staging will be performed to evaluate for the presence of mediastinal adenopathy. Each lymph node will be characterized according to published criteria. Staging will follow the TNM system of the AJCC. If present and accessible, at least one lymph node from each accessible station will be aspirated with a separate fine needle using routine FNA and cytological techniques. If multiple lymph nodes are present in a single station, the largest lymph node from that location will be sampled. Patients with cytologically proven mediastinal lymph node metastases (N2 or 3), or those with mediastinal invasion of tumor (T4), will be treated according to standard clinical practice (typically chemotherapy and/or radiotherapy). All complications, morbidity, length of stay attributed to the staging procedures will be recorded at 30 days, or at the time of surgery, whichever is first. All patients will will subsequently undergo surgical resection and complete mediastinal lymph node dissection.
11533764|NCT01117714|Active Comparator|Surgical Mediastinoscopy|Within two months following CT scan, surgical mediastinoscopy will be performed to evaluate for the presence of mediastinal adenopathy. Each lymph node will be characterized according to published criteria. Staging will follow the TNM system of the AJCC. Patients with cytologically proven mediastinal lymph node metastases (N2 or 3), or those with mediastinal invasion of tumor (T4), will be treated according to standard clinical practice (typically chemotherapy and/or radiotherapy). All complications, morbidity, length of stay attributed to the diagnostic method (medical or surgical) used for staging will be recorded at 30 days, or at the time of surgery, whichever is first. All patients will will subsequently undergo surgical resection and complete mediastinal lymph node dissection.
11533765|NCT01117701|Experimental|A - with SGW|Measurement of the forces needed to passage the ureteroscope in the ureter with a SGW in place.
11533766|NCT01117701|Experimental|B - without SGW|Measurement of the forces needed to passage the ureteroscope in the ureter without a SGW in place.
11533767|NCT01117688|Active Comparator|B - without SGW|Ureteroscopy without SGW in place.
11533768|NCT01117688|Active Comparator|A - with SGW|Ureteroscopy with SGW in place.
11533769|NCT01117675|Other|Arm I|Arm I: HIV-infected patients controlled through Virtual Hospital
11533770|NCT01117675|Other|Arm II|Arm II: HIV-infected patients controlled through Standard Care
11533771|NCT01117662|Experimental|Rituximab|Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
11533772|NCT01117662|Placebo Comparator|Control|Intravenous application of placebo (NaCl 0,9 %) matching active treatment
11533773|NCT01117649|Experimental|1|hyper-oncotic colloid
11533774|NCT01117649|Active Comparator|2|iso-oncotic colloid
11533775|NCT01117649|Active Comparator|3|crystalloid
11533776|NCT01117636|Experimental|Arm 1|
11533787|NCT01117610|Active Comparator|epidural injection (group I)|patients in Group I will receive epidural injection of 0.1% ropivacaine 10 ml before skin incision.
11533788|NCT01117610|Placebo Comparator|epidural injection group (group C)|control group will receive no medication preoperatively and during operation
11533789|NCT01117597|Active Comparator|low RF exposure level|Intervention with low RF exposure level SAR 1.5 W/kg
11533790|NCT01117597|Sham Comparator|sham RF exposure|Intervention with sham RF exposure
11533791|NCT01117597|Active Comparator|high RF exposure level|intervention with high RF exposure level SAR 6W/kg
11533792|NCT01117584|Experimental|ASP1941 lowest dose|oral tablet
11533793|NCT01117584|Experimental|ASP1941 low dose|oral tablet
11533794|NCT01117584|Experimental|ASP1941 high dose|oral tablet
11533795|NCT01117584|Experimental|ASP1941 highest dose|oral tablet
11533796|NCT01117584|Placebo Comparator|Placebo|oral tablet
11533797|NCT01117571||open label|iUni® Unicompartmental Knee Resurfacing Device
11533798|NCT01117545|Experimental|EFT|Six sessions of EFT (Emotional Freedom Techniques)
11533799|NCT01117545|No Intervention|Wait List|One month wait period
11533800|NCT01117532|Experimental|EFT|Four 90 minute group EFT classes
11533801|NCT01117532|No Intervention|No Treatment|
11533802|NCT01117519|Active Comparator|unbalanced infusion solution|
11533803|NCT01117519|Active Comparator|balanced infusion solution compound|
11533804|NCT01117493|Other|Usual care|Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.
11533805|NCT01117493|Experimental|Expert Patient Programme|Receives a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
11533806|NCT01117480||Moderate-to-severe rheumatoid arthritis|Participants with moderate-to-severe rheumatoid arthritis treated with adalimumab in routine clinical practice
11533807|NCT01117467|Experimental|Solo|Students will perform their simulation scenario solo and receive feedback within the group
11533808|NCT01117467|Experimental|Paired|Students will be paired with one of their peers for this simulation scenario
11533809|NCT01117454|Other|Flecainide then placebo|In this crossover study, half of the subjects will be randomized to flecainide plus standard therapy with beta-blockers first, then crossover to placebo plus standard therapy with beta-blockers.
11533810|NCT01117454|Other|Placebo then flecainide|In this crossover study, half of the subjects will be randomized to placebo plus standard therapy with beta-blockers first, then crossover to flecainide plus standard therapy with beta-blockers.
11533811|NCT01117441|Active Comparator|R1 control arm|see detailed protocol description
11533812|NCT01117441|Experimental|R1 experimental arm|see detailed protocol description
11533813|NCT01117441|Active Comparator|R2 control arm|see detailed protocol description
11533814|NCT01117441|Experimental|R2 experimental arm|see detailed protocol description
11533815|NCT01117441|Active Comparator|R-HR control arm|see detailed protocol description
11533816|NCT01117441|Experimental|R-HR experimental arm|see detailed protocol description
11533817|NCT01117428|Experimental|Sym004|
11533818|NCT01117415||Gall Bladder Surgery|Who have symptomatic cholelithiasis and wish to undergo laparoscopic cholecystectomy for treatment.
11533819|NCT01117389||Mothers of Childhood cancer survivors|Mothers or female primary caregivers of active patients (aged 9-17) and young adult female patients aged 18-26 in the After Completion of Therapy (ACT) clinic at SJCRH. Mothers or female primary caregivers of active patients (aged 9-17) and young adult female patients aged 18-26 in the ACT clinic surviving childhood cancer will be asked to complete a questionnaire which queries sociodemographic, medical, and psychological variables which may relate to HPV vaccination.
11533820|NCT01117389||Acquaintance control Group|"Mothers or female primary caregivers ( with daughters aged 9-17) and young adult females aged 18-26 referred for study participation by participants from the ACT clinic. Participants have daughters aged 9-17 years or young adult females aged 18-26 at the time of study enrollment For those acquaintance controls electing to complete the paper-and-pencil questionnaire, the study team will send it to them in the mail along with a pre-addressed, stamped, return envelope. For those electing to complete the on-line questionnaire, the participant's email address will be collected and a secured link to our on-line questionnaire will be sent to them in an email.
~A supplemental community control sample (meeting the inclusion and exclusion criteria outlined above) will also be utilized via the subject pool in the Department of Psychology at The University of Memphis."
11533821|NCT01117376|Active Comparator|Erythromycin|21 patients admitted in ICU with intolerance to enteral feeding defined as more than 250 ml of gastric residual volume (GRV) found by aspiration technique.
11533822|NCT01117376|Active Comparator|Methylnaltrexone|21 patients admitted in ICU with intolerance to enteral feeding defined as more than 250 ml of gastric residual volume (GRV) found by aspiration technique.
11533823|NCT01117363|Experimental|Rye porrige breakfast|
11533824|NCT01117363|Active Comparator|Refined wheat reference bread breakfast|
11533825|NCT01117350|Experimental|Insulin Glargine|"Insulin glargine administered once a day, in the morning or in the evening, at the most convenient time. The time of injection, once chosen was to remain unchanged during the whole duration of the study.
~The starting dose was 0.2 Unit per kilogram of body weight or 10 Units. Patients were empowered to adjust their insulin doses, under strict investigator's supervision. Insulin titration (by 2 or 4 Units) was done every 3 days according to the median value of Fasting Plasma Glucose (FPG) of the last 3 days. The goal was to achieve 70 < FPG ≤ 100 mg/dL (3.9 < FPG ≤ 5.5 mmol/L). Minor deviations from the titration scheme could be allowed, based on Investigator's judgment and patient's situation."
11533874|NCT01116986|Experimental|7, Patch, Gum, No Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
11533826|NCT01117350|Active Comparator|Liraglutide|"Liraglutide administered once a day, in the morning or in the evening, at the most convenient time. The time of injection , once chosen was to remain unchanged during the whole duration of the study.
~The dose was 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24. The dose might be decreased to 1.2 mg for safety reasons (e.g. gastro-intestinal tolerability), based on Investigator's judgment."
11533827|NCT01117337|No Intervention|Mesh Non Fixation Group|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed by ant means
11533828|NCT01117311|Experimental|VNB off first, then VNB on|Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB off first for the first intervention (Mixed Meal 2), then VNB on for the second intervention (Mixed Meal 3).
11533829|NCT01117311|Experimental|VNB on first, then VNB off|Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB on first for the first intervention (Mixed Meal 2), then VNB off for the second intervention (Mixed Meal 3).
11533830|NCT01117298|Experimental|Tadalafil|
11533831|NCT01117298|Placebo Comparator|Placebo|
11533832|NCT01117285|Active Comparator|3-day post-graduate course|3-day post-graduate course on the use of the COTiD program in clinical practice
11533833|NCT01117285|Experimental|Combined implementation strategy|The combined implementation strategy
11533834|NCT01117272||PCOS group|Who met the 2003 Rotterdam criteria.
11533835|NCT01117272||Mild hyperprolactinaemia group|Who were diagnosed with prolactin levels above the upper limit of normal (24.29 ng/ml) and under 100 ng/ml.
11533836|NCT01117272||Control group|Without PCOS and with normal prolactin levels.
11533837|NCT01117246|Experimental|Treated bone metastasis|Patients with bone metastasis causing pain.
11533838|NCT01117233|Experimental|Single IV Dose 1|
11533839|NCT01117233|Experimental|Single IV Dose 2|
11533840|NCT01117233|Experimental|Single IV Dose 3|
11533841|NCT01117233|Experimental|Single IV Dose 4|
11533842|NCT01117233|Experimental|Single IV Dose 5|
11533843|NCT01117220|Placebo Comparator|2|
11533844|NCT01117220|Active Comparator|1|
11533845|NCT01117194|Experimental|shoulder training, rehabilitation robot|
11533846|NCT01117194|No Intervention|control group|
11533847|NCT01117181|Experimental|Methylphenidate|Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention
11533848|NCT01117181|Placebo Comparator|Placebo|matching placebo and psychosocial intervention
11533849|NCT01117142||CLL/SLL|Chronic lymphocytic leukemia/small lymphocytic lymphoma
11533850|NCT01117142||Healthy Volunteers|Healthy Volunteers
11533851|NCT01117142||MBL|Monoclonal B-cell lymphocytosis
11533852|NCT01117142||MCL|Mantle Cell Lymphoma
11533853|NCT01117129|Experimental|A|
11533854|NCT01117129|Placebo Comparator|B|
11533855|NCT01117116|Active Comparator|fluticasone propionate and salmeterol|
11533856|NCT01117116|Active Comparator|budesonide and formoterol|
11533857|NCT01117064|Active Comparator|NMTD adjustment testing|We will determine effective NMTD device settings for reducing AHI.
11533858|NCT01117064|Active Comparator|CPAP vs NMTD device|We will randomly assign previously titrated CPAP vs. NMTD to each subject then compare the resultant AHI between the two devices.
11533859|NCT01117064|Active Comparator|NMTD efficacy and tolerability|Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
11533860|NCT01117051|Placebo Comparator|placebo|placebo
11533861|NCT01117051|Active Comparator|Resolor|prucalopride
11533862|NCT01117038|Experimental|enalapril and avanafil|
11533863|NCT01117038|Experimental|amlodipine and avanafil|
11533864|NCT01117025|Active Comparator|Circumferential PVI|
11533865|NCT01117025|Active Comparator|Circumferential PVI+renal denervation|
11533866|NCT01117012|Experimental|VX-770|VX-770 (ivacaftor) 150 milligram (mg) tablet orally twice daily (q12h).
11533867|NCT01116999|Experimental|Tracheal intubation|
11533868|NCT01116986|Experimental|1, Patch, Gum, Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
11533869|NCT01116986|Experimental|2, Patch, Gum, Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
11533870|NCT01116986|Experimental|3, Patch, Gum, Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
11533871|NCT01116986|Experimental|4, Patch, Gum, Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
11533872|NCT01116986|Experimental|5, Patch, Gum, No Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
11533873|NCT01116986|Experimental|6, Patch, Gum, No Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
11534219|NCT01114893|Placebo Comparator|Travoprost Vehicle|Travoprost Vehicle
11533875|NCT01116986|Experimental|8, Patch, Gum, No Prequit, Int In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
11533876|NCT01116986|Experimental|9, Patch, No Gum, Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
11533877|NCT01116986|Experimental|10, Patch, No Gum, Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
11533878|NCT01116986|Experimental|11, Patch, No Gum, Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
11533879|NCT01116986|Experimental|12, Patch, No Gum, Prequit, Int In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
11533880|NCT01116986|Experimental|13, Patch, No Gum, No Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
11533881|NCT01116986|Experimental|14, Patch, No Gum, No Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
11533882|NCT01116986|Experimental|15, Patch, No Gum, No Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
11533883|NCT01116986|Experimental|16, Patch, No Gum, No Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
11533884|NCT01116986|Experimental|17, No Patch, Gum, Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
11533885|NCT01116986|Experimental|18, No Patch, Gum, Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
11533886|NCT01116986|Experimental|19, No Patch, Gum, Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
11533887|NCT01116986|Experimental|20, No Patch, Gum, Prequit, Int In-Person, Int Phone, 16Wk|How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt
11533888|NCT01116986|Experimental|21, No Patch, Gum, No Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
11533889|NCT01116986|Experimental|22, No Patch, Gum, No Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
11533890|NCT01116986|Experimental|23, No Patch, Gum, No Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
11533891|NCT01116986|Experimental|24, No Patch, Gum, No Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
11533892|NCT01116986|Experimental|25, No Patch, No Gum, Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
11533893|NCT01116986|Experimental|26, No Patch, No Gum, Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
11533894|NCT01116986|Experimental|27, No Patch, No Gum, Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
11533895|NCT01116986|Experimental|28, No Patch, No Gum, Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:
~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
11533896|NCT01116986|Experimental|29, No Patch, No Gum, No Prequit, Min In-Person, Min Phone, 16|"This arm of the project will address the following question:
~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
11533897|NCT01116986|Experimental|30, No Patch, No Gum, No Prequit, Min In-Person, Int Phone, 8W|"This arm of the project will address the following question:
~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
11533898|NCT01116986|Experimental|31, No Patch, No Gum, No Prequit, Int In-Person, Min Phone, 8W|"This arm of the project will address the following question:
~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
11533899|NCT01116986|Experimental|32, No Patch, No Gum, No Prequit, Int In-Person, Int Phone, 16|"This arm of the project will address the following question:
~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
11533900|NCT01116973|Other|CICC comparison with PICC|All patients will be having CVP reading taken from the CICC
11533901|NCT01116973|Other|PICC group|The transition to the PICC, a 5.0-French, 18-gauge double lumen PICC (BARD, Power PICC Solo Catheter with Tip Location Stylet; Salt Lake City, UT) will be inserted
11533902|NCT01116960||Faculty; MD|Full time Faculty members working with the Department
11533903|NCT01116960||CRNAs|Full time CRNAs working within the department
11533904|NCT01116960||Residents|Residents working within the department
11533905|NCT01116947|Active Comparator|Intervention Arm|1. Treatment Arm (CASES) will receive high protein meals during thrice weekly hemodialysis in-center (each meal includes ~50 g of protein, ~850 Cal, and phos/protein ratio <10 mg/g) PLUS dietary counseling to continue similar high protein intake with low phosphorus to protein ratio and to avoid foods with high preservative content. Fosrenol 1.0 to 1.5 g per meal will be prescribed (use of pill crusher will be recommended) and will be titrated based on bi-weekly phosphorus levels.
11533906|NCT01116947|Active Comparator|Control Arm (CONTROLS)|2. Control Arm (CONTROLS) will receive salad boxes in-center (no protein, low calorie) and routine dietary counseling and will continue pre-existing phosphorus binder regimen.
11533907|NCT01116934||PLS patients|Eight PLS patients (one female) from 6 families.
11533908|NCT01116934||Healthy controls|Healthy donors had abstained from taking drugs for two weeks prior to the study. Due to wide spread use of oral contraceptives only male probands were chosen.
11533909|NCT01116921|Active Comparator|nCPAP Control Group|Infants in the Control Group were maintained continuously on nasal CPAP 6 cm H2O with no surfactant administered.
11533910|NCT01116921|Experimental|LMA Group|Once proper placement of the LMA was achieved, surfactant (Curosurf®, 2.5 ml/kg, Chiesi USA, Inc., Cary, NC) was administered. The LMA cuff was then deflated, LMA removed and the infant placed back on nasal CPAP 6 cm H2O.
11533911|NCT01116908|No Intervention|Control|
11533912|NCT01116908|Active Comparator|LifeStraw Family|
11533913|NCT01116895|Active Comparator|LEO 22811 0.5 mg|LEO 22811 0.5 mg: Oral solution
11533914|NCT01116895|Active Comparator|LEO 22811 1.5 mg|LEO 22811 1.5 mg: Oral solution
11533915|NCT01116895|Active Comparator|LEO 22811 3.0 mg|LEO 22811 3.0 mg: Oral solution
11533916|NCT01116895|Placebo Comparator|Placebo|Placebo: Oral solution
11533917|NCT01116882|Active Comparator|SOS|Patients randomized to the SOS arm are transferred to tertiary hospitals for their PCI procedure.
11533918|NCT01116882|Experimental|Non-SOS|Patients in the non-SOS arm are randomized to stay at the community hospitals for their PCI procedure.
11533919|NCT01116869||MBC patients|300 MBC patients, each of whom will provide a series of at least 3 blood draws (baseline, 3-4 weeks and 6-8 weeks after the initiation of the systemic therapy) for CTC analysis, will be enrolled. All MBC patients will be followed for a maximum of 36 months for disease progression and survival.
11533920|NCT01116869||Benign disease volunteers|100 Benign disease volunteers whom will donate blood 1 time for CTC analysis, will be enrolled as controls.
11533921|NCT01116869||Healthy volunteers|100 Healthy volunteers whom will donate blood 1 time for CTC analysis, will be enrolled as controls.
11533922|NCT01116856|Experimental|Nutrition|This groups will follow a diet.
11533923|NCT01116856|Experimental|Nutrition + resistance training|In this group, nutrition and resistance training will be combined.
11533924|NCT01116856|Experimental|Nutrition + aerobic training|In this group nutrition and aerobic training will be combined.
11533925|NCT01116856|Experimental|Nutrition + mixed training|In this group the nutrition will be combined with 50% of resistance training plus 50% of aerobic training.
11533926|NCT01116843|Experimental|PF-00299804|Patient will receive PF-00299804 pre-operatively at a dose of 45 mg once daily orally for 7-11 days depending on surgery schedule.
11534220|NCT01114893|Experimental|Travoprost Group A|Travoprost Group A
11533927|NCT01116843|Placebo Comparator|Placebo arm|Patient will receive matching Placebo for 7-11 days depending on surgery schedule.
11533928|NCT01116830|Placebo Comparator|Placebo|
11533929|NCT01116830|Experimental|RO4917838|
11533930|NCT01116817|Experimental|LPV/r monotherapy 400/100 mg twice daily, orally administered|LPV/r monotherapy 400/100 mg twice daily, orally administered
11533931|NCT01116817|Active Comparator|Lumbar puncture|LPV/r 400/100 mg twice daily + 2 NRTI, orally administered.
11533932|NCT01116804|Other|inoperable liver cancer patients|
11533933|NCT01116791|Experimental|CRS+HIPC|Patients with biliary, gastric, or pancreatic carcinoma and metastatic or recurrent disease confined to the abdominal compartment
11533934|NCT01116778|Experimental|eN-Lac® Capsules|
11533935|NCT01116778|Other|Placebo Capsules|
11533936|NCT01116765|Experimental|experimental group|Infants in the experimental group receive an oral stimulation program consisting of stimulation of the oral structures during 10 consecutive days
11533937|NCT01116765|Other|control group|Infant in the control group receive no stimulation only non nutritive sucking during feeding
11533938|NCT01116752|Active Comparator|Strict control|Children requiring intensive care and mechanical ventilation and/or vasopressor/inotropic support who develop critical illness hyperglycemia (persistent BG values if >140 mg/dL) will be randomized to have their glucose levels managed with insulin infusions and receive strict glycemic control (80-140 mg/dL)
11533939|NCT01116752|Active Comparator|Conservative control|Children requiring intensive care and mechanical ventilation and/or vasopressor/inotropic support who develop critical illness hyperglycemia (persistent BG values if >140 mg/dL) will be randomized to have their glucose levels managed with insulin infusions and receive conservative control (190-220 mg/dL).
11533940|NCT01116739|Experimental|COHS administered fluoride varnish and oral health education|Paraprofessionals, called community oral health specialists (COHS), will be trained to administer fluoride varnish and oral health education to head start children quarterly for 2 years.
11533941|NCT01116739|Active Comparator|Usual care|Usual care will include regular dental services provided by the Indian Health Service.
11533942|NCT01116726|Experimental|Motivational interviewing and enhanced community services|Motivational interviewing sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries, provided shortly after childbirth, and at 6, 12, and 18 months. Enhanced community services will involve development of culturally appropriate messages related to the mitigation of risk factors for ECC through public service announcements and brochures.
11533943|NCT01116726|Active Comparator|Enhanced community services|Enhanced community services will involve development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
11533944|NCT01116713|Active Comparator|Dexamethasone group|This group of patients received intravenous dexamethasone (8 mg) 60 minutes before skin incision.
11533945|NCT01116713|Placebo Comparator|Placebo group|Patients of these group received homologated placebo 60 minutes before skin incision.
11533946|NCT01116687|Experimental|Treatment (RO4929097)|See detailed description.
11533947|NCT01116674||Glycemic Control|Critically ill children at participating centers who require select vital organ support measure (i.e. mechanical ventilation, vasopressor, or continuous renal replacement therapy) will have routine blood glucose (BG) screening initiated (i.e. at least q 12 hours). If a patient has a BG reading of > 140 mg/dL, a repeat BG will be obtained in 1-2 hours. If this second BG is > 140 mg/dL the patient will be diagnosed with critical illness hyperglycemia and an insulin infusion will be started and BG will be maintained between 80-140 using a pediatric specific developed and tested algorithm.
11533948|NCT01116661|Experimental|ALA for glioma (WHO G1-IV) subjects|Up to 300 patients with diagnosed glioma (WHO G1-IV) eligible for surgery will be entered into the trial and will be given 5-Aminolevulinic Acid (ALA) orally at a dose of 20mg/kg body weight preoperatively
11533949|NCT01116648|Experimental|Arm I (cediranib maleate and olaparib)|Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11533950|NCT01116648|Active Comparator|Arm II (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11533951|NCT01116635|Experimental|50mg dose loading per vial of doxorubicin|
11533952|NCT01116635|Experimental|75mg dose loading per vial of doxorubicin|
11533953|NCT01116622|Experimental|Daily oral erlotinib and bexarotene capusles|Open label dose-ranging trial
11533954|NCT01116583|Active Comparator|Gabapentin|Gabapentin group
11533955|NCT01116583|Placebo Comparator|Placebo|Placebo group
11533956|NCT01116570|Experimental|Physical training|The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. As a result, lower limb muscles will be mainly solicited. These muscles are heterogeneous in terms of deficiency, but this latter is compatible with cycling. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. Over a 2 to 4 weeks initial period, the program will be conducted in the laboratory or at home under the supervision of a coach. Then a systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
11533957|NCT01116570|Other|control|None intervention
11533958|NCT01116557|Other|THERMOCOOL® group|Radiofrequency ablation to achieve PVI using the CARTO® 3 System, the THERMOCOOL® Catheter and the LASSO® Circular Mapping Catheter.
11533959|NCT01116557|Active Comparator|PVAC® group|Radiofrequency ablation to achieve PVI using fluoroscopy and the PVAC®
11533960|NCT01116544|Experimental|AMES therapy with EMG biofeedback|The AMES device provides a 30 minute treatment period of alternating passive flexion and then extension of the hand while vibrators vibrate the muscles of the hand. The subjects job is to attempt to assist the device in the movement. A computer screen will provide visual feedback of the amount of EMG activity the subject is able to generate in the hand. This study will examine whether AMES therapy combined with EMG biofeedback can restore hand opening to plegic stroke subjects.
11533961|NCT01116544|Experimental|AMES therapy with Torque biofeedback|The AMES device provides a 30 minute treatment period of alternating passive flexion and then extension of the hand while vibrators vibrate the muscles of the hand. The subjects job is to attempt to assist the device in the movement. A computer screen will provide visual feedback of the amount of torque (force) the subject is able to generate in the hand during the movement. This study will examine whether AMES therapy combined with Torque biofeedback can restore hand opening to plegic stroke subjects.
11533962|NCT01116531|Active Comparator|Duloxetine and tramadol|To ascertain the double-blinding of subjects and investigators, duloxetine and pregabalin will be administered as 2 similar capsules twice a day. Each of these capsules will contain either 30mg of duloxetine, 75 mg of pregabalin or placebo. Capsules will be prepared at the hospital pharmacy.
11533963|NCT01116531|Active Comparator|Pregabalin and tramadol|To ascertain the double-blinding of subjects and investigators, duloxetine and pregabalin will be administered as 2 similar capsules twice a day. Each of these capsules will contain either 30mg of duloxetine, 75 mg of pregabalin or placebo. Capsules will be prepared at the hospital pharmacy.
11533964|NCT01116518|Active Comparator|physiotherapy|
11533965|NCT01116518|Active Comparator|acromioplasty|
11533966|NCT01116518|Active Comparator|acromioplasty and rotator cuff reconstruction|
11533967|NCT01116505|No Intervention|gluten-containing diet|
11533968|NCT01116505|Active Comparator|Active comparator, gluten-free diet|
11533969|NCT01116492|Active Comparator|Lap Group|Patients in this group are operated for uncomplicated cholelithiasis with standard 4 port laparoscopic cholecystectomy
11533970|NCT01116492|Active Comparator|SILS group|Patients in this group are operated for uncomplicated cholelithiasis with Single Incision Laparoscopic Cholecystectomy
11533971|NCT01116479|Active Comparator|Haemoglobin (<6.0 mmol/l)|Blood transfusion thresholds:Haemoglobin < 6.0 mmol/l (9.9 g/dL)
11533972|NCT01116479|Experimental|Haemoglobin (< normal range)|Blood transfusion threshold: Haemoglobin < 7.1 mmol/l (11.7 g/dL) for female and 8.1 mmol/l (13.4 g/dL) for males
11533973|NCT01116466|Experimental|ActiGait|Receiving ActiGait - implantable drop foot stimulator
11533974|NCT01116453|Experimental|Acupuncture|
11533975|NCT01116453|Active Comparator|Usual Care|usual care followed by delayed acupuncture
11533976|NCT01116440|Experimental|BGS649 co-administered with Levora 28™|
11533977|NCT01116440|Placebo Comparator|Placebo co-administered with Levora 28™|
11533978|NCT01116427|Experimental|Abatacept|Receives abatacept during first course of treatment, switching to placebo during extension phase.
11533979|NCT01116427|Placebo Comparator|Placebo, followed by abatacept|Receives a placebo for first course of treatment, switching to abatacept in the extension phase.
11533980|NCT01116401|Experimental|GnRH Agonist Injection|We will be administering an injection of leuprolide acetate (a GnRH agonist) to all participants.
11533981|NCT01116388|Other|test product|product free of gluten and casein
11533982|NCT01116388|Other|control product|product containing gluten and milk protein
11533983|NCT01116375||Obese children with OSA|To determine whether, in obese children with moderate-severe OSA who are prescribed PAP therapy, increased hours of PAP usage per night over a one-year period is associated with a greater improvement in HOMA-IR
11533984|NCT01116362|Other|secondary repair|secondary closure beyond the first week.the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
11533985|NCT01116362|Other|primary repair|during first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
11533986|NCT01116349|Active Comparator|Surgical treatment|Patients included in the surgical group will have surgery to treat the fracture.
11533987|NCT01116349|Active Comparator|Conservative treatment group|Patients included in the conservative group will be taken to a plaster room where a Hanging Support System(HSS) brace will be installed by a qualified technician.
11533988|NCT01116336|Experimental|Erlotinib and Green Tea Polyphenon E|Patients will receive erlotinib, at pre-defined dose level, with polyphenon E.
11533989|NCT01116310|Experimental|Fitogyn|4 weeks with placebo followed by 16 weeks with Fitogyn, both taking two capsules per day during the breakfast.
11533990|NCT01116310|Placebo Comparator|Placebo|20 weeks with placebo, taking two capsules per day during the breakfast.
11533991|NCT01116297|Experimental|Imaging with S-FLARE imaging system|3 patients to be imaged by S-FLARE imaging system.
11533992|NCT01116284|Experimental|Revision of gastric bypass|A laparoscopic plication of the gastrojejunostomy will be performed after three 5-mm trocars are placed in the upper abdomen. Then using Ethibond suture, laparoscopic plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period with an expected discharge from the hospital within 24 hours.
11533993|NCT01116271|Experimental|1|Selumetinib (AZD6244) in combination with irinotecan
11533994|NCT01116258|Experimental|1|
11533995|NCT01116258|Placebo Comparator|2|
11533996|NCT01116245|Experimental|Low Dose|5x10^7 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
11533997|NCT01116245|Experimental|Middle Dose|3.3x10^8 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
11533998|NCT01116245|Experimental|High Dose|1x10^9 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
11533999|NCT01116245|Placebo Comparator|Placebo|normal saline x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
11534035|NCT01116037|Other|ATS 3f Aortic Bioprosthesis|ATS 3f Aortic Bioprosthesis, Model 1000 (equine pericardial bioprosthesis)
11534036|NCT01116024|Experimental|3f Enable Aortic Bioprosthesis Model 6000|Single arm study
11534037|NCT01116011|Experimental|AZD7268|
11534038|NCT01116011|Placebo Comparator|Placebo|
11534039|NCT01115998|Experimental|Power wheelchair|
11534000|NCT01116232|Experimental|anti-thymocyte globulin, rituximab, sirolimus, tacrolimus,|"anti-thymocyte globulin: Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter
~Rituximab: The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour;
~For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).
~Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose."
11534001|NCT01116219|Active Comparator|Stratum mut EGFR|"Bevacizumab 7.5 mg/kg i.v. every 3 weeks and
~Erlotinib 150 mg p.o. daily until progression."
11534002|NCT01116219|Active Comparator|Stratum wtEGFR|"Cohort 1:
~Induction chemotherapy with
~Bevacizumab 7.5 mg/kg i.v. and
~Pemetrexed 500 mg/m2 i.v. and
~Cisplatin* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression.
~Followed by maintenance therapy in patients without disease progression with
~Bevacizumab 7.5 mg/kg i.v. and
~Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression.
~Cohort 2:
~Induction chemotherapy with
~Pemetrexed 500 mg/m2 i.v. and
~Cisplatin* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression.
~Followed by maintenance therapy in patients without disease progression with
~o Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression."
11534003|NCT01116206|Experimental|Prucalopride|prucalopride 2- milligram (mg), orally once daily for 12 weeks
11534004|NCT01116206|Placebo Comparator|Placebo|Matching placebo, orally once daily for 12 weeks
11534005|NCT01116180|Active Comparator|Candesartan|
11534006|NCT01116180|Placebo Comparator|Placebo|
11534007|NCT01116167|Experimental|Letrozole -Berberine|
11534008|NCT01116167|Active Comparator|Letrozole|
11534009|NCT01116167|Active Comparator|Berberine|
11534010|NCT01116154|Experimental|Arm I|Patients receive oral vorinostat twice daily on days 1-14 and oral lenalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11534011|NCT01116141|Active Comparator|Methotrexate (MTX) + Folic Acid|20 mg MTX weekly + 1 mg folic acid daily
11534012|NCT01116141|Experimental|0.3 mg CH-4051|0.3 mg CH-4051 daily
11534013|NCT01116141|Experimental|1.0 mg CH-4051|1.0 mg CH-4051 daily
11534014|NCT01116141|Experimental|3.0 mg CH-4051|3.0 mg CH-4051 daily
11534015|NCT01116141|Experimental|3.0 mg CH-4051 + folic acid|3.0 mg CH-4051 + 1.0 mg folic acid daily
11534016|NCT01116128|Experimental|D-MP|
11534017|NCT01116115|Active Comparator|Standard vegetable oil based formula|
11534018|NCT01116115|Active Comparator|InFat™ based infant formula|
11534019|NCT01116115|No Intervention|Breast-fed|
11534020|NCT01116102|Experimental|24 ga catheter, dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
11534021|NCT01116102|Experimental|24 ga catheter, no dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
11534022|NCT01116102|Experimental|24 ga catheter, dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
11534023|NCT01116102|Experimental|24 ga catheter, no dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
11534024|NCT01116102|Experimental|25 ga needle, dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
11534025|NCT01116102|Experimental|25 ga needle, no dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
11534026|NCT01116102|Experimental|25 ga needle, dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
11534027|NCT01116102|Experimental|25 ga needle, no dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
11534028|NCT01116089|Active Comparator|PARI LC® PLUS nebulizer|
11534029|NCT01116089|Active Comparator|PARI eFlow® rapid electronic nebulizer|
11534030|NCT01116076|Experimental|DECISION+ Program|Exposure to the Decision+ Program
11534031|NCT01116076|No Intervention|Control|Usual Care
11534032|NCT01116063|Experimental|Single arm open label|All patients will receive the study drugs and will be evaluated
11534033|NCT01116050|Placebo Comparator|Placebo|
11534034|NCT01116050|Experimental|MISOPROSTOL|
11534040|NCT01115998|Other|Control group|
11534041|NCT01115985|Experimental|single-add first group|single administration first, then concomitant administration
11534042|NCT01115985|Experimental|combi-add first group|concomitant administration first, then single administration
11534043|NCT01115972|Experimental|single-add first group|single administration first, then concomitant administration
11534044|NCT01115972|Experimental|combi-add first group|concomitant administration first, then single administration
11534045|NCT01115959|Active Comparator|valproic acid|Valproic acid given orally 400mg twice daily
11534046|NCT01115959|Placebo Comparator|placebo|Placebo twice daily for one month
11534047|NCT01115946|Experimental|single-add first group|single administration first, then concomitant administration
11534048|NCT01115946|Experimental|combi-add first group|concomitant administration first, then single administration
11534049|NCT01115933|Experimental|XIENCE PRIME SV EECSS|XIENCE PRIME SV EECSS: Small Vessel Everolimus Eluting Coronary Stent System
11534050|NCT01115920|Experimental|Arm 1|Cohort 1, Dose 0.010 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
11534051|NCT01115920|Experimental|Arm 2|Cohort 2, Dose 0.025 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
11534052|NCT01115920|Experimental|Arm 3|Cohort 3, Dose 0.050 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
11534053|NCT01115920|Experimental|Arm 4|Cohort 4, Dose 0.100 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
11534054|NCT01115920|Experimental|Arm 5|Cohort 5, Dose 0.250 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
11534055|NCT01115907|Experimental|Freedom SOLO stentless valve implant|Appropriate subjects will receive the Freedom SOLO stentless valve implant as a replacement for a diseased or damaged native or prosthetic aortic valve.
11534056|NCT01115894|Experimental|active medication + psychotherapy|
11534057|NCT01115894|Experimental|placebo + psychotherapy|
11534058|NCT01115894|Experimental|active medication+brief supportive counseling|
11534059|NCT01115894|Experimental|placebo + brief supportive counseling|
11534060|NCT01115868|Experimental|Group 2 - 2 doses of Prevascar and placebo|
11534061|NCT01115868|Experimental|Group 1 - 2 doses of Prevascar and placebo|
11534062|NCT01115868|Experimental|Group 3 - 2 doses of Prevascar and placebo|
11534063|NCT01115868|Experimental|Group 4 - 2 doses of Prevascar and placebo|
11534064|NCT01115855|Experimental|Eplerenone arm|Add on standard heart failure therapy
11534065|NCT01115855|Placebo Comparator|Placebo arm|Add on standard heart failure therapy
11534066|NCT01115842|Experimental|Vitamin D|The patients will be given Vitamin D - 4000IU per day for 5 days (Day 1 through 5)
11534067|NCT01115842|No Intervention|control|
11534068|NCT01115803|Experimental|Arm A: LY2584702 + Erlotinib|Participants received 50 mg LY2584702 once daily (QD )+ 150 mg Erlotinib QD, 50 mg LY2584702 twice daily (BID) + 150 mg Erlotinib QD, 100 mg LY2584702 BID + 150 mg Erlotinib QD and 75 mg LY2584702 BID + 150 mg Erlotinib QD.
11534069|NCT01115803|Experimental|Arm B: LY2584702 + Everolimus|Participants received 50 mg LY2584702 QD + 10 mg Everolimus QD, 100 mg LY2584702 QD + 10 mg Everolimus QD and 50 mg LY2584702 BID + 10 mg Everolimus QD.
11534070|NCT01115790|Experimental|Prexasertib|
11534071|NCT01115777||Pediatric patients treated with radiotherapy|
11534072|NCT01115751|Experimental|LY2780301|"Part A: daily dosing
~Part B (if determined as needed by pharmacokinetic, pharmacodynamic, and safety data): twice daily dosing
~Part C: Dose and frequency as determined by Parts A and B of the study."
11534073|NCT01115738|Placebo Comparator|Placebo and 60 milligram (mg) Prasugrel|Placebo loading dose administered once orally before percutaneous coronary intervention (PCI) and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
11534074|NCT01115738|Experimental|600 mg Clopidogrel and 60 mg Prasugrel|600-mg clopidogrel loading dose administered once orally before PCI and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
11534075|NCT01115738|Experimental|600 mg Clopidogrel and 30 mg Prasugrel|600-mg clopidogrel loading dose administered once orally before PCI and 30-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
11534076|NCT01115725||Gonal-f® prefilled pen|
11534077|NCT01115712|Active Comparator|Pioglitazone 30 mg|Pioglitazone 30 mg
11534078|NCT01115712|Placebo Comparator|Placebo|Placebo
11534079|NCT01115699|Experimental|Repetitive Transcranial Magnetic Stimulation|All subjects will receive 10 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for a fixed-flexible period of 5 treatments per week for up to 6 weeks.
11534080|NCT01115686|Active Comparator|Branched-chain aminoacids|Branched-chain aminoacids are natural constituents of the food. Branched-chain aminoacids will be orally administered in the form of capsules.
11534081|NCT01115686|Placebo Comparator|placebo|The placebo will be orally administered in the form of capsules
11534082|NCT01115673|Experimental|ACE-1000|1000 mg Acetaminophen Caplet
11534083|NCT01115673|Active Comparator|ACE-650|650 mg Acetaminophen Caplet
11534084|NCT01115673|Placebo Comparator|ACE-0|0 mg Acetaminophen Caplet
11534085|NCT01115660|Experimental|stroke education|Patients in this arm receive a telephone call by a medication coach who reviews their condition and importance of adherence to medication regimen.
11534086|NCT01115660|No Intervention|control arm|Subjects in this arm received instruction at hospital discharge and a 3-month follow-up call to collect study data.
11534087|NCT01115647|Experimental|Ready-to-Use Therapeutic Foood (RUSF)|"Caretakers will receive weekly RUSF, 350g, and will be advised to feed it(50 g d-1 or 3 tablespoons/day) in one meal or on demand. These are pre-defined quantities. However, minimum quantities required for a timely (≤15 days) recovery from moderate malnutrition will be determined during the pilot phase.
~Besides supplementary food, parents will be provided with the usual nutrition counsels prevailing currently in the health services.Children will be home-visited once a week by assessors for anthropometry, 24-hours recall of dietary and breastfeeding intake, and morbidity signs. Feeding practices will be assessed, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members."
11534088|NCT01115647|Active Comparator|CSB++|"Caretakers will receive weekly CSB++ (450g) rations. Parents will be advised to feed the CSB++ (65g d-1 diluted in 370 g water) in one meal or on demand. These are pre-defined quantities. However, minimum quantities of CSB++ required for a timely (≤15 days) recovery from moderate malnutrition in the area will be determined during the pilot phase. Besides supplementary foods, parents will be provided with the usual nutrition counsels prevailing currently in the health services, i.e. to keep on breastfeeding, to increase diet diversity and to feed frequent snacks.
~Feeding practices will be also assessed, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members."
11534089|NCT01115647|Active Comparator|Children Centered Counseling (CCC)|"The counsellor will spend 1 hour daily (during the 3 first days and then weekly) within the household for identifying enhancing and blocking factors and adapt consequently the treatment strategies in agreement with the caretakers.
~As in the other study arms, children will be home-visited once a week by assessors for anthropometry, 24-hours recall of dietary and breastfeeding intake, and morbidity signs. Feeding practices will be also assessed in each arm, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members.There will be no dietary supplements intervention, outside normal practices in Burkina."
11534090|NCT01115634|Experimental|Fibroblast|Injection of autologous cultured fibroblast
11534091|NCT01115621|Active Comparator|Glutenfree diet|Glutenfree diet during the first year of life
11534092|NCT01115621|No Intervention|Control - normal diet|
11534093|NCT01115608|Experimental|Pharmacist follow-up|"The patients will receive pharmaceutical follow-up during one year after discharge from the hospital. Three meetings are arranged, one at discharge, one after three months and the last after one year. Patients will be called up for arrangement of consultation. Written information concerning drugs used will be supplied."
11534094|NCT01115608|No Intervention|Control group|The control group receives no follow-up from the pharmacist, but will after one year, when they are out of the study, receive one follow-up visit and drug review.
11534095|NCT01115595|Active Comparator|Intervention|injection by Mite extract with standard allergic medication (oral antihistamine and/or topical nasal steroid)
11534096|NCT01115595|Other|Control Group|Injection by buffer solution WITH standard allergic medication (oral antihistamine and/or topical nasal steroid
11534097|NCT01115582|Experimental|Cholic Acid Capsule|Manufactured cholic acid capsules
11534098|NCT01115569|Experimental|Hydrocodone Bitartrate|Open-label, all patients fulfilling the protocol Inclusion/Exclusion criteria will receive HC-CR in a flexible dosing regimen.
11534099|NCT01115556|Experimental|Lucentis 2.0 mg|Lucentis 2.0 mg
11534100|NCT01115556|Active Comparator|LUCENTIS 0.5 mg|
11534101|NCT01115543|Active Comparator|calcitriol|The subjects were randomized to receive calcitriol in a dose-escalating fashion for up to 24 weeks.
11534102|NCT01115543|Experimental|alfacalcidol|
11534103|NCT01115530|No Intervention|1|Control inpatient GEM rehabilitation and continue twice weekly low level walking/stretching to control for time/interaction with intervention/exercise groups
11534104|NCT01115530|Experimental|2|Resistance exercise (2x/week)
11534105|NCT01115530|Experimental|3|Nutritional (amino acid metabolite) supplement twice daily
11534106|NCT01115530|Experimental|4|Resistance exercise (2x/week) and nutritional (amino acid metabolite) supplement twice daily
11534107|NCT01115517|Experimental|Bevacizumab|
11534108|NCT01115517|Active Comparator|Mitomycin C|
11534109|NCT01115504|Experimental|Thiamine|Thiamine tablets of 300mg are prescribed for 1 months
11534110|NCT01115504|Placebo Comparator|Plascebo|Tablets of 300mg placebo are prescribed for 1 months
11534111|NCT01115491|Experimental|A|
11534112|NCT01115478|Active Comparator|Vitamin A|
11534113|NCT01115478|Active Comparator|Zinc|
11534114|NCT01115478|Active Comparator|Vitamin A + Zinc|
11534115|NCT01115478|Placebo Comparator|Placebo|
11534116|NCT01115465|Other|Macroplastique|Macroplastique will be used for the treatment in an open-label, five year, post-market study
11534117|NCT01115452|Experimental|5% KNO3 solution|Participants to apply 5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period.
11534118|NCT01115452|Experimental|2.5% KNO3 solution|Participants to apply 2.5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period.
11534119|NCT01115452|Placebo Comparator|Sterile Water|Participants to apply sterile water to a single sensitive tooth for two minutes, in each of the five day treatment period.
11534120|NCT01115439||falciparum malaria|Febrile children (above six months of age) and non-pregnant adults with confirmed uncomplicated P. falciparum infection
11534121|NCT01115426|Other|anti-angiotensin II drugs|Never treated patients with non-nephrotic proteinuria (1-3 g/day), microhematuria, no-evidence of renal failure or other relevant diseases and with diagnosis of I-II stage IgA- or pauciimmune-MsPGN were considered eligible.
11534122|NCT01115413||young maternal age|maternal age of < 18 years
11534123|NCT01115413||adult maternal age|maternal age >/= 18 years
11534124|NCT01115387||ARM at risk individuals|"A group of 1,500 participants (from 49 to 65 years old) who have at least one parent with age related maculopathy.
~These individuals with ARM-affected parents and relatives have a substantially higher risk (6-12 fold) of developing ARM than the general population. They will be followed prospectively with fundus photography every two years and questionnaires (distributed over six month intervals) to assess external risks for ARM development in order to investigate genotype-phenotype correlations of early onset clinical features of ARM."
11534125|NCT01115387||Partners/Spouses of ARM at risk individuals|"A group of 1,500 participants (from 49 to 65 years old) who are the spouses/partners of individuals with ARM affected parents.
~We will invite the partners or spouses to participate in order to compare their risk of developing ARM with those individuals with an increased risk of ARM based on a positive family history."
11534170|NCT01115140|Active Comparator|Group A3|placebo plus folic acid
11534171|NCT01115140|Placebo Comparator|Group A4|placebo cp, 2 cps daily
11534172|NCT01115140|No Intervention|Group B|observation
11534173|NCT01115127|Active Comparator|myo-inositol|30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.
11534221|NCT01114893|Experimental|Travoprost Group B|Travoprost Group B
11534126|NCT01115387||ARM affected individuals and relatives.|"Individuals who have experienced vision loss from ARM and have at least one brother or sister who also has experienced vision loss from ARM can participate in the study. They also need to have at least one adult child (from 49 to 65 years old) who wishes to participate in this study.
~We will allow for additional recruitment to compensate for additional family members (such as parents, aunts and uncles) who wish to participate as well as to address potential drop out and those who may be deemed ineligible based on review of their medical and/or eye records. As many as 4000 individuals in this group will be allowed to enroll."
11534127|NCT01115374|Active Comparator|manual lymphatic drainage|Application of manual lymphatic drainage
11534128|NCT01115374|Experimental|low frequency sound waves|Application of low frequency sound waves
11534129|NCT01115361|Experimental|PPFP in child immunization|Women attending immunization services for their infant will receive educational brochures, group education and individual counseling on the benefits of the health timing and spacing of births,, pregnancy risk and return to fertility during the extended postpartum period (12 months), and referral to family planning services for those who are interested.
11534130|NCT01115361|No Intervention|Control - Standard of care|The control arm will receive standard of care infant immunization services.
11534131|NCT01115335|Active Comparator|Gomco|NMC performed using a Gomco clamp
11534132|NCT01115335|Active Comparator|Mogen clamp|NMC performed using a Mogen clamp
11534133|NCT01115335|Active Comparator|Plastibell|NMC performed using a Plastibell device
11534134|NCT01115322|Experimental|Tazarotene Foam without irradiation|Subjects will be exposed to Tazarotene Foam Patch without irradiation
11534135|NCT01115322|Experimental|Tazarotene Foam with UVA and UVB irradiation|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB irradiation
11534136|NCT01115322|Experimental|Tazarotene Foam with UVA , UVB, and visible light irradiation|Subjects will be exposed to Tazarotene Foam with UVA and UVB and visible light irradiation
11534137|NCT01115322|Placebo Comparator|Vehicle Foam without irradiation|Subjects will be exposed to Vehicle Foam Patch without irradiation
11534138|NCT01115322|Placebo Comparator|Vehicle Foam with UVA and UVB irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB irradiation
11534139|NCT01115322|Placebo Comparator|Vehicle Foam with UVA and UVB and visible light irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB and visible light irradiation
11534140|NCT01115322|Sham Comparator|No Treatment without irradiation|Subjects will be exposed to a Blank Patch without irradiation
11534141|NCT01115322|Sham Comparator|No Treatment with UVA and UVB irradiation|Subjects will be exposed to a Blank Patch with UVA and UVB irradiation
11534142|NCT01115322|Sham Comparator|No Treatment with UVA and UVB and visible light irradiation|Subjects will be exposed to a Blank Patch with UVA and UVB and visible light irradiation
11534143|NCT01115309|Other|XprESS Balloon Device|Sinus dilation
11534144|NCT01115296|Active Comparator|'L. reuteri DSM 17938 and ATCC PTA 6475|L. reuteri will be delivered at a dose of 1x108 CFU of each strain of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day.
11534145|NCT01115296|Placebo Comparator|Placebo|Placebo
11534146|NCT01115283|Experimental|Perceptual learning|Patients will be asked to practice a range of visual discrimination tasks for a period of time (each therapy session:1-2 hrs, 4-5 sessions/wk for ~1-6 months).
11534147|NCT01115283|Experimental|Occlusion therapy|The fellow sound will be covered with a standard eye patch for a period of time (1-2 hrs/day, 4-5 days/wk for ~1-3 months). The idea is to push the brain to use the weaker amblyopic eye.
11534148|NCT01115283|Experimental|Video game|Patients will be asked to play videogames for a period of time (each therapy session:1-2 hrs, 4-5 sessions/wk for ~1-6 months).
11534149|NCT01115270||Hydrocephalus Patients|Those patients diagnosed with Normal Pressure Hydrocephalus.
11534150|NCT01115270||Normal Participants|Individuals who are not diagnosed with Normal Pressure Hydrocephalus.
11534151|NCT01115257|Other|group 1|90 eyes of 90 patients, with severe PDR, some with tractional retinal detachment (TRD) not involving the macula were included in the study and treated with vitrectomy
11534152|NCT01115257|Other|panretinalphotocoagulation (group 2)|90 eyes of 90 patients, with severe PDR, some with tractional retinal detachment (TRD) not involving the macula were included in the study and treated with panretinalphotocoagulation
11534153|NCT01115244|Experimental|Dapsone gel, 5%|ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
11534154|NCT01115244|No Intervention|Not treated|One arm of the patient will be left untreated.
11534155|NCT01115231||Group 1 (Control)|Case control subjects without AMD diagnosis
11534156|NCT01115231||Group 2 (Age-related Macular Degeneration)|Case (i.e., within 5 years) subjects will be recruited. Cases are defined as subjects with diagnosed AMD.
11534157|NCT01115218||Glaucoma patients|
11534158|NCT01115205|Experimental|Supervised walking groups|Patients included in walking groups, under the supervision of a qualified personal trainer.
11534159|NCT01115205|Active Comparator|Controls|Patients receiving the standard counselling procedures of the Verona Diabetic Clinic.
11534160|NCT01115192|Experimental|Group A|Patients with chronic blepharitis, that will be treated with blephacura
11534161|NCT01115192|Experimental|Group B|Patients with chronic blepharitis that will be treated with diluted baby shampoo
11534162|NCT01115179|Active Comparator|Propofol|Propofol anesthesia
11534163|NCT01115179|Active Comparator|Control|Anesthesia with isoflurane alone
11534164|NCT01115179|Active Comparator|Solvent|Anesthesia with isoflurane together with the solvent of propofol (intralipid)
11534165|NCT01115166||Cardiac surgery|Patients subjected to open cardiac surgery with the help of extracorporal circulation.
11534166|NCT01115153|Experimental|Antibiotic prophylaxis|Rate of Wound infection in patients with gangrenous appendicitis with single doses of antibiotic (before surgery)
11534167|NCT01115153|Active Comparator|Antibiotic treatment, wound infection|Rate of Wound infection in patients with gangrenous appendicitis with five days antibiotic therapy (after surgery)
11534168|NCT01115140|Active Comparator|Group A1|metformin plus placebo
11534169|NCT01115140|Experimental|Group A2|metformin plus folic acid
11534174|NCT01115127|Active Comparator|melatonin|30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months
11534175|NCT01115127|Active Comparator|melatonin plus myo-inositol|30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months
11534176|NCT01115114|Placebo Comparator|Treatment as Usual (TAU)|Study Intervention 1 Treatment as usual (TAU) will be psychiatry follow-up at local Community Mental Health Clinic at least every 3 months.
11534177|NCT01115114|Active Comparator|IMBED|Study Intervention 2 A Primary Care Provider (PCP) will be located within the community mental health clinic one day weekly to specifically run a Metabolic Syndrome Clinic.
11534178|NCT01115114|Active Comparator|Liaison|Study Intervention 3 A Medical Case Manager(MCM) will be assigned to a patient who is identified on the basis of routine screening to need medical follow-up for metabolic syndrome.
11534179|NCT01115101|Experimental|Oxycodon|
11534180|NCT01115101|Active Comparator|Patient controlled analgesia (PCA) device with Pritramid|
11534181|NCT01115088|Experimental|Aspartame|Food or beverages containing Aspartame in comparison to Stevia or Sucrose
11534182|NCT01115088|Experimental|Sucrose|Food or beverages containing Sucrose in comparison to Aspartame or Stevia
11534183|NCT01115088|Experimental|Stevia|Food or beverages containing Stevia in comparison to Aspartame or Sucrose
11534184|NCT01115075|Experimental|Dietitian|Recruitment of dietitians and senior level or graduate level dietetics students who are not restrained eaters. This group is skilled in identifying and accurately recording food than individuals not trained in dietetics.
11534185|NCT01115062|Experimental|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg)
11534186|NCT01115062|Experimental|LMX-4 Cream|LMX-4 (liposomal lidocaine 4%) cream
11534187|NCT01115062|Placebo Comparator|Placebo Patch|Placebo Patch
11534188|NCT01115049|Experimental|Experimental mouthwash|The experimental mouthwash (Buccagel®, Curaden Healthcare, Saronno, Italy) was made up of: purified water, dicaprylyl-ether, coco-caprylate caprate, xylitol, glyceryl-stearate, ceteareth-20, ceteareth-12, cetyl-palmitate, cetearyl-alcohol, chlorobutanol, aroma, hexetidine, methylparaben, propylparaben, sodium saccharin, citric acid and colorant C.I. 16255.
11534189|NCT01115049|Active Comparator|Chlorexidine-based mouthwash|A conventional commercial mouthwash (Curasept® ADS 0.20%, Curaden Healthcare, Saronno, Italy) made up of: water, xylitol, propylenglycol, Peg-40 of hydrogenated ricin oil, ascorbic acid, chlorhexidine digluconate, aroma, poloxamer 407, sodium metabisulfite, sodium citrate and colorant C.I. 42090.
11534190|NCT01115036|Experimental|panobinostat|
11534191|NCT01115023|Experimental|iron group|This group received an iron cooking pot for daily household cooking as an intervention
11534192|NCT01115023|No Intervention|Aluminium group|the subjects in this group were asked to continue cooking in the aluminium pot and not to cook in the iron pot if they possessed one.
11534193|NCT01115010|Experimental|Stiffening wire only if difficulty|Colonoscopy is performed with the unassisted colonoscope. The stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying.
11534194|NCT01115010|Experimental|Stiffening wire #1 transverse colon|Colonoscopy is started with the unassisted colonoscope. Stiffening wire #1 is introduced on entry of the tip of the colonoscope into the transverse colon.
11534195|NCT01115010|Experimental|Stiffening wire #2 transverse colon|Colonoscopy is started with the unassisted colonoscope. Stiffening wire #2 is introduced on entry of the tip of the colonoscope into the transverse colon.
11534196|NCT01114997|Active Comparator|Lidocaine|Pre-Induction: Lidocaine Loading: 1 mg/kg Post- Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
11534197|NCT01114997|Active Comparator|Esmolol|Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Post-Induction: Infusion dose 7.5 - 15 mcg /kg/min
11534198|NCT01114997|Experimental|Lidocaine + Esmolol (Combo)|"Performed with the administration of both drugs.
~Pre-induction:
~Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)
~Post-induction:
~Infusion rate: Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)"
11534199|NCT01114984||10% after breast biopsy|Incidence Post-operative pain after breast surgery.
11534200|NCT01114984||20% after lumpectomy|Incidence Post-operative pain after breast surgery
11534201|NCT01114984||30% after simple mastectomy|Incidence Post-operative pain after breast surgery
11534202|NCT01114984||50% after mastectomy with reconstruction|Incidence Post-operative pain after breast surgery
11534203|NCT01114984||50% after radical mastectomy|Incidence Post-operative pain after breast surgery
11534204|NCT01114984||50% after radi mastectomy+reconstruction|Incidence Post-operative pain after breast surgery after radical mastectomy with reconstruction
11534205|NCT01114984||40% after cosmetic augmentation|Incidence Post-operative pain after breast surgery
11534206|NCT01114984||40% after breast reduction|Incidence Post-operative pain after breast surgery
11534207|NCT01114971|Active Comparator|Fentanyl|"Fentanyl 50 micrograms/ml boluses will be given:
~at the induction time
~at the time before surgical incision, and
~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or Heart Rate (HR) > 80 bpm)"
11534208|NCT01114971|Experimental|Labetalol|"Labetalol 5 mg/ml boluses will be given:
~at the induction time
~at the time before surgical incision, and
~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
11534209|NCT01114971|Experimental|Esmolol|"Esmolol 10 mg/ml boluses will be given:
~at the induction time
~at the time before surgical incision, and
~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
11534210|NCT01114958|Experimental|IA Cisplatin / IV Thiosulfate|Single-arm study
11534211|NCT01114945|Experimental|Video-Mac|Video-Mac device used during intubation procedure
11534212|NCT01114945|Experimental|GlideScope|GlideScope device used during intubation procedure
11534213|NCT01114945|Experimental|McGrath|McGrath device used during intubation procedure
11534214|NCT01114945|Active Comparator|Direct Macintosh Laryngoscopy|Direct Macintosh Laryngoscopy (DL) used during intubation procedure
11534215|NCT01114932||BMI-I|Patients with BMI values between 18.5-24.9
11534216|NCT01114932||BMI-II|Patients with BMI values between 25-29.9
11534223|NCT01114880|Placebo Comparator|Placebo|Blinded placebo from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.
11534224|NCT01114880|Experimental|Adalimumab|Blinded adalimumab from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.
11534225|NCT01114854|Other|Topiramate IR followed by Topiramate ER|Dosing with IR followed by dosing with ER
11534226|NCT01114841|Experimental|Tazarotene Foam|Subjects will be exposed to patches containing Tazarotene foam 0.1%
11534227|NCT01114841|Placebo Comparator|Vehicle Foam|Subjects will be exposed to patches containing Vehicle Foam
11534228|NCT01114828|Experimental|3.75 mg|Once-daily oral administration of OPC-41061
11534229|NCT01114828|Experimental|7.5 mg|Once-daily oral administration of OPC-41061
11534230|NCT01114802|Experimental|Project Onward website + social network|This arm has the website which includes 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
11534231|NCT01114802|Active Comparator|Project Onward website|This arm has the website which includes 8 weeks of Internet-based cognitive behavioral therapy.
11534232|NCT01114776||Sickle Cell Disease (SCD)|Patients with sickle cell diseases, 16 years or older with 10-20 years of transfusion (defined as 0.2-0.6mg Fe/kg/day exposure with annual ferritin levels greater than 2500 in at least 60% of years of chronic transfusion); 0 to 9 years old at the initiation of chronic transfusions; no exchange transfusions in the previous 6 months; and iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months or ferritin level greater than 1500mg/dl.
11534233|NCT01114776||Thalassemia Major (TM)|Patients with β-thalassemia major and transfusion-dependent E-beta THAL. 16 years or older with 10-20 years of chronic transfusion (defined above), 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
11534234|NCT01114776||Diamond Blackfan Anemia (DBA)|Patients with DBA, 16 years or older with 10-20 years of transfusion, 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
11534235|NCT01114776||Controls|
11534236|NCT01114763||Metabolic syndrome|40 men with metabolic syndrome
11534237|NCT01114763||Control|40 physically active men
11534238|NCT01114750|Active Comparator|Oral Insulin in Dextran Matrix|A group consisting of male healthy volunteers will be given placebo and one single dose of insulin in dextran matrix, for estimation of post-dose relative bioavailability.
11534239|NCT01114750|Placebo Comparator|Placebo|A group consisting of male healthy volunteers will be given placebo and one single dose of insulin in dextran matrix, for estimation of post-dose relative bioavailability.
11534240|NCT01114737|Experimental|Sapropterin dihydrochloride|
11534241|NCT01114737|Placebo Comparator|Tablet without active ingredient|
11534242|NCT01114724|Experimental|Valiant Thoracic Stent Graft with the Captivia Delivery System|
11534243|NCT01114711||Frovatriptan|All subjects will be taking Frovatriptan tablets within 48 hours prior to the scan session (Visit 2).
11534244|NCT01114698|Experimental|JNJ26489112|
11534245|NCT01114698|Active Comparator|Venlafaxine XR|
11534246|NCT01114698|Placebo Comparator|Placebo|
11534247|NCT01114685|Active Comparator|Effects of taking AlgaeCal-1|Following a bone health plan with Algae-cal-1 supplement
11534248|NCT01114685|Active Comparator|Effects of taking AlgaeCal-2|Following a bone-health plan while consuming AlgaeCal 2
11534249|NCT01114672|Active Comparator|Ergocalciferol|
11534250|NCT01114672|Placebo Comparator|oral placebo|
11534251|NCT01114659||Women with PCOS|
11534252|NCT01114659||Normal Control|
11534253|NCT01114646|Other|Cemented Hip Hemiarthroplasty|This arm received a hemiarthroplasty with a cemented femoral prosthesis (VerSys LD/Fx, Zimmer, Warsaw, IN).
11534254|NCT01114646|Experimental|Press-Fit Hip Hemiarthroplasty|This arm received a press-fit hemiarthroplasty (VerSys Beaded FullCoat, Zimmer, Warsaw, IN),
11534255|NCT01114620|Experimental|Arepanrix Group|Healthy Japanese male and female adults, 65 years of age or older, who received one dose of the study vaccine Arepanrix™, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
11534256|NCT01114607|Experimental|Treatment sequence ABCDE|Eligible subjects will be randomized in sequence ABCDE and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
11534257|NCT01114607|Experimental|Treatment sequence ABDEC|Eligible subjects will be randomized in sequence ABDEC and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
11534258|NCT01114607|Experimental|Treatment sequence ABECD|Eligible subjects will be randomized in sequence ABECD and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
11534259|NCT01114607|Experimental|Treatment sequence ABCED|Eligible subjects will be randomized in sequence ABCED and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, E= a film coated tablet of GSK1605786 GSK formulation 500 mg once daily and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
11534278|NCT01114555|Experimental|Bevacizumab, Irinotecan and Temozolomide|This is a phase II study of the combination of irinotecan, temozolomide and bevacizumab in patients with resistant NB.
11534279|NCT01114542|Experimental|IDeg 0.4 U/kg|
11534260|NCT01114607|Experimental|Treatment sequence ABDCE|Eligible subjects will be randomized in sequence ABDCE and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
11534261|NCT01114607|Experimental|Treatment sequence ABEDC|Eligible subjects will be randomized in sequence ABEDC and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
11534262|NCT01114607|Experimental|Treatment sequence BACDE|Eligible subjects will be randomized in sequence BACDE and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
11534263|NCT01114607|Experimental|Treatment sequence BADEC|Eligible subjects will be randomized in sequence BADEC and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
11534264|NCT01114607|Experimental|Treatment sequence BAECD|Eligible subjects will be randomized in sequence BAECD and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
11534265|NCT01114607|Experimental|Treatment sequence BACED|Eligible subjects will be randomized in sequence BACED and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
11534266|NCT01114607|Experimental|Treatment sequence BADCE|Eligible subjects will be randomized in sequence BADCE and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
11534267|NCT01114607|Experimental|Treatment sequence BAEDC|Eligible subjects will be randomized in sequence BAEDC and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
11534268|NCT01114594||PKD|Patients with Autosomal Dominant Polycystic Kidney Disease
11534269|NCT01114594||non-PKD CKD|Patients with non-Polycystic Chronic Kidney Disease
11534270|NCT01114581|Active Comparator|Guaifenesin|Mucinex 1200mg (Guaifenesin)given as 2, 600mg tablets
11534271|NCT01114581|Placebo Comparator|Placebo|Given as 2 tablets
11534272|NCT01114568|Experimental|Ertugliflozin 10 mg: tablet→osmotic capsule (OC) fast→OC slow|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 6 hours (EP-Osmotic Capsule-Fast) and C) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 14 hours (EP-Osmotic Capsule-Slow). Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
11534273|NCT01114568|Experimental|Ertugliflozin 10 mg: tablet→OC slow→OC fast|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
11534274|NCT01114568|Experimental|Ertugliflozin 10 mg: OC fast→tablet→OC slow|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
11534275|NCT01114568|Experimental|Ertugliflozin 10 mg: OC fast→OC slow→tablet|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
11534276|NCT01114568|Experimental|Ertugliflozin 10 mg: OC slow→tablet→OC fast|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
11534277|NCT01114568|Experimental|Ertugliflozin 10 mg: OC slow→OC fast→tablet|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
11534280|NCT01114542|Experimental|IDeg 0.6 U/kg|
11534281|NCT01114542|Experimental|IDeg 0.8 U/kg|
11534285|NCT01114529|Experimental|Everolimus|Conversion from CNI to everolimus in combination with Myfortic and steroids
11534286|NCT01114529|Active Comparator|Calcineurin inhibitor, Prograf or Neoral|Control arm: CNI continuation, either Prograf or Neoral in combination with Myfortic and steroids
11534287|NCT01114516|No Intervention|control|emergent cerclage with no peri-operative antibiotics or indomethacin
11534288|NCT01114516|Experimental|indomethacin and antibiotics|perioperative antibiotics and indomethacin
11534289|NCT01114503|Experimental|Part A|Up to 4 cohorts of 5 patients receive dose rising treatments of otelixizumab
11534290|NCT01114503|Experimental|Part B - Otelixizumab|Parallel dosing group in Part B receive otelixizumab over 8 days at a dose decided upon results from Part A
11534291|NCT01114503|Active Comparator|Part B - Methylprednisolone|Parallel dosing group in Part B of weekly doses of methylprednisolone for 12 weeks
11534292|NCT01114490|Experimental|Part 1 - Group 1|Moderate Hepatic Patients
11534293|NCT01114490|Experimental|Part 1 - Group 2|Healthy Subjects
11534294|NCT01114490|Experimental|Part 2 - Group 1|Mild Hepatic Patients
11534295|NCT01114490|Experimental|Part 2 - Group 2|Healthy Subjects
11534296|NCT01114464||young women with breast cancer|
11534297|NCT01114451|Experimental|Early Staple Removal|Skin staple removal on post-operative day #3
11534298|NCT01114451|Experimental|Delayed Staple Removal|Skin staple removal on post-operative day 7-10
11534299|NCT01114438|Experimental|Device|
11534300|NCT01114412||Patients|Patients with overactive bladder syndrome
11534301|NCT01114412||Healthy volunteers|Healthy volunteers
11534302|NCT01114399|Experimental|Standard Broccoli|Standard Broccoli
11534303|NCT01114399|Experimental|High Glucosinolate Broccoli|High Glucosinolate Broccoli
11534304|NCT01114399|Experimental|Peas|Peas
11534305|NCT01114386||COPD patients, CHF patients|COPD and CHF patients with smoking history (> 10 pack/years), male and female, older than 50 years, referred to Hospital for dyspnea and chronic cough.
11534306|NCT01114373|Active Comparator|Melatonin|Subjects with mild to moderate essential hypertension will be given 24mg time release melatonin for 4 weeks either before or after exposure to 4 week of placebo with no washout period.
11534307|NCT01114373|Placebo Comparator|Placebo|Subjects with mild to moderate essential hypertension will be given placebo for 4 weeks either before or after exposure to 4 weeks of 24mg daily dose of time release melatonin with no washout period.
11534308|NCT01114360|Active Comparator|Melatonin|African-American subjects with mild to moderate essential hypertension will be given 8mg time release melatonin for 4 weeks. (either before or after placebo exposure).
11534309|NCT01114360|Placebo Comparator|Placebo|African-American subjects with mild to moderate essential hypertension will be given placebo for 4 weeks (either before or after exposure to melatonin)
11534310|NCT01114347|Experimental|Cranberry|Patients randomized to this arm will recieve one gel capsule containing cranberry PAC (36 mg of type A pro anthocyandines: Urell, Pharmatoka) per day starting at the day of the pelvic surgery (j0) until day 10 postop (j10). The gel capsule in taken orally in the morning with a large glass of water.
11534311|NCT01114347|Placebo Comparator|Placebo|The patients randomized to this arm will recieve one placebo gel capsule per day starting on the day of the pelvic surgery (j0) until the 10th day post-op (j10). The gel capsule is taken orally in the morning with a large glass of water. The placebo contains lactose and is conditioned in a manner to be identical in caliber and color with the experimental treatment gel capsules.
11534312|NCT01114334|Active Comparator|Guideline-based Medical Management|"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.
~The evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications"
11534313|NCT01114334|Experimental|Motivational Interview with GBMM|Motivational Interviewing for Depression combined with guideline-based medical management for depression
11534314|NCT01114308|Experimental|Probuphine|Patients are first inducted on SL BPN then switched to 4 buprenorphine implants
11534315|NCT01114308|Placebo Comparator|placebo implant|patients are first inducted on SL BPN then switched to 4 placebo implants
11534316|NCT01114308|Active Comparator|sublingual buprenorphine|patients are inducted on SL BPN, then continue on SL BPN
11534317|NCT01114295|Experimental|Overt Obscure Gastrointestinal Bleeders|The only cohort in this study are those patients identified as having overt, obscure gastrointestinal bleeding who will then undergo CE or CTE.
11534318|NCT01114282|Experimental|VELCADE with pralatrexate|Pralatrexate,10 mg/m2, IV bolus on days 1, 8, and 15 VELCADE,1.3 mg/m2, IV bolus on days 1, 8, and 15
11534319|NCT01114256||Fine needle aspiration (FNA) biopsies|Fine needle aspiration biopsies (FNA) will be performed prior to and 0 to 336 hours after the therapeutic monoclonal antibody infusion.
11534320|NCT01114230|Experimental|Dose Level 1|
11534321|NCT01114230|Experimental|Dose Level 2|
11534322|NCT01114230|Experimental|Dose Level 3|
11534323|NCT01114230|Experimental|Dose Level 4|
11534324|NCT01114230|Experimental|Dose Level 5|
11534325|NCT01114230|Experimental|Dose Level 6|
11534326|NCT01114230|Experimental|Dose Level 7|
11534327|NCT01114230|Experimental|Dose Level 8|
11534328|NCT01114230|Experimental|Dose Level 9|
11534378|NCT01113918||Obsity PCOS Women|"Polycystic ovary syndrome (PCOS) was diagnosed according to the European Society for Human Reproduction (ESHRE)/American Society of Reproductive Medicine (ASRM) case definition which requires presentation of signs and/or symptoms of a minimum of 2 of the following 3 criteria: polycystic ovary morphology (PCOM), oligomenorrhea or amenorrhea (Oligo-An), androgen excess (HA).
~Body mass index (BMI) was defined as body weight in kilograms divided by body height in meters squared (kg/m2). Obesity was defined as BMI≥25 kg/m2, according to the Asia-Pacific definition."
11534379|NCT01113918||Non-obesity PCOS Women|The subjects BMI were less than ≥25 kg/m2 and out of criteria of PCOS by European Society for Human Reproduction (ESHRE)/American Society of Reproductive Medicine (ASRM).
11534380|NCT01113905||Radiation Only|
11534329|NCT01114217|Experimental|Ferumoxytol|Participants received ferumoxytol or placebo during AMAG-FER-IDA-301 [NCT01114139]. Participants enrolled in AMAG-FER-IDA-303, a 6-month Extension Study, were evaluated monthly and could receive treatment with ferumoxytol only if they met criteria defined as persistent or recurrent IDA, hemoglobin <11.0 grams per deciliter (g/dL) and transferrin saturation (TSAT) <20% at any evaluation visit, (except study termination visit). Participants who met criteria began a 5-week treatment period (TP) and received 2 doses of ferumoxytol 510 mg intravenously (IV). The first IV 510-mg dose was administered on TP Day 1 (Baseline); the second 2-8 (5±3) days after Dose 1. The first treatment course with ferumoxytol for participants who previously received placebo in AMAG-FER-IDA-301 was considered Course 1; Course 2 included participants who previously received ferumoxytol in AMAG-FER-IDA-301; subsequent treatment courses were serially numbered.
11534330|NCT01114204|Experimental|Ferumoxytol|Participants received a total of 2 doses of IV ferumoxytol 510 milligrams (mg) (17 milliliters [mL]). The first IV 510 mg dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose, for a total cumulative dose of 1.02 grams (g).
11534331|NCT01114204|Active Comparator|Iron Sucrose|Participants received an IV injection or infusion of iron sucrose 200 mg (10 mL) on Day 1 (Baseline) and on 4 other non-consecutive days over a 14-day period, for a total cumulative dose of 1.0 g. Participants receiving their first ever exposure to IV iron sucrose, received a test dose on Day 1 prior to receiving the remainder of the first dose, as prescribed in the package insert for some countries.
11534332|NCT01114191|Experimental|Arm 1|
11534333|NCT01114178||claudicants|patients referred for a treadmill test
11534334|NCT01114165|Experimental|SeptiFast Test|Pathogen detection by SeptiFast Test as an adjunct to traditional microbiological assessments including blood culture
11534335|NCT01114165|Active Comparator|Only Conventional Diagnostics|Pathogen detection only by conventional microbiological assessments, e.g. blood culture
11534336|NCT01114152|Experimental|1|Dose level A, B, C and optional Dose level D and E: single administration and one to three times daily for 6 days (Japanese n=8)
11534337|NCT01114152|Placebo Comparator|2|placebo given (2 subjects in each dose group)
11534338|NCT01114139|Experimental|Ferumoxytol|Participants received a total of 2 doses of IV ferumoxytol 510 milligrams (mg) (17 milliliters [mL]). The first IV 510 mg dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose, for a total cumulative dose of 1.02 grams (g).
11534339|NCT01114139|Placebo Comparator|Placebo|Participants received a total of 2 doses of IV saline (17 mL). The first IV dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose.
11534340|NCT01114126|Experimental|Neu-P11 2mg|
11534341|NCT01114126|Experimental|Neu-P11 5 mg|
11534342|NCT01114126|Experimental|Neu-p11 20 mg|
11534343|NCT01114126|Experimental|Neu-P11 50 mg|
11534344|NCT01114126|Placebo Comparator|Placebo|
11534345|NCT01114113|Active Comparator|non-trigger meal|"Measurement of intestinal transport eating a non-trigger meal."
11534346|NCT01114113|Active Comparator|"trigger meal baseline"|"Measurement of intestinal transport after eating a trigger meal."
11534347|NCT01114113|Placebo Comparator|"trigger meal with placebo"|Measurement of intestinal transport with blinded placebo
11534348|NCT01114113|Active Comparator|"trigger meal with enzymes (blinded)"|Measurement of intestinal transport with blinded active enzyme capsule
11534349|NCT01114100|Active Comparator|sertraline, panic education|treatment with sertraline after panic education
11534350|NCT01114100|Placebo Comparator|placebo after panic education|treatment with placebo after panic education
11534351|NCT01114100|No Intervention|care as usual|patient received no diagnosis an no panic education, they had a 24 weeks follow up with a visit at 12 weeks and 24 weeks to evaluate their complaints
11534352|NCT01114087|Experimental|1|Patients presenting with chronic myeloid leukaemia or malignant GIST and receiving for the first time a treatment by imatinib, a tyrosin-kinase inhibitor, preceded or not by hydroxyurea therapy for less than one month.
11534353|NCT01114074||Factor XII deficiency|Patients deficient in coagulation factor XII
11534354|NCT01114074||Factor XI Deficiency|Patients deficient in coagulation factor XI
11534355|NCT01114074||Prekallikrein deficiency|Patients deficient in prekallikrein
11534356|NCT01114074||HMWK deficiency|Patients deficient in high molecular weight kininogen (HMWK)
11534357|NCT01114074||Control group|Healthy controls
11534358|NCT01114061|Experimental|InsuPatch|The arm with the treatment: using the insupatch device to heat the insulin infusion site.
11534359|NCT01114035|Experimental|Patients|intestinal epithelial dysplasia
11534360|NCT01114035|Other|Control|Children without intestinal epithelial dysplasia
11534361|NCT01114022|Active Comparator|Active comparator|cylindrical PVC cuff
11534362|NCT01114022|Experimental|Experimental 1|cylindrical polyurethane cuff
11534363|NCT01114022|Experimental|Experimental 2|conic PVC cuff
11534364|NCT01114022|Experimental|Experimental 3|conic polyurethane cuff
11534365|NCT01114009|Experimental|Lung recruitment maneuver|The maneuver briefly increases the alveolar pressure to open recruitable lung (50 cmH2O), sustained with adequate positive end-expiratory pressure(PEEP) after lung recruitment, to avoid derecruitment.
11534366|NCT01114009|Active Comparator|Lung protective strategy|Lung protective strategy group received lung protective strategy without recruitment maneuver
11534367|NCT01113996|No Intervention|Standard treatment - usual care|
11534368|NCT01113996|Experimental|Protein supplementation|
11534369|NCT01113996|Experimental|Protein supplementation and strength training|
11534370|NCT01113983|Experimental|TAVI - TF and TA approach|Transcatheter aortic valve implantation and transfemoral/ transapical approach
11534371|NCT01113970|Experimental|Single Arm|open label, single arm, unblinded
11534372|NCT01113957|Experimental|Arm A|ABT-888 in combination with temozolomide
11534373|NCT01113957|Active Comparator|Arm B|pegylated liposomal doxorubicin alone
11534374|NCT01113944|Active Comparator|Program 1|Program 1
11534375|NCT01113944|Active Comparator|Program 2|Program 2
11534376|NCT01113931|Experimental|Doxycycline Hyclate 200 mg tablet|Once daily
11534377|NCT01113931|Active Comparator|Vibramycin 100 mg capsule|Twice daily
11534381|NCT01113905||Radiation and Chemotherapy|
11534382|NCT01113892|Active Comparator|EXXCEL Soft|A vascular graft comprised of extruded, expanded polytetrafluroethylene (ePTFE), indicated for use as a vascular prosthesis for replacement or bypass of diseased peripheral arteries (510(k) K962433).
11534383|NCT01113892|Experimental|FUSION Bioline|A synthetic vascular graft constructed of two layers. The inner layer is comprised of extruded, ePTFE. The outer layer is comprised of knit polyester textile. These two layers are fused together with a proprietary polycarbonate-urethane adhesive. The vascular graft also has a heparin coating on the graft's luminal surface. The Bioline coating is a bioactive surface coating consisting of a covalent Heparin Sodium coupled to immobilized recombinant human albumin.
11534384|NCT01113879|Experimental|Aphasia therapy with an exercise adjuvant|"Aphasia therapy for anomia: The treatment is a traditional lexical/semantic stimulation approach during which subjects will attempt to name drawings of objects.
~Aerobic exercise: An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate."
11534385|NCT01113879|Placebo Comparator|Aphasia therapy with a stretching adjuvant|"Aphasia therapy for anomia: The treatment is a traditional lexical/semantic stimulation approach during which subjects will attempt to name drawings of objects.
~Stretching: Stretching will occur for 50 minutes a day, three days/week for 12 weeks."
11534386|NCT01113866||heart failure|
11534387|NCT01113840|Placebo Comparator|Control|Control group continues with their daily activity as they were prior to randomization. Receive bi-weekly follow-up phone calls to assess health status and encourage adherence with protocol.
11534388|NCT01113840|Active Comparator|Exercise|Exercise classes three times per week in a controlled, supervised environment.
11534389|NCT01113827|Active Comparator|150mg olive extract|
11534390|NCT01113827|Active Comparator|50mg olive extract|
11534391|NCT01113827|Placebo Comparator|Placebo control|
11534392|NCT01113801|Placebo Comparator|Placebo|
11534393|NCT01113801|Experimental|2 mg LY2382770|
11534394|NCT01113801|Experimental|10 mg LY2382770|
11534395|NCT01113801|Experimental|50 mg LY2382770|
11534396|NCT01113788||imaging|imaging with usual catheter/fluoroscopy, no cartosound
11534397|NCT01113775||presence of right ventricle dysfunction|
11534398|NCT01113775||absence of right ventricle dysfunction|
11534399|NCT01113762|Experimental|resurfacing|a hip replacement that leaves most of the underlying bone intact and mimics the natural biomechanical features of the hip joint
11534400|NCT01113762|Experimental|large head THA|a standard stemmed THA but with a large metal head, and a metal-metal articulation
11534401|NCT01113762|Active Comparator|28 mm ceramics-polyethylene|a standard 28 mm head uncemented THA
11534402|NCT01113762|Active Comparator|28 mm metal-polyethylene THA|a standard stemmed uncemented THA
11534403|NCT01113749|Experimental|Decision support|Structured decision aid with prompting to share information in discussion with primary treating health care providers.
11534404|NCT01113749|No Intervention|Control|Usual care
11534405|NCT01113736|Experimental|Human Peritoneal Membrane: AlloMEM™|For use as a homologous tissue where native peritoneum is absent or traumatized. By decreasing adhesions and providing a peritoneal remodeling capacity, both the time needed for ileostomy closure and the risk of enterotomy or seromyotomy would be reduced. The combination could lead to decreased complication rates and therefore decreased morbidity for the surgical patients requiring an ileostomy.
11534406|NCT01113723|Other|CMAC Device|CMAC Intubating device time to achieve successful tracheal intubation.
11534407|NCT01113723|Active Comparator|Fiberoptic bronchoscope|Fiberoptic bronchoscope Intubating device time to achieve successful tracheal intubation.
11534408|NCT01113710||Neupro®|Routine treatment in accordance with the local marketing authorization for Neupro® in RLS
11534409|NCT01113697||Clinical Investigator Collaborative (CIC) Asthma study cohort|Participants will be healthy volunteer research subjects with allergic asthma who will have an allergen inhalation challenge at CIC sites across Canada.
11534410|NCT01113697||Western Red Cedar Asthma study cohort|Participants will be volunteer research subjects with Western Red Cedar asthma, who will have a plicatic acid inhalation challenge at The Lung Centre at Vancouver General Hospital.
11534411|NCT01113697||Environmental Exposure Unit (EEU), Kingston General Hospital|Subjects will be over 19 years of age so that they qualify for studies involving allergen challenge.
11534412|NCT01113671|Placebo Comparator|Placebo|
11534413|NCT01113671|Experimental|d-alpha-tocopheryl acetate|
11534414|NCT01113658|Experimental|SNaP|SNaP disposable, mechanically powered Negative Pressure Wound Therapy System
11534415|NCT01113645||Cerebral perfusion evaluation|All patients are evaluated by GOS (Glasgow Outcome Score) and neurocognitive tests by FAB (frontal assessment battery) and MMSE (mini mental state examination) scores. Hemodynamic monitoring by CT perfusion scan, as well as by trans-cranial Doppler.
11534416|NCT01113632|Experimental|Ofatumumab 1000mg|Ofatumumab 300mg IV Day 1 followed by ofatumumab 1000mg weekly for a total of 8 weeks
11534417|NCT01113632|Experimental|Ofatumumab 2000mg|Ofatumumab 300mg IV Day 1 followed by ofatumumab 2000mg weekly for a total of 8 weeks
11534418|NCT01113619|Experimental|RP-G28|Study Drug RP-G28
11534419|NCT01113619|Placebo Comparator|Placebo|Study Drug Placebo
11534420|NCT01113606|Active Comparator|Obagi Nu-Derm System (ONDS)|
11534421|NCT01113606|Active Comparator|Standard of Care|
11534422|NCT01113593|Experimental|1|
11534423|NCT01113593|Experimental|2|
11534424|NCT01113593|Experimental|3|
11534425|NCT01113593|Experimental|4|
11534426|NCT01113593|Experimental|5|
11534427|NCT01113580|Experimental|Adults|Healthy volunteers aged 18 to 59 years
11534428|NCT01113580|Experimental|Older Adults|Healthy volunteers aged 60 years or older
11534429|NCT01113567|Placebo Comparator|Diet and lactose-free milk|Lactose-free milk
11534430|NCT01113567|Active Comparator|Diet and whole milk|Whole milk with lactose
11534431|NCT01113554|Experimental|Arm I|Patients attend exercise therapy sessions over 1 hour 3 times a week for 6 months. Exercise therapy sessions are comprised of a 10 minute warm-up of light stretching and aerobic type exercise (walking, cycling), 30 minutes of endurance type exercise (cycle, walking), and 20 minutes of resistance training exercise.
11534432|NCT01113541|Experimental|Active treatment (switch to oral Ziprasidone)|
11534434|NCT01113528|Placebo Comparator|Sugar pill|
11534435|NCT01113515|Placebo Comparator|Placebo|Placebo gel
11534436|NCT01113515|Experimental|Galnobax 20% QD|Esmolol Hydrochloride (Galnobax) 20% gel once daily
11534437|NCT01113515|Experimental|Galnobax 20% BID|Esmolol Hydrochloride (Galnobax) 20% gel twice daily
11534438|NCT01113515|Experimental|Galnobax 14% BID|Esmolol Hydrochloride (Galnobax) 14% gel twice daily
11534439|NCT01113502|Experimental|Eltrombopag|"Taken daily by mouth
~Phase I:
~Dose Level I: 50 mg; Dose Level II: 100 mg; Dose Level III: 200 mg; Dose Level IV: 300 mg
~Phase II:
~Starting Dose 200 mg"
11534440|NCT01113489|Experimental|beclomethasone dipropionate suspension for nebulization|
11534441|NCT01113489|Placebo Comparator|placebo|
11534442|NCT01113476|Experimental|Nab-paclitaxel, Gemcitabine + Bevacizumab|Starting doses of Nab-paclitaxel 50 mg/m^2, Bevacizumab 5 mg/kg + fixed dose of Gemcitabine 1000 mg/m^2
11534443|NCT01113463|Experimental|TPI 287|TPI 287 Starting dose 160 mg/m^2 intravenous (IV) every 3 weeks
11534444|NCT01113437|Experimental|Omalizumab|There are 2 arms of the study; patients in one arm receiving omalizumab and in the other arm receiving placebo.
11534445|NCT01113437|Placebo Comparator|Placebo|There are 2 arms of the study; patients in one arm receiving omalizumab and in the other arm receiving placebo.
11534446|NCT01113424|Experimental|NRT-2|2 mg single-dose of a new NRT product
11534447|NCT01113424|Active Comparator|GUM-2|2 mg single-dose of a marketed nicotine gum
11534448|NCT01113424|Experimental|NRT-4|4 mg single-dose of a new NRT product
11534449|NCT01113424|Active Comparator|GUM-4|4 mg single-dose of marketed nicotine gum
11534450|NCT01113411|Active Comparator|Intensive Rehabilitation|
11534451|NCT01113411|Active Comparator|Standard Rehabilitation|
11534452|NCT01113398|Experimental|AMG 102 with Avastin|Avastin will be administered as a continuous intravenous infusion at 10 mg/kg prior to AMG 102, which will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg. Subjects will receive infusions every 2 weeks.
11534453|NCT01113385|Experimental|Galactose|Oral galactose will be given at a dose of 0.2gm/kg/dose twice a day (BID) to a maximum of 15 gm BID for a period of 16 weeks.
11534454|NCT01113372|Experimental|Clopidogrel 3 months|Regime of dual antiplatelet therapy (DAPT) including aspirin+clopidogrel for 3 months.
11534455|NCT01113372|Active Comparator|Clopidogrel 12 months|Regime of dual antiplatelet therapy (DAPT) including aspirin+clopidogrel for 12 months.
11534456|NCT01113359||study group|hypertensive patients
11534457|NCT01113359||control group|healthy volunteer
11534458|NCT01113346|Experimental|Filtrum-STI|
11534459|NCT01113346|Placebo Comparator|Placebo|
11534460|NCT01113333|Experimental|SAR113945|SAR113945, single dose according to dose escalation design
11534461|NCT01113333|Placebo Comparator|Placebo|0.9% saline solution, single dose
11534462|NCT01113320|Placebo Comparator|Placebo|
11534463|NCT01113320|Active Comparator|Safinamide|
11534464|NCT01113307||Hard to heal wounds|
11534465|NCT01113294|Experimental|ablation|
11534466|NCT01113281|Experimental|VPM1002 in three dosages|
11534467|NCT01113281|Active Comparator|BCG|
11534468|NCT01113268|Other|1:cohort|Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
11534469|NCT01113255|Active Comparator|CHRONIC REPIRATORY FAILURE|
11534470|NCT01113255|Active Comparator|ACUTE RESPIRATORY FAILURE|
11534471|NCT01113242||A:|Patients with idiopathic PD and with MMSE < à 26
11534472|NCT01113242||B:|Patients with idiopathic PD and with MMSE ≥ à 26
11534473|NCT01113229|Experimental|Misoprostol|10 UI of oxytocin IV during delivery of the anterior shoulder of the newborn and two misoprostol tablets taken orally (400µg) following cord clamp
11534474|NCT01113229|Placebo Comparator|PLACEBO|10 UI of oxytocin IV during delivery of the anterior shoulder of the newborn and two placebo tablets taken orally following cord clamp.
11534475|NCT01113203|Experimental|Resistance training|Progressive high intensity resistance training performed twice a week for 16 weeks, and achieving in 7 exercises for the main muscles, the protocol of 4 sets of 6RM and 2 of 4RM.
11534476|NCT01113190|Active Comparator|CBI in ED with AMET at 3 months|computer-delivered brief intervention (CBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
11534477|NCT01113190|Active Comparator|CBI in ED with EUC at 3 months|computer-delivered brief intervention (CBI) at baseline with enhanced usual care-EUC at 3 months
11534478|NCT01113190|Active Comparator|IBI in ED with AMET at 3 months|intervener-delivered brief intervention (IBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
11534479|NCT01113190|Active Comparator|IBI in ED with EUC at 3 months|intervener-delivered brief intervention (IBI) at baseline with enhanced usual care-EUC at 3 months
11534480|NCT01113190|Active Comparator|EUC in ED with AMET at 3 months|enhanced usual care (EUC) at baseline with adapted motivational enhancement therapy-AMET at 3 months
11534481|NCT01113190|Active Comparator|EUC in ED with EUC at 3 months|enhanced usual care (EUC) at baseline with EUC at 3 months
11534482|NCT01113177||Distraction splint therapy|All JIA patients with asymmetric mandibular growth due to unilateral TMJ arthritis are offered non-surgical functional orthodontic splint therapy with a distraction splint. Mandibular growth is thereafter evaluated in the affected side compared with the mandibular growth in the healthy side of the same individual.
11534483|NCT01113164|Experimental|Ondansetron, Placebo, Sertraline|LL-carriers receiving ondansetron compared to either placebo or sertraline, will result in a significant reduction in alcohol consumption.
11534484|NCT01113164|Experimental|Sertraline, Placebo, Ondansetron|SL and SS-carriers receiving sertraline compared to either placebo or ondansetron, will result in a significant reduction in alcohol consumption.
11534485|NCT01113151|No Intervention|Washout|
11534486|NCT01113151|Active Comparator|Mablet|
11534487|NCT01113151|Placebo Comparator|Placebo|
11534488|NCT01113138|No Intervention|Baseline|
11534489|NCT01113138|Active Comparator|Mablet|
11534490|NCT01113138|Active Comparator|Magnesium sulfate|
11534492|NCT01113125|Placebo Comparator|Fucidin|
11534493|NCT01113112||Biobehavioral factors|Those with biobehavioral factors that contribute to a permissive local environment for macrophage-tumor interactions that enhance tumor growth in ovarian cancer
11534494|NCT01113099|Experimental|Academic detailing of physicians|
11534495|NCT01113099|No Intervention|Usual care|
11534496|NCT01113086|Experimental|Left active anodal DLPFC|We will place the anodal electrode on the left dorsolateral prefrontal cortex. Stimulation will be given at 2 mA for a total of 20 mins for 10 consecutive sessions (Monday through Friday).
11534497|NCT01113086|Experimental|Right active anodal DLPFC|We will place the anodal electrode on the right dorsolateral prefrontal cortex. Stimulation will be given at 2 mA for a total of 20 mins for 10 consecutive sessions (Monday through Friday).
11534498|NCT01113086|Placebo Comparator|Sham tDCS|Sham tDCS: For sham-controlled tDCS subjects, the same montage will be used; however current will be applied for only 30 seconds.
11534499|NCT01113086|Other|Open-Label Arm|In addition to this study we will have an open label arm in which subjects who received sham stimulation through the course of the study will have the opportunity to receive active stimulation free of charge. The same parameters and identical procedures as is done in the original study will be used. Data will be collected as an open label, which will therefore provide additional information. Data obtained from this open label portion of the study will be kept separate.
11534500|NCT01113073|Experimental|Elective open heart surgery|Patients who had undergone elective open heart surgery
11534501|NCT01113060||CAD patients|Representative sample of coronary artery disease patients receiving aspirin therapy for secondary prevention
11534502|NCT01113047|Experimental|Non responder Olmesartan/Amlodipine|Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
11534503|NCT01113034|Active Comparator|DAS181 Dry Powder 10 mg qd x 3 days|
11534504|NCT01113034|Placebo Comparator|Lactose Placebo|
11534505|NCT01113021|Experimental|LLLT and Physical Strength training in Humans|
11534506|NCT01113008|Experimental|Remote postcondtioning|Patients assigned to remote ischemic postconditioning (randomized controlled trial)
11534507|NCT01113008|Placebo Comparator|Control group|
11534508|NCT01112995|Experimental|Probiotic|subjects will be given a pill formulation of a probiotic Lactobacillus rhamnosus to be taken once a day.
11534509|NCT01112995|Placebo Comparator|Sugar pill|placebo identical to the active product will be given
11534510|NCT01112982|Other|Febuxostat Sub-Study|"To analyze the effect of urate-lowering therapy (specifically with febuxostat [Uloric]) on the synovial pannus in the index joint of a subgroup of patients. Subjects not currently on any urate-lowering therapy, or on a serum urate lowering drug other than febuxostat (Uloric) and who have a serum urate level of > or = to 9.0, will be treated with febuxostat (Uloric) and their serum urate level will be followed at months 1, 3, 6, and 9. Magnetic Resonance Imaging (with and without gadolinium) of the same index joint will be repeated at month 9 to assess for the presence and degree of synovial pannus. Because initiation of urate-lowering therapy can induce acute attacks of gout, these subjects will also be started on colchicine as a prophylactic (and remain on colchicine for 6 months)."
11534511|NCT01112982|Other|MRI of index joint|"To analyze synovial pannus in the Magnetic Resonance Imaging (with and without gadolinium) of the index joint on Subjects not currently on any urate-lowering therapy, or on a serum urate lowering drug other than febuxostat (Uloric)."
11534512|NCT01112969|Experimental|Internet-based supportive coaching OSCAR|Arm 1: Internet-based supportive coaching OSCAR
11534513|NCT01112969|Other|Waiting list control group (treatment as usual, TAU)|
11534514|NCT01112956||STD clinic patients|Patients attending sexually transmitted Disease clinics. If the initial testing result reported to the patient is confirmed by the Western Blot test, no follow-up specimens will be collected. If the initial testing result reported to the patient is different from the result by the Western Blot test, patients will be asked to provide a follow-up specimen 3-4 months after initial testing.
11534515|NCT01112956||Pregnant women|Women recruited from prenatal clinic. A follow-up visit may or may not needed depending on results from the initial test and Western blot test.
11534516|NCT01112956||Men who have Sex with men (MSM)|Men recruited from a clinic for MSM with high risk for HIV infection. A follow-up visit may or may not needed depending on results from the initial test and Western blot test.
11534517|NCT01112943|Experimental|Acupuncture|Acupuncture on predefined points once a week for 20 minutes over the seven week pulmonary rehabilitation course
11534518|NCT01112943|Active Comparator|Pulmonary Rehabilitation|A seven week exercise and educational class run twice a week using international guidelines.
11534519|NCT01112943|No Intervention|Control|Three assessments over the same time frame of three months but without intervention
11534520|NCT01112917|Experimental|VenaTech Convertible Vena Cava Filter|Implantation of the VenaTech Convertible Filter. The filter is pre-loaded in a cartridge (syringe) and provided as a system with introducer accessories and instructions to accommodate delivery and implantation either using the femoral or jugular approach.
11534521|NCT01112891|Experimental|1|
11534522|NCT01112891|Experimental|2|
11534523|NCT01112891|Experimental|3|
11534524|NCT01112878|Placebo Comparator|Sugar Pill|"Frequency and Dosage:
~once in the preoperative holding area and once before discharge from PACU
~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
11534525|NCT01112878|Active Comparator|Clonidine|"Dosage: 0.2 mg
~once in the preoperative holding area and once before discharge from PACU
~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
11534526|NCT01112878|Active Comparator|Gabapentin|"Dosage: 600 mg
~once in the preoperative holding area and once before discharge from PACU
~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
11534527|NCT01112865|Other|Mark VII/Current pen|Subject will use Mark VII pen for 2 months followed by Current pen for 2 months
11534528|NCT01112865|Other|Current pen/Mark VII|Subject will use current Genotropin pen for 2 months followed by Mark VII pen for 2 months
11534529|NCT01112852|Active Comparator|EVL + vasoconstrictor|Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
11534530|NCT01112852|Experimental|EVL + PPI|Pantoloc 40 mg intravenously per day was instituted on enrollment and continued for 5
11534531|NCT01112839|Active Comparator|Less Intensive Group|Participants in this group would receive print materials on diet and exercise and two individual counseling sessions; one at the beginning of the study and another 6 months later.
11534532|NCT01112839|Experimental|Intensive Group|Participants in this group would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
11534533|NCT01112826|Experimental|Capecitabine|Capecitabine 650 mg/m2 bid
11534534|NCT01112826|No Intervention|Standard treatment|Treatment according to National Comprehensive Cancer Network (NCCN) guideline.
11534535|NCT01112813|Experimental|Lithium|Lithium Carbonate, 0.4-0.8 mmol/L for 2 months
11534536|NCT01112800||Participants|Previously untreated patients referred to St. Jude Children's Research Hospital (SJCRH) between the ages of 0 and 21 years with a diagnosis of osteosarcoma, ESFT, rhabdomyosarcoma and intermediate and high-risk non-rhabdomyosarcoma soft tissue sarcomas whose planned treatment includes administration of a cumulative anthracycline dose ≥ 375 mg/m2.
11534537|NCT01112787|Experimental|Tazarotene Foam|Subjects will be exposed to patches containing Tazarotene Foam 0.1%,
11534538|NCT01112787|Placebo Comparator|Vehicle Foam|Subjects will be exposed to patches containing Vehicle Foam.
11534539|NCT01112787|Active Comparator|Sodium Laural Sulfate|Subjects will be exposed to patches containing Sodium Laural Sulfate.
11534540|NCT01112787|Placebo Comparator|Distilled Water|Subjects will be exposed to patches containing Distilled Water.
11534541|NCT01112774|Experimental|tDCS/Spinal cord injury|Subjects will be randomized to receive 10 sessions of either active or sham tDCS. Stimulation will be given on consecutive days (Monday- Friday) at 2 mA over the primary motor cortex area.
11534542|NCT01112774|Experimental|tDCS/Healthy subjects|Subjects will receive 2 sessions of stimulation: one active and one sham tDCS on two separate visits. The order in which they receive the stimulation will be randomized. Stimulation parameters will be at 2 mA for a total of 20 minutes.
11534543|NCT01112761|Experimental|Healthy Subjects|Each subject will undergo each of the three conditions (active anodal tDCS, cathodal tDCS and sham tDCS), but the order in which they do so will be randomized.
11534544|NCT01112761|Experimental|Athletes with history of concussion|Each subject will undergo each of the three conditions (active anodal tDCS, cathodal tDCS and sham tDCS), but the order in which they do so will be randomized.
11534545|NCT01112735|Experimental|ARTISS|ARTISS will be used as an adjuvant to standard of care.
11534546|NCT01112735|Other|Standard of care|Standard of care
11534547|NCT01112722|Active Comparator|Apitox, purified honeybee toxin, injections|active treatment drug 'Apitox, purified honeybee toxin, lyophilized in saline'
11534548|NCT01112722|Placebo Comparator|histamine injection|the histamine injection produces a similar local effect of pain and erythema as the active drug
11534549|NCT01112709|Experimental|SCT|This arm is a long-term, Social Cognitive Theory (SCT)-based intervention, emphasizing self-regulation and other SCT strategies to optimize training, with faded contact.
11534550|NCT01112709|Active Comparator|Control|"This arm will be the control condition; a Standard intervention with minimal contact."
11534551|NCT01112696|Other|Sensor|All subjects that wear sensors (all subjects)
11534552|NCT01112683|Experimental|Memantine|The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 & 10 mg/d divided dose week three, 10mg/BID week four).
11534553|NCT01112683|Placebo Comparator|Placebo|These are identically-looking pills to the ones in the Memantine Arm
11534554|NCT01112670|Experimental|ABCB1 Group 1|ABCB1 CGC/CGC genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
11534555|NCT01112670|Experimental|ABCB1 Group 2|ABCB1 CGC/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
11534556|NCT01112670|Experimental|ABCB1 Group 3|ABCB1 TTT/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
11534557|NCT01112644|Experimental|OXN PR|Different daily doses; intake every 12 hours
11534558|NCT01112644|Placebo Comparator|PLA|Different daily doses; intake every 12 hours
11534559|NCT01112631||Stage II patients post surgery|Stage II patients treated with surgery alone
11534560|NCT01112631||Stage III patients post surgery|Stage III patients treated with surgery and PORT
11534561|NCT01112605||otherwise healthy persons|healthy persons, no major trauma or surgery of ankle or calves, no bone or muscle disease, age 18-60
11534562|NCT01112579|Experimental|Treatment|
11534563|NCT01112579|Other|Control|
11534564|NCT01112553||Treximet|All migraine subjects will receive Treximet during a migraine episode at Visit 2.
11534565|NCT01112540|Placebo Comparator|Placebo Group|
11534566|NCT01112540|Experimental|Morphine|
11534567|NCT01112527|Experimental|Arm A|Patients with Glioblastoma that has returned or grown after chemotherapy or radiation treatment and who will be having a standard operation to remove the tumor.
11534568|NCT01112527|Experimental|Arm B|Participants with glioblastoma at first recurrence who are not surgical candidates and who have not had prior anti-VEGF therapy.
11534569|NCT01112527|Experimental|Arm C|Participants with glioblastoma who are not surgical candidates and who are at first recurrence from a therapeutic regimen containing bevacizumab.
11534570|NCT01112514|Experimental|ICG Injection|These participants underwent a colonoscopy after having an ICG injection.
11534571|NCT01112488|No Intervention|Control|usual care
11534572|NCT01112488|Experimental|multidisciplinary intervention|Patient engagement Programme
11534573|NCT01112462|Experimental|Tablet|Paracetamol 500 mg/Phenylephrine 5 mg tablet
11534574|NCT01112462|Active Comparator|Sachet|Paracetamol 1000 mg/Phenylephrine 10 mg sachet
11534575|NCT01112449|Experimental|Low dose selenized-yeast|200 µg/day of selenized-yeast (SY)
11534576|NCT01112449|Experimental|selenomethionine|The second group will receive 200 µg/day of selenomethionine (SM)
11534577|NCT01112449|Placebo Comparator|Placebo|no active medication.
11534578|NCT01112449|Experimental|High dose selenized-yeast|The fourth group will receive 285 µg/day of selenized-yeast (SY).
11534579|NCT01112436|Placebo Comparator|control group (group C)|control group will receive no medication preoperatively and during operation
11534580|NCT01112436|Active Comparator|periarticular injecion group (group I)|patients in Group I will receive oral oxycodone SR 10 mg and celecoxib 200 mg 1 hour preoperatively with sips of water, and receive periarticular injection of combination of ropivacaine 15 mg, morphine 10 mg, ketorolac 30 mg epinephrine 0.3 mg and cefmetazole 1000mg during operation.
11534581|NCT01112423|Experimental|BMS-823778 (2 mg)|
11534582|NCT01112423|Experimental|BMS-823778 (10 mg)|
11534583|NCT01112423|Experimental|BMS-823778 (20 mg)|
11534584|NCT01112423|Placebo Comparator|Placebo|
11534585|NCT01112397|Experimental|1|AZD1480 until Maximum Tolerated Dose (MTD) is reached
11534586|NCT01112397|Experimental|2|AZD1480 dose expansion of MTD
11534587|NCT01112384|Experimental|SB939|
11534588|NCT01112371|Experimental|Contractubex|
11534589|NCT01112371|No Intervention|Non treatment|
11534590|NCT01112358|Experimental|r-FSH + r-hLH|Lutropin alfa (r-hLH) will be administered at a daily dose of 150 International Units (IU) from the presence of at least one follicle greater than (>) 14 millimeter (mm) to complete ovarian stimulation. Follitropin alfa (r-FSH) will be administered at an initial dose of 225-450 IU per day (according to standard center practice); the dose will then be adjusted to ovarian response as assessed by ovarian ultrasound and/or serum estradiol. Participants will also receive analogous GnRH antagonist and natural progesterone, as per standard center practice. To complete follicular maturation and trigger ovulation, a single dose of 250 milligrams (mg) of recombinant Human Chorionic Gonadotropin (r-hCG) will be administered subcutaneously at 12 hours after the last injection of lutropin alfa and/or follitropin alfa and analogous GnRH antagonist.
11534591|NCT01112358|Active Comparator|r-FSH|Follitropin alfa (r-FSH) will be administered at an initial dose of 225-450 IU per day (according to standard center practice); the dose will then be adjusted to ovarian response as assessed by ovarian ultrasound and/or serum estradiol. Participants will also receive analogous GnRH antagonist and natural progesterone, as per standard center practice. To complete follicular maturation and trigger ovulation, a single dose of 250 mg of r-hCG will be administered subcutaneously at 12 hours after the last injection of follitropin alfa and analogous GnRH antagonist.
11534592|NCT01112319|Experimental|Elf_care|The trial group will receive with Elf_Care unit (Hot-Cold & Electrotherapy) during physiotherapy treatment ( 28 minutes twice a week)
11534593|NCT01112319|Active Comparator|control group|The control group will receive before physiotherapy COLD HOT or Electrotherapy treatment depends on the patient and physiotherapy prefer.
11534594|NCT01112306|Experimental|1|ACT-293987, twice daily
11534595|NCT01112293|Experimental|Investigational drug infusion-for safety and effectiveness|Phase II, Single-Arm, Multi-Site study. All subjects will receive the investigational agent, GC1008 in 3 week cycles of treatment
11534596|NCT01112280|Experimental|cap-assisted chromoendoscopy|To the tip of the colonoscope, transparent cap is fitted and applied. In addition, panchromoendoscopy using indigocarmine solution is preformed in this group.
11534597|NCT01112280|No Intervention|Standard colonoscopy|Neither transparent cap nor chromoendoscopy is applied in this group and standard colonoscopy is performed.
11534598|NCT01112267|Experimental|Tramadol Hydrochloride (HCl)/acetaminophen|Participants will receive 1 tablet containing fixed dose of combination of tramadol hydrochloride (HCl) 75 milligram (mg) /acetaminophen Extended Release (ER) 650 mg orally once daily on Days 1 to 3, 1 tablet twice daily (tramadol HCl 150 mg/acetaminophen 1300 mg) on Days 4 to 7, then 1 or 2 tablets twice daily on Days 8 to 28.
11534599|NCT01112267|Placebo Comparator|Placebo|Prticipants will receive 1 tablet matching placebo once daily orally on Days 1 to 3, 1 tablet twice daily on Days 4 to 7, then 1 or 2 tablets twice daily on Days 8 to 28.
11534600|NCT01112254|Experimental|MRI±biopsy|a MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm from the initial lesion), not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI ± biopsy results.
11534601|NCT01112254|No Intervention|Standard care|The patients will be operated without additional exams
11534602|NCT01112241|Experimental|albuterol-tiotropium|At visit 1, lung function measurements will be performed in triplicate before and 90 min after inhaling four separate doses of 100 μg of albuterol (Ventolin®) and soon after 18 μg of tiotropium bromide [Spiriva®] to ensure maximal or near-maximal bronchodilation. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber (Volumatic®) and tiotropium by a dry-powder device (Handihaler®).
11534603|NCT01112228||Obese patients|Obese patients for Bariatric surgery
11534604|NCT01112215|Active Comparator|azathioprine|
11534605|NCT01112215|Active Comparator|Enteric-coated Mycophenolate Sodium|
11534606|NCT01112189|Experimental|Patients with stem cells|Patients that receive the stem cells treatment
11534607|NCT01112189|Active Comparator|Compressed sleeve treatment|Patients that will receive the compressed sleeve treatment
11534608|NCT01112163|Experimental|Enhanced external counter pulsation|One session of enhanced external counter pulsation (60 minutes)
11534609|NCT01112150|Active Comparator|Pumping group|Patients in this arm will get a pumping session 2-3 times a day .
11534610|NCT01112150|Active Comparator|No pumping|These patients will not receive pumping but only classical treatment clinically indicated (diuretics, oxygen, Digoxin, Nitrates, ACE inhibitors etc, as necessary)
11534611|NCT01112137|Experimental|Hypertensive individuals: clopidogrel (600 mg, bolus)|
11534612|NCT01112137|Experimental|Hypertensive individuals: clopidogrel (75 mg daily)|
11534613|NCT01112137|Active Comparator|Normotensive individuals: clopidogrel (600 mg, bolus)|
11534614|NCT01112137|Active Comparator|Normotensive individuals: clopidogrel (75 mg, daily)|
11534615|NCT01112111||75 PCOS Patients - step up regime|Group A will be comprised of 75 patients and these will receive a low dose step stimulation regime
11534616|NCT01112111||75 PCOS patients -step down regime|Group B will be comprised of 75 patients who will receive a step down regime of stimulation
11534617|NCT01112111||75 PCOS patients - sequential regime|Group C will be comprised of 75 patients who will be treated using a sequential stimulation regime
11534618|NCT01112098|Experimental|Educational Pamphlet and letter|Letter invites patient to self-schedule a DXA; educational pamphlet includes information about DXA scans
11534619|NCT01112085|Experimental|Ranibizumab 0.05mg|Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
11534620|NCT01112085|Experimental|Ranibizumab 0.5mg|Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
11534621|NCT01112072|Active Comparator|Intacs combined with CXL|Intacs placement followed by collagen crosslinking with UV light and riboflavin
11534622|NCT01112072|Active Comparator|Intacs followed by CXL|Intacs placement, to be followed by corneal collagen crosslinking with UV light and riboflavin 3 months later
11534623|NCT01112059|Placebo Comparator|Placebo|Patients given placebo twice a day for 8 days at beginning of inpatient CF exacerbation
11534624|NCT01112059|Active Comparator|doxycycline|Patients given doxycycline 100 mg tablet twice a day for 8 days at the beginning of inpatient CF exacerbation
11534625|NCT01112046|Experimental|Endoscopic submucosal dissection|
11534626|NCT01112046|Active Comparator|Laparoscopic resection|
11534627|NCT01112033||chronic HCV infection|The study was performed on therapeutically naïve patients with chronic HCV infection. Patients with positivity of anti-HCV antibodies, and detectable HCV RNA in serum for at least 6 months, were included in the study.
11534628|NCT01112020|Experimental|CHG Catheter Dressing Patch|
11534629|NCT01112020|Active Comparator|Biopatch|Biopatch Protective Disk with CHG
11534630|NCT01112020|Active Comparator|Tegaderm CHG|Tegaderm CHG IV Securement Dressing
11534631|NCT01112007||prehypertension|Subjects with prehypertension, that is, individuals with systolic blood pressure in the range of 120-139 mmHg or diastolic BP between 80-89 mmHg.
11534632|NCT01111968|Experimental|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
11534633|NCT01111968|Experimental|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
11534634|NCT01111968|Experimental|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
11534635|NCT01111968|Experimental|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
11534636|NCT01111968|Experimental|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
11534637|NCT01111968|Experimental|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
11534638|NCT01111968|Experimental|pandemic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
11534639|NCT01111968|Experimental|pandemic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
11534640|NCT01111968|Experimental|pandemic vaccine 13|15µg of A/H1N1 with no adjuvant
11534641|NCT01111968|Placebo Comparator|placebo group 14|placebo
11534642|NCT01111955|Active Comparator|BMS-823778 (2 mg)|+ metformin
11534643|NCT01111955|Active Comparator|BMS-823778 (10 mg)|+ metformin
11534644|NCT01111955|Active Comparator|BMS-823778 (20 mg)|+ metformin
11534645|NCT01111955|Placebo Comparator|Placebo|+ metformin
11534646|NCT01111942|Active Comparator|radiation and weekly carboplatin|
11534647|NCT01111942|Other|conservation surgery|
11534648|NCT01111929|Active Comparator|Counseling for LAM|"Will receive proper postpartum counseling for LAM by trained research nurse. This is in addition to, adequate contraceptive counseling including information about LAM and its prerequisites.
~Women that choose to use LAM will be advised to return to our contraception outpatient clinic to have a long term method of contraception as soon as any of the requirements of LAM expires."
11534649|NCT01111929|Experimental|Counseling for LAM+ LNG-EC|LAM counseling and contraceptive counseling +two 0.75 mg Levonorgestrel EC pills
11534650|NCT01111903|Experimental|lenalidomide|Phase II: lenalidomide 20 mg/day in continuous regimen. Phase I: lenalidomide 25 mg/day 21 days/28 + carboplatin AUC 5 + caelyx 30 mg/m2
11534651|NCT01111890|Experimental|Azarga|Azarga (brinzolamide 1% / timolol 0.5%)
11534652|NCT01111890|Active Comparator|Cosopt|Cosopt (dorzolamide 2% / timolol 0.5%)
11534653|NCT01111864|Experimental|MixMe powder (iron & micronutrients)|
11534654|NCT01111864|Placebo Comparator|MixMe powder (micronutrients, no iron)|
11534655|NCT01111864|Experimental|Sprinkles (iron and micronutrients)|Vitamin A 300 µg; Vitamin C 30 mg; Folic Acid 160 µg; Iron 12.5 mg; Zinc 5 mg
11534656|NCT01111864|Placebo Comparator|Sprinkles (micronutrients, no iron)|Vitamin A 300 µg; Vitamin C 30 mg; Folic Acid 160 µg; Zinc 5 mg
11534657|NCT01111851|Experimental|Fosaprepitant 150 mg|Fosaprepitant 150 mg
11534658|NCT01111851|Experimental|Aprepitant 165 mg|Aprepitant 165 mg
11534659|NCT01111851|Experimental|Aprepitant 250 mg|Aprepitant 250 mg
11534660|NCT01111838|Experimental|STA-9090|This is an open-label Phase 2 clinical study in patients with advanced colorectal cancer (CRC). Patients will be treated with 200mg/m2 of STA-9090 during a 1-hour intravenous infusion 1 time per week for three consecutive weeks followed by a 1 week dose-free interval. Patients tolerating STA-9090 will be permitted to continue treatment until disease progression.
11534661|NCT01111825|Experimental|Temsirolimus plus Neratinib|This is an open-label, single arm, dose-escalation phase I-II study to determine the maximum tolerated dose (MTD) of temsirolimus with daily neratinib, and to determine the safety and efficacy of this combination when given to patients with advanced breast carcinoma. Patients with trastuzumab-refractory HER2-amplified disease or triple negative disease will be enrolled in both phases of this clinical trial.
11534662|NCT01111812||weight measurements|This study include 1000 weight measurements of children and adolescence, boys and girls, ages 5-18, that taking pat in a multi-disciplinary intervention program for treatment of the overweight and obese in Meir medical center.
11534663|NCT01111799|Experimental|Clomiphene citrate + IUI + endometrial biopsy|Clomiphene citrate + IUI + endometrial biopsy
11534664|NCT01111799|No Intervention|Clomiphene citrate + IUI|
11534665|NCT01111799|Experimental|gonadotrophines + IUI + endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
11534666|NCT01111799|No Intervention|gonadotrophines + IUI|
11534667|NCT01111799|Experimental|natural cycle + IUI + endometrail biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
11534668|NCT01111799|No Intervention|natural cycle + IUI|
11534669|NCT01111773|Experimental|Heated Lidocaine and Tetracaine Patch|
11535057|NCT01108978|Active Comparator|Dehypotin|
11534670|NCT01111747|Experimental|PRP|In this group PRP will be used in the patellar tendon donor site.
11534671|NCT01111747|Sham Comparator|Control|In this group PRP will not be aded to the patellar tendon donor site
11534672|NCT01111734|Experimental|Treatment Group|The study consists of eight weeks of open label N-Acetylcysteine. All eligible study subjects will be treated with 600mg of N-Acetylcysteine twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks. weeks. Subjects will be seen every two weeks during the 8-week study. Efficacy and safety assessments will be performed at each visit.
11534673|NCT01111734|Experimental|Control|40 healthy age-matched peers with undergo the same baseline testing as the NAC subjects as well as baseline fMRI. They will not engage in any follow up visits.
11534674|NCT01111721|Experimental|Project POWER Intervention Group|Intervention group participants will attend the Project POWER intervention sessions, complete a pre-intervention assessment and participate in 3, 6, and 12 month follow-up interviews when they will be asked to provide urine specimens for STI testing. The intervention consists of eight bi-weekly, 1.5 hour sessions. Intervention group participants will also attend one booster group session four weeks after the intervention before being released. Intervention participants will receive booster phone calls from a nurse-interventionist at 2, 6, and 10 weeks after release from prison. Booster phone calls will reinforce intervention content and support participant efforts to reduce risky sex behaviors and make healthy choices.
11534675|NCT01111721|Active Comparator|NC DOC Standard of Care for STIs|Control group participants will receive the North Carolina Department of Correction standard of care for Sexually Transmitted Infections, complete one interview in prison and participate in 3, 6, and 12 month follow up interviews when they will be asked to provide urine specimens for STI testing.
11534676|NCT01111708|Experimental|Close Rectal-Ileo Pouch Anal Anastomosis|
11534677|NCT01111708|Active Comparator|Conventional Ileo Pouch Anal Anastomosis|
11534678|NCT01111708|Active Comparator|Ileo Neo Rectal Anastomosis|
11534679|NCT01111695|Experimental|Honey and ionic silver dressing|
11534680|NCT01111682|Active Comparator|Mannitol|0.9% normal saline infusion and boluses of mannitol
11534681|NCT01111682|Active Comparator|Hypertonic Saline|3% hypertonic saline continuous infusion, with intermittent boluses as needed
11534682|NCT01111669|Experimental|Tranexamic Acid|Patients in the tranexamic acid (TA) group will receive a bolus of TA, prepared according to patient weight (15mg / kg loading dose). The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation for the duration of the operation.
11534683|NCT01111669|Placebo Comparator|Normal Saline|The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution as the intervention group. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of normal saline for the duration of the operation.
11534684|NCT01111656|Active Comparator|1|Interferon beta-1b 250ug subcutaneously every other day
11534685|NCT01111656|Experimental|2|Interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
11534686|NCT01111643||I|
11534687|NCT01111630|Experimental|once weekly|
11534688|NCT01111630|Active Comparator|three times weekly|
11534689|NCT01111617|Experimental|Real-Time fMRI|Real-Time fMRI
11534690|NCT01111604|Active Comparator|mFOLFOX-6|mFOLFOX-6
11534691|NCT01111604|Experimental|mFOLFOX-6 + Ramucirumab|mFOLFOX-6 + Ramucirumab
11534692|NCT01111604|Experimental|mFOLFOX-6 + Icrucumab|mFOLFOX-6 + Icrucumab
11534693|NCT01111591|No Intervention|2. Bile duct cancer - control|Bile duct cancer patients do not administration of COX inhibitor
11534694|NCT01111591|Experimental|3. Pancreas cancer - experimental|Pancreas cancer patients take a COX2 inhibitor 200mg every 12hours for 6 months
11534695|NCT01111591|No Intervention|4. Pancreas cancer - control|Pancreas cancer patients do not administration of COX inhibitor
11534696|NCT01111591|Experimental|Bile duct cancer - experimental|Bile duct cancer patients take a COX2 inhibitor 200mg every 12hours for 6 months
11534697|NCT01111578||New enteral feeding tube|
11534698|NCT01111565|Active Comparator|Escitalopram monotherapy|
11534699|NCT01111565|Active Comparator|Aripiprazole monotherapy|
11534700|NCT01111565|Active Comparator|Aripiprazole/Escitalopram combination therapy|
11534701|NCT01111552|Active Comparator|Escitalopram monotherapy|
11534702|NCT01111552|Active Comparator|Aripiprazole monotherapy|
11534703|NCT01111552|Active Comparator|Aripiprazole/Escitalopram combination therapy|
11534704|NCT01111539|Active Comparator|Escitalopram monotherapy|
11534705|NCT01111539|Active Comparator|Aripiprazole monotherapy|
11534706|NCT01111539|Active Comparator|Aripiprazole/Escitalopram combination therapy|
11534707|NCT01111526|Experimental|LBH589, in Addition to Glucocorticoids|Phase I Dose Escalation, Followed by Phase II Treatment at Maximum Tolerated Dose (MTD) of LBH589, in Addition to Glucocorticoids.
11534708|NCT01111513|Active Comparator|Continuous femoral block|Patients receive a continuous femoral block for 48 hours and they have patient controlled analgesics.
11534709|NCT01111513|Active Comparator|Single dose femoral block|Patients receive a single dose femoral block and have patient controlled analgesics.
11534710|NCT01111513|Active Comparator|Patient controlled analgesics|Patients do not receive a femoral block. They only have patient controlled analgesics.
11534711|NCT01111500|Active Comparator|external rotation immobilization|Patient will wear an external rotation brace to immobilize the injured arm.
11534712|NCT01111500|Active Comparator|internal rotation immobilization|Patient will wear an internal rotation brace to immobilize the injured arm.
11534713|NCT01111487|Active Comparator|Group I|This group will use a pressure level of 10 cmH2O.
11534714|NCT01111487|Active Comparator|Group II|This group will use a pressure level of 15 cmH2O.
11534715|NCT01111474|Active Comparator|Cyanoacrylate|3 applications of cyanoacrylate (48 hours interval)at the cervical region of the sensitive tooth
11534716|NCT01111474|Active Comparator|Laser|3 Low intensity laser application (48 hour interval). The application of 1Joule/cm^2 was performed for eight seconds at three points along the dental neck, using the infrared wavelength (795nm)
11534828|NCT01110577||Traveling cohort|Overweight patients with or without type 2 diabetes or pre-diabetes
11534717|NCT01111461|Experimental|Lenvatinib 24 mg|Participants with advanced endometrial cancer and disease progression following platinum-based, first line chemotherapy.
11534718|NCT01111448|Experimental|Temsirolimus|25 mg/day 1; 8; 15; 22 of each 28-day cycle
11534719|NCT01111435||Individuals with Multiple Sclerosis|
11534720|NCT01111422|No Intervention|Control|Age and sex matched peritoneal dialysis patients
11534721|NCT01111422|Experimental|N-acetylcysteine|N-acetylcysteine in stable peritoneal dialysis patients
11534722|NCT01111409|Experimental|VFIX|
11534723|NCT01111396||Patient with ALL under chemotherapy|This group consists of patients with initial diagnosis of acute lymphatic leukemia (ALL), who are enrolled into the GMALL 2003 chemotherapy study. There is no change of the initial GMALL 2003 treatment protocol for the present study.
11534724|NCT01111370|Experimental|CGM|continuous glucose monitoring system
11534725|NCT01111344|Experimental|Glizigen + Viusid|
11534726|NCT01111344|Placebo Comparator|Placebo|
11534727|NCT01111331|Experimental|BI 10773 25 mg|1 tablet 25 mg BI 10773 qd for 5 days
11534728|NCT01111331|Experimental|BI 10773 25 mg + Warfarin 25 mg|1 tablet 25 mg BI 10773 qd for 7 days plus 5 tablets 5 mg warfarin single dose
11534729|NCT01111331|Active Comparator|Warfarin 25 mg|5 tablets 5 mg warfarin single dose
11534730|NCT01111318|Experimental|BI 10773|50 mg single dose
11534731|NCT01111305|Active Comparator|Reslizumab + DEC|Reslizumab 1 mg/kg iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
11534732|NCT01111305|Placebo Comparator|Placebo + DEC|Placebo iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
11534733|NCT01111292|Experimental|Arm I (inositol)|Beginning within 14 days after colonoscopy, patients receive inositol PO QD on days 1-14 and BID on days 15-90.
11534734|NCT01111292|Placebo Comparator|Arm II (placebo)|Beginning within 14 days after colonoscopy, patients receive placebo PO QD on days 1-14 and BID on days 15-90.
11534735|NCT01111279|Placebo Comparator|Placebo|
11534736|NCT01111279|Experimental|gpASIT+TM|
11534737|NCT01111279|Experimental|gpASIT+TM/adjuvant|
11534738|NCT01111253|Active Comparator|Conservative strategy with antibiotics|"Hospital admission
~Intravenous fluids and at least 48 hours of intravenous antibiotics and subsequently switch to oral antibiotics if tolerated (otherwise continuation i.v.) to complete a full 10-day treatment duration
~Adequate pain relief
~Oral intake as tolerated
~Daily monitoring"
11534739|NCT01111253|No Intervention|Liberal strategy without antibiotics|"Admission only if discharge criteria are not met
~No initial antibiotics
~Intravenous fluids only for those not tolerating oral liquids
~Adequate pain relief
~Oral intake as tolerated
~Daily monitoring when admitted to the hospital
~Self-monitoring at home (Patient diary with temperature and VAS pain score until full recovery)"
11534740|NCT01111240||Psoriatic Arthritis|Participants with Psoriatic Arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 24 months.
11534741|NCT01111214||group 1|Hospitalized children ≤14 years of age with invasive pneumococcal disease
11534742|NCT01111201||questionnaires|There will be four versions of the questionnaire, each slightly modified to be more specific toward the treatment paradigms in the respective target patient population (Breast Cancer/ Lymphoma/Autologous Bone Marrow Transplant/ Allogeneic Bone Marrow Transplant). All questionnaire versions will consist of seven sections.
11534743|NCT01111188|Experimental|all subjects|Subjects will receive PD 0332991 plus bortezomib. The dose of each agent will be dependent on the time point the subject enters the trial.
11534744|NCT01111162|Experimental|Vaccine|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
11534745|NCT01111149|Placebo Comparator|Sugar Pill|Sugar pill will be given to patients as a comparison group to the active varenicline group. In the fist week, one placebo pill will be given per patient, followed by 2 pills per day for the remaining 12 weeks of the study.
11534746|NCT01111149|Experimental|Varenicline|Varenicline has not previously been examined for its efficacy and safety in subjects with schizophrenia. Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study. This is an experimental group to be compared against both placebo and bupropion HCl.
11534747|NCT01111149|Active Comparator|Bupropion HCl|Bupropion HCl is an established smoking cessation agent and will be used to compare its efficacy and safety against varenicline. Subjects in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study.
11534748|NCT01111136|Experimental|stress intervention|Stress intervention.
11534749|NCT01111123|Active Comparator|1|Lac-Hydrin lotion twice daily everyday + Ultravate ointment twice daily on weekends only
11534750|NCT01111123|Placebo Comparator|2|Lac-Hydrin lotion twice daily everyday + placebo ointment twice daily on weekends only
11534751|NCT01111110|Experimental|Anti-static then Static for Albuterol|albuterol anti-static first then static chamber second.
11534752|NCT01111110|Experimental|Static then Anti-static for Albuterol|static then antistatic albuterol
11534753|NCT01111097|Active Comparator|Cohort 1|Subjects are given a dose of Dichloroacetate 4mg/kg twice a day for 30 days
11534754|NCT01111097|Active Comparator|Cohort 2|Subjects are given a dose of Dichloroacetate 12.5mg/kg twice a day for 30 days
11534755|NCT01111071||STEMI|patients with discharge diagnosis of ST elevation myocardial infarction
11534756|NCT01111071||nSTEMI|patients with discharge diagnosis of non ST elevation myocardial infarction
11534757|NCT01111071||unstable angina|patients with discharge diagnosis of unstable angina
11534758|NCT01111058|Experimental|Everolimus (RAD001)|Subjects will receive Everolimus 10 mg daily
11534759|NCT01111058|Experimental|Placebo|Subjects will receive double-blind placebo
11534760|NCT01111045|Active Comparator|Arm 1|0.03 mg/ml BMP-7, single intraarticular knee injection
11534761|NCT01111045|Active Comparator|Arm 2|0.1 mg/ml BMP-7, single intraarticular knee injection
11534762|NCT01111045|Active Comparator|Arm 3|0.3 mg/ml BMP-7, single intraarticular knee injection
11534763|NCT01111045|Placebo Comparator|Arm 4|1 ml placebo, single intraarticular knee injection (control)
11534764|NCT01111032||Treadmill test|
11534765|NCT01111019|Experimental|r-hGH (Saizen®)|
11534829|NCT01110564||1|COPD patients
11534766|NCT01110980|Experimental|Swallowing therapy|Swallowing therapy in combination with individual dietary counselling
11534767|NCT01110980|Active Comparator|Individual dietary counselling|Swallowing therapy only on indication. (usual care)
11534768|NCT01110954|Active Comparator|PD L 506 2nd dose|Different dosage
11534769|NCT01110954|Experimental|PD L 506|
11534770|NCT01110941|Experimental|SOL|single arm
11534771|NCT01110928||Norditropin®|
11534772|NCT01110915|Experimental|MRI group|Subjects randomized to the MRI group will undergo a one-hour MRI scan, including 16 individual sequences in the chest and head region, at 9-12 weeks post-implant.
11534773|NCT01110915|Active Comparator|Control group|Subjects randomized to the Control group will wait for one hour without having any MRI scan at 9-12 weeks post-implant.
11534774|NCT01110902|Experimental|AGO178C 0.5 mg /day|
11534775|NCT01110902|Experimental|AGO178C 1 mg / day|
11534776|NCT01110902|Placebo Comparator|Placebo|
11534777|NCT01110889|Experimental|AGO178C 0.5 mg /day|
11534778|NCT01110889|Experimental|AGO178C 1 mg / day|
11534779|NCT01110889|Placebo Comparator|Placebo|
11534780|NCT01110876|Experimental|Phase I Group 1: Vorinostat + Erlotinib + Temozolomide|"Phase I 3-Drug Combination Vorinostat with Erlotinib + Temozolomide
~Starting doses Vorinostat 200 mg orally twice daily on Days 1-7 and 15-21 of every cycle; Erlotinib 200 mg orally once daily on Days 1-21; Temozolomide 125 mg/m^2 orally once daily on Days 1-7 and 15-21."
11534781|NCT01110876|Experimental|Phase I Group 2: Vorinostat + Erlotinib|"This Phase I arm to be activated only after completion of Part A of the Phase II trial of the 3-Drug combination. If part A of the Phase II trial shows lack of efficacy, trial will be terminated.
~Vorinostat orally twice daily, Days 1-14; and Erlotinib orally once daily Days 1-21 of every cycle."
11534782|NCT01110876|Experimental|Phase II Part A 3-Drug Combination|"Vorinostat+Erlotinib+Temozolomide where drug dosing based on the MTD identified in the Phase I portion of the study.
~Vorinostat 200 mg orally twice daily on Days 1-7 and 15-21 of every cycle; Erlotinib 200 mg orally once daily on Days 1-21; Temozolomide 100 mg/m^2 orally once daily on Days 1-7 and 15-21."
11534783|NCT01110876|Experimental|Phase II Part B 2-Drug Combination|"This Phase II Part B arm to be activated only after completion of Part A of the Phase I and II Part A trial of the 3-Drug combination. If part A of the Phase II trial shows lack of efficacy, trial will be terminated.
~Vorinostat orally twice daily, Days 1-14; and Erlotinib orally once daily Days 1-21 of every cycle."
11534784|NCT01110863||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
11534785|NCT01110850||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
11534786|NCT01110837|Active Comparator|Allergen|
11534787|NCT01110837|Placebo Comparator|Placebo|
11534788|NCT01110824|Experimental|Enalapril and carvedilol|Enalapril 2.5 to 10 mg BID plus Carvedilol 6.25 to 25 mg BID
11534789|NCT01110824|No Intervention|Control|Control arm without intervention
11534790|NCT01110811|Active Comparator|TIF procedure|Transoral Incisionless Fundoplication (TIF)
11534791|NCT01110811|Sham Comparator|Sham procedure|The intervention on the Sham procedure consisted of an upper gastrointestinal endoscopy, or EGD.(esophagogastricduodenoscopy).
11534792|NCT01110772|Experimental|2-octyl cyanoacrylate|As recommended, povidone iodine is used for skin antisepsis. After drying, a layer of cyanoacrylate is applied on the skin surface with the purpose of immobilizing skin bacteria.
11534793|NCT01110772|Active Comparator|iodine povacrylex in isopropyl alcohol|Iodine povacrylex in isopropyl alcohol (Duraprep 3M) This is considered a standard of care in our hospital as many other institutions. It's efficacy and safety have been demonstrated.
11534794|NCT01110759||Under Local Infiltration|
11534795|NCT01110759||Under Peripheral Nerve Block|
11534796|NCT01110746|Experimental|Formulation A|Single Injection
11534797|NCT01110746|Experimental|Formulation B|Single Injection
11534798|NCT01110720|Experimental|Davunetide 30 mg BID|
11534799|NCT01110720|Placebo Comparator|Placebo|
11534800|NCT01110707|Experimental|r-hFSH + r-hLH|
11534801|NCT01110707|Active Comparator|r-hFSH alone|
11534802|NCT01110681|Experimental|Solesta|"Open label. Solesta (Dextranomer in gel of stabilized non-animal hyaluronate) The study treatment consisted of 4 submucosal injections, 1 mL Solesta each, in the proximal part of the high pressure zone in the anal canal.
~Re-treatment is allowed one month after initial treatment if the subject is still incontinent."
11534803|NCT01110668|Experimental|Nilotinib|
11534804|NCT01110655|Experimental|Intravenous hypertonic saline|
11534805|NCT01110655|Experimental|Oral hypertonic saline|
11534806|NCT01110642|Experimental|Lovastatin solution|All patients will receive lovastatin solution
11534807|NCT01110629|Experimental|Arm 1|
11534808|NCT01110629|Placebo Comparator|Arm 2|
11534809|NCT01110616|Experimental|Sequence 1|MK3134-Lorazepam-Placebo-MK3134-Lorazepam
11534810|NCT01110616|Experimental|Sequence 2|MK3134-Lorazepam-Placebo-Lorazepam-MK3134
11534811|NCT01110616|Experimental|Sequence 3|MK3134-Placebo-Lorazepam-MK3134-Lorazepam
11534812|NCT01110616|Experimental|Sequence 4|MK3134-Placebo-Lorazepam-Lorazepam-MK3134
11534813|NCT01110616|Experimental|Sequence 5|Lorazepam-Placebo-MK3134-MK3134-Lorazepam
11534814|NCT01110616|Experimental|Sequence 6|Lorazepam-Placebo-MK3134-Lorazepam-MK3134
11534815|NCT01110616|Experimental|Sequence 7|Lorazepam-MK3134-Placebo-MK3134-Lorazepam
11534816|NCT01110616|Experimental|Sequence 8|Lorazepam-MK3134-Placebo-Lorazepam-MK3134
11534817|NCT01110616|Experimental|Sequence 9|Placebo-MK3134-Lorazepam-MK3134-Lorazepam
11534818|NCT01110616|Experimental|Sequence 10|Placebo-MK3134-Lorazepam-Lorazepam-MK3134
11534819|NCT01110616|Experimental|Sequence 11|Placebo-Lorazepam-MK3134-MK3134-Lorazepam
11534820|NCT01110616|Experimental|Sequence 12|Placebo-Lorazepam-MK3134-Lorazepam-MK3134
11534821|NCT01110603|Experimental|MK-4827 + carboplatin|
11534822|NCT01110603|Experimental|MK-4827 + carboplatin/paclitaxel|
11534823|NCT01110603|Experimental|MK-4827 + carboplatin/liposomal doxorubicin|
11534824|NCT01110590|Experimental|Arm 1|
11534825|NCT01110590|Experimental|Arm 2|
11534826|NCT01110590|Experimental|Arm 3|
11534827|NCT01110590|Placebo Comparator|Arm 4|
11534830|NCT01110551|Experimental|Group 2: low dose ; ID|D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, D4: 2 x 10^5 or placebo intradermally on Days 0 and 90.
11534831|NCT01110551|Experimental|Group 1: low dose; SC|D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, D4: 2 x 10^5 or placebo subcutaneously on Days 0 and 90.
11534832|NCT01110551|Experimental|Group 4: high dose; ID|D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, D4: 3 x 10^5 or placebo intradermally on Days 0 and 90.
11534833|NCT01110551|Experimental|Group 3: high dose; SC|D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, D4: 3 x 10^5 or placebo subcutaneously on Days 0 and 90.
11534834|NCT01110525|Experimental|1|AZD1981 + Oral contraceptive
11534835|NCT01110525|Placebo Comparator|2|Placebo + Oral contraceptive
11534836|NCT01110512|Experimental|Flavonid|
11534837|NCT01110512|Active Comparator|Daflon|
11534838|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 1|AGN-210961 Formulation 1 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
11534839|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 2|AGN-210961 Formulation 2 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
11534840|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 3|AGN-210961 Formulation 3 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
11534841|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 4|AGN-210961 Formulation 4 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
11534842|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 5|AGN-210961 Formulation 5 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
11534843|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 6|AGN-210961 Formulation 6 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
11534844|NCT01110499|Experimental|Part 2, AGN-210961 Formulation 7|AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
11534845|NCT01110499|Active Comparator|Part 2, bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% in both eyes once daily for 4 weeks.
11534846|NCT01110486|Experimental|Monotherapy, once daily|
11534847|NCT01110486|Experimental|Combination with carboplatin|
11534848|NCT01110486|Experimental|Combination with docetaxel|
11534849|NCT01110486|Experimental|Monotherapy, twice daily|
11534850|NCT01110486|Experimental|IV Monotherapy, once daily|
11534851|NCT01110473|Experimental|Monotherapy, once daily|
11534852|NCT01110473|Experimental|Monotherapy, twice daily|
11534853|NCT01110473|Experimental|Combination with Azacitidine|
11534854|NCT01110473|Experimental|IV monotherapy, once daily|
11534855|NCT01110447|Experimental|VSL#3|VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus.
11534856|NCT01110447|Placebo Comparator|Placebo|Placebo sachets contain corn starch
11534857|NCT01110434|Experimental|Topiramate|Topiramate (200 mg daily)
11534858|NCT01110434|Placebo Comparator|Sugar pill|
11534859|NCT01110421|Experimental|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose) will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
11534860|NCT01110421|Experimental|Cefepime|Cefepime 50 mg/kg per dose (up to 2 g/dose) will be administered every 8 hours as 30-minutes IV (at least 3 days of IV cefepime only or IV cefipime followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
11534861|NCT01110408|Experimental|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose) will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
11534862|NCT01110408|Experimental|Cefepime|Cefepime 50 mg/kg per dose (up to 2 g/dose) will be dministered every 8 hours as 30-minutes IV (at least 3 days of IV cefepime only or IV cefepime followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
11534863|NCT01110395|Experimental|MR Spectroscopy Post-Heart Transplant|Patients post heart transplant getting heart biopsy
11534864|NCT01110382|Experimental|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose)will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium). Total duration of treatment 5 to 14 days.
11534865|NCT01110382|Experimental|Meropenem|Meropenem 20 mg/kg per dose (up to 1 g/dose) will be administered every 8 hours as 30-minutes IV (at least 3 days of IV meropenem only or IV meropenem followed by oral amoxicillin/clavulanate potassium). Total duration of treatment 5 to 14 days.
11534866|NCT01110369|Experimental|Resistance exercise training and protein drink|
11534867|NCT01110369|Placebo Comparator|Resistance exercise training and placebo drink|
11534868|NCT01110356|Experimental|Ferinject|
11534869|NCT01110356|Placebo Comparator|Saline|
11534870|NCT01110343|Active Comparator|mindfulness intervention group|Mindfulness intervention is a formatted curriculum based on Mindfulness based stress reduction techniques which have proven effective in reducing stress related to pain, everyday living and medical and psychiatric disorders.
11534871|NCT01110343|Active Comparator|conventional parent support group|a 6 week behavioral program, with weekly 1.5 hour sessions with a trained parent mentor, 3 monthly booster sessions and follow-up.
11534872|NCT01110330|Experimental|Ketoconazole 2% cream (formulation F126)|ketoconazole 2% cream (formulation F126) A topical white homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
11534873|NCT01110330|Experimental|Ketoconazole 2% cream (formulation F012) (Nizoral)|ketoconazole 2% cream (formulation F012) (Nizoral) A topical white homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
11534917|NCT01110005|Active Comparator|D5 Lactated Ringer's solution (D5LR)|IV fluid containing glucose administered throughout labor at an average infusion rate of 125 ml/hr.
11534874|NCT01110330|Placebo Comparator|Placebo cream|Placebo cream A topical white homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
11534875|NCT01110317|Experimental|001|paliperidone palmitate 100 mg Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1 8 36 and 64.
11534876|NCT01110304|Active Comparator|Conservative treatment|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed.
11534877|NCT01110304|Active Comparator|Surgical treatment|Patients will undergo surgery to treat their AC joint dislocation.
11534878|NCT01110291||Breast cancer|Twenty patients with verified high risk breast cancer will be included in the study.
11534879|NCT01110278||Urge Incontinent Women|Women with documented urge/urgency incontinence with established care at the Oregon Health and Science University.
11534880|NCT01110278||Control Women|Women with no urge/urgency incontinence with established care at the Oregon Health and Science University.
11534881|NCT01110265|Placebo Comparator|placebo training|
11534882|NCT01110265|Experimental|attention training|
11534883|NCT01110252|Active Comparator|pre-procedure|emphysema patients evaluated prior to the stem cells infusion
11534884|NCT01110252|Experimental|post-procedure|emphysema patients evaluated 30 days after the stem cells infusion
11534885|NCT01110239|Experimental|remote limb preconditioning|Subjects with subarachnoid hemorrhage will undergo escalating times of limb ischemia to determine tolerability and safety. The leg will be made transiently ischemic with application of a blood pressure cuff for up to 3 cycles of 10 minutes.
11534886|NCT01110226|Experimental|Period 1: KML001 15mg plus Cisplatin 75mg/m2|KML001 15 mg orally daily days 1-14 with cisplatin IV on day1
11534887|NCT01110226|Experimental|Period 2: KML001 17.5mg plus Cisplatin 75mg/m2|KML001 17.5 mg orally daily days 1-14 with cisplatin IV on day1
11534888|NCT01110226|Experimental|Period 3: KML001 20mg plus Cisplatin 75mg/m2|KML001 20 mg orally daily days 1-14 with cisplatin IV on day1
11534889|NCT01110213|Experimental|Physical activity|Participants received individual tailored telephone counseling and group-tailored newsletters encouraging leisure time physical activity. Content was based on goal setting theory and decisional balance.
11534890|NCT01110213|Experimental|Fruit and vegetable|Participants received individual tailored telephone counseling and group-tailored newsletters encouraging fruit and vegetable intake. Content was based on goal setting theory and decisional balance.
11534891|NCT01110200|Active Comparator|ADVAIR DISKUS 250/50 mcg BID|Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
11534892|NCT01110200|Active Comparator|Serevent 50 mcg BID|Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
11534893|NCT01110187|Experimental|IV LCM (lacosamide)|Patients with severe traumatic brain injury (TBI) or subarachanoid hemorrhage (SAH) randomized to seizure prophylaxis with either lacosamide.
11534894|NCT01110187|Active Comparator|IV fPHT (fos-phenytoin)|Patients with TBI or SAH randomized to seizure prophylaxis with fos-phenytoin
11534895|NCT01110174|Experimental|HD PET/CT|utilization of PET/CT for diagnostic of breast cancer progression.
11534896|NCT01110161||Visceral fat mass|The study population will include Chinese adult men and women, over the age of 18 years. All subjects will be recruited at Fudan University. Subjects will represent a wide range of BMI values (18.5 - 40 kg/m2).
11534897|NCT01110148|Experimental|Video-based informed consent|patients receiving informed consent through video format
11534898|NCT01110148|Active Comparator|traditional informed consent|patients receiving traditional informed consent from the physicians.
11534899|NCT01110135|Experimental|Treatment (chemotherapy and colony-stimulating factor)|"Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60-240 minutes on days 1-3, dexamethasone PO on days 1-4, and filgrastim SC beginning on day 5 and continuing until peripheral blood stem cell collection is complete. Patients undergo leukapheresis daily for a minimum of 3 days or until > 5 x 10^6 CD34+/kg has been collected.
~."
11534900|NCT01110109||Continuous Suctioning|Anesthesia staff will suction secretions continuously at 20 mmHg with a safety stop of 5 seconds every 30 minutes.
11534901|NCT01110109||Intermittent Suctioning|Anesthesia staff will suction secretions intermittently using an intermittent suction regulator. The regulator will be set to suction at 100-150 mmHg. The regulator has a preset cycle of intermittent suctioning for 15 seconds with an 8 second pause.
11534902|NCT01110096|Experimental|Group A - family camp|Obese families participate in a two week camp with two years follow-up.
11534903|NCT01110096|Other|Group B - family lifestyle school|Families participate in a four day practical course about lifestyle.
11534904|NCT01110083|Experimental|Arm 1|
11534905|NCT01110070|Experimental|ChonDux plus microfracture|
11534906|NCT01110070|Active Comparator|Microfracture|
11534907|NCT01110057|Experimental|Active|GW856553
11534908|NCT01110057|Placebo Comparator|Placebo|Placebo
11534909|NCT01110044|Experimental|Group A|Subjects will be administered 251154 vaccine at birth, Infanrix hexa™ at 2, 4, 6 and 12-18 months of age, Synflorix™ at 2, 4, 6 and 12-18 months of age, Rotarix™ at 2 and 4 months of age.
11534910|NCT01110044|Active Comparator|Group B|Subjects will be administered no vaccine at birth, Infanrix hexa™ at 2, 4, 6 and 12-18 months of age, Synflorix™ at 2, 4, 6 and 12-18 months of age, Rotarix™ at 2 and 4 months of age.
11534911|NCT01110031|Experimental|Treatment|Six months treatmet with ofatumumab will be given to subjects with chronic lymphocytic leukemia.
11534912|NCT01110018|Active Comparator|Period 1|20μg intravenous infusion administered over 30 minutes
11534913|NCT01110018|Active Comparator|Period 2|1000μg Oral dose
11534914|NCT01110018|Active Comparator|Period 3|50μg Intravenous infusion administered over 30 minutes
11534915|NCT01110018|Active Comparator|Period 4|1000μg Inhaled dose
11534916|NCT01110018|Active Comparator|Period 5|100μg Intravenous infusion administered over 30 minutes
11534918|NCT01110005|Active Comparator|Lactated Ringer's solution (LR)|Non-glucose IV fluid administered throughout labor at an average infusion rate of 125 ml/hr.
11534919|NCT01109992|Active Comparator|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
11534920|NCT01109992|Experimental|Exercise + Regadenoson (Lexercise)|Exercise plus Regadenoson (Lexercise) Rubidium-82 Positron Emission Tomography
11534921|NCT01109979|Active Comparator|Estradiol+MPA|
11534922|NCT01109979|Active Comparator|Estradiol+DRSP|
11534923|NCT01109966|Active Comparator|Amino acid based formula|"Patients will be randomised to one of two arms:
~Group I: receiving a new amino-acid based formula Group II: receiving a standard AAF formula"
11534924|NCT01109966|Active Comparator|New amino acid based formula|"Patients will be randomised to one of two arms:
~Group I: receiving a new amino-acid based formula Group II: receiving a standard AAF formula"
11534925|NCT01109953||Breath-Hold PET/CT image|In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both.
11534926|NCT01109940|Experimental|AIN457|
11534927|NCT01109927|Experimental|Insulin treatment|Insulin given as soon as possible after diagnosis
11534928|NCT01109927|No Intervention|Conventional treatment|Diet, oral hypoglycemic agents and insulin first when clinically needed
11534929|NCT01109914|Experimental|Renal transplant recipients (MMF)|"Renal transplant recipients using prednisolone and mycophenolate mofetil (MMF) but no other immunosuppressive drug.
~Intervention: vaccination with Dukoral"
11534930|NCT01109914|Experimental|Renal transplant recipients (CNI)|"Renal transplant recipients using prednisolone and a calcineurin inhibitor (cyclosporine or tacrolimus) but no other immunosuppressive drug.
~Intervention: vaccination with Dukoral"
11534931|NCT01109914|Experimental|Healthy volunteers|"Healthy volunteers (partners, brothers or sisters of the renal transplant recipients).
~Intervention: vaccination with Dukoral"
11534932|NCT01109901|Other|anterior submuscular transposition|it is kind of surgical method
11534933|NCT01109901|Other|Anterior subcutaneous transposition|it is kind of surgical method
11534934|NCT01109888|Active Comparator|Cetrotide|
11534935|NCT01109862|Experimental|THA|Total hip arthroplasty
11534936|NCT01109862|Active Comparator|HAP|Bipolar Hemiarthroplasty
11534937|NCT01109849|Active Comparator|weight recovery treatment- monitoring|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the monitoring arm , participants will continue on their ER stimulant 7 days a week and have their weight, height and BMI checked monthly.
11534938|NCT01109849|Active Comparator|behavior therapy|10 week basic parent training, advanced 8 week parent training course. monthly boosters, option for individual parent training sessions, school consultant assigned to each subject
11534939|NCT01109849|Experimental|ER stimulant|daily use of 12 hour extended release methylphenidate product
11534940|NCT01109849|Experimental|weight recovery treatment- caloric supplement|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the caloric supplement arm, participants will continue on their ER stimulant 7 days a week, have their weight, height and BMI checked monthly and be prescribed a 150 kcal caloric supplement to be consumed every evening.
11534941|NCT01109849|Experimental|weight recovery treatment- drug holiday|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the drug holiday arm, participants will only take their ER stimulant on school days a week and have their weight, height and BMI checked monthly.
11534942|NCT01109836|Experimental|Motivation and lifestyle intervention|Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
11534943|NCT01109836|No Intervention|Control|Standard stroke care
11534944|NCT01109823|Active Comparator|patients with normal renal function|Patients with normal renal function hospitalized at the Department Intensive Care Unit who are being treated with levofloxacin I.V. (500mg, twice daily) for an infection.
11534945|NCT01109823|Active Comparator|patients with hyperfiltration|Patients with hyperfiltration hospitalized at the Department Intensive Care Unit who are being treated with levofloxacin I.V. (500mg, twice daily) for an infection.
11534946|NCT01109810||IVIg and SCIg therapy|
11534947|NCT01109797|Experimental|Transition Social Behavioral Intervention|
11534948|NCT01109797|Experimental|Diabetes Transition Clinic|
11534949|NCT01109784|Experimental|prasugrel|prasugrel per os 10mg/day
11534950|NCT01109784|Active Comparator|clopidogrel|clopidogrel per os 150mg/day
11534951|NCT01109771|Active Comparator|absorbable fixation left side|
11534952|NCT01109771|Active Comparator|absorbable fixation right side|
11534953|NCT01109758|Experimental|1|
11534954|NCT01109745|No Intervention|usual primary care|Number of participating children: 85
11534955|NCT01109745|Experimental|PELICAN Primary care|Intervention arm: the integration of the output of the Pelican instrument (i.e., individualised HRQL information) in daily care to guide disease management for children with asthma treated in primary care. Number of participants: 85 children
11534956|NCT01109745|No Intervention|usual secondary care|number of participating children: 50
11534957|NCT01109745|Experimental|PELICAN Secondary Care|Intervention arm: the integration of the output of the Pelican instrument (i.e., individualised HRQL information) in daily care to guide disease management for children with asthma treated in primary care. Number of participants: 50 children
11534958|NCT01109732|Experimental|Systematic physical training|Hospital-based SET two days per week for 12 weeks and one home-based exercise session every week. The group-based SET was based on The Norwegian Ullevaal Model, a modified cardiac rehabilitation program, and was slightly adjusted to be applicable to this patient group. Each SET session lasted for 60 minutes and consisted of warm-up exercises, three high-intensity, two moderate-intensity and cool-down exercises, including stretching. The exercises were generally simple aerobic dance movements and walking and involved the use of both upper and lower extremities. The warm-up exercises included large muscle movements that were repeated later in the higher-intensity intervals, but with greater force and a larger range of movement.
11535009|NCT01109316|Active Comparator|Insulin Aspart 6 Day|
11535010|NCT01109303|Active Comparator|TightRope System|Patients are operated on using the TightRope implant by Arthrex.
11534959|NCT01109732|No Intervention|Treatment as of today|The control group did not receive any additional follow-up regarding exercise at discharge beyond the general advice about the importance of exercise that is routinely provided at the hospital.
11534960|NCT01109706||patient treated by statines|
11534961|NCT01109706||patient without normolipidemic treatment|
11534962|NCT01109693|Active Comparator|Continue sertraline|Continue sertraline at the dosage at 3 weeks
11534963|NCT01109693|Active Comparator|Augment with mirtazapine|Add mirtazapine to sertraline
11534964|NCT01109693|Active Comparator|Switch to mirtazapine|Stop sertraline and switch to mirtazapine
11534965|NCT01109680|Experimental|14 C labelled Neramexane, capsule|
11534966|NCT01109667||oral anticoagulant|Patients receiving and not receiving oral anticoagulant therapy.
11534967|NCT01109667||INR Level|Group I: Patients not receiving OAT, Group II: Patients under OAT and INR values in good therapeutic range and Group III: Patients under OAT and INR values over the therapeutic range.
11534968|NCT01109628|Experimental|Protein drink|
11534969|NCT01109628|Placebo Comparator|Placebo drink|
11534970|NCT01109615|Experimental|Chemotherapy|
11534971|NCT01109602|Experimental|Arm 1: Yoga Group|"Yoga Group, 8 week bi-weekly in-person yoga training focused on strength, flexibility, and balance
~Yoga focused on strength, flexibility, and balance"
11534972|NCT01109602|Experimental|Arm 2: Yoga Group Plus|"Yoga Group Plus: 8 week, bi-weekly in-person yoga training focused on strength, flexibility, and balance paired with almost daily at home yoga focused on breathing and relaxation.
~Yoga focused on strength, flexibility, and balance
~Data for both yoga groups were combined for analyses as there were not any differences between these two groups."
11534973|NCT01109602|No Intervention|Arm 3: Wait list control group|wait-list control: will be assessed before and after 8 weeks. Will then be offered the 8 week yoga intervention.
11534974|NCT01109589||Children aged 0-2 yrs|
11534975|NCT01109589||Women aged 15-60 yrs|
11534976|NCT01109576|Experimental|DSL workshop participants|Three to five Veterans with DSL.
11534977|NCT01109563|Active Comparator|Computer Check-In Control|The Computer Check-In gives the participant contact with the research therapist, an assessment of marijuana use and the current impact of use, and a reminder about optional support sessions.
11534978|NCT01109563|Experimental|Marijuana Check-Ins|The MCI, a MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.
11534979|NCT01109550||with biliary candidiasis|Patients with positive fungal cultures of bile samples.
11534980|NCT01109550||without biliary candidiasis|Patients with negative fungal cultures of bile samples.
11534981|NCT01109537||RLS Diagnosis|
11534982|NCT01109537||Healthy Controls|
11534983|NCT01109524|Experimental|Cetuximab + Cisplatin + Vinorelbine|
11534984|NCT01109511|Active Comparator|oxycodone+naloxone|
11534985|NCT01109511|Active Comparator|Control|Oxycodone alone without naloxone
11534986|NCT01109498|Experimental|Dose cohort 3 x 10^11gc/kg|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
11534987|NCT01109498|Experimental|Alipogene Tiparvovec, Human LPL [S447X]|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections with immunosuppressants
11534988|NCT01109498|Experimental|Alipogene Tiparvovec, Human LPL [S447X], 1xE12 gc/kg|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections with immunosuppressants
11534989|NCT01109485|Experimental|Olopatadine|Olopatadine hydrochloride ophthalmic solution 0.1%
11534990|NCT01109472|Experimental|Patient Tailored Magazine|Patient responses from computer assisted telephone interviews will be used to develop a patient tailored educational magazine.
11534991|NCT01109459|Experimental|Pediatric vision screening|intervention
11534992|NCT01109459|Active Comparator|Pediatric blood pressure screening|control
11534993|NCT01109459|No Intervention|Primary care providers observation only|Observational
11534994|NCT01109446|Experimental|Platelet Rich Plasma|
11534995|NCT01109446|Sham Comparator|Isotonoic Saline Solution|
11534996|NCT01109446|Active Comparator|Steroid (Triamcinolonacetonid)|
11534997|NCT01109420||1/ Cohort 1|Affected with non-medullary thyroid cancer
11534998|NCT01109420||2/Cohort 2|Non-affected members of families with non-medullary thyroid cancer
11534999|NCT01109407||patients with MGUS or SMM|patients with either Monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM)
11535000|NCT01109394||1/Cohort 1|Adult or Pediatric subjects, with any malignancy, pre-malignancy, suspected malignancy, family history of malignancy, or without malignancy undergoing surgery or well visit.
11535001|NCT01109394||2/Cohort 2|Human samples, specimens and data collected on IRB approved protocols that are now closed
11535002|NCT01109394||3/Cohort 3|Parent/caregiver of a participating pediatric or adult subject who is being treated for, or who has previously been treated for any form of pediatric cancer.
11535003|NCT01109381|Experimental|Treatment with GT08|Initial phase - omeprazole, N-acetyl cysteine (NAC), lauric acid dose and duration titration from 1 up to 14 days of treatment. Secondary phase - 14 days treatment with omeprazole, NAC, lauric acid
11535004|NCT01109342||Vaccine Recipients|Participants received HIV preventive vaccine VRC-HIV ADV014-00-VP in previous trials RV 156A/WRAIR 1078A or RV 172/WRAIR 1218.
11535005|NCT01109342||Placebo Recipients|Participants received a placebo vaccine in previous trials RV 156A/WRAIR 1078A or RV 172/WRAIR 1218.
11535006|NCT01109329|Experimental|HMPV challenge virus|Participants will receive the HMPV challenge virus.
11535007|NCT01109316|Active Comparator|Insulin Lispro 2 Day|
11535008|NCT01109316|Experimental|Insulin Lispro 6 Day|
11535011|NCT01109303|Active Comparator|Screw fixation implant|Patients are operated on using the rigid four-cortices 3,5 mm screw fixation by Synthes.
11535012|NCT01109290||HED children|
11535013|NCT01109290||HED adults|
11535014|NCT01109290||Control children|
11535015|NCT01109290||Control adults|
11535016|NCT01109277||Healthy term and late-preterm neonates|
11535017|NCT01109264|Experimental|Bendamustine Hydrochloride|
11535018|NCT01109264|Active Comparator|Chlorambucil|
11535019|NCT01109251|Other|Intervention group|Group of patients presenting a non controlled AHT or a masked AHT, benefiting from an optimised caring at visit 0.
11535020|NCT01109251|Other|Control group|Patients presenting a non controlled AHT(persistent AHT, AHT necessiting an adaptation of the treatment by the generalist) with information of the generalist on the necessity of obtaining the tensional control according the HAS recommendations
11535021|NCT01109238||Process Feasibility|
11535022|NCT01109225|Experimental|Myocardial infarction|"All patients. Patients hospitalized for a first myocardial infarction with known shift of the segment ST revascularized in acute phase by primary angioplasty and dated less than 4 days.
~Intervention:
~blood sample
~MRI
~echocardiography
~urine sample
~pulmonary echography
~vascular check
~renal echography"
11535023|NCT01109212|Experimental|Bindarit|Patients treated with bindarit 2x300 mg bid plus irbesartan 2x150 mg once a day for 12 weeks
11535024|NCT01109212|Placebo Comparator|Placebo|patients treated with placebo 2 tablets bid plus irbesartan 2x150 mg once a day for 12 weeks
11535025|NCT01109199|Experimental|PolyGlycopleX (PGX)|
11535026|NCT01109199|Placebo Comparator|Rice Flour|
11535027|NCT01109186||kidney-transplanted patients|
11535028|NCT01109173|Experimental|Nepafenac 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional dose was administered between 30-120 minutes prior to surgery.
11535029|NCT01109173|Active Comparator|NEVANAC|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery.
11535030|NCT01109173|Placebo Comparator|Nepafenac Vehicle 0.3%|Nepafenac Ophthalmic Suspension 0.3% Vehicle, one drop in affected eye once daily for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional dose was administered between 30-120 minutes prior to surgery.
11535031|NCT01109173|Placebo Comparator|NEVANAC Vehicle|Nepafenac 0.1% vehicle, one drop in affected eye three times daily, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery.
11535032|NCT01109160|Experimental|Azithromycin|Add-on of study-drug (azithromycin) to 'standard of care': 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment).
11535033|NCT01109147|Active Comparator|aripiprazole|"Imagery: A fMRI session is conducted on schizophrenic patients under aripiprazole (medication taken and stabilized for at least six weeks before inclusion, no intervention on the medication is scheduled during the study).
~Genetic: pharmacogenetic sampling. One sample was collected for each subject."
11535034|NCT01109147|Active Comparator|risperidone|"Imagery: A fMRI session is conducted on schizophrenic patients under rsiperidone (medication taken and stabilized for at least six weeks before inclusion, no intervention on the medication is scheduled during the study).
~Genetic: pharmacogenetic sampling. One sample was collected for each subject."
11535035|NCT01109147|Other|control|Imagery: A fMRI session is conducted on healthy volunteers. Genetic: pharmacogenetic sampling. One sample was collected for each subject.
11535036|NCT01109134|Experimental|Tirofiban intracoronary bolus-only|Tirofiban bolus administered via intracoronary route at the time of primary PCI with no additional peri/postprocedural maintenance infusion
11535037|NCT01109134|Active Comparator|Tirofiban intravenous bolus+infusion|Tirofiban bolus administered intravenously before PCI, followed by periprocedural maintenance infusion
11535038|NCT01109121|Active Comparator|Allopurinol|Allopurinol
11535039|NCT01109121|Experimental|Combination 400|Tranilast and Allopurinol
11535040|NCT01109121|Experimental|Combination 600|Tranilast and Allopurinol
11535041|NCT01109108||Children <2 years of age|Children <2 years of age with and without respiratory tract infection
11535042|NCT01109108||Children 2<5 years of age|Children 2<5 years of age with and without respiratory tract infection
11535043|NCT01109095|Experimental|HER.CAR CMV-specific CTLs|Subject will be assigned a dose level at study entry.
11535044|NCT01109082||Adolescents with idiopathic scoliosis|Adolescents with idiopathic scoliosis
11535045|NCT01109069|Experimental|PCI-32765|
11535046|NCT01109056|Experimental|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
11535047|NCT01109056|Placebo Comparator|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
11535048|NCT01109030|Active Comparator|Pioglitazone+Citalopram+Chlordiazepoxide|Pioglitazone 15 mg Q12h will be given to the patients in active comparator group for 6 weeks. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.Chlordiazepoxide 10 mg/day for first three weeks
11535049|NCT01109030|Placebo Comparator|Placebo+ Citalopram+ Chlordiazepoxide|"Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.
~Chlordiazepoxide 10 mg each night for first three weeks."
11535050|NCT01109017||Norditropin®|
11535051|NCT01109004|Active Comparator|Tandem auto transplant|Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance
11535052|NCT01109004|Active Comparator|RVD consolidation|Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance
11535053|NCT01109004|Active Comparator|Lenalidomide maintenance|Initial autologous transplant followed by lenalidomide maintenance
11535054|NCT01108991|Active Comparator|COPD education + Usual care|Six weeks of COPD self-management education plus usual care
11535055|NCT01108991|Experimental|Physical activity self-management|Cognitive behavioral counseling to increase lifestyle physical activity delivered over five months plus six weeks of COPD self-management education and usual care
11535056|NCT01108978|Placebo Comparator|Placebo|
11535058|NCT01108965||Extraventricular Drainage|Includes hydrocephalus patients that are in recovery from shunt explanation.
11535059|NCT01108939|Experimental|Antimalarial treatment|
11535060|NCT01108939|Sham Comparator|Observation|
11535061|NCT01108926|Experimental|All Subjects|All Subjects will receive the same intervention
11535062|NCT01108913|Active Comparator|Bimosiamose|
11535063|NCT01108913|Placebo Comparator|Placebo|
11535064|NCT01108900||Patients with erectile dysfunction (ED)|100 ED patients in the study that were switched to sildenafil after a previous treatment with udenafil proved ineffective and/or was poorly tolerated
11535065|NCT01108861|Experimental|Endoprosthesis|GORE VIABAHN® Endoprosthesis
11535066|NCT01108861|Active Comparator|Plain old balloon angioplasty|Plain old balloon angioplasty
11535067|NCT01108848||Berinert|Patients requiring treatment with Berinert®
11535068|NCT01108835|Active Comparator|comprehensive care programme|Comprehensive care involving multidisciplinary input.
11535069|NCT01108835|No Intervention|Control group|Control arm with usual care
11535070|NCT01108809||Patients with arterial hypertension|
11535071|NCT01108796||Patients at cardiovascular risk|
11535072|NCT01108783|Experimental|Bilastine|
11535073|NCT01108783|Active Comparator|Desloratadine|
11535074|NCT01108783|Placebo Comparator|Placebo|
11535075|NCT01108770||HED affected males|
11535076|NCT01108770||Unaffected male controls|
11535077|NCT01108757|Experimental|Drug|
11535078|NCT01108757|Placebo Comparator|Placebo|
11535079|NCT01108744|Active Comparator|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
11535080|NCT01108744|Active Comparator|Mannitol|20% mannitol, dosed by patient's ideal body weight
11535081|NCT01108731|Active Comparator|Patients taking the drug Milnacipran|Randomize patients signing informed consent and give 50% of them Milnacipran -- blinded to the investigators.
11535082|NCT01108731|Placebo Comparator|Patients taking the placebo|Randomize patients signing informed consent and give 50% of them the placebo -- blinded to the investigators.
11535083|NCT01108718|Experimental|Participants: Tempur Pedic first.|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder who receive the Tempur-Pedic mattress first, then the Control Mattress.
11535084|NCT01108718|Placebo Comparator|Participants: Control Mattress first.|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic mattress.
11535085|NCT01108705|Experimental|Brivanib|
11535086|NCT01108705|Placebo Comparator|Placebo|
11535087|NCT01108692|Experimental|Active|Patients will be followed by telecardiology.
11535088|NCT01108692|Active Comparator|Control|Patients will be followed in the conventional manner. They will be equipped with telecardiology but data will not be used for patient surveillance.
11535089|NCT01108679||Buprenorphine|Opioid-dependent drug users who are initiating buprenorphine treatment at the Albert Einstein College of Medicine Division of Substance Abuse (DoSA) or at Montefiore's Comprehensive Health Care Center (CHCC).
11535090|NCT01108666|Experimental|Proton RT and Nelfinavir|
11535091|NCT01108653|Other|Group 1: Usual care sick-leave management|
11535092|NCT01108653|Other|Group 2: Structuralised sick-leave program|
11535093|NCT01108640||Elective surgical patients|
11535094|NCT01108640||Massive resuscitation patients|
11535095|NCT01108640||surgical patients on pressors|
11535096|NCT01108627|Active Comparator|corticosteroid + long acting beta agonist; steroids|
11535097|NCT01108627|Placebo Comparator|placebo + corticosteroid + long acting beta agonist; steroids|
11535098|NCT01108614|Experimental|Intervention|Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
11535099|NCT01108614|No Intervention|Usual|Routine HIV prevention, including health education, counseling and testing, condom promotion.
11535100|NCT01108601|Other|Ringer's Lactate|Each patient will act as their own control with one ear receiving treatment, and the contralateral ear acting as control.
11535101|NCT01108588|Experimental|Sequence 1|Aspirin - Clopidogrel - Placebo
11535102|NCT01108588|Experimental|Sequence 2|Clopidogrel - Placebo - Aspirin
11535103|NCT01108588|Experimental|Sequence 3|Placebo - Aspirin - Clopidogrel
11535104|NCT01108588|Experimental|Sequence 4|Aspirin - Placebo - Clopidogrel
11535105|NCT01108588|Experimental|Sequence 5|Clopidogrel - Aspirin - Placebo
11535106|NCT01108588|Experimental|Sequence 6|Placebo - Clopidogrel - Aspirin
11535107|NCT01108575|Experimental|Inspiratory muscle strength training|
11535108|NCT01108575|Sham Comparator|Sham Inspiratory muscle strength training|
11535109|NCT01108562|Placebo Comparator|Control Group|Patients will receive a Dilaudid PCA in combination with a placebo infusion of normal saline.
11535110|NCT01108562|Experimental|Lidocaine Group|Patients will be receive a Dilaudid PCA in combination with a continuous Lidocaine infusion.
11535111|NCT01108536|Experimental|adaptive trans-tibial socket|subjects are fitted with experimental sockets.
11535112|NCT01108523|Experimental|HP828-101|HP828-101 Experimental Formulation
11535113|NCT01108510|Experimental|ATV+COBI+FTC/TDF|COBI + RTV placebo + ATV + FTC/TDF once daily
11535114|NCT01108510|Active Comparator|ATV+RTV+FTC/TDF|RTV + COBI placebo + ATV + FTC/TDF once daily
11535115|NCT01108484|Experimental|Supervised exercise|Cardiorespiratory and resistance training
11535116|NCT01108484|Experimental|Exercise + diet counseling|Cardiorespiratory and resistance training + Diet counseling to improve food intake(more fruit and vegetable and less fat food)
11535117|NCT01108484|Experimental|Exercise + diet counseling + psycho support|Cardiorespiratory and resistance training + Diet counseling to improve food intake(more fruit and vegetable and less fat food) + Weekly sessions to modify the behaviour
11535118|NCT01108484|No Intervention|Control|They will keep their usual way of life
11535253|NCT01107509|Experimental|Neo-adjuvant everolimus|
11535254|NCT01107496|Experimental|SPN-812|viloxazine, oral, 300mg, tid, 6 weeks
11535119|NCT01108458|Experimental|Pertuzumab plus Erlotinib Hydrochloride|"Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks
~Erlotinib hydrochloride 150 mg/day by mouth"
11535120|NCT01108445|Active Comparator|RAD001|Subjects in this treatment arm will receive everolimus/RAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
11535121|NCT01108445|Active Comparator|Sunitinib|Subjects in this treatment arm will take sunitinib 50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
11535122|NCT01108432|Experimental|Electronic Referrals|Dental practices randomized to the experimental group will have options on how to refer patients to the tobacco cessation website.
11535123|NCT01108432|No Intervention|Routine Referral|Dental practices in this arm will refer patients to the Decide2Quit website by using an information prescription.
11535124|NCT01108419|Active Comparator|1 = Test Product normal dose|Fermented dairy product containing probiotics - normal dose
11535125|NCT01108419|Active Comparator|2 = Test Product high dose|Fermented dairy product containing probiotics - high dose
11535126|NCT01108419|Sham Comparator|3 = Control Product normal dose|Non-fermented dairy product - normal dose
11535127|NCT01108419|Sham Comparator|4 = Control Product high dose|Non-fermented dairy product - high dose
11535128|NCT01108406|Experimental|SoundBite Hearing System|"The objective of this study was to assess the long-term safety and quality of life impact of the SoundBite™ Hearing System.
~Safety was measured in terms of dental, audiological and medical adverse events related to device or procedure.
~Quality of Life was measured in terms of changes in Abbreviated Profile of Hearing Aid Benefit (APHAB) and as reported in a quality of life survey (SSD Questionnaire).
~The duration of the study was 6 months with measures taken at Day 1, 3 months and 6 months."
11535129|NCT01108393|Experimental|Agomelatine A|
11535130|NCT01108393|Placebo Comparator|Placebo|
11535131|NCT01108380|Experimental|1. CD34|"4 days injection of G-CSF (10μg/kg, Subcutaneous infusion)
~On 5th day, plasmapheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells)
~CD 34 cells will be selected by CliniMACS (Miltenyi Biotec, Bergisch- Gladbach, Germany) (at least 1x10(7) of CD 34 cell)
~In same day, right portal vein embolization with infusion of CD 34 cells into left portal vein will be performed."
11535132|NCT01108380|Active Comparator|2. Mononucelar cell|"4 days injection of G-CSF (10μg/kg, Subcutaneous infusion)
~On 5th day, plasma pheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells)
~In same day, right portal vein embolization with infusion of mononuclear cells into left portal vein will be performed."
11535133|NCT01108380|Other|3. Control|Without infusion of G-CSF, patients will be performed just right portal vein embolization
11535134|NCT01108354||ADHD patients|10 male adult ADHD patients and 10 female adult ADHD patients
11535135|NCT01108354||healthy controls|20 age- and sex-matched healthy volunteers
11535136|NCT01108341|Experimental|Bendamustine and Ofatumumab|There are 6 planned and 2 optional 28-day cycles in which participants are administered both bendamustine and ofatumumab in the following doses: Bendamustine administered at 90 mg/m^2 intravenously (iv) on study days 1 and 2. Ofatumumab administered at 300 mg iv on day 1 and 1000 mg iv on day 8 of cycle 1. Ofatumumab administered at 1000 mg iv on day 1 of all additional cycles.
11535137|NCT01108328|Experimental|PolyGlycopleX (PGX)|5 grams of PGX 3 times per day with each main meal (breakfast, lunch and dinner)
11535138|NCT01108328|Placebo Comparator|Rice flour|5 grams of rice flour 3 times per day at each main meal (breakfast, lunch and dinner)
11535139|NCT01108315|Experimental|Intervention|The participant used the web and/or phone-based PRO reporting symptoms to enter symptoms twice a week at minimum.
11535140|NCT01108315|No Intervention|Usual Care|The participants on this arm do not record their symptoms. They report symptoms as they would under usual care.
11535141|NCT01108302|No Intervention|PPH Treatment only|Auxilliary nurse midwives will be able to treat for PPH only, not provide Oxytocin in Uniject
11535142|NCT01108302|Experimental|Oxytocin in Uniject|Auxilliary Nurse Midwives will provide 10IU Oxytocin in Uniject device IM immediately after delivery
11535143|NCT01108289|Experimental|Oxytocin in Uniject|Community Health Officers will provide 10 IU Oxytocin in Uniject device IM immediately after delivery of baby
11535144|NCT01108289|No Intervention|PPH Treatment Only|Community Health Officers will be able to treat for PPH only, not provide Oxytocin in Uniject
11535145|NCT01108263|Active Comparator|Integra Flowable on wound bed|INTEGRA™ Flowable is a wound Matrix made of bovine (cow) collagen. It provides a scaffold for cellular and capillary growth. Dosage is dependent on the size of the wound. It will be applied once.
11535146|NCT01108263|Active Comparator|INTEGRA Flowable on wound & injected subcutaneously|INTEGRA™ Flowable is a wound Matrix made of bovine (cow) collagen. It provides a scaffold for cellular and capillary growth. Dosage is dependent on the size of the wound. It will be applied once.
11535147|NCT01108250|Experimental|polypoidal choroidal vasculopathy|patients with polypoidal choroidal vasculopathy
11535148|NCT01108250|Active Comparator|control|control group with no polypoidal choroidal vasculopathy
11535149|NCT01108237|Other|TruMatch™ Personalized Solutions|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using TruMatch™ Personalized Solutions
11535150|NCT01108237|Other|Historical Control|Total Knee Arthroplasty (PFC Sigma System) implanted using conventional and CAS surgical techniques without TruMatch™ instrumentation.
11535151|NCT01108224|Experimental|Psychosocial support|
11535152|NCT01108224|No Intervention|Control group|
11535153|NCT01108211|Experimental|Treatment Group|This group will receive Vibration Therapy.
11535154|NCT01108211|No Intervention|Observation Group|This group does not receive Vibration Therapy
11535155|NCT01108198|Active Comparator|mometasone furoate cream|The study patient consecutive patients who were referred to outpatient clinic of Pediatric surgery for surgical treatment of non-retractable foreskin. The study patients were randomized to have either mometasone cream or placebo
11535156|NCT01108198|Placebo Comparator|moisturizer|
11535157|NCT01108185||Acute Respiratory Infections|Slovak patients with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP).
11535158|NCT01108172|Active Comparator|Usual Care|
11535159|NCT01108172|Experimental|Virtual Ward|
11535160|NCT01108146|Experimental|Arm 1|"Drug: Hydrocortisone 10 mg
~Group 1: Administration of Hydrocortisone and/or Placebo in the following order:
~1 week placebo-1 week hydrocortisone 10 mg/d -1 week placebo - 1 week hydrocortisone 30 mg/d"
11535161|NCT01108146|Experimental|Arm 2|"Drug: Hydrocortisone 30 mg
~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:
~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo"
11535162|NCT01108133|Experimental|Hydrocortisone, fMRI, Intrusions|10 mg Hydrocortisone are administered one hour before the fMRI experiment. We use the script-driven imagery paradigm to induce intrusive memories during fMRI scanning.
11535163|NCT01108133|Experimental|Dexamethasone, fMRI, Intrusions|2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment. (DEX-Test). We use the script-driven imaging paradigm to induce intrusive memories during fMRI-scanning.
11535164|NCT01108133|Experimental|Placebo, fMRI, Intrusions|Placebo is administered one hour before the fMRI experiment. We use the script-driven imaging paradigm to induce intrusive memories during fMRI-scanning in patients with posttraumatic stress disorder.
11535165|NCT01108120|Experimental|continuous intra-femoral thrombolysis group|Continuous intra-femoral injection urokinase was taken by a mini-pump in 100 diabetic foot ulcers (Wegnar 2 ~ 4 stage) for 7 - 9 days.Then they receive conventional therapy. The healing rate of foot ulcers is observed during hospitalization period. At 1, 4 and 8 year during follow up, the recurrence rate of diabetic foot ulcers are observed.
11535166|NCT01108120|Experimental|conventional therapy group|Conventional therapy group receives an intravenous injection of prostaglandin E1 20 ug per day. The follow up was taken for 8 years.
11535167|NCT01108107|Other|Chemotherapy only|Chemotherapy only, if mutations in KRAS, BRAF or PIK3CA gene
11535168|NCT01108107|Other|Chemotherapy + biological treatment|Addition of biological treatment, if no mutations in KRAS, BRAF, and PIK3CA genes.
11535169|NCT01108094|Experimental|Cohort A - Itraconazole 400 mg|Oral itraconazole 400 mg as 200 mg twice daily, for 1 month, stratified by prior vismodegib history
11535170|NCT01108094|Experimental|Cohort B - Itraconazole 200 mg|Oral itraconazole 200 mg as 100 mg twice daily, for up to 3 months
11535171|NCT01108094|No Intervention|Untreated Control|Patients otherwise eligible but unwilling to take itraconazole were enrolled onto the control arm of the study and received no treatment
11535172|NCT01108081|Experimental|Arm 1|Physical activity
11535173|NCT01108081|Experimental|Arm 2|Diet
11535174|NCT01108081|Active Comparator|Arm 3|Health education
11535175|NCT01108081|Experimental|Arm 4|Combined physical activity and diet
11535176|NCT01108068|Experimental|Lithium|patients with OPPG will be treated with lithium for 6 months
11535177|NCT01108068|No Intervention|Unaffected controls|Family members of patients with OPPG will have DXA and pQCT to compare to OPPG patients. These unaffected participants will not receive lithium.
11535178|NCT01108055|Experimental|pazopanib + paclitaxel|"Cycle of 28 days. Pazopanib: 800mg daily
~Cycle of 28 days Paclitaxel: 80mg/m2 on days 1,8 and 15"
11535179|NCT01108042|Experimental|Taxotere, Cisplatin, 5-Fluorouracil (5-FU)|Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out.
11535180|NCT01108029|Active Comparator|memantine|memantine 20 mg/day (2 tablets 1 time a day in the morning)
11535181|NCT01108029|Placebo Comparator|placebo|2 tablets (1 time a day in the morning) during 3 months
11535182|NCT01108003|Experimental|Arm I|Patients receive oral broccoli sprout extract once daily on days 1-14 in the absence of disease progression or unacceptable toxicity.
11535183|NCT01108003|Placebo Comparator|Arm 2|Patients receive mango juice alone.
11535184|NCT01107990||Single right ventricles|
11535185|NCT01107990||Single left ventricles|
11535186|NCT01107977|Experimental|Iyengar yoga|
11535187|NCT01107977|No Intervention|Waitlist control|
11535188|NCT01107964|Active Comparator|Omega-3-acid ethyl esters|
11535189|NCT01107964|Placebo Comparator|Corn oil capsule|
11535190|NCT01107951|Other|Rituximab -dexamethasone|only one arm receive four doses weekly rituximab and four dosis daily dexamethasona
11535191|NCT01107938|Experimental|10 mg ilaprazole|
11535192|NCT01107938|Experimental|15 mg ilaprazole|
11535193|NCT01107938|Active Comparator|40 mg esomeprazole|
11535194|NCT01107925|Experimental|5 mg prasugrel|
11535195|NCT01107925|Active Comparator|10 mg prasugrel|
11535196|NCT01107925|Active Comparator|75 mg clopidogrel|
11535197|NCT01107912|Experimental|5 milligrams (mg) prasugrel|
11535198|NCT01107912|Active Comparator|10 mg prasugrel|
11535199|NCT01107912|Active Comparator|75 mg clopidogrel|
11535200|NCT01107899|Active Comparator|clopidogrel 600 mg|
11535201|NCT01107899|Active Comparator|prasugrel 60 mg|
11535202|NCT01107899|Experimental|prasugrel 30 mg|
11535203|NCT01107886|Experimental|Saxagliptin|
11535204|NCT01107886|Placebo Comparator|Placebo|Placebo
11535205|NCT01107873||duplex ultrasonography|conduct duplex ultrasonography after caudal block with sevoflurane anaesthesia in children
11535206|NCT01107860||Group I|
11535207|NCT01107860||Group II|
11535208|NCT01107834||Healthy Control|HIV-negative children born to healthy, HIV-negative women
11535209|NCT01107834||Exposed to HIV/HAART|HIV-negative children exposed to HIV and HAART in utero
11535210|NCT01107821|Experimental|Engenex™-pump|Negative Pressure Wound Therapy with the Engenex™-pump and Bio-Dome™ Dressing
11535211|NCT01107808|No Intervention|Control|The adolescents randomized to Standard of care group will receive the medical and behavioral counseling regarding their obesity as a patient of the Children's Center for Weight Management (CCWM). They will not receive any pharmacological treatment for their vitamin D deficiency or insulin resistance. Calcium and vitamin D dietary intake will be determined using a specific food frequency questionnaire at each study visit for all groups. This will be used to determine effect of nutrition counseling.
11535255|NCT01107496|Placebo Comparator|Placebo|placebo, oral, tid, 6weeks
11535256|NCT01107483||AC group|asymptomatic carriers
11535257|NCT01107483||CH group|patients with chronic hepatitis
11535258|NCT01107483||HC group|patients with hepatic cirrhosis
11535212|NCT01107808|Experimental|Calcium and Vit D|The participants in the vitamin D/calcium group will receive standard of care through the CCWM along with the addition of treatment with ergocalciferol (vitamin D2) and calcium carbonate for their vitamin D deficiency. The vitamin D treatment will be 50,000 IU orally weekly for 8 weeks. This treatment regimen for vitamin D deficiency has been found to be safe to children and adolescents. 32 33The dose of calcium supplementation will be calcium carbonate orally 1200mg daily. This is the daily recommended intake of calcium for adolescents
11535213|NCT01107808|Experimental|Metformin/ Vit D|The participants randomized into the vitamin D/calcium/Metformin treatment group will receive standard of care through the CCWM in addition to treatment for their Vitamin D deficiency with the same doses of ergocalciferol (vitamin D2) and calcium carbonate as previously outlined. Additionally, these participants will receive Metformin ER to treat insulin resistance. The Metformin ER will be started at 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks).
11535214|NCT01107782|Experimental|sildenafil|
11535215|NCT01107782|Placebo Comparator|Placebo control|
11535216|NCT01107769||VISIONAIRE™|Total knee arthroplasty with VISIONAIRE™ patient-matched cutting blocks
11535217|NCT01107769||Standard Instrumentation|Total knee arthroplasty with standard instrumentation
11535218|NCT01107756|Experimental|TAXOTERE (Docetaxel) + GRANOGYTE 34 (Lenograstim)|Taxotere (Docetaxel) is given as background treatment and should be administered by the treating physician in accordance with the prescribing information outlined in the package insert + Granocyte 34 (lenograstim)
11535219|NCT01107743||Amlodipine and Atorvastatin Combination Tablet|Subjects taking Amlodipine and Atorvastatin Combination Tablets
11535220|NCT01107730|Active Comparator|L-Carnitine|L-Carnitine intravenously (2 gr/day [1grX2] for 2 days prior to surgery, and postoperatively for 4 days
11535221|NCT01107730|Active Comparator|Vitamin C|VitC intravenously (2g/day [500mgX4] for 2 days prior to surgery, and postoperatively for 4 days
11535222|NCT01107730|Active Comparator|Placebo|
11535223|NCT01107717|Experimental|Triple Therapy|initiation a combination of metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) at the time diabetes is diagnosed
11535224|NCT01107717|Active Comparator|conventional therapy|sequential addition of metformin, glyburide and basal insulin
11535225|NCT01107704|Experimental|Family Support Intervention|
11535226|NCT01107704|No Intervention|Control Group|
11535227|NCT01107691|Experimental|Resistance training|1 set of progressive resistance training per session
11535228|NCT01107691|Experimental|3 sets per session|3 sets of progressive resistance training per session
11535229|NCT01107691|No Intervention|Control|Non exercise control group
11535230|NCT01107678|Experimental|YMCA PAN|YMCA PAN (Physical activity and nutrition)- Consists of organized physical activity and controlled serving sizes of healthy low fat snacks
11535231|NCT01107678|Experimental|YMCA Standard CAre|YMCA standard care - Follow the standard care of the YMCA after school Y-Care program for physical activity and nutrition
11535232|NCT01107665|Experimental|Pazopanib and Paclitaxel|Treatment on study will be administered in 4-week cycles. Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
11535233|NCT01107639|Experimental|Additional immunotherapy (cetuximab)|All patients in the experimental arm will be given additional immunotherapy (cetuximab) during cycles 1 and 2, during RT and after surgery.
11535234|NCT01107639|Active Comparator|Without additional immunotherapy|Standard therapy without immunotherapy (cetuximab).
11535235|NCT01107626|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 1
11535236|NCT01107626|Experimental|Arm II|Patients receive pemetrexed IV over 10 minutes on days 1.
11535237|NCT01107626|Experimental|Arm III|Patients receive bevacizumab as in arm I and pemetrexed as in arm II.
11535238|NCT01107613|Experimental|Intervention Arm|All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader letter sent to the primary care provider outlining the needs of this patient.
11535239|NCT01107613|No Intervention|Control/Standard Care|All patients will receive prednisone X 10 days and antibiotics X 5 days. This group will receive educational handouts on AECOPD.
11535240|NCT01107600|Experimental|Nobel Active®|Immediate implant and socket preservation
11535241|NCT01107587|Experimental|HRV group|Subjects will receive GSK Biologicals' human rotavirus vaccine 444563.
11535242|NCT01107587|Placebo Comparator|Placebo Group|Subjects will receive placebo.
11535243|NCT01107574|Experimental|Gabapentin and Osteopathic Manipulative Medicine|6 weeks of both Gabapentin 900 mg HS given orally was accompanied with Osteopathic Manipulative Medicine treatment 30 minutes weekly to the tender points of the musculoskeletal system of each patient for 6 weeks.
11535244|NCT01107574|Experimental|Gabapentin|Gabapentin was given orally at 900 mg at HS weekly for 6 weeks.
11535245|NCT01107574|Experimental|Osteopathic Manipulative Medicine|6 weeks of Osteopathic Manipulative Medicine Treatment was applied to the patients tender points in the musculoskeletal system weekly by a 30 minute treatment.
11535246|NCT01107561|Experimental|Seldinger technique|Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire.
11535247|NCT01107561|Active Comparator|Surgical airway approach|The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
11535248|NCT01107548|Experimental|Evidence-based treatment, lifestyle counseling|
11535249|NCT01107535||Infants receiving Synagis (palivizumab) immunoprophylaxis|Infants born <= 32 weeks of gestation and are younger than 6 months of age, children with bronchopulmonary dysplasia who have received medical treatment in the last 6 months until the first year of life, and children 12 months or younger with hemodynamically significant acyanotic congenital heart disease (pulmonary hypertension or heart failure in treatment) prescribed Synagis (palivizumab) immunoprophylaxis according to the usual clinical practice.
11535250|NCT01107522|Experimental|Arm A|Single Agent CTO
11535251|NCT01107522|Experimental|Arm B|Combination CTO and Temodar®
11535252|NCT01107522|Experimental|Arm C|Combination CTO, Temodar®, Radiation therapy
11535259|NCT01107483||ACLF group|patients with acute on chronic liver failure
11535260|NCT01107483||healthy control|healthy volunteers
11535261|NCT01107470||Group A1|Age 18-34y (with short protocol)
11535262|NCT01107470||Group A2|age 35-42y ( with short protocol)
11535263|NCT01107470||Group B1|age 18-34y ( with long protocol)
11535264|NCT01107470||Group B2|age 35-42y ( with long protocol)
11535265|NCT01107457|Experimental|10 mg Ixekizumab|"Part A:
~10 milligrams (mg) ixekizumab given subcutaneous (SC) on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.
~Part B: (optional)
~120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.
~Part C: (optional)
~80 mg ixekizumab given SC Q4W through approximately week 344."
11535266|NCT01107457|Experimental|25 mg Ixekizumab|"Part A:
~25 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.
~Part B: (optional)
~120 mg ixekizumab given SC (Q4W). Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.
~Part C: (optional)
~80 mg ixekizumab given SC Q4W through approximately week 344."
11535267|NCT01107457|Experimental|75 mg Ixekizumab|"Part A:
~75 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.
~Part B: (optional)
~120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.
~Part C: (optional)
~80 mg ixekizumab given SC Q4W through approximately week 344."
11535268|NCT01107457|Experimental|150 mg Ixekizumab|"Part A:
~150 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.
~Part B: (optional)
~Administered 120 mg ixekizumab SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.
~Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344."
11535269|NCT01107457|Placebo Comparator|Placebo|"Part A:
~Placebo given on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.
~Part B: (optional) 120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.
~Part C: (optional)
~80 mg ixekizumab given SC Q4W through approximately week 344."
11535270|NCT01107457|Experimental|120 mg Ixekizumab|"Part B: (optional)
~120 mg ixekizumab given SC every 4 weeks. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236.
~Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344."
11535271|NCT01107457|Experimental|80 mg Ixekizumab|"Part B: (optional)
~Subsequent to an amendment on May 2012, administration changed to 80 mg ixekizumab Q4W through Week 236.
~Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344."
11535272|NCT01107444|Experimental|LY2181308 + Docetaxel|"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.
~Docetaxel: 75 milligrams/square meter (mg/m^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."
11535273|NCT01107444|Active Comparator|Docetaxel|Docetaxel: 75 milligrams/square meter (mg/m^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.
11535274|NCT01107431|Active Comparator|Sucrose with Dietary Supplement|Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
11535275|NCT01107431|Active Comparator|Sucrose without Dietary Supplement|Consumed 70 grams of sucrose without simultaneously taking the dietary supplement
11535276|NCT01107418|Experimental|1|
11535277|NCT01107418|Experimental|2|
11535278|NCT01107418|Experimental|3|
11535279|NCT01107418|Experimental|4|
11535280|NCT01107405|Active Comparator|Loteprednol etabonate base (QD)|Loteprednol etabonate ophthalmic base dosed once/day.
11535281|NCT01107405|Active Comparator|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base dosed two times/day
11535282|NCT01107405|Active Comparator|Loteprednol etabonate base (QID)|Loteprednol etabonate ophthalmic base dosed four times/day.
11535283|NCT01107405|Active Comparator|Loteprednol etabonate suspension (QID)|Loteprednol etabonate ophthalmic suspension dosed four times/day
11535284|NCT01107405|Placebo Comparator|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate, dosed either QD, BID, or QID
11535285|NCT01107392|Experimental|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
11535286|NCT01107392|Placebo Comparator|Placebo (Normal saline)|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
11535287|NCT01107379||Balloon catheter device|Dilation of sinuses using Relieva Balloon Sinuplasty System
11535288|NCT01107353|Active Comparator|First Imipramine Pamoate, then Tofranil-PM|First 75 mg imipramine pamoate capsule, then 75 mg Tofranil-PM capsule (after washout period)
11535289|NCT01107353|Active Comparator|First Tofranil PM, then imipramine pamoate|First 75 mg Tofranil-PM capsule, then 75 mg imipramine pamoate capsule (after washout period)
11535290|NCT01107340|Other|AMIStem Hip System|Patients who comply with the protocol and received an AMIStem femoral component.
11535291|NCT01107314||trauma patient|SBP less than 90mmHg
11535292|NCT01107288|Experimental|Intervention group|Randomized to receive the intervention first
11535293|NCT01107288|Other|Delayed intervention control group|Randomized to wait-list control first
11535294|NCT01107275|Experimental|2 primary ID doses|two doses of rabies vaccines given intradermally on days 0 and 28
11535295|NCT01107275|Experimental|3 primary ID doses|three doses of rabies vaccines given intradermally on days 0, 7, and 28
11535339|NCT01107015|Active Comparator|Group 4: data analyzed intervention|Home diabetes monitoring by patient using mobile phone to communicate information and receive feedback; Physician can access raw and analyzed patient data; Physician receives report summary and treatment recommendations
11535340|NCT01107002|Experimental|Day 5 embryo transfer group|Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
11535341|NCT01106989|Experimental|Heated lidocaine/tetracaine patch|Active
11535296|NCT01107262||Poultry exposed adults|This seroepidemiological study proposes to compare adults with occupational exposure to poultry with non-poultry exposed adult controls for evidence of previous infections with AI viruses.In this study, any person with occupational exposure to poultry i.e. works in poultry production facility or raises a smaller number of poultry on his/her farm will be considered exposed. The questionnaire used in this study will capture poultry exposure data through a group of variables assessing type of occupational setting, length of time of exposure, flock size, type of work performed, and personal protective equipment (PPE) used.
11535297|NCT01107262||Poultry Non-exposed Adult Controls|Controls, adults who were never exposed to poultry, will be enrolled from urban areas such as the capital Beirut. Controls will be invited to volunteer by word of mouth at public/community sites.
11535298|NCT01107249|Other|BS Ultraflex or Wallstent stents|All subjects receive a stent of surgeons choice from selected stents.
11535299|NCT01107236|Experimental|IW-6118|
11535300|NCT01107236|Placebo Comparator|Placebo|
11535301|NCT01107236|Active Comparator|Naproxen Sodium|
11535302|NCT01107223|Experimental|Training to antibiotic prescription|Physicians randomized in the education group attended a two days seminar focussed on evidence-based guidelines on antibiotic use in respiratory tract infections.
11535303|NCT01107223|Placebo Comparator|control|
11535304|NCT01107210||stroke patients|50 patients recruited in the stroke rehabilitation unit in the University Hospital, Leuven, Belgium will be included
11535305|NCT01107197|Active Comparator|Isonitrogenous isocaloric formula|Patients were given standard diet plus 2 bottles of an hypercaloric oral formula isonitrogenous isocaloric to the experimental one
11535306|NCT01107197|Experimental|Enriched nutrition formula|Patients were given standard diet plus 2 bottles of an hypercaloric oral formula enriched in arginine, zinc and antioxidant oligoelements
11535307|NCT01107184|Experimental|Preconditioning|The remote ischemic stimulus will be applied after induction of anaesthesia, but before cardiopulmonary bypass.
11535308|NCT01107184|Experimental|Postconditioning|The remote ischemic stimulus during cardiopulmonary bypass.
11535309|NCT01107184|Experimental|Pre and postconditioning|The remote ischemic stimulus will be applied twice, after induction of anaesthesia and during cardiopulmonary bypass.
11535310|NCT01107184|Sham Comparator|Control|
11535311|NCT01107171|Placebo Comparator|placebo|Tang-min Lin pills analogue
11535312|NCT01107171|Experimental|Tang-min-ling pills high dosage|Tang-min-ling pills, high dosage, 12g, tid po
11535313|NCT01107171|Experimental|Tang-min-ling pills low dosage|low dosage group:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
11535314|NCT01107158||Group 1|Control group: these patients have mechanical dystocia; cholesterol metabolism factors are a priori not involved.
11535315|NCT01107158||Group 2|These patients have uterine dystocia
11535316|NCT01107145|Experimental|Mefloquine- Artesunate|Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
11535317|NCT01107145|Experimental|Artemether-Lumefantrine|Artemether-Lumefantrine, Lumet, Cipla 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
11535318|NCT01107145|Active Comparator|Chloroquine|Chloroquine (Farmaguinhos, Brazil): Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)
11535319|NCT01107132||Diabetic Retinopathy|T2DM Patient suffering from Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema (DME)
11535320|NCT01107119|Experimental|Integrated care pathway|"program for
~communication and information flow aimed at collaboration between hospitals, general practitioners and home care services
~systematic patient follow-up in home care services by using checklists"
11535321|NCT01107119|Active Comparator|usual care|usual care
11535322|NCT01107106||Adolescents|250 postmenarcheal adolescent girls
11535323|NCT01107106||Adults|250 adult women
11535324|NCT01107093|Placebo Comparator|Placebo|
11535325|NCT01107093|Active Comparator|CDB-2914|
11535326|NCT01107080||Degradation|30 mastectomy, partial mastectomy, and mammoplasty samples will be analyzed to define the effective post-excision time window in which the device must be used before the results can no longer be evaluated. The mammoplasty specimens are necessary to assess normal tissue outcomes.
11535327|NCT01107080||Reproducibility|25 Partial Mastectomy cases will be analyzed to distinguish between different implementation methods of the technology.
11535328|NCT01107067|Experimental|testosterone replacement therapy|
11535329|NCT01107054|Experimental|PF-00610355 450 µg|An orally inhaled dose of PF-00610355 450 µg
11535330|NCT01107054|Experimental|PF-00610355 1200 µg|An orally inhaled dose of PF-00610355 1200 µg
11535331|NCT01107054|Active Comparator|moxifloxacin 400 mg|A single oral dose of moxifloxacin 400 mg on Day 4.
11535332|NCT01107054|Placebo Comparator|placebo|A single oral dose of non-matched placebo on Day 4.
11535333|NCT01107041|Experimental|Mobilyze!|
11535334|NCT01107028||Rehab|Subjects randomized to the Rehab group will have data collected at baseline and then within one week enroll in a pulmonary rehabilitation program. Data will again be collected within one week of completing pulmonary rehabilitation and again six months later.
11535335|NCT01107028||Wait|Subjects randomized to the Wait group will have data collected at baseline and wait eight weeks before enrolling in a pulmonary rehabilitation program. Data will again be collected within one week of completing pulmonary rehabilitation and again six months later.
11535336|NCT01107015|No Intervention|Group 1: Usual Care|Provider-driven care, based in office, no special diabetes management; Patient self-monitoring of blood glucose (SMBG)
11535337|NCT01107015|Active Comparator|Group 2: patient intervention|Home diabetes monitoring by patient using mobile phone to communicate information and receive feedback
11535338|NCT01107015|Active Comparator|Group 3: patient-physician intervention|Home diabetes monitoring by patient using mobile phone to communicate and receive feedback; Physician can access unanalyzed information from the patient's electronic logbook
11535386|NCT01106664|Experimental|E|
11535518|NCT01105780|Placebo Comparator|002|Placebo Matching placebo
11535342|NCT01106976||Group 1 Parkinson disease subjects|Subjects with Parkinson disease who previously participate in a motor and brain PET (brain positron emission tomography) imaging study who were invited for a longitudinal observational study.
11535343|NCT01106963||Tibial shaft fractures|Patients had tibial shaft fractures in the last 3 years. All were treated with intramedullary (IM) reamed nails with 2 or 3 interlocking screws.
11535344|NCT01106950|Experimental|Treated Patients|Patients are treated with donor natural killer cells, fludarabine, cyclophosphamide, Denileukin diftitox, Donor lymphapheresis and IL-2.
11535345|NCT01106937||Patients with low Factor XIII|Postoperative occurence of pulmonary embolism in patients scheduled to undergo a neurosurgical procedure with laboratory-confirmed low levels of Factor XIII
11535346|NCT01106924|Experimental|Probiotic|daily probiotic consumption
11535347|NCT01106924|Placebo Comparator|Placebo|daily placebo consumption
11535348|NCT01106898|Experimental|Treatment (chemotherapy with or without maintenance therapy)|"SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity."
11535349|NCT01106885|No Intervention|Enhanced Usual Care|"Adult patients with diabetes and depression.
~Report screening results
~Notify PCP of screening results (optional per patient)
~PCP referrals
~Educational materials regarding diabetes, physical activity, and depression"
11535350|NCT01106885|Experimental|Staged Care Management|Adult patients with diabetes and depression
11535351|NCT01106872|Experimental|Treatment|Bevacizumab Combined with Gemcitabine, Docetaxel and Valproic Acid in Advanced Sarcoma
11535352|NCT01106859|Active Comparator|zopiclone|Zopiclone is taken at bedtime 9 hours before driving. The middle-of-the-night medication is a placebo matching zolpidem tartrate sublingual tablet.
11535353|NCT01106859|Experimental|zolpidem 3 hours prior|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is zolpidem tartrate sublingual tablet taken 3 hours prior to driving.
11535354|NCT01106859|Experimental|zolpidem 4 hours prior|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is zolpidem tartrate sublingual tablet taken 4 hours prior to driving.
11535355|NCT01106859|Placebo Comparator|Placebo|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is a placebo matching zolpidem tartrate sublingual tablet.
11535356|NCT01106846|Placebo Comparator|Group A: Saline group|Group A: Saline group , infusion of saline intravenously
11535357|NCT01106846|Active Comparator|Group B: 1% Ketamine group|Group B: Infusion of ketamine 1% intravenously
11535358|NCT01106833|Active Comparator|calcineurin inhibitor|Sirolimus + calcineurin inhibitor + prednisone
11535359|NCT01106833|Experimental|Sirolimus and prednisone|Sirolimus + prednisone
11535360|NCT01106820|Active Comparator|Resistance training|
11535361|NCT01106820|Active Comparator|Relaxation training|
11535362|NCT01106807|Experimental|CD07223 1.5% gel|500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks and Epiduo vehicle gel on the other half-face
11535363|NCT01106807|Experimental|CD07223 0.5% gel|500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks and Epiduo vehicle gel on the other half-face
11535364|NCT01106807|Active Comparator|Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel|500 microliters of Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel on one half-face and 500 microliters of the Epiduo vehicle gel on the other half-face in the morning and in the afternoon, 500 microliters of Epiduo vehicle gel on both half-faces
11535365|NCT01106794||Patient samples|Fresh-frozen and fixed tumor samples, correspondent normal brain tissue samples, cerebrospinal fluid, urine, and serum samples from patients affected with diffuse intrinsic pontine glioma or brainstem glioma
11535366|NCT01106781||1|Patients in this group should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation.
11535367|NCT01106768||test cohort|Evaluation of oral health needs of children with attention deficit disorder with or without hyperactivity
11535368|NCT01106768||not disorder cohort|children without attention deficit disorder
11535369|NCT01106755|Experimental|hemiparetic gait|gait training on ground level
11535370|NCT01106742|Experimental|AndoSan, UC|AndoSan as a supplement to 10 UC patents
11535371|NCT01106742|Experimental|AndoSan, CD|AndoSan as a supplement to 10 CD patients.
11535372|NCT01106729|Other|Cyanidin 3 glucoside|
11535373|NCT01106716|Placebo Comparator|A1: Placebo|Placebo
11535374|NCT01106716|Experimental|A2: KAI-1678|Experimental
11535375|NCT01106716|Active Comparator|A3: Lidocaine|Lidocaine
11535376|NCT01106703|Experimental|PG102 group|
11535377|NCT01106703|Placebo Comparator|placebo group|
11535378|NCT01106690|Other|Placebo/Sitagliptin|Each patient will receive matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients will be switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.
11535379|NCT01106690|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.
11535380|NCT01106690|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.
11535381|NCT01106677|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
11535382|NCT01106677|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
11535383|NCT01106677|Active Comparator|Sitagliptin 100 mg|Each patient will receive 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
11535384|NCT01106677|Other|Placebo/Sitagliptin|Each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52. Placebo and sitagliptin will be given with protocol-specified doses of metformin immediate release.
11535385|NCT01106664|Placebo Comparator|P|
11535387|NCT01106651|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
11535388|NCT01106651|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
11535389|NCT01106651|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
11535390|NCT01106638|Experimental|Intensive behavioral intervention|Eight session, behavioral intervention targeting HIV-infected smokers
11535391|NCT01106638|Active Comparator|Standard care|Advice to quit, smoking cessation brochure, offer of nicotine patch
11535392|NCT01106625|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
11535393|NCT01106625|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
11535394|NCT01106625|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
11535395|NCT01106612|Experimental|Initial coronary CT angiography|EKG-gated, computed tomography angiography of the coronary arteries during heart rate control
11535396|NCT01106612|Active Comparator|Initial nuclear stress test|Stress radionuclide myocardial perfusion imaging
11535397|NCT01106599|Experimental|A|
11535398|NCT01106586|Experimental|Stribild|
11535399|NCT01106586|Active Comparator|ATV/r + FTC/TDF|
11535400|NCT01106560|Active Comparator|Anterior Approach Group|(AMIS)
11535401|NCT01106560|Active Comparator|Posterior Approach Group|(Posterior)
11535402|NCT01106547|Experimental|Methylprednisolone|
11535403|NCT01106547|Placebo Comparator|placebo/sodium chloride|
11535404|NCT01106534|Placebo Comparator|12 month DAPT arm|placebo + aspirin
11535405|NCT01106534|Active Comparator|30 month DAPT arm|clopidogrel + aspirin OR prasugrel + aspirin
11535406|NCT01106521|Experimental|PBSI|PBSI is a form of accelerated partial breast irradiation involving the insertion of 103-palladium stranded seeds under ultra-sound guidance and light sedation after CT planning in lieu of whole breast adjuvant radiotherapy.
11535407|NCT01106508|Experimental|LEQ506|
11535408|NCT01106495|Experimental|Enhanced External Counterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. Patients with subclinical atherosclerosis whose serum LDL high than 160mg/ml receive EECP 1- hour session every working day over a 7 week period. Simvastatin is used to decrease cholesterol level for 7 weeks.
11535409|NCT01106495|Active Comparator|Control|Subjects whose LDL higher than 160 mg/dl with subclinical atherosclerosis. Simvastatin is used to decrease cholesterol level for 7 weeks.
11535410|NCT01106482|Active Comparator|Arm 1|
11535411|NCT01106482|Active Comparator|Arm 2|
11535412|NCT01106482|Active Comparator|Arm 3|
11535413|NCT01106482|Active Comparator|Arm 4|
11535414|NCT01106469|Experimental|001|JNJ-41443532 25mg tablet once daily
11535415|NCT01106469|Experimental|002|JNJ-41443532 100mg tablet once daily
11535416|NCT01106469|Experimental|003|JNJ-41443532 250mg tablet once daily
11535417|NCT01106469|Experimental|004|JNJ-41443532 500mg once daily (with 250mg tablets)
11535418|NCT01106469|Experimental|005|JNJ-41443532 1000mg once daily (with 250mg tablets)
11535419|NCT01106469|Experimental|006|JNJ-41443532 1500mg once daily (with 250mg tablets)
11535420|NCT01106469|Placebo Comparator|007|Placebo Matching placebo
11535421|NCT01106456|Experimental|All Nations Breath of Life (ANBL)|"All participants in the proposed study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT) then randomized into either the culturally-tailored All Nations Breath of Life program (ANBL) or Nontailored program (NT)."
11535422|NCT01106456|Experimental|Nontailored (NT)|"All participants in the proposed study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT) then randomized into either the culturally-tailored All Nations Breath of Life program (ANBL) or Nontailored program (NT)."
11535423|NCT01106443|Active Comparator|Total Thyroidectomy - CLND|Total thyroidectomy without central lymph node dissection.
11535424|NCT01106443|Experimental|Total Thyroidectomy +CLND|Total thyroidectomy with central lymph node dissection.
11535425|NCT01106443|Experimental|Hemi-thyroidectomy + CLND|Hemi-thyroidectomy with central lymph node dissection.
11535426|NCT01106443|Active Comparator|Hemi-thyroidectomy - CLND|Hemi-thyroidectomy without central lymph node dissection.
11535427|NCT01106430|Experimental|Lisdexamfetamine Dimesylate|
11535428|NCT01106430|Active Comparator|Atomoxetine Hydrochloride|
11535429|NCT01106417|Experimental|NeoFuse|"Anterior Cervical Discectomy and Fusion with NeoFuse.
~NeoFuseTM is constituted of STRO-3 immunological selected allogeneic MPCs, which are derived from adult bone marrow mononucleated cells that are culture-expanded and subsequently cryopreserved.
~The allogeneic MPCs are formulated in concentrations of nucleated cells in a 5 mL volume and are cryopreserved in 7.5% dimethyl sulfoxide (DMSO)/50% Alpha Modified Eagle's Medium (MEM) and 42.5% ProFreeze®. The final formulation consists of 0.15mL (approximately 10 million MPCs) of thawed NeoFuse™ thawed NeoFuseTM combined with the amount of MasterGraftTM Matrix to fill the PEEK cage per ACDF level."
11535430|NCT01106417|Active Comparator|MasterGraft Granules|"Anterior Cervical Discectomy and Fusion with MasterGraft Granules
~MASTERGRAFT® GRANULES are a medical-grade, polyporous resorbable ceramic hybrid composed of 15% hydroxyapatite (HA) and 85% beta-tricalcium phosphate (β-TCP). The combination of these natural bone materials provides surgeons with an osteoconductive, porous implant that improves osteointegration by allowing cells to colonize throughout the implant and optimize the bone healing process"
11535431|NCT01106404|Other|6-week AdaptiveStim followed by 6-week manual programming|
11535432|NCT01106404|Other|6-week manual followed by 6-week AdaptiveStim programming|
11535433|NCT01106391|Experimental|AAA stent graft system|Abdominal aortic aneurysm stent graft system
11535601|NCT01105260||control|group with classical rehabilitation program
11535434|NCT01106378||NEVO™ Sirolimus-eluting Coronary Stent System.|Subjects treated during routine clinical practice with the NEVO™ Sirolimus-eluting Coronary Stent System and diagnosed with acute STEMI for primary intervention and/or diabetes mellitus and/or multi vessel disease.
11535435|NCT01106378||CYPHER Select® Plus Coronary Stent|Subjects treated during routine clinical practice with the CYPHER Select® Plus Coronary Stent System and diagnosed with acute STEMI for primary intervention and/or diabetes mellitus and/or multi vessel disease
11535436|NCT01106365|Experimental|prefrontal cortex (PFC)|rTMS with the H-coil to the prefrontal cortex (PFC)
11535437|NCT01106365|Active Comparator|motor cortex|rTMS with the H-coil to the motor cortex
11535438|NCT01106365|Sham Comparator|sham treatment|sham treatment
11535439|NCT01106352|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) + docetaxel|Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection. In the randomized phase IIa part of the protocol, the dose established in the dose-escalation part of the protocol (Phase I) will be used, i.e. 5 doses of 50 kBq/kg b.w. every 6 weeks in combination with the approved step-down dose of docetaxel (60 mg/m^2) administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone.
11535440|NCT01106352|Active Comparator|Docetaxel|Docetaxel (75 mg/m2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m^2 is allowed as per the approved docetaxel label.
11535441|NCT01106339||A|Patients with somatoform disorders due to DSM-IV
11535442|NCT01106326|Experimental|Intervention|"Teens participating in this study will have:
~directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study
~three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications)."
11535443|NCT01106300||Multi-organ failure|Sedated ventilated patients in multi-organ failure
11535444|NCT01106300||Single-organ failure|Sedated ventilated patients in single organ failure
11535445|NCT01106287|Experimental|Treatment Sequence 1|Period 1: Placebo - Period 2: 80 mg - Period 3: 100 mg - Period 4: Placebo - Period 5: 140 mg
11535446|NCT01106287|Experimental|Treatment Sequence 2|Period 1: 60 mg - Period 2: 80 mg - Period 3: 100 mg - Period 4: 120 mg - Period 5: Placebo
11535447|NCT01106287|Experimental|Treatment Sequence 3|Period 1: 60 mg - Period 2: Placebo - Period 3: 100 mg - Period 4: 120 mg - Period 5: 140 mg
11535448|NCT01106287|Experimental|Treatment Sequence 4|Period 1: 60 mg - Period 2: 80 mg - Period 3: Placebo - Period 4: 120 mg - Period 5: 140 mg
11535449|NCT01106261|Experimental|Pulmonary metastasectomy|Pulmonary metastasectomy
11535450|NCT01106261|Active Comparator|Active monitoring|Active monitoring
11535451|NCT01106248|Other|Eribulin Mesylate|
11535452|NCT01106235|Experimental|Treatment (immunostimulant, autologous lymphocytes, and chemo)|Patients receive cyclophosphamide IV on days -3 and -2 followed by an infusion of IL-21 modulated, MART-1 specific CD8+ cytotoxic T lymphocytes over 30-60 minutes on day 0. Beginning within 24 hours of T cell infusion, patients receive low-dose aldesleukin SC BID for 14 days in the absence of disease progression or unacceptable toxicity.
11535453|NCT01106209||Prematurely born infants in the NICU|Preterm infant patients delivered at UUMC and hospitalized in the NICU who are ≤1500 grams or <30 weeks gestational age at birth
11535454|NCT01106209||Healthy term infants|Term infants delivered at UUMC without complication, either via cesarean section or vaginal delivery
11535455|NCT01106209||Infants having surgery at <1 year old|Infants admitted to the PCMC same-day surgery unit in preparation for elective surgery within the first year of life
11535456|NCT01106196||MI plus respiratory illness|Patients with an incident myocardial infarction who also have a record of a visit to primary care with a respiratory tract infection
11535457|NCT01106183|Active Comparator|Transfer Factor|Transfer factor supplement; 2 capsules per day
11535458|NCT01106183|Placebo Comparator|Sugar pill|
11535459|NCT01106170|Experimental|Arm 1|Participants will consume 330 mg of Provex CV supplement, by mouth, per day, for 4 weeks followed by 4 weeks of 330 mg of placebo (cornstarch)
11535460|NCT01106170|Experimental|Arm 2|Participants will consume 330 mg placebo (cornstarch), by mouth, per day for 4 weeks followed by 4 weeks of 330 mg of ProvexCV for 4 weeks.
11535461|NCT01106157|Experimental|Anti-Thymocyte Globin plus pegylated GCSF|Subjects will receive an infusion of Anti-Thymocyte Globin (ATG) followed by 6 doses of pegylated GCSF every 2 weeks for 10 weeks.
11535462|NCT01106157|Placebo Comparator|Placebo|Saline infusion will be given on both Day 1 and Day 2 followed by placebo injection given in identical volumes in identical syringes in the identical subcutaneous manner
11535463|NCT01106144||Acute myeloid leukemia|
11535464|NCT01106131|Experimental|CKD-501 0.5mg|
11535465|NCT01106131|Active Comparator|Pioglitazone 15mg|
11535466|NCT01106118||Group 1|
11535467|NCT01106105||control (Body Mass Index < 25)|
11535468|NCT01106105||Obese (Body Mass Index > 35)|
11535469|NCT01106092|Experimental|GSK2036874A GROUP 1|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 1) intramuscularly into the anterolateral region of the left thigh, at Day 0.
11535470|NCT01106092|Experimental|GSK2036874A GROUP 2|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 2) intramuscularly into the anterolateral region of the left thigh, at Day 0.
11535471|NCT01106092|Experimental|GSK2036874A GROUP 3|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 3) intramuscularly into the anterolateral region of the left thigh, at Day 0.
11535516|NCT01105806||cardiopulmonary resuscitation (CPR) narrative script|This pilot study involves a two-arm parallel design comparing the effectiveness of a CPR video versus a CPR narrative in advance directive (AD) completion over a 1 month timeframe post intervention.
11535472|NCT01106092|Active Comparator|ZILBRIX/HIB/POLIORIX GROUP|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of Zilbrix/Hib™ and Poliorix™ vaccines at Day 0, administered intramuscularly into the anterolateral regions of the left and right thighs, respectively.
11535473|NCT01106079|Experimental|Intensive management|
11535474|NCT01106079|Active Comparator|Standard management|
11535475|NCT01106066|Experimental|S-1/oxaliplatin/RT|Radiotherapy + 4 dose levels of oxaliplatin/S-1
11535476|NCT01106053|Experimental|Pramipexole|Open-label trial of pramipexole.
11535477|NCT01106040|Experimental|Lymphoseek, Lymphatic mapping, Injection|
11535478|NCT01106027|Experimental|Eculizumab|"Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery. Patients will be given 900 mg of eculizumab on Day 1 post-transplant. Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant.
~At week 4, patients will be assessed for donor specific anti-donor human leukocyte antigen (HLA) antibody (DSA). Patients with total DSA normalized values <5000 will stop eculizumab treatment. Patients with total DSA normalized values >5000 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly."
11535479|NCT01106014|Experimental|1|Selexipag is up-titrated from Day 1 to Week 12 to each patient's maximum tolerated dose in the range of 200-1600 µg twice a day (b.i.d.) in 200 µg steps starting with one 200 µg oral tablet on Day 1. From Day 2 onwards, a b.i.d. dose regimen with an interval of approximately 12 hours is followed. If this dose (selexipag 200 μg b.i.d.) is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg. Up-titration is followed by a stable maintenance treatment period from Week 12 onwards, up to Week 26, at the maximum tolerated dose
11535480|NCT01106014|Placebo Comparator|2|Matching placebo is administered orally with a dosing interval of approximately12 h. A (mock) up-titration scheme is followed
11535481|NCT01106001|Active Comparator|Levobupivacaine|Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children
11535482|NCT01106001|Placebo Comparator|Saline|Saline (also saline solution) is a general term referring to a sterile solution of sodium chloride (NaCl, more commonly known as salt) in water but is only sterile when it is placed intravenously, otherwise, a saline solution is a salt water solution.
11535483|NCT01105975|Experimental|30 milligram (mg) LY2484595 monotherapy|
11535484|NCT01105975|Experimental|100 mg LY2484595 monotherapy|
11535485|NCT01105975|Experimental|500 mg LY2484595 monotherapy|
11535486|NCT01105975|Placebo Comparator|Placebo|
11535487|NCT01105975|Active Comparator|20 mg Atorvastatin monotherapy|
11535488|NCT01105975|Experimental|100 mg LY2484595 + 20 mg Atorvastatin|
11535489|NCT01105975|Active Comparator|40 mg Simvastatin monotherapy|
11535490|NCT01105975|Experimental|100 mg LY2484595 + 40 mg Simvastatin|
11535491|NCT01105975|Active Comparator|10 mg Rosuvastatin monotherapy|
11535492|NCT01105975|Experimental|100 mg LY2484595 + 10 mg Rosuvastatin|
11535493|NCT01105949|Other|Marketed nasal strip|Marketed nasal strip
11535494|NCT01105949|Experimental|NexGen JB Organic PET/PE|NexGen JB Organic PET/PE, prototype nasal dilator strip
11535495|NCT01105949|Experimental|NexGen AB 2R11|NexGen AB 2R11
11535496|NCT01105936|Experimental|Paracetamol caplets|Two 665 mg sustained release paracetamol caplets administered orally with water.
11535497|NCT01105936|Placebo Comparator|Placebo caplets|Two placebo caplets administered orally with water.
11535498|NCT01105923|Experimental|Receive CDS intervention|Providers in clinics that will receive the CDS alert, as their clinic was randomized into our study.
11535499|NCT01105923|No Intervention|No CDS intervention|
11535500|NCT01105910|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
11535501|NCT01105910|Active Comparator|Sensitive Eyes|Sensitive Eyes Eye Drops (Bausch & Lomb)
11535502|NCT01105897||Surgically treated endometriosis patients|Women scheduled for operation on suspected endometriosis in two study hospitals specialized in the surgical treatment of endometriosis between January 2005 - December 2007 (Päijät-Häme Central Hospital) and January 2008 - December 2008 (Helsinki University Hospital).
11535503|NCT01105884|Active Comparator|Group 1|
11535504|NCT01105884|Active Comparator|Group 2|
11535505|NCT01105884|Active Comparator|Group 3|
11535506|NCT01105884|Active Comparator|Group 4|
11535507|NCT01105884|Active Comparator|Group 5|
11535508|NCT01105871|Active Comparator|naloxone|4 mg in 10 ml saline iv bolus
11535509|NCT01105871|Placebo Comparator|saline placebo|10 ml of normal saline iv bolus
11535510|NCT01105858||Volunteers|Adult volunteers &amp; family members recruited from the Phoenix metropolitan area
11535511|NCT01105832|Experimental|Proximal humeral fracture - intervention|20 patients will be randomized to 20 micrograms daily of Teriparatide (Forsteo)
11535512|NCT01105832|No Intervention|Proximal humeral fracture|20 patients will receive standard treatment (physiotherapy)
11535513|NCT01105819|Other|Standard oral care with chlorhexidine|The control group will receive a standard oral care. This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed
11535514|NCT01105819|Active Comparator|Lactobacillus plantarum 299|The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
11535515|NCT01105806||cardiopulmonary resuscitation (CPR) video|This pilot study involves a two-arm parallel design comparing the effectiveness of a CPR video versus a CPR narrative script in advance directive (AD) completion over a 1 month time frame post intervention.
11535517|NCT01105780|Experimental|001|JNJ-41443532 250mg tablet once daily for 1 day
11535519|NCT01105767|No Intervention|Group 1 Standard|Trainees received a preventive medicine briefing augmented with SSTI and MRSA SSTI prevention information and personal hygiene instructions. Trainees seeking medical care for an SSTI received standardized SSTI care (e.g., antimicrobial therapy, wound management, patient education) at the Troop Medical Clinic. High-touch common surfaces within the battalion areas were cleaned with standard Environmental Protection Agency-registered disinfectants.
11535520|NCT01105767|Active Comparator|Group 2 Enhanced Standard|Trainees received the components of the Standard group as well as supplemental training, education and hygiene. They were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit. Supplemental SSTI education for trainees and drill sergeants was also provided (e.g., pocket cards, posters). Drill sergeants received briefings on SSTI and skin inspection/minor wound care.
11535521|NCT01105767|Active Comparator|Group 3 Chlorhexidine|Trainees received the components of the Standard and Enhanced Standard groups and were offered chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) to use with a wash cloth after using their personal soap for the additional once-weekly shower. Trainees were provided with verbal and written/graphic instructions for use.
11535522|NCT01105754|No Intervention|Standard Care|Parents of children in the standard care group will complete the baseline assessment, but no asthma prompt will be created for either the caregiver or provider, and no information regarding the interview will be shared with the provider. After the baseline assessment, the office visit will proceed according to usual care.
11535523|NCT01105754|Experimental|Multifaceted Prompting Intervention|Multifaceted Prompting Intervention
11535524|NCT01105741||Active Crohn's disease - single arm|Active Crohn's disease, a decision is made to start treatment with adalimumab.
11535525|NCT01105728|Experimental|Study arm|Endoscopic resection
11535526|NCT01105715||Rheumatoid Arthritis (RA) Case Subjects|"Fulfill the American College of Rheumatology (ACR) 1987 Classification Criteria for RA
~Have currently active disease as assessed by Clinical Disease Activity Index (CDAI) score of >10
~Have > or = 3 swollen joints"
11535527|NCT01105715||Control Subjects|"Age, sex, and 5-year age categories matched to cases
~No historical diagnosis of RA and other primary autoimmune or inflammatory disorders"
11535528|NCT01105702|Experimental|TBL/RT|"Cycle 1(One 42-day cycle)
~Temozolomide 75 mg/m^2 orally (42 consecutive days), beginning the night prior to the first radiation treatment
~Radiation within 3-5 weeks of surgery
~Bevacizumab 10mg/kg, IV, starting 29 (+3) days post surgery and every 2 weeks
~Treatment Cycles 2-7 (28 days per cycle)
~Temozolomide at a dose of 150 mg/m^2 on Days 1-7
~Bevacizumab 10 mg/kg on Day 8 and Day 22
~Initiate Lithium carbonate treatment at 300 mg, orally, twice a day; dose increased every 7 days up to 600mg, orally, twice a day, to a serum lithium level of 0.8-1.2 mEq/L."
11535529|NCT01105676|Experimental|single group single arm study|Open no masking is used. All involved know the identity of the intervention assignment
11535530|NCT01105663||Sedated, Intubated, Morphine|Subjects will receive morphine/midazolam as part of clinical care. Pharmacokinetic and pharmacogenetic sampling and pharmacodynamic monitoring will occur as indicated. Pharmacokinetic samples will be assayed in the laboratory of the Division of Clinical Pharmacology and Therapeutics. Pharmacogenetic samples will be assayed in the laboratory of the Center for Applied Genomics at CHOP.
11535531|NCT01105663||Sedated, Intubated, Midazolam|Subjects will receive morphine/midazolam as part of clinical care. Pharmacokinetic and pharmacogenetic sampling and pharmacodynamic monitoring will occur as indicated. Pharmacokinetic samples will be assayed in the laboratory of the Division of Clinical Pharmacology and Therapeutics. Pharmacogenetic samples will be assayed in the laboratory of the Center for Applied Genomics at CHOP.
11535532|NCT01105650|Experimental|Arm 1: CsA|Patients receiving Cyclosporine (CsA) and Natural Killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
11535533|NCT01105650|Experimental|Arm 2: CsA plus Methylprednisolone (10mg)|Patients receiving Cyclosporine (CsA), methylprednisolone and natural killer cells (NK) infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
11535534|NCT01105650|Experimental|Arm 3: CsA plus Methylprednisolone (1 mg)|Patients receiving Cyclosporine (CsA), methylprednisolone and natural killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
11535535|NCT01105650|Experimental|Arm 4: CsA minus Methylprednisolone|Patients receiving Cyclosporine (CsA), no methylprednisolone, eliminating IL-2 doses 4-6 and receiving Natural Killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 3 doses given post NK cell infusion.
11535536|NCT01105637|Other|Exercise|
11535537|NCT01105624|Experimental|azithromycin ophthalmic solution, 1%|
11535538|NCT01105624|Experimental|rewetting drops|
11535539|NCT01105611|Experimental|Raltegravir|Raltegravir in combination with Tenofovir/Emtricitabine
11535540|NCT01105611|Active Comparator|Atazanavir/Ritonavir|Atazanavir 300mg orally once daily with Ritonavir 100mg orally once daily; together with combination of Tenofovir/Emtricitabine
11535541|NCT01105598|Experimental|Cohort 1|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
11535542|NCT01105598|Experimental|Cohort 2|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
11535543|NCT01105598|Experimental|Cohort 3|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
11535544|NCT01105598|Experimental|Cohort 4|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
11535545|NCT01105598|Experimental|Cohort 5|Free-living subjects (18 active/6 placebo) with mild dyslipidemia
11535546|NCT01105585|Experimental|ZCB00 IOL|Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens (IOL) randomly assigned to one eye, with AcrySof Natural IQ (SN60WF) IOL in the fellow eye for contralateral implantation
11535547|NCT01105585|Active Comparator|SN60WF IOL|AcrySof Natural IQ (SN60WF) intraocular lens (IOL) randomly assigned to one eye, with Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens in the fellow eye for contralateral implantation
11535602|NCT01105260||training|group with an 8 weeks interval training program on wheelchair independence
11535548|NCT01105572|Experimental|Intel Home Health Guide|Participants in the intervention group will receive the use of the Intel Healthguide, an Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback when transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager. Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care. Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes.
11535549|NCT01105572|No Intervention|Case Management Only|All participants in the comparison group, are identified for outreach and assistance by a nurse case manager. Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care. Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes.
11535550|NCT01105559||Group 1|Participants previously received 3 doses and a booster dose of the investigational vaccine DTaP IPV Hep B PRP-T.
11535551|NCT01105559||Group 2|Participants previously received 3 doses CombAct-Hib™ + Engerix™ B + OPV and a booster dose of CombAct-Hib™ + Oral poliovirus vaccine (OPV) vaccine.
11535552|NCT01105559||Group 3|Participants previously received 3 doses DTaP IPV Hep B PRP-T; a dose of Engerix™ B at birth, and a booster dose of DTaP IPV Hep B PRP-T vaccine.
11535553|NCT01105546|Experimental|prophylaxis|prophylaxis with recombinant activated FVII 90 µg/kg/day i.v.
11535554|NCT01105546|Active Comparator|on demand treatment|treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
11535555|NCT01105533|Experimental|Cohort 1|
11535556|NCT01105533|Experimental|Cohort 2|
11535557|NCT01105533|Experimental|Cohort 3|
11535558|NCT01105533|Experimental|Cohort 4|
11535559|NCT01105533|Experimental|Cohort 5|
11535560|NCT01105533|Experimental|Cohort 6|
11535561|NCT01105533|Experimental|Cohort 7|
11535562|NCT01105533|Experimental|Cohort 8|
11535563|NCT01105533|Experimental|Cohort 9|
11535564|NCT01105533|Experimental|Cohort 10|
11535565|NCT01105520||intralspinal processes|Patients with intralspinal processes
11535566|NCT01105507|Experimental|canakinumab arm|
11535567|NCT01105481|Experimental|amisulpride add-on|
11535568|NCT01105481|Placebo Comparator|placebo add-on|
11535569|NCT01105468||Mamma Carcinoma, no treatment|
11535570|NCT01105468||Mamma Carcinoma, treatment|
11535571|NCT01105468||No Mamma Carcinoma diagnosed by X-ray|
11535572|NCT01105455|Placebo Comparator|High fiber|High fiber carbohydrate foods with a high / medium glycemic index. Whole wheat bread and/or brown rice are provided to subjects if they wish. Subjects are provided with a list of other recommended carbohydrate foods.
11535573|NCT01105455|Active Comparator|Low GI|Carbohydrate foods with a low glycemic index. Low GI rice and whole grain bread provided to subjects if they wish. Subjects are provided with a list of recommended foods.
11535574|NCT01105442||Bupivacaine|Patients who received bupivacaine + sufentanil
11535575|NCT01105442||Levobupivacaine|Patients who received levobupivacaine and morphine on demand
11535576|NCT01105429|Active Comparator|BMS-820132 (0.3 mg) or Placebo|
11535577|NCT01105429|Active Comparator|BMS-820132 (1.0 mg) or Placebo|
11535578|NCT01105429|Active Comparator|BMS-820132 (3 mg) or Placebo|
11535579|NCT01105429|Active Comparator|BMS-820132 (10 mg) or Placebo|
11535580|NCT01105429|Active Comparator|BMS-820132 (30 mg) or Placebo|
11535581|NCT01105429|Active Comparator|BMS-820132 (75 mg) or Placebo|
11535582|NCT01105429|Active Comparator|BMS-820132 (150 mg) or Placebo|
11535583|NCT01105429|Active Comparator|BMS-820132 (300 mg) or Placebo|
11535584|NCT01105429|Active Comparator|BMS-820132 (TBD) or Placebo|
11535585|NCT01105416|Placebo Comparator|Enhanced Standard Care (ESC)|Standard emergency department care plus informational brochures
11535586|NCT01105416|Experimental|Brief Prevention Intervention (BPI)|Brief Prevention Intervention in the Pediatric ED
11535587|NCT01105403|Experimental|CD34+ mobilisation for transplantation|
11535588|NCT01105390|Experimental|Treatment (rilotumumab, cisplatin, pemetrexed disodium)|Patients receive anti-HGF monoclonal antibody AMG 102 (AMG 102) IV over 1 hour, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without disease progression may continue AMG 102 IV over 1 hour on day 1, every 3 weeks, as maintenance therapy in the absence of disease progression.
11535589|NCT01105377|Experimental|Treatment (entinostat, azacitidine)|Patients receive azacitidine subcutaneously on days 1-5 and 8-10 and oral entinostat on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11535590|NCT01105351|Active Comparator|folic acid plus B6 and B12|folic 400 µg plus vitamin B12 plus B6
11535591|NCT01105351|Placebo Comparator|Folic acid|folic acid alone
11535592|NCT01105338|Active Comparator|Green tea drink|Green tea drink
11535593|NCT01105338|Active Comparator|Green tea capsules|Green tea capsules
11535594|NCT01105338|Placebo Comparator|Green tea placebo capsules|Green tea placebo capsules
11535595|NCT01105338|Active Comparator|Lycopene capsules|Lycopene capsules
11535596|NCT01105338|Placebo Comparator|Lycopene placebo capsules|Lycopene placebo capsules
11535597|NCT01105338|Active Comparator|Tomato rich diet|Tomato rich diet
11535598|NCT01105312|Experimental|panobinostat (LBH589) and letrozole|Each patient will receive panobinostat (LBH589) and letrozole. Patients will be administered LBH589 PO, 3 days per week for a total of 4 weeks. Patients will also be administered letrozole 2.5 mg PO Days 1-28 every 4 weeks. There are two phases of the study. The first phase determines the maximum tolerated dose for LBH589 in combination with letrozole. The second phase is to assess and confirm the response rate and safety profile of LBH589 in combination with letrozole.
11535599|NCT01105286|Experimental|Calcipotriol ointment|
11535600|NCT01105273|Experimental|HAPLO|
11535604|NCT01105234|Experimental|Calcipotriol ointment|
11535605|NCT01105221|Experimental|Acupuncture|
11535606|NCT01105221|Active Comparator|Artificial tear drop|
11535607|NCT01105208|Experimental|Arm 1|
11535608|NCT01105208|Active Comparator|Arm 2|
11535609|NCT01105195|Active Comparator|DuraPrep|
11535610|NCT01105195|Active Comparator|ChloraPrep|
11535611|NCT01105182||Radiofrequency Ablation|
11535612|NCT01105169|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate.
11535613|NCT01105169|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
11535614|NCT01105169|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
11535615|NCT01105169|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
11535616|NCT01105156||Gastric Band Patients|
11535617|NCT01105143|Active Comparator|lifestyle intervention|Multimodal lifestyle intervention to reduce body weight
11535618|NCT01105143|Placebo Comparator|placebo|placebo
11535619|NCT01105130|Placebo Comparator|Arm I - Placebo|Patients receive oral placebo twice daily (total of 6 capsules per day).
11535620|NCT01105130|Experimental|Arm II - low dose|Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).
11535621|NCT01105130|Experimental|Arm III - high dose|Oral L-arginine twice daily = 6 capsules per day.
11535622|NCT01105117|Active Comparator|1|ACT-385781A (Actelion Epoprostenol)
11535623|NCT01105117|Active Comparator|2|Flolan®
11535624|NCT01105104|Other|MedMinder System|
11535625|NCT01105104|Other|MedMinder System - deactivated|
11535626|NCT01105091|Active Comparator|1|ACT-385781A (Actelion Epoprostenol)
11535627|NCT01105091|Active Comparator|2|Flolan®
11535628|NCT01105078|Other|Flow rate|Comparison between a flow rate of 2.5/l/min/m2 versus 3.0/l/min/m2
11535629|NCT01105065|Experimental|Patients with RVD|Patients who exhibited retinal vascular dysregulation at the initial visit. Intervention: brimonidine 0.15% three times per day for 8 weeks.
11535630|NCT01105052|Active Comparator|Bibliotherapy|A group receiving a self-help book to work on for six weeks with no therapist support.
11535631|NCT01105052|Experimental|Bibliotherapy with support|A group receiving a self-help book to work on for six weeks, together with brief weekly telephone calls (<15 minutes) from a therapist.
11535632|NCT01105052|No Intervention|Wait-list control group|This group receives no intervention until about five months after the two treatment groups, when participants in this group receive the self-help book without therapist support.
11535633|NCT01105039||lap. hernia repair|undergoing laparoscopic groin hernia repair
11535634|NCT01105026|Experimental|bioactive glass|
11535635|NCT01105013|Experimental|tonaftato|Apply the product in sufficient quantity to cover the affected area 2 times daily (every 12 hours) for 60 days.
11535636|NCT01104987||alendronate|A cross sectional study assessing the prevalence of osteoporosis and vertebral fractures in AS has been conducted during the spring in 2009. Patients with osteoporosis that fulfilled the inclusion criteria and did not have any exclusion criteria for the present trial were asked to join this study.
11535637|NCT01104961|Experimental|Contact Lens Packaging Solution #1|Test solution - contact lens packaging solution
11535638|NCT01104961|Experimental|Contact lens packaging solution #2|Test solution - contact lens packaging solution
11535639|NCT01104961|Placebo Comparator|Balanced salt solution|Control solution
11535640|NCT01104948|Experimental|DA-8031|
11535641|NCT01104948|Placebo Comparator|Placebo|
11535642|NCT01104935|Experimental|trastuzumab monotherapy|"H group (trastuzumab monotherapy group)
~Trastuzumab: 1-year treatment
~Loading dose, 8 mg/kg; from 2nd dose, 6 mg/kg; iv inj, qw, 18 times"
11535643|NCT01104935|Active Comparator|trastuzumab and chemotherapy|"H+CT group (combination therapy of trastuzumab and chemotherapy)
~Chemotherapy: 12 to 24 weeks
~Select chemotherapy from certain regimens (PTX, DTX, TC, AC, EC, FEC, CMF and TCb (CBDCA)) based on decision of a physician or a patient. Initiate administration of trastuzumab after completion of chemotherapy as a sequential combination. However, concomitant administration is allowed when combining trastuzumab with PTX, DTX and CMF. In cases of TCb (CBDCA), trastuzumab is used concomitant administration."
11535644|NCT01104909|Active Comparator|Clinical dry weight|Group which the dry weight will be assessed based on clinical examination.
11535645|NCT01104909|Active Comparator|Bioimpedance|Group which the dry weight will be assessed by bioimpedance data.
11535646|NCT01104896|Active Comparator|Nicotine|One or two 15mg nicotine patch(es) applied from 6am to 10pm according to the patients tobacco dependence measured by the Fagerström scale.
11535647|NCT01104896|Placebo Comparator|Placebo|One or two patch(es) with placebo
11535648|NCT01104883|Experimental|Adductor-Canal-Blockade|Adductor-Canal-Blockade with ropivacaine
11535649|NCT01104883|Placebo Comparator|Adductor-Canal-blockade with saline|Adductor-Canal-blockade with isotonic saline
11535650|NCT01104870|Active Comparator|Dose Group 1|UT-15C 0.25 mg twice daily
11535651|NCT01104870|Active Comparator|Dose Group 2|UT-15C 1.25 mg twice daily
11535652|NCT01104870|Active Comparator|Dose Group 3|UT-15C individual Maximum Tolerated Dose
11535653|NCT01104857|Experimental|Diaphragm muscle biopsy|Patients admitted to the ICU meeting severe sepsis / septic shock criteria
11535654|NCT01104857|Active Comparator|Elective laparotomy|
11535655|NCT01104844|Active Comparator|Half dose strength|Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg), i.e 2 tablets equating to ½ the dose in the standard investigational drug
11535656|NCT01104844|Active Comparator|Quarter dose strength|Investigational drug quarter dose strength (acetaminophen125mg + Ibuprofen 37.5mg) i.e. 2 tablets equating to ¼ the dose in the standard investigational drug.
11535657|NCT01104844|Active Comparator|Acetaminophen standard dose|Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
11535658|NCT01104844|Active Comparator|ibuprofen low dose|Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
11535659|NCT01104844|Active Comparator|Ibuprofen high dose|Ibuprofen High dose 300mg i.e. 2 tablets equating to twice the ibuprofen dose as in the standard investigational drug
11535660|NCT01104844|Placebo Comparator|placebo|2 Placebo tablets
11535661|NCT01104844|Experimental|Full Dose Strength|Investigational drug full dose strength (acetaminophen 500mg + ibuprofen 150mg) i.e. 2 tablets
11535662|NCT01104831|Placebo Comparator|21 degree Cooling|Room temperature water circulated through cryotherapy sleeve.
11535663|NCT01104831|Active Comparator|10 degree cooling|Cooled water circulated through a cryotherapy sleeve.
11535664|NCT01104805|Experimental|Therapeutic Education System (TES)|Participants randomized to this arm will replace approximately 2 hours of Standard Treatment with the Therapeutic Education System (TES) (comprised of a web-based version of the Community Reinforcement Approach and contingency management).
11535665|NCT01104805|Other|Treatment-as-Usual (TAU)|Participants randomized to TAU will receive standard treatment offered and prescribed, as usual, in the outpatient substance abuse treatment program.
11535666|NCT01104792|Experimental|Cariprazine|Participants received cariprazine 3.0, 4.5, 6.0, or 9.0 mg orally once a day for 48 weeks.
11535667|NCT01104779|Experimental|Cariprazine (3-6 mg/day)|Cariprazine once daily fixed-flexible low dose
11535668|NCT01104779|Experimental|Cariprazine (6-9 mg/day)|Cariprazine once daily fixed-flexible high dose
11535669|NCT01104779|Placebo Comparator|Placebo|Placebo
11535670|NCT01104766|Experimental|Cariprazine 3mg|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
11535671|NCT01104766|Experimental|Cariprazine 6mg|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
11535672|NCT01104766|Active Comparator|Aripiprazole 10mg|Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
11535673|NCT01104766|Placebo Comparator|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
11535674|NCT01104753||Non-interventional post-authorisation safety study|
11535675|NCT01104727|Active Comparator|Multi port|4-Ports Cholecystectomy (4PC): a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.
11535676|NCT01104727|Active Comparator|Single port|"Single-Port Cholecystectomy (SPC): a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.
~In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones."
11535677|NCT01104714||All patients|As the trial progresses, patients will be classified as either chemotherapy responders or non-responders.
11535678|NCT01104701|Active Comparator|Group A|2 mg exenatide once weekly subcutaneous (SC). This arm is used as a reference arm in the study.
11535679|NCT01104701|Experimental|Group B|Low dose 5 mg exenatide once monthly suspension SC.
11535680|NCT01104701|Experimental|Group C|Medium dose 8 mg exenatide once monthly suspension SC.
11535681|NCT01104701|Experimental|Group D|High dose 11 mg exenatide once monthly suspension SC.
11535682|NCT01104675|Experimental|ENMD-2076 treatment|
11535683|NCT01104662|Experimental|Daptomycin, Bacteremia, Severe Renal Impairment|Cohort 1. Daptomycin was given intravenously 6 milligrams per kilogram (mg/kg) per administration. For bacteremia participants with Creatinine Clearance (CLcr) below 30 milliliters per minute (mL/min) and currently receiving hemodialysis, daptomycin was administered immediately following each hemodialysis session (3 per week) for 14 to 42 days based on disease resolution or Investigator discretion. For participants not receiving dialysis, daptomycin was administered every 48 hours for 14 to 42 days based on disease resolution or Investigator discretion.
11535684|NCT01104662|Active Comparator|Vancomycin or SSP, Bacteremia, Severe Renal Impairment|Cohort 1. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by Methicillin-Susceptible Staphylococcus Aureus (MSSA) could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered intravenously (IV) until end of antibiotic therapy for bacteremia or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
11535685|NCT01104662|Experimental|Daptomycin, Bacteremia, Moderate Renal Impairment|Cohort 2. Daptomycin was given intravenously 6 milligrams per kilogram (mg/kg) per administration. For bacteremia participants with CLcr values between 30 and 50 mL/min not receiving dialysis, daptomycin was administered every 24 hours for 14 to 42 days based on disease resolution or Investigator discretion.
11535706|NCT01104545|Experimental|Panel A - Healthy|Healthy participants receive single oral dose of MK-3614 0.25 mg, 1.25 mg, 0.25 mg w/ food, 0.75 mg or matching placebo. There is at least a 7-day washout between the 4 dosing periods. All doses were administered after an 8-hour fast except for Period 3. Period 3 dose was administered after the ingestion of a high-fat breakfast.
11535750|NCT01104220|Experimental|Obese, scheduled for bariatric surgery|Subjects with a body mass index ≥35.0 kg/m² undergoing bariatric surgery
11535686|NCT01104662|Active Comparator|Vancomycin or SSP , Bacteremia, Moderate Renal Impairment|Cohort 2. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for bacteremia or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
11535687|NCT01104662|Experimental|Daptomycin, cSSSI, Severe Renal Impairment|Cohort 3. Daptomycin was given intravenously 4 milligrams per kilogram (mg/kg) per administration. For cSSSI participants with CLcr below 30 mL/min and currently receiving hemodialysis, daptomycin was administered immediately following each hemodialysis session (3 per week) for 7 to 14 days based on disease resolution or Investigator discretion. For participants not receiving dialysis, daptomycin was administered every 48 hours for 7 to 14 days based on disease resolution or Investigator discretion.
11535688|NCT01104662|Active Comparator|Vancomycin or SSP , cSSSI, Severe Renal Impairment|Cohort 3. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
11535689|NCT01104662|Experimental|Daptomycin, cSSSI, Moderate Renal Impairment|Cohort 4. Daptomycin was given intravenously 4 milligrams per kilogram (mg/kg) per administration. For cSSSI participants with CLcr values between 30 and 50 mL/min not receiving dialysis, daptomycin was administered every 24 hours for 7 to 14 days based on disease resolution or Investigator discretion.
11535690|NCT01104662|Active Comparator|Vancomycin or SSP , cSSSI, Moderate Renal Impairment|Cohort 4. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
11535691|NCT01104649|Experimental|Riluzole|Riluzole 50 mg is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)
11535692|NCT01104649|Placebo Comparator|Placebo comparator|Placebo is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)
11535693|NCT01104636||Single group prospective treatment cohort (varenicline)|
11535694|NCT01104623||ADHD - Patients|Adults (18-50 years old). All eligible subjects will experience the voice recording procedure followed by the assessment of adult ADHD diagnostics. The diagnostic guidelines for ADHD in adulthood will be accomplished as outlined by expert consensus of the German Society for Psychiatry, Psychotherapy and Neurology, with a semi-structured clinical interview following the DSM-IV-TR criteria and the ADHD-Checklist (ADHD-CL) for DSM-IV (Hesslinger et al., 2002) to assess the severity of ADHD-Symptoms. Childhood ADHD symptoms will be rated retrospectively amongst others by using the short version (WURS-k) of the Wender Utah Rating Scale (Ward et al., 1993), German version (Retz-Junginger et al., 2002). To strengthen the validity of the ADHD diagnosis the reported symptoms were corroborated by second party reports.
11535695|NCT01104623||Healthy Controls|Adults(18-50 years old). All eligible subjects will experience the voice recording procedure followed by the ADHD-Checklist (ADHD-CL) for DSM-IV (Hesslinger et al., 2002. To assess the severity of Non-ADHD, the absence of childhood ADHD symptoms will be rated retrospectively amongst others by using the short version (WURS-k) of the Wender Utah Rating Scale (Ward et al., 1993), German version (Retz-Junginger et al., 2002).
11535696|NCT01104610|Active Comparator|NIV-PSV without Target Volume|Pressure Support Non Invasive Ventilation without Target Volume
11535697|NCT01104610|Active Comparator|NIV-PSV with Target Volume|Non Invasive Pressure Support Ventilation with Target Volume set
11535698|NCT01104610|Active Comparator|NIV-CPAP|Pressure Support Ventilation in CPAP mode
11535699|NCT01104584|Experimental|Gadobutrol (Gadavist, BAY86-4875)|Patients first received an unenhanced magnetic resonance mammography (MRM), followed by a gadobutrol-enhanced MRM. Gadobutrol was administered at the standard dose of 0.1 mmol/kg body weight (bw) [0.1 ml/kg bw] as an intravenous injection (i.v.) at a rate of 2 ml/sec. Unenhanced MRM (UMRM) and combined unenhanced and contrast (gadobutrol)-enhanced MRM (CMRM) image sets were evaluated in a randomized fashion. After the evaluation of the UMRM or CMRM the respective X-ray mammography (XRM) was added and evaluated together with the UMRM images.
11535700|NCT01104571|Other|Part 1: Control|No peri-operative therapy given
11535701|NCT01104571|Experimental|Part 1: Trastuzumab|Trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery.
11535702|NCT01104571|Experimental|Part 1: lapatinib|Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery
11535703|NCT01104571|Other|Part 2: Control|No peri-operative therapy
11535704|NCT01104571|Experimental|Part 2: Trastuzumab|Trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery.
11535705|NCT01104571|Experimental|Part 2: lapatinib-trastuzumab combination|Lapatinib 1000mg/day p.o. continuously for 28 days, in combination with trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery. Both drugs should start 11 days (+2 or -1 day) before the scheduled surgery.
11535749|NCT01104220|No Intervention|Obese, metabolically abnormal|Subjects with body mass index ≥30.0 kg/m² and impaired fasting or oral glucose tolerance and increased liver fat.
11535918|NCT01103050|Active Comparator|Cetirizine + QAV680 Placebo|
11535707|NCT01104545|Experimental|Panel B - Healthy|Healthy participants receive single oral dose of MK-3614 0.5 mg. 0.75 mg, 0.25 mg twice a day (b.i.d.), 0.25 mg three times a day (t.i.d), or matching placebo. There is at least a 7-day washout between the 4 dosing periods. All doses were administered after an 8-hour fast
11535708|NCT01104545|Experimental|Panel C - Hypertensive|Hypertensive participants receive single oral dose of MK-3614 0.75 mg. 0.5 mg. 0.75 mg, 0.75 mg or matching placebo. There is at least a 7-day washout between the 4 dosing period. All doses were administered after an 8-hour fast
11535709|NCT01104532|Experimental|Dosing Regimen 1|
11535710|NCT01104532|Experimental|Dosing Regimen 2|
11535711|NCT01104532|Experimental|Dosing Regimen 3|
11535712|NCT01104532|Experimental|Dosing Regimen 4|
11535713|NCT01104519|Experimental|1|Niaspan - Placebo
11535714|NCT01104519|Experimental|2|Placebo - Niaspan
11535715|NCT01104506|Active Comparator|Painless plexus|Patient with a painless avulsion of brachial plexus
11535716|NCT01104506|Active Comparator|Healthy|Healthy volunteers
11535717|NCT01104506|Experimental|Painful plexus|Patient with a painful avulsion of brachial plexus
11535718|NCT01104493|Experimental|1|Single dose of monovalent vaccine
11535719|NCT01104493|Placebo Comparator|2|Placebo
11535720|NCT01104467|Experimental|Desmoteplase 70 µg/kg|
11535721|NCT01104467|Experimental|Desmoteplase 90 µg/kg|
11535722|NCT01104467|Placebo Comparator|Placebo|
11535723|NCT01104428|Placebo Comparator|placebo|
11535724|NCT01104428|Experimental|"Drug:ziying"|
11535725|NCT01104415|Experimental|Telotristat etiprate - Core Phase|Following a 2-week Run-In Period, participants received telotristat etiprate capsules at a starting dose of 150 mg, orally three times daily (TID) for 14 days in the Core Phase. Dose escalations (250 mg, 350 mg, 500 mg) occurred serially every 14 days, up to a maximum dosage of telotristat etiprate 500 mg TID, as guided by specific clinical criteria for dose escalation. Upon completion of 12 weeks of treatment, participants were eligible to receive telotristat etiprate in the optional Open-label Extension Period.
11535726|NCT01104415|Experimental|Telotristat etiprate - Extension Period|Participants received telotristat etiprate at their highest tolerated dose (250 mg or 500 mg), orally, TID for 124 weeks in the Open-label Extension Period. If neither dose was tolerated participants were discontinued from the study and completed the 2-week Follow-up Visit.
11535727|NCT01104402|No Intervention|Standard Care|Subjects will receive education about signs and symptoms indicative of worsening CF.
11535728|NCT01104402|Active Comparator|Home monitoring|Subjects will be randomized to monitor home spirometry and symptoms using a handheld device.
11535729|NCT01104376|Experimental|CYP2B6|"Healthy volunteers will receive Efavirenz and Vericonazole as follow:
~In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered. In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
11535730|NCT01104363|Experimental|Snow white Plaster 2|Test
11535731|NCT01104363|Active Comparator|Primopattern LC gel + PVS|Control
11535732|NCT01104350|Experimental|Radiotherapy and Concurrent Gemcitabine Chemotherapy|This is a Phase I dose-escalation study examining the safety and tolerability of intensity modulated external radiation therapy using image-guidance in combination with gemcitabine chemotherapy as an alternative to radical cystectomy.
11535733|NCT01104337|Experimental|Paracetamol 2g/d|18 patients on stable warfarin therapy received a 10-day regimen of paracetamol 2g/d
11535734|NCT01104337|Experimental|Paracetamol 3g/d|18 patients on stable warfarin therapy received a 10-day regimen of paracetamol 3g/d
11535735|NCT01104337|Placebo Comparator|Placebo|9 patients on stable warfarin therapy received a 10-day regimen of placebo
11535736|NCT01104311|Experimental|Aggressive BP lowering|Lowering of systolic blood pressure between 110mmHg and 120mmHg during study period
11535737|NCT01104311|Active Comparator|Modest BP lowering|Lowering of systolic blood pressure between 130mmHg and 140mmHg
11535738|NCT01104298|Active Comparator|Arm A|"Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.
~Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous"
11535739|NCT01104298|Experimental|Arm B|"Trabectedin Presentation: vials with trabectedin 1 mg and sucrose 400 mg. Pharmaceutical form: A white or whitish lyophilized powder as concentrate for solution for injection.
~Route of administration: for intravenous use after reconstitution and further dilution.
~Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.
~Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous"
11535740|NCT01104285||Standard care|Treatment of pleural effusion with diuresis
11535741|NCT01104285||Chest tube|Treatment of pleural effusion with diuresis and chest tube
11535742|NCT01104272|Experimental|Energy Level 1|Subcutaneous Adipose Tissue Treated With Energy Level 1.
11535743|NCT01104259|Experimental|Treatment (veliparib with cisplatin and vinorelbine tartrate)|Patients receive veliparib PO BID on days 1-14 (days 0-13 of course 1 only). Patients also receive cisplatin IV over 1 hour on day 1 and vinorelbine ditartrate IV over 10-20 minutes on days 1 and 8. Treatment repeats every 21 days for 6-10 courses in the absence of disease progression or unacceptable toxicity. Treatment with veliparib alone may continue in the absence of disease progression or unacceptable toxicity.
11535744|NCT01104246|Experimental|Testosterone Transdermal Systems|Testosterone
11535745|NCT01104233||The soft spreading|Patients with lung cancer underwent Video-assisted Thoracoscopic Surgery (VATS) with soft spreading (using LAP Protector).
11535746|NCT01104233||The rigid spreading|Patients with lung cancer underwent Video-assisted Thoracoscopic Surgery (VATS) with rigid spreading.
11535747|NCT01104220|No Intervention|Lean, metabolically normal|Subjects with body mass index 18.5 - 24.9 kg/m² and normal fasting blood glucose and oral glucose tolerance and liver fat.
11535748|NCT01104220|No Intervention|Obese, metabolically normal|Subjects with body mass index ≥30.0 kg/m² and normal fasting blood glucose and oral glucose tolerance and liver fat.
11535751|NCT01104220|No Intervention|Obese, scheduled for gallbladder surgery|Subjects with a body mass index ≥35.0 kg/m² undergoing gallbladder surgery
11535752|NCT01104220|No Intervention|Lean, scheduled for inguinal hernia, hysterectomy or myomectomy surgery|Subjects with body mass index 18.5 - 24.9 kg/m² and normal fasting blood glucose and oral glucose tolerance and liver fat.
11535753|NCT01104207|Experimental|Arm 1|Half of the study participants will receive 2000 pulses of 1 Hz active rTMS daily on 10 consecutive work days.
11535754|NCT01104207|Sham Comparator|Arm 2|Half of the study participants will receive 2000 pulses of 1 Hz placebo rTMS daily on 10 consecutive work days.
11535755|NCT01104194|Experimental|Fish-oil|
11535756|NCT01104194|Placebo Comparator|Placebo|Olive oil capsules, identical in appearance to fish oil capsules
11535757|NCT01104181|Experimental|swab and brush or swab and swab|we will determine which collection method is superior
11535758|NCT01104168||Nursing home residents with diabetes|
11535759|NCT01104155|Active Comparator|eribulin mesylate, 21 day cycle|
11535760|NCT01104155|Active Comparator|eribulin mesylate, 28 day cycle|
11535761|NCT01104142||MDI|Subject on multiple Daily Injections
11535762|NCT01104142||CSII|Subjects on Continuous Subcutaneous Insulin Infusion
11535763|NCT01104129||Control Group|Individual who has not had pancreatic cancer/IPMN; surgical resection for lesion of pancreas; history of colorectal, gastric cancer, esophageal, or head-and-neck cancer; administration of chemotherapy less than 1 week prior to enrollment; or an endoscopic procedure conducted less than 1 week prior to enrollment.
11535764|NCT01104129||Diagnosis of Pancreatic Cancer/IPMN|Patients diagnosed with Pancreatic Cancer/Intraductal Papillary Mucinous Neoplasm who are scheduled for surgical resection.
11535765|NCT01104116|Experimental|PET/CT imaging|Surgical patients will undergo [18F]-FDG PET/CT imaging
11535766|NCT01104103|Experimental|BOA(R)|Nurse or paramedic uses the BOA(R)-Constricting IV Band to attempt placement of an upper extremity IV in an adult
11535767|NCT01104103|Active Comparator|Standard care|Nurse or paramedic uses standard IV starting technique in the upper extremity of adults
11535768|NCT01104090|Active Comparator|C-MAC direct laryngoscopy|The laryngoscopy is performed with the CMAC used as Macintosh blade
11535769|NCT01104090|Experimental|C-MAC Indirect laryngoscopy|The CMAC is used as videolaryngoscope
11535770|NCT01104064|Experimental|Real rTMS combined with CIT|
11535771|NCT01104064|Sham Comparator|Sham rTMS combined with CIT|
11535772|NCT01104051||Radiofrequency Ablation|The treatment to be used in this trial is radiofrequency nerve ablation of lateral branches from S1 - S4 using radiofrequency treatments; Simplicity lll Electrode, a single RF electrode with a single percutaneous entry point.
11535773|NCT01104051||Sham|subjects to be blinded,to receive sham procedure; The treatment to be used in this trial is radiofrequency nerve ablation of lateral branches from S1 - S4 using radiofrequency treatments; Simplicity lll Electrode, a single RF electrode with a single percutaneous entry point.
11535774|NCT01104038|Active Comparator|Nutrition Education/Lifestyle Counseling|Children in this group will receive weekly group nutrition sessions , 30 minutes per week for 12 weeks, identical to those provided for the EXCEL intervention group and delivered by a registered dietician.
11535775|NCT01104038|Experimental|EXCEL|The EXCEL arm is the experimental arm of the study. Participants in this arm will receive supervised physical activity in the form of novel gaming (technology-mediated physical activity, 60 minutes per session, three times per week , for 12 weeks and 12 weeks of group nutrition education sessions.
11535776|NCT01104025|Experimental|Induction Therapy|ATG, rabbit: intravenous, 5 mg/kg/dose, 5 consecutive days Dexamethasone: intravenous, 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days Etoposide: intravenous, 150 mg/m2 weekly, starting 7 days after first dose of Thymoglobulin Methotrexate and hydrocortisone: intrathecal to patients with central nervous system involvement, age< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg, on day 7, 14, 21 and 42
11535777|NCT01104012||All patients|Allergy patients, asthma and rhinitis
11535778|NCT01103986|No Intervention|Control Group|
11535779|NCT01103986|Experimental|motivational/ health literacy education|
11535780|NCT01103973|Placebo Comparator|Control (Spa Certificate)|For every three months in the study control subjects received $50 spa gift certificates.
11535781|NCT01103973|Experimental|Mind/Body Program|Ten week group mind/body program. Skills include relaxation training, cognitive strategies, and lifestyle modifications.
11535782|NCT01103960|Experimental|Telmisartan80mg+Amlodipine5mg|combination therapy
11535783|NCT01103960|Active Comparator|amlodipine 5 mg|Monotherapy
11535784|NCT01103947|Active Comparator|EcoAnesthesia Mask first|"Both the standard adult facemask (Portex Adult, USA) and the new facemask (EcoAnesthesia Mask, Intersurgical, Inc., Liverpool, NY, USA) will be tested in each patient for three minutes. The order of usage of each mask will be randomly assigned to each patient. This group will receive the EcoAnesthesia Mask first."
11535785|NCT01103947|Active Comparator|Standard mask first|"Both the standard adult facemask (Portex Adult, USA) and the new facemask (EcoAnesthesia Mask, Intersurgical, Inc., Liverpool, NY, USA) will be tested in each patient for three minutes. The order of usage of each mask will be randomly assigned to each patient. Patients in this arm will receive the standard mask first."
11535786|NCT01103934|Active Comparator|Fluticasone Propionate plus Vitamin D3|Subjects will be treated with fluticasone propionate and Vitamin D once daily for 2 weeks during allergy season
11535787|NCT01103934|Placebo Comparator|Fluticasone Propionate plus Placebo|Subjects will be treated with fluticasone propionate and placebo for Vitamin D once daily for 2 weeks during allergy season
11535788|NCT01103921|Other|Glucose|
11535789|NCT01103921|Other|Fructose|
11535790|NCT01103921|Other|High-Fructose Corn Syrup|
11535791|NCT01103921|Other|Aspartame|No sugar
11535792|NCT01103908||Pediatric cardiac output (CO) after CPB|Cardiac output measurements made in pediatric patients after cardiopulmonary bypass.
11535793|NCT01103856|Experimental|Patient Mentor Intervention|The patient mentor intervention from TSHC has been adapted to the inpatient setting. Participants randomized to that arm will receive 2 sessions with a patient mentor during their hospitalization, as well as 5 phone call sessions over the 10 weeks after discharge and a brief meeting between the subject and the mentor when the subject attends their first outpatient visit at TSHC after discharge.
11535794|NCT01103856|Placebo Comparator|HIV transmission risk reduction|Participants randomized to the control arm will receive an attention control intervention delivered by a patient educator who is not an HIV patient mentor. We will use a modified version of the RESPECT intervention for our attention control group. Similar to the active intervention, these patients will receive 2 sessions in the hospital and 5 phone calls over 10 weeks after discharge.
11535795|NCT01103843|Active Comparator|Maintenance Dose Arm|Open label clopidogrel 75 mg daily or prasugrel 10 mg daily
11535796|NCT01103843|Active Comparator|Loading Dose Arm|Clopidogrel 600 mg or Prasugrel 60 mg at time of PCI.
11535797|NCT01103830|Experimental|Group 1|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
~Administration of Eurartesim will be in fed condition following a high-fat/low-Kcal meal."
11535798|NCT01103830|Active Comparator|Group 2|"4 tablets of Riamet® on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.
~Administration of Riamet® will be in fed condition following a high-fat/low-Kcal meal."
11535799|NCT01103830|Other|Group 3|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.
~Administration will be in the morning, in fed condition, following a high-fat/low-Kcal meal
~1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning."
11535800|NCT01103830|Experimental|Group 4|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
~Administration of Eurartesim will be in fed condition following a high-fat/high-Kcal meal."
11535801|NCT01103830|Experimental|Group 5|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
~Administration of Eurartesim will be in fasting condition."
11535802|NCT01103830|Other|Group 6|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.
~Administration will be in the morning, in fasting condition.
~1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning."
11535803|NCT01103817|No Intervention|Vitamin D Sufficient|"Sufficient is defined as a 25 OH vitamin D level >50 nmol/l measured at baseline. No clinical intervention will be assigned to this group.
~Subjects will have fasting bloodwork done. Other study measurements to be taken include: height and weight, stage of puberty, blood pressure, vitamin D and calcium intake information, diabetes risk information, demographic information and spot urine sample.
~We will also do a non-invasive test called a PAT or 'peripheral arterial tonometry' to look at the health of your blood vessels."
11535804|NCT01103817|Experimental|Vitamin D Deficient|"Deficient is defined as a 25 OH vitamin D level ≤ 37.5 nmol/l. This group will receive Vitamin D.
~Subjects will have fasting bloodwork done. Other study measurements to be taken include: height and weight, stage of puberty, blood pressure, vitamin D and calcium intake information, diabetes risk information, demographic information and spot urine sample.
~We will also do a non-invasive test called a PAT or 'peripheral arterial tonometry' to look at the health of your blood vessels."
11535805|NCT01103791|Experimental|Cohort 1|Docetaxel-PNP 20mg/m2
11535806|NCT01103791|Experimental|Cohort 2|Docetaxel-PNP 35mg/m2
11535807|NCT01103791|Experimental|Cohort 3|Docetaxel-PNP 45mg/m2
11535808|NCT01103791|Experimental|Cohort 4|Docetaxel-PNP 60mg/m2
11535809|NCT01103791|Experimental|Cohort 5|Docetaxel-PNP 75mg/m2
11535810|NCT01103791|Experimental|Cohort 6|Docetaxel-PNP 90mg/m2
11535811|NCT01103778|Experimental|Velcade® therapy|Patients with greater than 1gm of proteinuria per day will receive Velcade®.
11535812|NCT01103765|Placebo Comparator|classic strategy|after drug-eluting stent(DES) deployment perform of Intravascular ultrasound analysis without post-dilatation
11535813|NCT01103765|Active Comparator|post-dilatation strategy|After drug-eluting stent (DES) deployment IVUS analysis and systematic post-dilatation with noncompliant balloon 0.25mm larger than stent balloon. After post dilatation new IVUS analysis.
11535814|NCT01103752||Surgery|This group (n=220) consist of patients undergoing hip or knee replacement in a fast-track setup and they are tested 3 times for postoperative cognitive dysfunction.
11535815|NCT01103739|Experimental|cohort 1|
11535816|NCT01103739|Experimental|cohort 2|
11535817|NCT01103726|Experimental|Stage 1|
11535818|NCT01103726|Experimental|Stage 2|
11535819|NCT01103713|Experimental|AZCQ|Azithromycin/Chloroquine
11535820|NCT01103687|Experimental|Ad26.ENVA.01 (rAd26)|Participants will receive the Ad26.ENVA.01 (rAd26) vaccine at baseline.
11535821|NCT01103687|Placebo Comparator|Placebo Vaccine|Participants will receive the placebo vaccine at baseline.
11535822|NCT01103674|Other|Numeris-AF Guided Coagulation System|
11535823|NCT01103661|Other|Numeris-AF Guided Coagulation System|
11535824|NCT01103648|Active Comparator|Simvastatin arm|A subset of individuals started the study period taking monotherapy with simvastatin. After a 12-week period, ezetimibe was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
11535825|NCT01103648|Active Comparator|Ezetimibe arm|A subset of individuals started the study period taking monotherapy with ezetimibe. After a 12-week period, simvastin was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
11535826|NCT01103648|Experimental|Simvastatin-Ezetimibe arm|To each subset of individuals which started the study period taking monotherapy with simvastatin or ezetimibe (active comparators), the other drug (ezetimibe or simvastatin, respectively) was combined for more 12 weeks (combination period = experimental arm).
11535827|NCT01103635|Experimental|Arm I|Patients receive tremelimumab over 1 hour on day 1 and CD40 agonist monoclonal antibody CP-870,893 IV over 30 minutes on days 2, 22, 43, and 64. Treatment repeats every 12 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11535828|NCT01103622|Experimental|1|twice daily Day 1 to Day 7; digoxin on day 4
11535829|NCT01103622|Placebo Comparator|2|twice daily Day 1 to Day 7; digoxin on day 4.
11535919|NCT01103050|Placebo Comparator|QAV680 Placebo + Cetirizine Placebo|
11535830|NCT01103609|Experimental|1|twice daily on Day 1 to Day 10, with Warfarin on Day 4
11535831|NCT01103609|Placebo Comparator|2|twice daily on Day 1 to Day 10, with Warfarin on Day 4
11535832|NCT01103596||HIV-infected patients, 1st wave|HIV-infected ARV-experienced patients treated by a combination including Kaletra
11535833|NCT01103596||HIV-infected patients, 2nd wave|HIV-infected ARV-experienced patients treated by a combination including Kaletra
11535834|NCT01103583|Experimental|Hydroxyurea|
11535835|NCT01103583|Placebo Comparator|Placebo|
11535836|NCT01103570|Experimental|group 1 cholecystocholangiography|cholangiography via gall bladder
11535837|NCT01103570|Experimental|group2 cystic duct cholangiography|cystic duct cholangiography
11535838|NCT01103544||Patients with advanced / metastatic TCCU after CDDP-failure|
11535839|NCT01103531|Experimental|Exercise Group|Participants in this group will be scheduled for 24 exercise training sessions over an 8-week period (three times weekly) and will be supervised by a certified exercise physiologist.
11535840|NCT01103531|Active Comparator|Education Group|Participants in this group will meet with a counselor who will present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
11535841|NCT01103518|Experimental|Combination 1|Ethinyl Estradiol + Cyproterone acetate
11535842|NCT01103518|Active Comparator|Combination 2|Ethinyl Estradiol + Cyproterone acetate
11535843|NCT01103505|Other|ForeseeHome AMD Monitoring Device|Participants in the device monitoring arm will receive a packed device at home, with instructions to install and connect the device to a modem as well as instructions for daily use of the device in addition to standard care
11535844|NCT01103505|No Intervention|Standard care alone (control) arm|Standard care instruction per clinic routine for home vision monitoring to detect progression of AMD and routine eye exams
11535845|NCT01103492|Experimental|Ablation catheter|Procedure using the HALO90 Ablation catheter to heat a thin layer of rectal tissue using radiofrequency to reduce inflammation and bleeding in subjects with radiation proctitis.
11535846|NCT01103479|No Intervention|Control|Participants will complete interviewer-administered pre- and post-test
11535847|NCT01103479|Experimental|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer screening guidelines, communication skills, and health literacy training
11535848|NCT01103479|Experimental|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational digital video disc (DVD) on CRC and CRC screening
11535849|NCT01103466|Active Comparator|New ostomy appliance (Atlas)|Atlas= new base plate. Due to company confidentiality the product is just called Atlas and this is not short for any other names
11535850|NCT01103466|Active Comparator|SenSura|Commercially available ostomy appliance
11535851|NCT01103466|Active Comparator|Conform 2|Commercially available ostomy appliance
11535852|NCT01103453|Experimental|Intervention Group|Study group are persons diagnosed as suffering from Mild Cognitive Impairment will undergo a series of 9 sessions on a computer program of a virtual supermarket to improve their Executive and IADL functions.
11535853|NCT01103440|Other|Conventional Strategy|Patient receive 325 mg ASA orally and loading does of 600mg Clopidogrel at time of procedure
11535854|NCT01103440|Active Comparator|Aggressive Strategy|Patient receive 325mg ASA orally and loading does of 600mg Clopidogrel at time of procedure with addition of IV GP IIb/IIIa inhibitor bolus intra procedurally
11535855|NCT01103427|Active Comparator|Internet-based coaching .|"Arm 1. Those in the active comparator arm will benefit from automated internet-based coaching. The subjects will be recruited from the general population reporting not to be associated with the University Hospital of North Norway and randomized to arm 1 or 2."
11535856|NCT01103427|Experimental|SMS based coaching|"Arm 2. The subjects will receive automated coachingby SMS.The subjects will be recruited from the general population reporting not to be associated with the University Hospital of North Norway and randomized to arm 1 or 2."
11535857|NCT01103427|Experimental|SMS coaching UNN recruited|Arm 3.The subjects will be recruited from those reporting to be associated with the University Hospital of North Norway and randomized to arm 3 or 4.
11535858|NCT01103427|Experimental|Craving/Panic function. UNN recruited|"Arm 4. The subjects will in addition to the automated coachingby SMS get a SMS panic/craving function. The subjects will be recruited from subjects reporting to be associated with the University Hospital of North Norway and randomized to arm 3 or 4."
11535859|NCT01103414|Experimental|Mitoglitazone 50 mg capsules|Mitoglitazone 50 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
11535860|NCT01103414|Experimental|Mitoglitazone 100 mg capsules|Mitoglitazone 100 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
11535861|NCT01103414|Experimental|Mitoglitazone 150 mg capsules|Mitoglitazone 150 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
11535862|NCT01103414|Active Comparator|Pioglitazone 45 mg capsules|Pioglitazone 45 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
11535863|NCT01103414|Placebo Comparator|Matching placebo|Placebo capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
11535864|NCT01103401|Active Comparator|Tobramycin/Dexamethasone|
11535865|NCT01103401|Active Comparator|Tobramycin/Dexamethasone plus Ketorolac tromethamine|
11535866|NCT01103388|Experimental|Rituximab|
11535867|NCT01103388|No Intervention|No Rituximbab|
11535868|NCT01103375|Experimental|Treatment (enzyme inhibitor, immunotherapy)|Patients receive isotretinoin PO QD on days 1-21 and erlotinib hydrochloride PO QD on days 1-28.
11535869|NCT01103362|Experimental|flibanserin 100mg|flibanserin 100mg po qd
11535870|NCT01103349|Experimental|BI671800|Patients receive BI671800 capsules twice daily
11535871|NCT01103349|Active Comparator|Montelukast|Patients receive Montelukast encapsulated tablets once daily
11535872|NCT01103349|Placebo Comparator|Placebo|Patients receive placebo capsules and/or encapsulated placebo tablets
11535873|NCT01103336|Experimental|Nicorandil in saline|
11535874|NCT01103336|Placebo Comparator|saline|
11535875|NCT01103323|Experimental|Regorafenib (Stivarga, BAY73-4506)+BSC|Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care(BSC).
11535876|NCT01103323|Placebo Comparator|Placebo+BSC|Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care (BSC).
11535877|NCT01103310|Experimental|Arm 1|Cancer patients, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, PET/CT
11535878|NCT01103310|Experimental|Arm 2|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY94-9392 in blood
11535879|NCT01103297|Other|Variable Angle Distal Radius Plate|
11535880|NCT01103284|Experimental|DiaPep277|Administration of 1 mg DiaPep277®, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.
11535881|NCT01103284|Placebo Comparator|Placebo|Administration of placebo, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.
11535882|NCT01103271|Experimental|Open-label Placebo Immediate Treatment|Participants will begin taking placebo pills for four weeks immediately after enrolling in the study.
11535883|NCT01103271|Placebo Comparator|Open-label Placebo Waitlist Treatment|Participants will wait two weeks after enrolling in the study to begin taking placebo pills for four weeks.
11535884|NCT01103258|Active Comparator|high ligation and stripping|surgery consisting of high ligation in combination with long saphenous stripping
11535885|NCT01103258|Active Comparator|duplex guided foam sclerotherapy|duplex guided foam sclerotherapy
11535886|NCT01103245|Active Comparator|HCTZ plus ALI 150 then ALI 300|"Hydrochlorothiazide (HCTZ) 12.5mg daily for 1 month
~then HCTZ 12.5mg daily plus Aliskiren 150 mg (ALI 150) daily for 1 month
~then HCTZ 12.5mg daily plus Aliskiren 300mg ((ALI 300) for 1 month"
11535887|NCT01103245|Active Comparator|HCTZ plus ALI 150 then ALI 150 and SPL 25|"HCTZ 12.5mg daily for 1 month
~then HCTZ 12.5mg daily plus Aliskiren 150 mg daily for 1 month
~then HCTZ 12.5mg daily plus Aliskiren 150 mg daily and Spironolactone 25mg (SPL 25) daily for one month"
11535888|NCT01103245|Active Comparator|HCTZ plus SPL 25 then SPL 50|"HCTZ 12.5mg daily for 1 month
~then HCTZ 12.5mg daily plus Spironolactone 25 mg (SPL 25) daily for 1 month
~then HCTZ 12.5mg daily plus Spironolactone 50 mg daily for one month"
11535889|NCT01103245|Active Comparator|HCTZ plus SPL 25 then ALI 150 and SPL 25|"HCTZ 12.5mg daily for 1 month
~then HCTZ 12.5mg daily plus Spironolactone 25 mg daily for 1 month
~then HCTZ 12.5mg daily plus Aliskiren 150 mg daily and Spironolactone 25 mg daily for one month"
11535890|NCT01103232|Experimental|Electrical Muscle Stimulation|Electrical muscle stimulation of the right wrist flexor muscles was applied
11535891|NCT01103232|Sham Comparator|Control|Transcutaneous electrical nerve stimulation was applied
11535892|NCT01103219|Placebo Comparator|Control|Participants in this group will receive nutrition from birth and during the hospital stay until discharge according to the routines of the participating institutions.
11535893|NCT01103219|Active Comparator|Intervention|The participants in this group will receive increased supply of energy, protein, vitamin A, docosahexaenoic acid, and arachidonic acid from birth and during the hospital stay until discharge.
11535894|NCT01103206|Experimental|Control group|Parathyroid hormone suppression tests using successively (each test will be separate for a two week period) an intravenous calcium loading or cinacalcet will be performed in a group of 12 healthy volunteers.
11535895|NCT01103206|Experimental|Primary hyperparathyroidism dose I|Parathyroid hormone suppression test using the first dose of cinacalcet in patients with primary hyperparathyroidism.
11535896|NCT01103206|Experimental|Primary hyperparathyroidism dose II|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
11535897|NCT01103193|Active Comparator|remifentanil injected|a mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
11535898|NCT01103193|Active Comparator|sevoflurane in step up concentration|a mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
11535899|NCT01103180|Experimental|Escitalopram|10-20 mg of escitalopram for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
11535900|NCT01103180|Placebo Comparator|Placebo|Inert placebo (sugar pill) taken daily for eight weeks
11535901|NCT01103154|Active Comparator|Carvedilol|carvedilol 6.25mg per day
11535902|NCT01103154|Active Comparator|N+I|nadolol 40mg per day, ISMN 10 mg per day
11535903|NCT01103141|Active Comparator|Micropuncture|
11535904|NCT01103141|Active Comparator|Standard|
11535905|NCT01103115|Placebo Comparator|Placebo|Subjects in this group will take the placebo tablets
11535906|NCT01103115|Active Comparator|Ca600mg+VitD400IU|subjects receive a daily dose of 600 mg elemental calcium and 400 IU vitamin D3
11535907|NCT01103115|Active Comparator|Ca600mg+VitD800IU|subjects receive a daily dose of 600 mg elemental calcium and 800 IU vitamin D3
11535908|NCT01103102|Active Comparator|Lowest Dose|
11535909|NCT01103102|Active Comparator|Intermediate Dose|
11535910|NCT01103102|Active Comparator|Highest Dose|
11535911|NCT01103102|Placebo Comparator|Placebo Control|
11535912|NCT01103076|Active Comparator|Polyamide 210 H|Chronic HD patients will be treated in random order with either polyamide or HCO membranes (Polyflux 210 H or HCO 1100) for one month (12 HD sessions) before the crossover.
11535913|NCT01103076|Experimental|HCO 1100|Chronic HD patients will be treated in random order with either polyamide or HCO membranes (Polyflux 210 H or HCO 1100) for one month (12 HD sessions) before the crossover.
11535914|NCT01103063|Experimental|AZCQ|Azithromycin/chloroquine
11535915|NCT01103063|Active Comparator|SP|sulfadoxine-pyrimethamine (Fansidar)
11535916|NCT01103050|Active Comparator|QAV680 + Cetirizine Placebo|
11535917|NCT01103050|Experimental|QAV680 + Cetirizine|
11535921|NCT01103037|Placebo Comparator|QAV680 Placebo|
11535922|NCT01103024|Experimental|AIN457 300mg s.c every 2 weeks|
11535923|NCT01103024|Experimental|AIN457 300mg s.c every 4 weeks|
11535924|NCT01103024|Experimental|AIN457 150mg s.c every 4 weeks|
11535925|NCT01103024|Placebo Comparator|Placebo s.c every 2 weeks|
11535926|NCT01103011|Experimental|ND0611 dose 1, ND0611 dose 2, placebo|
11535927|NCT01102998||Brain Tumor Survivors|Brain tumor survivors ages 8 to 18 years who are at least 5 years post diagnosis and at least 2 years post active therapy or observation and their parents/guardians will be approached to participate during clinic visits.
11535928|NCT01102985|Experimental|aerobic resistance|12 month aerobic resistance exercise at a fitness center
11535929|NCT01102985|Active Comparator|home based physical activity|national recommendations for physical activity for adults
11535930|NCT01102972|Experimental|ATV + ABC/3TC|Subjects will change to ATV 400mg administered as two 200mg capsules orally, once daily and to the fixed-dose combination tablet of ABC 600mg/3TC 300mg (EPZICOM) administered as one tablet orally, once daily for 48 weeks. The subject's pre-study RTV will be discontinued.
11535931|NCT01102972|Active Comparator|ATV + RTV + TDF/FTC|Subjects will continue their pre-study therapy, un-modified, of ATV 300mg administered as one capsule orally, once daily plus RTV 100mg administered orally, once daily plus fixed dose combination tablet tenofovir 300mg/emtricitabine 200mg administered as one tablet orally, once daily for 48 weeks.
11535932|NCT01102959|Experimental|Photographic Material|Photographic Educational Material on Carbohydrate Counting
11535933|NCT01102946|Experimental|PRP plus ranibizumab|Patients will be submitted to panretinal photocoagulation plus intravitreal injections of ranibizumab
11535934|NCT01102946|Active Comparator|PRP|Patients will only be submitted to panretinal photocoagulation
11535935|NCT01102933||Unselected post-myocard infarct patients|Patients diagnosed with MI at Uppsala University Hospital
11535936|NCT01102920|Experimental|Tailored behavioural treatment and CPAP|Tailored behavioural treatment targeting physical activity and eating habits.
11535937|NCT01102920|Active Comparator|CPAP-treatment|CPAP-treatment as usual. Advice about benefits of physical activity and weight loss.
11535938|NCT01102907||Liquid Meal|
11535939|NCT01102907||Solid Meal|
11535940|NCT01102894|Experimental|Low fiber and High Fiber|Subjects consume a low fiber cereal and swallow the SmartPill device that measures gastrointestinal transit time Subjects consume a high fiber cereal along with swallowing the SmartPill device that measures gastrointestinal transit time
11535941|NCT01102881|Placebo Comparator|No fiber|No fiber added to muffins or cereal
11535942|NCT01102881|Experimental|Fiber made from corn starch|Muffins and cereal made with novel corn fiber
11535943|NCT01102881|Experimental|Glucose polymer fiber|Muffins and cereal made from glucose polymer fiber
11535944|NCT01102868|Sham Comparator|Needle in acupuncture point Li11|Acupuncture needle in the acupuncture point Li11
11535945|NCT01102868|Experimental|IMS of musculus pronator teres|Acupuncture needle in musculus pronator teres
11535946|NCT01102816|Experimental|Individualized acupuncture|
11535947|NCT01102816|No Intervention|Routine care|
11535948|NCT01102803|Placebo Comparator|Sugar Pill|Participants will receive placebo augmented cognitive behavioral therapy
11535949|NCT01102803|Experimental|D-Cycloserine|Participants will receive D-Cycloserine augmented cognitive behavioral therapy
11535950|NCT01102777|Other|Usual Care|Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
11535951|NCT01102777|Other|Internet-mediated Walking Program|"participants in the intervention arm are asked to participate in a walking program
~automated internet-mediated walking program: intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress"
11535952|NCT01102764|Experimental|Arm 1: PE via telemedicine|PE via telemedicine
11535953|NCT01102764|Active Comparator|Arm 2: PE in person|PE in person
11535954|NCT01102751||Vitamin D deficient females|(n =18, mean age 29.1±9.9 yrs)
11535955|NCT01102751||vitamin D sufficient healthy females|(control group; n = 19, mean age 28.5±5.2 yrs)
11535956|NCT01102751||genetically-determined hypophosphatemic rahitis|(n=13, mean age 26.5±15.1 yrs)
11535957|NCT01102738||Premature babies (<32 weeks)|All premature babies born at less than 32 completed weeks gestation who are admitted to an Imperial College NHS Healthcare Trust Neonatal Intensive Care Unit (St. Mary's Hospital or Queen Charlotte's & Chelsea Hospital), and whose parents/guardians have given their consent will be eligible to enter the study.
11535958|NCT01102725||Colorectal Surgery|Subject who are undergoing a colon or rectal resection
11535959|NCT01102712|Experimental|BTVA|
11535960|NCT01102699|Experimental|Filgrastim, G-CSF|Single s.c. dose of G-CSF (300 microg)
11535961|NCT01102686|Experimental|Pyrimethamine|
11535962|NCT01102673|Experimental|PF-04991532|This will be a crossover study with 2 cohorts and an interleaving design with placebo substitution. The study will be conducted over 4 treatment periods in Cohort 1 (n=9) and over 3 treatment periods in Cohort 2 (n=9). Six subjects will be allocated to receive PF-04991532 and three subjects will be allocated to receive placebo treatment during each dosing period, except for the 4th period of Cohort 1. The 4th period of Cohort 1 will be dedicated to assess the effect of food on PF-04991532 PK parameters at one of the doses previously tested in Cohort 1; hence all 9 subjects will be dosed with PF-04991532 in an open-label fashion. A washout period of at least 7 days will occur between each dose.
11535963|NCT01102673|Placebo Comparator|Placebo|This will be a crossover study with 2 cohorts and an interleaving design with placebo substitution. The study will be conducted over 4 treatment periods in Cohort 1 (n=9) and over 3 treatment periods in Cohort 2 (n=9). Six subjects will be allocated to receive PF-04991532 and three subjects will be allocated to receive placebo treatment during each dosing period, except for the 4th period of Cohort 1. The 4th period of Cohort 1 will be dedicated to assess the effect of food on PF-04991532 PK parameters at one of the doses previously tested in Cohort 1; hence all 9 subjects will be dosed with PF-04991532 in an open-label fashion. A washout period of at least 7 days will occur between each dose.
11535964|NCT01102660|Other|Treatment Sequence 1|
11535965|NCT01102660|Other|Treatment Sequence 2|
11535966|NCT01102660|Other|Treatment Sequence 3|
11535967|NCT01102660|Other|Treatment Sequence 4|
11535968|NCT01102647|Experimental|Phytosterol ester|Plant sterol compared with placebo
11535969|NCT01102634|Experimental|Acu-TENS|Application of TENS over acupuncture points
11535970|NCT01102634|Placebo Comparator|Placebo-TENS|Application of Acu-TENS but with no electricity
11535971|NCT01102621||case-control, head and neck cancer with radiotherapy|The group of exposed individuals had to be patients with disease-free survival interval of at least two years subsequent to treatment for head and neck cancer by means of radiotherapy alone or in combination, in which the auditory system was included in the field of irradiation.
11535972|NCT01102621||case-control, head an neck cancer without radiotherapy|The group of non-exposed individuals (control group) had to be patients who had not undergone oncological treatment that put their hearing at risk and who were age-matched (2 years). This group was formed by individuals who had had pelvic tumors or skin tumors and who had only undergone local surgery to remove their tumors, and by female volunteers from the hospital. All of these individuals were asked whether they would be willing to participate in a study, without knowing in advance whether they had any previous hearing problems or complaints.
11535973|NCT01102608|Experimental|1|
11535974|NCT01102595|Experimental|1: Temozolomide plus Radiation|"Group 1:
~Neoadjuvant phase: Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.
~Adjuvant phase: Temozolomide 75 mg/m2/d x 42-49 days with standard radiation therapy (60 Gy).
~Maintenance phase: Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
11535975|NCT01102595|Experimental|2: Temozolomide plus Radiation plus Bevacizumab|"Neoadjuvant phase: Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles + bevacizumab 10 mg/kg every 15 days.
~Adjuvant phase: Temozolomide 75 mg/m2/d x 42-49 days with standard radiation therapy (60 Gy) + bevacizumab 10 mg/kg every 15 days.
~Maintenance phase: Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
11535976|NCT01102569||Pancreatic cancer and Ashkenazi decent|Patients with pancreatic cancer will be asked to join the study if they identify themselves as being of Ashkenazi descent, as well as patients at a high-risk of pancreas cancer based on family history, and will be followed from the time of diagnosis.
11535977|NCT01102556||Surgery Patients/High-risk Patients|Patients who have undergone surgery for pancreatic cancer or pre-neoplastic lesions of the pancreas will be accrued to the study. In addition, patients who are determined to be at high-risk for pancreatic cancer (with a significant family history) will also be recruited for study enrollment.
11535978|NCT01102543||Premature babies < 28 GA|
11535979|NCT01102543||Premature babies > 28 & < 32 weeks GA|
11535980|NCT01102517|Experimental|VATS group|video-assisted thoracoscopic surgery
11535981|NCT01102517|Other|axillary thoracotomy|Control group
11535982|NCT01102504|Experimental|Tomato extract (Ateronon)|Supplementation of tomato extract containing 28 mg/day for 12 months in addition to routine treatment.
11535983|NCT01102504|Placebo Comparator|Placebo|Placebo
11535984|NCT01102491|Experimental|Ramosetron prophylaxis|ramosetron prophylaxis at the end of surgery with starting PCA and 1 day after surgery
11535985|NCT01102491|No Intervention|Control|no antiemetic prophylaxis
11535986|NCT01102452|Placebo Comparator|Commercially Available Wet Noodle|Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
11535987|NCT01102452|Experimental|PPB-R-203-02 Noodle|PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
11535988|NCT01102439|Active Comparator|Standard dose clopidogrel|300 mg Loading x 1 day, 75 mg/d x 13 days
11535989|NCT01102439|Experimental|Double dose clopidogrel|600 mg Loading x 1 day, 150 mg/d x 6 days, 75 mg/d x 7 days
11535990|NCT01102439|Active Comparator|Standard dose aspirin|Aspirin 81mg/d x 14 days
11535991|NCT01102439|Experimental|High dose aspirin|Aspirin 325 mg/d x 14 days
11535992|NCT01102426|Experimental|Plitidepsin+Dexamethasone|plitidepsin + dexamethasone combination
11535993|NCT01102426|Active Comparator|Dexamethasone|dexamethasone single agent
11535994|NCT01102413|Experimental|Monofer|Injections or infusions
11535995|NCT01102413|Active Comparator|Iron Sulphate|Oral intake
11535996|NCT01102400|Experimental|1|
11535997|NCT01102387|Experimental|LAS41003|
11535998|NCT01102387|Active Comparator|LAS189962|
11535999|NCT01102387|Active Comparator|LAS189961|
11536000|NCT01102374|Experimental|High Dose Vitamin D|100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
11536001|NCT01102374|Active Comparator|Standard Dose Vitamin D|12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
11536002|NCT01102361|Experimental|Transperineal Biopsy|Biopsy of the prostate using transperineal approach
11536003|NCT01102348|Experimental|PEP-uP Protocol (after)|PEP-uP protocol and treatment algorithm implemented for all patients in ICU.
11536004|NCT01102348|No Intervention|Standard feeding protocol (before)|Enteral feeds are guided by a standard feeding protocol specified by pre-printed ICU admission orders. The admitting physician has the option of initiating the enteral feeding protocol or keeping the patient nil per os (NPO).
11536005|NCT01102335|Experimental|Telbivudine|
11536006|NCT01102335|Active Comparator|TACE only|
11536007|NCT01102322||1|
11536008|NCT01102309|Experimental|Experimental Group (EG)|Group assigned to robot plus conventional therapy
11536009|NCT01102309|Active Comparator|Control Group (CG)|Group assigned to conventional therapy only
11536010|NCT01102296|Active Comparator|male homosexuals|HIV-uninfected male homosexuals will be provided 2 doses of HAV vaccine, which will be administered at baseline and 6th month of follow-up.
11536011|NCT01102296|Active Comparator|HIV-infected male homosexuals, group1|HIV-infected male homosexuals will be provided 3 doses of HAV vaccine, which will be administered at baseline, 1st, and 6th month of follow-up.
11536012|NCT01102296|Active Comparator|HIV-infected male homosexuals, group 2|HIV-infected male homosexuals will be provided 2 doses of hepatitis A vaccine, which will be administered at baseline and 6th month of follow-up.
11536013|NCT01102283||Stent Group|
11536014|NCT01102270|Active Comparator|Eszopiclone|Eszopiclone 3mg prior to sleep (1 night)
11536015|NCT01102270|Placebo Comparator|Sugar Pill|Sugar Pill (placebo) prior to sleep (1 night)
11536016|NCT01102257|Experimental|Omega-3 EFA Supplement|"The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 esssential fatty acid i.e Omega-3 EFA supplement comprised of:
~2000 mg EPA 1000 mg DHA"
11536017|NCT01102257|Placebo Comparator|Olive Oil|Gel Capsule
11536018|NCT01102244|Experimental|Tobradex ST|tobramycin 0.3%, dexamethasone 0.05%
11536019|NCT01102244|Active Comparator|Azasite|azithromycin 1%
11536020|NCT01102231|Experimental|A|Chemoradiotherapy
11536021|NCT01102218|Experimental|erythropoietin plus pentoxifylline|
11536022|NCT01102218|Active Comparator|erythropoietin alone|
11536023|NCT01102205||healthy|
11536024|NCT01102205||euthyroid hashimoto|
11536025|NCT01102205||hypothyroid hashimoto|
11536026|NCT01102192||Myasthenia gravis with thymoma|Myasthenia gravis with thymoma
11536027|NCT01102192||Myasthenia gravis without thymoma|Myasthenia gravis without thymoma
11536028|NCT01102192||Thymoma without Myasthenia gravis|Thymoma without Myasthenia gravis
11536029|NCT01102192||cardiac, or thyroid surgery|cardiac, or thyroid surgery
11536030|NCT01102179||Chronic kidney disease|"All patients with stage 2-5 (pre-dialysis) chronic kidney disease
~One-time blood draw (10 ml)"
11536031|NCT01102153||Coolgard|invasive cooling
11536032|NCT01102153||ArcticSun|non-invasive (surface) cooling
11536033|NCT01102140|Active Comparator|POMx|15 subjects will received 1000 mg of oral POMx for 12 weeks.
11536034|NCT01102140|Placebo Comparator|Control- sugar Pill|15 subjects will receive a matching sugar pill for 12 weeks.
11536035|NCT01102127||Goiter|Patients with nodular goiter
11536036|NCT01102114|Placebo Comparator|Placebo Vaccine|
11536037|NCT01102114|Experimental|NicVAX Vaccine|
11536038|NCT01102088|Experimental|Radiation + Chemotherapy|"Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.
~For the phase II part of the study once the MTD has been achieved proton therapy will be allowed. Treatment dose will be identical to that of the photon treatment where the PTV is treated to 50.4 Gy(RBE) (RBE=1.1) while the CTV is boosted to 63 Gy(RBE) in 28 fractions.
~Chemotherapy Administration: Schedule of chemotherapy, and modifications of chemotherapy drugs during chemoradiation treatment will be at the discretion of the treating medical oncologist per their standard of practice and with consideration to standard chemotherapy drugs in the treatment of esophageal cancer."
11536039|NCT01102075|Experimental|Electroacupuncture|The Electroacupuncture therapy protocol included a total of 12 acupuncture points at the CV12,CV6, bilateral ST25, SP15, SP14,LI4, LI11, ST36, ST44. All acupuncture points were prepared with 70% alcohol pads, and disposable stainless steel needles were used. Abdominal acupuncture points were inserted horizontally 6~6.5cm in depth and the others were inserted vertically 2~2.5cm in depth until patient can feel De-Qi. All acupuncture points were stimulated electrically with a frequency of 24 Hz an intensity of 0.27-1.3mA(tolerable strength) with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks by practitioner who had had 6 years of acupuncture training and 3 more years of clinical experience.
11536040|NCT01102075|Sham Comparator|Sham electroacupuncture procedure|The Sham electroacupuncture therapy protocol(Non-acupoint, No electrical stimulation)included the same number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment, but superficially at non acupuncture points 15 mm to the lateral of each acupuncture point was treated. The points were not stimulated electrically, but the sound of the pulse generator was heard by the participants. (Lee SH, LeeBC 2009) Those receiving EA or SEA therapy were treated on alternate days to prevent crosstalk among groups, which could have compromised the blinded study design.
11536041|NCT01102075|No Intervention|Waiting list|No treatment was done for waiting group, but could receive same treatments as Electroacupuncture group after the end of trial.
11536042|NCT01102062|Experimental|Orange Juice|1 glass (=200mL) of orange juice
11536043|NCT01102049|Experimental|self-administered food intake|self-administered food intake according to dietary protocol
11536044|NCT01102036|Placebo Comparator|Yoghurt without probiotics|Yoghurt without probiotic bacteria
11536045|NCT01102036|Active Comparator|Cultura yoghurt|Cultura yoghurt with L casei F19, acidophilus La5 adn B lactis Bb 12
11536046|NCT01102023|Experimental|solar salt based-diet|
11536047|NCT01102010|Experimental|Blood transfusion|"Restrictive strategy: Blood transfusion when hemoglobin is less than 6 mmol/l (9.7 g/dl)
~Liberal strategy: Blood transfusion when hemoglobin is less than 7 mmol/l (11.3 g/dl)"
11536048|NCT01101984|Experimental|DE-089|DE-089 ophthalmic solution
11536049|NCT01101984|Active Comparator|HA|0.1% sodium hyaluronate ophthalmic solution
11536050|NCT01101971|Experimental|first year medical students|
11536051|NCT01101958|Other|Chartis System-EBV Treatment|Subjects with heterogeneous emphysema, had their collateral ventilation status in the target treatment lobe assessed using the Chartis System (CV- or CV+) and underwent endobronchial lung volume reduction (ELVR) with endobronchial valves (EBV).
11536052|NCT01101932|Experimental|(Part 1) PF-04308515|
11536053|NCT01101932|Placebo Comparator|(Part 1) Solution Placebo|
11536054|NCT01101932|Experimental|(Part 2) PF-04308515 Tablet|
11536055|NCT01101919|Experimental|CP-690,550 Dose Group|
11536056|NCT01101906|Experimental|Arm A: OSI-906|150 mg BID
11536057|NCT01101906|Placebo Comparator|Arm B: Placebo|Placebo BID
11536058|NCT01101893|Experimental|Period 1|In period 1 all subjects will receive Raltegravir 400mg q12h from Day 1 to Day 5
11536059|NCT01101893|Experimental|Period 2|In period 2 all subjects will receive GSK2248761 200mg q24h from Day 1 to Day 5.
11536060|NCT01101893|Experimental|Period 3|Day 1 of Period 3 will be the day after Day 5 of Period 2. Subjects will receive GSK2248761 200mg q24h + raltegravir 400mg q12h from Day 1 to Day 5.
11536061|NCT01101880|Experimental|Treatment (chemotherapy and colony stimulating factor)|"INDUCTION THERAPY: Patients receive filgrastim SC daily beginning the day prior to chemotherapy and continuing until blood counts recover. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 5 days.
~CONSOLIDATION THERAPY: Patients receive filgrastim SC daily for 5 days beginning the day prior to chemotherapy. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 4 days.
~Treatment with induction therapy may continue for up to 2 courses and treatment with consolidation therapy may continue for up to 3 courses in the absence of disease progression or unacceptable toxicity."
11536062|NCT01101867|Experimental|Aspart flexible dose|aspart dose determined based upon carbohydrate intake.
11536063|NCT01101867|Active Comparator|Aspart fixed dose|fixed meal dose of aspart (based upon weight or total daily insulin dose)
11536064|NCT01101841|Experimental|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate)
11536065|NCT01101841|Placebo Comparator|Placebo capsules|Sugar pill
11536066|NCT01101815|Active Comparator|Oral Naltrexone + ART|Naltrexone (oral). 50 mg maintenance daily for 48 weeks, plus group drug counseling manual driven, N= 100
11536067|NCT01101815|Active Comparator|Naltrexone Implant + ART|Naltrexone Implant + ART. Monthly maintenance for 48 Weeks plus, group drug counseling manual driven, N=100
11536068|NCT01101802|Active Comparator|Mycophenolate mofetil|Patients were given 1gm bd mycophenolate mofetil for 8 weeks
11536069|NCT01101802|Placebo Comparator|Sugar pill|
11536070|NCT01101789|Active Comparator|triclosan|triclosan-coated sutures
11536071|NCT01101789|Placebo Comparator|control|sutures without triclosan-coating
11536072|NCT01101763||All Subjects|Healthy males
11536073|NCT01101737|No Intervention|Usual care|Patients not invited to the nurse-led clinic will continue with usual GP care
11536074|NCT01101737|Experimental|Nurse-led blood pressure clinic|Patients randomly allocated to the intervention will be invited to a specialist nurse-led blood pressure clinic.
11536075|NCT01101724|No Intervention|Standard of Care|In this group, the treating attending physician will be free to make rest recommendations as they see fit. An internal survey of physician practice found that the vast majority of physicians instruct patients rest for 1-2 days, then to return to school and physical activity after the patient's symptoms have resolved. The amount of rest will vary from patients to patient based on variation in symptom resolution and patient compliance. This advice is consistent with best practices outlined by the CDC.
11536076|NCT01101724|Experimental|Intervention|Mandated Rest.
11536077|NCT01101711||Patients with subarachnoid hemorrhage|
11536078|NCT01101698|Active Comparator|Vitamin K2, calcification score changes, vitamin D|90 μg vitamin K2+10μg cholecalciferol
11536079|NCT01101698|Active Comparator|Vitamin D, calcium score changes|10μg cholecalciferol (vitamin D)
11536080|NCT01101685|Active Comparator|Escitalopram|7 days dosing at 10mg per day
11536081|NCT01101685|Placebo Comparator|Placebo|7 days dosing at 10mg daily
11536082|NCT01101672|Experimental|Single-port laparoscopic colectomy|
11536083|NCT01101672|Active Comparator|Conventinal laparoscopic colectomy|
11536084|NCT01101659|Experimental|001|JNJ-40411813 500 mg as 20 mL of oral suspension single dose
11536085|NCT01101659|Placebo Comparator|002|Placebo 20 mL of oral suspension single dose
11536086|NCT01101659|Other|003|ketamine Ketanest S. vials of 20 ml with 5 mg/ml diluted with saline to 0.02 mg Ketamine per mL and per kg bodyweight of the volunteer
11536087|NCT01101659|Other|004|normal saline infusion 0.5 mL /min over 90 minutes
11536088|NCT01101646|Experimental|001|rabeprazole sodium four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
11536089|NCT01101646|Experimental|002|rabeprazole sodium two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
11536090|NCT01101646|Experimental|003|rabeprazole sodium four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
11536091|NCT01101633|Active Comparator|1|500 ml beverage containing alginate (3%)
11536092|NCT01101633|Active Comparator|2|330 ml beverage containing alginate (3%)
11536093|NCT01101633|Placebo Comparator|3|500 ml beverage without alginate (placebo)
11536094|NCT01101633|Placebo Comparator|4|330 ml beverage without alginate (placebo)
11536095|NCT01101620|Active Comparator|Levosimendan|
11536096|NCT01101620|Placebo Comparator|Placebo|
11536097|NCT01101607|Active Comparator|Pediatric Emergency Physician|Patients randomized to Pediatric Emergency Physician Group will have their fracture reduced by a Pediatric Emergency Physician
11536098|NCT01101607|Active Comparator|Orthopaedic physician|Patients to be randomized to Orthopaedic physician Group will have their fracture reduced by an Orthopaedic Physician
11536099|NCT01101594|Experimental|hLL1-DOX|4 Different dose levels of hLL1-DOX will be studied in groups of 3-6 patients. Once an optimal dose has been found, up to additional 30 patients will be studied at that dose level.
11536100|NCT01101581|Experimental|Veltuzumab and 90Y-Epratuzumab Tetraxetan|Veltuzumab and 90Y-Epratuzumab Tetraxetan target different b-cells. Veltuzumab will be administered in all 4 weekly study drug treatments. 90Y-Epratuzumab Tetraxetan will be administered only on days 8 & 15. The dose of veltuzumab remains the same for all patients.
11536101|NCT01101581|Experimental|90Y-epratuzumab tetraxetan|90Y-epratuzumab tetraxetan will be administered 6 mCi/m2 on days 8 and 15.
11536102|NCT01101568|Experimental|Single Sequence|Simvastatin will be administered on Day 1 and Day 10. Rosuvastatin will be administered on Day 3 and Day 12. GSK1292263 will be administered on Days 6 to 14.
11536103|NCT01101555|Experimental|COHORT 1: CUMULATIVE DOSE 1.5MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 3 days, dose 0.3, 0.5, 0.7, four patients in cohort, one of which is on placebo, escalation increment N/A
11536104|NCT01101555|Experimental|COHORT 2: CUMULATIVE DOSE 3.5MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 0.3, 0.5, 0.7, 1.0, 1.0 four patients in cohort, one of which is on placebo, escalation increment 2.3 fold.
11536105|NCT01101555|Experimental|COHORT 3: CUMULATIVE DOSE 6.0MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 7 days, dose 0.3, 0.7, 5 x 1.0 four patients in cohort, one of which is on placebo, escalation increment 1.7 fold.
11536193|NCT01101009|Active Comparator|Perindopril+amlodipine|
11536194|NCT01101009|Active Comparator|Olmesartan/amlodipine|
11536106|NCT01101555|Experimental|COHORT 4: CUMULATIVE DOSE 8.0MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 0.3, 0.7, 1.0, 2 x 3.0 four patients in cohort, one of which is on placebo, escalation increment 1.33 fold.
11536107|NCT01101555|Experimental|COHORT 5: CUMULATIVE DOSE 10MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 10 days, dose 10 x 1.0 four patients in cohort, one of which is on placebo, escalation increment 1.25 fold.
11536108|NCT01101555|Experimental|COHORT 6: CUMULATIVE DOSE 15MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 15 days, dose 15 x 1.0 six patients in cohort, one of which is on placebo, escalation increment 1.5 fold.
11536109|NCT01101555|Experimental|COHORT 7: CUMULATIVE DOSE 15MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 5 x 3.0 six patients in cohort, one of which is on placebo, escalation increment N/A
11536110|NCT01101542||Cervarix Group|Subjects received 3 doses of the Cervarix vaccine. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0,1, 6 month vaccination schedule. According to the prescribing information, if flexibility in the vaccination schedule is necessary, the second dose can be administered between 1 month and 2.5 months after the first dose.
11536111|NCT01101529|Placebo Comparator|Standard antiemetic therapy plus placebo|Standard anti-emetic prophylaxis consisting of 1/dexamethasone 6 mg daily during the chemotherapy days and 2/tropisetron (Navoban)5 mg daily during chemotherapy and 2 days after
11536112|NCT01101529|Experimental|aprepitant (Emend)|Aprepitant given orally 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after as an addition to standard antiemetic therapy as in the placebo arm.
11536113|NCT01101503|Experimental|Intensive multifactorial group|Intensive multifactorial therapy group receive intensive blood glucose, blood pressure and blood lipids control.
11536114|NCT01101503|Experimental|conventional multifactorial therapy group|Conventional multifactorial therapy group receive conventional blood glucose, blood lipids and blood lipids control to the local targets.
11536115|NCT01101477|Active Comparator|Titration by target effect site concentration (Cet) 0.5μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
11536116|NCT01101477|Active Comparator|Titration by Cet 0.2μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
11536117|NCT01101477|Active Comparator|Titration by Cet 0.1μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
11536118|NCT01101464|Experimental|Asenapine Sequence 1|
11536119|NCT01101464|Experimental|Asenapine Sequence 2|
11536120|NCT01101451|Active Comparator|Arm I (EBRT, IMRT)|Patients undergo pelvic EBRT or IMRT once daily, 5 days a week, for 5.5 weeks.
11536121|NCT01101451|Experimental|Arm II (cisplatin, EBRT, IMRT)|Patients receive cisplatin IV over 1-2 hours on day 1 and undergo radiotherapy as in Arm I. Treatment with cisplatin repeats every 7 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11536122|NCT01101438|Experimental|Arm I|Patients receive oral metformin hydrochloride twice daily (once daily in weeks 1-4). Treatment continues for up to 5 years in receptor positive (ER and/or PgR positive) subjects in the absence of disease progression or unacceptable toxicity.
11536123|NCT01101438|Placebo Comparator|Arm II|Patients receive oral placebo twice daily (once daily in weeks 1-4). Treatment continues for up to 5 years in receptor positive (ER and/or PgR positive) subjects in the absence of disease progression or unacceptable toxicity.
11536124|NCT01101412|Experimental|Arm I: Antimicrobial Solution|Antimicrobial solution into central or peripheral venous catheter (CVC or PVC) once daily for 90 days. Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug infusion or blood aspiration.
11536125|NCT01101412|Active Comparator|Arm II: Saline Solution|Saline solution into CVC or PVC once daily for 90 days. Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug infusion or blood aspiration.
11536126|NCT01101399|Active Comparator|Ferric carboxymaltose|Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the next scheduled chemotherapy cycle after randomisation or continuous chemotherapy. In subjects with weight ≤66 kg, the first dose iron will be 500 mg; the second dose (500 mg) will be administered on the visit 4 (week 2).
11536127|NCT01101399|No Intervention|Local standard of care.|Subjects will be treated according to the local institutional practice.
11536128|NCT01101386||Voriconazole|Pharmacokinetic Monitoring
11536129|NCT01101373||1|All subjects who received BAC for treatment resistant depression between 2000 and 2009
11536130|NCT01101360|Active Comparator|Matrix RF followed by Pulse Dye Laser|
11536131|NCT01101347|Experimental|Aneurysm-Embolization System|
11536132|NCT01101334|Experimental|CS-7017 plus erlotinib|
11536133|NCT01101334|Active Comparator|erlotinib|
11536134|NCT01101321|Experimental|Reformulated OXY 80 mg (Totowa)|Reformulated OXY 80 mg (Totowa) x 1 dose
11536135|NCT01101321|Active Comparator|Reformulated OXY 80 mg (Wilson)|Reformulated OXY 80 mg (Wilson) x 1 dose
11536136|NCT01101308|Experimental|Reformulated OXY 10 mg (Totowa)|Reformulated OXY 10 mg (Totowa) x 1 dose
11536137|NCT01101308|Active Comparator|Reformulated OXY 10 mg (Wilson)|Reformulated OXY 10 mg (Wilson) x 1 dose
11536138|NCT01101282|No Intervention|'Usual care'|"Participants will receive 'usual medical care' consisting of the following:
~Medical management: Bronchodilators, corticosteroids, antibiotics and supplemental oxygen will be provided (where appropriate) in accordance with Australian and New Zealand COPD management guidelines (COPDX guidelines).
~Non-invasive ventilation: if clinically indicated and prescribed in accordance with standardised hospital guidelines.
~Physical rehabilitation: Participants will be assessed by a physiotherapist and prescribed appropriate exercises to facilitate a safe and timely discharge. Participants will perform physical rehabilitation according to a standardised protocol with an aim of maximising physical function at discharge.
~Other allied health (e.g. occupational therapy, speech pathology, dietician) assessments and interventions, as required."
11536139|NCT01101282|Experimental|'Usual care' plus PEP mask therapy|"This will comprise:
~'Usual care'
~PEP mask therapy"
11536195|NCT01100996|No Intervention|fasted control|Volunteers are fasted for 10 hours and subjected to experimental endotoxemia
11536140|NCT01101269|Experimental|Subjects with diabetic nephropathy|Renal blood flow (RBF) will be measured using contrast enhanced ultrasound (CEU) and urine protein will be measured both on and off angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).
11536141|NCT01101269|Active Comparator|Healthy volunteers|Renal blood flow (RBF) will be measured using contrast enhanced ultrasound (CEU) and urine protein will be measured both on and off angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).
11536142|NCT01101256||Fondaparinux Prophylaxis group|
11536143|NCT01101256||Fondaparinux Therapy group|
11536144|NCT01101243|Active Comparator|Group 1|Body surface area: 88 %
11536145|NCT01101243|Active Comparator|Group 2|Body surface area: 22 %
11536146|NCT01101243|Active Comparator|Group 3|Body surface area: 88 %
11536147|NCT01101243|Active Comparator|Group 4|Body surface area: 88 %
11536148|NCT01101243|No Intervention|Group 5|Body surface area: 0 %
11536149|NCT01101230|Experimental|Almond|
11536150|NCT01101230|Placebo Comparator|Muffin|
11536151|NCT01101217|Placebo Comparator|placebo|placebo for 6 weeks
11536152|NCT01101217|Active Comparator|zinc|zinc sulfate 220 mg per day orally for 6 weeks
11536153|NCT01101204|Active Comparator|M1000 S10 F100|metformin 1000mg, fenofibrate 100mg and simvastatin 10mg
11536154|NCT01101204|Active Comparator|M1000 S10 F267|metformin 1000mg, fenofibrate 267mg and simvastatin 10mg
11536155|NCT01101204|Active Comparator|M1000 S40 F100|metformin 1000mg, fenofibrate 100mg and simvastatin 40mg
11536156|NCT01101204|Active Comparator|M1000 S40 F267|metformin 1000mg, fenofibrate 267mg and simvastatin 40mg
11536157|NCT01101204|Active Comparator|M2500 S10 F100|metformin 2500mg, fenofibrate 100mg and simvastatin 10mg
11536158|NCT01101204|Active Comparator|M2500 S10 F267|metformin 2500mg, fenofibrate 267mg and simvastatin 10mg
11536159|NCT01101204|Active Comparator|M2500 S40 F267|metformin 2500mg, fenofibrate 267mg and simvastatin 40mg
11536160|NCT01101204|Active Comparator|M2500 S40 F100|metformin 2500mg, fenofibrate 100mg and simvastatin 40mg
11536161|NCT01101204|Placebo Comparator|Therapeutic Lifestyle Change|Only therapeutic lifestyle change
11536162|NCT01101191|Experimental|Reformulated OXY 80 mg|Reformulated OXY 80 mg x 1 dose
11536163|NCT01101191|Active Comparator|Original OxyContin® (OXY) 80 mg|Original OxyContin® (OXY) 80 mg x 1 dose
11536164|NCT01101178|Experimental|Reformulated OXY 80 mg|Reformulated OXY 80 mg x 1 dose
11536165|NCT01101178|Active Comparator|Original OxyContin® (OXY) 80 mg|Original OxyContin® (OXY) 80 mg x 1 dose
11536166|NCT01101165|Experimental|Reformulated OXY 40 mg|Reformulated OXY 40 mg x 1 dose
11536167|NCT01101165|Active Comparator|Original OxyContin® (OXY) 40 mg|Original OxyContin® (OXY) 40 mg x 1 dose
11536168|NCT01101152|Experimental|Female|
11536169|NCT01101152|Experimental|Male|
11536170|NCT01101139|Experimental|Experimental|Single injection of Sugammadex 0.25 mg/kg
11536171|NCT01101139|Placebo Comparator|Placebo comparator|Single injection of Saline 0.9%
11536172|NCT01101126|Experimental|Disease Management|Comprehensive care delivered by designated nurses and pulmonologists, in collaboration with the primary practitioners and other healthcare professionals in the community
11536173|NCT01101126|Active Comparator|Unual care|Care delivered by the primary practitioner with the advice of a consultant pulmonologist
11536174|NCT01101113|Experimental|Cinacalcet|stepwise dose of cinacalcet + regular medical medication including vit D
11536175|NCT01101113|Active Comparator|Control|conventional treatment for secondary HPT including vit D and phosphate binder
11536176|NCT01101100|Experimental|AMG 827|AMG 827
11536177|NCT01101087|Experimental|Taurolock|
11536178|NCT01101087|Placebo Comparator|Placebo|
11536179|NCT01101074||6-23 months|
11536180|NCT01101074||2-8 years|
11536181|NCT01101074||9-17 years|
11536182|NCT01101074||18-44 years|
11536183|NCT01101074||45-60 years|
11536184|NCT01101074||>60 years|
11536185|NCT01101061|Experimental|Romosozumab|Japanese women in cohorts 1, 2, and 4 will receive a single dose of 1, 3, or 5 mg/kg romosozumab. Non-Japanese women in cohort 3 will receive a single dose of 3 mg/kg romosozumab.
11536186|NCT01101061|Placebo Comparator|Placebo|Participants will receive a single dose of placebo.
11536187|NCT01101048|Placebo Comparator|A|Two (2) women in each of cohorts 1 and 4, and two (2) men in cohort 2 will receive placebo every 2 weeks for a total of 6 doses. Two (2) women in each of cohorts 3 and 5, and two (2) men in cohort 6 will receive placebo every 4 weeks for a total of 3 doses. Six (6) women in cohort 7 will receive placebo every 2 weeks for a total of 12 doses. In addition, subjects in cohorts 4 have the option to receive an additional 6 doses of placebo; subjects in cohorts 5 and 6 have the option to receive an additional 3 doses. Subjects in cohort 7 have the option to transition to 6 months of alendronate treatment.
11536188|NCT01101048|Active Comparator|B|Six (6) women in each of cohorts 1 and 4, and six (6) men in cohort 2 will receive AMG 167 every 2 weeks for a total of 6 doses. Six (6) women in each of cohorts 3 and 5, and six (6) men in cohort 6 will receive AMG 167 every 4 weeks for a total of 3 doses. Eighteen (18) women in cohort 7 will receive AMG 167 every 2 weeks for a total of 12 doses. In addition, subjects in cohorts 4 have the option to receive an additional 6 doses of AMG 167; subjects in cohorts 5 and 6 have the option to receive an additional 3 doses. Subjects in cohort 7 have the option to transition to 6 months of alendronate treatment.
11536189|NCT01101035|Experimental|Febuxostat|Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.
11536190|NCT01101035|Active Comparator|Allopurinol|Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was <6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance [eCLcr] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was <6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but <60 mL/min).
11536191|NCT01101022|Active Comparator|SPD489|
11536192|NCT01101022|Placebo Comparator|Placebo|
11536196|NCT01100996|Placebo Comparator|control feeding|Volunteers are fed a control nutrition starting 1 hour prior to LPS administration until 6 hours after LPS
11536197|NCT01100996|Active Comparator|enriched feeding|volunteers receive the investigational feeding starting 1 hour prior to LPS administration until 6 hours after LPS
11536198|NCT01100970||Unipolar electric needle|
11536199|NCT01100970||Bipolar electric needle|
11536200|NCT01100970||Control|Infants who were born in a vaginal birth
11536201|NCT01100957|Active Comparator|Conventional flexible videoscope for intubation|
11536202|NCT01100957|Experimental|Single-patient flexible endoscope|Single-patient flexible video-endoscope used for tracheal intubation in this intervention-arm
11536203|NCT01100944|Experimental|Therapy in Thymic Malignancies|PXD101 (Belinostat) will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression. A conventional 3+3 dose escalation design was used with up to 3 additional patients added if one patient exhibited a dose limiting toxicity (DLT). Dose escalation was halted if at least 2 out of a maximum of 6 patients within a cohort exhibited a DLT.
11536204|NCT01100931|Experimental|YM155 in Solid Tumors|"Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m^2, dose level 2:5 mg/m^2 , dose level 3:6 mg/m^2, dose level 4:8 mg/m^2, dose level 5:10 mg/m^2 (MTD), dose level 6:12 mg/m^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).
~Phase II: 10 mg/m^2 (MTD)intravenous infusion over 72 hours every 21 days."
11536205|NCT01100918|Active Comparator|1: Dyssynchrony positive|
11536206|NCT01100918|Active Comparator|2a: Dyssynchrony negative|
11536207|NCT01100918|Active Comparator|2b: Dyssynchrony negative|
11536208|NCT01100892|No Intervention|Control group|Observation only. Does not receive once-daily insulin detemir.
11536209|NCT01100892|Experimental|Once-daily insulin detemir|Once-daily insulin detemir
11536210|NCT01100879|Active Comparator|Ferric carboxymaltose|Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the next scheduled chemotherapy cycle after randomisation or continuous chemotherapy. In subjects with weight ≤66 kg, the first dose iron will be 500 mg; the second dose (500 mg) will be administered on the visit 3 (week 2).
11536211|NCT01100879|No Intervention|Local standard of care.|Subjects will be treated according to the local institutional practice.
11536212|NCT01100866|Active Comparator|Group 1|POMELLA™ 2 x 500mg capsule once daily
11536213|NCT01100866|Placebo Comparator|Group 2|POMELLA™ placebo
11536214|NCT01100853|Active Comparator|Extended release VIVITROL injection 380 mg, 24 weeks|Efficacy of 24 week course of Extended Release VIVITROL 380 mg with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
11536215|NCT01100853|Placebo Comparator|VIVITROL placebo injection, 24 weeks|Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
11536216|NCT01100827||EGFR mutation status in patients|
11536217|NCT01100801|Experimental|TS-1 with cisplatin|"Chemotherapy injection (60mg/m2 cisplatin) will be given on day 1.
~14 days of Oral TS-1 (40mg/m²) will be prescribed. Subjects will take it after breakfast and evening meal on Day 1-14 of a 3-weekly treatment cycle. Each cycle is about 21 days."
11536218|NCT01100801|Experimental|TS-1 with oxaliplatin|"Chemotherapy injection (100mg/m2 oxaliplatin) will be given on day 1.
~14 days of Oral TS-1 (40mg/m²) will be prescribed. Subjects will take it after breakfast and evening meal on Day 1-14 of a 3-weekly treatment cycle. Each cycle is about 21 days."
11536219|NCT01100788|Placebo Comparator|Placebo|No treatment
11536220|NCT01100788|Experimental|scFOS 5 g|5 g scFOS
11536221|NCT01100788|Experimental|scFOS 8 g|8 g scFOS
11536222|NCT01100775|Experimental|Galantamine, then Placebo|Participants took lead-in 3 days of 4mg/ twice a day of galantamine followed by 8 mg on the 4th day, the day of testing. Then, after a period of at least one month, participants took lead-in 3 days of 4mg/ twice a day of placebo followed by 8 mg on the 4th day, the day of testing.
11536223|NCT01100775|Experimental|Placebo, then Galantamine|Participants took lead-in 3 days of 4mg/ twice a day of placebo followed by 8 mg on the 4th day, the day of testing. Then, after a period of at least one month, participants took lead-in 3 days of 4mg/ twice a day of galantamine followed by 8 mg on the 4th day, the day of testing.
11536224|NCT01100762|Experimental|Single Group|10 subjects with Parkinson's Disease receiving tPCS during the first session, treadmill walk, 7-10 days later (second session, and combined tPCS and treadmill 7-10 days week later (third session)
11536225|NCT01100736|Experimental|Bosentan|Bosentan 125mg twice daily will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of bosentan therapy
11536226|NCT01100736|Experimental|Sitaxsentan|Sitaxsentan 100mg once daily + placebo tablet will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of sitaxsentan therapy
11536227|NCT01100736|Placebo Comparator|Placebo|Placebo tablet twice daily will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of placebo therapy
11536228|NCT01100723|Experimental|Computer directed dosing decisions|This study will be an open-label, non-randomized, single arm design. Patients will have their mineral and bone disorders managed by the computer directed algorithm. The computer algorithm will make recommendations for dosing active vitamin D and cinacalcet. The doses of these medications recommended by the algorithm will then be prescribed to the subjects participating in the study unless overridden by the patients primary attending nephrology for other clinical or safety concerns. At any time in the study, subjects may be on neither, one, or both of these medication depending on their laboratory results and the output recommendations of the algorithm.
11536229|NCT01100710||healthy volunteers|
11536230|NCT01100697||thoracal lesion|spinal lesion at thoracal level detected at prenatal ultrasound exam
11536231|NCT01100697||lumbar lesion|spinal lesion at lumbar level detected at prenatal ultrasound exam
11536232|NCT01100697||sacral lesion|spinal lesion at sacral level detected at prenatal ultrasound exam
11536233|NCT01100684|Experimental|Treatment|0.5 mg asimadoline bid
11536234|NCT01100684|Placebo Comparator|Placebo|Placebo
11536235|NCT01100671||Healthy patients|
11536236|NCT01100658|Active Comparator|Methylphenidate|Administered 1 capsule each day for 1 week, .3 mg/kg dose.
11536237|NCT01100658|Placebo Comparator|Placebo|Administered 1 capsule each day for 1 week.
11536238|NCT01100645|Experimental|Test|Sominex ® (Passiflora incarnata L. 50 mg, Valeriana officinalis L. 40 mg and Crataegus oxyacantha L. 30 mg)
11536239|NCT01100645|Placebo Comparator|Placebo|Excipient
11536240|NCT01100632|Experimental|Treatment|Treatment with the combination of Panax ginseng, vitamins and minerals
11536241|NCT01100632|Placebo Comparator|Placebo|Placebo.
11536242|NCT01100619|Experimental|All subjects|All subjects will receive daily XL184, and two single doses of rosiglitazone, 3 weeks apart
11536243|NCT01100606|Experimental|EUR-1008 (APT-1008) in Apple Juice|
11536244|NCT01100606|Experimental|EUR-1008 (APT-1008) in Apple Sauce|
11536245|NCT01100593|Active Comparator|1.75 inch catheter length|Length of catheter to be used
11536246|NCT01100593|Active Comparator|2.5 inch catheter length|length of catheter to be used
11536247|NCT01100580|Active Comparator|water therapy|"The term water therapy refers to an abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer)."
11536248|NCT01100580|Experimental|low salt diet + water therapy|low salt diet refers to a salt intake of 4 g/day
11536249|NCT01100567|Placebo Comparator|Placebo platform|Randomized to stand on placebo platform for 10 minutes/day
11536250|NCT01100567|Active Comparator|Low-magnitude mechanical stimulation|Randomized to stand on LMMS platform 10 minutes/daily
11536251|NCT01100554|Experimental|all patients|
11536252|NCT01100541|Experimental|Polymeric plate characteristics|Evaluation, in the volunteers viewpoint, of the polymeric plate characteristics.
11536253|NCT01100528|Experimental|Arm I|Patients receive dacarbazine IV on days 1 and 29. Beginning 4 weeks after the second dose of dacarbazine, patients receive recombinant interferon alfa-2b subcutaneously 3 times a week for 24 weeks in the absence of disease progression or unacceptable toxicity.
11536254|NCT01100515|Experimental|Experimental arm|Hyperbaric oxygen therapy at 2 absolute atmosphere (1-hour plateau) followed by 4 hours of normobaric oxygen therapy
11536255|NCT01100515|Active Comparator|Control|6 hours course of normobaric oxygen therapy via a face full mask
11536256|NCT01100502|Experimental|Brentuximab vedotin|brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
11536257|NCT01100502|Placebo Comparator|Placebo|placebo every 3 weeks by IV infusion
11536258|NCT01100489|Experimental|Arm I|Patients undergo breast-conserving surgery consisting of partial mastectomies followed by external beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
11536259|NCT01100463|Placebo Comparator|Placebo Lotion|
11536260|NCT01100463|Experimental|0.1% Uracil|
11536261|NCT01100450|Experimental|Resistance Training|
11536262|NCT01100437|Experimental|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|EMBEDA (morphine sulfate plus naltrexone hydrochloride ER) capsules crushed and mixed in solution and administered orally at each patient's stable dose, given either once daily or twice daily.
11536263|NCT01100437|Experimental|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole|EMBEDA (morphine sulfate plus naltrexone hydrochloride ER) capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily
11536264|NCT01100424|Experimental|Contact lens wearers|Contact lens wearers experienced three currently available contact lens/contact lens care combinations in randomized order: balafilcon A + Optifree RepleniSH, balafilcon A + ReNu MultiPlus, and balafilcon A + Unisol 4 saline.
11536265|NCT01100424|No Intervention|Non-lens wearers|Non-lens wearers completed one study visit and served as the control group.
11536266|NCT01100411|Active Comparator|Air Optix Aqua|Contact lens material: Lotrafilcon A
11536267|NCT01100411|Active Comparator|Biofinity|Contact lens material: Comfilcon A
11536268|NCT01100411|Active Comparator|Proclear|Contact lens material: Omafilcon A
11536269|NCT01100411|Active Comparator|Acuvue Oasys|Contact lens material: Senofilcon A
11536270|NCT01100411|Active Comparator|Acuvue 2|Contact lens material: Etafilcon A
11536271|NCT01100411|Active Comparator|Purevision|Contact lens material: Balafilcon A
11536272|NCT01100398||NAFLD/NASH prevalence|Any subject between the ages of 18-70 without known fatty liver disease who meet inclusion criteria
11536273|NCT01100385|Placebo Comparator|Healthy (placebo)|
11536274|NCT01100385|Active Comparator|Healthy (Ateronon)|
11536275|NCT01100385|Placebo Comparator|Cardiovascular Group (placebo)|
11536276|NCT01100385|Active Comparator|Cardiovascular Group (Ateronon)|
11536277|NCT01100320|Experimental|Reformulated OXY 40 mg|Reformulated OXY 40 mg x 1 dose
11536278|NCT01100320|Active Comparator|Original OxyContin® (OXY) 40 mg|Original OxyContin® (OXY) 40 mg x 1 dose
11536279|NCT01100307|Experimental|pegaptanib sodium|
11536280|NCT01100307|Sham Comparator|sham injection|
11536281|NCT01100294|Experimental|Vaccination with Fluval P|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant. Dose: 0.25 ml (total 3 μg HA), single dose.
11536282|NCT01100281||PSP (Progressive supranuclear palsy)|
11536283|NCT01100281||FTD (Frontotemporal lobar degenerative)|
11536284|NCT01100281||Alzheimer's disease|
11536285|NCT01100268|Experimental|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
11536286|NCT01100255|Active Comparator|Group A|0.5mg/kg IV ketamine infusion over 40 minutes then IV saline infusion over 40 minutes
11536287|NCT01100255|Active Comparator|Group B|IV saline infusion over 40 minutes then 0.5mg/kg IV ketamine infusion over 40 minutes
11536435|NCT01099176|Experimental|Fenofibrate and atorvastatin|10mg of Atorvastatin and 267mg of fenofibrate
11537065|NCT01095055|Experimental|Group 2|AdCh63 AMA1 followed by MVA AMA1
11536288|NCT01100242|Experimental|Arm 1: VELCADE and Sorafenib|Patients will be given VELCADE® (bortezomib) 1mg/m2 intravenously on days 1,4,8 & 11 and sorafenib at a dosage of 200 mg orally twice per day. One full course is comprised of 21 days.
11536289|NCT01100216|Active Comparator|Nicotine Lozenge|4 mg nicotine lozenge (LOZ
11536290|NCT01100216|Active Comparator|Camel Snus Frost|
11536291|NCT01100216|Active Comparator|Stonewall Spearment Tablet|
11536292|NCT01100216|Active Comparator|Skoal Wintergreen|
11536293|NCT01100203|Active Comparator|Treatment|
11536294|NCT01100203|No Intervention|Control|
11536295|NCT01100190|Experimental|NUVANCE Facial Rejuvenation System|
11536296|NCT01100177|Experimental|Sunitinib plus radiothery|"Sunitinib at doses of 37.5mg/m2/daily in a continuous dosing during 8 weeks.
~After evaluation of efficacy, they will receive Sunitinib 37.5 mg/d and treatment with Radiation therapy (total dose 60 Gy).
~After radiation therapy, Sunitinib al 37.5 mg/d will be continued until progression."
11536297|NCT01100164|Experimental|eszopiclone 3 mg|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
11536298|NCT01100164|Active Comparator|zopiclone 7,5mg|Zopiclone once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
11536299|NCT01100151|Experimental|RDC-1036 (ALKS 37)|Capsules for oral administration
11536300|NCT01100151|Placebo Comparator|Placebo|Capsules for oral administration
11536301|NCT01100125|Experimental|sitagliptin|
11536302|NCT01100125|Active Comparator|insulin dose increase|
11536303|NCT01100112|Experimental|Budesonide|Budesonide-MMX 9 mg tablet
11536304|NCT01100099|Experimental|Gluten challenge.|Diagnosis of celiac disease. Before and after a gluten challenge small bowel biopsies will be taken, and blood samples will be drawn for tetramer staining of gluten specific T cells.
11536305|NCT01100086|Experimental|Reformulated OXY 10 mg|Reformulated OXY 10 mg x 1 dose
11536306|NCT01100086|Active Comparator|Original OxyContin® (OXY)10 mg|Original OxyContin® (OXY)10 mg x 1 dose
11536307|NCT01100073||Patients with Parkinson's disease|Early and advanced Parkinson's disease patients
11536308|NCT01100060|Experimental|Group 1|Co-administer the test chloroquine (CQ) formulation (620 mg CQ base) plus microsphere azithromycin (AZ) (2000 mg) on Day 1.
11536309|NCT01100060|Active Comparator|Group 2|Co-administer the individual tablets of CQ 2 x 500 mg (600 mg CQ base) tablets plus AZ IR 4 x 500 mg tablets on Day 1.
11536310|NCT01100047|Experimental|1|
11536311|NCT01100047|Placebo Comparator|2|
11536312|NCT01100034||1|pediatric patients with plaque psoriasis on etanercept
11536313|NCT01100021|Experimental|tamsulosin + avanafil|
11536314|NCT01100021|Experimental|Doxazosin + avanafil|
11536315|NCT01100008|Experimental|Magnetic resonance imaging|
11536316|NCT01099995|Active Comparator|One HBO session|hyperbaric oxygen therapy one dive at 2 absolute atmosphere (1-hour plateau) - oxygen was delivered via a full face mask - followed by 4 hours of normobaric oxygen therapy
11536317|NCT01099995|Experimental|2 HBO sessions|Two sessions of hyperbaric oxygen therapy at 2 absolute atmosphere (1-hour plateau) with oxygen delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
11536318|NCT01099982||Advanced Heart Failure Therapy Group|Patients diagnosed with end stage heart failure undergoing either VAD implantation or heart transplantation.
11536319|NCT01099982||Normal Hearts Group|Control samples will be obtained from individuals undergoing other types of cardiac surgery during which it is routine to discard some tissue intraoperatively.
11536320|NCT01099969|Experimental|Glidescope with non-styletted Endotrol ETT|The patients in this arm will be intubated using a Glidescope videolaryngoscope with non-styletted Endotrol endotracheal tube (ETT).
11536321|NCT01099969|Active Comparator|Glidescope with styletted regular ETT|The patientsin this arm will be intubated using the glidescope videolaryngoscope and regular endotracheal tube (ETT) with gliderite stylet.
11536322|NCT01099969|Experimental|McGrath with non-styletted Endotrol ETT|The patients in this arm will be intubated using McGrath videolaryngoscope and non-styletted Endotrol endotracheal tube (ETT).
11536323|NCT01099969|Active Comparator|McGrath with with styletted regular ETT|The patients receiving this arm will be intubation using McGrath videolaryngoscope and regular endotracheal tube (ETT) with Gliderite stylet.
11536324|NCT01099956||diabetes group|
11536325|NCT01099956||control group|
11536326|NCT01099943|Experimental|Intervention: Education, Decision Support Tools|Clinic sites randomized to the intervention group will participate in an educational intervention comprised of lectures on antimicrobial resistance and implement decision support tools to guide primary care providers in appropriate antibiotic prescribing for common infectious conditions.
11536327|NCT01099943|No Intervention|No education, no implemented decision support tools|Clinics randomized to the control will not participate in the education intervention and implementation of decision support tools.
11536328|NCT01099930|Active Comparator|Non-randomized control group|Patients meeting inclusion/exclusion criteria not consenting to treatment will be requested to consent to control group and followed while receiving standard of care.
11536329|NCT01099930|Experimental|Stem Cell Transplantation|Patients will undergo stem cell transplantation for the treatment of Multiple Sclerosis
11536330|NCT01099917|Experimental|Maitake|This is a phase II trial examining hematopoietic response in MDS patients.
11536331|NCT01099904|Experimental|1|Normal Renal Function
11536332|NCT01099904|Experimental|2|Mild Renal Impairment
11536333|NCT01099904|Experimental|3|Moderate Renal Impairment
11536334|NCT01099891|Experimental|EGF|
11536335|NCT01099891|Placebo Comparator|Placebo|
11536336|NCT01099878|Active Comparator|Cycling Exercise with Functional Electrical Stimulation|Cycling Exercise with Functional Electrical Stimulation
11536337|NCT01099878|Placebo Comparator|Cycling Exercise|Cycling Exercise
11536338|NCT01099839|Experimental|one group|"Subjects will receive ASP1941 alone, Miglitol alone and ASP1941 + Miglitol in different order."
11536339|NCT01099826|Experimental|lifestyle counseling tailored|
11536340|NCT01099826|Experimental|lifestyle counseling motivational|
11536341|NCT01099826|No Intervention|control|
11536624|NCT01097980|Experimental|Trazodone|Trazodone versus placebo in a randomized, double-blind manner
11536342|NCT01099813||Inpatients assessed for critical care|Patients admitted to Critical Care Units participating in the ICNARC CMP programme who have been assessed at any time on a ward prior to ICU admission by a critical care decision maker (e.g. the CCOT or any member of the medical staff on duty for the unit)
11536343|NCT01099800||Mexican/Mexican American families|Parents and children who self-identify as being of Mexican heritage whether US-born or Mexican-born
11536344|NCT01099800||Puerto Rican families|Parents and children who self-identify as Puerto Rican whether US-born or island-born.
11536345|NCT01099787||FAP IBS|
11536346|NCT01099774|Experimental|Bimatoprost 0.03% Formulation B Ophthalmic Solution|Bimatoprost 0.03% Formulation B Ophthalmic Solution
11536347|NCT01099774|Active Comparator|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% Ophthalmic Solution
11536348|NCT01099761|Experimental|ACE-031 0.5 mg/kg q4wk|
11536349|NCT01099761|Experimental|ACE-031 1.0 mg/kg q2wk|
11536350|NCT01099761|Placebo Comparator|Placebo|
11536351|NCT01099748|Active Comparator|Methadone|Dose of methadone must not change from 1 week prior to study start and through the duration of the study.
11536352|NCT01099748|Experimental|Lersivirine + Methadone|
11536353|NCT01099735||CPAP, Manometry|Patients undergoing Manometry before weight loss surgery
11536354|NCT01099722|Active Comparator|Inhaler|
11536355|NCT01099722|Active Comparator|inhaler|Symbicort
11536356|NCT01099709|Experimental|Reformulated OXY 10 mg|Reformulated OXY 10 mg x 1 dose
11536357|NCT01099709|Active Comparator|Original OxyContin® (OXY) 10 mg|Original OxyContin® (OXY) 10 mg x 1 dose
11536358|NCT01099696|Experimental|B. infantis 35624|B. infantis 35624 in white capsules
11536359|NCT01099696|Placebo Comparator|placebo|white placebo capsules (inert)
11536360|NCT01099683|Experimental|NRL001|All subjects will receive 10 mg NRL001 in a 2 g rectal suppository
11536361|NCT01099683|Placebo Comparator|Placebo|All subjects will receive placebo
11536362|NCT01099670|Experimental|7.5 mg NRL001|Nine subjects will receive 7.5 mg NRL001 in a 2 g suppository; three will receive matching placebo.
11536363|NCT01099670|Experimental|10 mg NRL001|Nine subjects will receive 10 mg NRL001 in a 2 g suppository; three will receive matching placebo.
11536364|NCT01099670|Experimental|12.5 mg NRL001|Nine subjects will receive 12.5 mg NRL001 in a 2 g suppository; three will receive matching placebo.
11536365|NCT01099670|Experimental|15 mg NRL001|Nine subjects will receive 15 mg NRL001 in a 2 g suppository; three will receive matching placebo.
11536366|NCT01099657|Experimental|Virtual Reality Hypnosis|Virtual Reality Hypnosis for chronic pain
11536367|NCT01099657|Experimental|Virtual Reality Distraction|Virtual Reality Distraction for Chronic Pain
11536368|NCT01099644|Experimental|131 I-8H9|This is a phase I study of 131I-8H9 for patients with DSRCT and other 8H9-reactive solid tumors metastatic to the peritoneum.
11536369|NCT01099631|Experimental|Salmonella typhimurium 10 to the 5th - Level 1|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
11536370|NCT01099631|Experimental|Salmonella typhimurium 10 to the 6th -- Level 2|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
11536371|NCT01099631|Experimental|Salmonella typhimurium 10 to the 7th -- Level 3|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
11536372|NCT01099631|Experimental|Salmonella typhimurium 10 to the 8th - Level 4|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
11536373|NCT01099631|Experimental|Salmonella typhimurium 10 to the 9th - Level 5|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
11536374|NCT01099631|Experimental|Salmonella typhimurium 10 to the 10th - Level 1|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
11536375|NCT01099618|Active Comparator|Metformin|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg (n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
11536376|NCT01099618|Active Comparator|Sitagliptin|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000 mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg (n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
11536377|NCT01099618|Placebo Comparator|Placebo|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000 mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg(n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
11536378|NCT01099605|Placebo Comparator|Pump device|One arm will have continuous subcutaneous infusion of normal saline.
11536379|NCT01099605|Active Comparator|Bupivacaine|will receive continuous infusion of bupivacaine
11536436|NCT01099176|Placebo Comparator|Therapeutic Lifestyle Change|Placebo and Therapeutic Lifestyle Change
11536437|NCT01099163|Experimental|3g CLA|3 g CLA (50:50%) AND other diabetes medication currently prescribed to participant, 100 IU vitamin E
11536438|NCT01099163|Active Comparator|3 g CLA|3 g CLA (50:50%) AND other diabetes medication currently prescribed to participant, vitamin E placebo
11536439|NCT01099163|No Intervention|3 g MCT + vit E placebo|3 g MCT AND other diabetes medication currently prescribed to participant, 100 IU vitamin E placebo
11536380|NCT01099579|Experimental|Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg|Patients weighing 5 to <10 kg received atazanavir (ATV), 150-mg powder dosed in 50-mg packets, and ritonavir (RTV) oral solution, 80 mg. Stage 1: Initial dose was determined by patient's weight on the day of first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage. All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from the powder to the capsule formulation of ATV. Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
11536381|NCT01099579|Experimental|Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg|Patients weighing 10 to <15 kg received ATV powder, 200 mg, dosed in 50-mg sachet packets and RTV oral solution, 80 mg. Stage 1: Initial dose was determined by the patient's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from the powder to the capsule formulation of ATV. Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
11536382|NCT01099579|Experimental|Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg|Patients weighing 15 to <25 kg received 250 mg of ATV powder dosed in 50-mg sachet packets, with 80 mg of RTV solution. Stage 1: Initial dose was determined by the patient's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from powder to the capsule formulation of ATV. Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
11536383|NCT01099566|Experimental|Prasugrel|
11536384|NCT01099566|Placebo Comparator|pills consisting of lactose-starch|
11536385|NCT01099553|Other|Standard preparation instructions|The control arm will receive written instructions on preparing for a colonoscopy per standard of care at Boston Medical Center
11536386|NCT01099553|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus instructions asking them to watch an educational video on the Center for Digestive Disorders website
11536387|NCT01099540|Experimental|Pazopanib|
11536388|NCT01099527|Experimental|Everolimus|"Everolimus (RAD001) dose escalation of capecitabine, everolimus
~Capecitabine dose escalation of capecitabine, everolimus"
11536389|NCT01099514|Experimental|Nilotinib|Nilotinib 400 mg (2 capsules) PO BID q 28 days
11536390|NCT01099501|Active Comparator|Oxepa|Oxepa (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
11536391|NCT01099501|Active Comparator|Control group|Pulmocare or Jevity (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
11536392|NCT01099488|Other|All subjects|Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received a GSK2231392A vaccine, were enrolled for blood withdrawal to support the development of CD8+ T cell immunological detection assays.
11536393|NCT01099475|Experimental|Pringle manoeuvre 15 minutes|When intermittent pedicle occlusion during parenchymal transection is necessary, 2 cycles of 15 minutes of hepatic inflow occlusion will be applied each followed by 5 minutes of reperfusion. During inflow occlusion, the complete portal triad was clamped using a rubber sling.
11536394|NCT01099475|Experimental|Pringle manoeuvre 30 minutes|When intermittent pedicle occlusion during parenchymal transection is necessary, 1 cycle of 30 minutes of hepatic inflow occlusion will be applied followed by 5 minutes of reperfusion. During inflow occlusion, the complete portal triad was clamped using a rubber sling.
11536395|NCT01099462||Children with fever|
11536396|NCT01099449|Experimental|Arm I|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and after oxaliplatin administration (part of FOLFOX chemotherapy comprising leucovorin calcium, fluorouracil, and oxaliplatin).
11536397|NCT01099449|Placebo Comparator|Arm II|Patients receive placebo IV over 30 minutes immediately before and after oxaliplatin administration (part of FOLFOX chemotherapy).
11536398|NCT01099449|Experimental|Arm III|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and placebo IV over 30 minutes immediately after oxaliplatin administration (part of FOLFOX chemotherapy).
11536399|NCT01099436|Experimental|TAC + Zoledronic acid|six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC) and zoledronic acid (Zometa)
11536400|NCT01099436|Active Comparator|TAC|six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC)
11536401|NCT01099423|Active Comparator|Immediate nephrectomy|Surgery followed by Sunitinib
11536402|NCT01099423|Experimental|Deferred nephrectomy|Sunitinib (3 cycles) followed by surgery followed by Sunitinib
11536403|NCT01099410||Group 1|volunteer subjects
11536404|NCT01099397||PEAR Participants|All participants eligible for PEAR study. Each participant will be have fasting and oral glucose tolerance test data collected.
11536405|NCT01099384|Active Comparator|Behavioral: written self-help materials|Behavioral: written self-help materials
11536406|NCT01099384|Experimental|Group behavioral counseling|Group behavioral counseling, weekend program
11536407|NCT01099371|Experimental|exercise|
11536498|NCT01098838|Experimental|Comparison of LCL161|tablet versus liquid
11536625|NCT01097980|Placebo Comparator|Placebo|Patients received placebo
11536408|NCT01099358|Experimental|Cetuximab and Cisplatin (D)|"Cycle 1 (1 week, combination therapy):
~400 milligrams per square meter (mg/m²) cetuximab administered (admin) intravenously (I.V) on week 1, day 1.
~100 mg/m² cisplatin administered I.V on week 1, day 1. Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/m²/day (d) administered starting on week 1, day 1.
~After 1 cycle, participants may continue treatment as determined by the physician until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.
~After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
11536409|NCT01099358|Experimental|Cetuximab and Cisplatin (C)|"Cycle 1 (4 weeks, combination therapy):
~100 mg/m² Cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3 and 4, day 1.
~Cycle 2-6 (3 weeks combination therapy):
~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 1, 2, and 3, day 1.
~After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.
~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
11536410|NCT01099358|Experimental|Cetuximab on Cisplatin (B)|"Cycle 1:
~400 mg/m² cetuximab admin I.V on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 2 and 3, day 1.
~Cycle 2:
~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1- 4.
~250 mg/m² cetuximab admin I.V on week 1-3, day 1.
~Cycle 3 + :
~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.
~250 mg/m² cetuximab admin I.V on week 1-3, day 1.
~After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.
~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
11536411|NCT01099358|Experimental|Cisplatin on Cetuximab (A)|"Cycle 1:
~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.
~400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3, day 1.
~Cycle 2 +:
~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.
~250 mg/m² cetuximab admin I.V on weeks 1-3, day 1.
~After 7 cycles, participants may then receive weekly Cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.
~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
11536412|NCT01099345||Group 1 - OAB with DO+|Subjects that DO+ nocturia
11536413|NCT01099345||Group 2- OAB with DO-|Subjects that DO- nocturia
11536414|NCT01099332|Active Comparator|Gastro-retentive zinc cysteine tablet|Once daily administration by mouth of a gastro-retentive, sustained-release preparation of zinc cysteine with excipients, all G.R.A.S., with adequate water.
11536415|NCT01099332|Placebo Comparator|Identical appearance of placebo with active comparator|Once daily administration of placebo of identical physical appearance to that of active comparator with similar amount of water.
11536416|NCT01099319|Experimental|Renalof|
11536417|NCT01099319|Placebo Comparator|Placebo|
11536418|NCT01099306|Active Comparator|intervention|pharmacist-physician collaborative approach to manage Metabolic syndrome
11536419|NCT01099306|No Intervention|control|physician only team to manage Metabolic syndrome
11536420|NCT01099293||Cirrhosis, w/o hepatic encephalopathy|Patients with liver cirrhosis without hepatic encephalopathy by clinical (West-Haven), neurophysiological tests (PHES) nor Critical Flicker Frequency evidence.
11536421|NCT01099293||Cirrhosis-minimal hepatic encephalopathy|Patients with cirrhosis, without clinical evidence of hepatic encephalopathy (West Haven 0) and with positive tests for both, PHES and CFF.
11536422|NCT01099293||Cirrhosis, Hepatic encephalopathy I|Patients with cirrhosis and clinical evidence of hepatic encephalopathy with a West Haven score of I.
11536423|NCT01099293||Control|Healthy subjects willing to participate in the study
11536424|NCT01099280|Experimental|oxytocin group|2 milliunits/min and doubled every 30 minutes to a maximum of 32 milliunits/min or until four contractions in 10 minutes was achieved
11536425|NCT01099280|Experimental|dinoprostone and oxytocin|a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
11536426|NCT01099267||Lenalidomide|No intervention was given during this extension study which gathered survival information on participants of study NCT00065156 (Celgene study CC-5013-MDS-003). During the CC-5013-MDS-003 study, participants initially took a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle. The study was amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.
11536427|NCT01099228|Active Comparator|131-I MIBG and 111I-n pentetreotide|131-I MIBG and 111I-n pentetreotide
11536428|NCT01099228|Active Comparator|131-I MIBG and In-111 DOTATATE|131-I MIBG and In-111 DOTATATE
11536429|NCT01099215|Other|PVS-10200|Each subject will receive one treatment of PVS-10200 delivered by ultrasound guided injection perivascular to the region of the target lesion within 24 hours of the completed angioplasty and stent placement.
11536430|NCT01099202|Experimental|Procrit|Starting dose 40,000 units subcutaneously once a week with chemotherapy.
11536431|NCT01099202|No Intervention|No Procrit|No intervention.
11536432|NCT01099189||Observed cohort|All patients recruited. Observed for clinical outcomes
11536433|NCT01099176|Experimental|Atorvastatin|10mg of Atorvastatin
11536434|NCT01099176|Experimental|Fenofibrate|267mg of Fenofibrate
11536440|NCT01099150|Experimental|42 healthy volunteers - crossover|"Acute consumption of three interventions (60 g dark chocolate enriched in flavan-3-ols, 60 g standard dark chocolate, or 60 g white chocolate) on three separate days (at least 2 weeks apart) in random order.
~Post-prandial measurements at t = 0 h, t = 2 h and t = 6 h."
11536441|NCT01099137|Experimental|Vildagliptin|Vildagliptin will be added to uncontrolled diabetic patients with sulphonylurea and metformin
11536442|NCT01099137|Active Comparator|Sulphonylurea dose-up|Sulphonylurea dose will be increased to uncontrolled diabetic patients with sulphonylurea and metformin
11536443|NCT01099124|Experimental|M2ES combined with chemotherapy|
11536444|NCT01099111||Irritable Bowel Syndrome|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
11536445|NCT01099111||Ulcerative Colitis|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
11536446|NCT01099111||Crohn's Disease|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
11536447|NCT01099111||Colo Rectal Cancer|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
11536448|NCT01099111||Control: Normal Subjects|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
11536449|NCT01099098||Patients with TB sequelae|
11536450|NCT01099098||People without TB sequelae|
11536451|NCT01099085|Active Comparator|XP/simvastatin|Capecitabine/cisplatin + simvastatin
11536452|NCT01099085|Placebo Comparator|XP/placebo|Capecitabine/cisplatin + placebo
11536453|NCT01099072|Active Comparator|Methylphenidate+placebo|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Placebo
11536454|NCT01099072|Experimental|methylphenidate+carnitine|
11536455|NCT01099059|Active Comparator|Ritalin|receive ritalin depending on weight
11536456|NCT01099059|Experimental|Amantadine|100-150 mg depending on weight (100 mg/day for <30 Kg and 150 mg/day for >30 Kg)
11536457|NCT01099046|No Intervention|medication only|medication = anti-diuretics
11536458|NCT01099046|Active Comparator|medication + water intake|anti-diuretics + water intake (at least 2.0 litters per day)
11536459|NCT01099046|Active Comparator|medication + tympanic tubing|anti-diuretics + tympanic tubing (under local anesthesia)
11536460|NCT01099046|Active Comparator|medication + regular sleep|anti-diuretics + regular sleep (regular sleep program under dark everynight)
11536461|NCT01099033||Hiatal/Paraesophageal hernia patients|patients with hiatal or paraesophageal hernias
11536462|NCT01099033||control group|patients without hiatal or paraesophageal hernias who are undergoing crural dissection for heller myotomy, or who are undergoing gastric bypass surgery
11536463|NCT01099007|Active Comparator|At Home|Participants in the At Home group receive a workbook from the research staff at their baseline visit that outlines an accepted nutrition and physical activity program to complete on their own.
11536464|NCT01099007|Experimental|In Person|Participants in the In Person group have weekly visits for the 12 weeks to the research office. The first visit can last up to one and a half hours and each subsequent visit can last approximately one hour. Group meetings provide appropriate nutrition and physical activity information as well as behavioral change strategies. Sessions also include some light physical activity (equal to brisk walking).
11536465|NCT01098994|Other|Haptoglobin 1/1|Individuals with type 1 diabetes and the Haptoglobin 1/1 phenotype
11536466|NCT01098994|Other|Haptoglobin 2/1|Individuals with type 1 diabetes and the Haptoglobin 2/1 phenotype
11536467|NCT01098994|Other|Haptoglobin 2/2|Individuals with type 1 diabetes and the Haptoglobin 2/2 phenotype
11536468|NCT01098981|Experimental|Target group|A combined treatment with transcranial US and systemic tPA
11536469|NCT01098981|Active Comparator|Control group|Systemic tPA alone
11536470|NCT01098968|No Intervention|Normal PE|2 Physical Education sessions / week
11536471|NCT01098968|Experimental|PE Volume|4 Physical Education sessions/week (increased volume)
11536472|NCT01098968|Experimental|PE Volume + Intensity|4 Physical Education sessions/week of high intensity (increased volume and intensity)
11536473|NCT01098955|Experimental|ACT Group 1|Acceptance and Commitment Therapy (ACT). Varenicline 2 mg daily for 12 weeks.
11536474|NCT01098955|Experimental|MBC Group 2|Motivational and Behavioral Counseling (MBC). Varenicline 2 mg daily for 12 weeks.
11536475|NCT01098942||Surgical|Roux-en-Y gastric bypass surgery
11536476|NCT01098942||Non-surgical|Non-surgical lifestyle weight management
11536477|NCT01098929||Congenital Diaphragmatic Hernia (CDH)|Individuals affected with congenital diaphragmatic hernia (CDH)
11536478|NCT01098929||Unaffected|Healthy family members of individuals affected with congenital diaphragmatic hernia (CDH)
11536479|NCT01098916|Experimental|X-rays at home|Home hospitalized elderly patients undergo X-rays at home
11536480|NCT01098916|Active Comparator|Hospital X-rays|Home hospitalized elderly patients undergo X-rays examinations in hospital
11536481|NCT01098903||Sunitinib|Patients with a malignancy treated with sunitinib
11536482|NCT01098890|Placebo Comparator|Placebo|Placebo will be administered every 12 hours for a total five doses. Patients will be followed for a total of 6 months.
11536483|NCT01098890|Active Comparator|tPA (tissue plaminogen activator)|Intraventricular TPA will be administered every 12 hours for a total five doses. Patients will be followed for a total of 6 months.
11536484|NCT01098877|Placebo Comparator|Placebo|
11536485|NCT01098877|Experimental|Cohort 1, 1mg|
11536486|NCT01098877|Experimental|Cohort 1, 3mg|
11536487|NCT01098877|Experimental|Cohort 1, 10mg|
11536488|NCT01098877|Experimental|Cohort 2, 30mg|
11536489|NCT01098877|Experimental|Cohort 2, 100mg|
11536490|NCT01098877|Experimental|Cohort 2, 300mg|
11536491|NCT01098877|Experimental|Cohort 3, 600mg|
11536492|NCT01098877|Experimental|Cohort 3, 900mg|
11536493|NCT01098877|Experimental|Cohort 3, up to 900mg (fed)|
11536494|NCT01098877|Placebo Comparator|Cohort 3, placebo (fed)|
11536495|NCT01098851||Obstructive Sleep Apnea|Surgery patients at high risk for Obstructive Sleep Apnea
11536496|NCT01098851||Surgery Patients|Surgery patients at low risk for Obstructive Sleep Apnea
11536497|NCT01098838|Experimental|Weekly dosing of LCL161|by mouth (oral)
11536499|NCT01098838|Experimental|Twice daily dosing of LCL161|by mouth for 4 days followed by a 3-day rest period every week
11536500|NCT01098825||District VI AAP clinicians|
11536501|NCT01098812|Active Comparator|Control IOL|Approved Intraocular control lens
11536502|NCT01098812|Experimental|Toric IOL|Investigational Toric IOL
11536503|NCT01098812|Experimental|Higher Cylinder Toric IOL|Investigational Toric IOLs with higher cylinder powers.
11536504|NCT01098799||Control|Healthy controls
11536505|NCT01098799||Chronic kidney disease-1|Chronic kidney disease not taking dialysis treatment
11536506|NCT01098799||Kidney Transplant|Kidney transplants
11536507|NCT01098786||Healthy|
11536508|NCT01098773||patients requiring ventilation|
11536509|NCT01098773||patients who weaned permanently|
11536510|NCT01098760|Experimental|Arm 1|
11536511|NCT01098747|Experimental|Treatment A|
11536512|NCT01098747|Active Comparator|Treatment B|
11536513|NCT01098747|Active Comparator|Treatment C|
11536514|NCT01098747|Placebo Comparator|Treatment D|
11536515|NCT01098734|Placebo Comparator|Group 1|0%; vehicle cream
11536516|NCT01098734|Active Comparator|Group 2|0.5% WBI-1001 cream
11536517|NCT01098734|Active Comparator|Group 3|1.0% WBI-1001 cream
11536518|NCT01098721|Placebo Comparator|Group 1|A placebo cream applied topically twice daily (BID)by each of 20 patients, once in the morning and once in the evening for 12 weeks.
11536519|NCT01098721|Active Comparator|Group 2|A 1.0% WBI-1001 cream applied topically twice daily (BID) by each of 40 patients, once in the morning and once in the evening for 12 weeks.
11536520|NCT01098695|Experimental|EcoFIT offered|
11536521|NCT01098695|No Intervention|No Feedback or services offered|
11536522|NCT01098656|Experimental|lenalidomide|
11536523|NCT01098656|No Intervention|Observation|
11536524|NCT01098630||Group I (limited participation)|Patients do not complete any questionnaires at baseline. At baseline, patients' medical record information is collected; sites complete the Functional Comorbidity Index; and physicians, nurses, and study coordinators complete the follow-up questionnaire. Staff complete the treatment review form after treatment or 7 months after study registration.
11536525|NCT01098630||Group II (full participation)|Patients complete the Patient Registration Survey and Patient Questionnaire at baseline. At baseline, patients' medical record information is collected; sites complete the Functional Comorbidity Index; and physicians, nurses, and study coordinators complete the follow-up questionnaire. Staff complete the treatment review form after treatment or 7 months after study registration.
11536526|NCT01098617||hemorrhage|The patients who had bleeding induced by endoscopic sphincterotomy
11536527|NCT01098604|Active Comparator|32mm ceramic head group|patients performed with THA using 32mm ceramic head
11536528|NCT01098604|Active Comparator|28mm ceramic head group|patients performed with THA using 28mm ceramic head
11536529|NCT01098591||Myocardial infarction|Patients with post-myocardial infarction receiving cell therapy either intracoronarily or intramyocardial
11536530|NCT01098591||Ischemic cardiomyopathy|Patients with ischemic cardiomyopathy treated with cell therapy either intracoronarily or intramyocardial
11536531|NCT01098578|Experimental|Floseal|Received 1 syringe of Floseal for treatment of posterior epistaxis.
11536532|NCT01098565|Experimental|Study device arm|
11536533|NCT01098552||High-risk radical prostatectomy patients|
11536534|NCT01098552||Primary external beam radiotherapy patients|
11536535|NCT01098552||Primary prostate brachytherapy patients|
11536536|NCT01098552||Hormone refractory prostate cancer patients|
11536537|NCT01098552||Active Surveillance|
11536538|NCT01098552||Prostate biopsy patients|
11536539|NCT01098539|Active Comparator|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
11536540|NCT01098539|Active Comparator|sitagliptin|albiglutide matching placebo + sitagliptin
11536541|NCT01098526|Experimental|Cohort 1|Subjects will receive a single dose of GSK1349572 100 mg in Period 1 followed by a washout of at least 6 days. Subjects will then receive GSK1349572 50 mg once a day for 5 days in Period 2. Period 3 will begin immediately after Period 2. In Period 3 subjects will receive GSK1349572 50 mg once a day in the morning and Efavirenz 600 mg once a day at bedtime for 14 days. There will be a screening visit up to 30 days before Period 1 and a follow up visit 7-14 days after the end of Period 3.
11536542|NCT01098513|Experimental|Part A|Subjects will be randomized in a three-way crossover design to receive a single dose of each of three different tablet formulations of GSK1349572 50 mg (2 tablets). Formulation AP, AW and AX.
11536543|NCT01098513|Experimental|Part B|A total of 18 subjects who complete Part A will return for Part B. Subjects from Part A will be asked to participate on a first come first served basis until there are 18 subjects, at which time enrolment to Part B will be closed. Part B will be a three way crossover design using either formulation AW or AX depending upon the results from Part A. Subjects will receive a single dose of 50 mg GSK1349572 with either a low fat, moderate fat or high fat meal in each period.
11536544|NCT01098500||Cancer patients|Adults (age ≥18 years) with at least two ICD-9 codes for a particular cancer within a 6 month timeframe and at least one code for a TKI drug that occurs on or after the first cancer diagnosis code
11536545|NCT01098487|Experimental|Open Label|Oral eltrombopag once daily, starting dose 50 mg (or 25 mg for subjects of East Asian ancestry).
11536546|NCT01098474|Experimental|SB692342 2 dose Group|Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, on a 0, 1 month schedule after having completed their primary EPI regimen.
11536547|NCT01098474|Experimental|SB692342 1 dose Group|Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, at Month 0, after having completed their primary EPI regimen.
11536548|NCT01098474|Active Comparator|Control Menjugate Group|Subjects received three doses of the control Menjugate™ vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, on a 0, 1, 7 months schedule. The first two doses were administered 1 month apart during the primary vaccination phase and the third dose was administered 6 months after the last primary vaccination dose.
11536592|NCT01098175||Control group|open surgery with exposure of the surgical wound to the air.
11536549|NCT01098474|Experimental|SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group|"Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, concomintantly with the last two doses of the primary EPI regimen containing Tritanrix™ HepB+Hiberix™ vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin™ vaccine, administered orally, and Prevnar® vaccine, administered instramuscularly in the right arm, on a 0, 1, 2 months schedule.
~All subjects received a booster dose of the Tritanrix™ HepB+Hiberix™, Polio Sabin™ and Prevnar® vaccines approximately 1 year after their last dose."
11536550|NCT01098474|Experimental|SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group|Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, concomitantly with the last dose of the primary EPI regimen containing Tritanrix™ HepB+Hiberix™ vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin™ vaccine, administered orally, and Prevnar® vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix™ HepB+Hiberix™, Polio Sabin™ and Prevnar® vaccines approximately 1 year after their last dose.
11536551|NCT01098474|Active Comparator|Control Tritanrix + Prevnar + Polio Sabin Group|Subjects received three doses of the primary EPI regimen containing Tritanrix™ HepB+Hiberix™ vaccine, administered in the anterolateral region of the left thigh, Polio Sabin™ vaccine, administered orally, and Prevnar® vaccine administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix™ HepB+Hiberix™, Polio Sabin™ and Prevnar® vaccines approximately 1 year after their last dose.
11536552|NCT01098461|Active Comparator|albiglutide 15mg weekly|once weekly subcutaneous injection of albiglutide 15mg
11536553|NCT01098461|Active Comparator|albiglutide 30mg weekly|once weekly subcutaneous injection of albiglutide 30mg
11536554|NCT01098461|Active Comparator|albiglutide 30mg every other week|subcutaneous injection of 30mg albiglutide every other week
11536555|NCT01098461|Placebo Comparator|placebo|once weekly subcutaneous injection of placebo to match albiglutide
11536556|NCT01098448|Active Comparator|Scaling and root planing|scaling and root planing as a solo therapy
11536557|NCT01098448|Experimental|Periodontal surgery|
11536558|NCT01098448|Experimental|systemic antibiotics|
11536559|NCT01098448|Experimental|Local delivery of tetracycline|
11536560|NCT01098448|Experimental|local antibiotic and systemic antibiotics|
11536561|NCT01098448|Experimental|local antibiotics and surgery|
11536562|NCT01098448|Experimental|systemic antibiotics and surgery|
11536563|NCT01098448|Experimental|local and systemic antibiotics and surgery|
11536564|NCT01098435|Experimental|RDC-0313 (ALKS 33)|2-capsules taken orally
11536565|NCT01098435|Placebo Comparator|Placebo|2-capsules taken orally
11536566|NCT01098422|Experimental|Yttrium-90 Radioactive Resin Microspheres|Yttrium-90 Radioactive Resin Microspheres
11536567|NCT01098409|Experimental|sodium nitrite 24 hours before|
11536568|NCT01098409|Experimental|sodium nitrite during surgery|
11536569|NCT01098409|Placebo Comparator|0.9% sodium chloride|
11536570|NCT01098383|Placebo Comparator|Placebo for AChEI and Choline|
11536571|NCT01098383|Experimental|AChEI and Choline|Acetyl-choline Esterase Inhibitor and Choline supplements
11536572|NCT01098357|Experimental|Biochaperone PDGF-BB low dose|BioChaperone PDGF-BB is a new formulation of the B isoform dimer of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) containing the new excipient Biochaperone, a dextran modified polymer. The finished product is a sterile multi-dose spray vial.
11536573|NCT01098357|Experimental|Biochaperone PDGF-BB High dose|BioChaperone PDGF-BB is a new formulation of the B isoform dimer of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) containing the new excipient Biochaperone, a dextran modified polymer. The finished product is a sterile multi-dose spray vial.
11536574|NCT01098357|Active Comparator|Regranex|Becaplermin gel (Regranex® Gel 0.01%, Systagenix, formerly and Johnson & Johnson) is a topical gel of rhPDGF-BB conditioned in a gel tube.
11536575|NCT01098357|Experimental|Very Low Dose BioChaperone PDGF-BB|BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
11536576|NCT01098318|Experimental|Rhodiola rosea|Herbal extract
11536577|NCT01098318|Active Comparator|Sertraline|Conventional anti-depressant
11536578|NCT01098318|Placebo Comparator|Sugar pill|Lactose monohydrate
11536579|NCT01098305|Active Comparator|Varenicline|
11536580|NCT01098305|Placebo Comparator|Placebo|
11536581|NCT01098292||Healthy Control|"Healthy Control participants do not suffer from any Urological Chronic Pelvic Pain Syndromes or from the following conditions:
~Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome"
11536582|NCT01098292||Positive Control|"Positive Control participants do not suffer from any Urological Pelvic Pain Syndromes like Interstitial Cystitis and/or Chronic Prostatitis. However Positive Controls have a history of one of the following conditions:
~Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome"
11536583|NCT01098266|Experimental|A: NGR-hTNF + BIC|NGR-hTNF plus Best Investigator's Choice
11536584|NCT01098266|Placebo Comparator|B: Placebo+BIC|Placebo plus Best Investigator's Choice
11536585|NCT01098253|Experimental|Adherence Intervention|Factors affecting adherence to oral hypoglycemic agents and antidepressants were addressed using a problem solving process.
11536586|NCT01098253|No Intervention|Usual Care|
11536587|NCT01098240|Experimental|Active Treatment|CP-601,927
11536588|NCT01098240|Placebo Comparator|Placebo|Placebo
11536589|NCT01098227||RSV positive subjects|Subjects admitted to Winthrop University Hospital with lower viral respiratory infection and RSV positive status by DFA and/or Viral culture
11536590|NCT01098227||RSV negative subjects|Subjects admitted to Winthrop University Hospital with a lower viral respiratory infection and RSV status negative by DFA and viral culture. these subjects may be positive for other viruses detected by DFA or viral culture (Adenovirus, Influenza A or B, Metapneumovirus or parainfluenza) or not
11536591|NCT01098227||Control group|Children in the same age range without respiratory conditions and who are well enough to perform the test from the out patient setting
11536593|NCT01098175||Full peritoneal conditioning|Full peritoneum cavity conditioning will be performed as follows. A continuous flow of less than 0.5 l/min of gas will be instilled in the lowest part of the operating wound. As gas premixed bottles with CO2+ 4% of oxygen and 10% of N2O will be used. This gas will be humidified and at 31-32 °C to be achieved by a commercial humidifier (Fisher and Paykel) programmed in order to maintain 100% relative humidity at 31-32°C upon entrance of the peritoneal cavity.
11536594|NCT01098162||Vimpat®|Routine treatment in accordance with the local marketing authorization for Vimpat® added to one Baseline antiepileptic drug.
11536595|NCT01098149|Active Comparator|AFB stand alone|Patients are switched in AFB treatment, without blood volume control.
11536596|NCT01098149|Active Comparator|BD and BVC|Patients are switched into bicarbonate dialysis with Blood Volume Control
11536597|NCT01098136|Active Comparator|Chiropractic treatment|Management for one-sided pelvic pain, as decided by the chiropractor
11536598|NCT01098136|Active Comparator|Conventional health care|Conventional health care for one-sided pelvic pain
11536599|NCT01098136|Active Comparator|Conventional and alternative treatment|Treament of pregnant women with other pelvic pain syndromes.
11536600|NCT01098123||Diet counseling, nutritional index|Lightweight as athletes with weight limit
11536601|NCT01098123||nutritional index|Heavyweight athletes without weight limit
11536602|NCT01098110|Experimental|Asenapine 5 mg BID|Participants received a 5 mg asenapine fast dissolving tablet twice daily (BID) for 6 weeks.
11536603|NCT01098110|Experimental|Asenapine 10 mg BID|Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.
11536604|NCT01098110|Placebo Comparator|Placebo BID|Participants received matching placebo BID for 6 weeks.
11536605|NCT01098097||Peginterferon alpha and ribavirin|Peginterferon alpha and ribavirin will be administered at the discretion of the treating physician, in accordance per label according to local guidelines for all participating countries.
11536606|NCT01098084|Experimental|Decitabine|
11536607|NCT01098071|Experimental|mometasone furoate nasal spray|
11536608|NCT01098058|Experimental|CBT plus treatment as usual|
11536609|NCT01098058|Active Comparator|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
11536610|NCT01098045||HIV-infection with fat redistribution (lipoatrophy)|"Evidence of HIV infection
~Age ≥ 20 and ≤ 60 years of age
~BMI measurement between 18-24 kg/m2
~HIV positive, on a stable HAART treatment regimen (including an NRTI) for > 12 months
~No evidence of fat redistribution rated by the investigator."
11536611|NCT01098045||Healthy controls|"No history of HIV infection
~Age ≥ 20 and ≤ 60 years of age
~BMI measurement between 18-29.9 kg/m2"
11536612|NCT01098045||HIV-infected with fat redistribution (lipohypertrophy)|"Evidence of HIV infection
~Age ≥ 20 and ≤ 60 years of age
~BMI measurement between 25-29.9 kg/m2
~HIV positive, on a stable HAART treatment regimen (including an NRTI) for > 12 months
~Evidence of significant fat redistribution rated by the investigator, including 1) significant fat atrophy of the face, arms or legs, and 2) significant increase in fat accumulation of the neck."
11536613|NCT01098045||Dicer Cohort|30 men [HV-infected with fat redistribution (n = 10), HIV-infected without fat redistribution (n=10), and healthy controls (n= 10)] will be recruited for this group.
11536614|NCT01098032|Active Comparator|Systemic alone therapy group|Systemic alone therapy group will be treated by intravenous sodium bicarbonate plus NAC administration. Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. (9) The initial i.v. bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days. Additional NAC dose (1.2 g) will be administered i.v. during the procedure.
11536615|NCT01098032|Experimental|RenalGuard System group|Prophylactic controlled hydration with saline (0.9%) plus N-acetylcystein (NAC; 6 g in total). In the RenalGuard group, an initial bolus (priming) of 250 ml will be administered. In case of left ventricular dysfunction (ejection fraction ≤30%) and/or unstable hemodynamic conditions the bolus will be reduced to 150 ml. Following the initial bolus, furosemide (0.25 mg/kg) will be administered in order to achieve the optimal urine flow (≥300 ml/h). The hydration will be continued throughout the duration of the procedure and will last 4 hours following the procedure. Additional doses of furosemide are allowed in case of decrease of urine flow <300 ml/h.
11536616|NCT01098019|Experimental|Xeomin|Each bottle of Xeomin will be reconstituted with 2 mL of NaCl 0.9 which will give a final concentration of 5 U of botulinum toxin A per 0.1 mL. The area affected will be injected with 0.1 mL at each 1-2 square cm for a maximum total dose of 200 units (4mL).
11536617|NCT01098019|Placebo Comparator|Placebo|Patients will receive 0.9% mL NaCl alone. The area affected will be injected with 0.1 mL at each 1-2 square cm for a maximum volume of 4 mL.
11536618|NCT01098006|Other|Immune tolerant patients Group|Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B viruss (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.
11536619|NCT01098006|Other|HBeAg positive Group|HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with activee inflammation and varying degrees of liver fibbrosis.
11536620|NCT01098006|Other|Inactive carriers Group|Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.
11536621|NCT01098006|Other|HBeAg negative Group|HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.
11536622|NCT01097993|Experimental|1 = Tested product|
11536623|NCT01097993|Active Comparator|2 = Control product|
11536626|NCT01097967|Active Comparator|CPAP in sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
11536627|NCT01097967|No Intervention|no CPAP in non sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
11536628|NCT01097967|Active Comparator|CPAP in non sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
11536629|NCT01097941|Active Comparator|LAIV/LAIV|
11536630|NCT01097941|Active Comparator|IIV/IIV|
11536631|NCT01097941|Active Comparator|IIV/LAIV|
11536632|NCT01097928||Patients undergoing Pulmonary Embolectomy|
11536633|NCT01097915||PROP taste sensitivity|"PROP Sensitive and non sensitive individuals are defined as Tasters and Non-tasters, respectively. Taster are further divided in Super-taster who perceived PROP as extremely bitter and Medium tasters who perceived PROP as moderately bitter."
11536634|NCT01097902|Active Comparator|Ibuprophen 800 mg|Oral ibuprofen 800 mg, administered 24 hours after exposure to UV radiation for the creation of an inflamed lesion, and 2 hours prior to site evaluation.
11536635|NCT01097902|Placebo Comparator|Placebo|Oral placebo administered 24 hours after exposure to UV radiation for the creation of an inflamed lesion, and 2 hours prior to site evaluation.
11536636|NCT01097889|Active Comparator|Treatment Group 1|
11536637|NCT01097889|Experimental|Treatment Group 2|
11536638|NCT01097876|Experimental|Active PF-04447943|
11536639|NCT01097876|Placebo Comparator|Placebo PF-04447943|
11536640|NCT01097863|Experimental|nelfilcon A, modified inversion indicator|Nelfilcon A investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for one week
11536641|NCT01097863|Experimental|nelfilcon A, no inversion indicator|Nelfilcon A investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for one week
11536642|NCT01097863|Active Comparator|nelfilcon A, inversion indicator|Nelfilcon A commercially marketed contact lenses worn in both eyes on a daily wear, daily disposable basis for one week.
11536643|NCT01097850|Other|Right|Application of henna paste to right hand/foot plus CeraVe moisturizer
11536644|NCT01097850|Other|Left|Application of henna paste to the left hand/foot plus CeraVe moisturizer
11536645|NCT01097837||Epilepsy|Cohort is comprised of women with epilepsy between 18 and 47.
11536646|NCT01097811|Active Comparator|Erythromycin|
11536647|NCT01097811|Active Comparator|Neomycin|
11536648|NCT01097798|Experimental|Aliviador|
11536649|NCT01097798|Active Comparator|Gelol|
11536650|NCT01097785|Active Comparator|Simvastatin|40 mg Simvastatin 1 pill every day for 30 days
11536651|NCT01097785|Placebo Comparator|Placebo|Placebo cap 1 pill every day for 30 days
11536652|NCT01097772|Other|Ovation Abdominal Stent Graft System|Implant of Ovation Abdominal Stent Graft System
11536653|NCT01097759||LigaSure|LigaSure is a vascular sealing device that can seal the hemorrhoidal plexus during hemorrhoidectomy (surgery)
11536654|NCT01097759||Stapler|Circular stapler that removes excess loose tissue above the anus and interrupts the blood supply during hemorrhoidal surgery
11536655|NCT01097746|Experimental|Treatment (paclitaxel, carboplatin, bevacizumab)|Participants receive paclitaxel IV over 3 hours on days 1, 8 and 15 and carboplatin IV over 1 hour on day 1. Beginning course 2, participants also receive bevacizumab IV over 1.5 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11536656|NCT01097733||Pre-procedural cardiac CT|CRT patients will undergo pre-procedural cardiac CT to assess for dyssynchrony, scar, and coronary venous anatomy. The CT venogram will be randomize to pre-knowledge to implanting physician or blinded. The CT dyssynchrony and scar assessment will remain blinded to caregivers and patients.
11536657|NCT01097720||LTG-exposed|Children exposed to LTG during pregnancy.
11536658|NCT01097720||VPA-exposed|Children exposed to VPA during pregnancy.
11536659|NCT01097720||CBZ-exposed|Children exposed to CBZ during pregnancy.
11536660|NCT01097707|Experimental|1mg LY500307|
11536661|NCT01097707|Experimental|3mg LY500307|
11536662|NCT01097707|Experimental|10mg LY500307|
11536663|NCT01097707|Experimental|25mg LY500307|
11536664|NCT01097707|Placebo Comparator|Placebo|
11536665|NCT01097694|Active Comparator|Imatinib mesylate|Group on active imatinib treatment
11536666|NCT01097694|Placebo Comparator|Placebo|Group on Placebo treatment
11536667|NCT01097681|Experimental|Normal renal function group|oral
11536668|NCT01097681|Experimental|Mild renal impairment group|oral
11536669|NCT01097681|Experimental|Moderate renal impairment group|oral
11536670|NCT01097668|Experimental|Intradermal injection|Injections will be given by the intradermal route
11536671|NCT01097668|Experimental|Subcutaneous injection|Injections will be given by the subcutaneous route
11536672|NCT01097655||HIV-infected Participants|"HIV-infected participants starting with Kaletra tablets.
~Participants included 3 subgroups:
~antiretroviral therapy (ART) treatment-naïve participants starting with Kaletra tablets
~participants receiving their first protease inhibitor (PI)-containing regimen (apart from Kaletra) pretreated with any non nucleoside reverse transcriptase inhibitor (NNRTI)-containing or nucleoside reverse transcriptase inhibitor (NRTI)-containing regimen
~participants pretreated with a PI-containing regimen (apart from Kaletra)."
11536673|NCT01097642|Active Comparator|Ixabepilone|Brand name is Ixempra ®; it is an epothilone B analog used in combination with other chemotherapeutics against cancer.
11536674|NCT01097642|Experimental|Ixabepilone plus Cetuximab|Cetuximab, brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor and monoclonal antibody used with Ixabepilone against cancer.
11536675|NCT01097629|Experimental|Suvorexant HD|Drug
11536676|NCT01097629|Experimental|Suvorexant LD|Drug
11536677|NCT01097629|Placebo Comparator|Placebo|Placebo Comparator
11536678|NCT01097616|Experimental|Suvorexant HD|Drug
11536679|NCT01097616|Experimental|Suvorexant LD|Drug
11536680|NCT01097616|Placebo Comparator|Placebo|Placebo Comparator
11536681|NCT01097590|Experimental|Active TLA Gut™ column|The active column contain an engineered protein with the ability to specifically bind the inflammatory cells.
11536738|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 1 at low dose|
11536739|NCT01097096|Placebo Comparator|Placebo + Adjuvant 1 at middle dose|
11536682|NCT01097590|Placebo Comparator|Placebo TLA Gut™column|The placebo column is identical to the active column except it does not contain the engineered protein that specifically bind the inflammatory cells.
11536683|NCT01097577|Experimental|pregabalin|Oral Pregabalin 75 mg capsule twice daily administered prior to PRK and continued for 5 days
11536684|NCT01097577|Placebo Comparator|Placebo|Oral placebo capsule (Lactose) twice daily administered prior to PRK and continued for 5 days
11536685|NCT01097564||COL4A1 genetic testing|COL4A1 genetic testing
11536686|NCT01097551||Patients with type 1 diabetes|Diabetes duration >= 5 years, age >= 18 and <= 60 years old, patients with no visible diabetic retinopathy, and no arterial hypertension
11536687|NCT01097551||Healthy subjects|Sex and age-matched control healthy subjects
11536688|NCT01097538|Active Comparator|Body-weight supported treadmill training|Supported treadmill walking
11536689|NCT01097538|Experimental|Total body recumbent stepper training|Recumbent stepper exercise training
11536690|NCT01097525|Active Comparator|Wavefront guided (WFG) PRK|
11536691|NCT01097525|Active Comparator|WFG LASIK|
11536692|NCT01097525|Active Comparator|Wavefront optimized (WFO) PRK|
11536693|NCT01097525|Active Comparator|WFO LASIK|
11536694|NCT01097512|Experimental|Regimen 1: AS703569/gemcitabine|Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle
11536695|NCT01097512|Experimental|Regimen 2: AS703569/gemcitabine|AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle
11536696|NCT01097499|Active Comparator|LED application|Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.
11536697|NCT01097499|No Intervention|No LED application|These patients will receive conventional dental implant treatment without the application of the LED therapy.
11536698|NCT01097486|Active Comparator|Allograft|Cervical Spinal Fusion with Allograft
11536699|NCT01097486|Experimental|NeoFuse|Cervical Spinal Fusion with NeoFuse
11536700|NCT01097473|Active Comparator|Exercise training|Subjects participate in a once weekly supervised exercise training group, duration of 60 min.
11536701|NCT01097473|No Intervention|Control|Control group receives no intervention
11536702|NCT01097460|Experimental|MM-111 + Herceptin|MM-111 will be combined with Herceptin
11536703|NCT01097447||Ciprofloxicine or Vigamox or other|up to qid till epithelialized.
11536704|NCT01097447||Topical Nonsteroidal (Acular, Acuvail, Voltaren Xibrom|up to qid for up to 5-10 days postop
11536705|NCT01097447||Topical steroid (FML, Pred Forte, Flarex|qid for up to 8 weeks
11536706|NCT01097434|Active Comparator|Arm 1|Biodegradable polymer limus-eluting stents
11536707|NCT01097434|Active Comparator|Arm 2|Permanent polymer limus-eluting stent
11536708|NCT01097421||Patient with parkinsons disease|
11536709|NCT01097408|Experimental|AZD7295|
11536710|NCT01097408|Placebo Comparator|Matched placebo|
11536711|NCT01097395|Active Comparator|Standard Weight-Based Ribavirin Dosing|1000 mg daily in patients weighing <75 kg and 1200 mg daily in patients weighing ≥ 75 kg
11536712|NCT01097395|Experimental|Concentration-Controlled Ribavirin Dosing|Dose adjusted based on first dose AUC0-12
11536713|NCT01097382|Experimental|AMBIEN CR|AMBIEN CR 12.5 mg once daily immediately before bedtime or in elderly/hepatically impaired patients: 6.25 mg once daily immediately before bedtime
11536714|NCT01097369||Anti-rasburicase antibodies|
11536715|NCT01097356|No Intervention|common care|HPV+ patients with LSIL on their PAP smear, waiting for 6 months to receive a new PAP smear
11536716|NCT01097356|Experimental|probiotic drinkers|HPV+, LSIL patients who will drink the study drink for 6 months
11536717|NCT01097343|Active Comparator|75 mg clopidogrel|
11536718|NCT01097343|Active Comparator|150 mg clopidogrel|
11536719|NCT01097330|Active Comparator|Ablation|Catheter based radiofrequency ablation for ischemic ventricular tachycardia
11536720|NCT01097330|Active Comparator|Amiodarone|amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study.
11536721|NCT01097304|Experimental|Treatment (ursodiol)|Patients receive ursodiol PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
11536722|NCT01097278|Experimental|Arm I|Participants receive oral cholecalciferol once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
11536723|NCT01097278|Active Comparator|Arm II|Participants receive oral placebo once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
11536724|NCT01097252|Active Comparator|weekly cisplatin|Weekly cisplatin 40mg/m2 during radiation therapy
11536725|NCT01097252|Experimental|tri-weekly cisplatin|cisplatin 75mg/m2 three cycles, every 3 weeks
11536726|NCT01097239|Experimental|High Intensity Focused Ultrasound|Transrectal High Intensity Focused Ultrasound (HIFU) treatment of the PelvicTumour
11536727|NCT01097226|Experimental|Apple flavanols|
11536728|NCT01097200|Other|Elevate meshes|The use of Elevate (American Systems trade mark) meshes for the treatment of pelvic prolapse.
11536729|NCT01097200|Other|Sacrocolpopexy|Sacrocolpopexy for the correction of the prolapse
11536730|NCT01097174||CyPass Micro-stent|Patients in whom CyPass Micro-stent implantation was attempted.
11536731|NCT01097161|Experimental|Speech treatment on prosodic basis|Patients receive 20 therapy sessions over a course of 3 months, with one double session per week.
11536732|NCT01097148|Active Comparator|Atracurium, TBW|Dose of atracurium 0.5 mg/kg based on total body weight
11536733|NCT01097148|Active Comparator|Atracurium IBW|dose 0.5 mg/kg based on ideal body weight
11536734|NCT01097135|No Intervention|Standard surgical skin preparation|
11536735|NCT01097135|Active Comparator|Standard Surgical Skin Preparation with Duraprep|standard surgical skin prep
11536736|NCT01097122|Experimental|Healthy young adult subjects|Forearm vibration will be applied in healthy young adult subjects
11536737|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 1 at middle dose|
11536740|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 2 at middle dose|
11536741|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 2 at low dose|
11536742|NCT01097096|Placebo Comparator|Placebo + Adjuvant 2 at middle dose|
11536743|NCT01097096|Active Comparator|CAD106 450μg + either Adjuvant 1 or 2 at middle dose|
11536744|NCT01097096|Active Comparator|CAD106 450μg + either Adjuvant 1 or 2 at low dose|
11536745|NCT01097096|Placebo Comparator|Placebo + either Adjuvant 1 or 2 at middle dose|
11536746|NCT01097070|Experimental|Bevirimat 200 mg twice daily, 15 days|
11536747|NCT01097070|Experimental|Bevirimat 300 mg once daily, 15 days|
11536748|NCT01097070|Experimental|Bevirimat 400 mg once daily, 15 days|
11536749|NCT01097057|Experimental|Treatment (rituximab, etoposide, carboplatin, ifosfamide)|Patients receive rituximab IV on day 1, etoposide IV on days 2-4, carboplatin IV on day 3, and ifosfamide IV on day 3 over 24 hours. Patients also receive G-CSF SC once daily beginning on day 6 and continuing until apheresis is completed and plerixafor SC once daily for up to 4 days beginning 24 hours after recovery from nadir and continuing until apheresis is completed. Patients may undergo up to 4 apheresis procedures until the optimal number of CD34+ cells are collected.
11536750|NCT01097044|Experimental|Afamelanotide|Dose: 16 mg implant; release of 16 mg over 7 to 10 days Mode of administration: Subcutaneous implantation Frequency: Every 60 days (on Days 0, 60 and 120)
11536751|NCT01097044|Placebo Comparator|Placebo|Dose: 16 mg implant; Mode of administration: Subcutaneous implantation Frequency: Every 60 days (on Days 0, 60 and 120)
11536752|NCT01097031||Continuous Infusion|
11536753|NCT01097031||Intermittent Infusion|
11536754|NCT01097031||Infusion Continuous|
11536755|NCT01097018|Active Comparator|Perifosine + Capecitabine|Perifosine 1 tablet daily + Capecitabine BID days 1 - 14 every 21 days
11536756|NCT01097018|Placebo Comparator|Placebo + Capecitabine|Placebo 1 tablet daily + Capecitabine BID days 1 - 14 every 21 days
11536757|NCT01097005||Klaricid|Those with an exposure
11536758|NCT01096992|Experimental|Phase 1 20 mg/m^2|Bendamustine, Fludarabine + Rituximab
11536759|NCT01096992|Experimental|Phase 2|Bendamustine 30 mg/m^2 by vein (fixed), Days 1,2,3 + Fludarabine + Rituximab
11536760|NCT01096992|Experimental|Phase 1 30 mg/m^2|Bendamustine, Fludarabine + Rituximab
11536761|NCT01096992|Experimental|Phase 1 40 mg/m^2|Bendamustine, Fludarabine + Rituximab
11536762|NCT01096992|Experimental|Phase 1 50 mg/m^2|Bendamustine, Fludarabine + Rituximab
11536763|NCT01096979|Experimental|LIPO-102, High|LIPO-102, High
11536764|NCT01096979|Experimental|LIPO-102, Low|LIPO-102, Low
11536765|NCT01096979|Experimental|Placebo|Pbo
11536766|NCT01096966|Experimental|Bupivacaine TTS|
11536767|NCT01096966|Placebo Comparator|Placebo patch|
11536768|NCT01096953|Active Comparator|Telepsychiatry|Psychiatry provided over telehealth network
11536769|NCT01096953|Active Comparator|Face-to-face care|Psychiatry provided in person
11536770|NCT01096940|Experimental|1|AZD1656
11536771|NCT01096940|Experimental|2|Simvastatin
11536772|NCT01096940|Experimental|3|AZD1656 + simvastatin
11536773|NCT01096927|Experimental|Non operative Treatment group|Patients with Lower Abdominal and suspected Acute Appendicitis, treated non-operatively with 7 days antibiotic therapy (Amoxicillin and Clavulanic Acid)
11536774|NCT01096914|Active Comparator|Radiofrequency|patients treated with percutaneous radiofrequency ablation
11536775|NCT01096914|Active Comparator|laser|Patients treated with percutaneous laser ablation
11536776|NCT01096901|Active Comparator|Comprehensive behavioral weight loss|The group will be implemented to induce a 6% weight loss over 3 months. The lessons will follow protocols from the Look AHEAD trial and Diabetes Prevention Program. This behavioral program has been shown to promote long-term weight loss and a reduction in diabetes and cardiovascular risk factors, and is based on the social cognitive theory.
11536777|NCT01096901|No Intervention|Education and Support Control group|Participants in this group will receive support and education about healthy eating and activity with lessons based on the Look AHEAD support and education control condition. Participants will attend monthly closed group meetings and meetings will be designed to promote retention but not weight loss.
11536778|NCT01096888|No Intervention|Standard WIC care|Patients randomized to this group will receive standard WIC care and an information packet surround healthy eating and activity topics.
11536779|NCT01096888|Active Comparator|Enhanced WIC weight loss program|Participants randomized into this condition will receive standard WIC care, but will also receive weight loss classes provided through the internet. Topics will cover behavioral weight loss topics, based off the protocols of the Look AHEAD program.
11536780|NCT01096875|Active Comparator|Atorvastatin|Hydroxymethylglutaryl-CoA Reductase Inhibitors
11536781|NCT01096875|Placebo Comparator|Placebo|Atorvastatin like pill
11536782|NCT01096862|Experimental|Group 1|lowest dose
11536783|NCT01096862|Experimental|Group 2|low dose
11536784|NCT01096862|Experimental|Group 3|high dose
11536785|NCT01096862|Experimental|Group 4|highest dose
11536786|NCT01096862|Experimental|Group 5|medium dose
11536787|NCT01096862|Placebo Comparator|Placebo|Matching placebo
11536788|NCT01096849|Experimental|plazomicin (10 mg/kg)|Patients received two intravenous (IV) infusions daily for 5 consecutive days: 10 milligrams per kilogram (mg/kg) plazomicin followed by placebo.
11536789|NCT01096849|Experimental|plazomicin (15 mg/kg)|Patients received two IV infusions daily for 5 consecutive days: 15 mg/kg plazomicin followed by placebo.
11536790|NCT01096849|Active Comparator|levofloxacin|Patients received two IV infusions daily for 5 consecutive days: placebo followed by 750 milligrams (mg) levofloxacin.
11536791|NCT01096836|Experimental|Diet counseling|Outcomes of the study may enhance diet counseling
11536792|NCT01096836|Experimental|exercise training|
11536793|NCT01096823|Experimental|Iyengar Yoga|
11536794|NCT01096823|No Intervention|Waitlist Control|
11536795|NCT01096810|Experimental|TBL 12|TBL 12, sea cucumber, will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression
11536796|NCT01096797|Experimental|Children undergoing adenotonsillectomy|Children between 2-6 years old undergoing elective adenoidectomy with or without tonsillectomy from the ENT Service of the San Gerardo Hospital.
11536797|NCT01096784|Active Comparator|rhIGF-I/rhIGFBP-3|Continuous IV Infusion
11536798|NCT01096784|No Intervention|Control|The comparator group will receive no treatment with rhIGF-1/rhIGFBP-3
11536799|NCT01096771|Experimental|ClinOleic 20%|96 hour continuous infusion.
11536800|NCT01096771|Active Comparator|Intralipid 20%|96 hour continuous infusion.
11536801|NCT01096758||PKU patients|
11536802|NCT01096758||healthy controls|
11536803|NCT01096745|Experimental|Gemcitabine/Cisplatin|
11536804|NCT01096745|Experimental|S-1/Cisplatin|D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
11536805|NCT01096732|Experimental|GDC-0449|Study drug.
11536806|NCT01096719|Experimental|Energy Density|
11536807|NCT01096719|Active Comparator|Lifestyle Treatment|
11536808|NCT01096719|Experimental|Energy Density + Lifestyle Treatment|
11536809|NCT01096706|Experimental|Nitric Oxide Clamp|Forearm blood flow response to Urocortins 2, 3 and Substance P in the presence of Nitric Oxide clamp
11536810|NCT01096706|Placebo Comparator|Saline Placebo|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of saline placebo.
11536811|NCT01096706|Experimental|Fluconazole|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of intra-arterial Fluconazole.
11536812|NCT01096706|Experimental|Aspirin|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of cyclooxygenase inhibition with Aspirin.
11536813|NCT01096706|Experimental|Combined|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of inhibition of cycloxygenase, EDHF and NO pathways with Aspirin, Fluconazole and NO clamp.
11536814|NCT01096693|Placebo Comparator|Saline Placebo|In this arm, the response in forearm blood flow to incremental doses of Urocortins 2, 3 and Substance P will be studied co infused with saline placebo.
11536815|NCT01096693|Active Comparator|Response to Urocortin infusion in presence of Astressin 2B|This arm studies the response to intra arterial infusion of incremental doses of Urocortins 2, 3 and Substance P in the presence or absence of a selective antagonist - Astressin 2B.
11536816|NCT01096680|Experimental|SPD489 20 mg|
11536817|NCT01096680|Experimental|SPD489 50 mg|
11536818|NCT01096680|Experimental|SPD489 70 mg|
11536819|NCT01096680|Active Comparator|Armodafinil|
11536820|NCT01096680|Placebo Comparator|Placebo|
11536821|NCT01096667|Placebo Comparator|Placebo|Placebo to ertugliflozin (resembling either 1 mg or 5 mg), placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days.
11536822|NCT01096667|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
11536823|NCT01096667|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
11536824|NCT01096667|Experimental|Ertugliflozin 25 mg|Ertugliflozin 25 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to HCTZ once daily for 28 days
11536825|NCT01096667|Active Comparator|HCTZ 12.5mg|HCTZ 12.5 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to ertugliflozin (resembling 25 mg) once daily for 28 days
11536826|NCT01096654|Active Comparator|CT-scan|In this group treatment will be based on the outcome of the CT-scan only. Patients will be treated by adrenalectomy (Adx) if an unilateral lesion is visible on the CT-scan and the contralateral gland is normal. If bilateral lesions, bilateral enlargement or symmetric normal adrenal glands are present patients will be treated by the mineralocorticoid receptor antagonist (MRA)
11536827|NCT01096654|Active Comparator|Adrenal Vein Sampling|"This group will be treated according to the results of the adrenal vein sampling only. Adrenal vein sampling will be performed under the continuous infusion of ACTH (adrenocorticotropic hormone). A cortisol ratio ≥ 3 between the adrenal vein and the inferior vena cava is set as the criterium for successful cannulation. The criterium for lateralization is a aldosterone/cortisol ratio ≥ 4 between the adrenal veins and a lower aldosterone/cortisol ratio in the contralateral adrenal vein than in the inferior vena cava.
~If AVS fails patients will be treated according to the CT-findings as described in the group with CT-scan only. Patients with a successful AVS will be treated by Adrenalectomy if unilateral production of aldosterone is shown. If no unilateral aldosterone production is present, i.e. the aldosterone/cortisol ratio is less than 4, patients will be treated by MRA."
11536828|NCT01096641|Other|Fatigued patients: Immediate start CBT|After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients. At the end of the therapy, after 6 months, a second assessment will take place.This assessment will include the same measurements as at baseline.
11536829|NCT01096641|Other|fatigues patients: delayed CBT (after 6 months)|The fatigued patients on the waiting list will start with CBT after 6 months
11536830|NCT01096641|No Intervention|non-fatiqued controls|Non-fatigued control group. This group is not included in the randomization.
11536831|NCT01096628|Experimental|Chiropractic + Exercise|
11536832|NCT01096628|Active Comparator|Exercise|
11536833|NCT01096615|Active Comparator|Tested product: Lactobacillus paracasei LP-33|Each patient will be randomly assigned to either tested product or comparative product (placebo) in accordance with a randomisation table
11536834|NCT01096615|Placebo Comparator|Comparative product : placebo|Each patient will be randomly assigned to either tested product or comparative product (placebo) in accordance with a randomisation table .
11536835|NCT01096602|Experimental|Group 1|DC AML Fusion Vaccine
11536836|NCT01096589|Experimental|Arm 1 - 3M Coban 2|3M Coban 2 - 2 apps/wk
11536837|NCT01096589|Experimental|Arm 2 - 3M Coban 2|3M Coban 2 - 3 apps/wk
11536838|NCT01096589|Experimental|Arm 3 - 3M Coban 2|Arm 3 - 3M Coban 2 - 5 apps/wk
11536839|NCT01096589|Active Comparator|Arm 4 - Comprilan|Comprilan short-stretch bandage 5 apps/wk
11536840|NCT01096576|Experimental|A|
11536841|NCT01096576|Placebo Comparator|B|
11536842|NCT01096563|Experimental|1|AZD9164
11536843|NCT01096563|Placebo Comparator|2|
11536844|NCT01096550|Experimental|Intensive Outpatient|Buprenorphine patients receiving 9 or more hours of outpatient counseling.
11536845|NCT01096550|Active Comparator|Outpatient|Buprenorphine patients receiving between 2 and 8 hours of outpatient counseling.
11536846|NCT01096537||Young workers|"Exposed young workers graduated in sectors at risk of occupational asthma (bakery, pastry-making or hairdressing)
~Non-exposed young workers graduated in sectors without specific occupational exposure as the sale or the food sectors."
11536847|NCT01096524|Other|Control group standard physiotherapy|Standard pathway of care pre-and post-TKA without using NMES.
11536848|NCT01096524|Experimental|Kneehab|Kneehab on the quadriceps of the affected leg, 20 minutes, twice per day, 5 days per week over 12-week intervention (6 weeks pre-op, 6 weeks post op).
11536849|NCT01096511||Group 1|
11536850|NCT01096498|Experimental|Arm 1|
11536851|NCT01096498|Active Comparator|Arm 2|
11536852|NCT01096485|Experimental|Arm 1|
11536853|NCT01096485|Active Comparator|Arm 2|
11536854|NCT01096472|Experimental|LAS41003|Once daily
11536855|NCT01096472|Active Comparator|LAS189962|Once daily
11536856|NCT01096472|Active Comparator|LAS189961|Once daily
11536857|NCT01096446|Experimental|Higher Infusion|Infants randomized into the experimental group will receive 2 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
11536858|NCT01096446|Other|Standard Infusion|Infants randomized into the control group will receive 0.5 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
11536859|NCT01096433|Experimental|CPAP|The subjects introduced with CPAP treatment
11536860|NCT01096420|Experimental|acupuncture|
11536861|NCT01096420|Active Comparator|topiramate|
11536862|NCT01096407||Paclitaxel-Induced Myalgias/Arthralgias|
11536863|NCT01096394||Ovarian cancer|Patients with presumed Stage III-IV ovarian, primary fallopian tube, or primary peritoneal papillary serous carcinoma.
11536864|NCT01096381||Will receive bevacizumab|
11536865|NCT01096381||Will not receive bevacizumab|
11536866|NCT01096368|Experimental|Arm I (radiotherapy, chemotherapy)|Patients receive vincristine IV over 1 minute on days 1 and 8 of cycles 1 and 2, carboplatin IV over 15-60 minutes on day 1 of cycles 1 and 2, and cyclophosphamide IV over 30-60 minutes on days 1-2 of cycle 1 only. Patients also receive etoposide IV over 60-120 minutes on days 1-3 of cycle 2 only. Cycle 1 continues for 3 weeks and cycle 2 continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
11536867|NCT01096368|Experimental|Arm II (radiotherapy, chemotherapy)|Patients undergo conformal radiotherapy over 6-7 weeks. Patients then receive vincristine IV on days 1, 8, and 15 of cycles 1-3 only, etoposide IV over 60-120 minutes on days 1-3, cisplatin IV over 1-8 hours on day 1, and cyclophosphamide IV over 30-60 minutes on days 2-3. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
11536868|NCT01096368|Active Comparator|Arm III (radiotherapy, observation)|Patients undergo conformal radiotherapy over 6-7 weeks and then undergo observation.
11536869|NCT01096355|Experimental|Group A|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3 and 8-10.
~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
11536870|NCT01096355|Experimental|Group B|"Patients receive oral RO4929097 once daily on days 1-7.
~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
11536871|NCT01096355|Experimental|Group C|"Patients receive oral RO4929097 once daily on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21.
~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
11536872|NCT01096355|Experimental|Group D|"Patients receive oral RO4929097 once daily on days 1, 8, and 15.
~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
11536873|NCT01096355|Experimental|Group E|"Patients receive oral RO4929097 once daily on days 1, 4, 8, 11, 15, and 18.
~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
11536874|NCT01096355|Experimental|Group F|"Patients receive oral RO4929097 once daily days 1-5, 8-12, and 15-19.
~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
11536875|NCT01096342|Experimental|Treatment|Patients receive dinaciclib IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11536876|NCT01096329|Active Comparator|Cohort 2|Testosterone Spray (5%) vs Intrinsa® Patch
11536877|NCT01096329|Active Comparator|Cohort 3|Testosterone Spray (1%) vs Intrinsa® Patch
11536878|NCT01096329|Active Comparator|Cohort 1|Testosterone Spray (5%) vs Testosterone Spray (1%)
11536879|NCT01096316|Experimental|Intervention|"The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:
~enhanced education of patients and providers
~engagement of patients
~depression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation."
11536880|NCT01096316|No Intervention|Usual Care|Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.
11536881|NCT01096303||COPD tobacco and/or marihuana users|COPD patients with history of tobacco and/or marihuana smoking.
11536882|NCT01096290|Experimental|Lubiprostone 24mcg BID for 30 days|Active medication
11536883|NCT01096290|Placebo Comparator|Placebo|Placebo, matched, blinded
11536884|NCT01096277|Active Comparator|Sitagliptin|100 mg sitagliptin per day for 2 weeks
11536885|NCT01096277|Placebo Comparator|Placebo|1 placebo tablet per day for 2 weeks
11536886|NCT01096277|No Intervention|Healthy Control|Healthy control subjects
11536887|NCT01096264|Other|Healthy volunteer|"Healthy volunteer undergoing two imagery evaluation :
~SSI technique for local PWV and arterial stiffness evaluation
~SphygmoCor® for aortic PWV."
11536888|NCT01096264|Other|vEDS patients|"vEDS patients undergoing two imagery evaluations:
~SSI technique for local PWV and arterial stiffness evaluation
~SphygmoCor® for aortic PWV."
11536889|NCT01096251|Experimental|CBT|CBT group: in-hospital treatment (diet, physical activity, dietitian counseling, 8 sessions of CBT) plus 8 outpatient telephone-based sessions of CBT-oriented psychological support and monitoring with the same CBT inpatient psychotherapists.
11536890|NCT01096251|Experimental|BST|BST group: in-hospital treatment (diet, physical activity, dietitian counseling, 8 sessions of BST) plus 8 outpatient telephone-based sessions of BST-oriented psychological support and monitoring with the same BST inpatient psychotherapists.
11536891|NCT01096225||vaccinated group|
11536892|NCT01096212|Experimental|generic sevoflurane|
11536893|NCT01096212|Active Comparator|origianl sevoflurane|
11536894|NCT01096186|Other|Open Label IPX066|Subjects received IPX066 95 mg, IPX066 145 mg, IPX066 195 mg, or IPX066 245 mg for approximately 9 months. The dose and dosing frequency was determined by the investigator.
11536895|NCT01096160|Experimental|Panel A: MK-8266 BID, 1 mg/Placebo|MK-8266 1 mg (0.7 mg in the morning [AM] + 0.3 mg in the evening [PM]), or as matching placebo BID.
11536896|NCT01096160|Experimental|Panel B: MK-8266 BID, 1.8 mg/Placebo|MK-8266 1.8 mg (1 mg in the AM + 0.8 mg in the PM), or as matching placebo BID.
11536897|NCT01096160|Experimental|Panel C: MK-8266 TID, 1.8 mg/Placebo|MK-8266 TID, 1.8 mg (0.6 mg every 6 hours [q6hr]), or as matching placebo TID.
11536898|NCT01096160|Experimental|Panel D: MK-8266 TID, 2.4 mg/Placebo|MK-8266 TID (Panel D), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel D was completed prior to initiation of Panel E.
11536899|NCT01096160|Experimental|Panel E: MK-8266 TID, 2.4 mg/Placebo|MK-8266 TID (Panel E), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel E was initiated after completion of Panel D.
11536900|NCT01096147|Active Comparator|SCS|patients receiving SCS for chronic leg and/or back pain.
11536901|NCT01096134|Experimental|HPV Vaccine|Eligible girls were offered 3 doses of the HPV vaccine
11536902|NCT01096121|Placebo Comparator|2|
11536903|NCT01096121|Experimental|1|Enalapril
11536904|NCT01096108|Experimental|Standard Contest|Smoking abstinence, 1 prize award (month 1)
11536905|NCT01096108|Experimental|Standard Contest plus MAPS|Smoking abstinence, 1 prize award (month 1) plus motivational and problem-solving counseling (MAPS - Counseling phone calls); 20 weeks.
11536906|NCT01096108|Experimental|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
11536907|NCT01096108|Experimental|Extended Contests plus MAPS|Extended quit and win contests (3 successive monthly contests) plus motivational and problem-solving counseling (MAPS). {Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3) plus Counseling phone calls.
11536908|NCT01096095|Placebo Comparator|Placebo|Placebo
11536909|NCT01096095|Experimental|Sodium phenylbutyrate|Active drug
11536910|NCT01096082|Placebo Comparator|Placebo|
11536911|NCT01096082|Experimental|Lithium Carbonate|
11536912|NCT01096069||Rituximab|Rheumatoid arthritis patients undergoing treatment with rituximab.
11536913|NCT01096056|Experimental|Influenza vaccine GSK2186877A formulation 1 Group|Subjects received 2 doses of influenza vaccine GSK2186877A formulation 1 at Day 0 and Day 21 and 1 dose of Fluarix vaccine at Month 6.
11536914|NCT01096056|Experimental|Influenza vaccine GSK2186877A formulation 2 Group|Subjects received 1 dose of influenza vaccine GSK2186877A formulation 2 at Day 0 and 1 dose of Fluarix vaccine at Month 6.
11536915|NCT01096043|Placebo Comparator|Placebo|Each Strata of the study will have a placebo control. In strata A, the chance of getting active drug is 4 out of 5, in Strata B the chance of getting active drug is 3 ot of 4, and in Strata C, the chance of getting active Drug is 4 out of 5. In the event that a patient is allocated to receive placebo, the treatment may be stopped if the patient's condition fails to improve or worsens during the placebo infusion.
11536916|NCT01096043|Experimental|Strata 1 CXL-1020|Patients assigned to CXL-1020 in strata one will have their dose increased from the initial dose 2 times during the study period. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
11536917|NCT01096043|Experimental|Strata 2 CXL-1020|In strata 2, patients who are assigned to active treatment will receive one of up to 3 possible fixed dose levels of CXL-1020 for a period of 6 hours. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
11536918|NCT01096043|Experimental|Strata 3 CXL-1020|In strata 3, patients assigned to receive CXL-1020 will receive a fixed dose of CXL-1020 for 6 hours, and then the dose may be increased or decreased, based on the investigators assessment of the patient. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
11536919|NCT01096030|Experimental|Regorafenib|
11536920|NCT01096017|Experimental|1|Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI ⇒salbutamol pMDI 200 μg +placebo Turbuhaler®
11536921|NCT01096017|Experimental|2|salbutamol pMDI 200 μg +placebo Turbuhaler® ⇒Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI
11536922|NCT01096004|Experimental|1|
11536923|NCT01096004|Placebo Comparator|2|
11536924|NCT01095991|Experimental|1|AZD1656, day 1-5, AZD1656 + Sitagliptin day 6-10, Sitagliptin day 11-15.
11537189|NCT01094275||Loss of Haplotype CYP2C19|clopidogrel 75mg alone
11536925|NCT01095991|Experimental|2|Sitagliptin day 1-5, AZD1656 + Sitagliptin day 6-10, AZD1656 day 11-15.
11536926|NCT01095978||Acute upper respiratory tract diseases, bronchitis, pneumonia|
11536927|NCT01095965|Experimental|Lifestyle education|Nutrition education comprised of 4 components: Curriculum (8 weeks), follow-up meetings (4 monthly plus 2-bimonthly), education materials for use at home and vegetable gardening demonstrations.
11536928|NCT01095952|Experimental|AVNS ON|Consulta downloaded with AVNS to provide high frequency bursting during fastly conducted AF. AVNS will be programmed on for five months. The feasibility and safety of the AVNS algorithm to reduce inappropriate shocks will be monitored.
11536929|NCT01095939|Placebo Comparator|Control Arm|
11536930|NCT01095939|Experimental|Benazepril|
11536931|NCT01095926|Experimental|Doxorubicin|
11536932|NCT01095913|Experimental|IC-Green Injections|ICG Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
11536933|NCT01095900||LIS group)|
11536934|NCT01095900||BT group|
11536935|NCT01095887|Experimental|eculizumab|Eculizumab was given on Day 0, day 1, and weekly for the first four weeks after transplant.
11536936|NCT01095861|Experimental|FlexTip ETT|FlexTip ETT
11536937|NCT01095861|Placebo Comparator|Control|Standard Flexible ETT Mallinckrodt Hi-Lo cuffed tracheal tube Catalog # 86114 Mallinckrodt, ST. Louis, MO, 63134
11536938|NCT01095848|Experimental|0.25ml dose DPX-0907|On each vaccination day the lyophilized antigen/adjuvant/liposome complex is re-suspended in the oil (Montanide 1SA51 VG) before injection. The vaccine is not an emulsion.
11536939|NCT01095848|Experimental|1ml dose DPX-0907|On each vaccination day the lyophilized antigen/adjuvant/liposome complex is re-suspended in the oil (Montanide 1SA51 VG) before injection. The vaccine is not an emulsion.
11536940|NCT01095835|Experimental|PEG-IFN48|Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks.
11536941|NCT01095835|Experimental|PEG-IFN96|Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by another 48 weeks of PEG-IFN treatment (total 96 weeks of treatment).
11536942|NCT01095835|Experimental|PEG-IFN+LAM96|Treatment with PEG-IFN and lamivudine in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by 48 weeks of only PEG-IFN treatment (total 96 weeks of treatment).
11536943|NCT01095822|Active Comparator|Aliskiren|25 patients with recently diagnosed hypertension and mild to moderate type 2 diabetes will constitute the proposed study population. The diagnosis of diabetes will be made based on the American Diabetes Association criteria, such as random plasma glucose >200 mg/dL with or without symptoms of hyperglycemia (polydipsia, polyuria, polyphagia) and weight loss, or fasting plasma glucose > 126 mg/dL, to be determined at least twice. Patients will qualify if they are insulin-free, treated with an oral antiglycemic agent,(metformin only) and/or managed on diet alone for no less than 30 days and have adequate glucose control at the time of their Screening Visit.
11536944|NCT01095822|Experimental|Aliskiren + Valsartan|25 patients with recently diagnosed hypertension, and mild to moderate type 2 diabetes will constitute the proposed study population. The diagnosis of diabetes will be made based on the American Diabetes Association criteria, such as random plasma glucose >200 mg/dL with or without symptoms of hyperglycemia (polydipsia, polyuria, polyphagia) and weight loss, or fasting plasma glucose > 126 mg/dL, to be determined at least twice. Patients will qualify if they are insulin-free, treated with an oral antiglycemic agent,(metformin only) and/or managed on diet alone for no less than 30 days and have adequate glucose control at the time of their Screening Visit.
11536945|NCT01095809|Experimental|bevacizumab|intravitreous bevacizumab 2,5 mg at baseline, week 4 and 8. reinjection is required.
11536946|NCT01095809|Experimental|triamcinolone acetonide|intravitreous triamcinolone 2 mg, frequency: 3 months
11536947|NCT01095796|Experimental|Stribild|Stribild plus placebo to match Atripla
11536948|NCT01095796|Active Comparator|Atripla|Atripla plus placebo to match Stribild
11536949|NCT01095783|Experimental|Physiotherapeutic intervention|
11536950|NCT01095783|Other|control|The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
11536951|NCT01095770|Active Comparator|Ablation Frontiers Ablation|This group will undergo AF ablation using Ablation Frontiers Technology.
11536952|NCT01095770|Active Comparator|LASSO ablation|This group will undergo atrial fibrillation ablation with traditional LASSO technology
11536953|NCT01095770|Active Comparator|Reveal XT monitoring|This group will be monitored pre and post ablation using a Reveal XT implantable loop recorder.
11536954|NCT01095770|Active Comparator|Permanent Pacemaker - dual chamber|This group will be monitored pre and post ablation with a dual chamber permanent pacemaker
11536955|NCT01095757|Other|Plerixafor + Chemo and G-CSF|Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.
11536956|NCT01095744||EOAD typical AD|this cohort is constituted with early onset typical AD.
11536957|NCT01095744||LOAD typical|this group is constituted with late onset typical AD
11536958|NCT01095744||atypical AD|this group is constituted with atypical form of focal cortical atrophy, like posterior cortical atrophy and logopenic progressive aphasia.
11536959|NCT01095744||young controls|under 65
11536960|NCT01095744||old controls|over 65
11536961|NCT01095731|Placebo Comparator|Sugar Pill, Hunt Hess Grade I-III|Good Grade (Hunt Hess I-III), n=15
11536962|NCT01095731|Experimental|Tiopronin, Hunt Hess Grade I-III|Good Grade (Hunt Hess I-III), n=15
11536963|NCT01095731|Experimental|Tiopronin, Hunt Hess Grade IV-V|Poor Grade (Hunt Hess IV-V), n=15
11536964|NCT01095731|Placebo Comparator|Sugar Pill, Hunt Hess Grade IV-V|Poor Grade (Hunt Hess IV-V), n=15
11537015|NCT01095406|Active Comparator|S1 ventilation|Mechanical ventilation with S1 the thrid hour of ventilation
11537016|NCT01095406|No Intervention|Servo i ventilation|1 hour ventilation in pressure support mode with Servo i
11537017|NCT01095393||Certolizumab pegol (CZP)|Patients with RA receiving treatment with certolizumab pegol (CZP; Cimzia®)
11537018|NCT01095393||Non-biologic DMARD|Subjects with RA receiving treatment with non-biologic DMARD
11537066|NCT01095042|Experimental|Control group|30 Asymptomatic Healthy Volunteers Intervention : Observation of emotional behavior in asymptomatic healthy volunteers subjected to stress.
11536965|NCT01095718|Experimental|Errorless Learning|"Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them.
~The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.
~The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.
~During cueing the patient will mostly receive verbal and visual cues and if necessary physical help."
11536966|NCT01095718|Active Comparator|Modeling|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step.Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.
~The therapist does the steps, at the same time he/she uses verbal cues during the performance. Then the therapist asks immediately to the patient to do the steps."
11536967|NCT01095718|Active Comparator|Trial and Error|"Trial and Error refers to the regular unstructured learning and is considered as control condition.
~Here the patient is encouraged to complete the task. When there is mistake, the therapist corrects it. Verbal cues will only be provided if the patient is unable to find and complete the correct next step or commit mistakes. The therapist use general instruction: Here is task, I will ask you to actions, followed by specific instruction, and I will help you after you have tried."
11536968|NCT01095705|Active Comparator|Conventional procedure|Local anaesthesia (Lidocaïne)
11536969|NCT01095705|Experimental|Conventional procedure + Hypnosis|Local anaesthesia (Lidocaïne) and Hypnosis
11536970|NCT01095692|Active Comparator|only surgery|
11536971|NCT01095692|Experimental|surgery + TOT|
11536972|NCT01095679|Experimental|Baclofen|
11536973|NCT01095679|Placebo Comparator|Placebo|Placebo
11536974|NCT01095666|Experimental|Group 1|
11536975|NCT01095666|Experimental|Group 2|
11536976|NCT01095666|Experimental|Group 3|
11536977|NCT01095653|Experimental|Group 1|
11536978|NCT01095653|Experimental|Group 2|
11536979|NCT01095653|Experimental|Group 3|
11536980|NCT01095640|Experimental|adapalene 0.3% topical gel (Actavis Mid-Atlaqntic LLC)|
11536981|NCT01095640|Active Comparator|Differin® (adapalene 0.3% topical gel)|
11536982|NCT01095640|Placebo Comparator|Vehicle Control|
11536983|NCT01095627|Other|Metacholine Challenge|Exhaled breath analysis following metacholine challenge
11536984|NCT01095614||12 women with oral contraception|
11536985|NCT01095614||12 women without any contraception|
11536986|NCT01095601|Other|Treatment A|2x100 mg Formulation II avanafil tablet, fasted
11536987|NCT01095601|Other|Treatment B|2x100 mg Formulation II avanafil tablet, fed
11536988|NCT01095601|Other|Treatment C|2x100 mg Formulation I avanafil tablet, fasted
11536989|NCT01095601|Other|Treatment D|1x50 mg Formulation II avanafil tablet, fasted
11536990|NCT01095588|Experimental|Avanafil|
11536991|NCT01095588|Placebo Comparator|Placebo|
11536992|NCT01095575|Active Comparator|group 1|NS preoperatively and MO postoperatively
11536993|NCT01095575|Active Comparator|group 2|MO preoperatively and NS postoperatively
11536994|NCT01095562|Experimental|ABT-126 Dose 1|
11536995|NCT01095562|Experimental|ABT-126 Dose 2|
11536996|NCT01095562|Placebo Comparator|Sugar Pill|
11536997|NCT01095549|Placebo Comparator|Control group|HD patients who will not receive far infrared therapy in this study.
11536998|NCT01095549|Experimental|Far infrared therapy|In this study, a WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt<mw>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on maintenance HD.
11536999|NCT01095510|Experimental|500 U CINRYZE (10-25 kg body weight)|Single IV dose of 500 U CINRYZE
11537000|NCT01095510|Experimental|1000 U CINRYZE (10-25 kg body weight)|Single IV dose of 1000 U CINRYZE
11537001|NCT01095510|Experimental|1000 U CINRYZE (>25 kg body weight)|Single IV dose of 1000 U CINRYZE
11537002|NCT01095510|Experimental|1500 U CINRYZE (>25 kg body weight)|Single IV dose of 1500 U CINRYZE
11537003|NCT01095497|Experimental|IV CINRYZE First, Then SC CINRYZE Dose 1|
11537004|NCT01095497|Experimental|IV CINRYZE First, Then SC CINRYZE Dose 2|
11537005|NCT01095484||Rotigotine|Patients who have a documented medical necessity to receive treatment with rotigotine treatment in accordance with standard medical practice.
11537006|NCT01095471|Experimental|PCV13|Initial vaccination with PCV13
11537007|NCT01095471|Experimental|PCV7|Initial intervention with PCV7
11537008|NCT01095458|Experimental|Phone based weight management group|Group based weight management program delivered via conference calls
11537009|NCT01095458|Experimental|Clinic based weight management group|Traditional clinical based group weight management program
11537010|NCT01095445|No Intervention|Standard of care treatment|Participants will be randomized to receive only the standard 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin).
11537011|NCT01095445|Active Comparator|Extended therapy|Participants will be randomized to receive 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin) in addition to their standard of care therapy.
11537012|NCT01095432||Main Study Group|All subjects who are undergoing a standard of care colonoscopy for flexible sigmoidoscopy and have a history of UC and agree to participate will be in the main study group.
11537013|NCT01095419|No Intervention|Control|Patients were seated in a chair for the same period then those from MT group, but did not receive intervention
11537014|NCT01095419|Experimental|Massage Therapy|Patients in the postoperative period of coronary artery bypass graft surgery, which receive intervention for 3 consecutive days
11537064|NCT01095055|Experimental|Group 1|AdCh63 AMA1
11537019|NCT01095380|Active Comparator|Treadmill training - manual assist (TM)|Participants in the TM group received partial body weight support unilateral or bilateral manual assistance from a trainer for stepping
11537020|NCT01095380|Active Comparator|Treadmill training - electrical stimulation (TS)|Participants in the TS group received partial body weight support and bilateral functional electrical stimulation to assist stepping
11537021|NCT01095380|Active Comparator|Overground Training (OG)|Training over ground with body weight support and electrical stimulation for dorsiflex assistance
11537022|NCT01095380|Active Comparator|Treadmill training - locomat robot (LR)|Treadmill training with partical body weight support and assistance of a robotic gait orthosis for stepping
11537023|NCT01095367|Active Comparator|Seprafilm™|Subject will have 3 sheets of Seprafilm™ placed in her abdominal cavity (in the pelvis, upper abdomen and below the incision) at the end of debulking surgery. At 7-21 days after surgery the subject will receive a contrast dye, Iohexol (Omnipaque™), into her intraperitoneal port. The subject will then undergo 3 abdominal X-rays, to assess the extent of abdominal adhesions.
11537024|NCT01095367|No Intervention|No Seprafilm™|Subject will undergo debulking surgery without Seprafilm™ placement (standard care). At 7-21 days after surgery the subject will receive a contrast dye, Iohexol (Omnipaque™), into her intraperitoneal port. The subject will then undergo 3 abdominal X-rays, to assess the extent of abdominal adhesions.
11537025|NCT01095354||Asthma Patients|Spirometry. Bronchodilator with Salbutamol. Induced sputum in > 10 years of age using Sodium Chloride Inhalation. Multiple Breath Washout (MBW).
11537026|NCT01095341||THP|THP: patients undergoing parathyroidectomy according to tertiary hyperparathyroidism
11537027|NCT01095341||Other causes|patients with hyperthyroidism not caused by parathyroidectomy
11537028|NCT01095328|Experimental|intervention|Screening for Q-fever during pregnancy
11537029|NCT01095328|No Intervention|control|No screening for Q-fever during pregnancy
11537030|NCT01095315|No Intervention|standard|parturients were placed back to the supine position immediately after spinal injection following standard protocol of spinal anesthesia
11537031|NCT01095315|Experimental|lateral|the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
11537032|NCT01095302|Experimental|Ombrabulin/ docetaxel/cisplatin|AVE8062 combined with docetaxel and cisplatin will be administered once in every 3 weeks, with 30-minute intravenous infusion
11537033|NCT01095289||Total Laryngectomized|
11537034|NCT01095276|Placebo Comparator|Nebulized saline|patients on mechanical ventilation who were randomized to receive a placebo comparator (vehicle solution for dornase alpha)
11537035|NCT01095276|Active Comparator|dornase alpha|patients on mechanical ventilation who were randomly assigned to receive dornase alpha by in-line nebulization
11537036|NCT01095263|Experimental|Sham then Stimulation|
11537037|NCT01095263|Experimental|Stimulation then Sham|
11537038|NCT01095250|Experimental|AIN457 300mg s.c every 2 weeks|AIN457 300 mg s.c. at baseline, Week 1 and Week 2, then every 2 weeks.
11537039|NCT01095250|Experimental|AIN457 300mg s.c. every 4 weeks|AIN457 300 mg s.c. at baseline and Week 2, then every 4 weeks.
11537040|NCT01095250|Experimental|AIN457 150mg s.c every 4 weeks|AIN457 150 mg s.c. at baseline and Week 2, then every 4 weeks
11537041|NCT01095250|Placebo Comparator|Placebo s.c every 2 weeks|Placebo s.c at baseline, Week 1 and Week 2, then every 2 weeks
11537042|NCT01095224|Experimental|rAd35 Env A and rAd5 Env A|Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env A vaccine at Month 3.
11537043|NCT01095224|Experimental|rAd35 Env A and rAd5 Env B|Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
11537044|NCT01095224|Experimental|rAd35 Env A and rAd35 Env A|Participants will receive the rAd35 Env A vaccine at baseline and at Month 3.
11537045|NCT01095224|Experimental|rAd5 Env A and rAd5 Env A|Participants will receive the rAd5 Env A vaccine at baseline and at Month 3.
11537046|NCT01095224|Experimental|rAd5 Env A and rAd5 Env B|Participants will receive the rAd5 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
11537047|NCT01095211|Active Comparator|B-Vitamins|folic acid, cobalamin, vitamin B6
11537048|NCT01095211|Placebo Comparator|placebo|none of the vitamins (99.5% mannitol)
11537049|NCT01095198|Active Comparator|2nd Reminder Letter|50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be be mailed a standard second reminder letter
11537050|NCT01095198|Experimental|Offer of Vaginal Self Collection|50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be selected to be mailed a second reminder letter and offer of vaginal self collection
11537051|NCT01095185|Experimental|Standard therapy + Simvastatin|"Standard therapy: Endoscopic variceal ligation (EVL)+ B Blockers (Propanolol titrated until achieve maximum tolerated dose)
~Simvastatin (20 mg for 15 days and after 40 mg/day until the end of the study)"
11537052|NCT01095185|Placebo Comparator|Standard therapy + placebo|"Standard therapy: Endoscopic variceal ligation (EVL)+ B Blockers (Propanolol titrated maximum tolerated dose).
~Placebo"
11537053|NCT01095172|Experimental|Rituximab|"Rituximab 375mg/m2
~Low dose tacrolimus with mycophenylate mofetil, hydrocortisone and 1 week prednisolone"
11537054|NCT01095172|Active Comparator|Control group|Low dose tacrolimus with mycophenylate mofetil and continued prednisolone
11537055|NCT01095159|Active Comparator|TVT-O|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).
11537056|NCT01095159|Active Comparator|TVT-S|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
11537057|NCT01095133|Experimental|Amiloride|
11537058|NCT01095133|Placebo Comparator|Placebo|
11537059|NCT01095107|Other|Control Arm = Decreased Energy Density|Decreased energy density = 35-50 grams of fat per day between meals and snacks
11537060|NCT01095107|Other|Treatment Arm = Increased Energy Density|increased increased energy density : Intake > 50 grams of fat per day between meals and snacks
11537061|NCT01095094|Experimental|Arm I|Patients receive oral ritonavir and lopinavir twice daily in the absence of disease progression or unacceptable toxicity.
11537062|NCT01095081||Group 1|
11537063|NCT01095068|Experimental|physical exercise|Physical exercise
11537067|NCT01095042|Experimental|Experimental group|"Persons reached by digestive pathologies (SII or IBD). Group SII : 30 patients Group IBD: 60 patients (30 patients RCH and 30 patients CD)
~Intervention : Observation of emotional behavior in person affected by digestive pathologies subjected to stress."
11537068|NCT01095029|Experimental|Off/Off|Pacemaker status: Bilateral Off for four weeks before first PET scann.
11537069|NCT01095029|Experimental|On/On|Pacemaker status: Bilateral On. PET scan one hour after activation and after four weeks continuous stimulation.
11537070|NCT01095029|Experimental|On/Off|Pacemaker status: Unilateral On. PET scan one hour after activation and after four weeks continuous stimulation.
11537071|NCT01095016|Experimental|Meptin swinghaler|
11537072|NCT01095016|Active Comparator|Berotec|
11537073|NCT01095003|Experimental|Vinflunine plus Capecitabine|"Patients received (in combination with capecitabine)
~• Vinflunine at the dose of 280 mg/m² and as a 20-minute IV. infusion on day 1 of each cycle repeated every 3 weeks."
11537074|NCT01095003|Active Comparator|Capecitabine single-agent|Capecitabine at the dose of 825mg/m² per os twice per day each morning and each evening for 14 consecutive days beginning on day 1 of each cycle repeated every 3 weeks (self-administered).
11537075|NCT01094977|Experimental|Low Dose|TXA 10mg/kg bolus before incision and 5 mg/kg infusion until skin closure
11537076|NCT01094977|Experimental|High Dose|TXA 100 mg/kg bolus before incision and 10 mg/kg infusion until skin closure
11537077|NCT01094977|Placebo Comparator|Placebo|Normal saline 10 ml before skin incision and infusion according to weight until skin closure
11537078|NCT01094951|Other|ENGAGE|"In stage 1, study investigators will train Neighborhood House caseworkers to screen their clients for depressive symptoms.
~In stage 2, study investigators will train Neighborhood House caseworkers to use the ENGAGE intervention in referring their clients to mental health services"
11537079|NCT01094938||Repair|
11537080|NCT01094925|Placebo Comparator|Placebo|
11537081|NCT01094925|Active Comparator|Gabapentin 300mg|
11537082|NCT01094925|Active Comparator|Gabapentin 600mg|
11537083|NCT01094899|Experimental|Type 1 Diabetics without Neuropathy|Adult male with type 1 diabetes and without peripherical neuropathy
11537084|NCT01094899|Experimental|Type 2 Diabetics without Neuropathy|Adult male with type 2 diabetes and without peripherical neuropathy
11537085|NCT01094899|Experimental|Type 1 Diabetics with Neuropathy|Adult male with type 1 diabetes and with peripherical neuropathy
11537086|NCT01094899|Experimental|Type 2 Diabetics with Neuropathy|Adult male with type 1 diabetes and with peripherical neuropathy
11537087|NCT01094886|Experimental|001|Rivaroxaban 10mg tablet daily receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
11537088|NCT01094873|Experimental|Arm A, group 1|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^8vp at week 14 and 1 dose Ad6NSmut 5 x 10^8vp at week 24, after starting PEG-IFN and ribavirin therapy.
~Patients: 2"
11537089|NCT01094873|Experimental|Arm A, group 2|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^9vp at week 14 and 1 dose Ad6NSmut 5 x 10^9vp at week 24, after starting PEG-IFN and ribavirin therapy.
~Patients: 2"
11537090|NCT01094873|Experimental|Arm A, group 3|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 14 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24, after starting PEG-IFN and ribavirin therapy.
~Patients: 6"
11537091|NCT01094873|Experimental|Arm A, group 4|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 2 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 12, after starting PEG-IFN and ribavirin therapy.
~Patients: 6"
11537092|NCT01094873|Experimental|Arm A, group 5|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at weeks 14 and 18, and 1 dose Ad6NSmut 2.5 x 10^10vp at week 28, after starting PEG-IFN and ribavirin therapy.
~Patients: 4"
11537093|NCT01094873|Experimental|Arm A, group 6|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at weeks 2 and 6, and 1 dose Ad6NSmut 2.5 x 10^10vp at week 16, after starting PEG-IFN and ribavirin therapy.
~Patients: 4"
11537094|NCT01094873|Experimental|Arm B, group 1|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^8vp at week 4 and 1 dose Ad6NSmut 5 x 10^8vp at week 14.
~Patients: 2"
11537095|NCT01094873|Experimental|Arm B, group 2|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^9vp at week 4 and 1 dose Ad6NSmut 5 x 10^9vp at week 14.
~Patients: 2"
11537096|NCT01094873|Experimental|Arm B, group 3|"Interventions: AdCh3NSmut; Ad6NSmut.
~1 dose AdCh3NSmut 2.5 x 10^10vp at week 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 14.
~Patients: 4"
11537097|NCT01094860|Experimental|Continuous Infusion Nelarabine|Starting dose 200 mg/m2 x 5 days
11537098|NCT01094847|Experimental|Treatment A|DWJ1252 given by oral administration under fasting conditions
11537099|NCT01094847|Active Comparator|Treatment B|DWJ1252 given by oral administration, 30 minutes after a meal
11537100|NCT01094847|No Intervention|Treatment C|mosapride by oral administration 30 minutes before meals
11537101|NCT01094834|Experimental|DWP05195|
11537102|NCT01094821|Experimental|3 mg ATI-7505|3 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
11537103|NCT01094821|Placebo Comparator|Placebo|Placebo capsule three times daily for 9 days followed by transit scintigraphy
11537104|NCT01094821|Experimental|10 mg ATI-7505|10 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
11537105|NCT01094821|Experimental|20 mg ATI-7505|20 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
11537106|NCT01094808|Experimental|Pregabalin 75 mg|Subjects randomized to this arm received a single dose of pregabalin 75 mg orally
11537107|NCT01094808|Experimental|Pregabalin 200 mg|Subjects randomized to this arm received a single dose of pregabalin 200 mg orally
11537108|NCT01094808|Placebo Comparator|Placebo|Subjects randomized to this arm received a single dose of placebo medication orally
11537109|NCT01094795||Patients initiating abatacept|
11537110|NCT01094795||Patients receiving other biologic disease-modifying drugs|
11537111|NCT01094795||Patients with early rheumatoid arthritis (RA)|
11537112|NCT01094795||Patients with prevalent RA identified by hospitalization|
11537114|NCT01094782|Active Comparator|Healthy - True Acupuncture|Healthy volunteers with no neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7.This group received true acupuncture treatment (the needles punctured the skin).
11537115|NCT01094782|Sham Comparator|Healthy - Sham Acupuncture|Healthy with no neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received sham acupuncture treatment (the needles did not puncture the skin).
11537116|NCT01094782|No Intervention|Healthy - No Treatment|Healthy volunteers with no neck or back pain who attended 3 visits over 4 weeks and received no sham or true acupuncture treatment.
11537117|NCT01094782|Active Comparator|Pain - True Acupuncture|Volunteers with radiating neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received true acupuncture treatment (the needles punctured the skin).
11537118|NCT01094782|Sham Comparator|Pain - Sham Acupuncture|Volunteers with radiating neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received sham acupuncture treatment (the needles did not puncture the skin).
11537119|NCT01094782|No Intervention|Pain - No Treatment|Volunteers with radiating neck or back pain who attended 3 visits over 4 weeks and received no sham or true acupuncture treatment.
11537120|NCT01094769|Experimental|Moxonidine|
11537121|NCT01094769|Placebo Comparator|Placebo|
11537122|NCT01094756|Active Comparator|Obese group - Group 1|If you have a BMI between 33kg - 45kg and weight under 350 lbs you could be in group 1.
11537123|NCT01094756|No Intervention|Lean group - Group 2|If you have a BMI between 18.5 kg - 24.9 kg you could be in group 2.
11537124|NCT01094743|Other|galyfilcon A prototype lens / lotrafilcon B lens|The galyfilcon A prototype lenses will be worn during the first period and lotrafilcon B lenses will be worn during the second period. Each period consists of daily lens wear for one week.
11537125|NCT01094743|Other|lotrafilcon B lens / galyfilcon A prototype lens|The lotrafilcon B lenses will be worn during the first period and galyfilcon A prototype lenses will be worn during the second period. Each period consists of daily lens wear for one week.
11537126|NCT01094730|Other|galyfilcon A prototype/marketed galyfilcon A|The galyfilcon A prototype lens worn daily for 12-16 days during the first period then the marketed galyfilcon A lens worn daily for 12-16 days during the second period.
11537127|NCT01094730|Other|marketed galyfilcon A/galyfilcon A prototype|The marketed galyfilcon A lens worn daily for 12-16 days during the first period then the galyfilcon A prototype lens worn daily for 12-16 days during the second period; during each period.
11537128|NCT01094717|Experimental|acitretin and active excimer laser|patients enrolled in the acitretin arm will be treated with acitretin 25 mg daily and excimer (active) to randomly assigned left or right side of body psoriasis lesions.
11537129|NCT01094717|Experimental|acitretin and sham excimer laser|Patients in this arm were treated with acitretin 25 mg daily and sham (placebo) excimer laser to randomly assigned left or right side of body psoriasis lesions.
11537130|NCT01094717|Experimental|tazarotene and active excimer laser|patients enrolled in this arm were treated with tazarotene 0.1% gel topical application daily and excimer (active) laser to randomly assigned left or right side of body psoriasis lesions.
11537131|NCT01094717|Experimental|tazarotene and sham excimer laser|patients enrolled in this arm were treated with tazarotene 0.1% gel topical application daily and sham excimer laser to randomly assigned left or right side of body psoriasis lesions.
11537132|NCT01094704|Experimental|Hypertonic Saline - 1 hour|sodium chloride (7%); mucociliary clearance measured 1 hour post dose
11537133|NCT01094704|Experimental|Hypertonic Saline - 4 hours|sodium chloride (7%); mucociliary clearance measured four hours post-dose.
11537134|NCT01094691|Experimental|Renal Allograft Biopsy|Urine left over from clinic visits is analyzed for 'Haufen' by negative staining electron microscopy as a marker of intra-renal polyomavirus nephropathy. Correlate Haufen, urine, and plasma data with the clinical presentation and with renal biopsy findings. Patients with PVN will be approached for study participation in which their routine samples will be monitored until urine is negative for 'Haufen', and a study protocol biopsy will be obtained for confirmation.
11537135|NCT01094678|Experimental|Stent|
11537136|NCT01094665|Experimental|Focal Laser Thermal Therapy|Thermal therapy delivered to lesion visible on MRI.
11537137|NCT01094652|Experimental|Whole grain diet|Participants in this group will be given whole grain snacks on school days and food packages consisting of whole grain breads, breakfast cereals, rice, snack foods, and pasta to replace their typical grains consumed at home.
11537138|NCT01094652|Active Comparator|Refined grain diet|Participants in this group will be given refined grain snacks on school days and food packages consisting of refined grain breads, breakfast cereals, rice, snack foods, and pasta to replace their typical grains consumed at home.
11537139|NCT01094639|Placebo Comparator|Supragingival prophylaxis|Plaque removal
11537140|NCT01094639|Active Comparator|Scaling root planing|SRP+oral hygiene
11537141|NCT01094626|Experimental|Experimental|Fifteen subjects will be randomly selected to undergo S-MRI prior to surgery. These subjects would receive Secretin, administered by IV bolus injection over 1 minute followed by a 30 second saline flush.
11537142|NCT01094626|No Intervention|Controls|Fifteen subjects will be selected as controls, undergoing MRI without secretin-enhancement and matched for age, sex, race and tumor-type.
11537143|NCT01094613|Experimental|Delayed Release 6MP|"6 Mercaptopurine delayed release oral tablet for targeted ileal delivery, to be administered once nightly before bedtime, for 12 weeks.
~The dose is 2 x 40 mg DR-6MP (total dose, 80 mg DR-6MP)."
11537144|NCT01094613|Active Comparator|Purinethol|6 Mercaptopurine Tablet (50 mg) administered orally, at doses of 1-1.5 mg/kg body weight, daily for 12 weeks. Individual patient doses range from 50 mg to 150 mg, including 75, 100 and 125 mg daily, as per patient weight at baseline, and then are up-titrated to clinical efficacy at two week intervals, as needed. Doses may be down-titrated as well if occurrences of AE's warrant dose reduction.
11537145|NCT01094600|Experimental|Secretin|Single arm (open label).
11537146|NCT01094587|Active Comparator|Sutured closure|
11537147|NCT01094587|Active Comparator|Sutureless closure|
11537190|NCT01094275||Loss of function haplotype of CYP2C|clopidogrel 75mg + omerprazole 20mg.
11537191|NCT01094262|Experimental|JNJ-42160443 (lower dose)|
11537148|NCT01094574|Active Comparator|Alfentanil|Experimental inflammation, and tissue injury sites were created, an infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
11537149|NCT01094574|Active Comparator|Propranolol|Experimental inflammation and tissue injury sites were created, an infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
11537150|NCT01094574|Placebo Comparator|Placebo|Experimental inflammation and tissue injury sites were created, an infusion of normal saline was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
11537151|NCT01094561|Experimental|Synthetic Human Secretin|Single arm (open label).
11537152|NCT01094548|Experimental|Tecemotide (L-BLP25) plus single low dose cyclophosphamide|
11537153|NCT01094548|Experimental|Tecemotide (L-BLP25) plus multiple low dose cyclophosphamide|
11537154|NCT01094535|Experimental|Secretin|One-arm (open label): Synthetic Human Secretin. Patients will undergo four Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) evaluations.
11537155|NCT01094522|Experimental|Methadone|One half the Study patients will be randomized to receive a loading dose of IV methadone, followed by IV doses (given by the ICU nurse), on a PRN basis, for pain control for up to 24 hours during their postoperative course while they are intubated.
11537156|NCT01094522|Active Comparator|Morphine|One half the Study patients will be randomized to receive a loading dose of IV morphine, followed by IV doses (given by the ICU nurse), on a PRN basis, for pain control for up to 24 hours during their postoperative course while they are intubated.
11537157|NCT01094509|Experimental|Tai Chi|Tai Chi exercises
11537158|NCT01094509|Experimental|Guided autobiography|Autobiographical writing during class sessions and at home
11537159|NCT01094509|Experimental|Qigong|Qigong exercises (exploratory, not part of the original protocol, added to gain experience with this intervention)
11537160|NCT01094509|Active Comparator|Successful aging|Seminars on the theme of successful aging
11537161|NCT01094509|Experimental|Combination|Combination of Tai Chi exercises and autobiographical writing
11537162|NCT01094509|Placebo Comparator|Comparison|No assigned experimental activity (exploratory, not part of the original protocol, added to gain experience with a placebo comparator)
11537163|NCT01094496|Experimental|CDX-1307 Vaccine Regimen|Chemotherapy with CDX-1307 vaccine regimen (neoadjuvant phase), followed by bladder removal surgery (cystectomy). CDX-1307 vaccine regimen will continue to be given for up-to 1 year post-surgery (adjuvant/long-term follow-up phase).
11537164|NCT01094483|Experimental|1|PN400 + ASA
11537165|NCT01094483|Placebo Comparator|2|Placebo + ASA
11537166|NCT01094457|Active Comparator|standard group|patients in this group received standard dual antiplatelet therapy, i.e. aspirin 300mg/d and clopidogrel 75mg/d
11537167|NCT01094457|Experimental|intensive group|patients in this group received intensive antiplatelet therapy and the regimen can be adjusted according to results of platelet aggregation function test by LTA
11537168|NCT01094444|Experimental|Vitamin K3-lotion|A lotion containing 1.5 mM Vitamin K3.
11537169|NCT01094444|No Intervention|B|Standard lotion without Vitamin K3
11537170|NCT01094418||IGT group|IGT diagnosed by endocrinologist
11537171|NCT01094418||DM group|DM diagnosed by endocrinologist and whose primary NCS screening shows SNAP amplitudes of sural and superficial peroneal nerves greater than 10mA DM patients with no previous diagnosis of peripheral polyneuropathy
11537172|NCT01094418||Normal healthy participants|Normal health participants with no previous history of DM, IGT, thyroid disorder, hypercholesterolemia, or other condition associated with peripheral polyneuropathy
11537173|NCT01094405|Experimental|EBV Vaccine|
11537174|NCT01094392||treatment every 6th week during 6 months|
11537175|NCT01094392||treatment every 2nd week during 6 months|
11537176|NCT01094379|Active Comparator|Standard lap chole|Laparoscopic cholecystectomy using four entry sites to the abdominal cavity
11537177|NCT01094379|Active Comparator|Single incision lap chole|Laparoscopic cholecystectomy using one entry site to the abdominal cavity
11537178|NCT01094366|Sham Comparator|No Paracervical Block for Pain Control|Subject will not receive a paracervical block during the procedure
11537179|NCT01094366|Active Comparator|Paracervical Block for Pain Control|Subject will receive a paracervical block during the procedure.
11537180|NCT01094353|Active Comparator|Mini-sling|The minisling Ophira™ is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
11537181|NCT01094353|Active Comparator|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
11537182|NCT01094340|Other|Thalidoide|CSF
11537183|NCT01094314|Active Comparator|sequential medium|
11537184|NCT01094314|Active Comparator|single medium|
11537185|NCT01094301|Experimental|The SPR System|The SPR System is an investigational two-staged device which delivers stimulation to the shoulder. Subjects with chronic post-stroke shoulder pain who meet eligibility criteria for the first stage (SPR Trial Stage) will receive a temporary Lead and External Stimulator. Subjects who qualify and who agreed to proceed will advance to the second stage (SPR Implant Stage) which uses an Implantable Pulse Generator (IPG) and Implantable Lead. Subjects will be followed until 36-months after IPG stimulation has been started.
11537186|NCT01094288|Experimental|Alisertib + Docetaxel|"Alisertib in escalating dose (10-40 mg), enteric-coated tablets (ECT), orally, twice daily for 7 days followed by 14-day rest period in Cycle 1, 3 and onwards (21-day cycle) and orally twice daily from Day 3 to Day 7 followed by 14 day rest period in Cycle 2 along with docetaxel 60-75 mg/m^2, intravenous (IV) infusion on Day 1 of each cycle for maximum of 12 months, or until the occurrence of progressive disease (PD), unmanageable adverse events (AEs) or withdrawal of consent.
~The starting alisertib dose is 10 mg, orally, twice daily (total 20 mg/day)."
11537187|NCT01094275||wild / normal type allele of CYP2C gene|clopidogrel 75 mg alone.
11537188|NCT01094275||wild / normal type allele of CYP2C|clopidogrel 75 mg + omeprazole 20 mg.
11537192|NCT01094262|Experimental|JNJ-42160443 (higher dose)|
11537193|NCT01094262|Active Comparator|Oxycodone CR (standard pain medication)|
11537194|NCT01094262|Placebo Comparator|Placebo|
11537195|NCT01094249|Experimental|001|divalproex sodium ER/paliperidone ER Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
11537196|NCT01094236|Experimental|Supervisor Treatment Group|Supervisors watched the CD intervention
11537197|NCT01094236|Experimental|Administrators - Treatment|School administrators got access to the intervention binder with CD's, workbook and worksheets
11537198|NCT01094236|Experimental|Students|3rd grade students at participating study schools
11537199|NCT01094236|Experimental|Supervisor Control Group|Supervisors watched a video on playground equipment safety
11537200|NCT01094236|Experimental|Administrators - Control|Administrators did not have access to any treatment materials.
11537201|NCT01094236|Experimental|School Staff|School staff surveyed at staff meetings
11537202|NCT01094223|Experimental|Mindfulness|
11537203|NCT01094223|Active Comparator|Health Education|
11537204|NCT01094210||G1|500 ppm F Test Toothpaste
11537205|NCT01094210||G2|1100 ppm F Control Toothpaste
11537206|NCT01094197||Transfused microchimeric subject|Former trauma patient who underwent blood transfusion and has recent evidence of long-term transfusion-associated microchimerism
11537207|NCT01094184|Experimental|Bevacizumab 10 mg/kg Q2W|Participants will receive bevacizumab at a dose of 10 milligrams per kilogram (mg/kg) every 2 weeks (Q2W) as intravenous infusion along with paclitaxel every week (Q1W) or docetaxel every 3 weeks (Q3W) as per discretion of the treating physician until disease progression, unacceptable toxicity or withdrawal of consent.
11537208|NCT01094184|Experimental|Bevacizumab 15 mg/kg Q3W|Participants will receive bevacizumab at a dose of 15 mg/kg Q3W as intravenous infusion along with paclitaxel Q1W or docetaxel Q3W as per discretion of the treating physician until disease progression, unacceptable toxicity or withdrawal of consent.
11537209|NCT01094171|Experimental|Poliorix Group|Subjects received 3 primary doses of PoliorixTM and InfanrixTM vaccines at 3, 4.5 and 6 months of age. All vaccines were administered intramuscularly in the anterolateral side of the left thigh (Poliorix) and the right thigh (Infanrix).
11537210|NCT01094158|Experimental|high dose|Aramchol 300 mg daily (high dose)
11537211|NCT01094158|Experimental|low dose|100 mg daily (low dose)
11537212|NCT01094158|Placebo Comparator|Placebo|Placebo and two doses will be compared. The Aramchol: placebo ratio is of 2:1.
11537213|NCT01094145|Sham Comparator|Placebo|Stimulator setting is OFF
11537214|NCT01094145|Active Comparator|Deep Brain Stimulation|Stimulator setting is ON
11537215|NCT01094132|Other|Review by colposcopy + multispectral digital colposcopy|All patients belong under this arm, as all will be reviewed by both conventional colposcopy and by Multispectral Digital Colposcopy (MDC). The nature of these techniques are explained below.
11537216|NCT01094119|Active Comparator|Bair Hugger heated blanket|Patients will be warmed during surgery with the Bair Hugger heated blanket.
11537217|NCT01094119|Active Comparator|LMA PerfecTemp system|Patients will be warmed during surgery with the PerfecTemp heated pad .
11537218|NCT01094106|Active Comparator|Ropivacaine 0,75%|Postoperative wound infusion 15 mg /h / 48h
11537219|NCT01094106|Placebo Comparator|NaCl 0,9%|Postoperative wound infusion with NaCl 0,9% 2 ml /h /48h
11537220|NCT01094093|Experimental|Part B|Four dose levels of AMG 139 administered as a single dose SC or IV in subjects with moderate-severe psoriasis (Part B).
11537221|NCT01094093|Experimental|Part A|Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers.
11537222|NCT01094080|Active Comparator|standard infant formula|infants are fed a commercial formula during the first 4 month of life, according to protocol
11537223|NCT01094080|Experimental|modified infant formula|infants are fed a modified infant formula (modified protein content and fatty acid pattern) during the first 4 month of life, according to protocol
11537224|NCT01094080|Other|breast milk|infants are breast fed
11537225|NCT01094067|Experimental|1|Placebo at visit 1, tezosentan at visit 2
11537226|NCT01094067|Experimental|2|Tezosentan at visit 1, placebo at visit 2
11537227|NCT01094054|Active Comparator|Dietary and lifestyle modification|Patients in this arm will eat meals that are identical in size and caloric composition to those consumed by participants in the other arm who undergo adjustable gastric banding
11537228|NCT01094054|Experimental|Adjustable gastric banding|Subjects will undergo gastric banding as per clinical practice
11537229|NCT01094041|Experimental|Gluten free diet|
11537230|NCT01094041|Experimental|Gluten rich diet|
11537231|NCT01094028|Experimental|Saline group|Only 30 mL of saline was injected directly in the umbilical vein after clamping. The injection was performed with a 30-mL syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute and at the end of the injection, the solution was milked toward the cord insertion.
11537232|NCT01094015|Active Comparator|Lidocaine-Prilocaine cream|
11537233|NCT01094015|Placebo Comparator|placebo|
11537234|NCT01094002|Experimental|Occupational therapy intervention (OTI)|198 subjects. The OTI schedule consisted of a daily 45-minute session, Monday through Friday, for the duration of hospitalisation. Activities were carried out in a structured manner and varied according to need and day of admission. On the first day, the patient's needs were analysed, including the need for iatrogenic prevention, retraining in basic and instrumental activities of daily living, technical aids, instruct the primary caregiver in patient mobilisation techniques, and social and occupational motivation. All OTI participants received an average of 5 sessions during hospitalisation.
11537235|NCT01094002|No Intervention|Conventional treatment model group|202 subjects. All subjects received medical treatment, nursing care, physical therapy, and social assistance in accordance with the usual practice of the geriatrics unit.
11537236|NCT01093989|Placebo Comparator|Immediate iron|Iron-deficient children will be randomized to receive iron concurrently with anti-malarial treatment or one month later (delayed iron group).
11537237|NCT01093989|Active Comparator|Delayed iron|
11537238|NCT01093976|Experimental|Dronabinol|Dronabinol (Marinol) - 2.5mg-15mg by mouth once a day for twelve-weeks
11537239|NCT01093963|Active Comparator|Lisdexamfetamine|Drug
11537240|NCT01093963|Placebo Comparator|Placebo|Drug
11537241|NCT01093950||PROSPECTIVE BODY CONTOURING SUBJECTS|"It is anticipated that the participants will undergo body contouring procedures including lipoplasty [internal fat suction removal], abdominoplasty [surgical removal of lower abdominal skin and fat], breast reduction [surgical removal of breast skin, fat, and breast tissue to reduce breast size], breast augmentation [surgical breast enlargement], thigh lift [surgical removal of upper thigh tissue], and brachioplasty [surgical removal of upper arm tissue].
~These procedures will be evaluated by pre- and post-operative digital scans, analog measurements, and clinical examinations and photographs."
11537242|NCT01093924|No Intervention|self-guided weight loss maintenance|15-month self-guided weight loss maintenance group will receive monthly reminders to maintain their weight loss and newsletters that contain health information.
11537243|NCT01093924|Experimental|DVD group|15-month weight loss maintenance intervention deliver via DVD.
11537244|NCT01093924|Experimental|face-to-face group|15-month weight loss/weight loss maintenance intervention delivered in a group setting
11537245|NCT01093911|Experimental|CDP7657|CDP7657 in dose escalating cohorts
11537246|NCT01093911|Placebo Comparator|Placebo|
11537247|NCT01093898||No intervention|
11537248|NCT01093885|Other|open label: medication Ambrisentan|"Open label study of Ambrisentan.
~Ambrisentan will begin at 5mg daily for the first month.
~Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week. Subjects will continue their present dose and schedule of disease modifying/antifibrotic medication for the duration of the study.
~** Dose escalation was attempted however none of the patients were able to increase. Therefore all subjects remained on 5 mg daily throughout the study. 12 patients on mycophenolate mofetil, 2 on mycophenolic acid and one on methotrexate"
11537249|NCT01093859|Experimental|PRX-105 Infusion|
11537250|NCT01093846|Experimental|AIN457 300 mg every 2 weeks|
11537251|NCT01093846|Experimental|AIN457 300 mg monthly|
11537252|NCT01093846|Placebo Comparator|Placebo|
11537253|NCT01093833|Experimental|Continuous Glucose Monitoring|Each subject will participate in one experimental intervention. Blood glucose will be measured with the BD continuous glucose monitor (BD CGM), with the Medtronic Guardian CGM and the YSI Glucose Analyzer as controls for 12-14 hours.
11537254|NCT01093820|Experimental|Epopoetinum beta|Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
11537255|NCT01093807|Placebo Comparator|Placebo|
11537256|NCT01093807|Experimental|Lercanidipine 10 mg|
11537257|NCT01093807|Experimental|Lercanidipine 20 mg|
11537258|NCT01093807|Experimental|Enalapril 10 mg|
11537259|NCT01093807|Experimental|Enalapril 20 mg|
11537260|NCT01093807|Experimental|Lercanidipine 10 mg/Enalapril 10 mg|
11537261|NCT01093807|Experimental|Lercanidipine 10mg/Enalapril 20 mg|
11537262|NCT01093807|Experimental|Lercanidipine 20mg/Enalapril 10 mg|
11537263|NCT01093807|Experimental|Lercanidipine 20mg/Enalapril20mg|
11537264|NCT01093794|Experimental|1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:
~Co-administration of 50 mg sitagliptin and 500 mg metformin
~sitagliptin/metformin 50 mg/500 mg FDC tablet
~sitagliptin/metformin 50 mg/850 mg FDC tablet
~Co-administration of 50 mg sitagliptin and 850 mg metformin"
11537265|NCT01093794|Experimental|2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:
~sitagliptin/metformin 50 mg/500 mg FDC tablet
~Co-administration of 50 mg sitagliptin and 850 mg metformin
~Co-administration of 50 mg sitagliptin and 500mg metformin
~sitagliptin/metformin 50 mg/850 mg FDC tablet"
11537266|NCT01093794|Experimental|3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:
~Co-administration of 50 mg sitagliptin and 850 mg metformin
~sitagliptin/metformin 50 mg/850 mg FDC tablet
~sitagliptin/metformin 50 mg/500 mg FDC tablet
~Co-administration of 50 mg sitagliptin and 500mg metformin"
11537267|NCT01093794|Experimental|4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:
~sitagliptin/metformin 50 mg/850 mg FDC tablet
~Co-administration of 50 mg sitagliptin and 500 mg metformin
~Co-administration of 50 mg sitagliptin and 850 mg metformin
~sitagliptin/metformin 50 mg/500 mg FDC tablet"
11537268|NCT01093781|Experimental|Aliskiren|Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
11537269|NCT01093755|Active Comparator|dexlansoprazole|Participants will be treated with dexlansoprazole 60-90 mg/day for 6 months
11537270|NCT01093755|Active Comparator|omeprazole|Participants will be treated with omeprazole 20mg/day for a minimum of 6 weeks. If symptomatic can increase dose by 20mg twice.
11537271|NCT01093742|Experimental|cohort 1|HM10560A 0.089 mg/kg or Placebo
11537272|NCT01093742|Experimental|cohort 2|HM10560A 0.179 mg/kg or Placebo
11537273|NCT01093742|Experimental|cohort 3|HM10560A 0.357 mg/kg or Placebo
11537274|NCT01093742|Experimental|cohort 4|HM10560A 0.714 mg/kg or Placebo
11537275|NCT01093729|Experimental|Cohort1|HM11260C 0.5mcg/kg or Placebo
11537276|NCT01093729|Experimental|Cohort2|HM11260C 2mcg/kg or Placebo
11537277|NCT01093729|Experimental|Cohort3|HM11260C 4mcg/kg or Placebo
11537278|NCT01093729|Experimental|Cohort4|HM11260C 8mcg/kg or Placebo
11537279|NCT01093729|Experimental|Cohort5|HM11260C 14mcg/kg or Placebo
11537280|NCT01093716|Experimental|rTMS|Compare the change in craving parameters following high frequency rTMS stimulation of right and left DLPFC in patients with alcohol dependence
11537281|NCT01093703|No Intervention|Conventional Therapy|In the conventional therapy group, no medication changes other than the ones needed to achieve target awake average SBP will be undertaken. Time at which patients are taking their BP medications will be recorded.
11537282|NCT01093703|Active Comparator|Intensive Therapy|In the intensive therapy group, BP medications will be adjusted to both control awake average systolic BP to target and to cover the overnight period in an attempt to control nocturnal hypertension.
11537283|NCT01093690|Experimental|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg orally four times a day on day 2-5
11537284|NCT01093690|Placebo Comparator|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
11537285|NCT01093677|Experimental|A|750 mg of LIM-0705 BID for 14 days. Up to 20 subjects.
11537286|NCT01093677|Placebo Comparator|B|Placebo BID for 14 days. Up to 10 subjects.
11537287|NCT01093664|Experimental|AFFITOPE AD02|
11537288|NCT01093651|Experimental|DPPIV inhibition|Four to six months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count >350 cells/µL) and virologic (plasma HIV RNA <50 copies/mL) status.
11537289|NCT01093651|Placebo Comparator|Placebo|Four to six months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count >350 cells/µL) and virologic (plasma HIV RNA <50 copies/mL) status.
11537290|NCT01093638|Experimental|Oral Formulation of Insulin|Oral formulation of insulin fed concomitantly with premature infant formula
11537291|NCT01093638|Placebo Comparator|Oral Formulation of Placebo|Oral formulation of placebo fed concomitantly with premature infant formula
11537292|NCT01093625|Experimental|Narafilcon B Contact Lens|Investigational Silicone Hydrogel Contact Lens
11537293|NCT01093625|Active Comparator|Spectacles|
11537294|NCT01093612|Experimental|Arm I|PART ONE: Patients are randomized to 1 of 3 dose levels. Patients undergo a PET scan 24-48 hours after injection of copper Cu 64-DOTA-trastuzumab. PART TWO: Patients undergo a PET scan 24-48 hours after injection of copper Cu 64-DOTA-trastuzumab.
11537295|NCT01093599|Active Comparator|Quit Line Only|Control Participants will call the Wisconsin Tobacco Quit Line intervention including phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
11537296|NCT01093599|Active Comparator|Quit Line plus MTS|Participants in the study group will receive the Quit Line intervention (talk to a Quit Line Counselor, receive quit smoking materials and get 4 weeks of nicotine patches) and also receive 4 weeks of training in mindfulness meditation through the mindfulness for smokers intervention.
11537297|NCT01093586|Experimental|Arm I|PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
11537298|NCT01093573|Experimental|Dose Level 1|Aza at 75 mg/m2 D1-7 & Midostaurin 25 mg BID D 8-21
11537299|NCT01093573|Experimental|Dose Level 2|Aza at 75 mg/m2 D1-7 & Midostaurin 50 mg BID D 8-21
11537300|NCT01093573|Experimental|Dose Level 3|Azacitidine 75 mg/m2 IV D1-7 & Midostaurin 75 mg PO BID D 8-21
11537301|NCT01093560|Experimental|young women with MetS|"Saturated fat (control)
~n-3 Polyunsaturated fat (experimental)
~monounsaturated fat"
11537302|NCT01093547|Active Comparator|Dianeal only|Patients in Dianeal during the daily exchanges and randomised to Dianeal during the long-dwell exchange
11537303|NCT01093547|Active Comparator|Dianeal; Extraneal long-dwell exchange|Patients in Dianeal during the daily exchanges and randomised to Extraneal during the long-dwell exchange
11537304|NCT01093534|Placebo Comparator|Placebo|Participants received 2 placebo tablets once daily for 12 weeks.
11537305|NCT01093534|Experimental|Solifenacin 5 mg|Participants received one 5 mg solifenacin tablet and one placebo tablet, once daily for 12 weeks.
11537306|NCT01093534|Experimental|Solifenacin 10 mg|Participants received two 5 mg solifenacin tablets once daily for 12 weeks.
11537307|NCT01093521|Experimental|100 mg/m2 dose|Five day continuous IV Gallium Nitrate (Ganite®) infusion at 100 mg/m2
11537308|NCT01093521|Experimental|200 mg/m2 dose|Five day continuous IV Gallium Nitrate (Ganite®) infusion at 200 mg/m2
11537309|NCT01093495|Experimental|CPAP group|Subjects in this group will continue receiving CPAP until no oxygen requirement for 24 hours, then will be weaned off CPAP completely as long as they tolerate. CPAP will be re-instituted if subjects meet failing criteria. Another trial off CPAP will start 24 hours after failure and/or after being on 21% for 24 hours. CPAP will be weaned off directly to room air at all times.
11537310|NCT01093495|Experimental|Nasal Cannula Group|Subjects will be weaned from CPAP (when FiO2 <0.30) to Nasal cannula (2 L/min) with whatever FiO2 they need until they are off oxygen and NC completely. However, if these infants fail on NC they will be put back to nCPAP. Infants will then be maintained on CPAP until stable on CPAP-30% for 24 hours. Infants will be tried for another weaning using NC. So, infants assigned to NC will be weaned only through NC. CPAP will be used only for stabilization in between trials if needed.
11537311|NCT01093482||mechanically ventilated patients|"Patients who are admitted to the participating intensive care units and require invasive mechanical ventilation (endotracheal tube or tracheostomy) for more than 12 hours.
~Patients who are admitted to the participating intensive care units and require non-invasive mechanical ventilation (Bilevel positive airway pressure (BIPAP) or continuous positive airway pressure (CPAP) with nasal or facial mask) for more than 1 hour."
11537312|NCT01093469|Experimental|Aquaphor Healing Ointment|Aquaphor Healing Ointment three times daily to atopic dermatitis
11537313|NCT01093469|Active Comparator|Atopiclair Nonsteroidal Cream|Atopiclair Nonsteroidal Cream three times daily to atopic dermatitis
11537314|NCT01093469|Active Comparator|EpiCream Skin Barrier Emulsion|EpiCream Skin Barrier Emulsion three times daily to atopic dermatitis
11537315|NCT01093456||chronic kidney disease|ESKD patients treated with peritoneal dialysis
11537316|NCT01093456||Healthy volunteers|healthy volunteers, aged 18 years and above
11537317|NCT01093443|Placebo Comparator|A|Patients undergo a standard treatment with a classical GnRH antagonist protocol.
11537318|NCT01093443|Active Comparator|B|Before undergoing a standard protocol for ovarian stimulation, patients in this group receive a pretreatment with GnRH antagonists during 3 consecutive days
11537319|NCT01093430|Experimental|Anterior superior iliac spine|The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
11537367|NCT01093053|Active Comparator|Standard Treatment|
11537368|NCT01093040|Experimental|Cohort 1|CAT-354 will be administered by SC injection
11537320|NCT01093430|Active Comparator|Control|The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
11537321|NCT01093417|Placebo Comparator|Placebo|Participants that have been randomized into this arm will receive placebo pills.
11537322|NCT01093417|Active Comparator|Vitamin D 4000 IU|Participants that have been randomized into this arm will receive Vitamin D 4000 IU (International Units) daily.
11537323|NCT01093404|Experimental|Thrombus aspiration|Thrombus aspiration is then followed by standard balloon angioplasty (PCI).
11537324|NCT01093404|Active Comparator|Standard balloon angioplasty (PCI)|
11537325|NCT01093391|Placebo Comparator|BARE METAL STENT|BARE METAL STENT - STENT CRONUS
11537326|NCT01093391|Experimental|DRUG ELUTING STENT|STENT INSPIRON WITH SIROLIMUS
11537327|NCT01093378||Fertile group|fertile group
11537328|NCT01093378||Infertility group|Fertility troubles
11537329|NCT01093365|Experimental|Schizophrenia|To measure the effects of varenicline on cognition of smokers with schizophrenia.
11537330|NCT01093352|No Intervention|Standard|Standard expose and bond.
11537331|NCT01093352|Experimental|Alveolar-decortication|Following surgical exposure of the impacted canine, additional perforations will be made in the surrounding cortical bone prior to wound closure.
11537332|NCT01093339||No treatment|Subjects w/ condition and subjects w/o condition of GERD (gastroesophageal reflux disease)
11537333|NCT01093326|Experimental|Ponesimod 10 mg|Ponesimod 10 mg oral use
11537334|NCT01093326|Experimental|Ponesimod 20 mg|Ponesimod 20 mg oral use
11537335|NCT01093326|Experimental|Ponesimod 40 mg|Ponesimod 40 mg oral use
11537336|NCT01093313|Experimental|Attention training|
11537337|NCT01093313|Active Comparator|Cognitive therapy|
11537338|NCT01093300|Experimental|Paclitaxel-eluting balloon catheter|Paclitaxel-eluting balloon catheter use for treatment of ISR lesion
11537339|NCT01093300|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent use for treatment of ISR lesion
11537340|NCT01093274|Active Comparator|Polyethylene glycol|Preparation with Polyethylene Glycol and bisacodyl
11537341|NCT01093274|Experimental|Picolax|Preparation with Sodium Picosulphate and Bisacodyl.
11537342|NCT01093261|Experimental|Hydrocortisone and fludrocortisone|Patients with glucocorticoid insufficiency
11537343|NCT01093261|Placebo Comparator|Placebo|Patients with glucocorticoid insufficiency
11537344|NCT01093261|No Intervention|Controlled|Adapted glucocorticoid function
11537345|NCT01093248||Heroin-addicted Patients|Heroin-addicted outpatient department (OPD) patients who seek help for methadone maintenance treatment
11537346|NCT01093222|Experimental|Treatment (sorafenib tosylate and erlotinib hydrochloride)|Patients receive sorafenib tosylate PO twice daily and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11537347|NCT01093209|Sham Comparator|Conventional Laser Therapy|
11537348|NCT01093209|Active Comparator|Interferential Laser Therapy|
11537349|NCT01093196|Active Comparator|Rd|Induction treatment with oral Lenalidomide and low dose dexamethasone followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone
11537350|NCT01093196|Experimental|MPR|Induction treatment with oral Lenalidomide, Prednisone and Melphalan followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone
11537351|NCT01093196|Experimental|CPR|Induction treatment with oral Lenalidomide, Cyclophosphamide and Prednisone for followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone.
11537352|NCT01093183|Experimental|Treatment (lenalidomide and cyclophosphamide)|Patients receive lenalidomide PO QD on days 1-21 and cyclophosphamide PO QD on days 1-28. Treatment repeats every 28 days for at least 4 courses in the absence of disease progression or unacceptable toxicity. Treatment modifications may apply according to response.
11537353|NCT01093170|Experimental|RNA-144101|
11537354|NCT01093157|Active Comparator|ACTH (HP Acthar gel) 40 units|
11537355|NCT01093157|Active Comparator|ACTH (HP Acthar gel) 80 units|
11537356|NCT01093131|Active Comparator|Intravenous Hydration|Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.
11537357|NCT01093131|Active Comparator|Intravenous hydration and sodium bicarbonate|Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
11537358|NCT01093131|Active Comparator|Oral hydration|Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure
11537359|NCT01093131|Active Comparator|Oral hydration and oral sodium bicarbonate|Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
11537360|NCT01093118|Experimental|TMI-358|Active treatment
11537361|NCT01093118|Placebo Comparator|MMI-467|
11537362|NCT01093092|Experimental|Treatment (calcitriol, cisplatin, gemcitabine hydrochloride)|Patients receive calcitriol PO on days 1, 2, 8, 9, 15 and 16; cisplatin IV over 2 hours on day 2; and gemcitabine hydrochloride IV over 30 minutes on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11537363|NCT01093079||Laparoscopic partial nephrectomy|
11537364|NCT01093079||Open Partial nephrectomy|
11537365|NCT01093066|Experimental|surgical resection and chemotherapy|"Maximal and optimal TURB using a standardized procedure. The TURB will always try to be optically complete.
~Neoadjuvant chemotherapy for 3 months with the intensified MVAC (6 cycles administered every 2 weeks): METHOREXATE: 30 mg/m2 D1 - VINBLASTINE: 3 mg/m2 D2 - ADRIAMYCINE 30 mg/m2 D2 - CISPLATINE 70 mg/m2 D2. + G-CSF: 5 µg/kg from D4 to D10 New maximal standardized TURB at the end of the chemotherapy. In case of a lesion localized at the bladder dome, and if a maximal TURB appears to be unsafe, a partial cystectomy without lymph node dissection will be performed."
11537366|NCT01093053|Experimental|Mind-Body Skills Groups|
11537369|NCT01093040|Experimental|Cohort 2|CAT-354 will be administered by SC injection
11537370|NCT01093040|Experimental|Cohort 3|CAT-354 will be administered by SC injection
11537371|NCT01093027|Other|15 - 30|The upper limb with tremor will be cooled with 15 degrees Celsius water for 10 minutes at Visit 1 and with 30 degrees Celsius water for 10 minutes at Visit 2.
11537372|NCT01093027|Other|30 - 15|The upper limb with tremor will be cooled with 30 degrees Celsius water for 10 minutes at Visit 1 and with 15 degrees Celsius water for 10 minutes at Visit 2.
11537373|NCT01093014|Experimental|Arm 1: High-force muscle stimulation|High-force muscle stimulation
11537374|NCT01093014|Experimental|Arm 2: Low-force muscle stimulation|Low-force muscle stimulation
11537375|NCT01093014|Experimental|Arm 3: Sequential low-force and high-force muscle stimulation|Sequential low-force and high-force muscle stimulation
11537376|NCT01093001|Active Comparator|Lead size|The pacemaker lead will be < or = to 7Fr. The ICD lead will be 9 Fr.
11537377|NCT01093001|Active Comparator|RV Lead position|50 patients will be randomized to RV apex lead placement.
11537378|NCT01093001|Active Comparator|Mid-Septum Lead position|50 patients will be randomized to RV mid-septum lead placement.
11537379|NCT01093001|Active Comparator|CS lead position|50 patients will have lead placed in the CS
11537380|NCT01092988|Experimental|Exablate 2100|MR Guided Focused Ultrasound treatment
11537381|NCT01092975|Experimental|1.25 mg phenylephrine|
11537382|NCT01092975|Experimental|2.5 mg phenylephrine|
11537383|NCT01092975|Experimental|5.0 mg phenylephrine|
11537384|NCT01092975|Experimental|10.0 mg phenylephrine|
11537385|NCT01092975|Experimental|20.0 mg phenylephrine|
11537386|NCT01092975|Experimental|40.0 mg phenylephrine|
11537387|NCT01092975|Experimental|60.0 mg phenylephrine|
11537388|NCT01092975|Experimental|80.0 mg phenylephrine|
11537389|NCT01092962|Experimental|Mycophenolate mofetil|Mycophenolate mofetil
11537390|NCT01092962|Active Comparator|Cyclophosphamide|Cumulative dose of 148mg/kg of cyclophosphamide in 84 days (2mg/kg/day during 12 weeks)
11537391|NCT01092923|Experimental|Air/Oxygen|Sevoflurane with Air/Oxygen Mix
11537392|NCT01092923|Experimental|sevoflurane in N2O/O2|
11537393|NCT01092910|Experimental|Esteem Implant|Subjects are implanted with the Esteem Totally Implantable Hearing System
11537394|NCT01092897||Subjects with PAH treated with Imatinib|
11537395|NCT01092884|Active Comparator|Polypodium leucotomos|Subjects randomized to this arm will receive oral supplementation with Polypodium leucotomos extract
11537396|NCT01092884|Placebo Comparator|Sugar pill|Subjects randomized to this arm will receive oral supplementation with placebo
11537397|NCT01092858|Experimental|Arm 1|
11537398|NCT01092858|Placebo Comparator|Arm 2|
11537399|NCT01092845|Experimental|PF-04457845 followed by placebo|
11537400|NCT01092845|Experimental|Placebo followed by PF-04457845|
11537401|NCT01092832|Experimental|Active voriconazole|All subjects in this study will receive active voriconazole in an open-label fashion; there is no comparator in this study.
11537402|NCT01092819||acute ischemic stroke|Patients presenting with symptoms of acute ischemic stroke within 8 hours from symptom onset and with an imaging-defined large cerebral vessel occlusion.
11537403|NCT01092806|Active Comparator|Prograf|Patients are treated until steady-state conditions with Prograf and then investigated with clamp
11537404|NCT01092806|Experimental|Advagraf|The patients are treated with Advagraf until steady-state conditions and then investigated with clamp
11537405|NCT01092793|Active Comparator|Krill|
11537406|NCT01092793|Active Comparator|Fish oil|
11537407|NCT01092793|No Intervention|Control|
11537408|NCT01092780|Experimental|MK-7288 10mg/Pbo/MK-7288 20mg/Modafinil|Participants received single doses of study drug in the following order: MK-7288 10 mg in Treatment Period 1, Placebo (Pbo) in Treatment Period 2, MK-7288 20 mg in Treatment Period 3 and Modafinil 200 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
11537409|NCT01092780|Experimental|MK-7288 20mg/MK-7288 10mg/Modafinil/Pbo|Participants received single doses of study drug in the following order: MK-7288 20 mg in Treatment Period 1, MK-7288 10 mg in Treatment Period 2, Modafinil 200 mg in Treatment Period 3 and Placebo in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
11537410|NCT01092780|Experimental|Modafinil/MK-7288 20mg/Pbo/MK-7288 10mg|Participants received single doses of study drug in the following order: Modafinil 200 mg in Treatment Period 1, MK-7288 20 mg in Treatment Period 2, Placebo in Treatment Period 3 and MK-7288 10 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
11537411|NCT01092780|Experimental|Pbo/Modafinil/MK-7288 10 mg/MK-7288 20mg|Participants received single doses of study drug in the following order: Placebo in Treatment Period 1, Modafinil 200 mg in Treatment Period 2, MK-7288 10 mg in Treatment Period 3 and MK-7288 20 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
11537412|NCT01092767|Experimental|Valiant Thoracic Stent Graft with the Captivia Delivery System|Valiant Thoracic Stent Graft with the Captivia Delivery System
11537413|NCT01092754|Other|A: Other|
11537414|NCT01092754|Other|B: Other|
11537415|NCT01092741|Experimental|Gleevec|Gleevec 400 mg by mouth (P.O.) twice daily = 800 mg total daily dose
11537416|NCT01092728|Active Comparator|Group 1: Completely Resectable|Dasatinib 100 mg daily for 7 days and then surgical resection on Day 8. Afterwards, Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).
11537417|NCT01092728|Active Comparator|Group 2: Unresectable|100 mg Dasatinib daily continued up to 12 months/12 cycles (1 cycle = 4 weeks of treatment).
11537418|NCT01092715|Experimental|Mobilization|Spinal mobilization and exercises
11537419|NCT01092715|Active Comparator|Massage|Neck massage and exercises
11537420|NCT01092702|Other|Varenicline|Everyone on study will receive Varenicline daily for 12 weeks
11537471|NCT01092325|Active Comparator|Echo Cohort B CXL-1020|CXL-1020 administered at a fixed rate for the initial 2 hours and at a higher fixed rate for the last 2 hours of a 4 hour infusion at doses which were studied in Cohort 1 or Cohort 2 and expected to be well tolerated and have hemodynamic effects
11537472|NCT01092312|Experimental|Signature Knee Guide|Vanguard Knee System with Signature Knee Guide
11537421|NCT01092689|Experimental|PhIP|Prior to surgery, consented subjects will ingest a capsule containing [14C]PhIP. This amount of [14C]PhIP (84 micrograms PhIP; 15.6 micro-curies) is equivalent to that in 2 very well done grilled/barbecued chicken breasts (Sinha 1995); the amount of radioactivity is equivalent to the dose received in a commercial airline flying at 30,000 ft. for 5 h (HPS 2007) or to the amount received during a typical chest x-ray.
11537422|NCT01092676|Active Comparator|Regular Ibuprofen Dosing|Regular Ibuprofen Dosing throughout 4 days of study
11537423|NCT01092676|Active Comparator|PRN Ibuprofen dosing|As needed Ibuprofen dosing
11537424|NCT01092663|Active Comparator|Colesevelam HCl: 3 tablets, 2x/day|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
11537425|NCT01092663|Active Comparator|Colesevelam plus Sitagliptin|"Colesevelam: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
~Sitagliptin: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks."
11537426|NCT01092650|Active Comparator|Smoked|Deuterated Phenanthrene spiked in a study cigarette
11537427|NCT01092650|Experimental|Oral|Deuterated phenanthrene in an oral dose
11537428|NCT01092637||Cooled|Child was allocated standard intensive care plus moderate whole body hypothermia treatment within 6 hours of birth
11537429|NCT01092637||Non-cooled|Child was allocated standard intensive care only within 6 hours of birth
11537430|NCT01092624|Experimental|Pessary and solifenacin|
11537431|NCT01092624|Placebo Comparator|Pessary and placebo|
11537432|NCT01092611|Other|Group A|Subjects who were administered the GSK HIV vaccine 732462 in primary studies and who accepted to participate in this study
11537433|NCT01092611|Other|Group B|Subjects who were administered placebo in primary studies and who accepted to participate in this study
11537434|NCT01092572|Experimental|Simvastatin 40 mg/d|simvastatin 40 mg per day taken orally
11537435|NCT01092572|Placebo Comparator|Sugar pill|
11537436|NCT01092559|Experimental|nitric oxide via GeNO Nitrosyl system|Nitric Oxide via GeNO Nitrosyl system
11537437|NCT01092546|Experimental|Arm 1|
11537438|NCT01092533|Experimental|Mycophenolate sodium + Prednisolone|Mycophenolate sodium 1440 mg/day Prednisolone: initial dose 1 mg/kg/day, maintenance dose 5 mg/day
11537439|NCT01092533|Active Comparator|Prednisolone|Prednisolone: initial dose 1 mg/kg/day, maintenance dose 5 mg/day
11537440|NCT01092520|Experimental|Gabapentin|
11537441|NCT01092507|Experimental|JE-CV Group|Participants will receive one dose of Japanese encephalitis chimeric virus vaccine (JE-CV)
11537442|NCT01092507|Active Comparator|SA14-14-2 vaccine Group|Participants will receive one dose of Japanese encephalitis live vaccine, SA14-14-2 vaccine. (CD.JEVAX®)
11537443|NCT01092494||OC use|OC use after postoperative gonadotropin-releasing hormone agonist treatment
11537444|NCT01092494||OC non-use|Only postoperative gonadotropin-releasing hormone agonist treatment
11537445|NCT01092481|Active Comparator|FOLFOX_12 or CAPOX_8|6 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX
11537446|NCT01092481|Experimental|FOLFOX_6 or CAPOX_4|3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX
11537447|NCT01092468|Placebo Comparator|Diathermy|Perforator flap elevation using conventional diathermy technique
11537448|NCT01092468|Active Comparator|Harmonic Scalpel|Perforator flap elevation using Harmonic Scalpel
11537449|NCT01092455||Citrasate and heparin reduction|Sequential hemodialysis treatment study in which all enrollees move through four (4) separate treatment phases. Results from the separate phases will be compared to standard bicarbonate dialysis with standard does of heparin.
11537450|NCT01092442||Retrospective Patients|Retrospective Patients: The patient group who had the CryoValve SG Pulmonary Human Heart Valve implanted prior to the February 2008 clearance of the valve.
11537451|NCT01092442||Prospective Patients|Prospective Patients: The patient group that had the CryoValve SG Pulmonary Human Heart Valve implanted after the February 2008 clearance of the valve.
11537452|NCT01092429||one,two,and three vessels disease; mortality|
11537453|NCT01092403|Experimental|ASM-024|ASM-024 once daily by inhalation
11537454|NCT01092403|Placebo Comparator|Placebo|Placebo once daily by inhalation
11537455|NCT01092390|Experimental|Lovaza|4 grams per day
11537456|NCT01092377|Experimental|DHA/EPA capsules and iron tablet|
11537457|NCT01092377|Experimental|DHA/EPA and placebo tablet|
11537458|NCT01092377|Placebo Comparator|placebo capsules & placebo tablet|
11537459|NCT01092377|Experimental|iron tablet and placebo capsules|
11537460|NCT01092364|Experimental|Cell phone intervention|Behavioral lifestyle intervention for weight loss, delivered by cell phone.
11537461|NCT01092364|Experimental|Personal counseling intervention|Behavioral lifestyle intervention for weight loss, delivered by personal counseling.
11537462|NCT01092364|No Intervention|Advice only|Advice only control group.
11537463|NCT01092351|Experimental|Nitrofurantoin|Adult patients with a microbiologically confirmed uncomplicated urinary tract infection
11537464|NCT01092338|Active Comparator|4000IU|Subjects in this arm take a daily dose of 4000IU of Vitamin D3
11537465|NCT01092338|Active Comparator|7000IU|Subjects in this arm of the study take a daily dose of 7000IU of Vitamin D3
11537466|NCT01092325|Experimental|Cohort 1 CXL-1020|An intravenous infusion of CXL-1020 administered for a total of 4 hours over a total of 3 occasions separated by at least one week. Each of the 3 doses of CXL-1020 are different, starting with the lowest dose and increasing to the highest dose.
11537467|NCT01092325|Placebo Comparator|Cohort 1 Placebo|A 4 hour infusion of Placebo administered one time randomly among the 3 active doses of CXL-1020 in cohort 1
11537468|NCT01092325|Experimental|Cohort 2 CXL-1020|An intravenous infusion of CXL-1020 administered for a total of 4 hours over a total of 3 occasions separated by at least one week. Each of the 3 doses of CXL-1020 are different, starting with the lowest dose and increasing to the highest dose.
11537469|NCT01092325|Placebo Comparator|Cohort 2 Placebo|A 4 hour infusion of Placebo administered one time randomly among the 3 active doses of CXL-1020 in cohort 1
11537470|NCT01092325|Active Comparator|Echo Cohort A CXL-1020|A 4 hour infusion of a fixed dose of CXL-1020 which was studied in Cohort 1 or Cohort 2 which is expected to be well tolerated and have hemodynamic effect
11537473|NCT01092312|Active Comparator|Conventional Approach|Vanguard Complete Knee System with Conventional Approach
11537474|NCT01092299|Experimental|Cohort 1 (2 arms)|Period 1: randomized to either fasting IR or ER1. Period 2: Cross-over to either IR or ER1. Period 3: ER1 in fed conditions.
11537475|NCT01092299|Experimental|Cohort 2 (2 arms)|Period 1: randomized to either fasting IR or ER2. Period 2: Cross-over to either IR or ER2. Period 3: ER2 in fed conditions.
11537476|NCT01092299|Experimental|Cohort 3( 2 arms)|Period 1: randomized to either fasting IR or ER3. Period 2: Cross-over to either IR or ER3. Period 3: ER3 in fed conditions.
11537477|NCT01092299|Experimental|Cohort 4 (2 arms)|Period 1: randomized to either fasting IR or MR4. Period 2: Cross-over to either IR or MR4. Period 3: MR4 in fed conditions.
11537478|NCT01092299|Experimental|Part 2: Extended/Modified release|Extended/Modified release capsule to be determined
11537479|NCT01092299|Placebo Comparator|Part 2: Placebo|
11537480|NCT01092286|Experimental|neuromuscular warm-up|coaches in this arm use the prescribed warm-up before team practices
11537481|NCT01092286|No Intervention|no warm-up|coaches use their usual warm-up before team practices
11537482|NCT01092273||Bimatoprost versus Travoprost|
11537483|NCT01092247|Placebo Comparator|Standard diet: Nutritional support|
11537484|NCT01092247|Experimental|Nutritional intervention: Ketogenic diet.|
11537485|NCT01092234|Active Comparator|Traditional ward|
11537486|NCT01092234|Experimental|Observational unit|Organizational change. Innovative organization of in-hospital care
11537487|NCT01092221|Experimental|Allopurinol|
11537488|NCT01092221|Placebo Comparator|Placebo|
11537489|NCT01092195|Active Comparator|Cohort 1|Female subjects post stem cell transplant on no systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
11537490|NCT01092195|Active Comparator|Cohort 2|Female subjects post stem cell transplant with chronic GVHD requiring systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
11537491|NCT01092195|Active Comparator|Cohort 3|Healthy normal female volunteers. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
11537492|NCT01092182|Experimental|A|Burkitt lymphoma Low Risk Arm
11537493|NCT01092182|Experimental|B|Burkitt lymphoma High Risk Arm
11537494|NCT01092182|Experimental|C|DLBCL high risk arm
11537495|NCT01092169||Sickle cell beta|
11537496|NCT01092156|Active Comparator|Education on Infant-led latching|
11537497|NCT01092156|No Intervention|Standard education|
11537498|NCT01092143|Experimental|BI671800 (low dose)|Patients receive BI671800 (low dose) capsules twice daily
11537499|NCT01092143|Active Comparator|Fluticasone|Patients inhale from Fluticasone MDI twice daily
11537500|NCT01092143|Placebo Comparator|placebo|Patients receive placebo capsules twice daily
11537501|NCT01092143|Experimental|BI671800 (medium dose)|Patients receive BI671800 (medium dose) capsules twice daily
11537502|NCT01092143|Experimental|BI671800 (high dose)|Patients receive BI671800 (high dose) capsules twice daily
11537503|NCT01092130|Experimental|Vitamin D|Patients were randomized by an automated computer system to 2000 IU oral cholecalciferol once daily or control (i.e. no extra medication), in a 1:1 ratio for a period of six weeks. Blood was collected in a sitting position on visits 2-4 and patients were asked to collect 24h urine samples prior to visits 2 and 4. Heart failure medication was maintained unchanged throughout the trial. Changes in diuretic dose were permitted if necessary to treat decompensation or renal dysfunction.
11537504|NCT01092117|Other|Ovation™ Abdominal Stent Graft System|Implant of Ovation™ Abdominal Stent Graft System
11537505|NCT01092104|Experimental|TBR-652 25 mg QD|TBR 25 mg QD for 10 days
11537506|NCT01092104|Placebo Comparator|Placebo|Matching Placebo QD for 10 days
11537507|NCT01092104|Experimental|TBR-652 50 mg QD|TBR-652 50 mg QD for 10 days
11537508|NCT01092104|Experimental|TBR-652 75 mg QD|TBR-652 75 mg QD for 10 days
11537509|NCT01092104|Experimental|TBR-652 100 mg QD|TBR-652 100 mg QD for 10 days
11537510|NCT01092104|Experimental|TBR-652 150 mg|TBR-652 150 mg QD for 10 days
11537511|NCT01092091|Experimental|PEG-BCT-100|Pegylated Recombinant Human Arginase I
11537512|NCT01092078|Experimental|Motivational Interviewing|Individuals in the motivational interviewing (MINT) arm of the study will receive telephone-based lifestyle interviewing for 6-months. Counseling will be aimed at modifying diet and/or physical activity behaviors associated with decreasing blood pressure.
11537513|NCT01092078|Experimental|Patient Navigation|Participants in the patient navigation arm will receive patient navigation for colonoscopy.
11537514|NCT01092078|Experimental|PLUS|Both patient navigation for colorectal cancer screening and motivational interviewing for blood pressure control
11537515|NCT01092065|Experimental|AFQ056 100 mg (Bid)|
11537516|NCT01092065|Placebo Comparator|Placebo|
11537517|NCT01092052|Experimental|1|
11537518|NCT01092039|Experimental|XIGO pill|Oral Xigo tablet
11537519|NCT01092039|Placebo Comparator|Placebo|Oral placebo tablet
11537520|NCT01092026|Experimental|cord blood transplant|Eiligible patients receive cord blood transplantation with coinfusion of mesenchymal stem cells
11537521|NCT01092013|Active Comparator|Operating room training|
11537522|NCT01092013|Active Comparator|Skills lab training|
11537523|NCT01092000||Faculty/Staff|
11537524|NCT01092000||Graduate Students|
11537525|NCT01092000||Undergraduate Students|
11537526|NCT01091987|Experimental|Non-pharmacological approach of insomnia|Non-pharmacological approach of insomnia based on cognitive-behavioural techniques (education on sleep, sleep hygiene, stimulus control, cognitive techniques)
11537527|NCT01091974|Experimental|1 - CBT-I + placebo|CBT-I and placebo
11537528|NCT01091974|Experimental|2 - CBT-I + Armodafinil|CBT-I + Armodafinil
11537529|NCT01091974|Placebo Comparator|3 - Placebo only|Placebo only
11537530|NCT01091974|Experimental|4 - Armodafinil only|Armodafinil only
11537531|NCT01091961|Active Comparator|Continuing ACEi/ARB|Patients in this group will continue to take their chronic ACEi/ARB medications up to and including the day of surgery.
11537532|NCT01091961|Active Comparator|Holding ACEi/ARB|Patients in this arm will hold their chronic ACEi/ARB medication at least 24 hours prior to surgery.
11537533|NCT01091948|Active Comparator|Fiberoptic Intubation|Subjects will be intubated with the Fiberoptic laryngoscope.
11537534|NCT01091948|Active Comparator|GlideScope® Video Laryngoscope|Subjects will be intubated with the GlideScope® Video Laryngoscope.
11537535|NCT01091935||Lidocaine|"Adults >18 yrs , attending St Joseph's Health Care Pain Clinic with a diagnosis of chronic neuropathic pain who are being treated with an lidocaine infusion of 5 mg/kg over 45 minutes
~Consecutive patients from two time periods:
~June 15 to August 21, 2009
~October 15-Dec 22,2009"
11537536|NCT01091922|Placebo Comparator|Low Flavanol|Low flavanol drink containing 23 mg of total flavanols. Macro- and micro-nutrient matched with active comparator
11537537|NCT01091922|Active Comparator|High Flavanols|High Flavanol drink containing 495 mg of total flavanols
11537538|NCT01091909|Experimental|post-extraction wound healing|53 individuals with diabetes and 29 controls, without diabetes, were followed for 60 days after dental extractions, and were examined after 3, 7, 21, and 60 postoperative days.
11537539|NCT01091896|No Intervention|1 - no bevacizumab|Patients will not receive bevacizumab before nor during vitrectomy
11537540|NCT01091896|Experimental|2- bevacizumab before vitrectomy|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
11537541|NCT01091896|Experimental|3- bevacizumab after vitrectomy|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
11537542|NCT01091883|Experimental|Exablate treatment|Exablate 2000
11537543|NCT01091883|Active Comparator|Radiation|External Beam Radiation
11537544|NCT01091870|Placebo Comparator|Placebo: soluble blue pigment|Soluble blue pigment for placebo controlling.
11537545|NCT01091870|Experimental|Sildenafil, 75mg daily|Sildenafil citrate, 75 mg daily divided in 3 doses. From third to 14th day after subarachnoid hemorrhage.
11537546|NCT01091870|Experimental|Sildenafil, 150 mg daily|Sildenafil citrate, 150 mg daily divided in 3 doses from third to 14th day after subarachnoid hemorrhage.
11537547|NCT01091857|Experimental|Exercise intervention (STRIDE)|
11537548|NCT01091857|Active Comparator|Health and Wellness Control|
11537549|NCT01091844|Active Comparator|Spontaneous Fill Technique|"We allow the bladder to spontaneously fill, then allow the patient to void and afterward catheterize the patient to check a postvoid residual (spontaneous fill technique)."
11537550|NCT01091844|Active Comparator|Retrograde Fill Technique|"We assess bladder emptying by filling the bladder retrograde through the catheter already in place with 300 mL of saline and then removing the catheter and allowing the patient to void (retrograde-fill technique). We will determine postvoid residual indirectly by subtracting voided volume from the 300 mL infused volume. No catheterization will be performed with this technique unless they void less than 200 mL."
11537551|NCT01091831|Active Comparator|CRD|Oral therapy with Cyclophosphamide, Lenalidomide and Dexamethasone.
11537552|NCT01091831|Active Comparator|MEL200|High dose Melphalan therapy (200 mg/m2) followed by stem cell support for 2 cycles every 4 months (for 1 cycle if at least VGPR was achieved after the 1st MEL200)
11537553|NCT01091818|Active Comparator|midazolam|
11537554|NCT01091818|Experimental|dexmedetomidin|
11537555|NCT01091792|Experimental|Bevacizumab|Bevacizumab + temozolomide + radiotherapy followed by adjuvant bevacizumab + temozolomide
11537556|NCT01091779||Hypertensive and normotensive|
11537557|NCT01091766|Active Comparator|bupivacaine|test solution consists of bupivacaine 0.125%
11537558|NCT01091766|Active Comparator|bupivacaine+epinephrine|test solution consists of bupivacaine 0.125% with epinephrine 1:200000
11537559|NCT01091766|Active Comparator|epinephrine|test solution consists of epinephrine 1:200000
11537560|NCT01091753|Placebo Comparator|morning administration group|
11537561|NCT01091753|Experimental|nocturnal administration group|
11537562|NCT01091740|Experimental|ZES resolute (Endeavor Resolute)|
11537563|NCT01091740|Active Comparator|EES (Xience)|
11537564|NCT01091727|Experimental|Botulinum toxin A|Botulinum toxin A 300U diluted with sterile saline (1 ml per injection site) and injected into 30 sites of the bladder, sparing the trigone.
11537565|NCT01091727|Placebo Comparator|Placebo|Sterile saline 30 cc injected into 30 sites in the bladder, sparing the trigone.
11537566|NCT01091714|Active Comparator|PRN Dry Eye Omega Benefits|4 capsules per day = 2240 mg Omega-3s
11537567|NCT01091714|Active Comparator|Nature's Made|2 capsules per day = 2400mg Omega-3s
11537568|NCT01091714|Active Comparator|Thera Tears|4 capsules per day = 2332mg Omega-3s
11537569|NCT01091701|Experimental|Ex vivo cultured adult allogenic MSCs|
11537570|NCT01091701|Placebo Comparator|Plasmalyte-A|
11537571|NCT01091688|Experimental|Just-in-Time intervention|"The infants and physicians in the experimental group will receive the Just-in-Time intervention sheets at the time of discharge."
11537572|NCT01091688|No Intervention|Routine discharge care|The infants and physicians in the routine discharge care arm will receive the same information and details as is per normal routine in the nursery.
11537573|NCT01091675|Experimental|etoricoxib|All the patients who fulfil the eligibility criteria will start a 4-week open label treatment period to evaluate the response to treatment with etoricoxib 90 mg.
11537574|NCT01091662|Experimental|eslicarbazepine acetate 1600 mg|Subjects randomized to 1600 mg QD of eslicarbazepine acetate will titrate from 600 mg QD(Day 0) to 1200 mg once a day(Week 2) to 1600 mg QD (Weeks 3-18) and may taper down from 1600 mg to 800 mg QD 3 days after the Week 18 visit.
11537575|NCT01091662|Experimental|eslicarbazepine acetate 1200 mg|"Subjects randomized to 1200 mg QD eslicarbazepine acetate will titrate from 400 mg QD (Day0) to 800 mg QDweek2) to 1200 mg QD(weeks 3-18) and may taper down from 1200 mg to 600 mg QD 3 days after the Week 18 visit.
~Subjects may continue in an open-label extension study with a starting dose of 1200 mg QD, or taper off their previous antiepileptic drugs during weeks 2-8."
11537576|NCT01091649|Active Comparator|A|Low dose ABT-450 capsule and ritonavir capsules (reference).
11537577|NCT01091649|Active Comparator|B|Low dose ABT-450 SDD Tablet Form 1 and ritonavir capsules (test 1)
11537578|NCT01091649|Active Comparator|C|Low dose ABT-450 SDD Tablet Form 2 and ritonavir capsules (test 2).
11537579|NCT01091649|Active Comparator|D|High dose ABT-450 capsule and ritonavir capsules (reference).
11537580|NCT01091649|Active Comparator|E|High dose ABT-450 SDD Tablet Form 1 or 2 and ritonavir capsule (test)
11537581|NCT01091636|Experimental|HIPEC|Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Ovarian Cancer after primary cytoreductive surgery or interval cytoreductive surgery
11537582|NCT01091636|No Intervention|No HIPEC|Primary cytoreductive surgery or interval cytoreductive surgery
11537583|NCT01091623|Active Comparator|strength training|
11537584|NCT01091623|Active Comparator|endurance training|
11537585|NCT01091623|Active Comparator|combined training|
11537586|NCT01091610||1|all emergency medical staff having suffered an accident during work
11537587|NCT01091610||2|non emergency medical personnel having suffered an injury due to a medical mission, e.g. transported patient having suffered additional injury due to an ambulance accident or collision of an ambulance with another vehicle.
11537588|NCT01091597|Active Comparator|usual ablation|Wide-area circumferential ablation of the pulmonary veins
11537589|NCT01091597|Experimental|Box isolation of the pulmonary veins|Single Box lesion set encompassing all four pulmonary veins and the posterior wall of the left atrium.
11537590|NCT01091584|Active Comparator|intervention group|The intervention is to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse.
11537591|NCT01091584|No Intervention|control group|usual care
11537592|NCT01091571|Placebo Comparator|Endotoxemia placebo|Endotoxin combined with placebo
11537593|NCT01091571|Experimental|Endotoxemia Dipyridamole|Endotoxin combined with Dipyridamol treatment
11537594|NCT01091558||Colonoscopy|Healthy volunteer who is having a screening colonoscopy
11537595|NCT01091558||Ulcerative Colitis|Patients with confirmed ulcerative colitis who are scheduled for endoscopy for medical reasons.
11537596|NCT01091545|Other|FFDM+DBT|Single-armed study. Women are their own controls with paired images of digital mammography and breast tomosynthesis.
11537597|NCT01091532|Experimental|Cohort 1|Subjects will be assigned to receive either UK-396,082 or placebo
11537598|NCT01091532|Experimental|Cohort 2|Subjects will be assigned to receive either UK-396,082 or placebo
11537599|NCT01091532|Experimental|Cohort 3|Subjects will be assigned to receive either UK-396,082 or placebo
11537600|NCT01091532|Experimental|Cohort 4|Subjects will be assigned to receive either UK-396,082 or placebo
11537601|NCT01091519||Toviaz(fesoterodine) plus educational materials|
11537602|NCT01091519||Toviaz(fesoterodine) alone|Toviaz(fesoterodine) without additional educational materials
11537603|NCT01091506|Experimental|L-methylfolate|L-methylfolate 15mg (a medical food)
11537604|NCT01091506|Placebo Comparator|Placebo|Placebo
11537605|NCT01091493|No Intervention|Non-Antibiotic|Patients will not receive antibiotics, although the study is double-blind.
11537606|NCT01091493|Active Comparator|Antibiotic|Patients will receive in a masked way, moxifloxacin.
11537607|NCT01091480||Patients with HCM|Patients ≥ 15 years with HCM(sarcomere of origin or not) defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic
11537608|NCT01091467||Patients with HF|Each patient seen in hospital emergency or for congestive heart failure and with an ejection fraction above 45%
11537609|NCT01091454|Experimental|Treatment (cisplatin and brostallicin)|Patients receive cisplatin IV over 2 hours on day 1 and brostallicin IV over 10 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11537610|NCT01091441||Patients with heart failure|Patients hospitalized for acute heart failure
11537611|NCT01091428|Experimental|Alisertib (Phase 1 - Ovarian cancer)|Participants with ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).
11537612|NCT01091428|Experimental|Alisertib (Phase 1 - Breast cancer)|Participants with breast cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).
11537613|NCT01091428|Experimental|Alisertib 40 mg BID+Paclitaxel 60 mg/m^2 (Phase 2)|Alisertib 40 mg, orally, BID on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).
11537614|NCT01091428|Experimental|Paclitaxel 80 mg/m^2 (Phase 2)|Paclitaxel 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).
11537615|NCT01091415|Experimental|calcium phosphate bone cement|one arm; volar locking plate alone the other arm; calcium phosphate bone cement as well as volar locking plate
11537616|NCT01091402||chronic urticaria|
11537617|NCT01091402||asthma|
11537618|NCT01091402||seasonal allergic rhinitis|
11537619|NCT01091402||normal controls|
11537620|NCT01091389|Experimental|GP ablation|Thoracoscopic PV isolation with GP ablation
11537621|NCT01091389|Experimental|No GP ablation|Thoracoscopic PV isolation with no GP ablation
11537622|NCT01091376|Experimental|Concomitant Erlotinib and radiotherapy|Patients received Erlotinib and radiation therapy.
11537623|NCT01091363|Experimental|deep cultural arm|deep cultural therapy
11537624|NCT01091363|Active Comparator|standard arm|brief cessation counseling
11537625|NCT01091350|Active Comparator|Diprifusor group|Propofol was infused via Diprifusor TCI (Target-controlled infusion)
11537626|NCT01091350|Experimental|Orchestra group|Propofol was infused via Orchestra TCI
11537627|NCT01091337|Experimental|Procaterol|"Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes
~+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment"
11537628|NCT01091337|Active Comparator|Salbutamol|Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
11537629|NCT01091324|Active Comparator|Dextromethorphan|
11537630|NCT01091324|Active Comparator|Silymarin|
11537631|NCT01091324|Placebo Comparator|sugar pill|
11537632|NCT01091298|Experimental|Group 1|
11537633|NCT01091298|Placebo Comparator|Group 2|
11537634|NCT01091285|Active Comparator|Single Balloon Catheter|Cervix Ripening is achieved by a single balloon catheter. Further induction by cytotec or/amniotomy and pitocin
11537635|NCT01091285|Active Comparator|Double balloon catheter|Cervix Ripening is achieved by a double balloon catheter. Further induction by cytotec or/amniotomy and pitocin
11537636|NCT01091272|Experimental|Cohort 1|Single dose 3 period interleaved cross-over with placebo substitution
11537637|NCT01091272|Experimental|Cohort 2|Single dose 4 period interleaved cross-over, placebo substitution, with food effect
11537638|NCT01091272|Experimental|Cohort 3|Single dose 4 period cross-over, placebo insertion, with food effect
11537639|NCT01091272|Experimental|Optional Cohort 4|Single dose 3 period cross-over with placebo substitution
11537640|NCT01091259|Experimental|Irinotecan with Bevacizumab|Irinotecan is administered every 3 weeks at a dose of 175 mg/m^2, bevacizumab is administered at 15 mg/kg every 3 weeks. Irinotecan is administered before bevacizumab. Patients will continue on therapy until evidence of disease progression, or until development of adverse events that prevent further treatment, or if the patients wishes to discontinue therapy.
11537641|NCT01091246|Experimental|Q/LAIV (MEDI3250)|Q/LAIV (quadrivalent live attenuated influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 temperature sensitive, cold-adapted, attenuated, 6:2 resassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], B/Victoria [B/Malaysia/2506/2004], and B/Yamagata [B/Florida/4/2006]).
11537642|NCT01091246|Experimental|FluMist/B/Yamagata|FluMist/B/Yamagata (trivalent live attenuated influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Yamagata [B/Florida/4/2006])
11537643|NCT01091246|Experimental|FluMist/B/Victoria|FluMist/B/Victoria (trivalent live attenuated influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature sensitive, cold-adapted, attenuated, 6:2 reassortant influenza stains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Victoria [B/Malaysia/2506/2004]).
11537644|NCT01091233||Paracentesis|Paracentesis as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
11537645|NCT01091220|Placebo Comparator|Placebo|0.9% saline
11537646|NCT01091220|Experimental|Certolizumab pegol|Certolizumab pegol 400 mg
11537647|NCT01091207|Experimental|Sorafenib|The patients will receive daily oral administration of sorafenib 400 mg twice daily.
11537648|NCT01091194|Other|Exercise|Interval-based aerobic exercise
11537649|NCT01091194|No Intervention|Control|No intervention other than regular follow up hospital visits
11537650|NCT01091181|Active Comparator|high incision group|hysterotomy at cesarean performed 2 cm above plica vesicouterina
11537651|NCT01091181|Active Comparator|low incision group|hysterotomy at cesarean performed 2 cm below plica vesicouterina
11537652|NCT01091168|Experimental|arm A: Vinflunine|Patients randomised in the test arm (arm A) received VFL at the dose of 280 mg/m² on day 1 of each cycle every 3 weeks, over a 20-minute intravenous (IV) infusion. Cycles were repeated every 3 weeks.
11537653|NCT01091168|Active Comparator|arm B: Alkylating agent of physician choice|Patients randomised in the control arm (arm B) received an alkylating agent used as a single agent which was available in the investigational center and was approved for the treatment of cancer in the country.
11537654|NCT01091155|Experimental|ColonRing TM|
11537655|NCT01091142|Experimental|NP001|
11537656|NCT01091142|Placebo Comparator|Placebo|
11537657|NCT01091129|Experimental|Treatment|Treatment with the miraDry System in both axilla
11537658|NCT01091116|Experimental|Double dose MEN16132 0.125 mg|Intra-articular administration of two 0.125 mg doses of MEN16132 at 2-week interval.
11537659|NCT01091116|Experimental|Double dose MEN16132 0.25 mg|Intra-articular administration of two 0.25 mg doses of MEN16132 at 2-week interval.
11537660|NCT01091116|Experimental|Double dose MEN16132 0.5 mg|Intra-articular administration of two 0.5 mg doses of MEN16132 at 2-week interval.
11537661|NCT01091116|Experimental|Single dose MEN16132 0.5 mg|Intra-articular administration of one 0.5 mg dose of MEN16132 followed by one intra-articular injection of placebo at 2-week interval.
11537662|NCT01091116|Placebo Comparator|Placebo|Intra-articular administration of two doses of Placebo at 2-week interval.
11537663|NCT01091103|Experimental|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression, unacceptable toxicity, or withdrawal.
11537664|NCT01091090|Experimental|Cognitive behavioral|Subjects with receive a cognitive behavioral intervention for smoking cessation
11537665|NCT01091090|Active Comparator|Control|Treatment as usual
11537666|NCT01091077|Placebo Comparator|Naringenin|Single dose of naringenin, compared to placebo in the same individual.
11537667|NCT01091064|Experimental|Early depart|Patients who will be liberated at triage with mild acute viral bronchiolitis
11537668|NCT01091064|No Intervention|Medical visit group|Patients with acute viral bronchiolitis who will wait to be seen by the physician
11537669|NCT01091051|Active Comparator|Ustekinumab|Ustekinumab S/C 45mg or 90mg depending on patient's weight or placebo injection. 10 with PPPP and 10 with PPP will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20
11537670|NCT01091051|Placebo Comparator|Placebo|Placebo S/C (Sodium Chloride). 10 with PPPP and 10 with PPP will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
11537671|NCT01091038|Placebo Comparator|Routine Care|Usual care of patients in the ambulatory setting
11537672|NCT01091038|Experimental|Basic Clinical Decision Support|Providers use basic clinical decision support
11537673|NCT01091025|Other|CF patients without known diagnose of CFRD|There is only one arm. All patients in the study had the same procedures (ie. an OGTT). Investigators used the screening criteria in parallel to this.
11537674|NCT01091012|Other|Sildenafil 20mg oral|
11537675|NCT01091012|Other|Sildenafil 10mg intravenous|
11537676|NCT01090999|No Intervention|1|"All patients will receive an initial in-hospital rehabilitation program which includes: Education, Physiotherapy, lower and upper extremities training and respiratory muscles training. Following completion of this program, patients will undergo concealed randomization to one of two maintenance strategies.
~The No Intervention group will undergo a standard, minimal monitoring program."
11537677|NCT01090999|Active Comparator|2|"All patients will receive an initial in-hospital rehabilitation program which includes: Education, Physiotherapy, lower and upper extremities training and respiratory muscles training. Following completion of this program, patients will undergo concealed randomization to one of two maintenance strategies.
~The active comparator group will undergo an intensive maintenance program after the initial in-hospital rehabilitation program."
11537678|NCT01090986||1|Patients with a restrictive pulmonary disease and hypercapnic chronic respiratory failure with standard criteria for NIV. Also COPD patients who need NIV because of another reason (obesity, nocturnal hyperventilation or nocturnal hypercapnic response to oxygen).
11537679|NCT01090973|Experimental|Oral drug treatment|LBH589 will be given orally (by mouth), 40 mg once-a-day, 3 times weekly every week on days 1, 3 & 5, then 8, 10 &12, then 15, 17 & 19, then 22, 24 & 26.
11537680|NCT01090960|Experimental|A|
11537681|NCT01090947||Patients referred to CAG.|Sequential design with ProtoCAD and CAG
11537682|NCT01090934|Experimental|high resolution EEG|
11537683|NCT01090934|Active Comparator|Stereo Electroencephalography|
11537684|NCT01090921|Experimental|Single-Arm|Bortezomib is administered at a dose of 1.6mg/m2 IV push over 3 to 5 seconds. Treatment is administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle. Dexamethasone is also administered at a dose of 40mg daily on day of and day after each dose of Bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone. The study duration for a given subject will be approximately 30 weeks.
11537685|NCT01090908||Ages 6-11 years|
11537686|NCT01090908||Ages 12-17 years|
11537687|NCT01090895|Active Comparator|Vitamin C|Vitamin C infusion
11537688|NCT01090895|Placebo Comparator|Placebo|Saline solution
11537689|NCT01090882|Sham Comparator|Control|Sham wash, sham injection
11537690|NCT01090882|Experimental|Subperitoneal injection|Local anaesthetic injection to diaphragm with sham wash over liver and gall bladder
11537691|NCT01090882|Active Comparator|Topical LA|Local anaesthetic washed over gall bladder and liver. Sham injection of diaphragm
11537692|NCT01090869|Active Comparator|Physical training, unchanged diet|Daily endurance training equivalent to 600 kcal/day and unchanged habitual diet
11537693|NCT01090869|Active Comparator|Physical training, increased diet|Daily endurance training equivalent to 600 kcal/day, and increased diet by 600 kcal/day.
11537694|NCT01090869|Active Comparator|Diet, unchanged physical activity|Energy-reduced diet by 600 kcal/day, and unchanged sedentary lifestyle
11537695|NCT01090869|No Intervention|Control|Unchanged sedentary lifestyle and diet
11537696|NCT01090856|No Intervention|No pre-dilation side branch|
11537697|NCT01090856|Active Comparator|Pre-dilation side branch|
11537698|NCT01090830|Experimental|Belinostat|This is a one arm, open label study of the investigational medication Belinostat.
11537699|NCT01090817|Experimental|Mesenchymal stromal cells|Mesenchymal stromal cells administered weekly for 4 weeks
11537700|NCT01090804|Experimental|breathing exercise|BreatheMAX breathing device is Water pressure Threshold Bottle. The level of water in the cylinder determines the load for treatment. In the treatment using 20% PNIP (Peak negative inspiratory pressure) was performed with 6-10 breaths/set; 10 set/day
11537701|NCT01090778|Other|Norditropin SimpleXx sc bolus injection|Single sc bolus injection of 3 mg growth hormone without interval exercise
11537702|NCT01090778|Other|Norditropin SimpleXx single sc injection|Single sc bolus injection of 3 mg growth hormone with interval exercise
11537703|NCT01090778|Other|Norditropin SimpleXx contin. sc infusion|Continuous sc infusion of 3 mg growth hormone without interval exercise
11537704|NCT01090778|Other|Norditropin SimpleXx cont. sc infusion|Continuous sc infusion of 3 mg growth hormone with interval exercise
11537705|NCT01090765|Experimental|TRC105 1 mg/kg every 2 weeks|Intravenous infusion at 1 mg/kg every 2 weeks
11537706|NCT01090765|Experimental|TRC105 3 mg/kg every 2 weeks|Intravenous infusion at 3 mg/kg every 2 weeks
11537707|NCT01090765|Experimental|TRC105 10 mg/kg every 2 weeks|Intravenous infusion at 10 mg/kg every 2 weeks
11537708|NCT01090765|Experimental|TRC105 10 mg/kg weekly|Intravenous infusion at 10 mg/kg weekly
11537709|NCT01090765|Experimental|TRC105 15 mg/kg every 2 weeks|Intravenous infusion at 15 mg/kg every 2 weeks
11537710|NCT01090765|Experimental|TRC105 20 mg/kg every 2 weeks|Intravenous infusion at 20 mg/kg every 2 weeks
11537711|NCT01090752|Placebo Comparator|Pioglitazone|placebo-controlled, randomized, cross-over study
11537712|NCT01090752|Placebo Comparator|Metformine|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
11537713|NCT01090739|Experimental|TOPAS|TOPAS Treatment for Fecal Incontinence
11537714|NCT01090726|Experimental|Storz videolaryngoscope|Macintosh overview followed by Airtraq overview followed by Storz videolaryngoscope overview and intubation.
11537715|NCT01090726|Active Comparator|Airtraq|Macintosh overview followed by Storz videolaryngoscope overview followed by Airtraq overview and intubation.
11537716|NCT01090713|Active Comparator|Lisdexamfetamine|drug
11537717|NCT01090713|Placebo Comparator|Placebo|Placebo comparator
11537718|NCT01090700|Experimental|001|TMC435 TMC435 150 mg daily for 7 days
11537719|NCT01090700|Other|002|Escitalopram Escitalopram 10 mg daily for 7 days
11537720|NCT01090700|Experimental|003|TMC435 + Escitalopram TMC435 150 mg + escitalopram 10 mg daily for 7 days
11537721|NCT01090687||Group I Microcalcifications|After classification as BI-RADS 4/5, approximately 75 to 100 subjects with primary findings based on microcalcifications will be recruited to have a breast CT scan.
11537773|NCT01090362||Cohort 5|Final cohort to commence August 2015 with a target of 11,000 patients enrolled. Last patient enrolled to complete 2 years of follow-up.
11537722|NCT01090687||Group II Soft tissue findings|After classification as BI-RADS 4/5, approximately 75 to 100 subjects with primary soft tissue findings, with or without associated microcalcifications, will be recruited to have a breast CT scan.
11537723|NCT01090674||1|Patients with amyotrophic lateral sclerosis.
11537724|NCT01090661|Experimental|mipomersen IV (supra-therapeutic dose)|200 mg of mipomersen IV / placebo SC
11537725|NCT01090661|Experimental|mipomersen SC (therapeutic dose)|200 mg of mipomersen SC / placebo IV
11537726|NCT01090661|Active Comparator|moxifloxacin IV|400 mg of moxifloxacin IV / placebo SC
11537727|NCT01090661|Placebo Comparator|placebo|Placebo IV / placebo SC
11537728|NCT01090648|Experimental|001|etravirine One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
11537729|NCT01090622|Placebo Comparator|Matching Placebo|
11537730|NCT01090622|Experimental|XPF-001|
11537731|NCT01090609|Experimental|Stent implantation|Cronus Stent implantation
11537732|NCT01090596|Active Comparator|Naproxen-Treated|
11537733|NCT01090596|Placebo Comparator|placebo|
11537734|NCT01090583||Cesarean Delivery Patients|
11537735|NCT01090570|Experimental|PLX3397 25 mg|
11537736|NCT01090570|Experimental|PLX3397 50 mg|
11537737|NCT01090570|Experimental|PLX3397 100 mg|
11537738|NCT01090570|Experimental|PLX3397 200 mg|
11537739|NCT01090570|Experimental|PLX3397 300 mg|
11537740|NCT01090570|Placebo Comparator|Placebo|
11537741|NCT01090557||RSV positive subjects|Subjects admitted to the hospital with Lower respiratory tract Viral infection symptoms from which nasopharyngeal mucous samples are positive for RSV by Direct Fluorescent Antibody technique and/or viral culture
11537742|NCT01090557||RSV negative subjects|Subjects admitted to the hospital with Lower respiratory tract Viral infection symptoms from which nasopharyngeal mucous samples are negative for RSV by Direct Fluorescent Antibody technique and/or viral culture (usually positive for influenza A & B, parainfluenza, human metapneumovirus or adenovirus)
11537743|NCT01090557||Control group|Children with same age range, ethnic background, and gender distribution as the study group coming for evaluation in the outpatient setting without evidence of viral infection
11537744|NCT01090518|Active Comparator|Prolonged Exposure therapy with Hydrocortisone|
11537745|NCT01090518|Placebo Comparator|Prolonged Exposure therapy with placebo|
11537746|NCT01090505|Experimental|Drug:S-1:80mg/m2;oxaliplatin 130mg/m2|Drug: Neoadjuvant chemotherapy(S-1+Oxaliplatin) followed by D2 gastrectomy
11537747|NCT01090505|No Intervention|surgery|Procedure/Surgery: Gastrectomy with D2 dissection
11537748|NCT01090492|Experimental|Secondary Raynaud 4 mg dose (period 1)|
11537749|NCT01090492|Experimental|Secondary Raynaud 4 mg dose (period 2)|
11537750|NCT01090492|Experimental|Secondary Raynaud 20 mg dose (period 1)|
11537751|NCT01090492|Experimental|Secondary Raynaud 20 mg dose (period 2)|
11537752|NCT01090492|Experimental|Primary Raynaud 4 mg dose (period 1)|
11537753|NCT01090492|Experimental|Primary Raynaud 4 mg dose (period 2)|
11537754|NCT01090492|Experimental|Primary Raynaud 20 mg dose (period 1)|
11537755|NCT01090492|Experimental|Primary Raynaud 20 mg dose (period 2)|
11537756|NCT01090479|No Intervention|Control|This group will perform an ordinary shower the night prior and the morning of their scheduled surgery date.
11537757|NCT01090479|Experimental|2% Chlorhexidine cloth|This group will use the 2% chlorhexidine wipes the night prior as well as the morning of their surgery date.
11537758|NCT01090453|Experimental|GSK2202083A Group|Subjects aged between and including 8 and 12 weeks of age at the time of first vaccination received 3 doses of GSK2202083A vaccine, co-administered with Prevenar 13® at 2, 4 and 12 months of age. The GSK2202083A and Prevenar 13® vaccines were administered intramuscularly into the right and left sides of the thigh, respectively. An optional 2-dose vaccination with Rotarix™ was offered to the study participants at 2 and 4 months of age.
11537759|NCT01090453|Active Comparator|Infanrix hexa Group|Subjects aged between and including 8 and 12 weeks of age at the time of first vaccination received 3 doses of Infanrix hexa™ vaccine, co-administered with Prevenar 13® and Menjugate® at 2, 4 and 12 months of age. The Infanrix hexa™ and Prevenar 13® vaccines were administered intramuscularly into the right and upper left sides of the thigh, respectively and the Menjugate® vaccine was administered intramuscularly in the lower left thigh. An optional 2-dose vaccination with Rotarix™ was offered to the study participants at 2 and 4 months of age.
11537760|NCT01090440|Experimental|Three-way cross- over|Three regimens will be administered in this study: A: GSK1144814 Tablet (100mg) Fasted State; B: GSK1144814 Tablet (200mg) Fasted State and C: GSK 1144814 Tablet (100mg) Fed State (FDA high fat breakfast).
11537761|NCT01090427|Experimental|Ustekinumab Half-standard Dosage|Participants will receive ustekinumab at half the standard dosage at Weeks 0, 4, 16, 28, and 40. In addition, all participants will receive a single SC dose of placebo at Week 12.
11537762|NCT01090427|Experimental|Ustekinumab Standard Dosage|Participants will receive ustekinumab at the standard dosage at Weeks 0, 4, 16, 28, and 40. In addition, all participants will receive a single SC dose of placebo at Week 12.
11537763|NCT01090427|Experimental|Placebo|Participants will receive matching placebo at Week 0 and 4, followed by ustekinumab at half-standard or standard dosage at Weeks 12, 16, 28, and 40.
11537764|NCT01090414|Experimental|Idelalisib|Participants will receive up to 350 mg of idelalisib twice daily until disease progression or unacceptable toxicity.
11537765|NCT01090401|Experimental|Patients with Linox smart S DX lead|
11537766|NCT01090388||1|Participants voluntarily completed a telephone interview using a questionnaire compiled using validated, patient-centered measures of cancer outcomes and psychosocial status.
11537767|NCT01090375|Experimental|Exercise|
11537768|NCT01090375|Placebo Comparator|Non Exercise|
11537769|NCT01090362||Cohort 1|Cohort complete with 5,088 retrospective patients and 5,499 prospective patients recruited from 19 countries.
11537770|NCT01090362||Cohort 2|Cohort completed with 11,351 patients enrolled from 30 countries
11537771|NCT01090362||Cohort 3|Cohort 3 completed with 11,139 patients enrolled globally from 32 countries
11537772|NCT01090362||Cohort 4|Cohort 4 ongoing (commenced Aug 2014) with 2600 patients recruited to date and a target of 11,000 patients enrolled from 35 countries.
11537774|NCT01090349|Experimental|Direct Alerts ON|Direct Alerts in implantable device were turned on
11537775|NCT01090349|Active Comparator|Direct Alerts OFF|Direct Alerts in implantable device were turned off
11537776|NCT01090336||Clopidogrel group|At the discretion of the attending cardiologist patients are treated with clopidogrel (600mg loading and 75mg daily dose)
11537777|NCT01090336||Prasugrel group|At the discretion of the attending cardiologist patients are treated with prasugrel (60mg loading and 10mg daily dose)
11537778|NCT01090323|Experimental|ICL670|
11537779|NCT01090310|Experimental|AIN457 300mg every 2 weeks|AIN457 300 mg subcutaneous (s.c.) weekly for 3 weeks followed by AIN457 300 mg s.c. every 2 weeks
11537780|NCT01090310|Experimental|AIN457 300 mg every 4 weeks|AIN457 300 mg s.c. at baseline for Week 2 followed by AIN457 300 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly
11537781|NCT01090310|Experimental|AIN457 150 mg every 4 weeks|AIN457 150 mg s.c. and placebo s.c. at Baseline and Week 2 followed by AIN457 150 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly
11537782|NCT01090310|Placebo Comparator|Placebo|Placebo s.c. every 2 weeks
11537783|NCT01090297|Active Comparator|Fixed pressure|
11537784|NCT01090297|Active Comparator|Auto-adjusting pressure|
11537785|NCT01090284||Heavy weight mesh|This cohort includes patients undergoing inguinal hernioplasty with polypropylene heavy weight mesh.
11537786|NCT01090284||Light weight mesh|This cohort includes patients undergoing inguinal hernioplasty with polypropylene light weight mesh.
11537787|NCT01090271|Experimental|Eccentric training|
11537788|NCT01090258|Experimental|Automated settings|Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
11537789|NCT01090258|Active Comparator|protocolized settings|Ventilator settings performed by the local respiratory therapists according to the local protocols
11537790|NCT01090245|Active Comparator|Attendance Information Group|Participants in the Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing. In addition, they will receive the standard treatment offered by the Walden House Los Angeles program.
11537791|NCT01090245|Experimental|Attendance Incentive Group|Participants in the Attendance Incentive Group could receive up to $841.50 in incentives for their treatment attendance and the standard treatment offered by the Walden House Los Angeles program.
11537792|NCT01090232|Experimental|chronic HEV infection|in kidney-transplant recipients with chronic HEV infection
11537793|NCT01090232|Active Comparator|control|the host responses in kidney-transplant recipients without viral infection (controls)
11537794|NCT01090219|Experimental|two differents meshes|Heavy-weight versus low-weight polypropylene meshes
11537795|NCT01090206|Other|Hemophilia, Vitamin D deficiency|"Hemophilia, Rickets - Vitamin D per endocrine consult
~Hemophilia, Vitamin D deficient - Vitamin D 2000 units daily plus calcium
~Hemophilia, Normal Vitamin D - no intervention - observation only"
11537796|NCT01090193|Other|obstructive jaundice|
11537797|NCT01090180|Experimental|Arm 1: Dexamethasone|Dexamethasone (oral)
11537798|NCT01090180|Placebo Comparator|Arm 2: Placebo|Placebo (inactive)
11537799|NCT01090167|Experimental|Clofarabine|
11537800|NCT01090154|Experimental|Cimzia|Treatment with open label Cimzia (certolizumab pegol)
11537801|NCT01090141|Active Comparator|Subjects recieving 100 mg of Micafungin|
11537802|NCT01090141|Active Comparator|Subjects recieving 300 mg of Micafungin|
11537803|NCT01090128|Experimental|All patients|All participants enrolled.
11537804|NCT01090102|Experimental|Mesalamine|
11537805|NCT01090102|Placebo Comparator|Placebo|
11537806|NCT01090089|Experimental|Lenalidomid, PBSCT|A1 Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
11537807|NCT01090089|Active Comparator|Lenalidomid|A2 Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
11537808|NCT01090076|Experimental|Abound|Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)
11537809|NCT01090076|Placebo Comparator|Placebo|Placebo comparator that contains none of the active ingredients
11537810|NCT01090050|Active Comparator|Sumatriptan/Naproxen Sodium|In Treatment Period Month 1: Subjects randomized to Sumatriptan/Naproxen Sodium will treat daily with 1 tablet Sumatriptan 85mg / Naproxen Sodium 500mg per day x 30 days. Subjects will be provided with 30 tablets of Sumatriptan/Naproxen Sodium for rescue. In Treatment Period Months 2 and 3: Subjects randomized to Sumatriptan/Naproxen Sodium will be provided with 14 tablets of Sumatriptan/Naproxen Sodium to treat on 14 or fewer days per month. Subjects will be provided with 14 tablets of Sumatriptan/Naproxen Sodium per month for rescue.
11537811|NCT01090050|Active Comparator|Naproxen Sodium|In Treatment Period Month 1: Subjects randomized to Naproxen Sodium will treat daily with 1 tablet Naproxen Sodium 500mg per day x 30 days. Subjects will be provided with 30 tablets of Naproxen Sodium for rescue. In Treatment Period Months 2 and 3: Subjects randomized to Naproxen Sodium will be provided with 14 tablets of Naproxen Sodium to treat on 14 or fewer days per month. Subjects will be provided with 14 tablets of Naproxen Sodium per month for rescue.
11537812|NCT01090037|Experimental|TRK-100STP|
11537813|NCT01090037|Placebo Comparator|Placebo|
11537814|NCT01090024|Experimental|BI 671800 AM and PM|Patients receiving two capsules twice daily
11537815|NCT01090024|Experimental|BI 671800 AM|Patients receiving four capsules in the morning
11537816|NCT01090024|Experimental|BI 671800 PM|Patients receiving four capsules in the evening
11537817|NCT01090024|Placebo Comparator|Placebo|Patients receiving four capsules twice a day
11537818|NCT01090011|Experimental|combination arm|patients to receive medium BIBW 2992 once daily plus biweekly cetuximab infusion at low, median and high dose level
11537819|NCT01090011|Experimental|sequential arm|patients to receive BIBW 2992 once daily, upon progression add biweekly cetuximab
11537820|NCT01089998|Experimental|Arm 1|
11537821|NCT01089998|Experimental|Arm 2|
11537822|NCT01089998|Experimental|Arm 3|
11537823|NCT01089998|Experimental|Arm 4|
11537824|NCT01089985|Experimental|Serum eye drops|Patient's autologous serum is diluted in saline solution
11537825|NCT01089972||20 gauge group|
11537826|NCT01089972||22 gauge group|
11537827|NCT01089959|Other|Esomeprazole|Effect of PPI esomeprazole on acid reflux & related arousals during sleep in patients with GERD.
11537828|NCT01089933|Experimental|Thoracic PVB + multimodal anesthesia|Thoracic PVB + multimodal anesthesia
11537829|NCT01089933|Active Comparator|Local anesthetic + multi-modal analgesia|Local anesthetic + multi-modal analgesia
11537830|NCT01089920|Experimental|High dose coffee|High dose of polyphenols from soluble coffee
11537831|NCT01089920|Experimental|Medium dose coffee|Medium dose of polyphenols from soluble coffee
11537832|NCT01089920|Experimental|Low dose coffee|Low dose of polyphenols from soluble coffee
11537833|NCT01089920|Experimental|High dose green tea|High dose of green tea polyphenols from infusion
11537834|NCT01089920|Experimental|Medium dose green tea infusion|Medium dose of green polyphenols from infusion
11537835|NCT01089920|Experimental|Low dose green tea infusion|low dose of polyphenols from an infusion of green tea
11537836|NCT01089894||18F-FLT 1|18F-FLT in differentiating benign from malignant pulmonary nodules
11537837|NCT01089894||18F-FLT 2|18F-FLT in evaluating therapeutic response of platinum-based chemotherapy (The chemotherapeutic drugs used in the study are all approved by the Department of Health, Taiwan.)
11537838|NCT01089894||18F-FLT 3|18F-FLT in evaluating therapeutic response of EGFR tyrosin kinase inhibitors (The target therapeutic drugs used in the study are all approved by the Department of Health, Taiwan.)
11537839|NCT01089881||Group 1|patients with BPH
11537840|NCT01089881||Group 2|patients with newly diagnosed prostate cancer
11537841|NCT01089881||Group 3|patients who have received curative treatment for prostate cancer and are suspicious of recurrence/metastases because of a persistent increase in their serum PSA.
11537842|NCT01089868||Group A|Patients who suffer from a suspected GBM and will undergo a microsurgical procedure for diagnosis verification. MRI and Positron Emission Tomography (PET) scans are scheduled prior to microsurgery, post microsurgery and after having completed radiochemotherapy and an additional scan after TMZ chemotherapy.
11537843|NCT01089868||Group B|Patients enrolled in Group B suffer from a suspected GBM which cannot be accessed microsurgically either due to a an eloquent location of the tumor, or patient's refusal to undergo surgery. In these patients, diagnosis will be obtained by means of stereotactic surgery. After an initial PET and MRI scan prior to biopsy, patients will be monitored by post radiochemotherapy as well as post 3-months chemotherapy MRI/PET scans.
11537844|NCT01089855|Experimental|Carbamazepine|
11537845|NCT01089842|Experimental|Health coaching|
11537846|NCT01089842|No Intervention|Control|
11537847|NCT01089829||CKD Stage 4|eGFR <30
11537848|NCT01089829||CKD Stage 5|Receiving Haemodialysis or Peritoneal dialysis therapy
11537849|NCT01089816||All|Anyone presenting with influenza-like-illness
11537850|NCT01089803||Patients Treated with Laryngectomy|Patients initially treated with laryngectomy and followed for 12 months after receiving this treatment.
11537851|NCT01089803||Patients Treated with Chemoradiation|Patients treated initially with chemoradiation and followed for 12 months after receiving treatment.
11537852|NCT01089790|Experimental|1|
11537853|NCT01089790|Active Comparator|2|
11537854|NCT01089764|Experimental|Couplelinks.ca Intervention|Intervention arm - Couple participates in the Couplelinks.ca program.
11537855|NCT01089764|No Intervention|No Intervention|Couple is waitlisted for participation in the Couplelinks.ca program.
11537856|NCT01089751|Experimental|Sanctura XR®|Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks.
11537857|NCT01089751|Placebo Comparator|Placebo|Placebo once daily on an empty stomach for 14 weeks.
11537858|NCT01089738|Experimental|Dosing|Ascending Doses
11537859|NCT01089725|Placebo Comparator|Placebo|
11537860|NCT01089725|Experimental|2.5 mg tanezumab SC and placebo IV|
11537861|NCT01089725|Experimental|5 mg tanezumab SC and placebo IV|
11537862|NCT01089725|Experimental|10 mg tanezumab SC and placebo IV|
11537863|NCT01089725|Experimental|10 mg tanezumab IV|
11537864|NCT01089712||Patients undergoing cardiac surgery|The patient population for this study consists of all patients undergoing cardiac surgical interventions. All patients who meet the eligibility criteria may be included in the study regardless of gender, race or ethnicity.
11537865|NCT01089699|Active Comparator|Professionally-led online support|Members assigned to 10-week online support group with a professional counsellor.
11537866|NCT01089699|Active Comparator|Peer-led online support|
11537867|NCT01089699|Active Comparator|self-study materials|
11537868|NCT01089686|Active Comparator|Venoplasty (treatment)|Patients will be randomized to treatment or non-treatment arm with a 2:1 ratio. Patients who meet the inclusion/exclusion criteria and who are randomized to the treatment arm of the study will receive venoplasty at the time of the diagnostic venogram.
11537869|NCT01089686|Sham Comparator|Sham procedure (non-treatment)|Patients will be randomized to treatment or non-treatment with a 2:1 ratio. Patients who meet the inclusion/exclusion criteria and who are randomized to the non-treatment arm of the study will receive the diagnostic venogram only.
11537870|NCT01089673||no treatment|retrospective data analysis
11537871|NCT01089660|Experimental|Study Group 1|Swine-origin A/H1N1 Vaccine Low-dose
11537872|NCT01089660|Experimental|Study Group 2|Swine-origin A/H1N1 Vaccine High-dose
11537873|NCT01089647|Active Comparator|budesonide and montelukast|treatment arm
11537874|NCT01089647|Placebo Comparator|placebo|sugar pill, salt water nasal spray
11537875|NCT01089621|Experimental|Duloxetine|
11537876|NCT01089608|Placebo Comparator|Unifluid|Eye drops in Single Dose Unit
11537877|NCT01089608|Experimental|Azithromycin|Eye drops Single dose unit
11537878|NCT01089595|Active Comparator|Nilotinib|Nilotinib 400 mg po bid
11537879|NCT01089595|Active Comparator|Nilotinib + Imatinib|Nilotinib 400 mg BID with Imatinib 400 mg daily
11537880|NCT01089582||AD patients|
11537881|NCT01089569|Active Comparator|Exenatide|5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
11538503|NCT01085578|Placebo Comparator|Cohort2|CG400549/placebo
11537882|NCT01089569|Active Comparator|Insulin Glargine|.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
11537883|NCT01089569|Active Comparator|Exenatide + Insulin Glargine|"Exenatide: 5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
~+ Insulin Glargine: 0.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results"
11537884|NCT01089556|Experimental|Duloxetine|"Initial Treatment:
~Duloxetine 30 milligram (mg) daily for 1 week
~Duloxetine 60 mg daily for 7 weeks
~Intensive Treatment:
~Duloxetine 90 mg (60 mg in the morning, 30 mg in the evening) daily for 1 week
~Duloxetine 120 mg (60 mg twice daily) daily for 7 weeks"
11537885|NCT01089556|Experimental|Pregabalin+Duloxetine|"Initial Treatment:
~Pregabalin 150 mg daily for 1 week
~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks
~Intensive Treatment:
~Pregabalin 300 mg (150 mg twice daily) daily for 8 weeks
~Duloxetine 30 mg daily for 1 week
~Duloxetine 60 mg daily for 7 weeks"
11537886|NCT01089556|Experimental|Pregabalin|"Initial Treatment:
~Pregabalin 150 mg daily for 1 week
~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks
~Intensive Treatment:
~Pregabalin 450 mg (300 mg in the morning, 150 mg in the evening) daily for 1 week
~Pregabalin 600 mg (300 mg twice daily) daily for 7 weeks"
11537887|NCT01089556|Experimental|Duloxetine + Pregabalin|"Initial Treatment:
~Duloxetine 30 mg daily for 1 week
~Duloxetine 60 mg daily for 7 weeks
~Intensive Treatment:
~Duloxetine 60 mg daily for 8 weeks
~Pregabalin 150 mg daily for 1 week
~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks"
11537888|NCT01089543|Experimental|Rabeprazole 10 mg|
11537889|NCT01089543|Experimental|Rabeprazole 20 mg|
11537890|NCT01089543|Experimental|Rabeprazole 40 mg|
11537891|NCT01089543|Placebo Comparator|Placebo|
11537892|NCT01089530|No Intervention|Standard care|
11537893|NCT01089517|Active Comparator|Lucentis|
11537894|NCT01089517|Experimental|E10030 low dose plus Lucentis|
11537895|NCT01089517|Experimental|E10030 high dose plus Lucentis|
11537896|NCT01089504|Active Comparator|Phenobarbital|Phenobarbital, 4-5 mg/kg/day, for 4 months
11537897|NCT01089504|Placebo Comparator|Placebo|Placebo in a volume equivalent to active drug for 4 months
11537898|NCT01089452|Active Comparator|Perindopril monotherapy|Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks
11537899|NCT01089452|Active Comparator|Perindopril/amlodipine|Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.
11537900|NCT01089452|Experimental|Olmesartan/amlodipine FDC|Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
11537901|NCT01089439|Active Comparator|1: INOMAX|"Nitric oxide by inhalation INOMAX:
~active arm treated with nitric oxide"
11537902|NCT01089439|Placebo Comparator|2: Placebo|placebo arm treated with placebo at the same conditions
11537903|NCT01089426|Other|Historical controls|A subset of patients previously seen, who have had at least 2 consecutive direct bilirubin levels > 2 mg/dL, who depended on parenteral nutrition for at least 90 days after surgical therapy for congenital or acquired intestinal diseases
11537904|NCT01089426|Experimental|Omegaven™|
11537905|NCT01089413||Cohort|
11537906|NCT01089400||Influenza A/H1N1 patients|
11537907|NCT01089400||Non influenza A/H1N1 patients|
11537908|NCT01089387|Experimental|injection of bone marrow cells|
11537909|NCT01089374|Other|Partial breast radiation after lumpectomy|Radiation per NSABP B-39/R0413 protocol.
11537910|NCT01089361|Placebo Comparator|Normal saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
11537911|NCT01089361|Experimental|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
11537912|NCT01089348|Experimental|Lactofiltrum|
11537913|NCT01089348|Active Comparator|Control|
11537914|NCT01089335||Papillary thyroid cancer|Patients with preoperatively diagnosed highly differentiated papillary thyroid cancer
11537915|NCT01089335||Tumour of uncertain malignant potential|Thyroid tumours with preoperative cytology indicating follicular neoplasia, or on cytology suspected but not proven malignancy
11537916|NCT01089322|Experimental|Stantardized treament|oral and inhaled corticosteroid plus LABA
11537917|NCT01089309|Experimental|Aldosteron blokade, Arterial stiffness, Glucose homeostasis|
11537918|NCT01089296|Other|Individually customized physiotherapy|The intervention involves handling the infant and changing its position. It focuses on improving symmetry, muscle balance and movement in infants. The parent who is with the infant during the admission period will carry out the daily intervention after being taught by the physiotherapist.
11537919|NCT01089296|No Intervention|Control|Ordinary follow up in the Neonatal Intensive Care Unit (NICU).
11537920|NCT01089283||LRRK2 mutation|Parkinson patients that carry mutation on LRRK2 gene
11537921|NCT01089283||GBA mutation|Parkinson patients that carry mutation on GBA gene
11537922|NCT01089283||no mutation|Parkinson patients that don't carry mutation on LRRK2 or GBA genes
11537923|NCT01089283||healthy|Healthy volunteers
11537924|NCT01089244||Group A|"Patients with a suspected WHO II low grade glioma, disease progression within
~1 year"
11537925|NCT01089244||Group B|Patients with a suspected WHO II low grade glioma, progression free within 1 year
11537926|NCT01089231|Placebo Comparator|Placebo - healthy subjects|Dietary Supplement: corn oil capsules (6 per day) about 3 months
11537927|NCT01089231|Placebo Comparator|Placebo - hyperlipedemic subjects|Dietary Supplement: corn oil capsules (6 per day) about 3 months
11537928|NCT01089231|Experimental|Fish oil - hyperlipidemic subjects|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months
11537929|NCT01089231|Experimental|Fish oil - healthy subjects|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months.
11537930|NCT01089218|No Intervention|control|control without intervention
11537931|NCT01089218|Active Comparator|Amoxicillin/clavulanate|
11537932|NCT01089205|Experimental|Torrent's Metformin tablets 750 mg|
11537933|NCT01089205|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA|
11537934|NCT01089192|Experimental|Torrent's Metformin tablets 750 mg|
11538504|NCT01085578|Other|Cohort3|CG400549
11537935|NCT01089192|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
11537936|NCT01089179|Experimental|Torrent's Metformin tablets 500 mg|
11537937|NCT01089179|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
11537938|NCT01089166|Experimental|Torrent's Metformin tablets 500 mg|
11537939|NCT01089166|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
11537940|NCT01089140|Experimental|. Tranexamic acid low dose 10 mg/kg|
11537941|NCT01089140|Experimental|Tranexamic acid 100mg/kg|
11537942|NCT01089140|Placebo Comparator|Saline Placebo|
11537943|NCT01089127|Experimental|Indacaterol 18.75 μg|Patients inhaled indacaterol 18.75 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
11537944|NCT01089127|Experimental|Indacaterol 37.5 μg|Patients inhaled indacaterol 37.5 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
11537945|NCT01089127|Experimental|Indacaterol 75 μg|Patients inhaled indacaterol 75 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
11537946|NCT01089127|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
11537947|NCT01089127|Active Comparator|Salmeterol 50 μg|Patients inhaled salmeterol 50 μg twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. In addition, patients inhaled placebo to indacaterol once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
11537948|NCT01089127|Placebo Comparator|Placebo|Patients inhaled placebo to indacaterol once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
11537949|NCT01089101|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience a sustained objective response from selumetinib on the phase I or phase II portions of the trial, and who have completed 2 years of treatment and stopped study drug may be enrolled on the re-treatment study after progression/recurrence. Patients in the re-treatment study may continue treatment indefinitely in the absence of disease progression or unacceptable toxicities.
11537950|NCT01089075|Placebo Comparator|placebo/20 mg hydrocortisone|Order of study treatment: 7 days placebo followed by 7 days 20 mg hydrocortisone
11537951|NCT01089075|Active Comparator|20 mg hydrocortisone/placebo|Order of study treatment: 7 days 20 mg hydrocortisone followed by 7 days placebo
11537952|NCT01089062|Other|Treatment A, then Treatment B, then Treatment C|"The second dose in each treatment group (A,B,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.
~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.
~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4."
11537953|NCT01089062|Other|Treatment A, then Treatment C, then Treatment B|"The second dose in each treatment group (A,C,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.
~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.
~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4."
11537954|NCT01089062|Other|Treatment B, then Treatment A, then Treatment C|"The second dose in each treatment group (B,A,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.
~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.
~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4."
11537955|NCT01089062|Other|Treatment B, then Treatment C, then Treatment A|"The second dose in each treatment group (B,C,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.
~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.
~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4."
11537999|NCT01088802|Experimental|Dose de-escalating radiation therapy with chemotherapy|This protocol combines selective radiation therapy dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks) in patients with HPV-associated cancers of the oropharynx
11538000|NCT01088789|Other|Arm A|Vaccine only.
11537956|NCT01089062|Other|Treatment C, then Treatment A, then Treatment B|"The second dose in each treatment group (C,A,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.
~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.
~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4."
11537957|NCT01089062|Other|Treatment C, then Treatment B, then Treatment A|"The second dose in each treatment group (C,B,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.
~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.
~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.
~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4."
11537958|NCT01089049|Experimental|Pre-Menopausal|
11537959|NCT01089049|Experimental|Post-Menopausal|
11537960|NCT01089036||survival|ECMO survival patients
11537961|NCT01089036||ECMO non-survival|ECMO non-survivals
11537962|NCT01089023|Experimental|1|
11537963|NCT01089010|Experimental|Treatment Sequence 1|Treatment sequence 1 consisted of three dosing periods in which patients received single oral doses of placebo, 250 mg, and 500 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
11537964|NCT01089010|Experimental|Treatment Sequence 2|Treatment sequence 2 consisted of three dosing periods in which patients received single oral doses of placebo, 500 mg, and 250 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
11537965|NCT01089010|Experimental|Treatment Sequence 3|Treatment sequence 3 consisted of three dosing periods in which patients received single oral doses of 250 mg, placebo and 500 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
11537966|NCT01089010|Experimental|Treatment Sequence 4|Treatment sequence 4 consisted of three dosing periods in which patients received single oral doses of 250 mg, 500 mg and placebo of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
11537967|NCT01089010|Experimental|Treatment Sequence 5|Treatment sequence 5 consisted of three dosing periods in which patients received single oral doses of 500 mg, placebo, and 250 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
11537968|NCT01089010|Experimental|Treatment Sequence 6|Treatment sequence6 consisted of three dosing periods in which patients received single oral doses of 500 mg, 250 mg, and placebo of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
11537969|NCT01088997|Experimental|High Dose Milrinone|Subjects will receive a bolus intravenous (IV) infusion of 50 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.5 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
11537970|NCT01088997|Experimental|Low Dose Milrinone|Subjects will receive a bolus intravenous (IV) infusion of 20 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.2 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
11537971|NCT01088984|Experimental|Bendamustine|Bendamustine 90 or 120 mg/m^2 administered as an intravenous (IV) infusion over 60 minutes on Days 1 and 2 of each 21-day cycle (maximum of 12 total cycles), with delays up to 2 weeks for neutrophil and platelet count recovery, for up to a 35-day cycle.
11537972|NCT01088971|Active Comparator|Duolac 7S|
11537973|NCT01088971|Placebo Comparator|starch capsule|
11537974|NCT01088958|Experimental|Micronutrient Sprinkles|Sales of Sprinkles in these groups of villages by community vendors
11537975|NCT01088945|Experimental|Enhanced Discharge Process|Caregivers of these infants will receive individual coaching in order to enhance their understanding of their infant's problems and enhance their knowledge and skills to care for their fragile infants.
11537976|NCT01088945|Active Comparator|Standard Discharge Process|These infants will receive the hospital's current standard of care for the discharge of fragile infants from the NICU.
11537977|NCT01088932|Experimental|SRX246|SRX246
11537978|NCT01088932|Placebo Comparator|Placebo|placebo
11537979|NCT01088919|Experimental|Dosing Regimen 1|
11537980|NCT01088919|Experimental|Dosing Regimen 2|
11537981|NCT01088919|Experimental|Dosing Regimen 3|
11537982|NCT01088919|Experimental|Dosing Regimen 4|
11537983|NCT01088906|Experimental|1 ARM|pemetrexed 500 mg/m2 IV + cisplatin 75 mg/m2 every 21 days
11537984|NCT01088893|No Intervention|observation|
11537985|NCT01088893|Experimental|Everolimus|
11537986|NCT01088880|Experimental|Canakinumab|
11537987|NCT01088867|Other|Acupuncture|14 weeks of electroacupuncture therapy.
11537988|NCT01088854|Experimental|positive airway pressure|
11537989|NCT01088841|Active Comparator|75 g glucose + 150 ppm lactisole|
11537990|NCT01088841|Active Comparator|75 g glucose + 300 ppm lactisole|
11537991|NCT01088841|Active Comparator|75 g glucose + 450 ppm lactisole|
11537992|NCT01088841|Placebo Comparator|75 g glucose|
11537993|NCT01088828||Group A|"Foetuses with clubfoot identified in utero (n=15). Of these:
~around 10 will be born with clubfoot and will form most of Group B,
~around 5 will be born without clubfoot and will form part of group C."
11537994|NCT01088828||Group B|Neonates affected by clubfoot (n=10)
11537995|NCT01088828||Group C|Control group of unaffected neonates (n=10)
11537996|NCT01088828||Group D|Young adults having completed treatment (n=5)
11537997|NCT01088828||Group E|Control group of young unaffected adults (n=5)
11537998|NCT01088815|Experimental|Gemcitabine, nab-paclitaxel, GDC-0449|Gemcitabine and nab-Paclitaxel in combination with GDC-0449 (Vismodegib)
11538001|NCT01088789|Other|Arm B|Arm B receives vaccine as well as a single dose of intravenous cyclophosphamide.
11538002|NCT01088789|Other|Arm C|In addition to Vaccine Arm C receives a daily dose of metronomic cyclophosphamide orally.
11538003|NCT01088776|Experimental|Supplement|
11538004|NCT01088776|Placebo Comparator|Control|
11538005|NCT01088763|Experimental|Arm I|"GROUP A: Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
~GROUP B: Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-5, 8-12, 15-19, and 22-26. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients may also receive concurrent oral dexamethasone twice daily on the days of gamma-secretase inhibitor RO4929097 administration.
~Once the MTD or recommended phase II dose of RO4929097 plus dexamethasone in children with solid tumors, including CNS tumors, or lymphoma has been identified, this dose is used for patients with relapsed-refractory T-ALL (phase 2 portion of the study) to evaluate RO4929097 in combination with dexamethasone using one of the studied schedules."
11538006|NCT01088750|Other|surgery alone|watch and wait strategy after complete resection of localised (e.g. Stage IA) nodular lymphocyte-predominant HL
11538007|NCT01088750|Experimental|CVP|3 cycles of intensity-reduced, anthracycline-free chemotherapy (Cyclophosphamide, vinblastine and prednisone)
11538008|NCT01088724|Experimental|chemotherapy|
11538009|NCT01088711|Experimental|Healthy Omarigliptin|Obese healthy participants receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel A).
11538010|NCT01088711|Placebo Comparator|Healthy Placebo|Obese healthy participants receive once-weekly placebo by mouth for 4 weeks (Panel A).
11538011|NCT01088711|Experimental|T2D Omarigliptin|Obese participants with T2D receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel B).
11538012|NCT01088711|Placebo Comparator|T2D Placebo|Obese participants with T2D receive once-weekly placebo by mouth for 4 weeks (Panel B).
11538013|NCT01088685|Experimental|Experimental Blister Patch|Experimental Hydrogel Blister patch
11538014|NCT01088685|Active Comparator|Marketed Pflaster|Scholls Blasen Pflaster
11538015|NCT01088672|Other|Acute Ischemic Stroke|Single arm post market surveillance study for CE marked mechanical thrombectomy device, Trevo retriever for treatment of eligible patients experiencing acute ischemic stroke Mechanical thrombectomy intervention for all subjects in Acute Ischemic Stroke
11538016|NCT01088659|Experimental|1|
11538017|NCT01088659|Experimental|2|
11538018|NCT01088633|Other|Exhaled particle analysis|
11538019|NCT01088620|Experimental|Panitumumab plus pemetrexed and cisplatin (PemCisP)|
11538020|NCT01088620|Active Comparator|Pemetrexed and cisplatin (PemCis)|
11538021|NCT01088607|Experimental|UDCA Withdrawal and Reinstitution|Each study subject will undergo serial UDCA withdrawal and reinstitution.
11538022|NCT01088594|Experimental|1|pioglitazone 45 mg
11538023|NCT01088594|Experimental|2|Rosiglitazone 8 mg
11538024|NCT01088594|Placebo Comparator|3|Placebo
11538025|NCT01088581|No Intervention|Observation group|No adjuvant chemotherapy after resection
11538026|NCT01088581|Active Comparator|Adjuvant group|Adjuvant chemotherapy after resection
11538027|NCT01088568|Experimental|TICL group|
11538028|NCT01088568|Active Comparator|LASIK group|
11538029|NCT01088555|Active Comparator|Control group|Healthy subjects with no history of kidney stones, heart liver or kidney disease, not pregnant /lactating.
11538030|NCT01088555|Active Comparator|Stone formers|History of calcium containing kidney stones, hypercalciuria on previous urine tests, no heart /liver / kidney disease, not pregnant/lactating
11538031|NCT01088542|No Intervention|No intervention|Communities in the no intervention arm received no intervention from the project and continued to implement prevention services as usual.
11538032|NCT01088542|Experimental|Communities That Care Intervention|Communities randomly assigned to the experimental condition received 5 years of training and technical assistance (from 2003 to 2008) to implement the Communities That Care (CTC) prevention system in their communities. They also received 5 years of funding to support a full-time community coordinator and 4 years of seed money to implement tested and effective prevention programs selected as a result of their CTC process.
11538033|NCT01088529|Experimental|AA+LHRHa|Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) and 1,000 mg abiraterone acetate (AA) plus 5 mg of prednisone daily for 3 months prior to radical prostatectomy.
11538034|NCT01088529|Experimental|LHRHa|Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) prior to radical prostatectomy.
11538035|NCT01088516|Experimental|Aluvia-based HAART|Study regimen: ZDV/3TC (combivir) + 2 Aluvia Tabs all PO BID to start at 14-30 weeks gestational age (GA) and continue through labor and as long as the mother breastfeeds
11538036|NCT01088503||ADP receptor inhibitor treatment|Participants admitted for non ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) and treated with an ADP receptor inhibitor during the index hospitalization.
11538037|NCT01088490||critically ill|Critically ill patients admitted to ICU
11538038|NCT01088477||Breast cancer patients with acquired anti-hormonal resistance|
11538039|NCT01088464|Experimental|Cohort 1|
11538040|NCT01088464|Experimental|Cohort 2|
11538041|NCT01088464|Experimental|Cohort 3|
11538042|NCT01088438|Experimental|Contextualization workshop|A four-hour course on contextualization.
11538043|NCT01088438|No Intervention|Control|No intervention
11538044|NCT01088425||Spontaneous|Mothers with children conceived after spontaneous cycle
11538045|NCT01088425||Vitrificatíon|Mothers with children conceived after vitrification cycle
11538046|NCT01088425||slow- rate freezing|Mothers with children conceived after slow- rate freezing cycle
11538047|NCT01088412||Treated|Participants treated with somatropin for improvement of growth
11538048|NCT01088412||Untreated|Untreated participants with presence or history of neoplastic disease evaluated for endocrine or growth disorder or with any SHOX deficiency related disorder
11538049|NCT01088399||Somatropin replacement treatment|Adult participants with growth hormone deficiency receiving somatropin replacement treatment.
11538104|NCT01088061||Obese control women|
11538050|NCT01088399||No treatment|Adult participants with growth hormone deficiency receiving no somatropin replacement treatment.
11538051|NCT01088386||Patients|All patients who will be receiving Zyprexa Relprevv must be enrolled into the Zyprexa Relprevv Patient Care Program
11538052|NCT01088373|Experimental|Azacitidine, Lenalidomide|
11538053|NCT01088360||Patients with rheumatoid arthritis initiating abatacept|
11538054|NCT01088360||Pts with RA initiating other biologic disease-modifying drugs|
11538055|NCT01088360||Pts w/ RA non-biologic disease-modifying anti-rheumatic drugs|
11538056|NCT01088347|Experimental|Advanced cervical cancer patients|
11538057|NCT01088334||IVTE, follow-up|no malignancy at basal screening, no extensive screening
11538058|NCT01088334||IVTE, screening|No malignancy at basal screening, screening by means of CT-Chest/abdomen and mammography in women
11538059|NCT01088321||Patients initiating abatacept|
11538060|NCT01088321||Patients initiating other biologic disease-modifying drugs|
11538061|NCT01088321||Pts initiate non-biologic disease-modify anti-rheumatic drugs|
11538062|NCT01088308|Experimental|Single Arm|All Patients underwent Intervention.
11538063|NCT01088295|Experimental|Telmisartan|Telmisartan 40mg po daily for 24 weeks
11538064|NCT01088282|Active Comparator|Implantation of difractive multifocal IOL|
11538065|NCT01088282|Sham Comparator|Implantation of monofocal IOL|
11538066|NCT01088269||AF|Hypertensive patients in AF
11538067|NCT01088269||Non-AF|Hypertensive Patients
11538068|NCT01088256|Active Comparator|etoricoxib, peripheral hyperalgesia|14 patient with neuropathic pain and peripheral hyperalgesia get etoricoxib 90mg for 8 days
11538069|NCT01088256|Active Comparator|etoricoxib, no peripheral hyperalgesia|14 patients with neuropathic pain without peripheral hyperalgesia get etoricoxib 90mg for 8 days
11538070|NCT01088256|Placebo Comparator|placebo, peripheral hyperalgesia|14 patients with neuropathic pain with peripheral hyperalgesia get placebo for 8 days
11538071|NCT01088256|Placebo Comparator|placebo, no peripheral hyperalgesia|14 patients with neuropathic pain without peripheral hyperalgesia get placebo for 8 days
11538072|NCT01088243|Experimental|Mesalamine|Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
11538073|NCT01088243|Placebo Comparator|Placebo|Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
11538074|NCT01088230|Experimental|Botox®|this group will receive an injection of botox in the wrist flexors and forearm pronators
11538075|NCT01088230|Placebo Comparator|Saline|This group will receive an injection of saline solution in the same muscle groups as the treatment group (wrist flexors and pronators).
11538076|NCT01088204|Active Comparator|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
11538077|NCT01088204|Experimental|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
11538078|NCT01088191|Active Comparator|Hyaluronan Alone|Hyaluronan Alone
11538079|NCT01088191|Experimental|MSB-CAR001|Single Dose of MSB-CAR001 Combined With Hyaluronan
11538080|NCT01088178|Experimental|Immediate Postplacental|Within 10 minutes from delivery of placenta
11538081|NCT01088178|Experimental|Early Postpartum|After 10 minutes from delivery of placenta but within 48hrs from delivery
11538082|NCT01088178|Experimental|Interval|After 6 weeks postpartum
11538083|NCT01088165|Experimental|Adalimumab treatment group|
11538084|NCT01088165|Active Comparator|Fumaric acid esters treatment group|
11538085|NCT01088152|Active Comparator|Usual care of celiac disease women|Written information corresponding to that offered when seeking medical advice for celiac disease in primary care
11538086|NCT01088152|Experimental|Celiac School|Structured education using problem-based learning at 10 sessions
11538087|NCT01088139|No Intervention|Control|
11538088|NCT01088139|Experimental|Nutritional Supplementation|
11538089|NCT01088126|Active Comparator|Focal ablation|PV isolation + CFAE-targeted focal ablation
11538090|NCT01088126|Active Comparator|Linear ablation|PV isolation + CFAE-guided linear ablation
11538091|NCT01088113||Tai Chi|Healthy subjects with Tai Chi practice
11538092|NCT01088113||Qigong|Healthy subjects with Qigong practice
11538093|NCT01088100||Patients with POCD - cases|Out of the 976 patients included in the ISPOCD2 study (Abildstrom H, Christiansen M et al. Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery. Anesthesiology 2004;101:855-61) the 93 patients with POCD whose blood samples are stored will be included together with 2x93 controls (without POCD), who will be matched by type of surgery, age, education, ASA-score and sex.
11538094|NCT01088100||Patients without POCD - controls|Out of the 976 patients included in the ISPOCD2 study (Abildstrom H, Christiansen M et al. Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery. Anesthesiology 2004;101:855-61) the 93 patients with POCD whose blood samples are stored will be included together with 2x93 controls (without POCD), who will be matched by type of surgery, age, education, ASA-score and sex.
11538095|NCT01088087|Placebo Comparator|Colostrum|
11538096|NCT01088087|No Intervention|Sugar pill|
11538097|NCT01088074|Active Comparator|Histoacryl Tissue Adhesive|Histoacryl Blue (HAB) Tissue Adhesive (n-butyl-2 cyanoacrylate; B. Braun Corp., Melsungen, Germany). Histocryl is a FDA-approved sterile liquid skin adhesive that has been utilized as a substitute for sutures for wound closure for approximately 40 years.
11538098|NCT01088074|Active Comparator|Dermabond|Dermabond High Viscosity Tissue Adhesive (2-ocytl cyanoacrylate; Ethicon, Somerville, NJ). Dermabond is also a FDA-approved liquid bonding agent that has been utilized for wound closure for approximately 10 years and proven as effective as sutures.
11538099|NCT01088074|Active Comparator|Staples|Visistat 35W Stapler (Teleflex Corp, Limerick, PA). The FDA-approved Weck staple system with stainless steel staples has been proven over years of use and remains the standard accepted closure approach due to speed of insertion as well as removal.
11538100|NCT01088074|Active Comparator|Running Subcuticular with Monocryl|Monocryl 4-0 Suture (Ethicon, Somerville, NJ). Monocryl is an FDA-approved absorbable, synthetic, suture indicated for soft tissue approximation.
11538101|NCT01088061||lean women with PCOS|
11538102|NCT01088061||Obese women with PCOS|
11538103|NCT01088061||lean control women|
11538105|NCT01088048|Experimental|Idelalisib + Rituximab|Idelalisib 100 mg or 150 mg twice daily + rituximab 375 mg/m^2 for 8 weekly doses
11538106|NCT01088048|Experimental|Idelalisib + Rituximab + Bendamustine|Idelalisib 150 mg twice daily + rituximab 375 mg/m^2 on Day 1 + bendamustine 90 mg/m^2 on Days 1 & 2 of Cycles 1-6 for participants with iNHL or MCL. Bendamustine 70 mg/m^2 for for participants with CLL only.
11538107|NCT01088048|Experimental|Idelalisib + Bendamustine|Idelalisib 100 mg or 150 mg twice daily + bendamustine 90 mg/m^2 or 70 mg/m^2 on Days 1 & 2 of Cycles 1-6.
11538108|NCT01088048|Experimental|Idelalisib + Ofatumumab|Idelalisib 150 mg twice daily + 12 doses of ofatumumab over the course of 6 months. For participants with CLL only.
11538109|NCT01088048|Experimental|Idelalisib + Fludarabine|Idelalisib 150 mg twice daily + oral fludarabine 40 mg/m^2 on Days 1-5 of Cycles 1-6. For participants with CLL only.
11538110|NCT01088048|Experimental|Idelalisib + Everolimus|Idelalisib 150 mg twice daily + oral everolimus 10 mg once daily. For participants with MCL only.
11538111|NCT01088048|Experimental|Idelalisib + Bortezomib|Idelalisib 150 mg twice daily + bortezomib 1.3 mg/m^2 once weekly for 3 weeks (Days 1, 8, and 15) followed by a 13-day rest period. For participants with MCL only.
11538112|NCT01088048|Experimental|Idelalisib + Chlorambucil|Idelalisib 150 mg twice daily + chlorambucil 10 mg/m^2 on Days 1-7 every 28 days. For participants with CLL only.
11538113|NCT01088048|Experimental|Idelalisib + Rituximab + Chlorambucil|Idelalisib 150 mg twice daily + rituximab 375 mg/m^2 + chlorambucil 10 mg/m^2 for participants with CLL only.
11538114|NCT01088048|Experimental|Idelalisib + Rituximab + Lenalidomide|Idelalisib 150 mg twice daily + rituximab 375 mg/m^2 + lenalidomide 5, 10 or 20 mg (M.D. Anderson Cancer Center only)
11538115|NCT01088035|Experimental|Carboplatin|
11538116|NCT01088022|Experimental|Aprepitant, Palonosetron, dexametasone|
11538117|NCT01088022|Placebo Comparator|Placebo, Palonosetron, Dexamethasone|
11538118|NCT01088009|Experimental|early add-on|
11538119|NCT01088009|Active Comparator|SOC|Patients will receive oral lamivudine 100mg,daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
11538120|NCT01088009|Other|De-novo combination|patients in this arm will receive oral lamivudine 100mg and adefovir 10mg for 104 weeks
11538121|NCT01087996|Experimental|Auto-hMSCs|Participants will receive an injection of 20 million, 100 million or 200 million autologous human mesenchymal stem cells.
11538122|NCT01087996|Experimental|Allo-hMSCs|Participants will receive an injection of 20 million, 100 million or 200 million allogeneic human mesenchymal stem cells.
11538123|NCT01087983|Experimental|Lapatinib + Sirolimus|Lapatinib starting oral dose of 500 mg daily for 21 day cycle. Sirolimus starting oral dose 1 mg daily.
11538124|NCT01087983|Experimental|Lapatinib + Metformin|Lapatinib starting oral dose of 500 mg daily for 21 day cycle. Metformin Starting oral dose 1000 mg daily.
11538125|NCT01087970|Experimental|Triplet Combination Therapy|"Cycle 1:
~Week 1 - Cetuximab 400 milligrams/square meter (mg/m²) on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin area under curve (AUC) 5 on Day 1 or Cisplatin 75 mg/m² on Day 1
~Week 2 - Cetuximab 250 mg/m² on Day 1
~Week 3 - Cetuximab 250 mg/m² on Day 1
~Cycle 2-6:
~Week 1 - Cetuximab 250 mg/m² on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin AUC 5 on Day 1 or Cisplatin 75 mg/m² on Day 1
~Week 2 - Cetuximab 250 mg/m² on Day 1
~Week 3 - Cetuximab 250 mg/m² on Day 1
~Following Cycle 6, Cetuximab Monotherapy: 250 mg/m² intravenously weekly on Day 1"
11538126|NCT01087957|Active Comparator|Ankle-Foot Orthosis (AFO)|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
11538127|NCT01087957|Active Comparator|WalkAide|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
11538128|NCT01087944|Experimental|1|"Peginterferon via auto-injector device.
~All participants will receive Peginterferon in a cross-over design."
11538129|NCT01087944|Active Comparator|2|"Peginterferon via pre-filled syringe.
~All participants will receive Peginterferon in a cross-over design."
11538130|NCT01087931|Active Comparator|Bupivacaine|This group will receive bupivacaine (10ml of 0.5%) administered directly into the surgical wound at the iliac crest bone harvest site.
11538131|NCT01087931|Placebo Comparator|Saline|This group will receive normal saline (10ml) administered directly into the surgical wound at the iliac crest bone harvest site.
11538132|NCT01087918|Experimental|First RAGT, then strength training|16 sessions of 45 minutes of robot-assisted gait training 4 times a week in first intervention period and 16 sessions of 45 minutes of strength training 4 times a week in second intervention period.
11538133|NCT01087918|Experimental|First strength training, then RAGT|16 sessions of 45 minutes of strength training 4 times a week in first intervention period and 16 sessions of 45 minutes of robot-assisted gait training 4 times a week in second intervention period.
11538134|NCT01087905|Active Comparator|2 Weeks of Nicotine Patch Only, No CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)
~2 Weeks of Nicotine patch dosed as follows:
~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks
~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks"
11538135|NCT01087905|Active Comparator|2 Weeks of Nicotine Patch Only plus CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling
~2 Weeks of Nicotine patch dosed as follows:
~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks
~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks"
11538136|NCT01087905|Active Comparator|2 Wks Nicotine Patch+Nic Gum, No CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)
~2 Weeks of Nicotine patch dosed as follows:
~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks
~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks
~2 Weeks of Nicotine gum dosed as follows:
~If < 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.
~If ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
11538163|NCT01087788|Other|Placebo to CZP 200 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 30 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
11538137|NCT01087905|Active Comparator|2 Wks Nicotine Patch+Nic Gum plus CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling
~2 Weeks of Nicotine patch dosed as follows:
~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks
~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks
~2 Weeks of Nicotine gum dosed as follows:
~If < 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.
~If ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
11538138|NCT01087905|Active Comparator|6 Weeks of Nicotine Patch Only, No CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)
~6 Weeks of Nicotine patch dosed as follows:
~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks
~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks"
11538139|NCT01087905|Active Comparator|6 Weeks of Nicotine Patch Only plus CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling
~6 Weeks of Nicotine patch dosed as follows:
~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks
~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks"
11538140|NCT01087905|Active Comparator|6 Wks Nicotine Patch+Nic Gum, No CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)
~6 Weeks of Nicotine patch dosed as follows:
~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks
~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks
~6 Weeks of Nicotine gum dosed as follows:
~If < 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.
~If ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
11538141|NCT01087905|Active Comparator|6 Wks Nicotine Patch+Nic Gum plus CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling
~6 Weeks of Nicotine patch dosed as follows:
~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks
~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks
~6 Weeks of Nicotine gum dosed as follows:
~If < 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.
~If ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
11538142|NCT01087892|Active Comparator|Dietary supplement Probiotic drink|"Double blind
~Probiotic containing the live strain 100g/day orally, twice daily for the duration of the course of antibiotics plus seven days"
11538143|NCT01087892|Placebo Comparator|Dietary supplement probiotic placebo drink|"Double blind
~'placebo' is actually a control product
~Placebo drink contains no strain 100gs orally, twice daily for the duration of the course of antibiotics plus seven days"
11538144|NCT01087879|Active Comparator|Oral contraceptive pill|9 weeks treatment with contraceptive pill.
11538145|NCT01087879|Active Comparator|Contraception vaginal ring|9 weeks treatment with vaginal ring.
11538146|NCT01087879|Active Comparator|Transdermal contraceptive patch|9 weeks treatment with a transdermal contraceptive patch.
11538147|NCT01087866|Experimental|Metformin|
11538148|NCT01087866|Active Comparator|Insulin|
11538149|NCT01087853|Active Comparator|Phase A1: Plasmalyte|Plasmalyte
11538150|NCT01087853|Active Comparator|Phase A2: 0.9% Saline|0.9% Saline
11538151|NCT01087853|Active Comparator|Phase B1: PlasmaVolume|PlasmaVolume
11538152|NCT01087853|Active Comparator|Phase B2: Voluven|Voluven
11538153|NCT01087840|Experimental|Raltegravir, NPEP|"Drug: Raltegravir Tablet 400mg taken orally, twice daily with or without food for 28 days along with Truvada 1 tablet taken orally daily for 28 days.
~Arms: Raltegravir/Truvada"
11538154|NCT01087814|Active Comparator|efavirenz|
11538155|NCT01087814|Experimental|over-encapsulated efavirenz|
11538156|NCT01087801|Active Comparator|ChiRhoStim|Human Secretin for Injection
11538157|NCT01087801|Placebo Comparator|Placebo|Saline for Injection
11538158|NCT01087788|Experimental|CZP 200 mg Q2W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.
~At every visit, subjects received one injection of 200 mg CZP and one injection of Placebo to maintain the study blind."
11538159|NCT01087788|Experimental|CZP 400 mg Q4W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 8 onwards.
~Subjects received 2 injections of Placebo every 4 weeks in between the 2 injections of 200 mg CZP to maintain the study blind."
11538160|NCT01087788|Placebo Comparator|Placebo|"Matching Placebo to Certolizumab Pegol (CZP) injections from Week 0 to Week 24. Placebo subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group and were re-randomized to either CZP 200 mg Q2W or CZP 400 mg Q4W arm on Week 16.
~After 24 weeks, all subjects were re-randomized to active treatment with CZP 200 mg every two weeks (Q2W) or CZP 400 mg every four weeks (Q4W)."
11538161|NCT01087788|Other|Placebo to CZP 200 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 22 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
11538162|NCT01087788|Other|Placebo to CZP 400 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 24 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
11538233|NCT01087346|Experimental|Genetic Information|Information about genetic factors in child obesity risk
11538164|NCT01087788|Other|Placebo to CZP 400 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 32 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
11538165|NCT01087775|Experimental|Cognitive Training|Plasticity Based Adaptive Cognitive Remediation (PACR)
11538166|NCT01087762|Experimental|CZP 200 mg Q2W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.
~At every visit, subjects received one injection of 200 mg CZP and one injection of Placebo to maintain the study blind."
11538167|NCT01087762|Experimental|CZP 400 mg Q4W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 8 onwards.
~Subjects received 2 injections of Placebo every 4 weeks in between the 2 injections of 200 mg CZP to maintain the study blind."
11538168|NCT01087762|Placebo Comparator|Placebo|"Matching Placebo to CZP injections from Week 0 to Week 24. Placebo subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16.
~After 24 weeks, all subjects were randomized to active treatment with CZP 200 mg Q2W or CZP 400 mg Q4W."
11538169|NCT01087762|Other|Placebo to CZP 200 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 22 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
11538170|NCT01087762|Other|Placebo to CZP 400 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 24 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
11538171|NCT01087762|Other|Placebo to CZP 200 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 30 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
11538172|NCT01087762|Other|Placebo to CZP 400 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 32 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
11538173|NCT01087749|Experimental|Chronic Kidney Disease|Propranolol, Losartan, and Eprosartan will be administered to patients who have been diagnosed with Chronic Kidney disease and have a glomerular filtration rate (GFR) below 40ml/min.
11538174|NCT01087749|Experimental|Healthy Volunteers|Propranolol, Losartan, and Eprosartan will be administered to healthy volunteers without chronic kidney disease.
11538175|NCT01087736|Experimental|Topiramate|Participants will be randomly assigned to either the topiramate arm or placebo arm. Neither the participant nor the researchers will know which arm the participant is in. Participants in the topiramate arm will be ingesting daily doses of topiramate that will gradually increase to a maximum, and then taper off.
11538176|NCT01087736|Placebo Comparator|Placebo|The Drug Product Services Laboratory at UCSF will purchase and supply our lab with USP or NF grade topiramate study capsules and matching placebo capsules. Randomization will be done by a consulting biostatistician, who will be the only one to know which participants are assigned to placebo. Dosing will follow the same procedures as with topiramate in that arm of the study. If adverse events occur, there will be a procedure in place for unblinding only that participant.
11538177|NCT01087723|Experimental|Bivalirudin|Given immediately upon enrollment as an intravenous (IV) bolus of 0.75 mg/kilogram (mg/kg), followed immediately by an infusion of 1.75 mg/kg/hour (mg/kg/h). This infusion was to be run continuously until completion of PCI, at which time the infusion was reduced to 0.25 mg/kg/h for at least 4 hours. An optional PCI-dose infusion of 1.75 mg/kg/h was also permitted for up to 4 hours at the discretion of the operator.
11538178|NCT01087723|Active Comparator|Standard of Care: Heparins with Optional GPI|"Standard-of-care anti-thrombotic therapy as outlined in the European Society of Cardiology Dosing Guidelines for Management of STE-ACS, not including bivalirudin: UFH (100 international units/kg [IU/kg] without GPI and 60 IU/kg with GPI). Any of the following approved GPIs were used either as a routine strategy or as a bail out: eptifibatide (two 180-micrograms/kilogram [μg/kg] IV boluses with a 10-minute [min] interval followed by an infusion of 2.0 μg/kg/min for 72-96 hours); tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18-24 hours); or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours [maximum dose of 10 μg/min]).
~For this study, the control consisted of treatment with UFH or low molecular weight heparin (LMWH) with or without GPI and is referred to as heparins with optional GPI."
11538179|NCT01087710|Experimental|novel nutritional formula|
11538180|NCT01087710|Active Comparator|Control nutritional product|1 8oz serving per day for 12 weeks
11538181|NCT01087697|Experimental|Implanted with NUC|Patients who have been implanted with the Neo-Urinary Conduit
11538182|NCT01087684|Active Comparator|Argon laser trabeculoplasty|Patients received standard argon laser treatment
11538183|NCT01087684|Active Comparator|Selective laser trabeculoplasty|Patients received a standard selective laser treatment
11538184|NCT01087671|Other|Open-lable study with one arm|
11538185|NCT01087658|Experimental|Glutamine and calcium magnesium|"Glutamine 10g p.o. 3-times a day beginning at day -2 for 7 consecutive days during each chemotherapy cycle. 1g of calcium and 1g of magnesium i.v. over 30 minutes just before the chemotherapy and repeated at the same dose after the completion of the oxaliplatine infusion.
~All patients will receive an oxaliplatin based chemotherapy with XELOX, FOLFOX-4 or mFOLFOX-6."
11538186|NCT01087658|Active Comparator|Calcium magnesium|"1g of calcium and 1g of magnesium i.v. over 30 minutes just before the chemotherapy and repeated at the same dose after the completion of the oxaliplatine infusion.
~All patients will receive an oxaliplatin based chemotherapy with XELOX, FOLFOX-4 or mFOLFOX-6."
11538187|NCT01087645|Experimental|Trial part 1|
11538188|NCT01087645|Experimental|Trial part 2|
11538189|NCT01087632|Experimental|Armolipid Plus|Armolipid Plus is an association of berberine 500 mg, red yeast rice titled in 3 mg monacolin K,- policosanol 10 mg,coenzyme Q10 2 mg,astaxanthin 0,5 mg,folic acid 0,2 mg
11538190|NCT01087632|Placebo Comparator|Placebo|Placebo matching Armolipid plus
11538191|NCT01087619|No Intervention|Follow-up|Patients diagnosed biochemically and clinically with primary hyperparathyroidism who are followed only
11538192|NCT01087619|Experimental|Surgery|Patients diagnosed biochemically and clinically with primary hyperparathyroidism who are treated with parathyroid surgery
11538193|NCT01087593|Experimental|Treatment with transdermal 17β-estradiol|
11538194|NCT01087593|Placebo Comparator|Control|
11538195|NCT01087580|Experimental|Chemotherapy alone, no radiation therapy|"A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days
~B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel"
11538196|NCT01087580|Experimental|Chemotherapy with Radiation Therapy|"A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
~GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.
~GROUPS 2 Bone metastasis (bone scan index < 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.
~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week."
11538197|NCT01087567|Experimental|Intensive insulin regimen|A weight based, basal bolus will be given for 12 weeks.
11538198|NCT01087567|Active Comparator|Routine Care|Routine Care patients receive oral medications based upon the 2009 ADA treatment recommendations: Metformin, Glimepiride, Pioglitazone.
11538199|NCT01087554|Experimental|Arm A: Vorinostat + Sirolimus|"Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.
~Expansion Phase starting dose: MTD from Escalation Phase.
~Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.
~Expansion Phase starting dose: MTD from Escalation Phase."
11538200|NCT01087554|Experimental|Arm B: Vorinostat + Everolimus|"Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.
~Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.
~Expansion Phase: MTD from Escalation Phase."
11538201|NCT01087554|Experimental|Arm C: Vorinostat + Temsirolimus|"Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.
~Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.
~Expansion Phase: MTD from Escalation Phase."
11538202|NCT01087541|No Intervention|Control|Usual clinical health care
11538203|NCT01087541|Experimental|Intervention|Behavioural program of education for health professionals. Standardized program of 6 hours for health professionals ( doctors and nurses )
11538204|NCT01087528|Experimental|1|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
11538205|NCT01087515|Other|Blood donation|
11538206|NCT01087502|Experimental|Linagliptin|52 weeks treatment
11538207|NCT01087502|Placebo Comparator|Placebo|First 12 weeks of treatment
11538208|NCT01087502|Active Comparator|Glimepiride|Placebo patients switch to glimepiride after 12 weeks (40 weeks treatment)
11538209|NCT01087489|Experimental|4% lidocaine|Eyes were anesthetized with 0.5% proparacaine and then with three cotton swabs soaked in 4% liquid lidocaine applied with moderate pressure to the site of the injection inferotemporally to the limbus. Each participant was assigned to have this prep during one of the consecutive study visits if unilateral or in one eye if patient requires bilateral injections given the same day
11538210|NCT01087489|Experimental|3.5% ophthalmic lidocaine gel|Eye was anesthetized with 0.5% proparacaine and then with 3.5% ophthalmic lidocaine gel applied to the surface of the eye. Each participant was randomly assigned to receive this preparation during one of two consecutive intravitreal injection (if unilateral disease) or in one eye if requiring bilateral injections given on the same day.
11538211|NCT01087476|Experimental|doxycycline hyclate|Patients will be randomly assigned to receive either a sub-microbial dose of doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
11538212|NCT01087463|Experimental|single arm|In this single arm study, the Quantum nailing system will be used in all patients.
11538213|NCT01087450||Stage1|1. Prospective dose response group. 3 subjects per dose at 200U/kg, 400U/kg and 600U/kg rHuEPO
11538214|NCT01087450||Stage 2 Randomized, blinded trial|Control group: Randomized to placebo treatment Treatment Group: Randomized to rHuEPO treatment
11538215|NCT01087437|Experimental|gastrolith calcium treatment|
11538216|NCT01087424|Experimental|R mini CHOP|Induction : 3 cycles every 3 weeks Consolidation :3 cycles every 3 weeks
11538217|NCT01087411|Experimental|Motivational Interviewing and omega 3|This arm is the group that receives the intervention program and eats fish liver oil capsules. Represents 25 % of all participants.
11538218|NCT01087411|Experimental|Motivational intervewing and placebo|This arm is the group that receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.
11538219|NCT01087411|Experimental|Controll and omega 3|This arm is the group that does not receives the intervention program and eats fish liver oil capsules. Represents 25 % of all participants.
11538220|NCT01087411|Placebo Comparator|Controll and placebo|This arm is the group that does not receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.
11538221|NCT01087398|Experimental|Intervention|
11538222|NCT01087385||Troponin T elevation|
11538223|NCT01087385||No troponin T elevation|
11538224|NCT01087359|Active Comparator|LPS + melatonin night|
11538225|NCT01087359|Placebo Comparator|LPS + placebo night|
11538226|NCT01087359|Active Comparator|LPS + melatonin day|
11538227|NCT01087359|Placebo Comparator|LPS + placebo day|
11538228|NCT01087359|Experimental|LPS night|
11538229|NCT01087359|Experimental|LPS day|
11538230|NCT01087346|Active Comparator|Control|Information about child health
11538231|NCT01087346|Experimental|Family Environment Information|Information about family environment factors in children's obesity risk
11538232|NCT01087346|Experimental|Gene times Family Environment Information|Information about interactions between genetic and family environment factors in children's obesity risk
11538234|NCT01087333||1|Patients with hematologic malignancy, including HCL, CLL, CTCL, ATL, NHL, ALL, or solid tumor, including mesothelioma.
11538235|NCT01087333||2|Healthy Volunteers
11538236|NCT01087320||Genetic Disorders|Patients or family probands with genetic cause of disorders that are intractable or difficult to identify with existing technique.
11538237|NCT01087307||1|Biologic and environmental samples anonymously obtained from adult volunteers for use in laboratory assay evaluation
11538238|NCT01087294|Experimental|1A/T cell arm (closed)|Dose escalation of CAR+ T cells based on the patients actual body weight
11538239|NCT01087294|Experimental|1B/T memory stem celll arm|Dose escalation with 6 dose levels of CAR+ T memory cells based on the patients actual body weight
11538240|NCT01087294|Other|2/Donor arm|Leukapheresis
11538241|NCT01087281||1|Neurologically normal healthy volunteers in good general health.
11538242|NCT01087281||2|Patients with unilateral or bilateral focal lesions of prefrontal, parietal, occipital or temporal cortex, or amygdala.
11538243|NCT01087255|No Intervention|Usual Care|Usual care patients will have outpatient care and monitoring procedures, as determined by them and their health care providers.
11538244|NCT01087255|Experimental|Electronic Pillbox Monitoring System|Usual care plus receive use of the wireless electronic pillbox and medication monitoring system
11538245|NCT01087242|Placebo Comparator|controlled group|Tang-min Lin analogue 6g,tid,po
11538246|NCT01087242|Experimental|Tang-min Lin pill|Tang-min Lin pills 6g,tid,po
11538247|NCT01087229|Experimental|equimolar oxygen-nitrous oxide mixture|"equimolar oxygen-nitrous oxide mixture
~Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture."
11538248|NCT01087229|Placebo Comparator|Placebo|Patients randomized to this arm will have the placebo.
11538249|NCT01087216|Active Comparator|Group Laser = Arm As A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
11538250|NCT01087216|Placebo Comparator|Bras B : the control group|patient to accept habitual treatment of corticoid
11538251|NCT01087203|Experimental|Tanezumab|
11538252|NCT01087203|Placebo Comparator|Placebo|
11538253|NCT01087190|Experimental|INH treatment group|"randomly allocated to INH treatment group in renal transplant recipients with ELISPOT (+)
~INH 300 mg po qd for 9 months"
11538254|NCT01087190|No Intervention|Control group|"randomly allocated to control group in renal transplant recipients with ELISPOT (+)
~no treatment"
11538255|NCT01087190|No Intervention|Observation group|"allocated to observation group in renal transplant recipients with ELISPOT (-)
~no treatment"
11538256|NCT01087177|Experimental|Exposure to Pedialink CEASE Trained Site|Parents at a practice where the clinicians were trained to address tobacco use through the Pedialink CEASE module.
11538257|NCT01087164|Experimental|Compliance|Parents will be randomized to receive high or no compliance condition where those in the experimental group will be asked about whether or not they will protect their daughter from cervical cancer or for males, their son from genital warts.
11538258|NCT01087164|Experimental|Message sidedness|Parents will be given either a one-sided verbal message or a two-sided verbal message about the HPV vaccine.
11538259|NCT01087151|Active Comparator|A|
11538260|NCT01087151|Experimental|B|
11538261|NCT01087151|Experimental|C|
11538262|NCT01087138|Experimental|Exercise|exercise class 3x's/week
11538263|NCT01087138|Experimental|exercise and calcium intake|exercise class 3x's/week and 1500mg calcium/day
11538264|NCT01087138|No Intervention|usual exercise and calcium|usual exercise and calcium intake
11538265|NCT01087125||Pregnant RA patients with abatacept exposure during pregnancy|
11538266|NCT01087112|Active Comparator|Child Health Centre care|TAU involved scheduled health visitor calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The health visitor is encouraged to promote attachment and to detect postnatal depressions. Mothers may be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Additional treatment was initiated in 1/3 of the cases. This was registered at the end-point interview.
11538267|NCT01087112|Experimental|Mother-Infant Psychoanalytic tmt|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. The analyst strives to recruit the baby for an emotional interchange, though this does not imply any belief that the infant understands verbal communication. The analyst addresses the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst takes great care in enrolling the participant mother. This is to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her all space needed to vent her own frustration, depression and anxiety.
11538268|NCT01087099|Experimental|Albendazole|Treatment with albendazole
11538269|NCT01087086|Experimental|Crononutrition|"Dietary pattern:
~Personalized diet
~Caloric restriction (-30% Total energy intake)
~High adherence to the Mediterranean Diet
~Macronutrient distribution (30% Protein, 40% Carbohydrates and 30% Fat)
~Low glycemic index/load
~Increased antioxidant capacity of the diet"
11538270|NCT01087086|Placebo Comparator|American Heart Association|"Dietary pattern:
~Personalized diet
~Caloric diet (-30% Total energy intake)
~Macronutrients distribution according to the American Heart Association (AHA) guidelines"
11538271|NCT01087073|Experimental|Patient Activation|Patient knowledge in diabetes self-management behaviors and clinical measures (HbA1c, LDL, HDL, BMI, BP) are tracked at baseline, 10-weeks (post-program), 3 months (post-program) and 6 months (post-program).
11538272|NCT01087073|Experimental|Provider Training Evaluation|Pre-post surveys are conducted at each training session to assess overall satisfaction with the curriculum, knowledge of SDM, and understanding of techniques to promote its use in the healthcare setting.
11538273|NCT01087073|Experimental|Quality Improvement Evaluation|We measure quality improvement efforts through biannual staff experience surveys and one-on-one provider and clinic staff interviews.
11538274|NCT01087073|Experimental|Community Outreach Evaluation|"Pre-post surveys will be disseminated at nutrition tours (Save-A-Lot, Walgreens, 61st Street Farmers Market) to assess change in knowledge of healthy eating behaviors and proper nutrition. Surveys will also assess participant satisfaction of the tours.
~Interviews will also be performed with community stakeholders to assess the costs/benefits of the collaboration and overall feedback on involvement."
11538275|NCT01087073|No Intervention|Global Evaluation of the Intervention|A chart review will be performed in order to evaluate our intervention to improve diabetes processes of care and clinical outcomes among our target population. Chart abstractions will be performed on medical records obtained from our six intervention clinics. In addition, chart abstractions from two University of Illinois at Chicago clinics and three FQHCs located on the West Side of Chicago will serve as control data.100 charts will be randomly selected from each clinic per year of the intervention. The chart review will contain charts from adult diabetes patients over a seven year period that matches the duration of the Improving Diabetes project.
11538276|NCT01087060||cysts surgically removed|
11538277|NCT01087060||cysts under surveillance|
11538278|NCT01087047||Physiological modifications|Pregnant women who attend the routine ultrasound control in our institution before 14 weeks of pregnancy
11538279|NCT01087047||MRI and acoustic|Women undergoing an MRI for obstetrical purpose
11538280|NCT01087034||Milwaukee brace|Children with an infantile scoliosis requiring Milwaukee bracing
11538281|NCT01087034||Cheneaux brace|Children with an infantile scoliosis requiring Cheaneaux bracing
11538282|NCT01087021|Experimental|cabazitaxel|"At every cycle (every 3 weeks), on Day 1, patients will receive cabazitaxel, administered by intravenous (IV) infusion over 1 hour, at 25 mg/m2.
~An IV premedication regimen composed of up to 4 treatments (antihistamine, corticosteroids, H2 antagonist other than cimetidine at all cycles, plus palonosetron at cycle 1) will be administered before cabazitaxel infusion."
11538283|NCT01087008|Experimental|Zoledronate acid|
11538284|NCT01087008|Other|No treatment control|
11538285|NCT01086982|Experimental|Octreotide acetate LAR 30 MG|Test
11538286|NCT01086982|Active Comparator|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|
11538287|NCT01086969|Experimental|Study Group|Participants in three age cohorts - Children: 2 - 11 years of age; Adolescents: 12 - 17 years of age, and Adults: 18 - 55 years of age will be enrolled.
11538288|NCT01086943|Experimental|device arm|
11538289|NCT01086930|Experimental|Intervention Group|"In addition to standard care participants in Group A will receive:
~• One hour of extra hand training five times per week for 8 weeks
~The training will be supervised by a therapist and provided to the target hand. It will consist of FES-assisted hand exercises on an instrumented exercise workstation (ReJoyce). The hand exercises will be incorporated into computer games and will involve the following tasks using different manipulanda:
~reaching
~grasping
~manipulating
~pulling
~rotating
~releasing"
11538290|NCT01086930|Other|Standard Care Group|Participants in the control group will not receive any training on the instrumented workstation or electrical stimulation to the hand or upper limb. They will however continue to receive standard care as well as three 15-minute specific hand activity sessions per week specifically devoted to the practice of hand activities in a one-to-one format with a therapist (as per the treatment received by the experimental group).
11538291|NCT01086917|Experimental|Group 1|to receive a dose of 2,500 PfSPZ Challenge
11538292|NCT01086917|Experimental|Group 2|to receive a dose of 10,000 PfSPZ Challenge
11538293|NCT01086917|Experimental|Group 3|to receive a dose of 25,000 PfSPZ Challenge
11538294|NCT01086891|Experimental|1|Patients with chronic obstructive pulmonary disease who show arterial oxygen desaturation to effort.
11538295|NCT01086891|Experimental|2|Patients with interstitial lung disease who show arterial oxygen desaturation to effort
11538296|NCT01086878|Experimental|Cotrimoxazole|
11538297|NCT01086865|Active Comparator|Petivit BC|
11538298|NCT01086865|Experimental|Apetiviton BC|
11538299|NCT01086852|Experimental|FACTOR X|Human Coagulation Factor X
11538300|NCT01086839|Experimental|sodium chloride 6%|"Cross-Over! experimental (days 1 - 28), then Wash-Out (28 days),then placebo comparator (days 57 - 85)."
11538301|NCT01086839|Placebo Comparator|sodium chloride 0,9%|"Cross-Over! placebo comparator (days 1 - 28), then Wash-Out (28 days),then experimental (days 57 - 85)."
11538302|NCT01086826|Active Comparator|RT+CDDP/5-FU|"RT:
~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)
~CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU 800 mg/m2/day for 4 will be administered as continuos iv infusion Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy."
11538303|NCT01086826|Experimental|RT+CETUXIMAB|"RT:
~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)
~CETUXIMAB:
~Cetuximab 400 mg/m2 as first dose, 7 days before the beginning of radiotherapy as 120 minutes IV infusion. Subsequent doses of 250 mg/ m2 will be administered as 60 minutes IV infusion, weekly, for 7 times."
11538304|NCT01086826|Active Comparator|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|"INDUCTION CTx(TPF):
~DOCETAXEL:
~75 mg/m², 1 hour IV infusion, Day and every 3 weeks
~CISPLATIN:
~80mg/m², intravenous infusion over 30-minute to 3 hours,Day 1 immediately after docetaxel administration and then every 3 weeks 5-FU 800 mg/m²/day, 24 hour continous infusion over 4 days, Day 1 after the end of cisplatin infusion, and every 3 weeks.
~RT:
~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)
~CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU 800 mg/m2/day for 4 will be administered as continuos iv infusion"
11538305|NCT01086826|Experimental|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|"DOCETAXEL:
~75 mg/m², 1 hour IV infusion, Day and every 3 weeks
~CISPLATIN:
~80mg/m², intravenous infusion over 30-minute to 3 hours,Day 1 immediately after docetaxel administration and then every 3 weeks 5-FU 800 mg/m²/day, 24 hour continous infusion over 4 days, Day 1 after the end of cisplatin infusion, and every 3 weeks.
~RADIOTHRAPY:
~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)
~CETUXIMAB:
~Cetuximab 400 mg/m2 as first dose, 7 days before the beginning of radiotherapy as 120 minutes IV infusion. Subsequent doses of 250 mg/ m2 will be administered as 60 minutes IV infusion, weekly, for 7 times."
11538306|NCT01086813|Experimental|1|
11538307|NCT01086800|Other|HLSE plus PAP|
11538308|NCT01086800|Other|HLSE plus Oxygen|
11538309|NCT01086800|Other|Healthy Lifestyles and Sleep Education|
11538310|NCT01086787||Non heart failure patients|Patients without heart failure undergoing open chest surgery
11538311|NCT01086787||Orthopedic patients|Patients without heart failure undergoing orthopedic surgery
11538312|NCT01086787||Heart failure patients|Patients with heart failure undergoing open chest surgery.
11538313|NCT01086774|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
11538314|NCT01086761|Experimental|MP0112 (0.04 mg)|Single 0.04 mg intravitreal injection of MP0112 in the study eye.
11538315|NCT01086761|Experimental|MP0112 (0.15 mg)|Single 0.15 mg intravitreal injection of MP0112 in the study eye.
11538316|NCT01086761|Experimental|MP0112 (0.4 mg)|Single 0.4 mg intravitreal injection of MP0112 in the study eye.
11538317|NCT01086761|Experimental|MP0112 (1.0 mg)|Single 1.0 mg intravitreal injection of MP0112 in the study eye.
11538318|NCT01086761|Experimental|MP0112 (2.0 mg)|Single 2.0 mg intravitreal injection of MP0112 in the study eye.
11538319|NCT01086761|Experimental|MP0112 (3.6 mg)|Single 3.6 mg intravitreal injection of MP0112 in the study eye.
11538320|NCT01086748|Experimental|160 mg LY2140023|80 mg LY2140023 administered orally, twice daily (BID) for up to 7 weeks.
11538321|NCT01086748|Active Comparator|4 mg Risperidone|2 mg risperidone administered orally, BID for up to 7 weeks.
11538322|NCT01086748|Placebo Comparator|Placebo|Placebo administered orally, BID for up to 7 weeks.
11538323|NCT01086748|Experimental|80 mg LY2140023|40 mg LY2140023 administered orally, BID for up to 7 weeks.
11538324|NCT01086735|Experimental|donor lymphocyte infusion|Donor T-cell transduction
11538325|NCT01086722|Experimental|"karolinska cocktail"|The karolinska cocktail contains dextromethorphan, caffeine, losartan and omeprazol
11538326|NCT01086696|Experimental|1|subjects with tumor types typically treatedwith taxanes
11538327|NCT01086696|Experimental|2|subjects with tumor types typically treatedwith taxanes
11538328|NCT01086683|Experimental|Intervention group|
11538329|NCT01086683|No Intervention|Control group|Wait list control group: The control group received usual care including clinical control visits but no systematic rehabilitation activities.
11538330|NCT01086670|Other|1|Subjects will be randomly assigned to use one of two novel lower extremity exercise devices: a motor-assisted cycle or an elliptical trainer.
11538331|NCT01086657|Experimental|Group 1|Inactivated H5N1 Vaccine at Enrollment and inactivated H5N1 Vaccine at Week 24
11538332|NCT01086657|Experimental|Group 2|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 4
11538333|NCT01086657|Experimental|Group 3|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 8
11538334|NCT01086657|Experimental|Group 4|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 12
11538335|NCT01086657|Experimental|Group 5|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 16
11538336|NCT01086657|Experimental|Group 6|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 24
11538337|NCT01086605|Experimental|Arm I|Patients receive pixantrone dimaleate IV over 1 hour on day 1. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11538338|NCT01086605|Experimental|Arm II|Patients receive pixantrone dimaleate IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11538339|NCT01086592|Active Comparator|Control|
11538340|NCT01086592|Experimental|Strengthening exercise|Strong progressive strengthening exercises of lower limbs.
11538341|NCT01086592|Experimental|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
11538342|NCT01086592|Experimental|Electrotherapy+weights|
11538343|NCT01086579|Experimental|Treatment Arm (IN.PACT Falcon Drug Eluting Balloon)|IN.PACT Falcon™ paclitaxel drug-eluting balloon (DEB) dilatation and provisional spot bare metal stenting (Bare Metal Stent).
11538344|NCT01086579|Active Comparator|Control Arm PES|Control Arm: paclitaxel-eluting stent (PES) implantation as per standard practice.
11538345|NCT01086566|Experimental|Multiple Boost Group-15 mcg|25 healthy adults who have previously received both Clade 1 and Clade 3 vaccines as a participant in study DMID 05-0043 will receive a single dose of 15 mcg of A/Indonesia/5/05.
11538346|NCT01086566|Experimental|Primed Group-15 mcg|30 healthy adults who have previously received H5N1 vaccine at any dose will receive a single dose of 15 mcg of A/Indonesia/5/05.
11538347|NCT01086566|Experimental|Unprimed Group-90 mcg|15 healthy adults with no previous receipt of H5N1 vaccine at any dose will receive 2 doses of 90 mcg of A/Indonesia/5/05 vaccine separated by 28 days.
11538348|NCT01086566|Experimental|Unprimed Group-15 mcg|15 healthy adults with no previous receipt of H5N1 vaccine at any dose will receive 2 doses of 15 mcg of A/Indonesia/5/05 vaccine separated by 28 days.
11538349|NCT01086566|Experimental|Primed Group-90 mcg|30 healthy adults who have previously received H5N1 vaccine at any dose will receive a single dose of 90 mcg of A/Indonesia/5/05.
11538350|NCT01086553|Experimental|A|9mg budesonide OD
11538351|NCT01086553|Active Comparator|B|3mg budesonide TID
11538352|NCT01086540|Experimental|Rituximab+PAH SOC|"Rituximab (1000 mg) will be administered as 2 intravenous infusions given 2 weeks apart.
~Concurrent stable-dose Pulmonary Arterial Hypertension (PAH) medical therapy will be continued/managed as per standard of care (PAH SOC)."
11538353|NCT01086540|Placebo Comparator|Placebo + PAH SOC|"Placebo will be administered as 2 intravenous infusions given 2 weeks apart.
~Concurrent stable-dose Pulmonary Arterial Hypertension (PAH) medical therapy will be continued/managed as per standard of care (PAH SOC)."
11538354|NCT01086527|Experimental|SLCO2B1{NM_007256.2}:c.[935G>A] + [=]|Individuals in this group will be homozygous for SLCO2B1{NM_007256.2}:c.[935G>A].
11538355|NCT01086514|Experimental|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|In this study we will perform Dual Energy Contrast Enhanced Digital Mammography (DE CEDM) on patients with newly diagnosed breast cancer using a dedicated research system, derived from a standard digital mammography unit and review workstation (Senographe DS and SenoAdvantage) modified to deliver the required dual energy paired exposures and visualization of combined images.
11538356|NCT01086488|Experimental|Nasopharyngeal Carcinoma|A: Experimental B: Active Comparator
11538357|NCT01086475|Experimental|D-cycloserine|Subjects randomized to D-cycloserine will be administered 50 mg 30 minutes prior to each of ten Social Skills Training Sessions
11538358|NCT01086475|Placebo Comparator|Placebo|Subjects randomized to placebo arm will receive placebo pill 30 minutes prior to each of ten Social Skills Training Sessions
11538359|NCT01086462|Experimental|GSK2239633|Single dose infusion of study drug over 15 minutes
11538360|NCT01086449|Experimental|Group A|
11538361|NCT01086436|Experimental|Rotavirus Group|Subjects will receive Rotarix™
11538362|NCT01086436|Placebo Comparator|Placebo Group|Subjects will receive placebo.
11538363|NCT01086423|Experimental|INFANRIX-IPV+HIB 1 GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.
11538364|NCT01086423|Experimental|INFANRIX-IPV+HIB 2 GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.
11538365|NCT01086423|Active Comparator|INFANRIX-HIB+POLIORIX GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.
11538366|NCT01086410|Active Comparator|FF/444 Dose B|Fluticasone furoate/GW642444 Dose B inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
11538367|NCT01086410|Active Comparator|FF/444 Dose A|Fluticasone furoate/GW642444 Dose A inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
11538368|NCT01086410|Placebo Comparator|Placebo|Placebo inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
11538369|NCT01086410|Active Comparator|Prednisolone|Placebo inhalation powder once daily for 6 weeks' treatment + 1 oral prednisolone 10mg capsule each day on the last 7 days of the study
11538370|NCT01086397||1|
11538371|NCT01086384|Experimental|Fluticasone furoate/GW642444|
11538372|NCT01086384|Experimental|fluticasone furoate|
11538373|NCT01086371|Experimental|RAS walking|Subjects will walk while listening to music 20 minutes per day every day during the study period.
11538374|NCT01086371|Active Comparator|RAS no walking|Subjects will be listening to music but not performing walking exercise, for 20 minutes per day every day during the study period.
11538375|NCT01086371|Active Comparator|Walking no RAS|Subjects will be walking without listening to music for 20 minutes per day every day during the study period
11538376|NCT01086358|Active Comparator|Triptan|Arm 1 subjects began with their prescribed triptan
11538377|NCT01086358|Active Comparator|Treximet 85Mg-500Mg Tablet|Arm 2 subjects began with Treximet (sumatriptan 85 mg/naproxen sodium 500 mg)
11538378|NCT01086345|Experimental|Arm I|Patients receive bevacizumab IV over 30 minutes on days 1 and 15. Patients also receive irinotecan hydrochloride IV on days 1 and 15 beginning in course 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
11538379|NCT01086332|Experimental|phase 1/2|An escalating study of gemcitabine when combined with 1250 mg of nelfinavir twice daily. Dose of gemcitabine is increased for new subjects based on the experiences and tolerance of prior subjects. When the maximum tolerated dose is identified, a recommended phase 2 dose will be assigned and further subjects will receive that dose.
11538380|NCT01086319||Patients exposed to saxagliptin|
11538381|NCT01086319||Patients exposed to oral antidiabetic drugs (not saxagliptin)|
11538382|NCT01086306||Patients exposed to Saxagliptin|
11538383|NCT01086306||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
11538384|NCT01086293||Patients exposed to Saxagliptin|
11538385|NCT01086293||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
11538386|NCT01086280||Patients exposed to Saxagliptin|
11538387|NCT01086280||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
11538388|NCT01086267|Experimental|BMS-908662 (A1)|Phase 1
11538389|NCT01086267|Experimental|Cetuximab (A1)|Phase 1
11538390|NCT01086267|Experimental|BMS-908662 (B1)|Phase 2
11538391|NCT01086267|Experimental|BMS-908662 + Cetuximab (B2)|Phase 2
11538392|NCT01086254|Experimental|Iniparib/ Gemcitabine/ Cisplatin|"Iniparib, 5.6 mg/kg, 60-min IV infusion twice weekly (days 1, 4, 8, and 11). Infusion starts after completion of GC regimen administration.
~Gemcitabine, 1250 mg/m2, 30-min IV infusion on day 1 and day 8 and cisplatin 75mg/m², 3- to 4-hour IV infusion on day 1 of each 3-week cycle after the end of gemcitabine infusion."
11538393|NCT01086254|Active Comparator|Gemcitabine/ Cisplatin|Gemcitabine, 1250 mg/m2, 30-min IV infusion on day 1 and day 8 and cisplatin 75mg/m², 3- to 4-hour IV infusion on day 1 of each 3-week cycle after the end of gemcitabine infusion.
11538394|NCT01086241|Active Comparator|A: routine 2D mammogram|Subject receives regular 2D mammogram.
11538395|NCT01086241|Active Comparator|B: Routine Mammogram + tomosynthesis|Routine Mammogram and tomosynthesis
11538396|NCT01086228||XIENCE V / PROMUS stent|Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
11538397|NCT01086215||Limb Ischemia|Patients presenting with limb ischemia for treatment
11538398|NCT01086215||Deep Vein Thrombosis|Patients presenting with deep vein thrombosis for treatment
11538399|NCT01086215||Hemodialysis Access|Patients presenting with thrombosed hemodialysis access for treatment
11538400|NCT01086215||Other Thrombotic Conditions|Patients presenting with a thrombotic condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment
11538401|NCT01086202||Tornier Reversed Shoulder Arthroplasty Medial Offset|
11538402|NCT01086202||Lateral offset arthroplasty|
11538403|NCT01086176||Patient-control|
11538404|NCT01086163||Omacor dose titration|"Stable documented coronary artery disease proven by angiography treated with statin and aspirin. In order to achieve homogeneity within this population, the following additional inclusion criteria will apply:
~survived first-time AMI more than 12 months ago
~stable medical treatment during the last 3 months (except removal of Plavix)
~Ethnicity: Caucasians
~Males, 50 - 60 yrs
~non-diabetics
~excluded are those who eat more than one meal of fish / week
~excluded are those who take omega-3 supplements of any sorts"
11538405|NCT01086150|Other|Healthy control patients|Subjects 18 to 70 years of age, non-diabetic with no nervous system disease. Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
11538451|NCT01085851|Active Comparator|Dexchlorpheniramine 1% cream|
11538406|NCT01086150|Other|Type I or Type II diabetes with painful diabetic neuropathy|18 to 70 years old with significantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
11538407|NCT01086150|Other|patients with non-painful diabetic peripheral neuropathy|18-70 years of age with Type I or Type II diabetes with non-painful or insignificantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at baseline, 4 weeks, and end of study.
11538408|NCT01086124||Echocardiography 1 month|Patients will all have an echocardiography 1 month post myocardial infarction and 3 months post myocardial infarction
11538409|NCT01086111||PMSF|type 2 diabetes patient receiving a protein sparing diet
11538410|NCT01086111||sleeve gastrectomy|type 2 diabetes patient receiving a gastric bypass
11538411|NCT01086111||RYGBP|type 2 diabetes patient receiving a gastric bypass
11538412|NCT01086098||All paced patients|
11538413|NCT01086085|Experimental|A|
11538414|NCT01086085|Experimental|B|
11538415|NCT01086085|Experimental|C|
11538416|NCT01086085|Experimental|D|
11538417|NCT01086072||Myocardial Infarction - STEMI|
11538418|NCT01086072||Myocardial Infarction - NSTEMI|
11538419|NCT01086059||Cohort 1 - Exposure cohort|Pregnant women with a current diagnosis of RA, JRA, or Crohn's disease who have used adalimumab in the first trimester of pregnancy for any length of time from the date of conception.
11538420|NCT01086059||Cohort 2 - Matched Diseased Comparison Cohort|Pregnant women with a current diagnosis of RA, JRA, or Crohn's disease who have not used adalimumab or any TNF antagonist in pregnancy.
11538421|NCT01086059||Cohort 3-Non-Diseased Comparison Cohort|Pregnant women without a current diagnosis of an autoimmune disease and who have not used adalimumab or any TNF antagonist at any time in pregnancy nor have they been exposed to any known human teratogen during pregnancy.
11538422|NCT01086059||Cohort 4 - Registry Group|Pregnant women who have used adalimumab for any length of time following the first day of the last menstrual period until the end of pregnancy who do not meet Cohort 1 inclusionary criteria.
11538423|NCT01086046|Active Comparator|Heparin|Heparin injection 10 IU/kg/hr within 24h
11538424|NCT01086046|Experimental|Low molecular weight heparin|"Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour
~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days"
11538425|NCT01086033||Humira|Participants with rheumatoid arthritis treated with Humira (adalimumab) as prescribed by the rheumatologist in the setting of routine clinical care.
11538426|NCT01086020|Active Comparator|atorvastatin|patients will be treated with atorvastatin 10mg/d after randomization, and continued for two years
11538427|NCT01086020|Experimental|atorvastatin and ezetimibe|patients will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d after randomization, and continued for two years
11538428|NCT01086007||Pain patients|Patients with pain related sexual dysfunction after laparoscopic inguinal hernia repair
11538429|NCT01086007||Non-pain patients|Patients with no pain related sexual dysfunction after laparoscopic inguinal hernia repair
11538430|NCT01085994||Procalcitonin-guided group|
11538431|NCT01085994||Routine practice group|
11538432|NCT01085981|Active Comparator|GRAS ingredients cream|"The study will be placebo controlled double blind study which will require two office visits after informed consent and sensitivity testing done with the study cream on the day of recruitment.
~On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit Then placebo or active cream will be applied and the pt restudied. the same process is repeated another day with the second arm cream."
11538433|NCT01085981|Placebo Comparator|placebo cream then doppler study|
11538434|NCT01085968|Experimental|PD Subjects|PD subjects who undergo to PC-based neurorehabilitation intervention. This intervention will train research subjects to improve movement initiation in response to visual stimuli.
11538435|NCT01085968|Active Comparator|Control Subjects|Age matched controls who undergo to PC-based neurorehabilitation intervention. This intervention will train research subjects to improve movement initiation in response to visual stimuli.
11538436|NCT01085955||Acute Peripartum|pregnant women who have recently given birth and diagnosed with peripartum cardiomyopathy
11538437|NCT01085955||Healthy Peripartum|Healthy pregnant women who have recently given birth, used as controls
11538438|NCT01085955||Healthy, non-pregnant women|Healthy non-pregnant women without cardiac disease, used as controls
11538439|NCT01085955||New Non-ischemic CMP|Women 18-60 years old who have been diagnosed with non-ishemic cardiomyopathy within the last 6 months and have an ejection fraction less than OR equal to 45% by echocardiogram.
11538440|NCT01085942||Asymptomatic rotator cuff tear|Subjects identified with an asymptomatic rotator cuff tear
11538441|NCT01085929|Active Comparator|Incision and Drainage|Abscess underwent incision and drainage
11538442|NCT01085929|Active Comparator|Ultrasound guided needle aspiration|Ultrasound was used to identify the abscess location. A needle was introduced into the abscess cavity and aspiration of the contents were attempted.
11538443|NCT01085903|Active Comparator|normal subjects|Normal subjects are persons without stroke who receive baseline, CPS, Post CPS and Follow up interventions.
11538444|NCT01085903|Active Comparator|stroke subjects|Stroke subjects are persons who have had a stroke affecting the right hemisphere and are subject to neglect or dysphagia who receive modafinil, placebo, baseline, CPS, Post CPS and Follow up interventions.
11538445|NCT01085890|Experimental|Motivational interviewing group|The participants in this arm had 2 group seminars with information on hypertension and related lifestyle factors. They participated in 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
11538446|NCT01085890|No Intervention|Treatment as usual|Participants in this group received treatment as usual for their high blood pressure, but no informational seminars and no extra visits with motivational interviewing and blood pressure measurement.
11538447|NCT01085877|Active Comparator|Trial part 1|
11538448|NCT01085877|Experimental|Trial part 2|
11538449|NCT01085864||Patients with lung nodules on CT scan.|Patients with lung nodules on CT scan.
11538450|NCT01085851|Experimental|Dexchlorpheniramine 1% lotion|
11538452|NCT01085838|Experimental|Cohort 1|The first cohort of 5 patients will start with a dosage of 100 mg erlotinib daily
11538453|NCT01085838|Experimental|Cohort 2|The second cohort of patients will receive 150 mg of erlotinib daily
11538454|NCT01085838|Experimental|Cohort 3|The third cohort of five patients will be enrolled to receive 300 mg of erlotinib daily
11538455|NCT01085825|Active Comparator|Manual Vacuum Aspiration|
11538456|NCT01085825|Active Comparator|Electric Vacuum Aspiration|
11538457|NCT01085812|Experimental|2|40, 80 or 120 mg/day Levomilnacipran ER capsules, oral administration, once daily dosing.
11538458|NCT01085812|Placebo Comparator|1|Matching placebo capsules, oral administration, once daily dosing.
11538459|NCT01085799|Experimental|Health Education Intervention|Groups of schools receiving the health education intervention
11538460|NCT01085799|No Intervention|Control Schools - Regular curriculum|Groups of schools not receiving the health education intervention
11538461|NCT01085786|Active Comparator|14-day sequential treatment|One in which the first component consists of a proton pump inhibitor and amoxicillin given for 7 days followed by the PPI, clarithromycin and metronidazole for 7 days.
11538462|NCT01085786|Experimental|14-day hybrid treatment|esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
11538463|NCT01085773|No Intervention|Standard written information on exercise|The Control group got the diabetes outpatients clinics standard written information on exercise as a part of the treatment for Type 2 Diabetes and were, like other Type 2 Diabetes patients in the clinic, advised at inclusion to be physically active.
11538464|NCT01085773|Experimental|Exercise on Prescription|In Denmark, Exercise on Prescription have focused on individual behavioral change and an exercise program for 16 weeks. The physical training consisted of both aerobic and strength training and took place in supervised groups
11538465|NCT01085773|Experimental|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
11538466|NCT01085760|Experimental|Vancomycin 125 mg orally 4 times a day|The patients will be randomized into four groups of ten patients: one group will receive low dose vancomycin, one group will receive high dose vancomycin, one group will receive low dose metronidazole and one group will receive high dose metronidazole.
11538467|NCT01085760|Experimental|Vancomycin 250 mg orally 4 times a day|
11538468|NCT01085760|Experimental|Metronidazole 250 mg orally 3 times a day|
11538469|NCT01085760|Experimental|Metronidazole 500 mg orally 3 times a day|
11538470|NCT01085747||Plastic stent|
11538471|NCT01085747||Covered SEMS|
11538472|NCT01085734|Active Comparator|Group 1|Group 1 receives Avastin at baseline followed by sham Osurdex at week 1. Additional Avastin based on macular edema
11538473|NCT01085734|Active Comparator|Group 2|Group 2 receives Avastin at baseline followed by Osurdex at week 1. Retreatment with Avastin based on macular edema
11538474|NCT01085721|Experimental|Dexchlorpheniramine pseudoephedrine guaifenesin|
11538475|NCT01085721|Active Comparator|Dexchlorpheniramine|
11538476|NCT01085708|Experimental|1|
11538477|NCT01085708|Experimental|2|
11538478|NCT01085708|Experimental|3|
11538479|NCT01085708|Active Comparator|4|
11538480|NCT01085695|Experimental|1|
11538481|NCT01085695|Experimental|2|
11538482|NCT01085695|Experimental|3|
11538483|NCT01085695|Active Comparator|4|
11538484|NCT01085682|Active Comparator|Lifestyle counseling|
11538485|NCT01085682|Active Comparator|Standard care|
11538486|NCT01085669||VEPTR patients|Children treated with VEPTR Implants for severe spinal or thoracic deformities
11538487|NCT01085656|Experimental|OXi4503|Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.
11538488|NCT01085643|Active Comparator|Lubiprostone|Same patients are included in both the Lubiprostone arm and the Placebo arm. The reason why the same patients are assigned to two arms is because an effect comparison is done after taking the placebo and later after taking the lubiprostone.
11538489|NCT01085643|Placebo Comparator|Placebo|Same patients are included in both the Lubiprostone arm and the Placebo arm. The reason why the same patients are assigned to two arms is because an effect comparison is done after taking the placebo and later after taking the lubiprostone.
11538490|NCT01085630|Experimental|Arm I|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11538491|NCT01085630|Active Comparator|Arm II|Patients undergo observation until disease progression.
11538492|NCT01085617|Active Comparator|B1 - Standard therapy|Standard chemotherapy for precursor B-cell ALL
11538493|NCT01085617|Experimental|B2 - Rituximab|Standard chemotherapy for precursor B-cell ALL plus weekly rituximab infusions during phase 1 induction
11538494|NCT01085617|Active Comparator|T1 - Standard therapy|Standard chemotherapy for T-cell ALL
11538495|NCT01085617|Experimental|T2 - Nelarabine|Standard chemotherapy for T-cell ALL plus an additional course of treatment with nelarabine following phase 2 induction
11538496|NCT01085617|Active Comparator|P1 - standard palifermin|6 doses of palifermin before/after myeloablative stem cell transplant (randomisation closed due to lack of clinical relevance in 2016)
11538497|NCT01085617|Experimental|P2 - collapsed palifermin|1 x large dose of palifermin before myeloablative stem cell transplant and 3 low doses after transplant (randomisation closed due to lack of clinical relevance in 2016)
11538498|NCT01085604||Low back pain|Individuals with current low back pain attributed to poor trunk neuromuscular control (clinical instability).
11538499|NCT01085591|Experimental|CB-183,315, 125 mg|125 milligrams (mg) CB 183,315 administered orally twice daily, alternating with twice daily oral administration of placebo tablets, for 10 days.
11538500|NCT01085591|Experimental|CB-183,315, 250 mg|250 mg CB 183,315 administered orally twice daily, alternating with twice daily oral administration of placebo tablets, for 10 days.
11538501|NCT01085591|Active Comparator|Vancomycin, 125 mg|125 mg vancomycin administered orally four times a day for 10 days.
11538502|NCT01085578|Placebo Comparator|Cohort1|CG400549/placebo
11538505|NCT01085565|Experimental|Exablate treatment|
11538506|NCT01085552|Other|1|Group A consists of 11 Caucasian male subjects Group B consists of 12 Japanese male subjects
11538507|NCT01085526|Active Comparator|alutard phl prat. treatment group|18 subjects receiving active treatment: basophil activity, plasma cells and immunoglobulins measured
11538508|NCT01085526|No Intervention|control group|control
11538509|NCT01085526|Active Comparator|alutard phl.prat., treatment group2|basophil activity, basophil biology measured
11538510|NCT01085513|Active Comparator|Patients|Patients previously indicated for manometry
11538511|NCT01085513|Active Comparator|Healthy volunteers|Healthy volunteers
11538512|NCT01085500|Experimental|Simulation Curriculum|General surgery residents will undergo a simulation-based educational curriculum (Mastery Learning TEP Curriculum) on TEP hernia repair
11538513|NCT01085500|Other|Current Practice|General surgery residents will undergo current practice of learning how to perform the TEP repair in the operating room under direct supervision of the staff surgeon without any simulation pre-training.
11538514|NCT01085487||Group 1|
11538515|NCT01085487||Group 2|
11538516|NCT01085487||Group 3|
11538517|NCT01085474||1|1. Pilot Study: 60 patients (all in the intervention group) 30 patients with intervention A and 30 patients with B intervention)
11538518|NCT01085474||2|Main Study: 600 patients (30 pharmacies control group and 30 pharmacies intervention group, 10 patients per pharmacy)
11538519|NCT01085448|Other|Low back pain|Individuals with current low back pain.
11538520|NCT01085435||S-ICD System Commercial Patients|Patients implanted with a CE marked S-ICD System, not participating in Cameron Health's Investigational Device Exemption (IDE) Clinical Study.
11538521|NCT01085422|Experimental|Arm A|
11538522|NCT01085409||Tinnitus|Patients with tinnitus
11538523|NCT01085409||Artery disease|Subjects with mobility constraints as a results of severe artery disease which in some cases led to leg amputation.
11538524|NCT01085409||Anxiety|Subjects with anxiety complaints
11538525|NCT01085409||Controls|Healthy controls
11538526|NCT01085370|No Intervention|Control Group|standard medical care only
11538527|NCT01085370|Experimental|Intervention group|2 sessions with early psychological interventions
11538528|NCT01085357|Experimental|CyPass Micro-Stent + Cataract Surgery|Subjects receive the CyPass Micro-Stent at the conclusion of their cataract surgery
11538529|NCT01085357|Active Comparator|Cataract Surgery Only|Subjects do not receive the CyPass Micro-Stent at the conclusion of their cataract surgery
11538530|NCT01085344|Experimental|Factor VIII|escalating dose Factor VIII
11538531|NCT01085331|Experimental|Part 1 or Safety Run-in Part: Pimasertib+FOLFIRI|
11538532|NCT01085331|Experimental|Part 2 or Phase 2 Randomized part: Pimasertib+FOLFIRI|Planned, not performed
11538533|NCT01085331|Experimental|Part 2 or Phase 2 Randomized part: Placebo+FOLFIRI|Planned, not performed
11538534|NCT01085318|Active Comparator|Arm 1 MS Patients|Rebif 44 tiw
11538535|NCT01085318|No Intervention|Arm 2 Healthy Control|
11538536|NCT01085305|Experimental|PCIT|Provision of Parent-Child Interaction Therapy
11538537|NCT01085305|Active Comparator|TAU|Treatment as usual from other therapists in the same clinics
11538538|NCT01085292|Experimental|Group A|
11538539|NCT01085292|Experimental|Group B - D|
11538540|NCT01085279|Experimental|Non-ablative fractional laser|"In each patient, one side of the face was treated with non-ablative fractional laser in four-five sessions.
~Note: this study had a split-face design. In each patient, each side of the face was randomized to receive either non-ablative fractional laser therapy or triple topical therapy."
11538541|NCT01085279|Active Comparator|Triple topical therapy|"In each patient, one side of the face was treated with triple topical therapy (Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1%) during 15 weeks.
~Note: this study had a split-face design. In each patient, each side of the face was randomized to receive either non-ablative fractional laser therapy or triple topical therapy."
11538542|NCT01085266|Experimental|Dimebon (latrepirdine)|Patients receive dimebon 10mg orally 3 times per day for 1 week and 20 mg orally 3 times per day thereafter.
11538543|NCT01085253||Parkinson|"without gait impairment
~with gait and/or balance impairment
~with sleep disorders (RBD)
~abnormalities of the brainstem and basal ganglia will be studied in relation with parkinsonism, gait and presence of RBD"
11538544|NCT01085253||PSP|supranuclear palsy patients study the abnormalities with the brainstem and basal ganglia and relation with the observed neurological signs (eye movements, balance, neuropsychological assessment and parkinsonism)
11538545|NCT01085253||controls|age matched controls
11538546|NCT01085240|Other|Start Later|The participants receive the Mission Possible intervention but it is delayed by 3 months.
11538547|NCT01085240|Experimental|Start Now|The participants start the Mission Possible program right away.
11538548|NCT01085227||Patients carrier of a LRRK2 mutation|
11538549|NCT01085227||Asymptomatic relatives of LRRK2 patients|
11538550|NCT01085214|Experimental|AZD6244 (Selumetinib) Treatment|Participants receive AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11538551|NCT01085201|Experimental|Stage 1|12-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
11538552|NCT01085201|Experimental|Stage 2|24-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
11538553|NCT01085201|Experimental|Stage 3|24-hour infusion to adults with SCD who are having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
11538554|NCT01085201|Experimental|Stage 4|24-hour infusion to children with SCD who are having a pain crisis. THIS STAGE IS COMPLETE AFTER STUDYING 3 PATIENTS BY AGREEMENT FROM THE FDA, IRB, AND DSMB. THIS STAGE IS CLOSED TO ACCRUAL.
11538555|NCT01085201|Experimental|Stage 2B|48-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AFTER STUDYING 3 PATIENTS BY AGREEMENT FROM THE FDA, IRB, AND DSMB. THIS STAGE IS CLOSED TO ACCRUAL.
11538556|NCT01085188|Experimental|Assertive Continuing Care (ACC)|Behavioral intervention comprised of the community reinforcement approach plus case management delivered in home and other community settings to youth and their caregivers.
11538557|NCT01085188|Experimental|Contingency Management (CM)|Using a prize drawing system (no, low, medium and large value prizes) with adolescents could earn escalating prize drawing opportunities by completing verifiable pro-social activities and providing negative urine test and breath alcohol test results.
11538558|NCT01085188|Experimental|ACC + CM|This arm is the combination of arms 1 and 2.
11538559|NCT01085188|Active Comparator|Usual Continuing Care (UCC)|UCC consists of a discharge recommendation to seek aftercare services at nearest treatment provider to where the patient lived. This service primarily consisted of outpatient group counseling.
11538560|NCT01085175|Experimental|Cohort 1|Low risk Heart Failure patients
11538561|NCT01085175|Experimental|Cohort 2|High risk Heart Failure patients with history of Implantable Cardioverter-Defibrillator firing
11538562|NCT01085149|Experimental|study group|simvastatin will be inserted to sockets
11538563|NCT01085149|No Intervention|control|sockets will be left to healing without material in socket
11538564|NCT01085136|Active Comparator|Investigator's choice of chemotherapy|Patients will be treated with investigator's choice of chemotherapy
11538565|NCT01085136|Experimental|BIBW 2992 and Paclitaxel|Patients will be treated with BIBW 2992daily with a medium dose and weekly administration of Paclitaxel at a dose of 80 mg/m2
11538566|NCT01085123|Experimental|1|PET 1: baseline, PET 2: 10 mg Zomig® Rapimelt, PET 3: 5 mg ZOMIG® Rapimelt, PET 4 2.5 mg ZOMIG® Rapimelt
11538567|NCT01085110||Persistent Pain patients|Patients with persistent postherniotomy pain after laparoscopic operation and pain related impaired daily function
11538568|NCT01085097|Experimental|laquinimod 0.5 mg + prednisolone/prednisone|laquinimod 0.5 mg + Mycophenolate Mofetil (MMF) + prednisolone/prednisone
11538569|NCT01085097|Experimental|laquinimod 1 mg + prednisolone/prednisone|laquinimod 1 mg + Mycophenolate Mofetil (MMF) + prednisolone/prednisone
11538570|NCT01085097|Placebo Comparator|placebo + prednisolone/prednisone|Mycophenolate Mofetil (MMF) + prednisolone/prednisone+ placebo
11538571|NCT01085084|Experimental|Laquinimod 0.5 mg arm|laquinimod 0.5 mg + placebo
11538572|NCT01085084|Experimental|Laquinimod 1 mg|laquinimod 1 mg
11538573|NCT01085084|Placebo Comparator|Placebo|placebo
11538574|NCT01085071|Active Comparator|Normal-high potassium (NHP)|A potassium target of 4.5 mmol/L.
11538575|NCT01085071|Active Comparator|Normal-low potassium (NLP)|A potassium target of 4.0 mmol/L.
11538576|NCT01085058|Experimental|A: lenograstim|total group
11538577|NCT01085045|Experimental|Inhaled PT003 (Dose 1)|PT003 MDI Dose 1
11538578|NCT01085045|Experimental|Inhaled PT003 (Dose 2)|PT003 MDI Dose 2
11538579|NCT01085045|Experimental|Inhaled PT005 (Dose 1)|PT005 MDI Dose 1
11538580|NCT01085045|Experimental|Inhaled PT005 (Dose 2)|PT005 MDI Dose 2
11538581|NCT01085045|Placebo Comparator|Inhaled Placebo|Placebo MDI
11538582|NCT01085045|Active Comparator|Tiotropium bromide 18 μg (Spiriva Handihaler®)|Tiotropium Bromide inhalation powder
11538583|NCT01085045|Active Comparator|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 12 μg
11538584|NCT01085045|Experimental|Inhaled PT001 (Dose 1)|PT001 MDI Dose 1
11538585|NCT01085032|Experimental|Arm A|Behavioral Counseling and Nicotine Patch
11538586|NCT01085032|Placebo Comparator|Arm B|Behavioral counseling and placebo patch
11538587|NCT01085019|Experimental|Dietary supplement: Cinnamon|
11538588|NCT01085019|Experimental|Dietary supplement: Oregano|
11538589|NCT01085019|Experimental|Dietary supplement: Ginger|
11538590|NCT01085019|Experimental|Dietary supplement: Rosemary|
11538591|NCT01085019|Experimental|Dietary supplement: Black pepper|
11538592|NCT01085019|Placebo Comparator|Dietary supplement: Placebo|
11538593|NCT01085006|Experimental|Tranexamic acid|
11538594|NCT01085006|Placebo Comparator|normal saline infusion|
11538595|NCT01084993|Active Comparator|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
11538596|NCT01084993|Active Comparator|Heparin|70 U/kg or standard practice
11538597|NCT01084980|Experimental|Tacrolimus|
11538598|NCT01084967||Healthy lean control group|BMI:18.5-22.9kg/m2. Age:14-30 years old. To be proved normal by the examinations of liver and kidney function,blood lipids profile,fasting and postprandial plasma glucose, fasting insulin and HbA1c.
11538599|NCT01084967||obesity group with BMI ≥30|obesity group 1500, lean healthy control group 1500
11538600|NCT01084941|Experimental|Lifestyle intervention|Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
11538601|NCT01084941|Active Comparator|Standard of care group|Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
11538602|NCT01084928|Experimental|Intervention Arm (Diet and Exercise)|The lifestyle intervention will include a 16-week intervention period, followed by an 8 week, less intensive maintenance period.
11538603|NCT01084915||SAGB VC group|Retrospectively patients with a SAGB-VC gastric band are inventorized. They will also be interviewed and BAROS scores will be taken.
11538604|NCT01084902|Experimental|latnoprost|once daily
11538605|NCT01084902|Active Comparator|Brinzolamide|two times daily
11538606|NCT01084889||symptomatic genital descensus|"Women with a symptomatic genital descensus : at least stage II (ICS-classification according pelvic organ prolapse quanification (POP-Q) system), or stage I with a symptomatic requiring intervention.
~Standard method to implant the TiLOOP® Total 6 surgical mesh transvaginally."
11538607|NCT01084876|Active Comparator|CT-P6 & Paclitaxel|CT-P6 + Paclitaxel
11538608|NCT01084876|Active Comparator|Herceptin & Paclitaxel|Trastuzumab + Paclitaxel
11538609|NCT01084863|Active Comparator|CT-P6 & Paclitaxel|CT-P6 + Paclitaxel
11538610|NCT01084863|Active Comparator|Herceptin & Paclitaxel|Trastuzumab + Paclitaxel
11538611|NCT01084850||Diabetes Type II|Patients with type 2 Diabetes Mellitus
11538612|NCT01084850||Control|Patients with no diabetes
11538658|NCT01084512||Paraplegic group|Paraplegic subjects
11538613|NCT01084824|Active Comparator|Liquid nitrogen and canthardin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterwards.
11538614|NCT01084824|Placebo Comparator|Liquid nitrogen and placebo|Liquid nitrogen applied to wart(s) then placebo vehicle afterwards.
11538615|NCT01084811||chronic rhinosinusitis with nasal polyps|
11538616|NCT01084811||chronic rhinosinusitis without nasal polyps|
11538617|NCT01084811||Control group|
11538618|NCT01084772|Other|VISIONAIRE Instrumentation|TKA with VISIONAIRE instrumentation
11538619|NCT01084772|Other|Standard Instrumentation|TKA with standard instrumentation
11538620|NCT01084759|Experimental|Etoposide and Testosterone|Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy).On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days.
11538621|NCT01084746|Active Comparator|PC-based tailored intervention|
11538622|NCT01084746|Active Comparator|Printed educational materials|
11538623|NCT01084746|No Intervention|No patient intervention|Patients will not receive a patient-directed intervention.
11538624|NCT01084707|Experimental|Oral Nicotine 24-SA|2 Self-administrations of Experimental Nicotine once every hour
11538625|NCT01084707|Experimental|Oral Nicotine 24|2 administrations of Experimental Nicotine by study personnel once every hour
11538626|NCT01084707|Experimental|Oral Nicotine 48|2 administrations of Experimental Nicotine by study personnel once every 30 minutes
11538627|NCT01084707|Active Comparator|NiQuitin™ Lozenge 4 mg|1 NiQuitin™ lozenge, administered by study personnel once every hour
11538628|NCT01084707|Active Comparator|Nicorette® Gum 4 mg|1 piece Nicorette® gum, chewed for 30 minutes once every hour
11538629|NCT01084681|Active Comparator|SILK Artery Reconstruction Device|One arm will receive only the commercially available SILK Artery Reconstruction Device [flow diverter] (no intracranial coils are to be used in association with the SILK device).
11538630|NCT01084681|Active Comparator|Coils|The other arm will be treated with commercially available intracranial coils: the coils can be used with eventual balloon remodeling and/or stents when necessary.
11538631|NCT01084668||Adalimumab|Participants with moderate to severe chronic plaque psoriasis treated with adalimumab after biologic disease modifying anti-rheumatic drug (BDMARD) failure
11538632|NCT01084655|Experimental|Phase 1: Orteronel 200 mg BID + Docetaxel + Prednisone|Orteronel (TAK-700) 200 milligram (mg), tablets, orally, twice daily (BID) starting from Day 1 along with docetaxel 75 milligram per square meter (mg/m^2), infusion, intravenously over 1 hour on Day 1 and prednisone 5 mg, tablets , orally, twice daily from Day 8 up to Day 21 of each treatment cycle. Cycle 1 of Phase 1 consisted of a 28-day treatment period and subsequent cycles consisted of 21-day treatment periods.
11538633|NCT01084655|Experimental|Phase 1: Orteronel 400 mg BID + Docetaxel + Prednisone|Orteronel (TAK-700) 400 mg, tablets, orally, twice daily starting from Day 1 along with docetaxel 75 mg/m^2, infusion, intravenously over 1 hour on Day 1 and prednisone 5 mg, tablets , orally, twice daily from Day 8 up to Day 21 of each treatment cycle. Cycle 1 of Phase 1 consisted of a 28-day treatment period and subsequent cycles consisted of 21-day treatment periods.
11538634|NCT01084655|Experimental|Phase 2: Orteronel 400 mg BID + Docetaxel + Prednisone|Orteronel (TAK-700) 400 mg, tablets, orally, twice daily starting from Cycle 1 Day 15 along with docetaxel 75 mg/m^2, infusion, intravenously over 1 hour on Day 1 and prednisone 5 mg, tablets, orally, twice daily from Day 1 up to Day 21 of each 21-day treatment cycle until disease progression or end of treatment (EOT).
11538635|NCT01084642||survey|Participants will be asked to complete a survey as a one time assessment.
11538636|NCT01084629||Surveillance Barrett's esophagus|Patients scheduled for endoscopic surveillance of Barrett's esophagus
11538637|NCT01084629||Barrett's esophagus post ablation|Patients scheduled for surveillance endoscopy who have undergone ablative therapies (PDT, RF ablation) for their Barrett's esophagus
11538638|NCT01084616||Vaginal Dryness|
11538639|NCT01084616||Non-vaginal dryness|
11538640|NCT01084603|Experimental|Oral Nicotine 1|One oral administration of 1 mg nicotine
11538641|NCT01084603|Experimental|Oral Nicotine 2|Two oral administrations of 1 mg nicotine
11538642|NCT01084603|Experimental|Oral Nicotine 4|Four oral administrations of 1 mg nicotine
11538643|NCT01084603|Active Comparator|NiQuitinTM Nicotine Lozenge 4 mg|One 4 mg marketed nicotine lozenge
11538644|NCT01084603|Active Comparator|Nicorette® Gum 4 mg|One marketed Nicorette® nicotine gum 4 mg chewed for 30 minutes
11538645|NCT01084590|Experimental|Healthy Eating/Physical Activity|This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
11538646|NCT01084590|Active Comparator|Safety/Injury Prevention|This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
11538647|NCT01084577|Active Comparator|Urgotul® Silver|Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
11538648|NCT01084577|Active Comparator|AQUACEL® Ag|AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
11538649|NCT01084564||1|moderate to severe uncontrolled asthma
11538650|NCT01084551|Experimental|SPM 962 4.5|started at 2.25 mg/day to 4.5 mg/day for 13 weeks
11538651|NCT01084551|Experimental|SPM 962 6.75|started at 2.25 mg/day to 6.75 mg/day for 13 weeks
11538652|NCT01084551|Placebo Comparator|placebo|for 13 weeks
11538653|NCT01084538||End stage chronic kidney disease|Secondary hyperparathyroidism defined as intact PTH > 300 pg/mL
11538654|NCT01084525|Experimental|OTO-104 (steroid) 3 mg|
11538655|NCT01084525|Placebo Comparator|Placebo|
11538656|NCT01084525|Experimental|OTO-104 (steroid) 12 mg|The start of 12 mg dose cohort is contingent on safety data from 3 mg dose cohort.
11538657|NCT01084512||Healthy group|control subjects
11538659|NCT01084512||Tetraplegic group|tetraplegic subjects
11538660|NCT01084499|Experimental|Femara First, Then Peratra (Sequence 1)|Participants first receives a branded letrozole (reference - Femara), then a generic letrozole (test - Peratra). Each treatment period is separated by a 5-week washout period.
11538661|NCT01084499|Experimental|Peratra First, Then Femara (Sequence 2)|Participants first receives a generic letrozole (test - Peratra) , then a branded letrozole (reference - Femara). Each treatment period is separated by a 5-week washout period.
11538662|NCT01084486|Experimental|Metformin, Adiponectine, Arterial Compliance|
11538663|NCT01084473|Experimental|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
11538664|NCT01084473|Active Comparator|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
11538665|NCT01084473|Placebo Comparator|Placebo|The study subjects will be given a saline infusion.
11538666|NCT01084460||EUS-suspected gastric GISTs|In this retrospective study, 50 patients with EUS-suspected gastric GISTs, less than 3 cm were enrolled and had EUS follow-up at least two times over a period of more than 24 months.
11538667|NCT01084447|Placebo Comparator|control group|In placebo muscular training group the respiratory exercise was used a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA) no load.
11538668|NCT01084447|Active Comparator|trained group|In trained group the respiratory exercise used a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)the load was initially set at 40% of the maximal inspiratory pressure.
11538669|NCT01084434|Experimental|Probiotic group|Group of 25 volunteers consuming probiotic product once a day for 7 weeks
11538670|NCT01084434|Experimental|Prebiotic group|Group of 25 volunteers consuming prebiotic product once a day for 7 weeks
11538671|NCT01084434|Experimental|Synbiotic group|Group of 25 volunteers consuming synbiotic product once a day for 7 weeks.
11538672|NCT01084434|Placebo Comparator|Placebo group|Group of 25 volunteers consuming placebo product once a day for 7 weeks
11538673|NCT01084421|Experimental|Computer based intervention|Participants receive content about adolescent sexual risk and HIV prevention, strategies to support sexual specific communication and parent-adolescent communication in general.
11538674|NCT01084421|No Intervention|Wait list control group|Participants will receive the computer based intervention at 3 months follow-up
11538675|NCT01084408|Active Comparator|Sequent®Please|
11538676|NCT01084408|Active Comparator|Taxus™Liberté™|
11538677|NCT01084395|Experimental|Adolescent Safer Sex Intervention|
11538678|NCT01084395|Experimental|Parent Safer Sex Intervention|
11538679|NCT01084395|Other|Adolescent Health Promotion Control|
11538680|NCT01084395|Other|Parent Health Promotion Control|
11538681|NCT01084382|Active Comparator|Arthrospira platensis supplement|
11538682|NCT01084382|Placebo Comparator|Protein/Dextran supplemented|
11538683|NCT01084369|Experimental|Testosterone, Vardenafil|All patients will receive Testosterone (n=40) of these (10 patients) will also receive Vardenafil
11538684|NCT01084356||hand|patients admitted for Tc MDP for evaluation of carpal/metacarpal and finger bone lesions
11538685|NCT01084356||thyroid|patients admitted for Tc thyroid scan
11538686|NCT01084356||parathyroid|patients investigated for parathyroid adenoma
11538687|NCT01084356||sentinel node|patients who are due to sentinel node biopsy
11538688|NCT01084343|Active Comparator|Panel 1|Subjects in this panel receive the low dose of vaccine (10 microgram of peptides). Twelve subjects are included in this panel, 8 of them receive the active vaccine and 4 receive the carrier only (placebo).
11538689|NCT01084343|Active Comparator|Panel 2|Subjects in this panel receive the high dose of vaccine (50 microgram of peptides). Twelve subjects are included in this panel, 8 of them receive the active vaccine and 4 receive the carrier only (placebo).
11538690|NCT01084330|Experimental|AUY922|
11538691|NCT01084330|Active Comparator|Docetaxel or Irinotecan|
11538692|NCT01084317||asthmatic children|patients under 18 age, with newly diagnosed asthma
11538693|NCT01084304||Active|Use of ovulation tests to aid conception
11538694|NCT01084304||Control|No ovulation tests to aid conception
11538695|NCT01084291|Experimental|DEN1 Vaccine|Participants will receive a single dose of investigational vaccine for dengue virus subtype 1.
11538696|NCT01084291|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine.
11538697|NCT01084278|Experimental|Healthy|Healthy participants with normal renal function (Creatinine Clearance [CrCl] ≥90 mL/min) received one colchicine 0.6 mg tablet on study day 1.
11538698|NCT01084278|Experimental|Mild renal impairment|Participants with mild renal impairment (estimated Glomerular Filtration Rate [eGFR] 60 to 89 mL/min) received one colchicine 0.6 mg tablet on study day 1.
11538699|NCT01084278|Experimental|Moderate renal impairment|Participants with moderate renal impairment (CrCl/eGFR 30 to 59 mL/min) received one colchicine 0.6 mg tablet on study day 1.
11538700|NCT01084278|Experimental|Severe renal impairment|Participants with severe renal impairment (eGFR 15 to 29 mL/min) received one colchicine 0.6 mg tablet on study day 1.
11538701|NCT01084278|Experimental|End stage renal disease (ESRD)|Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on study day 1 immediately following dialysis. After a 14-day washout, participants received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.
11538702|NCT01084252|Experimental|Phase 1:Isatuximab <=1 mg/kg Q2W|Participants with CD38+ hematological malignancies (HM), received Isatuximab at any one of the dose less than or equal to (<=) 1 milligram per kilogram (mg/kg) (i.e. either 0.0001 mg/kg or 0.001 mg/kg or 0.01 mg/kg or 0.03 mg/kg or 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg) as intravenous (IV) infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
11538703|NCT01084252|Experimental|Phase 1: Isatuximab 3mg/kg Q2W|Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
11538704|NCT01084252|Experimental|Phase 1: Isatuximab 5 mg/kg Q2W|Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
11538705|NCT01084252|Experimental|Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)|Participants with CD38+ HM along with participants with standard risk multiple myeloma were included this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
11538706|NCT01084252|Experimental|Phase 1:Isatuximab (CD38 + HM and High Risk Multiple Myeloma)|Participants with CD38+ HM along with participants with high risk multiple myeloma, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
11538707|NCT01084252|Experimental|Phase 1: Isatuximab 10 mg/kg QW|Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
11538708|NCT01084252|Experimental|Phase 1: Isatuximab 20 mg/kg Q2W|Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
11538709|NCT01084252|Experimental|Phase 1: Isatuximab 20 mg/kg QW|Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
11538710|NCT01084252|Experimental|Phase 2 Stage 1a: Isatuximab 3 mg/kg Q2W|Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable adverse event (AE), disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).
11538711|NCT01084252|Experimental|Phase 2 Stage 1a: Isatuximab 10 mg/kg Q2W|Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).
11538712|NCT01084252|Experimental|Phase2 Stage1a:Isatuximab 10mg/kg Q2W; Then Q4W|Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then every 4 week (Q4W), i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).
11538713|NCT01084252|Experimental|Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W|Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. on Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 53 weeks).
11538714|NCT01084252|Experimental|Phase 2 Stage 2: Isatuximab Alone|Participants with relapsed or relapsed/refractory multiple myeloma (RRMM), received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator's decision maximum exposure: 97 weeks).
11538715|NCT01084252|Experimental|Phase 2 Stage 2: Isatuximab + Dexamethasone|Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion (40 mg/day for less than [<] 75 years of age; 20 mg/day [greater than or equal to [>=] for 75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator's decision (maximum exposure: 97 weeks).
11538716|NCT01084239|No Intervention|Standard of care|Subjects in this arm (50% of the total cohort) continued to receive standard non-invasive evaluation of acute chest pain symptoms in the emergency department - mostly comprising of, but not limited to - exercise treadmill test, stress test with imaging and stress echocardiography.
11538717|NCT01084239|Experimental|Cardiac CT|Subjects in this arm (50% of the total cohort) were randomized to receive a cardiac computed tomography scan as part of the initial evaluation of acute chest pain symptoms, upon presentation to the emergency department.
11538718|NCT01084226|Active Comparator|Sterol|Additional plant sterols incorporated in the rye bread
11538719|NCT01084226|Placebo Comparator|control|No added plant sterol in the identical-looking rye bread
11538720|NCT01084213|Active Comparator|IPTp with SP|Study women will receive at least two doses of SP during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
11538721|NCT01084213|Experimental|IST using RDTs|Scheduled intermittent screening using rapid diagnostic tests and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester.
11538722|NCT01084200|Experimental|Propofol|anesthesia maintenance with propofol and remifentanil
11538723|NCT01084200|Experimental|Sevoflurane|Sevoflurane and Remifentanil for anesthesia maintenance
11538724|NCT01084200|Experimental|Sevoflurane+Propofol|Sevoflurane+Propofol for anesthesia maintenance
11538725|NCT01084187|Active Comparator|vardenafil on demand|four sexual attempts with 20 mg vardenafil during next four weeks
11538726|NCT01084187|Placebo Comparator|placebo|placebo of vardenafil during four weeks
11538727|NCT01084187|Active Comparator|daily vardenafil|10 mg of vardenafil each day during four weeks
11538847|NCT01083290|Experimental|Order of strenghts; 50 mg, 100 mg, 25 mg|
11538728|NCT01084174|Experimental|Active SLIT/Placebo OIT|These subjects will receive peanut powder given orally and placebo extract given sublingually.
11538729|NCT01084174|Experimental|Active OIT/Placebo SLIT|These subjects will receive peanut extract given sublingually and placebo powder given orally.
11538730|NCT01084161|Experimental|N1539 5 mg|
11538731|NCT01084161|Experimental|N1539 7.5 mg|
11538732|NCT01084161|Experimental|N1539 15 mg|
11538733|NCT01084161|Experimental|N1539 30 mg|
11538734|NCT01084161|Experimental|N1539 60 mg|
11538735|NCT01084161|Placebo Comparator|Placebo|
11538736|NCT01084161|Active Comparator|morphine|
11538737|NCT01084148|Experimental|V0034CR01B|cream
11538738|NCT01084148|Placebo Comparator|V0034 CR 01B vehicle|cream
11538739|NCT01084135|Experimental|Rivastigmine- Liquid form|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
11538740|NCT01084135|Placebo Comparator|Liquid placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
11538741|NCT01084109|Active Comparator|1|Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
11538742|NCT01084109|Active Comparator|2|Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
11538743|NCT01084096|Active Comparator|Intervention|Eligible women at high risk for preterm birth will be identified and four 6 mg doses of dexamethasone will be administered before delivery.
11538744|NCT01084096|No Intervention|Control|Control arm will not receive a specific intervention for comparison.
11538745|NCT01084083|Experimental|Group 1|After induction therapy with Paclitaxel and Cisplatin, patients undergo low-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 5 weeks (27 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 6 weeks.
11538746|NCT01084083|Experimental|Group 2|After induction therapy with Paclitaxel and Cisplatin, patients undergo standard-dose IMRT 5 days per week for approximately 6 weeks (33 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 7 weeks.
11538747|NCT01084070|Experimental|Early oral feeding|
11538748|NCT01084070|Active Comparator|Traditional Care|
11538749|NCT01084057|Experimental|Arm I (Cohort A)|Patients receive oral vorinostat once daily on days 1-14 and ixabepilone IV over 3 hours on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11538750|NCT01084057|Experimental|Arm II (Cohort B)|Patients receive oral vorinostat once daily on days 1-7 and 15-21. Patients also receive ixabepilone IV over 3 hours on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11538751|NCT01084044|Experimental|ulinastatin|
11538752|NCT01084044|Active Comparator|saline solution|
11538753|NCT01084044|Placebo Comparator|Sugar pill|
11538754|NCT01084031|Experimental|propofol|
11538755|NCT01084005|Experimental|linagliptin|patients receive linagliptin 5 mg tablets once daily
11538756|NCT01084005|Placebo Comparator|placebo|patients receive placebo tablets matching linagliptin 5 mg once daily
11538757|NCT01083992|Other|Galvus + vitamin D|Galvus in combination with vitamin D
11538758|NCT01083992|Other|Galvus|vitagliptin as monotherapy
11538759|NCT01083979|Experimental|Liposomes|Intravesical instillation of Liposomes in sterile water totally 40 cc at four weekly treatments.
11538760|NCT01083966|Experimental|Avastin|IA Avastin
11538761|NCT01083953|Experimental|Sevoflurane|1 arm will receive sevoflurane at varying concentrations at which extubation is attempted according to the Dixon up and down method
11538762|NCT01083953|Experimental|Desflurane|1 arm will receive desflurane at varying end tidal concentration at which extubation will be attempted according to Dixon up and down method
11538763|NCT01083940|Experimental|Reminders to providers|
11538764|NCT01083940|No Intervention|usual care|
11538765|NCT01083927|Active Comparator|Rotational Narrow Strip Graft|Technique of surgery
11538766|NCT01083927|Active Comparator|Full Graft|Surgical technique
11538767|NCT01083914||OPCAB|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
11538768|NCT01083914||CPB|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
11538769|NCT01083914||MECC|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
11538770|NCT01083901|Experimental|Resistance training with Acetaminophen|Acetaminophen
11538771|NCT01083901|Experimental|Resistance Training with ibuprofen|Ibuprofen
11538772|NCT01083901|Placebo Comparator|placebo|Placebo
11538773|NCT01083888|Experimental|1 group|Participants received a single oral dose of ASP1517 on Days 1 and 8
11538774|NCT01083875|Experimental|0.5% amlexanox oral rinse|Patients treated with an oral rinse containing the active 0.5% amlexanox
11538775|NCT01083875|Placebo Comparator|Vehicle|Patients treated with an oral rinse containing no active
11538776|NCT01083862|Experimental|Educational Intervention - Video & Text|"Educational Intervention - Video & Text describing Living with Coronary Artery Disease."
11538777|NCT01083862|Active Comparator|Educational Intervention - Text Only|"Educational Intervention - Text Only describing Living with Coronary Artery Disease."
11538778|NCT01083849||Paricalcitol|Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.
11538845|NCT01083303|Active Comparator|weaning at 1600 g|weaning infants from an incubator at 1600 g
11538779|NCT01083823|Active Comparator|Self-reported mood swings|Participants who self-identify as experiencing severe mood swings that interfere with life.
11538780|NCT01083823|Active Comparator|Healthy|Participants who self-identify as not experiencing mood swings in the past or at present and who deny past / present problems with substance use.
11538781|NCT01083810||therapy-naive|Patients who had not received prior antiretroviral drug therapy
11538782|NCT01083810||pre-treated|Patients that had previously received antiretroviral therapy, but are protease inhibitor naive
11538783|NCT01083810||non-B|Patients infected with non-B subtypes of HIV-1
11538784|NCT01083797|Other|dexmedetomidine, chloral hydrate|sedation with dexmedetomidine or chloral hydrate on separate occasions in the same patients
11538785|NCT01083784|Experimental|Prophylactic group|the group that used prophylactic anticonvulsants (valproate, clonazepam)
11538786|NCT01083784|No Intervention|Control group|control group
11538787|NCT01083771|Experimental|Olive Oil|At least 3 tablespoons of olive oil each day
11538788|NCT01083758|Other|LEO 80185 (Taclonex® Scalp topical suspension/ Xamiol® gel)|
11538789|NCT01083745||IVF patients - 1|Poor responders
11538790|NCT01083745||IVF patients - 2|Good responders
11538791|NCT01083732|Experimental|dabigatran etexilate|treatment with dabigatran oral solution as a single dose
11538792|NCT01083719|Experimental|FDG-PET|A comparison of FDG-PET versus MRI based target volume delineation in glioblastoma and the role of FDG-PET/CT in the alteration of MRI based target volumes.
11538793|NCT01083706|Experimental|Treatment (chemotherapy)|Patients receive azacitidine SC or IV on days 1-7. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11538794|NCT01083693||Rheumatoid, Psoriatic Arthritis, Ankylosing Spondylitis|Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, patients with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.
11538795|NCT01083680||Participants with Crohn's Disease (CD)|Participants with Crohn's Disease treated with adalimumab (HUMIRA®) in routine clinical practice.
11538796|NCT01083667|Experimental|Pyrimethamine|Open label. Only one arm will receive the intervention.
11538797|NCT01083654|Active Comparator|Standard Treatment Counseling|Standard Treatment (ST) will consist of 12 weeks of open-label varenicline and smoking cessation counseling consisting of four sessions: one in-person pre-quit counseling session during Study Visit 2, counseling during a phone call on the day after the quit day, and two additional in-person counseling sessions at Study Visits 3 and 4 (one week and three weeks after the quit day, respectively).
11538798|NCT01083654|Experimental|Culturally-Tailored Treatment|The Culturally-Tailored Treatment will consist of 12 weeks of open-label varenicline and culturally-tailored (for American Indians) smoking cessation counseling consisting of four sessions: one in-person pre-quit counseling session during Study Visit 2, counseling during a phone call on the day after the quit day, and two additional in-person counseling sessions at Study Visits 3 and 4 (one week and three weeks after the quit day, respectively).
11538799|NCT01083641|Experimental|Estrogen Therapy|Estrogen therapy
11538800|NCT01083628|Experimental|Group CBT for Depression with MoodText'|Group cognitive behavioral therapy utilizing the BRIGHT manual for depression along with automated text messaging for mood monitoring and reminder of session content
11538801|NCT01083628|Active Comparator|Group CBT for Depression|Standard group cognitive behavioral therapy utilizing the BRIGHT manual for depression
11538802|NCT01083615|Experimental|Custirsen|"Study treatment starts with a Loading Dose Period (1 week) during which 3 infusions of custirsen will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel (75 mg/m2 total dose) or cabazitaxel (25 mg/m2 total dose) on a 21-day cycle with weekly custirsen infusions (640 mg total dose) on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.
~Participants will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol."
11538803|NCT01083615|Placebo Comparator|Placebo|"Study treatment starts with a Loading Dose Period (1 week) during which 3 infusions of placebo (isotonic, 0.9% sodium chloride) will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel (75 mg/m2 total dose) or cabazitaxel (25 mg/m2 total dose) on a 21-day cycle with weekly placebo infusions on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.
~Participants will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol."
11538804|NCT01083602|Experimental|panobinostat + bortezomib & dexamethasone|panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma
11538805|NCT01083589|Experimental|Imatinib Mesylate + Docetaxel|Imatinib Mesylate (Gleevec) Oral 400 mg daily + Docetaxel (Taxotere) 60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
11538806|NCT01083576|Active Comparator|Paromomycin Alone Treatment|Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated cutaneous leishmaniasis (CL) lesions once daily for 20 days
11538807|NCT01083576|Active Comparator|WR 279,396|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days
11538808|NCT01083563||RA inadequate response to methotrexate|Individuals with rheumatoid arthritis who have had an inadequate response to methotrexate and will be starting on an anti-TNF agent.
11538809|NCT01083563||RA inadequate response to anti-TNF.|Individuals with rheumatoid arthritis who have had an inadequate response to an anti-TNF and will be be given a rituximab infusion.
11538810|NCT01083550|Experimental|DA intervention|Decision aid exposure + usual care
11538811|NCT01083550|No Intervention|Control|Usual care
11538812|NCT01083537|Experimental|Cisplatin|"Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.
~Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn
~Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour"
11538846|NCT01083290|Experimental|Order of strenghts; 25 mg, 50 mg, 100 mg|
11538813|NCT01083537|Experimental|Paclitaxel|"Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.
~Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo
~Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn
~Hydration: Infuse Paclitaxel in 250cc NS over 1 hour"
11538814|NCT01083524|Experimental|Group 1|Dichloroacetate Sodium 3.0 mg/kg, BID
11538815|NCT01083524|Experimental|Group 2|Dichloroacetate Sodium 6.25 mg/kg, BID
11538816|NCT01083524|Experimental|Group 3|Dichloroacetate Sodium 12.5 mg po bid
11538817|NCT01083511||Symptomatic|Individuals with signs and symptoms of a respiratory tract infection where it is suspected that such signs and symptoms are caused by a respiratory virus infection.
11538818|NCT01083498|Experimental|Ablative fractional laser|"In each patient, a square test region of 5-10 cm2 was treated with ablative fractional laser in three sessions in combination with intermittent topical bleaching with triple topical therapy (hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream) to prevent laser-induced postinflammatory hyperpigmentation.
~Note: this study had a split-lesion design. In each patient, two test regions were randomized to receive either ablative fractional laser therapy or no treatment."
11538819|NCT01083498|No Intervention|Control|"In each patient, a square test region of 5-10 cm2 was treated with topical bleaching with triple topical therapy (hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream)alone (to allow comparison of the regions).
~Note: this study had a split-lesion design. In each patient, two test regions were randomized to receive either ablative fractional laser therapy or no treatment."
11538820|NCT01083485|Experimental|Tablets Oxycodone Naloxone (OXN)|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)
11538821|NCT01083485|Active Comparator|Oxycodone|Oxycodone PR 20mg or 10mg (twice a day) BID for 2.5 days (total 5 dosages)
11538822|NCT01083472|Active Comparator|Strattice(TM) TM repair|Strattice(TM) TM will be placed in the intraperitoneal or retrorectus position to support the repair of abdominal wall defect
11538823|NCT01083472|Active Comparator|Standard of Care repair|Abdominal wall defect will be repaired using current standard of care techniques of either suture alone or suture with absorbable surgical mesh
11538824|NCT01083459||PCV13 immunized|Children who receive the 13-valent pneumococcal conjugate vaccine
11538825|NCT01083459||PCV13 unimmunized|PCV13 unimmunized Household members of PCV13 immunized children
11538826|NCT01083446|Active Comparator|A|Nutritional intervention, standard Israeli breakfast
11538827|NCT01083446|Active Comparator|B|Nutritional Intervention, fast
11538828|NCT01083433|No Intervention|Standard Diabetes Care|Patients will attend diabetes clinic as usual, once every 3 months.
11538829|NCT01083433|Experimental|Intensive Diabetes Clinic|Patients will attend diabetes clinic on a monthly basis for 4 months in a row. Each patient will have a 30 minute visit with a physician, 30 minutes dedicated to diabetes education, and 45 minutes with a child psychologist.
11538830|NCT01083433|Experimental|Intensive Diabetes Clinic plus CGM|Patients in this group will include all procedures as listed for group 2 (intensive diabetes clinic) in addition to wearing a continuous glucose monitor for 3-5 days each month. Patients will also have an additional 30 minutes with a psychology graduate student dedicated to adherence with the CGM.
11538831|NCT01083420|Active Comparator|Dexamethasone|Dexamethasone 0.01% mouthwash
11538832|NCT01083420|Experimental|Minocycline|Minocycline 0.2% mouthwash
11538833|NCT01083407|Experimental|0.12% Chlorhexidie Digluconate|Oral care included use of an oral gel containing chlorhexidine digluconate 0.12% as an active ingredient (chlorhexidine digluconate 0.12%; methylcellulose gel 2.12%, 25 g; gooseberry syrup, 4 drops; menthol solution 50%,3 drops; and distilled water, to 30 g).The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular,lingual, occlusal, and incisal). After each quadrant was cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto- anterior movements.
11538834|NCT01083407|Placebo Comparator|Toothbrushing|This group received the same oral care that experimental group with the use of a similarly formulated gel without the antiseptic agent.The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
11538835|NCT01083394|Active Comparator|conventional PTA|In stent restenosis is treated with PTA using a conventional balloon.
11538836|NCT01083394|Experimental|PTA with PEB|In stent restenosis is treated with PTA using a paclitaxel eluting balloon.
11538837|NCT01083381|Active Comparator|treatment group|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months. MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months.
11538838|NCT01083381|Placebo Comparator|Control group|Receives the same dosage of Risperidone. Placebo is given to this group in same form and appearance as MS14 in the other arm of the study.
11538839|NCT01083368|Experimental|Arm 1: Combination of temsirolimus and AVASTIN|Patients receive temsirolimus IV over 30-60 minutes once weekly and bevacizumab IV over 30-90 minutes once every two weeks . Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
11538840|NCT01083355||Mechanical ventilation|Critical care patients
11538841|NCT01083329|Placebo Comparator|placebo|for 16 weeks
11538842|NCT01083329|Active Comparator|nicotinic acid|"for 16 weeks :
~week 1 = 375 mg per day,
~week 2 = 500 mg per day,
~week 3 = 750 mg per day,
~week 4 = 1000 mg per day,
~week 5 = 1500 mg per day,
~weeks 6 to 16 = 2000 mg per day."
11538843|NCT01083316|Experimental|Single Arm - Investigational|"Induction:
~Bortezomib (Velcade) 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days
~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days
~Conditioning:
~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4
~Melphalan 70-100 mg/m2/day IV on days -2 and -1"
11538844|NCT01083303|Experimental|weaning at 1500 g|weaning infants from an incubator at 1500 g
11538848|NCT01083290|Experimental|Order of strenghts; 100 mg, 25 mg, 50 mg|
11538849|NCT01083277|Experimental|variable ventilation|A novel means of conducting mechanical ventilation that involves an approximately 40% variation in tidal volume around a set mean tidal volume
11538850|NCT01083277|Other|conventional ventilation|This is the control arm of the study, in which tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
11538851|NCT01083264|Experimental|Arm 1|
11538852|NCT01083264|Experimental|Arm 2|
11538853|NCT01083264|Experimental|Arm 3|
11538854|NCT01083251|Experimental|Peg + Vitamin D|Treatment arm with vitamin D will be treated first with vitamin D supplement for 3 months before the initiation of antiviral therapy. Vitamin D levels will be measures at baseline and three months after. The serum vitamin D-25-OH levels should be > 32 ng/ml before the initiation of antiviral treatment). HBV DNA levels will be also measure at baseline and after 3 months of mono therapy with vitamin D
11538855|NCT01083251|Active Comparator|Peginterferon|
11538856|NCT01083251|Active Comparator|Sebivo|Nucleotide Analog Telbivudine 600 mg daily
11538857|NCT01083251|Active Comparator|entecavir + vitamin d|baraclude 1 mg x1/ day + vitamin d
11538858|NCT01083238|Experimental|1|AZD5069 following a 10-hour fast
11538859|NCT01083238|Experimental|2|AZD5069 30 minutes after the start of a high fat meal
11538860|NCT01083225|Experimental|Client feedback|
11538861|NCT01083225|Active Comparator|Treatment as usual|
11538862|NCT01083212|Experimental|1|Gemfibrozil day 1-5 + AZD1656 day 4, 1 week without, Placebo day 1-5 + AZD1656 day 4
11538863|NCT01083212|Experimental|2|Placebo day 1-5 + AZD1656 day 4, 1 week without, Gemfibrozil day 1-5 + AZD1656 day 4
11538864|NCT01083199|Experimental|CONTINUUMTM|
11538865|NCT01083186||Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism|Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)
11538866|NCT01083173||Participants with HIV-1 infection|Participants treated with Kaletra (lopinavir/ritonavir 200 mg/50 mg and 100 mg/25 mg) tablet
11538867|NCT01083160||Non responders to other anti-TNF|Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.
11538868|NCT01083147||Dry AMD|subjects diagnosed as intermediate AMD in at least one eye
11538869|NCT01083134||percentage of stenosis|
11538870|NCT01083121||Adalimumab|Participants who were prescribed with adalimumab per approved prescribing information of adalimumab in Korea.
11538871|NCT01083108|Active Comparator|Non-surgical Arm|Low-calorie Diet
11538872|NCT01083108|Experimental|Surgical Arm|Roux-en-Y Gastric Bypass
11538873|NCT01083095|Active Comparator|3 +/- 1 bite|Volunteers were exposed to mosquito biting for 10 min
11538874|NCT01083095|Active Comparator|6 +/- 1 bite|Volunteers were exposed to mosquito biting for 10 min
11538875|NCT01083095|Active Comparator|9 +/- 1 bite|Volunteers were exposed to mosquito biting for 15 min
11538876|NCT01083069||COOL|Patients after therapy with mild hypothermia
11538877|NCT01083069||UnCool|Patients without therapy with mild hypothermia due to non-operational cooling-devices
11538878|NCT01083056||Epimacular Gliosis Without Macular Hole|
11538879|NCT01083056||Epimacular Gliosis With Macular Hole|
11538880|NCT01083043||Type 2 Diabetes Mellitus|
11538881|NCT01083030|Placebo Comparator|Conventional PTA|Angioplasty of SFA with uncoated balloon catheters
11538882|NCT01083030|Active Comparator|Drug coated balloon|Angioplasty of SFA with paclitaxel-coated balloon catheters
11538883|NCT01083017||chlorthalidone|
11538884|NCT01083017||motivational invervention|motivational interview(s) vs. repeated calls vs. no particular intervention
11538885|NCT01083017||standardized anti-hypertensive treatment|
11538886|NCT01083004|Active Comparator|Indocyanine green arm|
11538887|NCT01083004|Active Comparator|Brilliant blue|
11538888|NCT01082991|Other|prevention|
11538889|NCT01082978|Experimental|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
11538890|NCT01082978|Experimental|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
11538891|NCT01082978|No Intervention|Usual standard of care|Patients randomized to this arm of the trial will not be given a Portable Health File. This arm is the concurrent control comparator arm.
11538892|NCT01082965|Experimental|Treatment|
11538893|NCT01082965|Placebo Comparator|Placebo|
11538894|NCT01082952||Asthmatic patients|
11538895|NCT01082952||Non asthmatic patients|
11538896|NCT01082939|Experimental|CFAR|CFAR: Cyclophosphamide 250 mg/m^2/day intravenous (IV) Days 3-5, Fludarabine 25 mg/m^2/day IV Days 3-5, Alemtuzumab 30 mg IV Days 1, 3 and 5 over 2-4 hours, repeated every four weeks for a total of 6 planned cycles, and Rituximab Cycle 1 (Week 1): 375 mg/m^2/day IV Day 2 over 4- 6 hours, Cycle 2 - 6 (Week 1): 500 mg/m^2/day IV Day 2 over 4- 6 hours.
11538897|NCT01082926|Experimental|Arm I|Patients receive intratumoral GRm13Z40-2 therapeutic allogeneic lymphocytes over 10 minutes on days 1 and 3 and intratumoral aldesleukin over 3 hours on days 2-5 (days 1-5 in week 2). Treatment repeats every week for 2 courses in the absence of disease progression or unacceptable toxicity.
11538898|NCT01082913|Experimental|Sacral Surface Electrical (SSE)|
11538899|NCT01082913|No Intervention|control|
11538900|NCT01082900|Experimental|Prophylactic CPAP intervention|Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the DR via T piece (Neopuff)
11538901|NCT01082900|Active Comparator|No Intervention|Provision of standard care in the Delivery Room
11538902|NCT01082887|Experimental|TIL-Ad-INFg|
11538903|NCT01082874|Experimental|Active Clonidine and Active ASA|
11538904|NCT01082874|Experimental|Active Clonidine and Placebo ASA|
11538905|NCT01082874|Experimental|Placebo Clonidine and Active ASA|
11538906|NCT01082874|Placebo Comparator|Placebo Clonidine and Placebo ASA|
11538907|NCT01082861|Experimental|HPV&HBV vaccin|HPV&HBV vaccin
11538908|NCT01082861|Experimental|HPV vaccination|HPV vaccination
11538909|NCT01082861|Experimental|HBV vaccination|HBV vaccination
11538910|NCT01082848|Experimental|aripiprazole|
11538911|NCT01082848|Placebo Comparator|placebo|
11538912|NCT01082835||the group of Jiangzhuo Qinggan prescription|
11538913|NCT01082835||the group of irbesartan|
11538914|NCT01082822|Sham Comparator|standard of care|In the first step, the patient was periodontally treated until the inflammation was eliminated through control of bacterial biofilm and oral hygiene for about 6 months. Then the rigid fixed appliances were placed on the diseased teeth, reverse beveled open-flap surgery was performed in the buccal and palatal maxillary sides of the periodontitis-caught teeth to allow granulation tissue debridement and proper root preparation. The roots were completely scaled, and 17%EDTA was applied for 2 minutes to demineralize the root surfaces and bone wall defects, the flap was sutured.
11538915|NCT01082822|Experimental|PDLSC cell sheet transplantion|Periodontal ligament stem cell derived cell sheet or pellet with carrier such as Bioss was implanted into periodontal defect area at post surgical treatment.
11538916|NCT01082822|Experimental|the bio-ss implantation|implantation of Bioss at post surgical treatment
11538917|NCT01082809|No Intervention|Sunitinib|Sunitinib, 37.5 mg orally once daily continuously, comprising a 4-week cycle
11538918|NCT01082796|Other|CYP2C19 EMs group|cyp2c19*1/*1 carriers
11538919|NCT01082796|Other|CYP2C19 PMs group|cyp2c19*2/*2 or *2/*3
11538920|NCT01082783||patients with acute media infarct|
11538921|NCT01082783||controls with cardiovascular risks|
11538922|NCT01082770|Active Comparator|TEGO|TEGO needle free access devices will be used in patients randomised to this arm
11538923|NCT01082770|Placebo Comparator|Control|Patients will continue to receive current standard of practice, ie a 'bung' cap at the end of the hemodialysis line
11538924|NCT01082744|Active Comparator|Continuous paravertebral block with ropivacaine|
11538925|NCT01082744|Experimental|Continuous paravertebral block with ropivacaine and sufentanil|
11538926|NCT01082731|Experimental|Mefloquine- Artesunate|Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
11538927|NCT01082731|Active Comparator|Artemether- Lumefantrine|Artemether-Lumefantrine: 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
11538928|NCT01082718|Experimental|Pregnant women|Pregnant women with P. falciparum malaria
11538929|NCT01082718|Active Comparator|Non pregnant women|Non pregnant women with P. falciparum malaria
11538930|NCT01082705|Active Comparator|Artemether-lumefantrine|Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
11538931|NCT01082705|Experimental|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine administered once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
11538932|NCT01082692|Experimental|3mg DNA/dose|Subjects will receive a 4 dose series of PENNVAX-B containing 3mg of DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8 and Week 16.
11538933|NCT01082679|Other|methadone via specialty care|
11538934|NCT01082679|Other|Suboxone via specialty care|
11538935|NCT01082679|Other|Suboxone via primary care|
11538936|NCT01082666|Experimental|Continuous control|Continuous control of cuff pressure using a pneumatic device
11538937|NCT01082666|Active Comparator|Manual control|Manual control of cuff pressure is a routine practice in ICU patients
11538938|NCT01082653|Experimental|Safety|infusion of autologous bone marrow-derived stem cells
11538939|NCT01082640|Placebo Comparator|Placebo|Placebo-matching capsules, orally, twice daily for up to 12 months.
11538940|NCT01082640|Experimental|Febuxostat 30 mg BID|Febuxostat 30 mg, capsules, orally, twice daily (BID) for up to 12 months.
11538941|NCT01082640|Experimental|Febuxostat 40/80 mg QD|Participants initially received febuxostat 40 mg, capsules, once daily (QD) and one placebo-matching capsule QD and remained on this dose for up to 12 months if their serum urate (sUA) was <6.0 mg/dL at the Day 14 visit. Participants whose sUA was ≥6.0 mg/dL at the Day 14 visit received febuxostat 80 mg, capsule, QD, and one placebo-matching capsule QD at the Month 1 visit, and for the remainder of the study.
11538942|NCT01082627|Experimental|Somatostatin+common daily practice|
11538943|NCT01082627|Placebo Comparator|common daily practice|
11538944|NCT01082614|No Intervention|Standard fluid management|standard intraoperative fluid management as determined by usual monitoring and decision making applied by anesthesiology team
11538945|NCT01082614|Experimental|Goal directed therapy|Intraoperative fluid management guided by stroke volume variation determined by arterial pressure pulse wave contour analysis
11538946|NCT01082601||Optimal Medical therapy|Subjects with Class I,IIor III congestive heart failure on optimal medical therapy. Planned catheter ablation for paroxysmal or persistent atrial fibrillation. Paroxysmal AF defined as recurrent AF(2 or more episodes in one month) that terminate within seven days. Persistent AF defined as sustained beyond seven days, or lasting less than seven days but requiring pharmacologic or electrical cardioversion.
11538947|NCT01082588|Active Comparator|pravastatin|pravastatin 40mg, once a day, shortly after baseline for 12 consecutive weeks
11538948|NCT01082588|Placebo Comparator|Placebo|placebo, once a day, shortly after baseline for 12 consecutive weeks
11538949|NCT01082575||Major Surgery|Oxygen Monitoring
11538950|NCT01082562|Experimental|Arm 1 - BMS-844421|
11538951|NCT01082562|Placebo Comparator|Arm 2 - 0.9% sodium chloride injection solution|
11538952|NCT01082562|Experimental|Arm 3 - BMS-844421|
11538953|NCT01082562|Placebo Comparator|Arm 4 - 0.9% sodium chloride injection solution|
11538954|NCT01082562|Experimental|Arm 5 - BMS-844421|
11538955|NCT01082562|Placebo Comparator|Arm 6 - 0.9% sodium chloride injection solution|
11538956|NCT01082562|Experimental|Arm 7 - BMS-844421|
11538957|NCT01082562|Placebo Comparator|Arm 8 - 0.9% sodium chloride injection solution|
11538958|NCT01082562|Experimental|Arm 9 - BMS-844421|
11538959|NCT01082562|Placebo Comparator|Arm 10 - 0.9% sodium chloride injection solution|
11538960|NCT01082562|Experimental|Arm 11 - BMS-844421|
11538961|NCT01082562|Placebo Comparator|Arm 12 - 0.9% sodium chloride injection solution|
11538962|NCT01082562|Experimental|Arm 13 - BMS-844421|
11538963|NCT01082562|Placebo Comparator|Arm 14 - 0.9% sodium chloride injection solution|
11538964|NCT01082562|Experimental|Arm 15 - BMS-844421|
11538965|NCT01082562|Placebo Comparator|Arm 16 - 0.9% sodium chloride injection solution|
11538966|NCT01082549|Active Comparator|gemcitabine/carboplatin|
11538967|NCT01082549|Experimental|gemcitabine/carboplatin plus Iniparib|
11538968|NCT01082536||One ventricle pts, bypass, perfusion|1. Single ventricle patients who undergo cardiopulmonary bypass and selective cerebral perfusion.
11538969|NCT01082536||One ventricle pts, bypass only|Single ventricle patients who undergo cardiopulmonary bypass but not selective cerebral perfusion
11538970|NCT01082536||One ventricle pts, no bypass/perfusion|Single ventricle patients who undergo surgery, but do not undergo cardiopulmonary bypass or selective cerebral perfusion.
11538971|NCT01082536||Two ventricle pts, bypass, perfusion|Two ventricle patients who undergo cardiopulmonary bypass and selective cerebral perfusion.
11538972|NCT01082536||Two ventricle pts, bypass only|Two ventricle patients who undergo cardiopulmonary bypass but not selective cerebral perfusion.
11538973|NCT01082536||Two ventricle pts, no bypass/perfusion|Two ventricle patients who do not undergo cardiopulmonary bypass or selective cerebral perfusion.
11538974|NCT01082523|Active Comparator|Text message reminders|
11538975|NCT01082523|No Intervention|Control|
11538976|NCT01082510|Active Comparator|BCG maintenance therapy|
11538977|NCT01082510|Experimental|UFT maintenance therapy|
11538978|NCT01082497|Experimental|Mindfulness|
11538979|NCT01082497|Active Comparator|Education|8 - weekly workshops on affect consciousness for all staff
11538980|NCT01082484|Experimental|Treprostinil|Treprostinil iontophoresis (250, 25 and 2.5 microM)
11538981|NCT01082484|Experimental|Iloprost|Iloprost iontophoresis (200, 20 and 2 microM)
11538982|NCT01082484|Placebo Comparator|NaCl 0.9%|
11538983|NCT01082471|Experimental|M6G|An initial slow bolus injection up to 60 min prior to end of surgery. If required, two additional slow bolus injections to achieve baseline pain relief. Continuing on PCA for a minimum of 24 hours.
11538984|NCT01082471|Active Comparator|Morphine|An initial slow bolus injection up to 60 min prior to end of surgery. If required, two additional slow bolus injections to achieve baseline pain relief. Continuing on PCA for a minimum of 24 hours.
11538985|NCT01082445|Experimental|N-acetylcysteine|50 patients that receive 600 mg of acetylcysteine for 3 times a day.
11538986|NCT01082445|Placebo Comparator|Placebo|50 subjects taking placebo pills 3 times a day
11538987|NCT01082419|Other|Group A|healthy volunteers
11538988|NCT01082419|Other|Group B|patients with supposed disease free liver (normal hepatic and pancreatic biochemistry)
11538989|NCT01082419|Other|Group D|patients with cirrhosis
11538990|NCT01082419|Other|Group E|patients with liver tumour and surgery indication
11538991|NCT01082419|Other|Group F|patients with reversible liver diseases and with acute left cardiac insufficiency
11538992|NCT01082419|Other|Group C|patients with non cirrhotic hepatopathy
11538993|NCT01082419|Other|Group G|patients with reversible liver diseases and with biliary cholestasis
11538994|NCT01082406|Experimental|Trial part 1|
11538995|NCT01082406|Experimental|Trial part 2|
11538996|NCT01082393|Active Comparator|topical tacrolimus|
11538997|NCT01082393|Active Comparator|topical pimecrolimus|
11538998|NCT01082393|Active Comparator|local steroids|
11538999|NCT01082393|Placebo Comparator|cold cream|
11539000|NCT01082380|Experimental|1|
11539001|NCT01082367|Experimental|TOBI (tobramycin inhaled solution)/Placebo|Participants randomized to TOBI received the investigational treatment for 28 days twice daily (bi)d in the first treatment cycle. At the end of first treatment cycle, participants who were positive for P. aeruginosa entered the open label (OL) phase of the study and received TOBI for 28 days bid. Participants who were negative for P. aeruginosa at the end of first treatment cycle and agreed to participate in the cross-over treatment period received placebo for 28 days bid (second treatment cycle).
11539002|NCT01082367|Placebo Comparator|Placebo/TOBI|Participants randomized to placebo group received 0.9 % saline (NaCl) for 28 days bid in the first treatment cycle. At the end of first treatment cycle, participants who were positive for P. aeruginosa entered the OL phase of the study and received TOBI for 28 days bid. Participants who were negative for P. aeruginosa at the end of first treatment cycle and agreed to participate in the cross-over treatment period received TOBI for 28 days bid (second treatment cycle).
11539003|NCT01082341|Experimental|Fy(+)|14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites
11539004|NCT01082341|Active Comparator|Fy(+) control|Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites.
11539005|NCT01082341|Active Comparator|Fy(-)|Six Fy(-) volunteers will be exposed to infective mosquito bites.
11539006|NCT01082328|Experimental|Kuvan®|
11539007|NCT01082302|Active Comparator|oral intake of green tea beverage|Healthy volunteers are asked to drink a defined amount of green tea beverage over 7 days
11539008|NCT01082302|Experimental|Polyphenon E 15% ointment|3 times daily application of Polyphenon E 15% ointment on genital and perianal warts over 7 days
11539009|NCT01082276|Other|Rifampin/Lurasidone|Healthy Normal Subject
11539010|NCT01082263|Other|Midazolam/Lurasidone|Schizophrenia patient
11539011|NCT01082250|Other|Reference Formulation|Dosed 12.5% drugload 3X40mg
11539012|NCT01082250|Other|Test Formulation|25% Drugload 1X120mg
11539013|NCT01082237|Active Comparator|escitalopram|All subjects will receive escitalopram (ESC), brand name Lexapro (Forest Laboratories, Inc., New York) throughout the study. Dosing will start at 5 mg/d, be titrated to 10 mg after 4 days, and continue at 10 mg/d thereafter; an additional dose titration to 20 mg will be pursued at week 8 for those not significantly better (<50% improvement on IDS-30 at week 8 visit) and as tolerated.
11539014|NCT01082224|Experimental|Waitlisted with HCC-Exception Points|Participants undergo CT and MRI every 90 days for the trial with iodinated contrast dye and motexafin gadolinium, during liver transplant wait listing. Possible Eovist-enhanced MRI substudy participation
11539015|NCT01082211|Experimental|Partial Breast Re-Irradiation|Partial Breast Re-Irradiation (PBrI) 3D-Conformal External Beam 1.5 Gy x 15 (BID) to 45 Gy Total
11539016|NCT01082185|Other|Ovation Abdominal Stent Graft System|Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
11539017|NCT01082159|Other|lumbar decompression|Percutaneous lumbar decompression with mild® Device Kit.
11539018|NCT01082146|Experimental|Lurasidone|LURASIDONE 40mg
11539019|NCT01082120|Experimental|1|AZD1656 day 1-5, AZD1656 + Pioglitazone day 6-10, Pioglitazone day 11-15
11539020|NCT01082120|Experimental|2|Pioglitazone day 1-5, AZD1656 + Pioglitazone day 6-10, AZD1656 day 11-15
11539021|NCT01082107|Other|Solar disinfection of drinking water|
11539022|NCT01082094|Experimental|ACRX-100|"Cohort 1 = Low dose
~Cohort 2 = Middle dose
~Cohort 3 = High Dose"
11539023|NCT01082081|Experimental|Paracetamol 1000 mg|Paracetamol 1000 mg
11539024|NCT01082081|Experimental|Paracetamol 500 mg|Paracetamol 500 mg
11539025|NCT01082081|Placebo Comparator|Placebo|Placebo
11539026|NCT01082068|Experimental|Arm 1|XL147 (SAR245408) + letrozole
11539027|NCT01082068|Experimental|Arm 2|XL765 + letrozole
11539028|NCT01082055||Currently receiving antiarrythmic drugs|
11539029|NCT01082042||Standard Care|Individuals who attended the local falls group
11539030|NCT01082042||Intervention group|Individuals who undertook the 12 week exercise (Nintendo WiiFit) intervention
11539031|NCT01082029|Experimental|Lansoprazole|
11539032|NCT01082029|Placebo Comparator|Placebo|
11539033|NCT01082016|No Intervention|Control|Monitor sleep in ICU without attempts at promotion
11539034|NCT01082016|Experimental|Sleep promotion|Measure sleep in ICU with sleep promotion program in effect
11539035|NCT01082003|Other|Permanent Implant|Trental and Vitamin E for 6 months
11539036|NCT01082003|Other|Tissue Expander|Trental and Vitamin E for 6 months
11539037|NCT01081990|Placebo Comparator|Placebo Pill|
11539038|NCT01081990|Experimental|Flexeril|
11539039|NCT01081977|Active Comparator|Early Cord Clamping Group|Early Cord Clamping Group (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate).
11539040|NCT01081977|Experimental|Delayed Cord Clapming Group|Delayed Umbilical Cord Clamping Group (Clamping of Umbilical Cord within 2 minutes of shoulder delivery of neonate).
11539041|NCT01081964|Active Comparator|Levofloxacin 500mg|Levofloxacin 500mg once daily for 7 days
11539042|NCT01081964|Experimental|Zabofloxacin 5 days|Zabofloxacin 400mg for 5 days
11539043|NCT01081964|Experimental|Zabofloxacin 3 days|Zabofloxacin 400mg for 3 days
11539044|NCT01081951|Experimental|1|200mg, 400mg BID - CAPSULES Olaparib paclitaxel iv and carboplatin iv
11539045|NCT01081951|Active Comparator|2|paclitaxel iv and carboplatin iv
11539046|NCT01081938|Experimental|1|Insulin Glargine + Insulin Glulisine
11539047|NCT01081938|Active Comparator|2|Insulin Glulisine
11539048|NCT01081925||Congestive heart failure|Patients suffering from sudden worsening of congestive heart failure
11539049|NCT01081912|Active Comparator|Hydrocodone Bitartrate Capsules|Hydrocodone Bitartrate Controlled-Release Capsules
11539050|NCT01081912|Placebo Comparator|Placebo comparator|
11539051|NCT01081899|Experimental|The LCP-I Program.|The Italian version of the Liverpool Care Pathways version 11 for hospital) Programme.
11539052|NCT01081899|No Intervention|standard healthcare practices|No specific interventions are planned in the control wards.
11539053|NCT01081886|Experimental|PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
11539054|NCT01081886|Active Comparator|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
11539055|NCT01081873||Advanced prostate cancer participants|Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment within local reimbursement guidelines.
11539056|NCT01081860||Carpal tunnel syndrome|Patients with carpal tunnel syndrome
11539057|NCT01081860||Trigger finger|Patients with trigger fingers
11539058|NCT01081860||Dupuytren Contracture|Patients with Dupuytren
11539059|NCT01081860||Trauma to the hand|Patients with an acute trauma to the hand
11539060|NCT01081847|Active Comparator|Group A|Montanide ISA 720 Dose by peptide 50ug
11539061|NCT01081847|Active Comparator|Group B|Montanide ISA 51 Dose by peptide 50ug
11539062|NCT01081847|Active Comparator|Group C|Montanide ISA 720 Dose by peptide 100ug
11539063|NCT01081847|Active Comparator|Group D|Montanide ISA 51 Dose by peptide 100ug
11539064|NCT01081847|Placebo Comparator|Group E|Control Group. no peptide. Isotonic saline solution
11539065|NCT01081834|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
11539066|NCT01081834|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
11539067|NCT01081834|Experimental|Placebo/Sitagliptin|In the Main Study, each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52.
11539068|NCT01081821|Experimental|001|single dose NJ-39758979/ matching placebo Single oral dose of JNJ-39758979 (either 50 100 300 600mg) or Placebo
11539069|NCT01081821|Experimental|002|multi-dose JNJ-39758979 /matching placebo JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
11539115|NCT01081600||AUY922|Patients with HER2 positive breast cancer which has become trastuzumab resistent.
11539116|NCT01081587|Experimental|Nutritional Support Team|
11539070|NCT01081808|Other|Armed Activated T Cells|Activated T Cells (ATC) armed with the bispecific antibody OKT3 x Cetuximab (EGFRBi). ATC will be expanded for 14 days from a leukapheresis product, armed with EGFRBi, cryopreserved and infused in 8 divided doses. Patients will also receive low dose subcutaneous IL-2(3000,000 IU/m2/day) and GM-CSF (250ug/m2 twice per week)
11539071|NCT01081795|Experimental|Topiramate (JNS019) 50 mg|In titration period, topiramate 25 milligram (mg) tablet will be given once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and will be continued further for 18 weeks in the fixed dose period.
11539072|NCT01081795|Experimental|Topiramate 100 mg|In titration period, topiramate 25 mg tablet will be given once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and will be continued further for 18 weeks in the fixed dose period.
11539073|NCT01081795|Placebo Comparator|Placebo|In titration period, matching placebo tablet will be given once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice orally from Day 22 to Day 28 and will becontinued further for 18 weeks in the fixed dose period.
11539074|NCT01081782|Experimental|E1|
11539075|NCT01081782|Experimental|E2|
11539076|NCT01081782|Experimental|E3|
11539077|NCT01081782|Placebo Comparator|P|
11539078|NCT01081769|Experimental|Paliperidone Palmitate|paliperidone palmitate injection with 150 mg equivalent on Day 1 100 mg equivalent on Day 8 75 mg equivalent on Day 38 and flexible dosing with 25 50 75 100 or 150 mg equivalent once monthly thereafter
11539079|NCT01081769|Active Comparator|Oral Antipsychotics|oral antipsychotics daily treatment according to local label for maximally 24 months
11539080|NCT01081756|Experimental|Subjects treated with r-hCG|Subjects treated with r-hCG
11539081|NCT01081756|Active Comparator|Subjects treated with urinary hCG|Subjects treated with urinary hCG
11539082|NCT01081743|Experimental|Social worker|
11539083|NCT01081743|No Intervention|Control|Control group is followed-up as usually (usual care)
11539084|NCT01081730||001|ustekinumab as prescribed
11539085|NCT01081730||002|anti-TNF biologics as prescribed
11539086|NCT01081730||003|non-anti-TNF biologics as prescribed
11539087|NCT01081730||004|systemic non-biological treatments as prescribed
11539088|NCT01081730||005|general population non-treated cohort
11539089|NCT01081717||001|golimumab as prescribed
11539090|NCT01081717||002|anti-TNF biologics as prescribed
11539091|NCT01081717||003|non-anti-TNF biologics as prescribed
11539092|NCT01081717||004|systemic non-biological treatments as prescribed
11539093|NCT01081717||005|general population non-treated cohort
11539094|NCT01081704|Experimental|001|ustekinumab Single dose of 45 mg subcutaneous injection
11539095|NCT01081704|Experimental|002|ustekinumab Single dose of 90 mg subcutaneous injection
11539096|NCT01081691|Experimental|001|CNTO 5825 0.1 mg/kg single dose Intravenously (IV) or matching placebo
11539097|NCT01081691|Experimental|002|CNTO 5825 0.3 mg/kg single dose IV or matching placebo
11539098|NCT01081691|Experimental|003|CNTO 5825 1 mg/kg single dose IV or matching placebo
11539099|NCT01081691|Experimental|004|CNTO 5825 3 mg/kg single dose IV or matching placebo
11539100|NCT01081691|Experimental|005|CNTO 5825 10 mg/kg single dose IV or matching placebo
11539101|NCT01081691|Experimental|006|CNTO 5825 For atopic patient:10 mg/kg single IV dose or matching placebo
11539102|NCT01081691|Experimental|007|CNTO 5825 For atopic patient: 3 mg/kg single dose SC or matching placebo
11539103|NCT01081678|Placebo Comparator|Placebo|Participants received placebo to romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
11539104|NCT01081678|Experimental|Romosozumab 70 mg|Participants received 70 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
11539105|NCT01081678|Experimental|Romosozumab 140 mg|Participants received 140 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
11539106|NCT01081678|Experimental|Romosozumab 210 mg|Participants received 210 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
11539107|NCT01081665||Chronic Kidney Disease|All eligible patients treated with IV Paricalcitol (Zemplar)
11539108|NCT01081652|Experimental|Crinone 8% group|Female subjects undergoing IVF/ET treated with Crinone 8% intravaginally
11539109|NCT01081652|Active Comparator|Intramuscular progesterone group|Female subjects undergoing IVF/ET treated with 60 mg progesterone intramuscularly once daily
11539110|NCT01081639|Experimental|Gonal-f|
11539111|NCT01081639|Active Comparator|Puregon|
11539112|NCT01081626|Experimental|Group I: Chronic Low dose Protocol|Gonal-f will be injected on the second or third day of a spontaneous or progestogen-induced menstrual cycle (Day 0), with a daily dose of 75 International Units (IU) for 7 days. Ovarian response will be assessed on Day 7 of stimulation by ultrasound scan. If no follicle has reached at least 10 to 12 millimeter (mm) diameter, stimulation will be continued with the same dose for further 7 days. On Day 14 of stimulation, if no ovarian response is seen, the dose will be increased by 37.5 IU (total 112.5 IU) and administered for the next 7 days. Subsequent increments of 37.5 IU, at intervals of 7 days up to Day 35 of stimulation would be made, depending on ovarian response.
11539113|NCT01081626|Experimental|Group II: Low dose Protocol|Gonal-f will be administered on the second or third day of a spontaneous or progestogen-induced menstrual cycle (Day 0), with a daily dose of 75 IU for 7 days. Ovarian response will be assessed on Day 7 of stimulation by ultrasound scan. If no follicle has reached at least 10 to 12 mm diameter, the dose will be increased by 37.5 IU (total 112.5 IU) and administered for the next 7 days. Subsequent increments of 37.5 IU, at intervals of 7 days up to Day 35 of stimulation will be made, depending on ovarian response.
11539114|NCT01081613||AUY922|Patients with estrogen receptor (ER) positive, hormone therapy refractory breast cancer.
11539117|NCT01081587|Active Comparator|Usual care|
11539118|NCT01081574|Experimental|10 mg Bilastine once daily for 7 days|10 mg Bilastine dispersible oral tablet
11539119|NCT01081561|Active Comparator|Cross-linking|Corneal collagen cross-linking with riboflavin and UVA light
11539120|NCT01081561|Active Comparator|Cross-linking plus INTACS|Corneal collagen cross-linking with riboflavin and UVA light plus INTACS
11539121|NCT01081548|Experimental|Generic|
11539122|NCT01081548|Active Comparator|Lipitor|
11539123|NCT01081535|Experimental|ketorolac|
11539124|NCT01081535|Experimental|fentanyl|
11539125|NCT01081483|Active Comparator|ABT-072 Tablet|ABT-072 50 mg Tablet, every day (QD), single ascending doses, groups 1-3
11539126|NCT01081483|Placebo Comparator|Placebo|Placebo Tablet, QD, single doses, groups 1-3
11539127|NCT01081457|Active Comparator|ON|Stimulator switched ON
11539128|NCT01081457|Sham Comparator|OFF|Stimulator switched OFF
11539129|NCT01081444|Active Comparator|1|Active rTMS
11539130|NCT01081444|Placebo Comparator|2|sham rTMS
11539131|NCT01081431|Experimental|Lenalidomide|
11539132|NCT01081418|Experimental|Standard care|Standard care comprised a treatment network consisting of open and closed inpatient wards, day-clinics, an outpatient centre, and eight private psychiatrists. Each patient was treated by a private psychiatrist or by a psychiatrist in the outpatient centre. Home visits were possible, but office visits were the general rule. Patients were allowed to use all treatment offers in the outpatient centre. Outside office hours, patients could refer themselves to the psychiatric hospital. Psychosocial treatments as supportive therapy, psychoeducation, psychotherapy, and family intervention were provided infrequently and in a less intensive and unsystematic way, and only in the minority of cases. This 'standard of care' definition is in accordance with other studies.
11539133|NCT01081405|Experimental|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
11539134|NCT01081392|Experimental|LPS sequence 1|Nebulizers A then B then C
11539135|NCT01081392|Experimental|LPS sequence 2|Nebulizers B then C then A
11539136|NCT01081392|Experimental|LPS sequence 3|Nebulizers C then A then B
11539137|NCT01081392|Experimental|LPS sequence 4|Nebulizers A then C then B
11539138|NCT01081392|Experimental|LPS sequence 5|Nebulizers C then B then A
11539139|NCT01081392|Experimental|LPS sequence 6|Nebulizers B then A then C
11539140|NCT01081379||pre-conception immunity|pre-conception immunity- pregnant women with CMV seropositive
11539141|NCT01081379||primary CMV infection|primary CMV infection- pregnant women with primary CMV infection (defined as CMV IgG sero-conversion, the presence of low avidity IgG antibodies or the presence of IgM with no previous IgG antibodies).
11539142|NCT01081353|Experimental|Arm 1|
11539143|NCT01081353|Active Comparator|Arm 2|
11539144|NCT01081353|Active Comparator|Arm 3|
11539145|NCT01081353|Active Comparator|Arm 4|
11539146|NCT01081340|Experimental|Social network building intervention|Healthy lifestyle intervention focused on building reciprocal social ties between the intervention group members
11539147|NCT01081340|Active Comparator|Home visit|Home visits focused on preventable infant injuries
11539148|NCT01081327||Patients receiving Warfarin|
11539149|NCT01081314|Experimental|Standard DBT + PTSD Protocol|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team) plus a modified version of Prolonged Exposure therapy for PTSD.
11539150|NCT01081314|Active Comparator|Standard DBT|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
11539151|NCT01081301|Experimental|Living with Hope Program|Receive Living with Hope Program
11539152|NCT01081288|Active Comparator|Women aged 47-49 invited for breast screening|
11539153|NCT01081288|Active Comparator|Women aged 71-73 invited for breast screening|
11539154|NCT01081275|Active Comparator|CI Therapy|CI therapy involves repetitive practice with the more-affected hand on typical daily living activities (such as stacking objects, pouring, moving objects) for 3.5 hours per day, along with physical restraint of the better hand to keep it from assisting, and home practice exercises.
11539155|NCT01081275|Active Comparator|CAM treatments|CAM treatments are holistic physical treatments designed to work on the entire body to improve quality of life and overall health. This study will use yoga, relaxation exercises, aquatherapy (pool therapy), and massage.
11539156|NCT01081262|Experimental|Arm I (carboplatin and paclitaxel)|Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
11539157|NCT01081262|Experimental|Arm II (oxaliplatin and capecitabine)|Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
11539158|NCT01081262|Experimental|Arm III (carboplatin, paclitaxel, bevacizumab)|Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
11539159|NCT01081262|Experimental|Arm IV (oxaliplatin, capecitabine, bevacizumab)|Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III.
11539160|NCT01081249|Experimental|Placebo then Oxytocin|Participant was randomized to receive placebo before the first psychotherapy session, and then received the active drug at the second visit.
11539161|NCT01081249|Experimental|Oxytocin then placebo|Participant was randomized to receive placebo before the first psychotherapy session, and then received the active drug at the second visit.
11539162|NCT01081236||Compensated liver cirrhosis|
11539163|NCT01081236||Decompensated liver cirrhosis|
11539164|NCT01081223|Experimental|TVI-Brain-1|Biological/Vaccine: Cancer vaccine plus immune adjuvant, plus activated white blood cells
11539165|NCT01081210||Ultrasound screening|Patients admitted to Department of medicine at local hospital. Randomized inclusion, informed consent obtained.
11539166|NCT01081197||Out-day patients' clinic|Alcohol abusers referred to out-day patients' clinic which consent to participate in the study
11539167|NCT01081197||Control|Control group for the cardiac arm of the study will be matched controls from the Nord-Trøndelag Health Study (HUNT)
11539168|NCT01081184||primary Sjögren syndrome|
11539169|NCT01081184||Healthy volunteers|
11539170|NCT01081158|Experimental|Treatment-naïve 800 mg TID|"Period 1: SCH 900518 (800 mg TID) or placebo for 7 days
~Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 µg/kg QW) or placebo + PegIntron for 14 days."
11539171|NCT01081158|Experimental|Treatment-experienced: 800 mg TID|"Period 1: SCH 900518 (800 mg TID) or placebo for 7 days
~Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 ug/kg QW) or placebo + PegIntron for 14 days"
11539172|NCT01081158|Experimental|Treatment-naïve: 400 mg + RTV BID|"Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.
~Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days."
11539173|NCT01081158|Experimental|Treatment-experienced: 400 mg + RTV BID|"Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.
~Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days."
11539174|NCT01081145|Experimental|Extended-release Guanfacine HCl|
11539175|NCT01081145|Placebo Comparator|Placebo|
11539176|NCT01081132|Experimental|Extended-release Guanfacine HCl|
11539177|NCT01081132|Placebo Comparator|Placebo|
11539178|NCT01081119|Experimental|Project CHOICE|Middle school receives Project CHOICE
11539179|NCT01081119|No Intervention|No Project CHOICE|Middle school does not receive Project CHOICE
11539180|NCT01081106|Other|Low-Level Laser Therapy|
11539181|NCT01081093|Experimental|Biventricular pacing|
11539182|NCT01081067||Control|Routine cow milk-based infant formula
11539183|NCT01081067||Investigational|Cow milk-based infant formula containing probiotics
11539184|NCT01081054|Other|Ambulatory Treatment|Patients are treated ambulatory with oral antibiotic for 10 days; for the first five days these patients are contacted by telephone daily to progress oral intake.
11539185|NCT01081054|Active Comparator|Hospital treatment|Patients are hospitalized and treated with antibiotic, for the first days by endovenous antibiotic and with diet progression orally.
11539186|NCT01081041|Experimental|Safety Lead-In (cetuximab manufactured by ImClone)|"Cycle 1:
~Week 1 - Cetuximab 400 milligrams per square meter (mg/m^2) on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin area under the curve (AUC) 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4
~Week 2 - Cetuximab 250 mg/m^2 on Day 1
~Week 3 - Cetuximab 250 mg/m^2 on Day 1
~Cycle 2-6:
~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4
~Week 2 - Cetuximab 250 mg/m^2 on Day 1
~Week 3 - Cetuximab 250 mg/m^2 on Day 1
~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
11539187|NCT01081041|Experimental|Cetuximab manufactured by ImClone|"Cycle 1:
~Week 1 - Cetuximab 400 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4
~Week 2 - Cetuximab 250 mg/m^2 on Day 1
~Week 3 - Cetuximab 250 mg/m^2 on Day 1
~Cycle 2-6:
~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4
~Week 2 - Cetuximab 250 mg/m^2 on Day 1
~Week 3 - Cetuximab 250 mg/m^2 on Day 1
~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
11539188|NCT01081041|Experimental|Cetuximab manufactured by Boehringer Ingelheim|"Cycle 1:
~Week 1 - Cetuximab 400 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4
~Week 2 - Cetuximab 250 mg/m^2 on Day 1
~Week 3 - Cetuximab 250 mg/m^2 on Day 1
~Cycle 2-6:
~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4
~Week 2 - Cetuximab 250 mg/m^2 on Day 1
~Week 3 - Cetuximab 250 mg/m^2 on Day 1
~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
11539189|NCT01081028||Group One: Patients enrolled between Sep2009 and Nov2011|Newly diagnosed multiple myeloma patients enrolled between Sep 2009 and Nov 2011.
11539190|NCT01081028||Group Two: Patients enrolled between Dec2012 and mid-2016|Newly diagnosed multiple myeloma patients enrolled between Dec 2012 and mid-2016
11539191|NCT01081002|Active Comparator|Anesthesia (=A) with lidocaine 10%|3 min before sedation 4 puffs of terbutaline diluted lidocaine solution (Xylocaine ® 10% spray, Astra Zeneca, London, UK) will be sprayed on the pharynx
11539192|NCT01081002|Placebo Comparator|A with diluted gentian root solution|3 min before sedation 4 puffs of highly diluted gentian solution will be sprayed on the pharynx
11539193|NCT01080989|Other|health screening and clinical diagnosis and treatment for p|The study project can be divided into two parts: (1) health screening for the community and (2) clinical diagnosis and treatment for patients at National Referral Hospital (NRH) in Solomon islands.
11539194|NCT01080976||Primary Care Physicians|
11539195|NCT01080976||Diabetologists|
11539196|NCT01080963|Active Comparator|Daptomycin|
11539197|NCT01080963|Active Comparator|Cefuroxime|
11539198|NCT01080950||fever zinc vit. d|patients with fever but without sepsis
11539199|NCT01080950||sepsis zinc vit. d|patients with sepsis
11539200|NCT01080937||Patient with acute heart failure|Hospitalized patient, whatever the mode of initial admission with acute heart failure
11539201|NCT01080924|Experimental|Low frequency ultrasound spectroscopy|Low frequency ultrasound spectroscopy after broncholysis
11539202|NCT01080911|Experimental|spinal morphine 0.05 mg|spinal morphine 0.05 mg plus 0.5% heavy marcaine 3.5 ml
11539203|NCT01080911|Active Comparator|spinal morphine 0.1 mg|spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
11539204|NCT01080898||DMLA patients|patients > 50 years with suspicion of choroidal neo-vessels complicating age related macular degeneration (DMLA)
11539205|NCT01080885|Experimental|Busy Bodies/Better Bites|Healthy Eating/Physical Activity Intervention
11539206|NCT01080885|Active Comparator|Healthy Spots/Safe Tots|Injury Prevention and Safety Intervention
11539207|NCT01080872||Titanium-NO coated stent|Patients receiving titanium-nitride-oxide coated stents during the intervention.
11539208|NCT01080872||Everolimus eluting stent|Patients receiving everolimus eluting stents during the intervention.
11539209|NCT01080859||BAS|Patient's receiving BAS
11539210|NCT01080859||EES|Patients receiving EES
11539211|NCT01080846|Experimental|600 mcg of sublingual misoprostol|
11539212|NCT01080833|Active Comparator|ERCP mechanical simulator practice|Trainees who are offered ERCP Mechanical Simulator (EMS) training in addition to routine training (study group)
11539213|NCT01080833|No Intervention|No ERCP mechanical simulator practice|Trainees undergoing routine ERCP training only (control group).
11539214|NCT01080820|Placebo Comparator|Placebo + Viread|
11539215|NCT01080820|Active Comparator|Viread|
11539216|NCT01080820|Experimental|CMX157 + Viread|
11539217|NCT01080807|Experimental|150 mg/day armodafinil|
11539218|NCT01080807|Placebo Comparator|Matching placebo|
11539219|NCT01080794|Active Comparator|Double rTMS|High frequency rTMS stimulation of the bilateral primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC).
11539220|NCT01080794|Active Comparator|M1 Active rTMS + DLPFC Sham rTMS|High frequency stimulation of the primary motor cortex (M1) and sham stimulation of the dorsolateral prefrontal cortex (DLPFC).
11539221|NCT01080794|Active Comparator|DLPFC Active rTMS + M1 Sham rTMS|High frequency stimulation of the dorsolateral prefrontal cortex (DLPFC) and sham stimulation of the primary motor cortex (M1).
11539222|NCT01080794|Sham Comparator|Double Sham rTMS|Sham rTMS stimulation of the bilateral primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC).
11539223|NCT01080781||Group 1|normal pressures in right auricle (<10 mmHg) /and or pulmonary artery (<35 mmHg)
11539224|NCT01080781||Group 2|high pressures in right auricle (> 10 mmHg) /and or pulmonary artery (>35 mmHg)
11539225|NCT01080768|Experimental|Aliskiren/amlodipine + Placebo to amlodipine|"During the first week of active treatment, patients were instructed to take one tablet of aliskiren/amlodipine 150/5 mg and one capsule of placebo to amlodipine daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 2 tablets of aliskiren/amlodipine 150/5 mg/day and 1 capsule of placebo to amlodipine.
~The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."
11539226|NCT01080768|Active Comparator|Amlodipine + Placebo to aliskiren/amlodipine|"During the first week of active treatment, patients were instructed to take one capsule of amlodipine 5 mg and one tablet of placebo to aliskiren/amlodipine 150/5 mg daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 1 capsule of amlodipine 10 mg/day and 2 tablets of placebo to aliskiren/amlodipine 150/5 mg/day.
~The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."
11539227|NCT01080716|Experimental|Part 1/Arm 1 of Study: WRSS1 vaccine|WRSS1 is a live attenuated S. sonnei vaccine candidate derived from the Mosely strain of S.sonnei
11539228|NCT01080716|Placebo Comparator|Part 1/Arm 2 of Study: Placebo vaccine|Placebo
11539229|NCT01080716|Experimental|Part 2/Arm 1 of Study: S. sonnei 53G|10 volunteers from Study Arm 1/Part 1 (WRSS1 vaccine) plus 4 alternates from Arm 1/Part 1 are given 53G S. sonnei
11539230|NCT01080716|Active Comparator|Part 2/Arm 2 of Study: S sonnei 53G|10 subjects (naïve controls) plus 4 alternates are give 53G S sonnei
11539231|NCT01080703|Experimental|Lower extremity strengthening|
11539232|NCT01080690|Active Comparator|EGD|In this arm EGD will be performed before EUS
11539233|NCT01080690|Active Comparator|EUS|In this arm, EUS will be performed before EGD.
11539234|NCT01080677|Placebo Comparator|Placebo|Participants will receive placebo to match caffeine/propranolol (single dose)
11539235|NCT01080677|Experimental|Low dose|Participants will receive caffeine/propranolol 400/40 mg combination tablet (single dose)
11539236|NCT01080677|Experimental|High dose|Participants will receive caffeine/propranolol 1000/40 mg combination tablet (single dose)
11539237|NCT01080664|Experimental|Regimen 1|Regimen 1: AS703569 administered on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
11539238|NCT01080664|Experimental|Regimen 2|Regimen 2: AS703569 administered on Days 1, 2, 3, 4, 5, 6 of a 21-day cycle
11539239|NCT01080651|Active Comparator|CYP2C19 extensive metabolizer|
11539240|NCT01080651|Active Comparator|CYP2C19 poor metabolizer|
11539241|NCT01080638|Experimental|Abciximab IC bolus|After CAG, For patients with undergoing percutaneous coronary intervention, intracoronary only or intravenous bolus abciximab(0.25mg/kg body weight) administration with intravenous bolus group has subsequent 12-hours continuous infusion at a dose 0.125ug/kg per minute (maximum: 10ug/min)
11539242|NCT01080638|Active Comparator|Abciximab IV bolus and 12hr continuous|
11539243|NCT01080625|Experimental|phenylephrine|100 mcg of phenylephrine is administered at the time of reperfusion
11539244|NCT01080625|Experimental|epinephrine|10 mcg of epinephrine is administered iv at the time of reperfusion
11539245|NCT01080625|Placebo Comparator|control|10 ml of normal saline is administered at the time of reperfusion
11539246|NCT01080612|Experimental|330 mg pregabalin controlled release: 400 to 500 calories|
11539247|NCT01080612|Experimental|330 mg pregabalin controlled release: 600 to 750 calories|
11539248|NCT01080612|Experimental|330 mg pregabalin controlled release: 800 to 1000 calories|
11539249|NCT01080612|Other|300 mg pregabalin immediate release|
11539250|NCT01080599|Experimental|conventional pubic approach|
11539251|NCT01080599|Experimental|inguinal approach|
11539252|NCT01080586|Active Comparator|NEORAL® Capsule 100 mg|
11539253|NCT01080586|Experimental|Cyclosporine 100 mg Capsule|
11539254|NCT01080560|Active Comparator|NEORAL® Capsule 100 mg|
11539255|NCT01080560|Experimental|Cyclosporine 100 mg Capsule|
11539256|NCT01080547|Active Comparator|Conventional Treatment （Laparoscopic）|Randomized group of patients receiving laparoscopic colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.
11539257|NCT01080547|Active Comparator|FTMD Treatment （Laparoscopic）|Randomized group of patients receiving laparoscopic colectomy with Fast Track Multi-Displine（FTMD）treatment and XELOX chemotherapy.
11539258|NCT01080547|Active Comparator|Conventional Treatment（Open Surgery）|Randomized group of patients receiving open colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.
11539259|NCT01080547|Active Comparator|FTMD Treatment（Open Surgery）|Randomized group of patients receiving open colectomy with Fast Track Multi-Displine（FTMD） treatment and XELOX chemotherapy.
11539260|NCT01080534|Active Comparator|Prograf® Capsule 5 mg|
11539261|NCT01080534|Experimental|Tacrolimus Capsule 5 mg|
11539262|NCT01080521||Observational (cognitive function during chemotherapy)|Patients receive standard chemotherapy. Treatment repeats for 6 courses. Patients complete neurocognitive evaluations (Patient Assessment and Own Functioning scale and HeadMinder Custom Research Tool) and quality-of-life assessments (Hospital Anxiety and Depression Scale, FACT-O, and FACT/GOG-Ntx subscale) at baseline, before the fourth course of chemotherapy, at 3 weeks after the sixth course of chemotherapy, and at 6 months after the sixth course of chemotherapy.
11539263|NCT01080508||10 Asa I & II patients|
11539264|NCT01080495|Other|TEE (transesophageal echcardiography)|all patients get TEE and all parameters (radial strain, fractional shortening and fractional area change) are evaluated
11539265|NCT01080482|Active Comparator|Prograf® Capsule 5 mg|
11539266|NCT01080482|Experimental|Tacrolimus Capsule 5 mg|
11539267|NCT01080469|Active Comparator|Prograf® Capsule 1 mg|
11539268|NCT01080469|Experimental|Tacrolimus Capsule 1 mg|
11539269|NCT01080456|Active Comparator|Prograf® Capsule 1 mg|
11539270|NCT01080456|Experimental|Tacrolimus Capsule 1 mg|
11539271|NCT01080443|Active Comparator|Cellcept® 250 mg Capsule|
11539272|NCT01080443|Experimental|Mycophenolate Mofetil Capsule 250 mg|
11539273|NCT01080417|Active Comparator|Cellcept® 250 mg Capsule|
11539274|NCT01080417|Experimental|Mycophenolate Mofetil Capsule 250 mg|
11539275|NCT01080404|Experimental|Bariatric surgery (overall study)|A prospective follow-up study is to estimate the prevalence of OSA and associated metabolic abnormalities in Finnish morbidly obese subjects and to evaluate the effects of bariatric surgery on OSA and associated metabolic abnormalities. The study is conducted in seven hospitals in Finland and 300 patients are planned to be recruited in the study.
11539276|NCT01080404|Experimental|Bariatric surgery (randomised substudy)|As a substudy of a larger trial, a randomized study on the effects of bariatric surgery compared to CPAP treatment will be performed in obese (BMI 35-45) patients with OSA. The included 100 (15/center) patients are randomised to two groups: surgical intervention group (50) and CPAP group (50). Patients in the surgical intervention group undergo standardised surgical treatment (laparoscopic gastric bypass), including general health information, such as avoidance of smoking, alcohol drinking, and importance of healthy nutrition and regular exercise. The CPAP group will be assigned to CPAP treatment and they also receive the general health information.
11539277|NCT01080404|Active Comparator|CPAP (randomised substudy)|As a substudy of a larger trial, a randomized study on the effects of bariatric surgery compared to CPAP treatment will be performed in obese (BMI 35-45) patients with OSA. The included 100 patients are randomised to two groups: surgical intervention group (50) and CPAP group (50). Patients in the surgical intervention group undergo standardised surgical treatment (laparoscopic gastric bypass), including general health information, such as avoidance of smoking, alcohol drinking, and importance of healthy nutrition and regular exercise. The CPAP group will be assigned to CPAP treatment and they also receive the general health information.
11539278|NCT01080391|Active Comparator|Lenalidomide and Dexamethasone (Rd)|Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on days 1 to 21 and dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22.
11539279|NCT01080391|Experimental|Carfilzomib, Lenalidomide, and Dexamethasone (CRd)|Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m² was administered intravenously (IV) on days 1 and 2 of cycle 1, escalating to 27 mg/m² on days 8, 9, 15, and 16 of cycle 1 and continuing on days 1, 2, 8, 9, 15, and 16 of cycle 2 through cycle 12 and then from cycle 13 through cycle 18, 27 mg/m² on days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on days 1 to 21 from cycle 1 through cycle 18 and from cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22 from cycle 1 through cycle 18 and from cycle 19 and higher.
11539280|NCT01080378|Other|Higher Birth Weight|3447g to 3879g
11539281|NCT01080378|Other|Lower Birth Weight|2624g to 2964g
11539282|NCT01080378|Other|Normal Birth Weight|2965g to 3446g
11539283|NCT01080365|Experimental|1|Commercial Tablet
11539284|NCT01080365|Experimental|2|Clinical Tablet
11539285|NCT01080352|Experimental|Vitamin C treatment|"Each subjects receive 12 weeks of 1 weekly treatment with intravenous vitamin c.
~5grams are given at week 1, 30 grams at week 2 and 60 grams at week 3-12. If eligibility criteria are met the subject may continue with 1 weekly vitamin c treatment of 60 grams at week 13-20."
11539286|NCT01080339||Physical Activity and Nutrition|Supervised physical activity in the form of novel gaming and exercise equipment several times per week for 12 weeks will be provided in addition to weekly nutrition education sessions.
11539287|NCT01080339||Nutrition Education Only|Children in this group will receive weekly group nutrition sessions, identical to those provided for the Physical Activity + Nutrition group
11539288|NCT01080326|Experimental|Endoscopic Translumenal Omental Patch|Patients with the clinical diagnosis of a perforated viscus who are scheduled to undergo surgical exploration will be recruited. The endoscope will be gently advanced through the ulcer. Irrigation with saline will proceed. Then a viable mobile piece of omentum will be identified and pulled into the ulcer. After the omentum is located in the stomach, clips will be used to fix the Endoscopic Translumenal Omental Patch in place.
11539289|NCT01080313||Patients with head and neck cancer|
11539290|NCT01080300|Experimental|Gabapentin Extended Release|Active treatment
11539291|NCT01080300|Other|Placebo|Placebo
11539292|NCT01080287||Migraineurs with & w/out auras having orthostatic intolerance|Subjects between ages 18 and 65, having ICHD-II classification of migraine with or without aura, having symptoms of orthostatic intolerance
11539293|NCT01080287||Migraineurs with or without auras|Subjects between ages 18 and 65 having ICHD-II classification of migraine with or without auras
11539294|NCT01080274||positive ergometry|positive ergometry as specified by a cardiologist on site.
11539295|NCT01080274||negative ergometry.|negative ergometry as specified by cardiologist on site.
11539296|NCT01080274||patients with positive stress test|100 patients with positive ergometry test as specified by the cardiologist in charge. All patients are ambulatory patients referred for routine check up.
11539297|NCT01080261|Experimental|PROMUS Element|everolimus-eluting coronary stent
11539370|NCT01079754|Active Comparator|Spinal morphine 0.1 mg|Patient received spinal morphine 0.1 mg
11539298|NCT01080248|Experimental|Arm 1 (gemcitabine & pazopanib)|"Gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle.
~Pazopanib 800 mg PO daily of each 28 day cycle."
11539299|NCT01080235|Active Comparator|1|Control. Forty-two residency programs randomly assigned and stratified according to size, affiliation, geographic location, and presence of geriatrics fellowship. Twenty-one in the control arm. This group will use PIM as a data collection tool during baseline and follow-up time (i.e. audit of 50-75 charts, survey from 50-75 patients, and one system survey). They will not see the summary results of the data collected; they will not be required to complete a quality improvement plan based on the summary data. Local researchers will collect the data. Individual trainees will not do data collection or audits. At both baseline and follow-up, trainees will complete pre and post test surveys of 1) geriatric and 2) quality improvement knowledge, skills, and attitudes.
11539300|NCT01080235|Other|2|There are 21 residency programs in intervention arm who will 1) use PIM as a data collection tool (local researchers will audit 50-75 charts, survey 50-75 patients, and complete one system survey); 2) Each trainee will audit of up to five patient charts; collect 5 patient surveys; and complete the system survey as a group; 3) Summary data from these data streams will be reviewed by group; then they will design and implement a quality improvement plan; 4) At follow-up, local researchers will re-audit same 50-75 charts, collect surveys from same 50-75 patients, and complete one system survey. At baseline and follow-up, trainees and faculty will complete surveys of geriatric and quality improvement knowledge, skills, and attitudes.
11539301|NCT01080222|Experimental|Treatment Arm A|Treatment Arm A was discontinued as a result of patients meeting a pre-defined stopping rule related to viral breakthrough during the first four weeks of dosing.
11539302|NCT01080222|Experimental|Treatment Arm B|Treatment Arm B was discontinued as a result of patients meeting a pre-defined stopping rule relating to viral breakthrough.
11539303|NCT01080222|Experimental|Treatment Arm C|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.
~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 12 weeks for a total treatment duration of 24 weeks.
~Enrollment for this arm is complete. No additional subjects will be recruited."
11539304|NCT01080222|Experimental|Treatment Arm D|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.
~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 12 weeks for a total treatment duration of 24 weeks.
~Enrollment for this arm is complete. No additional subjects will be recruited."
11539305|NCT01080222|Experimental|Treatment Arm E|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.
~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 24 weeks for a total treatment duration of 36 weeks."
11539306|NCT01080222|Experimental|Treatment Arm F|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.
~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 24 weeks for a total treatment duration of 36 weeks."
11539307|NCT01080209|Experimental|Brimo PS DDS® 400 μg (2 implants)|Patients who received Brimo PS DDS® 400 μg (2 implants) in a previous study.
11539308|NCT01080209|Experimental|Brimo PS DDS® 400 μg (1 implant)|Patients who received Brimo PS DDS® 400 μg (1 implant) in a previous study.
11539309|NCT01080209|Experimental|Brimo PS DDS® 200 μg (2 implants)|Patients who received Brimo PS DDS® 200 μg (2 implants) in a previous study.
11539310|NCT01080209|Experimental|Brimo PS DDS® 200 μg (1 implant)|Patients who received Brimo PS DDS® 200 μg (1 implant) in a previous study.
11539311|NCT01080209|Experimental|Brimo PS DDS® 100 μg (1 implant)|Patients who received Brimo PS DDS® 100 μg (1 implant) in a previous study.
11539312|NCT01080209|Experimental|Brimo PS DDS® 50 μg (1 implant)|Patients who received Brimo PS DDS® 50 μg (1 implant) in a previous study.
11539313|NCT01080209|Sham Comparator|Sham|Patients who received sham in a previous study.
11539314|NCT01080196|Experimental|RENEW|"RENEW will occur on a recumbent ergometer that appears like a normal stepper ergometer. While resisting the foot pedal movement the participant experiences eccentric muscle contractions about the knee and hip while performing negative work. The progression of the 3 x/week (every other day), 12 week RENEW program will be determined as a function of the rating of perceived exertion (RPE) using a target workload on the monitor. RENEW will be increased very slowly over the first 3 weeks and, subsequently, to maintain an 11-13 perceived exertion. During the formal RENEW training regimen the participants become fully acclimated to the device (week 3-4) the total RENEW load will increase weekly with no increase in their RPE."
11539315|NCT01080196|No Intervention|TRADITIONAL|"The TRAD group will perform their lower extremity resistance exercise for 15 minutes per session with isotonic weight machines and cuff weights as part of their multicomponent exercise fall reduction program (MCERFP). The progression of the 3 x/week, 12 week TRAD program will be determined as a relative function of their 1 repetition maximum (1RM) weight that can be lifted in a safe and successful manner. The 1RM will be measured before the 12 week training program and every 2 weeks thereafter. A target resistance workload (i.e., weight level) commensurate with 60-70% of the 1RM of the knee and hip extensors will be calculated bi-monthly and 3 sets of 15 repetitions of 3-4 different knee and hip exercises will be used over a 15 minute time period."
11539316|NCT01080183|Experimental|Feedback form|patients receive feedback regarding their prms in addition to doctor receiving report
11539317|NCT01080183|No Intervention|usual care|patients do not receive feedback form prior to the encounter, clinicians continue to receive patient reported measures prior to the appointment
11539318|NCT01080170||Anastrazole|Newly diagnosed, non-metastatic, hormone-receptor positive breast cancer patients, who have undergone lumpectomy, have been advised to not require chemotherapy, but will need to undergo radiation therapy and will be initiating therapy with anastrazole.
11539319|NCT01080170||Control group - 2|Healthy controls.
11539320|NCT01080157||Volunteers 18+, at risk for diabetes|
11539321|NCT01080144|Experimental|Critical Flicker Frequency|Critical Flicker Frequency Procedure
11539367|NCT01079780|Experimental|Arm II|Patients receive ramucirumab IV over 60 minutes on day 1 and cetuximab and irinotecan hydrochloride as in arm I.
11539368|NCT01079767|Other|Temsirolimus|Temsirolimus
11539369|NCT01079754|Experimental|Spinal morphine 0.05 mg|Patient received spinal morphine 0.05 mg
11539322|NCT01080131|Experimental|Canakinumab 150 mg|"Participants received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Participants completing the 12 week core study could continue to be treated in a 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.
~In the second extension study participants were to receive open-label on demand treatment with canakinumab 150 mg sc upon new flare for 1 year, for a total duration of 18 months."
11539323|NCT01080131|Active Comparator|Triamcinolone acetonide 40 mg|"Participants received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Participants completing the 12 week core study could continue to be treated in a 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.
~In the second extension study participants were to switch to open-label on demand treatment with canakinumab 150 mg sc upon new flare for 1 year. Triamcinolone acetonide was not to be administered in the second extension study."
11539324|NCT01080118|Other|control group|Control group, taught with a standard Macintosh laryngoscope
11539325|NCT01080118|Experimental|Study group|Study group taught with the Airtraq video laryngoscope
11539326|NCT01080105|Experimental|AIM + surveillance|Participants will receive access to the AIM website and calls from a motivational coach for 12 weeks plus an additional year of surveillance and optional coach support.
11539327|NCT01080105|Experimental|AIM intervention|Participants will receive access to the AIM web based intervention and calls from a motivational coach for 12 weeks
11539328|NCT01080105|Active Comparator|Educational website|Participants will be given access to a static website with depression prevention related materials and handouts.
11539329|NCT01080092|Experimental|breathing technique group|technique as a stress management technique, reinforced by biofeedback
11539330|NCT01080092|Placebo Comparator|no breathing technique|the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
11539331|NCT01080079|Active Comparator|Group A -Terbinafine HCl|Terbinafine HCl
11539332|NCT01080079|Active Comparator|Group B - Terbinafine HCl|Terbinafine HCl
11539333|NCT01080079|Active Comparator|Group C - Terbinafine HCl|Terbinafine HCl
11539334|NCT01080079|Active Comparator|Group D Terbinafine HCl|Terbinafine HCl
11539335|NCT01080079|Active Comparator|Group E|Terbinafine HCl
11539336|NCT01080079|Placebo Comparator|Group F - Placebo|Placebo application
11539337|NCT01080066||Non-Interventional Study|
11539338|NCT01079988|Experimental|Cyclosporin|Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
11539339|NCT01079988|Experimental|Retinoids|Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
11539340|NCT01079988|Experimental|Systemic corticosteroids|Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
11539341|NCT01079988|Experimental|Methotrexate|Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
11539342|NCT01079988|Experimental|Systemic corticosteroids/methotrexate|"Corticosteroid starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%.
~Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks."
11539343|NCT01079962|Experimental|Bisoprolol|
11539344|NCT01079962|Active Comparator|Atenolol|
11539345|NCT01079949|Experimental|r-hLH + r-hFSH|
11539346|NCT01079949|Active Comparator|r-hFSH|
11539347|NCT01079936|Experimental|Lenalidomide + High-Dose Melphalan|Lenalidomide beginning dose level 25 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.
11539348|NCT01079923|Active Comparator|Single High Dose Supplementation|Age 18 to 40 years, non-pregnant, non-lactating, female subjects .
11539349|NCT01079923|Active Comparator|Daily Dose Supplementation|Age 18 to 40 years, non-pregnant, non-lactating, female subjects.
11539350|NCT01079910|Experimental|Experimental toothpaste|0.1% isopropylmethylphenol and 1150ppm fluoride
11539351|NCT01079910|Other|Marketed toothpaste|NaF/Silica toothpaste containing 1150ppm fluoride
11539352|NCT01079897|Active Comparator|Atopiclair|
11539353|NCT01079897|Experimental|EHK02-01|Ectoine containing cream
11539354|NCT01079871|Experimental|FID 114657 (ORB Preserved Ocular Emulsion)|ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
11539355|NCT01079858|Experimental|FID 114657 (ORB Preserved Ocular Emulsion)|ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
11539356|NCT01079845|Experimental|Low-glycemic Load Diet|
11539357|NCT01079845|Active Comparator|Low-fat Diet|
11539358|NCT01079832|Experimental|Arm I: CyberKnife Radiosurgery|Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.
11539359|NCT01079819|Active Comparator|A1 (BMS-708163)|
11539360|NCT01079819|Placebo Comparator|A2 (Placebo)|
11539361|NCT01079819|Active Comparator|B1 (BMS-708163)|
11539362|NCT01079819|Placebo Comparator|B2 (Placebo)|
11539363|NCT01079806|Active Comparator|Entecavir|Participants received entecavir, 0.015 mg/kg up to 0.5 mg, once daily, for 96 to 144 weeks, depending on response
11539364|NCT01079806|Placebo Comparator|Placebo|Participants received placebo, 0 mg, once daily, for 48 to 96 weeks, depending on response
11539365|NCT01079793|Experimental|ixabepilone|Adjuvant therapy
11539366|NCT01079780|Experimental|Arm I|Patients receive cetuximab IV over 60-120 minutes and irinotecan hydrochloride over 60-90 minutes on day 1.
11539670|NCT01077349|Experimental|high volume hemofiltration|
11539371|NCT01079741|Experimental|Dose-escalation component|Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen and Montanide will be held constant.
11539372|NCT01079741|Active Comparator|Phase II is the randomized component.|The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B).
11539373|NCT01079728||ischemic stroke patients|patients with an ischemic stroke in the anterior (ACA, MCA) and posterior flow area (PCA, BA) of any severity in the last 36h
11539374|NCT01079715|Experimental|Propranolol|Oral Propranolol administration is the experimental arm of this study
11539375|NCT01079715|No Intervention|Control|Control arm is treated following the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group
11539376|NCT01079676|Experimental|Filgrastim|
11539377|NCT01079676|Active Comparator|Granulokine|
11539378|NCT01079663|Experimental|Chlorhexidine chip (Periochip®)|
11539379|NCT01079663|Placebo Comparator|Placebo chip|
11539380|NCT01079650||children suffering from abdominal or testicle pain|
11539381|NCT01079637|Experimental|Midfoot Fusion Bolt|
11539382|NCT01079637|Experimental|Cast treatment|
11539383|NCT01079624|Experimental|GIP two doses and GLP-1 one dose|Intervention with infusion of GIP or GLP-1 intravenously
11539384|NCT01079624|Placebo Comparator|Saline infusion|Control
11539385|NCT01079598|Other|Treatment|RF ablation with ClosureRFS Stylet
11539386|NCT01079572|Experimental|web-based|The patient will undergo xrays at the closest PACs enabled imaging centre and will login and answer questions online. The surgeon will review the images and patient responses and determine whether the patient needs to be seen more urgently or a per routine.
11539387|NCT01079572|Active Comparator|in-person|Patients will attend their follow-up appointments in-person as per usual
11539388|NCT01079559|Active Comparator|Simplex™ P|All patients will receive preoperative antibiotics administered within the hour prior to surgery. All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
11539389|NCT01079559|Experimental|Simplex™ P with Tobramycin|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
11539390|NCT01079546||Sq.CC of head and neck TASMC|
11539391|NCT01079546||hadassa Jerusalem|
11539392|NCT01079546||sheba hospital|
11539393|NCT01079546||rambam Haifa|
11539394|NCT01079546||belinson Petah Tikva|
11539395|NCT01079546||Nazeret|
11539396|NCT01079546||soroka beer sheva|
11539397|NCT01079533|Active Comparator|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
11539398|NCT01079533|Experimental|Minimal Cue and TLC|Participants randomized to the experimental arm will receive a minimal cue after completing the baseline survey. A follow up survey will be sent 9 months after completion of the minimal cue to assess whether the participant received CRCS. If the participant has not had CRCS they will receive a more intensive telephone linked communication intervention. A second follow up will be sent 9 months after the TLC is delivered to assess final screening status.
11539399|NCT01079507||adult acute lymphoblastic leukemia|Patients were diagnosed as adult acute lymphoblastic leukemia.
11539400|NCT01079494|Active Comparator|intervention group|physician-pharmacist teamwork
11539401|NCT01079494|No Intervention|control|physician only team
11539402|NCT01079481|Experimental|taxol plus everolimus|
11539403|NCT01079468||Total Hip Arthroplasty|
11539404|NCT01079468||Total Hip Resurfacing Arthroplasty|
11539405|NCT01079455|Active Comparator|HA|Coxarthrosis
11539406|NCT01079455|Active Comparator|Corticosterone|Coxarthrosis
11539407|NCT01079455|Placebo Comparator|Bupivacaine|Coxarthrosis
11539408|NCT01079442|Active Comparator|Treatment arm: coffee|coffee administration
11539409|NCT01079442|Placebo Comparator|Water arm|The control drink consists of 100 ml warm water
11539410|NCT01079429||MGUS or SMM|Patients with Monoclonal gammopathy of undetermined significance or smoldering myeloma
11539411|NCT01079416||Capsule endoscopy|Study device
11539412|NCT01079416||Esophagogastroduodenoscopy|Gold standard
11539413|NCT01079390|Experimental|High dose acupuncture|six needle applied during acupuncture
11539414|NCT01079390|Experimental|Low dose acupuncture|two needles will be applied.
11539415|NCT01079390|Placebo Comparator|placebo acupuncture|sham acupuncture treatment will be applied
11539416|NCT01079377||Adolescent Surgical Candidates|Adolescents at the Center for Adolescent Bariatric Surgery, Columbia University Medical Center
11539417|NCT01079377||Obese Treatment-Seeking Adolescents|Obese Treatment-Seeking Adolescents, Maxcor Program for Overweight Education and Reduction (POWER) Program
11539418|NCT01079377||Normal-Weight Adolescents|Normal-Weight Adolescents
11539671|NCT01077349|Active Comparator|standard care|
11539419|NCT01079364|Experimental|Insulin glargine + Insulin glulisine|Daily injection of insulin glargine plus one injection of mealtime insulin glulisine at the main meal
11539420|NCT01079364|Active Comparator|Premixed insulin|twice daily premixed insulin (before breakfast and evening meal).
11539421|NCT01079338|Experimental|caffeine|
11539422|NCT01079325|Experimental|SB-509|
11539423|NCT01079325|Placebo Comparator|Placebo|Saline
11539424|NCT01079312|Active Comparator|Propofol infusion|Anaesthesiologist's managed intravenous infusion of propofol 10mg/ml
11539425|NCT01079312|Active Comparator|Patient-controlled sedation|self-administration of propofol and remifentanil mixture during ERCP
11539426|NCT01079299|Experimental|IPC plus standard compression|
11539427|NCT01079299|Active Comparator|Standard compression alone|
11539428|NCT01079286|Experimental|nelfinavir and temsirolimus|dose escalation
11539429|NCT01079273|Active Comparator|Vaccine|All Subjects enrolled in this study will receive the study vaccine (single-arm)
11539430|NCT01079260|Active Comparator|Standard ONS|
11539431|NCT01079260|Experimental|High Energy, Low volume ONS|High energy, low volume ONS
11539432|NCT01079247|Active Comparator|Liberal|Maintain hemoglobin at 10-11 g/dL
11539433|NCT01079247|Active Comparator|Restrictive|Maintain hemoglobin at 7-8 g/dL
11539434|NCT01079234|Experimental|Flex + insulin aspart|
11539435|NCT01079234|Experimental|Fixed + insulin aspart|
11539436|NCT01079234|Active Comparator|IGlar + insulin aspart|
11539437|NCT01079221|Experimental|Knee extensor exercise training|High intensity aerobic knee-extensor exercise training
11539438|NCT01079208|Placebo Comparator|standard starter infant formula|standard starter infant formula
11539439|NCT01079208|Experimental|test starter formula|test infant formula
11539440|NCT01079208|Experimental|test starter formula with synbiotics|starter formula with synbiotics and adapted protein levels
11539441|NCT01079195||Single Patient group with Hypertension|Single Patient group with Hypertension
11539442|NCT01079182||Ankylosing spondylitis|Participants with ankylosing spondylitis
11539443|NCT01079169|Experimental|Cranberry capsule|
11539444|NCT01079169|Placebo Comparator|Placebo capsule|
11539445|NCT01079143|Experimental|Certican EMT+|Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®.
11539446|NCT01079143|Experimental|Certican EMT-|Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®.
11539447|NCT01079143|Active Comparator|Neoral EMT+|Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®.
11539448|NCT01079143|Active Comparator|Neoral EMT-|Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®.
11539449|NCT01079130|Experimental|Indacaterol 18.75 µg|"Indacaterol 18.75 µg once daily in the morning via Concept1, a single-dose dry powder inhaler (SDDPI) and Placebo to Salmeterol in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI) for 2 weeks.
~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
11539450|NCT01079130|Experimental|Indacaterol 37.5 µg|"Indacaterol 37.5 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.
~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
11539451|NCT01079130|Experimental|Indacaterol 75 µg|"Indacaterol 75 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.
~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
11539452|NCT01079130|Experimental|Indacaterol 150 µg|"Indacaterol 150 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, MDDPI for 2 weeks.
~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
11539453|NCT01079130|Active Comparator|Salmeterol|"Salmeterol 50 µg twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI) and Placebo to Indacaterol once daily in the morning via Concept1, a SDDPI for 2 weeks.
~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
11539454|NCT01079130|Placebo Comparator|Placebo|"Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.
~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
11539455|NCT01079117|Active Comparator|Sevre-Long™|slow release oral morphine
11539456|NCT01079117|Active Comparator|Methadone|Methodone
11539457|NCT01079104|Active Comparator|Control|Standard Medical Therapy
11539458|NCT01079104|Experimental|Hepa Wash|"Treatment with the liver support system Hepa Wash"
11539459|NCT01079091|Experimental|ADVOS (Hepa Wash)|"Treatment with the liver support system Hepa Wash"
11539460|NCT01079078|Experimental|Test|Acetaminophen extended release gelcaps 650 mg of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
11539461|NCT01079078|Active Comparator|Reference|Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)of McNeil Consumer & Specialty Pharmaceuticals, Division of MCNEIL-PPC, Inc. Fort Washington, PA 19034 USA
11539462|NCT01079065|Experimental|Test|Famotidine Tablets, USP 20 mg of OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
11539463|NCT01079065|Active Comparator|Reference|Pepcid® AC Acid reducer famotidine tablets 20 mg of Johnson & Johnson. Merck Consumer Pharmaceutical Co. Fort Washington, PA 19034 USA
11539464|NCT01079052|Experimental|Test|Famotidine Tablets, USP 20 mg of OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
11539465|NCT01079052|Active Comparator|Reference|Pepcid® AC Acid reducer famotidine tablets 20 mg of Johnson & Johnson. Merck Consumer Pharmaceutical Co. Fort Washington, PA 19034 USA
11539466|NCT01079013|Experimental|treosulfan|
11539467|NCT01079000|Active Comparator|Control - usual care (UC)|Usual care after an ED visit for asthma will include the provision of discharge instructions/plan, and action plan, and verbal instructions for follow-up with their PCP, and a faxed copy of the ED chart to the patient's PCP.
11539468|NCT01079000|Experimental|Opinion leader (OL) guidance to patients' PCPs|In addition to UC, OL guidance will be provided to the patients' PCP. A letter signed by an influential, respected, and local clinical leader (Respirologist) will encourage follow-up within two weeks and provide management suggestions.
11539469|NCT01079000|Experimental|Care manager education to patients|In addition to UC and OL guidance provided to the patients' PCP, care manager self-management education will be provided to patients. A care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged.
11539470|NCT01078987|Active Comparator|Group 1|One to three 5-day course of plasma exchange (plasmapheresis)
11539471|NCT01078987|Active Comparator|Group 2|One to three 5-day course of plasma exchange (plasmapheresis)
11539472|NCT01078987|No Intervention|Group 3|No intervention taken
11539473|NCT01078987|Active Comparator|Group 4|One to three 5-day course of plasma exchange (plasmapheresis)
11539474|NCT01078974|Experimental|pomalidomide, dexamethasone, rituximab|"Drug: pomalidomide Taken orally once a day
~Drug: dexamethasone Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
~Drug: rituximab Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15"
11539475|NCT01078961|Experimental|Dose Escalation|
11539476|NCT01078948|Experimental|Active 2mA tDCS|The stimulator will be used to deliver anodal stimulation to the left prefrontal cortex and cathodal stimulation to the right prefrontal cortex. The placement of the anode is proposed to enhance activity in the left frontal cortex; the cathode aims to reduce activity in the right prefrontal cortex.
11539477|NCT01078948|Sham Comparator|Sham tDCS|The system setup is identical to that of active tDCS; however, the stimulator will be turned off after 30 seconds.
11539478|NCT01078922|Experimental|Ofatumumab|The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
11539479|NCT01078909|Experimental|300mg Fish Oil (EPA + DHA) Supplement|
11539480|NCT01078909|Experimental|600mg Fish Oil (EPA+DHA) Supplement|
11539481|NCT01078909|Experimental|900mg Fish Oil (EPA + DHA) Supplement|
11539482|NCT01078909|Experimental|1800mg Fish Oil (EPA + DHA) Supplement|
11539483|NCT01078909|Placebo Comparator|Placebo|
11539484|NCT01078883||Lung cancer|Patients with primary stage IIIb and IV lung cancer
11539485|NCT01078870|Experimental|A|
11539486|NCT01078870|Experimental|B|
11539487|NCT01078870|Experimental|C|
11539488|NCT01078844|Placebo Comparator|Placebo|Treatment as usual plus placebo
11539489|NCT01078844|Active Comparator|memantine|Treatment as usual plus memantine
11539490|NCT01078831||ARDS / ALI patients|
11539491|NCT01078818|Experimental|IV trivalent saccharose hydroxide ferrous|
11539492|NCT01078818|Active Comparator|Oral ferrous fumarate|
11539493|NCT01078818|Placebo Comparator|Oral and intravenous Placebo|
11539494|NCT01078805||FORTEO (teriparatide)-treated|FORTEO-treated
11539495|NCT01078792||COPD exacerbation|Patients admitted to hospital with COPD exacerbation
11539496|NCT01078779|Experimental|Chloroquine|
11539497|NCT01078779|Placebo Comparator|Placebo|
11539498|NCT01078766|Experimental|CIMT+HABIT|"Form of summer camp, for six hours per day for 10 consecutive work days."
11539499|NCT01078753|Experimental|Desmopressin|During treatment period I participants received 120 μg per day desmopressin oral lyophilisate tablet for 14 days. Participants for whom treatment was effective (a reduction of ≥ 75% from Baseline in the number of wet nights), and who showed no problems with tolerability, continued to receive the same treatment for a further 14 days in treatment period II. Participants for whom efficacy was inadequate (a reduction of <75% from Baseline in the number of wet nights), but who showed no tolerability problems, received an increased dose of desmopressin oral lyophilisate tablet 240 µg for 14 days in treatment period II.
11539500|NCT01078753|Placebo Comparator|Placebo|Participants received matching placebo tablets during treatment periods I and II according to the same efficacy criteria as participants in the Desmopressin treatment group.
11539501|NCT01078740||Non-CF subjects|Rectal tissue obtained from study subjects without cystic fibrosis (CF) as part of scheduled colonoscopy/biopsies performed for clinical care
11539502|NCT01078740||CF subjects|"Rectal tissue obtained from study subjects with cystic fibrosis (CF) in one of three ways:
~Rectal biopsy as part of scheduled colonoscopy/biopsies performed for clinical care
~Sigmoidoscopy/biopsy added onto a scheduled, unrelated procedure or surgery performed under general anesthesia
~Sigmoidoscopy/biopsy performed for the sole purpose of obtaining rectal tissue for the current study"
11539503|NCT01078714|Experimental|Bumetanide|
11539504|NCT01078714|Placebo Comparator|Control|
11539505|NCT01078701|Experimental|GHB11L1|Dose levels: 6.0 log10 TCID50/volunteer, 6.5 log10 TCID50/volunteer and 7.0 log10 TCID50/volunteer
11539506|NCT01078701|Placebo Comparator|SPGN buffer|SPGN buffer administration by liquid nasal spray
11539507|NCT01078675|Experimental|1|
11539508|NCT01078662|Experimental|1|olaparib 400mg BD
11539509|NCT01078649|Experimental|Debio 1143 (AT-406)|Open label study. All patients participating in the study will receive Debio 1143 (AT-406).
11539510|NCT01078636||EMCI (only cohort recruiting in this study)|Newly recruited early amnestic Mild Cognitive Impairment patients; estimated enrollment 200
11539672|NCT01077336||Hospitalized patients with candidemia|
11539673|NCT01077323||Exenatide Initiators|
11539511|NCT01078636||LMCI (not recruiting in this study)|Late Mild Cognitive Impairment patients; approximately 400 LMCI participants anticipated to follow from the original ADNI study
11539512|NCT01078636||CN (not recruiting in this study)|Cognitively Normal patients; approximately 200 CN participants anticipated to follow from the original ADNI study
11539513|NCT01078623|Active Comparator|Formoterol 12 μg|Formoterol fumarate 12 μg twice daily
11539514|NCT01078623|Placebo Comparator|Placebo|Placebo twice daily
11539515|NCT01078623|Experimental|Aclidinium 200 μg / formoterol 12 μg|Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
11539516|NCT01078623|Experimental|Aclidinium 200 μg / formoterol 6 μg|Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
11539517|NCT01078623|Experimental|Aclidinium 200 μg|Aclidinium bromide 200 μg twice daily
11539518|NCT01078610||Psoriatic arthritis patients|
11539519|NCT01078597||Patients with early Rheumatoid Arthritis|Patients , aged 18 years or over, diagnosed with Rheumatoid Arthritis, with evidence of disease activity within the last year.
11539520|NCT01078584||Hypertensive Participants|Hypertensive diabetics and non-diabetics, with or without isolated systemic hypertension and/or renal dysfunction, who were naïve to trandolapril or on trandolapril within past 30 days.
11539521|NCT01078571||RA patients in treatment with adalimumab (Humira)|RA patients in treatment with adalimumab (Humira) at 40mg alternate weeks
11539522|NCT01078558||Patients with rheumatic disease|Patients suffering from rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
11539523|NCT01078545||Adv. PCa patients with LUTS treated with GnRH analogue|Patients with advanced prostate cancer and lower urinary tract symptoms treated with GnRH analogue Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine)
11539524|NCT01078532|Experimental|SMART PHR|Patients receive the active PHR
11539525|NCT01078532|Other|Passive PHR|Usual PHR Care
11539526|NCT01078519|No Intervention|Massages baths|doulas, massages and baths
11539527|NCT01078519|Active Comparator|Combined spinal-epidural anesthesia|local anesthetics in low doses with opioids
11539528|NCT01078506||Hong Kong Chinese|Without a history of known intracranial pathologies.
11539529|NCT01078480|Experimental|Arm sling treatment|Displaced midshaft fracture of the collar bone treated with an arm sling
11539530|NCT01078480|Experimental|Operation|Displaced midshaft fracture of the collar bone treated with operation using a pre contoured titanium plate and screws.
11539531|NCT01078454|Experimental|ARM A (Mel-Dex)|Patients receive melphalan 0.22 mg/kg orally (PO) and dexamethasone 40 mg PO on days 1-4 every 4 weeks. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
11539532|NCT01078454|Experimental|ARM B (B-Mel-Dex)|Patients receive melphalan 0.22 mg/kg PO and dexamethasone 40 mg PO on days 1-4 and bortezomib 1.3 mg/m^2 intravenously (IV) on days 1, 4, 8, and 11 every 4 weeks. Treatment repeats every 4 weeks for 2 cycles. Patients then receive melphalan PO and dexamethasone PO on days 1-4 and bortezomib IV on days 1, 8, 15, and 22 every 5 weeks. Treatment repeats every 5 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
11539533|NCT01078441|Experimental|Treatment (combination chemotherapy)|Patients receive bortezomib 1.3 mg/m2 subcutaneously on days 1, 8, and 15; liposomal doxorubicin 30 mg/m2 intravenously (IV) over 1 hour on day 4; oral dexamethasone 20mg on days 1, 2, 8, 9, 15 and 16; and cyclophosphamide 750 mg/m2 IV over 2 hours on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11539534|NCT01078428|Active Comparator|Silicone gel|Gel containing silicone gel
11539535|NCT01078428|Placebo Comparator|Vaseline|Gel containing petrolatum gel
11539536|NCT01078402||Single patients group: RA, PsA and AS|Single patients group with: Active Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS)
11539537|NCT01078389|Experimental|Febuxostat 40 mg or 80 mg|Febuxostat 40 mg or 80 mg (based on serum urate levels at Day 14), capsules, orally, once daily for up to 24 Months.
11539538|NCT01078389|Placebo Comparator|Placebo|Febuxostat placebo-matching capsules, orally, once daily for up to 24 Months.
11539539|NCT01078376|Experimental|Cohort 1: Healthy Adults (18 years to 45 years old)|Azilsartan medoxomil 80 mg, tablets, orally, one day only
11539540|NCT01078376|Experimental|Cohort 1: Adolescents (≥12 to <17 years old)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
11539541|NCT01078376|Experimental|Cohort 2: Children (≥6 to <12 years old)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
11539542|NCT01078376|Experimental|Cohort 3: Children (≥1 to <6 years old)|Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
11539543|NCT01078363|Active Comparator|ramipril|ramipril, 5mg starting dose to maximum dose of 20mg daily dose for one year.
11539544|NCT01078363|Placebo Comparator|Placebo|Sugar pill manufactured to mimic ramipril 5mg starting dose , increasing to 20mg daily for one year.
11539545|NCT01078324||Ischemic colitis|Ischemic colitis, Diverticulosis
11539546|NCT01078311||HCC patients on Sorafenib|
11539547|NCT01078298|Experimental|varenicline|
11539548|NCT01078298|Placebo Comparator|placebo|placebo
11539549|NCT01078285||Control|
11539550|NCT01078285||Intervention Arm|
11539551|NCT01078272|Experimental|Remote Ischemic Preconditioning (RIPC)|Randomized subjects who are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
11539552|NCT01078272|Placebo Comparator|Sham Remote Ischemic Preconditioning|Patients who prior to stenting have the RIPC blood pressure cuff placed but not inflated for 3 5 minute episodes with 5 minute rest periods.
11539553|NCT01078246||Raltegravir Cohort Only|Participants with HIV-1 infection who received raltegravir (RAL) on or after 12 October 2007 (the market authorization date in the United States) (Raltegravir Cohort). These participants contributed data to the Raltegravir Cohort only.
11539554|NCT01078246||Historical and Raltegravir Cohorts Only|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), and 2) received RAL on or after 12 October 2007 (Raltegravir Cohort). These participants contributed data to the Historical and Raltegravir Cohorts only.
11539555|NCT01078246||Historical Cohort Only|Participants with HIV-1 infection who received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort). These participants contributed data to the Historical Cohort only.
11539556|NCT01078246||Historical and Concurrent Cohorts Only|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), and 2) received therapy with a new non-RAL antiretroviral therapy after 12 October 2007 (Concurrent Cohort). These participants contributed data to the Historical and Concurrent Cohorts only.
11539557|NCT01078246||Concurrent Cohort Only|Participants with HIV-1 infection who received therapy with a new non-RAL antiretroviral therapy after 12 October 2007 (Concurrent Cohort). These participants contributed data to the Concurrent Cohort only.
11539558|NCT01078246||Concurrent and Raltegravir Cohorts Only|Participants with HIV-1 infection who 1) received therapy with a new non-RAL antiretroviral therapy on or after 12 October 2007 (Concurrent Cohort), and 2) received RAL after 12 October 2007 (Raltegravir Cohort). These participants contributed data to the Concurrent and Raltegravir Cohorts only.
11539559|NCT01078246||Historical, Concurrent and Raltegravir Cohorts|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), 2) received therapy with a new non-RAL antiretroviral therapy on or after 12 October 2007 (Concurrent Cohort), and 3) received RAL after 12 October 2007 (Raltegravir Cohort). These participants contributed data to all three cohorts.
11539560|NCT01078233||Raltegravir Cohort|Participants with HIV-1 infection who started raltegravir on or after 21 December 2007 (the authorization date in the European Union) and had at least 1 month prospective follow-up in the Raltegravir Cohort. Participants from the Historical Cohort and Concurrent Cohort were eligible for inclusion in the Raltegravir Cohort.
11539561|NCT01078233||Historical Cohort|Participants with HIV-1 infection who started a new antiretroviral drug as part of a combination antiretroviral therapy (cART) regimen on or after 1 January 2006 and before 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Historical Cohort.
11539562|NCT01078233||Concurrent Cohort|Participants with HIV-1 infection who started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. Participants from the Historical Cohort were eligible for inclusion in the Concurrent Cohort.
11539563|NCT01078220||3-Dose Safety Population (Primary)|Females between ages 9 to 26 at receipt of the first dose of GARDASIL who are members of the participating MCOs and have completed the 3-dose regimen of GARDSIL vaccination with 12 months.
11539564|NCT01078220||Pregnancy Safety Population|Females who received at least one dose of GARDASIL during pregnancy.
11539565|NCT01078220||Autoimmune Safety Population|Females who have received at least one dose of GARDASIL and have been members in the same MCO for at least 12 months prior to receiving their first dose of GARDASIL.
11539566|NCT01078220||Any Dose Safety Population (Secondary)|Females who have received at least one dose of GARDASIL and have been members in the same MCO for at least 12 months prior to receiving their first dose of GARDASIL.
11539567|NCT01078194||Weight regain / weight loss failure|Weight regain of more than 10 kg from or weight loss of less than 50% EWL 18 months after lap. gastric bypass
11539568|NCT01078181|Active Comparator|banded gastric bypass|Banded gastric bypass (circular anastomosis 21mm) using the A.M.I. B-Band (Soft Gastric Bypass Band)
11539569|NCT01078181|Active Comparator|non-banded gastric bypass|non-banded gastric bypass (circular anastomosis 21mm)
11539570|NCT01078168|Active Comparator|Acitretin|oral, 30 mg per day, day 1-28
11539571|NCT01078168|Placebo Comparator|Placebo|oral, day 1-28
11539572|NCT01078155||Participants with Active Rheumatoid Arthritis (RA)|Participants (women and men) with active early and long-standing RA according to American College of Rheumatology revised criteria from 1987 were prescribed adalimumab in the usual manner in accordance with the terms of the local market authorization with regards to dose, population and indication as well as local guidelines. The decision to prescribe or not to prescribe an anti-TNF was taken prior to a participant's enrollment in the study.
11539573|NCT01078142|Experimental|Single arm|Bendamustin, Rituximab, Temsirolimus
11539574|NCT01078129|Active Comparator|behavior therapy - CRT|behavior program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions) by means REHACOM® software
11539575|NCT01078129|Sham Comparator|non-CRT|no intervention
11539576|NCT01078116||Patients with Rheumatoid Arthritis|Eligible rheumatoid arthritis patients treated with adalimumab according to the approved Summary of Product Characteristics (SmPC) in European Union
11539577|NCT01078090||Rheumatoid arthritis|Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 5 years.
11539578|NCT01078064||Study group|Patients with symptoms suggesting gastroesophageal reflux and referred to perform an impedance study.
11539579|NCT01078051|Active Comparator|Optimal medical therapy|optimal medical therapy
11539580|NCT01078051|Active Comparator|drug-eluting stent|Cypher, xience, Endeavor, Taxus
11539581|NCT01078038|Active Comparator|Cypher|Sirolimus-eluting stent
11539582|NCT01078038|Active Comparator|Xience V|Everolimus-eluting stent
11539583|NCT01078025||transvaginal hybrid cholecystectomy|
11539584|NCT01078025||laparoscopic cholecystectomy|
11539585|NCT01078012|Active Comparator|Trained counselling|Comparison of outcomes before intervention vs. 2 months after
11539586|NCT01077999|Active Comparator|Carboplatin + paclitaxel + radiotherapy|Carboplatin AUC = 2, Paclitaxel 50 mg/m2 (both weekly) , a total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
11539587|NCT01077999|Experimental|Carboplatin+ paclitaxel+ panitumumab+ radiotherapy|Carboplatin AUC = 2, Paclitaxel 50 mg/m2 (both weekly) , a total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy. Panitumumab panitumumab: 6mg/kg in weeks 1-3-5.
11539588|NCT01077973|Experimental|Treatment A|
11539589|NCT01077973|Active Comparator|Treatment B|
11539590|NCT01077973|Placebo Comparator|Treatment C|
11539674|NCT01077323||Other Antidiabetic Drug Initiators|
11539675|NCT01077323||Non-Diabetes Cohort|
11540272|NCT01072864|Experimental|40 g of walnuts|
11539591|NCT01077960|Experimental|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
11539592|NCT01077947|Active Comparator|Functional anesthetic discography|"The patients disc levels for surgical treatment will be based exclusively on their Functional anesthetic discography results. The discography will be performed at a maximum of two disc levels. Discs showing the following MRI findings will be considered for discography:
~Loss of disc signal intensity on T-2 weighted sagittal MR images.
~Loss of disc height on sagittal MR images.
~Patients will be followed-up at 3 weeks, 3 months, 6 months and 1 year after the surgery by research personnel. Patients will be asked to complete questionnaires before their discography and at every follow-up visit."
11539593|NCT01077947|Active Comparator|Provocative Discography|"The patients disc levels for surgical treatment will be based exclusively on their Provocative Discography results. The discography will be performed at a maximum of two disc levels. Discs showing the following MRI findings will be considered for discography:
~Loss of disc signal intensity on T-2 weighted sagittal MR images.
~Loss of disc height on sagittal MR images.
~The control disc, in the case provocative discography group must appear normal on the MRI - must have preserved disc height and central disc signal intensity on T-2 weighted images. The provocative discography will be performed using the standard IASP criteria. The patients will be followed-up at 3 weeks, 3 months, 6 months and 1 year after the surgery."
11539594|NCT01077934||Injured Extremity without compartment syndrome|
11539595|NCT01077934||Injured extremity with compartment syndrome|
11539596|NCT01077921|Experimental|Propranolol|Drug arm
11539597|NCT01077921|Placebo Comparator|Sugar pill|Placebo arm
11539598|NCT01077908|Experimental|ACT plus standard therapy|Adoptive Cellular Therapy (ACT) prepared using Multimer or Gamma Catch Selection in combination with standard best available antiviral drug therapy
11539599|NCT01077908|Active Comparator|Best available antiviral drug therapy|
11539600|NCT01077895|Experimental|CVVH with fluid removal|
11539601|NCT01077895|Active Comparator|CVVH without fluid removal|
11539602|NCT01077882|Placebo Comparator|current therapy|
11539603|NCT01077882|Experimental|current therapy with educational program|
11539604|NCT01077856||Pre-Vaccine|Registry, survey, and HPV status data from 2004-2006
11539605|NCT01077856||Post-Vaccine|Registry, survey, and HPV status data from 2011-2012
11539606|NCT01077843||Exposure|Ankylosing spondylitis patients currently exposed to anti-inflammatory treatments
11539607|NCT01077843||Non-exposure|Ankylosing spondylitis patients not currently exposed to anti-inflammatory treatments
11539608|NCT01077830||Ezetimibe/Simvastatin 10/40 mg|Participants who received Ezetimibe/Simvastatin 10/40 mg in the base study
11539609|NCT01077830||Placebo|Participants who received placebo in the base study
11539610|NCT01077817||Esophageal Cancer Cases|Participants with any United Kingdom General Practice Research Database (GPRD) Medical code for esophageal cancer (cases). Cases were confirmed and case onset dates determined by electronic algorithm (based on electronic medical record data) or by medical record review.
11539611|NCT01077817||Comparison Sample (Case-Cohort)|Participants who were matched to cases by age and membership in the GPRD on the case's onset date, and had not experienced any form of esophageal cancer or Paget's Disease and had not received oral or intravenous steroids or chemotherapy or radiotherapy, as indicated by GPRD codes.
11539612|NCT01077817||Non-treated Comparators|Participants who did not initiate treatment of osteoporosis with a study drug
11539613|NCT01077817||Alendronate|Participants initiating treatment for osteoporosis with alendronate
11539614|NCT01077817||Etidronate|Participants initiating treatment for osteoporosis with etidronate
11539615|NCT01077817||Ibandronate|Participants initiating treatment for osteoporosis with ibandronate
11539616|NCT01077817||Risedronate|Participants initiating treatment for osteoporosis with risedronate
11539617|NCT01077817||Raloxifene|Participants initiating treatment for osteoporosis with raloxifene
11539618|NCT01077804||Varivax vaccinated children|Children who are members of Kaiser Permanente Medical Care Program (KPMCP) and who received a first dose of the varicella vaccine, Varivax, in 1995 between the ages of 12 and 23 months.
11539619|NCT01077791|Experimental|original cognitive therapy|
11539620|NCT01077791|No Intervention|no intervention|
11539621|NCT01077765|Experimental|treatment|treatment
11539622|NCT01077752|Experimental|1|Patients with continuous ropivacaine preperitoneal infusion
11539623|NCT01077752|Active Comparator|2|Patients with intravenous lidocaine infusion
11539624|NCT01077752|Placebo Comparator|3|Patients without local anesthetics
11539625|NCT01077739|Experimental|Avastin (bevacizumab) + standard of care|
11539626|NCT01077726|Experimental|1|
11539627|NCT01077713|Experimental|1|
11539628|NCT01077713|Experimental|2|
11539629|NCT01077700|Experimental|ABT-288 Dose 1|low dose of ABT-288
11539630|NCT01077700|Experimental|ABT-288 Dose 2|high dose of ABT-288
11539631|NCT01077700|Placebo Comparator|Sugar Pill|inactive substance
11539632|NCT01077674||Entropy - BIS|Patients undergoing surgery in sevoflurane anaesthesia.
11539633|NCT01077661||Patients administrated Nebivolol|There is only one group. This group includes patients administrated Nebivolol
11539634|NCT01077648||Women diagnosed with advanced breast cancer|Women diagnosed with advanced breast cancer during January 1, 1995-December 31, 2007 and treated as part of the Henry Ford Health System
11539635|NCT01077635||HIV-1 infected children aged 6 ≤ 18 years|HIV-1 infected children aged 6 ≤ 18 years currently or having ever been exposed to FPV/RTV; this is the indicated group for the licensed dose in the paediatric population.
11539636|NCT01077622|Experimental|2000 mg dose|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
11539637|NCT01077609||Allergic rhinitis (AR) & Flixonase|Patients initiating treatment for allergic rhinitis on intranasal fluticasone propionate
11539638|NCT01077609||AR & prescription for intranasal steroid other than Flixonase|Random sample of patients initiating treatment for allergic rhinitis with an intranasal steroid other than Flixonase
11539779|NCT01076439|Active Comparator|Fluticasone Furoate Nasal Spray (Veramyst)|
11539780|NCT01076439|Placebo Comparator|Saline Nasal Spray (Placebo)|
11539639|NCT01077596||New users of antidepressants Jan. 1, 1996 to Dec. 31, 2006|All new users of antidepressants January 1, 1996 through December 31, 2006. Individuals 18 years of age or older with medical and pharmacy benefits and at least 6 months of health plan enrollment before the first antidepressant prescription.
11539640|NCT01077570||Repaglinide|
11539641|NCT01077557||No HIV infection|Subjects without HIV infection (Group 1) are adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. A 3:1 match of subjects without HIV infection to a subject with HIV infection will occur. Each member of the comparator group without HIV infection will be matched on gender, month/year of IHCIS enrolment, and duration of enrollment to the respective study subject with HIV infection.
11539642|NCT01077557||HIV infection with no antiretroviral (ARV) drug exposure|HIV infection with no ARV drug exposure (Group 2) represents adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. HIV exposure will be identified by ICD-9-CM code 042 or v08 in one or more diagnostic fields. This group will have no pharmacy dispensing for ARV drugs.
11539643|NCT01077557||HIV infection with ARV drug exposure|HIV infection with ARV drug exposure (Group 3) represents adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. HIV exposure will be identified by ICD-9-CM code 042 or v08 in one or more diagnostic fields. This group will have at least one pharmacy dispensing for an HIV antiretroviral drug.
11539644|NCT01077544|Experimental|Group 1|1 year to < 10 years pediatric patients with newly diagnosed CP-Ph+ CML, or CP or AP-Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or relapsed/refractory Ph+ ALL (acute lymphoblastic leukemia) treated at the proposed dose of 230 mg/m2 bid.
11539645|NCT01077544|Experimental|Group 2|>= 10 years to <18 years pediatric patients with newly diagnosed CP-Ph+ CML, or CP or AP-Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or relapsed/refractory Ph+ ALL (acute lymphoblastic leukemia) treated at the proposed dose of 230 mg/m2 bid.
11539646|NCT01077531|Active Comparator|Otelixizumab|Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
11539647|NCT01077531|Placebo Comparator|Placebo|Matching placebo for intravenous infusion
11539648|NCT01077518|Experimental|Ofatumumab and Bendamustine (Arm A)|Up to 8 cycles of bendamustine (90 mg/m2) on Days 1,2 every 21 days with12 doses of ofatumumab (1000 mg, Day 1 q21 days when with bendamustine and q28 days when given as monotherapy)
11539649|NCT01077518|Active Comparator|Bendamustine (Arm B)|Up to 8 cycles of bendamustine (120 mg/m2) on Days 1,2 every 21 days
11539650|NCT01077505|Experimental|albiglutide|albiglutide 50mg weekly
11539651|NCT01077492||Suspected mediastianl lymph nodes|Patients with (suspected) lung cancer requiring MLN staging after CT-PET during routine work-up according to existing staging guidelines.
11539652|NCT01077479|Experimental|Metformin|
11539653|NCT01077466|Experimental|Natalizumab|24 patients: 12 with secondary progressive multiple sclerosis 12 with primary progressive multiple sclerosis
11539654|NCT01077453|Experimental|Arm I (2.5 mg letrozole)|Patients receive 2.5 mg of letrozole PO thrice weekly for 6 months.
11539655|NCT01077453|Experimental|Arm II (1.0 mg letrozole)|Patients receive 1.0 mg of letrozole PO thrice weekly for 6 months.
11539656|NCT01077453|Experimental|Arm III (0.25 mg letrozole)|Patients receive 0.25 mg of letrozole PO thrice weekly for 6 months.
11539657|NCT01077453|Experimental|Arm IV (2.5 mg letrozole)|Patients receive 2.5 mg of letrozole PO once daily for 6 months.
11539658|NCT01077440||Men - age 18+|
11539659|NCT01077427|Active Comparator|Gemcitabine + Capecitabine|
11539660|NCT01077427|Experimental|Gemcitabine + Cisplatin + regional hyperthermia|
11539661|NCT01077401|Experimental|Ranibizumab 0.5mg|Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
11539662|NCT01077401|Experimental|Ranibizumab 2.0 mg|Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
11539663|NCT01077388|Experimental|Dietician electronic counseling|This arm will receive care and supportive emails and phone calls from a study dietician for about 6 months. We will also provide a blood pressure monitor, a pedometer, and a scale with instructions for using them at home.
11539664|NCT01077388|No Intervention|Self Care|This arm will continue to get care as usual from their regular doctor. They will also get a blood pressure monitor and a scale at the end of the study.
11539665|NCT01077375|Placebo Comparator|Placebo|Placebo tablets, twice a day, oral administration
11539666|NCT01077375|Experimental|Milnacipran|Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses.
11539667|NCT01077362|Experimental|Placebo|Participants will receive subcutaneous (SC) injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants will cross over to receive SC injections of ustekinumab 45 mg at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 40. If early escape, SC injections of 45 mg ustekinumab will be given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 40. For participants entering early escape, a SC placebo injection will be given at Week 24 to maintain the blind.
11539668|NCT01077362|Experimental|Ustekinumab 45 mg|Participants will receive SC injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 40. If early escape, SC injections of 90 mg ustekinumab will be given at Week 16 and every 12 weeks thereafter with the last dose at Week 40. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
11539669|NCT01077362|Experimental|Ustekinumab 90 mg|Participants will receive SC injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 40. If early escape, the same dosage schedule will continue. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
11539676|NCT01077310|Active Comparator|Intramuscular naltrexone|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
11539677|NCT01077310|Placebo Comparator|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail.
11539678|NCT01077297|Experimental|Tezosentan|
11539679|NCT01077284|Experimental|Febuxostat|Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
11539680|NCT01077284|Active Comparator|Allopurinol|Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.
11539681|NCT01077284|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 6 months.
11539682|NCT01077271||Premature infants 33 - 35 wGA prophylaxed with palivizumab|Premature infants 33 - 35 weeks gestational age (wGA) prophylaxed with Synagis (palivizumab)
11539683|NCT01077258||Rheumatoid arthritis|Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 24 months.
11539684|NCT01077245|Experimental|MIYA-BM|MIYA-BM Fine Granules (CBM588)
11539685|NCT01077245|Placebo Comparator|Placebo|Placebo Fine Granules (without CBM588)
11539686|NCT01077232||Psoriasis Patients|Patients with moderate to severe plaque psoriasis
11539687|NCT01077206|Active Comparator|Simvastatin 80mg|
11539688|NCT01077206|Active Comparator|Simvastatin 40mg|
11539689|NCT01077193|Other|Gastric Plication Surgery|
11539690|NCT01077180|Experimental|Rheos Device|
11539691|NCT01077180|Active Comparator|Medical Management|
11539692|NCT01077167|Experimental|1|
11539693|NCT01077154|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections once every 4 weeks for 6 months followed by placebo subcutaneous injections once every 3 months for 4.5 years.
11539694|NCT01077154|Experimental|Denosumab|Participants received denosumab 120 mg subcutaneous injections once every 4 weeks for 6 months followed by denosumab 120 mg subcutaneous injections once every 3 months for 4.5 years.
11539695|NCT01077128||Patients with psoriasis|All eligible patients with psoriasis treated with Adalimumab
11539696|NCT01077115|Experimental|Laparoscopic cholecystectomy|
11539697|NCT01077115|Active Comparator|Open cholecystectomy|
11539698|NCT01077102|Experimental|Eccentric exercise training|
11539699|NCT01077102|Active Comparator|Concentric exercise training|
11539700|NCT01077089||Transported TBI patients|Traumatically brain injured patients undergoing in-hospital transport.
11539701|NCT01077076|Experimental|Zegerid OTC Capsules|20 mg omeprazole and 1100 mg sodium bicarbonate
11539702|NCT01077076|Active Comparator|Prilosec OTC™ tablets containing 20 mg-equivalent omeprazole|20.6 mg omeprazole-magnesium complex.
11539703|NCT01077076|Placebo Comparator|Placebo|Inert substance
11539704|NCT01077063|Active Comparator|paracentesis|cutting and draining procedure for malignant ascites
11539705|NCT01077063|Active Comparator|Pleurx catheter|a catheter drainage system the subject uses himself/herself.
11539706|NCT01077050|Other|SciBase III|Subjects with suspected malignant melanoma or lesions designated for total excision were included into the study. To ensure no selection bias, all eligible lesions from a subject were included into the study. All study eligible skin lesion(s) were examined with the investigational device, photographed and removed by an excisional biopsy.
11539707|NCT01077037|Experimental|Decision Aid|Receives Decision Aid
11539708|NCT01077037|No Intervention|Control|Patient receives usual care.
11539709|NCT01077024|Experimental|Smoking-cessation treatment + substance treatment as usual|
11539710|NCT01077024|No Intervention|Substance-treatment as usual|Treatment as usual is outpatient stimulant-dependence treatment as typically provided by the participating site.
11539711|NCT01077011|Experimental|Lubricant eye drop|Lubricant eye drop
11539712|NCT01077011|Active Comparator|GenTeal Gel|GenTeal Gel
11539713|NCT01076998|Experimental|Lubricant eye drop|Lubricant eye drop
11539714|NCT01076998|Active Comparator|Refresh PM Ointment|Refresh PM Ointment
11539715|NCT01076985||Lopinavir/ritonavir group|All pregnant women in this noninterventional, post-marketing observational study, who were prescribed lopinavir/ritonavir (Kaletra) in accordance with the local Prescribing Information for the treatment of HIV infection.
11539716|NCT01076972||Lopinavir/ritonavir group|All patients in this non-interventional, post-marketing observational study, who were prescribed lopinavir/ritonavir (Kaletra) in accordance with the local Prescribing Information for the treatment of HIV infection.
11539717|NCT01076959||Humira|The sponsor was required to include all patients diagnosed with rheumatoid arthritis and who were treated Humira in routine medical practice during the review period by the PMDA. The safety analysis set included all patients who met all eligibility criteria and received at least one dose of Humira. The full analysis set included all patients who were treated with Humira for at least 2 weeks and had complete DAS 28 assessments at baseline and at least one other time point.
11539718|NCT01076946||TLVBS|patients with transient left ventricular ballooning
11539719|NCT01076933|Experimental|rTMS|rTMS sessions
11539720|NCT01076933|Sham Comparator|control|sham rTMS (control)
11539721|NCT01076920|Experimental|Intervention arm|
11539722|NCT01076907|Experimental|Warm water loading of sigmoid colon|Warm water loading of sigmoid colon and irrigation when spasms occur.
11539723|NCT01076907|Placebo Comparator|Control|No water loading, only air and waiting for spasms to subside.
11539724|NCT01076894|Active Comparator|epidural anesthesia|
11539725|NCT01076894|Active Comparator|intercostal anesthesia|
11539726|NCT01076881|Experimental|combined aerobic and resistance training|
11539727|NCT01076881|Active Comparator|resistance training alone|
11539728|NCT01076868|Experimental|Primaquine|Primaquine 14 days
11539729|NCT01076855||Elderly with mild dementia|>70 years old and presence of a carer
11539730|NCT01076842|Active Comparator|A Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
11539781|NCT01076426|Experimental|Probiotics|probiotics treatment
11539782|NCT01076426|Placebo Comparator|Placebo|
11539731|NCT01076842|Active Comparator|B Exenatide|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
11539732|NCT01076842|Active Comparator|C Levemir+Exenatide|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
11539733|NCT01076829|Active Comparator|Spice patty|hamburger meat cooked with spice mixture
11539734|NCT01076829|Placebo Comparator|salt patty|Subjects consume salt containing hamburger meat
11539735|NCT01076803|Experimental|Lanreotide (acetate)|
11539736|NCT01076790|Active Comparator|Dexmedetomidine|Analgo-sedative, adjuvant of propofol anesthesia
11539737|NCT01076777|Experimental|Physical exercise|Manualised Exercise performed in groups (5-8 participants per group). 3 sessions (á 60 minutes) per week for 12 consecutive weeks
11539738|NCT01076777|Active Comparator|Cognitive-behavioral therapy|Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
11539739|NCT01076764|Experimental|Otamixaban - 0.080 mg/kg bolus + 0.100 mg/kg/h infusion|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:
~Drug A: Otamixaban (0.080 mg/kg bolus followed by 0.100 mg/kg/h infusion)
~Drug B: Placebo (for UFH)
~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:
~Drug C: Placebo (for Eptifibatide)"
11539740|NCT01076764|Experimental|Otamixaban - 0.080 mg/kg bolus + 0.140 mg/kg/h infusion|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:
~Drug A: Otamixaban 0.080 mg/kg bolus followed by 0.140 mg/kg/h infusion)
~Drug B: Placebo (for UFH)
~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:
~Drug C: Placebo (for Eptifibatide)"
11539741|NCT01076764|Active Comparator|UFH + Eptifibatide|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:
~Drug A: Placebo (for Otamixaban)
~Drug B: UFH (60 IU/kg bolus followed by 12 IU/kg/h infusion)
~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:
~Drug C: Eptifibatide (180 mcg/kg bolus followed by 2 mcg/kg/min infusion)"
11539742|NCT01076751||CRPC patients|
11539743|NCT01076738||single group study|
11539744|NCT01076725|Active Comparator|Standard technique group|In the standard technique group(n = 63), the PLMA was inserted by index finger insertion technique.
11539745|NCT01076725|Experimental|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
11539746|NCT01076712|Experimental|Physiotherapy Interventions|Physiotherapy Interventions including strengthening exercise, balance training, gait training with visual cue, gait training with treadmill.
11539747|NCT01076712|Other|Education|Education
11539748|NCT01076699|Active Comparator|Group taking 0.075 mg RVX-100|This group is taking 0.075 mg RVX-100
11539749|NCT01076699|Active Comparator|Group taking 0.125 mg RVX-100|This group is taking 0.125 mg RVX-100
11539750|NCT01076699|Active Comparator|0.250 mg RVX-100|This group is taking 0.250 mg RVX-100
11539751|NCT01076699|Placebo Comparator|placebo|This group is taking a placebo
11539752|NCT01076686||Bupivacaine and low dose SKY0402|
11539753|NCT01076686||Bupivacaine and high dose SKY0402|
11539754|NCT01076686||Bupivacaine|
11539755|NCT01076686||High dose SKY0402|
11539756|NCT01076673|Experimental|PBSC and Hyaluronic Acid|Peripheral blood stem cells and hyaluronic acid injections
11539757|NCT01076673|Active Comparator|Hyaluronic Acid|Hyaluronic Acid
11539758|NCT01076647|Experimental|IDeg 3TW|
11539759|NCT01076647|Active Comparator|IGlar OD|
11539760|NCT01076634|Experimental|IDeg 100 U/mL|
11539761|NCT01076634|Experimental|IDeg 200 U/mL|
11539762|NCT01076621||A|
11539763|NCT01076595||Group 1|
11539764|NCT01076582|Experimental|Arm 1|
11539765|NCT01076582|Active Comparator|Arm 2|
11539766|NCT01076569||Ancillary-Correlative (molecular analysis)|Banked bone marrow samples from diagnosis and remission are used to develop a detailed molecular map of pediatric high-risk acute myeloid leukemia. Analysis includes genome SNP genotyping, expression, and methylation profiling.
11539767|NCT01076556|Experimental|Treatment (rituximab, cyclophosphamide, alvocidib)|Patients receive rituximab IV over 4 hours on days 1 (days 1-3 in course 1), cyclophosphamide IV over 30-60 minutes on days 1-3, and alvocidib IV over 4.5 hours on days 1 and 8 (day 8 only in course 1).
11539768|NCT01076543|Experimental|Treatment (lenalidomide, temsirolimus)|Patients receive lenalidomide PO on days 1-21 and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 2 courses may continue therapy for up to 52 weeks.
11539769|NCT01076530|Experimental|Arm I|Patients receive oral vorinostat and oral temozolomide once daily on days 1-5. Courses repeat every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
11539770|NCT01076504|Experimental|Amrubicin/Carboplatin with Pegfilgrastim|Systemic therapy
11539771|NCT01076478|Placebo Comparator|Arm 1|2 tablets BID
11539772|NCT01076478|Experimental|Arm 2|100 mg Cilostazol (2 tablets BID)
11539773|NCT01076478|Experimental|Arm 3|200 mg Cilostazol (2 Tablets BID)
11539774|NCT01076465|Experimental|Lifestyle counselling|Educational intervention, monitoring of clinical status, monitoring of treatment adherence
11539775|NCT01076465|Active Comparator|Comparator|Usual care
11539776|NCT01076452|Active Comparator|STN|Participants were randomized to receive deep brain stimulation on STN (Subthalamic Nucleus) target.
11539777|NCT01076452|Active Comparator|GPi|Participants were randomized to receive deep brain stimulation on GPi (Globus Pallidus) target.
11539778|NCT01076439|Active Comparator|Olopatadine Nasal Spray (Patanase)|
11539783|NCT01076413|Experimental|skill-based exercise|2 times per week for 12 weeks. warm-up, stretching, strengthening, and skill-based exercises. Pre-gait and gait activities including stepping patterns and walking patterns and treadmill training at various walking speeds
11539784|NCT01076413|Active Comparator|aerobic exercise training|warm-up, strengthening and aerobic conditioning (treadmill walking)
11539785|NCT01076400|Experimental|Part 1: MK-1775 + topotecan/cisplatin|Part 1: Dose escalation study. MK-1775 capsules will be administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3 . Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
11539786|NCT01076400|Experimental|Part 2: MK-1775 + topotecan/cisplatin|Part 2: MK-1775 capsules will be administered at the dose determined in Part 1 twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3. Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
11539787|NCT01076400|Placebo Comparator|Part 2: Placebo to MK-1775 + topotecan/cisplatin|Part 2: Placebo to MK-1775 capsules will be administered twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3. Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
11539788|NCT01076387|Active Comparator|open radical cystectomy|This is a prospective, randomized study designed to compare two techniques of radical cystectomy with PLND (open and robotic) for bladder cancer.
11539789|NCT01076387|Active Comparator|robotic-assisted radical cystectomy|This is a prospective, randomized study designed to compare two techniques of radical cystectomy with PLND (open and robotic) for bladder cancer.
11539790|NCT01076335|Experimental|Neoadjuvant Hormones + Docetaxel|Neoadjuvant Hormonal Therapy plus Docetaxel followed by Radical Prostatectomy
11539791|NCT01076322|Experimental|Treatment-A sequence|Meptin® Swinghaler / Ventolin® MDI
11539792|NCT01076322|Experimental|Treatment-B sequence|Ventolin® MDI / Meptin® Swinghaler
11539793|NCT01076309||Tamsulosin|Patients taking tamsulosin
11539794|NCT01076309||Non-tamsulosin|Patients not taking tamsulosin.
11539795|NCT01076283|Active Comparator|Baclofen|Baclofen 10 mg three times a day (t.i.d.) for 8-10 days
11539796|NCT01076283|Placebo Comparator|Cyproheptadine|Cyproheptadine 2 mg t.i.d. for 8-10 days
11539797|NCT01076270|Experimental|Filgrastim and plerixafor for PBSC mobilization|"Donors receive filgrastim subcutaneously (SC) and plerixafor SC on day -14 and undergo leukapheresis to collect peripheral blood stem cells (PBSC) on day -13. These cells are frozen to preserve them. Treatment modifications may apply according to sufficient collection of PBSC. Patients receive standard high-dose conditioning and undergo allogeneic PBSC transplantation on day 0 using the previously frozen cells.
~After completion of study treatment, donors are followed up 1 day after the last stem cell donation."
11539798|NCT01076257|Experimental|Constraint-induced Movement Therapy|
11539799|NCT01076257|Other|Transditional rehabilitation|
11539800|NCT01076244|Other|Minimally invasive lumbar decompression|
11539801|NCT01076231|Experimental|Arm I|"Patients undergo proton beam radiotherapy over 5.5-7.5 weeks. Patients receive concurrent chemotherapy comprising cisplatin IV on days 1, 8, 29, and 36 and etoposide IV on days 1-5 and days 29-33.Treatment continues in the absence of disease progression or unacceptable toxicity.
~Beginning 4-6 weeks after completion of chemoradiotherapy, patients may undergo surgical resection or additional chemoradiotherapy."
11539802|NCT01076218||Diabetes|Patients with type 1 diabetes requiring multiple daily insulin injections or using insulin pumps
11539803|NCT01076205||Adalimumab|Adults with moderate to severe active rheumatoid arthritis (RA) who initiated adalimumab therapy during routine clinical care.
11539804|NCT01076192||Moderate-to-severe chronic plaque psoriasis|Participants with moderate-to-severe chronic plaque psoriasis treated with adalimumab in routine clinical practice
11539805|NCT01076179||Human Immunodeficiency Virus (HIV)-Infected Participants|HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists
11539806|NCT01076166||Children with lower respiratory tract infection|Thai children with lower respiratory tract infections on Klacid Granules for Oral Suspension
11539807|NCT01076153||Patients with respiratory tract infection|Thai patients with upper or lower respiratory tract infections on Klacid MR.
11539808|NCT01076140|Active Comparator|Nebivolol|Nebivolol 5 mg daily for 2 weeks, then 5 or 10 mg daily for 2 weeks
11539809|NCT01076140|Active Comparator|Lisinopril|20 mg once daily for 2 weeks, then 20 or 40 mg once daily for 2 weeks
11539810|NCT01076127|Experimental|Ketllebell group|Basic ketllebell training 3 x 20 min a week for 8 weeks
11539811|NCT01076127|Sham Comparator|Control group|Control group. Receives a health examination before and after the intervention period, and are advised to stay active.
11539812|NCT01076114||Control|Patients with no evidence of glaucoma or as a suspect with normal intraocular pressure, normal cup to disc ratio with no other ocular pathology and a normal ophthalmic exam.
11539813|NCT01076114||Glaucoma Suspect|Patients with abnormal cup to disc ratio or increased intraocular pressure (>21mm/Hg) with an otherwise normal ophthalmic exam.
11539814|NCT01076101||Sisters who have a diagnosis of SLE|Sisters who have a diagnosis of SLE
11539815|NCT01076101||Unaffected Sisters|Sisters of SLE patients who do not have a diagnosis of SLE
11539816|NCT01076088|Experimental|Sitagliptin 50 mg + metformin 500 mg|Sitagliptin 50 mg and metformin 500 mg twice a day for 24 weeks.
11539817|NCT01076088|Experimental|Sitagliptin 50 mg + metformin 850 mg|Sitagliptin 50 mg and metformin 850 mg twice a day for 24 weeks.
11539818|NCT01076088|Active Comparator|Metformin 500 mg|Metformin 500 mg twice daily for 24 weeks.
11539819|NCT01076088|Active Comparator|Metformin 850 mg|Metformin 850 mg twice daily for 24 weeks.
11539820|NCT01076088|Experimental|Sitagliptin 100 mg|Sitagliptin 100 mg once daily for 24 weeks.
11539821|NCT01076088|Placebo Comparator|Placebo|Matching placebo tablets for 24 weeks.
11539822|NCT01076075|Active Comparator|placebo/pioglitazone|Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg; Phase B (Weeks 24-54): placebo to Sitagliptin 100 mg + pioglitazone 30 mg
11539896|NCT01075516||Standard Follow Up|ICD patients followed through periodic in-hospital visits
11539823|NCT01076075|Experimental|Sitagliptin|Phase A (Weeks 0-24): Sitagliptin 100 mg; Phase B (Weeks 24-54): Sitagliptin 100 mg + placebo to pioglitazone
11539824|NCT01076062|No Intervention|Expectant management (EM) arm|Standard of care: routine clinic appointments until they deliver, fetal heart rate and contraction monitoring during their 41st week if not delivered. Also if they have not gone into labor the subjects will be scheduled for an induction by 42 weeks.
11539825|NCT01076062|Experimental|Induction of Labor (IOL) arm|Elective induction of labor at 39 weeks.
11539826|NCT01076049|Experimental|Standard Care|purely observes standard operation of ER doctor
11539827|NCT01076049|Experimental|Irrisept Arm|
11539828|NCT01076036|Experimental|CorPath 200 System|Robotic-assisted PCI with the CorPath 200
11539829|NCT01076010|Experimental|Sorafenib crossover to tivozanib.|The subjects who failed sorafenib (had Response Evaluation Criteria in Solid Tumors [RECIST] - defined progressive disease) on the parent protocol AV-951-09-301 will be offered tivozanib hydrochloride on Protocol AV- 951-09-902.
11539830|NCT01076010|Experimental|First line tivozanib.|The subjects who were randomized to tivozanib (continued from the parent Protocol AV-951-09-301) and demonstrated clinical benefit and acceptable tolerability in Protocol AV-951-09-301.
11539831|NCT01076010|Active Comparator|First line sorafenib.|The subjects who were randomized to sorafenib (continued from the parent Protocol AV-951-09-301) and demonstrated clinical benefit and acceptable tolerability were to be offered long-term access to sorafenib.
11539832|NCT01075997|Experimental|A cell phone tips|This group will receive a cell phone and cell phone service for 1 year. This group will receive a daily video reminders and tips for the first 6 months of the study. For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent. The group will be instructed on how to use the cell phone. The group will be asked to check blood sugar on a schedule determined by their providers. The group will have blood sugars downloaded from from the glucometer by their providers at every visit and reviewed. The group will have the A1c measured. Also it will have this test repeated about every 3 months. They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
11539833|NCT01075997|Active Comparator|B no cell phone tips|This group will receive a cell phone and cell phone service for 1 year. For the second 6 months this group will be seen by their providers at least every 3 months. The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by their provider. The groups will have blood sugars downloaded from from the glucometer by their provider at every visit and reviewed. The group will have A1c measured. Also it will have this test repeated about every 3 months. They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
11539834|NCT01075984|Active Comparator|POS IV 200 mg single dose (Cohort 0)|POS 200 mg IV single dose infused over 1.5 hours on Day 1 followed 12 hours later by POS oral 400 mg, then by POS oral 400 mg BID on Days 2 through 6 and a single morning dose on Day 7 (Cohort 0)
11539835|NCT01075984|Placebo Comparator|Dextrose 5% in water (Cohort 0)|Placebo IV single dose infused over 1.5 hours on Day 1 followed 12 hours later by POS oral 400 mg, then by POS oral 400 mg BID on Days 2 through 6 and a single morning dose on Day 7 (Cohort 0)
11539836|NCT01075984|Experimental|POS IV 200 mg BID (Cohort 1)|POS 200 mg IV infused over 1.5 hours BID on Day 1, followed by POS 200 mg IV once daily on Days 2 through 14, then by POS 400 mg oral BID through Day 28 (Cohort 1)
11539837|NCT01075984|Experimental|POS IV 300 mg BID (Cohort 2)|POS 300 mg IV infused over 1.5 hours BID on Day 1, followed by POS 300 mg IV once daily on Days 2 through 14, then by POS 400 mg oral BID through Day 28 (Cohort 2). After Day 5, POS IV was administered continuously or intermittently, depending on oral tolerability.
11539838|NCT01075984|Experimental|POS IV 300 mg BID (Cohort 3)|POS 300 mg IV infused over 1.5 hours BID on Day 1, followed by POS 300 mg IV once daily on Days 2 through 5, then by POS 200 mg oral TID or POS 400 mg oral BID through Day 28, or POS 200-300 mg IV once daily as required (Cohort 3). After Day 5, POS IV was administered continuously or intermittently, depending on oral tolerability.
11539839|NCT01075971|Experimental|Buprenorphine hydrochloride|
11539840|NCT01075945|Experimental|Dihydroartemisinin- piperaquine|orally tablets
11539841|NCT01075945|Active Comparator|artemether- lumefantrine|oral tablets
11539842|NCT01075932|Active Comparator|1 g DHA-rich fish oil|1 g DHA-rich fish oil containing 450 mg DHA + 90 mg EPA plus 1 g olive oil
11539843|NCT01075932|Active Comparator|2 g DHA-rich fish oil|2 g DHA-rich fish oil containing 900 mg DHA + 180 mg EPA
11539844|NCT01075932|Placebo Comparator|Placebo|2 g olive oil
11539845|NCT01075919|Active Comparator|DHA-rich fish oil|1 g DHA-rich fish oil containing 450 mg DHA + 90 mg EPA
11539846|NCT01075919|Active Comparator|EPA-rich fish oil|1 g EPA-rich fish oil containing 300 mg EPA + 200 mg DHA
11539847|NCT01075919|Placebo Comparator|Placebo|1 g Olive oil
11539848|NCT01075906|Experimental|Colchicine|Colchicine Sprinkle Capsules, 0.3 mg - dose administered according to age range on Day 1
11539849|NCT01075906|Experimental|colchicine at steady state|colchicine sprinkle capsules 0.3 mg - dose administered according to age range on Day 15 following once daily dosing of colchicine on Days 2 - 14
11539850|NCT01075893||Adenomatous polyp|Patients who have begun the polyp-cancer sequence (ie. are in polyp surveillance after excision of a prior adenomatous polyp) will be used to test those patients at higher risk of colorectal.
11539851|NCT01075893||Patients at normal risk of cancer|Patients found to have endoscopically and histological normal mucosa.
11539852|NCT01075893||Ulcerative colitis|Patients who are under surveillance for known ulcerative colitis will be used to test those patients at higher risk of colorectal.
11539853|NCT01075867||Control group|Before ELIPS implementation 12 months follow-up
11539854|NCT01075867||Treatment group|After ELIPS implementation 12 months follow-up
11539855|NCT01075815|Experimental|rFSH + rhLH|Recombinant human luteinizing hormone (rhLH,Luveris®) injection 150 IU subcutaneously daily along with rFSH 300 IU subcutaneously daily from S1 to S4 and then rFSH dose can be adjusted depending on the ovarian response till r-hCG administration day.
11539856|NCT01075815|Active Comparator|rFSH|rFSH injection 300 IU subcutaneously daily from S1 to S4 and then dose can be adjusted depending on the ovarian response till r-hCG administration day.
11539857|NCT01075802|Experimental|Tamoxifen|Dose escalation of tamoxifen in patients with low endoxifen levels
11539858|NCT01075789|Placebo Comparator|Placebo|This arm will include children aged 6 years of age and older seen at the Royal Children's Hospital who are having an NGT inserted for a clinical indication and who have never experienced an NGT insertion before. These children will be randomised to be in this placebo arm or the treatment arm in a 1:1 ratio. The placebo for swallowing is a viscous, coloured, sucrose-flavoured gel designed to match the appearance of the treatment lignocaine gel to be swallowed by the treatment arm, and normal saline will be delivered to the nasal turbinates and nasopharynx in a similar way to atomised xylocaine in the treatment arm.
11539859|NCT01075789|Active Comparator|Lignocaine|This arm will include children aged 6 years of age and older seen at the Royal Children's Hospital who are having an NGT inserted for a clinical indication and who have never experienced an NGT insertion before. These children will be randomised to be in this treatment placebo arm or the treatment arm in a 1:1 ratio. The children in the treatment arm will receive xylocaine viscous 2% to swallow, and atomised 10% xylocaine to the nasal turbinates and nasopharynx.
11539860|NCT01075789|Active Comparator|Pre/post intervention evaluation group|This is a contemporaneous arm of children aged 6 years of age and older requiring nasogastric intubation for a clinical reason, who have previously had a nasogastric tube inserted. These children will be ask to rate by recall their previous NGT intubation on a VAS pain scale, and then will perform a post-procedure VAS pain assessment.
11539861|NCT01075776|Experimental|CNP|Infusion of CNP prior to IR injury
11539862|NCT01075776|Placebo Comparator|Saline|Effect of saline infusion prior to IR injury
11539863|NCT01075763|Experimental|Treatment arm - Rebif®|Subjets in this arm received interferon beta-1a (Rebif® 22 mcg tiw)
11539864|NCT01075763|Placebo Comparator|Placebo arm|Subjects in this arm received placebo
11539865|NCT01075750||Normal Saline|Patients receiving Normal Saline during and after the renal transplantation.
11539866|NCT01075750||Elomel Isoton|Patients receiving Elomel Isoton during and after renal transplantation
11539867|NCT01075737||Subjects with Multiple Sclerosis|Subjects with diagnosed MS according to the revised Mc Donald criteria 2005; aged >21 years.
11539868|NCT01075737||Caregivers|Caregivers (aged >21 years) for MS subjects.
11539869|NCT01075724|Active Comparator|Forced air|Forced Air Warming
11539870|NCT01075724|Experimental|Resistive HotDog Warming|Warming by resistive Warming
11539871|NCT01075711||NIS in-house doctors|This group will be assigned to general physicians, practicing doctors and interns (in-house doctors) with an observation period of 3 months. Three subjects are expected per in-house doctor therefore altogether, 1000 in-house doctors will be obtained or appointed for the observation study.
11539872|NCT01075711||NIS specialists|This group will be assigned to specialists (rheumatologist) with an observation period of 9 months. Ten subjects per rheumatologist are expected therefore altogether, 500 rheumatologists will be obtained or appointed for the observation study.
11539873|NCT01075698|Active Comparator|Non-ARB group|
11539874|NCT01075698|Active Comparator|ARB group|
11539875|NCT01075685|Experimental|Web-based alcohol programme|"Participants could log on to their account and access the programme whenever they wanted to.
~They received automated email reminders inviting them to use follow-up tools, especially the diary in order to register their alcohol intake on the previous week:
~4 weeks after starting the programme, so that they would take advantage of the monitoring stage in case they had not spontaneously done so.
~2 weeks later for 6-week follow-up."
11539876|NCT01075685|Placebo Comparator|Minimum information|Participants could log on to their account and access the programme whenever they wanted to. At 6 week follow-up they received an automated email reminder inviting them to use the diary in order to register their alcohol intake on the previous week.
11539877|NCT01075672|Experimental|Cognitive Behavioral Therapy|
11539878|NCT01075672|Experimental|Behavioral Medicine with Cognitive Behavioral Therapy|Participants enrolled in this arm of this study will be treated by the behavioral medicine interns with cognitive behavioral therapy focused on both their general health concerns and mental health concerns.
11539879|NCT01075659|Experimental|LHN1548|Two single doses of an experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
11539880|NCT01075659|Active Comparator|2019706|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
11539881|NCT01075659|Active Comparator|2020005|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
11539882|NCT01075646|Experimental|Ropivacaine|After a bolus administration of Ropivacaine a perfusion ot the same anesthetic is initiated through an elastomeric wound during 48 hours
11539883|NCT01075646|Placebo Comparator|saline solution|After a bolus administration of saline solution a perfusion ot saline solution is initiated through an elastomeric wound during 48 hours
11539884|NCT01075633|Experimental|Fecal occult blood testing|Immunochemical fecal occult blood test Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
11539885|NCT01075633|Active Comparator|Colonoscopy|Colonoscopy with sedation.
11539886|NCT01075620|Experimental|PFC sigma RP|Posterior stabilized rotating platform knee (press Fit Condylar Sigma rotating-platform, Depuy, Warsaw, Indiana)
11539887|NCT01075620|Active Comparator|LCS RP|non posterior stabilized Low Contact Stress Rotating-Platform; Depuy, Warsaw, Indiana
11539888|NCT01075594||1|Patients with dyslipidemia on lipid lowering therapy
11539889|NCT01075581|Active Comparator|Topical administration|An an intranasal injection of saline will be used as control, and thereafter cotton pledgets soaked in 1 mL epinephrine 1:1,000 will be placed in the nasal cavity during surgery when necessary.
11539890|NCT01075581|Experimental|Intranasal injection|An intranasal injection of 8 mL epinephrine 1:100,000 will be performed as traditionally practiced in ESS. Thereafter, cotton pledgets soaked in 1 mL epinephrine 1:1,000 will be placed in the nasal cavity during surgery when necessary.
11539891|NCT01075555|Active Comparator|sorafenib|sorafenib
11539892|NCT01075555|Experimental|sorafenib + pravastatine|sorafenib + pravastatine
11539893|NCT01075542|Experimental|Toric intraocular lens|Bilateral Toric intraocular lens implantation in cataract surgery
11539894|NCT01075542|Other|Monofocal intraocular lens|Bilateral Monofocal intraocular lens implantation in cataract surgery
11539895|NCT01075529|No Intervention|fluoxetine|
11539897|NCT01075516||Remote Follow Up|ICD patients followed with remote transmitters (Merlin@Home) that periodically communicate correct system functioning
11539898|NCT01075503|Experimental|retrograde infraclavicular|Patients were received retrograde infraclavicular brachial plexus block.
11539899|NCT01075503|Active Comparator|interscalene|Patients were received interscalene brachial plexus block.
11539900|NCT01075503|Active Comparator|supraclavicular|Patients were received supraclavicular brachial plexus block.
11539901|NCT01075490|Placebo Comparator|prematurely born, bupivacaine, placebo|
11539902|NCT01075490|Experimental|prematurely born, bupivacaine, clonidine|
11539903|NCT01075490|Placebo Comparator|term neonate, bupivacaine, placebo|
11539904|NCT01075490|Experimental|term neonate, bupivacaine, clonidine|
11539905|NCT01075477||Cohort|
11539906|NCT01075464|Experimental|A|
11539907|NCT01075464|Experimental|B|
11539908|NCT01075425|Experimental|Arm I|Patients receive belinostat IV over 30 minutes on days 1-5 and 8-12 and bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11539909|NCT01075412|Experimental|Group 2|Receives fourth [F18]Fluorothymidine (FLT) PET scan after 20 fractions of radiation therapy.
11539910|NCT01075412|Experimental|Group 1|Receives fourth [F18]Fluorothymidine (FLT) PET scan after 15 fractions of radiation therapy.
11539911|NCT01075399|Experimental|[F 18]HX4|[F18]HX4, 10 mCi, is administered in a single intravenous bolus injection, followed by a saline flush.
11539912|NCT01075386||Grade 2|Patients with Endometrial cancer of Grade 1 differentiation
11539913|NCT01075386||Benign|Patients without endometrial cancer
11539914|NCT01075386||Grade 1|Patients with Endometrial cancer of Grade 2 differentiation
11539915|NCT01075386||Grade 3|Patients with Endometrial cancer of Grade 3 differentiation
11539916|NCT01075347|Active Comparator|Autologous serum use|Patients treated with additional 20% autoserum after diabetic vitrectomy or penetrating keratoplasty
11539917|NCT01075347|Placebo Comparator|Non-autologous serum use|Patients treated with traditional medication(0.1% betamethasone, 0.3% gentamicin and 0.4% tropicamide eye drops application 4 times daily) after diabetic vitrectomy or penetrating keratoplasty
11539918|NCT01075334|Experimental|Porimore arm|Infertile men will receive 'Porimore' tablets for a period of time in which three intrauterine insemination cycles will be performed.
11539919|NCT01075334|Active Comparator|Folate and Zinc|
11539920|NCT01075321|Experimental|Arm I|Patients receive oral everolimus once daily and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
11539921|NCT01075308|Experimental|SB939|SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
11539922|NCT01075295|Experimental|Lifestyle Intervention|
11539923|NCT01075295|Active Comparator|TAU|
11539924|NCT01075282|Experimental|LY2189265 1.5 mg|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks
~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks
~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
11539925|NCT01075282|Experimental|LY2189265 0.75 mg|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks
~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks
~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
11539926|NCT01075282|Active Comparator|Insulin Glargine|"Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 78 weeks
~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks
~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
11539927|NCT01075269||Conventional open thyroidectomy group|All patients were told about the operative techniques involved in conventional open and robotic thyroidectomy, and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
11539928|NCT01075269||Robotic thyroidectomy group|All patients were told about the operative techniques involved in conventional open and robotic thyroidectomy, and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
11539929|NCT01075256|Active Comparator|5% calcium sodium phosphosilicate toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste.
11539930|NCT01075256|Active Comparator|7.5% calcium sodium phosphosilicate toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste.
11539931|NCT01075256|Placebo Comparator|Placebo toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with placebo toothpaste.
11539932|NCT01075243|Experimental|Paracetamol 1000mg|Paracetamol 1000mg
11539933|NCT01075243|Experimental|Paracetamol 650 mg|Paracetamol 650 mg
11539934|NCT01075243|Placebo Comparator|Placebo|Placebo
11539935|NCT01075230|Active Comparator|Standard TKA|
11539936|NCT01075230|Active Comparator|Standard TKA with PRP|
11539937|NCT01075217|Experimental|Isovue 250 (iopamidol)|
11539938|NCT01075217|Active Comparator|Visipaque 270 (iodixanol)|
11539939|NCT01075204||Clarithromycin modified release|Patients with upper or lower respiratory tract infection were administered clarithromycin modified release 500 mg once daily for 7 days and then followed for a further 3 days, per routine clinical practice.
11539940|NCT01075191||HIV-infected participants|"HIV-infected participants taking lopinavir/ritonavir (Kaletra) and one other protease inhibitor.
~Lopinavir/ritonavir (Kaletra) dosing and administration according to the Summary of Product Characteristics (three 133 mg/33 mg capsules twice daily or two 200 mg/50 mg tablets twice daily)."
11539941|NCT01075178||Palivizumab-treated subjects (CASES)|HSCHD infants, <2 yrs old at first dose of palivizumab
11539942|NCT01075178||Non-palivizumab-treated subjects (CONTROLS)|HSCHD infants, <2 yrs old that did not receive palivizumab
11539943|NCT01075165|Experimental|Silicone Spray|Apply spray silicone
11539944|NCT01075165|Placebo Comparator|Saline Spray|Apply Saline Spray
11539985|NCT01074892|Active Comparator|MPA 10 mg per oral cyclic for 6 months|The peroral treatment is used 10 days each month
11539945|NCT01075152|Experimental|Earlier HIV Therapy|HIV therapy initiated at 7-13 days of cryptococcal meningitis diagnosis. HIV therapy consisting of a nucleoside with lamivudine and efavirenz.
11539946|NCT01075152|Active Comparator|Deferred HIV Therapy|"HIV therapy initiated at 5 weeks after cryptococcal meningitis diagnosis (+/- 1 week).
~HIV therapy consisting of a nucleoside with lamivudine and efavirenz."
11539947|NCT01075139|Experimental|Brief Motivational Intervention|Subjects in this condition met one-on-one with a counselor for 30 minutes. Subjects received personalized feedback regarding their current physical activity levels and fruit/vegetable intake. Counselors used a motivational interviewing style to try to help resolve ambivalence about changing their current behaviors.
11539948|NCT01075139|Active Comparator|Educational information|Subjects in this condition received general educational information about the benefits associated with physical activity and fruit/vegetable intake.
11539949|NCT01075113|Experimental|Arm A|Sorafenib + Vorinostat. Patients receive sorafenib tosylate PO BID continuously and vorinostat PO QD, for 5 days each week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohort A has only one dose level: sorafenib 400 mg orally twice a day with vorinostat 300 mg orally. Cohort A was modified to include 2 dose levels: Dose level A1 (sorafenib 400 mg orally twice a day and vorinostat 200 mg orally once a day) and dose level A-1 (sorafenib 400 mg orally twice a day with vorinostat 100 mg orally once a day). The starting dose upon reopening after approval of this version will be dose level A-1a. Dose level A1 will only be used if dose level A-1a is not tolerable.
11539950|NCT01075113|Experimental|Arm B CLOSED|Reduced Dose 200mg Sorafenib + Vorinostat. Patients receive sorafenib tosylate PO BID continuously and vorinostat PO QD, for 5 days each week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohort B has 2 dose levels starting at the second dose level (sorafenib 200 mg orally twice a day with vorinostat 400 mg orally). Cohort B has been closed. Cohort B was intended to evaluate the possibility of dose intensification of vorinostat when patients were unable to tolerate standard dose sorafenib, and required dose-reduced sorafenib. The patients accrued to date in Cohort B were unable to tolerate therapy, and it has been determined that dose intensification of vorinostat is not possible, despite reducing the dose of sorafenib.
11539951|NCT01075100|Experimental|Weekly Ixabepilone +carboplatin|Subjects will receive ixabepilone and carboplatin on Days 1 and 8 of each 21-day cycle.
11539952|NCT01075087|Placebo Comparator|Placebo|(control group) will receive sterile normal saline in the block
11539953|NCT01075087|Active Comparator|Active comparator|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
11539954|NCT01075074|Active Comparator|Ropivacaine 0.05%|Subject received a bilateral transversus abdominis plane block block using 15 cc of 0.5% ropivacaine on each side
11539955|NCT01075074|Placebo Comparator|Normal Saline|Subjects received a bilateral transversus abdominis plane block using 15 cc of sterile normal saline.
11539956|NCT01075074|Active Comparator|Ropivacaine 0.25%|Subjects received a bilateral transversus abdominis plane block using 15cc of 0.25% ropivacaine on each side
11539957|NCT01075061|Other|healthy volunteers|healthy volunteers
11539958|NCT01075061|Other|Kallmann|Kallmann syndrome patients
11539959|NCT01075061|Other|Congenital Mirror Movement|patients with CMM
11539960|NCT01075048|Experimental|Phase 2: Tivantinib, cetuximab, irinotecan|Tivantinib in combination with irinotecan and cetuximab.
11539961|NCT01075048|Placebo Comparator|Phase 2: Placebo, cetuximab, irinotecan|Placebo in combination with irinotecan and cetuximab
11539962|NCT01075048|Experimental|Phase 1: Tivantinib, cetuximab, irinotecan|Tivantinib in combination with irinotecan and cetuximab.
11539963|NCT01075035||Normal Healthy Controls|Individuals with no history of Traumatic Brain Injury.
11539964|NCT01075035||Civilian TBI|Civilians who have had a Traumatic Brain Injury
11539965|NCT01075035||Military TBI|Combat military veterans who have had a Traumatic Brain Injury
11539966|NCT01075022|Experimental|Vitamin D|
11539967|NCT01075022|Placebo Comparator|Placebo|
11539968|NCT01074996|Active Comparator|S-1,|Subjects will receive S-1 until progression
11539969|NCT01074996|Experimental|S-1 plus Leucovorin|patients will receive S-1 plus Leucovorin until progression
11539970|NCT01074983||Written standard of care|
11539971|NCT01074983||Usual practice pattern|
11539972|NCT01074970|Active Comparator|Arm A: Cisplatin Monotherapy|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
11539973|NCT01074970|Active Comparator|Arm B: Combination Therapy|"Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles
~Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles"
11539974|NCT01074957|Active Comparator|Incentive Spirometry|Incentive Spirometry group (IS) was oriented to take a deep breathing through Voldyne 5000TM (Sherwood Medical; St Loius, MO, USA) from Functional Residual Capacity (FRC) to Total Lung Capacity (TLC).
11539975|NCT01074957|Active Comparator|Exercise group|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
11539976|NCT01074957|Active Comparator|Breath-Stacking|Breath-Stacking group (BS) performed successive inspiratory efforts using a facial mask adapted to an unidirectional valve
11539977|NCT01074944|Experimental|Twice Daily (BID) Dose Regimen|Patients will receive either 50 mg BID or 100 mg BID
11539978|NCT01074944|Experimental|Once Daily (QD) Dose Regimen|Patients will receive either 100 mg QD or 200 mg QD
11539979|NCT01074931||Lopinavir/ritonavir group|This study is a non-interventional, observational study in which lopinavir/ritonavir is prescribed in the usual manner in accordance with the terms of China market authorization with regards to dose, population and indication. It is planned to enroll approximately 100 patients in total.
11539980|NCT01074918|Experimental|Potassium Magnesium Citrate|
11539981|NCT01074918|Active Comparator|Potassium Chloride|
11539982|NCT01074905|Active Comparator|Artesunate|2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.
11539983|NCT01074905|Active Comparator|Chloroquine|25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.
11539984|NCT01074905|Experimental|Chloroquine/Primaquine|Chloroquine 3 days and Primaquine 14 days
11539986|NCT01074892|Active Comparator|MPA 10 mg per os continuous 6 months|Per oral MPA 10 mg is taken daily for 6 months
11539987|NCT01074892|Active Comparator|LNG-IUD for 6 months|Levonorgestrel impregnated IUD is inserted into the uterine cavity and kept in situ for 6 months
11539988|NCT01074879|Experimental|Whey protein|20 g whey protein + 20 g carbohydrates
11539989|NCT01074879|Experimental|Milk protein|20 g milk protein + 20 g carbohydrates
11539990|NCT01074879|Active Comparator|Carbohydrates|40 g carbohydrates
11539991|NCT01074866|No Intervention|Pressure support|Non invasive ventilation under pressure support (PS)
11539992|NCT01074866|Active Comparator|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally Adjusted ventilatory Assist
11539993|NCT01074853|Experimental|Propranolol|Chronic dose escalation of propranolol over period of 6 to 8 weeks.
11539994|NCT01074853|Placebo Comparator|Placebo|Matched placebo used for dose escalation period of 6 to 8 weeks
11539995|NCT01074840|Active Comparator|Peanut|Peanut flour will be given in increasing amounts.
11539996|NCT01074840|No Intervention|Control|Subjects will be enrolled who meet the inclusion/exclusion criteria and followed as matched controls. These subjects will not receive any treatment.
11539997|NCT01074827|Experimental|Treadmill group|Specific gait training on treadmill
11539998|NCT01074827|Experimental|Strength training group|Eight weeks of intensive strength training
11539999|NCT01074801|Active Comparator|Closed-loop|Subcutaneous insulin delivery to be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
11540000|NCT01074801|Active Comparator|Control arm|Subcutaneous insulin delivery to be administered according the standard insulin pump settings
11540001|NCT01074788|Experimental|mind body intervention group|
11540002|NCT01074775|Experimental|Challenge group|Recipients of three challenge infections with oral M bovis
11540003|NCT01074762|No Intervention|Routine general practice care|In the comparison group, doctors were free to choose any treatment and change it over time. The study coordinating centre did not contact comparison practices after the end of recruitment (late 1991) until 1995.
11540004|NCT01074749|Active Comparator|Optisense lead|Patients with an Accent pacemaker and an OptiSense atrial lead
11540005|NCT01074749|Active Comparator|Tendril lead|Patients with an Accent pacemaker and a Tendril atrial lead
11540006|NCT01074723|Experimental|b-cryptoxanthin|
11540007|NCT01074723|Experimental|phytosterols|
11540008|NCT01074723|Experimental|b-cryptoxanthin plus phytosterols|
11540009|NCT01074710|Experimental|C13-URA|administered C13-URA 50, 100, 200mg in same subjects
11540010|NCT01074710|Placebo Comparator|Placebo|2 same subjects
11540011|NCT01074697|Active Comparator|Fosaprepitant dimeglumine|
11540012|NCT01074697|Placebo Comparator|Saline water|
11540013|NCT01074671|Other|No control arm|There is no control arm as part of the study design.
11540014|NCT01074658||severe aortic valve stenosis|elderly patients with severe aortic valve stenosis requiring treatment
11540015|NCT01074645|No Intervention|Placebo|Placebo was the multivitamin capsule which was similar in appearance as of Tenofovir disoproxil fumarate and was given once a day till 3 month.
11540016|NCT01074645|Active Comparator|Tenofovir disoproxil fumarate (TDF)|Tenofovir disoproxil fumarate (TDF) is a potent, rapidly acting, oral acyclic nucleotide analogue, reverse transcriptase inhibitor that has been shown to be highly effective in suppressing hepatitis B virus replication. Tenofovir has also shown excellent activity against HBV in both LAM- naïve and LAM-resistant patients. Its efficacy has not been evaluated in patients of reactivation of hepatitis B who present as ACLF
11540017|NCT01074619|Experimental|1|Memantine
11540018|NCT01074619|Placebo Comparator|2|Placebo
11540019|NCT01074606|Experimental|Toric|AcrySof Toric Intraocular Lens (IOL)
11540020|NCT01074593|Experimental|Test|Bergamo - Interferon beta-1a
11540021|NCT01074593|Active Comparator|Comparator - Merck Serono|Merck Serono - Interferon beta-1a
11540022|NCT01074580||Deterioration, Crohn's disease|Patients > 18 years old with a deterioration of Crohn's disease defined by CDAI >150 and requiring treatment with systemic steroids or TNF alfa inhibitors
11540023|NCT01074567|Experimental|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
11540024|NCT01074554|Experimental|Antibiotic Regimen|"The Antibiotic Regimen consists of Levaquin 750 mg loading on day 1, then 500 mg po QD and Ethambutol 15-25 mg/kg for a maximum of 1200mg QD and Azithromycin 500mg on day 1, then 250 mg po QD and Rifampin 5-10 mg/kg for a maximum of 300mg po QD.
~All four drugs are given concomitantly."
11540025|NCT01074554|Placebo Comparator|Placebo Regimen|The placebo regimen consists of Lactose tablets, one for each antibiotic with equivalent pills
11540026|NCT01074541|Active Comparator|Group 1|UV intensity 10 MIN
11540027|NCT01074541|Active Comparator|Group 2|UV intensity 5 MIN
11540028|NCT01074541|Active Comparator|Group 3|UV intensity 1 MIN
11540029|NCT01074541|Active Comparator|Group 4|UV intensity 20 MIN
11540030|NCT01074528|Experimental|mindfulness based stress reduction|8-week mindfulness based stress reduction program
11540031|NCT01074528|No Intervention|control group|patients who have to wait before entering the MBSR program or who do not want to follow this program
11540032|NCT01074502|Experimental|apremilast|apremilast 20 mgs twice a day for 12 weeks
11540033|NCT01074476|Experimental|1|Glucosamine sulphate tablets
11540034|NCT01074476|Placebo Comparator|2|Placebo tablets
11540035|NCT01074463|Experimental|1|Pramipexole Dihydrochloride 0.25 mg Tablets
11540036|NCT01074463|Active Comparator|2|Mirapex® 0.25 mg Tablets
11540037|NCT01074450|Experimental|1|Pramipexole Dihydrochloride 0.25 mg Tablets
11540038|NCT01074450|Active Comparator|2|Mirapex® 0.25 mg Tablets
11540039|NCT01074437|Other|Group A: Corticosteroid with Placebo|Group A will receive oral, liquid Prednisolone, which is the standard corticosteroid that we use here at Seattle Children's, and oral liquid placebo. The dose of prednisolone that Group A will receive will be 1-2mg/kg/day for 7 days and then the dose will be slowly reduced and then stopped after 3 weeks. This is a standard dose for IH treatment. Gastric prophylaxis (Zantac) will be given to help prevent any stomach problems associated with prednisolone. This treatment will be given for two months, as is our standard practice.
11540040|NCT01074437|Other|Group B: Corticosteroid with Propranolol|Group B will receive oral liquid prednisolone, and oral propranolol. As in Group A, the dose of prednisolone will be 1-2mg/kg/day for 7 days and then the dose will be slowly reduced and then stopped after 3 weeks. Oral liquid propranolol will be dosed at 2 mg/kg/day, following initiation in the Cardiology Clinic. Gastric prophylaxis (Zantac) will be given to help prevent any stomach problems associated with prednisolone.
11540041|NCT01074411|Experimental|Treatment (bortezomib, carboplatin)|Patients receive bortezomib IP and carboplatin IP on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11540042|NCT01074385|Other|Immediate Dignity Therapy|At registration, subjects will be mailed a questionnaire. The subject will then receive two separate dignity therapy sessions, about a week apart. Subjects will then be asked to complete a questionnaire 1-2 weeks after completing therapy sessions and one month after completing therapy sessions.
11540043|NCT01074385|Other|Wait List Dignity Therapy|At registration, subjects will be mailed a questionnaire. The subject will then receive two separate dignity therapy sessions; the first session will take place about 6 weeks after registration, with the second session occurring 1-3 weeks after the first. Subjects will then be asked to complete a questionnaire about one month after completing therapy sessions.
11540044|NCT01074372|Experimental|Cohort 1|Dose 1 versus placebo
11540045|NCT01074372|Experimental|Cohort 2|Dose 2 versus placebo
11540046|NCT01074372|Experimental|Cohort 3|Dose 3 versus placebo
11540047|NCT01074372|Experimental|Cohort 4|Dose 4 versus placebo
11540048|NCT01074359|Experimental|A0001|A0001 (0.75 g BID)
11540049|NCT01074359|Placebo Comparator|Placebo|Placebo
11540050|NCT01074320||Breast cancer patients on AIs|Breast cancer patients beginning Aromatase Inhibitor therapy
11540051|NCT01074307|Experimental|Low Dose Bisoprolol|
11540052|NCT01074307|Experimental|High Dose Bisoprolol|
11540053|NCT01074294|Placebo Comparator|Sugar pill|
11540054|NCT01074294|Experimental|OPC-34712|
11540055|NCT01074268|Experimental|IDeg OD|
11540056|NCT01074268|Active Comparator|IDet|
11540057|NCT01074255||Korean Participants Treated With EMEND (aprepitant)|Participants receiving EMEND on Treatment Days 1, 2, and 3 concomitantly with a corticosteroid and a 5-hydroxytryptamine 3 (5-HT3) antagonist.
11540058|NCT01074242||Rotateq|Korean Infants vaccinated with Rotateq in usual practice. The Rotateq vaccination series consists of 3 ready-to-use liquid (oral) doses with the first dose to be administered at age 6-12 weeks and subsequent doses to be administered at 4 to 10-week intervals.
11540059|NCT01074229|Placebo Comparator|Placebo|sterile normal saline as placebo
11540060|NCT01074229|Active Comparator|Drug .5% Ropivacaine|Instillation of 20 cc of 0.5% ropivacaine
11540061|NCT01074229|Active Comparator|20 cc of 0.25% ropivacaine|Instillation of 20 cc of 0.25% ropivacaine
11540062|NCT01074216|Experimental|vitamin D, vitamin D3|This is a Phase II study involving Stage IV colorectal cancer patients with serum vitamin D deficiency, to determine the ability to correct vitamin D deficiency and to maintain serum vitamin D levels (25-hydroxy vitamin D) once achieved.
11540063|NCT01074203|Experimental|Nitazoxanide arm|All patients will receive nitazoxanide
11540064|NCT01074190|Experimental|Group 1|spinal fentanyl 15 micrograms plus bupivacaine 2.5 mg followed by a patient controlled epidural analgesia (PCEA) maintenance infusion of bupivacaine 1mg/mL
11540065|NCT01074190|Experimental|Group 2|spinal fentanyl 15 micrograms plus bupivacaine 2.5 mg spinal followed by a PCEA infusion of fentanyl 1 micrograms/mL plus bupivacaine 0.8 mg/mL
11540066|NCT01074190|Active Comparator|Group 3|spinal fentanyl 15 micrograms plus bupivacaine 2.5mg followed by a PCEA infusion of fentanyl 2 micrograms/mL plus bupivacaine 0.625 mg/mL
11540067|NCT01074177|Experimental|BIBW 2992|BIBW 2992 Taken orally once a day
11540068|NCT01074164|Placebo Comparator|Control group|This group of subjects will serve as the control group and will follow a standard-of-care treatment regimen for AD, including the use of moisturizers and topical corticosteroids.
11540069|NCT01074164|Experimental|Accu-patch pellet|This group of subjects will follow a standard-of-care treatment regimen for AD, including the use of moisturizers and topical corticosteroids. Additionally, they will use a titanium pellet (accu-patch pellet) to self-apply pressure at the LI11 acupuncture pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times weekly for 1 month.
11540070|NCT01074151||Pregnant patients exposed to Cymbalta|Pregnant patients exposed to Cymbalta (duloxetine) at any time during pregnancy, beginning on or after the first day of the last menstrual period
11540071|NCT01074138|Experimental|Treatment|Subjects will be enrolled into a 28-day dose-escalation study. If no DLT's are observed during the first 28 days, subjects are eligible to continue treatment in the Extension Phase and can remain on treatment until toxicity occurs or until disease progression.
11540072|NCT01074125|Experimental|1 g/day|1 g/day KRX-0502 (ferric citrate)
11540073|NCT01074125|Experimental|6 g/day|6 g/day KRX-0502 (ferric citrate)
11540074|NCT01074125|Experimental|8 g/day|8 g/day KRX-0502 (ferric citrate)
11540075|NCT01074112||Abdominal Trauma|Patients with mechanism of injury that could produce abdominal bleeding
11540076|NCT01074112||Female Abdominal Pain|Female patients of child bearing age complaining of abdominal pain
11540077|NCT01074112||Difficult Vascular Access|Patients whom vascular access is needed but difficult
11540078|NCT01074112||Abdominal Aortic Anuerysm|Patients who complain of or are suspected of having an abdominal aortic aneurysm
11540079|NCT01074112||Pulseless Electrical Activity|Patients whom are in cardiac arrest and no pulse can be determined yet they show an electrical rhythm on the monitor
11540080|NCT01074112||Kidney Stones (Hydronephrosis)|Patients who complain of flank pain
11540081|NCT01074112||Plueral Effusion|Patients with a history of renal or hepatic problems and complain of difficulty breathing of an unknown etiology
11540082|NCT01074112||ETT placement|field intubated patients who need another means of verifying tube placement
11540083|NCT01074112||Transcutaneous Pacing|Patients who are being externally paced and need a method of determining mechanical capture
11540084|NCT01074112||Paramedic Discretion|Patients in whom the paramedic feels that an ultrasound study would provide useful data in their treatment
11540085|NCT01074099|Active Comparator|Control|CABG only
11540086|NCT01074099|Experimental|BMAC enhanced CABG|Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery
11540087|NCT01074086|Experimental|RAD 001|RAD 001 in day 1 and day 7 from 10 mg to 50 mg
11540088|NCT01074073|Other|Lithium/Lurasidone|Schizophrenia Patients
11540089|NCT01074060|Experimental|Arm I|"MOBILIZATION: Patients receive cyclophosphamide IV. Patients also receive filgrastim subcutaneously (SC) daily beginning approximately 24 hours later.
~TREATMENT/APHERESIS: Beginning 10 days after cyclophosphamide, patients receive plerixafor IV over 30 minutes followed by filgrastim SC on each day of apheresis."
11540090|NCT01074047|Experimental|Azacitidine|Azacitidine daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
11540091|NCT01074047|Active Comparator|Conventional Care Regimen|Conventional Care Regimen
11540092|NCT01074034|Experimental|AV Therapy Assessment group|appropriate system performance of the atrial and ventricular tachyarrhythmia therapies in the ASSURE device
11540093|NCT01074021|Experimental|Nimotuzumab plus chemoradiotherapy|
11540094|NCT01074021|Placebo Comparator|placebo plus chemoradiotherapy|
11540095|NCT01074008|Experimental|ABT-450/r (50/100 mg) once daily (QD) + pegIFN/RBV|Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
11540096|NCT01074008|Experimental|ABT-450/r (100/100 mg) once daily (QD) + pegIFN/RBV|Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
11540097|NCT01074008|Experimental|ABT-450/r (200/100 mg) once daily (QD) + pegIFN/RBV|Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
11540098|NCT01074008|Experimental|ABT-072 (100 mg) once daily (QD) + pegIFN/RBV|Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
11540099|NCT01074008|Experimental|ABT-072 (300 mg) once daily (QD) + pegIFN/RBV|Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
11540100|NCT01074008|Experimental|ABT-072 (600 mg) once daily (QD) + pegIFN/RBV|Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
11540101|NCT01074008|Experimental|ABT-333 (400 mg) twice a day (BID) + pegIFN/RBV|Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
11540102|NCT01074008|Experimental|ABT-333 (800 mg) twice daily (BID) + pegIFN/RBV|Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
11540103|NCT01074008|Placebo Comparator|Placebo + pegIFN/RBV|Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
11540104|NCT01073995|Active Comparator|Kenalog and Sensorcaine|"The following drugs will be administered during a one time injection of the appropriate spinal level based off clinical and radiographic information:
~Intervention:
~Kenalog 40 mg/ml and Sensorcaine 0.25% 1cc"
11540105|NCT01073995|Placebo Comparator|Saline|Saline injections will be used to mimic the Steroid dose
11540106|NCT01073982|Placebo Comparator|cherry flavored fruit drink|
11540107|NCT01073982|Experimental|tart cherry juice|
11540108|NCT01073969|Placebo Comparator|Control cereal|grain-based ready to eat cereal that does not contain active wheat bran extract
11540109|NCT01073969|Active Comparator|low dose|grain-based ready to eat cereal containing a low dose of wheat bran extract
11540110|NCT01073969|Active Comparator|High dose|grain-based ready to eat cereal that contains a high dose of wheat bran extract
11540111|NCT01073956|Placebo Comparator|Inactive electrotherapy|Inactive electrotherapy is applied to the painful points
11540112|NCT01073956|Active Comparator|Ultrasound|Ultrasound electrotherapy is applied to the painful points
11540113|NCT01073956|Active Comparator|Monopolar radiofrequency|Monopolar radiofrequency electrotherapy is applied to the painful points
11540114|NCT01073943|Experimental|PicoPrep|"Day Before method and consists of two separate doses: the first dose during the afternoon or early evening before the colonoscopy and the second dose 6 hours later during the evening before the colonoscopy."
11540115|NCT01073943|Active Comparator|HalfLytely|HalfLytely and Bisacodyl Tablets Bowel Prep Kit was used according to the approved labeled dosage and administration instructions. The two bisacodyl tablets were taken the day prior to the procedure and the HalfLytely was taken following the first bowel movement or 6 hours after the bisacodyl tablets.
11540422|NCT01071902|Experimental|Moxidex|Moxidex otic solution
11540116|NCT01073930|Experimental|PICOPREP|"Split Dose method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day, during the morning prior to the colonoscopy."
11540117|NCT01073930|Active Comparator|HalfLytely|HalfLytely and Bisacodyl Tablets Bowel Prep Kit was used according to the approved labeled dosage and administration instructions. The two bisacodyl tablets were taken the day prior to the procedure and the HalfLytely was taken following the first bowel movement or 6 hours after the bisacodyl tablets.
11540118|NCT01073917|Other|Spontaneous Breathing|Patients will be breathing spontaneously during anesthesia
11540119|NCT01073917|Other|Pressure controlled ventilation|Patients in the PPV group will be ventilated by pressure control (tidal volume 8-10 ml/kg, frequency 10-14, I:E 1:1, no PEEP, target CO2 4.5 kPa).
11540120|NCT01073917|Other|Pressure Support Ventilation|The patients in the PSV group will breathing spontaneously on the ventilator with assistance by inspiratory support pressure. The support pressure will be adjusted to achieve a tidal volume of 8-10 ml/kg.
11540121|NCT01073904|Experimental|Arm 1|
11540122|NCT01073904|Active Comparator|Arm 2|
11540123|NCT01073891|Active Comparator|Arm 1|
11540124|NCT01073891|Experimental|Arm 2|
11540125|NCT01073891|Experimental|Arm 3|
11540126|NCT01073865|Experimental|1|"Zoladex 10.8 mg (goserelin acetate) will be injected once every 12 weeks (± 7 days).
~One oral tamoxifen 20 mg tablet also will be taken daily"
11540127|NCT01073865|Active Comparator|2|Zoladex 3.6 mg (goserelin acetate) will be injected once every 4 weeks (± 7 days). One oral tamoxifen 20 mg tablet will also be taken daily.
11540128|NCT01073852|Placebo Comparator|Placebo|Patients will be taking placebo medication throughout study.
11540129|NCT01073852|Active Comparator|Hydroxychloroquine|Patients will be taking hydroxychloroquine throughout study.
11540130|NCT01073839|Experimental|Cisplatin plus Gemcitabine|Patients after resection of cholangiocellular carcinoma will be allocated to treatment with cisplatin plus gemcitabine.
11540131|NCT01073826|Active Comparator|Tocilizumab|Infusion of Tocilizumab and sport intervention
11540132|NCT01073826|Active Comparator|Sitagliptin|Intake of Sitagliptin and sport intervention
11540133|NCT01073826|Placebo Comparator|Placebo|Intake of placebo and sport intervention
11540134|NCT01073813|Active Comparator|Minocycline 100mg|Patients are in one of three strata (currently on Glatiramer acetate (GA), Interferon beta (IFN), or neither disease modifying therapy (DMT). There will be a minimum of 12 patients per strata. Patients will be randomized within each strata in a 2:1 fashion to receive either Minocycline 100mg twice daily or no treatment.
11540135|NCT01073813|No Intervention|No treatment|Patients are in one of three strata (currently on Glatiramer acetate (GA), Interferon beta (IFN), or neither disease modifying therapy (DMT). There will be a minimum of 12 patients per strata. Patients will be randomized within each strata in a 2:1 fashion to receive either Minocycline 100mg twice daily or no treatment.
11540136|NCT01073800|Active Comparator|atorvastatin 80 mg|active treatment
11540137|NCT01073800|Placebo Comparator|placebo|
11540138|NCT01073787|Active Comparator|Normal saline|
11540139|NCT01073787|Experimental|Normal saline and possible medication|
11540140|NCT01073774|Experimental|Side by Side|
11540141|NCT01073774|Active Comparator|couples control condition|
11540142|NCT01073761|Experimental|Everybody|All Subjects will receive the same intervention
11540143|NCT01073748|Active Comparator|asthmatic subjects|Asthmatic children will be randomly exposed to paracetamol and placebo consecutively and their lung functions will be blindly compared.
11540144|NCT01073748|Other|Healthy children|Children with no asthma as control group.
11540145|NCT01073735||Cancer Survivors|Examine the construct validity, short-term stability, internal consistency and item-response performance of a health-related needs assessment self-report instrument for adult childhood cancer survivors.
11540146|NCT01073722|Active Comparator|Left double lumen tube|Traditionally, single lung ventilation is obtained with a double lumen tube (DLT). In our institution a polyvinyl DLT (Broncho-cath, Mallinckrodt,) without carinal hook, is used. This type of tube exists of a tube with two lumen with two distal cuffs. One lumen (called the bronchial lumen) extends some distance further, has a slight curvature and has a small blue cuff. The other lumen (called the tracheal lumen) has a larger cuff. A DLT tube exists in four sizes and one can choose in a left or a right configuration. Almost always, we use a left sided DLT. A DLT has a much larger diameter than a standard single lumen endotracheal tube
11540147|NCT01073722|Active Comparator|EZ-blocker|The EZ-blocker (EZB) is a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. It is intended for use in combination with a standard single lumen tube. After the EZB is advanced trough the distal end of the single lumen tube, both extensions spread out and find their way in the left and right main stem bronchi. The place where the two extensions are attached to the shaft now rests on the carina. Fiber optic bronchoscopy should be used for proper positioning. After placement of the EZB, one of the cuffs can be inflated to obtain lung separation under direct visual inspection with fiber optic bronchoscopy.
11540148|NCT01073709|Experimental|Test|Acetaminophen extended release gelcaps 650 mg of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
11540149|NCT01073709|Active Comparator|Reference|Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)of McNeil Consumer & Specialty Pharmaceuticals, Division of MCNEIL-PPC, Inc. Fort Washington, PA 19034 USA
11540150|NCT01073696|Active Comparator|granisetron IV|
11540151|NCT01073696|Experimental|granisetron patch|
11540152|NCT01073683|Experimental|larynx preservation|Decision between surgery and Chemo-rt according to response to initial induction chemotherapy
11540153|NCT01073670|Active Comparator|Acetaminophen|Participants received a loading dose of acetaminophen (2600 mg) at induction followed by 1300 mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
11540154|NCT01073670|Experimental|Indomethacin|Participants were given 100 mg of indomethacin at induction and then 50 mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
11540155|NCT01073670|Experimental|Combination|Participants were given a loading dose of 1300 mg of acetaminophen and 50 mg of Indomethacin followed by 650mg of acetaminophen and 25 mg of indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
11540212|NCT01073267|Experimental|TSEBT|Total Skin Electron Beam Therapy (TSEBT) to dose of 12 Gy
11540156|NCT01073657|Experimental|Supported Education|Veterans received supported education services. A Veteran peer met weekly as needed with a subject for up to six months in a psycho-social rehabilitation service for meeting education goals. Goals included choosing a college, getting admitted or enrolled, and maintaining enrollment and completing classes.
11540157|NCT01073657|Active Comparator|General Peer Support|Matched attention was provided by a Veteran peer who met weekly with Veterans but who focused on help with any personal goal (eg, employment, housing) but not on education.
11540158|NCT01073644||Sunitinb malate|
11540159|NCT01073631||1|Patients who are indicated for use of voriconazole tablet.
11540160|NCT01073618||A.|Patients who are indicated for VFEND according to drug package insert.
11540161|NCT01073605|Active Comparator|Genotonorm A|Continuous 0.7 IU/kg/week or 0.03 mg/kg/day
11540162|NCT01073605|Active Comparator|Genotonorm B|Continuous, 1.4 IU/kg/week or 0.06 mg/kg/day
11540163|NCT01073605|Active Comparator|Genotonorm C|Intermittent, 1.4 IU/kg/week or 0.06 mg/kg/day
11540164|NCT01073592||CNV patiens|
11540165|NCT01073579||Sabril®|All patients in the U.S. who are prescribed Sabril must participate in this patient registry in order to receive Sabril.
11540166|NCT01073566|Experimental|Finesse|Finesse Insulin Delivery Patch
11540167|NCT01073566|Active Comparator|Usual injection device|Pen/Syringe
11540168|NCT01073553|Experimental|Arm 1|
11540169|NCT01073553|Active Comparator|Arm 2|
11540170|NCT01073540|Experimental|Arm 1|
11540171|NCT01073540|Active Comparator|Arm 2|
11540172|NCT01073527|Active Comparator|Hypertonic saline-salbutamol combination|NaCl 5% - 4cc (with standard treatment - salbutamol 0.5cc)
11540173|NCT01073527|Placebo Comparator|normal saline-salbutamol combination|Standard treatment normal saline 4cc with salbutamol 0.5cc
11540174|NCT01073501|Placebo Comparator|Placebo|Placebo versus pregabalin
11540175|NCT01073501|Experimental|Pregabalin|Placebo versus pregabalin
11540176|NCT01073488|Experimental|EMONC: Community mobilization, HBLSS and Facility Improvement|The intervention group received training in community mobilization activities, Home Based Life Saving Skills (HBLSS) and facility improvement.
11540177|NCT01073488|No Intervention|Control|The control group did not receive an intervention, but collected outcome data through a baseline maternal/newborn birth registry.
11540178|NCT01073475||Pregnant women|Pregnant women in the MNH cluster
11540179|NCT01073475||Male and Female Infants|Male and Female Infants delivered in the clusters
11540180|NCT01073462||Paricalcitol IV|Participants with chronic kidney disease stage 5 with secondary hyperparathyroidism and cardiac morbidity received intravenous (IV) paricalcitol (Zemplar) prescribed according to current practice with regards to dose, population and indication for up to 2 years.
11540181|NCT01073449||Cardiac device|All patients implanted with a cardiac device, pacemaker(PM)or Implantable Cardioverter Defibrillator (ICD)
11540182|NCT01073436||Discontinuation|Subjects who agree to discontinue their tyrosine kinase inhibitor(TKI)therapy, namely,imatinib mesylate, dasatinib, or nilotinib,and then followed to see if they can maintain a durable remission.
11540183|NCT01073423|Experimental|Yoga|
11540184|NCT01073423|Active Comparator|Music Therapy|
11540185|NCT01073410||Healthy, non-asthmatic controls|People who are non-asthmatic and non-smokers.
11540186|NCT01073410||Asthmatics|People who have been diagnosed with asthma.
11540187|NCT01073397|Experimental|Behavioral|Weekly Integral Yoga sessions lasting 90 minutes for 10 weeks with home practice.
11540188|NCT01073397|Active Comparator|Health and Wellness Classes|Weekly classes on health and wellness lasting 90 minutes for 10 weeks, with additional home practice
11540189|NCT01073397|No Intervention|Waitlist|This group receives usual care for 10 weeks and is then randomized to one of the study arms.
11540190|NCT01073384|Experimental|BDP 3 mg|1 mg TID
11540191|NCT01073384|Experimental|BDP 6 mg|2 mg TID
11540192|NCT01073384|Experimental|BDP 9 mg|3 mg TID
11540193|NCT01073384|Experimental|BDP 12 mg|4 mg TID
11540194|NCT01073371|Active Comparator|liposome-encapsulated 3% prilocaine|
11540195|NCT01073371|Active Comparator|3% plain prilocaine|
11540196|NCT01073371|Active Comparator|3% prilocaine with 0,03IU/mL felypressin|
11540197|NCT01073358|No Intervention|Group A: No routine hilar lymphadenectomy|Resection of colorectal liver metastases without routine hilar lymphadenectomy
11540198|NCT01073358|Experimental|Group B: Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases.
11540199|NCT01073345||Major hepatic resection|Patients undergoing resection of > 2 liver segments
11540200|NCT01073345||Minor hepatic resection|Patients undergoing resection of </= 2 liver segments
11540201|NCT01073345||Control group|Patients undergoing exploratory laparotomy for hepatobiliary disease without resection (e.g. due to inoperable disease)
11540202|NCT01073332|Placebo Comparator|Placebo|The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
11540203|NCT01073332|Experimental|Arginine antioxidant supplements|Dietary Supplement: Niteworks
11540204|NCT01073319|Placebo Comparator|Placebo|Matching oral placebo capsule as control.
11540205|NCT01073319|Active Comparator|Rivastigmine 3 mg|
11540206|NCT01073319|Active Comparator|Rivastigmine 6 mg|
11540207|NCT01073306|Experimental|Dengue Virus Subtype 2 Vaccine|Participants will receive a single dose of investigational vaccine for dengue virus subtype 2.
11540208|NCT01073306|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine.
11540209|NCT01073293|Experimental|Concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1
11540210|NCT01073293|Experimental|Non-concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1
11540211|NCT01073280||undeterminated neurological disease, cerebral endoscopy|patients without neurological diagnosis that require cerebral , meningeal diagnosis
11540271|NCT01072864|Experimental|30 g of walnuts|
11540213|NCT01073241|Active Comparator|transurethral prostatic resection|The patients' prostate was resected with the conventional Nesbit TURP.
11540214|NCT01073241|Experimental|ventral wall of urethra-preserving enucleation of prostate|The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.
11540215|NCT01073228|Active Comparator|EVP-6124 0.3 mg|one 0.3 mg capsule every day for 183 days
11540216|NCT01073228|Active Comparator|EVP-6124 1 mg|one 1 mg capsule every day for 183 days
11540217|NCT01073228|Active Comparator|EVP-6124 2 mg|one 2 mg capsule every day for 183 days
11540218|NCT01073228|Placebo Comparator|Placebo|Placebo every day for 183 days
11540219|NCT01073215|Active Comparator|Group Condition|
11540220|NCT01073215|Experimental|Self-Guided Condition|
11540221|NCT01073202|Active Comparator|ursodeoxycholic acid|
11540222|NCT01073202|Placebo Comparator|identical-appearing placebo|
11540223|NCT01073189|Experimental|Intra-Renal Fenoldopam|Intra-Renal Fenoldopam: Patients randomized to this wing will undergo placement of Angiodynamics Benefit catheter and receive intra-renal infusion of fenoldopm mesylate
11540224|NCT01073189|Active Comparator|Diuretic Control|Patients in the control group will be randomized to receive intra-venous diuretics as a comparator control
11540225|NCT01073176|Experimental|TEAMS|TEAMS has been designed to promote executive skills, memory and fine motor control, and includes game-like activities that allow for increases in task complexity.
11540226|NCT01073163|Experimental|Bendamustine with Rituximab|Participants were administered bendamustine intravenous (IV) infusion at 90 mg/m^2 on Days 1 and 2 of each 28-day cycle, and rituximab IV infusion at 375 mg/m^2 on Day 1 of each 28-day cycle.
11540227|NCT01073137||Diabetic Subjects|
11540228|NCT01073137||Non diabetic subjects|
11540229|NCT01073124|Active Comparator|Normal Saline|Normal Saline injected intraarticularly into the knee joint
11540230|NCT01073124|Experimental|Dilute Methylene Blue Dye|1 ml methylene blue dye per 500 ml normal saline injected intraarticularly into the knee
11540231|NCT01073111|Active Comparator|zotarolimus-eluting stents (ENDEAVOR®)|
11540232|NCT01073111|Active Comparator|sirolimus-eluting stents (CYPHER SELECT® PLUS)|
11540233|NCT01073111|Active Comparator|everolimus-eluting stents (PROMUS®)|
11540234|NCT01073085|Experimental|Web-based coaching|"Those in the coaching arm will benefit from e-mails with advice, information, support for smoking cessation. These mails will be adapted to their personal profile."
11540235|NCT01073085|Active Comparator|Self-help guide|"Those in the active comparator arm will be allowed to download a self-help guide with step-by-step advice for smoking cessation."
11540236|NCT01073072|Experimental|Tutomesh|Technique of abdominal wall reconstruction strengthened by Tutomesh®
11540237|NCT01073072|Active Comparator|conventional repair|Conventional technique to repair incisional or abdominal wall hernias
11540238|NCT01073059|Experimental|Valproic acid|
11540239|NCT01073046||Place Naso-Gastric/Jejunal Tube Group|In this group a silastic naso-gastric/jejunal tube is placed (Rusch® distributed by Teleflex Medical Srl)
11540240|NCT01073046||No Naso-Gastric/Jejunal Tube Group|In this group a silastic naso-gastric/jejunal tube is not placed
11540241|NCT01073033|Experimental|oral supplement1|Oral supplement for pregnant and lactating mothers
11540242|NCT01073033|Active Comparator|oral supplement 2|Oral supplement for pregnant and lactating mothers
11540243|NCT01073033|No Intervention|Reference|No oral supplementation during pregnancy and lactating.
11540244|NCT01073020|Active Comparator|Gastric Band vs Intensive Medical Diabetes & Weight Management|
11540245|NCT01073020|Active Comparator|RYGB vs Intensive Medical Diabetes & Weight Management|
11540246|NCT01073007|Experimental|Simvastatin|Simvastatin 40 mg daily for 3 months.
11540247|NCT01073007|Placebo Comparator|Placebo|
11540248|NCT01072981|Experimental|HyperAcute-Pancreas Immunotherapy + Standard of Care|*Adjuvant Standard of Care Treatment (SOC) consisting of gemcitabine with or without 5FU chemoradiation + HyperAcute Immunotherapy
11540249|NCT01072981|Active Comparator|Standard of Care alone|*Adjuvant Standard of Care Treatment (SOC) consisting of gemcitabine with or without 5FU chemoradiation Alone
11540250|NCT01072968|Experimental|BF2.649|BF2.649 capsules dosed at 5 mg, 10 mg, 20 mg
11540251|NCT01072968|Placebo Comparator|Placebo|Capsules of placebo containing lactose with low, medium and high dosage
11540252|NCT01072955|Experimental|heparin of bovine origin|5.000UI/mL bottle with 5mL
11540253|NCT01072955|Active Comparator|heparin of porcine origin|5000 USP Heparin Units / mL vial with 10 mL vial
11540254|NCT01072942|Experimental|Arm 1|
11540255|NCT01072942|Placebo Comparator|Arm 2|
11540256|NCT01072929|Experimental|Armodafinil 150 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 150 mg/day. The 150 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment.
11540257|NCT01072929|Experimental|Armodafinil 200 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 200 mg/day. The 200 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment. This treatment arm was discontinued via a protocol amendment.
11540258|NCT01072929|Placebo Comparator|Placebo|Participants were administered placebo and titrated to match the armodafinil treatment arms. Total treatment was 8 weeks.
11540259|NCT01072916||IBS|Subjects with IBS-D
11540260|NCT01072916||Healthy|Healthy Subjects
11540261|NCT01072903||IBS|Subjects with IBS
11540262|NCT01072903||Healthy|Healthy Controls
11540263|NCT01072890|Experimental|Temsirolimus and Pazopanib|
11540264|NCT01072877|Experimental|Polidocanol injectable foam 0.125%|Polidocanol injectable foam 0.125%
11540265|NCT01072877|Experimental|Polidocanol injectable foam 0.5%|Polidocanol injectable foam 0.5%
11540266|NCT01072877|Experimental|Polidocanol injectable foam 1.0%|Polidocanol injectable foam 1.0%
11540267|NCT01072877|Experimental|Polidocanol injectable foam 2.0%|Polidocanol injectable foam 2.0%
11540268|NCT01072877|Placebo Comparator|Vehicle|Injection of vehicle comparator
11540269|NCT01072864|Experimental|5 g of walnuts|
11540270|NCT01072864|Experimental|20 g of walnuts|
11540521|NCT01071122|Experimental|Arm 1|
11540273|NCT01072851|Experimental|Multimedia educational tool|Multimedia education tool - A culturally competent video explaining the importance of and the process of colorectal cancer screening
11540274|NCT01072851|Experimental|Print educational tool|Print media - A culturally competent printed brochure explaining the importance of and the process of colorectal cancer screening
11540275|NCT01072851|Active Comparator|No intervention|Usual and customary waiting room process - Usual and customary office waiting period with access to standard nationally generated colorectal cancer screening informational material in the waiting room and/or exam room.
11540276|NCT01072838|Other|Dose Escalation|
11540277|NCT01072825||transgender people starting hormone treatment|
11540278|NCT01072812|Experimental|Posiphen® tartrate capsules|
11540279|NCT01072799|Experimental|Low dose H1N1|
11540280|NCT01072799|Experimental|Mid dose H1N1|
11540281|NCT01072799|Experimental|High dose H1N1|
11540282|NCT01072799|Placebo Comparator|Placebo|
11540283|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 1|Participants will receive the TetraVax-DV admixture 1 vaccine.
11540284|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 2|Participants will receive the TetraVax-DV admixture 2 vaccine.
11540285|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 3|Participants will receive the TetraVax-DV admixture 3 vaccine.
11540286|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 4|Participants will receive the TetraVax-DV admixture 4 vaccine.
11540287|NCT01072786|Placebo Comparator|Placebo|Participants will receive the placebo.
11540288|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 5|Participants will receive the TetraVax-DV admixture 5 vaccine.
11540289|NCT01072773|Experimental|Bortez/Cyc/Dex|Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.
11540290|NCT01072760|Experimental|K wire|
11540291|NCT01072747|Experimental|heparin of bovine origin|Laboratory Bergamo Ltda. 5.000UI/mL bottle with 5mL
11540292|NCT01072747|Active Comparator|heparin of porcine origin|APP Pharmaceuticals
11540293|NCT01072734|Experimental|Vaccine group|single group: all included patients will receive the vaccine
11540294|NCT01072721|Other|Fibrosis group|a single arm with the two interventions (elastometry and biopsy)
11540295|NCT01072695|Experimental|Arm 1|
11540296|NCT01072695|Experimental|Arm 2|
11540297|NCT01072695|Experimental|Arm 3|
11540298|NCT01072669|Active Comparator|ambrisentan|"drug arm
~use of ambrisentan in limited scleroderma patients with raynaud's to evaluate digital microvascular flow"
11540299|NCT01072669|Placebo Comparator|sugar pill|those getting sugar pill to evaluate if the active drug improves digital microvascular flow in limited scleroderma patients
11540300|NCT01072656|Active Comparator|Treatment group|Active stimulation and programmed to the settings found to be optimal during the titration process.
11540301|NCT01072656|Sham Comparator|Control group|IPG is set to ON but the voltage is set to 0V.
11540302|NCT01072643|Experimental|Dexmedetomidine|To study safety of DEX with regard to effect on PVR; There will be 3 study groups (n=8 per group). The groups will be based on DEX doses as follows- Group 1 - Bolus 1 mcg/kg followed by infusion 0.7 mcg/kg/hr Group 2 - Bolus 1.5 mcg/kg followed by infusion 1.05 mcg/kg/hr Group 3 - Bolus 2 mcg/kg followed by infusion 1.4 mcg/kg/hr
11540303|NCT01072630|Placebo Comparator|Placebo|Participants were administered placebo and titrated to match the armodafinil treatment arms. Total treatment was 8 weeks.
11540304|NCT01072630|Experimental|Armodafinil 150 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 150 mg/day. The 150 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment.
11540305|NCT01072630|Experimental|Armodafinil 200 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 200 mg/day. The 200 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment. This treatment arm was discontinued via a protocol amendment.
11540306|NCT01072617|Experimental|Safety of rTMS in schizophrenia patients|Participants will receive repetitive transcranial magnetic stimulation via MagPro x100 device to the vermis of cerebellum twice a day over 5 days
11540307|NCT01072604|Experimental|Arm 1|
11540308|NCT01072604|Experimental|Arm 2|
11540309|NCT01072604|Active Comparator|Arm 3|
11540310|NCT01072604|Active Comparator|Arm 4|
11540311|NCT01072591|Experimental|1|
11540312|NCT01072591|Placebo Comparator|2|
11540313|NCT01072578|Experimental|1|
11540314|NCT01072578|Experimental|2|
11540315|NCT01072565|Active Comparator|SMBG Only|You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be blinded (neither you nor the study doctor will be able to see the CGM measurements until your final study visit). Only your SMBG measurements will be considered to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of less than 7%.
11540316|NCT01072565|Active Comparator|SMBG and CGM|You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be downloaded at each study visit and will be considered along with your SMBG measurements to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of 7%.
11540317|NCT01072552||Treated|Palivizumab treated
11540318|NCT01072552||Untreated|Palivizumab untreated
11540319|NCT01072539||Patients who have approved indications of Tygacil|"Approved indications of Tygacil
~-complicated intraabdominal infection, complicated skin and skin structure infection, community-acquired bacterial pneumonia"
11540320|NCT01072526|Active Comparator|Intervention|Subjects will receive Euphrasia-based homeopathic therapy (Artificial Tears) in combination with cyclosporin solution (Restasis) .
11540321|NCT01072526|Placebo Comparator|Control|Subjects will receive placebo in combination with cyclosporin solution (Restasis) .
11540322|NCT01072513|Other|Semen analysis|Analysis of semen before and after proton radiation therapy.
11540323|NCT01072500|Active Comparator|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
11540324|NCT01072500|Active Comparator|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
11540325|NCT01072487|Experimental|Capnography|Arm with capnographic monitoring
11540326|NCT01072487|No Intervention|Standard|Standard monitoring.
11540327|NCT01072474|Experimental|Capnography|Arm with capnographic monitoring
11540328|NCT01072474|Placebo Comparator|Standard|Standard monitoring.
11540329|NCT01072461|Active Comparator|Train Paretic Hand and Arm Separate|Eight three hour training sessions of robotically facilitated hand and arm training in complex virtual environments, using activities that train the fingers in isolation and other activities that train the arm in isolation.
11540330|NCT01072461|Experimental|Train Paretic Hand and Arm Together|
11540331|NCT01072461|Experimental|Train Both Hands Together in VE|
11540332|NCT01072448|Experimental|Indacaterol 75 μg|Patients inhaled indacaterol 75 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11540333|NCT01072448|Placebo Comparator|Placebo to indacaterol|Patients inhaled placebo to indacaterol once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11540334|NCT01072435|Active Comparator|patient-controlled sedation|PCS
11540335|NCT01072435|Active Comparator|target-controlled infusion|TCI
11540336|NCT01072422|Experimental|counseling based on answers in TTQ|40 participating primary health care nurses will be randomly assigned to this arm. Each nurse will identify 5 consecutive patients with COPD who smoke (n = 200 total patients). The nurses will ask the patients to fill in the assessment protocol, TTQ. The nurses will then provide an intervention to each patient in the form of individual treatment on the basis of that patient's answers to the TTQ.
11540337|NCT01072409|Other|Single Arm|Single arm design
11540338|NCT01072396|Active Comparator|18 mcg tiotropium|Patient to receive 1 tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
11540339|NCT01072396|Placebo Comparator|Placebo|Patient to receive 1 placebo inhalation powder capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler
11540340|NCT01072396|No Intervention|Control|Age and gender matched control subjects to conduct incremental and constant work rate exercise tests for comparison to subjects with early stage COPD
11540341|NCT01072383|Experimental|BT061|receiving BT061 (active compound)
11540342|NCT01072383|Placebo Comparator|Placebo|receiving a placebo
11540343|NCT01072370|Active Comparator|Treatment Group 1|
11540344|NCT01072370|Sham Comparator|Treatment Group 2|
11540345|NCT01072357|Active Comparator|Avastin® (bevacizumab)|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 milliliter (mL) (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks.
~The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
11540346|NCT01072357|Placebo Comparator|0.9% NaCl & Refresh Liquigel|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% sodium chloride (NaCl). Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks.
~The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
11540347|NCT01072344|Experimental|Chamomile Extract|Pharmaceutical grade oral chamomile extract.
11540348|NCT01072344|Placebo Comparator|Placebo|Pharmaceutical grade lactose monohydrate.
11540349|NCT01072331|Experimental|MP-513 10 mg, once a day, for 4 weeks|
11540350|NCT01072331|Experimental|MP-513 20 mg, once a day, for 4 weeks|
11540351|NCT01072331|Placebo Comparator|Placebo of MP-513|
11540352|NCT01072318|Experimental|Letrozole, DFS|Efficacy evaluation of extended letrozole after 5 year fareston use
11540353|NCT01072305|Experimental|Intermittent pneumatic compression (IPC)|IPC from induction of general anesthesia to completion of skin closure.
11540354|NCT01072305|Placebo Comparator|control|IPC - placebo from induction of general anesthesia to closure of the skin
11540355|NCT01072292|Experimental|CBT-I|CBT-I
11540356|NCT01072292|Active Comparator|Wellness Education|Wellness Education
11540357|NCT01072279|Experimental|Burundi: T24|
11540358|NCT01072279|Experimental|Burundi: TNFP|
11540359|NCT01072279|Experimental|Burundi: T18|
11540360|NCT01072279|No Intervention|Burundi: Control|
11540361|NCT01072279|Experimental|Guatemala: PROCOMIDA|
11540362|NCT01072279|Experimental|Guatemala: no family ration|
11540363|NCT01072279|Experimental|Guatemala: LNS|
11540364|NCT01072279|Experimental|Guatemala: Sprinkles|
11540365|NCT01072279|Experimental|Guatemala: reduced family ration|
11540366|NCT01072279|No Intervention|Guatemala: control|
11540367|NCT01072266|Experimental|INCB028060|Subjects will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group of patients may be enrolled and receive study drug. The initial cohort will be treated with 10 mg QD. The second cohort will be treated with 20 mg QD. The third cohort will be treated with 50 mg QD. Subsequent cohorts will be treated with two times the dose of the prior cohort to a limited toxicity level.
11540368|NCT01072253||eye amputated|lost an eye
11540369|NCT01072240||Cohort|
11540370|NCT01072227||Single Group|
11540371|NCT01072214|Experimental|1.6 mg|The actual dosage is 10 mg/ml (GW786034) given 4 times a day for a maximum daily dosage of 1.6mg
11540372|NCT01072214|Experimental|TBD COHORT 2|Dose escalation amount to be determined (TBD) after results from Cohort 1 analyzed
11540522|NCT01071122|Active Comparator|Arm 2|
11540373|NCT01072214|Placebo Comparator|Placebo|Subjects will receive placebo (drops without drug).
11540374|NCT01072214|Experimental|TBD COHORT 3|Dose escalation amount to be determined (TBD) after results from Cohort 2 analyzed
11540375|NCT01072201|Experimental|Total toothpaste|Triclosan/copolymer/fluoride toothpaste
11540376|NCT01072201|Placebo Comparator|Ultrabrite toothpaste|Fluoride Toothpaste
11540377|NCT01072188|Active Comparator|ProClude Prophylaxis paste-A|Arginine Bicarbonate prophylaxis paste
11540378|NCT01072188|Placebo Comparator|Nupro-M Prophylaxis paste -B|Control prophylaxis paste (Fluoride free - placebo)
11540379|NCT01072175|Experimental|Arm Part A|Day 1: GSK2118436 75mg; Day 2 through Day 16: GSK1120212 2mg; Day 15: GSK2118436 75mg +GSK1120212 2mg Drug-drug interaction
11540380|NCT01072175|Experimental|Arm Part B|GSK2118436 + GSK1120212 Dose escalation to a maximum tolerated combination dose
11540381|NCT01072175|Experimental|Arm Part C|GSK2118436 + GSK1120212 cohort expansion for safety and efficacy
11540382|NCT01072162|Experimental|Arm B|25 mg powder for oral suspension single dose fasted.
11540383|NCT01072162|Experimental|Arm C|25 mg powder for oral suspension administered with a meal
11540384|NCT01072162|Experimental|Arm D|25 mg powder for oral suspension administered 2 hours prior to meal
11540385|NCT01072162|Experimental|Arm E|25 mg powder for oral suspension administered 2 hours after to meal
11540386|NCT01072162|Other|Arm A|Commercially available eltrombopag 25 mg tablet
11540387|NCT01072149|Experimental|50mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
11540388|NCT01072149|Experimental|100mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
11540389|NCT01072149|Experimental|200mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
11540390|NCT01072149|Placebo Comparator|placebo|placebo
11540391|NCT01072136|Placebo Comparator|Placebo|Placebo.
11540392|NCT01072136|Experimental|Azithromycin/Cefixime|A single dose of cefixime 400 mg (1 tablet oral at 400 mg) and azithromycin 1 gram (2 tablets oral at 500 mg each).
11540393|NCT01072110||Group 1: Patients with diarrhea undergoing endoscopy|Standard video colonoscope.
11540394|NCT01072110||Group 2: Patients with diarrhea undergoing endoscopy.|Confocal laser endomicroscopy (CLE).
11540395|NCT01072097|Active Comparator|Atorvastatin|6 months atorvastatin 20mg/day treatment
11540396|NCT01072097|Placebo Comparator|Placebo|6 months placebo treatment
11540397|NCT01072084||Patients with food allergy|
11540398|NCT01072084||Healthy subjects|
11540399|NCT01072071|No Intervention|Control group|Patients will be receiving standard of care ICU treatment of their underlying disease according to internationally accepted guidelines and recommendations.
11540400|NCT01072071|Experimental|Furosemide group|patients will be receiving standard of care ICU treatment of their underlying condition according to international guidelines and recommendations. In addition, furosemide will be administered in continuous infusion as per protocol in order to achieve a preset target diuresis that is adjusted according to haemodynamic tolerance.
11540401|NCT01072058|Other|TNF blockers|
11540402|NCT01072045|Active Comparator|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses.
11540403|NCT01072045|Active Comparator|Prednisone|Oral prednisone , at a dose of 2mg/kg/day, divided in 2 doses.
11540404|NCT01072032|Experimental|Low-Reward|Low-Reward Anklebot training Group: The low reward-feedback group receives the Anklebot training with only immediate feedback on target successes, without cumulative scores and with minimal social interaction with the research team.
11540405|NCT01072032|Active Comparator|High-Reward|High-Reward Anklebot training Group: The high-reward group receives cumulative scores and abundant social interaction and are eligible for prizes during each training session and at completion of the study
11540406|NCT01072019|Active Comparator|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
11540407|NCT01072019|Active Comparator|MRI generated patient specific custom cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
11540408|NCT01072006||Control Group|Control group without traumatic brain injury (TBI) or post-traumatic stress disorder (PTSD)
11540409|NCT01072006||PTSD Group|PTSD (not TBI)
11540410|NCT01072006||TBI Group|TBI (no PTSD)
11540411|NCT01072006||TBI+PTSD Group|Combined TBI history and PTSD
11540412|NCT01071993|Active Comparator|atorvastatin|
11540413|NCT01071993|Placebo Comparator|placebo|
11540414|NCT01071980|Active Comparator|Specific resistance training|3 x 20 min a week of specific resistance training for 20 weeks
11540415|NCT01071980|No Intervention|Control|Control group
11540416|NCT01071967|Experimental|Community-based nurse care management|Participants randomized to receive the intervention worked with a nurse care manager who provided them with a comprehensive set of geriatric and chronic disease preventive services.
11540417|NCT01071967|No Intervention|Usual care|Participants randomized to the control group received usual care without the involvement of a nurse care manager.
11540418|NCT01071954|Experimental|Romiplostim|Participants received romiplostim administered by subcutaneous injection once a week. The starting dose of romiplostim was 1 μg/kg; weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of between 50 x 10^9/L and 200 x 10^9/L.
11540419|NCT01071941|Experimental|Group 1|The first subjects will receive a single infusion of rRp450. Subsequent subjects will receive rRp450 as four doses administered every 1-2 weeks.
11540420|NCT01071928|Experimental|Docetaxel and ASA404 in Combination|
11540421|NCT01071915|Experimental|Degarelix 240/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenace of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
11540423|NCT01071902|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
11540424|NCT01071902|Placebo Comparator|Vehicle|Vehicle
11540425|NCT01071889|Other|Brotizolam|Treatment response will be evaluated for each treatment arm. Good Response (GR) - is considered as an improvement of 30% in efficacy parameters of Flumazenil treatment in comparison to placebo
11540426|NCT01071889|Other|Zolpidem|Treatment response will be evaluated for each treatment arm. Good Response (GR) - is considered as an improvement of 30% in efficacy parameters of Flumazenil treatment in comparison to placebo.
11540427|NCT01071876|Experimental|BF2.649|BF2.649 capsules dosed at 5mg, 10 mg, 20mg
11540428|NCT01071876|Placebo Comparator|Placebo|Capsules of Placebo containing lactose with low, medium and high dosage
11540429|NCT01071863||Rheumatoid Arthritis (RA) Patient Group|Patients with RA who have been refered for biological drug treatment
11540430|NCT01071863||Control Group|20 people of same age and sex as the RA patient cohort
11540431|NCT01071850|Experimental|ASP1941 lowest dose|oral tablet
11540432|NCT01071850|Experimental|ASP1941 low dose|oral tablet
11540433|NCT01071850|Experimental|ASP1941 high dose|oral tablet
11540434|NCT01071850|Experimental|ASP1941 highest dose|oral tablet
11540435|NCT01071850|Active Comparator|Metformin|oral tablet
11540436|NCT01071850|Placebo Comparator|Placebo|oral tablet
11540437|NCT01071837|Active Comparator|Re-Irradiation|33% of the patients will be randomized to reirradiation (RT) alone. They will receive 36 Gy (2 Gy per fraction)
11540438|NCT01071837|Experimental|Re-Irradiation + APG101|66% of the patients will be randomized to reirradiation (RT) + 400 mg APG101 weekly. They will receive 36 Gy (2 Gy per fraction) and 400 mg APG101 weekly as an intravenous infusion
11540439|NCT01071824|Active Comparator|Transverse coloplasty pouch (Short limb)|The short limb is the standard technique of transverse coloplasty pouch.
11540440|NCT01071824|Experimental|Transverse coloplasty pouch (Long limb)|The long limb relates to straight coloanal anastomosis.
11540441|NCT01071811|No Intervention|Control group|Participants assigned to the control group received a leaflet from the National Board of Health in Denmark recommending all adults to be physical active for 30 minutes each day of moderate intensity.
11540442|NCT01071811|Experimental|Pedometer group|Received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program, a handout with a summary of the pedometer program, and a calendar for registration of daily steps.
11540443|NCT01071798||Main Analysis Set|Participants who received at least one cycle of rituximab
11540444|NCT01071785|No Intervention|usual diet|no dietary or drug intervention. Patients followed their usual diet.
11540445|NCT01071785|Experimental|guar gum|guar gum
11540446|NCT01071772|Experimental|euglycemia|
11540447|NCT01071772|Experimental|hyperglycemia|
11540448|NCT01071759||pregnancy|
11540449|NCT01071746||Acute decompensation of cirrhosis|acute decompensation of liver function occuring secondary to precipitating events such as sepsis, GI bleed.
11540450|NCT01071733||ultrasound wrist|
11540451|NCT01071733||ultrasound finger|
11540452|NCT01071733||ultrasound ankle|
11540453|NCT01071720|Other|CKD-501 1mg (fed-fasted group)|CKD-501 1mg should be administered following a high-fat, high-caloric diet(fed condition) in one period and on an empty stomach(fasting condition) in the other period.
11540454|NCT01071720|Other|CKD-501 1mg (fasted-fed group)|CKD-501 1mg should be administered on an empty stomach(fasting condition) in one period and following a high-fat, high-caloric diet(fed condition) in the other period.
11540455|NCT01071707||Confirmed Diagnosis of IPF|Subjects in this cohort will continue beyond the screening visit(s) for longitudinal follow up visits for a minimum of 48 weeks and maximum of 80 weeks.
11540456|NCT01071707||No diagnosis of IPF|Subjects that complete screening visits and do not obtain a confirmed diagnosis of IPF will conclude the study at screening, at the time point where IPF is ruled out as a diagnosis.
11540457|NCT01071694||Group 1|
11540458|NCT01071681||Group 1|
11540459|NCT01071668||GEM-2 Cohort|Women who have a low risk pregnancy before onset of labor. Patients included in the study who will be hospitalized with spontaneous labor at term with intact membranes or preterm labor will be included in the study group. Patients with premature rupture of membranes or induction of labor will be analyzed separately.
11540460|NCT01071655|Experimental|2|"Patients with zero favorable genotype: BVZ + XELIRI.
~Patients with one favorable genotype: TS 3'UTR +6bp/+6bp and ERCC1-118 T/T: BVZ + XELOX or TS 3'UTR +6bp/-6bp and ERCC1-118 C/T ó C/C: BVZ + FUIRI.
~Patients with two favorable genotypes : BVZ + FUOX."
11540461|NCT01071655|Active Comparator|1|BVZ + XELOX
11540462|NCT01071642|No Intervention|continue ace-i and arb's versus dicontinue|
11540463|NCT01071642|Active Comparator|group b|
11540464|NCT01071642|Active Comparator|group c|
11540465|NCT01071629|Active Comparator|Combined interval and strength training|CHF Pts randomly designed at the combined interval and strength training group
11540466|NCT01071629|Active Comparator|Aerobic interval training|CHF Patients that randomly designed to participate at the interval training group
11540467|NCT01071577||Healthy Volunteers|Healthy volunteers wanting to donate BMSC for allogeneic use
11540468|NCT01071577||Patients|Patients donating BMSC for autologous use
11540469|NCT01071564|Experimental|Treatment (RO4929097 and vismodegib)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on day 1 or days -2, -1, and 1 of course 1 and days 1-3 and 8-10 of course 2 and all subsequent courses. Patients also receive vismodegib PO QD beginning day 8 of course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11540470|NCT01071551|Experimental|Lifestyle and health promotion|"The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care."
11540471|NCT01071551|Active Comparator|Physical activity only|Children allocated to this group will attend physical activity classes only.
11540523|NCT01071122|Active Comparator|Arm 3|
11540472|NCT01071538|Experimental|Buprenorphine|Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
11540473|NCT01071525|Active Comparator|Niacin|Hypercholesterolemic patients with high-density lipoprotein (HDL) less than 40 mg% will receive Niacin\Laropiprant.
11540474|NCT01071525|No Intervention|Control|Maching subjects will receive no medication, Blood tests will be drawn for laboratory tests.
11540475|NCT01071512|Experimental|Tysabri|Natalizumab 300 mg IV every 4 weeks
11540476|NCT01071499|Active Comparator|1|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
11540477|NCT01071499|Active Comparator|2|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
11540478|NCT01071499|Active Comparator|3|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
11540479|NCT01071473|Other|Exercise Group|Survivors of childhood cancer treated with anthracyclines and known to have cardiomyopathy will participate in a 12 week exercise intervention.
11540480|NCT01071460|Other|SFA Stenting|
11540481|NCT01071447|Active Comparator|Rheumatologist-led clinic|Rheumatologist-led clinic: The subjects are seeing a rheumatologist after six months and after 12-months of intervention and have the possibility to contact the rheumatology clinic
11540482|NCT01071447|Experimental|Nurse-led clinic|The subjects are seeing a rheumatology nurse after six months and a rheumatologist after 12 months of intervention and have the possibility to contact the rheumatology nurse during the intervention.
11540483|NCT01071421||Control Group (B): Other Infections|Other infections admitted to the hospital
11540484|NCT01071421||Community Acquired Pneumonia (Group A)|Patients admitted to hospital with Community Acquired Pneumonia defined by respiratory symptoms, fever and lung infiltrates
11540485|NCT01071408|Experimental|Stroke Prevention Program + Usual Care|Stroke Prevention Care Program + Usual Care. The Stroke prevention care program is in addition, not a substitute for usual care. Persons randomized to this arm are eligible to all care, including care by stroke specialists, while enrolled in the intervention.
11540486|NCT01071408|No Intervention|Usual care|
11540487|NCT01071395|Experimental|Amantadine|Amantadine 100mg tab BID or TID for duration of study
11540488|NCT01071395|Placebo Comparator|Placebo|Placebo one tab BID or TID for duration of study
11540489|NCT01071369|Active Comparator|Xylocaine|0.5% Xylocaine
11540490|NCT01071369|Active Comparator|Xylocaine and Celestone|0.5% Xylocaine with 6 mg of non-particulate Celestone.
11540491|NCT01071356|Experimental|Intensive MI|9 hours of Motivational Interviewing + outpatient substance abuse treatment
11540492|NCT01071356|Active Comparator|Single session MI|1.5 hours of Motivational Interviewing + 8 hours of time equivalent nutrition classes +outpatient substance abuse treatment
11540493|NCT01071317|Experimental|Comprehensive care|Reinforcement of diagnosis, education, medications, and referral
11540494|NCT01071317|Active Comparator|Typical care|Usual care
11540495|NCT01071304|Experimental|All Participants|In Part 1, all participants received a single oral dose of 2 mg midazolam on Day -2. On Days 1-5, all participants received daily single oral doses of ridaforolimus 40 mg ( 4 x 10 mg tablets). On Day 5, all participants received a single oral dose of 2 mg midazolam coadministered with the dose of ridaforolimus. Participants had the option to continue into Part 2 of this study.
11540496|NCT01071291|Experimental|Arm A|Arm A will receive a Niaspan treatment in Period 1 and Placebo treatment in Period 2
11540497|NCT01071291|Experimental|Arm B|Arm B will receive a Placebo treatment in Period 1 and Niaspan treatment in Period 2
11540498|NCT01071278||Patients treated within a disease management program|Participant prescribed Tredaptive® for dyslipidemia and also participated in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
11540499|NCT01071278||Patients treated outside a disease management program|Participant prescribed Tredaptive® for dyslipidemia and did not participate in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
11540500|NCT01071265|Placebo Comparator|Sham RIPC|Inflation of thigh pneumatic tourniquet to <15 mmHg
11540501|NCT01071265|Active Comparator|Active RIPC|300 mmHg inflation of thigh pneumatic tourniquet for three cycles of 5 minutes each with 5 minutes of no inflation between cycles.
11540502|NCT01071252|Experimental|AIN457 1x25mg|
11540503|NCT01071252|Experimental|AIN457 3x25mg|
11540504|NCT01071252|Experimental|AIN457 3x75mg|
11540505|NCT01071252|Experimental|AIN457 3x150mg|
11540506|NCT01071252|Placebo Comparator|Placebo|
11540507|NCT01071239|Experimental|Bone marrow processing|Bone Marrow processing using the CliniMACs device
11540508|NCT01071226|Experimental|Stratum 1|Patients receiving an unrelated donor or partially matched related donor.
11540509|NCT01071226|Experimental|Stratum 2|For the patient's whose donors are haploidentical or a 2 antigen mismatched where one of the mismatches includes DRB1
11540510|NCT01071200|Experimental|A|Subjects treated with r-hFSH and r-hLH (2:1 ratio of r-hFSH:r-hLH)
11540511|NCT01071200|Active Comparator|B|Subjects treated with r-hFSH alone
11540512|NCT01071187|Experimental|Varenicline|Treatment with varenicline with 0,5mg daily on day 1-3, 1mg daily on day 4-7 and 2mg daily on day 8-84.
11540513|NCT01071187|Placebo Comparator|Placebo|
11540514|NCT01071174|Placebo Comparator|Placebo Ring|Vaginal Ring containing no drug substance
11540515|NCT01071174|Experimental|Dapivirine Ring|Dapivirine Vaginal Ring 25mg
11540516|NCT01071161|Experimental|Azithromycin|
11540517|NCT01071161|Placebo Comparator|Placebo|
11540518|NCT01071148||Subgroup 1: Age < 35 years|Subjects who have experienced infertility and justifying IVF/ET treatment will be administered either Gonal-f or Pergoveris or Gonal-f and Luveris as per the discretion of the investigator.
11540519|NCT01071148||Subgroup 2: 42 > Age ≥ 35 years|Subjects who have experienced infertility and justifying IVF/ET treatment will be administered either Gonal-f or Pergoveris or Gonal-f and Luveris as per the discretion of the investigator.
11540520|NCT01071135|Experimental|Quetiapine XR|
11540524|NCT01071109|Experimental|Therapeutic Massage|
11540525|NCT01071109|No Intervention|No therapeutic massage|
11540526|NCT01071096|Active Comparator|OnabotulinumtoxinA|Minimum dose of 155 international units (U) OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas.
11540527|NCT01071096|Placebo Comparator|Saline|155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas.
11540528|NCT01071083|Active Comparator|natalizumab|
11540529|NCT01071083|Placebo Comparator|IV placebo|
11540530|NCT01071083|Active Comparator|interferon β-1a, glatiramer acetate, or methylprednisolone|
11540531|NCT01071070|Active Comparator|Group 1|Initial dosing based on a formula of intact parathyroid hormone value/80 (where intact parathyroid hormone value is the baseline value in pg/mL).
11540532|NCT01071070|Active Comparator|Group 2|Dose determined by US paricalcitol injection package insert dosing instructions (starting dose at 0.04 microgram/kg)
11540533|NCT01071057|Active Comparator|Naloxone/morphine|Naloxone (12 µg/ml) mixed in a single infusion with morphine (1 mg/ml). The study solutions will be prepared by a pharmacist and diluted in saline to produce equal volumes to ensure proper blinding.
11540534|NCT01071057|Placebo Comparator|saline/morphine|Patients will be randomly assigned to one of two groups (Naloxone/morphine or saline/morphine) using computer-generated random numbers. On arrival to the PACU patients will be started on IV PCA and randomized study drug
11540535|NCT01071044|Active Comparator|Lisdexamfetamine Dimesylate|Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
11540536|NCT01071044|Placebo Comparator|Sugar pill|"Matching Placebo 30, 50 or 70 mg"
11540537|NCT01071031|Experimental|Group 1|Low Dose HIV-v with water for injection
11540538|NCT01071031|Experimental|Group 2|Low Dose HIV-v with adjuvant
11540539|NCT01071031|Experimental|Group 3|High Dose HIV-v with water for injection
11540540|NCT01071031|Experimental|Group 4|High Dose HIV-v with adjuvant
11540541|NCT01071031|Placebo Comparator|Group 5|Control group: adjuvant only or water for injection only
11540542|NCT01071018|Experimental|QOD Schedule|QOD Schedule, MK2206 every other day
11540543|NCT01071018|Experimental|QW Schedule|QW Schedule, MK2206 once weekly
11540544|NCT01071005|Experimental|Test|Lorelin Depot - Bergamo
11540545|NCT01071005|Active Comparator|comparator|Lupron Depot® - Abbott
11540546|NCT01070979|Experimental|Estradiol acetate (E3A)|
11540547|NCT01070979|Active Comparator|Estradiol|
11540548|NCT01070979|Active Comparator|Conjugated equine estrogens (CEE):|
11540549|NCT01070966||VYTORIN® 10/10 (ezetimibe 10 mg/simvastatin 10 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/10 (ezetimibe 10 mg/simvastatin 10 mg tablets)
11540550|NCT01070966||VYTORIN® 10/20 (ezetimibe 10 mg/simvastatin 20 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/20 (ezetimibe 10 mg/simvastatin 20 mg tablets)
11540551|NCT01070966||VYTORIN® 10/40 (ezetimibe 10 mg/simvastatin 40 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/40 (ezetimibe 10 mg/simvastatin 40 mg tablets)
11540552|NCT01070966||VYTORIN® 10/80 (ezetimibe 10 mg/simvastatin 80 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/80 (ezetimibe 10 mg/simvastatin 80 mg tablets)
11540553|NCT01070953||EZETROL® 10 mg|Participants with Hypercholesterolemia treated with EZETROL®
11540554|NCT01070940|Placebo Comparator|Isotonic saline infusion|
11540555|NCT01070940|Active Comparator|Intravenous L-NMMA dose 2|
11540556|NCT01070940|Active Comparator|Intravenous L-NMMA dose 3|
11540557|NCT01070940|Active Comparator|Intravenous L-NMMA dose 1|
11540558|NCT01070927|Experimental|cohort 1|
11540559|NCT01070927|Experimental|cohort 2|
11540560|NCT01070901||Organ transplant recipients|
11540561|NCT01070888|Experimental|Budesonide/Formoterol first|This arm will receive blinded budesonide/formoterol and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. The second study period will be budesonide and dummy inhaler.
11540562|NCT01070888|Active Comparator|Budesonide first|This arm will receive blinded budesonide and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. The second study period will be budesonide/formoterol and dummy inhaler.
11540563|NCT01070875|Active Comparator|UFH 5000 U three times per day|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous three times a day.
11540564|NCT01070875|Active Comparator|UFH 5000 U two times per day|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
11540565|NCT01070862|Experimental|thalidomide + dexamethasone|Thalidomide 200 mg/d at bedtime + Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
11540566|NCT01070862|Active Comparator|Vincristin, Adriamycin, Dexamethasone|
11540567|NCT01070862|Experimental|thalidomide, melphalan, endoxan, dexamethasone|
11540568|NCT01070862|Active Comparator|melphalan, endoxan, dexamethasone (MCDex)|
11540569|NCT01070862|Experimental|Thalidomide, Dexamethasone|
11540570|NCT01070862|No Intervention|watch and wait|
11540571|NCT01070849|Active Comparator|a) educational booklet|
11540572|NCT01070849|Active Comparator|b) IRENA|
11540573|NCT01070849|Experimental|c) RÜCKGEWINN|
11540574|NCT01070836||natalizumab|US participants with relapsing MS receiving commercial natalizumab
11540575|NCT01070823||Relapsing Multiple Sclerosis|Participants receiving or considering treatment with Tysabri® (natalizumab).
11540576|NCT01070810|Placebo Comparator|1|50 ml D5W
11540577|NCT01070810|Experimental|2|200mg Thiamine in 50ml D5W
11540578|NCT01070797|Experimental|Group A|Group A is for CMV seropositive donors.
11540579|NCT01070797|Experimental|Group B|Group B is for CMV seronegative donors.
11540580|NCT01070784|Experimental|1|
11540581|NCT01070784|Active Comparator|2|
11540582|NCT01070745|Experimental|Indomethacin for resistant PDA|Treatment with second course of indomethacin
11540583|NCT01070745|Experimental|Ibuprofen for resistant PDA|Ibuprofen as second course of therapy
11540584|NCT01070732|Experimental|Paracetamol|All patients will receive one single dose of 1000mg paracetamol.
11540585|NCT01070719||Relapsing form of MS treated with natalizumab|Only patients diagnosed with a relapsing form of Multiple Sclerosis (MS) and who are being treated with Tysabri (natalizumab) will be included in this Phase IV observational study.
11540586|NCT01070706|Experimental|Paclitaxel, Gemcitabine, Sunitinib|Paclitaxel, Gemcitabine, Sunitinib
11540587|NCT01070693|Experimental|Prolene Hernia System device|Inguinal hernia repair either with a bilayer mesh (PHS)
11540588|NCT01070693|Experimental|Lichtenstein|Inguinal hernia repair with the Lichtenstein technique
11540589|NCT01070680|Active Comparator|dexmedetomidine|sedative medicine
11540590|NCT01070680|Placebo Comparator|sodium chloride 0,9%|
11540591|NCT01070667|Experimental|Dronedarone|Patients will receive 400 mg of dronedarone per day for 3 months.
11540592|NCT01070667|Placebo Comparator|Placebo|Patients will receive a placebo tablet once per day for 3 months. AF burden and other parameters described will be monitored from the participants permanent pacemaker. Participants will also be asked to fill out symptom diaries and questionaires.
11540593|NCT01070654|Experimental|40/30 Recruitment Manoeuvre|Patients with respiratory failure that will be first ventilated for 30 minutes according to standardized baseline protective ventilation and after that will receive the recruitment manoeuvre
11540594|NCT01070641|Active Comparator|Carvedilol|Each patient will receive Carvedilol 12.5mg QD
11540595|NCT01070641|Active Comparator|Esophageal Variceal Band Ligation|Each patient will undergo for serial esophageal variceal band ligations after 3 weeks of last session till the eradication of varices
11540596|NCT01070628|Experimental|Stalevo (levodopa/carbidopa/entacapone)|"125mg or 75mg of levodopa during treatment period 1 in groups 1 and 2 respectively.
~150mg or 100mg of levodopa during treatment period 2 in groups 1 and 2 respectively."
11540597|NCT01070628|Active Comparator|Sinemet (levodopa/carbidopa)|150mg or 100mg of levodopa during treatment period 3 in study groups 1 and 2 respectively
11540598|NCT01070602|Experimental|anterior corneal incision|
11540599|NCT01070589||Group 1: Obese|BMI>30
11540600|NCT01070589||Group 2: control|Group 2:Normal weight (BMI <25). age and gender matched.
11540601|NCT01070576||normal fracture healing|group in which normal fracture healing has occured
11540602|NCT01070576||atrophic|patients in which an atrophic non-union occured
11540603|NCT01070576||hypertrophic|patients in which a hypertrophic non-union occured
11540604|NCT01070563||Usual|CT angiography is performed 6 hours after the clinical diagnosis of brain death.
11540605|NCT01070563||TCD|When the diagnosis of brain death is made, TCD is performed and then every 2 hours until the flow patterns compatible with brain death are found. Then a CT angiography is performed.
11540606|NCT01070550||Cohort|Participants chronically infected with the hepatitis C virus including Genotypes 1 to 6.
11540607|NCT01070524|Experimental|CHF 5188 pMDI|
11540608|NCT01070524|Active Comparator|Budesonide extrafine pMDI|
11540609|NCT01070524|Active Comparator|Seretide(r) Evohaler(r)|
11540610|NCT01070511|Experimental|Tadalafil|
11540611|NCT01070511|Placebo Comparator|Placebo|
11540612|NCT01070498|Experimental|Trichuris suis ova (TSO)|
11540613|NCT01070485|Experimental|Radium-223 dichloride (Xofigo, BAY 88-8223)|Patients were to receive 4 intravenous administrations of Radium-223 at a dose of 50 kBq/kg body weight (b.w) at intervals of 4 weeks. Radium-223 was given as add-on therapy to existing bisphosphonate therapy.
11540614|NCT01070459|Placebo Comparator|Control group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
11540615|NCT01070459|Experimental|Aerobic exercise group|The patients continues their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heart rate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week training programme 4 information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
11540616|NCT01070459|Experimental|Follow-up first aerobic exercise group|
11540617|NCT01070459|Placebo Comparator|Follow-up control group|
11540618|NCT01070459|Experimental|Follow-up second aerobic exercise group|
11540619|NCT01070446|Experimental|1|This study involves children with CF who will take a water soluble vitamin supplement of choline bitartrate, 2 gm per day with meals.
11540620|NCT01070433|Experimental|MEBO Wound Ointment (MEBO)|Topical application twice a day
11540621|NCT01070433|Active Comparator|Standard of Care|Topical application twice a day
11540622|NCT01070420|Active Comparator|FFR via central venous line|
11540623|NCT01070420|Experimental|FFR via peripheral vein|
11540624|NCT01070407|Experimental|Arm A, group 1|4 volunteers
11540625|NCT01070407|Experimental|Arm A, group 2|4 volunteers
11540626|NCT01070407|Experimental|Arm A, group 3|5 volunteers
11540627|NCT01070407|Experimental|Arm B, group 5|4 volunteers
11540628|NCT01070407|Experimental|Arm B, group 6|4 volunteers
11540629|NCT01070407|Experimental|Arm B, group 7|5 volunteers
11540630|NCT01070407|Experimental|Arm C, group 9|5 volunteers
11540631|NCT01070407|Experimental|Arm C, group 10|5 volunteers
11540632|NCT01070407|Experimental|Arm C, group 11|4 volunteers
11540667|NCT01070147|Experimental|Control|The control group will receive a paper-based printed asthma guideline.
11540668|NCT01070134|Experimental|Mindfulness-based Behavioural Therapy (MIBT)|
11540633|NCT01070394|Experimental|LDX Treatment|Eligible participants received 12 weeks of open-label treatment. Those on treatment prior to baseline underwent a 7-day (for amphetamine or methylphenidate) or 28-day (for atomoxetine or other medications) washout period prior to initiating LDX treatment. The starting dose was 30mg/day, which could be titrated up by 20mg/day during visits 2-6 (for a maximum dose of 70mg/day). At discretion of investigator, the dose could be down-titrated by 20mg/day during visits 4-6. Once the dose was optimized (after visit 6), the dose was maintained for 8 weeks.
11540634|NCT01070381|Other|nelfilcon A / ocufilcon D|Nelfilcon A contact lenses worn first, with ocufilcon D contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
11540635|NCT01070381|Other|ocufilcon D / nelfilcon A|Ocufilcon D contact lenses worn first, with nelfilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
11540636|NCT01070368|Experimental|Food challenge, skin test|Skin test by two extract commercial, and in-house extract. and open challenge with wheat (except in patient with history of wheat anaphylaxis: assume as challenge positive)
11540637|NCT01070355|Placebo Comparator|Placebo|2 capsules twice daily
11540638|NCT01070355|Active Comparator|Eicosapentaenoic acid free fatty acid|2g daily (2 x 500mg capsules twice daily)
11540639|NCT01070342||Chidren ages 6 to 18|Children ages 6 to 18 years will be available for participation in this multicenter study. Subjects will be enrolled from community based general pediatric clinics and other well-child care areas within participating hospitals and clinics of the four participating sites. Enrollment will continue until a total of 85 subjects from each age category (6-<12 years and ≥12- <18 years) successfully complete the study.
11540640|NCT01070329|Experimental|Duloxetine|
11540641|NCT01070329|Placebo Comparator|Placebo|
11540642|NCT01070316|Experimental|Everolimus|Subjects will be administered study drug if they meet study criteria after 4 weeks of baseline phase. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily.
11540643|NCT01070303|Experimental|Adalimumab 40 mg every other week or every week|
11540644|NCT01070290|Experimental|1|ARQ 197
11540645|NCT01070290|Active Comparator|2|Investigator's choice of oxaliplatin, capecitabine or irinotecan
11540646|NCT01070277|Placebo Comparator|Placebo arm|"2 placebo pills X2 /day for 2 days followed by
~1 placebo Pill X2 / day for 7 days"
11540647|NCT01070277|Experimental|Tinidazole and Albendazole treatment|Tinidazole 1 gram BID for 2 days followed by Albendazole 400mg BID for 7 days
11540648|NCT01070264|Experimental|Noni Juice|This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day
11540649|NCT01070251|Active Comparator|Existing state-sponsored PA program|standard children-focused gym lessons approach
11540650|NCT01070251|Active Comparator|Participatory intervention plus state-sponsored PA program|Participatory parent-focused intervention over nine months in addition to state-sponsored PA program
11540651|NCT01070225|Experimental|Hydrocortisone and Propranolol|Participant administered 10 or 20mg propranolol orally. Participants meeting the parameters are randomised to receive 400mg Hydrocortisone intravenously. Participant then receives Histamine PC10 challenge, Administered 5mg Salbutamol via nebuliser, administered 500mcg Ipratropium Bromide via nebuliser; visit end
11540652|NCT01070225|Placebo Comparator|Placebo and propranolol|identical to other arm but participant receive placebo injection as opposed to hydrocortisone
11540653|NCT01070212|Experimental|soft gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
11540654|NCT01070212|Experimental|firm gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
11540655|NCT01070212|Experimental|no gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
11540656|NCT01070199|Experimental|liquid to liquid,|
11540657|NCT01070199|Experimental|liquid to solid,|
11540658|NCT01070199|Experimental|solid to liquid|
11540659|NCT01070199|Experimental|solid to solid|
11540660|NCT01070186|Experimental|Treatment|See intervention descriptions
11540661|NCT01070173||Short Stature|Poor linear growth
11540662|NCT01070173||Poor Weight Gain (Failure-To-Thrive)|Poor Weight Gain
11540663|NCT01070173||Isolated Gastrointestinal Symptoms|No growth symptoms
11540664|NCT01070160||A|Women with PCOS initiating Metformin and exposure to vaginal progesterone for 6-8 days prior ro Endometrium Biopsy
11540665|NCT01070160||B|Women with PCOS not planning initiating Metformin and exposure to vaginal progesterone for 6-8 days prior to Endometrium Biopsy
11540666|NCT01070160||Women with PCOS who previously initiated metformin|Women with PCOS who initiated metformin at least 3 months prior to enrollment who have completed a 6-10 day course of progesterone
11540669|NCT01070134|Active Comparator|PT (psychodynamic therapy)|
11540670|NCT01070121||RA patients/participants|
11540671|NCT01070108|Active Comparator|Set 1|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
11540672|NCT01070108|Active Comparator|set 2|2nd set received ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
11540673|NCT01070108|Active Comparator|set 3|3rd set one group had ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
11540674|NCT01070095|Experimental|Electronic Asthma Action Plan System|Electronic Asthma Action Plan System (eAAPS)
11540675|NCT01070082||Adult ICU patients undergoing procedure|
11540676|NCT01070069|Active Comparator|Standard EVAR (IntuiTrak)|EVAR using standard vascular exposure for access
11540677|NCT01070069|Experimental|PEVAR (ProGlide closure)|Percutaneous EVAR facilitated by the ProGlide closure device
11540678|NCT01070069|Experimental|PEVAR (ProstarXL closure)|Percutaneous EVAR facilitated by the Prostar XL closure device
11540679|NCT01070056|Active Comparator|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
11540680|NCT01070056|Experimental|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension (HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
11540681|NCT01070043|Experimental|Amlodipine 5mg/Valsartan 80 mg|During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks.
11540682|NCT01070043|Active Comparator|Valsartan 160 mg|In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks.
11540683|NCT01070043|Other|Run-In Valsartan 80 mg|During run-in period, oral valsartan 80 mg once daily for 4 weeks.
11540684|NCT01070017|Experimental|Intervention: DOT-HAART|Intervention group will receive community-based monthly adherence visits, standard care, and DOT-HAART.
11540685|NCT01070017|No Intervention|No DOT-HAART|Control group receives community-based monthly adherence visits and standard care, but no DOT-HAART.
11540686|NCT01070004|Experimental|Blue light|Exposure to 460-nm monochromatic light (blue light)
11540687|NCT01070004|Experimental|Physical activity|15 minutes of physical activity at a low intensity
11540688|NCT01069991|Experimental|Patient education group|Patient education program delivered to high school students with persistent asthma.
11540689|NCT01069991|Experimental|Wait list control group|Control students received no intervention until the one year follow up period was completed.
11540690|NCT01069965|Experimental|6. BGP-15|400 mg BGP-15 + Placebo
11540691|NCT01069965|Experimental|5. BGP-15|200 mg BGP-15 BID
11540692|NCT01069965|Experimental|4. BGP-15|200 mg BGP-15 + Placebo
11540693|NCT01069965|Experimental|3. BGP-15|Two 50 mg BGP-15 capsules by mouth in the morning; and two 50 mg BGP-15 capsules by mouth in the evening
11540694|NCT01069965|Experimental|2. BGP-15|100 mg BGP-15 + placebo
11540695|NCT01069965|Experimental|1. Placebo|Placebo BID
11540696|NCT01069952|Experimental|Active DBS|Participants will receive deep brain stimulation.
11540697|NCT01069939|Experimental|Esomeprazole 20mg|Esomeprazole 20mg once daily oral
11540698|NCT01069939|Placebo Comparator|Placebo|Placebo once daily oral
11540699|NCT01069913|Active Comparator|BG00012|BG00012 Standard Formulation
11540700|NCT01069913|Active Comparator|BG00012 API|BG00012 API
11540701|NCT01069900|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Subjects randomized to the moxifloxacin arm of this study received intravenous moxifloxacin plus ertapenem placebo (0.9 % sodium chloride [NaCl solution]) for a minimum of 3 days and, if switched to oral treatment, PO moxifloxacin plus PO amoxicillin/clavulanate placebo. Total treatment duration is 5-14 days.
11540702|NCT01069900|Active Comparator|Comparator Ertapenem|Subjects randomized to the comparator arm of this study received intravenous ertapenem plus moxifloxacin placebo (0.9 % NaCl solution) for a minimum of 3 days and, if switched to oral treatment, amoxicillin/clavulanate as an oral suspension plus PO moxifloxacin placebo. Total treatment duration is 5-14 days.
11540703|NCT01069887||adult with hematological malignancies|
11540704|NCT01069887||pediatrics with hematological malignancies|
11540705|NCT01069887||pediatrics receiving stem cell transplant|
11540706|NCT01069887||adult receiving stem cell transplant|
11540707|NCT01069874|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
11540708|NCT01069874|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
11540709|NCT01069861|Experimental|one|
11540710|NCT01069848|Experimental|Vedera KXS|
11540711|NCT01069835||1|Non-small cell lung cancer patients
11540712|NCT01069822|Experimental|1|midazolam + AZD6765 IV solution
11540713|NCT01069822|Active Comparator|2|
11540714|NCT01069809|Experimental|AGS-004|HIV-1 Immune Therapy
11540715|NCT01069809|Placebo Comparator|Inactive Injection|Inactive Placebo Injection
11540716|NCT01069796|Experimental|Association bevacizumab paclitaxel capecitabine breast cancer|"bevacizumab 10 mg/kg in IV, D1 and D15
~paclitaxel 80mg/m2 in IV, D1 to D8 and D15
~capecitabine 1600mg/m2/D, per os, D1 to D5, Weeks 1,2 and 3"
11540717|NCT01069783|Experimental|A3309 low dose|
11540718|NCT01069783|Experimental|A3309 high dose|
11540719|NCT01069783|Placebo Comparator|Placebo|
11540720|NCT01069757|Experimental|ARQ 197 and Erlotinib|ARQ 197 and erlotinib hydrochloride
11540721|NCT01069744||Control Group|Control group When neonates are considered ready for oral feedings these feedings will be started with the standard oral feeding protocol for the NICU but without the NTrainer stimulation regimen described previously.
11540722|NCT01069744||NTrainer System|NTrainer Experimental Group When neonates are considered ready for oral feedings these feedings will be started simultaneously with the NTrainer therapy. Control and experimental interventions will not be initiated until the infant is in an optimal behavioral state, i.e., drowsy to quiet alert (NIDCAP state 3 or 4). Preterm infants in the experimental group will receive alternating 3-minute epochs of patterned oral somatosensory stimulation and null conditions using the NTrainer© during the tube (gavage) feeding session up to 4 times per day.
11540723|NCT01069731||Infants born at 30 to 36 weeks gestation|Infants will be considered eligible if they are born at 30 to 36 weeks gestation and have no exclusion criteria.
11540724|NCT01069718||Clinical Group|In the Clinical group bottle feedings will be attempted by the bedside nurses, using techniques suggested in the feeding plan. The Infant Feeding Specialist will observe at least one feeding per day to assure that the feeding plan is being adhered to. If, in the judgment of the person feeding the infant, the infant is unable to complete the bottle feeding, the remaining volume will be given via an indwelling gavage tube. During all gavage feedings, both total and partial, infants will be offered a pacifier to suck on.
11540725|NCT01069718||NTrainer Group|"In the NTrainer group, three feedings per day will be given via gavage tube while the infant is receiving NTrainer stimulation. The stimulation will be done by alternating 3 minute epochs of NTrainer stimulation with 3 minutes of sucking on a regular pacifier, up to a total time of 30 minutes.
~Every other day, 15 minutes prior to a feeding that is not one of the study sessions, each infant's suck strength and coordination will be measured using the NTrainer device in its NeoSuck RT Assessment mode.
~On the day after the study intervention period is completed each infant will be assessed by an investigator unaware of the infant's study group assignment."
11540726|NCT01069705|Experimental|TIPnew|
11540727|NCT01069692|Placebo Comparator|Arm 1|Placebo
11540728|NCT01069692|Experimental|Arm 3|
11540729|NCT01069692|Experimental|Arm 2|
11540730|NCT01069692|Experimental|arm 4|SBR759A
11540731|NCT01069692|Experimental|arm 5|
11540732|NCT01069653|Experimental|CDCA1-KIF20A-1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
11540733|NCT01069653|Experimental|CDCA1-KIF20A-2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (2mg) and KIF20A peptide(2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
11540734|NCT01069653|Experimental|CDCA1-KIF20A-3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (3mg) and KIF20A peptide(3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
11540735|NCT01069640|Experimental|URLC10-1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
11540736|NCT01069640|Experimental|URLC10-2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
11540737|NCT01069640|Experimental|URLC10-3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
11540738|NCT01069627|Experimental|1|
11540739|NCT01069614|Experimental|Skin stretching device|Skin stretching device
11540740|NCT01069601|Experimental|transplanted adults|male and female adults who have previously undergone solid organ transplantation or allogeneic or autologous BMT
11540741|NCT01069588||Calaxo|Received Calaxo screw
11540742|NCT01069588||Milagro|Received a Milagro screw
11540743|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (1mg), CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
11540744|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (2mg), CDCA1 peptide (2mg) and KIF20A peptide(2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
11540745|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (3mg), CDCA1 peptide (3mg) and KIF20A peptide(3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
11540746|NCT01069562|Active Comparator|MANUAL|In the manual group isoflurane was administered using Tech 7 vapouriser. The dial setting was controlled by the anesthesiologist to achieve and maintain a BIS of 50 during anesthesia.
11540747|NCT01069562|Experimental|IAADS group|In this group, liquid isoflurane was injected into the circuit using a syringe pump controlled by the IAADS system.The IAADS system has the algorithm to regulate the rate of infusion of isoflurane such that BIS is achieved and maintained at 50 during anesthesia.
11540748|NCT01069549||subjects with diabetic nephropathy.|"Subjects with Type 2 Diabetes. Duration of diabetes should be more than or equal to 5 years. Age between 30 and 85 years. Diabetic nephropathy as defined by ADA.
~Subject must be of north Indian origin.
~Type 1 diabetes and kidney disease other than diabetes nephropathy are excluded form the study."
11540749|NCT01069549||Subjects without Diabetic nephropathy.|This group of subject with similar characteristics as group 1 without any evidence of nephropathy.
11540750|NCT01069536|Active Comparator|2 minutes bolus infusion|
11540751|NCT01069536|Active Comparator|15 minutes slow infusion|
11540881|NCT01068782|Experimental|Arm 4|
11540752|NCT01069523|Placebo Comparator|Placebo|Patients will be started on 1 mg of guanfacine extended release matching placebo tablets at week 1. A physician blind to drug status will titrate the study medication in week 2-3 to a maximum of 4 mg (4 tablets).
11540753|NCT01069523|Experimental|Guanfacine Extended Release|Patients will be started on 1 mg of guanfacine extended release at week 1. A physician blind to drug status will titrate the study medication in week 2-3 to a maximum of 4 mg (4 tablets).
11540754|NCT01069510|Placebo Comparator|Placebo|Patients will receive placebo
11540755|NCT01069510|Experimental|Spironolactone|Spironolactone 25 mg daily
11540756|NCT01069497|Experimental|Intervention Nursing Homes|Comprising 24 nursing homes implementing a specific infection prevention program
11540757|NCT01069497|No Intervention|Usual care Nursing Homes|
11540758|NCT01069484|Experimental|Postpartum pelvic floor muscle training|Beyond a customary leaflet (received from the postnatal ward) and the thorough initial instruction on how to contract the PFM correctly, the participants are given supervised pelvic floor muscle group training led by physiotherapists once a week. In addition, the participants train every day at home, with at least 3 sets of 8-12 contractions. Training period is 4 months.
11540759|NCT01069484|No Intervention|Control|Beyond the customary leaflet (received from the postnatal ward) and the thorough initial instruction on how to contract the PFM correctly, the control group participants received no further intervention. They were not discouraged from doing PFMT on their own.
11540760|NCT01069471|Experimental|HHD O1-EPA plus adjuvant|10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
11540761|NCT01069471|Experimental|HHD O1-EPA|10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA
11540762|NCT01069471|Experimental|LHD O1-EPA adjuvanted|2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
11540763|NCT01069471|Experimental|LHD O1-EPA|2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA
11540764|NCT01069458|Experimental|The High Protein Diet Group|The high protein diet (25% energy from protein, 55% energy from fat, 20% energy from carbohydrate) will be hypo-caloric and achieved by restricting the amount of sugar containing foods and drinks, reducing the intake of bread, rice, pasta, fruits and fruit-juices and increasing the intake of vegetables (instead of bread, rice, pasta and potatoes) and increasing the amounts of protein (from chicken, fish, and meat) and fat from oil and dressings for lunch and dinner and by choosing nuts and protein-rich yoghurts, egg, cheese, chicken wings, shellfish, fish and fish products as snacks.
11540765|NCT01069458|Active Comparator|The Low Fat Diet Group|The low fat diet (30% energy from fat, 20% energy from protein, 50% energy percent from carbohydrate) will be hypo-caloric and achieved by choosing low-fat diary and meat products, restricting amounts of visible fat and fatty snacks and increasing intake of whole meal bread, muesli, brown rice, whole meal pasta in the main meals and by choosing yoghurt with muesli, oat porridge with milk, fruits and hard bread with jam and soft gout-cheese as snacks.
11540766|NCT01069445|Active Comparator|Diet advices|will receive the Optimal Diet for Elderly
11540767|NCT01069445|Experimental|Diet advices + VSL-3|will receive the Optimal Diet for Elderly + VSL#3® probiotic blend
11540768|NCT01069445|Experimental|Diet advices + 5203-L|will receive the Optimal Diet for Elderly + AISA-5203-L fruit extracted terpene
11540769|NCT01069445|Experimental|Diet advices + Argan oil|will receive the Optimal Diet for Elderly + Argan oil
11540770|NCT01069432||Patients with CLL|Patients undergoing routine blood draws as part of their ongoing follow-up care for CLL at the Norris Cotton Cancer Center of DHMC.
11540771|NCT01069432||Normal Volunteers|Normal volunteers who have no history of active or prior hematologic malignancy.
11540772|NCT01069419||Cimzia|All patients will be treated with Cimzia according to normal clinical practice for the prescribing physician and as defined by the SmPC
11540773|NCT01069406||presence of uterine artery notch|patients with uterine artery notch during the 2nd and 3rd trimester
11540774|NCT01069393|Active Comparator|Standard DAFNE|Usual DAFNE course taught over 5 consecutive days in one week
11540775|NCT01069393|Experimental|DAFNE 5x1 day|DAFNE course taught 1 day a week for 5 consecutive weeks
11540776|NCT01069367|Experimental|Arm:1|
11540777|NCT01069354|Experimental|Radiesse® Mixed with Lidocaine|Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
11540778|NCT01069354|Active Comparator|Radiesse® without Lidocaine|Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
11540779|NCT01069341|Other|Treatment|All subjects enrolled received treatment with identical dosage of Ranibizumab
11540780|NCT01069328|Experimental|Arm 1|
11540781|NCT01069328|Experimental|Arm 2|
11540782|NCT01069328|Experimental|Arm 3|
11540783|NCT01069328|Experimental|Arm 4|
11540784|NCT01069328|Experimental|Arm 5|
11540785|NCT01069328|Experimental|Arm 6|
11540786|NCT01069315|Experimental|Normal saline and High pressure|Irrigation with normal saline delivered at high pressure
11540787|NCT01069315|Experimental|Soap solution and High pressure|Irrigation with soap solution delivered at high pressure
11540788|NCT01069315|Experimental|Normal saline and Low pressure|Irrigation with saline solution delivered at low pressure
11540789|NCT01069315|Experimental|Soap solution and Low pressure|Irrigation with soap solution delivered at low pressure
11540790|NCT01069302|Active Comparator|High loading and high maintenance|Clopidogrel loading 600mg and maintenance 150mg for 7days
11540791|NCT01069302|Active Comparator|High loading and low maintenance|Clopidogrel loading 600mg and maintenance 75mg for 7days
11540792|NCT01069302|Active Comparator|Low loading and high maintenance|Clopidogrel loading 300mg and maintenance 150mg for 7days
11540793|NCT01069302|Active Comparator|Low loading and low maintenance|Clopidogrel loading 300mg and maintenance 75mg for 7days
11540794|NCT01069289|Experimental|1|Symbicort Turbuhaler 160/4.5 microgram, 2 inhalations twice daily
11540795|NCT01069289|Active Comparator|2|Oxis Turbuhaler 4.5 microgram, 2 inhalations twice daily
11540796|NCT01069276||Patients with clinical signs of stroke|Patients with clinical signs of stroke
11541146|NCT01066975||young and fit|5 healthy subjects, age lower than 30 yrs and high physical fitness
11540797|NCT01069263|Active Comparator|Intravesical DMSO instillation|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
11540798|NCT01069263|Experimental|Hyperbaric Oxygen Therapy (HBOT)|Overall 60 treatments (5 days per weeks for 12 weeks). 90 minutes every session. Pressure of 2 atm. Inhalation of 100% oxygen.
11540799|NCT01069250||Brain injury|Patients after traumatic brain injury or spontaneous intracranial bleeding
11540800|NCT01069237||OPTI-FREE Replenish|Multi-Purpose Solution for soft contact lenses
11540801|NCT01069237||Clear Care|Lens Care Solution for contact lenses
11540802|NCT01069224||RC tear|This study will include a consecutive series of patients who met the study inclusion criteria. Study group patients will be diagnosed RC tear on clinical examination and imaging findings (US and MRI) that will be verified at arthroscopy in order to complete the enrollment.
11540803|NCT01069224||Control group|Control group will include patients suffering from shoulder instability that scheduled for elective surgical repair.
11540804|NCT01069211||ER expression : Low|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 3 or 4 point of total Allred score.
11540805|NCT01069211||ER expression : Intermediate|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 5 or 6 point of total Allred score.
11540806|NCT01069211||ER expression : High|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 7 or 8 point of total Allred score.
11540807|NCT01069198|Experimental|Intervention group|
11540808|NCT01069198|Placebo Comparator|Non-intervention group|Non-intervention group will receive placebo following the same schedule as intervention group.
11540809|NCT01069185|Experimental|Necessity endotracheal suctioning|Endotracheal suctioning depends on clinical manifestations
11540810|NCT01069185|Other|Routine endotracheal suctioning|Endotracheal suctioning every two hours
11540811|NCT01069172|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery group (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the femtosecond laser device. If necessary, ultrasound (U/S) phacoemulsification will also be applied to facilitate removal of the crystalline lens during cataract surgery.
11540812|NCT01069172|Active Comparator|CCC Surgery|For the continuous curvilinear capsulorhexis (CCC) group (CCC Surgery), subjects will receive the standard of care for CCC and U/S phacoemulsification surgery to facilitate removal of the crystalline lens during cataract surgery.
11540813|NCT01069159|Active Comparator|Propranolol|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive propranolol.
11540814|NCT01069159|Placebo Comparator|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
11540815|NCT01069146|Experimental|Mild therapeutic hypothermia|Sepsis treatment according to standard guidelines plus mild therapeutic hypothermia
11540816|NCT01069146|No Intervention|Control|Sepsis treatment according to standard guidelines
11540817|NCT01069133|Experimental|Rifaximin|
11540818|NCT01069120|Active Comparator|50 mg Proellex®|2, 25 mg capsules
11540819|NCT01069120|Active Comparator|25 mg Proellex®|1, 25 mg capsule
11540820|NCT01069107|Active Comparator|Consume of health services|One year follow-up of patients randomized to two different levels of health care
11540821|NCT01069094|Experimental|progenta 12.5 mg|Progenta (CDB-4124) 12.5 mg capsule
11540822|NCT01069094|Experimental|progenta 25 mg|Progenta (CDB-4124) 25 mg capsule
11540823|NCT01069094|Experimental|progenta 50 mg|Progenta (CDB-4124) 50 mg capsule
11540824|NCT01069094|Active Comparator|Lucron Depot|Lucron Depot, Leuprolide acetate for depot suspension
11540825|NCT01069094|Placebo Comparator|placebo|Placebo capsule
11540826|NCT01069081|Active Comparator|arm A|docetaxel and cisplatin chemotherapy
11540827|NCT01069081|Experimental|arm B|docetaxel and cisplatin chemotherapy combined with PPI 160mg per day.
11540828|NCT01069081|Experimental|arm C|docetaxel and cisplatin chemotherapy combined with PPI 200mg per day.
11540829|NCT01069055|Placebo Comparator|Placebo Control|Group I (Placebo Control) 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.
11540830|NCT01069055|Active Comparator|Lornoxicam|Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
11540831|NCT01069055|Active Comparator|Paracetamol|Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
11540832|NCT01069042|Active Comparator|preserved LVEF under ACEi treatment|preserved LVEF under ACEi treatment
11540833|NCT01069042|Experimental|Poor LVEF group|Poor LVEF under ACEi treatment
11540834|NCT01069029||Combined surgery|Patient which underwent combined surgery of MH and cataract extraction
11540835|NCT01069029||Successive surgery|Patients which underwent the two successive procedures
11540836|NCT01069016|Experimental|Sacral nerve modulation first|"Sacral nerve modulation is applied before the pudendal nerve stimulation. There is no wash-out period (pause) between the two treatments."
11540837|NCT01069016|Experimental|Pudendal nerve stimulation first|"Pudendal nerve stimulation is applied before the sacral nerve modulation. There is no wash-out period (pause) between the two treatments."
11540838|NCT01069003|Placebo Comparator|Placebo Arm|Subjects are randomized to receive 18 months of placebo thienopyridine and aspirin (ASA). Eligible subjects are without death, myocardial ischemia, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.
11540839|NCT01069003|Active Comparator|Thienopyridine Therapy|Subjects are randomized to receive 18 months of active thienopyridine and aspirin (ASA). Eligible subjects are without death, myocardial ischemia, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.
11540840|NCT01069003|Other|Surveillance Arm|Non randomized subjects followed through 24 months
11540841|NCT01068977|Experimental|Stage I|
11540842|NCT01068977|Experimental|Stage II|
11540843|NCT01068977|Experimental|Stage III|
11540844|NCT01068964|Experimental|0.03% Bimatoprost/0.5% Timolol in Same Bottle|Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
11540845|NCT01068964|Active Comparator|0.03% Bimatoprost and 0.5% Timolol in Separate Bottles|Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
11540846|NCT01068951|Active Comparator|Mesenchymal stem cells|Comparison of active treatment with autologous mesenchymal stem cells (in addition to standard treatment) to standard treatment of patients newly diagnosed with type 1 diabetes mellitus.
11540847|NCT01068951|No Intervention|Control|
11540848|NCT01068938||open angle glaucoma, glaucoma suspects|risk of progression, Latanoprost monotherapy
11540849|NCT01068925|Experimental|ARM 1|"Arm 1:
~GSK1349572 QD for 5 days (Treatment A)."
11540850|NCT01068925|Experimental|ARM 2|ARM 2: TPV/RTV 500/200mg BID (Treatment B).
11540851|NCT01068925|Experimental|ARM 3|ARM 3: GSK1349572 50mg QD and TPV/RTV 500/200mg BID (Treatment C).
11540852|NCT01068912|Experimental|1: Experimental|Low-dose favipiravir regimen: 1000 mg favipiravir twice a day (BID) x 1 day, and 400 mg favipiravir BID x 4 days
11540853|NCT01068912|Experimental|2: Experimental|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
11540854|NCT01068912|Placebo Comparator|Placebo|Placebo
11540855|NCT01068899||Children|healthy children
11540856|NCT01068899||Adult|healthy adults
11540857|NCT01068886|No Intervention|no stent|no stent through pancreatic anastomosis
11540858|NCT01068886|Experimental|stent|stent through pancreatic anastomosis
11540859|NCT01068873|Experimental|open label single arm|Drug: lopinavir/ritonavir plus maraviroc
11540860|NCT01068860|Experimental|Canakinumab 150 mg + Metformin|Eligible participants received a single subcutaneous injection Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening
11540861|NCT01068860|Placebo Comparator|Placebo + Metformin|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening
11540862|NCT01068860|Experimental|Canakinumab 150 mg + Metforimin + Sulfonylurea|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
11540863|NCT01068860|Placebo Comparator|Placebo + Metforimin + Sulfonylurea|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
11540864|NCT01068860|Experimental|Canakinumab 150 mg + Met + Sulfonyl + Thiazolidinedione|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose, and a Thiazolidinedione (Thiaz)at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
11540865|NCT01068860|Placebo Comparator|Placebo + Met + Sulfonyl + Thiazolidinedione|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose, and a Thiazolidinedione (Thiaz)at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
11540866|NCT01068860|Experimental|Canakinumab 150 mg + Insulin|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus for 3 months prior to screening and be on a stable dose of Insulin, 2 insulin injections per day for a total daily dose of less than 100 U with or without Metformin (Met)for 3 months prior to screening
11540867|NCT01068860|Placebo Comparator|Placebo + Insulin|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus for 3 months prior to screening and be on a stable dose of Insulin, 2 insulin injections per day for a total daily dose of less than 100 U with or without Metformin (Met)for 3 months prior to screening
11540868|NCT01068860|Experimental|Canakinumab 150 mg in patients with IGT|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg. Patients must have had Impaired Glucose Tolerance (IGT) as defined by the World Health Organization (WHO) criteria confirmed at screening visit.
11540869|NCT01068860|Placebo Comparator|Placebo in patients with IGT|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had Impaired Glucose Tolerance (IGT) as defined by the World Health Organization (WHO) criteria confirmed at screening visit.
11540870|NCT01068847|Experimental|1|Receives 2-4 of the drugs listed under Intervention
11540871|NCT01068834||KIF6 tested|Recruited subjects, completing a valid KIF6 test with results
11540872|NCT01068834||KIF6 test naïve|Database matched cohort not receiving a KIF6 test
11540873|NCT01068821|Active Comparator|Egg crate foam mattress|Patients will be placed on egg-crate foam mattress instead of a gel pad by randomization. All other positioning and measurements, including outcomes measures will be the same as for the the primary experimental intervention (gel pad).
11540874|NCT01068821|Active Comparator|Gel pad|Patients will be placed on gel pad instead of egg-crate foam mattress by randomization. All other positioning and measurements, including outcomes measures will be the same as for the the primary experimental intervention (gel pad).
11540875|NCT01068808||Nonallergic rhinitis|Nonallergic rhinitis (negative skin prick test)
11540876|NCT01068795|No Intervention|enoxaparin fixed|enoxaparin dosage will be fixed during pregnancy
11540877|NCT01068795|Experimental|enoxaparin adjusted|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
11540878|NCT01068782|Experimental|Arm 1|
11540879|NCT01068782|Experimental|Arm 2|
11540880|NCT01068782|Experimental|Arm 3|
11540882|NCT01068769|Experimental|Regorafenib|Regorafenib adminstered orally, 160 mg per day on days 1 through 21 of a 28 day cycle
11540883|NCT01068756|Other|Dapagliflozin/Rifampin|
11540884|NCT01068743|Other|Arm A (saxagliptin 2.5 mg + metformin 850 mg; Fasting)|A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fasted condition.
11540885|NCT01068743|Other|Arm B (saxagliptin 2.5 mg + metformin 850 mg FDC; Fasting)|A single oral dose of 2.5-mg saxagliptin/850-mg metformin fixed dose combination (FDC) administered in the fasted condition.
11540886|NCT01068743|Other|Arm C (saxagliptin 2.5 mg + metformin 850 mg; Fed)|A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fed condition.
11540887|NCT01068743|Other|Arm D (saxagliptin 2.5 mg + metformin 850 mg FDC; Fed)|A single oral dose of 2.5-mg saxagliptin/850-mg metformin FDC administered in the fed condition.
11540888|NCT01068730|Other|Treatment A|500 mg metformin (Diabex): Single oral dose of 500 mg metformin (Diabex) tablet administered in the fed condition
11540889|NCT01068730|Other|Treatment B|500 mg metformin (Glucophage™): Single oral dose of 500 mg metformin (Glucophage™) tablet administered in the fed condition
11540890|NCT01068730|Other|Treatment C|1000 mg metformin (Diabex): Single oral dose of 1000 mg metformin (Diabex) tablet administered in the fed condition
11540891|NCT01068730|Other|Treatment D|1000 mg metformin (Glucophage™): A Single oral dose of 1000 mg metformin (Glucophage™) tablet administered in the fed condition
11540892|NCT01068717|Other|Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fasted state
11540893|NCT01068717|Other|Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fasted state)|Single oral dose of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet administered in the fasted state
11540894|NCT01068717|Other|Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fed state
11540895|NCT01068717|Other|Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fed state)|Single oral dose of saxagliptin, 2.5 mg/metformin, 500 mg, FDC tablet administered in the fed state
11540896|NCT01068704|Active Comparator|BMS-690514 + Letrozole|
11540897|NCT01068704|Active Comparator|Lapatinib + Letrozole|
11540898|NCT01068678|Experimental|IDeg 3 times weekly (3TW)|
11540899|NCT01068678|Active Comparator|IGlar OD|
11540900|NCT01068665|Experimental|IDeg 200 U/mL OD|
11540901|NCT01068665|Active Comparator|IGlar OD|
11540902|NCT01068652|Active Comparator|Detemir + Met|Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.
11540903|NCT01068652|Active Comparator|BIAsp 30 + Met|Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.
11540904|NCT01068639||A|
11540905|NCT01068626|Active Comparator|Rosuvastatin|
11540906|NCT01068626|Placebo Comparator|Placebo for Rosuvastatin|
11540907|NCT01068613|Experimental|QAX028 high dose|
11540908|NCT01068613|Experimental|QAX028 low dose|
11540909|NCT01068613|Active Comparator|Tiotropium|
11540910|NCT01068613|Placebo Comparator|Placebo|
11540911|NCT01068600|Experimental|Indacaterol 75 µg|"Indacaterol 75 µg inhaled once daily in the morning via Concept1, a single dose dry powder inhaler (SDDPI), for 12 weeks.
~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
11540912|NCT01068600|Placebo Comparator|Placebo|"Placebo to indacaterol inhaled once daily in the morning via Concept1, a SDDPI, for 12 weeks.
~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
11540913|NCT01068587|Active Comparator|Erlotinib|
11540914|NCT01068587|Active Comparator|Foretinib plus Erlotinib|
11540915|NCT01068574||Single Observational Cohort|
11540916|NCT01068561|Experimental|Test group|open-label study of retinitis pigmentosa patients with best-corrected visual acuity (BCVA) worse than 20/200.
11540917|NCT01068548|No Intervention|Arm 1|pre-implementation of computer based intervention
11540918|NCT01068548|Experimental|Arm 2|post-implementation of computer based length of stay clinical reminder
11540919|NCT01068535||Women with Metabolic Syndrome|"Pre-menopausal women with Metabolic Syndrome
~Age 35-50 and any 3 of the following:
~Fasting triglycerides ≥ 150 mg/dL, Waist measurement ≥ 35 inches, HDL < 50mg/dL, Fasting glucose ≥ 100mg/dL but <126mg/dL or Blood pressure ≥ 130/85 or taking medication to treat high blood pressure."
11540920|NCT01068535||Non-Metabolic Syndrome (healthy) women|"Non-Metabolic syndrome pre-menopausal women age 35-50
~Body Mass Index ≤ 25
~Regular menstrual cycles (occur every 24-35 days)
~Fasting glucose < 100mg/dL
~HDL-C ≥ 50mg/dL
~Waist measurement ≤ 35 inches
~Fasting triglycerides < 150mg/dL"
11540921|NCT01068522|Experimental|ICP monitoring|Care based upon intracranial pressure.
11540922|NCT01068522|Active Comparator|Usual Care|Treatment based on clinical and imaging without intracranial pressure monitoring.
11540923|NCT01068509|Experimental|Non-randomized Cvac|Participants received 6-8 intradermal injections of Cvac at 4 sites along both upper arms and both thighs. The 6-8 injections contained ~ 60 × 10^6 dendritic cells. Following evaluation after the first dose, participants received additional injections as described for the randomized Cvac group below.
11540924|NCT01068509|Experimental|Randomized Cvac|Participants received 6-8 intradermal injections of Cvac at 4 sites along both upper arms and both thighs every 4 weeks for 24 weeks (7 doses at Weeks 8, 12, 16, 20, 24, 28, and 32), and then every 8 weeks for 24 weeks (3 doses at Weeks 40, 48, and 56). The 6-8 injections contained ~ 60 × 10^6 dendritic cells.
11540925|NCT01068509|No Intervention|Observational standard of care|Participants in this group did not receive any treatment during the study.
11540926|NCT01068483|Experimental|BKM120|Dose escalation followed by dose expansion
11540927|NCT01068470||patients with melanoma or kidney cancer|
11540928|NCT01068457||PTPS|Patients with pain after VATS
11540929|NCT01068457||Pain free|Patients reporting no pain late after VAT
11540930|NCT01068444|Experimental|Pioglitazone|Pioglitazone 30 mg/day for 6 months and 3 months of follow-up period after treatment
11540931|NCT01068444|Placebo Comparator|Placebo|Placebo 30 mg/day for 6 months and 3 months of follow-up period after treatment
11540932|NCT01068431|Active Comparator|trico bandage|Leg lymphedema stage 2-3
11540933|NCT01068431|Experimental|juxta fit compression device|leg lymphedema stage 2/3
11540934|NCT01068418|Experimental|Vitamin D3|15000IU of vitamin D3 daily: open-label, single-arm
11540935|NCT01068405|Experimental|Methotrexate|Patients with digital arthritis receiving methotrexate treatment at 10mg/week during 12 months
11540936|NCT01068405|Placebo Comparator|Placebo|Patients with digital arthritis receiving placebo at 10mg/week during 12 months
11540937|NCT01068392|Experimental|OXP|Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2HR D1 Prednisolone 100mg/Day D1-D5 Every 3 weeks Maximum 6 cycles of treatment will be given for this study. Subjects will be treated for at least 1 cycle and to a maximum of 6 cycles unless there is documented disease progression, unacceptable adverse events or withdrawal of consent.
11540938|NCT01068379|Experimental|Cryopexy|the cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
11540939|NCT01068379|Experimental|laser photocoagulation 4 weeks after|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
11540940|NCT01068353|Placebo Comparator|Placebo|
11540941|NCT01068353|Experimental|Etanercept|
11540942|NCT01068340||SBO Patients|Patients who develop small bowel obstruction requiring or not surgical intervention
11540943|NCT01068340||No SBO Patients|Patients who do not develop small bowel obstruction
11540944|NCT01068327|Experimental|Treatment (SRT, radiosensitizer, and chemotherapy)|See Detailed Description
11540945|NCT01068314|Experimental|Repetitive handgrip exercise|After baseline testing and randomization, subjects in this group are instructed to perform the intervention: daily repetitive handgrip exercise with upper arm compression band. Brachial artery endothelial function and venous compliance are tested at baseline and 6 weeks.
11540946|NCT01068314|No Intervention|No arm exercise|Time control. Subjects do usual activities without any exercise intervention. Brachial artery endothelial function and venous compliance are tested at baseline and 6 weeks.
11540947|NCT01068301|Other|Second Allogeneic Transplant Procedure Recipient|"Participants with Acute Lymphoblastic Leukemia (ALL); Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Chronic Myeloid Leukemia (CML); Juvenile Myelomonocytic Leukemia (JMML); Non-Hodgkin lymphoma (NHL) with evidence of bone marrow disease, receiving a second allogeneic transplant procedure.
~Intervention: Plerixafor"
11540948|NCT01068288|Experimental|Expectant Management|Expectant Management
11540949|NCT01068288|Experimental|Operative management|Operative management
11540950|NCT01068275|Active Comparator|Lumbar plexus catheter|
11540951|NCT01068275|Active Comparator|femoral nerve catheter|
11540952|NCT01068275|Active Comparator|single-shot femoral block|
11540953|NCT01068262|Experimental|Panel A - Odanacatib|Panel A - Healthy male subjects receiving Odanacatib
11540954|NCT01068262|Placebo Comparator|Panel A - Placebo|Panel A - Healthy male subjects receiving placebo
11540955|NCT01068262|Experimental|Panel B - Odanacatib|Panel B - Healthy female subjects receiving Odanacatib
11540956|NCT01068262|Placebo Comparator|Panel B - Placebo|Panel B - Healthy female subjects receiving placebo
11540957|NCT01068249|Experimental|Letrozole + RAD001|Letrozole and RAD001 (Everolimus)
11540958|NCT01068236|Experimental|Healthy lifestyle intervention|lifestyle/weight-loss intervention for overweight (95th - 99th percentile) female adolescents (13-15 years of age at study entry) to a usual-care control condition. The intervention will be 20-sessions and combines group visits, individual telephone coaching calls, and tailored pediatric primary care providers (PCP) visits.
11540959|NCT01068236|No Intervention|Usual care|In the usual care control condition adolescents and their family will receive individualized feedback from the assessments as well as handouts outlining healthy means of maintaining / reducing weight for adolescents through improving nutrition and physical activity. In addition, these participants will be encouraged to seek any appropriate health care/education services available through Kaiser Permanente or in the community.
11540960|NCT01068223|Experimental|001|A:JNJ-39758979/Placebo #1 Single oral dose of JNJ-39758979 600 mg and Placebo
11540961|NCT01068223|Placebo Comparator|002|B: JNJ-39758979 Matching Placebo /Placebo #2 A single dose of 2 different Placebos JNJ-39758979 Matching Placebo and Placebo #2
11540962|NCT01068223|Active Comparator|003|C:Cetirizine/JNJ-39758979 Matching Placebo Single oral dose of 10mg cetirizine and JNJ-39758979 Matching Placebo
11540963|NCT01068210|Experimental|Aerobic Training|A customized and supervised endurance exercise training program that will last 4 months (16 weeks). The regimen will be tailored to the individual fitness level. The exercise program will consist of three supervised sessions per week. During each session, the participant will cycle on a stationary bicycle at moderate intensity for approximately 30-60 minutes.
11540964|NCT01068210|Experimental|Resistance Training|A customized and supervised resistance exercise training program that will last 4 months (16 weeks). Resistance training will be performed on stationary weight machines, modification in equipment may be made by Exercise Physiologist. Patients will be progressively trained to perform two to three sets of 75-85% of maximal strength The participant will be trained to perform different resistance exercise, alternating between lower and upper body muscle groups. The exercise program will consist of three supervised sessions per week. Each session will last approximately 30-60 minutes.
11541147|NCT01066962|Active Comparator|darunavir/r + tenofovir/emtricitabine|
11541148|NCT01066962|Experimental|darunavir/r + raltegravir|
11540965|NCT01068210|Experimental|Combined Aerobic and Resistance Training|A customized and supervised endurance exercise training program that will last 4 months (16 weeks). The regimen will be tailored to the individual fitness level, and will be a combination of Arm A and Arm B, described above. At each session, the participant will complete aerobic training on a stationary bicycle and also resistance training using stationary weight machines. The exercise program will consist of three supervised sessions per week. Each session will last approximately 30-90 minutes.
11540966|NCT01068210|Active Comparator|Progressive Stretching Group (Attention-Control)|A customized and supervised progressive stretching program that will last 4 months (16 weeks). The progressive stretching program will consist of a series of stretching exercises alternating between lower and upper body muscle groups/joints. This program will consist of three exercise sessions a week. Each session will last approximately 30-60 minutes.
11540967|NCT01068197|Experimental|Low glycemic load dietary plan|"The subjects and their parents will be given instructions, and specific examples, to lower the glycemic load of their diets by replacing high-GI sources of carbohydrates with low-GI food sources, replacing energy from carbohydrate with energy from protein and fat, and attempt to balance meals and snacks with low-GI carbohydrate, proteins and low-fat food sources. The objective will be to achieve macronutrient composition for the low-GL diet of 45-50% low-GI carbohydrates, 20-25% protein, and 30-35% fat. All subjects will receive sessions on behavior modification, increasing physical activity and reducing sedentary behavior.
~At 3 months, subjects will be admitted to the GCRC for a 24 hour period for a meal study. They will be given standardized low-glycemic load diet for dinner, breakfast and lunch, followed by an ad lib snack platter. Their subjective, hormonal and metabolic responses will be serially measured."
11540968|NCT01068197|Active Comparator|Low fat diet|"For the low fat diet, subjects and their parents will be given instructions, and specific examples, to lower the fat content of their diet. The composition of the low-fat diet will be targeted to achieve 55-60% carbohydrates (with no discrimination by their glycemic index), 15-20% protein and 25-30% fat. All recruited children will receive sessions on behavior modification, increasing physical activity and reducing sedentary behavior.
~At 3 months, subjects will be admitted to the GCRC for a 24 hour period for a meal study. They will be given standardized high-glycemic load diet for dinner, breakfast and lunch, followed by an ad lib snack platter. Their subjective, hormonal and metabolic responses will be serially measured."
11540969|NCT01068184|Experimental|1|
11540970|NCT01068184|Placebo Comparator|2|
11540971|NCT01068171|Active Comparator|shoe, plain dressing|post-op shoe with plain occlusive dressing
11540972|NCT01068171|Active Comparator|shoe, collagen|post-op shoe with collagen dressing
11540973|NCT01068171|Active Comparator|boot, plain dressing|air boot with occlusive dressing
11540974|NCT01068171|Active Comparator|boot, collagen|air boot with collagen dressing
11540975|NCT01068171|Active Comparator|monitored air boot, plain dressing|air boot with retention strap to monitor whether boot is removed with occlusive dressing
11540976|NCT01068171|Active Comparator|monitored boot with collagen|air boot with retention strap to monitor whether boot is removed with collagen dressing
11540977|NCT01068158|Experimental|0.5% Ivermectin Cream|Up to 4 ounces of topical Ivermectin Cream applied to hair and scalp on day 1
11540978|NCT01068158|Placebo Comparator|Vehicle control|Up to 4 ounces of topical control applied to hair and scalp on day 1.
11540979|NCT01068145|Experimental|Very low dose SCH 527123|
11540980|NCT01068145|Experimental|Low dose SCH 527123|
11540981|NCT01068145|Experimental|Medium dose SCH 527123|
11540982|NCT01068145|Experimental|High dose SCH 527123|
11540983|NCT01068145|Placebo Comparator|Placebo to match SCH 527123|
11540984|NCT01068145|Experimental|Low dose SCH 527123 (Part 2)|
11540985|NCT01068145|Experimental|Medium dose SCH 527123 (Part 2)|
11540986|NCT01068145|Experimental|High dose SCH 527123 (Part 2)|
11540987|NCT01068145|Placebo Comparator|Placebo (Part 2)|
11540988|NCT01068132|Experimental|1|Cetuximab+FOLFIRI: cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1, followed after 1 hour by FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
11540989|NCT01068119|Experimental|Same-day discharge|Same-day discharge following PCI
11540990|NCT01068106|Active Comparator|BPLES|Biodegradable polymer limus-eluting stents
11540991|NCT01068106|Active Comparator|PPLES|Permanent polymer limus-eluting stent
11540992|NCT01068080||Myocardial fatty acid metabolism, Insulin resistance|"Myocardial fatty acid metabolism was evaluated by myocardial fatty acid imaging using BMIPP SPECT.
~Insulin resistance was evaluated by HOMA-IR."
11540993|NCT01068067|Experimental|pharmacogenetics plus SchE guided dosing|
11540994|NCT01068067|Active Comparator|standard dosing|
11540995|NCT01068054|Active Comparator|tacrolimus|Tacrolimus arm: active 0.1% tacrolimus eye ointment BID + placebo eye drops QID
11540996|NCT01068054|Active Comparator|cyclosporine|2% cyclosporine eye drops apply QID + placebo eye ointment apply bid
11540997|NCT01068041|Placebo Comparator|A|Placebo
11540998|NCT01068041|Active Comparator|B|250mg active ingredient
11540999|NCT01068041|Active Comparator|C|500mg active ingredient
11541000|NCT01068041|Active Comparator|D|1000mg active ingredient
11541001|NCT01068028|Placebo Comparator|Placebo for ORM-12741|
11541002|NCT01068028|Experimental|ORM-12741|
11541003|NCT01068015|Experimental|Intervention|This arm receives free circumcision service, POL intervention, intensive HIV counseling and intensive condom promotion.
11541004|NCT01068015|No Intervention|usual|This arm receives no extra HIV prevention services.
11541005|NCT01068002||Control, normotensive, pregnancy|Control, normotensive, pregnancy
11541006|NCT01068002||hypertension, pregnancy, no treatment|hypertension, pregnancy, no treatment
11541007|NCT01068002||hypertension, pregnancy, drug treatment|hypertension, pregnancy, drug treatment
11541008|NCT01067989|Experimental|intervention|same treatment for all patients
11541108|NCT01067274|No Intervention|R1 Arm B : no ATRA|Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN >1G/l over 2 days at minimum
11541009|NCT01067976|Experimental|Gadobutrol (Gadavist, BAY86-4875)|Patients first received an unenhanced MRM, followed by a gadobutrol-enhanced MRM. Gadobutrol was administered at the standard dose of 0.1 mmol/kg bw [0.1 ml/kg bw] as an intravenous injection (i.v.) injection at a rate of 2 ml/sec. UMRM and CMRM image sets were evaluated in a randomized fashion. After the evaluation of the UMRM or CMRM the respective XRM was added and evaluated together with the UMRM images.
11541010|NCT01067963|Experimental|Behavioral-education/counseling|"Computer assisted education and telephone counseling using motivational interviewing.
~Computer assisted education and motivational interviewing"
11541011|NCT01067963|Placebo Comparator|Group talks/social chat|Group session talks on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
11541012|NCT01067950|Experimental|Isolated Pancreas Transplant|
11541013|NCT01067950|Active Comparator|Intensive Insulin Therapy|
11541014|NCT01067924|Experimental|Motivational interviewing|
11541015|NCT01067924|Active Comparator|Standard of care|
11541016|NCT01067911|Active Comparator|1|In this study subjects will consume test meals containing vegetable oils (soy) and butter
11541017|NCT01067911|Active Comparator|2|In this study subjects will consume test meals containing vegetable oils (flaxseed) and butter
11541018|NCT01067911|Active Comparator|3|In this study subjects will consume test meals containing vegetable oils (high oleic safflower) and butter
11541019|NCT01067911|Active Comparator|4|In this study subjects will consume test meals containing vegetable oils (canola) and butter
11541020|NCT01067898|Experimental|200 000 IU vitamin D3 every three months|
11541021|NCT01067898|Experimental|100 000 IU vitamin D3 every three months|
11541022|NCT01067898|Placebo Comparator|placebo every three months|
11541023|NCT01067859|Experimental|Arm 1|
11541024|NCT01067859|Experimental|Arm 2|
11541025|NCT01067859|Placebo Comparator|Arm 3|
11541026|NCT01067846|Experimental|DCS and Cognitive Behavioral Therapy|Subjects will receive 250 mg of Seromycin or D-cycloserine (DCS) prior to computerized cognitive behavioral therapy.
11541027|NCT01067846|Placebo Comparator|Placebo and Cognitive Behavioral Therapy|Subjects will receive a 250 mg identical looking placebo pill prior to computerized cognitive behavioral therapy.
11541028|NCT01067833|Placebo Comparator|Placebo|Placebo
11541029|NCT01067833|Experimental|Dose 1|K201
11541030|NCT01067833|Experimental|Dose 2|K201
11541031|NCT01067833|Experimental|Dose 3|K201
11541032|NCT01067820|Experimental|RVX000222, 200 mg daily|
11541033|NCT01067820|Placebo Comparator|Placebo|
11541034|NCT01067807|Experimental|Proellex Formulation 1|25 mg Proellex Gelucire and PEG (original formulation)
11541035|NCT01067807|Experimental|25 mg Proellex Formulation 2|25 mg Proellex coated with MCC
11541036|NCT01067807|Experimental|25 mg Proellex Formulation 3|25 mg Proellex blended with MCC
11541037|NCT01067807|Experimental|50 mg Proellex Formulation 3|50 mg Proellex blended with MCC
11541038|NCT01067794||pemetrexed + platinum|Patients with pemetrexed + platinum doublet, with or without additional targeted agents
11541039|NCT01067794||gemcitabine + platinum|Patients with gemcitabine + platinum doublet, with or without additional targeted agents
11541040|NCT01067794||taxanes + platinum|Patients with taxanes + platinum doublet, with or without additional targeted agents
11541041|NCT01067794||vinorelbine + platinum|Patients with vinorelbine + platinum doublet, with or without additional targeted agents
11541042|NCT01067794||others + platinum|Patients with other platinum-based doublet, with or without additional targeted agents
11541043|NCT01067781|Experimental|1|Two vaccination regimen with an LT patch (no swabbing)
11541044|NCT01067781|Experimental|2|Two vaccination regimen with an LT patch (with swabbing)
11541045|NCT01067781|Placebo Comparator|3|Two vaccination regimen with a placebo patch (no swabbing)
11541046|NCT01067781|Placebo Comparator|4|Two vaccination regimen with a placebo patch (with swabbing)
11541047|NCT01067768|Experimental|Daily review|In the intervention group a nurse reviewed daily, by using a checklist designed for this study, the indications and pertinence of the catheter. If it was not indicated she asked the doctor to order the removal of the catheter, but the doctor would make the final decision.
11541048|NCT01067768|No Intervention|Routine care|In the control group, the attending team would remove the catheter as routine, without any suggestion by the research protocol.
11541049|NCT01067755||Bronchoscopy, lung neoplasm|Patients who have been recommended for bronchoscopy for the purpose of obtaining a biopsy sample of a central or peripheral pulmonary lesion, diagnosing mediastinal or hilar lymphadenopathy or for lung fiducial placement.
11541050|NCT01067742||Subjects with Mucolipidosis Type IV|
11541051|NCT01067716|Experimental|Refractive Error|
11541052|NCT01067703|Active Comparator|RIPC|
11541053|NCT01067703|Sham Comparator|CONTROL|
11541054|NCT01067677|Experimental|Metoclopramide|rescue emetic therapy
11541055|NCT01067677|Experimental|Ondansetron|Rescue emetic therapy
11541056|NCT01067677|Experimental|Diphenhydramine|Rescue emetic therapy
11541057|NCT01067677|Placebo Comparator|Saline|Placebo
11541058|NCT01067664||Patients undergoing IVF with rFSH and GnRH antagonists|
11541059|NCT01067651|Active Comparator|Plaster of Paris (POP)|
11541060|NCT01067651|Active Comparator|semi-rigid fiberglass softcast (SRF, 3M Scotchcast)|
11541061|NCT01067638|Experimental|tranexamic acid|Tranexamic Acid on Postoperative Blood loss and Coagulation in Patients with Preoperative Anemia Undergoing Off-Pump Coronary Artery Bypass Graft
11541062|NCT01067625|Experimental|TOGA subjects|
11541063|NCT01067599|Active Comparator|Low nicotine|Conventional smokeless tobacco product with 1) NNN plus NNK of <2 μg/gram and nicotine levels of >5 mg/g wet weight
11541064|NCT01067599|Active Comparator|Medium nicotine|Conventional smokeless tobacco product with ) NNN plus NNK of <2 μg/gram and nicotine levels of 3-5 mg/g wet weight.
11541065|NCT01067599|Active Comparator|High nicotine|Conventional smokeless tobacco product with NNN plus NNK of <2 μg/gram and nicotine levels of <3 mg/g wet weight
11541066|NCT01067547|Experimental|iron sulfate|Oral iron sulfate 300mg tid
11541067|NCT01067547|Active Comparator|intravenous iron sulfate|intravenous iron sulfate 300 mg
11541068|NCT01067521|Experimental|GA 40 mg / GA 40 mg|Also referred to as the 'Early Start' treatment arm, participants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the Double-Blind Period, and then continued that treatment as open-label therapy until the drug was commercially available or development stopped.
11541069|NCT01067521|Placebo Comparator|Placebo / GA 40 mg|Also referred to as the 'Delayed Start' treatment arm, participants were administered placebo subcutaneous injections three times a week for 12 months during the Double-Blind Period, and then switched to GA 40 mg/mL subcutaneous injections three times a week as open-label therapy until the drug was commercially available or development stopped.
11541070|NCT01067508|Experimental|Fiji Water|Participants are asked to consume one liter of this silicon-rich water daily for three months.
11541071|NCT01067508|No Intervention|Aquafina Water|Participants are asked to drink one liter of this deionized water daily for three months.
11541072|NCT01067495|Experimental|Exercise|
11541073|NCT01067482||Glaucoma patients|
11541074|NCT01067482||Glaucoma suspect group|
11541075|NCT01067482||Normal population|
11541076|NCT01067469|Experimental|Standard Dose Bevacizumab|Bevacizumab 10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
11541077|NCT01067469|Experimental|Low Dose Bevacizumab + Lomustine|Bevacizumab 5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle. Lomustine starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
11541078|NCT01067456|No Intervention|Dedicated CT arm|Subjects in this arm will continue to receive standard of care - that is the dedicated CT protocol to rule out either aortic dissection or acute coronary syndrome or pulmonary embolism.
11541079|NCT01067456|Experimental|Comprehensive Cardiothoracic CT arm|The intervention consisted in a change of the routine CT protocol (as in dedicated CT protocol) to a comprehensive cardiothoracic CT protocol which includes changes in contrast injection and coverage to enable evaluation of the presence of acute coronary syndrome/aortic dissection/pulmonary embolism in a single scan.
11541080|NCT01067443|Experimental|Amb+SSG|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
11541081|NCT01067443|Experimental|Amb+Milt|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
11541082|NCT01067443|Experimental|Milt|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
11541083|NCT01067430|Active Comparator|Etoricoxib 90 mg|Subject will take Etoricoxib 90 mg for 14 days
11541084|NCT01067430|Active Comparator|Diclofenac|Film coated tablet 50 mgs given three times a day for 14 days
11541085|NCT01067417|Active Comparator|Hydroxychloroquine|
11541086|NCT01067417|Placebo Comparator|Placebo|
11541087|NCT01067404||2008-09 study TIV recipients|Infants and toddlers who participated in earlier clinical trial (TITRE) to evaluate dosing (0.25mL versus 0.5mL) of trivalent influenza vaccine (TIV)
11541088|NCT01067391|Active Comparator|tadalafil 20 mg|Oral study medication to be administered once to each participant
11541089|NCT01067391|Placebo Comparator|placebo|oral study medication to be administered once to each study participant
11541090|NCT01067378|Active Comparator|Expert instructor debriefing|Expert instructor debriefing
11541091|NCT01067378|Experimental|Peer-led debriefing|Peer-led debriefing
11541092|NCT01067365|Experimental|12.5 mg Androxal|12.5 mg Androxal daily
11541093|NCT01067365|Experimental|25 mg Androxal|25 mg Androxal daily
11541094|NCT01067352|Experimental|Group A (A1)|Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive Saizen at the daily dose of 0.035 milligram (mg)/kilogram (kg) (Group A1) or no treatment (Group A2) for two years.
11541095|NCT01067352|No Intervention|Group A (A2)|Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive no treatment (Group A2) for two years.
11541096|NCT01067352|No Intervention|Group B|Participants were allocated to Group B being third percentile (thus showing a spontaneous catch-up growth).
11541097|NCT01067339|Experimental|Darapladib|Subjects randomized to this arm will receive a darapladib tablet, 160 mg, by mouth, once per day for 6 months.
11541098|NCT01067339|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a placebo tablet matching the study drug, once per day for 6 months.
11541099|NCT01067326|Active Comparator|Aliskiren|150 mg Aliskiren once daily for a period of 4 months.
11541100|NCT01067326|Placebo Comparator|Placebo|1 pill per day by mouth for 4 months.
11541101|NCT01067313|Experimental|Dialyzer Ultraflux EMiC2|Dialyzer Ultraflux EMiC2 used in Continuous Hemodialysis
11541102|NCT01067313|Active Comparator|Dialyzer Ultraflux AV1000S|Dialyzer Ultraflux AV1000S used in continuous Hemofiltration
11541103|NCT01067300|Active Comparator|Double unit unrelated cord blood transplantation|Transplantation of unrelated cord blood units is done at least 24 hours after last chemotherapy and carried out during the same day. The unit presenting the best degree of HLA compatibility with the patient will be transfused in first. If the 2 units have the same degree of HLA compatibility with the recipient, the unit with the higher cell dose will be transfused in first. A 2 hours time interval between the 2 transfusions will be respected.
11541104|NCT01067300|Active Comparator|single unit unrelated cord blood transplantation|Transplantation of a single unrelated cord blood unit at least 24 hours after last chemotherapy
11541105|NCT01067287|Active Comparator|Group 1|Monoclonal antibody CT-011 will be given 1-3 months following autologous transplant. 3 doses will be given at 6 week intervals.
11541106|NCT01067287|Active Comparator|Group 2|Vaccination with DC/myeloma fusion cells will be given 1-3 months following autologous transplant. Vaccination will be given at 6 weeks intervals. The monoclonal antibody CT-011 will be given 1 week following each vaccination. 3 doses of CT-011 will be given at 6 week intervals.
11541107|NCT01067274|Experimental|R1 Arm A : ATRA|"Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN >1G/l over 2 days at minimum
~All-trans retinoic acid (ATRA): 45mg/m2/day in two divided doses from D8 to D28"
11541109|NCT01067274|Experimental|R2 Arm 1A : AZACITIDINE and ATRA|Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5 All-trans retinoic acid (ATRA): 45mg/m2/d in two divided doses from D8 to D21
11541110|NCT01067274|Experimental|R2 Arm 1B : AZACITIDINE and No ATRA|Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5
11541111|NCT01067274|Experimental|R2 Arm 2A : ATRA|Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5 All-trans retinoic acid (ATRA): 45mg/ m2/d in two divided doses from D8 to D21
11541112|NCT01067274|Experimental|R2 Arm 2B : no ATRA|Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5
11541113|NCT01067261|Experimental|TMNS and pelvic floor muscle training|This group will receive both the normal pelvic floor muscle training and the TMNS vibration therapy following their radical prostatectomy. Treatment with TMNS will start before the surgery and continue 6 weeks after the surgery.
11541114|NCT01067261|Active Comparator|Pelvic floor muscle training only|This group will receive the normal pelvic floor muscle training after prostatectomy only.
11541115|NCT01067248||COPD, osteoporosis|The subjects are divided into 6 groups of 20 subjects each, I: COPD patients with osteoporosis based on T-score and without vertebral fractures, II: COPD patients with osteoporosis based on T-score and vertebral fractures, III: COPD patients with vertebral fractures and without osteoporosis based on T-score, IV: COPD patients without osteoporosis based on T-score and without vertebral fractures, V: healthy controls with osteoporosis based on T-score and without vertebral fractures, VI: healthy controls without osteoporosis based on T-score and without vertebral fractures.
11541116|NCT01067235|Experimental|BF2.649 + Modafinil placebo|
11541117|NCT01067235|Experimental|BF2.649 + Modafinil|
11541118|NCT01067222|Experimental|BF2.649|
11541119|NCT01067222|Active Comparator|Modafinil|
11541120|NCT01067222|Placebo Comparator|Placebo|
11541121|NCT01067209||Diabetic/Obese Gastric bypass patients|Subjects with obesity including those with known diabetes or those with a high likelihood of diabetes who will undergo gastric bypass surgery.
11541122|NCT01067196||Observation and quality of life|Central Nervous System Tumors
11541123|NCT01067183|Experimental|breathing and biofeedback device|This group of physicians were trained in the use of the relaxation breathing technique and the biofeedback device, and then used this portable stress reduction tool on a daily basis with twice weekly visits with the research team. After the 28 day RCT, they were invited to continue to use the device at their discretion during a trial extension from day 28-56 to see if any effect measured was maintained.
11541124|NCT01067183|No Intervention|control arm|This group did not undergo training in the breathing technique and use of the PSMD during the RTC trial day 0-28, but were visited twice weekly by the research team to collect outcome data. During the trial extension Day 28-56, this group did undergo a 1 hr training session with the PSMD and invited to use it at their discretion over the 28 days. Effectiveness outcome data (day 28-56) was collected at day 56.
11541125|NCT01067170|Experimental|Pneumatic compression stockings|
11541126|NCT01067157|Other|A|"Other = Lifestyle intervention
~A: Medical examination before and after inpatient therapy (clinic staff), questionnaires.
~Further medical examination and questionnaires after 6 months, 1, 2, 5 and 10 years at home by pediatrics or general practitioner.
~The lifestyle intervention includes an age-specific diet (1200-1800 kcal/d), 11 h/wk physical activity (walking, swimming, sports) and behavioural therapy."
11541127|NCT01067144|Placebo Comparator|Control|Active placebo given pre-operatively, followed by inactive placebo for 10 doses post-operatively
11541128|NCT01067144|Experimental|Gabapentin|1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.
11541129|NCT01067131|Experimental|PEV7C1, intravaginal|Vaccine containing virosomes intravaginally applied
11541130|NCT01067131|Placebo Comparator|PEV7C9, placebo, intravaginal|Placebo vaccine (excipient only) intravaginally applied
11541131|NCT01067131|Experimental|PEV7B2, intramuscular low dose|Intramuscular vaccine low dose of antigen
11541132|NCT01067131|Experimental|PEV7B1, intramuscular high dose|Intramuscular vaccine, high dose of antigen
11541133|NCT01067118|Active Comparator|Humalog U-100 Insulin|
11541134|NCT01067118|Experimental|LINjeta U-100|
11541135|NCT01067105|Experimental|ciclesonide|ciclesonide HFA 160 μg once daily
11541136|NCT01067092|Experimental|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
11541137|NCT01067092|Active Comparator|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
11541138|NCT01067079||Arm 1|
11541139|NCT01067066|Experimental|TPI 287 + Temodar|Starting dose of TPI 287 90 mg/m^2 IV on Days 1, 8, 15 + Temozolomide (Temodar) PO at 85 mg/m^2 on Days 1-5.
11541140|NCT01067053|Experimental|bevacizumab, capecitabine, oxaliplatin|"6 cycles (3 weeks each one) of:
~bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.
~capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.
~oxaliplatin: 130/mg/m2(iv),1st day of each cycle.
~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine"
11541141|NCT01067014||iO-Flex|
11541142|NCT01067001||2 Way Crossover|2 Way Crossover bioequivalence study
11541143|NCT01067001||Subjects will be randomly divided in to 2 groups.|A total of 18 normal, healthy, adult, human subjects will be enrolled in the study.
11541144|NCT01066988|Other|Right Eye|ORB Ocular Emulsion or SootheXP
11541145|NCT01066988|Other|Left Eye|ORB Ocular Emulsion or SootheXP
11541149|NCT01066949|Active Comparator|Support and discussion|The Support and Discussion protocol will consist of two integrated components: (a) brief educational materials presented at the start of each session, and (b) group leader facilitated discussion following presentation of the educational materials.
11541150|NCT01066949|Experimental|Behavioral Self management|Self-Regulation group sessions will be generally highly leader-directed though participants will be regularly encouraged to share their experiences dealing with the dialysis regimen. A consistent attempt will be made to focus all group discussion on self-regulatory principles as they relate to treatment adherence.Session material utilized by group-leaders will be highly structured and detailed across the seven sessions.
11541151|NCT01066923|Experimental|Daily ASA, Active cool, Acute ASA|Two weeks of daily aspirin therapy prior to exercise, active cooling following exercise, aspirin immediately post exercise
11541152|NCT01066923|Experimental|Daily ASA, Active cool, Acute placebo|Two weeks of daily aspirin therapy prior to exercise, active cooling following exercise, placebo immediately post exercise
11541153|NCT01066923|Experimental|Daily ASA, Passive cool, Acute ASA|Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, aspirin immediately post exercise
11541154|NCT01066923|Experimental|Daily ASA, Passive cool, Acute placebo|Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, placebo immediately post exercise
11541155|NCT01066923|Experimental|Daily placebo, active cool, Acute ASA|Two weeks of daily placebo prior to exercise, active cooling following exercise, aspirin immediately post exercise
11541156|NCT01066923|Experimental|Daily placebo, active cool, Acute placebo|Two weeks of daily placebo prior to exercise, active cooling following exercise, placebo immediately post exercise
11541157|NCT01066923|Experimental|Daily placebo, Passive cool, Acute ASA|Two weeks of daily placebo prior to exercise, passive cooling following exercise, aspirin immediately post exercise
11541158|NCT01066923|Placebo Comparator|Daily placebo, Passive cool, Acute placebo|Two weeks of daily placebo prior to exercise, passive cooling following exercise, placebo immediately post exercise
11541159|NCT01066910|Experimental|Parent-only|
11541160|NCT01066910|Active Comparator|Parent and child|
11541161|NCT01066897|Experimental|Pramipexole|Patients will receive 0.125 mg of pramipexole three times a day for the first week, 0.25 mg three times a day for the second week, and 0.5 mg three times a day for the third week. The dose will then be adjusted as needed by the treating physician (Dr. DeBattista), with a target range of 1.0 mg to 1.5 mg per day. Dose escalations will continue until 1) achievement of the primary endpoint (> 50% reduction from baseline on the HDRS scores; 2) intolerable side effects; or 3) completion of the 8-week study. Participants will be seen weekly the first four weeks and biweekly thereafter. Side effects, depression, and anhedonia will assessed at each visit.
11541162|NCT01066897|No Intervention|Healthy Controls|Non depressed, non-intervention comparison group
11541163|NCT01066884|Experimental|1|
11541164|NCT01066871|Experimental|Sprifermin (AS902330) 10 mcg|
11541165|NCT01066871|Experimental|Sprifermin (AS902330) 30 mcg|
11541166|NCT01066871|Experimental|Sprifermin (AS902330) 100 mcg|
11541167|NCT01066871|Placebo Comparator|Placebo|
11541168|NCT01066858||Maternal/infant antepartum exposure|"HIV-infected women exposed to TDF during pregnancy
~Infants of HIV-infected women exposed to TDF during pregnancy"
11541169|NCT01066858||Maternal/infant postpartum exposure|"HIV-infected women exposed to TDF while breastfeeding
~Infants of HIV-infected women exposed to TDF while breastfeeding"
11541170|NCT01066858||Maternal/infant antepartum no exposure|"HIV-infected women not exposed to TDF during pregnancy
~Infants of HIV-infected women not exposed to TDF during pregnancy"
11541171|NCT01066858||Maternal/infant postpartum no exposure|"HIV-infected women not exposed to TDF during breastfeeding
~Infants of HIV-infected women not exposed to TDF during breastfeeding"
11541172|NCT01066845||Patients prescribed Adcirca|all patients prescribed Adcirca during study period
11541173|NCT01066819||Cohort|Participants chronically infected with the hepatitis C virus including genotypes 1 to 6.
11541174|NCT01066806|Experimental|high calcium diet|
11541175|NCT01066806|Active Comparator|normal calcium diet|
11541176|NCT01066793||Cohort|Participants chronically infected with the hepatitis C virus including genotypes 1 to 6
11541177|NCT01066780|Experimental|Group A: ClearVoice Medium|Chronic use of ClearVoice MEDIUM for two weeks followed by chronic use of ClearVoice HIGH for two weeks.
11541178|NCT01066780|Experimental|Group B: ClearVoice High|Chronic use of ClearVoice HIGH for two weeks followed by chronic use of ClearVoice MEDIUM for two weeks.
11541179|NCT01066767|Experimental|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets Dr. Reddy's Laboratories Limited
11541180|NCT01066767|Active Comparator|Allegra|Allegra Tablets 180 mg Aventis Pharmaceuticals Inc.,
11541181|NCT01066754|Experimental|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets of Dr. Reddy's Laboratories Limited
11541182|NCT01066754|Active Comparator|Allegra|Allegra Tablets 180 mg of Aventis Pharmaceuticals Inc.,
11541183|NCT01066741|Experimental|Homeodent®|Mouthwash with Homeodent® is started on the first day of irradiation, then continued until the end of the irradiation period or until occurrence of grade ≥3 mucositis. In case of grade ≥3 mucositis, patients are instructed to mouthwash with Sodium Bicarbonate solution until complete disappearance of mucositis or until the end of irradiation.
11541184|NCT01066741|Active Comparator|1.4 % Sodium Bicarbonate solution|"Mouthwash with sodium bicarbonate is started on the first day of irradiation, then continued until the end of the irradiation period. In case of grade ≥3 mucositis, mouthwash is continued until complete disappearance of the mucositis or until the end of irradiation.
~In both arms, after the end of irradiation, patients can receive treatment with Sodium Bicarbonate solution until complete disappearance of the mucositis."
11541185|NCT01066728|Active Comparator|Theophylline|Oral loading dose of 6 mg per kilogram of body weight of theophylline followed by a maintenance dose of 2 mg per kilogram every 8 hours plus room air by nasal prongs at 0.5 l/min for 3 days.
11541186|NCT01066728|Experimental|CO2 inhalation|Equivalent loading and maintenance volume of oral normal saline plus CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
11541187|NCT01066715|Placebo Comparator|Placebo|
11541188|NCT01066715|Experimental|XOMA 052|
11541189|NCT01066702|Experimental|NeoCart|Autologous cartilagenous tissue implant
11541190|NCT01066702|Active Comparator|Microfracture|surgical intervention
11541191|NCT01066689|Experimental|A|Patients randomized into the arm blind A. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
11541192|NCT01066689|Placebo Comparator|B|Patients randomized into the arm blind B. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
11541193|NCT01066676|Experimental|Dexibuprofen|Dexibuprofen 400 mg powder for oral suspension
11541194|NCT01066676|Active Comparator|Ibuprofen|Ibuprofen 400 mg powder for oral suspension
11541195|NCT01066663|Experimental|Pyrimethamine|Single daily oral 50 mg dose.
11541196|NCT01066650|Active Comparator|Endeavor Resolute|
11541197|NCT01066650|Active Comparator|Xience V|
11541198|NCT01066637|Experimental|Dosimetry Group|To determine its potential for use in humans, we measured 18F-NOS myocardial activity in patients after orthotopic heart transplantation (OHT) (3 women and 9 men) and normal healthy volunteers (2 women and 2 men), and correlated it with pathologic allograft rejection, tissue iNOS levels, and calculated human radiation dosimetry.
11541199|NCT01066637|Experimental|Kinetic Analysis Group|Measurement of myocardial levels of enzyme nitric oxide synthase(iNOS) using PET and 18F-NOS in post heart transplant patients (5 women and 5 men) undergoing endomyocardial biopsy as part of their normal post-transplant evaluation. Kinetic data of the tracer will be compared with the heart tissue measurements of iNOS measured by immunohistochemistry.
11541200|NCT01066624|Active Comparator|0.9% Sodium Chloride irrigation solution|Standard of care for prevention and management of oral mucositis (0.9% Sodium Chloride irrigation solution): Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study.
11541201|NCT01066624|Active Comparator|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion. After patients are done with the cryotherapy they will follow the standard of care for prevention and management of oral mucositis until the end of the study.
11541202|NCT01066624|Active Comparator|Calcium phosphate (Caphosol) mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
11541203|NCT01066611|Active Comparator|1|CAL-263
11541204|NCT01066611|Placebo Comparator|2|Placebo
11541205|NCT01066598|Experimental|Rituximab plus prednisone|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d Treat 61 Patients
11541206|NCT01066585|Experimental|0.5% Ivermectin Cream|
11541207|NCT01066585|Placebo Comparator|Vehicle control|
11541208|NCT01066572|Experimental|Lisinopril|Experimental
11541209|NCT01066572|Placebo Comparator|Placebo|Placebo Comparator
11541210|NCT01066559|Experimental|High flux polymethylmetacrylate membrane|
11541211|NCT01066559|Active Comparator|Polysulfone membranes|
11541212|NCT01066546|Experimental|Dimebon|
11541213|NCT01066533|Experimental|Mineral Trioxide Aggregate(MTA)|MTA is a proper material for direct pulp capping,treatment of tooth perforations,root end filling.It is a safe and biocompatible material,which can induce cementum formation on root surface.In direct pulp capping, MTA can induce dentinal bridge formation on the expose surface to preserve pulp vitality.Although MTA has superior biocompatibility compared with the conventional materials,it has a delayed setting time, poor handling characteristics and off-white color
11541214|NCT01066533|Experimental|NEC cement|NEC cement is a proper material for direct pulp capping and treatment of tooth perforation. It is a new dental material that combines reasonable biocompatibility of MTA with appropriate setting time,handling characteristics,chemical properties and color.Like MTA, NEC cement can induce dentinal bridge formation in direct pulp capping to preserve pulp vitality.
11541215|NCT01066520|Experimental|Traumeel S ointment|Traumeel S ointment 2 g, 3 times daily topical during 14 days
11541216|NCT01066520|Experimental|Traumeel S gel|Traumeel S gel 2 g, 3 times daily topical during 14 days
11541217|NCT01066520|Active Comparator|Diclofenac gel|Diclofenac gel 2 g, 3 times daily topical during 14 days
11541218|NCT01066507||Breast cancer|Slides containing breast cancer paraffin embedded tissue sections.
11541219|NCT01066494|Experimental|Single-arm|Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
11541220|NCT01066481|Experimental|PF-01913539 5 mg three times daily|PF-01913539 5 mg three times daily for 6 months
11541221|NCT01066481|Experimental|PF-01913539 20 mg three times daily|PF-01913539 20 mg three times daily for 6 months
11541222|NCT01066481|Placebo Comparator|Placebo|Placebo three times daily for 6 months
11541223|NCT01066468|Experimental|Gleevec/Glivec|
11541224|NCT01066442|Experimental|BF2.649 ( Pitolisant)|BF2.649 (5mg, 10 mg, 20 mg) in capsules
11541932|NCT01061437|Active Comparator|Arm 1|Standard 14 day, 3-drug regimen
11541225|NCT01066442|Placebo Comparator|Placebo|Placebo of BF2.649 (5mg, 10mg, 20mg) in capsules
11541226|NCT01066429|No Intervention|Poor prognosis DLBCL|Newly diagnosed patients with DLBCL and an age-adjusted IPI 2-3
11541227|NCT01066416|Placebo Comparator|Medical therapy|Patients undergo surgery 6 months after randomization
11541228|NCT01066416|Experimental|Surgery|Patients undergo surgery at time of randomization
11541229|NCT01066403|Experimental|Pergolide|Patients will be randomly assigned to a sequence of treatments of either pergolide or placebo p.o. under continuous concomitant atypical neuroleptic therapy (stable at least 2 weeks prior trial begin).
11541230|NCT01066377|Experimental|Prebiotic and probiotic mix|Prebiotic: 8g/day, will be selected on the basis of ability to promote optimal growth and survival of the probiotic (inulin, fructooligosaccharides [FOS], galactooligosaccharides[GOS] and xylooligosaccharides[XOS] will be tested). Probiotic: 10^8 - 10^9 live bacteria/day, bifidobacterium longum bv. infantis CCUG52486.
11541231|NCT01066377|Placebo Comparator|Maltodextrin/milk powder|
11541232|NCT01066364|Placebo Comparator|Placebo (sugar) pill|Six tablets per day (identical to colesevelam)
11541233|NCT01066364|Experimental|Colesevelam arm|3.75 grams per day
11541234|NCT01066351|Experimental|Erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
11541235|NCT01066351|Placebo Comparator|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
11541236|NCT01066338||Normal karyotype|The patients were diagnosed as acute myeloid leukemia with normal karyotype.
11541237|NCT01066325|Experimental|NET|This arm will receive two 20-minutes sessions of NET 1 week apart. NET (Neuro Emotional Technique) is a non-invasive stress reduction technique.
11541238|NCT01066325|Active Comparator|Active Controls|This arm will receive two 20-minute sessions of stretching instructions 1 week apart.
11541239|NCT01066325|No Intervention|Inactive Controls|This arm will receive no intervention and no instructions.
11541240|NCT01066312||Practitioners|Healthcare practitioners who either use, have used or do not use MMT in practice
11541241|NCT01066312||Testees|Healthy adults with no experience with MMT
11541242|NCT01066299|Experimental|oxitocin nasal spray|oxytocin nasal spray
11541243|NCT01066299|Placebo Comparator|placebo|inactive nasal spray
11541244|NCT01066286||core binding factor positive|core binding factor positive acute myeloid leukemia
11541245|NCT01066273|Experimental|P-Stim device|Receiving the device that is activated
11541246|NCT01066260|Experimental|Probiotic|
11541247|NCT01066260|Placebo Comparator|Placebo|
11541248|NCT01066247|Active Comparator|Midazolam|intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
11541249|NCT01066247|Active Comparator|Morphine|intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
11541250|NCT01066234|Experimental|concurrent chemoradiotherapy|
11541251|NCT01066234|Active Comparator|chemotherapy only|
11541252|NCT01066221||Clostridium difficile patients|observational study
11541253|NCT01066208||WG classification|Patients with Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
11541254|NCT01066208||MPA classification|Patients with microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
11541255|NCT01066208||CSS classification|Patients with Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
11541256|NCT01066208||PAN classification|Patients with polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
11541257|NCT01066208||Control Classification|For each of the diseases being evaluated (WG, MPA, CSS, PAN, GCA, TAK), patients with the other 5 diseases will be the control group. Within these groups, 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
11541258|NCT01066208||WG diagnostic|Patients with a new presentation of Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
11541259|NCT01066208||MPA diagnostic|Patients with a new presentation of microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
11541260|NCT01066208||CSS diagnostic|Patients with a new presentation of Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
11541261|NCT01066208||PAN diagnostic|Patients with a new presentation of polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
11541262|NCT01066208||Control diagnostic|Patients without vasculitis, but presenting with similar features to the 6 different types of vasculitis being studied. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
11541263|NCT01066208||GCA classification|Patients with giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
11541264|NCT01066208||TAK classification|Patients with Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
11541265|NCT01066208||GCA diagnostic|Patients with a new diagnosis of giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
11541266|NCT01066208||TAK diagnostic|Patients with a new diagnosis of Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
11541267|NCT01066195|Experimental|gefitinib|
11541268|NCT01066195|Active Comparator|pemetrexed|
11541443|NCT01064882|Active Comparator|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03%
11541269|NCT01066182|Experimental|DHA supplement|3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
11541270|NCT01066182|Placebo Comparator|Sunflower oil capsule|The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
11541271|NCT01066169||Healthy volunteers|Healthy subjects without HIV, vaccinated with Pandemic Influenza A/H1N1
11541272|NCT01066169||HIV-infected patients|HIV-infected patients, vaccinated with Pandemic Influenza A/H1N1
11541273|NCT01066156|Experimental|Seroquel|This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
11541274|NCT01066143|Experimental|Seroquel XR|
11541275|NCT01066130|Experimental|Intensive treatment arm|Every second person with psychosocial problems was randomized into this arm. The intervention consisted of personalized, intensive psychosocial treatment provided by a medical social worker on the basis of the patient's problems for up to 2 years after inclusion.
11541276|NCT01066130|Experimental|Minimal treatment arm|Every second patient with psychosocial problems was assigned to this arm. Patients in this arm received minimal social support by a medical social worker.
11541277|NCT01066130|No Intervention|No need for psychosocial treatment|This arm consisted of individuals who did not need psychosocial treatment or measures. The need for such treatment and measures was determined at baseline for all persons included in the study.
11541278|NCT01066104|Placebo Comparator|Xolair placebo|Xolair placebo 150-375 mg is administered subcutaneously (SC) every 2 or 4 weeks depending on the patient's baseline serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg) ). Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site.
11541279|NCT01066104|Active Comparator|Xolair (omalizumab)|Xolair (omalizumab) 150-375 mg is administered subcutaneously (SC) every 2 or 4 weeks depending on the patient's baseline serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site.
11541280|NCT01066091|Placebo Comparator|mashed potatoes|Mashed potatoes is composed of potatoes and Skim milk powder.
11541281|NCT01066091|Experimental|Mashed potatoes + Oleic Acid|The test meal is mashed potatoes with 1g/Kg of weight of lipids with 75% of Oleic Acid
11541282|NCT01066091|Experimental|Mashed potatoes + Palmitic Acid|The test meal is mashed potatoes with 1g/Kg of weight of lipids with 39% of saturated fat with 32% of palmitic acid.
11541283|NCT01066078||CRT recipients|
11541284|NCT01066065||Raltegravir Cohort|Patients taking RAL 400 mg BID with Truvada
11541285|NCT01066065||Darunavir Cohort|Patients taking Darunavir 800 mg QD plus Norvir 100 mg QD with truvada
11541286|NCT01066052|Experimental|r-hGH|Participants (girls) will receive r-hGH as a subcutaneous injection administered by a parent in the evening. During Years 1-2, the dose of r-hGH received will depend on participants' baseline height standard deviation score (SDS) relative to the general population standard: participants with a height SDS of -2 standard deviation (SD) or lower will receive 0.05 milligrams per kilogram (mg/kg) per day r-hGH and those with a height SDS between -1 and -2 SD will receive 0.035 mg/kg per day r-hGH. After 2 years of treatment, all participants will receive a fixed dose of 0.05 mg/kg per day for a further 2 years.
11541287|NCT01066052|No Intervention|Historical Control|This arm will include matching (age and height) historical control participants (girls) with turner syndrome, who were born between 1961 and 1990 and were untreated.
11541288|NCT01066039|Experimental|Bisoprolol|
11541289|NCT01066026|Experimental|Metallic cannula|Nasolabial Fold with metallic cannula and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle. Hyaluronic acid injected with the new tool
11541290|NCT01066026|Active Comparator|Standard needle|Nasolabial Fold with standard needle and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle.
11541291|NCT01066013|Experimental|Prospective Antimicrobial de-escalation arm|Antimicrobial de escalation team will assess therapy and make recommendations to (a) change to antibiotic(s) with narrow spectrum,(b) stop antibiotics, (c) order new cultures/investigations or (d) consult with specialists or ID service for full evaluation (if patient's condition is worsening).
11541292|NCT01066013|No Intervention|Restrospective control arm|The control subjects will be drawn from historic data of patients on the same medical unit(s) and will be matched based on age, antibiotics, sex, and infectious diseases diagnosis.
11541293|NCT01066000|Experimental|Mircera|
11541294|NCT01065987|Experimental|Tizanidine HCl 4 mg|Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited
11541295|NCT01065987|Active Comparator|Zanaflex|Zanaflex 4 mg Tablets
11541296|NCT01065974|Active Comparator|Behavior Therapy|"Behavioral treatment strategies will be utilized to facilitate adherence to the treatment goals in all three treatments. Participants in the BT condition will receive only the BT intervention. Strategies that will be emphasized are listed below:
~Self monitoring
~Stimulus control
~Changing eating behaviors
~Goal setting
~Problem solving
~Social support
~Cognitive restructuring
~Relapse prevention"
11541297|NCT01065974|Experimental|Behavior Therapy + Meal Replacements|The BT +MR condition will implement behavioral treatment strategies in a way that is nearly identical to that of the BT condition. However, participants in this condition also will use MRs during weight loss and weight loss maintenance.
11541345|NCT01065584||Standard immunosuppression|Patients receiving standard immunosuppression after liver transplantation including calcineurininhibitors
11541346|NCT01065584||Immunosuppression without calcineurininhibitors|Patients receiving immunosuppression after liver transplantation not based on calcineurininhibitors
11541347|NCT01065571|Experimental|carrageenan-free diet with placebo|This is the experimental arm in which subjects will be on a no-carrageenan diet and receive placebo capsules. This will test whether the no carrageenan diet leads to longer relapse-free interval for patients with ulcerative colitis.
11541565|NCT01064037|Placebo Comparator|Arm 4|
11541298|NCT01065974|Experimental|Nutritrol|"Participants in this condition will be informed about the evidence indicating that the availability, structure and composition of foods they encounter or seek out in their daily lives will play a major role in determining their ability to maintain the weight they lose. We will present the treatment as an opportunity to make numerous changes to their personal food environment involving the variety, energy density, nutritional composition, and portion size of the foods they encounter in every day life.
~The Nutritrol condition is comprised of several components:
~Food structure
~Energy density
~Reduce variety of foods high in energy density and increase variety of foods low in energy density
~Protein intake
~Controlling the personal food environment
~Individualized weight loss maintenance prescriptions"
11541299|NCT01065961|Active Comparator|Decadron|Subject will be given Decadron 0.2mg/kg intraoperatively. This dose will be followed by 4 mg. every 6 hours for the first 24 hours.
11541300|NCT01065961|Placebo Comparator|Saline|subject will be given a blinded dose of placebo saline intraoperatively followed by placebo doses every 6 hours for 24 hours.
11541301|NCT01065948|Experimental|Patients|
11541302|NCT01065935|Active Comparator|ALN-RSV01|
11541303|NCT01065935|Placebo Comparator|Normal saline|
11541304|NCT01065909||Diabetes type 2|
11541305|NCT01065909||Chronic Pain|
11541306|NCT01065909||Atrial Fibrillation|
11541307|NCT01065896||Group 1|
11541308|NCT01065883|Experimental|community health worker|community health workers will provide education in the home
11541309|NCT01065883|Active Comparator|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
11541310|NCT01065870|Experimental|Group I|Patients with only venous involvement Treated with 6 cycles og GTX and then surgery
11541311|NCT01065870|Experimental|Group II|Patients with arterial involvement and may have venous involvement with tumor treated with 6 cycles of GTX, thenb GX/RT and then surgery
11541312|NCT01065857|Experimental|Citrafleet|The day prior to the colonoscopy in two dose times, first at 15:00h and second at 20:00h.
11541313|NCT01065857|Active Comparator|Klean Prep|The day prior to the colonoscopy from 16:00h to 20:00h.
11541314|NCT01065857|Experimental|Citrafleet Exploratory|The day of the colonoscopy in two dose times, first at 06:00h and second at 09:00h.
11541315|NCT01065844|Experimental|Nelfinavir|1250 mg Nelfinavir twice daily Monday-Sunday
11541316|NCT01065831|Experimental|Lifestyle counseling|This MINT-TLC group will be asked to attend 12 weekly counseling meetings focused on weight loss (if overweight), limiting sodium, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained Lay Health Advisors. Participants will attend weekly group classes targeted at lifestyle changes for the first 12 weeks (intensive phase); followed by three individual MINT sessions conducted monthly for the following three months (maintenance phase). The MINT-TLC sessions aim to help participants make useful therapeutic lifestyle changes (TLC) and develop skills to maintain these changes long-term.
11541317|NCT01065831|Placebo Comparator|Health Education Control Condition|Participants randomized to this control condition will receive traditional, group health education classes for 12 weeks delivered by experts on various health topics unrelated to hypertension such as cancer, health insurance, and depression.
11541318|NCT01065818|Experimental|Fluoro-L-Thymidine|Injection pre-Neoadjuvant Therapy (CRT, CT, or RT) and post-3 weeks Neoadjuvant Therapy (CRT, CT, RT)(3 weeks from the start of Neoadjuvant Therapy) prior to surgery.
11541319|NCT01065805|Experimental|1|18F-FLT PET
11541320|NCT01065792||1|Patients with HIV-1 infection taking Stocrin
11541321|NCT01065779||FOSAMAX PLUS or FOSAMAX PLUS D|Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg/2800 IU) or FOSAMAX PLUS D (70 mg/5600 IU).
11541322|NCT01065766||All participants|Korean participants with type 2 diabetes mellitus treated with sitagliptin/metformin
11541323|NCT01065753|Experimental|Life-style modification|Life-style modification for 40 study subjects with metabolic syndrome in comparison to 25 non-obesity subjects for control.
11541324|NCT01065740|Experimental|patient education|individual and group meetings with explanations about the disease, lifestyle counseling ; coaching by phone at 1 and 4 months; medical consultation at 3 months; physical exercise with coaching
11541325|NCT01065740|No Intervention|Usual care|
11541326|NCT01065727|Experimental|mitoxantrone followed by immunomodulator|
11541327|NCT01065727|Active Comparator|natalizumab|
11541328|NCT01065714|Experimental|Hydrogel vehicle|Parallel designed study. Split body treatment
11541329|NCT01065714|Active Comparator|Eucerin Lotion|Parallel study design. Split body study.
11541330|NCT01065701|Active Comparator|1mcg/kg|1mcg/kg intranasal dexmedetomidine administered 45 minutes befoe anesthesia induction
11541331|NCT01065701|Active Comparator|2mcg/kg|2mcg/kg intranasal dexmedetomidine given 45 minutes prior to anesthetic induction
11541332|NCT01065688|Active Comparator|Roux-en Y|Roux-en Y reconstruction after distal gastrectomy
11541333|NCT01065688|Experimental|Billroth-I|Billroth-I reconstruction after distal gastrectomy
11541334|NCT01065662|Experimental|Cediranib and Temsirolimus|Please see interventions section.
11541335|NCT01065649|Experimental|Nortriptyline|20 NERD patients will be treated with nortriptyline 10 mg a day in the first 7 days and 25 mg a day in the following 14 days
11541336|NCT01065649|Placebo Comparator|Placebo|Placebo arm
11541337|NCT01065636|Experimental|Diet + Resistance Exercise Training|Weekly behavioral/diet-induced weight loss plus supervised resistance exercise training three times a week
11541338|NCT01065636|Experimental|Diet + Aerobic Exercise Training|Weekly behavioral/diet-induced weight loss plus supervised aerobic exercise training three times a week
11541339|NCT01065636|Experimental|Diet + Combined Aerobic/Resistance Exercise|Weekly behavioral/diet-induced weight loss plus combined supervised resistance exercise training and aerobic exercise training three times a week
11541340|NCT01065636|No Intervention|Control Group (No Diet/No Exercise)|No diet No exercise training
11541341|NCT01065623|Experimental|Arm 1|
11541342|NCT01065610|Experimental|Oxytocin|Intranasal Oxytocin, 24 IU
11541343|NCT01065610|Placebo Comparator|Placebo|
11541344|NCT01065597|Experimental|Nonconvulsive electrotherapy|Open label single arm study of nonconvulsive electrotherapy
11541566|NCT01064024|Active Comparator|Phenazopyridine Hydrochloride Tablets, USP 200 mg|
11541348|NCT01065571|Active Comparator|carrageenan-free diet w/ carrageenan|The carrageenan-free diet with carrageenan supplement will mimic the carrageenan normally consumed in the diet. The study will permit blinded comparison of carrageenan-free vs. carrageenan consumption.
11541349|NCT01065558|Experimental|Ecopipam 12.5 - 200 mg/day|Patients were administered ecopipam on an escalated dosing schedule over 11 days starting at 12.5 mg/day and increasing to the maximal tolerated dose or to 200 mg/day.
11541350|NCT01065545|Experimental|Clofarabine|
11541351|NCT01065532|Active Comparator|1|SeQuent Please Drug-eluting balloon
11541352|NCT01065532|Active Comparator|2|Xience V Drug-eluting stent
11541353|NCT01065519|Active Comparator|1|drug-eluting stent
11541354|NCT01065519|Active Comparator|2|Biolimus A9-eluting Biomatrix stent
11541355|NCT01065506|Active Comparator|Standard Care plus Wellness Program|
11541356|NCT01065506|Active Comparator|Standard Care plus Exercise Program|
11541357|NCT01065493|Experimental|Software Assisted Lifestyle Counseling|
11541358|NCT01065493|Active Comparator|Lifestyle Counseling|Status quo smoking cessation counseling.
11541359|NCT01065480|Active Comparator|Live Teleconference Supervision|Clinicians from participating substance abuse treatment programs receive live supervision by MI trainer via teleconference while in session with client.
11541360|NCT01065480|Active Comparator|Taped Review Supervision|Clinicians from participating substance treatment programs audio record session with client and receive supervision after the session by MI trainer.
11541361|NCT01065467|Experimental|Treatment|LBH589
11541362|NCT01065454|Experimental|Riociguat (Adempas, BAY63-2521) up to 2 mg|Participants received riociguat up to 2 mg three times per day (tid) (increasing from 0.5 to 1 to 2 mg).
11541363|NCT01065454|Experimental|Riociguat (Adempas, BAY63-2521) up to 1 mg|Participants received riociguat up to 1 mg tid (increasing from 0.5 to 1 mg).
11541364|NCT01065454|Experimental|Riociguat (Adempas, BAY63-2521) fixed 0.5 mg|Participants received riociguat 0.5 mg tid (fixed dose).
11541365|NCT01065454|Placebo Comparator|Placebo|Participants received placebo tid.
11541366|NCT01065428||Weaning failure|Weaning failure:(1) failed SBT; (2) reintubation and /or resumption of support following successful extubation; or (3) die 48h following extubation.
11541367|NCT01065428||Weaning successful|Weaning successful:extubation and the absence of ventilatory support 48 h following the extubation
11541368|NCT01065415||control group|routine staging work-up with chest CT, PET/CT, and brain MRI
11541369|NCT01065415||study group|routine staging work-up plus whole body MRI for Coregistered MRI/PET
11541370|NCT01065402|Placebo Comparator|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
11541371|NCT01065402|Experimental|PPB-R-203-Based Meal|"PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. RS intake is associated with several changes in metabolism which may confer some health benefits.
~PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition."
11541372|NCT01065389|Experimental|Prgressive Resistance Exercise Training|Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
11541373|NCT01065389|Active Comparator|Unstructured Resistance Exercise|Unstructured Resistance Exercise thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
11541374|NCT01065376|Experimental|on the day of hCG|cabergoline administration for 8 days on the day of hCG.
11541375|NCT01065376|Experimental|on the day after oocyte retrieval|cabergoline administration for 8 days on the day after oocyte retrieval
11541376|NCT01065363|Experimental|Lifestyle conseling|
11541377|NCT01065350|Active Comparator|Propofol|As part of the induction, patients will be given 2 milligrams of propofol per kilogram (mg/kg) of body weight. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL.
11541378|NCT01065350|Experimental|Ketofol|"As part of the induction, patients will be given 20 mL syringe of an admixture called ketofol, which combines ketamine and propofol in one syringe. The dose is weight-based such that ketamine will represent 0.75 mg/kg of the dose and propofol, 1.5 mg/kg of the dose."
11541379|NCT01065337|No Intervention|control group|patients received standard of care wound treatment according guideline of the American Diabetes Association (ADA)
11541380|NCT01065337|Active Comparator|bone marrow stem cells intraarterial|bone marrow stem cells administered intraarterial
11541381|NCT01065337|Active Comparator|tissue repair cells intramuscular|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intramuscular
11541382|NCT01065337|Active Comparator|tissue repair cells intraarterial|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intraarterial
11541383|NCT01065337|Active Comparator|bone marrow stem cells intramuscular|bone marrow stem cells administered intramuscular
11541384|NCT01065324||Anally inserted enteroscopy group|Anally inserted enteroscopy group
11541385|NCT01065324||Orally inserted enteroscopy group|Orally inserted enteroscopy group
11541386|NCT01065311|Experimental|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of certain aspects of cognitive behavioral therapy for depression (Beck et al., 1979) and components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
11541387|NCT01065311|Active Comparator|CBASP|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions.
11541442|NCT01064882|Experimental|bimatoprost ophthalmic solution 0.015%|bimatoprost ophthalmic sterile solution 0.015%
11541388|NCT01065311|Active Comparator|Treatment-as-usual|"Standard psychiatric outpatient care:
~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist"
11541389|NCT01065298||Group 1:Stem cell Recipient|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4U/Kg for blood glucose control. They will undergo stem cell therapy initialy and G-CSF therapy at 2 months
11541390|NCT01065298||Group-2: Controls|Type 2 Diabetes mellitus patients on full doses of vildagliptin+metformin+pioglitazone and on Insulin >0.4U/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1.
11541391|NCT01065285|Experimental|Evaluation of vaccines against flu|Evaluation of vaccines against flu
11541392|NCT01065272|Active Comparator|Ventolin - Dexamethasone group|Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Dexamethasone is also given daily for 5 days.
11541393|NCT01065272|Placebo Comparator|Ventolin - Placebo group|Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Placebo is also given daily for 5 days.
11541394|NCT01065259|Experimental|OROS MPH|the group treated by OROS MPH
11541395|NCT01065259|Active Comparator|atomoxetine|the group treated by atomoxetine
11541396|NCT01065259|No Intervention|control|the normal control with no intervention
11541397|NCT01065246|Experimental|catumaxomab|
11541398|NCT01065233||alcoholic cirrhosis with viral infection|patient with alcoholic cirrhosis with viral infection (300 patients)
11541399|NCT01065233||alcoholic cirrhosis without viral infection|patient with alcoholic cirrhosis without viral infection
11541400|NCT01065220|Experimental|hormone treatment for MtF|"cyproterone acetate
~estradiol
~alpha-5-reductase-inhibitor"
11541401|NCT01065220|Experimental|hormone treatment for FtM|"testosterone undecanoate
~lynestrenol"
11541402|NCT01065207|No Intervention|patient|
11541403|NCT01065194|Experimental|Levosimendan|Chronic stable heart failure
11541404|NCT01065194|Placebo Comparator|Placebo|Chronic Stable Heart Failure
11541405|NCT01065168||endometrioma|ovarian endometrioma undergoing cystectomy
11541406|NCT01065155||Median central blood pressure|Median central blood pressure, lower median group 1 and higher group 2.
11541407|NCT01065129|Experimental|Dose Level 1|"AMD3100 320 μg/kg SC Days 1-5 of each 28 day cycle.
~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.
~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
11541408|NCT01065129|Experimental|Dose Level 2|"AMD3100 440 μg/kg SC Days 1-5 of each 28 day cycle.
~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.
~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
11541409|NCT01065129|Experimental|Dose Level 3|"AMD3100 560 μg/kg SC Days 1-5 of each 28 day cycle.
~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.
~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
11541410|NCT01065129|Experimental|Expanded DLT Cohort|After the MTD is determined, patients will be enrolled at the MTD dose of plerixafor. These patients will not receive G-CSF priming but will be treated with plerixafor and azacitidine for 2 cycles.
11541411|NCT01065116|Experimental|AL Blister-pack|
11541412|NCT01065116|Active Comparator|AL unit dose age specific pre-packs|
11541413|NCT01065103|Experimental|FFR measurement|
11541414|NCT01065090||training|one group will receive resistance training and one group the normal physiotherapeutic treatment
11541415|NCT01065090||physiotherapy|one group will receive resistance training and one group the normal physiotherapeutic treatment
11541416|NCT01065077|Experimental|Arm 1|
11541417|NCT01065077|Experimental|Arm 2|
11541418|NCT01065077|Experimental|Arm 3|
11541419|NCT01065077|Placebo Comparator|Arm 4|
11541420|NCT01065064|Experimental|RESTOR|Patients with cataract that had phacoemulsification and AcrySof® ReSTOR IOL implantation.
11541421|NCT01065051|Experimental|Riociguat (Adempas, BAY63-2521)|Participants received a single oral dose of 1 mg riociguat.
11541422|NCT01065051|Placebo Comparator|Placebo|Participants received a single oral dose of 1 mg placebo.
11541423|NCT01065038|Experimental|Anagrelide|
11541424|NCT01065038|Active Comparator|Hydroxyurea|
11541425|NCT01065025|Experimental|4SC-205|
11541426|NCT01065012|Experimental|Udenafil 50 mg|50 mg Udenafil
11541427|NCT01065012|Experimental|Udenafil 100 mg|100 mg Udenafil
11541428|NCT01065012|Experimental|Udenafil 150 mg|150 mg Udenafil
11541429|NCT01065012|Placebo Comparator|Placebo|Placebo Tablets matching Udenafil tablets
11541430|NCT01064999|Experimental|High intensity group|(RT 55Gy + CapOx) + a cycle of Xelox + Surgery
11541431|NCT01064999|Active Comparator|Low instensity group|(RT 50Gy + CapOx) + Surgery
11541432|NCT01064986|Placebo Comparator|A|IV Endotoxin plus saline vehicle (placebo)
11541433|NCT01064986|Active Comparator|B|IV Endotoxin plus IV hydrocortisone
11541434|NCT01064973|Experimental|STX209|STX209 (arbaclofen)
11541435|NCT01064960|Experimental|Treated leiomyomas|Pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure are treated with the Philips MR-guided HIFU system. Patients must have completed child bearing prior to enrolling in this study.
11541436|NCT01064934|Experimental|Lipid apheresis|Lipid apheresis
11541437|NCT01064934|Active Comparator|Standard care|Standard care
11541438|NCT01064921|Experimental|Arm I|Patients receive oral vorinostat on days 0-2 and cisplatin IV on days 7, 21 and 35. Patients undergo radiation therapy 5 days a week beginning on day 7. Patients also receive concurrent oral vorinostat along with the radiotherapy to be given 3 days per week (Monday, Tuesday, and Wednesday). Optional repeat tumor and normal mucosal biopsies will be performed and blood will be drawn for correlative studies.
11541439|NCT01064908||Carotid endarterectomy|Patients who are undergoing elective carotid endarterectomy under local anaesthesia
11541440|NCT01064895||Active Cohort|Patients receiving the Benephit device and targeted renal therapy.
11541441|NCT01064882|Experimental|bimatoprost ophthalmic solution 0.005%|bimatoprost ophthalmic sterile solution 0.005%
11541444|NCT01064869|Experimental|Psycho-educational intervention|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:
~1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour
~This will be followed by an individualised package incorporating:
~A structured asthma education programme, to address any gaps in asthma knowledge or requests for information
~Motivational interviewing based on stages of change model to encourage change and adherence
~Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
11541445|NCT01064869|No Intervention|usual care|Standard asthma management
11541446|NCT01064856|Experimental|Double-blind (DB) Adalimumab|Adalimumab 40 mg subcutaneous (SC) injection every other week (eow) up to Week 12 in double-blind period.
11541447|NCT01064856|Placebo Comparator|Double-blind Placebo|Placebo subcutaneous (SC) injection every other week (eow) up to Week 12 in the double-blind period.
11541448|NCT01064856|Experimental|Double-blind Adalimumab / Open-label Adalimumab|Adalimumab 40 mg SC injection eow up to Week 12 in double-blind period and from Week 12 to Week 156 in open-label period.
11541449|NCT01064856|Placebo Comparator|Double-blind Placebo / Open-label Adalimumab|Placebo SC injection every other week (eow) up to Week 12 in the double-blind period; adalimumab 40 mg subcutaneous injection eow from Week 12 to Week 156 in the open-label period.
11541450|NCT01064843||4 Imtec mini-dental implants (MDI)|4 Imtec MDI
11541451|NCT01064830|Active Comparator|topical cyclosporine suspension|apply 2 drops to 2 target nails under occlusion daily for 20 weeks
11541452|NCT01064830|Placebo Comparator|vehicle|apply to target nails daily under occlusion daily for 20 weeks
11541453|NCT01064817|Experimental|PRM-151|PRM-151 (recombinant human serum amyloid P, recombinant human pentraxin 2)
11541454|NCT01064817|Placebo Comparator|Placebo|Placebo
11541455|NCT01064804||relative bioavailability|
11541456|NCT01064791|Experimental|Arm 1|sotrastaurin (100mg bid) + tacrolimus + standard of care medications
11541457|NCT01064791|Experimental|Arm 2|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
11541458|NCT01064791|Experimental|Arm 3|sotrastaurin (300mg bid) + tacrolimus + standard of care medications
11541459|NCT01064791|Active Comparator|Arm 4|mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
11541460|NCT01064778|Active Comparator|Low GI|
11541461|NCT01064778|Experimental|High GI|
11541462|NCT01064765||Heart failure|Outpatients with heart failure, age 75 or less, left ventricular ejection fraction 40% or less, english speaking with no known dementia
11541463|NCT01064752||Minocycline|HIV-1 infected, not on anti-retroviral medication
11541464|NCT01064739|Experimental|Study Diet +/- fava beans|Participants underwent testing while on a methylxanthine-free diet providing 150 mEq sodium and 75 mEq potassium per day. The study involved a longitudinal design where the participants served as their own controls. Subjects consumed the standard fixed sodium diet on study day one. On study day two, participants ate 100 g of puréed fava beans and pods with study diet at breakfast (0800hr) and lunch (1200hr).
11541465|NCT01064726|Experimental|Ibuprofen|
11541466|NCT01064726|Experimental|Fluticasone propionate|
11541467|NCT01064726|Placebo Comparator|Placebo|
11541468|NCT01064713|Experimental|Tesetaxel|Therapy initiated at a flat dose of 40 mg for subjects in Cohort A and at a flat dose of 50 mg for subjects in Cohort B. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.
11541469|NCT01064700|No Intervention|Baseline|1 week period, in which subjects followed usual schedule, though they were asked to maintain a fairly stable sleep schedule. The baseline period was used for comparison with the experimental intervention.
11541470|NCT01064700|Experimental|Experimental Intervention|Randomized exposure to the 4-week experimental treatments.
11541471|NCT01064687|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks
~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
11541472|NCT01064687|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks
~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks
~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
11541473|NCT01064687|Active Comparator|Exenatide|"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks
~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks
~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
11541474|NCT01064687|Placebo Comparator|Placebo|"Placebo: subcutaneous (SC), once weekly for 26 weeks
~LY2189265 (Dulaglutide): After 26 weeks, participants were randomized to receive either 0.75 milligrams (mg) or 1.5 mg, SC, once weekly for an additional 26 weeks (from week 26 through week 52).
~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks
~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
11541475|NCT01064674||before renal transplantation|Patients with CKD IV° to V° who are actually registering for a renal transplantation in our department.
11541476|NCT01064661|Active Comparator|Blend probiotic of L-NCFM and B-LBi07|Blend probiotic pills of L-NCFM and B-LBi07 BID (2x10^10 cfu total bacteria per day)
11541477|NCT01064661|Active Comparator|Single probiotic of L-NCFM alone|Single probiotic pills of L-NCFM alone BID (2x10^10 cfu total bacteria per day)
11541478|NCT01064648|Experimental|Arm I (pemetrexed disodium, cisplatin, cediranib maleate))|Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cediranib maleate alone PO QD in the absence of disease progression or unacceptable toxicity.
11541479|NCT01064648|Active Comparator|Arm II (pemetrexed disodium, cisplatin, placebo)|Patients receive pemetrexed disodium and cisplatin as in arm I and placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive placebo alone PO QD in the absence of disease progression or unacceptable toxicity.
11541567|NCT01064024|Placebo Comparator|Placebo|Matching placebo to the phenazopyridine hydrochloride tablets
11541480|NCT01064635|Active Comparator|Letrozole for 3-2 years|Patients pre-treated with TAM for 2-3 years will receive letrozole 2,5 mg/die for 3-2 years. Total duration of early adjuvant endocrine therapy: 5 years
11541481|NCT01064635|Experimental|Letrozole for 5 year|Patients pre-treated with TAM for 2-3 years will receive letrozole 2,5 mg/die for additional 5 years. Total duration of early adjuvant endocrine therapy: 7 years for patients pretreated with 2 years of TAM and 8 years for patients pre-treated with 3 years of TAM
11541482|NCT01064622|Active Comparator|Arm I (gemcitabine hydrochloride and placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and placebo PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of disease progression, patients are unblinded and may crossover to arm II.
11541483|NCT01064622|Experimental|Arm II (gemcitabine hydrochloride and vismodegib)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and vismodegib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11541484|NCT01064609|Active Comparator|2. Biopsy with cryoprobes|Transbronchial cryobiopsy with a cryoprobe.
11541485|NCT01064609|Active Comparator|2.Biopsy with forceps|Transbronchial lung biopsy with conventional forceps.
11541486|NCT01064596||blood sample|Patient with 4 blood samples to measure anti-Xa activity
11541487|NCT01064583|Experimental|flavanol rich cocoa drink (596mg)|dissolved in water, twice daily intervention
11541488|NCT01064583|Experimental|flavanol poor cocoa drink ( 13mg)|dissolved in water, twice daily intervention
11541489|NCT01064544|Experimental|Starting with light therapy|Starts with 3 weeks of light therapy, followed by a control period
11541490|NCT01064544|Experimental|Ending with light therapy|Ends with 3 weeks of light therapy after a control period.
11541491|NCT01064531||MIS Femoral Neck Stem|Subject will be randomized to either MIS or Synergy implant.
11541492|NCT01064531||Synergy Hip System|Subject will be randomized to either Synergy or MIS implant.
11541493|NCT01064518|Active Comparator|Dose A|RT001 Topical Gel
11541494|NCT01064518|Placebo Comparator|Dose B|Placebo Comparator
11541495|NCT01064505|Experimental|QPI-1007|
11541496|NCT01064492|Experimental|ABC, ACB, BAC, BCA, CAB, and CBA|
11541497|NCT01064479|Experimental|Arm A (combination chemotherapy and erlotinib hydrochloride)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 2 hours or carboplatin IV over 2 hours on day 1 and erlotinib hydrochloride PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue erlotinib hydrochloride treatment.
11541498|NCT01064479|Active Comparator|Arm B (combination chemotherapy and placebo)|Patients receive docetaxel and cisplatin or carboplatin as in Arm I and placebo PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue placebo treatment.
11541499|NCT01064466|Experimental|ETOPOSIDE - Usual|"Etoposide Injection
~Combined Chemotherapy
~Etoposide Injection + Methotrexate Injection + Topotecan Injection
~Usual Approach Group"
11541500|NCT01064466|Experimental|ETOPOSIDE - Study|"Etoposide Capsule
~Combined Chemotherapy
~Etoposide Capsule + Methotrexate Tablet + HYCAMTIN - Topotecan Capsule
~Study Approach Group"
11541501|NCT01064453||Group 1|
11541502|NCT01064440|Experimental|Low Dose VM202|Patients in this group will receive 8mg total of VM202. Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
11541503|NCT01064440|Experimental|High Dose VM202|Patients in this treatment group will receive a total of 16mg VM202. Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 4mg of VM202 (16 injections of 0.5ml of VM202) Day42: 4mg of VM202 (16 injections of 0.5ml of VM202)
11541504|NCT01064440|Sham Comparator|Placebo|Patients in this group will receive a total of 8ml normal saline. Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
11541505|NCT01064427||Chemotherapy group|Breast cancer patients treated by adjuvant chemotherapy after their surgery. The time points of data collection are before the start of the first, second, fourth and sixth cycle of chemotherapy. If patients are treated by radiotherapy after the chemotherapy, there are 2 measurements points pre- and post radiotherapy.The others measurement points are at 12,18 and 24 months after surgery.
11541506|NCT01064427||No chemotherapy group|Breast cancer patients no treated by adjuvant chemotherapy after their surgery. For patients treated by radiotherapy after surgery, there are 2 measurement points pre- and post radiotherapy. The others measurement points are at 4,6,7,8,12,18 and 24 months after surgery.
11541507|NCT01064414|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks.
11541508|NCT01064414|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks.
11541509|NCT01064414|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 52 weeks.
11541510|NCT01064401|Experimental|Daclizumab High Yield Process 150 mg SC|Daclizumab High Yield Process (DAC HYP) 150mg subcutaneous (SC) injection once every 4 weeks plus placebo to IFN β-1a intramuscular (IM) injection once weekly for 96 to 144 weeks
11541511|NCT01064401|Active Comparator|IFN β-1a 30 µg IM|Interferon beta-1a (IFN β-1a) 30 µg IM once weekly plus placebo to DAC HYP SC once every 4 weeks for 96 to 144 weeks
11541512|NCT01064388|Experimental|1|
11541513|NCT01064388|Placebo Comparator|2|
11541514|NCT01064375|Experimental|CEA DNA prime (cohort I)|5 patients, tetwtCEA DNA intradermal delivery with electroporation, not previously vaccinated with CEA66 DNA. Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration. One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
11541515|NCT01064375|Experimental|CEA DNA boost (cohort II)|10 patients, tetwtCEA DNA intradermal delivery with electroporation, previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
11541516|NCT01064375|Experimental|CEA DNA prime + GM-CSF (cohort III)|5 patients, tetwtCEA DNA intradermal delivery with electroporation + GM-CSF, not previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
11541517|NCT01064362||Prophylaxis following major orthopedic surgery|Patients age 18 years and older in the PHARMO RLS database treated with either fondaparinux sodium or LMWH for thromboprophylaxis following hip fracture and/or hip/knee replacement surgery.
11541518|NCT01064349||Breast cancer patients with brain metastases|Female Erb2+ breast cancer patients with brain metastases diagnosed between January 2006 and December 2008 in 6 Asian countries (Indonesia, Korea, Malaysia, Philippines, Singapore, and Thailand).
11541519|NCT01064336||Pregnant women on eltrombopag|Any women with eltrombopag exposure during pregnancy that is reported prior to or after knowledge of the pregnancy outcome, substantiated by health care provider, and meeting the enrollment criteria: documentation that eltrombopag is being taken during pregnancy; timing of the prenatal exposure to eltrombopag (i.e. best estimation of which trimester in pregnancy that there was exposure to Eltrombopag for stratification and reporting purposes ); sufficient information to determine whether the pregnancy is being prospectively or retrospectively registered; whether the outcome of pregnancy was known at the time of the report; source of the report (i.e. health care professional, patient); full provider contact information to allow for follow-up (name, address, etc.)
11541520|NCT01064336||Infants|Infants through the first year of life whose mothers were exposed to eltrombopag during pregnancy.
11541521|NCT01064323|Other|Intermittent leg compression|Intermittent leg compression daily for 3 hrs a day for 4 weeks
11541522|NCT01064310|Experimental|pazopanib followed by sunitinib|800mg pazopanib orally for 10 weeks followed by 50mg sunitinib orally for 10 weeks
11541523|NCT01064310|Experimental|sunitinib followed by pazopanib|50mg sunitinib orally for 10 weeks followed by 800mg pazopanib orally for 10 weeks
11541524|NCT01064297||Women exposed to lamotrigine during pregnancy|
11541525|NCT01064284|Active Comparator|PLASMA DERIVED Factor VIII|Plasma-derived vWF/FVIII
11541526|NCT01064284|Active Comparator|rFVIII|Recombinant FVIII
11541527|NCT01064271|Experimental|Risperidone|Risperidone Tablets 1 mg of Dr Reddys Laboratories Limited
11541528|NCT01064271|Active Comparator|Risperdal®|Risperdal® Tablets, 1 mg of Janssen Pharmaceutica Products, L.P
11541529|NCT01064258|Active Comparator|fixed CPAP|subject will sleep with a fixed CPAP device at minimal pressure
11541530|NCT01064258|Experimental|autoCPAP|the subject will sleep connected to an autoCPAP device
11541531|NCT01064245|Experimental|Cough Variant Asthma|Those diagnosed with cough variant asthma.
11541532|NCT01064245|Experimental|Asthma|Those with diagnosed asthma.
11541533|NCT01064232|Experimental|Risperidone|Risperidone Tablets 1 mg of Dr Reddys Laboratories Limited
11541534|NCT01064232|Active Comparator|Risperdal|Risperdal® Tablets, 1 mg of Janssen Pharmaceutica Products, L.P
11541535|NCT01064219|Experimental|intrauterine hCG|intrauterine injection of 100 hCG followed by endometrial biopsy
11541536|NCT01064206||Buerger's disease patients|200 thromboangiitis obliterans patients (Buerger's disease or TAO)
11541537|NCT01064206||Control group|200 atheromatous arteritis patients
11541538|NCT01064193|Experimental|group 1 : IVF with biopsy|fresh IVF-embryo transfer treated with long protocol or antagonist protocol for the controlled ovarian hyperstimulation plus local injury to the endometrium of patients one menstrual cycle before the IVF
11541539|NCT01064193|Active Comparator|group 2|fresh IVF-embryo transfer treated with long protocol or antagonist protocol for the controlled ovarian hyperstimulation alone
11541540|NCT01064180|Experimental|Carvedilol|Carvedilol Tablets 25 mg of Dr Reddys Laboratories Limited
11541541|NCT01064180|Active Comparator|Coreg|Coreg Tablets 25 mg of GlaxoSmithKline
11541542|NCT01064167|Experimental|Tranexamic Acid group|
11541543|NCT01064167|Placebo Comparator|Control group|
11541544|NCT01064154|Experimental|Carvedilol|Carvedilol Tablets 25 mg of Dr Reddys Laboratories Limited
11541545|NCT01064154|Active Comparator|Coreg|Coreg Tablets 25 mg of GlaxoSmithKline
11541546|NCT01064141|Experimental|Group 1: Dengue Vaccine Group|Participants will receive CYD Dengue vaccine as Visits 1 and 2.
11541547|NCT01064141|Active Comparator|Group 2: Control Group|Participants will receive Control Vaccines. (Varicella at Visit 1 and Hepatitis A at Visit 2)
11541548|NCT01064141|Experimental|Group 3: Co-administration Group|Participants will receive CYD Dengue vaccine and childhood vaccines at Visit 1 and CYD Dengue vaccine at Visit 2.
11541549|NCT01064141|Experimental|Group 4: Sequential Administration Group|Participants will receive CYD Dengue vaccine and a Placebo vaccine at Visit 1 and CYD Dengue vaccine at Visit 2.
11541550|NCT01064128|Active Comparator|conventional laparoscopic hysterectomy|Three or four ports conventional laparoscopic hysterectomy
11541551|NCT01064128|Active Comparator|SPA laparoscopic hysterectomy|Single umbilical incision laparoscopic hysterectomy
11541552|NCT01064115|Experimental|Cetirizine|Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys Laboratories Limited
11541553|NCT01064115|Active Comparator|Zyrtec|Zyrtec Tablets 10 mg of Pfizer Labs
11541554|NCT01064102|Experimental|Cetirizine|Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys Laboratories Limited
11541555|NCT01064102|Active Comparator|Zyrtec|Zyrtec Tablets 10 mg of Pfizer Labs
11541556|NCT01064089|Experimental|HSP990|dose escalation
11541557|NCT01064076|Experimental|S-ICD System|This is a single arm study
11541558|NCT01064063|Active Comparator|AGC knee|Patients were randomised to receive an AGC Cruciate Retaining cement knee. This is the control group in the study; the AGC is the gold standard of Biomets' knee products.
11541559|NCT01064063|Experimental|Vanguard CR|Patients were randomised to receive a Vanguard Cruciate Retaining Knee from the Vanguard system which encompasses concepts used in the AGC family of knees. The Vanguard is specifically designed to give greater knees stability through use of more anatomic patello-femoral kinematics.
11541560|NCT01064050|Experimental|trachea-bronchial stent (Novatech)|
11541561|NCT01064050|No Intervention|control|
11541562|NCT01064037|Experimental|Arm 1|
11541563|NCT01064037|Experimental|Arm 2|
11541564|NCT01064037|Experimental|Arm 3|
11541568|NCT01064011|Other|External Ventricular drainage, Intraventricular Thrombolysis|
11541569|NCT01064011|Other|External Ventricular Drainage and Endoscopic Evacuation|
11541570|NCT01063998||Group 1|Patients demonstrate normal serum creatinine and no radiological evidence of a renal tumor.
11541571|NCT01063998||p 2|Patients diagnosed with renal cancer and normal creatinine.
11541572|NCT01063972|Experimental|Experimental 1|Experimental: 1 Centralized disease management
11541573|NCT01063972|Experimental|Experimental 2|Experimental: 2 Counseling alone
11541574|NCT01063959|Other|Safety|Chart review will evaluate the safety of the two procedures, incidence of complications operatively, hospital stay, and 6-week post-operative periods.
11541575|NCT01063959|Experimental|Weight Loss|Chart review will evaluate weight loss in subjects during the operative, 6-week post-operative, and follow-up of at least 18 months.
11541576|NCT01063959|Other|Insurance versus Private Pay|An insurance company issues an insurance policy to cover specific complications from the gastric bypass or the sleeve gastrectomy surgery which allows the surgeon to offer a fixed price to the patient. Comparison of surgical complications in subjects paying by insurance versus paying personally for the gastric bypass operation.
11541577|NCT01063946|Experimental|[14C]-AVE8062|Single, 30 minute, intravenous infusion of 25 mg/m² of [14C]-AVE8062 containing 1.85 MBq (50µCi) at the first cycle, followed by subsequent administrations with non-radiolabelled AVE8062 in combination with cisplatin every 3 weeks, according to the investigator's judgment.
11541578|NCT01063933|Experimental|Cohort I|Cohort I: >/= 12 years to < 18 years. Peramivir administered daily for five days or until the day of hospital discharge, whichever comes first.
11541579|NCT01063933|Experimental|Cohort II|Cohort II: >/= 6 years to < 12 years
11541580|NCT01063933|Experimental|Cohort III|Cohort III: >/= 2 years to < 6 years
11541581|NCT01063933|Experimental|Cohort V|Cohort V: >/= 91 days to < 181 days
11541582|NCT01063933|Experimental|Cohort VII|Cohort VII: birth to < 31 days
11541583|NCT01063933|Experimental|Cohort VI|Cohort VI: >/= 31 days to < 91 days
11541584|NCT01063933|Experimental|Cohort IV|Cohort IV: >/= 181 days to < 2 years
11541585|NCT01063920|Experimental|LT-NS001|LT-NS001 1200 mg b.i.d. p.o. for 12 weeks
11541586|NCT01063920|Active Comparator|Naprosyn®|Naprosyn® 500 mg b.i.d for 12 weeks
11541587|NCT01063907|Experimental|Phase 1: Cohort 1|Cohort 1: KW 2478 130 mg/m^2 and Bortezomib 1.0 mg/m^2
11541588|NCT01063907|Experimental|Phase 1: Cohort 2|Cohort 2: KW 2478 130 mg/m^2 and Bortezomib 1.3 mg/m^2
11541589|NCT01063907|Experimental|Phase 1: Cohort 3|Cohort 3: KW 2478 175 mg/m^2 and Bortezomib 1.0 mg/m^2
11541590|NCT01063907|Experimental|Phase 1: Cohort 4|Cohort 4: KW 2478 175 mg/m^2 and Bortezomib 1.3 mg/m^2
11541591|NCT01063907|Experimental|Phase 2|KW 2478 175 mg/m^2 and Bortezomib 1.0 mg/m^2
11541592|NCT01063894|Experimental|breakfast cereal|breakfast cereal and milk
11541593|NCT01063894|Placebo Comparator|water|water
11541594|NCT01063881|Experimental|Dapoxetine|Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity may be increased after 4 weeks to 60mg taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
11541595|NCT01063868|Experimental|001|Tapentadol extended release (ER) 100 150 200 250 mg twice daily for 52 weeks
11541596|NCT01063868|Active Comparator|002|Oxycodone controlled release (CR) 20 30 40 50 mg twice daily for 52 weeks
11541597|NCT01063855|Experimental|Dapoxetine + PDE5I|Dapoxetine 30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks + a PDE5I (phosphodiesterase-5 inhibitor) prescribed prior to study entry for the treatment of erectile dysfunction.
11541598|NCT01063855|Placebo Comparator|Placebo + PDE5I|Placebo tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks + a PDE5I (phosphodiesterase-5 inhibitor) prescribed prior to study entry for the treatment of erectile dysfunction.
11541599|NCT01063842|Experimental|001|tramadol hydrochloride / acetaminophen and placebo 1 tablet of tramadol/acetaminophen in the morning 1 tablet of placebo in the afternoon and evening for 3 days then 1 tablet of tramadol/acetaminophen in the morning evening and 1 tablet of placebo in the afternoon for 4 days then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
11541600|NCT01063842|Active Comparator|002|tramadol hydrochloride /acetaminophen 1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
11541601|NCT01063829|Experimental|Dose regimen 1|60 mg AIC246, one tablet per day
11541602|NCT01063829|Experimental|Dose regimen 2|120 mg AIC246, one tablet per day
11541603|NCT01063829|Experimental|Dose regimen 3|240 mg AIC246, one tablet per day
11541604|NCT01063829|Other|Placebo|Placebo arm
11541605|NCT01063816|Experimental|Arm 1|
11541606|NCT01063803|Experimental|Arm 1: ATN-103_30mg|
11541607|NCT01063803|Experimental|Arm 2: ATN-103_80 mg|
11541608|NCT01063790|No Intervention|Usual care|Patients undergoing elective inguinal hernia repair attend the pre-admission clinic no later than one week prior to surgery. During this visit they receive one-on-one pre-operative education from a registered nurse. It includes both verbal and written information. Verbal information provided to patients includes procedural information such as the admission process, and post-operative care in the post-anaesthetic care uni and day surgery unit. Post-discharge pain management information is minimal and consists of direction to not wait until the pain is severe before taking prescribed analgesics.
11541609|NCT01063790|Experimental|Individualized Education|
11541610|NCT01063777|Active Comparator|1|
11541611|NCT01063777|Active Comparator|2|
11541612|NCT01063764|Experimental|Levetiracetam|Open-label, single-arm
11541613|NCT01063751|Other|Tritanium® Primary Acetabular Shell|Tritanium® Primary Acetabular Shell
11541614|NCT01063738|Active Comparator|ICU Recovery Manual & placebo supplement|Patients will receive the standard self-directed rehabilitation package and a placebo nutritional supplement
11541615|NCT01063738|Experimental|ICU recovery manual & amino acid (AA) supplement|Patients will receive the standard self-directed rehabilitation package with the essential amino acid supplement
11541616|NCT01063738|Experimental|PEPSE & placebo supplement|Patients will receive the standard self-directed rehabilitation package plus PEPSE and the placebo nutritional supplement
11541617|NCT01063738|Experimental|PEPSE & AA supplement|Patients will receive the standard self-directed rehabilitation package plus PEPSE and the essential amino acid nutritional supplement
11541618|NCT01063725|Experimental|Femarelle|Women will receive Femarelle twice daily for 12 weeks
11541619|NCT01063725|Placebo Comparator|Placebo|Women will take placebo capsules twice daily for 12 weeks
11541620|NCT01063712|Other|Nit-Occlud PDA-R|Interventional, prospective clinical study, non randomized.
11541621|NCT01063699|Experimental|Lap Kasai|Patients in this arm had their necessary Kasai procedure in a laparoscopic way.
11541622|NCT01063686|No Intervention|Insemination cervical cap|
11541623|NCT01063673||Active runners|Observational follow-up study on 39 runners
11541624|NCT01063660|Experimental|Treosulfan|Patients with acute myeloid leukaemia (AML) according to WHO classification (> 20% myeloblasts in peripheral blood or bone marrow at initial diagnosis) with < 5% myeloblasts in the bone marrow, indicated for allogeneic transplantation
11541625|NCT01063647|Experimental|1|Treosulfan: 10 g/m² i.v. on 3 consecutive days (day -6 to -4)
11541626|NCT01063647|Experimental|2|Treosulfan:12 g/m² i.v. on 3 consecutive days (day -6 to -4)
11541627|NCT01063647|Experimental|3|Treosulfan: 14 g/m² i.v. on 3 consecutive days (day -6 to -4)
11541628|NCT01063621|Experimental|KW-6500|
11541629|NCT01063608|Experimental|Anti-H1N1v Vaccine|
11541630|NCT01063595|Experimental|Octaplas LG|Participants received 1200 mL of Octaplas LG intravenously once.
11541631|NCT01063595|Active Comparator|Octaplas SD|Participants received 1200 mL of Octaplas SD intravenously once.
11541632|NCT01063582||fighter pilots f-16|This group is made up of pilots from the F-16 Venezuelan military air force stationed in the Base Vicente Landaeta Gil de Barquisimeto, Lara State.
11541633|NCT01063582||aircraft maintenance personnel f-16|Staff responsible for the preparation of aircraft for the flight and maintenance in the hangar at the airbase Vicente Landaeta Gil de Barquisimeto, Lara. Venezuela
11541634|NCT01063569|Active Comparator|Oral hydrocortisone|
11541635|NCT01063569|Experimental|Continous subcutaneous hydrocortisone infusion|
11541636|NCT01063556|Experimental|1|
11541637|NCT01063556|Experimental|2|
11541638|NCT01063543||patients with blood sample|Patients with major orthopedic surgery and prophylactic doses of fondaparinux who have 3 blood sample during their hospitalization to measure anti-Xa activity
11541639|NCT01063530|Experimental|Diammine Silver Fluoride|Application fo diammine silver fluoride in cervical lesions
11541640|NCT01063530|Placebo Comparator|Distilled water|Application of distilled water in cervical lesions
11541641|NCT01063517|Experimental|1|Olaparib + paclitaxel
11541642|NCT01063517|Active Comparator|2|paclitaxel + placebo
11541643|NCT01063504|Active Comparator|Teriparatide 20 microgram daily for 2 months|
11541644|NCT01063504|Placebo Comparator|Placebo|
11541645|NCT01063491|Experimental|Early graft angiography after coronary artery bypass surgery|Treatment of any bypass graft abnormalities that are discovered will be performed if needed
11541646|NCT01063491|No Intervention|No early angiography after coronary artery bypass surgery|
11541647|NCT01063478|Experimental|RAD001, Chemotherapy, Radiation|RAD001 + Chemotherapy and Radiation
11541648|NCT01063465|Experimental|Early weightbearing|
11541649|NCT01063465|Experimental|Control group|
11541650|NCT01063452|Experimental|Truvalve|Atkinson Product Design urinary slide valve on the catheter
11541651|NCT01063452|Active Comparator|Control|Drainage bag on the catheter
11541652|NCT01063439|Experimental|BuEAM: Experimental|BuEAM: Experimental Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day Intervention: Drug: Busulfan, etoposide, cytarabine, and melphalan
11541653|NCT01063426|Experimental|Atorvastatin + enoxaparine arm|High dose atorvastatin arm before index surgery+ conventional enoxaparin
11541654|NCT01063426|Active Comparator|Conventional Enoxaprin|Conventional Enoxaparin before 12hr and on 1-7th day after index surgery
11541655|NCT01063413||Coleman Afterschool Program|Children enrolled in a community center-based after-school program.
11541656|NCT01063413||YMCA Fun Company|Children enrolled in a school-based after-school program.
11541657|NCT01063400||Activity monitoring|
11541658|NCT01063387|No Intervention|Sema4c positive +Common iliac lymph nodes control|"Sema4c Positive & Radical hysterectomy +Pelvic Radiotherapy "
11541659|NCT01063387|Active Comparator|Sema4c positive +Common iliac lymph nodes Experimental|"Sema4c Positive & Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation) "
11541660|NCT01063387|No Intervention|Sema4c Positive + PAN positive control arm|"Sema4c Positive &  Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation) "
11541661|NCT01063387|Experimental|Sema4c positive+ PAN positive Experimental|Sema4c Positive & Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation+ supraclavicular lymph nodes irradiation) '
11541662|NCT01063374|Active Comparator|low glycemic index, diabetic diet|low glycemic index, diabetic diet
11541663|NCT01063374|Active Comparator|high cereal fibre, diabetic diet|high cereal fibre, diabetic diet
11541664|NCT01063361|Experimental|Low glycemic Index Diet|Low glycemic Index Diet, emphasizing pulses
11541665|NCT01063361|Active Comparator|High Cereal Fibre Diet|
11541666|NCT01063348|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine - 600mg tablets by mouth (dosing 1200mg - 3000mg qd)
11541667|NCT01063348|Placebo Comparator|Placebo|Matching placebo taken daily
11541668|NCT01063309||Autosomal recessive CGD|Participants must have autosomal recessive CGD (p47phox, p67phox, or p22phox deficiency) as demonstrated by DHR or genetic screening.
11541669|NCT01063309||CGD carrier|Participants with confirmed as X-linked CGD carriers as demonstrated by DHR or genetic screening.
11541670|NCT01063309||Healthy Volunteer|Healthy volunteers over the age of 18, both male and female. That have not been diagnosed with CGD, Inflammatory Bowel Disease, or another primary disease of the immune system.
11541671|NCT01063309||IFN-gamma treated CGD|Participants with CGD the have been treated with Interferon gamma.
11541672|NCT01063309||Inflammatory bowel disease|Participants with Inflammatory Bowel Disease with a well-recognized granulomatous inflammation, but normal phagocyte function and ROS production. They have not been diagnosed with CGD.
11541673|NCT01063309||Other immune system disorders|Participants with other disorders such as Chediak-Higashi Syndrome, Leukocyte Adhesion Deficiency, myeloperoxidase deficiency, Hyper- IgE (Job's) Syndrome, IRAK4-deficiency, and NEMO-deficiency
11541674|NCT01063309||X-linked Chronic Granulomatous Disease (CGD)|Participants diagnosed with X-linked CGD confirmed by DHR.
11541675|NCT01063283|Active Comparator|Group A|Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg once, followed three weeks later by Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg and bevacizumab every 3 weeks for two doses
11541676|NCT01063283|Active Comparator|Group B|Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg once, followed three weeks later by Carboplatin+Pemetrexed+Bevacizumab 15 mg/kg and bevacizumab every 3 weeks for two doses
11541677|NCT01063270|Active Comparator|Antibiotics|
11541678|NCT01063270|Active Comparator|Antibiotics and Laser treatment|
11541679|NCT01063257|Experimental|Cohort A|Clofarabine treatment at D1-D5
11541680|NCT01063257|Experimental|Cohort B|Clofarabine treatment at D1, D3, D5, D8, D10
11541681|NCT01063244|Active Comparator|FoleyBalloon|foley balloon placed in the cervix
11541682|NCT01063244|Active Comparator|foley balloon with weight|foley balloon with weight attached
11541683|NCT01063231|Experimental|1|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
11541684|NCT01063218|Other|Emollient|Only one arm: Emollient (Cetaphil Advanced) to be applied twice a day
11541685|NCT01063205|Placebo Comparator|Placebo|
11541686|NCT01063205|Active Comparator|N-Acetylcysteine (NAC) 1800 mg|
11541687|NCT01063205|Active Comparator|N-Acetylcysteine (NAC) 3600 mg|
11541688|NCT01063192|Active Comparator|Gemcitabine|Arm 1: Gemcitabine alone
11541689|NCT01063192|Active Comparator|GOFL|Arm 2: GOFL (Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
11541690|NCT01063179|Experimental|Arm A: VMPT|Induction therapy with nine 5-week courses of VELCADE/Melphalan/Prednisone/Thalidomide (V-MPT) followed by maintenance therapy with Thalidomide and VELCADE
11541691|NCT01063179|Active Comparator|VMP|"Induction therapy with nine 5-week courses of either VELCADE/Melphalan/Prednisone (V-MP).
~No maintenance is scheduled."
11541692|NCT01063153|Experimental|Concerta|Open-Label Concerta (Osmotic Release Methylphenidate)
11541693|NCT01063153|No Intervention|Control group|Healthy subjects without ADHD will be assessed using EEG.
11541694|NCT01063140||RabAvert|
11541695|NCT01063140||Imovax|
11541696|NCT01063127||1|group A: 10 morbidly obese subjects who will undergo gastric banding will be studied basally, 1 week after low-calorie diet and 1 week after operation.
11541697|NCT01063127||2|group B: 10 morbidly obese subjects who will undergo gastric bypass will be studied basally, 1 week after low-calorie diet and 1 week after operation.
11541698|NCT01063114|Experimental|Proton Beam Radiation|Proton Beam Radiation
11541699|NCT01063101|Experimental|BAX 513|Capsule - one of 5 dose levels (per randomization) - BID (= twice a day)
11541700|NCT01063101|Placebo Comparator|Capsule (cellulose)|Capsule - one of 5 dose levels (per randomization) - BID
11541701|NCT01063088|Experimental|Vaccination|Single 0.5 mL intramuscular injection of PreFluCel 2009/2010
11541702|NCT01063075|Experimental|Cetuximab and Carboplatin (D)|"Group D:
~Cycle 1 (1 week, combination therapy):
~400 milligrams per square meter (mg/m ²) cetuximab administered intravenously (I.V) on week 1,day 1. Carboplatin area under the curve (AUC=5) administered I.V on week 1,day 1.
~Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/ m ²/day administered starting on week 1, day 1.
~After 1 cycle, participants may then receive cetuximab as determined by clinical exam or radiological imaging studies until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.
~After protocol amendment February 2014, any newly enrolled participants were placed into Group D only."
11541703|NCT01063075|Experimental|Cetuximab and Carboplatin (C)|"Group C: Cycle 1 (4 weeks, combination therapy): Carboplatin (AUC=5) administered I.V on week 1, day 1.1000 mg/m ²/day 5-FU administered as a 96-hour C.I. starting on week 1, day 1.
~400 mg/m² cetuximab administered I.V on week 2, day 1. 250 mg/m ² cetuximab administered I.V on week 3 and 4, day 1.
~Cycle 2-6 (3 weeks, combination therapy): Carboplatin (AUC=5) administered I.V on week1,day1.1000 mg/m ²/d 5-FU as a 96-hour C.I. starting on week1, day1. 250 mg/m ² cetuximab administered I.V on Week 1-3, day 1.
~After 6 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
11541704|NCT01063075|Experimental|Cetuximab and Carboplatin (B)|"Group B:
~Cycle 1 (3 weeks, single-agent cetuximab):
~400 mg/m² cetuximab administered I.V on week 1, day 1. 250 mg/m ² cetuximab administered I.V on weeks 2 and 3, day 1.
~Cycle 2 (3 weeks, combination therapy):
~Carboplatin (AUC=5) administered I.V week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 250 mg/m ² cetuximab administered I.V weeks 1- 3,day 1.
~After 6 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.
~Due to protocol amendment in September 2011,any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
11541705|NCT01063075|Experimental|Carboplatin and Cetuximab (A)|"Group A:
~Cycle 1 (3 weeks, combination therapy):
~Carboplatin (AUC=5) administered I.V on week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1.
~400 mg/m ² cetuximab administered I.V on week 2, day 1. 250 mg/m ² cetuximab administered I.V on week 3, day 1.
~Cycle 2 (3 weeks, combination therapy):
~Carboplatin (AUC=5) administered I.V on week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 250 mg/m ² cetuximab administered I.V on weeks 1- 3, day 1.
~After 7 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.
~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
11541796|NCT01062425|Experimental|Cediranib, TMZ, and RT|Cediranib (3 days) followed by radiation therapy (RT) + daily temozolomide (TMZ) + cediranib followed by cediranib monotherapy (4 weeks) followed by TMZ + cediranib for 12 cycle maximum.
11541706|NCT01063062|Experimental|tocilizumab|Participants received an 8 mg/kg tocilizumab intravenous (IV) infusion once every 4 weeks for 24 weeks (6 infusions). Participants taking concomitant methotrexate (MTX) at Baseline remained on a stable dose as per standard of care at the Investigator's discretion.
11541707|NCT01063049|Active Comparator|Nulytely|Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
11541708|NCT01063049|Experimental|Gatorade/Miralax + Placebo|Gatorade 64 oz (1/2 gallon), Miralax 306 g and a placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy as follows: Miralax 51 g and placebo at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
11541709|NCT01063049|Experimental|Gatorade/Miralax + Bisacodyl|Gatorade 64 oz (1/2 gallon), Miralax 306 g and Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy as follows: Miralax 51 g and Bisacodyl 10 mg at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
11541710|NCT01063036|Experimental|Entecavir + Tenofovir|
11541711|NCT01063023|Active Comparator|Arm A - Ortho Tri-Cyclen®|1 to 28 days
11541712|NCT01063023|Active Comparator|Arm B - Ortho Tri-Cyclen®|29 to 56 days
11541713|NCT01063023|Active Comparator|Arm C - Ortho Tri-Cyclen® + BMS-650032|"Ortho Tri-Cyclen®: 57 to 77 days
~BMS-650032: 68 to 77 days"
11541714|NCT01063010|Placebo Comparator|Placebo|Placebo IV for 90 minutes (+ 15 minutes)
11541715|NCT01063010|Experimental|Bevicizumab|IV infusion over 90 minutes
11541716|NCT01062984|Active Comparator|Continuous Venovenous Hemofiltration|
11541717|NCT01062984|Active Comparator|Continuous Venovenouos Hemodialysis|
11541718|NCT01062971|Active Comparator|A|IOP Dorzolamide-Timolol-Brimonidine group
11541719|NCT01062971|Active Comparator|B|IOP dorzolamide-timolol group
11541720|NCT01062958||Arm #1 (Test group)|50 subjects administered Neevo® or Neevo®DHA daily
11541721|NCT01062958||Arm #2 (Control group)|50 subjects administered a prenatal vitamin daily
11541722|NCT01062945|Placebo Comparator|Placebo|
11541723|NCT01062945|Active Comparator|Doxazosin|
11541724|NCT01062932|Placebo Comparator|Placebo|
11541725|NCT01062932|Active Comparator|Cycloserine|
11541726|NCT01062919|Experimental|Epidural analgesia group|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
11541727|NCT01062919|Experimental|Wound Group|patients in the epidural analgesia group will receive ropivacaine 0.2% through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
11541728|NCT01062906|Placebo Comparator|Control|The control group receives intravenous fentanyl at the induction of anesthesia followed by a continuous infusion of lidocaine during the surgery.
11541729|NCT01062906|Active Comparator|Lidocaine|The Lidocaine group will receive lidocaine as bolus at the induction of anesthesia followed by a continuous infusion of lidocaine until the end of surgery
11541730|NCT01062893|Placebo Comparator|0 mls saline injected|NO SALINE INJECTED
11541731|NCT01062893|Active Comparator|15 mls saline|15ML SALINE ADMINISTERED EPIDURALLY
11541732|NCT01062867|Experimental|ORG25435|Infusion of intravenous anaesthetic agent to induce anaesthesia
11541733|NCT01062854|Experimental|Earplugs|Subjects randomized to this arm of the study will wear earplugs during their baseline sleep study (polysomnogram).
11541734|NCT01062854|No Intervention|Comparison group|Subjects randomized to the comparison arm will not wear earplugs during their baseline sleep study.
11541735|NCT01062841|Active Comparator|Intervention: Targeted Infection Control|Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
11541736|NCT01062841|No Intervention|Control|Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.
11541737|NCT01062828||Gestational age < 32 weeks|Premature infants with gestational age between <32 weeks regardless of birth weight
11541738|NCT01062815|Experimental|Cycling Parenteral Nutrition|Infants in the intervention cycling group will receive infusion of carbohydrate/amino acids and intralipid over a 20-hour period. During the 4-hour window period, infants in this group will receive dextrose solution only at the same rate calculated for the carbohydrate/amino acid infusion.
11541739|NCT01062815|Active Comparator|Continuous Parenteral Nutrition|Infants in this control group will receive infusion of carbohydrates/amino acids and intralipids continuously, over 24 hours.
11541740|NCT01062802|Placebo Comparator|Placebo|
11541741|NCT01062802|Active Comparator|Statin group|
11541742|NCT01062789|Other|Use of an optical breath-hold control device|This is a feasibility study that will use this new device in place of a different bellows-based breath-hold control device for a series patients undergoing CT-guided lung biopsy. The new belt will be used in all patients in our study.
11541743|NCT01062776|Placebo Comparator|5 ml/kg of fluid, no dehydration|Volunteers receive an intravenous infusion of acetated Ringers solution over 15 min without preceding deliberate dehydration with furosemide.
11541744|NCT01062776|Placebo Comparator|10 ml/kg of fluid, no dehydration|Volunteers receive an intravenous infusion of acetated Ringers solution over 15 min without preceding deliberate dehydration with furosemide.
11541745|NCT01062776|Experimental|5 ml/kg of fluid, dehydration|Volunteers receive an intravenous infusion of 5 ml/kg acetated Ringers solution over 15 min after being dehydrated with furosemide.
11541746|NCT01062776|Experimental|10 ml/kg of fluid, dehydration|Volunteers receive an intravenous infusion of 10 ml/kg acetated Ringers solution over 15 min after being dehydrated with furosemide.
11541747|NCT01062763|Experimental|addition of spironolactone|spironolactone is added to previous antihypertensive treatment
11541748|NCT01062763|Placebo Comparator|Placebo|Addition of placebo
11541749|NCT01062750|Other|adipose tissue derived stromal cells|
11541750|NCT01062737|Experimental|ASU (Avocado Soybean Unsaponifiable)|
11541751|NCT01062724|No Intervention|Trophamine|This group of neonates will be receive the Trophamine amino acids solution from Pisa laboratories as an active comparator with Primene. The infants in this group will receive, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat or daily enteral intake (ml/kg/d). Besides, the intake of breast milk or formula will be record, during the first 28 days of total parenteral nutrition.
11541752|NCT01062724|Experimental|Primene 10% from Baxter|This group of neonates will be receive the Primene amino acids solution (10 %) from Baxter laboratories as other active comparator with Trophamine. The infants in this group will receive, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat or daily enteral intake (ml/kg/d). Besides, the intake of breast milk or formula will be record, during the first 28 days of total parenteral nutrition.
11541753|NCT01062711|Other|Control group 0 g protein|Control group in which a placebo drink containing no protein is given following unilateral knee extension exercise
11541754|NCT01062711|Experimental|10g whey|10g whey protein given following unilateral knee extension exercise
11541755|NCT01062711|Experimental|20g whey|20g whey protein given following unilateral knee extension exercise
11541756|NCT01062711|Experimental|30g whey|30g whey protein given following unilateral knee extension exercise
11541757|NCT01062711|Experimental|40g whey|40g whey protein given following unilateral knee extension exercise
11541758|NCT01062711|Experimental|20g soy|20g soy protein given following unilateral knee extension exercise
11541759|NCT01062711|Experimental|40g soy|40g soy protein given following unilateral knee extension exercise
11541760|NCT01062698|Active Comparator|IV thrombolysis + thrombectomy|
11541761|NCT01062698|Active Comparator|IV thrombolysis|
11541762|NCT01062685||Shock Cohort|"The SHOCK cohort will meet the American College of Chest physicians/Society of Critical Care Medicine criteria for septic shock, specifically:
~1) Suspected infection
~2) Any two of four criteria of systemic inflammatory response:
~a. Temperature > 100.4° or < 96.8° F
~b. Heart rate > 90 beats/minute
~c. Respiratory rate > 20 breaths/min. or PaCO2 < 32 mm Hg
~d. WBC >12,000 or < 4000 cells/µL or > 10% bands
~3) Hypotension despite adequate fluid resuscitation:
~a. SBP < 90 mm Hg after 20cc/kg crystalloid"
11541763|NCT01062685||Sepsis cohort|"The SEPSIS cohort will to meet:
~1) Suspected infection
~2) Any two of four criteria of systemic inflammatory response:
~a. Temperature > 100.4° or < 96.8° F
~b. Heart rate > 90 beats/minute
~c. Respiratory rate > 20 breaths/min. or PaCO2 < 32 mm Hg
~d. WBC >12,000 or < 4000 cells/µL or > 10% bands
~3) Absence of refractory hypotension"
11541764|NCT01062685||Non-Infected controls|The third cohort will be comprised of uninfected ED control patients who met the criteria of no suspected infection, no SIRS criteria met and no evidence of hypoperfusion that are age and sex matched on a 1:1 basis with the shock cohort.
11541765|NCT01062659||chronic Hepatitis C|Patients with chronic Hepatitis C (CHC) Genotype 1-4 who are naive to antiviral treatment
11541766|NCT01062646|Experimental|Multimodal music therapy|Multimodal music therapy comprises 16 sessions single music therapy, group music therapy (max. 6 children/group), parent-child sessions, and parent counseling. The manualized treatment integrates music therapy, behavioral interventions, and family-oriented interventions.
11541767|NCT01062646|Active Comparator|community treatment as usual|
11541768|NCT01062633|Experimental|A, observation|dietary supplement
11541769|NCT01062633|Experimental|B|dietary supplement
11541770|NCT01062633|Experimental|C|dietary supplement
11541771|NCT01062620|Experimental|AXL1717|
11541772|NCT01062607||1|Patients diagnosed with Bipolar Disorder I or II (DSM-IV-TR) at any phase of the disorder with at least one mood event during the 12 months before the study start.
11541773|NCT01062607||2|Patients diagnosed with Bipolar Disorder I or II (DSM-IV-TR) at any phase of the disorder with at least one mood event during the 12 months before the study start receiving Seroquel extended release at some point during the retrospective period .
11541774|NCT01062594|Active Comparator|Supervised exercise group|
11541775|NCT01062594|No Intervention|Control group - no exercise|
11541776|NCT01062581||Transplant Recipients and Living Donors|"All transplant recipients receiving transplants at the University of Minnesota (kidney, pancreas, liver, heart, lung, islet, intestine). All ages.
~All living donors donating an organ at the University of Minnesota (kidney, pancreas, liver, lung) (by law, living donors are required to be at least 18 years old)"
11541777|NCT01062568|Experimental|Obese group|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after ACTH, blood samples will be obtained for repeat hormone measurements.
11541778|NCT01062568|Experimental|Nonobese group|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after ACTH, blood samples will be obtained for repeat hormone measurements.
11541779|NCT01062555|Active Comparator|Phase I|
11541780|NCT01062555|Active Comparator|Phase I Substudy|The substudy is for patients who need to be on steroids long term
11541781|NCT01062555|Experimental|Phase II|
11541782|NCT01062555|Experimental|Phase II Substudy|The substudy is for patients who need to be on steroids long term
11541783|NCT01062542||Breast Cancer Survivors|
11541784|NCT01062542||Pediatric Cancer Survivors|
11541785|NCT01062542||Control group|
11541786|NCT01062529|Experimental|somatostatin|
11541787|NCT01062516|Active Comparator|1|oral esomeprazole 20 mg daily
11541788|NCT01062516|Active Comparator|2|oral famotidine 40mg daily
11541789|NCT01062490|Experimental|Treosulfan|Patients with myelodysplastic syndrome, (MDS) according to WHO classification (< 20 % myeloblasts in peripheral blood or bone marrow at initial diagnosis) indicated for allogeneic transplantation
11541790|NCT01062477|Experimental|Study Group 1|Participants will receive ACTACEL vaccine at 2, 3, and 4 months of age.
11541791|NCT01062477|Experimental|Study Group 2|Participants will receive ACTACEL vaccine at 3, 4, and 5 months of age.
11541792|NCT01062477|Active Comparator|Study Group 3|Participants will receive Wuhan DTaP and Act-HIB vaccines concomitantly at 3, 4 and 5 months of age.
11541793|NCT01062451|Placebo Comparator|Placebo|
11541794|NCT01062451|Active Comparator|Perindopril|
11541795|NCT01062451|Active Comparator|Candesartan|
11541929|NCT01061463||Unexposed group|French non-interventional cardiologists and non medical workers, not occupationally exposed to X-Rays
11541797|NCT01062425|Active Comparator|Placebo, TMZ, and RT|Placebo (3 days) followed by radiation therapy (RT) + daily temozolomide (TMZ) + placebo followed by placebo monotherapy (4 weeks) followed by TMZ + placebo for 12 cycle maximum.
11541798|NCT01062399|Experimental|Ph I: RT + TMZ + RAD001 2.5 mg/day|Radiation therapy (RT), concurrent temozolomide (TMZ), and concurrent RAD001 2.5 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
11541799|NCT01062399|Experimental|Ph I: RT + TMZ + RAD001 5 mg/day|Radiation therapy, concurrent temozolomide, and concurrent RAD001 5 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
11541800|NCT01062399|Experimental|Ph I: RT + TMZ + RAD001 10 mg/day|Radiation therapy, concurrent temozolomide, and concurrent RAD001 10 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
11541801|NCT01062399|Active Comparator|Ph II: RT + TMZ|Radiation therapy and concurrent temozolomide followed by post-radiation temozolomide
11541802|NCT01062399|Experimental|Ph II: RT + TMZ + RAD001|Radiation therapy, concurrent temozolomide, and concurrent RAD001 10 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
11541803|NCT01062373|Active Comparator|TG-DHA|TG-DHA: lactating mothers and their newborn with mothers supplemented with Triglyceride enriched in docosahexaenoic acid
11541804|NCT01062373|No Intervention|Control|Control: lactating mothers and their newborn with no supplementation given to the mother
11541805|NCT01062373|Experimental|GPL-DHA|GPL-DHA: lactating mothers and their newborn with mothers supplemented with Glycerophospholipid enriched in docosahexaenoic acid
11541806|NCT01062360|Experimental|Arm 1|
11541807|NCT01062360|Active Comparator|Arm 2|
11541808|NCT01062360|Active Comparator|Arm 3|
11541809|NCT01062360|Placebo Comparator|Arm 4|
11541810|NCT01062347|Experimental|zinc supplementation (20 mg/d, for 7 d)|
11541811|NCT01062334|Experimental|Microdialysis|
11541812|NCT01062321||Hepatitis-E, Pregnant & Non-pregnant|Pregnant,Acute Viral Hepatitis, Fulminant Hepatic Failure
11541813|NCT01062308|Experimental|Taping|The tri-pull method of taping was used.Taping was initiated by first applying three, two-inch wide and approximately ten-inch long, pieces of elastic adhesive tape strips. The first strip was applied from the mid-humerus deltoid tuberosity across the scapula. The second strip was applied from the deltoid tuberosity across the clavicle to the mid-clavicle, but before the supra-sternal notch. The third strip was placed from the deltoid tuberosity over the acromion process to the neck.
11541814|NCT01062308|Active Comparator|Sham Taping|This was done using the same tapes. Three strips of tapes were applied in same position without repositioning the joint. All other Physiotherapy measures like positioning, handling technique and range of motion exercises were equally done for both the groups.
11541815|NCT01062295|Experimental|Siesta-System|Use of Siesta-System
11541816|NCT01062295|Active Comparator|Standard headrest|Use of standard headrest
11541817|NCT01062282||Group 1|
11541818|NCT01062269|Active Comparator|Cholestyramine 4 grams|
11541819|NCT01062269|Active Comparator|Cholestyramine 12 grams|
11541820|NCT01062269|Placebo Comparator|Tang|
11541821|NCT01062256|Placebo Comparator|Placebo|Placebo
11541822|NCT01062256|Experimental|Guaifenesin|Guaifenesin
11541823|NCT01062256|Experimental|Buckwheat Honey|Buckwheat Honey
11541824|NCT01062243|Experimental|Brain Injury Education|The Brain Injury Inpatient Guide for Families and Caregivers (BIIG-FACS), developed by J. Niemeier and J. Kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation.
11541825|NCT01062230|Experimental|All patients|All participants enrolled.
11541826|NCT01062191|Experimental|Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing|Nanoflex Powder Dressing applied to joint
11541827|NCT01062191|Active Comparator|Aquacel AG, typical carboxymethylcellulose dressing|Sodium CMC dressing control applied to joint
11541828|NCT01062178|Experimental|comparison to biopsy|Comparing contrast enhanced US with biopsy result
11541829|NCT01062165|Experimental|Capsofungin|Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
11541830|NCT01062152|Experimental|Revlimid® in Combination with Telintra ®|Lenalidomide (Revlimid®) followed by Telintra® until MDS progression or lack of efficacy.
11541831|NCT01062139|Experimental|Petasites extract, levocetirizine|Cosalin (Petasites hybridus CO2 extract), Xarlin (levocetirizine) combination therapy group
11541832|NCT01062139|Active Comparator|Cosalin (Petasites hybridus CO2 extract)|Cosalin monotherapy
11541833|NCT01062113|Experimental|Celecoxib 400mg|
11541834|NCT01062113|Experimental|Celecoxib 200mg|
11541835|NCT01062113|Placebo Comparator|Placebo|
11541836|NCT01062100|Experimental|nuclear breast imaging|nuclear breast imaging using MBI Gamma camera
11541837|NCT01062087||Local anesthetic|Women who received local anesthetic during surgery in addition to general anesthesia
11541838|NCT01062087||No local anesthetic|Women who did not receive any local anesthetic during surgery, but did have general anesthesia
11541839|NCT01062074||Korean Participants Vaccinated with GARDASIL|Females and males 9-26 years old who are vaccinated with GARDASIL in usual practice. The GARDASIL vaccination series consists of three 0.5-mL intramuscular injections. The second and third doses are to be administered 2 months and 6 months after the first dose, respectively.
11541840|NCT01062061||VARIVAX|Attenuated live varicella vaccine was administered in usual practice. Recommended dosing is a single 0.5 mL subcutaneous injection in children 12 months to 12 years of age.
11541841|NCT01062048||All participants|Participants administered Januvia up to 100 mg once daily as monotherapy or combination therapy with a sulfonylurea or with insulin during the re-examination period (up to 6 years)
11541842|NCT01062035||ACP (advanced colon polyp) Group|Between the ages of 50 and 60 years old and have an ACP (advanced colon polyp)
11541843|NCT01062035||Control Group|Individuals between the ages of 50 and 60 years old who have had a negative screening colonoscopy.
11541887|NCT01061736|Experimental|Part B Cohort 1: Non-selected Doses|Sarilumab 100 mg qw, 150 mg qw or 100 mg q2w SC injections as in Part A on top of MTX up to dose selection. After dose selection, participants were not continued but were allowed to participate in the open-label, long-term, extension study SARIL-RA-EXTEND (LTS11210).
11541844|NCT01062022|Active Comparator|Control - Standard of Care|Participation in the study will involve your child completing a questionnaire about (a) your family's background, descriptive information about people in your family, and previous major life events, (b) his/her current functioning, (c) his/her feelings before, during, and after the combat injury, and (d) his/her current social relationships and adjustment. Your child will be asked to complete the questionnaire during the baseline assessment, and at 6 months, 12 months, and 24 months after the original assessment.
11541845|NCT01062022|Active Comparator|FOCUS-CI|Those participants in the FOCUS-CI intervention will be part of a family skill-building/resiliency training program designed to provide information and skills training in a variety of forms, including clinician-led sessions, handouts, on-line training modules, and individual family care management. Study participation will also involve completing a questionnaire about (a) your family's background, descriptive information about people in your family, and previous major life events, (b) his/her current functioning, (c) his/her feelings before, during, and after the combat injury, and (d) his/her current social relationships and adjustment. Questionnaires will be completed during the baseline assessment, and at 6 months, 12 months, and 24 months after the baseline assessment.
11541846|NCT01062009|No Intervention|Control group|No intervention
11541847|NCT01062009|Active Comparator|Low dose group|250 mcg/kg/day supplemental IV zinc sulfate divided every 8 hours for 7 days
11541848|NCT01062009|Active Comparator|Medium dose group|500 mcg/kg/day supplemental IV zinc sulfate q8 hours for 7 days
11541849|NCT01062009|Active Comparator|High dose group|750 mcg/kg/day supplemental IV zinc sulfate q8 hrs for 7 days
11541850|NCT01061996|Experimental|1|
11541851|NCT01061983|Experimental|Deep Brain Stimulation|Participants will receive deep brain stimulation.
11541852|NCT01061957||Raltegravir patients|HIV patients who initiated raltegravir due to virological failure
11541853|NCT01061957||Haart naive patients|HIV patients initiating HAART for the first time
11541854|NCT01061931|Active Comparator|Arctic Front® catheter|
11541855|NCT01061931|Active Comparator|HD Mesh Ablator® catheter|
11541856|NCT01061918|Active Comparator|Tecnis MF|
11541857|NCT01061918|Active Comparator|ReSTOR|
11541858|NCT01061905|Experimental|Calorie information only|Posting calorie information of sugar-sweetened and zero-calorie beverages prominently on a poster.
11541859|NCT01061905|Experimental|Exercise Equivalent Information|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
11541860|NCT01061905|Experimental|Calorie and Exercise Equivalent information|Posting of both calorie and exercise equivalent information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
11541861|NCT01061866|Experimental|Thalidomide|Open-labeled preliminary trial
11541862|NCT01061853|Experimental|T|TOPICAL SIROLIMUS AND PETROLATUM IN ORABASE
11541863|NCT01061853|Active Comparator|C|TOPICAL BETAMETHASONE 0.05% in ORABASE AND PHOSAL
11541864|NCT01061840|Experimental|1 x 10 ^7 cells/injection|Vigil™
11541865|NCT01061840|Experimental|2.5 x 10 ^7 cells/injection|Vigil™
11541866|NCT01061840|Experimental|1 x 10^6 or 4 x 10^6 cells/injection|Vigil™
11541867|NCT01061827||Dementia|
11541868|NCT01061827||Depression|
11541869|NCT01061827||Control|
11541870|NCT01061814|Experimental|mipomersen|30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) SC daily
11541871|NCT01061814|Placebo Comparator|Placebo|30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) SC daily
11541872|NCT01061801|Experimental|Emotional expression, patient present|Caregivers are asked to talk about their deepest thoughts and feelings regarding the patient's transplant and their role as caregiver, in the presence of the patient (one session).
11541873|NCT01061801|Experimental|Emotional expression, patient absent|Caregivers are asked to talk about their deepest thoughts and feelings regarding the patient's transplant and their role as caregiver, in the absence of the patient (3 sessions).
11541874|NCT01061801|Active Comparator|Comparison|Caregivers are asked to talk about their plans for the upcoming week (time management, sessions 1 and 3) and positive aspects of their life (session 2).
11541875|NCT01061788|Experimental|Everolimus, AMG 479, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479
~3-6 subjects, Study drug administered per dose level
~3-6 subjects, Study drug administered per dose level
~Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level
~Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab
~3-6 subjects, Study drug administered per dose level
~3-6 subjects, Study drug administered per dose level
~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level
~NSCLC Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
11541876|NCT01061775|Experimental|Exenatide|5mcg of exenatide will be given twice a day for 4 weeks and increased to 10 mcg twice a day for 20 weeks.
11541877|NCT01061762|Experimental|Low Literacy Adherence Counseling|3-counseling sessions for medication adherence improvement tailored for people with poor literacy
11541878|NCT01061762|Active Comparator|Standard Adherence Counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
11541879|NCT01061762|Active Comparator|Health Counseling Comparison|3-sessions of health improvement counseling.
11541880|NCT01061749|Experimental|Treatment (selumetinib, cixutumumab)|Patients receive selumetinib PO BID on days 1-28 and cixutumumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11541881|NCT01061736|Experimental|Part A: SAR 100 mg qw|Sarilumab 100 mg subcutaneous (SC) injection weekly (qw) on top of MTX for 12 weeks.
11541882|NCT01061736|Experimental|Part A: SAR 150 mg qw|Sarilumab 150 mg SC injection qw on top of MTX for 12 weeks.
11541883|NCT01061736|Experimental|Part A: SAR 100 mg q2w|Sarilumab 100 mg SC injection every other week (q2w) alternating with placebo on top of MTX for 12 weeks.
11541884|NCT01061736|Experimental|Part A: SAR 150 mg q2w|Sarilumab 150 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.
11541885|NCT01061736|Experimental|Part A: SAR 200 mg q2w|Sarilumab 200 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.
11541886|NCT01061736|Placebo Comparator|Part A: Placebo qw|Placebo (for sarilumab) qw on top of MTX for 12 weeks.
11541930|NCT01061450|Placebo Comparator|Placebo|Placebo
11541888|NCT01061736|Experimental|Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2)|Sarilumab 150 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
11541889|NCT01061736|Experimental|Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)|Sarilumab 200 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
11541890|NCT01061736|Experimental|Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2)|Placebo (for sarilumab) q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
11541891|NCT01061723|Placebo Comparator|Placebo|Placebo (for sarilumab) weekly (qw) for 12 weeks.
11541892|NCT01061723|Experimental|Sarilumab 100 mg q2w|Sarilumab 100 mg Subcutaneous (SC) injection alternating with placebo every other week (q2w) for 12 weeks.
11541893|NCT01061723|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg SC injection alternating with placebo q2w for 12 weeks.
11541894|NCT01061723|Experimental|Sarilumab 100 mg qw|Sarilumab 100 mg SC injection qw for 12 weeks.
11541895|NCT01061723|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection alternating with placebo q2w for 12 weeks.
11541896|NCT01061723|Experimental|Sarilumab 150 mg qw|Sarilumab 150 mg SC injection qw for 12 weeks.
11541897|NCT01061710||varenicline (Champix®)|Subjects who have been retreated with varenicline within 52 weeks and have been enrolled to varenicline protocol A3051109.
11541898|NCT01061684||NAFLD|pediatric patients with non-alcoholic fatty liver disease (NAFLD).
11541899|NCT01061671|Active Comparator|simvastatin|40 mgms of simvastatin daily
11541900|NCT01061671|Placebo Comparator|placebo|Matched placebo pill daily
11541901|NCT01061658|Experimental|Vaccine - High dosage|
11541902|NCT01061658|Experimental|Vaccine - Lower dosage|
11541903|NCT01061658|Placebo Comparator|Placebo|
11541904|NCT01061645|Experimental|MOC31-PE|
11541905|NCT01061606|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11541906|NCT01061593|Experimental|ATT+Immunoxel|TB patients with DS-TB, MDR-TB, XDR-TB or TB-HIV on standard ATT + Immunoxel honey lozenge once per day day
11541907|NCT01061593|Placebo Comparator|ATT+Placebo|TB patients with DS-TB, MDR-TB, XDR-TB or TB-HIV on standard ATT + Placebo lozenge made of corn syrup once/day
11541908|NCT01061580|Experimental|CABG plus BMAC Injection|Injection of Bone Marrow Aspirate Concentrate (BMAC) into ischemic myocardium following CABG during the same open procedure
11541909|NCT01061567||Male and female patients with Parkinson's disease|
11541910|NCT01061554|Experimental|Gastric stable emulsion|A gastric stable emulsion vehicle for administration of tri-glyceride based omega-3 oils
11541911|NCT01061554|Active Comparator|Soft gel capsule (TG)|Soft gel capsule for administration of tri-glyceride based omega-3 oils
11541912|NCT01061554|Active Comparator|Soft gel capsules (MPL)|Soft gel capsule for administration of marine phospholipids based omega-3 oils
11541913|NCT01061541|Experimental|Group A|
11541914|NCT01061541|Active Comparator|Group B|
11541915|NCT01061528|Experimental|New Smoking Cessation Counseling|"One 60-minute individual session
~Seven 2-hour group sessions
~Two individual brief telephone contacts over an eight-week period.
~Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue even after the treatment sessions have ended. Standard nicotine patch dosing will be used."
11541916|NCT01061528|Active Comparator|Standard Smoking Cessation Counseling|"One 60-minute individual session
~Seven 2-hour group sessions
~Two individual brief telephone contacts over an eight-week period.
~Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue even after the treatment sessions have ended. Standard nicotine patch dosing will be used."
11541917|NCT01061515|Experimental|Dose Level 1|"Intraperitoneal oxaliplatin 25 mg/m2 IP on day 1 of each cycle
~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle
~Capecitabine PO BID on days 1-7 of each cycle.
~Each cycle is 14 days long."
11541918|NCT01061515|Experimental|Dose Level 2|"Intraperitoneal oxaliplatin 50 mg/m2 IP on day 1 of each cycle
~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle
~Capecitabine PO BID on days 1-7 of each cycle.
~Each cycle is 14 days long."
11541919|NCT01061515|Experimental|Dose Level 3|"Intraperitoneal oxaliplatin 65 mg/m2 IP on day 1 of each cycle
~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle
~Capecitabine PO BID on days 1-7 of each cycle.
~Each cycle is 14 days long."
11541920|NCT01061515|Experimental|Dose Level 4|"Intraperitoneal oxaliplatin 85 mg/m2 IP on day 1 of each cycle
~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle
~Capecitabine PO BID on days 1-7 of each cycle.
~Each cycle is 14 days long."
11541921|NCT01061515|Experimental|Dose Level 5|"Intraperitoneal oxaliplatin 100 mg/m2 IP on day 1 of each cycle
~Bevacizumab 5 mg/kg CIVI on day 1 of each cycle
~Capecitabine PO BID on days 1-7 of each cycle.
~Each cycle is 14 days long."
11541922|NCT01061502|Experimental|Procellera Wound Dressing|Dressing indicated for partial and full-thickness wounds. Dressing changes every 5-7 days, more frequently if needed
11541923|NCT01061502|Active Comparator|Opsite Transparent Adhesive Dressing|Polyurethane film dressing. Dressing changes every 5-7 days, more frequently if needed
11541924|NCT01061489|Experimental|sensory-cognitive training|
11541925|NCT01061489|Experimental|physical fitness|
11541926|NCT01061489|No Intervention|waiting list (control group)|
11541927|NCT01061476|Other|Single arm - Sleep apnea|"Participants with sleep apnea will be recruited for the study. Each participant will undergo 3 sleep studies to assess the effect of the Provent™ device. Participants will only use the device while they are in the sleep laboratory. They will not use the device at home between sleep studies .
~Baseline sleep study (No device) - Assess the effects of no Provent™ on sleep apnea severity.
~Treatment sleep study (Provent™ device used) - Assess the effects of Provent™ on sleep apnea severity
~Physiology sleep study (Provent™ on/off) - Assess the physiological effects of the Provent™ device on breathing during sleep."
11541928|NCT01061463||Exposed group|French coronary interventional cardiologists and cardiologists specializing in cardiac arrhythmias treatments (electrophysiologists), occupationally exposed to X-Rays
11541931|NCT01061450|Experimental|Simvastatin|Simvastatin 80 mg/day
11541933|NCT01061437|Experimental|Arm 2|Concomitant Therapy - 5 day, 4-drug regimen
11541934|NCT01061437|Experimental|Arm 3|Sequential Therapy - 10 day, 4-drug regimen
11541935|NCT01061424|Active Comparator|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
11541936|NCT01061424|Experimental|community health worker|community health worker provides home visits for education
11541937|NCT01061411|Experimental|Treatment (sunitinib malate, dalteparin)|Patients receive sunitinib malate PO QD in weeks 1-4 and dalteparin SC QD in week 6 during course 1. In all subsequent courses, patients receive sunitinib malate PO QD in weeks 1-4 and dalteparin SC QD in weeks 1-6. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11541938|NCT01061398|Experimental|Cardiac CT Arm|Patients referred for stress imaging due to complaints consistent with possible angina, randomized to receive an additional cardiac CT scan.
11541939|NCT01061398|Active Comparator|No CT Arm|Patients with symptoms consistent with possible angina, randomized to receive the type of stress imaging test ordered by their physician.
11541940|NCT01061385|Experimental|ReShape Intragastric Balloon|Patients receiving the ReShape Intragastric Balloon
11541941|NCT01061385|Other|Control Arm|Weight loss using behavior modification (diet and exercise counseling) alone
11541942|NCT01061372|Placebo Comparator|Placebo|
11541943|NCT01061372|Experimental|Pregabalin 150 mg/day|
11541944|NCT01061372|Experimental|Pregabalin 300 mg/day|
11541945|NCT01061359||Non-Interventional Study|Chemotherapy containing Epirubicin
11541946|NCT01061346|Experimental|High Fat Diet with Fructose|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
11541947|NCT01061346|Experimental|High Fat Diet with Glucose|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
11541948|NCT01061346|Experimental|Low Fat Diet with Glucose|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein.
11541949|NCT01061333|Experimental|Placebo|Placebo
11541950|NCT01061333|Experimental|Montelukast|Montelukast
11541951|NCT01061333|Experimental|Nedocromil|Nedocromil
11541952|NCT01061333|Experimental|Mometasone|Mometasone
11541953|NCT01061320|Active Comparator|alpha tocopherol|
11541954|NCT01061320|Placebo Comparator|placebo|
11541955|NCT01061307|Experimental|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
11541956|NCT01061294|Other|Advanced CustomVue™ iLASIK procedure|
11541957|NCT01061281|Active Comparator|Tecnis MF IOL|
11541958|NCT01061281|Active Comparator|Crystalens AO IOL|
11541959|NCT01061268|Experimental|BLINK™ tears|
11541960|NCT01061268|No Intervention|No topical artificial tear|
11541961|NCT01061242|No Intervention|Baseline|Post-Intensive Care Unit (ICU) neurocognitive testing and sleep survey performed on patients exposed to ad-lib Medical ICU environment.
11541962|NCT01061242|Experimental|Sleep Promotion Group|Post-ICU neurocognitive testing and sleep survey performed on patients exposed to interventions in the pre-existing MICU sleep quality improvement project.
11541963|NCT01061229|Experimental|Homeopathic drug, potency C12|
11541964|NCT01061229|Placebo Comparator|Placebo|
11541965|NCT01061216|Experimental|Intradermal insulin infusion (ID)|
11541966|NCT01061216|Active Comparator|Subcutaneous insulin infusion (SC)|
11541967|NCT01061203|Active Comparator|Grazax|Grazax tablet 75.000 SQ-T. One tablet per day for administration under the tongue.
11541968|NCT01061203|Placebo Comparator|Tablet with no active grass|Tablet with no active grass component. One tablet per day administered under the tongue.
11541969|NCT01061190|Active Comparator|Propranolol|
11541970|NCT01061190|Placebo Comparator|Placebo|
11541971|NCT01061177|Experimental|Nilotinib|This was a single-arm study; therefore all participants received nilotinib (AMN107) 300 mg bid given as two 150 mg capsules twice daily.
11541972|NCT01061164||HIV-infected infants, children, and adolescents|Infants, children, and adolescents with HIV infection who have participated in PACTG 219C and/or select IMPAACT studies.
11541973|NCT01061151|Active Comparator|Antepartum Arm A|Mothers received ZDV + sdNVP + TRV Tail
11541974|NCT01061151|Experimental|Antepartum Arm B|Mothers received Triple ARV (3TC-ZDV + LPV-RTV)
11541975|NCT01061151|Experimental|Antepartum Arm C|Mothers received Triple ARV (TRV + LPV-RTV)
11541976|NCT01061151|Other|Late Presenters|Registration to facilitate a structure to screen women and infants for randomization in the Postpartum Component.
11541977|NCT01061151|Experimental|Postpartum Arm A (Maternal Prophylaxis)|Mothers received prophylaxis [preferred regimen: TRV + LPV-RTV]. Infants received short-course NVP.
11541978|NCT01061151|Experimental|Postpartum Arm B (Infant Prophylaxis)|Infants received extended NVP.
11541979|NCT01061151|Experimental|Maternal Health Arm A (Continue triple ARVs)|Mothers continued receiving triple ARV regimen [preferred regimen: TRV + LPV-RTV].
11541980|NCT01061151|Active Comparator|Maternal Health Arm B (Discontinue triple ARVs)|Mothers discontinued triple ARV regimen.
11541981|NCT01061138||Screening Patients|Female patients scheduled for routine annual screening mammograms
11541982|NCT01061138||Biopsy Patients|Female patients scheduled for routine breast biopsy procedures
11541983|NCT01061125||Unblinded|Transtelephonic (TTM) monitoring weekly for 5 months Holter monitor recording at 4 months and at 12 months Implantable Loop Recorder (ILR) weekly reports
11541984|NCT01061125||Blinded|TTM and Holter Monitor conventional follow up Implantable Loop Recorder (ILR) unblinded at 5 months
11541985|NCT01061112||CYP2C9*1/*1 Genotype|This genotype is considered the wild type genotype. Individuals with the CYP2C9*1/*1 genotype have two *1 alleles and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide & Fluconazole.
11541986|NCT01061112||CYP2C9*1/*3 Genotype|Individuals with the CYP2C9*1/*3 genotype have one *1 allele and one *3 allele and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide & Fluconazole.
11541987|NCT01061112||CYP2C9*3/*3 Genotype|Individuals with the CYP2C9*3/*3 genotype have two *3 alleles and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide & Fluconazole.
11541988|NCT01061099|Active Comparator|Stratum A|Subjects with a diagnosis of Type II or Type III osteogenesis imperfecta who have previously undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.
11541989|NCT01061099|Active Comparator|Stratum B|Subjects with Type II or III osteogenesis imperfecta who have not undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.
11541990|NCT01061086||1|Patients over 18 years old admitted to the hospital with Acute Coronary Syndrome.
11541991|NCT01061073|Experimental|Omexel|
11541992|NCT01061073|Active Comparator|spasfon|
11541993|NCT01061060|Experimental|Beraprost group|Prostaglandin I2
11541994|NCT01061060|Placebo Comparator|Placebo group|
11541995|NCT01061021|Experimental|Integrated Intervention|Five small group + 2 individual counseling behavioral intervention to simultaneously address HIV transmission risk reduction and HIV treatment adherence in men and women living with HIV/AIDS.
11541996|NCT01061021|Active Comparator|Comparison Group|Five small group + 2 individual counseling session intervention that serves as an attention control group. Content included stress reduction, nutrition, and exercise for health improvement.
11541997|NCT01061008|Experimental|Handgrip exercise|Handgrip exercise - patients allocated to this intervention will carry out an eight week post operative progressive handgrip exercise training program
11541998|NCT01061008|Active Comparator|Treatment as usual|
11541999|NCT01060995||SmartConsent|Subjects receiving SmartConsent informed consent
11542000|NCT01060995||Standard consent|Subjects receiving standard consent
11542001|NCT01060982|Experimental|HIFU treatment|
11542002|NCT01060969|Active Comparator|Acetazolamide|acetazolamide 125 mg BID
11542003|NCT01060969|Experimental|Acetazolamide and Tadalafil|Intervention arm
11542004|NCT01060956|Active Comparator|Reporting on two bacteria in urine culture|The microbiology laboratory will report on the isolation and susceptibilities of two different bacteria in urine culture
11542005|NCT01060956|Placebo Comparator|"reporting mixed growth"|The microbiology laboratory will report on mixed growth in urine culture
11542006|NCT01060943|Active Comparator|KOKEN(collagen)|atelocollagen filler
11542007|NCT01060943|Experimental|TheraFill|atelocollagen filler
11542008|NCT01060930|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust ~ 300 mcg/m3 - during intermittent exercise
11542009|NCT01060930|Experimental|Air exposure|1 hour exposure to filtered air during intermittent exercise
11542010|NCT01060904|Experimental|1|brentuximab vedotin combined with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
11542011|NCT01060904|Experimental|2|brentuximab vedotin combined with AVD (doxorubicin, vinblastine, dacarbazine)
11542012|NCT01060878|Experimental|Dose I|
11542013|NCT01060878|Experimental|Dose II|
11542014|NCT01060878|Experimental|Dose III|
11542015|NCT01060878|Placebo Comparator|Placebo|
11542016|NCT01060865|Experimental|Aliskiren|only one arm with the experimental drug [aliskiren]
11542017|NCT01060852|Experimental|Media Detective|10-lesson elementary school, substance use prevention program developed based upon the Message Interpretation Processing model designed to increase children's critical thinking skills about media messages and reduce intent to use tobacco and alcohol products.
11542018|NCT01060839|Experimental|Single session counseling|
11542019|NCT01060839|No Intervention|Standard of care|
11542020|NCT01060826|Experimental|somatostatin, intravenous bolus|A double- blind study designed to evaluate if the treatment with somatostatin in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will be randomized in two groups of treatment, one will receive somatostatin and another placebo.
11542021|NCT01060826|Placebo Comparator|Placebo, intravenous bolus|A double- blind study designed to evaluate if the treatment with somatostatin in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will be randomized in two groups of treatment, one will receive somatostatin and another placebo.
11542022|NCT01060813|Active Comparator|Exercise + Leucine|Patients will receive leucine 10 g/d po + exercise for 3 months
11542023|NCT01060813|Active Comparator|Leucine without exercise|patients will receive leucine 10 g/d po
11542024|NCT01060787||Fluocinolone Acetonide 0.59 mg|Participants who have had the fluocinolone acetonide (FA) drug delivery system 0.59 mg surgically implanted in the ocular vitreous chamber of one (1) eye for at least one (1) year.
11542025|NCT01060787||Fluocinolone Acetonide 2.1 mg|Participants who have had the fluocinolone acetonide (FA) drug delivery system 2.1 mg surgically implanted in the ocular vitreous chamber of one (1) eye for at least one (1) year.
11542026|NCT01060774|Experimental|Bupivacaine|0.5% bupivacaine/1:200,000 epinephrine
11542027|NCT01060774|Experimental|Lidocaine|2% lidocaine/1:200,000 epinephrine
11542028|NCT01060761|Active Comparator|Rehabilitation program|Counselling (supportive conversation with patient and their relatives together) Retreat Weekend (patient and their relatives together)
11542029|NCT01060761|No Intervention|Ususal treatment and support|Usual support and treatment at the hospital, no retreat Weekend.
11542030|NCT01060748|Experimental|ACE527|"First cohort: ACE527 vaccine doses of 9 x 10E10 cfu on study day 0 and 21 on an outpatient basis.
~Second cohort: ACE527 vaccine dose of 9 x 10E10 cfu on study day 0 and 21 on an outpatient basis."
11542031|NCT01060748|Placebo Comparator|Placebo vaccine|"First cohort: Placebo vaccine on study day 0 and 21 on an outpatient basis.
~Second cohort: Placebo vaccine on study day 0 and 21 on an outpatient basis."
11542032|NCT01060735|Experimental|Larger doses of vitamin D supplementation|The subjects enrolled in this arm will be supplemented during the third trimester of pregnancy with 2000IU vitamin D per day
11542033|NCT01060735|No Intervention|Conventional vitamin D supplementation|Regular supplementation during pregnancy with 400IU vitamin D
11542034|NCT01060722|Experimental|MOD-4023, dose level 1|
11542035|NCT01060722|Experimental|MOD-4023, dose level 2|
11542036|NCT01060722|Experimental|MOD-4023, dose level 3|
11542037|NCT01060709||elective colonoscopy and requiring sedation|
11542038|NCT01060696|Experimental|Hyoscine, Mefenamic acid, Placebo|Blind randomization to three groups. Mefenamic acid group Hyoscine group Placebo group
11542039|NCT01060683||Group 1: 15 patients|for elective hepatic resection
11542040|NCT01060683||Group 2: 15|for elective hepatic resection
11542041|NCT01060670|Experimental|Dermal Replacement Device|Device: INTEGRA® Dermal Regeneration Template
11542042|NCT01060670|Active Comparator|Moist Wound Therapy|0.9% Saline gel
11542043|NCT01060657||conventional (C) group|
11542044|NCT01060657||low dose (L) groups|
11542045|NCT01060631||patients with frontal or frontotemporal brain tumor.|
11542046|NCT01060631||patients without supratentorial brain tumor.|
11542047|NCT01060618|Experimental|Maraviroc + Trofile ESTA®|the patients have the Trofile ESTA® test performed and sent for evaluation. Once the results are obtained (about 1 month later), the patients take the medication Maraviroc during ten days. The viral load assessment throughout the Study help to make a prediction to assess if the patients would have a positive response Vs. CCR5 antagonist of a negative response
11542048|NCT01060605|Experimental|Rapamycin pre transplant|Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
11542049|NCT01060592|Experimental|Stoma Adjustment at Surgery|The first band adjustment will be made at surgery versus historical controls where the adjustment is not made for 3-4 weeks post-surgery. EndoFLIP device (FDA Device Listing Number : D091203)will be used to make the adjustment.
11542050|NCT01060592|No Intervention|Historic|Weight loss profile over time for 50 patients in the first 12 months after surgery as derived from historic control records. Band adjustments are made in a heuristic fashion during the year after surgery using the experience of surgeon alone
11542051|NCT01060579|Experimental|AR-12286 0.5% ophthalmic solution|
11542052|NCT01060579|Experimental|AR-12286 0.25% Ophthalmic Solution|
11542053|NCT01060579|Experimental|Latanoprost 0.005% ophthalmic solution|
11542054|NCT01060566|Experimental|VX-770|
11542055|NCT01060566|Experimental|Midazolam|
11542056|NCT01060566|Experimental|Rosiglitazone|
11542057|NCT01060566|Experimental|Fluconazole|
11542058|NCT01060553|Experimental|Arm 1|The treatment program consisted of 24 semi-individualized acupuncture treatments over 12 weeks. It combines front and back treatments to avoid point fatigue (tolerance due to frequent use). The front treat-ment uses 11 needles, bilateral at acupuncture points LR3, PC6, HT7, ST36, SP6, and one at Yintang; the back treatment uses 14 needles, bilateral at points GB20, and BL14, 15, 18, 20, 21, and 23. There are 15 other points from which the flexibly prescribed points could be chosen
11542059|NCT01060553|No Intervention|wait list control|subjects were put on a wait list control. due to small numbers completing in both groups, the data from the wait list who completed acupuncture are combined with the experimental treatment group for analysis.
11542060|NCT01060540|Experimental|CR+G|conventional risk counseling (lifetime risk, fasting plasma glucose, and family history) plus genetic testing for type 2 diabetes
11542061|NCT01060540|Active Comparator|CR+EYE|conventional risk counseling (lifetime risk, fasting plasma glucose, and family history) plus eye disease counseling
11542062|NCT01060527||IBS-D|
11542063|NCT01060527||IBS-C|
11542064|NCT01060527||Controll|
11542065|NCT01060514|Experimental|Pazopanib + Vinorelbine|
11542066|NCT01060501|Active Comparator|5-FU|Standard arm Systemic drug administration of 5-FU (intravenous)
11542067|NCT01060501|Experimental|5-FU + folinic acid|Experimental arm Systemic drug administration of 5-FU + folinic acid (intravenous)
11542068|NCT01060501|Experimental|5-FU + Interferon-alpha|Experimental arm Systemic drug administration of 5-FU + interferon-alpha (intravenous)
11542069|NCT01060488|Active Comparator|Group 1:|
11542070|NCT01060488|Active Comparator|Group 2:|
11542071|NCT01060475|Experimental|A|Low dose LIM-0705 and tacrolimus.
11542072|NCT01060475|Experimental|B|High dose LIM-0705 and tacrolimus.
11542073|NCT01060475|Experimental|C|Placebo LIM-0705 and tacrolimus.
11542074|NCT01060475|Experimental|D|High dose LIM-0705 and placebo tacrolimus.
11542075|NCT01060462||001|Pts. w/ neutropenic fever associated w/ hematologic malignancy Itraconazole 200 mg twice daily for 2 days for a total of 4 doses then 200 mg once daily for 12 days. After 14 days of IV administration itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
11542076|NCT01060449|Other|LV lead low output|"Low output on left ventricular pacing lead.
~Intervention: LV stimulus intensity"
11542077|NCT01060449|Other|LV lead high output|"High output on left ventricular lead
~Intervention: LV stimulus intensity"
11542078|NCT01060423|Experimental|hepatic TACE with irinotecan eluting beads and iv cetuximab|Irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX)
11542079|NCT01060423|Active Comparator|iv cetuximab and irinotecan|systemic treatment with intravenous cetuximab and irinotecan
11542080|NCT01060410||Cyclophosphamide,low dose,continuous|
11542081|NCT01060397|Experimental|Extended Brief Intervention|FRAMES motivational interviewing approach
11542082|NCT01060397|Experimental|Control|Usual care
11542083|NCT01060384|Experimental|Phase 1/Phase II|All participants will receive the same dose of Ofatumumab. There will be three planned dose cohorts for the Lenalidomide in the Phase 1 portion of this trial. A maximum of 18 patients will be enrolled in to Phase 1. Three evaluable patients will be enrolled in to each of the dose cohorts with an additional 3 patients to be enrolled in the maximum tolerated dose (MTD). An additional 29 evaluable patients will be enrolled in to Phase II using the MTD for Lenalidomide that was determined in Phase 1.
11542118|NCT01060163|Experimental|group ET|Patients receiving early CABG <=7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
11542119|NCT01060163|Placebo Comparator|group EP|Patients receiving early CABG <= 7 days of the cessation of clopidogrel, treated with placebo(saline solution)
11542084|NCT01060371||Spinocerebellar Ataxia 1|"If you decide to participate in this study, the following study procedures will be performed:
~blood collection for DNA testing, analysis (genetic modifier study) and banking
~Medical history
~Physical exam
~Scale for Assessment and Rating of Ataxia (SARA)
~Timed measure of your hand dexterity and walking (25 ft)
~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.
~Disease stage estimation by the clinician.
~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)
~Review of your medical records"
11542085|NCT01060371||Spinocerebellar Ataxia 2|"If you decide to participate in this study, the following study procedures will be performed:
~blood collection for DNA testing, analysis (genetic modifier study) and banking
~Medical history
~Physical exam
~Scale for Assessment and Rating of Ataxia (SARA)
~Timed measure of your hand dexterity and walking (25 ft)
~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.
~Disease stage estimation by the clinician.
~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)
~Review of your medical records"
11542086|NCT01060371||Spinocerebellar Ataxia 3|"If you decide to participate in this study, the following study procedures will be performed:
~blood collection for DNA testing, analysis (genetic modifier study) and banking
~Medical history
~Physical exam
~Scale for Assessment and Rating of Ataxia (SARA)
~Timed measure of your hand dexterity and walking (25 ft)
~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.
~Disease stage estimation by the clinician.
~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)
~Review of your medical records"
11542087|NCT01060371||Spinocerebellar Ataxia 6|"If you decide to participate in this study, the following study procedures will be performed:
~blood collection for DNA testing, analysis (genetic modifier study) and banking
~Medical history
~Physical exam
~Scale for Assessment and Rating of Ataxia (SARA)
~Timed measure of your hand dexterity and walking (25 ft)
~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.
~Disease stage estimation by the clinician.
~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)
~Review of your medical records"
11542088|NCT01060358||healthy|Healthy and active men and women between 21 and 45 years old with no history of low back pain or low back injury.
11542089|NCT01060345|Experimental|Women with Ductal Carcinoma in Situ|Women who have been diagnosed with ductal carcinoma in situ (DCIS) and will be taking Polyphenon E
11542090|NCT01060332||diabetics|
11542091|NCT01060306||Bare metal stent 1 month|Patients implanted with the bare metal stent Gazelle evaluated for neointimal coverage one month after implantation
11542092|NCT01060306||Biodegradable polymer stent 6 months|Patients implanted with the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) evaluated for neointimal coverage after full drug elution and polymer biodegradation (6 months)
11542093|NCT01060306||Biodegradable polymer stent 7 months|Patients implanted with the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) evaluated for neointimal coverage one month after full drug elution and polymer biodegradation (7 months)
11542094|NCT01060293|Active Comparator|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
11542095|NCT01060293|Active Comparator|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
11542096|NCT01060293|Active Comparator|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
11542097|NCT01060280|Active Comparator|Education group|Routine clinical practice (includes usual physiotherapy)plus education on active management.
11542098|NCT01060280|Active Comparator|Group GDS physiotherapy|Routine clinical practice (except usual physiotherapy, which is substituted for Group GDS)plus education on active management.
11542099|NCT01060280|Active Comparator|Individual GDS physiotherapy|Routine clinical practice (except for usual physiotherapy, which will be substituted by Group and Individual GDS) plus education on active management.
11542100|NCT01060267|Active Comparator|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
11542101|NCT01060267|No Intervention|Placebo Group endoscopic therapy|Endoscopic therapy of variceal bleeding.
11542102|NCT01060254|Experimental|JNJ-42160443|
11542103|NCT01060254|Placebo Comparator|Placebo|
11542104|NCT01060241|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
11542105|NCT01060241|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
11542106|NCT01060228|Other|001|paliperidone ER 1 tablet of 500 mg once daily on Day 1 and Day 15
11542107|NCT01060228|Other|002|divalproex sodium ER 2 tablets of 500 mg once daily from Days 5 through 18
11542108|NCT01060215|Active Comparator|Infusion|20cc saline infusion into the knee joint
11542109|NCT01060215|No Intervention|No infusion|
11542110|NCT01060202||Bortezomib|
11542111|NCT01060189|Experimental|Ulinastatin|1,000,000 units of ulinastatin in 50ml solution before skin incision; 50ml saline solution after neutralization
11542112|NCT01060189|Experimental|Tranexamic Acid|15mg/kg tranexamic acid in 50ml solution before skin incision; 15mg/kg tranexamic acid in 50ml solution after neutralization
11542113|NCT01060189|Placebo Comparator|Placebo|50ml saline solution before skin incision; 50ml saline solution after neutralization
11542114|NCT01060176|Experimental|High dosage|Tranexamic acid with a loading dose of 30 mg/kg and a maintenance infusion of 20 mg/kg/h
11542115|NCT01060176|Experimental|Medium dosage|Tranexamic acid with a loading dose of 20 mg/kg and a maintenance infusion of 15 mg/kg/h
11542116|NCT01060176|Experimental|Low dosage|Tranexamic acid with a loading dose of 10 mg/kg and a maintenance infusion of 10 mg/kg/h
11542117|NCT01060176|Placebo Comparator|Control|Saline solution
11542120|NCT01060163|Experimental|group LT|Patients receiving late CABG >7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
11542121|NCT01060163|Placebo Comparator|group LP|Patients receiving late CABG >7 days of the cessation of clopidogrel, treated with placebo(saline solution)
11542122|NCT01060163|Experimental|group BT|Patients receiving CABG without preoperative clopidogrel exposure, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
11542123|NCT01060163|Placebo Comparator|group BP|Patients receiving CABG without preoperative clopidogrel exposure, treated with placebo(saline solution)
11542124|NCT01060150|Experimental|OROS Methylphenidate HCl|
11542125|NCT01060137|Experimental|001|fentanyl matrix Fentanyl transdermal patch 12 - 25mcg/hr can increase with 12 - 25mcg/h based on pain assessment
11542126|NCT01060124|Experimental|Transdermal Therapeutic System (TTS)-Fentanyl D-trans|
11542127|NCT01060111|Experimental|Topiramate Standard|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
11542128|NCT01060111|Experimental|Topiramate Slow|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
11542129|NCT01060111|Experimental|Topiramate Slow and Propranolol Booster|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion. Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
11542130|NCT01060098||Rheumatoid arthritis|Participants with Rheumatoid arthritis
11542131|NCT01060098||Ankylosing spondylitis|Participants with Ankylosing spondylitis
11542132|NCT01060098||Psoriatic arthritis|Participants with Psoriatic arthritis
11542133|NCT01060085||Breast Cancer|Women shown to have DCIS or invasive breast cancer by fine needle aspiration cytology and/or core needle biopsy.
11542134|NCT01060072|Experimental|Loteprednol etabonate|Loteprednol etabonate 0.5% ophthalmic suspension
11542135|NCT01060072|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate ophthalmic suspension
11542136|NCT01060059||exenatide|The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide.
11542137|NCT01060059||basal insulin|The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin.
11542138|NCT01060046||Patients with previously implanted biologic mesh|All patients undergoing a repeat operation to repair a recurrent hernia or to revise a surgical site which has been previously repaired using a biologic mesh.
11542139|NCT01060046||Control patients|Any patient undergoing a surgical procedure where fascial biopsy would not compromise the integrity of the procedure.
11542140|NCT01060033|Other|Arm 1|"Clinical T1/T2-weighted MRI sequence per standard of care before treatment, during treatment per standard protocol, and at 3 months.
~Patients may have one or all of the following sequences in addition to the standard MRI imaging:
~MR Spectroscopy
~Fat-saturation and Diffusion-Weighted Imaging
~Dynamic Contrast Enhancement MRI (MR-DCE)
~Diffusion Tensor Imaging (DTI)"
11542141|NCT01060020|Experimental|Sildenafil 40mg or 80mg|A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab. Each dose will be equally distributed among those with preserved (≥50%) and reduced (<50%) EF.
11542142|NCT01060007|Experimental|Neoadjuvant radiation followed by FOLFOX|"Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.
~FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat ever other week for a total of 4 courses (this equals 6 weeks).
~If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days."
11542143|NCT01059994|Placebo Comparator|placebo sildenafil young|Younger subjects (ages 20-35) were administered placebo sildenafil orally daily for 1 week.
11542144|NCT01059994|Experimental|sildenafil young|Younger subjects (ages 20 -35) were administered sildenafil daily (25 mg/day) orally for 1 week.
11542145|NCT01059994|Placebo Comparator|placebo sildenafil older|Older subjects (ages 60-80) were administered placebo sildenafil orally daily for 1 week.
11542146|NCT01059994|Experimental|sildenafil older|Older subjects (ages 60 - 80) were administered sildenafil daily (25 mg/day) orally for 1 week.
11542147|NCT01059981||1|Dialysis patients
11542148|NCT01059981||2|Trauma patients
11542149|NCT01059981||3|Patients with carbon monoxide poisoning
11542150|NCT01059968||adolescent female endurance athletes|High school female cross country runners in San Diego.
11542151|NCT01059955|Experimental|Active treatment at day 0 and day 7|"Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and one at Day 7.
~The three iontophoresis doses are:
~Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA
~Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA
~Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA"
11542152|NCT01059955|Active Comparator|Active Treatment at Day 0, Sham Treatment at Day 7|"Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and a sham treatment Day 7.
~The three iontophoresis doses are:
~Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA
~Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA
~Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA"
11542153|NCT01059942||Hospitalist physicians/house-staff|Consented Academic Hospitalist and Internal Medicine Residency staff
11542322|NCT01058668|Experimental|Cariprazine (6-12 mg/day)|Cariprazine 6 mg - 12 mg capsules oral administration, once per day for 3 weeks.
11542154|NCT01059929|Active Comparator|Dexmedetomidine|Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
11542155|NCT01059929|Active Comparator|Propofol|Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
11542156|NCT01059903|Experimental|Rotigotine PR2.2.1 first|Rotigotine transdermal patch 4.5 mg/10 cm^2, test drug product PR2.2.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm^2, reference drug product PR2.1.1 separated by a washout phase of at least 5 days
11542157|NCT01059903|Experimental|Rotigotine PR2.1.1 first|Rotigotine transdermal patch 4.5 mg/10 cm^2, reference drug product PR2.1.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm^2, test drug product PR2.2.1 separated by a washout phase of at least 5 days
11542158|NCT01059890|Experimental|Cefotaxime|
11542159|NCT01059890|Experimental|Metrodinazole|
11542160|NCT01059890|Experimental|Ciprofloxacine|
11542161|NCT01059890|Experimental|Fosfocine|
11542162|NCT01059877|Active Comparator|1072nm Infrared Photobiomodulation|Received treatment for dementia with transcranial 1072nm infrared light stimulation.
11542163|NCT01059877|Placebo Comparator|Placebo|Placebo device simulated transcranial photobiomodulation
11542164|NCT01059864|Experimental|Arm 1|
11542165|NCT01059864|Experimental|Arm 2|
11542166|NCT01059851|Experimental|Participants with Severe Renal Impairment (Part I)|"Participants with severe renal impairment will receive a
~single dose of 20 mg open-label suvorexant during Part I of the
~study."
11542167|NCT01059851|Experimental|Healthy Participants (Severe Impairment Controls) (Part I)|Healthy participants matched to participants with severe renal impairment will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
11542168|NCT01059851|Experimental|Participants with Moderate Renal Impairment (Part II)|Participants with moderate renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
11542169|NCT01059851|Experimental|Healthy Participants (Moderate Impairment Controls) (Part II)|Healthy participants matched to participants with moderate renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
11542170|NCT01059851|Experimental|Participants with Mild Renal Impairment (Part II)|Participants with mild renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
11542171|NCT01059851|Experimental|Healthy Participants (Mild Impairment Controls) (Part II)|Healthy participants matched to participants with mild renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
11542172|NCT01059838|Experimental|single subject|
11542173|NCT01059825|Placebo Comparator|Placebo|Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days
11542174|NCT01059825|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
11542175|NCT01059825|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
11542176|NCT01059825|Experimental|Ertugliflozin 10 mg|Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days
11542177|NCT01059825|Experimental|Ertugliflozin 25 mg|Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days
11542178|NCT01059825|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days
11542179|NCT01059812|Experimental|IDegAsp BID|
11542180|NCT01059812|Active Comparator|BIAsp 30 BID|
11542181|NCT01059799|Experimental|IDeg OD|
11542182|NCT01059799|Active Comparator|IGlar OD|
11542183|NCT01059786|Experimental|Arm 1|Rituximab + Bendamustine at 70 mg/m2 for initial tolerability study (closed)
11542184|NCT01059786|Experimental|Arm 2|Rituximab + bendamustine at 90 mg/m2 for initial tolerability study (closed)
11542185|NCT01059786|Experimental|Arm 3|Rituximab + Bendamustine (at the tolerated dose)
11542186|NCT01059786|Active Comparator|Arm 4|Rituximab + Pentostatin
11542187|NCT01059773|Experimental|Immediate Methotrexate Cessation|Patients will receive ustekinumab by SC injection at Weeks 0, 4, 16, 28 and 40. The last dose of methotrexate will be taken anytime in the week prior to baseline (week 0).
11542188|NCT01059773|Active Comparator|Gradual Reduction of Methotrexate|Patients will receive ustekinumab by SC injection at Weeks 0, 4, 16, 28 and 40. Patients will gradually reduce the dose of methotrexate over the 4 week period after week 0.
11542189|NCT01059760|Other|Fasting Day First|28±4 hours of water-only fasting followed by 28±4 hours fed
11542190|NCT01059760|Other|Fed Day First|28± 4 hours fed followed by 28± 4 hours of fasting
11542191|NCT01059747||treatment group|
11542192|NCT01059721|Experimental|Soft tissue realignment|group cohort label
11542193|NCT01059708||CO poisoned children|Children, ages 6-16, who have been poisoned by carbon monoxide
11542194|NCT01059682|Experimental|Dalcetrapib|
11542195|NCT01059682|Placebo Comparator|Placebo|
11542196|NCT01059669||Patients|Patients with suspected Chronic Pancreatitis
11542197|NCT01059669||Control group|Healthy controls
11542198|NCT01059656|Experimental|1:Pazopanib|Pazopanib 800mg/j
11542199|NCT01059643|Experimental|LY2523355|
11542200|NCT01059630|Active Comparator|Bendamustine Alone|Participants will receive bendamustine 120 milligrams per meter square (mg/m^2) Intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.
11542201|NCT01059630|Experimental|Obinutuzumab + Bendamustine|"Induction phase: Participants will receive bendamustine 90 mg/m^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants will also receive obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6.
~Maintenance phase: Participants with complete response (CR), partial response (PR) or stable response (SD) then will receive obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurs first)."
11542202|NCT01059617|Experimental|Flulaval/Arepanrix Group|subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
11542203|NCT01059617|Experimental|Flulaval/Unadjuvanted Arepanrix Group|subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
11542204|NCT01059617|Experimental|Placebo/Arepanrix Group|subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
11542205|NCT01059617|Experimental|Placebo/Unadjuvanted Arepanrix Group|subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
11542206|NCT01059604||Pregnant women exposed to sumatriptan, naratriptan, or combo|Women exposed to sumatriptan, naratriptan or the sumatriptan-naproxen combination treatment during pregnancy
11542207|NCT01059591|Experimental|Active|GSK424887 once daily
11542208|NCT01059591|Placebo Comparator|Placebo|Placebo once daily
11542209|NCT01059578|Experimental|Active|GSK206136 once daily
11542210|NCT01059578|Placebo Comparator|Placebo|Placebo once daily
11542211|NCT01059565|Experimental|AZLI|Participants were randomized to receive AZLI for up to 24 weeks and may have continued to receive AZLI during the open-label phase for up to an additional 24 weeks.
11542212|NCT01059565|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match AZLI for up to 24 weeks and may have switched to AZLI during the open-label phase for up to 24 weeks.
11542213|NCT01059552|Experimental|vorinostat|Dose escalation of vorinostat, cisplatin, pemetrexed and radiation
11542214|NCT01059539|Experimental|Cariprazine 3-12 mg/day for 16 weeks|Participants received cariprazine 1.5 mg orally on Day 1 and cariprazine 3.0 mg orally on Days 2 and 3. Starting on Day 4, the dose could be increased in increments of 3 mg every 2 days up to a maximum dose of 12 mg, if the response was not adequate and there were no tolerability issues based on the judgment of the principal investigator.
11542215|NCT01059526||Patients naive to KALBITOR|HAE patients that have not been treated with KALBITOR (ecallantide) prior to enrollment in the study
11542216|NCT01059526||Patients non- naive to KALBITOR|HAE patients that have been treated with KALBITOR prior to enrollment in the study
11542217|NCT01059500|Other|Pilot Phase|First 300 patients will be assigned to arm 1 to test the accuracy of the webtool output.
11542218|NCT01059500|Experimental|Webtool output|Phase 2- Intervention, One group will receive the numeric PTP estimate from webtool output, the other groupwill not receive the nemuric PTP estimate
11542219|NCT01059487|Other|Traditional Chinese Medicine|Assessing efficacy of treating subjects/patients with Traditional Chinese Medicine (TCM) by administering SF-36v2 and PIQ-6 surveys to subjects/patients to create a baseline and then re-assessing quality of life achieved through TCM treatments by administering follow-up SF-12v2 and PIQ-6 surveys every four weeks
11542220|NCT01059474|Experimental|DMPS|We will recruit 10 healthy adult volunteers, over 18 years of age, who eat at least three servings of fish per week (since this diet is associated with detectable levels of mercury in the urine which may rise following chelation). Patients with known allergies to DMPS or sulfa drugs or history of neurologic or renal disease will be excluded. We will also control for number of mercury containing dental amalgams. History will be obtained regarding any potential mercury exposures or recent vaccinations.
11542221|NCT01059461|Experimental|Cerebrolysin®, neuroregeneration|Injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
11542222|NCT01059448|Experimental|210mg AMG 827|AMG 827 210mg at baseline, week 1, week2, and every 2 weeks thereafter
11542223|NCT01059435|Placebo Comparator|Placebo|Participants were randomized to receive a single dose of matching placebo administered by subcutaneous or intravenous injection.
11542224|NCT01059435|Experimental|Romosozumab|Participants were randomized to receive a single dose of romosozumab administered by subcutaneous or intravenous injection. The starting dose was 0.1 mg/kg, with sequential escalation up to 10 mg/kg.
11542225|NCT01059409|Experimental|Meniscal Allograft|
11542226|NCT01059396|Experimental|Propranolol|
11542227|NCT01059396|Experimental|carvedilol|
11542228|NCT01059396|Placebo Comparator|Placebo|
11542229|NCT01059383|Experimental|VECAM 40/300|
11542230|NCT01059383|Active Comparator|Esomeprazole 20 mg|
11542231|NCT01059370|Experimental|Autonomic dysrefleksia|Autonomic dysreflexia in SCI when emptying bowels or filling bladder
11542232|NCT01059357|Experimental|Transoral Robotic Surgery (TORS)|Transoral Robotic Surgery (TORS) using the Da Vinci Robotic Surgical System
11542233|NCT01059344|Experimental|Mesalamin|4.8g Mesalamin (800mg tablet)
11542234|NCT01059344|Placebo Comparator|Placebo|4.8g Placebo to Mesalamin (800 mg tablet)
11542235|NCT01059331|Experimental|Pregabalin|
11542236|NCT01059331|Placebo Comparator|Sugar pill|
11542237|NCT01059318|Experimental|Everolimus|"All patients received a starting dose of everolimus 2.5mg/day for 4 weeks, followed by a dose of 5 mg/day for 4 weeks and finally a dose of 10mg/day for 18 weeks.
~The 26 week treatment period was followed by an optional extension period wherein patients continued therapy until the last patient had completed 26-weeks of treatment. The longest period a patient participated in the study was 62 weeks."
11542238|NCT01059305|Experimental|Erlotinib|150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
11542239|NCT01059279||FMF patients|15 FMF patients with double mutations MEFV, mail sex, from the age from 18 to 30. treated with colchicine, without attacks not less than 2 months
11542240|NCT01059279||healthy people|Healthy individuals, that participated in the study of Heller Institute of Medical Research.
11542241|NCT01059266|Active Comparator|conventional regimen of PURETHAL Grasses|"Initial treatment:
~6 incremental weekly subcutaneous doses of 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 ml (week 1, 2, 3, 4, 5, 6).
~Maintenance treatment:
~0.5 ml in intervals according to registered scheme (week 8, 10, 12, 16)."
11542242|NCT01059266|Experimental|rush regimen of PURETHAL Grasses|"Initial treatment:
~3 incremental weekly subcutaneous doses of 0.1, 0.3, and 0.5 ml (week 1, 2, 3)
~Maintenance treatment:
~3 monthly doses of 0.5 ml (week 7, 11, 15)."
11542243|NCT01059253|Experimental|Training|15 training sessions
11542244|NCT01059188|Experimental|Cetuximab, Cisplatin, Docetaxel, Radiotherapy and Surgery|
11542245|NCT01059175|Experimental|CRT With Dual Site LV Pacing|Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
11542246|NCT01059175|Active Comparator|Standard CRT|Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
11542247|NCT01059162|Experimental|IOPtiMate|patients will undergo non-penetrating laser assisted filtering surgery by the IOPtiMate (OT-134) system
11542248|NCT01059149|Experimental|receive real rTMS|For real rTMS, pulses will be delivered at a frequency of 5 Hz for 6s with a 54s interval, with an intensity equal of 90% of the motor threshold as established at Baseline. 20-min real stimulation sessions will be administered 5 days a week for a period of 2 weeks
11542249|NCT01059149|Placebo Comparator|sham rTMS|For sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo procedures will be used administered 5 days a week for a period of 2 weeks.
11542250|NCT01059136|Experimental|1:Spironolactone|Aldosterone blockade on top of standard therapy
11542251|NCT01059136|No Intervention|2:Standard therapy|Standard therapy
11542252|NCT01059123|Experimental|1:Short treatment|amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day 6 days.
11542253|NCT01059123|Active Comparator|2:Usual treatment|amoxicillin 50 mg/kg/24H ; I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day up to day 14.
11542254|NCT01059110|Experimental|Salicylate ointment|Salicylate ointment under occlusion (pomade M.O Cochon®)
11542255|NCT01059110|Experimental|Imiquimod|Imiquimod : Aldara®
11542256|NCT01059110|Experimental|5-fluoro-uracil|5-fluoro-uracil cream : Efudix®
11542257|NCT01059110|Experimental|Cryotherapy|liquid nitrogen : Cryotherapy
11542258|NCT01059097|Active Comparator|High volume surgeons|high volume surgeons performed at least 18 PD/year.
11542259|NCT01059097|Active Comparator|Low volume surgeons|low volume surgeons performed less than 18 PD/year.
11542260|NCT01059071|Experimental|DFMO and Etoposide|
11542261|NCT01059058|Active Comparator|Test Group A: MI Paste Plus Group|
11542262|NCT01059058|Active Comparator|Test Group B: Fluoride Varnish Group|
11542263|NCT01059058|Placebo Comparator|Control Group|
11542264|NCT01059045|Experimental|Cryocontact therapy|
11542265|NCT01059045|No Intervention|Control|
11542266|NCT01059032|No Intervention|Unenhanced images|
11542267|NCT01059032|Other|Enhanced images|Enhanced images
11542268|NCT01059019|Sham Comparator|Control|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients.
11542269|NCT01059019|Experimental|Treatment|20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day
11542270|NCT01059006|Experimental|PresbyLASIK|Male or female patients with presbyopic symptoms who underwent PresbyLASIK.
11542271|NCT01058993|Experimental|AMD3100 or plerixafor|SINGLE arm study with increasing doses of Plerixafor
11542272|NCT01058980|Active Comparator|Dormant PV conduction|"After PVI, dormant conduction will be evaluated using intravenous adenosine. If dormant conduction is present, the patients will be randomized to two parallel groups:
~Group 1: No additional ablation
~Group 2: Additional ablation until elimination of dormant conduction."
11542273|NCT01058980|Active Comparator|No dormant PV conduction|If no dormant conduction is documented, patients will be selected in a random fashion to be included in a registry (follow-up as planned for group 1 and 2 above). The registry group will allow for further assessment of the role of dormant conduction as a predictor of AF recurrence by comparing the success rate after ablation in patients without dormant conduction with those of Group 1 and 2.
11542274|NCT01058967||major trauma victims|Code 3 patients (highest acuity) admitted to hospital via air ambulance service
11542275|NCT01058941|Experimental|Lipoic acid and Omega-3 fatty acids|Three 1-gram fish oil capsules per day (2 capsules in the morning and 1 capsule in the evening) plus two lipoic acid (LA) capsules per day in the morning. Total daily dose of study drug: 675 mg DHA, 975 mg EPA, 600 mg LA.
11542276|NCT01058941|Placebo Comparator|Placebo|Three placebo oil capsules per day (2 capsules in the morning and 1 capsule in the evening) plus two placebo LA capsules per day in the morning.
11542277|NCT01058928||Group ID 7.5|Patients with a tracheal tube ID (internal diameter) 7.5 mm
11542278|NCT01058928||Group ID 8.0|Patients with a tracheal tube ID 8.0 mm
11542279|NCT01058915|Active Comparator|Rosuvastatin 5mg|Rosuvastatin 5mg/day for one year
11542280|NCT01058915|Active Comparator|Rosuvaststin 40mg|Rosuvastatin 40mg/day
11542281|NCT01058902|Placebo Comparator|Negative control|Not on aspirin pre operatively, but refuse to enter trial or have a contraindication to aspirin
11542282|NCT01058902|Experimental|Aspirin treatment|group randomised to aspirin
11542283|NCT01058902|Experimental|No aspirin treatment|Randomised to no aspirin
11542284|NCT01058902|Active Comparator|Positive control|Already on aspirin. just observational limb
11542285|NCT01058889|Experimental|Telemedical device|Patient will receive a blood glucose measurement device and a telemedical device to monitor blood glucose measurements.
11542286|NCT01058889|No Intervention|Treatment as usual|
11542287|NCT01058876|Experimental|Usual Cigarette|African American and White Smokers will smoke their usual cigarette and also undergo an oral pharmacokinetics protocol after administration of 3 mg deuteriumlabeled nicotine and 5 mg deuterium-labeled cotinine.
11542288|NCT01058876|Experimental|Low-yield Cigarette|"African American and White smokers will smoke a commercial cigarette with a machine-determined nicotine yield of approximately 50% of their usual brand."
11542289|NCT01058863|Experimental|Albuterol Spiromax® 90 mcg|A single dose of albuterol 90 mcg delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler. Placebo inhalers used to maintain the blind.
11542290|NCT01058863|Experimental|Albuterol Spiromax® 180 mcg|A single dose of albuterol 180 mcg delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler (2 inhalations). Placebo inhalers used to maintain the blind.
11542291|NCT01058863|Active Comparator|ProAir® HFA 90 mcg|A single dose of albuterol 90 mcg delivered with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.
11542292|NCT01058863|Active Comparator|ProAir® HFA 180 mcg|A single dose of albuterol 180 mcg delivered with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler (2 inhalations). Placebo inhalers used to maintain the blind.
11542293|NCT01058863|Placebo Comparator|Placebo Inhaler|Placebo delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler, and with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.
11542294|NCT01058850|Experimental|Rindopepimut (EGFRvIII Vaccine, CDX-110)|
11542295|NCT01058824|Active Comparator|Lincomycin - Active Comparative - Hard Gelatin Capsule|
11542296|NCT01058824|Experimental|Lincomycin - Study Drug - Hard Gelatin Capsule|
11542297|NCT01058785|Experimental|Lucanix|Patients will receive injections of Lucanix for each dose cohort.
11542298|NCT01058772|Experimental|INDUCTION of LABOUR|"At enrollment patients assigned to the induction group will be admitted to the obstetric ward and will undergo induction of labour as described in the intervention section.
~Once patient's Bishop score exceeds 7 or regular contractions are diagnosed, patients will be transferred to the delivery ward for artificial rupture of membranes (ARM) or Oxytocin augmentation as indicated."
11542299|NCT01058772|No Intervention|EXPECTANT MANAGEMENT|"Patients enrolled in the conservative management arm will be followed up twice weekly for foetal wellbeing by Non-stress test and Biophysical profile. Patients will be followed up to 41+0 weeks.
~Patients, who will not deliver by this gestational age, will be admitted for labour induction (see the above protocol). Induction of labour will be offered when non-reassuring foetal status is suspected. All patients in the conservative arm will undergo foetal weight ultrasound estimation prior to induction. Patients with estimated foetal weight over 4000 gr will be offered a C-section."
11542300|NCT01058759|Experimental|Arm B: Enoxaparin|
11542301|NCT01058759|Active Comparator|Arm A: No Enoxaparin|
11542302|NCT01058746|Active Comparator|pts undergoing pancreatic resection Restrictive arm|All patients will receive Normosol or equivalent solution, 0.5 ml/kg/fasted hour IV (approximately from 8am to time of induction) during induction of anesthesia. All patients will then receive maintenance fluids consisting of Normosol or equivalent solution at 6 ml/kg/operative hour. After randomization occurs, those patients randomized to the Restricted Arm will continue to receive Normosol or equivalent solution at 6ml/kg/operative hour.
11542303|NCT01058746|Active Comparator|pts undergoing pancreatic resection Liberal arm|All patients will receive Normosol or equivalent solution, 0.5 ml/kg/fasted hour IV (approximately from midnight to time of induction) during induction of anesthesia. All patients will then receive maintenance fluids consisting of Normosol or equivalent solution at 6 ml/kg/operative hour. Those patients randomized to the Liberal Arm will receive an additional Normosol bolus or equivalent solution equal to (another) 1.5 ml/kg/fasted hour IV (to bring the total to 2 ml/kg/fasted hour) plus an additional bolus of Normosol or equivalent solution 6ml/kg/operative hour to bring the hourly rate to 12ml/kg/operative hour with a maximum of 1000 ml/operative hour.
11542304|NCT01058733|Other|Internet|New clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
11542305|NCT01058720|Experimental|Vitamin D3|Patients would receive 2000 IU of vitamin D3 daily for 12 weeks
11542306|NCT01058707|Experimental|MLN0128 QD|MLN0128 2 mg, 4 mg, 6 mg or 7 mg, capsule, orally, once daily (QD) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 52.1 weeks).
11542307|NCT01058707|Experimental|MLN0128 QW|MLN0128 7 mg, 10 mg, 15 mg, 20 mg, 30 mg or 40 mg capsule, orally, once weekly (QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 139.4 weeks).
11542308|NCT01058707|Experimental|MLN0128 QDx3d QW|MLN0128 6 mg, 9 mg, 12 mg, 16 mg or 20 mg capsule, orally, once daily every 3 days a week (QDx3d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 129.4 weeks).
11542309|NCT01058707|Experimental|MLN0128 QDx5d QW|MLN0128 7 mg, 10 mg or 13 mg capsule, orally, once daily every 5 days a week (QDx5d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 161.9 weeks).
11542310|NCT01058707|Experimental|MLN0128 5 mg QD|MLN0128 5 mg, capsule, orally, QD in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 98.3 weeks).
11542311|NCT01058707|Experimental|MLN0128 30 mg QW|MLN0128 30 mg, capsule, orally QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 240 weeks).
11542312|NCT01058707|Experimental|MLN0128 40 mg QW|MLN0128 40 mg, capsule, orally, QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 100.1 weeks).
11542313|NCT01058694|Experimental|Weekly SMS, brief message|Weekly SMS received on Monday at 12 noon
11542314|NCT01058694|Active Comparator|Control Group|Receives a phone, but no messages.
11542315|NCT01058694|Experimental|Daily SMS, Brief message|"Receive daily brief message at 12 noon: This is your reminder"
11542316|NCT01058694|Experimental|Daily SMS, Long Message|"Receive a daily long message at 12 noon: This is your reminder + encouragement"
11542317|NCT01058694|Experimental|Weekly SMS, Long Message|"Weekly message sent at 12 noon on Mondays: This is your reminder + encouragement"
11542318|NCT01058681|Other|isocaloric|impacts of isocaloric nutrition on LH pulsatility in euglycemic and hyperinsulinemic clamps
11542319|NCT01058681|Other|hypercaloric|impacts of hypercaloric nutrition on LH pulsatility in euglycemic and hyperinsulinemic clamps
11542320|NCT01058681|Other|per os and IV glucose during the clamp|impacts of per os glucose on LH pulsatility in euglycemic and hyperinsulinemic clamps
11542321|NCT01058668|Experimental|Cariprazine (3-6 mg/day)|Cariprazine 3 milligrams (mg) - 6 mg capsules oral administration, once per day for 3 weeks.
11542323|NCT01058668|Placebo Comparator|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
11542324|NCT01058655|Experimental|Phase I Cohort 1: Everolimus 5 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
11542325|NCT01058655|Experimental|Phase I Cohort 2: Everolimus 10 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
11542326|NCT01058655|Experimental|Phase I Cohort 3: Everolimus 10 mg + Tivozanib 1.5 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
11542327|NCT01058655|Experimental|Phase II: Everolimus 10 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
11542328|NCT01058642|Experimental|ADL5747|ADL5747 150 milligrams (mg) administered orally as 1 ADL5747 150-mg capsule and 1 placebo capsule twice daily (BID) for 14 days during 1 of 2 Treatment Periods.
11542329|NCT01058642|Placebo Comparator|Placebo|"Placebo: two placebo capsules administered orally BID for 14 days during 1 of 2 Treatment Periods.
~Participants were also administered placebo orally BID during a 14-day washout period that took place between Treatment Period 1 and Treatment Period 2."
11542330|NCT01058642|Active Comparator|Pregabalin|Pregabalin administered orally as a dose of 1 pregabalin 75-mg capsule and 1 placebo capsule BID for the first 3 days, increased to a dose of 1 pregabalin 150-mg capsule and 1 placebo capsule BID for the last 11 days of 1 of 2 fourteen-day Treatment Periods, followed by a dose of 1 pregabalin 75-mg capsule and 1 placebo capsule BID for 3 days as a taper period.
11542331|NCT01058629|Experimental|SynergEyes A2 Hybrid Contact Lens|
11542332|NCT01058603|Active Comparator|D3|
11542333|NCT01058603|Experimental|D5|
11542334|NCT01058564|Experimental|Implant device|
11542335|NCT01058551|Experimental|Reveal XT ILR|Implantable Loop Recorder Insertion
11542336|NCT01058538|Experimental|L19IL2|
11542337|NCT01058525|Active Comparator|nerve block|median nerve block (6 ml lidocaine 1.5 % with adrenalin 1:200000)
11542338|NCT01058525|Experimental|median nerve block after hydro-dissection|median nerve block (6 ml lidocaine 1.5 % with adrenalin 1:200000) after hydro-dissection (glucose 5% solution)
11542339|NCT01058512|Experimental|Single|single-arm study
11542340|NCT01058499|Experimental|MBSR|
11542341|NCT01058486|Experimental|Activity-Self Management|
11542342|NCT01058486|No Intervention|Usual Care|
11542343|NCT01058473||Sickle Cell Disease|
11542344|NCT01058460|No Intervention|cytology|Subjects in the control arm will receive conventional cytology testing and HPV testing at baseline. Follow up management will be based on the cytology result according to current practice.
11542345|NCT01058460|Experimental|HPV-cytology|Subjects in the HPV-cytology arm will receive HPV testing and cytology testing at baseline. Follow up management will be based on both results.
11542346|NCT01058447|Experimental|1|
11542347|NCT01058434|Experimental|TKI258|
11542348|NCT01058421|Experimental|Intensive physical therapy|four week intervention of daily intensive physical therapy
11542349|NCT01058421|Active Comparator|control group|
11542350|NCT01058408|Experimental|Rad001 with cisplatin|
11542351|NCT01058395|Experimental|800 mg loading then 200 mg Q12|Minocycline 800 mg. loading followed by 200 mg. Q 12 hours.
11542352|NCT01058395|Experimental|800 mg loading then 400 mg Q12|Minocycline 800 mg. loading followed by 400 mg. Q 12 hours.
11542353|NCT01058382||Progesterone Vaginal Suppositories|
11542354|NCT01058382||Intramuscular Progesterone-in-Oil|
11542355|NCT01058369|Experimental|Deferasirox|
11542356|NCT01058356||IBD research group in KASID|KASID is Korean Association Study of Intestinal Disease. It has several research group suh as inflammatory bowel disease (IBD) research group.
11542357|NCT01058343|Experimental|IFN-K 1|IFN kinoid dose 1
11542358|NCT01058343|Experimental|IFN-K-2|IFN kinoid dose 2
11542359|NCT01058343|Experimental|IFN-K 3|IFN kinoid dose 3
11542360|NCT01058343|Experimental|IFN-K 4|IFN kinoid dose 4
11542361|NCT01058343|Placebo Comparator|Saline|saline at same dose as IFN K
11542362|NCT01058330|Active Comparator|Plyometric physical training|Individualized plyometric training program to increase strength, coordination, and bone density.
11542363|NCT01058330|No Intervention|Control Group|This group will have no intervention
11542364|NCT01058317|Experimental|Children treated with propranolol|
11542365|NCT01058304|Experimental|Group Physical Therapy for Knee OA|Group Physical Therapy for Knee OA
11542366|NCT01058304|Active Comparator|Individual Physical Therapy for Knee OA|Individual Physical Therapy for Knee OA
11542367|NCT01058291|Experimental|KW-6500|
11542368|NCT01058291|Placebo Comparator|KW-6500 Placebo|
11542369|NCT01058278|Active Comparator|Prednisone acetate 1%|A topic cortisone-based treatment
11542370|NCT01058278|Active Comparator|diclofenac 0.1%|an non-steroidal anti-inflammatory drug
11542371|NCT01058278|Placebo Comparator|Artificial Tears|Pharmasciences DIN: 02229570
11542372|NCT01058265|Experimental|Integrative|Integrative Medical care is defined as a comprehensive medical evaluation that emphasizes wellness and healing of the whole person as major goals above and beyond suppression of a specific somatic disease. The patient is viewed as a whole person with mind and spirit as well as body and these dimensions are incorporated into diagnosis and treatment plans. An integrative medicine evaluation includes four aspects of health: physical, emotional, mental and spiritual health. Maximum improvement in health is achieved by addressing each aspect through an integrated treatment plan. The evaluation generally takes 90-120 minutes.
11542373|NCT01058265|Active Comparator|Standard|Standard general medical evaluation.
11542374|NCT01058252||Letrozole, recFSH, IVC, Monitoring|Infertile couple following MSP with IVC
11542375|NCT01058239|Experimental|Rituximab plus Bortezomib|This is a single arm trial adding the new drug bortezomib to the standard drug rituximab
11542539|NCT01057160|Active Comparator|previous used analgesic|
11542376|NCT01058213|Active Comparator|Aerobic training alone|8 weeks of gentle chair (sham) training followed by 8 weeks of interval aerobic training on a stationary bicycle
11542377|NCT01058213|Experimental|Sequential Resistance then Aerobic Training|8 weeks of resistance training of the lower body followed by 8 weeks of interval aerobic training on a stationary bicycle
11542378|NCT01058213|Active Comparator|Concurrent resistance and aerobic training|8 weeks of gentle chair (sham) exercise followed by 8 weeks of concurrent resistance training of the lower body and interval aerobic training on a stationary bicycle
11542379|NCT01058200|Active Comparator|vacuum extractor 'iCUP'|new vacuum extractor: sterile disposable plastic cup
11542380|NCT01058200|Sham Comparator|reference vacuum extractor|reference cup of the obstetrical ward: metallic cup
11542381|NCT01058187||Control|Marketed cow milk-based infant formula containing DHA and ARA
11542382|NCT01058187||Investigational 1|Cow milk-based infant formula with differing level of ARA from Control formula
11542383|NCT01058187||Investigational 2|Cow milk-based infant formula with a differing level of ARA from Control
11542384|NCT01058174|Experimental|micafungin|intravenous infusion
11542385|NCT01058174|Active Comparator|standard care|intravenous infusion
11542386|NCT01058161|Other|Suspects or affected by rheumatoid polyarthritis|
11542387|NCT01058161|Other|stiffening spondylitis with axial and peripheral infringement|
11542388|NCT01058161|Other|polyarthralgies with or without arthritis|Affected by connectivity with anti-nuclear antibody positive and / or specific antibodies, suffering of polyarthralgias with or without arthritis
11542389|NCT01058161|Other|Healthy control|
11542390|NCT01058161|Other|not inflammatory control|Presenting a degenerative osteoarthritis of the wrist traumatic comment, noticed radiologically, which will serve as not inflammatory control.
11542391|NCT01058122||Patients on the ward|
11542392|NCT01058109|Experimental|calcium group|dietary calcium intake of 1500 mg/d
11542393|NCT01058109|Experimental|calcium-rich diet (1500 mg/d)|calcium intake from food
11542394|NCT01058096|Experimental|Cariprazine|Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
11542395|NCT01058096|Placebo Comparator|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
11542396|NCT01058083|Experimental|BMS-770767 (Treatment A)|
11542397|NCT01058083|Experimental|BMS-770767 (Treatment B)|
11542398|NCT01058083|Experimental|BMS-770767 (Treatment C)|
11542399|NCT01058083|Experimental|BMS-770767 (Treatment D)|
11542400|NCT01058083|Placebo Comparator|Placebo (Treatment E)|
11542401|NCT01058070|Experimental|Implantable Device|
11542402|NCT01058057|Experimental|Atorvastatin|Atorvastatin 80mg seven days pre-treatment before PCI
11542403|NCT01058044|Experimental|adherence assessment group|evaluation of adherence using MEMS
11542404|NCT01058031|Experimental|Arm 1|MBSR
11542405|NCT01058018|Experimental|A - 100 mg per day RVX000222|Arm A: Treatment with RVX000222 at 50 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
11542406|NCT01058018|Experimental|B - 200 mg per day RVX000222|Arm B: Treatment with RVX000222 100 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
11542407|NCT01058018|Experimental|C - 300 mg per day RVX000222|Arm C: Treatment with RVX000222 150 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
11542408|NCT01058018|Placebo Comparator|D - Placebo|Arm D: Treatment with placebo for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
11542409|NCT01058005|Experimental|Natalizumab|
11542410|NCT01058005|Active Comparator|Interferon Beta-1a|
11542411|NCT01058005|Active Comparator|Glatiramer Acetate|
11542412|NCT01057992|Experimental|Implantable Device|
11542413|NCT01057979|Experimental|MET + CM for Exercise|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.
11542414|NCT01057979|Active Comparator|MET + Exercise Contracting|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
11542415|NCT01057966|Experimental|ICAPS AREDS Softgel Capsule - Full Strength|ICAPS Eye Vitamin and Mineral Supplement - Softgel
11542416|NCT01057966|Experimental|ICAPS AREDS Softgel Capsule - Half Strength|ICAPS Eye Vitamin and Mineral Supplement - Softgel (half -strength)
11542417|NCT01057966|Experimental|ICAPS AREDS coated tablets - Full Strength|ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets
11542418|NCT01057953|No Intervention|Patient|Blood sample for patient included
11542419|NCT01057940||PEJ placement|Patients who have failed conventional DPEJ placement and would otherwise require surgical intervention.
11542420|NCT01057927|Experimental|OC000459|
11542421|NCT01057927|Placebo Comparator|Placebo|
11542422|NCT01057914|Experimental|Supplemention|
11542423|NCT01057914|Experimental|Dietary advice|
11542424|NCT01057914|Experimental|Combination treatment|
11542425|NCT01057914|No Intervention|Usual care|
11542426|NCT01057901|Experimental|Flibanserin 100 mg|Flibanserin 100 mg administered at bedtime
11542427|NCT01057901|Placebo Comparator|Placebo|This is the matched placebo which will be administered two tablets daily at bedtime.
11542428|NCT01057888|Experimental|Autodialer|Autodialer reminder/recall
11542429|NCT01057888|Experimental|Letters|Mailed reminder letters
11542430|NCT01057888|No Intervention|Controls|Controls
11542431|NCT01057875|Experimental|coffee with caffeine|
11542432|NCT01057875|Placebo Comparator|decaffeinated coffee|Starbuck's Grande Pike Roast Decaf
11542433|NCT01057862|Experimental|Naltrexone|
11542434|NCT01057862|Placebo Comparator|Placebo|
11542435|NCT01057849|Experimental|Risperidone, Intensive|risperidone and intensive psychosocial intervention
11542436|NCT01057849|Active Comparator|risperidone, basic|risperidone and basic psychosocial support
11542437|NCT01057849|Experimental|olanzapine, intensive|olanzapine and intensive psychosocial intervention
11542438|NCT01057849|Active Comparator|olanzapine, basic|olanzapine and basic psychosocial support
11542439|NCT01057849|Experimental|aripiprazole, intensive|aripiprazole and intensive psychosocial intervention
11542440|NCT01057849|Active Comparator|aripiprazole, basiv|aripiprazole and basic psychosocial support
11542441|NCT01057836|Experimental|Neck strength training|
11542442|NCT01057836|Experimental|Neck endurance training|
11542443|NCT01057836|Active Comparator|Stretching|
11542444|NCT01057823||Inpatient Elders Age 50 and up|The study population is community-dwelling ambulatory patients age 50 or above hospitalized on the University of Chicago general medicine service. Exclusion criteria include: (1) transfer from the ICU or another hospital; (2) cognitively impaired; (3) not ambulatory; (4) residents of a nursing home or skilled nursing facility; (5) on bedrest; (6)documented sleep disorder in their medical history (i.e. obstructive sleep apnea, narcolepsy, etc).
11542445|NCT01057810|Experimental|Ipilimumab|
11542446|NCT01057810|Placebo Comparator|Placebo|
11542447|NCT01057797|Experimental|Upper Body Strength Training with Self-Efficacy|16 weeks of upper body strength training combined with an exercise-specific self-efficacy enhancing intervention
11542448|NCT01057797|Active Comparator|Upper body strength training|16 weeks of upper body strength training with weekly health education sessions
11542449|NCT01057797|Sham Comparator|Chair exercise|16 wks of gentle chair exercise with weekly health education
11542450|NCT01057784||Bariatric Surgery Patients|Patients undergoing bariatric surgery.
11542451|NCT01057784||Reproductive-Age Women - Bariatric Surgery Patients|This subgroup of patients will include 10 reproductive-age women.
11542452|NCT01057771|Experimental|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
11542453|NCT01057771|Experimental|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
11542454|NCT01057771|No Intervention|Waiting list control|Waiting list control subjects will be treated exactly like those in active intervention groups, but will not receive interventions.
11542455|NCT01057758|Placebo Comparator|PLACEBO|Half of the patients will be randomized to the placebo
11542456|NCT01057758|Active Comparator|Simvastatin|Half of the subjects will receive the active drug, Simvastatin.
11542457|NCT01057732||primary hyperparathyroidism|patients with primary hyperparathyroidism
11542458|NCT01057732||controls|subjects without primary hyperparathyroidism
11542459|NCT01057719|Experimental|Physiotherapy in Spain|Daily inpatient physiotherapy for four weeks in a warm climate
11542460|NCT01057719|Experimental|Physiotherapy in Norway|Daily inpatient physiotherapy for four weeks in a cold climate
11542461|NCT01057706|Experimental|9 months of chiropractic care and exercise|chiropractic, exercise
11542462|NCT01057706|Active Comparator|3 months of chiropractic care and exercise|chiropractic, exercise
11542463|NCT01057693|Experimental|pregabalin (Lyrica)|
11542464|NCT01057693|Placebo Comparator|Placebo|
11542465|NCT01057680|Experimental|creatine|This arm will involve creatine supplementation 0.1 g per kg body mass per day while participating in a resistance training program (1 hour per day, 3 days per week).
11542466|NCT01057680|Placebo Comparator|Sugar|This arm will involve placebo (maltodextrin) given every day while the participant does a resistance training program (1 hour per day, 3 days per week).
11542467|NCT01057667|Experimental|Arm A: With RO5024048|Patients in arm A will receive RO5024048 (1000mg orally twice daily) for 24 weeks in addition to Pegasys (180 micrograms sc weekly) and Copegus (1000mg or 1200mg orally daily).
11542468|NCT01057667|Active Comparator|Arm B: Standard treatment|Patients in arm B will receive standard treatment with Pegasys (180 micrograms sc weekly) and Copegus (1000mg or 1200mg orally daily) for 48 weeks.
11542469|NCT01057654|Experimental|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
11542470|NCT01057654|Active Comparator|Pravastatin|Pravastatin 40 mg per day
11542471|NCT01057641|Experimental|Spacer|"Implantation of a percutaneously implanted interspinous device (spacer)"
11542472|NCT01057641|Other|physiotherapy|The control group will receive at least physiotherapy and physical therapy (e.g. massage and fango). Under inpatient conditions therapy will last for seven days. After discharge physical therapy has to be continued for 5 weeks. A schedule will ensure the consistency of the physical therapy. The inpatient-treatment can be repeated every 6 months if necessary.
11542473|NCT01057628|Experimental|ASP1941 group|oral
11542474|NCT01057628|Placebo Comparator|placebo group|oral
11542475|NCT01057615|Experimental|Active Fish Oil + Vitamin C Placebo|Fifteen subjects will take 10 active fish oil capsules per day and 2 vitamin C placebo capsules per day for 3 weeks.
11542476|NCT01057615|Experimental|Fish Oil Placebo + Active Vitamin C|Fifteen subjects will take 10 fish oil placebo capsules per day and 2 active vitamin C capsules per day for 3 weeks.
11542477|NCT01057615|Experimental|Active Fish Oil + Active Vitamin C|Following a 2-week washout period, all subjects from the other two arms (n=30) will take 10 active fish oil capsules per day and 2 active vitamin C capsules per day for 3 weeks.
11542478|NCT01057602||Normal community dwelling elders|Individuals age 65 and older who live in the community
11542479|NCT01057589|Experimental|Pemetrexed + Cisplatin + Cetuximab|"Participants will receive pemetrexed,cisplatin and cetuximab for up to 6 cycles (21 days per cycle) followed by optional maintenance of pemetrexed and cetuximab until disease progression. Optional maintenance therapy is permitted after at least 4 cycles of triplet combination therapy have been given. Cetuximab will be administered as an initial dose of 400 milligram per meter squared (mg/m^2) intravenous (IV) infusion and as a 250 mg/m^2 IV weekly dose thereafter.
~As Standard of care dietary supplements included: 350 to 1000 micrograms (µg) oral Folic Acid 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed and 1000 µg vitamin B12 intramuscular injection (IM) during the week preceding the first dose of pemetrexed and every 9 weeks thereafter."
11542480|NCT01057576|Experimental|PMI 5011|An experimental group randomized to PMI 5011
11542481|NCT01057576|Placebo Comparator|Placebo|Placebo
11542482|NCT01057563|Active Comparator|BMS group|Patients undergoing PCI with BMS implantation
11542540|NCT01057147|Experimental|rebamipide 2% ophthalmic suspension|
11542483|NCT01057563|Active Comparator|PRE-DEB group|Patients undergoing PCI with BMS implantation after lesion predilation with DEB
11542484|NCT01057563|Active Comparator|POST-DEB group|Patients undergoing PCI with BMS implantation followed by postdilation with DEB
11542485|NCT01057550|Active Comparator|Autologous Fascial Sling|Retropubic, bottom up autologous sling
11542486|NCT01057550|Active Comparator|TVT|Standard retropubic TVT
11542487|NCT01057550|Active Comparator|Pelvicol|Retropubic mid urethral sling made from Pelvicol
11542488|NCT01057537|Experimental|polypill|Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2.
11542489|NCT01057537|Active Comparator|Usual Care|Participants in the usual care arm will take their usual cardiovascular medications. The participants will be seen as needed by their usual doctor between study visits.
11542490|NCT01057524|Active Comparator|Usual Airway Clearance Technique|Two self administered treatment sessions a day and two treatments a day assisted by a Physiotherapist both using the patient's usual airway clearance method.
11542491|NCT01057524|Experimental|High Frequency Chest Wall Oscillation (HFCWO)|Two self administered treatments a day using HFCWO and two treatment sessions a day assisted by a Physiotherapist using their 'usual' airway clearance method.
11542492|NCT01057511|Active Comparator|progesterone|Each subject in this group will be give progesterone oil 20mg via intramuscular route once a day for 7 days totally
11542493|NCT01057511|Experimental|Crinone 8%|Each subjects in this group will be given Crinone 8% 90mg via vaginal route once a day for 7 days totally.
11542494|NCT01057498|Experimental|1a - RNS60 in Healthy Subjects|Single dose administration of nebulized RNS60 testing for bronchoconstriction in healthy human subjects.
11542495|NCT01057498|Experimental|1b: RNS60 in Mild Asthmatics|Single-dose administration of nebulized RNS60 testing for bronchoconstriction in mild asthmatics.
11542496|NCT01057498|Experimental|2e: RNS60 in mild-to-moderate asthmatics|RNS60 in mild-to-moderate asthmatics who are not currently taking a chronic asthma medication.
11542497|NCT01057485|Experimental|AF ablation and AV node ablation|Patients will receive the combined procedure of AF ablation as well as AV node ablation
11542498|NCT01057485|Active Comparator|AV node ablation|Patient will receive AV node ablation alone
11542499|NCT01057472||Term born babies|Term born babies
11542500|NCT01057472||Preterm babies ready for discharge|Preterm babies ready for discharge
11542501|NCT01057472||Preterm stable babies 1500 grams|Preterm stable babies 1500 grams
11542502|NCT01057459||Ancillary-Correlative (biomarkers and treatment outcomes)|Genomic DNA is extracted from previously collected blood samples for KIR and HLA genotyping and polymorphism analysis.
11542503|NCT01057433|Experimental|Pitavastatin|Healthy adult subjects
11542504|NCT01057420|Other|Inhalation of 80% Oxygen|Inhalation of 80% Oxygen by nonrebreathing reservoir face masks for 4 hours
11542505|NCT01057407|Experimental|ASP group|
11542506|NCT01057407|Active Comparator|Sevelamer group|
11542507|NCT01057394|Active Comparator|Radiofrequency Ablation|PVI using RF ablation
11542508|NCT01057394|Experimental|Visually Guided Ablation|PVI using visually guided ablation with an endoscopic ablation system
11542509|NCT01057381|Active Comparator|Dexmedetomidine 0.75 mcg/kg|Intraoperative administration for analgesia.
11542510|NCT01057381|Active Comparator|Dexmedetomidine 1mcg/kg|Intra-operative administration of dexmedetomidine 1 mcg/kg for analgesia
11542511|NCT01057381|Active Comparator|Morphine 50 mcg/kg|Intra-operative administration of morphine 50 mcg/kg for analgesia
11542512|NCT01057381|Active Comparator|Morphine 100mcg/kg|Intra-operative administration of morphine 100mcg/kg for analgesia
11542513|NCT01057368|Active Comparator|Mindfulness Based Stress Reduction|
11542514|NCT01057368|Active Comparator|Health Enhancement Program|
11542515|NCT01057368|No Intervention|Wait List Controls|
11542516|NCT01057368|Active Comparator|Long Term Meditators|
11542517|NCT01057355|Experimental|Cyst ethanol lavage|Subjects receiving the study intervention
11542518|NCT01057342|Experimental|Paclitaxel, Carboplatin, ASA404|
11542519|NCT01057329||Anorexia nervosa|36 severe AN patients treated with aripiprazole
11542520|NCT01057329||Anorexia|36 severe anorexia nervosa patients treated with olanzapine
11542521|NCT01057329||Attention Deficit Hyperactivity Disorder|30 ADHD patients treated with atomoxetine
11542522|NCT01057329||Depressive disorder|30 depressed patients treated with duloxetine
11542523|NCT01057316|Experimental|Study Group A|
11542524|NCT01057316|Experimental|Study Group B|
11542525|NCT01057316|Experimental|Study Group C|
11542526|NCT01057277|Experimental|RAD001(Afinitor)|Radiation 47 days Cisplatin day 1,8,15,22,29,36,43 RAD001 Day 1 according to assigned group to day 47
11542527|NCT01057264|Experimental|HAI Abraxane + Gemcitabine + Bevacizumab|HAI (hepatic arterial infusions) Abraxane with Gemcitabine + Bevacizumab
11542528|NCT01057251|Experimental|1|
11542529|NCT01057251|Placebo Comparator|2|
11542530|NCT01057238|Experimental|Intensive Communication|regular family meeting every 5 days.
11542531|NCT01057238|No Intervention|Control|usual care
11542532|NCT01057225|Experimental|Arm I|Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28.
11542533|NCT01057212|Experimental|Bevacizumab and Ixabepilone|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks. Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule to the remaining 40 patients.
11542534|NCT01057186||hereditary hypophosphatemia|Norwegian patients with hereditary hypophosphatemia.
11542535|NCT01057186||Hereditary hyperphosphatemia|Norwegian patients with hereditary hyperphosphatemia (hyperphosphatemic familial tumoral calcinosis and hyperphosphatemia hyperostosis syndrome).
11542536|NCT01057173|Experimental|Transcatheter Aortic Valve Implantation|
11542537|NCT01057173|Active Comparator|Surgical Aortic Valve Replacement|
11542538|NCT01057160|Experimental|intake of rizatriptan 10 mg|
11542541|NCT01057147|Placebo Comparator|placebo eye drops|
11542542|NCT01057121|Experimental|Lenalidomide|Patients receive lenalidomide PO once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11542543|NCT01057108|Active Comparator|ESRD: FOSTRAP Chewing Gum|
11542544|NCT01057108|Active Comparator|CKD: FOSTRAP Chewing Gum|
11542545|NCT01057108|Placebo Comparator|ESRD Matching Placebo|
11542546|NCT01057108|Placebo Comparator|CKD Matching Placebo|
11542547|NCT01057082|Experimental|Juven|Participants in the treatment arm will receive the dietary supplement Juven.
11542548|NCT01057082|Placebo Comparator|Placebo|
11542549|NCT01057069|Experimental|HRD; 1x ddAC, 2x tCTC|HRD positive tumors; irrespective of response; - a fourth course of AC followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
11542550|NCT01057069|Active Comparator|HRD; 3x CP|HRD tumors; any response to 3x ddAC; 3 courses of CP
11542551|NCT01057069|Active Comparator|non-HRD;3x CP|non-HRD tumors; unfavourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel
11542552|NCT01057069|Active Comparator|non-HRD; response; 3x ddAC|non-HRD tumors; favourable response to 3x ddAC; 3 more courses of ddAC
11542553|NCT01057069|Active Comparator|non-HRD; response; 3x CP|non-HRD tumors; favourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel
11542554|NCT01057056|No Intervention|control group|control group - receiving standard treatment
11542555|NCT01057043|No Intervention|Waiting list|In case of acute pain patients may take paracetamol as rescue medication, maximum dosage 2 gram per day.
11542556|NCT01057043|Experimental|Cupping|In case of acute pain patients may take paracetamol as rescue medication, maximum dosage 2 gram per day.
11542557|NCT01057030|Active Comparator|A1 (BMS-708163)|Healthy Japanese Subjects
11542558|NCT01057030|Placebo Comparator|A2 (Placebo)|Healthy Japanese Subjects
11542559|NCT01057030|Active Comparator|B1 (BMS-708163)|Healthy Non-Japanese Subjects
11542560|NCT01057030|Placebo Comparator|B2 (Placebo)|Healthy Non-Japanese Subjects
11542561|NCT01057017|Experimental|intervention|"Bevacizumab: 7.5mg/kg, IV over 30-90 minutes every 3 weeks until disease progression.
~Panitumumab Dose Level 1: 6mg/kg over 60-120 minutes every 3 weeks until disease progression Dose Level 2: 9mg/kg over 60-120 minutes every 3 weeks until disease progression"
11542562|NCT01057004||all patients|chronical heart failure and EF ≤ 40 %
11542563|NCT01056991|Experimental|warming mattress|Patient warmed with electric mattress
11542564|NCT01056991|Active Comparator|warming blanket|Forced air warming blanket
11542565|NCT01056978||patients|Patients admitted in a palliative care unit
11542566|NCT01056965|Experimental|davunetide (Al-108, NAP) nasal spray|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with either davunetide 15 mg or placebo. Davunetide and placebo will be administered intranasally with a multi-dispensing, metered nasal spray pump device.
11542567|NCT01056965|Placebo Comparator|Placebo nasal spray|
11542568|NCT01056952|Experimental|Optiflow then CPAP|Standard low flow oxygen therapy then High flow oxygen nasal therapy (Optiflow)then Continuous positive airway pressure (CPAP)
11542569|NCT01056952|Experimental|CPAP then Optiflow|Standard low flow oxygen therapy then Continuous positive airway pressure (CPAP)then High flow oxygen nasal therapy (Optiflow)
11542570|NCT01056939|Active Comparator|NAVA|Children randomised in this arm will be treated with neurally adjusted ventilatory assist
11542571|NCT01056939|Active Comparator|Control|Patients randomized to control group will be treated with pressure controlled ventilation (PC) when they are newborns and older children in this group will be treated with pressure regulated volume controlled (PRVC) ventilation.
11542572|NCT01056926|Experimental|Nicotine Patch + Denic Smoking|Subjects will wear a nicotine patch and smoke denic cigarettes for 24 hours prior to scan
11542573|NCT01056926|Experimental|Placebo Patch + Denic Smoking|Subjects will wear a placebo patch and smoke denic cigarettes 24 hours prior to scan
11542574|NCT01056926|Experimental|Nicotine Patch + No Smoking|Subjects will wear a nicotine patch and not smoke for 24 hours prior to scan
11542575|NCT01056926|Experimental|Placebo Patch + No Smoking|Subjects will wear a placebo patch and not smoke for 24 hours prior to scan
11542576|NCT01056913|Other|NITI CAR27 (ColonRing)|
11542577|NCT01056900||Chondron Implantation|This clinical trial was a follow-up study involving 127 patients from 10 hospitals, for whom autologous chondrocyte transplantation was already performed. All the subjects were investigated as a single group
11542578|NCT01056887||Primary Polydip, D. insipidus|
11542579|NCT01056874|Active Comparator|Digoxin|
11542580|NCT01056874|Experimental|Digoxin + Maraviroc|
11542581|NCT01056861||Cervical dystonia (torticollis)|Subjects meeting the criteria fot torticollis who are receiving botulinum toxin injections.
11542582|NCT01056861||Control|age matched controls with out cervical dystonia (torticollis)
11542583|NCT01056848||CK-LX3401|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia.
11542584|NCT01056848||CK-LX3405|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia
11542585|NCT01056848||CK-LX3430|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia
11542586|NCT01056835|No Intervention|control|
11542587|NCT01056822|Active Comparator|1|Mycophenolate mofetil
11542588|NCT01056822|Experimental|2|Miycophenolate sodium
11542589|NCT01056809|Active Comparator|Traditional strategy|First resection of the primary colorectal tumour, then treatment of metastases with chemotherapy and if possible surgery.
11542590|NCT01056809|Active Comparator|Alternative strategy|First treatment of metastases with chemotherapy and if possible surgery, later resection of primary colorectal tumour if hope for cure or if symptoms develope that necessitates treatment
11542633|NCT01056471|Experimental|High dose|The dose of infused cells is 4*10e6 cells/Kg
11542634|NCT01056471|No Intervention|Placebo Control|
11542591|NCT01056796|Experimental|CAR™ 27|Any patient with a diagnosis of colorectal cancer that has been previously radiated to the pelvic area (6-8 weeks prior to surgery) and that is electively scheduled for an open or laparoscopic total mesorectal excision (TME) and low anterior resection surgery (< 10cm from the anal verge) which requires the creation of an anastomosis, will be offered participation in this study.
11542592|NCT01056783|Experimental|OC000459|OC000459 100mg twice daily
11542593|NCT01056783|Placebo Comparator|Placebo|
11542594|NCT01056770|Experimental|Vaccinia-naive group|2.5 * 10^5 pfu/dose
11542595|NCT01056757|Experimental|Ribavirin|
11542596|NCT01056744|Active Comparator|DES|Implantation of a XIENCE® V everolimus eluting coronary stent (drug-eluting stent, DES)
11542597|NCT01056744|Active Comparator|BMS/DEB|Implantation of a Coroflex Blue® coronary stent (bare metal stent, BMS) postdilated with a Sequent Please® paclitaxel-eluting balloon (drug-eluting balloon, DEB)
11542598|NCT01056731|Experimental|Aliskiren and Aliskiren_HCTZ|aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg 25 mg
11542599|NCT01056718|Other|Nebivolol treatment|10 week open label nebivolol treatment.
11542600|NCT01056705|Experimental|Cohort 1: Experiment Infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections;
11542601|NCT01056705|Experimental|Cohort 2: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections;
11542602|NCT01056705|Experimental|Cohort 3: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections;
11542603|NCT01056705|Experimental|Cohort 4: Experiment infants|Biological: Oral Poliomyelitis Vaccine (OPV).3x0.1ml oral;
11542604|NCT01056705|Experimental|Cohort 5: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Salk strains). 3x0.5ml intramuscular injections;
11542605|NCT01056692|Active Comparator|Active compound|OC000459 orally
11542606|NCT01056692|Placebo Comparator|Placebo|Placebo given orally
11542607|NCT01056679|Experimental|AVD-Rev|Patients with intermediate stage HL receive 4 cycles of AVD-Rev followed by 30 Gy IF-RT Patientes with advanced stage HL receive 6 to 8 cycles of AVD-Rev followed by 30 GY IF-RT depending on the FDG-PET results
11542608|NCT01056666|Experimental|Conveen optima urisheaths|
11542609|NCT01056666|Placebo Comparator|absorbent protections|The patient use their usual absorbent protection as comparator. All brands are allowed.
11542610|NCT01056653|Experimental|Group A Teal|Standard Dose - Two intervention home visits (at 4 and 6 months of age)
11542611|NCT01056653|Experimental|Group B Purple|High Dose - Four intervention home visits (at 4, 5, 6, and 7 months of age)
11542612|NCT01056653|Sham Comparator|Group C Yellow|Comparison Group - One home visit, information only (at 4 months of age)
11542613|NCT01056640|Experimental|Home Telemonitoring|The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line. This device has video monitoring which allows a real time face to face interaction with the provider. This allows for an individualized home care plan based upon multiple concerns which have not been adequately studied.
11542614|NCT01056640|Active Comparator|Usual Care|The usual care intervention will include appropriate primary care and specialty office practice visits as required. It also includes home health care, timely post-hospital outpatient visits, a nurse generated phone call progress report within one business day of hospital dismissal, and standard clinic phone triage during business hours. It also involves a 24 hour nurse triage line for questions. Patients will be informed of the general options currently available to patients including the above as well as options for care in extended hours and at Mayo Express care.
11542615|NCT01056627|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
11542616|NCT01056627|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
11542617|NCT01056614|Experimental|Treatment (chemotherapy, PBSC transplant)|Patients receive fludarabine phosphate IV over 30 minutes on days -9 to -6, busulfan IV over 3 hours on days -5 to -2, and anti-thymocyte globulin IV over 6 hours on days -3 and -2 and over 4 hours on day -1. Patients undergo allogeneic PBSC transplant on day 0. Patients then receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and taper to day 180 and methotrexate IV on days 1, 3, 6, and 11.
11542618|NCT01056601|Experimental|Pancreatic Cancer Patients|Pancreatic cancer patients who received treatment with bortezomib and panobinostat after progressing on gemcitabine.
11542619|NCT01056588|Placebo Comparator|Control Condition|In this condition, participants will receive reinforcement for timely breath samples with no contingency for a specific breath CO level.
11542620|NCT01056588|Active Comparator|CO-Contingent|In this condition, participants will receive reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking.
11542621|NCT01056575|Experimental|OC000459|
11542622|NCT01056549|Experimental|exenatide subcutaneous injection|Study A: lipoprotein turnover following subcutaneous exenatide administration, under conditions of pancreatic clamp. Study B: lipoprotein turnover study following subcutaneous placebo administration, under conditions of pancreatic clamp.
11542623|NCT01056536|Experimental|Structured intervention + free condoms|The subjects will receive a structured intervention on STI's and will be offered free condoms
11542624|NCT01056536|Active Comparator|Free condoms|Subjects will be offered free condoms at the end of the pre-travel consultation
11542625|NCT01056536|No Intervention|No intervention|The topic of STI's will not be actively discussed during the pretravel consultation
11542626|NCT01056523|Experimental|Ribavirin-Cytarabine arabinoside|Ribavirin will be given orally bid according to a dose escalation scheme daily for 28 days of a 28 day cycle Cytarabine arabinoside will be given 20 mg sc bid days 1 to 10 of a 28 day cycle
11542627|NCT01056510|Experimental|A|
11542628|NCT01056510|Experimental|B|
11542629|NCT01056497|Experimental|alpha lipoic acid|
11542630|NCT01056484|Experimental|Meditation|Mindfulness Based Relapse Prevention for Alcohol Dependence intervention + Standard of Care therapy
11542631|NCT01056484|Other|Wait-list control|Standard of Care therapy only
11542632|NCT01056471|Experimental|Low dose autologous mesenchymal cells|The dose of infused cells is 10e6 cells/Kg
11542635|NCT01056458|Active Comparator|Acupressure acupressure|
11542636|NCT01056458|Sham Comparator|sham acupressure|
11542637|NCT01056445|Active Comparator|carotid stenting and hemodynamic instability|27 patients undergone carotid stenting
11542638|NCT01056445|Active Comparator|carotid stenting without hemodynamic instability|no hemodynamic instability after carotid stenting
11542639|NCT01056419|Active Comparator|Total thyroidectomy|
11542640|NCT01056419|Active Comparator|Anti-thyroid drug|
11542641|NCT01056406|No Intervention|Control Group|Overweight and obese pregnant women who are randomly assigned to the control group will receive the current standard of optimal care in addition to 1 nutrition education session with the study nutritionist (a registered dietitian) at 6-16 weeks gestation.
11542642|NCT01056406|Experimental|Nutrition Education Group|Overweight and obese pregnant women randomly assigned to the nutrition education group, in addition to the current standard of optimal care, will receive twice monthly interaction with the study nutritionist (a registered dietitian) from 6-16 weeks gestation through 6 months postpartum.
11542643|NCT01056393|Experimental|ibalizumab 800mg Q2Weeks|Subject will receive 800mg of ibalizumab every 2 weeks administered by intravenous infusion. All patients also will receive optimized background regimen
11542644|NCT01056393|Experimental|ibalizumab 2000mg Q4Weeks|Subject will receive 2000mg of ibalizumab every 4 weeks administered by intravenous infusion. All patients also will receive optimized background regimen
11542645|NCT01056380|Active Comparator|Nitazoxanide|
11542646|NCT01056380|Placebo Comparator|Placebo|
11542647|NCT01056354||Influenza|Influenza A and subtypes such as H3N2 and 2009 H1N1 or influenza B
11542648|NCT01056354||Novel respiratory virus-1|MERS-CoV (Middle Eastern Respiratory Syndrome Coronavirus)
11542649|NCT01056354||Novel respiratory virus-2|SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus)
11542650|NCT01056341|Experimental|Propranolol oral solution|
11542651|NCT01056341|Placebo Comparator|Placebo|
11542652|NCT01056328|Experimental|St. Jude Medical Cardiac Ablation System|
11542653|NCT01056328|Active Comparator|FDA approved Open Irrigated Radio Frequency Ablation System|
11542654|NCT01056315|Experimental|A GRT3983Y|Participants randomly assigned to receive GRT3983Y.
11542655|NCT01056315|Placebo Comparator|B Placebo|Participants randomly assigned to placebo.
11542656|NCT01056302||Group 1|15 patients who underwent surgical repair of mandibular fractures at San Francisco VA Medical Center
11542657|NCT01056289|Active Comparator|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|
11542658|NCT01056289|Active Comparator|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|
11542659|NCT01056289|Placebo Comparator|Placebo|
11542660|NCT01056276|Experimental|Treatment|Bendamustine, Bortezomib,and Dexamethasone for 8 cycles or 2 cycles beyond a confirmed complete response, assessed by IMWG criteria. Patients with stable disease and no intolerable toxicity may continue maintenance therapy with Bortezomib and Dexamethasone until disease progression or intolerable toxicity.
11542661|NCT01056263||Non-Interventional Study|Subjects participating in this observational study originally participated in study A4061012 [NCT00076011], and may have also have participated in study A4061008 [NCT00828919].
11542662|NCT01056250|Other|SILS cholangiography|Performing cholangiography in all patients undergoing SILS cholecystectomy.
11542663|NCT01056237|Experimental|Multi-target therapy|(Tarcrolimus+mycophenolate mofetil)
11542664|NCT01056237|Active Comparator|Azathioprine|Aza
11542665|NCT01056224|Experimental|1.25 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
11542666|NCT01056224|Experimental|1.5 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
11542667|NCT01056224|Experimental|1.75 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.75 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
11542668|NCT01056224|Experimental|1 ug/kg normo-tensive 65-75 year olds|A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
11542669|NCT01056224|Experimental|1.25 ug/kg normo-tensive 65-75 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
11542670|NCT01056224|Experimental|1.5 ug/kg normo-tensive 65-75 year olds|"1.5 ug/kg normo-tensive 65-75 year olds
~A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old."
11542671|NCT01056224|Experimental|1 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
11542672|NCT01056224|Experimental|1.25 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
11542673|NCT01056224|Experimental|1.5 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
11542674|NCT01056211|Active Comparator|hypopigmented scars treated with laser|patients with hypopigmented scars treated with Starlux 300 Lux 1540nm Fractional laser hand piece
11542675|NCT01056211|Placebo Comparator|hypopigmented scars treated without laser|patients with hypopigmented scars treated without laser
11542676|NCT01056211|Active Comparator|hypertrophic scars treated with laser|
11542677|NCT01056211|Placebo Comparator|hypertrophic scars not treated with laser|
11542678|NCT01056211|Active Comparator|scars due to grafts and reconstructions treated with laser|scars due to grafts and reconstructions in the head and neck region
11542679|NCT01056211|Placebo Comparator|grafts and reconstructions scars not treated with laser|scars due to grafts and reconstructions in the head and neck region
11542680|NCT01056198|Active Comparator|Santyl|2 mm Santyl applied once daily
11542720|NCT01055899|Experimental|Dose 2|Second dose of SC REGN88
11542681|NCT01056198|Sham Comparator|Control|Daily gauze and optional sharp debridement
11542682|NCT01056185||Influenza|Influenza A and subtypes such as H3N2 and 2009 H1N1 or influenza B
11542683|NCT01056185||Novel Respiratory Virus-1|MERS-CoV (Middle East Respiratory Syndrome Coronavirus
11542684|NCT01056185||Novel Respiratory Virus-2|SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus)
11542685|NCT01056172|Active Comparator|A. 24 weeks in RVR patients.|Peginterferon alfa-2a and weight-based ribavirin (800-1200mg/day) for 24 weeks in patients with RVR.
11542686|NCT01056172|Experimental|B. 16 weeks in RVR patients.|Peginterferon alfa-2a and weight-based ribavirin (800-1200mg/day) for 16 weeks in patients with RVR.
11542687|NCT01056159|Experimental|Albuterol dry powder inhaler|The participants will receive albuterol delivered with the a DPI (dry powder inhaler) and placebo with an HFA MDI inhaler (hydrofluoroalkane metered dose inhaler).
11542688|NCT01056159|Active Comparator|Albuterol HFA MDI|The participants will receive albuterol delivered with an HFA MDI inhaler (hydrofluoroalkane metered dose inhaler) and placebo with albuterol in a DPI (dry powder inhaler).
11542689|NCT01056146|Active Comparator|Internet Resources Comparison (IRC)|Participants will receive the Internet resource comparison group treatment
11542690|NCT01056146|Experimental|I-InTERACT|Participants will receive the internet-based parenting skills program.
11542691|NCT01056133|Experimental|Omega-3 capsules-Fish Oil|Omega-3 fatty acids in the form of fish oil capsules (2g/d)
11542692|NCT01056120||ENERGY-Population|"Patient population in standard clinical care, according to the instructions for use and the inclusion / exclusion criteria. Registry patients should be enrolled consecutively to represent a typical set of patients at each site.
~The registry will collect clinical data from patients that have given their prior written consent. All data will be anonymized prior to data entry."
11542693|NCT01056107|Experimental|ROSE-010 30 mcg|A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
11542694|NCT01056107|Experimental|ROSE-010 100 mcg|A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
11542695|NCT01056107|Experimental|ROSE-010 300 mcg|A glucagon-like peptide-1 (GLP-1) analogue. A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
11542696|NCT01056107|Placebo Comparator|Placebo|Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
11542697|NCT01056094|Active Comparator|20mg Lutein|Dietary Supplement: 20mg Lutein; daily supplementation 12 week
11542698|NCT01056094|Active Comparator|10mg Lutein|Dietary Supplement: 10mg Lutein; daily supplementation 12 week
11542699|NCT01056094|Placebo Comparator|0mg Lutein|Dietary Supplement: 0mg Lutein; daily supplementation 12 week
11542700|NCT01056081|Experimental|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).
~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
11542701|NCT01056055||Suture anchor, Bone tunnel|Suture anchor group: patients who underwent the modified Brostrom procedure using suture anchor technique Bone tunnel group: patients who underwent the modified Brostrom procedure using bone tunnel technique
11542702|NCT01056042|Experimental|A|Intramuscular depot medroxyprogesterone acetate
11542703|NCT01056042|Active Comparator|B|ethinyl estradiol 30 micrograms combined with gestodene 75 micrograms
11542704|NCT01056029|Experimental|G-202|
11542705|NCT01056016|No Intervention|Wait-list control|Wait-list control group
11542706|NCT01056016|Experimental|ADHD Collaborative Intervention|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a Diagnostic and Statistical Manual-IV (DSM-IV) based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales. The intervention lasts for 6 months.
11542707|NCT01056003||all patients admitting endoscopy for EGD|
11542708|NCT01055990|Other|Heathy,aged 18-60 years,|They are healthy, are 18-60 years of age, did not have a history of infection with the 2009 H1N1 virus, and are appropriate to vaccination, without any interdictions. And they guardians confirmed that they understood the study procedures, provided written informed consent, and agreed to comply with the following visit schedule. Woman participants all are not pregnant,with a negative pregnancy test before vaccination.
11542709|NCT01055990|Experimental|clinically critical H1N1 patients|The critical H1N1 patients as recipients whose conditions are confirmed according to current standard for critical H1N1 diagnosis. The study wll research H1N1 viral load in blood of critical H1N1 patients and swab nucleic acid testing parallelity; measure H1N1 viral Load in blood and swabs (adopting Real-time PCR method) of 5 to 10 victims; and the planned blood taking time is the tenth day since the fever begins.
11542710|NCT01055964|Experimental|Tacrobell|
11542711|NCT01055964|Active Comparator|Prograf|
11542712|NCT01055951|Experimental|Solo MicroPump|
11542713|NCT01055938|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
11542714|NCT01055938|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
11542715|NCT01055925|Active Comparator|MPV|
11542716|NCT01055925|Active Comparator|Aquacel|
11542717|NCT01055912|Experimental|Lixivaptan|Capsule, 100mg Lixivaptan or matching placebo once daily.
11542718|NCT01055912|Placebo Comparator|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
11542719|NCT01055899|Experimental|Dose 1|First dose of SC REGN88
11542721|NCT01055899|Experimental|Dose 3|Third dose of SC REGN88
11542722|NCT01055886|Active Comparator|Nicotine Patch|Nicotine patch given pre-quit attempt at weeks 4 through 6
11542723|NCT01055886|Placebo Comparator|placebo patch|placebo patch given pre-quit from weeks 4 through 6
11542724|NCT01055860||Robotic sacral colpopexy|Our study population will be women who underwent Robotic assisted laparoscopic sacral colpopexy at the Morristown Memorial Hospital for correction of pelvic organ prolapse using a synthetic polypropylene mesh.
11542725|NCT01055847|Experimental|AI 75 mg|Aztreonam for Inhalation 75 mg twice daily
11542726|NCT01055847|Experimental|AI 225 mg|Aztreonam for Inhalation 225 mg twice daily
11542727|NCT01055847|Placebo Comparator|Placebo|Placebo
11542728|NCT01055834|Experimental|Eszopiclone 3 mg tablet|
11542729|NCT01055834|Experimental|Eszopiclone 1 mg tablet|
11542730|NCT01055821|Active Comparator|Arm A|Standard of care (SOC)
11542731|NCT01055821|Experimental|Arm B|Vaccine and Standard of care
11542732|NCT01055821|Experimental|Arm C|vaccine and standard of care
11542733|NCT01055808||Type 2 diabetes treated with insulin|
11542734|NCT01055795|Experimental|Bevacizumab, Everolimus and LBH589|"Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589
~3-6, All study drugs administered per dose level
~3-6, All study drugs administered per dose level
~3-6, All study drugs administered per dose level
~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B & C; 30, Recommended Phase II Dose for all three compounds"
11542735|NCT01055782|Experimental|With endoguide|Colonoscopy completed with endoguide
11542736|NCT01055782|No Intervention|Without endoguide|Colonoscopy completed without endoguide
11542737|NCT01055769|Other|Group 1|Subjects will accept Linezolid OS 600 MG first, after 4 days wash-out, then will accept Linezolid tablet 600 MG.
11542738|NCT01055769|Other|Group 2|Subjects will accept Linezolid tablet 600 MG first, after 4 days wash-out, then will accept Linezolid OS 600 MG.
11542739|NCT01055756|Experimental|Test (Cloratadd D)|Loratadine + Pseudoephedrine sulfate Test
11542740|NCT01055756|Active Comparator|Comparator (Claritin D)|Loratadine + Pseudoephedrine Comparator
11542741|NCT01055743|Experimental|Radical resection + Fluorouracil Implants|
11542742|NCT01055743|Active Comparator|Radical resection|
11542743|NCT01055730||Pulmonary rehabilitation|
11542744|NCT01055717|Placebo Comparator|Placebo muffin made with no oats|
11542745|NCT01055717|Active Comparator|Test muffin made with AV-enriched oats|
11542746|NCT01055704|Experimental|Methylnaltrexone|
11542747|NCT01055704|Experimental|Codeine|
11542748|NCT01055704|Experimental|Methylnaltrexone + codeine|
11542749|NCT01055704|Placebo Comparator|Placebo|
11542750|NCT01055691|Experimental|1|Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
11542751|NCT01055691|Experimental|2|Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
11542752|NCT01055691|Experimental|3|Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
11542753|NCT01055691|Experimental|4|Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
11542754|NCT01055678|Experimental|All Patients|Single arm study analyzing tumor hypoxia after EF5 injection
11542755|NCT01055652|Experimental|1|
11542756|NCT01055639|Active Comparator|In-person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT). ACT is a psychotherapy intervention comprised of meditation, goal-setting, and behavior change.
11542757|NCT01055639|Experimental|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT). Sessions were delivered via videoconferencing system. ACT is a psychotherapy intervention comprised of meditation, goal-setting, and behavior change.
11542758|NCT01055613|Experimental|Experimental multi-purpose solution|Multi-purpose contact lens care solution.
11542759|NCT01055613|Active Comparator|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution.
11542760|NCT01055600|Experimental|Study|Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
11542761|NCT01055587||major abdominal surgery|The investigators compare the levels of biomarkers in patients with and without complications in the early postoperative course following major abdominal surgery
11542762|NCT01055587||severe burn injury|The investigators compare levels of biomarkers within the first 20 days in patients with and without complications following severe burn injury
11542763|NCT01055574||ProDisc-L|Subjects who received single-level ProDisc-L total disc replacement prior to physical capability evaluations
11542764|NCT01055574||anterior lumbar interbody fusion (AILF)|Subjects who received single-level anterior lumbar interbody fusion prior to physical capability evaluations
11542765|NCT01055561|Experimental|Patients|
11542766|NCT01055561|Experimental|Healthy volunteers|
11542767|NCT01055548||Parents of babies born before 33 weeks gestation|
11542768|NCT01055535|Experimental|Microplasmin|
11542769|NCT01055522|Experimental|ARM 1: L19IL2 + Dacarbazin|
11542770|NCT01055522|Experimental|ARM 2: L19IL2 + Dacarbazin|
11542771|NCT01055522|Active Comparator|ARM 3: Dacarbazin|DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first
11542772|NCT01055509|Experimental|Cognitive Adaptation Training|Cognitive adaptation training and treatment as usual
11542773|NCT01055509|No Intervention|Treatment as ususal|Pharmacological treatment, weekly contact to professionals (often in patient's homes), psychoeducation, social skill training in groups and psychosocial intervention with relatives.
11542774|NCT01055496|Experimental|Arm 1 (R-CVP)|Subjects in arm 1 will be enrolled in dose escalation cohorts that will initially evaluate an escalating dose of cyclophosphamide in combination with set doses of inotuzumab ozogamicin, vincristine, prednisone, and rituximab.
11542775|NCT01055496|Experimental|Arm 2 (R-GDP)|Subjects in arm 2 will be enrolled in dose escalation cohorts that will initially evaluate escalating doses of gemcitabine and/or cisplatinum in combination with set doses of inotuzumab ozogamicin, dexamethasone, and rituximab.
11542777|NCT01055470|Active Comparator|Diclofenac|Tab.Diclofenac 50 mg ,Orally, 12 hrly in morning and in evening after taking food for 3 months.
11542778|NCT01055470|Experimental|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
11542779|NCT01055457|Experimental|Experimental Multi-Purpose Solution|contact lens care solution
11542780|NCT01055457|Active Comparator|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
11542781|NCT01055444|Experimental|Heated lidocaine/tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
11542782|NCT01055431|Placebo Comparator|Control|Control bread
11542783|NCT01055431|Active Comparator|Teff bread|Teff bread
11542784|NCT01055418|Placebo Comparator|placebo|
11542785|NCT01055418|Experimental|Vitamin C|
11542786|NCT01055405|Experimental|Sildenafil plus pulmonary rehabilitation|
11542787|NCT01055405|Placebo Comparator|Placebo plus pulmonary rehabilitation|
11542788|NCT01055392|Experimental|Lithium|Patients received low doses of lithium salts (from 150 mg to 450 mg of lithium salts daily) to achieve sub-therapeutic lithium levels (target serum lithium level of 0,25 - 0,5 mEq/L). Lithium doses were administered twice a day. Lithium doses were titrated to achieve the target serum lithium levels within the first two weeks after study recruitment. After achieving the target serum lithium level, lithium salts doses remained stable until the end of the study.
11542789|NCT01055392|Placebo Comparator|Placebo|Identical placebo tablets were administered twice-a-day for two years.
11542790|NCT01055379|Experimental|Rasagiline|
11542791|NCT01055379|Placebo Comparator|Placebo|
11542792|NCT01055366|Experimental|Elazop (Azarga)|Elazop Treatment arm
11542793|NCT01055340|Experimental|Treatment sequence 1|OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min - Placebo
11542794|NCT01055340|Experimental|Treatment sequence 2|OXM 0.6 pmol/kg/min - Placebo - OXM 3.0 pmol/kg/min
11542795|NCT01055340|Experimental|Treatment sequence 3|Placebo - OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min
11542796|NCT01055340|Experimental|Treatment sequence 4|OXM 3.0 pmol/kg/min - Placebo - OXM 0.6 pmol/kg/min
11542797|NCT01055340|Experimental|Treatment sequence 5|Placebo - OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min
11542798|NCT01055340|Experimental|Treatment sequence 6|OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min - Placebo
11542799|NCT01055327||Infants/foetuses w/malformations registered in EUROCAT network|Pregnancies resulting in foetus/infant with malformation registered through participating registers within the EUROCAT network
11542800|NCT01055314|Experimental|Group 1 (chemotherapy, radiation therapy, cixutumumab)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-5, 7, 8, 11, 12, 15, 16, 20-24, 28, 29, 32, 33, 35, 38, 41-44, 47, 48, 50, and 51; irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 1, 4, 20, 23, 47, and 50; ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 of weeks 9, 13, 17, 26, and 30; doxorubicin hydrochloride IV over 1-15 minutes on days 1 and 2 of weeks 7, 11, 15, 28, and 32; cyclophosphamide IV over 30-60 minutes on day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41, and 44; dactinomycin IV over 1-5 minutes on day 1 of weeks 35, 38, 41, and 44; and cixutumumab IV over 1 hour on day 1 of weeks 1-51. Patients also undergo radiation therapy on days 1-5 of weeks 20-24.
11542801|NCT01055314|Experimental|Group 2 (chemotherapy, radiation therapy, temozolomide)|Patients receive vincristine sulfate, irinotecan hydrochloride, ifosfamide, etoposide, doxorubicin hydrochloride, cyclophosphamide, and dactinomycin and undergo radiation therapy as in group 1. Patients also receive temozolomide PO on days 1-5 of weeks 1, 4, 20, 23, 47, and 50.
11542802|NCT01055301|Experimental|treatment|"Ind (1cycle):
~bort 1mg/m2 IV/SQ D1,4,8,11 D1-4: thalid 200mg/d & dex 20mg/d PO; cisplatin & dox 10mg/m2/d, cyclophos 400mg/m2/d, etoposide 40mg/m2/d contIV; enoxaparin 40mg/d SQ prn.
~PBSC Coll: at recovery per local standard
~Bridging (before/between trans/after Cons):
~thal 50mg/d D1-21 & dex 20mg D1,8,15 PO
~Tandem Trans (x2):
~bort 1mg/m2 IV/SQ D-4,-1 D-4to-1: mel 50 mg/m2 IV, thal 200mg/d & dex 40mg/d PO PBSC >/=200x10^6 cells
~Cons (1cycle):
~same as Ind except cis/dox 7.5mg/m2/d, cyclo 300mg/m2/d, no enox
~Maint(</= 3 yrs):
~D1,8,15,22:bort 1mg/m2 IV/SQ, dex 20mg/d PO; len 20mg/d PO D1-20"
11542803|NCT01055275||Cook Iliac Branch Graft|Patients implanted with a Cook Iliac Branch Graft
11542804|NCT01055262|Experimental|Heatwrap 1|Experimental heatwrap device for the lower back
11542805|NCT01055249|Other|Group A|Ibuprofen 600 mg (active comparator); Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)
11542806|NCT01055249|Other|Group B|Oral Placebo (placebo comparator), Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)
11542807|NCT01055236|Placebo Comparator|hydroxyzine|
11542808|NCT01055236|Placebo Comparator|placebo|starch tablet
11542809|NCT01055223||Type 2 diabetes subjects|Type 2 diabetes subjects
11542810|NCT01055197|Experimental|PCI|Prophylactic Cranial Irradiation (PCI)
11542811|NCT01055197|Experimental|PCI + Consolidation RT|Prophylactic Cranial Irradiation (PCI) plus consolidative radiation therapy (RT) to locoregional and residual metastatic disease
11542812|NCT01055184|Experimental|2009 H1N1 Vaccine|Participants will be stratified by age into two groups: those between 60 and 70 years old, and those older than 70 years of age. All participants will receive the 2009 H1N1 vaccine.
11542813|NCT01055171|Active Comparator|Propranolol|Patients will receive Propranolol in this condition.
11542814|NCT01055171|Placebo Comparator|Placebo|Patient to receive placebo in this condition.
11542815|NCT01055158|Experimental|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes.
11542816|NCT01055158|Active Comparator|Control|Enhanced Usual Care
11542817|NCT01055145|Active Comparator|levofloxacin|Levofloxacin 750mg po per day for 3 months
11542818|NCT01055145|Active Comparator|moxifloxacin|Moxifloxacin 400mg po per day for 3 months
11542819|NCT01055132|Other|Etafilcon A toric contact lens/Nelfilcon A toric|Etafilcon A toric contact lens first, then nelfilcon A toric second
11542820|NCT01055132|Other|Nelfilcon A toric/ Etafilcon A toric|Nelfilcon A toric contact lens first, then etafilcon A toric toric second
11542821|NCT01055119|Active Comparator|Omega-3 fatty acids|
11542822|NCT01055119|Placebo Comparator|Olive oil|
11542823|NCT01055106|Active Comparator|1D|
11542824|NCT01055106|Active Comparator|3D|
11542825|NCT01055106|Active Comparator|5D|
11542826|NCT01055106|Active Comparator|Metronidazole|
11542827|NCT01055093||Diabetes Cohort|Prospectively followed cohort of newly diagnosed patients with diabetes mellitus, aged 18-69 years at inclusion into the study
11542828|NCT01055093||Control Cohort|Prospectively followed cohort of glucose tolerant humans, aged 18-69 years at inclusion into the study
11542829|NCT01055080|Placebo Comparator|Cow's milk formula|
11542830|NCT01055080|Active Comparator|Bovine insulin-free whey based formula|
11542831|NCT01055080|Active Comparator|Whey-based hydrolysed formula|
11542832|NCT01055067|Experimental|Tivantinib (ARQ 197)|3 capsules of 120 mg each, administered twice a day (once in the morning and once in the evening - total daily dose of 720 mg) in continuous 4-week cycles
11542833|NCT01055041|Experimental|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period .All three participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
11542834|NCT01055041|Experimental|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all three participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks
11542835|NCT01055041|Experimental|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
11542836|NCT01055028|Experimental|Regimen A / Treatment 1|"Participants were to receive paclitaxel 200 mg/m² intravenously over 3 hours every 21 days followed by bevacizumab 15 mg/kg intravenously over (cycle 1: 90 min; cycle 2: 60 min; cycles 3 to 6: 30 min) every 21 days x 6 cycles.
~Maintenance bevacizumab (MB), 15 mg/kg once every 21 days intravenously for a maximum of 8 cycles, was initiated after the completion of paclitaxel + bevacizumab combination."
11542837|NCT01055028|Experimental|Regimen B / Treatment 2|"Patients were to receive paclitaxel 90 mg/m² weekly x 3 of a 28-day cycle followed by bevacizumab 15 mg/kg intravenously over (cycle 1: 90 min; cycle 2: 60 min; cycles 3 to 6: 30 min) every 21 days x 6 cycles.
~Maintenance bevacizumab (MB), 15 mg/kg once every 21 days intravenously for a maximum of 8 cycles, was initiated after the completion of paclitaxel + bevacizumab combination."
11542838|NCT01055015|Experimental|1|Q8003, Flexible dose
11542839|NCT01055015|Experimental|2|Q8003, Low dose
11542840|NCT01055002|Active Comparator|Artemether/lumefantrine tablets|Artemether (20 mg) and Lumefantrine (120 mg) tablets: Four tablets taken as a single dose twice a day with fatty food for three days (total dose of 24 tablets in 6 doses) on days 6-8
11542841|NCT01055002|Active Comparator|Atovaquone/Proguanil HCl tablets|Atovaquone (250 mg) and Proguanil HCl (100 mg) tablets: Four tablets taken as a single dose daily for 3 days (total dose of 12 tablets) on days 6-8
11542842|NCT01054989|Active Comparator|Fat intravenously|Intravenous application of fat
11542843|NCT01054989|Active Comparator|Fat orally|Oral fat load
11542844|NCT01054989|Active Comparator|LPS intravenously|Lipopolysaccharide (LPS; US Standard Reference endotoxin)
11542845|NCT01054989|Placebo Comparator|Glycerol intravenously|Intrevenous glycerol infusion
11542846|NCT01054976|Experimental|Galantamine|
11542847|NCT01054950|Experimental|Education and counseling|Phone calls using behavioral techniques
11542848|NCT01054950|Placebo Comparator|Control|Single phone call
11542849|NCT01054937|Experimental|4SC-203|
11542850|NCT01054937|Placebo Comparator|Placebo|
11542851|NCT01054924||U.S. CRC screening population|
11542852|NCT01054911|Experimental|Sunitinib pill|Patients will receive six weeks of sunitinib and then subsequently continue for an additional 6 weeks if the evaluation at 6 weeks shows stable disease or objective response. Restaging CT scans will be performed again after 12 weeks of therapy to determine response in preparation for surgical resection anticipated to occur around week 14-16.
11542853|NCT01054898|Experimental|advocacy intervention|A 12-week telephone social support and empowerment intervention consisting of empowerment training, scheduled weekly telephone calls, and 24-hour access to a hotline for abused women
11542854|NCT01054898|Active Comparator|Usual community services|Standard care for abused women in the community
11542855|NCT01054885|Experimental|Fluticasone Furoate Inhalation Powder|Inhaled Corticosteroid (ICS)
11542856|NCT01054885|Experimental|FF Inhalation Pwdr|Inhaled Corticosteroid (ICS)
11542857|NCT01054885|Experimental|Fluticasone Furoate/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
11542858|NCT01054885|Experimental|FF/GW642444 Inhalation Pwdr|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
11542859|NCT01054885|Experimental|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
11542860|NCT01054885|Placebo Comparator|Placebo|Placebo
11542861|NCT01054872|Experimental|Monozygotic (MZ) Twins|Participants will receive the DNA vaccine at baseline and Months 1 and 2. They will then receive the rAd5 vaccine at Month 6.
11542862|NCT01054872|Experimental|Dizygotic (DZ) Twins|Participants will receive the DNA vaccine at baseline and Months 1 and 2. They will then receive the rAd5 vaccine at Month 6.
11542863|NCT01054859|Experimental|Treatment A|0.5 g/Kg alcohol plus 200 mg avanafil tablet
11542864|NCT01054859|Active Comparator|Treatment B|0.5 g/kg alcohol
11542865|NCT01054859|Active Comparator|Treatment C|200 mg avanafil tablet
11542866|NCT01054846|Experimental|Helmet and helmet education|Each participant preschool child received a free bicycle Bell helmet, manufactured by Bell Sports Inc., Rantoul IL, USA. In addition, classroom bicycle helmet education was provided to all participant children and their caregivers, consisting of a video on rules of biking and the importance of proper helmet use and a classroom melon drop demonstration with and without a helmet to participants and their caregivers.
11542867|NCT01054846|Active Comparator|Helmet education|Each child did not receive a bicycle Bell helmet but the child and his/her caregiver was given bicycle helmet education package as above.
11542868|NCT01054833|Experimental|Needleless sling|Needleless® sling
11542869|NCT01054820|Experimental|FLECTORA Patch (diclofenac epolamine topical patch) 1.3%|One patch applied every 12 hours
11542870|NCT01054807|Other|GalyfilconHL/Galyfilcon8.7/Galyfilcon8.3|Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A 8.3 BC (Experimental)
11542871|NCT01054807|Other|Galyfilcon8.7/Galyfilcon8.3/GalyfilconHL|Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)
11542872|NCT01054807|Other|GalyfilconHL/Galyfilcon8.3/Galyfilcon8.7|Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A 8.7 BC (Experimental)
11542873|NCT01054807|Other|Galyfilcon 8.7/Galyfilcon HL/Galyfilcon 8.3|Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator) /Galyfilcon A 8.3 BC (Experimental)
11542874|NCT01054807|Other|Galyfilcon8.3/GalyfilconHL/Galyfilcon8.7|Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.7 BC (Experimental)
11542875|NCT01054807|Other|Galyfilcon8.3/Galyfilcon8.7/GalyfilconHL|Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)
11542876|NCT01054794|Active Comparator|Stimulation ON|
11542877|NCT01054794|Sham Comparator|Stimulation OFF|
11542878|NCT01054768|Experimental|alpha-lipoic acid and acetyl-L-carnitine|LA and ALCAR 1400 mg tablet twice a day for 6 months.
11542879|NCT01054768|Placebo Comparator|Placebo|1400 mg placebo tablet twice a day for 6 months.
11542880|NCT01054742||Standard of Care PegIntron Plus Ribavirin [Part 2]|Participants who had relapsed during Part 1 of the study, had detectable HCV-RNA on Day 1 of Part 2 of the study, and who were re-treated during Part 2 of the study with standard of care PegIntron plus ribavirin for 48 weeks.
11542881|NCT01054729|Experimental|Sofosbuvir 100 mg+PEG+RBV|Participants received sofosbuvir 100 mg (1 x 100 mg tablet) and placebo to match sofosbuvir (3 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
11542882|NCT01054729|Experimental|Sofosbuvir 200 mg+PEG+RBV|Participants received sofosbuvir 200 mg (2 x 100 mg tablets) and placebo to match sofosbuvir (2 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
11542883|NCT01054729|Experimental|Sofosbuvir 400 mg+PEG+RBV|Participants received sofosbuvir 400 mg (4 x 100 mg tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
11542884|NCT01054729|Active Comparator|Placebo+PEG+RBV|Participants received placebo to match sofosbuvir (4 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
11542885|NCT01054703|Experimental|Ethmoid Sinus Spacer placement|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
11542886|NCT01054690|Experimental|Silver alloyed urinary catheter|
11542887|NCT01054690|Placebo Comparator|Silicone urinary catheter|
11542888|NCT01054677|Experimental|Educational intervention on antibiotic prescribing|The participants in this group received an educational intervention.
11542889|NCT01054677|No Intervention|No educational intervention|The participants in this group did not receive the educational intervention
11542890|NCT01054664||impaired liver enzymes|
11542891|NCT01054664||normal liver enzymes|
11542892|NCT01054664||hepatitis C antibodies positive|
11542893|NCT01054651|Experimental|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
11542894|NCT01054651|Active Comparator|Praziquantel|
11542895|NCT01054638||HIV infected patients: HAART naive or experienced|Patients with a claims diagnosis of HIV infection (HIV, AIDS, or ARC) in the NHI or Impact Databases, according to either of the 3-digit International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes 042 HIV disease and V08 Asymptomatic HIV infection status
11542896|NCT01054638||Patients with HIV infection HAART naïve|A naïve subcohort of patients consisting of HAART initiators. Among the primary cohort, we will exclude patients with a dispensing for any HAART in the 6-month baseline period prior to the cohort entry date.
11542897|NCT01054625|Experimental|zalutumumab 4 mg/kg|zalutumumab 4 mg/kg iv single infusion week 1,3, 4 and 5
11542898|NCT01054625|Experimental|zalutumumab 8 mg/kg|zalutumumab 8 mg/kg iv single infusion week 1, 3, 4 and 5
11542899|NCT01054625|Experimental|zalutumumab 16 mg/kg|zalutumumab 16 mg/kg iv single infusion week 1, 3, 4 and 5
11542900|NCT01054599|Experimental|Memantine|Subjects will randomly assigned to take either a placebo or memantine for 13 weeks. The assignment will be double-blind, neither the study members nor the subject will know if he/she is taking memantine or a placebo.
11542901|NCT01054599|Placebo Comparator|Sugar Pill|Subjects will be randomly assigned to take either memantine or a placebo. The study is double-blind, and neither the study members nor the subject will know if he/she is taking memantine or a placebo.
11542902|NCT01054586||HIV pts w/ HBV or HCV, w/ or w/o mild to moderate HI|Patients with HIV coinfected with HBV or HCV with or without mild to moderate HI who are enrolled in one of the participating HIV patient cohorts. These patients will be exposed to FPV/RTV or LPV/RTV.
11542903|NCT01054573|Experimental|Telaprevir + Standard Treatment|Telaprevir 750 mg orally (by mouth) every 8h for 12 weeks plus standard treatment. Standard treatment is 180 mcg subcutaneous (under the skin) injection pegylated interferon (Peg-IFN) alfa-2a and 1000-1200 mg twice daily ribavirin (RBV) for 48 weeks.
11542904|NCT01054560|Experimental|SOLITAIRE™ Device|The SOLITAIRE™ Device (investigational device) is the experimental arm
11542905|NCT01054560|Active Comparator|MERCI® Device|The MERCI® Device (control device) is commercially available.
11542906|NCT01054547|Placebo Comparator|Liposomal ropivacaine, topical|The topical anesthetics were applied at the region of right and left maxillary lateral incisors at the buccal mucosa.
11542907|NCT01054547|Placebo Comparator|Liposomal ropivacaine, palatal mucosa|Topical formulations were applied at the palatal mucosa at the right canine region and efficacy of topical formulations was accessed through insertion of a 30 gauge needle and injection of anesthetic solution.
11542908|NCT01054534|Other|Placement of interstim lead|Placement of interstim lead using US image fusion technology
11542950|NCT01054274|Active Comparator|novel stent|Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.
11542951|NCT01054274|Experimental|conventional covered stent|Patients undergo placement of a conventional covered stent on day 1.
11542952|NCT01054261|Other|Normal|Normal renal function
11542909|NCT01054521|Experimental|Temperature-controlled RF (TCRF)|The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.
11542910|NCT01054521|Active Comparator|Bipolar RF (BRF)|The bipolar RF (BRF) probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
11542911|NCT01054508|Other|Arm 1: Placebo (4 weeks) --> Placebo (12 weeks) --> Placebo (4 weeks) --> Tredaptive (12 weeks)|Placebo (4 weeks) --> Placebo (12 weeks) --> Placebo (4 weeks) --> Tredaptive (12 weeks) There were two interventional periods of 12 weeks during which patients received either Placebo or Tredaptive (nicotinic acid/laropiprant). Patient who received Tredaptive were given dosages of 1g/20mg for 4 weeks followed by 2g/40mg for 8 weeks.
11542912|NCT01054508|Other|Arm 2: Placebo (4 weeks) --> Tredaptive (12 weeks) --> Placebo (4 weeks) --> Placebo (12 weeks)|Placebo (4 weeks) --> Tredaptive (12 weeks) --> Placebo (4 weeks) --> Placebo (12 weeks) There were two interventional periods of 12 weeks during which patients received either Placebo or Tredaptive (nicotinic acid/laropiprant). Patient who received Tredaptive were given dosages of 1g/20mg for 4 weeks followed by 2g/40mg for 8 weeks.
11542913|NCT01054495|Active Comparator|Acupuncture|Needle acupuncture at acupuncture point pericardium 6
11542914|NCT01054495|Sham Comparator|Sham acupuncture|Non-penetrating sham needling at acupuncture point pericardium 6
11542915|NCT01054495|Placebo Comparator|Laser acupuncture|Laser stimulation at acupuncture point pericardium 6
11542916|NCT01054482|Experimental|Pre-operative chemotherapy|Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op & Post-Op (total 4 cycles)
11542917|NCT01054482|Active Comparator|Pre-operative concurrent chemoradiation therapy|
11542918|NCT01054469|Placebo Comparator|TAP block with placebo|
11542919|NCT01054469|Active Comparator|TAP block with ropivacaine|
11542920|NCT01054456|Experimental|1|
11542921|NCT01054443|Placebo Comparator|placebo|
11542922|NCT01054443|Experimental|0.5 mg|
11542923|NCT01054443|Experimental|0.75 mg|
11542924|NCT01054443|Experimental|1.0 mg|
11542925|NCT01054430|Other|Normal|Subjects with normal hepatic function
11542926|NCT01054430|Other|Mild Hepatic Dysfunction|Subjects with mild hepatic impairment
11542927|NCT01054430|Other|Moderate hepatic dysfunction|Subjects with moderal hepatice impairment
11542928|NCT01054417||Appendicitis|Patients with suspected appendicitis who are to be operated upon by diagnostic laparoscopy
11542929|NCT01054404|Active Comparator|Furosemide|Furosemide 0.3 mg/kg
11542930|NCT01054404|Placebo Comparator|Placebo|Up to 5 mL saline
11542931|NCT01054391|Experimental|NEC Arm|Utilization of NEC (Neurovascular Embolization Cover) for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistulae
11542932|NCT01054365||Delayed Discharge Group (DDG)|D/C at least 24 hours after procedure or at usual discharge time (n =200)
11542933|NCT01054365||Early Discharge Group (EDG)|D/C 6 hours after procedure if no indication for extended stay after randomization (n=200)
11542934|NCT01054352|Experimental|001|JNJ38224342/placebo one of six (6) single ascending doses (25 100 300 600 1250 or 2000 mg) of JNJ 38224342 or matching placebo up to four (4) additional cohorts consisting of healthy male volunteers may be added
11542935|NCT01054352|Experimental|002|JNJ38224342/placebo multiple ascending oral doses (100 250 500 750 mg) of JNJ 38224342 or matching placebo administered for 14 consecutive days in healthy male or female volunteers.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
11542936|NCT01054352|Experimental|003|JNJ38224342 single oral 100mg dose of JNJ 38224342 as a solution versus a single oral dose of JNJ 38224342 as a capsule formulation with and without food in healthy male volunteers
11542937|NCT01054352|Experimental|004|JNJ38224342/placebo multiple oral doses of JNJ38224342 or matching placebo administered for up to 14 consecutive days in male and female volunteers number of days dosed and actual dose levels food requirements and regimens will be determined based on the data from Parts 1 2 and 3.
11542938|NCT01054339|Experimental|Low dose|rAAV1-CB-hAAT at dosage level of 6 x 10e11 vg/kg
11542939|NCT01054339|Experimental|Middle dose|rAAV1-CB-hAAT at dosage level of 1.9 x 10e12 vg/kg
11542940|NCT01054339|Experimental|High dose|rAAV1-CB-hAAT at dosage level of 6 x 10e12 vg/kg
11542941|NCT01054326|Experimental|Supervised physical therapy focusing of rotatorcuff exercises|Patients did specific exercises supervised by a physical therapists twice a week during two months. Focus was on early activation of rotator cuff and scapula stabilizers following different phases in a rehabilitation program Assessments before surgery,1 week after as well as 1,2,3 and 6 months after surgery.
11542942|NCT01054326|Active Comparator|Home exercises|Patients did home exercises following a programme during three months. Assessment considering shoulder function and pain was done before surgery, 1w after as well as 1,2,3 and 6 months after surgery,
11542943|NCT01054313|Experimental|Docetaxel + Sirolimus|Starting doses of Docetaxel 30 mg/m^2 IV every 3 weeks + Sirolimus 1 mg daily
11542944|NCT01054300|Experimental|Cohort 1: Ertu 2 mg/Placebo (Pbo)→Ertu 1 mg/Ertu 1 mg|Period 1: Ertu 2 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
11542945|NCT01054300|Experimental|Cohort 1: Ertu 1 mg/Ertu 1 mg→Ertu 2 mg/Pbo|Period 1: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Pbo in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
11542946|NCT01054300|Experimental|Cohort 2: Ertu 4 mg/Pbo→Ertu 2 mg/Ertu 2 mg|Period 1: Ertu 4 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
11542947|NCT01054300|Experimental|Cohort 2: Ertu 2 mg/Ertu 2 mg→Ertu 4 mg/Pbo|Period 1: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. Period 2: Ertu 4 mg in the AM and Pbo in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
11542948|NCT01054287|Experimental|Falls prevention|
11542949|NCT01054287|Placebo Comparator|Usual care|
11542953|NCT01054261|Other|Mild|Mild renal impairment
11542954|NCT01054261|Other|Moderate|Moderate renal impairment
11542955|NCT01054248|Experimental|MAS3|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
11542956|NCT01054248|Active Comparator|ALN+|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet)
11542957|NCT01054248|Experimental|DP|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
11542958|NCT01054235|Experimental|experimental|The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes). For control ,none of the intervention will be given.
11542959|NCT01054222|Other|Fesoterodine 4 mg|Dose determined as per previous drug regime in A0221045 and investigator's evaluation.
11542960|NCT01054222|Other|Fesoterodine 8 mg|Dose determined as per previous drug regime in A0221045 and investigator's evaluation.
11542961|NCT01054209|No Intervention|A: standard care, no warming|Control arm. Full standard care. No mattress warming. May receive warmed fluids if standard practise for clinician
11542962|NCT01054209|Active Comparator|B: electric warming mattress|Warming with warming mattress
11542963|NCT01054196|Experimental|all patients|subjects will receive daily doses of lenalidomide starting on Day -5 of transplant and melphalan on Days -2 and -1.
11542964|NCT01054183|Experimental|Intubation using GlideScope Ranger|The study site has two critical care transport teams per shift and will, at shift change, assign intubation team A to use the GlideScope Ranger for all intubations on that day.
11542965|NCT01054183|Active Comparator|intubation using direct laryngoscopy|The study site has two critical care transport teams per shift and will, at shift change, assign intubation team B. Team B will do intubations using direct laryngoscopy only that day.
11542966|NCT01054170|Experimental|AZD9668|
11542967|NCT01054170|Placebo Comparator|Placebo|
11542968|NCT01054144|Experimental|Response Adapted Therapy|Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.
11542969|NCT01054118|Experimental|001|JNJ-38431055 Liquid suspension of JNJ-38431055 administered as a single dose
11542970|NCT01054118|Active Comparator|002|Sitagliptin 100 mg Capsule containing 100 mg of sitagliptin administered as a single dose
11542971|NCT01054118|Experimental|003|JNJ-38431055 + Sitagliptin 100 mg Liquid suspension of JNJ-38431055 administered as a single dose and capsule containing 100 mg of sitagliptin administered as a single dose
11542972|NCT01054118|Placebo Comparator|004|Placebo Placebo suspension and placebo capsule administered as single doses
11542973|NCT01054105||Step I: BMPR-2 gene analysis|BMPR-2 gene analysis on 100 IPAH or heritable PAH Patients
11542974|NCT01054105||Step-II: Iloprost and Exercise Echo|Illoprost inhalation for 3 months & Check-up before and after treatment; WHO functional classification Assessment of exercise capacity (6M walk test) Cardiopulmonary exercise echocardiography NT-proBNP
11542975|NCT01054092|Experimental|before meal group|ASP1941 will be administered before meal
11542976|NCT01054092|Experimental|after meal group|ASP1941 will be administered after meal
11542977|NCT01054079|Experimental|Treatment (cinacalcet hydrochloride)|Patients receive cinacalcet hydrochloride PO QD for 20 weeks in the absence of disease progression or unacceptable toxicity.
11542978|NCT01054053||1|children born between 06/04/2004 and 17/04/2008 and called to menBvac vaccination and living around Neufchatel en Bray.
11542979|NCT01054040|No Intervention|Standard nutrition cardiac care|Patients will receive standard care of group nutrition counselling and individual counselling if requested
11542980|NCT01054027|Experimental|0 Drop|Left eye dose
11542981|NCT01054027|Experimental|1 Drop|Left eye dose
11542982|NCT01054027|Experimental|2 drop|Left eye dose
11542983|NCT01054027|Active Comparator|3 drops|Right eye dose for all groups
11542984|NCT01054014|Experimental|001|JNJ-40346527/Placebo Single oral dose of JNJ-40346527 (either 10 50 150 300 600 or 1000mg) or Placebo
11542985|NCT01054014|Experimental|002|JNJ-40346527/Placebo JNJ-40346527 once daily oral dose for 14 days (either 50 150 300 500 or 750mg) or Placebo
11542986|NCT01054014|Experimental|003|JNJ-40346527 JNJ-40346527 150mg one dose either fasting (or with food) then after 7 days off treatment JNJ-40346527 150mg either with food (or fasting)
11542987|NCT01054001|Active Comparator|Early|men with on- demand sildenafil 100mg dosing from the early postoperative period
11542988|NCT01054001|Active Comparator|Delayed|men with on- demand sildenafil 100mg dosing from the delayed postoperative period
11542989|NCT01053988|Experimental|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
11542990|NCT01053988|Experimental|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
11542991|NCT01053988|Experimental|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
11542992|NCT01053988|Placebo Comparator|Placebo|Placebo
11542993|NCT01053988|Experimental|FF/GW642444 Inhalation Pwdr|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
11542994|NCT01053962|Experimental|SP-304 0.3 mg|SP-304 0.3 mg tablet by mouth once daily for 14 consecutive days.
11542995|NCT01053962|Experimental|SP-304 1.0 mg|SP-304 1.0 mg tablet by mouth once daily for 14 consecutive days.
11542996|NCT01053962|Experimental|SP-304 3.0 mg|SP-304 3.0 mg tablet by mouth once daily for 14 consecutive days
11542997|NCT01053962|Experimental|SP-304 9.0 mg|SP-304 9.0 mg tablet by mouth once daily for 14 consecutive days.
11542998|NCT01053962|Placebo Comparator|Placebo|Placebo tablet by mouth once daily for 14 consecutive days
11542999|NCT01053949|Active Comparator|Drug on 21 days per 28 days cycle|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
11543000|NCT01053949|Active Comparator|Drug on 28 days per 28 days cycle|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
11543001|NCT01053936|Experimental|Bardoxolone methyl: 5 mg|
11543002|NCT01053936|Experimental|Bardoxolone methyl: 10 mg|
11543003|NCT01053936|Experimental|Bardoxolone methyl: 15 mg|
11543004|NCT01053936|Experimental|Bardoxolone methyl: 30 mg|
11543005|NCT01053936|Experimental|Bardoxolone methyl: 2.5 mg|
11543006|NCT01053923||MRI Scan|
11543007|NCT01053910|Experimental|Ramipril|Duration of treatment: 2 months 7 first days: 1.25mg once daily in patients with stable heart failure and 7 days 2.5mg once daily or 14 first days:2.5mg once daily in patients without heart failure for 14 more days:5mg once daily maintenance therapy for 1 month: 10 mg (5mg, 2 tablets)
11543008|NCT01053897|Experimental|GBT009|
11543009|NCT01053897|Placebo Comparator|Placebo|
11543010|NCT01053884|Other|Anidulafungin, safety, antifungal drug|single arm study
11543011|NCT01053871|Experimental|1|sedation using propofol
11543012|NCT01053871|Experimental|2|sedation using midazolam with fentanyl
11543013|NCT01053858|Active Comparator|bevacizumab|intravitreal bevacizumab or triamcinolone determined by single physician
11543014|NCT01053858|Active Comparator|triamcinolone|
11543015|NCT01053832|Other|Ventricular Pace Suppression- ON|
11543016|NCT01053832|Other|Ventricular Pace Suppression- OFF|
11543017|NCT01053819|Experimental|Etanercept|open label treatment(50 mg SQ)per Food and Drug Administration approval for 24 weeks
11543018|NCT01053793|Active Comparator|Glucose Standard|
11543019|NCT01053793|Experimental|Potato Variety|
11543020|NCT01053767|No Intervention|Arm 1|This is a phlebotomy study.
11543021|NCT01053741|Experimental|Seminal Fluid then Normosol|2.5 mL radiolabeled autologous seminal fluid administered rectally x1. Two week pause between interventions. Then 2.5 mL radiolabeled Normosol-R administered rectally X1.
11543022|NCT01053741|Experimental|Normosol then Seminal Fluid|2.5 mL radiolabeled Normosol-R administered rectally x1. Two week pause between interventions. Then 2.5 mL radiolabeled autologous seminal fluid administered rectally X1.
11543023|NCT01053728|Experimental|Cohort 1 : SAR161271 0.3 U/kg|Cross-over design of four formulation of SAR161271 0.3U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
11543024|NCT01053728|Experimental|Cohort 2 : SAR161271 0.6 U/kg|Cross-over design of four formulation of SAR161271 0.6U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
11543025|NCT01053728|Experimental|Cohort 3 : SAR161271 1.2 U/kg|Cross-over design of four formulation of SAR161271 1.2 U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
11543026|NCT01053702|Experimental|Dose 1|R475
11543027|NCT01053702|Experimental|Dose 2|R475
11543028|NCT01053702|Placebo Comparator|Dose 3|Placebo to match R475 dose
11543029|NCT01053689|Experimental|Glimepiride|Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited
11543030|NCT01053689|Active Comparator|Amaryl|Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc
11543031|NCT01053676|Experimental|Arm 1|
11543032|NCT01053676|Active Comparator|Arm 2|
11543033|NCT01053663|Experimental|1|
11543034|NCT01053637|Experimental|Hydrocodone/acetaminophen|Patients will receive 0.17 mg/kg hydrocodone component to a max of 10 mg hydrocodone.
11543035|NCT01053637|Placebo Comparator|Sugar water|Placebo
11543036|NCT01053611|Active Comparator|Group 1 BIS value 30|
11543037|NCT01053611|Active Comparator|Group 2 BIS value 30|
11543038|NCT01053611|Active Comparator|Group 3 BIS value 30|
11543039|NCT01053611|Active Comparator|Group 4 BIS valaue 30|
11543040|NCT01053611|Active Comparator|Group 1 BIS value 50|
11543041|NCT01053611|Active Comparator|Group 2 BIS value 50|
11543042|NCT01053611|Active Comparator|Group 3 BIS value 50|
11543043|NCT01053611|Active Comparator|Group 4 BIS value 50|
11543044|NCT01053611|Active Comparator|Group 1 BIS value 70|
11543045|NCT01053611|Active Comparator|Group 2 BIS value 70|
11543046|NCT01053611|Active Comparator|Group 3 BIS value 70|
11543047|NCT01053611|Active Comparator|Group 4 BIS value 70|
11543048|NCT01053585|Active Comparator|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
11543049|NCT01053585|Placebo Comparator|Placebo|Placebo suspension (single dose 90 minutes prior to physiologic measurement)
11543050|NCT01053572|Active Comparator|Celestone|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
11543051|NCT01053572|Active Comparator|sodium chloride solution|Group II will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and 0.9% sodium chloride solution to substitute for non-particulate Celestone
11543052|NCT01053572|Active Comparator|sodium choride solution|Group III will receive adhesiolysis, local anesthetic, normal sodium chloride solution instead of 10% hypertonic sodium chloride solution and non-particulate Celestone;
11543053|NCT01053572|Active Comparator|Double substitutes|Group IV will receive adhesiolysis, local anesthetic, and 0.9% sodium chloride solution to substitute for the 10% hypertonic sodium chloride, and 0.9% sodium chloride solution to substitute for non-particulate Celestone
11543054|NCT01053559|Other|certolizumab pegol|Subjects will receive FDA approved Cimzia injections as indicated on the product label. Subjects will undergo 3 wireless capsule endoscopies, one at screening,Day 84 and Day 168 as well as monthly bloodwork.
11543055|NCT01053546|Experimental|Arm I (Early exercise group)|Patients perform swallowing exercises comprising lingual press, head lift, breath hold, Masako swallow, high pitch e, effortful swallow, and neck stretch and massage for 2 weeks prior to beginning radiotherapy and again immediately after completion of radiotherapy.
11543056|NCT01053546|Experimental|Arm II (Late exercise group)|Patients begin performing swallowing exercises as in arm I 1 month after completion of radiotherapy.
11543057|NCT01053533|Experimental|Chinese herbal medicines plus western therapy|
11543058|NCT01053533|Active Comparator|western therapy|including supportive therapy and antivirus therapy when necessary
11543059|NCT01053520|Experimental|Sequence I|
11543060|NCT01053520|Experimental|Sequence II|
11543061|NCT01053520|Experimental|Sequence III|
11543111|NCT01053156|Placebo Comparator|Placebo pill|All patients will be on placebo for 3 months in this crossover study.
11543062|NCT01053507|Active Comparator|Treximet|In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.
11543063|NCT01053507|Placebo Comparator|Placebo|In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.
11543064|NCT01053494|Active Comparator|Arm I (WAITLIST CONTROL GROUP)|Patients and caregivers receive standard of care and are offered the massage intervention after 8 weeks.
11543065|NCT01053494|Experimental|Arm II (TOUCH)|"Caregivers undergo a 60-minute training session on simple massage techniques, including the Massage Toolkit, comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist. Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks."
11543066|NCT01053494|Experimental|Arm III (TOUCH+)|"Caregivers undergo a 60-minute training session on simple massage techniques, including the Massage Toolkit, comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist. Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks. Caregivers also receive a 45-minute massage by the massage therapist."
11543067|NCT01053481|Experimental|Vitamin D|Vitamin D supplement
11543068|NCT01053468|Experimental|PA Behavior Intervention|Physical Activity Resource Kit
11543069|NCT01053468|Active Comparator|Standard Materials|Receive physical activity handout from the Canadian Public Health Agency
11543070|NCT01053455||Starting on NCPAP|randomized to start on NCPAP
11543071|NCT01053455||Starting on SiPAP|randomized to SiPAP
11543072|NCT01053442|Experimental|NaFeEDTA|The maize porridge is fortified with 2.5mg iron as NaFeEDTA
11543073|NCT01053442|Active Comparator|FeSO4|The maize porridge is fortified with 2.5 mg iron as ferrous sulphate plus ascorbic acid.
11543074|NCT01053429||observational cohort|
11543075|NCT01053416|No Intervention|observation|
11543076|NCT01053416|Experimental|Yag laser iridotomy|the enrolled eyes will undergo an iridotomy performed by using a Yag-laser
11543077|NCT01053403|Active Comparator|MDMA|
11543078|NCT01053390|Active Comparator|epirubicin,cisplatin,LV（Leucovorin）、5-FU (5-Fluorouracil)|conventional regimen
11543079|NCT01053390|Experimental|Somatotatin|Conventional chemotherapy regimen plus somatostatin
11543080|NCT01053377|Active Comparator|Tamiflu|
11543081|NCT01053377|Placebo Comparator|Placebo Tamiflu|
11543082|NCT01053364|Experimental|Implant|
11543083|NCT01053338|Experimental|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets of Dr. Reddy's
11543084|NCT01053338|Active Comparator|Advil|Advil PM 200 mg/38 mg Tablets of Wyeth
11543085|NCT01053325|Experimental|CTX in HIV-negative women|CTX daily prophylaxis in HIV-negative pregnant women
11543086|NCT01053325|Experimental|CTX in HIV-positive women|CTX daily prophylaxis in pregnant women who are infected with HIV
11543087|NCT01053325|Active Comparator|SP IPT in HIV-negative women|Intermittent Preventive Treatment with SP in HIV-negative pregnant women
11543088|NCT01053325|Active Comparator|IPT SP in HIV-positive women|Intermittent Preventive Treatment with SP in HIV-positive pregnant women
11543089|NCT01053325|Active Comparator|CTX in HIV-positive pregnant women with CD4<350|Daily prophylaxis with cotrimoxazole in HIV-positive pregnant women with CD4<350
11543090|NCT01053312|Experimental|1 flutemetamol|
11543091|NCT01053299|Active Comparator|No treatment|Every child, without exception, born in the peroid 1.2.1998 - 31.12.2006, still alive, will be called for to take a Xray of their hips aimed at comparing the ultrasound-values taken newborn.
11543092|NCT01053273|Active Comparator|Caudal epidural Injection|Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
11543093|NCT01053273|Active Comparator|Percutaneous Adhesiolysis|Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone
11543094|NCT01053260|Active Comparator|LEARN Program|Participants will receive weekly weight loss counseling based on the LEARN Program for Weight Management.
11543095|NCT01053260|Experimental|LEARN Plus Contingency Management|Participants will receive weekly counseling based on the LEARN Program for Weight Management plus contingency management. Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
11543096|NCT01053247|Experimental|Test|Test product that contains the active pharmaceutical ingredient
11543097|NCT01053247|Active Comparator|Reference|Reference product that contains active pharmaceutical ingredient
11543098|NCT01053247|Placebo Comparator|Vehicle|Placebo that contains no active pharmaceutical ingredient
11543099|NCT01053234|Experimental|Insulin aspart|
11543100|NCT01053234|Experimental|NPH insulin|
11543101|NCT01053221|Experimental|MPA monotherapy|Subjects will discontinue calcineurin inhibitor (cyclosporine or tacrolimus) and remain on MPA (mycophenolate mofetil or mycophenolate sodium) monotherapy
11543102|NCT01053221|Active Comparator|Control: MPA and CNI|Subjects will continue with their current immunosuppressive regimen of MPA (mycophenolate mofetil or mycophenolate sodium) and calcineurin inhibitor (cyclosporine or tacrolimus)
11543103|NCT01053208|Experimental|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets of Dr. Reddy's
11543104|NCT01053208|Active Comparator|Advil|Advil PM 200 mg/38 mg Tablets of Wyeth
11543105|NCT01053195|Experimental|Lifestyle counseling|In the project areas, lifestyle counseling will be given every three months to individuals having prediabetes and every six months to those with normal glucose levels.
11543106|NCT01053195|No Intervention|Control|No intervention activity will be assigned for participants enrolled from the control areas.
11543107|NCT01053182|Active Comparator|Ivor-Lewis|Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach
11543108|NCT01053182|Active Comparator|Sweet|Esophagectomy via Left Side Thoracotomy
11543109|NCT01053169||Prophylaxis Cohort|Patients with coagulopathy due to liver disease or other condition requiring correction of coagulopathy who require surgical or diagnostic intervention
11543110|NCT01053169||Treatment Cohort|Patients experiencing acute bleeding perioperatively
11543112|NCT01053156|Experimental|Minocycline|All patients will be on minocycline for 3 months in this crossover trial.
11543113|NCT01053143|Experimental|Study Group|Participants aged 18 years and older at enrollment.
11543114|NCT01053130|Experimental|weight loss surgery|laparoscopic sleeve gastrectomy
11543115|NCT01053130|Active Comparator|Lifestyle Intervention|Diet and exercise with or without pharmacotherapy
11543116|NCT01053117|Experimental|Protocolized approach|Protocolized approach to convert catheter to arteriovenous fistula
11543117|NCT01053117|No Intervention|Current Care Model|
11543118|NCT01053104||capecitabine 2000mg/m2 (Colorectal)|capecitabine 2000mg/m2 d 1-14, q 3 weekly and oxaliplatin 130mg/m2 d1 q 3 weekly (CAPOX)
11543119|NCT01053104||capecitabine 2500mg/m2 (Colorectal)|capecitabine 2500mg/m2 d 1-14, q 3 weekly
11543120|NCT01053104||capecitabine 2000mg/m2 (Breast)|capecitabine 2000mg/m2d 1-14, q 3 weekly
11543121|NCT01053104||docetaxel 75mg/m2 (Breast)|capecitabine 2000mg/m2 d 1-14, q 3 weekly and docetaxel 75mg/m2 d1 q 3 weekly
11543122|NCT01053091|Experimental|Exercise|exercise
11543123|NCT01053091|No Intervention|Control|control
11543124|NCT01053078|Experimental|Naltrexone|
11543125|NCT01053078|Placebo Comparator|Placebo|
11543126|NCT01053065|Active Comparator|Atorvastatin 10 mg/day|Arm composed of 20 patients, receiving atorvastatin 10 mg/day
11543127|NCT01053065|Active Comparator|Atorvastatin 80 mg/day|Arm composed of 20 patients, receiving atorvastatin 80 mg/day
11543128|NCT01053065|Active Comparator|Cholestyramine - Sitosterol|Arm composed of 20 patients receiving cholestyramine 8 g/day plus sitosterol 2.5 g/day
11543129|NCT01053052|Experimental|Sonography with FemVue vs. HSG|FemVue sonography and HSG
11543130|NCT01053039|Active Comparator|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
11543131|NCT01053039|Placebo Comparator|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
11543132|NCT01053013|Experimental|Cancer macrobeads|Cancer macrobead placement in abdominal cavity
11543133|NCT01053000|Experimental|Lt. Arm Tazorac/Rt. Arm No Pretreatment|Apply Tazorac 0.1% gel for 1 week to the Left arm only and then receive ALA- PDT Treatment to both arms
11543134|NCT01053000|Experimental|Rt. Arm Tazorac/Lt. Arm No Pretreatment|Apply Tazorac 0.1% gel for 1 week to the Right arm only and then receive ALA- PDT Treatment to both arms
11543135|NCT01052987|Experimental|Tranilast|Tranilast tablets
11543136|NCT01052987|Active Comparator|Allopurinol|Allopurinol tablets
11543137|NCT01052987|Experimental|Combination|Tranilast plus Allopurinol
11543138|NCT01052987|Active Comparator|High dose Allopurinol|400 mg Allopurinol
11543139|NCT01052987|Experimental|High dose combination|Combination of Tranilast 300 mg and Allopurinol 400 mg
11543140|NCT01052974|Placebo Comparator|physiological serum|ropivacaïne controlled by placebo (physiological serum).
11543141|NCT01052974|Active Comparator|ropivacaine|ropivacaïne controlled by placebo (physiological serum).
11543142|NCT01052961|No Intervention|Non-intervention arm|patients may receive oseltamivir 75 mg bd for 5 days, decided by the managing physicians
11543143|NCT01052961|Active Comparator|oseltamivir, higher dose|oseltamivir 150 mg bd for 5 days for patients presented within 96 hours from onset
11543144|NCT01052948||Cohort 1|All persons who newly start one of the dopamine agonists (DA) after start of eligibility period
11543145|NCT01052948||Cohort 2|All persons who started levodopa after start of eligibility period and had not been treated with dopamine agonists anytime prior.
11543146|NCT01052948||Cohort 3|All persons with newly diagnosed hyperprolactinemia who had not been treated with dopamine agonists anytime prior.
11543147|NCT01052948||Cohort 4|healthy controls from general population matched on age, gender, index date and general practitioner (GP) practice to persons exposed to dopamine agonists
11543148|NCT01052935|No Intervention|Arm 1|This is a phlebotomy study.
11543149|NCT01052922|Active Comparator|2 sample InSure|
11543150|NCT01052922|Active Comparator|1 sample OC-Micron|
11543151|NCT01052922|Active Comparator|3 sample g-SENSA|
11543152|NCT01052909|Experimental|Glimepiride|Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited
11543153|NCT01052909|Active Comparator|Amaryl|Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc
11543154|NCT01052896|Experimental|Gabapentin|Half of the 100 patients enrolled will be placed on Gabapentin therapy to determine if they have improved dyspepsia symptoms.
11543155|NCT01052896|Placebo Comparator|Placebo|Half of the 100 patients will be placed on placebo look-alike of the gabapentin.
11543156|NCT01052883|Experimental|1|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A] then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment B]
11543157|NCT01052883|Experimental|2|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 [Treatment B] then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A]
11543158|NCT01052883|Experimental|3|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C] then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D]
11543159|NCT01052883|Experimental|4|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D] then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C]
11543160|NCT01052870|Other|androgen receptor gene polymorphism|Medication response will be assessed according to androgen receptor genotype
11543161|NCT01052870|Active Comparator|finasteride|medication for treating androgenetic alopecia in women
11543162|NCT01052857|Experimental|1|acupuncture daily fo 7 days
11543163|NCT01052857|No Intervention|2|observation
11543235|NCT01052298|Experimental|Arm 2|
11543164|NCT01052844|Placebo Comparator|Control group|"Placebo:
~Five and four days before chemotherapy (day -5 and day -4): 1x daily
~Three and two days before chemotherapy (day -3 and day -2): 2x daily
~One day before to five days after chemotherapy ( day -1 to day 5): 3x daily"
11543165|NCT01052844|Experimental|Gabapentin|"Gabapentin 300mg:
~Five and four days before chemotherapy (day -5 and day -4): 1x daily
~Three and two days before chemotherapy (day -3 and day -2): 2x daily
~One day before to five days after chemotherapy ( day -1 to day 5): 3x daily"
11543166|NCT01052831|Active Comparator|Naltrexone|For the first four weeks of the study, participants were administered naltrexone at 50mg per day. Participants not in response at week 4 were increased to 100mg per day for the remaining four weeks of the study.
11543167|NCT01052831|Placebo Comparator|Placebo|Participants received the placebo treatment which looked identical to active study medication.
11543168|NCT01052818||Stage IV NSCLC|Stage IV non small-cell lung cancer patients will be recruited for this protocol
11543169|NCT01052805||harvest nerve|harvest nerve from cadaveric donor and patients receiving nerve graft operation
11543170|NCT01052792|Experimental|Naproxen Sodium 550 mg Tablets|Naproxen Sodium 550 mg Tablets of Dr. Reddy's Laboratories Limited
11543171|NCT01052792|Active Comparator|Anaprox DS 550mg Tablets|Anaprox DS 550mg Tablets of Roche Pharmaceuticals Inc
11543172|NCT01052779|Experimental|Ferumoxytol|Participants received an IV injection of ferumoxytol (510 milligrams [mg], 17 milliliters [mL]) on Day 1 (Baseline). This was followed by a second injection of ferumoxytol (510 mg, 17 mL) 5±3 days later for a total cumulative dose of 1.02 grams (g).
11543173|NCT01052779|Active Comparator|Iron Sucrose|"Participants received iron sucrose based on hemodialysis status. Participants on hemodialysis received either slow IV injection or IV drip infusion of 100 mg of iron sucrose on Day 1 (Baseline) and at the following 9 consecutive hemodialysis sessions for a total cumulative dose of 1.0 g.
~Participants not on dialysis received either slow IV injection or IV drip infusion of 200 mg of iron sucrose on Day 1 (Baseline) and at 4 subsequent visits on nonconsecutive days over a 14-day period for a total cumulative dose of 1.0 g."
11543174|NCT01052766|Experimental|PET/CT and BH PET/CT|In collaboration with the Department of Radiation Oncology and the Interventional Radiology Service, patients with lung or liver cancer or lung or liver metastases in whom FDG PET/CT is part of the clinical standard of care for disease evaluation and response assessment will be enrolled in this study. We will perform a clinical PET/CT and BH PET/CT (for two bed positions covering the entire chest) prior to, and again 1-2 weeks after SBRT or RFA. This early time point is chosen because a few weeks after the completion of treatment, acute radiation injury in the lung begins and will likely be detectable as abnormal uptake on follow-up PET imaging making it difficult to assess tumor recurrence.
11543175|NCT01052753||ADHD group|
11543176|NCT01052753||Control group|
11543177|NCT01052727|Other|overnight stay group|Group of patients who rests at least one night in Hospital
11543178|NCT01052727|Other|day-care Group|Group of patients who is discharged tha same day of operation
11543179|NCT01052714|No Intervention|Usual Care|Control group with time-matched study visits
11543180|NCT01052714|Active Comparator|Lifestyle Balance|Weight management group education and individual counseling
11543181|NCT01052714|Other|Usual Care then Lifestyle Balance|Participants originally randomized to Usual Care, allowed to change over to Lifestyle Balance at month 6 per their request.
11543182|NCT01052701|Active Comparator|Ribavirin plus Abacavir|Ribavirin plus Abacavir Administration intervention
11543183|NCT01052701|Active Comparator|Ribavirin alone|Ribavirin alone administration
11543184|NCT01052688||Pregnant Women|Pregnant women who have been definitively diagnosed as carrying a fetus with aneuploidy.
11543185|NCT01052675||Pharmacodependance cases|Case report from one of the French CEIP for drug and substance problematic use, abuse or dependence except alcohol and tobacco.
11543186|NCT01052662|Experimental|Memantine 30mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.
~Memantine 5mg in the morning was started on week 2. The dose was titrated on a twice a day schedule until the target dose of 30 mg/day was achieved by week 4. The medication was discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
11543187|NCT01052662|Experimental|Memantine 15mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.
~Memantine 5mg in the morning was started on week 2. The dose was titrated on a twice a day schedule until the target dose of 15 mg/day was achieved by week 4. The medication was discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
11543188|NCT01052662|Placebo Comparator|Memantine 0mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.
~Matching placebo capsule was started on week 2. The placebo capsules were given on a twice a day schedule until week 12 and then discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
11543189|NCT01052649||Healthy volunteers|
11543190|NCT01052636|No Intervention|Control group|Patients receive only routine hospital care
11543191|NCT01052636|Experimental|Experimental group|Patients receive regular hospital routine care and interdisciplinary intervention program
11543236|NCT01052298|Experimental|Arm 3|
11543237|NCT01052298|Placebo Comparator|Arm 4|
11543238|NCT01052285|Placebo Comparator|Placebo|TAP block with 25 ml of saline Ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline.
11543239|NCT01052285|Active Comparator|Local infiltration|Ilioinguinal block with 10 ml of ropivacaine 0,375% Local infiltration with 40 ml of ropivacaine 0,375% Tap block with 25 ml of saline
11543276|NCT01052051|Placebo Comparator|Placebo for vitamin D3 and calcium carbonate|Placebo for daily vitamin D3 and calcium carbonate
11543192|NCT01052623|Experimental|Growth hormone-testing (GH/IGF-1-testing)|"Patients (girls over 8 years and boys over 10 years) are primed with estradiol 1 mg orally for 2 days, to help avoid false results of growth hormone (GH) levels in blood samples. Then provocation testing is done, with two tests back to back. It determines blood levels of GH and the body's response to testing with drugs called arginine and clonidine. Patients are admitted to the pediatric inpatient unit and will have an intravenous (IV) line placed in the arm. Arginine is given by IV over 30 minutes, and blood samples are taken as indicated.
~The next day, the clonidine test is performed according to current guidelines. Then the IGF-1 generation test is done to see if the patient has the ability to generate IGF-1 in response to injections of GH for 5 consecutive days."
11543193|NCT01052610|Active Comparator|Active group|Group of children with bronchial asthma and/ or allergic rhinitis 6-18 years old receiving annually house dust mites sublingual allergen extract
11543194|NCT01052610|Placebo Comparator|Placebo group|Group of children with bronchial asthma and/or allergic rhinitis 6-18 years old receiving placebo in sublingual applicator
11543195|NCT01052597|Placebo Comparator|Placebo|
11543196|NCT01052597|Experimental|Curcumin|
11543197|NCT01052584|Experimental|Chloroquine-P. vivax|P. vivax randomized to receive chloroquine 3-day regimen
11543198|NCT01052584|Experimental|Artemether-Lumefantrine: P. vivax|
11543199|NCT01052584|Experimental|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
11543200|NCT01052571|Active Comparator|Without Steroids|Group I patients receiving lumbar transforaminal epidural injections with an injection of local anesthetic (lidocaine 1% or bupivacaine 0.25%
11543201|NCT01052571|Active Comparator|steroids|Group II patients will receive lumbar transforaminal epidural injections with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
11543202|NCT01052558|Active Comparator|Cataract Surgery Only|
11543203|NCT01052558|Experimental|Treatment with Cataract Surgery & Stents|Ab interno trabecular micro-bypass stent surgery
11543204|NCT01052545|Experimental|Arm 1- Intervention: Audit-Feedback|Baseline surveillance for the clinical outcomes will begin in year 1 at the intervention site and continue for all 3 years of the project. Guideline distribution will begin in year 2 and continue throughout the project. Audit-feedback will occur during year 2 of the study at the intervention site. Feedback will be delivered to individual health care providers at the intervention site during year 2.Unit-level audit feedback will be delivered at the intervention site during years 2 and 3 of the study. Provider surveys of knowledge and attitudes concerning the ABU guidelines will be administered at the intervention site in years 2 and 3 of the project.
11543205|NCT01052545|No Intervention|Arm 2- Control|At the control site, baseline surveillance for the clinical outcomes will begin in year 1 at the and continue for all 3 years of the project. Guideline distribution will begin in year 2 and continue throughout the project. Audit-feedback will not occur at the control site. Provider surveys of knowledge and attitudes concerning the ABU guidelines will be administered at the control site in year 3 of the project.
11543206|NCT01052532||Mitral Regurgitation pre&post operation|Patients with severe Mitral Regurgitation without evidence of ischemia are tested prior to surgery and after valve repair.
11543207|NCT01052519|No Intervention|obese control|
11543208|NCT01052519|Active Comparator|obese goal-directed|
11543209|NCT01052519|Active Comparator|non-obese goal directed|
11543210|NCT01052506|Placebo Comparator|Placebo|Single dose of saline solution (8 cohorts IV; 1 cohort SC)
11543211|NCT01052506|Experimental|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV; 1 cohort SC)
11543212|NCT01052480|Experimental|Plasma and Standard Care|Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies (Anti-Influenza Immune Plasma) in addition to standard care.
11543213|NCT01052480|Active Comparator|Standard Care|Participants will receive standard care.
11543214|NCT01052454|No Intervention|Wait list|Women assigned to the waitlist have the opportunity of taking the MBSR program at no cost following final study assessment
11543215|NCT01052454|Experimental|Mindfulness-based stress reduction|Women in the MBSR arm attend eight weekly MBSR classes
11543216|NCT01052441||CT Scan|Subjects with typical or atypical chest pain suspected of coronary artery disease and referred for an elective invasive coronary angiography (ICA), and scheduled to undergo CCTA before ICA or after ICA, if no intervention has been performed.
11543217|NCT01052428|Active Comparator|Toprol XL|beta 1 receptor blockade; generic name metoprolol succinate
11543218|NCT01052428|Placebo Comparator|Placebo|Pill that looks like Toprol XL but does not have the active ingredients
11543219|NCT01052415|No Intervention|Standard care|Service providers and HIV patients, offered intervention at the end of study
11543220|NCT01052415|Experimental|Intervention|Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
11543221|NCT01052402|Experimental|Dose A|Two intramuscular injections (21 days apart, i.e. Days 0 and 21) of H5N1 Influenza Vaccine (Dose A) followed by a heterologous booster vaccination (Dose A) on Day 360
11543222|NCT01052402|Experimental|Dose B|Two intramuscular injections (21 days apart, i.e. Days 0 and 21) of H5N1 Influenza Vaccine (Dose B) followed by a heterologous booster vaccination (Dose B) on Day 360
11543223|NCT01052389|Experimental|Aripiprazole|Aripiprazole (N05AX12)
11543224|NCT01052389|Experimental|Olanzapine|Olanzapine (N05AH03)
11543225|NCT01052389|Experimental|Haloperidol|Haloperidol (N05AD01)
11543226|NCT01052363|Experimental|CA4P + Avastin|
11543227|NCT01052363|Experimental|Avastin + CA4P|
11543228|NCT01052350||Parkinson disease|individuals with Parkinson disease
11543229|NCT01052350||healthy control|individuals without Parkinson disease
11543230|NCT01052337|Active Comparator|propofol|
11543231|NCT01052337|Active Comparator|sevofluorane|
11543232|NCT01052311|Placebo Comparator|Placebo|Placebo pills once daily
11543233|NCT01052311|Active Comparator|Active treatment|Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) = tredaptive once daily from day 1 to 30. From day 31 to day 90 2 g of extended-release niacin and 20 mg of laropiprant once daily.
11543234|NCT01052298|Experimental|Arm 1|
11543240|NCT01052285|Experimental|Transversus abdominis plane block|25 ml of Ropivacaine 0,75%, Ilioinguinal block with 10 ml saline and local infiltration with 40 ml of saline.
11543241|NCT01052272|Active Comparator|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
11543242|NCT01052272|Active Comparator|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
11543243|NCT01052272|Active Comparator|Ramipril and Allopurinol|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily. It is anticipated that the starting dose of each drug will be initiated in hospital and that the second dose will be implemented prior to discharge from the hospital. The starting dose of Allopurinol is 300 mg daily.
11543244|NCT01052272|Active Comparator|Candesartan cilexetil and Allopurinol|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily. The starting dose of Allopurinol is 300 mg daily.
11543245|NCT01052259|Experimental|Deoxyspergualin, Treatment,|
11543246|NCT01052246|Experimental|Clindamycin 1% + benzoyl peroxide 5% & pulsed dye laser|
11543247|NCT01052246|Active Comparator|Clindamycin 1% + benzoyl peroxide 5%|
11543248|NCT01052233|Active Comparator|Arthroscopic partial meniscectomy|Arthroscopic partial resection of degenerative tear of medial meniscus
11543249|NCT01052233|Sham Comparator|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
11543250|NCT01052220|Experimental|BP Education and Self Regulation of BP|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will received a BP educational session at baseline and were asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.
~The PI made weekly visits with the intervention participants in the HD unit to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
11543251|NCT01052220|No Intervention|Usual Care|Participants in the usual care group did not receive the intervention but continued to receive their standard care in the hemodialysis unit which involved follow-up by the medical provider and BP medication adjustments as needed. .
11543252|NCT01052207||Critically Ill Patients|Evaluation of Oxidative Stress, Glucocorticoid Receptor function, and Adrenal Insufficiency amongst critically ill pediatric patients. Serum, and when available endotracheal samples, will be obtained within 24 hours of admission and at 5 days provided patients are 1) still in the PICU and 2) blood draws and endotracheal aspirates are part of their standard of care. Endotracheal aspirates will be sent on day 14, 21, and 28 provided patients are intubated and require suctioning as part of their standard of care.
11543253|NCT01052207||Healthy Controls|Healthy controls will be evaluated and defined as those who do not have any chronic medical condition, are not on steroids (inhaled or oral), and have not received steroids or etomidate in the last month. Given the time and need for multiple lab draws low dose adrenocorticotropin (ACTH) testing will not be done in healthy patients, nor will tracheal aspirate samples be obtained.
11543254|NCT01052194|Experimental|25 mg b.i.d. VX-509|
11543255|NCT01052194|Experimental|50 mg b.i.d. VX-509|
11543256|NCT01052194|Experimental|100 mg b.i.d. VX-509|
11543257|NCT01052194|Experimental|150 mg b.i.d. VX-509|
11543258|NCT01052194|Placebo Comparator|Placebo|
11543259|NCT01052181|Experimental|Vitamin D supplementation|Cholecalciferol sachets 120,000 IU monthly for 12 months
11543260|NCT01052181|Placebo Comparator|placebo|placebo with same taste, color, odor
11543261|NCT01052168|Active Comparator|Speed Group|The Speed Group, (n=20) will train in laparoscopic suturing on the validated FLS suturing model until the expert level of speed (i.e. task duration < 70 seconds) has been achieved on two consecutive attempts.
11543262|NCT01052168|Experimental|Motion Group|The Motion Group, (n=20) will train in laparoscopic suturing until expert levels of motion (pathlength 6700 and smoothness 560) have been achieved.
11543263|NCT01052168|Experimental|Speed and Motion Group|The Speed and Motion Group (n=20) will train in laparoscopic suturing until expert levels of speed AND motion have been achieved.
11543264|NCT01052142|Experimental|Lipovaxin-MM|
11543265|NCT01052129|Experimental|Naproxen Sodium 550 mg Tablets|Naproxen Sodium 550 mg Tablets of Dr.Reddy's Laboratories Limited
11543266|NCT01052129|Active Comparator|Anaprox DS 550 mg Tablets|Anaprox DS 550 mg Tablets of Roche Pharmaceuticals Inc
11543267|NCT01052116|Active Comparator|Soy Isoflavone|Oral isoflavone supplement (100 mg/day)
11543268|NCT01052116|Placebo Comparator|Placebo|Matching placebo
11543269|NCT01052103|Experimental|LY2140023|
11543270|NCT01052103|Placebo Comparator|Placebo|
11543271|NCT01052090|Experimental|Lifestyle counseling|
11543272|NCT01052077|Experimental|Brexipiprazole + ADT|OPC-34712 Tablets, Oral, 1 - 3 mg OPC-34712 + ADT
11543273|NCT01052077|Placebo Comparator|Placebo + ADT|Placebo + ADT
11543274|NCT01052064|Experimental|Transcranial magnetic stimulation|There are evidences that rTMS has a modulating effect in cortical and subcortical neural networks, reinforcing or depressing synaptic activity by mean of long term potentiation or depression like mechanism. Depression is the most study neuropsychiatric condition in which rTMS is useful as a therapeutic option; but in other diseases such as ADHD there are many pathophysiological elements that make it very likely that rTMS could be useful for symptomatic treatment modulating activity in prefrontal and basal ganglia neuronal networks.
11543275|NCT01052051|Experimental|vitamin D3 and calcium carbonate|Daily vitamin D3 2000 IU/day and calcium carbonate 1500mg/day supplementation
11543277|NCT01052038|Placebo Comparator|Group 1 Placebo|Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.
11543278|NCT01052038|Active Comparator|Group 2: Dexamethasone 0.05mg/kg|Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery
11543279|NCT01052038|Active Comparator|Group 3:Dexamethasone 0.1mg/kg|Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.
11543280|NCT01052025|Experimental|Curcumin|curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
11543281|NCT01052025|No Intervention|Placebo|
11543282|NCT01052012|Experimental|Active: SABER™-Bupivacaine|SABER™-Bupivacaine
11543283|NCT01052012|Active Comparator|Comparator: Bupivacaine HCl|Bupivacaine HCl
11543284|NCT01052012|Placebo Comparator|Placebo: SABER™-Placebo|SABER™-Placebo
11543285|NCT01051999|Experimental|Glutamine|Patients randomized to the glutamine arm will receive 0.7g/kg of oral glutamine powder per day
11543286|NCT01051999|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive 0.7g/kg of oral isonitrogenous L-alanine powder per day
11543287|NCT01051986|Active Comparator|SVG group|"patients who underwent off-pump coronary artery bypass using saphenous vein composite grafting based on the left internal thoracic artery
~use saphenous vein as a composite graft connected to the left internal thoracic artery"
11543288|NCT01051986|Active Comparator|RITA group|"patient who underwent off-pump coronary artery bypass using right internal thoracic artery composite grafting based on the left internal thoracic artery
~use right internal thoracic artery as a composite graft connected to the left internal thoracic artery"
11543289|NCT01051973|Experimental|Cognitive behavior therapy|
11543290|NCT01051973|Active Comparator|Stress management|
11543291|NCT01051960|Experimental|ambrisentan|ambrisentan dosed at either 5mg or 10mg orally once per day
11543292|NCT01051947|Experimental|Nebivolol|Nebivolol therapy for 2-6 weeks depending on blood pressure readings
11543293|NCT01051947|Experimental|Metoprolol|Metoprolol therapy for 2-6 weeks depending on blood pressure readings
11543294|NCT01051921|Experimental|CTS-1027, Peg IFN, Ribavirin|"Study drug (CTS-1027) plus Standard of Care treatment (pegylated interferon and ribavirin).
~CTS-1027, 15 mg taken twice daily. Pegylated interferon, 180 μg injected once a week. Ribavirin, 1000 mg or 1200 mg daily (depending on patient weight), taken in two divided doses."
11543295|NCT01051895|Experimental|HPV testing|Women randomized to this arm will undergo high risk HPV DNA testing using Hybrid Capture 2®.
11543296|NCT01051895|Active Comparator|Routine colposcopy|Women will be followed in the colposcopy clinic as usual, with no standardized protocol, tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
11543297|NCT01051882|Experimental|MSC-NTF cells IM|Intramuscular administration in early stage patients
11543298|NCT01051882|Experimental|MSC-NTF cells IT|Intrathecal administration in progressive stage patients
11543299|NCT01051869|Active Comparator|simple decompression|
11543300|NCT01051869|Active Comparator|anterior subcutaneous transposition|
11543301|NCT01051856|Active Comparator|SEAMGUARD with bioabsorbable staple|In this arm pancreatic transection will be executed using an endoscopic linear stapling device. The individual staple depth can be chosen by the operating surgeon. Bioabsorbable Mesh sleeves specifically manufactured for the chosen staple depth and cartridge length will be placed over the stapler before firing.
11543302|NCT01051856|Active Comparator|TissueLink with radiofrequency ablation|After pancreatic transection, with any method chosen by the operating surgeon, the pancreatic remnant will be treated with TissueLink alone for an ablation depth (thickness) of approximately 7 mm using electrosurgical generator settings of 100 W and a saline drip rate of 1-2 drops per second.
11543303|NCT01051830|Experimental|Interdisciplinary group|Diabetes intervention and rehabilitation program. The rehabilitation program includes geriatric consultation, the rehabilitation program (interventions to improve ROM, muscle strength and endurance, proprioceptive enhancement, balance capacity, aerobic and anaerobic capacity, flexibility, and body composition), and discharge-planning services. The DM intervention includes: dietary and DM education, blood pressure control, dyslipidemia management, a glycemic treatment regimen, and exercises.
11543304|NCT01051830|No Intervention|Control group|Routine care
11543305|NCT01051817|Experimental|AIN457|
11543306|NCT01051817|Placebo Comparator|Placebo|
11543307|NCT01051804|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
11543308|NCT01051804|Active Comparator|Optive|Optive Lubricant Eye Drops
11543309|NCT01051791|Experimental|Everolimus 10 mg daily|"The study of the efficacy of everolimus will proceed in two stages after the method of Simon1. In the first stage 15 patients will be accrued and treated. If 9 or fewer patients show clinical benefit the study will be terminated. If 10 or more patients show clinical benefit the study will proceed to the second stage, accruing an additional 26 patients. If the second stage is complete and a total of 29 or more patients show clinical benefit among the 41 patients treated, the treatment CBR for will be considered high enough to warrant further study. Conversely, if the evaluation of everolimus concludes at the first stage, or if 28 or fewer patients experience a clinical benefit after completing the second stage, the therapy will not be considered for further study.
~1"
11543310|NCT01051778|Experimental|enoxaparin 40 mg plus low dose aspirin|
11543311|NCT01051778|Active Comparator|Heparin calcium 5,000 U twice daily plus low dose aspirin|
11543312|NCT01051765|Experimental|irinotecan/cisplatin|irinotecan 130mg/m2 d1 cisplatin: 30mg/m2, d1,d2 every three weeks
11543313|NCT01051752||NTM infection|Patients with NTM infection are generally middle aged or higher aged, white males with COPD or bronchiectasis. They will be recruited from the outpatient clinics of University Centre for Chronic Diseases Dekkerswald, Tuberculosis Centre Beatrixoord or other outpatient clinics in The Netherlands. Both newly diagnosed and already treated patients with NTM disease will be recruited.
11543314|NCT01051739||Group 1|glaucoma
11543315|NCT01051739||Group 2|normal
11543316|NCT01051726|Experimental|Aromatherapy group 1|Participants will be given essential oil consisting of (Peppermint, Lavender, Clary Sage and Frankincense) together with a swab to put the oil on.
11543317|NCT01051726|Placebo Comparator|Control group 2|Participants receive a bottle of non essential oil and a swab.
11543318|NCT01051726|No Intervention|Control group 3|Standard maternity care to measure baseline.
11543319|NCT01051713|Experimental|Standard|"Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits."
11543320|NCT01051713|Experimental|Technology Supported condition|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
11543321|NCT01051713|No Intervention|Self-Guided|Participants in the Self-Guided condition will receive DPP DVDs (3 DVDs and 1 CD) at the beginning of the study. This condition will not receive any direct dietary or physical activity interventions outside of the DVDs. Although Self-Guided participants will be receiving the same 7% weight loss goal as the other two groups, they will not be receiving physical activity or diet goals. The DVDs cover the initial 12-weekly sessions of the DPP, with the sessions portrayed by professional actors. They will also be provided with a supplemental DVD which includes a manual for each of the 12 sessions. They will also be giving the Keeping Track booklets and asked to record their diet and activity daily.
11543322|NCT01051700|Experimental|5 mg|GW786034
11543323|NCT01051700|Experimental|10 mg|GW786034
11543324|NCT01051700|Experimental|20 mg|GW786034
11543325|NCT01051700|Placebo Comparator|Placebo|Placebo
11543326|NCT01051687|No Intervention|control skin patches|no intervention will be given to the patches
11543327|NCT01051687|Active Comparator|botulinum toxin A|Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.
11543328|NCT01051674|Experimental|High fiber diet|
11543329|NCT01051674|Experimental|Low-carbohydrate diet|
11543330|NCT01051661|Experimental|Arepanrix 2D 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
11543331|NCT01051661|Experimental|Arepanrix 2D 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
11543332|NCT01051661|Experimental|Arepanrix 1D 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
11543333|NCT01051661|Experimental|Arepanrix 1D 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
11543334|NCT01051661|Experimental|GSK2340273A 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
11543335|NCT01051661|Experimental|GSK2340273A 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
11543336|NCT01051648|Experimental|Triamcinolone acetenoide|Intra ocular injection of triamcinolone acetonide to visualize vitreous strands in the anterior chamber of the eye in complicated cataract surgery
11543337|NCT01051635|Experimental|Cohort A|LMP400 administered IV daily for 5 days perdose escalation table.
11543338|NCT01051635|Experimental|Cohort B|LMP776 administered IV daily for 5 days perdose escalation table.
11543339|NCT01051622|Experimental|PBMC Trafficking|In part B, Patients undergo a blood draw (up to150 mL) and the PBMC's are separated and selected or 99mTc-HMPAO labeling. The purified and labelled cells will be re-introduced into the patient by intravenous infusion and one SPECT scan and up to 8 serial planar scintigraphy scans will initially be conducted over up to 6 hours within 1 scan session. All suitable patients showing evidence of cellular uptake in the ileo-caecal region and/or small bowel at Visit 1 will be progressed to an identical second cell labeling and scanning session at Visit 2 (48 hours later). Subjects showing no evidence of cellular uptake in the ileo-caecal region or small bowel at Visit 1 (negative scan) will be withdrawn from the study and proceed to the follow-up.
11543340|NCT01051622|Experimental|T Lymphocyte Trafficking|"In part B, Patients undergo a blood draw (up to150 mL) and the T lymphocyte cells are separated and selected or 99mTc-HMPAO labeling. The purified and labelled cells will be re-introduced into the patient by intravenous infusion and one SPECT scan and up to 8 serial planar scintigraphy scans will initially be conducted over up to 6 hours within 1 scan session. All suitable patients showing evidence of cellular uptake in the ileo-caecal region and/or small bowel at Visit 1 will be progressed to an identical second cell labeling and scanning session at Visit 2 (48 hours later). Subjects showing no evidence of cellular uptake in the ileo-caecal region or small bowel at Visit 1 (negative scan) will be withdrawn from the study and proceed to the follow-up.
~visit."
11543341|NCT01051609||Intervention Group|There is only one arm in this trial. Please see interventions for more detailed descriptions.
11543342|NCT01051596|Experimental|ABT-888 and temozolomide|Temozolomide Days 1-5 and ABT-888 Days 1-7 of each 28-day cycle
11543343|NCT01051583|Experimental|Avastin , diode laser cyclophotcoagulation|Intravitreal Avastin injection in conjunction with diode laser cyclophotocoagulation
11543344|NCT01051583|Active Comparator|Diode Laser cyclophotocoagulation|Diode laser cyclophotocoagulation to control intraocular pressure
11543345|NCT01051570|Experimental|Carboplatin, RAD 001 & Prednisone|"Carboplatin: AUC=4 by Calvert's formula (max dose 600 mg)*IV over 30-60 min, Day 1 of a 21 day cycle
~RAD 001: 5 mg Orally daily, starting from Day 2 continuously
~Prednisone 5 mg Orally twice daily, continuously"
11543346|NCT01051557|Experimental|Treatment (temsirolimus and perifosine)|"PHASE I: Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and perifosine PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~PHASE II: Patients receive temsirolimus and perifosine as in phase I. Some patients may also undergo cytoreductive surgery."
11543347|NCT01051544|Active Comparator|von Willebrand factor-free FVIII concentrates|Patients treated with FVIII concentrates
11543348|NCT01051544|Active Comparator|FVIII/VWF concentrates|Patients treated with FVIII/VWF concentrates
11543349|NCT01051531|Experimental|Paliperidone palmitate|
11543350|NCT01051518|Experimental|CoreValve|
11543351|NCT01051505|Experimental|1|
11543352|NCT01051505|Placebo Comparator|2|
11543353|NCT01051479|Experimental|C11-Choline|
11543354|NCT01051466|Experimental|Duloxetine|
11543355|NCT01051466|No Intervention|Healthy Participants|
11543356|NCT01051440|Placebo Comparator|Placebo|Subjects will receive placebo for lisdexamfetamine.
11543357|NCT01051440|Active Comparator|Lisdexamfetamine|Subjects will start with 20 mg per day of lisdexamfetamine and may increase to a maximum of 40 mg.
11543358|NCT01051427|Active Comparator|Nasal catheter|In this arm will be the patients with epistaxis that cannot be stopped with anterior nasal packing and are randomized not to put Surgiflo. So they receive the usual treatment with a nasal catheter balloon into the nose.
11543359|NCT01051427|Experimental|Surgiflo|In this arm will be the patients with epistaxis that cannot be stopped with anterior nasal packing and are randomized to put into the nose Surgiflo.
11543360|NCT01051414|Experimental|BMS-790052 + BMS-650032|
11543361|NCT01051401|Experimental|Arm I (rosuvastatin)|Patients receive rosuvastatin PO once daily for 3 months in the absence of disease progression or unacceptable toxicity.
11543362|NCT01051401|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO once daily for 3 months in the absence of disease progression or unacceptable toxicity.
11543363|NCT01051388|Active Comparator|Group I|Low-dose PPI (Rabeprazole sodium 10 mg)
11543364|NCT01051388|Active Comparator|Group II|High-dose PPI (Rabeprazole sodium 20 mg)
11543365|NCT01051388|Active Comparator|Group III|Non-PPI (Gefarnate)
11543366|NCT01051375|Experimental|Waitlist Group|The intervention involves completion of a single workshop, provision of psychoeducational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list, within a month of our receiving the referral.
11543367|NCT01051375|No Intervention|Standard of Care|These patients continue to receive the standard of care while awaiting formal assessment.
11543368|NCT01051362|No Intervention|PLD and Carboplatin|Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
11543369|NCT01051349|Experimental|BIIB019|Participants received BIIB019, 150 mg subcutaneous injection every 4 weeks up to Week 288.
11543370|NCT01051336|Experimental|TARIS Placebo|
11543371|NCT01051336|Sham Comparator|Sham Procedure|
11543372|NCT01051323||1|
11543373|NCT01051310|Experimental|CoreValve|
11543374|NCT01051297||VTE -PROSPECTIVE|Patients diagnosed with VTE
11543375|NCT01051297||sleep study group -PROSPECTIVE|patients undergoing sleep study
11543376|NCT01051297||VTE-Retrospective|patients with VTE , chart review
11543377|NCT01051297||OSA-retrospective|PATIENT WITH OSA -CHART REVIEW
11543378|NCT01051297||OSA group -PROSPECTIVE|patients diagnosed with OSA
11543379|NCT01051284|Experimental|Cyberknofe and Gemcitabine|Cyberknife radiation and 6 cycles Gemcitabine
11543380|NCT01051271|Active Comparator|diphenhydramine|
11543381|NCT01051271|Placebo Comparator|saline|
11543382|NCT01051245|Active Comparator|Case management|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
11543383|NCT01051245|Placebo Comparator|Usual care group|Usual care provided by primary care physician and/or specialist. Free access to diabetes educational workshops. Regular delivery of educational brochures (not personally targeted).
11543384|NCT01051232|Placebo Comparator|Cohort 1|PF-00868554 (filibuvir) 100 mg or placebo
11543385|NCT01051232|Placebo Comparator|Cohort 2|PF-00868554 (filibuvir) 300 mg or placebo
11543386|NCT01051232|Placebo Comparator|Cohort 3|PF-00868554 (filibuvir) 500 mg or placebo
11543387|NCT01051219|Active Comparator|Losartan, daily medication|50 milligrams Losartan to be taken orally daily
11543573|NCT01049815|Experimental|Sevelamer hydrochloride|
11543388|NCT01051219|Placebo Comparator|Placebo|A matched placebo will be given for patients to take once daily
11543389|NCT01051193|Experimental|TRI476|TRI476
11543390|NCT01051180||Doppler|Those patients where the doppler was randomised to be on
11543391|NCT01051180||Non doppler patients|those with no doppler guidance
11543392|NCT01051167|Experimental|Cetuximab + Folfox-6-regime|"Cetuximab 500 mg/m² administered as an intravenous infusion over 120 minutes on day 1 every 2 weeks. Combined with the following FOLFOX-6-regime:
~Oxaliplatin 85 mg/m² i.v. for 2 h on day 1, Folinic acid 400 mg/m² i.v. for 2 h concurrently with Oxaliplatin on day 1, Fluorouracil 400 mg/m² i.v. bolus after Folinic Acid on day 1, followed by Fluorouracil 2400 mg/m² i.v. over 46 h."
11543393|NCT01051154|Active Comparator|Docosahexaenoic acid (DHA)|This group will be receive the DHA supplement
11543394|NCT01051154|Placebo Comparator|Placebo|This group will be receive placebo
11543395|NCT01051141|Active Comparator|CBI in ED with AMET at 3 months|computer brief intervention (CBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
11543396|NCT01051141|Active Comparator|CBI in ED with EUC at 3 months|
11543397|NCT01051141|Active Comparator|IBI in ED with AMET at 3 months|
11543398|NCT01051141|Active Comparator|IBI in ED with EUC at 3 months|
11543399|NCT01051141|Active Comparator|EUC in ED with AMET at 3 months|
11543400|NCT01051141|No Intervention|EUC in ED with EUC at 3 months|
11543401|NCT01051128|Experimental|Spasticity. Baclofen|This study is a non-randomized, open-label, multi-center study of the Prometra Programmable Implantable Pump System in the administration of Lioresal® intrathecal (baclofen) in patients suffering from severe muscle spasticity of spinal origin.
11543402|NCT01051115|Experimental|Dasatinib|Patients will be treated with dasatinib monotherapy 100mg daily. At four weeks patients will be re-evaluated. Patients with less than a partial response will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib.
11543403|NCT01051102|Experimental|IDegAsp|
11543404|NCT01051102|Active Comparator|BIAsp 30|
11543405|NCT01051089|Experimental|Lifestyle modification|supervised exercise with diet education
11543406|NCT01051089|No Intervention|Control|Control (ordinary care with usual education)
11543407|NCT01051076|Experimental|Factor VIII and von Willebrand Factor|
11543408|NCT01051063|Experimental|Partial Remission Group|Adult patients in partial remission post-induction chemotherapy, who received the GSK2130579A study product, administered sequentially, as follows: Cycle 1: 6 doses, each given at 2-week intervals; Cycle 2: 6 doses, each given at 3-week intervals; Cycle 3: 4 doses, each given at 6-week intervals; Cycle 4: 4 doses, each given at 3-month intervals, followed by 4 doses each given at 6-month intervals.
11543409|NCT01051063|Experimental|Complete Remission Group|Adult patients in complete remission with incomplete blood count recovery post-induction chemotherapy, who received the GSK2130579A study product, administered sequentially, as follows: Cycle 1: 6 doses, each given at 2-week intervals; Cycle 2: 6 doses, each given at 3-week intervals; Cycle 3: 4 doses, each given at 6-week intervals; Cycle 4: 4 doses, each given at 3-month intervals, followed by 4 doses each given at 6-month intervals.
11543410|NCT01051050|Other|Mandatory use of surgery wiki|Mandatory participation in journal club wiki which will include adding to and reviewing the information posted on the wiki. Contribution to the wiki will be required at least once during the study period.
11543411|NCT01051050|Other|Voluntary use of surgery wiki|Voluntary participation in the journal club wiki
11543412|NCT01051037|Experimental|Arm 1|Subjects will undergo PET/CT simulation, 3 Fraction SBRT, RFA, and then undergo follow up.
11543413|NCT01051024|Experimental|A|Diamel
11543414|NCT01051024|Placebo Comparator|B|Placebo
11543415|NCT01051011|Experimental|1|
11543416|NCT01051011|Experimental|2|
11543417|NCT01051011|Active Comparator|3|
11543418|NCT01050998|Experimental|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 milligram (mg) injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
11543419|NCT01050998|Experimental|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
11543420|NCT01050998|Experimental|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
11543421|NCT01050998|Experimental|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
11543422|NCT01050998|Placebo Comparator|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
11543423|NCT01050985|Experimental|temsirolimus and capecitabine|Treatment with the combination of temsirolimus and capecitabine
11543424|NCT01050972|Experimental|Cognitive and physical program|Experimental: Cognitive and physical program. Non randomized residents in the territory of Piedmont (Piemonte) Italy.
11543425|NCT01050946|Other|Haploidentical/cord transplant|Haploidentical/cord transplant with the precondition regimen at discretion of treating physician.
11543426|NCT01050933|Experimental|Carbon Monoxide|Healthy volunteers will receive 250 ppm of carbon monoxide by face mask. This dose will be administered for 1 hour with continuous COHb monitoring. At baseline and at each half hour time point, a blood sample will be drawn to be analyzed by the gas chromatograph. After 1 hour, the volunteer will be excused and asked to return in 4 hours and this procedure repeated. At any point, if the COHb level reaches 10%, administration of CO will be terminated.
11543427|NCT01050920||Blood Collection|
11543428|NCT01050907|Experimental|Miltefosine|2.5 mg/kg/day for 28 days
11543429|NCT01050894||osteoarthritis patients|
11543430|NCT01050881||Positive Blood Donors|Blood donors testing positive for HIV, HBV, HCV or HTLV in 2008 and 2009. Donors and patients notified of increased risk of vCJD in 2005.
11543431|NCT01050868|Experimental|Single Arm|
11543484|NCT01050504||Ancillary-correlative (blood and tissue collection)|Patients undergo collection of blood and tissue samples for analysis via mutation mapping, DNA sequencing, gene expression microarray, and gene profiling.
11543432|NCT01050855|Experimental|RIC: Distal Campath|"Day Treatment
~Day - 22 Inpatient: Alemtuzumab (Campath) test dose IV or SQ (subcutaneously) over 2 hours
~Day - 21 to-19 Alemtuzumab IV/ SQ
~Day - 7 to -3 Readmission to hospital Fludarabine IV
~Day - 2 Melphalan IV
~Day - 1 Begin cyclosporine infusion
~Day 0 Transplant: Bone marrow or cord blood infusion"
11543433|NCT01050855|Experimental|RIC:Intermediate Campath|"Day Treatment
~Day - 14 to-10 Inpatient: Alemtuzumab (Campath) IV or SQ (subcutaneously)
~Day - 7 to -3 Fludarabine IV
~Day - 2 Melphalan 140 mg/m2 IV
~Day - 1 Cyclosporine infusion starts
~Day 0 Transplant: Bone marrow or cord blood infusion"
11543434|NCT01050855|Experimental|RIC: Mini Busulfan|"Day Treatment
~Day - 8 Alemtuzumab (Campath) IV or SQ (subcutaneously)
~Day - 7 Alemtuzumab (Campath) IV or SQ (subcutaneously)
~Day - 6 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV
~Day - 5 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV
~Day - 4 Alemtuzumab (Campath) IV or SQ (subcutaneously) Fludarabine IV
~Day - 3 Fludarabine IV
~Day - 2 Fludarabine IV Cyclosporine infusion
~Day - 1 Rest
~Day 0 Transplant: Bone marrow or cord blood infusion"
11543435|NCT01050842|Experimental|Arm I|Patients receive oral bicalutamide and oral raloxifene on days 1-28.
11543436|NCT01050829|Experimental|Arm 1|
11543437|NCT01050829|Active Comparator|Arm 2|
11543438|NCT01050816|Experimental|Chondron implantation|ankle cartilage defect patients who had CHONDRON transplantation
11543439|NCT01050803|Experimental|FDSME group|In the FDSME group, sessions will be held interactive; and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions.
11543440|NCT01050803|Active Comparator|Control group|
11543441|NCT01050790|Experimental|Aza Len Lymphapheresis SCT ALI|Azacitidine will be administered to all the patients subcutaneously at a dose of 75 mg/m2 daily for five days(day 1-5). These cycles will be repeated at 28 day intervals depending on hematopoietic recovery. Starting on day 6 patients will receive lenalidomide 15 mg PO daily until day 21. No drug will be administered from day 22 to day 28. Lymphapheresis will occur after cycles 2 and 3.Patients will undergo a stem cell collection approximately two weeks after complete myeloid recovery from the third cycle of therapy. Stem Cell Transplant (SCT) will occur per transplant center protocols. Post-transplant single or tandem autologous lymphocyte infusions (ALI) will be performed no earlier than 30 days post-transplant and no later than 40 days.
11543442|NCT01050777|Experimental|Liposomal Paromomycin|Liposomes containing 10% Paromomycin
11543443|NCT01050777|Experimental|Liposomal meglumine antimoniate|Liposomes containing meglumine antimonate
11543444|NCT01050777|Placebo Comparator|Placebo|
11543445|NCT01050764|Experimental|T-reg Cell Infusion after Allogeneic Stem Cell Transplant|
11543446|NCT01050751|Experimental|Lersivirine (new formulation)|
11543447|NCT01050751|Active Comparator|Lersivirine (old formulation)|
11543448|NCT01050738|Active Comparator|Intracapsulare position|
11543449|NCT01050738|Active Comparator|Extracapsulare position|
11543450|NCT01050725||Radiation therapy patients|Individuals receiving radiation therapy as definitive or neo-adjuvant therapy for selected malignancies, including head and neck, lung, esophageal, rectal cervical and prostate cancers.
11543451|NCT01050712|Experimental|Carbon Monoxide|
11543452|NCT01050712|Placebo Comparator|Synthetic Air|
11543453|NCT01050699|Experimental|Dexmedetomidine|Dexmedetomidine plus saline
11543454|NCT01050699|Active Comparator|Usual Care|Midazolam and Fentanyl
11543455|NCT01050686|Active Comparator|subcutaneous wound drain|subcutaneous wound drain inserted
11543456|NCT01050686|Experimental|no subcutaneous wound drain|no subcutaneous wound drain inserted
11543457|NCT01050673|Active Comparator|VERSAJET|Excision with VERSAJET™ Hydrosurgery System
11543458|NCT01050673|Active Comparator|Conventional Therapy|Conventional operating room excision will consist of sharp instrumentation and electrocautery techniques, with the use of pulse lavage at the investigator's discretion. The type of sharp instrumentation, together with the brand of pulse lavage will be recorded.
11543459|NCT01050660|Active Comparator|3 gm/kg/day intravenous lipid emulsion|
11543460|NCT01050660|Experimental|Intravenous Fat Emulsion-restricted|
11543461|NCT01050647|Active Comparator|17-hydroxyprogesterone caproate|Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation
11543462|NCT01050647|Placebo Comparator|Castor oil injections|Weekly injections of Caster Oil (placebo)
11543463|NCT01050634||Observational|
11543464|NCT01050608||Sprixx Device Group|Treatment group utilizing multimodal hand hygiene device
11543465|NCT01050608||Standard Hand Hygiene Group|Utilizing wall mounted dispensers and CDC based guidelines.
11543466|NCT01050595|Active Comparator|Methylnaltrexone Bromide|
11543467|NCT01050595|Placebo Comparator|Placebo|
11543468|NCT01050582|Experimental|Risperidone|Risperidone as per local prescribing practices
11543469|NCT01050582|Experimental|Other atypical antipsychotic drugs|Other atypical antipsychotic drugs as per local prescribing practices
11543470|NCT01050569|Active Comparator|VLNC Cigarette|Very Low Nicotine Content Cigarette. Dosage: 0.05 mg to 0.09 mg nicotine yield cigarette; Frequency: Daily; Duration: 6 weeks.
11543471|NCT01050569|Active Comparator|Nicotine Patch|21 mg nicotine patch. Dosage: 21 mg; Frequency: Daily; Duration: 6 weeks.
11543472|NCT01050569|Experimental|VLNC Cigarette plus Nicotine Patch|Very Low Nicotine Content Cigarette plus 21 mg Nicotine Patch. Patch Dosage: 21 mg; Cigarette Dosasge: 0.05 to 0.09 mg nicotine yield; Frequency: Daily; Duration: 6 weeks
11543473|NCT01050556|Placebo Comparator|Placebo|Placebo daily
11543474|NCT01050556|Experimental|Folic Acid 400 ug|400 µg folic acid daily
11543475|NCT01050556|Experimental|Folic Acid 800 ug|800 µg folic acid daily
11543476|NCT01050556|Experimental|Creatine|creatine daily
11543477|NCT01050556|Experimental|Creatine + Folic Acid|creatine + folic acid daily
11543478|NCT01050543|Experimental|Sugammadex|
11543479|NCT01050543|Active Comparator|Neostigmine|
11543480|NCT01050530|Experimental|OPC-41061|
11543481|NCT01050530|Placebo Comparator|Placebo|
11543482|NCT01050517|Active Comparator|1|albendazole + ivermectin + praziquantel
11543483|NCT01050517|Placebo Comparator|2|albendazole + ivermectin + (1 week later) praziquantel
11543485|NCT01050491|Placebo Comparator|sitaxsentan, airway remodeling|Blinded, randomised placebo-controlled trial involving two parallel groups of severe asthmatic patients with irreversible airflow obstruction (FEV1≤ 70% of predicted) .
11543486|NCT01050491|Placebo Comparator|placebo, airway remodeling|Blinded, randomised placebo-controlled trial involving two parallel groups of severe asthmatic patients with irreversible airflow obstruction (FEV1≤ 70% of predicted) .
11543487|NCT01050478|Experimental|Paliperidone ER|Paliperidone ER: recommended dose: 6 mg/day. Can be 9 mg/day for patients with an acute exacerbation of schizophrenia. A benzodiazepine for sedation and/or rescue medication can be added with a maximum of 7.5 mg/day, at the investigators' discretion.
11543488|NCT01050465|Active Comparator|email|Patients randomized to this arm will receive an email health information prescription.
11543489|NCT01050465|Active Comparator|paper|Patients randomized to this arm will receive a paper health information prescription.
11543490|NCT01050452|Placebo Comparator|1|albendazole treatment
11543491|NCT01050452|Active Comparator|2|mebendazole treatment
11543492|NCT01050452|Active Comparator|3|ivermectin treatment
11543493|NCT01050452|Active Comparator|4|albendazole + ivermectin treatment
11543494|NCT01050452|Active Comparator|5|mebendazole + ivermectin treatment
11543495|NCT01050439|Experimental|UDAlloSCT + Therapy|This is a non-randomized study to test the safety and response of unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT) with either myleoablative (full intensity) or reduced intensity conditioning therapy in patients with selected malignant and non-malignant disorders. UDAlloSCT has been performed in both adults and children as an alternative transplant for patients who lack and HLA-matched family donor in both malignant and non-malignant disease with varying degrees of response.
11543496|NCT01050426|Active Comparator|Group 1|UFT/LV + RT
11543497|NCT01050426|Active Comparator|Group 2|UFT/LV + RT + Cetuximab
11543498|NCT01050413||1|colon cancer, prostate cancer, lung cancer, ovarian cancer
11543499|NCT01050400||Observant|Individuals within this group will receive pharmacotherapy according to the established institutional guidelines.
11543500|NCT01050400||Prospective CYP2D6 genetic screening|Individuals within the prospective group will receive their CYP2D6 genotype results prior to pharmacotherapy and their analgesic regimen will be tailored to their genetic results.
11543501|NCT01050374|Placebo Comparator|1|albendazole + praziquantel
11543502|NCT01050374|Active Comparator|2|mebendazole + praziquantel
11543503|NCT01050361|Experimental|EGHEM|The intervention group will be called EGHEM - Echo Guided HEmodyanmic Management - and will receive their intraoperative maintenance fluid and possible drug therapy (furosemide) based on their hourly intraoperative LVDD grade.
11543504|NCT01050361|No Intervention|SHEM|"The control group will be
~called SHEM - Standard HEmodynamic Management - and will NOT receive the study intervention, but will receive standard anesthesia and hemodynamic management based on current standards within the institution."
11543505|NCT01050348|Active Comparator|Atorvastatin calcium|Patients will receive study medication upon admission to hospital prior to percutaneous intervention of the culprit artery
11543506|NCT01050348|Placebo Comparator|Sugar Pill|Patients will receive study medication upon admission to hospital prior to percutaneous intervention of the culprit artery
11543507|NCT01050335||Surgical resident or attending|
11543508|NCT01050322|Active Comparator|Capecitabine Lapatinib|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
11543509|NCT01050322|Experimental|Vinorelbine Lapatinib|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
11543510|NCT01050322|Experimental|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
11543511|NCT01050309|Active Comparator|Cervix|
11543512|NCT01050309|Active Comparator|colon|
11543513|NCT01050309|Active Comparator|Intravenous|
11543514|NCT01050283|Experimental|1|[18F]-FDG-PET/CT (Computed Tomography) Imaging
11543515|NCT01050270|Other|Ondansetron /acetylcysteine 20.25h|Ondansetron followed by conventional acetylcysteine regimen
11543516|NCT01050270|Other|Placebo/acetylcysteine 20.25h|placebo followed by conventional acetylcysteine regimen
11543517|NCT01050270|Other|Ondansetron/acetylcysteine 12h|ondansetron followed by modified acetylcysteine regimen
11543518|NCT01050270|Other|Placebo/acetylcysteine 12h|placebo followed by modified acetylcysteine regimen
11543519|NCT01050257|Experimental|Oseltamivir (TAMIFLU®) 100 mg|Oseltamivir (TAMIFLU®) 100 mg intravenous (IV) infused over 2 hours, two times a day (every 12 hours) for 5 days. At the discretion of the investigator after 3 days of treatment (6 doses), participants could either continue IV treatment or switch to 75 mg oral oseltamivir twice daily to complete the 5 days of treatment. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug (IV or oral) for up to 5 days.
11543520|NCT01050257|Experimental|Oseltamivir (TAMIFLU®) 200 mg|Oseltamivir (TAMIFLU®) 200 mg intravenous (IV) infused over 2 hours, two times a day (every 12 hours) for 5 days. At the discretion of the investigator after 3 days of treatment (6 doses), participants could either continue IV treatment or switch to 150 mg oral oseltamivir twice daily for 5 days. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug (IV or oral) for up to 5 days.
11543521|NCT01050257|Experimental|Oseltamivir Open Label|Moderate/Severe renal impaired participants received open label oseltamivir IV or oseltamivir capsules at reduced doses for 5 days as per protocol. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug as per protocol.
11543522|NCT01050244|Experimental|Soy Protein|30g of soy protein from whole soybean soymilk powder given daily for 3 weeks
11543523|NCT01050244|Placebo Comparator|Milk Protein|30g of milk protein from whole milk powder given daily for 3 weeks
11543524|NCT01050231|Experimental|1|Robotic group(Type I)
11543525|NCT01050231|Active Comparator|2|Robotic group (Type II)
11543572|NCT01049828||Slightly or Non-Bothered Tinnitus Group|
11543526|NCT01050218|Other|DVS SR Open Label|Daily dose of 100mg or 200mg at the investigators discretion. Subjects already randomized at a dose of 400mg may continue at that dose level.
11543527|NCT01050205|Active Comparator|Current Intervention|"Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD). Upon choosing, participants will be randomly assigned to Current intervention Arm in which case they will receive the intervention immediately."
11543528|NCT01050205|Active Comparator|Delayed Intervention|"Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD). Upon choosing, participants will be randomly assigned to Delayed Intervention Arm in which case they will receive delayed intervention at 6 months."
11543529|NCT01050166||Labeled islets|Type 1 diabetic recipients after islet transplantation with islets labeled by iron contrast agent
11543530|NCT01050153|Active Comparator|Control (standard of care)|Dalteparin sodium 5000IU subcutaneously daily
11543531|NCT01050153|Experimental|TEG-guided thromboprophylaxis|Dalteparin sodium plus/minus anti-platelet medication (aspirin) per a TEG-guided algorithm
11543532|NCT01050140|Experimental|fructose|25% dietary energy from fructose
11543533|NCT01050140|Active Comparator|glucose|25% dietary energy from glucose
11543534|NCT01050127|Experimental|Low dose ABT-436|ABT-436 or placebo administered once daily for 7 days.
11543535|NCT01050127|Experimental|Mid Dose ABT-436|ABT-436 or placebo administered once daily for 7 days.
11543536|NCT01050127|Experimental|High Dose ABT-436|ABT-436 or placebo administered once daily for 14 days.
11543537|NCT01050114|Other|ARM 1: onaBoNT-A injection + placebo|onaBoNT-A 200 U (treatment 1)/ onaBoNT-A 200 U (treatment 2)/ onaBoNT-A 200 U (treatment 3) and placebo oral capsule daily
11543538|NCT01050114|Other|ARM 2: Placebo injection + oxybutynin ER|Placebo injection (treatment 1)/ onaBoNT-A 200 U (treatment 2)/ onaBoNT-A 200 U (treatment 3) and oxybutynin ER 10 mg capsule daily
11543539|NCT01050101|Placebo Comparator|High GI low fiber meal|No fiber control meal
11543540|NCT01050101|Active Comparator|Low GI high fiber viscous meal|80:20 ratio of viscous polysaccharide fiber to insoluble non-viscous producing fiber
11543541|NCT01050101|Active Comparator|Low GI high fiber non-viscous meal|20:80 ratio of viscous polysaccharide fiber source to insoluble non-viscous producing fiber
11543542|NCT01050088|Experimental|Sucrose|5cc sucrose solution
11543543|NCT01050088|Placebo Comparator|Saline|5cc saline p/o
11543544|NCT01050075|Experimental|Arm I|Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks during courses 3 and 4.
11543545|NCT01050075|Experimental|Arm II|Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients then undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks.
11543546|NCT01050062||Micombi® Combination Tablet AP|
11543547|NCT01050062||Micombi® Combination Tablet BP|
11543548|NCT01050049||Before guidelines implemented|
11543549|NCT01050049||After guidelines implemented|
11543550|NCT01050036|Experimental|HCT recipients|"Patient with CBF AML will be eligible in his/her 1st complete remission (CR1) status. Patients who have relapsed or have achieved 2nd complete remission should not be included in this study.
~1st postremission therapy after CR1 will be performed with high-dose cytarabine (HDAC) chemotherapy, consisting of intravenous cytarabine 3 g/m2 infusion during 3 hours twice a day on days 1, 3, and 5.
~After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information."
11543551|NCT01050023|Experimental|1 - Active Treatment|Provant device activated to emit RF energy
11543552|NCT01050023|Sham Comparator|2 - Inactive Treatment|Provant device not activated to emit RF energy
11543553|NCT01050010|Other|Dedicated extremity MRI|Structural deterioration radiographic assessed by dedicated extremity MRI
11543554|NCT01049997||NSTEMI75+|Patients, 75 years old or older, with Non ST Elevation Myocardial Infarction (NSTEMI)
11543555|NCT01049984|Experimental|Rasagiline 1 mg|Participants took a 1 mg rasagiline tablet orally each day for 18 weeks.
11543556|NCT01049984|Placebo Comparator|Placebo|Participants took a matching placebo tablet once daily for 18 weeks.
11543557|NCT01049971|Active Comparator|no wound protector|instead of wound protector, a woven drape is applied
11543558|NCT01049971|Experimental|wound protector|after minilaparotomy, wound protector is applied
11543559|NCT01049945|Experimental|Arm I|Patients receive dexamethasone orally or IV on days 1, 8, 15, and 22; bendamustine hydrochloride IV over 30 minutes on days 1 and 2; and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11543560|NCT01049932|Experimental|All subjects|TMC278LA 600mg injected intramuscularly (i/m)
11543561|NCT01049919|Experimental|Concentrated bone marrow aspirate (cBMA)|Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
11543562|NCT01049919|Sham Comparator|Placebo control (sham)|Placebo procedure (sham) consists of simulated bone marrow aspiration followed by simulated intramuscular injections into the affected limb
11543563|NCT01049906|Active Comparator|Nerve stimulation and Ultrasound|
11543564|NCT01049906|Active Comparator|Ultrasound without nerve stimulation|
11543565|NCT01049893|Experimental|AC220|Dose finding study. Number of arms dependant upon dose limiting toxicities.
11543566|NCT01049880|Experimental|Ascorbate|
11543567|NCT01049854|Experimental|Thiotepa/Cyclophosphamide/ATG|Full intensity with TBI
11543568|NCT01049854|Experimental|Busulfan/Melphalan/ATG|Full intensity without TBI
11543569|NCT01049854|Experimental|Busulfan/Fludarabine/Alemtuzumab|Reduced Intensity Chemotherapy
11543570|NCT01049854|Experimental|Fludarabine/Cyclophosphamide/ATG|Reduced Intensity Chemotherapy for Fanconi Anemia
11543571|NCT01049841|Experimental|perifosine + temsirolimus|This is a single arm, phase I study. Eligible patients will receive a loading dose of oral perifosine on the first day, followed by a maintenance dose starting on the second day until progression. Each patient is assigned to a group according to their body surface area (BSA). Temsirolimus will be combined with perifosine at four dose levels to determine the MTD for the combination therapy. Temsirolimus dosing will start on the same day as the perifosine load.
11543574|NCT01049815|Active Comparator|Calcium carbonate|
11543575|NCT01049802|Experimental|Active rTMS|Experimental subjects will receive subthreshold or suprathreshold rTMS to contralesional hemisphere for up to 20 minutes at 1 Hz followed by task oriented arm and hand therapy to affected limb.
11543576|NCT01049802|Placebo Comparator|Sham rTMS|Subject will receive sham rTMS to contralesional hemisphere for up to 20 minutes followed by task-oriented arm and hand rehabilitation to affected limb
11543577|NCT01049789|Active Comparator|TAU|Sites participating in Phase I and Phase II will be randomized to implement this treatment method or the other treatment method. All ATN 080 participants at a site randomized to implement TAU will receive that treatment method.
11543578|NCT01049789|Experimental|COMB|Sites participating in Phase I and Phase II will be randomized to implement this treatment method or the other treatment method. All ATN 080 participants at a site randomized to implement COMB will receive that treatment method.
11543579|NCT01049776|Experimental|Pazapanib (GW786034)|
11543580|NCT01049763|Experimental|Regimen A|oseltamivir 75 mg single dose
11543581|NCT01049763|Active Comparator|Regimen B|oseltamivir 150 mg single dose
11543582|NCT01049750||type 2 diabetic patients|males; type 2 diabetic patients
11543583|NCT01049724||PRK|Those patients undergoing photorefractive keratectomy
11543584|NCT01049724||LASIK|Those undergoing Laser-assisted insitu keratomileusis
11543585|NCT01049711||erythropoietin|
11543586|NCT01049698|Active Comparator|1. Resistance Training|3 d/wk resistance training
11543587|NCT01049698|Experimental|2. Resistance Training + Diet|Resistance training plus caloric restriction
11543588|NCT01049685|Active Comparator|Efavirenz Group|Naïve-treatment HIV patients, who started therapy with Efavirenz
11543589|NCT01049685|Active Comparator|Lopinavir/r Group|Naïve-treatment HIV patients, who started therapy with Lopinavir/ritonavir
11543590|NCT01049672|Active Comparator|Alfentanil|Hospice in-patients who require subcutaneous strong opioid administration will be given alfentanil
11543591|NCT01049672|Active Comparator|Diamorphine|Hospice in-patients who require strong opioids will be given diamorphine
11543592|NCT01049659|Other|neuropsychological tests|neuropsychological assessment of children around their second birthday
11543593|NCT01049646|Active Comparator|Angiotensin II|
11543594|NCT01049646|Placebo Comparator|Saline infusion|
11543595|NCT01049620|Experimental|Xelox+RAD001|
11543596|NCT01049607|Active Comparator|Clamp-Crush technique|
11543597|NCT01049607|Experimental|Stapler hepatectomy|
11543598|NCT01049594||Preterm infants|Delivery at less than 33 completed weeks of gestation
11543599|NCT01049581|Experimental|pediatric aquatic therapy|The children of the PAT group participated in a 1 hour/time, twice-per-week, 12-week, PAT program in addition to conventional rehabilitation programs
11543600|NCT01049581|No Intervention|conventional therapy|The children included in the control group continued with their original rehabilitation programs
11543601|NCT01049568|Experimental|Cell Phone Intervention|
11543602|NCT01049568|No Intervention|Control|"Control group participants will participate in all on-study evaluations, except the intervention exit interviews.
~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization."
11543603|NCT01049555|Other|Alzheimer and apathy|Alzheimer's disease patients with apathy
11543604|NCT01049555|Other|alzheimer without disease|Alzheimer's disease patients without apathy
11543605|NCT01049555|Other|Case control|subject without apathy neither Alzheimer's disease
11543606|NCT01049542|Experimental|Astressin 2B|Healthy volunteers will receive incremental doses of intra arterial Astressin 2B (a selective and potent Urocortin 2 & 3 antagonist). This serves as a dose finding Protocol for Astressin 2B, which will be used in subsequent protocols.
11543607|NCT01049529|Placebo Comparator|Placebo group|This group is receiving sunflower oil (the excipient for DHA)
11543608|NCT01049529|Active Comparator|DHA group|This group is receiving the docosahexaenoic acid (DHA) supplement
11543609|NCT01049516|Other|Minimal Contact Control|
11543610|NCT01049516|Experimental|PE-Massed|
11543611|NCT01049516|Active Comparator|PE-Spaced|
11543612|NCT01049516|Active Comparator|Present-Centered Therapy (PCT)|
11543613|NCT01049503|Active Comparator|Caries-active 550 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
11543614|NCT01049503|Active Comparator|Caries-active 550 ppm F, pH 4.5|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
11543615|NCT01049503|Active Comparator|Caries-active 1100 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
11543616|NCT01049503|Active Comparator|Caries-inactive 550 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
11543617|NCT01049503|Active Comparator|Caries-inactive 550 ppm F, pH 4.5|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
11543618|NCT01049503|Active Comparator|Caries-inactive 1100 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
11543619|NCT01049490|Active Comparator|Intramuscular|15 mcg H1N1 vaccine delivered via intramuscular injection (control)
11543620|NCT01049490|Active Comparator|Intradermal|Intradermal: H1N1 vaccine delivered via intradermal injection: Experimental
11544030|NCT01046799|Experimental|Entecavir|
11543621|NCT01049477|Experimental|Music therapy|Experimental arm includes women undergoing cesarean section delivery listening to music before and after c/s. STAI will be completed pre and post operatively.
11543622|NCT01049477|No Intervention|No music group|Subjects will not listen to music before and after c/s. STAI will be completed pre and post operatively.
11543623|NCT01049464|Placebo Comparator|5%D/W|The patients in this group will receive 5%D/W 20 ml intravenous in 10 min and then 5%D/W 100 ml infusion in 6 hours as the placebo drug.
11543624|NCT01049464|Experimental|Magnesium sulphate|The patients in this group will receive 2g of Magnesium sulphate diluted with 5%D/W into 20 ml solution, infusion intravenously in 10 min then 6g of Magnesium sulphate diluted with 5%D/W into 100 ml solution, infusion intravenously in 6 hours
11543625|NCT01049451|Experimental|ACTH IM monthly|Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
11543626|NCT01049451|Active Comparator|MP IV monthly|Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months.
11543627|NCT01049438|Experimental|Nasal, body, and systemic decolonization|
11543628|NCT01049425|Active Comparator|Epirubicin and Cyclophosphamid followed by Docetaxel|4 cycles of EC on day one every three weeks followed by 4 cycles of Docetaxel on day one every three weeks
11543629|NCT01049425|Experimental|Combination of Docetaxel and Cyclophosphamid|intravenous infusion on day one every three weeks
11543630|NCT01049412|Experimental|LY2605541 First, Then Insulin Glargine|Participants received LY2605541 for 8 weeks, followed by insulin glargine for 8 weeks.
11543631|NCT01049412|Active Comparator|Insulin Glargine First, Then LY2605541|Participants received insulin glargine for 8 weeks, followed by LY2605541 for 8 weeks.
11543632|NCT01049399|Placebo Comparator|Placebo|once daily administration of powder for oral suspension.
11543633|NCT01049399|Experimental|NP031112 800 mg|Group dosed with 800 mg once daily for 52 weeks
11543634|NCT01049399|Experimental|NP031112 600 mg|Group treated with 600 mg once daily for 52 weeks
11543635|NCT01049386|Active Comparator|Sugar absorption test|In 150 mL of water four different sugars will be dissolved. Absorption will be calculated based on concentrations of sugars in 0-5 hours urine and 0-24 h collected urine.
11543636|NCT01049386|Experimental|Sugar absorption test and high-fat breakfast|In 150 mL of water four different sugars will be dissolved. Absorption will be calculated based on concentrations of sugars in 0-5 hours urine and 0-24 h collected urine. Subjects will eat a high-fat breakfast together with the sugar drink, to investigate the disturbance caused by fat in intestinal absorption.
11543637|NCT01049373|Experimental|Lymphdiaral Basistropfen (HDC)|HDC (Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X), each 10 drops t.i.d. for 15 weeks.
11543638|NCT01049373|Placebo Comparator|Placebo Solution|10 drops t.i.d. for 15 weeks
11543639|NCT01049360|Experimental|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID)
11543640|NCT01049360|Experimental|Aclidinium 400 μg / formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID)
11543641|NCT01049360|Experimental|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID)
11543642|NCT01049360|Active Comparator|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily
11543643|NCT01049360|Placebo Comparator|Placebo|Placebo twice-daily
11543644|NCT01049347|Active Comparator|amitriptyline|
11543645|NCT01049347|Active Comparator|paroxetine|
11543646|NCT01049334|Experimental|flurbiprofen 8.75 mg lozenge|Participants sucked flurbiprofen 8.75mg lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
11543647|NCT01049334|Placebo Comparator|Placebo lozenge|Participants sucked vehicle placebo lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
11543648|NCT01049321|Experimental|DASH diet|DASH: Dietary approaches to stop hypertension eating plan
11543649|NCT01049321|Placebo Comparator|Diabetic diet|Diabetic diet: a usual diabetic diet
11543650|NCT01049308||Heart Failure|veteran population with documented heart failure
11543651|NCT01049295|Experimental|oil fish pearls|patients with invasive breast cancer who received 640 mg oil fish pearls 3 times a day
11543652|NCT01049295|Placebo Comparator|placebo|patient with invasive breast cancer who received corn oil pearls as placebo 3 times a day
11543653|NCT01049282|Experimental|12 TST negative volunteers antigen only|
11543654|NCT01049282|Experimental|12 TST negative volunteers|
11543655|NCT01049282|Experimental|12 BCG vaccinated volunteers|
11543656|NCT01049282|Experimental|12 with Latent TB infection >= 2 years ago|
11543657|NCT01049269||1:one group|
11543658|NCT01049243|Other|Fluocinonide Cream 0.1%|Fluocinonide Cream 0.1% open label
11543659|NCT01049230|Experimental|Proton beam radiation|Radiation therapy with proton beam
11543660|NCT01049217|Experimental|Active drug|
11543661|NCT01049217|Placebo Comparator|Control|
11543662|NCT01049204|Active Comparator|Group 1|Nadir CD4 count >200 cells/µl blood and randomised to Maraviroc 150mg BD
11543663|NCT01049204|Placebo Comparator|Group 2|Nadir CD4 count >200 cells/µl blood and randomised to placebo twice daily for 24 weeks
11543664|NCT01049204|Active Comparator|Group 3|Nadir CD4 count ≤200 cells/µl blood and randomised to Maraviroc 150mg BD
11543665|NCT01049204|Placebo Comparator|Group 4|Nadir CD4 count ≤200 cells/µl blood and randomised to placebo twice daily for 24 weeks
11543666|NCT01049191||Fracture|Subjects experiencing a prior osteoporotic fracture.
11543667|NCT01049191||Control|These will be age and bone density matched controls to the fracture group.
11543668|NCT01049178|Experimental|Oral silymarin dose|Dose escalation study
11543669|NCT01049178|Placebo Comparator|placebo|A randomized, double-masked, placebo-controlled cross-over clinical pilot investigation of an inducer of endogenous antioxidant enzymes, silymarin, in humans with atopic asthma.
11543670|NCT01049165|Active Comparator|Arm 1 (BMS-813160 or placebo)|
11543671|NCT01049165|Active Comparator|Arm 2 (BMS-813160 or placebo)|
11543672|NCT01049165|Active Comparator|Arm 3 (BMS-813160 or placebo)|
11543673|NCT01049165|Active Comparator|Arm 4 (BMS-813160 or placebo)|
11543674|NCT01049165|Active Comparator|Arm 5 (BMS-813160 or placebo)|
11543675|NCT01049165|Active Comparator|Arm 6 (BMS-813160 or placebo)|
11543676|NCT01049165|Active Comparator|Arm 7 [14C] BMS-813160|
11543677|NCT01049165|Active Comparator|Arm 8 (BMS-813160 or placebo)|
11543678|NCT01049165|Active Comparator|Arm 9 (BMS-813160 or placebo)|
11543679|NCT01049152||nondiabetic patients|nondiabetic patients with ESRD undergone hemodialysis
11543680|NCT01049152||diabetic patients|diabetic patients with ESRD undergone hemodialysis
11543681|NCT01049139|No Intervention|No Supplemental Information|Participants will be administered a standard HIV vaccine trial consent form but no additional information.
11543682|NCT01049139|Experimental|Supplemental information with 1-sided message|Participants will be administered a standard HIV vaccine trial consent form and supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
11543683|NCT01049139|Experimental|Supplemental information with 2-sided messages|Participants will be administered a standard HIV vaccine trial consent form and supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
11543684|NCT01049126||Late stage endometrial cancer|
11543685|NCT01049113|Experimental|ON 013105|ON 013105 administered intravenously as 2-hour infusion once a week for 3 weeks of 3-week cycles. This is dose escalation study; starting dose is 17 mg.
11543686|NCT01049100|Experimental|operative staging (A)|operative staging and systemic lymphadenectomy, paraaortal and pelvine, laparoscopic or open
11543687|NCT01049100|No Intervention|Standard (B)|No surgical intervention. Clinical Staging (FIGO) CT Abdomen / pelvic enlarged or suspicious lymphnodes--> CT controlled biopsy and histological analysis.
11543688|NCT01049074|Experimental|Verus acupuncture|
11543689|NCT01049074|Sham Comparator|Sham acupuncture|
11543690|NCT01049061|Experimental|MORAb-003|
11543691|NCT01049048|Placebo Comparator|Control|This group receives placebo chocolate cookies with no vitamin D3 added.
11543692|NCT01049048|Experimental|Vitamin D3|This group receives 2500 IU of Vitamin D3 added to a chocolate cookie daily.
11543693|NCT01049035|Experimental|Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months|Participants aged 2 months (at the time of enrollment) received Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein (MenACYW) Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.
11543694|NCT01049035|Experimental|Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months|Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.
11543695|NCT01049035|Experimental|Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months|Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.
11543696|NCT01049035|Experimental|Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months|Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.
11543697|NCT01049035|Experimental|Group 5: MenACYW Conjugate Vaccine: Month 12|Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.
11543698|NCT01049035|Other|Group 6: Control: 2, 4, 6, and 12 Months|Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.
11543699|NCT01049035|Other|Group 7: Control: 2, 4, 6, 12, and 15 Months|Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.
11543700|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 1|
11543701|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 2|
11543702|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 3|
11543703|NCT01049009|Active Comparator|Nebivolol followed by Metoprolol XL|Subjects are randomized to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after cross over.
11543704|NCT01049009|Active Comparator|Metoprolol XL followed by Nebivolol|Subjects are randomized to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after cross over.
11543705|NCT01048996||Non ALI/ARDS|Those patient who enrolled in the study but did not develop ALI or ARDS during their hospital course.
11543706|NCT01048996||ALI/ARDS|Those patients who enrolled in the study and developed ALI or ARDS during their hospital course.
11543707|NCT01048983|Other|Questionnaires and Phone Calls|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
11543708|NCT01048983|Active Comparator|Curcumin Only|
11543709|NCT01048983|Active Comparator|Armodafinil Only|
11543710|NCT01048983|Active Comparator|Minocycline Only|
11543711|NCT01048983|Active Comparator|Bupropion Only|
11543712|NCT01048983|Active Comparator|Curcumin + Armodafinil|
11543713|NCT01048983|Active Comparator|Curcumin + Minocycline|
11543714|NCT01048983|Active Comparator|Curcumin + Bupropion|
11543715|NCT01048983|Active Comparator|Armodafinil + Minocycline|
11543716|NCT01048983|Active Comparator|Armodafinil + Bupropion|
11543717|NCT01048983|Active Comparator|Minocycline + Buproprion|
11543718|NCT01048983|Active Comparator|Curcumin + Armodafinil + Minocycline|
11543719|NCT01048983|Active Comparator|Curcumin + Armodafinil + Bupropion|
11543720|NCT01048983|Active Comparator|Curcumin + Minocycline + Bupropion|
11543721|NCT01048983|Active Comparator|Armodafinil + Minocycline + Bupropion|
11543722|NCT01048983|Active Comparator|Curcumin + Armodafinil + Minocycline + Bupropion|
11543723|NCT01048970|Other|Control arm|Patients will receive nutritional assessment one week prior to treatment until completing two cycles
11543724|NCT01048970|Experimental|EPA-DHA arm|Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
11543725|NCT01048944|Active Comparator|Bupropion SR|150 mg bid bupropion SR
11543726|NCT01048944|Active Comparator|Nicotine Patch|21mg, 14mg, 7mg
11543727|NCT01048944|Placebo Comparator|Placebo Patch and Placebo Pill|Individuals were placed on both a placebo patch that were the same size as active patches given to the Nicotine Patch group and were also given placebo pills were the same size and identically packaged as the active pills (bupropion) given to the Bupropion SR group.
11543728|NCT01048944|No Intervention|Delayed-quit control|Smoke for 67 days while others have quit, then quit.
11543729|NCT01048931|Experimental|single-port LAVH|single port LAVH
11543730|NCT01048918||No Treatment|
11543731|NCT01048905|Experimental|Pharmacokinetics|8 hour pharmacokinetics after glutamine supplementation
11543732|NCT01048905|Experimental|Treatment|Patients will receive an 8-week course of oral L-glutamine 10 grams TID
11543733|NCT01048892|Experimental|Treatment (NTX-010)|
11543734|NCT01048879|Other|ECMO alone|Patients receiving oseltamivir and Extracorporeal Membrane Oxygenation (ECMO) therapy (patients were already receiving oseltamivir and ECMO due to an illness)- Procedure/Surgery: pharmacokinetic blood sampling
11543735|NCT01048879|Other|CVVHD Alone|"Patients receiving Continuous Venovenous Hemodialysis(CVVHD) and oseltamivir (Patients were already receiving oseltamivir and CVVHD as a result of an illness).
~Procedure/Surgery: pharmacokinetic blood and dialysate sampling"
11543736|NCT01048879|Other|CVVHD + ECMO|"Patient receiving oseltamivir and ECMO and CVVHD (patients were already receiving oseltamivir, ECMO, and CVVHD as part of an illness).
~Procedure/Surgery: pharmacokinetic blood and dialysate sampling"
11543737|NCT01048866|Experimental|flurbiprofen 8.75 mg lozenge|Participants were instructed to suck one study (flurbiprofen 8.75 mg) lozenge and efficacy assessments were taken in the clinic. Upon discharge, participants were instructed to use another study medication lozenge every 3-6 hours, up to a total of 5 study lozenges in 24 hours. Following efficacy assessments, participants were again instructed to use study medication lozenge every 3-6 hours, up to a total of 5 study lozenges per day (plus rescue medication if needed) for the remaining time in the 7 day study.
11543738|NCT01048866|Placebo Comparator|placebo lozenge|Participants were instructed to suck one study (placebo) lozenge and efficacy assessments were taken in the clinic. Upon discharge, participants were instructed to use another lozenge every 3-6 hours, up to a total of 5 study lozenges in 24 hours. Following efficacy assessments, participants were again instructed to use a lozenge every 3-6 hours, up to a total of 5 study lozenges per day (plus rescue medication if needed) for the remaining time in the 7 day study.
11543739|NCT01048853|Experimental|Conservative Surgery|Removal of the pelvic lymph nodes (pelvic lymphadenectomy)
11543740|NCT01048840||Subject with History of GERD|Children and adolescents ages 12-17 years, inclusive, seen at Children's Hospital, Boston or Massachusetts General Hospital between 1977 and 1990 for symptoms of GERD and also had biopsies and / or a pH probe that was positive for GERD.
11543741|NCT01048840||Controls with out GERD|Individuals that do not have a history of GERD or other GI problems prior to age 21 and whose date of birth are with in a year of a subjects
11543742|NCT01048827|Experimental|experimental|dose-escalation Busulfan
11543743|NCT01048814||Ovarian, Peritoneal, Fallopian Cancer|Recurrent, Peristent or Refractory
11543744|NCT01048801|Active Comparator|Rapid diagnostic test and treatment|
11543745|NCT01048801|Other|Treatment without rapid daignostic test|
11543746|NCT01048788|Experimental|OPC|
11543747|NCT01048762|Active Comparator|supervised exercise training|Intervention: supervised exercise training and dyspnea counseling in groups for 10 weeks Instruction on home based exercise training
11543748|NCT01048762|Sham Comparator|one instruction on homebased exercises|One instruction on home based exercise training and dyspnea management
11543749|NCT01048749|Active Comparator|aquatic vertical supsension|Spinal height measurement using a stadiometer following aquatic vertical suspension
11543750|NCT01048749|Active Comparator|land-based supine flexion condition|Spine height will be measured with a stadiometer following completion of the supine land-based flexion position.
11543751|NCT01048736|Active Comparator|Exercise|All treatment groups will receive 4d/wk of exercise
11543752|NCT01048736|Experimental|Exercise + Diet (-250 kcal/d deficit)|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; ~4.5 kg weight loss),
11543753|NCT01048736|Experimental|Exercise + Diet (-600 kcal/d deficit)|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; ~10.9 kg weight loss)
11543754|NCT01048723|Experimental|RAD001 Administration|RAD001 was administered orally as once daily dose of 10 mg PO daily x 2 weeks (14 X 10 mg tablets) continuously from study day 1 until the end of therapy (2 weeks later) or unacceptable toxicity.
11543755|NCT01048710||Tomofix_small|Surgical treatment using TomoFix TM Small
11543756|NCT01048710||Conservative treatment|"In the control group, patients who refused to have surgery will be allowed to be treated using different options of conservative treatment. The frequency of applications depends on the hospital and will therefore be documented in the study. An arthroscopy is not obligatory under this treatment group, but is permitted.
~The following conservative treatment methods are allowed:
~Physical therapy
~Specific exercises for the muscles
~Injections into the knee joint
~Brace
~Medication
~No therapy"
11543757|NCT01048697|Experimental|Ethambutol|"All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):
~40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) > 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)"
11543758|NCT01048684|Active Comparator|20% Mannitol 0.7 g/kg (low-dose)|Study subjects will be randomized to receive an infusion of 20% mannitol 0.7g/kg over 30 minutes after induction of general anesthesia.
11543759|NCT01048684|Experimental|20% Mannitol 1.4 g/kg (high dose)|Study subjects will be randomized to receive an infusion of 20% mannitol 1.4 g/kg over 30 minutes after induction of general anesthesia.
11543760|NCT01048671||Antiretroviral combination therapy including raltegravir|Participants received ARV combination treatment including raltegravir. Treatment of participants was at the discretion of the investigator who provided standard care in a real life setting.
11543761|NCT01048658|Active Comparator|Sevoflurane|Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
11543762|NCT01048658|Placebo Comparator|No Sevoflurane|Subject receives standard of care drug regimens for anesthesia with this procedure.
11543763|NCT01048645|Placebo Comparator|P/PC arm|Patients were assigned to receive placebo (P/PC) 1 week prior to treatment until completing two cycles
11543764|NCT01048645|Experimental|RA/PC arm|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two cycles
11543765|NCT01048632|Experimental|Oxandrolone|Following clinical evaluation, all patients will be receive oxandrolone in addition to their usual medications. Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
11543766|NCT01048619|Experimental|ON 01910.Na|The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
11543767|NCT01048606|Active Comparator|Placeco + exercise|Placebo (no phytoestrogen): Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day) Exercise (three 1h-sessions/week)
11543768|NCT01048606|Active Comparator|Phytoestrogens without exercise|Phytoestrogens (70mg/day of soy isoflavone) Without exercise (no structured exercise session)
11543769|NCT01048606|Experimental|Phytoestrogens + exercise|Phytoestrogens (70 mg/day soy isoflavone) Exercise (1h-sessions 3 times/week)
11543770|NCT01048606|No Intervention|Placebo without exercise|Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day) No exercise
11543771|NCT01048593|Experimental|Dose 1|114ug
11543772|NCT01048593|Experimental|Dose 2|513ug
11543773|NCT01048593|Experimental|Dose 3|684ug
11543774|NCT01048580|Experimental|Perifosine +Capecitabine|One cycle of therapy will be defined as 3 weeks (21 days). Perifosine 50 mg qd (Days 1-21) + Capecitabine 1000 mg/m2 BID (Days 1-14).
11543775|NCT01048567|Active Comparator|Lactobacillus acidophilus/rhamnosus|
11543776|NCT01048567|Placebo Comparator|Placebo|
11543777|NCT01048554|Other|Temozolomide/Bevacizumab|Patients will be treated with a combination of temozolomide at 75 mg/m2/day for six continuous weeks, followed by a two-week rest period and bevacizumab 10 mg/kg every 2 weeks without interruption. Cycles will be repeated every 8 weeks. Patients will be restaged every 8 weeks.
11543778|NCT01048541|Active Comparator|SpeediCath catheter|Standard treatment
11543779|NCT01048541|Experimental|Test product|
11543780|NCT01048528|Experimental|Stress Management|Stress Management and Relaxation Training workshops
11543781|NCT01048528|No Intervention|Wait-list|Wait-list comparison group
11543782|NCT01048515|Experimental|Caffeine|
11543783|NCT01048515|Placebo Comparator|Placebo|
11543784|NCT01048502|Experimental|Fenofibrate (Tricor) (145 mg/day)|Participants will be given 1 fenofibrate (Tricor) 145mg and 4 fish oil placebos - supplies of study drug will be provided to last 8 weeks.
11543785|NCT01048502|Placebo Comparator|Placebo|Participants will be given 5 placebo pills (4 fish oil placebo and 1 fenofibrate placebo) - supplies of study drug will be provided to last 8 weeks.
11543786|NCT01048502|Experimental|Lovaza (900 mg/day)|Participants will be given 1 Lovaza capsule, 3 Fish oil placebo capsules, and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
11543787|NCT01048502|Experimental|Lovaza (3,600 mg/day)|Participants will be given 4 Lovaza capsules and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
11543788|NCT01048489|Other|Lifestyle counseling|
11543789|NCT01048489|No Intervention|No counseling|
11543790|NCT01048476|Active Comparator|Group L20|Dietary Supplement: 20mg Lutein; daily supplementation one year
11543791|NCT01048476|Active Comparator|Group L10|Dietary Supplement: 10mg Lutein; daily supplementation one year
11543792|NCT01048476|Placebo Comparator|Group Placebo|Dietary Supplement: Placebo, 0 mg Lutein
11543793|NCT01048476|Active Comparator|Active Comparator: Group LZ|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
11543794|NCT01048463|Placebo Comparator|EN|The subjects take in 150g of Nutriall per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d. During the test period patients are treated with the first course of XELOX.
11543795|NCT01048463|Experimental|ENLDEPA|The subjects take in the same dose of Nutriall for the same duration as those in EN group. In addition, they take in 3 grams of EPA per day during the 21 days of treatment. The patients are treated with the first course of XELOX.
11543796|NCT01048463|Experimental|ENHDPEA|The subjects take in the same dose of supportan for the same duration as those in EN group. In addition, they take in 6 grams of EPA per day during the 21 days of treatment. The patients are treated with the first course of XELOX.
11543797|NCT01048450|Experimental|Treatment|Those who were diagnosed with hallux limitus/rigidus (end stage degeneration at the 1st metatarsal phalangeal joint)
11543798|NCT01048437|No Intervention|Standard transplant education|Missouri Kidney Program's standard Patient Education Program (PEP) transplant module.
11543799|NCT01048437|Experimental|Transplant education with video|Explore Transplant transplant module featuring video
11543800|NCT01048437|Experimental|Transplant education with speakers|Explore Transplant transplant module featuring live guest speakers.
11543801|NCT01048424|Experimental|Paced respiration|Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a Urinary Incontinence pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.
11543802|NCT01048424|Placebo Comparator|Control|Participants will be given a Urinary Incontinence pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.
11543803|NCT01048411|Active Comparator|Naja-comp.|s.c. injection of naja comp (homeopathic remedy) three times a week
11543804|NCT01048411|Placebo Comparator|Placebo|s.c. injection of placebo (NaCl-solution) three times a week
11543805|NCT01048398|Experimental|Remifentanil|
11543806|NCT01048398|Active Comparator|Paracetamol|intravenous paracetamol 1g
11543807|NCT01048385|Experimental|CoQ10|This group will be treated concomitantly with Coenzyme Q10
11543808|NCT01048385|Placebo Comparator|Control|Treated with capsules containing the vehicle.
11543809|NCT01048372||Early HIV infection|HIV infected adults with early evidence of suppressed cell-mediated immunity but whose disease has not progressed far enough to indicate antiretroviral therapy.
11543810|NCT01048372||Control|Healthy adults without HIV infection.
11543811|NCT01048359|Experimental|Brief Intervention|30-45 minute motivational interviewing based intervention with feedback addressing drug use, injury prevention and HIV risk.
11543812|NCT01048359|Active Comparator|Brief advice|This condition of the experiment acts a control and will be a short session in which the therapist will provide brief advice about drug use and give the patient a pamphlet.
11543813|NCT01048359|Experimental|Brief Intervention plus Booster|30-45 minute motivational interviewing based intervention with feedback addressing drug use, injury prevention and HIV risk plus a brief phone booster session at 1 month post-intake to review feedback, 2) assess progress, 2) renew motivation to change, and 3) evaluate and affirm commitment to change.
11543814|NCT01048346|Experimental|supported employment|Study consists of one experimental group and one control group. The intervention group received IPS
11543815|NCT01048333|Experimental|Formoterol, then Salmeterol, then Placebo|Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Placebo Diskus and Placebo Turbuhaler
11543816|NCT01048333|Experimental|Salmeterol, then Palcebo, then Formoterol|Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Placebo Diskus and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus
11543817|NCT01048333|Experimental|Placebo, then Formoterol, then Salmeterol|Placebo Diskus and Placebo Turbuhaler first,then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
11543818|NCT01048333|Experimental|Formoterol, then Placebo, then Salmeterol|Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Placebo Diskus and Placebo Turbuhaler, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
11543819|NCT01048333|Experimental|Salmeterol, then Formoterol, then Placebo|Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Placebo Diskus and Placebo Turbuhaler
11543820|NCT01048333|Experimental|Placebo, then Salmeterol, then Formoterol|Placebo Diskus and Placebo Turbuhaler first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus
11543821|NCT01048320|Other|Treatment|Gemcitabine plus Oxaliplatin in combination with imatinib mesylate
11543822|NCT01048307|Experimental|Prontosan wound irrigation solution|"Prontosan® Wound Irrigation Solution (experimental group):
~cleansing the wound bed at dressing change with Prontosan® Wound Irrigation Solution; a sterile gauze dressing impregnated with the Prontosan® solution will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;
~placing the primary dressing (Profore® WCL): the dressing will be impregnated with Prontosan® Wound Irrigation Solution;
~fixing the dressing to the wound using multilayered elastic compression bandaging (Profore®bandaging system)."
11543823|NCT01048307|Placebo Comparator|Saline irrigation (standard care control)|"Saline (control group):
~cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;
~placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;
~fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system)."
11543824|NCT01048294|Active Comparator|Standard Light Treatment|30 min of Standard bright light treatment (color 5000K)
11543825|NCT01048294|Experimental|Blue enriched Light treatment 20 min|20 minutes of Blue enriched light treatment (color 17000K)
11543826|NCT01048294|Experimental|Blue enriched light treatment 30 min|30 minutes of Blue enriched light treatment (color 17000K)
11543827|NCT01048268|Experimental|Healthy volunteers|
11543828|NCT01048268|Experimental|Patients with Type 1 diabetes mellitus|
11543829|NCT01048268|Experimental|Patients with type 2 diabetes mellitus|
11543830|NCT01048255|Experimental|VX-765|
11543831|NCT01048242|Experimental|Ramelteon|Ramelteon 8 mg oral before bedtime
11543832|NCT01048242|Placebo Comparator|sugar pill|
11543833|NCT01048229|Experimental|Rasagiline|
11543834|NCT01048229|Active Comparator|Pramipexole|pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
11543835|NCT01048203|Experimental|ABR-215050|
11543836|NCT01048190|Experimental|Infants I-1|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains). Group I-1: 15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
11543837|NCT01048190|Experimental|Infants I-2|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
11543838|NCT01048190|Experimental|Infant I-3|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
11543839|NCT01048177|Experimental|Treatment|
11543840|NCT01048164|Active Comparator|10 Massages|This group consists of individuals that wear lead aprons, and they will receive ten, 30-minute scheduled massage appointments during the hours the participant is working in the cardiac lab, over a 10 week period.
11543841|NCT01048164|Active Comparator|5 Massages|This group consists of individuals that wear lead aprons, and they will receive five, 30-minute scheduled massage appointments, during the hours the participant is working in the cardiac lab, over a 5 week period. This arm will not receive massages for the first 5 weeks and then will receive their massages during the second 5 week period.
11543842|NCT01048164|No Intervention|Control Group|This group will consist of those individuals that wear lead aprons with no desire to participate in the massage study yet are willing to provide information through questionnaires. They will be given the same questionnaire as those in the two massage therapy arms of the study, at the beginning, middle, and end of study.
11543843|NCT01048151|Experimental|Single|TNFerade™ Biologic + Radiation
11543844|NCT01048138|Experimental|Biperiden Lactate|5mg IV(in the vein)every 6 hours for 10 days
11543845|NCT01048138|Placebo Comparator|Placebo|5mg IV(in the vein)every 6 hours for 10 days
11543846|NCT01048125|Experimental|Study group|Subjects with documented stress cardiomyopathy who would serve as the study group. Sympathetic Nerve Activity; Mental StrCold Pressor Testess Test (Color Word Test); The Modified Oxford Technique for Baroreflex Sensitivity; Cold Pressor Test; Echocardiographic evaluation
11543847|NCT01048125|Active Comparator|Control|Control subjects will be age and sex matched otherwise healthy people with no prior cardiac disease or other severe medical conditions. Sympathetic Nerve Activity; Mental Stress Test (Color Word Test); The Modified Oxford Technique for Baroreflex Sensitivity; Cold Pressor Test; Echocardiographic evaluation
11543848|NCT01048112|Experimental|Repeated dose group|Will receive one dose of Campylobacter jejuni strain CG8421 at day 0 and a second dose at approximately day 98.
11543849|NCT01048112|Active Comparator|Single dose group|Will receive one dose of Campylobacter jejuni strain CG8421
11543850|NCT01048099|Experimental|PRO Onc Assay and Treatment|Blood specimens tested for circulating tumor cells followed by systemic treatment based on assay results with either trastuzumab or pertuzumab
11543851|NCT01048086|Experimental|Retinoic Acid|
11543852|NCT01048086|Placebo Comparator|Placebo|
11543853|NCT01048047|Experimental|aliskiren/amlodipine|aliskiren, 300 mg/amlodipine 10 mg
11543854|NCT01048047|Active Comparator|amlodipine|amlodipine 10 mg
11543855|NCT01048034|Experimental|Azacitidine +/- erythropoetin|
11543856|NCT01048021||Supraclavicular Block|
11543857|NCT01048008|Experimental|4-DM-CHOC-PEN|"DM-CHOC-PEN is an intervention and will be dosed @ 39 mg/M2,escalated in 1-patient cohorts at 40% dosage.
~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.
~The MTD will be where 2 DLTs are noted and the study is discontinued."
11543858|NCT01047995|Active Comparator|Group 1|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days
~Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days
~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
11543859|NCT01047995|Active Comparator|Group 2|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days
~Phase 2,
~Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days
~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
11543860|NCT01047982|Active Comparator|myo-inositol|
11543861|NCT01047982|Placebo Comparator|placebo|acid folic 400 mcg twice per day
11543862|NCT01047956|Experimental|MethNAC|Methadone and N-acetylcysteine for opioids abstaining
11543863|NCT01047956|Active Comparator|Methadone|Methadone alone
11543864|NCT01047943|Experimental|Psoriasis therapy|
11543865|NCT01047930|Other|AM-Ex; PM-Ex; C|within subject design, with each participant receiving all three conditions
11543866|NCT01047917|Experimental|Meditation DVD|All participants will receive a Meditation DVD to practice at home daily for a total of 4 weeks.
11543867|NCT01047904|Experimental|Iontophoresis-treated|Healthy volunteers will evaluate reliability and performance of Iontophoresis System in delivery of local anesthesia to the TM.
11543868|NCT01047891|Experimental|Experimental|
11543869|NCT01047865||pancreas-kidney transplant|pancreas-kidney transplant recipients with type 1 diabetes.
11543870|NCT01047852|Experimental|NIV|
11543871|NCT01047852|No Intervention|Control|
11543872|NCT01047839|Experimental|>=2 months to <3 years|IC51 0.25 ml, 2 i.m. vaccinations at Day 0 and 28
11543873|NCT01047839|Experimental|>=3 to <12 years|IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28
11543874|NCT01047839|Experimental|>=12 to <18 years|IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28
11543875|NCT01047826|Experimental|M.I.P.O. Group|subjects who have been randomized to the M.I.P.O. group
11543876|NCT01047826|Experimental|Intramedullary Nail group|Subjects who have been Randomized to the I.M. group
11543877|NCT01047813||Type 2 diabetes|This group contains 25 participants with type 2 diabetes
11543878|NCT01047813||control group|This group contains 25 participants withput type 2 diabetes. The control group is matched with age, education and lifestyle to the diabetes group.
11543879|NCT01047800|Experimental|Counseling group|Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician
11543880|NCT01047800|No Intervention|Control|Usual management in GI specialty clinic
11543881|NCT01047787||CHF Patients|Congestive Heart Failure Patients
11543882|NCT01047774|Experimental|Soy protein|
11543883|NCT01047774|Placebo Comparator|Milk protein|
11543884|NCT01047761|Experimental|exercise|Multimodal exercises that include walking, breathing exercises, dynamic balance, and core strengthening.
11543885|NCT01047748|Active Comparator|intra-fetal injection|Subjects will receive an intra-fetal digoxin injection one day prior to their second-trimester surgical abortion
11543886|NCT01047748|Active Comparator|intra-amniotic injection|Subjects will receive an intra-amniotic digoxin injection one day prior to their second-trimester surgical abortion
11543887|NCT01047735|Experimental|Roux-en-Y Gastric Bypass Surgery|Roux-en-Y Gastric Bypass Surgery
11543888|NCT01047735|Experimental|Laparoscopic Adjustable Gastric Banding|Laparoscopic Adjustable Gastric Banding
11543889|NCT01047735|Experimental|Lifestyle/Behavioral Weight Loss|Lifestyle Weight Loss Intervention
11543890|NCT01047722|Active Comparator|Patient drinks aspirin in Gatorade.|Patient drinks Gatorade containing 325 mg aspirin. Bleeding Volume Test is done one hour later.
11543891|NCT01047722|Placebo Comparator|Gatorade Placebo|Patient ingests Gatorade and one hour later a Bleeding Volume Test is performed
11543892|NCT01047709|Experimental|positional therapy|Avoidance of supine positioning.
11543893|NCT01047709|No Intervention|Control|Position ad lib.
11543894|NCT01047696|No Intervention|Open fire|Households continuing to use an open fire for cooking and heating
11543895|NCT01047696|Experimental|Chimney stove|Households randomized to receive a chimney stove (plancha) for cooking and heating
11543896|NCT01047683|Placebo Comparator|Placebo|
11543897|NCT01047683|Experimental|AMR101 (ethyl icosapentate) - 2 g/day|
11543898|NCT01047683|Experimental|AMR101 (ethyl icosapentate) - 4 g/day|
11543899|NCT01047670|Experimental|1|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
11543900|NCT01047670|Placebo Comparator|2|placebo
11543901|NCT01047657|Experimental|weight loss|
11543902|NCT01047657|No Intervention|Control|
11543903|NCT01047644|Experimental|3-month flushing schedule|3-month port-flushing schedule
11543904|NCT01047631|Experimental|Functional circuit training and lifestyle counseling|
11543905|NCT01047631|Active Comparator|Health education and independent walking|
11543906|NCT01047618||Thromboembolism|
11543907|NCT01047605|Experimental|PP1|Neurapas balance
11543908|NCT01047605|Experimental|PP2|Pascoflair 425 mg
11543909|NCT01047605|Placebo Comparator|PL1|P-Tabletten weiß
11543910|NCT01047592|Active Comparator|sarcosine|
11543911|NCT01047592|Active Comparator|sarcosine+ BE|
11543912|NCT01047592|Placebo Comparator|Placebo|
11543913|NCT01047579|Other|Rivastigmine transdermal|
11543914|NCT01047566|Experimental|Addition of dronedarone|Addition of Dronedarone to existing rate control medication (beta blocker and/or calcium antagonist)
11543915|NCT01047566|Active Comparator|Dose Increase|Dose increase of existing rate control medication (beta blocker or calcium antagonist or digoxin)
11543916|NCT01047553|Experimental|1|Formoterol 9 μg/dose
11543917|NCT01047540|Experimental|Dose regimen 1|
11543918|NCT01047540|Experimental|Dose regimen 2|
11543919|NCT01047540|Experimental|Dose regimen 3|
11543920|NCT01047540|Experimental|Dose regimen 4|
11543921|NCT01047540|Placebo Comparator|Placebo|
11543922|NCT01047527|Active Comparator|8 weeks transdermal nicotine|8 weeks of transdermal nicotine
11543923|NCT01047527|Active Comparator|24 weeks transdermal nicotine|24 weeks of transdermal nicotine
11543924|NCT01047527|Experimental|52 weeks transdermal nicotine|52 weeks of transdermal nicotine
11543925|NCT01047514|Experimental|Online Chronic Disease Self-management|6 week, online, small group online self-management workshop
11543926|NCT01047501|Placebo Comparator|Placebo|
11543927|NCT01047501|Experimental|AMR101 (ethyl icosapentate) - 2 g/day|
11543928|NCT01047501|Experimental|AMR101 (ethyl icosapentate) - 4 g/day|
11543929|NCT01047488|Active Comparator|Imipramine|Imipramine tablets and placebo capsules to pregabalin
11543930|NCT01047488|Active Comparator|Pregabalin|Pregabalin capsules and placebo tablets to imipramine
11543931|NCT01047488|Experimental|Imipramine plus pregabalin|Imipramine tablets and pregabalin capsules
11543932|NCT01047488|Placebo Comparator|Placebo|Placebo tablets to imipramine and placebo capsules to pregabalin
11543933|NCT01047475|Active Comparator|MB-6+FOLFOX4|MB-6 6 capsules tid be taken with meals plus FOLFOX4, will be given for 16 weeks
11543934|NCT01047475|Placebo Comparator|Placebo+FOLFOX4|Placebo, 6 capsules tid be taken with meals plus FOLFOX4, will be given for 16 weeks
11543935|NCT01047462|Active Comparator|Laparoscopic lavage|
11543936|NCT01047462|Active Comparator|Primary resection|
11543937|NCT01047449|Active Comparator|SVG harvest - conventional, placebo|
11543938|NCT01047449|Experimental|SVG harvest - no-touch, fish oils|
11543939|NCT01047449|Placebo Comparator|SVG harvest - no-touch, placebo|
11543940|NCT01047449|Active Comparator|SVG harvest - conventional, fish oils|
11543941|NCT01047436|Experimental|ArTiMist (artemether sublingual spray)|
11543942|NCT01047436|Active Comparator|Intravenous Quinine|
11543943|NCT01047423|Experimental|Simvastatin|40mg Simvastatin once daily for 12 weeks followed by 4 week washout period followed by placebo for 12 weeks
11543944|NCT01047423|Placebo Comparator|Placebo|Placebo for 12 weeks followed by 4 week washout period followed by 40mg Simvastatin once daily for 12 weeks
11543945|NCT01047410|No Intervention|Usual care|Patients assigned to the usual care group receive the standard medical care (usual care) during the 15 months lasting study period. Physical training does not form a part of the usual care of renal transplant and dialysis patients. After randomisation, patients assigned to the usual care group receive the advice to meet the 'Nederlandse Norm Gezond Bewegen (NNGB), i.e. the advice to perform 30 minutes of moderately intense physical activity at at least five but preferably all days of the week.
11543946|NCT01047410|Experimental|Exercise intervention|The exercise intervention in this group is identical to the exercise-only group. Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
11544031|NCT01046786|Active Comparator|Group A|Intraspinal injection of 1.6 million cord blood mononuclear cell
11544032|NCT01046786|Active Comparator|Group B|Intraspinal injection of 3.2 million cord blood mononuclear cell
11544693|NCT01042197|Active Comparator|7|Body surface area: 6 %
11543947|NCT01047410|Experimental|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
11543948|NCT01047397|Experimental|Group 1|Active Drug
11543949|NCT01047397|Placebo Comparator|Group 2|Placebo
11543950|NCT01047384|Experimental|Experimental|acupuncture-moxibustion therapy
11543951|NCT01047384|Active Comparator|Regular therapy|Regular therapy
11543952|NCT01047371||Patients with Osteoarthrosis|All consecutive patients scheduled for total hip or knee arthroplasty
11543953|NCT01047358||ajuvant group|adjuvant setting after two to three years of tamoxifen
11543954|NCT01047358||palliative group|palliative setting after progression of disease with anti-estrogen therapy
11543955|NCT01047345|Experimental|9vHPV Vaccine|Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.
11543956|NCT01047345|Placebo Comparator|Placebo|Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.
11543957|NCT01047332|Active Comparator|Uncovered Wallstent|Endoscopically-placed biliary self-expanding metal stent (SEMS) (uncovered type).
11543958|NCT01047332|Experimental|Partially Covered Wallstent|Endoscopically-placed biliary self-expanding metal stent (SEMS) (partially covered type).
11543959|NCT01047319|Experimental|Experimental: Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
11543960|NCT01047306||No Treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIA to identify potential surrogate endpoints for future ERT trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral and imaging measures.
11543961|NCT01047293|Experimental|All patients|All participants enrolled.
11543962|NCT01047280|Placebo Comparator|Safflower oil|This arm of the study constitutes the control phase
11543963|NCT01047280|Experimental|Clarinol G-80®|
11543964|NCT01047280|Experimental|G-c9, t11|
11543965|NCT01047254|Active Comparator|Bupropion|Buproprion 150-300 mg in a flexible dose
11543966|NCT01047254|Placebo Comparator|placebo capsule|Placebo
11543967|NCT01047241|Experimental|Intranasal sufentanil/ketamine|Intranasal combination of sufentanil and ketamine. Dose of sufentanil 0.5 mcg/kg and ketamine 0.5 mg/kg, single dose.
11543968|NCT01047215|Active Comparator|Aripipazole|Heart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication
11543969|NCT01047215|Active Comparator|Quetiapine|Heart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication
11543970|NCT01047202|Experimental|Group 1: 7.5 μg pandemic influenza A/H1N1 vaccine|120 subjects to receive two doses of 7.5 μg pandemic influenza A/H1N1 vaccine 21 days apart
11543971|NCT01047202|Experimental|Group 2 : 15 μg pandemic influenza A/H1N1 vaccine|120 subjects to receive two doses of 15 μg pandemic influenza A/H1N1 vaccine 21 days apart
11543972|NCT01047202|Sham Comparator|Group 3 : 7.5 μg seasonal trivalent vaccine|60 subjects to receive two doses of 7.5 μg seasonal trivalent vaccine 21 days apart
11543973|NCT01047189|Experimental|1|Ziana gel (clindamycin phosphate 1.2% and tretinoin 0.025%) applied once daily for 12 weeks
11543974|NCT01047189|Active Comparator|2|Generic clindamycin 1% gel plus tretinoin 0.025% cream
11543975|NCT01047176||1|Male or female > 18 year of age with indication to PCI
11543976|NCT01047163||Statin|Men aged 65-75yr on Simvastatin therapy presenting with muscle soreness
11543977|NCT01047163||Control|Men, aged 65-75yr not on Statin therapy
11543978|NCT01047150||Tetrofosmin Rest patients|Patients that had a Rest myocardial perfusion study using Tc99m tetrofosmin
11543979|NCT01047150||Sestamibi stress patients|Patients that had a stress myocardial perfusion imaging study using Tc99m Sestamibi
11543980|NCT01047150||Tetrofosmin stress patients|Patients that had a stress myocardial perfusion imaging study using Tc99m Tetrofosmin
11543981|NCT01047150||Sestamibi rest patients|Patients that had a rest myocardial perfusion imaging study using Tc99m Sestamibi
11543982|NCT01047137|Placebo Comparator|Control|Participants will meet with a psychiatry resident once a week for six consecutive weeks for general supportive therapy, which will not provide psychological stress intervention.
11543983|NCT01047137|Experimental|Intervention|Participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques.
11543984|NCT01047124|Experimental|Intervention|Specialist mood disorders team: treatment plan according to need
11543985|NCT01047124|No Intervention|Treatment as usual|
11543986|NCT01047111|Active Comparator|Ivor-Lewis Procedure|Arm A: Esophagectomy was conducted through right side thoracotomy plus midline laparotomy approach:Ivor-Lewis Procedure.
11543987|NCT01047111|Active Comparator|Sweet Procedure|Arm B: Esophagectomy was conducted through left side thoracotomy or thoracoabdominal incision: Sweet Procedure
11543988|NCT01047098|Experimental|Iron with meals|Prenatal vitamin without iron plus capsule containing 27 mg of iron taken with meals
11543989|NCT01047098|Experimental|Iron between meals|Prenatal vitamin without iron plus capsule containing 27 mg of iron taken between meals
11543990|NCT01047098|Placebo Comparator|Placebo|Prenatal vitamin without iron plus capsule containing calcium carbonate (placebo) taken between meals
11543991|NCT01047085|Active Comparator|Control group|Control group: Impedance pH measurements of healthy controls are performed to compare the results with the study group.
11543992|NCT01047085|Experimental|Study group|Study group: Pre-operative and post-operative impedance pH measurements are performed to patients in which elective cholecystectomy is planned.
11544694|NCT01042197|Active Comparator|8|Body surface area: 12 %
11543993|NCT01047072|Experimental|Arm I (transplant)|Patients receive fludarabine IV on days -4 to -2. Patients undergo total-body irradiation on day 0. Patients then undergo peripheral blood stem cell transplantation on day 0. Patients receive GVHD prophylaxis comprising tacrolimus PO twice daily on days -3 to 180 and taper and mycophenolate mofetil PO three times daily on days 0-28 and then twice daily until day 180 and taper.
11543994|NCT01047072|Active Comparator|Arm II (nontransplant)|Patients receive mycophenolate mofetil PO twice daily for 16 months, rituximab IV on days 1 and 15 and then repeated at 6 months, and cyclophosphamide IV at 28-32 day intervals or orally once daily for 16 months.
11543995|NCT01047059|Experimental|Trial Intervention|150mg Erlotinib daily, 15mg/kg b.w. Bevacizumab on d1, d22, d43 as medication FDG-PET, FLT-PET and DCE-MRI as diagnostical tools
11543996|NCT01047046||SNM device placement|Patients who have undergone a placement of a SNM device to treat refractory OAB. A retrospective chart review will be performed on all patients who underwent a one or two-stage placement of an SNM device, which includes an implantable pulse generator (IPG), for refractory urge incontinence and urgency frequency symptoms. The patients will be those of Dr. Karen Noblett, having their device placed after 2001.
11543997|NCT01047033|Active Comparator|Microcredit only|
11543998|NCT01047033|Experimental|Microcredit plus health education|Thirty minutes of a health education module administered to clients by loan officer at their monthly group meetings over the course of 8 months.
11543999|NCT01047020||ALL survivors|The study sample for this research will be recruited from participants in an institutionally funded cohort study, St. Jude Life, as well as from active ACT patients that meet eligibility criteria. The young adults in St. Jude Life are a highly motivated group who were followed in the After Completion of Therapy Clinic until age 18 years and a minimum of 10 years after their treatment ended if they were older than age 11 at the end of therapy
11544000|NCT01047020||Comparison Group|Potentially eligible comparison group participants will be recruited from the parent, older sibling, relative or friend population who accompany the ACT patient for follow-up at SJCRH. Parents (or siblings, relatives or friends who are 18 years or older) of children in remission, both from the active follow-up cohort (within five years of last treatment) and the After Completion of Therapy (ACT) cohort will be invited to complete the same assessments that the ALL survivor participants will complete. Comparison group participants are frequency matched to potentially eligible participants by race/ethnicity (white, black, other) age group (18 to 29, 30-39, 40-49 years) and gender.
11544001|NCT01047007|Experimental|Part 1:MK-1775 65 mg BID|Participants received 65 mg of MK-1775 administered orally twice a day (BID) on Days 1-5 of a 21-day cycle.
11544002|NCT01047007|Experimental|Part 2 A1:MK-1775 20 mg BID+5-FU 1000 mg|Participants received 20 mg of MK-1775 administered orally BID on Days 1-5 of a 21-day cycle and 1000 mg/m^2/day of 5-FU administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle.
11544003|NCT01047007|Experimental|Part 2 A2:MK-1775 20 mg QD+5-FU 1000 mg|Participants received 20 mg of MK-1775 administered orally once a day (QD) on Days 1-5 of a 21-day cycle and 1000 mg/m^2/day of 5-FU administered as an IV infusion on Days 1-4 of a 21-day cycle.
11544004|NCT01047007|Experimental|Parts 2B +3:MK-1775+5-FU+CDDP|Participants were to receive 20 mg or 65 mg of MK-1775 administered either BID or QD on Days 1-5 of a 21-day cycle; 1000 mg/m^2/day of 5-FU administered as an IV infusion on Days 1-4 of a 21-day cycle; and 60 mg/m^2 to 100 mg/m^2 of CDDP administered as an IV infusion on Day 1.
11544005|NCT01046994|Experimental|surgery|biliopancreatic diversion
11544006|NCT01046994|Active Comparator|standard medical care|patients treated according to the rules of good clinical practice
11544007|NCT01046981|Experimental|Tumescent Antibiotic Delivery|TAD followed by sequential serum and interstitial tissue fluid sampling for antibiotic concentration of subsequent 24 hours
11544008|NCT01046981|Experimental|Intravenous Antibiotic Delivery|Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum and interstitial tissue fluid sampling for antibiotic concentration of subsequent 24 hours.
11544009|NCT01046968|Experimental|Lepticore|
11544010|NCT01046955|Active Comparator|1mg/kg Thymoglobulin|LD kidneys receiving 1mg/kg Thymoglobulin for 7 days starting at the day of surgery.
11544011|NCT01046955|Active Comparator|Campath-1H at 0.3 mg/kg|Recipients of LD kidneys receiving Campath-1H at 0.3 mg/kg once on the day of surgery and again 3 days post-operatively.
11544012|NCT01046955|Active Comparator|Zenapax 1 mg/kg|Recipients of LD kidneys receiving Zenapax 1mg/kg on the day of surgery followed by the same dose every 2 weeks for a total of 5 dosages.
11544013|NCT01046942|Experimental|Clopidogrel+Aspirin, hypercoagulabel|
11544014|NCT01046942|Active Comparator|Aspirin,hypercoagulabel control|
11544015|NCT01046929|Experimental|limonene|
11544016|NCT01046916|Experimental|TAK-700|
11544017|NCT01046903||1|
11544018|NCT01046890|Experimental|darunavir/ritonavir + root of Echinacea purpurea|darunavir/ritonavir + root of Echinacea purpurea
11544019|NCT01046877|Experimental|Tympanostomy Tube placement|Tympanostomy Tube Delivery System (TTDS) used for placement of tympanostomy tubes in patients indicated for such treatment for chronic Otitis Media with Effusion (OME) or recurrent Acute Otitis Media(AOM).
11544020|NCT01046864|Experimental|Arm 1|
11544021|NCT01046864|Experimental|Arm 2|
11544022|NCT01046864|Experimental|Arm 3|Japanese Population
11544023|NCT01046851|Active Comparator|Nopan|
11544024|NCT01046851|Placebo Comparator|Placebo|
11544025|NCT01046838|Placebo Comparator|Placebo|placebo 3 x daily
11544026|NCT01046838|Active Comparator|sildenafil|40 mg sildenafil 3 x daily
11544027|NCT01046825|Other|Group A|"Completely resected stage I or completely resected abdominal stage II lesions.
~Group A will include: COPAD x 2 cycles."
11544028|NCT01046825|Other|Group B|"All cases not eligible for Group A or Group C. (Murphy Stage III and non-CNS Stage IV)
~Group B will include the intervention COP, COPD M3, CYM as follows:
~Pre-Phase: COP
~Induction: COPAD M3 x 2 cycles
~Consolidation: CYM x 2 cycles."
11544029|NCT01046825|Other|Group C|"Any CNS involvement and/or bone marrow involvement ≥ 25% blasts. For CNS involvement one or more of the following applies:
~Any L3 blasts in CSF
~Cranial nerve palsy (if not explained by extracranial tumor)
~Clinical spinal cord compression
~Isolated intracerebral mass
~Parameningeal extension: cranial and/or spinal
~Group C will include the intervention COP, COPADM8, CYVE as follows:
~Pre-Phase: COP
~Induction: COPADM8 cycle 1
~Induction: COPADM8 Cycle 2
~Consolidation: CYVE x 2 cycles
~and Maintenance"
11544033|NCT01046786|Active Comparator|Group C|Intraspinal injection of 6.4 million cord blood mononuclear cell
11544034|NCT01046786|Active Comparator|Group D|Intraspinal injection of 6.4 million cord blood mononuclear cell plus 30 mg/kg methylprednisolone
11544035|NCT01046786|Active Comparator|Group E|Intraspinal injection of 6.4 million cord blood mononuclear cell plus 30 mg/kg methylprednisolone plus 6 week course of oral lithium, titrated to maintain 0.6-1.0 mM serum level
11544036|NCT01046773|Active Comparator|Children with Crohn's disease less than 35 kg|These are children ages 8 to 18 years inclusive, with mild to moderately active Crohn's disease.
11544037|NCT01046773|Active Comparator|Children with Crohn's disease 35 kg or greater|These are children ages 8 to 18 years inclusive, with mild to moderately active Crohn's disease.
11544038|NCT01046760||Rolandic Epilepsy|Patients older than seven years old with clinical and electroencephalographic diagnosis of Rolandic Epilepsy
11544039|NCT01046747|Active Comparator|Pre-drill|These pins will be pre-drilled
11544040|NCT01046747|Active Comparator|No pre-drill|these pins will not be pre-drilled, but will rely on the self drilling function of the pin for insertion
11544041|NCT01046734||Adult Community|
11544042|NCT01046734||Adult Hospital|
11544043|NCT01046734||Children Hospital|
11544044|NCT01046734||Children Community|
11544045|NCT01046721|Active Comparator|Exenatide|subcutaneous administration of Exenatide (0.02ml)
11544046|NCT01046721|Placebo Comparator|0.9% Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
11544047|NCT01046708|Experimental|micronized progesterone|
11544048|NCT01046708|No Intervention|no utrogestan|
11544049|NCT01046695|Active Comparator|TENS Unit|"This arm will be adding the use of the TENS unit for 48 hours in addition to standard care for their post operative pain control.
~Patient's primary area of postoperative pain was determined by nursing personnel. Four electrodes were placed on or around the area of maximum pain. The TENS unit was turned on, 1 of 5 frequency patterns selected and the impulse turned up until the patient could feel the impulse. The location of the electrodes, the pattern, and/or the intensity of the TENS unit were adjusted until the patient achieved maximum comfort with the sensation."
11544050|NCT01046695|No Intervention|Control Arm|This arm will have standard care for their post operative pain control.
11544051|NCT01046682|Active Comparator|Salsalate|
11544052|NCT01046682|No Intervention|Usual care|
11544053|NCT01046669|Sham Comparator|Control|Standard medical care for septic shock
11544054|NCT01046669|Experimental|Treatment|Two (2) PMX cartridges will be administered approximately 24 hours apart plus standard medical care for septic shock
11544055|NCT01046643|Active Comparator|Estrogen followed by Placebo|Estrogen treatment with Estradiol (E2) followed by Placebo.
11544056|NCT01046643|Active Comparator|Progesterone followed by Placebo|Progesterone (P10) treatment followed by Placebo.
11544057|NCT01046643|Active Comparator|Placebo followed by Estrogen|Placebo followed by Estrogen treatment with Estradiol (E2)
11544058|NCT01046643|Active Comparator|Placebo followed by Progesterone|Placebo followed by Progesterone (P10) treatment.
11544059|NCT01046630|Experimental|1|single infusion
11544060|NCT01046630|Active Comparator|2|single infusion
11544061|NCT01046630|Placebo Comparator|3|single infusion
11544062|NCT01046604|No Intervention|No treatment|This is the group of patients that will not undergo any treatment with Lovaza prior to mitral valve repair surgery. This is the 'control' group.
11544063|NCT01046604|Active Comparator|Lovaza treated|This arm will be the group of patients that will be treated with Lovaza prior to undergoing mitral valve repair surgery.
11544064|NCT01046591||Cleft|Those with a repaired cleft palate
11544065|NCT01046591||Comparison|Those without a cleft palate repair
11544066|NCT01046578|Experimental|Single Dose 12mm follicle|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 12 mm
11544067|NCT01046578|Experimental|Single Dose 18mm follicle|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 18 mm
11544068|NCT01046578|Experimental|Single Dose Post Ovulation|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated 24-48 post ovulation
11544069|NCT01046578|Experimental|Multi Dose 12mm follicle|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 12 mm
11544070|NCT01046578|Experimental|Multi Dose 18mm follicle|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 18 mm
11544071|NCT01046578|Experimental|Multi Dose Post Ovulation|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated 24-48 hours post ovulation
11544072|NCT01046578|No Intervention|Control|No intervention given, followed for course of study on a natural cycle
11544073|NCT01046565|Active Comparator|Differin® Cream 0.1%|Adapalene Cream 0.1% - apply once daily on one side of the face for 3 weeks
11544074|NCT01046565|Active Comparator|Differin® Lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face
11544075|NCT01046552|Active Comparator|PES/LC|preoperative ES followed by LC within the same hospital admission
11544076|NCT01046552|Active Comparator|LC/IOES|laparoscopic cholecystectomy with intraoperative ercp under the same anesthesia
11544077|NCT01046539|Active Comparator|RDC-0313 + Buprenorphine|Cohort 1 (1 and 4 mg) + 8 mg Cohort 2 (dependent on Cohort 1 results)
11544078|NCT01046539|Placebo Comparator|Placebo|
11544079|NCT01046500|Active Comparator|metformin|
11544080|NCT01046500|Active Comparator|myo-inositol|
11544081|NCT01046474|Experimental|reducing beverages and sugar and increase physical activity|reduction of beverages and sugar and increasing physical activity
11544082|NCT01046474|No Intervention|control -no intervention|
11544083|NCT01046461|Experimental|Ramosetron, Aprepitant, Dexamethasone|
11544084|NCT01046448||4C|Children with chronic kidney disease stage IIIb to V (GFR 10 to 45 ml/min/1.73m²) at screening.
11544085|NCT01046435|Placebo Comparator|Supragingival scaling plus placebo|Plaque control instructions, supra gingival scaling and two placebos
11544320|NCT01044654|Experimental|Cohort 1|3 Subjects will receive a single infusion of 0.5-1.0 x 1010 SB-728-T
11544086|NCT01046435|Experimental|Root planing plus antibiotics|Plaque control instructions, subgingival scaling,root planing, metronidazole 250 mg and amoxicillin 500 mg. three times a day for 7 days
11544087|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment A)|
11544088|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment B)|
11544089|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment C)|
11544090|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment D)|
11544091|NCT01046422|Placebo Comparator|Placebo ± metformin (Treatment E)|
11544092|NCT01046409||Main vessel, side branch vessel|
11544093|NCT01046396|Active Comparator|Differin® Cream 0.1%|Adapalene Cream 0.1% - apply once daily on one side of the face for 3 weeks
11544094|NCT01046396|Active Comparator|Differin® Lotion 0.1%|Adapalene Lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
11544095|NCT01046383|Experimental|IMN1207|"Dietary Supplement: IMN1207
~Stratum A: CRP <40 mg/L and WBC < 11x109/L (i.e. subjects with relatively low levels of inflammation).
~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation."
11544096|NCT01046383|Placebo Comparator|Casein|"Dietary Supplement: Casein.
~Stratum A: CRP <40 mg/L and WBC < 11x109/L (i.e. subjects with relatively low levels of inflammation).
~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation."
11544097|NCT01046370|Experimental|ARP intervention|
11544098|NCT01046370|No Intervention|No intervention|
11544099|NCT01046357|Experimental|Active|AZD7687 oral suspension
11544100|NCT01046357|Experimental|Placebo|placebo oral suspension
11544101|NCT01046331||Adult H1N1|Patients admitted to adult ICU with confirmed or suspected H1N1 Influence infection
11544102|NCT01046331||Pediatric H1N1|Patients admitted to pediatric ICU with confirmed or suspected H1N1 Influenza infection
11544103|NCT01046318|Experimental|OPC-262 5 mg|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
11544104|NCT01046305||Part 1: Interview & Questionnaires|Patients interviews and questionnaires about CML symptoms once.
11544105|NCT01046305||Part 2: Symptoms Rating|Importance of symptoms to CML patients rated by physicians, nurses, patients, and caregivers.
11544106|NCT01046305||Part 3: MDASI-CML Questionnaires|Patients questionnaires about CML symptoms over 1 year using M. D. Anderson Symptom Inventory (MDASI) module (the MDASI-CML)
11544107|NCT01046292|Experimental|Ginkgo biloba|
11544108|NCT01046292|Placebo Comparator|Placebo control|
11544109|NCT01046279||Glioma Patient receiving Bevacizumab|Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV)assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
11544110|NCT01046266|Experimental|A|
11544111|NCT01046266|Active Comparator|B|
11544112|NCT01046253|Experimental|Investigational Test Product|Lansoprazole 30 mg Delayed-Release Capsule
11544113|NCT01046253|Active Comparator|Reference Listed Drug|Prevacid® 30 mg Delayed-Release Capsule
11544114|NCT01046240|Active Comparator|Intravenous palonosetron|Intravenous palonosetron: control arm (standard treatment)
11544115|NCT01046240|Experimental|subcutaneous palonosetron|subcutaneous palonosetron
11544116|NCT01046227||Serology after Novel H1N1 vaccination|This study is designed to investigate the antibodies titers before and after the novel H1N1 influenza vaccination in pediatric haemato-oncology patients.
11544117|NCT01046214|Experimental|Budeprion XL™|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
11544118|NCT01046214|Active Comparator|Wellbutrin XL®|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
11544119|NCT01046201||Obese Children|
11544120|NCT01046188|Experimental|Web-based Teaching Group|Patients randomized to the intervention group will receive a unique login and password to a link on the Ottawa Fertility Centre website. This will allow them access to a secure site containing required teaching modules. They will then complete an interactive teaching tool that contains the same educational content as the traditional presentation. Patients will be able to access a module that is specific to their stimulation protocol. The teaching tool does not need to be completed all at one time. Once completed, the information can still be accessed as many times as required.
11544121|NCT01046188|Active Comparator|Control group|Participants randomized to the control arm of the study will participate in a traditional didactic teaching session. This session will be carried out by the nurse educator. This session will be attended by up to 10 other couples that may or may not be participating in the study. The nurse educator administering the session will not know which couples are participating in the study. Slides shown and information conveyed will be the same as that provided to the web-based group, however all three stimulation protocols will be presented to the participants regardless of their actual treatment protocol.
11544122|NCT01046175|Experimental|Airstacking with manual resuscitator|Air-stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
11544123|NCT01046175|Active Comparator|Air-stacking with ventilator|Air-stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a ventilator.
11544124|NCT01046162|Active Comparator|Tafil Tablets 2 mg Pharmacia Upjohn|
11544125|NCT01046162|Active Comparator|Xanax Tablets 2 mg Pfizer LLC|
11544126|NCT01046149|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
11544127|NCT01046149|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
11544128|NCT01046136|Active Comparator|Mucinex|
11544129|NCT01046136|Placebo Comparator|placebo|
11544130|NCT01046123|Experimental|Whole brain radiotherapy|whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy
11544131|NCT01046110|Experimental|IDeg OD|
11544132|NCT01046110|Experimental|DPP-IV inhibitor|
11544184|NCT01045694|Active Comparator|Steroid - Triamcinolone Acetonide|Arm uses the standard of care - Steroid injection - as an active comparator to the experimental injection of Botulinum Toxin A for the treatment of basal thumb joint arthritis
11544133|NCT01046097||Synflorix Group|Subjects receiving Synflorix™ according to local Prescribing Information. Subjects were administered with Synflorix by investigators in the course of their normal clinical practice. The vaccination schedule consisted of three doses/two doses/one dose or the booster dose of 10Pn-PD-DiT to be administered as per the local PI. First dose of the vaccine could be administered to infants as early as 6 weeks of age and minimum interval between subsequent primary doses was 4 weeks.
11544134|NCT01046084|Experimental|Investigational Test Product|Lansoprazole 30 mg Delayed-Release Capsule
11544135|NCT01046084|Active Comparator|Reference Listed Drug|Prevacid® 30 mg Delayed-Release Capsule
11544136|NCT01046071|Experimental|transversus abdominis plane block|transversus abdominis plane block with ropivacaine
11544137|NCT01046071|Placebo Comparator|block with saline|20 ml of isotonic saline bilateral
11544138|NCT01046058|Experimental|Panel A: TMC435 150 mg|Participants enrolled in Panel A had moderate hepatic failure and received TMC435 150 mg once daily for 7 days.
11544139|NCT01046058|Experimental|Panel B: TMC435 150 mg|Participants enrolled in Panel B had severe hepatic impairment and received TMC435 150 mg once daily for 7 days after the safety of TMC435 150 mg once daily for 7 days was evaluated in participants enrolled in Panel A.
11544140|NCT01046045|Active Comparator|Everolimus|before and after everolimus; in other words, comparison of specified outcome before and after treatment with everolimus
11544141|NCT01046045|Active Comparator|Calcineurin-inhibitor immunosuppression|Cyclosporin-based immunosuppression without everolimus
11544142|NCT01046032|Active Comparator|Metformin|Drug (including placebo)
11544143|NCT01046032|Placebo Comparator|Sugar pill|Drug (including placebo)
11544144|NCT01046006|Experimental|Treatment|BDR will be administered in one 21-day treatment cycle followed by four 35-day treatment cycles to patients with WM. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of Bortezomib, dexamethasone 40mg iv and Rituximab 375 mg/m2 iv will be administered. A total of 8 infusions of rituximab will be administered. Subsequently patients rated as CR, PR, MR or SD will be followed without any treatment until there is evidence of progressive disease.
11544145|NCT01045993|Active Comparator|1|Heat device
11544146|NCT01045993|Sham Comparator|2|Placebo arm
11544147|NCT01045993|Active Comparator|3|Marketed analgesic
11544148|NCT01045993|Placebo Comparator|4|(Oral) Placebo comparator
11544149|NCT01045980|Experimental|Bioimpedance and Vitamin D|
11544150|NCT01045980|Experimental|Usual care and Vitamin D|Vitamin D3
11544151|NCT01045980|Experimental|Bioimpedance and Placebo|
11544152|NCT01045980|Placebo Comparator|Usual Care and Placebo|
11544153|NCT01045967|Experimental|Invesigational Test Product|Lansoprazole 30 mg delayed-release Capsules
11544154|NCT01045967|Active Comparator|Reference Listed Drug|Prevacid® 30 mg delayed-release Capsules
11544155|NCT01045941|Experimental|Patients with distal pancreatic cancer|Patients with distal pancreatic cancer amenable to a laparoscopic distal pancreatectomy
11544156|NCT01045928|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-21 and rituximab IV on day 1of courses 1, 3, 5, 7, 9, and 11.
11544157|NCT01045915|Experimental|Plasmid AMEP electrotransfer|
11544158|NCT01045902|Experimental|Arm 1|
11544159|NCT01045902|Active Comparator|Arm 2|
11544160|NCT01045889|Experimental|R-CHOP + PBSCT|All patients will receive chemoimmunotherapy with Rituximab + CHOP regimen for 6 cycles followed by high dose cyclophosphamide and stem cell collection, then high dose therapy with BEAM conditioning regimen and peripheral blood stem cell transplantation
11544161|NCT01045876|Experimental|Dexamethasone|
11544162|NCT01045876|Placebo Comparator|Placebo|
11544163|NCT01045863|Experimental|PART A: Ascending Cohorts|Single ascending dose cross-over. (0.05, 0.15, 0.5, 1.5, 5, 15 mg)
11544164|NCT01045863|Experimental|PART B: Food effect|Food effect on PF-03382792 PK
11544165|NCT01045863|Experimental|PART C: CSF Cohort|Optional CSF Cohort
11544166|NCT01045837|Active Comparator|Prednisolone and Gluten free diet|Gluten free diet and prednisolone in the dose of 1 mg/kg/d over a period of 4 weeks.
11544167|NCT01045837|Placebo Comparator|Gluten free diet|Gluten free alone will be given in this group
11544168|NCT01045811|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
11544169|NCT01045811|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
11544170|NCT01045798|Experimental|Caspofungin|caspofungin acetate
11544171|NCT01045798|Placebo Comparator|Placebo|normal saline
11544172|NCT01045785||aspirin responsive|PFA Col/EPI normal
11544173|NCT01045785||aspirin resistance|PFA Col/epi showed resistance
11544174|NCT01045772|Experimental|IL-1 trap|
11544175|NCT01045746|Experimental|Group 1|T0, Stochastic resonance whole-body vibration A intervention over four weeks, three time a week;T1, 16 days wash-out period; T2, Stochastic resonance whole-body vibration B intervention over four weeks, three times week, T3
11544176|NCT01045746|Experimental|Group 2|T0, Stochastic resonance whole-body vibration B intervention over four weeks, three time a week;T1, 16 days wash-out period;T2, Stochastic resonance whole-body vibration A intervention over four weeks, three times week, T3
11544177|NCT01045733|Experimental|IQ Toric IOL|AcrySof IQ Toric intraocular lens (IOL) randomly assigned to one eye, with AcrySof IQ Aspheric IOL with Limbal Relaxing Incision (LRI) procedure in the fellow eye for contralateral implantation.
11544178|NCT01045733|Active Comparator|IQ Aspheric IOL + LRI|AcrySof IQ Aspheric intraocular lens (IOL) with Limbal Relaxing Incision (LRI) procedure randomly assigned to one eye, with AcrySof IQ Toric IOL in the fellow eye for contralateral implantation
11544179|NCT01045720|Placebo Comparator|Placebo Comparator|
11544180|NCT01045720|Experimental|ChinesMed|
11544181|NCT01045707|Experimental|IDegAsp OD|
11544182|NCT01045707|Experimental|IGlar OD|
11544183|NCT01045694|Experimental|Botulinum Toxin Type A|Arm investigates the efficacy of Botulinum Toxin A injection for the treatment of basal thumb joint arthritis
11544321|NCT01044654|Experimental|Cohort 2|3 Subjects will receive a single infusion of 2.0 x 1010 SB-728-T
11544185|NCT01045694|Placebo Comparator|Lidocaine|Arm uses plain lidocaine injection to serve as a baseline for evaluating the efficacy of Botulinum toxin as compared to steroid injection for the treatment of basal thumb joint arthritis.
11544186|NCT01045681|Experimental|BVD|Bendamustine, Velcade and Dexamethasone
11544187|NCT01045668|Active Comparator|Clinical VT ablation|
11544188|NCT01045668|Active Comparator|clinical VT and substrate ablation|
11544189|NCT01045655|Experimental|MOMCare intervention|Depression care treatment with study depression care specialist (brief interpersonal psychotherapy or pharmacotherapy)
11544190|NCT01045655|No Intervention|Care Plus|Usual care group; referral to community mental health treatment
11544191|NCT01045642|Active Comparator|Prilosec 20 mg Tablets|
11544192|NCT01045642|Experimental|Omeprazole Magnesium DR 20 mg Capsules|
11544193|NCT01045629||SchizoComp|Competence Ability of schizophrenia
11544194|NCT01045629||NonSchizoComp|Competence of Non-schizophrenia
11544195|NCT01045616||Prematurity|
11544196|NCT01045590|Active Comparator|glibenclamide + Rosiglitazone|glibenclamide plus rosiglitazone
11544197|NCT01045590|Placebo Comparator|glibenclamide + placebo|
11544198|NCT01045577|Active Comparator|Masitinib (AB1010)|Masitinib (AB1010)
11544199|NCT01045577|Placebo Comparator|Placebo mactching masitinib|Placebo matching masitinib
11544200|NCT01045564|Experimental|A|One dose of study vaccine (GSK 1557484A) on Day 0, Day 182, and Day 364
11544201|NCT01045564|Experimental|B|One dose of study vaccine (GSK 1557484A) on Day 0, Day 91, and Day 364
11544202|NCT01045564|Experimental|C|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
11544203|NCT01045564|Experimental|D|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
11544204|NCT01045564|Experimental|E|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
11544205|NCT01045551|Experimental|Apremilast 20 mg (twice per day)|All subjects will receive Apremilast 20mg taken orally twice per day.
11544206|NCT01045538|Experimental|Vorinostat plus XP|Vorinostat 200~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
11544207|NCT01045525|Experimental|Phlebotomy + lifestyle and diet advices|
11544208|NCT01045525|Active Comparator|Lifestyle and diet advices|
11544209|NCT01045512|Active Comparator|statins, standardised physical training|
11544210|NCT01045512|No Intervention|to continue with current lifestyle|
11544211|NCT01045499|Experimental|laparoscopic gastric banding|Adolescent patients who have undergone laparoscopic adjustable gastric banding. Weight, BMI, and co-morbidity data will be compared to patient's pre-operative values.
11544212|NCT01045486|Active Comparator|Group A|Group A received active medication (ATP mixed probiotics) for 6 weeks followed by a crossover to 6 weeks of placebo after 4-weeks washout period.
11544213|NCT01045486|Placebo Comparator|Group B|Group B received placebo medication for 6 weeks followed by a crossover to 6 weeks of active medication (ATP mixed probiotics) after 4-weeks washout period.
11544214|NCT01045460|Experimental|ASCT + MILs|Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4.
11544215|NCT01045460|Experimental|ASCT + MILs + vaccine|Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4. The allogeneic myeloma vaccine will be administered on Days 21, 60, 180, and 300.
11544216|NCT01045447|Experimental|IDegAsp OD|
11544217|NCT01045447|Active Comparator|IGlar OD|
11544218|NCT01045434|Experimental|Omeprazole Magnesium DR 20 mg Capsules|Omeprazole Magnesium DR 20 mg Capsules of Dr Reddys Laboratories Limited
11544219|NCT01045434|Active Comparator|Prilosec 20 mg Tablets|Prilosec 20 mg Tablets of Procter and Gamble
11544220|NCT01045421|Experimental|MLN8237 (Alisertib)|MLN8237 administered as an enteric-coated tablet (ECT)
11544221|NCT01045408|Placebo Comparator|Berry|
11544222|NCT01045408|Placebo Comparator|Placebo|
11544223|NCT01045395|Placebo Comparator|Corn starch, 90mg/d|Corn starch, 90mg/d
11544224|NCT01045395|Experimental|Unique Marine Algae Concentrate (UMAC). 90mg/d|
11544225|NCT01045395|Experimental|Golden brown algae, 90mg/d|
11544226|NCT01045382|Experimental|Mensenchymal Stem Cells|"Efficacy of MSC infusion on one-year overall survival of patients transplanted with HLA-mismatched PBSC.
~Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2 Gy total body irradiation.
~MSC cells (1,5-3,0 x 10E6 MSC/Kg BW) will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
11544227|NCT01045382|Placebo Comparator|Placebo|"Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2Gy total body irradiation.
~Isotonic solution will be injected will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
11544228|NCT01045369|Experimental|Kaletra And Intelence|This is a Phase IV, 48-week, open-label, pilot study in 30 ARV-naïve patients examining the safety, viral response, and tolerability of Kaletra® and Intelence™ tablets.
11544229|NCT01045356||children less than 2 months old|
11544230|NCT01045356||children 2 months to 12 months old|
11544231|NCT01045356||Children > 2 months old and less than or equal to 20 kg|
11544232|NCT01045343|Active Comparator|Control Arm|
11544233|NCT01045343|Experimental|Integrated Diagnostics Arm|
11544234|NCT01045330|No Intervention|Usual Care Group|Usual care consists of standard hospital services provided by physicians, nurses, and support staff (e.g., physical therapist, dietitian) in the general surgery units.
11544235|NCT01045330|Experimental|Experimental Group|The intervention consisted of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
11544236|NCT01045317|Experimental|intravenous or oral administration|
11544364|NCT01044316|Active Comparator|Arm 1|
11544237|NCT01045304|Experimental|Gencitabine + iniparib twice weekly|"Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles.
~Iniparib, 5.6 mg/kg IV over 60 minutes on Days 1, 4, 8 and 11 of 3-week cycles"
11544238|NCT01045304|Experimental|Gencitabine + iniparib weekly|"Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles.
~Iniparib, 11.2 mg/kg IV over 60 minutes on Days 1 and 8 of 3-week cycles"
11544239|NCT01045291|Active Comparator|Fusion Pacing OFF|Subjects initially randomized to the Fusion Pacing OFF Arm will receive the Fusion Pacing software download at the implant visit, but the Fusion Pacing software will be programmed OFF. At 4 months subjects in this arm will crossover to the Fusion Pacing ON Arm.
11544240|NCT01045291|Experimental|Fusion Pacing ON|Subjects initially randomized to the Fusion Pacing ON Arm will receive the Fusion Pacing software download at the implant visit, and the Fusion Pacing software will be programmed ON. At 4 months subjects in this arm will crossover to the Fusion Pacing OFF Arm.
11544241|NCT01045265||Raltegravir treated men|Single group study of seminal plasma pharmacokinetics of raltegravir in men receiving chronic raltegravir therapy
11544242|NCT01045252||congenital heart disease|Neonates that are enrolled in the NICU and are confirmed of congenital heart diseases.
11544243|NCT01045252||sepsis|Neonates that are enrolled in the NICU and are diagnosed as sepsis.
11544244|NCT01045252||Health|Neonates that are enrolled in the NICU and have no congenital heart diseases and sepsis.
11544245|NCT01045239|Experimental|Micropulse 577 nm yellow diode laser|
11544246|NCT01045239|Active Comparator|532 nm green diode laser|
11544247|NCT01045226|Experimental|Arm I|Patients undergo proton radiotherapy once daily 5 days a week for approximately 9 weeks in the absence of disease progression or unacceptable toxicity.
11544248|NCT01045213|Experimental|Proactive Integrated Care|COPD education, self-management education, remote monitoring (Health Buddy, pulse oximeter, pedometer, spirometer) and enhance communication with cell phone contact with a coordinator.
11544249|NCT01045200||Follow-up|Patients curatively operated for rectal cancer
11544250|NCT01045187|Other|endometrial cancer|Patients are treated with electronic brachytherapy for an FDA cleared indication.
11544251|NCT01045174|Active Comparator|Breath-Actuated Nebulizer|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer.
11544252|NCT01045174|Active Comparator|Conventional continuous-ouput nebulizer|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer
11544253|NCT01045161|Experimental|1|Aclidinium bromide 200 μg dose twice per day, inhaled for 12 weeks of treatment At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks
11544254|NCT01045161|Experimental|2|Aclidinium bromide 400 μg dose twice per day, inhaled for 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 400 μg will continue to receive open label 400µg aclidinium bromide for 40 weeks
11544255|NCT01045161|Placebo Comparator|3|Dose-match placebo, oral inhalation twice per day for 12 weeks of treatment. At week 12, patients who were on placebo will receive open label 400µg aclidinium bromide for 40 weeks
11544256|NCT01045148|Other|CyberKnife Radiosurgery|CyberKnife Radiosurgery
11544257|NCT01045135||first time delivery|Women giving birth to their first child
11544258|NCT01045122|Other|Propofol|Is an alkylphenol, is primarily indicated for use as a general anesthetic and has minimal analgesic properties.
11544259|NCT01045122|Other|Dexmedetomidine|Dexmedetomidine is an alpha-2 adrenoreceptor agonist that has sedative, hypnotic, and analgesic effects.
11544260|NCT01045109|Experimental|open-label vitamin D3|One arm: open-label receiving vitamin D3 4,000 IU daily
11544261|NCT01045096|Experimental|Dexlansoprazole 15 mg QD|
11544262|NCT01045096|Experimental|Dexlansoprazole 30 mg QD|
11544263|NCT01045096|Experimental|Dexlansoprazole 60 mg QD|
11544264|NCT01045083|Experimental|1|
11544265|NCT01045070||coronary heart disease|
11544266|NCT01045057|Experimental|Puncture Set and Flexible Protector|Provox Vega Puncture Set is used to create the primary puncture and insert the prosthesis during total laryngectomy
11544267|NCT01045044||Breast cancer, chemotherapy|Up to 15 women with breast cancer who are to undergo systemic anthracycline based chemotherapy.
11544268|NCT01045044||Normal control|Up to 15 normal, healthy women.
11544269|NCT01045031||Controls|"Controls were subsequently contacted via personal contact and three additional advertisements (two in an Austrian newspaper (Krone) and one in an Austrian bicyclist journal (Bicyclist Sports). The controls were matched according to age, sex and years of education"
11544270|NCT01045031||marathon athletes|Runners participating in the 2008 Wachau half marathon (21,2 km) and the Vienna City marathon (42,5 km) as well as bicyclists participating at the Corinthian marathon (180km). Inclusion criteria:1) participation in at least one of these 3 marathons in the preceding two years,2)still in continuous training during the recruitment phase (at least 2 hours/week), 3) aged over 60. Exclusion criteria:(a) present or past exposure to neurotoxic substances (b) if they did not speak German as their native language (c) diseases that markedly affect CNS functions (d) manifest cardiovascular disease, (e) chronic alcoholism (daily alcohol intake > 60 g or diagnosed history of alcoholism) and (f) unwillingness to give informed consent.
11544271|NCT01045018|Active Comparator|mesalamine 400 mg tablet|
11544272|NCT01045018|Active Comparator|Asacol 400 mg Delayed Release Tablet|
11544273|NCT01045018|Placebo Comparator|Placebo delayed release tablet|
11544274|NCT01045005|Active Comparator|Type 1 Diabetes|Subjects with type 1 diabetes mellitus who are administered oxygen and carbon dioxide
11544275|NCT01045005|Active Comparator|Control Subjects|Healthy volunteers administered oxygen and carbon dioxide via respiratory apparatus
11544276|NCT01044992|Experimental|Drug and radiation|Levodopa and H215O PET
11544319|NCT01044667|Other|Patients taking Myfortic|Lung transplant patients converted from MMF to Myfortic as part of standard of care treatment will have GI and Quality of Life assessments done at the time of conversion to Myfortic and at 60 days, 90 days and 180 days.
11544365|NCT01044316|Active Comparator|Arm 2|
11544277|NCT01044966|Experimental|ITV DepoCyt + Temozolomide|Patients will undergo an induction phase of intraventricular (ITV) DepoCyt, using the dosage determined from the Phase I portionPatients with stable disease (clinically and radiographically), not exhibiting systemic toxicity, will undergo a three month consolidation phase of ITV DepoCyt, for one month (Cycles 3-6). Patients without progression or toxicity will undergo maintenance therapy using ITV DepoCyt every four weeks (+/- 3 days) for a maximum of 8 months (cycles 7-14) or until recurrence or toxicity ensues. Oral metronomic Temozolomide dosing of 75 mg/m2 daily for 21 days followed by 7 days off will be given throughout the Induction, Consolidation, and Maintenance Phases of the ITV DepoCyt described above.
11544278|NCT01044953||Soccer Players|German professional soccer players
11544279|NCT01044940||Birth asphyxia|Babies suffering from birth asphyxia
11544280|NCT01044940||Blood transfusion|Babies who receives blood transfusion
11544281|NCT01044940||Heart Surgery|Babies who need heart surgery
11544282|NCT01044927|Experimental|Proactive Integrated Care|COPD-specific education, self-management instruction, remote monitoring and enhanced communication with a coordinator
11544283|NCT01044927|Active Comparator|Standard Care Control|No intervention other that measurements taken at 0, 3, 6 and 9 months of the study.
11544284|NCT01044901||Subjects with Sickle Cell Disease|
11544285|NCT01044901||Healthy Volunteers|
11544286|NCT01044875|Active Comparator|green laser 532 nm conventional|Current type of laser used for treatment of proliferative diabetic retinopathy
11544287|NCT01044875|Active Comparator|Yellow 577 nm laser|new laser wavelength for treatment of PDR
11544288|NCT01044862|Active Comparator|Aromatase Inhibitors (AI)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
11544289|NCT01044862|Active Comparator|Clomiphene Citrate (CC)|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
11544290|NCT01044862|Active Comparator|Follicle Stimulating Hormone (FSH)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
11544291|NCT01044836|Experimental|Etanercept|
11544292|NCT01044823||Adult RA|
11544293|NCT01044823||pediatric JRA|
11544294|NCT01044810||Simultaneous interruption (Exposure gr)|stopped all drugs in NNRTI-based regimens simultaneously after allergic reactions to NVP-based regimens, and later started EFV-based regimens
11544295|NCT01044810||Naive (Control group)|HIV-1-infected patients who started EFV-based regimens as their initial ARV regimens.
11544296|NCT01044810||staggered interruption (exposure group)|"after having allergic reactions to NVP-based regimens, stopped NNRTIs first, continued the other NRTIs for a period of time, i.e. staggered interruption, and later started EFV-based regimens"
11544297|NCT01044771|Other|change from tenofovir to raltegravir|"Single arm study:
~Tenofovir containing nucleoside backbone changed over to raltegravir in all patients"
11544298|NCT01044758|Experimental|aMCI_62.5mg drug first, then placebo|"Amnestic MCI:
~62.5mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
11544299|NCT01044758|Experimental|aMCI_Placebo first, then 62.5mg drug|"Amnestic MCI:
~Placebo capsule twice daily (two weeks), washout (4 weeks), and 62.5mg levetiracetam twice daily (two weeks)"
11544300|NCT01044758|Experimental|aMCI_125mg drug first, then placebo|"Amnestic MCI:
~125mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
11544301|NCT01044758|Experimental|aMCI_Placebo first, then 125mg drug|"Amnestic MCI:
~Placebo capsule twice daily (two weeks), washout (4 weeks), and 125mg levetiracetam twice daily (two weeks)"
11544302|NCT01044758|Experimental|aMCI_250mg drug first, then placebo|Amnestic MCI: 250mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)
11544303|NCT01044758|Experimental|aMCI_Placebo first, then 250mg drug|"Amnestic MCI:
~Placebo capsule twice daily (two weeks), washout (4 weeks), and 250mg levetiracetam twice daily (two weeks)"
11544304|NCT01044758|Placebo Comparator|Control_Placebo first, then placebo|"Healthy control:
~placebo capsule twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
11544305|NCT01044745|Experimental|Treatment (Rituximab and allogeneic HCT transplant)|"CONDITIONING REGIMEN: Patients receive one of the following conditioning regimens as per the transplant physician: cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.
~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive rituximab IV on days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Patients also receive tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.
~TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0."
11544306|NCT01044732|Experimental|Group A - COLO, then TER|"Complete examination with standard colonoscope (COLO) followed by complete examination with Third Eye Retroscope (TER) used in conjunction with standard colonoscope"
11544307|NCT01044732|Active Comparator|Group B - TER, then COLO|"Complete examination with Third Eye Retroscope (TER) used in conjunction with standard colonoscope, followed by complete examination with standard colonoscope (COLO) alone"
11544308|NCT01044719|Active Comparator|10 days|
11544309|NCT01044719|Active Comparator|14 days|
11544310|NCT01044719|Active Comparator|21 days|
11544311|NCT01044706|Experimental|Bicalutamide 50 mg Tablet|Bicalutamide 50 mg Tablet
11544312|NCT01044706|Active Comparator|Casodex® 50 mg Tablet|Casodex® 50 mg Tablet
11544313|NCT01044693|Placebo Comparator|Placebo capsule|Placebo capsule
11544314|NCT01044693|Experimental|Nebivolol 5 mg|Nebivolol 5 mg capsule
11544315|NCT01044693|Active Comparator|Metoprolol tartrate 50 mg|Metoprolol tartrate 50 mg single oral dose
11544316|NCT01044693|Active Comparator|Sildenafil 25 mg|Sildenafil 25 mg single oral dose
11544317|NCT01044680|Experimental|Nutriose|17 g NUTRIOSE consumed twice daily for 12 weeks
11544318|NCT01044680|Placebo Comparator|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
11544322|NCT01044654|Experimental|Cohort 3|3 Subjects will receive a single infusion of 3.0 x 1010 SB-728-T
11544323|NCT01044654|Experimental|Cohort 4|Up to 4 HAART failure subjects will receive a single intravenous infusion of 0.5 to 3.0 x 1010 SB-728-T
11544324|NCT01044654|Experimental|Cohort 5|"Up to 20 subjects with heterozygote CCR5 delta-32 mutation will receive a single intravenous infusion of 0.5 to 3.0 x 1010 SB-728-T.
~Cohort 5 subjects will undergo a structured treatment interruption 2 months following infusion in which their anti-retroviral therapy will be discontinued for 16 weeks. HAART will be reinstituted in subjects whose CD4+ cell counts drop to <350 cells/mm3 and/or whose HIV-RNA increases to >100,000 on three consecutive weekly measurements.
~At the end of the STI, subjects with a sustained detectable viral load will be reinstituted on HAART. Subjects with HIV RNA levels below the limit of detection will remain off HAART. Subjects with an undetectable viral load will remain off HAART until HIV RNA levels are detectable or their CD4 count drops below 350 cell/mm3 on three consecutive weekly measurements."
11544325|NCT01044628|Experimental|Nocturnal oxygen therapy (N-O2)|Oxygen will be delivered overnight to the patients to allow their oxygen saturation to be >90%
11544326|NCT01044628|Sham Comparator|Sham concentrator|Sham therapy with ambient air will be given to the patients at night
11544327|NCT01044615||Mild traumatic brain injury patients|Subjects who have a verifiable diagnosis of mild traumatic brain injury sustained within 24 months prior to enrollment
11544328|NCT01044615||Normal Control|Normal, healthy adults with no history of brain injury.
11544329|NCT01044602|Active Comparator|Best Medical Management|Patients elect to treat obesity and type 2 diabetes mellitus through best medical management.
11544330|NCT01044602|Active Comparator|Surgical Treatment|Patients with type 2 diabetes mellitus choice to treat obesity with Roux-en-Y gastric bypass.
11544331|NCT01044589|Experimental|Biodesign Tissue Repair Graft|Biodesign Tissue Repair Graft
11544332|NCT01044589|Active Comparator|Overlapping Sphincter Repair|Control
11544333|NCT01044576||Multiple Sclerosis|Patients with relapsing-remitting or secondary progressive multiple sclerosis
11544334|NCT01044563|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
11544335|NCT01044563|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
11544336|NCT01044550|Other|Treatment|Laparoscopy on a group of randomly selected patients with left thoracoabdominal stab wounds to obtain the incidence of occult diaphragm injury
11544337|NCT01044550|Active Comparator|Control|Assess the incidence and clinical outcome of delayed diaphragm visceral herniation in the study group.
11544338|NCT01044537|Placebo Comparator|Placebo|In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo.
11544339|NCT01044537|Experimental|PF-04937319|In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo. There will be approximately 6 dosing levels of PF-04937319
11544340|NCT01044524|Experimental|1|SLV 334
11544341|NCT01044511|Experimental|Home visit|After SEMS placement, 2 home visits and a phonecall are made by a specialist nurse
11544342|NCT01044511|Active Comparator|Standard|Standard contact via Hotline and traditional referring methods
11544343|NCT01044498|Experimental|Tocilizumab 8 mg/kg + Ortho-Novum® 1/35 (Group 1)|Patients with rheumatoid arthritis received Ortho-Novum® 1/35 daily on Days 1-21 of 3 consecutive 28-day cycles. On the first day of Cycle 2, patients received tocilizumab 8 mg/kg administered intravenously.
11544344|NCT01044498|Other|Ortho-Novum® 1/35 (Group 2)|Healthy volunteers received Ortho-Novum® 1/35 tablets daily on Days 1-21 of one 28-day cycle.
11544345|NCT01044485|Other|lapatinib + docetaxel|"dose level Lapatinib (OD) Docetaxel (q3wks) Systematic Growth factor Minus 0 1250 mg 75 mg/m2 + systematic growth factor support
~0, 1250mg 75 mg/m2 No
~+1 1500mg 75mg/m2 No
~Minus +1* 1500mg 75mg/m2 + systematic growth factor support
~+2 1250mg 100mg/m2 No
~Minus +2* + systematic growth factor support
~+3 1500mg 100mg/m2 No
~Minus +3* + systematic growth factor support
~Apart within the minus dose levels, G-CSF support should be added only as rescue strategy if severe neutropenia occurred during the first cycle of studied dose.Patients will receive 4 cycles of the association. In case of benefit of the treatment, they should continue the treatment with lapatinib until progression.* patients will be included at level minus X only if 2 DLT out of 6 patients based on febrile neutropenia occurred at level X"
11544346|NCT01044459|Experimental|Aclidinium Bromide 200 µg|aclidinium bromide, inhaled, 52 weeks of treatment
11544347|NCT01044459|Experimental|Aclidinium Bromide 400 µg|aclidinium bromide, inhaled, 52 weeks of treatment
11544348|NCT01044446|Experimental|Icodextrin|peritoneal dialysate
11544349|NCT01044446|Active Comparator|Glucose-based dialysate|peritoneal dialysate
11544350|NCT01044433|Experimental|Arm I|Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14.
11544351|NCT01044420|Experimental|mFOLFIRI|
11544352|NCT01044394|Experimental|same day, reduced volume PEG-ELS prep|Patients with colonoscopies scheduled in the afternoon will complete 2 liters of PEG-ELS solution the morning of their colonoscopy.
11544353|NCT01044381|Experimental|Luliconazole Solution, 10%|
11544354|NCT01044368|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
11544355|NCT01044368|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
11544356|NCT01044355|Active Comparator|auto-titrating|Patients being treated for 6 weeks with auto-titrating continuous airway pressure.
11544357|NCT01044355|Active Comparator|Fixed|Patients receiving 6 weeks of treatment with fixed continuous positive airway pressure.
11544358|NCT01044342|Experimental|A|Single dose of AZD1446 10 mg
11544359|NCT01044342|Experimental|B|Single dose of AZD1446 80 mg
11544360|NCT01044342|Active Comparator|C|Single Dose of Donepezil 5 mg
11544361|NCT01044342|Placebo Comparator|D|Single dose of placebo to match AZD1446
11544362|NCT01044329|Active Comparator|Intravitreal bevacizumab|
11544363|NCT01044329|Active Comparator|Intravitreal triamcinolone|
11544366|NCT01044303|Experimental|Myfortic Escalation|Participants EC-MPS dose was escalated to a minimum daily dose of 1440mg or equivalent, with the maximum dose never exceeding the manufacturer's recommendations.
11544367|NCT01044290|Experimental|Outlook Intervention|"Subjects in the first group (Life Completion) completed a psychosocial intervention which consisted of meeting with the facilitator three times for 45-60 minutes each. In the first session, subjects were asked to discuss issues related to life review. In session two, participants spoke about issues of regret and forgiveness. In the final session, subjects focused on heritage and legacy."
11544368|NCT01044290|Active Comparator|Attention Control|"The subjects in the second group (attention control) met with a facilitator three times for 45 minutes and listened to a non-guided relaxation CD."
11544369|NCT01044290|No Intervention|Treatment as Usual|"Subjects in the third group (treatment as usual) were exposed to no intervention or attention control during the intervention window."
11544370|NCT01044277|Experimental|Group A|"Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo
~Other name Gluthathione peroxidases"
11544371|NCT01044277|Experimental|Group B|"Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo
~Other name Gluthathione peroxidases"
11544372|NCT01044277|Placebo Comparator|Group C|Placebo-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo
11544373|NCT01044264|Active Comparator|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Test product
11544374|NCT01044264|Active Comparator|DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Reference product
11544375|NCT01044264|Placebo Comparator|Placebo|
11544376|NCT01044251|Placebo Comparator|Placebo|10 days of treatment with placebo in a bid fashion that will look like the study medication.
11544377|NCT01044251|Experimental|Frovatriptan|Frovatriptan 2.5 mg po bid for 10 days
11544378|NCT01044238|Experimental|active medication (methylphenidate)|Condition receiving active medication: 18mg/day during week 1; 36mg/day during week 2; 54mg/day during remainder of study
11544379|NCT01044238|Placebo Comparator|Placebo|Condition randomly assigned to receive placebo, provided to appear identical to active medication
11544380|NCT01044225|Active Comparator|Cilengitide EMD 121974|A dose of 2000 mg by iv administration 2 weekly.
11544381|NCT01044225|Active Comparator|Cetuximab|An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
11544382|NCT01044212|Active Comparator|Docusate|Docusate is the standard of care regimen
11544383|NCT01044212|Experimental|Bowel medications|Docusate, Miralax, Metamucil wafers, Bisacodyl suppository
11544384|NCT01044199|Experimental|1: Pre-EP ID|Group of participants receiving PCEC rabies vaccine intradermally with the Pre-Exposure schedule.
11544385|NCT01044199|Active Comparator|2: Pre-EP IM|Group of participants receiving PCEC rabies vaccine intramuscular with the Pre-Exposure schedule.
11544386|NCT01044199|Experimental|3: Booster ID|Group of participants receiving PCEC rabies vaccine intradermally with the Booster schedule.
11544387|NCT01044199|Active Comparator|4: Booster IM|Group of participants receiving PCEC rabies vaccine intramuscular with the Booster schedule.
11544388|NCT01044186|Experimental|ICL670|
11544389|NCT01044160||Oncology Group|The study will recruit from outpatient clinics with procedures designed to obtain a representative sample of research participants, in terms of diagnosis and time since diagnosis.
11544390|NCT01044160||Control Group|The study will first identify a large cohort of children who are willing to participate, and then call them back individually as they are found to match participants in the cancer group.
11544391|NCT01044147|Experimental|VLM-S|"Participants in this arm receive standard lifestyle coaching, which is delivered on a specified schedule. They will also receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle."
11544392|NCT01044147|Experimental|VLM-M|"Participants in this arm receive modulated lifestyle coaching, where coaching frequency may be adjusted according to whether the participant is meeting program goals for program use and targeted behaviors. They will also receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle."
11544393|NCT01044147|Active Comparator|OGR|Participants in this arm will receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle, but not personalized lifestyle coaching.
11544394|NCT01044134|Experimental|Diet + Water|"Participants will be counseled to follow a standard weight-reducing diet including consumption of 1) ample vegetables, fruits, and legumes; 2) whole rather than refined grains; and 3) high-quality proteins at most meals and snacks. Moreover, we will recommend limiting intake of added fats and sugars and avoiding juices and sugar-sweetened beverages (per standard practice). Participants will also be counseled to increase their water intake to 8 cups per day, consistent with the popular 8 × 8 recommendation (eight 8-oz glasses of water)."
11544395|NCT01044134|Active Comparator|Diet|Participants will be counseled on the same standard weight-reducing diet, as described above, with no specific advice regarding water consumption. Furthermore, no specific dietary recommendations will be provided on altering fluid/beverage intake, other than to decrease calorie-containing beverages as noted above. When participants ask for a recommendation regarding water intake, they will be advised that drinking plain water is the best way to satisfy thirst and instructed to drink when thirsty.
11544396|NCT01044121|Experimental|Mattress Firmness|
11544397|NCT01044108|Experimental|Trial, part 1 (males only)|
11544398|NCT01044108|Experimental|Trial, part 2 (males and females)|
11544399|NCT01044095|Active Comparator|Autologous prime boost regimen 1|FluMist® live intranasal vaccine (LAIV) 0.2mL (0.1mL per nostril): 2 doses separated by 8 weeks (+/- 7 days)
11544400|NCT01044095|Active Comparator|Autologous prime boost regimen 2|Fluzone® inactivated seasonal influenza virus vaccine intramuscularly: 2 doses separated by 8 weeks (+7 days)
11544401|NCT01044095|Experimental|Heterologous prime boost regimen 1|FluMist® live, intranasal vaccine single dose, followed by Fluzone® inactivated influenza virus vaccine 8 weeks (+/-7 days) later
11544402|NCT01044095|Experimental|Heterologous prime boost regimen 2|Fluzone® inactivated seasonal influenza virus vaccine single dose, followed by FluMist® live, intranasal seasonal influenza vaccine 0.2mL 8 weeks (+/- 7 days) later
11544403|NCT01044082|Experimental|controlled cord traction|Controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs.
11544404|NCT01044082|Active Comparator|clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
11544405|NCT01044069|Experimental|Pts with B Cell Acute Lymphoblastic Leukemia|This is a phase I study. Patients with CD19+ ALL (CR, relapsed, MRD, or refractory) are eligible for enrollment. B-ALL patients in first CR will be enrolled but only treated if they develop MRD or a frank relapse, while patients with MRD or with documented relapsed/refractory disease are eligible for immediate treatment. The T cell doses originally proposed in this study were based on doses administered safely in prior autologous T cell adoptive therapy trials but the dose has been modified based on the toxicities observed in patients with morphologic evidence of disease. Patients will be treated with different doses of T cells depending on the amount of disease at the time of T cell infusion. Patients in Cohort 1 (<5% blasts in the BM) will continue to receive 10^6 19-28z+ T cells/kg as previously. Patients in Cohort 2 (≥5% blasts in the BM) will receive the reduced dose of 1x106 19-28z+ T cells/kg).
11544406|NCT01044056|Active Comparator|Levonorgestrel/ethinylestradiol oral contraceptive pill|Microgynon(R), 1 tablet every day for 21 days; each tablet contains 0.150 mg levonorgestrel (LNG) and 0.030 mg ethinylestradiol (EE).
11544407|NCT01044056|Active Comparator|Norelgestrominum and ethinylestradiol contraceptive patch|Evra(TM), One patch applied on lower abdomen for 7 days for 3 consecutive weeks, 3 patches in total. Each patch contains 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
11544408|NCT01044056|Active Comparator|Etonogestrel and ethinylestradiol contraceptive vaginal ring|Nuvaring(R), Place the ring in the vagina for 21 days, remove for one week. Repeat with new Ring. Dose: per ring 11.7 mg ENG and 2.7 mg EE releasing a daily average amount of 0.120 mg ENG and 0.015 mg EE.
11544409|NCT01044030|Experimental|Xylitol syrup|
11544410|NCT01044030|Placebo Comparator|Placebo|
11544411|NCT01044017|Experimental|A|
11544412|NCT01044017|Experimental|B|
11544413|NCT01044017|Placebo Comparator|C|
11544414|NCT01044004|Experimental|Post treatment remission armodafinil|Armodafinil 150 mg/day for 13 weeks
11544415|NCT01044004|Placebo Comparator|Post treatment remission placebo|Placebo 150mg/day for 13 weeks
11544416|NCT01044004|Experimental|Chemotherapy armodafinil|Armodafinil 150 mg/day for 13 weeks
11544417|NCT01044004|Placebo Comparator|Chemotherapy placebo|Placebo 150mg/day for 13 weeks
11544418|NCT01043991|Experimental|EPO|single bolus of EPO, 150 µg
11544419|NCT01043991|Placebo Comparator|Placebo|NaCl
11544420|NCT01043978|Experimental|Novel nipple|
11544421|NCT01043978|Active Comparator|Coventional nipple|
11544422|NCT01043965|Active Comparator|Diabetes|Type 2 diabetes patients without obstructive coronary disease. Interventional group: lifestyle changes and treatment with metformin.
11544423|NCT01043965|No Intervention|Control|Control group - normal, healthy individuals.
11544424|NCT01043952|Active Comparator|Control|"Patients receive general anesthesia with Propofol and Remifentanil following clinical practice.
~Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects.
~Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters."
11544425|NCT01043952|Experimental|Bispectral Index Monitor|"Patients receive a general anesthesia with Propofol and Remifentanil where the amount of anesthetics administered is decided taking into consideration the Bispectral Index Monitor.
~Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects.
~Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters."
11544426|NCT01043939|Active Comparator|Purple Grape Juice First|After 4 week run-in period, drink 6 ounces of purple grape juice twice daily, then 4 week washout, week 12 drink 6 ounces of clear apple juice for 4 weeks twice daily
11544427|NCT01043939|Active Comparator|Apple Juice First|After 4 week run-in period, drink 6 ounces of clear apple juice twice daily, then 4 week washout, week 12 drink 6 ounces of purple grape juice for 4 weeks twice daily
11544428|NCT01043926|Experimental|Participants with Moderate Hepatic Insufficiency (Part I)|Participants with moderate hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
11544429|NCT01043926|Experimental|Healthy Participants (Part I)|Healthy participants matched to participants with moderate hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
11544430|NCT01043926|Experimental|Participants with Mild Hepatic Insufficiency (Part II)|Participants with mild hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part II of the study (if conducted).
11544431|NCT01043926|Experimental|Healthy Participants (Part II)|Healthy participants matched to participants with mild hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part II of the study (if conducted).
11544432|NCT01043913|Experimental|Guaraná extract 50mg q12 hours|Guaraná extract pills of 50mg q12 hours for 21 days
11544433|NCT01043913|Placebo Comparator|Placebo 1 tab q12 hours|Placebo pills 1 tab q12 hours for 21 days
11544434|NCT01043900|Placebo Comparator|Sham rTMS|Patients with stable medication regimen receiving 30 daily sessions of PLACEBO rTMS delivered to the right dorsolateral prefrontal cortex
11544435|NCT01043900|Active Comparator|Active rTMS|Patients with stable medication regimen receiving 30 daily sessions of active rTMS delivered to the right dorsolateral prefrontal cortex
11544436|NCT01043887|Experimental|Patients with Moderate Hepatic Insufficiency|Patients with moderate hepatic insufficiency (a score of 7 to 9 on the Child-Pugh's scale) received a single 10 mg dose of ridaforolimus.
11544437|NCT01043887|Experimental|Healthy Control Subjects|Healthy control subjects were matched by race, age, gender, and body mass index (BMI) to the patients with moderate hepatic insufficiency. The healthy control subjects also received a single 10 mg dose of ridaforolimus.
11544438|NCT01043874|Experimental|Nilotinib|400 mg BID
11544439|NCT01043848|Experimental|Early pudendal stimulation|Subjects in this arm will start with the intervention within 2 weeks after SCI
11544543|NCT01043146|Placebo Comparator|placebo|intravenous 0.9 % NaCl
11544440|NCT01043848|Experimental|Late pudendal stimulation|Subjects in this arm will start with the intervention 12 weeks after SCI
11544441|NCT01043848|No Intervention|Control|Subjects in this arm will be treated according to standard therapy but will receive no pudendal stimulation
11544442|NCT01043835|Experimental|Laparoscopy-assisted gastrectomy|
11544443|NCT01043835|Active Comparator|Open gastrectomy|
11544444|NCT01043809|No Intervention|1|Randomly selected schools will not receive handwashing intervention
11544445|NCT01043809|Experimental|2|Randomly selected schools will get standard commercial school-based handwashing promotion
11544446|NCT01043809|Experimental|3|Randomly selected schools will receive standard commercial school-based handwashing promotion program, plus an added level of handwashing promotion (varies by country)
11544447|NCT01043796|Experimental|Insecticide treated nets and wall liners|
11544448|NCT01043796|Active Comparator|Insecticide treated nets alone|
11544449|NCT01043770|Experimental|Group lifestyle education|Multi-component behaviour change intervention
11544450|NCT01043770|No Intervention|Routine care|Routine care
11544451|NCT01043757|Experimental|Control|1) Control Group. Receives daily step goals via emails and has access to the study website to allow them to track their progress. Eligible for check-in incentives.
11544452|NCT01043757|Experimental|Fixed|"Receives control intervention plus are incentivized to attain their daily step goals through daily lotteries:
~Each day, we will draw a two-digit number. If the first digit OR the second digit of this daily number matches the participant's lucky number, they win the small jackpot. If both digits match, they receive the large jackpot. Participants who meet their step goal for the day and who upload their data will be entered into the same lottery each day, where the small jackpot is $10 and the large jackpot is $100."
11544453|NCT01043757|Experimental|Ascending|"Receives control intervention plus incentivized to attain daily step goals through lotteries:
~Each day, we will draw a two-digit number. If the first digit OR the second digit of this daily number matches the participant's lucky number, they win the small jackpot. If both digits match, they receive the large jackpot.
~Participants can increase their daily jackpots by meeting their step goals. Those who meet their goal for the first day of the week and who upload their data will be entered into a lottery where the small jackpot is $4 and the large jackpot is $40; if they successfully meet their step goal on the first day of the week, the jackpots for the second day increase to $6/$60, and so on such that if they reach their goals each day, the jackpots on day seven will reach $16/$160."
11544454|NCT01043757|Experimental|Decreasing|"Receives control intervention plus incentivized to attain daily step goals through lotteries:
~Daily drawing procedure same as Ascending condition; structure of incentives is different: Participants can decrease their daily jackpots by failing to meet their step goals. Those who meet their goal for the first day of the week and who upload their data will be entered into a lottery where the small jackpot is $16 and the large jackpot is $160; if they successfully meet their step goal on the first day of the week, the jackpots will remain at $16/$160; if they do not meet their goal the jackpots will decrease to $14/$140, and so on such that if they fail to reach their goals each day, the jackpots on day seven will decrease to $4/$40."
11544455|NCT01043744|Experimental|Artemether-Lumefantrine|Receive artemether-lumefantrine with direct observation of am dose on days 0, 1, and 2 of study
11544456|NCT01043744|No Intervention|No treatment|No antimalarial treatment given on day 0.
11544457|NCT01043731||Ginven indication for laparoscopic anterior resection|
11544458|NCT01043718|Experimental|More-Intensive|
11544459|NCT01043718|Active Comparator|Less-Intensive|
11544460|NCT01043705||CIED replacement with CRT and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with a CRT and the TYRX Anti-bacterial envelope, with or without lead revision.
11544461|NCT01043705||CIED replacement with ICD and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with an ICD and the TYRX Anti-bacterial envelope, with or without lead revision.
11544462|NCT01043705||CIED replacement with ICD or CRT and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with an ICD or CRT and the TYRX Anti-bacterial envelope, with or without lead revision.
11544463|NCT01043705||CIED replacement w/ CRT & no TYRX|(Retrospective Case-Control Arm) Patients who have undergone CIED replacement with a CRT and no TYRX Anti-bacterial envelope, with or without lead revision/addition.
11544464|NCT01043705||CIED replacement w/ CRT & TYRX vs. Case Match Arm|Patients who have undergone CIED replacement with a CRT and TYRX Anti-bacterial envelope, with or without lead revision/addition. Cohort is TYRX Case, Matched to Retrospective Case-Control Arm)
11544465|NCT01043692|Experimental|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
11544466|NCT01043679|Active Comparator|Seroquel|Efficacy and Safety of Seroquel
11544467|NCT01043679|Active Comparator|Utapine|Efficacy and Safety of Utapine
11544468|NCT01043666|Experimental|YM178 group|oral
11544469|NCT01043666|Placebo Comparator|placebo group|oral
11544470|NCT01043666|Experimental|tolterodine ER group|oral
11544471|NCT01043653||Maryland Assessment of Recovery in Serious Mental Illness|Individuals with serious mental illness treated in mental health outpatient programs
11544472|NCT01043640|Experimental|Transplant Patients|Includes patients who received allogeneic stem cell transplantation following treatment plan of Campath-1H, cyclophosphamide, cyclosporine A, mycophenolate mofetil, and busulfan.
11544473|NCT01043614|Experimental|Peer group education|Small groups of female college freshmen facilitated by peer educators
11544474|NCT01043601|Experimental|Inhaled PT005 7.2 µg|
11544475|NCT01043601|Experimental|Inhaled PT005 9.6 µg|
11544476|NCT01043601|Placebo Comparator|Inhaled Placebo|
11544477|NCT01043601|Active Comparator|Formoterol Fumarate 12 µg (Foradil Aerolizer)|
11544478|NCT01043588|Other|1 : TURP|Surgery: TransUrethral Resection of the Prostate
11544479|NCT01043588|Other|2 : PVP|Surgery: Photo selective Vaporization of the Prostate
11544480|NCT01043575|Experimental|1|Rifapentine
11544481|NCT01043575|Active Comparator|2|Rifampin
11544544|NCT01043133|Experimental|Intervention group|
11544545|NCT01043133|No Intervention|Control Group|
11544546|NCT01043120|Experimental|Barusiban|
11544547|NCT01043120|Placebo Comparator|Placebo|
11544548|NCT01043107||Compuer radiaton group|
11544549|NCT01043107||control group|
11544482|NCT01043562||Pediatric ICD pts|Inclusion criteria for study participants included: 1) weight ≤60 kg, 2) new or existing ICD system, and 3) clinically necessary assessment of the defibrillation efficacy of the ICD system. Transvenous systems utilized a high-voltage ICD coil with active-fixation lead attached to the right ventricular endocardial surface, whereas non-transvenous systems depended upon a high-voltage shocking coil placed within the pericardial, subcutaneous or pleural space. To be included in the post-shock pacing portion of the study, adequate sinus and AV node function had to be present at baseline. Exclusion criteria included 1) tenuous hemodynamic status felt to warrant abbreviation of the defibrillation efficacy testing or 2) inability to induce fibrillation during defibrillation threshold testing (DFT).
11544483|NCT01043549|Active Comparator|Stimulation|Repetitive transcranial stimulation of the posterior parietal cortex
11544484|NCT01043549|Sham Comparator|Sham stimulation|
11544485|NCT01043536|Experimental|radiotherapy + temozolomide|"Radiotherapy:
~dose given at PTV-g will be 70 Gy/28 fractions level 1 75 Gy/30 fractions level 2 80 Gy/32 fractions level 3
~dose given at PTV-a will be 56 Gy/28 fractions level 1 60 Gy/30 fractions level 2 60.8 Gy/32 fractions level 3
~Chemotherapy:
~temozolomide given at the dose of 75mg/m2"
11544486|NCT01043523||Group 1|
11544487|NCT01043510|Experimental|A1, first period|
11544488|NCT01043510|Active Comparator|A2, second period|
11544489|NCT01043510|Active Comparator|B1, first period|
11544490|NCT01043510|Experimental|B2, second period|
11544491|NCT01043484|Experimental|A|Bevacizumab + Capecitabine + Radiotherapy
11544492|NCT01043484|Active Comparator|B|Capecitabine + Radiotherapy
11544493|NCT01043471|Experimental|Chewing gum|
11544494|NCT01043471|Placebo Comparator|Water|
11544495|NCT01043458|Experimental|1|ABT-126 Low Dose
11544496|NCT01043458|Experimental|2|ABT-126 High Dose
11544497|NCT01043458|Experimental|3|Placebo for ABT-126
11544498|NCT01043445|Experimental|GPR119 agonist, 2-oleoyl glycerol|2-oleoyl glycerol; 2g. and vehicle
11544499|NCT01043445|Active Comparator|Oleic acid|oleic acid; 3.2g and vehicle
11544500|NCT01043445|Placebo Comparator|Vehicle|5 ml. of glycerol and 5 ml 96% ethanol
11544501|NCT01043432||Moderate/severe TBI and history of suicidal behavior Group 1|Moderate/severe TBI and history of suicidal behavior
11544502|NCT01043432||Moderate/Severe TBI and no history of suicidal behaviorGroup|Moderate/Severe TBI and no history of suicidal behavior
11544503|NCT01043432||No TBI and a history of suicidal behavior Group 3|No TBI and a history of suicidal behavior
11544504|NCT01043432||No TBI and no history of suicidal behavior Group 4|No TBI and no history of suicidal behavior
11544505|NCT01043419|Experimental|LENOXe™ (xénon 100 % v/v)|Influence of LENOXe™ (xénon 100 % v/v) anesthesia on Sympathetic Nervous Activity and Security under LENOXe™ (xénon 100 % v/v) anesthesia
11544506|NCT01043406|Experimental|Single Arm, Device Implant|
11544507|NCT01043393|Experimental|Psoriasis involving 10-15% BSA|Patients 18 years of age or older with a confirmed diagnosis of moderate to severe plaque psoriasis having involvement of 10-15% of their body surface area.
11544508|NCT01043393|Experimental|Psoriasis involving >15% of BSA|Patients 18 years of age or older with a confirmed diagnosis of moderate to severe plaque psoriasis having involvement of >15% of their body surface area.
11544509|NCT01043380|Experimental|LZ group|
11544510|NCT01043380|Active Comparator|L group|
11544511|NCT01043367|Experimental|A|Deprexil
11544512|NCT01043367|Placebo Comparator|B|Placebo
11544513|NCT01043354|Experimental|stage-matched intervention|Transtheoretical Model-based stage-matched intervention
11544514|NCT01043354|Experimental|framing effects intervention|counseling based on prospect theory
11544515|NCT01043354|Active Comparator|attention placebo intervention|counseling about general health topics
11544516|NCT01043341|Active Comparator|behavioral|the women received a folder about HPV infection and vaccines and answered a questionaire about sexual behavior, HPV infection and vaccines.
11544517|NCT01043341|No Intervention|no intervention|the women answered a questionaire about sexual behavior, HPV infection and vaccines
11544518|NCT01043328||GROUP OSCC|"The study group is composed by patients with a condition that requires a procedure/surgery for oral squamous cell carcinoma treatment.
~INTERVENTIONS: Collect blood, saliva and oral tissue."
11544519|NCT01043328||CONTROL GROUP|"Group without oral squamous cell carcinoma but with a condition that requires prosthetic procedure/surgery.
~INTERVENTIONS: Collect blood, saliva and oral tissue."
11544520|NCT01043315||Hospitalized Cardiac Patient|Adults admitted to Coronary intensive unit being treated for acute cardiovascular conditions
11544521|NCT01043302||Surgery+chemotherapy|Primary mass was resected and systemic chemotherapy was performed as an adjuvant treatment
11544522|NCT01043302||Chemotherapy|Only treated with chemotherapy
11544523|NCT01043289|Experimental|Bright light therapy|Early morning white light @ 7,000 lux for 60 minutes daily (4.2 x 10^5 lux-min) for 5 weeks
11544524|NCT01043289|Placebo Comparator|Dim red light|Early morning dim red light @ 70 lux for 60 minutes daily (3.0 x 10^3 lux-min) for 5 weeks
11544525|NCT01043276|Experimental|Treatment A|
11544526|NCT01043276|Experimental|Treatment B|
11544527|NCT01043276|Experimental|Treatment C|
11544528|NCT01043276|Experimental|Treatment D|
11544529|NCT01043276|Experimental|Treatment E|
11544530|NCT01043263|Experimental|EN3324 (axomadol)|
11544531|NCT01043263|Placebo Comparator|Placebo|
11544532|NCT01043250||Risperidone|Receiving risperidone treatment
11544533|NCT01043250||Olanzapine|Receiving olanzapine treatment
11544534|NCT01043250||Aripiprazole|Receiving aripiprazole
11544535|NCT01043224|Experimental|Clobetasol propionate plus calcipotriol|
11544536|NCT01043185|Experimental|A|AZD3355 30 mg
11544537|NCT01043185|Experimental|B|AZD3355 90 mg
11544538|NCT01043185|Experimental|C|AZD3355 120 mg
11544539|NCT01043185|Experimental|D|AZD3355 240 mg
11544540|NCT01043185|Placebo Comparator|E|Placebo
11544541|NCT01043172|Experimental|Gemcitabine|Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
11544542|NCT01043146|Active Comparator|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
11544550|NCT01043094|Experimental|Pitavastatin 4mg renal impaired|Subjects with severe renal impairment (glomerular filtration rate [GFR] of 15 to 29 mL/min/1.73 m2, inclusive) who are not being treated with hemodialysis
11544551|NCT01043094|Active Comparator|Pitavastatin 4mg healthy subjects|Healthy subjects (GFR greater than or equal to 90 mL/min/1.73 m2)
11544552|NCT01043068|Experimental|Pain control|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
11544553|NCT01043055||Breast Cancer Patients|
11544554|NCT01043055||Healthy Control Group|
11544555|NCT01043042||Hospitalized patients|patients hospitalized at VUH between 4/1/2008 to 10/31/2009
11544556|NCT01043029|Experimental|aleglitazar|
11544557|NCT01043029|Active Comparator|pioglitazone|
11544558|NCT01043016|Experimental|Photocyanine injection|Patients receive intravenous injection of Photocyanine injection from dosage of 0.1 mg/kg,0.2 mg/kg,0.33 mg/kg,0.5 mg/kg to 0.6 6mg/kg till the dose-limiting effect occur.
11544559|NCT01043003|Experimental|Arm I|Patients and caregivers undergo the Bilingual Breast Cancer Educational Intervention (BBCEI) comprising teaching sessions over 50-65 minutes about 4 specific domains (i.e., physical, psychological, social, and spiritual well being) once weekly during month 1 and also undergo evaluation sessions at months 1, 4, and 7. Patients and caregivers receive reinforcement telephone calls every other week.
11544560|NCT01043003|Active Comparator|Arm II|Patients and caregivers undergo usual care comprising evaluation sessions at months 1, 4, and 7. Patients and caregivers may undergo the 4 BBCEI teaching sessions during month 7. Patients and caregivers receive reinforcement telephone calls every other week.
11544561|NCT01042990|Active Comparator|Home Exercise Only|Participants receive education and instruction on a home exercise program which they do on their own, with intermittent encouragement from study personnel.
11544562|NCT01042990|Experimental|APA|Participants exercise in a gym setting 3x/week for six months, performing gait and balance exercises along with a progressive walking program.
11544563|NCT01042990|Experimental|APA+TM|Participants exercise in a gym setting 3x/week for six months, performing a combined program of adaptive physical activity (gait and balance training) and progressive treadmill walking.
11544564|NCT01042977|Experimental|1|dapagliflozin 10 mg tablet
11544565|NCT01042977|Placebo Comparator|2|matching placebo tablet
11544566|NCT01042951|Active Comparator|ShanChol Cholera Vaccine|
11544567|NCT01042951|Placebo Comparator|Placebo|
11544568|NCT01042938|Active Comparator|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks).
11544569|NCT01042938|Placebo Comparator|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks).
11544570|NCT01042925|Experimental|Arm 1|XL147 in combination with trastuzumab
11544571|NCT01042925|Experimental|Arm 2|XL147 in combination with trastuzumab and paclitaxel
11544572|NCT01042899|Experimental|Teen Online Problem Solving (TOPS)|Web intervention
11544573|NCT01042899|Experimental|Teen Online Problem Solving---Teen Only|Web Intervention
11544574|NCT01042899|Active Comparator|Internet Resources Comparison|Web Intervention
11544575|NCT01042886|Experimental|Family plus community focused intervention|
11544576|NCT01042886|Active Comparator|Standard Behavioral Weight Loss Maintenance Intervention|
11544577|NCT01042873|Other|Intravenous dobutamine|3 hours infusion of dobutamine
11544578|NCT01042860|Active Comparator|supplement|lutein supplement
11544579|NCT01042860|Placebo Comparator|placebo|Placebo
11544580|NCT01042834||Air pollution|The subjects will have to live in districts where important atmospheric pollution is established
11544581|NCT01042821|Active Comparator|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
11544582|NCT01042821|Active Comparator|Group 2|The flap comprised mucosa, submucosa only
11544583|NCT01042808||1|HIV-1 Infected patients treated with Isentress
11544584|NCT01042795|Experimental|Continuous Daily Dosing of Sunitinib|
11544585|NCT01042782|Experimental|RAD-MitC|RAD001 orally daily 5mg or 7.5mg or 10mg Mitomycin C 5mg/m2 every 3 weeks
11544586|NCT01042769|Experimental|Aleglitazar|
11544587|NCT01042769|Placebo Comparator|Placebo|
11544588|NCT01042743|Experimental|RAP|individuals who underwent robot-assisted surgery for primary right-sied colon cancer
11544589|NCT01042743|Active Comparator|LAP|Individuals who underwent laparoscopic surgery for primary right-side colon cancer
11544590|NCT01042730|Active Comparator|Pitavastatin 1 mg daily|
11544591|NCT01042730|Active Comparator|Pitavastatin 4 mg daily|
11544592|NCT01042717|Experimental|Plerixafor|Plerixafor 16 hours
11544593|NCT01042704|Experimental|Bendamustine, Lenalidomide and Dexamethasone|Treatment with Bendamustine in combination with Lenalidomide and Dexamethasone will be administered on an outpatient basis. Each treatment cycle will be 28 days dosed according to the Dose Escalation Schema.
11544594|NCT01042691|Experimental|Oxaliplatin|Subjects who are planning to undergo surgery for placement of HAI therapy pump will be considered for enrollment. Standard HAI therapy requires a laparotomy and placement of an intrahepatic arterial catheter that is connected to one of several commercially available subcutaneous electronic pumps. The pump is then used to deliver FUDR and Leucovorin directly to the liver, usually beginning four weeks after surgery and lasts on average for a period of six to twelve months after the study. This study will examine the addition of a one hour isolated hepatic perfusion with oxaliplatin to this standard treatment
11544595|NCT01042678|Experimental|MP0112 (0.04 mg)|Single 0.04 mg intravitreal injection of MP0112 in the study eye.
11544596|NCT01042678|Experimental|MP0112 (0.15 mg)|Single 0.15 mg intravitreal injection of MP0112 in the study eye.
11544597|NCT01042678|Experimental|MP0112 (0.4 mg)|Single 0.4 mg intravitreal injection of MP0112 in the study eye.
11544598|NCT01042678|Experimental|MP0112 (1.0 mg)|Single 1.0 mg intravitreal injection of MP0112 in the study eye.
11544599|NCT01042678|Experimental|MP0112 (2.0 mg)|Single 2.0 mg intravitreal injection of MP0112 in the study eye.
11544600|NCT01042678|Experimental|MP0112 (3.6 mg)|Single 3.6 mg intravitreal injection of MP0112 in the study eye.
11544601|NCT01042665||primary open angle glaucoma|"Patients with glaucomatous optic neuropathy defined as narrowing of the neuroretinal rim, notching, excavation, or RNFL defect; and repeatable standard automated perimetry abnormality defined as a glaucoma hemifield test (GHT) outside normal limits or pattern standard deviation (PSD) outside 95% normal limits were included."
11544602|NCT01042665||Ocular Hypertensive group|Ocular hypertension defined as an intraocular pressure ≥ 24 mm Hg and ≤ 32 mm Hg in one eye and IOP ≥ 22 mm Hg and ≤ 32 mm Hg in the fellow eye, with normal optic disc, normal visual field defined as follows mean Deviation (MD) or Pattern Standard Deviation (PSD) of p>5%, normal Glaucoma Hemifield Test (GHT) and reliable visual field exam
11544603|NCT01042652|Active Comparator|Nevirapine|
11544604|NCT01042652|Experimental|Raltegravir|
11544605|NCT01042639|Active Comparator|physical activity once a day|
11544606|NCT01042639|Experimental|physical activity twice a day|
11544607|NCT01042639|No Intervention|control|
11544608|NCT01042626|Experimental|Normocalcemic Hyperparathyroidism|
11544609|NCT01042626|Experimental|Hypercalcemic Hyperparathyroidism|
11544610|NCT01042626|Active Comparator|Healthy subjects|
11544611|NCT01042613|Other|Group A|Research participants are randomly assigned into group A (Accuvein AV300 assisted intravenous catheter insertion)
11544612|NCT01042613|Other|Group B|(standard technique of insertion of the intravenous cannula)
11544613|NCT01042600|Active Comparator|Endotracheal intubation|Endotracheal tube insertion for surfactant administration, following morphine and atropine pre-medication
11544614|NCT01042600|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
11544615|NCT01042587|Active Comparator|bright light|Bright light has been shown to entrain circadian rhythm so our treatment arm will use thirty minutes of early morning exposure to bright blue light for a four week period.
11544616|NCT01042587|Sham Comparator|red light|Low level red light is a weak entrainment stimulus of circadian rhythm. Elders in the control group will be exposed to low level red light as a placebo for thirty minutes daily for four weeks.
11544617|NCT01042561|Placebo Comparator|placebo|This group will recieve the current standard of care for infants in the NICU, recieving infant formula that provides less than 400 IU of vitamin D a day.
11544618|NCT01042561|Experimental|Vitamin d|This group will recieve standard of care infant formulas that provide less than 400 IU of vitamin D a day, in addition they will be supplemented with 400 IU of vitamin D3 daily.
11544619|NCT01042535|Experimental|Treatment (vaccine therapy, 1-methyl-d-tryptophan)|Participants receive adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine ID in weeks 1, 3, 5, and 10, and then every 3 weeks for 6 total doses. Participants also receive 1-methyl-d-tryptophan (indoximod) orally (PO) daily (QD) on days 1-21. Treatment with 1-methyl-d-tryptophan repeats every 28 days (patients with stable disease) for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11544620|NCT01042522|Experimental|Arm I (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11544621|NCT01042522|Experimental|Arm II (bleomycin sulfate, etoposide phosphate, cisplatin)|Patients receive bleomycin sulfate IV on day 1 and etoposide IV over 1 hour and cisplatin IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11544622|NCT01042509|Experimental|Alemtuzumab and rituximab|Patients with chronic GVHD after first-line therapy failure will receive Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25. THE STUDY HAVE ONLY ONE ARM.
11544623|NCT01042496|Active Comparator|Bipolar Group|Subjects underwent proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC) before and after treatment with Lamotrigine.
11544624|NCT01042496|Active Comparator|Control Group|Subjects underwent proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).
11544625|NCT01042470||control group|female patients without pelvic organ prolapse, stage 0 or I (POP-Q)
11544626|NCT01042470||pelvic organ prolapse|female patients with pelvic organ prolapse stage II or higher (POP-Q)
11544627|NCT01042457|Other|Mycophenolate mofetil|
11544628|NCT01042444|Experimental|Embolic Protection Device|The study will involve up to 20 patients to be enrolled using the GARDEX system during clinically indicated percutaneous intervention of SVG and followed through 30 days post procedure. Patients will be enrolled at up to 3 investigative sites. The study is a prospective multi center registry with sequential enrollment of qualified patients who consent to participate and meet the eligibility criteria.
11544629|NCT01042431||Ward population|Patients hospitalized in the Orthopedics B Ward in the Hillel Yaffe Medical Center that choose to participate in the study
11544630|NCT01042418|Experimental|Whole kernel breakfast|
11544631|NCT01042418|Placebo Comparator|Wheat reference breakfast|
11544632|NCT01042418|Active Comparator|Milled kernel breakfast|
11544633|NCT01042392|Active Comparator|Ramipril|"In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.
~In period II (double-blind treatment, randomized): Ramipril 5 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to Ramipril 10 mg only if BP remained ≥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.
~In period III (double-blind withdrawal): At visit 4, part of patients received the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
11544634|NCT01042392|Experimental|Aliskiren|"In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.
~In period II (double-blind treatment, randomized): Aliskiren 150 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to aliskiren 300 mg only if BP remained ≥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.
~In period III (double-blind withdrawal ): At visit 4, part of the patients received the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
11544635|NCT01042392|Placebo Comparator|Placebo to Ramipril|In period III (double-blind withdrawal ): At visit 4, part of patients from Ramipril arm received placebo to Ramipril for 1 day. The study ended at visit 5 (48 hours later than visit 4).
11544636|NCT01042392|Placebo Comparator|Placebo to Aliskiren|In period III (double-blind withdrawal ): At visit 4, part of the patients from Aliskiren arm received placebo to Aliskiren for 1 day. The study ended at visit 5 (48 hours later than visit 4).
11544637|NCT01042379|Active Comparator|Standard Therapy|Paclitaxel, Herceptin followed by Doxorubicin and Cyclophosphamide treatment depending on HR/HER-2 status.
11544638|NCT01042379|Experimental|AMG 386 with or without Trastuzumab|Arm is closed.
11544639|NCT01042379|Other|AMG 479 plus Metformin|Arm is closed.
11544640|NCT01042379|Experimental|MK-2206 with or without Trastuzumab|Arm is closed.
11544641|NCT01042379|Experimental|T-DM1 and Pertuzumab|Arm is closed.
11544642|NCT01042379|Active Comparator|Pertuzumab and Trastuzumab|Novel Control Investigational Agent
11544643|NCT01042379|Experimental|Ganetespib|Arm is closed.
11544644|NCT01042379|Other|ABT-888|Arm is closed.
11544645|NCT01042379|Other|Neratinib|Arm is closed.
11544646|NCT01042379|Experimental|PLX3397|Arm is closed.
11544647|NCT01042379|Experimental|Pembrolizumab 4 cycle|Arm is closed.
11544648|NCT01042379|Experimental|Talazoparib plus Irinotecan|Arm is closed.
11544649|NCT01042379|Experimental|Patritumab with or without Trastuzumab|Arm is closed.
11544650|NCT01042379|Experimental|Pembrolizumab 8 cycle|Arm is closed.
11544651|NCT01042379|Experimental|SGN-LIV1A|Novel Investigational Agent
11544652|NCT01042379|Experimental|Durvalumab plus Olaparib|Arm is closed.
11544653|NCT01042379|Experimental|SD-101 + Pembrolizumab|Novel Investigational Agent
11544654|NCT01042379|Experimental|Tucatinib|Novel Investigational Agent
11544655|NCT01042379|Experimental|Cemiplimab|Novel Investigational Agent
11544656|NCT01042379|Experimental|Cemiplimab plus REGN3767|Novel Investigational Agent
11544657|NCT01042366|Experimental|Vaccine co-cultured with melanoma cells|Dendritic Cells co-cultured with melanoma cells injected as a vaccine intra/peri-nodally under ultrasound guidance
11544658|NCT01042366|Experimental|Vaccine pulsed with tumor cell lysates|Dendritic Cells pulsed with tumor cell lysates were injected as a vaccine intra/peri-nodally under ultrasound guidance
11544659|NCT01042366|Experimental|Vaccine fused with tumor cells|Dendritic Cells fused with tumor cells were injected as a vaccine intra/peri-nodally under ultrasound guidance
11544660|NCT01042353|Experimental|E test|
11544661|NCT01042353|Active Comparator|standard culture method|
11544662|NCT01042340|Experimental|Intervention with energy dense formula|Patients were randomised to intervention with the energy dense formula Calogen.
11544663|NCT01042340|No Intervention|Control group|The patients that were randomised to control group were assigned to ordinary treatment.
11544664|NCT01042327|Experimental|dialyzer comparison|"Stable chronic kidney dialysis patients, currently dialyzing on the main Royal Free hospital dialysis unit will be asked to participate in the study. It is aimed to recruit 15 patients currently dialysing using the Fresenius FX100 dialyzer, who have used Fresenius polysulphone membranes for > 3 months.
~During a mid week dialysis session, dialysis adequacy will be assessed by on line clearance, and samples of both blood and dialysate taken to assess, both clearances and bio-compatibility.
~Thereafter patients would be switched to dialyse using the ELISIOTM-H dialyzer, but continue with the same dialysis prescription, and after 3 months, measurements repeated"
11544665|NCT01042314|Experimental|Donepezil and BMS-708163|
11544666|NCT01042301|Experimental|Long-term type 1 diabetic patients|Long-term type 1 diabetic patients
11544667|NCT01042301|Active Comparator|control patients|control patients
11544668|NCT01042301|Experimental|diabetic and transplanted patients|diabetic and transplanted patients
11544669|NCT01042301|Experimental|subjects with high risk for diabetes|subjects with high risk for diabetes
11544670|NCT01042301|Experimental|patients with recent type 1 diabetes|patients with recent type 1 diabetes
11544671|NCT01042301|Experimental|patients with Latent Autoimmune Diabetes|patients with Latent Autoimmune Diabetes
11544672|NCT01042288|Experimental|Carboplatin/Pemetrexed/Panitumumab|Systemic Therapy
11544673|NCT01042275||TOT|transobturator sling, outside-in (TOT)
11544674|NCT01042275||TVT-O|Tension-free transobturator tape, inside-out (TVT-O)
11544675|NCT01042275||IVS|retropubic Intravaginal Sling (IVS)
11544676|NCT01042275||TVT|retropubic tension-free vaginal tape (TVT)
11544677|NCT01042275||REMEEX|Re-adjustable mechanical external sling (REMEEX)
11544678|NCT01042262|Experimental|Oxygen Group|Subjects received 100% oxygen via nasal cannula (flow =2 L/min)
11544679|NCT01042262|Placebo Comparator|Control Group|Subjects were attached to a nasal cannula without any oxygen flow.
11544680|NCT01042249|Experimental|Treatment|Treated with Pelvic Floor Muscle Training in 12 weeks
11544681|NCT01042249|No Intervention|Control|Receives standard rehabilitation after stroke
11544682|NCT01042236|Experimental|Arm 1|
11544683|NCT01042210||Mothers, preeclampsia|Mothers with preeclampsia diagnosed according to the Guidelines by the Czech Society of obstetrics and gynecology as development of hypertension after the 20th week of pregnancy (systolic blood pressure, ≥140 mmHg; and/or diastolic blood pressure, ≥90 mmHg; measured at rest on two consecutive occasions at least 24 h apart) in previously normotensive women, and the onset of proteinuria (>300 mg of urinary protein/L over 24 h).
11544684|NCT01042210||Newborns, physiological pregnancy-delivery|The newborns from the physiological pregnancies with spontaneous, uncomplicated delivery.
11544685|NCT01042210||Newborns, pregnancy with preeclampsia|Newborns from the pregnancies complicated by preeclampsia.
11544686|NCT01042210||Mothers, Physiological pregnancy-labour|The cohort of non-preeclamptic mothers with physiological, uncomplicated conception, pregnancy and delivery.
11544687|NCT01042197|Active Comparator|2|Body surface area: 12 %
11544688|NCT01042197|Active Comparator|1|Body surface area: 6 %
11544689|NCT01042197|Active Comparator|3|Body surface area: 24 %
11544690|NCT01042197|Active Comparator|4|Body surface area: 6 %
11544691|NCT01042197|Active Comparator|5|Body surface area: 12 %
11544692|NCT01042197|Active Comparator|6|Body surface area: 24 %
11544695|NCT01042197|Active Comparator|9|Body surface area: 24 %
11544696|NCT01042184|Experimental|Group A|Group A: Sequential therapy for 14 days D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bid
11544697|NCT01042184|Experimental|Group B: Sequential therapy for 10 days|
11544698|NCT01042184|Active Comparator|Group C: Triple therapy for 14 days|
11544699|NCT01042158|Other|Tadalafil and ambrisentan upfront therapy|This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease (PAH-SSD).
11544700|NCT01042145|Active Comparator|Prednisone|Prednisone, 2mg/kg for 3 days
11544701|NCT01042145|Active Comparator|Dexamethasone|Dexamethasone, 0.6mg/kg for one day, then placebo for 2 days
11544702|NCT01042132|Active Comparator|1) IMN and EF/IMN|"Two parts of the study are randomized;
~1)initial intramedullary reaming and primary external fixation with secondary intramedullary nailing"
11544703|NCT01042132|Active Comparator|2) TR and RIA|Two parts of the study are randomized; 2)traditional reaming (TR)is compared to a new reaming device, RIA, which is a reamer connected to suction and flushing for prevention of increased intramedullary pressure
11544704|NCT01042119||Botox|patients who received intravesical injections of botulinum neurotoxin type A
11544705|NCT01042106|Experimental|DSP-8658|DSP-8658 2.5, 10, 20, 40 mg once daily
11544706|NCT01042106|Placebo Comparator|Placebo|Placebo 2.5, 10, 20, and 40 mg doses once daily
11544707|NCT01042093|Active Comparator|ROP/EPI/TOR/CLO|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
11544708|NCT01042093|Active Comparator|ROP/EPI/TOR|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml)
11544709|NCT01042093|Active Comparator|ROP/EPI/CLO|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
11544710|NCT01042093|Active Comparator|ROP/EPI|Ropivacaine 5mg/ml (49.25ml) Epinephrine 1 mg/ml (0.5 ml)
11544711|NCT01042080|Active Comparator|PSV-ET 25|Pressure support ventilation with expiratory trigger set at 25 %.
11544712|NCT01042080|Active Comparator|PSV-ET 50|Pressure support ventilation with expiratory cycling set at 50 %.
11544713|NCT01042080|Experimental|NAVA|NAVA level is adjusted to achieve similar peak inspiratory pressure levels than during PSV.
11544714|NCT01042067||Warfarin treatment group|Open label study. Patients in need of warfarin treatment (standard indications) are included in the study at the onset of warfarin treatment.
11544715|NCT01042054|Active Comparator|Epidural|Patients will follow a standard optimised recovery protocol, including epidural analgesia for the first 48 hours postoperatively.
11544716|NCT01042054|Experimental|Wound catheter|Patients will follow a standard optimised recovery protocol, but analgesia in the first 48 hours will be delivered through local anaesthetic wound catheters and additional patient-controlled analgesia, instead of epidural analgesia.
11544717|NCT01042041|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily. Beginning 2 weeks later, patients undergo chemoembolization with cisplatin, doxorubicin hydrochloride, and mitomycin C. Chemoembolization repeats once a month for up to 4 procedures in the absence of disease progression or unacceptable toxicity.
11544718|NCT01042028|Experimental|Phase II: Arm A|Regime A-ICE On progression or unacceptable toxicity patients can cross-over from regime A to regime B
11544719|NCT01042028|Active Comparator|Arm B|Arm B: CapOx On progression or unacceptable toxicity patients can cross-over from regime B to regime A.
11544720|NCT01042015|Active Comparator|Concurrent controls|These subjects would undergo standard resuscitative efforts.
11544721|NCT01042015|Experimental|Emergency preservation and resuscitation|These subjects would undergo the complete EPR protocol, including rapid induction of hypothermia, resuscitative surgery, and resuscitation with cardiopulmonary bypass.
11544722|NCT01042002|Experimental|High intensity exercise|
11544723|NCT01042002|No Intervention|Control|
11544724|NCT01041989|No Intervention|Standard health counseling at baseline|
11544725|NCT01041989|Experimental|Lifestyle counseling|Multi-domain lifestyle counseling including nutritional guidance, increased physical activity, cognitive training, increased social activity and intensive monitoring of vascular and metabolic risk factors.
11544726|NCT01041976|Experimental|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
11544727|NCT01041976|Placebo Comparator|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
11544728|NCT01041963|Active Comparator|Enalapril|
11544729|NCT01041963|Active Comparator|Enalapril plus Losartan|
11544730|NCT01041963|Placebo Comparator|Control|Drug: antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Administration of antihypertensive agents will select as follows : CCB→β-blocker→α-blocker-->hydralazine
11544731|NCT01041950|Experimental|Lumbar drainage|
11544732|NCT01041950|No Intervention|Control|
11544733|NCT01041937|Active Comparator|Cemented Tibia|Assessing the clinical outcomes of the different type of fixation
11544734|NCT01041937|Active Comparator|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
11544735|NCT01041911|Active Comparator|Euphorbia 50 mg|This arm subjects will be given 50 mg Euphorbia prostrata
11544736|NCT01041911|Active Comparator|Euphorbia 100 mg|In this arm subjects will be given 100 mg Euphorbia
11544737|NCT01041911|Active Comparator|Euphorbia 200 mg|In this arm subject will be given 200 mg Euphorbia tablets
11544738|NCT01041911|Placebo Comparator|Placebo|In this arm subjects will be given placebo tablets
11544739|NCT01041885|Experimental|INSTRUCT|INSTRUCT scaffold implantation
11544740|NCT01041872|Active Comparator|Propofol Astrazeneca|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
11544741|NCT01041872|Experimental|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
11544742|NCT01041872|Experimental|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
11544743|NCT01041872|Experimental|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
11544744|NCT01041872|Experimental|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
11544745|NCT01041872|Experimental|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
11544746|NCT01041859|Experimental|Tapentadol Extended Release (ER)|
11544747|NCT01041859|Placebo Comparator|Placebo|
11544748|NCT01041846||Decitabine|
11544749|NCT01041833|Experimental|atRA group|atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
11544750|NCT01041833|Placebo Comparator|Placebo Group|Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
11544751|NCT01041820|Experimental|Exercise group|Children will participate in a 10-week moderate to vigorous exercise program
11544752|NCT01041820|No Intervention|non-exercising|Participants will receive no intervention
11544753|NCT01041807||All participants|Participants with hypertension treated with amlodipine/losartan(Cozaar XQ)
11544754|NCT01041794||1|
11544755|NCT01041781|Experimental|Arm I|Patients receive gemcitabine hydrochloride* IV on days 1 and 8 OR pemetrexed disodium* IV on day 1. Patients also receive carboplatin IV on day 1 and oral celecoxib twice daily on days 1-21.
11544756|NCT01041781|Active Comparator|Arm II|Patients receive gemcitabine hydrochloride* OR pemetrexed disodium* and carboplatin as in arm I. Patients also receive oral placebo twice daily on days 1-21.
11544757|NCT01041768|Active Comparator|antidiabetic medical therapy|
11544758|NCT01041768|Experimental|Bariatric Surgery|
11544759|NCT01041755|Experimental|Intravenous infusion of L- Ornithine L- Aspartate|a) 20 g L-ornithine-L-aspartate
11544760|NCT01041755|Active Comparator|Lactose enemas|b) 20% Lactose enemas
11544761|NCT01041742|Experimental|OPCAB|
11544762|NCT01041729|Experimental|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
11544763|NCT01041729|Active Comparator|Control|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.
~Standard Medical Treatment"
11544764|NCT01041690|Experimental|Bevacizumab|
11544765|NCT01041677|Experimental|001|R256918 10 mg capsule twice daily
11544766|NCT01041677|Experimental|002|R256918 15 mg capsule twice daily
11544767|NCT01041677|Placebo Comparator|003|placebo placebo capsule twice daily
11544768|NCT01041638|Experimental|Treatment (Ch14.18, GM-CSF, IL-2, isotretinoin)|Patients receive sargramostim SC or IV over 2 hours on days 0-13 of courses 1, 3, and 5; monoclonal antibody Ch14.18 IV over 10 hours on days 3-6 of courses 1, 3, and 5 and on days 7-10 of courses 2 and 4; and isotretinoin PO BID on days 11-24 of course 1, on days 14-27 of courses 2, 4, and 6, and on days 10-23 of courses 3 and 5. Patients also receive aldesleukin IV continuously on days 0-3 and on days 7-10 of courses 2 and 4. Treatment repeats every 24-32 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11544769|NCT01041625|Experimental|Apremilast|Apremilast 20 mg PO administered BID over 12 weeks
11544770|NCT01041612|Active Comparator|Group A: C-SEMS, inserted above SO|-In group A, SO should be preserved without sphincterotomy, but small infundibulotomy with needle knife can be accepted for cannulation.
11544771|NCT01041612|Active Comparator|Group B: C-SEMS, inserted across SO|-In group B, small sphincterotomy (50% incision) will be done after biliary cannulation.
11544772|NCT01041599||Diabetic patients|Hypertensive and normotensive patients with type 2 diabetes mellitus
11544773|NCT01041599||Hypertensive patients|Patients with essential hypertension
11544774|NCT01041599||Healthy subjects|Healthy subjects
11544775|NCT01041586|Experimental|BTVA|
11544776|NCT01041573|Experimental|IC51 0.5 mL|Japanese Encephalitis Vaccine 6mcg im. at day 0 and day 28
11544777|NCT01041573|Experimental|IC51 0.25 mL|Japanese Encephalitis Vaccine 3mcg im. at day 0 and day 28
11544778|NCT01041573|Active Comparator|Havrix 720|Havrix®720 0.5 ml im. at day 0 and month 7
11544779|NCT01041573|Active Comparator|Prevnar|Prevnar 0.5 ml im. at day 0 and day 56 and month 7 or 0.5 ml im. at day 0, day 28 and day56 and month 7-13
11544780|NCT01041560||Stoke|Hemiplegia with unilateral changes in tone and muscle strength
11544781|NCT01041547||Healthy adults|healthy adults with BMI below 32, between ages 19-60 yrs, both males and females
11544782|NCT01041534||Adjustable Gastric Band (AGB) surgery|Patients who have undergone adjustable gastric band (AGB) surgery at the UWMC or other sites that have agreed to cooperate with our site (letter of cooperation and HIPAA waiver approved by our IRB) between April 1, 2007 and July 1, 2008.
11544783|NCT01041521|Experimental|Lovaza (omega three fatty acid)|"Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.
~Other Names:
~Lovaza was previously known as Omacor (omega-3-acid ethyl esters) capsules"
11544784|NCT01041521|No Intervention|sugar pill|"Dietary Supplement: sugar pill
~2 capsules given twice daily Arms: sugar pill"
11544785|NCT01041508|Active Comparator|A|Stratum A are those patients with related stem cell donors.
11544786|NCT01041508|Active Comparator|B|Stratum B are those patients with unrelated stem cell donors.
11544787|NCT01041495|Experimental|cyclobenzaprine ER|
11544788|NCT01041495|Placebo Comparator|placebo|
11544789|NCT01041482|Experimental|sorafenib|To study the efficacy of Sorafenib as an adjuvant therapy for reducing recurrence rate in locally advanced renal-cell carcinoma (RCC) after radical nephrectomy.
11544790|NCT01041469||with abnormalities|Down syndrome patients presenting with at least one sign of auto immune abnormality
11544791|NCT01041469||without abnormality|Down syndrome patients without any sign of recognized auto immune condition
11544792|NCT01041456||complicated and/or failed BPD|
11544793|NCT01041443|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive FdCyd IV over 3 hours and THU IV over 3 hours on days 1-10. Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.
11544794|NCT01041430|Active Comparator|Day Surgery Group|discharge planned on day of surgery, inguinal hernia repair
11544795|NCT01041430|Active Comparator|Inpatient Group|overnight admission at the hospital, inguinal hernia repair
11544796|NCT01041417|Experimental|GM-CSF|Subjects will receive GM-CSF 500μg (Sargramostim (Leukine), Sanofi Aventis) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks
11544797|NCT01041417|Placebo Comparator|Placebo|Subjects will receive a saline injection (placebo) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks
11544798|NCT01041404|Experimental|Trastuzumab, Fluoropyrimidine, Cisplatin|Participants received an initial loading dose of 8 milligrams per kilogram (mg/kg) trastuzumab i.v. on Day 1 of cycle, followed by 6 mg/kg i.v. every 3 weeks until disease progression; 800 mg/m2 fluorouracil i.v. on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.
11544799|NCT01041404|Active Comparator|Fluoropyrimidine, Cisplatin|Participants received 800 milligrams per square meter (mg/m2) fluorouracil intravenous (i.v.) on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine orally (p.o.) twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.
11544800|NCT01041391||Surgical treatment for Lumbar disc herniation|Patients who had or will have surgery for Lumbar disc herniation
11544801|NCT01041391||Non-surgical treatment for Lumbar disc herniation|Patients that have chosen conservative treatment for lumbar disc herniation
11544802|NCT01041365||Healthy adolescents|Healthy adolescent African American and Caucasian females, ages 14-18
11544803|NCT01041352|Active Comparator|Endotracheal group|airway management: endotracheal tube
11544804|NCT01041352|Active Comparator|laryngeal mask group|airway management: laryngeal mask
11544805|NCT01041339||acute chest pain ST elevation|patients admitted with acute chest pain sharing ST elevation in ER-ECG and elevated troponin
11544806|NCT01041339||controls|asymptomatic patients
11544807|NCT01041326|Experimental|Leve 1 Radiation|Subjects in Group 1 will receive 39.6 Gy (at 1.8 Gy/fx) to the whole pelvis. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
11544808|NCT01041326|Experimental|Level 2 Radiation|Subjects in Group 2 will receive 45 Gy (at 1.8 Gy/fx) to the whole pelvis. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
11544809|NCT01041326|Experimental|Level 3 Radiation|Subjects in Group 3 will receive 45 Gy to the whole pelvis, followed by a boost to the prostate and periprostatic tissue, for total doses of 50.4 Gy. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
11544810|NCT01041326|Experimental|Level 4 Radiation|Subjects in Group 4 will receive 45 Gy to the whole pelvis, followed by a boost to the prostate and periprostatic tissue, for total doses of 54 Gy. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
11544811|NCT01041313|Active Comparator|Opiate Naive|Subjects who have not taken opiate medication in previous 6 weeks before surgery
11544812|NCT01041313|Active Comparator|Opiate tolerant|Subjects who have taken opiate medications for the 6 weeks before surgery
11544813|NCT01041287|Active Comparator|Nebivolol/ Metoprolol|"Subjects were randomized to nebivolol for 3 months. They crossed over to take 3 months of metoprolol succinate. The initial 5 mg daily dose of nebivolol was titrated to 10 mg daily after 2 weeks if their BP remained >125/80, and subsequently titrated to 20 mg daily after another 2 weeks if the BP remained >125/80. Similarly, the initial 50 mg daily dose of metoprolol succinate was titrated to 100 mg daily after 2 weeks if BP remained >125/80, and further increased to 200 mg after 2 weeks if BP remained >125/80."
11544814|NCT01041287|Active Comparator|Metoprolol/Nebivolol|"Subjects were randomized to metoprolol succinate for 3 months. They crossed over to take 3 months of nebivolol. The initial 5 mg daily dose of nebivolol was titrated to 10 mg daily after 2 weeks if their BP remained >125/80, and subsequently titrated to 20 mg daily after another 2 weeks if the BP remained >125/80. Similarly, the initial 50 mg daily dose of metoprolol succinate was titrated to 100 mg daily after 2 weeks if BP remained >125/80, and further increased to 200 mg after 2 weeks if BP remained >125/80."
11544815|NCT01041274|Experimental|Citalopram|Participants will receive a daily dose of citalopram, with flexible dosing as determined by clinician, for 12 months.
11544816|NCT01041274|Placebo Comparator|Placebo|Participants will receive a daily dose of placebo for 12 months.
11544817|NCT01041261|No Intervention|Control arm|Subjects will be issued control study product (Carnation Instant Breakfast, no sugar added)
11544818|NCT01041261|Experimental|Treatment arm|Medical food
11544819|NCT01041248|Experimental|Tocilizumab|
11544820|NCT01041235|Experimental|ATI-1123|
11544821|NCT01041222|Experimental|Arm 1|0.15 mg ISIS 333611 continuous intrathecal infusion over 12 hours
11544822|NCT01041222|Experimental|Arm 2|0.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours
11544823|NCT01041222|Experimental|Arm 3|1.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours
11544824|NCT01041222|Experimental|Arm 4|3.0 mg ISIS 333611 continuous intrathecal infusion over 12 hours
11544825|NCT01041222|Placebo Comparator|Placebo (phosphate buffered saline)|
11544826|NCT01041209|Experimental|BPS|BPS guidance
11544827|NCT01041209|Active Comparator|Guideline|Enforced guidelines
11544828|NCT01041196||perforated ulcer after gastric bypass|
11544829|NCT01041183|Active Comparator|group I|0.3 mg IV ramosetron
11544830|NCT01041183|Active Comparator|group II|0.1 mg oral ramosetron
11544831|NCT01041183|Active Comparator|group III|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron
11544832|NCT01041157|Experimental|1|resistance training
11544833|NCT01041144|Experimental|Lifestyle counseling|
11544834|NCT01041131||Failed and/or Complicated VBG|
11544835|NCT01041105||Gastric bypass after previous Nissen|
11544836|NCT01041092|Placebo Comparator|sugar pill|
11544837|NCT01041092|Active Comparator|raloxifene hydrochloride|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
11544838|NCT01041079||Chronic marginal ulcer after RYGB|Patients with intractable or chronic marginal ulcer disease after gastric bypass complaining of abdominal pain, GI bleeding, obstruction, perforation and penetration. Sometimes with other associated diagnosis such as narcotic and tobacco dependence, protein-calorie malnutrition, excessive weight loss, poor pouch emptying syndrome, weight regain, inadequate initial weight loss, severe dumping syndrome among others.
11544839|NCT01041066|Active Comparator|group L|0.4 mg/kg labetalol
11544840|NCT01041066|Active Comparator|group N|20 ㎍/kg nicardipine
11544841|NCT01041027|Experimental|Treatment (paclitaxel, carboplatin, radiation therapy)|"CHEMOTHERAPY (weeks 1-9, 13-21): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 3 courses during weeks 13-21.
~RADIATION THERAPY (weeks 8-13 or 8-15): Patients with stage I disease undergo HDR brachytherapy once weekly for a total of 5 fractions during weeks 8-13. All other patients undergo EBRT QD 5 days a week for a total of 25 fractions during weeks 8-12 and HDR brachytherapy once weekly for a total of 3 fractions during weeks 13-15."
11544842|NCT01041014|Experimental|Professional medical interpreter|Limited English proficient Spanish-speaking patients seen in the treatment arm were provided with the services of a professionally-trained medical interpreter to facilitate communication between the patient and emergency department staff
11544843|NCT01041014|No Intervention|Control, Usual Language Services|Patients randomized to the control arm receive the services of the emergency departments' usual language services (i.e., a telephone language line or ad hoc interpreters).
11544844|NCT01041001|Experimental|Cartistem|A single dose of 500㎕/㎠ of cartilage defect
11544845|NCT01041001|Active Comparator|Microfracture treatment|
11544846|NCT01040988||Pacemaker|Patients meeting entry criteria with a pacemaker in place.
11544847|NCT01040988||ICD|Patients meeting entry criteria with an ICD in place.
11544848|NCT01040975|Experimental|Motivational Interviewing intervention|Web-based intervention targeting MD communication and Summary Report
11544849|NCT01040975|No Intervention|Control|MD receives Summary Report only
11544850|NCT01040962||Falls Risk Assessment, Diabetic Peripheral Neuropathy Patients|
11544851|NCT01040949|Active Comparator|a self help smoking cessation guide|Guia, a culturally relevant self-help smoking cessation guide in Spanish
11544852|NCT01040949|Experimental|couple-based counseling for smoking cessation plus Guia|couple-based counseling for smoking cessation plus Guis, culturally relevant self-help smoking cessation guide for Latinos
11544853|NCT01040936|Active Comparator|conventional group|patients will be treated by atorvastation 20mg/d after randomization, and continued for one year.
11544854|NCT01040936|Experimental|intensive group|patient will be loaded with 80mg atorvastatin, continued by atorvastatin 40mg/d for 30d, then receive atorvastatin 20mg/d for the following 11 months.
11544855|NCT01040923||Cardiac CT|All patients in the study will be those presenting themselves for cardiac CT angiography who meet the proper inclusion / exclusion criteria
11544856|NCT01040910|Active Comparator|cannabis smoking for IBD|patients with active disease receiving active cannabis for smoking
11544857|NCT01040910|Placebo Comparator|patients smoking non active cannabis|patients with active disease receiving cannabis from which active ingredients have been chemically removed
11544858|NCT01040897|Active Comparator|Active Control Arm|At Active Comparative Sites, Pediatric Residents will be trained to address injury prevention issues using The Injury Prevention Program (TIPP) approach
11544859|NCT01040897|Experimental|Health Communication and Obesity Prevention|Pediatric Residents will be training in effective health communication skills and given a toolkit of literacy/numeracy sensitive educational materials to use with families with children age 2 months to18 months during each well child visit
11544860|NCT01040884|Experimental|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
11544861|NCT01040871|Experimental|VR-CAP|VR-CAP arm received rituximab 375 mg/m2 IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, VELCADE 1.3 mg/m2 IV on Days 1, 4, 8, and 11, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.
11544862|NCT01040871|Active Comparator|R-CHOP|R-CHOP received rituximab 375 mg/m2IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, vincristine 1.4 mg/m2 (maximum total of 2 mg) IV on Day 1, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.Prednisone
11544863|NCT01040858|Experimental|Cognitive Strategies Training|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study). Cognitive Strategies training consisted of interactive didactic presentations, in-class discussions, and activities that introduced participants to a variety of cognitive strategies and external aids.
11544864|NCT01040858|Placebo Comparator|Placebo comparison group|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
11544865|NCT01040845|Experimental|Oral Contraceptive with Colchicine then Placebo|
11544866|NCT01040845|Placebo Comparator|Oral Contraceptive with Placebo then Colchicine|
11544867|NCT01040832|Experimental|Cetuximab plus EMD 1201081|
11544868|NCT01040832|Active Comparator|Cetuximab monotherapy|
11544869|NCT01040819|Experimental|Pioglitazone 15 mg|Patients will receive PIO 15 mg/d for two months. Serum and urine samples for 6-keto-PGF1a and 15-epi-lipoxin A4 will be taken at baseline, one month and 2 months.
11544870|NCT01040819|Experimental|Pioglitazone 30 mg/d|Patients will receive PIO 15 mg/d for one month. Then, dose will be increased to 30 mg/d for an additional month. Serum and urine samples for 6-keto-PGF1a and 15-epi-lipoxin A4 will be taken at baseline, one month and 2 months.
11544871|NCT01040806|Experimental|Health coaching|Patients with poorly controlled diabetes will receive counseling from a peer health coach -- a patient with diabetes trained in health coaching
11544872|NCT01040806|Active Comparator|Usual care|Patients will receive usual care
11544873|NCT01040793|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
11544874|NCT01040793|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
11544875|NCT01040793|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled orally from the Respimat inhaler
11544876|NCT01040780|Experimental|Icotinib|125 mg three times daily (375 mg per day) by mouth
11544877|NCT01040780|Active Comparator|Gefitinib|250 mg every 24 hours by mouth
11544878|NCT01040767|Active Comparator|Class|
11544879|NCT01040767|Active Comparator|Web|
11544880|NCT01040767|No Intervention|Control|
11544881|NCT01040754|Active Comparator|Acupuncture|
11544882|NCT01040754|No Intervention|Waitlist Control|
11544883|NCT01040741||Group 1: 6-23 months|
11544884|NCT01040741||Group 2: 2-8 years|
11544885|NCT01040741||Group 3: 9-17 years|
11544886|NCT01040741||Group 4: 18-44 years|
11544887|NCT01040741||Group 5: 45-60 years|
11544888|NCT01040741||Group: >60 years|
11544889|NCT01040728|Experimental|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
11544890|NCT01040728|Experimental|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
11544891|NCT01040728|Active Comparator|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
11544892|NCT01040728|Placebo Comparator|Placebo|Olodaterol placebo and/or Tiotropium placebo inhaled once daily
11544893|NCT01040715|Experimental|TNFa Kinoid dose 1|
11544894|NCT01040715|Experimental|TNFa Kinoid dose 2|
11544895|NCT01040715|Experimental|TNFa Kinoid dose 3|
11544896|NCT01040702|Experimental|ADHD -MPH|adults with ADHD diagnosis who receive a single dose of Methylphenidate
11544897|NCT01040702|Placebo Comparator|ADHD-placebo|adults with ADHD diagnosis who received placebo
11544898|NCT01040702|Experimental|non-ADHD-MPH|healthy adults who received a single dose of Methylphenidate
11544899|NCT01040702|Placebo Comparator|non-ADHD-placebo|healthy adults who received placebo
11544900|NCT01040689|Placebo Comparator|Placebo|olodaterol placebo and/or Tiotropium placebo inhaled once daily
11544901|NCT01040689|Experimental|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
11544902|NCT01040689|Experimental|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
11544903|NCT01040689|Active Comparator|Tiotropium 18 mcg|18mcg inhaled once daily from Handihaler
11544904|NCT01040676|No Intervention|Control Group|"Patients in this (the control group) will be eligible to receive the intervention (see Intervention Group) after 12 weeks (essentially when the trial is over)."
11544905|NCT01040676|Experimental|Intervention Group|Patients in the intervention group will receive automated telephone calls at regular intervals twice a week. The system will be programmed to call them at these intervals until contact. The ATNS system will solicit information from them in a culture specific manner, inquiring as to what foods they are eating each meal, each day, and each month. The ATNS system will then make proactive suggestions regarding low glycemic index foods, giving encouragement and feedback as appropriate.
11544906|NCT01040663|Other|Dash Diet|Subjects receive DASH diet for 4 weeks
11544907|NCT01040663|Other|Low GI Diet|Subjects will receive Low GI diet for 4 weeks
11544908|NCT01040663|Other|Western Style Diet|Subjects will receive western style diet for 4 weeks
11544909|NCT01040650||Normal Controls|Normal Controls
11544910|NCT01040650||Statin associated myopathy|subjects with statin associated myopathy
11544911|NCT01040637|Experimental|TD-1211 dose level 1|Ascending doses
11544912|NCT01040637|Experimental|TD-1211 dose level 2|Ascending doses
11544913|NCT01040637|Experimental|TD-1211 dose level 3|Ascending doses
11544914|NCT01040637|Experimental|TD-1211 dose level 4|Ascending doses
11544915|NCT01040637|Experimental|TD-1211 OIC dose level 1|Ascending doses
11544916|NCT01040637|Experimental|TD-1211 OIC dose level 2|Ascending doses
11544917|NCT01040637|Experimental|TD-1211 OIC dose level 3|Ascending doses
11544918|NCT01040637|Experimental|TD-1211 OIC dose level 4|Ascending doses
11544919|NCT01040637|Experimental|TD-1211 OIC dose level 5|Ascending doses
11544920|NCT01040637|Placebo Comparator|Placebo|Ascending doses
11544921|NCT01040624|Experimental|High-risk arm A (HR-A)|< 15% risk of + lymph nodes (LN)
11544922|NCT01040624|Experimental|HR-B|> 15% risk of + LN
11544923|NCT01040611|Experimental|Music therapy|This study examined the effectiveness of music therapy on anxiety, depression and physiological responses for patients with tuberculosis.
11544924|NCT01040611|No Intervention|Placebo|No music therapy apply to this arm
11544925|NCT01040585||Central America and the Caribbean|Panama, Costa Rica, Honduras, El Salvador and Nicaragua
11544926|NCT01040572||Obesity recidivism after gastric bypass|
11544927|NCT01040559|Experimental|Idarubicin|Dose escalation: level0 = idarubicin 5mg, level1 = idarubicin 10mg, level2 = idarubicin 15mg, level3 = idarubicin 20mg, level4 = idarubicin 25mg
11544928|NCT01040546|Experimental|Individualized education|Individualized consultation of health problem, dietary intake and exercise
11545456|NCT01036685||379-control|healthy control who can do MRI and tDCS
11544929|NCT01040546|Experimental|Grouped education|Grouped consultation of health problem, dietary intake and exercise
11544930|NCT01040533||Failed / complicated jejunoileal bypass|
11544931|NCT01040507||primary laparoscopic gastric bypass|
11544932|NCT01040494|Experimental|Aliskiren, add-on|HF patients will be randomized to receive add-on aliskiren 150 mg for 6 months
11544933|NCT01040494|Placebo Comparator|placebo, add-on|patients will be randomized to receive add-on placebo for 6 months
11544934|NCT01040481||Malabsorptive distal gastric bypass|
11544935|NCT01040468|Active Comparator|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss
11544936|NCT01040468|Active Comparator|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss
11544937|NCT01040468|Active Comparator|Intensive Lifestyle Modification|Lifestyle intervention for weight loss
11544938|NCT01040455|Experimental|lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
11544939|NCT01040455|Placebo Comparator|placebo|placebo once daily for eight weeks
11544940|NCT01040442|Experimental|vibration stimuli|
11544941|NCT01040429|Active Comparator|Clonidine capsula|
11544942|NCT01040429|Placebo Comparator|Lactose capsula|
11544943|NCT01040416||Bleeding marginal ulcer after RYGB|
11544944|NCT01040403|Experimental|olodaterol (BI 1744) low and placebo|low dose inhaled olodaterol orally once daily from the Respimat inhaler
11544945|NCT01040403|Experimental|olodaterol (BI 1744) low and low tio|low dose inhaled olodaterol and low dose inhaled tiotropium, both from the Respimat inhaler and once daily
11544946|NCT01040403|Experimental|olodaterol (BI 1744) low and medium tio|low dose inhaled olodaterol and medium dose inhaled tiotropium, both from the Respimat inhaler and once daily
11544947|NCT01040403|Experimental|olodaterol (BI 1744) low and high tio|low dose inhaled olodaterol and high dose inhaled tiotropium, both from the Respimat inhaler and once daily
11544948|NCT01040403|Experimental|olodaterol (BI 1744) high and placebo|high dose inhaled olodaterol orally once daily from the Respimat inhaler
11544949|NCT01040403|Experimental|Olodaterol (BI 1744) high and low tio|high dose inhaled olodaterol and low dose inhaled tiotropium, both from the Respimat inhaler and once daily
11544950|NCT01040403|Experimental|Olodaterol (BI 1744) high and medium tio|high dose inhaled olodaterol and medium dose inhaled tiotropium, both from the Respimat inhaler and once daily
11544951|NCT01040403|Experimental|Olodaterol (BI 1744) high and high tio|high dose inhaled olodaterol and high dose inhaled tiotropium, both from the Respimat inhaler and once daily
11544952|NCT01040377||Inadequate initial weight loss after gastric bypass|
11544953|NCT01040364||Interna hernia after primary gastric bypass|
11544954|NCT01040351|Experimental|1: Hydrosalpinx needle aspiration|After the retrieval of oocytes an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely .
11544955|NCT01040351|No Intervention|2. no aspiration|IVF-ET is done without prior aspiration of hydrosalpingeal fluid
11544956|NCT01040338||OPRM1 A118G AA genotype|Individuals with the AA genotype at the OPRM1 A118G polymorphism.
11544957|NCT01040338||OPRM1 A118G AG or GG genotype|Individuals with the */G allele at the OPRM1 A118G polymorphism
11544958|NCT01040325|Experimental|Active|358 subjects receive a two vaccination regimen with an LT patch
11544959|NCT01040325|Placebo Comparator|Placebo|358 subjects receive a two vaccination regimen with placebo patch
11544960|NCT01040312||UGT1A1 genotyped patients|UGT1A1 genotyped patients receive CPT-11 with platinum analogues
11544961|NCT01040299|Experimental|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
11544962|NCT01040299|Sham Comparator|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
11544963|NCT01040299|Active Comparator|control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
11544964|NCT01040286|Experimental|Flurbiprofen Chip|
11544965|NCT01040286|Active Comparator|Chlorhexidine chip|
11544966|NCT01040273|Experimental|Experiment|Anesthetics intraarticular injection
11544967|NCT01040273|Placebo Comparator|Placebo|saline intraarticular injection
11544968|NCT01040260|Experimental|Contingency management|Use of tangible rewards for verified abstinence
11544969|NCT01040260|Active Comparator|Counseling plus nicotine patches|Counseling plus nicotine patches
11544970|NCT01040247|Experimental|Day 0 Embryo Transfer|Embryo transfer will be performed on the same day as oocyte aspiration and fertilization
11544971|NCT01040247|Active Comparator|Day 2,3 Embryo Transfer|Embryo Transfer will be performed 2 or 3 days after oocyte aspiration and fertilization
11544972|NCT01040234||Active pain treatment|Bilateral dual TAP block
11544973|NCT01040221|Experimental|Trichuris Suis Ova (TSO)|the eggs of intestinal helminthes (trichuris suis ova) administered as 2500 ova doses every two weeks.
11544974|NCT01040221|Placebo Comparator|Placebo|placebo dosage received every two weeks.
11544975|NCT01040208|Experimental|flibanserin 50 mg to 100 mg qhs|Patient to receive one tablet of flibanserin 50 mg and one tablet of flibanserin placebo qhs for 14 days then will receive 2 flibanserin tablets of 50 mg qhs
11544976|NCT01040208|Experimental|flibanserin 100 mg qhs|Patient to receive 2 flibanserin tablets of 50 mg qhs
11544977|NCT01040208|Experimental|placebo 2 tablets qhs|Patient to receive 2 placebo tablets of 50 mg qhs
11545022|NCT01039883|Experimental|1|Subjects randomized to study product sequence 1 will receive the single albaconazole 400-mg tablet during the first dosing period and the four 100-mg albaconazole capsules during the second dosing period.
11545023|NCT01039883|Experimental|2|Subjects randomized to study product sequence 2 will receive the four 100-mg albaconazole capsules during the first dosing period and the single albaconazole 400-mg tablet during the second dosing period.
11545024|NCT01039870|Experimental|PVB|Paravertebral block initiated at the later part of thoracotomy is used for postoperative pain control
11544978|NCT01040195|Active Comparator|Combination DMARD|All patients included in the study, will be started on Sulfasalazine 1 gm once daily and in the absence of side effects increased to 2gm daily. All patients will also receive folic acid 5 mg thrice weekly. At the end of four weeks the patients will be reassessed with baseline hemogram, SGPT, SGOT and serum Creatinine. In the absence of any contraindication, patients will be randomized into two groups Group 1 to receive Combination Disease Modifying therapy with Sulfasalazine, Methotrexate and hydroxychloroquine (HCQ). Patient will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day.
11544979|NCT01040195|Placebo Comparator|Placebo|All patients included in the study, will be started on Sulfasalazine 1 gm once daily and in the absence of side effects increased to 2gm daily All patients will also receive folic acid 5 mg twice weekly. At the end of four weeks the patients will be reassessed with baseline hemogram, SGPT, SGOT and serum Creatinine. Group 2 patients will receive Sulfasalazine and placebo for methotrexate and hydroxychloroquine.
11544980|NCT01040182||ischemic stroke patients|
11544981|NCT01040182||healthy subjects without cerebrovascular disease|
11544982|NCT01040169|Placebo Comparator|Nupro C Prophylaxis paste|Fluoride Free
11544983|NCT01040169|Experimental|ProClude Prophylaxis paste|Arginine
11544984|NCT01040156||LAmb|
11544985|NCT01040156||Cas|
11544986|NCT01040130|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
11544987|NCT01040130|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
11544988|NCT01040130|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler
11544989|NCT01040117|Experimental|Sensory-motor Integration Training|
11544990|NCT01040117|Active Comparator|Conventional neurorehabilitation|
11544991|NCT01040104||Regular wound healing, young|Regular skin repair, controlled wound healing conditions in young individuals
11544992|NCT01040104||Regular wound healing, aged|Regular skin repair, controlled wound healing conditions in aged individuals
11544993|NCT01040104||Hypertrophic scarring, young|Skin repair with and without hypertrophic scarring in young individuals
11544994|NCT01040104||Hypertrophic scarring, aged|Skin repair with and without hypertrophic scarring in aged individuals
11544995|NCT01040104||Non-diabetic, young|Skin repair in non-diabetic young individuals
11544996|NCT01040104||Non-diabetic, aged|Skin repair in non-diabetic aged individuals
11544997|NCT01040104||Diabetic, young|Skin repair in young diabetic individuals
11544998|NCT01040104||Diabetic, aged|Skin repair in aged diabetic individuals
11544999|NCT01040091|Active Comparator|HIV-Infected Participants|HIV-infected participants will receive FTC, TDF, and EFV for 60 days by prescription from their physicians. Participants will receive Truvada (FTC/TDF) and EFV for the first 30 days. After Day 30, participants may switch to the TDF/FTC/EFV co-formulation through Day 60 as directed by their physician.
11545000|NCT01040091|Active Comparator|HIV-Uninfected Participants|HIV-uninfected participants will receive Truvada (FTC/TDF) for 30 days.
11545001|NCT01040078|Experimental|7.5ug H1N1 vaccine|360 subjects to receive two doses 7.5ug H1N1 influenza vaccine on Day 0 and Day 21.
11545002|NCT01040078|Experimental|15ug H1N1 vaccine|360 subjects to receive two doses 15ug H1N1 influenza vaccine on Day 0 and Day 21.
11545003|NCT01040078|Placebo Comparator|seasonal influenza vaccine|180 subjects to receive two doses seasonal influenza vaccine on Day 0 and Day 21.
11545004|NCT01040052|Experimental|Study Group|
11545005|NCT01040039||HCV+HIV+|
11545006|NCT01040039||HCV+HIV-|
11545007|NCT01040026|Experimental|NK cell infusions|10 NK cell infusions day 3-30; Treatment with in vitro expanded haploidentical NK cells
11545008|NCT01040013|Experimental|Laparoscopy|Laparoscopic Left-Sided Colectomy
11545009|NCT01040013|Active Comparator|laparotomy|Laparotomic Left-Sided Colectomy
11545010|NCT01040000|Experimental|NPC-1C/NEO-102|
11545011|NCT01039974|Experimental|Cohorts 1-2|Cohorts 1 and 2 will complete both periods Period 1 GSK962040 single dose Period 2 Ketoconazole repeat dose (10 days), GSK962040 single dose
11545012|NCT01039961|Experimental|1 mg IV|Unit Dose Strength: 0.4 mg/mL
11545013|NCT01039961|Experimental|?mg IV|dose to be determined based on PK of first IV dose
11545014|NCT01039961|Experimental|15 mg (oral)|two 7.5 mg tablets
11545015|NCT01039948|Experimental|Phase 2: AV-299 + gefitinib|Phase 2: AV-299 (formerly SCH 900105) administered IV at RP2D (as determined by Phase 1b portion) in combination with gefitinib 250 mg/day orally.
11545016|NCT01039948|Active Comparator|Phase 2: Gefitinib|Phase 2: Gefitinib 250 mg/day, orally.
11545017|NCT01039922||1|Patients with a histologically confirmed diagnosis of a neuroendocrine tumor irrespective of primary tumor location
11545018|NCT01039909|Placebo Comparator|Placebo|"The Placebo treatment group will be administered 8 placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days.
~During the clinic visits, the subjects will receive placebo approximately 15 minutes following the start of consumption of a standardized meal. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following the start of consumption of a standardized meal. Test material should be administered with approximately 400 mL of water at approximately the same time every dosing day. Subjects must wait at least 2 hours before consuming additional calories."
11545019|NCT01039909|Active Comparator|2.0g SRT2104|"The 2.0g SRT2104 treatment group will be administered 8 SRT2104 0.25g capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days.
~During the clinic visits, the subjects will receive SRT2104 approximately 15 minutes following the start of consumption of a standardized meal. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following the start of consumption of a standardized meal. Test material should be administered with approximately 400 mL of water at approximately the same time every dosing day. Subjects must wait at least 2 hours before consuming additional calories."
11545020|NCT01039896|Experimental|Group1|SLM0807
11545021|NCT01039896|Experimental|Group2|SLM0807 and HKB0701
11545025|NCT01039870|Active Comparator|TEA|Thoracic epidural block initiated before the surgical incision is used for postoperative pain control.
11545026|NCT01039857|Other|Structured solution focused therapy|Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy
11545027|NCT01039857|Experimental|Integrative clarification therapy|Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
11545028|NCT01039844|Experimental|Weekly LOC-paclitaxel Injection|LOC-paclitaxel IV by a 1 hour infusion on Day 1, 8, 15, 22 and 29; repeated every 42 days (6 weeks) per cycle.
11545029|NCT01039831||Patients with Parkinson's Disease|Consecutive patient sampling
11545030|NCT01039818|Active Comparator|Radiodine-200µCi|A subgroup of patients with Graves' Disease and goiter ≥48ml treated with 200µCi of ¹³¹I/ml thyroid tissue, corrected by 24h-RAIU, from a randomized controlled trial run at our institution between February 1997 and March 2000, serves as a historical control.
11545031|NCT01039818|Experimental|Radiodine-250µCi|Patients with Graves' Disease and goiter ≥48ml, prospectively assigned to receive 250 µCi of ¹³¹I/ml thyroid tissue, corrected by 24h-RAIU.
11545032|NCT01039805|Experimental|Cohort 1|Subjects randomized to either GSK962040 (50 mg) or placebo
11545033|NCT01039805|Experimental|Cohort 2|Subjects randomized to either GSK962040 (75 mg) or placebo
11545034|NCT01039792|Placebo Comparator|Placebo|Placebo
11545035|NCT01039792|Experimental|Active|Active Methyl B12
11545036|NCT01039779|Active Comparator|Lower-extremity exercise training|This training will be tailored by physical therapists for each participant. A series of exercises will be applied to increase the stability of the trunk muscles and to strengthen the leg muscles.
11545037|NCT01039779|Active Comparator|Tai chi exercise|Yang-style tai chi with 18 movements will be taught every week over the 6-month intervention period at a subject's residence by tai chi instructors
11545038|NCT01039766|Experimental|oxytocin|
11545039|NCT01039766|Placebo Comparator|Placebo|
11545040|NCT01039740|Experimental|Responders|Reponders is a patients group who showed 50% or greater decrease in the HAM-D score at 6 weeks after treating with mirtazapine
11545041|NCT01039740|Experimental|Non-responders|Non-responders is a patients group who did not show 50% or greater decrease in the HAM-D score at 6 weeks after treating with mirtazapine
11545042|NCT01039727|No Intervention|care as usual|care as usual
11545043|NCT01039727|Experimental|autosuggestive support|care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')
11545044|NCT01039727|Experimental|autosuggestive support ++|care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
11545045|NCT01039714||Total Thyroidectomy|
11545046|NCT01039701|Experimental|1|AZD1446 60mg once daily + donepezil 10mg
11545047|NCT01039701|Experimental|2|AZD1446 60mg three times daily + donepezil 10mg
11545048|NCT01039701|Experimental|3|AZD1446 30mg three times daily + donepezil 10mg
11545049|NCT01039701|Placebo Comparator|4|placebo + donepezil 10mg
11545050|NCT01039688|Experimental|5 mg BID CP-690,550|
11545051|NCT01039688|Experimental|10 mg BID CP-690,550|
11545052|NCT01039688|Active Comparator|methotrexate|
11545053|NCT01039675|Experimental|GSK573719/GW642444|
11545054|NCT01039675|Placebo Comparator|Placebo|
11545055|NCT01039662|Experimental|Oolong tea containing L-arabinose and indigestible dextrin|
11545056|NCT01039662|Placebo Comparator|Oolong tea|
11545057|NCT01039649||Lung Radiation|Patients with tumors in the lung that require radiation therapy
11545058|NCT01039636|Experimental|FBS0701 - 5 escalating doses|5 escalating doses of FBS0701 in 5 cohorts of 4 patients each.
11545059|NCT01039610|Experimental|Part A|GSK945237 2400mg single dose
11545060|NCT01039610|Experimental|Part B Cohort 1|GSK945237 400 mg QD, 7 Days 4 subjects GSK945237:2 subjects Placebo
11545061|NCT01039610|Experimental|Part B Cohort 2|GSK945237 400 mg QD, 14 Days 4 subjects GSK945237:2 subjects Placebo
11545062|NCT01039610|Experimental|Part B Cohort 3|GSK945237 400 mg BID, 14 Days 4 subjects GSK945237:2 subjects Placebo
11545063|NCT01039610|Experimental|Part B Cohort 4|GSK945237 800 mg BID, 14 Days 9 subjects GSK945237:3 subjects Placebo
11545064|NCT01039610|Experimental|Part B Cohort 5|GSK945237 1200 mg BID, 14 Days 9 subjects GSK945237:3 subjects Placebo
11545065|NCT01039610|Experimental|Part B Cohort 6|GS945237 1600 mg QD, 14 Days 9 subjects GSK945237:3 subjects Placebo
11545066|NCT01039610|Active Comparator|Part C|Linezolid 600 mg BID, 14 Days 9 subjects Linezolid:3 subjects Placebo
11545067|NCT01039610|Active Comparator|Part D|"2 period crossover Period 1: Placebo 1 day; GSK945237 dose to be determined, 5 Days Period 2: Placebo 5 days; moxifloxacin 400 mg single dose
~16 subjects"
11545068|NCT01039597|Experimental|Active study drug|ORE1001 300 mg oral capsules
11545069|NCT01039597|Placebo Comparator|Placebo control|300 mg oral capsules containing placebo material
11545070|NCT01039584|Placebo Comparator|Placebo|vehicle of the test product; applied intravaginally once within 48 hours of randomization
11545071|NCT01039584|Experimental|Test Product|Butoconazole Nitrate Vaginal Cream; applied intravaginally once within 48 hours of randomization
11545072|NCT01039584|Active Comparator|Reference Product|Gynazole 1 Vaginal Cream; applied intravaginally once within 48 hours of randomization
11545073|NCT01039558|Active Comparator|lansoprazole + ecabet sodium|
11545074|NCT01039558|Placebo Comparator|lansoprazole + placebo|
11545075|NCT01039545|Active Comparator|antibiotic|Norfloxacin for three days, followed by fosfomycin on day 4 if deemed necessary
11545076|NCT01039545|Experimental|symptomatic|Diclofenac retard for three days, followed by fosfomycin on day 4 if deemed necessary
11545077|NCT01039532||Basal Bolus regimen|Basal Bolus regimen
11545078|NCT01039532||Biphasic human insulin|Biphasic human insulin
11545079|NCT01039519|Experimental|ganetespib 200 mg/m^2|Ganetespib (STA-9090) 200 mg/m^2 intravenous infusion once weekly for 3 consecutive weeks followed by one week dose free interval (3 weeks on and 1 week off represent a treatment cycle). Treatment continues until disease progression or unacceptable toxicity.
11545080|NCT01039506||UGT1A1 genotyped patients|UGT1A1 genotyped patients receive CPT-11 based regimens
11545081|NCT01039493||Patients|
11545082|NCT01039493||Providers|
11545507|NCT01036022|Experimental|Group 1|GSK1399686 at 3-4 dose levels
11545083|NCT01039480||dual therapy (ASS/CLO)|patients with a prescription for dual antiplatelet therapy with aspirin AND clopidogrel
11545084|NCT01039480||clopidogrel users (CLO)|patients with a prescription for clopidogrel
11545085|NCT01039480||aspirin users (ASP)|patients with a prescription for aspirin
11545086|NCT01039467|Active Comparator|Managed Ventricular Pacing|Managed Ventricular Pacing group: programmed on
11545087|NCT01039467|Active Comparator|Search AV+|Search AV+: programmed on
11545088|NCT01039454|Placebo Comparator|Placebo|2 way cross over.
11545089|NCT01039454|Active Comparator|Active|2 Way cross over
11545090|NCT01039441|Placebo Comparator|instillation of normal saline 50ml under the diaphragm|
11545091|NCT01039441|Experimental|the instillation of 0.5% bupivacaine under the diaphragm|
11545092|NCT01039441|Experimental|CO2 removal by means of a pulmonary recruitment maneuver|
11545093|NCT01039441|Experimental|the instillation of bupivacaine + CO2 removal by maneuver|
11545094|NCT01039428|Experimental|HS219|
11545095|NCT01039428|Placebo Comparator|Placebo|
11545096|NCT01039402||1|Adults ≥ 50 years old
11545097|NCT01039389|Experimental|Collateral promotion; PCI after 6 months|
11545098|NCT01039389|Experimental|Collateral promotion; PCI at baseline|
11545099|NCT01039376|Experimental|ARM A: Ofatumumab|300 mg IV Week 1 followed by 1000 mg IV Week 2 1000 mg IV (a dose every 8 weeks for up to 2 years following the first 1000 mg dose)
11545100|NCT01039376|Other|ARM B: Observation and assessments as per Arm A|Disease status assessments to determine subject response or progression performed approximately every 8 weeks for up to 2 years for both arms according to IWCLL criteria
11545101|NCT01039363|Experimental|Vorinostat|Vorinostat combined with salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat maintenance
11545102|NCT01039337|Active Comparator|Hip school|This group will receive hip school during the intervention period of 6 weeks.
11545103|NCT01039337|Active Comparator|Hip School and Manual Treatment|This group receives both hip school and manual treatment during the 6 weeks.
11545104|NCT01039337|Active Comparator|Minimal control intervention|An information leaflet including exercises.
11545105|NCT01039324|Experimental|Intermediate Intervention (arm #1)|Care transition reports sent to primary care clinics, care transition letters sent to patients, release of information requests about care transitions sent on behalf of primary care clinics.
11545106|NCT01039324|Experimental|Full Intervention (arm #2)|E-mail notices sent to care managers about care transitions plus care transition reports sent to primary care clinics, care transition reports sent to patients, release of information requests about care transitions sent on behalf of primary care clinics.
11545107|NCT01039324|Experimental|Control (arm #3)|"Subjects assigned to the control group will receive usual care which is the standard of care coordination currently existent between patients, providers and care managers."
11545108|NCT01039311||Optical Coherence Tomography|Examine OCT images and compare them to conventional biopsies in same subject.
11545109|NCT01039298|Active Comparator|A|"All subjects in this study will receive surgery to treat their oral lesions. The margins (or boundaries) of the tissue to be removed during surgery will be defined by 2 different procedures (or study arms) in the operating room.
~The Control arm. Surgical boundaries for oral lesions will be defined under regular white light."
11545110|NCT01039298|Experimental|B|"All subjects in this study will receive surgery to treat their oral lesions. The margins (or boundaries) of the tissue to be removed during surgery will be defined by 2 different procedures (or study arms) in the operating room.
~The FV arm (experimental arm). Surgical boundaries for oral lesions will be defined by FV."
11545111|NCT01039285|Experimental|Surfactant instillation|2.5 ml/kg of Surfactant will be instilled in the trachea
11545112|NCT01039285|Placebo Comparator|Placebo instillation|2.5 ml/kg of Air will be instilled in the trachea
11545113|NCT01039272||oral cancer|patients with oral squamous cell carcinoma
11545114|NCT01039272||control group|healthy patients without any oral pathology
11545115|NCT01039259||subjects with lip piercing|
11545116|NCT01039259||subjects with tongue piercing|
11545117|NCT01039233|Experimental|Bicalutamide 50 mg Tablet|
11545118|NCT01039233|Active Comparator|Casodex® 50 mg Tablet|
11545119|NCT01039207|Experimental|Treatment (rilotumumab)|Patients receive rilotumumab IV over 30-60 minutes on days 1 and 14. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Tumor tissue and blood samples may be collected periodically for further laboratory analysis.
11545120|NCT01039194|Active Comparator|galantamine 8 mg (ER)|
11545121|NCT01039194|Active Comparator|galantamine 16 mg (ER)|
11545122|NCT01039194|Active Comparator|BMS-708163|
11545123|NCT01039168|Active Comparator|Workplace dialogue|Clinical examination and dialogue with supervisor to find solutions to reduce job-person mismatch and facilitate return to work
11545124|NCT01039168|Sham Comparator|Care as usual|No intervention besides of the care as usual being available for the patient
11545125|NCT01039155|Experimental|Treatment (azacitidine, oxaliplatin)|Patients receive azacitidine IV over 15-30 minutes on days 1-5 and oxaliplatin IV over 2 hours on days 2-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11545126|NCT01039142|Active Comparator|25 mg acitretin|capsule acitretin 25 mg/day will be administered to each patient for a period of 12 weeks
11545127|NCT01039142|Active Comparator|35 mg acitretin|capsule acitretin 35 mg/day will be administered to each patient for a period of 12 weeks
11545128|NCT01039142|Active Comparator|50 mg acitretin|capsule acitretin 50 mg/day will be administered to each patient for a period of 12 weeks
11545129|NCT01039129|Experimental|Endoscopic Cholecystectomy|20 patients in this arm will undergo cholecystectomy, or removal of the gallbladder, through this experimental approach. This arm will compose of patients with symptomatic gallstones (cholelithiasis).
11545130|NCT01039129|Experimental|Endoscopic Appendectomy|Participants will with chronic appendicitis will undergo appendectomy through this experimental approach.
11545131|NCT01039129|Experimental|Endoscopic Peritoneoscopy|20 patients in this arm will undergo diagnostic peritoneoscopy with or without biopsy for any indication.
11545508|NCT01036022|Experimental|Group 3|Placebo
11545132|NCT01039116|Experimental|Level of intervention intensity|"High Intensity: Behavioral Experimental:Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.
~Active Comparator: Low-intensity Participants were provided with educational materials 4 times yearly."
11545133|NCT01039103|Experimental|Nanocort|PEG-liposomal prednisolone sodium phosphate (Nanocort) 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
11545134|NCT01039103|Active Comparator|Solu-Medrol|Methylprednisolone (Solu-Medrol) 1 g, IV, infusion over 2 hours on days 1, 2 and 3
11545135|NCT01039090|Active Comparator|Per os dopaminergic treatment|
11545136|NCT01039090|Experimental|Continuous Apomorphine infusion|
11545137|NCT01039077|Active Comparator|Single incision laparoscopic gastric banding|Patients in this group will undergo laparoscopic gastric banding through a single periumbilical incision.
11545138|NCT01039077|Active Comparator|Five port laparoscopic gastric banding|Patients in this group will undergo conventional laparoscopic gastric banding using 5 small incisions.
11545139|NCT01039051|Experimental|Diet and Lifestyle counseling|increasing consumption of vegetables and fruits; maintaining energy balance through reducing excessive energy from meat, eggs and brown sugar and increasing energy expenditure from appropriate physical activity, such as doing maternal keep-fit exercises.
11545140|NCT01039025|Experimental|TMC|Topotecan, Melphalan, and Cyclophosphamide
11545141|NCT01039012|Other|Tai Chi plus Standard Care|
11545142|NCT01039012|Other|Standard Care|
11545143|NCT01038999||A HIV1-infected naive patients|
11545144|NCT01038999||B HIV1-infected patients|in 1st line of ARV therapy for at least 12 months
11545145|NCT01038999||C= control Non infected HIV volunters|
11545146|NCT01038986||CureXcell treated|Patients with chronic and/or refractory wounds for at least 4 weeks with no improvement that have been referred by their physician for CureXcell treatment
11545147|NCT01038960|Experimental|Exercise training|training
11545148|NCT01038960|No Intervention|Not training|No organized training
11545149|NCT01038947|Experimental|Uricase-PEG 20|Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner. The study will enroll both single dose cohorts and multi-dose cohorts.
11545150|NCT01038934|Experimental|buccal cytobrhsh|healthy young
11545151|NCT01038921|Experimental|Melatonin|Melatonin 8mg one hour before bedtime for 10 weeks
11545152|NCT01038921|Placebo Comparator|Placebo|Placebo administered 1 hour before bedtime for 10 weeks
11545153|NCT01038908|Active Comparator|1|Each patient will receive an injection of technetium-99m sulfur colloid directed subareolar or around the tumor. The material will be prepared as per manufacturer's specifications. The dose will be 20mBq given the same day of 80mBq given the day before. The Nuclear Medicine Department at St Paul's Hospital will perform the injection as per normal sentinel lymph node mapping protocol.
11545154|NCT01038908|Active Comparator|2|Each patient will receive an injection of technetium-99m sulfur colloid directed subareolar or around the tumor. The material will be prepared as per manufacturer's specifications. The dose will be 20mBq given the same day of 80mBq given the day before. The Nuclear Medicine Department at St Paul's Hospital will perform the injection as per normal sentinel lymph node mapping protocol.
11545155|NCT01038895|Active Comparator|Ramipril|10 mg/daily
11545156|NCT01038895|Experimental|Aliskiren|300 mg/ daily
11545157|NCT01038882|Active Comparator|Midazolam|The patients of this arma receives midazolam before the flexible bronchoscopy to maintain conscious sedation
11545158|NCT01038882|Placebo Comparator|Physiological serum|
11545159|NCT01038869|Experimental|Azelaic acid 15% (Finacea)|Open label pilot study, Topical gel to be appiled twice daily for 16 weeks
11545160|NCT01038856|Experimental|+JAK2V61F mutation|Patients with MPN diagnoses and polycythemia vera who also have a confirmed JAK2V617F mutation
11545161|NCT01038843|Experimental|VA106483 1mg|
11545162|NCT01038843|Experimental|VA106483 2mg|
11545163|NCT01038843|Experimental|VA106483 4mg|
11545164|NCT01038843|Placebo Comparator|Sugar pill|
11545165|NCT01038817|Active Comparator|fluoride varnish|"Duraphat:
~Application of fluoride varnish on one side of the mandibles (left or right, randomly selected)"
11545166|NCT01038817|No Intervention|control|no application on the other side
11545167|NCT01038804|Experimental|A. YM155 plus docetaxel|
11545168|NCT01038804|Active Comparator|B. docetaxel alone|
11545169|NCT01038791|Active Comparator|usual ventilation|application of usual mechanical ventilation without humidification system
11545170|NCT01038791|Experimental|heated humidifier|mechanical ventilation with heated humidifier
11545171|NCT01038791|Experimental|heat and moisture exchanger|mechanical ventilation with heat and moisture exchanger
11545172|NCT01038778|Experimental|Treatment (entinostat, aldesleukin)|"Patients receive entinostat PO every 2 weeks beginning on day -14 and high-dose aldesleukin IV every 8 hours on days 1-5 and 15-19. Cycles repeat every 84 days* in the absence of disease progression or unacceptable toxicity.
~NOTE: *Patients with evidence of tumor shrinkage may receive up to 3 cycles of high-dose aldesleukin therapy. Patients with stable disease by RECIST version 1.0 criteria, but without evidence of tumor shrinkage after two cycles will receive only entinostat until disease progression is documented."
11545173|NCT01038765|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
11545174|NCT01038765|No Intervention|Waiting list control group|3-month waiting list group
11545175|NCT01038752|Experimental|Suramin|This group will receive the combination of non-cytotoxic suramin with docetaxel and carboplatin.
11545176|NCT01038752|Placebo Comparator|Standard of care|This group will receive placebo with docetaxel and carboplatin.
11545177|NCT01038739|Experimental|A|
11545178|NCT01038739|Experimental|B|
11545179|NCT01038739|Placebo Comparator|C|
11545180|NCT01038726|Active Comparator|Exercise Training|
11545181|NCT01038726|Active Comparator|Combined Cognitive/Exercise Training|
11545182|NCT01038726|Active Comparator|Cognitive Training|
11545183|NCT01038726|Active Comparator|Combined Low Intensity Training|
11545184|NCT01038713|Experimental|Resectable; plastic stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive a plastic biliary stent to relieve their biliary obstruction.
11545185|NCT01038713|Experimental|Resectable; uncovered metal stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive an uncovered metal biliary stent to relieve their biliary obstruction.
11545186|NCT01038713|Experimental|Resectable; fully covered metal stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive a fully-covered metal biliary stent to relieve their biliary obstruction.
11545187|NCT01038713|Experimental|Unresectable; uncovered metal stent|Patients determined to have surgically non-resectable malignancy presenting with malignant biliary obstruction randomized to receive an uncovered metal biliary stent to relieve their biliary obstruction.
11545188|NCT01038713|Experimental|Unresectable; fully covered metal stent|Patients determined to have surgically non-resectable malignancy presenting with malignant biliary obstruction randomized to receive a fully-covered metal biliary stent to relieve their biliary obstruction.
11545189|NCT01038687|Experimental|A3309 15 mg|Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.
11545190|NCT01038687|Experimental|A3309 20 mg|Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.
11545191|NCT01038687|Placebo Comparator|Placebo|Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.
11545192|NCT01038674|Experimental|Anti-IL-20|
11545193|NCT01038674|Placebo Comparator|Placebo|
11545194|NCT01038661|Experimental|First line treatment: docetaxel 75 mg/m² + cisplatin 75 mg/m²|Docetaxel 75 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
11545195|NCT01038661|Experimental|First line treatment:: docetaxel 60 mg/m² + cisplatin 75 mg/m²|Docetaxel 60 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
11545196|NCT01038661|Experimental|Maintenance treatment: docetaxel (60 mg/m2)|Docetaxel 60 mg/m² on day 1, repeated every 3 weeks until progressive disease or up to 6 cycles
11545197|NCT01038661|Active Comparator|Maintenance treatment: best supportive care (BSC)|BSC until progressive disease
11545198|NCT01038648|Placebo Comparator|1|Advice life style at baseline only
11545199|NCT01038648|Active Comparator|sitagliptin arm : 2|"100mg/day sitagliptin
~advice on life style modification at baseline only"
11545200|NCT01038635|Experimental|5-Azacytidine + Lenalidomide|5-Azacytidine 75 mg/m^2 by vein daily x 5 days on days 1 to 5. Lenalidomide starting dose 10 mg orally daily x 5 days on days 6 to 10.
11545201|NCT01038622|Active Comparator|L-arginine|5-day L-arginine treatment (200 mg/kg)
11545202|NCT01038622|Placebo Comparator|placebo|5-day placebo treatment
11545203|NCT01038609|Placebo Comparator|Placebo|1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release) plus 1 placebo capsule (for morphine extended release), administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
11545204|NCT01038609|Active Comparator|Acetaminophen|1 dose of 1 placebo capsule (for morphine extended release) plus 1 acetaminophen tablet, administered once every 12 hours, and 1 dose of 1 acetaminophen tablet, administered once every 6 hours (for a total of 8 doses).
11545205|NCT01038609|Active Comparator|Morphine Extended Release|1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release) plus 1 morphine extended release capsule, administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
11545206|NCT01038609|Active Comparator|Morphine Extended Release / Acetaminophen|1 dose of 1 morphine extended release capsule plus 1 acetaminophen tablet, administered once every 12 hours, and 1 dose of 1 acetaminophen tablet, administered once every 6 hours (for a total of 8 doses).
11545207|NCT01038609|Experimental|Hydrocodone/Acetaminophen Extended Release|1 dose of 1 hydrocodone/acetaminophen extended release tablet plus 1 placebo capsule (for morphine extended release), administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
11545208|NCT01038596||osteoarthritic donors|pelvic compartment advanced-stage (Kellgren and Lawrence grade 3 or 4) osteoarthritic donors
11545209|NCT01038596||healthy donors|age-matched healthy donors
11545210|NCT01038583||Aspirin|100 mg enteric-coated aspirin
11545211|NCT01038583||Placebo|Placebo
11545212|NCT01038570|Experimental|Oxytocin|
11545213|NCT01038570|Placebo Comparator|Physiological serum|
11545214|NCT01038557|Active Comparator|Refrigerated RBCs 0-14 days old|Standard, refrigerated RBC units stored up to 14 days
11545215|NCT01038557|Active Comparator|Refrigerated RBCs 15-42 days old|Standard, refrigerated RBC units stored 15-42 days
11545216|NCT01038557|Experimental|Frozen RBCs|RBC units stored frozen at -80 degrees Celsius, then thawed and deglycerolized using the ACP 215.
11545217|NCT01038531|Active Comparator|low-tidal-volume ventilation|Goal tidal volume is 6 cc/kg ideal body weight.
11545218|NCT01038531|Experimental|APRV|APRV allows spontaneous breathing.
11545219|NCT01038518||Health2010|Cross-sectional general population study
11545220|NCT01038505|Active Comparator|Tacrolimus and Myfortic|Immunosuppressive
11545221|NCT01038505|Active Comparator|Tacrolimus and Sirolimus|Immunosuppressive
11545222|NCT01038492|Experimental|p16 Methylation in Sputum Testing|"Patients tested for smoking-related changes in their breathing
~shown a presentation on development of lung cancer
~complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic detail
~given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing
~a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits
~patients are called again at three months and asked about any changes in their attitudes or smoking habits"
11545223|NCT01038479|Active Comparator|Childsmile programme with xylitol|Childsmile program with maternal xylitol consumption;
11545224|NCT01038479|Placebo Comparator|Childsmile programme only|Childsmile programme
11545225|NCT01038466||CHAT trial participants|CHAT trial participants whose data was used in the final data analysis for the CHAT study
11545226|NCT01038453|Active Comparator|Cholecalciferol (Vitamin D3) 35 µg|Dietary Supplement: Cholecalciferol (Vitamin D3) 35 µg per day
11545227|NCT01038453|Active Comparator|Cholecalciferol (Vitamin D3) 70 µg|Dietary supplement: Cholecalciferol (Vitamin D3) 70 µg per day
11545228|NCT01038453|Placebo Comparator|placebo|
11545229|NCT01038440|Placebo Comparator|Control|
11545230|NCT01038440|Active Comparator|EPA 0.5 g/d|
11545231|NCT01038440|Active Comparator|EPA 1.5 g/d|
11545232|NCT01038440|Active Comparator|EPA 3.0 g/d|
11545233|NCT01038440|Experimental|SDA 0.5 g/d|
11545234|NCT01038440|Experimental|SDA 1.5 g/d|
11545235|NCT01038440|Experimental|SDA 3.0 g/d|
11545236|NCT01038440|Experimental|SDA 6.0 g/d|
11545237|NCT01038427|Experimental|Mometasone Furoate Nasal Spray (Lek d.d.)|
11545238|NCT01038427|Active Comparator|Nasonex® Nasal Spray|
11545239|NCT01038427|Placebo Comparator|Placebo Nasal Spray|
11545240|NCT01038414|Placebo Comparator|Brief-Duration Counseling|3-Month Duration
11545241|NCT01038414|Active Comparator|Moderate Duration Counseling|6-Month Duration
11545242|NCT01038414|Active Comparator|Extended Duration Counseling|12-Month Duration
11545243|NCT01038401|Other|HIV-1-infected patients on effective HAART|
11545244|NCT01038401|Other|Non Infected HIV Volunteers|
11545245|NCT01038388|Experimental|Bortezomib, lenalidomide, dexamethasone, vorinostat|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11; lenalidomide by mouth once a day on days 1-14; dexamethasone by mouth once a day on days 1, 2, 4, 5, 8, 9, 11, and 12; and vorinostat by mouth on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
~After 8 courses, patients may receive maintenance therapy comprising lenalidomide by mouth once a day on days 1-21, dexamethasone by mouth once a day on days 1, 2, 8, and 9, and bortezomib IV over 3-5 seconds or subcutaneously on days 1 and 8. Courses may repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11545246|NCT01038375||Adherence counseling|
11545247|NCT01038375||Usual care|
11545248|NCT01038362|Active Comparator|Almonds|National Cholesterol Education Program Step I diet plus almonds for 6 weeks
11545249|NCT01038362|Placebo Comparator|No Almonds|National Cholesterol Education Program Step 1 diet without almonds for 6 weeks
11545250|NCT01038336|Experimental|Multimedia HLPP|Multimedia Hearing Loss Prevention Program (HLPP)
11545251|NCT01038336|Active Comparator|Hearing Conservation Brochure|Hearing Conservation Brochure (HCB)
11545252|NCT01038336|No Intervention|Standard-of-Care|Standard-of-Care (SoC)
11545253|NCT01038323|Experimental|CBT and milnacipran|Subjects randomized to this group will receive a combination of eight telephone sessions of Cognitive Behavior Therapy (CBT) and a 21-week regimen of milnacipran.
11545254|NCT01038323|Placebo Comparator|CBT and placebo|Subjects randomized to this arm will receive a series of eight telephone sessions of Cognitive Behavioral Therapy (CBT) along with a 21-week regimen of a placebo(sugar pill)medication.
11545255|NCT01038323|Active Comparator|Educational with milnacipran|Subjects randomized to this group will receive a series of eight educational phone calls regarding fibromyalgia along with a 21-week regimen of milnacipran.
11545256|NCT01038297|Experimental|EXC 001|
11545257|NCT01038297|Placebo Comparator|Placebo|
11545258|NCT01038284|Sham Comparator|Control|
11545259|NCT01038284|Active Comparator|Patient education|
11545260|NCT01038271|Active Comparator|Standard Palliative Care Group|
11545261|NCT01038271|Active Comparator|Integrated Palliative Care Group|
11545262|NCT01038258|Other|No arms|No arms
11545263|NCT01038219||fever measurements|"1000 estimates and measurements of children's body temperatures will be carried out by parents and nurses in children's emergency and pediatric units as part of the routine work. The estimates and the measurements will be carried out on children who are referred to an emergency unit and who are hospitalized in the pediatric department-- both boys and girls of all ages. A patient might be measured several times.
~The measurements will be gathered in the course of one year. Before the routine taking of temperature, the accompanying parent will be asked to estimate the patient's temperature by feeling his forehead (with the back of the hand, the palm, lips). The parent will record his evaluation (without telling the nurse). Afterwards the nurse will do a similar evaluation (excepting the lip test), record it, and then the routine temperature measurement will be taken."
11545264|NCT01038206|Experimental|Family Function Intervention|Familias Unidas Intervention Program
11545265|NCT01038206|No Intervention|Treatment as Usual|The Public School system mandates that all high school students receive at least 5 lessons (55 minutes each) per year of HIV prevention.
11545266|NCT01038193||aSAH patients|Cognitive assessment
11545267|NCT01038180||pacemaker group|
11545268|NCT01038167|Experimental|Part A|Part A will be administered in two periods, separated by a washout. In Period 1, subjects will receive cyclosporine alone. In Period 2, subjects will receive cyclosporine in combination with telaprevir.
11545269|NCT01038167|Experimental|Part B|Part B will be administered in two periods, separated by a washout. In Period 1, subjects will receive tacrolimus alone. In Period 2, subjects will receive tacrolimus in combination with telaprevir.
11545270|NCT01038154|No Intervention|control|Not Receive pravastatin
11545271|NCT01038154|Experimental|Pravastatin|
11545272|NCT01038141|Active Comparator|Milligan Morgan|
11545273|NCT01038141|Active Comparator|Recto Anal Repair|
11545274|NCT01038128|Experimental|Memantine|Memantine, 10-40 mg daily
11545275|NCT01038115|Active Comparator|Cryoballoon|
11545276|NCT01038115|Active Comparator|Radiofrequency|
11545277|NCT01038115|Active Comparator|Cryoballoon + Radiofrequency together|
11545278|NCT01038102|Active Comparator|PUFA diet|Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%)
11545279|NCT01038102|Active Comparator|SFA diet|Diet high in saturated fat (15 E%)
11545280|NCT01038089|Experimental|resveratrol|Resveratrol
11545396|NCT01037309|Experimental|PRO044, cohort 8|Intravenous injection of maximally 5 mg/kg on day 1, 8, 15, 22 and 29
11545818|NCT01033539|Active Comparator|ATCC PTA 4659 high dose|
11545281|NCT01038076|Experimental|MedCHEC Tablet Computer & Adherence Care|Patients assigned to the intervention answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates provider and patient reports. Patients may be referred to an Adherence Care Manager on the basis of the reports. In addition, patients will receive standard information about adherence.
11545282|NCT01038076|No Intervention|Adherence Information Only|Patients assigned to the active comparator arm will receive standard information about adherence.
11545283|NCT01038063|Experimental|Artemether-lumefantrine|Children in this study arm will be treated with artemether-lumefantrine during a three year follow-up period each time a child develops uncomplicated malaria.
11545284|NCT01038063|Active Comparator|Dihydroartemisinin-piperaquine|Children in this study arm will be treated with dihydroartemisinin-piperaquine during a three year follow-up period each time a child develops uncomplicated malaria.
11545285|NCT01038024|Experimental|Antioxidant Supplements|
11545286|NCT01037998|Active Comparator|A|Iressa 250 mg daily treatment plus UFUR twice daily treatment
11545287|NCT01037998|No Intervention|B|Gefitinib 250 mg daily treatment
11545288|NCT01037985|Experimental|EXC 001|
11545289|NCT01037985|Placebo Comparator|Placebo|
11545290|NCT01037972||Whole body vibration|
11545291|NCT01037972||Conventional physiotherapy|
11545292|NCT01037959|Active Comparator|Norfloxacin|Patients with severe cirrhosis treated with norfloxacin
11545293|NCT01037959|Placebo Comparator|Placebo|Patients with severe cirrhosis treated with placebo
11545294|NCT01037946|No Intervention|Standard Care Arm|Families living with HIV, offered intervention at the end of study (24 months after recruitment)
11545295|NCT01037946|Experimental|Intervention|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
11545296|NCT01037933|Active Comparator|Humor intervention|"A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player."
11545297|NCT01037933|Active Comparator|Non-humor intervention|"A 45-minute non-humorous DVD The A to Z of Steam Railways using a portable DVD player."
11545298|NCT01037920|Experimental|Intervention|subjects in the intervention arm will complete a self-affirmation exercise prior to a physician visit
11545299|NCT01037920|Active Comparator|Control|subjects in the intervention arm will complete a sham exercise prior to a physician visit
11545300|NCT01037907|Experimental|BGC20-0134 (Pleneva TM)|Structured lipid
11545301|NCT01037907|Placebo Comparator|Placebo control|Placebo - dummy pill
11545302|NCT01037894|Experimental|Acupuncture|Acupuncture and conventional rehabilitation
11545303|NCT01037894|Active Comparator|Control|Conventional rehabilitation only
11545304|NCT01037881|Experimental|LEO 29102 0.03 mg/g cream|
11545305|NCT01037881|Experimental|LEO 29102 0.1 mg/g cream|
11545306|NCT01037881|Experimental|LEO 29102 0.3 mg/g cream|
11545307|NCT01037881|Experimental|LEO 29102 1.0 mg/g cream|
11545308|NCT01037881|Experimental|LEO 29102 2.5 mg/g cream|
11545309|NCT01037881|Placebo Comparator|LEO 29102 cream vehicle|
11545310|NCT01037881|Active Comparator|Elidel® cream (pimecrolimus) 10 mg/g|
11545311|NCT01037868|Experimental|Supportive SMS messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
11545312|NCT01037868|No Intervention|No supportive SMS text message|Patients in the non-intervention group would also receive text messages once every fortnight thanking them for participating in the study and a monthly phone call which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
11545313|NCT01037855||Group 1: 6-23 months|
11545314|NCT01037855||Group 2: 2-8 years|
11545315|NCT01037855||Group 3: 9-17 years|
11545316|NCT01037855||Group 4: 18-44 years|
11545317|NCT01037855||Group 5: 45-60 years|
11545318|NCT01037855||Group: >60 years|
11545319|NCT01037842|Active Comparator|Metformin+Mitiglinide|mitiglinide 10 mg three times a day added to metformin 500 mg three times a day
11545320|NCT01037842|Placebo Comparator|Metformin+Placebo|placebo three times a day added to metformin 500 mg three times a day
11545321|NCT01037829||Pregnancy women|Comparison of pregnancy outcomes between (Novartis) H1N1 vaccinated women and (Novartis) H1N1 unvaccinated women.
11545322|NCT01037816|Active Comparator|FS-67 patch|One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
11545323|NCT01037816|Placebo Comparator|Placebo Patch|One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
11545324|NCT01037790|Experimental|Arm 1|Metastatic breast cancer
11545325|NCT01037790|Experimental|Arm 2|Metastatic colorectal cancer that harbors the Kras or BRAF mutation
11545326|NCT01037790|Experimental|Arm 3|Advanced or metastatic esophageal and/or gastric cancer
11545327|NCT01037790|Experimental|Arm 4|Cisplatin-refractory, unresectable germ cell tumors
11545328|NCT01037790|Experimental|Arm 5|Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation , CCND2 amplification OR any other functional alteration at the G1/S checkpoint.
11545329|NCT01037777||presymptomatic carriers|
11545330|NCT01037777||non carrier relatives|
11545331|NCT01037764|Experimental|alloHCT|alloHCT arm: For HLA-matched sibling HCT, if a patient is 55 years old or less and without co-morbidity, the patient will receive Bu-Cy conditioning therapy and be transplanted with bone marrow cells. Patients who are older than 55 years or with co-morbidity will receive Bu-Flu-ATG conditioning and be transplanted with mobilized peripheral blood hematopoietic cells. For HLA-matched unrelated donor or HLA-mismatched familial donor HCT, the patient will receive Bu-Flu-ATG conditioning and well be transplanted with mobilized peripheral blood hematopoietic cells.
11545332|NCT01037751||Interview + Questionnaires|1-on-1 interview + Questionnaires, Part 1 of Study
11545333|NCT01037751||Questionnaires|Questionnaires Only, Part 2 of Study
11545334|NCT01037738|Active Comparator|ACS - Orthokin|Autologous conditioned serum (ACS) - Orthokin containing endogenous anti-inflammatory cytokines including IL-1Ra and growth factors (IGF-1, PDGF and TGF-ß1, among others) in the liquid blood phase.
11545335|NCT01037738|Placebo Comparator|Placebo|Physiologic solution
11545336|NCT01037725|Experimental|AZD5847 oral suspension|Active
11545337|NCT01037725|Placebo Comparator|Placebo to AZD5847|Placebo
11545338|NCT01037712|Experimental|ZELITREX|ZELITREX
11545339|NCT01037712|Placebo Comparator|Placebo|placebo
11545340|NCT01037699|Active Comparator|FSH YOUNGER|
11545341|NCT01037699|Active Comparator|FSH OLDER|
11545342|NCT01037699|Experimental|FSH LH YOUNGER (Recombinant Luteotrophin alfa)|
11545343|NCT01037699|Experimental|FSH LH OLDER|
11545344|NCT01037686|Other|PD, DBS, healthy controls|Patients with idiopathic PD before or after DBS surgery (during on or off-stimulation) and healthy controls.
11545345|NCT01037673|Experimental|PT progressive exercises|A progressive program of movement and strength exercises for the rotator cuff and scapular muscles combined with mobilisation of the joint capsule when needed
11545346|NCT01037673|Active Comparator|Movement exercises neck and shoulder|General movements for the neck and shoulder,
11545347|NCT01037660|Experimental|Metformin|Metformin
11545348|NCT01037647||Type 2 diabetic men|Men with type 2 diabetes
11545349|NCT01037647||Healthy men|Healthy men
11545350|NCT01037634|Experimental|Oseltamivir|Participants will receive Oseltamivir to treat influenza.
11545351|NCT01037595|Experimental|turmeric|turmeric 500 mg tid orally for 8 weeks
11545352|NCT01037595|Placebo Comparator|plasebo|placebo tid orally for 8 weeks
11545353|NCT01037582|Experimental|Trial part 1|
11545354|NCT01037582|Experimental|Trial part 2|
11545355|NCT01037556|Experimental|Arm 1: PR104|
11545356|NCT01037543|Experimental|Cohort 1|1.1 mcg/kg of HM10460A, placebo, or Neulasta
11545357|NCT01037543|Experimental|Cohort 2|3.3 mcg/kg HM10460A, placebo or Neulasta
11545358|NCT01037543|Experimental|Cohort 3|10 mcg/kg of HM10460A, placebo, or Neulasta
11545359|NCT01037543|Experimental|Cohort 4|30 mcg/kg of HM10460A, placebo, or Neulasta
11545360|NCT01037543|Experimental|Cohort 5|90 mcg/kg or HM10460A, placebo, or Neulasta
11545361|NCT01037543|Experimental|Cohort 6|270 mcg/kg of HM10460A, placebo, or Neulasta
11545362|NCT01037530|Experimental|Ramipril|
11545363|NCT01037517|Active Comparator|Successful Mobilizers|Successful Mobilizers are defined as having a peripheral blood CD34 > 10X106/L.
11545364|NCT01037517|Experimental|Poor Mobilizers|Poor Mobilizer are defined as patients who on Day -1 have a peripheral blood [CD34] ≤ 10 X106/L
11545365|NCT01037504|Experimental|A|Drug: AZD5423
11545366|NCT01037504|Placebo Comparator|B|Drug: Placebo
11545367|NCT01037491|Active Comparator|aspirin|Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD.patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks.
11545368|NCT01037491|Active Comparator|clopidogrel|Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD.patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks.
11545369|NCT01037478|Experimental|Resminostat (4SC-201)|oral administration
11545370|NCT01037465|Active Comparator|N-acetylcysteine|N-acetylcysteine
11545371|NCT01037465|Placebo Comparator|Placebo|Placebo
11545372|NCT01037452|Experimental|Combination product|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg tablet
11545373|NCT01037452|Active Comparator|PPI alone|Lansoprazole
11545374|NCT01037452|Active Comparator|Antacid alone|Calcium carbonate/magnesium hydroxide
11545375|NCT01037452|Placebo Comparator|Placebo|Placebo
11545376|NCT01037426|Other|Study group|Falls before versus after pacemaker implant
11545377|NCT01037413|Experimental|EXC 001|
11545378|NCT01037413|Placebo Comparator|Placebo|
11545379|NCT01037400||Total Knee Replacement Patients|Forty men and women ages 18-75 undergoing unilateral (n = 20) or bilateral (n = 20) knee replacement surgery with no musculoskeletal injury requiring medical attention in the past 3 months or producing pain in the previous 2 weeks and no inflammatory disease other than osteoarthritis.
11545380|NCT01037387|Active Comparator|Control|Conventional treatment for COPD
11545381|NCT01037387|Experimental|NIMV group|NIMV: Conventional treatment plus noninvasive mechanical ventilation
11545382|NCT01037374|Experimental|Difficult Airway Assessment Form|
11545383|NCT01037348|Experimental|ranibizumab 0.5mg|
11545384|NCT01037335|Placebo Comparator|control group|10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly.
11545385|NCT01037335|Active Comparator|intramuscular morphine|10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly
11545386|NCT01037335|Active Comparator|donor site morphine|5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
11545387|NCT01037322|Active Comparator|cannabidiol in drops|cannabidiol given in drops of olive oil sub lingual 5 mg twice daily
11545388|NCT01037322|Placebo Comparator|placebo in drops|olive oil given in drops sub lingual
11545389|NCT01037309|Experimental|PRO044, cohort 1|Subcutaneous injection of 0.5 mg/kg on day 1, 8, 15, 22 and 29.
11545390|NCT01037309|Experimental|PRO044, cohort 2|Subcutaneous injection of maximally 1.5 mg/kg on day 1, 8, 15, 22 and 29.
11545391|NCT01037309|Experimental|PRO044, cohort 3|Subcutaneous injection of maximally 5 mg/kg on day 1, 8, 15, 22 and 29.
11545392|NCT01037309|Experimental|PRO044, cohort 4|Subcutaneous injection of maximally 8 mg/kg on day 1, 8, 15, 22 and 29.
11545393|NCT01037309|Experimental|PRO044, cohort 5|Subcutaneous injection of maximally 10 mg/kg on day 1, 8, 15, 22 and 29
11545394|NCT01037309|Experimental|PRO044, cohort 6|Subcutaneous injection of maximally 12 mg/kg on day 1, 8, 15, 22 and 29
11545395|NCT01037309|Experimental|PRO044, cohort 7|Intravenous injection of maximally 1.5 mg/kg on day 1, 8, 15, 22 and 29
11545397|NCT01037309|Experimental|PRO044, cohort 9|Intravenous injection of maximally 8 mg/kg on day 1, 8, 15, 22 and 29
11545398|NCT01037296|Other|manual ablation|
11545399|NCT01037296|Experimental|robotic ablation|
11545400|NCT01037283|Other|Interpersonal and Social Rhythm Therapy|All participants receive eight sessions of Interpersonal and Social Rhythm Therapy.
11545401|NCT01037244|Placebo Comparator|Placebo|
11545402|NCT01037244|Experimental|Udenafil 50 mg|
11545403|NCT01037244|Experimental|Udenafil 100 mg|
11545404|NCT01037244|Experimental|Udenafil 150 mg|
11545405|NCT01037231|Experimental|Oxabact (tm)|
11545406|NCT01037231|Placebo Comparator|Placebo|
11545407|NCT01037218|Experimental|Udenafil 50 mg|50 mg Udenafil tablet plus 100 & 150 mg placebo tablets
11545408|NCT01037218|Experimental|Udenafil 100 mg|100 mg Udenafil tablet plus 50 & 150 mg placebo tablets
11545409|NCT01037218|Experimental|Udenafil 150mg|150 mg Udenafil tablet plus 50 & 100 mg placebo tablets
11545410|NCT01037218|Placebo Comparator|Placebo|50, 100 & 150 mg placebo tablets
11545411|NCT01037205|Active Comparator|DAS181 High Dose|DAS181 Dry Powder 10 mg qd x 3 days
11545412|NCT01037205|Active Comparator|DAS181 Low Dose|DAS181 Dry Powder 10 mg Day 1 Lactose Placebo Day 2 and Day 3
11545413|NCT01037205|Placebo Comparator|Lactose Placebo|Lactose (Respitose ML006 (DMV-Fonterra)) 1 capsule qd x 3 days
11545414|NCT01037192|Experimental|Vanco once daily|Subject receives vancomycin 30 mg/kg dose
11545415|NCT01037192|Active Comparator|Vanco twice daily|Subject receives vancomycin 15 mg/kg twice daily
11545416|NCT01037179|Experimental|AL-4943A|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, 2 drops instilled in each eye twice daily for 10 weeks
11545417|NCT01037166|Experimental|Entecavir (0.5 mg)|
11545418|NCT01037166|Experimental|Entecavir (1mg)|
11545419|NCT01037140|Active Comparator|cholecalciferol|
11545420|NCT01037140|Placebo Comparator|placebo|
11545421|NCT01037127|Experimental|Cohort A|Subjects who have had previous treatment with a BRAF inhibitor.
11545422|NCT01037127|Experimental|Cohort B|Subjects who have had previous chemotherapy or immunotherapy without a BRAF inhibitor.
11545423|NCT01037114|Experimental|Twinrix Group|"Subjects who received 2 doses of Twinrix (lot A, B or C) in the primary study.
~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Twinrix Group for data analyses during the first long-term follow-up NCT00289718 and this long-term follow-up.
~A challenge dose of the Havrix or Engerix-B vaccines can be administered in this study based on serology results at each time point."
11545424|NCT01037101|Active Comparator|IVET+DCS|
11545425|NCT01037101|Experimental|VRET+DCS|
11545426|NCT01037101|Experimental|VRET+Placebo|
11545427|NCT01037101|Active Comparator|IVET+Placebo|
11545428|NCT01037101|No Intervention|Wait-List|3 weeks Wait-List
11545429|NCT01037088|Experimental|Mild dose cannabis|3.53% THC by weight
11545430|NCT01037088|Experimental|Low dose cannabis|1.29% THC by weight
11545431|NCT01037088|Placebo Comparator|Placebo cannabis|placebo marijuana
11545432|NCT01037062|Experimental|Entecavir|
11545433|NCT01037049|No Intervention|Group 1|Patients who have surgery at 6 weeks after radiotherapy/chemoradiotherapy
11545434|NCT01037049|Experimental|Group 2|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy
11545435|NCT01037036|Experimental|Latanoprost Punctal Plug Delivery System followed by Xalatan|Subjects will have the Latanoprost Punctal Plug Delivery System placed for 4 week or until loss of efficacy. After removal of the Latanoprost Punctal Plug Delivery system, subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
11545436|NCT01037023||Patients administrated Topotecan|There is only one group. This group includes patients administrated Topotecan
11545437|NCT01036971||1|potential research subjects
11545438|NCT01036932|Active Comparator|G-CSF group|Patients with Acute on chronic liver failure after baseline investigations for the etiology of the acute event and the underlying chronic disease were given Granulocyte Colony Stimulating Factor therapy for a total duration of one month.
11545439|NCT01036932|Placebo Comparator|Placebo|After baseline characterization and work up for underlying acute and chronic liver disease, patients were given placebo along with the standard therapy
11545440|NCT01036893|No Intervention|oral contraceptives without prucalopride|
11545441|NCT01036893|Active Comparator|oral contraceptives with prucalopride|prucalopride
11545442|NCT01036854|Experimental|Regime 1|Regime 1 will be orally administered once daily in the morning over 6 consecutive days.
11545443|NCT01036854|Active Comparator|Regime 2|Regime 2 will be orally administered twice daily at 12 hours interval (morning and evening) over 6 consecutive days
11545444|NCT01036854|Active Comparator|Regime 3|Regime 3 will be orally administered three times daily at 8 hour intervals (morning, afternoon, evening) over 6 consecutive days.
11545445|NCT01036854|Experimental|Regime 4|Regime 4- Day 1- a single dose will be given. Day 2- one placebo capsule; Day 3- a single dose will be given . Day 4 & 5- two placebo capsules on each day; Day 6- a single does will be given.
11545446|NCT01036841|Active Comparator|desmopressin tablet|
11545447|NCT01036841|Experimental|desmopressin MELT-formulation|
11545448|NCT01036802|Active Comparator|Warfarin|Patients on the active treatment arm will be anticoagulated using the vitamin K antagonist, warfarin
11545449|NCT01036802|Placebo Comparator|Placebo|matching active products
11545450|NCT01036724||Carto 3|Those subjects whose cases use the CARTO 3 EP Navigation System.
11545451|NCT01036724||NAVX|Those subjects whose cases use the NAVX(TM) EP Navigational System.
11545452|NCT01036685||370-bench-control|healthy control who will only do behavioral tasks
11545453|NCT01036685||379-bench-other-psych-diagnosis|someone with a DSM-V disorder, stable and in treatment (i.e., no medication changes in the previous four weeks and a clearly identified treating psychiatrist) who will only dobehavioral tasks
11545454|NCT01036685||379-bench-smoker|daily smoker of tobacco cigarettes for at least one year (excluding quit attempts)who will only do behavioral tasks
11545455|NCT01036685||379-bench-user|someone with a DSM-V substance use disorder on a substance other than nicotine who will only do behavioral tasks
11545457|NCT01036685||379-other-psych -diagnosis|someone with a DSM-V disorder, stable and in treatment (i.e., no medication changes in the previous four weeks and a clearly identified treating psychiatrist) who can do MRI and tDCS
11545458|NCT01036685||379-smoker|daily smoker of tobacco cigarettes for at least one year (excluding quit attempts)who can do MRI and tDCS
11545459|NCT01036685||379-user|someone with a DSM-V substance use disorder on a substance other than nicotine who can do MRI and tDCS
11545460|NCT01036659|Active Comparator|Ecallantide in conjunction with Conventional Therapy|
11545461|NCT01036659|Placebo Comparator|Conventional therapy and placebo|
11545462|NCT01036659|No Intervention|Historical Evaluation|
11545463|NCT01036646||BSTE-0125-Original Protocol|
11545464|NCT01036646||BSTE-0125.a-Amended Protocol|
11545465|NCT01036633||Control Group no mucositis|Control patients with multiple myeloma who are not currently receiving chemotherapy and who do not suffer from oral mucositis
11545466|NCT01036633||Non-control Group Mucositis|Patients with multiple myeloma suffering from WHO Grade 3/4 Oral Mucositis
11545467|NCT01036594|Experimental|Ketoconazole + Hydrocortisone|"po = oral tid = 3 times per day qam = every morning qom = every evening bid = twice daily
~1 cycle = 28 days
~Ketoconazole: 200mg during first week of study (run-in phase), then 400mg po tid
~Hydrocortisone 20mg po qam and 10mg po qpm: If participant has ≥ 30% Prostate-specific antigen (PSA) decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by Prostate Specific Antigen Working Group (PSAWG) criteria) is documented. After that, drug will be discontinued. If participant has < 30% PSA decline at 12 week evaluation, participant goes off study."
11545468|NCT01036594|Experimental|Ketoconazole + Dexamethasone|"Ketoconazole: 400mg po tid
~Dexamethasone 0.5mg po bid: If ≥ 30% PSA decline (Prostate-specific antigen) at 12 week evaluation, administration starts when disease progression (by RECIST criteria OR by PSAWG criteria) is documented."
11545469|NCT01036581|Experimental|drug-using|Subjects must be between the ages of 18-55, be generally healthy and male or non-pregnant female. Smokers, non-smokers, drug using and non-drug using populations will participate in this study.
11545470|NCT01036581|Active Comparator|Healthy controls|Subjects must be between the ages of 18-55, be generally healthy and male or non-pregnant female. Smokers, non-smokers, drug using and non-drug using populations will participate in this study.
11545471|NCT01036581|Experimental|smokers|Subjects must be between the ages of 18-55, be generally healthy and male or non-pregnant female. Smokers, non-smokers, drug using and non-drug using populations will participate in this study.
11545472|NCT01036529|Experimental|Precision Spinal Cord Stimulator|Spinal Cord Stimulation
11545473|NCT01036529|Active Comparator|Back Surgery|Discectomy, laminotomy, laminectomy, foraminotomy, fusion with or without instrumentation
11545474|NCT01036490|No Intervention|Control|Control group
11545475|NCT01036490|Experimental|Exercise|Exercise Group
11545476|NCT01036438|Placebo Comparator|Mepilex product|
11545477|NCT01036438|Active Comparator|Mepilex Ag|
11545478|NCT01036412|Experimental|Chlorhexidine Gel Therapy|Following 2 x 5-minute applications of 2.5 ml in clinic, 2 x 5.0 ml syringes of 1% chlorhexidine gluconate gel, self-administered for a 5-minute application Week 2 & Week 4
11545479|NCT01036399|Experimental|Revlimid|"Oral Revlimid is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
~After this induction phase, the CR, PR and SD will continue Revlimid with the same schedule for other 8 months."
11545480|NCT01036360||physical activity|
11545481|NCT01036321|Active Comparator|Purified Isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler. 40 mg daily.
11545482|NCT01036321|Placebo Comparator|Methyl cellulose blend|Placebo.
11545483|NCT01036308|Experimental|TypTop|Lupinus albus Typ Top (lupin kernel fibre, dietary fibre content: 83%)
11545484|NCT01036308|Experimental|Soy fibre|Glycine max Hefeng (soy fibre; dietary fibre content: 77%)
11545485|NCT01036308|Experimental|Boregine|Lupinus angustifolius Boregine (lupin kernel fibre, dietary fibre content: 87%)
11545486|NCT01036282|Experimental|Computerized Cognitive Remediation|Two arms: 1. Computerized Cognitive Remediation treatment using COGPACK. and 2. PositScience. Each arm is further randomized to either MindReader or no Mindreader.(Social Cognition Training).
11545487|NCT01036282|Experimental|CRT + Social Cognition Training|Two 45-minute sessions of Computerized Cognitive Remediation using COGPACK, one 45-minute discussion session, plus one 45 minute Mind Reader Interactive Guide to Emotions per week for 12 weeks. compared to two 45-minute sessions of PositScience, plus one 45-min Discussion session plus one minute of Mind Reader, Interactive Guide to Emotions
11545488|NCT01036243|Experimental|Test formula 1|Hydrolyzed formula with probiotics
11545489|NCT01036243|Active Comparator|test formula 2|acidified hydrolyzed formula.
11545490|NCT01036243|Active Comparator|Test formula 3|hydrolyzed formula without probiotics
11545491|NCT01036243|Active Comparator|reference product|standard infant formula
11545492|NCT01036139|Experimental|BF2.649 (pitolisant)|BF2.649 (5mg, 10 mg, 20 mg) in capsules
11545493|NCT01036139|Placebo Comparator|Placebo|Placebo of BF2.649 (5mg, 10mg, 20mg) in capsules
11545494|NCT01036113|Experimental|Experimental: EZN-2208|Experimental: EZN-2208 EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
11545495|NCT01036087|Experimental|PNC + FEC|"PNC = Panitumumab + Nab-paclitaxel + Carboplatin, and
~FEC = 5-fluorouracil, epirubicin, and cyclophosphamide"
11545496|NCT01036061|Experimental|GSK618334 low Dose|GSK618334 Low Dose
11545497|NCT01036061|Experimental|GSK618334 Medium Dose|GSK618334 medium dose arm
11545498|NCT01036061|Experimental|GSK618334 High Dose|GSK618334 High Dose Arm
11545499|NCT01036061|Experimental|GSK618334 Placebo|Placebo for all 3 dose levels
11545500|NCT01036048||cabg disease|pts with saphenous vein graft disease
11545501|NCT01036035|Active Comparator|Treatment B|Study drug
11545502|NCT01036035|Active Comparator|Treatment D|Study drug
11545503|NCT01036035|Placebo Comparator|Treatment E|Placebo
11545504|NCT01036035|Active Comparator|Treatment A|Study Drug
11545505|NCT01036035|Active Comparator|Treatment C|Study Drug
11545506|NCT01036022|Experimental|Group 2|ASACOL 800mg t.i.d.
11545509|NCT01036009|No Intervention|Group I: Observation|Group I (observation): Patients with full donor chimerism and no evidence of MRD continue to undergo clinical monitoring for acute and chronic graft-vs-host disease and relapse until 3 years post-transplant. Patients undergo repeat chimerism testing at 12 and 24 months post-transplant.
11545510|NCT01036009|Experimental|Group II: Intervention|Group II (intervention): Patients undergo withdrawal of immunosuppression and receive donor lymphocyte infusions between days 60-365 post-transplant (or until full donor chimerism is achieved). Patients also undergo clinical monitoring and repeat chimerism testing as in group I.
11545511|NCT01035983|Experimental|Frovatriptan 2.5 mg|Frovatriptan 2.5 mg tablets administered orally 2 x 2.5 mg twice daily (loading dose) on day 1, followed by 2.5 mg twice daily days 2 to 6.
11545512|NCT01035944|Experimental|HemCon Operating Room|The HemCon dressing is the intervention for the HemCon Operating Room arm. The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
11545513|NCT01035944|Active Comparator|Control Operating Room|The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
11545514|NCT01035944|Experimental|HemCon Bedside|The intervention for the HemCon Beside arm is the HemCon Dressing. The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
11545515|NCT01035944|Active Comparator|Control Bedside.|The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
11545516|NCT01035905|Experimental|Nelfilcon A|Nelfilcon A contact lens
11545517|NCT01035905|Active Comparator|Narafilcon A|Narafilcon A contact lens
11545518|NCT01035879|Experimental|MBX-2982 25 mg|
11545519|NCT01035879|Experimental|MBX-2982 100 mg|
11545520|NCT01035879|Experimental|MBX-2982 300 mg|
11545521|NCT01035879|Active Comparator|Sitagliptin 100 mg|
11545522|NCT01035879|Placebo Comparator|Placebo|
11545523|NCT01035801|Experimental|IN105|Prandial Oral Insulin
11545524|NCT01035801|Active Comparator|Insulin Lispro Injection|
11545525|NCT01035788|Experimental|Mindfulness-Based CBCT|Mindfulness Based Cognitive Behavioral Conjoint Therapy for PTSD
11545526|NCT01035788|Active Comparator|CBCT Communication Skills|CBCT for PTSD - Communication Skills
11545527|NCT01035775|Experimental|Insertion|Inspection on colonoscope insertion in addition to inspection during withdrawal from the cecum.
11545528|NCT01035775|Active Comparator|Withdrawal|Inspection during withdrawal (usual care) without deliberate inspection during insertion.
11545529|NCT01035749|Experimental|AREPANRIX-ADJUVANTED F1 2D GROUP|Subjects received 2 doses of Arepanrix ™ formulation 1 adjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
11545530|NCT01035749|Experimental|AREPANRIX-ADJUVANTED F2 2D GROUP|Subjects received 2 doses of Arepanrix ™ formulation 2 adjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
11545531|NCT01035749|Experimental|AREPANRIX-ADJUVANTED F2 3D GROUP|Subjects received 3 doses of Arepanrix ™ formulation 2 adjuvanted vaccine on Day 0, Day 21 and Day 182 (booster).
11545532|NCT01035749|Experimental|AREPANRIX-UNADJUVANTED F2 2D GROUP|Subjects received 2 doses of Arepanrix ™ unadjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
11545533|NCT01035671|Experimental|Low Dose|A0001 (0.5 g BID)
11545534|NCT01035671|Experimental|High Dose|A0001 (0.75 g BID)
11545535|NCT01035671|Placebo Comparator|Placebo|Placebo
11545536|NCT01035658|Experimental|Dose Level 1|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (40mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
11545537|NCT01035658|Experimental|Dose Level -1|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (30mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
11545538|NCT01035658|Experimental|Dose Level 1 Sequential|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (30mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
11545539|NCT01035658|Experimental|Dose Level 2 Sequential|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (40mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
11545540|NCT01035645|Experimental|GSK1070806 or placebo|This is a single dose escalating study. On enrolment into the study, each subject will be assigned to a group. These groups will be aligned to specific dose levels of GSK1070806. All subjects will be randomised to receive either a single intravenously administered dose of GSK1070806 or matching placebo (saline). The randomisation is generated by GSK prior to study start.
11545541|NCT01035619|Experimental|Moxidectin|
11545542|NCT01035606|Experimental|Goal-oriented Attention Regulation Training|training in goal-directed attention regulation
11545543|NCT01035606|Active Comparator|Education|brain health education
11545544|NCT01035606|Experimental|Technology-assisted Goal-directed Self-Regulation Training|computer-assisted training in goal-directed attention regulation
11545545|NCT01035593|Active Comparator|Standard of Care (PP + IVIG)|Plasmapheresis and IVIG 100mg/kg every other day x 5 treatments
11545546|NCT01035593|Experimental|PP + IVIG + rhC1INH|Plasmapheresis + 100mg/kg IVIG every other day x 5 treatments plus rhC1Inh 100u/kg IV daily x 7 consecutive days (once daily on PP days, twice daily on non-PP days).
11545819|NCT01033526|Placebo Comparator|Arm 2|
11545547|NCT01035580|Experimental|curcurim|This was a 3 + 3 dose escalation trial starting at 500 mg of cur cumin capsules administered daily intravaginally for 14 days. The dose increased after safety was demonstrated in 3 subjects by 500 mg up to a max of 2000 mgs.
11545548|NCT01035567|Active Comparator|Hybrid revascularization|
11545549|NCT01035567|Active Comparator|Coronary Artery Bypass Grafting|
11545550|NCT01035554|Active Comparator|Usual Care (UC) + Printed Materials (PM)|If the participant is assigned to UC, they will receive standard care. They will not receive a HBPM to use for the study, but will be given one to keep at the 3 month Follow-Up Visit. If they are also assigned to PM, they will then be given written materials (pamphlets from the NIH) and will be asked to review the information in its entirety. The coordinator will be available to answer any questions they might have.
11545551|NCT01035554|Experimental|UC + Self-Paced Program Instruction (SPPI)|If the participant is assigned to UC, they will receive standard care. They will not receive a HBPM to use for the study, but will be given one to keep at the 3 month Follow-Up Visit. If they are also assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials from the National Institutes of Health.
11545552|NCT01035554|Experimental|Home Blood Pressure Monitor (HBPM) + PM|If the participant is assigned to HBPM, they will be asked to use the monitor once a day in the morning and once before they go to bed any 3 days of the week, each week of the study (total = 12 weeks). They will be asked to record their BP values in diaries they will be given to take home with them. If they are also assigned to PM, they will then be given written materials (pamphlets from the NIH) regarding hypertension education and will be asked to review the information in its entirety. The coordinator will be available to answer any questions they might have.
11545553|NCT01035554|Experimental|HBPM + SPPI|"If the participant is assigned to HBPM, they will be asked to use the monitor once a day in the morning and once before they go to bed any 3 days of the week, each week of the study (total = 12 weeks). They will be asked to record their BP values in diaries they will be given to take home with them.
~If they are also assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the PM from the National Institutes of Health."
11545554|NCT01035541||P group|Fluid Management according to measurements with PiCCO®
11545555|NCT01035541||C group|Conventional fluid management
11545556|NCT01035528|Active Comparator|insulin glargine|antidiabetic treatment with Lantus o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
11545557|NCT01035528|Active Comparator|metformin|use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
11545558|NCT01035515|Experimental|Arm One|Arm 1 of 6 cross-over arms
11545559|NCT01035515|Experimental|Arm Two|Arm 2 of 6 cross-over arms
11545560|NCT01035515|Experimental|Arm Three|Arm 3 of 6 cross-over arms
11545561|NCT01035515|Experimental|Arm Four|Arm 4 of 6 cross-over arms
11545562|NCT01035515|Experimental|Arm Five|Arm 5 of 6 cross-over arms
11545563|NCT01035515|Experimental|Arm Six|Arm 1 of 6 cross-over arms
11545564|NCT01035502|Experimental|Elacytarabine plus idarubicin|
11545565|NCT01035489|Active Comparator|CRT; RV apical lead placement|Right ventricular apical lead placement in CRT
11545566|NCT01035489|Active Comparator|CRT; RV high posterior septum|High posterior septal lead placement in CRT
11545567|NCT01035476|Experimental|Data Card Report|Patients receive detailed reports of acceptance and adherence, with linked recommendations to optimize NIPPV.
11545568|NCT01035476|No Intervention|Standard NIPPV Care|Patients receive routine monitoring and care related to NIPPV.
11545569|NCT01035463|Experimental|Treatment (stem cell transplantation)|"PRE-CONDITIONING (patients with CD20+ NHL): Patients receive rituximab IV per standard of care.
~PREPARATIVE REGIMEN: Patients receive carmustine IV on day -6, etoposide IV BID and cytarabine IV BID on days -5 through -2, and melphalan IV on day -1.
~AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: Patients undergo stem cell infusion on day 0.
~MAINTENANCE THERAPY: Beginning approximately 100 days post-transplant, patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity."
11545570|NCT01035450|Experimental|Everolimus-eluting stent|
11545571|NCT01035450|Active Comparator|Sirolimus-eluting stent|
11545572|NCT01035437|Experimental|HPPH|HPPH
11545573|NCT01035411|Experimental|1|AZD9668 2X30mg tablet
11545574|NCT01035385|Experimental|FOFLOX4,resectable liver metastasis from CRC|
11545575|NCT01035372|Experimental|dried plum|subjects will have 25% by weight (~ 600 kcal if eat 2500 kcal diet) of their usual diet substituted by dried plum powder
11545576|NCT01035359|Active Comparator|external fixation|Operation with external fixation and optional addition of k-wire
11545577|NCT01035359|Experimental|Volar plate|Operation with a Synthes volar two column plate (TCP)
11545578|NCT01035346|Experimental|A|
11545579|NCT01035346|Placebo Comparator|B|
11545580|NCT01035333|Experimental|orlistat 60mg|Patients assigned to treatment group for up to 6 months of therapy.
11545581|NCT01035320|Experimental|simvastatin + ezetimibe|Cross-over study with placebo only run-in period. All patients participate in this arm with simvastatin + ezetimibe either as first treatment period (8-10 weeks)or second treatment period (8-10 weeks). The primary comparison is ezetimibe vs. placebo on top of simvastatin. A secondary comparison will be simvastatin vs. placebo run-in.
11545582|NCT01035307||Genomic and Proteomic Profiling|
11545583|NCT01035294|Experimental|mindfulness based intervention|
11545584|NCT01035294|Active Comparator|usual care (UC)|
11545585|NCT01035281|Experimental|Nabilone|A one-week screening period will occur, during which pain scores and sleep scores will be tabulated. Following screening, a 4-week period of single blind treatment with flexible dosing of nabilone at 0.5 - 4 mg/day will initiate.
11545621|NCT01035034|Active Comparator|PCI with stenting|Percutaneous Coronary Intervention
11545725|NCT01034228|Placebo Comparator|ORS without Isoleucine|ORS without Isoleucine for the treatment of diarrhoea in children
11545586|NCT01035281|Placebo Comparator|Placebo|All subjects who experience at least a 30% reduction in their weekly mean pain score during the single blind flexible dosing phase will be considered a responder, and will be further continued in the study. During the double-blind portion of the study, subjects randomized to nabilone will continue on the dose of nabilone achieved at the completion of the single-blind phase, and this dose will be maintained throughout the double-blind phase. Subjects randomized to placebo will receive 1 mg of nabilone daily for one week, followed by 4 consecutive weeks of placebo. This dose of nabilone will permit a tapering for those subjects achieving a higher daily dose of nabilone during the single-blind phase, or will maintain those who were taking only 1 mg per day in the single-blind phase, preventing an abrupt termination of treatment in subjects who are randomized into the placebo portion.
11545587|NCT01035268|Experimental|surgery by fatty tissue transfer|
11545588|NCT01035268|No Intervention|simple supervision|
11545589|NCT01035255|Experimental|LCZ696|single-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks. Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization. LCZ696 200mg BID during double blind treatment period
11545590|NCT01035255|Active Comparator|Enalapril|single-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks. Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization. Enalapril 10 mg BID during double blind treatment period
11545591|NCT01035242|Experimental|"association splitting"|Association splitting (6 sessions) delivered by psychologists.
11545592|NCT01035242|Active Comparator|cognitive remediation|CogPack training(6 sessions) delivered by either psychologists or psychology students at an advanced master level.
11545593|NCT01035229|Experimental|Everolimus + Best Supportice Care (BSC)|Patients were assigned to the Everolimus + BSC arm in a ratio of 2:1 over the Placebo arm. Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the investigational drug. In addition to taking Everolimus, all patients also received BSC as per normal local practice.
11545594|NCT01035229|Placebo Comparator|Placebo + Best Supportive Care|Placebo Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the control drug. In addition to taking Placeb Everolimus, all patients also received BSC as per normal local practice.
11545595|NCT01035216|Experimental|GNKG168|The starting dose will be 0.25 mg/kg. If the dose is tolerable, subsequent cohorts will be enrolled and treated with 0.5, 0.75, 1.0 and 1.5 mg/kg. If 0.25 mg/kg proves to be intolerable, the dose will be reduced to 0.15 mg/kg.
11545596|NCT01035203|Active Comparator|Cognitive behavioural therapy|
11545597|NCT01035203|Experimental|Exercise|Endurance training (walking on a treadmill) 3 x weekly for 4 weeks
11545598|NCT01035190|Experimental|inhaled Budesonide|
11545599|NCT01035177||Control|Women without hip fracture, matched on age to the cases
11545600|NCT01035177||Patient|Female patients aged 60 and older with hip fracture
11545601|NCT01035164|Experimental|Arm 1|
11545602|NCT01035164|Experimental|Arm 2|
11545603|NCT01035164|Experimental|Arm 3|
11545604|NCT01035151|Active Comparator|Delayed Control|Women in the delayed control condition received culturally sensitive smoking cessation written materials at week 1, and mailed materials at week 6, 12, and 18. At the end of the study (i.e., after the 12 month data collection), participants were offered counseling, nicotine patches, and community health worker contacts.
11545605|NCT01035151|Experimental|Experimental|Women in neighborhoods randomized to the S2S received 24-week bundled multi-level intervention. Individual-led strategies were led by paid community health workers (CHWs). The CHWs provided 1:1 contact to reinforce social support, and enhanced self-efficacy with cessation attempts. A certified smoking cessation counselor led behavioral group sessions using the S2S handbook based on the PHS Guidelines. The weekly group sessions were initiated during the 1st week of the intervention, with a total of 6 group sessions over a 6-week period. Transdermal nicotine patches were offered to participants who set a quit date. Within the 24-week study period, the neighborhood tenant association, in partnership with study staff, implemented at least two neighborhood level anti-smoking activities
11545606|NCT01035138|Experimental|Drug: semagacestat|
11545607|NCT01035125|No Intervention|Waiting list|
11545608|NCT01035125|Experimental|Self-management program|One week self-management program
11545609|NCT01035112||MRI|Contrast-enhanced MRI using the standard department of Radiology MRI screening procedures. The duration of scanning may be variable, but will not exceed 90 minutes.
11545610|NCT01035099|Experimental|Titrated dose Letrozole|Patients who are randomized to the titrated dose of Letrozole, will start gonadotropins in the evening of day #2 of their menstrual cycle with injectable follicle stimulating hormone (FSH) and human menopausal gonadotropin (HMG). Oral Letrozole will be added to the stimulation in the following titrated regimen.
11545611|NCT01035099|Active Comparator|Fixed dose Letrozole|Patients who are randomized to fixed dose Letrozole will start Letrozole 5mg daily (orally) on the second day of their menstrual cycle and then gonadotropins on the fourth day of their menstrual cycle.
11545612|NCT01035086|Experimental|Boregine|Intervention: Lupinus angustifolius Boregine; 25 g lupin kernel fibre per day over 4 weeks; lupin kernel fibre was incorporated in different food
11545613|NCT01035086|Active Comparator|Reference|Intervention: Reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood ingredients); 25 g citrus fibre per day over 4 weeks; the citrus fibre was incorporated in different food
11545614|NCT01035086|Placebo Comparator|Placebo|different food without added fibre
11545615|NCT01035073|Experimental|Duloxetine|
11545616|NCT01035060||Older Adult|Healthy Men and Women Over 70 Years of Age
11545617|NCT01035060||Young Adult|Healthy Men and Women Aged 18-30 Years
11545618|NCT01035047|No Intervention|Inpatient Care|This is the comparison arm. Patients are admitted to the hospital and undergo usual care.
11545619|NCT01035047|Experimental|CDU-CMR Protocol|Patients will be transferred to the clinical decision unit and undergo a stress cardiac MRI evaluation.
11545620|NCT01035034|Experimental|One-stop hybrid coronary revasularization|Percutaneous Coronary Intervention; Coronary Artery Bypass
11545622|NCT01035021|Active Comparator|group N|Anesthesia is induced with propofol and remifentanil and LMA is inserted by the standard technique according to eht manufacturer's instruction. Rocuronium is administered for the operation.
11545623|NCT01035021|Active Comparator|group R|Anesthesia is induced with a propofol and remifentanil and rocuronium 0.06 mg/kg is injected. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction.
11545624|NCT01035008|Experimental|Diagnostic|The investigators are testing a new method called confocal laser endomicroscopy to see if it can detect pre-cancerous abnormalities in the lining of the cysts found in your pancreas. This will involve using a very thin fiber-shaped microscope which will be passed through a needle during the EUS procedure.
11545625|NCT01034995|Experimental|SSR125543 20 mg|1 capsule of SSR125543 20 mg + 1 capsule of placebo
11545626|NCT01034995|Experimental|SSR125543 50 mg|1 capsule of SSR125543 50 mg + 1 capsule of placebo
11545627|NCT01034995|Experimental|SSR125543 100 mg|2 capsules of SSR125543 50 mg
11545628|NCT01034995|Active Comparator|escitalopram 10 mg|1 capsule of escitalopram 10 mg + 1 capsule of placebo
11545629|NCT01034995|Placebo Comparator|placebo|2 capsules of placebo
11545630|NCT01034982|Experimental|1|tosylate salt tablet
11545631|NCT01034982|Experimental|2|free suspension
11545632|NCT01034982|Experimental|3|tosylate salt tablet
11545633|NCT01034982|Experimental|4|free suspension
11545634|NCT01034969||Participants with hereditary angioedema (HAE)|All participants with hereditary angioedema (HAE) who are administered Cinryze (C1 inhibitor [human]) or Firazyr (Icatibant) for the treatment or prevention of angioedema attacks in routine clinical practice will be included into the study.
11545635|NCT01034956||Facial Soft Tissue Filler Patients|Patients previously treated by Principal Investigator with facial soft tissue fillers within the past 2 years
11545636|NCT01034943|Active Comparator|External fixation|Operation with external fixation and optional addition of k-wire
11545637|NCT01034943|Active Comparator|Volar plate|Operation with Synthes volar two column plate (TCP)
11545638|NCT01034930|Active Comparator|Retentive Anchors|23 patients will receive as retention system for overdentures Retentive Anchors (Straumann).
11545639|NCT01034930|Active Comparator|Magnets|23 patients will receive Magnets (Straumann) as retention system for overdenture.
11545640|NCT01034930|Active Comparator|Locator System|23 patients will receive Locator System (Straumann) as retention for the mandibular overdenture.
11545641|NCT01034917|Experimental|Etravirine group|To switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
11545642|NCT01034917|Active Comparator|Control group|Continue with the same antiretroviral regimen
11545643|NCT01034904||Patients|Patients who have moderate or severe Hemophilia A, living in Canada and who are using Helixate FS either on-demand or prophylaxis
11545644|NCT01034878|Experimental|Sunitinib|50 mg once daily 6 weeks cycle 4 weeks on and 2 weeks off
11545645|NCT01034865||HCC PTS|Patients with HCC with either: (i) a hepatic mass larger or equal to 5cm, or; (ii) a hepatic mass lesion confirmed by fine needle aspirate (FNA) or by pathology in the cases of surgical resection, or; (iii) a hepatic mass lesion with characteristic CT or MRI or angiographic appearance.
11545646|NCT01034865||LD|Patients with chronic liver disease without evidence of HCC
11545647|NCT01034852||Surgical ablation|Patients undergoing surgical ablation for Atrial Fibrillation that have failed one or more previous attempts at catheter ablation for Atrial Fibrillation
11545648|NCT01034839||acute myeloid leukemia, adults|Adults treated for acute myeloid leukemia in our hospital between 1978 and 2007
11545649|NCT01034826||life style modification|everyone in this study was advised about their life style, diet, exercise habits.
11545650|NCT01034813||Burn Range of motion|burn patients with hypertropic scar
11545651|NCT01034813||control range of motion|control subjects without scaring
11545652|NCT01034787|Experimental|Open Label CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of every 90-day cycle for up to 4 cycles or until disease progression or intolerance of toxicity.
11545653|NCT01034774|Active Comparator|ACHN-490 Injection|ACHN-490 Injection will be given either 1 or 5 consecutive days at a dose of 15mg/kg.
11545654|NCT01034774|Placebo Comparator|Placebo is Normal Saline|Placebo will be given either 1 or 5 consecutive days to mask when ACHN-490 Injection is given.
11545655|NCT01034761|Experimental|Pop-up alerts|Providers will receive pop-up alerts in the electronic medical record when prescribing one of the specified medications from the Beers list.
11545656|NCT01034761|No Intervention|Usual care|
11545657|NCT01034748|Experimental|1|Single 45 mg oral dose of [14C]PF-00299804
11545658|NCT01034735|Experimental|Arm A|
11545659|NCT01034735|Experimental|Arm B|
11545660|NCT01034735|Experimental|Arm C|
11545661|NCT01034722||Western Diet|Volunteer mothers with western diet.
11545662|NCT01034722||Vegetarians|volunteer mothers with vegetarians diet
11545663|NCT01034722||Bedouins|Volunteer mothers who are Bedouins
11545664|NCT01034709||Symptomatic|Subjects with a confirmed CMV viremia by the site's CMV-LDT as well as CMV symptoms
11545665|NCT01034709||Asymptomatic|Subjects who must have been serologically positive for CMV IgG prior to transplantation and do not have any CMV symptoms
11545666|NCT01034683|Experimental|Esophageal Carcinoma|
11545667|NCT01034670|Experimental|endoscopy arm|imaging performed in conjunction with the regularly scheduled endoscopy during which the newer imaging techniques will be used to detect premalignant conditions. includes wide field fluorescence, microscopy, Raman spectroscopy and/or ultrasound.
11545668|NCT01034657|Experimental|LBH589|During the core phase, all participants received oral LBH589 40 mg (30 mg after a protocol amendment) for 4 months. During the randomization phase, participants with hematological improvement of the erythropoetic system (HI-E) and participants with stable disease, who were randomized to single agent LBH589, continued on single agent LBH589 40mg/30mg for an additional 4 months.
11545669|NCT01034657|Experimental|LBH589 + Epoetin Alfa|During the randomized phase, participants randomized to LBH589 + Epoetin Alfa (ESA) received oral LBH589 40mg/30mg + ESA 30000 international units (IU)/week injected subcutaneously for 4 months.
11545670|NCT01034644||PRISMS patients|This single group includes all the patients from the PRISMS study
11545671|NCT01034631|Active Comparator|Combination Arm A: Everolimus + BNC105P|Combination Arm A: Everolimus 10 mg, BNC105P MTD (from Phase 1 study) 21 day cycle
11545672|NCT01034631|Active Comparator|Sequential Arm B:Everolimus followed by BNC105P Monotherapy|"Sequential Arm B: Everolimus 10 mg, 21 day cycle
~Patients to receive BNC105P monotherapy at 16 mg/m2 following progression or intolerable toxicity on everolimus therapy."
11545673|NCT01034618|Placebo Comparator|Placebo|
11545674|NCT01034618|Experimental|Intact protein|
11545675|NCT01034618|Experimental|Protein hydrolysate|
11545676|NCT01034605|Experimental|inulin|oligofructose
11545677|NCT01034592|Experimental|Lenalidomide|Subjects will initially receive lenalidomide 2.5 mg, and may escalate up to 2.5 mg/wk up to 5 mg 3x/wk, depending toxicity and response.
11545678|NCT01034579|Other|Rebif® Cohort|
11545679|NCT01034579|Other|Copaxone® Cohort|
11545680|NCT01034566|Experimental|Arm I|Patients undergo proton beam radiotherapy 5 days a week for 6 (preoperative patients) or 8 (post-operative patients) weeks in the absence of disease progression or unacceptable toxicity.
11545681|NCT01034553|Experimental|Arm I|Patients receive oral aurora A kinase inhibitor MLN8237 once daily on days 1-14 and bortezomib IV on days 1, 4, 8 and 11.
11545682|NCT01034540|Experimental|POM3|POM3 for the first six weeks of treatment. Placebo for the second six weeks of treatment
11545683|NCT01034540|Placebo Comparator|Placebo|Placebo for the first six weeks of treatment. POM3 for the second six weeks of treatment
11545684|NCT01034527|Experimental|Neuromuscular Training|Combination of exercises and phases designed to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
11545685|NCT01034527|No Intervention|Speed Training|Sham training will consist of sagittal plane only running drills designs solely to enhance sprint speed. A sham sagittal plane sprint training protocol that will be instituted with the teams that are randomly selected for sham treatment. Five phases will be utilized to facilitate progressions designed to improve the athletes' forward sprinting speed. Training volume will be approximately equivalent for the TNMT and sham protocols. They each will take athletes approximately 30 minutes to complete
11545686|NCT01034514|Experimental|4DCT arm|Patients breathe in 99mTc-DTPA and then undergo ventilation scans using a SPECT scanner over 2 hours. Patients also receive 99mTc-MAA IV and then undergo perfusion scans using a SPECT scanner over 2 hours. Patients may also undergo a pre- and post-treatment Xe-CT ventilation scan over 15 minutes and a pre-treatment 4D-CT scan over 5-10 minutes.
11545687|NCT01034501|Active Comparator|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
11545688|NCT01034501|Sham Comparator|sham procedure|Not activation of laser device
11545689|NCT01034488|Active Comparator|Heparin sodium - APP|5000UI / mL
11545690|NCT01034488|Experimental|Heparin - Eurofarma|5000 UI/ mL
11545691|NCT01034475|Experimental|CPI-613|CPI-240 mg/m2
11545692|NCT01034462|Experimental|1|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing.
11545693|NCT01034462|Placebo Comparator|2|Matching placebo capsules, oral administration, once daily dosing.
11545694|NCT01034436|Placebo Comparator|Low intake of ALA and triacylglycerols|Sunflower oil
11545695|NCT01034436|Experimental|high intake of ALA and triacylglyceroles|Canola and linseed oils
11545696|NCT01034436|Experimental|high intake of ALA and diacylglycerols|Canola and linseed oils
11545697|NCT01034423|Experimental|omega-3 high quality|
11545698|NCT01034423|Experimental|omega-3 low quality|
11545699|NCT01034423|Placebo Comparator|placebo|
11545700|NCT01034410|Active Comparator|Control|cytarabine 2g/m2 bid Days 4-7
11545701|NCT01034410|Experimental|AS1411-40|AS1411 40mg/kg/day d1-7 plus cytarabine 2g/m2 bid days 4-7
11545702|NCT01034410|Experimental|AS1411-80|AS1411 80mg/kg/day d1-7, cytarabine 2g/m2 bid days 4- 7/ bid d4-7
11545703|NCT01034397|Experimental|1|
11545704|NCT01034397|Placebo Comparator|2|
11545705|NCT01034371|Experimental|One-stop hybrid revasularization|
11545706|NCT01034371|Active Comparator|Off-pump coronary artery bypass|
11545707|NCT01034358|Experimental|Human Papillomavirus Vaccine|The Gardasil HPV vaccine was administered in 3 doses: baseline, 2 months, and 6 months.
11545708|NCT01034345|Experimental|Sirolimus|Patients randomized to this arm will discontinue maintenance immunosuppression based on calcineurin inhibitors and start treatment with sirolimus.
11545709|NCT01034345|Active Comparator|Calcineurin inhibitor|Patients randomized to this arm will keep the same maintenance immunosuppression based on calcineurin inhibitors.
11545710|NCT01034332|Experimental|One-cycle induction chemotherapy|TP-HDFL, TP-CCRT, Esophagectomy
11545711|NCT01034319|Experimental|Diabetes Genetic Counseling|Subjects will have been genotyped and will received genetic counseling based on their results
11545712|NCT01034319|Placebo Comparator|No Genotyping or Counseling|Patients will not be genotyped and will therefore not receive genetic counseling
11545713|NCT01034306|Experimental|CF101 1 mg|
11545714|NCT01034306|Placebo Comparator|Placebo|
11545715|NCT01034293|Experimental|low feeding frequency (3x)|
11545716|NCT01034293|Experimental|High feeding frequency (14x)|
11545717|NCT01034267|Experimental|1|(Open-label) F2695 SR capsules, oral administration, once daily, flexible dosing
11545718|NCT01034254|Experimental|influenza vaccine|Pregnant women assigned to the intervention group will receive one dose of seasonal influenza vaccine at the time of enrollment. The vaccine that will be given will be the current seasonal influenza recommended vaccine at the time of enrollment.
11545719|NCT01034254|Placebo Comparator|saline placebo|Pregnant women assigned to the control group will receive one dose of placebo (normal saline).
11545720|NCT01034241|Experimental|Control|Diet consists of 15% dairy protein and low Glycemic Index (GI < 40), 55 En% carbohydrates and 30 En% fat
11545721|NCT01034241|Experimental|High dairy protein|Diet consists of 25% dairy protein and low GI (GI < 40), 45 En% carbohydrates and 30 En% fat
11545722|NCT01034241|Experimental|vegetable protein|Diet consists of 15 En% vegetable protein and low GI (GI < 40), 55 En% carbohydrates and 30 En% fat
11545723|NCT01034241|Experimental|High GI|Diet consists of 15 En% dairy protein and high GI(GI > 60, 55 En% carbohydrates and 30 En% fat
11545724|NCT01034228|Active Comparator|Isoleucine|Glucose ORS with L-Isoleucine
11545726|NCT01034215|Active Comparator|Imagery Practice, live trainer|Patients attend a five week training program, with the instructor in the room with them, and actively practice imagery techniques, both in the classroom, and daily, outside of the classroom. Classes are four hours a week for five weeks. Patients practice what they learn for a full 17 weeks, beginning with the first week of class.
11545727|NCT01034215|Active Comparator|"Envision the Rhythms of Life /video"|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD.
11545728|NCT01034215|No Intervention|Waitlist Control Group|No treatment delivery during the 17 weeks of testing live delivery (trainer in the room with patients) vs. distance delivery (trainer delivers program via telemedicine/videoconferencing equipment)
11545729|NCT01034202|Experimental|Norditropin® SimpleXx® 0.02 mg/kg + NNC126-0083|
11545730|NCT01034202|Experimental|Norditropin® SimpleXx® 0.04 mg/kg + NNC126-0083|
11545731|NCT01034202|Placebo Comparator|Norditropin® SimpleXx® 0.02 mg/kg + placebo|
11545732|NCT01034202|Placebo Comparator|Norditropin® SimpleXx® 0.04 mg/kg + placebo|
11545733|NCT01034202|Experimental|NNC126-0083|
11545734|NCT01034202|Placebo Comparator|Placebo|
11545735|NCT01034189|Experimental|Targeted therapy|Concurrent chemoradiotherapy with cetuximab, paclitaxel, and cisplatin followed by, if feasible, esophagectomy
11545736|NCT01034176|Active Comparator|Levofloxacin|Levofloxacin 500 mg every day (dose adjusted for renal function) for 30 days
11545737|NCT01034176|Placebo Comparator|placebo|placebo identical to levofloxacin drug daily for 30 days
11545738|NCT01034163|Experimental|Panobinostat (PAN)|Participants received 45 mg orally 3 times a week (TIW), every other week (QOW),
11545739|NCT01034163|Placebo Comparator|Placebo|Participants received matching placebo to PAN TIW, QOW.
11545740|NCT01034150|Active Comparator|Somatosensory stimulation|Active group
11545741|NCT01034150|Placebo Comparator|Control group|Placebo stimulation
11545742|NCT01034137|Experimental|Tocilizumab + Methotrexate|Participants will receive intravenous (IV) TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + oral capsules of MTX 10-30 mg/week in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week. The weekly dose of MTX will be taken on one particular day of the week.
11545743|NCT01034137|Active Comparator|Tocilizumab + Placebo Methotrexate|Participants will receive IV TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + weekly oral matching placebo MTX capsules in climbing dosages. The weekly dose of placebo MTX will be taken on one particular day of the week.
11545744|NCT01034137|Active Comparator|Methotrexate + Placebo Tocilizumab|Participants will receive weekly oral MTX in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week + matching placebo TCZ IV 8 mg/kg every four week for a maximum of 26 infusions. The weekly dose of MTX will be taken on one particular day of the week.
11545745|NCT01034124|Placebo Comparator|Water|
11545746|NCT01034124|Active Comparator|Cranberry juice|
11545747|NCT01034111|Experimental|Sitagliptin|Sitagliptin as add-on therapy to a stable dose of metformin
11545748|NCT01034098||Post-menopausal women|Post-menopausal women (without hormone replacement therapy)
11545749|NCT01034046|Active Comparator|Insulin Sensitive Study Participants|Insulin sensitive subjects stratified using fasting insulin levels.
11545750|NCT01034046|Active Comparator|Insulin Resistant Study Subjects|Insulin resistant subjects stratified using fasting insulin levels.
11545751|NCT01034007|Experimental|Tissue Engineered Vascular Grafts|
11545752|NCT01033994|Experimental|AS902330|
11545753|NCT01033994|Placebo Comparator|Placebo|
11545754|NCT01033981||Central America and Caribbean|Dominican Republic, Guatemala, Panama, Costa Rica, Honduras, Trinidad & Tobago
11545755|NCT01033955|Experimental|Drug (Rosuvastatin) Crestor|The first dose of encapsulated study drug or placebo (day 1) will be administered within 4 hours of randomization as a loading dose of 40 mg. The placebo will be identical in appearance to Rosuvastatin. Thereafter, doses of 20 mg will be administered daily starting on the next calendar day at 10 pm daily (+/- 4 hours) as a maintenance dose from days 2 to 14. If the patient is of Asian descent, is <18 years, or serum creatinine is greater than or equal to 248 μmol/L (2.8 mg/dL) dose adjustments will be made according to a dose adjustment algorithm.
11545756|NCT01033955|Placebo Comparator|Placebo|An identical appearing placebo will be administered to patients in the second study arm.
11545757|NCT01033942|Experimental|FTC/TDF as PrEP|Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
11545758|NCT01033942|Placebo Comparator|Placebo Pill Control|Blinded administration of placebo pill; HIV behavioral intervention
11545759|NCT01033942|Active Comparator|No Pill Control|Subjects receive HIV behavioral intervention but no pill.
11545760|NCT01033929|Experimental|0.01µg C-Tb|12-24 patients depending on a safety evaluation will receive a low dose of 0.01 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.
11545761|NCT01033929|Experimental|0.1µg C.Tb|12-24 patients depending on a safety evaluation will receive a high dose of 0.1 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.
11545762|NCT01033916|No Intervention|STRICT Glucose Control (80-120 mg/dL)|The STRICT arm of the study will have a target Blood Glucose level ranging from 80-120 mg/dL. This is currently the standard of care for post CABG patients.
11545763|NCT01033916|Active Comparator|LIBERAL (Target Glucose:121-180 mg/dL)|
11545764|NCT01033903|Experimental|Misoprostol 800 micrograms intravaginally|
11545765|NCT01033903|No Intervention|expectant managment|
11545766|NCT01033877|Experimental|TdaP vaccine|
11545767|NCT01033877|Active Comparator|Td vaccine|
11545768|NCT01033864|Experimental|MMF, Prednisone|Participants received mycophenolate mofetil (MMF) orally (PO) at a dose of 1 gram per day (g/day) twice daily (BID), and prednisone, PO, up to 5 milligrams per day (mg/day) for at least 1 month.
11545769|NCT01033864|Active Comparator|EC-MPS|Participants received mycophenolate sodium (EC-MPS), PO, at a dose of 720 mg/day BID, and prednisone PO up to 5 mg/day for at least 1 month.
11545770|NCT01033851|Active Comparator|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is an 8-week group intervention that trains participants in mindfulness meditation techniques.
11545771|NCT01033851|Active Comparator|Stress Management Education|Stress Management Education (SME) is an 8-week group intervention that educates participants about stress physiology and health lifestyle changes.
11545772|NCT01033838|Active Comparator|laparoscopic-assisted rectosigmoid resection|
11545773|NCT01033838|Experimental|laparoscopic rectosigmoid resection and transrectal retrieval|
11545774|NCT01033825|Experimental|Ciclesonide HFA Nasal Aerosol 320 mcg|Ciclesonide HFA Nasal Aerosol 320 mcg once daily
11545775|NCT01033825|Experimental|Ciclesonide HFA Nasal Aerosol 160 mcg|Ciclesonide HFA Nasal Aerosol 160 mcg once daily
11545776|NCT01033825|Placebo Comparator|HFA Nasal Aerosol placebo|HFA Nasal Aerosol Placebo once daily
11545777|NCT01033825|Experimental|Ciclesonide Aqueous Nasal Spray 200 mcg|Ciclesonide Aqueous Nasal Spray 200 mcg once daily
11545778|NCT01033825|Placebo Comparator|AQ Nasal Spray Placebo|AQ Nasal Spray Placebo once daily
11545779|NCT01033825|Active Comparator|Placebo HFA plus Dexamethasone 6 mcg|Placebo HFA plus Dexamethasone 6 mg once daily
11545780|NCT01033825|Active Comparator|Placebo AQ plus Dexamethasone 6 mg|Placebo AQ plus Dexamethasone 6 mg once daily
11545781|NCT01033812||Index Recruiter|Young African American or Latina women who served as index recruiters in ATN 067 and members of their female friendship network members who tested HIV positive based on HIV screening and a confirmatory test result that was conducted in ATN 067.
11545782|NCT01033812||Male Sexual Partners|Any male partner who engaged in at least one episode of oral, vaginal or anal sex during the course of their lifetime with an 084 index recruiter.
11545783|NCT01033799|Sham Comparator|Control Product|
11545784|NCT01033799|Active Comparator|Tested Product|
11545785|NCT01033773|Other|Diabetes education and medication management|All enrolled patients received the intervention. There was no comparative arm. The analysis was done as pre and post.
11545786|NCT01033760|Experimental|arm 1|darunavir, ritonavir, emtricitabine/tenofovir, maraviroc, raltegravir
11545787|NCT01033760|Active Comparator|arm 2|darunavir, ritonavir, emtricitabine/tenofovir
11545788|NCT01033747|Experimental|Deferasirox|Deferasirox group consists of all participants who were initially randomized to 10 and 20 mg/kg/day deferasirox orally daily in the main study and remained on the same treatment during the comparative prolongation study (NCT00379483) and at the beginning of the 5-year non-comparative study
11545789|NCT01033747|Experimental|Deferasirox Crossover|Deferasirox Crossover group consists of participants who were initially randomized to 40 mg/kg/day deferoxamine (DFO)subcutaneously in the main study and comparative prolongation study and crossed over to 5mg/kg/day to 30 mg/kg/day deferasirox orally daily at the beginning of the 5-year non-comparative extension study
11545790|NCT01033734|Experimental|Single arm|
11545791|NCT01033708|Active Comparator|treatment as usual|Treatment as usual
11545792|NCT01033708|Experimental|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
11545793|NCT01033669||Dry Powder Inhalers|
11545794|NCT01033656|Experimental|Anakinra|experimental drug of study
11545795|NCT01033656|Active Comparator|comparator|comparators:methotrexate, azathioprine, leflunomide or supfasalazine
11545796|NCT01033643|Experimental|Panel A|0.25 mg MK3614 or Placebo
11545797|NCT01033643|Experimental|Panel B|0.50 mg and 0.25 mg MK3614 or Placebo
11545798|NCT01033643|Experimental|Panel C|0.50 mg and 0.25 mg MK3614 or Placebo
11545799|NCT01033643|Experimental|Panel D|0.50 mg MK3614 or Placebo
11545800|NCT01033643|Experimental|Panel E|0.50 mg, 0.25 mg and 0.75 mg MK3614 or Placebo
11545801|NCT01033630|Placebo Comparator|Placebo|Image-matched placebo of active treatment
11545802|NCT01033630|Active Comparator|D&G 1g|Randomly allocated into three groups, D&G capsule 1g/day
11545803|NCT01033630|Active Comparator|D&G 2g|Randomly allocated into three groups, D&G capsule 2g/day
11545804|NCT01033617|Placebo Comparator|Placebo|Saline solution with autologous plasma.
11545805|NCT01033617|Experimental|CD133+ stem cells|Autologous CD133+ intramyocardial injection at time of coronary artery bypass grafting.
11545806|NCT01033604|Experimental|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
11545807|NCT01033604|Active Comparator|Split skin graft alone|Full thickness defects treated with split skin graft alone.
11545808|NCT01033591|Experimental|Exercise|Supervised exercise + Optimized treatment according to the European Society of Cardiology guidelines
11545809|NCT01033591|Other|Control|Optimized treatment according to the European Society of Cardiology guidelines
11545810|NCT01033578|No Intervention|Control|Receive hepatectomy and thrombectomy alone, no postoperative adjuvant treatments
11545811|NCT01033578|Experimental|PVIC Group|Portal Vein Infusion Chemotherapy (PVIC): 5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) was continuously infused into portal vein through tube by a infusion pump implanted in operation. Treatment started 2 weeks after the operation and was repeated every 4 weeks for six cycles.
11545812|NCT01033578|Experimental|TACE Group|Transcatheter Arterial Chemoembolization (TACE): 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles.
11545813|NCT01033578|Experimental|PVIC+TACE Group|Combination of PVIC and TACE. PVIC started 2 weeks after operation and TACE started 6 weeks after operation. Both PVIC and TACE were repeated at 8 weeks intervals for 3 cycles.
11545814|NCT01033565|Experimental|Natrol|Subjects receive Natrol (sustained release melatonin) 5mg tablet 30 minutes prior to bedtime for 10 to 14 days
11545815|NCT01033552|Experimental|Transplant in Epidermolysis Bullosa|
11545816|NCT01033539|Active Comparator|Placebo control|Placebo control without probiotics ATCC PTA 4659
11545817|NCT01033539|Active Comparator|ATCC PTA 4659 Low dose|
11545821|NCT01033513||Literature Only (Control)|The participants on this arm served as the control group. Five types of literature were mailed to the participants in the literature only arm. A letter was included with the materials thanking participants for their participation, requesting that the participants read the literature, and encouraging them to contact the RDs with any questions. The Clinical Study Manager's telephone number was provided for questions about diet or lifestyle changes. The RDs documented all contacts with participants on a phone summary. Other than the delivery of literature and responses to specific questions asked by the participant or the participant's primary caregiver through telephone calls, the RDs had no further interaction with the participant until the conclusion of the participant's trial period.
11545822|NCT01033513||Meals Only|Participants in the meals only arm received a pre-intervention assessment (but no nutrition counseling). The RDs gave the participants in the meals only arm a phone number and encouraged them to phone with questions or problems, especially problems associated with the meals. Subsequently, the meals only participants received seven diagnosis-appropriate therapeutic meals a week, delivered once per week. The meals were specially designed to address the participants' medical diagnoses. They were developed using the ADA MNT protocols for caloric and nutrient content requirements for individuals with the specified diagnoses, in addition to meeting AoA Nutrition Program dietary requirements. The meals were provided primarily in frozen form. However, some shelf-stable and refrigerated components were also included. In conformance with AoA regulations, appropriate meals were also offered to the spouse of any participant receiving a therapeutic meal.
11545823|NCT01033513||MNT Only|The participants in this arm received MNT from the project RDs, who employed the Hyperlipidemia Medical Nutrition Therapy MNT Protocol, developed by ADA (2002). Because ADA had not finalized MNT protocols for hypertension, the RDs followed the protocol for hyperlipidemia for participants diagnosed with either hyperlipidemia or hypertension, with adjustments, as appropriate, to benefit those individuals who were diagnosed with hypertension.All MNT sessions were in the participants' homes, and if a caregiver was required for the individual to participate in the project, every effort was made to include this person in the MNT sessions. The MNT intervention took place over at least three sessions, and, in conformance with the ADA protocol, each participant received individualized counseling and education.
11545824|NCT01033513||Meals and MNT|The participants assigned to the MNT plus meals arm received both of the interventions, as described above.
11545825|NCT01033500|Experimental|SIK|Basiliximab induction with maintenance immunosuppression consisting of belatacept, sirolimus or everolimus, and mycophenolate after simultaneous islet kidney transplantation.
11545826|NCT01033487|Placebo Comparator|Placebo|
11545827|NCT01033487|Active Comparator|active comparator|
11545828|NCT01033487|Experimental|PF-03635659|
11545829|NCT01033474||donor eggs|
11545830|NCT01033474||infertile patients|
11545831|NCT01033461|Experimental|calcium and probiotic|intervention
11545832|NCT01033461|Experimental|probiotic|intervention
11545833|NCT01033461|Placebo Comparator|placebo|placebo, no intervention
11545834|NCT01033448|Experimental|Single arm|
11545835|NCT01033435||chronic Hemodialysis patients, treated in our unit.|
11545836|NCT01033435||chronic Hemodialysis patients , No intervention|chronic Hemodialysis patients, treated in our unit.
11545837|NCT01033422|Experimental|CF101 1mg|CF101 1mg orally q12 hours
11545838|NCT01033422|Placebo Comparator|Placebo|matching placebo orally q12 hours
11545839|NCT01033422|Experimental|CF101 2mg|CF101 2mg orally q12 hours
11545840|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^7|Arm 1 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^7 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^7 CFU oral dosage through Day 28.
11545841|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^8|Arm 2 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^8 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^8 CFU oral dosage through Day 28.
11545842|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^9|Arm 3 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^9 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^9 CFU oral dosage through Day 28.
11545843|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^10|Arm 4 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^10 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^10 CFU oral dosage through Day 28.
11545844|NCT01033396|Experimental|PF-03654764 + Allegra|
11545845|NCT01033396|Experimental|PF-03654764|
11545846|NCT01033396|Active Comparator|Allegra-D|
11545847|NCT01033396|Placebo Comparator|Placebo|
11545848|NCT01033383|Placebo Comparator|3 placebo capsules|3 placebo capsules qd
11545849|NCT01033383|Experimental|1 cranberry capsule & 2 placebo capsules|1 active cranberry capsule and 2 placebo capsules qd
11545850|NCT01033383|Experimental|2 cranberry capsules & 1 placebo capsule|2 active cranberry capsules and 1 placebo capsules qd
11545851|NCT01033383|Experimental|3 cranberry capsules|3 active cranberry capsules qd
11545852|NCT01033370|Other|Open label, non-randomized, pilot study|All subjects who provide consent for trial participation with an acute aortic emergency and elevated BP (systolic blood pressure [SBP] ≥120 mm Hg) requiring IV antihypertensive therapy for up to 48 hours will be administered an infusion of clevidipine to evaluate the efficacy and safety of the IV drug.
11545853|NCT01033357|Active Comparator|Graft, Vascular Wrap|Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
11545854|NCT01033357|Placebo Comparator|Graft|Lifespan® ePTFE Vascular Graft Only
11545855|NCT01033344|Placebo Comparator|Placebo|Solution resembling active solution but without peptides
11545856|NCT01033344|Experimental|Group 1|Cat-PAD dose group 1
11545857|NCT01033344|Experimental|Group 2|Cat-PAD Dose group 2
11545858|NCT01033318|Experimental|Part 1 A-1|"Part 1; Panel A; Sequence 1:
~2 mg MK1809 / placebo / 50 mg MK1809 / 150 mg MK1809 / 100 mg Losartan"
11546338|NCT01030081|Active Comparator|Nifedipine GITS (Adalat® XL 30)|
11545859|NCT01033318|Experimental|Part 1 A-2|"Part 1; Panel A; Sequence 2:
~Losartan / 10 mg MK1809 / placebo / 150 mg MK1809 / 280 mg MK1809"
11545860|NCT01033318|Experimental|Part 1 A-3|Part 1; Panel A; Sequence 3 2 mg MK1809 / 10 mg MK1809 / Losartan / Placebo / 280 mg MK1809
11545861|NCT01033318|Experimental|Part 1 A-4|Part 1; Panel A; Sequence 4 2 mg MK1809 / Losartan / 50 mg MK1809 / 150 mg MK1809 / Placebo
11545862|NCT01033318|Experimental|Part 1 A-5|"Part 1; Panel A; Sequence 5:
~Placebo / 10 mg MK1809 / 50 mg MK1809 / Losartan / 280 mg MK1809"
11545863|NCT01033318|Experimental|Part 1 B-1|"Part 1; Panel B; Sequence 1:
~5 mg MK1809 / Placebo / 100 mg MK1809 / 210 mg MK1809 / Placebo with food"
11545864|NCT01033318|Experimental|Part 1 B-2|"Part 1; Panel B; Sequence 2:
~5 mg MK1809 / 25 mg MK1809/ Placebo / Losartan / 25 mg MK1809 with food"
11545865|NCT01033318|Experimental|Part 1 B-3|"Part 1; Panel B; Sequence 3:
~5 mg MK1809 / Losartan / 100 mg MK1809 / 210 mg MK1809 / Losartan with food"
11545866|NCT01033318|Experimental|Part 1 B-4|"Part 1; Panel B; Sequence 4:
~Losartan / 25 mg MK1809/ 100 mg MK1809 / Placebo / 25 mg MK1809 with food"
11545867|NCT01033318|Experimental|Part 1 B-5|"Part 1; Panel B; Sequence 5:
~Placebo / 25 mg MK1809/ Losartan / 210 mg MK1809 / 25 mg MK1809 with food"
11545868|NCT01033318|Experimental|Part 2 C-1|"Part 2; Panel C; Sequence 1:
~50 mg MK1809 / Placebo / 150 mg MK1809 / 210 mg MK1809 / Losartan"
11545869|NCT01033318|Experimental|Part 2 C-2|"Part 2; Panel C; Sequence 2:
~50 mg MK1809 / 100 mg MK1809/ Placebo / Losartan / 280 mg MK1809"
11545870|NCT01033318|Experimental|Part 2 C-3|"Part 2; Panel C; Sequence 3:
~Losartan / 100 mg MK1809/ 150 mg MK1809 / 210 mg MK1809 / Placebo"
11545871|NCT01033318|Experimental|Part 2 C-4|"Part 2; Panel C; Sequence 4:
~50 mg MK1809 / Losartan / 150 mg MK1809 / Placebo / 280 mg MK1809"
11545872|NCT01033318|Experimental|Part 2 C-5|"Part 2; Panel C; Sequence 5:
~Placebo / 100 mg MK1809/ Losartan / 210 mg MK1809 / 280 mg MK1809"
11545873|NCT01033305|Placebo Comparator|Placebo|
11545874|NCT01033305|Experimental|CyCol™|
11545875|NCT01033292|Experimental|BSI-201|BSI-201 in combination with gemcitabine and carboplatin.
11545876|NCT01033279|No Intervention|Usual care|Patients followed by usual care at the hospital's anticoagulation clinic
11545877|NCT01033279|Experimental|Self-management|Self-monitoring and self-adjustment of oral anticoagulation according to predefined algorithms
11545878|NCT01033266||CPET CPAP|
11545879|NCT01033253|Experimental|Computerized Tailored Intervention|Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
11545880|NCT01033253|No Intervention|Control|Computerized assessments of Transtheoretical Model constructs at 0, 2, 6, and 12 months
11545881|NCT01033240|Experimental|Safety Cohort 1 CS-1008 and sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (2 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth [PO] twice daily [BID]) over 4 weeks observation, and may continue treatment until progression.
11545882|NCT01033240|Experimental|Treatment Group 1 CS-1008 and sorafenib|Combination of CS-1008 and sorafenib. Treatment Group 1: CS-1008 (6 mg/kg [or as determined] loading, 2 mg/kg/week maintenance) + sorafenib twice daily {BID} (N=50)
11545883|NCT01033240|Active Comparator|Treatment Group 3 with sorafenib alone|Combination of CS-1008 and sorafenib. Treatment Group 3: sorafenib BID (N=50)
11545884|NCT01033240|Experimental|Safety Cohort 2 CS-1008 and sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (4 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth [PO] twice daily [BID]) over 4 weeks observation, and may continue treatment until progression.
11545885|NCT01033240|Experimental|Safety Cohort 3 CS-1008 and sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (6 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth [PO] twice daily [BID]) over 4 weeks observation, and may continue treatment until progression.
11545886|NCT01033240|Experimental|Treatment Group 2 with CS-1008 and sorafenib|Combination of CS-1008 and sorafenib. Treatment Group 2: CS-1008 (6 mg/kg [or as determined] loading, 6 mg/kg/week [or maximum tolerated dose {MTD}] maintenance) + sorafenib BID (N=50)
11545887|NCT01033227|No Intervention|No drug|No study drug administered
11545888|NCT01033227|Experimental|Sodium nitrite injection, USP|Administration if sodium nitrite injection, USP
11545889|NCT01033214|Experimental|TAArget Thoracic Stent Graft|those treated with the investigational device
11545890|NCT01033201||Lung transplant|All lung transplant patients presenting for screening/surveillance and diagnostic bronchoscopies at Mayo Clinic Florida are eligible for participation.
11545891|NCT01033188|Active Comparator|Single-bundle technique|Anatomic single-bundle technique
11545892|NCT01033188|Active Comparator|Double-bundle technique|Anatomic double bundle technique
11545893|NCT01033175|Other|COPD patients with ACD|"In the 1st part of this clinical study the prevalence ACD in COPD subjects will be estimated in a consecutive population of COPD subjects who will visit the hospital's pulmonary clinics as outpatients. During the first visit, subjects will give a detailed medical history and will undergo clinical examination and pulmonary function testing 15 minutes post-bronchodilation. Eligible patients will then undergo peripheral venous blood analysis. The first 30 COPD subjects from the population described above, fulfilling the criteria of ACD will constitute the first arm (group of cases).ACD is defined by low Hb levels (men: <13 mg/dl, women: <12 mg/dl), no other cause of anemia present, normal or increased serum ferritin and decreased total iron binding capacity."
11545894|NCT01033175|Other|COPD patients without ACD|"Thirty matched patients with COPD without ACD from the initial cohort will constitute the second arm (the controls)"
11545895|NCT01033162|No Intervention|Usual Care|A group using a Basic ICCS provided by KPNW
11545896|NCT01033162|Experimental|Intervention|A group using an enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)
11545897|NCT01033149|Other|N-acetylcysteine|open label N-acetylcysteine, flexible dose
11545941|NCT01032902||Known HIV positive|Patients from HIV clinics with documented infections
11546339|NCT01030068|Experimental|Yoga|Yoga plus smoking cessation
11545898|NCT01033136|Experimental|MCET-V|Multiple Channel Exposure Therapy -Veterans (MCET-V) is a 12-session cognitive-behavioral treatment for persons with comorbid PTSD and panic attacks. It is an integrated treatment designed to target panic and PTSD symptoms simultaneously.
11545899|NCT01033136|Active Comparator|CPT|Cognitive Processing Therapy (CPT) is a 12-session cognitive-behavioral treatment for persons with PTSD. It is a gold-standard cognitive behavioral intervention designed to target PTSD symptoms.
11545900|NCT01033123|Experimental|BSI-201|BSI-201 in combination with gemcitabine and carboplatin.
11545901|NCT01033097|Experimental|DNK333 5 mg|
11545902|NCT01033097|Placebo Comparator|Placebo to DNK333 5mg|
11545903|NCT01033097|Experimental|DNK333 25 mg|
11545904|NCT01033097|Placebo Comparator|Placebo to DNK333 25 mg|
11545905|NCT01033097|Experimental|DNK333 100 mg|
11545906|NCT01033097|Placebo Comparator|Placebo to DNK333 100 mg|
11545907|NCT01033097|Active Comparator|Betamethasone 4 mg|
11545908|NCT01033097|Experimental|DNK333 1 mg|
11545909|NCT01033097|Placebo Comparator|placebo 1mg|
11545910|NCT01033084|Experimental|Sham stimulation / sertraline|In this arm, patients will receive sham stimulation and sertraline 50mg/day. In sham stimulation, the tDCS device is set in the same fashion as the active stimulation, but the device is turned off after one minute of stimulation.
11545911|NCT01033084|Sham Comparator|Sham stimulation / placebo pill|"Placebo pills are sugar pills having the same size and shape of the active pills.
~In sham stimulation, the tDCS device is set in the same fashion as the active stimulation, but the device is turned off after one minute of stimulation."
11545912|NCT01033084|Experimental|Active stimulation / Sertraline|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
~Patients will receive Sertraline 50mg/day."
11545913|NCT01033084|Experimental|Active stimulation / placebo pill|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
~Placebo pills are sugar pills having the same size and shape of the active pill"
11545914|NCT01033071|Experimental|Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD|
11545915|NCT01033071|Experimental|Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD|
11545916|NCT01033071|Active Comparator|Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD|
11545917|NCT01033058|Active Comparator|usual care|
11545918|NCT01033058|Experimental|intensive statin treatment|
11545919|NCT01033032|Experimental|Amrubicin Phase I/II|Systemic therapy with amrubicin
11545920|NCT01033019|Experimental|LDE225 0.75%|Participants topically applied 0.75% LDE225 cream twice daily for 6 weeks.
11545921|NCT01033019|Placebo Comparator|Vehicle|Participants topically applied matching placebo cream twice daily for 6 weeks.
11545922|NCT01033006|Active Comparator|Arm 1: catheter injection|40 ml of LA through the catheter
11545923|NCT01033006|Active Comparator|Arm 2: transarterial injection|30 ml deep and 10 ml superficial to the artery
11545924|NCT01033006|Active Comparator|Arm 3: catheter and transarterial injection|20 + 10 ml transarterial block and 10 ml through the catheter
11545925|NCT01032993|Active Comparator|Coenzyme Q10|600 mg of CoQ10 taken as 300 mg (three 100 mg wafers) two times daily. Study wafers: ChewQ (Tishcon Corp, Westbury, NY) are chewable wafers each containing 100 mg of Coenzyme Q10 (ubidecarenone USP). All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
11545926|NCT01032993|Placebo Comparator|Placebo|Placebo was manufactured by the manufacturer of ChewQ, Tishcon Corp (Westbury, NY), included the same excipients, but no active CoQ10, and looked and tasted identical to active agent. All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
11545927|NCT01032980||HUMENZA Vaccine Group|Participants vaccinated with HUMENZA according to the recommendations provided in the product leaflet and local recommendations.
11545928|NCT01032980||PANENZA Vaccine Group|Participants vaccinated with PANENZA according to the recommendations provided in the product leaflet and local recommendations.
11545929|NCT01032967|Active Comparator|Surgery, esophagectomy|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
11545930|NCT01032967|Active Comparator|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
11545931|NCT01032954|Active Comparator|"125 to 170 IU of 'Botulinum toxin' "|group with intervention of 125 to 170 IU of 'Botulinum toxin'
11545932|NCT01032954|Active Comparator|171 to 210 IU of 'Botulinum toxin'|Patients who have received 171 to 210 IU of 'Botulinum toxin'
11545933|NCT01032954|Active Comparator|211 to 250 IU of Botulinum toxin|Patients who have received 211 to 250 U of Botulinum toxi'
11545934|NCT01032941|Placebo Comparator|Placebo|Patients in this group will be given placebo 2 packets BID for 8 weeks.
11545935|NCT01032941|Experimental|VSL#3|Patients in this group will be given 2 packets of VSL#3 BID for 8 weeks.
11545936|NCT01032928|Experimental|Respiratory Phase Training|Chronically dysphagic, medically stable patients at least 6 months post treatment for head and neck cancer with non-optimal respiratory-swallowing patterns participated in up to 8 sessions of respiratory phase training to learn an optimal respiratory - swallow phase pattern
11545937|NCT01032915|Experimental|AIN457 300mg s.c weekly for 3 weeks|AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
11545938|NCT01032915|Experimental|AIN457 300mg s.c at baseline and Week 2|AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
11545939|NCT01032915|Experimental|AIN457 150mg s.c at baseline and Week 2|AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
11545940|NCT01032915|Placebo Comparator|Placebo s.c weekly for 3 weeks|Placebo s.c weekly for 3 weeks then every 2 weeks
11545942|NCT01032902||High Risk for Infection with HIV|Patients from defined HIV high-risk populations - i.e. intravenous drug users, or patients presenting with symptoms of sexually transmitted disease.
11545943|NCT01032902||Low-Risk for Infection with HIV|"Individuals not known to belong to any of the defined high-risk groups - i.e. healthy patients presenting for routine physicals or other unrelated non-life threatening illnesses, or individuals from a general low risk population such as students, employees of academic or other institutions, etc…"
11545944|NCT01032889|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
11545945|NCT01032889|Experimental|Deoxycholic acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
11545946|NCT01032889|Experimental|Deoxycholic acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
11545947|NCT01032876|Experimental|Deep Hypothermic Circulatory Arrest|
11545948|NCT01032876|Experimental|Antegrade Cerebral Perfusion|
11545949|NCT01032863||Young healthy Indian adults|Persons aged between 25 and 40 years of age who are relatives of patients being treated in Amrita Institute of Medical Sciences (Inpatient or Outpatient) and voluntary blood donors at the same institute who are willing to participate in the study.
11545950|NCT01032850|Experimental|Arm 1: Sorafenib & Capecitabine|Intervention: Sorafenib & Capecitabine: Sorafenib twice a day by mouth (400mg) Capecitabine twice a day by mouth (850mg)
11545951|NCT01032837|Experimental|Oseltamivir standard dose 5 days|Adults and children 13 years and older received 75 mg oseltamivir and a placebo capsule twice daily for 5 days. Children aged 1 - 12 years received a weight-based dose (from 30 to 75 mg) oseltamivir suspension and placebo suspension orally twice daily for 5 days. Participants received matching placebo for the second 5 days of treatment.
11545952|NCT01032837|Experimental|Oseltamivir standard dose 10 days|Adults and children 13 years and older received 75 mg oseltamivir and a placebo capsule twice daily for 10 days. Children aged 1 - 12 years received a weight-based dose (from 30 to 75 mg) oseltamivir suspension and placebo suspension orally twice daily for 10 days.
11545953|NCT01032837|Experimental|Oseltamivir high dose 5 days|Adults and children 13 years and older received 150 mg (2 x 75 mg) oseltamivir capsules twice daily for 5 days. Children aged 1 - 12 years received a weight-based dose (from 60 to 150 mg) oseltamivir suspension orally twice daily for 5 days. Participants received matching placebo for the second 5 days of treatment.
11545954|NCT01032837|Experimental|Oseltamivir high dose 10 days|Adults and children 13 years and older received 150 mg (2 x 75 mg) oseltamivir capsules twice daily for 10 days. Children aged 1- 12 years received a weight-based dose (from 60 to 150 mg) oseltamivir suspension orally twice daily for 10 days.
11545955|NCT01032824|Experimental|Intervention|Individual telephone counseling intervention.
11545956|NCT01032824|Other|Group Arm|Attention-matched comparison arm
11545957|NCT01032824|Other|Book Arm|Information-matched control arm.
11545958|NCT01032811||Study Participants|St. Jude Children's Research Hospital patients from Leukemia, Neuro-Oncology, Radiation Oncology, and After Completion of Therapy (ACT) clinics.
11545959|NCT01032785||Healthy term newborn|Any healthy term newborn born in Wolfson Medical Center
11545960|NCT01032772|Experimental|CHOICES Plus Intervention|A two session intervention utilizing a motivational interviewing approach to encourage changes in alcohol use, contraceptive use, and smoking. The interventions will (a) provide norms-based-but personalized-feedback, (b) encourage attendance at a contraceptive counseling visit, (c) encourage participation in the smoking cessation program, (c) increase motivation to change each of the target behaviors, (d) decrease temptation to engage in risk behaviors, (e) increase confidence to avoid risk behaviors, and (f) develop a personalized, tailored change plan.
11545961|NCT01032772|Active Comparator|Information|Women in the information condition receive advice and educational material from the research assistant about women's health and related referrals.
11545962|NCT01032759|Active Comparator|Memantine|
11545963|NCT01032759|Placebo Comparator|Placebo|Placebo
11545964|NCT01032733|Experimental|Lifestyle Counseling|In the experimental condition, participants attended a group-based weight management session plus three supervised exercise sessions each week.
11545965|NCT01032733|Placebo Comparator|Educational Control|Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss.
11545966|NCT01032720|Experimental|Ultrasound-guided knee CS injection|Ultrasound will be used to image knee joint and guide needle for intra-articular knee CS injection.
11545967|NCT01032720|Sham Comparator|Sham Ultrasound knee CS injection|CS knee injection will be performed in the same method as the US-guided knee injection but the US machine will be turned off.
11545968|NCT01032694||Z-max treated group|Patients with Community-Acquired Pneumonia
11545969|NCT01032694||Amoxiclav treated group|Patients with Community-Acquired Pneumonia
11545970|NCT01032681|Experimental|Group 1|Dose escalation of EMD 521873 monotheraphy 3 doses per cycle
11545971|NCT01032681|Experimental|Group 2|Low dose CPA + Dose escalation of EMD 521873 three doses per cycle
11545972|NCT01032681|Experimental|Group 3|Dose escalation of EMD 521873 monotheraphy 1 dose per cycle
11545973|NCT01032668|Experimental|high dose clopidogrel|
11545974|NCT01032655|Experimental|sequential, susceptibility guided|single arm
11545975|NCT01032642|Experimental|thin catheter group|group of women where thin catheter will be used for hysterosalpingography
11545976|NCT01032629|Placebo Comparator|Placebo|Each patient will receive placebo (inactive medication) on background standard of care for diabetes once daily for the duration of the study
11545977|NCT01032629|Experimental|Canagliflozin (JNJ-28431754) 100 mg|Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily on background standard of care for diabetes once daily for the duration of the study
11545978|NCT01032629|Experimental|Canagliflozin (JNJ-28431754) 300 mg|Each patient will receive canagliflozin (JNJ-28431754) 300 mg once daily on background standard of care for diabetes once daily for the duration of the study
11545979|NCT01032616|Experimental|Study Period 1|AA given by parenteral and enteral routes with tracer 1-13C phenylalanine given to observe differences
11545980|NCT01032616|Experimental|Study Period 2|AA given by parenteral and enteral routes with tracer 1-13C phenylalanine given to observe differences
11545981|NCT01032603|Active Comparator|Bilateral lateral rectus recession|Bilateral lateral rectus recession surgery
11545982|NCT01032603|Active Comparator|Unilateral lateral rectus recession|Unilateral lateral rectus recession w/ medial rectus resection surgery
11545983|NCT01032590|Experimental|Arm I|Arm I (12-week Internet-based weight-loss intervention): After a baseline evaluation, subjects will start a 12 week Internet-based weight-loss intervention.
11545984|NCT01032590|Active Comparator|Arm II|Arm II (wait-list control): Patients are instructed to continue their usual dietary and physical activity routines during a 12-week wait period. After the waiting period, patients receive the Internet-based weight-loss intervention for 12 weeks as in arm I.
11545985|NCT01032577||cardiomyopathy, with implant indications|30-50 volunteers age >18, male and female with ability to give informed consent, who are expected to live more than one year, with indication for defibrillator implant and who are not pacemaker dependent.
11545986|NCT01032551|Experimental|Vascular Access Patient Decision Aid|The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
11545987|NCT01032551|No Intervention|Usual Care|"The control group (those not randomized to the PtDA) will have usual care. Usual care involves a brief discussion, just prior to the CA procedure, with the treating physician, regarding the patient's eligibility for both vascular accesses, followed by the advantages and disadvantages of both. The details and duration of the discussion is left to the discretion of the treating physician as per their individual standard of care. There will be no access to a formal PtDA in this group."
11545988|NCT01032538||Patients with knee osteoarthritis|Patients with knee osteoarthritis that are about to get an operation with oxford unicondylar knee
11545989|NCT01032512|Experimental|IMMUNE-ENHANCING|"40 patients will be instructed to consume 600 ml of the special immune-enhancing formula plus 20 g glutamine (Supportan R + Glutamine plus R, which contain 900 Kcal and 60 g protein/day, with 24.4 g glutamine, 2,2 g arginine and 4.4 g of omega 3 fatty acids, in a lower volume due to its higher energy density)."
11545990|NCT01032512|Sham Comparator|CONTROL|40 patients that do not agree to participate, do not have enough time before the operation, do not tolerate the product and/or drink less than 100 cc/day.
11545991|NCT01032499|Active Comparator|oxytetracycline|
11545992|NCT01032499|Experimental|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
11545993|NCT01032486||Azilect|Subjects with a diagnosis of idiopathic Parkinson's disease eligible to Azilect® treatment based on the investigator's clinical assessment and according to the Canadian product monograph.
11545994|NCT01032473||GAD|Children between the ages of 7-11 years diagnosed with Generalized Anxiety Disorder (GAD)
11545995|NCT01032473||Control|Children between the ages of 7-11 years free of significant medical or behavioral problems (matched to children diagnosed with GAD based on age, gender, and ethnicity).
11545996|NCT01032460|Active Comparator|macintosh|
11545997|NCT01032460|Active Comparator|C-MAC|
11545998|NCT01032460|Active Comparator|Airtraq|
11545999|NCT01032434|Experimental|sertraline|sertraline: 50-200mg/day
11546000|NCT01032421||GNRH|Observational (IVF is not done as part of the study)
11546001|NCT01032408|Experimental|HIV-1 Infected Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria®), the first on Study Day 1, and the second on Study Day 22
11546002|NCT01032408|Experimental|HIV-1 Infected Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22
11546003|NCT01032408|Experimental|Healthy Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria®), the first on Study Day 1, and the second on Study Day 22
11546004|NCT01032408|Experimental|Healthy Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22
11546005|NCT01032395|Experimental|Chronic Disease Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria® or Fluad®), the first on Study Day 1, and the second on Study Day 22.
11546006|NCT01032395|Experimental|Chronic Disease Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.
11546007|NCT01032395|Experimental|Healthy Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria® or Flaud®), the first on Study Day 1, and the second on Study Day 22.
11546008|NCT01032395|Experimental|Healthy Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.
11546009|NCT01032382|Active Comparator|Paromomycin Alone Treatment|
11546010|NCT01032382|Active Comparator|WR 279,396|
11546011|NCT01032369|Experimental|CBT|with behavioral intervention-CBT.
11546012|NCT01032369|Other|Without CBT|Without behavioral intervention-CBT
11546013|NCT01032356|Experimental|Dynasplint|Patients will be treated with the current standard of care and the Wrist Extension Dynasplint.
11546014|NCT01032343|Active Comparator|Omega-3 PUFA capsule|
11546015|NCT01032343|Placebo Comparator|Gelatine capsule|
11546016|NCT01032330|No Intervention|Observation|Patients randomized to the observation group will receive no treatment (other than refractive correction).
11546017|NCT01032330|Active Comparator|Occlusion Therapy|Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
11546062|NCT01031992|Experimental|Group II|First placebo for 3 months, than verum for 3 months (3 times 1 g Tranexamic acid daily).
11546018|NCT01032317|Other|Single-arm Study|This study was completed prior to the implementation of the requirement for specific identification of study arms. As the requirement was not made retroactive to completed studies, we believe this study to be exempt from the stipulation. Also, per PRS definition, since this is for a single-arm/feasibility study, the data elements are optional.
11546019|NCT01032304|Experimental|Erdosteine|600 mg/day for 12 months
11546020|NCT01032304|Placebo Comparator|Placebo|Placebo for 12 months
11546021|NCT01032291|Experimental|lenalidomide plus cetuximab|Combination therapy of lenalidomide plus cetuximab
11546022|NCT01032291|Experimental|lenalidomide|Single agent therapy of lenalidomide
11546023|NCT01032278|Experimental|Cardiac Biomarker Testing|Biomarker testing for cardiac biomarkers, B-type natriuretic peptide (BNP) and Troponin I (TnI), and symptom questionnaires of participants undergoing anthracycline-based chemotherapy.
11546024|NCT01032265|Active Comparator|Web-based treatment|Web-based treatment with information (including life style), PFMT, elements of CBT and regular mail contact with an urotherapist
11546025|NCT01032265|Active Comparator|Pamphlet treatment|Information (including life style), and PFMT exercises.
11546026|NCT01032252|No Intervention|observational|Control group: followed by monthly falls calenders and four testing periods
11546027|NCT01032252|Experimental|Exercise group|16 week intervention, and followed by monthly fall calenders as well as 4 testing periods
11546028|NCT01032239|Active Comparator|ITB therapy|Intrathecal Baclofen therapy (Intrathecal baclofen + implantable pump)
11546029|NCT01032239|No Intervention|Best Medical Treatment (BMT)|Use one or a combination oral antispastic medication.
11546030|NCT01032213|Placebo Comparator|group C|control group
11546031|NCT01032213|Experimental|group M|magnesium group
11546032|NCT01032200|Experimental|Arm I - Armodafinil|Patients receive oral armodafinil once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.
11546033|NCT01032200|Placebo Comparator|Arm II - Placebo|Patients receive oral placebo once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.
11546034|NCT01032187|Active Comparator|Meglumine antimoniate|20mg/kg/day IV for 20 days
11546035|NCT01032187|Experimental|Anfo B|Amphotericin B-deoxycholate, 1mg/kg/day IV for 14 days
11546036|NCT01032174||Azithromycin SR|Acute Bacterial Maxillary Sinusitis
11546037|NCT01032174||Amoxiclav 1000 mg|Acute Bacterial Maxillary Sinusitis
11546038|NCT01032161||Delirium|Delirium was determined by RASS-PAEDS
11546039|NCT01032161||no Delirium|no Delirium was determined by RASS-PAEDS
11546040|NCT01032148|Experimental|LBH589|LBH589 administered orally as once daily dose of 20 mg po q M, W, F on a q 28 day cycle, escalating to a maximum dase of 60 mg
11546041|NCT01032135|Active Comparator|1-MI-IOP Engaged|Randomized to treatment as usual, and they attend regularly but dropped out of treatment after randomization.
11546042|NCT01032135|Experimental|2-MI-IOP Non-Engaged|Randomized to treatment as usual, and do not attend.
11546043|NCT01032135|Active Comparator|3-MI-PC Engaged|Randomized to treatment choice, but remain attending treatment as usual then dropped out of treatment after randomization.
11546044|NCT01032135|Experimental|4-MI-PC Non-engaged|Randomized to treatment choice, and do not attend treatment as usual, so the choice option is used.
11546045|NCT01032122|Experimental|rituximab|
11546046|NCT01032109|Experimental|Bevacizumab|
11546047|NCT01032083|Active Comparator|Citalopram|An SSRI antidepressant
11546048|NCT01032083|Placebo Comparator|Placebo|
11546049|NCT01032070|Experimental|Erlotinib|Erlotinib was administered orally at a dose of 85 mg/m^2 per day continuously until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity.
11546050|NCT01032070|Active Comparator|Etoposide|Etoposide 50 mg/m^2 per day was administered orally for 21 days followed by a 7-day rest period until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity.
11546051|NCT01032057|Active Comparator|Gemcitabine|GEMCAP induction chemotherapy (28 day cycle of IV gemcitabine 1000mg/m2 day 1, 8,15 and capecitabine 830mg/m2 bd for 21 days po) followed by gemcitabine 300mg/m2 weekly (IV) + 50.4Gy radiation over five and half weeks (1.8Gy per fraction, Monday-Friday)
11546052|NCT01032057|Active Comparator|chemoradiotherpay with capecitabine|GEMCAP induction chemotherapy (28 day cycle of IV gemcitabine 1000mg/m2 day 1, 8,15 and capecitabine 830mg/m2 bd for 21 days po), followed by capecitabine 830mg/m2 bd (po, Mon-Fri) + 50.4Gy radiation over five and half weeks (1.8Gy per fraction, Monday-Friday)
11546053|NCT01032044|Active Comparator|Standard endoscopic evaluation|Standard high-definition white light endoscopy guided evaluation
11546054|NCT01032044|Experimental|pCLE-guided evaluation|Endoscopic evaluation of BE guided by probe-based Confocal Laser Endomicroscopy (pCLE guided evaluation)
11546055|NCT01032031|Active Comparator|Green tea + vit C high dose|
11546056|NCT01032031|Placebo Comparator|Placebo|
11546057|NCT01032018|Active Comparator|Referred Care|Immediately after the initial post-ACS screening, the participant's physician will be notified in writing if the participant is depressed according to the BDI. Depending upon the physician's own evaluation of the participant, he or she may elect to defer depression treatment, initiate it, or to refer the patient to a mental health specialist.
11546058|NCT01032018|Experimental|Stepped Care|Stepped Care participants will be given a description of the choices available in this arm, including choosing antidepressant medication and/or telephone-based, Problem-Solving Therapy (PST). If the patient is randomized to Stepped Care, their physician will be informed that depression treatment is being provided by the trial. Patients will select their preferred treatment approach. Depression symptoms will be monitored to determine whether the patient is improving relative to his/her baseline score. Relapse monitoring and maintenance therapy will continue for the duration of the study.
11546059|NCT01032005|Placebo Comparator|Fortified salt|Common table salt that has been fortified with iodine only
11546060|NCT01032005|Experimental|Double fortified salt|Common table salt that has been fortified with iron and well as the usual iodine
11546061|NCT01031992|Experimental|Group I|First verum (3 times 1 g Tranexamic acid daily) for three months, than placebo for 3 months.
11546390|NCT01029678|Experimental|experimental|
11546063|NCT01031979|Experimental|Yohimbime Group|Patients will take one 21.6 mg. dose of yohimbine one hour before first imaginal exposure in PE.
11546064|NCT01031979|Placebo Comparator|Placebo Group|Patients will take a placebo one hour before first imaginal exposure in PE.
11546065|NCT01031966|Active Comparator|H1N1sw monovalent vaccine|
11546066|NCT01031966|Experimental|Thymosin alpha 1 3.2mg|
11546067|NCT01031966|Experimental|Thymosin alpha 1 6.4 mg|
11546068|NCT01031953|Experimental|Fosaprepitant|
11546069|NCT01031940|Active Comparator|macintosh|
11546070|NCT01031940|Active Comparator|C-MAC|
11546071|NCT01031940|Active Comparator|Airtraq|
11546072|NCT01031914|Experimental|Paced Breathing Sleep/Wake detection|All subjects enrolled will have oobstructive sleep apnea (OSA) and will be current Continuous Positive Airway Pressur (CPAP) users.
11546073|NCT01031901|Placebo Comparator|TSC Placebo Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating alone to facial angiofibromas
11546074|NCT01031901|Experimental|TSC 1% Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to facial angiofibromas
11546075|NCT01031901|Experimental|TSC 5% Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to facial angiofibromas
11546076|NCT01031901|Placebo Comparator|NF1 Placebo Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating alone to cutaneous neurofibromas
11546077|NCT01031901|Experimental|NF1 1% Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to cutaneous neurofibromas
11546078|NCT01031901|Experimental|NF1 5% Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to cutaneous neurofibromas
11546079|NCT01031888|Active Comparator|1|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy receiving topical insulin eye drops in addition to conventional postoperative eye drops
11546080|NCT01031888|Active Comparator|2|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for penetrating keratoplasty receiving topical insulin eye drops in addition to conventional postoperative eye drops
11546081|NCT01031888|Placebo Comparator|3|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy treated with conventional postoperative eye drops
11546082|NCT01031888|Placebo Comparator|4|corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for penetrating keratoplasty receiving conventional postoperative eye drops
11546083|NCT01031862|Other|Healthy Volunteers|12 healthy volunteers
11546084|NCT01031849|Experimental|Kaletra, all patients|Patients will change actual treament for monotherapy LPV/r. They only will take Kaletra 2/day
11546085|NCT01031836|Experimental|MEDI-545 1.0 mg/kg|Cohort 1
11546086|NCT01031836|Experimental|MEDI-545 3.0 mg/kg|Cohort 2
11546087|NCT01031836|Experimental|MEDI-545 10.0 mg/kg|Cohort 3
11546088|NCT01031836|Experimental|MEDI-545 100 mg|Cohort 4
11546089|NCT01031836|Experimental|MEDI-545 600 mg|Cohort 5
11546090|NCT01031836|Experimental|MEDI-545 1,200 mg|Cohort 6
11546091|NCT01031823|Experimental|Social Skills Training|All participants will take part in this arm of the study.
11546092|NCT01031810|Other|tranylcypromine|patients will receive treatment with tranylcypromine
11546093|NCT01031797||High SLEDAS|High SLE disease activity score
11546094|NCT01031797||Low SLEDAS|SLE patient with low score
11546095|NCT01031784|Experimental|Holmium-166 microspheres, intra-arterial|intra-arterial administration of holmium-166 microspheres in the liver
11546096|NCT01031758|Other|Group 1|Group 1 is comprised of 6 healthy subjects with HDL-C levels between the 25th and 75th percentile.
11546097|NCT01031758|Other|Group 2|Group 2 is comprised of 6 healthy subjects with high HDL-C levels > 75th percentile.
11546098|NCT01031758|Other|Group 3|Group 2 is comprised of 6 healthy subjects with low HDL-C levels < 25th percentile.
11546099|NCT01031745|Experimental|Contingency|
11546100|NCT01031745|Active Comparator|Control|
11546101|NCT01031732|Experimental|Two-incision|MIS-2 THA
11546102|NCT01031732|Experimental|Watson-Jones|MIS-WJ
11546103|NCT01031732|Experimental|MIS-AL|
11546104|NCT01031732|Experimental|MIS-PL|
11546105|NCT01031719|Experimental|Group A: High Risk Population|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
11546106|NCT01031719|Experimental|Group B: High Risk Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
11546107|NCT01031719|Experimental|Group C: Healthy Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
11546108|NCT01031719|Experimental|Group D: Healthy Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
11546109|NCT01031706|Experimental|Hypertonic saline|6% NaCl, 4 ml TID via eFlow
11546110|NCT01031706|Placebo Comparator|Placebo|0.12% x 4ml via eFlow nebulizer
11546111|NCT01031693|Active Comparator|Group A|Active TMS
11546112|NCT01031693|Sham Comparator|Group B|Sham TMS
11546113|NCT01031680|Experimental|1|Dapagliflozin 10 mg tablet
11546114|NCT01031680|Placebo Comparator|2|Matching placebo tablet
11546115|NCT01031628|Active Comparator|Arm A|Patients with blood level less than 1100 will continue imatinib 400 mg daily
11546116|NCT01031628|Active Comparator|Arm B|Patients with blood level less than 1100 dose adjust imatinib mesylate to goal blood level ≥1100 ng/mL
11546117|NCT01031628|Active Comparator|Arm C|Patients with blood level ≥1100 will continue imatinib 400 mg daily
11546118|NCT01031628|Active Comparator|Arm D|Patients with tumors that harbor exon 9 mutations will continue imatinib mesylate at 400 mg or dose escalate up to 800 mg daily
11546119|NCT01031615|Experimental|Child and Family Traumatic Stress Interv|4-session secondary prevention model that focuses on family communication about symptoms of a child aged 7-16.
11546197|NCT01030965|Placebo Comparator|Placebo|once-daily via novel dry powder inhaler
11546120|NCT01031615|Active Comparator|Psychoeducational Comparison|4-sessions focused on individual child using psychoeducation and relaxation skills
11546121|NCT01031602||Psych Needs Assessment|Female Sexual Function Index (FSFI), Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire given to underserved and minority women with a gynecologic cancer or premalignant condition.
11546122|NCT01031550|Active Comparator|standard anesthetic management|standard anesthetic management with propofol 100-150mcg/kg/min
11546123|NCT01031550|Experimental|preconditioning with 2 MAC isoflurane group|After induction, anesthesia will be maintained with 1MAC (minimum alveolar concentration) of Isoflurane according to age and end-expiratory concentration. Thirty minutes before the anticipated inflow occlusion and commencement of liver transaction, Isoflurane concentration will be gradually increased to 2 MAC over a period of 5 minutes (induction) and maintained at 2 MAC for 10 minutes (preconditioning). Then the concentration of Isoflurane will be decreased to 1 MAC during next 15 minutes (washout).
11546124|NCT01031537|Other|FSME-IMMUN 0.5mL Baxter|FSME-IMMUN 0.5mL Baxter is non-US licensed vaccine for tick-borne encephalitis virus. The FSME-IMMUN 0.5mL Baxter is available as 0.5mL in a pre-loaded vaccine syringe. All participants received active vaccine using a rapid immunization schedule, with vaccine administration on Days 0, 14, 161 and 245. Participants that tested seropositive for tick-borne encephalitis virus or subjects that developed positive viral neutralizer titers after the 3rd or 4th vaccine were given a booster of FSME-IMMUN 0.5mL Baxter vaccine at 3, 6 and 9 years after enrollment.
11546125|NCT01031524|Experimental|vaccine|30 µg of PfCS102 formulated in Montanide ISA 720
11546126|NCT01031524|Placebo Comparator|adjuvant|Montanide ISA 720
11546127|NCT01031511|Experimental|Treatment Group - CBT|
11546128|NCT01031511|No Intervention|Control Group|
11546129|NCT01031498|Active Comparator|Ondansetron: Standard of Care|Standard of care, Ondansetron 8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
11546130|NCT01031498|Experimental|Palonosetron Group 1 (5 Days)|Palonosetron once a day 0.25 mg IV injection for 5 days, given over 30 seconds, 30 minutes before chemotherapy treatment.
11546131|NCT01031498|Experimental|Palonosetron Group 2 (3 Days)|Palonosetron once a day 0.25 mg IV injection on Days 1, 3, and 5 of chemotherapy treatment, given over 30 seconds, 30 minutes before chemotherapy treatment.
11546132|NCT01031485|Active Comparator|Spread with milk peptides and plant sterols|
11546133|NCT01031485|Placebo Comparator|Standard spread|
11546134|NCT01031472|Experimental|Part A|Subjects will be randomized in a three way crossover design to either a single dose of GSK2248761 100mg Gelucire capsule administered with food and a single dose of 100mg of formulation 1 or a single dose of 100mg of formulation 3 administered in the fed and fasted state
11546135|NCT01031472|Experimental|Part B|A total of twelve subjects who complete Part A will participate in Part B. Subjects from Part A will be asked to participate on a first come first serve basis until there are 12 subjects, at which time enrolment to Part B will be closed. Part B will be a 2 way cross over study design. Subjects will be randomized to one of a single dose of GSK2248761 100mg Formulation 2 or 4 (based on the evaluation of Part A data) administered with food or in the fasted state. Subjects in Part B will not receive the reference formulation since they previously received this in Part A
11546136|NCT01031459||Group 1|
11546137|NCT01031446|Experimental|Treatment|
11546138|NCT01031420|Experimental|dose dense MVAC|standard doses of MVAC given every 14 days x 3.
11546139|NCT01031407||Group 1|Healthy Volunteers
11546140|NCT01031407||Group 2|Individuals with Autism Spectrum Disorders
11546141|NCT01031407||Group 3|Parents of Healthy Volunteers, or Individuals with Autism Spectrum Disorders
11546142|NCT01031394|Active Comparator|Group 1|1 aerobic and 1 resistance training per week
11546143|NCT01031394|Active Comparator|Group 2|2 aerobic and 2 resistance training each per week
11546144|NCT01031394|Active Comparator|Group 3|3 aerobic and 3 resistance training per week
11546145|NCT01031381|Other|Rad001/Bevacizumab|Patients will receive RAD001 by mouth everyday and Bevacizumab IV every 14 days until clinical progression.
11546146|NCT01031368|Experimental|Treatment (chemotherapy, G-CSF, cord blood infusion)|"INDUCTION THERAPY: Patients receive clofarabine IV over 1 hour and cytarabine hydrochloride IV over 2 hours on days 1-5. Patients receive an infusion of non-HLA matched ex vivo expanded cord blood progenitors on day 6. G-CSF is administered SC on days 0-5 and from day 7 until blood counts recover. Treatment modifications may apply according to response.
~CONSOLIDATION THERAPY: Patients receive clofarabine IV over 1 hour and cytarabine hydrochloride IV over 2 hours on days 1-5. Patients also receive G-CSF SC beginning on day 0 and continuing until blood counts recover."
11546147|NCT01031355|Experimental|Arm 1|
11546148|NCT01031355|Active Comparator|Arm 2|
11546149|NCT01031355|Active Comparator|Arm 3|
11546150|NCT01031342|Experimental|Early colonoscopy|Colonoscopy performed within 12 hours of presentation
11546151|NCT01031342|Active Comparator|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
11546152|NCT01031329||Complicated Acute otitis media Group|"This group was divided into 3 sub-groups.
~One sub-group includes treatment failure subjects who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment or reappearance of symptoms within 10 days following the end of antibiotic treatment.
~The second sub-group includes subjects with recurrent acute otitis media, who have had new episodes of acute otitis media within the past 6 months or the fourth (or greater) new episode within the past year.
~The third sub-group includes subjects with spontaneous otorrhoea if perforation has occurred < 24 hours prior to the visit."
11546153|NCT01031316|Experimental|Nondisclosure|
11546154|NCT01031316|Active Comparator|Disclosure|
11546155|NCT01031303|Experimental|Study Group|
11546156|NCT01031290|Experimental|Group A|Active TMS
11546157|NCT01031290|Sham Comparator|Group B|Sham TMS
11546158|NCT01031264||Social drinkers|
11546159|NCT01031225|Experimental|1|
11546160|NCT01031199|Experimental|Arm 1|
11546161|NCT01031199|Experimental|Arm 2|
11546162|NCT01031186|Experimental|Cohort 1, Session 1|In Dosing Session 1, the subjects will be administered 0.5 mg GSK356278 and placebo in a fasted state.
11546163|NCT01031186|Experimental|Cohort 1, Session 2|In Dosing Session 2, the subjects will be administered GSK356278 (0.5 mg and 1.5 mg) and placebo in a fasted state.
11546164|NCT01031186|Experimental|Cohort 1, Session 3|In Dosing Session 3, the subjects will be administered GSK356278 (1.5 mg and 4 mg) and placebo in a fasted state.
11546165|NCT01031186|Experimental|Cohort 1, Session 4|In Dosing Session 4, the subjects will be administered GSK356278 (4 mg and 8 mg) and placebo in a fasted state.
11546166|NCT01031186|Experimental|Cohort 1, Session 5|In Dosing Session 5, the subjects will be administered GSK356278 8 mg and placebo in a fasted state.
11546167|NCT01031186|Experimental|Cohort 2, Session 1|In Dosing Session 1, the subjects will be administered 8 mg GSK356278 and placebo in a fasted state.
11546168|NCT01031186|Experimental|Cohort 2, Session 2|In Dosing Session 2, the subjects will be administered GSK356278 (8 mg and 16 mg) and placebo in a fasted state.
11546169|NCT01031186|Experimental|Cohort 2, Session 3|In Dosing Session 3, the subjects will be administered GSK356278 (16 mg and 30 mg) and placebo in a fasted state.
11546170|NCT01031186|Experimental|Cohort 2, Session 4|In Dosing Session 4, the subjects will be administered GSK356278 (30 mg and 50 mg) and placebo in a fasted state.
11546171|NCT01031186|Experimental|Cohort 2, Session 5|In Dosing Session 5, the subjects will be administered GSK356278 50 mg and placebo in a fasted state. The subjects will undergo food assessment session in Session 5 incase they experience nausea. In food assessment session, the subjects will receive a dose of GSK356278 after a standard breakfast.
11546172|NCT01031160||U.S. high school students|U.S. high school students who were in 10th grade in the 2009-2010 school year.
11546173|NCT01031147||Magnetic resonance angiography|Three-dimensional time-of-flight magnetic resonance angiography(3D-TOF-MRA) was used to detect the intracranial aneurysms in this study
11546174|NCT01031134|Experimental|Shared Decision Making|1 in person session followed by 2 telephone calls 1 and 2 weeks later.
11546175|NCT01031134|Active Comparator|Usual Care|Physician Usual Care of depressed patients.
11546176|NCT01031108|Other|Type 2 Diabetic Group|The Type 2 Diabetic Treatment Group will be randomized to receive test material (2.0g SRT2104 or placebo) in the form of 8 capsules per day for 28 days. After 28 days of dosing, subjects will cross over to receive placebo or 2.0g SRT2104 for an additional 28 days. Dosing of SRT2104 or placebo will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized morning meal (220 cc of Ensure Plus®). Subjects must wait at least 1-2 hours after dosing before consuming additional calories. Water is permitted ad libitum.
11546177|NCT01031108|Other|Otherwise Healthy Cigarette Smoking Group|The Otherwise Healthy Cigarette Smoking Treatment Group will be randomized to receive test material (2.0g SRT2104 or placebo) in the form of 8 capsules per day for 28 days. After 28 days of dosing, subjects will cross over to receive placebo or 2.0g SRT2104 for an additional 28 days. Dosing of SRT2104 or placebo will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized morning meal (220 cc of Ensure Plus®). Subjects must wait at least 1-2 hours after dosing before consuming additional calories. Water is permitted ad libitum.
11546178|NCT01031095|Experimental|Low dose intracoronary heparin|Low dose intracoronary heparin: In this group elective coronary intervention was performed with low dose intracoronary Heparin
11546179|NCT01031095|Active Comparator|Standard treatment arm|Standard treatment arm: In this group elective coronary intervention performed with standard dose intravenous heparin
11546180|NCT01031082||HIV-negative Group|This group is sub-divided into two sub-groups. One sub-group includes HIV-negative/ presumed negative subjects with a new episode of acute otitis media who have not yet received antibiotic therapy for the episode and the other sub-group includes HIV-negative/ presumed negative subjects with treatment failure who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment.
11546181|NCT01031082||HIV-positive Group|This group is sub-divided into two sub-groups. One sub-group includes HIV-positive subjects with a new episode of acute otitis media who have not yet received antibiotic therapy for the episode and the other sub-group includes HIV-positive subjects with treatment failure who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment.
11546182|NCT01031069|Experimental|HIV+/Cervarix Group|HIV seropositive female subjects, between and including 15 and 25 years of age, who received 3 doses of Cervarix vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
11546183|NCT01031069|Active Comparator|HIV+/Gardasil Group|HIV seropositive female subjects, between and including 15 and 25 years of age, who received 3 doses of Gardasil vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
11546184|NCT01031069|Experimental|HIV-/Cervarix Group|HIV seronegative female subjects, between and including 15 and 25 years of age, who received 3 doses of Cervarix vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
11546185|NCT01031069|Active Comparator|HIV-/Gardasil Group|HIV seronegative female subjects, between and including 15 and 25 years of age, who received 3 doses of Gardasil vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
11546186|NCT01031043|Experimental|Topical Bethanechol|patients will be given either 5 mg (first phase) or 10 mg (second phase) of bethanechol in 1 ml of solution containing an absorption enhancer. Administration will be performed by throat spray device
11546187|NCT01031017|Placebo Comparator|placebo|group taking placebo
11546188|NCT01031017|Active Comparator|study group|group taking progesterone
11546189|NCT01031004|Experimental|narafilcon B|contact lens
11546190|NCT01031004|Active Comparator|etafilcon A|contact lens
11546191|NCT01030991||HFpEF|HFpEF cohort (observational study)
11546192|NCT01030978|Experimental|Family-based Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
11546193|NCT01030978|Active Comparator|Standard Diet & Activity Education (Control)|
11546194|NCT01030965|Experimental|GSK573719 125mcg|125mcg once-daily via novel dry powder inhaler
11546195|NCT01030965|Experimental|GSK573719 250mcg|250mcg once-daily via novel dry powder inhaler
11546196|NCT01030965|Experimental|GSK573719 500mcg|500mcg once-daily via novel dry powder inhaler
11546198|NCT01030952|Experimental|Nateglinide|Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
11546199|NCT01030952|Active Comparator|Acarbose|Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
11546200|NCT01030939|Experimental|Cohort 1: SB-649868|Healthy adult male subjects
11546201|NCT01030939|Experimental|Cohort 2|Healthy adult female subjects
11546202|NCT01030939|Experimental|Cohort 3|Healthy male elderly subjects
11546203|NCT01030939|Experimental|Cohort 4|Healthy female elderly subjects
11546204|NCT01030926|Experimental|A1, first period|
11546205|NCT01030926|Active Comparator|A2, second period|
11546206|NCT01030926|Active Comparator|B1, first period|
11546207|NCT01030926|Experimental|B2, second period|
11546208|NCT01030913||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
11546209|NCT01030900|Experimental|1|EPOCH + Rituximab + campath every 3 weeks for six cycles
11546210|NCT01030887|Active Comparator|Exercise Programme|This will consist of an 8-week exercise programme, performed twice per week.
11546211|NCT01030887|Placebo Comparator|Usual Care|Standard practice including opportunistic exercise advice and patients' self-directed physical activity
11546212|NCT01030874|No Intervention|Arm 1|Usual rehab care
11546213|NCT01030874|Experimental|Arm 2|Treatment for, and prevention of, orthostatic hypotension
11546214|NCT01030861|Active Comparator|teplizumab|Intravenous infusions of teplizumab given for 14 consecutive days. Each infusion takes about 30 minutes and is followed by a 2 hour observation period.
11546215|NCT01030861|Placebo Comparator|Placebo infusion|Intravenous infusion of placebo (saline) will be given for 14 consecutive days. Infusions will take approximately 30 minutes and will be followed by a two hour observation period.
11546216|NCT01030848||Patients with knee osteoarthritis|
11546217|NCT01030822|Experimental|Group A|Subjects previously primed with pneumococcal vaccine GSK1024850A in the first year of life and receiving a booster dose of GSK1024850A at 9-18 months of age.
11546218|NCT01030822|Experimental|Group B|Subjects previously primed with pneumococcal vaccine GSK1024850A in the first year of life and receiving a booster dose of GSK1024850A at 15-18 months of age.
11546219|NCT01030822|Experimental|Group C|Unprimed subjects receiving a catch-up vaccination (2+1 schedule) in the second year of life.
11546220|NCT01030809|No Intervention|Usual Care practice|Patients managed according to usual care practices
11546221|NCT01030809|Active Comparator|Treatment Algorithm|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
11546222|NCT01030783|Experimental|tivozanib (AV-951)|
11546223|NCT01030783|Active Comparator|sorafenib|
11546224|NCT01030770|Experimental|Arm A (treatment)|Arm A: Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls) (Lucentis®)
11546225|NCT01030770|Placebo Comparator|Arm B (control):|Arm B: Single subconjunctival injection of 0.05mls of 0.9% sodium chloride (Minims Saline®)
11546226|NCT01030757|Experimental|Tomotherapy|Intervention: Stereotactic Body Radiation Therapy using Tomotherapy. Tomotherapy treatment: A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the PTV.
11546227|NCT01030744||Gestational Diabetes|Women with gestational diabetes who are referred to and followed in the Vanderbilt Eskind Diabetes Clinic and are participants in the gestational diabetes educational program.
11546228|NCT01030731|Experimental|Ceftobiprole (end-stage renal disease subjects).|Ceftobiprole 250mg single dose over 2 hours.
11546229|NCT01030731|Active Comparator|Ceftobiprole (healthy subjects)|Ceftobiprole 250 mg single dose over 2 hours.
11546230|NCT01030718|Experimental|dasatinib (CML-CP)|CML - Chronic Phase
11546231|NCT01030718|Experimental|dasatinib (CML-AP/BP)|CML - Accelerated Phase and Blast Phase
11546232|NCT01030718|Experimental|dasatinib (Ph+ ALL)|Ph+ Acute Lymphoblastic Leukemia
11546233|NCT01030692|Placebo Comparator|Placebo|Placebo capsules as control
11546234|NCT01030692|Active Comparator|Rivastigmine 3 mg|Rivastigmine 3 mg
11546235|NCT01030692|Active Comparator|Rivastigmine 6 mg|Rivastigmine 6 mg
11546236|NCT01030692|Active Comparator|Huperzine A 0.4 mg|Huperzine A 0.4 mg
11546237|NCT01030692|Active Comparator|Huperzine A 0.8 mg|Huperzine A 0.8 mg
11546238|NCT01030679|Experimental|CKD-501 0.5mg|
11546239|NCT01030679|Experimental|CKD-501 1mg|
11546240|NCT01030679|Experimental|CKD-501 2mg|
11546241|NCT01030679|Placebo Comparator|Placebo|
11546242|NCT01030666|Experimental|doxycycline|"The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects
~modified/simplified papilla preservation flap; scaling
~Prefgel/Emdogain
~0.12% chlorhexidine gluconate solution
~Ibuprofen 400 mg (if necessary)
~1% chlorhexidine gluconate gel (if necessary)"
11546243|NCT01030666|Placebo Comparator|placebo|"The patients of the control group will take placebo once a day for 7 days after regenerative therapy of an infrabony defect
~modified/simplified papilla preservation flap; scaling
~Prefgel/Emdogain
~0.12% chlorhexidine gluconate solution
~Ibuprofen 400 mg (if necessary)
~1% chlorhexidine gluconate gel (if necessary)"
11546244|NCT01030653|Experimental|Voriconazole low dose first then high dose|Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (200 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (300 mg Every 12 Hours x 7 Doses)
11546245|NCT01030653|Experimental|Voriconazole high dose first then low dose|Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (300 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (200 mg Every 12 Hours x 7 Doses)
11546246|NCT01030640|Placebo Comparator|placebo|formulation without active drug
11546247|NCT01030640|Active Comparator|tanezumab|
11546248|NCT01030614|Active Comparator|Dexamethasone group|One hundred five patients were randomized to receive intravenous dexamethasone (8 mg) before laparoscopic cholecystectomy
11546249|NCT01030614|Placebo Comparator|Placebo group|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
11546250|NCT01030601|No Intervention|Control|Diabetics undergoing routine cataract surgery
11546251|NCT01030601|Experimental|Treatment|Diabetics undergoing cataract surgery with injection of 0.5mg in 0.05cc of dexamethasone at the end of surgery
11546252|NCT01030575|Experimental|Inositol low volume|10 mg/kg/day Intravenous inositol 5%
11546253|NCT01030575|Experimental|Inositol mid-level volume|40 mg/kg/day Intravenous inositol 5%
11546254|NCT01030575|Experimental|Inositol high volume|80 mg/kg/day Intravenous inositol 5%
11546255|NCT01030575|Placebo Comparator|Placebo|Glucose 5% given in volumes equal to that of the comparator drug
11546256|NCT01030562||Alternate Arm|Subjects who meet eligibility requirements but do not fit into any of the primary experimental arms.
11546257|NCT01030562||Control Arm|Subjects with an on-time interval between Dose 1 and 2 and an on-time interval between Dose 2 and 3.
11546258|NCT01030562||Experimental/Primary Arm 1|This primary arm will consist of subjects receiving the second dose on time/third dose substantially late.
11546259|NCT01030562||Experimental/Primary Arm 2|This primary arm will consist of subjects receiving the second dose substantially late/third dose on time.
11546260|NCT01030562||Experimental/Primary Arm 3|This primary arm will consist of subjects receiving the second dose substantially late/third dose substantially late.
11546261|NCT01030536|Experimental|CAT-8015 20 microgram per kilogram (mcg/kg)|Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
11546262|NCT01030536|Experimental|CAT-8015 30 mcg/kg|Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
11546263|NCT01030536|Experimental|CAT-8015 40 mcg/kg|Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
11546264|NCT01030536|Experimental|CAT-8015 50 mcg/kg|Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
11546265|NCT01030536|Experimental|CAT-8015 60 mcg/kg|Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
11546266|NCT01030523|Experimental|Short Implants|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
11546267|NCT01030523|Active Comparator|Long Implants|ASTRA TECH Implants System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm)
11546268|NCT01030510|Active Comparator|group R|In group R, remifentanil was infused first before administrating propofol and rocuronium
11546269|NCT01030510|Active Comparator|group P|in group P, remifentanil was administered last after the propofol and rocuronium injection
11546270|NCT01030484||NAFLD|adult patients with non-alcoholic fatty liver disease (NAFLD).
11546271|NCT01030471|Experimental|Lifestyle counseling|
11546272|NCT01030471|No Intervention|Wait list control group|
11546273|NCT01030458|Experimental|amlodipine plus valsartan|In the experimental group, Exforge will be used in two dosage steps, respectively, amlodipine 5 mg plus 160 mg valsartan and amlodipine 10 mg plus 160 mg valsartan.
11546274|NCT01030458|Active Comparator|hydrochlorothiazide plus bisoprolol|In the reference group, the Lodoz will be used in two dosage steps, respectively 6.25 mg hydrochlorothiazide plus 5 mg or 6.25 mg hydrochlorothiazide plus 10 mg bisoprolol
11546275|NCT01030445||Elevated Mean Arterial Blood Pressure|Mean arterial pressure greater than 1 standard deviation above the mean based on age
11546276|NCT01030445||Decrease Mean Arterial Blood Pressure|Mean arterial pressure greater than 1 standard deviation below the mean based on age
11546277|NCT01030445||Normal Mean Arterial Blood Pressure|Mean arterial pressure within the standard deviation of the mean based on age
11546278|NCT01030432|Experimental|Phase 2a: Arm 1|
11546279|NCT01030432|Placebo Comparator|Phase 2a: Arm 2|
11546280|NCT01030432|Experimental|Phase 2b: Arm 1|
11546281|NCT01030432|Placebo Comparator|Phase 2b: Arm 2|
11546282|NCT01030419|Experimental|FlexToBa physical activity DVD|Participants in this arm will receive a physical activity program delivered by DVD that focuses on exercises targeting flexibility, toning and balance. These exercises will be progressive in nature throughout the six months and will also focus on modifications for all ability levels. Participants will be provided with three DVDs including: an Introduction to physical activity, Sessions 1-3, and Sessions 4-6, which they will be asked to watch and participate in over the course of six months.
11546283|NCT01030419|Placebo Comparator|Usual care-Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 12-month follow-up testing.
11546284|NCT01030406|Active Comparator|40/0mg taken first|8x oxycodone/niacin 5/0mg tablets
11546285|NCT01030406|Active Comparator|80/0mg taken first|8x oxycodone/niacin 10/0mg tablets
11546286|NCT01030406|Experimental|40/240mg taken first|8x oxycodone/niacin 5/30mg tablets
11546287|NCT01030406|Experimental|80/480mg taken first|8x oxycodone/niacin 10/60mg tablets
11546288|NCT01030406|Placebo Comparator|0/0mg taken first|Placebo
11546337|NCT01030081|Experimental|Amlodipine (Norvasc®)|
11546289|NCT01030393|Experimental|intrauterine hCG|"Experimental arm : intrauterine injection of 100 iu(group1)or 200 iu (group2) of hCG before embryo transfer.
~Intrauterine injection of 500 iu hCG before embryo transfer"
11546290|NCT01030380|Experimental|Slendertone Face NMES|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
11546291|NCT01030380|No Intervention|Control Group: No NMES|Control Group: No NMES over the course of 12 weeks.
11546292|NCT01030367|Experimental|1|PETN
11546293|NCT01030367|Experimental|2|ISDN
11546294|NCT01030367|No Intervention|3|
11546295|NCT01030354|Active Comparator|Dietary Intervention and Higher protein meal replacement|A higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass
11546296|NCT01030354|Active Comparator|Dietary Intervention and Standard Protein Meal Replacement|Standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
11546297|NCT01030341|Experimental|CGMS and insulin pump|Continuous glucose monitoring in conjunction with insulin pump
11546298|NCT01030328|Active Comparator|TriLipix + Atorvastatin|Two tables of TriLipix + Atorvastatin taken once a day by mouth.
11546299|NCT01030328|Placebo Comparator|2|2 sugar pills
11546300|NCT01030315|Experimental|Cohort 1|The lowest dose level of HM10760A
11546301|NCT01030315|Experimental|Cohort 2|Second dose level of HM10760A
11546302|NCT01030315|Experimental|Cohort 3|Third dose level of HM10760A
11546303|NCT01030315|Experimental|Cohort 4|Fourth dose level of HM10760A
11546304|NCT01030315|Experimental|Cohort 5|The highest dose level of HM10760A
11546305|NCT01030302||001|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
11546306|NCT01030289|Active Comparator|real tDCS First Visit|On the First Visit, A single 20-minute tDCS session will be conducted using 2.0mA current. Using the international 10-20 EEG system, the anode will be placed over F4, which corresponds to the right dorsolateral prefrontal cortex (DLPFC), and the cathode will be placed over F3, which corresponds to the left dorsolateral prefrontal cortex. Electrodes will be standard sponge electrodes soaked In a sterile solution of .9% sodium chloride insulated by a latex casing.
11546307|NCT01030289|Sham Comparator|sham tDCS First Visit|On the First Visit, For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
11546308|NCT01030289|Active Comparator|real tDCS Second Visit|Participant returns for the second visit 48-72 hours after completing the first visit. A single 20-minute tDCS session will be conducted using 2.0mA current. Using the international 10-20 EEG system, the anode will be placed over F4, which corresponds to the right dorsolateral prefrontal cortex (DLPFC), and the cathode will be placed over F3, which corresponds to the left dorsolateral prefrontal cortex. Electrodes will be standard sponge electrodes soaked In a sterile solution of .9% sodium chloride insulated by a latex casing.
11546309|NCT01030289|Sham Comparator|sham tDCS Second Visit|Participant returns for the second visit 48-72 hours after completing the first visit. For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
11546310|NCT01030276|Experimental|Bright light|
11546311|NCT01030276|Placebo Comparator|"Inactive placebo-light"|
11546312|NCT01030263|Experimental|CEM|Biopsies obtained with fluorescence-aided confocal endomicroscopy.
11546313|NCT01030263|Other|RFQ|Random four-quadrant biopsies.
11546314|NCT01030250||Under 65 years|Breast cancer patients receiving adjuvant chemotherapy. Those under 65 years of age will be prospectively evaluated for outcome.
11546315|NCT01030250||Over 65 years|Breast cancer patients receiving adjuvant chemotherapy. Those over 65 years of age will be prospectively evaluated for outcome.
11546316|NCT01030237|Experimental|FID 114657|FID 114657
11546317|NCT01030237|Active Comparator|Soothe XP Lubricant Eye Drops|Soothe XP Lubricant Eye Drops
11546318|NCT01030224|Experimental|AZD9742 IV Infusion|Active
11546319|NCT01030224|Placebo Comparator|Placebo to AZD9742 IV Infusion|Placebo
11546320|NCT01030211|Active Comparator|Platelet transfusion|4 units of platelets for patients with platelet count <20x10^3/uL
11546321|NCT01030211|Other|Supportive care|No platelet transfusion for patients with platelet count <20x10^3/uL
11546322|NCT01030198|Experimental|Fresh surgical scars|Treatment of scars
11546323|NCT01030198|Experimental|Mature scars|Treatment of scars
11546324|NCT01030185|Experimental|NovaShunt's Automated Fluid Shunt|The Automated Fluid Shunt (AFS) Device
11546325|NCT01030159||001|
11546326|NCT01030146|Other|NeilMed® Sinus Rinse™ System|NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
11546327|NCT01030133|Active Comparator|Real TMS|Participants in the real Transcranial Magnetic Stimulation (TMS) group will receive real stimulation across all interventions; the operator role Real TMS and receiver role Real TMS. rTMS will be used to stimulate the left prefrontal cortex using two Neuronetics TMS machines with figure-8, iron core coils at 10Hz and at 110% of resting motor threshold [5 second trains following each trial (25 trials per visit)].
11546328|NCT01030133|Sham Comparator|Sham TMS|Participants in the sham Transcranial Magnetic Stimulation (TMS) group will receive sham stimulation across all interventions; the operator role Sham TMS and receiver role Sham TMS. Sham Stimulation involves 5 second trains of 10Hz rTMS in pairs alternating between real TMS and eSham TMS (randomly ordered). All sham treatment will be delivered with a specially designed, manufacture-provided sham TMS coil that looks and sounds identical to a real TMS coil but no magnetic current is transferred to the participant.
11546329|NCT01030133|Other|All Participants Operator Role|All participants in Operator Role (Receiving real or sham TMS)
11546330|NCT01030120|Active Comparator|etanercept|etanercept 50mg BIW
11546331|NCT01030120|Placebo Comparator|placebo|matching placebo
11546332|NCT01030107||Children with Insufficient Sleep|Children who sleep approximately 9-10 hours/night
11546333|NCT01030094||Topiramate|Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
11546334|NCT01030094||Carbamazepine|Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
11546335|NCT01030094||Valproic acid|Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
11546336|NCT01030094||Normal Control|Healthy female participants will be observed in Normal control group.
11546340|NCT01030068|Active Comparator|Wellness|Health & Wellness classes plus smoking cessation therapy
11546341|NCT01030055|Experimental|TKI258 - bioavailability|
11546342|NCT01030055|Experimental|TKI258 - food|
11546343|NCT01030042|Experimental|Cetuximab/Irinotecan|Cetuximab/irinotecan followed, after progression, by FOLFOX-4 (Oxaliplatin, leucovorin and 5-fluorouracil)
11546344|NCT01030042|Active Comparator|FOLFOX 4|FOLFOX-4 (Oxaliplatin, leucovorin and 5-fluorouracil) followed, after progression, by irinotecan/cetuximab
11546345|NCT01030029|Active Comparator|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
11546346|NCT01030029|Placebo Comparator|pstim device without acupuncture|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
11546347|NCT01030016|Experimental|atenolol|subjects received 6 weeks of atenolol
11546348|NCT01029990|Experimental|Telephone arm|A midwife tries to contact the woman by telephone and offer her an appointment for a PAP-smear
11546349|NCT01029990|Experimental|Self-test arm|
11546350|NCT01029990|No Intervention|Control arm|No intervention other than what is routine in the screening program
11546351|NCT01029964|Active Comparator|6-9 years|Age at start of treatment
11546352|NCT01029964|Active Comparator|10-13 years|Age at start of treatment
11546353|NCT01029964|Active Comparator|14-16 years|Age at start of treatment
11546354|NCT01029964|No Intervention|Control 6-9 years|Untreated control group
11546355|NCT01029938|Active Comparator|Covered stent|The Willis covered stent specifically designed for intracranial vasculature was developed by our institution and the MicroPort Medical Company (Shanghai, China), and coil embolization, which has been widely applied for nearly two decades, is currently the endovascular approach that is first recommended for intracranial aneurysm treatment.
11546356|NCT01029938|Active Comparator|Coil|Coil embolization, which has been widely applied for nearly two decades, is currently the endovascular approach that is first recommended for intracranial aneurysm treatment.
11546357|NCT01029925|Experimental|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart.
11546358|NCT01029912|Experimental|CCNMES|Contralaterally Controlled Neuromuscular Electrical Stimulation (CCNMES) Electrical Stimulator
11546359|NCT01029912|Active Comparator|Cyclic NMES|Cyclic Neuromuscular Electrical Stimulation (NMES) Electrical Stimulator
11546360|NCT01029886|Experimental|1|
11546361|NCT01029886|Active Comparator|2|
11546362|NCT01029873|Experimental|ALT-801|
11546363|NCT01029847|Placebo Comparator|Placebo|
11546364|NCT01029847|Active Comparator|Adalimumab|TNF-alpha inhibitor
11546365|NCT01029834|Experimental|Intervention- Lifestyle family based|Behavioral family based
11546366|NCT01029834|Active Comparator|Information control|Child intervention only
11546367|NCT01029821|Other|Low-Molecular-Weight Heparin for DVT|Low-Molecular-Weight Heparin for DVT Prophylaxis after Open Reduction and Internal Fixation of ankle fractures
11546368|NCT01029795|Experimental|LY2599506|Combinations of 50-milligram (mg) or 100-mg capsules of LY2599506 or matching placebo capsules (each dose contains at least 1 capsule of active drug). LY2599506 will be administered, based on predefined glycemic targets, in escalating doses from 100 mg/day up to 800 mg/day.
11546369|NCT01029795|Active Comparator|Glyburide|Combinations of 2.5-mg capsules of Glyburide or matching placebo capsules (each dose contains at least 1 capsule of active drug). Glyburide will be administered, based on predefined glycemic targets, in escalating doses from 5 mg/day up to 20 mg/day.
11546370|NCT01029782|Active Comparator|IV cefazolin plus oral probenecid and placebo cephalexin|
11546371|NCT01029782|Active Comparator|Oral cephalexin and saline IV plus probenecid placebo|
11546372|NCT01029769|Active Comparator|initial olanzapin|
11546373|NCT01029769|Active Comparator|initial amisulpride|
11546374|NCT01029769|Active Comparator|early responders|
11546375|NCT01029769|Active Comparator|early non-responders switched|
11546376|NCT01029769|Active Comparator|ealy non-responders non-switched|
11546377|NCT01029756|Active Comparator|Macintosh Laryngoscope|
11546378|NCT01029756|Active Comparator|Pentax AWS Videolaryngoscope|
11546379|NCT01029743||Group 1|
11546380|NCT01029743||Group 2|
11546381|NCT01029730|Experimental|Bendamustine/Bortezomib/Rituximab|Treatment for all patients will be given in cycles of 28 days (4 weeks). All patients will receive treatment with bendamustine, bortezomib, and rituximab for a maximum of 6 cycles. Rituximab should be administered first.
11546382|NCT01029717|Experimental|Standard polyurethane Central Venous Catheter|"Standard polyurethane Central Venous Catheter
~All CVCs used in the trial are CE marked medical devices used for their intended purpose."
11546383|NCT01029717|Active Comparator|Antibiotic impregnated polyurethane CVC|"Antibiotic impregnated polyurethane CVC (minocycline and rifampicin)
~All CVCs used in the trial are CE marked medical devices used for their intended purpose."
11546384|NCT01029717|Active Comparator|Heparin bonded polyurethane CVC|"Heparin bonded polyurethane CVC
~All CVCs used in the trial are CE marked medical devices used for their intended purpose."
11546385|NCT01029704|Experimental|EGT0001442|
11546386|NCT01029704|Placebo Comparator|Placebo|
11546387|NCT01029691|Experimental|Positive Airway Pressure (compliant)|This arm was women who used auto-titrating positive airway pressure (APAP) for at least 4 hours per night
11546388|NCT01029691|No Intervention|Standard care|
11546389|NCT01029691|Experimental|Positive Airway Pressure (non-compliant)|No one was assigned to this arm, but for results data quality purposes, women assigned to PAP who were explicitly non-compliant (used less than 4 hours per night), were analyzed separately from women who were compliant with the PAP assignment.
11546391|NCT01029665||CDH survivors|School age (ages 4-6) Congenital Diaphragmatic Hernia survivors treated at Duke University Medical Center.
11546392|NCT01029652|Experimental|Canakinumab 150 mg|"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive re-dose of study drug on demand upon occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after previous dose. Patients completing 12 weeks core study were allowed to continue treatment in another 12-week extension for any new gout flare on demand with same treatment as assigned in core study.
~After completing the first extension, patients were offered to enter second extension study, whereby all patients were treated open-label on demand with canakinumab 150 mg sc upon new flare for 1 year for a total duration of 18 months following randomization in core study. Patients completing first 12 weeks extension study were allowed to continue to be treated in another single-arm, open-label 48 weeks extension when all patients from both treatment arms received canakinumab on demand"
11546393|NCT01029652|Active Comparator|Triamcinolone acetonide 40 mg|"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.
~Patients under this arm who agreed to continue to 2nd extension period of 12 months, were switched to canakinumab 150 mg sc for any new gout flare during this period Triamcinolone acetonide was not to be administered in the 48-week session."
11546394|NCT01029639|No Intervention|Treatment|Diabetic patients will complete hypoglycemia unawareness questionnaires at baseline and quarterly thereafter to monitor and assess progress with complications resulting from their diabetes. Comparisons will be performed on low blood sugar incidences reported by subjects requiring heath care intervention other than by the subject themselves.
11546395|NCT01029639|Experimental|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
11546396|NCT01029626|Other|Endoscopy|If the Glasgow-Blatchford score is zero, the endoscopy is delayed as an outpatient
11546397|NCT01029613||Rheumatoid arthritis|
11546398|NCT01029600|Active Comparator|Arthroscopic Capsulotomy|Arthroscopic capsular release
11546399|NCT01029600|Active Comparator|Distention with steroid|Arthrographic distention with contrast, saline, steroid and local anaesthetic
11546400|NCT01029587|Experimental|Eculizumab|Patients will receive eculizumab in conjunction with systemic anticoagulation before and after kidney transplant operation
11546401|NCT01029574|Experimental|Rotator cuff repair plus PRP|Conventional arthroscopic repair of rotator cuff with application of PRP.
11546402|NCT01029574|Placebo Comparator|Rotator cuff repair alone|Conventional arthroscopic repair of rotator cuff without application of PRP
11546403|NCT01029561|Active Comparator|CPAP and diet|The patients with severe OSA (AHI>=30) who do not fulfill the specific exclusion criteria wil be randomized. In the CPAP and diet arm, patients wil receive Continuous Positive air pressure therapy and the regular dietary treatment.
11546404|NCT01029561|Active Comparator|Diet|The diet arm wil receive the Conventional diet treatment that usually receive the patients included in the Bariatric Surgery Program
11546405|NCT01029535|Experimental|Juvederm® VOLUMA™|Juvederm® VOLUMA™ injected in both sides of face (up to 4 mL per side) at Investigator's discretion to achieve at least a 2-point improvement in the Mid-face Volume Deficit Scale. Participants who completed Week 8 of Phase 1 were eligible to participate in Phase 2 and could receive an additional optional treatment if applicable.
11546406|NCT01029522|Experimental|Lipilou 20mg|
11546407|NCT01029522|Active Comparator|Lipitor 20mg|
11546408|NCT01029509|Experimental|OPB-31121|OPB-31121 200 mg twice daily for 21 days followed by 7 days of rest
11546409|NCT01029483|Experimental|Low carbohydrate diet|6 week ad libitum low carbohydrate diet; research diet provided at 120% of estimated energy requirement for weight maintenance; carbohydrate intake limited to 28g/d
11546410|NCT01029483|Active Comparator|High Carbohydrate Diet-ad libitum|High complex carbohydrate diet (55% carbohydrate, 18% protein, 27% fat. 120% of estimated energy needs for weight maintenance provided, participants allowed to eat as much or as little as desired to satisfy appetite
11546411|NCT01029483|Active Comparator|High Carbohydrate Diet-Energy-matched|High carbohydrate diet (55% carbohydrate, 18% protein and 27% fat). Energy intake restricted to ~68% of energy needs for weight maintenance. Participants required to eat all food provided and nothing else
11546412|NCT01029470|Experimental|Luveris|Those subjects who experience hyponresponse to FSH stimulation during mid-follicle phase after pituitary downregulation will receive Luveris 75IU or 150IU IH injection daily till HCG day.
11546413|NCT01029444|Experimental|Insulin|Brittle diabetic patients or patients with uncontrolled blood sugars will complete blood sugar diaries weekly and have hemoglobin A1c lab tests performed quarterly to evaluate progress in stabilizing blood sugars.
11546414|NCT01029431|Experimental|1|All subjects will have both Air-Q ILA & PLMA
11546415|NCT01029418|Experimental|AZD6244 and sorafenib|AZD6244+ sorafenib
11546416|NCT01029405|Active Comparator|1. AN2728 Ointment B|2%, administered twice daily
11546417|NCT01029405|Placebo Comparator|2. AN2728 Ointment B Vehicle|
11546418|NCT01029405|Active Comparator|3. AN2728 Ointment B|2%, administered once daily
11546419|NCT01029405|Active Comparator|4. AN2728 Ointment B|0.5%, administered twice daily
11546420|NCT01029405|Active Comparator|5. AN2728 Ointment B|0.5%, administered once daily
11546421|NCT01029392|Experimental|Required Vitamin D|Those children whose Vitamin D level was low (<30 ng/mL) are given Vitamin D supplementation
11546422|NCT01029392|No Intervention|Normal Vitamin D|Those children whose Vitamin D level was normal (50-80 ng/mL) did not receive Vitamin D supplementation
11546423|NCT01029379||200 patients,ASA 1|
11546424|NCT01029366|Experimental|CART-19 CLL|CART-19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion days 0, 1, 2 and 11 in the absence of disease progression or unacceptable toxicity.Minimum/maximum total dose: 1.5x10^7 / 5x10^9 administered to patients with chronic Lymphocytic Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL).
11546425|NCT01029366|Experimental|CART-19 ALL|CART-19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion days 0, 1, 2 and 11 in the absence of disease progression or unacceptable toxicity.Minimum/maximum total dose: 1.5x10^7 / 5x10^9 administered to patients with chronic Lymphocytic Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL).
11546426|NCT01029353|Active Comparator|Laparotomy|
11546427|NCT01029353|Active Comparator|Peritoneal drain placement|
11546428|NCT01029340|Experimental|Arm 1: Recombinant Factor VIII (BAY81-8973) then Kogenate FS|Part A - Arm 1: Participants first received one single intravenous (IV) injection of BAY81-8973 50 IU/kg, then 1 single IV injection of Kogenate FS (BAY14-2222) 50 IU/kg with a wash-out period of at least 2-3 days in between
11546429|NCT01029340|Experimental|Arm 2: Kogenate FS then Recombinant Factor VIII (BAY81-8973)|Part A - Arm 2: Participants first received one single intravenous (IV) injection of Kogenate FS (BAY14-2222) 50 IU/kg, then 1 single IV injection of BAY81-8973 50 IU/kg with a wash-out period of at least 2-3 days in between
11546430|NCT01029340|Experimental|Arm 3: Recombinant Factor VIII by CS/EP then by CS/ADJ|Part B - Arm 3: Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months
11546431|NCT01029340|Experimental|Arm 4: Recombinant Factor VIII by CS/ADJ then by CS/EP|Part B - Arm 4:. Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay Per European Pharmacopeia for 6 months
11546432|NCT01029340|Experimental|Arm 5: Recombinant Factor VIII by CS/EP|Part C - Arm 5: Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
11546433|NCT01029327||Healthy subjects|
11546434|NCT01029314||Cardiopulmonary bypass surgery|Thirty to fifty cardiac surgery patients undergoing cardiopulmonary bypass will have serial triplicate temperatures taken by both the Genius 2 tympanic thermometer and the Exergen-TAT 5000 temporal artery thermometer at predetermined perioperative time points. These temperature readings will be compared to at least one core temperature (i.e., pulmonary artery).
11546435|NCT01029301|Experimental|Experimental: Endymed study group|
11546436|NCT01029288|Active Comparator|Statin Choice Decision Aid|Subjects will receive an intervention of Statin Choice Decision Aid and usual care for antihyperglycemic medication discussion with their clinician.
11546437|NCT01029288|Active Comparator|Diabetes Medication Choice Decision Aid|Subjects will receive an intervention of Diabetes Medication Choice Decision Aid and usual care for lipid therapy medication discussion with their clinician.
11546438|NCT01029275|Experimental|Arm A|pre-operative medical treatment with Sandostatin
11546439|NCT01029275|No Intervention|Arm B|pituitary surgery as a first line treatment
11546440|NCT01029262|Experimental|Arm #1 - Lenalidomide plus placebo|Lenalidomide 10 mg by mouth (PO) daily plus 2 placebo capsules for participants with a creatinine clearance ≥ 60 mL/min for at least 168 days until disease progression, intolerable side effects or withdrawal of consent. Lenalidomide 5 mg PO daily plus 2 placebo capsules for participants with a creatinine clearance ≥ 40 and < 60 mL/min.
11546441|NCT01029262|Placebo Comparator|Arm #2 - placebo|Three placebo capsules once daily for at least 168 days until disease progression occurred, intolerable side effects or withdrawal of consent.
11546442|NCT01029249||ACTG A5257 participants|Participants in this study will also be enrolled in ACTG A5257.
11546443|NCT01029223|Experimental|ivabradine|
11546444|NCT01029223|Experimental|metoprolol|
11546445|NCT01029223|Placebo Comparator|placebo|
11546446|NCT01029197|Experimental|CBT Intervention|The CBT intervention includes psychoeducation and coping and social skills delivered in a group format, and exposure therapy delivered in individual sessions
11546447|NCT01029197|Active Comparator|Treatment as Usual|The TAU Condition will receive usual services at the community clinic, which may include medications, individual or group therapy
11546448|NCT01029184|Active Comparator|complete non allergenic cereals|existing commercialized product
11546449|NCT01029184|Experimental|complete non allergenic cereals plus|commercialised product with the addition of a novel ingredient
11546450|NCT01029171|Experimental|1|OEP (Otago Exercise Program; home-based balance and strength retraining program)
11546451|NCT01029171|Active Comparator|2|CON (control; usual care)
11546452|NCT01029158|Experimental|1a|250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
11546453|NCT01029158|Experimental|1b|250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
11546454|NCT01029158|Experimental|1c|250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
11546455|NCT01029158|Experimental|1d|500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
11546456|NCT01029158|Experimental|2a|250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then 250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
11546457|NCT01029158|Experimental|2b|500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
11546458|NCT01029158|Experimental|2c|500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
11546459|NCT01029158|Experimental|2d|500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then 500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose (i.e. two doses in total).
11546460|NCT01029145||1|Bipolar patients that experience a new episode of any type
11546461|NCT01029132|Experimental|non-responder group|patients who did not maintained or improved cognitive function
11546462|NCT01029132|Experimental|responder group|patients who maintained or improved cognitive function
11546463|NCT01029080||Sepsis|All patients with sepsis defined by actually sepsis guidelines
11546464|NCT01029067|Active Comparator|Cognitive Remediation|Computerized cognitive remediation (CogPack training). A fixed series is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with group MCT, eight sessions are administered. Each session lasts approximately 45-60 minutes.
11546465|NCT01029067|Experimental|Metacognitive Training|The group metacognitive training program (MCT) is fully documented (Moritz, Woodward, & Metacognition Study Group, 2007; VanHam Campus Press) and can be obtained in more than 15 languages cost-free via the following link: www.uke.de/mkt. The group program is delivered to groups of 3-10 patients by trained psychologists addressing delusion-related metacognitive biases (e.g., jumping to conclusions). The eight modules are presented via a video projector using pdf-converted Power-Point slides. Each group session lasts approximately 45-60 minutes. Individualized MCT (MCT+) follows group sessions and accords to the general guidelines for cognitive-behavioral therapy. For each patient, 8 one-to-one sessions were carried in addition to one session relating to the medical history.
11546466|NCT01029054|Experimental|carfilzomib, lenalidomide w/dexamethasone|"Phase I: carfilzomib will be taken with a combination of lenalidomide plus dexamethasone in a series of escalating dosages to determine the maximum tolerated dose level
~Phase II: carfilzomib will be given at the MTD established in the Phase I portion of the study"
11546467|NCT01029041|Experimental|Strengthening exercise|This group does global strengthening exercise
11546468|NCT01029041|Experimental|Stretching exercise|This group does global stretching exercise
11546469|NCT01029041|No Intervention|Control|This group does nor do any kind of exercise during the study
11546470|NCT01029015||Group 1 -OAB|Subjects with overactive bladder (OAB)
11546471|NCT01029015||Group 2 - Insomnia|Subjects with insomnia
11546472|NCT01029015||Group 3 - Normal|Normal Subjects
11546473|NCT01029002|Experimental|Vitamin D 50000 IU|Patients randomized to this arm will receive 50,000 IU of ergocalciferol in one unmarked pill once weekly.
11546474|NCT01029002|Placebo Comparator|Placebo|Patients randomized to this arm will receive a placebo pill once weekly.
11546475|NCT01028989|Other|Reduced Glycemic Load Diet|"36-40% fat; 40-42% carbohydrate; 18-22% protein
~Glycemic Load <=46 per 1000 calories"
11546476|NCT01028989|Other|Standard Diet|"25-27% fat; 55-57% carbohydrate; 18-22% protein
~Glycemic Load >=77 per 1000 calories"
11546477|NCT01028976|Placebo Comparator|Placebo|Two tablets, daily, for 8 weeks
11546478|NCT01028976|Experimental|Vitamin C|Two tablets, daily, for 8 weeks
11546479|NCT01028963|Placebo Comparator|Placebo|
11546480|NCT01028963|Active Comparator|Active control|
11546481|NCT01028963|Experimental|Active Study Medication (Group C)|CCX140-B
11546482|NCT01028963|Experimental|Active Study Medication (Group D)|CCX140-B
11546483|NCT01028950|Experimental|YM150 group|
11546484|NCT01028937|Experimental|Hyperopia|The NTK Optimal Keratoplasty System/Procedure is indicated for the temporary improvement of distance uncorrected visual acuity (in patient eyes that have manifest refraction, spherical equivalent equal to +1.0 to +2.5 Diopters, with less than or equal to 0.75 Diopters of refractive astigmatism (minus cylinder format) and with uncorrected distance visual acuity less than 20/40 but greater than or equal to 20/80. Patients must be at least 40 years of age with a documented stability of refraction for the prior 12 months, as demonstrated by a change of less than or equal to 0.5 Diopters in MRSE. The magnitude of D-UCVA improvement by Opti-K treatment may diminish over time, caused by some regression of effect in addition to natural progressive loss of accommodation and, for most patients, progressive hyperopic shift with increasing age.
11546485|NCT01028924|Experimental|Teduglutide 5 mg|Treatment A, subcutaneous injection
11546486|NCT01028924|Experimental|Teduglutide 20 mg|Treatment B, subcutaneous injection
11546487|NCT01028924|Placebo Comparator|Placebo|subcutaneous injection
11546488|NCT01028924|Active Comparator|Moxifloxacin|400 mg, oral
11546489|NCT01028911|Experimental|PF-03654746|
11546490|NCT01028911|Placebo Comparator|Placebo|
11546491|NCT01028885|Experimental|Arm I|"Patients undergo MRI and CT scan-based simulation for treatment planning with endorectal balloon target immobilization. The treatment target volumes and surrounding organs at risk are contoured, treatment plan developed and approved.
~Patients then undergo 39 fractions of image-guided intensity-modulated radiotherapy over 8 weeks. Patients also undergo weekly MRI scans of the pelvis (in the planned treatment position) during radiotherapy."
11546492|NCT01028872|Sham Comparator|Sensar IOL|
11546493|NCT01028872|Active Comparator|Tecnis IOL|
11546494|NCT01028872|Active Comparator|AcrySof IQ|
11546495|NCT01028859|Experimental|CKD-516 inj|
11546496|NCT01028846|Active Comparator|Diazoxide|1-2 mg/kg total dose given intravenously during pancreatic clamp study
11546497|NCT01028846|Placebo Comparator|Placebo|Intravenous normal saline during pancreatic clamp study
11546498|NCT01028833|Experimental|Power mobility|Intervention included provision of power wheelchair and power mobility training program. Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
11546499|NCT01028833|No Intervention|Control|Children in the control group will not receive any additional intervention, but will continue to receive the early intervention or other services they were receiving prior to enrollment in this study.
11546500|NCT01028820|Experimental|Open-Label, Flexible-Dose Aripiprazole|This is a single group assignment pharmacodynamics study in which all study participants are given an open-label, flexible dose of aripiprazole for up to 8 weeks.
11546501|NCT01028807|Experimental|1. Experimental group: Early feeding:|After 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
11546502|NCT01028807|Active Comparator|Control group : Obligatory 5 day fasting|Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
11546503|NCT01028794|Experimental|autologous bone marrow mononuclear cell|On day 7-10 after stroke, patient has 25ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.
11546504|NCT01028794|Experimental|autologous bone marrow mononuclear cells|On day 7-10 after stroke, patient has 50ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.
11546505|NCT01028781|Other|Thalidomide|Thalidomide was administered and pain reports were recorded over the course of 6 months.
11546506|NCT01028768|Experimental|Teduglutide|
11546507|NCT01028755|Experimental|Arm 1|
11546508|NCT01028729|Experimental|Endostar with chemotherapy|All eligible patients will receive Endostar in combination with Gemcitabine plus Platinum-based chemotherapy for 4 cycles (21 days for each cycle). Endostar treatment will continue after completion of chemotherapy cycles until disease progression.
11546509|NCT01028716|Experimental|Treatment (nonmyeloablative HCT, TBI)|Patients receive fludarabine IV over 30-60 minutes daily on days -6 through -2 and cyclophosphamide IV over 1-2 hours on days -6, -5, and 3-4. Patients undergo total-body irradiation on day -1. Patients undergo donor peripheral blood stem cell transplant on day 0. Patients then receive tacrolimus IV once daily or PO BID on days 5-180 (may be continued if active GvHD is present), mycophenolate mofetil IV or PO TID on days 5-35 (may be continued if GvHD present), and filgrastim IV beginning on day 5 until the ANC is >= 1,000/mm^3 for three consecutive days.
11546510|NCT01028703||Donors|"110 will be cases that undergo uninephrectomy"
11546511|NCT01028703||Controls|"110 controls"
11546512|NCT01028690|Active Comparator|Lactobacillus reuteri|L. reuteri is one species of lactobacillus that naturally inhabits the gastrointestinal tract of humans
11546513|NCT01028690|Placebo Comparator|placebo|Placebo will be delivered in a chewable tablet form (1.5g per dose)
11546514|NCT01028677|Experimental|intranasal spray with oxytocin|Twice daily intranasal oxytocin spray (24 IU, 6 insufflations/dose) for 6 weeks
11546515|NCT01028677|Placebo Comparator|intranasal spray without oxytocin|Twice daily intranasal spray without oxytocin (six 0.1 ml insufflations/dose) for 6 weeks.
11546516|NCT01028664|Experimental|Glaucoma or ocular hypertension patients|
11546517|NCT01028651||Portopulmonary hypertension|
11546518|NCT01028638||Renal Cancer|Renal Cancer patients treated with everolimus
11546519|NCT01028625|Active Comparator|Cognitive Behavior Therapy|
11546520|NCT01028625|Other|Usual Care|Participants who are randomly assigned to usual care will receive whatever treatment (if any) for depression their own physician may prescribe. In most cases, treatment (if any is provided) is likely to consist of a serotonin reuptake inhibitor (SSRI) antidepressant such as sertraline or citalopram.
11546521|NCT01028612|Experimental|thermal ablation with external beam radiation|
11546522|NCT01028599|Experimental|Exercise|
11546523|NCT01028586|Active Comparator|Arm 1|Number of Cycles: until progression or unacceptable toxicity develops.
11546524|NCT01028586|Active Comparator|Arm 2|Number of Cycles: until progression or unacceptable toxicity develops.
11546525|NCT01028586|Placebo Comparator|Arm 3|Placebo
11546526|NCT01028573|Active Comparator|Group 1|4L of PEG-ELS (Golytely) consumed on the evening before colonoscopy
11546527|NCT01028573|Experimental|Group 2|2L of PEG-ELS (Golytely) consumed on the evening before and 2L consumed on the morning of colonoscopy
11546528|NCT01028573|Experimental|Group 3|238g of PEG-3350 mixed with 2L of Gatorade
11546529|NCT01028573|Experimental|Group 4|1L of PEG-3350 + Gatorade
11546530|NCT01028560|Active Comparator|No immunotherapy, receive standard of care asthma treatment|This group consists of children who do not receive allergy immunotherapy. Both groups - the experimental as well as the control group receive otherwise standard of care asthma and allergy treatment
11546531|NCT01028560|Experimental|Allergen immunotherapy|This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile. The maximum number of injections at each visit is 1-3 injections per child. In addition to allergy immunotherapy. this group receives standard of care asthma and allergy treatment
11546532|NCT01028547|Active Comparator|dexamethasone 8mg|
11546533|NCT01028547|Placebo Comparator|normal saline|
11546534|NCT01028534|Active Comparator|ARB plus increased ARB|angiotensin II receptor blockers for the first 3 months and increasing dose of angiotensin II receptor blockers for the next 3 months
11546535|NCT01028534|Active Comparator|ARB plus CCB|angiotensin II receptor blockers for the first 3 months and adding calcium channel blockers for the next 3 months
11546536|NCT01028534|Active Comparator|CCB plus ARB|calcium channel blockers for the first 3 months and adding angiotensin II receptor blockers for the next 3 months
11546537|NCT01028521|Experimental|CM3.1-AC100|
11546538|NCT01028521|Placebo Comparator|Placebo|
11546539|NCT01028508|Active Comparator|PHARM|lithium and venlafaxine
11546540|NCT01028508|Experimental|STABLE|ECT + VLF + Li
11546541|NCT01028495|Experimental|gemcitabine and RX-0201|"Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.
~RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off."
11546592|NCT01028131|No Intervention|Control|Participants randomized by the computer into this condition will only view the 20-minute video clips of music and tv videos.
11546593|NCT01028131|Experimental|Computerized brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model (ask, advise, assess, assist & arrange) and Motivational Interviewing.
11547014|NCT01025492|Placebo Comparator|Placebo|Matching placebo tablet orally, once daily for 12 weeks
11546542|NCT01028482|Experimental|sertraline, psychotherapy|"both study groups will receive concomitant psychotherapy treatment. There will be 2 main comparison groups: 1) an sertraline treated group and 2) a drug placebo - controlled group. While this design lacks a blinded drug-only condition, we will have an open drug-only arm that will be of considerable value. Furthermore, while a true placebo group is also lacking, and a certain response to psychotherapy is expected, we believe that the drug condition will show a definite superiority to the psychotherapy + placebo condition. The rational for including psychotherapy in the treatment protocol is the fact that this is a well-established treatment for PPD, and for ethical considerations it is unreasonable not to administer any active treatment to women suffering from PPD. It is our conviction that this is the only design, albeit its limitations, which will allow a comparison between medication-treated vs. placebo-treated PPD patients."
11546543|NCT01028482|Placebo Comparator|placebo, psychotherapy|"both study groups will receive concomitant psychotherapy treatment. There will be 2 main comparison groups: 1) an sertraline treated group and 2) a drug placebo - controlled group. While this design lacks a blinded drug-only condition, we will have an open drug-only arm that will be of considerable value. Furthermore, while a true placebo group is also lacking, and a certain response to psychotherapy is expected, we believe that the drug condition will show a definite superiority to the psychotherapy + placebo condition. The rational for including psychotherapy in the treatment protocol is the fact that this is a well-established treatment for PPD, and for ethical considerations it is unreasonable not to administer any active treatment to women suffering from PPD. It is our conviction that this is the only design, albeit its limitations, which will allow a comparison between medication-treated vs. placebo-treated PPD patients."
11546544|NCT01028469|Experimental|Artelon MTP Spacer|Metatarsophalageal hemi-implant
11546545|NCT01028456|Placebo Comparator|100 lux|100 lux / 30 minutes day
11546546|NCT01028456|Experimental|Light Therapy 10,000 lux|10,000 lux / 30 minutes a day for 3 months
11546547|NCT01028443|Active Comparator|Cyclosporine A 2%|
11546548|NCT01028443|Placebo Comparator|Artificial tears|
11546549|NCT01028430||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
11546550|NCT01028417|Experimental|Group 1|Group 1 receives the intervention - insertion of platinum microcoil followed by nodule excision
11546551|NCT01028417|No Intervention|Group 2|Group 2 receives the standard of care - nodule excision, but without the microcoil insertion
11546552|NCT01028404|Experimental|Trial part 1|
11546553|NCT01028404|Experimental|Trial part 2|
11546554|NCT01028391|Experimental|Sitagliptin + Pioglitazone|
11546555|NCT01028391|Active Comparator|Pioglitazone + Placebo|
11546556|NCT01028378|Experimental|Topography-guided LASIK|Topography-guided LASIK for Myopia or Hyperopia
11546557|NCT01028365||No treatment|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
11546558|NCT01028352|Other|Duloxetine|
11546559|NCT01028339|Active Comparator|Mannitol|
11546560|NCT01028339|Experimental|Hypertonic saline|
11546561|NCT01028326|Experimental|Group A|Group A of children will receive 2 doses of PCV10 vaccine, one at the time of enrolment and one 2 months later, followed by a dose of DTaP vaccine 4 months later
11546562|NCT01028326|Experimental|Group B|Group B of children will receive PCV10 vaccine, followed by a dose of DTaP vaccine after 2 months, and another dose of PCV10 4 months later.
11546563|NCT01028326|Active Comparator|Group C|Group C of children will receive a dose of hepatitis A vaccine, followed by a dose of DTaP vaccine after 2 months, and another dose of hepatitis A 4 months later, along with a dose of PCV10.
11546564|NCT01028313|Experimental|1|Systemic Therapy
11546565|NCT01028300|Other|ProDisc L|
11546566|NCT01028287|Active Comparator|ACTH-16 units|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
11546567|NCT01028287|Active Comparator|ACTH-32 units|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
11546568|NCT01028274|Placebo Comparator|Placebo|
11546569|NCT01028274|Experimental|Investigational Product 1|
11546570|NCT01028274|Experimental|Investigational Product 2|
11546571|NCT01028261|Experimental|ZGN-433|
11546572|NCT01028261|Placebo Comparator|Normal Saline|
11546573|NCT01028248|Active Comparator|2.0 mg Ranibizumab|
11546574|NCT01028248|Active Comparator|0.5 mg Ranibizumab|
11546575|NCT01028235||Obstructive Dysphagia|Patients who complained of dysphagia, which had an obstructive etiology for their symptoms at the time of endoscopy (ring, mass, stricture, etc)
11546576|NCT01028235||Non-obstructive Dysphagia|Patients whose endoscopy was normal and without any obvious etiology for their symptoms noted.
11546577|NCT01028222|Experimental|Nilotinib|400 mg twice daily
11546578|NCT01028222|Active Comparator|DTIC|850 mg/m2 IV every 3 weeks
11546579|NCT01028209|Experimental|Assess [18F] PBR06 and PET imaging|
11546580|NCT01028196||1 - schizophrenia|Psychiatrists will enrol patients meeting inclusion/exclusion criteria with schizophrenia as they routinely attend the clinic or are examined in hospital in a consecutively manner.
11546581|NCT01028196||2 - recurrent depression|Psychiatrists will enrol patients meeting inclusion/exclusion criteria with recurrent depression as they routinely attend the clinic or are examined in hospital in a consecutively manner.
11546582|NCT01028183||Extremely Premature Infants|< 30 weeks gestation (N=5000)
11546583|NCT01028183||Premature Infants|30-36 weeks gestation (N=2000)
11546584|NCT01028183||Hospitalized Term Infants|>=37 weeks gestation (N=2000)
11546585|NCT01028183||Healthy Term Infants|>=37 weeks gestation (N=1000)
11546586|NCT01028170|Experimental|Furosemide with Hypertonic Saline|Furosemide with 150 mL of 2.4% NaCl
11546587|NCT01028170|Active Comparator|Pulse Furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
11546588|NCT01028157|Placebo Comparator|General Health Control|
11546589|NCT01028157|Experimental|HIV Risk Reduction & Relapse Prevention|
11546590|NCT01028144|Experimental|ACT Program|Motivational and Behavioral Skills Physical activity after-school program
11546591|NCT01028144|Active Comparator|General Health|General health education after-school program
11546594|NCT01028131|Experimental|Contingency Management Alone|Participants randomized by the computer into this condition will view a 20-minute music and tv video clip after completing the brief assessment. The research assistant will then briefly describe the CM process, with some time to discuss questions regarding procedure to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
11546595|NCT01028131|Experimental|Combined Brief Intervention and CM|Combined intervention. Participants in this condition will receive both the brief intervention and the brief description of the CM process.
11546596|NCT01028118|Other|Therapy for Women reporting violence|Asking about life experience with violence and Cognitive Behavior Therapy.
11546597|NCT01028105|No Intervention|No MRSA screening, Group b|Standard of care
11546598|NCT01028105|Other|MRSA screening, Group a|MRSA preoperative screening
11546599|NCT01028092|Active Comparator|Control|anti R-IL2 induction + Mycophenolate Mofetil + cyclosporine A + corticosteroids
11546600|NCT01028092|Experimental|CNI-free|Thymoglobulin + Mycophenolate Mofetil + everolimus + corticosteroids
11546601|NCT01028092|Experimental|Switch|anti R-IL2 + Mycophenolate Mofetil + (Cyclosporine then Everolimus) + corticosteroids
11546602|NCT01028079|Active Comparator|Arm 2|
11546603|NCT01028079|Placebo Comparator|Arm 3|
11546604|NCT01028079|Experimental|Arm 1|
11546605|NCT01028066|Active Comparator|Traditional|Traditional nutritional counseling
11546606|NCT01028066|Experimental|Behavioral|Dialogic nutritional counseling
11546607|NCT01028053|Experimental|Flutemetamol (18F) Injection|Flutemetamol (18F) Injection
11546608|NCT01028040|Experimental|AZD3043|
11546609|NCT01028027|Experimental|Loteprednol and tobramycin|Loteprednol etabonate and tobramycin ophthalmic suspension
11546610|NCT01028027|Active Comparator|Tobramycin and dexamethasone|Tobramycin and dexamethasone ophthalmic suspension
11546611|NCT01028014|Active Comparator|Pseudoephedrine|Pseudoephedrine 120mg extended release tablets
11546612|NCT01028014|Active Comparator|Solifenacin|Solifenacin 5mg capsule
11546613|NCT01028014|Active Comparator|Tamsulosin|Tamsulosin 0.4mg capsule
11546614|NCT01028014|Active Comparator|Imipramine|Imipramine 25mg tablet
11546615|NCT01028014|Active Comparator|Cyclobenzaprine|Cyclobenzaprine 10mg tablet
11546616|NCT01028014|Placebo Comparator|Lactose capsules|Sham
11546617|NCT01027962|Other|ICBT Program|Intensive Computerized Brain Training using software packages donated by Posit Science.
11546618|NCT01027962|No Intervention|Control Intervention|Commercially available computer games that do not contain violent stimuli but are appealing to youth between 10 and 19 years of age.
11546619|NCT01027962|No Intervention|Healthy Control Group|No participation in computer activity.
11546620|NCT01027949|Experimental|Treprostinil diethanolamine (UT-15C)|All open will receive active study drug
11546621|NCT01027936||Normal Healthy Volunteers|
11546622|NCT01027923|Experimental|Dose Level 1|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5
~Plerixafor 320 mcg/kg/day IV over 30 minutes on days 0-5
~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5
~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
11546623|NCT01027923|Experimental|Dose Level 2|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5
~Plerixafor 420 mcg/kg/day IV over 30 minutes on days 0-5
~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5
~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
11546624|NCT01027923|Experimental|Dose Level 3|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5
~Plerixafor 560 mcg/kg/day IV over 30 minutes on days 0-5
~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5
~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
11546625|NCT01027910|Experimental|PCI-24781 without mandated GCSF|PCI-24781 in combination with doxorubicin without mandated GCSF
11546626|NCT01027910|Experimental|PCI-24781 with mandated GCSF|PCI-24781 in combination with doxorubicin with mandated GCSF
11546627|NCT01027897|Experimental|Doripenem group|Patients will receive doripenem for the treatment of their infection
11546628|NCT01027884|Placebo Comparator|Placebo|Placebo 900 mg/day
11546629|NCT01027884|Experimental|Idebenone|Idebenone 900 mg/day
11546630|NCT01027871|Experimental|LY2605541 Dosing Algorithm 1|Participants took both LY2605541 and their pre-study insulin for first several days
11546631|NCT01027871|Experimental|LY2605541 Dosing Algorithm 2|Participants took only LY2605541 with first dose doubled
11546632|NCT01027871|Active Comparator|Insulin glargine|
11546633|NCT01027858|Experimental|1|AT (aerobic-based exercise training)
11546634|NCT01027858|Active Comparator|2|CON (control; usual care)
11546635|NCT01027845|Experimental|10Pn Group|"Healthy male or female subjects, between 90 and 118 days of age who received 3 doses of Synflorix (10Pn) vaccine, administered intramuscularly on alternating (left/right) sides of the anterolateral thigh and DPT KAKETSUKEN Syringe (DTPa) vaccine administered subcutaneously on alternating (left/right) sides of the distal one third of the upper arm. Both vaccines were administered at 3, 4, and 5 months of age, followed by a booster dose at 17-19 months of age."
11546636|NCT01027845|Active Comparator|DTPa Group|"Healthy male or female subjects, between 90 and 118 days of age who received 3 doses of the DPT KAKETSUKEN Syringe (DTPa) vaccine, administered subcutaneously on alternating (left/right) sides of the distal one third of the upper arm at 3, 4, and 5 months of age, followed by a booster dose at 17-19 months of age."
11546637|NCT01027832|No Intervention|Control arm|no intervention
11546638|NCT01027832|Experimental|Experimental arm|antibiotics
11546639|NCT01027819|Active Comparator|Mobile bearing|Mobile bearing type between polyethylene insert and tibial component MB type will be randomly used in total knee arthroplasty
11546640|NCT01027819|Active Comparator|Fixed bearing|Fixed bearing type between polyethylene insert and tibial component FB type will be randomly used in total knee arthroplasty
11546641|NCT01027806|Active Comparator|Montelukast|
11546642|NCT01027806|Placebo Comparator|Placebo|
11546693|NCT01027442|Placebo Comparator|Conventional implant placement method|"The patients in ths group will be treated by conventional, free-hand implant placement"
11546643|NCT01027793|Active Comparator|Tretinoin|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
11546644|NCT01027793|Active Comparator|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center.
11546645|NCT01027780|Active Comparator|Mindfulness-Based Stress Reduction|Participation in the Mindfulness-Based Stress Reduction (MBSR) program following the initial assessment period, just prior to the start of the immunological measures.
11546646|NCT01027780|No Intervention|Wait-list control|Wait-list control participants were offered MBSR training after completion of their primary assessments periods.
11546647|NCT01027767||Surgery/Radiation Arm|Patients that have had surgery along with radiation therapy
11546648|NCT01027767||Surgery Arm|Patients that have had surgery of a benign lesion.
11546649|NCT01027754|Experimental|Varenicline|Drug treatment in combination with telephone quitline referral and brief individual counseling based on PHS guidelines at weeks 2, 4, 8, and 12
11546650|NCT01027754|Placebo Comparator|Placebo|Matched placebo capsules in combination with telephone quitline referral and brief individual counseling based on PHS guidelines at weeks 2, 4, 8, and 12
11546651|NCT01027741|Experimental|Phone Referral|Participants receive phone referral to cancer control and prevention services.
11546652|NCT01027741|Experimental|Tailored Cancer Communication|Participants will receive phone referral to cancer control and prevention services as well as tailored materials in the mail.
11546653|NCT01027741|Experimental|Cancer Control Navigator|Participants will receive phone referral to cancer control and prevention services as well as a personal cancer control navigator.
11546654|NCT01027741|No Intervention|Control|Participants receive only recommendation to talk to health care professional.
11546655|NCT01027728|Experimental|CCX354-C|
11546656|NCT01027715|Experimental|EEG seizure treatment group|EEG data available to physicians. Treatment based on EEG seizures. Treatment will be dictated by the detailed treatment protocol. Standard antiepileptic medications will be used.
11546657|NCT01027715|No Intervention|Clinical Seizure treatment Group|Seizure treatment in this group will be based on standard care - treating clinical seizures only. While EEG data will be collected in this group, the data will not be available to the treating physicians. A one-hour EEG report will be available to the treating team. Continuous EEG monitoring and treatment will only be allowed if the initial EEG shows status.
11546658|NCT01027702|Experimental|Infusion of donor lymphocytes|Patients will receive an infusion of donor lymphocyte after T-cell depleted transplant.
11546659|NCT01027689|Active Comparator|Alprazolam commercial immediate release oral tablet|
11546660|NCT01027689|Experimental|Alprazolam test sublingual tablet|
11546661|NCT01027676|Experimental|study arm|single arm Gefitinib plus vorinostat
11546662|NCT01027663|No Intervention|Iron Deficiency Anemia|
11546663|NCT01027663|No Intervention|Hereditary Hemochromatosis|
11546664|NCT01027663|Active Comparator|Iron Supplements|
11546665|NCT01027650|Experimental|Stage 1 Cohort 1|AGN208397 intravitreal injection 75 ug on Day 1.
11546666|NCT01027650|Experimental|Stage 1 Cohort 2|AGN208397 intravitreal injection 300 ug on Day 1.
11546667|NCT01027650|Experimental|Stage 1 Cohort 3|AGN208397 intravitreal injection 600 ug on Day 1.
11546668|NCT01027650|Experimental|Stage 1 Cohort 4|AGN208397 intravitreal injection 900 ug on Day 1.
11546669|NCT01027650|Experimental|Stage 2 Arm 1|AGN208397 intravitreal injection 600 ug on Day 1.
11546670|NCT01027650|Experimental|Stage 2 Arm 2|AGN208397 intravitreal injection 450 ug on Day 1.
11546671|NCT01027650|Experimental|Stage 2 Arm 3|AGN208397 intravitreal injection 300 ug on Day 1.
11546672|NCT01027650|Active Comparator|Stage 2 Arm 4|Dexamethasone 700 ug intravitreal implant on Day 1.
11546673|NCT01027637|Experimental|Alloderm reconstruction|All patients recieving the intervention Alloderm for breast reconstruction
11546674|NCT01027624||Hyperchlesterolaemia|Participants undertreated with hypercholesterolaemia
11546675|NCT01027611|Experimental|proparacaine HCL 0.5%|
11546676|NCT01027611|Experimental|proparacaine + lidocaine|
11546677|NCT01027611|Experimental|lidocaine gel|
11546678|NCT01027598|Experimental|Erlotinib + Pazopanib|"Erlotinib: 150 mg orally daily
~Pazopanib: 600 mg orally daily"
11546679|NCT01027598|Placebo Comparator|Erlotinib + Placebo|"Erlotinib: 150 mg orally daily
~Placebo: orally daily"
11546680|NCT01027572|Experimental|Thalamic stimulation|Patients in Vegetative or Minimally Conscious State
11546681|NCT01027559|Active Comparator|Depressed Group: CBT|Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.
11546682|NCT01027559|No Intervention|Healthy Control Group|Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.
11546683|NCT01027559|Active Comparator|Depressed Group: SRT|Depressed participants randomized to receive the antidepressant sertraline (SRT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.
11546684|NCT01027546|Placebo Comparator|placebo, tranexamic acid|
11546685|NCT01027533||Restor +3|patients will be implanted bilaterally with Restor + 3
11546686|NCT01027533||restor +4|Patients will be implanted bilaterally with Restor +4
11546687|NCT01027520|Experimental|Intervention|Application of Coban dressing
11546688|NCT01027494||Treatment|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension, 4 drops in outer ear canal of infected ear(s) while awake 2 times per day for 7 days
11546689|NCT01027494||Healthy|No intervention
11546690|NCT01027468|Experimental|group 1|bevacizumab intravitreal injection
11546691|NCT01027455|Placebo Comparator|Dry Cold|Dry (0% relative humidity) and cold (20 degrees Celsius - Room Temperature) carbon dioxide gas intraperitoneal insufflation for laparoscopic appendicectomy
11546692|NCT01027455|Experimental|Humidification|Humidified (98% relative humidity) and warm (37 degrees Celsius) carbon dioxide gas intraperitoneal insufflation for laparoscopic appendicectomy
11546731|NCT01027286|No Intervention|Control|No Vitagel used.
11546694|NCT01027442|Active Comparator|Computer-guidedimplant placement|In this group, the patients will be treated by implants placed via computer generated SLA guides
11546695|NCT01027429|Active Comparator|procaine penicillin and gentamicin|Procaine penicillin, 50,000 IU/kg by intramuscular injection plus gentamicin, 5 mg/kg intramuscular injection, both given once daily for 7 days
11546696|NCT01027429|Experimental|Amoxicillin and gentamicin|Oral amoxicillin (80-90 mg/kg) divided twice daily and intramuscular gentamicin, 5 mg/kg once daily, both given for 7 days
11546697|NCT01027429|Experimental|procaine penicillin, gentamicin, and amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
11546698|NCT01027416|No Intervention|No Intervention|
11546699|NCT01027416|Active Comparator|Tamoxifen|Tamoxifen 20 mg orally 1x/day for 4 weeks
11546700|NCT01027403||Healthy volunteers|
11546701|NCT01027403||Acute decompensated heart failure|
11546702|NCT01027390|Experimental|1 hr training 50% supervision|1 hr training 50% supervision
11546703|NCT01027390|Experimental|3 x 20 min training 50% supervision|3 x 20 min training 50% supervision
11546704|NCT01027390|Experimental|3 x 20 min training initial instructions|3 x 20 min training initial instructions
11546705|NCT01027390|Experimental|10 x 6 min training 50% supervision|10 x 6 min training 50% supervision
11546706|NCT01027390|No Intervention|reference|no training
11546707|NCT01027377|Experimental|A|Cohort to receive a single low dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single low dose intravenous injection of rFVIIIFc with safety and PK assessments
11546708|NCT01027377|Experimental|B|Cohort to receive a single high dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single high dose intravenous injection of rFVIIIFc with safety and PK assessments
11546709|NCT01027364|Experimental|Fixed Weekly Interval|"50 IU/kg rFIXFc via intravenous (IV) injection once every 7 days initially, then at a dose indicated by the participant's baseline pharmacokinetic (PK) assessment that ensured a target trough of 1% to 3% above baseline or higher, as clinically indicated. Adjustments to the initial weekly dose of rFIXFc (50 IU/kg) were to be made based on baseline PK assessments, occurrence of spontaneous bleeding episodes, and the trough levels, which were to be monitored at Weeks 4, 16, 26, and 39.
~Prior to the first dose of rFIXFc, participants in the Sequential PK subgroup were to receive a single dose of 50 IU/kg BeneFIX administered IV in the clinic, followed by PK sampling. A single dose of 50 IU/kg rFIXFc was administered following a 120-hour washout from BeneFIX, followed by PK sampling for a baseline PK profiling. At Week 26 (±1 week) subjects were to receive a single dose of 50 IU/kg rFIXFc for repeat PK profiling."
11546710|NCT01027364|Experimental|Individualized Interval|100 IU/kg rFIXFc via IV injection once every 10 days initially, then at an interval derived from the baseline PK assessment that ensured a target trough of 1% to 3% above baseline or higher, as clinically indicated. Adjustments to the initial 10-day interval were to be made based on baseline PK assessments and trough levels, which were monitored at Weeks 4, 16, 26, and 39.
11546711|NCT01027364|Experimental|On Demand|20 to 100 IU/kg rFIXFc via IV injection, or the dose indicated by the participant's baseline PK to target a plasma level of 20% to 100%, as needed for the treatment of mild to severe bleeding episodes
11546712|NCT01027364|Experimental|Surgery|The surgical period and dosing are dependent on the type of surgery the participant undergoes. Participants who started the study in one of the other treatment arms prior to surgery will return to the original treatment arm. Participants who joined the study in the Surgery arm will be assigned to one of the other treatment arms following post-operative rehabilitation.
11546713|NCT01027351|Experimental|5rMenB|Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV) (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.
11546714|NCT01027351|Experimental|5rMenB+OMV NZ|Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.
11546715|NCT01027351|Experimental|3rMenB|Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine without OMV (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.
11546716|NCT01027351|Experimental|3rMenB+OMV NZ|Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.
11546717|NCT01027351|Experimental|Naive_4042|Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 40 and 42 months of age in the present study.
11546718|NCT01027351|Experimental|Naive_6062|Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 60 and 62 months of age in the present study.
11546719|NCT01027338|Experimental|Tai Chi Exercise|
11546720|NCT01027338|No Intervention|Usual Care|
11546721|NCT01027325|Experimental|High CHO/Low Amylose|55% Carbohydrate (11.2% Amylose, 26.3% Amylopectin) 20% Protein 25% Fat
11546722|NCT01027325|Experimental|Low Carbohydrate/Hi Amylose|40% Carbohydrate (26.3% Amylose, 11.2% Amylopectin) 20% Protein 40% Fat
11546723|NCT01027325|Experimental|High CHO/High Amylose|55% Carbohydrate (26.3% Amylose, 11.2% Amylopectin) 20% Protein 25% Fat
11546724|NCT01027325|Experimental|Low Carbohydrate/Low Amylose|40% Carbohydrate (11.2% Amylose, 26.3% Amylopectin) 20% Protein 40% Fat
11546725|NCT01027325|Active Comparator|Baseline|40% Carbohydrate 20% Protein 40% Fat
11546726|NCT01027312||Glaucoma Patients|Glaucoma patients covering the entire range of visual field loss from none to advanced.
11546727|NCT01027312||Control Group|Aged matched people with no eye diseases.
11546728|NCT01027299|Active Comparator|Standard pacing|Standard pacing settings prescribed by the cardiac surgeon or intensivist after revascularisation.
11546729|NCT01027299|Active Comparator|BiVentricular pacing (BiV).|The group of patients receiving biventricular pacing after cardiac surgery.
11546730|NCT01027286|Experimental|Vitagel|
11546732|NCT01027273|Experimental|Peer-Led Stroke Recurrence Prevention Education|The intervention group will participate in a 6-session course held over a 6-week period. The Prevent Return of Stroke Workshop, led by trained peer educators, aims to help participants control the risk factors for stroke, thereby preventing recurrence of strokes.
11546733|NCT01027273|Placebo Comparator|Usual Care (Delayed Intervention)|The control group will be offered the chance to take part in the 6-week session intervention after 12 months after enrollment into the trial.
11546734|NCT01027260|Active Comparator|Itopride 50 mg|
11546735|NCT01027260|Active Comparator|Itopride 100 mg|
11546736|NCT01027260|Placebo Comparator|Placebo|
11546737|NCT01027234|Experimental|1|
11546738|NCT01027234|Placebo Comparator|2|
11546739|NCT01027221|No Intervention|0|primarily resectable pancreatic cancer patients
11546740|NCT01027221|Active Comparator|0,5 Gy|neoadjuvant Radiation of 0,5 Gy two days before resection
11546741|NCT01027221|Active Comparator|2 Gy|neoadjuvant Radiation of 2 Gy 2 days before resection
11546742|NCT01027221|Active Comparator|5 Gy|neoadjuvant Radiation of 5 Gy 2 days before resection
11546743|NCT01027208|Experimental|Ixabepilone|
11546744|NCT01027195|Placebo Comparator|Standard Bovie Electrocautery|Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.
11546745|NCT01027195|Experimental|Bipolar Radiofrequency|Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (<100 degrees Celsius) than standard Bovie electrocautery.
11546746|NCT01027182|No Intervention|Raltegravir|
11546747|NCT01027169|Experimental|Arm 1|subjects with mild hepatic impairment
11546748|NCT01027169|Experimental|Arm 2|subjects with moderate hepatic impairment
11546749|NCT01027169|Experimental|Arm 3|matched subjects with normal hepatic function
11546750|NCT01027156|Experimental|High Intensity Exercise|
11546751|NCT01027143|Experimental|omega-3 fatty acids|3 softgels (EPA, DHA) twice daily
11546752|NCT01027143|Placebo Comparator|control|Soybean oil: 3 matched softgel caps twice daily
11546753|NCT01027130||healthy control|240 female subjects without preeclampsia
11546754|NCT01027130||preeclampsia|120 female subjects with preeclampsia
11546755|NCT01027117|Active Comparator|Treatment A|Revatio 20 mg intact tablet. This is the reference treatment arm.
11546756|NCT01027117|Experimental|Treatment B|Treatment B: Revatio 20 mg crushed tablet mixed with apple sauce.
11546757|NCT01027117|Experimental|Treatment C|Treatment C: Revatio 20 mg extemporaneously prepared suspension (EP).
11546758|NCT01027091||patients with positive slope|patients with positive slope in the levels of free serum calcium levels between 6th and 12th postoperative hour
11546759|NCT01027091||patients with negative or no slope|patients with negative or no slope in the levels of free serum calcium levels between 6th and 12th postoperative hour.
11546760|NCT01027078||OSA|patients diagnosed with obstructive sleep apnea who do not have existing cardiovascular disease
11546761|NCT01027078||control|patients without obstructive sleep apnea who are matched in weight and age to the OSA patients
11546762|NCT01027065|Experimental|Tritherapy: CYT107+ vaccine+ antiviral|
11546763|NCT01027065|Experimental|Bitherapy: CYT107 + antiviral|
11546764|NCT01027052|Active Comparator|Hamburger meat patty with Spice Blend|Hamburger meat patty containing spice blend will be consumed on 3 separate occasions
11546765|NCT01027052|Placebo Comparator|Hamburger meat patty with salt|Hamburger meat patty containing salt will be consumed on 3 separate occasions
11546766|NCT01027039||Patients using noise-reducing headphones|Patients using noise-reducing headphones
11546767|NCT01027039||Patients using no headphones|Patients using no headphones
11546768|NCT01027039||Patients using headphones with music|Patients using headphones with music
11546769|NCT01027026|Experimental|Group 1 Fast Track Group|The patients are discharged the same day after coronary angiography to the refering Hospital
11546770|NCT01027026|Active Comparator|Group 2: Ordinary care|Ordinary Cardiology care in the Intervention hospital
11546771|NCT01027013|Experimental|rebamipide 2% ophthalmic suspension|
11546772|NCT01027013|Placebo Comparator|Placebo eye drops|
11546773|NCT01027000|Experimental|Treatment (Combination of chemotherapy and transplant)|See detailed description
11546774|NCT01026987|Experimental|Related Donors: G-CSF & AMD3100|G-CSF 10 ug/kg SC daily for 5 days. AMD3100 320 mcg/kg IV over 30 min on Day 5. Leukapheresis on Day 5.
11546775|NCT01026987|Other|Recipient|Stem Cell Infusion on Day 0
11546776|NCT01026974|Experimental|4rMenB|Subjects received three primary doses of rMenB vaccine (at the age of 6-8 months; 2 months after and at 12 months) in parent study (NCT00433914) and one booster dose of rMenB vaccine at 40 months of age in the present study.
11546777|NCT01026974|Experimental|4rMenB+OMV NZ|Subjects received three primary doses of rMenB+OMV NZ vaccine (at the age of 6-8months; 2 months after and at 12 months) in parent study (NCT00433914) and one booster dose of rMenB+OMV NZ vaccine at 40 months of age in the present study.
11546778|NCT01026974|Experimental|Naive_4042|Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.
11546779|NCT01026974|Experimental|Naive_6062|Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study.
11546780|NCT01026961|Experimental|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate
11546781|NCT01026961|Active Comparator|Phenylephrine hydrochloride|Phenylephrine hydrochloride 10mg
11546782|NCT01026948||Propess and Monica AN24 care package|Women who are eligible and consent to recruitment will receive the Propess and Monica AN24 care package for outpatient induction of labour
11546783|NCT01026935|Experimental|sutured mesh|200 patients are randomized to inguinal hernia repair with sutured light weight (38g/m2) polypropylene mesh (Lichtenstein repair)
11547013|NCT01025492|Active Comparator|Trilipix|Trilipix (fenofibric acid) 135 mg tablet orally, once daily for 12 weeks
11546784|NCT01026935|Experimental|non-sutured mesh|200 patients are randomized to receive a light weight mesh that adheres to tissues with polylactic micro hooks without sutures
11546785|NCT01026922||SmartPill Participants|It is a single-center study, children aged 8-17 years with severe upper GI symptoms (ie, nausea, vomiting, retching, abdominal pain) referred for antroduodenal manometry (ADM) studies underwent a wireless motility capsule (smartpill) test. The scintigraphic gastric emptying study was done when clinically indicated either at the time of the ADM or at a different time within 1 year of the wireless motility capsule test. In summary, we studied symptomatic adolescents using scintigraphic gastric emptying studies, ADM, and the wireless motility capsule test, with the goal of identifying the diagnostic yield of each test and exploring how they compare in detecting motor abnormalities in the GI tract.
11546786|NCT01026909|Experimental|Injection|Patients in this arm receive one single dose of Triamcinolone hexacetonide injectable suspension (Aristopan), USP, 20mg/mL Parenteral. They will aso be enrolled in physical therapy.
11546787|NCT01026909|No Intervention|Control|Patients will be enrolled in physical therapy
11546788|NCT01026883|Other|Healthy subjects|Hematocrit level of each subject will be assessed by two different techniques
11546789|NCT01026870|Active Comparator|Mometasone furoate (MF) metered-dose inhaler 100 mcg BID|2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks
11546790|NCT01026870|Placebo Comparator|Placebo metered-dose inhaler BID|2 inhalations from a matching placebo inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
11546791|NCT01026857|Experimental|PLC Colon release tablet 1 g|40 patients each arm
11546792|NCT01026857|Experimental|PLC colon release tablet 2 g|40 patients each arm
11546793|NCT01026857|Placebo Comparator|Placebo PLC colon release tablet 2 g|40 patients each arm
11546794|NCT01026844|Experimental|Erlotinib plus hydroxychloroquine|erltoinib 150mg per day plus HCQ in esclating doses of 400mg, 600mg, 800mg and 1000mg per day
11546795|NCT01026844|Experimental|Hydroxychloroqine|hydroxychloroquine given at escalating doses of 400mg, 600mg, 800mg and 1000mg per day
11546796|NCT01026831|Experimental|Tafluprost|Preservative-free tafluprost
11546797|NCT01026831|Active Comparator|timolol maleate|Preservative-free timolol maleate
11546798|NCT01026818|Experimental|Tadalafil daily [5 milligrams (mg)]|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
11546799|NCT01026818|Experimental|Tadalafil on demand (20 mg)|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
11546800|NCT01026818|Placebo Comparator|Placebo|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
11546801|NCT01026805||Hysteroscopic Morcellator|11 women previously receiving hysteroscopic myomectomy or polypectomy using the hysteroscopic morcellator device.
11546802|NCT01026792|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. For complete responders, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity or for 2 courses after complete response criteria are first met. For other patients, treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11546803|NCT01026779||Cases of rotavirus gastroenteritis|Patients will be eligible as cases if they have been identified by the investigator's ongoing rotavirus surveillance studies as having been hospitalized with laboratory-confirmed rotavirus gastroenteritis between January 1, 2007 and June 31, 2009. To be eligible as a case, the child must meet the following criteria: 1) immunocompetent; 2) born after April 15, 2006 (to select a population that would have been in the age group eligible for at least 1 dose of RV5 (RotaTeq); and 3) > 2 months of age on the day of admission.
11546804|NCT01026779||Control Subjects|Three controls for each case will be identified using KIDSNET, the state child health registry. Controls will be matched to cases by age and county of residence at birth.
11546805|NCT01026766||Non obese/ Warming blankets|
11546806|NCT01026766||Non obese/ Warming intravenous fluids|
11546807|NCT01026766||Obese/ Warming intravenous fluids|
11546808|NCT01026766||Obese/ Warming blankets|
11546809|NCT01026753|No Intervention|FOBT by laboratory requisition or directly by PCP|The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit.
11546810|NCT01026753|Experimental|FOBT by lab req. or directly from PCP + study magnet|The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit. The family physician provides each patient with a study magnet containing a PHCC telephone number and study specific website address.
11546811|NCT01026740|Experimental|001|Ceftobiprole 500 mg, single infusion over 2 hours
11546812|NCT01026727|Experimental|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|MPC-4326 300 mg or 400mg BID plus a 2-3 drug optimized background regimen (OBR)for 24 weeks.
11546813|NCT01026727|Active Comparator|3-4 drug antiretroviral drugs|3-4 commercially available antiretroviral (ARV)drugs for 24 weeks.
11546814|NCT01026714|Experimental|flurbiprofen 50mg po|
11546815|NCT01026714|Experimental|flurbiprofen 50 mg po + CYP2C9 inducer|
11546816|NCT01026714|Experimental|flurbiprofen 50 mg po + CYP2C9 inhibitor|
11546817|NCT01026701||001|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
11546818|NCT01026688|Experimental|Intervention|
11546819|NCT01026688|Other|Control|
11546820|NCT01026675||Pregnant women 6-13 weeks|
11546821|NCT01026662||Abdominoplasty|Subjects scheduled for abdominoplasty surgery
11546822|NCT01026649|Experimental|2 stage|Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
11546823|NCT01026649|Active Comparator|1 stage|Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
11546824|NCT01026636|Experimental|Ceftobiprole|Ceftobiprole 7mg/kg - 15mg/kg per day as 2h infusion
11546885|NCT01026259|Active Comparator|No warming to surgical incision|Incisions covered with same postoperative dressing as in Arm 1 but without warming treatments.
11546825|NCT01026623|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 60-70 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11546826|NCT01026610|Experimental|LB80380 90 mg|LB80380 90 mg (90 mg + placebo), once daily oral dose
11546827|NCT01026610|Experimental|LB80380 150 mg|LB80380 150 mg (60 mg + 90 mg), once daily oral dose
11546828|NCT01026610|Active Comparator|entecavir 0.5 mg|entecavir 0.5 mg, once daily oral dose
11546829|NCT01026597|Experimental|Cohort 1|Dose 1 versus placebo
11546830|NCT01026597|Experimental|Cohort 2|Dose 2 versus placebo
11546831|NCT01026597|Experimental|cohort 3|Dose 3 versus placebo
11546832|NCT01026597|Experimental|cohort 4|Dose 4 versus placebo
11546833|NCT01026597|Experimental|cohort 5|Dose 5 versus placebo
11546834|NCT01026584|Other|drug|
11546835|NCT01026571||Bicuspid aortic valve|Collection of patients who are known to have bicuspid aortic valve disease, diagnosed by prior cardiac imaging
11546836|NCT01026571||Relative|Collection of patients who are a relative to a patient known to have bicuspid aortic valve disease, diagnosed by prior cardiac imaging
11546837|NCT01026558|Active Comparator|Ceftobiprole (not morbidly obese subjects)|Ceftobiprole 500 mg single-dose over 2 hours.
11546838|NCT01026558|Experimental|Ceftobiprole (morbidly obese subjects)|Ceftobiprole 500 mg single-dose over 2 hours.
11546839|NCT01026545|Experimental|Cohort 1|
11546840|NCT01026545|Experimental|Cohort 2|
11546841|NCT01026545|Experimental|Cohort 3|
11546842|NCT01026545|Experimental|Cohort 4 (optional)|If intermediate or repeat dose level is needed; dose will not exceed 1100 mg.
11546843|NCT01026545|Experimental|Cohort 5 (Japanese)|
11546844|NCT01026545|Experimental|Cohort 6 (Japanese)|
11546845|NCT01026532||Segmental antigen challenge|Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
11546846|NCT01026519|Experimental|Dose 1|Active dose
11546847|NCT01026519|Experimental|Dose 2|Active dose
11546848|NCT01026519|Experimental|Dose 3|Active 3
11546849|NCT01026519|Placebo Comparator|Dose 4|Placebo dose
11546850|NCT01026493|Experimental|Phase I: Dose Level 1|ABT-888 20 mg x 21 days plus temozolomide 60 mg x 21 days
11546851|NCT01026493|Experimental|Phase I: Dose Level 2a|ABT-888 40 mg x 21 days plus temozolomide 60 mg x 21 days
11546852|NCT01026493|Experimental|Phase I: Dose Level 2b|ABT-888 20 mg x 21 days plus temozolomide 75 mg x 21 days
11546853|NCT01026493|Experimental|Phase I: Dose Level 3|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
11546854|NCT01026493|Experimental|Phase II: Arm 1/BEV-NAIVE|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
11546855|NCT01026493|Experimental|Phase II: Arm 2/BEV-NAIVE|ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days
11546856|NCT01026493|Experimental|Phase II: Arm 1/BEV-FAILURE|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
11546857|NCT01026493|Experimental|Phase II: Arm 2/BEV-FAILURE|ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days
11546858|NCT01026480||IPAA Patients|Patients who have had their IPAA procedures performed by Dr. Becker
11546859|NCT01026467||Supportive Care (frailty index, geriatric assessment, chemo)|Patients complete a frailty index and geriatric assessment prior to beginning chemotherapy. Patients receive standard-of-care chemotherapy comprising carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 2 courses
11546860|NCT01026454|Active Comparator|acyclovir|acyclovir 400 mg orally twice daily
11546861|NCT01026454|Active Comparator|valacyclovir|valacyclovir 1.5 g orally twice daily
11546862|NCT01026441|Other|Treatment for cellulite and circumference reduction|All subjects will be treated with the device
11546863|NCT01026428|Experimental|Safinamide + Levodopa|
11546864|NCT01026428|Placebo Comparator|Placebo + Levodopa|
11546865|NCT01026415|Experimental|1|midazolam +/- brentuximab vedotin
11546866|NCT01026415|Experimental|2|brentuximab vedotin +/- rifampin
11546867|NCT01026415|Experimental|3|brentuximab vedotin +/- ketoconazole
11546868|NCT01026415|Experimental|4|special populations
11546869|NCT01026402|Experimental|AZD2014|AZD2014 dose escalation phase in Part A and expansion phase in Part B.
11546870|NCT01026389|Active Comparator|Gadovist|Patient received contrast-enhanced MRA with Gadovist
11546871|NCT01026389|Experimental|Dotarem, interventional|Patients received contrast-enhanced MRA with Dotarem
11546872|NCT01026363|Experimental|ergocalciferol|Ergocalciferol intervention arm
11546873|NCT01026363|Experimental|calcitriol|calcitriol intervention arm
11546874|NCT01026350|Experimental|study group|
11546875|NCT01026337||Arm I|"Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.
~Patients undergo dynamic contrast-enhanced MRI at baseline and after the first 4 weeks of sunitinib malate."
11546876|NCT01026324|Experimental|Treatment (dinaciclib)|Patients receive dinaciclib IV over 4 hours on day 1. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
11546877|NCT01026311|Placebo Comparator|placebo|
11546878|NCT01026311|Active Comparator|Coenzyme Q10|200mg of coenzyme Q10
11546879|NCT01026298|No Intervention|Control Group|8 weeks, no intervention for OSA
11546880|NCT01026298|Active Comparator|CPAP group|8-week randomized-controlled period of CPAP treatment
11546881|NCT01026285||antipsychotic treatment|Risperidone Long-Acting injectable or oral antipsychotics According to label
11546882|NCT01026272||healthy subjects|subjects with no sign of inflammatory disease, or diagnosis of MS
11546883|NCT01026272||Patients with MS|
11546884|NCT01026259|Experimental|Local incision warming|Local warming applied to surgical incision for 6 treatments beginning in post anesthesia recovery through the second postoperative day.
11546886|NCT01026246|Experimental|Group B: 20 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 20 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
11546887|NCT01026246|Experimental|Group A: 5 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 5 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
11546888|NCT01026246|Experimental|Group C: 80 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 80 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
11546889|NCT01026233|Experimental|1|brentuximab vedotin
11546890|NCT01026220|Experimental|Regimen I (consolidation therapy)|Patients receive 2 more courses of ABVE-PC comprising doxorubicin hydrochloride IV over 1-120 minutes and cyclophosphamide IV over 30-60 minutes on days 1 and 2; bleomycin sulfate IV over at least 10 minutes or subcutaneously (SC) and vincristine sulfate IV on days 1 and 8; etoposide IV over 1-2 hours on days 1-3; oral prednisone twice daily on days 1-7; and filgrastim SC or IV daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression.
11546891|NCT01026220|Experimental|Regimen II (consolidation therapy)|Patients receive ifosfamide IV continuously on days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, and filgrastim SC or IV beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression. Patients then receive 2 more courses of ABVE-PC in the absence of unacceptable toxicity or disease progression.
11546892|NCT01026220|Experimental|Induction: all patient|All patients receive ABVE-PC induction therapy then they are assigned to Group 2 (RER), Group 3 (SER) or taken off study if they develop progressive disease.
11546893|NCT01026207||Chronic Obstructive Pulmonary Disease|Patients recruited from the Pneumology Clinic of UNIFESP, diagnosed with COPD stage II and III of Global Initiative for Chronic Obstructive Lung Disease, stable for three months, and with symptoms suggestive of Obstructive Sleep Apnea Syndrome.Patients has been underwent one night by polysomnography and one night with portable monitoring.
11546894|NCT01026194|Placebo Comparator|Placebo / Teneli + Pio|
11546895|NCT01026194|Experimental|Teneli / Teneli + pio|
11546896|NCT01026181||LSG|Laparoscopic Sleeve Gastrectomy
11546897|NCT01026181||LRYGB|Laparoscopic Roux-en-Y Gastric Bypass
11546898|NCT01026181||LAGB|Laparoscopic Adjustable Gastric Banding
11546899|NCT01026155|Experimental|Respiratory muscle traininig|Low caloric diet and physical activities + Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
11546900|NCT01026155|Active Comparator|Control|Low caloric diet and physical activities
11546901|NCT01026142|Active Comparator|A: Capecitabine + Trastuzumab|
11546902|NCT01026142|Experimental|B: Capecitabine + Trastuzumab + Pertuzumab|
11546903|NCT01026129|Experimental|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of remifentanil 0.25 mcg/kg before emergence of a desflurane-based anesthesia.
11546904|NCT01026129|Experimental|Remifentanil 0.5 mcg/kg|Administration of a bolus dose of remifentanil 0.5 mcg/kg before emergence of a desflurane-based anesthesia.
11546905|NCT01026129|Active Comparator|Lidocaine|Bolus dose of intravenous remifentanil 1mg/kg given once before emergence of general anesthesia.
11546906|NCT01026116|Active Comparator|EC-wP|epirubicin/cyclophosphamide followed weekly paclitaxel
11546907|NCT01026116|Experimental|EP-wP|epirubicin/paclitaxel followed by weekly paclitaxel
11546908|NCT01026103|Experimental|Tri Staple|This is a single arm study.
11546909|NCT01026090|Experimental|Dronedarone pre-cardioversion|Dronedarone 400 mg twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion
11546910|NCT01026090|Placebo Comparator|Placebo pre-cardioversion|Placebo (for dronedarone) twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion
11546911|NCT01026077||Fibromyalgia/prospective pregnancies|Women taking Savella during pregnancy. Register prospectively, provide verbal consent.
11546912|NCT01026064|Experimental|Part C- Azithromycin|2 x 250 mg once daily over 3 days
11546913|NCT01026064|Placebo Comparator|Part C- Placebo|Once daily over 3 days
11546914|NCT01026038|Experimental|1|1 dose (0.5 mL), IM of 13vPnC vaccine.
11546915|NCT01026025|Experimental|Duet TRS|This is a single arm study.
11546916|NCT01026012|Experimental|Combined Protocol|patient with submaximal symptom limited maximal exercise testing will also be administered regadenoson pharmacological stress test.
11546917|NCT01025999||RYGB|UWMC patients undergoing RYGB surgery with routine placement of Gastrostomy tube.
11546918|NCT01025986||Noninfectious Uveitis|
11546919|NCT01025973||Diabetes Mellitus|Patients with type 1, type 2 or gestational diabetes mellitus
11546920|NCT01025973||Normal pregnancy|Patient without diabetes mellitus
11546921|NCT01025960|Other|Standard Inspection Colonoscopy|The colonoscope will be inserted rapidly to reach the cecum. Inspection of the large bowel will occur during the withdrawal of the colonoscope.
11546922|NCT01025960|Active Comparator|Dual Inspection Colonoscopy|The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
11546923|NCT01025947||Study group|Patients with cryptogenic stroke (TOAST criteria) and with an implantable EKG loop recorder implanted
11546924|NCT01025934|Active Comparator|7 days|
11546925|NCT01025934|Active Comparator|20 days|
11546926|NCT01025934|Sham Comparator|sham|
11546927|NCT01025921|Placebo Comparator|Inhaled colistin|They will receive inhaled colistin three times daily for 10 days.
11546928|NCT01025921|Placebo Comparator|Inhaled normal saline|Inhaled normal saline three times daily for 10 days
11546929|NCT01025908|Experimental|Cognitive Behavioral Therapy|25 panic disorder patients
11546930|NCT01025908|Active Comparator|Supportive psychotherapy|25 panic disorder agoraphobia
11546931|NCT01025895|Active Comparator|single bundle|acl reconstruction - single bundle technique
11546932|NCT01025895|Experimental|double bundle|acl reconstruction - double bundle technique
11546933|NCT01025882|Experimental|Regimen 1|Patients undergo a single fraction of margin-intensive stereotactic body radiotherapy (SBRT) on day 1. Patients undergo pancreatoduodenectomy between days 15-43.
11546934|NCT01025882|Experimental|Regimen 2|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Patients undergo a single fraction of SBRT between days 21-28 followed by pancreatoduodenectomy between days 35-63.
11546935|NCT01025869|Other|Stent System|Cinatra™ Corolimus Eluting Coronary Stent System
11546936|NCT01025856|Active Comparator|high fibre/low glycemic index diet - P A|patients will follow for two months a diet high fibre/low glycemic index without physical activity program
11546937|NCT01025856|Active Comparator|Rich in MUFA diet - PA|Patients will follow for two months a rich in MUFA diet without a physical activity program.
11546938|NCT01025856|Active Comparator|high fibre/low glycemic index diet+PA|Patients will follow for two months a high fibre and low glycemic index diet associated with a physical activity program.
11546939|NCT01025856|Active Comparator|Rich in MUFA diet+PA|Patients will follow for 2 months a rich in MUFA diet with a physical activity program.
11546940|NCT01025843|Experimental|Pbo → 5 mg → Candesartan → 24 mg → 38 mg|Placebo in Period 1; 5 mg MK-5478 in Period 2; Candesartan in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
11546941|NCT01025843|Experimental|1 mg → 5 mg → 12 mg → Candesartan → Pbo|1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Candesartan in Period 4; and Placebo in Period 5. There was a minimum 7 days washout between periods.
11546942|NCT01025843|Experimental|1 mg → Candesartan → Pbo → 24 mg → 38 mg|1 mg MK-5478 in Period 1; Candesartan in Period 2: Placebo in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
11546943|NCT01025843|Experimental|1 mg → 5 mg → 12 mg → Pbo → Candesartan|1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Placebo in Period 4; and Candesartan in Period 5. There was a minimum 7 days washout between periods.
11546944|NCT01025843|Experimental|Pbo→ 8 mg→ 18 mg → 2 mg fed→Candesartan|Placebo in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Candesartan in Period 5. There was a minimum 7 days washout between periods.
11546945|NCT01025843|Experimental|2 mg→Pbo → Candesartan → Pbo fed→38 mg|2 mg MK-5478 in Period 1; Placebo in Period 2; Candesartan in Period 3; Placebo in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
11546946|NCT01025843|Experimental|2 mg→Candesartan→Pbo→Candesartan fed→38 mg|2 mg MK-5478 in Period 1; Candesartan in Period 2; Placebo in Period 3; Candesartan in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
11546947|NCT01025843|Experimental|2 mg → 8 mg → 18 mg → 2 mg fed → Pbo|2 mg MK-5478 in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Placebo in Period 5. There was a minimum 7 days washout between periods.
11546948|NCT01025843|Experimental|Candesartan→8 mg→ 18 mg →2 mg fed→38 mg|Candesartan in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
11546949|NCT01025843|Experimental|Candesartan→Pbo → 12 mg → 24 mg→38 mg|Candesartan in Period 1; Placebo in Period 2; 12 mg MK-5478 in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
11546950|NCT01025830|Experimental|Generic|generic fixed dose combination of Stavudine, Lamivudine and Nevirapine (Triomune)
11546951|NCT01025830|Active Comparator|Brand|3 separate single pills of Zerit (Stavudine)Epivir (Lamivudine) Viramune (Nevirapine)
11546952|NCT01025817|Experimental|Everolimus (EVR) & low dose of tacrolimus|Everolimus (EVR) and tacrolimus treatment arm: Therapeutic drug monitoring of everolimus and tacrolimus was mandatory throughout the study. From Day 5 onwards, the everolimus 0.75 mg b.i.d. dose was increased if the trough level was < 3 ng/mL, or reduced if the trough level was > 8 ng/mL. Tacrolimus was initiated according to local practice. In this treatment arm, the tacrolimus dose was adjusted from Day 3 onwards, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From Month 2 until Month 6, the target tacrolimus trough level was 3 ng/mL to 6 ng/mL. After Month 6, the tacrolimus dose was adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL.
11546953|NCT01025817|Active Comparator|Mycophenolate mofetil & standard dose tacrolimus|Mycophenolate mofetil and tacrolimus (MMF) treatment arm: MMF dose was initiated at 1 g b.i.d. (2 g/day). Adjustments were to be made for adverse events including, but not limited to, gastrointestinal intolerance and decrease in WBC. MMF trough or AUC was not used to adjust dosing. In this group, tacrolimus was initiated according to local practice. Tacrolimus dose was adjusted from Day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 12 ng/mL. From Month 2 until Month 6, target tacrolimus trough level was reduced to 7 - 10 ng/mL. After Month 6, target level of tacrolimus was reduced to 5 - 8 ng/mL.
11546954|NCT01025804||Infants|
11546955|NCT01025791|Experimental|Panel A, Healthy Male Participants, Sequence 1|MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: placebo/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
11546956|NCT01025791|Experimental|Panel A, Healthy Male Participants, Sequence 2|MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: placebo/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
11546957|NCT01025791|Experimental|Panel A, Healthy Male Participants, Sequence 3|MK-8266 in Period 1: 0.1 mg/ Period 2: placebo/ Period 3: 0.5/ Period 4: 1.0 mg/ Period 5: placebo.
11546958|NCT01025791|Experimental|Panel A, Healthy Male Participants, Sequence 4|MK-8266 in Period 1: placebo/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
11546959|NCT01025791|Experimental|Panel B, Healthy Male Participants, Sequence 1|MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: placebo/ Period 4: 0.4 mg fed/ Period 5: na.
11546960|NCT01025791|Experimental|Panel B, Healthy Male Participants, Sequence 2|MK-8266 in Period 1: 0.4 mg/ Period 2: placebo/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.
11546961|NCT01025791|Experimental|Panel B, Healthy Male Participants, Sequence 3|MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.
11546962|NCT01025791|Experimental|Panel B, Healthy Male Participants, Sequence 4|MK-8266 in Period 1: placebo/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na.
11547015|NCT01025466|Active Comparator|rivastigmine patch monotherapy|
11546963|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 1|Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
11546964|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 2|Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na
11546965|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 3|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2 placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
11546966|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 4|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na
11546967|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 5|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
11546968|NCT01025791|Placebo Comparator|Panel C, Mild/Moderate Hypertension, Sequence 6|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: placebo/ Period 5: na
11546969|NCT01025778|Experimental|Remission induction and haplo-SCT|Remission induction with Clofaranie, Etoposide and Cyclophosphamide combination followed by haplidentical stem cella transplantation if remission achieved.
11546970|NCT01025765|No Intervention|Standard care of CHC|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
11546971|NCT01025765|Experimental|Pioglitazone|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
11546972|NCT01025765|Experimental|Acarbose|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
11546973|NCT01025765|Experimental|Metformin|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
11546974|NCT01025752|Experimental|Arm 1|Ten session IVR-based cognitive behavior therapy intervention for chronic low back pain
11546975|NCT01025752|Active Comparator|Arm 2|Ten session face to face cognitive behavior therapy for chronic low back pain
11546976|NCT01025726|Experimental|Full Intervention|Police Patrolled Walking Program plus Social Marketing Intervention
11546977|NCT01025726|Experimental|Walking Only|Police Patrolled Walking Only Intervention
11546978|NCT01025726|Active Comparator|General Health|General Health Education Intervention
11546979|NCT01025713|Experimental|1|GS-9411 2.4 mg
11546980|NCT01025713|Experimental|2|GS-9411 4.8 mg
11546981|NCT01025713|Placebo Comparator|Placebo|Placebo
11546982|NCT01025700|Experimental|Cesemat|
11546983|NCT01025700|No Intervention|Placebo|
11546984|NCT01025687|Experimental|glucose beverage|
11546985|NCT01025687|Experimental|noncaloric beverage with TV|
11546986|NCT01025687|Experimental|glucose beverage with TV|
11546987|NCT01025687|Experimental|noncaloric beverage|
11546988|NCT01025674|Experimental|7 Treatment Schools|The Positive Action program was implemented over 6 years, starting with Grade 3, then continuing through Grade 8.
11546989|NCT01025674|No Intervention|7 Control Schools|Standard educational practice
11546990|NCT01025661|No Intervention|Waiting list control|The waiting list controls did not receive any intervention during the study period.
11546991|NCT01025648|Experimental|T1 - E004 90 mcg/actuation|T1 - E004 (epinephrine inhalation aerosol) 90 mcg/actuation - treatment by 2 actuations of E004 at 90 mcg/actuation
11546992|NCT01025648|Experimental|T2 - E004 125 mcg/actuation|E004 (epinephrine inhalation aerosol), 125 mcg, 2 actuations
11546993|NCT01025648|Experimental|T3 - 160 mcg/actuation|E004 (epinephrine inhalation aerosol), 160 mcg - E004 (epinephrine inhalation aerosol), 160 mcg/ actuation, 2 actuations
11546994|NCT01025648|Experimental|T4 - 220 mcg/actuation|E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations
11546995|NCT01025648|Active Comparator|A - Active control|epinephrine inhalation aerosol, CFC propelled 220 mcg Epinephrine Inhalation Aerosol, CFC-MDI, 2 actuations
11546996|NCT01025648|Placebo Comparator|P, Placebo HFA|E004 placebo single treatment with 2 inhalations
11546997|NCT01025635|Experimental|Azelaic acid foam, 15% (BAY39-6251)|Participants received azelaic acid foam, 15% topically twice daily for 12 weeks
11546998|NCT01025635|Placebo Comparator|Vehicle foam|Participants received vehicle foam topically twice daily for 12 weeks
11546999|NCT01025596|Experimental|CYT107|
11547000|NCT01025583|Active Comparator|group 1 (standard ORS)|Children with acute diarrhea receive standard hypotonic ORS.
11547001|NCT01025583|Active Comparator|Group 2 (hypotonic super-ORS)|Children with acute diarrhea receive hypotonic super-ORS containing zinc and prebiotics.
11547002|NCT01025570|Experimental|Gem/Bos|"Gemcitabine 1000 mg/m2, D1,8,15 of each cycle
~Bostutinib 400 mg daily concurrently with Gemcitabine"
11547003|NCT01025557|Experimental|Chocolate milk|
11547004|NCT01025557|Experimental|Milk|
11547005|NCT01025557|Experimental|Infant formula|
11547006|NCT01025557|Experimental|Soy beverage|
11547007|NCT01025557|Experimental|Water|
11547008|NCT01025544|Active Comparator|Arm 1|
11547009|NCT01025544|Active Comparator|Arm 2|
11547010|NCT01025531||patients with newly diagnosed Hepatitis C|Hepatitis C patients newly diagnosed
11547011|NCT01025518|Experimental|resistance training and dietary supplement|
11547012|NCT01025518|Placebo Comparator|Resistance training and placebo ingestion|12 weeks of resistance training and placebo ingestion
11547050|NCT01025115|Experimental|A|Diamel
11547016|NCT01025466|Active Comparator|Combination therapy with memantine|
11547017|NCT01025453|Experimental|Pts getting Temsirolimus and Sorafenib|We propose a phase II study to evaluate the efficacy of the combination sorafenib with temsirolimus in patients with thyroid cancer of follicular cell origin (e.g., papillary, follicular, Hurthle cell). A maximum of 36 subjects will be evaluated during the study. Restaging scans, with evaluation of response, will be done every 2 cycles (8 weeks of treatment). Treatment will continue until clinical disease progression, unacceptable toxicity, treatment delay > 4 weeks, or at the discretion of the treating physician or patient.
11547018|NCT01025440|Active Comparator|CPAP|"Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA.
~Dose: The CPAP pressure will be set to the individual subject's therapeutic pressure -as determined by PSG on Night 2.
~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)"
11547019|NCT01025440|Active Comparator|HFCPAP|"Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA.
~Dose: During HF CPAP 35 L/min wil be administered.
~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)"
11547020|NCT01025427|Experimental|Elite controller|Sixteen controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
11547021|NCT01025401|No Intervention|Motor manifestations during seizures|
11547022|NCT01025362|Experimental|Lactation counseling|"Intervention arm: The mother and child health centres will implement The Baby-Friendly Initiative to improve their lactation counseling.
~Other Names: The Baby Friendly Community Health Service"
11547023|NCT01025362|Active Comparator|Standard care|The comparison group was mother and child health centres which continued offering standard care.
11547024|NCT01025349|Experimental|metastatic breast cancer|Patients with histological or cytological proven metastatic breast cancer were recruited. The previous hormonal therapy for metastatic breast cancer or cytotoxic therapy was allowed. The Her2/Neu over-expressive status should be negative. Patients with brain metastasis are excluded.
11547025|NCT01025336|Other|23vPS Naive|Group 1.1 13vPnC/13vPnC Group 1.2 13vPnC/23vPS Group 2 23vPS/13vPNC
11547026|NCT01025336|Other|Prior 23vPS>/= 5 years|Group 1 13vPnC/13vPnC Group 2 23vPS/13vPnC
11547027|NCT01025323|Active Comparator|Minimal Intervention Group|Participants in this arm receive advice and printed guidelines but no counseling or systematic instruction.
11547028|NCT01025323|Active Comparator|Enhanced Intervention Group|Participants in this group receive advice and the same printed guidelines as the Minimal Intervention Group, together with dietary and physical activity counseling provided by a dietician and/or coordinator, periodic professional reviews of their progress and systematic instruction.
11547029|NCT01025297|Experimental|CYT107|
11547030|NCT01025284|Experimental|Part A LY2523355|8 milligrams per square meter (mg/m²) per dose based on participant's body surface area, administered intravenously as a 1-hour infusion on Days 1, 5, 9 of each 21-day cycle, until disease progression or unacceptable toxicity.
11547031|NCT01025284|Experimental|Part B LY2523355|5 or 6 mg/m² per dose based on participant's body surface area, administered intravenously as a 1-hour infusion on Days 1, 2, 3 plus granulocyte colony-stimulating factor (G-CSF) support administered subcutaneously beginning on Day 4 of each 21-day cycle, until disease progression or unacceptable toxicity.
11547032|NCT01025271|Other|open label|patients meeting entry criteria enrolled and pk samples obtained around dosing of daptomycin
11547033|NCT01025258|Active Comparator|frequent clinic visits|
11547034|NCT01025245|Experimental|remifentanil, MgSO4|Experimental 1 : Intraoperative remifentanil infusion at 0.2 ㎍/㎏/min and MgSO4 30 mg/kg IV at the induction followed by intraoperative infusion at 10 mg/kg/hr Drug : remifentanil, MgSO4 Experimental 2 : Intraoperative remifentanil infusion at 0.2 ㎍/㎏/min and normal saline Drug : remifentanil Active comparator : Intraoperative remifentanil infusion at 0.05 ㎍/㎏/min and normal saline Drug : remifentanil
11547035|NCT01025232|Active Comparator|4 Week Re-treatment|Subjects can receive re-treatment every 4 weeks if there is persistent or recurrent intraretinal, subretinal, or sub-RPE fluid on any OCT modality, or any evidence of hemorrhage on clinical evaluation. Subjects will go no longer than 12 weeks without treatment.
11547036|NCT01025232|Active Comparator|6 Week Re-treatment|Subjects can receive re-treatment every 6 weeks if there is persistent or recurrent intraretinal, subretinal, or sub-RPE fluid on any OCT modality, or any evidence of hemorrhage on clinical evaluation. Every 6 weeks regimen will test potential longer duration of action of 2.0 mg ranibizumab. Subjects will go no longer than 12 weeks without treatment.
11547037|NCT01025206|Experimental|BI-505|
11547038|NCT01025193|Experimental|Belimumab|Belimumab will be administered intravenously at a dose of 10mg/kg on days 0, 14, 28 and every 28 days for up to 52 weeks to normalize alloantibody levels in sensitized patients awaiting kidney transplantation. Subjects who are not able to undergo transplantation before the end of the treatment period will have final follow-up evaluation 8 weeks after the last dose of belimumab is administered.
11547039|NCT01025180|Other|Procalcitonin level|duration of the antibiotic treatment guided by procalcitonin level
11547040|NCT01025180|No Intervention|physician's appreciation|duration of the antibiotic treatment based on physician's appreciation
11547041|NCT01025167|Experimental|Test|Supportan(R) (500 ml)/disease-specific enteral tube feed for oncologic patients with special key substrates
11547042|NCT01025167|Placebo Comparator|Control|Fresubin(R) energy fibre (500 ml)/a nutritionally complete enteral standard feed (isoenergetic)
11547043|NCT01025154|Experimental|Clofarabine, Cytarabine + Idarubicin|Induction Cycle: Clofarabine 20 mg/m^2 intravenous (IV) daily for 5 days; Idarubicin 10 mg/m^2 IV daily for 3 days; Cytarabine 1 g/m^2 IV daily for 5 days
11547044|NCT01025141|Experimental|MINISCREW|device
11547045|NCT01025141|Active Comparator|Reference|dental anchorage
11547046|NCT01025128|Active Comparator|group A low D|ultra-Orthodox clinics patients aged 18-39 with lowest vitamin D levels
11547047|NCT01025128|No Intervention|group A high D|ultra-Orthodox clinics patients aged 18-39 with highest vitamin D levels
11547048|NCT01025128|Active Comparator|group B low D|mixed population clinics patients aged 18-39 with lowest vitamin D levels
11547049|NCT01025128|No Intervention|group B high D|mixed population clinics patients aged 18-39 with highest vitamin D levels
11547051|NCT01025115|Placebo Comparator|B|Placebo
11547052|NCT01025102|Experimental|Naropin 0.1%|
11547053|NCT01025089|Experimental|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|This is a multicenter, open-label phase II trial of neoadjuvant chemotherapy and concurrent cetuximab in patients with clinical Masaoka stage II-IVA thymoma or thymic carcinoma.. Patients will initially receive weekly cetuximab for 4 weeks to assess tumor response to cetuximab alone. Patients will then undergo weekly cetuximab along with concurrent CAP for 4 cycles. At the completion of this regimen, patients will undergo surgical resection and the specimen will be evaluated for CPR.
11547054|NCT01025076|Experimental|StomaphyX Group|"Primary Roux-en-Y gastric bypass with evidence of enlarged gastric pouch volume or enlarged stoma diameter of ≥ 20 mm via endoscopy or fluoroscopy.
~Patients also demonstrate a weight regain of 15% of excess body weight loss."
11547055|NCT01025063||Lucentis (PRN group)|
11547056|NCT01025063||Lucentis (3 Injections over three months)|
11547057|NCT01025063||PDT (Reduced Fluence) and Lucentis|
11547058|NCT01025050|Experimental|Group A|In this group the smallest ring diameter will be applied.
11547059|NCT01025050|Experimental|Group B|In this group the intermediate ring diameter will be applied.
11547060|NCT01025050|Experimental|Group C|In this group the biggest ring diameter will be applied.
11547061|NCT01025037|Other|Conexa Reconstructive Tissue Matrix|Conexa will be placed as a soft tissue reinforcement at the rotator cuff repair site
11547062|NCT01025024||POAG group|Elevated intraocular pressure normal open angle glaucomatous optic nerve head abnormality glaucomatous visual field defect
11547063|NCT01025024||Normal control|Normal intraocular pressure No optic disc abnormality No visual field defect No significant ocular and systemic disease
11547064|NCT01025011||healthy volunteers, anemic patients|healthy volunteers from the eye and gynecology department pregnant patients with anemia
11547065|NCT01024998|Experimental|2 x 10^8 vector genomes (vg) AAV2-sFLT01|
11547066|NCT01024998|Experimental|2 x 10^9 vector genomes (vg) AAV2-sFLT01|
11547067|NCT01024998|Experimental|6 x 10^9 vector genomes (vg) AAV2-sFLT01|
11547068|NCT01024998|Experimental|2 x 10^10 vector genomes (vg) AAV2-sFLT01|
11547069|NCT01024985||multiple sclerosis|
11547070|NCT01024985||neuromyelitis optica|
11547071|NCT01024985||controls|
11547072|NCT01024972|Experimental|Dantrolene|Dantrolene 1.25mg/kg IV every 6 hours x 7 days
11547073|NCT01024972|Placebo Comparator|Placebo|Equiosmolar volume (5% Mannitol)
11547074|NCT01024959|Experimental|PCA3 Assay|
11547075|NCT01024946|Experimental|Pts getting everolimus|This is a multicenter, open label, phase II study of everolimus as a second or third line therapy for the treatment of advanced malignant pleural mesothelioma, which will also evaluate Merlin/NF2 loss as a biomarker to predict sensitivity to everolimus. Patients who have disease progression after one or two prior chemotherapy regimens will be eligible. In the first stage of this design, 19 patients will be accrued. If 6 or less patients among the first 19 patients show clinical benefit, then the study will be terminated and declared negative. If 7 or more patients show clinical benefit, than an additional 20 patients will be accrued to the second stage. At the end of the study, if 17 or more patients show clinical benefit out of a total of 39 patients enrolled, the regimen will be considered worthy of further investigation.
11547076|NCT01024933|Placebo Comparator|Educational and Behavioral|The Education and Behavioral Contract (Control group) will receive an educational workbook and behavioral contract. Each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
11547077|NCT01024933|Experimental|PASA group-intervention|The PASA group (Positive Affect/Self-Affirmation/Motivational Interviewing) will receive a positive-affect and self-affirmation intervention with motivational interviewing.These patients will also receive an educational workbook and behavioral contract. This is the intervention.
11547078|NCT01024920|Experimental|BIBF 1120|Non-marketed substance: Twice daily oral doses of 200mg BIBF 1120 given continuously.
11547079|NCT01024920|Active Comparator|sunitinib|Marketed substance: Once a day oral doses of 50mg sunitinib given in repeated 6 week cycles: 4 weeks active, 2 weeks rest.
11547080|NCT01024907|Experimental|Arm I|Patients undergo proton beam radiation therapy for 6 weeks in the absence of disease progression or unacceptable toxicity.
11547081|NCT01024894|Experimental|CYT107|
11547082|NCT01024881|Active Comparator|group 1|neutral shoulder position during infraclavicular subclavian catheterization
11547083|NCT01024881|Experimental|group 2|lowered shoulder position during infraclavicular subclavian catheterization
11547084|NCT01024868||TAP block|Patients before undergoing laparoscopic or other abdominal surgery
11547085|NCT01024855|Experimental|RevitaLens OcuTec Multipurpose Solution (Investigational MPS)|
11547086|NCT01024855|Active Comparator|Opti-Free RepleniSH Multipurpose Solution (MPS, Control)|
11547087|NCT01024842|Experimental|Low dose vaccinees|Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10^8 pfu.
11547088|NCT01024842|Experimental|High dose vaccinees|Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10^8 pfu.
11547089|NCT01024842|Placebo Comparator|Low dose placebo|Individuals will receive three intramuscular injections of low dose placebo
11547090|NCT01024842|Placebo Comparator|High dose placebo|Individuals will receive three intramuscular injections of high dose placebo
11547091|NCT01024829|Other|Whole tumor boost|Patients in this arm will receive radiotherapy (66Gy) in 24 fractions of 2.75 Gy with an integrated boost to the primary tumor as a whole
11547092|NCT01024829|Other|Boost 50% SUV area|Patients in this arm receive radiotherapy (66Gy) in 24 fractions of 2.75Gy with an integrated boost to the 50% SUVmax area of the primary tumor (of the pre-treatment FDG-PET-CT scan)
11547093|NCT01024816|Experimental|Restorative yoga intervention|
11547094|NCT01024816|Active Comparator|Stretching group|
11547095|NCT01024790|Experimental|Exercise group|
11547096|NCT01024790|No Intervention|Usual care|
11547097|NCT01024777|Active Comparator|High dose cholecalciferol|Patients in the high dose arm will receive 10,000 international units of cholecalciferol daily.
11547098|NCT01024777|Active Comparator|Low dose cholecalciferol|Patients enrolled in the low dose arm will receive up to 1000 international units of cholecalciferol daily.
11547919|NCT01018810|Experimental|3 mg LY2525623|
11547099|NCT01024751|Experimental|Bausch & Lomb Multi-Purpose Solution|Multi-Purpose Solution to be used for disinfecting contact lenses.
11547100|NCT01024751|Active Comparator|Ciba's Multi-Purpose Solution|Multi-Purpose Solution to be used for disinfecting contact lenses.
11547101|NCT01024738|Placebo Comparator|Fluoride toothpaste|negative control toothpaste
11547102|NCT01024738|Active Comparator|Triclosan/Fluoride toothpaste|positive control toothpaste (Total toothpaste)
11547103|NCT01024738|Active Comparator|Chlorhexidine Oral Rinse|positive control oral rinse
11547104|NCT01024725||Not (yet) vaccinated persons|The participants do not want to take the vaccine (available only in the national vaccination campaign) or have not received it yet
11547105|NCT01024725||Vaccinated persons|The participants have taken the vaccine according to the national vaccination campaign
11547106|NCT01024699||XLIF|This group will have the XLIF procedure done.
11547107|NCT01024699||MAS TLIF|This group will have the MAS TLIF procedure done.
11547108|NCT01024686|Experimental|p52-p36- GAP Vaccine|"p52-/p56- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito.
~p52-/p56- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito.
~Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum."
11547109|NCT01024686|No Intervention|Infectivity Control|Active Control: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum
11547110|NCT01024686|Experimental|p52-p36- GAP Vaccine + Infectivity Challenge|"p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito.
~Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum."
11547111|NCT01024673||patients with H1N1|patients who are clinical found to be positive for H1N1 will be enrolled
11547112|NCT01024660|Active Comparator|1|5 mg Donepezil (first 14 days), 10 mg Donepezil (next 70 days)
11547113|NCT01024660|Placebo Comparator|2|
11547114|NCT01024647|Active Comparator|Loss of Reponse Reinduction Responders|Loss of Response Reinduction Responders:certolizumab pegol (Cimzia) 200 mg every 2 weeks
11547115|NCT01024647|Active Comparator|Response loss Reinduction Non-Responders|Response Loss Reinduction Non-Responders:certolizumab pegol(Cimzia) 400 mg every 2 weeks
11547116|NCT01024647|Active Comparator|Responders|Responders: certolizumab pegol(Cimzia) 400 mg every 4 weeks
11547117|NCT01024647|Active Comparator|Non-Responders|Non-Responders: certolizumab pegol (Cimzia) 400 mg every 2 weeks
11547118|NCT01024634|Other|African American Group|A group of young African American males and females
11547119|NCT01024634|Other|Caucasian Group|a group of young Caucasian men and women
11547120|NCT01024621|Experimental|1|confocal laser endomicroscopy
11547121|NCT01024621|Active Comparator|2|standard endoscopy
11547122|NCT01024608|Experimental|BDP HFA 320 µg/day|During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning.
11547123|NCT01024608|Placebo Comparator|Placebo|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily each morning.
11547124|NCT01024595||Without treatment|
11547125|NCT01024582|Experimental|accelerated partial breast irradiation|pre-operative radiation of the in situ tumor in the breast
11547126|NCT01024569|Experimental|Wellness Recovery Action Planning (WRAP)|WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks. Topics include: Introduction to WRAP, Developing a Wellness Toolbox, Creating a Daily Maintenance Plan, Identifying Triggers, Identifying Early Warning Signs, Managing When Things Break Down, and Crisis Planning. Coursework is interactive, using lecture, question and answer, group discussion, and individual or group exercises. Each session includes a lecture on recovery topics such as self-esteem, changing negative thoughts to positive ones, peer support, and lifestyle issues.
11547127|NCT01024569|No Intervention|Comparison Wait-List Group|Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend WRAP groups after their final research interview.
11547128|NCT01024543|Sham Comparator|Placebo|Placebo
11547129|NCT01024543|Experimental|Angiotensin II|Angiotensin II
11547130|NCT01024543|Active Comparator|Phenylephrine|Phenylephrine
11547131|NCT01024517|Experimental|Single oral dose, solution|
11547132|NCT01024517|Experimental|Single oral dose, solid, fasted|
11547133|NCT01024517|Experimental|Single oral dose, solid, fed.|
11547134|NCT01024504|Experimental|XELOX/Avastin|Capecitabine Oxaliplatin Bevacizumab
11547135|NCT01024491|Experimental|paroxetine 15mg|Active treatment with daily dose of paroxetine 15mg.
11547136|NCT01024491|Experimental|paroxetine 20 mg|Active treatment daily dose of paroxetine 20 mg
11547137|NCT01024491|Experimental|placebo|placebo
11547138|NCT01024465|Experimental|ReShape Duo Balloon|Patients seeking weight loss with a starting BMI in the 30-40 range, received the ReShape Duo Balloon
11547139|NCT01024452|Experimental|DAWN AC|
11547140|NCT01024452|Active Comparator|Hamilton Nomogram|
11547141|NCT01024439|Active Comparator|single port|Patients will undergo transumbilical single incision laparoscopic appendicectomy.
11547142|NCT01024439|Active Comparator|conventional Lap|Patients will undergo conventional laparoscopic appendicectomy.
11547143|NCT01024426|Experimental|Health Facility intervention|In the clusters randomized to enhanced health facility-based care, the intervention is designed to address these barriers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
11547144|NCT01024426|Other|Standard of care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
11547145|NCT01024413|Experimental|erlotinib|erlotinib 150 mg oral till disease progression
11547146|NCT01024413|Active Comparator|gefitinib|gefitinib 250mg oral till disease progression.
11547147|NCT01024400|Experimental|vaccine|
11547148|NCT01024387|Experimental|AMG 479|Patients receive AMG 479 at a dose of 18 mg/kg administered IV on day 1 (± 3 days) of every 3-week cycle. Treatment should continue until disease progression, unacceptable toxicity or withdrawal of consent.
11547149|NCT01024361|No Intervention|Routine|Routine protocol of the service
11547150|NCT01024361|Experimental|CPAP-DR|Infants randomized to this arm will have nasal CPAP installation at delivery room before the 15th minute of life
11547151|NCT01024348|Active Comparator|Tramadex-OD|Patients will undergo knee arthroscopy under spinal anesthesia without any opioid. 30 minutes prior to surgery and 24 hours afterwards, patients will take a tablet of 100 mg Tramadex-OD. Breakthrough pain will be managed with 1 gr paracetamol (per os) as needed.
11547152|NCT01024348|Active Comparator|Control group|Patients will undergo knee arthroscopy under spinal anesthesia without any opioid.Postoperative pain will be managed throughout the study with 1 gr paracetamol (per os) every 6 hours as required.
11547153|NCT01024335|Active Comparator|Naltrexone and placebo|A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month while placebo will be taken daily for the first 5 weeks of treatment.
11547154|NCT01024335|Experimental|Naltrexone and dronabinol|A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month (the total of two injections, once at the end of hospitalization, and once at end of first month of outpatient treatment), while dronabinol (15 mg bid) will be taken daily for the first 5 weeks of treatment.
11547155|NCT01024322||Ciprofloxicine or Vigamox or other.|
11547156|NCT01024322||Nonsteroidal (Acular, Voltaren Xibrom, etc)|
11547157|NCT01024322||Steroid (FML, Pred Forte, Flarex, etc.)|
11547158|NCT01024309|Active Comparator|Mini-Posterior Approach|Mini-Posterior surgical approach for total hip arthroplasty
11547159|NCT01024309|Experimental|Direct Anterior Approach|Direct Anterior surgical approach for total hip arthroplasty
11547160|NCT01024296|Experimental|Gastric Bypass Surgery Patients|Surgical site closure using Port Close device
11547161|NCT01024270|Experimental|sublingual, oral and vaginal administration of misoprostol|
11547162|NCT01024257|Experimental|conjunctival autograft plus beta-irradiation|
11547163|NCT01024257|Active Comparator|conjunctival autograft|
11547164|NCT01024244|Placebo Comparator|0 milligrams (mg) Placebo|Participants received 2 placebo capsules by mouth (po), twice daily (BID), prior to morning and evening meals for 12 weeks.
11547165|NCT01024244|Experimental|100 mg LY2599506|Participants received 50-mg capsules of LY2599506 po BID (One 50 mg LY2599506 capsule + 1 matching placebo capsule), prior to morning and evening meals for 12 weeks.
11547166|NCT01024244|Experimental|200 mg LY2599506|Participants received two 50-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks.
11547167|NCT01024244|Experimental|400 mg LY2599506|Participants received two 100-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks.
11547168|NCT01024244|Experimental|200 mg LY2599506 once daily|Participants received 200-mg of LY2599506 po once daily (QD) (Two 100 mg LY2599506 capsules prior to morning meal, 2 matching placebo capsules prior to evening meal for 12 weeks).
11547169|NCT01024231|Experimental|Cohort 1: BMS-936558 (0.3 mg/kg)+Ipilimumab (3 mg/kg)|"BMS-936558 (MDX1106-04) 0.3 mg/kg solution, 60 minutes intravenous infusion every 3 (q3) weeks for 21 weeks in induction and every 12 (q12) weeks for 84 weeks in maintenance
~Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
11547170|NCT01024231|Experimental|Cohort 2: BMS-936558 (1 mg/kg)+Ipilimumab (3 mg/kg)|"Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance
~BMS-936558 (MDX1106-04) 1 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance"
11547171|NCT01024231|Experimental|Cohort 3: BMS-936558 (3 mg/kg)+Ipilimumab (3 mg/kg)|"Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance
~BMS-936558 (MDX1106-04) 3 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance"
11547172|NCT01024231|Experimental|Cohort 4: BMS-936558 (10 mg/kg)+Ipilimumab (3 mg/kg)|"BMS-936558 (MDX1106-04) 10 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance
~Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
11547173|NCT01024231|Experimental|Cohort 5: BMS-936558 (10 mg/kg)+Ipilimumab (10 mg/kg)|"BMS-936558 (MDX1106-04) 10 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance
~Ipilimumab (BMS-734016) 10 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
11547174|NCT01024231|Experimental|Cohort 6: BMS-936558 (1 mg/kg)|BMS-936558 (MDX1106-04) 1 mg/kg solution, 60 minutes intravenous infusion, once q2 weeks for a total maximal duration of 96 weeks
11547175|NCT01024231|Experimental|Cohort 7: BMS-936558 (3 mg/kg)|BMS-936558 (MDX1106-04) 3 mg/kg solution, 60 minutes intravenous infusion, once q2 weeks for a total maximal duration of 96 weeks
11547176|NCT01024231|Experimental|Cohort 8: Nivolumab+Ipilimumab|"Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg solution intravenously q3 weeks, 4 doses for 12 weeks
~Followed by Nivolumab 3 mg/kg solution alone intravenously q2 weeks, 48 doses for a maximum of 96 weeks"
11547177|NCT01024192|Experimental|1|Zolpidem 12.5mg tablet at bed time during 12 weeks
11547178|NCT01024179|Active Comparator|Group B: CTO|Chronic total occlusion
11547179|NCT01024179|Active Comparator|Group A : Non-CTO|"Non-chronic total occlusion :
~Fibrous plaque+fibro-calcific plaque + Lipid plaque(<2 quadrants )
~Lipid-rich plaque ( ≥2 quadrants )"
11547180|NCT01024166||Patient|Patient computer system use questionnaire
11547181|NCT01024166||Caregiver|Caregiver computer system use questionnaire
11547182|NCT01024166||Healthcare Provider|Physician and Nurse computer system use questionnaire
11547183|NCT01024153|Experimental|Active video game play|
11547184|NCT01024140|Experimental|Escitalopram|Flexible dose (5-20mg/day) of escitalopram monotherapy.
11547185|NCT01024127||Ancillary-correlative (predictors of AML treatment outcomes)|Germline DNA is obtained from previously collected peripheral blood or bone marrow samples for array-based genotyping studies, including genome-wide association studies (single nucleotide polymorphisms) and fine mapping genotyping. Clinical trial simulations are performed to test the clinical applicability of using genetic variation data in the management of infectious complications.
11547186|NCT01024114||Positive MBI scan|Women who are previously enrolled in an MBI study that present with a positive MBI scan.
11547187|NCT01024101|Experimental|Paclitaxel|
11547188|NCT01024088||GBS PATIENT|
11547189|NCT01024088||CONTROL|
11547190|NCT01024075|Placebo Comparator|Saline|Sinufoam is mixed with saline and placed within the ethmoid cavity at the completion of sinus surgery
11547191|NCT01024075|Active Comparator|Dexamethasone|Sinufoam is mixed with dexamethasone and placed within the ethmoid cavity at the completion of sinus surgery
11547192|NCT01024062|Experimental|Paclitaxel|
11547193|NCT01024049||Asymptomatic LVD|patients over 18 years old with patients with cardiovascular risk (obesity, diabetes, dyslipidemia, arterial hypertension, age, gender, familial history) and asymptomatic left ventricular dysfunction (LVD).
11547194|NCT01024049||healthy controls|individuals over 18 years old free of disease and treatments.
11547195|NCT01024049||patients with cardiovascular risk|patients with cardiovascular risk (obesity, diabetes, dyslipidemia, arterial hypertension, age, gender, familial history)
11547196|NCT01024049||chronic heart failure patients|patient with chronic heart failure
11547197|NCT01024049||acute heart failure patients|acute heart failure patients
11547198|NCT01024036|Experimental|Siltuximab+best supportive care (BSC)|Siltuximab 11 mg/kg will be administered as a 1-hour intravenous infusion every 3 weeks + BSC.
11547199|NCT01024036|Placebo Comparator|Placebo+BSC|Placebo will be administered as a 1-hour intravenous infusion every 3 weeks + BSC. Participants who do not respond to placebo during the blinded treatment period will have option to crossover and receive siltuximab 11 mg/kg which will be administered by 1-hour intravenous infusion every 3 weeks + BSC during the unblinded treatment period.
11547200|NCT01024023|Active Comparator|PPAM Aid|Suitable participants randomised to the treatment arm will receive the non articulated pneumatic early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
11547201|NCT01024023|Active Comparator|AMA Aid|Suitable participants randomised to the treatment arm will receive the articulated early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
11547202|NCT01024010|Experimental|Arm A (PCO, closed to accrual as of 8/23/2011)|Patients receive induction therapy comprising ofatumumab IV on day 1 (days 1-2 of course 1 only), pentostatin IV over 30 minutes on day 1, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11547203|NCT01024010|Experimental|Arm B (PCO with ofatumumab consolidation)|Patients receive induction therapy as in Arm A. Patients then receive consolidation therapy comprising ofatumumab IV on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11547204|NCT01023997||primary open-angle glaucoma|
11547205|NCT01023997||ocular hypertension patients|
11547206|NCT01023997||normal controls|
11547207|NCT01023997||Exfoliation patients|patients with exfoliation syndrome or exfoliative glaucoma
11547208|NCT01023984|Active Comparator|TEM - Transanal Endoscopic Microsurgery|TEM under general anesthesia
11547209|NCT01023984|Active Comparator|ESD - Endoscopic Submucosal Dissection|ESD under sedation
11547210|NCT01023971||Group A|Patients investigated with mfERG and MP-1
11547211|NCT01023971||Group B|Patients investigated by Laser Doppler Flowmetry
11547212|NCT01023958|Experimental|single arm|open label
11547213|NCT01023945|Experimental|ASP1941 high dose group|oral
11547214|NCT01023945|Experimental|ASP1941 low dose group|oral
11547215|NCT01023945|Placebo Comparator|Placebo group|oral
11547216|NCT01023932||Auditory Neuropathy Patients|
11547217|NCT01023919|Active Comparator|Group B: Non-DM|Coronary artery disease with diabetes mellitus
11547218|NCT01023919|Active Comparator|Group A: DM|Coronary artery disease with diabetes mellitus
11547219|NCT01023906||18-49 years|Younger
11547220|NCT01023906||50-85 years|Older
11547221|NCT01023893||End-stage renal disease|
11547222|NCT01023880|Experimental|1|CEP-18770
11547223|NCT01023867|Experimental|Alzheimer's disease group|Patients with Alzheimer's disease treated donepezil
11547224|NCT01023867|Experimental|Mixed Dementia group|Patients with Mixed Dementia treated donepezil
11547225|NCT01023854|Experimental|Continuous Paravertebral block|Continuous Paravertebral block
11547226|NCT01023854|Placebo Comparator|Placebo|Placebo
11547227|NCT01023841|Active Comparator|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
11547228|NCT01023841|Placebo Comparator|Vehicle Sterile Solution|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
11547229|NCT01023828||TOBACCO SMOKING|Group of patients with diagnosis of NSCLC and exposure to tabacco smoking
11547230|NCT01023828||WOOD SMOKE|Patients whit diagnosis of NSCLC and exposure to wood smoke
11547231|NCT01023828||TABACCO SMOKING AND WOOD SMOKE|Patients whit diagnosis of NSCLC and exposure to tabacco smoking and wood smoke
11547232|NCT01023828||WHITOUT EXPOSURE|Patients whit diagnosis of NSCLC and whitout exposure to risk factor
11547268|NCT01023581|Experimental|Alogliptin 12.5 BID|Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
11547269|NCT01023581|Active Comparator|Metformin 500 BID|Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.
11547233|NCT01023815|Experimental|Group A -Once-a-day regimen|"Everolimus: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole daily dose of everolimus was taken in the morning, at the same time of the CsA and steroid dosing. At the Rand+1W visit, the everolimus dose was adjusted to reach and maintain everolimus blood levels between 5 and 8 ng/mL until end of Month 12.
~Cyclosporine: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole cyclosporine daily dose was taken in the morning. The dose was then adjusted to maintain C2 levels between 350 and 700 ng/mL.
~Prednisone: In patients randomized to Group A before Amendment 1 approval, the dose of prednisone was kept stable at 5 mg/day in the morning."
11547234|NCT01023815|Experimental|Group B - Steroid Withdrawal group|"Everolimus: after randomization the everolimus dose was adjusted, if necessary, to maintain a C0 within 6-10 ng/mL until M12.
~Cyclosporine:after randomization the cyclosporine dose was adjusted to maintain CsA C2 levels within 300-500 ng/mL until M12.
~Prednisone: starting from Visit 5 (day 90 ± 28 days), oral prednisone was tapered until complete stop. It was recommended to taper prednisone by 1 mg/week until complete stop in 5 to 6 weeks."
11547235|NCT01023815|Active Comparator|Group C - Standard twice-a-day group|"Everolimus: after randomization the everolimus dose was adjusted, if necessary, in order to maintain a C0 within 6-10 ng/mL until M12.
~Cyclosporine: after randomization the cyclosporine dose was gradually adjusted to reach and maintain C2 blood levels of 200-450 ng/mL between Month 6 and Month 12.
~Prednisone: the dose of prednisone was kept stable at 5 mg/day in the morning."
11547236|NCT01023815|Experimental|Not Randomized Population (NRP)|"NRP defined in whom a renal transplantation was performed, received at least one dose of study drug (everolimus) but who did not qualify for randomization at Visit 5, Day 90. This group was addressed as not randomized patients (NRP) and described with respect to baseline characteristics, treatment and outcome variables."
11547237|NCT01023802||Neoadjuvant therapy for breast cancer|Women who present to the Internal Medicine Breast Cancer Clinic with breast cancer and who after discussion with the consulting surgeon and oncologist have agreed to undergo neoadjuvant chemotherapy or neoadjuvant hormone therapy.
11547238|NCT01023789|Experimental|ABSORB BVS|Absorb Bioresorbable Vascular Scaffold (BVS) System implantation in the treatment of coronary artery disease
11547239|NCT01023776|Other|live monovalent H1N1 vaccine|A/California/07/09 live monovalent H1N1 vaccine 0.2 given intranasally, 2 doses given 28 days apart
11547240|NCT01023763|No Intervention|Usual care|"Nursing home residents who require intravenous fluids and intravenous antibiotics was treated as usual (hospital admissions for intravenous treatment).
~In control nursing homes that had not completed the training program (intervention period), nursing home residents who require intravenous fluids and intravenous antibiotics was treated as usual. The majority of these patients were admitted to hospital for intravenous treatment. A few nursing homes or nursing home departments had sufficient expertise and capacity to provide treatment locally."
11547241|NCT01023763|Other|A training program in iv treatment|"A structured training program in intravenous treatment in nursing homes:
~Each of 30 participating nursing homes sequentially received theory and practical training in intravenous treatment. In nursing homes that had completed the training program (intervention period), and had sufficient expertise and capacity, nursing home residents in need of intravenous fluids or antibiotics were treated locally; otherwise they were hospitalized."
11547242|NCT01023750||Fenofibrate|
11547243|NCT01023737|Experimental|Hydroxychloroquine and Vorinostat|Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily and HCQ will be administered starting on Day 2 of Cycle 1 and both will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
11547244|NCT01023724|Active Comparator|bromfenac 0.09%|bromfenac 0.09% drops to be given pre operatively for one day BID, and then postoperatively for 14 days.
11547245|NCT01023724|Active Comparator|Acuvail|Acuvail to be given preoperatively at BID for one day pre op and then post operatively for 14 days.
11547246|NCT01023711|Other|Inactivated H1N1 Vaccine|Subject will recieve 0.5 mL IM injection of Inactivated H1N1 vaccine
11547247|NCT01023698|Experimental|photocoagulation|Laser photocoagulation
11547248|NCT01023685|Experimental|CAD106|
11547249|NCT01023672|Other|Armodifinil|150-250 mg armodafinil by mouth daily
11547250|NCT01023659|Active Comparator|Bupropion + motivational emails|participants receive Zyban (300mg/day) plus weekly motivational emails for 12 weeks.
11547251|NCT01023659|Active Comparator|Varenicline + motivational emails|participants receive Champix (2mg/day) plus weekly motivational emails for 12 weeks.
11547252|NCT01023659|Active Comparator|Motivational emails|participants receive weekly motivational emails for 12 weeks.
11547253|NCT01023646|Other|carbohydrate load|Food challenge - Carbohydrate load
11547254|NCT01023646|Other|Carbohydrate + Protein|Food challenge - carbohydrate + protein
11547255|NCT01023646|Other|Carbohydrate + Fat|Food challenge - carbohydrate + fat
11547256|NCT01023646|Other|Fiber|Food challenge - carbohydrate + fiber
11547257|NCT01023633|Active Comparator|Arm A: FOLFOX 4 continuous (Oxaliplatin, LV, 5-FU)|The arm A (FOLFOX4 continuous arm):receive FOLFOX4 every 2 weeks until progression or for maximum 24 cycles.
11547258|NCT01023633|Experimental|Arm B: FOLFOX4 Stop and go (Oxaliplatin, LV, 5-FU)|The arm B will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles
11547259|NCT01023620|Experimental|Pioglitazone|10 male patients with lipodystrophy taking daily Pioglitazone 45 mg
11547260|NCT01023620|Sham Comparator|Observation/Comparison|10 male patients with lipodystrophy not taking daily Pioglitazone
11547261|NCT01023607|Active Comparator|Group A:|Atorvastatin 20mg
11547262|NCT01023607|Experimental|Group B:|Atorvastatin 60mg
11547263|NCT01023607|Active Comparator|Group C:|Rosuvastatin 10mg
11547264|NCT01023594|Active Comparator|External stent|Feeding tube insert at pancreatojejunostomy site as a stent. And stent tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall.
11547265|NCT01023594|Active Comparator|Internal stent|short(5cm)internal stent insertion at pancreatojejunostomy site
11547266|NCT01023581|Placebo Comparator|Placebo|Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
11547267|NCT01023581|Experimental|Alogliptin 25 QD|Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
11547270|NCT01023581|Active Comparator|Metformin 1000 BID|Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.
11547271|NCT01023581|Experimental|Alogliptin 12.5 BID + Metformin 500 BID|Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.
11547272|NCT01023581|Experimental|Alogliptin 12.5 BID + Metformin 1000 BID|Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.
11547273|NCT01023568|Active Comparator|Macintosh blade|Intubation with Macintosh blade laryngoscope
11547274|NCT01023568|Active Comparator|Glidescope|Intubation with Glidescope laryngoscope
11547275|NCT01023568|Active Comparator|Truview PCD|Intubation with the Truview PCD laryngoscope
11547276|NCT01023555|No Intervention|0.5cc 2 Bottles|
11547277|NCT01023555|Active Comparator|1cc single bottle|
11547278|NCT01023542|Active Comparator|1|Basiliximab 20 mg day 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low level cyclosporine [start at day 5 after OLT, trough-level 100-150 ng/mL (CsA)] + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx.
11547279|NCT01023542|Active Comparator|2|Basiliximab 20 mg Tag 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx + low-level cyclosporine (start within 30 days after LTx; trough level 100-150ng/mL (CsA).
11547280|NCT01023542|Experimental|3|Basiliximab 20 mg Tag 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx + everolimus (start within 30 days after LTx; trough-level 6-10 ng/mL).
11547281|NCT01023529||Prostate cancer|Patients with incurable prostate cancer requiring palliation of symptoms from a soft-tissue pelvic tumor.
11547282|NCT01023529||Rectal Cancer|Patients with incurable rectal cancer requiring palliation of symptoms from a soft-tissue pelvic tumor.
11547283|NCT01023516|Experimental|1|
11547284|NCT01023516|Placebo Comparator|2|
11547285|NCT01023503||1|Adults, with a new statin prescription or a change in their stain treatment
11547286|NCT01023490|Placebo Comparator|Placebo|
11547287|NCT01023490|Active Comparator|Vitamin D|34,500 IU vitamin D per week
11547288|NCT01023477|Experimental|Chloroquine Standard Dose (500mg/week)|Patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month standard dose chloroquine (500 mg/week).
11547289|NCT01023477|Experimental|Chloroquine Low Dose (250mg/week)|Patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month low dose chloroquine (250mg/week).
11547290|NCT01023464|Other|Period 1|FID 114657 or SootheXP
11547291|NCT01023464|Other|Period 2|FID 114657 or SootheXP
11547292|NCT01023438|Experimental|Assisted uptitration|Uptitration of recommended drugs by primary care physician with specialist support
11547293|NCT01023438|Active Comparator|Usual care|Usual communication strategy from cardiologist to primary care physician
11547294|NCT01023425|Experimental|switching group|switching patients with Alzheimer's disease(AD) from galantamine or rivastigmine to donepezil because they were not responding adequately
11547295|NCT01023425|Experimental|naive group|naive patients with AD who initiated therapy with donepezil
11547296|NCT01023412|Active Comparator|Nutritional product|Oral nutritional supplement containing immuno nutrients
11547297|NCT01023412|Placebo Comparator|Isocaloric control|Isocaloric and isonitrogenous control without immuno nutrients
11547298|NCT01023399|Experimental|Artesunate + Amodiaquine|"Oral fixed combination of artesunate (AS) and amodiaquine (AQ)
~Once daily, dose according to age
~Infants 2-11 months: AS 25/AQ 67,5 mg (3 tablets/ blister)
~Toddlers 1-5 years: AS 50/AQ 135 mg (3 tablets/ blister)
~Children: 6-13 years: AS 100/AQ 270 mg (3 tablets/ blister)
~Adults: >= 14 years: AS 100/AQ 270 mg (6 tablets/ blister)
~3 day-treatment"
11547299|NCT01023373|Experimental|B:PTRS|B: the same medical therapy, as previously described in group A, associated with PTRS
11547300|NCT01023373|Active Comparator|A:medical therapy|hypotensive drugs, statins and antiplatelet therapy
11547301|NCT01023360|Experimental|Clopidogrel and proton pump inhibitors|all participating healthy people should receive clopidogrel and 3 kinds of PPI sequentially with one week interval between each PPI.
11547302|NCT01023347|Active Comparator|Paclitaxel (Genexol®) and Cisplatin|
11547303|NCT01023347|Experimental|Paclitaxel loaded polymeric micelle (Genexol-PM®) & Cisplatin|
11547304|NCT01023334|Experimental|Intraocular lidocaine,topical anesthesia,MSICS|experimental group:manual small incision cataract surgery under topical anesthesia with intracameral lidocaine
11547305|NCT01023334|Experimental|intracameral balanced salt solution,topical anesthesia,MSICS|control group:manual small incision cataract surgery under topical anesthesia with intracameral balanced salt solution.
11547306|NCT01023321|Experimental|1|single ascending doses
11547307|NCT01023321|Placebo Comparator|2|single dose placebo
11547308|NCT01023321|Experimental|3|multiple dose, 7 or 14 days, oral solution
11547309|NCT01023321|Placebo Comparator|4|multiple dose, 7 or 14 days, oral solution
11547310|NCT01023308|Experimental|Panobinostat + Bortezomib + Dexamethasone|
11547311|NCT01023308|Placebo Comparator|Placebo + Bortezomib + Dexamethasone|
11547312|NCT01023295|Placebo Comparator|Placebo|single dose
11547313|NCT01023295|Experimental|15 mg/m^2|15 mg/m^2 fosbretabulin, single dose
11547314|NCT01023295|Experimental|25 mg/m^2|25 mg/m^2 fosbretabulin, single dose
11547315|NCT01023295|Experimental|35 mg/m^2|35 mg/m^2 fosbretabulin, single dose
11547316|NCT01023295|Experimental|45 mg/m^2|45 mg/m^2 fosbretabulin, single dose
11547317|NCT01023282|Experimental|ACR325|
11547318|NCT01023282|Placebo Comparator|Placebo|
11547319|NCT01023269|Other|ON / OFF|Stimulation ON for 4 weeks, followed by stimulation OFF for 4 weeks.
11547320|NCT01023269|Other|OFF / ON|Stimulation OFF for 4 weeks, followed by stimulation ON for 4 weeks.
11547321|NCT01023256|Experimental|Group 1: MOR103, experimental|Biological: MOR103 0.3 mg/kg or placebo
11547322|NCT01023256|Experimental|Group 2: MOR103, experimental|Biological: MOR103 1.0 mg/kg or placebo
11547406|NCT01022645||Levonorgestrel IUD|
11547323|NCT01023256|Experimental|Group 3: MOR103, experimental|Biological: MOR103 1.5 mg/kg or placebo
11547324|NCT01023243|Placebo Comparator|1 CAre of the Feet for Those at Risk|secular trends for physician documentation in the medical record for care of the feet for high risk patients
11547325|NCT01023243|Active Comparator|Care of the feet for those at risk|the impact of 1) patient survey regarding last foot exam, tobacco and aspirin use on documentation of foot exam and 2) patient education material: Care of the Foot For Those at Risk, on documentation of foot examination in the medical record
11547326|NCT01023243|Active Comparator|Impact of Quality Survey|Impact of patient survey regarding last foot exam, tobacco and aspirin use on documentation of foot exam in the medical record
11547327|NCT01023230|Experimental|DV-601|
11547328|NCT01023217|Experimental|Adefovir plus Entecavir|Adefovir + Entecavir for 104 weeks
11547329|NCT01023217|Active Comparator|Adefovir plus Lamivudine|Adefovir + Lamivudine for 52 weeks, and thereafter, Adefovir + Entecavir for 52 more weeks
11547330|NCT01023204|Experimental|Paclitaxel|
11547331|NCT01023191|Active Comparator|Percutaneous insertion|To undergo insertion of catheter using percutaneous technique under local anaesthetic
11547332|NCT01023191|Active Comparator|Open insertion|To undergo insertion of catheter using open technique under general anaesthetic
11547333|NCT01023178|Active Comparator|Vivelle-Dot|17Beta Estradiol - transdermal
11547334|NCT01023178|Active Comparator|Premarin|Conjugated estrogens
11547335|NCT01023178|Active Comparator|Estrace|17beta Estradiol
11547336|NCT01023165|Experimental|IV bolus insulin, metabolic integrity|Diabetic patients will complete diagnostic testing and complete quality of life questionnaires at baseline and every six months thereafter while enrolled in the study to monitor and assess progress with metabolic integrity and complications resulting from their diabetes. Comparisons will be performed on lab values performed at baseline and every six months thereafter. Supervising physician may request testing be performed more frequently as deemed medically necessary, testing may include retinal photography, nerve conduction and labs. Meds and medical intervention information is collected weekly at the Intravenous Bolus Insulin treatment sessions. An annual evaluation is performed to review clinical data collected and evaluate progress for analysis and comparison.
11547337|NCT01023152|Experimental|Automated cuff-inflator|
11547338|NCT01023139|No Intervention|Standard of care (SOC)|No intervention following phase 1 of the study is done during this 2nd phase. Participants will have their height and weights examined at 3 month and 6 month following end of phase 1. During these two visits, they will receive counseling from the physician regarding food choices and exercise maintenance.
11547339|NCT01023139|Experimental|Continuing Behavioral Therapy (CoBT)|This arm follows the end of the phase 1 which incorporates behavioral therapy, nutrition counseling and pharmacotherapy with Sibutramine while medically supervised. Participants randomized to this arm no longer receive medication and will receive behavioral therapy once a month and then evaluated at 3 months and six months for weight loss maintenance.
11547340|NCT01023126|No Intervention|EO|Exercise three times a week, one under supervision and two freely chosen by the participant
11547341|NCT01023126|Experimental|EGT|Exercise three times a week, one under supervision and two freely chosen by the participant
11547342|NCT01023113|Experimental|PASCAL laser, PRP in 2-3 sitting at 3 days interval.|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery by PASCAL laser
11547343|NCT01023113|Active Comparator|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery by conventional laser
11547344|NCT01023100|Experimental|Open label|
11547345|NCT01023087||Treatment|Patients with sepsis treated with polymyxin E (colistin)
11547346|NCT01023087||Control|Patients with sepsis treated with other, non-nephrotoxic antibiotic medication
11547347|NCT01023074|No Intervention|Non-MS Control|Non-MS control group
11547348|NCT01023074|Active Comparator|MS: Auditory Training|MS group receiving auditory training
11547349|NCT01023074|Placebo Comparator|MS: Control Activity|MS group not receiving auditory training, doing control activity
11547350|NCT01023061|Experimental|Treatment (antihormone therapy and radiation therapy)|Patients receive abiraterone acetate and prednisone daily for 24 weeks. Patients also receive leuprolide acetate or goserelin in weeks 1 and 13. Patients undergo external beam radiotherapy starting in week 15 for 8.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
11547351|NCT01023048|Experimental|PGD testing|
11547352|NCT01023035|Experimental|Treated/Not Randomized|Participants received 4 weeks of PEG2b/RBV followed by 24 or 44 weeks of boceprevir plus PEG2b/RBV depending on Hepatitis C Virus RNA (HCV-RNA) levels. Participants continued with this treatment if their serum hemoglobin remained >10 g/dL throughout the 28- or 48-week treatment period.
11547353|NCT01023035|Experimental|Ribavirin Dose Reduction|After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Ribavirin (RBV) Dose Reduction Arm received reduced doses of RBV for management of the anemia in combination with PEG2b and boceprevir therapies.
11547354|NCT01023035|Experimental|Erythropoietin Use|After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Erythropoietin Use Arm received erythropoietin for management of the anemia in addition to PEG2b/RBV and boceprevir therapies.
11547355|NCT01023022||Medtronic CareLink® Network|"Patients with implanted Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices, who will be monitored by the Medtronic CareLink® System.
~The System consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website."
11547356|NCT01023009||eye occlusion|
11547407|NCT01022645||Copper IUD or Tubal Ligation|
11547408|NCT01022632|Active Comparator|Fluoxetine|Fluoxetine : 20 mg Once a day in morning after taking food for 6 weeks
11547409|NCT01022632|Experimental|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
11547453|NCT01022294|Experimental|Arm 1|Inhalation of nitrousoxide-oxygen during the first experimental session; inhalation of atmospheric air during the second session
11547357|NCT01022996|Experimental|RAD001|"Patients with a history of classical Hodgkin lymphoma (ie, nodular sclerosing, mixed cellularity, lymphocyte-rich, lymphocyte-depleted) whose disease had progressed after receiving high-dose chemotherapy with AHSCT (if eligible) and/or after therapy with a gemcitabine- or vinorelbine- or vinblastine-containing regimen, were enrolled into this study. All patients were assigned to a daily dose of everolimus 10 mg (two 5-mg tablets), selfadministered orally and continuously from Cycle 1 Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death, or discontinuation from the study for any other reason.
~A treatment cycle consisted of 28 days."
11547358|NCT01022983|Active Comparator|Levosimendan|
11547359|NCT01022983|Placebo Comparator|Povidon, waterfree etanol, glucosis 5%|
11547360|NCT01022970|Placebo Comparator|Placebo|
11547361|NCT01022970|Active Comparator|QAX576|
11547362|NCT01022957|Experimental|Study group|Neurological, ophthalmological, olfactive exams and cerebral MRI
11547363|NCT01022944|Other|Group 2 :|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
11547364|NCT01022944|Other|Group 1|Children with chronic middle ear effusion having adenoidectomy.
11547365|NCT01022918|Experimental|Bevacizumab/Irinoecan|"Neoadjuvant Treatment Patient will receive bevacizumab 10mg/kg plus irinotecan 125mg/m² 4 times every two weeks.
~Radiochemotherapy Then they will receive conformational radiotherapy for 6 weeks (30 Gy, 2Gy/fractions) associated with Temodal ( 75mg/m²/day) from first day up to the end of radiotherapy and 4 injections of Avastin (15mg/kg Day 1, day 15, day 29 and day 43).
~Adjuvant treatment:
~Patients will receive bevacizumab 15mg/kg plus irinotecan 125mg/m² 12 times every two weeks."
11547366|NCT01022918|Active Comparator|Stupp|patient will receive 6 weeks chemotherapy treatment associating conformational 30 Gy (2Gy/ fraction)and Temodal(75mg/m²/day, followed by 6 months adjuvant therapy consisting in 5 days every 28 days of Temodal (150-200mg/m².
11547367|NCT01022905|Experimental|High-risk patients ( 5 cohorts)|
11547368|NCT01022905|Active Comparator|Healthy controls|
11547369|NCT01022892||Phase 1 - Pilot phase|Total of 10 patients currently undergoing EVAR Surveillance. These 10 patients include 5 patients with endoleak known from a recent CT scan and 5 patients with no endoleak and shrinking aneurysm.
11547370|NCT01022892||Phase 2 - Blinded from CT Scan|This phase of study involves recruitment of 150 patients currently under post-EVAR surveillance. The physicians and ultrasound technologists will be blinded to the result of the CT Scan when performing and interpreting the CUS. The current schedule for EVAR Surveillance will be maintained so that an individual may receive more than one enhanced CT Scan and CUS during the 18 months of the study.
11547371|NCT01022853|Experimental|BIBF 1120 and BI 6727|Finding Maximum Tolerated Dose of BI 6727 in combination with BIBF 1120
11547372|NCT01022840|Placebo Comparator|Placebo|Placebo as saline solution
11547373|NCT01022840|Experimental|Low dose|S-Ketamine
11547374|NCT01022840|Active Comparator|High dose|
11547375|NCT01022827|Experimental|posterior shoulder stiffness massage group|The inclusion criteria of patients with glenohumeral internal rotation limitation and posterior shoulder stiffness were: [1] limitation of internal rotation ROM compared to the sound side; [2] mild glenohumeral joint hypomobility according to joint play assessment; [3] stiffness in the posterior shoulder region.
11547376|NCT01022827|Placebo Comparator|posterior shoulder stiffness placebo group|
11547377|NCT01022814||Pregnant woman|
11547378|NCT01022801|Experimental|Entecavir (0.01 mg)|
11547379|NCT01022801|Experimental|Entecavir (0.1 mg)|
11547380|NCT01022801|Experimental|Entecavir (0.5 mg)|
11547381|NCT01022788|Experimental|Home-based counselling visits by volunteers|Home-based counselling in pregnancy and the first few days of life to encourage women and families to adopt key newborn care behaviours
11547382|NCT01022788|No Intervention|Standard care through existing health system|
11547383|NCT01022775|Experimental|1: Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
11547384|NCT01022775|Active Comparator|2: Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
11547385|NCT01022762|Active Comparator|repaglinide|1 mg repaglinide twice daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 4 mg three times daily
11547386|NCT01022762|Active Comparator|gliclazide|80 mg gliclazide once daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 160 mg twice daily
11547387|NCT01022749|Experimental|2|patients with IBD receiving immunosuppressants (TNF blockers excluded) (n=100)
11547388|NCT01022749|Experimental|3|patients with IBD receiving immunosuppressants including TNF blockers (n=100)
11547389|NCT01022749|Experimental|1|patients with IBD not receiving immunosuppressant (n=100)
11547390|NCT01022749|Active Comparator|4|patients with IBD receiving immunosuppressants including TNF blockers (n=20)
11547391|NCT01022736|Experimental|gabapentin|patients scheduled for cardiac bypass surgery will be administered gabapentin (600mg, orally). Blood will be drawn and plasma gabapentin levels determined 1 hour before surgery, 10 minutes into surgery, 10 minutes before separation from bypass, 30 minutes following bypass, and then before and 2 hours after each dose of gabapentin.
11547392|NCT01022723||Lung Cancer patients|Lung Cancer (particular focus on non smokers with adenocarcinoma)
11547393|NCT01022723||Patients with Nasopharyneal carcinoma|Patients with Nasopharyneal carcinoma
11547394|NCT01022723||Breast Cancer patients|Breast cancer patients
11547395|NCT01022723||Prostate Cancer patients|Prostate cancer patients
11547396|NCT01022723||Colorectal Cancer patients|Colorectal cancer patients
11547397|NCT01022723||Gastric Cancer patients|Gastric cancer patients
11547398|NCT01022710||Group 1|Veterans with sensorineural hearing loss
11547399|NCT01022697|Active Comparator|A|Glucose drink
11547400|NCT01022697|No Intervention|B|Fasting
11547401|NCT01022684||Healthy patients|
11547402|NCT01022671|Experimental|Belotecan|Single arm
11547403|NCT01022658|Active Comparator|detemir|Insulin detemir at dinner or bedtime
11547404|NCT01022658|Active Comparator|aspart|Insulin aspart before each meal
11547405|NCT01022658|Active Comparator|detemir and aspart|
11547410|NCT01022632|Experimental|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
11547411|NCT01022619||Premature labor|Women at the third trimester of pregnancy with premature contractions and cervical dilation of effacement
11547412|NCT01022619||Control|Women at the third trimester of pregnancy with uncomplicated pregnancy
11547413|NCT01022619||Pre-eclampsia|Women at the third trimester with pre-eclampsia
11547414|NCT01022619||Gestational diabets|Women at the third trimester of pregnancy with gestational diabetes requiring insulin
11547415|NCT01022606|Other|Patients with walking limitation|Patients with claudication and Walking-Induced Transient Hack (W.I.T.H.) tcpO2 profiles are tested on treadmill with invasive pO2 arterial sampling and body temperature recording
11547416|NCT01022580|Active Comparator|Infasurf surfactant (ONY, Inc.)|Infants already receiving inhaled nitric oxide will receive scheduled doses of late surfactant (Infasurf) on study days 0, 2, 4, 6 and 8.
11547417|NCT01022580|Sham Comparator|sham|Infants already receiving inhaled nitric oxide will not receive additional doses of late surfactant (Infasurf).
11547418|NCT01022567|Active Comparator|Operative treatment|Regular open appendicectomy
11547419|NCT01022567|Active Comparator|Antibiotic treatment|Ertapenem 1 g i.v. x 1 three days
11547420|NCT01022541|Other|This is a single arm study|This is a single arm study
11547421|NCT01022528|Experimental|Dexamethasone|
11547422|NCT01022528|Placebo Comparator|Saline|
11547423|NCT01022515||patients with pheochromocytoma|Patients with pheochromocytoma / paraganglioma are being followed as recommended according to international standards. No intervention is expected except regular measurement of plasma CgA (as usual) and EM66 (research purpose) levels.
11547424|NCT01022515||Patients with essential hypertension|Patients with essential hypertension will be selected as controls. EM66 and CgA plasma levels will be assessed in these patients after having excluded the presence of a pheochromocytoma / paraganglioma with normal urinary metanephrines / normetanephrines excretion levels.
11547425|NCT01022502|Active Comparator|refined indigo naturalis ointment|Refined indigo naturalis ointment was applied topically to one of 2 bilaterally symmetrical psoriatic plaque lesions of the same patient for 8 weeks, starting on the date of enrollment in the study
11547426|NCT01022502|Active Comparator|crude indigo naturalis ointment|Crude indigo naturalis ointment was applied topically to one of 2 bilaterally symmetrical psoriatic plaque lesions of the same patient for 8 weeks, starting on the date of enrollment in the study
11547427|NCT01022489|Experimental|Transcranial magnetic stimulation: rTMS|rTMS : 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
11547428|NCT01022489|Placebo Comparator|placebo (sham coil) treatment|
11547429|NCT01022476|Experimental|Raltegravir potassium|raltegravir 400 mg twice a day
11547430|NCT01022463|Active Comparator|Ivabradine|Crossover study to compare ivabradine and atenolol
11547431|NCT01022463|Placebo Comparator|Atenolol|
11547432|NCT01022437|Experimental|Geranium Oil and component PN-34|
11547433|NCT01022424|Experimental|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
11547434|NCT01022411|Experimental|A|Brown rice
11547435|NCT01022411|Placebo Comparator|B|White rice
11547436|NCT01022398|Experimental|Vitamin D|Subjects will receive Vitamin D supplementation 10,000 international units of cholecalciferol (vitamin D3) by mouth weekly
11547437|NCT01022398|Placebo Comparator|Placebo|Subjects will receive placebo (an exact replica of the vitamin D capsule that does not contain any medically active substance) by mouth weekly
11547438|NCT01022385|No Intervention|12-hour fast|
11547439|NCT01022385|Active Comparator|24-hour low-residual diet and 12-hour fast|
11547440|NCT01022372||control group|
11547441|NCT01022372||endometriosis group|
11547442|NCT01022372||endometrioma group|
11547443|NCT01022359|Active Comparator|Tesio Catheter|Patients randomised to receive the established catheter type in use at our centre [control]
11547444|NCT01022359|Active Comparator|LifeCath|Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)
11547445|NCT01022346|Placebo Comparator|Placebo|Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
11547446|NCT01022346|Experimental|RO5217790|RO5217790 will be administered at a dose of 5*10^7 plaque forming unit (pfu) subcutaneously on Days 1, 8, and 15.
11547447|NCT01022333|Experimental|DIM group (BRCA1 carriers)|This group will have up to 100 women who are carriers of a BRCA1 deleterious mutation. To ensure safety, women in this group will not be able to participate in the study if they are under medications with warfarin, theophylline, or anticonvulsants; or if they are pregnant, breast-feeding or planning to become pregnant within 6 months of the research project. Women in this group will receive 300 mg per day of Rx Balance BioResponse DIM for six weeks. Supplements will be given free of charge. A blood sample (20cc) and a urine sample (20cc) will be collected from these women during two clinic visits; the second visit will be during the six weeks of DIM supplementation (4-6 weeks after the first clinic visit).
11547448|NCT01022333|No Intervention|No DIM group (BRCA1 carriers)|This group will have up to a 100 women who are carriers of a BRCA1 deleterious mutation. This group will not receive DIM. Women that choose not to take DIM will be in this group. A blood sample (20cc) and a urine sample (20cc) will be collected from these women during two clinic visits; the second visit will be 4-6 weeks after the first clinic visit.
11547449|NCT01022333|No Intervention|General Control Group|This group will have up to 100 women who do not carry a BRCA1 mutation but who come from BRCA1 carrier family (a family with at least one individual that has tested positive for a BRCA1 mutation). A control subject is considered negative for a BRCA1 mutation if she has been confirmed by direct DNA sequencing to not be a carrier of this gene. A blood sample (20cc) and a urine sample (20cc) will be collected from these women at a single clinic visit.
11547450|NCT01022320|Experimental|Surgical outcome|20 consecutive cases of patients who underwent the lateral pharyngoplasty
11547451|NCT01022307||Group 1: no history of TBI|184 participants with no history of traumatic brain injury (TBI).
11547452|NCT01022307||Group 2: with a history of TBI|28 patients with a history of TBI. Most of these patients had suffered mild TBI.
11547454|NCT01022294|Experimental|Arm 2|Inhalation of atmospheric air during the first experimental session; inhalation of nitrousoxide-oxygen during the second session
11547455|NCT01022281||Normal Controls|Normal age matched controls without exfoliation
11547456|NCT01022281||Exfoliation Syndrome|Patients with exfoliation syndrome
11547457|NCT01022268||Infection, inflammation or allergy|"Children presenting via any means to St Mary's Hospital; this would include the A&E department, the general and infectious disease wards and the paediatric intensive care unit.
~Children needing blood tests for any clinical reason Children who, in the clinical judgement of the doctor assessing them, have presented because of a condition consistent with an infectious, inflammatory or allergic process"
11547458|NCT01022268||controls|children who do not have an infectious, inflammatory or allergic condition, who anyway require blood tests for clinical reasons
11547459|NCT01022255|Experimental|Arm 1|
11547460|NCT01022242|Placebo Comparator|Placebo|Placebo is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
11547461|NCT01022242|Experimental|PXL01|PXL01 is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
11547462|NCT01022229|Experimental|Compound Natural Health Product|15 study participants who will receive the compound natural health product.
11547463|NCT01022229|Placebo Comparator|Placebo|15 participants will receive placebo natural health product.
11547464|NCT01022216|Active Comparator|V.A.C.® Therapy|Vacuum Assisted Closure device that utilizes controlled negative pressure
11547465|NCT01022216|Experimental|Procellera™ Wound Dressing with V.A.C.® Therapy|Procellera wound dressing used as a primary contact layer on the wound bed, used in conjunction with NPWT
11547466|NCT01022203|Experimental|Structured Approach Therapy|Couple-Based Intervention called Structured Approach Therapy provides skills training to couple so they can reduce PTSD.
11547467|NCT01022203|Active Comparator|PTSD Family Education|Couple-Based Education called PTSD Family Education teaches couple about PTSD symptoms, related problems, and treatment.
11547468|NCT01022190|Experimental|Drug: Etoricoxib (Arcoxia, MSD), 90 mg.|Intervention drug: Etoricoxib (Arcoxia, MSD), 90 mg, orally, one time a day, for a 7 day period.
11547469|NCT01022177|Active Comparator|diabetics|subjects with HbA1c >7,0 and pathological glucose tolerance testing
11547470|NCT01022177|Active Comparator|healthy|healthy subjects with HbA1c <7,0 and negative glucose tolerance testing
11547471|NCT01022164|Other|fibrin glue|
11547472|NCT01022151|Placebo Comparator|Placebo [group P]|
11547473|NCT01022151|Active Comparator|Aminophylline 2 mg/Kg [group A2]|
11547474|NCT01022151|Active Comparator|Aminophylline 3 mg/Kg [group A3]|
11547475|NCT01022151|Active Comparator|Aminophylline 4mg/Kg [group A4]|
11547476|NCT01022151|Active Comparator|Aminophylline 5 mg/Kg [group A5]|
11547477|NCT01022151|Active Comparator|Doxapram 1 mg/kg [group D]|
11547478|NCT01022138|Experimental|HER2Bi-armed activated T cells/Cyclophosphamide/biomarker|"HER2Bi-armed activated T cells Immediately after pheresis, the lymphocytes are activated with soluble monoclonal anti-CD3 antibody, which cross-links the CD3 receptors on T cells and activates them.
~Cyclophosphamide After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide
~Laboratory biomarker analysis The association between the [18F]-FDG PET/CT assessments (percent changes from baseline in SUVpeak) and immunologic biomarker changes as well as tumor response will be explored."
11547479|NCT01022112|Experimental|TA-7284-Low|
11547480|NCT01022112|Experimental|TA-7284-Low-middle|
11547481|NCT01022112|Experimental|TA-7284-High-middle|
11547482|NCT01022112|Experimental|TA-7284-High|
11547483|NCT01022112|Placebo Comparator|Placebo|
11547484|NCT01022099|Active Comparator|navigated TKA|
11547485|NCT01022099|Other|conventional TKA|
11547486|NCT01022086||early stage/adjuvant|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
11547487|NCT01022086||locally advanced/neoadjuvant|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
11547488|NCT01022086||metastatic|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
11547489|NCT01022086||anthracycline-containing|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
11547490|NCT01022086||non-anthracycline containing|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
11547491|NCT01022073||Globus Pallidus interna Group|Cohort of subjects who received DBS-GPi as part of the CSP 468 intervention trial, and still have their device working and in place.
11547492|NCT01022073||Subthalamic Nucleus Group|Cohort of subjects who received DBS-STN as part of the CSP 468 intervention trial, and still have their device working and in place.
11547493|NCT01022060|Experimental|A|Renalof
11547494|NCT01022060|Placebo Comparator|B|Placebo
11547495|NCT01022047|Experimental|Noex|The patients shall use the NOEX drug only once a day (one application in each nostril) during the 12 weeks of treatment
11547496|NCT01022047|Active Comparator|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
11547558|NCT01021696|Active Comparator|Pregabalin|Intervention group, individual pain treatment
11547497|NCT01022034|Active Comparator|Pexy group|This group of patients with full thickness rectal prolapse will receive standard sacral rectopexy with mesh or sutures
11547498|NCT01022034|Sham Comparator|Non-pexy group|These patients will receive full rectal mobilization from the sacrum but without rectopexy
11547499|NCT01022021|Active Comparator|rituximab|
11547500|NCT01022021|Active Comparator|bendamustine|bendamustine, 90 mg/M2
11547501|NCT01022008|Experimental|Osteodistraction techniques|Osteodistraction techniques
11547502|NCT01021995|Experimental|echinacea|
11547503|NCT01021995|Placebo Comparator|placebo|
11547504|NCT01021982||Glaucoma|Glaucoma Patients with visual field defects
11547505|NCT01021982||Retinitis Pigmentosa|Retinitis Pigmentosa Patients with visual field defects
11547506|NCT01021956|Experimental|WST11 (STAKEL)|Single doses of 2.5 mg/kg of STAKEL® in combination with transpupilar illumination of the macula at escalating doses from 12.5 to 75 Joules/cm².
11547507|NCT01021943|Placebo Comparator|Placebo|Half of the subjects will be assigned to receive either spironolactone or placebo for 6 months
11547508|NCT01021943|Active Comparator|spironolactone|Half of the subjects will be randomized to receive spironolactone for 6 months
11547509|NCT01021930|Active Comparator|Group A: DM|Coronary artery disease with diabetes mellitus
11547510|NCT01021930|Active Comparator|Group B: Non-DM|Coronary artery disease without diabetes mellitus
11547511|NCT01021917||Other Dieters (OD)|Those participating in weight loss programs other than Medifast Direct or Take Shape For Life.
11547512|NCT01021917||Take Shape For Life (TSFL)|Those using Medifast meal replacement products for weight loss while working closely with a Take Shape For Life certified Health Coach.
11547513|NCT01021917||Medifast Direct (MD)|Those using Medifast meal replacement products specifically for weight loss that were purchased directly from the company and individually monitored by the customer.
11547514|NCT01021891|Experimental|Non-Diabetic Subj. w/o COPD|Single dose, 30 units
11547515|NCT01021891|Experimental|Non-Diabetic Subj. with COPD|Single dose, 30 units
11547516|NCT01021878|Experimental|icodextrin|glucose sparing alternative dialysis solution
11547517|NCT01021878|Active Comparator|dextrose|dianeal, Control group, standard treatment
11547518|NCT01021865||With type 2 Diabetes|
11547519|NCT01021865||Without type 2 diabetes|
11547520|NCT01021852|Experimental|MK-6096 2.5 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 2.5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for overnight polysomnography (PSG) recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment for the remaining 11 days. During Treatment Period 2, participants receive dose-matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
11547521|NCT01021852|Experimental|Placebo/MK-6096 2.5 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment for the remaining 11 days. During Treatment Period 2, participants receive MK-6096 2.5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
11547522|NCT01021852|Experimental|MK-6096 5 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
11547523|NCT01021852|Experimental|Placebo/MK-6096 5 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
11547524|NCT01021852|Experimental|MK-6096 10 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 10 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
11547641|NCT01021085||Pregnant women|Pregnant women who have conceived via ART and are between days 36 and 56 of gestation
11547525|NCT01021852|Experimental|Placebo/MK-6096 10 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 10 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
11547526|NCT01021852|Experimental|MK-6096 20 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 20 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
11547527|NCT01021852|Experimental|Placebo/MK-6096 20 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 20 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
11547528|NCT01021839|Active Comparator|Bovine Carotid Artery Graft|
11547529|NCT01021839|Active Comparator|Expanded Polytetrafluoroethylene Grafts|
11547530|NCT01021826||Hip and knee replacements recipients|Osteoarthritis patients undergoing elective primary hip and knee replacement and being followed-up in this study.
11547531|NCT01021813|Experimental|Suvorexant|After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to <65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the Treatment Phase.
11547532|NCT01021813|Placebo Comparator|Placebo|After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the Treatment Phase.
11547533|NCT01021800|Experimental|Cell infusion|
11547534|NCT01021774|Active Comparator|Advancement flap surgery|
11547535|NCT01021774|Active Comparator|Collagen plug|
11547536|NCT01021761|Active Comparator|Xibrom|Xibrom to be given 1 drop 2 times (BID) the day before surgery and 3 doses pre op the day of surgery prior to surgery
11547537|NCT01021761|Active Comparator|Nevanac|Nevanac to be given 1 drop 2 times (BID) the day before surgery and 3 doses pre op the day of surgery prior to surgery
11547538|NCT01021761|Active Comparator|Acuvail|Acuvail to be given preoperatively. One drop 2 times (BID), 1 day pre op and day of surgery 3 doses prior to surgery.
11547539|NCT01021748|Experimental|MK-2206 45 mg QOD + AZD6244 75 mg QD|Participants receive MK-2206 45 mg oral tablets once every other day (QOD) PLUS AZD6244 75 mg oral capsules once daily (QD) starting on Day 1 of each 28-day cycle.
11547540|NCT01021748|Experimental|MK-2206 45 mg QOD + AZD6244 75 mg BID|Participants receive MK-2206 45 mg oral tablets QOD PLUS AZD6244 75 mg oral capsules twice daily (BID) starting on Day 1 of each 28-day cycle.
11547541|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 50 mg BID|Participants receive MK-2206 90 mg oral tablets once weekly (QW) PLUS AZD6244 50 mg oral capsules BID starting on Day 1 of each 28-day cycle.
11547542|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 75 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 75 mg oral capsules QD starting on Day 1 of each 28-day cycle.
11547543|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 75 mg BID|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 75 mg oral capsules BID starting on Day 1 of each 28-day cycle.
11547544|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
11547545|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 150 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 150 mg oral capsules QD starting on Day 1 of each 28-day cycle.
11547546|NCT01021748|Experimental|MK-2206 100 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 100 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
11547547|NCT01021748|Experimental|MK-2206 135 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 135 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
11547548|NCT01021735|Active Comparator|Anti-TNF therapy|Etanercept or adalimumab by s/c injection
11547549|NCT01021735|Experimental|Rituximab therapy|Rituximab given by IV infusion
11547550|NCT01021722|Experimental|Modified suture technique|Sutured in a modified manner
11547551|NCT01021722|No Intervention|Historical sphincter group|The outcome of historical sphincter tears
11547552|NCT01021722|No Intervention|Normal primaparous deliveries|Normal deliveries
11547553|NCT01021709|Experimental|tDCS with alternative electrode montage|Treating major depression with either alternative tDCS electrode montage.
11547554|NCT01021696|No Intervention|Treatment as usual|Control group
11547555|NCT01021696|Active Comparator|Paracetamol|Intervention group
11547556|NCT01021696|Active Comparator|Morphine|Intervention group, individual pain treatment
11547557|NCT01021696|Active Comparator|Buprenorphine plaster|Intervention group, individual pain treatment
11547687|NCT01020695||PTSD veterans|18 PTSD veterans
11547559|NCT01021683||Itraconazole|Participants who have been receiving itraconazole will be observed prospectively. Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
11547560|NCT01021670||001|Dapoxetine hydrochloride One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks
11547561|NCT01021670||002|Alternate care/non-dapoxetine hydrochloride treatment(s) As prescribed or directed
11547562|NCT01021657||Glaucoma|
11547563|NCT01021644|Experimental|aerobic exercise-training|
11547564|NCT01021644|Active Comparator|stretch exercise|
11547565|NCT01021631|Active Comparator|Liberal Transfusion Strategy|Liberal Group - transfusion when hematocrit is lower than 30%
11547566|NCT01021631|Active Comparator|Restrictive Transfusion Strategy|Restrictive Group - transfusion when hematocrit is lower than 24%
11547567|NCT01021618|Active Comparator|Vasodilator-exercise stress|Four-minute infusion of dipyridamole (0.56 mg/kg) followed by symptom-limited exercise; injection of technetium-99m labeled radiopharmaceutical at peak hyperemia or peak exercise followed by SPECT myocardial perfusion imaging
11547568|NCT01021618|Experimental|Exercise-vasodilator stress|Symptom-limited exercise followed by a bolus intravenous injection of regadenoson (0.4 mg/5 mL) in patients failing to achieve a standard clinical endpoint; injection of technetium-99m labeled radiopharmaceutical 15 seconds after administration of regadenoson (or at peak exercise if regadenoson not administered) followed by SPECT myocardial perfusion imaging.
11547569|NCT01021605|Experimental|Hemolung Respiratory Assist System|
11547570|NCT01021592||001|
11547571|NCT01021579|Active Comparator|Metformin plus Simvastatin|PCOS patients(n=42) will be assigned to the simvastatin (20mg/day) plus metformin (500mg three times a day, n=42; group 1)
11547572|NCT01021579|Placebo Comparator|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
11547573|NCT01021566|Experimental|Combined hemoperfusion-hemodialysis|On admission thirty patients will receive the combined hemoperfusion-hemodialysis treatment regimen three hours everyday for three days.
11547574|NCT01021566|Active Comparator|Methadone, conventional treatment for opiate detoxification|On admission thirty patients receive the 10-day methadone treatment regimen.
11547575|NCT01021553|Placebo Comparator|placebo|placebo
11547576|NCT01021553|Active Comparator|50 mg|50 mg GSK557296
11547577|NCT01021553|Active Comparator|150 mg|150 mg GSK557296
11547578|NCT01021527|Experimental|Treatment Sequence 1|A-B-C-C
11547579|NCT01021527|Experimental|Treatment Sequence 2|B-C-A-C
11547580|NCT01021527|Experimental|Treatment Sequence 3|C-A-B-C
11547581|NCT01021527|Experimental|Treatment Sequence 4|A-C-B-C
11547582|NCT01021527|Experimental|Treatment Sequence 5|B-A-C-C
11547583|NCT01021527|Experimental|Treatment Sequence 6|C-B-A-C
11547584|NCT01021514||Type 2 DM, Healthy control|Type 2 DM patients are treating in the Diabetic Clinic of Korea university Guro hospital, and their age- and sex-matched healthy controls are underwent a routine health checkup at Korea university Guro hospital.
11547585|NCT01021514||Type 2 DM, Heatlhy control|
11547586|NCT01021501|Experimental|nifedipine controlled release tablets|Prospective, open, non-randomized, non-controlled study to evaluate the effect and safety of nifedipine controlled release tablets in hypertensive patients on chronic maintenance hemodialysis and the influence of hemodialysis on the plasma concentration of nifedipine
11547587|NCT01021488|Experimental|Experimental: Rosuvastatin + enoxaparin arm|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
11547588|NCT01021488|Active Comparator|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
11547589|NCT01021475|Experimental|Usual drug FD therapy + Visceral Manipulation|
11547590|NCT01021475|Active Comparator|Usual drug FD therapy|
11547591|NCT01021462|Experimental|Period 1 + Period 2|graded infusion of intravenous glucose
11547592|NCT01021449||Control|Healthy subjects
11547593|NCT01021449||Schizophrenia|Schizophrenic patients
11547594|NCT01021436|Experimental|Amikacin inhalation solution|Subjects received 125 mg/mL of aerosolized amikacin via the PDDS clinical device at a nominal dose of 400 mg every 12 h for 7-14 days
11547595|NCT01021423|Experimental|Lenalidomide|Lenalidomide - 15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
11547596|NCT01021423|Experimental|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
11547597|NCT01021410||Acetaminophen Group|Subjects who completed COMIRB 06-1265 and were assigned to the acetaminophen treatment group for that study.
11547598|NCT01021397|Experimental|1|Participants will receive one dose of vaccine virus at study entry and between Weeks 22 and 27
11547599|NCT01021397|Placebo Comparator|2|Participants will receive one dose of vaccine virus placebo at study entry and between Weeks 22 and 27
11547600|NCT01021384|Other|Problem Solving Education|
11547601|NCT01021371|Experimental|Patient interview and communication to GP from hospital|Intervention group: The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group about their rehabilitation needs and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus.
11547602|NCT01021371|No Intervention|Control group: Usual practice, no intervention|
11547603|NCT01021358|Experimental|Arm A (ABT-263 and Ketoconozole)|
11547604|NCT01021332|Experimental|Total Group|Participants who received at least one dose of open-label fixed dose combination (FDC) treatment
11547605|NCT01021319||Acute ischemic stroke|Patients with acute ischemic stroke confirmed by acute or follow-up MRI with defined andwell-known symptom onset.
11547606|NCT01021306|Active Comparator|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner.
11547607|NCT01021306|Active Comparator|Dental Care & Self Care|Intraoral splints are removable orthopedic appliances fabricated of hard acrylic resin positioned between the remaining teeth of the patient. They are designed in theory to support the function of the TMJ and relieve associated pain. Stabilization splints are believed to function by stabilizing the intracapsular structure of the TMJ, reducing activity of masticatory muscles, distributing occlusal forces, and reducing bruxism (teeth grinding).
11547608|NCT01021306|Sham Comparator|Sham AMCT & Self Care|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except no thrust will be delivered. Self-care only participants successfully completing the 6 month assessment will be given the option for RIST or AMCT for one month.
11547609|NCT01021306|Placebo Comparator|Self-care only group|All patients will be offered the self-care checklist of homecare approaches at baseline. Self-care only participants successfully completing the 6 months assessment will be given the option for RIST or AMCT for one month.
11547610|NCT01021293|Experimental|Poliorix Group|Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Poliorix™ (IPV) vaccine at 2, 3 and 4 months of age, administered intramuscularly into the anterolateral side of the right thigh.
11547611|NCT01021293|Active Comparator|Control Group|Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Oral Poliomyelitis Vaccine (OPV) at 2, 3 and 4 months of age, according to the vaccination policy recommended in China.
11547612|NCT01021280||Type II BS|Adolescents and young adults with type II Bartter syndrome
11547613|NCT01021280||Type IV BS|Adolescents and adults with type IV Bartter syndrome
11547614|NCT01021280||Controls|Age and sex- matched controls
11547615|NCT01021267|Experimental|Saw palmetto berry extract|Saw palmetto berry extract, organic saw palmetto, ethanolic extract 96%
11547616|NCT01021241|Experimental|Uricase-PEG 20|Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner
11547617|NCT01021228||group1|continuous volatile anesthesia (sevoflurane) during the liver resection
11547618|NCT01021228||group2|continuous intravenous anesthesia (propofol) during the liver resection
11547619|NCT01021228||group3|preconditioning volatile anesthesia (sevoflurane) 30 minutes before ischemia (inflow occlusion)
11547620|NCT01021215|Experimental|Arm I: Zileuton|Zileuton 1200 mg twice orally twice a day on days 1-6.
11547621|NCT01021215|Experimental|Arm II: Zileuton and Celecoxib|Combined Zileuton 1200 mg twice daily plus Celecoxib 200 mg twice daily on days 1-6.
11547622|NCT01021202|Experimental|Early tracheostomy|Percutaneous dilation tracheostomy < 72h on mechanical ventilation
11547623|NCT01021202|Experimental|Late tracheostomy|Percutaneous dilation tracheostomy > 10 days on mechanical ventilation
11547624|NCT01021189|Experimental|1|AZD1446
11547625|NCT01021189|Placebo Comparator|2|Placebo
11547626|NCT01021176|Placebo Comparator|0mg 0 spray|No Diltiazem
11547627|NCT01021176|Active Comparator|2mg 2 Spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 2mg/2 spray Diltiazem
11547628|NCT01021176|Active Comparator|4mg 4 Spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 4mg/4 spray Diltiazem
11547629|NCT01021176|Active Comparator|8mg 8 spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 8mg/8 spray Diltiazem
11547630|NCT01021163|Placebo Comparator|N-acetylcysteine , saline|
11547631|NCT01021150|Experimental|Ombrabulin/cisplatin|AVE8062 combined with 75 mg/m2 of cisplatin will be administered once in every 3 weeks, with 30-minute intravenous infusion
11547632|NCT01021137||TBI & Blast|OEF/OIF Veterans complaining of dizziness and/or imbalance with history of blast exposure and a diagnosis of mild TBI
11547633|NCT01021137||Blast Only|OEF/OIF Veterans complaining of dizziness and/or imbalance with history of blast exposure without TBI
11547634|NCT01021137||TBI Only|OEF/OIF Veterans complaining of dizziness and/or imbalance with a history of mild TBI and no blast exposure
11547635|NCT01021137||Healthy Controls|Age and gender matched control participants with no complaints of dizziness and/or imbalance or history of TBI or blast exposure
11547636|NCT01021137||Excluded|Participants who did not meet inclusion criteria, did not return to complete evaluation, and/or were excluded from data analysis.
11547637|NCT01021124||QFT (+) vs QFT (-)|
11547638|NCT01021111|Experimental|Activity Training with Feedback|Subject is tested prior to training and retested with feedback training designed to modify the mechanics of landing during jumping and running activities
11547639|NCT01021098||Natural History Study|The core Natural History Study of ILI is an observational, longitudinal cohort study using data from clinical findings, medical chart review, and diagnostic, virologic and immunologic laboratories to describe the epidemiology and immunology of ILI. This study aims to describe the clinical history of influenza and other viral respiratory pathogens in a population of US military active duty members and their dependents. The primary focus will be the etiology, natural history and immunology of ILI in otherwise healthy adults and children. We will recruit subjects with ILI in both the outpatient and inpatient setting, and will serially collect biological specimens (e.g. nasal/throat swabs, blood, rectal swabs) over a 28-day period. In addition, we will collect a single buccal (cheek) swab.
11547640|NCT01021098||HIV-Positive Cohort|In addition, given a number of human immunodeficiency virus (HIV)-infected subjects who serve in the active duty force, we will also examine a subset of HIV-positive military beneficiaries as part of this consortium. An additional objective of the study will be to descriptively examine the clinical and laboratory characteristics of ILI events among HIV-infected persons using the military's substantial experience in following a stable HIV-infected population. We will recruit subjects with ILI in both the outpatient and inpatient setting, and will serially collect biological specimens (e.g. nasal/throat swabs, blood, rectal swabs) over a 28-day period. In addition, we will collect a single buccal (cheek) swab.
11547688|NCT01020695||controls|20 controls
11547642|NCT01021072|Experimental|MTD|The study will utilize a standard 3+3 design for dose escalation. Once the maximum tolerated dose has been reached, an expansion cohort, as well as tumor specific expansion cohorts will be explored.
11547643|NCT01021059|Experimental|1|rh IL-15 daily for 12 days of 42 days cycle.
11547644|NCT01021046|Experimental|GCCT,corneal allograft survival ,DALK|experimental group: deep anterior lamellar keratoplasty using glycerin-cryopreserved corneal tissue
11547645|NCT01021046|Experimental|FCT,corneal allograft survival ,DALK|control group: deep anterior lamellar keratoplasty using fresh corneal tissue
11547646|NCT01021033||Stroke patients|Stroke patients
11547647|NCT01021020|Experimental|1|Colchicine (fasted)
11547648|NCT01021020|Experimental|2|Colchicine (fed)
11547649|NCT01021020|Active Comparator|3|Colchicine/Probenecid (fasted)
11547650|NCT01021007|Placebo Comparator|A|control mouthrinse
11547651|NCT01021007|Experimental|B|new prototype mouthrinse
11547652|NCT01020994|Experimental|LAS41003|
11547653|NCT01020994|Active Comparator|LAS189962|
11547654|NCT01020994|Active Comparator|LAS189961|
11547655|NCT01020981||Group 1|Michigan State Army National Guard soldiers who have returned from OEF/OIF deployments starting December 2008
11547656|NCT01020981||Group 2|Indiana State Army National Guard soldiers who have returned from OEF/OIF deployments starting December 2008
11547657|NCT01020968|Experimental|Ixmyelocel-T|The treatment arm of the study will receive catheter-based injections of the study cellular product.
11547658|NCT01020968|Placebo Comparator|Vehicle Control|will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control.
11547659|NCT01020955|Active Comparator|NutropinAq and Increlex|NutropinAq (0.15 mg/day for 1 month, 0.3 mg/day for 5 months) and Increlex (15 µg/kg/day for 1 month and 30 µg/kg/day for 5 months).
11547660|NCT01020955|Placebo Comparator|NutropinAq and placebo|NutropinAq (0.15 mg/day for 1 month, 0.3 mg/day for 5 months) and placebo for 6 months.
11547661|NCT01020942|Experimental|Pretreatment|
11547662|NCT01020942|No Intervention|Control|
11547663|NCT01020916|Experimental|Target Temperature 33°C|
11547664|NCT01020916|Active Comparator|Target Temperature 36°C|
11547665|NCT01020903|Active Comparator|Aprepitant|
11547666|NCT01020903|Placebo Comparator|Placebo|
11547667|NCT01020877|Experimental|1|Metronidazole Vaginal Gel
11547668|NCT01020877|Active Comparator|2|MetroGel-Vaginal®
11547669|NCT01020864|Experimental|Chemotherapy|"Patients will be treated with Cetuximab, Carboplatin and Vinorelbine i.v. day 1, every 2nd week.
~Patients will be treated until progression and/or in case of unacceptable toxicity or if the patient wishes to stop treatment."
11547670|NCT01020851|Experimental|tailored intervention|Participants in this arm will receive 6 monthly telephone calls of a behaviorally tailored intervention based on the transtheoretical model.
11547671|NCT01020851|Active Comparator|attention placebo|Participants in this arm will receive 6 monthly telephone delivered counseling sessions about general health topics
11547672|NCT01020838|Experimental|Florbetaben (BAY94-9172)|
11547673|NCT01020825||ASCs|Patients randomized to experimental treatment (ASC transplantation) in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
11547674|NCT01020825||Fibrin glue|Patients randomized to the control treatment (application of fibrin glue) in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
11547675|NCT01020825||ASCs + Fibrin Glue|Patients randomized to the control treatment (application of fibrin glue) + intralesional injection of ASCs in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
11547676|NCT01020812|Experimental|Stereotactic body radiotherapy (SBRT)|"SBRT will be delivered on Varian's linear accelerator with On-Board Imaging (OBI) capabilities. The tumor will be tracked with the ethiodol material from the TACE procedure, and respiratory gating will be used to minimize motion due to respiration. Treatment will be given in either 3 or 5 fractions . SBRT will take place after the treatment planning and within 12 weeks of the last TACE procedure.
~Doses: 45 Gy at 15 Gy/fraction , 36 Gy at 12 Gy/fraction, 45 Gy at 9 Gy/fraction, 40 Gy at 8 Gy/fraction"
11547677|NCT01020799|Experimental|AZD7268|The AZD7268 15 mg BID arm consisted of 3 AZD7268 5 mg capsules dosed orally in the morning and evening. In addition, 2 placebo tablets to match encapsulated escitalopram tablets were dosed orally in the morning only.
11547678|NCT01020799|Placebo Comparator|Placebo|The placebo arm consisted of 3 placebo capsules to match AZD7268 capsules dosed orally in the morning and evening. In addition, 2 placebos to match encapsulated escitalopram tablets were dosed orally in the morning only.
11547679|NCT01020799|Active Comparator|Escitalopram|The escitalopram 20 mg QD arm consisted of 3 placebo to match AZD7268 capsules dosed orally in the morning and evening. In addition, during Week 1, one encapsulated 10-mg escitalopram tablet and 1 placebo to match encapsulated escitalopram tablet were dosed orally in the morning only. During Weeks 2 through 4, two encapsulated 10-mg escitalopram tablets were dosed orally in the morning only.
11547680|NCT01020786|Experimental|Pemetrexed + Carboplatin|After four 21-day cycles of Pemetrexed plus Carboplatin treatment, Pemetrexed monotherapy is continued until study discontinuation.
11547681|NCT01020773|Active Comparator|SBT group|In the SBT group, the patients underwent a 1 hr SBT with inspiratory PS of 7 cmH2O with other settings remaining constant (FiO2, PEEP, trigger sensitivity). The patients who tolerated the SBT underwent immediate extubation.
11547682|NCT01020773|No Intervention|no-SBT group|In no-SBT group, as soon as a patient met readiness criteria, he or she underwent extubation without SBT process.
11547683|NCT01020760|No Intervention|No posture|Patients will undergo routine phacoemulsification, pars plana vitrectomy, ILM peel and gas fluid exchange with 14% C3F8. They will be advised to avoid supine posturing for seven days after surgery, but will not be advised to posture in the face down or prone position.
11547684|NCT01020760|Experimental|Face down posture|Patients will undergo routine phacoemulsification, pars plana vitrectomy, ILM peel and gas fluid exchange with 14% C3F8. They will be advised to posture in the face down or prone position for 50 minutes per hour for seven days.
11547685|NCT01020734|Experimental|transplantation|perform allogeneic HCT for patients with AML in CR1; then analyze various pre-transplantation variable, including donor type, for correlation to outcomes
11547686|NCT01020721||Glaucoma|South korean patients with primary congenital glaucoma
11547689|NCT01020656||group 1|patients with no anticoagulants used as the control group
11547690|NCT01020656||group 2|patients treated with anticoagulant therapy (warfarin, fluindone, acenocoumarol)
11547691|NCT01020656||group 3|patients treated with aspirin
11547692|NCT01020656||group 4|patients treated with clopidogrel therapy
11547693|NCT01020656||group 5|patients treated with both anticoagulant and aspirin medications
11547694|NCT01020656||group 6|patients treated with both anticoagulant and clopidogrel medications
11547695|NCT01020656||group 7|patients treated with both aspirin and clopidogrel medications
11547696|NCT01020643|Experimental|controlled sedation using propofol|
11547697|NCT01020630|Experimental|Sunitinib|25 mg (2 capsules of 12.5 mg) for oral administration
11547698|NCT01020630|Placebo Comparator|Placebo|2 capsules for oral administration
11547699|NCT01020591|Active Comparator|Osteopathic evaluation|osteopathic evaluation of motion and tissue mobility
11547700|NCT01020591|Experimental|Osteopathic evaluation with treatment|osteopathic evaluation of motion and tissue mobility followed by osteopathic manual therapy release of the tight or restricted tissues
11547701|NCT01020578||Impaired glucose tolerance|Patients diagnosed with impaired glucose tolerance
11547702|NCT01020578||Control|Patients with normal blood glucose
11547703|NCT01020565|Experimental|Entecavir (0.1 mg)|
11547704|NCT01020565|Experimental|Entecavir (0.5 mg)|
11547705|NCT01020539|Experimental|Matched Family Donor|"Patients will receive a reduced intensity fludarabine (6 days)/busulfan (2 days) conditioning regimen followed by a stem cell transplant from a related family donor using bone marrow or cord blood stem cells. Then followed by Gemtuzumab Ozogamicin, once at about 2-6 months post alloSCT and once at least 2 months after the first dose. Patients with JMML will also receive cis-retinoic acid (Isotretinoin).
~During and following transplantation patients will receive methylprednisolone for immune suppression. Graft-versus-host-disease (GVHD) prophylaxis will consist of tacrolimus, mycophenolate mofetil and additionally methotrexate in recipients of unrelated adult transplants."
11547706|NCT01020539|Experimental|Unrelated Donor|"Patients will receive a reduced intensity fludarabine (6 days)/busulfan (2 days) conditioning regimen followed by a stem cell transplant from an unrelated donor using matched bone marrow or cord blood stem cells.Then followed by Gemtuzumab Ozogamicin, once at about 2-6 months post alloSCT and once at least 2 months after the first dose. Patients with JMML will also receive cis-retinoic acid (Isotretinoin).
~During and following transplantation patients will receive methylprednisolone for immune suppression and unrelated donor transplant recipients will additionally receive Anti-Thymocyte Globulin. GVHD prophylaxis will consist of tacrolimus, mycophenolate mofetil and additionally methotrexate in recipients of unrelated adult transplants."
11547707|NCT01020526|Experimental|Pregabalin|
11547708|NCT01020474|Placebo Comparator|Placebo|
11547709|NCT01020474|Experimental|drug-pregabalin|
11547710|NCT01020461|Experimental|Venous blood sampling|To use Accuvein to improve the effectiveness of venous blood sampling
11547711|NCT01020461|Experimental|Peripheral IV catheter placement|To use Accuvein to improve the effectiveness of placing peripheral IV catheter
11547712|NCT01020448|Experimental|Triptorelin (Decapeptyl®) 22.5 mg|
11547713|NCT01020435|Active Comparator|Spinal Manipulation High Velocity|This non-rotary upper cervical procedure uses an impulse thrust with a controlled depth (high velocity). The participant's head is supported by a specially designed cushion and the doctor usually approaches the participant from in front of his or her head to contact soft tissue over the atlas transverse process, posterior to the lateral mass or occasionally on the C2 lamina or spinous process, with the pisiform process of one hand. The thrust is delivered by a contraction of the triceps muscles of both arms, which straightens the arms and applies the thrust to the participant.
11547714|NCT01020435|Placebo Comparator|Sham Spinal Manipulation|The sham assessment procedures will be similar to the active group. It has been developed and validated by Vernon et al.
11547715|NCT01020422|No Intervention|Breast hypertrophy|Patients with macromastia will be evaluated in regard to sexual function and depression predictors at 3 moments: initial interview, after 3 months and after 6 months
11547716|NCT01020422|Experimental|Reduction Mammaplasty|Breast hypertrophy patients randomized to this group will immediately be scheduled for reduction mammaplasty and will be will be evaluated in regard to sexual function and depression predictors preoperatively and 3 and 6 months postoperatively
11547717|NCT01020409||cardiac surgery with CPB use|Adult patients, who signed the informed consent, intervention: first-time scheduled heart surgery with CPB use.
11547718|NCT01020396|Experimental|1|Metronidazole Vaginal Gel, 0.75% (Teva Pharmaceuticals, USA)
11547719|NCT01020396|Active Comparator|2|MetroGel-Vaginal® metronidazole vaginal gel, 0.75% (3M Pharmaceuticals)
11547720|NCT01020370||Alemtuzumab Group|
11547721|NCT01020370||Interferon Beta-1a SC Group|
11547722|NCT01020357|Active Comparator|caffeine|
11547723|NCT01020357|Placebo Comparator|placebo|
11547724|NCT01020344|Active Comparator|Lung volume reduction surgery|This group will receive lung volume reduction surgery
11547725|NCT01020344|No Intervention|No lung volume reduction surgery|This group will not receive LVRS during the 3 months of the study
11547726|NCT01020331|Experimental|ACTIVE|
11547727|NCT01020305|Experimental|Temsirolimus + Bicalutamide|"Temsirolimus 25 mg administered intravenously (IV) once weekly for 12 weeks
~Casodex (bicalutamide) administered 50 mg/day orally (PO)"
11547728|NCT01020279|Other|Parallel Group A|Celecoxib 200 mg (Active Comparator) ; Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)
11547729|NCT01020279|Other|Parallel Group B|oral Placebo (Placebo Comparator); Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)
11547730|NCT01020266|Active Comparator|Electroacupuncture|
11547731|NCT01020266|Sham Comparator|Control|
11547732|NCT01020253|Active Comparator|Alendronate medication|
11547733|NCT01020253|Active Comparator|Alfacalcidol medication|
11547734|NCT01020253|No Intervention|Non-medication|
11547735|NCT01020240|No Intervention|Avaliation|This group will have 15 women in puerperium and will be realize an interview to avalide the cesarean discomforts in immediate puerperium. These dates will be use for elaborate the orientations guide.
11547915|NCT01018823|Placebo Comparator|Placebo|Placebo to Ertugliflozin once daily for 14 days
11547736|NCT01020240|No Intervention|Orientation|In this group will be realize an interview to avalide the cesarean discomforts in immediate puerperium or in the first post operatory and in the second post operatory wil be realize a new interview.
11547737|NCT01020240|Experimental|Guide|in This group wiil be realize an interview to avalide the cesarean discomforts in immediate puerperium or in the first post operatory, will be realize the orientations and the guide will be give, and in the second post operatory will be realize a new interview.
11547738|NCT01020227|Experimental|Integrative Therapies|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
11547739|NCT01020227|No Intervention|Standard Care|Patients were given no intervention but were contacted at 6 weeks and 6 months for data collection purposes
11547740|NCT01020214|Experimental|1|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
11547741|NCT01020214|Active Comparator|2|Benicar HCT® Tablets 40 mg/25 mg
11547742|NCT01020201||PONV group|patients with postoperative nausea and vomiting
11547743|NCT01020201||Control group|patients without postoperative nausea and vomiting
11547744|NCT01020175|Other|Bone marrow transplantation|Patients received bone marrow transplantation
11547745|NCT01020175|Other|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
11547746|NCT01020162|Active Comparator|Non-surgical|TENS, amitriptyline, gabapentin.
11547747|NCT01020162|Active Comparator|Surgical intervention|Resection of the ilioinguinal nerve
11547748|NCT01020136|Experimental|Sequence 1 (BABA)|Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: B -> A -> B -> A
11547749|NCT01020136|Experimental|Sequence 2 (ABAB)|Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: A -> B-> A -> B
11547750|NCT01020123|Experimental|1|AZD1656
11547751|NCT01020123|Experimental|2|AZD1656
11547752|NCT01020123|Experimental|3|AZD1656
11547753|NCT01020123|Experimental|4|AZD1656
11547754|NCT01020123|Experimental|5|AZD1656
11547755|NCT01020123|Placebo Comparator|6|
11547756|NCT01020123|Active Comparator|7|Glipizide administered to 1 group of patients
11547757|NCT01020084||Control|Subjects with normal salivary flow rate
11547758|NCT01020084||Hyposalivation|Subjects presenting low salivary flow rate as a side effect of systemic isotretinoin therapy.
11547759|NCT01020071|Other|laser treatment|laser peripheral iridotomy and laser peripheral iridoplasty
11547760|NCT01020058|Active Comparator|Lichtenstein in local anesthesia (LLA)|Patient operated in local anesthesia, with an anterior mesh repair according to Lichtenstein
11547761|NCT01020058|Active Comparator|TEP|Patient receives a totally extraperitoneal laparoscopic repair
11547762|NCT01020045||HIV-seropositive, HIV seronegative|No intervention - biologic samples were collected from both HIV positive and HIV negative subjects
11547763|NCT01020045||Treatment naive subjects|HIV-seropositive subjects naive to antiretroviral therapy. HIV-seronegative subjects otherwise healthy.
11547764|NCT01020032|Experimental|Music therapy|"Individual receptive music therapy by U sequence method"
11547765|NCT01020019|Experimental|Lofexidine and Dronabinol|Maintained at 1.8mg/day Lofex. and 60 mg/day of Dronabinol
11547766|NCT01020019|Placebo Comparator|Placebo|Lofex. matched placebo Dronabinol placebo
11547767|NCT01020006|Active Comparator|Gemcitabine|Subjects receive Gemcitabine 1000 mg/m2 weekly intravenous infusion.
11547768|NCT01020006|Experimental|PCI-27483 + Gemcitabine|"Part A: Subjects received PCI-27483 0.8 mg/kg BID as initial dose and may be escalated to 1.2, and 1.5 mg/kg BID. At the same time, subjects received Gemcitabine 1000 mg/m2 weekly intravenous infusion.
~Part B: Subjects received the PCI-27483 at 1.2 mg/kg BID and Gemcitabine 1000 mg/m2 weekly intravenous infusion."
11547769|NCT01019993|Active Comparator|good pulmonary functions (group N)|The patients were allocated if they have forced vital capacity (FVC %) and/or forced expiratory volume in 1 sec (FEV1%) of 80% of predicted or more
11547770|NCT01019993|Active Comparator|pulmonary dysfunction (group PD)|The patients were allocated if they have FVC and/or FEV1 of 50%-79% of predicted
11547771|NCT01019980|Experimental|Diclofenac potassium|
11547772|NCT01019980|Active Comparator|Acetaminophen|
11547773|NCT01019941|Other|1st cycle:CKD-810 -> 2nd cycle:Taxotere inj.|
11547774|NCT01019941|Other|1st cycle:Taxotere inj.-> 2nd cycle:CKD-810|
11547775|NCT01019928|Experimental|First AZD1386, then washout, then placebo|
11547776|NCT01019928|Experimental|First placebo, then washout, then AZD1386|
11547777|NCT01019915|Other|Heart failure patients. Intervention CRT|CRT implantation in heart failure. Effect of intervention after 6 months of treatment.
11547778|NCT01019889|Experimental|Placebo|Placebo (encapsulated starch + lactose)
11547779|NCT01019889|Experimental|SCRT(Socheongryong-tang )|encapsulated Socheongryong-tang extract
11547780|NCT01019889|Experimental|YPS (Yeongyopaedok-san)|Encapsulated Yeongyopaedok-san extract
11547781|NCT01019876|Experimental|Fludarabine|
11547782|NCT01019876|Experimental|Cyclohosphamide 200|
11547783|NCT01019876|Experimental|Cyclophosphamide 40|
11547784|NCT01019876|Experimental|Cyclophosphamide 30|
11547785|NCT01019863|Experimental|Oxaliplatin|oxaliplatin associated with Rituxan,Gemcitabine, and Dexamethasone in patients with refractory or relapsed Non hodgkinien lymphoma
11547834|NCT01019434|Experimental|Temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
11547835|NCT01019421|Experimental|Lu AE58054|
11547836|NCT01019421|Placebo Comparator|Placebo|
11547837|NCT01019408|Active Comparator|CQ25|Falciparum positive patients receiving standard 3-day treatment course of CQ 25mg/kg.
11547838|NCT01019408|Active Comparator|CQ40|Falciparum positive patients receiving a 5-day treatment course of CQ 40 mg/kg.
11547916|NCT01018810|Experimental|180 mg LY2525623|
11547786|NCT01019850|Other|Treatment for All Patients|Patients on study will receive vorinostat orally once daily on days 1 to 14. The starting dose level is 180 mg/M2. The maximum dose is 400 mg. Patients will receive 131- I Metaiodobenzylguanidine on day 3, 1hr after vorinostat dosing. Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg. Peripheral Blood Stem Cell Infusion is planned for 2 weeks after MIBG infusion (day 17). The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing. Patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines.
11547787|NCT01019837|Experimental|Monovalent MF59- Adjuvanted vaccine|Focetria (Monovalent MF59-Adjuvanted vaccine) 7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate Intra muscular
11547788|NCT01019824|Experimental|Low Dose|160 mg dose
11547789|NCT01019824|Experimental|High Dose|320 mg dose
11547790|NCT01019824|Placebo Comparator|Placebo|Placebo Comparator
11547791|NCT01019798|Experimental|open label|
11547792|NCT01019785|Active Comparator|High dose Vitamin D|
11547793|NCT01019785|Sham Comparator|Low dose Vitamin D|
11547794|NCT01019772|Experimental|LBVH0101|
11547795|NCT01019772|Active Comparator|Hiberix|
11547796|NCT01019759|No Intervention|No add-on AF-surgery|patient undergoing only scheduled valve and/or coronary bypass surgery
11547797|NCT01019759|Experimental|PV isolation|patient undergoing add-on epicardial microwave energy pulmonary vein isolation
11547798|NCT01019746|Experimental|control propofol administration|
11547799|NCT01019733|Experimental|Patients|Children whom will receive intrathecal autologous stem cells
11547800|NCT01019707|Placebo Comparator|Sugar pill|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
11547801|NCT01019707|Active Comparator|Atomoxetine|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
11547802|NCT01019694|Experimental|Combivent Respimat 20/100 microgram(mcg)|patient to take 1 inhalation 4 times a day
11547803|NCT01019694|Active Comparator|Combivent CFC-MDI 36/206 microgram-mcg|patient to take 2 inhalations 4 times a day
11547804|NCT01019694|Active Comparator|Atrovent HFA 42 mcg + Albuterol HFA|patient to take 2 inhalations of each 4 times a day
11547805|NCT01019681|Experimental|UBC injection into one leg of PVD pt|25 participants with severe peripheral vascular disease in leg(s) and they do not qualify for surgical treatment.
11547806|NCT01019668|Active Comparator|verteporfin PDT, half-dose|use different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
11547807|NCT01019668|Active Comparator|verteporfin PDT, half-fluence|use different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
11547808|NCT01019655|Experimental|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
11547809|NCT01019655|No Intervention|Control|No intervention other than usual care at the study site
11547810|NCT01019642|Experimental|Vitamin D|Cholecalciferol, 4,000 IU/d for 6 months
11547811|NCT01019642|Placebo Comparator|Placebo|placebo
11547812|NCT01019616|Experimental|Chemotherapy|
11547813|NCT01019616|No Intervention|Control|
11547814|NCT01019603|Experimental|1|Tazarotene foam 0.1%
11547815|NCT01019603|Active Comparator|2|Tazaroc Gel 0.1%
11547816|NCT01019590|Experimental|1|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
11547817|NCT01019590|Active Comparator|2|Benicar HCT ® Tablets 40 mg/25 mg
11547818|NCT01019577|Experimental|Ixabepilone|
11547819|NCT01019564|Experimental|Easy Rub MPS|Complete Easy Rub Formula MPS
11547820|NCT01019564|Active Comparator|Aquify MPS|
11547821|NCT01019551|Experimental|ARM A : ART intensification alone|Raltegravir PO 400 mg BID Maraviroc PO 150, 300 or 600 mg BID depending on the concomitant ART regimen
11547822|NCT01019551|Experimental|ARM B : ART intensification + Immunomodulation|Raltegravir PO 400 mg BID during 56 weeks Maraviroc PO 150, 300 or 600 mg BID depending on the concomitant ART regimen during 56 weeks 3 weekly injections of r-hIL-7 (CYT107) at a 20 micrograms/kg dose starting at Week 8
11547823|NCT01019525||Mouth Breathing|Children aged between 8-12 years, with clinical diagnosis of mouth breathing
11547824|NCT01019525||Nasal Breathing|Children aged between 8-12 years old, with normal breathing
11547825|NCT01019499|Active Comparator|berry products|Berry products
11547826|NCT01019499|Placebo Comparator|control products|Control products
11547827|NCT01019486|Experimental|Type 1 Diabetic Subjects|Regadenoson 400mcg slow IV bolus to identify assess myocardial blood flow (MBF). Stratified by coronary calcium score of below 100 or greater than score of 100 for low and high risk individuals respectively.
11547828|NCT01019486|Active Comparator|Nondiabetic Subjects|Regadenoson myocardial perfusion imaging (MPI) Intervention: Regadenoson (400mcg slow IV bolus) stress to assess myocardial blood flow (MBF) and MPI to identify occult coronary artery disease (CAD). These individuals serve as an active control with higher risk non-diabetic individuals with scores greater than 100.
11547829|NCT01019473|Experimental|AFQ056A|
11547830|NCT01019473|Placebo Comparator|Placebo|
11547831|NCT01019447|Active Comparator|Study group|The study group in which Triclosan-coated polyglactin 910 antimicrobial sutures will be used.
11547832|NCT01019447|Active Comparator|Control group|The control group in which polyglactin 910 antimicrobial sutures will be used.
11547833|NCT01019434|Other|Temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
11547914|NCT01018823|Experimental|Ertugliflozin up to 100 mg|Ertugliflozin up to 100 mg, once daily for 14 days
11547839|NCT01019395|Experimental|Group 1|Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion.
11547840|NCT01019395|Experimental|Group 2|Group 2: Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion
11547841|NCT01019395|Experimental|Group 3|Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion.
11547842|NCT01019382|Experimental|All patients|All patients entering the trial
11547843|NCT01019369|Experimental|Self Administration of DMPA|Self administration of subcutaneous depot medroxyprogesterone acetate
11547844|NCT01019369|Active Comparator|Clinic administration of DMPA|Clinic administration (routine care) of DMPA
11547845|NCT01019356|Experimental|Rosiglitazone|Lean and obese PCOS women
11547846|NCT01019356|Active Comparator|Acarbose|Obese PCOS women
11547847|NCT01019356|No Intervention|Control|Obese and lean healthy women evaluated only at baseline
11547848|NCT01019343|Placebo Comparator|Healthy Volunteers|Healthy Volunteers
11547849|NCT01019343|Active Comparator|Movement Disorder|Subjects diagnosed with movement disorder
11547850|NCT01019330||Femoral|Subjects receiving femoral artery cardiac catheterization
11547851|NCT01019330||Radial|Subjects receiving radial artery cardiac catheterization
11547852|NCT01019317|Experimental|Cytarabine + Fludarabine|Fludarabine 15 mg/m^2 intravenous (IV) every 12 hours for 5 days; Cytarabine 0.5 grams/m^2 IV over 2 hours every 12 hours for 5 days.
11547853|NCT01019291|Experimental|NO2|NO2 400 µg/m3
11547854|NCT01019291|Experimental|Formaldehyde|Formaldehyde 100 µg/m3
11547855|NCT01019291|Experimental|NO2 + Formaldehyde|mixture of Formaldehyde and NO2
11547856|NCT01019291|Placebo Comparator|Placebo|
11547857|NCT01019265|Experimental|Norspan patch (Buprenorphine TDS)|
11547858|NCT01019265|Active Comparator|TramadolSR tab (Tridol SR tab)|
11547859|NCT01019252|Experimental|CBT for ADHD first, then follow-up|Participants received Cognitive Behavioral Therapy following randomization.
11547860|NCT01019252|No Intervention|Wait list first, then CBT for ADHD|Cross-over: Participants were assigned to a wait list after the initial assessment. They received Cognitive Behavioral Therapy after the 4 month assessment.
11547861|NCT01019239|Experimental|Laparoscopic Washout|Two 5mm ports will be placed in the suprapubic and right lower quadrants to facilitate triangulation of instruments during manipulation and lavage. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. Peritoneal lavage will be performed in all four quadrants using at least 4 litres of warmed saline until the drainage is clear. Two non-suction Penrose drains will be placed. Intravenous antibiotics will be continued for a minimum of 72hours and oral antibiotics will be continued for one week. Oral fluids will be commenced on the first postoperative day and diet will be introduced subsequently, depending on clinical status. Early mobilisation will be encouraged.
11547862|NCT01019239|Active Comparator|Conventional Treatment|Operative procedure will be similar to that previously described.Patients randomised to the second arm will undergo standard management (according to local preference) which will consist of Hartmanns Procedure or Primary resection of the diseased segment and anastomosis. Post operative care will be standardised between arms as described in the protocol
11547863|NCT01019226||cardiac MRI|Ischemic cardiomyopathy, non ischemic cardiomyopathy, myocarditis, cardiomyopathy
11547864|NCT01019213|Placebo Comparator|Septal pacing|Septal lead will be activated.
11547865|NCT01019213|Experimental|His-pacing|His lead will be activated 80 ms before septal lead
11547866|NCT01019200||Psoriasis|Individuals with a diagnosis of psoriasis as confirmed by the principle investigator will comprise the psoriasis or case group. Participants must meet inclusion and exclusion criteria as defined below. This group will consist of 100 individuals.
11547867|NCT01019200||Control|Individuals without psoriasis, but meeting inclusion and exclusion criteria, will be selected to be within the control group. For each patient with psoriasis within the psoriasis group, an age, sex, and BMI-matched control will be selected. The group will consist of 100 individuals.
11547868|NCT01019174|Active Comparator|oral application|oral application Cyclophosphamide
11547869|NCT01019174|Active Comparator|intravenous application|intravenous application Cyclophosphamide
11547870|NCT01019161|Experimental|AZD1152|100 mg Lyophile 5 mL Diluent
11547871|NCT01019161|Experimental|C14 AZD1152|AZD1152 radiolabelled IV solution. 1.05 mg/ml will be presented as a 15 ml fill in a 20 ml vial.
11547872|NCT01019135|Active Comparator|Women-Only Cardiac Rehabilitation|The women-only CR programs include on-site group exercise training sessions 1-2 days/week. Participants are encouraged to walk at home on alternate days of the week. Education sessions are also given in a group format, wherein participants engage in on-site female-only group exercise sessions, as well as female-only group education sessions.
11547873|NCT01019135|Active Comparator|Co-ed Cardiac Rehabilitation|The traditional hospital-based co-ed CR programs include on-site group exercise training sessions 1-2 days/week. Participants are encouraged to walk at home on alternate days of the week. Education sessions are also given in a group format.
11547874|NCT01019135|Active Comparator|Home-Based Cardiac Rehabilitation|In the monitored home-based programs, patients attend an intake appointment where an exercise test is performed as the basis for exercise prescription. Patients are given written guidelines for aerobic conditioning based on their treadmill test. Patients are cautioned about symptoms, and taught how to check their heart rate during walking sessions. Patients are provided with reading materials regarding CVD, risk factors and lifestyle modification. These are discussed with an allied health professional from the home-based CR program by telephone during weekly scheduled telephone calls.
11547875|NCT01019109||Titanium rod|Titanium rods used as a part of PSF construct
11547876|NCT01019109||CoCr Rod|Cobalt Chrome rods used as a part of PSF construct
11547877|NCT01019083|Placebo Comparator|zinc supplementation-Placebo|Determine if the immunogenicity of oral typhoid can be enhanced in children by introducing zinc supplementation: Our recent studies on the interactions of oral cholera vaccine with breast milk and zinc provide some basis for improving immunogenicity, but additional work is needed to improve many of the oral vaccines. In this study we also plan to evaluate if the immune response to Cholera and Vivotif can be enhanced by supplementation with zinc using methods described earlier. We would like to study children, 2-5 years of age for this purpose.
11547917|NCT01018810|Placebo Comparator|Intravenous Placebo|
11547878|NCT01019083|Placebo Comparator|Anti Parasite Drug- Placebo|There is a high burden of enteric parasites in the gut of people living in densely populated areas of less developed countries. The effect of concurrent parasitic infestations on immune responses has not been studied widely, although it is an area of utmost importance for natural protection as well as vaccine immuno-prophylaxis. In this study we plan to determine the impact of pretreatment with antiparasitic agents (albendazole and secnidazole) on the immunogenicity of the oral cholera and typhoid vaccines in children, 2-5 years of age
11547879|NCT01019083|Experimental|Effect of Arsenic in Dukoral- Control|In this study, we aim to evaluate if immunogenicity of the oral cholera vaccine is modified in children living in a high arsenic contaminated area in Bangladesh. The plan is to study children 2-5 year old living in Shahrasti thana near Matlab where the tubewell water is highly contaminated with arsenic and this study will not be randomized double-blind, and compare their responses with responses of age matched children living in arsenic free area, such as in Mirpur area of Dhaka city. We only plan to study the effect of Dukoral vaccinees since this vaccine has been widely studied in Bangladesh. If an impact of arsenic is seen on immune response to this vaccine, future studies could be done with other vaccines including Vivotif.
11547880|NCT01019083|Experimental|zinc supplementation|Determine if the immunogenicity of oral typhoid can be enhanced in children by introducing zinc supplementation: Our recent studies on the interactions of oral cholera vaccine with breast milk and zinc provide some basis for improving immunogenicity, but additional work is needed to improve many of the oral vaccines. In this study we also plan to evaluate if the immune response to Cholera and Vivotif can be enhanced by supplementation with zinc using methods described earlier. We would like to study children, 2-5 years of age for this purpose.
11547881|NCT01019083|Experimental|administration of antiparasitic drugs|There is a high burden of enteric parasites in the gut of people living in densely populated areas of less developed countries. The effect of concurrent parasitic infestations on immune responses has not been studied widely, although it is an area of utmost importance for natural protection as well as vaccine immuno-prophylaxis. In this study we plan to determine the impact of pretreatment with antiparasitic agents (albendazole and secnidazole) on the immunogenicity of the oral cholera and typhoid vaccines in children, 2-5 years of age
11547882|NCT01019083|Experimental|Effect of arsenic on Dukoral response|In this study, we aim to evaluate if immunogenicity of the oral cholera vaccine is modified in children living in a high arsenic contaminated area in Bangladesh. The plan is to study children 2-5 year old living in Shahrasti thana near Matlab where the tubewell water is highly contaminated with arsenic and this study will not be randomized double-blind, and compare their responses with responses of age matched children living in arsenic free area, such as in Mirpur area of Dhaka city. We only plan to study the effect of Dukoral vaccinees since this vaccine has been widely studied in Bangladesh. If an impact of arsenic is seen on immune response to this vaccine, future studies could be done with other vaccines including Vivotif.
11547883|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh A|
11547884|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh B|
11547885|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh C|
11547886|NCT01019070|Active Comparator|BMS-650032 in Healthy Subjects|
11547887|NCT01019044||Rectal mucosa biopsy|Rectal mucosa samples collection
11547888|NCT01019018|Active Comparator|Stevens cannula|Subtenon with stevens cannula
11547889|NCT01019018|Experimental|Olive tip|Olive tip group
11547890|NCT01019005|Experimental|Tibial|
11547891|NCT01019005|Experimental|Wound|
11547892|NCT01019005|No Intervention|Sham|
11547893|NCT01018992|Placebo Comparator|Placebo|Adult women with DSM-IV defined PTSD will receive matching placebo for 6 weeks
11547894|NCT01018992|Experimental|GSK561679|Adult women with DSM-IV-defined PTSD will receive GSK561679 at a fixed dose of 350 mg/day for 6-weeks
11547895|NCT01018979|Experimental|TG-0054 (2.24 mg/kg)|TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
11547896|NCT01018979|Experimental|TG-0054 (3.14 mg/kg)|TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
11547897|NCT01018966|Experimental|Ixabepilone|
11547898|NCT01018953|Experimental|BIM 23A760|This dose adaptive study is planned to treat up to 20 patients in each starting dose cohort, with a maximum of three starting dose cohorts. The doses planned to be assessed are 1, 2, 4, 6 and 8 mg, however, the maximum starting dose will be 4 mg. The starting dose of the first cohort will be 1 mg; the first cohort will include at least five patients. After the first fifteen patients have been treated for 4 weeks, the results will be reviewed by a Data Review Committee. An extension phase (Part B) is planned for those subjects completing the initial study and fulfilling specific eligibility criteria (symptoms control, willingness to participate, safety and tolerability).
11547899|NCT01018940||Plavix|
11547900|NCT01018940||Prasugrel|
11547901|NCT01018927||Additional MRI images|Prospective review of 100 CMR studies performed on multiple myeloma patients referred for cardiac evaluation by MRI. Three additional MRI images will be performed to determine the role of cardiac MR (CMR) in detecting features of early myocardial infiltration
11547902|NCT01018914|Active Comparator|Prograf with Myfortic|
11547903|NCT01018914|Experimental|Advagraf with Myfortic|
11547904|NCT01018888|Experimental|Keratoprosthesis|
11547905|NCT01018862|Active Comparator|MP03-36 (0.15% solution)|822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
11547906|NCT01018862|Active Comparator|MP03-33 (0.10% solution)|548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
11547907|NCT01018862|Placebo Comparator|Placebo|0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
11547908|NCT01018849|Active Comparator|Vitamin D (cholecalciferol)|Subjects receive 150,000 IU of Vitamin D3 every 2 months
11547909|NCT01018849|Placebo Comparator|Placebo|Subject will receive a placebo - an exact replica of the Vitamin D3 capsule that does not contain the active ingredient, Vitamin D3
11547910|NCT01018836|Experimental|Riluzole; Radiation Therapy|
11547911|NCT01018823|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, oral, once daily for 14 days
11547912|NCT01018823|Experimental|Ertugliflozin up to 5 mg|Ertugliflozin up to 5 mg, oral, once daily for 14 days
11547913|NCT01018823|Experimental|Ertugliflozin up to 25 mg|Ertugliflozin up to 25 mg, oral, once daily for 14 days
11547918|NCT01018810|Placebo Comparator|Subcutaneous Placebo|
11547920|NCT01018810|Experimental|10 mg LY2525623|
11547921|NCT01018810|Experimental|30 mg LY2525623|
11547922|NCT01018810|Experimental|90 mg LY2525623|
11547923|NCT01018797|Experimental|INTRASTROMAL CORNEAL RING SEGMENT|Eighteen eyes of 18 patients, 8 men and 10 women, with high levels (> 5 diopters [D]) of postkeratoplasty astigmatism were studied in a nonrandomized, retrospective, observational case series. PK was performed to treat keratoconus in 15 patients, corneal scar after trauma in 2 patients, and Fuchs endothelial dystrophy in 1 patient.
11547924|NCT01018784|Experimental|MORAb-009|
11547925|NCT01018771|Experimental|Actifuse ABX|Actifuse ABX bone substitute
11547926|NCT01018771|Active Comparator|INFUSE, plus Mastergraft granules|
11547927|NCT01018758|Experimental|palonosetron|
11547928|NCT01018745|Experimental|BMS-907351 (XL184)|
11547929|NCT01018732|Experimental|I: MenACWY-CRM vaccine|Subjects had been given one dose of Meningococcal ACWY (MenACWY) vaccine conjugated to CRM197 (cross-reactive material-mutant of diptheria toxin) 5 years ago. All subjects were given one dose of the Men ACWY in the present study.
11547930|NCT01018732|Experimental|II: Licensed Polysaccharide Meningococcal vaccine|Subjects had been given one dose of a licensed MenACWY polysaccharide meningococcal vaccine (Menomune) 5 years ago. All subjects were given one dose of Men ACWY vaccine in the present study.
11547931|NCT01018732|Experimental|III: Meningococcal Naive|Subjects were age matched with groups 1 and 2 (age inclusive: 16 years to 23 years) and enrolled at visit 1 and given one dose of Men ACWY vaccine during the present study.
11547932|NCT01018719||Left side breast cancer|
11547933|NCT01018719||Right side breast cancer|
11547934|NCT01018706||STEMI patients treated with PCI|Four hundred patients with STEMI treated with primary PCI or rescue PCI.
11547935|NCT01018693|Experimental|VAK694 AND Immunotherapy (alutard)|
11547936|NCT01018693|Experimental|: VAK694 placebo AND Immunotherapy (alutard)|
11547937|NCT01018693|Experimental|VAK694 placebo AND Immunotherapy (alutard) placebo|
11547938|NCT01018680|Placebo Comparator|Placebo|
11547939|NCT01018680|Experimental|Duloxetine|
11547940|NCT01018667||CRT group|
11547941|NCT01018667||OPT group|
11547942|NCT01018654|Experimental|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
11547943|NCT01018654|Active Comparator|Standard Cognitive-Behavioral Treatment|Standard Cognitive-Behavioral Treatment for Substance Abuse
11547944|NCT01020708|Active Comparator|Comparator|Mesalamine enema
11547945|NCT01020708|Experimental|ALTH12-1:4|ALTH12-1:4 experimental treatment dose
11547946|NCT01020708|Experimental|ALTH12-2:4|ALTH12-2:4 experimental treatment dose
11547947|NCT01020487|Experimental|Part 1: Paricalcitol|Participants received a single 3 µg dose of paricalcitol capsules on Study Day 1.
11547948|NCT01020487|Placebo Comparator|Part 2: Placebo|Participants received placebo capsules three times a week (TIW) for 12 weeks during the double-blind treatment phase. From Weeks 12 to 24 participants received open-label paricalcitol at an initial dose of 1 µg three times a week. Doses could be increased in 1 μg increments every 4 weeks based on chemistry evaluations to target Kidney Disease Outcomes Quality Initiatives (KDOQI) target levels.
11547949|NCT01020487|Experimental|Part 2: Paricalcitol|Participants received paricalcitol three times a week for 12 weeks during the double-blind treatment period and during the open-label period (Weeks 12-24). The initial dose of paricalcitol was 1 µg TIW. Doses could be increased in 1 μg increments every 4 weeks based on chemistry evaluations to target KDOQI target levels.
11547950|NCT01020383|Experimental|ALX-0081|
11547951|NCT01020383|Active Comparator|GPIIb/IIIa inhibitor|
11547952|NCT01020292|Experimental|NFV and Concurrent ChemoRads|
11547953|NCT01020097|Other|Arm I|Patients undergo fluorine F-18 EF5 positron emission tomography imaging. Scana are performed 180 minutes following injection.
11547954|NCT01019512|Active Comparator|Arm I|Patients undergo complex decongestive therapy comprising daily compression garment (sleeve and glove) use, daily manual lymphatic drainage (self-administerd), and nighttime bandaging with low stretch Comprilan bandages.
11547955|NCT01019512|Experimental|Arm II|Patients undergo daily compression with garments (sleeve and glove), nighttime bandaging with low stretch Comprilan bandages, and daily Flexitouch treatment over 1 hour every evening.
11547956|NCT01019512|Experimental|Arm III|Patients undergo daily compression with garments (sleeve and glove) and daily Flexitouch treatment over 1 hour every evening.
11547957|NCT01019278|Experimental|Arm I|Patients undergo external proton beam radiotherapy once daily, 5 times per week, for up to 9 weeks. Patients also receive cisplatin IV once weekly for 6 weeks during radiotherapy.
11547958|NCT01019187|Placebo Comparator|Arm I|Patients receive oral placebo twice daily for 47 days.
11547959|NCT01019187|Experimental|Arm II|Patients receive oral armodafinil twice daily for 47 days.
11547960|NCT01019187|Experimental|Arm III|Patients receive oral placebo twice daily for 47 days. Patients undergo cognitive behavioral therapy for insomnia comprising sleep restriction therapy, stimulus control instruction, sleep hygiene guidelines, and a session of cognitive therapy for 7 weeks.
11547961|NCT01019187|Experimental|Arm IV|Patients receive oral armodafinil twice daily for 47 days. Patients undergo cognitive behavioral therapy for insomnia as in Arm III for 7 weeks.
11547962|NCT01019122||Dexa Scan|Eligible patients from 2003 study will receive a follow-up Dexa scan.
11547963|NCT01018901|Experimental|Arm I|Patients and their partners complete surveys. Sexual function of men is assessed by the International Index of Erectile Function; sexual function of women is assessed by the Female Sexual Function Index.
11547964|NCT01018875|Experimental|Arm 1, Dose 1, ABT-288|Low Dose
11547965|NCT01018875|Experimental|Arm 2, Dose 2, ABT-288|High dose
11547966|NCT01018875|Active Comparator|donepezil|
11547967|NCT01018875|Placebo Comparator|sugar pill|
11547968|NCT01018641|Experimental|1|SA3Ag in both stage 1 and stage 2
11547969|NCT01018641|Experimental|2|SA3Ag in stage 1 followed by placebo in stage 2.
11547970|NCT01018641|Placebo Comparator|3|Placebo in both stage 1 and stage 2
11547971|NCT01018641|Experimental|4|SA3Ag in stage 1 and no vaccine in stage 2.
11547972|NCT01018641|Placebo Comparator|5|Placebo in stage 1 and no vaccine in stage 2.
11547992|NCT01018524|Active Comparator|large hernias - sublay mesh|
11547973|NCT01018628|Active Comparator|Cohort 1 - Dose Level A (25 mg/day)|Cohort 1 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 25 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 25 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
11547974|NCT01018628|Active Comparator|Cohort 2 - Dose Level B (75 mg/day)|Cohort 2 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 75 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 75 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
11547975|NCT01018628|Active Comparator|Cohort 3 - Dose Level C (250 mg/day)|Cohort 3 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 250 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 250 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
11547976|NCT01018628|Active Comparator|Cohort 4 - Dose Level D (500 mg/day)|Cohort 4 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 500 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 500 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
11547977|NCT01018628|Active Comparator|Cohort 5 - Dose Level E (1000 mg/day)|Cohort 5 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 1000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 1000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
11547978|NCT01018628|Active Comparator|Cohort 6 - Dose Level F (2000 mg/day)|Cohort 6 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 2000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 2000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
11547979|NCT01018628|Active Comparator|Cohort 7 - Dose Level G (3000 mg/day)|Cohort 7 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 3000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 3000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
11547980|NCT01018628|Active Comparator|Cohort 8 - Dose Level H (500 mg/day in fed state)|Cohort 8 will be administered at approximately the same time every dosing day and 30 minutes following the start of consumption of a standardized high-fat meal. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The dose of SRT2379 administered to subjects in the fed state is planned to be 500 mg, however this may be modified upwards or downwards following evaluation of safety and pharmacokinetic data from earlier cohorts. The fed cohort will be the final cohort dosed in the study.
11547981|NCT01018615|Experimental|low dose silymarin and low dose EGCG|
11547982|NCT01018615|Experimental|high dose silymarin and low dose EGCG|
11547983|NCT01018602|Active Comparator|vildagliptin|
11547984|NCT01018602|Placebo Comparator|inactive pill without active agent|participants receive an inactive pill without active agent, but undergo the same examinations, visits and tests as the group treated with vildagliptin.
11547985|NCT01018589|Experimental|A|Cicatrix cream
11547986|NCT01018576|Experimental|Delayed cord clamping|
11547987|NCT01018563|Experimental|MORAb-003|Maintenance infusions of MORAb-003 every 3 weeks
11547988|NCT01018550|Experimental|AMG 853|
11547989|NCT01018550|Placebo Comparator|Placebo|
11547990|NCT01018524|Active Comparator|small hernias - suture repair|
11547991|NCT01018524|Active Comparator|small hernias - mesh repair|
11548281|NCT01016327|Experimental|1|
11547993|NCT01018524|Active Comparator|large hernias - onlay mesh|
11547994|NCT01018511|Placebo Comparator|Placebo|Participants received 3 tablets once a day for 12 weeks. Placebo tamsulosin hydrochloride oral controlled absorption system (OCAS) 0.4 mg tablet; Placebo fixed dose combination (FDC) tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
11547995|NCT01018511|Active Comparator|TOCAS 0.4 mg|Participants received 3 tablets once a day for 12 weeks. Tamsulosin hydrochloride OCAS (TOCAS) 0.4 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
11547996|NCT01018511|Experimental|FDC 0.4 mg/6 mg|Participants received 3 tablets once a day for 12 weeks. Placebo TOCAS 0.4 mg tablet; FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
11547997|NCT01018511|Experimental|FDC 0.4 mg/9 mg|Participants received 3 tablets once a day for 12 weeks. Placebo TOCAS 0.4 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
11547998|NCT01018498|Experimental|Restricted FODMAPs diet|Restricted fermentable substrate diet for 1 week
11547999|NCT01018485|Experimental|Botulinum Toxin First Dose|Blinded and Randomized injection of 20 upper limbs with Botulinum Toxin Type A
11548000|NCT01018485|Experimental|Botulinum Toxin Second Dose|20 patients will receive Placebo as first dose and Botulinum Toxin as second dose injection 3 months after initiation of the study
11548001|NCT01018472|Experimental|Bifidobacterium infantis|
11548002|NCT01018472|Placebo Comparator|Placebo|
11548003|NCT01018459|Experimental|Group D: 10^11 vp/mL or placebo|10 subjects will receive 10^11 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
11548004|NCT01018459|Experimental|Group A: 10^9 vp/mL or placebo|10 subjects will receive 10^9 viral particles (vp)/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
11548005|NCT01018459|Experimental|Group B: 10^10 vp/mL or placebo|10 subjects will receive 10^10 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
11548006|NCT01018459|Experimental|Group C: 5 x 10^10 vp/mL or placebo|10 subjects will receive 5 x 10^10 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
11548007|NCT01018446|Experimental|Busulfan, Pharmacokinetic|To develop a method to determine optimal dose of busulfan through pharmacokinetic study in hematopoietic stem cell transplantation.
11548008|NCT01018433|Experimental|T-SIB|Treatment for self-injurious behaviors; study intervention
11548009|NCT01018433|Other|Treatment as Usual|
11548010|NCT01018420|Experimental|Colchicine|
11548011|NCT01018420|Active Comparator|Moxifloxacin|
11548012|NCT01018407|Experimental|Discrete Trial Training|Targets nonverbal imitation, match-to-sample, verbal imitation, imitation of play activities, receptive language, and expressive language. 5 hours per week of individual instruction for 4 months (Two 30-minute sessions per day, five days per week) with reductions in classroom pull out sessions in months 5 and 6 with implementation of 1 hour per week of in-home parent training for the last 2 months.
11548013|NCT01018407|Experimental|Interpersonal Developmental Approach|Targets Joint Attention and Symbolic Play. 5 hours per week of individual instruction for 4 months (Two 30-minute sessions per day, five days per week) with reductions in classroom pull out sessions in months 5 and 6 with implementation of 1 hour per week of in-home parent training for the last 2 months.
11548014|NCT01018394|Active Comparator|nicotine lozenges|40 subjects will be assigned to receive nicotine lozenges for 8 weeks. They will use the nicotine lozenges ad lib, up to 8 lozenges per day.
11548015|NCT01018394|Active Comparator|tobacco free snuff|41 subjects will receive tobacco free snuff for 8 -12 weeks. The tobacco-free snuff will be used ad lib - as needed.
11548016|NCT01018381|Active Comparator|Conventional Therapy|Conventional therapy is given, including PEIT, TOCE, PEIT + TOCE, TOCE + RFA for hepatocellular carcinoma or Entecavir for hepatitis B virus.
11548017|NCT01018381|Experimental|Conventional Therapy plus MGN-3|
11548018|NCT01018368|Experimental|VX-770|
11548019|NCT01018368|Experimental|Rifampin|
11548020|NCT01018355|Experimental|Device closure of PFO|Device closure of PFO followed by 6 month treatment with clopidogrel 75 mg and 75 - 150 mg of aspirin daily followed by a life long treatment with dipyridamol 200 mg twice daily plus 75-150 mg aspirin daily
11548021|NCT01018355|Active Comparator|Medical anticoagulative treatment|Life long treatment with dipyridamol 200 mg twice daily plus 75-150 mg aspirin daily
11548022|NCT01018342|Experimental|1|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
11548023|NCT01018342|Active Comparator|2|Macrobid® Capsules 100 mg
11548024|NCT01018329|Experimental|I|Patients undergo multimodality MRI imaging at baseline, weeks 1, 2, 3, 5, and 6 and then 4-6 weeks after completion of radiation therapy.Patients undergo MRI imaging at baseline, weeks 1, 2, 3, 5, 6 and then 6 weeks after radiation therapy.
11548025|NCT01018303|Experimental|Antioxidant-enriched multivitamin supplement|
11548026|NCT01018290||Navigated TMS examination|20 patients with brain tumor in the vicinity of the central motor region scheduled for elective surgery will undergo pre-operative Navigated TMS examination to determine the localization of primary motor cortex and motor representation areas of specific muscles
11548027|NCT01018264|Experimental|solifenacin succinate (VESIcare)|
11548028|NCT01018264|Placebo Comparator|placebo|
11548029|NCT01018251|Experimental|Arm I|Patients undergoing definitive surgery after cancer diagnosis undergo 3'-deoxy-3'-[18F] fluorothymidine (FLT)-PET prior to definitive surgery. Patients undergoing neoadjuvant chemotherapy prior to definitive surgery undergo FLT-PET prior to and after completion of neoadjuvant chemotherapy
11548030|NCT01018238|Placebo Comparator|Placebo arm|
11548031|NCT01018238|Experimental|Cohort 1|
11548032|NCT01018238|Experimental|Cohort 2|
11548033|NCT01018238|Experimental|Cohort 3|
11548034|NCT01018238|Experimental|Cohort 4|
11548035|NCT01018225|Experimental|darifenacin|
11548036|NCT01018225|Placebo Comparator|Sugar Pill|
11548037|NCT01018212|Experimental|A|Cicatrix cream
11548038|NCT01018199|Experimental|Group 1- C-reactive protein (CRP) guided antibiotic therapy|Intervention on antibiotic therapy will be based on circulating RCP levels
11548039|NCT01018199|Active Comparator|Group 2 - procalcitonin (PCT) guided antibiotic therapy|Intervention on antibiotic therapy will be based on circulating PCT levels
11548040|NCT01018186|Experimental|Fluticasone furoate/GW642444|
11548041|NCT01018186|Active Comparator|Fluticasone propionate|
11548042|NCT01018173|Placebo Comparator|placebo|
11548043|NCT01018173|Experimental|taspoglutide|
11548044|NCT01018160||001|
11548045|NCT01018147|Experimental|CT Imaging|Patients undergo 4-D, 4-dimensional computed tomography, CT imaging prior to radiotherapy sessions and once a week at the end of treatment.
11548046|NCT01018134|Experimental|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered once daily to affected area
11548047|NCT01018134|Experimental|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered twice daily to affected area
11548048|NCT01018134|Experimental|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered once daily to affected area
11548049|NCT01018134|Experimental|Desoximetasone 0.25% twice daily|Desoximetasone topical spray 0.25% administered twice daily to affected area
11548050|NCT01018134|Placebo Comparator|Vehicle once daily|Vehicle administered to affected areas once daily
11548051|NCT01018134|Placebo Comparator|Vehicle twice daily|Vehicle administered to affected areas twice daily
11548052|NCT01018121|Experimental|Clinic and Home Behavioral Intervention|
11548053|NCT01018121|Active Comparator|Pediatrician Counseling|
11548054|NCT01018108|Other|I|Patients undergo acupuncture twice weekly for 2 weeks and then once weekly for 6 weeks. Patients undergo single photon emission computed tomography imaging with iodine 123-I ADAM before and after completion of acupuncture.
11548055|NCT01018095|Active Comparator|Single dose|Metronidazole 2 gm single dose
11548056|NCT01018095|Active Comparator|7 day dose|Metronidazole 500 mg dose x 7 days
11548057|NCT01018069|Active Comparator|AEG35156|Patient receive AEG35156 prior to chemotherapy
11548058|NCT01018069|Sham Comparator|Control|Patients receive chemotherapy only
11548059|NCT01018056|Experimental|D-serine (glutamate agonist)|24 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive D-serine for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
11548060|NCT01018056|Experimental|Riluzole (glutamate antagonist)|24 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive riluzole for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
11548061|NCT01018056|Placebo Comparator|Placebo|12 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive placebo for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
11548062|NCT01018043||001|Adult Cancer Patients Tracking anemia management in Adult Cancer Patients
11548063|NCT01018030|Experimental|FFNS 110 mcg QD|
11548064|NCT01018030|Experimental|FFNS 110 mcg BID|
11548065|NCT01018030|Placebo Comparator|Placebo Nasal Spray|
11548066|NCT01018017|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered eight SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following consumption of a standard morning meal at home (200 cc of Ensure Plus®).
11548067|NCT01018017|Placebo Comparator|Placebo|The placebo treatment group will be administered eight placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following consumption of a standard morning meal at home (200 cc of Ensure Plus®).
11548068|NCT01017991|Experimental|Infant formula with probiotic|Infant formula with probiotic for 0 to 12 months of age
11548069|NCT01017991|Placebo Comparator|Standard infant formula|Infant formula for 0 to 12 months of age
11548070|NCT01017978|Other|MRI Scan|MRI scan of soft tissue tumor
11548071|NCT01017952|Experimental|FF/GW642444 Inhalation Powder 100/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
11548072|NCT01017952|Experimental|FF/GW642444 Inhalation Powder 50mcg/25mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
11548073|NCT01017952|Experimental|FF/GW642444 Inhalation Powder 200/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
11548074|NCT01017952|Experimental|GW642444 25mcg QD|Long Acting Beta Agonist(LABA)
11548075|NCT01017939|Experimental|Group A: abiraterone + prednisone + dextromethorphan|Group A will assess the effect of multiple doses of abiraterone acetate plus prednisone on CYP2D6 using 2 single doses of dextromethorphan hydrobromide as a probe drug.
11548076|NCT01017939|Experimental|Group B: abiraterone + prednisone + theophylline|Group B will assess the effect of multiple doses of abiraterone acetate plus prednisone on CYP1A2 using 2 single doses of theophylline as a probe drug.
11548077|NCT01017926|Active Comparator|Triazolam Reference Arm|There will be a clearance period of at least 3 days between the two phases of the study.
11548078|NCT01017926|Experimental|Triazolam Trial Arm|
11548079|NCT01017913|Active Comparator|Electrotherapy equipment|The TENS equipment was calibrated on 20 hertz frequency, and a pulse width of 330 ms with two channels.
11548080|NCT01017913|Active Comparator|electrotherapy equipment|The CI was adjusted with 4000 HZ bases frequency, modulation frequency range 20 HZ, ∆F10 HZ, slope 1/1 and quadripolar manner.
11548081|NCT01017913|No Intervention|Control|The patients of the Control group stayed without any treatment in the same period
11548082|NCT01017887||Airseal port for laparoscopic surgery|Airseal access port for laparoscopic surgery with standard ports.
11548083|NCT01017887||Standard Laparoscopy ports|Uses standard laparoscopy ports.
11548084|NCT01017874|Experimental|Pemetrexed + Cisplatin + Gefitinib|
11548085|NCT01017874|Active Comparator|Gefitinib|
11548086|NCT01017861||Pregnant, 12th week|Pregnant women in the 12th week of pregnancy.
11548087|NCT01017861||Pregnant, 28th week|Pregnant women in the 28th week of pregnancy.
11548088|NCT01017861||Pregnant, full term|Pregnant women at full term, in hospital for an elective cesarean section.
11548089|NCT01017861||Non pregnant women|Non pregnant women
11548090|NCT01017848||Adults, nondiabetics|adults who are nondiabetic, no CKD, no urinary tract infection, no bladder dysfunction
11548091|NCT01017835||statin treatment, isolated hypertension|treatment with statins, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking
11548092|NCT01017835||placebo treatment, isolated hypertension|treatment with placebo, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking
11548093|NCT01017809|Other|Oxali/Topotecan|Patients enrolled to NYU 03-67 will be receiving Oxaliplatin 85 mg/m2 IV over 120 minutes on Day 1 and 15 Topotecan 0.4mg/m2/day CIV from D1 to 15 (in addition to the assigned intervention)
11548094|NCT01017796|Experimental|A. Experimental|1200mg acetylcysteine and 2g ascorbic acid at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
11548095|NCT01017796|Placebo Comparator|B. Control|200ml 0,9% normal saline IV
11548096|NCT01017783|Other|Healthy Choices|
11548097|NCT01017783|Experimental|Diet Substitution A|
11548098|NCT01017783|Experimental|Diet Substitution B|
11548099|NCT01017770|Experimental|Artemether -lumefantrine|Experimental Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso
11548100|NCT01017770|Experimental|Artesunate-amodiaquine|Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso
11548101|NCT01017757||Renal transplant patients|
11548102|NCT01017731|Experimental|IMC-1121B|"Active-control participants (first 16 participants) will receive one dose of moxifloxacin orally 7 days before the first treatment with ramucirumab. All participants will undergo triplicate electrocardiogram (ECG) tests (consisting of three individual ECGs performed consecutively within a period of 4 minutes) and vital signs at various times over the trial period.
~For Cycle 1, all participants will also receive 2 infusions of diphenhydramine before ramucirumab therapy (the first infusion is 1 day before therapy and the second infusion is 15 minutes before therapy). For Cycles 2, 3, and 4, all participants will receive diphenhydramine 15 minutes before ramucirumab therapy. For Cycle 5 and beyond, diphenhydramine infusions before ramucirumab therapy are at the investigator's discretion. Ramucirumab [10 milligrams per kilogram (mg/kg)] intravenously over 60 minutes, once every 3 weeks for minimum of 9 weeks without a break in between."
11548103|NCT01017692||Lumbar Spinal Stenosis|Subjects who have undergone or will undergo an MRI, with symptoms of LSS
11548104|NCT01017679|Experimental|1|Oral Drug gefitinib(Iressa) 500 mg Everyday
11548105|NCT01017679|Active Comparator|2|Oral Drug gefitinib(Iressa) 250 mg Everyday
11548106|NCT01017666|Experimental|Rosiglitazone 8mg PO|Cohort 1
11548107|NCT01017666|Experimental|Midazolam 2mg PO, Warfarin 25mg PO|Cohort 2
11548108|NCT01017653|Experimental|Panitumumab and irinotecan|
11548109|NCT01017640|Experimental|Arm I (veliparib)|Patients receive veliparib PO BID in the absence of disease progression or unacceptable toxicity.
11548110|NCT01017640|Experimental|Arm II (veliparib and mitomycin C)|Patients receive veliparib PO BID on days 1-7, 1-14, or 1-21. Patients also receive mitomycin C IV over 10-20 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11548111|NCT01017627|Other|Early anemia management|Upon return to the dialysis unit following hospitalization, patients will be immediately identified and have immediate implementation of the unit anemia protocol rather than waiting for the next regularly scheduled unit labs and regular follow-up. Thus, labs will be obtained within the first 3-7 days following hospitalization and appropriate titration of Epo and iron medications within the 7 days after discharge from hospital and under the direction of the pre-specified algorithm used in the patient's facility; all drug dosing will comply with package insert instructions
11548112|NCT01017627|Other|case control|"Each case will be data-matched to an intra-facility (primary control), and then an inter-facility (validation control) control patient. Matching criteria will be by age, gender, diabetic status, attending nephrologist, length of hospitalization stay, and hospital discharge date (to minimize the difference in the date between the case and control). These patients did not have early intervention but followed the usual practice of waiting for the next regularly scheduled dialysis unit labs with anemia management to follow using the regular unit algorithm."
11548113|NCT01017614|Experimental|Monofer|"administered as intravenous infusions (A1)
~administered as intravenous bolus injections (A2)"
11548114|NCT01017614|Active Comparator|Iron Sulphate|tablets administered orally
11548115|NCT01017601|Experimental|Arm I|Patients receive a single dose of Seneca Valley virus-001 (NTX-010) IV over 1 hour on day 1.
11548116|NCT01017601|Placebo Comparator|Arm II|Patients receive a single dose of placebo IV over 1 hour on day 1.
11548117|NCT01017588|Experimental|back exercise|strengthening back exercise
11548118|NCT01017575|Experimental|Arm A (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
11548119|NCT01017575|Experimental|Arm B (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
11548120|NCT01017575|Placebo Comparator|Arm C (Placebo, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
11548121|NCT01017575|Experimental|Arm D (Daclatasvir, plus peginterferon alfa-2a, Ribavirin)|Non-Responder
11548122|NCT01017575|Experimental|Arm E (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Non-Responder
11548123|NCT01017562||condition of joint implant|
11548124|NCT01017549|Other|Treatment|This is a single arm study where all patients are treated with FDA cleared electronic brachytherapy treatment.
11548125|NCT01017536|Placebo Comparator|Placebo|Thirteen subjects received placebo vaccine that did not contain any AERAS-402.
11548126|NCT01017536|Experimental|Investigational Vaccine|Thirteen subjects received active vaccine 3 x 10^10 vp AERAS-402.
11548127|NCT01017523|Experimental|1 (Couples)|Diabetes self-management education, telephone support and behavior change for couples.
11548128|NCT01017523|Active Comparator|2 (Individual)|Diabetes self-management education, telephone support and behavior change for individuals.
11548129|NCT01017523|Placebo Comparator|3 (Control)|Diabetes self-management education only.
11548130|NCT01017497|Experimental|1mm margin|GTV expanded by 1 mm
11548131|NCT01017497|Experimental|3mm margin|GTV expanded by 3 mm
11548132|NCT01017484|Experimental|DASH|The Dietary Approaches to Stop Hypertension Dietary pattern.
11548133|NCT01017484|Experimental|Control|The typical American diet as estimated from the NHANES survey.
11548134|NCT01017471|Experimental|control|carpal tunnel release using standard incision
11548135|NCT01017458|Experimental|1|MK0773 + placebo injection
11548136|NCT01017458|Active Comparator|2|placebo to MK0773 + testosterone injection
11548137|NCT01017458|Placebo Comparator|3|placebo to MK0773 + placebo injection
11548138|NCT01017445|Experimental|Quadricep strengthening exercise|Quadricep strengthening exercise
11548139|NCT01017419||Audiology counseling|
11548140|NCT01017406|Experimental|Plantar fascia stretching exercise|Patient perform plantar fascia stretching 3 times per day
11548141|NCT01017393|Experimental|ketamine|epidural ketamine added to the patient controlled epidural analgesia regimen
11548142|NCT01017393|Active Comparator|ketamine free|epidural ketamine NOT added to the patient controlled epidural analgesia regimen
11548143|NCT01017380|Experimental|placebo|identical placebo
11548144|NCT01017367|Experimental|MDX-1100|MDX-1100 10 mg/kg administered i.v. over 60 minutes on days 1, 15, 29, 43, 57, and 71
11548145|NCT01017367|Placebo Comparator|Placebo|Placebo (saline) administered i.v. over 60 minutes on days 1, 15, 29, 43, 57, and 71
11548146|NCT01017354|Experimental|High-dose vitamin D3|monthly high-dose vitamin D3 supplement dose (60'000 IU/month, equivalent to 2000 IU daily)
11548147|NCT01017354|Experimental|standard vitamin D + 25(OH)D|standard vitamin D3 supplement dose combined with 25(OH)D (24'000 IU/month, equivalent to 800 IU daily PLUS 300 mcg 25(OH)D, equivalent to 10 mcg per day)
11548148|NCT01017354|Active Comparator|standard vitamin D|standard vitamin D3 supplement dose (24'000 IU/month, equivalent to 800 IU daily)
11548149|NCT01017341|No Intervention|No hip protector|no hip protector
11548150|NCT01017328||surgery with general anesthesia|
11548151|NCT01017315|Experimental|No application of baby talcum|control
11548152|NCT01017302|Experimental|1|
11548153|NCT01017302|Placebo Comparator|2|
11548154|NCT01017302|Experimental|3|
11548155|NCT01017302|Placebo Comparator|4|
11548156|NCT01017289|Experimental|Quantum|In this single arm study, the Quantum nailing system will be used in all patients.
11548157|NCT01017276|Experimental|ASP group|
11548158|NCT01017263|Active Comparator|Open label Vyvanse|Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
11548159|NCT01017250|Experimental|Stereotactic Radiosurgery|Avastin and Radiosurgery
11548160|NCT01017237|Active Comparator|Dex plus midazolam|Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg i.v.
11548161|NCT01017237|Active Comparator|Dex plus midazolam and ketamine|Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg and 0.25 mg/kg ketamine i.v.
11548162|NCT01017211|Experimental|auricular acupuncture protocol|
11548163|NCT01017211|Sham Comparator|sham auricular acupuncture|
11548164|NCT01017198|Experimental|BIIB021 and Food|The food phase will assess the effect of a high fat meal on the pharmacokinetics of BIIB021.
11548165|NCT01017198|Experimental|BIIB021 and Antacid|Antacid phase will assess the effect of an antacid on the pharmacokinetics of BIIB021.
11548166|NCT01017185|Experimental|Oncolytic virotherapy, intratumoral injection of HF10|
11548167|NCT01017159|Active Comparator|Subcutaneous immunoglobulin|
11548168|NCT01017159|Placebo Comparator|Saline|
11548169|NCT01017146|Experimental|1|Tazarotene foam, 0.1%
11548170|NCT01017146|Placebo Comparator|2|Vehicle Foam
11548171|NCT01017133|Other|Arm I|With 6 weeks prior to surgery, patients undergo fluorine F18 (18F)-EF5 PET at 10 minutes and 90 minutes after injection of 18F-EF5. Patients also undergo fludeoxyglucose F18 (18F-FDG) PET at 1 hour and 3 hours after injection of 18F-FDG.
11548172|NCT01017120|Experimental|1|Tazarotene foam, 0.1%
11548173|NCT01017120|Placebo Comparator|2|Vehicle Foam
11548174|NCT01017107|Experimental|Activated protein C|
11548175|NCT01017094|Experimental|dry dressing|local application
11548176|NCT01017081|Active Comparator|Control|Non-mandatory request to maintain lateral positioning to improve air exchange, to cough in order to clear secretion, and to perform diaphragmatic and deep breathing, for five minutes, once a day, during hospital stay.
11548177|NCT01017081|Experimental|Physiotherapy|"Physiotherapy: Children younger than 5 years: Manual Thoracic vibration (TV), thoracic compression (TC), positive expiratory pressure (PEP), and forced exhalation with the glottis open (huffing). Children aged 5 years or older: same procedures in addition to the ventilatory patterns, and a forced expiratory technique (FET), consisting of one or two huffs (forced expirations) followed by a period of relaxed, controlled diaphragmatic breathing, three times per day, for 10 to 12 minutes, during hospital admission."
11548178|NCT01017068|Experimental|A1 (glaucoma)|
11548179|NCT01017068|Experimental|A2 (glaucoma)|
11548180|NCT01017068|Experimental|A3 (glaucoma)|
11548181|NCT01017068|Experimental|A1 (normals)|
11548182|NCT01017068|Experimental|A2 (normals)|
11548183|NCT01017068|Experimental|A3 (normals)|
11548184|NCT01017055||Voice and Swallowing Evaluations|
11548185|NCT01017042|Experimental|colchicine|colchicine 1.2mg by mouth initially then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
11548186|NCT01017029|Active Comparator|Immediate introduction of everolimus|
11548187|NCT01017029|Experimental|Delayed introduction of everolimus|delayed introduction) + Cyclosporin + steroids
11548188|NCT01017003|Experimental|1|0.6mg colchicine tablet
11548189|NCT01017003|Experimental|2|colchicine 0.6mg q12 hours for 10 days
11548190|NCT01016977|Active Comparator|Duac & taz|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
11548191|NCT01016977|Active Comparator|Acanya & taz|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
11548192|NCT01016964|Sham Comparator|Sham Device|Sham device
11548193|NCT01016964|Active Comparator|LLT Device 2009 12 Beams|HairMax LaserComb 2009 model 12 beam
11548194|NCT01016951|Experimental|A|AZD9164
11548195|NCT01016951|Placebo Comparator|B|Placebo
11548196|NCT01016938||Group I|This is a pilot study and there is only one group.
11548197|NCT01016925|No Intervention|Control|
11548198|NCT01016925|Experimental|femoral tunnelized perineural catheter|
11548199|NCT01016912|Experimental|Arm A (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
11548200|NCT01016912|Experimental|Arm B (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
11548201|NCT01016912|Placebo Comparator|Arm C (Placebo, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
11548202|NCT01016912|Experimental|Arm D (BMS-790052, plus peginterferon alfa-2b, Ribavirin)|Non-Responder
11548203|NCT01016912|Experimental|Arm E (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Non-Responder
11548204|NCT01016899||Non-melanoma skin cancer|Early stage squamous or basal cell carcinoma
11548205|NCT01016886|Experimental|1|
11548206|NCT01016873|Experimental|16 Gy IRay|16 Gy IRay + PRN Lucentis®
11548207|NCT01016873|Sham Comparator|Sham 16 Gy IRay|Sham 16 Gy IRay + PRN Lucentis®
11548208|NCT01016873|Experimental|24 Gy IRay|24 Gy IRay + PRN Lucentis®
11548209|NCT01016873|Sham Comparator|Sham 24 Gy IRay|Sham 24 Gy IRay + PRN Lucentis®
11548210|NCT01016860|Experimental|OSI-906 and/or irinotecan|Dose Escalation Phase: Treatment for Cycle 1 will commence on Day -3 of a 21-day cycle (3 weeks) when a single dose OSI-906 is given with full pharmacokinetics(PK) sampling at predetermined time points. Irinotecan will be administered intravenously over 90 minutes on Day 1 and Day 8 with full PK sampling on Day 1. The institution of oral dosing of OSI-906 2-4, 8-10, 15-17 (for cycle 1 only) will be given followed by full PK sampling of both drugs on Day 8. Pre-dose samples of OSI-906 will be drawn on Cycle 1 Days 8, 10, 15, 17 and Cycle 2 Days 1, 8, 10, 15 and 17. For Cycle 2 and thereafter, both drugs will be administered starting on Day 1.
11548211|NCT01016847|Active Comparator|leukotriene receptor antagonist (LTRA) montelukast|Montelukast (LTRA) administered with moderate dose of inhaled steroid
11548212|NCT01016847|Placebo Comparator|Sugar Pill|High dose of inhaled steroid administered with sugar pill
11548213|NCT01016834|Other|Sumavel(R) DosePro(R)|Single arm study (Sumavel DosePro)
11548214|NCT01016821|Other|Oxycodone, labour pain|
11548215|NCT01016808|Experimental|Q8003 12 mg/8 mg|Combination
11548216|NCT01016808|Active Comparator|Morphine sulfate 12 mg|Single component
11548217|NCT01016808|Active Comparator|Oxycodone HCl 8 mg|Single component
11548218|NCT01016795|Active Comparator|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
11548219|NCT01016795|Active Comparator|Cyclophosphamide and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
11548220|NCT01016782|Experimental|Test|Test product that contains active pharmaceutical ingredient
11548221|NCT01016782|Active Comparator|Reference|Reference product that contains active pharmaceutical ingredient
11548222|NCT01016782|Placebo Comparator|Vehicle|Placebo that contains no active pharmaceutical ingredient
11548223|NCT01016769|Experimental|Temsirolimus + Weekly Paclitaxel + Carboplatin|"In Part 1 (Phase I) of the study, the primary endpoint is to establish the phase II recommended dose for the combination of temsirolimus + weekly paclitaxel + carboplatinPart 1 (Phase I) features a standard 3 + 3 phase I dose escalation design. Up to 3 dose levels are planned in the Phase I portion of the study.
~In Part 2 (Phase II) of the study, the primary endpoint is to determine the objective response rate (CR or PR) after two cycles (approximately 6 weeks) of treatment with the combination of temsirolimus + weekly paclitaxel + carboplatin as palliative therapy for recurrent or metastatic HNSCC. A two-stage design will be employed."
11548224|NCT01016743|Active Comparator|Active repetitive transcranial Stimulation|Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).
11548225|NCT01016730|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
11548226|NCT01016717|Active Comparator|Omeprazole|Patients will be taking omeprazole tablets 40 mg QD for 30 days
11548227|NCT01016717|Active Comparator|Pantoprazole|Patients will be taking Pantoprazole tablets 40 mg QD for 30 days
11548228|NCT01016704|No Intervention|Control|
11548229|NCT01016704|Experimental|Incentive|
11548230|NCT01016691|Experimental|High Dose Drug Device/ bimatoprost 0.03%|drug device containing 65 micrograms of bimatoprost released over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
11548231|NCT01016691|Experimental|Low Dose Drug Device / bimatoprost 0.03%|drug device containing 45 micrograms of bimatoprost released over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
11548232|NCT01016691|Other|Placebo Device / bimatoprost 0.03%|placebo drug device worn over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
11548233|NCT01016678|Other|Active, Active, Active, Placebo|One fifth of the 105 subjects will be randomized to this arm and treat their four migraines in this order. First three will be treated with Active Treximet and the last or 4th migraine will be treated with Placebo.
11548234|NCT01016678|Other|Active, Active, Placebo, Active|This is another of the five treatment arms. One fifth of the 105 subjects will be randomized to this group and will treat the first two migraines with Active drug, Treximet, and then the third migraine with placebo and the last (4th) migraine with Treximet.
11548328|NCT01015950|Experimental|Pumpy'Sup|Lipid-based nutrient supplement
11548329|NCT01015950|Experimental|SCSB|Processed, fortified, cereal-based food blend (SCSB for malnourished children)
11548235|NCT01016678|Other|Active, Placebo, Active, Active|Approximately one fifth of the 105 subjects will be randomized to this group and treat their first migraine with Active Treximet and the second migraines with Placebo. The final two migraines treated will be with Active study drug.
11548236|NCT01016678|Other|Placebo, Active, Active, Active|One fifth of the 105 subjects will be randomized to this treatment arm, where they will treat the first headache with placebo and the remaining three migraines will be treated with Active treximet.
11548237|NCT01016678|Other|Active, Active, Active, Active|One fifth of the subject will treat all their migraines with Active Treximet.
11548238|NCT01016665|Placebo Comparator|Placebo|Placebo
11548239|NCT01016665|Other|Tamoxifen|Tamoxifen 20 mg day 26 days
11548240|NCT01016665|Other|Anastrozole|Anastrozole 1mg 26 days
11548241|NCT01016652|Other|etafilcon A multifocal / etafilcon A sphere|period 1: etafilcon A multifocal worn, period 2: etafilcon A sphere worn.
11548242|NCT01016652|Other|etafilcon A sphere / etafilcon A multifocal|period 1: etafilcon A sphere worn, period 2: etafilcon A multifocal worn.
11548243|NCT01016639|Experimental|Chemoradiotherapy|
11548244|NCT01016626|Experimental|CKD-4101 tablet|
11548245|NCT01016626|Active Comparator|Mycophenolate Mofetil capsule|
11548246|NCT01016613||Chronic Kidney Disease Cohort|chronic kidney disease patients with any type of kidney disease
11548247|NCT01016613||Matched Control Group|Healthy controls
11548248|NCT01016613||Trios|First degree relatives of pediatric chronic kidney disease cohort members
11548249|NCT01016600|Experimental|Cohort 1|"Induction regimen (total 2 cycles)
~Lenalidomide 50 mg PO daily days 1-28
~Azacitidine 25 mg/m2 IV days 1-5
~Maintenance Regimen
~Lenalidomide 10 mg PO daily days 1-28
~Azacitidine 75 mg/m2 IV days 1-5"
11548250|NCT01016600|Experimental|Cohort 2|"Induction regimen (total 2 cycles)
~Lenalidomide 50 mg PO daily days 1-28
~Azacitidine 50 mg/m2 IV days 1-5
~Maintenance Regimen
~Lenalidomide 10 mg PO daily days 1-28
~Azacitidine 75 mg/m2 IV days 1-5"
11548251|NCT01016600|Experimental|Cohort 3|"Induction regimen (total 2 cycles)
~Lenalidomide 50 mg PO daily days 1-28
~Azacitidine 75 mg/m2 IV days 1-5
~Maintenance Regimen
~Lenalidomide 10 mg PO daily days 1-28
~Azacitidine 75 mg/m2 IV days 1-5"
11548252|NCT01016600|Experimental|Phase II|"Induction regimen (total 2 cycles)
~Lenalidomide 50 mg PO daily days 1-28
~Azacitidine 75 mg/m2 (dose determined in Phase I) mg/m2 IV days 1-5
~Maintenance Regimen
~Lenalidomide 10 mg PO daily days 1-28
~Azacitidine 75 mg/m2 IV days 1-5"
11548253|NCT01016587||COPD patients|Not hospitalized COPD patients, degree 2-4.
11548254|NCT01016574|Other|women with stage I or II breast cancer|
11548255|NCT01016561|Experimental|Arm I|Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.
11548256|NCT01016548|Experimental|Two doses of vaccine|Second dose is given 21 days after the initial dose. The same dose and route of administration are used.
11548257|NCT01016548|Active Comparator|One dose of vaccine|Given at baseline only.
11548258|NCT01016535||Children, Health Professionals|
11548259|NCT01016522|Experimental|KetoCal|KetoCal tube feeding formula
11548260|NCT01016509|No Intervention|control|No hyperglycemia patient group
11548261|NCT01016509|Active Comparator|Insulin 1|Conventional insulin treatment
11548262|NCT01016509|Experimental|Insulin|Intensive insulin treatment
11548263|NCT01016496|Experimental|Action observation plus repetition|Observation of actions and repetition of the same actions
11548264|NCT01016496|Active Comparator|repetition only|repetition of gestures
11548265|NCT01016483|Experimental|Safety Run-in Part: Regimen 1|Subjects will receive pimasertib capsule orally once daily (qd) doses of 15, 30, 45, 68, 90, and 120 milligram (mg) on Day 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15,16, 17, 18, 19, 22, 23, 24, 25, 26 and gemcitabine 1000 milligram per square meter (mg/m^2) intravenous (IV) infusion for 30 minutes on Days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (1 Cycle = 8 weeks).
11548266|NCT01016483|Experimental|Safety Run-in Part: Regimen 2|Subjects will receive pimasertib capsule orally twice daily (bid) doses of 60 and 75 mg continuously for a 28-day cycle and gemcitabine 1000 mg/m^2 intravenous (IV) infusion for 30 minutes on Days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (1 Cycle = 8 weeks) (bid - continuous regimen).
11548267|NCT01016483|Active Comparator|Phase II: Arm 1 (Gemcitabine + Placebo)|Subjects will receive gemcitabine 1000 mg/m^2 IV infusion on for 30 minutes on Day 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (Cycle 1) then on Days 1, 8, and 15 of a 28-day cycle and placebo matched to pimasertib orally bid - continuous regimen.
11548268|NCT01016483|Experimental|Phase II: Arm 2 (Gemcitabine + Pimasertib)|Subjects will receive gemcitabine 1000 mg/m^2 IV infusion for 30 minutes on Day 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (Cycle 1) then on Days 1, 8, and 15 of a 28-day cycle and pimasertib capsule orally bid - continuous regimen.
11548269|NCT01016470|Placebo Comparator|B|Placebo
11548270|NCT01016470|Experimental|A|VIUSID/ALZER. The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with early PD by UPDRS motor
11548271|NCT01016444||Albuterol responsive|Those who respond clinically to albuterol.
11548272|NCT01016444||Albuterol unresponsive|Albuterol non-responsiveness is defined as a failure of the PEFR in an acutely ill asthmatic to exceed 40% of predicted following ≥7.5 mg of albuterol (2.5 mg albuterol aerosols q.20 min x3).
11548273|NCT01016431|Experimental|Rate adaptive|Patients will have their ICD programmed in a AAI-R mode, with peak atrial rate set at 85% of age-adjusted predicted maximal HR
11548274|NCT01016431|Active Comparator|Control|ICDs will be programmed in the usual VVI backup pacing mode at 40 bpm
11548275|NCT01016418|Experimental|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
11548276|NCT01016405||Severity of dry eye in patients undergoing cataract surgery|
11548277|NCT01016366|Experimental|Lu AA24493|
11548278|NCT01016366|Placebo Comparator|Placebo|
11548279|NCT01016340|Active Comparator|MCS-5|Group 1: MCS-5 5 mg/day for 16 weeks;Group 2: MCS-5 10 mg/day for 16 weeks;Group 3: MCS-5 20 mg/day for 16 weeks
11548280|NCT01016340|Placebo Comparator|Placebo|Group 4: Placebo for 16 weeks
11548282|NCT01016314|Experimental|Aspen Spinous Process System|Subjects randomized to the Aspen study arm will have the Aspen device implanted as supplemental posterior fixation only and according to the manufacturer's recommendations.
11548283|NCT01016314|Active Comparator|Pedicle Screw Fixation|Subjects randomized to the pedicle screw group will have the pedicle screws implanted according to the standard procedures and practices at that institution. The procedure may be performed according to surgeon preference, including a traditional open, minimally invasive or percutaneous approach. Only pedicle screws cleared by FDA for this indication will be used in this study.
11548284|NCT01016301|Active Comparator|Pharmacist service,|The pharmacist service consists of medication review, drug treatment discussion with the patient, and a medication report.
11548285|NCT01016301|No Intervention|Control|Usual care
11548286|NCT01016288||22 G Needle EUS-FNA|Patients referred for an EUS examination and EUS-FNA of a solid mass lesion adjacent to the upper GI tract using a 22 G needle
11548287|NCT01016288||25 G Needle EUS-FNA|Patients referred for an EUS examination and EUS-FNA of a solid mass lesion adjacent to the upper GI tract using a 25 G needle
11548288|NCT01016275||Iliac lesions TASC A or B|All lesion types belonging to the iliac TASC A or B.
11548289|NCT01016262|Experimental|MAX-002|
11548290|NCT01016262|Placebo Comparator|Placebo|
11548291|NCT01016262|Active Comparator|Canasa®|
11548292|NCT01016249|Active Comparator|Treatment 1. 5% Saline + Epinephrine|Nebulization with 4ml of 5% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
11548293|NCT01016249|Other|Treatment 3. 3% Saline + Epinephrine|Nebulization with 4ml of 3% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
11548294|NCT01016249|Other|Treatment 2 . 0.9% Saline + Epinephrine|Nebulization with 4ml of 0.9% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
11548295|NCT01016223|Active Comparator|Beclomethasone dipropionate inhaler|
11548296|NCT01016223|Placebo Comparator|Matched inhaler|
11548297|NCT01016210|Experimental|60 infertile women|Candidates for IVF-ET treatment
11548298|NCT01016210|No Intervention|control|no treatment
11548299|NCT01016197|Active Comparator|Conservative|Four weeks of splinting followed by mobilisation.
11548300|NCT01016197|Experimental|Surgery|Surgical repair of the tendon with a bone anchor followed by four weeks of splinting and then mobilisation.
11548301|NCT01016184|Active Comparator|vitamin D|
11548302|NCT01016184|Active Comparator|placebo|
11548303|NCT01016158|Experimental|umbilical cord serum eyedrops|patients with recurrent corneal erosions were treated with 20% umbilical cord serum eye drops 3 to 4 times a day in addition to artificial tears
11548304|NCT01016145|Active Comparator|First generation antipsychotic|Subjects randomized to this arm will receive treatment with haloperidol or chlorpromazine.
11548305|NCT01016145|Experimental|Second generation antipsychotics|Subjects randomized to this arm will receive treatment with a second-generation antipsychotic: risperidone or olanzapine or aripiprazole or quetiapine or ziprasidone
11548306|NCT01016119|Placebo Comparator|Placebo|In this group we will use Placebo cream, in the early rehabilitations in the upper extremity
11548307|NCT01016119|Experimental|Folrex|In this group we will use Folrex cream, in the early rehabilitations in the upper extremity
11548308|NCT01016106|Active Comparator|AA pts AD and IV|African American patients with a diagnosis of atopic dermatitis and ichthyosis vulgaris. During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT
11548309|NCT01016106|Active Comparator|AA patients (controls)|African American patients with no personal or family history of ichthyosis vulgaris or atopy. During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT
11548310|NCT01016093|Experimental|Intervention|Patients in this arm received zoledronic acid.
11548311|NCT01016093|Placebo Comparator|Control|Patients in this arm received placebo as control group
11548312|NCT01016080|Active Comparator|oral glutathione|glutathione, 500 mg, taken orally twice daily
11548313|NCT01016080|Placebo Comparator|placebo capsules|identical-appearing placebo capsules
11548314|NCT01016067|Experimental|INFUSE/MASTERGRAFT|Patients received INFUSE/MASTERGRAFT granules with rigid internal fixation.
11548315|NCT01016067|Active Comparator|Autograft bone|Patients received autograft bone with rigid internal fixation.
11548316|NCT01016054|Experimental|A. PLD plus AGS-8M4|Women with platinum resistent ovarian cancer
11548317|NCT01016054|Experimental|B. Carboplatin and gemcitabine plus AGS-8M4|Women with platinum sensitive ovarian cancer
11548318|NCT01016041|Experimental|everolimus stent|
11548319|NCT01016041|Active Comparator|paclitaxel eluting|
11548320|NCT01016028||Questionnaire + Sensory Tests + Interview|
11548321|NCT01016015|Experimental|Treatment (cixutumumab and temsirolimus)|Patients receive cixutumumab IV over 60 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11548322|NCT01016002|Experimental|Intervention|
11548323|NCT01015989|Active Comparator|CARE+ Kenya brief computer risk assessment session (control)|
11548324|NCT01015989|Active Comparator|Full CARE+ Spanish computer-counseling group|
11548325|NCT01015976|Experimental|Post bariatric surgery|Roux en Y bariatric surgery
11548326|NCT01015976|Other|Control|No surgery
11548327|NCT01015963||Ancillary-correlative (DNA sample analysis)|Blood samples collected on clinical trial CLB-9871 are examined via ABCC2 and SLC01B3 genotyping using TaqMan analysis. Other genes related to the pharmacokinetics and side effects of docetaxel may be considered for future genotyping. In some cases, panels of drug response SNPs on high-density arrays may be genotyped.
11548330|NCT01015950|Experimental|Misola|Locally processed, fortified food blend (Misola)
11548331|NCT01015950|Active Comparator|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, oil) and a multiple micronutrient powder (Mix-Me) are provided to simulate the currently recommended enhanced home-prepared rehabilitation food mixture (farines enrchies) according to the national Mali CMAM protocol."
11548332|NCT01015937|Active Comparator|Turmeric|"diabetic nephropathy patient
~more than 300 mg/proteinuria"
11548333|NCT01015937|Active Comparator|ACE inhibitor + ATI blocker|"diabetic nephropathy
~more than 300 mg/day proteinuria"
11548334|NCT01015924|Active Comparator|Elastic Stable Intramedullary Nailing|Operative intervention with closed or open reduction and intramedullary stabilization of midshaft clavicle fractures
11548335|NCT01015924|Active Comparator|Plate osteosynthesis|Open reduction and plate fixation of midshaft clavicle fractures
11548336|NCT01015911|Experimental|1|SGN-75
11548337|NCT01015898|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
11548338|NCT01015872|Experimental|CPAP|the subjects introduced with CPAP treatment
11548339|NCT01015859|No Intervention|DDD long AV delay|Pacemaker is programmed in DDD mode with long AV delay (250 msec)
11548340|NCT01015859|Active Comparator|AAI SafeR|Pacemaker is programmed in AAI SafeR mode
11548341|NCT01015846|Experimental|Intervention|
11548342|NCT01015846|Active Comparator|Core stability exercise|Traditional core stability exercise
11548343|NCT01015833|Experimental|Arm I (doxorubicin hydrochloride, sorafenib tosylate)|Patients receive doxorubicin hydrochloride IV on day 1 and sorafenib tosylate PO QD or BID on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, patients may continue to receive sorafenib tosylate PO QD or BID in the absence of disease progression or unacceptable toxicity.
11548344|NCT01015833|Experimental|Arm II (sorafenib tosylate)|Patients receive sorafenib tosylate PO QD or BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11548345|NCT01015820|Experimental|Cancer group|Participants in this group had pathologically confirmed pancreatic adenocarcinoma. They received an EGD with EUS. During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
11548346|NCT01015820|Other|Control group|Participants in this group were without pancreatic adenocarcinoma. Participants in the control group received an EGD with EUS for the indication of abdominal pain. During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
11548347|NCT01015807|Placebo Comparator|Placebo|Sterile Saline used for TAP block = Bupivacaine Placebo + Clonidine Placebo
11548348|NCT01015807|Active Comparator|TAP (Bupi)|2x20mL 0.375% Bupivacaine + 2x1mL of 0.9% NaCl = 150mg Bupivacaine + Clonidine Placebo
11548349|NCT01015807|Active Comparator|Clo-TAP (Bupi + Clon)|2x20mL 0.375% Bupivacaine + 2x1mL Clonidine = 150mg Bupivacaine + 150µg Clonidine
11548350|NCT01015794|Experimental|Adrenergic agonist|
11548351|NCT01015781|Experimental|Arm 1|Progressive Tinnitus Management
11548352|NCT01015781|Other|Arm 2|Wait List Control
11548353|NCT01015768|Experimental|Test eye|Uses ReNu Multiplus as multipurpose soaking solution
11548354|NCT01015768|Active Comparator|Control|A new lens (PureVision) is soaked for 2 hours in non-preserved saline
11548355|NCT01015755|Experimental|thirst intervention|
11548356|NCT01015742|Experimental|Experimental|Stem cell Transplant using two unrelated umbilical cord blood units.
11548357|NCT01015729|Active Comparator|1|Esomeprazole 20 mg/ASA 81 mg Fixed Dose Combination Capsule
11548358|NCT01015729|Active Comparator|2|Esomeprazole Clinical Trial Capsule 20 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
11548359|NCT01015729|Active Comparator|3|Esomeprazole MUPS Tablet 20 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
11548360|NCT01015716|Active Comparator|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
11548361|NCT01015716|Experimental|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
11548362|NCT01015703|Experimental|CoVaccine HT|
11548363|NCT01015690||unexplained infertility|patients with unexplained infertility
11548364|NCT01015690||healthy controls|women who wish to conceive, no more tha 3 previous cycles, age above 18
11548365|NCT01015690||references|lesbian women with a regular cycle without use of anticonception and not at risk of becoming pregnant
11548366|NCT01015677|Experimental|MK-6913 75 mg|MK-6913 75 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 1 and Stage 2)
11548367|NCT01015677|Active Comparator|17-β estradiol 1 mg|17β-estradiol 1 mg tablet and matching placebo for MK-6913 75 mg capsule once daily for 4 weeks (Stage 1 and Stage 2)
11548368|NCT01015677|Placebo Comparator|Placebo|Matching placebo for MK-6913 75 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 1 and State 2)
11548369|NCT01015677|Experimental|MK-6913 25 mg|MK-6913 25 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 2)
11548370|NCT01015651|Active Comparator|remifentanil-2|In this group, patients are receiving a continuous i.v. infusion of remifentanil according to a target effect site concentration of 2 ng/ml.
11548371|NCT01015651|Active Comparator|remifentanil-4|In this group, patients are receiving a continuous i.v. infusion of remifentanil according to a target effect site concentration of 4 ng/ml.
11548372|NCT01015638|Experimental|Clindamycin and BPO 5% gel|Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
11548373|NCT01015638|Active Comparator|Clindamycin phosphate and BPO 2.5% gel|Once Daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel.
11548374|NCT01015625|Other|A: Surgical Therapy|Local therapy consists of lumpectomy or mastectomy with or without radiotherapy (according to center tumor board decision) with a resection free margin of at least 1 mm or more demonstrated on paraffin embedded histological sections. Intraoperative frozen sections are allowed but not definitive for margin assessment. Sentinel node biopsy may be performed and has always to be followed by axillary dissection of level I and II (axillary surgery level I and II is mandatory).
11548524|NCT01014637|Experimental|RV4104A-cylcopiroxolamine-ciclopirox|
11548375|NCT01015625|Other|B: Surgery on Demand|In Arm B (no local therapy) it may be necessary to perform local therapy on demand (surgery, radiotherapy). Reasons may be uncontrolled bleeding or infected exulcerations with a septic component and no treatment benefit from conservative therapy. This will be considered as protocol deviation. However, the patient's follow up is recorded and data are available for analyses as intention to treat.
11548376|NCT01015612|Experimental|Medtronic CoreValve® System Implantation|Patients with symptomatic severe aortic stenosis who have an elevated surgical risk
11548377|NCT01015599|Experimental|HOP'N After-School Program|After-school program with daily physical activity following CATCH guidelines, daily fruit/vegetable snack, and weekly nutrition and physical activity education based on social cognitive theory.
11548378|NCT01015586|Experimental|Lamotrigine|Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks
11548379|NCT01015586|Placebo Comparator|Placebo|Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks
11548380|NCT01015573|Experimental|healthy subjects|
11548381|NCT01015560|Experimental|treatment|MLN1202 8mg/kg IV Days 1, 15, 29 given as 1 6 week cycle
11548382|NCT01015547|Experimental|Infliximab plus Methotrexate|infliximab 3-5 mg/kg every 6 weeks, plus methotrexate 15 mg/m2 weekly given orally (dose escalation if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.
11548383|NCT01015547|Experimental|Combination of DMARDs|methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75), plus standard doses of sulfasalazine and hydroxychloroquine. no oral prednisolone. intra-articular steroids allowed.
11548384|NCT01015547|Active Comparator|Methotrexate alone|Conventional drug therapy: methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.
11548385|NCT01015534|Experimental|Whole brain irradiation plus Temozolomide|Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks, and a fixed dose of oral Temozolomide, 1h before each fraction of whole brain irradiation, 200 mg on Monday, Wednesday, Friday; 300 mg on Tuesday, and Thursday. Without adjuvant cycles of Temozolomide.
11548386|NCT01015534|Active Comparator|Whole brain irradiation|Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks
11548387|NCT01015521|Experimental|Aminoflavone Prodrug|Aminoflavone to treat ER positive breast cancer patients
11548388|NCT01015521|Experimental|Aminoflavone Prodrug with pretreatment|Aminoflavone Prodrug to treat Triple Negative Breast Cancer
11548389|NCT01015508|Other|High predisposition|High predisposition for weight regain
11548390|NCT01015508|Other|low predisposition|low predisposition for weight regain
11548391|NCT01015508|Other|Medium predisposition|Medium predisposition for weight regain
11548392|NCT01015495|Experimental|ranibizumab|
11548393|NCT01015482|Experimental|Remifentanil|Remifentanil Infusion
11548394|NCT01015482|Active Comparator|Midazolam|Active Placebo
11548395|NCT01015469|Active Comparator|Group A|Conventional laparoscopic Roux-en-Y gastric bypass (Golden Standard)
11548396|NCT01015469|Experimental|Group B|Conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring
11548397|NCT01015456|Experimental|1|Oral mycophenolate sodium 1440 mg per day for 12 months
11548398|NCT01015456|Active Comparator|2|Intravenous cyclophosphamide monthly for 6 months
11548399|NCT01015443|Experimental|Investigational Arm|Tecemotide (L-BLP25) + Single low dose cyclophosphamide + Best supportive care (BSC)
11548400|NCT01015443|Placebo Comparator|Control Arm|Saline + Placebo + Best supportive care (BSC)
11548401|NCT01015430|Placebo Comparator|Placebo (for RO4917523 ascending doses)|
11548402|NCT01015430|Placebo Comparator|Placebo (for RO4917523 fixed dose)|
11548403|NCT01015430|Experimental|RO4917523 ascending doses|
11548404|NCT01015430|Experimental|RO4917523 fixed dose|
11548405|NCT01015417|Active Comparator|Amoxicillin clavulanic acid|Postoperative administration of 2g of Augmentin, 3 times daily for 5 days.
11548406|NCT01015417|Other|No medication|no postoperative antibiotics
11548407|NCT01015404|Experimental|Experimental H|high volume (0.6mL、0.3% Trafermin)
11548408|NCT01015404|Experimental|Experimental L|low volume (0.2mL、0.3% Trafermin)
11548409|NCT01015391|Experimental|T2|
11548410|NCT01015391|Active Comparator|AZA|
11548411|NCT01015378||Diverticulitis of the sigmoid colon - first episode|
11548412|NCT01015365|Other|Surgical revision|Surgical cementless One-stage revision of the chronic infected hip arthroplasty
11548413|NCT01015352|Active Comparator|Arm A|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days for 6 courses and 12 additional maintenance courses in responders.
11548414|NCT01015352|Active Comparator|Arm B|"Azacitidine: 75mg/sqm SQ per day for 5 days every 28 days for 6 courses AND
~Epoetin beta : 60000U weekly SQ injections (to be adapted according to Hb as described above)
~12 additional maintenance courses are planned in responders"
11548415|NCT01015339|Active Comparator|Cisplatin plus capecitabine|
11548416|NCT01015339|Experimental|Paclitaxel plus Capecitabine|
11548417|NCT01015326||Expert Interviews|Expert cohort consists of providers with expertise in administering epidermal growth factor receptor inhibitors (EGFRI) or treating patients with EGFRI-associated skin toxicities. Experts will be asked open-ended questions about symptoms and issues as they relate to HRQL in patients with EFGRI skin toxicities. Experts will then be presented with a pool of potential items and will be asked through interview and questionnaire to relate items according to how common and how important they are when occurring in patients with this condition.
11548418|NCT01015326||Patient Interviews|Patient cohort will consist of those treated with an epidermal growth factor receptor inhibitor (EGFRI) and referred to a specialized dermatology clinic for skin rash management. Patients will be asked open-ended questions about symptoms and issues as they relate to their HRQL to elicit personal experiences about how EGFRI skin toxicities and its treatment affects patients. Patients will be asked through interview and questionnaire to rate items according to how often they are experienced and how important they are to the patient.
11548419|NCT01015313|Experimental|intensive sodium management|
11548420|NCT01015313|No Intervention|standard care|
11548874|NCT01012154|Experimental|All patients|
11548421|NCT01015287|Experimental|Non pre-treatment|A placebo oral loading dose is given at the time of diagnosis and a 60 milligrams (mg) oral loading dose of prasugrel is given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.
11548422|NCT01015287|Experimental|Split Loading Dose|A 30 mg oral loading dose of prasugrel is given at diagnosis and a 30 mg oral dose of prasugrel is given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days
11548423|NCT01015274||Healthy control male|
11548424|NCT01015261|Experimental|Bone Marrow Transplantation|
11548425|NCT01015261|Active Comparator|Chemotherapy|
11548426|NCT01015248|Experimental|Rituximab and Bendamustine|
11548427|NCT01015235|Placebo Comparator|Arm 1: Placebo|Placebo
11548428|NCT01015235|Active Comparator|A2: KAI-1678|Test Drug
11548429|NCT01015235|Active Comparator|A3: Ketorolac|Active Comparator
11548430|NCT01015222|Experimental|Dasatinib, Bevacizumab + Paclitaxel|"Dose Escalation Starting Dose Levels: 50 mg Dasatinib daily by mouth (PO), 5 mg/kg Bevacizumab IV on Day 1 and 15; Paclitaxel 40 mg/m2 IV on Day 1, 8 and 15
~Dose Expansion Starting Dose Levels: Maximum tolerated dose from Dose Escalation."
11548431|NCT01015209|Active Comparator|Cohort 1: 18 healthy subjects|18 healthy subjects receiving Chitosan- N- Acetylcysteine eye drops at a dose of 0.1%, 0.2% or 0.3% (6 subjects per group)
11548432|NCT01015209|Active Comparator|Cohort 2: 12 healthy patients|12 healthy subjects receiving Chitosan- N- Acetylcysteine eye drops at a dose of 0.1%, 0.2% or 0.3%
11548433|NCT01015196|Active Comparator|Idarubicine|
11548434|NCT01015196|Experimental|Daunorubicine|
11548435|NCT01015183|Experimental|Intervention|Received Zinc Sulfate
11548436|NCT01015183|Placebo Comparator|Control|Control group
11548437|NCT01015170|Experimental|Bupropion HCl|Up to 8 week of bupropion SR (150mg BID) + counseling.
11548438|NCT01015157|Active Comparator|Standard stapling without reinforcement|Standard Echelon 60 linear stapling with GOLD cartridges
11548439|NCT01015157|Active Comparator|Seamguard gastric stapling line reinforcement|
11548440|NCT01015144||Atorvastatin|
11548441|NCT01015144||No statin|
11548442|NCT01015131|Experimental|All Participants|18F-FLT-PET imaging
11548443|NCT01015118|Experimental|BIBF 1120|patients to receive BIBF 1120 standard dose twice daily PO in combination with combination with carboplatin and paclitaxel
11548444|NCT01015118|Placebo Comparator|Placebo|patients to receive capsules identical to those containing BIBF 1120 in combination with combination with carboplatin and paclitaxel
11548445|NCT01015105||patients with hip fracture|
11548446|NCT01015092||unselected HIV outpatient attendees|All HIV patients attending for general HIV care at 2 London Hospitals
11548447|NCT01015079||Entire Taiwan women|
11548448|NCT01015066|Active Comparator|buprenophine/naloxone|Participants with this arm will receive 4-16 mg/d buprenorphine/naloxone (Suboxone).
11548449|NCT01015066|Experimental|Naltrexone|Participants assigned to this arm will receive 50 mg/d naltrexone.
11548450|NCT01015053|Experimental|Regional block|"An ultrasound-guided rectus sheath block will be performed by the regional block anesthesiologist in the regional block arm."
11548451|NCT01015053|Active Comparator|Wound infiltration|"Local wound infiltration will be performed by the surgeon in the wound infiltration arm."
11548452|NCT01015040|Active Comparator|solifenacin succinate tablet (fasting)|
11548453|NCT01015040|Experimental|solifenacin succinate suspension (fasting)|
11548454|NCT01015040|Experimental|solifenacin succinate suspension (fed)|
11548455|NCT01015027|Experimental|Dose 1|(3:1, active:placebo)
11548456|NCT01015027|Experimental|Dose 2|(3:1, active:placebo)
11548457|NCT01015027|Experimental|Dose 3|(3:1, active:placebo)
11548458|NCT01015027|Experimental|Dose 4|(3:1, active:placebo)
11548459|NCT01015014|Active Comparator|AN3365|
11548460|NCT01015014|Placebo Comparator|Saline|
11548461|NCT01015001|Active Comparator|Active rTMS|1Hz rTMS sessions applied to the left temporoparietal cortex of the subjects
11548462|NCT01015001|Placebo Comparator|Sham rtms|Same number of pulses but applied with and angled coil (90 degrees) and placed over the fronto´temporal region
11548463|NCT01014988|Other|Single Arm|A single arm open-label design has been selected to achieve the primary objective of providing regulatory authorities with safety data on IV zanamivir in an expedited manner. This study design also facilitates the provision of safety data on a real-time basis, if necessary.
11548464|NCT01014975|Experimental|20 mg Plasmin (Human)|20 mg of Plasmin (Human)
11548465|NCT01014975|Experimental|40 mg Plasmin (Human)|40 mg of Plasmin (Human)
11548466|NCT01014975|Experimental|80 mg Plasmin (Human)|80 mg of Plasmin (Human)
11548467|NCT01014962|Experimental|Albaconazole 400 mg cohort 1|Albaconazole 400 mg
11548468|NCT01014962|Placebo Comparator|Placebo cohort 1|Placebo once daily
11548469|NCT01014962|Experimental|Albaconozole 400 mg cohort 2|Albaconozole 400 mg every 12 hours
11548470|NCT01014962|Placebo Comparator|Placebo cohort 2|Placebo every 12 hours
11548471|NCT01014962|Experimental|Albaconozole 400 mg cohort 3|Albaconozole 400 mg every 8 hours
11548472|NCT01014962|Placebo Comparator|Placebo cohort 3|Placebo every 8 hours
11548473|NCT01014949|Other|Control, Diabetes and Metabolic Syndrome|
11548474|NCT01014936|Experimental|MSC2156119J Regimen 1|Subjects will be administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.
11548475|NCT01014936|Experimental|MSC2156119J Regimen 2|Subjects will be administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.
11548476|NCT01014936|Experimental|MSC2156119J Regimen 3|Subjects will be administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.
11548477|NCT01014923|Experimental|Intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
11548478|NCT01014923|No Intervention|Control|Parents receive a Department of Transportation booklet on teen driving
11548479|NCT01014910|Active Comparator|Continuous pulse oximetry monitoring|Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.
11548480|NCT01014910|Active Comparator|Intermittent pulse oximetry monitoring|Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
11548481|NCT01014897|Experimental|subcortical|Subcortical stroke patients will receive tDCS stimulation and sham in random order
11548482|NCT01014897|Experimental|cortical|subjects will receive active and sham tDCS in random order
11548483|NCT01014884|Other|Control Group|The control group will receive usual care as provided by your Health Plan.
11548484|NCT01014884|Other|Intervention group|Additional visits will be conducted by a member of the multidisciplinary team (case manager/nurse, social worker and/or pharmacist that will be either face to face or by telephone.
11548485|NCT01014871|Other|intra-individual comparison|
11548486|NCT01014858|Experimental|Donepezil|5mg of Donepezil for the first 8 weeks raising to 10mg thereafter if patient adjusted to 5mg dose. 10mg does continues for the remainder of the study.
11548487|NCT01014858|Placebo Comparator|Placebo|Patient commences medication to match appearance of 5mg donepezil for first 8 weeks then 10mg for the remainder of the study.
11548488|NCT01014845|Experimental|Hepatitis E vaccine|Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
11548489|NCT01014845|Placebo Comparator|HBV vaccine|Hepatitis B vaccine, containing 5mcg of HBsAg recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
11548490|NCT01014832|Experimental|Uncontrolled diabetes|Uncontrolled diabetes
11548491|NCT01014806|Experimental|Low dose|
11548492|NCT01014806|Experimental|High dose|Investigational Influenza VLP Vaccine 60ug/strain
11548493|NCT01014806|Active Comparator|TIV|Trivalent Influenza Vaccine 15ug/strain, Commercially Licenced
11548494|NCT01014793||Responders to cabergoline|patients with active disease under octreotide treatment received addition of increasing doses of cabergoline (1.0, 2.0 and 3.5mg/week)
11548495|NCT01014780||Normal (non-dry) dry eye subjects|These are healthy individuals, age 18 and above, who do not exhibit dry eyes by signs and symptoms
11548496|NCT01014780||Dry eye subjects|These are subjects, age 18 years and above, who do exhibit signs and symptoms of dry eye.
11548497|NCT01014767|Experimental|Standard Arm (1)|Alternating chemotherapy cycles with etoposide 100 mg/m2 over 1 hour on days 1-5, carboplatin 350 mg/m2 over 2 hours on day 2 and 3, vincristine 1.5 mg/m2 on day 5 alternating with: etoposide 100 mg/m2 over 1 hour on days 1-5, cyclophosphamide 1 g/m2 over 1 hour on day 2 and 3, vincristine 1.5 mg/m2 on day 5. Six blocks are given in 4 week intervals (day1 to day1). Radiation is given between the second and the third cycle only to a small subgroup of patients defined by age histology staging and response to the first to cycles of chemotherapy.
11548498|NCT01014767|Experimental|Doxorubicin/cisplatin arm (2)|Doxorubicin 25 mg/m²/day over 12 hrs on days 1-3, Dactinomycin 45 µg/kg/day (max. 2 mg), i.v. on day 1, and Cisplatin 70 mg/m²/d over 6 hrs on day 4, and Vincristine 1.5 mg/m²/day (max. 2 mg), i.v. on days 8, 15. An identical second cycle is started on day 28 if the side effects allow it. The further treatment is identical to the standard arm with four more cycles of chemotherapy following radiation in some of the patients in all treatment arms.
11548499|NCT01014767|Experimental|Methotrexate Arm (3)|Methotrexate 5g/m^2 over 24 hours with leucovorin rescue at hour 42 given three times on days 1 15 and 29. The further treatment is identical in all four treatment arms.
11548500|NCT01014767|Experimental|Temozolomide Irinotecan arm (4)|Temozolomide is given at 150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day x 5 days as one hour infusions. Two of these cycles are followed by the common radiation - four cycle chemotherapy protocol.
11548501|NCT01014754||NSF|Biopsy-proven diagnosis of NSF
11548502|NCT01014754||Kidney dysfunction plus gadolinium exposure|Those on dialysis or with eGFR ≤ 30 ml/min/1.73 m2 who have had a medical imaging procedure using GBCA in the 2 years prior to skin biopsy.
11548503|NCT01014754||Kidney dysfunction without gadolinium exposure|Those on dialysis or with eGFR ≤ 30 ml/min/1.73 m2 who have never been exposed to GBCA and have had skin biopsy.
11548504|NCT01014754||Normal kidney function with gadolinium exposure|Those with normal kidney function who have undergone a medical imaging procedure using Gd-based contrast agent (GBCA) in the 2 years prior to a skin biopsy.
11548505|NCT01014754||Normal kidneys without gadolinium exposure|Those with normal kidney function who have never been exposed to GBCA and have had a skin biopsy.
11548506|NCT01014754||Controls|Existing skin tissue from neonatal skin (<6 months) will be used as controls, as they presumably have never been exposed to gadolinium
11548507|NCT01014741|Experimental|Ibutilide arm|
11548508|NCT01014741|Placebo Comparator|Placebo arm|
11548509|NCT01014728|Active Comparator|Intravenous anesthesia|Intravenous anesthesia with propofol for endoscopic sinus surgery
11548510|NCT01014728|Active Comparator|Inhalation anesthesia|Inhalation anesthesia with sevoflurane for endoscopic sinus surgery
11548511|NCT01014715|Other|Single Arm|Phase II-Preoperative Radiation followed by Lumpectomy
11548512|NCT01014702|Experimental|Laser Treatment|
11548513|NCT01014702|Active Comparator|Phacoemulsifcation|
11548514|NCT01014689|Active Comparator|Adapalene 0.1% / BPO 2.5% gel|
11548515|NCT01014689|Placebo Comparator|Adapalene 0.1% / BPO 2.5% Vehicle Gel|
11548516|NCT01014676|Active Comparator|Probiotic milk|
11548517|NCT01014676|Placebo Comparator|Standard milk|
11548518|NCT01014663|Active Comparator|Therapeutic Exercise|
11548519|NCT01014663|Active Comparator|Non-Contact Boxing Training|
11548520|NCT01014650|Placebo Comparator|IV normal saline|Single IV dose of normal saline as a control for safety and tolerability observations
11548521|NCT01014650|Experimental|IV GLYX-13|Single IV dose of GLYX-13
11548522|NCT01014650|Experimental|SC GLYX-13|Single SC dose
11548523|NCT01014637|Active Comparator|Amorolfine 5%|
11548525|NCT01014624|Experimental|prasugrel|prasugrel 10mg administered for 7 days
11548526|NCT01014624|Active Comparator|clopidogrel|clopidogrel 75mg administered for 7 days
11548527|NCT01014611||Class II NYHA Heart Failure|Fraction of ejection between 40% and 30%
11548528|NCT01014611||Class III NYHA Heart Failure|Fraction of ejection lower than 30%
11548529|NCT01014611||Healthy volunteers|Matched with patients on age and physical activity
11548530|NCT01014598|Experimental|Treatment (cisplatin)|Patients receive cisplatin intra-arterially via isolated lung suffusion over 2 hours. Beginning approximately 2 weeks later (6-8 weeks if indicated for patients with sarcoma undergoing surgery after cisplatin), patients receive standard chemotherapy regimen.
11548531|NCT01014585|Placebo Comparator|1|Placebo tablets administered orally twice daily
11548532|NCT01014585|Experimental|2|Milnacipran tablets administered orally twice daily
11548533|NCT01014572|Experimental|Aerobic Exercise Training + Placebo|
11548534|NCT01014572|Experimental|Tai Chi and/or Yoga Training + Placebo|
11548535|NCT01014572|Experimental|Aerobic Exercise Training + Alagebrium|
11548536|NCT01014572|Experimental|Tai Chi and/or Yoga Training + Alagebrium|
11548537|NCT01014559|Active Comparator|Prolonged release tablet|OxyCodone Naloxone controlled release tablet
11548538|NCT01014559|Active Comparator|Tablet|Oxycodone PR Tablets
11548539|NCT01014546|Experimental|Treatment (arsenic trioxide with or without ascorbic acid)|Patients receive arsenic trioxide PO QD in orange juice on days 1-21. Patients may also receive ascorbic acid PO QD on days 1-21. Treatment repeats every 28 days for up to 168 days in the absence of disease progression or unacceptable toxicity.
11548540|NCT01014533|Placebo Comparator|Placebo|After 3 nights in the UM sleep lab and randomization, this arm receives placebo for one week. They then return to the sleep lab for the same procedures.
11548541|NCT01014533|Active Comparator|Gabapentin|After spending 3 baseline nights in the UM sleep lab, alcohol dependent subjects are randomized. This arm receives gabapentin . On nights 1 and 2 of medication, the dose is 600 mg by mouth 30 min before bedtime. On nights 3-10, the dose is 1200 mg by mouth 30 min before bedtime. On nights 8-10 of medication, subjects return to the UM sleep lab and complete 3 sleep nights with the same procedures. On night 11, the dose is reduced to 600 mg by mouth 30 min before bedtime, and then stopped.
11548542|NCT01014520|Experimental|Gabapentin|Neurontin
11548543|NCT01014520|Experimental|Amitriptyline|Elavil
11548544|NCT01014507|Active Comparator|A|
11548545|NCT01014507|Experimental|B|
11548546|NCT01014494|Experimental|Active - Adaprev|Adaprev (Class III medical device)
11548547|NCT01014494|No Intervention|Standard Care|No different treatment to normal
11548548|NCT01014481|Experimental|start antiretroviral treatment|the optimal timing to initiate antiretroviral therapy in HIV-infected patients who are receiving tuberculosis treatment between at 4 weeks and at 12 weeks after tuberculosis treatment
11548549|NCT01014468|Active Comparator|Ranibizumab|Intravitreal injection of Ranibizumab (3 monthly injection followed by monthly injections as long as required)
11548550|NCT01014468|Active Comparator|Bevacizumab|Intravitreal injection of Bevacizumab (3 monthly injection followed by monthly injections as long as required)
11548551|NCT01014455|Experimental|CO reminder|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
11548552|NCT01014455|Placebo Comparator|no CO reminder|a brief intervention that recommends fasting but does not mention that CO will be checked
11548553|NCT01014442|Experimental|Mycophenolate Mofetil; Cystic Fibrosis|Participants with cystic fibrosis will receive mycophenolate mofetil 1.5 g, orally (PO), BID from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.
11548554|NCT01014442|Experimental|Mycophenolate Mofetil; Other|Participants with COPD, emphysema, idiopathic pulmonary fibrosis, or A1AD will receive mycophenolate mofetil 1.5 g, PO, BID, from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.
11548555|NCT01014429|Experimental|1|
11548556|NCT01014416|Experimental|Arm 1|Single dose, Tolvaptan 15mg or Placebo/day
11548557|NCT01014416|Experimental|Arm 2|Single dose, Tolvaptan 30mg or Placebo/day
11548558|NCT01014416|Experimental|Arm 3|Single dose, Tolvaptan 60mg or Placebo/day
11548559|NCT01014403|Experimental|enoxaparin 30 mg SQ q12 hours|Enoxaparin started at 24 hours post-injury and continued until 96 hours post-injury.
11548560|NCT01014403|Placebo Comparator|placebo|vehicle administered sq q 12 hours
11548561|NCT01014390|Experimental|WallFlex Biliary RX FC Stent System|The WallFlex Biliary RX Fully Covered Stent System is being evaluated for treatment of benign biliary strictures.
11548562|NCT01014364|Experimental|Corticosteroids|Hydrocortisone
11548563|NCT01014364|Placebo Comparator|Control|isotonic saline
11548564|NCT01014351|Experimental|Paclitaxel/Carboplatin/Everolimus|Systemic Therapy using everolimus, paclitaxel and carboplatin given during a 21-day treatment cycle
11548565|NCT01014338|Active Comparator|ACE-inhibitor|
11548566|NCT01014338|Placebo Comparator|Sugar Pill|
11548567|NCT01014325|Experimental|Allergen extract|
11548568|NCT01014325|Placebo Comparator|Placebo|
11548569|NCT01014312|Experimental|Depression Care Management (DCM)|Participants will receive Depression Care Management.
11548570|NCT01014312|Active Comparator|Enhanced Care|Participants will receive the standard of care from their primary care physicians enhanced by a summary of the study's diagnostic interview.
11548571|NCT01014286||Advanced Adenocarcinoma|Stage IV adenocarcinoma who have undergone biopsy with remnant tissue.
11548572|NCT01014273|Active Comparator|Trans-femoral access|Femoral artery PCI access site
11548573|NCT01014273|Active Comparator|Trans-radial access|Radial artery PCI access site
11548574|NCT01014260|Placebo Comparator|Placebo|placebo
11548575|NCT01014260|Active Comparator|Doxycycline|Doxycycline
11548576|NCT01014247|Active Comparator|Arm 1|
11548577|NCT01014247|Placebo Comparator|Arm 2|
11548578|NCT01014234|Experimental|Rapamycin|Maintenance treatment with rapamycin + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.
11548579|NCT01014234|Active Comparator|cyclosporine|Maintenance treatment with cyclosporine + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.
11548580|NCT01014221|Experimental|Acupuncture group|acupuncture administered in 8 sessions over 4 weeks
11548581|NCT01014221|Active Comparator|Steroid group|2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
11548582|NCT01014208|Experimental|OFATUMUMAB + DHAP CHEMOTHERAPY REGIMEN|This study is a parallel arm study, with ofatumumab + DHAP. The Investigators are required to prospectively choose to treat all of their subjects with either DHAP chemotherapy regimens in combination with ofatumumab. All subjects will receive the same ofatumumab regimen and dose.
11548583|NCT01014208|Active Comparator|RITUXIMAB + DHAP CHEMOTHERAPY REGIMEN|This study is a parallel arm study, with rituximab + DHAP. The Investigators are required to prospectively choose to treat all of their subjects with either DHAP chemotherapy regimens in combination with rituximab. All subjects will receive the same rituximab regimen and dose.
11548584|NCT01014195||Group 1|"Survivors of pediatric leukemia treated on Total Therapy Protocol XV (TOTXV) at St. Jude Children's Research Hospital (SJCRH), who are ≥ 8 years of age and ≥ 5 years from diagnosis.
~Intervention: Neurocognitive and behavioral evaluation"
11548585|NCT01014182||Early PCI|Routine invasive strategy with early PCI performed in STEMI patients within 24 hours from successful fibrinolysis
11548586|NCT01014182||Standard Therapy|Standard therapy in STEMI patients with fibrinolysis and/or conventional ischaemic-guided therapy.
11548587|NCT01014169|No Intervention|Usual care|Mothers in the control group will receive the nursing discharge newborn information from the nurse practitioner [sometimes via a Spanish interpreter, if required] according to current standard of care, which includes verbal information and written handouts.
11548588|NCT01014169|Experimental|Note taking|The mothers in the intervention group will be given a pen and encouraged to take written notes in the notes section of the discharge envelope using their language of preference when receiving the standard newborn information.
11548589|NCT01014156|Experimental|epoprostenol intraveneously|epoprostenol iv versus placebo iv, both on top of low molecular weight heparin
11548590|NCT01014143|Placebo Comparator|Fluoride toothpaste|Negative control
11548591|NCT01014143|Active Comparator|Triclosan/Fluoride toothpaste|positive control toothpaste
11548592|NCT01014143|Active Comparator|Chlorhexidine Oral Rinse|Positive Control mouthrinse
11548593|NCT01014130|Active Comparator|Arm 2|Conventionally Fractionated Radiotherapy (ConRT) - Standard of Care
11548594|NCT01014130|Experimental|Arm 1|Hypofractionated radiotherapy (HypoRT) - Investigational
11548595|NCT01014117|Placebo Comparator|Placebo|"The Placebo treatment group will be administered eight oral placebo capsules once daily for 7 days.
~A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days."
11548596|NCT01014117|Active Comparator|Placebo and 2.0g SRT2104|This treatment group will be administered eight oral placebo capsules once daily for 6 days followed by 2.0g SRT2104 administered as eight oral SRT2104 capsules on Day 7. A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days.
11548597|NCT01014117|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered eight oral SRT2104 capsules once daily for 7 days. A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days.
11548598|NCT01014104|Experimental|Case|Administration of Methylprednisolone
11548599|NCT01014104|Sham Comparator|Control|
11548600|NCT01014091|Experimental|GSK2340272A F1 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 1 (F1) in the deltoid region of the arm, according to a 0-21 day schedule.
11548601|NCT01014091|Experimental|GSK2340272A F1 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 1 (F1) in the deltoid region of the arm, according to a 0-21 day schedule.
11548602|NCT01014091|Experimental|GSK2340272A F2 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 2 (F2) in the deltoid region of the arm, according to a 0-21 day schedule.
11548603|NCT01014091|Experimental|GSK2340272A F2 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 2 (F2) in the deltoid region of the arm, according to a 0-21 day schedule.
11548604|NCT01014091|Experimental|GSK2340272A F3 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 3 (F3) in the deltoid region of the arm, according to a 0-21 day schedule.
11548640|NCT01013831|Experimental|Prevention (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
11548605|NCT01014091|Experimental|GSK2340272A F3 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 3 (F3) in the deltoid region of the arm, according to a 0-21 day schedule.
11548606|NCT01014078|Experimental|Azithromycin Ophthalmic Solution, 1%|
11548607|NCT01014078|Placebo Comparator|Placebo|
11548608|NCT01014065||1|Patients with renal cell carcinoma scheduled to receive sunitinib
11548609|NCT01014039|Active Comparator|Flexible Sigmoidoscopy Screening arm|Intervention by flexible sigmoidoscopy screening
11548610|NCT01014039|No Intervention|Control arm|No intervention (no screening)
11548611|NCT01014013|Experimental|ertapenem sodium (MK0826)|ertapenem sodium
11548612|NCT01014013|Active Comparator|ceftriaxone sodium|ceftriaxone sodium
11548613|NCT01014000|Active Comparator|Empirical|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
11548614|NCT01014000|Experimental|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
11548615|NCT01013974|Experimental|GSK573719 250 microgram (μg) arm|Each subject will receive the first dose of GSK573719 250 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
11548616|NCT01013974|Experimental|GSK573719 500 μg arm|Each subject will receive the first dose of GSK573719 500 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
11548617|NCT01013974|Experimental|GSK573719 1000 μg arm|Each subject will receive the first dose of GSK573719 1000 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
11548618|NCT01013974|Placebo Comparator|Placebo|Each subject will receive GSK573719 matching placebo on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
11548619|NCT01013961|Active Comparator|Arm A (standard dose)|"Patients receive alemtuzumab subcutaneously (SC) on days 1-3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 and standard-dose rituximab 375 mg/m^2/week intravenously (IV) on days 8, 15, 22, and 29 in cycle 1 (33-day cycle). In cycle 2 and subsequent cycles (28-day cycle), patients receive alemtuzumab SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 and standard-dose rituximab IV on days 3, 10, 17, and 24. Treatment repeats every 28 days for up to 3 cycles.
~Alemtuzumab dose for cycle 1 week 1 requires a 'dose ramp' (3 mg day 1, 10 mg day2, and 30 mg day 3 of cycle 1) and then is 30 mg 3 times a week."
11548620|NCT01013961|Experimental|Arm B (low dose)|"Patients receive alemtuzumab SC on days 1-3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 and low-dose rituximab at 20 mg/m^2 IV on days 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 in cycle 1 (33-day cycle). In cycle 2 and subsequent cycles (28-day cycle), patients receive alemtuzumab SC and low-dose rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 3 cycles.
~Alemtuzumab dose for cycle 1 week 1 requires a 'dose ramp' (3 mg day 1, 10 mg day2, and 30 mg day 3 of cycle 1) and then is 30 mg 3 times a week."
11548621|NCT01013948||N/A (Survey study)|
11548622|NCT01013935|Active Comparator|Full CARE+ Spanish computer-counseling group|
11548623|NCT01013935|Active Comparator|Brief risk assessment study group only (control)|
11548624|NCT01013922||No treatment|Patients with a smoking history of 15 pack years or more.
11548625|NCT01013909|Experimental|Arm 1|
11548626|NCT01013909|Experimental|Arm 2|
11548627|NCT01013909|Placebo Comparator|Arm 3|
11548628|NCT01013909|Placebo Comparator|Arm 4|
11548629|NCT01013909|Active Comparator|Arm 5|
11548630|NCT01013896|Active Comparator|Cystic Fibrosis Education|This intervention is designed to increase knowledge and enhance the skills needed to optimize CF-management. The strategies used to achieve improved adherence include providing didactic education and skills training, and proscriptively using behavioral modification strategies, such as positive reinforcement for desired behaviors, and problem-solving training to overcome barriers.
11548631|NCT01013896|Experimental|Motivational Interviewing|The Counselor's overarching goal for the intervention is to motivate and assist the participant to improve his/her adherence to the CF pulmonary medications. The intervention will begin by providing the patient personal feedback on their adherence (using pharmacy refill data) and health outcomes (e.g., trajectory of lung function values, frequency of exacerbations) as well as clinic-level figures showing the association between adherence and health outcomes.
11548632|NCT01013883||systolic dysfunction|patients having left ventricular systolic dysfunction on echocardiography
11548633|NCT01013883||distolic heart failure|patients with clinical heart failure and preserved LV systolic dysfunction
11548634|NCT01013870|Experimental|MTBI subjects randomized to drug|"Of 200 MTBI subjects enrolled, 1:1 randomization will be used to assign half (i.e 100) to the treatment arm of the phase II drug trial of atorvastatin. These subjects will receive a daily weight-based dose of atorvastatin 1mg/kg (up to 80 mg) for seven days and started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving a placebo.
~NOTE: The 100 Orthopedic Injury subjects recruited for and participating in the Observational studies are not included in the Medication study portion of this protocol."
11548635|NCT01013870|Placebo Comparator|MTBI subjects randomized to placebo|"Of 200 MTBI subjects enrolled, 1:1 randomization will be used to assign half (i.e 100) to the placebo arm of the phase II drug trial of atorvastatin. These subjects will receive a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug.
~NOTE: The 100 Orthopedic Injury subjects recruited for and participating in the Observational studies are not included in the Medication study portion of this protocol."
11548636|NCT01013857|Active Comparator|Health coaching|Phone patients every week to discuss medication adherence
11548637|NCT01013857|Experimental|Health coaching plus home-titration|Health coaches call patients every week to discuss medication adherence and to intensify medications if appropriate according to physician-created algorithm
11548638|NCT01013844|Active Comparator|Solo Learning|Participant learning alone (without partner).
11548639|NCT01013844|Active Comparator|Dyadic Learning|Participant and partner learning together.
11548641|NCT01013818|Experimental|HGS1029|
11548875|NCT01012102|Experimental|Group 1|EMD 640744 30μg and Montanide® ISA 51 VG
11548642|NCT01013805|Experimental|Arm 1|Integrated Preoperative Radiotherapy (external beam radiotherapy) and Chemotherapy (Oxaliplatin, Fluorouracil and Leucovorin), then surgical resection.
11548643|NCT01013792|Experimental|Non-adherent Wound Dressing|The non-adherent dressing is the same as the Tegaderm Matrix dressing, with potassium chloride, rubidium chloride, calcium chloride, zinc chloride, potassium citrate and citric acid removed. This dressing is a Class I medical device (21 CFR Sec. 878.4020 Occlusive wound dressing) that is exempt from premarket notification procedures.
11548644|NCT01013792|Active Comparator|Tegaderm Matrix Dressing with PHI|A commercial wound dressing to be used per manufacturer's instructions for use.
11548645|NCT01013779|Experimental|Arm A|Conventional radical radiotherapy in this trial means that those patients with microscopic disease receive a dose of 50Gy using daily incremental fractions of 2Gy over 25 fractions and those with macroscopic disease receive 54Gy in 27 fractions.
11548646|NCT01013766|Other|AM/PM/BID|Subjects will receive a dose of 100mg in the AM on Day 1, followed by a dose of 100mg in the PM on Day 4, and a dose of 50mg BID on Day 6.
11548647|NCT01013766|Other|PM/AM/BID|Subjects will receive a dose of 100mg in the PM on Day 1, followed by a dose of 100mg in the AM on Day 4, followed by 50mg BID on Day 6.
11548648|NCT01013753|Experimental|Olodaterol (BI 1744) low|Low dose inhaled orally once daily from the Respimat inhaler
11548649|NCT01013753|Experimental|Olodaterol (BI 1744) very low|Very low dose inhaled orally once daily from the Respimat inhaler
11548650|NCT01013753|Experimental|Olodaterol (BI 1744) medium|Medium dose inhaled orally once daily from the Respimat inhaler
11548651|NCT01013753|Experimental|Olodaterol (BI 1744) high|High dose inhaled orally once daily from the Respimat inhaler
11548652|NCT01013753|Active Comparator|Formoterol 12 mcg|12mcg inhaled twice daily from the Aerolizer inhaler
11548653|NCT01013753|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
11548654|NCT01013740|Experimental|Lapatinib + Vinorelbine|Lapatinib + Vinorelbine
11548655|NCT01013740|Active Comparator|Lapatinib + Capecitabine|Lapatinib + Capecitabine
11548656|NCT01013727|Experimental|Postural Reconstruction|
11548657|NCT01013727|Active Comparator|muscular stretching|
11548658|NCT01013714|Active Comparator|Routine Care + Cardiac Sympathetic Denervation (CSD)|"Patients in this arm receive routine care and undergo cardiac sympathetic denervation. The procedure must be scheduled to occur within one month of randomization.
~Follow-up Visits
~Follow up at 4 weeks after optimization of medical therapy and surgery
~All patients are followed at the ICD clinic at 7 months or as needed.
~Information regarding ICD therapy and arrhythmias will be obtained from ICD interrogations at the follow up visits.
~Monthly phone calls will be used to determine for interval events, including presence of side-effects.
~VT Ablation is permitted in both arms for ICD shock after optimization."
11548659|NCT01013714|Placebo Comparator|Routine Care|"Patients in this arm remain on prescribed drug regimen and will not undergo CSD.
~Follow-up Visits
~Medical follow up at 4 weeks after optimization of medical therapy.
~All patients are followed at the ICD clinic at 7 months or as needed.
~Information regarding ICD therapy and arrhythmias will be obtained from ICD interrogations at the follow up visits.
~Monthly phone calls will be used to determine for interval events, including presence of side-effects.
~VT Ablation is permitted in both arms for ICD shock after optimization."
11548660|NCT01013701|Active Comparator|Fluticasone Furoate|nasal steroid
11548661|NCT01013701|Placebo Comparator|Placebo|nasal spray vehicle without drug
11548662|NCT01013688|Experimental|left atrial RF ablation groups|Excised the left atrial appendage Encircling the left pulmonary veins and an extension to the posterior mitral valve annulus From the left atrial appendage to the left superior pulmonary vein A connecting line between both islands of pulmonary veins From the middle of the mitral valve ablation line down towards the base of the atria ligament of Marshall
11548663|NCT01013688|Experimental|Bi-atrial radiofrequency ablation group|In the basis of left atrial group,excised the right atrial appendage; from the amputated right atrial appendage towards the inferior vena cava; from the midterm of interatrial septum to the AV groove; ablation between the superior and inferior caval cannulation sites; radiofrequency ablation for Waterston's groove
11548664|NCT01013688|No Intervention|Amiodarone group|No radiofrequency ablation procedure during the valve surgery; Amiodarone 200 mg/day for 12 months after surgery
11548665|NCT01013675|Experimental|1|15 mcg hemagglutinin (HA) per viral strain; 0.5 mL single dose
11548666|NCT01013675|Active Comparator|2|15 mcg hemagglutinin (HA) per viral strain; 0.5 mL single dose
11548667|NCT01013662|Active Comparator|glycemic control between 180 and 220 mg/dl|
11548668|NCT01013662|Active Comparator|glycemic control for levels between 80 and 110 mg/dl|
11548669|NCT01013649|Active Comparator|Arm I (gemcitabine hydrochloride or combination chemotherapy)|Patients receive either gemcitabine hydrochloride or allowable combination chemotherapy per standard of care for 5 months.
11548670|NCT01013649|Experimental|Arm II (gemcitabine hydrochloride, erlotinib hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 4/2/14)
11548671|NCT01013649|Experimental|Arm III (chemotherapy)|Patients receive the same treatment as in arm I for 1 month.
11548672|NCT01013649|Experimental|Arm IV (chemotherapy, chemoradiotherapy)|Patients receive the same treatment as in arm I for 1 month. Beginning within 7-21 days after completion of chemotherapy, patients undergo radiotherapy (3-dimensional conformal radiotherapy or intensity-modulated radiotherapy) 5 days per week for 5.5 weeks (28 fractions). During radiotherapy, patients receive either capecitabine PO BID 5 days per week or fluorouracil IV continuously for 5.5 weeks or until radiotherapy is completed.
11548673|NCT01013636||Anaplasma|
11548674|NCT01013623|Active Comparator|Best Medical Therapy|The best medical therapy group will not initially undergo surgery, but will be treated with the therapy that medical oncologists or surgeons feel is best for the patient. This treatment may include standard or experimental therapies.
11548675|NCT01013623|Active Comparator|Surgery Alone|The surgery alone group will undergo complete resection (surgical removal) of all known disease, if possible. After surgery, patients will be followed regularly and monitored for disease recurrence.
11548804|NCT01012752|Active Comparator|modified allergen extract|
11548676|NCT01013623|Active Comparator|Surgery + BCG|The Surgery + BCG group will first have a complete resection (surgical removal) of all known disease, if possible. After recovery from surgery, two doses of BCG will be given two weeks apart. Each dose is given as 8 separate injections into the skin (called intradermal injections).
11548677|NCT01013610|Active Comparator|Multiple Dose|
11548678|NCT01013610|Placebo Comparator|Placebo|
11548679|NCT01013597|Experimental|LBH589|
11548680|NCT01013584|Active Comparator|1,000 IU|1,000 IU/day of vitamin D3
11548681|NCT01013584|Active Comparator|5,000 IU|5,000 IU/day of vitamin D3
11548682|NCT01013584|Active Comparator|10,000 IU|10,000 IU/day of vitamin D3
11548683|NCT01013571|Experimental|1|12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; health care professional-managed
11548684|NCT01013571|Experimental|2|12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; patient-managed
11548685|NCT01013558|Active Comparator|remifentanil|
11548686|NCT01013558|Placebo Comparator|saline|
11548687|NCT01013545|Experimental|JAE-EMT|The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist. This intervention condition uses spoken language as the mode of communication. Individual, single word targets will be selected based on the child's level of language production and specific interests. The targets are systematically modeled in response to child actions and attention during play. A sequence of milieu teaching prompts will also be used to elicit targets from the child when use of the target language is functional for the child.
11548688|NCT01013545|Experimental|JAE-AAC|The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist. The mode of communication introduced in this intervention condition is a developmentally chosen augmentative communication device. These devices are provided with a set of individually selected visual-graphic symbols and a relevant lexicon. The use of the device is taught within natural communicative exchanges within play routines and daily activities.
11548689|NCT01013532|Experimental|Cilostazol+ Probucol|100mg cilostazol bid plus probucol plus placebo of aspirin
11548690|NCT01013532|Active Comparator|Aspirin + Probucol|aspirin plus placebo cilostazol plus probucol
11548691|NCT01013532|Experimental|Cilostazol|cilostazol plus placebo of aspirin
11548692|NCT01013532|Active Comparator|Aspirin|aspirin plus placebo of cilostazol
11548693|NCT01013506|Experimental|Letrozole +/-goserelin, OSI-906 (Arm I )|Patients receive oral letrozole once daily on days 1-28 plus subcutaneous goserelin (the latter for pre-menopausal women only) on day 1 and oral IGF-1R inhibitor OSI-906 twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11548694|NCT01013506|Experimental|Letrozole +/- goserelin, OSI-906, erlotinib (Arm II)|Patients receive oral letrozole and subcutaneous goserelin (the latter for pre-menopausal women only) and oral IGF-1R inhibitor OSI-906 as in arm I. Patients also receive oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11548695|NCT01013493||myopic|
11548696|NCT01013493||non myope-healthy|
11548697|NCT01013480|Active Comparator|STX209|
11548698|NCT01013467|Active Comparator|color coded bloodpressure booklet|
11548699|NCT01013454|Experimental|Varenicline transdermal delivery system|
11548700|NCT01013441|Experimental|Treatment Arm|
11548701|NCT01013415|Experimental|ARM 1|HAART, IL-2
11548702|NCT01013415|Experimental|ARM 2|HAART, T cells
11548703|NCT01013415|Experimental|ARM 3|HAART, IL-2, T cells
11548704|NCT01013402|Experimental|volunteers for insulin hypoglycemia test|None of the subjects had diabetes mellitus or any other metabolic diseases. They were not taking any medicine and they did not have anemia or polycythemia. Also none of the patients had any condition causing hypoxia or any compromise in peripheral circulation.
11548705|NCT01013389|Experimental|Actifuse ABX|Actifuse ABX bone substitute
11548706|NCT01013389|Active Comparator|INFUSE, plus master granules (MGG)|synthetic bone substitute used in posterolateral instrumented lumber fusion with interbody fusion
11548707|NCT01013376|Experimental|Active|Topical administration of MC-1101
11548708|NCT01013376|Placebo Comparator|Vehicle|Vehicle
11548709|NCT01013363|No Intervention|No music|Participants will not use the digital music player during their procedure.
11548710|NCT01013363|Experimental|Music|Participants will use the digital music player during their procedure.
11548711|NCT01013350||Never Exposed to Cladribine|All participants who received placebo matched to cladribine in previously conducted clinical trials (NCT Number: NCT00213135, NCT00436826 , NCT00641537, NCT00938366 and NCT00725985).
11548712|NCT01013350||Exposed to Cladribine|All participants who received cladribine in previously conducted clinical trials (NCT Number: NCT00213135, NCT00436826, NCT00641537, NCT00938366 and NCT00725985).
11548713|NCT01013337|Experimental|Arm I (Acupuncture)|Patients undergo 10, 20-minute sessions of acupuncture over 8 weeks (twice weekly for 2 weeks and 6 weekly treatments).
11548714|NCT01013337|Sham Comparator|Arm II (Placebo)|Patients undergo 10, 20-minute sessions of sham acupuncture treatments over 8 weeks (twice weekly for 2 weeks and 6 weekly treatments) via Streitberger needles at non-acupuncture points.
11548715|NCT01013337|No Intervention|Arm III (Control)|Wait-list control patients are contacted by phone at the same frequency as real and placebo acupuncture groups for data collection at weeks 1, 4, and 8.
11548716|NCT01013324|Experimental|Single Arm|All subjects will receive single-agent XL147 dosed daily
11548717|NCT01013311||Cardiac Sarcoidosis|Patients with Cardiac Sarcoidosis who had an ICD implanted
11548718|NCT01013298|Experimental|Video-guided PCT|Patients that will be extubated and re-intubated with the ETT-TVT, and monitored throughout intubation and PCT
11548719|NCT01013285|Experimental|bevacizumab, temozolomide, external beam radiation|
11548720|NCT01013272|Active Comparator|Entecavir|Ongoing entecavir 0.5mg daily
11548721|NCT01013272|Active Comparator|Lamivudine|Switch to lamivudine 100mg daily
11548722|NCT01013259|Placebo Comparator|Placebo|
11548723|NCT01013259|Experimental|Mutaflor|
11548724|NCT01013246|Experimental|Video game play|
11548725|NCT01013233|Experimental|training|Patients in this group start the cognitive training over 6 weeks directly after randomization.
11548726|NCT01013233|Placebo Comparator|control|In this control group begin the training in a cross-over design 7 weeks after randomization.
11548727|NCT01013220|Experimental|Depression Product Detailing|Employers receive education on how to purchase high quality depression management products to improve the quality of depression treatment depressed employees receive. Materials delivered in this arm of the study are available at www.caremanagementfordepression.org
11548728|NCT01013220|Placebo Comparator|Depression HEDIS Detailing|Employers receive education on how to obtain and use HEDIS depression indicators to encourage health plans to improve the quality of depression treatment depressed employees receive
11548729|NCT01013207|Experimental|Nexus (S9) CPAP device|"Fifty subjects with obstructive sleep apnea (OSA), established on CPAP therapy (≥ 6 months) were recruited into this study. These patients use their CPAP device every night while sleeping to treat their OSA.
~Nexus (S9) is a new CPAP device with improved humidification system (heated tube and climate control), reduced noise, improved comfort of breathing and new user interface. During the study, patients will use this CPAP every night in place of their own CPAP for a period of 4 weeks. Compliance data from the Nexus will then be compared to the patient's usual CPAP pre trialling Nexus and post trialling Nexus."
11548730|NCT01013194|Experimental|Treated patients|Cirrhotic patients treated with Human Fetal Liver Cell Transplantation.
11548731|NCT01013194|No Intervention|Control patients|Cirrhotic patients on Standard therapy.
11548732|NCT01013168|Experimental|OncoSorb® column|
11548733|NCT01013142|Experimental|MN-221|
11548734|NCT01013142|Placebo Comparator|MN-221 Placebo|
11548735|NCT01013116|Experimental|modified allergen extract of house dust mites|
11548736|NCT01013116|Placebo Comparator|Placebo|
11548737|NCT01013103|Other|Atorvastatin, Ischemic Heart Disease|
11548738|NCT01013103|Placebo Comparator|Atorvastatin vs Placebo Cardiac Surgery|
11548739|NCT01013090|Active Comparator|Epidural crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-epidural anesthesia in patients undergoing Cesarean section
11548740|NCT01013090|Active Comparator|Epidural colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-epidural anesthesia in patients undergoing Cesarean section
11548741|NCT01013090|Active Comparator|Spinal crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-spinal anesthesia in patients undergoing Cesarean section
11548742|NCT01013090|Active Comparator|Spinal colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-spinal anesthesia in patients undergoing Cesarean section
11548743|NCT01013090|Active Comparator|CSEA crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-CSEA anesthesia in patients undergoing Cesarean section
11548744|NCT01013090|Active Comparator|CSEA colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-CSEA anesthesia in patients undergoing Cesarean section
11548745|NCT01013077|Experimental|Optive|Commercial drop.
11548746|NCT01013077|Experimental|Soothe|Commercial drop.
11548747|NCT01013077|Experimental|New Emulsion|New formulation.
11548748|NCT01013064|Experimental|Cohort1|
11548749|NCT01013064|Experimental|Cohort2|
11548750|NCT01013064|Experimental|Cohort3|
11548751|NCT01013064|Experimental|Cohort4|
11548752|NCT01013064|Experimental|Cohort5|
11548753|NCT01013064|Experimental|Cohort6|
11548754|NCT01013051||Post Gastric Bypass|
11548755|NCT01013051||Obese Controls|age, BMI, gender matched
11548756|NCT01013038|Active Comparator|Conventional percutaneous coronary intervention|
11548757|NCT01013038|Experimental|Thrombus aspiration|
11548758|NCT01013025||Patients treated with Vantas implant|Patients were enrolled if they had had a Vantas implant placed for treatment of adenocarcinoma of the prostate, and if the patients were scheduled for explant of the implant, and the physician had difficulty locating the implant.
11548759|NCT01013012|Active Comparator|Group A|Group A : saline 1 ml + ramosetron 6μg/kg
11548760|NCT01013012|Experimental|Group B|Group B : dexamethasone 4 mg + ramosetron 6μg/kg
11548761|NCT01012999|Experimental|Intranasal sufentanil, pain relief|Intranasal sufentanil administered at a dose of 0.5 mcg/kg times one dose at beginning of thirty minute period
11548762|NCT01012986||2nd Grade|students of 2nd grade
11548763|NCT01012986||4th Grade|students of 4th Grade
11548764|NCT01012973|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.
11548765|NCT01012973|Sham Comparator|Sham treatment|Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.
11548766|NCT01012960|Placebo Comparator|Placebo|Placebo= normal saline
11548767|NCT01012960|Active Comparator|methylnaltexone|peripheral opioid antagonist
11548768|NCT01012947|Experimental|Lifestyle Counseling Usual Care|Usual care participants in the group A received no additional services.
11548769|NCT01012947|Experimental|Lifestyle Counseling Telephone, Bimonth|Participants in the group B received bimonthly telephonic care management based on manual.
11548770|NCT01012947|Experimental|Lifestyle Counseling Telephone, Month|Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.
11548771|NCT01012947|Experimental|Lifestyle Counseling Visit, Bimonth|Participants in the group D received health educator-initiated visit counseling bimonthly.
11548772|NCT01012947|Experimental|Lifestyle Counseling Visit, Reward|Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
11548773|NCT01012934|Experimental|1|Alendronate Sodium Tablets, 70 mg
11548774|NCT01012934|Active Comparator|2|Fosamax Tablets, 70 mg
11548805|NCT01012752|Placebo Comparator|Placebo|
11548946|NCT01011634|Active Comparator|Oral medication|
11548775|NCT01012921|Active Comparator|Bio-Gide® membrane|Bio-Gide® membrane This is a biodegradable bilayer membrane for bone and tissue regeneration. It has a natural collagen structure and is of porcine origin
11548776|NCT01012921|Experimental|MembraGel|MembraGel The Straumann membrane is a synthetic degradable barrier membrane
11548777|NCT01012908|Experimental|Norzyme|Pancreatic Enzymes - Norzyme (Bergamo)
11548778|NCT01012908|Active Comparator|Creon (Solvay)|Pancreatic Enzymes - Creon (Solvay)
11548779|NCT01012895|Experimental|Arm 1: Sentinel A|BMS-790052 (60mg) once daily + BMS-650032 (600 mg) twice daily
11548780|NCT01012895|Experimental|Arm 2: Sentinel B|BMS-790052 (60mg) once daily + BMS-650032 (600mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
11548781|NCT01012895|Experimental|Arm 3: Expansion A1|BMS-790052 (60mg) once daily + BMS-650032 (200mg) twice daily
11548782|NCT01012895|Experimental|Arm 4: Expansion A2|BMS-790052 (60mg) once daily + BMS-650032 (200mg) once daily
11548783|NCT01012895|Experimental|Arm 5: Expansion B1|BMS-790052 (60mg) once daily + BMS-650032 (200 mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
11548784|NCT01012895|Experimental|Arm 6: Expansion B2|BMS-790052 (60mg) once daily + BMS-650032 (200 mg) once daily + Pegylated-interferon alfa-2a + Ribavirin
11548785|NCT01012895|Experimental|Arm 7: Expansion B3|BMS-790052 (60 mg) once daily + BMS-650032 (200 mg) twice daily + Ribavirin
11548786|NCT01012882|Experimental|sublingual application of allergen extract|
11548787|NCT01012882|Placebo Comparator|sublingual application of placebo|
11548788|NCT01012869|Experimental|everolimus-eluting stent|patients undergoing treatment of a coronary chronic total occlusion (at least 3-months old) using everolimus-eluting stents (Xience, Abbott Vascular) or Promus (Boston Scientific)
11548789|NCT01012856|Active Comparator|Cognitive-Behavioral Therapy for Depression (CBT)|
11548790|NCT01012856|Experimental|Exposure-Based Cognitive Therapy for Depression (EBCT)|
11548791|NCT01012843|Active Comparator|Antibiotic|Patients who received antibiotic treatment after abscess drainage
11548792|NCT01012843|Placebo Comparator|Placebo|Patients who received placebo after abscess drainage
11548793|NCT01012830|Experimental|Huperzine A|200 micrograms (mcg) of HuperzineA taken twice daily.
11548794|NCT01012817|Experimental|Treatment (veliparib and topotecan hydrochloride)|Patients receive veliparib PO on days 1-3, 8-10, and 15-17 (veliparib is omitted on days 1-3 of course 2) and topotecan hydrochloride IV over 30 minutes on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11548795|NCT01012791|Experimental|Zumba exercise group|
11548796|NCT01012791|No Intervention|Non-Zumba exercise group|
11548797|NCT01012778|Experimental|Climbup ADHD and Dyslexia Program|"Open label - intervention with pre and post parameters collected
~Intervention: Yoga, Meditation, Play therapy for children with ADHD and Dyslexia twice a week in classroom with 6 week and 12 month, primary outcomes in terms of Vanderbilt ADHD scores"
11548798|NCT01012765|Experimental|Indacaterol - placebo - tiotropium|In treatment period 1, patients received indacaterol 150µg once daily; in treatment period 2, patients received placebo to indacaterol once daily; in treatment period 3, patients received tiotropium 18µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
11548799|NCT01012765|Experimental|Placebo - Tiotropium - Indacaterol|In treatment period 1, patients received placebo to indacaterol once daily; in treatment period 2, patients received tiotropium 18µg once daily; in treatment period 3, patients received indacaterol 150µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
11548800|NCT01012765|Experimental|Tiotropium - indacaterol - placebo|In treatment period 1, patients received tiotropium 18µg once daily; in treatment period 2, patients received indacaterol 150µg once daily; in treatment period 3, patients received placebo to indacaterol once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
11548801|NCT01012765|Experimental|Placebo - indacaterol - tiotropium|In treatment period 1, patients received placebo to indacaterol once daily; in treatment period 2, patients received indacaterol 150µg once daily; in treatment period 3, patients received tiotropium 18µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
11548802|NCT01012765|Experimental|Indacaterol - tiotropium - placebo|In treatment period 1, patients received indacaterol 150µg once daily; in treatment period 2, patients received tiotropium 18µg once daily; in treatment period 3, patients received placebo to indacaterol once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
11548803|NCT01012765|Experimental|Tiotropium - placebo - indacaterol|In treatment period 1, patients received tiotropium 18µg once daily; in treatment period 2, patients received placebo to indacaterol once daily; in treatment period 3, patients received indacaterol 150µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
11548806|NCT01012739|Experimental|Indacaterol 150μg-placebo-Indacaterol 60μg-Indacaterol 120μg|In treatment period 1, patients received indacaterol 150 μg via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received placebo to indacaterol via the Concept1 DPI; in treatment period 3, patients received indacaterol 60 μg via the Simoon DPI; and in treatment period 4, patients received indacaterol 120 μg via the Simoon DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
11548807|NCT01012739|Experimental|Indacaterol 60μg-Indacaterol 150μg-Indacaterol 120μg-placebo|In treatment period 1, patients received indacaterol 60 μg via the Simoon dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 150 μg via the Concept1 DPI; in treatment period 3, patients received indacaterol 120 μg via the Simoon DPI; and in treatment period 4, patients received placebo to indacaterol via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
11548808|NCT01012739|Experimental|Indacaterol 120μg-Indacaterol 60μg-placebo-Indacaterol 150μg|In treatment period 1, patients received indacaterol 120 μg via the Simoon dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 60 μg via the Simoon DPI; in treatment period 3, patients received placebo to indacaterol via the Concept1 DPI; and in treatment period 4, patients received indacaterol 150 μg via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
11548809|NCT01012739|Experimental|Placebo-Indacaterol 120μg- Indacaterol 150μg- Indacaterol 60μg|In treatment period 1, patients received placebo to indacaterol via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 120 μg via the Simoon DPI; in treatment period 3, patients received indacaterol 150 μg via the Concept1 DPI; and in treatment period 4, patients received indacaterol 60 μg via the Simoon DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
11548810|NCT01012713|Experimental|Open-Label Treatment|All patients will receive treatment with Clobex Spray, Vectical Ointment, and Excimer Laser
11548811|NCT01012700|No Intervention|intranasal or IV|Each study group consists of 12 volunteers randomized in a 2:1 ratio to receive poly ICLC or placebo: in group 1, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, subcutaneously; and in group 2, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, intranasally. A total of up to 24 volunteers will be enrolled in the study.
11548812|NCT01012700|Active Comparator|Hiltonol (poly ICLC)|Each study group consists of 12 volunteers randomized in a 2:1 ratio to receive poly ICLC or placebo: in group 1, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, subcutaneously; and in group 2, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, intranasally. A total of up to 24 volunteers will be enrolled in the study.
11548813|NCT01012674|Experimental|Dotarem and TOF MRA|Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.
11548814|NCT01012661|Experimental|Radiesse® Mixed with Lidocaine|Injectable Dermal Filler. The same 50 participants received both the treatment device and the control device at the same time (left and right sides of face).
11548815|NCT01012661|Active Comparator|Radiesse® without Lidocaine|Injectable Dermal Filler. The same 50 participants received both the treatment device and the control device at the same time (left and right sides of face.
11548816|NCT01012635||Neurofeedback, tDCS (2 levels), Self-hypnosis, Meditation|
11548817|NCT01012622|Experimental|OROS Methylphenidate Hydrochloride|
11548818|NCT01012609|Experimental|pts with high-grade astrocytoma|This is a 2-group parallel (high-grade astrocytoma, diffuse pontine tumor), single stage study investigating cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan in pediatric and young adult patients. Optional exploratory components of the study include (1) correlation of tumor molecular markers with outcome, (2) CSF proteomics, and (3) assay of serum cytokine levels in patients who develop a cetuximab-associated rash.
11548819|NCT01012609|Experimental|pts with diffuse pontine tumor|This is a 2-group parallel (high-grade astrocytoma, diffuse pontine tumor), single stage study investigating cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan in pediatric and young adult patients. Optional exploratory components of the study include (1) correlation of tumor molecular markers with outcome, (2) CSF proteomics, and (3) assay of serum cytokine levels in patients who develop a cetuximab-associated rash.
11548820|NCT01012596||Creighton Model|New and return users of the Creighton Model FertilityCare System, a method of Natural Family Planning.
11548821|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 7.5 mcg H1N1v full MF59 adjuvant|
11548822|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 3.75 mcg H1N1v half MF59 adjuvant|
11548823|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 15 mcg H1N1v unadjuvanted|
11548824|NCT01012557|Active Comparator|Non-pregnant mothers, 7.5 mcg H1N1v full MF59 adjuvant|
11548825|NCT01012544|Active Comparator|stent thrombosis patients|Patients with a history of a stent thrombosis
11548826|NCT01012544|Active Comparator|Patients without a history of a stent thrombosis|Patients without a history of stent thrombosis
11548827|NCT01012531|Active Comparator|highly polymerized allergen extract|
11548828|NCT01012531|Placebo Comparator|Placebo|
11548829|NCT01012518|Active Comparator|Conventional PCT|PCT performed without video guidance, as conventionally performed
11548830|NCT01012518|Experimental|Video-assisted PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
11548831|NCT01012505||20 preterm infants|20 preterm infants without active disease
11548832|NCT01012492|Experimental|Abatacept|Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
11548833|NCT01012479|Experimental|Candesartan QD + Hydrochlorothiazide QD|
11548834|NCT01012453|No Intervention|Hand Eczema in health care workers|
11548835|NCT01012440|Experimental|Beast cancer subjects|Subject will have assessment of neoadjuvant chemotherapy treatment response by both MRI and PEM to compare methods
11548836|NCT01012427|Experimental|Patients with 3.0 cm or smaller renal cancer|The interventions in this study are part of clinical care and include percutaneous image-guided biopsy, percutaneous renal tumor cryoablation, CT/MR imaging of the ablation bed, and repeat pathologic sampling of the tumor bed with percutaneous biopsy. The cryoablation is done as the therapeutic intervention in patients with small renal cancer. The CT/MR imaging is done to evaluate the treatment for residual disease after the ablation. The repeat biopsy (e.g. three cores) is done to confirm that the neoplasm has been eradicated. These patients have continued imaging, and if necessary, percutaneous biopsy to ensure no recurrent disease.
11548837|NCT01012414|Experimental|oral paricalcitol 2 mcg daily|oral paricalcitol 2 mcg daily
11548838|NCT01012414|Placebo Comparator|Placebo|one oral placebo drug daily
11548839|NCT01012401|Experimental|CHESS with Clinician Report + Internet access|An Internet-based system, Comprehensive Health Enhancement Support System for Lung Cancer(CHESS-LC) integrates over 14 services to provide tailored cancer information, support, and interactive tools.
11548840|NCT01012401|Active Comparator|Usual care with Internet access|Control group patients will be given a list of URLs for 10-high quality lung cancer-related sites
11548841|NCT01012388|Experimental|Radiesse|
11548842|NCT01012375|Experimental|1|AZD1446 tid
11548843|NCT01012375|Experimental|2|AZD1446 tid
11548844|NCT01012375|Experimental|3|AZD1446 qd
11548845|NCT01012375|Placebo Comparator|4|Matching placebo capsule
11548846|NCT01012362|Experimental|Optimum Tolerated Dose Determination|"Patient receives assigned dose level:
~Dose Level 1 = 400 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 2 = 400 milligrams (mg) of pazopanib and ixabepilone 40 mg/m2. Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 4 = 800 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2."
11548847|NCT01012362|Experimental|Optimum Tolerated Dose Confirmation|Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2.
11548848|NCT01012349|Experimental|Test|Administration of GeoLab Association (acetylsalicylic acid, sodium bicarbonate and citric acid)
11548849|NCT01012349|Active Comparator|Comparator|Acetylsalicylic acid - (Aspirin - Bayer)
11548850|NCT01012336|Experimental|Aprepitant|
11548851|NCT01012323|Experimental|NewGam|Participants received NewGam 200-800 mg/kg intravenously every 3 weeks (17 infusions) or 4 weeks (13 infusions) for 1 year.
11548852|NCT01012310|Experimental|Cohort 1|
11548853|NCT01012310|Experimental|Cohort 2|
11548854|NCT01012310|Experimental|Cohort 3|
11548855|NCT01012310|Experimental|Cohort 4|
11548856|NCT01012297|Experimental|Arm I Gem+Doce+Placebo|Patients receive a placebo IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim subcutaneously (SC) on days 9-15 or pegfilgrastim SC on day 9 or 10.
11548857|NCT01012297|Experimental|Arm II Gem+Doce+Bev|Patients receive bevacizumab IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10.
11548858|NCT01012284|Experimental|Panel A|8 patients with moderate hepatic impairment classified as moderate as per the Child Pugh Classification.
11548859|NCT01012284|Experimental|Panel B|8 healthy participants who will match to patients with hepatic impairment in Panel A with regards to sex, age (more or less to 5 years), and body mass index.
11548860|NCT01012258|Experimental|Cetuximab|All eligible subjects will receive cetuximab treatment only during week 1 of the treatment course and concomitant cetuximab and boost radiotherapy (RT) during week two to week seven of the treatment course
11548861|NCT01012245||patients with glaucoma and ocular hypertension|
11548862|NCT01012232|Active Comparator|low volume local anesthetic|bolus injection of local anesthetic in low volume/high concentration (10 mL, 10 mg/mL)
11548863|NCT01012232|Experimental|high volume local anesthetic|bolus injection of ropivacaine in high volume/low concentration (20 ml, 5 mg/mL)
11548864|NCT01012219|Experimental|Period 1|In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).
11548865|NCT01012219|Experimental|Period 2|In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).
11548866|NCT01012219|Experimental|Period 3|
11548867|NCT01012206|No Intervention|Control group|Children in control group obtained no lifestyle counseling (intervention).
11548868|NCT01012206|Active Comparator|Intervention group|Children in the intervention group and their parents were given lifestyle counseling and participated in an intervention program regarding food habits and physical activity.
11548869|NCT01012193|Active Comparator|adjunctive cilostazol|adjunctive cilostazol 100mg bid to dual antiplatelet therapy
11548870|NCT01012193|Active Comparator|high maintenance-dose clopidogrel|double dose of clopidogrel 150mg/day
11548871|NCT01012167|Active Comparator|1: galantamine/placebo-oxytocin|Subjects randomized to galantamine will receive galantamine and placebo-oxytocin
11548872|NCT01012167|Active Comparator|2: oxytocin/placebo-galantamine|Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine
11548873|NCT01012167|Placebo Comparator|3: placebo-galantamine /placebo-oxytocin|Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin
11548876|NCT01012102|Experimental|Group 2|EMD 640744 100μg and Montanide® ISA 51 VG
11548877|NCT01012102|Experimental|Group 3|EMD 640744 300μg and Montanide® ISA 51 VG
11548878|NCT01012089|Experimental|Daptomycin|Pediatric patients on hemodialysis or peritoneal dialysis with suspected or confirmed infection and who were receiving standard of care antibiotics were also eligible to receive a single dose of daptomycin 5mg/kg IV. Serial blood draws were obtained to assess daptomycin pharmacokinetics
11548879|NCT01012076|Active Comparator|Active Control|The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning. Over the course of the intervention, parent and interventionist cover a hierarchy of intervention topics, aiming to improve the parent's ability to successfully promote the child's social and emotional competency.
11548880|NCT01012076|Experimental|Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). Over the course of the intervention, parent and interventionist cover a hierarchy of intervention topics, aiming to promote the ability of the parent-child dyad to successfully manage shared toy play.
11548881|NCT01012063|Experimental|group IE|The group IE received iron sucrose and erythropoietin-β (Epo-β) during the operation
11548882|NCT01012063|Placebo Comparator|group C|The group C received saline as same method.
11548883|NCT01012050|Experimental|NV Group|Performed nebulization coupled with noninvasive ventilation
11548884|NCT01012050|Active Comparator|NEB group|Performed nebulization alone.
11548885|NCT01012037|Experimental|linagliptin low dose|linagliptin low dose twice daily
11548886|NCT01012037|Placebo Comparator|placebo|placebo matching linagliptin
11548887|NCT01012037|Experimental|linagliptin medium dose|linagliptin medium dose once daily
11548888|NCT01012011||Group 1|
11548889|NCT01011985||AVF|Initial access is an AVF
11548890|NCT01011985||AVG|Initial vascular access is an AVG
11548891|NCT01011985||TC|Initial vascular access is a tunneled catheter, with or without a maturing AVF or AVG
11548892|NCT01011972|Experimental|XMT-1107|Dose escalation groups of XMT-1107, I.V. (in the arm) beginning at 6 mg/m^2, doubling in dose to 24 mg/m^2, then 40 mg/m^2, then 60 mg/m^2, then 80 mg/m^2 with subsequent doses at 33% of the previous until disease progression or unacceptable side effects are experienced.
11548893|NCT01011959|Active Comparator|1|dose 1 vs. placebo
11548894|NCT01011959|Active Comparator|2|dose 2 vs. placebo
11548895|NCT01011959|Active Comparator|3|dose 3 vs. placebo
11548896|NCT01011959|Active Comparator|4|dose 4 vs. placebo
11548897|NCT01011959|Active Comparator|5|dose 5 vs. placebo
11548898|NCT01011959|Active Comparator|6|dose 6 vs. placebo
11548899|NCT01011946|Experimental|Positron Emission Mammography|
11548900|NCT01011933|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Blood and archived tumor tissue samples are collected for biomarker studies.
11548901|NCT01011920|Experimental|MTX+ AraC|Arm A Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3
11548902|NCT01011920|Experimental|Ara-C +Rituximab|Arm B Rituximab 375 mg/m2 conventional infusion d -5 & 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3
11548903|NCT01011920|Experimental|Ara-C + rituximab+thiotepa|Arm C Rituximab 375 mg/m2 conventional infusion d -5 & 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3 Thiotepa 30 mg/m2 30 min. Infusion d 4
11548904|NCT01011920|Experimental|WBRT 36 Gy +/- boost 9 Gy|ARM D: WBRT with 36 Gy in the case of CR to primary chemotherapy or the same WBRT dose followed by a tumor-bed boost of 9 Gy with 1-2 cm of margin surrounding enhanced residual lesion (total tumor-bed dose 45 Gy) in patients who achieved a PR or SD after primary chemotherapy. Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions.
11548905|NCT01011920|Experimental|BCNU + Thiotepa + APBSCT|Arm E BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6 Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 & -4 Reinfusion of PBSC ≥5 x 106 CD34+ cells/kg day 0
11548906|NCT01011907|Experimental|varenicline|Drug: varenicline (Chantix) 12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
11548907|NCT01011907|Placebo Comparator|placebo|Drug: placebo for varenicline 12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
11548908|NCT01011894|Experimental|pts getting lenalidomide|Patients with intermediate or high-risk chronic lymphocytic leukemia (≥ 65 years old) will receive lenalidomide until disease progression at the 20mg dose level (recognizing that progression at this dose requires non-protocol alternate therapy) or unacceptable toxicity.
11548909|NCT01011881||patients with pleuritis|
11548910|NCT01011868|Experimental|BI 10773 low dose|Patients receive BI 10773 low dose daily
11548911|NCT01011868|Experimental|BI 10773 high dose|Patients receive BI 10773 high dose daily
11548912|NCT01011868|Placebo Comparator|placebo|Patients receive placebo to match BI 10773 daily
11548913|NCT01011855|Active Comparator|Radiant warmer bed sequence 1|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
11548914|NCT01011855|Active Comparator|Radiant warmer bed sequence 2|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
11548915|NCT01011855|Active Comparator|Radiant warmer bed sequence 3|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
11548947|NCT01011621|Experimental|0.5% prednisolone acetate cream|
11548948|NCT01011621|Active Comparator|0.1% betamethasone valerate cream|
11548916|NCT01011855|Active Comparator|Radiant warmer bed sequence 4|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
11548917|NCT01011855|Experimental|Radiant warmer bed sequence 5|Clinical care provided on three different types of cleared radiant warmer beds with infant temperature measurements taken for 20 hours on each of the three radiant warmer beds.
11548918|NCT01011855|Experimental|Radiant warmer bed sequence 6|Clinical care provided on three different types of cleared radiant warmer beds with infant temperature measurements taken for 20 hours on each of the three radiant warmer beds.
11548919|NCT01011842|Experimental|radiation therapy arm|
11548920|NCT01011829|Active Comparator|Varenicline|"Varenicline:
~0.5 mg daily for days 1-3
~0.5 mg twice daily for days 4-7
~1 mg twice daily from day 8 until end of week 8."
11548921|NCT01011829|Placebo Comparator|Placebo|8 weeks of daily matching oral placebo in tablet form
11548922|NCT01011816|Experimental|BIOSTAT BIOLOGX|One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc
11548923|NCT01011816|Placebo Comparator|Saline|One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc
11548924|NCT01011803|Experimental|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were [diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
11548925|NCT01011790|Experimental|Stress Management Tool|All subjects will use the Healing Rhythms™ meditation program for 4 weeks.
11548926|NCT01011777|Experimental|Autologous Muscle Derived Cells|Surgeon will endoscopically inject previously harvested autologous muscle derived cells (MDC) into the same bladder exstrophy patient's urinary sphincter to improve outflow resistance and rhabdosphincter contractility. We will assess tolerability and induction of continence.
11548927|NCT01011764|Active Comparator|SKILLS group|The SKILLS intervention targets a specific set of social skills over 8 bi-weekly sessions. The intervention is delivered to a small group of children with autism at school during lunchtime. The content delivered to the group of young children with autism including lessons developed from a manual by Seattle Children's Hospital Research Foundation. Children are given weekly homework assignments to reinforce the topics discussed in the group sessions.
11548928|NCT01011764|Experimental|ENGAGE group|The ENGAGE intervention targets two social domains, and two learning contexts. The two social domains are peer acceptance and social engagement with peers. The social group will be small and include children with ASD as well as their typical peers. There will be a greater number of typical peers included to model social behaviors and foster friendships. The typical peers will be selected based on results from the friendship survey and teacher nominations. The two learning contexts are direct instruction in a group social skills format during lunchtime and individualized embedded generalization activities in the school day.
11548929|NCT01011751|Experimental|Cyproterone acetate|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, cyproterone acetate 50 mg, tablet-in-capsule, along with cyproterone acetate placebo-matching capsule, orally, once daily in the morning and cyproterone acetate 50 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Cyproterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks.
11548930|NCT01011751|Experimental|Medroxyprogesterone acetate|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, medroxyprogesterone acetate 10 mg, tablet-in-capsule, along with medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning and medroxyprogesterone acetate 10 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks.
11548931|NCT01011751|Experimental|Venlafaxine|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, venlafaxine 75 mg, capsule, orally, once daily in the morning and venlafaxine placebo-matching capsule, orally, once daily in the evening for 8 weeks. Venlafaxine 37.5 mg, capsule, orally, once daily in the evening for the next 2 weeks.
11548932|NCT01011738||Cohort|
11548933|NCT01011725|Experimental|Postmenopausal Women- Active Agent Group|
11548934|NCT01011725|Placebo Comparator|Postmenopausal Women- Placebo|Placebo
11548935|NCT01011699|Active Comparator|sevelamer|"Titration phase with sevelamer (Renagel) with the aim of phosphatemia control in 4 weeks of treatment, with stable dose of calcic carbonate.
~Increase of sevelamer dose up to 12 tablets, as follows:
~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week)."
11548936|NCT01011699|Active Comparator|nicotinamide|"Titration phase with nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks of treatment, with stable dose of calcic carbonate.
~Increase of nicotinamide dose up to 4 tablets, as follows:
~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week)."
11548937|NCT01011686|Experimental|ANT-SM|autologous adipose-derived stem cell
11548938|NCT01011673|Active Comparator|Ketorolac|Ketorolac 30mg IVSS
11548939|NCT01011673|Active Comparator|Metoclopramide|metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
11548940|NCT01011660|Active Comparator|A,1,IV|A means active; 1 means Amlodipine+Amiloride Compound; IV means phase IV
11548941|NCT01011660|Active Comparator|A,2,IV|A means active; 2 means Amlodipine+Telmisartan; IV means phase IV
11548942|NCT01011660|Active Comparator|A,3,IV|A means active; 3 means Amlodipine+Amiloride Compound with or no Simvastatin; IV means phase IV
11548943|NCT01011660|Active Comparator|A,4,IV|A means active; 4 means Amlodipine+Telmisartan with or no Simvastatin; IV means phase IV
11548944|NCT01011647||Acute coronary conditions|"Patients hospitalized with the following conditions
~Unstable angina
~Acute myocardial infarction
~Congestive heart failure"
11548945|NCT01011634|Active Comparator|Moderate sedation|
11548949|NCT01011608|Experimental|Medical Food Supplement|Medical food supplement to be given in divided portions in morning, afternoon and evening
11548950|NCT01011608|Active Comparator|standard hospital food|standard hospital diet
11548951|NCT01011582||Novel H1N1 influenza|
11548952|NCT01011582||Seasonal influenza|
11548953|NCT01011569||cage|patient who underwent stand alone cage insertion after discectomy
11548954|NCT01011569||plate|patient who underwent plate fixation and autologous ilia bone graft after discectomy
11548955|NCT01011556|Active Comparator|20 mcg Subcutaneous Teriparatide|Received 20 micrograms (mcg) subcutaneously once daily in an unblinded manner.
11548956|NCT01011556|Experimental|30 mcg Transdermal Teriparatide|Received 30 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
11548957|NCT01011556|Experimental|50 mcg Transdermal Teriparatide|Received 50 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
11548958|NCT01011556|Experimental|80 mcg Transdermal Teriparatide|Received 80 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
11548959|NCT01011543|Active Comparator|Endoscopic approach|CT thorax is done in all patients to localize the exact anatomical site of the disease. This evaluation is followed by fluoroscopy-guided bronchoscopy for BAL (bronchoalveolar lavage) and TBB (transbronchial biopsies). A sputum sample immediately after the endoscopy will be collected if possible.
11548960|NCT01011543|Active Comparator|Induced sputum|Sputum induction after administration of 6-8 mL 3% NaCl aerosol by an ultrasonic nebulizer; sputum will be collected 15-30 minutes after administration of the aerosol. This process will be done twice in every patient.
11548961|NCT01011530|Experimental|MLN4924|MLN4924 via IV infusion
11548962|NCT01011517|Experimental|grape seed supplement|Nature's Pearl 650 mg, two capsules daily
11548963|NCT01011517|Placebo Comparator|placebo|placebo
11548964|NCT01011491|Experimental|Medifast 5 & 1 Plan|Medifast's 5 & 1 Plan is a meal replacement plan for weight loss and weight maintenance.
11548965|NCT01011491|Active Comparator|Food-based|The food-based arm followed a meal plan of self-selected foods that provided the same number of calories as the Medifast 5 & 1 plan.
11548966|NCT01011478|Placebo Comparator|Group 1: placebo|Patients receive oral placebo once daily for 5 years.
11548967|NCT01011478|Experimental|Group 2: rosuvastatin|Patients receive oral rosuvastatin once daily for 5 years.
11548968|NCT01011465|Experimental|Oxytocin|One primary experimental manipulation is the receipt of intranasal oxytocin vs placebo spray prior to participation in a psychosocial stress protocol
11548969|NCT01011465|Placebo Comparator|Placebo|The comparison condition for receipt of oxytocin is receipt of a saline intranasal spray
11548970|NCT01011465|Experimental|Social Support|Participants bring a friend to the laboratory who sits with them while they engage in the stress protocol tasks
11548971|NCT01011465|Placebo Comparator|No Social Support|Individuals in this condition do not have a friend present while they are engaging in the laboratory protocol.
11548972|NCT01011465|Other|Female Gender|Effects of oxytocin and social support are examined among women versus men
11548973|NCT01011465|Other|Male Gender|Consider effects of oxytocin and social support in men versus women
11548974|NCT01011452|Active Comparator|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
11548975|NCT01011452|Placebo Comparator|Placebo|
11548976|NCT01011439|Experimental|Milciclib Maleate (PHA-848125AC)|100 and 50 mg Capsule 150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle
11548977|NCT01011426|Active Comparator|Bisacodyl|
11548978|NCT01011426|Placebo Comparator|empty opague capsule|
11548979|NCT01011413|Active Comparator|600 milligram (mg) Efavirenz|Eligible patients will be centrally randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
11548980|NCT01011413|Experimental|400mg Efavirenz|Eligible patients will be centrally randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
11548981|NCT01011387|Other|NPWT system|Negative pressure wound therapy
11548982|NCT01011348|Other|Placebo vs Q10 100mg vs Q10 300mg|
11548983|NCT01011348|Other|Q10 100mg vs Placebo vs Q10 300mg|
11548984|NCT01011348|Other|Placebo vs. Q10 300mg vs. Q10 100mg|
11548985|NCT01011348|Other|Q10 300mg vs. Placebo vs. Q10 100mg|
11548986|NCT01011335|Experimental|Active Vaccine|Monovalent rAT or Monovalent rLukS-PV or Bivalent rLukS-PV / rAT
11548987|NCT01011335|Placebo Comparator|Placebo with Alum|
11548988|NCT01011335|Placebo Comparator|Saline Placebo|
11548989|NCT01011322|Experimental|LT-02 Dose 1|0.2g IMP per dose
11548990|NCT01011322|Experimental|LT-02 Dose 2|0.4g IMP per dose
11548991|NCT01011322|Experimental|LT-02 Dose 3|0.8g IMP per dose
11548992|NCT01011322|Placebo Comparator|Sugar pill|placebo matching to 0g of IMP,
11548993|NCT01011309|Experimental|LEISH-F2 + MPL-SE vaccine|Recombinant three antigen Leishmania polyprotein + MPL-SE adjuvant
11548994|NCT01011309|Active Comparator|Sodium stibogluconate (SSG)|20 mg/kg/day IV for 20 days
11548995|NCT01011296|Experimental|Single IV Dose 1|
11548996|NCT01011296|Experimental|Single IV Dose 2|
11548997|NCT01011296|Experimental|Single IV Dose 3|
11548998|NCT01011283|Active Comparator|1|
11548999|NCT01011283|Active Comparator|2|
11549000|NCT01011270||Back pain|The aim of this study was to investigate the effect of rehabilitation of the dynamic ;(RDM) in balance and balance of industrial operators. The sample consisted of industrial operators, individuals with low back pain, referred to the industry of Physical Therapy
11549001|NCT01011270||Balance|the treatment with RDM reflected in significant improvement in back pain and postural balance of industrial operators.
11549002|NCT01011257|Active Comparator|Aspirin 81 mg, 1 tab twice daily|All participants to take one aspirin (81mg per tab) twice daily.
11549003|NCT01011257|Active Comparator|Clopidogrel 75 mg 1 tab daily|Only stable CAD participants will take Clopidogrel (75mg per tab) daily.
11549004|NCT01011244|Experimental|ADIPOPLUS|patients with a fistula in Crohn's disease
11549005|NCT01011218|Experimental|BBT-I + Armodafinil|"Two Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone.
~Armodafinil 150 mg/day by mouth."
11549006|NCT01011218|Experimental|Behavioral placebo + Armodafinil|"Control behavioral intervention is a sleep hygiene handout completed by participant.
~Armodafinil 150 mg/day by mouth."
11549007|NCT01011218|Sham Comparator|BBT-I without Armodafinil|"Two Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone.
~No pharmaceutical intervention."
11549008|NCT01011218|Placebo Comparator|Behavioral placebo without Armodafinil|"Control behavioral intervention is a sleep hygiene handout completed by participant.
~No pharmaceutical intervention."
11549009|NCT01011205|Experimental|Dosing Regimen 1|Advagraf + MMF + Corticosteroids (Bolus)
11549010|NCT01011205|Experimental|Dosing Regimen 2|Advagraf + MMF + Basiliximab + Corticosteroids (Bolus)
11549011|NCT01011205|Experimental|Dosing Regimen 3|Advagraf (5 days delay) + MMF + Basiliximab + Corticosteroids (Bolus)
11549012|NCT01011192||ke0 of 0.26 min-1|Individual volunteers using Marsh's pharmacokinetic target-controlled infusion model with ke0 of 0.26 min-1 (Asena PK® - Cardinal Health)
11549013|NCT01011192||ke0 of 1.21 min-1|Individual volunteers using Marsh's pharmacokinetic target-controlled infusion model with ke0 of 1.21 min-1 (Primea Orchestra® - Fresenius-Kabi basis)
11549014|NCT01011179|Experimental|Internet-based JIA Self-Management Program|
11549015|NCT01011179|Active Comparator|Attention Control Group|
11549016|NCT01011166|Experimental|IDX184 50 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 50 mg or placebo once daily (QD) in combination with Peg-IFN/RBV on Days 14-28 and Peg-IFN/RBV on Days 14-28.
11549017|NCT01011166|Experimental|IDX184 100 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 50 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV alone on Days 14-28.
11549018|NCT01011166|Experimental|IDX184 100 mg BID + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 100 mg or placebo twice daily (BID) in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV alone on Days 14-28.
11549019|NCT01011166|Experimental|IDX184 150 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 150 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
11549020|NCT01011166|Experimental|IDX184 200 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 100 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
11549021|NCT01011166|Experimental|IDX184 200 mg BID + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 200 mg or placebo BID in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
11549022|NCT01011153||All Dermatologists|
11549023|NCT01011140||Online Survey|Survey of Palliative care physicians from Latin America and Spain
11549024|NCT01011127||pravastatin|
11549025|NCT01011127||rosuvastatin|
11549026|NCT01011114|Active Comparator|Cincalcet|cinacalcet will be titrated as needed to achieve serum phosphorus of > 2.5 mg/dl randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at ~ 2.5 mg/l.
11549027|NCT01011114|Placebo Comparator|Control|"subjects will receive placebo pill titrated as needed to achieve phosphorus > 2.5 mg/dl.
~randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at ~ 2.5 mEq/l."
11549028|NCT01011088||Early phase|Psychoses within the first 3 months after baby born
11549029|NCT01011088||Delayed phase|Psychoses > 3 months to one year after baby born
11549030|NCT01011075|Experimental|Imatinib mesylate + Paclitaxel|Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses bracketing each paclitaxel infusion (days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
11549031|NCT01011062|Experimental|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
11549032|NCT01011062|Experimental|Losartan + hyperinsulinaemia|
11549033|NCT01011062|Placebo Comparator|Saline|Infusion of Saline as a volume control intervention
11549034|NCT01011049|Experimental|Group 1: Fluzone ID After Fluzone ID|Participants will receive Fluzone intradermal (ID) following Fluzone ID in Study FID31
11549035|NCT01011049|Experimental|Group 2: Fluzone IM After Fluzone ID|Participants will receive Fluzone intramuscular (IM) following Fluzone ID in Study FID31
11549036|NCT01011049|Experimental|Group 3: Fluzone IM After Fluzone IM|Participants will receive Fluzone intramuscular (IM) following Fluzone IM in Study FID31
11549037|NCT01011049|Experimental|Group 4: Fluzone ID After Fluzone IM|Participants will receive Fluzone intradermal (ID) following Fluzone intramuscular (IM) in Study FID31
11549038|NCT01011036|Other|1|
11549039|NCT01011036|Other|2|
11549040|NCT01011036|Other|3|
11549041|NCT01011023|Experimental|WITHOUT NASOGASTRIC TUBE|1. Experimental group (EG): without NGT, by removing the NGT at the end of the surgery, once the stomach had been aspirated,
11549042|NCT01011023|Active Comparator|WITH NASOGASTRIC TUBE|2. Control group (CG): with NGT, with radiographic corroboration of correct placement after the surgery. Both groups were given: 5-day fasting because it was the therapeutic gold standard at our hospital and our country, intravenous solutions and antibiotics for 5 days, ranitidine, and analgesics, without use of any antiemetic drug. Once the fasting period ended, in the CG the NGT was clamped and withdrawn, and in both groups oral fluids and diet were started. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
11549043|NCT01011010|Other|Single Arm|Single Arm Trial
11549044|NCT01010997||Dry AMD|Intermediate AMD subjects
11549045|NCT01010997||Wet - treated AMD|AMD subjects under treatments
11549046|NCT01010984|Experimental|Transcatheter Arterial Chemoembolization|TACE using LC beads loaded with Doxorubicin
11549047|NCT01010971|Experimental|Ciclesonide HFA Nasal Aerosol 160 μg|160 μg once daily
11549048|NCT01010971|Experimental|Ciclesonide HFA Nasal Aerosol 80 μg|80 μg once daily
11549049|NCT01010971|Placebo Comparator|Placebo|Placebo
11549175|NCT01010100|Placebo Comparator|Arm 2|
11549050|NCT01010958|Experimental|Valproate|Valproic Acid taken orally, daily to reach serum levels between 50 to 100 µg/mL.
11549051|NCT01010945|Experimental|erlotinib, gemcitabine, nab-paclitaxel|Patients receive the following treatment in 28-day cycles: 1) erlotinib: orally once daily from days 1 through 28 continuous dosing; 2) gemcitabine (following nab-paclitaxel): intravenously over 30 minutes on days 1, 8 and 15 every 28 days; and 3) nab-paclitaxel: intravenously over 30 minutes on days 1, 8 and 15 every 28 days.
11549052|NCT01010932|Experimental|Dotarem and TOF MRA|Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.
11549053|NCT01010906|Experimental|Mild Hepatic Insufficiency (HI)|Participants with mild hepatic insufficiency (HI) administered a single 300 mg oral tablet of vaniprevir
11549054|NCT01010906|Experimental|Healthy Control to Mild HI|Healthy, matched to mild HI, control participants administered a single 300 mg oral tablet of vaniprevir
11549055|NCT01010906|Experimental|Moderate HI|Participants with moderate HI administered a single 300 mg oral tablet of vaniprevir
11549056|NCT01010906|Experimental|Healthy Control to Moderate HI|Healthy, matched to moderate HI, control participants administered a single 300 mg oral tablet of vaniprevir
11549057|NCT01010906|Experimental|Severe HI|Participants with severe HI administered a single 200 mg oral tablet of vaniprevir
11549058|NCT01010906|Experimental|Healthy Control to Severe HI|Healthy, matched to severe HI, control participants administered a single 200 mg oral tablet of vaniprevir
11549059|NCT01010893|Experimental|Influenza vaccination|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose).
11549060|NCT01010893|Experimental|Influenza vaccination and co-vaccination|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).
11549061|NCT01010867|Experimental|Lactobacillus plantarum|There is a single intervention arm in this study. Target accrual for the intervention is 30 subjects. Subjects receive supplementation with Lactobacillus plantarum strains 299 and 299v.
11549062|NCT01010854|Experimental|VPA FEC100|Valproic Acid with FEC100
11549063|NCT01010841|Active Comparator|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
11549064|NCT01010841|Experimental|Low-glycemic-load diet + medical food|Modified Mediterranean-style, low-glycemic-load diet + medical food
11549065|NCT01010828|Active Comparator|Tri-Vector Approach|
11549066|NCT01010828|Experimental|Mini Mid-Vastus Approach|
11549067|NCT01010815||UC group|clinically and microscopically confirmed UC patients between the age of 19 and 75 years
11549068|NCT01010815||Control group|normal healthy controls
11549069|NCT01010802|Experimental|Erythropoietin|"There are evidences of neuroprotecting therapeutic alternatives in such substances as erythropoietin (EPO) which is a well-known cytokine as a hematopoietic growth factor, so, it is therefore important to control tissular oxygenation. It is considered that EPO protects the neurons by a combination of several mechanisms.
~EPOrh is used with high effectiveness in the treatment of anemias with deficiency of erythropoietin."
11549070|NCT01010789|Experimental|Armodafinil|Flexible dose 150-250mg/day
11549071|NCT01010789|Placebo Comparator|Mathing Placebo|
11549072|NCT01010776|Experimental|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 milligram (mg) will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
11549073|NCT01010763|Experimental|M2a Magnum|Total HIp Arthroplasty using with the M2a Magnum Large Metal Articulation is an ultra-high performance metal-on-metal articulation with a big ball (greater than or equal to 38mm) in acetabulums as small as 44mm.
11549074|NCT01010763|Active Comparator|M2a Taper|Total Hip Arthroplasty using with the M2a Taper Acetabular System consists of a titanium outer shell with cobalt chromium (Co-Cr-Mo) metallic liner, which articulates with with a cobalt chromium (Co-Cr-Mo) modular femoral head.
11549075|NCT01010750|Active Comparator|LDX + MAS-IR Placebo|Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
11549076|NCT01010750|Active Comparator|MAS-IR + LDX Placebo|Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
11549077|NCT01010750|Placebo Comparator|Placebo|Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
11549078|NCT01010737|Experimental|Multimeric-001 250 mcg|250mcg of Multimeric-001 was administered twice at an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
11549079|NCT01010737|Active Comparator|Adjuvant: Montonide isa 51 VG|Adjuvanted PBS was administered twice with a 19-23 day interval via the IM route to 10 participants and then a TIV boost was administered.
11549080|NCT01010737|Active Comparator|Placebo|PBS was administered twice with a 19-23 day interval via the IM route to 10 participants and then a TIV boost was administered.
11549081|NCT01010737|Experimental|Multimeric-001 500 mcg|500mcg of M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
11549082|NCT01010737|Experimental|Adjuvanted Multimeric-001 500mcg|5000mcg of Adjuvanted M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
11549083|NCT01010737|Experimental|Adjuvanted Multimeric-001 250mcg|250mcg of Adjuvanted M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
11549084|NCT01010724|Experimental|bIAP|Dosage 200 IU bIAP/kg: 1000 IU prior to anaesthesia administered as a bolus followed by intravenous continuous infusion of 5,6 IU/kg/hr for approximately 36 hours.
11549085|NCT01010724|Placebo Comparator|Placebo|
11549086|NCT01010711|Other|migraine dietary supplement|"the average days of migraine during a 4 week-run-in-period are compared with the average days of migraine during intervention with a specific dietary supplement from week 8 - 12"
11549087|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 1|formulation 1
11549088|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 2|formulation 2
11549089|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 3|formulation 3
11549090|NCT01010698|Active Comparator|cimetidine (or acyclovir) reference|reference product
11549091|NCT01010672|Experimental|Ridaforolimus 40 mg|
11549092|NCT01010659|Experimental|Lacrimal Tube|Dacryocystorhinostomy with silicone lacrimal intubation
11549093|NCT01010646|Experimental|GP1N IFN alfa-2bXL 27 MUI + Ribavirin|IFN alfa-2bXL 27 MUI, powder and solvent for solution injection
11549094|NCT01010646|Experimental|GP2N IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI, powder and solvent for solution injection
11549095|NCT01010646|Active Comparator|GP3N IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg,administered once a week for 12 weeks by subcutaneous injections
11549096|NCT01010633|Experimental|Loteprednol Etabonate|Loteprednol etabonate
11549097|NCT01010633|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate
11549098|NCT01010620||Screening|Screening Assessment battery. Specific to study(or studies) the individual is screening for.
11549099|NCT01010607|Experimental|Vibraton Mirror (VM)|subjects will receive tendon vibration AND mirror therapy
11549100|NCT01010607|Active Comparator|Mirror (M)|Subjects will receive treatment only with Mirror, together with sham vibration (over bone instead of tendon)
11549101|NCT01010607|Sham Comparator|Sham (S)|Opaque board instead of mirror, bone vibration instead of tendon vibration
11549102|NCT01010594|Active Comparator|Fruit restricted|Type 2 diabetics are advised to restrict their fruit intake to two pieces or less daily.
11549103|NCT01010594|Active Comparator|Fruit ad libitum|Type 2 diabetics are advised to eat at least two pieces of fruits daily
11549104|NCT01010581|Experimental|SC12267 (4SC-101) + Methotrexate|
11549105|NCT01010581|Placebo Comparator|Placebo + Methotrexate|
11549106|NCT01010568|Experimental|Ofatumumab and Bendamustine|Ofatumumab and Bendamustine
11549107|NCT01010555|Active Comparator|lotrafilcon B|Lotrafilcon B contact lens randomly assigned to one eye, with balafilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear senofilcon A contact lens randomly assigned to one eye and enfilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
11549108|NCT01010555|Active Comparator|balafilcon A|Balafilcon A contact lens randomly assigned to one eye, with lotrafilcon B contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear senofilcon A contact lens randomly assigned to one eye and enfilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
11549109|NCT01010555|Active Comparator|senofilcon A|Senofilcon A contact lens randomly assigned to one eye, with enfilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear lotrafilcon B contact lens randomly assigned to one eye and balafilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
11549110|NCT01010555|Active Comparator|enfilcon A|Enfilcon A contact lens randomly assigned to one eye, with senofilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear lotrafilcon B contact lens randomly assigned to one eye and balafilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
11549111|NCT01010542|Active Comparator|ILV-095|
11549112|NCT01010542|Placebo Comparator|placebo|
11549113|NCT01010529|Experimental|occupational therapy|
11549114|NCT01010529|No Intervention|No occupational therapy|Patients and their caregivers in the control group will have no occupational therapy intervention until their last measurement has taken place (3 months).
11549115|NCT01010516|Active Comparator|High-dose rosuvastatin|40 mg of rosuvastatin
11549116|NCT01010516|Active Comparator|Stain plus fenofibrate|existing statin plus micronized fenofibrate 200 mg
11549117|NCT01010516|Active Comparator|Statin plus niacin ER/laropiprant|existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
11549118|NCT01010503|Experimental|Single Arm|
11549119|NCT01010490|Experimental|Torsional ultrasound|Torsional ultrasound with the INFINITI phacoemulsification system (Alcon Lab, USA)
11549120|NCT01010490|Active Comparator|Longitudinal ultrasound (INFINITI)|Longitudinal ultrasound with the INFINITI phacomachine (Alcon Lab, USA)
11549121|NCT01010490|Active Comparator|Longitudinal ultrasound (LEGACY)|Longitudinal ultrasound with the LEGACY phacomachine (Alcon Lab, USA)
11549122|NCT01010477|Experimental|Nicotine Nasal Spray|Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. . Nasal spray will be used from the TQD through the end of Week 20.
11549123|NCT01010477|Placebo Comparator|Placebo nasal spray|Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Nasal spray will be used from the TQD through the end of Week 20.
11549124|NCT01010464|Experimental|Adhesion Reduction Plan|Lysis of adhesions and application of Seprafilm
11549125|NCT01010464|No Intervention|Standard Management|Standard management and no application of Seprafilm
11549126|NCT01010451|Experimental|Antimicrobial pulpotomy|Pulpotomy of primary molars with pulp inflammation or necrosis due to carious lesions using an antimicrobial paste
11549127|NCT01010451|Active Comparator|Calcium hydroxide pulpectomy|Pulpectomy of primary molars with pulp inflammation or necrosis due to carious lesions using a calcium hydroxide paste as intracanal medication
11549128|NCT01010438||Adults|Adult patients referred for sleep studies, including both patients with suspected OSA and patients that have been invited to a sleep lab for reasons not related to OSA such as insomnia, para-insomnia and similar.
11549172|NCT01010113|Placebo Comparator|Test formula 1|Standard formula with prebiotics
11549173|NCT01010113|Experimental|test product|Infant formula with synbiotics
11549129|NCT01010438||Children (1-17)|Pediatric patients referred for sleep studies, including both patients with suspected OSA and patients that have been invited to a sleep lab for reasons not related to OSA such as insomnia, para-insomnia and similar.
11549130|NCT01010425|Experimental|ACP-001, dose-level 1|
11549131|NCT01010425|Experimental|ACP-001, dose-level 2|
11549132|NCT01010425|Experimental|ACP-001, dose-level 3|
11549133|NCT01010425|Experimental|ACP-001, dose-level 4|
11549134|NCT01010412|Experimental|Ultrasound|Ultrasound guided nerve localization through direct visualization of the nerves and surrounding structures.
11549135|NCT01010412|Active Comparator|Nerve Stimulation|Standard of Care
11549136|NCT01010399|Experimental|Boosted Lexiva with Lovaza|
11549137|NCT01010386|Placebo Comparator|atmospheric (20%) oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
11549138|NCT01010386|Active Comparator|physiologic (5%) oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
11549139|NCT01010373|Experimental|AS101 infusions|In addition to induction chemotherapy AS101 will be given intravenously. The patient will also receive AS101 infusions during the time break till the next chemotherapy course, as long as the patient does not achieve complete remission and the platelet count is <20,000/μl; ANC <1000. AS101 will be administered likewise up to two consolidation or equivalent chemotherapy courses (re-induction or salvage in the event that no CR is achieved following first induction chemotherapy), i.e., total of three chemotherapy courses.
11549140|NCT01010347|Active Comparator|Splint|Preformed velcro volar splints are compared to traditional circumferential casting.
11549141|NCT01010347|Placebo Comparator|Cast|The circumferential cast is the standard of treatment against which the splint is compared.
11549142|NCT01010334|Active Comparator|Arm 1|Standard of Care Treatment
11549143|NCT01010334|Experimental|Arm 2|Treatment Arm of a separate protocol (physician discretion)
11549144|NCT01010321||all study Population|all
11549145|NCT01010308|Experimental|Intervention Group:|"The patients in this study are infants aged 1 month to 1 year of age with head and neck hemangiomas currently causing /or with impending function loss (e.g. vision, airway obstruction, feeding, etc), or hemangiomas currently causing/or with potential for facial disfigurement
~Infants aged 1 month to 1 year of age with head and neck hemangiomas that received treatment with systemic propranolol in the past 2 years as a control group"
11549146|NCT01010308|No Intervention|Historical control group|Ten infants (1-12 months of age) treated with propranolol will be identified from a Dermatology Database. Patients will be considered as controls if they were treated with propranolol before 1 year of age and had digital photography documentation of their hemangioma.
11549147|NCT01010308|No Intervention|Angiogenesis marker control group|The angiogenesis marker control group will consist of 6 -10 patients seen in the Dermatology clinic for conditions other than IH and not receiving corticosteroids or beta blockers.
11549148|NCT01010295|Experimental|doxycycline|doxycycline 100 mg twice daily for 3 weeks
11549149|NCT01010282|Active Comparator|Glycerin and Polysorbate 80 based artificial tear|Glycerin and Polysorbate 80 based artificial tear
11549150|NCT01010282|Experimental|Artificial Tears Formulation 1|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear
11549151|NCT01010282|Experimental|Artificial Tears Formulation 2|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear
11549152|NCT01010269|Active Comparator|Vanguard Complete Knee|Vanguard Completed Knee with Microplasty Tibial Tray is designed to hold the tibial knee bearings in a microplsty knee procedure. The Co-Cro-Mo trays are designed with a shorter stem.
11549153|NCT01010269|Active Comparator|Vanguard High Flex RP|VGRD High Flex RP knee is an extension to the exsting Vanguard Knee and has been specifically desinged to facilitate greather than 135 degrees of knee flextion as required by certain patients.
11549154|NCT01010256||Subjects diagnosed with CMML|Subjects ages 18 and older with a CMML diagnosis based on the WHO 2009 criteria, and who have signed an informed consent are eligible to participate in the study population of this clinical trial. A total of 12 patients will be consented.
11549155|NCT01010256||Control Group|The control group will consist of subjects ages 18 years or older who are healthy (i.e. no hematologic disorders) and have signed an informed consent. A total of 10 healthy control subjects will be consented.
11549156|NCT01010230|Placebo Comparator|LMHF mechanical stimulation placebo device|The placebo device is identical in appearance and function to the active platform; except when activated, it emits the same sound as the active device but does not deliver the vibration.
11549157|NCT01010230|Active Comparator|LMHF mechanical stimulation|"Low magnitude, high frequency mechanical stimulation device (vibrating) platform"
11549158|NCT01010217|Experimental|Haploidentical related|Arm 1 - Stem Cell Transplantation (SCT), Melphalan 140 mg/m^2 , Thiotepa 5 mg/kg, Fludarabine 40 mg/m^2 + high-dose post-transplant cyclophosphamide 50 mg/kg/day
11549159|NCT01010217|Experimental|1 Antigen Mismatch Related or Unrelated|Arm 2 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide.
11549160|NCT01010217|Experimental|Matched Unrelated Donor (MUD)|Arm 3 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide
11549161|NCT01010204|Experimental|Varenicline|We will be comparing Varenicline to placebo in a double-blind placebo controlled, randomized study.
11549162|NCT01010204|Placebo Comparator|Placebo|We will be using placebo in a randomized, controlled, and blinded trial to compare to varenicline in subjects with bipolar disorder.
11549163|NCT01010191|Experimental|Cellulose pill|The active intervention is a sugar pill.
11549164|NCT01010191|No Intervention|No treatment|The control arm is wait list control
11549165|NCT01010178|Experimental|Macrolid, Theophylline, Corticosteroids|Approved drug in this setting
11549166|NCT01010165||septic arthritis|
11549167|NCT01010165||crystal arthritis|
11549168|NCT01010165||rheumatismal disease|
11549169|NCT01010152|Experimental|Codeine Sulfate|30 mg tablet
11549170|NCT01010152|Active Comparator|Tylenol #3|30 mg tablet
11549171|NCT01010126|Experimental|Treatment (temsirolimus, bevacizumab)|Patients receive temsirolimus IV on days 1, 8, 15, and 22, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11549176|NCT01010087|Active Comparator|Standard Oseltamivir dose 75 mg bid|Standard dosing
11549177|NCT01010087|Experimental|High Dose Oseltamivir arm 225mg bid|High dose arm of the study
11549178|NCT01010061|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
11549179|NCT01010061|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
11549180|NCT01010061|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
11549181|NCT01010048|Experimental|progesterone,tamsulosin,propantheline Bromide and nifedipine|different effect of these drugs use to treat urinary calculus after ESWL
11549182|NCT01010035||type 2 diabetes|patients with diagnosis of Type 2 diabetes mellitus
11549183|NCT01010035||Control|non type 2 diabetes mellitus
11549184|NCT01010022|Experimental|1|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
11549185|NCT01010022|Active Comparator|2|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
11549186|NCT01010009|Experimental|Resveratrol 250mg|
11549187|NCT01010009|Experimental|Resveratrol 500mg|
11549188|NCT01010009|Placebo Comparator|Placebo|
11549189|NCT01009996||Coronary bifurcation lesions|
11549190|NCT01009983|Experimental|Arm 1|Patients receive paclitaxel IV and carboplatin IV on days 1, 8, and 15. Patients also receive panitumumab IV on days 1 and 15.
11549191|NCT01009970|Experimental|1|R-COMP
11549192|NCT01009957|Experimental|Everolimus|Everolimus + standard therapy for CKD
11549193|NCT01009957|No Intervention|Control|Standard therapy for CKD
11549194|NCT01009944|Experimental|Lisinopril, Atenolol|
11549195|NCT01009931|Experimental|TPA + Dexamethasone and CMT|12-O-tetradecanoylphorbol-13-acetate (TPA) plus Dexamethasone & Choline magnesium trisalicylate (Trilisate)
11549196|NCT01009918|Experimental|Arm I lisinopril|Patients receive oral lisinopril once daily.
11549197|NCT01009918|Experimental|Arm II Coreg CR®|Patients receive oral Coreg CR® once daily.
11549198|NCT01009918|Placebo Comparator|Arm III placebo|Patients receive oral placebo once daily.
11549199|NCT01009905||A|
11549200|NCT01009892|Active Comparator|Codeine Sulfate, 30 mg|tablet
11549201|NCT01009892|Active Comparator|Codeine Sulfate, 60 mg|tablet
11549202|NCT01009892|Active Comparator|Codeine Sulfate, 15 mg|tablet
11549203|NCT01009879|Experimental|Etanercept|
11549204|NCT01009866|Experimental|MR1-1|All subjects are enrolled onto this arm. All subjects will receive MR1-1.
11549205|NCT01009840|Experimental|IV busulfan|Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.
11549206|NCT01009827||AMTU Clients|All HIV-infected adolescents and young adults engaged in care at the 15 sites and their affiliates who are between 12 and 24 years of age, inclusive, are aware of their HIV status and understand written and/or verbal English will be eligible for inclusion in the study. In addition, new patients who have their initial clinic visit within the enrollment period will also be eligible for participation.
11549207|NCT01009814|Experimental|BMS-663068 600 mg Q12H + RTV 100 mg Q12H|All participants received BMS-663068 600 milligram (mg) and Ritonavir (RTV) 100 mg every 12 hours (Q12H) from Day 1 to Day 8.
11549208|NCT01009814|Experimental|BMS-663068 1200 mg QHS + RTV 100 mg QHS|All participants received BMS-663068 1200 mg and RTV 100 mg every night (quaque hora somni [QHS]) from Day 1 to Day 8.
11549209|NCT01009814|Experimental|BMS-663068 1200 mg Q12H + RTV 100 mg Q12H|All participants received BMS-663068 1200 mg and RTV 100 mg Q12H from Day 1 to Day 8.
11549210|NCT01009814|Experimental|BMS-663068 1200 mg Q12H + RTV 100 mg QAM|All participants received BMS-663068 1200 mg Q12H and RTV 100 mg every 24 hours in the morning (quaque ante meridiem [QAM]) from Day 1 to Day 8.
11549211|NCT01009814|Experimental|BMS-663068 1200 mg Q12H|All participants received BMS-663068 1200 mg Q12H from Day 1 to Day 8.
11549212|NCT01009801|Active Comparator|Arm I|Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
11549213|NCT01009801|Experimental|Arm II|Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
11549214|NCT01009788|Experimental|TMZ/ABT888|Combination therapy with temozolomide and veliparib
11549215|NCT01009775|Experimental|YM155 plus docetaxel|
11549216|NCT01009762|Placebo Comparator|Saline|Sterile saline for injection is used as placebo arm. It is administered i.m. in the same way as for the active vaccine, week 0, 2, 4, 8.
11549217|NCT01009762|Active Comparator|AFO-18 vaccine|the intervention is injection of the experimental therapeutic peptide vaccine (AFO-18) consisting of 18 peptides in CAF01 adjuvant intra muscularly (i.m.) week 0, 2, 4, 8
11549218|NCT01009749|Experimental|MESA|
11549219|NCT01009749|Active Comparator|MESH|
11549220|NCT01009684||DNG/EV|Users of the oral contraceptive containing Dienogest and Estradiol valerate
11549221|NCT01009684||Other OCs|Users of oral contraceptives (OCs) containing other progestins and estrogens
11549222|NCT01009671|Experimental|ART 44|Evaluation of safety and efficacy at D-8, D0, W2, W4 and W12
11549223|NCT01009671|Active Comparator|ART 50|Evaluation of safety and efficacy at D-8, D0, W2, W4 and W12
11549224|NCT01009658|Active Comparator|MSG first|
11549225|NCT01009658|Placebo Comparator|NaCl first|
11549226|NCT01009645|Experimental|Fact Only|The educational message used will contain facts only.
11549227|NCT01009645|Experimental|Fact and Myth|The educational material seen by this arm will contain facts and myths only.
11549228|NCT01009645|Experimental|Fact, Myth, Why|The educational material seen by this arm will contain myths, facts, and refutations of the myths.
11549229|NCT01009645|Placebo Comparator|Control|This arm will receive fact/myth educational materials originally developed and used by the CDC.
11549230|NCT01009632|Experimental|Voice rest|
11549231|NCT01009632|Experimental|Resonant voice exercise|
11549232|NCT01009632|Experimental|Spontaneous speech|
11549233|NCT01009619|Experimental|Azithromycin|250 mg daily for 5 days, followed by 250 mg three times a week (Mon.-Wed.-Fri.) until the end of study
11549234|NCT01009619|Placebo Comparator|Placebo|PLacebo daily for 5 days, followed by placebo three times a week (Mon.-Wed.-Fri.) until end of study.
11549235|NCT01009606|Active Comparator|Arm 1 : Control : usual strategy|
11549236|NCT01009606|Experimental|Arm 2: Comparator : modified strategy|
11549237|NCT01009593|Experimental|ABT-869|
11549238|NCT01009593|Active Comparator|Sorafenib|
11549239|NCT01009580|Experimental|IDegAsp BID|
11549240|NCT01009580|Experimental|BIAsp 30 BID|
11549241|NCT01009567|Sham Comparator|Control|Receive human albumin 20% infusion
11549242|NCT01009567|Experimental|Cabergoline|Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval
11549243|NCT01009554|Experimental|Potassium Oxylate|1.5% potassium oxalate sensitive mouthwash
11549244|NCT01009554|Active Comparator|Sodium Fluoride|Sodium Fluoride Dentifrice
11549245|NCT01009541|Experimental|Pregabalin controlled release, 82.5 mg|
11549246|NCT01009541|Experimental|Pregabalin controlled release, 165 mg|
11549247|NCT01009541|Experimental|Pregabalin controlled release, 330 mg|
11549248|NCT01009541|Other|Pregabalin immediate release, 150 mg|Reference Treatment
11549249|NCT01009528|Experimental|Intervention|Admission to electronic feedback system
11549250|NCT01009528|No Intervention|control|Control group. No special attention
11549251|NCT01009515|Experimental|Chemotherapy Combination|Chemotherapy Combination of paclitaxel, carboplatin, temozolomide: Carboplatin at an AUC of 5 on Day 1, paclitaxel at 175 mg/m2 on Day 1, and temozolomide at 125 mg/m2 Day 2-Day 6, on a 28 day cycle.
11549252|NCT01009502|Experimental|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
11549253|NCT01009476||001|
11549254|NCT01009476||002|
11549255|NCT01009463|Experimental|FF/GW642444 Inhalation Powder 100/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
11549256|NCT01009463|Experimental|FF/GW642444 Inhalation Powder 200/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
11549257|NCT01009463|Experimental|FF/GW642444 Inhalation Powder 50mcg/25mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
11549258|NCT01009463|Experimental|GW642444 25mcg QD|Long Acting Beta Agonist(LABA)
11549259|NCT01009450|Active Comparator|LC was done using traditional method|LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
11549260|NCT01009450|Active Comparator|LC was done using harmonic ACE|LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
11549261|NCT01009437|Active Comparator|Control Arm - No Ritonavir|Five ER+, HER2- breast cancer patients meeting all study eligibility will be enrolled prior to the start of phase I recruitment to act as controls (no ritonavir will be given-will receive therapeutic conventional surgery) to confirm that anesthesia does not affect EET levels. Core biopsies, surgical tumor/normal tissue and pre- and post- surgery blood samples will be collected for comparison with the treatment group.
11549262|NCT01009437|Experimental|Ritonavir - Escalating Doses (I)|"Standard phase I dose escalation (with therapeutic conventional surgery) will be used with 3 levels of ritonavir given - 200 mg bid, 400 mg bid, and 600 mg bid for the following groups:
~ER+, HER2-
~ER+, HER2+
~ER-, HER2+
~ER-, PR+, HER2-
~ER-, PR-, HER2-"
11549263|NCT01009437|Experimental|Ritonavir - Maximum Tolerated Dose (II)|Phase II: Once the maximum tolerated dose (MTD) of ritonavir is established, 19 ER+, HER2- patients will be enrolled at MTD during the phase II component along with therapeutic conventional surgery.
11549264|NCT01009424|Experimental|1|R7103 (dose 1) followed by placebo or placebo followed by R7103 (dose 1)
11549265|NCT01009424|Experimental|2|R7103 (dose 2) followed by placebo or placebo followed by R7103 (dose 2)
11549266|NCT01009424|Experimental|3|R7103 (dose 3) followed by placebo or placebo followed by R7103 (dose 3)
11549267|NCT01009424|Experimental|4|R7103 (dose 4) followed by placebo or placebo followed by R7103 (dose 4)
11549268|NCT01009424|Experimental|5|R7103 (dose 5) followed by placebo or placebo followed by R7103 (dose 5)
11549269|NCT01009424|Experimental|6|R7103 (dose 6) followed by placebo or placebo followed by R7103 (dose 6)
11549270|NCT01009411||Control|Patients in active phase of labor not augmented
11549271|NCT01009411||Augmented|Augmentation leading to normal progress
11549272|NCT01009411||Caesarean section|Augmentation leading to Caesarean section
11549273|NCT01009385|Active Comparator|prone position|
11549274|NCT01009385|Active Comparator|sitting position|
11549275|NCT01009372|Experimental|breaks during laparoscopic surgery|Intraoperative Breaks were instituted in the intervention group. The other group operated conventionally without breaks
11549276|NCT01009359|Experimental|Arm 1|
11549277|NCT01009359|Experimental|Arm 2|
11549278|NCT01009359|Experimental|Arm 3|
11549279|NCT01009346|Experimental|RAD001|Daily RAD001 in combination with weekly cetuximab and cisplatin/ carboplatin on Day 1, 8 of each 28 day cycle.
11549280|NCT01009333|Experimental|Low InterStim rate setting at 5.2 Hz|
11549281|NCT01009333|Experimental|Medium InterStim rate setting at 14 Hz|
11549282|NCT01009333|Experimental|High InterStim rate setting at 25 Hz|
11549283|NCT01009320||Pacemaker with magnets|Patients with pacemakers who will be tested for magnetic interference with a magnetic drape.
11549284|NCT01009294|Experimental|Ataluren|Ataluren was provided as a vanilla-flavored powder to be mixed with water, apple juice, or milk. Study drug dosing was based on milligrams of drug per kilogram of body weight. The dose level for ataluren was 20 milligrams/kilograms (mg/kg) in the morning, 20 mg/kg at midday, and 40 mg/kg in the evening. Administration within 30 minutes after a meal was recommended. Study drug was taken for up to 50 days.
11549285|NCT01009281|Experimental|AIN457|
11549286|NCT01009255|Experimental|GSK239512|Oral tablets
11549287|NCT01009255|Placebo Comparator|Placebo|Placebo to match GSK239512.
11549288|NCT01009242|Experimental|0.1mg/kg and 1mg/kg CDP6038 IV and Placebo IV|Cohort 1, Group 1 will compare 0.1mg/kg, 1mg/kg CDP6038 and placebo IV.
11549289|NCT01009242|Experimental|1 mg/kg CDP6038 SC and Placebo SC|Cohort 1, Group 2 will compare 1mg/kg CDP6038 and placebo sc.
11549290|NCT01009242|Experimental|Optimized CDP6038 SC|Cohort 2, Group 3 will compare optimized sc doses of CDP6038 based on outcome of Cohort 1 with placebo.
11549291|NCT01009229|Other|1|
11549292|NCT01009216|Experimental|ABT-384|
11549293|NCT01009203|Experimental|Temsirolimus and Erlotinib|Erlotinib (Tarceva) at 150 mg by mouth daily + Temsirolimus (Torisel) at 15 mg intravenously weekly. Each cycle is comprised of 28 days
11549294|NCT01009190|Experimental|ARM A|Carboplatin plus PF-01367338
11549295|NCT01009190|Experimental|ARM A EXPANSION|Carboplatin plus PF-01367338
11549296|NCT01009177|Experimental|Bosentan|
11549297|NCT01009177|Placebo Comparator|Placebo|
11549298|NCT01009151|Experimental|Heart Care Self Tracker|Web-based Home Tele-monitoring system
11549299|NCT01009138|Experimental|Diabetes-Specific CBT (DS-CBT)|Cognitive Behavioral Intervention (Group) focusing on Diabetes-Specific Problems
11549300|NCT01009138|Active Comparator|Standard Diabetes Education|Standard Diabetes Education Lessons will be given to quantify the unspecific antidepressive Effects of Participation in Group Sessions with social Contact and Acquisition of Knowledge.
11549301|NCT01009125|Experimental|$2 cash incentive|
11549302|NCT01009125|Experimental|$5 cash incentive|
11549303|NCT01009112|Experimental|CBT for Insomnia|"Patients change their sleep times and habits in order to reduce alertness and over thinking when they are trying to sleep. This helps them learn how to sleep overnight in one solid block of time"
11549304|NCT01009112|Experimental|Imagery Rehearsal Therapy|"Patients rescript the narrative of a nightmare to eliminate the distressing elements and create a new pleasant dream scene. They then rehearse this scene in their imagination at least twice each day. This reduces the frequency and intensity of the target nightmare and often reduces other nightmares, too."
11549305|NCT01009112|Experimental|Prolonged Exposure|This behavioral treatment for PTSD involves 1) systematic and repeated exposure to objects and situations that are avoided due to trauma-related distress, 2) prolonged, repeated recounting of trauma memories through visualization, and 3)therapist-guided discussions of thoughts and emotions related to the exposure exercises. The goals of PE are to reduce the anxiety and distress elicited by trauma-related memories and situations, show patients these memories and situations are distinct from the trauma, and teach patients they can tolerate the distress caused by these memories and situations.
11549306|NCT01009112|Active Comparator|Suportive Care Therapy|This is an active therapy where the focus of the intervention is on helping patients better understand their emotional response to their PTSD and sleep symptoms.
11549307|NCT01009099|Experimental|Arm 1|exercise training with breathing retraining
11549308|NCT01009099|Active Comparator|Arm 2|exercise training
11549309|NCT01009086|Experimental|Placebo|Participants will receive subcutaneous (SC) injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants will cross over to receive SC injections of ustekinumab 45 mg at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 88. If early escape, SC injections of 45 mg ustekinumab will be given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 88. For participants entering early escape, a SC placebo injection will be given at Week 24 to maintain the blind.
11549310|NCT01009086|Experimental|Ustekinumab 45 mg|Participants will receive SC injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, SC injections of 90 mg ustekinumab will be given at Week 16 and every 12 weeks thereafter with the last dose at Week 88. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
11549311|NCT01009086|Experimental|Ustekinumab 90 mg|Participants will receive SC injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, the same dosage schedule will continue. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
11549312|NCT01009073|Experimental|Arm A (ABT-263 and erlotinib)|
11549313|NCT01009073|Experimental|Arm B (ABT-263 and irinotecan)|
11549314|NCT01009073|Experimental|Arm C (ABT-263 monotherapy)|
11549315|NCT01009060|Experimental|GSK239512|Repeat dose.
11549316|NCT01009060|Placebo Comparator|Placebo|Repeat dose. Placebo to match GSK239512
11549317|NCT01009047|Experimental|Paliperidone extended-release (ER)|Paliperidone ER will be administered as oral capsule at a dose of 6 milligram (mg) for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
11549318|NCT01009047|Active Comparator|Aripiprazole|Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
11549319|NCT01009034||12 male HIV-positive patients|Male HIV-positive patients who have been receiving stable antiretroviral therapy that includes maraviroc for a minimum of three months.
11549320|NCT01009021|Other|Placebo first (scheme 2)|scheme 2 patients (n=15) received a brown-coated tablet of saccharine (placebo) 45 minutes before the first PRP episode [placebo treatment episode (PTE)] at baseline to the right eye and two weeks after received one 50 mg tablet of potassium diclofenac 45 minutes before the second PRP episode [diclofenac treatment episode (DTE)] to the left eye
11549475|NCT01007851|Placebo Comparator|Saline|
11549606|NCT01007006|No Intervention|Control|Control arm will receive only medication management, no TMRDU.
11549321|NCT01009021|Other|Diclofenac first (scheme 1)|scheme 1 patients (n=15) received one 50 mg tablet of potassium diclofenac 45 minutes before the first PRP episode [diclofenac treatment episode (DTE)] at baseline to the right eye and two weeks after received an identical brown-coated tablet of saccharine (placebo) 45 minutes before the second PRP episode [placebo treatment episode (PTE)] to the left eye
11549322|NCT01009008|Experimental|Post-mastectomy|Post-mastectomy patients undergoing expander reconstruction
11549323|NCT01008995|Experimental|001|placebo Subcutaneous injection at Week 0 and 4,ustekinumab 45 mg subcutaneous injection at Week 12 and 16
11549324|NCT01008995|Experimental|002|placebo Subcutaneous injection at Week 12,ustekinumab 45 mg subcutaneous injection at Week 0 4 and 16
11549325|NCT01008982|Experimental|single arm|
11549326|NCT01008956|Experimental|Single Group|Subjects enrolled in this group will be stratified by age (18 to 40 years and 41 to 64 years)
11549327|NCT01008943|Experimental|1|
11549328|NCT01008930|Experimental|PEM Scan|HR PEM images (High Resolution PEMFlex Solo II scan images)
11549329|NCT01008917|Experimental|single treatment-non randomized study|Phase I study is to test the safety of the combination of sorafenib with temsirolimus at different dose levels
11549330|NCT01008904|Experimental|Supportive care (magnesium oxide)|Patients receive magnesium oxide by mouth daily or twice daily for 4 weeks.
11549331|NCT01008865|Experimental|Studer Pouch|Studer Pouch orthotopic urinary diversion
11549332|NCT01008865|Experimental|T-Pouch|T-Pouch orthotopic urinary diversion
11549333|NCT01008852|Experimental|Treatment Group 1|
11549334|NCT01008852|Experimental|Treatment Group 2|
11549335|NCT01008852|Experimental|Treatment Group 3|
11549336|NCT01008852|Experimental|Treatment Group 4|
11549337|NCT01008852|Placebo Comparator|Treatment Group 5|
11549338|NCT01008839||Old age group of healthy women|Old women over 70 years old
11549339|NCT01008839||young group of healthy women|aged 25-35 years
11549340|NCT01008826|Experimental|glucoraphanin-rich broccoli extract|
11549341|NCT01008826|Experimental|sulforaphane-rich broccoli extract|
11549342|NCT01008813|Experimental|adjuvanted A(H1N1)v influenza vaccine|Two injections at day 0 and day 21
11549343|NCT01008813|Experimental|non-adjuvanted A(H1N1)v influenza vaccine|Two injection at day 0 and day 21
11549344|NCT01008800|Experimental|Center-Based classroom intervention|Four days a week for 2.5 hours a day the child will participate in a classroom with peers in an attempt to increase social communication, language abilities, and other skills. Parents will also receive education sessions 1-3 times per month for 1-2 hours each. Treatment will last for 6 months.
11549345|NCT01008800|Active Comparator|Parent Training|Parents are taught strategies on how to interact with their children to increase their skills. Parent training sessions are given 2 times a month at our center and once a month at home for 60-90 minutes each. Treatment will last for 6 months.
11549346|NCT01008787|No Intervention|Focus Group|Qualitative interviews examining social support for PA conducted with African American (AA) women recruited from Wheeler Avenue Baptist Church located in Houston used to design Culturally-Appropriate Peer-based Motivational Interviewing (CAPMI) intervention.
11549347|NCT01008787|Active Comparator|Intervention Group 1|CAPMI Intervention: Training + Weekly Partner Questionnaire + Interview + PA Newsletter
11549348|NCT01008787|Active Comparator|Intervention Group 2|Interview + PA Newsletter
11549349|NCT01008774|Experimental|A|
11549350|NCT01008774|Active Comparator|B|
11549351|NCT01008774|No Intervention|C|
11549352|NCT01008761|Active Comparator|Zithromax, 100 mgmgs; 5mls suspension|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
11549353|NCT01008761|Placebo Comparator|Suspension placebo,|placebo (suspension produced by CDC Edmonton.) given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days.
11549354|NCT01008748|Experimental|Smoking Cessation Treatment|Nicotine replacement therapy (NRT), self-help materials, + brief in-person and telephone counseling, all conducted in Spanish. Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
11549355|NCT01008735||women with hodgkin lymphoma treated with chemotherapy|
11549356|NCT01008709|Placebo Comparator|Teleflex HemoLock clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur
11549357|NCT01008709|Active Comparator|Aesculap U-Clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur.
11549358|NCT01008696|Experimental|Rabeprazole|Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
11549359|NCT01008696|Active Comparator|Lansoprazole|Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
11549360|NCT01008683||Stem cell and and heart transplant patients|Stem cell and and heart transplant patients
11549361|NCT01008670||Device Implant Recipients|Patients undergoing CRT implantation, or candidates for future CRT devices currently undergoing ICD or pacemaker implantation.
11549362|NCT01008657|Experimental|"extranodular no touch multipolar RFA"|
11549363|NCT01008657|Active Comparator|intranodular multipolar RFA|
11549364|NCT01008644|Experimental|Saline|The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min.
11549365|NCT01008644|Experimental|Water|The subjects will drink tap water for 2 hours, the volume calculated as 20ml/kg/hour
11549366|NCT01008631|Experimental|dialysis|Two doses of sodium thiosulfate
11549367|NCT01008631|Experimental|healthy volunteer|One dose of sodium thiosulfate
11549519|NCT01007513||At risk patient for preterm delivery|Patient referred to the MFM clinic for a risk evaluation for preterm delivery.
11549520|NCT01007500|Experimental|Group Dexamethasone|
11549368|NCT01008618|Experimental|Fentanyl (Titration period)|One-day adhesive transdermal patch containing fentanyl (JNS020QD) applied to chest, abdomen, upper arm and thigh and replaced every day, starting at the dose of 12.5 microgram per hour (mcg/hr) for at least first 2 days, which will be increased by 12.5 mcg/hr at one time based on the medical examination of number of rescue treatments and visual analog scale (VAS) score of the participants. The dose will be increased up to maximum of 50 mcg/hr. The treatment will be continued for 10-29 days and then the eligible participants from this group will be randomly assigned to either of the two groups in the double-blind period.
11549369|NCT01008618|Experimental|Fentanyl (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to fentanyl group, will be administered one-day adhesive transdermal patch containing fentanyl, applied to chest, abdomen, upper arm and thigh and replaced every day, the dose of which will be same as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will be continued for 12 weeks.
11549370|NCT01008618|Placebo Comparator|Placebo (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to placebo group, will be administered one-day adhesive transdermal placebo patch indistinguishable from fentanyl in appearance, applied to chest, abdomen, upper arm and thigh and replaced every day. The dose of fentanyl (from titration period) will be gradually decreased to prevent withdrawal symptoms and the dose of the matching placebo will be gradually increased up to same dose as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will continue for 12 weeks.
11549371|NCT01008605|Experimental|Caverject Impulse|representative users
11549372|NCT01008592||Group 1|Subjects with chronic idiopathic urticaria exhibiting dermatographism.
11549373|NCT01008566|Experimental|Treatment (cixutumumab, sorafenib tosylate)|Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22 and oral sorafenib tosylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11549374|NCT01008553|Experimental|Fentanyl (Titration period)|One-day adhesive transdermal patch (patch containing a drug that is put on the skin so the drug will enter the body through the skin) containing fentanyl (JNS020QD) applied to chest, abdomen, upper arm and thigh and replaced every day, starting at the dose of 12.5 microgram per hour (mcg/hr) for at least first 2 days, which will be increased by 12.5 mcg/hr at one time based on the medical examination of number of rescue treatments and visual analog scale (VAS) score of the participants. The dose will be increased up to maximum of 50 mcg/hr. The treatment will continue for 10-29 days and then the eligible participants from this group will be randomly assigned to either of the two groups in the double-blind period.
11549375|NCT01008553|Experimental|Fentanyl (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to fentanyl group, will be administered one-day adhesive transdermal patch containing fentanyl, applied to chest, abdomen, upper arm and thigh and replaced every day, the dose of which will be same as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will be continued for 12 weeks.
11549376|NCT01008553|Placebo Comparator|Placebo (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to placebo group, will be administered one-day adhesive transdermal placebo patch indistinguishable from fentanyl in appearance, applied to chest, abdomen, upper arm and thigh and replaced every day. The dose of fentanyl (from titration period) will be gradually decreased to prevent withdrawal symptoms and the dose of the matching placebo will be gradually increased up to same dose as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will continue for 12 weeks.
11549377|NCT01008527|Experimental|Infusion and Peptide Administration|Patients get the study drug Oncovir poly IC:LC with or without CP 870-893. Up to 6 groups of 3 to 10 patients each will be treated in this study. The first group (between 3 and 6 patients) gets peptide vaccine with poly IC:LC. Second, third and fourth groups of 3 to 6 patients receive peptide vaccine with poly IC:LC and the antibody CP 870,893 at increasing doses from 0.01, 0.025 and 0.05 mg/kg. CP 870-893 will be given to 10 patients at a dose of 0.1 mg/kg to patients in the fifth group, and 0.2 mg/kg to the sixth group. The CP 870,893 will be given as an intravenous infusion over 30 minutes and will be given once every 2 weeks for the first 6 infusions. CP-870-893 will then be given every 4 to 6 weeks for 3 injections. The final 3 injections of CP 870,893 will be given every 8 to 12 weeks. These infusions will take place on weeks 1, 3, 5, 7, 9, 11, 17, 21, 25, 33, 41, and 53 for a total of 12 infusions.
11549378|NCT01008501||Experimental|Individuals with recurrent or sporadic hydatidiform moles and their first-degree family members. Sometimes additional family members are also enrolled.
11549379|NCT01008488|Active Comparator|Antibiotic|
11549380|NCT01008488|No Intervention|No antibiotic|
11549381|NCT01008475|Experimental|Safety part: EMD 525797 250 mg + Standard of Care (SoC)|EMD 525797 250 mg in combination with cetuximab and irinotecan
11549382|NCT01008475|Experimental|Safety part: EMD 525797 500 mg + SoC|EMD 525797 500 mg in combination with cetuximab and irinotecan
11549383|NCT01008475|Experimental|Safety part: EMD 525797 750 mg + SoC|EMD 525797 750 mg in combination with cetuximab and irinotecan
11549384|NCT01008475|Experimental|Safety part: EMD 525797 1000 mg + SoC|EMD 525797 1000 mg in combination with cetuximab and irinotecan
11549385|NCT01008475|Experimental|Randomized part: EMD 525797 500 mg + SoC|EMD 525797 500 mg in combination with cetuximab and irinotecan
11549386|NCT01008475|Experimental|Randomized Part: EMD 525797 1000 mg + SoC|EMD 525797 1000 mg (or dose as defined by safety monitoring committee (SMC)] in combination with cetuximab and irinotecan.
11549387|NCT01008475|Other|Randomized Part: SoC|Cetuximab and irinotecan
11549388|NCT01008462|Experimental|Treatment (autologous HCT, donor HCT)|See Detailed Description
11549389|NCT01008449|Active Comparator|Absorbable Subcuticular Surgical Suture|Patients in this arm will receive absorbable subcuticular suture for wound closure of cesarean deliveries.
11549390|NCT01008449|Active Comparator|Surgical staples|Patients in this arm will receive surgical staples for wound closure.
11549391|NCT01008436|Active Comparator|Control|Traditional best-practice surgical hemostasis
11549392|NCT01008436|Experimental|Omni-stat Celox|Administration of 6 gr of Omni-stat Celox intraoperatively at the time of Hemostasis
11549521|NCT01007500|Active Comparator|Group Ondansetron|
11549393|NCT01008423|Experimental|Budesonide|Participants who were diagnosed with active mild to moderate UP or UPS, will receive 2 milligrams (mg)/25 milliliter (mL) of budesonide foam, rectally twice daily for a period of 2 weeks followed by 2 mg/25 mL of budesonide foam, rectally once daily for a period of 4 weeks.
11549394|NCT01008423|Placebo Comparator|Placebo|Participants who were diagnosed with active mild to moderate UP or UPS will receive 25 mL of placebo matching to budesonide foam twice daily for a period of 2 weeks followed by once daily for a period of 4 weeks.
11549395|NCT01008410|Experimental|Budesonide|Participants who were diagnosed with active mild to moderate UP or UPS, will receive 2 milligrams (mg)/25 milliliter (mL) of budesonide foam, rectally twice daily for a period of 2 weeks followed by 2 mg/25 mL of budesonide foam, rectally once daily for a period of 4 weeks.
11549396|NCT01008410|Placebo Comparator|Placebo|Participants who were diagnosed with active mild to moderate UP or UPS will receive 25 mL of placebo matching to budesonide foam twice daily for a period of 2 weeks followed by once daily for a period of 4 weeks.
11549397|NCT01008397|Experimental|AHIST for seasonal allergic rhinitis|AHIST for SAR: each green tablet contains 12mg chlorpheniramine tannate.
11549398|NCT01008384|No Intervention|placebo|
11549399|NCT01008384|Experimental|Vitamin D3|Vitamin D3 given for 8 weeks
11549400|NCT01008371||Obese|Healthy obese subjects
11549401|NCT01008371||Non-obese|Healthy non-obese subjects
11549402|NCT01008345|Experimental|ezetimibe|will receive the active treatment with ezetimibe and statin
11549403|NCT01008345|Placebo Comparator|placebo|
11549404|NCT01008332|Experimental|Cohort 1|ToleroMune HDM, subjects to receive either active or placebo comparator
11549405|NCT01008332|Experimental|Cohort 2|ToleroMune HDM, subjects to receive either active or placebo comparator
11549406|NCT01008332|Experimental|Cohort 3|ToleroMune HDM, subjects to receive either active or placebo comparator
11549407|NCT01008332|Experimental|Cohort 4|ToleroMune HDM, subjects to receive either active or placebo comparator
11549408|NCT01008332|Experimental|Cohort 5|Toleromune HDM, subjects to receive either active or placebo comparator
11549409|NCT01008319|Active Comparator|Traditional Administration|The traditional approach to ovulation induction with clomiphene citrate involves administration of 50mg/day for five days (starting on cycle day 3, 4, or 5). If ovulation does not occur then a progestin is prescribed to induce menses (which occurs within one week of stopping the progestin) and then a higher dose of medication is used in the next cycle.
11549410|NCT01008319|Experimental|Stair-Step Administration|The stair-step protocol the dose of clomiphene citrate would be increased without administering progestin and inducing a period. This would eliminate the days of progestin (10 days) and the waiting for the period (usually 3 to 7 days) and finally waiting to start clomiphene citrate on cycle day 3 at the earliest (3 more days) for a total of up to 20 days difference for the 100 mg dose of clomid. If they did not ovulate on 100mg, then the process repeats and another 20 days before they start 150mg. Therefore, the time to ovulation and pregnancy may be reduced, and hopefully pregnancy, by using the stair-step protocol. This method utilizes ultrasound monitoring for follicle development before increasing the dose of clomiphene citrate.
11549411|NCT01008306||Renal transplanted children and young adults|"Renal transplanted children and adolescents (2-18yrs) transplanted between 1993-2006.
~Renal transplanted young adults aged 20-35 yrs old, transplanted from 1983 onwards."
11549412|NCT01008293|Experimental|VSL#3|
11549413|NCT01008293|Active Comparator|Lactulose|30-60 ml of lactulose per day (2 months) to ensure 2-3 soft stools
11549414|NCT01008280|Experimental|Baclofen|baclofen 10 mg po tid
11549415|NCT01008280|Placebo Comparator|Placebo|placebo given tid
11549416|NCT01008267||SWL under general anesthesia|Patients who failed in SWL under sedation(a standard protocol), will undergo a second SWL process under general anesthesia.
11549417|NCT01008267||SWL under general selective anesthesia|Patients who failed in SWL under sedation(a standard protocol), will undergo a second SWL process under general selective anesthesia, using a bronchial blocker.
11549418|NCT01008254|Experimental|Musical prompt|
11549419|NCT01008254|Active Comparator|Delayed musical prompt|
11549420|NCT01008254|No Intervention|No musical prompt|
11549421|NCT01008241||Adult Residents of South Florida|Persons 18 years of age or older, residing in Broward or Miami-Dade Counties.
11549422|NCT01008228|Active Comparator|tube thoracic drainage|drainage performed with tube drainage CH 16 or ch 20
11549423|NCT01008228|Experimental|exsufflation|exsufflation with a specific thoracentesis system
11549424|NCT01008215|Experimental|Algorithm|Algorithm (available in paper version and web-based version) will be used for warfarin maintenance dosing.
11549425|NCT01008215|No Intervention|Care as usual|Control group
11549426|NCT01008150|Active Comparator|Arm 1: paclitaxel + trastuzumab then A C|4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Trastuzumab concurrently with paclitaxel weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Following paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
11549427|NCT01008150|Experimental|Arm 2: paclitaxel + neratinib then A C|4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
11549428|NCT01008150|Experimental|Arm 3: paclitaxel + trastuzumab + neratinib then A C|4 cycles of paclitaxel 80 mg/m2 on days 1, 8, and 15 of a 28 day cycle. Trastuzumab concurrently with paclitaxel, weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Neratinib 200 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/trastuzumab/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
11549522|NCT01007461|Experimental|IK-1001|IK-1001 Sodium Sulfide (Na2S) for Injection
11549523|NCT01007461|Placebo Comparator|Placebo|0.9% Sodium Chloride (NaCl)
11549429|NCT01008150|Experimental|Arm 3 NR: paclitaxel+trastuzumab+neratinib|Non-randomized: 4 cycles of paclitaxel 80 mg/m2 on days 1, 8, and 15 of a 28 day cycle. Trastuzumab concurrently with paclitaxel, weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Neratinib 200 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/trastuzumab/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
11549430|NCT01008137|Experimental|Group 1: Day 0-PANFLU.1; Day 21-ANFLU|50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.
11549431|NCT01008137|Experimental|Group 2: Day 0-ANFLU; Day 21-PANFLU.1|50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.
11549432|NCT01008137|Experimental|Group 3: Day 0-PANFLU.1+ANFLU|50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.
11549433|NCT01008124|Experimental|Liberatory Maneuver|Liberatory Maneuver
11549434|NCT01008124|Placebo Comparator|Placebo Maneuver|Placebo Maneuver
11549435|NCT01008111|Active Comparator|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
11549436|NCT01008111|Placebo Comparator|Dermabond-Placebo Comparator|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
11549437|NCT01008098|Experimental|PTSD group|
11549438|NCT01008085|Experimental|Self-expanding stent|Stentys stent
11549439|NCT01008085|Active Comparator|Balloon-expandable stent|VISION/Driver
11549440|NCT01008072||without buprenorphine preparation|
11549441|NCT01008072||with buprenorphine preparation|
11549442|NCT01008059|Experimental|Alfentanil|Alfentanil (0.5-1 mg IV bolus) followed 3 hours later or simultaneously by 1-4 mg oral deuterium-labeled (d3) alfentanil on each study visit.
11549443|NCT01008046|Experimental|combined N-acetyl cysteine - CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
11549444|NCT01008046|Active Comparator|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles.
11549445|NCT01008033|Experimental|IDP-108|
11549446|NCT01008033|Placebo Comparator|Vehicle|
11549447|NCT01008020|No Intervention|Dietary supplement: placebo|
11549448|NCT01008020|Active Comparator|Tea catechin extracts|
11549449|NCT01008007|Experimental|A|Viusid in combination with the conventional treatment for acute fever of viral etiology
11549450|NCT01008007|Active Comparator|B|Conventional treatment for acute fever of viral etiology
11549451|NCT01007994|Active Comparator|New Medication|A new anti-hypertensive medication (enalapril, propranolol or isradipine) will be added at 8pm.
11549452|NCT01007994|No Intervention|Control|Subjects in the control group will continue to take their medications as usual.
11549453|NCT01007981||CRT device|Patients with Cardiac Resynchronization Therapy(CRT) device implanted in the last 5 years will be studied by the new echo modality.Study doesn't involve acute device implantation.
11549454|NCT01007968|Experimental|HDACi|
11549455|NCT01007955||Severely Obese|Severely obese individuals scheduled to undergo gastric bypass surgery
11549456|NCT01007929|Experimental|1|14C-AZD1236
11549457|NCT01007916|Other|Lotrafilcon B / Habitual|Lotrafilcon B contact lenses worn first, with habitual contact lenses worn second. Both products worn bilaterally as often as is typical for habitual lenses, and in the same modality as is typical for habitual lenses, as prescribed by regular eye care practitioner, with extended wear not to exceed 6 nights.
11549458|NCT01007916|Other|Habitual / Lotrafilcon B|Habitual contact lenses worn first, with lotrafilcon B lenses worn second. Both products worn bilaterally as often as is typical for habitual lenses, and in the same modality as is typical for habitual lenses, as prescribed by regular eye care practitioner, with extended wear not to exceed 6 nights.
11549459|NCT01007903|No Intervention|Usual Care|
11549460|NCT01007903|Experimental|Tai Chi|
11549461|NCT01008189|Active Comparator|Self study comparison group|Caregivers and children and adolescents each received three books about coping with grief after the death of a loved one and a syllabus to guide reading
11549462|NCT01008189|Experimental|Family Bereavement Program|12- session group for caregivers and bereaved children and adolescents plus 2 individual sessions
11549463|NCT01008163|Experimental|1|YY-351, PO, 1T tid. / Placebo, 1T tid.
11549464|NCT01008163|Experimental|2|YY-351. PO, 2T bid. / Placebo 2T qd.
11549465|NCT01008163|Experimental|3|YY-351, PO, 2T tid.
11549466|NCT01008163|Placebo Comparator|4|Placebo, PO, 2T tid.
11549467|NCT01007942|Experimental|Everolimus + vinorelbine + trastuzumab|Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
11549468|NCT01007942|Placebo Comparator|placebo + vinorelbine + trastuzumab|Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only
11549469|NCT01007877|No Intervention|No break|
11549470|NCT01007877|Placebo Comparator|Placebo Energy Drink|During a 15 minute break, subjects consume a placebo energy drink
11549471|NCT01007877|Experimental|Red Bull Energy Drink|during a 15 minute break, subjects consume Red Bull Energy Drink
11549472|NCT01007864|Experimental|piribedil|
11549473|NCT01007864|Active Comparator|pramipexole or ropinirole|
11549474|NCT01007851|Experimental|GnRH agonist|
11549476|NCT01007838|Experimental|Chronic kidney disease progressive resistance training group|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
11549477|NCT01007838|Sham Comparator|Chronic kidney disease sham exercise group|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
11549478|NCT01007838|Experimental|Healthy controls progressive resistance training group|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
11549479|NCT01007838|Sham Comparator|Healthy controls sham exercise group|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
11549480|NCT01007812|Other|Lotrafilcon B / Comfilcon A|Lotrafilcon B silicone hydrogel, toric, soft contact lenses worn for one week, followed by Comfilcon A silicone hydrogel, toric, soft contact lenses worn for one week.
11549481|NCT01007812|Other|Comfilcon A / Lotrafilcon B|Comfilcon A silicone hydrogel, toric, soft contact lenses worn for one week, followed by Lotrafilcon B silicone hydrogel, toric, soft contact lenses worn for one week.
11549482|NCT01007799|Placebo Comparator|Placebo|Placebo pills to take for 12 weeks
11549483|NCT01007799|Active Comparator|Vitamin D|Vitamin D supplement for 12 weeks
11549484|NCT01007773|Experimental|Dexmedetomidine|In conjunction with conventional sedative and analgesic agents.
11549485|NCT01007773|Active Comparator|Standard of Care|Patients randomized to conventional sedation will have as the main pharmacologic agents to achieve sedation and analgesia propofol and fentanyl, respectively.
11549486|NCT01007760|Placebo Comparator|Room air|
11549487|NCT01007760|Active Comparator|Low dose exposure second-hand smoke|
11549488|NCT01007760|Active Comparator|High dose exposure second-hand smoke|
11549489|NCT01007747|Experimental|Geranium oil|
11549490|NCT01007734||1|
11549491|NCT01007721|Experimental|BI 671800 ED 100 mg|2 capsules of BI 671800 ED 25 mg plus 2 capsules of BI 671800 ED placebo (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
11549492|NCT01007721|Experimental|BI 671800 ED 400 mg|2 capsules of BI 671800 ED 100 mg plus 2 capsules of placebo (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
11549493|NCT01007721|Active Comparator|Montelukast 10 mg|1 over-encapsulated montelukast 10 mg tablet (qd in the morning) plus 4 capsules of BI 671800 ED placebo (bid in the morning and evening) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
11549494|NCT01007721|Active Comparator|Fluticasonepropionate nasal spray 200¿g|Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 ¿g per nostril) plus 4 capsules of BI 671800 ED placebo (bid in the morning and evening) plus 1 overencapsulated montelukast placebo tablet (qd in the morning)
11549495|NCT01007721|Placebo Comparator|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening), plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
11549496|NCT01007721|Experimental|BI 671800 ED 800 mg|4 capsules of BI 671800 ED 100 mg (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
11549497|NCT01007708|Experimental|IDP-108|
11549498|NCT01007708|Placebo Comparator|Vehicle|
11549499|NCT01007695|Experimental|All patients|All participants enrolled.
11549500|NCT01007682|No Intervention|Screening for working memory capacity|
11549501|NCT01007682|Experimental|Distressing movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
11549502|NCT01007669|Active Comparator|Reference|Health check only
11549503|NCT01007669|Experimental|Intervention|Physical activity and Health check
11549504|NCT01007656|Experimental|GD Antrodia camphorata|"GD Antrodia Camphorata is the extract from mycelium of the fungus Antrodia Camphorata which is an endemic species in Taiwan. According to the literatures, mycelium of Antrodia camphorata is beneficial to health. Moreover, the study product GD Antrodia Camphorata has been approved by Department of Health, Taiwan as a health supplement (approval number A00124)."
11549505|NCT01007643|Experimental|Wii Fit (TM) Interactive Video Game|Wii Fit (TM) Interactive Video Game
11549506|NCT01007643|Active Comparator|Traditional Home Exercise Program|Traditional Home Exercise Program
11549507|NCT01007630|Active Comparator|Rasagiline|0.5mg of Rasagiline for 14 days, then switch to 1mg of Rasagiline for remainder of the study (approximately 10 weeks total).
11549508|NCT01007630|Placebo Comparator|Placebo|0.5mg of placebo for 14 days, then switch to 1mg of placebo for remainder of the study (approximately 10 weeks total)
11549509|NCT01007604|Active Comparator|Exercise and lifestyle counselling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
11549510|NCT01007604|Experimental|PCD with peristaltic pulse waveform|Daily use for two hours
11549511|NCT01007591|Active Comparator|LEO 80190 ointment|
11549512|NCT01007591|Active Comparator|Hydrocortisone 10 mg/g ointment|
11549513|NCT01007578|Experimental|Paclitaxel treatment|Paclitaxel-coated balloon catheter angioplasty treated subjects
11549514|NCT01007565|Experimental|periarticular injection, pain level|
11549515|NCT01007552|Experimental|Gemcitabine, Capecitabine and Bevacizumab|Estimate the toxicity of the regimen, and estimate the quality of life (QOL).
11549516|NCT01007539|Experimental|CDP-choline|
11549517|NCT01007539|Placebo Comparator|Placebo (fructose)|
11549518|NCT01007526|Experimental|CCRT plus VIDL|CCRT followed by VIDL chemotherapy Concomitant chemo-radiotherapy followed by VIDL chemotherapy with risk-based application of autologous stem cell transplantation Patients who are planned to be treated with CCRT plus VIDL chemotherapy and/or autologous stem cell transplantation
11549524|NCT01007448|Experimental|Bexarotene 150 milligrams (mg)/square meter (m^2)/day|Participants will receive bexarotene 150 mg/m^2/day once daily for 24 weeks.
11549525|NCT01007448|Experimental|Bexarotene 300 mg/m^2/day|Participants will receive bexarotene 300 mg/m^2/day once daily for 24 weeks.
11549526|NCT01007435|Experimental|(A) Tocilizumab 8 mg/kg + placebo to methotrexate|Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.
11549527|NCT01007435|Experimental|(B) Tocilizumab 8 mg/kg + methotrexate|Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
11549528|NCT01007435|Experimental|(C) Tocilizumab 4 mg/kg + methotrexate|Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
11549529|NCT01007435|Active Comparator|(D) Placebo to tocilizumab + methotrexate|Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.
11549530|NCT01007422||Supportive Care|
11549531|NCT01007409|Active Comparator|Group B|Period 1: fed control → Period 2: fasted control
11549532|NCT01007409|Active Comparator|Group A|Period 1: fasted control → Period 2: fed control
11549533|NCT01007396|Other|new healthcare workers|doctors and nurses who were newly hired in 2008 at the Samsung Medical Center
11549534|NCT01007383|Experimental|LEO 27847 oral solution (0.05 mg/mL)|LEO 27847
11549535|NCT01007383|Experimental|LEO 27847 oral solution (0.75 mg/mL)|LEO 27847
11549536|NCT01007383|Placebo Comparator|LEO 27847 oral solution (placebo)|Placebo
11549537|NCT01007370|Active Comparator|LMA-Fastrach|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.
~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification
~Insertion of LMA-Fastrach (sizes 3,4 or 5), establishment of ventilation
~Evaluation of glottic view through LMA-Fastrach using fibrescope (one out of ten patients)
~Tracheal intubation through the LMA-Fastrach
~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
11549538|NCT01007370|Active Comparator|I-gel|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.
~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification
~Insertion of I-gel (sizes 3,4 or 5), establishment of ventilation
~Evaluation of glottic view through I-gel using fibrescope (one out of ten patients)
~Tracheal intubation through the I-gel
~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
11549539|NCT01007357|No Intervention|Body MRI healthy volunteers|Body MRI to optimize sequences in healthy individuals and in disorder subjects
11549540|NCT01007344|Active Comparator|flaxseed|2 muffins and 1 slice of bread for a total of 30g flaxseed per day
11549541|NCT01007344|Placebo Comparator|whole wheat flour|2 muffins and 1 slice of bread containing whole wheat flour per day
11549542|NCT01007318|Active Comparator|Single port|Single port through the transumbilical incision was made by wound retractor combined with surgical glove and then 3 trocal was inserted to the finger part of the surgical glove. Laparoscopic instrument was working through the single port and resected appendix removed through it.
11549543|NCT01007318|Active Comparator|3 port|3 port laparoscopic appendectomy was done by conventional method
11549544|NCT01007305|Experimental|Bilateral salpingo-oophorectomy|Removal of both ovaries and fallopian tubes at the time of hysterectomy for benign conditions.
11549545|NCT01007305|Active Comparator|Ovarian conservation|No ovaries or fallopian tubes removed at the time of hysterectomy for benign conditions.
11549546|NCT01007292|Experimental|YM155 plus rituximab|
11549547|NCT01007279|Active Comparator|CLOPIDOGREL|
11549548|NCT01007279|Experimental|ROSUVASTATIN|
11549549|NCT01007266|Other|Group A|Buddy Group - Individuals with type 2 diabetes receive conventional diabetes treatment and are assigned a patient partner (Buddy)
11549550|NCT01007266|Active Comparator|Group B|Individuals receive conventional treatment for type 2 diabetes
11549551|NCT01007253|Other|FF/PL, PL/OLO, FF/OLO, PL/PL|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:
~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL)
~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),
~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO), and
~placebo (PL) nasal spray and PL eye drops (PL/PL)."
11549552|NCT01007253|Other|PL/OLO, FF/OLO, PL/PL, FF/PL|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:
~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),
~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),
~placebo (PL) nasal spray and PL eye drops (PL/PL), and
~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL)."
11549553|NCT01007253|Other|FF/OLO, PL/PL, FF/PL, PL/OLO|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:
~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),
~placebo (PL) nasal spray and PL eye drops (PL/PL),
~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL), and
~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO)."
11549554|NCT01007253|Other|PL/PL, FF/PL, PL/OLO, FF/OLO|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:
~placebo (PL) nasal spray and PL eye drops (PL/PL),
~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL),
~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO), and
~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO)."
11549555|NCT01007240|Experimental|soft liner with nano particles|the obturators of this patients will be relined with soft liner, with incorporated nano particles. after a week, the soft liner will be taken off, and will be checked for bacterial adhesion.
11549556|NCT01007227|Other|Lifestyle instruction|
11549557|NCT01007214|Experimental|Prostate cancer|A total of 30 patients diagnosed with prostate cancer who have elected to undergo radical prostatectomy are enrolled over a six year period.
11549558|NCT01007201|Experimental|H1N1 vaccine of 15 μg HA on Day 0 and 21|15 μg HA (0.5 mL) per injection, 2 injections 50 children (aged over 3 years old to 6 years old) and 50 children/teenagers (aged over 6 years old to 18 years old) were assigned to receive two injections of H1N1 vaccine 3 weeks apart
11549559|NCT01007201|Experimental|H1N1 vaccine of 7.5 μg HA on Day 0 and 21|7.5 μg HA (0.25 mL) per injection, 2 injections 50 toddlers (aged over 1 year old to 3 years old) were assigned to receive two injections of H1N1 vaccine 3 weeks apart
11549560|NCT01007188|Active Comparator|1.5PD|average American diet plus 1.5 oz per day almonds
11549561|NCT01007188|Other|Base|average American diet without almonds
11549562|NCT01007188|Active Comparator|3.0PD|average American diet plus 3.0 oz per day almonds
11549563|NCT01007175|Experimental|Cohort 1|
11549564|NCT01007175|Experimental|Cohort 2|
11549565|NCT01007175|Experimental|Cohort 3|
11549566|NCT01007175|Experimental|Cohort 4|
11549567|NCT01007175|Experimental|Cohort 5|
11549568|NCT01007149|Experimental|Omalizumab|Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.
11549569|NCT01007149|Placebo Comparator|Placebo|Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks.
11549570|NCT01007136|Experimental|tDCS and occupational therapy|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
11549571|NCT01007136|Sham Comparator|Sham and occupational therapy|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
11549572|NCT01007123|Experimental|A3309 low dose|Administered once daily for the duration of the study
11549573|NCT01007123|Experimental|A3309 intermediate dose|Administered once daily for the duration of the study.
11549574|NCT01007123|Experimental|A3309 high dose|Administered once daily for the duration of the study
11549575|NCT01007123|Placebo Comparator|Placebo|Administered once daily for the duration of the study
11549576|NCT01007110|Active Comparator|Docosahexaenoic Acid (DHA)|Docosahexaenoic Acid (DHA)
11549577|NCT01007110|Placebo Comparator|Placebo|soy/corn oil placebo
11549578|NCT01007097|Experimental|TAK-875 6.25 mg QD|
11549579|NCT01007097|Experimental|TAK-875 25 mg QD|
11549580|NCT01007097|Experimental|TAK-875 50 mg QD|
11549581|NCT01007097|Experimental|TAK-875 100 mg QD|
11549582|NCT01007097|Experimental|TAK-875 200 mg QD|
11549583|NCT01007097|Active Comparator|Glimepiride 2 mg or 4mg QD|
11549584|NCT01007097|Placebo Comparator|Placebo QD|
11549585|NCT01007084|Experimental|Propranolol|
11549586|NCT01007084|Placebo Comparator|Sugar pill|
11549587|NCT01007071|Experimental|Growth hormone|Subjects randomized to growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Dose adjustments based on serum insulin-like growth factor-1 (IGF-1) levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 standard deviation (SD) to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
11549588|NCT01007071|Placebo Comparator|Placebo|Subjects randomized to placebo for 16 weeks. As noted above, placebo subjects will be initiated on a daily subcutaneous injection, with dose changes based on changes in active drug subjects.
11549589|NCT01007058||Response Markers|Urine Collection and Bladder wash of Bladder Cancer Patients with Treatment of BCG or BCG plus interferon
11549590|NCT01007045||"Clinically likely"|Subjects deemed clinically likely to have DVT based on modified Well's criteria
11549591|NCT01007045||"Clinically unlikely"|Subjects deemed clinically unlikely to have DVT based on modified Well's criteria
11549592|NCT01007032|Experimental|Cixutumumab|Participants receive IV cixutumumab every 2 or 3 weeks. A cycle equals 6 weeks, with radiological evaluation of tumor response after each cycle. After 1st cycle, pts with a complete response (CR), PR, or SD continue to receive cixutumumab cohort dose and schedule disease progression. 3 pts enroll in each cohort. Starting dose in Cohort 1 is 6 mg/kg every 2 weeks. Dose escalation from Cohort 1 to Cohort 2 (10 mg/kg every 2 weeks) occurs at least 3 pts in Cohort 1 completes 1 cycle of therapy. Enrollment into Cohort 3 (starting dose: 15 mg/kg administered every 3 weeks) will not proceed until at least 3 pts have completed one cycle of therapy in Cohort 2. Pts enroll in Cohort 4 once at least 3 pts have completed once cycle of therapy in Cohort 3; pts in Cohort 4 receive 20 mg/kg every 3 weeks.
11549593|NCT01007019|Experimental|YH4808 30mg|"1.Single dose
~2.12 volunteers were administered YH4808 30mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
11549594|NCT01007019|Experimental|YH4808 50mg|"1.Single dose
~2.12 volunteers were administered YH4808 50mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
11549595|NCT01007019|Experimental|YH4808 100mg|"1.Single dose
~2.12 volunteers were administered YH4808 100mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
11549596|NCT01007019|Experimental|YH4808 200mg|"1.Single dose
~2.12 volunteers were administered YH4808 200mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
11549597|NCT01007019|Experimental|YH4808 400mg|"1.Single dose
~2.12 volunteers were administered YH4808 400mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
11549598|NCT01007019|Experimental|YH4808 100mg(repeat doses)|"1.Repeat doses
~2.12 volunteers were administered YH4808 100mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
11549599|NCT01007019|Experimental|YH4808 200mg(repeat doses)|"1.Repeat doses
~2.16 volunteers were administered YH4808 200mg or active/placebo comparators.(YH4808:active:placebo=8:6:2)"
11549600|NCT01007019|Experimental|YH4808 400mg(repeat doses)|"1.Repeat dose
~2.12 volunteers were administered YH4808 400mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
11549601|NCT01007019|Experimental|YH4808 600mg|"1.Single dose
~2.12 volunteers were administered YH4808 600mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
11549602|NCT01007019|Experimental|YH4808 800mg|"1.Single dose
~2.12 volunteers were administered YH4808 800mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
11549603|NCT01007019|Placebo Comparator|Placebo|
11549604|NCT01007019|Active Comparator|Esomeprazole 40mg|
11549605|NCT01007006|Experimental|TMRDU|Telepharmacy Robotic Medicine Delivery Unit (TMRDU) group will receive TMRDU plus medication management
11549607|NCT01006993|Experimental|NeuroFlo Treatment|
11549608|NCT01006980|Experimental|Vemurafenib|
11549609|NCT01006980|Active Comparator|Dacarbazine|
11549610|NCT01006967|Active Comparator|ActiveStep|Subjects will use the ActiveStep treadmill as part of their physical therapy program for balance
11549611|NCT01006967|Active Comparator|Standard physical therapy|Subjects will receive a standard physical therapy program for gait and balance.
11549612|NCT01006954|Active Comparator|Flare Up|Flare up protocol in poor responders for IVF/ICSI
11549613|NCT01006954|Experimental|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
11549614|NCT01006941|Experimental|Trichuris suis ova|
11549615|NCT01006928||Mothers|Mother of infants in NICU
11549616|NCT01006915|Experimental|Surgical decompression|Surgical decompression of the common peroneal, tibial, and deep peroneal nerves
11549617|NCT01006915|No Intervention|Standard medical care|Standard diabetic care and medical care provided for diabetic sensorimotor polyneuropathy
11549618|NCT01006902||Individuals age 65 or older|Individuals age 65 or older receiving chemotherapy for cancer or short term androgen deprivation therapy for individuals 65 or older with prostate cancer.
11549619|NCT01006889|Experimental|Exenatide (twice daily)|Patients with T2DM well-controlled on an intensified insulin regimen for the previous 6 months by the will have their insulin aspart discontinued and replaced for exenatide twice daily while continuing the bedtime detemir insulin. Safety and efficacy parameters will be measured before and after 6 months of treatment.
11549620|NCT01006876|Active Comparator|Study Arm|Patients receive continuous Coumadin therapy throughout the study.
11549621|NCT01006876|Active Comparator|Control Arm|Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
11549622|NCT01006863|Active Comparator|Ephedrine 0.15 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 1.5 mg/kg of ephedrine
11549623|NCT01006863|Active Comparator|Ephedrine 0.1 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 1 mg/kg of ephedrine
11549624|NCT01006863|Active Comparator|Ephedrine 0.07 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 0.7 mg/kg of ephedrine
11549625|NCT01006863|Placebo Comparator|Placebo|received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution
11549626|NCT01006863|Active Comparator|Phenylephrine|received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/kg of phenylephrine
11549627|NCT01006824|Experimental|1|Capsule Endoscopy
11549628|NCT01006824|Active Comparator|2|Dedicated small bowel contrast radiography
11549629|NCT01006811|Experimental|modified Atkins diet|
11549630|NCT01006798|Experimental|Cohort 1|three vaccinations of 10^7vp Ad4-H5-Vtn or placebo
11549631|NCT01006798|Experimental|Cohort 2|three vaccinations of the 10^8vp Ad4-H5-Vtn or placebo
11549632|NCT01006798|Experimental|Cohort 3|three vaccinations of 10^9 Ad4-H5-Vtn or placebo
11549633|NCT01006798|Experimental|Cohort 4|three vaccinations of 10^10 Ad4-H5-Vtn or placebo
11549634|NCT01006798|Experimental|Cohort 5|three vaccinations of 10^11 Ad4-H5-Vtn or placebo
11549635|NCT01006785|Experimental|Treatment I|DLBS1425 150 mg three times daily
11549636|NCT01006785|Experimental|Treatment II|DLBS1425 300 mg three times daily
11549637|NCT01006772|No Intervention|Control Group|Control group patients receive usual clinical practice provided by Stroke Unit at Stobhill Hospital in Glasgow. They receive physiotherapy and early mobilisation as deemed appropriate to treat their oown impairments.
11549638|NCT01006772|Experimental|Experimental group|Intervention Group patients receive custom made solid ankle foot orthosis (AFO)treatment.
11549639|NCT01006759|Experimental|leprosy disability|intervention of a series of cases with leprosy that made treatment in a Clinical Hospital
11549640|NCT01006746||ICD patient and Home Monitoring|Patients primo implanted with ICD
11549641|NCT01006733|Experimental|Target INR 1.8 and Pharmacogenetic|The target International Normalized Ratio (INR) is 1.8. Warfarin initiation is via Pharmacogenetic dosing.
11549642|NCT01006733|Experimental|Target INR 2.5 and Pharmacogenetic|The target INR is 2.5. Warfarin initiation is via Pharmacogenetic dosing.
11549643|NCT01006733|Experimental|Target INR 1.8 and Clinical|The target INR is 1.8. Warfarin initiation is via clinical dosing.
11549644|NCT01006733|No Intervention|Target INR 2.5 and Clinical|The target INR is 2.5. Warfarin initiation is via clinical dosing.
11549645|NCT01006720||Sgx 0.25|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
11549646|NCT01006720||Sgx 0.5|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
11549647|NCT01006720||Sgx 0.75|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
11549648|NCT01006720||Sgx 1.0|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
11549649|NCT01006720||Sgx 1.25|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
11549650|NCT01006720||Neo 10|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
11549651|NCT01006720||Neo 25|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
11549652|NCT01006720||Neo 40|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
11549653|NCT01006720||Neo 55|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
11549654|NCT01006720||Neo 70|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
11549655|NCT01006720||Saline|Saline group: Saline as placebo
11549656|NCT01006707|Other|Ondansetron, then Placebo|Some participants received ondansetron pretreatment during the second session, and then placebo during the third session.
11549657|NCT01006707|Other|Placebo, then Ondansetron|Some participants received placebo pretreatment during the second session, and then ondansetron pretreatment during the third session.
11549658|NCT01006694|Active Comparator|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
11549659|NCT01006694|Experimental|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
11549660|NCT01006681|Experimental|Monovalent MF59-Adjuvanted vaccine|
11549661|NCT01006668|Experimental|Sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
11549662|NCT01006668|Active Comparator|Propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary
11549663|NCT01006655|Placebo Comparator|placebo, adenosine challenge test|Controlled or partially controlled multiple trigger wheezing children received 4 weeks of placebo, preceded and succeeded by AMP challenge test,
11549664|NCT01006655|Active Comparator|Qvar, adenosine challenge test|Patients will receive 4 weeks of inhale QVAR (HFA beclomethasone) 100µg through a spacer device, twice a day
11549665|NCT01006642||Healthy controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
11549666|NCT01006642||Functional dyspepsia-EPS|Functional dyspepsia-EPS(epigastric pain syndrome) Patients admitted to outpatient department with symptoms meeting ROME III criteria
11549667|NCT01006642||Functional dyspepsia-PDS|Functional dyspepsia-PDS(postprandial distress syndrome) Patients admitted to outpatient department with symptoms meeting ROME III criteria
11549668|NCT01006629|Experimental|palivizumab|palivizumab 15 mg/kg intramuscularly every 30 days for 3 to 5 injections
11549669|NCT01006616|Experimental|Navarixin 10 mg|Participants receive navarixin 10 mg, as one navarixin 10 mg capsule and two placebo capsules, administered orally once daily (QD) for up to 2 years
11549670|NCT01006616|Experimental|Navarixin 30 mg|Participants receive navarixin 30 mg, as one navarixin 30 mg capsule and two placebo capsules, administered orally QD for up to 2 years
11549671|NCT01006616|Experimental|Navarixin 50 mg|Participants receive navarixin 50 mg, as two navarixin 10 mg capsules and one navarixin 30 mg capsule, administered orally QD for up to 2 years
11549672|NCT01006616|Placebo Comparator|Placebo|Participants receive placebo to navarixin, as three placebo capsules, administered orally QD for up to 2 years
11549673|NCT01006603|Experimental|1|Saxagliptin 5 mg
11549674|NCT01006603|Active Comparator|2|Glimepiride 1 - 6 mg
11549675|NCT01006590|Experimental|1|Saxagliptin 5 mg
11549676|NCT01006590|Active Comparator|2|Metformin 500 -1000 mg
11549677|NCT01006577|Other|colon j pouch|Control intervention: Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
11549678|NCT01006577|Experimental|side-to-end anastomosis (STE)|Experimental intervention: Low anterior resection for rectal cancer < 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon is closed with a linear stapler. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
11549679|NCT01006551|Experimental|Ziprasidone|
11549680|NCT01006538|Experimental|Arm A (treatment)|Arm A: A single surgical procedure with epimacular brachytherapy using the VIDION® System, with Lucentis® (0.5 mg) administered on a monthly basis as required.
11549681|NCT01006538|Active Comparator|Arm B (control):|Arm B: Lucentis® (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria below.
11549682|NCT01006525||Insomniacs|Primary insomniacs, ages 21-70, in good general health.
11549683|NCT01006499|Placebo Comparator|Placebo group|Receiving standard treatment plus placebo (5 mls/Kg of normal saline intravenously given over 4 hours).
11549684|NCT01006499|Active Comparator|Pentoxifylline group|Standard treatment plus 6 mg/Kg of Pentoxifylline intravenously (given over 4 hours) daily for three days.
11549685|NCT01006499|Active Comparator|Pentaglobin group|Standard treatment plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days
11549686|NCT01006499|Active Comparator|Pentoxifylline plus Pentaglobin group|Standard treatment plus 6 mg/Kg of Pentoxifylline plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days.
11549687|NCT01006486|Experimental|Anticoagulation clinic|Anticoagulation clinic, including all procedures related to a standardized use of coumarins.
11549688|NCT01006486|Active Comparator|Standard care|Standard use of coumarins, as prescribed by their physicians.
11549689|NCT01006473|Experimental|Exercise training group|Exercise training is performed in subgroups of 6 patients supervised by two physiotherapists. Exercise prescription consisted of a 15-min warm-up, walking up to 30 min, followed by a 15-min cooling-down. The exercise intensity during the first 2 weeks corresponds to 55% at 65% of the HR peak reached at the baseline exercise test. In posterior sessions, individual adjustments are performed with gradual increases in order to reach the adequate target HR training intensity, as determined by the Karvonen formula {(maximal HR - HR at rest) x 50 to 70% + HR at rest}. Exercise training is performed in the morning, three times a week (on alternate days) for a total of 12 weeks (36 sessions).
11549690|NCT01006473|No Intervention|Inactive control group|No intervention
11549691|NCT01006460|Experimental|Adapt 232|
11549692|NCT01006460|Experimental|Arctic root group|
11549693|NCT01006460|Active Comparator|Ginseng group|
11549694|NCT01006460|Placebo Comparator|Placebo group|
11549695|NCT01006447|Active Comparator|Instructor contact 1 class|
11549696|NCT01006447|Active Comparator|Instructor contact 4 classes|
11549697|NCT01006434||Thrombolysis group (Pilot phase)|Patients receiving intravenous thrombolysis for acute ischemic stroke. Pilot phase (100 Patients).
11549698|NCT01006434||Thrombolysis group|Patients receiving intravenous thrombolysis for acute ischemic stroke.
11549699|NCT01006408|Active Comparator|Low Level Laser|Low Level Laser twice a week for 8 weeks
11549700|NCT01006408|Sham Comparator|Placebo and Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
11549701|NCT01006395|Active Comparator|zoledronic acid|intervention
11549702|NCT01006395|Placebo Comparator|Placebo|
11549703|NCT01006382||Adolescents and young adults with food allergy|Adolescents aged 13-21 years with a diagnosis of food allergy
11549704|NCT01006369|Experimental|FOLFOX6 + Bevacizumab + Hydroxychloroquine|
11549705|NCT01006369|Experimental|XELOX + Bevacizumab + Hydroxychloroquine|
11549706|NCT01006356|Experimental|Hydromorphone hydrochloride (HCl) oral osmotic system (OROS)|Hydromorphone HCl OROS 8 milligram (mg) once daily for 2 weeks.
11549707|NCT01006343|Experimental|Higher Protein (HP)|Subjects will be required to follow their seven day menu plan for the 12 weeks of intervention. The HP menus will contain 30% protein, 45% carbohydrate, and 25% fat. Subjects in the HP group will be provided with portioned, cooked and frozen pork products as part of their HP menu plan.
11549708|NCT01006343|Experimental|Lower Protein (LP)|Subjects will be required to follow their seven day menu plan for the 12 weeks of intervention. The LP group menus will contain 18% protein, 57% carbohydrate, 25% fat. The LP group will follow a lacto-ovo vegetarian menu with no striated tissue foods. Subjects in the LP group will be provided with selected, portioned dairy products.
11549709|NCT01006330||Elderly medical inpatients|
11549710|NCT01006317|No Intervention|Control|Financial coverage of MCH care within the local reimbursement system (CMS).
11549711|NCT01006317|Experimental|Clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
11549712|NCT01006317|Experimental|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
11549713|NCT01006317|Experimental|Financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
11549714|NCT01006291|Experimental|IDeg OD FF|
11549715|NCT01006291|Experimental|IDeg OD|
11549716|NCT01006291|Experimental|IGlar OD|
11549717|NCT01006278||Surgical group with knee pain|patients 18 years of age or greater with a history of knee pain for more than three but less than six months who failed conservative management with the presence of mechanical symptoms including locking, catching, or giving way; positive physical exam findings including joint line tenderness, McMurray's exam, or Steinman's exam; and MRI of the knee positive for meniscus tear in a location correlating with physical examination. Exclusion criteria were as follows: the presence of high grade gonarthrosis including Kellgren-Lawrence grade IV; a history of prior knee surgery or trauma; ligamentous incompetence on examination or MRI; and diagnosis of inflammatory arthritides, crystalline arthropathies, or other rheumatologic diseases.
11549718|NCT01006278||Group 2|volunteer group
11549719|NCT01006265|Experimental|ACT-128800 Dose 1|ACT-128800 Dose 1
11549720|NCT01006265|Experimental|ACT-128800 Dose 2|ACT-128800 Dose 2
11549721|NCT01006265|Experimental|ACT-128800 Dose 3|ACT-128800 Dose 3
11549722|NCT01006265|Placebo Comparator|Placebo|Matching placebo
11549723|NCT01006252|Experimental|Tasisulam-sodium|Individualized tasisulam-sodium dose was dependent on participant's height, weight, and gender. Dose was adjusted based on laboratory parameters. Treatment was administered intravenously on Day 1 of a 28-day cycle, until disease progression.
11549724|NCT01006252|Active Comparator|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m^2) administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
11549725|NCT01006239||Biorepository|Patients undergoing surgical resection of a solid tumor.
11549726|NCT01006226|Experimental|64Cu-ATSM PET|
11549727|NCT01006213|Experimental|Lifestyle counseling vs motivational intervention|
11549728|NCT01006200||Structural /dynamic airway obstruction|Obstructive granulation tissue formation after SEMS implantation was defined as granulation tissue obstructing the lumen of the SEMS under bronchoscopic examination.
11549729|NCT01006187|Active Comparator|Group 1|1 liposomal lidocaine 4% cream .
11549730|NCT01006187|Active Comparator|Group 2|Vapocoolant spray
11549731|NCT01006187|Active Comparator|Group 3|Rubbing adjacent to the injection site
11549732|NCT01006187|Active Comparator|Group 4|Distraction by means of self-selected reading material or internet
11549733|NCT01006174|Experimental|A|Subjects will be assigned to consume 3 grams soybean oil, 8 grams canola oil, and 20 grams butter that is added to a salad.
11549734|NCT01006174|Experimental|B|Subjects will be assigned to consume 8 grams soybean oil, 20 grams canola oil, and 3 grams butter that is added to a salad.
11549735|NCT01006174|Experimental|C|Subjects will be assigned to consume 20 grams soybean oil, 3 grams canola oil, and 8 grams butter that is added to a salad.
11549736|NCT01006161|Experimental|Low dose SCH 527123|
11549737|NCT01006161|Experimental|Medium dose SCH 527123|
11549738|NCT01006161|Experimental|High dose SCH 527123|
11549739|NCT01006161|Placebo Comparator|Placebo|
11549740|NCT01006148|Experimental|Bone substitute|Enrollees will receive Allogenix Plus(TM), a demineralized bone matrix, to fill in calvarial gaps after cranial vault remodeling and fronto-orbital advancement.
11549741|NCT01006135||COPD patients|
11549742|NCT01006122|Placebo Comparator|Placebo|
11549743|NCT01006122|Active Comparator|PF-03654746|At the end of the second arm of the study, the patient will have completed the study and have a 7-10 day follow-up visit.
11549744|NCT01006096|Experimental|Erlotinib|
11549745|NCT01006096|Placebo Comparator|Placebo tablets|
11549746|NCT01006083||Low-risk patients, not on APAs|Patients not at risk of coronary and/or cerebrovascular disease, and not consuming APAs
11549747|NCT01006083||High-risk patients, not on APAs|Patients at high risk for cardio/cerebrovascular disease (diabetes mellitus, cigarette smoking, hypercholesterolemia, hypertension, morbid obesity), but not taking APAs.
11549748|NCT01006083||APA for primary prevention|High-risk patients with cardiovascular risk factors (as above), in whom APA is prescribed as primary prevention of coronary artery disease (CAD).
11549749|NCT01006083||APA for secondary prevention|Patients with a history of a coronary syndrome (stable/unstable angina); MI; transient ischemic attack (TIA)/stroke; severe carotid artery stenosis/stenting; or peripheral vascular disease, on APAs for secondary prevention.
11549800|NCT01005784|Active Comparator|fixed|
11549750|NCT01006070||Patients with existing spinal fractures|Myeloma patients with documented x-ray evidence of spinal fractures.
11549751|NCT01006070||Patients without spinal fractures|Myeloma patients with bony disease in the spine without existing fractures.
11549752|NCT01006057|Experimental|ESRD|
11549753|NCT01006057|Experimental|Mild|
11549754|NCT01006057|Experimental|Moderate|
11549755|NCT01006057|Experimental|Normal|
11549756|NCT01006057|Experimental|Severe|
11549757|NCT01006044|Experimental|Vaccination|Autologous Dendritic cells loaded with tumor lysate
11549758|NCT01006031|Experimental|PegIFN alfa-2a and Ribavirin|HIV-coinfected patients with compensated cirrhosis by hepatitis C virus, genotype 1 or 4.
11549759|NCT01006018|Experimental|Sitagliptin + Pioglitazone PLACEBO|"Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth
~+ pioglitazone PLACEBO daily by mouth"
11549760|NCT01006018|Experimental|Sitagliptin + Pioglitazone|"Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth
~+ pioglitazone (TZD) 15 mg daily by mouth"
11549761|NCT01006018|Placebo Comparator|PLACEBO|"Sitagliptin (DPP-IV inhibitor) PLACEBO daily by mouth
~+ pioglitazone (TZD) PLACEBO daily by mouth"
11549762|NCT01005992|Experimental|Laser treated scar|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
11549763|NCT01005992|Active Comparator|Standard scar management|The standard scar management arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
11549764|NCT01005979|Experimental|A|
11549765|NCT01005966|Other|Run in|Placebo
11549766|NCT01005966|Experimental|Sodium Fluoride Toothpaste|Sodium fluoride toothpaste
11549767|NCT01005966|Active Comparator|Amine Fluoride Toothpaste|Amine Fluoride
11549768|NCT01005966|Other|675ppmf toothpaste|Dose response
11549769|NCT01005966|Active Comparator|Sodium monofluorophosphate/sodium fluoride Toothpaste|Sodium monofluorophosphate/sodium fluoride Toothpaste
11549770|NCT01005966|Placebo Comparator|0 ppmf toothpaste|
11549771|NCT01005953||Professionals treating autistic children|Special educators, occupational therapists, speech pathologists, behavior analysts who work with children on the spectrum.
11549772|NCT01005953||Families with autistic children (3-10)|
11549773|NCT01005940|Experimental|Mandibular advancement device|Subject is evaluated when receiving intervention with mandibular advancement device.
11549774|NCT01005940|No Intervention|No mandibular advancement device|Subject is evaluated when not receiving treatment with mandibular advancement device.
11549775|NCT01005927|Placebo Comparator|No Fructooligosaccharide|0 g fructooligosaccharide added to calcium-containing beverage
11549776|NCT01005927|Active Comparator|3 g Fructooligosaccharide|3 g fructooligosaccharide added to calcium-containing beverage
11549777|NCT01005914|Experimental|Group 1|"Drug:cyclophosphamide Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
~Drug:cytarabine Day 2 & 3: 3g/m2 IV over 2 hours q12 X 4
~Drug:dexamethasone Day 1-4; 11-14: 40 mg daily
~Drug:doxorubicin hydrochloride Day 4: 50 mg/m2 IV over 2 hours
~Drug:imatinib mesylate 600 mg/day
~Drug:methotrexate Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
~Drug: methylprednisolone Day 1-3: 50mg IV BID
~Drug: pegaspargase Day 3/Day4: 2,500 IU/ m2 IV
~Drug: vincristine sulfate Day 4 & 11: 2 mg IV"
11549778|NCT01005901|Experimental|Glycopyrronium bromide|Glycopyrronium bromide 50µg delivered once daily via Single Dose Dry Powder Inhaler (SDDPI). At visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.
11549779|NCT01005901|Placebo Comparator|Placebo|Placebo delivered once daily via SDDPI. At Visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.
11549780|NCT01005888|Experimental|C1INH-nf First, then Placebo|1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by matching placebo (saline) administered IV every 3 to 4 days for 12 weeks.
11549781|NCT01005888|Experimental|Placebo First, then C1INH-nf|Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by 1,000 U of C1INH-nf administered IV every 3 to 4 days for 12 weeks.
11549782|NCT01005875|Experimental|Radiation followed by Sorafenib|Radiation therapy, stereotactic body radiation therapy followed by Sorafenib
11549783|NCT01005862|Experimental|PF-04360365|
11549784|NCT01005862|Placebo Comparator|Placebo|single dose administered intravenously
11549785|NCT01005849|Experimental|Protecflor|
11549786|NCT01005849|Placebo Comparator|Placebo|
11549787|NCT01005836|Experimental|Cognitive-behavioral therapy: Anxiety|CBT for child anxiety. Coping Cat.
11549788|NCT01005836|Other|Usual care: Anxiety|Usual clinic care
11549789|NCT01005836|Experimental|Cognitive behavioral therapy: depression|CBT for youth depression. The Primary and Secondary Control Enhancement Training protocol.
11549790|NCT01005836|Other|Usual care: Depression|Usual clinic care for depression
11549791|NCT01005823|Active Comparator|LEO 29102 cream 0.3 mg/g|
11549792|NCT01005823|Active Comparator|LEO 29102 cream 1.0 mg/g|
11549793|NCT01005823|Active Comparator|LEO 29102 cream 2.5 mg/g|
11549794|NCT01005823|Placebo Comparator|LEO 29102 placebo cream|
11549795|NCT01005810|Active Comparator|N-Acetylcysteine|
11549796|NCT01005810|Placebo Comparator|Placebo|
11549797|NCT01005797|Experimental|Expansion A|Expansion A -RCC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
11549798|NCT01005797|Experimental|Expansion B|Expansion B -NSCLC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
11549799|NCT01005797|Experimental|Expansion C|Expansion C -STS cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
11549802|NCT01005771|Experimental|GF-001001-00 2%|
11549803|NCT01005771|Experimental|GF-001001-00 1%|
11549804|NCT01005771|Experimental|GF-001001-00 0.25%|
11549805|NCT01005771|Placebo Comparator|Placebo|
11549806|NCT01005745|Experimental|TIL With High Dose IL-2|"Day -7 and -6: Cyclophosphamide 60 mg/kg/day I.V. in 250 ml NS over approximately 2 hours. Mesna 20 mg/kg with D5W or NS at 125 ml/hour infused intravenously over 24 hours.
~Day -5 to Day -1: Fludarabine 25 mg/m^2 intravenous piggyback (IVPB0 daily over approximately 30 minutes for 5 days.
~Day 0: T cell infusion in 250-1000 ml NS over approximately 15-60 minutes depending on volume to be infused.
~Days 1-5: High dose IL-2, 720,000 IU/kg IV bolus (about 15 minutes) every 8-16 hours for up to 15 doses, beginning approximately 12-16 hours after T cell infusion."
11549807|NCT01005719|Experimental|Zegerid|Participants receiving Zegerid (omeprazole/sodium bicarbonate) in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants also took approximately 2 oz of water with their medication.
11549808|NCT01005719|Active Comparator|Prevacid®|Participants receiving Prevacid® (lansoprazole) in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants also took approximately 2 oz of water with their medication.
11549809|NCT01005719|No Intervention|No treatment|Participants receiving No treatment in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants took approximately 2 oz of water once daily for 7 days.
11549810|NCT01005706|Active Comparator|Tacrolimus Withdrawal Arm|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.
~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
11549811|NCT01005706|Active Comparator|Tacrolimus Minimization Arm|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.
~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
11549812|NCT01005680|Experimental|Pemetrexed plus Cisplatin|
11549813|NCT01005680|Active Comparator|Gemcitabine plus Cisplatin|
11549814|NCT01005667|Experimental|BirthTrack Monitor|
11549815|NCT01005667|No Intervention|Control - no BirthTrack Monitor|
11549816|NCT01005654||1/ Cohort 1|Subjects with endocrine neoplasm or pre or potentially malignant condition of the endocrine system, scheduled to have surgery or biopsy
11549817|NCT01005641|Experimental|A|phase II
11549818|NCT01005628||001|bortezomib Injection into a vein 1.3 mg/m2 twice a week for 21 days
11549819|NCT01005615|Sham Comparator|No FES Cycling|
11549820|NCT01005615|Active Comparator|FES Cycling|
11549821|NCT01005602|Experimental|Digoxin Dosing per Nomogram|Subjects will have their digoxin maintenance dose determined according to the nomogram we have developed.
11549822|NCT01005602|Other|Standard Digoxin Dosing|This arm represents historical control subjects in whom the dose of digoxin was determined at the physician's discretion using traditional dosing methods.
11549823|NCT01005576|Experimental|Conditioning regimen|Hydroxyurea days -50 to -21 Alemtuzumab days -21 to -19 Fludarabine days -8 to -4 Thiotepa day -4 Melphalan day -3 Stem cell infusion day 0
11549824|NCT01005563|Experimental|Arm 1: Beef/Pork|Participants consuming diet with beef/pork as predominate sources of protein
11549825|NCT01005563|Experimental|Arm 2: Soy/Legumes|Participants consuming diet with soy/legumes as predominate sources of protein
11549826|NCT01005550|Experimental|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
11549827|NCT01005550|Experimental|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
11549828|NCT01005550|Experimental|10 mg of ropivacaine|10 mg of ropivacaine are used for the spinal anaesthesia
11549829|NCT01005550|Experimental|12 mg of ropivacaine|12 mg of ropivacaine are used for the spinal anaesthesia
11549830|NCT01005511|Experimental|Grindcare|24 patients receiving active treatment
11549831|NCT01005511|Placebo Comparator|Placebo treatment|24 patients receive a placebo treatment
11549832|NCT01005498|Experimental|Low carbohydrate diet (F)|The group attended to low carbohydrate diet
11549833|NCT01005498|Active Comparator|Traditional diet (K)|The group attended to traditional diet
11549834|NCT01005485||Group A|Patients undergoing open vascular surgery on arterial structures to better define optimal laboratory and collection techniques for isolation of CECs.
11549835|NCT01005485||Group B|Healthy controls will be recruited from the general medical population, community.
11549836|NCT01005485||Acute Myocardial Infarction|Patients with acute myocardial infarction with or without ST segment deviation.
11549837|NCT01005472|Experimental|sunitinib malate, temozolomide|
11549838|NCT01005459|Active Comparator|tetracaine 2mg|
11549839|NCT01005459|Active Comparator|Bupivacaine 2 mg|
11549840|NCT01005446||RSP Device|Post Market Study
11549841|NCT01005433|Active Comparator|Dexmedetomidine 0.6 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia
11549842|NCT01005433|Active Comparator|Dexmedetomidine 0.4 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 4 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia
11549843|NCT01005433|Active Comparator|Dexmedetomidine 0.2 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia.
11549960|NCT01004458|Active Comparator|Early treatment group|The experimental group receiving CBT
11549844|NCT01005433|Placebo Comparator|Placebo|The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 20 min before induction of anesthesia
11549845|NCT01005420|Experimental|Blueberry Powder|"A blueberry smoothie will be consumed at the breakfast and dinner meals.
~Nutritional Value:(based on one 16oz smoothie and subjects had to consume two a day)
~206.4 Kcals
~40.3 g Carbohydrate
~11.5 g Protein
~0.08 g Fat
~0.05 g Sat fat
~4.2 g Fiber
~Ingredients:
~245.0 g Dannon Light & Fit yogurt
~105 .0 g Skim milk
~22.5 g Freeze-dried blueberry powder
~5.0 g Imitation vanilla flavor
~1.0 g Splenda
~16 oz plastic cup with lid
~Smoothie total weight - 378.5 g"
11549846|NCT01005420|Placebo Comparator|Placebo|"A placebo smoothie will be consumed at the breakfast and dinner meals.
~Nutritional Value:(based on one 16oz smoothie and subjects had to consume two a day)
~201.3 Kcals
~40.3 g Carbohydrate
~10.7 g Protein
~0.08 g Fat
~0.05 g Sat fat
~4.3 g Fiber
~Ingredients:
~245.0 g Dannon Light & Fit yogurt
~105 .0 g Skim milk
~5.0 g Benefiber
~12.0 g Sugar
~4.0 g Artificial blueberry flavor(liquid & powder)
~1.5 g Red food color
~0.7 g Blue food color
~16 oz plastic cup with lid
~Smoothie total weight - 373.2 g"
11549847|NCT01005407|Experimental|HEPLISAV and/or Placebo|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
11549848|NCT01005407|Active Comparator|Engerix-B(1)|1.0 mL Engerix-B
11549849|NCT01005394||Navigated TMS|single arm study where all subjects will be studied using the Navigated TMS device
11549850|NCT01005381|Experimental|Small Particle Size Calcium Carbonate|Subjects are given small particle size calcium carbonate supplement twice daily (total of 625 mg/d from supplement).
11549851|NCT01005381|Active Comparator|Large Particle Size Calcium Carbonate|Subjects are given a large particle size calcium carbonate supplement twice daily (total of 625 mg/d from supplement).
11549852|NCT01005381|Placebo Comparator|Calcium Placebo|Subjects are given two placebo tablets daily, which are identical to the large and small particle size calcium carbonate supplements.
11549853|NCT01005381|Active Comparator|No Vitamin D supplement|Subjects are given calcium carbonate supplement once daily (325 mg/d from supplement).
11549854|NCT01005381|Experimental|Vitamin D supplement|Subjects are given a calcium supplement once daily (325 mg/d from supplement) with 1000 IU/d vitamin D supplement.
11549855|NCT01005368||Group 1|Blood and bone marrow is collected at baseline, 3 months after completion of induction therapy, 2 months after completion of consolidation therapy, 1 year after completion of study treatment, and at disease relapse. Samples are analyzed by FISH for interphase cytogenetics, PCR for IgV_H mutational status, flow cytometry for surface expression of CD38 cells, western blot to assess Mcl-1, Bcl-2, BAK-1, ATM, ZAP-70, and Bar expression, and sequencing for p53 and ATM function.
11549856|NCT01005355|Experimental|IMC-1121B|Participants receiving IMC-1121B intravenously
11549857|NCT01005342|Experimental|Mixture of fiber|Single intake of a mixture of spray-dried oat drink, rye bran and sugar beet fiber
11549858|NCT01005342|Experimental|Sugar beet fiber|Single intake of sugar beet fiber
11549859|NCT01005342|Experimental|Rye bran|Single intake of rye bran
11549860|NCT01005342|Experimental|Oat bran|Single intake of oat bran
11549861|NCT01005342|Experimental|Spray-dried oat drink|Single intake of spray-dried oat drink
11549862|NCT01005342|Placebo Comparator|Control|Single intake of a meal with no added fiber
11549863|NCT01005329|Experimental|Treatment (IMRT, cisplatin,bevacizumab,carboplatin,paclitaxel)|Patients undergo pelvic IMRT once daily, 5 days a week, for 5 weeks. Patients may also undergo optional nodal boost radiotherapy and/or vaginal brachytherapy boost. Patients also receive concurrent cisplatin IV over 1 hour on days 1 and 29 and bevacizumab IV over 30-90 minutes on days 1, 15, and 29. Beginning 4-6 weeks after completing IMRT, cisplatin, and bevacizumab, patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment with carboplatin and paclitaxel repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11549864|NCT01005316||Cohort A: Non-Sensitized|"Cohort A will include participants who are alloantibody Luminex(TM) LABScreen. There is no study mandated care or treatment. All care given is clinical site standard of care. All sites follow a similar standard of care regimen. Non-sensitized recipients receive steroid-free maintenance immunosuppression:
~Induction Therapy (anti-T cell antibody induction)
~Tacrolimus (Prograf®)
~Mycophenolate Mofetil- MMF (CellCept®)."
11549865|NCT01005316||Cohort B: Sensitized|"Cohort B will include participants who are alloantibody positive (Sensitized) as determined by Luminex LabScreen for Class I or Class II with specificities identified by single antigen testing.
~There is no study mandated care or treatment. All care given is clinical site standard of care. All sites follow a similar standard of care regimen.
~Sensitized recipients receive:
~Induction Therapy (anti-T cell antibody induction)
~Intraoperative plasma exchange/pheresis
~Short-term post-operative plasmapheresis
~Post-transplant course of intravenous immunoglobulin (IVIG) therapy
~Maintenance corticosteroids (Prednisone)
~Tacrolimus (Prograf®)
~Mycophenolate Mofetil-MMF (CellCept®)."
11549866|NCT01005303|Placebo Comparator|Placebo|
11549867|NCT01005303|Active Comparator|Micronutrient|
11549868|NCT01005290|Experimental|Combination pill|A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
11549869|NCT01005290|Active Comparator|Ramipril|A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
11549870|NCT01005264|Active Comparator|non-removable fiberglass|Softcast3M®, 3M Health Care, St. Paul, MN (USA) were used for construction of the pressure-relief apparatus
11549871|NCT01005264|Active Comparator|Stabil-D®|Composed of a specifically designed rigid, boat shaped, and fully rocker bottom sole
11549872|NCT01005251|Experimental|60 mg|PPI+lesogaberan (AZD3355) 60 mg bid
11549873|NCT01005251|Experimental|120 mg|PPI+lesogaberan (AZD3355) 120 mg bid
11549874|NCT01005251|Experimental|180 mg|PPI+lesogaberan (AZD3355) 180 mg bid
11549875|NCT01005251|Experimental|240 mg|PPI+lesogaberan (AZD3355) 240 mg bid
11549876|NCT01005251|Placebo Comparator|Placebo|PPI+ Placebo
11549877|NCT01005238|Active Comparator|telbivudine|patients in this arm will continue to take telbivudine
11549878|NCT01005238|Experimental|lamivudine|patients in this arm will take lamivudine
11549961|NCT01004458|No Intervention|Waiting list group|The waiting list group served as referents during the trial
11549879|NCT01005225||Solid tumors|Participants 18 years of age or older who have been diagnosed with a solid tumor or benign hyperplasia that needs surgical removal will be included in this study.
11549880|NCT01005199|Experimental|Arm A: Sorafenib standard|• Arm A (standard treatment): Sorafenib 2 x 400 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (46 patients).
11549881|NCT01005199|Experimental|Arm B: Sorafenib + everolimus|• Arm B (investigational treatment): Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (60 patients)
11549882|NCT01005186|Experimental|Active|Active
11549883|NCT01005186|Experimental|Active 2|Active
11549884|NCT01005173||Group A|Subjects receiving recommended doses of acetaminophen in the hospital. 140 Subjects
11549885|NCT01005173||Group B|Healthy Volunteers - No acetaminophen exposure within 14 days of enrollment 23 Subjects
11549886|NCT01005173||Group C|Acetaminophen Overdose Subjects - Hospitalized 90 Subjects
11549887|NCT01005160|Experimental|CKD501|
11549888|NCT01005147|Experimental|Tranexamic acid arm|
11549889|NCT01005147|Placebo Comparator|Control arm|Will receive a placebo in place of tranexamic acid treatment
11549890|NCT01005121|Experimental|colchicine|patients will receive 2 mg of colchicine daily
11549891|NCT01005108|Experimental|placebo pill|
11549892|NCT01005108|Experimental|placebo accupuncture|
11549893|NCT01005108|Experimental|accupuncture|
11549894|NCT01005108|Experimental|gabapentin|
11549895|NCT01005095|Experimental|High dose vitamin D|800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
11549896|NCT01005095|Active Comparator|Low dose vitamin D|800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
11549897|NCT01005082|Experimental|Low salt diet plus water therapy|
11549898|NCT01005082|Active Comparator|water therapy alone|
11549899|NCT01005069|Experimental|Treatment I|
11549900|NCT01005069|Experimental|Treatment II|
11549901|NCT01005069|Experimental|Treatment III|
11549902|NCT01005069|Experimental|Treatment IV|
11549903|NCT01005069|Placebo Comparator|Placebo|
11549904|NCT01005056||Marvelon®|Single arm study. All participants receive Marvelon® according to the approved dosage and administration method.
11549905|NCT01005043|Experimental|heavy ion radiotherapy|Heavy ion radiotherapy of osteosarcoma with 60 to 66 GyE (20-22 days). Before and after radiotherapy, but not during radiotherapy, chemotherapy is recommended to standard therapy protocols like EURAMOS 1 which is not part of this study.
11549906|NCT01005030||PostCEPT Subjects|Subjects with current Parkinson Disease Diagnosis currently enrolled in PostCEPT study
11549907|NCT01005030||Control Subjects|Non-blood relatives of PostCEPT Subjects matched for age and other demographics
11549908|NCT01005017|Active Comparator|Percutanous RF lesioning|Radiofrequent lesioning uses a high frequency alternating current to heat tissues leading to thermal coagulation. It produces predictable and accurate lesions of the splanchnic nerves.
11549909|NCT01005017|No Intervention|Optimal medical treatment|
11549910|NCT01005004|Experimental|HuCNS-SC cells|Intracerebral implantation of HuCNS-SC via direct injection during surgery
11549911|NCT01004991|Experimental|All patients|subjects will receive azacytidine dose dependent on dose-escalation schedule at time of enrollment - all will receive standard dose RCHOP
11549912|NCT01004978|Experimental|Arm I (sorafenib tosylate and TACE)|Patients receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of sorafenib tosylate is reached, patients undergo TACE comprising doxorubicin hydrochloride, mitomycin C, and cisplatin (closed to accrual as of 10/1/2010); conventional chemoembolization comprising doxorubicin hydrochloride only; or chemoembolization comprising doxorubicin-eluting beads. Treatment with TACE repeats approximately every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11549913|NCT01004978|Active Comparator|Arm II (placebo and TACE)|Patients receive placebo PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of placebo is reached, patients undergo TACE as in Arm I.
11549914|NCT01004965||Group 1|"Samples are obtained: 1) pretreatment, 2) at the time of documentation of refractory disease in acute myeloid leukemia (AML) patients who do not achieve complete response (CR) after induction therapy, and 3) at the time of first relapse in patients who achieve CR.
~Marrow cells are preferentially used for all samples, but peripheral blood is acceptable if marrow is not available and the blood contains 20% or more blasts."
11549915|NCT01004952||screening questionnaire|This study will involve two phases. Guided by EDTM, we will first build models of decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing)using in-home ethnographic interviews with 25 melanoma FDRs (Phase I). In Phase II, we will test the validity of each composite model. This will be completed using EMA data collection with 60 different melanoma FDRs from Phase I who will report on their sunscreen use, shade-seeking, use of hat, and use of UVR protective clothing and decision-making regarding these outcomes via interactive voice response (IVR) system and audio narrative diaries (using a digital voice recorder). We will examine the validity of each model and examine the influence of theory-driven affective and cognitive predictors of UVR protection maintenance across time.
11549916|NCT01004939||fondaparinux prescribed subjects|fondaparinux prescribed subjets
11549917|NCT01004926|Experimental|Echelon|
11549918|NCT01004900|Active Comparator|Trabeculoplasty|
11549919|NCT01004900|Active Comparator|Control (Medication)|
11549920|NCT01004887||Single group|Patients with newly diagnosed high-grade gliomas participating in NCCTG/Alliance or Mayo protocols. Previously collected blood and tissue samples are analyzed via PCR, IHC, flow cytometry, and FISH.
11549921|NCT01004874|Experimental|Bevacizumab, XRT, Temozolomide, Topotecan|Patients are treated with standard radiation therapy and daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation. Following completion of radiation therapy, patients have a MRI and, if there is no evidence of disease progression, patients receive 12 cycles of Avastin, temozolomide, and topotecan. Beginning a minimum of 14 days after the last radiation treatment, the Avastin is dosed at 10 mg/kg every other week; temozolomide is given at 150 mg/m2 daily the first 5 days in combination with topotecan on days 2 through 6 at 1.5 mg/ m2 for patient not taking EIAEDs and 2.0 mg/ m2 for patients taking EIAEDs on days 2-6 of each 28-day.
11549923|NCT01004848|Experimental|Peer-Led Lifestyle Education on Weight Loss|"Project HEED (Help Educate to Eliminate Diabetes), a community-based, peer-led weight loss program for overweight adults with pre-diabetes.
~The intervention group will participate in an 8-session course held over a 10-week period. Project HEED (Help Educate to Eliminate Diabetes), led by trained peer educators, aims to help participants lose weight, thereby preventing their progression to diabetes."
11549924|NCT01004848|Placebo Comparator|Delayed Intervention|The control group will be offered the chance to participate in the 8-session course 1 year after enrollment into the trial.
11549925|NCT01004835||Migraine Disease|Patients 10 to 18 years of age with the diagnosis of Migraine disease and at least one of their biologic parents will be included in this study.
11549926|NCT01004822|Experimental|Active Drug|Weekly infusions of CVX-241 at specified doses
11549927|NCT01004809||Dutasteride|Patients administrated dutasteride with male hair loss
11549928|NCT01004770|Experimental|1 (AH113111 Injection)|
11549929|NCT01004770|Active Comparator|2 (Visipaque Injection)|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
11549930|NCT01004757|Active Comparator|LOGI diet|diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled, aerobic exercise
11549931|NCT01004757|Active Comparator|Low Fat diet|cross over design of three weeks Low Fat diet followed by two weeks LOGI diet always combined with heart rate controlled aerobic exercise
11549932|NCT01004744|Experimental|Presurgical anastrozole|1mg PO daily for two weeks prior to surgery
11549933|NCT01004731|Experimental|Cetuximab in combination with Carboplatin/Gemcitabine|Approximately 30 patients with advanced NSCLC will be enrolled. Patients will receive 3-week cycles of Cetuximab in combination with Carboplatin/Gemcitabine.
11549934|NCT01004718|Experimental|Fludeoxyglucose F18 (FDG) PET/CT scans|Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration.
11549935|NCT01004705|Experimental|Fixed Dose Combination Pill|Once daily oral dose of combination of acetylsalicylic acid, simvastatin, and ramipril (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 or 10 mg ramipril)
11549936|NCT01004705|Active Comparator|Simvastatin|Once daily oral dose of Simvastatin 40 mg
11549937|NCT01004666||Women with equivocal findings on Mammography, US and/or MRI|Women with equivocal findings on Mammography, US and/or MRI
11549938|NCT01004666||Discrepancy between clinical examination and imaging|Women with discrepancy between clinical examination and breast imaging
11549939|NCT01004666||Women with dense breast|Women with dense breast
11549940|NCT01004666||Women in high risk for Breast Cancer|Women in high risk for Breast Cancer. Including patients with genetic high risk and/or strong family history.
11549941|NCT01004653|Experimental|H1N1 influenza A Vaccine (Split virion), Inactivated|15 μg H1N1 influenza A Vaccine (Split virion), Inactivated
11549942|NCT01004640||Group 1|"Peripheral blood samples and bone marrow aspirates are collected at baseline and at 3, 6, and 9 months after starting therapy. If patient continues to receive protocol treatment after 9 months, additional peripheral blood samples are collected every 6 months and bone marrow aspirates are taken annually. In the event of disease progression (blast crisis), an additional peripheral blood sample and bone marrow aspirate are collected.
~Samples are examined by quantitative Southern blot analysis with probes to BCR, quantitative reverse transcriptase-polymerase chain reaction analysis for BCR/ABL fusion transcripts, and cytogenetic analysis."
11549943|NCT01004627|No Intervention|Control group - selective duplex|Patients will receive a duplex ultrasound only if specifically requested following physical examination.
11549944|NCT01004627|Experimental|Obligatory Duplex scan|Patients will receive a duplex ultrasound regardless of clinical findings. Arterial and venous duplex ultrasound examination
11549945|NCT01004614|Experimental|Cohort 1|24 subjects (12 subjects per sequence) will receive treatment A) one 5 mg amlodipine 3rd OD tablet (test) with water and treatment B) one 5 mg amlodipine 2nd OD tablet (reference) with water.
11549946|NCT01004614|Active Comparator|Cohort 2|24 subjects (12 subjects per sequence) will receive treatment C) one 5 mg amlodipine 3rd OD tablet (test) without water, and treatment D) one 5 mg amlodipine 2nd OD tablet (reference) without water
11549947|NCT01004601|Active Comparator|low dose docetaxel|Low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)
11549948|NCT01004601|Active Comparator|Pemetrexed|Pemetrexed (500 mg/m2 every 3 weeks)
11549949|NCT01004588|Experimental|Protein drink|protein drink
11549950|NCT01004588|Placebo Comparator|Placebo drink|Placebo drink
11549951|NCT01004575|Experimental|Kaname|patients that are treated by implanting Kaname Cobalt-Chromium coronary stent
11549952|NCT01004549||Bilateral intraocular lens implantation.|
11549953|NCT01004536|No Intervention|no treatment|The other half of cesarean section wound that is to be left untreated.
11549954|NCT01004536|Experimental|silicone gel|Randomly-designated half of cesarean section wound that is to be subject to application ot silicone gel
11549955|NCT01004523||Single group|Previously preserved paraffin-embedded tissue blocks are obtained and used for biomarker studies. Blood samples obtained during treatment are also obtained. Loss of heterozygosity of specific chromosomal regions are performed using PCR analysis of microsatellite repeats (41,118-120) on DNA extracted from the paraffin-embedded archival specimens. FISH and flow cytometry may also be used to assess chromosomal loss of deletion. Immunohistochemistry is also performed.
11549956|NCT01004510|Experimental|Zoledronic Acid|Zometa administered as a 15 minute IV infusion of either 4 mg, 3.5mg, 3.3 mg or 3.0 mg every 4 weeks based on the patient's baseline calculated creatinine clearance(CrCl)using the Cockcroft-Gault formula.
11549957|NCT01004497|Experimental|Modified Hyper-CVAD + Dasatinib|Dasatinib: 100 mg once daily, PO, for 4 weeks Cyclophosphamide: 300 mg/m2, IV, every 12 hours, days 1~3 Vincristine: 1.4 mg/m2/day (maximum 2 mg/day), IV, days 4 & 11 Daunorubicin: 45 mg/m2/day, IV, days 4 & 11 Dexamethasone: 40 mg/day, IV, days 1~4 & days 11~14 Cytarabine: 2 g/m2, IV, every 12 hours, days 1~5 Mitoxantrone: 12 mg/m2/day, IV, days 1~2
11549958|NCT01004484|Active Comparator|Yogurt with probiotics and inulin|A probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10^7 cfu/g; 5x10^9 cfu/serving) and Inulin (3gr/serving).
11549959|NCT01004484|Placebo Comparator|Placebo|Acidified dairy snack without yogurt cultures, probiotic or inulin.
11549964|NCT01004445|Placebo Comparator|Arm 3|
11549965|NCT01004432|Experimental|Open-label (OL) Overall Group: Golimumab 50 mg SC + MTX|All enrolled and dosed participants receive golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks + Methotrexate (MTX) from Week 0 to Week 12.
11549966|NCT01004432|Experimental|Double blind (DB) Group 2a: Golimumab 50mg SC & Placebo IV+MTX|Participants, who do not achieve Disease Activity Score in 28 joints (DAS28) good response at Week 16, will be randomly assigned to receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 16 to Week 48, along with placebo matched to golimumab intravenous infusion (IV) at Week 16, 20, 28, 36, and 44.
11549967|NCT01004432|Experimental|DB Group 2b: Golimumab 2mg/kg IV & Placebo SC + MTX|Participants, who do not achieve DAS28 good response at Week 16, will be randomly assigned to receive golimumab 2 milligram per kilogram (mg/kg) intravenous infusion (IV) + MTX, at Week 16, 20, 28, 36 and 44, along with placebo matched to golimumab SC injection every 4 weeks from Week 16 to Week 48.
11549968|NCT01004432|Experimental|OL Group 1: Golimumab 50 mg SC + MTX|Participants, who achieve DAS28 good response at Week 16, will receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 16 to Week 48.
11549969|NCT01004432|Experimental|OL Study Extension Group: Golimumab 50 mg SC + MTX|Participants who complete the main study (Week 0 to Week 52), do not meet lack of efficacy criteria, and participate in the OL study extension, will receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 52 to Week 72.
11549970|NCT01004419|Experimental|Vandetanib plus fulvestrant|vandetanib by mouth once daily for 28 days plus fulvestrant intra-muscular injection each cycle
11549971|NCT01004406|Experimental|intensive LDL-lowering therapy (ILLT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to LDL-apheresis and an oral daily dose of 40-80mg of Atorvastatin or equivalent
11549972|NCT01004406|Active Comparator|standard statin monotherapy (SMT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to an oral daily dose of 40-80mg of Atorvastatin or equivalent without LDL-apheresis
11549973|NCT01004393|Experimental|Methylnaltrexone bromide|A single dose of methylnaltrexone will be administered subcutaneously to eligible subjects based on weight at the study entry. Since we will include subjects at all stages of cancer management, administering this study drug is considered experimental. We will use the dose approved by FDA, i.e., 0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg.
11549974|NCT01004380|Experimental|Farletuzumab|2.5 mg/kg once weekly administered i.v. during the Combination treatment period and 7.5 mg/kg Q3W administered i.v. during the Maintenance period
11549975|NCT01004367|Experimental|1|Environmental- and individual based components carried out in the school.
11549976|NCT01004354|Experimental|Vitamin D|
11549977|NCT01004341|Other|Family-based weight control|Group-based family therapy for weight loss in children age 8-12 years.
11549978|NCT01004328|Experimental|Intervention Group 1|All participants
11549979|NCT01004315|Experimental|KUC-7483|
11549980|NCT01004315|Placebo Comparator|Placebo|
11549981|NCT01004315|Active Comparator|Tolterodine|
11549982|NCT01004302|Sham Comparator|Sham surgery|
11549983|NCT01004302|Active Comparator|Active radiosurgery|
11549984|NCT01004289|Active Comparator|Control|Primary angioplasty and stenting without additional intervention.
11549985|NCT01004289|Experimental|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion.
11549986|NCT01004276|Experimental|Improved module|
11549987|NCT01004276|No Intervention|Standard module|
11549988|NCT01004263|Experimental|Rizatriptan|Rizatriptan benzoate
11549989|NCT01004250|Experimental|Study Treatment|
11549990|NCT01004237|Active Comparator|pravastatin|
11549991|NCT01004237|Active Comparator|valsartan|
11549992|NCT01004237|Active Comparator|pravastatin combined with valsartan|
11549993|NCT01004224|Experimental|BGJ398|
11549994|NCT01004211|Active Comparator|Standard transurethral resection|Patients will be submitted to standard white light transurethral resection and/or cold cup biopsies of all visible lesions known or suspected to be bladder cancer; 6 random cold cup biopsies from healthy mucosa of bladder trigone, anterior, posterior and lateral walls will be taken in case of a second transurethral resection of newly diagnosed high grade non muscle invasive bladder cancer or of recurrent high grade non muscle invasive bladder cancer
11549995|NCT01004211|Experimental|Narrow band imaging transurethral resection|The system will be switched to narrow band imaging by simply pushing a button. Transurethral resection and/or cold cup biopsies of all visible lesions known or suspected to be bladder cancer will be performed; 6 random cold cup biopsies from healthy mucosa of bladder trigone, anterior, posterior and lateral walls will be taken in case of a second transurethral resection of newly diagnosed high grade non muscle invasive bladder cancer or of recurrent high grade non muscle invasive bladder cancer.
11549996|NCT01004198|Experimental|MP4OX - 250|250 mL dose
11549997|NCT01004198|Experimental|MP4OX - 500|500 mL dose
11549998|NCT01004198|Active Comparator|Ringers Lactate solution|500 mL dose
11549999|NCT01004185|Experimental|High Dose|2.0 - 4.8 g/day Asacol dependent on body weight
11550000|NCT01004185|Experimental|Low Dose|1.2 - 2.4 g/day Asacol dependent upon body weight
11550001|NCT01004172|Experimental|carboplatin, bevacizumab, trastuzumab (if HER2+)|"Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days.
~carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle
~bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle
~trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only
~*8mg/kg loading dose in cycle 1 for some participants
~HER-2: human epidermal growth factor receptor 2"
11550002|NCT01004159|Experimental|cetuximab with irinotecan|
11550003|NCT01004146|Placebo Comparator|Control group|Patients assigned to the control group were educated on the proper technique of using the incentive spirometer and were instructed to use it for 3 breaths once per day to become able to use the device properly and consistently.
11550052|NCT01003834|Placebo Comparator|Control|Screening only
11550053|NCT01003834|Active Comparator|Assessment|Screening plus assessment
11550004|NCT01004146|Experimental|Experimental Group|Patients assigned to the experimental group were instructed to use the spirometer by inhaling as slowly and deeply as possible in a set of 10 times and to repeat the process at least 5 times every day until the day of surgery.
11550005|NCT01004133||Subjects 80 years of age or older without chronic diseases.|
11550006|NCT01004120|Placebo Comparator|MDn|
11550007|NCT01004120|Active Comparator|B-GOS|
11550008|NCT01004107|Experimental|Radiesse Injectable Dermal Filler|Device: Radiesse Injectable Dermal Filler
11550009|NCT01004107|Active Comparator|Delayed Treatment|Cross over to treatment with Radiesse Injectable Dermal Filler at 3 Months
11550010|NCT01004094|Experimental|simple goal setting|This group will only set a goal.
11550011|NCT01004094|Experimental|goal setting plus action intentions|This group will set goals and form action intentions (plans) to facilitate goal attainment.
11550012|NCT01004094|Experimental|goal setting plus coping intentions|This group will set goals and form coping intentions (plans) to facilitate goal attainment.
11550013|NCT01004094|Experimental|goal setting plus action intentions plus coping intentions|This group will set goals, form action intentions (plans), and form coping intentions (plans) to facilitate goal attainment.
11550014|NCT01004081|Experimental|BIIB021 BID + exemestane|BIIB021 100 mg BID + exemestane 25 mg QD
11550015|NCT01004081|Experimental|BIIB021 TIW + exemestane|BIIB021 450 mg TIW + exemestane 25 mg QD
11550016|NCT01004068|Experimental|SET-diet plus clomiphene|Structured exercise program plus hypocaloric diet for two months and received one-cycle of clomiphene citrate for one cycle
11550017|NCT01004068|Active Comparator|Clomiphene citrate|One month of observation followed by one-cycle of clomiphene citrate therapy
11550018|NCT01004068|Experimental|SET plus diet|Lifestyle modifications for two months.
11550019|NCT01004055|Experimental|Procellera™ Wound Dressing|
11550020|NCT01004055|Active Comparator|ACTICOAT™|
11550021|NCT01004055|Active Comparator|Mepilex® Ag|
11550022|NCT01004042|Active Comparator|Depressed subjects|Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.
11550023|NCT01004042|Active Comparator|Non Depressed subjects|Subjects with no diagnosis of depression
11550024|NCT01004029|Placebo Comparator|Vehicle|Castor Oil
11550025|NCT01004029|Active Comparator|Hydroxyprogesterone Caproate Injection, 250 mg/mL|HPC 250 mg/mL in oil
11550026|NCT01004016|Placebo Comparator|Placebo|
11550027|NCT01004016|Experimental|KPS-0373|
11550028|NCT01004003|Experimental|BIBF 1120|Phase I dose escalation and phase II using dose determined in phase I ( 200 mg BID)
11550029|NCT01004003|Active Comparator|Sorafenib|
11550030|NCT01003990|Experimental|Atazanavir|
11550031|NCT01003990|Experimental|Atazanavir/Ritonavir|
11550032|NCT01003990|Active Comparator|Lopinavir/Ritonavir|Ritonavir-boosted Lopinavir (LPV/RTV 400/100 mg) administered twice a day (BID) with Tenofovir/ Emtricitabine (TDF/FTC).
11550033|NCT01003977||Xience V|Patients treated with a Xience V everolimus-eluting stent
11550034|NCT01003964|Experimental|ERCC1 negative - GP|Gemcitabine (1250 mg/m2) IV on D 1, 8. Cisplatin (75 mg/m2) IV on D1 every 3 weeks.
11550035|NCT01003964|Experimental|ERCC1 positive - IP|Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks
11550036|NCT01003964|Experimental|ERCC1 positive - GP|Gemcitabine (1250 mg/m2) IV on day1, 8 Cisplatin (75 mg/m2) IV on day1 every 3 weeks
11550037|NCT01003964|Experimental|ERCC1 negative - IP|Irinotecan (65 mg/m2) IV on day1, 8 Cisplatin (30 mg/m2) IV on day 1, 8 every 3 weeks
11550038|NCT01003951|Experimental|Acupuncture|Each patient will receive two acupuncture treatments each week for four consecutive weeks. At the end of four weeks, the intervention will be complete.
11550039|NCT01003938|Experimental|topotecan and erlotinib|Topotecan 0.4 mg/m^2/day administered via continuous infusion for 9 days beginning on Day 1, every 21 days cycle; erlotinib 150 mg daily for 9 days every 21 days cycle. Both drugs will be given for a minimum of 2 cycles.
11550040|NCT01003925||Usual Care|Patients randomized to the control group will be sent the post-test measures suitably modified to reflect the fact that they did not participate in the conjoint analysis program. Four weeks after the post-test measures are completed, a staff member will call the subject to complete a 10 minute follow-up questionnaire to assess if any changes in treatment have occurred and to take further measurements (same measurements given to treatment group).
11550041|NCT01003925||Conjoint Analysis Group|Patients randomized to the experimental group will meet the research staff to complete the conjoint analysis software and post-test measures. The post-test measures include preparedness for decision-making, personal uncertainty, osteoarthritis knowledge, arthritis self-efficacy, and satisfaction with the results of the conjoint analysis program. The in-person visit takes approximately 60 minutes to complete. Four weeks after the in-person visit, a staff member will call the subject to complete a 10 minute follow-up questionnaire to assess if any changes in treatment have occurred and to take further measurements (i.e. global pain assessment, arthritis self-efficacy, personal uncertainty, and osteoarthritis knowledge).
11550042|NCT01003899|Experimental|afatinib (BIBW 2992)|patient to receive afatinib(BIBW 2992) po QD in an open-label manner
11550043|NCT01003886||Open Label|Adult male diagnosed with BPH and prescribed with Doxazosin mesylate GITS
11550044|NCT01003873||Bypass gastric|First arm is represented by obese patients that will be studied before and after a gastric bypass. They will be studied before surgery as well as 1 month and 6 months after surgery.
11550045|NCT01003873||Lifestyle intervention|The second group is represented by obese patients that will be studied before lifestyle intervention, 6 months after the beginning of the intervention and after a time that will allow patients to lose the same amount of weight that patients that had been through surgery had lost one month after surgery.
11550046|NCT01003873||Control subjects|The third group is a control group of normal weight people that will be studied at one time and after 6 months with stable weight.
11550047|NCT01003860||0.5% Ropivicaine (150 mg)|
11550048|NCT01003860||0.75% Ropivicaine (225 mg)|
11550049|NCT01003847|Active Comparator|fenofibrate|
11550050|NCT01003847|Active Comparator|fatty acid|drug
11550051|NCT01003847|Active Comparator|Placebo|
11550054|NCT01003834|Experimental|Computer Intervention|Screening, assessment, and computer-delivered intervention
11550055|NCT01003834|Active Comparator|Therapist Intervention|Screening, Assessment, and therapist-delivered intervention
11550056|NCT01003808|Experimental|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
11550057|NCT01003795||Promus|Patients treated with at least one Promus, everolimus-eluting, Stent
11550058|NCT01003769|Experimental|Treatment (lenalidomide in combination with AT-101)|Patients receive lenalidomide PO QD on days 1-21. Beginning in course 2, patients also receive AT-101 PO BID on days 1-3. Treatment repeats every 28 days for up to 11 courses (49-56 days for course 12 or last course of treatment) in the absence of disease progression or unacceptable toxicity.
11550059|NCT01003756|Experimental|Knee Intervention|Patients undergoing Total Knee Replacement. Exercise 8-10 weeks preoperatively
11550060|NCT01003756|No Intervention|Knee Control|Patients undergoing Total Knee Replacement. Receives standard instructions
11550061|NCT01003756|Experimental|Hip Intervention|Patient undergoing Total Hip Replacement. Exercise 8-10 weeks preoperatively
11550062|NCT01003756|No Intervention|Hip Control|Patients undergoing Total Hip Replacement. Receives standard instructions
11550063|NCT01003730|Active Comparator|1|High tidal volume (15mL/kg PBW0 with low PEEP (3cm H2O
11550064|NCT01003730|Active Comparator|2|Low tidal volume (6mL/kg PBW) and high PEEP (3cm H2O)
11550065|NCT01003730|Active Comparator|3|low tidal volume (6mL/kg PBW) and high PEEP (10cm H2O)
11550066|NCT01003717||Endeavor|Patients treated with at least 1 Endeavor, zotarolimus-eluting, Stent as the primary treatment for acute coronary syndrome
11550067|NCT01003704||General Anesthesia only|
11550068|NCT01003704||Peripheral nerve block|
11550069|NCT01003704||spinal|
11550070|NCT01003691|Experimental|Arm 1|
11550071|NCT01003678|Experimental|Level 1|1 mg daily for 5 consecutive days followed by 23 days off drug
11550072|NCT01003665||Intensive Care treatement|ASA status 3 or 4 patients with invasive blood pressure measurement on the intensive care unit
11550073|NCT01003652||Harmonic Focus /conventional haemostasis|
11550074|NCT01003652||Harmonic Focus|
11550075|NCT01003652||new surgical device|
11550076|NCT01003652||Harmonic Focus / conventional haemostasis|Harmonic Focus group refers to the use of ultracision shears for haemostasis and conventional haemostasis group refers to the tie-and-clamp technique in total thyroidectomy
11550077|NCT01003639|Active Comparator|Acetazolamide|Acetazolamide given in escalating doses
11550078|NCT01003639|Placebo Comparator|Sugar pill|"Given in escalating dose (number of pill)"
11550079|NCT01003626|Experimental|IFP Measurement|Tumor interstitial fluid pressure (IFP) assessments
11550080|NCT01003613|Active Comparator|Tranilast|CAT with FG and Tranilast and MMC 0.02%
11550081|NCT01003613|Placebo Comparator|Control|CAT with FG and MMC 0.02%
11550082|NCT01003600||Questionnaire|This study is a cross-sectional survey study to be administered to adults who completed treatment for nonmetastatic colorectal cancer at MSKCC or at Queens Cancer Center (QCC) at Queens Hospital between 6 months and 2 years ago and have no evidence of disease at the time of study enrollment.
11550083|NCT01003587|Experimental|District health information package|
11550084|NCT01003587|No Intervention|No Intervention|
11550085|NCT01003574|Other|Control Arm|Control arm will receive standard care for risk of cardiac sequelae - a mailed, tailored (neither generic nor targeted) print summary of individualized information about the survivor's treatment, late effects risks, and recommended follow-up and lifestyle modifications.
11550086|NCT01003574|Other|Test Arm|Test arm will receive standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
11550087|NCT01003561|Experimental|ultrasonographic exam|
11550088|NCT01003548|Active Comparator|Static culture|Embryos individually cultured in microdrops of 40 microliters of G-IVFplus series V
11550089|NCT01003548|Experimental|Smart plataform|Embryos culture in dynamics microfluidic culture system
11550090|NCT01003535||[123I]5-IA-85380 SPECT|
11550091|NCT01003522|Other|Treatment Arm A|Stenting of central lesion and subsequent standard palliative treatment and dyspnoea symptom control
11550092|NCT01003522|Other|Treatment Arm B|Standard palliative treatment and standard dyspnoea symptom control.
11550093|NCT01003509|No Intervention|study, control|Control: Only modified shouldice repair performed Study: Modified Shouldice + Moloney repairs performed
11550094|NCT01003509|No Intervention|modified shouldice and double|one arm is only modified shouldice, other one is double
11550095|NCT01003496|Active Comparator|Treatment as Usual (TAU)|
11550096|NCT01003496|Experimental|TAU + Long-Term Recovery Management (LTRM)|
11550097|NCT01003483|Experimental|orlistat|
11550098|NCT01003470|Experimental|acupuncture|
11550099|NCT01003470|Active Comparator|rehabilitation|
11550100|NCT01003470|Active Comparator|acupuncture and rehabilitation|
11550101|NCT01003457||detrusor overactivity|
11550102|NCT01003444|Experimental|Cohort 1|Muscle biopsy in healthy volunteers
11550103|NCT01003431|Experimental|1|RotaTeq™ + DTwP
11550104|NCT01003431|Active Comparator|2|Rotarix™ + DTwP
11550105|NCT01003431|Active Comparator|3|RotaTeq™ + DTaP
11550106|NCT01003418|Experimental|GSK2340272A Group 1|Healthy male or female children, between and including 8 and 12 weeks of age at the time of first vaccination, received 2 primary doses of GSK2340272A vaccine, according to a 0-28 day schedule. Subjects also received routine infant immunisation (Infanrix™-IPV/Hib) and Prevenar™ vaccine at Day 14, Month 3 and Month 10. All vaccines were administered intramuscularly into the anterolateral region of the thigh.
11550107|NCT01003418|Experimental|GSK2340272A Group 2|Healthy male or female children, between and including 8 and 12 weeks of age at the time of first vaccination, received 2 primary doses of GSK2340272A vaccine, according to a 0-4 month schedule. Subjects also received routine infant immunisation (Infanrix™-IPV/Hib) and Prevenar™ vaccine at Day 14, Month 3 and Month 10. All vaccines were administered intramuscularly into the anterolateral region of the thigh.
11550108|NCT01003405|Experimental|KUC-7483|
11550262|NCT01002313||normal control|
11550109|NCT01003392||Normal|Normal volunteers, with no diagnosed chronic disease.
11550110|NCT01003392||Coronary artery disease|Group of patients with diagnosed coronary artery disease.
11550111|NCT01003392||Diabetes|Diabetic patients.
11550112|NCT01003379|Experimental|TC-5619|TC-5619 capsules will be administered once a day in a forced titration scheme at 1 mg for 4 weeks, 5 mg for 4 weeks and 25 mg for 4 weeks (12 weeks total).
11550113|NCT01003379|Placebo Comparator|Placebo|
11550114|NCT01003366|Experimental|bevel down|approaching the IJV with the needle bevel facing down
11550115|NCT01003366|Active Comparator|bevel up|approaching the IJV with the needle bevel facing up
11550116|NCT01003340|Experimental|Wee Wheezers asthma education|6 lesson asthma education delivered at home by Community Health Workers
11550117|NCT01003327|Other|I-gel inserted first|The I-gel airway is insewrted first, then the LMA-Unique
11550118|NCT01003327|Other|LMA-Unique inserted first|LMA-Unique airway is inserted first, then the I-gel
11550119|NCT01003314|Experimental|Group 1|
11550120|NCT01003314|Experimental|Group 2|
11550121|NCT01003301|Experimental|Omalizumab|Active treatment: Experimental This arm will receive treatment with omalizumab at the dose FDA-approved for the treatment of allergic asthma.
11550122|NCT01003301|Placebo Comparator|Placebo|This arm will receive treatment with a placebo injections based on the FDA-approved dosing schedule approved for omalizumab for the treatment of allergic asthma.In general injection number and frequency are determined by a subject's weight and IgE level.
11550123|NCT01003288|Experimental|Pandemic influenza H1N1 vaccine|Influenza vaccine
11550124|NCT01003275|Active Comparator|Paricalcitol followed by placebo|Participants will receive paricalcitol for 8 weeks, then an 8-week wash-out, then placebo for 8 weeks.
11550125|NCT01003275|Active Comparator|Placebo followed by paricalcitol|Participants will receive placebo for 8 weeks, then an 8-week wash-out, then paricalcitol for 8 weeks.
11550126|NCT01003262|Experimental|Emergency Department Observation|The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria
11550127|NCT01003262|Active Comparator|Unstructured, inpatient evaluation|
11550128|NCT01003249|Active Comparator|Baclofen, Then Placebo|Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. There will be a washout period after three week. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group. Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg
11550129|NCT01003249|Placebo Comparator|Placebo, Then Baclofen|Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. There will be a washout period after three week. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group. Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg
11550130|NCT01003236|Placebo Comparator|placebo|1 tablet 3 times daily
11550131|NCT01003236|Experimental|Milk Thistle extract|1 tablet of the extract (equivalent to 140 mg silymarin) 3 times per day
11550132|NCT01003223|Experimental|PKM modeling with graphical report|
11550133|NCT01003210|Experimental|Homeopathic ear drops|Commercially available homeopathic ear drops
11550134|NCT01003210|No Intervention|standard therapy|standard therapy for otitis media, no ear drops
11550135|NCT01003197||complication group < III|
11550136|NCT01003197||complication group >= III|
11550137|NCT01003184|Experimental|1|
11550138|NCT01003184|Active Comparator|2|
11550139|NCT01003171|Experimental|MCS-2|
11550140|NCT01003158|Experimental|Monotherapy part|AZD8931 monotherapy
11550141|NCT01003158|Experimental|Combination part|AZD8931 plus paclitaxel
11550142|NCT01003145|Experimental|H1N1 vaccine of 15 μg HA on Day 0|"15 μg HA (0.5 mL) per injection, 1 injection
~50 adults (aged 18~60 years) were assigned to receive one injection of H1N1 vaccine"
11550143|NCT01003145|Experimental|H1N1 vaccine of 15 μg HA on Day 0 and 21|"15 μg HA (0.5 mL) per injection, 2 injections
~50 adults (aged 18~60 years) and 50 elders (aged over 60 years) were assigned to receive two injections of H1N1 vaccine 3 weeks apart"
11550144|NCT01003145|Experimental|H1N1 vaccine of 30 μg HA on Day 0 and 21|"30 μg HA (1 mL) per injection, 2 injections
~50 adults (aged 18~60 years) and 50 elders (aged over 60 years) were assigned to receive two injections of H1N1 vaccine 3 weeks apart"
11550145|NCT01003132|No Intervention|Treatment As Usual|Treatment as usual as determined by the clinical team responsible for the individual's care
11550146|NCT01003132|Active Comparator|Acceptance and Commitment Therapy|Up to 10 sessions of Acceptance and Commitment Therapy plus treatment as usual
11550147|NCT01003119|Experimental|A CHESS|Those in the ACHESS arm will also be given a smart-phone with access to the ACHESS system (the intervention) for a full 12 months. The ACHESS intervention includes: 1) the Core CHESS system that has been tested in several diseases, 2) a proactive computer-based relapse prevention system, 3) data transfer from the phone to a computer accessible by the patient's counselor/care manager, and 4) systems for the patient to maintain contact with his/her Care Manager
11550148|NCT01003119|No Intervention|Usual Care|Those randomized into the Usual Care group will receive usual medical care.
11550149|NCT01003106|Experimental|BRVO- Ranibizumab 0.5mg alone|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg of ranibizumab alone as per protocol without laser photocoagulation.
11550150|NCT01003106|Experimental|BRVO- Pro re nata (prn) ranibizumab with laser|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, and additional laser photocoagulation if required.
11550151|NCT01003106|Experimental|BRVO- Ranibizumab 2.0mg alone|Branch retinal vein occlusion patients randomized to this group will receive 2.0mg of ranibizumab alone as per protocol without laser photocoagulation.
11550263|NCT01002313||Patient treatment group|Treatment with prednisone
11550152|NCT01003106|Experimental|BRVO- Pro re nata (prn) ranibizumab|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, without additional laser photocoagulation.
11550153|NCT01003106|Experimental|CRVO- Ranibizumab 0.5mg alone|Central retinal vein occlusion patients randomized to this group will receive 0.5mg of ranibizumab alone as per protocol without laser photocoagulation
11550154|NCT01003106|Experimental|CRVO- Pro re nata (prn) ranibizumab with laser|Central retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, and additional laser photocoagulation if required.
11550155|NCT01003106|Experimental|CRVO- Ranibizumab 2.0mg alone|Central retinal vein occlusion patients randomized to this group will receive 2.0mg of ranibizumab alone as per protocol without laser photocoagulation.
11550156|NCT01003106|Experimental|CRVO- Pro re nata (prn) ranibizumab|Central retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, without additional laser photocoagulation.
11550157|NCT01003093|Experimental|Antigen group + high adjuvans|The antigen group + high adjuvans group received two injections of antigen (Ag85B + ESAT-6) + IC31 (500 nmol KLK + 20 nmol ODN1a) two months apart.
11550158|NCT01003093|Experimental|Antigen group|The antigen group received two injections of antigen (Ag85B + ESAT-6) two months apart.
11550159|NCT01003093|Experimental|Antigen + low adjuvans group|The antigen group + low adjuvans group received two injections of antigen (Ag85B + ESAT-6) + IC31 (100 nmol KLK + 4 nmol ODN1a) two months apart.
11550160|NCT01003080|Experimental|TKA with the Aquamantys for hemostasis|This arm will receive the total knee arthroplasty with the Aquamantys device used for hemostasis.
11550161|NCT01003080|Active Comparator|TKA without the Aquamantys for hemostasis|This group will receive total knee arthroplasty using the standard treatment for hemostasis.
11550162|NCT01003067|No Intervention|No Mesh|
11550163|NCT01003067|Experimental|Mesh Implementation|
11550164|NCT01003054|Experimental|Autologous Transplantation|Busulfan 130 mg/m^2 intravenous (IV) every 24 hours Days -7 to -4; Cyclophosphamide 60 mg/kg over 4 hours Day -3 and -2; Imatinib Mesylate Starting dose 100 mg/day, and Autologous Stem Cell Transplantation on Day 0.
11550165|NCT01003041||lifestyle counseling|in the future parents will be advised to expose their infants to phonetic sounds in order to develop their phonetic categories in the future
11550166|NCT01003028|Experimental|Limited|Limit the maximum plasma concentration target to 9.8 ng/ml
11550167|NCT01003028|Active Comparator|Control|Use 20 ng/ml as max plasma concentration
11550168|NCT01003015|Experimental|Arm 1|
11550169|NCT01003002||PD Cohort|The cohort for this study is Parkinson's disease patients that are beginning oral levodopa treatment within one month of the screening visit. This cohort has not previously (to the screening visit) been treated with oral levodopa.
11550170|NCT01002989||All eligible patients|"Subjects assessed for hypertension, were subjected to the measurement of ankle brachial index (ABI) by two methods:
~Doppler
~WatchBP Office oscillometric The order for performing the two methods was randomized."
11550171|NCT01002963|Experimental|PF-04418948 30 mg|
11550172|NCT01002963|Experimental|PF-04418948 100 mg|
11550173|NCT01002963|Experimental|PF-04418948 300 mg|
11550174|NCT01002963|Experimental|PF-04418948 1000 mg|
11550175|NCT01002963|Experimental|PF-04418948 3000 mg|
11550176|NCT01002963|Experimental|PF-04418948 4500 mg|
11550177|NCT01002963|Experimental|PF-04418948 6000 mg|
11550178|NCT01002950|Experimental|ACU-4429 tablet|
11550179|NCT01002950|Placebo Comparator|Matching placebo tablet|
11550180|NCT01002937||Tumour tissue, renal cell carcinoma|> 2mm x 2mm of tumour tissue obtained from paraffin blocks taken from biopsies or nephrectomy specimens.
11550181|NCT01002924|Experimental|All Participants|All participants invited to enroll on study will receive EC145 (vintafolide) 2.5 mg by intravenous bolus on Monday, Wednesday, and Friday of Weeks 1 and 3 in each 4-week cycle.
11550182|NCT01002911|Experimental|Aggressive Antibiotic therapy|Patients receive preoperative intravenous antibiotics, intracavitary antibiotics during surgery and postoperative antibiotics.
11550183|NCT01002911|Active Comparator|Conventional Antibiotic Therapy|Preoperative intravenous antibiotics
11550184|NCT01002898|Experimental|lopinavir/ritonavir|
11550185|NCT01002872|Active Comparator|Lanthanum Carbonate|
11550186|NCT01002872|Placebo Comparator|Placebo|
11550187|NCT01002859|Active Comparator|cyclosporin|Intravenous cyclosporin injection.
11550188|NCT01002859|Placebo Comparator|Pacebo|Intravenous injection of NaCl solution.
11550189|NCT01002846|Experimental|traditional acupuncture|Procedure : ST 36 and PC 6 are selected, subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth
11550190|NCT01002846|Sham Comparator|sham acupuncture|Procedure : Beside 1cm of ST 36 and PC 6 are selected( not meridian point), subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
11550191|NCT01002833|Experimental|PfA|Exposure of human volunteers to bites of mosquitoes infected with the A strain of Plasmodium falciparum
11550192|NCT01002833|Experimental|PfB|Exposure of human volunteers to bites of mosquitoes infected with the B strain of Plasmodium falciparum
11550193|NCT01002833|Active Comparator|NF54|Exposure of human volunteers to bites of mosquitoes infected with the NF54 strain of Plasmodium falciparum
11550194|NCT01002820|Experimental|participants|all subjects participating in 0602 are receiving ganaxolone for seizure control
11550195|NCT01002807|Other|FDC of dapagliflozin/metformin XR|
11550196|NCT01002807|Other|FDC of dapagliflozin/reduced mass metformin XR|
11550197|NCT01002807|Other|dapagliflozin and Glucophage® XR|
11550198|NCT01002794|Experimental|Arthroscopic partial meniscectomy|Standard arthroscopic partial meniscectomy - NGD 1
11550199|NCT01002794|Experimental|Exercise Therapy|Supervised neuromuscular- and strength training
11550200|NCT01002768|Experimental|IDeg|
11550201|NCT01002768|Experimental|IGlar|
11550264|NCT01002287|Experimental|SprayShield Adhesion Barrier|SprayShield Adhesion Barrier
11550265|NCT01002287|Sham Comparator|Control|Good Surgical Technique Alone
11550202|NCT01002755|Experimental|Treatment (lenalidomide, ofatumumab)|Participants receive ofatumumab IV over 4 hours on days 1, 8, 15, and 22 of course 1, day 1 of courses 2-6, and day 1 of every even course beginning course 8. Beginning day 9 of course 1, participants also receive lenalidomide PO daily. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11550203|NCT01002742|Experimental|Placebo|Corticosteroids with placebo
11550204|NCT01002742|Experimental|Mycophenolate Mofetil|Corticosteroids with Mycophenolate Mofetil
11550205|NCT01002703|Experimental|RBP|Lenalidomide and Bendamustine and Prednisone
11550206|NCT01002690|Experimental|Etoricoxib|10-13 days treatment with etoricoxib
11550207|NCT01002677|Experimental|Curriculum|
11550208|NCT01002677|Active Comparator|Self-directed|
11550209|NCT01002664|Active Comparator|MCS-2|Drug Name: MCS-2 Dosage: 2 soft-gel capsules Frequency: Qd per day after dinner Duration: 12 weeks
11550210|NCT01002664|Placebo Comparator|Placebo|Drug Name: MCS-2 placebo Dosage: 2 soft-gel capsules Frequency: Qd per day after dinner Duration: 12 weeks
11550211|NCT01002651|Experimental|Wheat Bran Extract (high dose)|
11550212|NCT01002651|Experimental|Wheat Bran Extract (low dose)|
11550213|NCT01002651|Placebo Comparator|placebo|
11550214|NCT01002638|Experimental|Occlusive Dressing|
11550215|NCT01002638|Active Comparator|Surgery|
11550216|NCT01002625|Experimental|1. PF-04457845 followed by placebo|PF-04457845 followed by placebo
11550217|NCT01002625|Experimental|2. Placebo followed by PF-04457845|Placebo followed by PF-04457845
11550218|NCT01002599|Experimental|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
11550219|NCT01002599|Active Comparator|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
11550220|NCT01002586|Experimental|Wii-Fit arm|Half hour daily, five days a week, for 8 weeks
11550221|NCT01002586|Active Comparator|Walking arm|Half hour daily, five days a week, for 8 weeks
11550222|NCT01002573|Experimental|ibuprofen|Ibuprofen, 10 mg/kg
11550223|NCT01002573|Active Comparator|Acetaminophen|Acetaminophen, 10mg/kg
11550224|NCT01002560||Malignant melanoma tumour tissue|
11550225|NCT01002560||Benign pigmented lesions & other skin cancers|Normal skin, benign melanocytic tumours, and skin cancers from lineages other than melanocytic, to be used as negative controls
11550226|NCT01002547|Placebo Comparator|Arm 1|Diabetic with proven NASH by biopsy
11550227|NCT01002547|Active Comparator|Arm 2|Diabetic with proven NASH by biopsy
11550228|NCT01002547|Other|Arm 3|Diabetic with proven NASH by biopsy
11550229|NCT01002534|No Intervention|baseline|visit 1
11550230|NCT01002534|Active Comparator|Vardenafil|nasal instillation of Vardenafil ( visit 2 or 3)
11550231|NCT01002534|Placebo Comparator|Placebo|Nasal instillation of placebo (visit 3 or 2)
11550232|NCT01002521||Cases|Persons With Diabetes (PWD) who have current non-healing ulcer(s)
11550233|NCT01002521||Controls|Persons With Diabetes (PWD) with no current ulcers and no history of ulcers
11550234|NCT01002495|Experimental|Cohort 1|Eight endocardial injection for a total dose of 1mg VM202
11550235|NCT01002495|Experimental|Cohort 2|Eight endocardial injections for a total dose of 2mg VM202
11550236|NCT01002495|Experimental|Cohort 3|Twelve endocardial injections for a total dose of 3mg VM202
11550237|NCT01002482|Experimental|CGAO-based Glucose Control|Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.
11550238|NCT01002482|Active Comparator|Standard-Care Glucose Gontrol|Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.
11550239|NCT01002469|Experimental|sodium [1-13C] acetate|
11550240|NCT01002456|Other|Level 1: site-specific information|provide site-specific information on nonadherence
11550241|NCT01002456|Other|Level 2: site-, patient-specific info|provide site- and patient-specific information on nonadherence
11550242|NCT01002443|Active Comparator|H. pylori eradication|
11550243|NCT01002443|Placebo Comparator|placebo|
11550244|NCT01002430|Experimental|Gene therapy|
11550245|NCT01002430|No Intervention|Control|Control patients will have electroanatomic mapping procedure but no gene injections.
11550246|NCT01002417|Placebo Comparator|Placebo|Both the phase 2b and phase 3 parts of the study have the placebo arm.
11550247|NCT01002417|Active Comparator|MCS-2 15 mg/day|For the phase 2b part of the study. It can also be used in the phase 3 part of the study if MCS-2 15 mg/day is selected as the optimal dosage.
11550248|NCT01002417|Active Comparator|MCS-2 30 mg/day|For the phase 2b part of the study. It can also be used in the phase 3 part of the study if MCS-2 30 mg/day is selected as the optimal dosage.
11550249|NCT01002404|Active Comparator|angled tipped guide wire|angled tipped guide wire used to deep biliary cannulation
11550250|NCT01002404|Active Comparator|straight tipped guidewire|straight guide wire used to deep biliary cannulation
11550251|NCT01002391|Experimental|Postoperative day 1|Dressing is removed on the first postoperative day
11550252|NCT01002391|Experimental|Postoperative day 6|Dressing is removed on the sixth postoperative day
11550253|NCT01002378|Experimental|Arm 1|
11550254|NCT01002378|Experimental|Arm 2|
11550255|NCT01002378|Experimental|Arm 3|
11550256|NCT01002365|Active Comparator|Post op care|
11550257|NCT01002365|Active Comparator|Oxygen administration- different %|
11550258|NCT01002339|Experimental|Tacrolimus with rapid steroid withdrawal|Basiliximab induction. Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
11550259|NCT01002339|Active Comparator|Tacrolimus with steroids minimization|Basiliximab induction.Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
11550260|NCT01002339|Experimental|CsA with steroid minimization|Basiliximab induction. Ciclosporin A (CsA) plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
11550261|NCT01002326|Experimental|Cognitive-Behavioral Therapy|
11550266|NCT01002274|Experimental|MCS-2|2 soft-gel capsules Qd for 40 weeks
11550267|NCT01002261||Liver cirrhosis / healthy subjects|10 patients with liver cirrhosis and 10 sex and age-matched healthy subjects
11550268|NCT01002261||Liver cirrhosis and healthy subjects|Patients with liver cirrhosis and healthy subjects
11550269|NCT01002248|Experimental|Perifosine added to combination|"Perifosine added to the combination of Bortezomib and Dexamethasone. Perifosine is is supplied as a film-coated tablet containing 50 mg of active ingredient. Perifosine will be administered orally on an outpatient basis throughout the study. Daily administration will be one 50 mg tablet.
~The first dose of perifosine should be taken on the same day that bortezomib and dexamethasone are administered (Cycle 1 Day 1)."
11550270|NCT01002248|Placebo Comparator|Perifosine Placebo added to combination|Perifosine placebo added to the combination of Bortezomib and Dexamethasone. The placebo for perifosine is provided in 256 mg white to off-white, round, biconvex film-coated tablets to permit a blinded trial with perifosine 50 mg film coated tablets. Placebo will be administered orally on an outpatient basis throughout the study. Daily administration will be one perifosine placebo tablet. The first dose of placebo should be taken on the same day that bortezomib and dexamethasone are administered (Cycle 1 Day 1).
11550271|NCT01002235|Experimental|Cohort 1|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 4 mg.
11550272|NCT01002235|Experimental|Cohort 2|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 8mg.
11550273|NCT01002235|Experimental|Cohort 3|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 16mg.
11550274|NCT01002222|Experimental|MCS-2|
11550275|NCT01002209|Sham Comparator|Sham Hyperbaric Oxygen Treatment|
11550276|NCT01002209|Experimental|Hyperbaric oxygen treatment (HBO)|
11550277|NCT01002196|Experimental|stimulus fading procedures|
11550278|NCT01002196|Active Comparator|guidance of defocused communication|
11550279|NCT01002183|No Intervention|single arm|Fos-clin/Arte
11550280|NCT01002157|Experimental|Vitamin K2 supplementation|
11550281|NCT01002157|Placebo Comparator|Placebo control|
11550282|NCT01002131||Digital Volume tomography|three-dimensional digital imaging using cone beam tomography (CBCT)
11550283|NCT01002118|Placebo Comparator|Placebo|4 capsules inert oil Placebo each day for 16 weeks
11550284|NCT01002118|Active Comparator|Omega-3 Fatty Acid Ethyl Esters|4 capsules Omega-3 Fatty Acid Esters each day for 16 weeks
11550285|NCT01002105|Experimental|Baclofen|The study was a double-blind, placebo-controlled, randomized trial comparing 50 mg/day of baclofen to placebo over 12 weeks, in addition to a low-intensity psychosocial intervention program, with 26-week and 52-week follow-up observations.
11550286|NCT01002105|Other|Psychosocial intervention|Intervention of the addition of placebo to low-intensity psychosocial intervention program. This was the control group
11550287|NCT01002092|Active Comparator|Chemotherapy|
11550288|NCT01002092|Experimental|Endostar plus Chemotherapy|
11550289|NCT01002079|Experimental|BMS-708163|
11550290|NCT01002079|Other|Rifampin|
11550291|NCT01002079|Experimental|Rifampin + BMS-708163|
11550292|NCT01002053||Diabetics with peripheral neuropathy|Patients with diabetes and peripheral neuropathy.
11550293|NCT01002040|Active Comparator|One Dose Influenza vaccine|Arepanrix H1N1 Influenza vaccine (one dose)
11550294|NCT01002040|Active Comparator|Two Doses Influenza vaccine|Arepanrix H1N1 Influenza vaccine (2 doses, 3 weeks apart)
11550295|NCT01002027|Active Comparator|CBT-counselling with Nurse|CBT-counselling with Maternal Health Nurse, adjunctive to management by general medical practitioner
11550296|NCT01002027|Active Comparator|CBT-Counselling by Psychologist|CBT-counselling with Psychologist, adjunctive to management by general medical practitioner
11550297|NCT01002027|No Intervention|Routine management|Ongoing management by general medical practitioner
11550298|NCT01002014|Experimental|Nipple Sparing Mastectomy|Patients who undergo nipple sparing mastectomy with preservation of the nipple areolar complex.
11550299|NCT01001988|Experimental|Study group|Participants received a single dose of JE-CV administered in Study JEC02. In Study JEC05 there were yearly visits with blood samples taken for immunogenicity assessment.
11550300|NCT01001975|Experimental|SPF Testing|Following Food and Drug Administration (FDA) guidelines for SPF testing, exposure control and product-protected site erythema responses are scored after 16 to 24 hours post-exposure to full spectrum light (Ultraviolet B radiation [UVB] and UVA).
11550301|NCT01001975|Experimental|UVA Protection Testing|Determination of Ultraviolet A Protection Factor (PFA). Following FDA guidelines, test sites exposed to UVA are scored for pigmentation responses 2 to 4 hours post-exposure.
11550302|NCT01001962|Active Comparator|Metformin|527 Patients treated with Metformin 850x2mg titrated to 1000x2mg Daily oral
11550303|NCT01001962|Active Comparator|Empagliflozin|527 Patients treated with empagliflozin 10mg titrated to 25 mg Daily oral
11550304|NCT01001949|Experimental|Wheat Bran Extract|
11550305|NCT01001949|Placebo Comparator|placebo|
11550306|NCT01001936|Experimental|1|
11550307|NCT01001923|Experimental|REGN475/SAR164877|REGN475/SAR164877, single injection, dose depending on the participant's body weight
11550308|NCT01001923|Placebo Comparator|Placebo|Placebo (for REGN475/SAR164877), single injection
11550309|NCT01001910|Experimental|Treatment (pemetrexed disodium, carboplatin)|Patients receive pemetrexed disodium IV over 8-15 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
11550310|NCT01001897|Experimental|misoprostol|400 micrograms of misoprostol inserted buccally or vaginally prior to IUD insertion
11550311|NCT01001897|Placebo Comparator|Placebo|Troches identical to experimental drug inserted buccally or vaginally prior to IUD insertion
11550312|NCT01001884|Experimental|counseling|caregiver psychoeducational consultation program (CPCP)
11550313|NCT01001871|Experimental|Vitamin/mineral fortificant with iron|
11550314|NCT01001871|Placebo Comparator|Vitamin/mineral fortificant without iron|
11550315|NCT01001858|Active Comparator|Domiciliary group|In this group OSA diagnosis was performed at patient's home by mean of non-attended RP. All follow-up visits were conducted by a trained nurse in patient's home.
11550607|NCT00999765||Bipolar Disorder - stable|
11550316|NCT01001858|Active Comparator|Hospital Group|In this group diagnosis was made by in-hospital PSG. Follow-up was performed at hospital by a specialist Physician
11550317|NCT01001858|Active Comparator|Mixed Group|In this group diagnosis was made by home RP, and follow-up at hospital
11550318|NCT01001845|No Intervention|Lifestyle counseling|
11550319|NCT01001845|Active Comparator|vit E|200mg 2 times per day for 3 weeks
11550320|NCT01001845|Experimental|Milk Thistle extract|1 tablet (equivalent to 140 mg silymarin) 3 times a day for 3 weeks
11550321|NCT01001845|Experimental|vit E + Milk Thistle Extract|200mg vit E twice a day + 1 tablet of Milk Thistle extract 3 times a day for 3 weeks
11550322|NCT01001832|Active Comparator|Subcutaneous (SC) abatacept, 125 mg|
11550323|NCT01001832|Active Comparator|Intravenous (IV) abatacept, 125 mg|
11550324|NCT01001819||1|Chronic Rhinosinusitis w/o nasal polyps
11550325|NCT01001819||2|No sinus disease
11550326|NCT01001806|Active Comparator|Acuvail|Acuvail to be given preoperatively. One drop 2 times daily (BID), 1 day pre op and day of surgery 3 doses prior to surgery
11550327|NCT01001806|Active Comparator|Xibrom|Xibrom to be given 1 drop 2 times daily (BID) the day before surgery and 3 doses the day of surgery prior to surgery
11550328|NCT01001806|Active Comparator|Nevanac|One day before surgery 1 drop 2 times daily (BID), then 3 doses the day of surgery
11550329|NCT01001780|Experimental|Pentostatin, Cyclophosphamide, Rituximab|
11550330|NCT01001767|Active Comparator|Lovaza|Lovaza 1 gram by mouth twice a day for 24 weeks.
11550331|NCT01001767|Placebo Comparator|Placebo|Placebo capsule by mouth twice a day x 24 weeks.
11550332|NCT01001754|Experimental|PEG-rIL-29 at 120 µg|
11550333|NCT01001754|Experimental|PEG-rIL-29 at 180 µg|
11550334|NCT01001754|Active Comparator|Peginterferon alfa-2a at 180 µg|
11550335|NCT01001728|Active Comparator|Prone Position|Patients will lie on their fronts on an in-house designed board comprising an arm positioning device registerable to the couch-top, together with a styrofoam/ memory foam mattress. The ipsilateral breast will drop through an aperture in the mattress. The distance from the nipple to the superior, inferior and lateral aspects of the aperture will be recorded along with the distance of the nipple from the couch-top. Arms will be extended as far as possible above the head and the position of the arm immobilisation handles recorded. The head will be turned to the contralateral side. The contralateral breast will be pulled laterally such that it is as flat as possible beneath the patient. Measurements will be taken in order to relate the position of the bi-lateral tattoos to the orthogonal lasers. A fourth tattoo will be marked on the patient's back in line with the A-P laser. The position will be reproduced at treatment using measurements from the tattoo to the laser.
11550336|NCT01001728|Active Comparator|Supine position|For the supine position, patients will be positioned on a customized supine breast board co-registerable to the couch-top to CT and the treatment machines. Arms will be placed above the head in supports. Arm and head position will be recorded along with the angle of the board (which is adjusted such that the sternum is parallel to the couch-top). Tattoos will be marked bi-laterally and medially in a defined relationship to orthogonal lasers. The position will be reproduced at treatment using the above measurements, tattoos and lasers.
11550337|NCT01001715|Experimental|REGN475/SAR164877|REGN475/SAR164877, single injection, dose depending on the participant's body weight
11550338|NCT01001715|Placebo Comparator|Placebo|Placebo (for REGN475/SAR164877), single injection
11550339|NCT01001702|Experimental|Oral Aripiprazole|Flexible dose of oral aripiprazole between 5 mg and 30 mg once daily for 72 months.
11550340|NCT01001689|Experimental|Nutritional counseling + exercise groups|Women in this arm will receive 2 telephone consultations on nutritional health during pregnancy, be invited to 2 evening meetings with nutritional topics and have access to a password protected internet site with topics related to nutrition and fitness in pregnancy. They will also be enrolled in an exercise group which will meet twice weekly, and be encouraged to exercise on their own 1-2 times each week.
11550341|NCT01001689|No Intervention|control|Women in this arm of the study will receive routine pregnancy care.
11550342|NCT01001676|Active Comparator|Conventional Balloon Angioplasty|
11550343|NCT01001676|Experimental|Drug Eluting Balloon Angioplasty|
11550344|NCT01001663|Experimental|FemoSeal®|Closure device for femoral artery access closure
11550345|NCT01001663|Active Comparator|Manual compression|Conventional manual compression
11550346|NCT01001650|Experimental|Group 1|4 doses of 7,500 PfSPZ/immunization.
11550347|NCT01001650|Experimental|Group 2|4 doses of 30,000 PfSPZ/immunization
11550348|NCT01001650|Experimental|Group 3|4 doses of 135,000 PfSPZ/immunization
11550349|NCT01001650|Experimental|Group 4|4 or 6 doses of 135,000 PfSPZ/immunization.
11550350|NCT01001637|Active Comparator|curcumin|
11550351|NCT01001637|Placebo Comparator|Placebo|
11550352|NCT01001624|Experimental|A|Melanil facial cream
11550353|NCT01001624|Active Comparator|B|Hydroquinone 2% cream
11550354|NCT01001611|Experimental|CKD-501 0.5mg|
11550355|NCT01001611|Placebo Comparator|Placebo|
11550356|NCT01001598|Other|danazol|Subjects with either Fanconi anemia or Dyskeratosis congenita
11550357|NCT01001585|Experimental|slow induction with sevoflurane|Only children with a BIS greater than 95 prior to inhalation of sevoflurane will be included in the study. Inductions will be done using a tight fitting mask with continuous monitoring of end tidal gas concentrations. During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached. Inspired sevoflurane will be increased only after end tidal concentration of sevoflurane is constant for at least one minute. Each induction (except for the patients requiring very low doses of sevoflurane) will take approximately 10 minutes.
11550358|NCT01001572|Active Comparator|Valsartan 160 mg|One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks
11550359|NCT01001572|Experimental|Valsartan/amlodipine 160/5 mg|One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks
11550360|NCT01001572|Other|Single-Blind Run-In Valsartan 160 mg|Single-Blind Run-In treatment with one capsule Valsartan 160 mg taken orally once daily at approximately 9:00 AM for 4 weeks.
11550361|NCT01001559||Deplin + antidepressant|Deplin in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)
11550362|NCT01001559||Antidepressant alone|SSRI or SNRI alone
11550363|NCT01001546|Experimental|Arm 1|Internet-based smoking cessation
11550364|NCT01001546|Other|Arm 2|Clinic-based smoking cessation
11550365|NCT01001533||Children sedated by DEX|All pediatric patients (1 month to 18 years of age) eligible for Radiology Sedation Service for CT scan and Nuclear Medicine Scan procedure.
11550366|NCT01001520|Placebo Comparator|Placebo (Sugar Pill)|11-day placebo-controlled medication period
11550367|NCT01001520|Active Comparator|Tolcapone|11-day phase, tapered dosing scheduled (Day 1: 100mg three times daily, Days 2-8: 200mg three times daily, Day 9: 200mg twice daily, Day 10: 200mg once daily, Day 11: 100mg once daily); oral dosing; medication is encapsulated by the University of Pennsylvania's Investigational Drug Service (IDS)
11550368|NCT01001507|Experimental|Integrated HIV/FP services|Family planning services are integrated into HIV care and treatment services at this facility.
11550369|NCT01001507|No Intervention|Standard (non-integrated), referral-based, services|Patients from the HIV care and treatment clinic will be referred for family planning services, and will not receive FP services by the HIV care provider
11550370|NCT01001494|Experimental|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation
11550371|NCT01001494|Experimental|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation
11550372|NCT01001494|Placebo Comparator|Placebo|Placebo
11550373|NCT01001481||001|
11550374|NCT01001468|Experimental|VB-201 20 mg|
11550375|NCT01001468|Experimental|VB-201 80 mg|
11550376|NCT01001468|Placebo Comparator|Placebo|Single daily dose of oral placebo
11550377|NCT01001455||blood pressure monitor|Cuff circumference:22cm-36cm
11550378|NCT01001455||stethoscopy|Cuff circumference: 22cm-36cm
11550379|NCT01001442|Experimental|BT062|BT062 was to be administered as single-dose IV infusions via a 0.22 μm in-line filter preferably in a forearm vein, according to medically accepted procedures on Days 1, 8, and 15 of each 28-day cycle. Alternatively BT062 may have been administered through a central venous line or a peripherally inserted central catheter (PICC). Other administration routes were only to be allowed after approval from Biotest. Each subject was to be monitored carefully for the effects of exposure to BT062. No subject was to have received more than 3 doses of BT062 per 28-day treatment cycle.
11550380|NCT01001429|Active Comparator|Propofol|propofol 1mg/kg as a bolus intravenously followed by an infusion of 25-100 ug/kg/min
11550381|NCT01001429|Experimental|dexmedetomidine infusion|Subject will receive a bolus of0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug.
11550382|NCT01001403|Experimental|nafamostat|The Nafamostat mesilate group received 0.2 mg/kg of nafamostat mesilate intravenously 1 min before reperfusion of the liver graft.
11550383|NCT01001403|Placebo Comparator|Control|The control group received 10 ml of normal saline (same volume as nafamostat)intravenously 1 min before reperfusion of the liver graft.
11550384|NCT01001390|Other|Group One|Group one will take a six minute walk test with AFO device, and after a rest of fifteen minutes, they will take another six minute walk test without AFO, with similar speed to the previous test.
11550385|NCT01001390|Other|Group Two|Group two will take a six minute walk test without AFO device, and after a rest of fifteen minutes, they will take another six minute walk test with AFO, with similar speed to the previous test.
11550386|NCT01001377|Active Comparator|Cetuximab|"Cetuximab 400 mg/m^2 as an initial dose, followed by 250 mg/m^2 intravenously (IV) every 7 days.
~Participants were treated until disease progression, intolerability, withdrawal of consent, or death."
11550387|NCT01001377|Experimental|Panitumumab|Panitumumab 6 mg/kg IV every 14 days. Participants were treated until disease progression, intolerability, withdrawal of consent, or death.
11550388|NCT01001364|Experimental|Formoterol/Budesonide|
11550389|NCT01001364|Active Comparator|Foraseq|
11550390|NCT01001351|Placebo Comparator|Placebo|
11550391|NCT01001351|Experimental|PRT-201|
11550392|NCT01001338|Experimental|RDEA594 200 mg qd|RDEA594 200 mg qd plus allopurinol qd
11550393|NCT01001338|Experimental|RDEA594 200 mg, 400 mg qd|"RDEA594 200 mg then 400 mg qd plus allopurinol qd.
~Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after protocol amendment 16 dated 07 October 2015."
11550394|NCT01001338|Placebo Comparator|Matching Placebo|"RDEA594 matching placebo qd plus allopurinol qd, then allopurinol qd alone in open label period.
~Patients on allopurinol qd alone were discontinued after protocol amendment 16 dated 07 October 2015."
11550395|NCT01001338|Experimental|RDEA594 600 mg qd|"RDEA594 200 mg then 400 mg then 600 mg plus allopurinol qd
~Patients on lesinurad 600 mg had their dose changed to lesinurad 200 mg after protocol amendment 16 dated 07 October 2015."
11550396|NCT01001325|Experimental|Seasonal influenza vaccination|Receipt of Fluviral seasonal (2009-2010, Canadian) influenza vaccination as per manufacturers specification
11550397|NCT01001325|Placebo Comparator|Placebo|0.5 mL normal saline
11550398|NCT01001312|Experimental|Daxor Blood Volume Analysis|Subjects in this treatment arm will receive guideline recommended treatment based on direct blood volume measurement for assessment of volume status.
11550399|NCT01001312|Active Comparator|Clinical volume status assessment|Subjects in this treatment arm will receive guideline recommended treatment based on clinical assessment of volume status.
11550400|NCT01001299|Experimental|Single arm|
11550401|NCT01001286|Active Comparator|Youth Club|The intervention will be compared to a waitlist comparison group. The group will enter NFE after the four-month posttest. During the four months, the youth will be offered a biweekly recreational youth club. The club will be led by Jordanian university student volunteers out of community-based organizations. Club activities will take place approximately every two weeks, including games, sports, arts and crafts, cultural activities, and trips. The Club will not include any significant education components or youth empowerment methodology--the hypothesized active ingredients of QS NFE.
11550439|NCT01001078|Active Comparator|Standard endotracheal tube|A Standard endotracheal tube will be inserted in case both other airway devices (LMA Supreme and iGel) devices fail to provide adequate ventilation.
11550440|NCT01001052|Experimental|Colcrys™ - young subjects (18-30 yrs)|One single dose of Colcrys™ 0.6mg taken by mouth on day 1
11550402|NCT01001286|Experimental|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.
~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
11550403|NCT01001273|Experimental|Study Group|Hyperinsulinemic Normoglycemic Clamp will be started at the time of surgery (before incision) and will be continue for 3 days.
11550404|NCT01001273|No Intervention|Control Group|Patients in the control group will receive standard care.
11550405|NCT01001260||No Aspirin Treatment|
11550406|NCT01001260||81 mg Aspirin Treatment|
11550407|NCT01001260||325 mg Aspirin|
11550408|NCT01001234|Experimental|Stage 1: rizatriptan|
11550409|NCT01001234|Placebo Comparator|Stage 1: placebo|
11550410|NCT01001234|Experimental|Stage 2: rizatriptan|
11550411|NCT01001234|Placebo Comparator|Stage 2: placebo|
11550412|NCT01001221|Experimental|Cabazitaxel + gemcitabine|"Cabazitaxel and gemcitabine on Day 1 then gemcitabine alone on Day 8 every 3 weeks until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision.
~On Day 1, cabazitaxel was given either first followed by gemcitabine (part 1a) or after gemcitabine with 1 hour gap between the two infusions (part 1b). Required premedication with antihistamine, corticosteroid and H2 antagonist was administered intravenously 30 minutes before each dose of cabazitaxel."
11550413|NCT01001208|Experimental|Etanercept Plus Methotrexate|Participants received 50 mg etanercept twice weekly (BIW) for the first 12 weeks and then 50 mg etanercept once weekly (QW) for the second 12 weeks. Participants also received active methotrexate titrated as follows: 7.5 mg per week (3 capsules) for weeks 1 and 2, 10 mg per week (4 capsules) for weeks 3 and 4, and then up to 15 mg per week (6 capsules) or the maximum tolerated dose for the remainder of the 24-week treatment period.
11550414|NCT01001208|Active Comparator|Etanercept Plus Placebo|Participants received 50 mg etanercept twice weekly (BIW) for the first 12 weeks and then 50 mg etanercept once weekly (QW) for the second 12 weeks. Participants also received oral placebo that was the same number of capsules per week as the methotrexate dosing regimen.
11550415|NCT01001195|Experimental|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
11550416|NCT01001195|Experimental|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
11550417|NCT01001195|Experimental|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
11550418|NCT01001195|Active Comparator|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
11550419|NCT01001182||Non interventional|Patients with RA diagnosis receiving any treatment for RA (DMARDS or biologics)
11550420|NCT01001169|Experimental|GSK2340274A_F1 6M-9Y GROUP|Healthy male or female Japanese children, between and including 6 months to 9 years of age, who received two doses of GSK2340274A vaccine (formulation 1), administered intramuscularly into the deltoid region of the arm (intramuscularly into the anterolateral part of the thigh for subjects below 12 months of age at the entry of the study), according to 0, 21-day schedule. Within this group, enrolment of subjects was stratified by age into two subgroups, from 6 to 35 months and from 3 to 9 years.
11550421|NCT01001169|Experimental|GSK2340274A_F2 10Y-17Y GROUP|Healthy male or female Japanese children, between and including 10 to 17 years of age, who received two doses of GSK2340274A vaccine (formulation 2), administered intramuscularly into the deltoid region of the arm, according to 0, 21-day schedule.
11550422|NCT01001143|Experimental|Dose Level 1|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.
~Bexarotene 100 mg/m2 PO daily for each 28 day cycle."
11550423|NCT01001143|Experimental|Dose Level 2|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.
~Bexarotene 200 mg/m2 PO daily for each 28 day cycle."
11550424|NCT01001143|Experimental|Dose Level 3|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.
~Bexarotene 300 mg/m2 PO daily for each 28 day cycle."
11550425|NCT01001130||fluticasone furoate group|Korean patients administered fluticasone furoate according to the Prescription information
11550426|NCT01001117|Experimental|Laser treated|Eye treated with LensAR Laser System
11550427|NCT01001117|Active Comparator|Control Eye|Contralateral eye treated with conventional phaco-emulsification
11550428|NCT01001104|Experimental|0.75 mg LY2189265|
11550429|NCT01001104|Experimental|0.5 mg LY2189265|
11550430|NCT01001104|Experimental|0.25 mg LY2189265|
11550431|NCT01001104|Placebo Comparator|Placebo|
11550432|NCT01001091|Experimental|AL-38583 0.01%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
11550433|NCT01001091|Experimental|AL-38583 0.05%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
11550434|NCT01001091|Experimental|AL-38583 0.2%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
11550435|NCT01001091|Placebo Comparator|AL-38583 Vehicle|AL-38583 ophthalmic solution vehicle, 1 drop instilled in each eye 3 times per day for 2 weeks
11550436|NCT01001091|Active Comparator|MAXIDEX|Dexamethasone ophthalmic suspension, 0.1%, 1 drop instilled in each eye 3 times per day for 2 weeks
11550437|NCT01001078|Active Comparator|I-Gel supraglottic airway device|Group in which the I-Gel will be used in the first and second attempts to secure the airway. If a third attempt is needed, the LMA Supreme will be used. If the third attempt fails, a standard endotracheal tube will be used.
11550438|NCT01001078|Active Comparator|LMA Supreme supraglottic airway device|Group in which the LMA Supreme will be used in the first and second attempts to secure the airway. If a third attempt is needed, the I-Gel will be used. If the third attempt fails, a standard endotracheal tube will be used.
11550608|NCT00999752|Active Comparator|Arm A|Nebivolol to reach blood pressure control
11550441|NCT01001052|Experimental|Colcrys™ - elderly subjects (≥60 yrs)|One single dose of Colcrys™ 0.6mg taken by mouth on day 1
11550442|NCT01001039||control|Patients seen in the Otology clinic who have not had sinus surgery in the past 2 months or a history of sinusitis in the last 6 months.
11550443|NCT01001039||cases|Patients seen in the Rhinology Clinic with a complaint of facial pain. They must have evidence of chronic sinusitis.
11550444|NCT01001026|Other|1|Adults: One doses of H1N12009 vaccine
11550445|NCT01001026|Other|2|Children: Two doses of H1N12009 vaccine given 3 weeks apart
11550446|NCT01001013|Experimental|LC15-0444 200 mg|LC15-0444 200 mg
11550447|NCT01001013|Experimental|Pioglitazone 30 mg|Pioglitazone 30 mg
11550448|NCT01001013|Experimental|LC15-0444 200 mg + pioglitazone 30 mg|LC15-0444 200 mg + pioglitazone 30 mg
11550449|NCT01000987|Experimental|varenicline|varenicline 1mg/day or 2mg/day
11550450|NCT01000987|Placebo Comparator|placebo|placebo
11550451|NCT01000974|Experimental|Hiberix Group|Pooled group of subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of 3 different lots of Hiberix® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age The Hiberix® vaccine was administered intramuscularly in the right thigh. Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.
11550452|NCT01000974|Active Comparator|ActHIB Group|Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of ActHIB® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The ActHIB® vaccine was administered intramuscularly in the right thigh. The Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.
11550453|NCT01000974|Active Comparator|Pentacel Group|Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of Pentacel® vaccine co-administered with 3 doses of Prevnar13® vaccine, 2 or 3 doses of Engerix™-B vaccine at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The Pentacel® vaccine was administered intramuscularly in the right thigh. The Engerix™-B vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally. If subjects in the Pentacel Group had received a birth dose of Hepatitis B vaccine then they were to receive Engerix™-B vaccine only at 2 and 6 months of age.
11550454|NCT01000961|Experimental|RP103 Q12H|
11550455|NCT01000961|Active Comparator|Cystagon® Q6H|
11550456|NCT01000948|Experimental|ZD4054|The study had only one arm: intervention
11550457|NCT01000935|Active Comparator|Platelet Rich Plasma|The platelet concentrate extracted from patient's own blood (PRP) will be applied to the surgical site after completion of the repair.
11550458|NCT01000935|No Intervention|Surgical repair (standard-of-care)|Patients will have a rotator cuff repair without the PRP application.
11550459|NCT01000922|Experimental|Regular Human Insulin|Single injection
11550460|NCT01000922|Experimental|Lispro|Single injection
11550461|NCT01000922|Experimental|VIAject|Single injection
11550462|NCT01000922|Experimental|VIAject 50%|Single injection
11550463|NCT01000922|Experimental|VIAject/Insulin glargine|Single injection
11550464|NCT01000922|Experimental|Insulin Glargine/VIAject|Single injection
11550465|NCT01000896|Experimental|AZD0530 + carboplatin and paclitaxel|AZD0530 in combination with carboplatin and paclitaxel
11550466|NCT01000870|Experimental|Access MNI-513 and PET Imaging|
11550467|NCT01000857|Experimental|Open label treatment with 2-period crossover design|"Group 1: Paroxetine CR 25 mg/day for 14 days / Paroxetine IR 20 mg/day for 14 days.
~Group 2: Paroxetine IR 20 mg/day for 14 days / Paroxetine CR 25 mg/day for 14 days.,
~PK results will be compared between the Paroxetine CR treatment period and the Paroxetine IR treatment period."
11550468|NCT01000831|Active Comparator|Adjuvanted Arepanrix 2 doses|Two doses of adjuvanted H1N1 Arepanrix vaccine given 3 weeks apart
11550469|NCT01000818|Experimental|Period 1|MK0518
11550470|NCT01000818|Experimental|Period 2|famotidine + MK0518
11550471|NCT01000818|Experimental|Period 3|omeprazole + MK0518
11550472|NCT01000805|Experimental|Duloxetine|
11550473|NCT01000805|Placebo Comparator|Placebo|
11550474|NCT01000792|Experimental|Levocetirizine|Levo 5 mg o.d.
11550475|NCT01000779|Active Comparator|Endoscopic Variceal Ligation|endoscopic therapy to obliterate varices
11550476|NCT01000779|Active Comparator|Propranolol|drugs to decrease portal pressure
11550477|NCT01000766||Acute drug-induced liver injury|
11550478|NCT01000753||Observational (specimen collection)|See Detailed Description
11550479|NCT01000740|Experimental|1|Long term survivors who has been used IRESSA for more than 3 years and are still on gefitinib treatment
11550480|NCT01000740|No Intervention|2|Long term survivors who has been used IRESSA for more than 3 years but have already terminated from EAP
11550481|NCT01000740|No Intervention|3|Fast-progressors who defined as no more than 1 follow-up visit after recruitment with the reason of discontinuation being
11550482|NCT01000727|Experimental|Darapladib 160 mg|Single daily oral tablet
11550483|NCT01000727|Placebo Comparator|Placebo|Single daily oral tablet
11550484|NCT01000688|Experimental|vildagliptin treatment first, acarbose treatment second|
11550485|NCT01000688|Experimental|acarbose treatment first, vildagliptin treatment second|
11550486|NCT01000662|Active Comparator|ARM 1 daily boost|Radiation Therapy
11550487|NCT01000662|Active Comparator|ARM 2 weekly boost|Radiation Therapy
11550488|NCT01000649|Experimental|FE 202158 1.25|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 1.25 ng/kg/min.
~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
11550609|NCT00999752|Active Comparator|Arm B|Hydrochlorothiazide for blood pressure control
11551317|NCT00994734|Experimental|home administration of mifepristone|
11550489|NCT01000649|Experimental|FE 202158 2.5|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 2.5 ng/kg/min.
~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
11550490|NCT01000649|Experimental|FE 202158 3.75|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 3.75 ng/kg/min.
~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
11550491|NCT01000649|Placebo Comparator|PLCBO|Patients in the arm received an intravenous infusion for up to 7 days of placebo.
11550492|NCT01000636|Experimental|Metvix PDT|
11550493|NCT01000623|Experimental|Arm I|Patients receive oral venlafaxine once or twice daily in weeks 2-8. Patients see a therapist once a week to learn hypnosis in weeks 2-5. Patients continue hypnosis at home in weeks 6-8.
11550494|NCT01000623|Active Comparator|Arm II|Patients receive oral venlafaxine once or twice daily in weeks 2-8. Patients see a therapist once a week to learn focused attention in weeks 2-5. Patients continue focused attention at home in weeks 6-8.
11550495|NCT01000623|Active Comparator|Arm III|Patients receive oral placebo once or twice daily in weeks 2-8. Patient see a therapist once a week to learn hypnosis in weeks 2-5. Patients continue hypnosis at home in weeks 6-8.
11550496|NCT01000623|Active Comparator|Arm IV|Patients receive oral placebo once or twice daily in weeks 2-8. Patient see a therapist once a week to learn focused attention in weeks 2-5. Patients continue focused attention at home in weeks 6-8.
11550497|NCT01000610|Experimental|single arm|
11550498|NCT01000597|Other|Treatment Y|Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).
11550499|NCT01000597|Other|Treatment Z|A single intravenous dose of 250mcg FF given over 20 minutes (Day 1).
11550500|NCT01000584|Other|1|Group A: One dose of the licensed H1N1 vaccine and one dose of the seasonal influenza vaccine given concurrently
11550501|NCT01000584|Other|2|Group B: One dose of seasonal influenza vaccine given 3 weeks after administration of one dose of the licensed H1N1 vaccine
11550502|NCT01000571||H1N1 pandemic influenza vaccine recipient|Children and young adults between the ages of 6 months and 21 years and 13 kg or greater in body weight with underlying conditions of cancer, HIV, sickle cell disease or receipt of a stem cell transplant more than a year prior to study entry and who will receive inactivated H1N1 swine-origin monovalent influenza vaccine in the winter/fall of 2009-2010 as part of their routine clinical care.Target total accrual of up to 400 children and young adults stratified based on their underlying diagnosis as follows: 150 children or young adults with cancer, 100 with human immunodeficiency virus (HIV), 100 with sickle cell disease, and 50 with receipt of a stem cell transplant more than a year prior to study entry.
11550503|NCT01000545|Placebo Comparator|placebo gelcaps + best medical treatment|Patient will receive 4 placebo gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
11550504|NCT01000545|Active Comparator|SLX 500LRU/day + best medical treatment|Patient will receive 1 SLX gelcap and 3 placebo gelcaps twice a day.Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
11550505|NCT01000545|Active Comparator|SLX 1000LRU/day + best medical treatment|Patient will receive 2 SLX gelcaps and 2 placebo gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
11550506|NCT01000545|Active Comparator|SLX 2000LRU/day + best medical treatment|Patient will receive 4 SLX gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
11550507|NCT01000532||Pacemaker therapy|
11550508|NCT01000519|Active Comparator|Aerobic Training|50 minutes of aerobic training, 18 sessions within 2 months period
11550509|NCT01000519|Experimental|Progressive Resistance Training|50 minutes of progressive resistance training consisting of nine resistance exercises, each conducted 3 sets of 10 repetitions. 18 sessions over 2 months period.
11550510|NCT01000506|Active Comparator|Mepolizumab 750mg|Mepolizumab 750mcg i.v. every 4 weeks
11550511|NCT01000506|Active Comparator|Mepolizumab 250mg|Mepolizumab 250mcg i.v. every 4 weeks
11550512|NCT01000506|Active Comparator|Mepolizumab 75mg|Mepolizumab 75mcg i.v. every 4 weeks
11550513|NCT01000506|Placebo Comparator|Placebo|Placebo saline every 4 weeks i.v.
11550514|NCT01000493|Experimental|Orvepitant 60 mg|60 mg/day
11550515|NCT01000493|Placebo Comparator|Placebo|
11550516|NCT01000480|Experimental|Pemetrexed|Pemetrexed and cisplatin are given as induction therapy followed after by pemetrexed and cisplatin with concurrent radiotherapy.
11550517|NCT01000467|Active Comparator|2|Group 2(probucol 500mg BID)
11550518|NCT01000467|Active Comparator|1|Group 1(Probucol 250mg)
11550519|NCT01000467|Active Comparator|3|Group 3(Probucol 500mg once daily)
11550520|NCT01000441|Active Comparator|arm 1 (2d anti-TNF):|infliximab, etanercept, adalimumab
11550521|NCT01000441|Active Comparator|arm 2 (other biotherapy)|abatacept, rituximab or tocilizumab
11550522|NCT01000415|Experimental|Cisplatin plus gemcitabine|Experimental arm: neoadjuvant chemotherapy (cisplatin plus gemcitabine) followed by surgery Control arm: concurrent chemoradiation (cisplatin/carboplatin)during standard radiation
11550523|NCT01000402|Other|Psychopharmacotherapy|No specific arms; Treatment decision based on available guidelines
11550524|NCT01000376|Experimental|Group 1|
11550525|NCT01000376|Experimental|Group 2|
11550565|NCT01000077||Discarded Operating Room Tissue|The purpose of this research study is to use the discarded (tissue that would normally be thrown out) tissue from your surgery in order to obtain cells that can be grown in a laboratory to study how to use cells like these to fix sick and diseased organs. We will test if these cells can be used to build new and healthy tissues. This technique is called tissue engineering. In this study we will be comparing cells obtained from different individuals.
11550526|NCT01000363||Spanish speaking group|Diabetes medical group visits will be held at the Grady North DeKalb satellite clinic the third Thursday of the month starting in October 2009. There will be two cohorts of patients- English speaking patients and Spanish speaking patients. Each group will be scheduled for 4 2-hour group visits throughout a period of 9 months. These visits will be every 8 weeks for each group. During the visit, the patient will be seen by a physician, attend a diabetes education session, re-fill their diabetes medications, get orders for labs due, vaccinations and diabetes-related referrals.
11550527|NCT01000363||English speaking group|"Each group will be scheduled for 4 2-hour group visits throughout a period of 9 months. These visits will be every 8 weeks for each group. During the visit, the patient will be seen by a physician, attend a diabetes education session, re-fill their diabetes medications, get orders for labs due, vaccinations and diabetes-related referrals.
~This visit will only focus on the patient's diabetes care. Each patient will continue to see their regular physician for their health care.
~All of the services that will be provided at the medical group visit are standard of care and are the same that the patient will receive in a one-on-one visit. However, this format will allow the patient to been seen by the physician and receive diabetes education in one visit."
11550528|NCT01000350|Experimental|Exercise Post Saline|Saline infusion 1L hours before exercise test
11550529|NCT01000350|Placebo Comparator|Placebo|Placebo given prior to exercise test
11550530|NCT01000337|Active Comparator|sevoflurane|Volatile anesthetic
11550531|NCT01000337|Active Comparator|Propofol|Intravenous anesthetic
11550532|NCT01000324|Experimental|Twinrix Group|Pooled group of subjects from groups who were vaccinated with either Lot 1, Lot 2 or Lot 3 of Twinrix in the primary study according to a 0, 1, 6-Month schedule
11550533|NCT01000311|Experimental|MenACWY-CRM + Routine Vaccines|"Infants received 3 doses of MenACWY-CRM at 2, 4 and 6 months as a infant series vaccination and a toddler dose at 12 months of age.
~Infants also received routine vaccines - 3 doses each of DTaP-IPV/Hib, HBV and PCV at 2, 4 and 6 months; and 1 dose each of PCV and MMR at 12 months."
11550534|NCT01000311|Experimental|Routine Vaccines|"Infants received routine vaccines - 3 doses each of DTaP-IPV/Hib, HBV and PCV at 2, 4 and 6 months; and 1 dose each of PCV and MMR at 12 months.
~In addition subjects were offered a dose of MenACWY-CRM at 18 months as a benefit of participating in this study. However, blood was not drawn for immunogenicity analysis after this dose."
11550535|NCT01000298|Placebo Comparator|Placebo|
11550536|NCT01000298|Experimental|Amoxicillin|
11550537|NCT01000298|Experimental|cefdinir|cefdinir
11550538|NCT01000285|Experimental|Arm 1|"Bortezomib 1.0 mg/m2 intravenous (IV) Days 1-4
~Etoposide 50 mg/m2/d 96 hour continuous intravenous infusion (CIVI) on Days 1-4
~Vincristine 0.4 mg/m2/d 96 hour CIVI on Days 1-4
~Doxorubicin 10 mg/m2/d 96 hour CIVI on Days 1-4
~Prednisone 60 mg/m2/d PO on Days 1-5
~Cyclophosphamide 375 mg/m2 IV on Day 5
~Raltegravir 400 mg PO twice per day (BID) every day starting with cycle 2 therapy for the entire duration of the cycle.
~Cycles will be repeated every 21-28 days for 2 cycles beyond best response, or a maximum of 6 cycles."
11550539|NCT01000259||Ancillary-Correlative|Previously collected tumor tissue samples are analyzed for TIL via immunohistochemistry and double immunofluorescence assays using standard immunostaining.
11550540|NCT01000246|Experimental|influenza vaccine day 4|influenza vaccine day 4 of chemotherapy
11550541|NCT01000246|Experimental|influenza vaccine day 16|influenza vaccine day 16 of chemotherapy
11550542|NCT01000246|Active Comparator|influenza vaccine|influenza vaccine in patients with heartfailure
11550543|NCT01000233|Active Comparator|Phytine (Phytate)|300 mg tid* 24 months
11550544|NCT01000233|Placebo Comparator|Placebo|
11550545|NCT01000220|Active Comparator|Omeprazole|
11550546|NCT01000220|Placebo Comparator|placebo|
11550547|NCT01000207|Experimental|1|Dose ranging
11550548|NCT01000207|Experimental|2|Dose ranging
11550549|NCT01000194|Experimental|High polyunsaturated fat meal|A high fat milkshake containing 55g of fat, mainly PUFA
11550550|NCT01000194|Experimental|High monounsaturated fat meal|A high fat milkshake containing 55g of fat, mainly MUFA
11550551|NCT01000194|Experimental|High saturated fat meal|A high fat milkshake containing 55g of fat, mainly SFA
11550552|NCT01000181||Patients undergoing carotid endarterectomy|
11550553|NCT01000168|Experimental|Treadmill therapy|"Patients assigned to the Treadmill therapy group received daily 30 minutes specific walking training on treadmill with body weight support alternatively overground, and 30 minutes functional training, treated by a physiotherapist."
11550554|NCT01000168|Active Comparator|Conventional walking therapy|Patients assigned to the comparative conventional walking therapy group received daily 30 minutes specific traditional walking training overground and 30 minutes functional training, treated by a physiotherapist.
11550555|NCT01000155|Experimental|Vorinostat|Patients received vorinostat in a pulsed fashion, once a day for 3 consecutive days every week to a maximum dose of 400 mg per dose (1200 mg/wk), for 12 to 16 weeks at the maximum dose. The first 3 patients were enrolled in an intrapatient dose escalation schedule of 100 mg/d, then 200 mg/d, each for 3 consecutive days a week for 4 weeks, and then 400 mg/d, 3 consecutive days per week for 16 weeks. The last 2 patients were enrolled to receive 400 mg/d, 3 consecutive days per week for 12 weeks, without an initial dose escalation.
11550556|NCT01000142|No Intervention|Treatment as Usual Control Group|
11550557|NCT01000142|Sham Comparator|Light Touch Group|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
11550558|NCT01000142|Experimental|Standard OMT Group|
11550559|NCT01000116|Active Comparator|Fibrin glue|
11550560|NCT01000116|Active Comparator|Tacks|
11550561|NCT01000103|Active Comparator|1: Real rTMS treatment|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
11550562|NCT01000103|Sham Comparator|2: Sham rTMS treatment|Simulation of rTMS
11550563|NCT01000090||Acromegaly patients, somatostain analogues|
11550564|NCT01000090||Acromegaly patients, surgery|
11550606|NCT00999778|Active Comparator|Caregiver-Mediated Intervention|One hour 1:1 with parent, child and interventionist, each week, for 10 weeks social communication and joint engagement strategies will be targeted
11550566|NCT01000077||Discarded Placenta|During a standard surgery or delivery of a baby unneeded tissue is usually discarded. We would like to explore the opportunity to grow the cells of these discarded tissues in the laboratory. The cells will be placed in special dishes and supplemented with a mixture of salts and nutrients that were designed to allow the cells to survive outside the body and grow. This procedure is called tissue culture of cells. We will attempt to isolate a population of cells from the tissue culture and study them in the laboratory.
11550567|NCT01000064|Active Comparator|Vyvanse|"Vyvanse capsule, 30-70 mg, each morning for 6 weeks.
~Placebo capsule each morning for 6 weeks.
~Brain scans (fMRI) performed at baseline, 6th week visit and 12th week visit."
11550568|NCT01000064|Placebo Comparator|Placebo|"Vyvanse capsule, 30-70 mg, each morning for 6 weeks.
~Placebo capsule each morning for 6 weeks.
~Brain scans (fMRI) performed at baseline, 6th week visit and 12th week visit."
11550569|NCT01000051|Experimental|Eltrombopag|Starting dose 50 mg/day orally for 8 weeks
11550570|NCT01000051|Placebo Comparator|Placebo|Once a day orally for 8 weeks
11550571|NCT01000038|Experimental|Wii-Fit Intervention|Intervention: Subjects in this arm participate in Wii-Fit exercises
11550572|NCT01000038|Active Comparator|Walking Intervention|Intervention: Subjects in this arm participate in walking
11550573|NCT01000025|Active Comparator|PF-00299804|Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11550574|NCT01000025|Placebo Comparator|Placebo|Patients receive oral placebo once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11550575|NCT00999999|Active Comparator|Standard|Standard dural closure
11550576|NCT00999999|Experimental|Experimental|Experimental dural closure, adding of Investigational Medicinal Product (IMP)
11550577|NCT00999986|No Intervention|placebo|
11550578|NCT00999986|Active Comparator|cyclophosphamide|
11550579|NCT00999973|Active Comparator|Mitomycin c 0.02%|
11550580|NCT00999973|Placebo Comparator|Placebo|
11550581|NCT00999960|Active Comparator|1: without simulator|without simulator
11550582|NCT00999960|Experimental|2: with simulator|with simulator
11550583|NCT00999921|Experimental|Tamoxifen|10 mg once daily from 5th day to 25th day of menstrual cycle for 3 months
11550584|NCT00999921|Experimental|Evening Primrose Oil|1000 mg daily for 3 months
11550585|NCT00999908|Experimental|Indacaterol 150 μg-tiotropium 18 μg-placebo|Patients received indacaterol 150 μg once. After a 5-9 days washout period, patients received tiotropium 18 μg once. After a second 5-9 days washout period, patients received placebo (matching indacaterol) once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
11550586|NCT00999908|Experimental|Tiotropium 18 μg-placebo-indacaterol 150 μg|Patients received tiotropium 18 μg once. After a 5-9 days washout period, patients received placebo (matching indacaterol) once. After a second 5-9 days washout period, patients received indacaterol 150 μg once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
11550587|NCT00999908|Experimental|Placebo-indacaterol 150 μg-tiotropium 18 μg|Patients received placebo (matching indacaterol) once. After a 5-9 days washout period, patients received indacaterol 150 μg once. After a second 5-9 days washout period, patients received tiotropium 18 μg once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
11550588|NCT00999895||Antipsychotic outpatients with schizophrenia|Switched treatment of antipsychotic outpatients with schizophrenia
11550589|NCT00999882|Experimental|AZD8055|Dose escalation
11550590|NCT00999869|Experimental|Botulinum toxin A|At first visit, patients will be randomized by blocked randomization into 2 sides of scalp. Experimental side will be injected with botulinum toxin A ( Botox) 2 units per 6.05 cm2 of lesion ( Concentration 2 units of Botox per 0.1 ml of normal saline ).
11550591|NCT00999869|Active Comparator|Triamcinolone acetonide|At visit0, patients will be injection with triamcinolone acetonide concentration at 10 mg/ml on the comparison side
11550592|NCT00999856|Active Comparator|Cohort 1|In the Cohort 1 an uncoated Insert and the photometer version 1 is used. Twelve trial subjects are appointed into 4 subgroups. The difference between these subgroups is the wearing time of the insert.
11550593|NCT00999856|Active Comparator|Cohort 2|Cohort 2 consists of 12 trial subjects who are appointed to 2 subgroups. One group will wear the insert for a minimum of 12 month and the other group for a minimum duration of 18 month. In Cohort 2 an improved insert is used. The photometer will be the same than in cohort 1.
11550594|NCT00999856|Active Comparator|Cohort 3|Cohort 3 only differs in the used photometer from cohort 2.
11550595|NCT00999856|Active Comparator|Cohort 4|Twelve trial subjects are appointed to two subgroups that differ in the minimum wearing duration of the insert (12 month and 18 month). In Cohort 4 a new insert will be tested together with a better photometer.
11550596|NCT00999856|Active Comparator|Cohort 5|The difference between Cohort 5 and Cohort 4 is that the best tested insert and the best evaluated photometer will be used.
11550597|NCT00999830|Experimental|IPH 2101 0.2 mg/kg|One infusion of IPH2101 every 4 weeks at the dose of 0.2 mg/kg by intravenous route over 1 hour, for 4 or up to 8 cycles.
11550598|NCT00999830|Experimental|IPH2101 2.0 mg/kg|One infusion of IPH2101 every 4 weeks at the dose of 2 mg/kg by intravenous route over 1 hour, for 4 or up to 8 cycles.
11550599|NCT00999817|Other|A|Single 30 mg dose of dextromethorphan
11550600|NCT00999817|Experimental|B|Single 45 mg dose of PF-00299804 plus a single 30 mg oral dose of dextromethorphan
11550601|NCT00999804|Experimental|24-week arm|Participants will receive 24-weeks of lapatinib plus trastuzumab. Participants who are estrogen receptor (ER) and/or progesterone receptor (PR) positive will also receive endocrine therapy.
11550602|NCT00999804|Active Comparator|12-week arm|Participants will receive 12-weeks of lapatinib plus trastuzumab. Participants who are estrogen receptor (ER) and/or progesterone receptor (PR) positive will also receive endocrine therapy.
11550603|NCT00999791|Active Comparator|Avastin|
11550604|NCT00999791|Active Comparator|Diclofenac|
11550605|NCT00999778|Active Comparator|Caregiver Education Intervention|10 1:1,one hour sessions weekly for 10 weeks with parent and interventionist. Behavioral education strategies will be targeted
11550610|NCT00999739|Experimental|two vaccines|people allocated to arm two vaccines will receive one dose of heptavalent pneumococcal conjugate vaccine at day 0 and 23-valent polysaccharide vaccine at week4 , 110 HIV-infected people will be included Intervention: administration of two vaccines
11550611|NCT00999739|Experimental|One vaccine|people allocated to arm one will receive only one doses of pneumococcal polysaccharide 23-valent vaccine. 110 HIV-infected adults will be included in this arm Intervention: administration of one vaccine
11550612|NCT00999713|Experimental|Calfactant|Endotracheal calfactant administration
11550613|NCT00999713|Placebo Comparator|Placebo (air)|Endotracheal air administration
11550614|NCT00999700|Experimental|ARM A|Induction chemotherapy: TCF (Vermorken, N Eng J Med 2007) Definitive treatment: RT + C-mab (Bonner, N Eng J Med 2006)
11550615|NCT00999700|Active Comparator|ARM B|RT + Cddp (RTOG, Adelstein, J Clin Oncol 2003)
11550616|NCT00999687|Experimental|Indigo naturalis extract in oil|Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
11550617|NCT00999687|Placebo Comparator|Olive oil|Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
11550618|NCT00999648|Experimental|Manual therapy|Myofascial trigger point pressure release
11550619|NCT00999648|Placebo Comparator|Control|Placebo myofascial trigger point pressure release
11550620|NCT00999635|Experimental|Custom made insole|Custom made functional moulded insole
11550621|NCT00999635|Active Comparator|Prefabricated Insole|Prefabricated accommodative moulded insole
11550622|NCT00999609|Experimental|AAV2-hRPE65v2,voretigene neparvovec-rzyl|voretigene neparvovec rzyl, 1.5 E11 vector genomes, per eye, administered by subretinal injection in a volume of 0.3mL, 6-18 days apart
11550623|NCT00999609|No Intervention|Control|No intervention
11550624|NCT00999596||FFDM (Full Field Digital Mammography)|Mammograms from the Philips Digital System
11550625|NCT00999583|Experimental|EPO|five injections maximum of 40000 UI EPO
11550626|NCT00999583|Active Comparator|Control|Classical take care
11550627|NCT00999570||Patients operated by AR trained surgeons|patients who had their total knee replacements performed by surgeons who have completed a fellowship training in adult reconstruction surgery
11550628|NCT00999570||Patients operated by non-AR surgeons|patients who had their total knee replacements performed by orthopaedic surgeons who did not complete an adult reconstruction fellowship training
11550629|NCT00999557|Experimental|Arm I|Patients apply topical bimatoprost ophthalmic solution to base of upper eyelid margins OR to eyebrow region once daily for 4 months in the absence of unacceptable toxicity.
11550630|NCT00999557|Placebo Comparator|Arm II|Patients apply topical placebo solution to base of upper eyelid margins OR to eyebrow region once daily for 4 months in the absence of unacceptable toxicity.
11550631|NCT00999544|Experimental|Placebo aprepitant/0 mg oxycodone IN PO|Placebo aprepitant/Placebo oxycodone IN/PO
11550632|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 15 IN 0 PO|Placebo aprepitant/ oxycodone 15 IN 0 PO
11550633|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 30 IN 0 PO|Placebo aprepitant/ oxycodone 30 IN 0 PO
11550634|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 0 IN 20 PO|Placebo aprepitant/ oxycodone 0 IN 20 PO
11550635|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 0 IN 40 PO|Placebo aprepitant/ oxycodone 0 IN 40 PO
11550636|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 0 IN 0 PO|Aprepitant 40 mg/ oxycodone 0 IN 0 PO
11550637|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 0 IN 20 PO|Aprepitant 40 mg/ oxycodone 0 IN 20 PO
11550638|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 0 IN 40 PO|Aprepitant 40 mg/ oxycodone 0 IN 40 PO
11550639|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 15 IN 0 PO|Aprepitant 40 mg/ oxycodone 15 IN 0 PO
11550640|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 30 IN 0 PO|Aprepitant 40 mg/ oxycodone 30 IN 0 PO
11550641|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 0 IN 0 PO|Aprepitant 200 mg/ oxycodone 0 IN 0 PO
11550642|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 0 IN 20 PO|Aprepitant 200 mg/ oxycodone 0 IN 20 PO
11550643|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 0 IN 40 PO|Aprepitant 200 mg/ oxycodone 0 IN 40 PO
11550644|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 15 IN 0 PO|Aprepitant 200 mg/ oxycodone 15 IN 0 PO
11550645|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 30 IN 0 PO|Aprepitant 200 mg/ oxycodone 30 IN 0 PO
11550646|NCT00999531|Experimental|1|GS-9411 9.6 mg
11550647|NCT00999531|Experimental|2|GS-9411 4.8 mg
11550648|NCT00999531|Experimental|3|GS-9411 2.4 mg
11550649|NCT00999531|Placebo Comparator|4|Saline Placebo
11550650|NCT00999518|Experimental|Group 1|
11550651|NCT00999518|Experimental|Group 2|
11550652|NCT00999518|Experimental|Group 3|
11550653|NCT00999518|Experimental|Group 4|
11550654|NCT00999518|Placebo Comparator|Group 5|
11550655|NCT00999505|Active Comparator|Amantadine|Amantadine 200mg twice a day
11550656|NCT00999505|Placebo Comparator|Placebo|Placebo capsules twice a day
11550657|NCT00999479|Experimental|Monophasic OCP|Patients randomized to this study arm will receive combined oral contraceptive pills. Patients will follow up at 2, 6, 12, 18 and 24 months. On follow up visits pts will have clinical assessment with vaginal and rectal examinations and with transvaginal ultrasonography. As a measure of compliance, patients will return their empty pill packages
11550658|NCT00999479|Placebo Comparator|Placebo|Patients assigned to this arm will use non-hormonal, barrier contraceptives to prevent pregnancy.Patients will follow up at 2, 6, 12, 18 and 24 months. On follow up visits pts will have clinical assessment with vaginal and rectal examinations and with transvaginal ultrasonography. As a measure of compliance, patients will return their empty pill packages.
11550659|NCT00999466|Experimental|1|AZD8848 (30 μg PILOT part and 60 μg MAIN part)
11550660|NCT00999466|Placebo Comparator|2|Placebo
11550767|NCT00998803||Immunocompromised participants|Immunocompromised (<= 21 years of age) due to cancer, receipt of stem cell transplant, human immunodeficiency virus (HIV) or Sickle cell disease
11550661|NCT00999453|Experimental|LDL-cholesterol 70 mg/dL or lower|'Experimental arm' is defined as patients treated to lower the level of low-density lipoprotein to 70 mg/dl or lower. 'Control arm' is defined as patients treated to lower low-density lipoprotein to a level of 100 mg/dl or lower.
11550662|NCT00999453|Active Comparator|LDL-cholesterol 100 mg/dL or lower|'Experimental arm' is defined as patients treated to lower the level of low-density lipoprotein to 70 mg/dl or lower. 'Control arm' is defined as patients treated to lower low-density lipoprotein to a level of 100 mg/dl or lower.
11550663|NCT00999440|Experimental|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done.Patients who start with any opiate and then switch to methadone, move to methadone follow up
11550664|NCT00999427|Experimental|A|The randomly selected group of subjects who will receive the intervention. The radiologist performing the transrectal prostate biopsy on these subjects will have a gauze soaked with Povidone-iodine over his/her index finger, and will insert this into the rectum. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin to the other. This will be allowed to dry for 2 minutes before proceeding with the biopsy.
11550665|NCT00999427|No Intervention|B|The randomly selected group of subjects who will receive the standard of care biopsy without any added intervention.
11550666|NCT00999401|Experimental|sapacitabine and seliciclib|Sequential or concomitant administration of sapacitabine and seliciclib
11550667|NCT00999375|Experimental|Group A|
11550668|NCT00999375|Active Comparator|Group B|
11550669|NCT00999362||Early kidney-transplant recipients|Patients receiving a kidney transplantation at Aarhus University Hospital, Skejby and receiving tacrolimus as part of their immunosuppressive regime.
11550670|NCT00999362||stable kidney transplant recipients|Tacrolimus treated kidney-transplant recipients from the out-door clinic at Aarhus University Hospital, Skejby and more than two years after transplantation
11550671|NCT00999349|Experimental|Silymarin (LEGALON)|
11550672|NCT00999349|Placebo Comparator|Placebo|
11550673|NCT00999336|Active Comparator|Group H|Healthy subjects matched to the renal impairment groups
11550674|NCT00999336|Experimental|Group A|Patients with mild renal impairment
11550675|NCT00999336|Experimental|Group B|Patients with moderate renal impairment
11550676|NCT00999336|Experimental|Group C|Patients with severe renal impairment
11550677|NCT00999323||coronary artery disease|patients who have been revascularized by PCI with stent implantation due to an acute coronary syndrome
11550678|NCT00999310||Klinefelter syndrome|
11550679|NCT00999310||Control men|
11550680|NCT00999310||Control women|
11550681|NCT00999310||parents of Klinefelter groupe|
11550682|NCT00999297|Placebo Comparator|Sugar pill (Placebo o mg/d)|0 mg/d sugar pill
11550683|NCT00999297|Active Comparator|Dihydrocapsiate|Drug 3 mg/d or 9 mg/d including Placebo
11550684|NCT00999297|Active Comparator|3 mg/d or 9 mg/d Dihydrocapsiate|Drug including Placebo
11550685|NCT00999284|Placebo Comparator|Placebo|Sham infusion of sodium chloride 0.9%
11550686|NCT00999284|Active Comparator|Low dose arm|Infusion of 0.3 mg/kg/h ZK200775 over 4 hours
11550687|NCT00999284|Active Comparator|High dose arm|Infusion of 0.75 mg/kg/h ZK200775 over 4 hours
11550688|NCT00999271||Healthy subjects|30 healthy subjects without family history of diabetes or gastrointestinal disease, a normal oral glucose tolerance test (OGTT) and no intake of medicine
11550689|NCT00999258|Active Comparator|sirolimus|the subjects will undergo conversion from tacrolimus to sirolimus OR they will continue to receive tacrolimus.
11550690|NCT00999258|No Intervention|tacrolimus|
11550691|NCT00999245|Other|High Demand / Low Infusion|PCA dosing plan
11550692|NCT00999245|Other|Low Demand / High Infusion|PCA plan for Low Demand / High Infusion
11550693|NCT00999232|Experimental|Erythromycin|
11550694|NCT00999232|Placebo Comparator|Placebo|
11550695|NCT00999219|Experimental|FK199B-first group|
11550696|NCT00999219|Experimental|Zolpidem-first group|
11550697|NCT00999206|Experimental|1|
11550698|NCT00999206|Experimental|2|
11550699|NCT00999206|Experimental|3|
11550700|NCT00999206|Active Comparator|4|
11550701|NCT00999193|Active Comparator|Conservative Treatment|
11550702|NCT00999193|Experimental|ORIF w. locking plate, no luxation|
11550703|NCT00999193|Experimental|Hemiarthroplasty, no luxation|
11550704|NCT00999180|Active Comparator|Btx-A and Kinesiotherapy|The botulinum toxin group will have the syringe filled with botulinum toxin type A (Dysport). During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training.
11550705|NCT00999180|Placebo Comparator|Saline and Kinesiotherapy|The control group will have the syringe filled with saline.During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training.
11550706|NCT00999167|Experimental|HPN-100|
11550707|NCT00999167|Placebo Comparator|Placebo|
11550708|NCT00999141|Experimental|FS VH S/D 4 s-apr|One side of face will be treated with the investigational product (FS VH S/D 4 s-apr) as an adjuvant to the standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
11550709|NCT00999141|No Intervention|Standard of Care (SoC)|Other side of face will receive standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
11550710|NCT00999128|Experimental|Part 1|
11550711|NCT00999128|Experimental|Part 2|
11550712|NCT00999115|Experimental|Allogenic ASCs|Intralesional dose of 20 million cells at baseline with a possible second administration of 40 million in case of incomplete fistula closure following week 12 assessment.
11550819|NCT00998439|Experimental|Paclitaxel coated balloon catheter|
11550713|NCT00999102|Experimental|Nebivolol, followed by Metoprolol|Participants first received Nebivolol at a dose of 5 mg daily for 4 weeks, followed by 10 mg daily for another 4 weeks (i.e., weeks 1-8 in total). The participants then received Metoprolol at a dose of 50 mg daily for 4 weeks, followed by 100 mg daily for another 4 weeks (i.e., weeks 9-16 in total).
11550714|NCT00999102|Experimental|Metoprolol, followed by Nebivolol|Participants first received Metoprolol at a dose of 50 mg daily for 4 weeks, followed by 100 mg daily for another 4 weeks (i.e., weeks 1-8 in total). The participants then received Nebivolol at a dose of 5 mg daily for 4 weeks, followed by 10 mg daily for another 4 weeks (i.e., weeks 9-16 in total)
11550715|NCT00999089|Active Comparator|CCAB|Conventional Coronary Artery Bypass
11550716|NCT00999089|Active Comparator|OPCAB|Off-Pump Coronary Artery Bypass
11550717|NCT00999089|Active Comparator|PACAB|Pump-Assisted Coronary Artery Bypass
11550718|NCT00999076||Sputum with positive AFB smear|
11550719|NCT00999050|Experimental|diabetic pts <35BMI|All patients will be in a single arm receiving bypass surgery to assist with diabetes management
11550720|NCT00999037|Experimental|Renvela|Daily renvela with meals for 12 weeks
11550721|NCT00999037|Placebo Comparator|placebo|
11550722|NCT00999024||Healthy subjects|20 healthy subjects will be included
11550723|NCT00999024||COPD Patients|20 Patients with Grade IV COPD will be included
11550724|NCT00999011|Active Comparator|One 20 minute period of activity daily|passive and/or active range of motion, chair sitting, sitting at edge of bed, standing and walking
11550725|NCT00999011|Active Comparator|Two periods of 20 minute activity daily|passive and/or active range of motion, chair sitting, sitting at edge of bed, standing and walking
11550726|NCT00998998|Experimental|1|6 or 12 month old infants with iron deficiency anemia assigned to receive home stimulation program via weekly home visits over 1 year
11550727|NCT00998998|Active Comparator|2|6 or 12 month old infants with iron deficiency anemia assigned to surveillance (weekly visits to monitor health and iron supplement) over 1 year
11550728|NCT00998998|Experimental|3|Nonanemic infants identified at 6 or 12 months assigned to receive home stimulation program via weekly home visits over 1 year
11550729|NCT00998998|Active Comparator|4|Nonanemic infants identified at 6 and 12 months assigned to surveillance (weekly visits to monitor health) over 1 year
11550730|NCT00998985|Experimental|400 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 400 mg Grazoprevir or Placebo
11550731|NCT00998985|Experimental|600 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 600 mg Grazoprevir or Placebo
11550732|NCT00998985|Experimental|800 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 800 mg Grazoprevir or Placebo
11550733|NCT00998985|Experimental|400 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 400 mg Grazoprevir or Placebo
11550734|NCT00998985|Experimental|600 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 600 mg Grazoprevir or Placebo
11550735|NCT00998985|Experimental|800 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 800 mg Grazoprevir or Placebo
11550736|NCT00998985|Experimental|200 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 200 mg Grazoprevir or Placebo
11550737|NCT00998985|Experimental|100 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 100 mg Grazoprevir or Placebo
11550738|NCT00998985|Experimental|50 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 50 mg Grazoprevir or Placebo
11550739|NCT00998985|Experimental|200 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 200 mg Grazoprevir or Placebo
11550740|NCT00998985|Experimental|100 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 100 mg Grazoprevir or Placebo
11550741|NCT00998985|Experimental|50 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 50 mg Grazoprevir or Placebo
11550742|NCT00998985|Experimental|30 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 30 mg Grazoprevir or Placebo
11550743|NCT00998985|Experimental|10 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 10 mg Grazoprevir or Placebo
11550744|NCT00998972|No Intervention|control|control arm without any specific intervention
11550745|NCT00998972|Experimental|N-acetylcysteine|administration of 600 mg intravenous N-acetyl cysteine before and 2 hours after angiography performed for the diagnosis of brain death
11550746|NCT00998959|Experimental|Mindfulness based stress reduction and problem solving therapy|
11550747|NCT00998959|Other|Psychoeducation|
11550748|NCT00998933|Experimental|1|
11550749|NCT00998920|Experimental|10mg BID|S-equol capsule, oral, single dose
11550750|NCT00998920|Experimental|20 mg BID|
11550751|NCT00998920|Experimental|40mg BID|
11550752|NCT00998920|Experimental|80 mg BID|
11550753|NCT00998920|Experimental|160 mg BID|
11550754|NCT00998920|Placebo Comparator|Placebo|
11550755|NCT00998907|Active Comparator|PDS II|PDS II® loop suture is used for abdominal wall closure
11550756|NCT00998907|Experimental|PDS plus|"antibacterial coated PDS plus is used for abdominal wall closure"
11550757|NCT00998894||decision-support alerts|In patients experiencing a Triple Low (a combination of low MAC, low MAP, and low BIS), a warning alert will be generated for clinicians.
11550758|NCT00998894||routine practice|In patients experiencing a Triple Low (a combination of low MAC, low MAP, and low BIS), a warning alert will not be generated for clinicians.
11550759|NCT00998881|Experimental|Teneligliptin 20 mg|Teneligliptin 20 mg, orally, once daily
11550760|NCT00998881|Placebo Comparator|Placebo|Teneligliptin placebo-matching tablets, orally, once daily
11550761|NCT00998868||hemiplegia|patients with hemiplegia, without other musculoskeletal disorders of the shoulder
11550762|NCT00998855||Adolescents|Post pubertal, sedentary lean and obese Hispanic adolescents
11550763|NCT00998842||healthy subjects|five male, five female, ages 18-64
11550764|NCT00998829||Study population|The group comprises the entire study population
11550765|NCT00998816|Placebo Comparator|Placebo capsules|one placebo capsule will be administered 1 hour before lateral thoracotomy, 12 hours following the thoracotomy and then every 12h BID for 10 days following lateral thoracotomy.
11550766|NCT00998816|Active Comparator|pregabalin capsules|Pregabalin capsules (150mg) will be administered one hour before lateral thoracotomy, 12 hours following the thoracotomy and then every 12 hours (BID) for 10 days following lateral thoracotomy.
11550820|NCT00998439|Active Comparator|uncoated balloon catheter (POBA)|
11550768|NCT00998790|Experimental|AMS AdVance Sling Group|European Male subjects >40 years old who were implanted with the AMS AdVance Male Sling to treat Stress Urinary Incontinence.
11550769|NCT00998777|Experimental|Shoulder Strengthening|The shoulder strengthening program is a 6-week intervention aimed to improve shoulder and scapular stabilizer strength and scapular kinematics. The program includes 10 exercises: shoulder flexion, Ys,Ts,Ws, Throwing Acceleration, Throwing Deceleration, Low Rows, Dynamic Hug, IR @ 90, and ER @ 90. The program also includes 2 stretches: sleeper stretch and corner stretch.
11550770|NCT00998764|Experimental|Bapineuzumab 0.5 mg/kg|
11550771|NCT00998751|Experimental|masitinib (AB1010)|oral masitinib 7.5 mg/kg/day
11550772|NCT00998738|Experimental|Arm I (calcium gluconate, magnesium sulfate)|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and after each ixabepilone administration.
11550773|NCT00998738|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV over 30 minutes immediately before and after each ixabepilone administration.
11550774|NCT00998725||HIV+ARV+|
11550775|NCT00998725||HIV+ARV-|
11550776|NCT00998725||HIV negative|
11550777|NCT00998712||1|Black women in the third trimester of a pregnancy complicated by gestational diabetes.
11550778|NCT00998712||2|Black women in the third trimester of a normal, uncomplicated pregnancy.
11550779|NCT00998712||3|White women in the third trimester of a pregnancy complicated by gestational diabetes.
11550780|NCT00998712||4|White women in the third trimester of a normal, uncomplicated pregnancy.
11550781|NCT00998699|Active Comparator|XOMA 052|
11550782|NCT00998699|Placebo Comparator|Placebo|
11550783|NCT00998686|Experimental|dutogliptin/PHX1149T|
11550784|NCT00998686|Active Comparator|sitagliptin|
11550785|NCT00998673|Experimental|Arm 1|
11550786|NCT00998673|Other|Arm 2|
11550787|NCT00998660|Experimental|Patients receiving an Activa RC implant|
11550788|NCT00998647||with modified ultrafiltration|"elective cardiac surgery patients undergoing complex surgical intervention:
~coronary artery bypass grafting AND valve surgery double valve surgery aortic surgery Re-Dos"
11550789|NCT00998647||without modified ultrafiltration|"elective cardiac surgery patients undergoing complex surgical intervention:
~coronary artery bypass grafting AND valve surgery double valve surgery aortic surgery Re-Dos"
11550790|NCT00998634|Experimental|LITHIUM CARBONATE 150 and/or 300 mg|
11550791|NCT00998634|Placebo Comparator|PLACEBO|
11550792|NCT00998621||Hepatitis C infection|
11550793|NCT00998621||Hepatitis C + HIV infections|
11550794|NCT00998608|Experimental|HR|risperidone 2mg/d + haloperidol 2mg/d
11550795|NCT00998595|Experimental|Promotora|This group receives additional education and proactive follow-up by removing barriers to already existing services and reminders by a lay community health workers (Promotora)
11550796|NCT00998595|No Intervention|Standard of Care|These subjects receive the routine standard of postpartum care
11550797|NCT00998582|Active Comparator|Abacavir|Participants randomized to this arm will continue abacavir and their other HIV medications with no changes
11550798|NCT00998582|Experimental|Tenofovir|Participants randomized to this arm will switch from taking abacavir (co-formulated with lamivudine as Epzicom) and start taking tenofovir (co-formulated with emtricitabine as Truvada), and continue their other HIV medications
11550799|NCT00998569|Experimental|Neurocognitive Enhancement|neurocongnitive enhancement
11550800|NCT00998569|Other|Wait List|no intervention
11550801|NCT00998556|Experimental|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks, thereafter the patients continue to be observed in the follow-up part of the study up to month 6. The study medication is taken on top of standard therapy for heart failure. Part of this therapy are ACE inhibitors. ACE inhibitors are potentially harmful for the baby when getting into the breast milk, as bromocriptine stops milk production, no additional drug is needed.
11550802|NCT00998556|No Intervention|Control Group|The control group will receive standard therapy for heart failure. Part of this therapy are ACE inhibitors. Since ACE inhibitors are potentially harmful for the baby when getting into the breast milk, it is necessary to stop lactation in the control group as well.To stop lactation, application of bromocriptine (2.5mg/day) for up to one week.
11550803|NCT00998543||Smallpox Vaccine (LISTER Strain) Group|Participants were vaccinated with the second-generation smallpox vaccine in Study VVL04 (NCT 00258947).
11550804|NCT00998530||African American HIV+|African American women with HIV and infected with Trichomonas
11550805|NCT00998530||Caucasian HIV-|Caucasian women who are HIV negative and infected with Trichomonas
11550806|NCT00998530||African American HIV-|African American women who are HIV negative and are infected with Trichomonas
11550807|NCT00998517|Active Comparator|Soy/peanut fortified spread|
11550808|NCT00998517|Experimental|Milk fortified corn/soy blend|
11550809|NCT00998517|Active Comparator|Supplementary Plumpy®|
11550810|NCT00998504|Placebo Comparator|placebo|starch pill
11550811|NCT00998504|Active Comparator|resVida|synthetic pill containing 75 mg of resveratrol
11550812|NCT00998478|Experimental|Activity prescription|
11550813|NCT00998478|No Intervention|Normal Curriculum|Followed normal curriculum including physical education
11550814|NCT00998465||Obese, hypertension|Obese patients with hypertension and a body mass index 40-50 kg/m2
11550815|NCT00998465||Control|Control subjects without hypertension and body mass index < 30 kg/m2
11550816|NCT00998465||Obese, normotension|Obese patients without hypertension and a BMI between 40-50 kg/m2
11550817|NCT00998452|No Intervention|MOVE!|Participants will receive the usual VA MOVE! Program. These elements include a baseline assessment, brief clinic counseling session about weight, printed targeted health information on weight management and behaviors, and opportunities to participate in group sessions at the VA site and telephone follow-up from MOVE! clinic staff.
11550818|NCT00998452|Active Comparator|MOVE*VETS|Participants will receive the same MOVE! program as the control group plus 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from volunteer veteran peer counselors.
11550821|NCT00998426|Experimental|All study participants|Study procedures will occur one timebetween post-op day 1 and post-op day 7. Study procedures to include blood glucose monitoring prior to and after (various time points for 2 hours after) infusion with HBIG.
11550822|NCT00998413|Experimental|Multifaceted intervention|Multifaceted intervention:physical exercise, nutrition, and behavioural intervention.
11550823|NCT00998413|No Intervention|Control|standard usual care
11550824|NCT00998400|No Intervention|Clinical Management|Control group
11550825|NCT00998400|Experimental|CBT + WBT|Patients treated with Cognitive-Behavioral Therapy in combination with Well-Being Therapy and lifestyle modification
11550826|NCT00998387||medical ICU|admitted to medical ICU at Seoul National University Hospital longer than 24 hours
11550827|NCT00998374||Pyloric-sparing vs. non-pyloric sparing|Pyloric: SG & DS Non-pyloric: RYGB
11550828|NCT00998361|Experimental|Stem Cell Transplant|All the patient who are affected by refractory or resistant or relapsed Soft tissue sarcoma o Ewing sarcoma who find an HLA compatible allogeneic donor and are submitted to Stem cell transplantation
11550829|NCT00998348|No Intervention|Comparison Group|The comparison group will receive children's picture books (1 per month for the duration of the 8-month program).
11550830|NCT00998348|Experimental|Parenting Program|The parenting program is an 8-month obesity prevention intervention for parents with preschool-age children.
11550831|NCT00998335|Active Comparator|Insulin detemir only|Patients with uncontrolled T2DM are treated with insulin detemir for 6 months. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl. This group will receive Long-acting bedtime insulin detemir (Levemir).
11550832|NCT00998335|Experimental|Insulin detemir plus aspart|After baseline evaluations, insulin detemir will be given at bedtime and titrated to achieve a fasting plasma glucose between 80-100 mg/dl. After 3 months patients will be admitted to assess the metabolic effects of intervention. After this, insulin aspart (insulin detemir plus aspart) will be added before breakfast, lunch and dinner titrated to normalize the postprandial plasma glucose. After another 3 months patients are readmitted and all study procedures repeated. This group will receive Insulin detemir and pre-meal insulin aspart.
11550833|NCT00998309||Azithromycin SR|Patients taking Azithromycin.
11550834|NCT00998296|Experimental|BIBW 2992 + BIBF 1120|This is a phase I dose escalation clinical trial and the data obtained shall determine the MTD for the combination of BIBW 2992/BIBF 1120 in 28-day of treatment.
11550835|NCT00998283|Experimental|Cohort 1|Administration of HM10460A 5μg/kg or Placebo
11550836|NCT00998283|Experimental|Cohort 2|Administration of HM10460A 15μg/kg or placebo
11550837|NCT00998283|Experimental|Cohort 3|Administration of HM10460A 45μg/kg or placebo
11550838|NCT00998283|Experimental|Cohort 4|Administration of HM10460A 135μg/kg or placebo
11550839|NCT00998283|Experimental|Cohort 5|Administration of HM10460A 350μg/kg or placebo
11550840|NCT00998270|Active Comparator|Autologous arm|
11550841|NCT00998270|Experimental|Allogeneic arm|
11550842|NCT00998257||Group 1|
11550843|NCT00998244|Experimental|Very Low Carbohydrate Diet|Very Low Carbohydrate Diet
11550844|NCT00998244|Active Comparator|Low Fat Diet|Low Fat Diet
11550845|NCT00998231|Active Comparator|Major Depressive Episode (MDE)|20 subjects with major depressive episode will be included and followed during a 6 months interval which includes 4 visits (at the inclusion, 2 and 8 weeks later and finally 6 month later)
11550846|NCT00998231|Active Comparator|Control|20 subjects without major depressive episode will be included and followed during a 6 months interval which includes 4 visits (at the inclusion, 2 and 8 weeks later and finally 6 month later)
11550847|NCT00998218|Experimental|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) for 4 weeks
11550848|NCT00998218|Placebo Comparator|Sugar pill|Placebo comparator BID for 4 weeks.
11550849|NCT00998205|Other|Dobutamine stress echo (DSE)|Dobutamine intravenous infusion would be undertaken starting at 10 micrograms/kg per minute in three minute intervals increased to 20, 30, 40 or 50 micrograms/kg per minute or to a peak heart rate response of at least 85% age predicted maximum heart rate. If at the end of the Dobutamine protocol, there is inadequate heart rate response, intravenous atropine boluses of 0.5 milligrams (maximum 1.0 mg) would be used as needed to achieve a heart rate of at least 85% of age predicted maximum heart rate.
11550850|NCT00998179|Active Comparator|Acu-TENS|Application of Acu-TENS prior to exercise
11550851|NCT00998179|Placebo Comparator|Placebo-TENS|Application of Acu-TENS (without electrical output from the machine) prior to exercise
11550852|NCT00998166|Experimental|Pemetrexed, Cisplatin, Bevacizumab|Chemotherapy infusion on Day 1 of a 3-week cycle
11550853|NCT00998153|Experimental|1|RRFT
11550854|NCT00998153|Active Comparator|2|Usual care
11550855|NCT00998114|Experimental|Exercise and diastolic dysfunction|Aerobic exercise for 30-45 minutes five times a week for six months
11550856|NCT00998088|Experimental|Erythropoietin|
11550857|NCT00998088|No Intervention|Control arm|
11550858|NCT00998088|Experimental|cell saver|
11550859|NCT00998088|Experimental|drain|
11550860|NCT00998088|Experimental|Erythropoietin and cell saver|
11550861|NCT00998088|Experimental|Erythropoietin and drain|
11550862|NCT00998075|Active Comparator|1|Esomeprazole 40 mg/ASA 325 mg Fixed Dose Combination Capsule
11550863|NCT00998075|Active Comparator|2|Esomeprazole Clinical Trial Capsule 40 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
11550864|NCT00998075|Active Comparator|3|Esomeprazole MUPS Tablet 40 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
11550865|NCT00998062||1|Data from epidemiological studies performed after the year 2000 with patients between 35 and 74 years old
11550866|NCT00998049|Experimental|Plerixafor|"Plerixafor 160mg/kg/dose by IV on days 5-8
~Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8."
11550867|NCT00998036|Experimental|Temsirolimus, cisplatin, erlotinib|Cisplatin and temsirolimus will be administered weekly on days one and eight of a three week cycle. Erlotinib will be taken by mouth daily.
11550868|NCT00998023|Experimental|Mynx VCD|Mynx Vascular Closure Device
11550869|NCT00998023|Active Comparator|AngioSeal VCD|AngioSeal Vascular Closure Device
11550912|NCT00997646||Patients in hospitalist-run ward|Patients was admitted from ER to a hospitalist-run ward.
11550870|NCT00998010|Experimental|Experimental|Patients receive bortezomib IV on days 1, 4, 8, 11, 29, 32, 36, and 39 and oral temozolomide on days 1-42.Patients undergo external-beam fractionated regional radiotherapy 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.2-6 weeks after radiotherapy, patients receive bortezomib IV on days 1, 4, 8, and 11 and oral temozolomide on days 1-5.Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11550871|NCT00997997||Group 1|
11550872|NCT00997984|Experimental|Extended-release Guanfacine Hydrochloride (SPD503) AM|
11550873|NCT00997984|Experimental|placebo|
11550874|NCT00997984|Experimental|SPD503 PM|
11550875|NCT00997971|Experimental|Modilac Rose 1|Infant formula with partially hydrolysed rice protein
11550876|NCT00997958|Experimental|CellCept|Administered in tablet form twice daily one hour after eating.
11550877|NCT00997945|Experimental|1|ZD4054 (Zibotentan) 10mg
11550878|NCT00997932|Other|Complete Cohort|The complete cohort of all women enrolled and stated they wanted an LNG-IUS between 48 and 72 hours of vaginal delivery.
11550879|NCT00997919|Experimental|A|
11550880|NCT00997919|Experimental|B|
11550881|NCT00997906|Experimental|Arm I|Patients receive cisplatin IV over 2 hours once weekly on weeks 1-8 and undergo intensity-modulated radiotherapy once daily, 5 days a week, on weeks 1-7 (6½ weeks for a total of 33 fractions).
11550882|NCT00997906|Experimental|Arm II|Patients receive induction chemotherapy comprising gemcitabine hydrochloride IV over 30 minutes, carboplatin IV over 1 hour, and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning at least 3 weeks after the last dose of induction chemotherapy, patients receive cisplatin and undergo radiotherapy as in arm I.
11550883|NCT00997893|Experimental|Estradiol/Medroxyprogesterone Acetate|"Women in estradiol intervention group will take one active estradiol pill (1 mg) and one placebo pill at dinner, for a total daily dose of 1 mg estradiol and 0 mg Novasoy®. The UIC investigational drug service will obtain the estradiol tablets through the regular Hospital Pharmacy Purchases vendor, will encapsulate them, and will manufacture an identical appearing placebo to maintain blind.
~Medroxyprogesterone acetate (MPA): The UIC IDS will dispense MPA (10 mg/d for 10 days) at the time of randomization. This progestin treatment is necessary to protect the uterine lining. These pills will be encapsulated in order to maintain blind ."
11550884|NCT00997893|Experimental|Phytoestrogen|Phytoestrogen: Women in the phytoestrogen intervention group will take one active Novasoy® (55 mg) pill at breakfast and active Novasoy® (55 mg) pill at dinner, for a total daily dose of 110 mg Novasoy® and 0 mg estradiol. The UIC Investigational Drug Service will obtain the Novasoy® tablets from Archer Daniels Midland and will encapsulate the tablets to maintain blind.
11550885|NCT00997893|Placebo Comparator|Placebo|Placebo: Women in this intervention group will take one placebo pill at breakfast and one placebo pill at dinner, for a total daily dose of 0 mg Novasoy® and 0 mg estradiol. The UIC investigational drug service will encapsulate the placebo tablets (lactose) in the same manner that they will encapsulate the estradiol and Novasoy® tablets to maintain blind.
11550886|NCT00997880|Experimental|Rosuvastatin calcium 40mg|high-dose (40mg rosuvastatin)
11550887|NCT00997880|Active Comparator|Rosuvastatin calcium10mg|low-dose statin (10mg rosuvastatin)
11550888|NCT00997867|Active Comparator|Catheter 0-1cm past needle tip|Patients will be receiving a sciatic (popliteal), femoral, or interscalene nerve block and will be randomized to having the catheter placed 0-1cm past the needle tip. The patient will be called the following day by research staff to assess their post-surgical pain.
11550889|NCT00997867|Active Comparator|Catheter placed 5-6cm past needle tip|Patients will be receiving a sciatic (popliteal), femoral, or interscalene nerve block and will be randomized to having the catheter placed 5-6cm past the needle tip. Patients will be called the following day by research staff to assess their post-surgical pain.
11550890|NCT00997854|Active Comparator|Group 1 Bolus Feeds|This group will receive feeds administered by bolus method over no more than 30 minutes per feed.
11550891|NCT00997854|Experimental|Group 2- Slow Infusion Feeds|This group will receive feeds administered by slow infusion over pump for 2 hours.
11550892|NCT00997841|Active Comparator|POC algorithm|cardiac surgery patients suffering from increased perioperative bleeding and being treated following Point of Care based algorithm
11550893|NCT00997841|Active Comparator|conventional algorithm|cardiac surgery patients suffering from increased perioperative bleeding and being treated following conventional coagulation management algorithm
11550894|NCT00997828|Experimental|everolimus-eluting stent|everolimus-eluting stent
11550895|NCT00997828|Active Comparator|coronary artery bypass graft surgery|coronary artery bypass graft surgery
11550896|NCT00997815|Experimental|Botulinum toxin A|The area of alopecia is splited into experimental and control sides by blocked randomization. Experimental sides injected with botulinum toxin A at 2 units per 0.1 ml of dilution with normal saline entire all area.
11550897|NCT00997815|Placebo Comparator|Placebo|Using normal saline
11550898|NCT00997802|Other|CT colonography and optical colonoscopy|
11550899|NCT00997789|Experimental|Rebamipide, Serum concentration, Tablet|The test preparation, Rebamide® (containing 100 mg of rebamipide; lot No. KP005; expiration date, April 2010; Kyungdong Pharmaceutical Company, Seoul, Korea) and the reference preparation, Mucosta® (containing 100 mg of rebamipide; lot No. MC704067; expiration date, May 2010; Korea Otsuka Pharmaceuticals Co., Ltd., Seoul, Korea)
11550900|NCT00997776|Experimental|Exercise|High intensity lower extremity exercise
11550901|NCT00997776|Sham Comparator|Attention control|lower extremity TENS
11550902|NCT00997763|Active Comparator|XIENCE V|everolimus-eluting stent
11550903|NCT00997763|Active Comparator|CYPHER|Using Cypher stent
11550904|NCT00997750|Experimental|Lornoxicam|Lornoxicam 8mg/day and 12mg/day for 15 days
11550905|NCT00997737|Experimental|DB, VI and FV|Breathing exercises
11550906|NCT00997724|Experimental|a-VATS|Patients with NSCLC underwent assisted-VATS sleeve lobectomy with bronchoplasty.
11550907|NCT00997711|Experimental|Cypher|Sirolimus-eluting stent
11550908|NCT00997685|Experimental|Capecitabine plus oxaliplatin，mCRC|
11550909|NCT00997672|Experimental|Lithium CARBONATE 150 and/or 300 mg|
11550910|NCT00997672|Placebo Comparator|Placebo|Placebo comparator
11550911|NCT00997659|Experimental|chromium picolinate|
11551058|NCT00996567|Experimental|Cetuximab (Erbitux)|
11550913|NCT00997646||Patients in conventional ward|Patients was admitted from ER to a non hospitalist-run ward.
11550914|NCT00997633||Peritoneal carcinomatosis|Patients undergoing cytoreductive surgery and intraperitoneal chemotherapy treatment
11550915|NCT00997620|Placebo Comparator|Placebo|Placebo treatment given as a once daily dose intranasally.in subjects with active seasonal allergic rhinitis.
11550916|NCT00997620|Experimental|Fluticasone Furoate|IFluticasone Furoate 110 mcg given intranasly once daily in am as an active treatment of seasonal allergic rhinitis
11550917|NCT00997607|Experimental|Ebola vaccine only|Participants will receive only the Ebola vaccine or a placebo injection.
11550918|NCT00997607|Experimental|Marburg vaccine only|Participants will receive only the Marburg vaccine or a placebo injection.
11550919|NCT00997607|Experimental|Ebola and Marburg vaccine|Participants will receive both the Ebola and Marburg vaccines, one in each arm or placebo injections.
11550920|NCT00997594|Active Comparator|Adrenal radiofrquency (RF) ablation|Patients who wll receive adrenal RF ablation.
11550921|NCT00997594|Active Comparator|Abdominal RF ablation other than adrenal gland|Patients who will receive abdominal radiofrequency ablation other than adrenal gland.
11550922|NCT00997581|Experimental|apremilast|Experimental treatment for acute gout
11550923|NCT00997581|Active Comparator|indomethacin|Medication currently used for the treatment of acute gout
11550924|NCT00997568||TEE Procedure|Patients who have been scheduled for a TEE procedure by their physician
11550925|NCT00997555|Experimental|bronchoscopy intervention group|Group undergoing scheduled bronchoscopy.
11550926|NCT00997555|No Intervention|Control group|Standard treatment without scheduled bronchoscopy.
11550927|NCT00997542|Active Comparator|Allopurinol|
11550928|NCT00997542|Placebo Comparator|Placebo|
11550929|NCT00997529|Experimental|1|
11550930|NCT00997516|Experimental|SILS appendectomy|The study population will consist of patients who come to the emergency room with acute abdominal pain and are found to have acute appendicitis on the basis of clinical evaluation and CT of the abdomen/pelvis.
11550931|NCT00997516|Active Comparator|Conventional laparoscopic appendectomy|The study population will consist of patients who come to the emergency room with acute abdominal pain and are found to have acute appendicitis on the basis of clinical evaluation and CT of the abdomen/pelvis.
11550932|NCT00997490|Experimental|Verum|Neurapas balance, film-coated tablet
11550933|NCT00997490|Placebo Comparator|Placebo|
11550934|NCT00997477|Experimental|Formoterol and Budesonide|
11550935|NCT00997451|Experimental|Behavioral Self-Management|Cognitive-behavioral self-management
11550936|NCT00997451|Active Comparator|Symptom Monitoring|
11550937|NCT00997451|No Intervention|Standard Medical Care|
11550938|NCT00997438|Experimental|MS - Secondary Progressive|1200 mg of Lipoic acid supplement
11550939|NCT00997438|Experimental|MS - Relapsing Remitting|1200mg of Lipoic acid supplement
11550940|NCT00997438|Experimental|Healthy Controls|1200 mg of Lipoic acid supplement
11550941|NCT00997425|Experimental|Door Cover/Floor Cover|Baseline One (14 days), First Intervention (14 days), Baseline Two (14 days), Second Intervention (14 days)
11550942|NCT00997412|Experimental|MA|MA group: 1 tablet AZA placebo and 4 tablets MA (180mg/tab,720 mg/day) twice daily
11550943|NCT00997412|Active Comparator|AZA|AZA group: 1 tablet AZA (50mg/tab) and 4 tablets MA placebo twice daily
11550944|NCT00997399|Experimental|LBH589|
11550945|NCT00997386|Experimental|busulfan, and melphalan, and alemtuzumab|Three drug regimen using busulfan, and melphalan, and alemtuzumab.
11550946|NCT00997373|Experimental|Letrozole|letrozole 2.5 mg PO daily for 2-3 weeks prior to hysterectomy.
11550947|NCT00997373|No Intervention|control|no treatemtn prior to hysterectomy
11550948|NCT00997360|Experimental|1|PKI-179
11550949|NCT00997347|Experimental|64-70 days' gestational age|Women whose pregnancies are estimated to have a gestational age of 64-70 days
11550950|NCT00997347|No Intervention|57-63 days' gestational age|Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range.)
11550951|NCT00997334|Experimental|Erlotinib|Erlotinib was given at a dose of 150mg orally once per day for 28 days (+/- 3 days); Patients are treated until disease progression or until unaccepted drug toxicity.
11550952|NCT00997321|Active Comparator|Propofol|propofol 1 milligram per kilogram intravenous bolus followed by 0.5 millligrams per kilogram as needed for mooderate procedural sedation
11550953|NCT00997321|Active Comparator|Ketamine|ketamine 1 milligram per kilogram followed by 0.5 millgram per kilogram as needed for moderate procedural sedation
11550954|NCT00997308|Experimental|AZD1446 Low|Low dose of AZD1446
11550955|NCT00997308|Experimental|AZD1446 High|High dose of AZD1446
11550956|NCT00997308|Placebo Comparator|Placebo|
11550957|NCT00997295||Heat moisture exchanger (HME)|This group was submitted to general anesthesia with low flow gas and heat moisture exchanger
11550958|NCT00997295||Low flow gas (LFG)|This group was submitted to general anesthesia with only low flow gas
11550959|NCT00997295||Humidity of the respiration|"Heat and moisture group:
~The first group (G1)will be submitted to low flow gas anesthesia and heat and moisture exchanger (HME)
~Control group:
~The second group(G2)Will be submitted to low flow gas anesthesia"
11550960|NCT00997295||HME and LFG|
11550961|NCT00997282|Experimental|OPC-262 2.5 mg|orally administered once daily for 24 weeks
11550962|NCT00997282|Experimental|OPC-262 5 mg|orally administered once daily for 24 weeks
11550963|NCT00997282|Placebo Comparator|Placebo|orally administered once daily for 24 weeks
11550964|NCT00997269|Experimental|CoQ-10 supplementation|
11550965|NCT00997269|Placebo Comparator|CoQ-10 placebo supplementation|
11550966|NCT00997256|Experimental|Verum|Neurapas balance, film-coated tablets
11550967|NCT00997256|Placebo Comparator|Placebo|Film-coated sugar-pill
11550968|NCT00997243|Experimental|5-azacytidine and Lintuzumab|"Cycle 1- 5-azacytidine (Vidaza, AZA) 75mg/m2 IV/SC(subcutaneous)daily on days 1-7.
~Subsequent Cycles (cycles to be repeated every 28 days) AZA 75mg/m2 IV/SC daily on days 1-7."
11550969|NCT00997204|Experimental|Icatibant- Naive Treatment Phase|Single subcutaneous injection of icatibant, 30 mg
11550970|NCT00997204|Experimental|icatibant- Self administration Phase|Single subcutaneous injection of icatibant, 30 mg
11550971|NCT00997191|Active Comparator|Laser Group|Focal / grid Laser photocoagulation in diabetic macular edema
11550972|NCT00997191|Experimental|Triamcinolone group|Intravitreal triamcinolone associated to laser photocoagulation for diabetic macular edema
11550973|NCT00997191|Experimental|Bevacizumab group|Intravitreal Bevacizumab associated to laser photocoagulation for diabetic macular edema
11550974|NCT00997178|Experimental|Non-surgical periodontal therapy|Non-surgical periodontal therapy consisted of scaling and root planing plus chlorhexidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months
11550975|NCT00997178|Other|Delayed non-surgical periodontal therapy|No periodontal treatment for 6 months
11550976|NCT00997165||Metabolic syndrome (MS)|Patients suspected of metabolic syndrome without sleep apnea or liver steatosis
11550977|NCT00997165||MS with sleep apnea|Metabolic syndrome with sleep apnea
11550978|NCT00997165||MS with Liver steatosis|Metabolic syndrome with liver steatosis
11550979|NCT00997152|Experimental|Dose 1 JTT-654|
11550980|NCT00997152|Experimental|Dose 2 JTT-654|
11550981|NCT00997152|Placebo Comparator|Placebo|
11550982|NCT00997126|Active Comparator|Propofol|Propofol 1m g/kg IV followed by 0.5 mg/kg IV prn sedation
11550983|NCT00997126|Active Comparator|Alfentanil|Sedation using alfentanil 10 ug/kg followed by 5 ug/kg prn sedation
11550984|NCT00997113|Active Comparator|Propofol|propofol only for deep procedural sedation
11550985|NCT00997113|Active Comparator|Propofol/alfentanil|Propofol with alfentanil for deep procedural sedation
11550986|NCT00997100|Other|ABR-215757|
11550987|NCT00997087|Placebo Comparator|Sugar Pill, Placebo|
11550988|NCT00997087|Active Comparator|Flumazenil|
11550989|NCT00997074|Experimental|ibuprofen|the group will receive 2 tablets of ibuprofen 400 mg at the time of misoprostol administration. The information about the effect of the analgesics on the pain, and on the course of medical abortion, will be prospectively gathered from questionnaires completed by the study participants
11550990|NCT00997074|No Intervention|placebo|this group will receive 2 placebo tablets together with the misoprostol
11550991|NCT00997061||HYCAMTIN|
11550992|NCT00997048|Experimental|Laying open|
11550993|NCT00997048|Active Comparator|Sinus excision|
11550994|NCT00997035|Active Comparator|Oral Voriconazole|
11550995|NCT00997035|Placebo Comparator|Placebo|
11550996|NCT00997022|Experimental|Sorafenib|Daily sorafenib taken orally
11550997|NCT00997009|Experimental|Arm A|chemotherapy plus cetuximab
11550998|NCT00997009|Active Comparator|Arm B|chemotherapy
11550999|NCT00996996|Experimental|open-label, single arm|Tositumomab and Iodine I 131 Tositumomab
11551000|NCT00996983|Experimental|A|
11551001|NCT00996957|Experimental|ACE-041|Patients assigned to 1 of 9 possible dosing groups
11551002|NCT00996944|Experimental|Ropinirole IR|
11551003|NCT00996944|Placebo Comparator|Placebo|
11551004|NCT00996931|Experimental|Lenalidomide|
11551005|NCT00996918|Experimental|Bapineuzumab 0.5 mg/kg|bapineuzumab
11551006|NCT00996918|Experimental|Bapineuzumab 1.0 m/kg|bapineuzumab
11551007|NCT00996905|No Intervention|Beginner Conventional (BC)|Beginner level (residents) doing epidural insertions the conventional way (ie. no ultrasound scanning)
11551008|NCT00996905|Experimental|Beginner Ultrasound (BU)|Beginner level (residents) doing epidural insertions with the help of ultrasound scanning.
11551009|NCT00996905|No Intervention|Experienced Conventional|Experienced level (fellows) doing epidural insertions the conventional way.
11551010|NCT00996905|Experimental|Experienced Ultrasound|Experienced level (fellows) doing epidural insertions with the help of ultrasound scanning.
11551011|NCT00996892|Experimental|Dose Escalation Stage 1: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 20 milligrams [mg]) and pictilisib capsules (at a starting dose of 80 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
11551012|NCT00996892|Experimental|Dose Escalation Stage 1A: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D.Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
11551013|NCT00996892|Experimental|Dose Escalation Stage 1B: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 40 mg) and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
11551014|NCT00996892|Experimental|Dose Expansion Stage 2: Cobimetinib + Pictilisib|Participants will received cobimetinib capsules and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR) T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; and KRAS mutant colorectal cancer (CRC).
11551015|NCT00996892|Experimental|Dose Expansion Stage 2A: Cobimetinib + Pictilisib|Participants received cobimetinib capsules on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1A. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant NSCLC; EGFR T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; KRAS mutant CRC, and KRAS mutant endometrioid carcinoma.
11551016|NCT00996892|Experimental|Dose Expansion Stage 2B: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules and pictilisib capsules from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1B. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant endometrioid carcinoma.
11551017|NCT00996879|Experimental|Midazolam + BMS-791325|
11551018|NCT00996866|Placebo Comparator|Placebo|Half of subjects will be randomized to the placebo group.
11551019|NCT00996866|Active Comparator|Vitamin D3|This is the study group that receives Vitamin D supplementation.
11551020|NCT00996853||Total vaccinated cohort|The Total vaccinated cohort will include all subjects with at least one vaccine administration documented.
11551021|NCT00996840|Experimental|Cohort 1 - SB-681323 Intravenous 3mg|3mg SB-681323 Intravenous administration, infused over 4 hours
11551022|NCT00996840|Experimental|Cohort 2 - SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
11551023|NCT00996840|Experimental|Cohort 3 - SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
11551024|NCT00996840|Experimental|Cohort 4 - SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
11551025|NCT00996840|Experimental|Combined Placebo|Placebo to match intervention
11551026|NCT00996814|Experimental|Proactive Ethics Intervention|These patients have an ethics consultant involved in their care beginning on the fifth day of treatment in the ICU
11551027|NCT00996814|No Intervention|Usual Care|These patients receive usual care in the ICU.
11551028|NCT00996801|Placebo Comparator|Placebo|Participants received either matching placebo to alendronate (administered orally, once-weekly) or matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
11551029|NCT00996801|Experimental|MK-5442 5 mg|Participants received 5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
11551030|NCT00996801|Experimental|MK-5442 7.5 mg|Participants received 7.5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
11551031|NCT00996801|Experimental|MK-5442 10 mg|Participants received 10 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
11551032|NCT00996801|Experimental|MK-5442 15 mg|Participants received 15 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
11551033|NCT00996801|Active Comparator|Alendronate 70 mg|Participants received 70 mg alendronate (orally, once-weekly) plus matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
11551034|NCT00996788|Experimental|Rebamipide|Rebamipide 100 mg tid for 28 days
11551035|NCT00996775|Active Comparator|standard care only|standard care only - harmful effects of alcohol use and NIAAA limits
11551036|NCT00996775|Experimental|Brief alcohol intervention|Group receiving brief alcohol intervention
11551037|NCT00996762|Experimental|Part 1-3|2-period crossover, Period 1 (D1-7) will receive either the commercial formulation or the alternative formulation. Period 2 (D1-7) will receive the formulation not received in Period 1. There will be 3 parts with 3 different alternative formulations. Subjects will only participate in one part.
11551038|NCT00996749|Experimental|Treatment (omega-3 fatty acid)|Patients receive long-term omega-3 PUFA supplementation PO.
11551039|NCT00996736|Active Comparator|Topical Natamycin|
11551040|NCT00996736|Experimental|Topical Voriconazole|
11551041|NCT00996723|Other|1|
11551042|NCT00996697|Active Comparator|Triple therapy|Symbicort and tiotropium
11551043|NCT00996697|Placebo Comparator|Combination therapy|Symbicort and placebo
11551044|NCT00996684|Experimental|microplasmin, intravitreal injection|Subjects will receive one intravitreal injection of microplasmin on Day 0.
11551045|NCT00996684|Placebo Comparator|Placebo|Subjects will receive one intravitreal injection of the placebo on Day 0.
11551046|NCT00996671|Experimental|Dose Escalation Cohorts|single dose administration escalating doses starting at 20 mg and continue escalation; the highest dose in this study will not exceed the mean Day 1 exposure in male dogs at the NOAEL dose (6 mg/kg/day).
11551047|NCT00996671|Experimental|Food effect Cohort|Dose to be selected based on emerging safety and PK data; subjects will be given FDA standard high fat meal followed by single dose of study drug.
11551048|NCT00996658|Experimental|Linagliptin|Linagliptin tablets once daily
11551049|NCT00996658|Placebo Comparator|Placebo|Placebo tablets once daily
11551050|NCT00996645|No Intervention|Feedback report only|This arm will receive performance feedback reports but no worksheet to facilitate goal-setting and action plans.
11551051|NCT00996645|Experimental|Goal-Setting Worksheet|This arm will receive a theory-informed worksheet to facilitate the development of goals and action plans in response to the performance feedback reports.
11551052|NCT00996632|Experimental|A|Patients were operated using an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
11551053|NCT00996632|Active Comparator|B|Patients were operated using a conventional diarthermy knife
11551054|NCT00996619||People undergoing GI tract endoscopy|
11551055|NCT00996606|Experimental|Tocilizumab in Active RA|Participants with active RA will receive tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions will be given from Baseline to Week 44, and participants will be assessed through Week 48.
11551056|NCT00996593|Experimental|open-label, single arm|
11551057|NCT00996580|Experimental|DR-103|"Four 91-day cycles of the DR-103 regimen:
~42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by;
~21 days combination therapy of 25 mcg EE/150 mcg LNG followed by;
~21 days combination therapy of 30 mcg EE/150 mcg LNG followed by;
~7 days of 10 mcg EE."
11551059|NCT00996554|Experimental|Double-Layer-Suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
11551060|NCT00996554|Active Comparator|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread).
11551061|NCT00996541|Experimental|Intervention|
11551062|NCT00996541|Placebo Comparator|Control|
11551063|NCT00996528|Experimental|Philani Intervention Program|
11551064|NCT00996528|No Intervention|Standard Care|No intervention during study. Referral to clinic-based health care that is delivered by the province. Offered intervention at end of study, i.e. after 18 months.
11551065|NCT00996515|Experimental|Cohort 5|Erlotinib 150mg/day PO Day 1-28 and Vidaza 100mg/m2/day SQ Day 1-4 and 15-18
11551066|NCT00996515|Experimental|Cohort 4|Erlotinib 200 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day SQ 1-4 and 15-18
11551067|NCT00996515|Experimental|Cohort 3|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-3 and 15-17
11551068|NCT00996515|Experimental|Cohort 2|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-2 and 15-16
11551069|NCT00996515|Experimental|Cohort 1|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1 and 15
11551070|NCT00996502|Experimental|Combination regimen|"Bevacizumab, Erlotinib, Docetaxel, Prednisone (dose escalation)
~Phase I:
~Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid
~Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid
~Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid"
11551071|NCT00996489|Experimental|Coaptite|
11551072|NCT00996476|Experimental|TMC12/PR24 50 mg|Participants received TMC435 50 mg once daily with PegIFNa-2a and ribavirin (PR) for 12 weeks followed by PR until Week 24 Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
11551073|NCT00996476|Experimental|TMC12/PR24 100 mg|Participants received TMC435 100 mg once daily plus PegIFNa-2a and ribavirin (PR) for 12 weeks followed by PR until Week 24. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
11551074|NCT00996476|Experimental|TMC24/PR24 50 mg|Participants received TMC435 50 mg once daily plus PegIFNa-2a and ribavirin (PR) for 24 weeks. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435, PR) at Week 24. All other participants continued PR until Week 48.
11551075|NCT00996476|Experimental|TMC24/PR24 100 mg|Participants received TMC435 100 mg once daily plus PegIFNa-2a and ribavirin (PR) for 24 weeks. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
11551076|NCT00996476|Experimental|PR48 Control|Participants received PegIFNa-2a and ribavirin (PR) for 48 weeks (PR48 control group)
11551077|NCT00996463|Active Comparator|IL SSG|Intralesional sodium stibogluconate
11551078|NCT00996463|Experimental|ETC+MWT|Electro-thermo-coagulation with subsequent moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
11551079|NCT00996463|Experimental|MWT|Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
11551080|NCT00996437|Placebo Comparator|Saline Injection|Saline injection at baseline, 4 and 8 weeks
11551081|NCT00996437|Active Comparator|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks
11551082|NCT00996424|Experimental|Acetylcysteine|Inhalation with N-Acetylcysteine
11551083|NCT00996424|Placebo Comparator|normal saline|Inhalation with normal saline solution
11551084|NCT00996411|Experimental|Salvinorin A|
11551085|NCT00996398|Experimental|Cold water immersion|14°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
11551086|NCT00996385|Experimental|Velcade plus Eloxatin|Six 20-day cycles
11551087|NCT00996372|Experimental|flibanserin 100mg|flibanserin 100mg po qd
11551088|NCT00996372|Placebo Comparator|placebo|placebo one tablet po qd
11551089|NCT00996359|Experimental|Irradiated allogeneic lymphocytes after Total Body Irradiation|
11551090|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 1, Level 1|"Arm 1, Level 1: Irinotecan intravenously at 80 mg/m2 + Temsirolimus intravenously at 15 mg on a weekly basis for 3 consecutive doses followed by one week of rest.
~One cycle is four weeks."
11551091|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 1, Level 2|"Arm 1, Level 2: Irinotecan intravenously at 80 mg/m2 + Temsirolimus intravenously at 20 mg on a weekly basis for 3 consecutive doses followed by one week of rest.
~One cycle is four weeks."
11551092|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 2, Level 1|"Arm 1, Level 2: Irinotecan intravenously at 50 mg/m2 + Temsirolimus intravenously at 25 mg on a weekly basis for 3 consecutive doses followed by one week of rest.
~One cycle is four weeks."
11551093|NCT00996333|Experimental|Gemzar, Taxotere, Xeloda|"Gemcitabine, Docetaxel, Capecitabine:
~Gemzar intravenously on Day 4 and 11 Taxotere intravenously on Day 4 and 11 Xeloda tablet taken orally every day for 14 days"
11551094|NCT00996320|Experimental|Intervention Schedule|Interns on the intervention schedule work the a modified ICU schedule averaging about 60 hours per week over 4 weeks, with maximum scheduled shift length 16 hours.
11551095|NCT00996320|No Intervention|Traditional Schedule|Interns on the traditional schedule work the usual ICU schedule averaging about 80 hours per week over 4 weeks, with maximum shift length 30 hours.
11551096|NCT00996307|Experimental|3.75_(50)MF59|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
11551097|NCT00996307|Experimental|7.5_(0)MF59|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
11551098|NCT00996307|Experimental|7.5_(50)MF59|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
11551099|NCT00996307|Experimental|15_(0)MF59|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
11551100|NCT00996294|Experimental|surgery|patients will be submitted to biliopancreatic diversion or gastric bypass
11551101|NCT00996281|Experimental|Azilsartan Medoxomil and Chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily for up to 52 weeks.
~For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of azilsartan medoxomil 80 mg and chlorthalidone 25 mg."
11551102|NCT00996281|Active Comparator|Olmesartan Medoxomil and Hydrochlorothiazide QD|"Participants in the United States:
~Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg.
~Participants in Europe:
~Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 20 mg and hydrochlorothiazide 25 mg."
11551103|NCT00996268|Experimental|Part A|Three groups of sixteen healthy subjects will be randomized to single doses of 3 different formulations of GSK2212836.
11551104|NCT00996268|Experimental|Part B|Four cohorts of at least 10 subjects will participate in a 2-week repeat dose period with 4 dose levels (based on data obtained in Part A) of the GSK2212836 test formulations or placebo.
11551105|NCT00996255|Experimental|Dose-Escalation|
11551106|NCT00996242|Experimental|L-lysine|
11551107|NCT00996229|Experimental|Caloric restriction + placebo supplementation|
11551108|NCT00996229|Experimental|Omega-3 supplementation|
11551109|NCT00996229|Placebo Comparator|Placebo supplementation|
11551110|NCT00996229|Experimental|Resveratrol supplementation|
11551111|NCT00996216|Experimental|Open-label eltrombopag|Open-label eltrombopag with dose titrations to support adequate platelet counts.
11551112|NCT00996203|Experimental|1|
11551113|NCT00996190|Active Comparator|Phenylephrine Intermittent Bolus|Bolus syringe will contain 120 micrograms/mL of phenylephrine. Infusion solution bag will contain placebo (saline solution).
11551114|NCT00996190|Active Comparator|Phenylephrine Continuous Infusion|Infusion solution bag will contain 120 micrograms/mL of phenylephrine. Bolus syringe will contain placebo (saline solution).
11551115|NCT00996177|Experimental|IONSYS|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem
11551116|NCT00996177|Active Comparator|Patient-Controlled Analgesia|IV Morphine Patient-Controlled Analgesia (IV PCA)
11551117|NCT00996164|Experimental|flibanserin 100 mg|flibanserin 100mg po qd
11551118|NCT00996164|Placebo Comparator|Placebo|placebo 1 tab po qd
11551119|NCT00996138|Other|Arm 1|Dose ranging
11551120|NCT00996138|Other|Arm 2|Dose ranging
11551121|NCT00996125|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix vaccine. Cervarix vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
11551122|NCT00996125|Experimental|Placebo Group|Subjects received 3 doses of placebo. Placebo vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
11551123|NCT00996112||Historical|
11551124|NCT00996112||Prospective|
11551125|NCT00996099|Active Comparator|CGM-eMPC|
11551126|NCT00996099|Other|Control|
11551127|NCT00996086||CRT device-recipients|
11551128|NCT00996073|Active Comparator|Autograft|Lumbar Interbody Fusion with Autograft
11551129|NCT00996073|Experimental|Low Dose|Lumbar Interbody Fusion with NeoFuse-Low Dose
11551130|NCT00996073|Experimental|High Dose|Lumbar Interbody Fusion with NeoFuse-High Dose
11551131|NCT00996060|Experimental|Hydralazine and Valproic Acid|Starting dose of Hydralazine is 25 mg orally daily, days 1-28. (See Intervention for Dose Escalation Schema) Valproic acid 250 mg orally three times per day for days -14 through -8, then 500 mg orally three times per day daily for days -7 through 28, with the dose titrated to keep the serum level between 0.4 and 0.7 mM.
11551132|NCT00996034|Experimental|Healthy Smoker|There is only one arm to the study. All subjects will receive NicVax, [123I]5-I-A-85380,and Nicotine bitartrate.
11551133|NCT00996021|Experimental|Arm 1|This is a three way crossover study with 3 periods. Subjects will receive a single dose of either GSK1349572 250 mg suspension, placebo suspension or moxifloxacin 400 mg tablet in each of the three periods. The order in which the treatments are given will be randomized. There is a screening visit within 30 days prior to the first dose of study drug and a follow-up visit within 10-14 days after the last dose of study drug.
11551134|NCT00996008|Placebo Comparator|Placebo only|Subjects will apply placebo cream to all 4 target lesions
11551135|NCT00996008|Active Comparator|Active plus placebo|Subjects will receive CT 327 on 2 of 4 target lesions located on one side of their body. On the remaining 2 target lesions on the other side of their body, placebo will be applied.
11551136|NCT00995995||All patients|
11551137|NCT00995969|Placebo Comparator|Placebo only|Subjects will apply placebo cream to both target lesions
11551138|NCT00995969|Active Comparator|Active plus placebo|Subjects will apply CT 327 to one target lesion and placebo to the other target lesion
11551139|NCT00995930|Placebo Comparator|Placebo|subcutaneous (SQ) monthly
11551140|NCT00995930|Experimental|ACZ885|150 mg SQ monthly
11551141|NCT00995917|Experimental|Vitamin K acupoint injection|Participants will receive the vitamin K intervention within 2 days of the onset of painful menstrual cramps.
11551142|NCT00995917|Sham Comparator|Saline Injection|Participants will receive the saline treatment within 2 days of the onset of painful menstrual cramps.
11551143|NCT00995904|Experimental|Treatment A, then Treatment B, then Treatment C|Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
11551144|NCT00995904|Experimental|Treatment A, then Treatment C, then Treatment B|Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
11551145|NCT00995904|Experimental|Treatment B, then Treatment A, then Treatment C|Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
11551146|NCT00995904|Experimental|Treatment B, then Treatment C, then Treatment A|Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 4
11551147|NCT00995904|Experimental|Treatment C, then Treatment A, then Treatment B|"Study visits were separated by 3-7 day intervals.
~Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4"
11551148|NCT00995904|Experimental|Treatment C, then Treatment B, then Treatment A|Study visits were separated by 3-7 day intervals. Treatment C: 21ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 2; Treatment B: 42ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 4
11551149|NCT00995878|Active Comparator|Focused Ultrasound (MRgFUS)|
11551150|NCT00995878|Active Comparator|Uterine Artery Embolization (UAE)|
11551151|NCT00995865|Active Comparator|High dose|
11551152|NCT00995865|Active Comparator|Mid Dose|
11551153|NCT00995865|Placebo Comparator|Placebo|NaCl Injectable 0.9%
11551154|NCT00995852|Active Comparator|bilateral|"Treatment arm B - incomplete bilateral treatment of in total two lobes (contralateral).
~The study will only use Intrabronchial Valves™"
11551155|NCT00995852|Active Comparator|unilateral|Treatment arm A - unilateral treatment with complete closure of the worst lobe of the lungs
11551156|NCT00995839|Experimental|continuous terlipressin|
11551157|NCT00995839|Experimental|vasopressin|
11551158|NCT00995839|Experimental|terlipressin bolus dose|
11551159|NCT00995826|Placebo Comparator|placebo|
11551160|NCT00995826|Experimental|CS-8958 DPI|
11551161|NCT00995800|Active Comparator|Fluticasone propionate / Formoterol fumarate|
11551162|NCT00995800|Placebo Comparator|Fluticasone propionate / Formoterol fumarate placebo|
11551163|NCT00995787|Experimental|AZD1656|
11551164|NCT00995787|Placebo Comparator|Placebo|
11551165|NCT00995774|Experimental|Robotic then Conventional|robotic arm therapy first, conventional therapy second
11551166|NCT00995774|Experimental|Conventional then Robotic|conventional therapy first, robotic therapy second
11551167|NCT00995761|No Intervention|biweekly schedule|docetaxel 40mg/m2 on day 1,15 every 4weeks cisplatin 40mg/m2 on day 1,15 every 4weeks
11551168|NCT00995735||Transgastric|Patients submitted to Transgastric NOTES surgery
11551169|NCT00995735||Transvaginal|Patients submitted to Transvaginal surgery
11551170|NCT00995722|Experimental|Prednisone + Pyridostigmine|Corticosteroid
11551171|NCT00995722|Placebo Comparator|Placebo + Pyridostigmine|Matched, inactive substance
11551172|NCT00995709|Experimental|AIN457C 300 mg every 2 week dosage regimen|AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg each. every 2 weeks
11551173|NCT00995709|Experimental|AIN457C 300 mg monthly dosage regimen|AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg e
11551174|NCT00995709|Placebo Comparator|Placebo|Placebo was administered in 2 s.c. injections every 2 weeks
11551175|NCT00995696|Experimental|PhaST|Group receiving PhaST IVR phone calls.
11551176|NCT00995696|No Intervention|Usual Care|Group NOT receiving IVR phone calls.
11551177|NCT00995683|Experimental|half sodium lactate|infusion of 0.5 ml/kg/day during 48 hours
11551178|NCT00995683|Active Comparator|isotonic sodium chloride|infusion of 0.5 ml/kg during 48 hours
11551179|NCT00995670|Experimental|Sevoflurane and Glucose|"Endothelial function will be measured via forearm blood flow (FBF). Subjects may get I/R injury (ischemia) without glucose or sevoflurane (placebo); I/R with glucose only (glucose trial); I/R with sevoflurane only (sevo trial); I/R with glucose and sevoflurane (combo trial). Baseline FBF was taken in every trial before any intervention, and FBF was taken during intervention and post I/R.
~Glucose: 5% dextrose will be infused at 12 ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 1 hr to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent I/R injury.
~Sevoflurane: 1 minimum alveolar concentration (MAC) for 20 min (after 1 hr glucose and before I/R) 26 volunteers were studied 67 times in this arm."
11551180|NCT00995670|Experimental|Vitamin C and Glucose|"To determine if vitamin C can restore the impairment of the endothelium (FBF) caused by the glucose (dextrose infusion). All subjects received glucose and I/R injury (ischemia), either with or without vitamin C. Control baseline FBF was taken in every trial before any intervention, and FBF was taken during intervention and post I/R.
~Placebo data were the placebo studies from the Sevoflurane and Glucose arm, when appropriate; new subjects (not enrolled in Sevoflurane and Glucose arm) underwent a separate placebo trial.
~Glucose: 5% dextrose will be infused at 12ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 60 min.
~Vitamin C: 1 gm iv bolus injection 5 min before I/R injury 16 volunteers were studied 25 times in this arm."
11551181|NCT00995670|Experimental|Statins and Glucose|"Volunteers ingested a 40 mg simvastatin (statin) pill for the two evenings prior to study day and the morning of the study to determine the effect of simvastatin on modulating the I/R injury during hyperglycemia (high glucose). Volunteers were studied with statin alone and with statin and glucose.
~Placebo data were the placebo studies from the Sevoflurane and Glucose arm, when appropriate; new subjects (not enrolled in Sevoflurane and Glucose arm) underwent a separate placebo trial.
~Glucose: 5% dextrose will be infused at 12ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 60 min.
~Statin: 40 mg of simvastatin 17 volunteers were studied 31 times in this arm."
11551182|NCT00995657|Active Comparator|High dose ICS|Fluticasone Propionate 250mcg bid
11551183|NCT00995657|Active Comparator|Low dose ICS|Fluticasone propionate 50mcg bid
11551184|NCT00995631|No Intervention|Premenopausal, Control|Premenopausal women randomized to Control (delayed liposuction surgery)
11551221|NCT00995449|Placebo Comparator|Placebo|
11551185|NCT00995631|Active Comparator|Premenopausal, Surgery|Premenopausal women randomized to surgery (femoral lipectomy)
11551186|NCT00995631|No Intervention|Postmenopausal, Control|Postmenopausal women randomized to Control (delayed liposuction surgery)
11551187|NCT00995631|Active Comparator|Postmenopausal, Surgery|Postmenopausal women randomized to surgery (femoral lipectomy)
11551188|NCT00995618|Experimental|Tranilast|Tranilast tablets
11551189|NCT00995618|Active Comparator|Febuxostat|Febuxostat tablets
11551190|NCT00995618|Experimental|Combination|Tranilast plus febuxostat
11551191|NCT00995605|Experimental|Groups SAD|AMAP102 or Placebo as single ascending doses in five groups
11551192|NCT00995605|Experimental|Groups MAD|AMAP102 or Placebo as multiple ascending doses twice daily for seven days in two groups
11551193|NCT00995592|Experimental|Mentor mothers|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
11551194|NCT00995592|No Intervention|Control|Control cases were visited and their infants were weighed 4 times over one year period. After one year, mothers were provided Philani nutrition intervention program.
11551195|NCT00995579||Healthy college volunteers|
11551196|NCT00995566||Thelin Registry Patients|
11551197|NCT00995553|Experimental|Cognitive Remediation|A 48-session working memory focused cognitive remediation program is conducted. Training tasks have been selected from 3 software programs, PSS CogRehab, BrainTrain, and custom made N-back tasks.
11551198|NCT00995553|Placebo Comparator|Computer Skills|This is a 48-session, time matched comparison group in which participants practice keyboarding skills and the fundamentals of Microsoft Office Word, Powerpoint, and Excel programs.
11551199|NCT00995540|Placebo Comparator|Placebo|Placebo subcutaneous injection tid for 12 weeks
11551200|NCT00995540|Active Comparator|100 mg INGAP Peptide tid|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
11551201|NCT00995540|Active Comparator|200 mg INGAP Peptide tid|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
11551202|NCT00995514||Clopidogrel|Patients receiving clopidogrel 75 mg/day as prescribed by their physician, and are extensive metabolizers by CYP2C19 genotype
11551203|NCT00995514||Prasugrel|Patients receiving prasugrel 5 or 10 mg/day as prescribed by their physician
11551204|NCT00995501|Active Comparator|Intensive Glucose Control, Dexamethasone, light anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl
~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.
~Light anesthesia target BIS of 55"
11551205|NCT00995501|Active Comparator|Intensive Glucose Control, Dexamethasone, Deep anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl
~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.
~Deep anesthesia target BIS of 35"
11551206|NCT00995501|Active Comparator|Intensive Glucose Control, placebo, Light anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl
~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.
~Light anesthesia target BIS of 55"
11551207|NCT00995501|Active Comparator|Conventional Glucose Control, Dexamethasone, Light anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl
~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.
~Light anesthesia target BIS of 55"
11551208|NCT00995501|Active Comparator|Intensive Glucose Control, Placebo, Deep anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl
~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.
~Deep anesthesia target BIS of 35"
11551209|NCT00995501|Active Comparator|Conventional Glucose Control, Dexamethasone, Deep anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl
~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.
~Deep anesthesia target BIS of 35"
11551210|NCT00995501|Active Comparator|Conventional Glucose Control, Placebo, Light anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl
~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.
~Light anesthesia target BIS of 55"
11551211|NCT00995501|Placebo Comparator|Conventional Glucose Control, Placebo, Deep anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl
~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.
~Deep anesthesia target BIS of 35"
11551212|NCT00995488|Experimental|ABI-007|ABI-007 combined with Carboplatin, and Gemcitabine
11551213|NCT00995475|Experimental|Inhaled corticosteroid, Then placebo|FP 250μg per actuation pMDI one puff twice daily (total daily dose 500μg) for two weeks then FP 250μg per actuation pMDI four puffs twice daily (total daily dose 2000μg) for two weeks. After a washout period of 2 weeks, they then received FP matched placebo pMDI one puff twice daily for two weeks then FP four puffs twice daily for two weeks.
11551214|NCT00995475|Placebo Comparator|Placebo control, Then inhaled corticosteroid|FP matched placebo pMDI one puff twice daily for two weeks then FP four puffs twice daily for two weeks. After a washout period of 2 weeks, they then received FP 250μg per actuation pMDI one puff twice daily (total daily dose 500μg) for two weeks then FP 250μg per actuation pMDI four puffs twice daily (total daily dose 2000μg) for two weeks.
11551215|NCT00995462|No Intervention|Control|
11551216|NCT00995462|Experimental|Small-group seminar for 2 years|
11551217|NCT00995462|Experimental|Small-group seminars for 1 year followed by email intervention|
11551218|NCT00995449|Experimental|KB003 70 mg|
11551219|NCT00995449|Experimental|KB003 200 mg|
11551220|NCT00995449|Experimental|KB003 600 mg|
11551222|NCT00995436|Active Comparator|Extraoral anchorage|The intervention is the placement of Headgear, to be worn 100 hours per week
11551223|NCT00995436|Active Comparator|Miniscrews|The intervention is the of miniscrews to supplement anchorage
11551224|NCT00995436|Active Comparator|Nance palatal arch|Anchorage supplemented by Nance palatal arch fixing molars together with an arch
11551225|NCT00995423|Active Comparator|CoroflexTM|highly flexible CoroflexTM Please-Stent features
11551226|NCT00995423|Active Comparator|TAXUS|Paclitaxel-eluting stent
11551227|NCT00995410|Experimental|PA32540 tablet|325 mg enteric coated (EC) ASA and 40 mg omeprazole to be taken by mouth once daily
11551228|NCT00995397|Experimental|Dexchlorpheniramine 1% lotion|
11551229|NCT00995397|Active Comparator|Dexchlorpheniramine 1% cream|
11551230|NCT00995384|Other|CT scan|CT Scan for endocarditis patients. All patients receive intervention.
11551231|NCT00995371|Active Comparator|Vertos mild® Minimally-Invasive Lumbar Decompression|Patients in the Vertos mild® treatment group will be treated by appropriately trained physicians in accordance with the product labeling and indications for use.
11551232|NCT00995371|Active Comparator|Epidural Steroid Injection|Patients in the Epidural Steroid Injection (ESI) group will have ESI performed by appropriately trained physicians in accordance with product labeling and indications for use.
11551233|NCT00995358|Experimental|vaccination|
11551234|NCT00995345|Experimental|Dose 1: KRP-104 40 mg|Tablet, once-daily for 24 weeks
11551235|NCT00995345|Experimental|Dose 2: KRP-104 80 mg|Tablet, once-daily for 24 weeks
11551236|NCT00995345|Experimental|Dose 3: KRP-104 100 mg|Tablet, once-daily for 24 weeks
11551237|NCT00995345|Experimental|Dose 4: KRP-104 20/120mg|Tablet, once-daily for 24 weeks (dose switch from 20 to 120 mg at week 12)
11551238|NCT00995345|Placebo Comparator|Placebo|Tablet, once-daily for 24 weeks
11551239|NCT00995332|Experimental|ATRA+valproc acid+low-dose cytarabine|
11551240|NCT00995319||radiation patients|cancer patients with radiotherapy concerning the head and neck area/oral cavity
11551241|NCT00995306|Active Comparator|1|Civamide Cream 0.075%
11551242|NCT00995306|Active Comparator|2|Civamide Cream 0.01%
11551243|NCT00995293|Experimental|Docetaxel Cisplatin 5-Fluorouracil (DCF)|"4 cycles of the following products every 3 weeks (unless disease progression/relapse or unacceptable toxicity occured or the patient refused treatment):
~Docetaxel 60mg/m² on day 1
~Cisplatin 75mg/m² on day 1
~5-FU 750mg/m²/day on day 1 to day 5"
11551244|NCT00995293|Experimental|Cisplatin 5-Fluorouracil (CF)|"4 cycles of the following products every 3 weeks (unless disease progression/relapse or unacceptable toxicity occured or the patient refused treatment):
~Cisplatin 75mg/m² on day 1
~5-FU 750mg/m²/day on day 1 to day 5"
11551245|NCT00995280|Active Comparator|1|Single lumen needle use in oocyte retrieval
11551246|NCT00995280|Active Comparator|2|Double lumen needle with follicle flushing during oocyte retrieval
11551247|NCT00995267|Experimental|behavioral intervention|Behavioral intervention arm comprises 5 joint parent-child school-based nutritional activities in which nutritional information was combined with Adler's behavioral concepts. and a 5-session parental workshop.
11551248|NCT00995267|No Intervention|control arm|
11551249|NCT00995254|No Intervention|Control group|Control group will ONLY receive SHI after completion of the study
11551250|NCT00995254|Experimental|Intervention group|Intervention group will receive smoking hygiene intervention (SHI) at three individualized contacts.
11551251|NCT00995241|Experimental|Raltegravir 800 mg / 24 hours|Raltegravir 800 mg / 24 hours
11551252|NCT00995215|Experimental|Spinal Cord Stimulation|The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.
11551253|NCT00995202|Other|Standard Monitoring CEA/ Standard Imagery|No specific follow-up of CEA and Standard imagery
11551254|NCT00995202|Other|Intensive monitoring CEA/ Standard Imagery|Intensive follow-up CEA and Standard imagery .
11551255|NCT00995202|Other|Intensive Monitoring CEA / Intensive Monitoring Imagery|Intensive follow-up CEA and Intensive imagery
11551256|NCT00995202|Other|Standard Monitoring CEA/ Intensive Monitoring Imagery|No specific follow-up of CEA and Intensive Imagery
11551257|NCT00995189|Experimental|OFR|Opti-Free RepleniSH contact lens care solution used for 30 days
11551258|NCT00995189|Active Comparator|RNM|ReNu MultiPlus contact lens care solution used for 30 days
11551259|NCT00995176||1|Women residing in areas from defined geographic areas with high HIV prevalence and poverty
11551260|NCT00995176||2|Men residing in areas from defined geographic areas with high HIV prevalence and poverty
11551261|NCT00995150|Experimental|LNG20|LNG20 levonorgestrel-releasing intrauterine system
11551262|NCT00995150|Active Comparator|Mirena|Levonorgestrel-releasing intrauterine system for contraception
11551263|NCT00995137|Experimental|relapse B-Lineage ALL|"All patients meeting the eligibility criteria.
~Intervention: NK Cell Infusion"
11551264|NCT00995124|Experimental|NeutraLice Lotion|Single application of head lice product.
11551265|NCT00995124|Experimental|NeutraLice Advance|single application of head lice product
11551266|NCT00995124|Active Comparator|Moov Head Lice Solution|Single application for head lice with 10 min application time.
11551267|NCT00995098|Experimental|Early enteral nutrition|Twenty patient will be enrolled into this arm. Enteral nutrition administration will start within 24 hours after admission through naso-jejunal tube and continue for 7 days after admission.Naso-jejunal tube will be set up by endoscopy.
11551268|NCT00995098|Active Comparator|Control: Parenteral Nutrition|Twenty patient will be enrolled into this arm. PN administration will start within 24 hours after admission and continue for 7 days after admission.Parenteral nutrition will be administered through subclavian central venous catheter.
11551269|NCT00995085|Experimental|Metadoxine SR|Metadoxine is a pyrolate salt of Pyridoxine
11551270|NCT00995072|Experimental|Arm A|Nebivolol 5 mg daily for 12 weeks followed by Metoprolol succinate 100 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to metoprolol.
11551271|NCT00995072|Experimental|Arm B|Metoprolol succinate 100 mg daily for 12 weeks followed by nebivolol 5 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to nebivolol.
11551272|NCT00995059|Experimental|Arm 1|CONDITIONING: Patients receive bortezomib IV and then undergo fractionated total-body irradiation on days -5 and -2. Patients receive thymoglobulin IV over 6 hours on days -5 to -2 and melphalan IV over 30 minutes on days -4 to -3. ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -3, patients receive oral sirolimus and taper beginning on day 61. Beginning on day -2, patients receive oral or IV tacrolimus and taper beginning on day 101.
11551273|NCT00995046|Active Comparator|usual prophylaxis regimen|All patients will receive their usual prophylaxis regimen during the first 6 months
11551274|NCT00995046|Experimental|individually tailored prophylaxis regimen|All patients will receive an individually tailored prophylaxis regimen in accordance with TGT results during the second 6 month-period.
11551275|NCT00995033|Experimental|NicVAX conjugate vaccine|
11551276|NCT00995033|Placebo Comparator|Placebo|Biological
11551277|NCT00995020|Experimental|SWETZ|The intervention administered in this arm is the straight wire excision of the transformation zone, a electrosurgical method to perform a cone biopsy using a 1 cm straight wire of 0.20 mm wire. The activated wire is used in much the same way as a cold knife or laser beam fashioning the surgical specimen to achieve two centimeters cm at cervical canal..
11551278|NCT00995020|Active Comparator|LLETZ cone|The intervention administered in this arm is the large loop excision of transformation zone as a cone biopsy, performed using a large loop electrode of 2 cm depth, applied to the cervix to achieving two centimeters at cervical canal .
11551279|NCT00995007|Active Comparator|Group 2|Sequential Group (carboplatin followed by vandetanib)
11551280|NCT00995007|Active Comparator|Group 1|Combo Group (both drugs together)
11551281|NCT00994994|Active Comparator|Tranexamic acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit.
11551282|NCT00994994|Placebo Comparator|Placebo|same volume of normal saline was given.
11551283|NCT00994981|Experimental|magnesium|Using a table of random numbers, the patients were randomized to receive magnesium solution or normal saline. Allocation concealment was ensured using sequentially numbered, sealed opaque envelopes. Immediately after patient's arrival in the operating room, an anesthesiologist who was not involved in this study opened the envelopes and prepared the study solution outside the operating room.
11551284|NCT00994981|Placebo Comparator|normal saline|Using a table of random numbers, the patients were randomized to receive magnesium solution or normal saline. Allocation concealment was ensured using sequentially numbered, sealed opaque envelopes. Immediately after patient's arrival in the operating room, an anesthesiologist who was not involved in this study opened the envelopes and prepared the study solution outside the operating room.
11551285|NCT00994955|Experimental|selective retina therapy (SRT)|Focal laser treatment with an SRT-Laser which selectively affects the retinal pigment epithelium while sparing the photoreceptor layer.
11551286|NCT00994929|Experimental|Neumega (Oprelveken, Interleukin 11)|Neumega (Oprelveken, interleukin-11 (IL-11) 25 microgram/kilogram by subcutaneou injection once daily for four days, followed on day 4 DDAVP 0.3 microgram/kilogram intravenously 30 minutes after neumega
11551287|NCT00994903|Placebo Comparator|Placebo|Placebo tablets (Inert calcium lactate)
11551288|NCT00994903|Experimental|Simvastatin|40mg of Simvastatin given 3-7 days pre-op and continued till 14 days post-op
11551289|NCT00994890|Experimental|Tanezumab 2.5 mg|
11551290|NCT00994890|Experimental|Tanezumab 5 mg|
11551291|NCT00994890|Experimental|Tanezumab 10 mg|
11551292|NCT00994877||Septic Patients|
11551293|NCT00994877||Healthy Control|
11551294|NCT00994864|Other|adjuvant FOLFOX (1 pre-operative cycle)|One cycle of preoperative standard FOLFOX chemotherapy followed by eleven cycles post-operatively. PET/CT before and after the pre-operative chemotherapy cycle.
11551295|NCT00994851|Experimental|SENNA+ CASSIA|Daily administration (capsule) of Naturetti (SENNA+ CASSIA) at bedtime, during 30 days
11551296|NCT00994851|Placebo Comparator|Placebo|Daily administration (capsule) of placebo at bedtime, during 30 days
11551297|NCT00994838|Active Comparator|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
11551298|NCT00994838|No Intervention|standard diet|
11551299|NCT00994825|Placebo Comparator|Placebo|"Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%"
11551300|NCT00994825|Experimental|Levosimendan|Levosimendan
11551301|NCT00994812|Experimental|Metformin|
11551302|NCT00994799||ranibizumab group|patients receiving intravitreal ranibizumab for diabetic macular edema
11551303|NCT00994799||laser|patients receiving macular grid-pattern laser therapy
11551304|NCT00994786|Experimental|pregabalin|
11551305|NCT00994786|Placebo Comparator|Placebo|
11551306|NCT00994773|Experimental|Simvastatin|Simvastatin orally
11551307|NCT00994773|Experimental|Simvastatin and tenofovir|Simvastatin combined with tenofovir
11551308|NCT00994773|Experimental|Simvastatin and entecavir|Simvastatin combined with entecavir
11551309|NCT00994760||GENISIS|
11551310|NCT00994747|Active Comparator|Group EEEEEEE|Infant is fed Enfamil from 0.5-7.5 months of life
11551311|NCT00994747|Experimental|Group ENEEEEE|Infant is fed Enfamil during 0.5-1.5 months of life, Nutramigen from 1.5-2.5 months of life and then Enfamil 2.5-7.5 of life.
11551312|NCT00994747|Experimental|Group EENEEEE|Infant is fed Enfamil 0.5-2.5 months of life, Nutramigen from 2.5-3.5 months of life and then Enfamil from 3.5 to 7.5 months of life
11551313|NCT00994747|Experimental|Group EEENEEE|Infant is fed Enfamil from 0.5-3.5 months of life, Nutramigen from 3.5-4.5 months of life and then Enfamil from 4.5-7.5 months of life.
11551314|NCT00994747|Experimental|Group ENNNEEE|Infant if fed Enfamil from month 0.5-1.5 months of life, Nutramigen from 1.5 to 3.5 months of life and then Enfamil again 3.5-7.5 months of life.
11551315|NCT00994747|Experimental|Group NNNNNNN|Infant is fed Nutramigen from 0.5-7.5 months of life.
11551316|NCT00994734|No Intervention|clinic administration of mifepristone|
11551318|NCT00994721||pancreatic cancer|resected pancreatic cancer
11551319|NCT00994682|Active Comparator|Pioglitazone|After all patients receive dietary counseling at the research unit (CTSA), patients with prediabetes or type 2 diabetes mellitus (T2DM) and NASH will be started on pioglitazone (or placebo) in a randomized, double-blind,placebo-controlled study design. Pioglitazone will be given at 30 mg/day for the first 2 months and titrated to 45 mg/day thereafter (if well tolerated).
11551320|NCT00994682|Placebo Comparator|Placebo|After dietary counseling to all patients at the research unit (CTSA), patients with prediabetes or type 2 diabetes mellitus (T2DM) and NASH will be started on pioglitazone (or placebo) in a randomized, double-blind,placebo-controlled study design. Pioglitazone will be given at 30 mg/day for the first 2 months and titrated to 45 mg/day thereafter (if well tolerated).
11551321|NCT00994669||healthy control male|
11551322|NCT00994669||lung cancer male|
11551323|NCT00994656||posterior spinal fusion subject|Subject will have a history of either idiopathic or neuromuscular scoliosis who is now scheduled to have a posterior spinal fusion.
11551324|NCT00994643|Experimental|Treatment (Interleukin Therapy, Monoclonal Antibody)|Patients receive interleukin-2 SC twice weekly and rituximab IV once weekly in weeks 5-8 and 25-28. Courses repeat every 4 weeks for up to 7 months in the absence of disease progression or unacceptable toxicity.
11551325|NCT00994630||BP I patients manic phase|
11551326|NCT00994617|Experimental|Combination Therapy|Patients treated with combination therapy of Hydrochlorthiazide plus Losartan. Losartan will be force-titrated from 50 to 100mg, Hydrochlorothiazide will be force-titrated from 12.5mg to 25mg
11551327|NCT00994617|Active Comparator|Monotherapy|Initial monotherapy Hydrochlorothiazide 12.5mg -25mg Crossed over with Losartan 50 -100mg at 8 weeks
11551328|NCT00994604|Experimental|broccoli sprout extract|This a before and after treatment study. The subjects will consumer broccoli sprout extract (BSE) for two weeks (14d). Lung function and Chest CT will be performed before and after BSE consumption.
11551329|NCT00994591|Experimental|Pharmacokinetic dosing|
11551330|NCT00994578|No Intervention|Internet Only|Patients assigned to the internet only group will enter the initial CHESS portal which will take them to a window displaying a standard web search engine and common cancer information sites. We will monitor their internet usage via logins to the CHESS portal.
11551331|NCT00994578|Experimental|CHESS|Participants in the CHESS arm will be given access to the University of Wisconsin CHESS website, modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support. The participant's usage of the site will be monitored.
11551332|NCT00994578|Experimental|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each visit, and access to the patient's audio-recorded conversations for review. The participant's usage of the site will be monitored.
11551333|NCT00994578|Experimental|CHESS/COPE|Participants in the CHESS+COPE arm will receive training in, and access to, both components on the CHESS website, with the accompanying levels of support. The participant's usage of the site will be monitored.
11551334|NCT00994565|No Intervention|Usual care|
11551335|NCT00994565|Active Comparator|Activity monitoring and distance counseling|
11551336|NCT00994552|Active Comparator|Pressure support ventilation|Pressure support ventilation
11551337|NCT00994552|Active Comparator|Pressure control ventilation|Pressure control ventilation
11551338|NCT00994526|Placebo Comparator|Ham|
11551339|NCT00994526|Experimental|Ham + calcium|
11551340|NCT00994526|Experimental|Ham + vitamin E|
11551341|NCT00994513|Active Comparator|ALA|alpha lipoic acid 1200 mg/day
11551342|NCT00994513|Placebo Comparator|Placebo|placebo 1200 mg/day
11551343|NCT00994500|Experimental|Treatment (vorinostat, bortezomib)|Patients receive oral vorinostat once daily on days 1-5 and 8-12 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11551344|NCT00994487|Experimental|Breastfed child|Female, normal weight, 3 to 5 year old children, exclusively breastfed from birth to 3 months of age
11551345|NCT00994487|Active Comparator|Bottle Fed Child|Female, normal weight, 3 to 5 year old children, exclusively bottle fed from birth to 3 months of age
11551346|NCT00994474|Active Comparator|Fractional carbon dioxide laser treatment|
11551347|NCT00994474|Active Comparator|Fractional Er:YAG laser treatment|
11551348|NCT00994461|Experimental|Celecoxib|
11551349|NCT00994461|Active Comparator|Loxoprofen|
11551350|NCT00994461|Placebo Comparator|Placebo|
11551351|NCT00994448|Experimental|Bupropion|
11551352|NCT00994448|Placebo Comparator|Placebo (sugar pill)|
11551353|NCT00994422|Experimental|0.5% ivermectin cream|
11551354|NCT00994422|Placebo Comparator|vehicle control|
11551355|NCT00994396|Placebo Comparator|Placebo pill|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos
11551356|NCT00994396|Experimental|Vitamin D|4000 IU vitamin D3 (cholecalciferol) per day for 6 months.
11551357|NCT00994370||liver cancer|Patients referred for SIRT will be considered for this investigation. These patients will predominantly have stage IV colorectal metastases with liver dominant metastases or hepatocellular carcinoma. A team of oncologists, interventional radiologists, radiation oncologists and oncologic surgeons will determine that the patients are not candidates for surgical resection or ablative therapy. The patients will then be screened to confirm the patient's eligibility to receive standard of care SIRT treatment. SIRT treatment and imaging studies included in this investigation are standard of care for the patients' liver dominant disease.
11551358|NCT00994357|Experimental|Real-time Continuous Glucose Monitoring|Real-time Continuous Glucose Monitoring at five times for up to 6 days during pregnancy, and during delivery, in addition to standard monitoring and treatment.
11551359|NCT00994357|Active Comparator|Control group|Standard monitoring and treatment of diabetic patients during pregnancy.
11551360|NCT00994344|Experimental|Darunavir/ritonavir|to switch from the triple therapy based regimens to Darunavir/ritonavir
11551361|NCT00994344|Active Comparator|Lopinavir/ritonavir|to switch from the triple therapy based regimens to Lopinavir/ritonavir
11551362|NCT00994331|Active Comparator|Group A-CT Coregistration|5 subjects with CT co-registration in a magnetically navigated PCI (Group A)
11551363|NCT00994331|Active Comparator|Group B-Angiographic|5 subjects with angiographic co-registration in a magnetically navigated PCI (Group B)
11551364|NCT00994331|Active Comparator|Group C-Standard Angiography|5 subjects with standard angiography in a conventional PCI (Group C)
11551365|NCT00994318|Experimental|FCM (high ferritin target)|Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 400 - 600 mcg/L
11551366|NCT00994318|Experimental|FCM (low ferritin target)|Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 100 - 200 mcg/L
11551367|NCT00994318|Active Comparator|Oral Iron|Ferrous sulphate 100 mg iron twice daily, continuous
11551368|NCT00994305|Active Comparator|N-acetylcysteine|N-acetylcysteine 600 mg bid po 0-7 PO
11551369|NCT00994305|Sham Comparator|control|No treatment: standard care provided. No N-acetylcysteine administration.
11551370|NCT00994292|Experimental|1. YM150 Dose V, twice daily|
11551371|NCT00994292|Experimental|2. YM150 Dose W, once daily|
11551372|NCT00994292|Experimental|3. YM150 Dose X, twice daily|
11551373|NCT00994292|Experimental|4. YM150 Dose Y, once daily|
11551374|NCT00994292|Experimental|5. YM150 Dose Y, twice daily|
11551375|NCT00994292|Experimental|6. YM150 Dose Z, once daily|
11551376|NCT00994292|Placebo Comparator|7. Placebo|
11551377|NCT00994279|Active Comparator|Arm 1: Yoga Intervention|Yoga Intervention
11551378|NCT00994279|Active Comparator|Arm 2: Educational Wellness Group|Educational Wellness Group
11551379|NCT00994266|Experimental|A|Diamel
11551380|NCT00994266|Placebo Comparator|B|Placebo
11551381|NCT00994253|Experimental|Aliskiren|"Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day.
~Patients will be assigned to the treatment arm containing aliskiren. The prescribed drugs will include: Lisinopril 40mg + amlo 5mg + aliskiren 150-300mg"
11551382|NCT00994253|Active Comparator|Hydrochlorothiazide|"HCTZ will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day.
~Patients will be assigned to the treatment arm containing HCTZ. The prescribed drugs will include: Lisinopril 40mg + amlo 5mg + HCTZ 12.5-25mg"
11551383|NCT00994240|Active Comparator|ED&C times 3 cycles|
11551384|NCT00994240|Active Comparator|ED & C times 1 cycle|
11551385|NCT00994227|Experimental|surgery|
11551386|NCT00994214|Experimental|BIM 23A760 1 mg|
11551387|NCT00994214|Experimental|BIM 23A760 2 mg|
11551388|NCT00994214|Experimental|BIM 23A760 4 mg|
11551389|NCT00994214|Experimental|BIM 23A760 6 mg|
11551390|NCT00994175|Experimental|Pioglitazone, Then Placebo|Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the first treatment phase, followed by 45 mg daily for an additional 14 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the placebo phase for 16 weeks in the second treatment phase to receive the placebo.
11551391|NCT00994175|Experimental|Placebo, Then Pioglitazone|Placebo was administered for 16 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the Pioglitazone treatment group. Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the treatment phase, followed by 45 mg daily for an additional 14 weeks.
11551392|NCT00994162|Experimental|Negative Pressure Wound Therapy|Application of NPWT therapy to the wound
11551393|NCT00994149|Experimental|Diazoxide|Infants in this are will receive 10mg/kg/d of diazoxide divided and given every eight hours
11551394|NCT00994149|Placebo Comparator|Ora-plus|Liquid suspension modified to match intervention. Given every eight hours. Provided in shielded syringes.
11551395|NCT00994136|Experimental|Normal saline|In the intervention group the use of heparin as locking solution in the catheter lumen (or lumina) when the catheter is not longer in use is omitted. Catheters are locked under positive pressure with normal saline in stead injecting an extra volume of heparinised saline (100IU/ml).
11551396|NCT00994136|No Intervention|Heparin lock|
11551397|NCT00994123|Experimental|Phase 1: Dose-Escalation|Escalating doses of MM-121 (QOW IV) and erlotinib (daily PO)
11551398|NCT00994123|Active Comparator|Phase 2: Control|Erlotinib (daily)
11551399|NCT00994123|Experimental|Phase 2: Treatment|MM-121 (QOW IV) and erlotinib (daily PO)
11551400|NCT00994110|Experimental|SOM230|This is a randomized, double-blind, placebo controlled phase III trial of SOM230 vs. saline placebo in patients undergoing pancreaticoduodenectomy or distal pancreatectomy with or without splenectomy at Memorial Sloan-Kettering Cancer Center.
11551401|NCT00994110|Placebo Comparator|placebo|This is a randomized, double-blind, placebo controlled phase III trial of SOM230 vs. saline placebo in patients undergoing pancreaticoduodenectomy or distal pancreatectomy with or without splenectomy at Memorial Sloan-Kettering Cancer Center.
11551402|NCT00994097|Experimental|A: NGR-hTNF + cisplatin/gemcitabine or cisplatin/pemetrexed|NGR-hTNF with cisplatin/gemcitabine regimen in patients with squamous histology or with cisplatin/pemetrexed regimen in patients with nonsquamous histology
11551403|NCT00994097|Active Comparator|B: cisplatin/gemcitabine or cisplatin/pemetrexed|Cisplatin/gemcitabine regimen is administered in patients with squamous histology and cisplatin/pemetrexed regimen is administered in patients with nonsquamous histology
11551404|NCT00994084|Active Comparator|Lifestyle modification|This arm receives the intervention program that includes structured physical activities and nutrition and behavior lessons
11551405|NCT00994084|Placebo Comparator|Control|This arm receives no intervention
11551406|NCT00994058|Experimental|Intevention with Inhibitor|
11551407|NCT00994045|Active Comparator|Fresh Frozen Plasma|
11551408|NCT00994045|Experimental|Fibrinogen concentrate|
11551409|NCT00994032|Active Comparator|vertebroplasty|
11551410|NCT00994032|Active Comparator|Medical Treatment|
11551411|NCT00994006|Active Comparator|Magnesium oxide tables|Subjects will be instructed to take Magnox 520 qd
11551412|NCT00994006|Active Comparator|Magnesium citrate tablets|Subjects will be instructed to take magnesium diasporal tablets t.i.d.
11551413|NCT00993993||"group early intervention"|
11551414|NCT00993993||"group late intervention"|
11551415|NCT00993980|Experimental|1|qigong
11551416|NCT00993980|Active Comparator|2|exercise therapy
11551417|NCT00993967|Experimental|Idebenone|1350 mg/day or 2250 mg/day for patients weighing ≤45 kg or >45 kg, respectively.In case of poor tolerability, dose reduction to 450 mg/day or 900 mg/day, respectively, were allowed.
11551418|NCT00993954|Experimental|Nurse Reduction|Patients randomized to reduction by nurse.
11551419|NCT00993954|Active Comparator|Physician Reduction|Patients randomized to treatment by Emergency Department Physician in traditional ED manner
11551420|NCT00993941|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were randomly assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
11551421|NCT00993941|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were randomly assigned to Group B were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as Bone Mesenchymal Stem Cells(BMSC) transplantation via portal vein.
11551422|NCT00993928|Experimental|Arm A: Home-based sleep intervention with Device #1|Participants listen to a pre-recorded mp3 device #1 before retiring to sleep. Only patients in Arm A will have assigned bed and wake times based on their baseline diary.
11551423|NCT00993928|Active Comparator|Arm B: Home-based sleep intervention with Device #2|Participants will listen to a pre-recorded mp3 device #2 before retiring to sleep. At the end of the study, participants assigned to pre-recorded mp3 device #2 will be offered pre-recorded mp3 device #1 for their own use.
11551424|NCT00993915||Main group|Newly diagnosed or known coronary artery disease and known dislipidemia and high risk of cardiovascular complications
11551425|NCT00993902|Sham Comparator|Single IUI|Single IUI will be carried on after 36-38 hours of HCG administration
11551426|NCT00993902|Active Comparator|Double IUI|
11551427|NCT00993889|Experimental|VR during Physical Therapy|The subject will receive virtual reality during painful physical therapy sessions.
11551428|NCT00993889|Experimental|VR background pain|The subjects receives virtual reality, not during a physical therapy procedure, another time of the day for background pain.
11551429|NCT00993889|Experimental|No VR|The subject will receive the usual standard treatment. At the end of the study, before being discharged from the hospital, the subject can experience the VR, not during a procedure.
11551430|NCT00993876|Experimental|Selective serotonin reuptake inhibitor (SSRI)|citalopram
11551431|NCT00993876|Experimental|Serotonin-norepinephrine reuptake inhibitor (SNRI)|reboxetine
11551432|NCT00993876|Active Comparator|IPT|interpersonal psychotherapy
11551433|NCT00993863|Placebo Comparator|Placebo|
11551434|NCT00993863|Experimental|ADL5859 30 mg|
11551435|NCT00993863|Experimental|ADL5859 100 mg|
11551436|NCT00993863|Experimental|ADL5859 200 mg|
11551437|NCT00993863|Active Comparator|ibuprofen 400 mg|
11551438|NCT00993850|Other|Bipolar disorder education|Psychoeducation
11551439|NCT00993850|Other|Cognitive behavioral therapy|Cognitive behavioral therapy for insomnia
11551440|NCT00993837|Experimental|conversion|
11551441|NCT00993824|Placebo Comparator|Welchol then Placebo|3.75 grams of colesevelam HCl (Welchol) at evening meal for 12 weeks, and then crossover to placebo at evening meal for 12 weeks.
11551442|NCT00993824|Placebo Comparator|Placebo then Welchol|Placebo taken for 12 weeks at evening meal, and then crossover to 3.75 grams of colesevelam HCl taken at evening meal fro 12 weeks.
11551443|NCT00993811|Experimental|Circumcision|Males undergoing circumcision
11551444|NCT00993798|Experimental|SABER-Bupivacaine Treatment 1a|double-blind
11551445|NCT00993798|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 1b|double-blind
11551446|NCT00993798|Active Comparator|Bupivacaine HCl Treatment 1c|double-blind
11551447|NCT00993798|Experimental|SABER-Bupivacaine Treatment 2a|double-blind
11551448|NCT00993798|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 2b|double-blind
11551449|NCT00993798|Active Comparator|Bupivacaine HCl Treatment 2c|double-blind
11551450|NCT00993785|Experimental|OTW Catheter System|
11551451|NCT00993759|No Intervention|No treatment|
11551452|NCT00993759|Experimental|3804-250A lotion|
11551453|NCT00993746|Active Comparator|Bupivacaine plus lidocaine|Group 1: bupivacaine 20 ml plus lidocaine 10 ml
11551454|NCT00993746|Experimental|Bupivacaine alone|Group 2: bupivacaine 30 ml
11551455|NCT00993733|Experimental|CVVHDF on-line|CVVHDF using a central water treatment plant, providing dialysate directly to the patient. They will perform a continuous veno-venous haemodiafiltration.
11551456|NCT00993733|Experimental|classical CVVHDF|CVVHDF using a mobile generator with dialysate bags. They will perform a continuous veno-venous haemodiafiltration.
11551457|NCT00993720|Experimental|type 1 DM with betacell function: Liraglutide|
11551458|NCT00993720|Experimental|type 1 DM without betacell function: Liraglutide|
11551459|NCT00993720|No Intervention|type 1 DM without betacell function: Insulin|
11551460|NCT00993707|Active Comparator|0.01% CTX-100 (formerly ETX-100)|
11551461|NCT00993707|Active Comparator|0.03% CTX-100 (formerly ETX-100)|
11551462|NCT00993707|Placebo Comparator|Placebo|
11551463|NCT00993681|Experimental|1|900 subjects will receive a two vaccination regimen with an LT patch
11551464|NCT00993681|Placebo Comparator|2|900 subjects will receive a two vaccination regimen with a placebo patch
11551465|NCT00993668|Placebo Comparator|Placebo|Placebo
11551466|NCT00993668|Experimental|Cimzia|Certolizumab pegol
11551467|NCT00993655|Active Comparator|IV carboplatin + IV paclitaxel|ARM 1: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intravenous day 1; Paclitaxel 60 mg/m2 intravenous day 8. Cycles given Q 21 days x 3 cycles
11551468|NCT00993655|Active Comparator|IP cisplatin + IV/IP paclitaxel|ARM 2: Paclitaxel 135 mg/m2 intravenous day 1 plus Cisplatin 75 mg/m2 intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles (Phase II cisplatin arm closed to accrual on 2014-FEB-03)
11551518|NCT00993343|Active Comparator|sirolimus + tacrolimus|
11551519|NCT00993330||1|20 healthy subjects between 18 and 40 years
11551469|NCT00993655|Active Comparator|IP carboplatin + IV/IP paclitaxel|ARM 3: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles
11551470|NCT00993642|Experimental|All Participants|
11551471|NCT00993629|Active Comparator|Arm 1|adjunctive pregnenolone
11551472|NCT00993629|Placebo Comparator|Arm 2|adjunctive placebo
11551473|NCT00993616|Experimental|Treatment|Patients receive belinostat IV over 30 minutes on days 1-5 and carboplatin IV over 30-60 minutes on day 3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who are clinically responding or who, in the opinion of their physician, would continue to benefit from treatment may continue treatment beyond 6 courses.
11551474|NCT00993603|Experimental|Lifestyle programme.|8 month lifestyle programme.
11551475|NCT00993590|Experimental|M CHESS group|The intervention group will receive access for 12 months to M-CHESS via a smartphone to: (1) contact their case managers and primary provider; (2) communicate with the managed care organization case managers; (3) communicate with peers; (4) share information about changes in health status; (5) receive reminders to take medications and complete medical follow-up; (6) receive feedback on use of their asthma action plan; (7) receive tailored inquiries and insights regarding attendance or use of asthma resources; and (8) access audio and video versions of asthma educational materials and lower reading level versions of text materials; (9) provide monthly study outcome data monthly for 12 months.
11551476|NCT00993590|Active Comparator|Control group|The control group will receive standard care plus a smartphone for 12 months; they will provide study outcome data monthly for the next 12 months.
11551477|NCT00993577|Experimental|Exercises|Global Postural Reeducation Static Stretching Exercises
11551478|NCT00993551|Experimental|12 month surgery|Infants will receive primary surgery at age 12 months using Sommerlad technique
11551479|NCT00993551|Experimental|6 month surgery|Infants will receive primary surgery at age 6 months using Sommerlad technique.
11551480|NCT00993538|Experimental|1|
11551481|NCT00993525|Experimental|Intravitreal anti-VEGF|Intravitreal injection of 0.5 mg of ranibizumab
11551482|NCT00993512|Experimental|TPCS2a|No comparative treatment is given in this open-label phase I, dose escalating safety study
11551483|NCT00993499|Experimental|BIBW 2992 + Sirolimus|Dose escalation of the combination BIBW 2992 plus Sirolimus.
11551484|NCT00993486|Experimental|L1 (dose 1.0x10E4 T-cells/kg)|
11551485|NCT00993486|Experimental|L2 (dose 5.0x10E4 T-cells/kg)|
11551486|NCT00993486|Experimental|L3 (dose 1.3x10E5 T-cells/kg)|
11551487|NCT00993486|Experimental|L4 (dose 3.2x10E5 T-cells/kg)|
11551488|NCT00993486|Experimental|L5 (dose 7.9x10E5 T-cells/kg)|
11551489|NCT00993486|Experimental|L6 (dose 2.0x10E6 T-cells/kg)|
11551490|NCT00993486|Experimental|L7 (dose 5.0x10E6 T-cells/kg)|
11551491|NCT00993473|Experimental|Lantus (insulin glargine)|Lantus given as basal insulin once a day in the morning by subcutaneous injection
11551492|NCT00993473|Active Comparator|NPH insulin|Neutral Protamine Hagedorn (NPH) human insulin given as basal insulin either once or twice per day generally in the morning and /or at bedtime by subcutaneous injection
11551493|NCT00993460||Normal body weight|Female subjects, ages 21-65 yrs, with BMI of 21-27 kg/m2 with normal glucose tolerance.
11551494|NCT00993460||Roux-en-Y gastric bypass|Female subjects ages 21-65 with insulin resistance and scheduled for Roux-en-Y gastric bypass at Vanderbilt University Medical Center will be studied before and 4-6 weeks after surgery.
11551495|NCT00993447|Experimental|CYD Dengue Vaccine Group|Sanofi pasteur's CYD Dengue vaccine group (Dengvaxia®)
11551496|NCT00993447|Sham Comparator|Control Vaccine Group|
11551497|NCT00993434|Active Comparator|Kid STRIDE Booklet|
11551498|NCT00993434|Placebo Comparator|Safety Booklet|
11551499|NCT00993421|Placebo Comparator|placebo|
11551500|NCT00993421|Experimental|LY377604 (75 mg)|
11551501|NCT00993421|Active Comparator|sibutramine (30 mg)/metoprolol (200 mg)|
11551502|NCT00993421|Experimental|LY377604 (40 mg)/sibutramine (30 mg)|
11551503|NCT00993421|Experimental|LY377604 (75 mg)/sibutramine (30 mg)|
11551504|NCT00993421|Experimental|LY377604 (15 mg)/sibutramine (30 mg)|
11551505|NCT00993421|Experimental|LY377604 (75 mg)/sibutramine (15 mg)|
11551506|NCT00993408|Experimental|ACT-293987 (NS-304) and matching placebo|"Subjects will be randomized to the study following screening.
~Each subject will then undergo an acute hemodynamic study with right heart catheterization after a single oral administration of ACT-293987 (NS-304)on Day 0. The objectives are to collect data about the drug effect on the right heart hemodynamic parameters (PVR, calculated SVR and PVR/SVR) measured by right heart catheterization after single oral dose administration of NS-304 and to assess the safety and tolerability of a single oral dose of NS-304."
11551507|NCT00993395|Experimental|Peer Mentor Intervention|peer mentor-based disease management focusing on three domains: medical care, recovery, and social stabilization
11551508|NCT00993382|Experimental|Celivarone 50 mg|Celivarone, 50 mg once daily up to 10-15 days before the common study end date
11551509|NCT00993382|Experimental|Celivarone 100 mg|Celivarone, 100 mg once daily up to 10-15 days before the common study end date
11551510|NCT00993382|Experimental|Celivarone 300 mg|Celivarone, 300 mg once daily up to 10-15 days before the common study end date
11551511|NCT00993382|Active Comparator|Amiodarone|Amiodarone, 600 mg once daily for 10 days (loading dose) then 200 mg once daily up to 10-15 days before the common study end date
11551512|NCT00993382|Placebo Comparator|Placebo|Matching placebo once daily up to 10-15 days before the common study end date
11551513|NCT00993369||Healthy newborns conceived naturally|
11551514|NCT00993369||Healthy newborns conceived with IVF|
11551515|NCT00993356|Other|Group 2|After a baseline evaluation, patients underwent transsphenoidal surgery (direct surgery group).
11551516|NCT00993356|Experimental|Group 1|Patients received lanreotide for 16 weeks before the surgical resection [starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH > 5 mU/L on GH day curve (GHDC)] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
11551517|NCT00993343|Active Comparator|Cyclosporine + Methotreaxte|
11551520|NCT00993330||2|20 healthy subjects between 41 and 50 years
11551521|NCT00993330||3|20 healthy subjects between 51 and 60 years
11551522|NCT00993330||4|20 healthy subjects between 61 and 70 years
11551523|NCT00993330||5|20 healthy subjects between 71 and 80 years
11551524|NCT00993330||6|20 healthy subjects between 81 and 90 years
11551525|NCT00993317|Placebo Comparator|Placebo of CDP870+MTX|
11551526|NCT00993317|Experimental|CDP870 200mg+MTX|
11551527|NCT00993304|Experimental|A|
11551528|NCT00993304|Placebo Comparator|B|
11551529|NCT00993291|No Intervention|Baseline frequency|Baseline DBS frequency
11551530|NCT00993278|Active Comparator|Low-Carbohydrate (Modified Atkins) Diet|
11551531|NCT00993278|Active Comparator|Low-Fat (Heart Healthy) Diet|
11551532|NCT00993265|Experimental|N-acetylcysteine (NAC)|Patients randomized to this arm will receive N-Acetylcysteine, at a standard dose titrated to 2400 mg. They will receive NAC in addition to the medication regimen they are on at enrollment.
11551533|NCT00993265|Placebo Comparator|Placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
11551534|NCT00993239|Experimental|Birinapant (TL32711)|
11551535|NCT00993226|Experimental|SABER-Bupivacaine Treatment 1a|double-blind
11551536|NCT00993226|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 1b|double-blind
11551537|NCT00993226|Active Comparator|Bupivacaine HCl Treatment 1c|double-blind
11551538|NCT00993226|Experimental|SABER-Bupivacaine Treatment 2a|double-blind
11551539|NCT00993226|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 2b|double-blind
11551540|NCT00993226|Active Comparator|Bupivacaine HCl Treatment 2c|double-blind
11551541|NCT00993213|Active Comparator|Liposuction|Standard of Care with Liposuction
11551542|NCT00993213|Sham Comparator|No Liposuction|Standard of Care without Liposuction'
11551543|NCT00993200|Active Comparator|Warfarin, control|Subjects naive to warfarin therapy with anticipated warfarin duration of at least 12 weeks managed by usual care dosing.
11551544|NCT00993200|Experimental|Warfarin: PERMIT|Subjects naive to warfarin therapy with anticipated warfarin duration of at least 12 weeks managed by warfarin pharmacogenetic dosing (warfarin dosing using genetic information incorporated into the PERMIT algorithm).
11551545|NCT00993187|Experimental|Sitagliptin/Metformin FDC|Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks.
11551546|NCT00993187|Active Comparator|Glimepiride|Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day.
11551547|NCT00993174|Experimental|Topical anesthesia|Patients undergo strabismus surgery for esotropia using topical anesthesia (instillation of drops plus gel)
11551548|NCT00993174|Active Comparator|Sub-Tenon's anesthesia|Patients undergo surgery for strabismus (esotropia) using sub-Tenon's administration of anesthetic (xylocaine)
11551549|NCT00993161|Experimental|patients|Patients with neuromuscular disorder and controls
11551550|NCT00993161|Experimental|Controls|healthy controls
11551551|NCT00993148|Experimental|Maraviroc plus darunavir/ritonavir|Single arm open label trial of maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily for 96 weeks
11551552|NCT00993122|Active Comparator|ribavirin pre-treatment|patient will receive ribavirin in monotherapy for 8 weeks before the combined 48 weeks antiviral therapy
11551553|NCT00993122|Active Comparator|combined stardard therapy|patients will receive the standard combined therapy with ribavirin and pegylated interferon for 48 weeks
11551554|NCT00993109|Experimental|Arm 1|
11551555|NCT00993109|Active Comparator|Arm 2|
11551556|NCT00993096|Experimental|IDegAsp low|
11551557|NCT00993096|Experimental|IDegAsp middle|
11551558|NCT00993096|Experimental|IDegAsp high|
11551559|NCT00993096|Experimental|BIAsp 30 low|
11551560|NCT00993096|Experimental|BIAsp 30 middle|
11551561|NCT00993096|Experimental|BIAsp 30 high|
11551562|NCT00993083|Experimental|Vaccinated|14 volunteers (2 in lead safety group and 12 in main study group) to receive MVA-NP+M1 via the IM route. Volunteers will then be challenged with Influenza 30 days post vaccination.
11551563|NCT00993083|No Intervention|Control|12 volunteers who will not receive vaccine but will also be challenged with Influenza on day 30
11551564|NCT00993070|Experimental|Capsaicin|
11551565|NCT00993070|Placebo Comparator|placebo|
11551566|NCT00993057|Active Comparator|Q1 hour protocol|change of insulin infusion every hour
11551567|NCT00993057|Active Comparator|Q30min protocol|change of insulin infusion every 30 minutes
11551568|NCT00993044|Experimental|Single Arm|
11551569|NCT00993031|Experimental|Group A|ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg
11551570|NCT00993031|Active Comparator|Group B|ZDV 300mg/3TC 150mg/EFV 600mg
11551571|NCT00993018|Experimental|JNJ-42160443 (1 mg)|JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
11551572|NCT00993018|Experimental|JNJ-42160443 (3 mg)|JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
11551573|NCT00993018|Experimental|JNJ-42160443 (10 mg)|JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
11551574|NCT00993018|Placebo Comparator|Placebo|Placebo will be administered as a single, subcutaneous injection every 28 days for up to 52 weeks.
11551575|NCT00993005|Experimental|A|Cicatrix
11551576|NCT00993005|Placebo Comparator|B|Placebo
11551627|NCT00992589|Experimental|Rabeprazole sodium 10 mg|
11551577|NCT00992992|Experimental|Tositumomab and Iodine I 131 Tositumomab followed by CHOP|Tositumomab and Iodine I 131 Tositumomab followed by CHOP
11551578|NCT00992979|Experimental|Therapeutic Massage|
11551579|NCT00992979|Active Comparator|Relaxation Control|Relaxation Control Session
11551580|NCT00992953|Experimental|Virtual Reality Therapy|10 Weeks of Virtual Reality Exposure with Stimulus Control, with up to twice a week, 90 min sessions
11551581|NCT00992953|Active Comparator|Treatment As Usual|Traditional Therapy and Psychiatric Medication
11551582|NCT00992940|Experimental|Patient-Controlled Sedation/Analgesia|Patient controls the amount of sedation and analgesia delivered, according to their own requirements.
11551583|NCT00992940|Active Comparator|Anesthetist-Controlled Sedation/Analgesia|Patient sedation and analgesia requirements are delivered by the anesthetist.
11551584|NCT00992927|Experimental|CPIHD|Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
11551585|NCT00992927|Active Comparator|CRIHD|Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
11551586|NCT00992914|Active Comparator|Lidocaine injection|Stellate Ganglion Injection with Lidocaine
11551587|NCT00992914|Placebo Comparator|saline injection|Superficial subcutaneous injection
11551588|NCT00992901|Experimental|Exendin-(9-39)|To evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion
11551589|NCT00992901|Experimental|atropine|To evaluate the effect of neural activation on insulin secretion and glucose metabolism
11551590|NCT00992901|Experimental|GLP-1 and GIP|to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones
11551591|NCT00992888|Experimental|albumin liver dialysis|
11551592|NCT00992888|No Intervention|Standard medial care without dialysis|
11551593|NCT00992862|Experimental|Moexipril HCl 15mg Tablets|
11551594|NCT00992862|Active Comparator|Univasc® 15mg Tablets|
11551595|NCT00992849|Experimental|Bevacizumab|Arm type to experimental based on single group assignment. Bevacizumab (trade name Avastin, Genentech/Roche) is a humanized monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF).VEGF is a chemical signal that stimulates the growth of new blood vessels.
11551596|NCT00992836|Experimental|Influenza A (H1N1) 2009 monovalent vaccine|All participants received two doses of the H1N1 influenza virus vaccine, administered 21 days apart.
11551597|NCT00992823|Active Comparator|Group 1:iron weekly supplementation|
11551598|NCT00992823|Active Comparator|Group 2: cycle supplementation|two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
11551599|NCT00992810|Experimental|Lateral-to-Medial Approach|Needle approach to the brachial plexus nerves will be made using a lateral-to-medial direction.
11551600|NCT00992810|Experimental|Medial-to-Lateral Approach|Needle approach to the brachial plexus nerves will be made using a lateral-to-medial direction.
11551601|NCT00992797|Experimental|Cholecalciferol|
11551602|NCT00992797|Placebo Comparator|Placebo|
11551603|NCT00992784|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A
11551604|NCT00992784|Active Comparator|Fluarix elderly Group|Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine
11551605|NCT00992784|Active Comparator|Fluarix young Group|Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine
11551606|NCT00992771|Experimental|Varneicline|
11551607|NCT00992771|Placebo Comparator|Placebo|
11551608|NCT00992758|Experimental|Treatment, Non-Randomized, Open Label|Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
11551609|NCT00992745|Experimental|Previous ProstaScint®|Subjects with a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 alone.
11551610|NCT00992745|Experimental|No Previous ProstaScint®|Subjects without a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 and 111-In capromab pendetide imaging.
11551611|NCT00992732|Experimental|HQK-1004 + Valganciclovir|
11551612|NCT00992719|Active Comparator|Group 3: Non-pregnant Women: 15 mcg H1N1 Vaccine|100 non-pregnant women to receive 15 mcg inactivated H1N1 vaccine.
11551613|NCT00992719|Experimental|Group 2: Pregnant Women: 30 mcg H1N1 Vaccine|100 pregnant women to receive 30 mcg inactivated H1N1 vaccine.
11551614|NCT00992719|Experimental|Group 1: Pregnant Women: 15 mcg H1N1 Vaccine|100 pregnant women to receive 15 mcg inactivated H1N1 vaccine.
11551615|NCT00992693|Experimental|Treatment with IV Ribavirin|In this open label treatment study, the investigators intend to treat all subjects who present with a tentative diagnosis of VHF and meet entry criteria with a 10 day course of IV Ribavirin.
11551616|NCT00992680|Experimental|Group A|Anastomotic Coupler System + standard of care per GOLD
11551617|NCT00992680|No Intervention|Group B|Standard of care per GOLD alone
11551618|NCT00992667|Experimental|Asthmatics|Ten nonsmoking patients, suffering from mild bronchial asthma participated in the study (mean age 30±9 years, 5 men, 5 women). Asthma was diagnosed based on GINA 2008 criteria. The patients were free of any medication, at least 7 days before, and had not suffered from any infectious diseases including upper respiratory tract infections for at least 3 months prior to the study. Patients who did not meet these criteria were excluded from the study.
11551619|NCT00992641|Experimental|Experimental diet|Diet based on Nordic recommendations: rich in whole grain products, berries, fruits and vegetables, recommended fat quality. Realised based on eating habits of each Nordic country.
11551620|NCT00992641|Active Comparator|Control diet|Diet based on the information of the current dietary intake and food consumption in Nordic countries.
11551621|NCT00992628|Active Comparator|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
11551622|NCT00992628|Active Comparator|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
11551623|NCT00992615|Experimental|Arm 20 cores|
11551624|NCT00992615|Active Comparator|arm 12 cores|
11551625|NCT00992602|Experimental|Treatment (liposomal cytarabine, high-dose methotrexate)|See Detailed Description
11551626|NCT00992589|Experimental|Rabeprazole sodium 5 mg|
11551628|NCT00992589|Placebo Comparator|Placebo|
11551629|NCT00992563|Experimental|AL-39324 Concentration Level A|AL-39324 ophthalmic suspension, single intravitreal injection
11551630|NCT00992563|Experimental|AL-39324 Concentration Level B|AL-39324 ophthalmic suspension, single intravitreal injection
11551631|NCT00992563|Experimental|AL-39324 Concentration Level C|AL-39324 ophthalmic suspension, single intravitreal injection
11551632|NCT00992563|Experimental|AL-39324 Concentration Level D|AL-39324 ophthalmic suspension, single intravitreal injection
11551633|NCT00992563|Experimental|AL-39324 Concentration Level E|AL-39324 ophthalmic suspension, single intravitreal injection
11551634|NCT00992563|Active Comparator|Lucentis|Ranibizumab 10 mg/mL solution, single intravitreal injection
11551635|NCT00992550|Experimental|Hookah visit, then cigarette visit|4-day inpatient stays for profile of biomarker excretion
11551636|NCT00992550|Experimental|Cigarette visit, then Hookah visit|4-day inpatient stay for profile of biomarker excretion
11551637|NCT00992537|Experimental|IDeg|
11551638|NCT00992537|Experimental|IDegAsp|
11551639|NCT00992537|Active Comparator|IAsp|
11551640|NCT00992524|Active Comparator|Oral Titrated Misoprostol Solution|
11551641|NCT00992524|Active Comparator|Vaginal Misoprostol|
11551642|NCT00992511|Experimental|GSK2340272A New 1D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
11551643|NCT00992511|Experimental|GSK2340272A New 2D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
11551644|NCT00992511|Experimental|GSK2340272A INI 1D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the Initial process-manufactured (INI 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
11551645|NCT00992511|Experimental|GSK2340272A INI 2D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the Initial process-manufactured (INI 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
11551646|NCT00992485|Experimental|autologous adipose derived stem cell|
11551647|NCT00992472|Experimental|Prochlorperazine suppositories, 25mg|
11551648|NCT00992472|Active Comparator|Compazine® suppositories, 25mg|
11551649|NCT00992459|Experimental|Buphenyl (NaPBA) /HPN 100 Placebo|Subjects in Arm A were randomly assigned to receive NaPBA + HPN 100 placebo for 2 weeks and then crossed over to receive HPN 100 + NaPBA Placebo for 2 weeks.
11551650|NCT00992459|Experimental|HPN-100/NaPBA Placebo|Subjects in Arm B were randomly assigned to receive HPN-100 + NaPBA placebo for 2 weeks and then crossed over to receive NaPBA + HPN 100 placebo for 2 weeks.
11551651|NCT00992446|Experimental|Treatment (chemotherapy, ASCT, bortezomib, vorinostat))|All patients receive carmustine IV over 3 hours on day -7; cytarabine IV BID over 3 hours and etoposide IV BID over 2 hours on days -6 to -3; and melphalan IV over 30 minutes on day -2. Only patients with history of CD20+ NHL receive additional rituximab IV on days -19 and -12. Patients undergo ASCT on day 0. Patients then receive bortezomib IV on days 2 and 8, and vorinostat PO QD on days 1-14. Treatment with bortezomib and vorinostat repeats for total of 12 courses in the absence of disease progression or unacceptable toxicity.
11551652|NCT00992433|Experimental|Group 2, 30 mcg|CD4<200, n=60; CD4 greater than or equal to 200, n=60. 30 mcg H1N1 vaccine on Day 0 and Day 21.
11551653|NCT00992433|Experimental|Group 1, 15 mcg|CD4<200, n=60; CD4 greater than or equal to 200, n=60. 15 micrograms (mcg) H1N1 vaccine on Day 0 and Day 21.
11551654|NCT00992420||GRAVITAS Study Arm A|"Tailored clopidogrel regimen - total first day dose 600-mg, then 150-mg every day for 6 months"
11551655|NCT00992420||GRAVITAS Study Arm B|"Standard clopidogrel regimen - a placebo loading dose (six placebo tablets) and then clopidogrel 75-mg and 1 placebo tablet every day for 6 months."
11551656|NCT00992420||GRAVITAS Study Arm C|Responders: A random sample of clopidogrel responders treated with a placebo loading dose (six placebo tablets) and then the standard clopidogrel regimen of 75-mg and 1 placebo tablet every day for 6 months.
11551657|NCT00992407|Experimental|Risperidone long acting injectables|
11551658|NCT00992407|Active Comparator|Risperidone tablets|
11551659|NCT00992394|Other|Arm 1|Subjects randomized to arm 1 stop their etanercept treatment on entry into the study and may be retreated by etanercept 50 mg once weekly after medical review and agreement between the subject and the investigator
11551660|NCT00992394|Other|Arm 2|Subjects randomized to arm 2 in which subjects continue on treatment with etanercept at 25 mg once weekly, but with the option to have their drug treatment increased to 50 mg once weekly after medical review and agreement between the subject and the investigator
11551661|NCT00992381|Experimental|1|PN400
11551662|NCT00992381|Active Comparator|2|Naproxen
11551663|NCT00992368|Active Comparator|reduction mammaplasty|submitted to surgery
11551664|NCT00992368|No Intervention|not reduction mammaplasty|not submitted to surgery
11551665|NCT00992355|Active Comparator|Tobramycin 0.3% - Dexamethasone 0.1%|
11551666|NCT00992355|Active Comparator|Tobramycin-Dexamethasone plus Ketorolac tromethamine|
11551667|NCT00992342|Experimental|PF-03893787 5 mg|
11551668|NCT00992342|Experimental|PF-03893787 15 mg|
11551669|NCT00992342|Experimental|PF-03893787 50 mg|
11551670|NCT00992329|Experimental|ciprofloxacin tab1|formulation 1
11551671|NCT00992329|Experimental|ciprofloxacin tab2|formulation 2
11551672|NCT00992329|Experimental|ciprofloxacin tab 3|formulation 3
11551673|NCT00992329|Active Comparator|ciprofloxacin reference|reference product
11551674|NCT00992316||Pf-04531083|To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04531083 In Healthy Male Subjects
11551675|NCT00992290|Experimental|Lactobacillus GG|
11551676|NCT00992290|Placebo Comparator|Placebo|
11551677|NCT00992277|Experimental|Facial|Skin rejuvenation treatments
11551784|NCT00991406|Experimental|Arm 1: FES|Case-control study: pre- and post-stimulation (FES).
11551678|NCT00992264|Experimental|Message Tone|"Prescriptive or Motivational
~Persons are randomized to receive intervention content written in either a prescriptive or motivational tone."
11551679|NCT00992264|Experimental|Testimonials|Persons are randomized to receive a personally tailored testimonial or not.
11551680|NCT00992264|Experimental|Navigation|"Dictated or Non-Dictated
~Persons are randomly assigned to be able to freely navigate the website or to have their navigation of the website pre-determined based on their baseline readiness to quit smoking."
11551681|NCT00992264|Experimental|Proactive Outreach|"Email or No-Email communication
~Persons are randomized to receive periodic email reminders to return to the intervention website or not."
11551682|NCT00992238|Experimental|Flavoxate Hydrochloride Tablets, 100mg|
11551683|NCT00992238|Active Comparator|Urispas® Tablets, 100mg|
11551684|NCT00992225|Experimental|LY573636-sodium|
11551685|NCT00992212|Experimental|Group A (Seasonal TIV + 7.5mcg HA+ full dose MF59)|
11551686|NCT00992212|Experimental|Group B (Ajuvanted Seasonal TIV + 7.5mcg HA+ full dose MF59)|
11551687|NCT00992212|Experimental|Group C (7.5mcg HA+ full dose MF59)|
11551688|NCT00992212|Experimental|Group D (7.5mcg HA+ full dose MF59 + Seasonal TIV)|
11551689|NCT00992212|Experimental|Group E (3.75mcg HA+ ½ dose MF59+ Seasonal TIV)|
11551690|NCT00992199|No Intervention|control arm|adjuvant intravenous system chemotherapy
11551691|NCT00992199|Experimental|IP Chemo arm|adjuvant system intravenous chemotherapy combined with adjuvant intraperitoneal chemotherapy
11551692|NCT00992186|Experimental|Carlumab|
11551693|NCT00992173|Experimental|Ultratrace Iobenguane I 131|
11551694|NCT00992160|Experimental|Active|Vestipitant 15mg once daily
11551695|NCT00992160|Placebo Comparator|Placebo|Placebo
11551696|NCT00992147|Experimental|autologous cultured adipocytes|
11551697|NCT00992121|Other|Part I and 2 week dosing Part II|Part I - bevacizumab 3 infusions at 2 week intervals Part II - pazopanib dosing 2 weeks in 3-week cycles
11551698|NCT00992121|Other|Part I and 3 week dosing Part II|Part I - bevacizumab 3 infusions at 2 week interval, Part II - pazopanib dosing 3 weeks in 3-week cycles
11551699|NCT00992108|Active Comparator|Lidocaine|lidocaine injection group
11551700|NCT00992108|Experimental|Botulinum|
11551701|NCT00992082|Active Comparator|Group LIA|Local Infiltration Analgesia
11551702|NCT00992082|Active Comparator|Group M|Intrathecal morphine
11551703|NCT00992069|Experimental|TMC207 alone and with EFV|Participants will receive single-dose TMC207 alone and then single-dose TMC207 with EFV.
11551704|NCT00992056|Experimental|Metoprolol/Nebivolol|Metoprolol/Nebivolol: Metoprolol 50 mg titrated to 100 mg then nebivolol 5 mg titrated to 10 mg
11551705|NCT00992056|Experimental|Nebivolol/Metoprolol|Metoprolol 50 mg titrated to 100 mg then Nebivolol 5 mg titrated to 10 mg
11551706|NCT00992043|Placebo Comparator|exercise and placebo|
11551707|NCT00992043|Experimental|exercise and creatine|
11551708|NCT00992030|Experimental|ARM A|Rituximab plus ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles
11551709|NCT00992030|Active Comparator|ARM B|ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles followed by involved field irradiation
11551710|NCT00992017|Experimental|H1N1 vaccine|Pregnant women enrolled received two doses of H1N1 vaccine, administered 21 days apart.
11551711|NCT00992004|Experimental|Arantal®|Highly bioavailable turmeric extract (food supplement)
11551712|NCT00992004|Placebo Comparator|Placebo|Same capsule without the active ingredients (only excipients)
11551713|NCT00991978|Experimental|89Zr-bevacizumab PET|89Zr-bevacizumab PET
11551714|NCT00991965||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
11551715|NCT00991952|Experimental|Arm A (irinotecan hydrochloride, alvocidib)|Patients receive irinotecan hydrochloride IV over 30 minutes and alvocidib IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11551716|NCT00991952|Active Comparator|Arm B (irinotecan hydrochloride)|Patients receive irinotecan hydrochloride as in Arm A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11551717|NCT00991939|Experimental|High dose pulse dexamethasone|
11551718|NCT00991939|Active Comparator|Standard prednisone therapy|
11551719|NCT00991926||orlistat plus normo-caloric diet|10 subjects received normo-caloric diet plus + orlistat (Xenical, Roche, UK) at a dose of 120 mg tid. The duration of follow-up was 10 days
11551720|NCT00991926||normo-caloric diet|10 subjects received normo-caloric diet without the additional treatment. The duration of follow-up was 10 days
11551721|NCT00991913||Delirium|Delirium was determined by CAM-ICU
11551722|NCT00991913||no Delirium|no Delirium was determined by CAM-ICU
11551723|NCT00991900||Healthy subjects|
11551724|NCT00991887|No Intervention|No Radiation Therapy (XRT)|This group will not receive radiation therapy after surgery.
11551725|NCT00991887|Active Comparator|Radiation Therapy (XRT)|Radiotherapy will be administered no later than 72 hours postoperatively.
11551726|NCT00991861|Experimental|LAS41007 o.d.|Once daily
11551727|NCT00991861|Experimental|LAS41007 b.i.d.|Twice daily
11551728|NCT00991861|Active Comparator|LAS106521|
11551729|NCT00991848|Experimental|Lidocaine|Patients received 240 mg lidocaine diluted in 125 mL 0.9% saline. The solutions were infused over a period of 1 h, once a week, for 4 weeks (T1, T2, T3 and T4).
11551730|NCT00991822|Active Comparator|1|Patients with open angle glaucoma
11551731|NCT00991822|Active Comparator|2|Patients with open angle glaucoma
11551732|NCT00991809|Experimental|Alfentanil|Subjects received a series of acute alfentanil administrations each session (15 mcg/kg IM per session), with sessions spaced at 3-4 day intervals.
11551733|NCT00991809|Active Comparator|Diphenhydramine|Subjects received a series of acute diphenhydramine administrations each session (25 mg IM per session), with sessions spaced at 3-4 day intervals.
11551734|NCT00991796|Experimental|CS-1008|CS-1008 with carboplatin and paclitaxel
11551735|NCT00991796|Placebo Comparator|Placebo|Placebo with carboplatin and paclitaxel
11551736|NCT00991770|Experimental|Massage Therapy|Massage therapy provided by a certified Massage Therapist
11551737|NCT00991770|Active Comparator|Control|Empathic support conversation
11551738|NCT00991757|Experimental|001|carisbamate Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
11551739|NCT00991744|Experimental|Liposomal cytarabine|Intrathecal liposomal cytarabine (25 - 50 mg) combined with intrathecal prednisolone sodium succinate and oral dexamethasone 6 times during maintenance treatment for high-risk ALL
11551740|NCT00991744|Active Comparator|Intrathecal triple|Intrathecal methotrexate, cytarabine and prednisolone
11551741|NCT00991731|Active Comparator|Faith-based|Faith-based interventions incorporate tenets of the faith-based organization (e.g., religious beliefs, scriptural references) and involve the faith-based organization in the planning of the intervention from beginning to end
11551742|NCT00991731|Active Comparator|Non-faith-based|A curriculum designed for delivery without biblical references. In the traditional teachings of how to increase physical activity.
11551743|NCT00991731|No Intervention|Control|"This group will receive a printed pamphlet Energize Yourself! Stay Physically Active, published by the National Heart Lung and Blood Institute, that encourages participation in at least 30 minutes of daily physical activity all at once or in bouts lasting 10 minutes at a time."
11551744|NCT00991718|Experimental|A|On Day 1, subjects received a single oral dose of non-labeled GDC-0449 and a single IV tracer dose of 14C-GDC-0449.
11551745|NCT00991718|Experimental|B|On Day 1, subjects received a single oral dose of 14C-GDC-0449.
11551746|NCT00991718|Experimental|C|On Days 1-7, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects also received a single IV tracer dose of 14C-GDC-0449.
11551747|NCT00991718|Experimental|D|On Days 1-6, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects received a single oral dose of 14C-GDC-0449.
11551748|NCT00991705|Other|Group B|Atorvastatin (7 days) → Fimasartan + Atorvastatin (7 days)
11551749|NCT00991705|Other|Group A|Fimasartan (7 days) → Fimasartan + Atorvastatin (7 days)
11551750|NCT00991692|Experimental|Treatment dosage levels examined|
11551751|NCT00991679||Normal control subjects|Normal control subjects who did not show the clinical symptom and findings of dry eye syndrome.
11551752|NCT00991679||dry eye patients|Patients with dry eye syndrome who had symptoms of dry eye for more than 3 months, low tear film break up time (BUT, ≤7 sec), low Schirmer test (<10 mm), low tear clearance rate (<8X), and positive fluorescein or rose bengal vital staining (≥3) and were not treated with anti-inflammatory agents such as topical cyclosporine or steroids were included in the study.
11551753|NCT00991666|Experimental|1|AMD Patients
11551754|NCT00991666|Active Comparator|2|healthy controls
11551755|NCT00991653||Breast cancer|Diagnosed with breast cancer 1/1/2003 - 31/12/2007.
11551756|NCT00991640|No Intervention|Control|No intervention
11551757|NCT00991640|Experimental|Preceptorships|Preceptorships with e-learning
11551758|NCT00991627|Active Comparator|Pharmacological|Patients in this group will receive a basal infusion of ephedrine. Hypotension will be treated for a reduction in systolic blood pressure 20% below baseline values.
11551759|NCT00991627|Experimental|Non-Pharmacological|Patients in this group will undergo uterine lateral displacement through the use of a wedge-shaped cushion placed under their right hip. Hypotension will be treated for a reduction in systolic blood pressure 40% below baseline values.
11551760|NCT00991614||EVOLUTION® Duodenal Stent|
11551761|NCT00991601|Experimental|biopsy arm|patients with tumors in liver and/or pancreas
11551762|NCT00991588||PCL, posterolateral reconstruction|All patients who are entered into study who receive a PCL and/or posterolateral knee ligament reconstruction
11551763|NCT00991575||Diabetes, type 1|
11551764|NCT00991549|Experimental|1|interdisciplinary weight loss intervention
11551765|NCT00991549|Active Comparator|2|Small group seminars without interdisciplinary intervention
11551766|NCT00991536||Chronic respiratory failure|Patients with restrictive pulmonary disorders leading to progressive hypercapnic respiratory failure and requiring nocturnal non-invasive ventilation
11551767|NCT00991523|Experimental|sweetened beverage|
11551768|NCT00991523|Placebo Comparator|placebo control|placebo
11551769|NCT00991510|Experimental|Reference/Test/Test|"The reference product was CellCept® and test product was Myfenax®. In period I, participants received CellCept on Days 1-14. In period II, participants crossed-over to receive Myfenax on Days 15-28. In period III, participants received Myfenax until the end of the study (Days 29-112).
~Doses of mycophenolate mofetil were at least 500 mg twice daily, morning and evening."
11551770|NCT00991510|Experimental|Test/Reference/Reference|"The test product was Myfenax® and the reference product was CellCept®. In period I, participants received Myfenax on Days 1-14. In period II, participants crossed-over to receive CellCept on Days 15-28. In period III, participants received CellCept until the end of the study (Days 29-112).
~Doses of mycophenolate mofetil were at least 500 mg twice daily, morning and evening."
11551771|NCT00991497|Active Comparator|24 hours compression bandaging|
11551772|NCT00991497|Active Comparator|5 days compression bandaging|
11551773|NCT00991484||control group|
11551774|NCT00991484||individuals from hernia-family|
11551775|NCT00991471|Experimental|Interaction with MDRN STAT|Interaction with MDRNSTAT at triage to obtain orders for investigations and/or treatment
11551776|NCT00991471|Experimental|Control: No MDRNSTAT|Control group
11551777|NCT00991458|Experimental|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
11551778|NCT00991458|Experimental|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
11551779|NCT00991458|Placebo Comparator|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
11551780|NCT00991445|Active Comparator|Group MIS|Minimal Invasive Surgery
11551781|NCT00991445|Active Comparator|Conventional Exposure|
11551782|NCT00991432||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
11551783|NCT00991419|Experimental|A|[18F]4694
11551785|NCT00991393||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
11551786|NCT00991380|Experimental|Lifestyle counselling|
11551787|NCT00991380|Active Comparator|Usual Care|
11551788|NCT00991367|Experimental|A|Cicatrix
11551789|NCT00991367|Placebo Comparator|B|Placebo
11551790|NCT00991354|Experimental|Group 1|Participants will receive 3 mg of PENNVAX-B vaccine or placebo at Months 0, 1, and 3.
11551791|NCT00991354|Experimental|Group 2|Participants will receive 3 mg of PENNVAX-B vaccine and 1 mg of IL-12 vaccine or placebo at Months 0, 1, and 3.
11551792|NCT00991354|Experimental|Group 3|Participants will receive 3 mg of PENNVAX-B vaccine and 1 mg of IL-12 vaccine or placebo at Months 0, 1, and 3.
11551793|NCT00991341|Active Comparator|Shorter-storage red blood cell units|Red blood cell units stored <= 10 days
11551794|NCT00991341|Active Comparator|Longer-storage red blood cell units|Red blood cell units stored >= 21 days
11551795|NCT00991328|Active Comparator|Cerebral Desaturation, i.e; SctO2 < 60 % for 5 minutes|Once the cerebral desaturation is established, the study personnel will attempt to optimize the level of oxygen within the brain of the study patients.
11551796|NCT00991328|No Intervention|Patients with SctO2 less than 60 %.|The study patients will not get any intervention in this arm if the Sct02 falls below 60%
11551797|NCT00991302|Experimental|CAP-IT|"Participants received the modified CAP-IT adherence intervention in addition to standard care.
~Modified client adherence profiling and intervention tailoring (CAP-IT): Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)"
11551798|NCT00991302|No Intervention|Standard care|Participants received standard care.
11551799|NCT00991289|Experimental|NTZ/PEG/RBV|Participants received nitazoxanide (NTZ) alone for 4 weeks followed by 48 weeks of NTZ with pegylated interferon (PEG) and ribavirin (RBV). Participants who did not achieve early virologic response (EVR) at Week 16 or had detectable hepatitis C virus (HCV) viral load at Week 28 discontinued treatment.
11551800|NCT00991276|Experimental|pregabalin|
11551801|NCT00991276|Placebo Comparator|placebo|
11551802|NCT00991276|Active Comparator|pramipexole|
11551803|NCT00991263||Group 1|Tissue blocks from CALGB-9344 and CALGB-9741 are utilized to purify RNA to be tested in the PAM50 assay (a 50-gene quantitative PCR assay, that provides an intrinsic breast cancer subtype diagnosis) and generate risk of relapse (ROR) scores. For more information, see Details section.
11551804|NCT00991250|Experimental|SentoClone®|SentoClone®: Specific tumour-reactive lymphocytes located in lymph nodes directly draining primary tumours or metastases are identified and expanded. These lymphocytes are infused to the patient to treat metastatic disease.
11551805|NCT00991250|Active Comparator|Temodal® or Dacarbazine Medac®|"To be decided by each centre as one of the following:
~Temodal® (temozolomide)
~Dacarbazine Medac® (dacarbazine) The reference treatment regimen should follow the general guiding principles for each of the two reference treatments."
11551806|NCT00991237|Experimental|Pain reduction|
11551807|NCT00991224|Experimental|Arm 1|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir >200 and a recorded historical viral load setpoint, will receive a WT-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption.
11551808|NCT00991224|Experimental|Arm 2|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir >200 and a recorded historical viral load setpoint, will receive a α/6-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption.
11551809|NCT00991224|Experimental|Arm 3|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir >200. Subject will undergo an 16 week treatment interruption during which a single infusion of WT-gag-TCR modified autologous T cells at 8 weeks post STI.
11551810|NCT00991224|Experimental|Arm 4|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir of >200. Subject will undergo a 16-week treatment interruption during which a single infusion of α/6-gag-TCR modified autologous T cells at 8 weeks post STI.
11551811|NCT00991211|Experimental|Bendamustine + Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
11551812|NCT00991211|Active Comparator|CHOP + Rituximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w
11551813|NCT00991198|Experimental|A|Aria Regimens 0.5% conc
11551814|NCT00991198|Experimental|B|Aria Regimen (5 products) 0.25% conc
11551815|NCT00991198|Placebo Comparator|C|Aria Regimen Control without O2
11551816|NCT00991172|Placebo Comparator|placebo injection|
11551817|NCT00991172|Experimental|active|subcutaneous injection of REGN475
11551818|NCT00991172|Experimental|active 2|subcutaneous injection of REGN475
11551819|NCT00991159|Experimental|RN316|
11551820|NCT00991146|Experimental|canakinumab|
11551821|NCT00991133|Experimental|Clofarabine|Patients received a maximum of 2 cycles of the intravenous (IV) 5-drug regimen (clofarabine, etoposide,cyclophosphamide, PEG-asparaginase, and vincristine) plus intrathecal methotrexate, and then entered follow-up. Patients who achieved complete remission (CR) or complete remission with incomplete platelet recovery (CRp) after 1 cycle of study drugs were eligible to receive a second cycle of study drugs upon recovery of peripheral blood counts, and patients who did not have leukemic progression were eligible to receive a second treatment cycle at the investigator's discretion.
11551822|NCT00991107|Experimental|HE3286|HE3286 20 mg (10 mg BID)
11551823|NCT00991094||Observational (questionnaire)|Patients undergoing standard of care proton therapy are assessed for toxicities weekly during proton treatment, then from 1 to 3 times up to 90 days from the start of treatment and annually thereafter. Patients also complete questionnaires over 15-20 minutes at baseline, weekly during treatment, and every 2 weeks during follow up for up to 3 months.
11551874|NCT00990795|Placebo Comparator|Placebo|Placebo: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
11551824|NCT00991081|Active Comparator|Standard treatment|"Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling.
~A self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail
~A standard 8-week course of genetically-tailored pharmacotherapy
~Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)
~Participants with the A2 allele (CC) were assigned to receive bupropion"
11551825|NCT00991081|Experimental|Genetic feedback plus standard treatment|"In addition to the standard treatment, participants in this arm received the following interventions:
~Genetic feedback, verbal - During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment
~Genetic feedback, printed - After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype"
11551826|NCT00991068|Experimental|Synera|Synera topical patch
11551827|NCT00991055|Experimental|Pioglitazone|
11551828|NCT00991055|Placebo Comparator|Placebo|
11551829|NCT00991042|Other|cytokine levels|Serum levels of pro-inflammatory cytokines were measured using the Enzyme Linked Immuno Sorbent Assay (ELISA) technique in 23 patients with pain due to herniated disk disease (G1) as well as in 10 control healthy subject
11551830|NCT00991029|Active Comparator|clopidogrel|Patients assigned to clopidogrel in addition to aspirin
11551831|NCT00991029|Placebo Comparator|placebo|Patients assigned to placebo in addition to aspirin
11551832|NCT00991016|Experimental|PF-04805712|
11551833|NCT00991003|Experimental|Colon capsule endoscopy and colonoscopy|Patients underwent CCE on day 1 and conventional colonoscopy on day 2
11551834|NCT00990990|Experimental|Cohort 1|
11551835|NCT00990990|Experimental|Cohort 2|
11551836|NCT00990990|Experimental|Cohort 3|
11551837|NCT00990990|Experimental|Cohort 4|
11551838|NCT00990990|Experimental|Cohort 5|
11551839|NCT00990990|Experimental|Cohort 6 (optional)|
11551840|NCT00990990|Experimental|Linezolid Cohort|
11551841|NCT00990977|No Intervention|controls|assessment only
11551842|NCT00990977|Experimental|cases|MBSR including brief information session and assessments
11551843|NCT00990951|Experimental|Senna alexandrina and associations|Association of Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub
11551844|NCT00990938|Placebo Comparator|Saline|If randomized to placebo the patient will receive a subcutaneous injection once per week for 4 weeks
11551845|NCT00990938|Experimental|IMO-2125|If randomized to receive the experimental treatment, IMO-2125, the patient will receive a subcutaneous injection once per week for 4 weeks
11551846|NCT00990925|Experimental|Weight Loss Education Group|Involvement in weekly manualized, educational group on nutrition and lifestyle modifications to help with weight loss.
11551847|NCT00990925|Other|Usual Care|Treatment as usual
11551848|NCT00990912|Experimental|Carboplatin|
11551849|NCT00990912|Experimental|Irinotecan (12 (9) mg/m²/day)|
11551850|NCT00990912|Active Comparator|Irinotecan (10 (10) mg/m²/day|
11551851|NCT00990886|Experimental|001|Oxybutynin chloride 15 mg once daily for 12 weeks
11551852|NCT00990886|Placebo Comparator|002|Placebo Once daily for 12 weeks
11551853|NCT00990860|Experimental|Sorafenib|
11551854|NCT00990847|Experimental|Procaterol|Procaterol inhalation solution 50 micro g per 0.5 mL diluted in 2mL of NaCl 0.9%, so that the volume of the inhalation solution will be similar to that of the comparator drug. The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.
11551855|NCT00990847|Active Comparator|Salbultamol|Salbultamol inhalation solution for nebulization containing 2.5 mg in 2.5 mL aqueous solution. The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.
11551856|NCT00990834|Experimental|Statin exposure|Subjects' endpoints will be measured before and after one to eight months of statin exposure.
11551857|NCT00990821|Experimental|Part I, Panel A|100 mg MK-0517 (nonpolysorbate 80 formulation [non-PS80]) or placebo → 150 mg MK-0517 (non- PS80) or placebo → 125 mg aprepitant
11551858|NCT00990821|Experimental|Part I, Panel B|100 mg MK-0517 (PS80 formulation [PS80]) or placebo → 150 mg MK-0517 (PS80) or placebo → 125 mg aprepitant
11551859|NCT00990821|Experimental|Part I, Panel C|40 mg MK-0517 (non-PS80) or placebo → 40 mg aprepitant
11551860|NCT00990821|Experimental|Part II|2 mg midazolam → 100 mg MK-0517 (PS80) + 2 mg midazolam
11551861|NCT00990821|Experimental|Part III, Panel 1, Treatment Sequence 1|125 mg aprepitant → 90 mg MK-0517 (PS80)
11551862|NCT00990821|Experimental|Part III, Panel 1, Treatment Sequence 2|40 mg MK-0517 (non-PS80) → 125 mg aprepitant
11551863|NCT00990821|Experimental|Part III, Panel 2|40 mg MK-0517 (non-PS80)
11551864|NCT00990821|Experimental|Part IV|40 mg MK-0517 (non-PS80 formulation)
11551865|NCT00990821|Experimental|Part V, Treatment Sequence 1|125 mg aprepitant → 100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80 formulation)
11551866|NCT00990821|Experimental|Part V, Treatment Sequence 2|100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80) → 125 mg aprepitant
11551867|NCT00990821|Experimental|Part V, Treatment Sequence 3|115 mg MK-0517 (PS80) → 125 mg aprepitant → 100 mg MK-0517 (PS80)
11551868|NCT00990821|Experimental|Part V, Treatment Sequence 4|125 mg aprepitant → 115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80)
11551869|NCT00990821|Experimental|Part V, Treatment Sequence 5|100 mg MK-0517 (PS80) → 125 mg aprepitant → 115 mg MK-0517 (PS80)
11551870|NCT00990821|Experimental|Part V, Treatment Sequence 6|115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80) → 125 mg aprepitant
11551871|NCT00990808|Experimental|Panel A|Period 1: atorvastatin + placebo to MK0859; Period 2: atorvastatin + MK0859
11551872|NCT00990808|Experimental|Panel B|Period 1: placebo to atorvastatin + placebo to MK0859; Period 2: MK0859 + placebo to atorvastatin
11551873|NCT00990795|Experimental|Cyclosporine|Cyclosporine Group: Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
11551974|NCT00989976|Other|8.5 h sleep|Subjects will have normal sleep times
11551875|NCT00990782|Experimental|Single Arm|PillCam ESO Capsule Endoscope - all patients receive capsule endoscopy before and after RFA procedure.
11551876|NCT00990769|Experimental|"High-normal BIS (Lighter anesthesia)"|Depth of anesthesia is titrated to a BIS of 55-60
11551877|NCT00990769|Experimental|"Low-normal BIS (Deeper anesthesia)"|Depth of anesthesia is maintained at a BIS level of 40-45
11551878|NCT00990756|Experimental|PF-03526299 1.396 mg|
11551879|NCT00990756|Experimental|PF-03526299 4mg|
11551880|NCT00990743|Experimental|SYL040012|
11551881|NCT00990730||rheumatoid arthritis subjects|60 subjects with rheumatoid arthritis, defined by American College of Rheumatology Criteria, enrolled in the UCSF RA cohort
11551882|NCT00990730||healthy controls|20 matched controls without rheumatoid arthritis
11551883|NCT00990717|Experimental|NK-92 cells|Preparation of irradiated NK-92 cells suspended in a saline and plasma solution. NK-92 working cell bank was established from a master cell bank supplied by Conkwest Inc. (San Diego CA).
11551884|NCT00990704|Experimental|Paricalcitol|2 mcg adjusted by +/- 1 mcg, up to a maximum of 7 mcg, administered 3 times per week through intravenous catheter immediately before completion of dialysis
11551885|NCT00990704|Active Comparator|Maxacalcitol|5 or 10 mcg adjusted by +/- 2.5 mcg, up to a maximum of 20 mcg, administered 3 times per week through intravenous catheter immediately before completion of dialysis
11551886|NCT00990691|Experimental|Desipramine high dose|"12 patients with Rett syndrome receiving a daily dose of desipramine correlated with the weight :
~From 15 to 25 kg : 50 mg ;
~From 26 to 35 kg : 75 mg ;
~From 36 to 45 kg : 100 mg ;
~> 46 kg : 150 mg."
11551887|NCT00990691|Experimental|Desipramine low dose|"12 patients with Rett syndrome receiving a daily dose of desipramine correlated with the weight :
~From 15 to 25 kg : 25 mg ;
~From 26 to 35 kg : 50 mg ;
~From 36 to 45 kg : 75 mg ;
~> 46 kg : 100 mg."
11551888|NCT00990691|Placebo Comparator|Placebo|12 patients with Rett syndrome receiving a daily dose of placebo.
11551889|NCT00990678|Experimental|"Strong vitamin D"|Calcium 400 Mg + Vitamin D3 10 microg, 3 times daily Rocaltrol 1.25 mg to 2.5 mg daily
11551890|NCT00990678|Active Comparator|Vitamin D|calcium 400 mg + 10 microgram Vitamin D3, 3 times daily
11551891|NCT00990678|Placebo Comparator|Calcium|Tablet Calcium 400 mg x 3 daily
11551892|NCT00990665|Experimental|CRT-D and LV lead|
11551893|NCT00990652|Experimental|Bortezomib + Temozolomide|Patients receive an injection of bortezomib 1.7mg/m^2 on days 1, 4 and 8. Patients then undergo their standard of care surgery on day 8 or 9 to remove the tumor. Once recovered from surgery, patients receive combination treatment with temozolomide and bortezomib in periods called cycles (1 cycle = 28 days). Temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle, and bortezomib injections are given on days 7 and 21 of each cycle.
11551894|NCT00990639|Experimental|candesartan+UDCA group|oral candesartan(8 mg/day) in addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months
11551895|NCT00990639|Placebo Comparator|UDCA group|ursodeoxycholic acid(UDCA,600 mg/day)only for 6 months
11551896|NCT00990626||1|Schizophrenic outpatients
11551897|NCT00990613|Other|Cohort 1|
11551898|NCT00990613|Other|Cohort 2|
11551899|NCT00990600|Experimental|Simplified one pill regimen|Fixed dose combination of tenofovir + emtricitabine + efavirenz
11551900|NCT00990587|Experimental|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at escalating doses depending on when they enter into the trial.
11551901|NCT00990574|Active Comparator|spinal anesthesia group (SAG)|Participants will undergo the standard procedures involved in placement of a spinal anesthetic in the sitting position.
11551902|NCT00990574|Active Comparator|The WSCG (wiley spinal catheter group)|The WSCG (wiley spinal catheter group) will undergo the standard procedures involved in placement of a spinal anesthetic in the sitting position.
11551903|NCT00990561|Active Comparator|Twice Daily Ultravate|Patients will apply both Ultravate ointment and LacHydrin lotion twice daily
11551904|NCT00990561|Active Comparator|Once daily Ultravate|Patients will apply Ultravate ointment once daily, but will use LacHydrin lotion twice daily
11551905|NCT00990548||Cardiovascular Service Line patients|Patients admitted to the Cardiovascular Service Line at a major teaching hospital during a consecutive 11-month period.
11551906|NCT00990535|Experimental|Octreotide-LAR|Patients will receive every 21 days an injection of octreotide-LAR 30 mg until progression is documented.
11551907|NCT00990522|Experimental|debridement|monthly vs weekly debridement
11551908|NCT00990509|Experimental|Albumin|
11551909|NCT00990509|Placebo Comparator|Placebo|
11551910|NCT00990496|Experimental|GBM Treatment|
11551911|NCT00990457|Active Comparator|Low-carbohydrate Diet Plus Exercise|Participants will follow a low-carbohydrate weight loss diet plus participate in a supervised exercise training program for 6 months.
11551912|NCT00990457|Active Comparator|Low-Fat, Low-Calorie Diet Plus Exercise|Participants will follow a low-calorie, low-fat weight loss diet plus participate in a supervised exercise training program for 6 months.
11551913|NCT00990444|Placebo Comparator|Placebo|Treatment with vehicle capsule containing excipients only, taken in conjunction with standard meal.
11551914|NCT00990444|Active Comparator|Oral Insulin in Dextran|Treatment with fixed insulin dose taken in conjunction with standard meal.
11551915|NCT00990431|Active Comparator|Carbon dioxide laser treatment|
11551916|NCT00990431|Active Comparator|Erbium:YAG laser treatment|
11551917|NCT00990405|Experimental|Lansoprazole+Clarithromycin+Amoxycillin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
11551918|NCT00990392|Experimental|Polysporin Triple Therapy|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
11551919|NCT00990392|Placebo Comparator|Placebo|Petroleum jelly
11551920|NCT00990379||Controls|Healthy men and women, 18 years of age or older, who have no history of significant medical conditions.
11551921|NCT00990379||HIV positive|Men and women, 18 years of age or older, who have been diagnosed with HIV infection. Patients may be on or off of ARVs.
11551922|NCT00990379||Parkinson's Disease|Men and women, 18 years of age or older, who have been diagnosed with Parkinson's Disease.
11551923|NCT00990366|Active Comparator|biliary stent without an antireflux valve|patients with biliary obstruction who need a biliary stent, selected for the stent without an antireflux valve arm
11551924|NCT00990366|Active Comparator|biliary stent with an antireflux valve|patients with biliary obstruction, who need a biliary stent, selected for the stent with an antireflux valve arm
11551925|NCT00990353||Prism adaptation therapy|Patients receive prism adaptation therapy by protocol (Frassinetti et al., 2002)
11551926|NCT00990353||Bromocriptine pharmacotherapy|Patients receive bromocriptine pharmacotherapy by protocol (Barrett et al., 1999)
11551927|NCT00990340|Active Comparator|Tev-Tropin® needle-free|needle-free injection method (T-jet®)for 14 days before cross-over to other arm
11551928|NCT00990340|Active Comparator|Tev-Tropin® by Needle-syringe|needle-syringe injection method for 14 days before cross-over to other arm
11551929|NCT00990327|Experimental|Apadenoson|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson or the active comparator: adenosine.
11551930|NCT00990327|Active Comparator|Adenosine|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson or the active comparator: adenosine.
11551931|NCT00990314|Experimental|B.I.D|Beraprost Sodium Modified Release Tablet, 60mcg, B.I.D (twice a day dosing)
11551932|NCT00990314|Experimental|Q.I.D|Beraprost Sodium Modified Release Tablet, 60mcg, q.i.d (four times a day dosing)
11551933|NCT00990301|Experimental|Moexipril HCl/ Hydrochlorothiazide 15mg/25mg Tablets|
11551934|NCT00990301|Active Comparator|Uniretic® 15mg/25mg Tablets|
11551935|NCT00990288|Experimental|Hemostatic Matrix|2 vials of Floseal applied once at the end of surgery
11551936|NCT00990288|No Intervention|Control|No intervention.
11551937|NCT00990275|Experimental|Post-alcohol|
11551938|NCT00990262||Acute Chest Pain|Patients who presented to the emergency department with acute chest pain, with negative initial biomarkers and normal or non-ischemic ECG
11551939|NCT00990249|Experimental|Busulfan + Clofarabine + Stem Cell Transplant|"Busulfan test dose 32 mg/m^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.
~Clofarabine 40 mg/m^2 by vein over 1 hour daily Day -6 through Day -3. Thymoglobulin 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors.
~Stem cell infusion on Day 0."
11551940|NCT00990236|Active Comparator|Enoxaparin 30 mg BID|standard dose enoxaparin thromboprophylaxis (30 mg twice daily)
11551941|NCT00990236|Experimental|Enoxaparin dose adjusted based on TEG|enoxaparin dose modified based on TEG results
11551942|NCT00990223|Experimental|Cohort 1|Healthy Volunteers - eplerenone versus placebo.
11551943|NCT00990197|Active Comparator|Day 1|Patients randomized to wearing the patch on day 1 will apply a patch on the morning of their treatment day and keep it on for 24 hours. These patients will not wear a patch on day 2.
11551944|NCT00990197|Active Comparator|Day 2|Patients randomized to wearing the patch on day 2 will apply a patch on the morning of their treatment day and keep it on for 24 hours. These patients will not wear a patch on day 1.
11551945|NCT00990184|Experimental|Colesevelam Hydrochloride|
11551946|NCT00990171||PD-BCM|"Patients at National Taiwan University Hospital (NTUH)
~Patients who have received PD more than 3 months
~Patients who sign the informed consents
~Patients who aged between 20-90 years"
11551947|NCT00990158|Active Comparator|Low dose vitamin K + usual warfarin|Low dose oral vitamin K (0.150 mg orally once daily) + warfarin continuation with usual warfarin monitoring
11551948|NCT00990158|Placebo Comparator|Usual warfarin therapy + placebo|Patients continue usual warfarin and take one placebo per day
11551949|NCT00990145|Experimental|Intervention|EDP-322 v. Placebo
11551950|NCT00990132|Active Comparator|Long term oxygen therapy|LTOT will be established as per current national guidelines
11551951|NCT00990132|Experimental|Home mechanical ventilation|Patients will be set up on LTOT as per national guidelines and nocturnal non-invasive ventilation in accordance with study protocol.
11551952|NCT00990119|Experimental|High FLow Therapy|Use of High Flow Therapy for support of Respiratory Insufficiency
11551953|NCT00990119|Active Comparator|NiPPV|
11551954|NCT00990106|Active Comparator|prazosin hydrochloride|"prazosin Pfizer Minipress
~oral capsules
~Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose."
11551955|NCT00990106|Placebo Comparator|placebo|"placebo
~oral capsules
~Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose."
11551956|NCT00990093|Experimental|test intermittent catheter|CH 12 hydrophilic coated catheter
11551957|NCT00990093|Experimental|intermittent catheter|CH 12 hydrophilic coated catheter
11551958|NCT00990080|Active Comparator|Group 1|Pediacel® at 2 and 4 months of age followed by Infanrix™-IPV/Hib at 6 months.
11551959|NCT00990080|Active Comparator|Group 2|Infanrix™-IPV/Hib at 2 months of age followed by Pediacel® at 4 and 6 months.
11551960|NCT00990067|Other|duloxetine, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
11551961|NCT00990054|Experimental|plerixafor|
11551962|NCT00990041||PBMC|
11551963|NCT00990041||periodontitis|
11551964|NCT00990028|Experimental|Rosuvastatin|20 mg oral during 10 days
11551965|NCT00990028|Placebo Comparator|Placebo|
11551966|NCT00990015|Experimental|PF-04308515|
11551967|NCT00990015|Placebo Comparator|Placebo|
11551968|NCT00990002||Control|A children's milk-based beverage
11551969|NCT00990002||experimental probiotic 1|children's milk-based beverage containing a bioactive ingredient
11551970|NCT00990002||experimental probiotic 2|children's milk-based beverage containing a different bioactive ingredient
11551971|NCT00989989|Experimental|Adjunctive treatment|Adjunctive administration of ranibizumab 0.5 mg intravitreal injections and active laser.
11551972|NCT00989989|Experimental|Monotherapy treatment|Monotherapy ranibizumab 0.5 mg intravitreal injections plus sham laser.
11551973|NCT00989989|Active Comparator|Laser control|Active laser treatment plus sham intravitreal injections.
11551975|NCT00989976|Other|restricted bedtimes|4.5 h bedtimes
11551976|NCT00989963|Experimental|Maximum Tolerated Dose (MTD)|Patients in the MTD treatment group will dose escalate weekly by 60µg b.i.d. until they reach the maximum dose of 600µg b.i.d. or they reach an intolerable dose which requires them to down-titrate by 60µg b.i.d. In these instances and at the Investigator's discretion, further attempts at dose escalation may be made.
11551977|NCT00989963|Experimental|Low Fixed Dose|The low dose group will receive 60µg twice a day(b.i.d.)
11551978|NCT00989963|Experimental|High Fixed Dose|Patients in the high dose group will dose escalate weekly by 60µg twice a day (b.i.d.) until they reach the fixed dose of 240µg b.i.d. Once patients in these treatment groups have reached their assigned maximum dose of active drug,
11551979|NCT00989950|Experimental|Daytrana 9 hr wear|
11551980|NCT00989950|Experimental|Daytrana 10 hr wear|
11551981|NCT00989950|Experimental|Daytrana 11 hr wear|
11551982|NCT00989950|Experimental|Daytrana 12 hr wear|
11551983|NCT00989937|Experimental|Group 1|20 IU BID for the first week, 40 IU BID for the following two weeks, one week washout, 3 week placebo trial
11551984|NCT00989937|Placebo Comparator|Group 2|Three week placebo trial, one week washout, 20 IU BID for the fifth week, 40 IU BID for the following two weeks
11551985|NCT00989924||Diabetes mellitus|The Diabetic patient who receives follow-up at NTUH diabetics caring network
11551986|NCT00989911|Experimental|Bosentan|Bosentan
11551987|NCT00989898|Active Comparator|Closed-loops at Dinner|Automated closed-loop control starts at 18:00
11551988|NCT00989898|Active Comparator|Closed-loop at Bedtime|Automated closed-loop control starts at 21:00
11551989|NCT00989885||Obstructive Sleep Apnea|475 patients that sought the CESF to probable diagnosis of some sleep disorder, subsequently diagnosed with Obstructive Sleep Apnea.
11551990|NCT00989859||Plethysmographic monitoring|Plethysmographic monitoring
11551991|NCT00989846||lung disease|patients with various chronic or acute lung diseases
11551992|NCT00989833|Active Comparator|A|budesonide 400yg + terbutaline 0.4 mg as-needed
11551993|NCT00989833|Active Comparator|B|placebo + terbutaline 0.4 mg as-needed
11551994|NCT00989833|Active Comparator|C|placebo + budesonide/formoterol 160/4.5 yg as-needed
11551995|NCT00989820|No Intervention|Surgery|This is the standard arm. Surgery without hyperbaric oxygen treatment
11551996|NCT00989820|Experimental|Hyperbaric oxygen therapy with surgery|Intervention arm. Hyperbaric oxygen therapy with surgery.
11551997|NCT00989794|Experimental|GelrinC|GelrinC one step implantation to the femoral condyle lesion
11551998|NCT00989781|Experimental|PCOS women|"Each subject will undergo pelvic 3D ultrasound followed by an iv recombinant human chorionic gonadotropin (r-hCG) stimulation test. One month later the r-hCG test will be repeated 24 hr after an injection of recombinant human follicle stimulating hormone (FSH).
~After 1 month, subjects will receive a 7 hr dose-response infusion of adrenocorticotropin (ACTH) with blood sampling. Dexamethasone will be given prior to ACTH.
~After 1 month, subject will receive r-hCG as described above followed the next day by an oral glucose tolerance test (OGTT). Subsequently, subjects will take Diazoxide 3 times a day for 2 weeks. At weekly intervals (2 weeks), the r-hCG stimulation test will be repeated followed the next day by an OGTT as described above."
11551999|NCT00989781|Experimental|Normal women|"Each subject will undergo pelvic 3D ultrasound followed by an iv recombinant human chorionic gonadotropin (r-hCG) stimulation test. One month later the r-hCG test will be repeated 24 hr after an injection of recombinant human follicle stimulating hormone (FSH).
~After 1 month, subjects will receive a 7 hr dose-response infusion of adrenocorticotropin (ACTH) with blood sampling. Dexamethasone will be given prior to ACTH.
~After 1 month, subject will receive r-hCG as described above followed the next day by an oral glucose tolerance test (OGTT). Subsequently, subjects will take Diazoxide 3 times a day for 2 weeks. At weekly intervals (2 weeks), the r-hCG stimulation test will be repeated followed the next day by an OGTT as described above."
11552000|NCT00989768|Experimental|Botulinum toxin type - A|Dysport® compared to Botox®
11552001|NCT00989755|Experimental|Fax to Quit plus Enhanced Academic Detailing (F2Q + EAD)|Clinics in this group receive Fax to Quit materials and in person training from a Regional Outreach Specialist (ROS). The ROS also provides on-going training/technical assistance and performance feedback.
11552002|NCT00989755|Placebo Comparator|Fax to Quit alone|Clinics in this group receive Fax to Quit materials and can download materials from a website.
11552003|NCT00989742|Active Comparator|Doxycycline|
11552004|NCT00989742|Placebo Comparator|Placebo|
11552005|NCT00989729|Active Comparator|Methylprednisolone|75 patients will receive a single preoperative dosage of Methylprednisolone
11552006|NCT00989729|Placebo Comparator|Physiological Saline|75 patients will receive a single preoperative dosage of Physiological Saline
11552007|NCT00989716|Active Comparator|Glyceryl trinitrate transdermal patch|
11552008|NCT00989716|Experimental|Continue or stop pre-stroke antihypertensives|
11552009|NCT00989703|Experimental|1|GLPG0259 25/50/75 mg/day for 14 days
11552010|NCT00989703|Placebo Comparator|2|placebo for 14 days
11552011|NCT00989677||Rheumatoid Arthritis|
11552012|NCT00989664|Experimental|open-label single arm|Tositumomab and Iodine-131 Tositumomab radioimmunotherapy for chemotherapy-refractory low-grade B-cell lymphomas and low-grade lymphomas that have transformed to higher grade histologies.
11552013|NCT00989651|Experimental|Regimen I (paclitaxel, carboplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes (beginning in course 2) on day 1. Patients also receive veliparib PO BID on days 1-21. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment with bevacizumab repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
11552014|NCT00989651|Experimental|Regimen II (paclitaxel, carboplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Patients also receive carboplatin, bevacizumab, and veliparib as in Regimen I. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment with bevacizumab repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
11552091|NCT00989079|Experimental|Cohort 2 Sequence 1|Period 1 (fasted) Placebo → Period 2 (fasted) E 30 mg → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.
11552015|NCT00989651|Experimental|Regimen III (paclitaxel, cisplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 3 hours on day 1 and IP on day 8, and cisplatin IP on day 1 or 2. Patients also receive bevacizumab and veliparib as in Regimen I. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
11552016|NCT00989638||Women at high risk for breast cancer|
11552017|NCT00989625|Active Comparator|10mg Sumatriptan/60mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
11552018|NCT00989625|Active Comparator|30mg Sumatriptan/180mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
11552019|NCT00989625|Active Comparator|85mg Sumatriptan/500mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
11552020|NCT00989612|Experimental|GSK2340274A GROUP|Healthy subjects, aged 20 to 64 years, male and female, received 2 doses of GSK2340274A vaccine, injected intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
11552021|NCT00989599|Experimental|compress of Chamomilla recutita infusion|Patients who developed phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
11552022|NCT00989599|Active Comparator|compress of lukewarm water|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
11552023|NCT00989586|Experimental|Phase I|Phase I portion of the study, a standard 3+3 dose escalation schema will be followed. Patients will receive veltuzumab IV weekly on day 1 for 4 doses and milatuzumab weekly on for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab alone on day 1 and milatuzumab alone on day 2 to prevent overlapping infusion reactions. Starting week 2, veltuzumab will be given on day 1 and milatuzumab will be given on day 4.
11552024|NCT00989586|Experimental|Phase II|Patients will receive veltuzumab IV weekly for 4 doses and milatuzumab IV weekly on day 2 of week 1 and on day 4 of weeks 2-4 for 4 total doses during induction therapy. Patients may continue on therapy to receive extended induction therapy provided they do not experience significant toxicity or rapid disease progression during the initial 4 week induction.
11552025|NCT00989573|Placebo Comparator|Placebo|oral administration of placebo once-daily for 8weeks
11552026|NCT00989573|Experimental|OPC-6535 25 mg|oral administration of OPC-6535 25 mg once-daily for 8 weeks
11552027|NCT00989573|Experimental|OPC-6535 50 mg|oral administration of OPC-6535 50mg once-daily for 8 weeks
11552028|NCT00989560|Active Comparator|Active arm|
11552029|NCT00989560|No Intervention|Standard care arm|
11552030|NCT00989547|Active Comparator|A|
11552031|NCT00989547|No Intervention|B|
11552032|NCT00989534|Experimental|Sleep loss and circadian alignment|Sleep restriction without circadian misalignment
11552033|NCT00989534|Experimental|Sleep loss and circadian misalignment|
11552034|NCT00989521|Placebo Comparator|placebo|normal saline for inhalation
11552035|NCT00989521|Active Comparator|PUR003|PUR003 for inhalation
11552036|NCT00989508|Experimental|Perhexiline|Pre-operative administration of Perhexiline tablets according to dosing schedule
11552037|NCT00989508|Placebo Comparator|Placebo marked PEXSIG|Pre-operative administration of placebo tablets according to dosing schedule
11552038|NCT00989495|Experimental|Brace - Randomized|Participants were randomized to be braced
11552039|NCT00989495|No Intervention|Observation - Randomized|Participants were randomized to be observed only
11552040|NCT00989495|Experimental|Brace - preference based|Participants chose to be braced
11552041|NCT00989495|No Intervention|Observation - preference-based|Participants chose to be observed only
11552042|NCT00989482|Experimental|Computer Kiosk Eduction|
11552043|NCT00989469|Experimental|Sorafenib and irinotecan|
11552044|NCT00989456|Experimental|exercise and education|Supervised physical exercise in groups, plus a self management education programme (patient education).
11552045|NCT00989456|Active Comparator|exercise only|Supervised physical exercise in groups.
11552046|NCT00989443|Experimental|Cidofovir|
11552047|NCT00989430|Experimental|Prism Adaptation Treatment|Two weeks of prism adaptation treatment followed by 4 weekly assessments and long-term follow-ups at the 3rd and 6th months.
11552048|NCT00989430|No Intervention|Control: Standard Rehabilitation Care|Participants will continue with their standard inpatient rehabilitation care. They will be assessed with cognitive and functional scales for tracking their recovery.
11552049|NCT00989417|Active Comparator|CONTROL Group - Without Home Monitoring|Patients receiving the standard of care. Due to safety concerns, the patients are followed every 6 months after a first follow-up, which is performed between 1 and 3 months after implantation.
11552050|NCT00989417|Experimental|ACTIVE GROUP With Home Monitoring|After a first follow-up (between 1 and 3 months after implantation), the patients are followed one time per year. Within this period, the additional ICD follow-up or therapeutic intervention will be primarily triggered on cardio-reports reception, Data/IEGM-online analysis on internet site or patient/physician call.
11552051|NCT00989404|Experimental|Period|10 mg BID Zanamivir or placebo for 5 days
11552052|NCT00989391|Experimental|Cohort 1|Subjects will be assigned to receive either PF-03654764 or placebo.
11552053|NCT00989391|Experimental|Cohort 2|Subjects will be assigned to receive either PF-03654764 or placebo.
11552054|NCT00989391|Experimental|Cohort 3|Subjects will be assigned to receive either PF-03654764 or placebo.
11552055|NCT00989378||control|normal healthy men and women
11552056|NCT00989365|Other|Patient cousenling|Improve medicine use Self control asthma crisis Ambient hygiene
11552092|NCT00989079|Experimental|Cohort 2 Sequence 2|Period 1 (fasted) E 2.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.
11552057|NCT00989339|Experimental|Twenty-four Hour TPN and Saline Infusion|Subjects will be admitted to the Grady research center on the evening before each study. The next morning, after an overnight fast, they will receive, in random order, Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr. The interval between admissions will be 1 month.
11552058|NCT00989326|Active Comparator|CONTROL group|The patients receive standard of care for 18 months. The CONTROL group patients will be equipped with Home Monitoring. However, the Home Monitoring data will not be used for patient surveillance; i. e. the patient will be followed in the conventional manner.
11552059|NCT00989326|Experimental|ACTIVE group|The patients are followed by Home monitoring only. Every patient must be seen by his physician 18 months after enrolment for regular follow-up. Within this period, the additional Pace Maker follow-up or therapeutic intervention will be primarily triggered on cardio-reports reception or patient/physician call
11552060|NCT00989313||1|
11552061|NCT00989300|Experimental|Treatment group|patients received clopidogrel 75 mg with rabeprazole 20 mg, omeprazole 20 mg, or placebo in a crossover manner
11552062|NCT00989300|Placebo Comparator|Placebo group|
11552063|NCT00989287|Experimental|GSK2340272A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
11552064|NCT00989287|Experimental|GSK2340269A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
11552065|NCT00989274|Active Comparator|Vaccine Sanofi A(H1N1) 15 ug & trivalent|120 participants selected by random
11552066|NCT00989274|Active Comparator|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|120 participants selected in random form
11552067|NCT00989274|Active Comparator|Vaccine Sanofi A(H1N1) 7.5 ug|120 participants selected in random form
11552068|NCT00989261|Experimental|Cohort 1; ≥60 years of age|"Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission <12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.
~Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)
~After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day."
11552069|NCT00989261|Experimental|Cohort 2; ≥18 years of age|"Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.
~Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)
~After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day."
11552070|NCT00989248|Experimental|comparation VE/VO2 and VE/VCO2|
11552071|NCT00989235|Active Comparator|Abatacept (10 mg/Kg)|
11552072|NCT00989235|Active Comparator|Abatacept (5 mg/Kg)|
11552073|NCT00989222|Other|Volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
11552074|NCT00989222|Other|External fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
11552075|NCT00989209|Active Comparator|A: myofunctional prior to botulinum|All the facial paralysis patients received treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol. To the participants of Group A, botulinum toxin was applied after myofunctional therapy.
11552076|NCT00989209|Active Comparator|B: myofunctional after botulinum|All the facial paralysis patients received treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol. To the participants of Group B, botulinum toxin was applied before myofunctional therapy.
11552077|NCT00989196|Experimental|Human-cl rhFVIII|
11552078|NCT00989196|Active Comparator|Kogenate FS|
11552079|NCT00989170|Experimental|Family Program for the Prevention of Weight Gain|Use of an enhanced Family Program on the prevention of weight gain in families with overweight children.
11552080|NCT00989170|Active Comparator|No enhanced Family Program|
11552081|NCT00989157|Experimental|Active drug|All subjects received drug. Single arm.
11552082|NCT00989131|Experimental|Paclitaxel, micellar (Paclical®)|
11552083|NCT00989131|Active Comparator|Paclitaxel, CrEL (Taxol®)|
11552084|NCT00989118|Experimental|Laser treatment|
11552085|NCT00989118|Active Comparator|Endometrioma cystectomy|
11552086|NCT00989092|Other|Observational Group|Participants in the observation group were evaluated once every 2 weeks for the first 12 weeks (test period). No darbepoetin alfa was administered to the observation group during this period. Darbepoetin alfa could be initiated at a dose of 3.0 μg/kg once every 2 weeks beginning with the first visit after the test period at which the participants hemoglobin concentration was less than or equal to 11.0 g/dL. The dose of darbepoetin alfa could be increased to 5.0 μg/kg once every 2 weeks after 6 weeks of darbepoetin alfa treatment in participants with a hemoglobin change from baseline of less than 1.0 g/dL.
11552087|NCT00989092|Active Comparator|21 week treatment group|Participants in the treatment group received darbepoetin alfa subcutaneously (SC) at a dose of 3.0 μg/kg once every 2 weeks for 21 weeks. The dose of darbepoetin alfa could be increased at week 7 (to 5.0 μg/kg once every 2 weeks) or at week 13 (to 9.0 μg/kg once every 2 weeks) in participants with a hemoglobin change from baseline of less than 1.0 g/dL who dose escalated at week 7.
11552088|NCT00989079|Experimental|Cohort 1 Sequence 1|Period 1 (fasted) Placebo → Period 2 (fasted) ertugliflozin (E) 10 mg → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
11552089|NCT00989079|Experimental|Cohort 1 Sequence 2|Period 1 (fasted) E 0.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
11552090|NCT00989079|Experimental|Cohort 1 Sequence 3|Period 1 (fasted) E 0.5 mg → Period 2 (fasted) E 10 mg → Period 3 (fasted) Placebo → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
11552143|NCT00988702|Experimental|Dan Tian Breathing|subjects received one-month's training on the Dan Tian Breathing
11552093|NCT00989079|Experimental|Cohort 2 Sequence 3|Period 1 (fasted) E 2.5 mg → Period 2 (fasted) E 30 mg → Period 3 (fasted) Placebo. Each dose of study drug will be separated by a minimum of 7 days.
11552094|NCT00989053|Active Comparator|escitalopram|
11552095|NCT00989053|Placebo Comparator|placebo|
11552096|NCT00989027|No Intervention|No treatment|A control sample from each patient (no uterotonic drug applied) will be measured concurrently with samples treated with various drugs.
11552097|NCT00989027|Active Comparator|Treatment|Samples from each patient will be bathed in solutions containing varying concentrations of either oxytocin, carboprost and ergonovine, and contractility will be measured.
11552098|NCT00989014|Experimental|CD07805/47 0.5% Topical Gel|0.5% Topical Gel
11552099|NCT00989014|Experimental|CD07805/47 0.18% Topical Gel|0.18% Topical Gel
11552100|NCT00989014|Experimental|CD07805/47 0.07% Topical Gel|0.07% Topical Gel
11552101|NCT00989014|Placebo Comparator|CD07805/47 Vehicle Topical Gel|Vehicle Topical Gel
11552102|NCT00989001|Experimental|Vernakalant|Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
11552103|NCT00989001|Placebo Comparator|Placebo|Placebo (saline) administered IV at same volume and rate as per dosing schedule for vernakalant
11552104|NCT00988988|Active Comparator|Steroid Cream|1% steroid cream
11552105|NCT00988988|Active Comparator|AGEE cream|AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled
11552106|NCT00988988|Active Comparator|placebo|inactive cream
11552107|NCT00988975|Active Comparator|Pelvicol graft|
11552108|NCT00988975|No Intervention|No graft material|No graft material
11552109|NCT00988962|No Intervention|High-Risk No Treatment|
11552110|NCT00988962|Experimental|High-Risk Treatment|
11552111|NCT00988962|No Intervention|Low-Risk|
11552112|NCT00988949|Experimental|PF-04455242 18 mg|Subjects in this arm will receive a single 18 mg oral dose of PF-04455242 prior to spiradoline challenge
11552113|NCT00988949|Placebo Comparator|Placebo|Subjects in this arm will receive placebo prior to spiradoline challenge.
11552114|NCT00988949|Experimental|PF-04455242 30 mg|Subjects in this arm will receive a single 30 mg oral dose of PF-04455242 prior to spiradoline challenge.
11552115|NCT00988936|Experimental|[F-18]RDG-K5|
11552116|NCT00988923|Experimental|group a: Hyperthermia (HT)|HT were treated for 20 minutes per session, a total of 8 sessions with device;
11552117|NCT00988923|No Intervention|group b: No intervention|device was switched in off, only bolus was active
11552118|NCT00988910||Group 1|
11552119|NCT00988910||Group 2|
11552120|NCT00988897|Experimental|1|"Patients will receive modified FOLFOX-6 regimen:
~oxaliplatin 85mg/m2, day 1 (given as a 2-hour infusion)
~LV 400mg/m2, day 1 (given as a 2-hour infusion simultaneous to oxaliplatin)
~5-FU given as a bolus IV 400mg/m2 dose on day 1 followed by 2400mg/m2 continuous infusion over 46 hours (day 1 and 2)
~A cycle is defined as 2 weeks. Patients will receive cycles of modified FOLFOX-6 regimen every 2 weeks up to a maximum of 8 cycles. Use of bevacizumab is at the discretion of the treating physician."
11552121|NCT00988884|Experimental|Concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1
11552122|NCT00988884|Experimental|Non-concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1
11552123|NCT00988871||Liver transplantation (LT) recipients|LT recipients who had both PICC and CICC at the same time according to the LT protocol of our hospital
11552124|NCT00988858|Experimental|LY2603618 and Pemetrexed|
11552125|NCT00988845|Experimental|Indole-3-carbinol|
11552126|NCT00988832||Infliximab|Infliximab as prescribed by a physician in normal practice for Crohn's disease
11552127|NCT00988819||No treatment|
11552128|NCT00988806|Active Comparator|Levosimendan|infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours.
11552129|NCT00988806|Placebo Comparator|Placebo|infusion of placebo for 24 hours.
11552130|NCT00988793|Active Comparator|Laparoscopic distal pancreatectomy|Comparison between two different types of surgery, open vs. laparoscopic distal pancreatectomy
11552131|NCT00988793|Active Comparator|Open distal pancreatectomy|Comparison between two different types of surgery, open vs. laparoscopic distal pancreatectomy
11552132|NCT00988780|Experimental|Maraviroc|"Maraviroc 600mg po BID
~Background antiretroviral regimen (Efavirenz 600mg QD + Tenofovir 300 mg /Emtricitabine 200 mg QD) plus Maraviroc 600 mg BID"
11552133|NCT00988780|Placebo Comparator|Placebo|"Placebo po BID
~Background antiretroviral regimen (Efavirenz 600mg QD + Tenofovir 300 mg /Emtricitabine 200 mg QD plus Placebo po BID"
11552134|NCT00988767|Experimental|intramuscular injections|Patients received 4 injections of DNA vaccine at M0, M2, M4 and M10
11552135|NCT00988754|Active Comparator|A|Medical examination once per year, school and family-based lifestyle intervention including a weekly health lesson, school-affiliation to sports clubs and regularly trainings for teachers and parents
11552136|NCT00988754|No Intervention|B|Medical examination and information on a healthy lifestyle.
11552137|NCT00988741|Experimental|ARQ 197|
11552138|NCT00988741|Placebo Comparator|placebo|
11552139|NCT00988728|Experimental|SCH 900435|SCH 900435 (Org 25935): a Glycine Uptake Inhibitor
11552140|NCT00988728|Placebo Comparator|Placebo|
11552141|NCT00988728|Active Comparator|Olanzapine|
11552142|NCT00988715|Experimental|Treatment (PRIT, transplant)|Patients undergo pretargeted radioimmunotherapy comprising a test dose of BC8-SA conjugate IV on day -22 and 111In-DOTA-biotin IV on day -20, followed by a therapy dose of BC8-SA conjugate IV on day -14 and 90Y-DOTA-biotin IV on day -12. Patients receive fludarabine phosphate IV on days -4 to -2. Patients undergo TBI and then peripheral blood stem cell transplant on day 0. Patients with matched related donors receive cyclosporine IV on days -3 to 56 and taper to day 180 and mycophenolate mofetil PO BID on days 0-27. Patients with matched unrelated donors receive cyclosporine IV on days -3 to 100 and taper to day 180 and mycophenolate mofetil PO TID on days 0-40 and taper to day 96.
11552144|NCT00988702|Active Comparator|Progressive muscle relaxation training|Subjects received one-month's conventional progressive muscle relaxation training
11552145|NCT00988689|Experimental|Soup with no added starch|
11552146|NCT00988689|Experimental|Soup + 50 g of whole grain starch|
11552147|NCT00988689|Experimental|Soup + 50 g of high amylose corn starch|
11552148|NCT00988689|Experimental|Soup + 50 g of regular corn starch|
11552149|NCT00988689|Experimental|Soup + 50 g maltodextrin starch|
11552150|NCT00988676||colonoscopy|
11552151|NCT00988663|Active Comparator|Memantine arm|Patient receiving ECT and Memantine
11552152|NCT00988663|Placebo Comparator|placebo|25 patients receiving ECT will will receive placebo
11552153|NCT00988650|Active Comparator|North American diet|Control North American diet for five weeks in isocaloric conditions
11552154|NCT00988650|Experimental|Mediterranean diet|Mediterranean diet for five weeks in isocaloric conditions
11552155|NCT00988650|Experimental|weight loss period|Weight loss period of 20-week (minimum 5% reduction in body weight)
11552156|NCT00988650|Active Comparator|Weight stabilizing mediterranean diet|Mediterranean diet for five weeks in isocaloric weight stabilizing conditions
11552157|NCT00988637|Other|1) Vectical™ Ointment and Clobex® Spray|Vectical™ Ointment weekdays & Clobex® Spray weekends regimen
11552158|NCT00988637|Other|2) Clobex® Spray and Vectical™ Ointment|Clobex® Spray morning and Vectical™ Ointment evening regimen
11552159|NCT00988624|Experimental|Period 1|
11552160|NCT00988624|Experimental|Period 2|
11552161|NCT00988624|Experimental|Period 3|
11552162|NCT00988624|Experimental|Period 4|
11552163|NCT00988624|Experimental|Period 5|
11552164|NCT00988598|Active Comparator|PF-04447943|
11552165|NCT00988598|Placebo Comparator|Placebo|
11552166|NCT00988585|Placebo Comparator|Olive Oil|Olive Oil 600 mg/day
11552167|NCT00988585|Active Comparator|EPA 1800|1800 mg/day
11552168|NCT00988585|Active Comparator|DHA|DHA 600 mg/day
11552169|NCT00988585|Active Comparator|EPA 600|EPA 600 mg/day
11552170|NCT00988572|Experimental|Intervention group|Vestibular rehabilitation, twice a week for 9 weeks
11552171|NCT00988572|No Intervention|Control group|The patients in the control group does nothing, except for normal treatment for their wrist fracture.
11552172|NCT00988559|Experimental|PMED Delivery - groups 1 and 2|Subjects will receive pNGVL4a-CRT/E7(detox) via gene gun at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
11552173|NCT00988559|Experimental|IM injections - groups 5 and 6|Subjects will receive pNGVL4a-CRT/E7(detox) intramuscularly at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
11552174|NCT00988559|Experimental|Intralesional delivery - group 3 and 4|Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
11552175|NCT00988559|Experimental|Intralesional delivery + imiquimod - group 7|Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally and imiquimod applied to the cervix at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
11552176|NCT00988546|Other|1|exam documentation performed using dictation
11552177|NCT00988546|Experimental|2|exam documentation performed using computer based template
11552178|NCT00988533|Experimental|0.5% Ivermectin Cream|
11552179|NCT00988520|Experimental|0.6 mg/kg intubation dose under sevoflurane|
11552180|NCT00988520|Experimental|0.9 mg/kg intubation dose under sevoflurane|
11552181|NCT00988520|Experimental|continuous dose following 0.6 mg/kg intubation dose + propofol|
11552182|NCT00988520|Experimental|continuous dose following 0.9 mg/kg intubation dose + propofol|
11552183|NCT00988507|Experimental|Ferroquine high dose + artesunate|Ferroquine at 6 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
11552184|NCT00988507|Experimental|Ferroquine medium dose + artesunate|Ferroquine at 4 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
11552185|NCT00988507|Experimental|Ferroquine low dose + artesunate|Ferroquine at 2 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
11552186|NCT00988507|Experimental|Ferroquine alone at medium dose|Ferroquine at 4 mg/kg/d OD alone for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
11552187|NCT00988494|Experimental|High concentration|DE-105 high concentration
11552188|NCT00988494|Experimental|Low concentration|DE-105 low concentration
11552189|NCT00988494|Placebo Comparator|Placebo|DE-105 placebo
11552190|NCT00988468|Experimental|Manual Therapy|Subjects will receive oscillatory (grade 1 & 2) manual knee mobilization for 15 minutes at various knee range of motion positions.
11552191|NCT00988468|Experimental|Therapeutic Exercise|Subjects will perform 15 minutes of combined resistance exercise and aerobic exercise.
11552192|NCT00988468|Placebo Comparator|Control|Subjects will watch a 15 minute instructional video on a health topic.
11552193|NCT00988455|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
11552194|NCT00988442|Experimental|Enhanced nursing telephone support with standard care|Participants received enhanced nursing telephone support plus care as usual.
11552195|NCT00988442|Active Comparator|Standard care|Participants received care as usual.
11552196|NCT00988429|Active Comparator|800 mg QD Eslicarbazepine acetate|tablets
11552197|NCT00988429|Active Comparator|1200 mg QD Eslicarbazepine acetate|tablets
11552198|NCT00988429|Placebo Comparator|Placebo|tablets
11552199|NCT00988403|Experimental|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
11552200|NCT00988403|Experimental|Fructan - 10 grams|Subjects will consume 10 grams of fructan
11552201|NCT00988403|Experimental|Fructan - 12.5 grams|Subjects will consume 12.5 grams of fructan
11552202|NCT00988403|Experimental|5 grams Fructan|"Experimental - 5 grams Fructan
~Subjects will consume 5 grams of Fructan."
11552307|NCT00987818|Experimental|PCT guided antibiotic therapy|
11552308|NCT00987818|Placebo Comparator|Standard antibiotic therapy|
11552309|NCT00987805|Experimental|Banhasasim-tang|
11552203|NCT00988390|Other|Intervention, mothers living with HIV|Mothers living with HIV, Cognitive-behavioral intervention delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions)
11552204|NCT00988390|No Intervention|Control, mothers living with HIV|Mothers living with HIV, offered intervention at end of study (18 months after recruitment)
11552205|NCT00988390|No Intervention|Control, non-HIV-infected mothers|Neighborhood control mothers not infected with HIV, did not receive any intervention
11552206|NCT00988377|Experimental|10 g whey protein|
11552207|NCT00988377|Experimental|20 g whey protein|
11552208|NCT00988377|Experimental|30 g whey protein|
11552209|NCT00988377|Experimental|40 g whey protein|
11552210|NCT00988377|Experimental|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
11552211|NCT00988364|Active Comparator|Ezetimibe|Randomly chosen participants will receive ezetimibe 10mg daily for 3 months.
11552212|NCT00988364|Active Comparator|Simvastatin|Randomly chosen participants will receive Simvastatin 20mg daily for 3 months.
11552213|NCT00988364|Active Comparator|Vytorin|Randomly chosen participants will receive Vytorin 20/10mg daily for 3 months.
11552214|NCT00988364|Placebo Comparator|Placebo|Randomly chosen participants will receive Placebo tab 1 daily for 3 months.
11552215|NCT00988351|Active Comparator|PSG CPAP titration then CPAP treatment|Patients diagnosed with sleep apnea will have a continuous positive airway pressure (CPAP) titration with polysomnography (PSG) followed by continuous positive airway pressure (CPAP) Treatment
11552216|NCT00988351|Active Comparator|Auto-Adjusting Positive Airway Pressure|Following diagnosis of obstructive sleep apnea patients will be have auto-adjusting positive airway pressure treatment without a titration.
11552217|NCT00988338|Other|Trinity Evolution|
11552218|NCT00988325|Experimental|Oseltamivir 3 mg|infants 3 to <12 months
11552219|NCT00988325|Experimental|Oseltamivir 2.5 mg|infants 1 to <3 months of age
11552220|NCT00988325|Experimental|Oseltamivir 2 mg|infants 0 to 30 days (post natal) of age
11552221|NCT00988312|Experimental|s.c. vaccination|vaccine given subcutaneously
11552222|NCT00988312|Experimental|i.v. vaccination|vaccines are given intravenously
11552223|NCT00988286|Experimental|CEP|
11552224|NCT00988273||Control|In patients undergoing endoscopy for indications other than Crohn's disease or ulcerative colitis
11552225|NCT00988273||Diseased group|Patients with Crohn's disease or ulcerative colitis undergoing endoscopy.
11552226|NCT00988260|Experimental|Ganirelix 0.125 mg|
11552227|NCT00988260|Experimental|Ganirelix 0.25 mg|
11552228|NCT00988260|Experimental|Ganirelix 0.5 mg|
11552229|NCT00988247|Experimental|BDP HFA 320 µg/day|During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning.
11552230|NCT00988247|Placebo Comparator|Placebo|During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily each morning.
11552231|NCT00988234|Experimental|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
11552232|NCT00988234|Experimental|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
11552233|NCT00988234|Experimental|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
11552234|NCT00988234|Experimental|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
11552235|NCT00988221|Experimental|Tocilizumab 10 mg/kg in patients weighing < 30 kg|Patients received tocilizumab 10 mg/kg intravenously every 4 weeks.
11552236|NCT00988221|Experimental|Tocilizumab 8 mg/kg in patients weighing < 30 kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.
11552237|NCT00988221|Experimental|Tocilizumab 8 mg/kg in patients weighing ≥ 30 kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.
11552238|NCT00988221|Placebo Comparator|Placebo|Patients received placebo to tocilizumab intravenously every 4 weeks.
11552239|NCT00988208|Experimental|Docetaxel, Prednisone, Lenalidomide (DPL)|25 mg lenalidomide orally once each day on Days 1-14; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice daily on each day of the treatment cycle
11552240|NCT00988208|Experimental|Docetaxel and Prednisone (DP)|Oral placebo once each day on Days 1-14 of the treatment cycle; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice each day on each day of the treatment cycle
11552241|NCT00988195|Experimental|PEG-BCT-100|Pegylated Recombinant Human Arginase I
11552242|NCT00988182|Experimental|whey protein, 5g|
11552243|NCT00988182|Experimental|whey protein, 10g|
11552244|NCT00988182|Experimental|whey protein, 20g|
11552245|NCT00988182|Experimental|whey protein, 40g|
11552246|NCT00988182|Experimental|water control|
11552247|NCT00988169|Experimental|oral erlotinib and pulsed doses of oral AT-101|This will be an open-label, single institution, phase II trial. The study will assess the efficacy of the combination of the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and the novel pan-Bcl-2 inhibitor, AT-101, in treatment-naïve advanced (Wet Stage IIIB and IV)NSCLC patients with EGFR activating mutations A planned pause of 21 days will be performed after enrollment of the 10th and 20th patient to assess for excessive toxicity.
11552248|NCT00988156|Active Comparator|Eslicarbazepine acetate|To receive Eslicarbazepine acetate in addition to concomitant therapy
11552249|NCT00988156|Placebo Comparator|Placebo|To receive placebo in addition to concomitant therapy
11552250|NCT00988143|Experimental|Study Group 1|Participants will receive the 2009-2010 Trivalent Influenza Vaccine (TIV) (Pediatric dose have no preservatives)
11552251|NCT00988143|Active Comparator|Study Group 2|Participants will receive the 2008-2009 Trivalent Influenza Vaccine (TIV)
11552252|NCT00988143|Active Comparator|Study Group 3|Participants will receive the Quadrivalent Influenza Vaccine (QIV)
11552253|NCT00988117|Experimental|Rivastigmine Patch 9.5 cm2|
11552254|NCT00988104|Active Comparator|Cognitive Behavioral Therapy|
11552255|NCT00988104|Active Comparator|Supportive Counseling|
11552256|NCT00988091|Placebo Comparator|IA-SA|Each participant received a single intra-articular (IA) injection of buffered saline (SA) into the target knee, and was followed for a total of 26 weeks in the double-blind period. Participants had the option of continuing into the open-label period in which they could receive a single intra-articular injection of 1.2% sodium hyaluronate (IA-BioHA) into the target knee and be followed for an additional 26 weeks.
11552257|NCT00988091|Experimental|IA-BioHA|Each participant received a single intra-articular (IA) injection of 1.2% sodium hyaluronate (BioHA) into the target knee, and was followed for a total of 26 weeks in the double-blind period. Participants had the option of continuing into the open-label period in which they received a single intra-articular injection of 1.2% sodium hyaluronate (IA-BioHA) into the target knee and were followed for an additional 26 weeks.
11552258|NCT00988078|Experimental|Metformin|Metformin 500mg three times a day for six months
11552259|NCT00988078|Placebo Comparator|Placebo|1 capsule three times a day for six months
11552260|NCT00988065|Experimental|Sugammadex 4 mg/kg|Participants were to receive one dose of sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
11552261|NCT00988065|Experimental|Sugammadex 16 mg/kg|Participants were to receive one dose of sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
11552262|NCT00988065|Placebo Comparator|Placebo|Participants were to receive one dose of placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
11552263|NCT00988052|Experimental|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
11552264|NCT00988039|Active Comparator|bPI + 2NRTIs|
11552265|NCT00988039|Experimental|bPI + raltegravir|
11552266|NCT00988039|Experimental|bPI monotherapy|
11552267|NCT00988026|Experimental|Minocycline 100 mg|Minocycline
11552268|NCT00988026|Active Comparator|Lymecycline 300 mg|Group B: Lymecycline
11552269|NCT00988013|Experimental|IM-TMI (3Gy)|Patients will receive 3Gy per day for 1 day (total of 3Gy).
11552270|NCT00988013|Experimental|IM-TMI (6Gy)|Patients will receive 3Gy per day for 2 days (for a total of 6Gy).
11552271|NCT00988013|Experimental|IM-TMI (9Gy)|Patients will receive 3Gy per day for 3 days (for a total of 9Gy).
11552272|NCT00988013|Experimental|IM-TMI (12Gy)|Patients will receive 3Gy per day for 4 days (for a total of 12Gy).
11552273|NCT00988000|Other|Agree to the alternative study invitation|Agree with alternative of telephone consultation (instead of face to face) offered as an initial consultation to new referrals
11552274|NCT00988000|Other|Decline the alternative study invitation|Decline, no respond to the alternative of telephone consultation
11552275|NCT00988000|Other|Comparator|Choose and book
11552276|NCT00987987|Experimental|1|1
11552277|NCT00987974|Experimental|rosuvastatin 3days|8 Subjects will use rosuvastatin 20 mg/day for 3 days
11552278|NCT00987974|Active Comparator|atorvastatin 3 days|8 Subjects will use atorvastatin 80 mg/day for 3 days.pj
11552279|NCT00987974|Placebo Comparator|placebo 3days|8 Subjects will use placebo for 3 days.
11552280|NCT00987974|Experimental|rosuvastatin 7 days|8 Subjects will use rosuvastatin 20 mg/day for 7 days.
11552281|NCT00987974|Active Comparator|atorvastatin 7 days|8 Subjects will use atorvastatin 80 mg/day for 7 days.
11552282|NCT00987974|Placebo Comparator|placebo 7 days|8 Subjects will use placebo for 7 days.
11552283|NCT00987961|No Intervention|Treatment as usual|Participants in this arm will receive the standard detox treatment for individuals hospitalized with opioid dependence.
11552284|NCT00987961|Experimental|Linkage|Participants in this arm will receive a maintenance schedule of Suboxone during their hospital stay, and an appointment with an outpatient Suboxone provider for after their discharge.
11552285|NCT00987948|Experimental|Maraviroc|
11552286|NCT00987935|Experimental|Nintedanib (BIBF 1120)|Phase I dose escalation and phase II using dose determined in phase I
11552287|NCT00987935|Active Comparator|Sorafenib|Twice daily dosing in phase II
11552288|NCT00987922|Experimental|Hypothermia|
11552289|NCT00987922|No Intervention|Control|
11552290|NCT00987909|Placebo Comparator|Placebo|Solution resembling the active solutions, but without allergen extract
11552291|NCT00987909|Experimental|Cat hair allergen extract, dose group 1|
11552292|NCT00987909|Experimental|Cat hair allergen extract, dose group 2|
11552293|NCT00987909|Experimental|Cat hair allergen extract, dose group 3|
11552294|NCT00987896|Experimental|Megachannel Application|Colonoscopy with loaded Megachannel is performed
11552295|NCT00987883||Malnutrition cohort|The patients with undernutrition
11552296|NCT00987883||Well nourished cohort|Patient that well nourished and without undernutrition
11552297|NCT00987870|Experimental|BFH772 cream 1%|
11552298|NCT00987870|Placebo Comparator|Placebo to BFH772 cream 1%|
11552299|NCT00987870|Experimental|BFH772 ointment 1%|
11552300|NCT00987870|Placebo Comparator|Placebo to BFH772 ointment|
11552301|NCT00987870|Active Comparator|calcipotriol/betamethasone ointment|
11552302|NCT00987857|Active Comparator|2 yearly endoscopies|Two years endoscopies
11552303|NCT00987857|Experimental|endoscopy at need|Endoscopy only when patient reports symptoms
11552304|NCT00987831|Experimental|Blood drawing only Group C|Healthy controls, age, sex and ethnicity matched to the active study participants were recruited for two time blood donation as controls for the biomarker studies
11552305|NCT00987831|Experimental|Group A SLE prospective study|In Group A SLE patients enter with active disease. Any immune suppressant (e.g. methotrexate, azathioprine or mmf) is withdrawn and after blood drawing, depomedrol up to 160 mg IM is given. This may be repeated for a maximum of 160mg up to four times total in the first two weeks. Depomedrol is expected to last 1-3 months, serial biomarkers will be drawn until time of flare, at which time biomarkers will be drawn, patient is defined as meeting endpoint and new treatment initiated. Patients may elect to continue to donate blood samples per protocol up to one year.
11552306|NCT00987831|Experimental|Group B SLE one blood donation|SLE patients who meet the same entry criteria as Group A could elect to donate blood one time and not to continue in the prospective protocol. No extra intervention was performed other than blood draw and medical records review. This allowed an extension of cross sectional comparisons between biomarker changes related to background treatments by combining Group A baseline data with Group B data.
11552310|NCT00987805|Placebo Comparator|Placebo drug|The placebo of this study is corn-starch granules. It has the same form, color, flavor and amount like experimental herbal extracted formula
11552311|NCT00987792||Group 1|
11552312|NCT00987779|Experimental|Period I: Tablet(400 mg single dose)|Period I: Tablet in fasting state, Period II: Liquid formulation in fasting state, Period III: Liquid formulation in fed state
11552313|NCT00987779|Experimental|Period I: Liquid formulation(400 mg single dose)|Period I: Liquid formulation in fasting state, Period II: Tablet in fasting state, Period III: Liquid formulation in fed state
11552314|NCT00987766|Experimental|Treatment|Gemcitabine + Oxaliplatin + Erlotinib
11552315|NCT00987753|Experimental|infusion of L-377202|
11552316|NCT00987740|Experimental|Hemolung Respiratory Assist System|
11552317|NCT00987727|Experimental|1|carboxymethylcellulose 0.5% and glycerin 0.9% (OPTIVE® MD)
11552318|NCT00987727|Active Comparator|2|sodium hyaluronate 0.18% (VISMED® Multi)
11552319|NCT00987714|Experimental|Protocolized Care|Algorithm to manage Pulse Pressure Variation, Cardiac Index, and Mean Arterial Pressure will be used in these donors.
11552320|NCT00987714|No Intervention|Standard Care|This is the Organ Procurement Organization current practices.
11552321|NCT00987701|Active Comparator|Crystalloid resuscitation|Crystalloid (Ringer's lactate) will be delivered before (15min) or after (15min) neuraxial anesthesia
11552322|NCT00987701|Active Comparator|Colloid resuscitation|Colloid (6% hydroxyethyl starch ) will be delivered before (15min) or after (15min) neuraxial anesthesia
11552323|NCT00987688|Experimental|Hypothermia|Early and sustained hypothermia.
11552324|NCT00987688|No Intervention|Normothermia|Standard management
11552325|NCT00987662|Active Comparator|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP>135/85 mmHg add HCZ 12.5 mg.
11552326|NCT00987662|Active Comparator|Amplodipine|Treatment with amlodipine 10 mg for 4 weeks. If BP>135/85 mmHg add hydrochlorothiazide 12.5 mg
11552327|NCT00987636|Experimental|R1|Standard Risk R1: in a randomised trial, to examine whether add-on treatment with zoledronic acid in addition to induction and maintenance chemotherapy improves event-free survival in patients with localised Ewing sarcoma and good histological response or with initial tumour volume <200 mL compared to no add-on treatment.
11552328|NCT00987636|Experimental|R2|High Risk R2: in a randomised trial, to examine whether high-dose chemotherapy using busulfan-melphalan with autologous stem cell reinfusion, compared with standard chemotherapy, improves event-free survival in patients with localised Ewing sarcoma and poor histological response or tumour volume ≥200 mL (R2loc). In patients with pulmonary metastases high dose busulfan-melphalan chemotherapy with autologous stem cell reinfusion is randomised versus standard chemotherapy plus whole lung irradiation (R2pulm).
11552329|NCT00987636|Experimental|R3|Very High Risk R3: in a randomised trial, to examine whether the addition of high dose chemotherapy using treosulfan-melphalan followed by autologous stem cell reinfusion to eight cycles of standard adjuvant chemotherapy, compared to eight cycles of standard adjuvant chemotherapy alone, improves event-free survival in patients with primary disseminated disease.
11552330|NCT00987623|Experimental|nelfilcon A|Commercially marketed contact lens worn in both eyes on a daily wear, daily disposable basis for one week.
11552331|NCT00987623|Active Comparator|narafilcon A|Commercially marketed contact lens worn in both eyes on a daily wear, daily disposable basis for one week.
11552332|NCT00987610|Active Comparator|slender guidewire|Percutaneous coronary intervention (PCI) using guidewires with small distal tip equal to 0.010 inch or less
11552333|NCT00987610|Active Comparator|normal guidewire|Percutaneous coronary intervention (PCI) using guidewires with normal distal tip equal to 0.014 inch
11552334|NCT00987597|Experimental|cognitive behavioural approach|specific technique of cigarette exposure and nicotinic treatment adjustment
11552335|NCT00987597|Active Comparator|usual approach|recommendations and nicotinic substitutes
11552336|NCT00987571||Carpal Tunnel patients|These patients have documented carpal tunnel syndrome
11552337|NCT00987571||Normal Subjects|These individuals have no carpal tunnel syndrome
11552338|NCT00987558|Experimental|Treatment Sequence A|Simvastatin 80mg treatment period followed by Simvastatin 80 mg + eslicarbazepine acetate 800 mg treatment period
11552339|NCT00987558|Experimental|Treatment Sequence B|Simvastatin 80mg + eslicarbazepine acetate 800 mg treatment period followed by Simvastatin 80 mg treatment period
11552340|NCT00987545|Placebo Comparator|Placebo|
11552341|NCT00987545|Experimental|QAX576|
11552342|NCT00987532|Experimental|parent intervention plus gym lessons|Parent-focused participatory preschool intervention in addition to twice weekly gym lessons over 6 months. The participatory intervention includes parents, teachers and children.
11552343|NCT00987532|Active Comparator|gym lessons only|Twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
11552344|NCT00987519||Acute bronchiolitis|Patients with acute bronchiolitis - the presence of nasal discharge, cough, wheezing and/or crackles on lung auscultation.
11552345|NCT00987519||Acute gastroenteritis|Patients with 3 or more loose or liquid stools in 24 hours prior to entering the study.
11552346|NCT00987519||Febrile convulsion|Patients with a cerebral paroxysm accompanied by fever without signs of central nervous system infection.
11552347|NCT00987519||Control group|Patients referred to pediatric surgery for elective surgical procedure - judged to be free of clinical signs and symptoms of infection.
11552348|NCT00987506||XIENCE V®|Participants receiving XIENCE V® EESS
11552349|NCT00987493|Experimental|Treatment with rituximab, bendamustine and lenalidomide|
11552350|NCT00987480|Experimental|chemotherapy-based cytoreductive regimen plus a CD34+ selected|This phase II trial is designed to investigate the safety and efficacy of a chemotherapy-based cytoreductive regimen plus a CD34+ selected T-cell depleted peripheral blood stem cell (PBSC) stem cell transplant for the treatment of patients with Fanconi anemia and severe hematologic disease.
11552351|NCT00987467|Experimental|Cyclosporine 0.05% ophthalmic|cyclosporine 0.05% ophthalmic eye drops will be used starting with 1 drop in both eyes 6 times daily for first month, followed by 1 drop in both eyes 4 times daily for the following month, then will be adjusted by clinician as needed for appropriate disease control
11552395|NCT00987246|Placebo Comparator|Placebo|
11552396|NCT00987233|Experimental|triamcinolone acetonide aqueous nasal spray|
11552352|NCT00987454|Active Comparator|Erythropoietin|Epoetin alfa 40,000 international units will be given by subcutaneous injection to eligible patients, allocated to the treatment arm, on Study Days 1; 8 and15 during the intensive care unit stay.
11552353|NCT00987454|Placebo Comparator|Placebo|Sodium Chloride 0.9% in m/L will be given by subcutaneous injection to eligible patients, allocated to the placebo arm, on Study Days 1; 8 and15 during the intensive care unit stay.
11552354|NCT00987441|Active Comparator|Local anesthetic plus opioid 1|Local anesthetic (ropivacaine 0.125%) plus first opioid dose (sufentanil 0.3 microgram/ml) delivered peridural space
11552355|NCT00987441|Active Comparator|Local anesthetic plus opioid 2|Local anesthetic (ropivacaine 0.125%) plus second opioid dose (sufentanil 0.4 microgram/ml) delivered peridural space
11552356|NCT00987441|Active Comparator|Local anesthetic plus opioid 3|Local anesthetic (ropivacaine 0.125%) plus third opioid dose (sufentanil 0.5 microgram/ml) delivered peridural space
11552357|NCT00987441|Active Comparator|Local anesthetic 1 plus opioid|First local anesthetic dose (ropivacaine 0.0625%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
11552358|NCT00987441|Active Comparator|Local anesthetic 2 plus opioid|Second local anesthetic dose (ropivacaine 0.1875%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
11552359|NCT00987441|Active Comparator|Local anesthetic 3 plus opioid|Third local anesthetic dose (ropivacaine 0.25%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
11552360|NCT00987428|Experimental|groupe 1|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
11552361|NCT00987428|Active Comparator|Groupe 2|usual procedure
11552362|NCT00987415|Active Comparator|allopurinol|Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
11552363|NCT00987415|Placebo Comparator|sugar pill|Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
11552364|NCT00987402|Active Comparator|Plain soap and water|Surgical hand preparation with plain soap and water
11552365|NCT00987402|Active Comparator|Alcohol based hand rubs|Surgical hand preparation with alcohol based alcohol hand rub
11552366|NCT00987389|Experimental|Plasma Exchange with Standard Glucocorticoids|Participants in this arm undergo plasma exchange and take a standard glucocorticoid dose.
11552367|NCT00987389|Active Comparator|No Plasma Exchange with Standard Glucocorticoids|Participants in this arm do not undergo plasma exchange and take a standard glucocorticoid dose.
11552368|NCT00987389|Experimental|Plasma Exchange with Reduced-Dose Glucocorticoids|Participants in this arm undergo plasma exchange and take a reduced glucocorticoid dose.
11552369|NCT00987389|Active Comparator|No Plasma Exchange with Reduced-Dose Glucocorticoids|Participants in this arm do not undergo plasma exchange and take a reduced glucocorticoid dose.
11552370|NCT00987376|Experimental|1|Prostate cancer patients
11552371|NCT00987363|Experimental|Low dose (1x10 E8)|Dose of 1x10 E8 autologous bone marrow-derived mononuclear cells
11552372|NCT00987363|Experimental|Intermediate dose (5x10 E8)|Dose of 5x10 E8 autologous bone marrow-derived mononuclear cells
11552373|NCT00987363|Experimental|High dose (1x10 E9)|Dose of 1x10 E9 autologous bone marrow-derived mononuclear cells
11552374|NCT00987363|No Intervention|Control|Conventional treatment established by the good clinical practice
11552375|NCT00987350|Active Comparator|Trivalent influenza vaccine by needle and syringe|Thirty volunteers will receive 1 intramuscular (IM) dose of licensed trivalent inactivated 2009-10 seasonal influenza vaccine by the standard needle and syringe method
11552376|NCT00987350|Experimental|Trivalent influenza vaccine by jet injection|Thirty volunteers will receive 1 intramuscular (IM) dose of licensed trivalent inactivated 2009-10 seasonal influenza vaccine by the experimental method of jet injection
11552377|NCT00987337|Experimental|Arm A|"Filibuvir 300 mg BID + pegIFN/RBV x 24 weeks (subjects with undetectable HCV RNA at week 4)
~- or - Filibuvir 300 mg BID + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks (subjects with detectable HCV RNA at week 4)"
11552378|NCT00987337|Experimental|Arm B|"Filibuvir 600 mg BID + pegIFN/RBV x 24 weeks (subjects with undetectable HCV RNA at week 4)
~- or - Filibuvir 600 mg BID + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks (subjects with detectable HCV RNA at week 4)"
11552379|NCT00987337|Placebo Comparator|Arm C|Placebo + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks
11552380|NCT00987324|Experimental|Paclitaxel-eluting stent|Paclitaxel-eluting stent (Taxus)
11552381|NCT00987324|Active Comparator|Plain Balloon|plain balloon angioplasty
11552382|NCT00987324|Experimental|Paclitaxel-eluting balloon|SeQuent Please
11552383|NCT00987311|Active Comparator|1-Test product A|1-Dairy product containing probiotics A (test product A)
11552384|NCT00987311|Active Comparator|2-Test product B|2-Dairy product containing probiotics B (test product B)
11552385|NCT00987311|Sham Comparator|3-Control|3-Dairy product without probiotics (control)
11552386|NCT00987298||Visceral fat mass|The study population will include adult men and women, ages 18 to 90 years. All subjects will be recruited at Oregon Health and Science University (OHSU). Subjects will represent a wide range of BMI values (18.5 - 40 kg/m2).
11552387|NCT00987285|Experimental|Computer Assisted Self Management plus Social Support|an interactive, automated self-management (ASM) program that uses web and interactive voice recognition (IVR) media combined with enhanced support in the form of group Diabetes Care Management visits and live follow up phone calls from Diabetes Care Managers
11552388|NCT00987285|No Intervention|Usual care|will receive a health-risk appraisal, interactive CD-ROM program that provides standardized advice on behavior change, but not the hypothesized key intervention processes of goal setting, barriers identification, problem solving, or social environmental support.
11552389|NCT00987285|Experimental|Computer Assisted Self Management|An interactive, automated self-management (ASM) program that uses web and interactive voice recognition (IVR) media.
11552390|NCT00987272|Experimental|Pataday+Pataday Vehicle|Olopatadine Hydrochloride Ophthalmic Solution 0.2%, 1 drop in 1 eye and Olopatadine 0.2% Vehicle in the contralateral eye
11552391|NCT00987272|Active Comparator|Patanol+Patanol Vehicle|Olopatadine Hydrochloride Ophthalmic Solution, 0.1%, 1 drop in 1 eye and Olopatadine 0.1% Vehicle in the contralateral eye
11552392|NCT00987259||Post MI patients|Patients recruited following a successfully reperfused myocardial infarction using primary angioplasty.
11552393|NCT00987246|Experimental|LAS41005|
11552394|NCT00987246|Active Comparator|LAS106521|
11552397|NCT00987233|Active Comparator|Nasacort® AQ Nasal Spray|
11552398|NCT00987233|Placebo Comparator|Placebo|
11552399|NCT00987220||Placebo|
11552400|NCT00987220||donepezil (Aricept)|
11552401|NCT00987207|Experimental|cyclosporine|A single bolus of 2.5 mg/kg cyclosporine is administered before aortic cross-declamping
11552402|NCT00987207|Other|Control|No cyclosporine A is administered before aortic cross-declamping
11552403|NCT00987181||Angiography high risk|Patients with multiple risk factors, positive non-invasive test, or known pre-existing coronary artery/vascular disease. Patients with diabetes mellitus will be identified, and subject to a sub-group analysis.
11552404|NCT00987181||Angiography Low Risk|Patients with chest pain symptoms, minimal risk factors, and inconclusive evidence of myocardial ischaemia on non-invasive testing.
11552405|NCT00987168|Experimental|Sandostatine LP|
11552406|NCT00987155|Experimental|high intensity interval training|8 weeks of high intensity 4 times 4 interval training at 85-90% of peak heart rate during hybrid cycling
11552407|NCT00987142|Experimental|CX501|Cultured chimeric skin
11552408|NCT00987142|Active Comparator|Non adherent dressing|Occlusive non adherent dressing
11552409|NCT00987116|Active Comparator|Starting dose Prednisone Azathioprine|Classical Strategy
11552410|NCT00987116|Active Comparator|Starting dose Prednisone - Azathioprine|Rapid strategy
11552411|NCT00987103|Experimental|Sublingual - Rectal - Oral|Administration order of rank: Sublingual - Rectal - Oral
11552412|NCT00987103|Experimental|Sublingual - Oral - Rectal|Administration order of rank: Sublingual - Oral - Rectal
11552413|NCT00987103|Experimental|Oral - Sublingual - Rectal|Administration order of rank: Oral - Sublingual - Rectal
11552414|NCT00987103|Experimental|Oral - Rectal - Sublingual|Administration order of rank: Oral - Rectal - Sublingual
11552415|NCT00987103|Experimental|Rectal - Sublingual - Oral|Administration order of rank: Rectal - Sublingual - Oral
11552416|NCT00987103|Experimental|Rectal - Oral - Sublingual|Administration order of rank: Rectal - Oral - Sublingual
11552417|NCT00987090|Active Comparator|Alzheimer Disease|subjects who have developed symptoms of Alzheimer Disease aged from 45 to 85 years old
11552418|NCT00987090|Placebo Comparator|Control|subjects without symptoms of Alzheimer Disease aged from 45 to 85 years old.
11552419|NCT00987077|Experimental|Selective Retinatherapy (SRT)|Treatment was performed with the SRT-Laser system (Medical Laser Center Lübeck, Germany), which consists of a Q-switched frequency doubled Nd:YLF laser (527nm), operating with a pulse repetition rate of 100 Hz. The pulse duration (full width at half maximum) was 1.7 µs. The laser energy was transmitted via fiber to a Lumenis slitlamp allowing the application of a fixed spot size diameter of 200 µm in air. A Mainster central field contact lens with a magnification of 1.05 was used for all irradiations. Per foot switch, 30 pulses are emitted, the pulse energy was chosen by the physician up to a maximum of 370 µJ. According to the treatment protocol, prior to each treatment 5 test shots with increasing energy were applied adjacent to the vessel arcades, in each patient in order to determine the appropriate pulse energy for treatment by recording the OA-value.
11552420|NCT00987077|No Intervention|control group|Patients randomized to control group achieve no treatment and are followed up for three months.
11552421|NCT00987077|Experimental|crossover|After 3 months follow up patients of control group with persistence of disease activity were allocated to crossover group and received either SRT. Crossover group was followed up for further 3 months.
11552422|NCT00987064|Active Comparator|Temperature controlled Laminar Airflow|Active treatment with Temperature controlled Laminar Airflow (TLA)
11552423|NCT00987064|Placebo Comparator|Placebo TLA|Placebo treatment with TLA (no filtration function)
11552424|NCT00987051|Experimental|1|Patients with endometrial cancer
11552425|NCT00987038|Other|PF-04171327 and Midazolam|
11552426|NCT00987025|Experimental|Telehealth|Telehealth participants will be recruited from centers that have a telehealth blood pressure station installed. Participants will be asked to use the station once per week. Blood pressure measures will be monitored by nurse researchers - out of range values will result in appropriate medical recommendations.
11552427|NCT00987025|Active Comparator|Control|Control participants will receive education material.
11552428|NCT00987012|Experimental|Pomegranate juice|
11552429|NCT00987012|Placebo Comparator|Placebo drink|
11552430|NCT00986999|Experimental|rosuvastatin|rosuvastatin 10 mg qd increased to 20 mg qd as tolerated
11552431|NCT00986986|Experimental|Active Drug (extended release niacin)|Subjects in this arm will be given 12 weeks of extended release niacin. Intervention: extended release niacin (Niaspan) starting at 500 mg by mouth daily and titrated to a maximum dose of 1500 mg by mouth daily. Titration will depend on patient tolerability.
11552432|NCT00986986|No Intervention|Observation|Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin
11552433|NCT00986973|Experimental|Sapropterin (KUVAN)|All subjects will receive Sapropterin (KUVAN) therapy at a dose of 20/mk/kg/day for four months.
11552434|NCT00986960|Active Comparator|Adrenocorticotropin hormone|
11552435|NCT00986960|Placebo Comparator|Placebo|
11552436|NCT00986947|Experimental|IvIg with Rituximab|
11552437|NCT00986921|Experimental|mifepristone|women in the mifepristone are would take mifepristone 200 mg for cervical preparation the day before their procedure, and not have dilators inserted. In this group, the sstandard procedure of osmotic dilator insertion is NOT performed.
11552438|NCT00986921|Active Comparator|Osmotic dilator insertion|Women assigned to this arm would have the standard procedure for cervical preparation, which is insertion of osmotic dilators the day before the abortion procedure
11552439|NCT00986882|Experimental|SAF312A (2 doses in part B; 5 - 6 doses in part C)|
11552440|NCT00986882|Placebo Comparator|Placebo|
11552441|NCT00986882|Active Comparator|Ibuprofen|
11552442|NCT00986869||echocardiogram|All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
11552443|NCT00986856|Experimental|Fucidin® cream|
11552444|NCT00986856|Placebo Comparator|Fucidin® cream vehicle|
11552445|NCT00986843|Experimental|HM30181AK tablet + Irinotecan tablets|HM30181AK tablet + Irinotecan tablets
11552446|NCT00986830|Experimental|Balloon Dilation|Balloon dilation of the maxillary sinuses using the FinESS Sinus Treatment device.
11552447|NCT00986817|Experimental|Terlipressin|
11552448|NCT00986817|Placebo Comparator|Placebo|
11552449|NCT00986804|Experimental|Level 1|Decitabine 5.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
11552450|NCT00986804|Experimental|Level 2|Decitabine 7.5 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
11552451|NCT00986804|Experimental|Level 3|Decitabine 10.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
11552452|NCT00986804|Experimental|Level 4|Decitabine 15.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
11552453|NCT00986791|No Intervention|Control group|Treatment as usual
11552454|NCT00986791|Experimental|GSP-A|Gold-Standard-Program for Alcohol cessation intervention (GSP-A): 6-week intensive patient education program with pharmaceutical support
11552455|NCT00986778|Active Comparator|Lamivudine plus Adefovir|
11552456|NCT00986778|Active Comparator|Entecavir|
11552457|NCT00986778|Experimental|Entecavir plus Adefovir|
11552458|NCT00986765|Experimental|Lovenox® , 4000 UI/day (+ Aspegic®)|Lovenox® (enoxaparin), 4000 UI/day (+ Aspegic® (Aspirin), 100 mg)
11552459|NCT00986765|Active Comparator|Aspegic ®, 100 mg/day|Aspegic® (Aspirin),100 mg/day
11552460|NCT00986752|Active Comparator|Stenting|Due to randomization one nitinol stent will be implanted after dilation with a conventional balloon.
11552461|NCT00986752|Experimental|Stenting after PEB|Due to randomization one nitinol stent will be implanted after dilation with a Paclitaxel eluting balloon.
11552462|NCT00986752|Experimental|Atherectomy|The third randomization arm is Atherectomy.
11552463|NCT00986700|Other|different types of bad time food|Different types of bad time food
11552464|NCT00986687||Vitrified oocytes|
11552465|NCT00986687||Control oocytes|
11552466|NCT00986674|Experimental|Arm I (carboplatin, paclitaxel, cetuximab)|Patients receive carboplatin IV over 15-30 minutes and paclitaxel IV over 3 hours on days 1 and 22 and cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cetuximab alone on days 1, 8, 15, 22, 29, and 36. Treatment with cetuximab repeats every 42 days in the absence of disease progression or unacceptable toxicity.
11552467|NCT00986674|Experimental|Arm II (carboplatin, paclitaxel, cixutumumab)|Patients receive carboplatin and paclitaxel as in arm I. Patients also receive cixutumumab IV over 1 hour on days 1, 15, and 29. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cixutumumab alone on days 1, 15, and 29. Treatment with cixutumumab repeats every 42 days in the absence of disease progression or unacceptable toxicity.
11552468|NCT00986674|Experimental|Arm III (carboplatin, paclitaxel, cetuximab, cixutumumab)|Patients receive carboplatin, paclitaxel, and cetuximab as in arm I. Patients also receive cixutumumab as in arm II. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cetuximab as in arm I and cixutumumab as in arm II.
11552469|NCT00986661|Experimental|PV-10 Injection (Intralesional)|Subjects in each of three cohorts will receive a single dose of PV-10 to one Target Lesion.
11552470|NCT00986609|Experimental|Arm I|Patients receive MUC-1 peptide vaccine subcutaneously and poly-ICLC vaccine intramuscularly in weeks 0, 4, 8, 12, 52, and 56, in the absence of disease progression or unacceptable toxicity. Patients may receive additional vaccines in weeks 34 and 38 if anti-MUC1 immunity falls below the two-fold enhancement from baseline
11552471|NCT00986596|Active Comparator|vitamin D3|vitamin D3 capsule 4000 IU p.o. daily
11552472|NCT00986596|Placebo Comparator|placebo|microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
11552473|NCT00986583|Other|Statin use group|Patients taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.
11552474|NCT00986583|Other|non statin use|Patients not taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.
11552475|NCT00986570|Experimental|Xeomin®|Botulinum Toxin A
11552476|NCT00986544|Sham Comparator|Absence of drain|
11552477|NCT00986544|Active Comparator|Drain|drain positioned in the subhepatic space after laparoscopic cholecystectomy
11552478|NCT00986531|Experimental|1|80 mg AZD8529
11552479|NCT00986531|Placebo Comparator|2|Placebo
11552480|NCT00986518|Experimental|adaptive cell immunotherapy|
11552481|NCT00986505|Experimental|Lidocaine|Comparison between intravenous lidocaine and saline infusion
11552482|NCT00986479|Experimental|AZD6765 (150 mg) / Placebo|Patients randomized to receive a single intravenous (iv) infusion of AZD6765 (150 mg) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of placebo (saline solution) over 60 minutes during the second period.
11552483|NCT00986479|Placebo Comparator|Placebo / AZD6765 (150 mg)|Patients randomized to receive a single intravenous (iv) infusion of placebo (saline solution) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of AZD6765 (150 mg) over 60 minutes during the second period.
11552484|NCT00986466|Experimental|exercise with vitamin D 800 IU/d|
11552485|NCT00986466|Active Comparator|exercise with placebo|
11552486|NCT00986466|Active Comparator|no exercise with vitamin D 800 IU/d|
11552487|NCT00986466|Placebo Comparator|no exercise with placebo|
11552488|NCT00986453|Experimental|PlasmaBlade arm|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
11552489|NCT00986453|Active Comparator|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
11552490|NCT00986440|Experimental|CS-7017|
11552491|NCT00986440|Placebo Comparator|Placebo|Placebo matching CS-7017
11552492|NCT00986427|Active Comparator|1|Subjects will apply Restasis® to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
11552493|NCT00986427|Placebo Comparator|2|Subjects will apply Refresh® Dry Eye therapy to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
11552494|NCT00986414|Experimental|AFQ056-10mg|
11552495|NCT00986414|Experimental|AFQ056-25mg|
11552496|NCT00986414|Experimental|AFQ056-50mg|
11552497|NCT00986414|Experimental|AFQ056-75mg|
11552498|NCT00986414|Experimental|AFQ056-100mg|
11552499|NCT00986414|Placebo Comparator|Placebo|
11552500|NCT00986401|Experimental|Glucophage® then Sanctura XR® (AB)|Treatment Period 1: Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD) for 4 days + Glucophage® (500 mg, BID) for 3.5 days.
11552501|NCT00986401|Experimental|Sanctura XR® then Glucophage® (BA)|Treatment Period 1: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD for 4 days) + Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Glucophage® (500 mg, BID) for 3.5 days.
11552502|NCT00986375|Experimental|Intervention Group (IG)|Patients in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
11552503|NCT00986375|Active Comparator|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
11552504|NCT00986362|Experimental|Ocriplasmin|
11552505|NCT00986362|Placebo Comparator|Placebo|
11552506|NCT00986349|Experimental|Diabetes|Single Arm
11552507|NCT00986336|Experimental|001|
11552508|NCT00986336|Experimental|002|
11552509|NCT00986336|Experimental|003|
11552510|NCT00986336|Experimental|004|
11552511|NCT00986323|Active Comparator|Temeperature controlled Laminar Airflow|Active treatment with Temperature controlled Laminar Airflow (TLA)
11552512|NCT00986323|Placebo Comparator|Placebo TLA|Placebo TLA treatment
11552513|NCT00986310|Active Comparator|fluoxetine|Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo (one pill), to be started one week prior to the scheduled hospital admission date. The dose will be increased to two pills per day on day 1 of hospitalization bringing the total dose of fluoxetine to 40 mg/day in patients randomized to receive this medication. On the day of discharge from the hospital, the study medication will be reduced to 1 pill per day and the patient will be instructed to stop the medication one week following discharge.
11552514|NCT00986310|Placebo Comparator|Placebo|Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo (one pill), to be started one week prior to the scheduled hospital admission date. The dose will be increased to two pills per day on day 1 of hospitalization. On the day of discharge from the hospital, the study medication will be reduced to 1 pill per day and the patient will be instructed to stop the medication one week following discharge.
11552515|NCT00986297|Other|arm one|IGRT
11552516|NCT00986284|Experimental|Gefitinib, Neoadjuvant therapy|Patients with EGFR mutation will be recruited and treated with gefitinib.
11552517|NCT00986271|Other|With and without MODS developement|EVLI was determinated by PiCCO plus system.
11552518|NCT00986258|Experimental|Tapentadol Prolonged Release|"Other Names:
~Nucynta
~Palexia"
11552519|NCT00986245|Active Comparator|Ropinirole PR QD first, then BID|Give Roipinirole prolonged release (PR) once-daily (QD) dose first, then twice-daily (BID) dosing
11552520|NCT00986245|Active Comparator|Ropinirole PR BID first, and then QD|Give Ropinirole prolonged release (PR) twice-daily (BID) dosing, and then once-daily (QD) dosing
11552521|NCT00986232|Experimental|1|ProQuad (low dose)
11552522|NCT00986232|Experimental|2|ProQuad (middle dose)
11552523|NCT00986232|Experimental|3|ProQuad (high dose)
11552524|NCT00986232|Active Comparator|4|M-M-R II + PUVV
11552525|NCT00986219||Asthma Language between patients and physicians|
11552526|NCT00986206||Biomarker testing|Collect serum for biomarker testing for LAP and HE4 and discovery of new biomarkers.
11552527|NCT00986193|Active Comparator|Conventional Aortic Valve Surgery|Insertion of a biological valve
11552528|NCT00986193|Experimental|Transapical Aortic Valve Implantation|Transapical implantation of an Edwards SAPIENtm valve
11552529|NCT00986180|Experimental|001|NUCYNTA 50 75 or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
11552530|NCT00986180|Active Comparator|002|Oxycodone IR 5 10 or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
11552531|NCT00986167|Experimental|Quetiapine XR|The study population will be patients admitted to the acute psychiatry inpatient wards of St Vincent's or the Alfred and determined by a Psychiatrist to be experiencing a psychotic illness (including mania with psychotic features and drug-induced psychosis) and acting in an aggressive manner (determined by a score of at least 1 on the OAS).
11552532|NCT00986154|Experimental|heparin/edoxaban tosylate|
11552533|NCT00986154|Active Comparator|heparin/warfarin|
11552534|NCT00986141||laser trabeculoplasty|Subjects with POAG and on medical treatment who are undergoing SLT
11552535|NCT00986141||Surgery|Glaucoma laser treatment
11552536|NCT00986128|Experimental|001|
11552537|NCT00986128|Experimental|002|
11552538|NCT00986115|Active Comparator|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
11552539|NCT00986115|Placebo Comparator|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
11552540|NCT00986102|Other|001|doripenem 500mg vial by injection every 8 hours for 5 to 14 days
11552541|NCT00986089||women who have an IUD placed at the time of c-section|
11552542|NCT00986076|Experimental|Enoxaparin infusion|"Congenital Cataract Surgery with IOL implantation
~Intraocular infusion of Enoxaparin"
11552543|NCT00986076|Placebo Comparator|Balanced Salt Solution Infusion|Congenital Cataract Surgery with IOL implantation Intraocular infusion of Balanced Salt Solution
11552544|NCT00986063|Active Comparator|Standard of care|AIDS patients taking care with standard of care
11552545|NCT00986063|Experimental|Genetic test|AIDS patients who required highly active antiretroviral therapy(HAART) whom genotype status will be determined before initiation of HAART
11552546|NCT00986050|Active Comparator|Bare metal stent (BMS)|
11552547|NCT00986050|Active Comparator|Drug eluting stent (DES)|
11552548|NCT00986050|Active Comparator|Abciximab|
11552549|NCT00986050|No Intervention|No abciximab|
11552550|NCT00986037|Experimental|IV ABT-308 in asthmatics|ABT-308 single escalating doses in mild to moderate asthmatics
11552551|NCT00986037|Experimental|SC ABT-308 in asthmatics|ABT-308 multiple SQ doses in mild to moderate asthmatics
11552552|NCT00986037|Experimental|IV ABT-308 in healthy volunteers|ABT-308 single escalating IV doses in healthy volunteers
11552553|NCT00986024|Experimental|aerobic exercise|
11552554|NCT00986024|Experimental|strength training|
11552555|NCT00986024|No Intervention|control group|
11552556|NCT00985998|Experimental|Nimotuzumab|
11552557|NCT00985985|Experimental|2mg nicotine lozenge|2 mg nicotine lozenge
11552558|NCT00985985|Placebo Comparator|2 mg placebo|2 mg placebo
11552559|NCT00985985|Experimental|4 mg nicotine lozenge|4 mg nicotine lozenge
11552560|NCT00985985|Placebo Comparator|4 mg placebo|4 mg placebo
11552561|NCT00985972||Intervention|Groups of school intervention that involves a combination of the physical activity and nutrition education in subjects 6 to 18 years of age
11552562|NCT00985972||Control|Groups included in the same school communities that serve as reference for individuals involved in intervention.
11552563|NCT00985959|Experimental|Phase I: JNJ-26866138 0.7 mg/m2|JNJ-26866138 0.7 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles.
11552564|NCT00985959|Experimental|Phase I: JNJ-26866138 1.0 mg/m2|JNJ-26866138 1.0 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
11552565|NCT00985959|Experimental|Phase I: JNJ-26866138 1.3 mg/m2|JNJ-26866138 1.3 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
11552566|NCT00985959|Experimental|Phase II: JNJ-26866138 1.3 mg/m2|JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5-9 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
11552567|NCT00985946|Experimental|panobinostat|This is a single arm trial. All patients will take panobinostat
11552568|NCT00985933|Experimental|1|180 mg of AZD8529
11552569|NCT00985933|Experimental|2|50 mg AD8529
11552570|NCT00985933|Placebo Comparator|3|Placebo
11552571|NCT00985920|Experimental|Tranexamic acid, 1.5 g|1.5 g of tranexamic acid in 50 cc of normal saline solution is given to the patients.
11552572|NCT00985920|Experimental|Tranexamic acid, 3.0 g|3.0 g of tranexamic acid in 50 cc of normal saline is given to the patients.
11552573|NCT00985920|Placebo Comparator|Placebo, saline|50 cc of sterile normal saline solution is given to the patients.
11552574|NCT00985907|Experimental|Doxil® + Melphalan + Velcade (DMV)|
11552575|NCT00985894|Experimental|Teledermatology|Online Telemedicine Group
11552576|NCT00985894|Active Comparator|Usual Care|Conventional in-office care
11552577|NCT00985881|Experimental|Arm 1: stochastic resonance|Mechanical stochastic resonance
11552578|NCT00985881|Other|Arm 2: current clinical practice|Current clinical practice
11552579|NCT00985855|Experimental|Cisplatin, vinorelbine|patients will receive induction chemotherapy (cisplatin, docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and vinorelbine associated with a weekly cetuximab infusion during the radiotherapy.
11552580|NCT00985855|Experimental|Cisplatin, etoposide|patients will receive induction chemotherapy (cisplatin, docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and etoposide associated with a weekly cetuximab infusion during the radiotherapy.
11552581|NCT00985842|Other|Arm 1|Comparison of five different clinically used suspension and socket systems
11552582|NCT00985829|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
11552583|NCT00985816|Active Comparator|L reuteri DSM 17938|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties (Connolly, 2005). The placebo consists of an identical formulation except that the L. reuteri is not present. This dose of the oil formulation with L. reuteri has been shown to induce significant colonisation in infants and is well-tolerated (Abrahamsson et al., 2007; Savino et al., 2007; Indrio et al., 2008).
11552584|NCT00985816|Placebo Comparator|Placebo|
11552585|NCT00985803|No Intervention|Group Control|
11552586|NCT00985803|Experimental|Endurance|
11552587|NCT00985803|Experimental|Cardiovascular|
11552588|NCT00985790|Experimental|GSK2321138A Group|"Subjects aged between 18 and 47 months received the GSK2321138A. Primed subjects (subjects who had received a 2-dose priming immunization with Fluarix™ vaccine in study NCT00764790 - or the GSK2321138A-Primed Group) received 1 dose of GSK2321138A vaccine at Day 0. Unprimed subject (subjects who had not received any 2-dose priming influenza immunization in any previous year - or the the GSK2321138A-Unprimed Group) received 2 doses of GSK2321138A vaccine at Days 0 and 28. The GSK2321138A vaccine was administered intramuscularly in the deltoid of the right arm."
11552589|NCT00985790|Active Comparator|Fluarix Group|"Subjects aged between 18 and 47 months received the Fluarix™ vaccine. Primed subjects (subjects who had received a 2-dose priming immunization with Fluarix™ vaccine in study NCT00764790 - or the Fluarix-Primed Group) received 1 dose of Fluarix™ vaccine at Day 0. Unprimed subject (subjects who had not received any 2-dose priming influenza immunization in any previous year - or the the Fluarix-Unprimed Group) received 2 doses of Fluarix™ vaccine at Days 0 and 28. The Fluarix™ vaccine was administered intramuscularly in the deltoid of the right arm."
11552630|NCT00985517|Experimental|Phase 1: Cohort 1|CERE-120 9.4 x 10^11 vg, injected by a neurosurgeon directly in the substantia nigra and in the putamen
11552590|NCT00985777|Experimental|Phase I Dose Escalation|Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days and one dose on Day 15.
11552591|NCT00985764||placental previa|
11552592|NCT00985751|Experimental|Group 1|
11552593|NCT00985751|Experimental|Group 2|
11552594|NCT00985751|Experimental|Group 3|
11552595|NCT00985751|Experimental|Group 4|
11552596|NCT00985751|Experimental|Control Group|
11552597|NCT00985738|Experimental|Dutasteride|The drug, Dutasteride, will be administered at 0.5 mg dose and given everyday (QD), for 3 months.
11552598|NCT00985738|Placebo Comparator|Placebo|The placebo group will receive a placebo drug for 3 months, instead of the intervention drug, Dutasteride.
11552599|NCT00985725|Experimental|Active|SPD489
11552600|NCT00985725|Placebo Comparator|Placebo|Placebo
11552601|NCT00985712|Experimental|HumaPen Luxura|Participant's insulin dose of Insulin Lispro or Huminsulin Normal is delivered subcutaneously via HumaPen Luxura daily for 24 weeks
11552602|NCT00985712|Experimental|HumaPen Memoir|Participant's insulin dose of Insulin Lispro or Huminsulin Normal is delivered subcutaneously via HumaPen Memoir daily for 24 weeks
11552603|NCT00985686|Experimental|Study Arm|Arm where participants began the LEAP Project intervention upon recruitment for an 8 week period.
11552604|NCT00985686|Active Comparator|Waitlist Arm|"Arm where participants received the LEAP Project intervention after an 8 week wait period.
~At 8 weeks, the results from the wait-list arm (no intervention) were compared to the results of the study arm (intervention completed)."
11552605|NCT00985673|Experimental|Flulaval/placebo/unadjuvanted Arepanrix Group|subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
11552606|NCT00985673|Experimental|Flulaval/placebo/Arepanrix Group|subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
11552607|NCT00985673|Experimental|Flulaval/unadjuvanted Arepanrix/placebo Group|subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
11552608|NCT00985673|Experimental|Flulaval/Arepanrix/placebo Group|subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
11552609|NCT00985673|Experimental|Unadjuvanted Arepanrix/placebo/Flulaval Group|subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
11552610|NCT00985673|Experimental|Arepanrix/placebo/Flulaval Group|subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
11552611|NCT00985660|Experimental|Test:|Nisoldipine ER Tablets, 30 mg
11552612|NCT00985660|Active Comparator|Reference|Sular Extended-release Tablets, 30 mg
11552613|NCT00985647|Active Comparator|3TC 300mg/150mg|Group 1: Participants will be administered 3TC 300 mg once daily orally for 10 days. A 10 day wash-out period will follow (days 11-20). From day 21, participants will be administered 3TC 150 mg once daily for 10 days
11552614|NCT00985647|Active Comparator|3TC 150mg/300mg|Group 2: Participants will be administered 3TC 150 mg once daily orally for 10 days. A 10 day wash-out period will follow (days 11-20). From day 21, participants will be administered 3TC 300 mg once daily for 10 days
11552615|NCT00985634|Experimental|LeGoo|Subjects in this arm, which is assigned at random, will receive the study device.
11552616|NCT00985634|Active Comparator|Control|Subjects in this arm will not receive the study device, but receive the standard of care for vessel occlusion (vessel loops.)
11552617|NCT00985621|Experimental|1|
11552618|NCT00985621|Experimental|2|
11552619|NCT00985621|Active Comparator|3|
11552620|NCT00985621|Placebo Comparator|4|
11552621|NCT00985608|Active Comparator|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
11552622|NCT00985608|Active Comparator|Group A: NCA 600mg +antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
11552623|NCT00985569||Lubiprostone|Subjects switching from current bowel medicines to lubiprostone
11552624|NCT00985556|Experimental|Arm I|Patients receive oral S-1 twice daily on days 1-14 and oxaliplatin IV over 2 hours on day 1.
11552625|NCT00985556|Experimental|Arm II|Patients receive oral capecitabine twice daily on days 1-14 and oxaliplatin as in arm I.
11552626|NCT00985543|Active Comparator|LPV/r 400/100 mg|Lopinavir/ritonavir 400/100 mg twice daily (2 heat-stable 200/50 mg tablets twice daily (BID))
11552627|NCT00985543|Experimental|LPV/r 200/150 mg|Lopinavir/ritonavir 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID)
11552628|NCT00985543|Experimental|LPV/r 200/50 mg|Lopinavir/ritonavir 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID)
11552629|NCT00985530|Experimental|Arm 1|Tamibarotene + Arsenic Trioxide
11552631|NCT00985517|Experimental|Phase 1: Cohort 2|CERE-120 2.4 x 10^12 vg, injected by a neurosurgeon directly in the substantia nigra and in the putamen
11552632|NCT00985517|Experimental|Phase 2: CERE-120|CERE-120 2.4 x 10^12 vg, injected by a neurosurgeon directly in the substantia nigra and in the putamen
11552633|NCT00985517|Sham Comparator|Phase 2: Sham Surgery|Neurosurgical procedure that mimics the procedure for CERE-120 delivery. No injections were administered during sham surgery.
11552634|NCT00985504|Experimental|Duloxetine|
11552635|NCT00985504|Active Comparator|Escitalopram|
11552636|NCT00985491|Experimental|Device|All patients will be implanted with the Endobarrier Liner device.
11552637|NCT00985478|Experimental|A|SLV342 suspension or capsule
11552638|NCT00985478|Placebo Comparator|B|matching placebo
11552639|NCT00985465|Experimental|Pn-Pn group|subjects from the Pn-Pn group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in the Malian centre of study NCT00678301, receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A
11552640|NCT00985465|Experimental|Zil-Pn group|subjects from the unprimed group of the NCT00678301 Malian study centre, not previously vaccinated with any pneumococcal vaccine, receiving two doses of pneumococcal conjugate vaccine GSK1024850A
11552641|NCT00985452|Other|Group 2: Intervention|Subjects in Group two will received an activated GlowCaps system, which will remind them to take their medication.
11552642|NCT00985452|Other|Group 3: Intervention/financial incentive|Subjects in group 3 will receive an activated GlowCaps system, which will provide them with reminders to take their medication, Subjects in group 3 will also receive an additional financial incentive, the amount will be based on how often they remembered to take their medication during the 6-month study.
11552643|NCT00985452|Other|Group 1: Control|Subjects in group one will receive a de-activated GlowCaps system, which will not provide the reminder service.
11552644|NCT00985439|Experimental|Diclofenac Test (lower dose)|One 18-mg Diclofenac Test Capsule and 1 placebo capsule
11552645|NCT00985439|Experimental|Diclofenac Test (upper dose)|One 35-mg Diclofenac Test Capsule and 1 placebo capsule
11552646|NCT00985439|Active Comparator|Celecoxib 400 mg|
11552647|NCT00985439|Placebo Comparator|Placebo|
11552648|NCT00985426|Experimental|HEPLISAV|0.5 mL HEPLISAV and 0.5 mL Placebo
11552649|NCT00985426|Active Comparator|Engerix-B|2.0 mL Engerix-B
11552650|NCT00985400|Experimental|Exercise Program|Arm I (exercise program): Oncologist advice; Resistance bands & pedometer with written/DVD instructions for resistance exercise twice a week for 16 weeks. Brief moderate-intensity walks multiple times a day for a total of 30 minutes increasing steps weekly by 10% to reach a minimum of 10,000 steps a day. Monthly newsletters; Telephone counseling weekly for 4 weeks then monthly for 12 weeks; and tailored message telephone prompts once every 2 weeks during last 12 weeks of the study intervention.
11552651|NCT00985400|Experimental|Relaxation Intervention|Arm II (relaxation program): Oncologist advice; Written/CD audio instructions on diaphragmatic breathing and guided imagery. Practice relaxation techniques for 15 minutes/day, 5-7 days/week, for 16 weeks. Monthly newsletters, telephone counseling, and tailored-message telephone prompts as in arm I.
11552652|NCT00985387||Solifenacin treatment|Male and female OAB patients who were treated with solifenacin
11552653|NCT00985374|Experimental|1|
11552654|NCT00985361|Experimental|Vitamin D 2000 international units daily|
11552655|NCT00985361|Active Comparator|Vitamin C 500mg daily|
11552656|NCT00985348|Experimental|Treatment 1/Treatment 2|
11552657|NCT00985348|Experimental|Treatment 2/Treatment 1|
11552658|NCT00985335|Experimental|External Application of Neem-based Cream|Non Controlled, non-randomized, single group pilot study.
11552659|NCT00985322|Experimental|ACE inhibitor Ramipril|
11552660|NCT00985322|Active Comparator|non-RAS inhibitor antihypertensive therapy|
11552661|NCT00985296||Ragweed+ Dust Mite+ CAC w/ DM|
11552662|NCT00985296||Ragweed + Dust Mite + CAC w/Saline|
11552663|NCT00985296||Ragweed + Dust Mite - CAC|
11552664|NCT00985283|Experimental|Preventive home visit|receives preventive home visit intervention 4 times over 1 year
11552665|NCT00985283|Active Comparator|comparison group|receives information packets on local services for older adults and health promotion material twice during 1 year
11552666|NCT00985270|Active Comparator|Rifampicin|
11552667|NCT00985270|Placebo Comparator|Placebo|
11552668|NCT00985257|Other|Subjects with diabetes|Subjects with diabetes (or parents/guardians, if applicable)and healthcare professionals (HCPs) use a new blood glucose monitoring system. Subjects were 4 to 24 years of age with type 1 and type 2 diabetes.
11552669|NCT00985244|Active Comparator|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin
11552670|NCT00985244|Placebo Comparator|Placebo|Subjects in this group will receive 3 times a week placebo
11552671|NCT00985231|Experimental|PureVision Multi-Focal contact lenses|
11552672|NCT00985231|Active Comparator|SofLens59 contact lens|
11552673|NCT00985218|Experimental|experimental arm|Embryos cultured in SMART System
11552674|NCT00985218|Active Comparator|Control|Embryos cultured in microdrops in dishes
11552675|NCT00985205|Experimental|Enteral Glutamine|0.5 g/kg/day mixed in water and given via nasogastric or feeding tube as boluses q 4 hrs or TID or QID if po
11552676|NCT00985205|Placebo Comparator|Placebo|Mixed in with water and given via nasogastric or feeding tube as boluses q 4hrs or TID or QID if po
11552677|NCT00985192|Experimental|Everolimus|Patients receive oral everolimus once daily on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity
11552678|NCT00985179|Experimental|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
11552679|NCT00985179|No Intervention|Waiting control group (WCG)|
11552680|NCT00985166|Experimental|1|ProQuad + Placebo
11552681|NCT00985166|Active Comparator|2|M-M-R II + Placebo
11552682|NCT00985166|Active Comparator|3|M-M-R II + Varivax
11552683|NCT00985153|Experimental|1|ProQuad Lot 1
11552684|NCT00985153|Experimental|2|ProQuad Lot 2
11552685|NCT00985153|Experimental|3|ProQuad Lot 3
11552686|NCT00985153|Active Comparator|4|M-M-R II + Varivax
11552687|NCT00985140||12 Gy TSEBT|Prospective assignment to receive 12 Gy total skin electron beam therapy (TSEBT) for mycosis fungoides
11552688|NCT00985127|Experimental|40 mg|40 mg BCX4208
11552689|NCT00985127|Experimental|80 mg|BCX4208
11552690|NCT00985127|Experimental|120 mg|BCX4208
11552691|NCT00985127|Placebo Comparator|sugar pill|
11552692|NCT00985127|Experimental|160mg|BCX4208
11552693|NCT00985127|Experimental|240mg|BCX4208
11552694|NCT00985127|Experimental|320mg|BCX4208
11552695|NCT00985114|Experimental|Device|EndoBarrier implanted for 6 months. Subject followed for 6 months after device was explanted.
11552696|NCT00985114|Active Comparator|Diet + Lifestyle counseling|Multidisciplinary lifestyle and nutritional counseling for 12 months
11552697|NCT00985101||diabetes no complications|
11552698|NCT00985101||diabetes with complications|
11552699|NCT00985088|Experimental|GSK2340274A F1_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 1 (F1) of GSK2340274A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
11552700|NCT00985088|Experimental|GSK2340274A F2_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 2 (F2) of GSK2340274A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
11552701|NCT00985088|Experimental|GSK2340274A F2_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 2 (F2) of GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline placebo at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
11552702|NCT00985088|Experimental|GSK2340274A F1_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 1 (F1) of GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline placebo at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
11552703|NCT00985088|Experimental|GSK2340273A F1_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 1 (F1) of GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
11552704|NCT00985088|Experimental|GSK2340273A F2_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 2 (F2) of GSK2340273A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
11552705|NCT00985088|Experimental|GSK2340273A F2_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 2 (F2) of GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline at Day 21, administered intramuscularly into the deltoid region of the dominant arm. Subjects above (>) 60 years old received an additional dose of Formulation 2 (F2) of GSK2340273A vaccine after Day 42, administered into the deltoid region of the non-dominant arm.
11552706|NCT00985088|Experimental|GSK2340273A F3_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 3 of GSK2340273A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
11552707|NCT00985062|Active Comparator|Mild Ovarian Stimulation|
11552708|NCT00985062|Active Comparator|Conventional Ovarian Stimulation|
11552709|NCT00985036||Glioma|patients who are diagnosed with and are being treated for glioma
11552710|NCT00985036||meningioma|patients who are diagnosed with and are being treated for meningioma
11552711|NCT00985023|Active Comparator|Steel screw fixation|
11552712|NCT00985023|Experimental|Bioabsorbable screw fixation|
11552713|NCT00984997|Experimental|Surgery + Radiotherapy + Chemotherapy|"Surgery followed by radiotherapy and chemotherapy started at the beginning of radiotherapy. Segmentectomy or lobectomy with en bloc resection of the involved chest. Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week. Cisplatin 50 mg/M^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.
~Etoposide given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29. Prophylactic Cranial Irradiation 25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional."
11552714|NCT00984984|Experimental|methylprednisolone PO|
11552715|NCT00984984|Active Comparator|methylprednisolone IV|
11552716|NCT00984971|Experimental|Tenofovir|
11552717|NCT00984971|Placebo Comparator|HEC Placebo|
11552718|NCT00984971|Other|Open label tenofovir tablet|
11552719|NCT00984958|Other|Bulkamid|Injection with Bulkamid
11552720|NCT00984958|Other|expectance|The expectance arm will after 2 month have the same treatment as the treatment arm
11552721|NCT00984945|Active Comparator|H5 VLP vaccine 5 µg|
11552722|NCT00984945|Active Comparator|H5 VLP vaccine 10 µg|
11552723|NCT00984945|Active Comparator|H5 VLP vaccine 20 µg|
11552724|NCT00984945|Placebo Comparator|Placebo (Formulation buffer)|
11552725|NCT00984932|Experimental|Rosuvastatin|
11552726|NCT00984906|Other|Empty Easyhaler type A|
11552727|NCT00984906|Other|Empty Easyhaler type B|
11552728|NCT00984906|Other|Empty Turbohaler|
11552729|NCT00984893||Zoledronic acid|
11552730|NCT00984893||Oral Bisphosphonates|
11552731|NCT00984880|Experimental|1|Intravenous solution given as a single ascending bolus dose
11552732|NCT00984880|Experimental|2|Intravenous solution given as a single ascending bolus dose followed by a single infusion
11552733|NCT00984867|Active Comparator|1|Dapagliflozin 10 mg tablet
11552734|NCT00984867|Placebo Comparator|2|Matching placebo tablet
11552735|NCT00984854|Experimental|Intradermal Juvidex|
11552736|NCT00984854|Placebo Comparator|Placebo (vehicle)|
11552737|NCT00984841|Experimental|Tailored letter|Patients in the tailored letter group received by mail a tailored letter detailing their diabetes measures, together with enclosed orders for lab tests when due, and reminder of or scheduling for an office appointment.
11552738|NCT00984841|Active Comparator|Usual Care|Patients in the usual care group were part of a practice wide quality improvement process.
11552739|NCT00984828|Experimental|vel 8 - ASCT|8 cycles of velcade with ASCT
11552740|NCT00984828|Active Comparator|vel4 - ASCT|4 cycles of velcade with ASCT
11552741|NCT00984815|Experimental|HZT-501|Open-label treatment with HZT-501
11552742|NCT00984802|Experimental|Low dose|
11552743|NCT00984802|Experimental|Mid Dose|
11552744|NCT00984802|Experimental|High Dose|
11552745|NCT00984802|Placebo Comparator|Placebo|
11552746|NCT00984789|Experimental|Arm 1|
11552747|NCT00984789|Active Comparator|Arm 2|
11552748|NCT00984763|Experimental|Group 1|AMA1-C1/Alhydrogel® + CPG 7909 vaccine given twice two months apart followed by malaria parasite challenge
11552749|NCT00984763|No Intervention|Group 2|Control: malaria parasite challenge without prior vaccinations
11552750|NCT00984750|Experimental|1|Statin and acetyl-L-carnitine
11552751|NCT00984750|Placebo Comparator|2|Statin and placebo
11552752|NCT00984724|Experimental|Standard Treatment|Standard Treatment (ST): Mailed Packet with standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months). Referral to Quitline.
11552753|NCT00984724|Experimental|MAPS-6|Standard Treatment (ST) plus 6 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 6 MAPS proactive telephone counseling sessions over 2-year period.
11552754|NCT00984724|Experimental|MAPS-12|Standard Treatment (ST) plus 12 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 12 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline.
11552755|NCT00984724|Experimental|Standard Treatment + NRT|Standard Treatment (ST): Mailed Packet with standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months). Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
11552756|NCT00984724|Experimental|MAPS-6 + NRT|Standard Treatment (ST) plus 6 proactive telephone counseling sessions; delivered 4 times (at Baseline, 6, 12, and 18 months). 6 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline. Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
11552757|NCT00984724|Experimental|MAPS-12 + NRT|Standard Treatment (ST) plus 12 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 12 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline. Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
11552758|NCT00984698|Experimental|Structured Therapy|Cognitive Behavioral Social Rhythm Group Therapy is designed to improve mood and sleep by stabilizing social rhythms, increasing exposure to ambient light, changing dysfunctional bed/bedtime associations, activating the imagery system by changing nightmare content, and challenging dysfunctional automatic thoughts that might contribute to behavioral inactivation and nonadherence to the therapy protocol. There is no discussion of past traumatic events.
11552759|NCT00984698|Active Comparator|Unstructured Therapy|Present Centered Group Therapy includes education about the typical symptoms and features associated with PTSD and MDD, with a focus on how these symptoms affect interpersonal relationships. It uses the group format to decrease isolation, normalize symptoms, and provide the experience of giving and receiving support. Some relaxation training is provided early in therapy. There is no discussion of past traumatic events.
11552760|NCT00984685||depression|Patients diagnosed with depression before April 15, 2009
11552761|NCT00984672||Bone morphogenetic protein within an interbody cage|Transforaminal Lumbar Interbody Fusion with the use of BMP
11552762|NCT00984672||Other bone grafting techniques within cage (non-BMP)|Use of iliac crest autograft, allograft, or local autogenous bone grafting within the cage during Transforaminal Lumbar Interbody Fusion.
11552763|NCT00984659|Experimental|FSC|Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day
11552764|NCT00984659|Experimental|SAL|Salmeterol 50mcg DISKUS twice a day
11552765|NCT00984659|Placebo Comparator|Placebo|Placebo DISKUS twice a day
11552766|NCT00984646|Experimental|Intradermal Prevascar|
11552767|NCT00984646|Placebo Comparator|Placebo (vehicle)|
11552768|NCT00984633|Experimental|0.6 mg/kg intubation dose + sevoflurane|
11552769|NCT00984633|Experimental|0.9 mg/kg intubation dose + sevoflurane|
11552770|NCT00984633|Experimental|0.6 mg/kg intubation dose + propofol|
11552771|NCT00984633|Experimental|0.9 mg/kg intubation dose + propofol|
11552772|NCT00984620|Experimental|short arm|patients to receive BI201335 with PegIFN/RBV for 12 wks followed by 12 weeks PegIFN/RBV with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)
11552773|NCT00984620|Experimental|long arm|patients to receive BI201335 with PegIFN/RBV for 24 wks with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)
11552774|NCT00984607|Experimental|barium sulfate tablet|After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring.
11552775|NCT00984594|Other|Primary injury site|CR-Plug will be placed in the site of the primary injury
11552776|NCT00984594|Other|Backfill site|Autograft will be placed in the site of the primary injury; CR Plug will be placed in the harvest site
11552777|NCT00984581|Experimental|Intradermal avotermin|
11552778|NCT00984581|Placebo Comparator|Placebo|
11552779|NCT00984568|Experimental|Top-Hold|Level 1: Infliximab IV 5 mg/kg at Weeks 0, 2, and 6, and every 8 weeks thereafter. Level 2: Infliximab IV 5 mg/kg every 4 weeks. Level 3: Prednisolone induction + AZA 2.0-2.5 mg/kg/day.
11552780|NCT00984568|Active Comparator|Step-Up|Level 1: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral 5-aminosalicylic acid (5-ASA) 2 g/day. Level 2: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral azathioprine (AZA) at a dose of 2.0-2.5 mg/kg/day. Level 3: Infliximab 5 mg/kg at Weeks 0, 2, and 6 and every 8 weeks thereafter.
11552781|NCT00984555||A1 (Inoculation with 7 timepoints)|Semen exposure via inoculation, Vaginal swabs at 7 time points
11552782|NCT00984555||A2 (Inoculation with 4 timepoints)|Semen exposure via inoculation, Vaginal swabs at 4 time points
11552783|NCT00984555||B1 (intercourse with 7 timepoints)|Semen exposure via unprotected intercourse, Vaginal swabs at 7 time points
11552784|NCT00984555||B2 (Intercourse with 4 timepoints)|Semen exposure via unprotected intercourse, Vaginal swabs at 4 time points
11552785|NCT00984542|Experimental|Bendamustine|
11552786|NCT00984529||1|Cardiologist´s office patients
11552787|NCT00984516|Experimental|Intradermal Juvidex|
11552788|NCT00984516|Placebo Comparator|Placebo (vehicle)|
11552789|NCT00984503|Experimental|Intradermal Juvista|
11552790|NCT00984503|Placebo Comparator|Placebo|
11552791|NCT00984503|Experimental|Intradermal and topical Juvista|
11552792|NCT00984503|Placebo Comparator|Intradermal and topical placebo|
11552793|NCT00984490|Experimental|Metformin|Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery
11552794|NCT00984477|Experimental|1|AZD5122 oral suspension (part A and B)
11552795|NCT00984477|Placebo Comparator|2|Placebo oral suspension (part A)
11552796|NCT00984477|Experimental|3|AZD5122 oral and IV infusion (part B)
11552797|NCT00984438|Experimental|BCNU wafter followed by chemotherapy|Surgical Implantable BCNU wafer followed by Chemotherapy with Irinotecan and Bevacizumab for up to one year
11552798|NCT00984425|Experimental|Lapatinib and Sorafenib 1° level of dose|Lapatinib 750 mg/die + Sorafenib 200 mg bid
11552799|NCT00984425|Experimental|Lapatinib and Sorafenib 2° level of dose|2° level (II cohort): Lapatinib 1000 mg/die + Sorafenib 200 mg bid
11552800|NCT00984425|Experimental|Lapatinib and Sorafenib 3° level of dose|3° level (III cohort): Lapatinib 1000 mg/die + Sorafenib 400 mg bid
11552801|NCT00984425|Experimental|Lapatinib and Sorafenib 4° level of dose|4° level (IV cohort): Lapatinib 1250 mg/die + Sorafenib 400 mg bid
11552802|NCT00984412|Experimental|AATT|
11552803|NCT00984399|Experimental|vaginal 17β-estradiol, questionnaire , symptom checklist|This is a prospective longitudinal pilot study, and the targeted patient population is postmenopausal women with breast cancer being treated with adjuvant aromatase inhibitors who are initiated on vaginal 17β-estradiol to relieve symptoms of atrophic vaginitis.
11552804|NCT00984386|Experimental|Intradermal Zesteem|
11552805|NCT00984386|Placebo Comparator|Placebo|
11552806|NCT00984360|Experimental|A118G|
11552807|NCT00984360|Experimental|Wild-type|
11552808|NCT00984347|Active Comparator|Oxytocin induction|women in need for induction of labor due to medical indications, will receive continuous IV oxytocin
11552809|NCT00984347|Active Comparator|Breast Stimultion|nipple stimulation with a breast pump, calibrated at the lowest suction strength,operated alternately: 15 min one breast, 15 min second breast, 15 min rest, till appearance of regular uterine contractions (3 contractions in 10 min). the manipulation will continue for 3 hours of regular contractions.
11552810|NCT00984334|Placebo Comparator|Capsules with no active drug|Placebo capsules once daily for three weeks then twice daily for three weeks.
11552811|NCT00984334|Active Comparator|Naloxone SR 2.5 mg capsules|Naloxone SR 2.5 mg capsules once daily for three weeks then twice daily for three weeks.
11552812|NCT00984334|Experimental|Naloxone SR 10mg capsules|Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
11552813|NCT00984334|Experimental|Naloxone SR 20 mg capsules|Two Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
11552814|NCT00984334|Experimental|Naloxone SR 5mg capsules|Naloxone SR 5 mg capsules once daily for three weeks then twice daily for three weeks.
11552815|NCT00984321|Experimental|Psychoeducational Intervention Group|
11552816|NCT00984321|Experimental|Expressive Writing Intervention|
11552817|NCT00984321|Active Comparator|Control Group|
11552818|NCT00984308|Experimental|Intervention|The intervention group received unattended polysomnography and auto-titrating CPAP if sleep apnea was diagnosed
11552819|NCT00984308|Other|Control|The control group received usual clinical care which may include receipt of sleep diagnostic and therapeutic services
11552820|NCT00984295|Experimental|1|ProQuad + Tripedia + Comvax at Day 0 (Concomitant)
11552821|NCT00984295|Experimental|2|ProQuad at Day 0, Tripedia + Comvax at Day 42(Nonconcomitant)
11552822|NCT00984295|Active Comparator|3|Varivax + M-M-R II at Day 0, Tripedia + Comvax at Day 42 (Control)
11552823|NCT00984282|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (12 hours apart without food), 28 days comprise a cycle
11552824|NCT00984282|Placebo Comparator|Placebo|Participants received 2 tablets of Sorafenib-matching placebo orally twice daily (12 hours apart without food), 28 days comprise a cycle
11552825|NCT00984269|No Intervention|No Tourniquet|Patients undergoing hand/wrist surgery without the use of a tourniquet.
11552826|NCT00984269|Experimental|Tourniquet|Patients undergoing hand/wrist surgery with the use of a tourniquet.
11552827|NCT00984256|Experimental|Drug|"5 groups, each group receiving Malarone tablet(s) (250/100mg)prior to challenge.
~Group 1 - 1 tablet 1 day before challenge Group 2 - 1 tablet 4 days before challenge Group 3 - 1 tablet 7 days before challenge Group 4 - 2 tablets 7 days before challenge Group 5 - 4 tablets 7 days before challenge"
11552828|NCT00984256|Placebo Comparator|Control -no prophylaxis|
11552829|NCT00984243|Experimental|Photodynamic Therapy|PHOTODYNAMIC THERAPY (PDT)
11552830|NCT00984230|No Intervention|Breastfeeding (Reference)|
11552831|NCT00984230|Active Comparator|Basic starter formula: BSF|
11552832|NCT00984230|Experimental|BSF + Lactoferrin + Probiotics + OS|
11552833|NCT00984230|Experimental|BSF + Lactoferrin + Probiotics|
11552834|NCT00984217|Experimental|Panitumumab|Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-8 doses).
11552835|NCT00984204|Experimental|Treatment arm|
11552836|NCT00984191|Experimental|99mTc positive|99mTechnetium-MIBI SPECT-CT positive compare : Scan - Pathologic report
11552837|NCT00984191|Experimental|99mTc Negative_Neck dissection|99mTc Negative but have neck dissection indication compare : 99mTc - Pathologic report
11553063|NCT00982657|Experimental|Expanded cohort|CVX-060 + sunitinib
11552838|NCT00984191|Experimental|99mTc Negative_No neck dissection|99mTc Negative and No other indication for neck dissection compare : 99mTc - 7. 131I (post-treatment) whole body scan
11552839|NCT00984178|No Intervention|Control group|standard treatment
11552840|NCT00984178|Experimental|Bone marrow mononuclear progenitors|intracoronary transplantation of bone-marrow mononuclear progenitor cells
11552841|NCT00984178|Experimental|GCSF|progenitor cells mobilization through Granulocite- Colony Stimulating Factor treatment (G-CSF)
11552842|NCT00984178|Experimental|GCSF plus bone marrow mononuclear cells|combined treatment (intracoronary transplantation plus cell mobilization with G-CSF).
11552843|NCT00984165|Experimental|Donor Lymphocyte Infusion/Radiation|Subjects will receive a unmanipulated donor lymphocyte infusion (DLI) on Day 1 after radiation (single, 8-Gy fraction to the maximum number of lesions).
11552844|NCT00984165|Active Comparator|Radiation/No Donor Lymphocyte Infusion|Subjects will receive radiation (single, 8-Gy fraction to the maximum number of lesions).
11552845|NCT00984165|Active Comparator|Donor Lymphocyte Infusion - Control|Subjects will receive a unmanipulated donor lymphocyte infusion (DLI) on Day 0.
11552846|NCT00984165|Active Comparator|Donor Lymphocyte Infusion - Donor|Healthy subjects who donated lymphocytes for infusion on a treatment Arm.
11552847|NCT00984152|Active Comparator|1|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
11552848|NCT00984152|Active Comparator|2|TDF/FTC + Efavirenz (Atripla) Once-Daily
11552849|NCT00984139|Experimental|Engerix-B Group|Subjects who were vaccinated with 3 doses of Engerix-B in infancy and who received a single challenge dose of Engerix-B , intramuscularly in the deltoid region of the non-dominant arm, at 12-13 years of age (Day 0).
11552850|NCT00984126|Experimental|Turoctocog alfa|
11552851|NCT00984113|Experimental|A-Patients with mild renal impairment|
11552852|NCT00984113|Experimental|B-Healthy subjects matched to Group A|
11552853|NCT00984113|Experimental|C-Patients with moderate renal impairment|
11552854|NCT00984113|Experimental|D-Healthy subjects matched to Group C|
11552855|NCT00984113|Experimental|E-Patients with severe renal impairment|
11552856|NCT00984113|Experimental|F-Healthy subjects matched to Group E|
11552857|NCT00984100|Experimental|Notes Transvaginal Cholecystectomy|Patients who undergo a NOTES Transvaginal cholescystectomy.
11552858|NCT00984087|Experimental|Active rTMS treatment|
11552859|NCT00984061|Experimental|colchicine alone|colchicine baseline pharmacokinetics
11552860|NCT00984061|Experimental|colchicine with clarithromycin|colchicine pharmacokinetics in presence of clarithromycin
11552861|NCT00984048||FOLFOX, XELOX or FOLFIRI +/- bevacizumab|Patients are scheduled to receive first-line treatment for metastatic disease. They should be receiving at least one component of either FOLFOX, XELOX or FOLFIRI regimen with or without bevacizumab.
11552862|NCT00984035||Prospecitive Analysis|Patients currently receiving cisplatin as treatment for their cancer.
11552863|NCT00984035||Restrospective Analysis|Patients that have previously received cisplatin as treatment for their cancer.
11552864|NCT00984022|Active Comparator|Iodoform dressing|Iodoform dressing for cutaneous abscess
11552865|NCT00984022|Active Comparator|Aquacel dressing|Aquacel dressing for cutaneous abscess
11552866|NCT00984009|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
11552867|NCT00984009|Experimental|Colchicine with Grapefruit Juice|colchicine pharmacokinetics in presence of grapefruit juice
11552868|NCT00983996|Experimental|1|Alendronate Sodium Tablets, 10 mg
11552869|NCT00983996|Active Comparator|2|Fosamax Tablets, 10 mg
11552870|NCT00983983|Experimental|High fat/high calorie|High fat/high calorie diet: Oxepa
11552871|NCT00983983|Active Comparator|High calorie|High calorie diet: Jevity 1.5
11552872|NCT00983983|Placebo Comparator|Control|Control diet: Jevity 1.0
11552873|NCT00983970|Experimental|Interactive video cycling|Interactive video cycling arm utilized the Gamebike that interfaced a Sony Play Station 2 with a stationary bicycle and a 42 inch flat screen TV. The Gamebike has a handle bar mounted game controller allowing the participant to play most Sony Play Station 2 raced-based video games. The Gamebike reads the participants' speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks.Participants were told that they could exercise at any intensity or duration that they desired, and reading materials were provided for those who did not chose to exercise for the full 60 minute session.
11552874|NCT00983970|Active Comparator|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device.
11552875|NCT00983957|Experimental|BMS-790052 plus Ortho Tri-Cyclen®|
11552876|NCT00983944|Experimental|Arm I (EPOCH-R)|Patients receive rituximab IV on day 1; etoposide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV continuously over 96 hours on days 1-4; cyclophosphamide IV over 30 minutes on day 5; and oral prednisone twice daily on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11552877|NCT00983944|Experimental|Arm II (R-VACOP-B)|Patients receive rituximab IV and doxorubicin hydrochloride IV on day 1 of weeks 1, 3, 5, 7, 9, and 11; cyclophosphamide IV over 30 minutes on day 1 of weeks 1, 5, and 9; etoposide IV over 1 hour on day 1 and then orally on days 2 and 3 of weeks 3, 7, and 11; bleomycin sulfate IV and vincristine sulfate IV on day 1 of weeks 2, 4, 6, 8, 10, and 12; and oral prednisone on days 1-7 of week 1 and then every other day in weeks 2-10.
11552878|NCT00983931|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
11552879|NCT00983931|Experimental|Colchicine with Cyclosporine|-colchicine pharmacokinetics in presence of cyclosporine
11552880|NCT00983918|Active Comparator|Desflurane|General Anesthesia with Desflurane
11552881|NCT00983918|Active Comparator|Sevoflurane|General Anesthesia with Sevoflurane
11552882|NCT00983918|Active Comparator|Isoflurane|General Anesthesia with Isoflurane
11552883|NCT00983918|Active Comparator|Propofol|General Anesthesia with Propofol
11552884|NCT00983905|Active Comparator|Theophylline alone|baseline theophylline kinetics
11552885|NCT00983905|Experimental|Theophylline with steady-state Colchicine|theophylline pharmacokinetics upon administration with colchicine at steady-state
11552886|NCT00983892|Experimental|CarePartners+|Patients receive automated telephonic symptom assessment and symptom management advice; caregivers receive the intervention (Intervention = access to a caregiver Web site that updates them on patient's symptoms and provides tailored problem solving advice).
11552887|NCT00983892|No Intervention|CarePartners-|Patients receive automated telephonic symptom assessment and symptom management advice; caregivers receive nothing (i.e. no access to the caregiver website, or 'intervention').
11552888|NCT00983866|Experimental|Tailored Telephone Counseling|
11552889|NCT00983866|No Intervention|Standard Trial Recruitment Procedures|
11552890|NCT00983853|Experimental|Part A|The dose of ribavirin used (fixed versus weight-based) is region dependent
11552891|NCT00983853|Experimental|Part B|The dose of ribavirin used (fixed versus weight-based) is region dependent
11552892|NCT00983840|Experimental|Family Eats|8-session program on health eating
11552893|NCT00983840|Active Comparator|Family eats- plain|Family eats without role model stories and goal setting
11552894|NCT00983827|Experimental|Aquatic treadmill training|Aquatic treadmill training (ATT) is a pool-based treadmill training that combines the three concepts of unweighting the body, treadmill training, and the resistance effects of water into one modality.
11552895|NCT00983814|Experimental|Droxidopa+Carbidopa|Droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) in combination with carbidopa (25mg or 50mg TID)
11552896|NCT00983814|Placebo Comparator|Placebo|Placebo
11552897|NCT00983801|Experimental|Ixabepilone|
11552898|NCT00983788|Experimental|Bezafibrate|
11552899|NCT00983788|Placebo Comparator|Placebo|
11552900|NCT00983775|Experimental|healthy low dose insulin|16 healthy non-diabetic volunteers. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight.
11552901|NCT00983775|Experimental|healthy high dose insulin|16 healthy non-diabetic volunteers. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight.
11552902|NCT00983775|Experimental|type 1 diabetes mellitus|16 people with type 1 diabetes mellitus. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight.
11552903|NCT00983762||MIS knee arthroplasty|Persons scheduled for Minimally Invasive Surgery Mini-Incision (MIS) Total Knee Arthroplasty (TKA)
11552904|NCT00983762||Unicompartmental knee arthroplasty|Persons scheduled for Unicompartmental knee arthroplasty
11552905|NCT00983762||Standard knee arthroplasty|Persons scheduled for Standard Para-patellar surgery TKA
11552906|NCT00983762||Heathly knee subjects|Persons with healthy knees
11552907|NCT00983749|Experimental|Full-pressure ECP|"Patients in the Full-pressure ECP arm receive a 1-hour treatment of ECP at full pressure, which will be applied in a tiered, dose-escalating manner up to 300mmHg, while assessments are made."
11552908|NCT00983749|Sham Comparator|Sham-pressure ECP|A 1-hour treatment of ECP at an inactive pressure (75mmHg)
11552909|NCT00983736|Experimental|Active|
11552910|NCT00983736|Placebo Comparator|Placebo|
11552911|NCT00983710|Experimental|1|Participants will receive a new patient education program designed to help men manage side-effects related to treatment for localized prostate cancer. The intervention will be targeted to low health literacy men.
11552912|NCT00983710|Active Comparator|2|Usual care, including a booklet on coping with localized prostate cancer. After the 6-month primary outcome data are collected, control group men will be offered the opportunity to cross-over and receive the new educational intervention.
11552913|NCT00983697|Experimental|FDG PET/CT|Planning for Therapeutic conventional surgery of the N0 neck is documented prior to and immediately after review of the fludeoxyglucose F 18 (FDG)-PET/CT scan completed per protocol.
11552914|NCT00983684|Experimental|Intra-operative radiotherapy|A single fraction of radiotherapy given intra-operatively and targeted to the tissues at the highest risk of local recurrence.
11552915|NCT00983684|Active Comparator|Post-operative radiotherapy|Standard post-operative radiotherapy.
11552916|NCT00983671||children with asthma|children with diagnosed asthma, age 6-18 years
11552917|NCT00983671||cystic fibrosis|children with cystic fibrosis, age 6-18 years
11552918|NCT00983671||chronic lung disease|children with chronic lung disease, also known as bronchopulmonary dysplasia, age 6-18 years
11552919|NCT00983671||pneumonia|children with clinical signs of pneumonia, age 6-18 years
11552920|NCT00983658|Experimental|huMAb OX40L|
11552921|NCT00983658|Placebo Comparator|Placebo|
11552922|NCT00983645|Active Comparator|Neoral|Neoral is a pill indicated for the prophylaxis of organ rejection in kidney transplants
11552923|NCT00983645|Active Comparator|Prograf|Prograf is a medication used for the prophylaxis of rejection in allogeneic kidney transplants and may be used concomitantly with adrenal corticosteroids.
11552924|NCT00983632|Experimental|vagus stimulation|electrical vagus stimulation to X.nerve on neck
11552925|NCT00983619|Experimental|Part A-MEDI-551 0.5 mg/kg|Participants will receive intravenous (IV) infusion of MEDI 551 0.5 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
11552926|NCT00983619|Experimental|Part A-MEDI-551 1 mg/kg|Participants will receive IV infusion of MEDI 551 1 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
11552927|NCT00983619|Experimental|Part A-MEDI-551 2 mg/kg|Participants will receive IV infusion of MEDI 551 2 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
11552928|NCT00983619|Experimental|Part A-MEDI-551 4 mg/kg|Participants will receive IV infusion of MEDI 551 4 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
11553064|NCT00982657|Experimental|Phase II - Arm A|CVX-060 + sunitinib
11552929|NCT00983619|Experimental|Part A-MEDI-551 8 mg/kg|Participants will receive IV infusion of MEDI 551 8 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
11552930|NCT00983619|Experimental|Part A-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI 551 12 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
11552931|NCT00983619|Experimental|Part B-MEDI-551 6 mg/kg|Participants will receive IV infusion of MEDI- 551 6 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
11552932|NCT00983619|Experimental|Part B-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI- 551 12 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
11552933|NCT00983619|Experimental|Part B-MEDI-551 24 mg/kg|Participants will receive IV infusion of MEDI- 551 24 mg/kg weekly for 4 weeks during Cycle 1 (over 2 days on Day 1 and Day 2, and on Days 8, 15, and 22) and thereafter from Cycle 2, on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
11552934|NCT00983619|Experimental|Part C-MEDI-551 8 mg/kg + rituximab|Participants will receive IV infusion of MEDI- 551 8 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg will be administered on Day 1 of each 28-day cycle. The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
11552935|NCT00983619|Experimental|Part C-MEDI-551 12 mg/kg + rituximab|Participants will receive IV infusion of MEDI- 551 12 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg will be administered on Day 1 of each 28-day cycle. The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
11552936|NCT00983619|Experimental|Part D-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and thereafter Day 1 of 28- day cycles from Cycle 2 onwards. Treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches CR or withdraws consent.
11552937|NCT00983606||1|32 to 35 WGA Infants less than six months of age by RSV season peak.
11552938|NCT00983593|Experimental|Group Therapy|Group therapy following the Mind-Body Bridging program.
11552939|NCT00983580|Experimental|Arm I (acetylsalicylic acid and eflornithine)|Patients receive acetylsalicylic acid PO once daily and eflornithine PO twice daily on days 1-28.
11552940|NCT00983580|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO three times daily on days 1-28.
11552941|NCT00983567|Experimental|Teen web|Main web - with all components
11552942|NCT00983567|Active Comparator|Minimal teen web|Teen web minus behavioral components
11552943|NCT00983554|No Intervention|Placebo|
11552944|NCT00983554|Experimental|Anastrazole and Testosterone|
11552945|NCT00983554|Experimental|Dutasteride and Testosterone|
11552946|NCT00983554|Experimental|Testosterone|
11552947|NCT00983541|Experimental|All patients|All participants enrolled.
11552948|NCT00983515|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
11552949|NCT00983515|Experimental|Colchicine with Ritonavir|-colchicine pharmacokinetics in presence of steady-state ritonavir
11552950|NCT00983502||Integrative Medicine|Patients of MD practitioners trained in Complementary and Alternative Medicine
11552951|NCT00983502||Naturopath Doctors|Patients of practitioners who are not MD's and are trained in Naturopathic Medicine
11552952|NCT00983502||Chronic Fatigue Specialists|Patients of MD's who specialize in treating Chronic Fatigue and related conditions
11552953|NCT00983502||Control Group|Patients treated by primary care MDs in practice-based research networks
11552954|NCT00983489|Active Comparator|counselling|counselling: Breast feeding counselling will be done to mothers
11552955|NCT00983489|Active Comparator|Video demonstration|Video demonstration to mothers on the advantages of exclusive breast feeding
11552956|NCT00983489|No Intervention|Standard Care|Standard care includes the routine care provided to the neonates as per hospital protocol
11552957|NCT00983476|Experimental|Arm 1|in-person MOVE! SMI
11552958|NCT00983476|Experimental|Arm 2|web-based MOVE! SMI
11552959|NCT00983476|No Intervention|Arm 3|usual care + educational handouts regarding weight loss
11552960|NCT00983463||Obese, bariatric surgery, liver biopsy|Obese subjects approved and scheduled for bariatric surgery at Vanderbilt University Medical Center
11552961|NCT00983463||Normal BMI, abdominal surgery, liver biopsy|Normal weight subjects having elective abdominal surgery at Vanderbilt University Medical Center.
11552962|NCT00983463||Liver transplantation donors and recipients|All livers made available for implantation or explantation will be eligible.
11552963|NCT00983450|Experimental|study group|People after a first ischemic or hemorrhagic stroke, up to 60 days following the event.
11552964|NCT00983450|Experimental|CONTROL|People after a first ischemic or hemorrhagic stroke, up to 60 days following the event.
11552965|NCT00983437|Experimental|Armodafinil|Armodafinil tablets 150 mg or 250 mg administered orally, once daily in the morning.
11552966|NCT00983424|Experimental|Treatment arm|Cyclosporine A + nab-paclitaxel
11552967|NCT00983411||Healthy and OHS subjects|10 healthy subjects: 20 to 60 years old 10 patients with Obesity hypoventilation syndrome: 20 to 70 years old treated with nocturnal non invasive ventilation for at least three months.
11552968|NCT00983398|Experimental|Treatment (mannitol, melphalan, carboplatin, STS)|Patients receive mannitol IA over 30 seconds, melphalan IA over 10 minutes, and carboplatin IA over 10 minutes. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats every 4-6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
11552969|NCT00983385|Experimental|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol immediate release (IR) tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
11552970|NCT00983372|Active Comparator|Colchicine alone|-colchicine baseline pharmacokinetics
11552971|NCT00983372|Experimental|Colchicine with steady-state Diltiazem|-colchicine pharmacokinetics in presence of steady-state diltiazem
11552972|NCT00983359|Experimental|Treatment (conformal stereotactic radiation therapy)|Patients undergo conformal stereotatic radiation
11552973|NCT00983346|Experimental|All patients|All participants enrolled.
11552974|NCT00983333|Experimental|Web-based communication tool for health care professionals|
11552975|NCT00983333|Experimental|Web-based communication training tool for patients|
11552976|NCT00983333|No Intervention|Usual care for patient participants|
11552977|NCT00983320|Experimental|medication|quetiapine
11552978|NCT00983320|Placebo Comparator|placebo|placebo
11552979|NCT00983307|Experimental|Erlotinib and radiotherapy|Patients will be treated with Erlotinib and hypofractionated radiotherapy.
11552980|NCT00983294|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
11552981|NCT00983294|Experimental|Colchicine with steady-state Azithromycin|colchicine pharmacokinetics in presence of steady-state azithromycin
11552982|NCT00983281||Hextend|Patients that received Hextend as part of their fluid resuscitation.
11552983|NCT00983281||Standard of Care|Patients that received standard fluid resuscitation but no Hextend.
11552984|NCT00983268|Experimental|Treatment Arm|
11552985|NCT00983255|Experimental|SAD/ Part A|Single IV infusions of placebo or TR-701 FA given at 50, 100, 200, and 400 mg.
11552986|NCT00983255|Experimental|MAD / Part B|Multiple IV infusion of placebo or TR-701 FA given daily for 7 days at 200 and 400 mg.
11552987|NCT00983255|Experimental|Bioavailability / Part C|TR-701 FA tablet given once orally as a 200 mg tablet or TR-701 FA for injection given once as a 200 mg IV infusion.
11552988|NCT00983255|Experimental|Venous Tolerability/ Part D|IV infusions of placebo and 200 mg TR-701 FA given daily for 3 days,
11552989|NCT00983242|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
11552990|NCT00983242|Experimental|Colchicine with Verapamil HCl ER|colchicine pharmacokinetics in presence of steady-state verapamil
11552991|NCT00983229|Active Comparator|CTrach|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.
~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.
~Insertion of CTrach (sizes 3,4 or 5), establishment of ventilation.
~Direct evaluation of laryngeal view through CTrach
~Tracheal intubation through CTrach LMA
~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation
~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
11552992|NCT00983229|Active Comparator|Intubating Laryngeal Mask Airway (ILMA)|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.
~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.
~Insertion of ILMA (sizes 3,4 or 5), establishment of ventilation.
~Evaluation of laryngeal view through ILMA using fibrescope
~Tracheal intubation through ILMA using fibrescope.
~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation
~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
11552993|NCT00983229|Active Comparator|I-gel|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.
~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.
~Insertion of I-gel (sizes 3,4 or 5), establishment of ventilation.
~Evaluation of laryngeal view through I-gel using fibrescope
~Tracheal intubation through I-gel using fibrescope
~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation
~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
11552994|NCT00983216|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
11552995|NCT00983216|Experimental|Colchicine with Steady-State Ketoconazole|-colchicine pharmacokinetics in presence of steady-state ketoconazole
11552996|NCT00983203|Experimental|FID 114657|FID 114657
11552997|NCT00983203|Active Comparator|Soothe XP Lubricant Eye Drops|Soothe XP Lubricant Eye Drops
11552998|NCT00983190|Other|Single Group Assignment|
11552999|NCT00983177|Active Comparator|colchicine|
11553000|NCT00983177|Placebo Comparator|Lactose capsule|
11553001|NCT00983164|No Intervention|group I|group I - controls
11553002|NCT00983164|Experimental|group II|group II - patients with hepatitis C without treatment
11553003|NCT00983164|Experimental|group III|group III - patients with hepatitis C treated weekly with pegylated interferon combined with daily ribavirin
11553004|NCT00983151|Experimental|Active|
11553005|NCT00983151|Placebo Comparator|Placebo|
11553006|NCT00983138|Experimental|recombinant asparaginase|
11553007|NCT00983125|Experimental|clonidine|
11553008|NCT00983125|Other|no clonidine|
11553009|NCT00983112|Experimental|Evicel|
11553010|NCT00983112|Placebo Comparator|Placebo|
11553011|NCT00983073|Experimental|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol IR tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
11553012|NCT00983060|Experimental|NIM811|
11553013|NCT00983060|Placebo Comparator|Placebo|
11553014|NCT00983047|Active Comparator|Docetaxel|The chemotherapy treatment:Docetaxel was administered every 3 weeks 75mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\PR\SD. No more than 4 cycles chemotherapy was given.
11553065|NCT00982657|Active Comparator|Phase II - Arm B|sunitinib alone
11553066|NCT00982644|Experimental|IDeg OD|
11553067|NCT00982644|Active Comparator|IGlar OD|
11553015|NCT00983047|Experimental|Nimotuzumab and Docetaxel|"The chemotherapy treatment:Docetaxel was administered every 3 weeks 75mg/m2,efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\PR\SD.No more than 4 cycles chemotherapy was given.
~Nimotuzumab treatment:Dose of 200mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxic."
11553016|NCT00983034|Active Comparator|Membranous nephropathy|Patients with primary membranous nephropathy diagnosed by biopsy
11553017|NCT00983034|Active Comparator|IgA nephropathy|Patients with IgA nephropathy diagnosed by biopsy
11553018|NCT00983034|Active Comparator|Focal segmental glomerulosclerosis|Patients with primary focal segmental glomerulosclerosis diagnosed by biopsy
11553019|NCT00983021|Experimental|A|
11553020|NCT00983021|Experimental|B|
11553021|NCT00983021|Active Comparator|C|
11553022|NCT00983021|Experimental|D|
11553023|NCT00983008|Experimental|Protected Time Group|Interns working 30 hour shifts every 3rd night and an average of 80 hours per week in a medical intensive care unit.
11553024|NCT00982995|Experimental|Palonosetron|Palonosetron 0.25 mg I.V. bolus
11553025|NCT00982982|Active Comparator|THC and Iomazenil|"Iomazenil: 3.7 μg/kg intravenously over 10 minutes
~Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. It is administered intravenously for 10 minutes"
11553026|NCT00982982|Placebo Comparator|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
11553027|NCT00982969||TB suspected|Soldiers who are clinically suspected with tuberculosis
11553028|NCT00982930|Experimental|TIPnew|
11553029|NCT00982917|Experimental|teachers taught curriculum|Teachers taught Stamp-in-Safety curriculum
11553030|NCT00982917|Experimental|teachers do not learn curriculum|Teachers are not taught Stamp-in-Safety curriculum
11553031|NCT00982904|Experimental|Fexinidazole|
11553032|NCT00982904|Placebo Comparator|Placebo|
11553033|NCT00982891|Experimental|Morphine, low dose, in addition to conventional treatment|Morphine dose titration
11553034|NCT00982878|Experimental|Maraviroc|
11553035|NCT00982865|Experimental|MSC1936369B Regimen 1|Subjects will be administered MSC1936369B (pimasertib) capsules 1 to 120 milligram (mg) orally, once daily (QD) on Days 1 to 5, 8 to 12, 15 to 19 of each 21-day treatment cycle until progressive disease (PD) or intolerable toxicity or investigator/subject decision.
11553036|NCT00982865|Experimental|MSC1936369B Regimen 2|"MSC1936369B Regimen 2 (Without Food Effect): Subjects will be administered MSC1936369B capsules 1 to 255 mg orally QD on Days 1 to 15 of each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.
~MSC1936369B Regimen 2 (With Food Effect): : Subjects will be administered MSC1936369B capsules 90 or 150 mg orally QD on Day 1 to 15 of each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision. Subjects in the Regimen 2 FE cohort were assigned in a 1:1 ratio to either the fed/fasted sequence or fasted/fed sequence for Day 1 of Cycle 1 and Day 1 of Cycle 2."
11553037|NCT00982865|Experimental|MSC1936369B Regimen 3 once daily|Subjects will be administered MSC1936369B capsules 60 to 90 mg orally QD in each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.
11553038|NCT00982865|Experimental|MSC1936369B Regimen 3 twice daily (BID)|Subjects will be administered MSC1936369B capsules 45 to 75 mg orally BID in each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.
11553039|NCT00982852||Acute|Patients in acute need for angioplasty or left heart catheterization.
11553040|NCT00982852||Chronic or non-acute|Patients will planned angioplasty or left heart catheterization.
11553041|NCT00982839|Active Comparator|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
11553042|NCT00982839|Experimental|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
11553043|NCT00982826|Experimental|1|ABT-072 tablet single ascending dose
11553044|NCT00982826|Experimental|2|Placebo tablet
11553045|NCT00982826|Experimental|3|ABT-072 tablet administered under non-fasting conditions.
11553046|NCT00982826|Experimental|4|ABT-072 tablet administered under fasting conditions
11553047|NCT00982826|Experimental|5|ABT-072 tablet multiple ascending dose
11553048|NCT00982800|Placebo Comparator|Placebo Sugar Pill|"Patients are stratified based on their initial pain score in the recovery room. patients with a pain numeric rating scale of greater than or equal to 7/10 are stratified to the high group. then randomized to receive gabapentin 200 mg tid x 9 doses, or placebo x 9 doses. Patients with a pain score equal to or less than 6/10 are stratified to the low group, then randomized to receive gabapentin 200mg tid x 9 doses or placebo x 9 doses.
~All patients receive Acetaminophen 1gm every 6 hours for 3 days, Celecoxib 400mg as a loading dose then 200mg twice a day for 3 days. Patients also receive patient controlled analgesia (PCA) of hydromorphone for 24 hrs, then are transitioned to oxycodone 5-15 mg every 2 hours as needed."
11553049|NCT00982800|Active Comparator|Gabapentin 200 mg tid x 9 doses|
11553050|NCT00982787|Experimental|1|
11553051|NCT00982787|Placebo Comparator|2|
11553052|NCT00982748|Active Comparator|Group B|Study participants in this arm attend yoga breathing classes once per week over the span of one chemotherapy cycle.
11553053|NCT00982748|Experimental|Group A|Participants in this study arm attend weekly yoga breathing classes during two consecutive cycles of chemotherapy
11553054|NCT00982722|Experimental|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2
11553055|NCT00982722|Active Comparator|calciumcarbonate|calcium carbonate 500 mg x 2
11553056|NCT00982709|Active Comparator|Exercise Types|comparing two different exercise programs for PD
11553057|NCT00982696|Experimental|Single Arm|Opioid Growth Factor (OGF)
11553058|NCT00982670||Systemic lupus erythematosus|Patients should fulfill the diagnostic criteria of the 1997 American College of Rheumatology for systemic lupus erythematosus
11553059|NCT00982670||Normal control|Age- and sex-matched health volunteers will serve as controls.
11553060|NCT00982657|Experimental|Cohort 1|CVX-060 + sunitinib
11553061|NCT00982657|Experimental|Cohort 2|CVX-060 + sunitinib
11553062|NCT00982657|Experimental|Cohort 3|CVX-060 + sunitinib
11553068|NCT00982631|Experimental|temsirolimus/PLD|temsirolimus (Torisel) with pegylated liposomal doxorubicin (PLD,Doxil,Caelyx);a dose escalating study in a 3+3 design
11553069|NCT00982618|Experimental|LIDOCAINE group|LIDOCAINE group : Beside general anesthesia, patients will receive intravenous lidocaine bolus 1.5 mg/kg just prior induction and an infusion of lidocaine 2mg/kg/h will be started and maintained during the whole surgical procedure. Entering the recovery room, this infusion will be decreased at the rate of 1mg/kg/hour for the 48 first hours
11553070|NCT00982618|Experimental|Epidural Group|Epidural Group: Beside general anesthesia, patient will receive epidural freezing medication for 48 hours.
11553071|NCT00982618|Active Comparator|PCA group|Beside general anesthesia, the patients will receive neither lidocaine nor epidural catheter. The patients will receive the same analgesia protocol consisting of PCA morphine for a total duration of 48 hours.
11553072|NCT00982605||non small cell lung cancer|cancer patients
11553073|NCT00982592|Experimental|Arm I (FOLFOX regimen and placebo)|Patients receive FOLFOX chemotherapy comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil bolus and then IV over 46-48 hours on day 1. Patients also receive placebo PO QD on days 1-14. Courses repeat every 2 weeks in the absence of unacceptable toxicity or disease progression.
11553074|NCT00982592|Experimental|Arm II (FOLFOX regimen and vismodegib)|Patients receive FOLFOX chemotherapy as in arm I. Patients also receive vismodegib PO on days 1-14. Courses repeat every 2 weeks in the absence of unacceptable toxicity or disease progression.
11553075|NCT00982579|Experimental|Vaccinees|Vaccinated at 20 weeks of age (n=24)
11553076|NCT00982579|No Intervention|Controls|No experimental vaccine (n=24)
11553077|NCT00982566|Experimental|Sequence I|
11553078|NCT00982566|Experimental|Sequence II|
11553079|NCT00982566|Experimental|Sequence III|
11553080|NCT00982566|Experimental|Sequence IV|
11553081|NCT00982566|Experimental|Sequence V|
11553082|NCT00982566|Experimental|Sequence VI|
11553083|NCT00982566|Experimental|Sequence VII|
11553084|NCT00982566|Experimental|Sequence VIII|
11553085|NCT00982566|Experimental|Sequence IX|
11553086|NCT00982566|Experimental|Sequence X|
11553087|NCT00982566|Experimental|Sequence XI|
11553088|NCT00982566|Experimental|Sequence XII|
11553089|NCT00982566|Experimental|Sequence XIII|
11553090|NCT00982566|Experimental|Sequence XIV|
11553091|NCT00982566|Experimental|Sequence XVI|
11553092|NCT00982566|Experimental|Sequence XV|
11553093|NCT00982553|Experimental|Phase 1_ribavirin|Treatment with Single dose ribavirin (800 mg) administered on day 1
11553094|NCT00982553|Experimental|Phase2_raltegravir|Treatment with Raltegravir (400 mg twice daily) administered from days 15-19
11553095|NCT00982553|Experimental|Phase3_ribavirin+raltegravir|Treatment with Ribavirin (800 mg) and Raltegravir (400 mg) administered day 20
11553096|NCT00982540|No Intervention|preemptive|Patients with persistent fever and neutropenia despite appropriate antibacterial therapy
11553097|NCT00982527|Placebo Comparator|Placebo|Saline blinded infusion
11553098|NCT00982527|Active Comparator|Fenoldopam|Drug infusion
11553099|NCT00982514||Standard dose asparaginase|Children who according to the protocol NOPHO ALL 2008 receive standard dose asparaginase
11553100|NCT00982514||Reduced dose asparaginase|Children who receive reduced dose asparaginase according to NOPHO ALL 2008
11553101|NCT00982501|Experimental|WS® 1442 900 mg|
11553102|NCT00982501|Experimental|WS® 1442 1800 mg|
11553103|NCT00982501|Active Comparator|Nordic walking training 2x30 min|
11553104|NCT00982501|Active Comparator|Nordic walking training 4x45 min|
11553105|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Chronic phase|Participants with chronic phase disease continued on the previous study dose of dasatinib, ranging from 50 mg once daily (QD) to 120 mg twice daily (BID).
11553106|NCT00982488|Other|Imatinib, 400 mg BID, Chronic phase|Participants with chronic phase disease received 400 mg of imatinib twice BID.
11553107|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, AP|Participants with advanced phase disease, accelerated phase (AP), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
11553108|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, MBP|Participants with advanced phase disease, myeloid blast cell (MBP), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
11553109|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, Ph+ ALL|Participants with advanced phase disease, Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
11553110|NCT00982475|Active Comparator|PVI with robotic navigation|
11553111|NCT00982475|Placebo Comparator|PVI manually|
11553112|NCT00982462|Placebo Comparator|Corn oil placebo|Micro-encapsulated powder containing corn oil placebo.
11553113|NCT00982462|Experimental|Long-chain polyunsaturated fatty acids|Micro-encapsulated powder containing 1:1 ratio of the omega-3 long-chain polyunsaturated fatty acids, docosahexaenoic acid (DHA) and the omega-6 fatty acid, arachidonic acid (ARA) from algal and fungal sources, respectively.
11553114|NCT00982449|Active Comparator|4 mCi of I-FIAU|GROUP B 1-3 days after any chemotherapy that may activate viral TK, 4 mCi of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT-4.
11553115|NCT00982449|Active Comparator|2 mCi of I-FIAU|GROUP A 1-3 days after any chemotherapy that may activate viral TK, 2 mCi of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT-2.
11553116|NCT00982436|Experimental|Neoadjuvant/Concomitant Chemoradiation|Three cycles of docetaxel/carboplatin neoadjuvant chemotherapy followed by chemoradiotherapy for 7 weeks with weekly carboplatin
11553117|NCT00982423|Experimental|Furosemide|Subjects received their clinically prescribed dose of furosemide for a 3 week stabilization period, then were assessed for cardiorenal and humoral function. Subjects then had a 50% reduction of the furosemide dose for a 3 week stabilization period, and were assessed for cardiorenal and humoral function again.
11553118|NCT00982410|Experimental|Arm 1|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
11553119|NCT00982410|Placebo Comparator|Arm 2|educational supportive group
11553120|NCT00982397|Experimental|Single-chamber detetction|Patients implanted with a Protecta VR-ICD.
11553121|NCT00982397|Experimental|Dual-chamber detection|Patients implanted with a Protecta DR-ICD or CRT-D.
11553122|NCT00982384|Experimental|Disease management|Comprehensive disease management in addition to best care according to clinical guidelines for COPD patients
11553123|NCT00982384|Active Comparator|Best care|Best care according to clinical guidelines for COPD patients
11553124|NCT00982371||Controls|female; >65 years old; BMI >25kg/m2; postmenopausal >5 yrs; NO clinical diagnosis of type 2 diabetes for >5 years (according to Canadian Diabetes Association criteria)
11553125|NCT00982371||Type 2 Diabetes|female; >65 years old; BMI >25kg/m2; postmenopausal >5 yrs; clinical diagnosis of type 2 diabetes for >5 years (according to Canadian Diabetes Association criteria)
11553126|NCT00982358|Placebo Comparator|Placebo|
11553127|NCT00982358|Active Comparator|Valsartan|
11553128|NCT00982345|Other|Open label Quetiapine|Open-label Quetiapine XL 50 - 400 mg daily treatment 8 weeks
11553129|NCT00982332|Active Comparator|betamethasone|patients treated with a single intramuscular injection of betamethasone
11553130|NCT00982332|Placebo Comparator|isotonic sodium chloride solution|
11553131|NCT00982319|Experimental|Broccoli sprout extract|Patients will be randomized to 14 day intervention of broccoli sprout extract and mango juice consisting of a dose of 100 µmols of sulforaphane dissolved in 150 mL mango juice once a day.
11553132|NCT00982319|Placebo Comparator|Mango juice|Patients will be randomized to 14 day intervention of 150 mL mango juice without broccoli sprout extract extract once a day.
11553133|NCT00982293|Active Comparator|Active fields|
11553134|NCT00982293|Sham Comparator|Inactive device|"Placebo treated group, will receive the 3 times weekly for 13 weeks (39) sessions, however, the device will not be on."
11553135|NCT00982280|Experimental|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol IR tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
11553136|NCT00982267|Experimental|SU014813|
11553137|NCT00982254|Experimental|Oral Insulin|oral insulin capsule formulation
11553138|NCT00982254|Active Comparator|Subcutaneous Insulin|Subcutaneous injection of regular human insulin
11553139|NCT00982241|Active Comparator|normal fluid intake|1500 ml /day (+/- 300 ml) for 2,5 days
11553140|NCT00982241|Active Comparator|high fluid intake|2400 ml/day (+/- 300 ml )for 2,5 days
11553141|NCT00982241|Active Comparator|low fluid intake|fluid intake 900 ml/day (+/- 300ml) for 2,5 days
11553142|NCT00982228|Experimental|IDeg OD|
11553143|NCT00982228|Active Comparator|IGlar OD|
11553144|NCT00982202|Experimental|PGZ|
11553145|NCT00982202|Placebo Comparator|Placebo|
11553146|NCT00982189|Experimental|Lisinopril|Lisinopril 10mg once daily
11553147|NCT00982189|Placebo Comparator|Lisinopril Placebo|Placebo pill (matched to lisinopril) once daily
11553148|NCT00982189|Experimental|Pravastatin|Pravastatin 20mg once daily
11553149|NCT00982189|Placebo Comparator|Pravastatin placebo|Placebo pill (matched to pravastatin) once daily
11553150|NCT00982176||1|
11553151|NCT00982150|Experimental|Talampanel|Talampanel 50mg tid
11553152|NCT00982137|Experimental|ChimeriVax™-JE then STAMARIL®|Participants will receive ChimeriVax™-JE on Day 0 and STAMARIL® on Day 30
11553153|NCT00982137|Experimental|STAMARIL® then ChimeriVax™-JE|Participants will receive STAMARIL® on Day 0 and ChimeriVax™-JE on Day 30
11553154|NCT00982137|Experimental|ChimeriVax™-JE and STAMARIL®, then Diluent|Participants will receive ChimeriVax™-JE and STAMARIL® on Day 0 and diluent on Day 30.
11553155|NCT00982137|Experimental|Diluent then ChimeriVax™-JE and STAMARIL®|Participants will receive Diluent on Day 0 and ChimeriVax™-JE and STAMARIL® on Day 30.
11553156|NCT00982124|Experimental|Treatment Arm (only)|Zoledronic acid infusion
11553157|NCT00982111|Experimental|Necitumumab + Pemetrexed + Cisplatin|Necitumumab + Pemetrexed + Cisplatin
11553158|NCT00982111|Active Comparator|Pemetrexed + Cisplatin|Pemetrexed + Cisplatin
11553159|NCT00982098|Experimental|Early Rehabilitation|"Before surgery: 15 minutes pelvic floor muscle training and 15 minutes biofeedback, for 4 sessions.
~After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).
~Patients will be instructed to carry on exercises at home for the following 11 months."
11553160|NCT00982098|No Intervention|Counseling and home-based exercises|"Before surgery: 15 minutes pelvic floor muscle training and 15 minutes biofeedback, for 4 sessions.
~After surgery: Patients will be instructed to carry on pelvic floor exercises at home for the year after prostatectomy."
11553161|NCT00982085||Soldiers|Soldiers: The soldiers who respond the questionnaires
11553162|NCT00982072|Active Comparator|prednisolone|prednisolone tablets
11553163|NCT00982072|Experimental|tacrolimus|tacrolimus tablets
11553164|NCT00982059||All|All patients enrolled in the study will be undergoing the same procedures.
11553165|NCT00982046|Active Comparator|ACUVUE OASYS|Acuvue Oasys contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
11553166|NCT00982046|Active Comparator|AIR OPTIX AQUA|Air Optix Aqua contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
11553167|NCT00982046|Active Comparator|Biofinity|Biofinity contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
11553222|NCT00981669|Placebo Comparator|placebo|3 doses with 6 weeks interval
11553168|NCT00982033|Active Comparator|Aliskiren|50 % of subjects participating in this trial will be on the active medication, Aliskiren 300mg qd, the other 50% will be on placebo.
11553169|NCT00982033|Placebo Comparator|Placebo|50% of subjects will be randomized to placebo.
11553170|NCT00982020|Experimental|Olanzapine/standard behavioral weight intervention|
11553171|NCT00982020|Experimental|Olanzapine/intense behavioral weight intervention|
11553172|NCT00982007|Experimental|Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)|Intravenous (IV) iron
11553173|NCT00982007|Active Comparator|Cohort 1 (Group B) - Ferrous Sulfate|Oral iron - Ferrous Sulfate tablets
11553174|NCT00982007|Active Comparator|Cohort 2 (Group D) - IV Iron (standard of care)|Other IV iron
11553175|NCT00982007|Experimental|Cohort 2 (Group C) - Ferric Carboxymaltose (FCM)|Intravenous (IV) iron
11553176|NCT00981994|Experimental|Electronic Decision Support|Use of electronic decision support to provide the treatment algorithm for providers managing patients with acute respiratory infections.
11553177|NCT00981994|Experimental|Paper Decision Support|Use of paper based tools to provide the treatment algorithm for providers managing patients with acute respiratory infections.
11553178|NCT00981994|No Intervention|Usual Care|Usual Care
11553179|NCT00981981|Placebo Comparator|Control|Wheat bran cereal
11553180|NCT00981981|Active Comparator|3g high MW|Cereal containing 3g high molecular weight oat beta glucan
11553181|NCT00981981|Active Comparator|4g medium MW|Cereal containing 4g oat beta glucan with medium molecular weight
11553182|NCT00981981|Active Comparator|3g medium MW|Cereal containing 3g oat beta glucan with medium molecular weight
11553183|NCT00981981|Active Comparator|4g low MW|Cereal containing 4g oat beta glucan with low molecular weight
11553184|NCT00981968|Experimental|Japanese Cohort|Single and multiple oral doses of sitaxentan sodium or placebo in 12 healthy subjects.
11553185|NCT00981968|Experimental|Western Cohort|Single oral dose of sitaxentan sodium in 10 healthy subjects.
11553186|NCT00981955|Active Comparator|75mg caffeine|
11553187|NCT00981955|Active Comparator|50mg l-theanine|
11553188|NCT00981955|Active Comparator|75mg caffeine and 50mg l-theanine|
11553189|NCT00981955|Placebo Comparator|0mg caffeine/l-theanine|
11553190|NCT00981929|Active Comparator|Tramadol|CYP2D6 metric
11553191|NCT00981929|Active Comparator|Omeprazole, losartan, caffeine|CYP2C19, CYP2C9 and CYP1A2 metrics
11553192|NCT00981929|Active Comparator|Tramadol, omeprazole, losartan and caffeine|CYP2D6, CYP2C19, CYP2C9 and CYP1A2 metrics
11553193|NCT00981903|Experimental|VTE Treatment Group|
11553194|NCT00981903|No Intervention|Control|
11553195|NCT00981890|Experimental|Sunitinib|
11553196|NCT00981877|Active Comparator|1|This group will receive S. Boulardii Probiotic and Oral rehydration as needed
11553197|NCT00981877|Active Comparator|2|This group will receive a mixed Probiotic preparation and oral rehydration as needed
11553198|NCT00981877|Placebo Comparator|3|This group will receive a placebo, and oral rehydration as needed
11553199|NCT00981864|Experimental|Concurrent Boost RT|
11553200|NCT00981851|Active Comparator|beta 2 agonist + anticholinergic aerosol|
11553201|NCT00981851|Placebo Comparator|placebo inhalation|
11553202|NCT00981838|Experimental|1|Rituximab (375 mg/m2).
11553203|NCT00981825|Placebo Comparator|A|fluoride toothpaste control
11553204|NCT00981825|Active Comparator|B|triclosan/fluoride toothpaste
11553205|NCT00981812|Experimental|PEM Breast Biopsy|All patients underwent PEM biopsy.
11553206|NCT00981799|Experimental|Nelarabine Dose Level 1|The study will begin at Dose Level 1 at 480 mg/m2 Nelarabine (75% of single agent maximum tolerated dose) and 330 mg/m2 Cyclophospamide and will escalate to the next Dose Level if the maximum tolerated dose (MTD) is not exceeded. The first 3 patients will be enrolled into Dose Level 1. If 0/3 experiences dose limiting toxicity (DLT) at a given dose level, then the dose is escalated to the next higher level and 3 more patients are enrolled. If 1/3 experiences DLT at current dose, the up to 3 more patients are accrued at the same dose level. If 2 or more DLTs are observed in a 3-patient or 6-patient cohort at a given dose level, then the MTD has been exceeded, dose escalation will be stopped, and up to 3 additional patients will be enrolled at the next lower dose level (unless 6 patients have already been treated at that prior dose). If the MTD is exceeded at Dose Level 0, the study will be closed.
11553207|NCT00981799|Experimental|Nelarabine Dose Level 2|Patients in this arm will be administered Nelarabine at 650 mg/m2 (100% of single agent MTD) and 330 mg/m2 Cyclophosphamide.
11553208|NCT00981799|Experimental|Nelarabine Dose Level 3|Patients in this arm will be administered Nelarabine at 650 mg/m2 (100% of single agent MTD) and 400 mg/m2 Cyclophosphamide
11553209|NCT00981799|Experimental|Nelarabine Dose Level 0|Patients in this arm will be administered Nelarabine 325 mg/m2 (50% of single agent MTD) and 330 mg/2 Cyclophosphamide. Patients will only enter this arm if the MTD at Dose Level 1 has been exceeded. If the MTD is exceeded at Dose Level 0, the study will be closed.
11553210|NCT00981786|Active Comparator|Brinzolamide/Timolol therapy|Chronic therapy for 3 months with brinzolamide/timolol drops given twice daily added to travoprost drops
11553211|NCT00981786|Active Comparator|Brimonidine/Timolol therapy|Chronic therapy for 3 months with brimonidine/timolol drops given twice daily added to travoprost drops
11553212|NCT00981773|Experimental|Immediate switch|"Continue current boosted protease inhibitor
~Switch NRTI backbone to maraviroc 150 mg bid"
11553213|NCT00981773|Active Comparator|Continue current antiretroviral therapy|Continue current antiretroviral regimen until week 12 then switch therapy as per arm 1.
11553214|NCT00981747|Experimental|All study participants|Study participants are patients that have been diagnosed with idiopathic pulmonary fibrosis (IPF).
11553215|NCT00981721|Experimental|1|cediranib 20mg
11553216|NCT00981721|Experimental|2|cediranib 30mg
11553217|NCT00981708|Experimental|Treatment|Lenalidomide, Dexamethasone and cyclophosphamide
11553218|NCT00981695|Experimental|Vaccinees|18 breast-fed and 18 formula-fed infants at the age of 20 weeks
11553219|NCT00981695|No Intervention|Controls|18 breast-fed and 18 formula-fed infants at the age of 20 weeks
11553220|NCT00981682|Experimental|SER120 (desmopressin)|
11553221|NCT00981669|Experimental|rotavirus vaccine|3 doses with 6 weeks interval
11553380|NCT00980486||BMI 30-39|BMI 30-39
11553223|NCT00981656|Experimental|TURBT + Concurrent RT + Chemotherapy|Transurethral resection of the bladder tumor (TURBT) + Concurrent Radiation Therapy (RT) + Chemotherapy
11553224|NCT00981643|Experimental|Multiple Sclerosis, Meditation group|Multiple Sclerosis, Meditation instruction and practice group
11553225|NCT00981643|No Intervention|Multiple Sclerosis, Control group|Multiple Sclerosis, Control group
11553226|NCT00981643|Experimental|Peripheral Neuropathy, Meditation group|Peripheral Neuropathy, Meditation instruction and practice group
11553227|NCT00981643|No Intervention|Peripheral Neuropathy, Control group|Peripheral Neuropathy, Control group
11553228|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 1|Participants received ChimeriVax™-JE (Japanese Encephalitis) a dose of 3.0 log10 Plaque-forming units (PFU) on Day 0.
11553229|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 2|Participants received ChimeriVax™-JE a dose of 4.0 log10 PFU on Day 0.
11553230|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 3|Participants received ChimeriVax™-JE a dose of 5.0 log10 PFU on Day 0.
11553231|NCT00981630|Placebo Comparator|Placebo|Participants received ChimeriVax diluent, 0.5 mL on Day 0.
11553232|NCT00981617|Experimental|ALKS33 (RDC-0313) (1 mg)|1 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
11553233|NCT00981617|Experimental|ALKS33 (RDC-0313) (2.5 mg)|2.5 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
11553234|NCT00981617|Experimental|ALKS33 (RDC-0313) (10 mg)|10 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
11553235|NCT00981617|Placebo Comparator|Placebo|Matching placebo (capsules without active study drug) provided for daily oral administration
11553236|NCT00981604|Active Comparator|SILS Cholecystectomy|Single Incision Laparoscopic Cholecystectomy
11553237|NCT00981604|Active Comparator|Standard Laparoscopic Cholecystectomy|4 port laparoscopic cholecystectomy
11553238|NCT00981591|Experimental|Inhaled Iloprost|
11553239|NCT00981591|Placebo Comparator|Inhaled Placebo|
11553240|NCT00981578|Experimental|ExAblate 2100 Treatment|ExAblate 2100 ablation for the treatment of painful bone metastases.
11553241|NCT00981565|Active Comparator|Operative|
11553242|NCT00981565|Active Comparator|Conservative|
11553243|NCT00981552|Other|Cervix Cancer|Patients treated with cervical cancer in 2008 at Sunnybrook Odette Cancer Centre
11553244|NCT00981539|Active Comparator|treatment : receives pre operative enema|one arm will receive pre operative enema
11553245|NCT00981539|No Intervention|no enema|this group will not receive pre operative enema
11553246|NCT00981526|Experimental|A: Telmisartan|(existing Clozapine or Olanzapine treatment) + (Telmisartan)
11553247|NCT00981526|Placebo Comparator|B: Placebo|(existing Clozapine or Olanzapine treatment) + (Placebo)
11553248|NCT00981513|Active Comparator|Influenza vaccination|Live attenuated influenza vaccine (seasonal and pandemic strains) by nasal spray
11553249|NCT00981513|Placebo Comparator|Saline placebo|Saline nasal spray
11553250|NCT00981500||Gastric Bypass|morbidly obese subjects undergoing gastric bypass surgery
11553251|NCT00981500||gastric banding|morbidly obese subjects undergoing laparoscopic gastric banding surgery
11553252|NCT00981500||sleeve gastrectomy|morbidly obese subjects undergoing sleeve gastrectomy
11553253|NCT00981487|Experimental|Fed|A single oral dose of EUR-1025 (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The Ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast.
11553254|NCT00981487|Experimental|Fasting|A single oral dose of EUR-1025 (1 x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.
11553255|NCT00981474|Active Comparator|Control|Blood pressure targets during cardiopulmonary bypass based on institutional standards of empiric management.
11553256|NCT00981474|Experimental|Intervention|Blood pressure management based on cerebral autoregulation data.
11553257|NCT00981461|Active Comparator|LLT Device 2009 9 Beam|HairMax LaserComb
11553258|NCT00981461|Sham Comparator|control device|control device
11553259|NCT00981448|Experimental|Zinc supplement|
11553260|NCT00981435|Experimental|Artificial Tears|Topical artificial tears dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
11553261|NCT00981435|Experimental|Non-steroidal anti-inflammatory|Topical ketorolac 0.5% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
11553262|NCT00981435|Experimental|Steroid|Topical prednisolone 1% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
11553263|NCT00981422||Glaucoma patients|POAG patients selected by an ophthalmologist from the Glaucoma Service, Ophthalmology Institute, University of Parma
11553264|NCT00981422||Healthy|healthy subjects with negative history for (a) neurodegenerative diseases, (b) autoimmune diseases, (c) cancer, (d) viral infection, (e) diabetes, and (f) systemic inflammation
11553265|NCT00981409|Experimental|Fondaparinux|
11553266|NCT00981409|Other|unfractionated heparin|
11553267|NCT00981396|Active Comparator|CBT|Cognitive Behavioral Therapy
11553268|NCT00981396|Experimental|EFT|Emotional Freedom Techniques, a novel but efficacious stress-reduction technique
11553269|NCT00981383|Experimental|Treatment|Omega-3 Fatty Acid Supplement, 1.9 g ω-3 FAs daily
11553270|NCT00981383|Placebo Comparator|Placebo|Matching placebo, less than 0.12 g ω-3 FAs daily
11553271|NCT00981370|Other|Single Arm study|Single Arm study, all subjects to receive study medication, deferasirox (Exjade).
11553272|NCT00981357|Experimental|PF-04457845 followed by placebo|
11553273|NCT00981357|Experimental|Placebo followed by PF-04457845|
11553274|NCT00981357|Active Comparator|Naproxen followed by placebo|
11553275|NCT00981357|Active Comparator|Placebo followed by Naproxen|
11553276|NCT00981331|Experimental|Subtalar joint manipulation|Each subject in this group will recieve a subtalar joint manipulation to their symptomatic ankle
11553277|NCT00981331|Sham Comparator|Sham Manipulation|Each subject in this group will recieve a sham subtalar joint manipulation to their symptomatic ankle
11553278|NCT00981318|Other|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid|single arm
11553381|NCT00980486||BMI >40|BMI >40
11553382|NCT00980473|Active Comparator|Iridoplasty|
11553279|NCT00981305|Experimental|Lactate-containing Vaginal Lubricant|apply 3cc of lactate-containing vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)
11553280|NCT00981305|Placebo Comparator|Placebo|apply 3cc of placebo vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)
11553281|NCT00981292|Active Comparator|135mg EGCG|
11553282|NCT00981292|Active Comparator|270mg EGCG|
11553283|NCT00981292|Placebo Comparator|0mg EGCG|
11553284|NCT00981279||HIV seroposite patients|Seroposite HIV patients that take their treatment at the Clinical Hospital of The Federal University of Goias, and have their records in the hospital.
11553285|NCT00981266|Other|Augmentation|"The study population will consist of women aged 22 or over who are undergoing primary breast augmentation.
~The Augmentation cohort will include candidates for general breast enlargement, post-lactational involution and/or asymmetry."
11553286|NCT00981266|Other|Augmentation Revision|"The study population will consist of women aged 22 or over who are undergoing augmentation revision.
~The Augmentation Revision cohort will include candidates with previous augmentation with silicone-filled or saline-filled implants."
11553287|NCT00981253|Experimental|SMT-enhanced Cardiac Rehabilitation|Standard exercise-based cardiac rehabilitation with weekly stress management training for 12 weeks.
11553288|NCT00981253|Active Comparator|Standard Cardiac Rehabilitation|Standard cardiac rehabilitation consisting of supervised exercise for 12 weeks.
11553289|NCT00981240|Experimental|Dose escalation|Cohorts of 3 to 6 patients will be included at each dose level. The starting dose is 1.2mg/m2/day. The dose will be increased in new cohorts of patients according to toxicities observed during the first 4-week treatment period. The escalation process will continue until the MTD is determined. Additional 15 patients will be included at the MTD.
11553290|NCT00981227|Experimental|ESL 400 mg twice-daily|ESL 400 mg twice-daily
11553291|NCT00981227|Experimental|ESL 800 mg once-daily|ESL 800 mg once-daily
11553292|NCT00981227|Experimental|ESL 600 mg twice daily|ESL 600 mg twice daily
11553293|NCT00981227|Experimental|ESL 1200 mg once daily|ESL 1200 mg once daily
11553294|NCT00981227|Experimental|ESL 800 mg twice daily|ESL 800 mg twice daily
11553295|NCT00981227|Placebo Comparator|placebo|placebo
11553296|NCT00981214|Experimental|EUR-1008 (APT-1008)|
11553297|NCT00981201|Experimental|Celecoxib + Placebo|
11553298|NCT00981201|Experimental|Celecoxib + Celecoxib|
11553299|NCT00981201|Active Comparator|Placebo + Celecoxib|
11553300|NCT00981201|Placebo Comparator|Placebo + Placebo|
11553301|NCT00981175|Experimental|Study Group 1: ChimeriVax™-JE Vaccine first, then Placebo|Participants received ChimeriVax™-JE on Day 0 and ChimeriVax diluent on Day 28
11553302|NCT00981175|Experimental|Study Group 2: Placebo first, then ChimeriVax™-JE Vaccine|Participants received ChimeriVax diluent on Day 0 and ChimeriVax™-JE on Day 28.
11553303|NCT00981162|Experimental|Treatment (sorafenib tosylate and everolimus)|Patients receive everolimus PO once daily and sorafenib tosylate PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11553304|NCT00981149|Experimental|duloxetine study drug|Drug
11553305|NCT00981149|Placebo Comparator|Placebo|Placebo
11553306|NCT00981136|Active Comparator|SILS|Single Incision Laparoscopic Surgery (SILS) where a single incision in the umbilicus is all that is used to remove the appendix. The specific methods (staple/tie/port use/etc) will vary depending on surgeon.
11553307|NCT00981136|Active Comparator|3 port|Standard laparoscopic appendectomy with 3 ports and intracorporeal stapling.
11553308|NCT00981123||1|
11553309|NCT00981110|Active Comparator|Mepore Self-adhesive absorbent dressing|Mepore Self-adhesive absorbent dressing
11553310|NCT00981110|Experimental|AQUAGEL Ag Hydrofiber Wound Dressing|AQUAGEL Ag Hydrofiber Wound Dressing
11553311|NCT00981097||Specimen Collection|Subjects with a diagnosis of HIV and an untreated aggressive B-cell lymphoma.
11553312|NCT00981084|Experimental|armodafinil and placebo|All participants will receive one dose of armodafinil and one dose of placebo in a cross-over design
11553313|NCT00981071||A platoon with TB outbreak|
11553314|NCT00981058|Experimental|Necitumumab + Gemcitabine + Cisplatin|
11553315|NCT00981058|Active Comparator|Gemcitabine + Cisplatin|
11553316|NCT00981045|Experimental|Ferric Carboxymaltose (FCM)|2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
11553317|NCT00981045|Active Comparator|Iron Sucrose (Venofer)|5 doses of 200 mg for a total cumulative dose of 1000 mg
11553318|NCT00981032|Experimental|Pre-visit Summary|Patients in this arm will receive a pre-visit summary prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
11553319|NCT00981032|Experimental|Clinical Decision Sharing Tool|Patients in this arm will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
11553320|NCT00981019||mortality*incidence*5-year survival*early stage|Physicians will be faced in scenarios about screening with information on mortality and 5-year survival, followed by information on mortality*incidence and 5-year survival*early stage in a random order.
11553321|NCT00981006|Experimental|human cardiac stem cell therapy|single administration of 0.5 million cells/kg(patient body weight) of human cardiac stem cells and 200 microgram of bFGF at coronary artery bypass grafting (CABG)
11553322|NCT00980980|No Intervention|Arm 1: Usual Care-Active Surveillance|Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+
11553323|NCT00980980|Active Comparator|Arm 2: Targeted Decolonization|Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
11553324|NCT00980980|Active Comparator|Arm 3: Universal Decolonization|Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance, Continuation of Contact Precautions for MRSA+
11553383|NCT00980473|Active Comparator|Control (Medication)|
11553598|NCT00979095||Control group|Patients without hernias
11553325|NCT00980954|Experimental|Arm I: Cisplatin/Radiation Therapy|Patients undergo standard EBRT or IMRT to the pelvis once daily 5 days a week for 5-6 weeks. Patients also receive concurrent cisplatin IV over 1 hour once weekly for 6 weeks.
11553326|NCT00980954|Experimental|Arm II: Cisplatin/Radiation Therapy + Carboplatin/Paclitaxel|Patients receive chemoradiotherapy as in arm I. Beginning 4-6 weeks after completion of chemoradiotherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11553327|NCT00980941|Experimental|Soup with no added starch|
11553328|NCT00980941|Experimental|Soup + 50 g of whole grain starch|
11553329|NCT00980941|Experimental|Soup + 50 g of high amylose corn starch|
11553330|NCT00980941|Experimental|Soup + 50 g of regular corn starch|
11553331|NCT00980941|Experimental|Soup + 50 g maltodextrin starch|
11553332|NCT00980915||At risk for Acute Lung Injury|"Controls-High risk patients at risk of Acute Lung Injury(ALI) but do not develop ALI
~Cases-High risk patients that do develop Acute Lung Injury"
11553333|NCT00980889|Active Comparator|steel|Insertion of Metalic Steel Stent, Wallstent® in malignant distal bile duct obstruction
11553334|NCT00980889|Active Comparator|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
11553335|NCT00980876|Active Comparator|Cipro HC|Reference product
11553336|NCT00980876|Experimental|Ciprofloxacin HCl and Hydrocortisone|Test product
11553337|NCT00980863|Active Comparator|Lifestyle intervention to increase physical activity|
11553338|NCT00980863|No Intervention|waiting control group|
11553339|NCT00980850|Experimental|Groups A1 and A2|Baxter vaccine
11553340|NCT00980850|Experimental|Groups B1 and B2|GSK vaccine
11553341|NCT00980824|Experimental|therapy|Cognitive behavioural therapy. Six sessions of structured focused therapy.
11553342|NCT00980824|Active Comparator|Standard treatment|referral to specialised or generic mental health service
11553343|NCT00980798|Experimental|001|OROS hydromorphone HCl 4 to 32 mg taken orally once daily for 16 weeks
11553344|NCT00980798|Placebo Comparator|002|Placebo placebo tablet once daily for 16 weeks
11553345|NCT00980785|Placebo Comparator|Placebo|Matching Placebo
11553346|NCT00980785|Experimental|Active|Ramipril 5mg/day
11553347|NCT00980759|Experimental|EFI(Extended-Field Irradiation)|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
11553348|NCT00980759|Experimental|Pelvic RT|Pelvic Irradiation with chemotherapy(cisplatin)
11553349|NCT00980746|Experimental|ESL 400 mg BID|ESL 400 mg twice daily (BID)
11553350|NCT00980746|Experimental|ESL 800 mg QD|ESL 800 mg once-daily (QD)
11553351|NCT00980746|Experimental|ESL 600 mg BID|Eslicarbazepine 600 mg twice daily
11553352|NCT00980746|Experimental|ESL 1200 mg QD|Eslicarbazepine acetate 1200 mg once daily
11553353|NCT00980746|Experimental|ESL 800 mg BID|Eslicarbazepine acetate 800 mg twice daily
11553354|NCT00980746|Placebo Comparator|Placebo|Placebo
11553355|NCT00980733|Active Comparator|Fortified Yoghurt|Yoghurt with fortification of Micronutrients, yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
11553356|NCT00980733|Placebo Comparator|Yoghurt|Plain Yoghurt same as in fortified arm but without fortification
11553357|NCT00980733|No Intervention|Control|Non blinded group given no intervention
11553358|NCT00980707|Experimental|inhaled corticosteroid|All asthmatics will start inhaled corticosteroids.
11553359|NCT00980694|Experimental|Ubiquinol|up to 600 mg per day, oral capsules for 8 weeks
11553360|NCT00980681|Experimental|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg.
11553361|NCT00980681|Other|Time Of Flight|Each subject will undergo a TOF Magnetic Resonance Angiography
11553362|NCT00980655|Experimental|1|
11553363|NCT00980642|Other|General anesthesia|Temperature is measured by Draeger double-sensor and esophageal stethoscope temperature sensor every 5-min during the surgery.
11553364|NCT00980642|Other|Regional anesthesia|Temperature is measured by Draeger double-sensor and Foley catheter temperature sensor every 5-min during the surgery.
11553365|NCT00980616|Experimental|Ropivacaine, serum, adrenalin|235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin.
11553366|NCT00980616|No Intervention|No infiltration|B: no infiltration
11553367|NCT00980603|Active Comparator|docetaxel|
11553368|NCT00980603|Experimental|doctaxel plus cisplatin|
11553369|NCT00980603|Experimental|docetaxel plus S-1|
11553370|NCT00980590|Experimental|Airway Scope|Intubation with Airway Scope
11553371|NCT00980590|Active Comparator|Macintosh laryngoscope|Intubation with Macintosh laryngoscope
11553372|NCT00980577|Active Comparator|NS|stimulating catheter will be inserted using stimulator
11553373|NCT00980551|Experimental|Topotecan/Vincristine with subtenon Carboplatin|
11553374|NCT00980538|Experimental|Etravirine|Etravirine Dosed by weight up to a maximum dose of 200 milligram (mg) bid until switched to an etravirine (ETR)-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
11553375|NCT00980525||IL-1 genotype positive|There are three known IL-1 genes arranged in a cluster on human chromosome 2q13. Although the clinical application is still debatable, polymorphism in the IL-1 gene cluster was found to be associated with increased susceptibility to periodontal diseases. Conflicting studies demonstrate that a possible relationship between IL-1 genotype and clinical parameters of gingivitis may exist.This study will involve 15 subjects who are genotype positive and 15 subjects who are genotype negative.
11553376|NCT00980525||IL-1 genotype negative|There are three known IL-1 genes arranged in a cluster on human chromosome 2q13. Although the clinical application is still debatable, polymorphism in the IL-1 gene cluster was found to be associated with increased susceptibility to periodontal diseases. Conflicting studies demonstrate that a possible relationship between IL-1 genotype and clinical parameters of gingivitis may exist.This study will involve 15 subjects who are genotype positive and 15 subjects who are genotype negative.
11553377|NCT00980512|Experimental|Parent Training|Parent Training of foster parents
11553378|NCT00980512|No Intervention|Control|Control group
11553379|NCT00980486||BMI <30|BMI <30
11553384|NCT00980460|Experimental|High-risk group (regimen H)|Patients receive up front VIT chemotherapy comprising vincristine sulfate IV over 1 minute on days 1 and 8 and irinotecan hydrochloride IV over 90 minutes on days 1-5, and temsirolimus IV over 30 minutes on days 1 and 8. Treatment with VIT repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with disease response then receive 6 courses of C5VD with 4 courses of VIT in between each 2-course block. Patients with no disease response receive 6 courses of C5VD in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection or liver transplant after course 4 of C5VD followed by 2 courses of adjuvant C5VD. Patients may also receive dexrazoxane IV over 5-15 minutes on days 1-2 of courses 5 and 6.
11553385|NCT00980460|Experimental|High-risk group (regimen W)|(regimen W replaced by regimen H as of Amendment 3B) Patients receive up front VI chemotherapy comprising vincristine sulfate IV on days 1 and 8 and irinotecan hydrochloride IV over 90 minutes on days 1-5. Treatment with VI repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with disease response then receive 6 courses of C5VD with 1 courses of VI in between each 2-course block. Patients with no disease response receive 6 courses of C5VD in the absence of disease progression or unacceptable toxicity.
11553386|NCT00980460|Experimental|Intermediate-risk group (regimen F)|Patients receive C5VD chemotherapy comprising cisplatin IV over 6 hours on day 1, fluorouracil IV over 2-4 minutes on day 2, vincristine sulfate IV over 1 minute on days 2, 9, and 16, and doxorubicin hydrochloride IV over 15 minutes on days 1-2. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo surgical resection after course 2 OR surgical resection or liver transplantation after course 4 of C5VD. Patients may also receive dexrazoxane IV over 5-15 minutes on days 1-2 of courses 5 and 6. (Closed to accrual as of 3/12/2012)
11553387|NCT00980460|Experimental|Low-risk group (regimen T)|Patients undergo surgery and then receive adjuvant cisplatin IV over 6 hours on day 1, fluorouracil IV over 2-4 minutes on day 2, and vincristine sulfate IV over 1 minute on days 2, 9, and 16. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
11553388|NCT00980460|Experimental|Very low-risk group|Patients undergo surgery and then receive no further treatment.
11553389|NCT00980447|Experimental|UMN-0501 45µg|Recombinant H5N1 vaccine 45µg
11553390|NCT00980447|Experimental|UMN-0501 90µg|Recombinant H5N1 vaccine 90µg
11553391|NCT00980447|Experimental|UMN-0501 135µg|Recombinant H5N1 vaccine 135µg
11553392|NCT00980434||1|patients with neurological symptoms
11553393|NCT00980434||2|patients without neurological symptoms
11553394|NCT00980421|Experimental|IT|Iron Tablet group (12.5 mg/d) + Placebo Biscuit
11553395|NCT00980421|Experimental|IZ|Iron (12.5mg/d)+Zinc (10 mg/d) Tablet Group + Placebo Biscuit
11553396|NCT00980421|Experimental|IB|Iron Fortified Biscuit Group(12.5 mg/d)+ Placebo Tablet
11553397|NCT00980421|Placebo Comparator|CO|Placebo Tablet + Placebo Biscuit
11553398|NCT00980408|Placebo Comparator|Sugar pill, behavioral glutamic acid|Placebo condition for D-Cycloserine
11553399|NCT00980408|Placebo Comparator|Sugar pill, fMRI, glutamic acid|Placebo condition for D-Cycloserine, fMRI
11553400|NCT00980408|Placebo Comparator|Sugar pill, memantine, behavioral|Placebo condition Memantine, behavioral
11553401|NCT00980408|Placebo Comparator|Sugar pill, memantine, fMRI|Placebo condition Memantine, fMRI
11553402|NCT00980408|Active Comparator|D-Cycloserine behavioral|
11553403|NCT00980408|Active Comparator|D-Cycloserine, fMRI|
11553404|NCT00980408|Active Comparator|Memantine, behavioral|
11553405|NCT00980408|Active Comparator|Memantine, fMRI|
11553406|NCT00980395|Experimental|VCR (Velcade, Cladribine and Rituximab)|"Rituximab 375 mg/m2 IV day1
~Cladribine 4 mg/m2 IV over 2 hours days 1-5
~Bortezomib 1.3 mg/m2 IV days 1 and 4
~Repeat every 28 days for a maximum of 6 cycles"
11553407|NCT00980369||Chronic anal fissures|Group A: with vertical incision Group B: with parallel incision
11553408|NCT00980369||Parallel incision, vertical insicion|
11553409|NCT00980356|Active Comparator|Vildagliptin, 50 mg, peroral|
11553410|NCT00980356|Placebo Comparator|Placebo pill|
11553411|NCT00980343|Experimental|Arm I (pre-surgery vismodegib)|"Patients receive oral Hedgehog antagonist GDC-0449 (vismodegib) once daily for 7 days before therapeutic conventional surgery. Beginning within 28 days after surgical resection, all patients receive oral Hedgehog antagonist GDC-0449 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Other: pharmacological study; laboratory biomarker analysis"
11553412|NCT00980343|Experimental|Arm II (no vismodegib pre-surgery)|"Patients do not receive treatment before therapeutic conventional surgery.
~Beginning within 28 days after surgical resection, all patients receive oral Hedgehog antagonist GDC-0449 (vismodegib) once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Other: laboratory biomarker analysis"
11553413|NCT00980330|Experimental|TMC435 100 mg 12 Wks + PR48|Participants will receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.
11553414|NCT00980330|Experimental|TMC435 100 mg 24 Wks + PR48|Participants willl receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.
11553415|NCT00980330|Experimental|TMC435 100 mg 48 Wks + PR48|Participants will receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
11553416|NCT00980330|Experimental|TMC435 150 mg 12 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.
11553417|NCT00980330|Experimental|TMC435 150 mg 24 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.
11553418|NCT00980330|Experimental|TMC435 150 mg 48 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
11553419|NCT00980330|Placebo Comparator|Placebo 48 Wks + PR48|Participants will receive Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
11553420|NCT00980304|Experimental|Rituximab in combination with ICE as salvage therapy|
11553421|NCT00980278|Active Comparator|sinus lift plus dental implant|"Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.
~Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
~Biological/Vaccine: N/A; only sinus augmentation and dental implant"
11553422|NCT00980278|Experimental|sinus lift plus BRCs and dental implant|"transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.
~Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
~Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant"
11553423|NCT00980252|Experimental|CBT|UK-based intervention
11553424|NCT00980239|Experimental|Group 1|Group 1 = Irinotecan + Bevacizumab
11553425|NCT00980239|Experimental|Group 2|Group 2 = Irinotecan, Bevacizumab + Oxaliplatin
11553426|NCT00980239|Experimental|Group 3|Group 3 = Irinotecan, Bevacizumab + Cetuximab
11553427|NCT00980213||sunitinib|advanced renal cell cancer patients treated with sunitinib as first-line therapy
11553428|NCT00980200|Experimental|C/E/A/B/D|GW642444 Dose 2 QD/GW642444 Dose 4 QD/placebo/GW642444 Dose 1 BD/GW642444 Dose 3 QD
11553429|NCT00980200|Experimental|D/C/E/A/B|GW642444 Dose 3 QD/GW642444 Dose 2 QD/GW642444 Dose 4 QD/placebo/GW642444 Dose 1 BD
11553430|NCT00980200|Experimental|A/B/C/D/E|placebo/GW642444 Dose 1 BD/GW642444 Dose 2 QD/GW642444 Dose 3 QD/GW642444 Dose 4 QD
11553431|NCT00980200|Experimental|B/A/D/E/C|GW642444 Dose 1 BD/placebo/GW642444 Dose 3 QD/GW642444 Dose 4 QD/GW642444 Dose 2 QD
11553432|NCT00980200|Experimental|E/D/B/C/A|GW642444 Dose 4 QD/GW642444 Dose 3 QD/GW642444 Dose 1 BD/GW642444 Dose 2 QD/placebo
11553433|NCT00980187|Active Comparator|Hydrochlorothiazide|
11553434|NCT00980187|Experimental|Indapamide SR|
11553435|NCT00980174|Placebo Comparator|2|Subjects will receive placebo for denosumab (SC injection every 6 months) for 1 year (double-blind phase) followed by 60 mg denosumab (SC injection every 6 months) for 1 year (open-label phase)
11553436|NCT00980174|Experimental|1|60 mg denosumab (SC injection every 6 months) for 1 year (double-blind phase) followed by 60 mg denosumab(SC injection every 6 months) for 1 year (open-label phase). These subjects will be on denosumab for a total of 2 years.
11553437|NCT00980161||Peg-IFN + RBV with SVR|HCV patients receiving peginterferon alfa-2a and ribavirin with sustained virologic response
11553438|NCT00980161||Peg-IFN + RBV without SVR|HCV patients receiving peginterferon alfa-2a and ribavirin without sustained virologic response
11553439|NCT00980148|Experimental|Arm2|Doxycycline 100 mg oral twice a day (BID) for 7 days; 153 subjects
11553440|NCT00980148|Experimental|Arm 1|Azithromycin 1 gm oral single dose; 153 subjects
11553441|NCT00980135|Experimental|Arm 1|
11553442|NCT00980135|Experimental|Arm 2|
11553443|NCT00980135|Other|Arm 3|
11553444|NCT00980109|Placebo Comparator|placebo oseltamivir|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
11553445|NCT00980109|Active Comparator|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
11553446|NCT00980109|Placebo Comparator|placebo inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
11553447|NCT00980109|Active Comparator|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
11553448|NCT00980083|Placebo Comparator|Placebo|
11553449|NCT00980083|Active Comparator|Exendin(9-39)|
11553450|NCT00980070|Experimental|Positioning Device|use of positioning device
11553451|NCT00980070|Active Comparator|Control|institutional standard of care
11553452|NCT00980057|Experimental|Adaptive CRT (aCRT) arm|Intervention: Cardiac resynchronization therapy (CRT-D) with Adaptive CRT algorithm ON
11553453|NCT00980057|Active Comparator|Echo-optimized arm|Intervention: Cardiac resynchronization therapy (CRT-D) with standard biventricular pacing (Adaptive CRT algorithm OFF)
11553454|NCT00980044|Experimental|Tramadol 200 mg then placebo|Tramadol 200 mg daily for 1 week then placebo given for 1 week
11553455|NCT00980044|Placebo Comparator|Placebo for two weeks|Medication
11553456|NCT00980044|Experimental|Tramadol 600 mg then placebo|Tramadol 600 mg daily given for 1 week given then placebo given for 1 week
11553457|NCT00980031|Placebo Comparator|Lactose Tablet|Compounded capsule using Lactose Monohydrate Powder
11553458|NCT00980031|Active Comparator|Eplerenone|25 mg tablet placed in a capsule filled with Lactose Monohydrate Powder.
11553459|NCT00980018|Experimental|nilotinib|To measure improvement of (CTCAE grading scale) of imatinib related chronic low grade non hematologic Adverse Event after switch to treatment with nilotinib at End of Cycle 3
11553460|NCT00980005|Experimental|Flulaval Group|"subjects received Flulaval™ vaccine according to their priming status and age:
~3-8 years: primed subjects 1 dose at Day 0; unprimed subjects 1 dose at Day 0 and a second dose at Day 28
~9-17 years: 1 dose at Day 0 Flulaval vaccine was administered intramuscularly into the non-dominant deltoid."
11553461|NCT00980005|Active Comparator|Fluzone Group|"subjects received Fluzone® Sanofi Pasteur's vaccine according to their priming status and age:
~3-8 years: primed subjects 1 dose at Day 0; unprimed subjects 1 dose at Day 0 and a second dose at Day 28
~9-17 years: 1 dose at Day 0 Fluzone vaccine was administered intramuscularly into the non-dominant deltoid."
11553462|NCT00979992|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11553463|NCT00979979||HCV patients|HCV patients with detectable viremia; all sera are tested both by Abbott RealTime HCV genotype II test and by direct HCV sequencing both at 5'UTR and NS5B
11553595|NCT00979108|Experimental|Over-door traction and exercise.|Subjects will receive traction utilizing an over-the-door traction unit in addition to neck and postural exercises.
11553464|NCT00979979||Non-HCV patients|Patient without evidence of HCV infection (negative both for anti-HCV and HCV RNA); all sera are both tested by Abbott RealTime HCV genotype II test and by direct HCV sequencing at 5'UTR and NS5B
11553465|NCT00979966|Experimental|A|Temsirolimus
11553466|NCT00979966|Experimental|B|Sunitinib
11553467|NCT00979953|Experimental|ADL5859|One 50-milligrams (mg) ADL5859 capsule, one 100-mg ADL5859 capsule, and 2 placebo capsules administered orally twice daily (BID) for 14 days
11553468|NCT00979953|Experimental|ADL5747|One 150-mg ADL5747 capsule and 3 placebo capsules administered orally BID for 14 days
11553469|NCT00979953|Active Comparator|Oxycodone CR|"One 10-mg Oxycodone controlled release (CR) capsule and 3 placebo capsules administered orally BID Days 1 through 4
~One 20-mg Oxycodone CR capsule and 3 placebo capsules administered orally BID Days 5 through 14"
11553470|NCT00979953|Placebo Comparator|Placebo|Four placebo capsules administered orally BID for 14 days
11553471|NCT00979940|No Intervention|No atorvastatin|Patients do not receive Atorvastatin prior to PCI in cath lab
11553472|NCT00979940|Experimental|atorvastatin|Atorvastatin 80mg po given prior to PCI in cath lab
11553473|NCT00979927|Placebo Comparator|Saline|
11553474|NCT00979927|Active Comparator|SPC3649|
11553475|NCT00979914|Experimental|Patient education programme|Patients with osteoarthritis who were referred to the patient education programme.The patients followed the patient education programme.
11553476|NCT00979914|No Intervention|Control|Patients randomized to control group
11553477|NCT00979901|Experimental|1|montelukast
11553478|NCT00979901|Experimental|2|loratadine
11553479|NCT00979901|Placebo Comparator|3|placebo
11553480|NCT00979901|Experimental|4|montelukast/loratadine
11553481|NCT00979875|Experimental|Lispro+PH20, Lispro, Glulis+PH20, Glulis, Aspart+PH20, Aspart|"All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C). Each intervention was separated by a 3- to 14-day washout.
~Intervention A: Participants received a single, subcutaneous (SC) injection of 95 units per milliliter (U/mL) Lispro + 5 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20 (PH20) and a single, SC injection of 95 U/mL Lispro alone 3 to 14 days apart.
~Intervention B: Participants received a single, SC injection of 95 U/mL Glulisine (Glulis) + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Glulis alone 3 to 14 days apart.
~Intervention C: Participants received a single, SC injection of 95 U/mL Aspart + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Aspart alone 3 to 14 days apart."
11553482|NCT00979862|Experimental|Treatment cediranib maleate, cilengitide)|"Part A (dose finding): Patients receive cediranib maleate PO once daily on days 1-28 and cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
~Part B (dose expansion): Patients are assigned to 1 of 2 groups according to prior anti-VEGF therapy (yes vs no). Patients in both groups receive cediranib maleate (administered at the safe dose determined in part A) and cilengitide as in part A."
11553483|NCT00979849|Experimental|A|AZD8683
11553484|NCT00979849|Placebo Comparator|B|Placebo
11553485|NCT00979836|Experimental|Calcium Dobesilate|
11553486|NCT00979836|Placebo Comparator|Placebo|The placebo is a capsule with the same presence of experimental drug.
11553487|NCT00979823|Experimental|Early SimCare Diabetes Group|This group will receive an email web-link to 3 simulated learning cases each month for 6 months. After 6 months (18 total learning cases), they will then complete 4 simulated assessment cases, a diabetes knowledge survey, and a satisfaction survey.
11553488|NCT00979823|Active Comparator|Delayed SimCare Diabetes Group|Beginning in the spring of 2011, residents in this group will receive an email web-link to complete 4 simulated assessment cases and a diabetes knowledge survey. They will subsequently be sent 3 learning cases a month for 6 months and a satisfaction survey to complete.
11553489|NCT00979810|Experimental|18F-FLT PET scan|This is a pilot study intended to collect preliminary data on 15 patients diagnosed with untreated high-grade glioma who are scheduled to undergo surgical resection.
11553490|NCT00979797|Experimental|Maternal & Child Health|Community-based interventions to promoto Maternal and Child Survival in collaboration with GoB, Donors and NGOs.
11553491|NCT00979784|Active Comparator|1|
11553492|NCT00979784|Experimental|2|
11553493|NCT00979771|Experimental|GSK706769|100 mg GSK706769 twice daily orally (BID) for 28 days
11553494|NCT00979771|Placebo Comparator|Placebo|GSK706769 matched-placebo twice daily orally (BID) for 28 days
11553495|NCT00979758|Sham Comparator|Atorvastatin|Atorvastatin routine dose
11553496|NCT00979758|Placebo Comparator|Intensive Atorvastatin|Atorvastatin Intensive dose
11553497|NCT00979758|Active Comparator|Atorvastatin+Transplantation|Atorvastatin routine dose+ Mononuclear cells Transplantation
11553498|NCT00979758|Experimental|Intensive Atorvastatin+Transplantation|Atorvastatin intensive dose+ Mononuclear cells Transplantation
11553499|NCT00979745|Experimental|Afamelanotide|
11553500|NCT00979745|Placebo Comparator|Placebo|
11553501|NCT00979732|Active Comparator|GSE capsule active|Grape seed extract capsule 150 mg/BID
11553502|NCT00979732|Placebo Comparator|GSE capsule placebo|placebo grape seed extract capsule 150 mg/BID
11553503|NCT00979732|Active Comparator|GSE beverage active|grape seed extract beverage 150 mg/BID
11553504|NCT00979732|Placebo Comparator|GSE beverage placebo|grape seed extract placebo beverage 150 mg/BID
11553505|NCT00979719|Experimental|Intervention Group (IG)|Patients in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
11553506|NCT00979719|Placebo Comparator|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, & Fuchs, 2007) Göhner, W. & Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.
11553507|NCT00979719|No Intervention|Passive Control Group (PCG)|patients are asked to answer the questionnaires only
11553508|NCT00979706|Active Comparator|HAART|Patients assigned to this arm will receive standard HAART
11553509|NCT00979706|Experimental|HAART + Immunotherapy|Patients assigned to this arm will receive HAART plus cyclosporin A during the first two months and after that will receive IFN, GM-CSF and IL-2.
11553510|NCT00979693|Experimental|Full Dose|Participant will receive 25 mg psilocybin during two day-long sessions of psychotherapy in combination with psilocybin, with each session scheduled seven to 14 days apart.
11553511|NCT00979693|Active Comparator|Active Placebo|The participant will receive 4 mg psilocybin during two day-long sessions of psychotherapy in combination with psilocybin, with sessions scheduled seven to 14 days apart.
11553512|NCT00979680|Active Comparator|High-dose Radiotherapy|
11553513|NCT00979680|Active Comparator|Chemo-radiotherapy|
11553514|NCT00979667|Experimental|Oseltamivir|
11553515|NCT00979667|Experimental|Zanamivir|
11553516|NCT00979667|Placebo Comparator|Placebo of Oseltamivir|
11553517|NCT00979654|Experimental|Sifalimumab (MEDI-545) 500 or 600 milligram (mg)|All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
11553518|NCT00979641|Experimental|chemoterapy|docetaxel/paclitaxel + bevacizumab
11553519|NCT00979628|Experimental|Basal Plus Regimen|glargine subcutaneously once daily plus corrective doses of glulisine subcutaneously before meals and bedtime as needed
11553520|NCT00979628|Experimental|Basal Bolus|glargine subcutaneously once daily plus glulisine subcutaneously before meals (plus corrective doses of glulisine as needed)
11553521|NCT00979628|Active Comparator|sliding scale regular insulin (SSRI)|sliding scale regular insulin subcutaneously four-times daily in patients with T2DM admitted to general medicine and surgery wards.
11553522|NCT00979615|Experimental|1|Olopatadine HCL Nasal Spray, 0.6%
11553523|NCT00979615|Active Comparator|2|Azelastine HCl Nasal Spray, 137 mcg
11553524|NCT00979602|Experimental|GSK2340274A Group|Healthy male or female subjects between and including 18 to 60 years of age and older (>60 years) and between 18 to 64 years of age and older (>64 years), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.
11553525|NCT00979602|Experimental|GSK2340273A Group|Healthy male or female subjects between and including 18 to 60 years of age and older (>60 years) and between 18 to 64 years of age and older (>64 years), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.
11553526|NCT00979589|Active Comparator|Combination Clopidogrel and asprin|
11553527|NCT00979589|Placebo Comparator|Asprin and placebo|
11553528|NCT00979576|Experimental|BIBF 1120 BID + Pemetrexed|Phase I part: Find MTD by using low, medium or high BIBF 1120 twice daily and 500mg/m^2 pemetrexed once every 3 weeks
11553529|NCT00979576|Experimental|BIBF 1120 BID (RD) + Pemetrexed|PHase II part: Study arm
11553530|NCT00979576|Experimental|BIBF 1120 BID(Placebo) + Pemetrexed|Phase II part: Comparator arm
11553531|NCT00979550|Experimental|Aldara cream|Imiquimod (Aldara cream) will be applied nightly for four weeks after standard of care laser treatment for port wine stain.
11553532|NCT00979550|Placebo Comparator|non-medicated petroleum cream|Non-medicated petroleum cream will be applied nightly for four weeks after standard of care laser treatment for port wine stain.
11553533|NCT00979537|Experimental|Test: Nisoldipine ER Tablets, 40 mg|Nisoldipine Extended-release Tablets, 40 mg
11553534|NCT00979537|Active Comparator|Reference: Sular Tablets 40 mg|Sular Tablets, 40 mg
11553535|NCT00979524|Experimental|Comprehensive Mental Health Services|Intervention group participants will receive an array of mental health education and services based on their level of need. Study participants will fall into low, moderate, or elevated risk based on results of baseline screening. Services will be provided to each group as specified below. Low risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) education activities to promote knowledge and change attitudes around mental health; Moderate risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) Short-term mental health services delivered by the LCSW-C, (c) Depression prevention intervention, (d) Education activities to promote knowledge and change attitudes around mental health; High risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) Mental health treatment services, (c) Education activities to promote knowledge and change attitudes around mental health.
11553536|NCT00979524|Active Comparator|Usual Care (Employment Training Services)|"Newly enrolling Westside YO members will receive usual care services, which constitute a moderate level of mental health services and supports. The usual care services related to mental health at the Westside will include (1) the ACASI screen for all newly enrolling Westside YO members, (2) the initial visit with a LCSW-C, and (3) mental health training for Westside Case Advocates. More extensive mental health educational activities and services (e.g., additional sessions with LCSW-C, SOS Club) provided to the intervention group will not be available at the Westside YO Center during the initial study period. Also, Eastside Case Advocates will receive more extensive and ongoing mental health training."
11553537|NCT00979511|Experimental|1 Hi-Calcium milk & exercise|
11553538|NCT00979511|Experimental|2 Hi-calcium milk with passive exercise|
11553539|NCT00979511|Experimental|3Low-Calcium with exercise|
11553540|NCT00979511|Experimental|4 Low-calcium milk with passive exercise|
11553541|NCT00979472|Experimental|with urgency|
11553542|NCT00979472|Experimental|without urgency|
11553543|NCT00979459|Experimental|MK-1006 80 mg DFC|Participants received a single dose of four 20 mg dry filled capsules of MK-1006
11553544|NCT00979459|Experimental|MK-1006 80 mg FCT|Participants received a single dose of two 40 mg film coated tablets of MK-1006
11553545|NCT00979446|Experimental|Guided|
11553546|NCT00979446|Active Comparator|Self-directed|
11553547|NCT00979433|Experimental|Bubble CPAP|All neonates randomised to bubble CPAP will be put on Bubble CPAP following initial extubation in first week of life.
11553548|NCT00979433|Other|Conventional CPAP|All neonates randomly allocated to conventional/ventilator derived CPAP.
11553549|NCT00979420||HIV treatment|
11553550|NCT00979407|Experimental|GSK2340272A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
11553596|NCT00979108|Experimental|Mechanical traction and exercise|Mechanical cervical traction will be utilized in addition to neck and postural exercises.
11553551|NCT00979407|Experimental|GSK2340274A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340274A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
11553552|NCT00979394||Patients with type 2 diabetes|
11553553|NCT00979381||1|Patients with metastasized renal cell carcinoma or GIST who have been treated with sunitinib or sorafenib for at least 4 weeks
11553554|NCT00979381||2|patients with metastasized RCC who did not receive a systemic treatment for their RCC (nephrectomy is allowed)
11553555|NCT00979381||3|healthy volunteers
11553556|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 1)|
11553557|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 2)|
11553558|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 3)|
11553559|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 4)|
11553560|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 5)|
11553561|NCT00979342|Experimental|Cervical Block, 6 injection sites|Subject will receive a cervical block of 1% lidocaine and 0.25% bupivacaine, with injections in the following locations: 2cc at 12:00, 10cc at 3:00, 10 cc at 9:00, 5 cc at 4:00, 5 cc at 8:00, and 5 cc at 6:00.
11553562|NCT00979342|Experimental|Cervical Block, 2 injection sites|Subject will receive a cervical block of 1% lidocaine and 0.25% bupivacaine, with injections in the following locations: 10 cc at 4:00, and 10 cc at 8:00.
11553563|NCT00979342|Experimental|Ibuprofen q. 8 hours|Subjects will receive a post procedure pain management regimen of ibuprofen 800 mg every 8 hours, for the first 24 hours and then PRN.
11553564|NCT00979342|Experimental|Ibuprofen PRN|Subjects will receive a post procedure pain management regimen of ibuprofen 800 mg PRN.
11553565|NCT00979329||mRCC or GIST treated with sunitinib/sorafenib|
11553566|NCT00979316|Experimental|BMS-708163 (800 mg)|
11553567|NCT00979316|Experimental|BMS-708163 (200 mg)|
11553568|NCT00979316|Placebo Comparator|Placebo|
11553569|NCT00979316|Active Comparator|Moxifloxacin|
11553570|NCT00979303|No Intervention|Control Group|Control Patients - Undergo ablation procedures with radiation/fluoroscopy only
11553571|NCT00979303|Experimental|Study Group|Study Group Patients - Undergo ablation procedures using intracardiac echocardiography and 3D navigational system in addition to radiation.
11553572|NCT00979290||Separate anti-TB drugs|
11553573|NCT00979290||Fix-dosed combination anti-TB drugs|
11553574|NCT00979264|No Intervention|Control|Standard quality improvement approaches available through participation in Get With the Guidelines - Heart Failure.
11553575|NCT00979264|Active Comparator|Intervention|Enhanced and/or intensive quality improvement approaches, coupled with standard approaches available through participation in Get With the Guidelines - Heart Failure.
11553576|NCT00979251|Experimental|ADS-8902|Amantadine and Ribavirin administered with Oseltamivir phosphate
11553577|NCT00979251|Active Comparator|Comparator|Oseltamivir Phosphate
11553578|NCT00979238|Other|Group 1|"All participants who meet the eligibility requirements.
~Intervention: Gene Transfer and drug (scAAV2/8-LP1-hFIXco)."
11553579|NCT00979225|Experimental|Medication report|Medication reports delivered to providers at the point of care
11553580|NCT00979225|Experimental|Med. report plus care manager notices|Medication reports delivered to providers at the point of care and notices sent electronically to care managers
11553581|NCT00979225|No Intervention|Control|
11553582|NCT00979212|Active Comparator|Induction CT+RT|Chemotherapy (paclitaxel and carboplatin) plus radiation therapy followed by surgery (if operable) followed by consolidation chemotherapy (paclitaxel and carboplatin)
11553583|NCT00979212|Experimental|Induction CT+RT+Panitumumab|Panitumumab plus chemotherapy (paclitaxel and carboplatin) plus radiation therapy followed by surgery (if operable) followed by consolidation chemotherapy (paclitaxel and carboplatin)
11553584|NCT00979199|Other|Non invasive cardiac imaging|Intervention: Non invasive cardiac imaging. 'Anatomical' information provided by CTCA is obtained in every patient together with the 'functional' information provided by stress radionuclide cardiac imaging (SPECT or PET), to assess myocardial perfusion, and/or by stress MRI or ECHO imaging to assess myocardial contraction.
11553585|NCT00979173|Experimental|AC480|Patients who are not on enzyme inducing anti-epileptic drugs (EIAEDs) and are scheduled to undergo salvage surgical resection treated with preoperative AC480 at 300 mg BID followed by post-surgical AC480 at 300 mg BID.
11553586|NCT00979160|Experimental|Dasatinib|Patient will be treat at a starting dose of 20mg once daily, that can be escalated up to 100mg once daily.
11553587|NCT00979147|Experimental|Modular Metal Tibial Baseplate|Patients who were randomized to receive the modular polished tibial baseplate/XLK TKA
11553588|NCT00979147|Active Comparator|All Polyethylene Tibial Baseplate|Patients who were randomized to receive the nonmodular APT/GVF TKA design.
11553589|NCT00979134|Experimental|Part A|Ascending doses of AZD4547 administered orally to patients to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD)
11553590|NCT00979134|Experimental|Part B|Dose expansion phase, at the RD defined in Part A
11553591|NCT00979134|Experimental|Part C|Expansion phase in patients with FGFR1 and FGFR2 amplified tumours commencing at the RD defined from Part A
11553592|NCT00979121|Active Comparator|Rosuvastatin|"Half of the subjects were randomized to the active drug (Rosuvastatin).
~Dosage, Form, and Frequency: drug was provided as 10mg tablets and administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). An initial 40mg loading dose was administered followed by a daily 20 mg maintenance dose. Maintenance dosing was adjusted for renal failure not compensated by renal replacement therapy.
~Duration: drug was administered daily until:
~28 days after randomization or 3 days after ICU discharge (whichever comes first),
~Discharge from study hospital,
~Death"
11553593|NCT00979121|Placebo Comparator|Placebo|"Half of the subjects were randomized to placebo.
~10mg tablets identical to active drug were administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). Dosage, frequency, and duration was provided in the same manner as the active drug."
11553594|NCT00979108|Active Comparator|Standard exercise|Subjects will be instructed in neck and postural exercises.
11553597|NCT00979095||Multiple hernia|Patients with more than 3 primary hernias
11553697|NCT00978341|Other|Placebo|
11553599|NCT00979069|Experimental|Aerobic Group|12 weeks of aerobic exercise 3 times a week
11553600|NCT00979069|No Intervention|Control Group|No contact control
11553601|NCT00979056|Experimental|Rifaximin|
11553602|NCT00979056|Placebo Comparator|Lactose|
11553603|NCT00979043|Active Comparator|Dietary weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
11553604|NCT00979043|Active Comparator|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
11553605|NCT00979043|Active Comparator|Dietary weight-loss & exercise|Participants received both the dietary weight-loss and exercise interventions for 18-months
11553606|NCT00979043|No Intervention|Health lifestyle control|The healthy-lifestyle control served as the usual care comparison group. For 3 months, participants met monthly with a health educator to discuss topics such as osteoarthritis, obesity, and exercise. Regular phone contact was maintained during months 4-18.
11553607|NCT00979017|Experimental|Avastin in combination with temozolomide and irinotecan|Avastin 10 mg/kg every 14 days. Temozolomide 200 mg/m2 daily x 5 days in a 28-day cycle. Irinotecan dose depends on whether the patient is on an enzyme-inducing antiepileptic drug (EIAED). EIAED 340 mg/m2 every other week and no EIAED 125 mg/m2 every other week. Irinotecan dose also depends on if the patient has the UGT 1A1 polymorphism (7/7). If so, they do not metabolize the irinotecan normally, so these patients will start out at a two dose level reduction. EIAED starting dose will be 275 mg/m2 and no EIAED starting dose will be 75 mg/ m2.
11553608|NCT00979004|Experimental|ICA-105665|
11553609|NCT00978978|Active Comparator|Propofol, endoscopies, liver diseases|Propofol, endoscopies, liver diseases
11553610|NCT00978978|Active Comparator|midazolam and fentanyl, endoscopies, liver diseases|Control: midazolam and fentanyl, endoscopies, liver diseases
11553611|NCT00978965||All patients|
11553612|NCT00978952|Experimental|Investigational Group|Use of Large Diameter Advanta™ V12 Covered Stent.
11553613|NCT00978939|Experimental|Aggressive Drainage Arm|Patients will drain up to 1 liter of pleural fluid everyday
11553614|NCT00978939|Active Comparator|Standard Drainage Arm|Patients will drain up to 1 liter of pleural fluid every other day
11553615|NCT00978913|Experimental|DC vaccination and Cyclophosphamide|
11553616|NCT00978900|Active Comparator|Acesulfame K|
11553617|NCT00978900|Active Comparator|Sucralose|
11553618|NCT00978900|Active Comparator|Aspartame|
11553619|NCT00978900|Active Comparator|Glucose|
11553620|NCT00978900|Active Comparator|Fructose|
11553621|NCT00978900|Placebo Comparator|Water|
11553622|NCT00978887|Experimental|A|Retorna (facial cream)
11553623|NCT00978887|Placebo Comparator|B|Placebo (facial cream)
11553624|NCT00978874|Experimental|All subjects|
11553625|NCT00978861|Experimental|whitening|30% Hydrogen peroxide
11553626|NCT00978848||Women seeking emergency contraception|Women seeking emergency contraception
11553627|NCT00978848||Women seeking urine pregnancy testing|Women seeking urine pregnancy testing
11553628|NCT00978835|Experimental|Nurse case management|Telephone calls by a nurse every two months to assess adherence to diet, physical activity, and pill-taking regimens. The nurse will then identify barriers to adherence to these recommendations and use motivational interviewing approaches to offer solutions to the barriers identified. No changes to medication are made.
11553629|NCT00978835|Active Comparator|Nurse Education|Didactic, non-interactive education by a nurse on general health topics.
11553630|NCT00978822|Experimental|Clevidipine butyrate injectable emulsion|
11553631|NCT00978809|Active Comparator|Semont|BPPV patients treated by Semont maneuver by a physical therapist.
11553632|NCT00978809|No Intervention|control|healthy volunteers.
11553633|NCT00978809|Active Comparator|Epley maneuver|BPPV patients treated with Epley maneuver by a physical therapist.
11553634|NCT00978796|Active Comparator|Sitagliptin|Patients will receive sitagliptin for 4 weeks and then cross over to sugar pill
11553635|NCT00978796|Placebo Comparator|Sugar pill|Subjects will receive sugar pill for 4 weeks and then cross over to active sitagliptin
11553636|NCT00978783|Active Comparator|speaking valve|
11553637|NCT00978783|Active Comparator|Positive end expiratory pressure|
11553638|NCT00978757|Experimental|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
11553639|NCT00978757|Placebo Comparator|Placebo|Placebo: saline solution
11553640|NCT00978731|Experimental|Dasatinib|
11553641|NCT00978718|Placebo Comparator|Arm I|Patients receive oral placebo daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
11553642|NCT00978718|Experimental|Arm II: 200 μg selenium (Se) as high-Se Baker's yeast daily|Patients receive 200 μg of oral selenium (Se) as high-Se Baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
11553643|NCT00978718|Experimental|Arm III: 400 μg Se as high-Se baker's yeast daily|Patients receive 400 μg of oral Se as high-Se baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
11553644|NCT00978692|Experimental|Toric orthokeratology lenses|Children wearing toric ortho-k lenses at night for correcting astigmatism and myopia will be the study group
11553645|NCT00978692|Other|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive error will be serve as control group
11553646|NCT00978679|Experimental|Orthokeratology|Myopic children wearing orthokeratology at night will be the study group
11553647|NCT00978679|Other|Others|Myopic children wearing single-vision spectacles in the daytime will serve as control group
11553648|NCT00978666||Healthy controls|Healthy comparison adolescent females
11553649|NCT00978666||Anorexia Nervosa|Adolescent females currently ill with Anorexia Nervosa, restricting type
11553650|NCT00978653|Experimental|Allopurinol|Hyperuricemic (uric acid (UA)>7 mg/dL), nondiabetic CKD patients without any comorbidity, age<60 years with creatinine clearance (CrCl) between 20 and 60ml/min were evaluated.
11553651|NCT00978640|Experimental|fasting and exercise|36 h fast and 1 h ergometer cycling 50% VO2max
11553652|NCT00978640|Experimental|exercise|1 h ergometer cycling 50% VO2max
11553653|NCT00978627|Experimental|IDegAsp OD|
11553654|NCT00978627|Active Comparator|IDet|
11553655|NCT00978614|Experimental|Neramexane, Placebo, Moxifloxacin|
11553656|NCT00978601|Experimental|Multimodal analgesic protocol group|Women who received the multimodal analgesic protocol during minimally invasive myomectomy.
11553657|NCT00978601|No Intervention|No use of multimodal analgesic protocol group|Women who did not receive the multimodal analgesic protocol during minimally invasive myomectomy.
11553658|NCT00978588|Experimental|HES 130/0.4|
11553659|NCT00978588|Active Comparator|5% albumin|
11553660|NCT00978575|Active Comparator|Intravenous iron|
11553661|NCT00978575|Active Comparator|Oral iron|
11553662|NCT00978575|Placebo Comparator|Isotonic Sodium and placebo tablets|
11553663|NCT00978562|Experimental|Diagnostic (DSC-MRI with ferumoxytol, DCE-MRI with gadolinium)|Patients receive ferumoxytol and gadolinium IV and then undergo DSC-MRI and DCE-MRI. An optional MRI without injection of a contrast agent may be obtained after 20-24 hours at the discretion of the clinician. Patients may receive up to 3 more scans at least 3 weeks apart over up to 2 years.
11553664|NCT00978536|Other|group 1|MS with cortical cognitive troubles
11553665|NCT00978536|Other|group 2|MS with subcortical cognitive troubles
11553666|NCT00978536|Other|group 3|MS in the early stage of the disease when cognitive troubles are absent or inconspicuous
11553667|NCT00978523|Experimental|Treatment with AR-12|This is a single-agent, open-label, Phase 1, dose-escalation study in adult patients with advanced or recurrent solid tumors or lymphoma. Patients will receive orally administered AR-12 once daily for 28 consecutive days. The first dosing cycle will be followed by at least a 7 day off-treatment period; however, no off-treatment period will be scheduled between subsequent treatment cycles
11553668|NCT00978497|Placebo Comparator|1|Peginterferon and ribavirin + placebo BID for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
11553669|NCT00978497|Experimental|2|ANA598 200 mg BID + Peginterferon and ribavirin for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
11553670|NCT00978497|Experimental|3|ANA598 400mg BID + Peginterferon and ribavirin for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
11553671|NCT00978484|Active Comparator|Static Virtual Reality|Exposure Therapy using a still computer image
11553672|NCT00978484|Experimental|Dynamic Virtual Reality|Virtual Reality Exposure Therapy using full, immersive Virtual Reality
11553673|NCT00978471|Experimental|experimental arm thiotepa|4 courses of conventional chemotherapy followed by high-dose Thiotepa with peripheral stem cell rescue. Surgical resection of all tumor masses will be performed as soon as possible.
11553674|NCT00978471|Other|Reference arm|4 courses of conventional chemotherapy. Surgical resection of all tumor masses will be performed as soon as possible.
11553675|NCT00978458|Active Comparator|Arm I|Patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily 5 days a week for 5½ weeks (28 fractions).
11553676|NCT00978458|Experimental|Arm II|Patients undergo radiotherapy as in arm I and receive concurrent oral temozolomide once daily for 5½ weeks. Beginning 28 days after completion of chemoradiotherapy, patients receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
11553677|NCT00978445|Experimental|Home/Standard|all participants recieved vMetric protocol at home and in clinical setting, in this ARM the standard protocol was at home first then in clinic INR and interaction with a care giver.
11553678|NCT00978445|Experimental|Standard/Home|all participants recieved vMetric protocol at home and in clinical setting, in this ARM the standard protocol was an in clinic INR and interaction with a care giver, then the Home protocol was as described.
11553679|NCT00978432|Experimental|Arm 1a (RAD001 followed by LBH589)|"Part 1a: Sequential single agent therapy with RAD001 and LBH589. Each agent will be given for four-six 28-day cycles.
~Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period.
~Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease.
~There will be a 1-6 week 'washout' period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient's best interest."
11553680|NCT00978432|Experimental|Arm 1b (LBH589 followed by RAD001)|"Part 1b: Sequential single agent therapy with LBH589 and RAD001 . Each agent will be given for four-six 28-day cycles.
~Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period.
~Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease.
~There will be a 1-6 week 'washout' period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient's best interest."
11553681|NCT00978432|Experimental|Doublet (Combination RAD001 and LBH589)|Subjects will receive the doublet of RAD001 and LBH589 given in two to thirteen, 28-day cycles. Subjects will be evaluated for the disease status after completion of cycle two and then after every 4 cycles. Subjects with progressive disease will stop after 2 cycles. Subjects with stable disease or better may receive up to 13 cycles. LBH589 will start at 15mg po three days a week at least 2 days apart such as on days M/W/F or T/Th/Sat and RAD001 will start at 7.5mg po daily.
11553682|NCT00978419|Active Comparator|Rosuvastatin|Rosuvastatin
11553683|NCT00978419|Placebo Comparator|Placebo|Placebo
11553684|NCT00978406||Healthy volunteers|Healthy volunteers
11553685|NCT00978393|Experimental|A|
11553686|NCT00978393|Experimental|B|
11553687|NCT00978393|Experimental|C|
11553688|NCT00978393|Experimental|D|
11553689|NCT00978393|Experimental|E|
11553690|NCT00978393|Experimental|F|
11553691|NCT00978380|Experimental|A|
11553692|NCT00978367|Experimental|Drug, intradermal avotermin (Juvista)|
11553693|NCT00978367|Placebo Comparator|Placebo (vehicle)|
11553694|NCT00978354|Active Comparator|Furosemide|Furosemide intravenous continuous infusion
11553695|NCT00978354|Placebo Comparator|Normal Saline|Normal saline titrated continuous intravenous infusion
11553696|NCT00978341|Experimental|Pregabalin|
11553698|NCT00978328||001|oxycodone immediate release (OXYRX) Characteristics of pts. receiving prescription medications containing OXYRX
11553699|NCT00978315|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
11553700|NCT00978315|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
11553701|NCT00978302|Placebo Comparator|Placebo (vehicle)|
11553702|NCT00978302|Experimental|Avotermin|
11553703|NCT00978263|Experimental|Glargine|Initial basal Insulin therapy was according to the dose administrated at bedtime in the last day hospitalization. basal Insulin doses were titrated every 3 days to achieve target FPG values between 80 and 130 mg/dl.
11553704|NCT00978263|Experimental|metformin-based Oral Antidiabetic Drugs|Subject in metformin-based OAD group was visited every two weeks in the first month and the every four weeks for another five months. The subjects will start with Metformin 425mg bid, The dosage was titrated (up to 850mg bid) based on the fasting blood glucose every two weeks. If the patients fail to achieve the target, gliclazide-MR (Diamicron, Servier), or glimepiride (Amaryl, Sanofi-Aventis) would be added.
11553705|NCT00978250|Experimental|5-Fluro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)|FdCyd (100 mg/m(2)) + THU (350 mg/m(2)) administered 5 days/week for 2 weeks in 28-day cycles
11553706|NCT00978237|Active Comparator|EFV and Fixed combinations of analogues|EFV + Fixed combinations of analogue tenofovir + emtricitabine, or abacavir + lamivudine
11553707|NCT00978237|Experimental|LPV/r and combination of analogues.|
11553708|NCT00978224|Experimental|A|Viusid in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet
11553709|NCT00978224|Placebo Comparator|B|Placebo in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet
11553710|NCT00978211|Experimental|DOTA-TOC|Treatment arm
11553711|NCT00978198|Experimental|Part 1|single administration
11553712|NCT00978198|Experimental|Part 2|multiple administration
11553713|NCT00978159|Active Comparator|esomeprazole|esomeprazole 20 mg
11553714|NCT00978159|Active Comparator|Famotidine|famotidine 40 mg
11553715|NCT00978146|Experimental|Desmoid tumor|Patients with desmoid tumors
11553716|NCT00978133|Active Comparator|Skin Staples|Skin closure with skin staples
11553717|NCT00978133|Experimental|Dermabond|Closure of abdominal wound with dermabond (2-octylcyanoacrylate)
11553718|NCT00978120|Experimental|H1N1 vaccine high dose|Participants will be stratified according to asthma severity and will receive the high dosage of the H1N1 vaccine.
11553719|NCT00978120|Experimental|H1N1 vaccine low dose|Participants will be stratified according to asthma severity and will receive the low dosage of the H1N1 vaccine.
11553720|NCT00978081|Experimental|Arm I|Patients receive oral aminolevulinic acid and then undergo continuous photodynamic therapy 4-6 hours later.
11553721|NCT00978081|Experimental|Arm II|Patients receive aminolevulinic acid as in arm I and then undergo fractionated photodynamic therapy 4-6 hours later.
11553722|NCT00978068|Active Comparator|Lopinavir/ritonavir (LPV/r) +2 NRTI|Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
11553723|NCT00978068|Active Comparator|Nevirapine (NVP) or Efavirenz (EFV) +2 NRTI|Nevirapine (NVP) or Efavirenz (EFV) +2 nucleoside reverse transcriptase inhibitor (NRTI)
11553724|NCT00978055|Experimental|1|Liothyronine Sodium Tablets, 50 mcg
11553725|NCT00978055|Active Comparator|2|Cytomel® Tablets, 50 mcg
11553726|NCT00978042|Experimental|VOLUMA® XC Treatment Arm|Participants treated with JUVÉDERM® VOLUMA® XC Injectable Gel, volume determined by the investigator (up to 12 mLs) at study start. Participants were eligible for re-treatment if applicable.
11553727|NCT00978042|Other|Control Arm_No Treatment then VOLUMA® XC|No treatment for 6 months, then participants were treated with JUVÉDERM® VOLUMA® XC Injectable Gel, volume determined by the investigator (up to 12 mLs). Participants were eligible for re-treatment if applicable.
11553728|NCT00978029|Placebo Comparator|Placebo|Matching placebo tablet sublingual, once daily
11553729|NCT00978029|Experimental|SCH 39641 6 Amb a 1-U|6 Units Short Ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) in an AIT, sublingual, once daily
11553730|NCT00978029|Experimental|SCH 39641 12 Amb a 1-U|12 Amb a 1-U in an AIT, sublingual, once daily
11553731|NCT00978016|Experimental|arbaclofen placarbil-Cohort 1|"arbaclofen placarbil 20 mg QD with PPI*
~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
11553732|NCT00978016|Experimental|arbaclofen placarbil-Cohort 2|"arbaclofen placarbil 40 mg QD with PPI*
~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
11553733|NCT00978016|Experimental|arbaclofen placarbil-Cohort 3|"arbaclofen placarbil 20 mg BID with PPI*
~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
11553734|NCT00978016|Experimental|arbaclofen placarbil-Cohort 4|"arbaclofen placarbil 30 mg BID with PPI*
~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
11553735|NCT00978016|Placebo Comparator|Placebo-Cohort 5|"Placebo dose with PPI*
~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
11553736|NCT00978003||1/Healthy Volunteers|Adults age 18-55.
11553737|NCT00977977|Experimental|Combination of Rituximab plus cyclosporine|2 infusions (each 1000 mg) separated by 2 weeks;repeated after 6 months. Daily therapy for 6 months (3-5 mg /kg), then tapered and discontinued.
11553738|NCT00977964|Experimental|Milk Based Protein Formula Process A|
11553739|NCT00977964|Experimental|Milk Based Protein Formula Process B|
11553740|NCT00977964|Experimental|Milk Based Protein Formula Process C|
11553741|NCT00977964|Experimental|Milk Based Protein Formula Process D|
11553742|NCT00977964|Experimental|Milk Based Protein Formula Process E|
11553743|NCT00977964|Experimental|Milk Based Protein Formula Process F|
11553744|NCT00977951|Experimental|Intradermal avotermin|
11553745|NCT00977951|Placebo Comparator|Placebo (vehicle)|
11553746|NCT00977938|Placebo Comparator|12m DAPT Study Arm|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
11553747|NCT00977938|Active Comparator|30m DAPT Study Arm|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine treatment in addition to aspirin.
11553748|NCT00977925|Experimental|Fibrin Pad|
11553749|NCT00977925|Active Comparator|Standard of Care|
11553750|NCT00977912|Experimental|"Milk containing B. Lactis"|"Milk = Breast-milk from the mother, pasteurized breast-milk from a donor, or preterm formula."
11553751|NCT00977912|Placebo Comparator|"Milk containing placebo"|"Milk = Breast-milk from the mother, pasteurized breast-milk from a donor, or preterm formula."
11553752|NCT00977886|Placebo Comparator|Placebo|
11553753|NCT00977886|Experimental|ELB353|
11553754|NCT00977873|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
11553755|NCT00977873|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
11553756|NCT00977860|Other|SBRT|
11553757|NCT00977847|Experimental|Interactive Voice Response Practice|"The introductory letter to patients will allow them an opportunity to opt-out of the study using a toll-free number. If they do not opt-out within 2 weeks of receiving the letter, the IVR system will make up to 15 call attempts over a 2 week period to reach the patient. The system will make outbound calls during preset hours. The system continuously checks the call list for the next scheduled call. Once contact is made, the spoken script greets the patient by name, authenticates identify, and will ask the patient the programmed questions. The IVR server will send completed family history assessments to the patients EHR as an HL7 compliant summary note as well as transmitting the separate coded responses for each condition/ family member to coded family history fields in the EHR."
11553758|NCT00977847|Experimental|Wireless Tablet PC Practice|Patients will receive an info letter in advance of their visit explaining the project with description of what information they will be asked to provide. Study staff will train the practice staff to hand out and collect the tablets for the patient. Staff will be trained to verify a patient's identity to ensure that the family history is sent to the correct EHR record. The initial screen of the tablet PC portal will include a paragraph of informed consent, and patients in this practice will be given the opportunity to decline participation. For patients who participate, the completed family history data will be transmitted to the patient's EHR as an HL7 compliant note and transmitting separate coded responses for each condition/ family member to coded family history fields.
11553759|NCT00977847|Experimental|Internet Portal Practice|Patients in this practice will receive the informational letter either by email or mail one month before their scheduled visit. It will have directions to access the MFHP website and how to transfer data through the hospitals secure internet portal (Patient Gateway). About 1/3 of patients are signed up to use this service. Those who do not have a Patient Gateway account will be provided with directions on how to establish this service. Patients will be required to have a Gateway account to ensure that the MFHP data file is sent securely to the correct EHR record. Patients in this arm will receive an initial email or letter with a single follow-up reminder sent 2 weeks later. For patients who participate, the completed family history data will be transmitted to the patient's EHR.
11553760|NCT00977847|Active Comparator|Usual Care Physician Assesment Practice|Usual standard family history assessments will be conducted by physicians during the patient visit. This arm will allow us to account for any temporal trends in family history assessment.
11553761|NCT00977834||Group 1|Patients with lymphoma or lung cancer
11553762|NCT00977834||Group 2|Caregivers
11553763|NCT00977821|Active Comparator|fresh|Embryo transfer with fresh oocytes
11553764|NCT00977821|Experimental|Frozen|Embryo transfer with vitrified oocytes
11553765|NCT00977808|Experimental|Closed-Loop Model Predictive Control (MPC)|Insulin dosing was performed by a model-predictive control (MPC) algorithm.
11553766|NCT00977808|Placebo Comparator|Open-Loop|Insulin dosing was performed by the patient (using their normal routine and personal insulin pump) under a physician's supervision.
11553767|NCT00977795|Experimental|Tumor fluorescence|A single arm in this open-label study where all patients are treated with the study drug. Areas of the brain that are fluorescent and areas that are not fluorescent are evaluated for presence of tumor cells
11553768|NCT00977769|Experimental|carbetocin 100 µg|Carbetocin injection, 100µg, single injection
11553769|NCT00977769|Active Comparator|oxytocin 5 u|Oxytocin 5U, injection, single injection
11553770|NCT00977769|Placebo Comparator|placebo (NaCl)|Saline single injection
11553771|NCT00977756||Group G|Participants will receive a medication regimen including RAL + ATV + RTV.
11553772|NCT00977756||Group H|Participants will receive a medication regimen including RAL + TDF.
11553773|NCT00977756||Group I|Participants will receive a medication regimen including ETV + DRV + RTV.
11553774|NCT00977756||Group J|Participants will receive a medication regimen including MVC + ATV + RTV.
11553775|NCT00977756||Group K|Participants will receive a medication regimen including MVC + LPV + RTV.
11553776|NCT00977756||Group L|Participants will receive a medication regimen including MVC + RAL + ETV.
11553777|NCT00977756||Arm M|Participants will receive a medication regimen of DRV
11553778|NCT00977756||Arm N|Participants will receive a medication regimen of DRV
11553779|NCT00977756||Arm O|Participants will receive a medication regimen of unboosted ATV
11553780|NCT00977756||Arm P|Participants will receive a medication regimen of RPV
11553781|NCT00977756||Arm Q|Participants will receive a medication regimen of RPV
11553782|NCT00977730|Active Comparator|Protandim|
11553783|NCT00977730|Placebo Comparator|Sugar pill|
11553784|NCT00977717||FOLFOX|Stage III colorectal cancer patients who are treated with adjuvant FOLFOX chemotherapy
11553785|NCT00977704|Active Comparator|Restylane and Perlane|Restylane and Perlane administered by injection. Recommended volume of 6.0 mL. Injection on study day 1 with an optional touch up on study day 14.
11553786|NCT00977691|Experimental|Cohort 1|PBSC transplant with no post-transplant cyclophosphamide (PT-Cy)
11553787|NCT00977691|Experimental|Cohort 2|PBSC transplant with 50 mg/kg post-transplant cyclophosphamide (PT-Cy)
11553788|NCT00977691|Experimental|Cohort 3|PBSC transplant with 100 mg/kg post-transplant cyclophosphamide (PT-Cy)
11553789|NCT00977678||Open access gastroscopy|Patients referred to open access gastroscopy
11553790|NCT00977678||Conventional outpatient gastroscopy|Gastroscopy after preceding appointment
11553791|NCT00977665|Experimental|rasagiline mesylate|rasagiline tablet, 1 mg/day for up to 48 weeks.
11553792|NCT00977665|Placebo Comparator|placebo|placebo tablet for up to 48 weeks.
11553793|NCT00977652|Active Comparator|Active stimulation|Percutaneous posterior tibial nerve stimulation
11553794|NCT00977652|Sham Comparator|sham stimulation|Inefficient percutaneous posterior tibial nerve stimulation
11553795|NCT00977626|Experimental|Part 1 AZD2423 or Placebo|AZD2423 or Placebo Oral Solution, multiple dosing during 10-14 days
11553796|NCT00977626|Experimental|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
11553797|NCT00977626|Experimental|Part 3 - AZD2423|AZD2423 Oral solution single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
11553798|NCT00977613|Other|life style counseling|Treated stage 2 and 3 colorectal cancer patients were counseled to exercise at least to the equivalent of 18 metabolic hours per week and were assessed over 6 months.
11553799|NCT00977600|Experimental|GT4P-F|GT4P-F (80% GT4P) was supplied as an odorless, colorless, tasteless liquid oil in 125 ml bottles. This formulation was designed to be mixed in water and create a self-emulsifying suspension, thus administered in water for the trial. The administered dose was calculated to contain the number of moles of PBA equivalent to 3 g/m2 of PBA. GT4P-F was mixed in 50 ml of water, taken orally, and then the cup rinsed with 50 ml of water and taken orally. GT4P-F was stored at ambient temperature away from light.
11553800|NCT00977600|Experimental|GT4P-API|GT4P-API was supplied as an odorless, colorless, tasteless oil in 125 ml bottles. The administered dose was calculated to contain the number of moles of PBA equivalent to 3 g/m2 of PBA. GT4P-API was taken orally and washed down with 100 ml of water. GT4P-API was stored at ambient temperature, away from light.
11553801|NCT00977600|Active Comparator|Ammonul|Ammonul® was supplied as single-use glass vials of 10% sodium phenylacetate and 10% sodium benzoate for intravenous injection. Ammonul® was diluted before use with sterile dextrose injection 10% to a concentration of 9 mg/ml. Once diluted it was kept at room temperature and used within 24 hours. The dose was 2.75 g/m2 and was administered as an intravenous infusion over a 120-minute period. Ammonul® was stored at 25°C, within a range of 15-30°C.
11553802|NCT00977600|Active Comparator|Buphenyl|Sodium phenylbutyrate or Buphenyl® was supplied as a white powder in 250 g bottles. The required amount of powder (equivalent to 3 g/m2 of PBA) was weighed out, mixed in 100 ml of water, and administered orally. Doses were calculated on a weight/volume basis and corrected for sodium content and purity. Buphenyl® was stored at ambient temperature.
11553803|NCT00977587|Active Comparator|Saccharomyces Cerevisiae CNCM I-3856|2 weeks of treatment with Saccharomyces Cerevisiae CNCM I-3856 1 capsule twice a day, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).
11553804|NCT00977587|Placebo Comparator|placebo|"Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:
~Calcium phosphate, Dibasic 472.0 mg
~Maltodextrin DE14 112.1 mg
~Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day"
11553805|NCT00977574|Experimental|Arm I (paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11553806|NCT00977574|Experimental|Arm II (paclitaxel, carboplatin, temsirolimus)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11553807|NCT00977574|Experimental|Arm III (ixabepilone, carboplatin, bevacizumab)|Patients receive ixabepilone IV over 1 hour, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11553808|NCT00977561|Experimental|Arm A|Figitumumab (CP-751,871) Plus Chemotherapy [Cisplatin (Or Carboplatin) And Etoposide] All drugs to be administered on a 21 day cycle
11553809|NCT00977561|Active Comparator|Arm B|Chemotherapy [Cisplatin (Or Carboplatin) And Etoposide] All drugs to be administered on a 21 day cycle
11553810|NCT00977548|Experimental|Erlotinib Treatment|Erlotinib was given as an oral 150 mg daily dose for 16 weeks. The dose was adjusted for diarrhea, rash and pulmonary toxicity.
11553811|NCT00977522|Experimental|PF-03463275|
11553812|NCT00977522|Placebo Comparator|Placebo|
11553813|NCT00977496||Nasal Swab|New chronic hemodialysis patients with no evidence of nasal carriage of Staphylococcus aureus from Boston Dialysis Center Inc., the outpatient hemodialysis clinic of Tufts Medical Center
11553814|NCT00977483|Experimental|Drug: Thioctic Acid|600mg tablet Thioctic Acid (alpha-lipoic acid) once daily throughout the trial
11553815|NCT00977483|Placebo Comparator|Drug: Placebo|1 tablet once daily throughout the trial
11553816|NCT00977470|Experimental|Erlotinib|Erlotinib 150 mg oral daily
11553817|NCT00977470|Experimental|Erlotinib and Hydroxychloroquine|Erlotinib 150 mg oral daily plus Hydroxychloroquine (HCQ) 1000 mg oral daily
11553911|NCT00976872|Active Comparator|omega-3|"omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA"
11554003|NCT00976326|Experimental|C: Subjects with moderate liver impairment|
11553818|NCT00977457|Experimental|Diagnostic (specimen collection)|Patients receive prostatic massage and undergo a digital rectal examination. Laboratory assessments are performed and blood samples are collected for molecular biology testing. On the day of the scheduled prostatectomy, a second blood collection is performed prior to surgery.
11553819|NCT00977444|Experimental|kondrium|intraarticular injections once month
11553820|NCT00977444|Experimental|kondrium f|
11553821|NCT00977444|Active Comparator|corticosteroid|intraarticular injections once month
11553822|NCT00977431|Experimental|Regimen U|BIBW2992 + Radiotherapy
11553823|NCT00977431|Experimental|Regimen M|BIBW2992 + Temozolomide + Radiotherapy
11553824|NCT00977418|No Intervention|No intervention|Seniors undergo all testing but remain current lifestyle
11553825|NCT00977418|Experimental|Training|Groups will undergo either physical or mental training. Physical training is 1 hour aerobic training 3 times per week for 12 weeks. Mental training is 1 hour Strategic Memory Advanced Reasoning Training 3 times per week.
11553826|NCT00977405|No Intervention|Control|Primary closure after standard washing of wound with chlorhexidine solution
11553827|NCT00977405|Experimental|Collatamp G|Primary closure of wound with collatamp G in subcutaneous layer
11553828|NCT00977379|Active Comparator|WBRT Followed by Standard of Care|Participants will receive 3000 centi-Gray (cGy) WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) followed by standard of care therapy at the discretion of the treating oncologist starting no earlier than 2 weeks after completion of WBRT. The participants will be followed during the treatment until the halting of standard of care for any reason (central nervous system [CNS] or extra-cranial tumor progression, unacceptable toxicity, change of therapeutic strategy, withdrawal of participant consent, or death).
11553829|NCT00977379|Experimental|WBRT+Capecitabine Followed by Capecitabine Maintenance|Participants will receive 3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) concurrent with capecitabine 825 milligrams per square meter (mg/m^2) orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by capecitabine 1000 mg/m^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2, one week after completion of WBRT and continuing until the halting of capecitabine for any reason (CNS or extra-cranial progression, unacceptable toxicity, withdrawal of participant consent or death).
11553830|NCT00977366|Active Comparator|Hydrochloric acid infusion|
11553831|NCT00977366|Placebo Comparator|Saline|
11553832|NCT00977353|Experimental|sarcosine|sarcosine
11553833|NCT00977353|Active Comparator|citalopram|citalopram
11553834|NCT00977340|Experimental|Imagery Rehearsal Treatment|Imagery Rehearsal Treatment; 1 session on-site and 4 weeks of individual daily training; following principles Krakow and Zadra (2006)
11553835|NCT00977340|Experimental|Confrontation|Confrontation with nightmare content, until fear reaction habituates; 1 session on-site and 4 weeks of individual daily training
11553836|NCT00977340|Placebo Comparator|Imagination|Imagination of a safe and pleasant site; 1 session on-site and 4 weeks of individual daily training
11553837|NCT00977327|Other|Intraoperative MR|Use of intraoperative MR during resection of intraaxial tumor, Glioma
11553838|NCT00977327|Other|Intraoperative Ultrasound|Use of intraoperative ultrasound during resection of intraaxial tumor, Glioma
11553839|NCT00977314|Experimental|SoundBite Hearing System|The objective of this study was to assess the safety and effectiveness of the SoundBite hearing system by Sonitus Medical and to support its intended use for the treatment of unilateral hearing loss. The SoundBite hearing system is a Bone Conduction Device (BCD) and is occasionally referred to as such in the protocol and within this report.
11553840|NCT00977301|Experimental|fosamprenavir/ritonavir/olanzapine|single dose of 15 mg olanzapine after 13 days of fosamprenavir/ritonavir 700mg/100mg BID
11553841|NCT00977301|Active Comparator|single dose olanzapine|Single dose of 10 mg olanzapine
11553842|NCT00977288|Experimental|1|MK0859 10 mg + placebo
11553843|NCT00977288|Experimental|2|MK0859 40 mg + placebo
11553844|NCT00977288|Experimental|3|MK0859 100 mg + placebo
11553845|NCT00977288|Experimental|4|MK0859 300 mg + placebo
11553846|NCT00977288|Experimental|5|MK0859 10 mg + atorvastatin 10mg
11553847|NCT00977288|Experimental|6|MK0859 40 mg + atorvastatin 10mg
11553848|NCT00977288|Experimental|7|MK0859 100 mg + atorvastatin 10mg
11553849|NCT00977288|Experimental|8|MK0859 300 mg + atorvastatin 10mg
11553850|NCT00977288|Placebo Comparator|9|Placebo + atorvastatin 10mg
11553851|NCT00977288|Placebo Comparator|10|Placebo
11553852|NCT00977262|Experimental|Healthy control subjects, High saturated fat shake|
11553853|NCT00977262|Experimental|Healthy control subjects, High Monounsaturated fat shake|
11553854|NCT00977262|Experimental|Healthy control subjects, High Polyunsaturated fat shake|
11553855|NCT00977262|Experimental|Healthy obese subjecs, High saturated fat shake|
11553856|NCT00977262|Experimental|Healthy obese subjects, High monounsaturated fat shake|
11553857|NCT00977262|Experimental|Healthy obese subjects, High polyunsaturated fat shake|
11553858|NCT00977262|Experimental|Obese diabetes type 2 subjects, High Saturated fat shake|
11553859|NCT00977262|Experimental|Obese diabetes type 2 subjects, High Monounsaturated fat shake|
11553860|NCT00977262|Experimental|Obese diabetes type 2 subjects, High polyunsaturated fat shake|
11553861|NCT00977249|Active Comparator|varenicline|"Varenicline for 12 weeks.
~The treatment schedule for varenicline is:
~Varenicline tablets, 0.5 mg x 1 daily, day 1-3 Varenicline 0.5 mg x 2, day 4-6 Varenicline 1 mg x 2, day 7 up to 12 weeks"
11553862|NCT00977249|Placebo Comparator|placebo|Placebo for 12 weeks
11553863|NCT00977236|Experimental|Orthokeratology lenses|Children wearing orthokeratology at night for partial correction and spectacles at daytime for residual refractive error will be study group
11553864|NCT00977236|Other|Single-vision spectacle lenses|Children wearing single-vision spectacles in the daytime for correcting the refractive error will serve as control group
11553865|NCT00977223|Experimental|Aprepitant|7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
11553866|NCT00977223|Placebo Comparator|placebo|7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
11553867|NCT00977210|Experimental|OXi4503|
11554004|NCT00976326|Experimental|D: Subjects with severe liver impairment|
11553868|NCT00977197|Active Comparator|Pregabalin|"Subjects randomized to this arm will receive the following dosage:
~75 mg (one tablet) twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study."
11553869|NCT00977197|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo matching the study drug.
11553870|NCT00977184|Experimental|Real rTMS|
11553871|NCT00977184|Sham Comparator|Sham rTMS|
11553872|NCT00977171|Experimental|Droxidopa|
11553873|NCT00977158||Throat Swab|Infants who have been diagnosed with cystic fibrosis
11553874|NCT00977145|Experimental|intratumoral IFN-gamma plus MELITAC 12.1,|intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1, an emulsion of a mixture of 12 class I MHC-restricted melanoma-derived peptides (12-MP) and a class II MHC-restricted tetanus toxoid-derived helper peptide (Peptide-tet).
11553875|NCT00977132|Experimental|Lenalidomide|Lenalidomid in combination valproic acid
11553876|NCT00977119||Capecitabine|Women with breast cancer receiving capecitabine as treatment for their breast cancer.
11553877|NCT00977106|Experimental|1|
11553878|NCT00977106|Placebo Comparator|2|
11553879|NCT00977106|Experimental|3|
11553880|NCT00977093|Experimental|Perfusion CMR examination|All patients will undergo perfusion CMR examination, single-photon emission computed tomography, and conventional invasive coronary angiography.
11553881|NCT00977080|Active Comparator|IV Paricalcitol|Participants in the IV stratum received intravenous (IV) paricalcitol and, if hypercalcemia (calcium >= 10.5 mg/dL), received 30 mg of oral cinacalcet. Paricalcitol was dosed at 0.07 mcg/kg with titration every 2 weeks.
11553882|NCT00977080|Active Comparator|Cinacalcet (at sites with IV paricalcitol)|Participants in the IV stratum received 30 mg of oral cinacalcet daily with a low-dose vitamin D receptor activator (VDRA) (doxercalciferol IV 1 mcg 3 times weekly (TIW) at sites in the US and alfacalcidol capsules 0.25 mcg daily at sites in Russia).
11553883|NCT00977080|Active Comparator|Oral paricalcitol|Participants in the oral stratum received oral paricalcitol and, if hypercalcemia (calcium >= 10.5 mg/dL), received 30 mg of oral cinacalcet. Paricalcitol was dosed at mcg = IPTH/60 3 times weekly (TIW) with titration every 2 weeks.
11553884|NCT00977080|Active Comparator|Cinacalcet (at sites with oral paricalcitol)|Participants in the oral stratum received 30 mg of oral cinacalcet daily with a low-dose vitamin D receptor activator (VDRA) (alfacalcidol capsules 0.25 mcg daily).
11553885|NCT00977067|Experimental|A|
11553886|NCT00977054|Experimental|DFPP and Peg-IFN + RBV|Double filtration plasmapheresis (Day 1, Day 2, Day 4, Day 8, and Day 9 from the onset of treatment; overall 5 session, each session for 4 hours) and weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1 to week 48; body weight < 75 kg, 1,000 mg/day and body weight >= 75 kg, 1,200 mg/day)
11553887|NCT00977054|Active Comparator|Peg-IFN + RBV|Weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1-48; body weight < 75 kg, 1,000 mg/day and body weight >=75 kg, 1,200 mg/day)
11553888|NCT00977041|Experimental|Neurofeedback|See Intervention description below.
11553889|NCT00977028|Experimental|Tumescent Lidocaine with liposuction|Determine maximum safe mg/kg dosage of tumescent lidocaine with liposuction
11553890|NCT00977028|Experimental|Tumescent Lidocaine No Liposuction|Determine maximum safe mg/kg dosage of tumescent lidocaine without liposuction
11553891|NCT00977015|Experimental|Treatment A - PF-04764793|PF-04764793 using inhaler A
11553892|NCT00977015|Active Comparator|Treatment B - PF-04764793|PF-04764793 using inhaler B
11553893|NCT00977002|Experimental|PPNIV|Patient randomized to this group will be ventilated with Positive Pressure Noninvasive Ventilation post extubation
11553894|NCT00977002|Active Comparator|O2I|Patient randomized to this group will be submitted to traditional oxygen therapy post extubation
11553895|NCT00976989|Experimental|T+P Concomitant Anthracycline-based chemotherapy|5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab (T) and pertuzumab (P) every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
11553896|NCT00976989|Experimental|T+P Sequential Anthracycline-based chemotherapy|FEC every three weeks for three cycles, followed by docetaxel, trastuzumab (T) and pertuzumab (P) every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.
11553897|NCT00976989|Experimental|T+P Concomitant Non-Anthracycline chemotherapy|Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab (P) every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
11553898|NCT00976976|Experimental|DXP|
11553899|NCT00976963|Active Comparator|Fosfomycin|Mix sachet with 1/2 glass cold water and stir. Drink immediatley
11553900|NCT00976963|Active Comparator|TMP/SMX|Sulfamethoxazole-Trimethoprim 800-160 MG Oral Tab (TMP/SMX) Take one twice daily for 3 days for urinary tract infection
11553901|NCT00976950||Patients with HIV-1 infection|
11553902|NCT00976937|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide along with sitagliptin placebo: lixisenatide 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24 along with placebo matching to sitagliptin 100 milligram (mg) capsule orally QD up to Week 24.
11553903|NCT00976937|Active Comparator|Sitagliptin|Sitagliptin along with 2-step initiation regimen of volume matching lixisenatide placebo: sitagliptin 100 mg capsule orally QD up to Week 24 along with volume matching lixisenatide placebo 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
11553904|NCT00976924|Experimental|Andon|Andon blood glucose test strips with test meter
11553905|NCT00976924|Active Comparator|Lifescan|Lifescan blood glucose test strips with test meter
11553906|NCT00976911|Active Comparator|1|
11553907|NCT00976911|Experimental|2|
11553908|NCT00976898|Experimental|Proton Beam Irradiation|This is a single arm study. All study participants will receive proton radiation therapy.
11553909|NCT00976885||Subjects with normal health|
11553910|NCT00976885||Subjects with Stroke|
11553912|NCT00976872|Placebo Comparator|placebo|hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
11553913|NCT00976859|No Intervention|Waitlist control group|
11553914|NCT00976859|Experimental|Imagery Modification|Via a internet research patients collect data on skin renewal which is discussed afterwards; in a guided imagery modification the patients imagines the process of skin renewal and the building of new skin cells
11553915|NCT00976846|Experimental|Baxter Xenium XPH 210|Device: Baxter Xenium XPH 210 dialyzer
11553916|NCT00976833|Active Comparator|Usual Care|Usual Care
11553917|NCT00976833|Other|Standardized Rehabilitation|Intervention arm to receive Standardized Rehabilitation Therapy
11553918|NCT00976820|Experimental|Arepanrix/F1 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh [for children under (<) 12 months of age]. The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
11553919|NCT00976820|Experimental|Arepanrix/F2 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children < 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
11553920|NCT00976820|Experimental|GSK2340273A/F1 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children < 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
11553921|NCT00976820|Experimental|GSK2340273A/F2 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children < 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
11553922|NCT00976807|No Intervention|Control|
11553923|NCT00976807|Experimental|Intervention|Pulmonary Rehabilitation
11553924|NCT00976794|Experimental|lithium plus carbamazepine|combination of the two drugs in standard dosage
11553925|NCT00976794|Active Comparator|lithium plus valproate|combination of the two drugs in standard dosage
11553926|NCT00976768|Experimental|FOLFIRI arm|Patients receiving FOLFIRI
11553927|NCT00976755|Experimental|Arm A: Everolimus|"Everolimus:
~10mg daily"
11553928|NCT00976742|Experimental|Endurance Exercise Training|
11553929|NCT00976729|Placebo Comparator|Placebo i.v.|
11553930|NCT00976729|Experimental|0.03 mg/kg i.v.|
11553931|NCT00976729|Experimental|0.09 mg/kg i.v.|
11553932|NCT00976729|Experimental|0.25 mg/kg i.v.|
11553933|NCT00976729|Experimental|0.5 mg/kg i.v.|
11553934|NCT00976729|Experimental|1.0 mg/kg i.v.|
11553935|NCT00976729|Experimental|2.0 mg/kg i.v.|
11553936|NCT00976729|Placebo Comparator|Placebo s.c.|
11553937|NCT00976729|Experimental|0.25 mg/kg s.c.|
11553938|NCT00976729|Experimental|0.5 mg/kg s.c.|
11553939|NCT00976716|Experimental|Celecoxib|
11553940|NCT00976703|Active Comparator|weighted bag|For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.
11553941|NCT00976703|Active Comparator|leg taping|For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
11553942|NCT00976690|Active Comparator|1|Azathioprine : 2mg/kg/day
11553943|NCT00976690|Active Comparator|2|Mesalazine : 4g/day
11553944|NCT00976677|Active Comparator|Arm I|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes (with or without bevacizumab IV over 30-90 minutes) on day 1. Patients also receive placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with stable or responding disease may continue to receive placebo (with or without bevacizumab) as above in the absence of disease progression or unacceptable toxicity.
11553945|NCT00976677|Experimental|Arm II|Patients receive paclitaxel and carboplatin (with or without bevacizumab) as in arm I. Patients also receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with stable or responding disease may continue to receive erlotinib hydrochloride (with or without bevacizumab) as above in the absence of disease progression or unacceptable toxicity.
11553946|NCT00976664|Active Comparator|Orthotic group|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period.
11553947|NCT00976664|Other|Shoe Orthotic Wait group|The group serves as a cross-over control group. Subjects are asked to avoid any new therapies for the first 6 weeks of the 12 week study and during the last 6 weeks they are fitted for the custom-made shoe orthotics.
11553948|NCT00976651|Active Comparator|Recombinant FSH|Patients undergo a standard antagonist protocol for in-vitro fertilisation, and are stimulated with recombinant gonadotropins. Histology and gene expression is studied on the endometrium.
11554000|NCT00976339|Experimental|Cholecalciferol 30,000 IU|Participants will receive Cholecalciferol 30,000 IU (3 capsules) weekly for one year.
11554001|NCT00976326|Experimental|A: Healthy volunteers|
11554002|NCT00976326|Experimental|B: Subjects with mild liver impairment|
11554005|NCT00976313||1|male patients
11553949|NCT00976651|Experimental|human chorionic gonadotropin|"Patients undergo an antagonist protocol for in-vitro fertilisation and are stimulated with recombinant gonadotropins. When the patient has an estradiol value of 600 ng/L or more and when the patient has at least 6 follicles of 12 mm, the administration of gonadotropins is stopped and replaced by low dose human chorionic gonadotropins.
~Histology and gene expression is studied on the endometrium"
11553950|NCT00976638|Active Comparator|Chromogenic Arm|Active surveillance of colonization with MRSA or VRE by chromogenic agar with isolation of positive patients.
11553951|NCT00976638|Active Comparator|Molecular Arm|Active surveillance of colonization with MRSA and VRE by PCR; and of ESBL by chromogenic agar with isolation of positive patients
11553952|NCT00976625|No Intervention|1|Control group without intervention. Treatment group with aortic valve replacement.
11553953|NCT00976625|Other|2|
11553954|NCT00976612||Nilotinib|Patients who receive nilotinib with failure to both imatinib and sunitinib
11553955|NCT00976599|Experimental|CP-690,550 + methotrexate|
11553956|NCT00976599|Placebo Comparator|Placebo + methotrexate|
11553957|NCT00976586||Patients wiht Incontinentia Pigmenti|Patients wiht Incontinentia Pigmenti
11553958|NCT00976573|Experimental|Arm I (bevacizumab, paclitaxel, and carboplatin)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, paclitaxel IV over 60 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11553959|NCT00976573|Experimental|Arm II(bevacizumab, paclitaxel, carboplatin, and everolimus)|Patients receive bevacizumab, paclitaxel, and carboplatin as in Arm I. Patients also receive everolimus PO QD on 3 days a week. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11553960|NCT00976560|Experimental|GW856553|GW856553 7.5 mg BID
11553961|NCT00976560|Placebo Comparator|Placebo|Matching Placebo BID
11553962|NCT00976547||Tinnitus patients|Group of 48 tinnitus patients
11553963|NCT00976534|Experimental|1|
11553964|NCT00976534|Placebo Comparator|2|
11553965|NCT00976521|Experimental|Local infusion, thrombus aspiration|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter following thrombus aspiration.
11553966|NCT00976521|Experimental|Local infusion, no aspiration|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter and no aspiration
11553967|NCT00976521|Active Comparator|No local infusion, thrombus aspiration|No local infusion of abciximab, thrombus aspiration.
11553968|NCT00976521|Active Comparator|No local infusion, no aspiration|No local infusion abciximab and no thrombus aspiration
11553969|NCT00976508|Experimental|1|
11553970|NCT00976495|Experimental|Dapagliflozin|
11553971|NCT00976495|Active Comparator|Hydrochlorothiazide|
11553972|NCT00976482||Pacemaker|Patients currently implanted with permanent Pacemaker according to guidelines
11553973|NCT00976469|Experimental|Dose A (3.75 µg HA antigen, 0.25 mL)|Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5 µg) of H1N1 pandemic influenza vaccine at a 21-day interval.
11553974|NCT00976469|Experimental|Dose B (7.5µg HA antigen, 0.5 mL)|Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5µg) of H1N1 pandemic influenza vaccine at a 21-day interval. A booster vaccination with a licensed seasonal trivalent influenza vaccine for the season 2010/2011 will be administered to at least 30 subjects in each age stratum (who have received Dose B) at 360 days after the first vaccination.
11553975|NCT00976456|Active Comparator|Bevacizumab + Pemetrexed|Bevacizumab + Pemetrexed
11553976|NCT00976456|Active Comparator|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab + Pemetrexed + Carboplatin
11553977|NCT00976443|Placebo Comparator|Placebo (normal saline)|Gastric injections of normal saline
11553978|NCT00976443|Active Comparator|BTA 100 U|Gastric injections of botulinum toxin A, 100 Units
11553979|NCT00976443|Active Comparator|BTA 300 U|BTA 300 U, gastric injections under EUS guidance
11553980|NCT00976430|Experimental|Therapy for Parkinson's disease|Stem cell derived from the bone marrow of the patient will be stereotactically transplanted in the striatum.These stem cell are the expected to grow up into dopamine secreting neural cells.
11553981|NCT00976417||1. Patients in the control group|
11553982|NCT00976417||2. Patients in the intervention group|
11553983|NCT00976404|Active Comparator|Maraviroc + raltegravir intensification|ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)
11553984|NCT00976404|Experimental|Maraviroc + raltegravir intens. plus DNA + HIV-rAd5 vaccine|ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)
11553985|NCT00976391|Active Comparator|albiglutide + insulin glargine|albiglutide in combination with insulin glargine
11553986|NCT00976391|Active Comparator|insulin glargine + preprandial lispro insulin|insulin glargine in combination with preprandial lispro insulin
11553987|NCT00976378|Experimental|0.05 mg/kg NOX-A12|
11553988|NCT00976378|Experimental|0.15 mg/kg NOX-A12|
11553989|NCT00976378|Experimental|0.45 mg/kg NOX-A12|
11553990|NCT00976378|Experimental|1.35 mg/kg NOX-A12|
11553991|NCT00976378|Experimental|2.7 mg/kg NOX-A12|
11553992|NCT00976378|Experimental|5.4 mg/kg NOX-A12|
11553993|NCT00976378|Experimental|10.8 mg/kg NOX-A12|
11553994|NCT00976378|Experimental|5.4 mg/kg NOX-A12 plus apheresis|
11553995|NCT00976365|Experimental|THL-P|Solution for study only.
11553996|NCT00976365|Placebo Comparator|Sugar pill|THL-p
11553997|NCT00976352|Experimental|rAAV1-CMV-GAA administration-cohort 1|rAAV1-CMV-GAA (study agent) Administration: 1.0 x 10e12 vector genomes. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.
11553998|NCT00976352|Experimental|rAAV1-CMV-GAA administration-cohort 2|rAAV1-CMV-GAA (study agent) Administration: 5.0 x 10e12 vector genomes Cohort 2 = 6 subjects. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.
11553999|NCT00976339|Experimental|Cholecalciferol 20,000 IU|Participants will receive Cholecalciferol 20,000 IU (2 capsules) weekly for one year.
11554006|NCT00976313||2|female patients
11554007|NCT00976300|Experimental|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months.
11554008|NCT00976300|Active Comparator|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals).
11554009|NCT00976287|Active Comparator|Conserved Therapy|Conserved Therapy
11554010|NCT00976287|Experimental|Interventional Therapy|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
11554011|NCT00976274|Placebo Comparator|starch capsule|
11554012|NCT00976274|Experimental|Korea red ginseng|
11554013|NCT00976261|Experimental|GSK1614235|Glucose lowering agent under investigation.
11554014|NCT00976261|Active Comparator|Sitagliptin|Glucose lowering comparator
11554015|NCT00976261|Placebo Comparator|Placebo|Placebo to match GSK1614235 and placebo to match Sitagliptin
11554016|NCT00976248|Experimental|RAD001|RAD001, oral, 10 mg, daily
11554017|NCT00976235|Experimental|IMT|
11554018|NCT00976222|Other|1 Arm Ranibizumab|
11554019|NCT00976209|Experimental|Phenylephrine Hydrochloride Extended Release Tablets, 30 mg|
11554020|NCT00976209|Active Comparator|Phenylephrine Hydrochloride Immediate Release Tablets, 10 mg|
11554021|NCT00976183|Experimental|Vorinostat|All study patients will receive the indicated dose of Vorinostat in conjunction with paclitaxel and carboplatin.
11554022|NCT00976170|Experimental|1|
11554023|NCT00976157||Ventilator-associated pneumonia|
11554024|NCT00976144|Experimental|GSK573719, GW642444, GSK573719+GW642444, placebo|This is a four-way cross-over study. Subjects, healthy volunteers, will receive a single dose of GSK573719 (500ug), GW642444 (50ug), GSK573719 (500ug)+GW642444 (50ug) administered concurrently, or placebo at each of the four treatment periods. There is a minimum wash-out period of seven days between doses. On enrolment into the study, subjects will be assigned to one of four treatment sequences which are based on a Williams design in accordance with the randomization schedule generated by GSK prior to study start.
11554025|NCT00976131|Placebo Comparator|Arm A|Cycle 3 of doxorubicin with Coenzyme Q10, Cycle 4 with Coenzyme Q10 Placebo
11554026|NCT00976131|Experimental|Arm B|Cycle 3 of doxorubicin with Coenzyme Q10 Placebo, Cycle 4 with Coenzyme Q10
11554027|NCT00976118|Placebo Comparator|placebo|
11554028|NCT00976118|Experimental|oral masitinib (AB1010)|masitinib (AB1010) 3 or 6 mg/kg/day
11554029|NCT00976105|Active Comparator|Part A: Zolpidem or placebo|This part is designed to examine the acute effects of up to 10mg of a known hypnotic sedative drug (Zolpidem) on cognitive and mood changes sensitve to sedation and tiredess.
11554030|NCT00976105|Experimental|Part B: GSK1521498 or placebo|At least 15 hours after Part A is completed subjects will enter Part B of the study.
11554031|NCT00976092|Experimental|Prasugrel + Bivalirudin|60 mg prasugrel plus bivalirudin
11554032|NCT00976092|Active Comparator|Clopidogrel + Heparin|clopidogrel as loading and heparin
11554033|NCT00976079|Experimental|Active TENS|Active TENS therapy for 4 weeks plus standard physical therapy for same time period.
11554034|NCT00976079|Placebo Comparator|Placebo TENS|Placebo TENS for 4 weeks plus standard physical therapy for same time period.
11554035|NCT00976079|No Intervention|Control Group|No TENS, standard physical therapy for 4 weeks.
11554036|NCT00976066|Experimental|GSK1521498|Subjects will receive a dose of the experimental compound GSK1521498
11554037|NCT00976066|Active Comparator|Naltrexone|Subjects will receive a dose of the licensed pharmaceutical product, Naltrexone
11554038|NCT00976053|Active Comparator|SPECT myocardial perfusion imaging|
11554039|NCT00976053|Active Comparator|PET myocardial perfusion imaging|
11554040|NCT00976040|Experimental|Early antiretroviral therapy|Subjects randomized to this arm will initiate antiretroviral therapy within 7 days of enrollment.
11554041|NCT00976040|No Intervention|Standard antiretroviral therapy|Subjects randomized to this arm will initiate antiretroviral therapy approximately 4 weeks after enrollment.
11554042|NCT00976027|Experimental|Fluzone® High Dose Group|
11554043|NCT00976027|Active Comparator|Fluzone® Group|
11554044|NCT00976014||Intensive Lipid-lowering therapy|Subjects on intensive long-term lipid lowering therapy (lowering LDL-C plus raising of HDL-C).
11554045|NCT00976014||Usual Care|"Subjects with Atherosclerosis who have been on conventional standard of care treatment."
11554046|NCT00976001|Other|Follow-up at an out-patient stroke unit|Information, measurement of handicap, further rehabilitation efforts, drug therapy for secondary prevention of stroke.
11554047|NCT00976001|Other|Follow-up with the general practitioner|
11554048|NCT00975988||TYKERB® tablets|There is only one group. This group includes patients administrated TYKERB® tablets
11554049|NCT00975975|Experimental|Basiliximab|Basiliximab will be given by IV on Day +7 post transplant for recipients of matched unrelated cells. Basiliximab will be given by IV on Day +9 post transplant for recipients of matched related cells.
11554050|NCT00975962|Experimental|Thrombolysis + Remote perconditioning|"Remote perconditioning (rIPerC) undertaken in ambulance on rute to hospital in case of suspected stroke.
~The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC."
11554051|NCT00975962|Active Comparator|Thrombolysis|Thrombolysis without pretreatment with remote perconditioning
11554052|NCT00975949||Fluconazole Group|These subjects received fluconazole in our NICU fluconazole prophylaxis study during 1998-2000
11554053|NCT00975949||Placebo Group|These subjects received a placebo during our NICU fluconazole prophylaxis study during 1998-2000
11554054|NCT00975936|Experimental|[14C]-GSK706769|Single dose of 50µg [14C]-GSK706769 containing 250 nCi
11554055|NCT00975936|Experimental|[14C]-GSK706769 + Ketoconazole|An oral, 5-day repeat dose of 200 mg Ketoconazole (Q12) with a concomitant single oral dose of 50 µg [14C]-GSK706769 containing 250 nCi on day 3.
11554056|NCT00975923|Experimental|Collaborative Group|Quality Improvement Virtual Learning Collaborative with Interactive Teleconferences and Tool Kit
11554057|NCT00975923|Active Comparator|Tool Kit Group|Tool Kit of Evidence-Based Guidelines, Education Seminars, and Aide for Quality Improvement Methods
11554058|NCT00975910|Placebo Comparator|Saline|
11554059|NCT00975910|Active Comparator|Lidocaine|
11554060|NCT00975884|Experimental|GSK2340272A (D21) GROUP|Healthy male or female adults, above 18 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21 (D21).
11554061|NCT00975884|Experimental|GSK2340272A (M6) GROUP|Healthy male or female adults, above 18 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Month 6 (M6).
11554062|NCT00975858|Active Comparator|Percutaneous Coronary Intervention|
11554063|NCT00975858|Experimental|Off Pump Coronary Artery Bypass Surgery|
11554064|NCT00975845||BioCleanse Tibialis Tendon Allograft|Tibialis Tendon allograft from donor 18-65 years old
11554065|NCT00975832||women with polycystic ovary syndrome|
11554066|NCT00975832||women without polycystic ovary syndrome|
11554067|NCT00975832||women from 18-40 years of age|
11554068|NCT00975819|Experimental|Sirolimus|
11554069|NCT00975806|Experimental|Cohort A|Participants received an oral dose of lenalidomide MTD (mg) capsule administered in combination with a single dose of sunitinib 37.5 mg on days 1-21 of each 21-day cycle
11554070|NCT00975806|Experimental|Cohorts F and G|Participants received an oral daily dose of lenalidomide on Days 1 to 21 in combination with a single oral daily dose of sunitinib 37.5 mg on days 1 to 14 or days 1 to 21 of each 21-day cycle
11554071|NCT00975793|No Intervention|Standard Care|Randomised allocation of standard care at the clinician's discretion in accordance with current best practice.
11554072|NCT00975793|Experimental|Early Goal Directed Therapy|Randomised allocation of early goal-directed therapy (EGDT).
11554073|NCT00975780|Experimental|enhanced oral care|
11554074|NCT00975780|Active Comparator|Usual care|The usual oral care provided at the nursing home
11554075|NCT00975767|Experimental|MGCD265+erlotinib|
11554076|NCT00975767|Experimental|MGCD265+docetaxel|
11554077|NCT00975754|Experimental|1|Pulmicort pMDI
11554078|NCT00975754|Experimental|2|Budesonide pMDI
11554079|NCT00975754|Experimental|3|Budesonide pMDI + Aerochamber Zero-stat spacer
11554080|NCT00975754|Experimental|4|Pulmicort repulses via Spira Nebuliser
11554081|NCT00975754|Experimental|5|Pulmicort Turbohaler
11554082|NCT00975741|Experimental|Monodose device|Mometasone furoate 400 µg DPI capsules administered through a monodose device.
11554083|NCT00975741|Active Comparator|Multidose device|Mometasone furoate 400 µg DPI capsules administered through a multidose device
11554084|NCT00975728|Experimental|Group 1 Product 825 (2-servings day)|30 subjects drinking 2 servings day of Product 825 for 8 weeks
11554085|NCT00975728|Experimental|Group 1 Product 824 (2 servings-day)|30 subjects drinking 2 servings-day of Product 824 for 8 weeks
11554086|NCT00975728|Experimental|Group 2 Product 825 (1 serving-day)|30 subjects drinking 1 serving-day of Product 825 for 8 weeks
11554087|NCT00975728|Experimental|Gruop 2 Product 824 (1 serving-day)|30 subjects drinking 1 serving-day of Product 824 for 8 weeks
11554088|NCT00975715|Experimental|TRI476|Participants received TRI476 based on body weight with titration up to the maintenance dose, in addition to their traditional antiepileptics dosage.
11554089|NCT00975715|Placebo Comparator|Placebo|Participants received placebo to TRI476 without any adjustment to the dosing regimen, in addition to their traditional antiepileptics dosage.
11554090|NCT00975702|No Intervention|No RIPC Group|This group is the control group or the comparator group with RIPC
11554091|NCT00975702|Experimental|RIPC Group|In this group deceased donors will receive Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet of the lower limb prior to organ recovery.
11554092|NCT00975676|Experimental|Triptorelin plus tamoxifen|Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.
11554093|NCT00975676|Experimental|Triptorelin plus exemestane|Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years.
11554094|NCT00975663|Experimental|1|Optimized TDM of tacrolimus and MMF dosing
11554095|NCT00975663|Active Comparator|2|Current tacrolimus and MMF dosing strategies
11554096|NCT00975650|Experimental|Test 8.0, Ref 5.0, Test 14.0, Test 11.0|Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days;
11554097|NCT00975650|Experimental|Test 11.0, Test 8.0, Ref 5.0, Test 14.0|Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days
11554098|NCT00975650|Experimental|Test 14.0, Test 11.0, Test 8.0, Ref 5.0|Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days;
11554099|NCT00975650|Experimental|Ref 5.0, Test 14.0, Test 11.0, Test 8.0|Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days
11554100|NCT00975637|Experimental|140 mg SC|140 mg SC
11554101|NCT00975637|Experimental|70 mg SC|70 mg SC
11554102|NCT00975637|Experimental|280 mg SC|280 mg SC
11554103|NCT00975637|Placebo Comparator|210 mg SC|210 mg SC
11554104|NCT00975637|Experimental|Placebo|Placebo
11554105|NCT00975611|Active Comparator|Amantadine 100mg BID|Subjects take amantadine 100mg tablets twice per day (BID)
11554106|NCT00975611|Active Comparator|Amantadine, 200mg BID|Subjects take amantadine 200mg tablets twice per day (BID)
11554107|NCT00975611|Placebo Comparator|Amantadine, placebo BID|Subjects take placebo tablets twice per day (BID)
11554108|NCT00975585|Active Comparator|senofilcon A both eyes|soft contact lens worn daily for 2 weeks, with a 2-week replacement regimen.
11554109|NCT00975585|Active Comparator|lotrafilcon B both eyes|soft contact lens worn daily for 4 weeks, with a 4-week replacement regimen
11554110|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 7.5 μg|
11554111|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 15 μg|
11554112|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 30 μg|
11554113|NCT00975572|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|
11554114|NCT00975572|Placebo Comparator|Placebo control|
11554115|NCT00975572|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|
11554116|NCT00975559||Normal volunteers|Normal study volunteers with no prior history of coronary artery disease
11554117|NCT00975559||Apical Ballooning Syndrome|Women who have had a documented Apical Ballooning event as shown by coronary angiogram
11554118|NCT00975559||Coronary Endothelial Dysfunction|Patients who have been diagnosed with Endothelial Dysfunction via a coronary angiogram with acetylcholine challenge
11554119|NCT00975559||Myocardial Infarction|Women diagnosed with a Myocardial Infarction who subsequently had a Percutaneous Intervention
11554120|NCT00975533|Experimental|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM. The device is intended to improve glycemic control and induce weight loss.
11554121|NCT00975533|Active Comparator|Control|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
11554122|NCT00975520|Active Comparator|Radiation Therapy|Investigational Treatment
11554123|NCT00975520|Other|Observation|Observation
11554124|NCT00975507|Experimental|1|ProQuad™ (V221) + Placebo Followed by ProQuad™
11554125|NCT00975507|Active Comparator|2|M-M-R™ II + VARIVAX™
11554126|NCT00975494|Active Comparator|sildenafil|sildenafil 50 mg three times/day
11554127|NCT00975494|Placebo Comparator|Placebo|Placebo
11554128|NCT00975481|Experimental|dimebon 20 mg|
11554129|NCT00975481|Experimental|dimebon 40 mg|
11554130|NCT00975481|Experimental|dimebon 60 mg|
11554131|NCT00975481|Placebo Comparator|placebo|
11554132|NCT00975481|Active Comparator|alprazolam 1 mg|
11554133|NCT00975481|Active Comparator|alprazolam 3 mg|
11554134|NCT00975468|Active Comparator|Pressure-Controlled Ventilation|The patients' lungs ventilation will be initiated with a peak airway pressure that provided a tidal volume of 8 ml.kg-1. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
11554135|NCT00975468|Placebo Comparator|Volume Controlled Ventilation|The patients' lungs will ventilated with a tidal volume of 8 ml.kg-1. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
11554136|NCT00975455||Subjects with hematuria|
11554137|NCT00975442|Experimental|Eccentric training|
11554138|NCT00975442|Placebo Comparator|Forearm band|
11554139|NCT00975429|Experimental|WST11 - 4mg (TOOKAD® Soluble)|4mg/kg Treatment with WST11-mediated VTP
11554140|NCT00975429|Experimental|WST11 - 6mg|6mg/kg Treatment with WST11-mediated VTP
11554141|NCT00975416|Placebo Comparator|Methadone|Intranasal oxytocin administered in the context of cognitive behavioral therapy to methadone dependent outpatients
11554142|NCT00975416|Placebo Comparator|Outpatient Cocaine|Intranasal oxytocin administered in the context of cognitive behavioral therapy to cocaine dependent outpatients
11554143|NCT00975416|Placebo Comparator|Inpatient Cocaine|Intranasal oxytocin administered in the context of cognitive behavioral therapy to cocaine dependent inpatients
11554144|NCT00975403|Experimental|Dead space breathing|
11554145|NCT00975403|Sham Comparator|Room air breathing|
11554146|NCT00975390|Experimental|1|Carbohydrate ingestion
11554147|NCT00975390|Experimental|2|Carbohydrate and protein ingestion
11554148|NCT00975390|Experimental|3|Carbohydrate and caffeine ingestion
11554149|NCT00975377|No Intervention|No hair removal|Patients randomized to the no hair removal cohort will not undergo any preoperative hair removal.
11554150|NCT00975377|Active Comparator|Hair clipping|Patients in the clipping cohort undergo hair removal at the surgical site. Hair removal will occur on the day of surgery immediately prior to the scheduled operation.
11554151|NCT00975364||blood sampling|Consented volunteers provide a one-off blood sample
11554152|NCT00975351|Experimental|IV dose of 5-methyltetrahydrofolic acid|IV test dose of 13C5-labelled 5-methyltetrahydrofolic acid to all eligible volunteers, followed by regular blood samplings over 2hr period taken via a cannula.
11554153|NCT00975338||Prospective LIFEspan|LIFEspan youths with Cerebral Palsy or Acquired Brain Injury
11554154|NCT00975338||Prospective Non-LIFEspan|LIFEspan youths with Spina Bifida
11554155|NCT00975338||Retrospective Non-LIFEspan|Non-LIFEspan youths with Cerebral Palsy or Acquired Brain Injury
11554156|NCT00975338||LIFEspan Staff|All staff affiliated with the LIFEspan model of linked transition care
11554157|NCT00975338||Caregivers|Parents of participating youths
11554158|NCT00975325|Active Comparator|"Yohimbine, Yohimbine Spiegel"|
11554159|NCT00975325|Active Comparator|Yohimbine Yocon-Glenwood|
11554160|NCT00975312|Experimental|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand.
11554161|NCT00975299|Experimental|Arm 1|
11554162|NCT00975299|Experimental|Arm 2|
11554163|NCT00975286|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
11554248|NCT00974727|Experimental|Gardening Program|
11554164|NCT00975286|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
11554165|NCT00975273|Experimental|Breathing Training|Patients will receive biofeedback assisted breathing training
11554166|NCT00975273|Active Comparator|Breathing Awareness|Patients will receive biofeedback assisted breathing awareness training.
11554167|NCT00975247|Active Comparator|Received Booklet|Patients who have received colonoscopy preparation booklet
11554168|NCT00975247|No Intervention|Did not receive booklet|Patients who did not receive colonoscopy preparation booklet
11554169|NCT00975234|Experimental|Skeletal myoblasts|Patients who are receiving skeletal myoblasts
11554170|NCT00975234|Placebo Comparator|Placebo|Revascularisation surgery
11554171|NCT00975221|Experimental|Cinacalcet|Participants received cinacalcet at a starting dose of 30 mg orally BID and were eligible for a dose titration once every 3 weeks during the 12-week dose-titration phase based on corrected total serum calcium concentration and safety assessments. Participants continued to receive cinacalcet for another 16 weeks during the efficacy assessment phase and then continued into the open-label extension phase and received cinacalcet at a starting dose of 30 mg BID for 24 weeks. The dose of cinacalcet could have been increased or decreased as needed to maintain a corrected total serum calcium concentration within the normal range through Week 52.
11554172|NCT00975221|Placebo Comparator|Placebo|Participants received placebo orally twice a day (BID) for 12 weeks during the dose titration phase and for another 16 weeks during the efficacy assessment phase. Participants then continued into the open-label extension phase and received cinacalcet at a starting dose of 30 mg BID for 24 weeks. The dose of cinacalcet could have been increased or decreased as needed to maintain a corrected total serum calcium concentration within the normal range through Week 52.
11554173|NCT00975195|Experimental|fluticasone high dose|fluticasone priopionate high dose and tiotropium inhalation and salmeterol xinafoate
11554174|NCT00975195|Experimental|fluticasone medium & low doses|fluticasone priopionate medium and high doses; and tiotropium inhalation; and salmeterol xinafoate; and placebo matched to fluticasone priopionate
11554175|NCT00975182|Experimental|A|
11554176|NCT00975169||TZDs User|
11554177|NCT00975156|Experimental|Lokomat Intervention|Lokomat gait training (five days a week for eight weeks for a total of 40 sessions).
11554178|NCT00975156|Active Comparator|Standard of Care|Conventional physical therapy focusing on gait training for five days a week for eight weeks for a total of 40 sessions.
11554179|NCT00975143|Experimental|CIP-Isotretinoin|
11554180|NCT00975143|Active Comparator|Isotretinoin|
11554181|NCT00975130|Experimental|SC-GLM50|In Part 1 of the study, participants received subcutaneous golimumab treatment at a dose of 50 mg once monthly for 6 months in combination with background DMARD treatment.
11554182|NCT00975130|Experimental|IV GLM 2 mg/kg + GLM50-SC|After 6 months of treatment in study Part 1, participants with good or moderate response but not in remission will receive intravenous (IV) golimumab at a dose of 2 mg/kg once monthly for a period of 6 months or until remission is achieved. Participants will receive IV GLM at a dose of 2 mg/kg at the start of Month 7, and then at the start of Month 8 and Month 10 if the subject has not achieved remission at any of these IV administration visits. If remission is achieved, participants were switched to subcutaneous golimumab at a dose of 50 mg once monthly until study end, in combination with background DMARD treatment.
11554183|NCT00975130|Experimental|GLM50-SC|After 6 months of treatment in study Part 1, participants with good or moderate response but not in remission will receive subcutaneous golimumab at a dose of 50 mg once monthly for a period of 6 months, in combination with background DMARD treatment.
11554184|NCT00975117|Placebo Comparator|Placebo|
11554185|NCT00975117|Experimental|Spermotrend|
11554186|NCT00975104|Experimental|AMG 745 0.3 mg/kg|0.3 mg/kg AMG 745
11554187|NCT00975104|Experimental|AMG 745 1.0 mg/kg|1.0 mg/kg, AMG 745
11554188|NCT00975104|Placebo Comparator|Placebo|Placebo
11554189|NCT00975104|Experimental|AMG 745 3.0 mg/kg|3.0 mg/kg, AMG 745
11554190|NCT00975091|Active Comparator|Entecavir 0.5|
11554191|NCT00975091|Active Comparator|Entecavir 1.0|
11554192|NCT00975078|Experimental|adrenal insufficiency|
11554193|NCT00975065|Experimental|Galvus group|"the combination of metformin plus Vildagliptin:
~vildagliptin 50 mg bid plus metformin 1500mg
~Additional SU therapy(After 12th week only under the following conditions): If A1c is ≥ 7.0% or investigator determines that the patient have metabolic problems at 12th week of therapy, investigator can prescribe additional sulfonylurea(glimepiride) to the current therapy."
11554194|NCT00975065|Active Comparator|Diabex group|"metformin alone arm:
~metformin 1500mg plus metformin 500mg or 1000mg
~Additional SU therapy(After 12th week only under the following conditions): If A1c is ≥ 7.0% or investigator determines that the patient have metabolic problems at 12th week of therapy, investigator can prescribe additional sulfonylurea(glimepiride) to the current therapy"
11554195|NCT00975052|Active Comparator|A|Sitagliptin alone
11554196|NCT00975052|Active Comparator|B|Metformin alone
11554197|NCT00975052|Experimental|C|Sitagliptin and metformin concomitantly
11554198|NCT00975052|Placebo Comparator|D|Placebo
11554199|NCT00975039|Experimental|WST11|Treatment with WST11-mediated VTP
11554200|NCT00975026|Active Comparator|Massages|Chair massage for 30 minutes once a week.
11554201|NCT00975026|Active Comparator|Massages + Stretches|Chair massage for 30 minutes once a week in addition to stretching exercises, to be done twice daily for 20 minutes.
11554202|NCT00975026|No Intervention|No Intervention|
11554203|NCT00975013||Bone Density Study Group|Morbidly obese, (BMI >40 kg/m2, or 35 kg/m2 with comorbidities) female patients who have given consent to undergo additional testing including bone densitometry, and lab testing preoperatively and at 6 and 12 months after undergoing elective laparoscopic roux-en-Y gastric bypass.
11554204|NCT00975000|Experimental|Cinacalcet|Participants received cinacalcet at a starting dose of 30 mg orally once daily for 52 weeks. Cinacalcet dose was titrated every 4 weeks during the dose-titration phase and during study visits in the maintenance phase based on intact parthyroid hormone (iPTH) values, corrected total serum calcium values, and safety assessments.
11554205|NCT00975000|Placebo Comparator|Placebo|Participants received placebo orally once daily for 52 weeks.
11554249|NCT00974727|No Intervention|Control|Subjects received the standard of care for the summer.
11554206|NCT00974987|Experimental|Treatment group|BNCT(boron neutron capture therapy), XRT(X-ray radiation treatment) and TMZ(temozolomide) treatment
11554207|NCT00974974|Experimental|IPX066|Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IPX066.
11554208|NCT00974974|Active Comparator|IR CD-LD|Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IR CD-LD (active comparator).
11554209|NCT00974961|Active Comparator|Levobupivacaine|Lumbar puncture with Levobupivacaine for spinal anesthesia
11554210|NCT00974961|Active Comparator|Bupivacaine|Lumbar puncture with Bupivacaine for spinal anesthesia
11554211|NCT00974948|Active Comparator|Neurolysis|Patients will undergo EUS followed by EUS-guided, bilateral neurolysis with bupivicaine and absolute alcohol.
11554212|NCT00974948|No Intervention|Conventional therapy|EUS will be performed with no celiac plexus neurolysis.
11554213|NCT00974935|Experimental|Cohort 1|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01 mcg intramuscular.
11554214|NCT00974935|Experimental|Cohort 2|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.1 mcg intramuscular.
11554215|NCT00974935|Experimental|Cohort 3|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.5 mcg intramuscular.
11554216|NCT00974935|Experimental|Cohort 4|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 2.5 mcg intramuscular.
11554217|NCT00974935|Experimental|Cohort 5|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 10 mcg intramuscular.
11554218|NCT00974935|Experimental|Cohort 6|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 20 mcg intramuscular.
11554219|NCT00974935|Experimental|Cohort 7|Two doses of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 20 mcg intramuscular 21 days apart.
11554220|NCT00974922|Active Comparator|Phase I: Aliskiren|Two weeks of single-blind placebo, followed by randomization in a double-blind fashion to Aliskiren 150 mg to 300 mg once daily for 6 weeks
11554221|NCT00974922|Active Comparator|Phase I: Cholecalciferol|Two weeks of single-blind placebo, followed by randomization in a double-blind fashion to Cholecalciferol (3000 I.U.) once daily for 6 weeks
11554222|NCT00974922|Active Comparator|Phase II: Aliskiren and Vitamin D3|Aliskiren 150-300 mg orally once daily and Cholecalciferol 3000 I.U. in combination once daily for 6 weeks
11554223|NCT00974909|Active Comparator|Treatment group|Treatment group
11554224|NCT00974909|Sham Comparator|sham group|Sham group
11554225|NCT00974896|Experimental|AMG 479 + Sorafenib cohorts|The aim is to determine the safety, tolerability and PK of AMG 479 with sorafenib. AMG 479 will be given bi-weekly; sorafenib will be given daily.
11554226|NCT00974896|Experimental|AMG 479 + Erlotinib cohorts|The aim is to determine the safety, tolerability and PK of AMG 479 with erlotinib. AMG 479 will be given bi-weekly; erlotinib will be given daily.
11554227|NCT00974883||Suspected GCA|Patients who present with new onset of headache and suspected diagnosis of GCA. They will all require a temporal artery biopsy to assist in the diagnosis
11554228|NCT00974883||Training cohort|Patients with any condition or healthy volunteers who are willing to consent ot have their temporal and axillary arteries examined using ultrasound, for training purposes
11554229|NCT00974870|Experimental|needling treatment|Needling treatment applied to half of the face at each study visit
11554230|NCT00974870|No Intervention|Control|No treatment applied to half of the face
11554231|NCT00974857|Active Comparator|Study group|"Pre-dialytic overhydration(OH) will be estimated by Body Composition Monitor (BCM) at least once a month.
~If OH is positive, dry weight will be reached by ultrafiltration without regard to the level of blood pressure.
~If OH is negative and:
~Systolic blood pressure(SBP)< 100 mmHg with/or intradialytic hypotension episodes(IDHE) and/or clothing and/or erythrocytosis(htc>36%);dry weight will be increased.
~SBP normal(100-150 mmHg) w/o IDHE and clothing and erythrocytosis;dry weight will not be changed.
~SBP normal(100-150 mmHg) with IDHE and/or clothing and/or erythrocytosis;dry weight will be increased.
~SBP>150 mmHg captopril test(CT)will be done. If CT is positive, ACEI/ ARBs will be used and dry weight will be increased if IDHE and/or clothing and/or erythrocytosis(htc>36%) are present.
~If CT is negative, BCM measurement will be repeated and if same,ABPM will be performed for confirmation."
11554232|NCT00974857|Other|Control Group|BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
11554233|NCT00974831|Experimental|AA Drink|Amino Acid Drink Mixture
11554234|NCT00974831|Placebo Comparator|Glucose drink|
11554235|NCT00974818|Experimental|pts getting Mitomycin C (MMC)|Patients will receive a induction course of 6 cycles of weekly intravesical therapy of MMC, followed by a maintenance schedule consisting of 3 weekly cycles of the same drug at 3, 6, 12, 18, and 24 months.
11554236|NCT00974818|Experimental|pts getting Bacillus Calmette-Guerin (BCG)|Patients will receive a induction course of 6 cycles of weekly intravesical therapy of either BCG, followed by a maintenance schedule consisting of 3 weekly cycles of the same drug at 3, 6, 12, 18, and 24 months.
11554237|NCT00974805|Experimental|Seretide 500 Accuhaler|Seretide 500 Accuhaler one inhalation BD
11554238|NCT00974779|Experimental|HCO dialyzer|Hemodialysis with the HCO1100 hemodialyzer membrane with high molecular weight cut off.
11554239|NCT00974779|Active Comparator|Placebo|Regular dialysis using a polyamide high-flux hemodialyzer
11554240|NCT00974766|Active Comparator|Low-dose glucocorticoid|Low-dose steroid
11554241|NCT00974766|Active Comparator|High-dose glucocorticoid|High-dose steroid
11554242|NCT00974753|Placebo Comparator|PPV-MP + Placebo (Saline drops)|PPV-MP= pars plana vitrectomy membrane peel
11554243|NCT00974753|Active Comparator|PPV-MP + Ketorolac 0.5%|PPV-MP= pars plana vitrectomy membrane peel
11554244|NCT00974753|Placebo Comparator|PhacoVit-MP + Placebo (Saline drops)|PhacoVit-MP= phacovitrectomy membrane peel
11554245|NCT00974753|Active Comparator|PhacoVit-MP + Ketorolac 0.5%.|PhacoVit-MP= phacovitrectomy membrane peel
11554246|NCT00974740|Placebo Comparator|atorvastatin matching placebo|atorvastatin matching placebo
11554247|NCT00974740|Experimental|atorvastatin|40 mg atorvastatin for 4 weeks (run-in period), then 80 mg atorvastatin, total treatment period was 18 months
11554250|NCT00974714|Experimental|1|Oral L-arginine 2 g twice a day, for 14 weeks
11554251|NCT00974714|Placebo Comparator|2|oral placebo twice a day for 14 weeks
11554252|NCT00974701|Experimental|Patients to undergo PillCam procedure|Patients presenting to ER with acute overt upper GI bleeding
11554253|NCT00974688|Active Comparator|Group 1|
11554254|NCT00974688|Active Comparator|Group 2|
11554255|NCT00974675|Experimental|CAT-354 1 mg/kg|CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
11554256|NCT00974675|Experimental|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
11554257|NCT00974675|Experimental|CAT-354 10mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
11554258|NCT00974675|Placebo Comparator|Placebo|Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.
11554259|NCT00974662|Experimental|WST11|Treatment with WST11-mediated VTP
11554260|NCT00974649|No Intervention|Included in questionnaire study|
11554261|NCT00974636|Experimental|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day for two weeks
11554262|NCT00974636|Placebo Comparator|Ususal Salt Diet|Usual salt intake (approximately >180-200 mmol/day in the average American diet).
11554263|NCT00974623||Spinal Fusion|Patients who undergo a planned spinal fusion procedure requiring approved bone grafting materials (e.g., bone grft substitutes, allograft or autograft).
11554264|NCT00974610||Breast|
11554265|NCT00974610||Lung|
11554266|NCT00974610||Melanoma|
11554267|NCT00974610||Pancreatic|
11554268|NCT00974610||Colorectal|
11554269|NCT00974584|Experimental|GDC-0941+Paclitaxel+Carboplatin|Bevacizumab-ineligible non-small cell lung cancer (NSCLC) participants may receive up to 6 cycles (21-day cycle) of combination chemotherapy with paclitaxel and carboplatin along with GDC-0941
11554270|NCT00974584|Experimental|GDC-0941+Paclitaxel+Carboplatin+Bevacizumab|Bevacizumab-eligible NSCLC particpants may receive up to 6 cycles of combination chemotherapy with paclitaxel and carboplatin along with GDC-0941 and bevacizumab.
11554271|NCT00974584|Experimental|GDC-0941+Pemetrexed+Cisplatin|Bevacizumab-ineligible NSCLC participants may receive up to 6 cycles of combination chemotherapy with pemetrexed and cisplatin along with GDC-0941.\n
11554272|NCT00974584|Experimental|GDC-0941+Pemetrexed+Cisplatin+Bevacizumab|Bevacizumab-eligible NSCLC participants may receive up to 6 cycles of combination chemotherapy with pemetrexed and cisplatin along with GDC-0941 and bevacizumab.\n
11554273|NCT00974571|Experimental|1|montelukast
11554274|NCT00974571|Active Comparator|2|cetirizine
11554275|NCT00974571|Placebo Comparator|3|placebo
11554276|NCT00974558|Experimental|fan directed to cheeks|Blow draft of air generated by fan across cheeks
11554277|NCT00974532|Active Comparator|Subjects with normal kidney function|eGFR > 60 ml/min/m²
11554278|NCT00974532|Experimental|CKD late Stage 3 and Stage 4|eGFR 15-40 ml/min/m²
11554279|NCT00974519|Active Comparator|Fuzheng 3|Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
11554280|NCT00974519|Active Comparator|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
11554281|NCT00974519|Placebo Comparator|Placebo|Placebo, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
11554282|NCT00974506|Active Comparator|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine therapy by general practitioner
11554283|NCT00974506|Active Comparator|Routine care therapy|Routine care therapy by general practitioner
11554284|NCT00974493|Active Comparator|Oral antibiotics|
11554285|NCT00974493|Active Comparator|Intravenous antibiotics|
11554286|NCT00974480|Experimental|Redermic|Cream was applied twice a day every day, morning and evening for 24 weeks.
11554287|NCT00974480|Active Comparator|Rejuva-A|Week 1, Rejuva-A cream was applied to face in the evening twice a week. Weeks 2 & 3, Rejuva-A cream was applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream was applied to the face in the evening every other day. In cases of intolerance, returned to the previous dosage and remained there until the end of study. Hydrating cream was applied to the face in the morning every day for 24 weeks.
11554288|NCT00974480|Active Comparator|Combination of Redermic and Rejuva-A|Week 1, Rejuva-A cream was applied to face in the evening twice a week. Weeks 2 & 3, Rejuva-A cream was applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream was applied to the face in the evening every other day. In cases of intolerance, returned to the previous dosage and remained there until the end of study. Redermic was applied every evening when Rejuva-A™ was not applied, as well as every morning.
11554289|NCT00974467|Experimental|After The Injury website|
11554290|NCT00974467|Other|Usual care|Treatment as usual
11554291|NCT00974454|Active Comparator|Fuzheng 2|Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
11554292|NCT00974454|Placebo Comparator|Placebo|Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
11554293|NCT00974441|Experimental|Divalproex Sodium|500 mg Extended Release Tablet
11554294|NCT00974441|Active Comparator|Depakote®|500 mg Extended Release Tablet
11554295|NCT00974428|Active Comparator|Wobenzym® N and placebo|Wobenzym® N 2 tablets of the treatment and 2 placebo tablets three times per day
11554296|NCT00974428|Active Comparator|Wobenzym® N|Wobenzym® N 4 tablets three times per day
11554297|NCT00974428|Placebo Comparator|Placebo|Placebo 4 tablets three times per day
11554298|NCT00974415|Experimental|treatment|CO2 treatment
11554299|NCT00974415|Sham Comparator|sham|sham treatment
11554300|NCT00974402|Experimental|Patients with PTSD Symptoms|Patients with Post-Traumatic Stress Disorder (PTSD) symptoms willing to undergo Cognitive Behavioral Therapy in a primary care setting.
11554301|NCT00974376|Experimental|Gabapentin 1200mg/day|1200mg/day of gabapentin for 12 weeks given in conjunction with 12 weeks of manual-guided behavioral counseling.
11554302|NCT00974376|Placebo Comparator|Placebo|1200mg/day of placebo for 12 weeks given in conjunction with 12 weeks of manual-guided behavioral counseling.
11554303|NCT00974363|Experimental|Group A|Subjects who received GSK Biologicals' meningococcal vaccine 134612 in the primary vaccination study 109069.
11554304|NCT00974363|Active Comparator|Group B|Subjects who received MencevaxTM ACWY in the primary vaccination study 109069.
11554305|NCT00974350|Experimental|Group 1: SABER™-Bupivacaine|2.5 mL SABER™-Bupivacaine /Once
11554306|NCT00974350|Experimental|Group 2: SABER™-Bupivacaine|5.0 mL SABER™-Bupivacaine /Once
11554307|NCT00974350|Placebo Comparator|Group 3: SABER™-Placebo|2.5 mL or 5.0 mL SABER™-Placebo/Once
11554308|NCT00974337||Shock|"Preterm VLBW infants with shock (BP <3rd centile for gestation and birth weight with at least one of the following:
~Prolonged capillary refill time (>3sec)
~Reduced urine output (<1 mL/kg/hr)
~Metabolic acidosis (Base deficit >5)"
11554309|NCT00974337||No shock|Hemodynamically stable infant with normal blood pressure, capillary refill time, and urine output
11554310|NCT00974324|Experimental|treatment|endostar combined with CHOP regimen
11554311|NCT00974311|Experimental|Enzalutamide|Formerly MDV3100
11554312|NCT00974311|Placebo Comparator|Placebo|
11554313|NCT00974298||Elbow replacement|There are no other arms other then an uncemented total elbow replacement.
11554314|NCT00974285|Active Comparator|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
11554315|NCT00974285|Placebo Comparator|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
11554316|NCT00974272|Experimental|Exenatide|
11554317|NCT00974272|Placebo Comparator|Placebo|
11554318|NCT00974259|Experimental|pBrO2 and ICP management|Treatment protocol based on pBrO2 and ICP values.
11554319|NCT00974259|Active Comparator|ICP management|Treatment protocol based on ICP values only.
11554320|NCT00974246|Experimental|COPD, ECF residents, Advair diskus|open label treatment with Advair diskus in COPD patients
11554321|NCT00974233|Experimental|Induction/Maintenance chemotherapy|Bendamustine + rituximab induction therapy followed by lenalidomide maintenance therapy
11554322|NCT00974220|Placebo Comparator|placebo|nebulized 0.9% saline placebo
11554323|NCT00974220|Experimental|fentanyl|nebulized fentanyl citrate (50 mcg)
11554324|NCT00974194|Experimental|SinglePort CCK|CCK using Triport
11554325|NCT00974194|Active Comparator|LS CCK|CCK using three or four trocars
11554326|NCT00974181|Active Comparator|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Conor Medsystems COSTAR™ stent loaded with the antiproliferative compound paclitaxel (10 µg), pre-mounted on a rapid exchange, percutaneous transluminal coronary angioplasty balloon catheter.
11554327|NCT00974181|Active Comparator|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Conor Medsystems COSTAR™ stent loaded with the antiproliferative compound paclitaxel (30 µg), pre-mounted on a rapid exchange, percutaneous transluminal coronary angioplasty balloon catheter.
11554328|NCT00974168|Active Comparator|A|Radiation Cumulative BED ≤ 100 Gy2
11554329|NCT00974168|Active Comparator|B|Cumulative BED ≤ 130 Gy2
11554330|NCT00974155|Experimental|EMC (Early Medication Change)|
11554331|NCT00974155|Active Comparator|TAU (Therapy As Usual)|
11554332|NCT00974142|Experimental|Cyclosporine|
11554333|NCT00974142|Placebo Comparator|Placebo|
11554334|NCT00974129||Patients with Infantile Hemangiomas|
11554335|NCT00974103|Experimental|Chiropractic treatment, exercise|Chiropractic treatment and exercise
11554336|NCT00974103|Experimental|Exercises|Exercise advise
11554337|NCT00974090|Placebo Comparator|Placebo / Teneli + SU|
11554338|NCT00974090|Experimental|Teneli / Teneli + SU|
11554339|NCT00974077|Other|Wait List Control|Patients do ot receive psychotherapy. The wait list control group will be assessed according to study protocol and offered MBCT after 6 month
11554340|NCT00974077|Experimental|Mindfulness Based Cognitive Therapy|The published protocol of MBCT will be used. This is an eight week group program. Participants learn mindfulness techniques but also cognitive techniques to prevent new depressive episodes
11554341|NCT00974064||A-Healthy Non smokers|Healthy nonsmokers. Defined as non-smokers by self report and urine cotinine levels consistent with a nonsmoker (urine cotinine <5 ng/mL).
11554342|NCT00974064||B-Healthy smoker|"Healthy current smokers. Subjects categorized as healthy according to criteria under Collection (#1204012331) protocol."
11554343|NCT00974064||C-Healthy smoker to quit|Healthy smokers willing to quit. Defined by self-report and urine cotinine levels consistent with an active smoker (urine cotinine >50 ng/mL).
11554344|NCT00974064||D-Current smoker w. COPD|Current smokers with COPD. COPD as defined by the GOLD criteria and currently smoking as defined by self-report and urine cotinine levels consistent with an active smoker (urine cotinine >50 ng/mL)
11554345|NCT00974064||E-Current COPD smoker to quit|Current smokers with COPD willing to stop smoking. Subjects have COPD as defined by the GOLD criteria
11554346|NCT00974051|Active Comparator|Control|Subjects complete the same exercise routine, however no treatment is given at 9:00pm.
11554347|NCT00974051|Experimental|Terbutaline|Subjects complete same exercise routine. At 9:00pm, an oral dose of 2.5 mg of Terbutaline is administered.
11554348|NCT00974051|Experimental|20% Basal Insulin Reduction|All subjects complete the same exercise session. At 9:00pm, subject's basal rate is decreased by 20% for six hours.
11554349|NCT00974038|Experimental|CBT, SP|cognitive behavioral therapy, supportive psychotherapy
11554350|NCT00974025|Experimental|Vitamin C|High-dose Vitamin C in 4 age-based doses will be given in two-daily doses for four weeks
11554351|NCT00974025|Placebo Comparator|Placebo|Placebo will be given in two-daily doses for four weeks
11554352|NCT00974012|Experimental|Divalproex Sodium|500 mg Extended Release Tablet
11554353|NCT00974012|Active Comparator|Depakote®|500 mg Extended Release Tablet
11554354|NCT00973999|Experimental|Injection into salivary gland|
11554355|NCT00973986|Active Comparator|CYP3A4*1/*1|
11554356|NCT00973986|Active Comparator|CYP3A4*1/*1G|
11554357|NCT00973986|Active Comparator|CYP3A4*1G/*1G|
11554815|NCT00970827|Active Comparator|1|Leg postconditioning
11554358|NCT00973973|Experimental|Elagolix 150 mg|Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period.
11554359|NCT00973973|Placebo Comparator|Placebo|Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period.
11554360|NCT00973947|Other|Control|Immobilisation: Standard headrest plus individual customised mask (orfit)
11554361|NCT00973947|Other|TRial Arm|Immobilisation: Customised headrest plus individual customised mask (orfit)
11554362|NCT00973934|Experimental|Magnetic Seizure therapy (MST)|Eligible patients will be randomized to receive either a course of thrice weekly MST using either a focal or non focal stimulating coil.
11554363|NCT00973934|Active Comparator|Right Unilateral Electroconvulsive Therapy|
11554364|NCT00973921||Stent deployment evaluation|The study group consisted of patients that underwent IVUS guided stent implantation. Stent deployment evaluation was done with the experimental StentOptimizer as well as IVUS and QCA.
11554365|NCT00973908|Active Comparator|VSL#3|Patients will receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
11554366|NCT00973908|Placebo Comparator|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
11554367|NCT00973882|Experimental|Carboplatin-Etoposide|
11554368|NCT00973856|Experimental|PURELL Left Hand/ Placebo Right Hand|"One product will be assigned to each hand to minimize treatment confusion for the participants.
~PURELL VF481 Left Hand/ Placebo Right Hand"
11554369|NCT00973856|Placebo Comparator|Placebo Solution Left Hand/ PURELL Right hand|"One (1) product will be assigned to each hand to minimize treatment confusion for the participants PURELL VF481 Right Hand/ Placebo Left Hand
~One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed"
11554370|NCT00973830|Experimental|Carve-In|Patients in this arm are given the Diabetes Guide and engage in six sessions of brief counseling with a nurse or medical assistant from their clinic. Counseling focuses on behavioral changes patients can make to improve their diabetes.
11554371|NCT00973830|Experimental|Carve-Out|Patients in this arm are given the Diabetes Guide and engage in six sessions of brief counseling over-the-phone with a diabetes health educator stationed in Chicago, IL. Counseling focuses on behavioral changes patients can make to improve their diabetes.
11554372|NCT00973830|No Intervention|Control|Patients in this arm receive standard care. They receive no Diabetes Guide or brief counseling sessions
11554373|NCT00973817|Experimental|ELAD|Use of ELAD for up to 6 days to stabilize liver function plus standard of care treatment plus standard of care treatment. Standard of care for acute on chronic hepatitis patients including medications and treatments typically given to patients admitted with acute hepatitis (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
11554374|NCT00973817|Other|Standard of care|Standard of care for acute on chronic hepatitis patients including medications and treatments typically given to patients admitted with acute hepatitis (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
11554375|NCT00973791|Active Comparator|Prior crystalloid|Crystalloid (Ringer's Lactate) was given before spinal anesthesia
11554376|NCT00973791|Active Comparator|Posterior crystalloid|Crystalloid (Ringer's Lactate) was given after spinal anesthesia
11554377|NCT00973791|Active Comparator|Prior colloid|Colloid (6% hydroxyethyl starch) was given before spinal anesthesia
11554378|NCT00973791|Active Comparator|Posterior colloid|Colloid (6% hydroxyethyl starch) was given after spinal anesthesia
11554379|NCT00973765|Active Comparator|bactrim DS (800/160) 2 pills po BID x 7 days|active comparator
11554380|NCT00973765|Placebo Comparator|Matched placebo 2 pills po BID x 7 days|placebo
11554381|NCT00973752|Experimental|Experimental|All patients treated on same arm
11554382|NCT00973739|Experimental|Lapatinib|"Lapatinib PO dosed according to age:
~Children/adolescents (less than 18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO twice daily
~Adults (18 years of age or older): 1,500 mg PO once daily
~Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment."
11554383|NCT00973726|Other|Glucose|Subjects are given an oral glucose tolerance test.
11554384|NCT00973713|Experimental|RAD001 10mg/d|
11554385|NCT00973700|Experimental|2x7.5adj|Two doses of MF59 adjuvanted (adj) A/H1N1
11554386|NCT00973700|Experimental|7.5adj_1_8|MF59 adjuvanted (adj) A/H1N1 on days 1 and 8
11554387|NCT00973700|Experimental|7.5adj_1_22|MF59 adjuvanted (adj) A/H1N1 on study days 1 and 22
11554388|NCT00973700|Experimental|15_1_22|A/H1N1 on study days 1 and 22
11554389|NCT00973700|Experimental|2x15_1_22|Two doses of A/H1N1 (one in each arm) on study days 1 and 22
11554390|NCT00973687|Placebo Comparator|10 mg/mL Unsweetened Formulation|no prior vomiting
11554391|NCT00973687|Experimental|1 mg/mL Ora Sweet Formulation|no prior vomiting
11554392|NCT00973687|Active Comparator|10 mg/mL Unsweetened with prior vomiting|with prior vomiting
11554393|NCT00973687|Experimental|1 mg/mL Ora Sweet with prior vomiting|with prior vomiting
11554394|NCT00973674|Experimental|Premarin IV|Patients randomized to receive a single dose of 0.5 mg/kg Premarin® IV
11554395|NCT00973674|Placebo Comparator|Placebo|Patients randomized to receive a single dose of placebo IV. Due of the faint yellow color of the reconstituted Premarin®, the placebo dose will be prepared with 0.14 ml of Vial 1 of Infuvite Adult Multivitamin and 14 ml of sterile water to generate a similar color and volume. This aliquot will be used only for those study patients who are randomized to the placebo arm. The placebo volume will be approximately equal to the volume which the patient would have received had the patient been randomized to the Premarin arm Considering the small amount of IV multivitamin needed for fluid tinting, it is not expected that the IV multivitamin will have any effect on patients with traumatic brain injury.
11554396|NCT00973661|Experimental|Electronic tools|
11554397|NCT00973661|No Intervention|Usual care|
11554512|NCT00972972|Placebo Comparator|placebo dietary supplement|Placebo juice extracts
11554816|NCT00970827|Active Comparator|2|Arm postconditioning
11554398|NCT00973635|No Intervention|Traditional training|"Patients of subjects with no detailed curriculum for handoff skills during non-intervention months.
~Learners provided a brief outline of how to perform discharge summaries (handout).
~Learners given two core articles describing some of the communication issues regarding handoff safety.
~Handoff teaching left to discretion of the subintern's team (typically the see one, do one, teach one method).
~No feedback given to these subinterns on their performance of their handoff skills."
11554399|NCT00973635|Experimental|Intervention|Group that receives educational intervention.
11554400|NCT00973622|Experimental|Smokers|Healthy adult smokers aged 19-55 who are not currently interested in quitting smoking.
11554401|NCT00973622|Experimental|Non-smokers|Healthy adult non-smokers aged 19-55
11554402|NCT00973609|Active Comparator|Fluoropyrimidine + Bevacizumab|Standard therapy
11554403|NCT00973609|Experimental|Bevacizumab monotherapy|
11554404|NCT00973609|Experimental|No maintenance treatment|
11554405|NCT00973583|Active Comparator|vitamin D|
11554406|NCT00973583|Placebo Comparator|placebo|
11554407|NCT00973570|Experimental|"Intervention group"|"The intervention group benefits from the TABADO program"
11554408|NCT00973570|No Intervention|"Control group"|"The control group not benefit from any specific intervention other than the treatment and education usually available"
11554409|NCT00973557||Taking Bevacizumab|Patients who are currently being treated for cancer by the drug Bevacizumab.
11554410|NCT00973544||control|drains would be removed when daily discharge will be below 20 cc for 2 consecutive days
11554411|NCT00973544||study|drains will be removed on post operative day (POD) 10
11554412|NCT00973531|Other|Ambulatory APAP and SMT|Subjects placed on the APAP machine
11554413|NCT00973531|Other|Titration Polysomnogram with CPAP and SMT|Subjects placed on CPAP machine
11554414|NCT00973518||Alzheimer's Disease subjects|Subjects diagnosed with dementia of Alzheimer's type (DSM-IV-TR).
11554415|NCT00973518||Healthy Control subjects|Age & gender-matched subjects determined to be healthy.
11554416|NCT00973505||CYP19|CYP19 genetic polymorphism
11554417|NCT00973492||patients with functional insulinotherapy|There is only one group in this study. The participants will attend a functional insulinotherapy class.
11554418|NCT00973479|Experimental|Group I: Placebo + Methotrexate (MTX)|Participants will receive placebo at Weeks 0, 4, 12, and 16. Participants will cross over to golimumab at Week 24, and receive administrations at Weeks 24, 28, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will be eligible for early escape (receive golimumab) at Week 16 if they demonstrate a less than 10 percent improvement in both tender and swollen joint count. These participants will receive golimumab at Weeks 16, 20, and every 8 weeks thereafter.
11554419|NCT00973479|Placebo Comparator|Group II: Golimumab + Methotrexate (MTX)|Participants will receive golimumab at Weeks 0, 4, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will receive a placebo infusion at Week 16 and Week 24 to maintain the blind.
11554420|NCT00973466||HIV-infection|All HIV-infected patients attending the Clinic for Infectious Diseases at Berne university hospital, having been sexually active during the past 12 months and having given written informed consent
11554421|NCT00973453|Other|Slow regimen|
11554422|NCT00973453|Other|Intermediate regimen|
11554423|NCT00973453|Other|Fast regimen|
11554424|NCT00973414|Active Comparator|Prior crystalloid|Crystalloid (Ringer's Lactate) was given before CSEA
11554425|NCT00973414|Active Comparator|Posterior crystalloid|Crystalloid (Ringer's Lactate) was given after CSEA
11554426|NCT00973414|Active Comparator|Prior colloid|Colloid (6% hydroxyethyl starch) was given before CSEA
11554427|NCT00973414|Active Comparator|Posterior colloid|Colloid (6% hydroxyethyl starch) was given after CSEA
11554428|NCT00973401||Diabetic individuals|
11554429|NCT00973375||Endeavor group and Excel group|Endeavor group: measurements from the vessels implanted Endeavor stent(s). Excel group: measurements from the vessels implanted Excel stent(s).
11554430|NCT00973362|Other|Adjunct (i.e. Normal Pap)|The Adjunct study will evaluate APTIMA HPV Assay clinical performance for detecting high-risk HPV types in female subjects 30+ years of age with negative (NILM) cytology results from routine Pap testing. This will be accomplished by evaluating the assay performance compared to known cervical disease status at baseline and after a 3-year follow-up period. A comparator FDA-Approved HPV DNA test is reported.
11554431|NCT00973362|Other|ASC-US|The ASC-US study will evaluate the APTIMA HPV Assay clinical performance for detecting high-risk HPV types in subjects with ASC-US Pap test results from routine Pap testing and known cervical disease status (based on colposcopic biopsy results). A comparator FDA-Approved HPV DNA test is reported. There is no follow-up period.
11554432|NCT00973349|Experimental|3.75_(50)MF59|50% of MF59 with 3.75 µg A/H1N1 antigen
11554433|NCT00973349|Experimental|7.5 w/o MF59|0% of MF59 with 7.5 µg A/H1N1 antigen
11554434|NCT00973349|Experimental|7.5_(50)MF59|50% of MF59 with 7.5 µg A/H1N1 antigen
11554435|NCT00973349|Experimental|7.5_(100)MF59|100% of MF59 with 7.5 µg A/H1N1 antigen
11554436|NCT00973349|Experimental|15 w/o MF59|0% of MF59 with 15 µg A/H1N1 antigen
11554437|NCT00973349|Experimental|15_(50)MF59|50% of MF59 with 15 µg A/H1N1 antigen
11554438|NCT00973349|Experimental|15_(100)MF59|100% of MF59 with 15 µg A/H1N1 antigen
11554439|NCT00973349|Experimental|30 w/o MF59|0% of MF59 with 30 µg A/H1N1 antigen
11554440|NCT00973336|Experimental|Calcium and vitamin D|Intervention
11554441|NCT00973336|No Intervention|No treatment (control)|
11554442|NCT00973323|Experimental|Arm 1|
11554443|NCT00973323|Experimental|Arm 2|
11554444|NCT00973323|Experimental|Arm 3|
11554445|NCT00973323|Active Comparator|Arm 4|
11554446|NCT00973310|Experimental|Combined Treatment arm|All the patients received oral erlotinib and concurrent radiation therapy
11554447|NCT00973297|Experimental|Falls prevention|
11554448|NCT00973297|No Intervention|Control group|Routine rehabilitation treatment
11554612|NCT00972231||Thalassemia Group|Patients suffering from Thalassemia Major and patients with Thalassemia Intermedia
11554613|NCT00972231||Sickle Cell Group|Patients with Sickle Cell Anemia and Sickle Cell Thalassemia
11554449|NCT00973284|Experimental|Norwalk VLP Vaccine 100 µg|Norwalk Virus-like Particle (VLP) Vaccine 100 µg, dry powder, intranasally using a delivery device with a puff of air, 50 µg in each nostril, on Days 0 and 21 in the Vaccination Stage. Norwalk Virus, 48 Reverse Transcription Polymerase Chain Reaction (RT-PCR) units, solution, orally, on Day 42 in the Challenge Stage.
11554450|NCT00973284|Placebo Comparator|Placebo|Norwalk VLP placebo-matching vaccine, dry powder, intranasally using a delivery device with a puff of air, 50 µg in each nostril, on Days 0 and 21 in the Vaccination Stage. Norwalk Virus, 48 RT-PCR units, solution, orally, on Day 42 in the Challenge Stage.
11554451|NCT00973271|Experimental|290 mg DCCR|
11554452|NCT00973271|Experimental|435 mg DCCR|
11554453|NCT00973271|Active Comparator|135 mg fenobric acid|
11554454|NCT00973271|Placebo Comparator|Placebo|
11554455|NCT00973258|Experimental|Nutritional Intervention|Nutritional intervention
11554456|NCT00973258|Experimental|Physical Exercise|Physical exercise training intervention
11554457|NCT00973258|Experimental|Cognitive Training|Cognitive training intervention
11554458|NCT00973258|Experimental|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
11554459|NCT00973258|Placebo Comparator|Control Group|Participants will receive their usual diet and placeboes.
11554460|NCT00973245|Experimental|Arm 1|
11554461|NCT00973245|Experimental|Arm 2|
11554462|NCT00973245|Active Comparator|Arm 4|
11554463|NCT00973245|Experimental|Arm 3|
11554464|NCT00973232|Experimental|Part A, Arm A|
11554465|NCT00973232|Experimental|Part A, Arm B|
11554466|NCT00973232|Active Comparator|Part A, Arm C|
11554467|NCT00973232|Active Comparator|Part A, Arm D|
11554468|NCT00973232|Experimental|Part B, Arm E|
11554469|NCT00973232|Active Comparator|Part B, Arm F|
11554470|NCT00973232|Active Comparator|Part B, Arm G|
11554471|NCT00973219|Active Comparator|Peg-Interferon alfa 2a + Adefovir|50 HBeAg negative chronic hepatitis B patients with low viral load will receive Peg-Interferon alfa 2a + Adefovir for a period of 48 weeks.
11554472|NCT00973219|Active Comparator|Peg-Interferon alfa 2a + Tenofovir|50 HBeAg negative chronic hepatitis B patients with low viral load will receive Peg-Interferon alfa 2a + Tenofovir for a period of 48 weeks.
11554473|NCT00973219|No Intervention|no treatment|50 HBeAg negative chronic hepatitis B patients with low viral load will not receive treatment during a period of 48 weeks
11554474|NCT00973193|Experimental|panitumumab|
11554475|NCT00973180|Experimental|Enhanced Label|Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
11554476|NCT00973180|No Intervention|Standard Label|Subjects in this arm will receive their prescriptions labeled with a standard label.
11554477|NCT00973167|No Intervention|Control|Remains sedentary with normal lifestyle
11554478|NCT00973167|Experimental|Treatment|Receive LMHFV treatment for 18 months.
11554479|NCT00973154|Active Comparator|Prednisone|Drug
11554480|NCT00973154|Placebo Comparator|Placebo|
11554481|NCT00973141|Experimental|JNJ-42160443 1mg every 4 weeks|
11554482|NCT00973141|Experimental|JNJ-42160443 3mg every 4 weeks|
11554483|NCT00973141|Experimental|JNJ-42160443 3mg every 8 weeks|
11554484|NCT00973141|Experimental|JNJ-42160443 6mg every 8 weeks|
11554485|NCT00973141|Experimental|JNJ-42160443 10mg every 8 weeks|
11554486|NCT00973141|Placebo Comparator|Matching placebo every 4 or 8 weeks|
11554487|NCT00973128|Experimental|Group 1|Group 1: Cutaneous leishmaniasis patients randomized in Corte to receive antimony (20mg/daily for 10 days) plus GM-CSF Treatment: antimony (20mg/daily for 10 days) plus GM-CSF (400 µg, divided in two doses a week apart)
11554488|NCT00973128|Active Comparator|Group 2|Group 2: antimony in standard dose plus saline administered in an identical fashion to the GM-CSF.
11554489|NCT00973115|Experimental|Simvastatin CR 20mg- morning administration|
11554490|NCT00973115|Active Comparator|Simvastatin CR 20mg- evening administration|
11554491|NCT00973102|Experimental|Premarin IV|Patients who were randomized to receive a single dose of 0.5 mg/kg Premarin® IV.
11554492|NCT00973102|Placebo Comparator|Placebo|Patients who were randomized to receive a single dose of 0.5 mg/kg placebo. Due of the faint yellow color of the reconstituted Premarin®, the placebo dose will be prepared with 0.14 ml of Vial 1 of Infuvite Adult Multivitamin and 14 ml of sterile water to generate a similar color and volume. This aliquot will be used only for those study patients who are randomized to the placebo arm. The placebo volume will be approximately equal to the volume which the patient would have received had the patient been randomized to the Premarin arm Considering the small amount of IV multivitamin needed for fluid tinting, it is not expected that the IV multivitamin will have any effect on patients with hemorrhagic shock.
11554493|NCT00973089|No Intervention|Complete caries removal|Control group
11554494|NCT00973089|Other|Incomplete caries removal|Test group
11554495|NCT00973076|Experimental|AZD8055|AZD8055 will be administered orally
11554496|NCT00973063|No Intervention|conventional gloving|
11554497|NCT00973063|Experimental|routine sterile gloving|
11554498|NCT00973050|Experimental|Bicalutamide (test)|Bicalutamide Tablet, 50 mg
11554499|NCT00973050|Active Comparator|Casodex® (reference)|Casodex® Tablet, 50 mg
11554500|NCT00973037||CYP2D6|CYP2D6 genotype
11554501|NCT00973024|Experimental|JNJ-42160443 1 mg|
11554502|NCT00973024|Experimental|JNJ-42160443 3 mg|
11554503|NCT00973024|Experimental|JNJ-42160443 6 mg/3mg|
11554504|NCT00973024|Experimental|JNJ-42160443 10 mg|
11554505|NCT00973011|Experimental|A|
11554506|NCT00972998|Experimental|Healthy individuals|
11554507|NCT00972985|Experimental|modafinil|All healthy control subjects receive modafinil in this crossover design
11554508|NCT00972985|Experimental|methylphenidate|All healthy control subjects receive methylphenidate in this crossover design
11554509|NCT00972985|Experimental|lorazepam|All healthy control subjects receive lorazepam in this crossover design
11554510|NCT00972985|Placebo Comparator|placebo|All healthy control subjects receive placebo in this crossover design
11554511|NCT00972972|Active Comparator|dietary supplement|Extracts of bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.)
11554513|NCT00972959|Experimental|Bortezomib/Dexamethasone/Zoledronic Acid|"For this study, Velcade will be administered at the standard dose of 1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle.
~Dexamethasone will be administered at a dose of 12 mg/m2 p.o., on days 1-2, 4-5, 8-9 and 11-12 of the same cycle.
~Zoledronic acid will be administered at a dose of 4 mg, iv (15-minute infusion), every 28 days for up to 8 cycles, and then every 28 days for the next 18 months"
11554514|NCT00972946|Experimental|Administration of labelled cells|MRI scanning before and after administration of iron-labelled cells
11554515|NCT00972946|Experimental|Administration of Endorem|MRI scanning before and after intravenous administration of Endorem
11554516|NCT00972933|Experimental|Ipilimumab|Induction ipilimumab 10 mg/kg IV day 0, 21 (baseline, week 3) Maintenance Ipilimumab 10 mg/kg IV days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
11554517|NCT00972920|Active Comparator|Blind TAP block|"TAP block technique as first described by McDonnell. Sterile field obtained with chlorhexidine wash and use of sterile gloves. Identification of triangle of Petit just above iliac crest and between external oblique and latissimus dorsi muscles. Insertion of regional anaesthesia needle perpendicular to skin, and its advancement until sensation of two 'pops' indicating advancement of needle through both external oblique and internal oblique muscle layers.
~After confirmation of negative aspiration the local anaesthetic is injected slowly, (1mg/kg of levobupivacaine), concentration 2.5 mg/mL. Repeat procedure bilaterally (to a maximum dose of 2mg/kg of levobupivacaine)."
11554518|NCT00972920|Active Comparator|Ultrasound-guided TAP block|"Technique as described by Hebbard. Sterile field obtained with chlorhexidine wash and use of sterile gloves. Ultrasound probe covered with sterile sheath.
~Identification of triangle of Petit with USS probe perpendicular to skin. Insertion of regional anaesthesia needle transversely to the probe, using in-plane (IP) technique, moving posteriorly. Advancement of the needle under ultrasound control until its tip is located between internal oblique and transversus abdominis muscle layers."
11554519|NCT00972907|Experimental|Treatment|Nifedipine coated suppositories BID.
11554520|NCT00972868|Experimental|COPD|Thirty adult (> 18 years of age) patients in acute hypercapnic respiratory failure resulting from COPD and requiring Noninvasive Positive Pressure Ventilation (NPPV)
11554521|NCT00972855|Experimental|Bicalutamide|Bicalutamide 50 mg Tablet
11554522|NCT00972855|Active Comparator|Casodex®|Casodex® 50 mg Tablet
11554523|NCT00972829|Experimental|Crestor|Crestor 10 or 20 milligrams
11554524|NCT00972829|Active Comparator|Ezetimibe|Ezetimibe 5 or 10 milligrams
11554525|NCT00972816|Experimental|3.75_(50)MF59|3.75 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
11554526|NCT00972816|Experimental|7.5_(0) MF59|7.5 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
11554527|NCT00972816|Experimental|7.5_(50) MF59|7.5 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
11554528|NCT00972816|Experimental|7.5_(100) MF59|7.5 μg A/H1N1 antigen with 100% MF59 adjuvant administered on study day 1 and day 22
11554529|NCT00972816|Experimental|15_(0) MF59|15 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
11554530|NCT00972816|Experimental|15_(50)MF59|15 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
11554531|NCT00972816|Experimental|15_(100) MF59|15 μg A/H1N1 antigen with 100% MF59 adjuvant administered on study day 1 and day 22
11554532|NCT00972816|Experimental|30_(0) MF59|30 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
11554533|NCT00972803|Experimental|pistacia Mutica|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
11554534|NCT00972803|Placebo Comparator|placebo|The subjects were asked to use a mouthwash containing Placebo twice a day for 4 days.
11554535|NCT00972803|Active Comparator|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
11554536|NCT00972790|Sham Comparator|Control Group|The patients in the control arm will receive sham nerve blocks with 20 ml of saline + epinephrine 1:200,000, in a manner identical to that described for the treatment group.
11554537|NCT00972790|Active Comparator|Intervention Group|The patients in the intervention group will receive bilateral scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000.
11554538|NCT00972777|Experimental|Besifloxacin|0.6% ophthalmic suspension
11554539|NCT00972777|Placebo Comparator|Vehicle|
11554540|NCT00972764||Control|
11554541|NCT00972764||Laryngomalacia Cases|
11554542|NCT00972738|Experimental|1|montelukast
11554543|NCT00972738|Active Comparator|2|loratadine
11554544|NCT00972738|Placebo Comparator|3|placebo
11554545|NCT00972725|Experimental|GSK732461+Nivaquine Group|Subjects received a single dose of Nivaquine® tablets orally, 2 days prior to receiving a booster dose of the GSK732461 vaccine.
11554546|NCT00972725|Active Comparator|GSK732461 Group|Subjects received a booster dose of the GSK732461 vaccine intramuscularly, in the deltoid region of the non-dominant arm.
11554547|NCT00972712|Experimental|A|Bortezomib and Tipifarnib
11554548|NCT00972699|Experimental|Mentor Mothers Intervention|In the intervention arm, participants will receive the Department of Health-delivered Prevention of Mother to Child Transmission (PMTCT) program plus the Project Masihambisane mentor mothers support program. HIV positive mentor mothers, who have been through the PMTCT program, will be recruited and trained to deliver the intervention to pregnant mothers living with HIV.
11554549|NCT00972699|No Intervention|Control|Mothers living with HIV in the standard of care control clinics will receive the Department of Health-delivered PMTCT program.
11554550|NCT00972686|Experimental|GSK2126458|GSK2126458 will be dosed continuously (every day) for the duration a 28 day cycle. The 28 day cycles will continue until the subjects withdraw from the study.
11554551|NCT00972673|Experimental|arm 1|In Arm 1 subjects will receive 200, 400 or 800 microgram of powdered inhalation of GW685698X once daily for 7 days from Day 5 to Day 11.
11554552|NCT00972673|Placebo Comparator|arm 2|In Arm 2 subjects will receive Placebo powdered inhalation once daily for 7 days from Day 5 to Day 11.
11554553|NCT00972660|Active Comparator|Control group|"Patients with newly diagnosed extensive cGVHD receive prednisone and cyclosporine or tacrolimus.
~Patients with refractory extensive cGVHD receive primary treatment (eg,prednisone and cyclosporine or tacrolimus, or plus mycophenolate mofetil, or methotrexate.)"
11554554|NCT00972660|Experimental|Mesenchymal stem cell (MSC)|"Patients with newly diagnosed extensive cGVHD receive MSC plus prednisone and cyclosporine or tacrolimus.
~Patients with refractory extensive cGVHD receive MSC plus their primary immunosuppressive treatment (eg. prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate.)"
11554555|NCT00972647|No Intervention|Unguided|Fluoroscopy images taken without laser beam guidance
11554556|NCT00972647|Experimental|Laser guided|Fluoroscopy images taken with laser beam guidance
11554557|NCT00972621|Experimental|Vitrax II|Investigational dispersive viscoelastic
11554558|NCT00972621|Active Comparator|Viscoat|Marketed control dispersive viscoelastic
11554559|NCT00972595|Experimental|A|clinical trial formulation
11554560|NCT00972595|Active Comparator|B|non-U.S. marketed formulation
11554561|NCT00972582|Experimental|Leucine|
11554562|NCT00972569|Active Comparator|BNP with PDE-V|BNP (Nesiritide) will be infused starting at 0.0025 g/Kg/min IV for 3 hours, if tolerated increased to 0.005 g/kg/min for 45 hours without bolus with PDEV inhibition, they will also receive Sildenafil 12.5 mg at timepoints 0,12, 24 and 36 hours
11554563|NCT00972569|Active Comparator|BNP (Nesiritide) will be infused at 0.005 u/Kg/min IV for 48 h|BNP (Nesiritide) will be infused at 0.025 ug/Kg/min IV for 3 hours then 0.005ug/kg/min 45 hours without bolus. No PDE-V is given.
11554564|NCT00972569|No Intervention|standard care|Patients randomized to this group will continue to receive therapy at the discretion of the heart failure specialist who is managing the patient (with the exception of BNP and low dose dopamine). Blood and Urine will be collected after the patient has been randomized for 48 hours
11554565|NCT00972556|Experimental|GMTA|
11554566|NCT00972556|Active Comparator|20% FC|
11554567|NCT00972543|Active Comparator|Raptiva|Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
11554568|NCT00972543|Placebo Comparator|Placebo|Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
11554569|NCT00972530|No Intervention|Activity|Normal activity without restrictions
11554570|NCT00972530|Active Comparator|immobilisation|48 hours postinjection rest
11554571|NCT00972517|Experimental|Group A|Subjects receiving alternative dose of GSK23440272A vaccine
11554572|NCT00972504|Active Comparator|GSK835726 (10mg)|10mg oral dose
11554573|NCT00972504|Active Comparator|GSK1004723 (1000mcg)|1000mcg nasal spray solution
11554574|NCT00972504|Active Comparator|Cetirizine 10mg|10mg cetirizine as active comparator
11554575|NCT00972504|Placebo Comparator|placebo|placebo
11554576|NCT00972491|Other|0 sec, 60 sec, 90 sec|LMA will be inserted at 0, 60, and 90 seconds after eyelash reflex disappears
11554577|NCT00972478|Experimental|Treatment (combination chemotherapy)|Patients receive vorinostat PO once daily on days 1-5 or 1-9 (according to dose level), rituximab IV, cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 3. Patients also receive prednisone PO once daily on days 3-7. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
11554578|NCT00972452|Experimental|Exercise|5-10d exercise training
11554579|NCT00972439|Active Comparator|Ortho-Novum® 1/35|Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.
11554580|NCT00972439|Active Comparator|Ovcon Fe®|Ovcon Fe® is an oral contraceptive that contains less progestin.
11554581|NCT00972426|Experimental|Treatment A Group|Mikelan LA + Xalatan
11554582|NCT00972426|Active Comparator|Treatment B Group|Timoptol XE + Xalatan
11554583|NCT00972413|Experimental|Group I|
11554584|NCT00972413|Experimental|Group II|
11554585|NCT00972413|Experimental|Group III|
11554586|NCT00972387|Active Comparator|Order 1|Supplement order for each time trial run, 1-4 respectively: CHO, CHO-P, CHO-CHO, PLA
11554587|NCT00972387|Active Comparator|Order 2|Supplement order for each time trial run, 1-4 respectively: CHO-P, CHO-CHO, PLA, CHO
11554588|NCT00972387|Active Comparator|Order 3|Supplement order for each time trial run, 1-4 respectively: CHO-CHO, PLA, CHO, CHO-P
11554589|NCT00972387|Active Comparator|Order 4|Supplement order for each time trial run, 1-4 respectively: PLA, CHO, CHO-P, CHO-CHO
11554590|NCT00972374|Experimental|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
11554591|NCT00972374|Experimental|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
11554592|NCT00972374|Sham Comparator|Sham (no implant)|Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
11554593|NCT00972348|Experimental|Access to Personal Health Record|Full access to the Personal Health Record including lists of diagnoses, medications and laboratory values.
11554594|NCT00972348|Active Comparator|No access to the PHR|No access to the PHR but patients will complete surveys.
11554595|NCT00972335|Experimental|Combination Therapy|"Everolimus; this drug will be dosed at 10 mg orally DAILY for the duration of the study.
~Bevacizumab; this drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study"
11554596|NCT00972322|Experimental|MK-8245 50 mg|MK-8245, 50 mg, twice daily for 28 days
11554597|NCT00972322|Placebo Comparator|Placebo|Placebo to MK-8245, 50 mg, twice daily
11554598|NCT00972309|Experimental|1|TARP pepties
11554599|NCT00972309|Experimental|2|TARP dendritic cells
11554600|NCT00972296||Persons with hemophilia with ankle pain|
11554601|NCT00972283|Experimental|IDeg OD|
11554602|NCT00972283|Active Comparator|IGlar OD|
11554603|NCT00972270|Experimental|IMPELLA LP 2.5|
11554604|NCT00972270|Active Comparator|Intra-Aortic Balloon Pump|
11554605|NCT00972257|Active Comparator|Drug: Dorzolamide/Timolol|
11554606|NCT00972257|Active Comparator|Treatment with Brimonidine/Timolol|
11554607|NCT00972244|Experimental|1|1mg dapagliflozin
11554608|NCT00972244|Experimental|2|2.5mg dapagliflozin
11554609|NCT00972244|Experimental|3|5mg dapagliflozin
11554610|NCT00972244|Experimental|4|10mg dapagliflozin
11554611|NCT00972244|Placebo Comparator|5|Placebo
11554614|NCT00972218|Experimental|Enteropathic spondyloarthritis|Patients have concomitant inflammatory spinal symptoms and inflammatory bowel disease.
11554615|NCT00972205|Experimental|Paclitaxel and CBT-1|
11554616|NCT00972192|Active Comparator|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and counseling immediately after the baseline interview. Patients underwent phlebotomy and serologic testing and results were disclosed the following day with post-test counseling (before they were discharged from the hospital).
11554617|NCT00972192|No Intervention|HIV testing post-discharge|Participants who were randomized to the control group were given a referral card and an appointment, by the interviewers, to return for free HIV testing and counseling at Mulago hospital one week after discharge. Participants who returned had their transport reimbursed.
11554618|NCT00972179|Active Comparator|AMG 157|Six subjects in each cohort (cohorts 1 to 6) will receive AMG 157 for a total of 36 subjects.
11554619|NCT00972179|Placebo Comparator|AMG 157 Placebo|Two subjects in each cohort (cohorts 1 to 6) will receive placebo, for a total of 12 subjects.
11554620|NCT00972153|No Intervention|No device used|
11554621|NCT00972153|Sham Comparator|Device attached, not activated|
11554622|NCT00972153|Experimental|Device deployed and activated|
11554623|NCT00972140|Experimental|Formoterol-HFA|Formoterol-HFA pMDI 12µg twice daily
11554624|NCT00972140|Active Comparator|Formoterol-DPI|Formoterol-DPI 12µg twice daily
11554625|NCT00972114|Experimental|CABG combined cardiomyoplasty|Coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
11554626|NCT00972114|Active Comparator|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
11554627|NCT00972114|Active Comparator|CABG alone|Coronary artery bypass graft surgery alone
11554628|NCT00972101|Experimental|Regimen 1: No TBI|High Dose Chemotherapy without Total Body Irradiation (TBI)
11554629|NCT00972101|Experimental|Regimen 2: TBI|High Dose Chemotherapy with Total Body Irradiation (TBI)
11554630|NCT00972088|Other|capsule endoscopy|patients eligible according to inclusion criteria who underwent a capsule endoscopy
11554631|NCT00972075|Experimental|Circadin|Circadin is 2 mg of prolonged release melatonin
11554632|NCT00972075|Placebo Comparator|Placebo|
11554633|NCT00972062|Placebo Comparator|Placebo cream|Cream base used in compounding medications into cream media
11554634|NCT00972062|Experimental|Herbal Cream|Herbal cream (Bach's Rescue Remedy Cream) applied to skin site reactions from MS medications
11554635|NCT00972049|Experimental|1|Capsule administered once orally
11554636|NCT00972049|Placebo Comparator|2|Capsule administered once orally
11554637|NCT00972036|Experimental|Unresectable colon cancer patients with liver metastases|This study will be performed to evaluate the safety of Selective Internal Radiation Therapy (SIRT) in patients with liver only colorectal cancer metastases that have received hepatic arterial infusion pump and have progressed through at least one line of chemotherapy.
11554638|NCT00972023|Experimental|DHEA, surgical resection|Day-14 (approx. 2 wks prior to surgery): begin a 2 week course of DHEA; Day-7 (approx. 1 wk after starting treatment): answer question about pill diary; Day 0 (approx. 2 wks after starting treatment, within 48 hours prior to surgery;
11554639|NCT00971997|Experimental|Lispro 50/50|
11554640|NCT00971984||Alpha thalassemia patients|Patients diagnosed with alpha thalassemia mutations and anemia
11554641|NCT00971971|No Intervention|Control|Traditional SLED
11554642|NCT00971971|Experimental|Profiling|dialysate temperature reduction with Na and ultrafiltration (UF) profiling
11554643|NCT00971958|Active Comparator|Mogen Clamp|
11554644|NCT00971958|Active Comparator|Plastibell|
11554645|NCT00971958|Active Comparator|AccuCirc|AccuCirc is a device approved by the FDA for circumcision of male infants up to ten days of life.
11554646|NCT00971945|Experimental|Paclitaxel|
11554647|NCT00971932|Experimental|Cetuximab + Cisplatin/Carboplatin + Fluorouracil (5-FU)|
11554648|NCT00971906|Experimental|low dose of antigen + low dose of adjuvant|
11554649|NCT00971906|Experimental|high dose of antigen + high dose of adjuvant|
11554650|NCT00971906|Experimental|high dose of antigen|
11554651|NCT00971893||Methylprednisolone Group|
11554652|NCT00971880||Patients receiving blood transfusions|All the patients with blood disorders that require blood transfusions
11554653|NCT00971867|Experimental|Paclitaxel|
11554654|NCT00971854|Experimental|60 Hz stimulation|Experimental reduced frequency pallidal stimulation
11554655|NCT00971854|No Intervention|130 Hz stimulation|Current standard pallidal stimulation setting
11554656|NCT00971841|Experimental|Paclitaxel|One hour intravenous infusion on Days 1, 8, 15, 22, 29, 36, followed by 1 week of rest (6 weeks on, 1 week off). One treatment course consists of 49 days. Day 1 dose same level as last dose of original Study CA139-540 (100mg/m2, 80 mg/m2, or 60 mg/m2). Treatment to continue until disease progression or unacceptable toxicity apparent.
11554657|NCT00971828||Idiopathic inflammatory myopathy|IIM patients will be recruited via the Adult Onset Myositis clinic, Salford Royal NHS Foundation Trust. Suitable patients will be asked if they are willing to partake in the study, via a letter, including a patient information leaflet. If willing, they will contact our study co-ordinator, who will facilitate the visit to the WTCRF. The patient will then sign a consent form and be able to enter the study.
11554658|NCT00971815|Active Comparator|escitalopram|A pill containing Escitalopram
11554659|NCT00971815|Placebo Comparator|placebo|a placebo pill
11554660|NCT00971802|Experimental|Cohort 1|Healthy volunteers - PF-03882845 versus Placebo
11554661|NCT00971802|Experimental|Cohort 2|Healthy volunteers - PF-03882845 versus Placebo
11554662|NCT00971802|Experimental|Cohort 3|Healthy volunteers - PF-03882845 versus Placebo
11554663|NCT00971802|Experimental|Cohort 4|Healthy volunteers - PF-03882845 versus Placebo
11554664|NCT00971789|Experimental|Sirolimus Patients|sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects.
11554811|NCT00970866|Active Comparator|Lipid-based Nutrient Supplements (LNS)|
11554665|NCT00971763|Experimental|R-GCVP|"Up to 6 x 21 day cycles of R-GCVP:
~Gemcitabine 750mg/m^2 days 1 & 8 (increasing to 875mg/m^2 for cycle 2 & 1g/m^2 for subsequent cycles if tolerated satisfactorily)
~Cyclophosphamide 750mg/m^2 day 1
~Vincristine 1.4mg/m^2 day 1 (capped at 2mg)
~Prednisolone 100mg/day days 1-5
~Rituximab 375mg/m^2 day 1
~Neulasta 6mg day 9"
11554666|NCT00971750||Ultrasound Study Group|Patients with no history of gallbladder surgery who are undergoing elective laparoscopic roux-en-Y gastric bypass that have consented to undergo a preoperative transabdominal ultrasound in addition to routine preoperative assessment for surgery.
11554667|NCT00971737|Active Comparator|Cyclophosphamide and Vaccine only|Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.
11554668|NCT00971737|Experimental|Cyclophosphamide, Vaccine and Trastuzumab|Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.
11554669|NCT00971724|Placebo Comparator|Placebo|Treatment with placebo for 15 days
11554670|NCT00971724|Experimental|Prednisolone 7.5 mg daily|Treatment with prednisolone 7.5 mg daily for 15 days
11554671|NCT00971724|Experimental|Prednisolone 15 mg daily|Treatment with prednisolone 15 mg daily for 15 days
11554672|NCT00971724|Experimental|Prednisolone 30 mg daily|Treatment with prednisolone 30 mg daily for 15 days
11554673|NCT00971724|Experimental|Prednisolone 75 mg|Treatment with prednisolone 75 mg for a single day
11554674|NCT00971724|Experimental|Prednisolone 15 mg twice daily|Treatment with prednisolone 15 mg twice daily for a single day
11554675|NCT00971711|Experimental|Probiotic|To determine the safety and effectiveness of the probiotic VSL#3 in adults with irritable bowel syndrome (IBS).
11554676|NCT00971698||Sickle Cell Patients|Patients with homozygous Sickle Cell Anemia
11554677|NCT00971698||Sickle Cell Thalassemia|Patients with Sickle Cell Thalassemia
11554678|NCT00971685|Experimental|Lenalidomide plus Dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
11554679|NCT00971672||Toddlers from Jewish origin|Toddlers from Jewish origin aged 18 to 36 months
11554680|NCT00971672||Toddlers from non Jewish origin|Toddlers aged 18 to 36 months belonging to non Jewish (Arab) population
11554681|NCT00971659|Experimental|insulin glargine + exenatide + metformin|
11554682|NCT00971659|Experimental|Insulin glargine + sitagliptin + metformin|
11554683|NCT00971659|Active Comparator|insulin glargine + metformin|
11554684|NCT00971646||OAB|Patients with overactive bladder syndrome
11554685|NCT00971646||Osteoporosis|Patients with osteoporosis
11554686|NCT00971633|Experimental|1|Treatment Sequence A-B-C
11554687|NCT00971633|Experimental|2|Treatment Sequence B-C-A
11554688|NCT00971633|Experimental|3|Treatment Sequence C-A-B
11554689|NCT00971633|Experimental|4|Treatment Sequence A-C-B
11554690|NCT00971633|Experimental|5|Treatment Sequence B-A-C
11554691|NCT00971633|Experimental|6|Treatment Sequence C-B-A
11554692|NCT00971620|Experimental|BTX-A|BTX-A intralesional injection
11554693|NCT00971620|Experimental|Placebo/Saline|Saline intralesional injection
11554694|NCT00971607|Active Comparator|1|Sevoflurane
11554695|NCT00971607|Placebo Comparator|2|Oxygen
11554696|NCT00971594|Experimental|WL+AEX|Weight loss plus aerobic exercise
11554697|NCT00971581|Experimental|FDC KETOPROFEN+OMEPRAZOLE|One capsule of Ketoprofen 200 mg + Omeprazole 20 mg FDC once daily Treatment duration: 4 weeks
11554698|NCT00971568||Urine sample|To prepare for SELDI-TOF we will use 15 samples. Each sample (25ul) will be analyzed with the Luminex 100 IS (MiraiBio, South San Francisco, CA) using a LINCOplex cytokine/che-
11554699|NCT00971555||Late preterm|Late preterm infants admitted to the NICU
11554700|NCT00971542|Experimental|low dose of antigen + low dose of adjuvant|
11554701|NCT00971542|Experimental|high dose of antigen + high dose of adjuvant|
11554702|NCT00971542|Experimental|high dose of antigen|
11554703|NCT00971529||lifestyle|70 volunteers were double-blinded, placebo-controlled and randomized into 2 groups (smoking with tea filters or regular filters).
11554704|NCT00971529||tea filter|The investigators then recruited 59 volunteers with longer smoking history and stronger desire for quitting smoking for smoking cessation test using the tea filter.
11554705|NCT00971516|Active Comparator|Diabetes|compare cytokines between diabetes and non diabetes patients
11554706|NCT00971516|Active Comparator|Implants|Compare implant healing phases
11554707|NCT00971503|Sham Comparator|saline injection|
11554708|NCT00971503|Experimental|Autologous bone marrow implantation|
11554709|NCT00971490|Experimental|Group 1|
11554710|NCT00971490|Placebo Comparator|Group 2|
11554711|NCT00971490|Sham Comparator|Group 3|
11554712|NCT00971477|Experimental|Teledermatology|Online Telemedicine Group
11554713|NCT00971477|Active Comparator|Usual Care|Conventional in-office care
11554714|NCT00971464|Experimental|Eccentric viewing|"Eccentric viewing is the use of a retinal locus other than the anatomical fovea for fixation in cases when there is central vision loss. This other area (or areas) is called the preferred retinal locus (PRL). In eccentric viewing the patient is aware that they are looking to the side or using their side vision. Most patients with a dense central scotoma will develop eccentric viewing naturally over time. It is thought, however, that, in many cases the naturally developed PRL is not in the ideal position. The four components of eccentric viewing that will be taught are: 1) The optimal direction for eccentric viewing 2) Using large objects to teach eccentric viewing 3) Repetitive practicing of the technique and 4) Maintaining the eye in the eccentric viewing position."
11554756|NCT00971217|Experimental|Combined Exercise/Online CBT|Participants will simultaneously par-take in both the exercise and the online CBT conditions already outlined.
11554812|NCT00970853|Active Comparator|Control|Control group
11554813|NCT00970853|Experimental|MOM Program home visiting|Mixed professional support home visiting program.
11554814|NCT00970840|Experimental|LNS-20gM or LNS-P&L|
11554715|NCT00971464|Active Comparator|CCTV arm|A CCTV is an electro-optical device mainly used for reading, but which can also be used for writing or viewing pictures. It is comprised of a video camera which faces downwards towards the reading material and which inputs the image to a digital monitor. Magnification is variable over a large range. By means of a zoom lens and the brightness, contrast, and image polarity (black letters on white or white on black) can be controlled to provide the best combination of viewing conditions for an individual user. The significant advantages of CCTV over optical magnifiers are that it provides high levels of magnification with a greater field of view (compared to the equivalent optical device), allows reading at a more normal viewing distance of about 40 - 50 cms and allows binocular viewing.
11554716|NCT00971451|Experimental|knee joint cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
11554717|NCT00971451|Experimental|TENS|continuous TENS for duration of the 1 hour exercise session
11554718|NCT00971451|No Intervention|No intervention|no modality intervention; just exercise
11554719|NCT00971438|Experimental|Diagnostic imaging|Patients with a scoring suggesting an equivocal diagnosis of acute appendicitis are randomised to either diagnostic imaging (US or CT) or a repeat examination after 4-8 hours in-hospital observation.
11554720|NCT00971438|Active Comparator|Repeat examination after observation|Patients with a clinical scoring suggesting an equivocal diagnosis of appendicitis are randomised to either 4-8 hours of in-hospital observation or diagnostic imaging (US or CT)
11554721|NCT00971425|Experimental|Placebo-Pandemrix-Fluarix Group|Subjects received one dose of placebo intramuscularly in the deltoid region of the dominant arm at Day -21, 2 doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21, and 1 dose of Fluarix intramuscularly in the deltoid region of the dominant arm at Day 42.
11554722|NCT00971425|Experimental|Fluarix-Pandemrix-Placebo Group|Subjects received 1 dose of Fluarix intramuscularly in the deltoid region of the dominant arm at Day -21, 2 doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid of the non-dominant arm at Day 0 and 21, and 1 dose of placebo intramuscularly in the deltoid of the non-dominant arm at Day 42.
11554723|NCT00971399|Experimental|RMS|ramosetron 0.1mg q.d. SL on D1-5
11554724|NCT00971399|Active Comparator|ODS|ondansetron 8mg, b.i.d SL on D1-5
11554725|NCT00971386|Other|Normal Healthy Subjects|Normal healthy subjects without history, signs-symptoms or diagnosis of heart failure
11554726|NCT00971386|Other|Chronic Ambulatory Heart Failure|Diagnosis of Chronic Heart Failure and currently on optimal medical therapy
11554727|NCT00971386|Other|Acute Heart Failure|Patients admitted to the hospital with acute congestive heart failure.
11554728|NCT00971373|Experimental|Exp Scrubs|antimicrobial impregnated scrubs
11554729|NCT00971373|No Intervention|Non-antimicrobial scrubs|Non-antimicrobial scrubs
11554730|NCT00971360||Conversion disorder|
11554731|NCT00971360||Healthy control|
11554732|NCT00971347|Active Comparator|Nutrition brochure|Control participants will receive only a nutrition brochure, Finding Your Way to a Healthier You, based on a USDHHS/USDA publication, Dietary Guidelines for Americans 2005.
11554733|NCT00971347|Experimental|Chewing gum + nutrition brochure|Participants in the experimental arm will be instructed to incorporate gum chewing in their diet with a goal of at least 90 minutes per day. The schedule is 20 minutes each after breakfast, lunch and dinner plus 10 minutes mid-morning, mid-afternoon and 1 to 2 hours after dinner. Experimental participants also will be told to chew gum instead of unplanned eating in response to hunger, cravings, preoccupation with eating, or negative feelings.
11554734|NCT00971321|Experimental|GSK 2340272A F1 Group|Healthy male or female children, between and including 6 and 35 months of age, who received 2 doses of GSK2340272A Formulation 1 (F1) vaccine according to a 0, 21-day schedule, intramuscularly administered in the deltoid region of the arm or in the anterolateral region of the thigh if the subject was less than (<) 12 months at study entry.
11554735|NCT00971321|Experimental|GSK 2340272A F2 Group|Healthy male or female children, between and including 6 and 35 months of age, who received 2 doses of GSK2340272A Formulation 2 (F2) vaccine according to a 0, 21-day schedule, intramuscularly administered in the deltoid region of the arm or in the anterolateral region of the thigh if the subject was less than (<) 12 months at study entry.
11554736|NCT00971308|Experimental|BMS-824393 (Panel 1)|
11554737|NCT00971308|Experimental|BMS-824393 (Panel 2)|
11554738|NCT00971308|Experimental|BMS-824393 (Panel 3)|
11554739|NCT00971308|Experimental|BMS-824393 (Panel 4)|
11554740|NCT00971308|Experimental|BMS-824393 (Panel 5)|
11554741|NCT00971295|Experimental|Treatment Sequence A|Eslicarbazepine acetate + Metformin period followed by washout period followed by Metformin period
11554742|NCT00971295|Experimental|Treatment Sequence B|Metformin period followed by washout period followed by Eslicarbazepine acetate + Metformin period
11554743|NCT00971282|Experimental|intra-individual comparison|
11554744|NCT00971256||Bladder cancer patients|Bladder cancer patients from one Beaumont Urologist.
11554745|NCT00971243|Experimental|MP-513 Lowest Dose and Metformin|
11554746|NCT00971243|Experimental|MP-513 Low Dose and Metformin|
11554747|NCT00971243|Experimental|MP-513 Medium Dose and Metformin|
11554748|NCT00971243|Experimental|MP-513 High Dose and Metformin|
11554749|NCT00971243|Placebo Comparator|Placebo and Metformin|
11554750|NCT00971230|Experimental|FTC/TDF- Daily|FTC/TDF dosed daily
11554751|NCT00971230|Experimental|FTC/TDF-Intermittent|FTC/TDF dosed intermittently
11554752|NCT00971230|Placebo Comparator|Placebo-Daily|Placebo dosed daily
11554753|NCT00971230|Placebo Comparator|Placebo-Intermittent|Placebo dosed intermittently
11554754|NCT00971217|Experimental|Exercise|"Participants will engage in 2 exercise sessions each week for 10 weeks. Each session will last 50 minutes and will commence with a 5 minute warm up on the bike or treadmill and conclude with a 5 minute cool down. The participants will be required to exercise on their own without interference from others. Participants will wear heart rate monitors to ensure that they are exercising to moderate intensity (70-80% of age predicted maximum heart rate).
~Exercise: Aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines."
11554755|NCT00971217|Experimental|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a web-site specifically aimed at young men once per week and complete the set cognitive-behavioural tasks.
11554757|NCT00971217|No Intervention|Control|Individuals will be advised that the start of their intervention will be delayed by 10 weeks. After 10 weeks individuals in the control condition will be given the opportunity to avail of an induction session in the gym and subsequently use the gym facilities for three sessions if they so desire. Participants will be asked to refrain from exercise for the 10 week study period.
11554758|NCT00971204|Experimental|Treatment with HeartLight System|Treatment of paroxysmal atrial fibrillation (PAF) with HeartLight System
11554759|NCT00971191|Experimental|treatment|Patients treated with brief exposure to PF-00299804 prior to surgical resection
11554760|NCT00971178|Active Comparator|Local Dexmedetomidine|
11554761|NCT00971178|Placebo Comparator|Normal Saline|
11554762|NCT00971178|Active Comparator|IV dexmedetomidine|
11554763|NCT00971165|Active Comparator|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily for 18 months
11554764|NCT00971165|Experimental|losartan|Oral losartan up to 100 mg daily, once a day, for 18 month
11554765|NCT00971152|Active Comparator|450 IU daily dose of gonadotrophin|
11554766|NCT00971152|Experimental|600 IU daily dose of gonadotrophin|
11554767|NCT00971139|Experimental|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
11554768|NCT00971139|No Intervention|Control group|Patients receiving usual care
11554769|NCT00971126|Experimental|Single Group Assignment|
11554770|NCT00971113|Experimental|sc-FOS+Sideritis euboea group|Jelly supplemented with short chain fructooligosaccharides and Sideritis euboea extract
11554771|NCT00971113|Placebo Comparator|placebo group|Jelly without short-chain fructooligosaccharides and Sideritis euboea
11554772|NCT00971100|Experimental|low dose of antigen + low dose of adjuvant|
11554773|NCT00971100|Experimental|high dose of antigen + high dose of adjuvant|
11554774|NCT00971100|Experimental|high dose of antigen|
11554775|NCT00971087|Other|Biopsy|subjects presenting for a breast biopsy procedure, subject will be imaged before her biopsy procedure with the investigational 2D plus 3D mammography system
11554776|NCT00971087|Other|screening|subjects presenting for routine asymptomatic mammograms and will then have an investigational 2D plus 3D mammogram
11554777|NCT00971074|Experimental|Hylan G-F 20|Single injection of Hylan G-F 20 into the affected knee.
11554778|NCT00971074|Sham Comparator|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
11554779|NCT00971061|Experimental|MSPI|Molteno single-plate implant
11554780|NCT00971061|Active Comparator|AVI|Ahmed valve implant
11554781|NCT00971048|Experimental|HP828-101|
11554782|NCT00971048|Active Comparator|Standard of Care|For DFU SoC is a hydrogel. For PU SoC is a hydrocolloid gel.
11554783|NCT00971035|Experimental|A|
11554784|NCT00971035|Experimental|B|
11554785|NCT00971035|Experimental|C|
11554786|NCT00971035|Placebo Comparator|D|
11554787|NCT00971022||Low-income Populations|
11554788|NCT00971009|Experimental|OPPC service|A practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
11554789|NCT00971009|Experimental|WebChoice IHCA|WebChoice is an interactive health communications application (IHCA) that in addition to offer a practice-integrated nurse administered online patient-provider communication (OPPC) service, allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
11554790|NCT00971009|No Intervention|Control group|The control group receives usual care
11554791|NCT00970996|Experimental|Biochemotherapy|Abraxane with Cisplatin, Temozolomide, interleukin-2 and interferon a2b
11554792|NCT00970983|Active Comparator|QUART|Patients in this arm will receive quadrantectomy, axillary dissection and radiotherapy (the current standard therapy).
11554793|NCT00970983|Experimental|QURT (SN-)|Patients will receive quadrantectomy, sentinel node investigation and radiotherapy. Selective axillary dissection will be performed if sentinel node is positive.
11554794|NCT00970970||Von Hippel Lindau|Adult patients with Von Hippel-Lindau disease
11554795|NCT00970957|Experimental|Central RVO - Macular edema - Avastin|Patients with Macular edema secondary to CENTRAL Retinal Vein Occlusion that will be treated with intravitreal injection of avastin once per month during the first 3 months. Re-treatments will be given as per protocol.
11554796|NCT00970957|Sham Comparator|Central RVO - Macular edema - Sham|Patients with Macular edema secondary to CENTRAL Retinal Vein Occlusion that will have a sham procedure performed. Injection without needle.
11554797|NCT00970957|Experimental|Branch RVO - Macular edema - Avastin|Patients with Macular edema secondary to BRANCH Retinal Vein Occlusion that will be treated with intravitreal injection of avastin once per month during the first 3 months. Re-treatments will be given as per protocol.
11554798|NCT00970957|Sham Comparator|Branch RVO - Macular edema - Sham|Patients with Macular edema secondary to BRANCH Retinal Vein Occlusion that will have a sham procedure performed. Injection without needle.
11554799|NCT00970944|Experimental|Amantadine HCL|100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4.
11554800|NCT00970944|Placebo Comparator|Placebo|
11554801|NCT00970931|Placebo Comparator|placebo|
11554802|NCT00970931|Experimental|chlortalidone-amiloride|
11554803|NCT00970918|Experimental|1|
11554804|NCT00970905|Experimental|Aprepitant & Ondansetron|
11554805|NCT00970879|Experimental|cotrimoxazole (high)|CD4 cell count≥350/mm3
11554806|NCT00970879|Active Comparator|mefloquine|CD4 cell count≥350/mm3
11554807|NCT00970879|Experimental|cotrimoxazole (low)|CD4 cell count<350/mm3
11554808|NCT00970879|Active Comparator|mefloquine & cotrimoxazole|CD4 cell count<350/mm3
11554809|NCT00970866|Active Comparator|Iron and Folic Acid (IFA)|
11554810|NCT00970866|Active Comparator|Multiple Micronutrient (MMN)|
11554817|NCT00970827|Placebo Comparator|3|Control group
11554818|NCT00970814|Active Comparator|Levetiracetam XR|Group received Levetiracetam
11554819|NCT00970814|Placebo Comparator|Sugar Pill|Placebo
11554820|NCT00970788|No Intervention|verbal group|Verbal description of goals of care.
11554821|NCT00970788|Experimental|Video group|Video decision aid.
11554822|NCT00970775|Experimental|1. AZD2423|
11554823|NCT00970775|Placebo Comparator|2. Placebo|
11554824|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.1 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.
11554825|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.15 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.
11554826|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.2 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.
11554827|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.1 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.
11554828|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.15 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.
11554829|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.2 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.
11554830|NCT00970762|Active Comparator|Vecuronium 0.1 INT, 0.025 MNT|Participants in this group received a 0.1 mg/kg intubating dose of vecuronium followed by 0.025 mg/kg maintenance dose of vecuronium.
11554831|NCT00970749||history of chlamydia infection|Women who self-reported a history of cervical infection with Chlamydia trachomatis
11554832|NCT00970749||no history of chlamydia infection|Women who self-reported no history of cervical infection with Chlamydia trachomatis
11554833|NCT00970736||1|20 healthy participants between 60 and 80 years of age. Ten men and 10 women.
11554834|NCT00970723|Experimental|intensive treatment|with a systematic screening for sleep apnea and/or uncontrolled high blood pressure, and intensified intervention on both anomalies if detected
11554835|NCT00970723|Active Comparator|conventional treatment|in accordance with national guidelines
11554836|NCT00970710|Experimental|Lifestyle counseling|VACOPP (Vaasa Childhood Obesity Primary Prevention Study): Intensified lifestyle counseling including physical activity and nutritional information beginning during maternity health care and continuing during child health care clinic visits.
11554837|NCT00970697|Experimental|becaplermin gel|application of a continuous thin layer of becaplermin gel (Regranex Gel®) during 8 weeks. The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment.
11554838|NCT00970697|Active Comparator|Duoderm Hydrogel™|application of a continuous thin layer of hydrogel dressing (Duoderm Hydrogel®), during 8 weeks. Duoderm Hydrogel™ is a sodium carboxymethylcellulose aqueous-based gel, similar in composition to becaplermin excipient.
11554839|NCT00970684|Experimental|Bevacizumab, Docetaxel, and Gemcitabine|Treatment repeats every 21 days for up to 6 courses.
11554840|NCT00970658|Experimental|Salonsip|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
11554841|NCT00970658|Active Comparator|Sabiá|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
11554842|NCT00970645|Active Comparator|traditional mediastinoscopy/thoracoscopy|Traditional Mediastinoscopy used to detect or stage lung cancers.
11554843|NCT00970645|Active Comparator|EBUS/EUS|Minimal invasive technique for staging/detecting lung cancer.
11554844|NCT00970632|Placebo Comparator|Placebo|Placebo tablet with tamsulosin dose orally (po) once daily (QD) and placebo capsule with tadalafil dose po QD for 12 weeks
11554845|NCT00970632|Experimental|Tadalafil 5 milligram (mg)|Tadalafil 5 mg tablet po QD and placebo capsule po QD for 12 weeks
11554846|NCT00970632|Active Comparator|Tamsulosin 0.4 mg|Tamsulosin 0.4 mg capsule po QD and placebo tablet po QD for 12 weeks
11554847|NCT00970619|No Intervention|Conventional anticoagulation therapy|Conservative treatment consists of an initial treatment with therapeutic doses of low molecular weight heparin (LMWH) in combination with vitamin K-antagonists, followed by treatment with vitamin K-antagonist alone (after completing LMWH treatment of at least 5-7 days and after an international normalized ratio (INR) above 2 has been reached on two consecutive measurements). Or alternatively the new direct activated factor X inhibitors can be used as anticoagulation therapy. Anticoagulant treatment will be installed according to national and international guidelines (ACCP 2008 [23], CBO 2008 [24]) tailored based on the character of the event (6 months of therapy for idiopathic DVT and 3 months for provoked DVT).
11554848|NCT00970619|Experimental|Ekos Endowave system thrombolysis|Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
11554849|NCT00970606|Placebo Comparator|Placebo tablet|Placebo
11554850|NCT00970606|Experimental|Rosuvastatin (crestor)|Experimental arm
11554851|NCT00970593|Placebo Comparator|OAP-189|
11554852|NCT00970593|Placebo Comparator|2|
11554853|NCT00970580|Experimental|BIIB022 in Combination with Paclitaxel and Carboplatin|BIIB022 in Combination with Paclitaxel and Carboplatin
11554854|NCT00970567|Other|Arm 1|stop after positive ketone bodies in urine
11554855|NCT00970567|Other|Arm 2|stop after positive ketone bodies in blood, normal therapy
11554856|NCT00970567|Other|Arm 3|stop after positive ketone bodies in blood, additional therapy
11554857|NCT00970554|Active Comparator|Patching only|
11554858|NCT00970554|Experimental|Patching plus telescope group|
11554859|NCT00970541|Active Comparator|Cinnamon Supplementation|A 500mg (consumed as two, 250mg capsules) of cinnamon extract (Cinnamon Bark P.E> 20:1) will be consumed before meals, three times per day.
11554860|NCT00970541|Placebo Comparator|Placebo|A 500 mg placebo (wheat flour) will be consumed before meals, three times per day.
11554861|NCT00970528|Experimental|Arm 1|
11554862|NCT00970528|Active Comparator|Arm 2|
11554863|NCT00970515|Experimental|Laparoscopic approach|group A: Laparoscopic approach
11554864|NCT00970515|Active Comparator|Open approach|group B: Open anterior approach
11554865|NCT00970502|Experimental|erlotinib + celecoxib|
11554866|NCT00970489|Experimental|Omega-3 fatty acid capsules|
11554867|NCT00970489|Placebo Comparator|Olive Oil capsule|
11554868|NCT00970463||GH|Patients with GHD
11554869|NCT00970463||Pegvisomant and Somatostatin analogues|Acromegaly
11554870|NCT00970450|Experimental|Paracetamol|
11554871|NCT00970450|Experimental|Paracetamol/Tropisetron|
11554872|NCT00970450|Placebo Comparator|Saline|Proband will receive Saline
11554873|NCT00970450|Active Comparator|Tropisetron|Proband will receive Tropisetron alone
11554874|NCT00970437|Active Comparator|CBASP|CBASP as the experimental intervention will follow a manual (McCullough, 2000; German version: Schramm et al., 2006). The approach is specifically tailored for the treatment of chronic forms of depression, particularly with early-onset by focusing on the problems resulting from an inhibition of maturation in early childhood and by using the therapeutic relationship in a personal, disciplined way as well as other specific techniques (e.g. Interpersonal Discrimination Exercise, Situation Analysis). CBASP integrates behavioural, cognitive, and interpersonal strategies.
11554875|NCT00970437|Placebo Comparator|SYSP|The comparator for CBASP is SYSP, a system of supportive psychotherapy, an active but less specific, manualized control treatment. SYSP - defined as non-interpersonal and non-cognitive-behavioral therapy - resembles supportive clinical management, client-centered therapy, counseling, and psychoeducation about depression. There is no specific explanatory mechanism for treatment effect offered to the patient and it does not focus on specific themes.
11554876|NCT00970424|Placebo Comparator|1|placebo, oral tablet administered once daily on background of pioglitazone
11554877|NCT00970424|Experimental|2|dutogliptin, oral tablet administered once daily on background of pioglitazone
11554878|NCT00970411|Experimental|KRN951|
11554879|NCT00970398|No Intervention|Reference group|Human milk breastfeeding
11554880|NCT00970398|Active Comparator|Control formula|Standard infant formula, with no Osteopontin supplemented.
11554881|NCT00970398|Active Comparator|Formula with 50% Osteopontin|Infant formula supplemented with bovine milk Osteopontin at 50% level of that of breast milk.
11554882|NCT00970398|Active Comparator|Formula with 100% Osteopontin|Infant formula supplemented with bovine milk Osteopontin at 100% level of that of breast milk.
11554883|NCT00970385|Active Comparator|CHOP 21|"Induction therapy CHOP every 21 days:
~cyclophosphamide 750 mg/m2 intravenously (IV) day 1
~doxorubicin 50 mg/m2 IV day 1
~vincristine 1,4 mg/m2 (maximum 2 mg) day 1
~prednisone 100 mg/m2/D from D1 to D5."
11554884|NCT00970385|Experimental|VIP/ABVD arm|"VIP cycle:
~etoposide 100 mg/m2/D IV from D1 to D3
~ifosfamide 1000 mg/m2/D from D1 to D5
~cisplatin 20 mg/m2/D as a continuous infusion from D1 to D5
~ABVD cycle:
~doxorubicin50 mg/m2/D on D1 and D14
~bleomycin 10 mg/m2/D
~vinblastine 10 mg/m2/D
~dacarbazine 375 mg/m2/D Each alternating cycle was repeated three times for a total of 6 cycles (3 VIP, 3 rABVD)."
11554885|NCT00970372||Involuntary patients|Compulsory treated patients according to the Norwegian Social and Welfare Act of 1992. Most patients have dualdiagnosis.
11554886|NCT00970372||Voluntary patients|Voluntary patients on the same wards. Most patients have dual-diagnosis.
11554887|NCT00970359|Experimental|pts with thyroid cancer with and without BRAF mutation|Patients receive selumetinib orally (PO) twice daily (BID) for 4 weeks. Within 1 month, patients with adequate RAI uptake may receive 131I per standard of care and continue selumetinib until 2 days following 131I.
11554888|NCT00970346|Experimental|Inhaled OligoG CF-5/20|
11554889|NCT00970333|Experimental|assess [18F]-FEPPA PET imaging|
11554890|NCT00970320|No Intervention|Control group, RCT2|Participants reporting anal incontinence 6 months postpartum receiving written information only for 6 months. After 6 months they are offered the same intervention as the intervention group, i.e. PFMT for 6 months.
11554891|NCT00970320|Active Comparator|Intervention group, RCT 2|Participants reporting anal incontinence 6 months postpartum receiving pelvic floor muscle training (PFMT) for 6 months (+6 months).
11554892|NCT00970320|No Intervention|Control group, RCT3|Women with obsteric anal sphincter injury receiving written information only for 6 months. After 6 months they are offered the same intervention as the intervention group, i.e. PFMT for 6 months.
11554893|NCT00970320|Active Comparator|Intervention group, RCT 3|Women with obsteric anal sphincter injury receiving pelvic floor muscle training (PFMT) for 6 months (+6 months).
11554894|NCT00970320|No Intervention|Prevalence Study|1571 primiparae delivering at Ostfold Hospital Trust or St. Olav's Hospital during the period May 2009 to December 2010.
11554895|NCT00970307|Experimental|GSK2202083A + SYNFLORIX GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of GSK2202083A vaccine and Synflorix™ vaccine at 2, 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. GSK2202083A and Synflorix™ vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
11554896|NCT00970307|Active Comparator|INFANRIX HEXA + MENJUGATE GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 2, 3 and 4 months of age, 2 doses of Menjugate® vaccine at 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. Infanrix hexa™ and Menjugate® vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
11554897|NCT00970307|Active Comparator|INFANRIX HEXA + SYNFLORIX GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of Infanrix hexa™ vaccine and Synflorix™ vaccine at 2, 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. Infanrix hexa™ and Synflorix™ vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
11554898|NCT00970294|Experimental|Health Promotion Program|Supervised exercise, educational sessions, dietary counseling
11554899|NCT00970281|Experimental|10 mg Olanzapine|
11554900|NCT00970281|Placebo Comparator|Placebo|
11554901|NCT00970268|Experimental|1|Aclidinium bromide dose, inhaled, for 52 weeks of treatment
11554902|NCT00970268|Experimental|2|Aclidinium bromide dose, inhaled, for 52 weeks of treatment
11554903|NCT00970255|Active Comparator|Frenotomy|
11554904|NCT00970255|Sham Comparator|Sham Frenotomy|
11554905|NCT00970229|Experimental|Assess [123I]MNI-420 and SPECT Imaging|To assess [123I]MNI-420 and SPECT Imaging in PD, HD subjects and similarly aged healthy subjects.
11554906|NCT00970203|Experimental|Cohort A|"3 months of androgen ablation followed at PSA progression by 3 months of the combination of androgen ablation + DC1 vaccine
~AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells"
11554907|NCT00970203|Experimental|Cohort B|"3 months of the combination of androgen ablation + DC1 vaccine followed at PSA progression by 3 months of androgen ablation
~AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells"
11554908|NCT00970177|Experimental|low dose of antigen + low dose of adjuvant|
11554909|NCT00970177|Experimental|high dose of antigen + high dose of adjuvant|
11554910|NCT00970177|Experimental|high dose of antigen|
11554911|NCT00970138|Experimental|A 850|apatinib 850 mg qd, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11554912|NCT00970138|Experimental|B 425|apatinib 425 mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11554913|NCT00970138|Placebo Comparator|C pla|placebo bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
11554914|NCT00970125|Experimental|Cancer subjects|
11554915|NCT00970112|Placebo Comparator|Placebo|Placebo 1 hour before surgery
11554916|NCT00970112|Experimental|Etoricoxib|Etoricoxib 1 hour before surgery
11554917|NCT00970112|Experimental|Dexamethaone|Dexamethasone 1 hour before surgery
11554918|NCT00970099|Active Comparator|Exercise|12 week exercise regimen
11554919|NCT00970099|Placebo Comparator|non-exercise|Normal lifestyle routine with no exercise for 12 weeks.
11554920|NCT00970086|Experimental|transversus abdominal plane block|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.
~Transversus abdominal plane block: Identification of the anatomical structures with ultrasound, insertion of the stimuplex needle G22, 50mm, in an in-plane approach and administration of 0.4ml/kg levobupivacaine 0.25%."
11554921|NCT00970073|Experimental|Delayed CNI Group 1|Thymoglobulin 3mg total, administered on Days 0 and 2 (after transplant), plus MMF and corticosteroids. CNI administration delayed until 10 days post transplant. tacrolimus 3-8 (trough concentration)
11554922|NCT00970073|Experimental|Delayed CNI Group 2|Thymoglobulin 4.5mg total, plus MMF and corticosteroids. CNI therapy delayed until 10 days post transplant.tacrolimus 3-8 (trough concentration)
11554923|NCT00970073|Active Comparator|Early CNI / Control Arm|Standard post liver transplant therapy to include: tacrolimus 8-12 (trough concentration) initiated within 48 hours post-transplant, plus mycophenolate mofetil (MMF) and corticosteroids to be administered within 24 hours after transplant (Day 0).
11554924|NCT00970060|Experimental|Exercise program|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
11554925|NCT00970047||Pregnant females|Women who are pregnant and between 6 and 16 weeks of gestation and who are 18 to 64 years of age.
11554926|NCT00970034||AF|Patients with degenerative mitral valve regurgitation and permanent atrial fibrillation who require mitral valve repair or replacement.
11554927|NCT00970034||SR|Patients with degenerative mitral valve regurgitation and maintaining sinus rhythm who require mitral valve repair or replacement.
11554928|NCT00970021|Placebo Comparator|Water with artificial colour|Placebo
11554929|NCT00970021|Active Comparator|Extract of agaricus blazei Murill|Agaricus blazei Murill
11554930|NCT00970008|Active Comparator|Massage 30 min - 2x wk for 4 wks & 1x wk for 4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
11554931|NCT00970008|Active Comparator|Massage 60 min - 2x wk for 4 wks & 1x wkly for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
11554932|NCT00970008|Active Comparator|Massage 30 min sessions - 1x/wk for 8wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
11554933|NCT00970008|Active Comparator|Massage 60 min sessions - 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
11554934|NCT00970008|No Intervention|Usual Care Control|Continue on usual care for eight (8) week period.
11554935|NCT00969995||migraine1|50 subjects with migraine without aura
11554936|NCT00969995||migraine 2|50 subjects with migraine with aura
11554937|NCT00969995||tension|50 subjects with tension headache
11554938|NCT00969995||cluster|50 subjects with cluster headache
11554939|NCT00969995||Healthy|50 healthy subjects
11554940|NCT00969982|Experimental|mifepristone+misoprostol|200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 10 doses within 48 hours (maximum 5 doses per 24 hours).
11554941|NCT00969982|Active Comparator|misoprostol|Placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion up to a maximum of 10 doses within 48 hours (maximum 5 doses per 24 hours).
11554942|NCT00969969|Active Comparator|Arthrodesis|Fusion
11554943|NCT00969969|Experimental|Cartiva|Synthetic Cartilage Implant
11554944|NCT00969956||Group A|150 Type 1 Diabetes, duration of 15 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 2 years (+/- 2 years) (50% women / men)
11554945|NCT00969956||Group B|150 Type 1 Diabetes, duration of 20 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 7 years (+/- 2 years) (50% women / men)
11554946|NCT00969956||Group C|150 Type 1 Diabetes, duration of 25 years (+/- 2 years) and 150 Type 2 Diabetes duration of 12 years (+/- 2 years) (50% women / men)
11554947|NCT00969956||Group D|50 LADA (Late Autoimmune Diabetes in Adults), debut after 35 years of age, duration of 5-10 years (50% women / men)
11554948|NCT00969943||Cocaine-dependent Men|
11554949|NCT00969943||Cocaine-dependent Women|
11554950|NCT00969943||Control Men|
11554951|NCT00969943||Control Women|
11554952|NCT00969930||healthy controls|
11554953|NCT00969930||BD type I patients|
11554954|NCT00969917|Experimental|IPI-504|IPI 504 administered twice weekly for 2 weeks followed by 1 week off treatment
11554955|NCT00969904|Active Comparator|1|
11554956|NCT00969904|Placebo Comparator|2|
11554957|NCT00969891||AML patients in induction treatment|
11554958|NCT00969878|Placebo Comparator|Placebo injection|TA-CD placebo will be administered intra muscular. A total of 5 injections will be given over 12 weeks (i.e., at Day 1 and at the beginning of Weeks 3, 5, 9 and 13).
11554959|NCT00969878|Experimental|TA-CD Vaccination|TA-CD 400 μg will be administered intramuscular. A total of 5 injections will be given over 12 weeks (i.e., at Day 1 and at the beginning of Weeks 3, 5, 9 and 13).
11554960|NCT00969865||Individualized Managment Group|Participants receiving, in addition to standard of care, blood tests for markers of heart disease, DNA and RNA analysis, and coronary artery calcium scan.
11554961|NCT00969865||Standard Management Group|Participants who receive standard of care.
11554962|NCT00969852|Experimental|Sertraline|Single Arm
11554963|NCT00969839|Experimental|Intramedullary Fixation System|Humeral fractures to be treated with the Intramedullary Fixation System
11554964|NCT00969826|Experimental|GCPGC 30 μg/kg|Ten volunteers were administered GCPGC 30 μg/kg or placebo (active:placebo=8:2)
11554965|NCT00969826|Experimental|GCPGC 100 μg/kg|Ten volunteers were administered GCPGC 100 μg/kg or placebo (active:placebo=8:2)
11554966|NCT00969826|Experimental|GCPGC 300 μg/kg|Ten volunteers would be administered GCPGC 300 μg/kg or placebo (active:placebo=8:2)
11554967|NCT00969826|Experimental|Neulasta 100 μg/kg|Eight volunteers were administered Neulasta 100 μg/kg
11554968|NCT00969813|Experimental|Normal hepatic function|
11554969|NCT00969813|Experimental|Mild hepatic impairment|
11554970|NCT00969813|Experimental|Moderate hepatic impairment|
11554971|NCT00969800|Experimental|Active Cleverin Gel|Active Cleverin Gel, which generates chlorine dioxide gas, is placed in a room of subject.
11554972|NCT00969800|Sham Comparator|Inactive Cleverin Gel|Inactive Cleverin Gel is placed in a room of subject. It does not generate chlorine dioxide gas.
11554973|NCT00969787|Experimental|DWP05195|
11554974|NCT00969761|Experimental|A. BI 6727-cisplatin|patient to receive 3-weekly infusion escalating dose of BI 6727 combined to cisplatin
11554975|NCT00969761|Experimental|B. BI 6727-carboplatin|patient to receive 3-weekly infusion escalating dose of BI 6727 combined to carboplatin
11554976|NCT00969735|Active Comparator|Cryoablation|Deflectable over-the-wire cryoablation balloon catheter (Arctic Front®, Cryocath Technologies)
11554977|NCT00969735|Active Comparator|Radiofrequency ablation|Open irrigation ablation catheter (Navistar® Thermo-cool®, Biosense Webster Inc).
11554978|NCT00969722|Experimental|ARM I|Intravenous MAb-3F8 plus Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
11554979|NCT00969722|Active Comparator|ARM II|Oral 13-cis-Retinoic Acid (RA) plus Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
11554980|NCT00969709|Experimental|1|40 mg Levomilnacipran ER capsules, low dose, oral administration, once daily.
11554981|NCT00969709|Experimental|2|80 mg Levomilnacipran ER capsules, medium dose, oral administration, once daily dosing
11554982|NCT00969709|Experimental|3|120 mg Levomilnacipran ER capsules, high dose, oral administration, once daily dosing
11554983|NCT00969709|Placebo Comparator|4|Matching placebo capsules, oral administration, once daily.
11554984|NCT00969696|Active Comparator|Galatamine|Galantamine is used for the treatment of mild to moderate Alzheimer's disease and various other memory
11554985|NCT00969696|Placebo Comparator|Sugar Pill|Sugar Pill
11554986|NCT00969683|Active Comparator|Double lumen tube without a hook|Broncho-Cath™, Mallinckrodt France, Parc d'Affaires Technopolis, 3 avenue du Canada, Bât Sigma, Les Ulis, 91975 Courtaboeuf Cedex
11554987|NCT00969683|Experimental|Double lumen tube with a hook|Broncho-Cath™, Mallinckrodt France, Parc d'Affaires Technopolis, 3 avenue du Canada, Bât Sigma, Les Ulis, 91975 Courtaboeuf Cedex
11554988|NCT00969644|Active Comparator|GH|
11554989|NCT00969644|Active Comparator|Pegvisomant|
11554990|NCT00969631|Experimental|Metformin-CC|
11554991|NCT00969631|Active Comparator|Laparoscopic ovarian diathermy (LOD)|
11554992|NCT00969618|Experimental|Atomoxetine|
11554993|NCT00969605|Active Comparator|Pressure support ventilation|
11554994|NCT00969605|Active Comparator|Adaptive support ventilation|
11554995|NCT00969592|Active Comparator|insulin glulisine, insulin aspart|insulin glulisine administration during first glucose clamp, insulin aspart administration during second glucose clamp
11554996|NCT00969592|Active Comparator|insulin aspart, insulin glulisine|insulin aspart administration during first euglycemic clamp, insulin glulisine administration during second clamp
11554997|NCT00969566|Experimental|Metformin+Sitagliptin|Initial combination of metformin and sitagliptin
11554998|NCT00969553|Experimental|BI 6727|Schedule A
11554999|NCT00969540|Active Comparator|Active Mattress Cover|Subjects in this arm will be given the placebo mattress cover followed active mattress cover .
11555000|NCT00969540|Placebo Comparator|Placebo Mattress Cover|Subjects in this arm will be given the active mattress cover followed by the placebo mattress cover.
11555001|NCT00969527|Experimental|A|Oncoxin + Viusid
11555002|NCT00969527|Placebo Comparator|B|
11555003|NCT00969514||Robotic cystectomy|Patients undergoing robotic laparoscopic cystectomy at Beaumont Hospital-RO
11555004|NCT00969501|Experimental|EUFLEXXA|ACTIVE CONTROL
11555053|NCT00969111|Experimental|Postop High Risk|IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE
11555054|NCT00969111|Experimental|Salvage Non-High Risk|Proton to 70.2 CGE
11555055|NCT00969111|Experimental|Salvage High Risk|IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE
11555005|NCT00969488|Experimental|high protein diet group|"Women in high protein diet will be stimulate to consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group. The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats). The experimental groups will also receive six cans of sardine to increase the women's commitment to the study.
~Both women group will receive a nutritional plan based on an 1800 kcal diet."
11555006|NCT00969488|Active Comparator|normal protein diet group|The control group will receive a diet to lose weight with norma protein intake and will receive 2kg of pasta to increase the women's commitment to the study. The nutritional plan based on an 1800 kcal diet.
11555007|NCT00969475|No Intervention|Control|Half of each subject's wound will not be treated.
11555008|NCT00969475|Experimental|Laser resurfacing|Half of each subject's wound will be treated with a fractional CO2 laser.
11555009|NCT00969462|No Intervention|Doxorubicin|Single arm
11555010|NCT00969449|Experimental|Arm 1|
11555011|NCT00969449|Active Comparator|Arm 2|
11555012|NCT00969436|Experimental|Priorix-Tetra Group|Subjects received 2 doses of Priorix-Tetra® vaccine, 1 at Day 0 and 1 at Month 6, administered subcutaneously in the left anterolateral thigh.
11555013|NCT00969436|Experimental|Priorix/ Priorix-Tetra Group|Subjects received 1 dose of Priorix™ vaccine at Day 0 and 1 dose of Priorix-Tetra® vaccine at Month 6, both administered subcutaneously in the left anterolateral thigh.
11555014|NCT00969436|Active Comparator|Control Group|Subjects received 1 dose of Priorix™ vaccine at Day 0 and 1 dose of Priorix™ vaccine co-administered with Varilirix™ vaccine at Month 6, administered subcutaneously in the left and right anterolateral thigh.
11555015|NCT00969423|Experimental|5 mm equipment|5 mm videoscopic equipment
11555016|NCT00969423|Experimental|10 mm|Use of standard 10 mm VATS equipment
11555017|NCT00969410|Experimental|AV-299 administered IV (monotherapy)|Subjects will be enrolled sequentially and treated with AV-299 (formerly SCH 900105) in dose escalating cohorts. Accrual to the next cohort will occur only if <= 1 out of 6 subjects experiences a dose-limiting toxicity (DLT) during the first 2 cycles. If >= 2 subjects in the same dose cohort experience a DLT during the first 2 cycles, dose-escalation will be terminated.
11555018|NCT00969397|Experimental|Topical Antiangiogenic|Topical Antiangiogenic Agents
11555019|NCT00969397|Experimental|Pulsed Dye Laser|Pulsed Dye Laser
11555020|NCT00969384|Experimental|waist circumferences|"Intervention (active awareness):
~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
11555021|NCT00969384|Experimental|Lifestyle counseling|"Intervention (active awareness):
~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
11555022|NCT00969371|Experimental|Lenstec Tetraflex IOL implantation|patients in Study arm received TetraFlex Lens
11555023|NCT00969371|Active Comparator|Control IOL|commercially approved PCIOL implanted
11555024|NCT00969345|Sham Comparator|Control Group|Stretching exercises performed twice a day for 10 minutes (4 months)
11555025|NCT00969345|Active Comparator|Respiration Group|Respiratory Yoga exercises performed twice a day for 10 minutes (4 months)
11555026|NCT00969332|Experimental|Omegaven|0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
11555027|NCT00969319||Group 1|
11555028|NCT00969306|Active Comparator|Chloroquine|Patients receive Chloroquine
11555029|NCT00969280|Experimental|Standardized Acupuncture group|
11555030|NCT00969280|Placebo Comparator|Non-acupoint shallow penetration group|
11555031|NCT00969267|Experimental|Stimulation A|with needle A stimulation
11555032|NCT00969267|Active Comparator|Stimulation B|with stimulation
11555033|NCT00969267|Sham Comparator|Stimulation C|without needle
11555034|NCT00969254|Experimental|Pílulas de Lussen|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.
~* Drug A: Pílulas de Lussen®
~** Drug B: placebo."
11555035|NCT00969254|Active Comparator|Pyridium®|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.
~* Drug A: Pyridium®
~** Drug B: placebo."
11555036|NCT00969228|Experimental|Rotarix Group|Subjects received 2 oral doses of Rotarix according to a 0, 1 or 2-month schedule.
11555037|NCT00969228|Placebo Comparator|Placebo Group|Subjects received 2 oral doses of placebo according to a 0, 1 or 2-month schedule.
11555038|NCT00969215|Experimental|Laser treatment|Half of each subject's scar will be treated with a fractional CO2 laser.
11555039|NCT00969215|No Intervention|No treatment|Half of each subject's scar will not be treated.
11555040|NCT00969202|Experimental|Stereotactic Radiosurgery using NovalisTx|Single arm study using the Novalis Tx to perform radiosurgery to treat low grade prostate cancer.
11555041|NCT00969189||Children|between 10 and 30 kgs
11555042|NCT00969189||Infants|between 5 - 10 kg
11555043|NCT00969176|No Intervention|paracetamol|not applicable, since all included cases will receive intravenous paracetamol
11555044|NCT00969163|Experimental|1|2.5 mg testosterone gel
11555045|NCT00969163|Experimental|2|300 ug testosterone gel
11555046|NCT00969163|Placebo Comparator|3|placebo gel
11555047|NCT00969150|Placebo Comparator|2|Matching placebo capsules, oral administration, once daily dosing.
11555048|NCT00969150|Experimental|1|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing.
11555049|NCT00969137|Active Comparator|Nicotine|Intravenous Nicotine
11555050|NCT00969137|Placebo Comparator|Saline|Saline infusion
11555051|NCT00969124|Experimental|Third Eye Retroscope|All subjects underwent the same intervention, consisting of examination of the colon using a colonoscope along with the Third Eye Retroscope device, with removal of any polyps that were detected during the procedure.
11555052|NCT00969111|Experimental|Postop Non-High Risk|Proton to 66.6 CGE
11555058|NCT00969059|Placebo Comparator|PLACEBO|Eligible participant with at least moderate intensity of pain (an average daily pain score of ≥ 4 on the 11 point PI-NRS at baseline) will receive placebo for 28 days.
11555059|NCT00969059|Experimental|Active|Eligible participant with at least moderate intensity of pain (an average daily pain score of ≥ 4 on the 11 point PI-NRS at baseline) will receive 7.5 mg twice daily (bid) GW856553 for 28 days.
11555060|NCT00969046|Experimental|Bolus|20 min bolus infusion
11555061|NCT00969046|Experimental|CIV-1d|1 day continuous infusion
11555062|NCT00969046|Experimental|CIV-5d|5 day continuous infusion
11555063|NCT00969033|Experimental|CS-1008 with irinotecan|CS-1008 and irinotecan
11555064|NCT00969033|Active Comparator|irintoecan|irinotecan alone
11555065|NCT00969020|Active Comparator|Telemedicine|RRS via telemedicine. By developing the concept of Remote Rehabilitation Support (RRS) the investigators will try to bring preoperative education of the patient, dissemination of information and postoperative support to a new level.
11555066|NCT00969020|No Intervention|Standard|The standard procedure for THA used under The Lundbeck Center for fast track hip and knee surgery
11555067|NCT00969007|Experimental|Lifestyle counseling|
11555068|NCT00968994|Experimental|exSALT SD7™ Wound Dressing|The exSALT™ SD7 Wound Dressing provides an antimicrobial barrier that inhibits microbial growth in the dressing. The exSALT™ SD7 Wound Dressing consists of 3 layers: two non-adherent polyethylene mesh wound contact layers and one absorbent core made of polyester. All three layers are silver coated. The concentration of silver on the exSALT™ SD7 Wound Dressing is approximately 0.4 mg/cm2 (2.5% w/w).
11555069|NCT00968994|Active Comparator|Xeroform® Petrolatum Dressing|Xeroform® Petrolatum Dressing (Xeroform® / Control Dressing) is fine mesh gauze impregnated with 3% Bismuth Tribromophenate in a special petrolatum blend. The dressing is a non adherent dressing that clings and conforms to all body parts.
11555070|NCT00968981|Experimental|A|
11555071|NCT00968981|Experimental|B|
11555072|NCT00968981|Experimental|C|
11555073|NCT00968968|Experimental|Arm 1: Lapatinib plus Trastuzumab|
11555074|NCT00968968|Active Comparator|Arm 2: Trastuzumab|
11555075|NCT00968955|Active Comparator|Local infiltration with ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
11555076|NCT00968955|Placebo Comparator|Local infiltration with saline|Local infiltration with saline (150 ML) (placebo)
11555077|NCT00968942|Active Comparator|Dose A|RT001
11555078|NCT00968942|Placebo Comparator|Dose B|Placebo
11555079|NCT00968929|Experimental|r-SK group|Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
11555080|NCT00968929|Active Comparator|UK group|Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
11555081|NCT00968916|Experimental|1|"Level 1:
~15.5 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal
~Level 2:
~25 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal
~Level 3:
~35 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal
~Level 4:
~50 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal"
11555082|NCT00968903|Active Comparator|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
11555083|NCT00968903|Placebo Comparator|Saline|Saline iv pre-operatively in equivalent volume (placebo)
11555084|NCT00968890|Experimental|Pandemrix+Fluarix and Pandemrix+Placebo|Subjects received two doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm co-administered with Fluarix™ on Day 0 and with a placebo on Day 21 intramuscularly in the deltoid region of the dominant arm.
11555085|NCT00968890|Experimental|Pandemrix+Placebo and Pandemrix+Fluarix|Subjects received two doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm co-administered with a placebo on Day 0 and with Fluarix™ on Day 21 intramuscularly in the deltoid region of the dominant arm.
11555086|NCT00968877|Active Comparator|Cholecalciferol|
11555087|NCT00968877|Placebo Comparator|Placebo|
11555088|NCT00968864|Experimental|CliniMACS® (T cell depletion)|Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.
11555089|NCT00968851|Active Comparator|EVP-6124 0.3 mg|one 0.3 mg capsule every day for 84 days
11555090|NCT00968851|Active Comparator|EVP-6124 1.0 mg|one 1.0 mg capsule every day for 84 days.
11555091|NCT00968851|Placebo Comparator|Placebo|Placebo every day for 84 days
11555092|NCT00968838|Experimental|Non-radiated White Blood Cell Transfusion|Four (4) non-radiated white blood cell transfusions. Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.
11555093|NCT00968838|Experimental|White Blood Cell Transfusion|Four (4) standard white blood cell transfusions (with radiation). Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.
11555094|NCT00968825|Active Comparator|Dose D|RT001
11555095|NCT00968825|Placebo Comparator|Dose E|Placebo
11555096|NCT00968812|Active Comparator|Glimepiride|Each patient will receive glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.
11555097|NCT00968812|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.
11555098|NCT00968812|Experimental|Canagliflozin 300 mg|Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.
11555099|NCT00968799|Experimental|HIPEC treatment|"Cytoreduction
~Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with cisplatin
~Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution. Perfusion volume depends on body size (3 - 6 l).
~If cisplatin amount exceeds the equivalent of 62.5 mg/m² body surface, cisplatin is dosed by body surface (62.5 mg/m²)(safety margin).
~Perfusion is performed with the open or Coliseum technique for 90 min."
11555100|NCT00968786|No Intervention|no home monitoring|no automated measuring devices for patients use at home
11555101|NCT00968773|Experimental|The Rebound hernia repair device with no fixation|Competent adults who have a unilateral, bilateral inguinal hernia that is primary in nature.
11555102|NCT00968773|Active Comparator|Standard Hernia Mesh using fixation|Competent adults who have a unilateral or bilateral inguinal hernia that is primary in nature.
11555103|NCT00968760|Experimental|CD19-specific T cell Infusion without IL-2|"Conditioning Regimen of Chemotherapy (Carmustine, Cytarabine, Etoposide, and Melphalan), Stem Cell Transplant, and Gene Transfer
~Group 1 - low dose of T cells without IL-2.
~Group 3 - higher dose of T cells without IL-2."
11555104|NCT00968760|Experimental|CD19-specific T cell Infusion with IL-2|"Conditioning Regimen of Chemotherapy (Carmustine, Cytarabine, Etoposide, and Melphalan), Stem Cell Transplant, and Gene Transfer
~Group 2 - higher dose of T cells with IL-2.
~Group 4 - higher dose of T cells with IL-2."
11555105|NCT00968747|Experimental|Fasting (Healthy).|Participants will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily and two fat samples will be obtained by a trained surgeon. (We are no longer recruiting for Study Arm A).
11555106|NCT00968747|Experimental|Fasting (NAFLD)|Participants with liver-biopsy diagnosed non-alcoholic fatty liver disease (NAFLD) will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily, and participants will have an MRI before and after the fast.
11555107|NCT00968747|Experimental|Hypocaloric diet (NAFLD)|Participants will follow a low-calorie diet until they lose 3-5% of their body weight. Participants will have weekly outpatient visits at Beth Israel Deaconess Medical Center in Boston, MA for weight measurements. Participants will have blood drawn before and after the diet. Participants will also have an MRI before and after the diet.
11555108|NCT00968747|Experimental|Oral carbohydrate challenge|Participants will fast for 16 hours overnight then ingest drinks containing fructose, glucose or a mixture of fructose and glucose. Blood will be drawn postprandially at specified timepoints for up to 5 hours
11555109|NCT00968734|Experimental|Low fat meal|
11555110|NCT00968734|Experimental|Hight fat meal|
11555111|NCT00968721||IBD patients|
11555112|NCT00968708|Experimental|Placebo|Alogliptin placebo matching tablets, orally, once daily. Participants continued to receive standard of care for cardiovascular disease and diabetes according to regional guidelines.
11555113|NCT00968708|Experimental|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for participants with normal or mildly impaired renal function as defined by estimated glomerular filtration rate (eGFR) ≥ 60 mL/min). Alogliptin 12.5 mg, tablets, orally, once daily for participants with moderately impaired renal function (eGFR ≥30 and <60 mL/min). Alogliptin 6.25 mg, tablets, orally, once daily for participants with severely impaired renal function or end stage renal disease (eGFR <30 mL/min). Participants continued to receive standard of care for cardiovascular disease and diabetes according to regional guidelines.
11555114|NCT00968695|Experimental|Albumin|The subjects will be receiving albumin 20% infusions
11555115|NCT00968669|Experimental|MEDI528 30 mg|MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
11555116|NCT00968669|Experimental|MEDI528 100 mg|MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
11555117|NCT00968669|Experimental|MEDI528 300 mg|MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
11555118|NCT00968669|Experimental|Placebo|Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
11555119|NCT00968643|Active Comparator|Arm I (control)|Patients undergo radiotherapy to the area of spinal cord compression once daily for 5 days (total of 20 Gy).
11555120|NCT00968643|Experimental|Arm II|Patients undergo a single fraction of radiotherapy to the area of spinal cord compression (total of 10 Gy).
11555121|NCT00968630|Experimental|Treatment (HIV-specific immune reconstitution after HCT)|Patients undergo leukapheresis for analysis of HIV-1 latent reservoir at baseline and at days +90, +180, +365, and +730, and then annually thereafter as feasible.
11555122|NCT00968617|Experimental|MK2578 1.0 mcg/kg|MK2578
11555123|NCT00968617|Experimental|MK2578 2.0 mcg/kg|MK2578
11555124|NCT00968617|Experimental|MK2578 3.6 mcg/kg|MK2578
11555125|NCT00968617|Active Comparator|Darbepoetin alfa|darbepoetin alfa
11555126|NCT00968604|Experimental|BikDD Nanoparticle|BikDD Nanoparticle starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
11555127|NCT00968591|Experimental|RAD001|
11555128|NCT00968578|Active Comparator|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
11555129|NCT00968578|Placebo Comparator|Saline|Saline iv pre-operatively in equivalent volume (placebo)
11555130|NCT00968565|Experimental|Citrate|Sodium citrate will be infused as the blood enters the ECMO circuit and calcium chloride will be infused as the blood leaves the ECMO circuit and enters the patient
11555131|NCT00968552||Patients undergoing stent placement|Patients who are scheduled to undergo stent placement via endoscopy as part of their routine medical care.
11555132|NCT00968539|Experimental|GSK2340272A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
11555133|NCT00968539|Experimental|GSK2340269A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
11555134|NCT00968526|Experimental|GSK2340272A 2D Group|Healthy male or female adults, aged 18 to 60 years (18-60y) and above (>60y), who received two doses (2D) of GSK2340272A vaccine, one administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and the other one, administered intramuscularly in the deltoid region of the dominant arm at Day 21.
11555135|NCT00968526|Experimental|GSK2340272A 1D Group|Healthy male or female adults, aged 18 to 60 years (18-60y) and above (>60y), who received a single dose (1D) of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
11555136|NCT00968513|Active Comparator|Usual Care|(N=150) brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
11555172|NCT00968201|Placebo Comparator|2|Placebo
11555173|NCT00968188|Experimental|Active intervention|Highly interactive, motivational, culturally tailored, online HIV prevention.
11555137|NCT00968513|Experimental|Brief Treatment|(N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization.
11555138|NCT00968513|Experimental|Extended Treatment|(N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
11555139|NCT00968500||Parents Who Have Lost a Child to Cancer|The overall goal of the proposed cross-sectional study is to obtain information necessary to the development of an effective Meaning-Centered Grief Intervention for parents who lost a child to cancer. In order to identify a subset of parents with whom we will conduct qualitative interviews with a subset of participants to address Aims 1 and 2, we will first screen participants to determine their levels of Prolonged Grief Disorder symptoms using a quantitative assessment (PG-13). The screening measure (PG-13) and the additional questionnaires included in the quantitative battery of measures will be analyzed to achieve Aim 3.
11555140|NCT00968487|Experimental|Lyophilized Plasma|
11555141|NCT00968487|Active Comparator|Fresh Frozen Plasma|
11555142|NCT00968461|Experimental|Phenethyl Isothiocyanate (PEITC)|Starting dose 40 mg capsules by mouth, 4 times a day, on Days 1-3 and 8-10 of each cycle.
11555143|NCT00968448|Active Comparator|Training|respiratory muscle training (pressure threshold loading)
11555144|NCT00968448|Sham Comparator|sham training|training with low resistance
11555145|NCT00968435|Experimental|(IMRT) + cisplatin + bevacizumab + cetuximab|This is a single-institution, non-randomized, phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab + cetuximab.
11555146|NCT00968422|Experimental|Low dose ABT-384|
11555147|NCT00968422|Experimental|Mid dose ABT-384|
11555148|NCT00968422|Experimental|High dose ABT-384|
11555149|NCT00968422|Placebo Comparator|Placebo|
11555150|NCT00968409|Other|FFNP-PET/CT Imaging|All subjects will receive an injection of F-18-FFNP followed by PET/CT imaging, laboratory testing and safety testing.
11555151|NCT00968396|Experimental|Stem Cell Collection + Transplantation|Apheresis: On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation. Co-culture Stem Cell Infusion on Day 0. Melphalan 100 mg/m^2 IV over 30 minutes daily on Days -2 and -1.
11555152|NCT00968383|Active Comparator|Optimal medical therapy|Conventional medical management, including aspirin, clopidogrel, statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) and/or aldosterone antagonist and risk factor modification
11555153|NCT00968383|Experimental|PCI with optimal medical therapy|Conventional medical management, including aspirin, clopidogrel, statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) and/or aldosterone antagonist and risk factor modification plus percutaneous coronary intervention and coronary stenting
11555154|NCT00968370|Active Comparator|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
11555155|NCT00968370|Other|Hospital management|Hospital management: all children admitted at the hospital will be managed with injection Ceftriaxone and other micronutrients for the total duration of hospitalization as per approved protocol.
11555156|NCT00968357|Experimental|SCV-07|Cohort 1: SCV-07 0.1 mg/kg. Cohort 2: 1.0 mg/kg per day administered SC
11555157|NCT00968344|Experimental|Leucine|3-4 g Leucine added to daily meals during bed rest
11555158|NCT00968344|Placebo Comparator|Placebo|3-4 g Alanine added to daily meals during bed rest
11555159|NCT00968331|Experimental|REVLIMID plus RITUXIMAB|"Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
~Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles."
11555160|NCT00968318|Other|Rate of seroma formation|Excision of strip of deep fascia was assessed regarding the rate of seroma formation with tissue expander insertion
11555161|NCT00968305||Children with asthma|African American children with clinically diagnosed stable asthma
11555162|NCT00968292|Experimental|Congenital/Traumatic|Individuals who were born with a limb deficiency or who have had a traumatic amputation.
11555163|NCT00968292|Experimental|Dysvascular/Diabetic|Individuals who have had an amputation as a result of vascular disease.
11555164|NCT00968279||Atrial Fibrillation|
11555165|NCT00968266|Experimental|Group intervention|"In short, the intervention consists of two group sessions moderated by a pharmacist. During these sessions, patients' self-perceived needs to take medication ('necessity beliefs'), concerns about taking medication ('concern beliefs'), and practical barriers are discussed. To explore a patient's individual ambivalence regarding his/her beliefs and barriers, the pharmacist uses Motivational Interviewing techniques. In between the sessions, participants make a homework assignment about their own beliefs and barriers, and eight weeks after the second session, a follow-up call to the individual patients is made by the pharmacist.
~Patients in the experimental arm also receive a brochure about the DMARDs they currently use (see: control arm)"
11555166|NCT00968266|Active Comparator|Control arm: usual care|In the control arm, patients receive a brochure about the DMARDs they are currently using.
11555167|NCT00968253|Experimental|Phase I: RAD001 + Combination Chemo|"Optimal dose finding of Everolimus (RAD001) beginning dose 5 mg + two different chemotherapy combinations during alternating cycles, Hyper-CVAD on Cycles 1, 3, 5, & 7 and Methotrexate & Cytarabine (Ara-C) during Cycles 2, 4, 6, & 8.
~First chemotherapy combination Hyper-CVAD = Cyclophosphamide, Vincristine, Adriamycin (doxorubicin), and Dexamethasone; Second chemotherapy combination Methotrexate and Ara-C."
11555168|NCT00968253|Experimental|Phase II: MTD RAD001 + Combination Chemo|MTD dose of Everolimus + two different chemotherapy combinations during alternating cycles, Hyper-CVAD on Cycles 1, 3, 5, & 7 and Methotrexate & Ara-C during Cycles 2, 4, 6, & 8.
11555169|NCT00968227|Experimental|Transfusion|
11555170|NCT00968214||Single group|DNA from blood specimens that have been previously collected from patients are analyzed for single nucleotide polymorphisms.
11555171|NCT00968201|Experimental|1|Montelukast
11555174|NCT00968188|Active Comparator|Information only|Medically fact based online intervention.
11555175|NCT00968175|Active Comparator|Group 1: CPN + analgesic therapy|Receives ultrasound guided celiac plexus neurolysis (CPN) in addition to standard analgesic therapy
11555176|NCT00968175|No Intervention|Analgesic therapy alone|Will not receive ultrasound guided celiac plexus neurolysis (CPN); only standard analgesic therapy for pain management
11555177|NCT00968162|Experimental|Dose de-escalation|
11555178|NCT00968149|Experimental|1|Montelukast
11555179|NCT00968149|Placebo Comparator|2|Placebo
11555180|NCT00968136||a short-term trial of the ketogenic diet|
11555181|NCT00968136||long-term trial of the ketogenic diet.|
11555182|NCT00968110|Experimental|Xolair|All patients will receive Xolair treatment for 16 weeks.
11555183|NCT00968071|Experimental|Decitabine + Gemtuzumab Ozogamicin|Decitabine 20 mg/m^2 intravenously (IV) over an hour and half daily for 5 days, Gemtuzumab Ozogamicin 3 mg/m^2 IV on day 5.
11555184|NCT00968045|Placebo Comparator|Placebo|100 ml infusion of saline is given during 15 minutes after anesthesia induction before start of surgery.
11555185|NCT00968045|Experimental|Study drug|Fibrinogen 2g in 100 ml sterile water given during 15 minutes after anestesiainduction before surgery start
11555186|NCT00968019||Presillion stent|Patients treated with the Presillion stent in up to two de novo coronary artery lesions
11555187|NCT00968006|Experimental|Treatment|Sitagliptin 100 mg once daily for 4 weeks
11555188|NCT00968006|No Intervention|Control|No change in anti-diabetic treatment regimen for at least 4 weeks.
11555189|NCT00967993||KRX-0502 (ferric citrate)|"KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate. All patients initiated on study drug will start with a fixed dose of KRX-0502 (ferric citrate) of 6 caplets per day.
~Patients will be titrated at Visits 4, 5, and 6 based on serum phosphorus lab results. If serum phosphorus levels go below normal, there will be a decrease in pills; if serum phosphorus levels go above normal, there wil be an increase in pills. The maximum number of KRX-0502 (ferric citrate) caplets per day will be 12, or 12 g/day of ferric citrate.
~Patients will take study drug orally with meals or snacks or within one hour after their meals or snacks."
11555190|NCT00967980|Active Comparator|1. Femoral Nerve Block|Patients will be randomized with a computer program to receive a femoral catheter. The catheter will be placed using standard technique. The time of catheter placement will be recorded as well as the pain/discomfort of catheter placement as reported by the patient on a 0-10 scale where 0=no pain/discomfort and 10=worst imaginable pain/discomfort.
11555191|NCT00967980|Active Comparator|2. Psoas Compartment Catheter|Patients will be randomized with a computer program to receive a psoas compartment catheter. The catheter will be placed using standard technique. The time of catheter placement will be recorded as well as the pain/discomfort of catheter placement as reported by the patient on a 0-10 scale where 0=no pain/discomfort and 10=worst imaginable pain/discomfort.
11555192|NCT00967967|Other|Mometasone furoate and desloratadine|Mometasone and desloratadine treatment
11555193|NCT00967941||Ancef|
11555194|NCT00967941||Vancomycin and Cefazolin|
11555195|NCT00967941||Daptomycin and Cefazolin|
11555196|NCT00967928|Experimental|Single arm|All subjects receive RAD001 in combination with standard field whole pelvic radiation and cisplatin.
11555197|NCT00967915|Experimental|Frenotomy|Group of neonates that will receive frenotomy for tongue-tie
11555198|NCT00967915|Sham Comparator|No frenotomy|Group of infants that will undergo sham procedure (no frenotomy performed)
11555199|NCT00967902|Experimental|Combo|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
11555200|NCT00967902|Active Comparator|Taxus® Liberté® Stent|Commercially available product
11555201|NCT00967863|Experimental|Arm I|Patients undergo 80 Gy of conformal or intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
11555202|NCT00967863|Experimental|Arm II|Patients undergo 70 Gy of conformal or intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
11555203|NCT00967850|Experimental|Intravitreal Bevacizumab|Intravitreal injections of bevacizumab
11555204|NCT00967850|Active Comparator|Visudyne|Photodynamic Therapy with Visudyne
11555205|NCT00967837|Experimental|Diabetes with non healing wounds|To determine and monitor progress of diabetic patients with non healing wounds that have failed conventional 60 day treatment respond to pulsatile intravenous insulin therapy in improving and completing healing in non healing wounds
11555206|NCT00967811|Experimental|1. Formulation E1|Formulation E1 of Latanoprost-PPDS
11555207|NCT00967811|Experimental|2. Formulation E2|Formulation E2 of Latanoprost-PPDS
11555208|NCT00967798|Experimental|Sitagliptin|"CF patients receiving Sitagliptin.
~Intervention: Dose is 100 mg taken orally once a day in the morning with breakfast. Duration is one year or until converted to CF diabetes, whichever comes sooner."
11555209|NCT00967798|Placebo Comparator|Sugar pill|"CF patients receiving placebo.
~Intervention: Placebo is taken orally once a day in the morning with breakfast. Duration is one year or until converted to CF diabetes, whichever comes sooner."
11555210|NCT00967785|Active Comparator|Treatment Arm|Neutropenia and infections
11555211|NCT00967772|Experimental|Naftopidil|
11555212|NCT00967759|Experimental|Decongex Plus|
11555213|NCT00967759|Active Comparator|Bronpheniramine isolated|
11555214|NCT00967759|Active Comparator|Fenilefrine isolated|
11555215|NCT00967746|Experimental|ENG-MIUS low|Low dose: ENG-MIUS containing 38 mg ENG with a skin thickness of approximately 350 μm
11555216|NCT00967746|Experimental|ENG-MIUS intermediate|Intermediate dose: ENG-MIUS containing 61 mg ENG with a skin thickness of approximately 140 μm
11555217|NCT00967746|Experimental|ENG-MIUS high|High dose: ENG-MIUS containing 72 mg ENG with a skin thickness of approximately 50 μm
11555218|NCT00967746|Active Comparator|Multiload|Multiload-cu 375®
11555219|NCT00967733|Active Comparator|High ALA-Low Linoleic|
11555220|NCT00967733|Placebo Comparator|Low ALA-Low Linoleic|
11555221|NCT00967733|Active Comparator|High ALA-High Linoleic|
11555222|NCT00967733|Placebo Comparator|Low ALA-High Linoleic|
11555223|NCT00967720||Barriers, Adherence, Asthma|
11555224|NCT00967707|Active Comparator|Gabapentin + venlafaxine|
11555225|NCT00967707|Active Comparator|Gabapentin + donepezil|
11555226|NCT00967694|Experimental|Nitrous oxide administration|All 20 healthy volunteers had their intraocular pressure (IOP) measured at baseline and then after 3, 6, 9, and 12 minutes of nitrous oxide administration, and then after 5, 10, and 15 minutes of breathing room air. There was therefore only one study arm, with each individual serving as their control for baseline and then intervention values of IOP measurement.
11555227|NCT00967681|Experimental|A|Oncoxin, a nutritional supplement
11555228|NCT00967681|Placebo Comparator|B|
11555229|NCT00967668|Experimental|ASPIRE-Phone Lifestyle Coaching|Phone-based coaching using small change approach to improve physical activity and diet. Initial treatment of 3 months, followed by 21 months of follow-up phone support (phone-only ASPIRE-VA).
11555230|NCT00967668|Experimental|ASPIRE-Group Lifestyle Coaching|On-site weekly group visits using small change approach to improve physical activity and diet. Initial treatment of 3 months, followed by 21 months of follow-up phone support (phone-only ASPIRE-VA).
11555231|NCT00967668|Active Comparator|MOVE! Usual Care|Usual care MOVE!, which consists of weekly on-site group visits that follow MOVE! protocols with unstructured follow-up phone support
11555232|NCT00967642|No Intervention|standard treatment|glycemia before meals and subcutaneous regular insulin if higher than 200 mg/dl
11555233|NCT00967642|Other|Intravenous Insulin|intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
11555234|NCT00967629|Other|Sevelamer Carbonate crossover|Participants will be patients with stage II-IV CKD due to diabetic nephropathy randomized to start either with sevelamer carbonate or calcium carbonate
11555235|NCT00967629|Other|Calcium Carbonate crossover|Participants will be patients with stage II-IV CKD due to diabetic nephropathy randomized to start either with sevelamer carbonate or calcium carbonate
11555236|NCT00967616|Active Comparator|FOLFIRI|"Participants who received irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI). FOLFIRI was administered by intravenous (IV) injection once every 2 weeks. The FOLFIRI regimen consisted of:
~Irinotecan, 180 mg/m^2 IV infusion over 30 to 120 minutes
~Leucovorin, 400 mg/m^2 IV infusion to match the duration of the irinotecan infusion
~5-FU, 1200 mg/m^2/day x 2 days (total 2400 mg/m^2 over 46 to 48 hours continuous infusion)"
11555237|NCT00967616|Experimental|CS7017+FOLFIRI|"Participants who received CS7017 plus irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI). Two CS-7017 tablets were administered by mouth (PO) twice a day (BID) every 12 hours. FOLFIRI was administered IV once every 2 weeks. The FOLFIRI regimen consisted of:
~Irinotecan, 180 mg/m^2 IV infusion over 30 to 120 minutes
~Leucovorin, 400 mg/m^2 IV infusion to match the duration of the irinotecan infusion
~5-FU, 1200 mg/m^2/day x 2 days (total 2400 mg/m^2 over 46 to 48 hours continuous infusion)"
11555238|NCT00967603|No Intervention|observation|no therapy until progression
11555239|NCT00967603|Experimental|sunitinib|sunitinib until progression or for a maximum of 6 months
11555240|NCT00967590|Experimental|1|
11555241|NCT00967590|Placebo Comparator|2|
11555242|NCT00967577|Experimental|J591|
11555243|NCT00967564||001|epidemiologic study QoL assessment
11555244|NCT00967551|Active Comparator|Micronutrient Sprinkles without zinc|Micronutrient sprinkles without zinc
11555245|NCT00967551|Experimental|Micronutrient sprinkles with zinc|Micronutrient sprinkles with zinc gluconate
11555246|NCT00967538|Experimental|Etanercept|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
11555247|NCT00967525|Experimental|1|Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.
11555248|NCT00967512|Experimental|cenersen, idarubicin, cytarabine|cenersen, idarubicin, cytarabine
11555249|NCT00967512|Placebo Comparator|placebo, idarubicin, cytarabine|placebo, idarubicin, cytarabine
11555250|NCT00967499|Active Comparator|1|
11555251|NCT00967499|Active Comparator|2|
11555252|NCT00967486|Active Comparator|Routine Shunt|These patients are called routine as the routine method of carotid endarterectomy is used.
11555253|NCT00967486|Active Comparator|Selective Shunt|These patients are selectively used for shunting or not shunting based on systolic pressure < 40mmHg. This group is further used as subgroup analysis.
11555254|NCT00967473|Experimental|Toric Intraocular Lens|ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Models SN60T9/SN60T8
11555255|NCT00967460|No Intervention|Control group: No intervention|No intervention, regular childcare program
11555256|NCT00967460|Experimental|Intervention group|Promoting unstructured spontaneous PA through an adaptation of the built environment and the provision of a supportive social environment
11555257|NCT00967434|Active Comparator|Group A- atorvastatin in pre and postop|Atorvastatin 80 mg administered daily for at least 7 preoperative days, 80 mg on day of surgery and 80 mg daily for up to 7 postoperative days.
11555258|NCT00967434|Active Comparator|Group B- Atorvastatin postop|Placebo administered for up to 7 preoperative days, atorvastatin 80 mg administered on day of surgery and daily for up to 7 postoperative days.
11555259|NCT00967434|Placebo Comparator|Group C- Placebo|Patients receive placebo daily for up 7 preoperative days, placebo on day of surgery and placebo daily for up to 7 postoperative days.
11555260|NCT00967421|Experimental|BAC 0.5|BAC level 0.5 g/dL (drink + placebo pill)
11555261|NCT00967421|Experimental|BAC 1.0|BAC level 1.0 g/dL (drink + placebo pill)
11555262|NCT00967421|Placebo Comparator|placebo|BAC level 0,0 g/dL (placebo drink+ placebo pill)
11555263|NCT00967408|Experimental|Rehabilitation + Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
11555264|NCT00967408|Placebo Comparator|Rehabilitation + Placebo|Rehabilitative treatment + Non active Placebo tablets for 6 months
11555265|NCT00967395|Experimental|Healing|patients receive healing while blindfolded and with hearing protector. The healer is behind a screen and not allowed to speak with the subject.
11555266|NCT00967395|Sham Comparator|Sham healing|Same design of room as with the healing, while in this case a student is behind the screen
11555267|NCT00967395|No Intervention|Control|Business as usual in the third arm
11555268|NCT00967382|No Intervention|Control|"Subjects randomized to control will receive identical obstetrical care and follow-up, but not antenatal dalteparin.
~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
11555269|NCT00967382|Active Comparator|dalteparin sodium|"Subjects randomized to the treatment group will receive daily injections of dalteparin during the antenatal period. They will be taught how to self-administer sub-cutaneous injections of dalteparin 5000 IU once daily (o.d.) until gestational age 20, then twice daily (bid) until 37 weeks gestation or onset of labour.
~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
11555270|NCT00967369|Experimental|Arm A (bortezomib, ifosfamide, carboplatin, etoposide)|ARM A: Patients receive bortezomib IV over 5 seconds on days 1 and 4, ifosfamide IV continuously over 24 hours on day 1, carboplatin IV over 1 hour on day 1, and etoposide IV over 2 hours on days 1-3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11555271|NCT00967369|Active Comparator|Arm B (ifosfamide, carboplatin, etoposide)|Patients receive ifosfamide, carboplatin and etoposide as in Arm A. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11555272|NCT00967356|Experimental|A|AZD5985
11555273|NCT00967356|Placebo Comparator|B|Placebo
11555274|NCT00967343|Experimental|ATIR|
11555275|NCT00967330|Experimental|1|
11555276|NCT00967330|Active Comparator|2|
11555277|NCT00967317|Experimental|Auris-Sedina|"Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.
~The medication should be used for a maximum of 3 days when they should return to the doctor."
11555278|NCT00967317|Active Comparator|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
11555279|NCT00967304|Experimental|1 Discontinue OAT or AAA|"Patients classified as being at low risk of recurrent VTE by the HER DOO2rule.
~If the clinical decision rule indicates that a patient is at low recurrence risk (<3% per year); anticoagulant therapy will be withdrawn and the participant will then be followed for 1 year for any VTE recurrence and/or bleeding."
11555280|NCT00967304|No Intervention|2 Observation arm|"Men and patients classified as being at high risk of recurrent VTE by the HER DOO2rule.
~If the clinical decision rule indicates that a patient is at high recurrence risk then the decision to continue or discontinue anticoagulant therapy will be left to the discretion of physicians and patients as per current standard of care and this decision recorded. High risk patients (females classified as being at high risk of recurrent VTE by the CDR, and all males) will then be followed as an observational cohort for 1 year for any VTE recurrence and/or bleeding."
11555281|NCT00967278||Off-Pump|Patients with coronary artery disease undergoing elective off-pump CABG
11555282|NCT00967265|Experimental|Introduction seminar|Psychoeducation for patients on waiting list
11555283|NCT00967265|Active Comparator|Usual care|Usual care
11555284|NCT00967252||atorvastatin 10 mg or equivalent dose|Patients already taking atorvastatin 10 mg or equivalent dose in another statin who is undergoing high risk surgery
11555285|NCT00967252||atorvastatin 20 mg or equivalent dose|Patients already taking atorvastatin 20 mg or equivalent dose in another statin who is undergoing high risk surgery
11555286|NCT00967252||atorvastatin 40 mg or equivalent dose|Patients already taking atorvastatin 40 mg or equivalent dose in another statin who is undergoing high risk surgery
11555287|NCT00967252||atorvastatin 80 mg or equivalent dose|Patients already taking atorvastatin 80 mg or equivalent dose in another statin who is undergoing high risk surgery
11555288|NCT00967252||non-statin group|Patients who are not taking or cannot take a statin drug who is undergoing high risk surgery
11555289|NCT00967226|Experimental|propranolol for treatment of hemangiomas|Assessing efficacy and tolerability of propranolol in management of symptomatic hemangiomas
11555290|NCT00967226|Active Comparator|Prednisolone|Assessing efficacy and tolerability of prednisolone in management of symptomatic hemangiomas and comparing to propranolol.
11555291|NCT00967213|Experimental|Ranibizumab|three session of monthly injection of Lucentis® (week 0, 4, 8). After 4 weeks from third injection, a session of verteporfin PDT (week 12) and fourth injection of Lucentis® (week 16) will be added at intervals of 4 weeks. Two more combined treatment with verteporfin PDT and Lucentis® injection 4 weeks apart can be added at the treating physician's discretion in 3-month intervals (week 28, week 40).
11555292|NCT00967187|Experimental|MPC-4326 200 mg BID X 14 Days|
11555293|NCT00967187|Experimental|MPC-4326 300 mg BID X 14 Days.|
11555294|NCT00967174|Experimental|Three Treatments Applied to Lower Back|Treatments were applied on the lower back, according to treatment sequence, daily for 21 days.
11555295|NCT00967161|Experimental|Evolution Medial Pivot Knee|20 Patients will receive the EMP Knee Implant
11555296|NCT00967161|Active Comparator|Triathlon PS Knee|20 Patients will receive the Triathlon PS Knee
11555297|NCT00967148|Experimental|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
11555298|NCT00967148|Active Comparator|Standard of care|The control arm will receive a subcutaneous injection of 4,500 U of tinzaparin daily beginning with the first postoperative dose and continued for the duration of hospitalization.
11555299|NCT00967135|Experimental|Pregabalin|Study subjects will be randomized to receive on the morning of surgery, at least 30 minutes before induction, a 150 mg oral dose of pregabalin. Patients will then receive a 150 mg oral dose of pregabalin on the evening of the surgery. Subsequently, patients will receive a 150 mg oral dose of pregabalin twice daily on the following four postoperative days.
11555300|NCT00967135|Placebo Comparator|Placebo|Study subjects will be randomized to receive a matching placebo on the morning of surgery, at least 30 minutes before induction. Patients will then receive a placebo on the evening of the surgery. Subsequently, patients will receive a placebo twice daily on the following four postoperative days.
11555301|NCT00967122|No Intervention|No Arm|
11555302|NCT00967109|Active Comparator|Allowed drop in hemoglobin to 4,5-5,5 mmol/L|Transfusion with red blood cells to level between 4.5-5.5 mmol/L
11555303|NCT00967109|Experimental|Allowed drop in hemoglobin to 5,5-6,5 mmol/L|Transfusion with red blood cells to level between 5.5-6.5 mmol/L
11555304|NCT00967096|Experimental|1|The primary clinical endpoint to be assessed in this study will be the proportion of Rifaximin doses successfully administered. Because of mucositis, compliance with oral agents, even those that are well tolerated in other settings, may be limited in the early post-transplant period. Thus, it will be important to demonstrate the feasibility of administering Rifaximin to BMT patients before embarking on larger scale studies. Secondary outcomes will include AGVHD, event-free survival, overall survival, non-relapse mortality, neutrophil and platelet engraftment.
11555305|NCT00967083||family caregivers of lung cancer patients|In this 2-year pilot study, we plan to screen family caregivers of lung cancer patients within 4 to 6 weeks after the a new visit to the thoracic clinic. We will screen spouses, adult children, and other family members using the HAD-18 to determine their level of anxiety and depressive symptoms at enrollment.
11555306|NCT00967070|Experimental|Both Treatments Applied on Lower Back|Treatments were applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
11555307|NCT00967057|Experimental|Arm I (induction therapy)|Patients receive idarubicin IV over 1 hour on days 1 and 2; oral dexamethasone twice daily on days 1-5 and 15-19; intrathecal (IT) methotrexate on days 1 and 8; vincristine sulfate IV on days 3, 10, 17, and 24; and pegaspargase intramuscularly (IM) on days 3 and 17 or asparaginase IM on days 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25.
11555308|NCT00967057|Experimental|Arm II (induction therapy)|Patients receive mitoxantrone IV over 1 hour on days 1 and 2. Patients also receive dexamethasone, methotrexate, vincristine sulfate, and pegaspargase or asparaginase as in arm I.
11555309|NCT00967044|Experimental|Panobinostat + Everolimus|Panobinostat (LBH589) Plus Everolimus (RAD001)
11555310|NCT00967031|Experimental|Lapatinib + capecitabine|lapatinib 1250mg/day + capecitabine 2000mg/m2/day
11555311|NCT00967018|Experimental|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. For patients treated with goserelin in the previous trials (CS28, CS30 and CS31),a starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to the end of the trial. For patients treated with degarelix in the previous trials, maintenance doses of 80 mg (20 mg/mL) degarelix were continued and were administered as single 4 mL s.c. injections at 28 day intervals to the end of the trial.
11555312|NCT00967005|Experimental|N Acetyl Cysteine|The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and PG symptoms in nicotine dependent pathological gamblers.
11555313|NCT00967005|Placebo Comparator|Sugar Pill|
11555314|NCT00966992|No Intervention|Arm 1 (No Zometa)|Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. All interventions on this arm are standard of care.
11555315|NCT00966992|Experimental|Arm 2 (Zometa)|Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. Women randomized to zoledronic acid will receive 4 mg intravenously (IV) with their first dose chemotherapy and 3, 6 and 9 months after completion of radiation (total of 4 doses) along with scheduled follow-up dual-energy X-ray absorptiometry (DEXA) and biomarker studies.
11555316|NCT00966979|Other|Triathlon PKR|All subjects enrolled will receive the Triathlon PKR device.
11555317|NCT00966966|Experimental|1|SAM-531_gemfibrozil
11555318|NCT00966953|Placebo Comparator|Fluoride Toothpaste|fluoride control
11555319|NCT00966953|Active Comparator|Total/Whitening|positive control
11555320|NCT00966953|Experimental|antibacterial plant extract 1|Honokiol
11555321|NCT00966953|Experimental|antibacterial plant extract 2|magnolol
11555322|NCT00966940|Other|Travoprost-to-tafluprost|Travoprost first, with tafluprost second. Each product dosed for six weeks.
11555323|NCT00966940|Other|Tafluprost-to-travoprost|Tafluprost first, with travoprost second. Each product dosed for six weeks.
11555324|NCT00966927||subjects with spina bifid|subjects with spina bifid between 14 and 21 years old referred to Unit for Care of Spina Bifid Hospital of Parma
11555325|NCT00966914|Placebo Comparator|Placebo|Placebo in combination with cisplatin and either paclitaxel or docetaxel
11555326|NCT00966914|Active Comparator|Tavocept (BNP7787)|Tavocept (BNP7787) in combination with cisplatin and either docetaxel or paclitaxel
11555327|NCT00966901|Experimental|Three Treatment Sites UV Exposed|All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)
11555328|NCT00966888|Experimental|Arm I|Beginning 12 weeks after mastectomy or 6 weeks after adjuvant chemotherapy, patients undergo radiotherapy 5 days a week for 3-5 weeks in the absence of disease progression or unacceptable toxicity.
11555329|NCT00966888|Active Comparator|Arm II|Patients receive standard of care and observation only.
11555330|NCT00966875|Experimental|3 mg LY2439821 (bDMARD-naive population)|3 milligrams (mg) LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. [Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)]
11555331|NCT00966875|Experimental|10 mg LY2439821 (bDMARD-naive population)|10 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
11555332|NCT00966875|Experimental|30 mg LY2439821 (bDMARD-naive population)|30 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
11555333|NCT00966875|Experimental|80 mg LY2439821 (bDMARD-naive population)|80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
11555334|NCT00966875|Experimental|180 mg LY2439821 (bDMARD-naive population)|180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
11555335|NCT00966875|Experimental|80 mg LY2439821 (TNFa-IR population)|80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. [Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR)]
11555336|NCT00966875|Experimental|180 mg LY2439821 (TNFa-IR population)|180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
11555337|NCT00966875|Placebo Comparator|Placebo (bDMARD-naive population)|Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
11555338|NCT00966875|Placebo Comparator|Placebo (TNFa-IR population)|Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
11555339|NCT00966849|Experimental|Conditional Cash Transfer|Vulnerable households in this arm will receive conditional cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
11555340|NCT00966849|Experimental|Unconditional Cash Transfer|Vulnerable households in this arm will receive unconditional cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
11555341|NCT00966849|Other|Control|Vulnerable households in this arm will not receive cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
11555342|NCT00966836|Experimental|Pre-emptive everolimus|
11555343|NCT00966836|Experimental|Prophylaxis mycophenolate|
11555344|NCT00966836|Experimental|Prophylaxis Everolimus|
11555345|NCT00966836|Active Comparator|Pre-emptive mycophenolate|
11555346|NCT00966823|Experimental|Detachable balloon|Intervention: Fetuses treated with endoscopic tracheal occlusion
11555347|NCT00966810|Experimental|CML allogeneic stem cell transplantation|Patients with chronic myeloid leukemia suitable for allogeneic stem cell transplantation with a matched related donor.
11555348|NCT00966771||IUD|Women presenting for emergency contraception who select the copper IUD
11555349|NCT00966771||Oral levonorgestrel|Women presenting for emergency contraception who select oral levonorgestrel
11555350|NCT00966758|Other|1|
11555351|NCT00966745|Active Comparator|milrinone|milrinone infusion
11555352|NCT00966745|Placebo Comparator|placebo|
11555353|NCT00966732|Experimental|yoga condition|assigned to start the yoga program right away
11555354|NCT00966732|No Intervention|wait-list control condition|This condition will control for any effects of symptom measurement reactivity in patients receiving routine fibromyalgia medical care. After the 3-month assessment, the yoga intervention program will be provided to these patients.
11555355|NCT00966719|Active Comparator|Lactation Consultant|"In hospital meeting with lactation consultant
~1 to 3 follow up visits at weekly intervals with lactation consultant"
11555356|NCT00966719|No Intervention|current treatment for jaundice|Babies will receive current standard of care for jaundice (IV fluids and phototherapy)
11555357|NCT00966706|Experimental|Arm I|Patients receive cisplatin, gemcitabine hydrochloride, and docetaxel on days 1 and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11555358|NCT00966706|Experimental|Arm II|Patients receive cisplatin, gemcitabine hydrochloride, and epirubicin hydrochloride on days 1and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11555359|NCT00966693|Experimental|Treatment (lenalidomide, thalidomide, dexamethasone)|"Participants receive lenalidomide PO on days 1-21 and thalidomide PO QD on days 1-28. Participants also receive dexamethasone PO QD on days 1-4, 9-12, and 17-20 of courses 1-2, and days 1, 8, 15, and 22 of subsequent courses. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Participants who have stable or responding disease to treatment receive lenalidomide PO on days 1-21 and thalidomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants may receive dexamethasone at the discretion of the investigator."
11555360|NCT00966680||1|Observational study comparing the speed of general versus spinal anesthesia during emergency cesarean
11555361|NCT00966667||cancer survivor|cancer survivor
11555362|NCT00966654|Placebo Comparator|Saline|Saline
11555363|NCT00966654|Active Comparator|GLP-1|GLP-1 (7-36) amide
11555364|NCT00966641|Experimental|PL 3100|Active experimental drug
11555365|NCT00966641|Active Comparator|Naproxen|Active comparator
11555366|NCT00966628|Active Comparator|Ringer's lactate|
11555367|NCT00966628|Experimental|Hypertonic sodium lactate|
11555368|NCT00966615|Experimental|Balance group|peritoneal dialysis with neutral peritoneal dialysis solution with minimal glucose-degradation-product
11555369|NCT00966615|Active Comparator|Control group|conventional PD solution
11555370|NCT00966602|Experimental|Treatment Period 1|
11555371|NCT00966602|Experimental|Treatment Period 2|
11555372|NCT00966602|Experimental|Treatment Period 3|
11555373|NCT00966589|Sham Comparator|conservative treatment|physiotherapy
11555374|NCT00966589|Active Comparator|surgery|laparoscopic hernioplasty (TEP)
11555375|NCT00966576|Experimental|Brinzolamide/Timolol Maleate Fixed Combination|
11555376|NCT00966563|Active Comparator|Mangafodipir treatment|Treatment will be undertaken with a ready-to use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI. Formulation content: MnDPDP 10 mmol/ml.
11555377|NCT00966563|Placebo Comparator|NaCl 0.9%|
11555378|NCT00966550|Active Comparator|Tomato|Tomato with high carb/fat meal
11555379|NCT00966550|Placebo Comparator|Non-Tomato|Non-tomato with high carb/fat meal
11555380|NCT00966524|Experimental|Video|Teaching tracheal intubation to medical students using video-guided feedback during the procedure.
11555381|NCT00966524|Active Comparator|Standard|Teaching tracheal intubation to medical students using direct visualization feedback during the procedure.
11555382|NCT00966511||Lung resection candidates|Study participants will be patients who are candidates for lung resection (lobectomy or greater)
11555383|NCT00966498|Experimental|1|This study is a single-arm, non-randomized trial. Peripheral blood stem cells will be harvested by mobilization with chemotherapy followed by G-CSF. Following adequate peripheral blood stem cell collection, the patients would be transplanted using the conditioning regimen consisting of thiotepa and cyclophosphamide (tandem one) and busulfan and melphalan (tandem two). They will receive G-CSF post transplant. There will be 6-8 weeks interval between tandem transplants. All patients would be carefully observed for any toxicity, transplant-related complications, relapse and disease-free survival.
11555384|NCT00966485|Active Comparator|80 mg ASA dose|6 months post stent on 80 mg ASA
11555385|NCT00966485|Active Comparator|500 mg ASA dose|6 months posr stent on ASA alone
11555386|NCT00966472|Experimental|Erlotinib + Rosuvastatin|To determine the recommended phase II dose (RP2D) of rosuvastatin that can be given in combination with standard erlotinib treatment in patients with advanced incurable squamous cell cancer and NSCLC.
11555387|NCT00966459|Other|1|
11555388|NCT00966446|Experimental|Unsupervised Decolonization|Households undergo decolonization for MRSA. The intervention includes applying Mupirocin ointment twice daily for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided.
11555389|NCT00966446|Experimental|Supervised Decolonization|Households undergo decolonization for MRSA. The intervention includes applying Mupirocin ointment twice daily for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Study staff is in contact with household members during this intervention to ensure compliance.
11555390|NCT00966446|No Intervention|No Intervention|Households do not undergo active MRSA decolonization protocol
11555391|NCT00966433|Experimental|Spontaneous ventilation|Pt's will be allowed to breathe spontaneously through the PLMA during surgery without the assistance of positive pressure ventilation.
11555392|NCT00966433|Experimental|Pressure support ventilation|Pt's will receive positive pressure assistance with each spontaneous breath through the PLMA.
11555393|NCT00966433|Active Comparator|Pressure control ventilation|Pt.'s will be placed on the ventilator and ventilated with pressure control. through the PLMA.
11555394|NCT00966420|Experimental|mucosa resection|
11555395|NCT00966407||Healthy Young Adults|College-age (18-35 years) participants recruited from Howard University, East Carolina University, and University of Massachusetts, Amherst, University of Calgary, Winston-Salem University
11555396|NCT00966394||ADHD medication|Children with ADHD and pharmacologic treatment
11555397|NCT00966394||ADHD without medication|Children with ADHD without pharmacologic treatment
11555398|NCT00966394||healthy|Healthy children ASA1
11555399|NCT00966381|No Intervention|Control|The minimal care group will receive standard public health information on nutrition from the American Heart Association twice during the 16-week intervention. Upon completion of the endpoint measurement (20 wks postpartum), they will be given all intervention materials.
11555400|NCT00966381|Experimental|Exercise Group|The intervention group will participate in a 16-week exercise and diet intervention from 4 to 20 wks postpartum. The PI will travel to the participant's homes three times per week during the 16-week intervention to guide mothers with the exercise program, ensure dietary compliance, and provide social support. The 16-wk exercise protocol consists of strength training three times per week and walking 10,000 steps per day at least five days per week.
11555401|NCT00966368|Experimental|IDeg E|
11555402|NCT00966368|Experimental|IDeg M|
11555403|NCT00966355|Active Comparator|Terlipressin|treat with terlipressin IV for 5 days and endoscopic treatment
11555404|NCT00966355|Active Comparator|Somatostatin|treat with somatostatin IV for 5 days and endoscopic treatment
11555405|NCT00966355|Active Comparator|Octreotide|treat with octreotide IV for 5 days and endoscopic treatment
11555406|NCT00966342|Other|Vaccine|Everyone gets licensed Influenza vaccine
11555407|NCT00966329|Experimental|to switch from the NNRTI/PI to maraviroc|to switch from the NNRTI/PI to maraviroc
11555408|NCT00966329|Active Comparator|to continue with the same approach|to continue with the same approach
11555409|NCT00966316|Experimental|pathway|aspirin，Chinese herbs；acupuncture；rehabilitation；health education；
11555410|NCT00966303|Experimental|Cardiac Rehabilitation|9 patients with cardiomyopathy in functional class III or IV, submitted to an 8-week program with exercises and respiratory muscle training.
11555411|NCT00966290|Experimental|ACC group|Anticoagulant clinic-based shared-care group
11555412|NCT00966290|Active Comparator|UC group|Usual care group
11555413|NCT00966277|Experimental|Group 1: Dalteparin|Dalteparin 5000 units subcutaneous, by injection under the skin, daily for 16 weeks.
11555414|NCT00966277|No Intervention|Group 2: Control|No study drug.
11555415|NCT00966264|Active Comparator|LNG-IUS|Levonorgestrel releasing intrauterine system
11555416|NCT00966264|Other|Hysterectomy|Hysterectomy
11555417|NCT00966251|Experimental|CT-011|
11555418|NCT00966238|Experimental|VAX125|HA1 influenza vaccine
11555419|NCT00966225|Experimental|One gram LIP-01 per day|One gram LIP-01 per day for 12 weeks
11555420|NCT00966225|Experimental|Two grams LIP-01 per day|Two grams LIP-01 per day for 12 weeks
11555421|NCT00966225|Experimental|0.333 grams LIP-01 per day|0.333 grams LIP-01 per day for 12 weeks
11555422|NCT00966212|No Intervention|health promotion materials|
11555423|NCT00966212|Active Comparator|print parent education|
11555424|NCT00966199|Experimental|Hypertensive elderly|community dwelling hypertensive elderly from general practices
11555425|NCT00966186|Active Comparator|Standard technique|Proseal laryngeal mask airway was inserted according to the manufacture's instruction manual (insertion with help of index finger insertion)
11555426|NCT00966186|Experimental|Rotational technique|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was fel
11555476|NCT00965796|Experimental|Lidocaine, pain intensity and Saline|(2 mg/kg/h) and patients of group 2 (n = 20) received 0.9% saline infusion throughout the surgical procedure
11555427|NCT00966160|Active Comparator|PI|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over a 56-week run-in and a 420-week follow-up
11555428|NCT00966160|Active Comparator|NNRTI|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over a 56-week run-in and a 420-week follow-up
11555429|NCT00966147|Experimental|Lidco group|All patients monitored by the lidco system and treated to optimize oxygen delivery
11555430|NCT00966134||probands|
11555431|NCT00966121|Active Comparator|Endoscopic band ligation|Perform endoscopic band ligation (EBL) until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
11555432|NCT00966121|Active Comparator|EBL+Propranolol|Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
11555433|NCT00966108||Healthy subjects|
11555434|NCT00966108||Glaucoma patients|
11555435|NCT00966095||men scheduled for prostate biopsy|
11555436|NCT00966082|Active Comparator|Endoscopic band ligation|Perform endoscopic band ligation (EBL) until eradication of esophageal varices, and then follow-up endoscopy with 3-6 months interval
11555437|NCT00966082|Active Comparator|endoscopic band ligation+Propranolol|Perform endoscopic band ligation (EBL) until eradication of esophageal varices, and then follow-up endoscopy with 3-6 months interval, with propranolol
11555438|NCT00966069|Active Comparator|Healthcare worker visit|"Healthcare worker performs home visit when study child has acute respiratory illness to collect a respiratory swab (nasopharyngeal swab).
~At the healthcare worker home visit, the HCW will collect the nasopharyngeal swab, and a parent will collect an anterior nasal swab. The HCW swab is to be returned immediately to the laboratory, and the parent collected swab was placed in a post box for return to the laboratory by surface mail."
11555439|NCT00966069|Experimental|Parent collection|Home collection of respiratory swab (anterior nose) and mailed return when study subject has an acute respiratory illness.
11555440|NCT00966056|Active Comparator|Mitomycin C|Cases recruited into this arm receive topical application of mitomycin c (1mg/ml)following surgical synechiolysis
11555441|NCT00966056|Active Comparator|Teflon septal splint|Cases recruited into this arm receive insertion of teflon internal nasal septal splint following surgical synechiolysis
11555442|NCT00966030|Experimental|1|MK0974 Tablet
11555443|NCT00966030|Active Comparator|2|MK0974 Liquid filled capsule
11555444|NCT00966017||DS|Those with Down syndrome
11555445|NCT00966017||Non-DS|Healthy controls
11555446|NCT00966004|Experimental|YM178 group|oral
11555447|NCT00966004|Placebo Comparator|Placebo group|oral
11555448|NCT00966004|Active Comparator|tolterodine group|oral
11555449|NCT00965991|Active Comparator|Metformin|
11555450|NCT00965991|Active Comparator|Glyburide|
11555451|NCT00965978|Experimental|Low dose group|Receives low dose of ONO-5920/YM529 with and without food
11555452|NCT00965978|Experimental|High dose group|Receives high dose of ONO-5920/YM529 with and without food
11555453|NCT00965965|Experimental|Experimental patient education document|
11555454|NCT00965965|Active Comparator|Traditional patient education document|
11555455|NCT00965926|Experimental|Low dose group|3 way cross-over. Fasting, normal diet and high-fat diet
11555456|NCT00965926|Experimental|High dose group|3 way cross-over. Fasting, normal diet and high-fat diet
11555457|NCT00965913|Experimental|Three Interventions on Lower Back|Three treatments were applied on the lower back, according to treatment sequence, daily for 21 days
11555458|NCT00965900|Active Comparator|Endoscopic band ligation|Endoscopic band ligation until eradication of esophageal varices with 4 weeks interval, and then follow-up endoscopy with 3-6 months interval until 36 months after enrollment
11555459|NCT00965900|Active Comparator|Propranolol|start with 20 mg b.i.d, and adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min. After reaching target HR, then follow-up according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)
11555460|NCT00965900|Active Comparator|EBL+Propranolol|"EBL until eradication of esophageal varices with 4 weeks interval, and then follow-up endoscopy with 3-6 months interval until 36 months after enrollment
~start with 20 mg of propranolol b.i.d, and adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min. After reaching target HR, then follow-up according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
11555461|NCT00965887|Active Comparator|1|MK0974 Ethanolate
11555462|NCT00965887|Active Comparator|2|MK0974 Hydrate
11555463|NCT00965874|Experimental|Magnesium Sulfate high dose infusion|9 g Magnesium sulfate infusion over 30 minutes
11555464|NCT00965874|Active Comparator|Magnesium Sulfate low dose infusion|4.5 magnesium sulfate infusion over 30 minutes
11555465|NCT00965874|Placebo Comparator|placebo|serum salin
11555466|NCT00965861||1|The SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date.
11555467|NCT00965848|Experimental|Nosocomial Pneumonia|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with nosocomial pneumonia up to maximum of 14 days.
11555468|NCT00965848|Experimental|Complicated Intra-Abdominal Infections|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with complicated intra-abdominal infections up to maximum of 14 days.
11555469|NCT00965848|Experimental|Complicated Urinary Tract Infections|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with complicated urinary tract infections up to maximum of 10 days.
11555470|NCT00965835||DS|Those with Down syndrome
11555471|NCT00965835||Non-DS|Healthy controls
11555472|NCT00965822|Active Comparator|1|
11555473|NCT00965822|Placebo Comparator|2|
11555474|NCT00965809|Experimental|ACTIVE THC|Subjects will take 5MG of THC in 6 drops of olive oil orally.
11555475|NCT00965809|Placebo Comparator|Placebo|Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
11555477|NCT00965783|Experimental|1|Sleep time restriction
11555478|NCT00965783|Experimental|2|Sleep time extension
11555479|NCT00965770||IUD|Repeat abortion rate in women receiving IUDs immediately post-abortion
11555480|NCT00965757|Experimental|1|
11555481|NCT00965757|Placebo Comparator|2|
11555482|NCT00965744|Experimental|Vessel sealing system LigaSure (VS group)|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
11555483|NCT00965744|No Intervention|Conventional hand-tied method (CH group)|Patients in CH group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the conventional hand-tied method.
11555484|NCT00965731|Active Comparator|Erlotinib|
11555485|NCT00965731|Experimental|Erlotinib + PF-02341066|
11555486|NCT00965705|Active Comparator|Guided Self Help|
11555487|NCT00965705|Active Comparator|Cognitive Behavioral Therapy|
11555488|NCT00965705|Active Comparator|Dialectical Behavioral Therapy|
11555489|NCT00965666|Experimental|Open Label|
11555490|NCT00965653|Experimental|1|
11555491|NCT00965653|Active Comparator|2|
11555492|NCT00965601|Active Comparator|CTB Group|Subjects will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
11555493|NCT00965601|No Intervention|Usual Care|Subjects will not receive any type of intervention
11555494|NCT00965588|Experimental|Vaccine (UB 311)|
11555495|NCT00965575|Experimental|Melatonin|Subjects will take sustained release melatonin 30 minutes prior to bedtime for four weeks
11555496|NCT00965575|Placebo Comparator|Placebos|Subjects will take a placebo 30 minutes before bedtime for four weeks
11555497|NCT00965562|Active Comparator|I|Fluoxetine
11555498|NCT00965562|Active Comparator|II|Calcium
11555499|NCT00965562|Placebo Comparator|III|
11555500|NCT00965549|Experimental|Lantus + Apidra basal plus one|"Before randomization (common with arm 2):
~A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy.
~8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued.
~After randomization:
~24 weeks of treatment period: Insulin (Lantus®) + metformin (if applicable) + a single injection of insulin glulisine (Apidra®), the latter administered at the patients largest meal of the day"
11555501|NCT00965549|Active Comparator|NovoMix 30 Biphasic|"Before randomization (common with arm 1):
~A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy.
~8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued.
~After randomization:
~24 weeks of treatment period: Insulin aspart/ insulin protamine crystallised insulin aspart (NovoMix® 30) + metformin (if applicable)"
11555502|NCT00965536||1|Seroquel
11555503|NCT00965536||2|Seroquel Prolong
11555504|NCT00965523|Experimental|Eribulin Mesylate|
11555505|NCT00965510|Experimental|Care Coordination|Patients receive care coordination to improve their diabetes.
11555506|NCT00965510|No Intervention|control|patients with type II diabetes receive usual health care
11555507|NCT00965497|Experimental|Escitalopram|All patients will receive escitalopram 20 mg daily.
11555508|NCT00965484|Experimental|Genotropin pen|All subjects will receive genotropin pen to use for 2 months.
11555509|NCT00965471|Experimental|managed group|
11555510|NCT00965471|Placebo Comparator|control group|
11555511|NCT00965458|Experimental|Alefacept|Subjects in this group receive weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
11555512|NCT00965458|Placebo Comparator|Placebo|Subjects in this group received weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
11555513|NCT00965445||cardiac surgery with CPB|
11555514|NCT00965432|Placebo Comparator|Placebo|
11555515|NCT00965432|Active Comparator|STX107|
11555516|NCT00965419|Experimental|Edivoxetine|All enrolled participants were administered starting dose of 0.1 milligram per kilogram per day (mg/kg/day), or participant specific known stable dose, rollover participants (LNBJ [No NCT number]) and (LNBF [NCT00922636]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
11555517|NCT00965406|Placebo Comparator|glucose insulin potassium (GIK)|Glucose + insulin +6 potassium (GIK) infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours.
11555518|NCT00965406|Experimental|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
11555519|NCT00965406|No Intervention|Control group|No intervention and patients were treated with updated international recommendations of acute coronary syndrome.
11555520|NCT00965393|Placebo Comparator|1|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times. Systemic infusion of placebo (saline).
11555521|NCT00965393|Active Comparator|2|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times. Systemic infusion of bradykinin receptor antagonist (HOE-140).
11555522|NCT00965367|Experimental|Acustimulation|
11555523|NCT00965367|No Intervention|Standard treatment group|
11555524|NCT00965354||Influenza diagnosis|Patients admitted to hospital with a suspected or confirmed influenza diagnosis on admission
11555525|NCT00965341|Active Comparator|Testosterone|Testosterone Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
11555526|NCT00965341|Placebo Comparator|Placebo|Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
11555527|NCT00965328|Active Comparator|hemofiltration at 4L/h|Hemofiltration was started at 4L/h and crossed over to 2L/h after 60 minutes of hemofiltration
11555528|NCT00965328|Active Comparator|hemofiltration at 2L/h|hemofiltration was started at 2L/h and crossed over to 4L/h after 60 min
11555529|NCT00965302|Active Comparator|Intensive medical management of Type 2 DM|Intensive medical management of Type II diabetes will include visits every three months for a year with an endocrinologist, with lifestyle counseling, weight management, regular exercise, and glucose control forming the core of the medical therapy.
11555530|NCT00965302|Experimental|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy is performed as part of a bariatric surgical program emphasizing healthy dietary choices, regular exercise, and glucose control.
11555531|NCT00965289|Experimental|HDT combined with rituximab before ASCT|The study treatment consisted on 2 courses of high-dose R-CHOP-like regimen, followed by a course of high-dose methotrexate with cytarabin. For patients who achieved at least a PR, ASCT started with a BEAM regimen.
11555532|NCT00965263|Experimental|Low dose Vaccine|All participants were vaccinated four times: in week 1, 3, 5, and 9. Dose: 82ul
11555533|NCT00965263|Experimental|High Dose Vaccine|All participants were vaccinated four times: in week 1, 3, 5, and 9. Dose: 360ul
11555534|NCT00965250|Experimental|Thymoma|Patients will receive IMC-A12 at a dose of 20 mg/kg intravenously once every three weeks. The most common tumors of the thymus are thymomas (well differentiated neoplasms and moderately differentiated neoplasms) and thymic (poorly differentiated neoplasms) carcinomas.
11555535|NCT00965250|Experimental|Thymic Carcinoma|Patients will receive IMC-A12 at a dose of 20 mg/kg intravenously once every three weeks. The most common tumors of the thymus are thymomas (well differentiated neoplasms and moderately differentiated neoplasms) and thymic (poorly differentiated neoplasms) carcinomas.
11555536|NCT00965237|Other|Multifocal CL / Single vision CL + reading glasses|Lotrafilcon B multifocal contact lenses (CL) worn first, with lotrafilcon B single vision contact lenses (CL) and over-reader spectacles worn second. Both contact lens products worn bilaterally on a daily wear basis; over-reader spectacles worn on an as-needed basis.
11555537|NCT00965237|Other|Single vision CL + reading glasses / Multifocal CL|Lotrafilcon B single vision contact lenses (CL) and over-reader spectacles worn first, with lotrafilcon B multifocal contact lenses (CL) worn second. Both contact lens products worn bilaterally on a daily wear basis; over-reader spectacles worn on an as-needed basis.
11555538|NCT00965224|Experimental|standard therapy + vaccination|
11555539|NCT00965224|No Intervention|standard therapy|
11555540|NCT00965198||Clearlink Arm, EUH|Standard catheter access device at Emory University Hospital
11555541|NCT00965198||VLINK Arm, EUHM|Novel, silver-coated catheter access device at Emory University Hospital Midtown
11555542|NCT00965198||Clearlink, EUM|Standard catheter access device at at Emory University Hospital Midtown
11555543|NCT00965198||VLINK Arm, EUH|Novel, silver-coated catheter access device at Emory University Hospital
11555544|NCT00965185|Experimental|Atorvastatin|20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
11555545|NCT00965185|Placebo Comparator|placebo|
11555546|NCT00965172|Experimental|Caphosol|Caphosol (calcium phosphate)
11555547|NCT00965172|Active Comparator|Baking Soda|Control Group (standard of care)
11555548|NCT00965146|Experimental|Scorpio® CR Total Knee System|Scorpio® CR Total Knee System Study Device
11555549|NCT00965133|No Intervention|Normal daily activity|
11555550|NCT00965120|Placebo Comparator|1|Ischaemia 20 minutes. Blood pressure cuff will be inflated to 200mmHg around the upper arm for 20 minutes to induce ischaemia. Systemic infusion of placebo (saline).
11555551|NCT00965120|Active Comparator|2|Ischaemia 20 minutes. Blood pressure cuff will be inflated to 200mmHg around the upper arm for 20 minutes to induce ischaemia. Systemic infusion of bradykinin receptor antagonist (HOE-140).
11555552|NCT00965107|Experimental|Thiopental|Thiopental for induction of anaesthesia.
11555553|NCT00965107|Active Comparator|Propofol|Propofol for induction of anaesthesia.
11555554|NCT00965094|Experimental|Everolimus|At BL1, all study patients received induction therapy with basiliximab (Simulect®; 2x20mg on day 0 - 2 hours prior to transplantation, and on day 4 after transplantation) and commenced an immunosuppressive regimen consisting of MPA (Myfortic®; target dose: 1440 mg/day, which was also the maximum daily dose) + tacrolimus (Prograf®; based on C0-h levels; Table 9-2) and with corticosteroids. AT BL2 [Month 3 (+1 week) after transplantation], eligible patients were randomized, using living and cadaveric donation as stratum. Patients were switched to the CNI-free regimen. Everolimus was added to the patients immunosuppressive regimen and tacrolimus was removed successively.
11555555|NCT00965094|Active Comparator|Reference Therapy|At BL1, all study patients received induction therapy with basiliximab (Simulect®; 2x20mg on day 0 - 2 hours prior to transplantation, and on day 4 after transplantation) and commenced an immunosuppressive regimen consisting of MPA (Myfortic®; target dose: 1440 mg/day, which was also the maximum daily dose) + tacrolimus (Prograf®; based on C0-h levels; Table 9-2) and with corticosteroids. AT BL2 [Month 3 (+1 week) after transplantation], eligible patients were randomized, using living and cadaveric donation as stratum. Patients continued on the prior immunosuppressive regimen consisting of MPA + tacrolimus with corticosteroids.
11555556|NCT00965081|Experimental|Duloxetine|
11555557|NCT00965081|Placebo Comparator|Placebo|
11555558|NCT00965055|Placebo Comparator|Atorvastatin|
11555559|NCT00965055|Experimental|Atorvastatin/Ezetimibe|
11555560|NCT00965042|Experimental|Ceftobiprole|Ceftobiprole 500 mg by 2 hour intravenous infusion every 8 hours for 7 days
11555561|NCT00965016|Sham Comparator|No Hypothermia, No intervention, ECMO|No hypothermia used during ECPR
11555562|NCT00965016|Active Comparator|Hypothermia, intervention, ECMO|Hypothermia + intervention
11555563|NCT00965016|Active Comparator|Hypothermia, no intervention, ECMO|Hypothermia without intervention after ECMO
11555564|NCT00965003|Experimental|MRI scan with surface coil|Patients with known laryngeal cancer, with suspected cartilage involvement by conventional computed tomography scanning, who undergo high resolution magnetic resonance imaging enhanced with a surface coil placed over the larynx.
11555565|NCT00964990|Experimental|001|JNJ-42160443 SC injection (1 3 or 10 milligrams) once every 28 days
11555566|NCT00964990|Placebo Comparator|002|Placebo SC injection once every 28 days
11556103|NCT00961272||HIV-infected, pre-menopausal women|
11555567|NCT00964977|No Intervention|no irradiation|Patients within this arm only receive curative intended radical surgery
11555568|NCT00964977|Active Comparator|Radiation|Patients receive radiation within 6 weeks after curative intended radical surgery.
11555569|NCT00964964|Experimental|SIBA 3W|
11555570|NCT00964964|Experimental|SIBA OD|
11555571|NCT00964951|Experimental|Group 3: 15 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
11555572|NCT00964951|Experimental|Group 1: 3.75 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
11555573|NCT00964951|Experimental|Group 4: 7.5 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
11555574|NCT00964951|Experimental|Group 2: 7.5 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
11555575|NCT00964951|Experimental|Group 5: 15 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
11555576|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 1)|
11555577|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 2)|
11555578|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 3)|
11555579|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 4)|
11555580|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 5)|
11555581|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 6)|
11555582|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 7)|
11555583|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 8)|
11555584|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 9)|
11555585|NCT00964912|Active Comparator|BMS-820836 (Part 2, Panel A)|
11555586|NCT00964912|Active Comparator|BMS-820836 (Part 2, Panel B)|
11555587|NCT00964886|Experimental|Arm 1|desipramine hydrochloride
11555588|NCT00964886|Experimental|Arm 2|cognitive behavioral therapy
11555589|NCT00964886|Experimental|Arm 3|desipramine hydrochloride and cognitive behavioral therapy
11555590|NCT00964886|Placebo Comparator|Arm 4|anticholinergic medication; active placebo
11555591|NCT00964873|Experimental|1 Part 1|
11555592|NCT00964860|No Intervention|Brushing Only|Brushing Only with an Oral B manual toothbrush and Crest Cavity Protection, sodium fluoride dentifrice
11555593|NCT00964860|Experimental|Brushing + Flossing|Brushing with an Oral B manual toothbrush and Crest Cavity Protection, sodium fluoride dentifrice, plus flossing with Glide floss
11555594|NCT00964847|Active Comparator|Blood pressure education/walking program|
11555595|NCT00964847|Active Comparator|Combined intervention|
11555596|NCT00964847|Experimental|Yoga Exercise Program|
11555597|NCT00964834|Experimental|Doxycycline and Valortim|Randomized such that sixteen volunteer subjects to be renadomized to receive Doxycycline and Valortim
11555598|NCT00964834|Experimental|Placebo Antibiotic and Valortim|Randomized such that four volunteer subjects to receive Placebo Antibiotic and Valortim.
11555599|NCT00964834|Experimental|Placebo Antibiotic and Placebo Valortim|Randomized such that four volunteer subjects to receive Placebo Antibiotic and Placebo Valortim.
11555600|NCT00964821||Flu vaccine|Patients and normal volunteers who have received a flu vaccine
11555601|NCT00964821||Non-vaccine|Patients and normal volunteers who have not received the flu vaccine
11555602|NCT00964808|Experimental|Buprenorphine|Double dummy; Group A: Active Buprenorphine and placebo oxycodone
11555603|NCT00964808|Experimental|Oxycodone|"Double Dummy:
~Group B: Placebo Buprenorphine and Active Oxycodone"
11555604|NCT00964795|Experimental|Open-label Intravitreal Aflibercept Injection|Open-label Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) 2mg (40 mg/mL) was administered no more frequently than every 4 weeks, but no less frequently than every 12 weeks until amendment 4. Starting with amendment 4, Intravitreal Aflibercept Injection was administered no less frequently than every 8 weeks. Within these limits, the investigator would determine the interval of Intravitreal Aflibercept Injection administration on an as-needed basis according to the protocol-suggested re-treatment criteria, however the injections must have occurred at least every 12 weeks prior to amendment 4, and at least every 8 weeks starting from amendment 4 as noted above.
11555605|NCT00964782|Active Comparator|Sildenafil crossover to placebo|Sildenafil dosage (0.5mg/kg (max 20mg)) administered at the time of enrollment followed by a battery of exercise tests. After a washout period, the process will be repeated with treatment 2, placebo drug administered before the exercises.
11555606|NCT00964782|Placebo Comparator|Placebo crossover to sidenafil|Patient will receive a look-alike placebo administered at the time of enrollment followed by a battery of exercise tests. After a washout period, the process will be repeated with treatment 2 Sildenafil dosage will be 0.5mg/kg (max 20mg) administered before the exercises.
11555607|NCT00964769|Experimental|Pneumococcal polysaccharide vaccine|The immunogenic response to the pneumococcal polysaccharide vaccine was compared between children, adults and elderly.
11555608|NCT00964756|Experimental|Gene therapy|
11555609|NCT00964743|Experimental|Intrathecal DepoCyt and Oral Sorafenib|This is a single arm pilot study. Investigators planned to enroll approximately 10 patients to receive concurrent intrathecal DepoCyt and oral Sorafenib. DepoCyt: through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses (a total of 10 DepoCyt treatments). Oral Sorafenib: at 400 mg twice a day throughout the treatment course until disease progression or death.
11555610|NCT00964730|Experimental|Talampanel|
11555611|NCT00964730|Placebo Comparator|Placebo|
11555612|NCT00964730|Other|Moxifloxacin|
11555613|NCT00964717|Active Comparator|Chiropractic|Real Chiropractic treatment
11555614|NCT00964717|Sham Comparator|Sham Chiropractic|stimulation utilizing 'activator' thumper
11555615|NCT00964717|No Intervention|No treatment|No add on therapy - patients lay down for a period of 15 minutes without any treatment or intervention
11555616|NCT00964704|Experimental|Single Arm|
11555617|NCT00964691|Active Comparator|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
11555618|NCT00964691|Active Comparator|IPTp with Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
11555619|NCT00964678|Experimental|carvedilol|Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI
11555620|NCT00964665|Experimental|Group 1 ABF656 900ug Q2w|
11555621|NCT00964665|Experimental|Group 2 ABF656 900ug Q4w|
11555622|NCT00964665|Experimental|Group 3 AB656 1200ug Q4w|
11555623|NCT00964665|Experimental|Group 4 ABF656 1500ug Q4w|
11555624|NCT00964665|Active Comparator|Group 5 Pegasys® 180µg qw|
11555625|NCT00964652|Experimental|PD Group|Nine subjects with idiopathic PD, previously diagnosed by one specialist physician participated in this study.
11555626|NCT00964639|Placebo Comparator|Saline|
11555627|NCT00964639|Active Comparator|Naropin|
11555628|NCT00964600|Experimental|TAP blockade|bilateral TAP blockade at the end of cesarean delivery
11555629|NCT00964600|No Intervention|No TAP|These patients would have usual analgesic drugs after cesarean
11555630|NCT00964587|Active Comparator|Usual Care|Packet of standard print patient education materials on CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA).
11555631|NCT00964587|Experimental|Self Study|One 90-minute educational session. Print materials and DVDs for self-study
11555632|NCT00964587|Experimental|Group Problem-Solving Training|One 90-minute education session. Group problem-solving training (eight, 90-minute sessions)
11555633|NCT00964587|Experimental|Individual Problem-Solving Training|One 90-minute education session. Individual problem-solving training (eight, 60-minute sessions)
11555634|NCT00964574|Experimental|APIDRA + LANTUS basal|The 2 first weeks, patients will receive subcutaneous injection of Insulin Glulisine and Insulin Glargine once daily in hospital. The rest of the treatement is to be take at home until week 12
11555635|NCT00964561|Experimental|Ciprofloxacin and Valortim|First two subjects to receive treatment arm of Ciprofloxacin and Valortim. Total of sixteen volunteers to be randomized to receive Ciprofloxacin and Valortim.
11555636|NCT00964561|Experimental|Placebo Antibiotic and Valortim|Randomized such that four subjects to receive Placebo Antibiotic and Valortim.
11555637|NCT00964561|Experimental|Placebo Antibiotic and Placebo Valortim|Randomized such that 4 subjects to receive Placebo Antibiotic and Placebo Valortim.
11555638|NCT00964548|Experimental|Dantrolene (low dose)|
11555639|NCT00964548|Experimental|Dantrolene (high dose)|
11555640|NCT00964535|Experimental|Budesonide/formoterol Easyhaler|
11555641|NCT00964535|Experimental|Charcoal and Budesonide/formoterol EH|
11555642|NCT00964535|Active Comparator|Symbicort Turbohaler|
11555643|NCT00964535|Active Comparator|Charcoal and Symbicort Turbohaler|
11555644|NCT00964522|No Intervention|Standard care|The arm A is the one of standard education and care.
11555645|NCT00964522|Active Comparator|Nurse education and care program|The arm B will receive programmed education and care about the chemotherapy by a nurse of the Medical Oncology service before the beginning of the treatment and in each cycle, in a specific nurse consultation.
11555646|NCT00964496|Active Comparator|Thalidomide Group|
11555647|NCT00964496|Other|Iron-controlled Group|
11555648|NCT00964483|Experimental|DASH materials|Participant randomized to a 12-week, group-based lifestyle intervention using modified DASH materials and intervention delivery approaches to help them adopt the DASH diet. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium.
11555649|NCT00964483|Active Comparator|Delayed intervention|"The intervention participants will receive an NHLBI brochure entitled Your Guide to Lowering Blood Pressure. They will then receive the modified DASH materials and the intervention at the end of the study, following the intervention group's completion of the study."
11555650|NCT00964457|Active Comparator|Capecitabine, oxaliplatin|
11555651|NCT00964457|Active Comparator|capecitabine, oxaliplatin and cetuximab|capecitabine, oxaliplatin ane cetuximab
11555652|NCT00964431|Experimental|Indomethacin Test (lower dose)|
11555653|NCT00964431|Experimental|Indomethacin Test (upper dose)|Single dose
11555654|NCT00964431|Active Comparator|Celecoxib 400 mg|
11555655|NCT00964431|Placebo Comparator|Placebo|
11555656|NCT00964418|Experimental|IDeg|
11555657|NCT00964418|Active Comparator|IGlar|
11555658|NCT00964405|Experimental|LAMA|After randomization subject will inhale either GSK233705 50, 100 or 200 microgram once daily for 7 days.
11555659|NCT00964405|Placebo Comparator|Placebo|After randomization subjects will inhale placebo once daily for 7 days.
11555660|NCT00964392|Experimental|More-Experienced Physicians (MEP)|Physicians who perform greater than or equal to 50 atrial fibrillation ablation procedures per year.
11555661|NCT00964392|Experimental|Less-Experienced Physicians (LEP)|Physicians who perform less than 50 atrial fibrillation ablation procedures per year.
11555662|NCT00964379|Active Comparator|intraperitoneal colostomy|
11555663|NCT00964379|Active Comparator|extraperitoneal colostomy|
11555664|NCT00964366|Experimental|Clindamycin/BPO gel|Once-daily applications of clindamycin/BPO gel to the randomized side of the face either left or right.
11555665|NCT00964366|Active Comparator|Dapsone gel|Twice-daily applications of dapsone gel to one side of the face.
11555666|NCT00964353|Active Comparator|Clinically Guided Cohort|Estimated Effective Warfarin dosing calculations are based on clinical data algorithms
11555667|NCT00964353|Experimental|Pharmacogenetically Guided Cohort|Estimated Effective Warfarin dosing calculations are based on genetic and clinical data algorithms.
11555668|NCT00964340|Placebo Comparator|Placebo|The Placebo treatment group will be administered eight placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
11555669|NCT00964340|Active Comparator|0.5g SRT2104|The 0.5g SRT2104 treatment group will be administered 2 SRT2104 capsules with 6 matching placebo capsules, for a total of 8 capsules per day. 0.5g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
11555670|NCT00964340|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered 8 SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
11555671|NCT00964314|Experimental|five elements music|Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.
11555672|NCT00964314|Active Comparator|western music|Listening western music based on conventional therapy in China.
11555673|NCT00964314|No Intervention|Without music|no music therapy will be done in the arm.
11555674|NCT00964301|Experimental|Intervention Group|Participants, caregivers and school nurse will attend telemedicine education sessions at school.
11555675|NCT00964301|Active Comparator|Usual care|Usual care participant will receive routine care from their primary care provider.
11555676|NCT00964288|Other|Period 1|
11555677|NCT00964288|Other|Period 2|
11555678|NCT00964288|Other|Period 3|
11555679|NCT00964288|Other|Period 4|
11555680|NCT00964275|Experimental|Arm I|Patients undergo diagnostic fludeoxyglucose F 18 PET in addition to standard methods.
11555681|NCT00964275|Active Comparator|Arm II|Patients only undergo standard diagnostic methods.
11555682|NCT00964262|Experimental|SR Exenatide (PT302)|Intervention: Drug: SR Exenatide (PT302)
11555683|NCT00964249|Experimental|LABA|After randomization subject will inhale either 12.5 microgram or 25 microgram GW642444M once daily for 7 days.
11555684|NCT00964249|Placebo Comparator|Placebo|After randomization subjects will inhale placebo once daily for 7 days.
11555685|NCT00964236||Sapropterin|Individuals with phenylketonuria (PKU) who are beginning treatment with Kuvan (sapropterin).
11555686|NCT00964236||Control|Healthy individuals without phenylketonuria (PKU).
11555687|NCT00964223|Experimental|Duac gel|Subjects will apply Duac gel once a day to one-half of their face and and apply Epiduo gel on the other side of their face once daily for the first 2 weeks.
11555688|NCT00964223|Active Comparator|Epiduo gel|Subjects will apply Duac gel once a day to one-half of their face and and apply Epiduo gel on the other side of their face once daily for the first 2 weeks.
11555689|NCT00964197|Experimental|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
11555690|NCT00964184|Experimental|Drug|1 gm metformin per day
11555691|NCT00964184|Other|control|lifestyle intervention
11555692|NCT00964158|Experimental|Group A|
11555693|NCT00964145||Nulliparous female patients|Nulliparous female patients ages 21-70 years old.
11555694|NCT00964132|Experimental|NRX194204|
11555695|NCT00964106|Experimental|Probe drugs|"Caffeine 100 mg CYP1A2 Pioglitazone 15 mg CYP2C8 Flurbiprofen 40 mg CYP2C9 Omeprazole 20 mg CYP2C19 Dextromethorphan 45 mg CYP2D6 Midazolam 3 mg (Part 1, Part 2 Cohorts B and C)
~1 mg (Part 2 Cohort A) CYP3A4/5 Rosuvastatin 10 mg OATP1B1"
11555696|NCT00964106|Experimental|Default Inhibitors|A Ketoconazole 400 mg once-daily Day 1 through Day 9 CYP3A4 B Fluconazole 400 mg x1 dose on Day 1 200 mg once-daily Day 2 through Day 9 CYP2C9 C Rifampin 600 mg x1 dose on Day 1 and Day 8 OATP1B1
11555697|NCT00964093|No Intervention|No intervention|
11555698|NCT00964080|Experimental|Study of MBP-426/leucovorin/5-FU|Study of MBP-426/leucovorin/5-FU. MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered ata dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
11555699|NCT00964067|Active Comparator|Treadmill group|Interval exercise performed on treadmills, supervised
11555700|NCT00964067|Active Comparator|Exercise groups|Supervised and organised in groups of ten
11555701|NCT00964067|Active Comparator|home-based exercise|Interval training at home, free choice of modality
11555702|NCT00964054|Experimental|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
11555703|NCT00964054|Active Comparator|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
11555704|NCT00964041|Experimental|D-cycloserine|Participants will receive D-cycloserine weekly, one hour before any assessments, for eight weeks.
11555705|NCT00964041|Placebo Comparator|Placebo|Participants will receive placebo weekly, one hour before any assessments, for eight weeks.
11555706|NCT00964028|Experimental|INFANRIX-IPV/HIB M2-M3-M4 GROUP|Healthy male or female subjects between and including 60 and 90 days of age at the time of the first vaccination, received 3 doses of Infanrix-IPV/Hib™ vaccine at 2, 3 and 4 months of age (M2-M3-M4), administered intramuscularly into the upper right side of the thigh.
11555707|NCT00964028|Experimental|INFANRIX-IPV/HIB M3-M4-M5 GROUP|Healthy male or female subjects between and including 60 and 90 days of age at the time of the first vaccination, received 3 doses of Infanrix-IPV/Hib™ vaccine at 3, 4 and 5 months of age (M3-M4-M5), administered intramuscularly into the upper right side of the thigh.
11555708|NCT00964015|Active Comparator|Starch group|Patients randomized to the Starch group will receive Voluven (6% Hydroxyethyl Starch 130/0.4) for their intravenous bolus and fluid resuscitation requirements.
11555709|NCT00964015|Active Comparator|Saline group|Patients randomized to the Saline group will receive 0.9% Normal Saline for their intravenous fluid bolus and resuscitation requirements
11555710|NCT00963989|Experimental|Penumbra Device Arm|
11556300|NCT00960037|Experimental|Vitamin D|Vitamin D3 supplementation based on baseline 25(OH)D level
11555711|NCT00963976|Experimental|Target systolic BP < 150 mmHg|Systolic blood pressure will be reduced to <150 mmHg within 1 hour of randomization.
11555712|NCT00963976|Active Comparator|Target systolic BP < 180 mmHg|Systolic blood pressure will be reduced, to <180 mmHg within 1 hour of randomization.
11555713|NCT00963963|Active Comparator|health promotion materials|Parents receive health promotion booklets
11555714|NCT00963963|Active Comparator|attention-controlled parent print materials|Booklets on adolescent sexuality and health
11555715|NCT00963963|Experimental|audio-CD parent education|audio-CDs on parenting practices
11555716|NCT00963950|Experimental|Intervention group|transvaginal cholecystectomy
11555717|NCT00963950|Active Comparator|laparoscopic cholecystectomy|Laparoscopic cholecystectomy (4 port)
11555718|NCT00963937|Active Comparator|Sumatriptan 25 mg|
11555719|NCT00963937|Active Comparator|Sumatriptan 50 mg|
11555720|NCT00963937|Placebo Comparator|Placebo|
11555721|NCT00963924|Experimental|D-cycloserine|Participants will receive D-cycloserine weekly, one hour before the first cognitive remediation session of the week, for eight weeks.
11555722|NCT00963924|Placebo Comparator|Placebo|Participants will receive placebo weekly, one hour before the first cognitive remediation session of the week, for eight weeks.
11555723|NCT00963898|Experimental|Mental Retardation|
11555724|NCT00963885|Placebo Comparator|Part 1: Placebo|Placebo in combination with standard doses of Pegasys and Copegus.
11555725|NCT00963885|Experimental|Part 1: RO5190591 300mg po|RO5190591 300mg po every 8 hours in combination with standard doses of Pegasys and Copegus.
11555726|NCT00963885|Experimental|Part 1: RO5190591 600mg po|RO5190591 600mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
11555727|NCT00963885|Experimental|Part 1: RO5190591 900mg po|RO5190591 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
11555728|NCT00963885|Placebo Comparator|Part 2: Placebo|If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive placebo in combination with standard doses of Pegasys and Copegus.
11555729|NCT00963885|Experimental|Part 2: RO5190591 300mg po|If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
11555730|NCT00963872|Experimental|Complement Fragment 3A - Small Cell Dose|Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
11555731|NCT00963872|Experimental|Complement Fragment A - Larger Cell Dose|Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
11555732|NCT00963859|Experimental|Robotic-assisted laparoscopic surgery|Robotic-assisted laparoscopic extended pelvic lymph node dissection
11555733|NCT00963846|Placebo Comparator|placebo|
11555734|NCT00963846|Experimental|huperzine 0.2 mg BID|
11555735|NCT00963846|Experimental|huperzine 0.4 mg BID|
11555736|NCT00963846|Experimental|huperzine 0.8 mg BID|
11555737|NCT00963833||Group 1|
11555738|NCT00963820|Experimental|0.24 mg/m^2|Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate
11555739|NCT00963820|Experimental|0.48 mg/m^2|Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
11555740|NCT00963820|Experimental|0.80 mg/m^2|Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
11555741|NCT00963820|Experimental|1.20 mg/m^2|Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period.
11555742|NCT00963820|Experimental|1.68 mg/m^2|Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
11555743|NCT00963820|Experimental|2.23 mg/m^2|Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
11555744|NCT00963820|Experimental|2.97 mg/m^2|Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
11555745|NCT00963820|Experimental|3.95 mg/m^2|Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
11555746|NCT00963820|Experimental|Relapsed and Refractory (RR)|Ixazomib citrate, 2.97 mg/m^2 established Maximum Tolerated Dose (MTD), capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
11555747|NCT00963820|Experimental|VELCADE-Relapsed (VR)|Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
11555748|NCT00963820|Experimental|PI naïve|Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
11555749|NCT00963820|Experimental|Carfilzomib|Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
11555750|NCT00963807|Experimental|Treatment|Patients receive docetaxel IV and cisplatin IV on day 1. Treatment repeats every 3 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo FDG PET/CT, FLT PET/CT, and thoracic CT at baseline and the end of cycles 1 and 2 and then undergo surgery.
11555751|NCT00963794|Other|Electromagnetic measurement|Electromagnetic measurement to detect rectal cancer.
11555752|NCT00963781|Experimental|Six months DAPT|All patients will be assigned to 6 months of DAPT
11555753|NCT00963768|Experimental|Cohort 1|JNJ-28431754 30 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
11555754|NCT00963768|Experimental|Cohort 2|JNJ-28431754 100 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
11555755|NCT00963768|Experimental|Cohort 3|JNJ-28431754 300 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
11555756|NCT00963768|Experimental|Cohort 4|JNJ-28431754 600 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
11555757|NCT00963768|Experimental|Cohort 5|JNJ-28431754 at 30 mg/day, 100 mg/day, or 300 mg/day or placebo (the dose level to be determined from the prior cohort of patients tested and considered to be well tolerated).
11555758|NCT00963755||Primary prostate cancer|Patients referred with a suspicion of prostate cancer based on elevated PSA and rectal examination in whom a prostate biopsy is planned and radical prostatectomy is envisioned in the event of a positive biopsy finding
11555759|NCT00963755||Prostate cancer relapse|Patients previously treated for prostate cancer and being investigated for biochemical relapse, (mostly in the Urology and Radiation Therapy Department, but not exclusively), for whom surgical or radiation therapy is envisioned in the event of a positive FCH-PET finding
11555760|NCT00963742|Experimental|Lenstec Softec HD IOL implantation|390 eyes of 390 study subjects all receiving the investigational IOL; IOL implanted after surgical removal of cataract
11555761|NCT00963729|Experimental|Arm I|Patients receive fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11555762|NCT00963729|Experimental|Arm II|Patients receive oral letrozole daily for 18-23 weeks until day of surgery.
11555763|NCT00963716|Experimental|Hot biopsy|Hot biopsy i.e. Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
11555764|NCT00963716|Active Comparator|Cold biopsy|Cold biopsy i.e. Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
11555765|NCT00963703|Experimental|Rituximab|
11555766|NCT00963690|Experimental|CloSys HD with standard compression|CloSys Arm
11555767|NCT00963690|Active Comparator|Standard compression alone|Manual compression arm
11555768|NCT00963677|Experimental|Intubation without difficulty|The patients are not predicted for difficult intubation
11555769|NCT00963677|Experimental|Difficult intubation|The patients will be anticipated for difficult intubation without difficult ventilation
11555770|NCT00963664|Experimental|Interferon and lovastatin treatment|Patients receive outpatient treatment with lovastatin (oral) and interferon alfa-2b (subcutaneous injection) as per protocol parameters.
11555771|NCT00963651||Suspicion of pulmonary nodules|Eligible participants will include those referred for x-ray computed tomography (CT) of the chest for suspicion of a pulmonary nodule or other unrelated reasons.
11555772|NCT00963638|Experimental|MagTabSR|
11555773|NCT00963638|Placebo Comparator|Sugar Pill|
11555774|NCT00963625|Experimental|Blastocyst transfer in PTEC cycle|Transfer of two blastocysts derived from thawed bipronuclear oocytes that were subject to post-thaw extended culture (PTEC).
11555775|NCT00963625|Active Comparator|Fresh blastocyst transfer.|Transfer of two fresh autologous blastocysts following controlled ovarian stimulation.
11555776|NCT00963612|Other|Single Arm|"In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo Liver BOLD-MRI before hepatic resection."
11555777|NCT00963599|Experimental|1|montelukast/loratadine
11555778|NCT00963599|Experimental|2|loratadine
11555779|NCT00963599|Experimental|3|montelukast
11555780|NCT00963599|Placebo Comparator|4|placebo
11555781|NCT00963586||HNC Maastricht|Patients treated for HNC in the University Hospital Maastricht/MAASTRO clinic, the Netherlands
11555782|NCT00963586||HNC Groningen|Patients treated for HNC in the University Medical Center Groningen, the Netherlands
11555783|NCT00963573|Experimental|loratadine/betamethasone oral solution|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
11555784|NCT00963560|Experimental|ReSTOR +3|Bilateral implantation of ReSTOR +3 Intraocular Lens (IOL)
11555785|NCT00963560|Active Comparator|Crystalens HD|Bilateral implantation of Crystalens HD Intraocular Lens (IOL)
11555786|NCT00963560|Active Comparator|Crystalens AO|Bilateral implantation of Crystalens AO Intraocular Lens (IOL)
11555787|NCT00963547|Experimental|Pt. 1: MK-2206 45mg, QOD + Trastuzumab|Participants in Part 1 (Pt. 1) receive MK-2206 45 mg every other day (QOD), taken orally. In combination with MK-2206, trastuzumab is administered by intravenous (IV) infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg every 3 weeks (q3wk).
11555788|NCT00963547|Experimental|Pt. 1: MK-2206 60mg, QOD + Trastuzumab|Participants in Pt. 1 receive MK-2206 60 mg QOD, taken orally. In combination with MK-2206, trastuzumab is administered by IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk.
11555789|NCT00963547|Experimental|Pt. 1: MK-2206 135mg, QW + Trastuzumab|Participants in Pt. 1 receive MK-2206 135 mg once weekly (QW), taken orally. In combination with MK-2206, trastuzumab is administered by IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk.
11555790|NCT00963547|Experimental|Pt. 1: MK-2206 200mg, QW + Trastuzumab|Participants in Pt. 1 receive MK-2206 200 mg QW, taken orally. In combination with MK-2206, trastuzumab is administered by IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk.
11555791|NCT00963547|Experimental|Pt. 2: MK-2206 (Pt.1 MTD) + Trastuzumab + Lapatinib 500mg, QD|Participants in Part 2 (Pt. 2) receive MK-2206 (dosed either QOD or QW) taken orally at the maximum tolerated dose defined in Part 1 (Pt. 1 MTD). MK-2206 is administered in combination with trastuzumab (IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk) as well as lapatinib 500 mg taken orally once daily (QD).
11555792|NCT00963547|Experimental|Pt. 2: MK-2206 (Pt.1 MTD) + Trastuzumab + Lapatinib 750mg, QD|Participants in Pt. 2 receive MK-2206 (dosed either QOD or QW) taken orally at the Pt. 1 MTD. MK-2206 is administered in combination with trastuzumab (IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk) as well as lapatinib 750 mg taken orally QD.
11555793|NCT00963547|Experimental|Pt. 2: MK-2206 (Pt.1 MTD) + Trastuzumab + Lapatinib 1000mg, QD|Participants in Part 2 (Pt. 2) receive MK-2206 (dosed either QOD or QW) taken orally at the Pt. 1 MTD. MK-2206 is administered in combination with trastuzumab (IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk) as well as lapatinib 1000 mg taken orally QD.
11555794|NCT00963534|Experimental|lenalidomide, bendamustine, rituximab|
11555795|NCT00963508|Experimental|Malathion Gel|Malathion gel 0.5% 30 minute application
11555796|NCT00963508|Active Comparator|Nix Crème Rinse|Nix Crème Rinse applied to scalp for 10 minutes
11555797|NCT00963495|Experimental|Clioquinol|Patients will take Clioquniol at various doses depending on which dose level they come into the study at. Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
11555798|NCT00963482|Experimental|Intervention group|Cognitive-behavioural smoking cessation program
11555799|NCT00963482|Other|Control group|Autogenic training
11555800|NCT00963469|Experimental|1|montelukast
11555801|NCT00963469|Active Comparator|2|loratadine
11555802|NCT00963469|Placebo Comparator|3|placebo
11555803|NCT00963443|Experimental|Arm 1|
11555804|NCT00963443|Active Comparator|Arm 2|
11555805|NCT00963443|Active Comparator|Arm 3|
11555806|NCT00963443|Placebo Comparator|Arm 4|
11555807|NCT00963430|Experimental|Group 2: 30 mcg H1N1 vaccine|60 subjects to receive 30 mcg of inactivated H1N1 vaccine on Day 0 and Day 21.
11555808|NCT00963430|Experimental|Group 1: 15 mcg H1N1 vaccine|60 subjects to receive 15 mcg of inactivated H1N1 vaccine on Day 0 and Day 21.
11555809|NCT00963417|Active Comparator|Triptorelin plus tamoxifen|Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus tamoxifen for 5 years.
11555810|NCT00963417|Experimental|Triptorelin plus exemestane|Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus exemestane for 5 years.
11555811|NCT00963404|Experimental|Tumor-boost|Image-guided tumorboost of the bladder cancer.
11555812|NCT00963391|Experimental|ABHS use|Centers assigned to the intervention group were provided with ABHS dispensers with a gel solution with ethyl alcohol at 62% as active ingredient (Purell®, GOJO Industries, Dayton, Ohio). Proper safety measures were followed. Standardized ABHS training workshops for staff and children in centers allocated to the intervention were carried out simultaneously with dispenser installation. Thirty minute refresher sessions about ABHS technique were provided to staff and children on a monthly basis, for a total of 8 sessions per center.
11555813|NCT00963391|No Intervention|No treatment|Centers assigned to the control group received no hand hygiene recommendations other than to continue with current hand hygiene practices and no further information on hand hygiene other than the general information received before trial initiation was provided.
11555814|NCT00963365|Experimental|AZD6765 oral solution|Active
11555815|NCT00963365|Experimental|AZD6765 IV infusion|Active
11555816|NCT00963365|Placebo Comparator|Placebo to AZD6765 oral solution|Placebo
11555817|NCT00963365|Placebo Comparator|Placebo to AZD6765 IV infusion|Placebo
11555818|NCT00963352||Patients operated for colon cancer|
11555819|NCT00963339||Dry AMD|subjects diagnosed as intermediate AMD in at least one eye
11555820|NCT00963313||Adalimumab, injection|Adalimumab, one injection every fourteen days during 24 weeks.
11555821|NCT00963287|Experimental|bascial prescription|Decoction ,two times a day,one bag of decoction one time
11555822|NCT00963287|Placebo Comparator|low does of bascial decoction|Decoction ,two times a day, one bag decoction of one time
11555823|NCT00963274|Experimental|bortezomib + romidepsin|Bortezomib via a short intravenous infusion (3-5 seconds) followed by romidepsin via a 4 hour intravenous infusion weekly x 3 every 4 weeks. In order to identify appropriate doses, different subjects will be treated with different drug doses and observed for the effects, especially the side effects associated with higher doses.
11555824|NCT00963261|Experimental|psycho-oncological intervention|stepped care psycho-oncological intervention
11555825|NCT00963261|No Intervention|control group|
11555826|NCT00963235|Experimental|1|
11555827|NCT00963222|Active Comparator|with atherosclerosis/ vitamin A|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive 25000 IU/day vitamin A
11555828|NCT00963222|Placebo Comparator|with atherosclerosis/ placebo|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive placebo
11555829|NCT00963222|Active Comparator|without atherosclerosis/ vitamin A|patients in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive 2500 Iu/day vitamin A
11555830|NCT00963222|Placebo Comparator|without athrosclerosis/ placebo|patients in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive placebo
11555831|NCT00963209|Experimental|Tamoxifen|
11555832|NCT00963196|Active Comparator|One unsuccessful trial|Patients with one unsuccessful previous antidepressant trial
11555833|NCT00963196|Active Comparator|One successful trial|Patients with one previous successful antidepressant trial
11555834|NCT00963196|Active Comparator|No previous trial|Patients with no prior antidepressant therapy
11555835|NCT00963183|Experimental|A|Drug: AZD5423
11555836|NCT00963183|Placebo Comparator|B|Drug: Placebo
11556104|NCT00961259|Experimental|Fenofibric Acid 35 mg (1 x 35 mg tab)|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
11555837|NCT00963157|Experimental|Group 1: 3.75 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
11555838|NCT00963157|Experimental|Group 5: 15 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
11555839|NCT00963157|Experimental|Group 4: 7.5 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
11555840|NCT00963157|Experimental|Group 2: 7.5 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
11555841|NCT00963157|Experimental|Group 3: 15 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
11555842|NCT00963131|Experimental|antioxidant tablets|the study arm received antioxidant tablets (Icaps) for 3 months or until the resolution of the disease
11555843|NCT00963131|Placebo Comparator|placebo tablets|the control arm received placebo tablets for 3 months or until the resolution of the disease
11555844|NCT00963118|Placebo Comparator|placebo|Rice powder based nutrition bar
11555845|NCT00963118|Experimental|Angelica keiskei|Angelica keiskei (green leafy vegetable) based nutrition bar
11555846|NCT00963118|Experimental|Glycine max|Glycine max (black soybeans) based nutrition bar
11555847|NCT00963118|Experimental|Angelica keiskei + Glycine max|Angelica keiskei (green leafy vegetable) and glycine max (black soybeans) based nutrition bar
11555848|NCT00963105|Experimental|Lenalidomide 5 mg|"Participants received a starting dose of 5 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.
~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
11555849|NCT00963105|Experimental|Lenalidomide 10 mg|"Participants received a starting dose of 10 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.
~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
11555850|NCT00963105|Experimental|Lenalidomide 15 mg|"Participants received a starting dose of 15 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.
~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
11555851|NCT00963079|Experimental|Blastocyst transfer in PTEC cycle|Transfer of two blastocysts derived from thawed bipronuclear oocytes that were subject to post-thaw extended culture (PTEC).
11555852|NCT00963079|Active Comparator|Fresh blastocyst transfer|Transfer of two fresh autologous blastocysts following controlled ovarian stimulation.
11555853|NCT00963066|Active Comparator|Pressure Support ventilation|
11555854|NCT00963066|Experimental|NAVA flow triggering|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with flow triggering
11555855|NCT00963066|Experimental|NAVA EMG triggering|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with trigger adjusted on diaphragmatic electromyogram
11555856|NCT00963053|Experimental|VA111913 100mg twice daily|
11555857|NCT00963053|Placebo Comparator|Starch pill|
11555858|NCT00963040|Experimental|Syntocinon®|
11555859|NCT00963040|Placebo Comparator|Sterile water|
11555860|NCT00962988|Experimental|Cost-Free Group|
11555861|NCT00962988|Other|Prescription Only Group|
11555862|NCT00962975|Experimental|Single Arm|
11555863|NCT00962962|Other|Low-Amount/Moderate Intensity Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week
11555864|NCT00962962|Other|High-Amount/Moderate-Intensity Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week
11555865|NCT00962962|Other|High-Amount/Vigorous-Intensity Exercise|Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week
11555866|NCT00962962|Other|Low-Amount/Moderate-Intensity Exercise + Diet|"Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week
~Diet - The CLI sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight."
11555867|NCT00962949|Experimental|Control|Healthy controls
11555868|NCT00962949|Experimental|Postural Tachycardia Syndrome|Patients with Postural Tachycardia Syndrome
11555869|NCT00962936|Experimental|CT-011|
11555870|NCT00962910|Experimental|Pathway|A care pathway will be implemented in this experimental group.
11555871|NCT00962910|No Intervention|Usual Care|Usual Care will be provided.
11555872|NCT00962897||Surgical Bypass Group|Those patients that underwent bypass of blockage in the thigh with surgery.
11555873|NCT00962897||Stent-graft group|Patients that underwent treatment of blockage in the thigh with balloon angioplasty and stent placement.
11555874|NCT00962884|Experimental|ITD breathing device|Breathing through the Res-Q-Gard ITD device from Advanced Circulatory Systems Inc.
11555875|NCT00962884|Sham Comparator|Sham Device|Breathing device similar to active Res-Q-Gard device but with one-way resistance valve removed.
11555876|NCT00962871|Active Comparator|1|
11555877|NCT00962871|Experimental|2|
11555878|NCT00962871|Experimental|3|
11555879|NCT00962871|No Intervention|4|
11555928|NCT00962455|Experimental|e-learning & performance feedback|Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality
11555929|NCT00962455|Active Comparator|Usual practice|Usual practice regarding spirometry execution in family practice
11555880|NCT00962845|Experimental|Hydroxychloroquine|Patients must have tumor accessible for pre-treatment biopsy (see 5.1.2). Patients will be enrolled on the trial, undergo biopsy of their tumors if no banked tumor is available, and then begin an oral dose of HCQ at the dose of 200 mg twice daily. At the end of two weeks the patients will undergo resection of their tumors. HCQ will be given to the patients up to the day of the operation but not resumed postoperatively.
11555881|NCT00962832|Placebo Comparator|Part 1 - Placebo intravenously|Participants received placebo intravenously every 4 weeks for 24 weeks.
11555882|NCT00962832|Experimental|Part 1 - Rontalizumab 750 mg intravenously|Participants received rontalizumab 750 mg intravenously every 4 weeks for 24 weeks.
11555883|NCT00962832|Placebo Comparator|Part 2 - Placebo subcutaneously|Participants received placebo subcutaneously every 2 weeks for 24 weeks.
11555884|NCT00962832|Experimental|Part 2 - Rontalizumab 300 mg subcutaneously|Participants received rontalizumab 300 mg subcutaneously every 2 weeks for 24 weeks.
11555885|NCT00962832|Experimental|Part 3 - Rontalizumab 750 mg intravenously|Participants received rontalizumab 750 mg intravenously every 4 weeks for 120 weeks.
11555886|NCT00962819||cross-sectional|College-aged students who were immunized with MMR.
11555887|NCT00962806|Active Comparator|Exercise|8 week intensive exercise group
11555888|NCT00962806|Other|Control Lifestyle counseling|Lifestyle counseling without intensive exercise
11555889|NCT00962780|Experimental|1|3 doses of 13vPnC and 1 dose of 23vPS, each dose given approximately 1 month apart
11555890|NCT00962767|Experimental|a|2 doses of gemtuzumab ozogamicn administered at monthly intervals
11555891|NCT00962767|Active Comparator|b|2 years maintenance therapy with intermittent ATRA plus 6-Mercaptopurine (6-MP) and methotrexate (MTX)
11555892|NCT00962754|No Intervention|physician insight fluid balance|physician has insight in fluid balance chart, this is standard practice
11555893|NCT00962754|Experimental|fluid balance data masked to physician|physician no insight in the fluid balance chart
11555894|NCT00962741|Experimental|1|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
11555895|NCT00962728|Experimental|ITD breathing device|Breathing through the Res-Q-Gard ITD device from Advanced Circulatory Systems Inc.
11555896|NCT00962728|Sham Comparator|Sham Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
11555897|NCT00962715|Experimental|TIV|TIV (Influenza Vaccine Trivalent Inactivated) alone
11555898|NCT00962715|Experimental|TIV + PEGrIFN-α|TIV + Pegylated Interferon
11555899|NCT00962715|Experimental|TIV + IFNα|TIV + Interferon
11555900|NCT00962702|Experimental|Exclusion of Left Atrial Appendage|Exclusion of Left Atrial Appendage
11555901|NCT00962689||Chronic Rhinosinusitis|Patients with chronic rhinosinusitis as defined by American Academy of Otolaryngology-Head and Neck Surgery and American Rhinologic Society guidelines
11555902|NCT00962689||Control Group|Patients undergoing endoscopic sinus surgery for diseases other than chronic rhinosinusitis (i.e., access to pituitary gland, etc)
11555903|NCT00962676||immunocompromised group|
11555904|NCT00962676||non-immunocompromised group|
11555905|NCT00962663|Experimental|ICA-105665|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
11555906|NCT00962663|Active Comparator|Ibuprofen|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
11555907|NCT00962663|Placebo Comparator|Placebo|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
11555908|NCT00962650|Experimental|NOTES Toolbox|Multiple devices designed for trans-orifice use during surgical procedures; used for transvaginal cholecystectomy in this trial
11555909|NCT00962637|Experimental|1|Androxal™ 12.5 mg
11555910|NCT00962637|Experimental|2|Androxal™ 25 mg
11555911|NCT00962637|Active Comparator|3|AndroGel®
11555912|NCT00962637|Placebo Comparator|4|Placebo
11555913|NCT00962611|Experimental|Copanlisib|
11555914|NCT00962598|Placebo Comparator|Corn Oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment.
11555915|NCT00962598|Experimental|Omega-3 Fatty Acids|The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d.
11555916|NCT00962585|Placebo Comparator|Placebo|Placebo
11555917|NCT00962585|Experimental|S-equol 10 mg BID|S-equol 20 mg total daily dose
11555918|NCT00962585|Experimental|S-equol 50 mg BID|S-equol 100 mg total daily dose
11555919|NCT00962585|Experimental|S-equol 150 mg BID|S-equol 300 mg total daily dose
11555920|NCT00962546||CTA/CTP|Patients undergo CTA/CTP imaging prior to cerebral angiography
11555921|NCT00962533|Experimental|ROADMAP Group (Group I)|"Patients were to take telbivudine 600 mg orally daily from Baseline.At Week 24, patients in Group I were split into Group I-A or Group I-B based on their virologic load:
~Group I-A: This group of patients was those with HBV DNA ≥300 copies/mL at Week 24 and adefovir was to be added at Week 28;
~Group I-B: This group of patients was those with HBV DNA <300 copies/mL at Week 24. Telbivudine monotherapy was to be continued until there was a viral breakthrough (confirmed by two examinations with at least 1 month interval with compliance factor excluded) and then adefovir was to be added;
~The total treatment duration was 104 weeks."
11555922|NCT00962533|Active Comparator|SOC (Standard of Care) Group (Group II)|patients were to take telbivudine 600 mg monotherapy from Baseline until Week 104. If viral breakthrough (defined as HBV DNA 1 log10 above nadir) was confirmed (by two examinations with at least a 1 month interval with compliance factor excluded), adefovir 10 mg daily was to be added.
11555923|NCT00962494|Experimental|online workshop|
11555924|NCT00962481|Active Comparator|Bimosiamose|
11555925|NCT00962481|Placebo Comparator|Placebo|
11555926|NCT00962468|Experimental|Pathway|A care pathway will be implemented in this experimental group.
11555927|NCT00962468|No Intervention|Usual care|Usual care will be provided.
11555930|NCT00962442|Active Comparator|nutritional support + N-Acétylcysteine|N-Acétylcysteine 300 mg/kg intravenously for 14 days Beside usual meals, patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days
11555931|NCT00962442|Placebo Comparator|nutritional support + placebo|placebo perfusion for 14 days Beside usual meals patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days
11555932|NCT00962429|Active Comparator|Lipoic acid|alpha lipoic acid
11555933|NCT00962429|Placebo Comparator|Placebo|sugar pill
11555934|NCT00962416|Active Comparator|1|Biolimus eluting Stent (Biomatrix)
11555935|NCT00962416|Active Comparator|2|Bare metal stent (Gazelle)
11555936|NCT00962403|Experimental|Yoga treatment|
11555937|NCT00962403|No Intervention|Waitlist|Waitlist control, no active treatment, treatment as usual, active treatment offered after waitlist control period. This study began as a single arm treatment trial and then transitioned to a randomized controlled trial.
11555938|NCT00962390|Experimental|150mg S-equol|
11555939|NCT00962390|Experimental|50mg S-equol|
11555940|NCT00962390|Experimental|10 mg S-equol|
11555941|NCT00962390|Placebo Comparator|Placebo|
11555942|NCT00962377|Other|AlloMap Molecular testing|Gene expression profiling in the monitoring of asymptomatic heart transplant patients for acute cellular rejection.
11555943|NCT00962377|Active Comparator|Endomyocardial biopsy|Right ventricular endomyocardial biopsy in the monitoring of asymptomatic heart transplant patients for acute cellular rejection
11555944|NCT00962364||AMI|Patients with acute myocardial infarction treated with intracoronary administration of bone marrow derived cells
11555945|NCT00962364||ICM|Patients with ischemic cardiomyopathy treated with intracoronary administration of bone marrow derived cells
11555946|NCT00962364||DCM|Patients with dilated cardiomyopathy treated with intracoronary administration of bone marrow derived cells
11555947|NCT00962351|Other|Metal-on-Polyethylene|
11555948|NCT00962351|Other|Metal-on-Metal, 28mm femoral head|
11555949|NCT00962351|Other|Metal-on-Metal, 36mm femoral head|
11555950|NCT00962338||lap. inguinal herniorrhaphy|Patients undergoing planned lap. inguinal herniorrhaphy
11555951|NCT00962325|Experimental|Activity behaviors counseling|
11555952|NCT00962325|No Intervention|Standard care control|6 weeks of standard preoperative care
11555953|NCT00962312|Experimental|Capecitabine and Lapatinib|
11555954|NCT00962299|Active Comparator|Beclomethasone|Inhaled corticosteroids
11555955|NCT00962299|Placebo Comparator|Placebo|Placebo Comparator
11555956|NCT00962286|Experimental|Furosemide, obesity, glomerular hyperfiltration|
11555957|NCT00962273|Experimental|Pandemic Stress Vaccine - Interactive|
11555958|NCT00962273|Active Comparator|Pandemic Stress Vaccine - Didactic|
11555959|NCT00962273|No Intervention|Wait list|Some participants are assigned to an eight week waiting condition prior to the course commencing.
11555960|NCT00962247|Experimental|Sedentary; usual, 25% reduced, 50% reduced|The initial 3 weeks of the study, children were asked to maintain their usual targeted sedentary behaviors (TV, video game, computer use) measured by a television reduction device (TV Allowance). The following 3 weeks children were asked to reduce their targeted sedentary behaviors (TV, video game, computer use) by 25% from the usual sedentary condition using a television reduction device (TV Allowance). The final 3 weeks of the study, children were asked to reduce their targeted sedentary behaviors (TV, video game, computer use) by 50% from the usual sedentary condition using a television reduction device (TV Allowance)
11555961|NCT00962234||Metabolism|Lung cancer patients who exhibit abnormalities in lipid measures.
11555962|NCT00962221||subclinical hypothyroidism|Patients with subclinical hypothyroidism
11555963|NCT00962208|Experimental|orthokeratology lenses|Children wearing orthokeratology at night for correcting of refractive error will be study group
11555964|NCT00962208|Other|single-vision spectacle lenses|Children wearing single-vision spectacles in the daytime for correcting the refractive error will serve as control group
11555965|NCT00962195|Experimental|purple sweet potato juice|Daily oral intake of 3x 125 ml of PSP-juice for a period of 8 weeks
11555966|NCT00962195|Placebo Comparator|Control juice|Daily oral intake of 3x 125 ml of control juice for a period of 8 weeks
11555967|NCT00962182|Experimental|Enzyme treatment|Enzyme for 12 weeks
11555968|NCT00962182|Placebo Comparator|Placebo control|Placebo enzyme for 12 weeks
11555969|NCT00962182|Experimental|Enzyme + gluten|Enzyme and 500 mg gluten b.i.d. for 12 weeks
11555970|NCT00962169|Experimental|Quality improvement program|
11555971|NCT00962169|Experimental|Electronic patient device (EPD)|
11555972|NCT00962156|Experimental|HES 130/0.4|Volume expansion
11555973|NCT00962156|Active Comparator|Ringer acetate|Volume expansion
11555974|NCT00962143|Active Comparator|Achilles repair without OrthADAPT Augmentation|Achilles repair without OrthADAPT Augmentation
11555975|NCT00962143|Experimental|Achilles repair with OrthADAPT augmentation|Achilles repair with OrthADAPT augmentation
11555976|NCT00962130|Experimental|Blood Glucose Measurement|Subjects have sensors placed on skin before surgery and these sensors will measure the subject's glucose until the third day after surgery when they are removed.
11555977|NCT00962117||Obese/Non-obese|
11555978|NCT00962104|Experimental|Atomoxetine|
11555979|NCT00962104|Placebo Comparator|Placebo|
11555980|NCT00962091|Experimental|Dose Escalation|A single dose of alisertib 15 mg, oral solution (OS) was administered on Day 1, followed by alisertib 40 mg, powder-in-capsule (PIC), orally, twice a day (BID) on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle. A single dose of alisertib 50 mg PIC, orally, was administered on Cycle 2 Day 1 followed by alisertib 40 mg on Days 3 through 9, followed by a 14-day rest period in Cycle 2 in a 23-day cycle. Subsequent cycles, alisertib 40 or 50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
11556000|NCT00961974|No Intervention|Standard Care|"Routine diabetes support and education from diabetes health care team
~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
11555981|NCT00962091|Experimental|Part A: Relative Bioavailability OS/PIC (Sequence A)|A single dose of alisertib 25 mg, OS, administered on Day 1, followed by alisertib 40 mg PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. A single dose of alisertib 50 mg PIC, orally, administered on Cycle 2 Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in a 23-day cycle. Subsequent cycles, alisertib 40-50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
11555982|NCT00962091|Experimental|Part A: Relative Bioavailability PIC/OS (Sequence B)|A single dose of alisertib 50 mg, PIC, orally administered on Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. Cycle 2 Day 1 alisertib 25 mg, OS, once on Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in a 23-day cycle. Subsequent cycles followed by alisertib 40-50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in Cycle 3, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
11555983|NCT00962091|Experimental|Part B: OS Food Effect Fed/Fasted (Sequence A)|Alisertib 35 mg (35 mg = relative bioavailability estimate in Part A as dose of OS that was calculated to yield the area under the concentration time curve of a 50-mg PIC dose): A single dose of alisertib 35 mg oral solution (OS), in fed state, administered on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. Cycle 2 Day 1 alisertib 35 mg administered, OS, in fasted state, once on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 3 onwards, participants received alisertib 40 mg, PIC, orally, BID on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted, based on individual tolerance, followed by a 14-day rest period, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
11555984|NCT00962091|Experimental|Part B: OS Food Effect Fasted/Fed (Sequence B)|A single dose of alisertib 35 mg, OS, in fasted state, administered on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 2 Day 1 alisertib 30 mg, OS administered in fed state, once on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 3 onwards, participants received alisertib 40 mg PIC, orally, BID on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
11555985|NCT00962091|Experimental|Part C: ECT Food Effect Fed/Fasted (Sequence A)|Alisertib 50 mg, enteric-coated tablets (ECT), orally, in fed state, once on Day 1, followed by alisertib 40 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle, followed by alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 40 or 50 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 2 in a 23-day cycle. Cycle 3 onwards, participants were administered alisertib 40 mg BID ECT on Days 1-7 with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
11555986|NCT00962091|Experimental|Part C: ECT Food Effect Fasted/Fed (Sequence B)|Alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 40 mg, ECT, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle, followed by alisertib 50 mg, ECT, orally, in fed state, once on Day 1, followed by alisertib 40 or 50 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 2, a 23-day cycle. Cycle 3 onwards participants were administered alisertib 40 mg BID ECT on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
11555987|NCT00962078|Other|interval training|interval training in lung transplant candidates
11555988|NCT00962078|Other|Continuous Training|continuous training in lung transplant candidates
11555989|NCT00962065|Experimental|Low Dose|A low dose of LX4211; daily oral intake for 28 days
11555990|NCT00962065|Experimental|High Dose|A high dose of LX4211; daily oral intake for 28 days
11555991|NCT00962065|Placebo Comparator|Placebo|Matching placebo dosing with daily oral intake for 28 days
11555992|NCT00962039|Experimental|Citalopram|Citalopram was initiated at 10 mg daily for one week, with dosage increased to 20 mg daily during week 2, with an optional increase to 40 mg daily at week 4 or thereafter if response was judged to be suboptimal (CGI-I or CGI-S > 2).
11555993|NCT00962039|Placebo Comparator|Placebo|Placebo administered in capsules identical to those containing citalopram using microcrystalline cellulose.
11555994|NCT00962026|Experimental|Rilonacept|
11555995|NCT00962013|Other|Restoration® Modular|All subjects were enrolled into a single arm and received the Restoration® Modular Revision Hip System to replace the femoral portion of a failed previous implant.
11555996|NCT00962000|Other|600 mL/min|Dialysis Flow Rate Start 600mL/min Subject starting dialysis flow rate set at 600mL/min. ABAB sequence where A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min and B represents three consecutive treatments with a dialysate flow rate of 800 mL/min.
11555997|NCT00962000|Other|800 mL/min|Dialysis Flow Rate Start 800mL/min Subject starting dialysis flow rate set at 800mL/min. BABA sequence where B represents three consecutive treatments with a dialysate flow rate of 800 mL/min and A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min.
11555998|NCT00961987|Experimental|Collaborative model|Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.
11555999|NCT00961987|Active Comparator|Usual care|At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
11556241|NCT00960414|Active Comparator|SHINE B|
11556001|NCT00961974|Experimental|Care Plus|"Routine diabetes support and education from diabetes health care team
~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
11556002|NCT00961974|Experimental|Care Ultra|"Routine diabetes support and education from diabetes health care team
~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
11556003|NCT00961961|Other|Lithium plus Fluoxetine Phase I|All participants were started in this arm. Those who met criteria for entry into Phase II were then randomized to one of the two Phase II arms.
11556004|NCT00961961|Other|Lithium plus Placebo Phase I|No participants began their participation on Lithium plus Placebo.
11556005|NCT00961961|Experimental|Lithium plus Fluoxetine Phase II|Patients who responded to Lithium plus Fluoxetine in Phase I and were randomized to continue on both compounds.
11556006|NCT00961961|Placebo Comparator|Lithium plus Placebo Phase II|Patients who responded to Lithium plus Fluoxetine in Phase I and were randomized to switch from Fluoxetine to placebo.
11556007|NCT00961922|Experimental|Neurofeedback|Children in this group receive 30 sessions of neurofeedback
11556008|NCT00961922|Sham Comparator|Placebo feedback|The children in this group receive 30 sessions of placebo feedback, based on muscular tension.
11556009|NCT00961922|No Intervention|Siblings|The siblings will be tested 1 time, they will function as a healthy control group.
11556010|NCT00961909|Experimental|1active|
11556011|NCT00961909|Placebo Comparator|1placebo|
11556012|NCT00961909|Experimental|2active|
11556013|NCT00961909|Placebo Comparator|2placebo|
11556014|NCT00961896|Active Comparator|LDE225 (applied in parallel with vehicle) [Part I]|Participants were exposed to both topically applied 0.75% LDE225 cream and LDE225 vehicle cream twice daily for 28 days where each treatment was randomized to two different test areas on each participant.
11556015|NCT00961896|Placebo Comparator|Vehicle cream (applied in parallel with LDE225 [Part I]|Participants were exposed to both topically applied 0.75% LDE225 cream and LDE225 vehicle cream twice daily for 28 days where each treatment was randomized to two different test areas on each participant.
11556016|NCT00961896|Active Comparator|LDE225 0.25% [Part II]|Participants were exposed to topically applied 0.25% LDE225 cream twice daily for 6 weeks.
11556017|NCT00961896|Active Comparator|LDE225 0.75% [Part II]|Participants were exposed to topically applied 0.75% LDE225 cream twice daily where some basal cell carcinomas (BCCs) were teated for 6 weeks and some BCCs were treated for 9 weeks.
11556018|NCT00961883|Experimental|1|Thirty participants will receive injections in the following order: NYVAC-B for injections one and two, placebo for injection three, and rAd5 for the fourth and final injection. Two participants in this group will receive placebo vaccines only.
11556019|NCT00961883|Experimental|2|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
11556020|NCT00961883|Experimental|3|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
11556021|NCT00961883|Experimental|4|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
11556022|NCT00961870|Experimental|Healthy postmenopausal women|Forearm vibration will be applied in women without postmenopausal osteoporosis
11556023|NCT00961870|Experimental|Osteoporotic postmenopausal women|Forearm vibration will be applied in women with postmenopausal osteoporosis
11556024|NCT00961870|Experimental|Healthy young adult women|Forearm vibration will be applied in healthy young adult women
11556025|NCT00961870|Experimental|Healthy young adult men|Forearm vibration will be applied in healthy young adult men
11556026|NCT00961857|Active Comparator|Treatment A|Individual Tablets of 50 mg sitagliptin and 500 mg metformin
11556027|NCT00961857|Experimental|Treatment B|Sitagliptin/metformin 50 mg/500 mg tablet
11556028|NCT00961857|Active Comparator|Treatment C|Individual Tablets of 50 mg sitagliptin and 1000 mg metformin
11556029|NCT00961857|Experimental|Treatment D|sitagliptin/metformin 50 mg/1000 mg tablet
11556030|NCT00961844|Experimental|DC vaccine + Temozolomide|Dendritic cell loaded with h-TERT mRNA, survivin mRNA and autologous tumor cell mRNA, lymphodepletion treatment and T cell expansion and reinfusion.
11556031|NCT00961831|Experimental|Arm 1|
11556032|NCT00961831|Experimental|Arm 2|
11556033|NCT00961805|Experimental|Dance Group|Belly dance
11556034|NCT00961805|No Intervention|Control Group|Waiting list
11556035|NCT00961792|Experimental|Beverage with Heavy Alcohol Dose|Beverage containing 0.8 g/kg alcohol
11556036|NCT00961792|Experimental|Beverage with Low Alcohol Dose|Beverage containing 0.4 g/kg alcohol
11556037|NCT00961792|Placebo Comparator|Beverage with No alcohol (Placebo)|Beverage containing 0.0 g/kg alcohol to act as placebo
11556038|NCT00961792|Experimental|Beverage with Diphenhydramine|Beverage containing 1.5 standard dose of Diphenhydramine (Benadryl)
11556039|NCT00961792|Experimental|Beverage with Caffeine|Beverage containing the equivalent of 1.5 times participant's average caffeine consumption
11556040|NCT00961779|Placebo Comparator|Placebo (Normal saline infusion)|
11556041|NCT00961779|Experimental|NNZ-2566|NNZ-2566 reconstituted in bicarbonate buffer and normal saline. 6/8 subjects in each cohort (5 cohort in total) to receive NNZ-2566 experimental treatment.
11556042|NCT00961766|Experimental|BG00010 (Neublastin)|Participants may be randomized to escalating doses of BG00010 or matching placebo
11556043|NCT00961766|Placebo Comparator|Placebo|Participants may be randomized to escalating doses of BG00010 or matching placebo
11556044|NCT00961753|Experimental|Optimized Ibuprofen|
11556045|NCT00961753|Active Comparator|Standard Ibuprofen|
11556101|NCT00961311|Experimental|Trial Arm|All patients with systematic ischemic heart disease with stenotic lesions that are amenable to percutaneous treatment.
11556102|NCT00961298|Experimental|Duloxetine|Two weeks of placebo run in followed by 12 weeks of Duloxetine.
11556046|NCT00961740|Other|Cognitive Behavioral Therapy|Design: 49 children (aged 8-12)with obesity was recruited, the children were randomly assigned to a group that started a cognitive behavioural intervention immediately after recruitment, and another group that received the same treatment after a 12-week wait list condition. For further description of the treatment, see summary. Arm 1 (this arm) started receiving a cognitive behavioural intervention immediately after randomization.
11556047|NCT00961740|Other|12-weeks waitlist condition|After an initial pre-assessment no contact were made before assessment after 12-weeks and start of intervention after this assessment. After the 12-week waitlist condition the families were offered the same familibased cognitive behavioral intervention as in arm one.
11556048|NCT00961727||PEWS System of Care|
11556049|NCT00961714|Experimental|OsseoFix|
11556050|NCT00961675|Active Comparator|FST201|
11556051|NCT00961675|Active Comparator|Ciprodex|
11556052|NCT00961662|Experimental|2.5 active|2.5 Active - 2.5 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
11556053|NCT00961662|Active Comparator|5.0 mid dose|5.0 mid dose - 5.0 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
11556054|NCT00961662|Active Comparator|7.5 high dose|7.5 high dose - 7.5 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
11556055|NCT00961649|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
11556056|NCT00961649|Active Comparator|Brinz|Brinzolamide ophthalmic suspension, 1% and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
11556057|NCT00961649|Active Comparator|Brim|Brimonidine tartrate ophthalmic solution, 0.2% and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
11556058|NCT00961649|Active Comparator|Brinz+Brim|Brinzolamide ophthalmic suspension, 1% and brimonidine tartrate ophthalmic solution, 0.2%: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
11556059|NCT00961636|Experimental|ERN/LRPT|"One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg
~tablets daily (2g/40 mg total) for 28 weeks"
11556060|NCT00961636|Experimental|ERN/LRPT then ERN|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks then Two 1g tablets ERN (2g total) once daily for 12 weeks.
11556061|NCT00961636|Placebo Comparator|Placebo|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks.
11556062|NCT00961610||Internet support group Intervention|
11556063|NCT00961610||Control group|
11556064|NCT00961597|Experimental|Meniscus repair with PRP|Meniscus repair for tears extending into the red/white region with PRP
11556065|NCT00961597|Active Comparator|Meniscus repair without PRP|
11556066|NCT00961571|Experimental|sunitinib and cepecitabine|Administration of sunitinib and capecitabine
11556067|NCT00961558|No Intervention|Observation arm|Patient will not to undergo any form of Assisted Reproductive Technologies for a period of 6 months
11556068|NCT00961558|Other|Surgery Arm|Patients will have varicocelectomy within 1 month of assessment and will not undergo any form of Assisted Reproductive Technologies for a period of 6 months after surgery
11556069|NCT00961532|Experimental|DDAVP|DDAVP 0.4 mcg/kg intravenously in 250 mL NS over 30 minutes
11556070|NCT00961506|Experimental|LESS cholecystectomy|LESS cholecystectomy
11556071|NCT00961506|Active Comparator|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
11556072|NCT00961493|Experimental|1|
11556073|NCT00961493|Active Comparator|2|
11556074|NCT00961480|Active Comparator|Treatment A|50 mg sitagliptin and 500 mg metformin as individual tablets
11556075|NCT00961480|Experimental|Treatment B|sitagliptin/metformin 50 mg/500 mg tablet
11556076|NCT00961480|Active Comparator|Treatment C|50 mg sitagliptin and 1000 mg metformin as individual tablets
11556077|NCT00961480|Experimental|Treatment D|sitagliptin/metformin 50 mg/1000 mg tablet
11556078|NCT00961480|Active Comparator|Treatment E|50 mg sitagliptin and 850 mg metformin as individual tablets
11556079|NCT00961480|Experimental|Treatment F|sitagliptin/metformin 50 mg/850 mg tablet
11556080|NCT00961467|Experimental|RMPT (Arm A -thalidomide 50 mg/day)|
11556081|NCT00961467|Experimental|RMPT (Arm B - thalidomide 100 mg/day)|
11556082|NCT00961441|Experimental|Children 12-16 years old|
11556083|NCT00961441|Experimental|Adults 18-55 years old|
11556084|NCT00961415|Experimental|Part 1|
11556085|NCT00961415|Experimental|Part 2A|
11556086|NCT00961415|Active Comparator|Part 2B|
11556087|NCT00961402|Experimental|Wellness Control|Participants will receive health and wellness information and no exercise information.
11556088|NCT00961402|Experimental|Exercise Intervention|Intervention will include motivational telephone-based intervention to increase exercise to 5 days per week for 30 minutes or more each session.
11556089|NCT00961389||delirious patients|minimal any positive CAM-ICU score during ICU admission
11556090|NCT00961389||non-delirious patients|without any positive CAM-ICU score during ICU admission
11556091|NCT00961376|Active Comparator|Cohort A|PBMC re-infusion
11556092|NCT00961376|Experimental|Cohort B|CD25 depletion
11556093|NCT00961363|Experimental|Sitagliptin|Sitagliptin
11556094|NCT00961363|Placebo Comparator|Placebo|Placebo
11556095|NCT00961350|Experimental|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
11556096|NCT00961350|Active Comparator|EC Aspirin|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
11556097|NCT00961337|Experimental|Vaccination township|Shinwu township was randomly designated as intervention township which freely vaccinated on grade 1-4 and 5-9 students.
11556098|NCT00961337|No Intervention|Control townships|Guanyin township was designated as control township which only provide free vaccination on grade 1-4 students.
11556099|NCT00961324|Experimental|IDeg|
11556100|NCT00961324|Experimental|IGlar|
11556105|NCT00961259|Experimental|Fenofibric Acid 105 mg (3 x 35 mg tab)|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
11556106|NCT00961259|Experimental|Fenofibric Acid 105 mg (1 x 105 mg tab)|1 x 105 mg tablet administered after an overnight fast of at least 10 hours
11556107|NCT00961246|Active Comparator|general health information group|participants received general health information
11556108|NCT00961246|Experimental|individually-tailored intervention|participants received individually-tailored intervention
11556109|NCT00961233|Experimental|inhaled/swallowed budesonide|
11556110|NCT00961233|Active Comparator|viscous/swallowed budesonide|
11556111|NCT00961220|Experimental|Treatment (O6-benzylguanine, carmustine)|Patients receive O6-benzylguanine IV over 1 hour and apply topical carmustine to the total skin surface (excluding the lips, eyelids, and ulcerated lesions) 1 hour after completing O6-benzylguanine infusion on days 1-2. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11556112|NCT00961207|Active Comparator|Aliskiren in Macroalbuminuria|Aliskiren 150 mg daily for 2 weeks and then increased to 300 mg daily for 4 weeks.
11556113|NCT00961207|Active Comparator|Aliskiren Microalbuminuria|Aliskiren 150 mg daily for 2 weeks and then increased to 300mg daily for 4 weeks
11556114|NCT00961194|Placebo Comparator|placebo|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).
~The oral ketamine will be administered in form of syrup."
11556115|NCT00961194|Experimental|dose of ketamine tested = 0.35 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).
~The oral ketamine will be administered in form of syrup."
11556116|NCT00961194|Active Comparator|dose of ketamine tested = 0.7 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).
~The oral ketamine will be administered in form of syrup."
11556117|NCT00961194|Active Comparator|dose of ketamine tested = 1.4 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).
~The oral ketamine will be administered in form of syrup."
11556118|NCT00961181|Experimental|Paclitaxel Releasing Balloon|Percutaneous coronary intervention with paclitaxel releasing balloon
11556119|NCT00961168|Experimental|Lung-Protective Ventilation|Lung-Protective Ventilation comparing volume vs. pressure control
11556120|NCT00961155|Active Comparator|cyklezonid|children will receive 160 mcg once daily cyklezonid for 3 months
11556121|NCT00961155|Active Comparator|montelukast sodium|children will receive 5 or 10 mg montelukast sodium for 3 months
11556122|NCT00961155|Placebo Comparator|placebo|children will receive placebo for 8 weeks out of allergy season to house dust mite
11556123|NCT00961155|Active Comparator|formoterol|children will receive formoterol aerolzol 12mcg twice daily for 3 months
11556124|NCT00961129||patients with colorectal cancer|patients with colorectal cancer in any stage or survivors
11556125|NCT00961116|Experimental|Fenofibric Acid (Fibricor™)|1 x 105 mg fenofibric acid (Fibricor™)tablet administered after an overnight fast of at least 10 hours
11556126|NCT00961116|Experimental|Fenofibrate (Tricor®)|1 x 145 mg fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
11556127|NCT00961103||SMA II and SMA III|patients with SMA II and SMA III
11556128|NCT00961090|Other|Single-Arm|Single-Arm All subjects received 20mg/kg of Aminolevulinic Acid diluted in 50cc of water, orally, approximately 3 hours prior to surgery.
11556129|NCT00961064|Experimental|1|Eltrombopag will be initiated at 50 mg/day (Asians 25 mg/day) and dose adjusted up to 150mg/day based response and safety
11556130|NCT00961051|Experimental|Investigational MPS|Investigational multipurpose disinfecting solution (study MPS)
11556131|NCT00961051|Active Comparator|Predicate MPS|Opti-Free RepleniSH multipurpose disinfecting solution (predicate MPS)
11556132|NCT00961038|Experimental|Arm 1|
11556133|NCT00961038|Experimental|Arm 2|
11556134|NCT00961038|Placebo Comparator|Arm 3|
11556135|NCT00961025|Placebo Comparator|Placebo|
11556136|NCT00961025|Experimental|DA-1229|DA-1229
11556137|NCT00961012|Experimental|Intervention|"Experimenter A places the subject in the High Fowler's position by raising the foot of the bed to its highest position, 50 degrees, and the head of the bed to its highest position, 60 degrees. Experimenter A sets the timer for 8 minutes as per pressure mapping protocol. For more stable values, a settling time of 8 minutes is required to factor in creep of the pressure mapping sensors and mattress. Experimenter A aims the laser beam to the top of the scapulae where the subject's shoulder meets the mattress surface. Experimenter B initiates a FSA file with the subject's number, takes a pressure reading once 8 minutes is up, measures the trunk displacement, obtains spirometry readings as per protocol, and takes a measure of discomfort. Experimenter B leaves the room, Experimenter A sets the timer for 5 minutes and opens the randomization/ allocation envelope."
11556138|NCT00961012|No Intervention|Control group|"Experimenter A reminds the subject to remain immobile.
~For both intervention and control group. After the five-minute period, experimenter A calls experimenter B to return. Experimenter B takes a pressure reading, measures the trunk displacement, obtains spirometry readings, and takes a measure of discomfort."
11556139|NCT00960999|Experimental|Single-fraction SBRT (34 Gy)|Single-fraction stereotactic body radiation therapy (SBRT) of 34 Gy
11556140|NCT00960999|Experimental|Multiple-fraction SBRT (48 Gy)|Multiple-fraction stereotactic body radiation therapy (SBRT) given in four daily 12 Gy fractions for a total dose of 48 Gy
11556141|NCT00960986|Experimental|Duloxetine 60 mg with food|Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks
11556142|NCT00960986|Experimental|Duloxetine 60 mg without food|Duloxetine 60 mg capsule po QD without food for 8 weeks
11556143|NCT00960986|Experimental|Duloxetine 30 mg with food|Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks
11556144|NCT00960986|Experimental|Duloxetine 30 mg without food|Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks
11556145|NCT00960973|Experimental|Vitamin K|Vitamin K supplementation (menatetrenone 30 mg, 3 times a day for 4 weeks)
11556146|NCT00960973|Placebo Comparator|Placebo control|Placebo control
11556147|NCT00960960|Experimental|Part 1 (Cohort 1-2): Pictilisib 60 mg +Paclitaxel +Bevacizumab|Pictilisib 60 mg will be administered orally (PO) once daily (QD) for 21 consecutive days of each 28-day cycle (21+7 schedule) with paclitaxel 90 milligrams per meter square (mg/m^2) intravenously (IV) on Days 1, 8, and 15 and bevacizumab 10 milligrams per kilogram (mg/kg) IV on Days 1 and 15 of each 28-day cycle. In Cohort 1 (Part 1), pictilisib will be evaluated with paclitaxel only; participants in Cohort 1 (Part 1) will be eligible to receive bevacizumab starting at Cycle 2. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
11556148|NCT00960960|Experimental|Part 1 (Cohort 3): Pictilisib 100 mg+ Paclitaxel + Bevacizumab|Pictilisib 100 mg will be administered PO QD for 21 consecutive days of each 28-day cycle (21+7 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
11556149|NCT00960960|Experimental|Part 2 (Arm A: Cohort 1a): Pictilisib 165 mg + Paclitaxel|Pictilisib 165 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity
11556150|NCT00960960|Experimental|Part 2 (Arm A: Cohort 2a): Pictilisib 250 mg + Paclitaxel|Pictilisib 250 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
11556151|NCT00960960|Experimental|Part 2 (Arm A: Cohort 3a): Pictilisib 330 mg + Paclitaxel|Pictilisib 330 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
11556152|NCT00960960|Experimental|Part2(Arm B:Cohort 1b):Pictilisib 200mg+Paclitaxel+Bevacizumab|Pictilisib 200 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
11556153|NCT00960960|Experimental|Part2(Arm B:Cohort 2b):Pictilisib 250mg+Paclitaxel+Bevacizumab|Pictilisib 250 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
11556154|NCT00960960|Experimental|Part2(Arm B:Cohort 3b):Pictilisib 260mg+Paclitaxel+Bevacizumab|Pictilisib 260 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
11556155|NCT00960960|Experimental|Part2(Arm C:Cohort 1c):Pictilisib 180mg+Paclitaxel+Trastuzumab|Pictilisib 180 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and trastuzumab 2-4 mg/kg IV on Days 1, 8, 15, and 22 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
11556156|NCT00960960|Experimental|Part2(Arm C:Cohort 2c):Pictilisib 260mg+Paclitaxel+Trastuzumab|Pictilisib 260 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and trastuzumab 2-4 mg/kg IV on Days 1, 8, 15, and 22 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
11556157|NCT00960960|Experimental|Part 3: Pictilisib 260 mg + Letrozole|Pictilisib 260 mg will be administered PO QD continuously with letrozole 2.5 mg PO QD for each 28-day cycle. Study treatment will continue until disease progression or unacceptable toxicity.
11556158|NCT00960934|Experimental|MK-5442 2.5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.
11556159|NCT00960934|Experimental|MK-5442 5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.
11556160|NCT00960934|Experimental|MK-5442 7.5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.
11556161|NCT00960934|Experimental|MK-5442 10 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.
11556162|NCT00960934|Experimental|MK-5442 15 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.
11556163|NCT00960934|Placebo Comparator|Placebo|Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.
11556164|NCT00960921|Experimental|Iron group|Patients with high altitude pulmonary hypertension receive six intravenous infusions of iron sucrose, administered on days 0, 4, 8, 12, 16 and 20 of the study. The total study period is 28 days. Pulmonary artery systolic pressure is measured before each infusion, and again on day 28.
11556165|NCT00960921|Placebo Comparator|Saline group|Patients with high altitude pulmonary hypertension receive six intravenous infusions of normal saline, administered on days 0, 4, 8, 12, 16 and 20 of the study. The total study period is 28 days. Pulmonary artery systolic pressure is measured before each infusion, and again on day 28.
11556166|NCT00960908||Resolute|Prospective recruitment of Resolute arm will start in March 2009
11556167|NCT00960908||Endeavor|The retrospective recruiting period of Endeavor arm comprises a fixed 2-year time between January 2006 and December 2008. The patients, who were treated with Endeavor in that period, will be enrolled if they agree to participate in this study.
11556168|NCT00960882|Experimental|DMMET-01|
11556169|NCT00960869|Experimental|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole dosed once daily (QD)
11556170|NCT00960869|Active Comparator|EC-Aspirin 325 mg|EC-Aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole) dosed once daily (QD)
11556171|NCT00960856|Experimental|Fenofibric Acid 105 mg - Low-Fat Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
11556172|NCT00960856|Experimental|Fenofibric Acid 105 mg - Standard Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a standard breakfast.
11556173|NCT00960856|Experimental|Fenofibric Acid 105 mg - High-Fat/High-Calorie Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
11556174|NCT00960856|Experimental|Fenofibric Acid 105 mg - Fasted State|Fenofibric Acid 105 mg tablet administered after an overnight fast of at least 10 hours
11556175|NCT00960843|Active Comparator|Conventional Adjustment Group|Subject whose band adjustments will be made via conventional standard of care (e.g., volume, hunger).
11556176|NCT00960843|Active Comparator|Intraband Pressure Arm|Subjects whose band adjustments will be guided by intraband pressure readings.
11556177|NCT00960830|Placebo Comparator|mirtazapine|
11556178|NCT00960830|Placebo Comparator|mirtazapine, sugar pill|
11556179|NCT00960817|Active Comparator|1. Routine treatment|Control group
11556180|NCT00960817|Experimental|2. Dipyridamole treatment|Group that receives Dipyridamole treatment
11556181|NCT00960804|Experimental|Tanezumab 5 mg|
11556182|NCT00960804|Experimental|Tanezumab 10 mg|
11556183|NCT00960804|Placebo Comparator|Placebo|
11556184|NCT00960791|Experimental|1|14C-labelled AZD1656
11556185|NCT00960778|Experimental|Women- denicotinized cigarette|Treatment-seeking nicotine-dependent women will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues after four days of denicotinized cigarette (less than 0.5 gram nicotine) use.
11556186|NCT00960778|Experimental|Men- denicotinized cigarette|Treatment-seeking nicotine-dependent men will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues after four days of denicotinized cigarette (less than 0.5 gram nicotine) use.
11556187|NCT00960778|Experimental|Women -nicotine patch|Treatment-seeking nicotine-dependent women will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues under after receiving three days of a 21 mg nicotine patch.
11556188|NCT00960778|Experimental|Men- nicotine patch|Treatment-seeking nicotine-dependent men will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues under after receiving three days of a 21 mg nicotine patch.
11556189|NCT00960765||Roux-En-Y Gastric Bypass|
11556190|NCT00960765||Gastric Banding|
11556191|NCT00960765||Sucessful Response to RYGB|
11556192|NCT00960765||Failed Response to RYGB|
11556193|NCT00960752|Active Comparator|Group 1: gp100 and MAGE-3 + R848|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.
~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
11556194|NCT00960752|Active Comparator|Group 2: gp100 and MAGE-3|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.
~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
11556195|NCT00960752|Active Comparator|Group 3-Metastatic Melanoma: gp100 + MAGE-3 + R848|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.
~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
11556196|NCT00960739|Experimental|Topotecan / 131-iodine MIBG association|"The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle). *
~Iobenguane I 131: 444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity up to 11,100 MBq per injection. *
~A dosimetry is performed during hospitalization.
~A second dose of 131-iodine MIBG (maximum 11 100 MBq) is administered to D21 so as to obtain a total body irradiation of 4 Gy. *
~Autologous hematopoietic stem cell transplantation : Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG.
~If the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled."
11556197|NCT00960726|Experimental|NOV-002|
11556242|NCT00960401||cardiac counseling|10 left sided breast cancer patients 10 right sided breast cancer patients
11556243|NCT00960401||coronary artery evaluation|10 left sided breast cancer 10 right sided breast cancer
11556301|NCT00960037|Placebo Comparator|Placebo|
11556302|NCT00960024|Experimental|Individual Placement and Support-vocational rehabilitation|
11556303|NCT00960024|Active Comparator|Vocational rehabilitation available at study site|
11556304|NCT00960011|Experimental|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
11556305|NCT00960011|Active Comparator|POLYPROPYLENE|Use of Polypropylene mesh for open inguinal hernia repair
11556198|NCT00960713||The RITAI cohort|Every patient treated by rituximab off-label for auto-immune diseases in the public hospitals of the Midi-Pyrénées County (South of France) is eligible for the study, whatever the dose and planned infusions number. The enrolment is definitive when the first rituximab infusion begins. Follow-up visits are planned at months 1, 3, 6, 12 and 18 after the first infusion. At each visit, the investigators will record the adverse events that have occurred since the last visit. Serious or unexpected adverse events will be systematically monitored and declared to the Department of Pharmacology Pharmacovigilance unit and to Health Authorities (AFSSAPS). Imputability will be quoted according to the French method. A biological collection will be constituted to allow pharmaco-immunological studies.
11556199|NCT00960687|Experimental|Fenofibric Acid (Fibricor™)|1 x 105 mg fenofibric acid (Fibricor™)tablet administered 30 minutes after the initiation of a standard breakfast.
11556200|NCT00960687|Experimental|Fenofibrate (Tricor®)|1 x 145 mg fenofibrate (Tricor®) tablet administered 30 minutes after the initiation of a standard breakfast.
11556201|NCT00960674|Experimental|Tactile massage|A gentle form of massage given once a week for three weeks
11556202|NCT00960674|Experimental|Relaxation|Relaxation (by the use of a CD with relaxation exercises used at least once a week for 10 weeks)
11556203|NCT00960661|Experimental|Exenatide (BET)|Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET)
11556204|NCT00960661|Active Comparator|Insulin Lispro (BBT)|Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT)
11556205|NCT00960648||Xience/Promus|Active prospective registration of patients receiving everolimus eluting stent
11556206|NCT00960648||Cypher|Retrospective historical controls that received sirolimus-eluting stent
11556207|NCT00960635|Active Comparator|calcitriol|
11556208|NCT00960635|Placebo Comparator|pill without agent|
11556209|NCT00960622|Experimental|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
11556210|NCT00960622|Active Comparator|Combivir or Trizivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months or Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
11556211|NCT00960609||caval confluence HV involvement|Patients carriers of primary or metastatic tumour with direct contact or invasion of one HV at the caval confluence.
11556212|NCT00960583|Experimental|Exercise program|"Exercise program comprising muscle strengthening, cardiovascular training and stretching exercises.
~Program duration : 12 weeks Sessions frequency : twice per week Session duration : 1h30"
11556213|NCT00960583|Active Comparator|Routine follow-up|Routine follow-up after functional multidisciplinary rehabilitation by attending physician (Advice to stay active)
11556214|NCT00960570|Active Comparator|Efavirenz Alone|Baseline Efavirenz pharmacokinetics.
11556215|NCT00960570|Experimental|Efavirenz with Steady State Fenofibric Acid|Efavirenz pharmacokinetics in the presence of steady state Fenofibric Acid.
11556216|NCT00960557|Experimental|Combretastatin A1 Diphosphate|
11556217|NCT00960544|Experimental|Capecitabine|Capecitabine - Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
11556218|NCT00960531|Experimental|ACC-001 (3mcg) + QS-21|ACC-001 (3mcg) + QS-21
11556219|NCT00960531|Experimental|ACC-001 (10mcg) + QS-21|ACC-001 (10mcg) + QS-21
11556220|NCT00960531|Experimental|ACC-001 (30mcg) + QS-21|ACC-001 (30mcg) + QS-21
11556221|NCT00960518|Placebo Comparator|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
11556222|NCT00960518|Experimental|TACE+adefovir|patients received adefovir, at a dose of 10 mg daily after TACE treatment, for 48 weeks
11556223|NCT00960505|Experimental|Alternate day fasting (ADF)|Fast day diet: 25% energy intake, Feast day diet: Ad libitum energy intake (alternating days)
11556224|NCT00960505|Experimental|Calorie restriction (CR)|75% energy intake every day
11556225|NCT00960505|Active Comparator|Control|Usual diet
11556226|NCT00960492|Experimental|Arm 1|XL184 will be initiated at the start of the 6-7 week concurrent phase of RT (+TMZ; some subjects found to have specific gene activity in their tumor tissue may not receive TMZ), given as a single agent during the rest phase (4 weeks), if applicable, and continued subsequently in the maintenance phase.
11556227|NCT00960492|Experimental|Arm 2|XL184 will be initiated during the maintenance phase with TMZ
11556228|NCT00960492|Experimental|MTD Expansion|XL184 will be initiated at the start of the 6-7 week concurrent phase of RT (+TMZ; some subjects found to have specific gene activity in their tumor tissue may not receive TMZ), given as a single agent in the rest phase (4 weeks), if applicable, and continued subsequently in the maintenance phase. Subjects in this group will receive XL184 and TMZ at the maximally tolerated dose levels determined in Arms 1 and 2.
11556229|NCT00960479|Experimental|1|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)
11556230|NCT00960479|Active Comparator|2|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)
11556231|NCT00960466|Active Comparator|Usual Care Arm|The usual care group will receive their Chemotherapy or Radiotherapy as normal.
11556232|NCT00960466|Experimental|DT&PL arm|"During the second week of radiotherapy/second cycle of chemotherapy, patients in the Distress Thermometer and Problem List (DT&PL) arm of the study will complete the DT&PL (estimated 15 minutes to complete) with the trained radiographer/nurse.
~The DT&PL assessment will be repeated at the end of therapy fractions/cycles. This will elicit concerns about post-therapy issues and facilitate continuity of care between the cancer team and primary care. Depending on the duration of therapy, therapists may choose to use the DT&PL at other points during patient care. A copy of the DT&PL will be stored in the medical record to track the frequency of use and to check that those assigned to usual care were not monitored with the DT&PL."
11556233|NCT00960453|Other|Sitagliptin 25mg|Repeated administrations for 4 days
11556234|NCT00960453|Other|Sitagliptin 50mg|Repeated administrations for 4 days
11556235|NCT00960453|Other|Sitagliptin 100mg|Repeated administrations for 4 days
11556236|NCT00960440|Experimental|Sequence 1|
11556237|NCT00960440|Experimental|Sequence 2|
11556238|NCT00960440|Placebo Comparator|Sequence 3|
11556239|NCT00960440|Placebo Comparator|Sequence 4|
11556240|NCT00960414|Experimental|SHINE A|
11556244|NCT00960375|Experimental|BTSCS|BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
11556245|NCT00960375|Active Comparator|StSST|The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide test at the start of each group meeting. StSST groups provide education about smoking and support for quitting.
11556246|NCT00960362|Placebo Comparator|A|
11556247|NCT00960362|Experimental|B|Intravenous cohort 1; 0.01 mg/kg
11556248|NCT00960362|Experimental|C|Intravenous cohort 2; 0.1 mg/kg
11556249|NCT00960362|Experimental|D|Intravenous cohort 3; 0.6 mg/kg
11556250|NCT00960362|Experimental|E|Intravenous cohort 4; 3.0 mg/kg
11556251|NCT00960362|Experimental|F|Intravenous cohort 5; 10 mg/kg
11556252|NCT00960362|Experimental|G|Intravenous cohort 6; 30 mg/kg
11556253|NCT00960349|Other|Treatment A|Cediranib 20mg + Cisplatin + S-1
11556254|NCT00960349|Other|Treatment B|Cediranib 20mg + Cisplatin + Capecitabine
11556255|NCT00960336|Experimental|single arm|
11556256|NCT00960323|Active Comparator|Colchicine Alone|baseline colchicine pharmacokinetics
11556257|NCT00960323|Experimental|Colchicine with Atorvastatin|Colchicine pharmacokinetics in the presence of atorvastatin at steady state.
11556258|NCT00960310|Experimental|1|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
11556259|NCT00960310|Active Comparator|2|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
11556260|NCT00960297|Experimental|Carboplatin/Paclitaxel/Bevacizumab|Preoperative chemotherapy and bevacizumab
11556261|NCT00960284|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
11556262|NCT00960284|Experimental|Arm II|Patients receive cisplatin IV over 1 hour and epirubicin hydrochloride IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Patients also receive fluorouracil IV continuously beginning on day 1 or oral capecitabine. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
11556263|NCT00960271||NON SMALL CELL LUNG CANCER|Non small cell lung cancer, with clinical N2 disease, otherwise operable.
11556264|NCT00960258|Experimental|Arm 1|
11556265|NCT00960245|Experimental|1|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
11556266|NCT00960245|Active Comparator|2|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
11556267|NCT00960232|Experimental|Vitamin D|vitamin D 40.000 IU per weel
11556268|NCT00960232|Placebo Comparator|Placebo|Placebo
11556269|NCT00960219|Experimental|DAAOI-1|
11556270|NCT00960219|Placebo Comparator|placebo|
11556271|NCT00960206|Experimental|Trident®System|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
11556272|NCT00960206|Experimental|ABC System|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
11556273|NCT00960206|Active Comparator|Control|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
11556274|NCT00960193|Active Comparator|Colchicine Alone|baseline colchicine pharmacokinetics
11556275|NCT00960193|Experimental|Colchicine with Seville Orange Juice|colchicine pharmacokinetics in presence of Seville orange juice
11556276|NCT00960180|Experimental|1|
11556277|NCT00960180|Placebo Comparator|2|
11556278|NCT00960167|Experimental|Dose Level I|42 Gy in 12 fractions.
11556279|NCT00960167|Experimental|Dose Level II|49 Gy in 14 fractions.
11556280|NCT00960167|Experimental|Dose Level III|56 Gy in 16 fractions.
11556281|NCT00960167|Experimental|Dose Level IV|63 Gy in 18 fractions.
11556282|NCT00960154|Experimental|PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
11556283|NCT00960154|Active Comparator|SOC|The SOC consists of scalpel for the skin incision and traditional electrosurgery for the entirety of the subcutaneous dissection.
11556284|NCT00960141|Experimental|1|montelukast
11556285|NCT00960141|Active Comparator|2|loratadine
11556286|NCT00960141|Placebo Comparator|3|placebo
11556287|NCT00960128||A|Adult cohort
11556288|NCT00960128||B|Paediatric cohort
11556289|NCT00960115|Experimental|Tecemotide (L-BLP25) + Cyclophosphamide|Active
11556290|NCT00960115|Placebo Comparator|Placebo + Saline|Control
11556291|NCT00960102|Active Comparator|bilateral cochlear implant|
11556292|NCT00960102|Active Comparator|cochlear implant and hearing aid|
11556293|NCT00960102|Active Comparator|bilateral hearing aid|
11556294|NCT00960089|Experimental|LIQUICURE|Medical Device
11556295|NCT00960076|Experimental|1|Saxagliptin
11556296|NCT00960076|Active Comparator|2|Metformin Extended Release
11556297|NCT00960063|Experimental|Temozolomide+Irinotecan+Robatumumab|Participants receive temozolomide 100 mg/m^2/day intravenously (IV) on Days 1-5 PLUS irinotecan 10 mg/m^2/day IV on Days 1-5 and Days 8-12 PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
11556298|NCT00960063|Experimental|Vincristine+Doxorubicin+Cyclophosphamide+Robatumumab|Participants receive vincristine 2 mg/m^2 (maximum 2 mg) IV on Day 1 PLUS cyclophosphamide 1200 mg/m^2 IV on Day 1 PLUS doxorubicin hydrochloride 75 mg/m^2 IV continuously over 48 hours PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
11556299|NCT00960063|Experimental|Ifosfamide+Etoposide+Robatumumab|Participants receive ifosfamide 1800 mg/m^2 per day IV PLUS etoposide 100 mg/m^2 per day IV on Days 1-5 PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
11556306|NCT00959998|Active Comparator|Relaxation acupressure|
11556307|NCT00959998|Experimental|High Intensity Stimulating Acupressure|
11556308|NCT00959998|Experimental|Low Intensity Stimulating Acupressure|
11556309|NCT00959985|No Intervention|Group 1A|Mild Lymphedema: Only required to meet with the lymphedema physical therapist
11556310|NCT00959985|Active Comparator|Group 1B|Mild Lymphedema: Fitted for compression sleeve
11556311|NCT00959985|Active Comparator|Group 2A|Moderate lymphedema: Fitted with a compression sleeve
11556312|NCT00959985|Active Comparator|Group 2B|Moderate Lymphedema: Fitted with compression sleeve and instructed to wear a short-stretch compression bandage
11556313|NCT00959972|Experimental|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
11556314|NCT00959972|Experimental|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
11556315|NCT00959959|Experimental|650 mg TOK-001|
11556316|NCT00959959|Experimental|1300 mg TOK-001|
11556317|NCT00959959|Experimental|1950 mg TOK-001|
11556318|NCT00959959|Experimental|975 mg TOK-001|
11556319|NCT00959959|Experimental|975 mg TOK-001, supplement|
11556320|NCT00959959|Experimental|1950 mg TOK-001, split dose|
11556321|NCT00959959|Experimental|2600 mg TOK-001|
11556322|NCT00959959|Experimental|2600 mg TOK-001, split dose|
11556323|NCT00959946|Experimental|1|In part 1 (phase 1), ascending and descending multiple oral doses of bosutinib + capecitabine. Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14 + bosutinib 200 mg QD; capecitabine 625 mg/m2 BID on days 1-14 + bosutinib 300 mg QD. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID and bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
11556324|NCT00959933|Experimental|1|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)
11556325|NCT00959933|Active Comparator|2|Rebetol 200 Capsules (Schering Corporation, U.S.A.)
11556326|NCT00959920|Active Comparator|Indwelling foley catheter|Insertion of an indwelling foley catheter when bladder emptying is necessary. The indwelling catheter will remain in place until the time of delivery.
11556327|NCT00959920|Active Comparator|Intermittent straight catheterization|Intermittent straight catheterization will be performed as needed during labor.
11556328|NCT00959907|Active Comparator|BoNT A1 (4U)|BoNT A1 (4U): Botulinum toxin A (Dysport®)4 units
11556329|NCT00959907|Active Comparator|BoNT-A2 (2U)|BoNT-A2(2U): Botulinum toxin A (Botox®) 2 units
11556330|NCT00959894|Experimental|Etravirine 400 mg once daily|Etravirine 400 mg once daily with fixed dose tenofovir/emtricitabine (Truvada) one tablet once daily
11556331|NCT00959881|Experimental|Donepezil plus placebo|
11556332|NCT00959881|Experimental|Donepezil plus begacestat|
11556333|NCT00959855|Experimental|Pulmonary Rehabilitation|Pulmonary rehabilitation classes based on the British Thoracic Society guidelines will be undertaken for two hours for 16 sessions within an eight week period.
11556334|NCT00959855|No Intervention|Pulmonary Rehabiliation|The control group will be assessed in the same time frame without participating in the rehabilitation class. They will avail of the next available class after the 12 month assessment.
11556335|NCT00959842|Experimental|Lovaza|Lovaza was given as the only agent; there was no comparator agent or arm
11556336|NCT00959829|Placebo Comparator|silence|"The control group listened silence and was evaluated the same things."
11556337|NCT00959816|Experimental|Single Dose (Part 1)|
11556338|NCT00959816|Experimental|Multiple Dose (Part 2)|
11556339|NCT00959803|Experimental|Single dose|3 way crossover with randomized placebo substitution to evaluate single escalating oral doses of PF 04447943 in 9 healthy young adult subjects.
11556340|NCT00959803|Experimental|Multiple dose|3:1 active PF 04447943 to placebo randomization in 8 healthy elderly subjects.
11556341|NCT00959790|Experimental|High vegetable dose|Consumption of 200 grams of vegetables daily, for four weeks.
11556342|NCT00959790|Experimental|Low vegetable dose|Consumption of 50 grams of vegetables daily, for four weeks.
11556343|NCT00959790|Active Comparator|Weight loss interventio|Consumption of - 1000 kcal daily, for four weeks to be used as a positive control for the vegetables interventions.
11556344|NCT00959777|Experimental|DA-3031|
11556345|NCT00959777|Active Comparator|filgrastim|
11556346|NCT00959764|Experimental|Oral calcitonin and placebo nasal spray|Intervention: Oral calcitonin tablet (along with placebo intranasal spray)
11556347|NCT00959764|Active Comparator|Intranasal calcitonin & oral placebo|Intervention: Commercially available, active comparator, intranasal calcitonin-salmon (plus matching oral placebo tablet).
11556348|NCT00959764|Placebo Comparator|Placebo: tablet & intranasal spray|Intervention: Both oral matching placebo tablets and matching intranasal placebo spray
11556349|NCT00959751|Experimental|NXN-188 600 mg|3 x 200 mg capsules, PRN
11556350|NCT00959751|Placebo Comparator|Placebo|3 x 0 mg capsules, PRN
11556351|NCT00959738|Other|A|diverting loop ileostomy with rod
11556352|NCT00959738|Other|B|diverting loop ileostomy without rod
11556353|NCT00959725|Experimental|Intravitreal infliximab.|
11556354|NCT00959712|No Intervention|Control|Subjects are given a pedometer and step count log in which to record their daily step counts for 1 year.
11556355|NCT00959712|Active Comparator|ECA Interaction|"Subjects are given pedometers and step count logs in which to record their daily steps for 1 year. Subjects are also given a tablet computer and instructed to interact with the ECA (Embodied Conversational Agent) Tanya every day for 2 months."
11556356|NCT00959699|Placebo Comparator|PegIFN-2b + RBV|PegIFN-2b (1.5 µg/kg/week subcutaneously) plus RBV (600-1400 mg/day, orally, divided into two daily doses) for 4 weeks followed by placebo to boceprevir plus PegIFN-2b/RBV for 44 weeks with 24 weeks post-treatment follow-up (Control Arm). Participants who do not achieve HCV-RNA <9.3 IU/mL by Treatment Week 24 (TW24) are eligible to cross-over and receive boceprevir along with the PegIFN-2b and RBV for up to 44 weeks.
11556456|NCT00958971|Experimental|TKI258 - Negative|These are the participants who had a negative T(4;14) status
11556357|NCT00959699|Active Comparator|PegIFN-2b + RBV + Boceprevir|PegIFN-2b (1.5 µg/kg/week subcutaneously) plus RBV (600- 1400 mg/day, orally, divided into two daily doses) for 4 weeks followed by boceprevir (800 mg, orally, 3 times per day) plus PegIFN-2b/RBV for 44 weeks with 24 weeks post-treatment follow-up.
11556358|NCT00959686|Experimental|Bendamustine|Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
11556359|NCT00959660|Active Comparator|Exercise Training|Exercise participants will undergo a 1-hour supervised exercise program 3 times per week for 20 weeks consisting primarily of walking exercise using an individualized exercise prescription based on the initial exercise stress testing results.
11556360|NCT00959660|Active Comparator|Dietary Intervention|A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb) weight loss per week.
11556361|NCT00959660|Active Comparator|Attention control|Attention control participants will be provided a counseling session regarding general health education at baseline and will be contacted by staff via telephone every 2 weeks to discuss general health status.
11556362|NCT00959660|Active Comparator|Diet and Exercise|A hypocaloric diet will be developed to achieve a 2450 kcal/week deficit in addition to undergoing a 1-hour supervised exercise program 3 times per week for 20 weeks consisting primarily of walking exercise using an individualized exercise prescription based on the initial exercise stress testing results.
11556363|NCT00959647|Experimental|Vismodegib 150 mg|Participants received 150 mg vismodegib orally once a day until disease progression, intolerable toxicity, or withdrawal from the study. If a participant had been receiving combination chemotherapy and/or biotherapy (FOLFOX, FOLFIRI, bevacizumab) in a parent study, the same combination chemotherapy and/or biotherapy as specified in the parent study could be continued in this study at the discretion of the investigator.
11556364|NCT00959634|Experimental|1|Dose 1 BID
11556365|NCT00959634|Experimental|2|Dose 2 BID
11556366|NCT00959634|Placebo Comparator|3|Placebo BID
11556367|NCT00959621|Active Comparator|ASA|The patients received either Enoxaparine+placebo, Enoxaparine+ASA (Aspirin 100 mg) or ASA alone.ASA or placebo were blinded in the two first groups.
11556368|NCT00959621|Active Comparator|Klexane|Clexane (enoxaparine) 40 mg sc
11556369|NCT00959621|Active Comparator|Aspirin and Enoxaparine|
11556370|NCT00959608|Active Comparator|Basic|Basic program participants receive 10-15 minute PCP weight management counseling at approximately four month intervals for up to 24 months and weight management materials.
11556371|NCT00959608|Experimental|Basic Plus|Half of study participants are randomly assigned to Basic Plus program, where in addition to receiving the same intervention as the Basic program participants, the Basic Plus participants also receive counseling from a lifestyle coach at the primary care provider's office (monthly in year 1 and bimonthly in year 2).
11556372|NCT00959595|Experimental|EMLA cream|
11556373|NCT00959595|Placebo Comparator|Placebo cream|A placebo cream identical in appearance and consistency to the experimental cream
11556374|NCT00959582|Experimental|1|18-F-FDG PET/CT imaging
11556375|NCT00959569|Experimental|esmolol|the study group will receive esmolol (1-3 mg/kg)
11556376|NCT00959569|Placebo Comparator|normosaline|normosaline (same ml of the study drug)
11556377|NCT00959543|Other|waterpolo players|30 throwing shoulders of waterpolo players
11556378|NCT00959543|Other|controle group|15 healthy patients (non waterpolo players); 30 shoulders
11556379|NCT00959530|Experimental|lingualized|complete denture fabricated by lingualized occlusion scheme
11556380|NCT00959530|Placebo Comparator|Full Bilaterally Balanced Articulation|complete denture fabricated by Full Bilaterally Balanced Articulation scheme
11556381|NCT00959517|Experimental|CQ|
11556382|NCT00959517|Experimental|CQ+PQ|
11556383|NCT00959517|Experimental|CQ + AS|
11556384|NCT00959517|Experimental|SP|
11556385|NCT00959517|Experimental|SP + PQ|
11556386|NCT00959517|Experimental|SP + AS|
11556387|NCT00959491||Colonoscopy indication|All outpatients referred to colonoscopy according to inclusion criteria in the specified period time of one year .
11556388|NCT00959478|Experimental|Educational tool & Carbon Monoxide Alarm|"Parents will be randomly assigned into a control and intervention group. Both groups will complete a computer based survey at enrollment and at their home visits occuring two weeks and approximately six months following enrollment. Participants will be given the following materials at enrollment.
~Intervention:
~Fast Facts about Carbon Monoxide Educational Tool
~Kidde Nighthawk Carbon Monoxide Alarm
~Control:
~- Central Ohio Poison Control Center Flyer"
11556389|NCT00959465|Experimental|Cohort 1/Dose Level A|Subjects in Cohort 1 will be randomized 1:1 to receive two vaccinations of Dose A or Dose B of H1N1 pandemic influenza vaccine at a 21-day interval.
11556390|NCT00959465|Experimental|Cohort 1/Dose B|Subjects in Cohort 1 will be randomized 1:1 to receive two vaccinations of Dose A or Dose B of H1N1 pandemic influenza vaccine at a 21-day interval.
11556391|NCT00959465|Experimental|Cohort 2/Dose C|A second cohort may be enrolled with all subjects in this cohort receiving two vaccinations of Dose C of H1N1 pandemic influenza vaccine at a 21-day interval.
11556392|NCT00959452|Experimental|Psychotherapy|
11556393|NCT00959439|Experimental|1|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)
11556394|NCT00959439|Active Comparator|2|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)
11556395|NCT00959426|Experimental|PF-04620110|
11556396|NCT00959426|Placebo Comparator|Placebo Comparator|
11556397|NCT00959413||A|Participants who have a CD4 count of 200 cells/mm3 or less and a viral load greater than 1,000 copies/ml
11556398|NCT00959413||B|Participants who have a CD4 count of 200 cells/mm3 or less and a viral load of 1,000 copies/ml or less
11556399|NCT00959413||C|Participants will have a CD4 count that is greater than 200 cells/mm3 and a viral load that is greater than 1,000 copies/ml
11556400|NCT00959413||D|Participants will have a CD4 count that is greater than 200 cells/mm3 and a viral load that is 1,000 copies/ml or less
11556401|NCT00959400|Experimental|Fentanyl Transdermal|
11556453|NCT00958997||Type 1 diabetic subjects|Patients with Type 1 diabetes who have a diagnosis of Type 1 diabetes mellitus defined by ADA criteria or judgment of physician
11556454|NCT00958997||Healthy control subjects|Age-weight-BMI matched to the subjects with type-1 diabetes
11556402|NCT00959387|Experimental|Induction TP chemotherapy followed by CRT|paclitaxel 175mg/m2 as a 3-h infusion on Day 1, and cisplatin 80mg/m2 as a 2-h infusion on Day 1 three weekly followed by concurrent chemoradiotherapy based on cisplatin. All patient were given adequate hydration and antiemetics. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
11556403|NCT00959374|Active Comparator|V-loc and Monocryl|Subjects served as their own control, and they were randomized to receive an intervention of a standard closure using 3-0 Monocryl™ on one side of the body and the test closure device, V-Loc 180/90, on the other side. The standard closure technique was agreed on by study investigators for control side, and included mandatory closure of the deep dermal layer with interrupted 3-0 Monocryl™ sutures, spaced no further than 2 cm apart, followed by closure of the intradermal layer with running 3-0 Monocryl™ sutures. The test closure side, closure of the deep dermal layer was optional. If deep dermal sutures were used, interrupted 3-0 Monocryl™ sutures were required to be placed no closer than 5 cm apart followed by closure of the intradermal layer with test device, V-Loc 180/90.
11556404|NCT00959361|Experimental|pharmaceutical care|consultation with the pharmacists
11556405|NCT00959361|No Intervention|control|usual care without consultation with the pharmacists
11556406|NCT00959348||Asthma|Asthma patients on inhaled corticosteroids
11556407|NCT00959348||Control|Select matched controls from the general population database of Cardiovascular Risk Factor Prevalence Study 2 (CRISPS2)
11556408|NCT00959335|Active Comparator|2|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
11556409|NCT00959335|Experimental|1|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
11556410|NCT00959309|Experimental|Intervention|
11556411|NCT00959309|Active Comparator|Control|
11556412|NCT00959296||Patients with a device implant|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
11556413|NCT00959283||Ancillary-correlative|Patients undergo peripheral blood collection periodically for biomarker analysis. Samples are analyzed for GATA1 mutations by real-time PCR, polymorphisms, cytogenetics, and K-RAS mutations, gene expression, drug sensitivity patterns, and minimal residual disease by flow cytometry.
11556414|NCT00959257||Asthma|Asthma patients on inhaled corticosteroids
11556415|NCT00959257||Control|Select matched controls from the general population database of Cardiovascular Risk Factor Prevalence Study 2 (CRISPS2)
11556416|NCT00959218|Experimental|Dronabinol|
11556417|NCT00959218|Placebo Comparator|Placebo|
11556418|NCT00959205|Active Comparator|Angiography|Conventional fluoroscopically guided activation mapping
11556419|NCT00959205|Experimental|CARTO 3D|CARTO (3D Electroanatomic imaging)
11556420|NCT00959192|Experimental|ACC-001 + QS-21|Active vaccine + adjuvant, IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
11556421|NCT00959192|Placebo Comparator|QS-21|Adjuvant, IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
11556422|NCT00959179||Device therapy patients for CHF.|enroll all consecutive patients undergoing implantable cardioverter defibrillator (ICD) and ICD with biventricular pacemaker (CRT-D) implantation for heart failure from in-patient and out-patient referral setting
11556423|NCT00959179||ICD and CRT-D patients|enroll all consecutive patients undergoing implantable cardioverter defibrillator (ICD) and ICD with biventricular pacemaker (CRT-D) implantation for heart failure from in-patient and out-patient referral setting
11556424|NCT00959166|Other|HIV/acute HCV coinfection|Subjects with HIV/acute HCV coinfection (aHCV cases) were required to have acute HCV, defined by a new positive plasma HCV RNA test within 12 months of a negative HCV RNA test.
11556425|NCT00959166|Other|HIV mono|HIV-infected individuals without hepatitis C co-infection
11556426|NCT00959153|Experimental|Kidney stones|Kidney stones
11556427|NCT00959140|Experimental|CD3+ T-cell depletion|CD3+ T-cell depletion
11556428|NCT00959127|Experimental|ARRY-438162 (MEK 162)|
11556429|NCT00959114|Experimental|ALV003|ALV003 is an orally administered mixture of two recombinant proteases (cysteine endoprotease B-isoform 2 and prolyl endopeptidase) engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues common in gluten.
11556430|NCT00959114|Placebo Comparator|Placebo comparator|Excipients for ALV003 absent the experimental compounds
11556431|NCT00959101|Experimental|A|
11556432|NCT00959101|Experimental|B|
11556433|NCT00959101|Active Comparator|C|
11556434|NCT00959088||1|HIV-infected individuals with suspected TB co-infection.
11556435|NCT00959075|Experimental|Oral thiamin supplementation|Vitamin B1 (Oral thiamin) 100mg BID for 6 months
11556436|NCT00959075|Placebo Comparator|Sugar pill|oral placebo 1 tablet BID for 6 months
11556437|NCT00959062|Experimental|clonidine|
11556438|NCT00959062|Placebo Comparator|placebo|
11556439|NCT00959049|Experimental|Afluria Cohort A|Age 6 months to < 3 years
11556440|NCT00959049|Experimental|Afluria Cohort B|Age 3 to < 9 years
11556441|NCT00959049|Experimental|Afluria Cohort C|Age 9 to < 18 years
11556442|NCT00959049|Active Comparator|Fluzone Cohort A|Age 6 months to < 3 years
11556443|NCT00959049|Active Comparator|Fluzone Cohort B|Age 3 to < 9 years
11556444|NCT00959049|Active Comparator|Fluzone Cohort C|Age 9 to < 18 years
11556445|NCT00959036|Experimental|Treatment Group 1|ATN-103 10 mg every 4 weeks until week 12
11556446|NCT00959036|Experimental|Treatment Group 2|ATN-103 10 mg every 8 weeks until week 12
11556447|NCT00959036|Experimental|Treatment Group 3|ATN-103 30 mg every 4 weeks until week 12
11556448|NCT00959036|Experimental|Treatment Group 4|ATN-103 80 mg every 4 weeks until week 12
11556449|NCT00959036|Experimental|Treatment Group 5|ATN-103 80 mg every 8 weeks until week 12
11556450|NCT00959036|Placebo Comparator|Treatment Group 6|Placebo every 4 weeks
11556451|NCT00959010|Experimental|Omega 3 Premium|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA
11556452|NCT00959010|Placebo Comparator|Placebo|capsules containing middle chain triglycerides
11556455|NCT00958971|Experimental|TKI258 - Positive|These are the participants who had a positive T(4;14) status
11556457|NCT00958971|Experimental|TKI258 Non-interpretable|These are the participants who had a non-interpretable T(4;14) status
11556458|NCT00958958|Other|Quality improvement program|"There are multifaceted Interventions for the clinic hospital team Including
~Distribution of educational materials
~Case manager
~Reminders
~Practical training"
11556459|NCT00958958|No Intervention|Hospital standard treatment|Hospital standard treatment
11556460|NCT00958945||FloSeal - Knee - control|100 Historical Control Patients, knees - no FloSeal (retrospective)
11556461|NCT00958945||FloSeal - Knee - 5ml|100 Patients, knees - 5mL FloSeal (retrospective)
11556462|NCT00958945||FloSeal - Knee - 10ml|100 Patients, knees- 10mL FloSeal (prospective)
11556463|NCT00958945||FloSeal - Hip - Control|100 Historical Control patients, hips-no FloSeal (retrospective)
11556464|NCT00958945||FloSeal - Hip - 5ml|100 retrospective patients, hips-5mL of FloSeal (retrospective)
11556465|NCT00958932|Experimental|Speech recognition (TEAM intervention)|
11556466|NCT00958932|Active Comparator|Speech recognition (Usual care)|
11556467|NCT00958919|Experimental|naloxone|
11556468|NCT00958919|Placebo Comparator|normal saline|
11556469|NCT00958906|Experimental|Intravitreal infliximab|
11556470|NCT00958893|Experimental|25 mg Proellex|25 mg Proellex daily
11556471|NCT00958880|Placebo Comparator|Sugar Pill|Participants will receive placebo (sugar pill) augmented Group Cognitive Behavioral Therapy
11556472|NCT00958880|Experimental|Yohimbine Hydrochloride|Participants will receive Yohimbine Hydrochloride augmented Group Cognitive Behavioral Therapy
11556473|NCT00958867|Experimental|1|Six-month, twice-weekly aerobic training (AT) program
11556474|NCT00958867|Experimental|2|Six-month, twice-weekly resistance training (RT) program
11556475|NCT00958867|Active Comparator|3|Six-month, twice-weekly stretch & relax (S & R; control) program
11556476|NCT00958841|Experimental|pasireotide LAR 60mg|Patients received pasireotide LAR at 60 mg approximately once every 28 days for 6 months during the core treatment period and additional treatment cycles up to a total of 48 months during the extension phase.
11556477|NCT00958828|Other|Nelfilcon A / Narafilcon A|Nelfilcon A contact lenses, then Narafilcon A contact lenses
11556478|NCT00958828|Other|Narafilcon A / Nelfilcon A|Narafilcon A contact lenses, then Nelfilcon A contact lenses
11556479|NCT00958815||HIV-seronegative with no CVD risk factors|Healthy, 35-60 yr old HIV-seronegative men and women with no CVD risk factors (normal fasting glucose tolerance, normal fasting lipid/lipoprotein levels, normotensive, waist circumference <102cm (men) and <88cm (women).
11556480|NCT00958815||HIV+ with CVD risk factors|35-60 yr old HIV-infected men and women with insulin resistance, dyslipidemia, hypertension, and central adiposity.
11556481|NCT00958802|Placebo Comparator|Arm A|Chondrocyte culture with FBS medium
11556482|NCT00958802|Experimental|Arm B|Chondrocyte culture with PRP
11556483|NCT00958789|Other|Triathlon TS Knee|Triathlon TS Knee System
11556484|NCT00958776|Experimental|Peramivir+SOC|"Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
~Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care."
11556485|NCT00958776|Placebo Comparator|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
11556486|NCT00958763|Experimental|Motivational Interviewing, Single - MIS|
11556487|NCT00958763|Experimental|Motivational Interviewing, Group - MIG|
11556488|NCT00958763|Other|Usual Care Group - UCG|
11556489|NCT00958750|Active Comparator|5% MTF|5% minoxidil topical foam used once daily
11556490|NCT00958750|Active Comparator|2% MTS|2% minoxidil topical solution twice daily use
11556491|NCT00958737|Experimental|Arm I|"Patients receive modified FOLFOX 6 comprising oxaliplatin IV 85 mg/m² over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1. Treatment repeats every 14 days for 6 courses (3 months).
~Patients receive XELOX comprising oxaliplatin IV 130 mg/m² over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which will be administered orally at a dose of 1000 mg/m2 twice-daily (equivalent to a total daily dose of 2000 mg/m2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment)"
11556492|NCT00958737|Experimental|Arm II|Patients receive modified FOLFOX 6 or XELOX as in arm I. Treatment repeats every 14 days for 12 courses (6 months)or regarding XELOX every 21 days for 8 courses (6 month).
11556493|NCT00958724|Experimental|Neratinib and Vinorelbine|Neratinib: 240 mg administered daily by mouth continuously, Vinorelbine: 25 mg/m^2 administered IV on Day 1 and 8 of 21 day cycle
11556494|NCT00958711|Experimental|Biologic - Unite Biomatrix|
11556495|NCT00958711|Active Comparator|Saline and Gauze|
11556496|NCT00958698|Experimental|Arm I (nurse-assisted intervention module)|Patients are given password-protected access to their own web-based message board to communicate with a research nurse. The nurse leads patients through WRITE Symptoms? intervention module, with personalized support and advice. The nurse will encourage the patient to try new selected strategies, continue with effective strategies, and work with local health care providers in an ongoing process to improve symptom management.
11556497|NCT00958698|Experimental|Arm II (self-directed intervention module)|Patients are given password-protected access to an interactive web-based computer program that will lead them through a modified WRITE Symptoms? intervention module (comprising the same elements as in arm I) without guidance and individualized recommendations from a nurse. Patients work through 3 selected symptoms using the WRITE Symptoms? intervention module over approximately 4 weeks. The program will generate an encouragement for the patient to try new selected strategies, continue with effective strategies, and continue the new approach to symptom management with local health care providers in an ongoing process to improve symptom management.
11556498|NCT00958698|Active Comparator|Arm III (standard care from local provider)|Patients are given password-protected access to online questionnaires. Patients are prompted monthly to complete online questionnaires. Patients receive standard symptom management from their local health care providers.
11556680|NCT00957385|Active Comparator|A|Arm A will receive Revlimid.
11556499|NCT00958685|Experimental|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
11556500|NCT00958685|Experimental|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
11556501|NCT00958659||Ancillary-Correlative (gene expression profiling)|Previously collected samples are analyzed for 59 prognostic genes by real-time quantitative PCR-based gene expression profiling.
11556502|NCT00958646|Experimental|Osteopathic Manipulation|Standardized OMT procedure
11556503|NCT00958646|Placebo Comparator|Placebo|Light touch placebo procedure
11556504|NCT00958633|Active Comparator|8 week arm|"During the double-blind phase, all patients will continue treatment with their anti-manic medication(s)and will be randomized to one of two treatment arms for up to 52 weeks:
~Group 1 patients randomized to the 8 week arm will discontinue antidepressant treatment after 8 weeks, as recommended in current clinical practice guidelines. The antidepressant will be tapered in a double-blind manner beginning at 6 weeks, and will be substituted with placebo by 8 weeks.
~Escitalopram 10 - 30 mg Wellbutrin XL 150 - 450 mg"
11556505|NCT00958633|Active Comparator|52 week arm|"During the double-blind phase, all patients will continue treatment with their anti-manic medication(s) and will be randomized to one of two treatment arms for up to 52 weeks:
~Group 2 patients randomized to the 52 week arm will continue treatment with their antidepressant medication for 52 weeks, or until withdrawal from the study.
~Escitalopram 10 - 30 mg Wellbutrin XL 150 - 450 mg"
11556506|NCT00958620|Active Comparator|Active ESWT|
11556507|NCT00958620|Sham Comparator|Sham ESWT|
11556508|NCT00958607|Active Comparator|Self-Directed Program|
11556509|NCT00958607|Active Comparator|Stroke Support Person|
11556510|NCT00958607|No Intervention|Standard Care|"Participants in this arm receive Standard Care which consists of being given a copy of the Heart& Stroke Foundation's stroke resource titled Let's Talk About Stroke"
11556511|NCT00958581|Placebo Comparator|Normal Saline|Patients infused with normal saline before and during the surgical procedure as a placebo.
11556512|NCT00958581|Experimental|Tranexamic acid|Patients receive TXA before and during the surgical case.
11556513|NCT00958581|Experimental|Epsilon Aminocaproic Acid|Patients will receive EACA before and during the surgical case.
11556514|NCT00958568|Experimental|Olanzapine and Fluoxetine combination (OFC)|
11556515|NCT00958568|Active Comparator|Fluoxetine|
11556516|NCT00958542|Experimental|Surgical Arm|Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
11556517|NCT00958542|No Intervention|Non-Surgical Arm|Non-Surgical No intervention - Includes patients who have either refused to have surgery or have not been recommended to have surgery at this point. These patients will continue to be monitored closely, however, will not receive any other intervention.
11556518|NCT00958529|Experimental|inulin|0, 5, 10 g inulin
11556519|NCT00958516|Experimental|LEO 29102 cream|
11556520|NCT00958503|Placebo Comparator|Placebo|Placebo
11556521|NCT00958503|Active Comparator|Thiamphenicol|Active comparator
11556522|NCT00958490|Active Comparator|First walking group|Group walking at 2 months postop
11556523|NCT00958490|Active Comparator|Second group walking|Group walking at 3 months postop
11556524|NCT00958477|Experimental|EMD 525797|
11556525|NCT00958464||1|MRI protocol on 2 separate occasions
11556526|NCT00958451|Active Comparator|Paricalcitol|Arm 1: 40 patients will be assigned to paricalcitol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.
11556527|NCT00958451|Active Comparator|Ergocalciferol|Arm 2: 40 patients will be assigned to the Ergocalciferol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.
11556528|NCT00958438|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept ) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
11556529|NCT00958438|Experimental|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.
11556530|NCT00958438|Experimental|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
11556531|NCT00958425|Experimental|Hyaluronic acid gel|
11556532|NCT00958425|Active Comparator|Saline|
11556533|NCT00958412|Experimental|Proellex®|25 mg Proellex®
11556534|NCT00958399|Placebo Comparator|No fiber|No fiber added to study products
11556535|NCT00958399|Experimental|Resistant Starch|Muffins, cereal, and bars made with a resistant starch
11556536|NCT00958399|Experimental|Resistant starch + soluble fiber|Muffins, cereal, and bars made with a mixture of resistant starch and a soluble fiber
11556537|NCT00958399|Experimental|Fiber made from corn starch|Muffins, cereal, and bars made with novel corn fiber
11556538|NCT00958399|Experimental|Fiber made from corn starch + soluble fiber|Muffins, cereal, and bars made with a mixture of novel corn fiber and a soluble fiber
11556539|NCT00958386|Experimental|1|Panitumumab+irinotecan
11556681|NCT00957385|No Intervention|B|Arm B will not receive Revlimid but an observational arm
11556540|NCT00958360|Experimental|Arm 1|Interdisciplinary Low Vision Rehabilitation: Low vision examination, prescription and dispensing of low vision devices, low vision therapy and homework.
11556541|NCT00958360|Active Comparator|Arm 2|Basic Low Vision Care: Low vision examination, prescription and dispensing of low vision devices without low vision therapy or assigned homework.
11556542|NCT00958347|Other|Omnifit HA Hip Stem|Participants underwent total hip replacement surgery using the Omnifit HA Hip Stem.
11556543|NCT00958334|Experimental|Proellex 25 mg|Two Proellex® 12.5 mg capsules once daily
11556544|NCT00958334|Experimental|Proellex 12.5 mg|One Proellex® 12.5 mg capsules once daily
11556545|NCT00958334|Placebo Comparator|Placebo|Capsule once a day
11556546|NCT00958321|Experimental|3-DCRT|Patients will receive a total dose of 60-66 Gy in 30-33 fractions with 3-DCRT
11556547|NCT00958308|Placebo Comparator|Placebo|Two capsules of placebo (devoid of microorganisms) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
11556548|NCT00958308|Active Comparator|BIO-K+ CL-1285|Two probiotic capsules (BIO-K+ CL-1285®) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
11556549|NCT00958308|Other|BIO-K+ CL-1285® & placebo|One probiotic capsule (BIO-K+ CL-1285®) and one placebo capsule (devoid of microorganisms) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
11556550|NCT00958282|Active Comparator|lisdexamfetamine/Behavior Therapy|lisdexamfetamine 70mg/day plus Behavior Therapy
11556551|NCT00958282|Placebo Comparator|placebo|Placebo Comparator once per day
11556552|NCT00958269|Experimental|dutogliptin (double-blind, placebo-controlled period)|weeks 1-26
11556553|NCT00958269|Experimental|dutogliptin (single-blind, active-controlled period)|weeks 27-52
11556554|NCT00958269|Placebo Comparator|placebo (double-blind, placebo-controlled period)|weeks 1-26
11556555|NCT00958269|Placebo Comparator|placebo (single-blind, active-controlled period)|weeks 27-52
11556556|NCT00958269|Active Comparator|sitagliptin (single-blind, active-controlled period)|weeks 27-52
11556557|NCT00958256|Experimental|Bortezomib with Cyclophosphamide and Rituximab|Bortezomib 1.3 mg/m^2 intravenously (IV) on Days 1, 4, 8, and 11 of the cycle; Cyclophosphamide 300 mg/m^2 IV every 12 hours on Days 2, 3, and 4, and Rituximab 375 mg/m^2 IV on Day 1. Mesna 600 mg/m^2 for 3 days, G-CSF 5 micrograms/kg subcutaneously daily for 7 days after last dose of Bortezomib. Cycles repeated every 21 days for up to six cycles.
11556558|NCT00958243|Placebo Comparator|Placebo|Placebo
11556559|NCT00958243|Experimental|CSL425 (7.5 mcg)|7.5 mcg of hemagglutinin antigen per dose
11556560|NCT00958243|Experimental|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose
11556561|NCT00958230|Experimental|dCell Vascular Patch|This Xenograft device is manufactured from Porcine Pericardium Tissue which has been decellularised leaving a scaffold style structure for ingrowth of human endothelial cells after placement into the operative site.
11556562|NCT00958217|Experimental|Cognitive Processing Therapy-Modified|12 individually delivered sessions of Cognitive Processing Therapy-Modified (CPT-M) provided once weekly following initial group delivery of 12 sessions of Integrated Cognitive Behavioral Therapy
11556563|NCT00958217|Active Comparator|Integrated Cognitive Behavioral Therapy|12 individually delivered sessions of Integrated Cognitive Behavioral Therapy (ICBT) once weekly following initial group delivery of 12 sessions of ICBT
11556564|NCT00958217|No Intervention|Integrated Cognitive Behavioral Group Therapy|All participants were enrolled in an initial group-delivered Integrated Cognitive Therapy Group, consisting of 12 sessions over approximately 12 weeks prior to randomization to one of the study individually delivered interventions (CPT-M or ICBT). Individuals who were no longer participating in the study at the end of group sessions were not randomized.
11556565|NCT00958204|Experimental|1|Light treatment using a fluorescent light box (30 minutes daily) plus a placebo pill every day
11556566|NCT00958204|Experimental|2|Negative ion generator (30 minutes daily) plus 20 mg of fluoxetine per day
11556567|NCT00958204|Active Comparator|3|Light treatment using a fluorescent light box (30 minutes daily) plus 20 mg of fluoxetine per day
11556568|NCT00958204|Placebo Comparator|4|Negative ion generator (30 minutes daily) plus placebo pill every day
11556569|NCT00958191|Other|Trident® X3 Polyethylene Insert|Participants who received the Trident® X3 Polyethylene Insert.
11556570|NCT00958178|Experimental|Rebreathing method of preoxygenation|Subjects will breathe Oxygen through a close fitting mask, but the flow will be low so that they rebreathe some of their expired air. After 30 seconds, the flow will be turned up so that they will breathe 100% Oxygen.
11556571|NCT00958178|Active Comparator|T method of preoxygenation|Tidal breathing of 100% oxygen through a well fitting facemask, for 4 minutes.
11556572|NCT00958165|Experimental|EAS-AC|PVI with EAS-AC
11556573|NCT00958152|Experimental|Cohort 1|
11556574|NCT00958152|Experimental|Cohort 2|
11556575|NCT00958152|Experimental|Cohort 3|
11556576|NCT00958139|Experimental|Permethrin treatment of clothing|0.5% permethrin sprayed one time on uniform shorts, pants, and socks
11556577|NCT00958139|Sham Comparator|Placebo|Water sprayed on uniform shorts, pants, and socks
11556578|NCT00958126|Experimental|CSL425 (7.5 mcg)|7.5 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
11556579|NCT00958126|Experimental|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
11556580|NCT00958126|Experimental|CSL425 (30 mcg)|30 mcg of hemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
11556581|NCT00958126|Placebo Comparator|Placebo|Vaccine diluent. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
11556582|NCT00958113||Autoimmune Thyroid Disease|Patients with Hashimoto's disease or Graves' disease
11556583|NCT00958113||Unaffected Population|Population not known to be affected by Hashimoto's Disease or Graves' Disease
11556682|NCT00957372|Experimental|ESL 800 mg daily (Part I)|ESL 800mg daily
11556584|NCT00958100|Experimental|Tenofovir Emtricitabine Raltegravir|Patients switching to raltegravir with tenofovir+emtricitabine as backbone
11556585|NCT00958100|Experimental|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
11556586|NCT00958100|Experimental|Abacavir free|Patients switched to raltegravir whose backbone therapy should not be randomized in order to avoid the use of abacavir (HLA-B*5701 positive patients,Framingham score 20% or higher)
11556587|NCT00958087||Sarcoidosis with cardiac involvement|
11556588|NCT00958087||Dilated cardiomyopathy|
11556589|NCT00958087||Sarcoidosis without cardiac involvement|
11556590|NCT00958087||Healthy controls|
11556591|NCT00958074|Experimental|Cohort I (>=65 years old)|200 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
11556592|NCT00958074|Experimental|Cohort II (<65 years old)|400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
11556593|NCT00958061||Vietnam-Era Women Veterans|For this study we will use a cohort of women who are on a roster of Vietnam Era women veterans (4,644 Vietnam, 1,213 near Vietnam, 5,465 non-Vietnam) previously identified and characterized by a review of their military personnel records and link it to a list of 8,061 women who presumably served in Southeast Asia. This final cohort could potentially contain approximately 14,000 women. After deceased individuals are removed from the active cohort and contact information is updated, we estimate that there could be approximately 10,000 women to whom the informed consent and mailed survey will be initially mailed.
11556594|NCT00958048|Experimental|2|ALS with non-invasive ventilation
11556595|NCT00958048|No Intervention|1|ALS without non-invasive ventilation
11556596|NCT00958035|Experimental|LATISSE®|bimatoprost ophthalmic 0.03% solution
11556597|NCT00958035|Placebo Comparator|Placebo|vehicle sterile solution
11556598|NCT00958022|Experimental|LBH589 and carboplatin with etoposide|"The main goal during the Phase I portion of this research study is to find out the highest and safest dose of LBH589 that can be given in combination with carboplatin with etoposide in subjects with lung cancer without causing severe side effects. The main goal of the Phase II portion of this study is to find how lung cancer responds to the LBH589 in combination with carboplatin and etoposide.
~This study will also investigate how the body processes the combination of LBH589 and carboplatin with etoposide."
11556599|NCT00957996|Experimental|Peramivir 300 mg|Peramivir 300 mg twice daily
11556600|NCT00957996|Experimental|Peramivir 600 mg|Peramivir 600 mg once daily
11556601|NCT00957983|Active Comparator|BGC20-1531 200mg|
11556602|NCT00957983|Placebo Comparator|sugar pill|
11556603|NCT00957983|Active Comparator|BGC20-1531 400mg|
11556604|NCT00957970|Active Comparator|Stemless femoral component|Stemless PROXIMA femoral component
11556605|NCT00957970|Active Comparator|Stemmed femoral component|IPS, proximal anatomical fit stemmed femoral component
11556606|NCT00957957||1|Participants having elective Roux-en-Y gastric bypass surgery (RYGBP)
11556607|NCT00957957||2|Participants having elective gastric banding surgery (GB)
11556608|NCT00957944|Experimental|Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)|Two single applications of rotigotine patches from two different manufacturing sites in the order A-B separated by a washout phase of at least 5 days
11556609|NCT00957944|Experimental|Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)|Two single applications of rotigotine patches from two different manufacturing sites in the order B-A separated by a washout phase of at least 5 days
11556610|NCT00957931|Experimental|Mesenchymal stromal cells|
11556611|NCT00957918|Experimental|Nicotine|Active drug is nicotine dihydrate bitartrate, provided as an oral capsule at escalating doses, 1 mg to 6 mg, once every 6 hours
11556612|NCT00957918|Placebo Comparator|placebo|Subjects in this arm receive placebo capsules orally
11556613|NCT00957905|Experimental|Part A (alvocidib and oxaliplatin)|Patients receive alvocidib IV over 1 hour and oxaliplatin IV over 2 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11556614|NCT00957905|Experimental|Part B (alvocidib and FOLFOX)|Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours followed by fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11556615|NCT00957879|Active Comparator|ergocalciferol|Weekly ergocalciferol for 12 weeks
11556616|NCT00957879|Active Comparator|calcitriol|Daily calcitriol for 12 weeks
11556617|NCT00957853|Experimental|Group 1: Cetuximab|Cetuximab: 400 mg/m2 i.v. over 120 minutes on week 1, and 250 mg/m2 on week 2 and 3 i.v. over 60 minutes
11556618|NCT00957853|Experimental|Group 2: IMC-A12|IMC-A12: 6 mg/kg/week i.v. over 1 hour on weeks 1 and 2 and 3.
11556619|NCT00957853|Experimental|Group 3: Cetuximab + IMC-A12|"Cetuximab: 400 mg/m2 i.v. over 120 minutes on week 1, and 250 mg/m2 on week 2 and 3 i.v. over 60 minutes.
~IMC-A12: 6 mg/kg/week i.v. over 1 hour on weeks 1 and 2 and 3."
11556620|NCT00957840|Other|Omaya reservoir group- observational|These infants have been identified with severe enough post hemorrhagic ventricular dilation (PHVD) that they require a reservoir placed for serial cerebro-spinal fluid (CSF) removal. There is no randomization, and infants are compared to a baseline. Observational data will be collected to include NIRS and aEEg which will be done twice weekly, and CSF will be analyzed with each reservoir tap for protein biomarkers.
11556621|NCT00957827|Experimental|keflex|keflex 500mg twice a day for five days
11556622|NCT00957827|Placebo Comparator|placebo|placebo 500mg twice a day for five days
11556623|NCT00957814|Experimental|Control|Usual care with medical and nursing staff
11556624|NCT00957814|Experimental|Intervention|Usual care with medical and nursing staff and additional nutritional guidance about diet and its relationship with disease, sources of nutrients, and reduction of dietary sodium and fats. Enforcement of the nutritional guidance was performed after 4 weeks.
11556625|NCT00957801|Active Comparator|Testosterone injection|Testosterone enanthate given as a single 100 mg Intramuscular (IM) injection
11556626|NCT00957801|Active Comparator|Testosterone gel|Testosterone topical gel (Androgel 1%) 10 mg administered daily for seven days
11556627|NCT00957801|Active Comparator|Testosterone injection and Medrol 6 day dose pack|Testosterone enanthate given as a single 100mg Intramuscular (IM) injection. Medrol 6 day dose pack was administered as directed with daily doses decreasing by 4mg per day with an additional 4mg given on day 7. Day one dose: 24mg, day two dose: 20mg, day three dose: 16mg, day four dose: 12mg, day five dose: 8mg, day six dose: 4 mg, day seven dose: 4mg.
11556628|NCT00957801|Active Comparator|Medrol 6 day dose pack|Medrol 6 day dose pack was administered as directed with daily doses decreasing by 4mg per day with an additional 4mg given on day 7. Day one dose: 24mg, day two dose: 20mg, day three dose: 16mg, day four dose: 12mg, day five dose: 8mg, day six dose: 4 mg, day seven dose: 4mg.
11556629|NCT00957788|Experimental|Cohort 0|
11556630|NCT00957788|Experimental|Cohort 1|
11556631|NCT00957788|Experimental|Cohort 2|
11556632|NCT00957788|Experimental|Cohort 3|
11556633|NCT00957775|Active Comparator|Usual care|Participants will receive the usual care (e.g., individual therapy, group therapy, self-help groups) provided at the treatment site.
11556634|NCT00957775|Experimental|Computer-delivered ACRA|Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
11556635|NCT00957762||Body Composition|120 subjects will help create the regression models. The remaining 50 subjects will be recruited to determine if the equations work for the population.
11556636|NCT00957749|Experimental|cPMP|
11556637|NCT00957736||Allogeneic stem cell transplant|Stem cells from a genetically non-identical donor transplanted into a patient.
11556638|NCT00957723|Other|Triathlon® CR Total Knee System|Participants receive the Triathlon® CR Total Knee System
11556639|NCT00957710|Other|langauge therapy|Naming therapy
11556640|NCT00957684|Experimental|ESL 400 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
11556641|NCT00957684|Experimental|ESL 800 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
11556642|NCT00957684|Experimental|ESL 1200 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
11556643|NCT00957684|Placebo Comparator|placebo|Placebo matching tablets
11556644|NCT00957684|Experimental|ESL - PART II|During Part II of the study all patients received Eslicarbazepine Acetate (ESL), including those who had been treated with placebo during Part I. ESL was supplied as scored 800 mg tablets; once daily administration by oral route.
11556645|NCT00957671|Experimental|Human Growth Hormone|recombinant human growth hormone (rhGH) self administered daily for one year
11556646|NCT00957658|Other|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem Study Device
11556647|NCT00957619|Active Comparator|pentoxyfilline group|pentoxyfilline group
11556648|NCT00957619|Placebo Comparator|placebo group|placebo group
11556649|NCT00957593|Active Comparator|Oxytocin|Continuation of oxytocin per protocol once the patient reaches active labor
11556650|NCT00957593|Active Comparator|Oxytocin discontinuation|Oxytocin will be stopped once the patient reaches active labor
11556651|NCT00957580|Experimental|Regimen 1 (Part 1)|
11556652|NCT00957580|Experimental|Regimen 2 (Part 1)|
11556653|NCT00957580|Experimental|Regimen 3 (Part 1)|
11556654|NCT00957580|Experimental|Regimen 1 (Part 2)|
11556655|NCT00957580|Experimental|Regimen 2 (Part 2)|
11556656|NCT00957554|Experimental|irbesartan/amlodipine|Before randomisation: irbesartan 150 mg for 7 to 10 days (common in the 2 arms) then After randomisation: irbesartan/amlodipine 150/5 mg fixed combination for 5 weeks followed by irbesartan/amlodipine 300/5 mg fixed combination for additional 5 weeks
11556657|NCT00957554|Active Comparator|irbesartan|Before randomisation: irbesartan 150 mg for 7 to 10 days (common in the 2 arms) then After randomisation: irbesartan 150 mg for 5 weeks followed by irbesartan 300 mg for 5 additional weeks
11556658|NCT00957541|Experimental|CRT Therapy|All patients will receive CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
11556659|NCT00957528|Placebo Comparator|Placebo|Weekly placebo treatment for a duration of 5 months.
11556660|NCT00957528|Experimental|Monthly Cycled Testosterone|A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.
11556661|NCT00957528|Experimental|Continuous Testosterone|Weekly testosterone treatment for a duration of 5 months
11556662|NCT00957502|Experimental|One year aged staples|Subjects implanted with sterile staples aged to approximately one year.
11556663|NCT00957502|Experimental|18 month aged staples|Subjects implanted with sterile staples aged to approximately 18 months.
11556664|NCT00957489|Experimental|Functional appliance|
11556665|NCT00957476|Active Comparator|Omega-3 Fish Oil|800mg DHA & 1200mg EPA
11556666|NCT00957476|Placebo Comparator|Placebo|Wheat germ oil
11556667|NCT00957463||smoker, with high apnea-hypopnea index|subjects who smoke either in the past or currently, with confirmed moderate-severe OSA
11556668|NCT00957463||smoker, mild OSA or without OSA|subjects who smoke either in the past or currently, with mild OSA or without OSA
11556669|NCT00957463||nonsmoker, with high apnea-hypopnea index|subjects who never smoke, with confirmed moderate-severe OSA
11556670|NCT00957463||nonsmoker, with mild OSA or without OSA|subjects who never smoke, with mild OSA or without OSA
11556671|NCT00957450||1|"Impact of organ motion
~Characterize the impact of normal organ motion in the pelvic on tumour movement, during treatment. This will be assessed in patients with pelvic cancer."
11556672|NCT00957437|Experimental|Part A: 3 way crossover|AZD1305: ER test formulation 1 (w/wo food) and reference formulation
11556673|NCT00957437|Experimental|Part B1: single arm|AZD1305: ER test formulation 1
11556674|NCT00957437|Experimental|Part B2: 3 way crossover|AZD1305: ER test formulation 2 (w/wo food) and reference formulation
11556675|NCT00957424|Other|Overall|Single-armed study
11556676|NCT00957411|Active Comparator|Arm I|Patients receive cisplatin IV over 1 hour once weekly during weeks 1-6. Patients also undergo pelvic radiotherapy 5 days a week during weeks 2-5 or 2-6.
11556677|NCT00957411|Experimental|Arm II|Patients receive cisplatin and undergo radiotherapy as in arm I. Patients also receive cetuximab IV over 1 hour once weekly during weeks 1-6.
11556678|NCT00957398||IBS-D|12 IBS-D patients who will all undergo MTS.
11556679|NCT00957398||IBS-C|12 IBS-C patients who will all undergo MTS.
11556683|NCT00957372|Experimental|ESL 1200 mg daily (Part I)|ESL 1200mg daily
11556684|NCT00957372|Placebo Comparator|placebo (Part I)|placebo
11556685|NCT00957372|Experimental|ESL - Open-label Extension (Part II)|All patients were treated with only ESL during Part II.
11556686|NCT00957359|Experimental|Psilocybin|Drug intervention
11556687|NCT00957359|Active Comparator|Niacin|Active control
11556688|NCT00957346|Experimental|Mifepristone + Misoprostol|200 mg mifepristone followed by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
11556689|NCT00957346|Placebo Comparator|Misoprostol|Placebo resembling 200mcg mifepristone followed by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses
11556690|NCT00957333||case|ketamine + Cystitis
11556691|NCT00957320|Experimental|1|"Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL. The dose of sirolimus will be dose escalated following standard phase 1 statistical methods.
~For patients with active CNS leukemia, intrathecal methotrexate, hydrocortisone and cytarabine (triple IT) will be administered weekly, with leucovorin rescue at the treating physician's discretion."
11556692|NCT00957294||Schizophrenia|Patients with first-episode schizophrenia age 18-45 years
11556693|NCT00957294||Depression|First-time hospitalized patients with depression age 18-45 years
11556694|NCT00957294||healthy controls|Healthy controls matched on age and gender (18-45 years)
11556695|NCT00957281||Asthma|Asthma patients on inhaled corticosteroids
11556696|NCT00957268|Experimental|Alogliptin 12.5 mg (age 10 to < 14 years)|Alogliptin 12.5 mg, tablets, orally, 1 dose only.
11556697|NCT00957268|Experimental|Alogliptin 25 mg (age 10 to < 14 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
11556698|NCT00957268|Experimental|Alogliptin 12.5 mg (age 14 to < 18 years)|Alogliptin 12.5 mg, tablets, orally, 1 dose only.
11556699|NCT00957268|Experimental|Alogliptin 25 mg (age 14 to < 18 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
11556700|NCT00957268|Experimental|Alogliptin 25 mg (age 18 to 65 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
11556701|NCT00957255|Active Comparator|RCR without augmentation|Rotator cuff repair without OrthoADAPT augmentation
11556702|NCT00957255|Experimental|RCR with augmentation|Rotator cuff repair with OrthoADAPT augmentation
11556703|NCT00957242|Active Comparator|warfarin|Oral warfarin titrated to an international normalization ratio (INR) of 2-3
11556704|NCT00957242|Placebo Comparator|placebo|Oral placebo (1mg or 2.5mg)
11556705|NCT00957229|Placebo Comparator|Sugar pill|placebo pill by mouth once daily
11556706|NCT00957229|Experimental|GDC-0449|vismodegib 150MG by mouth once daily
11556707|NCT00957216|Placebo Comparator|sugar pill|
11556708|NCT00957216|Active Comparator|Coenzyme Q10|The CoQ10 arm will be compared with the placebo arm to determine if high-dose CoQ10 is safe and well tolerated in subjects with sporadic adult-onset spinocerebellar ataxias
11556709|NCT00957203|Experimental|Istradefylline|
11556710|NCT00957190|Experimental|Cosopt|Cosopt ('Dorzolamide 20 mg and Timolol 5 mg) bid And Xalatan hs Vs Xalatan hs Alone
11556711|NCT00957177|Placebo Comparator|Placebo|Placebo
11556712|NCT00957177|Active Comparator|Pregabalin group|Receiving 300mg pregabalin preoperative
11556713|NCT00957164|Active Comparator|Pain Treatment Only|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
11556714|NCT00957164|Active Comparator|PTSD Treatment Only|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
11556715|NCT00957164|Active Comparator|Combined Pain and PTSD Treatment|This treatment arm will involve 5 sessions each of the Pain-Only and PTSD-Only treatments described above.
11556716|NCT00957164|No Intervention|Treatment as Usual|The treatment as usual group will complete the assessments given in each of the other study arms, but will not participate in treatment through the study. Instead, participants randomized to this group will be encouraged to seek treatment for pain and/or PTSD through existing channels. Referrals for treatment will be made for those with clinically significant symptoms for pain and/or PTSD at intake.
11556717|NCT00957125|Experimental|Epirubicin Docetaxel Bevacizumab|"Epirubicin and docetaxel i.v. infusion q 3 weeks for 2 cycles.
~If complete response this treatment continues for 4 cycles, totally 6 cycles.
~If partial response or stable disease, epirubicin and docetaxel and bevacizumab i.v. infusion q 3 weeks for 4 cycles.
~If progressive disease after the first 2 cycles individualized treatment."
11556718|NCT00957112|Experimental|Arm I|Patients undergo a 20-minute acupuncture session once a week for 6 weeks. Patients also receive written information about fatigue and its possible management.
11556719|NCT00957112|No Intervention|Arm II|Patients receive standard care. They also receive written information about fatigue as in arm I.
11556720|NCT00957112|Experimental|Arm A|Patients receive treatment as in arm I for 4 more weeks.
11556721|NCT00957112|No Intervention|Arm B|Patients receive standard care as in arm II for 4 more weeks.
11556722|NCT00957112|Experimental|Arm C|Patients learn to self-acupuncture and do so weekly for 4 more weeks.
11556723|NCT00957099||Imaging|Women diagnosed with breast cancer having pre-treatment MRI for spread of disease
11556724|NCT00957086|Active Comparator|Nimotuzumab|Comprising Adjuvant Cisplatin, Concurrent RT and Nimotuzumab
11556725|NCT00957086|Placebo Comparator|Placebo|Comprising Adjuvant Cisplatin, Concurrent RT and Placebo
11556726|NCT00957073|Experimental|Device|Rheos® system
11556727|NCT00957073|No Intervention|Medical Management|Medical Management Therapy
11556728|NCT00957060|Experimental|glimepiride|The initial dose is 2 mg once a day. At week 2, the dose can be increased to 4 mg once a day according to the titration. At week 4 and 12, the dose can be increased from 2 mg to 4 mg or from 4 mg to 6 mg according to the titration.
11556729|NCT00957060|Active Comparator|sitagliptin|100 mg once a day. The dose will not be titrated.
11556730|NCT00957047|Experimental|ESL 400 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 400 mg tablets for Part I
11556731|NCT00957047|Experimental|ESL 800 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 800-mg tablets for Part I
11556732|NCT00957047|Experimental|ESL 1200 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 400-mg and 800-mg tablets for Part I
11556733|NCT00957047|Placebo Comparator|placebo|Placebo tablets matching the 400-mg and 800-mg active substance tablets were supplied
11556734|NCT00957047|Experimental|ESL - Part II|All patients in Part II (Open-label Extension ) received ESL on an open-label basis, starting at 800 mg once daily.
11556735|NCT00957034|Placebo Comparator|placebo|placebo patch
11556736|NCT00957034|Experimental|300 µg/day testosterone|300 micrograms/day transdermal testosterone patch
11556737|NCT00957034|Experimental|450 µg/day testosterone|450 micrograms/day transdermal testosterone patch
11556738|NCT00957021|Other|Triathlon® PS Total Knee System|Triathlon® PS Total Knee System
11556739|NCT00957008|Experimental|A - GWL|Group Weight Loss Program (GWL) - Participants in this group attended a 14-session group weight loss program administered by trained facilitators plus 6 one-on-one telephone sessions with a facilitator.
11556740|NCT00957008|Experimental|B - GWL+SWA|Group weight loss program plus use of the Senseware Armband - Participants in this group attended a 14-session group weight loss program administered by trained facilitators plus 6 one-on-one telephone sessions with a facilitator and wore a SenseWear Armband. The SenseWear system includes the Armband, a real-time display device, and a personalized Weight Management Solutions web account. Participants received training in using the Armband and were asked to wear it at least 16 hours per day.
11556741|NCT00957008|Experimental|C - SWA Alone|Use of the senseware armband alone program - The intervention for the SWA Alone group was the SenseWear system includes the Armband, a real-time display device, and a personalized Weight Management Solutions web account. Participants received training in using the Armband and were asked to wear it at least 16 hours per day.
11556742|NCT00957008|No Intervention|D - Standard Care|Standard Care - Participants in this group received a self-directed weight loss manual that focused on cognitive and behavior change principles and learning activities based on Active Living Every Day and Healthy Eating Every Day
11556743|NCT00956969|Experimental|Anger awareness and expression|Training for anger awareness and expression
11556744|NCT00956969|Active Comparator|Relaxation Training|Teach patients relaxation training
11556745|NCT00956969|No Intervention|No-treatment control|Assessment only control condition
11556746|NCT00956956|Experimental|PF-04455242 treatment|
11556747|NCT00956956|Placebo Comparator|Placebo|
11556748|NCT00956943|Active Comparator|21mg transdermal nicotine + placebo patch|21mg transdermal nicotine + placebo patch
11556749|NCT00956943|Experimental|42mg transdermal nicotine|42mg transdermal nicotine
11556750|NCT00956930|Experimental|Arm I (radioembolization)|Patients undergo radioembolization with yttrium Y 90 glass microspheres by hepatic artery infusion for approximately 1-3 courses.
11556751|NCT00956930|Experimental|Arm II (transarterial chemoembolization [TACE])|Patients undergo TACE with mitomycin C, doxorubicin hydrochloride, and cisplatin by hepatic artery infusion for approximately 1-3 courses.
11556752|NCT00956917|Active Comparator|Akern EFG|
11556753|NCT00956917|Active Comparator|RJL device|
11556754|NCT00956904|Experimental|3-D TRUS navigation software during T-RALP|
11556755|NCT00956891||group A|autologous MSCs transplantation were performed plus medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin)
11556756|NCT00956891||group B|only medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin) were performed without autologous MSCs transplantation.
11556757|NCT00956878||Cancer Pain Patients|
11556758|NCT00956865|Active Comparator|Voucher|Voucher for transportation reimbursement
11556759|NCT00956865|Active Comparator|Voucher and call|Voucher for transportation and telephone calls
11556760|NCT00956865|Active Comparator|Voucher and call and contact|Voucher for transportation, telephone calls, and a contact at the senior center
11556761|NCT00956852||Lung cancer|Non-small cell lung cancer patients undergoing surgical lung resections
11556762|NCT00956839|Active Comparator|Group A|IM Vitamin D3 3,00,000 Units single dose
11556763|NCT00956839|Active Comparator|Group B|IM vitamin D3 6,00,000 Units single dose
11556764|NCT00956839|Active Comparator|Group C|Oral vitamin D3 500 Units/ day
11556765|NCT00956826|Experimental|Electrode added to device|With an electrode and a regular vacuum device
11556766|NCT00956813|Experimental|Arm I|Patients receive oral flaxseed in the form of a bar similar to a granola bar once daily.
11556767|NCT00956813|Placebo Comparator|Arm II|Patients receive oral placebo bar once daily.
11556768|NCT00956800|Experimental|telemedicine/study group|
11556769|NCT00956800|Active Comparator|control group|
11556770|NCT00956787|Experimental|Treatment with AR-67|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days.
11556771|NCT00956774|Active Comparator|Balloon Catheter|
11556772|NCT00956774|Active Comparator|Cervical Vacuum Cup|
11556773|NCT00956774|Active Comparator|acorn-tipped cannula|
11556774|NCT00956761|Experimental|1|
11556775|NCT00956748|Active Comparator|Ciprodex otic solution|ciprofloxacin 0.3% / dexamethasone 0.1% otic solution
11556776|NCT00956748|Experimental|Ciprodex with 2% NAC|Ciprodex otic solution (ciprofloxacin 0.3% / dexamethasone 0.1%) augmented with 2% N-acetylcysteine
11556777|NCT00956735|Experimental|Pistachio Diet|Incorporates 3.0 oz (2 servings) of pistachios into a daily diet
11556778|NCT00956735|No Intervention|Non-Pistachio|Does not incorporate pistachios into a daily diet
11556779|NCT00956722|Experimental|Treatment|Active treatment with Bovine colostrum
11556780|NCT00956709|Active Comparator|Levobupivacaïne 0,5 %|
11556781|NCT00956709|Active Comparator|Ropivacaïne 0,5%|
11556782|NCT00956696||Topiramte|single arm, flexible dosing
11556783|NCT00956683|Experimental|Ultrasound|Ultrasound guided infraclavicular block
11556784|NCT00956683|Active Comparator|Dual Endpoint Nerve Stimulator|Nerve stimulator guided dual endpoint infraclavicular block
11556785|NCT00956670|Experimental|Supportive care (lymphedema assessment)|"Patients with vulvar cancer undergo a radical vulvectomy or hemi-vulvectomy followed immediately by an ipsilateral or bilateral inguinal-femoral lymphadenectomy. (Closed to accrual as of June 9, 2014)
~Patients with cervical cancer undergo a radical hysterectomy or trachelectomy and bilateral pelvic lymphadenectomy +/- para-aortic nodal sampling via vaginal, laparoscopic, or open route.
~Patients with endometrial cancer undergo a laparoscopic-assisted vaginal hysterectomy, a total laparoscopic hysterectomy, or total abdominal hysterectomy with pelvic lymphadenectomy +/- para-aortic node sampling.
~Patients undergo limb measurements at baseline, weeks 4-6, and at 3, 6, 9, 12, 18, and 24 months."
11556786|NCT00956644|Experimental|irbesartan/amlodipine|Before randomisation : amlodipine 5 mg for 7 to 10 days (common to 2 arms) then After randomisation : irbesartan/amlodipine 150/5 mg fixed combination for 5 weeks followed by irbesartan/amlodipine 150/10 mg fixed combination for 5 additional weeks
11556787|NCT00956644|Active Comparator|amlodipine|Before randomisation : amlodipine 5 mg for 7 to 10 days (common to 2 arms) then After randomisation : amlodipine 5 mg for 5 weeks followed by amlodipine 10 mg for 5 additional weeks
11556788|NCT00956631|Other|interlaminar decompression|Commercially available product (mild® Device Kit) used to perform interlaminar decompression
11556789|NCT00956605|Experimental|EEG biofeedback intervention|
11556790|NCT00956605|Active Comparator|Non EEG biofeedback computerized attention training|
11556791|NCT00956605|No Intervention|waitlist control|
11556792|NCT00956592|Active Comparator|CMAC Video laryngoscope|Subjects will have their intubation attempted first with the CMAC video laryngoscope
11556793|NCT00956592|Active Comparator|Macintosh blade|Patients will have their first intubation attempted utilizing the conventional Macintosh design laryngoscope blade
11556794|NCT00956579||Healthy individuals|"No intervention
~Healthy participants ages 14-32 for a neuroimaging study"
11556795|NCT00956579||Individuals with Autism Spectrum Disorder|"No intervention
~ASD participants ages 14-32 for a neuroimaging study."
11556796|NCT00956566|Active Comparator|low fat hypocaloric diet|
11556797|NCT00956566|Active Comparator|Low carbohydrate hypocaloric diet|
11556798|NCT00956553|Active Comparator|Cervarix|Three doses of Cervarix at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.
11556799|NCT00956553|Active Comparator|Gardasil|Three doses of Gardasil at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.
11556800|NCT00956540|Experimental|Deflating|Deflating tracheal cuff (total air suction under negative pressure using a syringe) during periods of disconnection from mechanical ventilation in the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support. During ventilatory support the tracheal cuff remain pressurized (30 mmHg).
11556801|NCT00956540|No Intervention|Not deflating|The tracheal cuff remain inflated all the time during the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support
11556802|NCT00956540|Experimental|Deflating 2|Deflating tracheal cuff during periods of disconnection from mechanical ventilation in the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate mange the airway.
11556803|NCT00956540|No Intervention|Not deflating 2|The tracheal cuff remain inflated all the time during the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate mange the airway.
11556804|NCT00956527|Experimental|Modified traditional martial arts training|"Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in at risk youth) and how these issues relate to martial arts concepts."
11556805|NCT00956514|Experimental|Transcranial Magenetic Stimulation|All subjects will be assigned to active, open-label treatment with the NeuroStar TMS System for 6 weeks (30 treatment sessions).
11556806|NCT00956488|Experimental|supported treadmill ambulation training|
11556807|NCT00956462|Experimental|NSAID|
11556808|NCT00956462|Active Comparator|Steroids|
11556809|NCT00956449|Experimental|1|
11556810|NCT00956436|Experimental|Sorafenib Monotherapy|Sorafenib Monotherapy
11556811|NCT00956436|Experimental|Sorafenib with BIIB022|Sorafenib with BIIB022
11556812|NCT00956423|Experimental|moderate-intensity exercise training|
11556813|NCT00956423|Active Comparator|low-intensity stretching|
11556814|NCT00956410|Experimental|CAD106|
11556815|NCT00956397|Active Comparator|Control Participants|
11556816|NCT00956397|Active Comparator|FD Participants|
11556817|NCT00956397|Placebo Comparator|FD (Placebo) Participants|
11556818|NCT00956384|Experimental|One-stage dermal matrix/implant|One-stage breast reconstruction with dermal matrix and implant
11556819|NCT00956384|Active Comparator|Two-stage tissue expander/implant|Two-stage breast reconstruction with tissue expander and implant
11556820|NCT00956371|Placebo Comparator|P|
11556821|NCT00956371|Experimental|E|
11556822|NCT00956358||Pre-HSCT|Haematological conditions requiring haemopoietic stem cell transplantation
11556823|NCT00956358||Post-HSCT with BOS|Occurence of bronchiolitis obliterans syndrome after haemopoietic stem cell transplantation
11556824|NCT00956358||Control|Healthy HSCT donors
11556825|NCT00956345|Experimental|25U/kg|
11556826|NCT00956345|Experimental|50U/kg|
11556827|NCT00956345|Experimental|100U/kg|
11556828|NCT00956332|Experimental|MGA - Low therapeutic dose|
11556829|NCT00956332|Experimental|MGA - Intermediate therapeutic dose|
11556830|NCT00956319|Experimental|Zolpidem group|
11556831|NCT00956319|Active Comparator|Estazolam group|
11556832|NCT00956306|Experimental|Child-Pugh A|
11556833|NCT00956306|Experimental|Child-Pugh B|
11556834|NCT00956306|Experimental|Healthy Volunteers|
11556835|NCT00956293|Active Comparator|Control group|During the pre-randomized treatment phase, all participants received a CNI-based regimen consisting of basiliximab, mycophenolic acid (MPA), cyclosporin A (CsA) and corticosteroids (optional). Upon randomization, participants in this group continued with a CNI-based regimen of MPA and CsA.
11556836|NCT00956293|Experimental|Everolimus group|During the pre-randomized treatment phase, all participants received a CNI-based regimen consisting of basiliximab, mycophenolic acid (MPA), cyclosporin A (CsA) and corticosteroids (optional). Upon randomization, participants in this group made a stepwise switch to a CNI-free regimen of everolimus and MPA.
11556837|NCT00956267|Experimental|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
11556838|NCT00956267|Active Comparator|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
11556839|NCT00956254|Experimental|Fentanyl sublingual spray 100 µg|Participants received a single administration of fentanyl sublingual spray 100 µg sublingually.
11556840|NCT00956241|Other|j-pouch coloanal anastomosis|although a j-pouch coloanal anastomosis is a common type of anastomosis, a comparison with the side-to-end has not been made.
11556841|NCT00956241|Other|side-to-end coloanal anastomosis|in the Netherlands, the side-to-end anastomosis is the standard procedure to perform an anastomosis in case of rectal resection. therefore, the side-to-end group was our control group
11556842|NCT00956228|Experimental|Radioimmunoguided IMRT|All patients recieved Intensity Modulated Radiotherapy to the prostate with 75.6 Gy in 42 fractions. Additionally, they recieve a concurrent boost to the region of the prostate which enhanced on the prostascint scan to 82 Gy.
11556843|NCT00956215|Active Comparator|80mg of Aprepitant|Patients will be randomized to receive 80mg of Aprepitant with 50 ml of water no later than 30 minutes before induction of anesthesia.
11556844|NCT00956215|Placebo Comparator|80 mg of placebo|. Patients will be randomized to placebo with 50 ml of water no later than 30 minutes before induction of anesthesia.
11556845|NCT00956202|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 Influenza vaccine formulation 1 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
11556846|NCT00956202|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 Influenza vaccine formulation 2 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
11556847|NCT00956202|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Influenza vaccine formulation 3
11556848|NCT00956189|Experimental|Amisulpride|A slow plateau cross-titration method was used to switch original antipsychotics to Amisulpride.
11556849|NCT00956189|Experimental|Aripiprazole|A slow plateau cross-titration method was used to switch original antipsychotics to Aripiprazole.
11556850|NCT00956176|Experimental|Cidofovir|
11556851|NCT00956163|Experimental|Diagnostic (fluorine F 18 sodium fluoride PET)|Patients undergo technetium Tc 99m methylene diphosphonate bone scan, fluorine F 18 sodium fluoride PET/CT scan, and whole-body MRI for the detection of bone metastases. Patients with discordant imaging results (negative bone scan and positive PET/CT scan and/or MRI) undergo additional imaging at 6, 12, 18, and 24 months.
11556852|NCT00956150|Active Comparator|60 GWS Rifaximin|
11556853|NCT00956150|Placebo Comparator|60 GWS Placebo|
11556854|NCT00956150|Experimental|Healthy Control|Patient is a healthy control and will not be on study intervention. Asked to perform Lactulose Breath Test to compare results with GWS patients.
11556855|NCT00956137|Experimental|Ultrasound|Use of ultrasound to identify vertebral interspaces for needle insertion.
11556856|NCT00956137|Active Comparator|Palpation|Use of manual palpation to identify vertebral landmarks and vertebral interspaces for needle insertion.
11556857|NCT00956124||uveitic patients|
11556858|NCT00956124||patients with diabetes|
11556859|NCT00956111|Experimental|split-virion, adjuvanted H1N1 vaccine of 7.5 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
11556860|NCT00956111|Experimental|split-virion, adjuvanted H1N1 vaccine of 15 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
11556861|NCT00956111|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
11556862|NCT00956111|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
11556863|NCT00956111|Experimental|whole-virion, adjuvanted H1N1 vaccine of 5 μg|100 adults to receive whole-virion, adjuvanted H1N1 vaccine of 5 μg on day 0 and 21.
11556864|NCT00956111|Experimental|whole-virion, adjuvanted H1N1 vaccine of 10 μg|"200 participants: 100 adults to receive whole-virion, adjuvanted H1N1 vaccine of 10 μg on day 0 and 21.
~100 elders to receive whole-virion, adjuvanted H1N1 vaccine of 10 μg on day 0 only."
11556865|NCT00956111|Placebo Comparator|Placebo control|100 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
11556866|NCT00956098|Placebo Comparator|placebo|
11556867|NCT00956098|Experimental|oltipraz|
11556868|NCT00956085|Experimental|Memantine|Open label memantine titrated in 5mg increments weekly to target dose of 10mg po bid for up to 6 weeks. Memantine was continued to 12 weeks in those with treatment response,13 either previous response to ketamine (≥ 35% Y-BOCS reduction 1 week after IV ketamine) or current response to memantine (≥ 35% Y-BOCS reduction from pre- to post-6 weeks of memantine).
11556869|NCT00956072|Experimental|Arm I|Patients undergo surgery of residual disease.
11556870|NCT00956072|Active Comparator|Arm II|Patients receive imatinib mesylate therapy according to standard of care.
11556871|NCT00956059|Experimental|prednisone, MMF and FK506|
11556872|NCT00956059|Active Comparator|prednisone|
11556873|NCT00956046|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 Influenza vaccine formulation 1 at Visits 1 and 2; and a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
11556874|NCT00956046|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 Influenza vaccine formulation 2 at Visits 1 and 2; and a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
11556875|NCT00956046|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Influenza vaccine formulation 3
11556876|NCT00956033||Patients with multiple myeloma|
11556877|NCT00956020|Experimental|Treatment|Skin injection with platelet rich fibrin matrix on the inner aspect of the upper arm, with biopsies over a period from 30 minutes to 12 weeks after treatment.
11556878|NCT00956007|Active Comparator|Arm I: Intensity-Modulated Radiotherapy|Patients undergo intensity-modulated radiotherapy (IMRT) once daily 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
11556879|NCT00956007|Experimental|Arm II: IMRT plus cetuximab|Patients undergo IMRT as in arm I. Patients also receive cetuximab IV over 1-2 hours once weekly beginning at least 5 days prior to the start of IMRT and continuing for 4 weeks after the completion of IMRT (for a total of 11 doses) in the absence of disease progression or unacceptable toxicity.
11556880|NCT00955981|Experimental|RDEA594 200 mg qd for 28 days|
11556881|NCT00955981|Experimental|RDEA594 200 mg, 400 mg|RDEA594 200 mg qd for 7 days followed by 400 mg qd for 21 days
11556882|NCT00955981|Experimental|RDEA594 200 mg, 400 mg and 600 mg|RDEA594 200 mg qd for 7 days followed by 400 mg qd for 7 days followed by 600 mg qd for 14 days
11556883|NCT00955981|Placebo Comparator|Matching placebo|RDEA594 matching placebo qd for 28 days
11556884|NCT00955968|Experimental|Continue HAART|Continue receiving HAART within 0-42 days after delivery or other pregnancy outcome.
11556885|NCT00955968|Active Comparator|Stop HAART|Stop receiving HAART within 0-42 days after delivery or other pregnancy outcome and resume HAART when protocol specified criteria were met.
11556886|NCT00955955|Experimental|6(S)-5-MTHF(Deplin)|"Participants will receive 15 mg/day of Deplin, a medical food, for 8 weeks.
~The SPCD approach, is modified and conducted as follows:
~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.
~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
11556887|NCT00955955|Experimental|Placebo/Deplin|"Participants will receive placebo for the first 4 weeks, and then 15 mg/day of Deplin (6(S)-5-MTHF) for the next 4 weeks.
~The SPCD approach, is modified and conducted as follows:
~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.
~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
11556888|NCT00955955|Experimental|Placebo/Placebo|"Participants will receive placebo for both phases of the study.
~The SPCD approach, is modified and conducted as follows:
~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.
~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
11556889|NCT00955942|Experimental|Arm I|Patients consume flaxseed muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.
11556890|NCT00955942|Placebo Comparator|Arm II|Patients consume placebo muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.
11556891|NCT00955929|Experimental|PRN Sildenafil|Placebo QHS (blinded) and sildenafil 100mgs (open-label) as required for sexual relations. The placebo will be omitted on nights that 100mgs is used. Placebo will start within 24-48 hours post-surgery.
11556892|NCT00955929|Experimental|Nightly Sildenafil Arm|Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery.
11556893|NCT00955929|Experimental|Combination Therapy Arm|Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL), at initial dose of 5 units (0.05ml) will be given; the first 2 injections will be done in the MSKCC urology outpatient clinic (if needed, the investigator can determine appropriate amount of injections for patient training).
11556894|NCT00955916|Experimental|CLAG Regimen with Gleevec®|Combined chemotherapy treatment (CLAG regimen) with Gleevec® (imatinib mesylate).
11556895|NCT00955903|Experimental|Weight Loss|Participants receive Exercise and Reduced Calorie Diet Interventions
11556896|NCT00955903|Active Comparator|Control|Participants receive Exercise Intervention
11556897|NCT00955903|Active Comparator|Weight Maintenance|Participants receive Exercise and a Weight Maintenance Diet Interventions
11556898|NCT00955890|No Intervention|control arm|anthracycline chemotherapy only
11556899|NCT00955890|Experimental|low dose dexrazoxane group|anthracycline chemotherapy plus low dose dexrazoxane(10:1)
11556900|NCT00955890|Experimental|middle dose dexrazoxane group|anthracycline chemotherapy plus middle dose dexrazoxane(15:1)
11556901|NCT00955877|Experimental|DepoDur80|DepoDur will be administered at 80μg/kg (not to exceed 5 mg total/patient) under direct vision in the L1 laminectomy defect prior to wound closure.
11556902|NCT00955877|Experimental|DepoDur120|DepoDur will be administered at 120μg/kg (not to exceed 10 mg total/patient) under direct vision in the L1 laminectomy defect prior to wound closure.
11557270|NCT00953056|Experimental|Cohort I - RotaTeq™, Adults|Adults randomized to receive a single dose of RotaTeq™.
11556903|NCT00955877|Placebo Comparator|Control|Preservative-free normal saline (2.5ml) will be placed in the L1 laminectomy defect and also dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter prior to wound closure.
11556904|NCT00955851||Pneumonia patients|The study group will consist of individuals diagnosed with pneumonia and admitted to the Medicine ward under the Pneumonia Core Measure Protocol.
11556905|NCT00955838|Experimental|Manus|
11556906|NCT00955838|Experimental|BCI_Manus|
11556907|NCT00955825|Experimental|300 IR|300 IR grass pollen allergen extract tablet
11556908|NCT00955825|Placebo Comparator|Placebo|Pacebo tablet
11556909|NCT00955812|Experimental|OPB-31121|OPB-31121 50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
11556910|NCT00955799|Experimental|Neramexane mesylate|Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day
11556911|NCT00955799|Placebo Comparator|Placebo|Placebo: identical placebo tablets
11556912|NCT00955786|Experimental|CX-3543|
11556913|NCT00955773|Experimental|Group I|20 to 30 solid tumor subjects will be dosed with GSK1120212 in combination with everolimus to identify Maximum Tolerated Dose. Subjects will continue on study drug until disease progression or withdraw consent.
11556914|NCT00955773|Experimental|Group II|20 subjects with pancreatic cancer will receive the recommended dose identified in group I. Subjects will remain on study drug until disease progression or withdrawal from consent.
11556915|NCT00955773|Experimental|Group III|Approximately 40 lung cancer subjects will receive the recommended dose identified in group I. Subjects will remain on study until disease progression or withdrawal of consent.
11556916|NCT00955747|Placebo Comparator|Sugar Substitute Splenda|1.5 g Sugar Substitute Splenda, dissolved in 125 ml of water three times per day. If intestinal problems occur, the dose should be reduced to 1 g dissolved in water tid or additionally reduced to 0.5 g dissolved in 125 ml of water tid if problems still persisted, until patients adapted to treatment.
11556917|NCT00955747|Experimental|Tagatose|15 g Tagatose dissolved in 125 ml of water three times a day. The Tagatose dosage will be decreased to 10 g dissolved in 125 ml of water tid or decreased additionally to 5 g Tagatose dissolved in 125 ml of water tid, if needed due to gastrointestinal effects, until patients adapt to the treatment
11556918|NCT00955734|Experimental|Early motion|This group of patients will begin wrist motion 1 week after surgery.
11556919|NCT00955734|Active Comparator|Immobilization|This group will be casted for 6 weeks after surgery
11556920|NCT00955721|Experimental|Phase 1: GEMOX + Sorafenib|"Gemcitabine and Oxaliplatin (GEMOX) and Sorafenib.
~Gemcitabine: 1000 or 750 mg/m2, IV, Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.
~Oxaliplatin: 100 or 75 mg/m2, IV, Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.
~Sorafenib: 200 mg, Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops."
11556921|NCT00955721|Experimental|Phase 2 - RPTD GEMOX + Sorafenib|"Recommended Phase Two Dose (RPTD) of Gemcitabine and Oxaliplatin (GEMOX) and Sorafenib:
~Gemcitabine: Recommended Phase II Dose determined from Phase I, Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.
~Oxaliplatin: Recommended Phase II Dose determined from Phase I, Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.
~Sorafenib: Recommended Phase II Dose determined from Phase I, Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops."
11556922|NCT00955708||Implants|Patients successfully implanted with the ACUITY Spiral Lead
11556923|NCT00955682|Experimental|Group A|Subjects who received GSK vaccine 134612 in the primary vaccination study 109069 and will be boosted 4 years after primary vaccination with the same meningococcal vaccine as given in the primary study.
11556924|NCT00955682|Active Comparator|Group B|Subjects who received Meningitec™ vaccine in the primary vaccination study 109069 and will be boosted 4 years after primary vaccination with the same meningococcal vaccine as given in the primary study.
11556925|NCT00955669|Active Comparator|Symptoms and Objective Examination|
11556926|NCT00955656||primary care providers|"Primary care providers who receive the survey will be the primary care provider identified by study participants enrolled in our ongoing study entitled, Asthma in the Delta Region of Arkansas: Characterization of Disease and Impact of Environmental Factors (ARIA#53054)"
11556927|NCT00955643|Experimental|hyperbaric therapy|Hyperbaric therapy by oxygen
11556928|NCT00955643|Experimental|dental scaling and root planing|dental scaling and cleaning
11556929|NCT00955630|Active Comparator|Monthly injections|3 monthly injections of ranibizumab followed by prn injections
11556930|NCT00955630|Active Comparator|PRN injections|injections of ranibizumab on a prn basis from the start of the study
11556931|NCT00955617|Experimental|Dotarem / Gadovist|Contrast-enhanced MRA - Imaging examination contrast enhanced-MRA first with Dotarem in period 1 then with Gadovist in period 2
11556932|NCT00955617|Experimental|Gadovist / Dotarem|Contrast-enhanced MRA - Imaging examination contrast enhanced-MRA first with Gadovist in period 1 then with Dotarem in period 2
11556933|NCT00955604||Group R+AD|Group R+AD Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) for at least 14 days
11556934|NCT00955604||Group R|At least 2 months of rasagiline
11556935|NCT00955604||Group AD|At least 2 months of Anti-PD and Rasagiline
11556936|NCT00955591|Other|swab test|
11556937|NCT00955578||Segmental Dysplastic Nevi|One patient who has been diagnosed with SDN and has had previous biopsies in the past, comparing to current biopsies
11556938|NCT00955565|Experimental|Navigated|
11556939|NCT00955565|Active Comparator|Conventional|
11556940|NCT00955552|Active Comparator|Condroflex|
11556941|NCT00955552|Experimental|Glucosamine/chondroitin sulphate|Glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association (Eurofarma) T.I.D. before each meal
11556942|NCT00955539|Active Comparator|CRT group 1|
11556943|NCT00955539|Active Comparator|CRT group 2|
11556944|NCT00955526|Experimental|Istradefylline 20mg|
11556945|NCT00955526|Experimental|Istradefylline 40mg|
11556946|NCT00955526|Placebo Comparator|Placebo|
11556947|NCT00955513|Experimental|diclofenac diethylamine gel 2.32% gel twice a day|drug
11556948|NCT00955513|Experimental|diclofenac diethylamine gel 2.32% gel three times a day|drug
11556949|NCT00955513|Placebo Comparator|placebo|placebo
11556950|NCT00955500|Active Comparator|Normal-protein diet|Daily diet containing 35 kcal/kg/day, 0.7 grams of proteins/kg/day + 30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams).
11556951|NCT00955500|Active Comparator|Low-protein diet|Daily diet containing 35 kcal/kg/day, 0.7 grams of proteins/kg/day + 30 grams of oral maltodextrine
11556952|NCT00955487|Experimental|Inhaled Nitric Oxide (iNO)|Participants will receive a low concentration of iNO until they are 30 weeks corrected gestational age or for 14 days if they were born at 29 weeks or more.
11556953|NCT00955487|Placebo Comparator|Nitrogen (placebo)|Participants will receive nitrogen (placebo) while in the hospital.
11556954|NCT00955474|Experimental|Quetiapine|Patients assigned to receive Quetiapine
11556955|NCT00955474|Active Comparator|Quetiapine and SSRI|Patients assigned to receive Quetiapine and SSRI
11556956|NCT00955461|Experimental|Laser treatment|Split-Face Comparison of an Electro-optic Q-Switched Nd: YAG Laser to a Fractionated Laser
11556957|NCT00955448|Experimental|SIS Mesh (Cook Medical)|Anterior prolapse repair will be reinforced using SIS mesh
11556958|NCT00955448|Active Comparator|No-mesh|Anterior prolapse repair with no mesh reinforcement
11556959|NCT00955409|Other|1|ACC-001(3µg) + QS21
11556960|NCT00955409|Other|2|ACC-001(10µg) + QS21
11556961|NCT00955409|Other|3|ACC-001(30µg) + QS21
11556962|NCT00955396|Other|Period 1|
11556963|NCT00955396|Other|Period 2|
11556964|NCT00955383|Active Comparator|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
11556965|NCT00955383|Placebo Comparator|Placebo|Matching placebo
11556966|NCT00955357|Experimental|First Add-on|Lacosamide added to first adequate monotherapy (no history of Antiepileptic Drug [AED] polytherapy) and epilepsy diagnosis < or = 24 months at Screening.
11556967|NCT00955357|Experimental|Later Add-on|Lacosamide added to 1 to 3 Antiepileptic Drugs (AEDs) (with tentatives of at least 2 prior AED treatment regimens) and epilepsy diagnosis > or = 5 years at Screening.
11556968|NCT00955344|Experimental|Web-based intervention (eToolbox)|This arm will allow diplomats of the American Board of Internal Medicine to complete the Practice Improvement Module that will embed a link to the web-based intervention (eToolbox).
11556969|NCT00955344|Active Comparator|Practice Improvement Module|This arm will allow diplomats of the American Board of Internal Medicine to complete the Practice Improvement Module without any link to the Web-based eToolbox.
11556970|NCT00955318|Experimental|KW-6500|
11556971|NCT00955305|Active Comparator|Arm A (CPB)|Patients receive carboplatin intravenously (IV) over 30 minutes, paclitaxel IV over 3 hours, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Treatment with bevacizumab may continue in the absence of disease progression or unacceptable toxicity.
11556972|NCT00955305|Experimental|Arm B (CPB+cixutumumab)|Patients receive carboplatin, paclitaxel, and bevacizumab as in Arm A. Patients also receive cixutumumab (IMC-A12) IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Treatment with bevacizumab and cixutumumab may continue in the absence of disease progression or unacceptable toxicity.
11556973|NCT00955292|Experimental|Quarfloxin|
11556974|NCT00955279|Placebo Comparator|Placebo|Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
11556975|NCT00955279|Experimental|Golimumab|Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
11556976|NCT00955279|Experimental|Ustekinumab|Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
11556977|NCT00955266|Active Comparator|Calcium Chloride|Calcium chloride, 10mg/kg
11556978|NCT00955266|Placebo Comparator|Placebo|Normal saline
11556979|NCT00955253|Experimental|Guanfacine (Day 2) then Placebo (Day 4)|All patients received a single dose of guanfacine on Day 2 and a single dose of placebo on Day 4.
11556980|NCT00955253|Experimental|Placebo (Day 2) then Guanfacine (Day 4)|All patients received a single dose of placebo on Day 2 and a single dose of guanfacine on Day 4.
11556981|NCT00955227|No Intervention|Statins only|In this arm- 15 Patients with heart disease and hypercholesterolemia will receive standard statin treatment as determined by the Cardiologist. Patients in this arm will be excluded if they are on ezetimibe.
11556982|NCT00955227|Active Comparator|Statins and ezetimibe|In this arm- 15 Patients with heart disease and hypercholesterolemia will receive standard statin treatment as determined by the Cardiologist. In addition, these patients will be on ezetimibe.
11556983|NCT00955227|Experimental|Statins and flax oil only|In this arm- 15 Patients receiving standard statin treatment as determined by their cardiologist will also receive two flaxseed oil capsules/day each containing 500 mg of ALA.
11556984|NCT00955227|Experimental|Statins and ezetimibe and flax oil|In this arm- 15 Patients with heart disease and hypercholesterolemia that are on standard statin treatment as determined by their cardiologist, will also receive (as an intervention) ezetimibe and flaxseed oil capsules containing 500mg of ALA.
11556985|NCT00955214|Experimental|2.5mm Paclitaxel-eluting stent|
11556986|NCT00955201|No Intervention|Arm 1|Sedentary Control Group
11556987|NCT00955201|Experimental|Arm 2|Aerobic Exercise Group
11556988|NCT00955201|Experimental|Arm 3|Isokinetic Strength Exercise Group
11556989|NCT00955201|Experimental|Arm 4|Combined Aerobic and Isokinetic Strength Exercise Group
11556990|NCT00955175|Experimental|Group 1|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 24 fractions (total of 72 Gy).
11556991|NCT00955175|Experimental|Group 2|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 22 fractions (total of 66 Gy).
11556992|NCT00955175|Experimental|Group 3|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 20 fractions (total of 60 Gy).
11556993|NCT00955162|Active Comparator|Subutex|
11556994|NCT00955162|Experimental|Suboxone|
11556995|NCT00955149|Experimental|Arm A|Erlotinib (Tarceva) 25 mg by mouth once daily.
11556996|NCT00955149|Experimental|Arm B|Erlotinib (Tarceva) 50 mg by mouth once daily for 6 months
11556997|NCT00955136|Experimental|High MI impulses, myocardial infarction, echocardiography|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
11556998|NCT00955123||Active inflammatory bowel disease|Patients with moderate to severe active inflammatory bowel disease (ulcerative colitis and Crohn's disease)
11556999|NCT00955110|Experimental|Oxymorphone ER 15 mg|15mg
11557000|NCT00955110|Active Comparator|Oxycodone CR 30 mg|30mg
11557001|NCT00955110|Placebo Comparator|Placebo|
11557002|NCT00955110|Experimental|Oxymorphone ER 30mg|30mg
11557003|NCT00955110|Active Comparator|Oxycodone CR 60mg|60mg
11557004|NCT00955097|Experimental|Definity Contrast Dye|During liver surgery Definity contrast dye will be administered follwed by an ultrasound to better detect liver tumors
11557005|NCT00955071|No Intervention|Control|
11557006|NCT00955071|Active Comparator|Exercise: LVLI|low volume, low intensity
11557007|NCT00955071|Active Comparator|Exercise: HVLI|high volume, low intensity
11557008|NCT00955071|Active Comparator|Exercise: LVHI|low volume, high intensity
11557009|NCT00955058|Active Comparator|cyproterone compound|Before and after treatment
11557010|NCT00955058|Experimental|oral contraceptive pill|Treatment
11557011|NCT00955045|Experimental|istradefylline|
11557012|NCT00955032|Experimental|High-Frequency Repetitive Transcranial Magentic Stimulation|High-Frequency repetitive transcranial magnetic stimulation patients randomized to this treatment will receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of Motor Evoked Potential (MEP) threshold, respectively.
11557013|NCT00955032|Sham Comparator|Sham Repetitive Transcranial Magentic Stimulation|Sham repetitive transcranial magnetic stimulation patients randomized to receive the sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
11557014|NCT00955006|Experimental|Group 1|Participants will receive three injections of VRC-HIVDNA-016-00-VP at Months, 0, 1, and 2 and one injection of VRCHIVADV014-00-VP at Month 6.
11557015|NCT00954993|Experimental|Vaniprevir 600 mg - 300 mg|For each participant in period 1, 600 mg of Vaniprevir was taken twice daily on Days 1-3 and a single dose of Vaniprevir 600 mg was taken on Day 4. Period 1 was followed by a minimum 30-day, up to approximately 140 day, washout interval. In period 2, 300 mg of Vaniprevir was taken twice daily by each participant on Days 1-3 and a single dose of Vaniprevir 300 mg was taken on Day 4.
11557016|NCT00954980||Endovenous Sclerotherapy|For those who have been diagnosed with varicose veins of the leg and have been scheduled to undergo an endovenous sclerotherapy procedure
11557017|NCT00954967|No Intervention|Usual care|The subjects in the control group will receive the usual care for smoking cessation in diabetic smokers.
11557018|NCT00954967|Experimental|Lifestyle Counseling|The intervention is based on lifestyle advice, motivational interviewing and the use of medications, using the Clinical Practice Guidelines of the Catalan Institute of Health. Health professionals in the intervention group receive a training on the abovementioned techniques.
11557019|NCT00954954|Active Comparator|Standard|Knees that will be implanted with standard posterior stabilized RP-MB knee prostheses
11557020|NCT00954954|Active Comparator|High-flexion|Knees that will be implanted with high-flexion posterior stabilized RP-MB knee prostheses
11557021|NCT00954941|Experimental|Group 1: Ondansetron|Ondansetron 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.
11557022|NCT00954941|Active Comparator|Group 2: Ondansetron + Aprepitant|Ondansetron 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy. Aprepitant 125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
11557023|NCT00954928||Anticoagulated patients|Those patients taking Coumadin, Plavix, Aspirin, Lovenox.
11557024|NCT00954928||Control patients|Those patients having hand or wrist surgery who do not take any anticoagulant medication.
11557025|NCT00954915|Experimental|teplizumab|Anti CD-3 monoclonal antibody
11557026|NCT00954902|Sham Comparator|No spice, no stress|Subject are given placebo capsules and told they contain an antioxidant concentrate
11557027|NCT00954902|Sham Comparator|No Spice, Stress|Subjects are given placebo capsules and told they are receiving an equivalent amount of an antioxidant concentrate.
11557028|NCT00954902|Experimental|Spice, no stress|
11557029|NCT00954902|Experimental|Spice and Stress|
11557030|NCT00954889|Experimental|Tamsulosin|
11557031|NCT00954889|Placebo Comparator|placebo|
11557032|NCT00954850||Severe asthmatics|Main study group
11557033|NCT00954850||Mild-moderate asthmatics|Control group
11557034|NCT00954837|Other|Fine needle aspiration|Patient with solid nodules more than 10 mm in diameter will be biopsied by ultrasound-guided fine-needle aspiration(FNA)after consultation with an endocrinologist or ENT specialist.
11557035|NCT00954824|Experimental|Endotoxin (LPS)|Single administration low-dose (3 ng/kg) endotoxin (LPS).
11557036|NCT00954811|Active Comparator|HCG for ovulation triggering and luteal progesterone|conventional triggering with HCG and conventional luteal support with progesterone
11557037|NCT00954811|Experimental|Agonist triggering and rec-LH luteal support plus progesterone|new method of triggering with GnRH-agonist and proof of concept intervention with novel way of luteal support with rec-LH plus the usual co-treatment with progesterone
11557272|NCT00953056|Experimental|Cohort II - RotaTeq™, Children|Children randomized to receive a single dose of RotaTeq™.
11557038|NCT00954798|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 vaccine formulation 1 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13.
11557039|NCT00954798|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 vaccine formulation 2 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13.
11557040|NCT00954798|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 vaccine formulation 3
11557041|NCT00954785|Placebo Comparator|Placebo drug|
11557042|NCT00954785|Experimental|Etoricoxib|
11557043|NCT00954785|Active Comparator|Diclofenac|
11557044|NCT00954772||Staged Bilateral STN DBS|
11557045|NCT00954772||Simultaneous Bilateral STN DBS|
11557046|NCT00954759|Experimental|Chiropractic treatment|Manipulation and/or mobilisation
11557047|NCT00954759|Placebo Comparator|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
11557048|NCT00954746||Follow-up|Subjects Previously Treated with AA4500
11557049|NCT00954733|Experimental|All participants|All participants, one arterial blood draw
11557050|NCT00954720||Patient undergoing transplant|Patients with acute leukemia or MDS undergoing ablative stem cell transplantation. No intervention.
11557051|NCT00954707|Placebo Comparator|12m DAPT Group|
11557052|NCT00954707|Active Comparator|30m DAPT Group|
11557053|NCT00954694|Experimental|introductory exercise regimen|sedentary adults will be introduced to an introductory fitness regimen using the NuStep
11557054|NCT00954681|Experimental|quetiapine treatment|Open label treatment with quetiapine
11557055|NCT00954668|Experimental|immediate angiography|Immediate invasive angiography < 2 h after randomization
11557056|NCT00954668|Active Comparator|early invasive angiography|early invasive angiography 12-72 h after randomization
11557057|NCT00954655||Group 1|Tumor samples are used for polymorphism and mutation analysis.
11557058|NCT00954642|Experimental|A|
11557059|NCT00954642|Experimental|B|
11557060|NCT00954629|Experimental|2PX|Pain medication
11557061|NCT00954629|Placebo Comparator|Placebo|
11557062|NCT00954603|Experimental|quetiapine|atypical antipsychotic drug
11557063|NCT00954603|Active Comparator|haloperidol|typical antipsychotic drug
11557064|NCT00954590|Experimental|Dimebon (latrepirdine)|Dimebon, 20 mg orally three times daily
11557065|NCT00954590|Placebo Comparator|Placebo|Placebo orally three times daily
11557066|NCT00954551||All adult patients with SAH in ICU|All adult patients admitted for an expected ICU stay of more than 24 hrs over a 6-month period (tentative) between xx and xx 2009 with a diagnosis of SAH will be prospectively evaluated.
11557067|NCT00954538|Experimental|Part I, Healthy Participants|Healthy participants will receive a single intravenous (IV) dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part I of the study
11557068|NCT00954538|Experimental|Part II, HE and AD Participants|HE and AD participants will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part II of the study
11557069|NCT00954538|Experimental|Part III, HE and AD Participants|HE and AD participants will receive two separate IV doses of ~150 megabecquerel (MBq) [18F]MK-3328 in Part III of the study
11557070|NCT00954525|Experimental|Intravenous Vitamin C|
11557071|NCT00954512|Experimental|Regimen A: FOLFIRI (± Cetuximab) + Robatumumab|Participants with colorectal adenocarcinoma receive FOLFIRI (Irinotecan 180 mg/m^2+ folinic acid 400 mg/m^2+ 5-fluorouracil [5-FU] 400 mg/m^2 bolus followed by 2400 mg/m^2 intravenous [IV] infusion over 46 hours) (± cetuximab initial dose of 400 mg/m^2 IV followed by once-weekly doses of 250 mg/m^2 IV) PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 2-week cycle.
11557072|NCT00954512|Experimental|Regimen B: Carboplatin + Paclitaxel + Robatumumab|Participants with non-small cell lung cancer receive carboplatin administered at an area under the curve (AUC) of 6 mg/mL/min IV PLUS paclitaxel 225 mg/m^2 IV PLUS robatumumab 15 mg/kg IV on Day 1 of each 3-week cycle.
11557073|NCT00954512|Experimental|Regimen C: Epirubicin + Cisplatin + 5-FU + Robatumumab|Participants with gastric adenocarcinoma receive epirubicin 50 mg/m^2 IV PLUS cisplatin 60 mg/m^2 IV PLUS 5-FU 200 mg/m^2/day administered via a 21-week continuous IV infusion PLUS robatumumab 15 mg/kg IV on Day 1 of each 3-week cycle.
11557074|NCT00954512|Experimental|Regimen D: Trastuzumab + Robatumumab|Participants with human epidermal growth factor receptor 2 positive (Her2+) breast cancer receive trastuzumab 4 mg/kg IV once every week PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle.
11557075|NCT00954512|Experimental|Regimen E: mTor Inhibitor (Everolimus) + Robatumumab|Participants with renal cell cancer receive mammalian target of rapamycin (mTor) inhibitor (everolimus) 10 mg orally once per day PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle.
11557076|NCT00954512|Experimental|Regimen F: Gemcitabine (± Erlotinib) + Robatumumab|Participants with pancreatic adenocarcinoma receive gemcitabine 1000 mg/m^2 IV on Days 1, 8, 15, 22, 29, 36, and 43 in Cycle 1 and on Days 1, 8 and 15 in subsequent cycles (± erlotinib 100 mg per day orally) PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle. (Cycle 1 is 8 weeks.)
11557077|NCT00954499|Active Comparator|Standard care|
11557078|NCT00954499|Experimental|Tactile stimulation|
11557079|NCT00954486|Experimental|Epoetin alfa, 10,000 units/week|Epoetin alfa is a recombinant erythropoietin.
11557080|NCT00954473||Ancillary-correlative (osteosarcoma genetic risk)|Blood samples undergo polymorphism analysis of common single-nucleotide polymorphisms and haplotypes to examine genetic variation, gene-gene interactions, and the population structure.
11557081|NCT00954447|Experimental|Linagliptin|patient receives a tablet with intended final marketed dose
11557082|NCT00954447|Placebo Comparator|Placebo|patient receives a tablet identical to those containing Linagliptin
11557083|NCT00954434|Experimental|red wine|intervention: dietary supplement intake of red wine on a daily basis, 1 glass/day for women, 2 for men
11557084|NCT00954434|No Intervention|total abstention from alcohol|
11557085|NCT00954421|Experimental|Deep Brain Stimulation|Multiple Sclerosis Tremor treated with VIM and VO Deep Brain Stimulation
11557086|NCT00954408||Patients with dystonia|Patients with dystonia, 21-100 years of age.
11557271|NCT00953056|Placebo Comparator|Cohort I - Placebo, Adults|Adults randomized to receive a single dose of matching placebo to RotaTeq™.
11557087|NCT00954395||1. anticoagulation suspension|eligible patients undergo measurement of residual venous obstruction (RVO) with compression ultrasound (CUS) in case of a previous deep vein thrombosis (DVT) and/or of pulmonary artery pressure (PAP) with echocardiography in case of previous pulmonary embolism (PE). In patients with RVO is less < 4 mm in case of a previous DVT and/or PAP is normal with echocardiography in case of previous PE and in those who have undergone additional 6 months of therapy for previously altered RVO, D-dimer is measured during anticoagulation. If D-dimer is below age and gender cut-offs , anticoagulation is interrupted and D-dimer is then re-assessed after 15, 30, 60 and 90 days. If all the D-dimer measurements are below the cut-offs, anticoagulation is definitely interrupted and patients are followed-up for two years.
11557088|NCT00954395||2. anticoagulation prolongation|If RVO is greater than 4 mm at CUS of the lower limbs and/or PAP is increased (> 35 mmHg, > 40 mmHg in the elderly or obese), anticoagulation is prolonged for additional 6 months and the measures of RVO and/oR PAP are repeated. In those in whom PAP is altered also after 6 months of additional therapy, anticoagulation is prolonged. In patients with RVO is less < 4 mm in case of a previous DVT and/or PAP is normal with echocardiography in case of previous PE and in those who have undergone additional 6 months of therapy for previously altered RVO, D-dimer is measured during anticoagulation. If D-dimer is above age and gender cut-offs , anticoagulation is prolonged. If D-dimer is below the cut-offs , anticoagulation is interrupted and D-dimer is then re-assessed after 15, 30, 60 and 90 days. If one of these D-dimer measurement is above the cut-off , anticoagulation is resumed for at least 6 months and patients are re-evaluated.
11557089|NCT00954382||IQ trend|all subjects
11557090|NCT00954369|Experimental|[F-18]W372|Approximately twenty (20) adult subjects including ten (10) healthy volunteers and ten (10) high probability AD subjects, as defined by protocol criteria
11557091|NCT00954356|Experimental|XPF-001|
11557092|NCT00954356|Placebo Comparator|Placebo|
11557093|NCT00954343|Experimental|Group I|
11557094|NCT00954343|Experimental|Group II|
11557095|NCT00954343|Experimental|Group III|
11557096|NCT00954343|Experimental|Group IV|
11557097|NCT00954343|No Intervention|Group V|
11557098|NCT00954330|Experimental|surgery|All twenty-five patients underwent ligament repair, where the ruptured ends of the FTA (in 11 cases) or FTA and FC (in 14 cases) ligaments were rejoined by using absorbable sutures. A supine position and a tourniquet were used. A curvilinear skin incision of 5-10 cm was made; the retinacular structures were incised and the hematoma was removed.
11557099|NCT00954330|Active Comparator|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle
11557100|NCT00954317|Active Comparator|Low epidural|epidural placed in the lower lumbar vertebral column
11557101|NCT00954317|Experimental|high epidural|high epidural
11557102|NCT00954304|Experimental|1mg group|Administration of HM30181AK 1mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
11557103|NCT00954304|Experimental|5mg group|Administration of HM30181AK 5mg on day 4 and Loperamide 16mg(Loperamide 2mg x 8cap) on day 1,4,8,11,15
11557104|NCT00954304|Experimental|10mg group|Administration of HM30181AK 10mg(HM30181AK 5mg x 2tab)on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
11557105|NCT00954304|Experimental|15mg group|Administration of HM30181AK 15mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
11557106|NCT00954304|Experimental|60mg group|Administration of HM30181AK 60mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
11557107|NCT00954291||Granisetron|14 mg Granisetron
11557108|NCT00954278|Experimental|sorafenib|
11557109|NCT00954265|Active Comparator|Urinary-HCG group|These patients received u-HCG for ovulation triggering during ovarian stimulation for IVF
11557110|NCT00954265|Experimental|Recombinant HCG group|These patients received rec-HCG for ovulation triggering during ovarian stimulation for IVF
11557111|NCT00954252|Experimental|Test Article|
11557112|NCT00954252|Placebo Comparator|Placebo|
11557113|NCT00954226|Experimental|Arm I (standard-dose erlotinib hydrochloride)|Patients receive standard-dose erlotinib hydrochloride PO QD for 2-3 weeks (up to 8 weeks if surgery is delayed).
11557114|NCT00954226|Experimental|Arm II (high-dose erlotinib hydrochloride)|Patients receive high-dose erlotinib hydrochloride PO QD for 2-3 weeks (2-8 weeks for current smokers or up to 8 weeks if surgery is delayed).
11557115|NCT00954213|Experimental|DIR/Floortime parent intervention|
11557116|NCT00954200|Placebo Comparator|Placebo|
11557117|NCT00954200|Active Comparator|ibuprofen|
11557118|NCT00954187|Experimental|Gabapentin|Neurontin
11557119|NCT00954187|Experimental|Pregabalin|Lyrica
11557120|NCT00954174|Experimental|Arm I (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1.
11557121|NCT00954174|Experimental|Arm II (paclitaxel, ifosfamide)|Patients receive ifosfamide IV over 1 hour on days 1-3 followed by paclitaxel as in Arm I.
11557122|NCT00954161|Experimental|first aid and helping behaviour|The helping behaviour training is given after 24 hours first aid training and aims to sensitise participants towards a helping reaction and teach participants how to deal with barriers to helping
11557123|NCT00954161|Active Comparator|first aid only|This group receives training in first aid only without training in helping behaviour.
11557124|NCT00954148|Active Comparator|PET/CT follow-up|PET/CT with history and physical exams at 3,9,18,36,60 months only
11557125|NCT00954148|Other|conventional follow-up|NCCN recommendations
11557126|NCT00954135|Active Comparator|letrozolo+cyclophosphamide|
11557127|NCT00954135|Experimental|letrozolo+sorafenib+cyclophosphamide|
11557128|NCT00954122|Experimental|Quetiapine XR|Quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards.
11557129|NCT00954109|Experimental|Exercise|exercise - supervised exercise (treadmill walking or cycle ergometer use)
11557216|NCT00953446|Experimental|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|"ASL MRI
~Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment"
11557217|NCT00953433|Experimental|Endoflex tube|Use of Endoflex tube for intubation.
11557130|NCT00954096|Experimental|Transdermal nicotine patch or placebo|A single blood specimen (85ml) will be drawn. They will be asked to empty their bladder. The patch will be applied. Following application of the patch, heart rate and blood pressure will be measured every 15 minutes for the 1st hour, every 30 minutes for the next 3 hours and hourly after that until the end of the study. Urine will be collected in two 4-hour aliquots. FMD will be measured after approximately 6 hours of nicotine exposure. After 8 hours exposure, following the end of the 2nd urine collection, the patch will be removed and the subject discharged. Following a minimum of 2 weeks (maximum 8 weeks) washout, the subject will repeat the study, receiving the other patch.
11557131|NCT00954083|Experimental|DIR/Floortime intervention|1=DIR/Floortime intervention
11557132|NCT00954083|Active Comparator|routine care|2=routine care
11557133|NCT00954070||Case (subjects with NERD)|The investigators cases are subjects with confirmed NERD and include male or female patients aged between 21 and 65 years, who present with typical clinical manifestations of gastroesophageal reflux and have no esophageal mucosal breaks upon conventional white-light endoscopy examination but show evidence of pathologic gastroesophageal reflux on 24-hr pH monitoring.
11557134|NCT00954070||Control|Healthy individuals aged between 21 and 65 years who are asymptomatic for GERD and other digestive diseases
11557135|NCT00954057|Experimental|LIPO-102|Intraorbital Injection
11557136|NCT00954057|Placebo Comparator|Placebo|Intraorbital Injection
11557137|NCT00954044|Experimental|Exercising Together|Partnered progressive resistance exercise
11557138|NCT00954044|Placebo Comparator|Usual Care|Usual Care Control
11557139|NCT00954031||case|hospitalized patients, adult or child, including the diagnosis of APA was made, after consulting their physician.
11557140|NCT00954031||The control group|"Two patients witnesses will be matched to each case:
~Chronological criterion: consultation for a sore throat 10 days (± 3 days) before the date of hospitalization of cases, between 13 and J-J-7.
~Age criteria: year of birth ± 5 years Geographical criteria: living in the same department, failing in an adjacent Department Social criteria: beneficiary or otherwise of the CMU, to avoid a selection bias leading social most frequently at the onset of the APA"
11557141|NCT00954018||Cystic Fibrosis patient during outpatient clinic visit|
11557142|NCT00954018||Cystic Fibrosis patients during hospitalization|
11557143|NCT00954018||CF patients about to have sinus surgery and bronchoscopy|
11557144|NCT00954005|Experimental|Rituximab, Gemcitabine and Oxaliplatin|Drug: Rituximab on day 0 or 1 of each 28-day cycle Drug: Gemcitabine on day 1 and 15 of each 28-day cycle Drug: Oxaliplatin on day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²) of each 28-day cycle
11557145|NCT00953979|Active Comparator|Sulfasalazine|Sulfasalazine is a drug in treatment RA, AS and ulcerative colonitis. In this study, Sulfasalazine is used to act as an active comparator to access the efficacy of kunxian capsule.
11557146|NCT00953979|Placebo Comparator|placebo|The placebo capsule was used to be a comparator of kunxian capsule
11557147|NCT00953966|Other|Starch 1|Starch 1
11557148|NCT00953966|Other|Starch 2|Starch 2
11557149|NCT00953966|Other|Starch 3|Starch 3
11557150|NCT00953966|Other|Starch 4|Starch 4
11557151|NCT00953966|Other|Starch 5|Starch 5
11557152|NCT00953966|Other|Starch 6|Starch 6
11557153|NCT00953966|Other|Starch 7|Starch 7
11557154|NCT00953953||Acutely Decompensated Systolic HF|Patients with moderate or severe Heart Failure (defined ast NYHA class III or IV).
11557155|NCT00953953||Chronic HF Patients on Dialysis|Patients who have heart failure (defined as NYHA class II, III, or IV) and are on dialysis.
11557156|NCT00953953||Ambulary Chronic HF|Patients with diagnosis of chronic heart failure (NYHA class II and III) who are on optimal medical therapy.
11557157|NCT00953953||Acutely Decompensated Diastolic HF|Patients with moderate or severe Heart Failure (defined ast NYHA class III or IV).
11557158|NCT00953940|Experimental|Isotonic saline|Isotonic saline
11557159|NCT00953940|No Intervention|No treatment|Habitual therapy
11557160|NCT00953927|Experimental|Investigational Vaccine|MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.
11557161|NCT00953927|Placebo Comparator|Control Group|Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.
11557162|NCT00953914|Experimental|Pyridostigmine|
11557163|NCT00953914|Placebo Comparator|Placebo|If a subject is randomized to placebo, he will receive placebo pills 3 times daily for 1 day.
11557164|NCT00953888|Experimental|Active|AZD5069 oral solution
11557165|NCT00953888|Placebo Comparator|Placebo|Placebo oral solution
11557166|NCT00953862|Experimental|Atomoxetine Treatment Arm|Patients who were identified as having adult ADHD on the ACDS were offered an open label treatment trial with atomoxetine, up to 120 mg/day over 10 weeks. Atomoxetine was titrated over a period of four weeks based upon clinical response and observed side-effects. All patients receiving atomoxetine gave written informed consent prior to participation and were assessed for ADHD symptoms via the Adult Investigator Adult ADHD Symptom Rating Scale (AISRS) every 1-2 weeks. All patients received a physical exam, review of systems and routine blood work prior to treatment. Data were analyzed for patients completing at least 2 weeks of atomoxetine therapy. Treatment response was pre-hoc defined as having a >=30% reduction in total AISRS scores from baseline.
11557167|NCT00953849|Experimental|Arm 1: Celecoxib|Celecoxib treatment prior to surgery
11557168|NCT00953849|Experimental|Arm 2: Calcitriol|Treatment with Calcitriol prior to surgery
11557169|NCT00953849|Experimental|Arm 3: Celecoxib plus Calcitriol|Treatment with Celecoxib plus Calcitriol prior to surgery.
11557170|NCT00953849|No Intervention|Arm 4: No Treatment|no treatment prior to surgery
11557171|NCT00953810|No Intervention|control|General heart failure population staying under regular care of their primary care physician
11557172|NCT00953810|Active Comparator|Intervention|Like control plus one education training regarding heart failure aspects and management
11557173|NCT00953784|No Intervention|1|Standard management
11557174|NCT00953784|Active Comparator|2|Extended management: with no bowel prep except enema,restricted fluids, increased O2,body warming and use of skin protectors during surgery as previously described
11557175|NCT00953771|Experimental|Danazol, Plex, Steroids|Everyone will receive Danazol with plasma exchange and corticosteroids
11557176|NCT00953758|Experimental|1|
11557177|NCT00953745|Active Comparator|Depressed Participants|"Subjects with treatment-resistant depression (TRD) will be administered the Hamilton Depression Rating Scale (HAM-D 17) for entry and will receive escitalopram combined with an adjunctive placebo capsule for 8 weeks.
~Subjects who fail to respond will continue to receive escitalopram and additionally change to receive a placebo tablet resembling the active augmentation agent Aripiprazole (ARP) for 2 weeks.
~Subjects who fail to respond to escitalopram after the 2 phase placebo treatment will enter the ARP augmentation phase of the study and will receive escitalopram augmentation with ARP.
~Subjects will have 3 neuroimaging scans: F-DOPA PET, raclopride PET, and functional MRI conducted after 10 weeks of treatment and repeated after 6 weeks of ARP treatment."
11557178|NCT00953745|No Intervention|Control Participants|Non-depressed, age- and sex-matched subjects without a DSM-IV Axis I diagnosis will serve as controls. They will not receive antidepressant, ARP, or any drug augmentation and will be used as quality control to compare the pre-ARP and post-ARP treatment brain images.
11557179|NCT00953732||1|
11557180|NCT00953719|Active Comparator|36 mm|36 mm ceramic head on ceramic acetabular liner
11557181|NCT00953719|Other|28 mm ceramic-on-polyethylene|28 mm ceramic-on-polyethylene historical control
11557182|NCT00953706|Placebo Comparator|Placebo|Placebo matched to ivacaftor tablet orally every 12 hours (q12h) for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).
11557183|NCT00953706|Experimental|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally q12h for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).
11557184|NCT00953680|Active Comparator|losartan /HCTZ combination tablet|single dose losartan 100 mg/HCTZ 12.5 mg combination tablet
11557185|NCT00953680|Active Comparator|losartan tablet + HCTZ capsule|Single dose losartan 100 mg tablet + HCTZ 12.5 mg capsule
11557186|NCT00953667|Experimental|Niacin and Endotoxin|All subjects are expected to have the same interventions- Niacin and Endotoxin.
11557187|NCT00953654|Experimental|Strength Training|Lower-body strength training exercise twice weekly for 6 weeks at an intensity progressing from 50% to 75% predicted one-repetition maximum
11557188|NCT00953654|Experimental|Endurance Training|Six-week lower-body dynamic cycling exercise condition completed twice weekly and matched to the strength training arm on total work completed, total time actively engaged in exercise and load progression.
11557189|NCT00953654|No Intervention|Waiting List Control|Waiting list control condition in which participants will maintain their current lifestyle and will not enter a six-week exercise training intervention, but will complete outcome measures along the same time progression as the intervention arms.
11557190|NCT00953641|Active Comparator|Pre-Menopausal 1|Pre-Menopausal group, receiving Misoprostol
11557191|NCT00953641|Placebo Comparator|Pre-Menopausal 2|Patients will insert a placebo vaginal suppository 12h or more prior to the endometrial biopsy
11557192|NCT00953641|Active Comparator|Post-Menopausal 1|Post-Menopausal patients will insert a Misoprostol vaginal suppository 12h or more prior to the endometrial biopsy
11557193|NCT00953641|Placebo Comparator|Post-Menopausal 2|Placebo vaginal suppository prior to the endometrial biopsy
11557194|NCT00953628|Active Comparator|o Group A=uHCG ovul trig|HCG for triggering
11557195|NCT00953628|Experimental|o Group B=recHCG ovul trig|recombinant HCG for triggering
11557196|NCT00953615|Experimental|Thalidomide|Participants will be treated with Thalidomide, starting at a dose of 100 mg per day, increasing the dose by 100 mg every 14 days to a maximum of 400 mg per day.
11557197|NCT00953589|Experimental|Locteron ® PANEL A|PANEL A: Locteron™ 480 µg dosed every 2 weeks in two subcutaneous injections (160 µg and 320 µg)
11557198|NCT00953589|Experimental|Locteron ® PANEL B|PANEL B: Locteron™ 480 µg dosed every two weeks in single subcutaneous injections
11557199|NCT00953589|Active Comparator|PEG-Intron® PANEL A|PEG-Intron® 1.5 µg/kg body weight weekly subcutaneous injection
11557200|NCT00953589|Active Comparator|PEG-Intron® PANEL B|PEG-Intron® 1.5 µg/kg body weight weekly subcutaneous injection
11557201|NCT00953576|Experimental|Phase I Dose Level 1 (DL1): KHAD+L (250 mg)|"For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.
~Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
~Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 250 mg orally 1x day
~Participants are treated until unacceptable toxicity, disease progression or withdrawal."
11557202|NCT00953576|Experimental|Phase I Dose Level 2 (DL2): KHAD+L (500 mg)|"For the initial four weeks (1 cycle=28 days), participants will receive KHAD treatment.
~Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
~Participants will start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 500 mg orally 1x day"
11557203|NCT00953576|Experimental|All Phase I Participants|"For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.
~Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day
~Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: according to the established dose escalation schedule
~Participants are treated until unacceptable toxicity, disease progression or withdrawal."
11557204|NCT00953563|No Intervention|compression therapy|
11557205|NCT00953563|Active Comparator|Biologic with compression therapy|
11557206|NCT00953550|Experimental|Rocuronium-Sugammadex|
11557207|NCT00953550|Active Comparator|Succinylcholine|
11557208|NCT00953537|Other|capecitabine|
11557209|NCT00953524|Experimental|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1
11557210|NCT00953524|Experimental|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2
11557211|NCT00953524|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Vaccine formulation 3
11557212|NCT00953524|Placebo Comparator|Placebo Group|Participants will receive a placebo vaccine
11557213|NCT00953511|Other|genetic|
11557214|NCT00953498|Active Comparator|pioglitazone|treatment with pioglitazone (dose from 30 mg:day to 45 mg/day)
11557215|NCT00953498|Active Comparator|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
11557218|NCT00953433|Active Comparator|Endotracheal tube with stylet|Use of conventional endotracheal tube with a stylet for intubation.
11557219|NCT00953420|Experimental|Chemotherapy and Immunotherapy|"Docetaxel 60 mg/m2 IV on Day 1
~Carboplatin with target AUC of 5 (mg/ml x min) on Day 1
~Dexamethasone 5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1
~After cycle 1, subsequent cycles of chemotherapy may start once ANC > 1000 and platelets > 100,000 post nadir
~Up to an additional 2 cycles of chemotherapy, given per the above schedule, may be given if the EBV-specific cytotoxic T lymphocytes product is not available after the initial 4 cycles"
11557220|NCT00953407|Experimental|Nelfilcon A|Nelfilcon A contact lens
11557221|NCT00953407|Active Comparator|Narafilcon A|Narafilcon A contact lens
11557222|NCT00953407|Active Comparator|Etafilcon A|Etafilcon A contact lens
11557223|NCT00953407|Active Comparator|Omafilcon A|Omafilcon A contact lens
11557224|NCT00953407|Active Comparator|Hilafilcon B|Hilafilcon B contact lens
11557225|NCT00953394|Experimental|treatment arm|continuous 5 fluouracil infusion plus long-acting octreotide
11557226|NCT00953381|Experimental|5 mg ilaprazole|
11557227|NCT00953381|Experimental|10 mg ilaprazole|
11557228|NCT00953381|Experimental|20 mg ilaprazole|
11557229|NCT00953381|Active Comparator|20 mg omeprazole|
11557230|NCT00953368|Active Comparator|Remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
11557231|NCT00953368|Placebo Comparator|control|sham placement of a blood-pressure cuff around the upper limb without inflation
11557232|NCT00953355|Experimental|Folate|Folate plus metformin
11557233|NCT00953355|Placebo Comparator|Placebo|Placebo plus metformin
11557234|NCT00953342|Experimental|Aerobic exercise|12 weeks of supervised aerobic exercise and standard care
11557235|NCT00953342|Placebo Comparator|Usual care|12 weeks of standard care
11557236|NCT00953329|Experimental|Alefacept 15 mg IM qweek|Alefacept will be given to subjects with plaque psoriasis who have failed treatment with Fnbrel.
11557237|NCT00953316||at-risk infants|Includes all children born at less than 37 weeks gestation and other high risk newborns such as those with a history of breathing problems and/or low tone.
11557238|NCT00953303|Experimental|glucocorticoid|
11557239|NCT00953303|Active Comparator|Standard care|
11557240|NCT00953290|Experimental|Treated Thigh|The thigh treated with the RF device
11557241|NCT00953290|No Intervention|Untreated Thigh|The untreated thigh
11557242|NCT00953277|Experimental|Avance Nerve Graft|Processed Human Nerve Tissue Scaffold
11557243|NCT00953264|Experimental|life style intervention|
11557244|NCT00953251||patients with acute coronary syndrome|patients with acute coronary syndrome
11557245|NCT00953251||Non-STEMI and unstable angina|
11557246|NCT00953225|Experimental|Vitamin D3|4,000 IU vitamin D3 daily for one year
11557247|NCT00953225|Placebo Comparator|Placebo|Placebo daily for one year
11557248|NCT00953212|Active Comparator|Group A|Beta Blockers, Ascorbic Acid and Amiodarone
11557249|NCT00953212|Active Comparator|Group B|Beta Blockers and Ascorbic Acid
11557250|NCT00953212|Active Comparator|Group C|Beta Blockers and Amiodarone
11557251|NCT00953212|Active Comparator|Group D|Beta Blockers alone
11557252|NCT00953199|Experimental|Lidocaine|Study subjects receive a 1:1 combination of 5 ml Diatrizoate 60% and 5 ml Lidocaine Hydrochloride 2%
11557253|NCT00953199|Active Comparator|Normal Saline|The control arm receives a 1:1 combination of 5 ml Diatrizoate and 5ml saline.
11557254|NCT00953186|Active Comparator|HBOT|100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks
11557255|NCT00953186|Placebo Comparator|Placebo|air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks
11557256|NCT00953173||LapBand|Patients who have already consented to receive the LAP-BAND AP® Adjustable Gastric Banding System
11557257|NCT00953160|Experimental|RF treatment|Abdomen, flank or thigh treated with RF device
11557258|NCT00953147|Experimental|Ciclesonide HFA 80 mcg once daily|Ciclesonide HFA nasal aerosol will be supplied in a 40 mcg canister, to be administered as 1 puff in each nostril (80 mcg per day).
11557259|NCT00953147|Experimental|Ciclesonide HFA 160 mcg once daily|Ciclesonide HFA nasal aerosol will be supplied in a 80 mcg canister, to be administered as 1 puff in each nostril (160 mcg per day).
11557260|NCT00953147|Placebo Comparator|Placebo once daily|The placebo HFA nasal aerosol is identical to active drug, but does not contain ciclesonide.
11557261|NCT00953134|Experimental|1|IFA - Iron and Folic Acid (60 mg of ferrous fumarate and 400 mcg folic acid)
11557262|NCT00953134|Active Comparator|2|FA - Folic Acid (400 mcg folic acid)
11557263|NCT00953121|Experimental|Cohort A-Grade IV No Failure|Recurrent GBM patients who have not previously failed bevacizumab, irinotecan, or carboplatin
11557264|NCT00953121|Experimental|Cohort B-Grade III No Failure|Recurrent Grade 3 malignant glioma patients who have not previously failed either bevacizumab, irinotecan or carboplatin
11557265|NCT00953121|Experimental|Cohort C-Failed Prior Therapy|Recurrent Grade IV GBM patients who have failed prior bevacizumab therapy, but not prior CPT-11 or carboplatin therapies
11557266|NCT00953108|Experimental|quetiapine|
11557267|NCT00953108|Active Comparator|escitalopram|
11557268|NCT00953095|Experimental|Caregiver Mediated Model (CMM)|focuses on joint attention/engagement intervention using an established evidence based treatment (Kasari et al., 2006). It involves meeting the parent and child in their home for one hour, twice a week for 12 weeks. In this intervention, the parent-child pair meet with the interventionist (as opposed to the group training in the CEM condition). Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input and coaching from the interventionist) as they implement these techniques with their child.
11557269|NCT00953095|Experimental|Caregiver Education Model (CEM)|focuses on teaching parents information about autism, behavior modification, and community services using a manualized approach (Brereton & Tonge, 2005). Parents will receive information on child development each week, and will be able to ask questions and discuss the information vis-à-vis their own child. This intervention is manualized (Brereton & Tonge 2005). In the CEM condition, parents meet in a group (without their children) in a community-based setting to receive the intervention. Intervention sessions occur once a week for 2 hours.
11557273|NCT00953056|Placebo Comparator|Cohort II - Placebo, Children|Children randomized to receive a single dose of matching placebo to RotaTeq™.
11557274|NCT00953056|Experimental|Cohort III - RotaTeq™, Infants|Infants randomized to receive 3 doses of RotaTeq™.
11557275|NCT00953056|Placebo Comparator|Cohort III - Placebo, Infants|Infants randomized to receive 3 doses of matching placebo to RotaTeq™.
11557276|NCT00953043|Active Comparator|Lubiprostone|Subjects randomized to this arm received 24 micrograms of lubiprostone per day for three days.
11557277|NCT00953043|Placebo Comparator|Placebo|Subjects randomized to this arm received placebo medication for three days.
11557278|NCT00953030|Experimental|COACH|"web-based risk assessments with an action plan that is negotiated with a Coach who provides personalized follow-up reinforcement"
11557279|NCT00953030|Experimental|RealAge|a web-based health risk assessment and risk profile with disease-specific follow-up reinforcement modules
11557280|NCT00953030|No Intervention|light health education control|
11557281|NCT00953017|Active Comparator|Miralax plus Amitiza|106 patients randomized to Miralax plus Amitiza will take one 24mcg gelcap of Amitiza at noon the day prior to their colonoscopy. On the day prior to the colonoscopy, the patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
11557282|NCT00953017|Active Comparator|Miralax plus Dulcolax|107 patients randomized to Miralax plus Dulcolax will take two 5mg tablets of Dulcolax at noon the day prior to their colonoscopy. On the day prior to the colonoscopy, the patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
11557283|NCT00953017|Active Comparator|Miralax|106 patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
11557284|NCT00953017|Active Comparator|Golytely (polyethylene glycol)|106 patients will take 1 gallon of golytley (Polyethylene glycol) and drink 1/2 of the solution at 4 p.m. The remaining 1/2 of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy
11557285|NCT00953004|Experimental|fiber drink|
11557286|NCT00953004|Experimental|fiber bread|
11557287|NCT00953004|Experimental|placebo|
11557288|NCT00952978|Experimental|10 mg ilaprazole|
11557289|NCT00952978|Active Comparator|20 mg omeprazole|
11557290|NCT00952965||blood pressure monitor|wrist circumference: 14cm-25cm
11557291|NCT00952965||stethoscopy|wrist circumference: 14cm-25cm
11557292|NCT00952913|Experimental|1|Bosutinib
11557293|NCT00952913|Experimental|2|bosutinib + lansoprazole
11557294|NCT00952900|Experimental|Early Biobehavioral Intervention|This intervention involves the use of non-invasive treatment modalities such as relaxation/biofeedback, stress management, and cognitive coping skills. It is based upon previous clinical research studies demonstrating the efficacy of this intervention in allowing acute TMD patients to better cope with stress and lifestyle issues that produce the TMD pain/discomfort.
11557295|NCT00952900|Active Comparator|Attention Control Group|This intervention involves the presentation of helpful information to patients that explains etiology and potential treatment modalities used to modify/reduce TMD pain/discomfort.
11557296|NCT00952900|No Intervention|No Active Treatment Comparison Group|Unlike the other two treatment groups, that involve high-risk acute TMD patients, this group includes low-risk acute TMD patients. Past studies have shown that these low risk patients do not need any early intervention in order to prevent chronicity.
11557297|NCT00952887|Experimental|ACE-031|8 dosing groups
11557298|NCT00952887|Placebo Comparator|Placebo|
11557299|NCT00952861|Active Comparator|Doxycycline|Doxycycline 200 mg QD in 5 days
11557300|NCT00952861|Placebo Comparator|Placebo|Matching placebo QD i 5 days
11557301|NCT00952848|Experimental|MC5-A Scramble instrument|Treatment of chronic neuropathic pain with the MC5-A device
11557302|NCT00952835||asthma and rhinitis control|
11557303|NCT00952822|Experimental|1|ADVATE reconstituted in 2 mL sterile water for infusion
11557304|NCT00952822|Active Comparator|2|ADVATE reconstituted in 5 mL sterile water for infusion
11557305|NCT00952796|Experimental|1|patients with intra-abdominal infection treated with moxifloxacin 400mg once daily
11557306|NCT00952796|Active Comparator|2|patients with intra-abdominal infection treated with ampicillin/sulbactam 1.5g 4 times daily
11557307|NCT00952783||1|
11557308|NCT00952770|Experimental|Atorvastatin|Group receiving atorvastatin 20mg/day
11557309|NCT00952770|Active Comparator|Simvastatin/Ezetimibe|Group receiving simvastatin/ezetimibe 10/10mg
11557310|NCT00952757||1.|Patients diagnosed of schizophrenia or bipolar disorder with APS-related hyperprolactinaemia who have been switched to quetiapine based on the clinician's judgement
11557311|NCT00952731|Experimental|oral placebo, afimoxifene|4-hydroxytamoxifen gel 2mg/breast applied daily. Oral placebo taken daily.
11557312|NCT00952731|Active Comparator|tamoxifen citrate, placebo gel)|Placebo gel applied to the breasts daily. 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules).
11557313|NCT00952718|No Intervention|Control|No intervention.
11557314|NCT00952718|Experimental|Inspiratory muscle training|With intervention.
11557315|NCT00952705|Experimental|Q/LAIV-BFS (MEDI8662)|Q/LAIV-BFS (quadrivalent influenza vaccine) (MEDI8662) was supplied in the blow-fill-seal delivery system that delivers a nominal dose of 0.2 mL into a single nostril. Each dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), B/Victoria (B/Malaysia/2506/2004), and B/Yamagata (B/Florida/4/2006).
11557366|NCT00952302|Placebo Comparator|CMS - placebo first|Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive a placebo (saline) infusion first followed by iron infusion.
11557469|NCT00951561|Active Comparator|Ibuprofen|
11557470|NCT00951548|Experimental|VSL#3|Probiotic preparation VSL#3
11557316|NCT00952705|Active Comparator|FluMist/B/Yamagata|FluMist/B/Yamagata was administered intranasally using a Becton Dickinson Accuspray™ device. A total volume of 0.2 mL was administered intranasally (approximately 0.1 mL into each nostril). Each dose contained 10^7.0 ± 0.5 FFU of each of 3 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), and B/Yamagata (B/Florida/4/2006)
11557317|NCT00952705|Active Comparator|FluMist/B/Victoria|FluMist/B/Victoria was administered intranasally using a BD Accuspray™ device. A total volume of 0.2 mL was administered intranasally (approximately 0.1 mL into each nostril). Each dose contained 10^7.0 ± 0.5 FFU of each of 3 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), and B/Victoria (B/Malaysia/2506/2004).
11557318|NCT00952679|Experimental|experimental arm|
11557319|NCT00952666|Experimental|Device|Both the Robot-Assisted Laparoscopic Radical Prostatectomy (RALRP) and the Transrectal Ultrasound (TRUS) are common performed procedures, but are normally performed separately. In this proposed feasibility study, the procedures will be combined.
11557320|NCT00952653|Experimental|DVS SR|
11557321|NCT00952640|Active Comparator|vitamin A directly post-partum|200.000 IU of vitamin A within 3 days of delivery
11557322|NCT00952640|Experimental|vitamin A delayed|200.000 IU vitamin A 6 weeks post-partum
11557323|NCT00952627|Experimental|Pycnogenol|200 mg/day
11557324|NCT00952627|Placebo Comparator|Control|placebo
11557325|NCT00952614|Experimental|Retisert for Retinal Vein Occlusion|0.59 mg Fluocinolone Acetonide (Retisert implant) for Retinal Vein Occlusion
11557326|NCT00952601|Experimental|Modified Atkins Diet|Patients are started on the modified Atkins diet at 15 grams per day.
11557327|NCT00952588|Experimental|AZD1152 1200 mg|AZD1152 1200 mg, iv, 7 day infusion monotherapy
11557328|NCT00952588|Active Comparator|LDAC 20 mg|LDAC 20 mg, sc, bd, 10 days (400mg per cycle)
11557329|NCT00952575|Active Comparator|polyclonal anti-D immunoglobulin|
11557330|NCT00952575|Experimental|Monoclonal anti-D immunoglobulin|
11557331|NCT00952562|Active Comparator|cholecalciferol|3000 IU cholecalciferol per day for 16 weeks
11557332|NCT00952562|Placebo Comparator|placebo|
11557333|NCT00952549|Experimental|Facial Yoga Toning Program|Patients will be instructed on 18 exercises which are intended to strengthen and tone the muscles of facial expression. DVD is provided.
11557334|NCT00952536|Active Comparator|Triple therapy|Daily Juice Plus+ with 2 vegetable & 2 fruit & 2 berry capsule (test group 1)
11557335|NCT00952536|Active Comparator|Dual Therapy|Juice Plus+ with 2 vegetable & 2 fruit & 2 placebo capsule (test group 2)
11557336|NCT00952536|Placebo Comparator|Control|Daily Placebo in the form of 6 capsules (control group)
11557337|NCT00952523|Experimental|Tretinoin & Adapalene-Benzoyl Peroxide|Tretinoin and Adapalene-Benzoyl Peroxide facial gels applied once daily in a split face model
11557338|NCT00952510||Whiplash patients|The cohort is based on 100 whiplash patients which underwent the measure procedure to obtain cervical range of motion.
11557339|NCT00952497|Experimental|Cisplatin, Capecitabine, Telatinib|
11557340|NCT00952484|Active Comparator|2 mg/kg|2 mg/kg subcutaneous injection three times per week.
11557341|NCT00952484|Active Comparator|3 mg/kg|3 mg/kg subcutaneous injection three times per week.
11557342|NCT00952471|No Intervention|Baseline Period|Patients in the baseline period were cared for using the standard historical electronic order set.
11557343|NCT00952471|Active Comparator|Post Intervention Period|Patients in the Post intervention period were cared for with evidence-bsed modified order set changes
11557344|NCT00952458|Experimental|BIS monitoring|Dosing of sedatives with BIS monitoring
11557345|NCT00952458|No Intervention|Standard monitoring|Dosing of sedatives without BIS monitoring
11557346|NCT00952445|Experimental|T0903131 Besylate|1.0 mg
11557347|NCT00952445|Experimental|T0903131 Besylate|10.0 mg
11557348|NCT00952445|Placebo Comparator|Placebo|Once daily, oral
11557349|NCT00952432|Active Comparator|ACUPUNCTURE|ACUPUNCTURE
11557350|NCT00952432|Active Comparator|MEDICATION|Carbamazepine
11557351|NCT00952419|Experimental|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1
11557352|NCT00952419|Experimental|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2
11557353|NCT00952419|Placebo Comparator|Placebo Group|Participants will receive a placebo vaccine
11557354|NCT00952406||Survey of Women PFDs|Women with PFDs
11557355|NCT00952393|Other|Pharmacokinetic|This single arm examines the pharmaco-kinetics of the release of 3-2,4 dimethoxy-benzilidene anabaseine in a hypomellose sustained release formulation.
11557356|NCT00952380|Other|Single Arm|Single arm open-label
11557357|NCT00952367||Per-protocol population|In all, 3641 participants were enrolled; however, 38 were excluded because of violation of inclusion/exclusion criteria and 3 participants were excluded for unavailability of nasopharyngeal swab sample. The record presents demographic and result data for 3600 participants in the per-protocol population. These participants completed collection of the nasopharyngeal swab sample, the Epidemiology questionnaire, and 24 hours safety observation.
11557358|NCT00952354||research group|60 children aged from 3 to 10 years, both genders, observed in a symbolic play situation with their language therapists
11557359|NCT00952341|Experimental|Aprepitant (MK-0869)|
11557360|NCT00952341|Placebo Comparator|Standard Therapy|
11557361|NCT00952328|Experimental|Limited Formula|Participants will supplement feedings with early limited formula following nursing
11557362|NCT00952328|No Intervention|Control|Participants are instructed to continue exclusively breastfeeding; no use of formula
11557363|NCT00952315|Active Comparator|Stonebreaker|Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
11557364|NCT00952315|Active Comparator|Lithoclast Select|Lithoclast Select will be used to breakup and remove kidney stone. Duration will be timed and documented.
11557365|NCT00952315|Active Comparator|Cyberwand|The dual probe Cyberwand device will be used to fragment and remove the kidney stone. Duration will be timed and documented.
11557367|NCT00952302|Experimental|CMS - iron|Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive an iron infusion first followed by placebo (saline) infusion.
11557368|NCT00952302|Placebo Comparator|SLR - placebo|Sea level residents (SLR) taken to high altitude for one week, and receiving placebo (saline) infusion on Day 3 at high altitude.
11557369|NCT00952302|Experimental|SLR - iron|Sea level residents (SLR) taken to high altitude for one week, and receiving iron infusion on Day 3 at high altitude.
11557370|NCT00952289|Experimental|Ruxolitinib|Participants received ruxolitinib orally twice a day. The starting dose was determined based on Baseline platelet count. Patients with Baseline platelet count > 200,000/μL began a dose regimen of 20 mg twice daily. Patients with Baseline platelet count of 100,000/μL to 200,000/μL (inclusive) began a dose regimen of 15 mg twice daily. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily. Patients receiving benefit could continue treatment until the later of marketing approval or when the last randomized patient remaining in the study had completed Week 144 (36 months).
11557371|NCT00952289|Placebo Comparator|Placebo|Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting certain protocol requirements detailed below were given the opportunity to cross over to ruxolitinib treatment.
11557372|NCT00952276|Experimental|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1 (with adjuvant)
11557373|NCT00952276|Experimental|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2 (with adjuvant)
11557374|NCT00952276|Active Comparator|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 vaccine formulation 3
11557375|NCT00952276|Active Comparator|A/H1N1 Vaccine Group 4|Participants will receive A/H1N1 vaccine formulation 4
11557376|NCT00952276|Placebo Comparator|Placebo Group 5|Participants will receive a placebo vaccine
11557377|NCT00952263|Experimental|MBL-HCV1|
11557378|NCT00952250|Active Comparator|Targeted Feedback Reports|Conventional feedback reports
11557379|NCT00952250|Experimental|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement.
11557380|NCT00952237|Experimental|IL-2 and GM-CSF for Mobilization|Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
11557381|NCT00952224||Acute myocardial infarction patients|Patients undergoing primary percutaneous coronary intervention in ST-elevation myocardial infarction plus magnetic resonance imaging
11557382|NCT00952211|Active Comparator|CPAP|CPAP at therapeutic pressure
11557383|NCT00952211|Sham Comparator|sub-therapeutic CPAP|CPAP administered at sub-therapeutic pressure
11557384|NCT00952198|Experimental|ARRY-403|
11557385|NCT00952198|Placebo Comparator|Placebo|
11557386|NCT00952159||Not Poor metabolizer|
11557387|NCT00952159||Poor metabolizer|
11557388|NCT00952146|Experimental|Transgastric peritoneoscopy|Only one arm, feasibility study
11557389|NCT00952133|Experimental|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery.
11557390|NCT00952133|Placebo Comparator|Palonosetron only|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Intravenous Palonosetron and Saline solution
11557391|NCT00952120|Experimental|GSUC|Gauze-based wall suction negative pressure wound therapy for 4-5 days
11557392|NCT00952120|Active Comparator|Vacuum-assisted closure|Vacuum-assisted closure (VAC) negative pressure wound therapy using commercially available device (KCI, Inc) for 4-5 days
11557393|NCT00952107|Experimental|Imaging system operation|
11557394|NCT00952094|Active Comparator|KRN1493 50mg group|KRN1493 50mg single oral administration
11557395|NCT00952094|Active Comparator|KRN1493 75mg group|KRN1493 75mg single oral administration
11557396|NCT00952094|Active Comparator|KRN1493 100mg group|KRN1493 100mg single oral administration
11557397|NCT00952081|Experimental|clevidipine,brain tumor,hypertension|21 or older, Clevidipine in brain tumor resection, epilepsy focus resection during acute hypertension under general anesthesia
11557398|NCT00952068|Experimental|Tramadol Contramid® OAD 200mg|1 Tramadol Contramid® OAD 200mg tablet daily.
11557399|NCT00952055||Patients diagnosed with acute coronary syndrome (ACS)|
11557400|NCT00952042|Experimental|Heavy slow resistance training|12 wks of heavy slow resistance training. training three times per week. each session: 3 heel-raise exercises. 12-6RM. Slow contractions.
11557401|NCT00952042|Active Comparator|Eccentric resistance training|12 wks of eccentric resistance training. 3 x 15 Eccentric heel-raises performed twice daily.
11557402|NCT00952029|Experimental|Maintenance with bevacizumab|FOLFIRI + Avastin and during the chemotherapy-free interval maintenance with bevacizumab
11557403|NCT00952029|Active Comparator|No maintenance with bevacizumab|FOLFIRI + Avastin and during the chemotherapy-free interval NO maintenance
11557404|NCT00952003|Experimental|interventional arm|Oxaliplatin, Irinotecan and Bevacizumab for 3 cycles followed by Docetaxel and Bevacizumab for a further 3 cycles. Upon completion of the combination therapy cycles Bevacizumab will be continued until progression.
11557405|NCT00951977||Subjects who have formerly donated a kidney|
11557406|NCT00951977||Matched community control Subjects|
11557407|NCT00951964|Other|1|patients receive the treatment in first and placebo in second part of study
11557408|NCT00951964|Other|2|patients receive placebo in first and treatment in second part of study
11557409|NCT00951951|Active Comparator|Anterior Surgical Approach|(AMIS)
11557410|NCT00951951|Active Comparator|Posterior Approach Group|Posterior surgical approach for total hip replacement.
11557411|NCT00951925||No Treatment|
11557412|NCT00951912|Placebo Comparator|Placebo|10g soy protein isolated powder patch by mouth everyday for 6months
11557413|NCT00951912|Experimental|Daidzein|10g soy protein isolated plus 50mg daidzein powder patch by mouth everyday for 6 months
11557414|NCT00951912|Experimental|Genistein|10g soy protein isolated plus 50mg genistein powder patch by mouth everyday for 6 months
11557415|NCT00951899|Experimental|Colesevelam|Treatment with colesevelam hydrochloride in addition to Metformin and Diet
11557416|NCT00951899|Placebo Comparator|Placebo|Treatment with placebo in addition to Metformin and Diet
11557417|NCT00951873|Experimental|A|
11557418|NCT00951873|Placebo Comparator|B|
11557419|NCT00951873|Experimental|C|
11557420|NCT00951860||Newborn|Every child born in the CHU of Saint-Étienne (inborn), any term of its birth, in the hospital neonatal unit at the time of registration (after 37 weeks corrected for prematurity) or in the maternity
11557421|NCT00951847|Experimental|1|Oxcarbazepine oral suspension 300 mg/5 mL of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
11557422|NCT00951847|Active Comparator|2|Trileptal® (oxcarbazepine) oral suspension 300 mg/5 mL of Novartis
11557423|NCT00951834|Experimental|Epigallocatechin-Gallate|"Months 1-3: 200 mg EGCG/die (200-0-0 mg)
~Months 4-6: 400 mg EGCG/die (200-0-200 mg)
~Months 7-9: 600 mg EGCG/die (400-0-200 mg)
~Months 10-18: 800 mg EGCG/die (400-0-400 mg)
~add-on to Donepezil."
11557424|NCT00951834|Placebo Comparator|Placebo|add-on to Donepezil.
11557425|NCT00951821|Experimental|Concurrent treatment|Concurrent treatment - experimental condition: Adolescent participants and their parents will receive concurrent cognitive behavioral therapy.
11557426|NCT00951821|Active Comparator|Adolescent treatment only|Adolescent treatment only - Active Comparator: Only adolescent participants will receive cognitive behavioral therapy.
11557427|NCT00951808|Active Comparator|Blood Transfusion Trial Cohort|Twenty participants will receive a blood transfusion while in the hospital.
11557428|NCT00951808|Active Comparator|Standard Care Trial Cohort|Twenty participants will not receive a blood transfusion and will receive standard care.
11557429|NCT00951808|Active Comparator|Standard Care Observational Cohort|Approximately 300 participants who are ineligible for or decline the blood transfusion part of the study will participate in the observational portion of the study and receive standard care.
11557430|NCT00951795||Adults|Adult men and women over age of 18
11557431|NCT00951795||Pediatrics|Pediatric boys and girls ages 12-18
11557432|NCT00951782|Active Comparator|High frequency TMS + smoking cue|
11557433|NCT00951782|Sham Comparator|Sham TMS + smoking cue|
11557434|NCT00951782|Active Comparator|Low frequency TMS +smoking cue|
11557435|NCT00951782|Sham Comparator|Sham TMS - no cue|
11557436|NCT00951782|Active Comparator|High frequency TMS - no cue|
11557437|NCT00951782|Active Comparator|Low frequency - no cue|
11557438|NCT00951769||Control,|Control
11557439|NCT00951769||DAS: Difficult Airway Society, UK|DAS difficult airway algorithm
11557440|NCT00951769||Australian|Australian difficult airway algorithm
11557441|NCT00951756|Other|High Fat Low Fiber Diet|
11557442|NCT00951756|Other|Low Fat High Fiber Diet|
11557443|NCT00951743|Experimental|Adaptavir Treatment|MDAPTA (Adaptavir) will be administered intranasally at 0.01 mg twice per day. Individuals with plasma viral load (PCR Roche Amplicor Ultrasensitive assay) less than 200 copies/mL, sustained for the previous 90 days, with CD4>350 cells/mm3 will be eligible to participate.
11557444|NCT00951743|Placebo Comparator|Placebo|Placebo will be administered intranasally at 0.01 mg twice per day. Individuals with plasma viral load (PCR Roche Amplicor Ultrasensitive assay) less than 200 copies/mL, sustained for the previous 90 days, with CD4>350 cells/mm3 will be eligible to participate.
11557445|NCT00951730||Down syndrome|Adult and children with Down syndrome.
11557446|NCT00951717|No Intervention|Treatment as usual|Participants will receive standard postpartum education and discharge materials provided by the hospital and a list of community and Internet resources by mail.
11557447|NCT00951717|Experimental|Behavioral education|Participants will receive behavioral education on postpartum depression and a list of community and Internet resources by mail.
11557448|NCT00951704||Cardiac arrest|
11557449|NCT00951691|Experimental|Enhanced acute medical rehabilitation|Participants will receive enhanced acute medical rehabilitation.
11557450|NCT00951691|Active Comparator|Treatment as usual|Participants will receive treatment as usual.
11557451|NCT00951678||ER patients|"Subjects must be 18 yrs or older, male or female, and must have the anatomy that we will be examining. Patients will be given the option of enrolling in the study whilst being cared for in Tampa General Hospital Emergency Room.
~We anticipate enrolling normal, healthy volunteers, elderly persons (>65) not cognitively impaired, persons with social, economic or educational disadvantages , and persons who do not understand English fluently."
11557452|NCT00951665|Experimental|Phase lb Regimen 1|Participants received trastuzumab emtansine (T-DM1) every three weeks (Q3W) + paclitaxel weekly (QW) intravenously.
11557453|NCT00951665|Experimental|Phase Ib Regimen 2|Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously.
11557454|NCT00951665|Experimental|Phase Ib Regimen 3|Participants received T-DM1 QW + paclitaxel QW intravenously.
11557455|NCT00951665|Experimental|Phase Ib Regimen 4|Participants received T-DM1 QW + paclitaxel QW + pertuzumab Q3W intravenously.
11557456|NCT00951665|Experimental|Phase IIa Group A|Participants received maximum tolerated dose (MTD) from Phase 1b i.e. T-DM1 3.6mg/kg Q3W + paclitaxel 80mg/m^2 QW intravenously.
11557457|NCT00951665|Experimental|Phase IIa Group B|Participants received MTD from Phase 1b i.e. T-DM1 3.6mg/kg Q3W + paclitaxel 80mg/m^2 QW + pertuzumab Q3W intravenously.
11557458|NCT00951652|Experimental|CBT plus supportive listening|14 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques and the second hour will be supportive listening
11557459|NCT00951652|Active Comparator|CBT plus Interpersonal and emotional processing therapy|14 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques and the second hour will be Interpersonal and emotional processing therapy
11557460|NCT00951639|Experimental|5g Cassia cinnamon|Experimental treatment group
11557461|NCT00951639|Active Comparator|50 minutes endurnace exercise|Endurance exercise treatment known to influence blood glucose
11557462|NCT00951639|Placebo Comparator|5g Cellulose|Placebo equivalent in weight and appearance to experimental treatment
11557463|NCT00951600|Experimental|1|Oxcarbazepine oral suspension 300 mg/5mL of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
11557464|NCT00951600|Active Comparator|2|Trileptal® (oxcarbazepine) oral suspension 300 mg/5mL of Novartis
11557465|NCT00951587|Experimental|1|Patients that are indicated for colonoscopy or who are suspected or known to suffer from colonic diseases.
11557466|NCT00951574|Placebo Comparator|saline solution|Pre-filled syringes of 0.4 ml, 1 subcutaneous injection/day (every 24 hours).
11557467|NCT00951574|Experimental|nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
11557471|NCT00951548|Placebo Comparator|placebo|Corn Starch
11557472|NCT00951535|Other|Arm A|Treatment will be delivered in 1.8 Gy fractions; dose escalation will be in 1.8 Gy increments from 75.6 Gy to a maximum 81 Gy.
11557473|NCT00951522|Experimental|1|GS-9411 2.4 mg
11557474|NCT00951522|Experimental|2|GS-9411 4.8 mg
11557475|NCT00951522|Experimental|3|GS-9411 7.2 mg
11557476|NCT00951522|Experimental|4|GS-9411 9.6 mg
11557477|NCT00951522|Placebo Comparator|5|Placebo
11557478|NCT00951509||Condition 1 (PC Screens with No Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
11557479|NCT00951509||Condition 2 (PC Screens with Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
11557480|NCT00951509||Condition 3 (VR Screens with No Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
11557481|NCT00951509||Condition 4 (VR Screens with Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
11557482|NCT00951509||Condntion 5 (Real-world driving)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
11557483|NCT00951496|Experimental|Arm I (paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1 in courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone in courses 7-22 in the absence of disease progression or unacceptable toxicity.
11557484|NCT00951496|Experimental|Arm II (paclitaxel, bevacizumab, carboplatin IP)|Patients receive paclitaxel as in Arm I and carboplatin IP on day 1. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
11557485|NCT00951496|Experimental|Arm III (paclitaxel IP, bevacizumab, cisplatin IP)|Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IP on day 2, and paclitaxel IP on day 8. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
11557486|NCT00951483|Experimental|Intervention Cohort|Patients will undergo baseline psychological and laboratory tests then receive Quetiapine-XR(Seroquel-XR) with flexible dosing at the discretion of the treating physician based on clinical response and tolerability. The dose range will be from 50-300mg. The total duration of the treatment will be 12 weeks.
11557487|NCT00951483|No Intervention|Healthy Control|Participants without major depressive disorder or anxiety are enrolled as a comparison group without intervention.
11557488|NCT00951470|Other|No CDT|CDT=complete decongestive therapy
11557489|NCT00951470|Other|Modified CDT Program|CDT=complete decongestive therapy
11557490|NCT00951470|Other|Full CDT Program|CDT=complete decongestive therapy
11557491|NCT00951457|Experimental|Overall study|"Dose escalation phase:
~Days -3, -2, -1: 3 - 10 - 30 mg Alemtuzumab s.c.
~Treatment phase:
~Bendamustine 70 mg/m2 i.v. on d1 + d2 repeat every 28 days for 4 cycles
~Alemtuzumab 30 mg s.c. 3x per week (days 1, 3, 5) continuously in parallel with chemotherapy cycles for a maximum of 16 weeks"
11557492|NCT00951444|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and MK-0646 IV over 60 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients with stable disease or partial or complete response may then receive MK-0646 alone on days 1 and 15. Treatment with MK-0646 repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11557493|NCT00951444|Active Comparator|Arm II|Patients receive gemcitabine hydrochloride and carboplatin as in arm I. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients may crossover to arm upon disease progression.
11557494|NCT00951431|Experimental|PPI|
11557495|NCT00951431|Placebo Comparator|Control|
11557496|NCT00951405|Experimental|A|
11557497|NCT00951405|Experimental|B|
11557498|NCT00951405|Experimental|C|
11557499|NCT00951392|Experimental|Problematic aging|
11557500|NCT00951392|Experimental|successful aging|
11557501|NCT00951379|Experimental|Arm I (Pioglitazone Hydrochloride)|Three (3) Pioglitazone 15 mg capsules by mouth once daily for 24 weeks
11557502|NCT00951379|Placebo Comparator|Arm II (Placebo)|Three (3) placebo capsules by mouth once daily for 24 weeks
11557503|NCT00951366||Bronchopulmonary Dysplasia (BPD)|
11557504|NCT00951353||Pediatric Renal Transplant Recipients|
11557505|NCT00951340|Active Comparator|CBT with listening therapy|Participants will receive CBT with listening therapy.
11557506|NCT00951340|Experimental|CBT with emotional processing and interpersonal therapy|Participants will receive CBT with emotional processing and interpersonal therapy.
11557507|NCT00951301|Active Comparator|mangosteen juice|subjects randomized 1:1 to this arm will receive juice containing the mangosteen ingredient
11557508|NCT00951301|Placebo Comparator|placebo juice|subjects randomized 1:1 to this arm will receive specially prepared juice not containing mangosteen ingredient
11557509|NCT00951288|Active Comparator|Saffron|Crocus Sativus extract
11557510|NCT00951288|Placebo Comparator|Placebo|Placebo comparator
11557511|NCT00951275|Experimental|1|
11557512|NCT00951262|Experimental|life review|a life review program includes 3-session life review and formulation of a life review book as a gift for advanced cancer patients.
11557513|NCT00951262|No Intervention|controlled group|the subjects in the controlled group do not receive the life review program
11557514|NCT00951249|Experimental|A|HIV-infected and uninfected black MSM
11557515|NCT00951236|Active Comparator|One injection|
11557516|NCT00951236|Active Comparator|Two Injections|
11557562|NCT00950885|Placebo Comparator|Placebo|placebo control group will receive 4 doses of identically-appearing capsules containing cellulose
11557563|NCT00950885|Experimental|Low dose melatonin|0.5 mg melatonin
11557564|NCT00950885|Experimental|High dose melatonin|3.0 mg melatonin
11557517|NCT00951223||Patients with Chronic Hepatitis C|HCV positive patients who have failed previous HCV therapy This observational prospective registry is designed to evaluate the safety, adherence, and efficacy of prescribed, patientadministered therapy with Infergen® (Interferon alfacon-1) and other prescribed therapies in patients chronically infected with HCV. The primary endpoint for efficacy will be the SVR rate at 24 weeks after therapy ends. Safety will be assessed by monitoring AEs, reduction/discontinuation of therapy because of AEs, routine laboratory results and by other means determined by the Investigator
11557518|NCT00951210|Experimental|PLX-PAD low dose|IM injection Single treatment; multiple injections
11557519|NCT00951210|Experimental|PLX-PAD high dose|IM injection Double treatment; multiple injections
11557520|NCT00951197||elderly subjects retired from agriculture|
11557521|NCT00951171|Experimental|Cervical occulsion|Insemination Eliptosphere catheter filled with 1cc of air for 15 minutes. H/S Eliptosphere by Copper surgical (U.S. Patent No. 5,624,399)
11557522|NCT00951171|Active Comparator|Standard IUI|Insemination with TOmcat catheter
11557523|NCT00951158|Experimental|CLA|Open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. oral dose 7.5 g/day 28 day cycle
11557524|NCT00951132|Experimental|2|Rosuvastatin
11557525|NCT00951132|Placebo Comparator|1|Placebo
11557526|NCT00951119|Experimental|resperate device|"Resperate© is a device that helps to slow down breathing. This device can measure the breathing patterns through a breathing sensor mounted on the upper abdomen or chest. Furthermore, music-like sound patterns can be composed similar to this breathing pattern, which the patient can hear through the headphones of the Resperate©. By prolonging the expiration, which can be voluntarily used by the user, the frequency of respiration can be slowed down and become more stable (aim<10 breathings per minute)."
11557527|NCT00951119|Sham Comparator|control device|Resperate device without slowing of breathing
11557528|NCT00951106|Experimental|Pyrimethamine/sulfdoxine (Fansidar)|Pyrimethamine/sulfdoxine (Fansidar)
11557529|NCT00951093||Patients assessed for GERD|Patients who had an open gastric bypass were assessed for GERD before and after surgery following the Montreal Consensus through a validated questionnaire in Portuguese language
11557530|NCT00951080|Experimental|SNaP Wound Care System|
11557531|NCT00951080|Active Comparator|Traditional NPWT System|
11557532|NCT00951067|Active Comparator|Group A|Exercise, Elevation, and Garment Compression
11557533|NCT00951067|Active Comparator|Group B|Pneumatic Compression Device (B)
11557534|NCT00951067|Active Comparator|Group C|Pneumatic Compression Device (C)
11557535|NCT00951067|Active Comparator|Group D|Pneumatic Compression Device (D)
11557536|NCT00951067|Active Comparator|Group E|Pneumatic Compression Device (E)
11557537|NCT00951041|Experimental|GSK2340272A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine. The first vaccine dose was administered intramuscularly in the deltoid region of the non-dominant arm at Day 0, and the second vaccine dose was administered intramuscularly in the deltoid region of the dominant arm at Day 21.
11557538|NCT00951041|Experimental|GSK2340269A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine. The first vaccine dose was administered intramuscularly in the deltoid region of the non-dominant arm at Day 0, and the second vaccine dose was administered intramuscularly in the deltoid region of the dominant arm at Day 21.
11557539|NCT00951028|Active Comparator|Enhanced treatment as usual|Participants will receive the life-steps intervention and treatment as usual.
11557540|NCT00951028|Experimental|CBT for adherence and depression (CBT-AD)|Participants will receive the life-steps and CBT-AD interventions.
11557541|NCT00951028|Active Comparator|ISP for adherence and depression (ISP-AD)|Participants will receive the life-steps and ISP-AD interventions.
11557542|NCT00951015|Experimental|10 mg GSK1349572|subjects will receive GSK1349572 10mg once daily blinded to dose
11557543|NCT00951015|Experimental|25mg GSK1349572|subjects will receive GSK1349572 25mg once daily blinded to dose
11557544|NCT00951015|Experimental|50mg GSK1349572|subjects will receive GSK1349572 50mg once daily blinded to dose
11557545|NCT00951015|Other|efavirenz control|efavirenz will serve as the internal control arm
11557546|NCT00951002||acellualr dermal matrix|patients treated with acellular dermal matrix plug
11557547|NCT00950989|Experimental|AMG 827 210 mg|210 mg AMG 827
11557548|NCT00950989|Experimental|AMG 827 140 mg|140 mg AMG 827
11557549|NCT00950989|Experimental|AMG 827 70 mg|70mg AMG 827
11557550|NCT00950989|Placebo Comparator|Placebo|Placebo
11557551|NCT00950976|Experimental|Citrulline|
11557552|NCT00950976|Placebo Comparator|lemonade|Equal volume and flavor to citrulline.
11557553|NCT00950963|Experimental|Phone Counseling|The telephone outreach intervention was considered an adjunct to usual care. The study nurse focused on optimizing lipids utilizing published guidelines through phone contact.
11557554|NCT00950963|Active Comparator|Standard Care|Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
11557555|NCT00950950|Placebo Comparator|Placebo|Participants were randomized to receive matching placebo administered by subcutaneous injection once every 4 weeks (Q4W) for 3 months.
11557556|NCT00950950|Experimental|Romosozumab|Participants were randomized to receive 3 mg/kg romosozumab administered by subcutaneous injection once every 4 weeks (Q4W) for 3 months.
11557557|NCT00950937||HIV Group|HIV infected persons
11557558|NCT00950937||Control Group|Non HIV-infected persons
11557559|NCT00950924|Experimental|Bifocal Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
11557560|NCT00950924|Placebo Comparator|Single Vision Soft Contact Lenses|Subjects will be fitted with single vision soft contact lenses with goal of corrected emmetropia at a distance of 20 feet.
11557561|NCT00950911|Experimental|1|
11557565|NCT00950872|Experimental|Duet TRS|Subjects receive Duet TRS
11557566|NCT00950859|Experimental|GSK1349572 Cohort I|Single Arm, Cohort I
11557567|NCT00950859|Experimental|GSK1349572 Cohort II|Single Arm, Cohort II
11557568|NCT00950846|Experimental|Umbilical Cord Blood Transplant Treatment Plan|Busulfan, Cytoxan, Fludarabine, Cord Blood Stem Cell Infusion
11557569|NCT00950833|Active Comparator|AP-AP Group|subjects from the AP-AP group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in study NCT00496015, receiving an additional dose of pneumococcal conjugate vaccine GSK1024850A for immune memory assessment
11557570|NCT00950833|Active Comparator|NAP-pre Group|subjects from the NAP-pre group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in study NCT00496015 receiving an additional dose of pneumococcal conjugate vaccine GSK1024850A for immune memory assessment
11557571|NCT00950833|Active Comparator|Unprimed Group|Age-matched subjects from the unprimed group of the NCT00496015 study, not previously vaccinated with any pneumococcal vaccine, receiving two doses of pneumococcal conjugate vaccine GSK1024850A
11557572|NCT00950820|Experimental|Panitumumab + XELOX|KRAS mutational status wild-type: Panitumumab plus Oxaliplatin and Capecitabine (XELOX)
11557573|NCT00950820|Other|XELOX (KRAS mutational status wt)|KRAS mutational status wild-type: Oxaliplatin and Capecitabine (XELOX)
11557574|NCT00950820|Other|XELOX (KRAS mutational status mutant)|KRAS mutational status mutant: Oxaliplatin and Capecitabine (XELOX)
11557575|NCT00950807|Placebo Comparator|Placebo|Placebo
11557576|NCT00950807|Active Comparator|Tiotropium|Tiotropium
11557577|NCT00950807|Experimental|Arm 1|GSK573719 1000mcg once daily
11557578|NCT00950807|Experimental|Arm 2|GSK573719 500mcg once daily
11557579|NCT00950807|Experimental|Arm 3|GSK573719 250mcg once daily
11557580|NCT00950807|Experimental|Arm 4|GSK573719 125mcg once daily
11557581|NCT00950807|Experimental|Arm 5|GSK573719 62.5 mcg once daily
11557582|NCT00950807|Experimental|Arm 6|GSK573719 250mcg twice daily
11557583|NCT00950807|Experimental|Arm 7|GSK573719 125mcg twice daily
11557584|NCT00950807|Experimental|Arm 8|GSK573719 62.5mcg twice daily
11557585|NCT00950794|Active Comparator|Hokunalin(tulobuterol) tape|Hokunalin(tulobuterol) tape: long-acting Beta2-agonist
11557586|NCT00950794|Experimental|Salmeterol(408DP-02)|Salmeterol(408DP-02)：long-acting Beta2-agonist
11557587|NCT00950781||Group|Group
11557588|NCT00950768|Active Comparator|Mel100|
11557589|NCT00950768|Experimental|Mel200|
11557590|NCT00950755|Experimental|Tositumomab and Iodine I 131 Tositumomab (anti-B1 antibody)|In the first phase (dosimetric dose) patients will receive an infusion of unlabeled Anti B1 Antibody (450 mg) followed by an infusion of Anti B1 Antibody (35 mg) which has been trace-labeled with 5 mCi of Iodine 131. Whole body gamma camera scans will be obtained following the dosimetric dose. Using the dosimetric data, a patient-specific dose of Iodine 131 Anti B1 Antibody to deliver the desired total body dose of radiotherapy will be calculated. In the second phase, (radioimmunotherapeutic dose), patients will receive an infusion of unlabeled Anti B1 Antibody (450 mg) followed by an infusion of 35 mg Anti B1 Antibody labeled with the patient-specific dose of Iodine 131 to deliver a whole body dose of 75 cGy. Patients will be treated with saturated solution potassium iodide, Lugol's solution, or potassium iodide tablets starting at least 24 hours prior to the first infusion and continuing for 14 days following the last infusion of Iodine 131 Anti B1 Antibody.
11557591|NCT00950742|Experimental|BIBW 2992 + Trastuzumab|Find maximum tolerated dose of the non-marketed substance:BIBW 2992 given orally with fixed weekly infusion doses of 2mg/kg Herceptin. Escalating doses of BIBW 2992 starting at 20mg daily.
11557592|NCT00950729|Active Comparator|Driving with Running Shoes|
11557593|NCT00950729|Active Comparator|Driving with Plaster cast|
11557594|NCT00950729|Active Comparator|Driving with Aircast|
11557595|NCT00950716|Active Comparator|Usual care|The 'control arm' will receive standard usual care with clinicians' follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
11557596|NCT00950716|Active Comparator|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
11557597|NCT00950690||Study Drug - Xalatan 0.005% eye drops|
11557598|NCT00950677|Active Comparator|exenatide|exenatide one dose
11557599|NCT00950677|Active Comparator|pramlintide|pramlintide one dose
11557600|NCT00950664|Experimental|Dysport® to Botox®|Dysport® injection in first intervention period and Botox® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA)
11557601|NCT00950664|Experimental|Botox® to Dysport®|Botox® injection in first intervention period and Dysport® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA)
11557602|NCT00950651|Experimental|1 Tramadol HCl Contramid® Once A Day|
11557603|NCT00950651|Active Comparator|2 Tramadol HCl Twice a day (SR)|
11557604|NCT00950638|Active Comparator|dose comparison|
11557605|NCT00950638|Active Comparator|Dose comparison|
11557606|NCT00950625|Active Comparator|intraperitoneal lignocaine|Intraperitoneal lignocaine will be compared with intraperitoneal bupevacaine for pain control after laparoscopic cholecystectomy
11557607|NCT00950625|Active Comparator|intraperitoneal bupevacaine|intraperitoneal lignocaine will be compared with intraperitoneal bupevacaine after laparoscopic cholecystectomy
11557608|NCT00950612|Experimental|Group A|
11557609|NCT00950612|Placebo Comparator|Group B|
11557610|NCT00950599|Experimental|Saxagliptin (2.5 mg)|
11557611|NCT00950599|Experimental|Saxagliptin (5 mg)|
11557612|NCT00950599|Experimental|Saxagliptin (10 mg)|
11557613|NCT00950599|Experimental|Saxagliptin (20 mg)|
11557614|NCT00950599|Experimental|Saxagliptin (40 mg)|
11557615|NCT00950599|Experimental|Saxagliptin (100 mg)|
11557616|NCT00950599|Placebo Comparator|Placebo|
11557617|NCT00950586|Experimental|Cohort 1|14 days dosing
11557618|NCT00950586|Experimental|Cohort 2|Single dose followed by 14 days repeat dosing
11557619|NCT00950586|Experimental|Cohort 3|Up to 28 days repeat dosing with drug interaction
11557620|NCT00950573||hemodialysis|patients treated with conventional hemodialysis
11557621|NCT00950573||peritoneal dialysis|patients treated with peritoneal dialysis
11557622|NCT00950573||nocturnal hemodialysis|patients treated with frequent nocturnal hemodialysis
11557623|NCT00950573||kidney transplantation|patients treated with renal transplantation
11557624|NCT00950560||inpatient|
11557625|NCT00950560||outpatient|
11557626|NCT00950560||emergency patient|
11557627|NCT00950547|Active Comparator|Control|Traditional Chest drains
11557628|NCT00950547|Experimental|CARDIOPAT|CARDIOPAT Cell Saver after Surgery
11557629|NCT00950534|Experimental|General Practitioner initiation with insulin glargine|Patients will be prescribed insulin glargine by their Investigator and they will be taught how to administer insulin glargine according to Australian guidelines. Patients will be treated for 24 weeks.
11557630|NCT00950534|Active Comparator|Usual standard of care|Patients will be treated by their Investigator with the usual standard of care for 24 weeks (e.g., OAD dose titration, addition of a second or third OAD, or referral to an endocrinologist)
11557631|NCT00950521|Active Comparator|PBSC Treatment|Patients in PBSC treatment will receive brain implant of autologous peripheral blood stem cell(CD34+) plus convention stroke treatment that include rehabilitation and antiplatelet medication
11557632|NCT00950521|Active Comparator|Control|Control group receive conventional stroke treatment that include rehabilitation and antiplatelet medication
11557633|NCT00950508|Active Comparator|High volume plasma exchange|3 successive plasma exchanges over 3 days
11557634|NCT00950508|Placebo Comparator|Standard medical treatment|
11557635|NCT00950495|Active Comparator|Mandibular advancement device (MAD)|an MAD is placed in the mouth prior to sleep. After waking up in the morning, the appliance is removed.
11557636|NCT00950495|Active Comparator|nasal CPAP|The device is turned on, and the nasal mask is placed on the nose prior to sleep. After waking up in the morning, the device is turned off and the mask is removed
11557637|NCT00950495|Placebo Comparator|placebo|the placebo appliance is placed in the mouth prior to sleep. After waking up in the morning, the appliance is removed.
11557638|NCT00950482|Active Comparator|TA|Active TA
11557639|NCT00950482|Active Comparator|AA|Alternative Acupuncture
11557640|NCT00950482|Active Comparator|WC|Waiting Group
11557641|NCT00950469||patients with acute coronary syndrome|"94 consecutive patients without ST-segment elevation admitted to the Chest Pain Unit of the University of Heidelberg were enrolled with symptoms suggestive of ACS.
~Unstable angina and non-ST-segment elevation myocardial infarction were diagnosed using the joint European Society of Cardiology/American College of Cardiology/American Heart Association/World Heart Federation Task Force redefinition of myocardial infarction guidelines. Patients with ST-segment elevation were excluded."
11557642|NCT00950456||H1N1 Pandemic Influenza Vaccine|Subjects will be enrolled and vaccinated according to national policy and standard practice.
11557643|NCT00950443|Experimental|1|Children with upper airway obstruction
11557644|NCT00950443|Active Comparator|2|Children without upper airway obstruction
11557645|NCT00950430|Experimental|PiB PET, FDG PET, Tau PET|
11557646|NCT00950417|Experimental|Esophageal Cancer|
11557647|NCT00950404|Active Comparator|Viagra 50 mg tablet, administered with water.|
11557648|NCT00950404|Experimental|Formulation B ODT tablet 50 mg, administered without water.|
11557649|NCT00950404|Experimental|Formulation C ODT tablet 50 mg, administered without water.|
11557650|NCT00950404|Experimental|Formulation D ODT tablet 50 mg, administered without water.|
11557651|NCT00950391|Experimental|Tacrolimus|Treatment with tacrolimus following nerve repair/reconstruction
11557652|NCT00950378||CVI|Varicose veins, varicose veins with leg swelling, venous stasis skin color changes, no open ulcers
11557653|NCT00950378||No treatment|Subjects with no venous disease CEAP (clinical etiology antomy pathophysiology)Class 0
11557654|NCT00950365|Active Comparator|Arm A (pemetrexed)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11557655|NCT00950365|Experimental|Arm B (pemetrexed disodium, erlotinib hydrochloride)|Patients receive pemetrexed disodium IV as in Arm A and erlotinib hydrochloride PO QD on days 2-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11557656|NCT00950352|Experimental|Citicoline|In a double-blind randomization design, subjects with methamphetamine dependence will be treated with citicoline or placebo for 8-9 weeks.
11557657|NCT00950352|Placebo Comparator|Placebo|In a double-blind randomization design, subjects with methamphetamine dependence will be treated with citicoline or placebo for 8-9 weeks.
11557658|NCT00950339|Experimental|4 weeks of omeprazole, 20mg twice daily|"Each patient will undergo 3 phases of drug therapy:
~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).
~At the end of each phase- each patient will undergo the following evaluation:
~Platelet reactivity"
11557659|NCT00950339|Experimental|4 weeks of famotidine 40mg twice daily|"Each patient will undergo 3 phases of drug therapy:
~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).
~At the end of each phase- each patient will undergo the following evaluation:
~Platelet reactivity"
11557660|NCT00950339|Experimental|4 weeks of pantoprazole 40mg once daily|"Each patient will undergo 3 phases of drug therapy:
~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).
~At the end of each phase- each patient will undergo the following evaluation:
~Platelet reactivity"
11557661|NCT00950326|Active Comparator|B1-Physio|In Group B1, patients will be given physiotherapy of the hip or knee joint three times a week
11557691|NCT00950105|Experimental|CPSI-2364 1 mg p.o.|Single dose
11557692|NCT00950105|Experimental|CPSI-2364 10 mg p.o.|single dose
11557693|NCT00950105|Experimental|CPSI-2364 30 mg p.o.|single dose
11557662|NCT00950326|Experimental|A1 Hydro|In this group patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region.
11557663|NCT00950326|Active Comparator|C- Hydro & Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
11557664|NCT00950313|Active Comparator|Self Assessment|Patients are approached and asked to complete a risk score that will determine their current risk of diabetes and the likelihood of requiring further testing.
11557665|NCT00950313|Active Comparator|Electronic risk score|Patients diabetes riks is determined based on their data held on practice systems. Patients are then invited for further testing based on this score.
11557666|NCT00950300|Active Comparator|Herceptin IV + Chemotherapy|Participants will receive Herceptin via IV infusion for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin IV will be given on Day 1 of each 21-day cycle, as 8 milligrams per kilogram (mg/kg) for a loading dose during Cycle 1 and as 6 mg/kg during subsequent cycles.
11557667|NCT00950300|Experimental|Herceptin SC + Chemotherapy|Participants will receive Herceptin via SC injection for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin SC will be given on Day 1 of each 21-day cycle, as a 600-milligram (mg) fixed dose.
11557668|NCT00950287||cohort|One group of preterm infants
11557669|NCT00950274|Active Comparator|CD133+ autologous bone marrow stem cells|
11557670|NCT00950274|Placebo Comparator|Placebo|
11557671|NCT00950261|Experimental|tri-weekly cisplatin|Patients in this arm will postoperatively receive cisplatin 75mg/m2 intravenously every 3 weeks, 3 cycles with radiation
11557672|NCT00950248|Active Comparator|Idebenone|Idebenone (150mg tablets) administered orally as five tablets, three times per day with food.
11557673|NCT00950248|Placebo Comparator|Placebo|Placebo tablets administered orally as five tablets, three times per day with food.
11557674|NCT00950235|Other|Usual Care|This arm will receive one additional nutrition counseling session that typically received in the health system. This arm will be compared to our intervention group
11557675|NCT00950235|Experimental|Weight Management Counseling|In-person and group session counseling
11557676|NCT00950222|Experimental|1:Imipenem/Amikacin|"patients will receive as empirical therapy for VAP imipenem associated with amikacin.After primary outcome measure, antibiotic therapy will be left at the discretion of the physician in charge of the patient.
~Imipenem: recommended usual dosage for VAP treatment, IV (in the vein), every 8 hours
~Amikacin: recommended usual dosage for VAP treatment (20mg/kg), IV (in the vein), single dose (at H0) for the 48 first hours of treatment"
11557677|NCT00950209|Active Comparator|euglycaemic hyperinsulinic clamp|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l."
11557678|NCT00950209|Active Comparator|euglycaemic hyperinsulinic clamp with Endolipide and heparin|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l but will be also infused with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids."
11557679|NCT00950209|Active Comparator|hyperglycaemic hyperinsulinic clamp|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose."
11557680|NCT00950196|Experimental|amantadine (PKMERZ)|
11557681|NCT00950183|Other|Foot and Ankle Surgery|Please note that the study was terminated prior to randomization of patients.
11557682|NCT00950170|Experimental|1|The investigator treats subjects with ReFacto AF in the usual care setting.
11557683|NCT00950157|Experimental|"Directive open question statement"|"Survey describes the surrogate outcome of the drug along with a directive warning (i.e., stating the issue and why it matters) for drugs shown to improve surrogate outcomes.
~This directive warning mentions that it is not known whether the drug will help patients feel better, and that readers should ask their doctor if there is an available drug shown to improve patient outcomes."
11557684|NCT00950157|Experimental|Non-directive open question statement|"Survey describes the surrogate outcome of the drug along with a non-directive warning (i.e., stating the issue only) for drugs shown to improve surrogate outcomes.
~This non-directive warning mentions only that it is not known whether the drug will help patients feel better."
11557685|NCT00950157|Experimental|No open question statement|Survey only describes the surrogate outcome of the drug.
11557686|NCT00950131|Experimental|Directive new drug warning|"Survey contains information about when the drug was approved by the FDA (2009)and a directive warning (i.e., stating the issue and why it matters) for new drugs.
~This directive warning mentions that serious drug side effects may emerge only after the drug is already on the market, and the reader should ask their doctor there is an available drug with a longer track record."
11557687|NCT00950131|Experimental|Non-directive new drug warning|"Survey contains information about when the drug was approved by the FDA (2009) and a non-directive warning (i.e., just stating the issue) for new drugs.
~This non-directive warning mentions only that serious drug side effects may emerge only after the drug is already on the market."
11557688|NCT00950131|Experimental|No new drug warning|Survey contains information about when the drug was approved by the FDA (2009) only.
11557689|NCT00950118||Congenital Diaphragmatic Hernia (CDH)|Humans affected with congenital diaphragmatic hernia (CDH)
11557690|NCT00950118||Unaffected|Healthy family members of individuals affected with congenital diaphragmatic hernia (CDH)
11557694|NCT00950105|Experimental|CPSI-2364 90 mg|single dose
11557695|NCT00950105|Experimental|CPSI-2364 270 mg p.o.|single dose
11557696|NCT00950092|Other|Treatment|
11557697|NCT00950079|Experimental|Sodium bicarbonate|sodium bicarbonate
11557698|NCT00950079|Active Comparator|Saline|saline infusion
11557699|NCT00950066|Placebo Comparator|Placebo|"Before randomization (common with other arms):
~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.
~After randomization:
~8 weeks of treatment with placebo once a day."
11557700|NCT00950066|Active Comparator|Irbesartan 150mg|"Before randomization (common with other arms):
~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.
~After randomization:
~8 weeks of treatment with Irbesartan 150 mg once a day."
11557701|NCT00950066|Active Comparator|Irbesartan 150 mg / Amlodipine 5 mg|"Before randomization (common with other arms):
~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.
~After randomization:
~8 weeks of treatment with Irbesartan 150 mg / Amlodipine 5 mg once a day."
11557702|NCT00950066|Active Comparator|Amlodipine|"Before randomization (common with other arms):
~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.
~After randomization:
~8 weeks of treatment with Amlodipine 5 mg once a day."
11557703|NCT00950066|Active Comparator|Irbesartan 300 mg|"Active Comparator: Irbesartan
~Before randomization (common with other arms):
~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.
~After randomization:
~8 weeks of treatment with Irbesartan 300 mg once a day."
11557704|NCT00950066|Active Comparator|Irbesartan 300 mg / Amlodipine 5 mg|"Before randomization (common with other arms):
~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.
~After randomization:
~8 weeks of treatment with Irbesartan 300 mg / Amlodipine 5 mg once a day."
11557705|NCT00950053|Active Comparator|Achilles decompression & debridement|
11557706|NCT00950053|Active Comparator|Achilles decompression,debride&FHLtransf|Achilles tendon decompression and debridement augmented with FHL transfer. The preferred skin incision will be followed by central-splitting Achilles debridement, resection of a Haglund's lesion if present and pathologic, followed by FHL harvest for patients in group 2. The fixation technique in group 2 will utilize an interference screw for the FHL. For all patients, the Achilles will be reattached with lateral and medial suture anchors (just distal to interference screw in FHL patients).
11557707|NCT00950040|Experimental|Brief alcohol intervention|Brief alcohol intervention delivered in 2 15-minute in-person sessions and 2 5-minute telephone sessions.
11557708|NCT00950040|Active Comparator|General Health Education|General health education intervention delivered in 2 15-minute in-person sessions and 2 5-minute telephone sessions.
11557709|NCT00950027|Experimental|povidone iodine|Povidone iodine
11557710|NCT00950027|Placebo Comparator|placebo|
11557711|NCT00950014|Experimental|Percentage format only|Numbers are presented in percentage format (e.g., 35%, 0.2%) only.
11557712|NCT00950014|Experimental|Fixed frequency format only|Numbers are presented in fixed frequency format only (5 out of 1000, 0.6 out of 1000). Denominators remains the same for each number.
11557713|NCT00950014|Experimental|Variable frequency format|Frequency denominators are adjusted to keep the numerator greater than 1, so they may change throughout the survey (e.g., 6 out of 1000, 42 out of 100)
11557714|NCT00950014|Active Comparator|Fixed combination format|Numbers are presented with both percentages and frequencies, and frequency denominators remain fixed (e.g., _ out of 1000).
11557715|NCT00950014|Experimental|Variable combination format|Numbers are presented with both percentages and frequencies, but frequency denominators may vary (e.g., _ out of 1000, _ out of 100).
11557716|NCT00950001|Experimental|Arm I (SRS)|Patients undergo stereotactic radiosurgery to the surgical cavity within 30 days of the craniotomy.
11557717|NCT00950001|No Intervention|Arm II (observation)|Patients undergo clinical observation after craniotomy.
11557718|NCT00949988|Active Comparator|Dasatinib - 100 mg (Phase I)|Dasatinib - 100 mg (Phase I)
11557719|NCT00949988|Active Comparator|Dasatinib - 70 mg (Phase I)|Dasatinib - 70 mg (Phase I)
11557720|NCT00949975|Active Comparator|1|AZD9668 active treatment
11557721|NCT00949975|Active Comparator|2|AZD9668 active treatment
11557722|NCT00949975|Active Comparator|3|AZD9668 active treatment
11557723|NCT00949975|Placebo Comparator|4|AZD9668 placebo treatment
11557724|NCT00949962|Active Comparator|Arm I|Patients undergo post-operative conformal external beam irradiation for 6.5 weeks.
11557725|NCT00949962|Experimental|Arm II|Beginning on day -5 to -3, patients receive an antiandrogen for 2-4 weeks. Beginning on day 0, patients receive leuprolide acetate subcutaneously once (6-month depot) and undergo conformal external beam irradiation 5 times weekly for 6.5 weeks.
11557726|NCT00949949|Experimental|Cohort I (everolimus and gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and everolimus PO once daily or 3 times weekly.
11557727|NCT00949949|Experimental|Cohort II (everolimus, gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 1 hour on days 1 and 8 and everolimus PO once daily or 3 times weekly.
11557728|NCT00949949|Experimental|Cohort III (MTD)|Patients receive treatment as in cohort II.
11557729|NCT00949923|Active Comparator|tea capsules|3 tea capsules daily for 3 weeks
11557730|NCT00949923|No Intervention|Control|No tea capsules
11557731|NCT00949910|Experimental|Erlotinib|Erlotinib will be given as a single agent in this expanded access program (EAP) to participants with inoperable, locally advanced, recurrent, or metastatic NSCLC. Treatment will continue until unacceptable toxicity, disease progression, or withdrawal for any other reason.
11557732|NCT00949897|Active Comparator|Biofoam|
11557733|NCT00949897|Active Comparator|Iliac Crest Allograft with locked plate|
11557734|NCT00949884|Experimental|Olmesartan|Olmesartan 20 mg once daily for four weeks followed by 40mg one daily for four weeks.
11557735|NCT00949884|Placebo Comparator|Placebo followed by Olmesartan|Placebo capsule of olmesartan once daily for 2 weeks, followed by olmesartan 20 mg once daily for two weeks, followed by olmesartan 40 mg for 4 weeks
11557910|NCT00948428|Active Comparator|Aldara™|Aldara™ (imiquimod) cream, 5%
11557736|NCT00949884|Active Comparator|Losartan|Losartan 50 mg once daily for four weeks, followed by losartan 100 mg once daily for four weeks
11557737|NCT00949832|Active Comparator|Vitamin D + Calcium|Vitamin D and calcium supplementation
11557738|NCT00949832|Placebo Comparator|Calcium|Calcium supplementation
11557739|NCT00949832|Active Comparator|Vitamin D2|Vitamin D2 response
11557740|NCT00949832|Active Comparator|Vitamin D3|Vitamin D3 response
11557741|NCT00949819||no treatment|Men with previously untreated, early stage prostate cancer.
11557742|NCT00949806|Experimental|Administrated|All patients included will receive an intradermal administration of BNT
11557743|NCT00949793|Experimental|All patients|
11557744|NCT00949780|Active Comparator|chloral hydrate , sedative|
11557745|NCT00949767|Experimental|BMS-866949 (Panel 1)|
11557746|NCT00949767|Experimental|BMS-866949 (Panel 2)|
11557747|NCT00949767|Experimental|BMS-866949 (Panel 3)|
11557748|NCT00949767|Experimental|BMS-866949 (Panel 4)|
11557749|NCT00949767|Experimental|BMS-866949 (Panel 5)|
11557750|NCT00949767|Experimental|BMS-866949 (Panel 6)|
11557751|NCT00949767|Experimental|BMS-866949 (Panel 7)|
11557752|NCT00949754|Active Comparator|histamine|histamine in saline administered ID as active control for Apitox
11557753|NCT00949754|Experimental|Apitox pure honeybee venom|ID study drug
11557754|NCT00949728|Other|Fibrin glue|
11557755|NCT00949715|Active Comparator|RV Mid-Septal Pacing|Pacing lead located in the right ventricle at the middle of the muscle separating the right and left sides of the heart
11557756|NCT00949715|Active Comparator|RV Apical Pacing|Pacing lead located at the bottom of the right ventricle of the heart, in the right ventricular apex
11557757|NCT00949702|Experimental|Single arm|
11557758|NCT00949689|Experimental|Cognitive Behavioral Therapy for insomnia and depression|cognitive behavioral therapy for insomnia followed by cognitive behavioral therapy for depression
11557759|NCT00949689|Active Comparator|contol|participants will receive sleep hygiene, time management techniques and cognitive therapy for depression
11557760|NCT00949676||Heart Failure|
11557761|NCT00949663|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
11557762|NCT00949663|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
11557763|NCT00949663|Experimental|Type 2 Diabetes Mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
11557764|NCT00949650|Experimental|BIBW 2992|BIBW 2992 tablet once daily until progression
11557765|NCT00949650|Active Comparator|Cisplatin/Pemetrexed|Cisplatin and Pemetrexed IV once every 3 weeks for up to 6 cycles
11557766|NCT00949637|Experimental|Scouting curricular implementation|Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
11557767|NCT00949637|Active Comparator|Standard-care attentional control|Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
11557768|NCT00949624|Experimental|Cohort 1|60 mg BID/ 75 mg/m2
11557769|NCT00949624|Experimental|Cohort 2|100 mg BID/75 mg/m2
11557770|NCT00949624|Experimental|Cohort 3|100 mg BID/100 mg/m2
11557771|NCT00949624|Experimental|Cohort 4b|CP-868,596 + AG-013736 + TXT 75
11557772|NCT00949611|Experimental|FRAX + Decision Aid|
11557773|NCT00949611|No Intervention|Usual care|
11557774|NCT00949611|Experimental|FRAX estimated fracture risk|
11557775|NCT00949598|Experimental|Arm I|Patients receive oral letrozole once daily for 16 weeks.
11557776|NCT00949598|Experimental|Arm II|Patients receive oral tamoxifen citrate once daily for 16 weeks.
11557777|NCT00949585|Other|Dietary potassium intake: 100 mmol/day|Participants will be given one of two diets: one contains 100 mmol of potassium per day, and the other contains 40 mmol of potassium per day
11557778|NCT00949585|Other|Dietary potassium intake: 40 mmol/day|Diet containing 40 mmol/day of potassium
11557779|NCT00949572|Experimental|Intramuscular administration|Intramuscular injection of HPV vaccine proteins
11557780|NCT00949572|Experimental|Sublingual administration|Sublingual administration of HPV vaccine proteins
11557781|NCT00949546||placebo controlled|A randomized, double-blind trial of 3 months duration comparing etanercept 50 mg sc twice weekly to placebo in 20 patients with HS. Patients will be randomized with equal allocation to the two treatment groups.
11557782|NCT00949533|Experimental|Standard Dose|Oseltamivir capsule will be administered orally at a dose of 75 mg BID in adult participants and children will receive oseltamivir powder for oral suspension dose (at 12 milligrams/ milliliter [mg/mL]) based on their body weight with a starting dose of 30 mg BID to a maximum dose of 75 mg BID; for 5 days.
11557783|NCT00949533|Active Comparator|Double Dose|Oseltamivir capsule will be administered orally at a dose of 150 mg BID in adult participants and children will receive oseltamivir powder for oral suspension dose (at 12 mg/mL) based on their body weight with a starting dose of 60 mg BID to a maximum dose of 150 mg BID; for 5 days.
11557784|NCT00949507||anaesthesia using propofol|the children are anaesthetized using intravenous anaesthesia with propofol and remifentanil; a binasal catheter is used for administration of oxygen during the anaesthesia
11557785|NCT00949507||anaesthesia using sevoflurane|the patients are anaesthetized using sevoflurane 1 MAC; a laryngeal mask is used
11557786|NCT00949494|Active Comparator|Synvisc|
11557787|NCT00949494|Placebo Comparator|Placebo|
11557788|NCT00949481|Experimental|Supply|In each country, this arm will be comprised of women attending family planning clinics within the 5 facilities randomized to this group.
11557789|NCT00949481|Experimental|Demand|In each country, this arm will be comprised of women attending immunization clinics within the 5 facilities randomized to this group.
11557790|NCT00949481|No Intervention|Control|In each country, this arm will be comprised of women attending family planning and immunization clinics in 5 facilities randomized to this group.
11557791|NCT00949468||Keratitis group|37 patients with keratitis
11557792|NCT00949468||Control Study Group|37 control volunteers
11557793|NCT00949455|Experimental|Arm I|Patients receive oral lapatinib ditosylate once daily in the absence of disease progression or unacceptable toxicity.
11557794|NCT00949455|Placebo Comparator|Arm II|Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity.
11557795|NCT00949442|Experimental|1|"Before randomization (common with arm 2):
~2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride
~After randomization:
~36 weeks of study treatment phase: Insulin Glargine + OAD(s) at stable dose"
11557796|NCT00949442|Active Comparator|2|"Before randomization (common with arm 1):
~2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride
~After randomization:
~36 weeks of study treatment phase: NPH + OAD(s) at stable dose"
11557797|NCT00949403|Experimental|Obese Females (pre-bariatric surgery)|Twenty obese females (18-45 years of age, BMI > or equal to 45) who are scheduled to undergo bariatric surgery at Barnes-Jewish Hospital will be screened for enrollment over 2 years. They will be imaged with PET/CT and radiopharmaceuticals C-11 Acetate and C-11 Palmitate will be injected.
11557798|NCT00949390||Phase I and CAM Survey|Complementary and alternative medicine (CAM) in patients with advanced malignancies currently treated on University of Texas MD Anderson Cancer Center Phase I clinical trials.
11557799|NCT00949377|Experimental|Methylnaltrexone Bromide|
11557800|NCT00949377|Placebo Comparator|Normal Saline|
11557801|NCT00949364|Experimental|Pomalidomide|Every patient will remain on treatment until disease progression for at least 12 cycles, withdrawal of patient's informed consent or the occurrence of unacceptable toxicity. If a patient may benefit from treatment with pomalidomide the investigator together with the principle investigator will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision. This additional treatment will be performed within the follow-up period of the study, data will be collected and duration will be maximally 12 cycles.
11557802|NCT00949351|Placebo Comparator|Aliskiren|
11557803|NCT00949338|Active Comparator|Arm I|Patients empty their bladders and consume 6 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a bladder volume instrument (BVI) periodically during treatment.
11557804|NCT00949338|Experimental|Arm II|Patients empty their bladders and consume 3 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a BVI periodically during treatment.
11557805|NCT00949325|Experimental|temsirolimus plus liposomal doxorubicin|Single arm study: Dose escalation of temsirolimus plus constant dose of liposomal doxorubicin.
11557806|NCT00949312||Stage II unresected Colon Cancer|
11557807|NCT00949273||cylindrical abdominoperineal resection|patients underwent cylindrical abdominoperineal resection for advanced very low rectal cancer
11557808|NCT00949273||abdominoperineal resection|patients underwent conventional abdominoperineal resection for advanced very low rectal cancer
11557809|NCT00949260||Normal, Non-Pregnant|Normal, non-pregnant patients will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
11557810|NCT00949260||Normal, Pregnant|Normal, pregnant patients in their 3rd trimester will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
11557811|NCT00949260||Pregnant, PIH|Pregnant patients in their 3rd trimester with pregnancy-induced hypertension that has not been treated will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
11557812|NCT00949247|Experimental|Docetaxel,Carboplatin,Trastuzumab and Bevacizumab|
11557813|NCT00949234|Other|Open-Label|This was an open-label demonstration project. Therefore, medications were not blinded and participants were made aware of the regimen they received for PEP.
11557814|NCT00949221|Other|Group 1|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months
11557815|NCT00949221|Other|Group 2|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Intensive strategy using continuous glucose monitoring for 12 months
11557816|NCT00949221|Other|Group 3|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring).
11557817|NCT00949208||A|The study population will consist of healthy volunteers who fulfill all the inclusion criteria and do not meet any of the exclusion criteria.
11557818|NCT00949195||COPD patients|COPD patients with severe obstruction performed the tests.
11557819|NCT00949195||Healthy subjects|Age-matched healthy subjects performed the same test also.
11557820|NCT00949182|Experimental|Sorafenib Tosylate, Doxorubicin, Mytomicin C|Micro and Macro arteriolar blockade of hepatocellular carcinoma (HCC): Treatment with Sorafenib 400mg two weeks prior to embolization HACE which includes the use of agents such as Doxorubicin Hydrochloride and Mytomicin C, continuing same Sorafenib dose after the procedure (dose adjustment according to tolerance).
11557821|NCT00949169||Carrotid IMT group according to maximal IMT|We defined increased IMT group as whom had maximal IMT ≥ 1.0 mm.
11557822|NCT00949156||Retrospective cohort|The 198 cases of CP with primary surgery in our hospital (since July, 1997 until now) were divided into three topographical groups based on the pre-operative MRI, intraoperative findings and the tumor-membrane relationship. The presurgical manifestation, the different surgical approach, intraoperative techniques, and postoperative complication were described and analyzed to establish a normalized surgical treatment of individual CP patient, which has the highest rate of the totally tumoral resection and the lowest rate of the hypothalamic injury.
11557911|NCT00948428|Placebo Comparator|Vehicle cream|Vehicle cream (Actavis)
11557912|NCT00948415|Experimental|SURI Enhanced|
11557913|NCT00948415|Active Comparator|SURI Standard|
11557823|NCT00949156||Prospective cohort|The anticipated 40 cases of CP were surgical treated by our standard procedure, which is recruited in the prospective cohort. With the long-term follow up, QOL including the cognition, circadian rhythm, endocrine, Water-Electrolyte, and body weight et al were evaluated to assess the rationality of the treatment. Then according to the results, the surgical treatment was modified, and the endocrinic substitution therapy was also been developed.
11557824|NCT00949143|Experimental|forward position|
11557825|NCT00949143|Experimental|rear position|
11557826|NCT00949130|Experimental|NXL103|BID for 7-14 days orally
11557827|NCT00949130|Active Comparator|Linezolid|BID for 7-14 days orally
11557828|NCT00949117|Experimental|Arm I- cyproheptadine hydrochloride|Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
11557829|NCT00949117|Experimental|cyproheptadine HCl & PediaSure or Ensure|Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (> 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
11557830|NCT00949104|Active Comparator|Sucrose|1 ml of 24% sucrose was administered 2 minutes before the procedure
11557831|NCT00949104|Placebo Comparator|Placebo|Double distilled water
11557832|NCT00949091|Experimental|1|
11557833|NCT00949078|Experimental|Open Label Omalizumab Group A|Omalizumab was dosed according to package insert. Patients who have a decrease in peanut allergen induced basophil histamine release (Pn-BHR) to less than 20% of baseline will be assigned to this group.
11557834|NCT00949078|Experimental|Open Label Omalizumab Group B|Omalizumab was dosed according to package insert. Patients who do not have a decrease in peanut allergen induced basophil histamine release (Pn-BHR) to less than 20% of baseline will be assigned to this group.
11557835|NCT00949065|Active Comparator|Intravenous immunoglobulins (IvIg)|3 x 0.36-0.44g/Kg IvIg every 4 weeks, then 3 months washing out, then 3x NaCl 0.9% every 4 weeks
11557836|NCT00949065|Placebo Comparator|NaCl 0.9%|NaCl 0.9%, 3x, every 4 weeks, then 3 months washing out, then 0.36-0.44g/Kg IvIg, 3x, every 4 weeks
11557837|NCT00949039|Experimental|Chemotherapy|Isolated pelvis perfusion
11557838|NCT00949039|Active Comparator|Control|Standard treatment
11557839|NCT00949026|Experimental|A|
11557840|NCT00949000|Other|ICD Implant|Implantation of a commercially available AnalyST or AnalyST Accel ICD
11557841|NCT00948987|Experimental|Aspirin|single dose of aspirin 325 mg p.o.
11557842|NCT00948974|Active Comparator|cognitive therapy|cognitive therapy and exposure
11557843|NCT00948974|Active Comparator|acceptance and committment therapy|acceptance and commitment therapy and exposure
11557844|NCT00948935|Experimental|Chemotherapy|Gemcitabine (Days 1, 8), irinotecan (days 1, 8) and panitumumab (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
11557845|NCT00948922|Other|A: Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant: Fludarabine+Melphalan+Bortezomib followed by Allogeneic Rescue.
11557846|NCT00948922|Other|B: Autologous Stem Cell Transplant|Autologous Stem Cell Transplant: Melphalan+Bortezomib followed by Autologous Rescue.
11557847|NCT00948922|Other|BE: Group B Expansion|Group B Expansion on Bortezomib Maintenance: Autologous Only.
11557848|NCT00948909|Placebo Comparator|A. Sugar Pill|
11557849|NCT00948909|Experimental|B. ABT-126|
11557850|NCT00948909|Experimental|C. ABT-126|
11557851|NCT00948909|Active Comparator|D. donepezil|
11557852|NCT00948896|Experimental|1|
11557853|NCT00948896|Experimental|2|
11557854|NCT00948896|Experimental|3|
11557855|NCT00948896|No Intervention|4|
11557856|NCT00948883||Patient-Case|Transplanted patient with cancer
11557857|NCT00948883||Patient-Control|Transplanted patient without cancer
11557858|NCT00948870|Experimental|Shugan Decoction|
11557859|NCT00948870|Placebo Comparator|low does of Shugan decoction|
11557860|NCT00948857|Experimental|DHEA active treatment|Dehydroepiandrosterone 25 mg tid po
11557861|NCT00948857|Placebo Comparator|DHEA Placebo|Blinded placebo
11557862|NCT00948818|Experimental|Linaclotide|Linaclotide 290 micrograms
11557863|NCT00948818|Placebo Comparator|Placebo|Matching placebo
11557864|NCT00948805|Experimental|GnRH agonist|3,6 mg of goserelin acetate (GnRH agonist) will be administered on the 21st day of the menstrual cycle previous to ovarian stimulation. 250 mg of hCG will be administered on the first day of menses and a starting dose of 150 IU of FSH will be started 2 days later as a part of a long ovarian stimulation protocol. Ovulation will be triggered with a 250 mg of hCG when at least 2 follicles attain 18mm and to accommodate oocyte retrieval within 36 hours.
11557865|NCT00948805|Active Comparator|Control|250 mg of hCG will be administered on the first day of menses and a starting dose of 150 IU of FSH will be started 2 days later as a part of a long ovarian stimulation protocol. Ovulation will be triggered with a 250 mg of hCG when at least 2 follicles attain 18mm and to accommodate oocyte retrieval within 36 hours.
11557866|NCT00948792|Active Comparator|Long transfusion group|This group of thrombocytopenic neonates who (as determined by the attending physician) are in need of a platelet transfusion will receive the transfusion over a period of two hours.
11557867|NCT00948792|Experimental|Short transfusion group|This group of thrombocytopenic neonates who (as determined by the attending physician) are in need of a platelet transfusion will receive the transfusion over a period of 30 minutes.
11557868|NCT00948779|Other|antibiotics|antibiotic education for children in an emergency care unit: Patient and family's therapeutic education to improve the use of antibiotics at home.
11557869|NCT00948779|Experimental|the antipyretic therapy|antibiotic education for children in an emergency care unit: Patient and family's therapeutic education to improve the antipyretic therapy at home.
11557870|NCT00948766|Experimental|Rivastigmine 13.3 mg/24 h transdermal patch|In the core study, patients were titrated to the rivastigmine 13.3 mg/24 h dose in 2 steps. For Weeks 1-4, patients received rivastigmine 4.6 mg/24 h. For Weeks 5-8, patients received rivastigmine 9.5 mg/24 h and placebo. For Weeks 9-24, patients received rivastigmine 13.3 mg/24 h and placebo. In the extension study, all patients were switched to rivastigmine 9.5 mg/24 h for a 4-week titration period and were then titrated up to 13.3 mg/24 h for a further 20 weeks of treatment.
11557914|NCT00948402|Experimental|metformin|
11557871|NCT00948766|Active Comparator|Rivastigmine 4.6 mg/24 h transdermal patch|In the core study, patients received rivastigmine 4.6 mg/24 h daily. For Weeks 1-4, patients received rivastigmine 4.6 mg/24 h. For Weeks 5-24, patients received rivastigmine 4.6 mg/24 h and placebo. No patients received this treatment in the extension study.
11557872|NCT00948753|Experimental|Phase 1: 150mg Maraviroc|150mg twice daily
11557873|NCT00948753|Experimental|Phase 1: 300mg Maraviroc|300mg twice daily
11557874|NCT00948753|Experimental|Phase 2: 300mg Maraviroc|300mg twice daily
11557875|NCT00948740|Experimental|ergocalciferol|After signing informed consent, all participants who meet the study criteria will receive ergocalciferol 50,000 IU weekly for 8 weeks. After completing the ergocalciferol course, participants will take a maintenance dose of cholecalciferol 1,000 IU daily.
11557876|NCT00948727|Experimental|Dose adjustment according CN activity|
11557877|NCT00948714|Experimental|Case|
11557878|NCT00948714|Active Comparator|Control|
11557879|NCT00948701|Experimental|Phone-based PA program (RTR Plus)|"The PA intervention consists of PA counseling, matched to participants' motivational readiness, plus educational materials. RTR volunteers or coaches will be asked to contact participants by telephone once a week for 12 weeks. The purpose of these calls is to build a supportive relationship with the participant, monitor PA participation, identify any health concerns, assist the participant to identify relevant barriers to PA and help her to problem solve to overcome such barriers."
11557880|NCT00948701|Active Comparator|Standard RTR services (RTR)|RTR volunteers will contact the participants in this group by telephone once a week, providing support and information integral to RTR. The volunteers will also review the educational materials sent to all participants receiving RTR services. This will allow the volunteers to build a relationship with the participants over 12 weeks and ensure that these participants receive a minimal intervention, reducing the risk of attrition at the 12-week assessment.
11557881|NCT00948688|Experimental|Vorinostat, 5-FU, Radiation Therapy|Vorinostat at varying doses; orally, days 1-7, weeks 1-6 5-FU 225 mg/m2/day; intravenous; days 1-5, weeks 1-6 until completion of radiation therapy; Radiation therapy; 180cGy daily Monday-Friday; 28 days of treatment (6 weeks)
11557882|NCT00948675|Experimental|Pemetrexed + Carboplatin + Pemetrexed|Pemetrexed and Carboplatin followed by Pemetrexed
11557883|NCT00948675|Active Comparator|Paclitaxel + Carboplatin + Bevacizumab|Paclitaxel, Carboplatin, and Bevacizumab followed by Bevacizumab
11557884|NCT00948662|Experimental|1|active arm/healthy young
11557885|NCT00948662|Placebo Comparator|2|placebo arm
11557886|NCT00948662|Other|3|ketoconazole interaction evaluation
11557887|NCT00948649|Active Comparator|Varenicline|Participants will complete a 21-day study phase that will include a 10-day drug run-up and monitoring phase (days 1-10), a 3-day abstinence phase (days 11-13), and a programmed lapse (day 14) followed by a 7-day observation phase in which participants are asked to remain abstinent and will receive modest monetary reinforcement for doing so (days 15-21).
11557888|NCT00948649|Placebo Comparator|Placebo|Participants will complete a 21-day study phase that will include a 10-day drug run-up and monitoring phase (days 1-10), a 3-day abstinence phase (days 11-13), and a programmed lapse (day 14) followed by a 7-day observation phase in which participants are asked to remain abstinent and will receive modest monetary reinforcement for doing so (days 15-21).
11557889|NCT00948636||Related Donors|Related Hematopoietic Stem Cell Donors
11557890|NCT00948623|Experimental|1|
11557891|NCT00948623|Sham Comparator|2|
11557892|NCT00948610|Placebo Comparator|Placebo|Placebo-participant will receive placebo saline solution via IV route.
11557893|NCT00948610|Active Comparator|Remicade|Remicade-Participant will be given 10 mg/kg of drug via IV route.
11557894|NCT00948584|Experimental|insulin titration by specialized system|Insulin dose titration system by using a SMS automatically produced by a knowledge matrix
11557895|NCT00948571||head down, laparoscopic|20 patients with laparoscopic surgery (radical robotic prostatectomy) in head down position
11557896|NCT00948571||head down, open|"20 patients undergoing opensurgery (open radical prostatectomy) in head down position."
11557897|NCT00948571||horizontal, open|"20 patients undergoing open surgery in horizontal position (open hemicolectomy)"
11557898|NCT00948545||No treatment|Observing individuals pre and post bariatric surgery
11557899|NCT00948519|Experimental|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
11557900|NCT00948519|Active Comparator|Laser only|same as above, without ICG
11557901|NCT00948506|Placebo Comparator|1% topical cidofovir|1% topical cidofovir to one side of the face and placebo to the other side of the face
11557902|NCT00948506|Placebo Comparator|3% topical cidofovir|3% topical cidofovir to one side of the face and placebo to the other side of the face
11557903|NCT00948467|Experimental|TAK-733|
11557904|NCT00948454||Light smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Subjects will bring their own cigarettes on that day and smoke their regular amount. Female subjects will also have a pregnancy test done on the test day.
11557905|NCT00948454||Heavy Smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Subjects will bring their own cigarettes on that day and smoke their regular amount. Female subjects will also have a pregnancy test done on the test day.
11557906|NCT00948454||Non Smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Female subjects will also have a pregnancy test done on the test day.
11557907|NCT00948441|Experimental|Group 1|25% ethanol for 12 weeks; wash out period for 4 weeks; heparin lock for 12 weeks
11557908|NCT00948441|Experimental|Group 2|heparin lock for 12 weeks; wash out period for 4 weeks; 25% ethanol lock for 12 weeks
11557909|NCT00948428|Active Comparator|Generic Imiquimod|imiquimod cream, 5%
11557915|NCT00948402|Active Comparator|oral contraceptive|
11557916|NCT00948389|Active Comparator|Dasatinib|
11557917|NCT00948389|Active Comparator|Lomustine|
11557918|NCT00948376||Patients|All ages
11557919|NCT00948376||Fetuses|
11557920|NCT00948363|Active Comparator|Kiwi fruits|
11557921|NCT00948363|Placebo Comparator|Apple|
11557922|NCT00948350|Active Comparator|translaryngeal injection|translaryngeal injection of local anesthetics before the awake intubation
11557923|NCT00948350|Active Comparator|spray as you go|local anesthetics are given through the fiberoptic during awake intubation
11557924|NCT00948337|Experimental|Photonovella of Secondary Cancer Screening|
11557925|NCT00948337|Active Comparator|Photonovella of Dietary Suppelment of Cancer survivor|
11557926|NCT00948324|Active Comparator|CSII|CSII: Patients in continuous subcutaneous insulin infusion group received insulin analogue with an insulin pump along.
11557927|NCT00948324|Active Comparator|ALA|ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD.
11557928|NCT00948324|Active Comparator|RSG|RSG:CSII combined with three months rosiglitazoneor 4mg QD.
11557929|NCT00948324|Active Comparator|MET|MET:CSII combined with metformin 500mg BID-TID.
11557930|NCT00948298|Placebo Comparator|Placebo|
11557931|NCT00948298|Experimental|Vitamin D|
11557932|NCT00948285|Experimental|MRI|Preoperative staging with mammogram, ultrasound, and MRI, followed by surgery (n=200)
11557933|NCT00948285|No Intervention|Non-MRI|Preoperative staging with mammogram and ultrasound alone, followed by surgery (n=200)
11557934|NCT00948272|Experimental|VRVg Group|
11557935|NCT00948272|Active Comparator|Verorab Group|
11557936|NCT00948259|Experimental|NP031112|Patients will receive 400 mg of NP031112 for 4 weeks, if tolerated, they will receive 600 mg for 4 additional weeks. Patients that tolerate this dose will receive 800 mg for 6 weeks and the patients that tolerate this will escalate to 1000 mg for an additional 6 weeks. Patients that are not eligible for dose escalation will remain on the tolerated dose for the remainder of the study.
11557937|NCT00948259|Placebo Comparator|Placebo|Patients will receive 400 mg for 4 weeks, if tolerated, they will receive 600 mg for 4 additional weeks. Patients that tolerate this will receive 800 mg for 6 weeks and the patients that tolerate this will escalate to 1000 mg for an additional 6 weeks. Patients that are not eligible for escalation will remain on the tolerated dose for the remainder of the study.
11557938|NCT00948246||Easyband|Subjects who had the Easyband device implanted laparoscopically.
11557939|NCT00948233||Intervention|Educational video game
11557940|NCT00948233||Standard Care|Pamphlets on stopping tobacco use
11557941|NCT00948220|Experimental|Treatment|Chronic hepatitis C patients on standard antiviral therapy with peginterferon alfa-2a and ribavirin
11557942|NCT00948220|No Intervention|Control|Chronic hepatitis C patients without standard antiviral therapy
11557943|NCT00948207|Experimental|My Living Story|"My Living Story elicits a dignity-enhancing life story via a telephone interview, and delivers the edited transcript on the patient's personal miLivingStory social network. miLivingStory also provides a direct link to miStory, a life review education website with links to high quality websites that provide cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks.
~miLivingStory and miStory are both password protected."
11557944|NCT00948207|Active Comparator|My Own Resources|"My Own Resources offers usual care access to high quality websites that provide cancer information, databases to do your own research, social support, and interactive planning tools. Participants will receive access to the website miOwnResources."
11557945|NCT00948194|No Intervention|No nitric oxide|This arm will not receive nitric oxide, but will receive other standard inhaled anesthetics
11557946|NCT00948194|Experimental|Nitric Oxide|Will receive Nitric oxide and other standard inhaled anesthetics
11557947|NCT00948181||Surgeon|To detect the degree of intraoperative stress, venous blod will be drawn from one surgeon during 8 pheochromocytoma resections.
11557948|NCT00948181||Anesthesiologist|To detect the degree of intraoperative stress, venous blood will be drawn from one anesthesiologist during 8 pheochromocytoma resections.
11557949|NCT00948181||Patients with pheochromocytoma|Venous blood will be drawn from 8 patients with pheochromocytoma during tumor resection.
11557950|NCT00948155|Experimental|Varenicline before placebo|"Drug (Varenicline (Chantix)): Placebo
~Intervention to be administered is: participants will receive standard dosing regimen of Varenicline for 21 days total, followed by 14-day washout and 21 days of placebo. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21."
11557951|NCT00948155|Experimental|Placebo then Varenicline|"Placebo: Drug Varenicline (Chantix)
~Intervention to be administered is: participants will receive 21 days of placebo, followed by 14-day washout and standard dosing regimen of Varenicline for 21 days total. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21.
~Intervention 'Drug (Varenicline (Chantix)): Placebo'"
11557952|NCT00948142|Active Comparator|Linezolid|600 mg BID
11557953|NCT00948142|Experimental|CEM-102 Regimen A|
11557954|NCT00948142|Experimental|CEM-102 Regimen B|
11557955|NCT00948129|Active Comparator|Group I (standard care)|Participants undergo standard of care smoking cessation intervention consisting of brief advice to quit smoking, NRT, and self-help written materials.
11557956|NCT00948129|Experimental|Group II (enhanced care)|Participants undergo standard of care smoking cessation intervention as in Group I and attend a health feedback counseling session at baseline. Participants also receive access to a smoking cessation hotline telephone number and supportive text messages daily for 12 weeks.
11557957|NCT00948129|Experimental|Group III (intensive care)|Participants undergo standard of care smoking cessation intervention as in Group I and attend a health feedback counseling session at baseline. Participants also receive access to a smoking cessation hotline telephone number, supportive text messages daily for 12 weeks, and a smoking cessation telephone call over 15 minutes weekly for 12 weeks.
11557958|NCT00948116||Diabetes mellitus, renal impairment|Patients with both diabetes mellitus and eGFR <60 ml/min
11557959|NCT00948103|Placebo Comparator|Oxygen|
11557960|NCT00948103|Active Comparator|Nitrous Oxide|
11557961|NCT00948090|Experimental|IV Busulfan|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant
11557962|NCT00948077|Active Comparator|Treatment A|"Study agents (Rifater+EMB) will be given approximately 45 minutes prior to the breakfast."
11557963|NCT00948077|Experimental|Treatment B|"Study agents (Rifater+EMB) will be given approximately 45 minutes after the breakfast is finished."
11557964|NCT00948064|Experimental|Vorinostat with Azacitidine|ARM A: Azacitidine 75 mg/m^2/day by vein over 15 - 30 minutes daily for 5 days (Days 1 - 5). Vorinostat 200 mg by mouth three time a day with food for 5 days (Days 1 - 5). Courses repeated every 3 to 8 weeks.
11557965|NCT00948064|Experimental|Azacitidine|ARM B: Azacitidine 75 mg/m^2 /day by vein over 15 - 30 minutes daily for 5 days (Days 1 - 5). Courses repeated every 3 to 8 weeks.
11557966|NCT00948051|Experimental|Fructo-oligosaccharides|
11557967|NCT00948051|Placebo Comparator|Placebo|
11557968|NCT00948038|Active Comparator|Soy|Soy-based supplement to normal diet
11557969|NCT00948038|Experimental|Milk|Milk-based supplement to normal diet
11557970|NCT00948025|Active Comparator|Avance Nerve Graft|Commercially available Avance Nerve Graft for repair of nerve gap
11557971|NCT00948025|Active Comparator|Hollow Tube Conduit|Commercially available hollow tube conduit for repair of nerve gap.
11557972|NCT00948012||Patients without pulmonary hypertension|Patients with sickle cell with normal response of pulmonary artery pressure to exercise
11557973|NCT00948012||Exercise-induced pulmonary hypertension|Patients with sickle-cell anemia with exercise-induced pulmonary hypertension.
11557974|NCT00947999||Healthy Control Group|Subjects in particular group will not have a diagnosis of SCI and do not experience chronic pain. Subjects in this group will be matched roughly to subjects in the SCI chronic pain group based on age, gender and race/ethnicity.
11557975|NCT00947999||Subjects with SCI and Chronic Pain|Individuals recruited into this particular group will have a diagnosis of a spinal cord injury and experience pain on a daily basis with an average intensity of 4 out of 10 on a 0-10 scale.
11557976|NCT00947999||Subjects with SCI and No Chronic Pain|Subjects in particular group will have a diagnosis of SCI and not have chronic pain. Subjects in this group will be matched roughly to subjects in the SCI chronic pain group based on age, gender and race/ethnicity.
11557977|NCT00947986|Experimental|Johnson's Baby Shampoo|1% diluted solution
11557978|NCT00947973|Experimental|Challenging Horizons Program after-school model|Participants will receive the CHP after-school model.
11557979|NCT00947973|Experimental|Challenging Horizons Program consultation model|Participants will receive the CHP consultation model.
11557980|NCT00947973|No Intervention|Community care|Participants will have access to standard community care.
11557981|NCT00947960|Other|Active/Placebo|Subjects receive 1-2 grams/kilogram body weight triheptanoin divided into 4 equal doses taken with meals and snack for 6 months crossing over to receive placebo vegetable oil at the same dose and frequency for the next 6 months during the randomization phase.
11557982|NCT00947960|Other|Placebo/Active|Subjects receive 1-2 grams/kilogram body weight placebo vegetable oil divided into 4 equal doses taken with meals and snack for 6 months crossing over to receive triheptanoin at the same dose and frequency for the next 6 months during the randomization phase.
11557983|NCT00947947|Experimental|intervention media condition|Received a stage tailored DVD-based intervention
11557984|NCT00947947|Placebo Comparator|standard of care|received only clinical standard of care
11557985|NCT00947934|Experimental|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation.
11557986|NCT00947921|Active Comparator|Plasty|Patients treated with restrictive Annuloplasty
11557987|NCT00947921|Active Comparator|Prosthesis|Patients treated with valve replacement
11557988|NCT00947908|Experimental|A|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
11557989|NCT00947895|Active Comparator|Methylprednisolone|Intravenous (IV) methylprednisolone (Solumedrol) 1000 mg daily for 3 days.
11557990|NCT00947895|Active Comparator|ACTH|Intramuscular (IM) ACTH 80 mg/day for 5 days.
11557991|NCT00947882|Placebo Comparator|Placebo|
11557992|NCT00947882|Experimental|Degarelix 10 mg|
11557993|NCT00947882|Experimental|Degarelix 20 mg|
11557994|NCT00947882|Experimental|Degarelix 30 mg|
11557995|NCT00947856|Experimental|BV Retreatment|Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (retreatment after relapse)
11557996|NCT00947856|Experimental|BV Extension|Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (continued treatment)
11557997|NCT00947843|Placebo Comparator|aspirin+placebo|aspirin protect (Bayer) 100mg + placebo clopidogrel 75mg for 1mo
11557998|NCT00947843|Active Comparator|aspirin+pregrel|pregrel is a generic brand name of clopidogrel
11557999|NCT00947843|Active Comparator|Aspirin+Plavix|plavix is a original brand name of clopidogrel
11558000|NCT00947817|Experimental|patient|
11558001|NCT00947817|Other|control|
11558002|NCT00947804||1. Patients with symptoms of ACS|Patients whom present emergently to the Cardiac Catheterization Lab with current symptoms of Acute Coronary Syndrome (ACS), whom at the time of admission to the cardiac catheterization lab are believed to be suffering from STEMI, NSTEMI, or Unstable Angina, with the possible need for emergency Percutaneous Coronary Intervention (PCI), or Coronary Artery Bypass Grafting (CABG).
11558003|NCT00947804||2. Patients without symptoms of ACS|Non-emergency patients presenting to the Cardiac Catheterization Lab for elective coronary angiography, and possible PCI. These are patients whom may have experienced typical or atypical ACS symptoms intermittently, and have elected to have cardiac catheterization to rule out obstructive CAD. Patients in this group will be selected randomly, with consent obtained, prior to cardiac catheterization.
11558056|NCT00947505|Active Comparator|HairMax LaserComb 2009, 7 Beam|Lower level laser phototherapy medical device with 7 laser beams
11558004|NCT00947791|Experimental|Ketamine/Midazolam|Patients receive both treatment conditions (ketamine and midazolam) in a single arm, crossover design. Patients are randomized to ketamine-midazolam. Each treatment occurs as a single intravenous infusion on one treatment day. The two treatment conditions occur 2 weeks apart.
11558005|NCT00947791|Experimental|Midazolam/Ketamine|Patients receive both treatment conditions (ketamine and midazolam) in a single arm, crossover design. Patients are randomized to midazolam-ketamine. Each treatment occurs as a single intravenous infusion on one treatment day. The two treatment conditions occur 2 weeks apart.
11558006|NCT00947778|Active Comparator|session of training 1|Arm from which members will perform their training session after the first session of evaluation
11558007|NCT00947778|Active Comparator|Session of training 2|Arm from which members will perform their training session after the second session of evaluation
11558008|NCT00947765|Experimental|Autologous blood injection group|This is the study group in whom autologous blood injection was injected at lateral epicondylitis site.
11558009|NCT00947765|Active Comparator|Local corticosteroid injection group|This is the control group in whom the commonly used treatment modality-local corticosteroid injection was given at lateral epicondyle site.
11558010|NCT00947752|Active Comparator|F1 Glatiramer acetate 20mg/1.0ml|
11558011|NCT00947752|Experimental|F2 Glatiramer acetate 20mg/0.5ml|
11558012|NCT00947739|Experimental|Cohort 1|80 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48)PO, DAILY
11558013|NCT00947739|Experimental|Cohort 2|160 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
11558014|NCT00947739|Experimental|Cohort 3|320 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
11558015|NCT00947739|Experimental|Cohort 4|640 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
11558016|NCT00947739|Experimental|Cohort 5a|1280 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
11558017|NCT00947739|Experimental|Cohort 6|2560 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
11558018|NCT00947739|Experimental|Cohort 7|18 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
11558019|NCT00947739|Experimental|Cohort 8|36 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
11558020|NCT00947739|Experimental|Cohort 9|72 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
11558021|NCT00947739|Experimental|Cohort 10|144 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
11558022|NCT00947739|Experimental|Cohort 11|288 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
11558023|NCT00947739|Experimental|Cohort 12|576 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
11558024|NCT00947739|Experimental|Cohort 13|750mg/m2 PO Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
11558025|NCT00947739|Experimental|Cohort 14|1000mg/m2 PO Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
11558026|NCT00947739|Experimental|Cohort 5b|1280 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
11558027|NCT00947713|Experimental|Low dose hCG group|
11558028|NCT00947713|Active Comparator|Clomiphen citrate plus HMG|
11558029|NCT00947700|No Intervention|Assessment & Monitoring|No Intervention. Parent-Child participants in assessment and monitoring visits but does not receive any study provided treatment.
11558030|NCT00947700|Experimental|Assessment, Monitoring + Intervention|Parent-Child participants in assessment and monitoring visits but also the Promoting First Relationships PFR intervention (http://pfrprogram. Org). PFR is a 10 weekly 60-85 minute in-home visits by a masters level mental health provider trained in the PFR curriculum. The PFR curriculum focuses on increasing parenting sensitivity using attachment theory-informed, strength-based consultation strategies. The curriculum is fully manualized and fidelity was assessed according to the manual.
11558031|NCT00947687|Experimental|PUR003|
11558032|NCT00947687|Placebo Comparator|Placebo|
11558033|NCT00947674|Experimental|Cellsorba EX|
11558034|NCT00947674|Sham Comparator|Sham treatment|
11558035|NCT00947661|Experimental|SPARC0912|Test drug
11558036|NCT00947661|Experimental|Reference0912|Reference drug
11558037|NCT00947648|Other|"Raw Group"|Participants will eat cooked food and the addition of raw fruits and vegetables.
11558038|NCT00947648|Other|"Cooked Group"|Participants will eat only cooked foods.
11558039|NCT00947635|Experimental|Islet transplant|People with Type 1 diabetes undergoing islet transplantation
11558040|NCT00947635|Experimental|Liver transplant|People with liver failure undergoing liver transplantation
11558041|NCT00947635|Experimental|Control|Healthy normal people which serve as control group
11558042|NCT00947622|Placebo Comparator|Placebo stimulation|Placebo stimulation at the occipital head area for 1800 seconds at 0 mA, three times a week, during one week (with seconds of stimulation to get onset tingling sensation)
11558043|NCT00947622|Experimental|Effective transcranial stimulation|Effective stimulation at the occipital head are for 1800 seconds at 2 mA, 3 times a week for 1 week
11558044|NCT00947609||HIV-infected and HIV-uninfected children|HIV-infected and HIV uninfected children with recent exposure to adults with active tuberculosis will be referred to the two study sites (HIV-NAT/Chulalongkorn and Queen Sirikit) for eligibility screening and enrollment in the study.
11558045|NCT00947596|Experimental|Atropine Dry Powder Inhaler|
11558046|NCT00947596|Active Comparator|Atropen Autoinjector|
11558047|NCT00947570|Experimental|Cognitive behavioral therapy|Participants with panic disorder or generalized anxiety disorder (GAD) will receive a course of individual cognitive behavioral therapy targeted at their principal disorder.
11558048|NCT00947557|Active Comparator|Dutogliptin|Dutogliptin
11558049|NCT00947557|Placebo Comparator|Placebo|Placebo
11558050|NCT00947544|Experimental|HPN-100 and NaPBA|1 week of NaPBA treatment followed by 1 week of HPN-100 treatment.
11558051|NCT00947531|Experimental|Cerebrolysin|
11558052|NCT00947531|Placebo Comparator|0.9% Saline Solution|
11558053|NCT00947518|Experimental|Chlorhexidine skin cleansing|Wiping the skin (except the face) once immediately after birth using baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)
11558054|NCT00947518|Placebo Comparator|Saline skin cleansing|Wiping the skin (except the face) once immediately after birth using baby wipes containing normal saline
11558055|NCT00947518|No Intervention|No skin cleansing|No skin application
11558057|NCT00947505|Active Comparator|Control Device|Identical to the Active device, but with 7 LED's instead of lasers
11558058|NCT00947479|Other|continuous positive airway pressure (CPAP)|CPAP will be applied in all patients
11558059|NCT00947466|Experimental|Patch|
11558060|NCT00947453|Experimental|montelukast group|Identified patients with asthma to recieve Montelukast 10 mg (Merck Sharp & Dohme Ltd, Herts, UK) at 0800 am once daily for 8 weeks.
11558061|NCT00947440|Active Comparator|Tablet 1 vs. Capsule|Single dose of 2 x 50 mg tablets (Tablet 1) vs. 100 mg ABT-072 (contents of capsules) suspended in liquid.
11558062|NCT00947440|Active Comparator|Tablet 2 vs. Capsule|Single dose of 2 x 50 mg tablets (Tablet 2) vs. 100 mg ABT-072 (contents from capsules) suspended in liquid.
11558063|NCT00947427|Placebo Comparator|Placebo|Placebo solution given by subcutaneous injection on monthly basis for 12 months
11558064|NCT00947427|Experimental|Canakinumab|Subcutaneous injection of canakinumab at dose of 2.0 mg/kg given monthly of 12 months
11558065|NCT00947414|Active Comparator|Shockwave plus strength training|6 sessions of extracorporeal shock wave plus daily gluteal strength exercises
11558066|NCT00947414|Sham Comparator|Sham extracorporeal shock wave plus gluteal strength exercise|SHAM extracorporeal shock wave plus gluteal strength exercise
11558067|NCT00947401||elective post surgery patients|
11558068|NCT00947388|Experimental|Bendamustine plus Alemtuzumab|
11558069|NCT00947375|Experimental|Starch|In these study participants are randomly (by chance) assigned for two treatment arms of a clinical trial.
11558070|NCT00947375|No Intervention|Lifestyle councelling|May be required to comply with US Public Law 110-85, Section 801
11558071|NCT00947362|Experimental|ETC + DAC N-055|
11558072|NCT00947362|Active Comparator|ETC + physiological saline|
11558073|NCT00947349|Experimental|BI 201335 NA low TN|patient to receive a capsule containing low dose of BI 201335 NA/Drug for treatment-naive (TN) patients
11558074|NCT00947349|Experimental|BI 201335 NA high TN|patient to receive a capsule containing high dose of BI 201335 NA/Drug for treatment-naive (TN )patients
11558075|NCT00947349|Experimental|BI 201335 NA high TE|patient to receive a capsule containing high dose of BI 201335 NA/Drug for treatment-experienced (TE) patients
11558076|NCT00947349|Placebo Comparator|Placebo in Treatment Naive (TN) Patients|
11558077|NCT00947336|Active Comparator|Norfloxacin + Synbiotic|
11558078|NCT00947336|Placebo Comparator|Norfloxacin + Placebo|
11558079|NCT00947323|Placebo Comparator|placebo|
11558080|NCT00947323|Experimental|Simvastatin|Treatment arm.
11558081|NCT00947310|Experimental|A|Standard ICD Programming
11558082|NCT00947310|Experimental|B|High rate cutoff
11558083|NCT00947310|Experimental|C|Long ICD duration delay
11558084|NCT00947297|Experimental|HPN-100|Patients who were treated with HPN-100
11558085|NCT00947284|Experimental|Women|Both arms of this study will receive identical interventions. The only difference will be the sex of the participants in each study arm.
11558086|NCT00947284|Experimental|Men|Both arms of this study will receive identical interventions. The only difference will be the sex of the participants in each study arm
11558087|NCT00947271|Experimental|DVD 1 plus assessment 1|Participants will view educational DVD 1 and complete the first version of the study assessment.
11558088|NCT00947271|Experimental|DVD 1 plus assessment 2|Participants will view educational DVD 1 and complete the second version of the study assessment.
11558089|NCT00947271|Experimental|DVD 2 plus assessment 1|Participants will view educational DVD 2 and complete the first version of the study assessment.
11558090|NCT00947271|Experimental|DVD 2 plus assessment 2|Participants will view educational DVD 2 and complete the second version of the study assessment.
11558091|NCT00947245|Experimental|BMS-791325 - Part A, Dose 1|
11558092|NCT00947245|Experimental|BMS-791325 - Part A, Dose 2|
11558093|NCT00947245|Experimental|BMS-791325 - Part A, Dose 3|
11558094|NCT00947245|Experimental|BMS-791325 - Part B, Dose 1|
11558095|NCT00947245|Experimental|BMS-791325 - Part B, Dose 2|
11558096|NCT00947245|Experimental|BMS-791325 - Part B, Dose 3|
11558097|NCT00947232|Experimental|Motivational interviewing|Motivational interviewing for people aging with multiple sclerosis or spinal cord injury to increase physical activity and decrease depression.
11558098|NCT00947232|Active Comparator|Education|Education about physical activity for people aging with multiple sclerosis or spinal cord injury to decrease depression.
11558099|NCT00947219|Active Comparator|HairMax LaserComb 2009, 12 Beam|Low Level Laser Medical Device 2009 with 12 laser beams
11558100|NCT00947219|Active Comparator|HairMax LaserComb 2009 9 Beam|Low Level Laser Mecial Device 2009 with 9 laser beams
11558101|NCT00947219|Active Comparator|Control device|The control device appears identical to the active device, but utilizes 9 LED lights instead of laser lights. The randomized devices are blinded to the study investigator and distributed in a blinded manner to the participants.
11558102|NCT00947206|Experimental|LHWO about CRC|The intervention group participants will be exposed to 2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt.
11558103|NCT00947206|Active Comparator|Nutrition education + CRC brochure|The comparison group will receive a bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
11558104|NCT00947193|Experimental|Ataluren Overall Study|Ataluren was provided as a vanilla-flavored powder to be mixed with water or milk. Ataluren was taken 3 times per day, with dosing based on the participant's body weight. The dose level for ataluren was 5 mg/kg in the morning, 5 mg/kg at midday, and 10 mg/kg in the evening or 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 14 days, followed by an interval of 14 days without treatment.
11558105|NCT00947180|Active Comparator|Electrogalvanic stimulation|High voltage electrical stimulation was delivered through an anal plug to induce relaxation of pelvic floor muscles.
11558106|NCT00947180|Active Comparator|Digital massage|The therapist massaged the levator ani muscles by applying firm pressure with a gloved finger and rotating from left to right.
11558107|NCT00947180|Experimental|Biofeedback|Electromyographic (EMG) activity was recorded from a probe in the anal canal, averaged and displayed to patients to help them learn to relax pelvic floor muscles during straining.
11558108|NCT00947167|Experimental|Pertuzumab and Erlotinib|
11558109|NCT00947154|Experimental|Open-label aripiprazol|Aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
11558110|NCT00947141|Experimental|Group A|"Group A: (low level infection) has 2 arms:
~Start treatment when 2 consecutive levels CMV PCR >200copies / ml
~Monitor (Treatment starts when CMV PCR >3,000 copies / ml (current site clinical protocol))"
11558111|NCT00947141|Experimental|Group B|"Group B: (patients receiving pre-emptive therapy) has 2 arms:
~Stop treatment when 2 levels CMV PCR <3,000 copies / ml
~Monitor (Treatment stops when there are 2 consecutive levels of CMV PCR <200 copies / ml (current site clinical protocol))"
11558112|NCT00947128|Experimental|1|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
11558113|NCT00947128|Active Comparator|2|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
11558114|NCT00947115|Experimental|Cervarix 15-25 years group|Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study HPV-014 (NCT00196937).
11558115|NCT00947115|Experimental|Cervarix 26-45 years group|Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study HPV-014 (NCT00196937).
11558116|NCT00947115|Experimental|Cervarix 46-55 years group|Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study HPV-014 (NCT00196937).
11558117|NCT00947102||Pancreatic tubular adenocarcinoma|Patients with pancreatic tubular adenocarcinoma
11558118|NCT00947089|Experimental|group A-the treatment group|Group A-patients have their wound, the site of the previous stoma, wad with ORC
11558119|NCT00947089|Active Comparator|group B-the control group|control group-patients have their wound wad with iodoform gauze
11558120|NCT00947076|Experimental|1|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)
11558121|NCT00947076|Active Comparator|2|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)
11558122|NCT00947063|Experimental|1|Promethazine HCl 50 mg Tablets (Sandoz, Inc)
11558123|NCT00947063|Active Comparator|2|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)
11558124|NCT00947050|Active Comparator|rest first|rest first, cfi, exercise, cfi
11558125|NCT00947050|Active Comparator|exercise first|ex first
11558126|NCT00947037|Experimental|Extension|Open label extension, 1 arm
11558127|NCT00947024|Experimental|1|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.
11558128|NCT00947024|Active Comparator|3|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.
11558129|NCT00947024|Experimental|2|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.
11558130|NCT00947011|Placebo Comparator|Placebo|
11558131|NCT00947011|Active Comparator|Januvia|
11558132|NCT00946998|Active Comparator|Sertraline|Patients with predialysis Chronic Kidney Disease stages 3-5 and with major depressive episode
11558133|NCT00946998|Placebo Comparator|Placebo|Patients with predialysis Chronic Kidney Disease stages 3-5 and with major depressive episode
11558134|NCT00946985|Experimental|001|paliperidone palmitate 50 75 100 or 150 mg eq. monthly injection for 2 years
11558135|NCT00946985|Active Comparator|002|oral risperidone 2 4 6 or 8 mg tabs once daily for two years
11558136|NCT00946959|Experimental|cardiac surgery|This arm will include patients older than 18 years and candidate to cardiac surgery.
11558137|NCT00946959|No Intervention|cardiac angiography|Patients older than 18 years who undergo coronary angiogram. This arm will include patients with coronary revascularization and patients without coronary revascularization.
11558138|NCT00946946|Experimental|Azathioprine|2.0-2.5 mg/kg/BW azathioprine tablets/day AND mesalazine placebo tablets
11558139|NCT00946946|Active Comparator|Mesalazine|4g mesalazine tablets/day AND azathioprine placebo tablets
11558140|NCT00946933|Placebo Comparator|Placebo|0.025 g/kg/day of NaCl (sodium chloride)
11558141|NCT00946933|Active Comparator|High salt diet|0.2 g/kg/day of NH4Cl (ammonium chloride)
11558142|NCT00946920|Experimental|Degarelix 240 mg/480 mg|
11558143|NCT00946920|Active Comparator|Goserelin acetate|
11558144|NCT00946907|Active Comparator|aspirin|
11558145|NCT00946907|Placebo Comparator|placebo|
11558146|NCT00946894|Experimental|Total thyroidectomy|Patients who underwent total thyroidectomy
11558147|NCT00946894|Experimental|Dunhill operation|Patients who underwent unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
11558148|NCT00946894|Active Comparator|Bilateral subtotal thyroidectomy|Patients who underwent bilateral subtotal thyroidectomy
11558149|NCT00946881|Experimental|WST11 (TOOKAD® Soluble)|WST11-mediated-VTP The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers using 753 nm laser light at escalating fixed energy doses
11558150|NCT00946868||Intermittent claudication patients|Patients with intermittent claudication with metabolic syndrome and patients with intermittent claudication without metabolic syndrome.
11558151|NCT00946855||soccer players|players of the first two German soccer leagues
11558152|NCT00946842|Experimental|Panel A: Treatment Sequence ABC|Participants will receive the 3 treatments (Treatment A,B and C) in sequence ABC with food and subsequent treatments will be separated by 4 weeks.
11558153|NCT00946842|Experimental|Panel A: Treatment Sequence ACB|Participants will receive the 3 treatments (Treatment A,B and C) in sequence ACB with food and subsequent treatments will be separated by 4 weeks.
11558203|NCT00946569|Experimental|Treatment A (JNJ39758979)|Participants will receive JNJ39758979 300mg once daily for 12 weeks.
11558154|NCT00946842|Experimental|Panel A: Treatment Sequence BAC|Participants will receive the 3 treatments (Treatment A,B and C) in sequence BAC with food and subsequent treatments will be separated by 4 weeks.
11558155|NCT00946842|Experimental|Panel A: Treatment Sequence BCA|Participants will receive the 3 treatments (Treatment A,B and C) in sequence BCA with food and subsequent treatments will be separated by 4 weeks.
11558156|NCT00946842|Experimental|Panel A: Treatment Sequence CBA|Participants will receive the 3 treatments (Treatment A,B and C) in sequence CBA with food and subsequent treatments will be separated by 4 weeks.
11558157|NCT00946842|Experimental|Panel A: Treatment Sequence CAB|Participants will receive the 3 treatments (Treatment A,B and C) in sequence CAB with food and subsequent treatments will be separated by 4 weeks.
11558158|NCT00946842|Experimental|Panel B: Treatment Sequence DEF|Participants will receive the 3 treatments (Treatment D,E and F) in sequence DEF with food and subsequent treatments will be separated by 4 weeks.
11558159|NCT00946842|Experimental|Panel B: Treatment Sequence DFE|Participants will receive the 3 treatments (Treatment D,E and F) in sequence DFE with food and subsequent treatments will be separated by 4 weeks..
11558160|NCT00946842|Experimental|Panel B: Treatment Sequence EDF|Participants will receive the 3 treatments (Treatment D,E and F) in sequence EDF with food and subsequent treatments will be separated by 4 weeks.
11558161|NCT00946842|Experimental|Panel B: Treatment Sequence EFD|Participants will receive the 3 treatments (Treatment D,E and F) in sequence EFD with food and subsequent treatments will be separated by 4 weeks.
11558162|NCT00946842|Experimental|Panel B: Treatment Sequence FDE|Participants will receive the 3 treatments (Treatment D,E and F) in sequence FDE with food and subsequent treatments will be separated by 4 weeks.
11558163|NCT00946842|Experimental|Panel B: Treatment Sequence FED|Participants will receive the 3 treatments (Treatment D,E and F) in sequence FED with food and subsequent treatments will be separated by 4 weeks.
11558164|NCT00946816|Active Comparator|Anorexia Nervosa|
11558165|NCT00946816|Active Comparator|Obesity|
11558166|NCT00946816|Active Comparator|Healthy volunteers|
11558167|NCT00946803|Experimental|PC-CB Intervention|Patient-Controlled Cognitive-Behavioral Intervention
11558168|NCT00946803|No Intervention|Wait list|Wait list control group. Offered PC-CB Intervention after the study.
11558169|NCT00946790|Experimental|1|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)
11558170|NCT00946790|Active Comparator|2|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)
11558171|NCT00946777|Experimental|Systane® Ultra|
11558172|NCT00946764|Experimental|1|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)
11558173|NCT00946764|Active Comparator|2|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)
11558174|NCT00946751|Experimental|1|Levetiracetam Tablets, 750 mg (Sandoz Inc.)
11558175|NCT00946751|Active Comparator|2|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)
11558176|NCT00946738|Active Comparator|physical therapy|
11558177|NCT00946738|No Intervention|control|
11558178|NCT00946725|Experimental|1|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)
11558179|NCT00946725|Active Comparator|2|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)
11558180|NCT00946712|Experimental|Arm I (chemo +/- bevacizumab)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes with or without bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients receiving bevacizumab may continue to receive bevacizumab (as above) in the absence of disease progression or unacceptable toxicity.
11558181|NCT00946712|Experimental|Arm II (chemo, cetuximab, +/- bevacizumab)|Patients receive paclitaxel and carboplatin with or without bevacizumab as in Arm I. Patients also receive cetuximab IV over 1-2 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients may continue to receive cetuximab with or without bevacizumab (as above) in the absence of disease progression or unacceptable toxicity.
11558182|NCT00946699|Experimental|1|MEDI-551
11558183|NCT00946699|Experimental|2|MEDI-551
11558184|NCT00946699|Experimental|3|MEWDI-551
11558185|NCT00946699|Experimental|4|MEDI-551
11558186|NCT00946699|Experimental|5|MEDI-551
11558187|NCT00946699|Placebo Comparator|6|Placebo
11558188|NCT00946686|Experimental|1|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)
11558189|NCT00946686|Active Comparator|2|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)
11558190|NCT00946673|Experimental|vorinostat & stereotactic radiosurgery|
11558191|NCT00946647|Experimental|Panobinostat + 5-Azacytidine|"In phase I: Panobinostat : Escalating doses starting with 20 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.
~In phase II: Panobinostat : Rapid Phase II doses at 30 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.
~In both phases, dose of 5-Azacytidine was 75 mg/m^2, subcutaneously Daily for Day 1 to Day 7."
11558192|NCT00946647|Active Comparator|5-Azacytidine|"The dose of 5-Aza was fixed at 75 mg/m2/day for 7 days in Week 1 of each cycle. 5-Aza was sourced locally, except in 4 countries (Hungary, Switzerland, UK, and Spain, for which a central purchase was used by Novartis.
~Dose of 5-Azacytidine : 75 mg/m^2 subcutaneously daily from Day 1 to Day 7."
11558193|NCT00946634|Experimental|Ozone Gas|Endodontic protocol preconized by University of Sao Paulo associated to ozone gas 40 mg/L
11558194|NCT00946634|Active Comparator|Control|Regular endodontic protocol preconized by University of Sao Paulo
11558195|NCT00946634|Experimental|Aqueous Ozone|Endodontic protocol preconized by University of Sao Paulo associated to Aqueous ozone 40mg/L
11558196|NCT00946621|Experimental|1|Ramipril 10 mg Capsule (Sandoz)
11558197|NCT00946621|Active Comparator|2|Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)
11558198|NCT00946608|Experimental|1|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)
11558199|NCT00946608|Experimental|2|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)
11558200|NCT00946608|Active Comparator|3|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)
11558201|NCT00946595|Active Comparator|efavirenz/emtricitabin/tenofovir|
11558202|NCT00946595|Experimental|lopinavir/ritonavir|
11558204|NCT00946569|Placebo Comparator|Treatment B (Placebo)|Participants will receive matching placebo once daily for 12 weeks.
11558205|NCT00946556|Placebo Comparator|Placebo|Participants will be assigned 2 months of placebo or active drug, with an intervening one month washout period.
11558206|NCT00946556|Experimental|Valacyclovir|Participants will be assigned 2 months of placebo or active drug, with an intervening one month washout period.
11558207|NCT00946530|Experimental|Bright Light|received bright light
11558208|NCT00946530|Placebo Comparator|Control|received regular light
11558209|NCT00946517||Parents|Parents or caregivers of type 1 diabetics
11558210|NCT00946517||Child|Type 1 diabetics
11558211|NCT00946504|Experimental|1|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)
11558212|NCT00946504|Active Comparator|2|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)
11558213|NCT00946491|Experimental|1|Haloperidol 10 mg Tablets (Cord Laboratories)
11558214|NCT00946491|Active Comparator|2|Haldol 10 mg Tablets (McNeil Pharmaceuticals)
11558215|NCT00946478|Active Comparator|Pimecrolimus|
11558216|NCT00946478|Sham Comparator|Vehicle cream|
11558217|NCT00946465|Experimental|1|Ramipril 10 Capsule (Sandoz)
11558218|NCT00946465|Active Comparator|2|Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)
11558219|NCT00946426||Diagnostic|Hyperinsulinemic euglycemic clamp
11558220|NCT00946413|Experimental|CBT plus parent education|
11558221|NCT00946413|Experimental|CBT alone|
11558222|NCT00946400||Suspected HIT|Those who are clinically suspected of having HIT will be enrolled in this study.
11558223|NCT00946387|Experimental|1|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
11558224|NCT00946387|Active Comparator|2|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
11558225|NCT00946361||Diagnostic|
11558226|NCT00946348|Experimental|Dronabinol|Dronabinol 10mg or 15 mg
11558227|NCT00946348|Active Comparator|Cannabis|Cannabis cigarette
11558228|NCT00946335|Experimental|Treatment (veliparib, temozolomide)|"Patients receive oral ABT-888 twice daily and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for 13-26 courses in the absence of disease progression or unacceptable toxicity.
~Blood samples are collected for pharmacokinetics and further laboratory analysis."
11558229|NCT00946322|Experimental|Arm 1: CTAP|Couple-Based Treatment for Alcohol Use Disorders and PTSD
11558230|NCT00946309|Experimental|High Sulforaphane Extract|
11558231|NCT00946309|Placebo Comparator|Placebo|
11558232|NCT00946296|Active Comparator|Potassium Iodide|8 drops of Potassium Iodide in a glass of water, by mouth, daily for 7 days prior to operation.
11558233|NCT00946296|No Intervention|No Treatment|The experimental group receives no treatment.
11558234|NCT00946283|Experimental|Lactobacillus GG|Open label trial of Culturelle (Lactobacillus GG) administered to patients after engraftment, post allogeneic stem cell transplantation.
11558235|NCT00946270|Experimental|Group 3 CC-4047 + Prednisone|CC-4047 0.5 mg orally daily starting on day 1 through 28. Prednisone given during first 3 cycles of therapy. It will be dosed orally at the dose of 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
11558236|NCT00946270|Experimental|Group 1 CC-4047|CC-4047 3.0 mg orally daily starting on day 1 through 21.
11558237|NCT00946270|Experimental|Group 2 CC-4047|CC-4047 0.5 mg orally daily starting on day 1 through 28.
11558238|NCT00946257|Experimental|Cohort 1|0.3 mg dose
11558239|NCT00946257|Experimental|Cohort 2|0.6 mg dose
11558240|NCT00946257|Experimental|Cohort 3|1.2 mg dose
11558241|NCT00946257|Experimental|Cohort 4|1.8 mg dose
11558242|NCT00946257|Experimental|Cohort 5|2.4 mg dose
11558243|NCT00946257|Experimental|Cohort 6|3.0 mg dose
11558244|NCT00946244||Term infants|Healthy term infants
11558245|NCT00946244||Usual care program|VLBW preterm infants who received usual medical care during hospitalization after birth
11558246|NCT00946244||Clinic-based intervention program|VLBW preterm infants who received specific early intervention program delivered at clinic before 1 year of corrected age (in previous study)
11558247|NCT00946244||Home-based intervention program|VLBW preterm infants who received specific early intervention program delivered at home before 1 year of corrected age (in previous study)
11558248|NCT00946231||Heart Failure|Subjects admitted to the hospital with decompensated heart failure.
11558249|NCT00946218||Part A|Children with presumptive dengue infection enrolled for empiric cost modeling with retrospective clinical estimation and comparison of test performance to the standard of care.
11558250|NCT00946218||Part B|Children with definitive dengue infection enrolled for gene expression analysis.
11558251|NCT00946205|Experimental|Laparoscopic anterior mesh rectopexy|
11558252|NCT00946205|Active Comparator|Laparoscopic posterior rectopexy|
11558253|NCT00946192|Experimental|Estrogen Patch|17Beta-estradiol transdermal patch twice weekly application for 12 months
11558254|NCT00946192|Active Comparator|Estrogen Pill|One pill containing estrogen and progesterone taken daily for 21 days followed by placebo pills only for 7 days; regimen repeated for 12 months.
11558255|NCT00946192|Sham Comparator|Control|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
11558256|NCT00946179|Experimental|Group 1|Participants aged 18 to 60 years at enrollment
11558257|NCT00946179|Experimental|Group 2|Participants aged 61 years or older at enrollment
11558258|NCT00946166|Placebo Comparator|Placebo Control|Subjects receive standard treatment for pneumonia and a simvastatin-like placebo
11558259|NCT00946166|Experimental|Simvastatin|Subjects receive simvastatin in addition to standard pneumonia treatment
11558260|NCT00946153|Experimental|Lenvatinib|
11558261|NCT00946140||Patients with ovarian cancer currently undergoing treatment|All of the patients will be treated per their treatment protocols by their physicians and they will be referred to this study for the DCE-MRI scans at baseline, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
11558262|NCT00946127||Shunt Arm|Ventriculoperitoneal Shunt
11558263|NCT00946127||ETV arm|Endoscopic Third Ventriculostomy
11558303|NCT00945763|Experimental|N1539 60 mg|
11558304|NCT00945763|Active Comparator|Motrin|
11558264|NCT00946101|Active Comparator|MEDI3414 [Influenza A (H1N1) vaccine]|MEDI3414- Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 FFU (fluorescent focus units) of influenza virus type A/California/07/2009.
11558265|NCT00946101|Placebo Comparator|Placebo|Placebo - Placebo was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer
11558266|NCT00946088|Active Comparator|Progesterone|Progesterone 400mg per vagina qhs.
11558267|NCT00946088|Placebo Comparator|Polyethylene glycol&hydrogenated vegetable oil|Polyethylene glycol&hydrogenated vegetable oil per vagina
11558268|NCT00946062|Active Comparator|regular O&M-training|orientation and mobility training in use of the identification cane as provided by mobility trainers
11558269|NCT00946062|Experimental|standardised O&M-training|standardised orientation and mobility training in use of the identification cane as provided by mobility trainers who received instruction in using the standardised protocol
11558270|NCT00946049|Experimental|Vicryl Plus|
11558271|NCT00946049|Active Comparator|Vicryl|
11558272|NCT00946023|Experimental|Transplant|Non-myeloablative allogeneic bone marrow transplant (BMT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD (graft vs host disease) prophylaxis. Rituximab will be given as post-transplant maintenance.
11558273|NCT00946010||1|Click here for more information about this study: Investigation of Hepatitis B and Hepatitis C in Taiwan
11558274|NCT00945997|Active Comparator|A|
11558275|NCT00945997|Active Comparator|B|
11558276|NCT00945984||LESS|Patients who underwent LESS radical nephrectomy
11558277|NCT00945984||Conventional laparoscopy|Patients who underwent conventional laparoscopic radical nephrectomy
11558278|NCT00945971|Experimental|Physical activity|The intervention group will participate in an exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be performed at the start and in the end of this study.
11558279|NCT00945958|Experimental|SPARC0913|
11558280|NCT00945945|Experimental|DLX30-PLA|Per the protocol, patients randomized to the duloxetine group were to receive duloxetine for the entire 13-week acute treatment period. Patients were to start at a 30 mg daily (QD) dose of duloxetine for 1 week, then increase to 60 mg QD of duloxetine for the following 12 weeks. However, due to a study drug labeling error, patients randomized to this group received 30 mg of duloxetine for the initial 1-week, but received placebo instead of receiving 60 mg QD of duloxetine for the next 12 weeks. The resulting unintended, mixed treatment group was labeled as DLX30-PLA throughout this document. Per protocol, the last week of the study (week 14) was intended to be a 1-week taper period. Patients in this treatment group were to receive 30 mg QD of duloxetine during that week, and that did occur per protocol.
11558281|NCT00945945|Placebo Comparator|PLA-DLX60|Per the protocol, patients randomized to the placebo group were to receive placebo for the entire 13-week acute treatment period. Patients were to start on placebo for the first week, then continue on placebo for the following 12 weeks. However, due to a study drug labeling error, patients in this group received placebo for the initial 1-week, but received 60 mg QD of duloxetine instead of receiving placebo for the next 12 weeks. The resulting unintended, mixed treatment group was labeled as PLA-DLX60 throughout this document. Per protocol, the last week of the study (week 14) was intended to be a 1-week taper period. Patients in this treatment group were to receive placebo that week, and that did occur per protocol.
11558282|NCT00945932|Experimental|28 day repeat dose|
11558283|NCT00945906|Experimental|FXIII|Subjects were administered FXIII Concentrate (Human) by intravenous (IV) infusion approximately every 28 days to maintain a trough FXIII level of approximately 5 to 20%.
11558284|NCT00945893|Experimental|MEDI3414 [Influenza A (H1N1) vaccine]|MEDI3414 - Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 fluorescent focus units (FFU) of live, attenuated influenza virus reassortant A/California/7/2009 strain that was propagated in chicken eggs. H1N1 monovalent influenza vaccine (MEDI3414) contained no preservatives and no adjuvants.
11558285|NCT00945893|Placebo Comparator|Placebo|Placebo -Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
11558286|NCT00945854|Active Comparator|Wholegrain cereal diet|Treatment with a diet based on wholegrain cereals and foods with low glycemic index
11558287|NCT00945854|Active Comparator|Refined cereal diet|Treatment with a diet based on refined cereals and foods with high glycemic index
11558288|NCT00945841|Other|1|
11558289|NCT00945828|Experimental|Annual Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study.
11558290|NCT00945828|Experimental|Quarterly Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study.
11558291|NCT00945815|Experimental|treatment|AraC 1 g/m2/d IV Days 1-5 clofarabine 40 mg/m2/d IV Days 2-6 epratuzumab 360 mg/m2/d IV Days 7, 14, 21, 28 acetaminophen 650 mg/d PO Days 7, 14, 21, 28 diphenhydramine 50 mg/d IV Days 7, 14, 21, 28 IT methotrexate 12 mg IT at least 1 wk apart during induction All give 1 cycle
11558292|NCT00945802|Experimental|FST-201 (dexamethasone 0.1%) Otic Suspension|
11558293|NCT00945802|Active Comparator|ciprofloxacin 0.3%, dexamethasone 0.1%|
11558294|NCT00945789|Experimental|EPO HIE Group|Infants with hypoxic ischemic encephalopathy receive human recombinant erythropoietin
11558295|NCT00945789|No Intervention|Control HIE|Infants with hypoxic ischemic encephalopathy who do not receive treatment drug (EPO)
11558296|NCT00945789|Other|Healthy Controls|Healthy newborn without hypoxic ischemic encephalopathy
11558297|NCT00945776|Active Comparator|Weekly phone calls|Will be called weekly to answer questions regarding usage.
11558298|NCT00945776|Active Comparator|Frequently asked questions|Providing written general answers to commonly asked questions.
11558299|NCT00945776|Active Comparator|Usual care|
11558300|NCT00945763|Placebo Comparator|placebo|
11558301|NCT00945763|Experimental|N1539 15 mg|
11558302|NCT00945763|Experimental|N1539 30 mg|
11558305|NCT00945750|Experimental|Sequence 1: FCT with water → CT without water → CT with water|Participants received famotidine 20 mg FCT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 3).
11558306|NCT00945750|Experimental|Sequence 2: CT without water → CT with water → FCT with water|Participants received famotidine 20 mg CT as a single dose without water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 3).
11558307|NCT00945750|Experimental|Sequence 3: CT with water → FCT with water → CT without water|Participants received famotidine 20 mg CT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 3).
11558308|NCT00945750|Experimental|Sequence 4: FCT with water → CT with water → CT without water|Participants received famotidine 20 mg FCT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 3).
11558309|NCT00945750|Experimental|Sequence 5: CT without water → FCT with water → CT with water|Participants received famotidine 20 mg CT as a single dose without water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 3).
11558310|NCT00945750|Experimental|Sequence 6: CT with water → CT without water → FCT with water|Participants received famotidine 20 mg CT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 3).
11558311|NCT00945737|Active Comparator|Soy protein|
11558312|NCT00945737|Placebo Comparator|Milk protein|
11558313|NCT00945724|Experimental|R-CHOP, Depocyte, Methotrexate|
11558314|NCT00945711||1|Eating Disorder Diabetes Mellitus T1 patients
11558315|NCT00945711||2|Eating Disorder only patients
11558316|NCT00945698|Other|ST-DI (Delayed intervention)|"1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age
~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
11558317|NCT00945698|Experimental|LNS-10gM|"140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age
~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
11558318|NCT00945698|Experimental|LNS-20gM|"280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age
~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
11558319|NCT00945698|Experimental|LNS-20gNoM|"280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age
~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
11558320|NCT00945698|Experimental|LNS-40gM|"560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age
~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
11558321|NCT00945698|Experimental|LNS-40gNoM|"560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age
~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
11558322|NCT00945685|Experimental|Endymion study group|
11558323|NCT00945672|Experimental|PF-04360365 10 mg/kg|
11558324|NCT00945672|Experimental|PF-04360365 7.5 mg/kg|
11558325|NCT00945672|Placebo Comparator|placebo|
11558326|NCT00945659|Active Comparator|Standard Care|"Standard Care constitutes intensified diabetes management, an enrollment criterion for the study, consisting of either continuous subcutaneous insulin infusion (insulin pump) or multiple daily injections using a basal-bolus approach. All patients must be using carbohydrate counting and have prescribed correction factors for targeted insulin bolus dose adjustments."
11558327|NCT00945659|Active Comparator|Continuous Glucose Sensor|Patients will have the same diabetes management regimen as those in the Standard Care group. In addition they will be given a continuous glucose sensor, receive expert instruction in its use, and be guided by a physician and diabetes educator in achieving glycemic benefits through retrospective and real-time interpretation of CGS results and by learning to respond judiciously to the various CGS alarms.
11558328|NCT00945659|Experimental|CGS + Behavior Therapy|Patients in the use group will receive the same medical management as the Continuous Glucose Sensor group above. In addition, they will have 6 scheduled encounters with a behavior therapist that are designed to reduce or eliminate typical behavioral and/or psychological barriers to optimal use of CGS as part of diabetes care.
11558329|NCT00945646|Experimental|FST-201 (dexamethasone 0.1%) Otic Suspension|
11558330|NCT00945646|Placebo Comparator|vehicle|
11558331|NCT00945620|Placebo Comparator|right side|The trans-abdominis block will be placed in every pat with one side being injected with ropivicaine, the other side placebo injection. Hence is subject can serve as their own control. Subjects will receive additional pain medications as needed
11558332|NCT00945620|Placebo Comparator|Left side|The trans-abdominis block will be placed in every pat with one side being injected with ropivicaine, the other side placebo injection. Hence is subject can serve as their own control. Subjects will receive additional pain medications as needed
11558376|NCT00945295|Active Comparator|Cohort #2|Cohort 2 will receive BoNT-A alone
11558377|NCT00945282|Experimental|Cohort 1|In Cohort 1 subjects will receive either GSK2248761 30 mg or placebo once a day for 7 days. On Day 8 subjects will receive either Kaletra or HAART for 28 days. The doctor will choose the most appropriate medications for HAART.
11558419|NCT00944957|Experimental|Raltegravir first|Patients treated with Raltegravir for first 2 weeks
11558420|NCT00944957|Experimental|Efavirenz first|Patients treated with Efavirenz for first 2 weeks
11558421|NCT00944944||Gyn Pts with lymphedema|
11558422|NCT00944944||Gyn Pts without Lymphedema|
11558333|NCT00945607|Experimental|Guided Relaxation Training|"Eligible subjects who have been randomized to the intervention arm will be scheduled for GRT introduction and training with a research staff member. The GRT sessions will consist of six weekly on-site sessions in which the subject is provided instructions and then allowed to listen to the GRT CD. Subjects will be instructed to conduct independent GRT sessions at home, twice daily, at least four hours apart, for the duration of the study. Subjects will also be instructed that on the days of one-on-one sessions with a research staff member at TCCC, that they will only be required to perform the independent session once at home.
~Subjects will be provided with a diary to record the date and time of each independent GRT session performed at home. Subjects will be instructed to bring their completed diary with them at each subsequent visit."
11558334|NCT00945607|No Intervention|Standard of Care(SOC)|Eligible subjects who are randomized to the SOC arm will not receive the GRT sessions. During the six week treatment phase, these subjects will only receive SOC provided to all subjects newly diagnosed with breast cancer at TCCC. This consists of an education session with the nurse or nurse practitioner. In addition, they will also be provided with supportive care and symptom management as needed. This arm will also be provided with a diary to record their stress level at least twice daily.
11558335|NCT00945594|Experimental|Flexible cystoscopy|16F flexible cysto urethroscope (Storz, Culver city, CA)
11558336|NCT00945594|Experimental|Rigid cystoscopy|17F, 70° scope (Storz, Culver city, CA)
11558337|NCT00945581|Experimental|AN777|Powder twice a day
11558338|NCT00945581|Placebo Comparator|Placebo powder|Powder twice a day
11558339|NCT00945568|Experimental|Aminolaban EN|Aminoleban EN™ was administered at a dose of 100 g per day commencing two weeks prior to surgery. A 100 g dose of Aminoleban EN™ contains 13.0 g of free amino acids, 13.0 g of gelatin hydrolysate, 1.0 g of casein, 62.1 g of carbohydrate, 7.0 g of lipid, glycyrrhizin, and other components, producing 420 kcal. The AEN group included 40 patients who were administered 100 g of Aminoleban EN™ as 50 g during the day and 50 g as a late evening snack.
11558340|NCT00945568|No Intervention|Control|The patients were divided into two groups including one group administered Aminoleban (the AEN group) and a control group given no additional dietary supplementation. The total caloric energy intake per day during the study period was assumed to be equal to Aminolaban EN group.
11558341|NCT00945555||All participants|Participants with febrile neutropenia who received antibacterial treatment per investigator's judgment
11558342|NCT00945542|Other|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
11558343|NCT00945542|Experimental|Preemptive transfusion|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. This corresponds to an FFP:RBC transfusion ratio of 1:1.
~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
11558344|NCT00945516|Active Comparator|Flared end FCSEMS|Flared end FCSEMS will be inserted for the benign bile duct stricture.
11558345|NCT00945516|Active Comparator|Anchoring FCSEMS|Anchoring FCSEMS will be inserted for benign bile duct stricture
11558346|NCT00945503|Experimental|GSK1018921|All subjects will received a dose of GSK1018921 and will peforme three PET scans using the ligand [11C]GSK931145, but in order to obtain adequate sampling of the exposure-time-occupancy curves, a range of doses will be evaluated, and the timing of the post-dose scans will differ between subjects.
11558347|NCT00945490|Experimental|NX-1207|
11558348|NCT00945490|Placebo Comparator|Placebo|
11558349|NCT00945477|Experimental|Advanced prostate cancer, treatment, pazopanib|Pazopanib
11558350|NCT00945464||No treatment|Women over the age of 30 undergoing breast imaging at the Scripps Polster Breast Care Center.
11558351|NCT00945451|Experimental|CyberKnife irradiation|
11558352|NCT00945438|Experimental|Group 1|Participants aged 18 to 59 years at enrollment.
11558353|NCT00945438|Experimental|Group 2|Participants aged 60 years or older at enrollment.
11558354|NCT00945425|Experimental|1|Low dose or placebo, twice daily
11558355|NCT00945425|Experimental|2|Low dose or placebo, once daily
11558356|NCT00945425|Experimental|3|Middle dose or placebo, twice daily
11558357|NCT00945425|Experimental|4|High dose or placebo, once daily
11558358|NCT00945412|Experimental|Micropolysaccharide Hemospheres (MPH)|
11558359|NCT00945412|Active Comparator|Electrocautery|
11558360|NCT00945399|Experimental|Autologous Chondrocytes Implantation|
11558361|NCT00945399|Active Comparator|Microfracture|
11558362|NCT00945373|Experimental|Erythematotelangiectatic Rosacea|2.5% gel calcium dobesilate and pulsed dye laser
11558363|NCT00945360|Experimental|aromatase inhibitors: Letrozole|All consenting patients will be started on Letrozole at a dose of 2.5 mg/day for 8 weeks.
11558364|NCT00945347|No Intervention|Baseline|Visit 1
11558365|NCT00945347|Active Comparator|Miglustat|Nasal instillation of Miglustat (visit 2 or 3)
11558366|NCT00945347|Placebo Comparator|Placebo|Nasal instillation of placebo (visit 3 or 2)
11558367|NCT00945334|Experimental|Group 1|Group 1 will receive neomycin (500 mg po bid) and placebo (tid) for 14 days
11558368|NCT00945334|Experimental|Group 2|Group 2 will receive neomycin (500 mg po bid) and rifaximin (550mg po tid) for 14 days
11558369|NCT00945321|Active Comparator|1|aprepitant 165 mg
11558370|NCT00945321|Active Comparator|2|aprepitant 185 mg
11558371|NCT00945321|Experimental|3|fosaprepitant 150 mg
11558372|NCT00945321|Experimental|4|aprepitant with food
11558373|NCT00945308|Active Comparator|Eptifibatide (intracoronary)|
11558374|NCT00945308|Active Comparator|Eptifibatide (intravenous)|
11558375|NCT00945295|Active Comparator|Cohort #1|Cohort 1 will receive BoNT-A plus rehabilitation therapy for the duration of the study (for up to 2 injections of BoNT-A).
11558378|NCT00945282|Experimental|Cohort 2|In Cohort 2 subjects will receive either GSK2248761 in the range of 10 mg - 20 mg or 40 mg - 90 mg or placebo once a day for 7 days. On Day 8 subjects will receive either Kaletra or HAART for 28 days. The doctor will choose the most appropriate medications for HAART. The dose for Cohort 2 will be determined following evaluation of results from Cohort 1. Cohort 2 may not be done.
11558379|NCT00945269|Experimental|Treatment (cellular adoptive immunotherapy)|Patients receive autologous T-cell IV over 30-60 minutes on days 0 and 28 and low-dose aldesleukin SC twice daily on days 0 to 13 and 28 to 41. Beginning 4-6 days before second T-cell infusion, patients receive denileukin diftitox IV over 30 minutes on days 1-3.
11558380|NCT00945256|Active Comparator|Young Aerobic Exercise|45 minutes of treadmill walking at 40% VO2 peak
11558381|NCT00945256|Active Comparator|Elderly Aerobic Exercise|45 minutes of treadmill walking at 40% VO2 peak
11558382|NCT00945256|Active Comparator|Young Sodium Nitroprusside|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
11558383|NCT00945256|Active Comparator|Elderly Sodium Nitoprusside|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
11558384|NCT00945256|Active Comparator|Elderly Sodium Nitroprusside and Amino Acid Drink|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min and 7.5g amino acid drink taken orally
11558385|NCT00945243|Other|Treatment|Treatment of cervical DDD with the Zero-P device
11558386|NCT00945230|Experimental|Actigraphic Neurosurgical Outcomes|Actigraphic measurements that will be obtained by attaching the actigraphic watch device to the individual's non-dominant wrist and operationally defined repeated observational measurements. All measurements will continue through a baseline period and continue through the identified post surgical period. Actigraphic measurements will occur every 30 seconds with brief periods of non-measurement during the actual neurosurgical procedure and periods when the actigraphic device has reached storage capacity (approximately every 22 days) when data is retrieved and the device prepared resume measurements.
11558387|NCT00945217||Postmenopausal women|women with natural menopause
11558388|NCT00945204|Experimental|access to intermediate care clinics|
11558389|NCT00945204|No Intervention|usual care|
11558390|NCT00945191|Experimental|CS-1008 with paclitaxel and carboplatin|CS-1008 will be administered with paclitaxel and carboplatin.
11558391|NCT00945178|Experimental|Part A: A|AZD1386
11558392|NCT00945178|Experimental|Part A: B|Placebo for AZD1386
11558393|NCT00945178|Experimental|Part B: A|Naproxen
11558394|NCT00945178|Experimental|Part B: B|Placebo for Naproxen
11558395|NCT00945165|Experimental|Exercise|
11558396|NCT00945165|Experimental|No exercise|
11558397|NCT00945152|Experimental|Drug Vancogel,Treatment,Kill MRSA,Heal|Treatment of open wounds with Vancogel(R) 1.25-1.50% to eliminate MRSA. End point is: a negative culture report after 1-3 topical applications. The infected wounds with MRSA will be treated with the Vancomycin 1.25 to 1.50% complex gel formulation and will have conventional management in order to heal the wound. Vancogel is anticipated to accelerate wound healing by eliminating MRSA. A randomized, double blind study protocol approved by FDA.
11558398|NCT00945152|Placebo Comparator|Placebo|Half of the patients in the study will be given a placebo consisting of all ingredients in Vancogel except the active principal Vancomycin in order to compare their clinical efficacy in rate of wound healingafter 1-3 applications
11558399|NCT00945139|Experimental|Single Arm: Doxil and Avastin|Patients receive both agents, doxil and Avastin.
11558400|NCT00945113|Experimental|Treatment group|attendance at one-week speech therapy group
11558401|NCT00945100|Active Comparator|Control|2 hours daily patching
11558402|NCT00945100|Active Comparator|Intensified treatment|42 hours per week of patching (averaging 6 hours daily)
11558403|NCT00945074|Experimental|Condition 1|"Condition 1:
~Subjects receive Standard Acu/Moxa (fixed protocol)"
11558404|NCT00945074|Experimental|Condition 2: Individualized Acupuncture/Moxibustion|"Condition 2:
~Subjects receive Individualized Acupuncture/Moxibustion (patient-oriented, based on traditional Chinese medicine diagnosis)."
11558405|NCT00945074|Sham Comparator|Condition 3: Control|"Condition 3:
~Subjects receive Sham Acupuncture/Placebo Moxibustion (control group)"
11558406|NCT00945061|Experimental|Intraoperative radiation therapy|Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.
11558407|NCT00945061|Experimental|Intracavitary balloon brachytherapy|Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.
11558408|NCT00945035|Active Comparator|A|Etoricoxib, 20% tablet
11558409|NCT00945035|Active Comparator|B|Etoricoxib, 30% tablet
11558410|NCT00945022|Experimental|Lipsus|
11558411|NCT00945009|Experimental|Arm 1 (Bilateral Wilms Tumors)|Patients start with three drug chemotherapy (Regimen VAD; vincristine, dactinomycin and doxorubicin) and are evaluated and six and 12 weeks for feasibility of undergoing a partial nephrectomy/renal sparing surgery. At week 12 definitive surgery takes place followed by chemotherapy and radiation therapy based on histology and stage. Treatment continues for 25 or 31 weeks depending on histology. Patients are followed for up to 10 years following end of therapy.
11558412|NCT00945009|Experimental|Arm 2 (Unilateral High Risk tumors bilaterally predisposed)|Patients start with either 2 drug or three drug chemotherapy (Regimen VA, VAD) and are evaluated a 6 and 12 weeks for feasibility of undergoing a partial nephrectomy. At week 12 definitive surgery takes place followed by chemotherapy.
11558413|NCT00945009|Experimental|Arm 3 (DHPLN)|Patients with this rare disease are diagnosed based on cross-sectional imaging characteristics and undergo 2 drug chemotherapy (Regimen;VA). Patients are reassessed at 6 weeks and 12 weeks. If disease has responded or stayed stable chemotherapy is completed for 19 weeks (Regimen EE4A). If disease has progress a biopsy is performed to assess histology and adjust therapy based on the biopsy. This therapy may include, nephrectomy, chemotherapy or radiation therapy.
11558414|NCT00944996|Active Comparator|antidepressant|
11558415|NCT00944996|No Intervention|Healthy volunteers|
11558416|NCT00944970|Other|binodenoson then adenosine|binodenoson (experimental); adenosine (active comparator)
11558417|NCT00944970|Other|adenosine then binodenoson|adenosine (active comparator); binodenoson (experimental)
11558418|NCT00944970|Active Comparator|adenosine then adenosine|
11558423|NCT00944918|Experimental|1|fulvestrant and anastrozole
11558424|NCT00944918|Experimental|2|fulvestrant and placebo
11558425|NCT00944918|Active Comparator|3|exemestane alone
11558426|NCT00944905|Experimental|MDX-1203|Accelerated titration design (ATD)of 6 dose levels. Subjects will be assigned to a dose level in the order they enter the study
11558427|NCT00944892|Experimental|Dose 1|
11558428|NCT00944892|Experimental|Dose 2|
11558429|NCT00944892|Experimental|Dose 3|
11558430|NCT00944892|Placebo Comparator|Placebo|
11558431|NCT00944879||HPV vaccine|Those choosing to receive the HPV vaccine
11558432|NCT00944879||no HPV vaccine|Those choosing not to receive the HPV vaccine
11558433|NCT00944866||RA with drug|
11558434|NCT00944866||RA without drug|
11558435|NCT00944853|Experimental|Zinc syrup|Liquid Zinc Syrup (ZnSO4) solution provided daily
11558436|NCT00944853|Experimental|Zinc tablet|Dispersible zinc tablets provided daily
11558437|NCT00944853|Placebo Comparator|Placebo|Liquid placebo supplement provided daily
11558438|NCT00944840|Active Comparator|SP and amodiaquine|Study subjects received intermittent preventive treatment with SP plus amodiaquine.
11558439|NCT00944840|Placebo Comparator|SP placebo plus amodiaquine placebo|Intermittent preventive treatment with SP placebo and amodiaquine placebo
11558440|NCT00944827|Experimental|GTE|The experimental group will receive 20 mg atorvastatin (Lipitor) daily and 600 mg. of pure catechin in capsules
11558441|NCT00944827|Placebo Comparator|CON|The control group will receive 20 mg atorvastatin (Lipitor) and Placebo in identical capsules containing 600 mg placebo for 12 weeks
11558442|NCT00944814|Experimental|LNS with zinc|LNS containing 10 mg zinc per 20 g dose of LNS
11558443|NCT00944814|Placebo Comparator|LNS without zinc|LNS containing no zinc
11558444|NCT00944801|Experimental|Pegylated Liposomal Doxorubicin|Radiotherapy is planned with dedicated computed tomography and three-dimensional planning systems and delivered to the gross tumor volume with a 2 to 3 cm margin for the clinical target volume. After a 4-week break, patients receive adjuvant TMZ 150 to 200 mg/m2 day 1 to 5 in 28 days until tumor progression or up to at least 12 cycles. In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
11558445|NCT00944788|Experimental|qi-gong|
11558446|NCT00944788|No Intervention|Usual care|
11558447|NCT00944775|Experimental|exercise training|10-month exercise training program
11558448|NCT00944775|No Intervention|controls|usual care sedentary lifestyle
11558449|NCT00944762|Experimental|Ecosystem Focused Therapy (EFT)|Participants will receive EFT.
11558450|NCT00944762|Active Comparator|Education in stroke and depression|Participants will receive education in stroke and depression.
11558451|NCT00944749|Experimental|Single Arm|
11558452|NCT00944736|Active Comparator|VSL#3|
11558453|NCT00944736|Placebo Comparator|Placebo|
11558454|NCT00944723|Experimental|Zinc-fortified bread (10 mg zinc/d)|Daily consumption of zinc fortified bread for 1 month
11558455|NCT00944723|Experimental|Zinc fortified bread (20 mg zinc/d)|Daily consumption of zinc fortified bread for 1 month.
11558456|NCT00944723|Experimental|Zinc supplemented group|Daily consumption of non-fortified bread and daily intake of zinc supplement (10 mg zinc/d)
11558457|NCT00944723|Placebo Comparator|Non-fortified group|Daily consumption of non-fortified bread and a placebo supplement for 1 month.
11558458|NCT00944710|Active Comparator|Intensified treatment|Weekend atropine 1% with plano lens over the sound eye
11558459|NCT00944710|Active Comparator|Control|Weekend atropine 1%
11558460|NCT00944697|Placebo Comparator|Tablets|A placebo tablet to match the active reference treatment
11558461|NCT00944697|Active Comparator|Tablet|Oxycodone Naloxone tablets
11558462|NCT00944684|Experimental|A|PegIFN-alpha 2a + RBV (commenced according to kidney function) adjusted to plasma levels. Treatment with erythropoetin 3x3,000IU/week up to 3x10,000IU/week in case of hemolytic anemia
11558463|NCT00944684|Active Comparator|B|PegIFN-alpha 2a + RBV (weight based; 1,000 or 1,200 mg/day)
11558464|NCT00944671|Active Comparator|A|Famotidine/antacid combination tablet with water
11558465|NCT00944671|Experimental|B|Famotidine/Antacid EZ Chew tablet without water
11558466|NCT00944671|Experimental|C|Famotidine/Antacid EZ Chew tablet with water
11558467|NCT00944658|Placebo Comparator|Placebo|placebo twice a day for 12 weeks, 4 weeks follow up
11558468|NCT00944658|Active Comparator|Apremilast|30 mg twice a day for 12 weeks, 4 weeks follow up
11558469|NCT00944645|Active Comparator|A|MK0524A Source 1 (Phase III manufacturing site)
11558470|NCT00944645|Active Comparator|B|MK0524A Source 2 (commercial manufacturing site)
11558471|NCT00944632|Active Comparator|Zk 245186 0.01% ointment|Active treatment, lowest dose
11558472|NCT00944632|Active Comparator|ZK 245186 0.03% ointment|Active comparator middle dose
11558473|NCT00944632|Active Comparator|ZK 245186 0.1% ointment|Active comparator highest dose
11558474|NCT00944632|Placebo Comparator|Vehicle ointment|Placebo comparator
11558475|NCT00944619|Experimental|Closed loop (algorithm)|Subcutaneous delivery of Novorapid insulin, dose calculated by computer-driven control algorithm, based on continuous glucose sensor readings
11558476|NCT00944619|Placebo Comparator|Open loop|Subcutaneous delivery of Novorapid insulin according to usual pump regime
11558477|NCT00944606|Active Comparator|Vitamin D|
11558478|NCT00944606|Placebo Comparator|Placebo|
11558479|NCT00944593|Experimental|300kcal liquid Nutrient|300kcal liquid nutrient delivered by NJ tube over 60 minutes before ingestion of a standard oral liquid nutrient test meal
11558480|NCT00944593|Placebo Comparator|Normal Saline|Normal Saline delivered via NJ tube over 60 minutes ahead of a standard liquid nutrient test meal
11558481|NCT00944580|Experimental|Vaccine Intervention|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine: A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
11558482|NCT00944554|Placebo Comparator|Placebo|Group given placebo.
11558483|NCT00944554|Experimental|Varenicline|Experimental group given varenicline dosing.
11558484|NCT00944528|Experimental|Single dose radiosurgery: Dose Level 1|A single 15 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
11558485|NCT00944528|Experimental|Single dose radiosurgery: Dose Level 2|A single 18 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
11558486|NCT00944528|Experimental|Single dose radiosurgery: Dose Level 3|A single 21 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
11558487|NCT00944515|Active Comparator|azithromycin|azithrimycin 3 days/week
11558488|NCT00944515|Placebo Comparator|placebo|placebo 3 days/week
11558489|NCT00944502|Experimental|Dexamethasone and complex vitamins|"Group A: Vitatonus dexa injectable:
~1 ampoule intramuscularly every 3 days for 10 days.
~Group B: Vitatonus DEXA tablet:
~1 tablet orally every 8 hours for 10 days."
11558490|NCT00944502|Active Comparator|Dexamethasone|"Group C: Dexamethasone Injectable:
~1 ampoule intramuscularly every 3 days for 10 days.
~Group D: Dexamethasone tablet:
~1 tablet orally every 8 hours for 10 days."
11558491|NCT00944489||1|Patients with diagnosis of essential hypertension under the criteria established by the Joint National Committee VII (9) and those patients under pharmacological treatment with the same therapeutic regime during at least the last 6 months.
11558492|NCT00944476||Pts/volunteers getting regular MRI exam|Fat-free MRI images utilizing standard magnetization transfer imaging will be acquired on 10 patients known or suspected sarcoma of the of the extremity or trunk, in addition to their traditional clinical MRI. In addition, we will perform the same scans on 4 volunteers who have no history of sarcoma.
11558493|NCT00944463|Experimental|Gemcitabine+simvastatin|Gemcitabine and simvastatin
11558494|NCT00944463|Placebo Comparator|Gemcitabine+Placebo|Gemcitabine plus Placebo
11558495|NCT00944450|Active Comparator|1|Sitagliptin anhydrous formulation
11558496|NCT00944450|Active Comparator|2|Sitagliptin monohydrate FMI formulation
11558497|NCT00944437|Active Comparator|Helmet|Patients in this group will receive continuous positive airway pressure delivered through a helmet connected to a high-flow reservoir system.
11558498|NCT00944437|Experimental|Mask|Patients in this group will receive continuous positive-airway pressure delivered through a novel full-face mask connected to a high-flow system. Expiratory pressure will be maintained using an expiratory valve connected to a T-tube.
11558499|NCT00944424|Experimental|Arm A|Arm A = Docetaxel + High dose Vitamin D2
11558500|NCT00944424|Active Comparator|Arm B|Docetaxel + Standard dose Vitamin D2
11558501|NCT00944398|Experimental|Zinc fortified group|Daily consumption of zinc-fortified complementary food
11558502|NCT00944398|Placebo Comparator|Non-fortified group|Daily consumption of non-fortified complementary food and placebo supplement.
11558503|NCT00944398|Experimental|Zinc supplement group|Daily consumption of zinc supplement and non-fortified complementary food.
11558504|NCT00944385|Experimental|ulinastatin|Administer with 30,000U /ulinastatin
11558505|NCT00944385|Placebo Comparator|C group|administer normal saline
11558506|NCT00944372|Experimental|Group 1|Control, age greater than or equal to 18 with normal renal function
11558507|NCT00944372|Experimental|Group 2|Age 18 to less than 65 with mild renal impairment
11558508|NCT00944372|Experimental|Group 3|Age 18 to less than 65 with moderate to severe renal impairment
11558509|NCT00944372|Experimental|Group 4|Age 18 to less than 65 with end stage renal impairment
11558510|NCT00944372|Experimental|Group 5|Age 65 to less than 75 with mild renal impairment
11558511|NCT00944372|Experimental|Group 6|Age 65 to less than 75 with moderate to severe renal impairment
11558512|NCT00944372|Experimental|Group 7|Age 65 to less than 75 with end stage renal impairment
11558513|NCT00944372|Experimental|Group 8|Age greater than or equal to 75 with mild renal impairment
11558514|NCT00944372|Experimental|Group 9|Age greater than or equal to 75 with moderate to severe renal impairment
11558515|NCT00944372|Experimental|Group 10|Age greater than or equal to 75 with end stage renal impairment
11558516|NCT00944359|Experimental|Daily preventive Zn; placebo treatment|7 mg zinc per day for 12 months and placebo supplement during diarrhea episode
11558517|NCT00944359|Experimental|Therapeutic Zn; daily placebo|20 mg of zinc for 10 days during episodes of diarrhea and daily placebo supplement
11558518|NCT00944359|Experimental|Intermittent Zn; placebo treatment|10 mg zinc for 10 days every 3 months, daily placebo during 80 days of 3 months period and placebo during diarrhea episode
11558519|NCT00944359|Active Comparator|Surveillance control group|Surveillance control group will be randomly assigned to intervention groups every 3 months
11558520|NCT00944359|No Intervention|Non-intervention|Standard care provided by health system
11558521|NCT00944333|Experimental|Clopidogrel 6|6 month dual antiplatelet therapies in patients after second generation DES implantation
11558522|NCT00944333|Experimental|Clopidogrel 12|12 month dual antiplatelet therapies in patients after second generation DES implantation
11558523|NCT00944307|Active Comparator|raltegravir alone|Subjects will receive a single dose of 400 mg raltegravir orally
11558524|NCT00944307|Experimental|raltegravir plus antacid|Subjects will receive a single dose of 400mg raltegravir orally simultaneously with an antacid
11558525|NCT00944294|Other|binodenoson then adenosine|binodenoson (experimental); adenosine (active comparator)
11558526|NCT00944294|Other|adenosine then binodenoson|adenosine (active comparator); binodenoson (experimental)
11558527|NCT00944281|Experimental|LNS-Zn5|Daily intake of 20 g LNS containing 5 mg of zinc and a daily placebo supplement
11558528|NCT00944281|Experimental|LNS-Zn10|Daily intake of 20 g LNS containing 10 mg of zinc and a daily placebo supplement
11558529|NCT00944281|Placebo Comparator|LNS-Zn0|Daily intake of 20 g LNS containing 0 mg of zinc and a daily placebo supplement
11558530|NCT00944281|Experimental|Suppl-Zn5|Daily intake of zinc supplement containing 5 mg of zinc and 20 g LNS containing 0 mg of zinc
11558531|NCT00944281|No Intervention|Delayed intervention group|Standard care from age 8 to 18 months. Daily consumption of LNS from age 18 to 28 months.
11558532|NCT00944268|Experimental|Liquid and solid|
11558533|NCT00944255||RA with drug|
11558534|NCT00944255||RA without drug|
11558535|NCT00944229|Active Comparator|1 Drug Treatment - LOVAZA|Drug Treatment - LOVAZA 4 gm q24 for 8 weeks
11558536|NCT00944229|Placebo Comparator|2 placebo|Placebo 4 capsules q24 for 8 weeks
11558537|NCT00944216|Experimental|Treatment|
11558538|NCT00944203|Experimental|Test Area|Test Area = Standard Treatment plus Ipomea pes-caprae oinment
11558539|NCT00944203|No Intervention|Control Area|Control = Standard Treatment
11558540|NCT00944190|Experimental|Self-management Intervention|Telephone based self management intervention targeted at pain, fatigue, depression, and cognitive difficulties.
11558541|NCT00944190|Active Comparator|Education|Education about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
11558542|NCT00944164|Experimental|Healthy eating/physical activity|
11558543|NCT00944164|Active Comparator|Safety/Injury prevention|
11558544|NCT00944151|Placebo Comparator|Single injection with Saline infused TAP catheter|Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given normal saline in infusion pump, attached to catheter.
11558545|NCT00944151|Active Comparator|Single injection with Ropivicaine infused TAP catheter|Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given 0.2% ropivicaine in infusion pump, attached to catheter
11558546|NCT00944138|Experimental|Mindful meditation|Participants assigned to the mindful meditation plus standard care arm will receive individualized instruction on mindful meditation at the time they are randomized to this arm. The participants will be led through a 20 minute relaxation exercise. They will then be led through a brief eating exercise where they will be instructed to eat the food very slowly and pay attention to how the food tastes and the sensations of swallowing the food. This is done to enhance the person's awareness of what and how they are eating and enhance their intuitive sense of satiety. Finally, they will receive an MP3-player with several relaxation instructional audios loaded on the MP3 player.
11558547|NCT00944138|Active Comparator|Music for relaxation|Participants assigned to the control arm will receive the dietary counseling and will be told that relaxation can help reduce appetite. However, techniques to relax will not be taught. Instead, participants will be encouraged to sit quietly listening to music (of their choice) every day for 20 minutes. Participants assigned to the standard care arm will receive an MP3-player and will be given a choice of selection of music that they can load on their MP3 player (classical music, country music, jazz, etc.).
11558548|NCT00944125|Active Comparator|Dual Site LV Pacing|Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.
11558549|NCT00944125|Active Comparator|BiV Pacing|Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.
11558550|NCT00944112|Experimental|Restrictive RBC Transfusion Group|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70g/L with a target Hb concentration of 71-90g/L during the intervention period.
11558551|NCT00944112|Experimental|Liberal RBC Transfusion Group|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90g/L with a target Hb concentration of 91-110g/L during the intervention period.
11558552|NCT00944099|Experimental|Grazing|participants will be given an eating frequency prescription to eat every 2 to 3 hours
11558553|NCT00944099|Experimental|Three Meals|participants will be given an eating frequency prescription of eating 3 meals per day
11558554|NCT00944086||Recruitment Manoeuvre ,Laparoscopy|
11558555|NCT00944073|Experimental|Group 2: 30 mcg H1N1 Vaccine|300 subjects to receive 30 mcg of Inactivated H1N1 Vaccine on Day 0 and Day 21.
11558556|NCT00944073|Experimental|Group 1: 15 mcg H1N1 Vaccine|300 subjects to receive 15 mcg of Inactivated H1N1 Vaccine on Day 0 and Day 21.
11558557|NCT00944060|Experimental|lifestyle intervention|Control group: usual WIC care
11558558|NCT00944047|Experimental|Intervention Arm|Nab-paclitaxel, trastuzumab, doxorubicin, cyclophosphamide, Growth Factor Support, Surgery
11558559|NCT00944034|Experimental|B+R246_12|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.
11558560|NCT00944034|Experimental|B+R246_18|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.
11558561|NCT00944034|Experimental|B+R246_24|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.
11558562|NCT00944034|Experimental|B246_12|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.
11558563|NCT00944034|Experimental|B246_18|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.
11558564|NCT00944034|Experimental|B246_24|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.
11558565|NCT00944034|Experimental|B+R234_12|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.
11558566|NCT00944034|Experimental|B+R234_18|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.
11558567|NCT00944034|Experimental|B+R234_24|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.
11558568|NCT00944034|Experimental|B12 14|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.
11558569|NCT00944034|Experimental|B18 20|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.
11558570|NCT00944034|Experimental|B24 26|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.
11558571|NCT00944021|Experimental|PA-824 50 mg/qd|
11558572|NCT00944021|Experimental|PA-824 100mg/qd|
11558573|NCT00944021|Experimental|PA-824 150mg/qd|
11558574|NCT00944021|Experimental|PA-824 200mg/qd|
11558575|NCT00944021|Active Comparator|Rifafour e-275mg|
11558576|NCT00944008|Experimental|Depocyte|
11558577|NCT00943995|Other|Treatment Arm|Getting Growth Hormone therapy TIW instead of nightly in the Pediatric Tanner 1 Hemodialysis population.
11558578|NCT00943969|Other|obemo|
11558579|NCT00943956|Experimental|Everolimus|Everolimus + radiation
11558580|NCT00943943|Experimental|G-CSF and Plerixafor with Sorafenib|G-CSF 10 mcg/kg adjusted body weight subcutaneous injection. Plerixafor fixed dose of 240 mcg/kg adjusted body weight subcutaneous injection in abdomen. Patients will receive the 1st doses of G-CSF and Plerixafor on day 1. G-CSF and Plerixafor every other day for 7 total doses, repeated every 28 days. Sorafenib starting dose 400 mg twice daily orally after G-CSF/Plerixafor injections.
11558581|NCT00943930||Marijuana-dependent volunteers|
11558582|NCT00943917|Experimental|ITCA 650 20 mcg/day|
11558583|NCT00943917|Experimental|ITCA 650 40 mcg/day|
11558584|NCT00943917|Active Comparator|Exenatide Injection|
11558585|NCT00943917|Experimental|ITCA 650 20/20|
11558586|NCT00943917|Experimental|ITCA 650 20/60|
11558587|NCT00943917|Experimental|ITCA 650 40/40|
11558588|NCT00943917|Experimental|ITCA 650 40/80|
11558589|NCT00943917|Experimental|Ex Inj/ITCA 650 40|
11558590|NCT00943917|Experimental|Ex Inj/ITCA 650 60|
11558591|NCT00943904|Experimental|Interstim stimulation|Patients who receive the interstim implant in order to evaluate effectiveness of treatment
11558592|NCT00943891||Tumor biopsies|
11558593|NCT00943878|Experimental|Group 3: H1N1+placebo; H1N1+TIV; placebo|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + placebo; Day 21, 15 mcg H1N1 Vaccine + trivalent influenza vaccine (TIV); and Day 42, placebo.
11558594|NCT00943878|Experimental|Group 1: H1N1+placebo; H1N1+placebo; TIV|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + placebo; Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, trivalent influenza vaccine (TIV).
11558595|NCT00943878|Experimental|Group 2: H1N1+TIV; H1N1+placebo; placebo|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + trivalent influenza vaccine (TIV); Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, placebo.
11558596|NCT00943878|Experimental|Group 4: TIV+placebo; H1N1+placebo; H1N1|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, trivalent influenza vaccine (TIV) + placebo; Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, 15 mcg H1N1 vaccine.
11558597|NCT00943865|Active Comparator|hypocaloric diet + exercise advice|Group 1 (control: tailored hypocaloric diet and exercise advised): patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant. Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
11558598|NCT00943865|Experimental|pragmatic diet+ pedometer 10000 steps|Group 2 (pragmatic diet + step counter) - Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control. Subjects were provided with pedometers and were instructed to perform at least 10.000 steps daily, diary recorded.
11558599|NCT00943865|Experimental|pragmatic diet + fitness|Group 3 (pragmatic diet + fitness) - They received the same diet intervention (low carbohydrates, high protein and vegetables style diet and favoring daily brazilian cook habits colored handbook) and hand sized portion control instructions of group 2. They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions.
11558600|NCT00943852|Active Comparator|1|losartan 100 mg
11558601|NCT00943852|Active Comparator|2|ISMN 60 mg
11558602|NCT00943852|Active Comparator|3|losartan 100 mg + ISMN 15 mg
11558603|NCT00943852|Active Comparator|4|losartan 100 mg + ISMN 60 mg
11558604|NCT00943852|Placebo Comparator|5|Placebo
11558605|NCT00943839|Experimental|SUVEGIL|
11558606|NCT00943826|Experimental|Bevacizumab + RT + Temozolomide|In the Concurrent Phase participants will receive radiotherapy (RT) in daily fractions of 2 Gy to be given 5 days per week for 6 weeks and temozolomide 75 mg/m^2 daily from the first day to the last day of radiotherapy (it may continue for a maximum of 49 days in case of delay to the end of radiation therapy) and bevacizumab 10 mg/kg IV every 2 weeks for 6 weeks. There will be a 4 week treatment break. Participants will then enter the Maintenance Phase where they receive six 28-day cycle of bevacizumab 10 mg/kg IV q2w and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants will then enter the Monotherapy Phase where they will receive bevacizumab 15 mg/kg IV q3w until disease progression/unacceptable toxicity.
11558607|NCT00943826|Placebo Comparator|Placebo + RT + Temozolomide|In the Concurrent Phase participants will receive radiotherapy in daily fractions of 2 Gy to be given 5 days per week for 6 weeks and temozolomide 75 mg/m^2 daily from the first day to the last day of radiotherapy (it may continue for a maximum of 49 days in case of delay to the end of radiation therapy) and placebo IV every 2 weeks for 6 weeks. There will be a 4 week treatment break. Participants will then enter the Maintenance Phase where they will receive six 28-day cycle of placebo IV q2w and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants will then enter the Monotherapy Phase where they will receive placebo IV q3w until disease progression/unacceptable toxicity.
11558696|NCT00943150|Experimental|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
11558608|NCT00943813||Patients in clinic waiting room|When patients are approached in the clinic, they will be given the permission form and asked to participate in the assessment through allowing video-recording and completing the survey. Procedures will be similar to our current operations, with the RSA starting the video-recording equipment before the fellow enters the room and stopping it when the fellow leaves the room. One additional step will be added: When the RSA goes into the room to turn off and remove the video-recording equipment, she will also give the patient the survey, to complete. We expect this survey to take no longer than 5 minutes. In our experience, it is usually at least 10 minutes from when the fellow leaves the room until the attending comes back into the room. Thus, we believe there will be sufficient time for the patient to complete the survey.
11558609|NCT00943800|Experimental|Good Risks patients|For patients transplanted in remission.
11558610|NCT00943800|Experimental|High Risk Patients eligible for radiation|
11558611|NCT00943800|Experimental|High Risk Patients not eligible for radiation|
11558612|NCT00943787|Other|SMBG followed by clamp|One month of self-monitored blood glucose (SMBG) field data was used to calculate measures of glucose variability and risk of hypoglycemia, while the hyperinsulinemic, euglycemic and hypoglycemic clamp procedure was used to evaluate insulin sensitivity and epinephrine response during induced hypoglycemia.
11558613|NCT00943774||All subjects|All subject participants
11558614|NCT00943761|Experimental|Vaniprevir 300 mg b.i.d. + peg-IFN + RBV|Participants received vaniprevir 300 mg twice daily (b.i.d.) in combination peg-IFN 180 mcg weekly and ribavirin (1000 or 1200 mg) administered as a divided dose twice daily.
11558615|NCT00943761|Experimental|Vaniprevir 600 mg b.i.d. + peg-IFN + RBV|Participants received vaniprevir 600 mg b.i.d. in combination peg-IFN 180 mcg weekly and ribavirin (1000 or 1200 mg) administered as a divided dose twice daily.
11558616|NCT00943748|Active Comparator|deferiprone|deferiprone 30 mg/kg/day
11558617|NCT00943748|Placebo Comparator|placebo|placebo : 30 mg/kg/day, in 2 liquid doses
11558618|NCT00943735||Fesoterodine arm|subjects who present with OAB symptoms during medical office visits and who appear to be candidates for fesoterodine therapy
11558619|NCT00943722|Experimental|9- to 15-Year-Old Females (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
11558620|NCT00943722|Experimental|9- to 15-Year-Old Females (Lot 2)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 2.
11558621|NCT00943722|Experimental|9- to 15-Year-Old Females (Lot 3)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 3.
11558622|NCT00943722|Experimental|9- to 15-Year-Old Males (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
11558623|NCT00943722|Experimental|16- to 26-Year-Old Females (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
11558624|NCT00943709|Experimental|Arm I|Patients with goal blood glucose 80-14 mg/dL receive the Robert Wood Johnson Hospital IV insulin infusion protocol followed by insulin glargine and insulin glulisine (Apidra™) subcutaneously for 4 weeks.
11558625|NCT00943709|Active Comparator|Arm II|Patients with goal blood glucose < 250 mg/dL are started on subcutaneous insulin sliding scale at the discretion of the treating physician with blood glucose monitoring and adjustment according to the insulin sliding scale.
11558626|NCT00943683|Experimental|1|Montelukast
11558627|NCT00943683|Placebo Comparator|2|Placebo
11558628|NCT00943670|Experimental|T-DM1 / T-DM1 + pertuzumab|"Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg.
~From Cycle 4, participants with early progressive disease (demonstrated prior to the end of Cycle 6) could receive combined pertuzumab and trastuzumab emtansine. Pertuzumab was administered after trastuzumab emtansine by IV infusion at a loading dose of 840 mg on Day 1, starting at the cycle after tumor progression was determined, followed by 420 mg IV infusion every 3 weeks in subsequent cycles.
~Participants who met criteria for ongoing clinical benefit were allowed to continue study treatment in the absence of disease progression or unacceptable toxicity for up to 1 year."
11558629|NCT00943631|Experimental|Group 2: H1N1 Vaccine 30 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 30 mcg of H1N1 vaccine on Days 0 and 21.
11558630|NCT00943631|Experimental|Group 1: H1N1 Vaccine 15 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 15 mcg of H1N1 vaccine on Days 0 and 21.
11558631|NCT00943618|Active Comparator|Group 1|Varenicline and Bupropion
11558632|NCT00943618|Placebo Comparator|Group 2|Varenicline and Placebo
11558633|NCT00943618|Placebo Comparator|Group 3|Placebo that looks like varenicline and a placebo that looks like bupropion.
11558634|NCT00943605|Active Comparator|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
11558635|NCT00943605|Experimental|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
11558636|NCT00943592|Experimental|Treatment|
11558637|NCT00943579|Experimental|Kuvan®|Kuvan® (sapropterin) will be administered to all subjects at 20 mg/kg/day for 16 weeks.
11558638|NCT00943566|Experimental|Sufentanil Transdermal Delivery System|Experimental drug
11558639|NCT00943566|Active Comparator|Control|Sustained release morphine sulfate
11558640|NCT00943553|Experimental|1|
11558641|NCT00943553|Experimental|2|
11558642|NCT00943540|Experimental|Raltegravir BID-QD|"Week 1-4
~600 mg of atazanavir to be taken once daily
~400 mg of raltegravir to be taken twice daily
~300 mg of lamivudine (or 200 mg of emtricitabine) to be taken once daily
~Week 5-8
~600 mg of atazanavir to be taken once daily
~800 mg of raltegravir to be taken once daily
~300 mg of lamivudine (or 200 mg of emtricitabine) to be taken once daily"
11558643|NCT00943527||1|Premenopausal Women who are not taking hormones or birth control. Ages 35-45 who have had a negative mammograph performed at the Mayo Clinic in Rochester within the last year.
11558911|NCT00941551||Group B|not-receiving levothyroxine postoperatively
11558644|NCT00943527||2|Women Initiating Hormone Therapy and have had a negative mammogram preformed at the Mayo Clinic Rochester within the last year.
11558645|NCT00943527||3|Women Initiating Tamoxifen who have had a negative mammogram preformed at the Mayo Clinic Rochester.
11558646|NCT00943514||1|chronic or recurring respiratory infections including pulmonary nontuberculous mycobacterial disease
11558647|NCT00943514||2|Relatives
11558648|NCT00943501|Experimental|I.a|
11558649|NCT00943501|Placebo Comparator|I.b|
11558650|NCT00943501|Experimental|II.a|
11558651|NCT00943501|Placebo Comparator|II.b|
11558652|NCT00943488|Experimental|Group 1: H1N1 Vaccine 15 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 15 mcg of H1N1 vaccine on Days 0 and 21.
11558653|NCT00943488|Experimental|Group 2: H1N1 Vaccine 30 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 30 mcg of H1N1 vaccine on Days 0 and 21.
11558654|NCT00943475|Active Comparator|anaesthesia, circumcision|
11558655|NCT00943462||Glioblastoma Multiforme (GBM)|We will conduct a prospective study on 20 consecutive patients who are seen at the Hôpital Notre-Dame neuro-oncology clinic for a diagnosis of GBM and who meet our inclusion criteria. We will meet with the eligible patients in order to provide them with a detailed description of the study procedures as well as to have them sign a consent form.
11558656|NCT00943449|Experimental|4SC-201|
11558657|NCT00943449|Experimental|4SC-201 + Sorafenib|
11558658|NCT00943436|Active Comparator|Active males|Males who participate in at least 30 minutes of physical activity on 5 or more days per week for the last month.
11558659|NCT00943436|Active Comparator|Inactive males|Males who participate in less than 1 hour of physical activity per week for the last month.
11558660|NCT00943423|Active Comparator|Arm I|Within 6 weeks after completion of course 3 of chemotherapy, patients undergo involved field radiotherapy to disease areas.
11558661|NCT00943423|Experimental|Arm II|Patients receive no further treatment.
11558662|NCT00943410|Active Comparator|Surgical Candidate|After 5 consecutive weeks of treatment with Radiation and Herceptin, these subjects will receive mastectomy excision
11558663|NCT00943410|Active Comparator|Non-Surgical Candidate|After 5 weeks of consecutive treatment with radiation and herceptin, these subjects will not be eligible for surgery. They will continue with radiation and herceptin for an additional 2 weeks.
11558664|NCT00943397|Experimental|1|Montelukast
11558665|NCT00943397|Active Comparator|2|Usual Care
11558666|NCT00943384|Experimental|chronOS Strip|This is a single arm, outcome study for treatment of patients with degenerative disc disease (DDD), with or without stenosis, with interbody fusion, posterolateral pedicle screw system, and the study device (chronOS Strip).
11558667|NCT00943371|Experimental|1|MK6349
11558668|NCT00943371|Placebo Comparator|2|Placebo to MK6349
11558669|NCT00943358|Active Comparator|Vaccine|adjuvanted influenza vaccine
11558670|NCT00943358|Active Comparator|Vaccine 2|non-adjuvanted vaccine
11558671|NCT00943345|Active Comparator|GS dual sugar permeability test|"Golden standard GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).
~Coeliac patients will only have 1 test to assess basal GI permeability."
11558672|NCT00943345|Other|Multi sugar test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).
~Coeliac patients will only have 1 test to assess basal GI permeability."
11558673|NCT00943345|Other|Protein test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).
~Coeliac patients will only have 1 test to assess basal GI permeability."
11558674|NCT00943345|Other|PEG test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).
~Coeliac patients will only have 1 test to assess basal GI permeability."
11558675|NCT00943332||spica casting|
11558676|NCT00943332||intramedullary nailing|
11558677|NCT00943332||submuscualr plating|
11558678|NCT00943319|Experimental|Busulfan and fludarabine|Intravenous busulfan (Busulfan®) in combination with fludarabine
11558679|NCT00943306|Experimental|lomitapide|Maximum tolerated dose of lomitapide in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.
11558680|NCT00943293|Experimental|Vaccine|
11558681|NCT00943280||1 EGD|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to EGD.
11558682|NCT00943280||2 Transnasal|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to Transnasal endoscopy.
11558683|NCT00943280||3 PillCam|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to PillCam.
11558684|NCT00943267|Experimental|Activated protein C|
11558685|NCT00943267|Placebo Comparator|Saline|
11558686|NCT00943254|Experimental|Arm 1|"Patients randomized to this arm receive the diagnosis of metabolic syndrome and subsequent education using paper-based and DVD materials"
11558687|NCT00943254|Experimental|Arm 2|"Patients in this arm receive the diagnosis of metabolic syndrome and subsequent education using paper-based material"
11558688|NCT00943254|No Intervention|Arm 3|Patients randomized to control receive the diagnosis of individual cardiovascular risk factors with paper-based educational material
11558689|NCT00943228|Experimental|mycophenolate mofetil|mycophenolate mofetil 2000mg BID (4g/day) for 14 days, followed by mycophenolate 1000mg BID (2g/day) thereafter
11558690|NCT00943202|Experimental|Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine; Day 21: 15 mcg H1N1 vaccine; Day 42: TIV.
11558691|NCT00943202|Experimental|Group 2: Day 0-H1N1+TIV; Day 21-H1N1|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine + TIV; Day 21: 15 mcg H1N1 vaccine.
11558692|NCT00943202|Experimental|Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1|150 subjects to receive-Day 0: TIV; Day 21: 15 mcg H1N1 vaccine; Day 42: 15 mcg H1N1 vaccine.
11558693|NCT00943202|Experimental|Group 3: Day 0-H1N1; Day 21-H1N1+TIV|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine; Day 21: 15 mcg H1N1 vaccine + TIV.
11558694|NCT00943176|Placebo Comparator|Sugar Pill|
11558695|NCT00943176|Experimental|Modafinil|
11558697|NCT00943150|Active Comparator|Standard of Care (SOC)|The scalpel and electrocautery will be used for the abdominoplasty procedure.
11558698|NCT00943137|Experimental|5-FU dosage adjustments|The dose of continuous infusion 5-FU will be adjusted every cycle until patients reached the therapeutic plasma range (450 to 550 microgram/L).
11558699|NCT00943124|Experimental|MK0524B then Simvastatin + MK0524A|"Period 1: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg).
~Period 2: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets."
11558700|NCT00943124|Experimental|Simvastatin + MK0524A then MK0524B|"Period 1: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets.
~Period 2: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg)."
11558701|NCT00943111|Experimental|Investigational|Eliglustat tartrate
11558702|NCT00943111|Active Comparator|Imiglucerase|
11558703|NCT00943098|Experimental|Diclofenac HPBCD s.c. 75mg/ml|
11558704|NCT00943098|Active Comparator|Voltarol 75mg/3ml i.m.|
11558705|NCT00943085|Experimental|Family-focused therapy|Participants will receive family-focused therapy.
11558706|NCT00943085|Active Comparator|Brief educational treatment|Participants will receive one session of diagnostic feedback, recommendations for continued treatment, and crisis intervention as needed.
11558707|NCT00943072|Experimental|VEGF Trap-Eye|Monthly IVT injection of VEGF Trap-Eye 2.0 mg until Week 24 Primary Endpoint
11558708|NCT00943072|Sham Comparator|Sham|Monthly Sham IVT injection until Week 24 Primary Endpoint
11558709|NCT00943059|Experimental|Acipimox|Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.
11558710|NCT00943059|Placebo Comparator|Cellulosum mycrocryst capsula|Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.
11558711|NCT00943046|Experimental|Siello pacemaker lead|Patients with Siello Pacemaker lead
11558712|NCT00943033|Experimental|Mindfulness-Based Cognitive Therapy plus treatment as usual|
11558713|NCT00943033|No Intervention|MBCT Waitlist plus Treatment as Usual|
11558714|NCT00943020|Active Comparator|Nutricia PreOp + Lipid|Nutricia PreOp + Lipid
11558715|NCT00943020|Active Comparator|Nutrica PreOP + Glutamine|Nutrica PreOP + Glutamine
11558716|NCT00943020|Experimental|Nutricia PreOP|Nutricia PreOP: carbohydrate only drink
11558717|NCT00943007|Active Comparator|Conventional Neuronavigation|Standard form of neuronavigation: based on preoperative MRI without intraoperative correction for brain shift
11558718|NCT00943007|Experimental|Intraoperative MRI|Standard neuronavigation plus intraoperative MRI to correct for brain shift
11558719|NCT00942994|Experimental|Triple Therapy (Aliskiren/Amlodipine/HCTZ)|At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg.
11558720|NCT00942994|Active Comparator|Dual Therapy (Aliskiren/Amlodipine)|At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg.
11558721|NCT00942981||healthy volunteers|healthy volunteers
11558722|NCT00942981||patients|patients with schizophrenia, schizoaffective disorder or other psychotic disorders aged18-60
11558723|NCT00942968|Experimental|1|
11558724|NCT00942955||CLT|The patients whose blood are analyzed by conventional central laboratory.
11558725|NCT00942955||POCT|the patients group whose lab analyze by POCT device.
11558726|NCT00942929||Adolescents hospitalized for anorexia nervosa|Adolescent 12-18 years old, fulfilling the DSM IV criteria for anorexia nervosa, hospitalized for medical stabilization and/ or initiation of refeeding
11558727|NCT00942929||Controls|Adolescents 12-18 years old without anorexia nervosa hospitalized for reasons other than those involving the respiratory system and with no underlying lung disease
11558728|NCT00942916||Patients with confirmed diagnosis of NTM pulmonary disease|Those with sputum mycobacterial culture yielded the same NTM species for at least two sets within one year.
11558729|NCT00942916||Patients with not definite NTM pulmonary disease|Those who had sputum culture yielded NTM but did not satisfy the criteria for diagnosis with NTM pulmonary disease.
11558730|NCT00942903|Experimental|Compliant HME users|Laryngectomized patients who are currently compliant (24/7) users of a Provox HME
11558731|NCT00942890|Experimental|NMES plus Standard Rehab Protocol|"NMES (EMPI 300PV stimulator) plus standard of care intervention. NMES is to the quadriceps muscle of the residual and intact limb plus rehabilitation. Therapy is 12-wks of NMES home training w/ the EMPI 300PV muscle stimulator. Participants perform training at home for 5days/wk; sessions consisted of 15 to 20 min. of NMES to each leg eliciting15 contractions/leg (10 seconds on:50 seconds off), plus a 5-minute patient treatment log, 5x/wk for 12-wks. Each contraction will be elicited by an electrical impulse generated by a battery-operated device. Two 3 X 5 electrodes are placed over the quadriceps muscle group. Participants will train at 30-40% of MVC during weeks 1-6, and 40-50% of MVC during weeks 7-12; incremental increases will be made at the study visits."
11558732|NCT00942890|Active Comparator|Standard Rehab Protocol|TMARP standard of care intervention: 12 weeks of the Traditional Military Amputee Rehabilitation Program (TMARP). TMARP training starts 1 week after surgical closure of the residual limb. Physical Therapy performs Pre-Prosthetic Training for about 6 weeks, preparing for the prosthetic. After pre-prosthetic training, patients are fitted with their prosthetic leg and began post-prosthetic training with PT. The training focus is lower limb prosthetic proficient in ambulation.
11558733|NCT00942877|Experimental|Treatment|Pediatric patients (<16 years old) will be treated with 12 mg/m2/day once a day for 28 days (28-day cycles).
11558734|NCT00942851|Experimental|active|AH-8 containing topical intervention
11558735|NCT00942851|Placebo Comparator|placebo|topical intervention WITHOUT AH-8
11558912|NCT00941538||Screening, Control|
11558736|NCT00942825|Experimental|A CBP501 +Cisplatin + Pemetrexed|CBP501 25 mg/m2 + Cisplatin 75 mg/m2 + Pemetrexed 500mg/m2
11558737|NCT00942825|Active Comparator|B Cisplatin + Pemetrexed|Cisplatin + Pemetrexed
11558738|NCT00942812|Experimental|Intervention|A diarrhea Pack comprising of low osmolality ORS, Zinc, water purification sachets and pictorial chart.
11558739|NCT00942812|Other|Control|Standard Care through National LHW (Lady Health Workers)program
11558740|NCT00942799|Experimental|Study Drug: Genz-644282 (28-day dosing schedule)|Genz-644282 (Each cohort will be based on dose-escalation)
11558741|NCT00942799|Experimental|Study Drug: Genz-644282 (21-day dosing schedule)|Genz-644282 (Each cohort will be based on dose-escalation)
11558742|NCT00942786||No treatment|Consecutive patients undergoing emergency surgery
11558743|NCT00942773|Active Comparator|CYP2C19 extensive metabolizer|
11558744|NCT00942773|Active Comparator|CYP2C19 heterozygous extensive metabolizer|
11558745|NCT00942773|Active Comparator|CYP2C19 poor metabolizer|
11558746|NCT00942760||Research MRI|High Grade Glioma patients who show progression based on MRI
11558747|NCT00942747|Experimental|Temsirolimus|Weekly IV temsirolimus
11558748|NCT00942734|Experimental|RAD001 + Erlotinib|RAD001 1 tablet (5 mg) by mouth every day of each 28 day study cycle. Erlotinib one tablet (150 mg) by mouth every day of each 28 day study cycle.
11558749|NCT00942721|Experimental|Web-based CBT for PPD|Participants will receive Web-based CBT for PPD.
11558750|NCT00942708|Other|Fluoxetine|Fluoxetine will be added starting at 20 mg and titrated as tolerated to 80 mg daily.
11558751|NCT00942695|Other|base|average American diet without pistachios
11558752|NCT00942695|Active Comparator|1.5PD|average American diet plus 1.5 oz per day pistachios
11558753|NCT00942695|Active Comparator|3.0PD|average American diet plus 3.0 oz per day pistachios
11558754|NCT00942682|Experimental|Sorafenib and RAD001|"Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have neuroendocrine tumors, not everyone who participates in this research study will receive the same dose of the study drug. The dose the participant will be given will depend on the number of participants who have been enrolled in the study.
~Each treatment cycle lasts 28 days. Participants will take RAD001 orally once a day in the morning. Participants will take sorafenib orally twice daily.
~Participants will remain on this research study as long as they continue to benefit from the study medications."
11558755|NCT00942669|Experimental|SleepStrip OTC(TM)|Participants will receive the SleepStrip OTC(TM) for a night (or two) test at home, before or after undergoing an independent PSG test at the Sleep lab. The reading of both methods will be analyzed.
11558756|NCT00942643|No Intervention|no treatment|being observed at 4 weeks and 12 weeks
11558757|NCT00942643|Active Comparator|CPAP treatment|a machine delivers positive airway pressure into the upper airway via nasal mask
11558758|NCT00942617|Experimental|40 mg non-enteric coated aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
11558759|NCT00942604|Active Comparator|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
11558760|NCT00942604|Placebo Comparator|Vehicle gel|Vehicle gel once daily for 2 consecutive days
11558761|NCT00942591|Experimental|1|Interferon beta-1b AND atorvastatin
11558762|NCT00942591|Active Comparator|2|Interferon beta-1b
11558763|NCT00942578|Experimental|Single Arm - 4 Drug Combination|A two dose level escalation of Lenalidomide from 15mg to 20mg to 25mg- standard 3+3 dose escalation approach in combination with docetaxel, Bevacizumab and prednisone.
11558764|NCT00942565|Active Comparator|Tramadol/acetaminophen|The tramadol and acetaminophen combination was given to patients at the same day after surgery.
11558765|NCT00942565|Active Comparator|acetaminophen|Acetaminophen was used as active control.
11558766|NCT00942539|Experimental|Midazolam|Administration of Midazolam prior Lumbar Puncture
11558767|NCT00942526|No Intervention|1|no intervention with perioperative oral anti-infective agent or water for gargling
11558768|NCT00942526|Sham Comparator|2|perioperative gargling with water
11558769|NCT00942526|Experimental|3|perioperative oral gargling with oral anti-infective agent for seven days
11558770|NCT00942500|Experimental|Post-conditioning|
11558771|NCT00942500|No Intervention|Conventional primary PCI|
11558772|NCT00942487|Experimental|Nebivolol|
11558773|NCT00942487|Active Comparator|Metoprolol|
11558774|NCT00942474|Experimental|Research Arm|Facilitate nerve stimulation lead placement with the nerve access tool
11558775|NCT00942461|Active Comparator|Laparoscopic Surgery group|Group of patients that are operated with laparoscopic approach
11558776|NCT00942461|Active Comparator|Open surgery Group|Group of patients operated with open approach
11558777|NCT00942448|Experimental|Diclofenac HPBCD s.c. 25mg/ml|
11558778|NCT00942448|Experimental|Diclofenac HPBCD s.c. 50mg/ml|
11558779|NCT00942448|Active Comparator|Diclofenac HPBCD s.c. 75mg/ml|
11558780|NCT00942448|Placebo Comparator|Placebo s.c. (1ml)|
11558781|NCT00942435|Experimental|YM150 group|
11558782|NCT00942435|Active Comparator|mechanical prophylaxis group|
11558783|NCT00942422|Experimental|defined green tea catechin extract / correlative analysis|Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11558784|NCT00942409|Experimental|Ad-ISF35|Ad-ISF35, intranodal injection, 3.3 x 10^10 ISF35 viral particles, every 2-4 weeks up to six total injections.
11558785|NCT00942396|Experimental|mammography|Women must be at least 40 years of age, presenting for routine breast cancer screening or presenting with one or both breasts scored 4 or 5 on the BI-RADS scale as a result of SFM either for routine breast cancer screening or for follow-up or diagnostic mammography
11558786|NCT00942383||IOUS-USEI|Receive intraoperative ultrasound (IOUS) using the Siemens Anteras to acquire ultrasound elasticity imaging (USEI) during standard of care surgical radiofrequency ablation and microwave ablation
11558787|NCT00942370||accelerometric device|
11558974|NCT00941083|Experimental|RAL QD 800 mg/24 hs|
11558788|NCT00942357|Experimental|Arm I (cisplatin, radiation therapy, paclitaxel, carboplatin)|Patients receive cisplatin IV on days 1 and 29. Patients also undergo radiation therapy QD, 5 days a week, for 5-6 weeks. Some patients may then undergo brachytherapy over 2-3 weeks. Beginning within 8 weeks after completion of chemoradiotherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11558789|NCT00942357|Active Comparator|Arm II (paclitaxel and carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11558790|NCT00942331|Active Comparator|Arm I (gemcitabine hydrochloride, cisplatin, placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV and placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive placebo IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
11558791|NCT00942331|Experimental|Arm II (gemcitabine hydrochloride, cisplatin, bevacizumab)|Patients receive gemcitabine hydrochloride and cisplatin as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
11558792|NCT00942318|Experimental|PPE|PPE : CSII +/- Metformin.
11558793|NCT00942318|Active Comparator|injections|INJ: basal/bolus MDI +/- Metformin
11558794|NCT00942305|Placebo Comparator|Placebo|
11558795|NCT00942305|Experimental|CMX001|
11558796|NCT00942292|Active Comparator|Lipidem (fish oil)|Lipidem (TPN containing fish oil)
11558797|NCT00942292|Active Comparator|Lipofundin (TPN)|Control arm (no fish oil)
11558798|NCT00942266|Experimental|Arm I|Patients receive low-dose oral vorinostat once daily on days 1-3, leucovorin calcium IV over 2 hours on day 2, and fluorouracil IV over 46 hours on days 2 and 3. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
11558799|NCT00942266|Experimental|Arm II|Patients receive high-dose oral vorinostat once daily on days 1-3 and leucovorin calcium and fluorouracil as in arm I. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
11558800|NCT00942253|Experimental|Dopamine Agonist Group|"Dialysis patients will receive dopamine agonist for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist and aerobic intradialytic exercise.
~Patients will be given evening doses of dopamine agonists, 2 hours before bedtime. The dopamine agonists' dose will be 0.25 mg/dose and remain constant until the end of the study."
11558801|NCT00942253|Placebo Comparator|Placebo Group|"Dialysis patients will receive placebo for 24 weeks following a 24 weeks period of combined treatment with placebo and aerobic intradialytic exercise.
~Patients will be given evening doses of placebo, 2 hours before bedtime."
11558802|NCT00942240|Experimental|ACU-4429 tablet|
11558803|NCT00942240|Placebo Comparator|matching placebo tablet|
11558804|NCT00942227|Active Comparator|Extension oriented treatment approach|Extension exercises. Subjects are instructed in a progression of extension oriented movements for the lumbar spine. Manual therapy may be added to further increase extension movement and/or reduction of symptoms.
11558805|NCT00942227|Experimental|Mechanical traction plus extension-oriented treatment|Mechanical lumbar traction will be utilized in addition to extension oriented exercises. Subjects are also instructed in a progression of extension oriented movements for the lumbar spine. Manual therapy may be added to increase extension movement and/or reduce radicular symptoms.
11558806|NCT00942201|Active Comparator|Single dose dexamethasone|Single dose dexamethasone 0.6 mg/kg, rounded to nearest 2 mg, max 16 mg administered in ED
11558807|NCT00942201|Active Comparator|Two dose dexamethasone|First dose in ED, a prescription for second dose to be administered on Day 3 after discharge
11558808|NCT00942188|Experimental|0.6 milligrams (mg) LY2189102|
11558809|NCT00942188|Experimental|18 mg LY2189102|
11558810|NCT00942188|Experimental|180 mg LY2189102|
11558811|NCT00942188|Placebo Comparator|Placebo|0.9% Sodium Chloride
11558812|NCT00942175|Other|Regimen A|Clopidogrel 75 mg QD
11558813|NCT00942175|Other|Regimen B|Clopidogrel 75 mg QD and Lansoprazole 30 mg QD
11558814|NCT00942175|Other|Regimen C|Clopidogrel 75 mg QD and Dexlansoprazole 60 mg QD
11558815|NCT00942175|Other|Regimen D|Clopidogrel 75 mg QD and Omeprazole 80 mg QD
11558816|NCT00942175|Other|Regimen E|Clopidogrel 75 mg QD and Esomeprazole 40 mg QD
11558817|NCT00942162|Experimental|Overall Study Group|Subjects planned to receive intramuscularly up to 24 doses of MAGE-A3 ASCI (the study product), in 4 cycles.
11558818|NCT00942149|Experimental|Daptomycin cohort|
11558819|NCT00942136|Experimental|Cohort 1, Sequence 1|Subjects in Cohort 1, Sequence 1 will receive a single dose of GSK134972 50 mg after a fast of 10 hours in Period 1. Following a 7 day washout, they will receive a single dose of GSK134972 50 mg after a high fat meal in Period 2. After the last PK sample is collected in Period 2, they will receive a single daily dose of omeprazole 40 mg for 5 days. On Day 5 they will receive a single dose of GSK134972 50 mg 2 hours after the omeprazole dose. Subjects will have a screening visit 30 days prior to the first dose and a follow-up visit 7-14 days after the last dose of medication.
11558820|NCT00942136|Experimental|Cohort 2|Subjects will receive a single dose of either GSK1349572 250 mg or placebo as a suspension. Subjects will have a screening visit within 30 days prior to the dose of study medication and a follow up visit 7-14 days after the dose of study medication.
11558821|NCT00942136|Experimental|Cohort 1, Sequence 2|Subjects in Cohort 1, Sequence 2 will receive a single dose of GSK134972 50 mg after a a high fat meal in Period 1. Following a 7 day washout, they will receive a single dose of GSK134972 50 mg after fast of 10 hours in Period 2. After the last PK sample is collected in Period 2, they will receive a single daily dose of omeprazole 40 mg for 5 days. On Day 5 they will receive a single dose of GSK134972 50 mg 2 hours after the omeprazole dose. Subjects will have a screening visit 30 days prior to the first dose and a follow-up visit 7-14 days after the last dose of medication.
11558822|NCT00942110|Experimental|CPAP|
11558823|NCT00942097|Placebo Comparator|Nutritional plus Placebo (homeopathy)|Nutritional oriented diet for pregnancy period add homeopathic preparation from inert substance.
11558824|NCT00942097|Active Comparator|Nutr and Homeop Sulph Puls Lyc Lackt Con Sep Nuxv Calcc Phos|Nutrition oriented diet for pregnancy period add active homeopathic medication (Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos)
11558825|NCT00942084|Active Comparator|Protocol V2&up-Grp1-Acyclo10 mg/kg IVq12|Gestational Age 23-29 weeks Postnatal Age < 14 days Dosage 10 mg/kg IV q12 Number of Infants 8
11558826|NCT00942084|Active Comparator|Protocol V2&up-Grp2_Acyclo20 mg/kg IVq12|Gestational Age 23-29 weeks Postnatal Age 14-44 days Dosage 20 mg/kg IV q12 Number of Infants 8
11558827|NCT00942084|Active Comparator|Protocol V2&up-Grp3-Acyclo20 mg/kg IVq8|Gestational Age 30-34 weeks Postnatal Age <45 days Dosage 20 mg/kg IV q8 Number of Infants 4
11558828|NCT00942084|Other|Protocol V1-Grps1-4-Acyclo 500 mg/m2 IVq8h|All patients in protocol V1 were to be dosed with 500 mg/m2 IV q8h. Protocol V1 Group 1: Gestational Age: 23-29 Weeks; PNA: <14 days; Protocol V1 Group 2: Gestational Age: 30-42 Weeks; PNA: <14 days; Protocol V1 Group 3: Gestational Age: 23-29 Weeks; PNA: 14-60 days; Protocol V1 Group 4: Gestational Age: 30-42 Weeks; PNA: 14-60 days
11558829|NCT00942071|Experimental|1. MVA-NP+M1 ID|12 volunteers to receive MVA-NP+M1 via ID route
11558830|NCT00942071|Experimental|2. MVA-NP+M1 IM|16 volunteers to receive MVA-NP+M1 via IM route
11558831|NCT00942071|Experimental|3. MVA-NP+M1 IM upper age group|30 volunteers to receive MVA-NP+M1 via IM route
11558832|NCT00942058||CA9 level|Serum and urinary CA9 level
11558833|NCT00942019||obese smokers|BMI > 30 kg/m2 CO ≥ 15 ppm
11558834|NCT00942019||non-obese smokers|BMI < 25 kg/m2 CO ≥ 15 ppm
11558835|NCT00942019||obese non-smokers|BMI > 30 kg/m2 CO ≤ 6 ppm
11558836|NCT00942019||non-obese non-smokers|BMI < 25 kg/m2 CO ≤ 6 ppm
11558837|NCT00942006|Active Comparator|LNB-doxycycline|
11558838|NCT00942006|Active Comparator|LNB-ceftriaxone|
11558839|NCT00941993|Experimental|local anesthesia|tympanic membrane local anesthesia delivery system
11558840|NCT00941967|Experimental|Arm I|Patients receive oral sorafenib tosylate as in arm I. Patients also receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV over 2 hours on day 2. Treatment with gemcitabine hydrochloride and oxaliplatin repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.
11558841|NCT00941967|Experimental|Arm II|Patients receive oral sorafenib tosylate twice daily on days 1-14.
11558842|NCT00941954|Experimental|Lifestyle counseling|A group-based structured educational programme.
11558843|NCT00941954|Active Comparator|Control|Written Information (booklet).
11558844|NCT00941941|Experimental|Non-mesh Hernia Repair|Reinforcement with a strip of external oblique aponeurosis
11558845|NCT00941941|Active Comparator|Mesh Hernia Repair|Polypropylene mesh placement
11558846|NCT00941928|Experimental|Haploidentical NK cells + Epratuzumab|Haploidentical donor-derived NK cell infusion, Epratuzumab 360 mg/m^2 once a day by vein (IV) on Day -4, Day -1 and Days 3, 6, 10, 13 and 17, and low-dose interleukin-2 (IL-2) Subcutaneous injections three times a week for 9 doses on Days 0 to 21; Fludarabine 25 mg/m^2 once a day IV on Day -6 through Day -2 over 30 minutes; Cyclophosphamide 60 mg/kg once a day IV on Days -5 and -4 over 2 hours. Mesna 12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
11558847|NCT00941915|Experimental|Stereotactic Radiotherapy|Five fractions of 7.4 Gy each
11558848|NCT00941902||Patients scheduled to bariatric surgery|
11558849|NCT00941889|Placebo Comparator|Placebo|Patients who are in the control group received a placebo of saline in the upper extremity at initial visit, 2 months and 6 months after enrollment.
11558850|NCT00941889|Active Comparator|Gardasil|The treatment group received a 0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity at initial visit, and again at two months and six months after enrollment.
11558851|NCT00941876|Experimental|A. Facilitated Referral|Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
11558852|NCT00941863|Experimental|Sorafenib 100 mg (50-mg tablet)|Dose-escalation cohort 1: Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
11558853|NCT00941863|Experimental|Sorafenib 200 mg (50-mg tablet)|Dose-escalation cohort 2: Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
11558854|NCT00941863|Experimental|Sorafenib 400 mg (50-mg tablet)|Dose-escalation cohort 3: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
11558855|NCT00941863|Experimental|Sorafenib 400 mg (200-mg tablet)|Dose-escalation cohort 4: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet). Treatment were planned until primary completion date (PCD).
11558856|NCT00941863|Experimental|Sorafenib 400 mg (Expansion)|Dose-expansion cohort: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion. Treatment were planned until primary completion date (PCD). 25 of 119 participants from the Expansion Phase, were still on the treatment as of 31 May 2005. Of these, 6 subjects were continuing to receive sorafenib in combination with carboplatin and/or paclitaxel and 19 subjects were receiving single-agent sorafenib until 18 Sep 2008.
11558857|NCT00941850|Experimental|Triple site CRT|These patients will continue to receive CRT via existing device but will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced
11558858|NCT00941850|No Intervention|Optimised medical and device therapy|These patients will receive optimised medical and device therapy.
11558859|NCT00941837|Experimental|Olive Oil|
11558860|NCT00941837|Experimental|Coconut oil|
11558861|NCT00941837|Experimental|Palm Olein|
11558862|NCT00941798|Experimental|QMF149 Twisthaler® 500/400|QMF149 Twisthaler® (indacaterol maleate 500 µg/mometasone furoate 400 µg), once daily (QD)
11558863|NCT00941798|Active Comparator|Mometasone Twisthaler®|Mometasone Twisthaler®, 400 µg QD
11558864|NCT00941785|Experimental|DHA-PQ|Three monthly administrations of dihydroartemisinin (DHA) plus piperaquine (PQ) in August, September and October.
11558865|NCT00941785|Active Comparator|SP-AQ|Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine
11558969|NCT00941122||MRSA/VRE patients|patients known to be colonized with MRSA/VRE
11558970|NCT00941109|Experimental|1|
11558971|NCT00941109|Experimental|2|
11558972|NCT00941109|Experimental|3|
11558973|NCT00941109|Experimental|4|
11558866|NCT00941759||Known or suspected Stage IV disease & an intact primary|Pt will be asked to undergo a research core needle biopsy of the primary tumor. If pts are not agreeable to a research biopsy then the original diagnostic biopsy material will be requested. They will also undergo a diagnostic biopsy of a metastatic site, if not already performed, and a blood draw as appropriate for correlative science studies. Additionally, patients will complete a general medical questions form at the time of enrollment.
11558867|NCT00941759||Unsuspected metastatic disease W/I 3 months of primary b|A blood sample will be collected and patients will complete a general medical questions form at the time of enrollment. Paraffin tissue from the prior surgical procedure will be obtained as Tissue sample. Paraffin tissue from the diagnostic biopsy of a metastatic site will also be obtained. In the event that fresh frozen tissue is available for either site this will also be requested.
11558868|NCT00941746|Experimental|Lowest dose of PG110|single, slow intravenous infusion
11558869|NCT00941746|Experimental|Second dose of PG110|single, slow intravenous infusion
11558870|NCT00941746|Experimental|Third dose of PG110|single, slow intravenous infusion
11558871|NCT00941746|Experimental|Fourth dose of PG110|single, slow intravenous infusion
11558872|NCT00941746|Experimental|Fifth dose of PG110|single, slow intravenous infusion
11558873|NCT00941746|Experimental|Top dose of PG110|single, slow intravenous infusion
11558874|NCT00941746|Experimental|Placebo|single, slow intravenous infusion that matches PG110 in appearance
11558875|NCT00941746|Experimental|Seventh Dose of PG110|single, slow intravenous infusion
11558876|NCT00941746|Experimental|Eight Dose of PG110|single, slow intravenous infusion
11558877|NCT00941733|Experimental|Drug Eluting Balloon|Intervention: IN.PACT Amphirion™
11558878|NCT00941733|Active Comparator|Standard PTA|Intervention: Standard PTA
11558879|NCT00941720|Experimental|Busulfan Treatment|
11558880|NCT00941707|Experimental|JNJ-38518168|
11558881|NCT00941707|Placebo Comparator|Placebo|
11558882|NCT00941694|Experimental|Self-Management Intervention|Will receive 6 asthma self-management group or individual session over a 7 week period
11558883|NCT00941694|Placebo Comparator|Control|Group will receive 3 phone calls not related to asthma self management over a 7 week period
11558884|NCT00941681|Experimental|Cohort 1: MR 50 mg BID|Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.
11558885|NCT00941681|Experimental|Cohort 2: IR 37.5 mg TID|Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.
11558886|NCT00941681|Experimental|Cohort 3: MR 100 mg BID|Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days
11558887|NCT00941668|Active Comparator|Total Toothpaste|Triclosan/Copolymer/fluoride toothpaste
11558888|NCT00941668|Placebo Comparator|Fluoride toothpaste|sodium monofluorophosphate toothpaste
11558889|NCT00941655|Experimental|Surgery + HIPEC + Systemic Chemotherapy|"Surgery -gastric resection, metastasectomy, and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m^2 intravenous (IV) over 5 minutes. Leucovorin 20 mg/m^2 IV and Oxaliplatin 460 mg/m^2 diluted in 2.0 L/m^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.
~Systemic chemotherapy - Irinotecan 165 mg/m^2 IV over 90 minutes, Oxaliplatin 85 mg/m^2 over 120 minutes, Leucovorin 200 mg/m^2 IV 120 minutes, 5FU 3200 mg/m^2 continuous IV infusion over 48 hours."
11558890|NCT00941655|Experimental|Systemic Chemotherapy Alone|Irinotecan 165 mg/m^2 IV over 90 minutes, Oxaliplatin 85 mg/m^2 over 120 minutes, Leucovorin 200 mg/m^2 IV 120 minutes, 5FU 3200 mg/m^2 continuous IV infusion over 48 hours.
11558891|NCT00941642|Active Comparator|Lovaza|Single blind, active treatment arm Lovaza, is the only fish oil supplement approved by the FDA. The Lovaza treatment group will take 4g of Lovaza daily for a minimum of 48 weeks.
11558892|NCT00941642|Placebo Comparator|Placebo|Single blind, Placebo arm study drug will contain 994.0 mg of corn oil and 6mg of alpha tocopherol as an excipient in a soft gelatin capsule shell. Subjects will take 4g daily for a minimum of 48 weeks.
11558893|NCT00941629|Active Comparator|Cognitive Processing Therapy FTF|Cognitive Processing Therapy delivered in traditional face-to-face sessions (FTF)
11558894|NCT00941629|Experimental|Cognitive Processing Therapy TMH|Cognitive Processing Therapy delivered over videoconferencing equipment to a distant location (or telemental health; TMH)
11558895|NCT00941616|Experimental|PK|Includes subjects participating in the pharmacokinetic component of the study.
11558896|NCT00941616|Experimental|Prophylaxis|Includes subjects receiving 12 months of prophylactic therapy.
11558897|NCT00941616|Experimental|On-demand|Includes subjects receiving 12 months of on-demand treatment.
11558898|NCT00941616|Experimental|Cross-over to prophylaxis|"Includes subjects completing 12 months of on-demand treatment (the On-demand arm) who cross-over to prophylactic therapy for an additional 12-month period."
11558899|NCT00941603|Experimental|SCH 900271 15 mg|Participants receive SCH 900271 15 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
11558900|NCT00941603|Experimental|SCH 900271 10 mg|Participants receive SCH 900271 10 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
11558901|NCT00941603|Experimental|SCH 900271 5 mg|Participants receive SCH 900271 5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
11558902|NCT00941603|Experimental|SCH 900271 2.5 mg|Participants receive SCH 900271 2.5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
11558903|NCT00941603|Experimental|SCH 900271 1 mg|Participants receive SCH 900271 1 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
11558904|NCT00941603|Placebo Comparator|Placebo|Participants receive two placebo tablets once daily in the morning with water in a fasted state for 8 weeks
11558905|NCT00941590||Patients with tick borne encephalitis.|
11558906|NCT00941577|Experimental|AIR645|AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor) solution (diluent: physiologic saline solution)
11558907|NCT00941577|Placebo Comparator|Physiologic saline solution|Physiologic saline solution
11558908|NCT00941564|Experimental|Commercially available infant formula A|Varying fat blend from comparator product
11558909|NCT00941564|Active Comparator|Commercially available infant formula B|
11558910|NCT00941551||Group A|receiving levothyroxine postoperatively
11558913|NCT00941525|Other|Ocular hypertensives|"This study includes two groups.
~Subjects with ocular hypertension and
~Controls. Group 2 undergoes only 1 visit (visit 1) without any intervention. Group 1 undergoes visit 1 without intervention. Then they receive treatment (1 eyedrop of latanoprost (0.005%) dosed once a day in both eyes at 8:00pm for a 4-weeks period for 1 month) and undergo the visit 2 under the effect of treatment."
11558914|NCT00941499|Experimental|Group 1|HAI oxaliplatin in combination with HAI 5-fluorouracil and IV bevacizumab
11558915|NCT00941499|Experimental|Group 2|HAI oxaliplatin in combination with IV 5-fluorouracil, leucovorin, bevacizumab, and cetuximab
11558916|NCT00941499|Experimental|Group 3|HAI oxaliplatin in combination with IV bevacizumab.
11558917|NCT00941499|Experimental|Group 4|HAI oxaliplatin in combination with IV bevacizumab and cetuximab.
11558918|NCT00941486|Experimental|FST-100 (0.1% dexamethasone) Ophthalmic Suspension|
11558919|NCT00941486|Placebo Comparator|Vehicle|
11558920|NCT00941473|Active Comparator|Epidural Steriod Injection|This study focuses on the changes in bone mineral density over time of the cohort previously described in the inclusion criteria (post-menopausal white women)
11558921|NCT00941460|Experimental|one week on one week off|One week on temozolomide is followed by a week without temozolomide.
11558922|NCT00941460|Experimental|three weeks on, one week off|Temozolomide is given over 3 weeks, followed by a week without temozolomide.
11558923|NCT00941447|Experimental|Self-Regulation|Self Regulation Arm focuses on increasing participants self-monitoring blood glucose (SMBG) AND awareness of self-regulatory approaches to managing diabetes.
11558924|NCT00941447|Experimental|Self-Monitoring|Self-Monitoring Arm focuses on increasing participants self-monitoring blood glucose (SMBG) and providing nutrition education ONLY.
11558925|NCT00941434|Experimental|RUTF|Children with Severe malnutrition will be treated with Ready to use therapeutic food (RUTF) till their weight for age z scores are no longer in severe malnutrition group
11558926|NCT00941421|Other|videocapsul and OGDFE|Each patient have a Fiberoptic endoscopy by videocapsul, followed by one traditional oeso-gastro-duodenal fiberoptic endoscopy
11558927|NCT00941408||Diagnostic tumor core biopsy|
11558928|NCT00941395|Experimental|Arm I (smoker, survey)|Participants who currently smoke complete a survey over 30 minutes and discuss the survey results with the counselor over 30 minutes at week 2. Participants also complete 3 internet surveys over 20 minutes.
11558929|NCT00941395|Experimental|Arm II (non-smoker, survey)|Participants who currently do not smoke complete a survey over 30 minutes and discuss the survey results with the counselor over 30 minutes at week 2.
11558930|NCT00941382|Experimental|Sibutramin-Metformin|Sibutramine-metformin therapy in a single tablet
11558931|NCT00941382|Active Comparator|Sibutramine|Sibutramine monotherapy
11558932|NCT00941382|Active Comparator|Metformin|Metformin monotherapy
11558933|NCT00941369|Experimental|1|Insulin glargine: Lantus® (100 U/ml) in TactiPen® re-usable pen
11558934|NCT00941369|Active Comparator|2|Neutral Protamine Hagedorn basal insulin: Insuman® Basal (100 I.U./ml) in TactiPen® re-usable pen
11558935|NCT00941356|Experimental|1|Bio-K+ CL1285 contains 50 billion of live bacteria
11558936|NCT00941356|Placebo Comparator|2|placebo devoid of bacteria
11558937|NCT00941343|Experimental|1|XATRAL 10mg OD
11558938|NCT00941330|Experimental|A: Exemestane|ARM A: Patients will be treated with exemestane.
11558939|NCT00941330|Active Comparator|B: Docetaxel and Cytoxan|ARM B: Patients will be treated with docetaxel and cytoxan.
11558940|NCT00941304|Active Comparator|Standard Opioid|Oxycodone 5-mg oral capsule and 2 buccal placebo films
11558941|NCT00941304|Experimental|High Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.5-mg modified formulation 1, buccal placebo film, and oral placebo capsule
11558942|NCT00941304|Experimental|Mid Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.5-mg modified formulation 2, buccal placebo film, and oral placebo capsule
11558943|NCT00941304|Experimental|Low Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.25-mg modified formulation 2, buccal placebo film, and oral placebo capsule
11558944|NCT00941304|Placebo Comparator|Placebo|Oral placebo capsule and 2 buccal placebo films
11558945|NCT00941291||vitrectomy in pseudophakic eyes|
11558946|NCT00941291||vitrectomy and cataract:combined procedure|
11558947|NCT00941291||vitrectomy followed by cataract extraction|
11558948|NCT00941291||vitrectomy on phakic eyes|
11558949|NCT00941278|Experimental|PH-10 Treatment|
11558950|NCT00941265|Other|levodopa 100 mg and benserazide 25 mg|2 weeks with Daily CAT on list A+ levodopa and benserazide
11558951|NCT00941265|Other|placebo|2 weeks with Daily CAT on list B + placebo.
11558952|NCT00941252|Active Comparator|Imiquimod|topical therapy for 16 weeks with imiquimod containing therapy
11558953|NCT00941252|Placebo Comparator|Placebo|topical therapy for 16 weeks with a placebo containing vaginal suppository
11558954|NCT00941239|Experimental|metformin ER|Extended Release Metformin
11558955|NCT00941239|Active Comparator|metformin|Immediate release metformin
11558956|NCT00941226||Cerebral Palsy|Those kids who have cerebral palsy and are helped by carers
11558957|NCT00941213|Active Comparator|Monopolar Electrosurgery|Preparation during the operation with Monopolar Electrosurgery
11558958|NCT00941213|Experimental|Ultrasound scissors|Preparation during the operation with ultrasound scissors
11558959|NCT00941200||Blood collection|
11558960|NCT00941187||patients after a first episode of pulmonary embolism|
11558961|NCT00941174|Active Comparator|Capsule: 400 microg 13C5-Calcium-L-Leucovorin|
11558962|NCT00941174|Active Comparator|IV Injection: : 100 microg 13C5-Calcium-L-Leucovorin|
11558963|NCT00941161|Experimental|combination|long acting Metformin/Glimepiride
11558964|NCT00941161|Active Comparator|metformin|metformin hydrocloride
11558965|NCT00941161|Active Comparator|glimepiride|glimepiride
11558966|NCT00941148|Active Comparator|Insulin glargine|Insulin glargine, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
11558967|NCT00941148|Active Comparator|NPH Insulin|NPH Insulin, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
11558968|NCT00941148|Active Comparator|Insulin detemir|Insulin detemir, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
11558975|NCT00941083|Active Comparator|RAL BID 400 mg/12 hs|
11558976|NCT00941083|Experimental|RAL BID to QD|
11558977|NCT00941070|Experimental|Treatment (cisplatin, triapine, radiation therapy)|"Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, and 30 and triapine IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Patients also undergo pelvic external beam radiotherapy 5 days a week during weeks 1-5. Patients may undergo parametrial boost radiation and intracavitary low-dose or high-dose rate brachytherapy as clinically indicated.
~Patients undergo whole-body F-18 fluorodeoxyglucose-PET/CT imaging at baseline, at 3 months after completion of study treatment, and at disease progression. Patients complete Sexual Function-Vaginal Changes Questionnaire and a smoking behavior questionnaire at baseline, at 3 months after completion of study treatment, and at disease progression."
11558978|NCT00941057|Experimental|Estradiol + dienogest + levomefolate|Treatment A
11558979|NCT00941057|Active Comparator|Estradiol + dienogest|Treatment B
11558980|NCT00941057|Active Comparator|Levomefolate|Treatment C
11558981|NCT00941044|Experimental|non-invasive NAVA|application of non-invasive neurally adjusted ventilatory assist in healthy volunteers
11558982|NCT00941031|Experimental|Induction Single Dose|"Induction with single injection - Single: secukinumab (AIN457) 150 mg s.c. administered at Week 1, Baseline through Week 12"
11558983|NCT00941031|Experimental|Induction Monthly Dose|"Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9, Baseline through Week 12"
11558984|NCT00941031|Experimental|Induction Early Loading Dose|"Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5, Baseline through Week 12"
11558985|NCT00941031|Placebo Comparator|Placebo Dose|Placebo administered at weeks 1, 2, 3, 5, 9, Baseline through Week 12
11558986|NCT00941018|Experimental|SAD cohort 1|Single ascending dose (SAD) cohort 1 will participate in three dosing periods separated by 2 weeks. Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control. The starting dose will be 300 mg. Subsequent doses will be determined by the pk and safety data from previous cohorts.
11558987|NCT00941018|Experimental|SAD cohort 2|SAD cohort 2 will participate in three dosing periods separated by 2 weeks. Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control. The doses to be administered will be determined by the pk and safety data from previous cohorts.
11558988|NCT00941018|Experimental|MAD cohort 1|Multiple ascending dose (MAD) cohort 1 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous SAD cohorts.
11558989|NCT00941018|Experimental|MAD cohort 2|MAD cohort 2 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.
11558990|NCT00941018|Experimental|MAD cohort 3|MAD cohort 3 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohorts.
11558991|NCT00941018|Experimental|MAD cohort 4|MAD cohort 4 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.
11558992|NCT00941005|Experimental|Electroacustimulation|Received electroacustimulation at the wrist using a small, battery-powered electroacustimulation device.
11558993|NCT00941005|Sham Comparator|Control|Received a device that was not turned on.
11558994|NCT00940992|Experimental|DER 45 EV Gel, 1%|DER 45 EV Gel, 1% topically applied once daily to face for 12 weeks
11558995|NCT00940992|Placebo Comparator|Vehicle|Placebo Gel applied topically once a day for 12 weeks
11558996|NCT00940992|Experimental|DER 45 EV Gel, 5%|DER 45 EV Gel, 5% applied topically once a day for 12 weeks
11558997|NCT00940979|No Intervention|No use of integuseal|
11558998|NCT00940979|Experimental|Use of Integuseal|Application of a layer of Integuseal (Cyanoacrylate) from a ready to use applicator preoperative before incision Polymerisation immobilise the bacteria that survived the conventional skin preparation This way there will be les contamination of the wound.
11558999|NCT00940966|Experimental|energy restricted very-low carbohydrate|non-energy restricted ketogenic diet .
11559000|NCT00940966|Active Comparator|ADA diet|standard ADA diet
11559001|NCT00940966|Active Comparator|low glycemic index|restricted ketogenic diet
11559002|NCT00940953|Experimental|Captisol-Enabled Budesonide + Azelastine|
11559003|NCT00940953|Active Comparator|Rhinocort Aqua+Astelin|
11559004|NCT00940953|Placebo Comparator|Placebo|
11559005|NCT00940940|Experimental|Live attenuated herpes zoster vaccine|
11559006|NCT00940940|Placebo Comparator|Placebo|
11559007|NCT00940914|Other|pain disorders|patients with Parkinson's disease presenting pain disorders
11559008|NCT00940914|Other|without pain disorders|patients with Parkinson's disease without pain disorders
11559009|NCT00940901|Experimental|sildenafil|Participants assigned to this arm were given sildenafil 50 mg tablet daily for 16 weeks.
11559010|NCT00940901|Placebo Comparator|placebo|Participants assigned to this arm were given a placebo pill for the first 8 weeks, and then Sildenafil 50 mg for weeks 9-16.
11559011|NCT00940888||No treatment: ICD/CRTD-indicated|
11559012|NCT00940875|Experimental|1|
11559013|NCT00940875|Active Comparator|2|
11559014|NCT00940862|Experimental|adalimumab|A total of 20 patients will be randomized to adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
11559015|NCT00940862|Active Comparator|Non-systemic treatment.|A total of 10 patients will be randomized to non systemic therapy for psoriasis (topical treatments and/or UVB phototherapy).
11559016|NCT00940849|Experimental|Dietary Supplement: Plant sterol containing drink|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
11559017|NCT00940836|Active Comparator|Resfenol|"Patients in this arm will receive 15 capsules containing a combination described below. They are instructed to take one capsule at 7, 11, 15, 19 and 23h every day, starting after baseline evaluation. The duration of the treatment goes from 48 to 72 hours, depending on patient availability for the second evaluation.
~Patients also receive co interventional acetaminophen pills, that they are allowed to take in case of persisting pain or fever, up to 4 times a day."
11559018|NCT00940836|Placebo Comparator|Placebo|"Patients in this arm will receive 15 capsules of placebo, that they are instructed to take in the same posology and in the same duration than the active comparator.
~Patients also receive co interventional acetaminophen pills, that they are allowed to take in case of persisting pain or fever, up to 4 times a day."
11559019|NCT00940823|Active Comparator|Ahmed FP7 Valve|Ahmed valve glaucoma drainage device implant for treatment of refractory glaucoma.
11559020|NCT00940823|Active Comparator|Baerveldt-350 Tube|Baerveldt tube glaucoma drainage device implant for treatment of refractory glaucoma.
11559021|NCT00940810|Experimental|PDD procedure|
11559022|NCT00940810|Active Comparator|Conservative Care|
11559023|NCT00940797|Experimental|DMMET-01|
11559024|NCT00940797|Placebo Comparator|Control|
11559025|NCT00940784|Experimental|Clopidogrel|Subjects will be randomized to clopidogrel (oral-75 mg per day) in addition to low dose aspirin and hydroxyurea
11559026|NCT00940784|Placebo Comparator|Placebo|Subjects will be randomized placebo in addition to low dose aspirin and hydroxyurea
11559027|NCT00940771|Experimental|boosted Atazanavir|Boosted Atazanavir was switched for the PI or NNRTI in the patients regimen
11559028|NCT00940758|Experimental|PEP02|
11559029|NCT00940745|Experimental|Stereotactic Aspiration and Thrombolysis|To position haematoma's location, drills several millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
11559030|NCT00940745|Active Comparator|conservative treatment|dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
11559031|NCT00940732|Experimental|Destigmatisation and Mental Health Literacy|
11559032|NCT00940732|Experimental|Help-seeking list|
11559033|NCT00940732|Experimental|Feedback|
11559034|NCT00940732|No Intervention|Control|
11559035|NCT00940719|Experimental|Vitamin D3|Patients receive 1dd 500ug vitamin D3 for 3 months
11559036|NCT00940706|Experimental|Physical activity in groups|Exercises of physical activity
11559037|NCT00940706|Experimental|Activity monitoring with accelerometers|Each subject will wear the accelerometer 24 hours a day for 4 days The activity will be recorded and analyzed
11559038|NCT00940706|Active Comparator|Treadmill|Treadmill with safety adaptations for handicapped persons
11559039|NCT00940693|Active Comparator|duloxetine|
11559040|NCT00940693|Placebo Comparator|placebo|
11559041|NCT00940680|Experimental|amlodipine/losartan 5/100mg|
11559042|NCT00940680|Active Comparator|losartan 100mg|
11559043|NCT00940667|Experimental|amlodipine/losartan 5/50mg|
11559044|NCT00940667|Active Comparator|amlodipine 5mg|
11559045|NCT00940654||Patients with fever|
11559046|NCT00940654||Patients without any fever|
11559047|NCT00940641|Experimental|1|IV dose of AZD7325
11559048|NCT00940641|Experimental|2|14C oral dose of AZD7325
11559049|NCT00940628|Experimental|1|
11559050|NCT00940628|Other|2|
11559051|NCT00940615|Experimental|1|participants in the aerobic exercise intervention
11559052|NCT00940615|Active Comparator|2|participants in the stretching/toning control condition
11559053|NCT00940602|Experimental|Deferasirox|10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.
11559054|NCT00940602|Placebo Comparator|Placebo|10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.
11559055|NCT00940589|Experimental|Circadin|Drug
11559056|NCT00940589|Placebo Comparator|Placebo|drug
11559057|NCT00940576|Experimental|mare´s milk|oral intake of of 250 ml mare´s milk
11559058|NCT00940576|Placebo Comparator|placebo drink|oral intake of of 250 ml placebo drink
11559059|NCT00940563|Experimental|Imatinib|
11559060|NCT00940550|Experimental|Prolonged-release melatonin 2 mg|
11559061|NCT00940550|Active Comparator|Temazepam 20 mg|
11559062|NCT00940550|Active Comparator|Zolpidem 10 mg|
11559063|NCT00940550|Placebo Comparator|Placebo|
11559064|NCT00940537||NAFLD|Non-diabetic, obese with diagnosed NAFLD (HTGC greater or equal to 5.5%)
11559065|NCT00940537||Non-NAFLD|Non-diabetic, obese with no previous diagnosis of NAFLD
11559066|NCT00940524|Experimental|Chemotherapy|A phase I study designed to determine the dose of dasatinib that can be safely administered with cytarabine and high-dose mitoxantrone in Ph+ ALL / lymphoid blast crisis of known chronic myelogenous leukemia patients.
11559067|NCT00940511|Experimental|Coordinated care|Individuals will be passively enrolled in Medicaid managed care. Those who do not opt out of managed care will be provided with care coordination.
11559068|NCT00940511|No Intervention|Usual care|The usual care group will remain in fee-for-service Medicaid and receive services normally available through that system.
11559069|NCT00940498|Experimental|1|PF-05212384 (also known as PKI-587)
11559070|NCT00940485|Experimental|Peginterferon alfa-2a + entecavir|Participants received PEGASYS® (peginterferon alfa-2a)180 micrograms (mcg) subcutaneously once weekly for 48 weeks, plus entecavir 0.5 milligram (mg) orally once daily for 8 weeks.
11559071|NCT00940485|Active Comparator|Entecavir|Participants received entecavir 0.5 mg orally once daily for 48 weeks.
11559072|NCT00940472|Experimental|Experimental Drug|DMMET-01 + Diet
11559073|NCT00940472|Active Comparator|Metformin|Metformin + Diet
11559074|NCT00940459|Experimental|Acuvue Oasys|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
11559075|NCT00940459|Experimental|Biofinity|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
11559076|NCT00940459|Experimental|Air Optix|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
11559077|NCT00940459|Experimental|PureVision|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
11559078|NCT00940459|Active Comparator|Acuvue 2|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
11559079|NCT00940446|Experimental|Insorb staples|Subcuticular Absorbable staples
11559080|NCT00940446|Active Comparator|Control|Metal staple wound closure
11559081|NCT00940433|Active Comparator|open properitoneal|patients undergoing open properitoneal hernia repair
11559082|NCT00940433|Active Comparator|Lechtenstien repair|Patients undergoing Lechtestien hernia repair
11559083|NCT00940433|Active Comparator|Laparoscopic transperitoneal repair|Patients undergoing TAPP repair
11559084|NCT00940433|Active Comparator|Lap totally extraperitoneal approach|Patients undergoing TEP approach
11559085|NCT00940420|Experimental|A|
11559086|NCT00940420|Experimental|B|
11559087|NCT00940394|Other|standard care|Families receive routine community and family mental health care services
11559088|NCT00940394|Experimental|mutual support group|bi-weekly, 12-session, family-led mutual support group
11559089|NCT00940394|Active Comparator|psychoeducation group|bi-weekly, 12-session, family psychoeducation group program
11559090|NCT00940381|Experimental|Sirolimus + Cetuximab|Sirolimus beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle. Cetuximab Beginning dose 100 mg/m^2 by vein over two hours on Day 1, and 65 mg/m^2 on Days 8, 15 and 22 for a 28 day cycle.
11559091|NCT00940368|Experimental|Ginger arm|"The patients in this arm will be randomly selected in each cycle of chemotherapy. The unit of randomization is the cycle of chemotherapy. In each cycle of chemotherapy of all patients recruited in the study will be categorized using the computer generated random numbers. The patients in the ginger arm; Group A will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group A:
~Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram ginger powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram ginger powder per day"
11559092|NCT00940368|Placebo Comparator|Placebo arm|"Patients (children and adolescents) will be included in this arm after randomization of the cycle of chemotherapy of the patient. Starch powder/Glucose powder is used as placebo.The patients in the placebo arm; Group B will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group B:
~Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram placebo powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram placebo powder per day"
11559093|NCT00940355|Experimental|Intervention pulmonary nurse|group III: intervention conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, increasing motivation to engage in additional treatment, and improving health status.
11559094|NCT00940355|No Intervention|Usual care|group II: usual care as delivered by the outpatient clinic.
11559095|NCT00940342|Experimental|Treated and Relapsed - Group 1|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
11559096|NCT00940342|Experimental|Treated and High-Risk for Progression - Group 2|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
11559097|NCT00940342|Experimental|70 Years of Age and Refused Chemo - Group 3|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
11559098|NCT00940329|Active Comparator|Treatment A|
11559099|NCT00940329|Active Comparator|Treatment B|
11559100|NCT00940316|Experimental|Arm A: Erlotinib + Panitumumab + Irinotecan|Patients receive oral erlotinib hydrochloride once daily on days 1-14, panitumumab IV over 30-90 minutes on day 1, and irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
11559101|NCT00940316|Experimental|Arm B: Erlotinib + Panitumumab|Patients receive oral erlotinib hydrochloride once daily on days 1-14 and panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients receive irinotecan hydrochloride as in arm A.
11559102|NCT00940316|Experimental|Arm C: Erlotinib + Panitumumab|Patients receive erlotinib hydrochloride and panitumumab as in arm B.
11559103|NCT00940303|Experimental|1|
11559104|NCT00940290|Other|GRADE system|A clinical recommendation built and graded with the GRADE working group system
11559105|NCT00940290|Other|SIGN grading system|A clinical recommendation built and graded with the Scottish Intercollegiate Guidelines Network system
11559106|NCT00940290|Other|NICE grading system|A clinical recommendation built and graded with National Institute of Clinical Excellence grading system
11559107|NCT00940290|Other|CEBM-Oxford|A clinical recommendation built and graded with the Centre for Evidence-Based Medicine grading system
11559108|NCT00940277|Experimental|Enhanced Couples Group|Enhanced Couples Group: consists of eight 90-minute sessions, conducted weekly. ECG has a didactic educational content presented by the group leader or practice of specific relationship communication, relationship support, and couple-focused stress management. ECG participants are also given instruction about what types of behaviors are unsupportive and training in how to not behave in an unsupportive manner.
11559162|NCT00939991|Experimental|1|Phase I- Bevacizumab will be administered intravenously every other week. Temozolomide will be administered on a continuous daily dosing schedule. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen.
11559163|NCT00939978|Active Comparator|Venoferrum|
11559164|NCT00939978|Placebo Comparator|saline|
11559165|NCT00939952|Active Comparator|ertapenem 500 mg IV x1|All patients will receive ertapenem 500 mg IV once.
11559109|NCT00940277|Experimental|Support Group|Support Group: 8 weekly 90-minute group counseling sessions. Using a standard approach to supportive therapy, the group interventionists will focus on encouraging participants to share their experiences with cancer, express their emotions related to the experience, voice problems they have in coping with the cancer, and offer support and advice to other members of the group. The co-facilitators will facilitate expression of affect and the sharing of the group's common issues related to cancer. Each session has a broad topic for discussion. Topics include communication with health care providers, issues related to occupational life, and coping with medical procedures and treatment. No formal or didactic information will be provided.
11559110|NCT00940264||Given indication for cholecystectomy|
11559111|NCT00940251|Placebo Comparator|CORN STARCH|
11559112|NCT00940251|Active Comparator|Mersina, Diet and exercise|
11559113|NCT00940225|Experimental|Arm 1|RDT Open-Label
11559114|NCT00940225|Experimental|Arm 2|RDT Randomized Blinded-XL184
11559115|NCT00940225|Placebo Comparator|Arm 3|RDT Randomized Blinded
11559116|NCT00940225|Experimental|Non-Randomized Expansion (NRE) Cohorts|Drug: XL184
11559117|NCT00940212|Experimental|A|AZD2423
11559118|NCT00940212|Experimental|B|Placebo
11559119|NCT00940199||Standard of Care|I:Application of L-M-X topical anesthetic cream 4% to the breast within one hour of sub-areaolar injection of 4 ml 99mTc-sulfur colloid (1 mCi in normal saline)
11559120|NCT00940199||1 mCi in sodium bicarbonate|II. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in sodium bicarbonate)
11559121|NCT00940199||1 mCi in 1% Lidocaine|III. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in 1% Lidocaine)
11559122|NCT00940199||1 mCi in sodium bicarbonate + 1% Lidocaine|IV. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in sodium bicarbonate + 1% Lidocaine)
11559123|NCT00940186||pikamilone|
11559124|NCT00940186||dosage|low dosage group: administrate pikamilone tablet 50 mg; middle dosage group: administrate pikamilone tablet 100 mg; hige dosage group: administrate pikamilone tablet 200 mg.
11559125|NCT00940186||tablet|
11559126|NCT00940173|Other|Group 1|Dose Group 1 (Receiving a dose of 10,000 IEQ/kg of DIABECELL(R))
11559127|NCT00940173|Other|Group 2|Dose Group 2 (Receiving a dose of 15,000 IEQ/kg of DIABECELL(R))
11559128|NCT00940173|Other|Group 3|Dose Group 3 (Receiving a dose of 20,000 IEQ/kg of DIABECELL(R))
11559129|NCT00940173|Other|Group 4|Dose Group 4 (Receiving a dose of 5,000 IEQ/kg of DIABECELL(R))
11559130|NCT00940160|Active Comparator|QAX576 1 mg/kg|
11559131|NCT00940160|Active Comparator|QAX576 3 mg/kg|
11559132|NCT00940160|Active Comparator|QAX576 10 mg/kg|
11559133|NCT00940160|Placebo Comparator|Placebo|
11559134|NCT00940147||1|patients with OAC, Score finding
11559135|NCT00940147||2|patients without OAC, Score finding
11559136|NCT00940134|Placebo Comparator|placebo|Study participants will receive a 3 hour IV infusion of saline while fasting.
11559137|NCT00940134|Experimental|PYY3-36 + GLP-1|Study participants will receive a 3 hour IV infusion of (GLP-1 + PYY3-36) while fasting.
11559138|NCT00940134|Active Comparator|GLP-1|Study participants will receive a 3 hour IV infusion of PYY3-36 while fasting.
11559139|NCT00940134|Active Comparator|PYY3-36|Study participants will receive a 3 hour IV infusion of PYY3-36 while fasting.
11559140|NCT00940121|Experimental|1. mirabegron, low dose|Oral mirabegron 25 mg
11559141|NCT00940121|Experimental|2. mirabegron, middle dose|Oral mirabegron 50 mg
11559142|NCT00940121|Experimental|3. mirabegron, higher dose|Oral mirabegron 100 mg
11559143|NCT00940108|Experimental|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
11559144|NCT00940108|Experimental|CSL425 (30 mcg)|30 mcg of hemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
11559145|NCT00940095|Experimental|Clazosentan 5 mg/h|Continuous intravenous infusion of clazosentan (5 mg/h) started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
11559146|NCT00940095|Experimental|Clazosentan 15 mg/h|Continuous intravenous infusion of clazosentan (15 mg/h) started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
11559147|NCT00940095|Placebo Comparator|Placebo|Continuous intravenous infusion of placebo matching clazosentan started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
11559148|NCT00940082||youth control group|healthy people which ages from 30 to 59
11559149|NCT00940082||youth diabetes group|type 1 and type 2 diabetes patients which ages from 30 to 59
11559150|NCT00940082||the elderly diabetes group|type 1 and type 2 diabetes patients which ages from 60 to 90
11559151|NCT00940082||elderly control group|healthy people which ages from 60 to 90
11559152|NCT00940069|Experimental|TS high expression genotype|TS high expression genotype delivered to pemetrexed 500 mg/m2 and cisplatin 75 mg/m2,for not less than 4 cycle, administered intravenously every 3 weeks.
11559153|NCT00940069|Experimental|TS low expression genotype|TS low expression genotype delivered to pemetrexed 500 mg/m2 and cisplatin 75 mg/m2,for not less than 4 cycle, administered intravenously every 3 weeks.
11559154|NCT00940056|Experimental|Endoscopic ablation of atrial fibrillation|
11559155|NCT00940056|Active Comparator|Rate control|
11559156|NCT00940043||Rupture of fetal membranes|women with rupture of fetal membranes before onset of labor
11559157|NCT00940030|Experimental|MBP+enema|mechanical bowel preparation and enema
11559158|NCT00940030|Active Comparator|enema|
11559159|NCT00940017|Experimental|1|
11559160|NCT00940004|Active Comparator|cytokine matured DC|vaccination with autologous dendritic cells matured with standard cytokine cocktail and electroporated with mRNA encoding tumor associated antigens
11559161|NCT00940004|Experimental|TLR ligand matured DC|vaccination with autologous TLR-ligand matured dendritic cells electroporated with mRNA encoding tumor associated antigens
11559166|NCT00939939|Experimental|sitagliptin|
11559167|NCT00939939|Active Comparator|glimepirid|
11559168|NCT00939913|Placebo Comparator|intravenous N-acetlycysteine|"intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)as compared to placebo
~Acetadote provided by Cumberland Pharmaceuticals Inc."
11559169|NCT00939913|Placebo Comparator|Placebo|Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
11559170|NCT00939900|Experimental|aclasta|aclasta group
11559171|NCT00939900|No Intervention|control|control group
11559172|NCT00939887|Experimental|Treatment|
11559173|NCT00939874|Experimental|Raltegravir|
11559174|NCT00939861|Experimental|1|laparoscopy
11559175|NCT00939861|Experimental|2|laparotomy
11559176|NCT00939848|Experimental|B|The experimental arm will consist of cisplatin 25 mg/m2 plus gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle with cediranib 20mg oral daily (continuous dosing).
11559177|NCT00939848|Placebo Comparator|Arm A|The control arm will consist of cisplatin 25 mg/m2 plus gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle with a matching placebo 20mg oral daily (continuous dosing)
11559178|NCT00939822|Experimental|Simvastatin|40 mg. Simvastatin/day
11559179|NCT00939822|Placebo Comparator|Placebo|Matching Placebo
11559180|NCT00939809|Experimental|Treatment (urokinase-derived peptide A6)|Patients receive A6 subcutaneously once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11559181|NCT00939796|Experimental|Tympanostomy Tube Delivery System (TTDS)|Tympanostomy tube placement with Acclarent tube delivery system
11559182|NCT00939783|Experimental|Dimebon 20 mg TID|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
11559183|NCT00939770|Experimental|Treatment (crizotinib)|Patients receive crizotinib PO BID on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11559184|NCT00939757|Experimental|1. mirabegron, lower dose|
11559185|NCT00939757|Experimental|2. mirabegron, higher dose|
11559186|NCT00939744||EAU2|Women who will have a c-section at the CHUS
11559187|NCT00939731|Experimental|PIC|
11559188|NCT00939731|Experimental|IRT|
11559189|NCT00939718|Active Comparator|Vitamin B12 with antidepressants|Subjects in this arm will receive vitamin B12 supplement (injectable)along with their routine antidepressant treatment as prescribed by their primary physicians. subjects will be blind to their arm allocation and will receive injections in a concealed manner with injection vials covered with foil.
11559190|NCT00939718|Placebo Comparator|Placebo injections dextrose water|Subjects in this arm will receive placebo injections which will contain only dextrose water. They will also receive 6 injections on a weekly basis and the injection vials will be covered with foil to ensure masking.
11559191|NCT00939705|Experimental|Torrent Topiramate|
11559192|NCT00939705|Active Comparator|Topamax|
11559193|NCT00939692|Experimental|Torrent Topiramate|tablet containing 25 mg of topiramate (Torrent Pharmaceuticals)
11559194|NCT00939692|Active Comparator|Topamax|tablet containing 25 mg of topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.)
11559195|NCT00939679|Experimental|Earlier gastric bypass surgery (7 weeks)|These patients will undergo gastric bypass surgery 7 weeks after starting a low calorie diet, and will continue the low calorie diet for 3 weeks following surgery.
11559196|NCT00939679|Active Comparator|Later gastric bypass surgery (10 weeks)|These patients will undergo gastric bypass surgery 10 weeks after starting a low calorie diet.
11559197|NCT00939666|Experimental|Wait&see or TEM with intensive follow-up|All patients will be included in this arm
11559198|NCT00939653|Experimental|Single Arm - Clofarabine with Chemo|All patients receive the same treatment regimen consisting of clofarabine, etoposide, cyclophosphamide, cytarabine, and filgrastim. Up to 4 courses of therapy may be given.
11559199|NCT00939640|Experimental|Dietary intervention|Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
11559200|NCT00939627|Placebo Comparator|Arm I (cetuximab and placebo)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 and oral placebo twice daily on days 1-21.
11559201|NCT00939627|Experimental|Arm II (cetuximab and sorafenib tosylate)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 and oral sorafenib tosylate twice daily on days 1-21.
11559202|NCT00939601|Active Comparator|Motivational Enhancement Therapy|MET will involve counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
11559203|NCT00939601|Active Comparator|Educational Counseling|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
11559204|NCT00939601|No Intervention|Standard Care|
11559205|NCT00939588|Experimental|Aliskiren and Valsartan|
11559206|NCT00939588|Active Comparator|Telmisartan and Ramipril|
11559207|NCT00939575||Preeclampsia|Women hospitalized for pre-eclampsia after 20 0/7 weeks of gestation. The diagnosis of preeclampsia include a combination of the following criteria: after 20 weeks of gestation in a previously normotensive woman, a diastolic blood pressure > 90 mmHg recorded twice at least four hours apart or > 110 mmHg, with proteinuria > 300 mg/24h or > 30 mg / mmol protein / urinary creatinine in a urine sample or factor (s) serious maternal / fetal (according to SOGC consensus ).
11559208|NCT00939575||control|Women will be matched to women with pre-eclampsia according to gestational age at diagnosis of preeclampsia, maternal age (in stratum of 5 years), gender, ethnicity (4 categories: Caucasian, black, Asian and other) and body mass index (5 classes: <20, 20-25, 26-30, 31-35 and <35). Patients of this group should be at low risk of obstetric complications at recruitment and planning to deliver at the CHUS.
11559209|NCT00939562|Experimental|doxycycline monohydrate tablet|
11559210|NCT00939562|Active Comparator|doxycycline carragenate tablet|
11559211|NCT00939549|Experimental|High-dose cyclohosphamide|
11559256|NCT00939133|Active Comparator|Tretinoin microsphere 0.04% gel|
11559257|NCT00939133|Placebo Comparator|Vehicle gel|
11559212|NCT00939536|Experimental|Torrent's Zolpidem Tartrate Tablets 10 mg|Normal Healthy Human Subjects receiving Torrent's Zolpidem Tartrate Tablets 10 mg
11559213|NCT00939536|Active Comparator|Sanofi-Synthelabo's Ambien® 10 mg Tablets|Normal Healthy Human Subjects receiving Sanofi-Synthelabo's Ambien® 10 mg Tablets
11559214|NCT00939523|Experimental|Lapatinib|All participants will be asked to take Lapatinib daily for a total of six months during the research study.
11559215|NCT00939510|Experimental|Lenalidomide (RevlimidTM ) and GM-CSF|
11559216|NCT00939484|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO once daily on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
11559217|NCT00939471|Other|Relieva™ Balloon Sinuplasty™ System|Balloon Dilation of sinus ostium
11559218|NCT00939445|Active Comparator|Online HDF|Online HDF
11559219|NCT00939445|Active Comparator|Short Daily Hemodialysis|Short Daily Hemodialysis
11559220|NCT00939432||Gender|male/female
11559221|NCT00939432||Age|18-100 years
11559222|NCT00939432||Educational level|primary school, secondary school, university
11559223|NCT00939419|Other|Health worker TB care group|
11559224|NCT00939419|Other|Community health worker TB care group|
11559225|NCT00939419|Other|Self-administered treatment group|
11559226|NCT00939406|No Intervention|Control|Control group consists of subjects randomized to the control arm who will receive lumbar decompression surgery (laminotomy or laminectomy) alone
11559227|NCT00939406|Experimental|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
11559228|NCT00939393|Active Comparator|FESS in OR with or without balloons|Functional Endoscopy Sinus Surgery
11559229|NCT00939393|Active Comparator|Balloon sinuplasty in physician office|Balloon Sinuplasty in physician office using Acclarent devices
11559230|NCT00939380|Experimental|P-SCIP|Arm I (Parent Social-Cognitive Intervention Program [P-SCIP]): Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns. Participants receive a laptop computer and a CD-ROM after the first session.
11559231|NCT00939380|Experimental|BPC|"Arm II (Best-recommended Psychosocial Care [BPC]): Participants undergo usual care and receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD, and 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks."
11559232|NCT00939367|Experimental|Test|Torrent's Zolpidem TartrateTablets 10 mg
11559233|NCT00939367|Active Comparator|Reference|Sanofi-Synthelabo Inc's Ambient® Tablets 10 mg
11559234|NCT00939341|Experimental|1|Symbicort Turbuhaler 160/4.5 µg delivered dose
11559235|NCT00939289||Adults with T1DM|Adults (18+ years-old) diagnosed with type 1 diabetes mellitus; treated with multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy
11559236|NCT00939276|Experimental|NEVANAC|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
11559237|NCT00939276|Placebo Comparator|Nepafenac Vehicle|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
11559238|NCT00939263||1|cohorts 1 (item weighting phase): 100 children with Eosinophilic Esophagitis, 150 adults with Eosinophilic Esophagitis
11559239|NCT00939263||2|cohorts 2 (evaluation phase): 200 children with Eosinophilic Esophagitis, 200 adults with Eosinophilic Esophagitis
11559240|NCT00939250|Experimental|Diabetes and depression intervention|Measurement based care for diabetes and depression, disease self management for diabetes and depression
11559241|NCT00939250|Active Comparator|Diabetes intervention|Measurement based care for diabetes, disease self management for diabetes
11559242|NCT00939237|Experimental|Active Ateronon|7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
11559243|NCT00939237|Placebo Comparator|Placebo|placebo dietary supplement supplied as one capsule taken daily
11559244|NCT00939224||Cohort Phase 1|Cardiac Catheterization
11559245|NCT00939211|Experimental|AZD9164 100 mcg First, then Placebo for Spririva|1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
11559246|NCT00939211|Experimental|AZD9164 400 mcg First, then Placebo for Spiriva|1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
11559247|NCT00939211|Experimental|AZD9164 1200 mcg First, then Placebo for Spiriva|1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
11559248|NCT00939211|Active Comparator|Spiriva 18 mcg First, then Placebo for AZD9164|1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)
11559249|NCT00939211|Placebo Comparator|Placebo for Spiriva First, then Placebo for AZD9164|1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)
11559250|NCT00939198|Experimental|Na-ASP-2 Hookworm Antigen Skin Test|All participants will be skin tested with Na-ASP-2 skin test reagent applied to their arms, using both the prick-puncture and intradermal techniques.
11559251|NCT00939185||Azithromycin group|
11559252|NCT00939172|Experimental|TTP607|
11559253|NCT00939159|Experimental|LBH589|LBH589 20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.
11559254|NCT00939146|Other|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
11559255|NCT00939146|Other|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
11559258|NCT00939120|Experimental|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
11559259|NCT00939120|Placebo Comparator|placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
11559260|NCT00939107|Experimental|McKenzie exercises|McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
11559261|NCT00939107|Active Comparator|Spinal manipulation|Spinal manipulation in combination with information of clinical findings and advice about back care
11559262|NCT00939094|Experimental|A|
11559263|NCT00939094|Placebo Comparator|B|
11559264|NCT00939081|Active Comparator|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
11559265|NCT00939081|Experimental|Adaptive recommendation|The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
11559266|NCT00939068|Experimental|Telbivudine|Drug administration and follow up: the subjects in Telbivudine group start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continue to one month after delivery.And their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.
11559267|NCT00939068|Other|Control|The pregnant subjects in Control group are intervented with no drugs, but their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.
11559268|NCT00939055|Experimental|StomaphyX|Post-Roux-en-Y revisional surgery using the StomaphyX device.
11559269|NCT00939055|Sham Comparator|Sham Procedure|No intervention
11559270|NCT00939042|Active Comparator|1|PCI plus BNNC Therapy after acute myocardial infarction
11559271|NCT00939042|Active Comparator|2|Percutaneous Coronary Intervention after acute myocardial infarction
11559272|NCT00939029|Active Comparator|Active|2 nicotine patches each at 21 mg/day for a total of 42 mg/day for 8 weeks
11559273|NCT00939029|Placebo Comparator|placebo|2 patches (containing non active ingredients) per day for 8 weeks
11559274|NCT00939016|Active Comparator|High SD/ Low DR|This group contains females that exhibit characteristics of high social desirability and low dietary restraint.
11559275|NCT00939016|Active Comparator|High SD/ High Dr|This group contains females that exhibit characteristics of high social desirability and high dietary restraint.
11559276|NCT00939016|Active Comparator|Low SD/ High DR|This group contains females that exhibit characteristics of low social desirability and high dietary restraint.
11559277|NCT00939016|Active Comparator|Low SD/ Low DR|This group contains females that exhibit characteristics of low social desirability and low dietary restraint.
11559278|NCT00939003|Experimental|Adalimumab|
11559279|NCT00939003|Placebo Comparator|Placebo|
11559280|NCT00939003|Experimental|Open-label Adalimumab|
11559281|NCT00938990|Active Comparator|Midazolam|
11559282|NCT00938990|Experimental|Etomidate|
11559283|NCT00938977|Active Comparator|CPAP|Response to treatment before/after treatment in patients with OSAS and SOH
11559284|NCT00938977|Active Comparator|Bilevel support ventilation|Before and after effect of Bilevel support ventilation in patients with SOH without OSA
11559285|NCT00938964|Experimental|Lidocaine|Lidocaine infusion for 48 hours
11559286|NCT00938964|Placebo Comparator|Placebo|Normal saline infusion for 48 hours
11559287|NCT00938951|Experimental|Systane® Ultra|Systane® Ultra
11559288|NCT00938938|Experimental|Press guide plus press release|Participants in the intervention group will receive a press guide (a one-page summary of study findings written by the investigators) in addition to the journal's full narrative press release for the selected article, a copy of the article's abstract, and a link to the full text of the journal article.
11559289|NCT00938938|No Intervention|Press release only|Participants in the control group will receive the journal's full narrative press release for the selected article, a copy of the article's abstract, and a link to the full text of the journal article.
11559290|NCT00938925|Experimental|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
11559291|NCT00938925|Experimental|nail lacqer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
11559292|NCT00938912|Experimental|Lacosamide|Subjects and their caregivers may chose to receive Lacosamide oral solution (syrup) or Lacosamide tablets. The maximum duration of LCM administration will be approximately 2 years.
11559293|NCT00938886|Experimental|Naltrexone|50 mg daily naltrexone for 10 weeks
11559294|NCT00938886|Placebo Comparator|Placebo|Daily matched placebo pill
11559295|NCT00938873||Mindfulness Based Cognitive Therapy|The present study will use participants who have experienced more than three episodes of depression as judged by South London and Maudsley NHS Trust. No restrictions are placed in terms of participants' use of antidepressant medication. Participants will be 18 to 65 years old and would have participated in an MBCT course run by South London and Maudsley NHS Trust.
11559296|NCT00938860|Experimental|Neoral|Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
11559297|NCT00938860|Active Comparator|tacrolimus|Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
11559390|NCT00938223|Active Comparator|4-peptide vaccine|Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A 2) and a tetanus helper peptide.
11559428|NCT00937976|Other|Control-delayed periodontal therapy|
11559298|NCT00938834|Active Comparator|CFQ Qigong training group|"Qigong training con- sisted of an initial workshop conducted over three con- secutive half-days by a qualified CFQ instructor. Participants received training in level 1 CFQ; this con- sisted of instruction in seven key movements known as the hexagram and ancillary exercises. Hexagram move- ments consist of choreographed movements that emphasize softness, relaxation, downward releases and full body distribution of qi. Once initial training was complete, participants were asked to practice CFQ at home for 45 to 60 minutes per day for eight weeks; time could be broken up into shorter sessions during the day. Participants returned for a 60 minute weekly review/group practice sessions for these eight weeks."
11559299|NCT00938821||Caudal Block|Review of charts of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B).
11559300|NCT00938808|Active Comparator|One per day, Formula diet|The Cambridge Programme. Formula diet One-daily
11559301|NCT00938808|Experimental|Repeated formula diet|Dietary instruction (low-energy diet) 3x5 weeks per year
11559302|NCT00938795|Other|Uncertainty Management Intervention|The Uncertainty Management Intervention will consist of six 30-minute phone calls with a study educator to discuss issues of psychological distress, uncertainty management, symptom control, self efficacy for symptom management, and quality of life.
11559303|NCT00938795|Other|Comparison Conditions for Liver Disease|Six 30-minute telephone calls that provide structured education about liver disease.
11559304|NCT00938782|Active Comparator|Active Monitoring with SEDLine Monitor|Patient group randomized to active monitoring with SEDLine monitor for titration of anesthesia.
11559305|NCT00938782|No Intervention|Blinded monitoring with SeEDLine Monitor|Patient group randomized to blinded monitoring with SEDLine monitor for titration of anesthesia. Data captured but not used for titration of anesthesia.
11559306|NCT00938769|Other|Self-Efficacy Training for Caregivers|The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.
11559307|NCT00938769|Other|Comparison Conditions for Caregivers|Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for support.
11559308|NCT00938743|Active Comparator|Atomoxetine|Treatment with a final dosis of 40-80mg atomoxetine daily
11559309|NCT00938743|No Intervention|Waiting list|
11559310|NCT00938730|Experimental|1. YM150, Dose W, twice daily|
11559311|NCT00938730|Experimental|2. YM150, Dose X, once daily|
11559312|NCT00938730|Experimental|3. YM150, Dose X, twice daily|
11559313|NCT00938730|Experimental|4. YM150, Dose Y once daily|
11559314|NCT00938730|Experimental|5. YM150, Dose Y twice daily|
11559315|NCT00938730|Experimental|6. YM150, Dose Z, once daily|
11559316|NCT00938730|Active Comparator|7. Warfarin|
11559317|NCT00938717|Placebo Comparator|Placebo|
11559318|NCT00938717|Experimental|290 μg Linaclotide|
11559319|NCT00938704|Active Comparator|1|carboxymethylcellulose 0.5%, glycerin 0.9%
11559320|NCT00938704|Active Comparator|2|sodium hyaluronate 0.18%
11559321|NCT00938691|Experimental|Tepha|
11559322|NCT00938691|Active Comparator|Vicryl|
11559323|NCT00938678|Experimental|Treatment Group 1|
11559324|NCT00938678|Active Comparator|Treatment Group 2|
11559325|NCT00938665||Control Group|
11559326|NCT00938665||AD Group|
11559327|NCT00938652|Active Comparator|Arm G/C|gemcitabine/carboplatin on Days 1 and 8 of 21-day cycle(s)
11559328|NCT00938652|Experimental|Arm G/C/I|gemcitabine/carboplatin on Days 1 and 8, plus iniparib on Days 1, 4, 8, and 11 of 21-day cycle(s)
11559329|NCT00938639|Experimental|CSL425 (15 mcg)|15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
11559330|NCT00938639|Experimental|CSL425 (30 mcg)|30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
11559331|NCT00938626|Experimental|Armed-activated T cells/Immunotherapy|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
11559332|NCT00938613|Experimental|Captisol-Enabled Budesonide|32 ug/spray
11559333|NCT00938613|Active Comparator|Rhinocort Aqua|32 ug/spray
11559334|NCT00938613|Placebo Comparator|Placebo|posphate buffered saline
11559335|NCT00938600|Experimental|A1 - non-pregnant single-dose|
11559336|NCT00938600|Experimental|A2 - non-pregnant; weekly dose|
11559337|NCT00938600|Experimental|B1 - pregnant; single-dose|
11559338|NCT00938600|Experimental|B2 - pregnant; weekly dose|
11559339|NCT00938600|Active Comparator|C1 - active control; pregnant women|
11559340|NCT00938587|Experimental|PF-04171327 10 mg|
11559341|NCT00938587|Experimental|PF-04171327 25 mg|
11559342|NCT00938587|Active Comparator|Prednisone|
11559343|NCT00938587|Placebo Comparator|Placebo|
11559344|NCT00938574|Experimental|Drug Atu027|
11559345|NCT00938561||With and without Chronic Kidney Disease|A cohort of 10 patients subjects with and without kidney disease exhibiting a broad range of age and kidney function
11559346|NCT00938548|Placebo Comparator|Placebo|Patients receive oral Placebo 1 hour prior to surgery, and 12 hours later
11559347|NCT00938548|Experimental|Pregabalin|Patients receive oral pregabalin 1 hour prior to surgery, and 12 hours later
11559348|NCT00938535|Experimental|Obesity Prevention|
11559349|NCT00938535|No Intervention|Usual Care|This arm includes usual care.
11559350|NCT00938522|Experimental|Cilostazol loading|
11559351|NCT00938522|Placebo Comparator|Placebo|
11559352|NCT00938483|Experimental|Extensively hydrolyzed infant formula|New extensively hydrolyzed formula, NPS-202
11559353|NCT00938483|Active Comparator|Infant formula - Extensively hydrolyzed Nutramigen Lipil|Currently marketed extensively hydrolyzed formula (Nutramigen Lipil)
11559427|NCT00938015||PsA Patients|CU patients
11559354|NCT00938470|Experimental|Arm I (combination chemotherapy, radiation therapy, surgery)|Patients receive docetaxel IV over 1 hour and oxaliplatin IV over 2 hours on day 1. Patients also receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. After completion of the second course, patients receive fluorouracil IV continuously on days 1-5 and oxaliplatin IV over 2 hours on days 1, 15, and 29. Patients also undergo radiotherapy 5 days a week for 5.5 weeks in the absence of disease progression or unacceptable toxicity. Approximately 4-12 weeks after completion of radiotherapy, patients undergo surgery.
11559355|NCT00938470|Active Comparator|Arm II (oxaliplatin, fluorouracil, radiation, and surgery)|Patients receive fluorouracil IV continuously on days 1-5 and oxaliplatin IV over 2 hours on days 1, 15, and 29. Patients also undergo radiotherapy and then surgery as in Arm I.
11559356|NCT00938457|Experimental|Arm I|Patients undergo either percutaneous placement of metallic fiducial markers within the liver or respiratory-correlated cone-beam computed tomography for stereotactic targeting and planning. Patients then undergo single-fraction stereotactic body radiotherapy over approximately 1 hour within 1 week of the marker placement.
11559357|NCT00938444||Patients with moderate to severe RA|Patients with moderate to severe RA treated with Tocilizumab
11559358|NCT00938431|Experimental|Lacosamide - Age 5 - 11 years|Cohort 1 (Age 5 - 11 years); up to 8 mg/kg/day
11559359|NCT00938431|Experimental|Lacosamide - (Age 12 - 17 years)|Cohort 2 (Age 12 - 17 years); 12 mg/kg/day.
11559360|NCT00938431|Experimental|Lacosamide (Age 2 - 4 years)|Cohort 3 (Age 2 - 4 years); 12 mg/kg/day.
11559361|NCT00938431|Experimental|Lacosamide (Age 5 - 11 years)|Cohort 4 (Age 5 - 11 years); 12 mg/kg/day.
11559362|NCT00938431|Experimental|Lacosamide (Age 1 month - < 2 years)|Cohort 5 (Age 1 month to < 2 years); 12 mg/kg/day
11559363|NCT00938405|Experimental|Colesevelam HCl|Beginning at Visit 1, two weeks after screening, subjects in the active treatment group will take 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
11559364|NCT00938405|Placebo Comparator|Comparison group|Beginning at Visit 1, two weeks after screening, subjects in the comparison group will be administered placebo, taking 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
11559365|NCT00938392|Experimental|FluNG Aged Group|Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).
11559366|NCT00938392|Experimental|FluNG Fresh Group|Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).
11559367|NCT00938379|Experimental|20% deet insect repellent|experimental intervention
11559368|NCT00938379|Placebo Comparator|lotion without repellent active|
11559369|NCT00938366|Experimental|Cladribine followed by Cladribine + Pantoprazole|Subjects will receive a single dose of cladribine10 milligram (mg) orally on Day 1. After a wash out period of 10-25 days, subjects will receive pantoprazole 40 mg orally for 2 consecutive days. On Day 2 of the pantoprazole administration, a single dose of cladribine 10 mg will be administered orally 3 hours after the second pantoprazole dose.
11559370|NCT00938366|Experimental|Cladribine + pantoprazole followed by Cladribine|Subjects will receive pantoprazole 40 mg orally for 2 consecutive days. On Day 2 of the pantoprazole administration, a single dose of cladribine 10 mg will be administered orally 3 hours after the second pantoprazole dose. After a wash out period of 10-25 days, subjects will receive a single dose of cladribine 10 mg orally.
11559371|NCT00938353|Experimental|BDP UDV|
11559372|NCT00938353|Placebo Comparator|Placebo|
11559373|NCT00938340|Experimental|Whole walnut|85g whole walnuts, ground, incorporated into inert food carrier
11559374|NCT00938340|Experimental|"Walnut meat"|Separated, ground walnut de-fatted nut meat incorporated into inert food carrier
11559375|NCT00938340|Experimental|Walnut oil|Walnut oil extracted from nut meat and incorporated into inert food carrier
11559376|NCT00938340|Experimental|Walnut skins|Separated, ground walnut skins incorporated into inert food carrier
11559377|NCT00938327||Rotarix Group|Subjects who have received 2 oral doses (or a second dose for subjects who had already received the first dose prior to joining the study) of Rotarix™ at an interval of not less than 4 weeks between the doses.
11559378|NCT00938314|Experimental|NTx®-265 Low Dose|hCG 385 µg (10,000 international unit [IU]), subcutaneously (SC), on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, intravenously (IV), on Day 7, 8, and 9 of study participation
11559379|NCT00938314|Experimental|NTx®-265 Medium Dose|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
11559380|NCT00938314|Experimental|NTx®-265 High Dose|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
11559381|NCT00938314|Placebo Comparator|Saline Placebo|
11559382|NCT00938301|Active Comparator|Treatment|2 cohorts will recieve single rising doses of PF-04455242 or placebo in a cross-over fashion.
11559383|NCT00938301|Placebo Comparator|Placebo|2 cohorts will receive single rising doses of PF-04455242 or placebo in a cross-over fashion.
11559384|NCT00938288|Other|1|Single group
11559385|NCT00938275|Experimental|0.5g SRT2104|"Cohort 1 (10 males) & Cohort 2 (10 females) must attend the clinic on 4 separate treatment visits during the study; each treatment visit will be one week apart. At each treatment visit, subjects will receive one of the following 4 treatments:
~A) 0.5g SRT2104 administered as an oral suspension in the fasted state B) 0.5g SRT2104 administered as an oral suspension following consumption of a standard meal C) 0.5g SRT2104 administered as two 0.25g capsules in the fasted state D) 0.5g SRT2104 administered as two 0.25g capsules following consumption of a standard meal.
~For treatments A and C, subjects will have fasted for at least 10 hours overnight. Water will be restricted from 1h prior to dosing until 1h post dose. A light lunch will be provided 4h post dose. For treatments B and D, subjects will receive SRT2104 within 30 min following the start of consumption of a standardized non high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat)."
11559386|NCT00938262|Experimental|Fimasartan, Ketoconazole, Rifampicin|
11559387|NCT00938249|Experimental|Monascus Garlic Fermented Extract|
11559388|NCT00938249|Placebo Comparator|Placebo|
11559389|NCT00938236|Other|Inhaled cyclosporine|Extended access to inhaled cyclosporine for patients from treatment and control arms of Phase 3 study CIS001
11559391|NCT00938223|Active Comparator|12-peptide vaccine|Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.
11559392|NCT00938210|No Intervention|Laparoscopic surgery|Patients undergoing laparoscopic colonic surgery are compared with a historical cohort of patients undergoing similar open colonic surgery (right hemicolectomy and sigmoid resections).
11559393|NCT00938197|Active Comparator|Part A|
11559394|NCT00938197|Active Comparator|Part B|
11559395|NCT00938184|Experimental|Treatment sequence A/B/C|Eligible subjects will be randomized in sequence A/B/C and will receive A: single tablet of paroxetine 12.5 milligrams, B: single tablet of paroxetine 25 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
11559396|NCT00938184|Experimental|Treatment sequence A/C/B|Eligible subjects will be randomized in sequence A/C/B and will receive A: single tablet of paroxetine 12.5 milligrams, C: two tablets of paroxetine 25 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
11559397|NCT00938184|Experimental|Treatment sequence B/A/C|Eligible subjects will be randomized in sequence B/A/C and will receive B: single tablet of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
11559398|NCT00938184|Experimental|Treatment sequence B/C/A|Eligible subjects will be randomized in sequence B/C/A and will receive B: single tablet of paroxetine 25 milligrams, C: two tablets of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
11559399|NCT00938184|Experimental|Treatment sequence C/A/B|Eligible subjects will be randomized in sequence C/A/B and will receive C: two tablets of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
11559400|NCT00938184|Experimental|Treatment sequence C/B/A|Eligible subjects will be randomized in sequence C/B/A and will receive C: two tablets of paroxetine 25 milligrams, B: single tablet of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
11559401|NCT00938171|Active Comparator|local anesthesia|local anesthesia with propofol sedation Target-controlled infusion (TCI) system will be used to maintain proper sedation level)
11559402|NCT00938171|Active Comparator|General anesthesia|Patients receiving general anesthesia
11559403|NCT00938158|Experimental|Stage 1 normal renal function|Subject with estimated glomerular filtration rate (GFR) greater than 80 milliliter per minute (mL/min)
11559404|NCT00938158|Experimental|Stage 1 moderate/severe renal function|Subject with estimated GFR >= 20 mL/min and less than 50 mL/min
11559405|NCT00938158|Experimental|Stage 2 normal renal function|Subject with GFR greater than 80 mL/min
11559406|NCT00938158|Experimental|Stage 2 moderate renal impairment|Subject with estimated GFR >= 30 mL/min and less than 50 mL/min
11559407|NCT00938158|Experimental|Stage 2 subjects requiring hemodialysis|Subjects who require hemodialysis
11559408|NCT00938158|Experimental|Stage 2 severe renal impairment not requiring hemodialysis|Subjects with GFR less than 30 mL/min
11559409|NCT00938158|Experimental|Stage 2 mild renal impairment|Subjects with GFR >= 50 mL/min and <= 80 mL/min
11559410|NCT00938145|Experimental|MRI+surgery|3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI
11559411|NCT00938145|Experimental|MRI+surgery+chemotherapy|3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI/chemotherapy
11559412|NCT00938132|Experimental|Fimasartan|
11559413|NCT00938119||Diabetes patients with PCI|this is single group
11559414|NCT00938106|Experimental|(MR BT) in Cervix Cancer|
11559415|NCT00938093|Active Comparator|Cognitive-behavioral therapy|cognitive-behavioral therapy
11559416|NCT00938093|Placebo Comparator|Enhanced usual care|enhanced usual care
11559417|NCT00938080|Experimental|AG013: one mouth rinse/day|
11559418|NCT00938080|Experimental|AG013: three mouth rinses/day|
11559419|NCT00938080|Experimental|AG013: six mouth rinses/day|
11559420|NCT00938080|Placebo Comparator|one mouth rinse/day|
11559421|NCT00938080|Placebo Comparator|three mouth rinses/day|
11559422|NCT00938080|Placebo Comparator|six mouth rinses/day|
11559423|NCT00938067|Experimental|Staying Connected: Care Management|The intervention combines case management, psychopharmacological and culturally appropriate and individually tailored trauma support activities with evidence-based treatments.A key feature is the provision of a continuous healing relationship by a care management treatment team.The care manager, informed by the Native healer interviews, will provide a culturally appropriate and ongoing helping relationship to each intervention patient in the weeks and months post-injury and will remain in close contact with the trauma survivor subject for 6 months.Together, the care manager and trauma survivor subject will work on a plan to readjust to daily activities. The care management team will also coordinate psychopharmacological interventions for PTSD and related co-morbidities with primary care and or other community providers.
11559424|NCT00938041|Experimental|Retreatment of NHL with Iodine-131 Anti-B1 Antibody|Patients with non-Hodgkin's lymphoma who previously responded with a duration of response of at least 3 months to Iodine-131 Anti-B1 Antibody therapy will undergo two phases of study. In the first phase, patients will receive a dosimetric dose of unlabeled Anti-B1 Antibody (450 mg) followed by Anti-B1 Antibody (35 mg) which has been radiolabeled with 5 mCi of Iodine-131. Whole body gamma camera scans will be obtained after the dosimetric dose and data from three imaging time points will be used to calculate a patient-specific dose to deliver the desired total body dose of radiotherapy. In the second phase, patients will receive the therapeutic dose of unlabeled Anti-B1 Antibody (450 mg) followed by 35 mg of Anti-B1 Antibody labeled with the patient-specific dose to deliver the desired whole body dose of radiation. Patients will be treated with thyroid blocking medication at least 24 hours prior to the first infusion and continuing for 14 days following the last infusion.
11559425|NCT00938028||Microbiome, Metabolome, Stool, Toddler|healthy infant stool samples
11559426|NCT00938015||PsA Patients (New)|New patients
11559429|NCT00937976|Other|Intensive Periodontal Therapy|
11559430|NCT00937963|Experimental|Palm Oil|Traditional palm oil normally used in foods
11559431|NCT00937950|Other|HPV-052 study subjects Group|The study group consisted of a subset of HPV-008 (NCT00122681) study subjects (15-25 years old at first study vaccination), who at their last study visit (Visit 10, Month 48) in HPV-008 (NCT00122681) study displayed normal cervical cytology, but were tested positive for oncogenic HPV infection, or were pregnant and hence no cervical sample could be collected at their HPV-008 (NCT00122681) concluding visit.
11559432|NCT00937937|Experimental|Arm I|Patients receive dinaciclib IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11559433|NCT00937924|Placebo Comparator|1|Control. Normal Saline Injections.
11559434|NCT00937924|Experimental|2|Diphenhydramine injections given as adjunct sedative.
11559435|NCT00937924|Experimental|3|Promethazine given as an adjunct sedative.
11559436|NCT00937911|Experimental|YM150 group|
11559437|NCT00937898|Experimental|DASH Diet|High fruit and vegetable, low sodium diet
11559438|NCT00937898|Active Comparator|Average American Diet|Typical American diet (16% protein, ~50% carbohydrate, 33% fat)
11559439|NCT00937885|Experimental|Implementation of reminiscence|Individual and group reminiscence sessions held with residents, supplemented by reminiscence boxes, posters and exhibitions.
11559440|NCT00937885|No Intervention|Usual nursing care|
11559441|NCT00937872|Experimental|SRT2104|Single arm with crossover from single dose of oral suspension formulation to single dose intravenous formulation.
11559442|NCT00937859|Experimental|SER120|SER120
11559443|NCT00937859|Placebo Comparator|Placebo|
11559444|NCT00937846|Experimental|GSK1034702|Single oral 5 mg dose in liquid formulation
11559445|NCT00937833|Experimental|Urethrovesical Sling|Surgisis Male Sling placed at the time of prostatectomy
11559446|NCT00937833|Active Comparator|Control|Prostatectomy
11559447|NCT00937820|Experimental|YM150 group|
11559448|NCT00937807|Active Comparator|sévoflurane|hypnotic use in standard general anesthesia
11559449|NCT00937807|Experimental|LENOXe™ (xénon 100 % v/v)|Safety of use in terms of hemodynamic stability to the LENOXe™ (xénon 100 % v/v) within the framework of the carotid surgery on the old person
11559450|NCT00937794||No treatment|This is a screening study designed to evaluate the behavioral, physical, and neurodevelopmental status in pediatric patients with Hunter syndrome who have early signs and symptoms of CNS involvement and who are currently receiving treatment with Elaprase.
11559451|NCT00937768|Experimental|Arm A (antihormone therapy)|Patients receive leuprolide acetate IM on day 1 OR goserelin acetate SC on day 1. Courses repeat every 3 months for 9 months in the absence of disease progression or unacceptable toxicity.
11559452|NCT00937768|No Intervention|Arm B (no antihormone therapy)|Patients undergo observation every 3 months for 9 months.
11559453|NCT00937755||olanzapine|olanzapine 10-20 mg/day
11559454|NCT00937755||quetiapine|quetiapine 300-600 mg/day
11559455|NCT00937755||risperidone|risperidone monotherapy, 2-4 mg/day
11559456|NCT00937742|Experimental|Non-tomato products|Non-tomato products (i.e. teriyaki marinade, sprite, applesauce) to be consumed daily in replace of tomato products
11559457|NCT00937729||enfuvirtide|all patients would received enfuvirtide and and optimised background
11559458|NCT00937716||Diagnosis of Schizophrenia|Patients with a diagnosis of schizophrenia that have been off antipsychotic medicine and would like to resume treatment will be enrolled in the study.
11559459|NCT00937716||Healthy Volunteers|Healthy Volunteers without a psychiatric diagnosis, central nervous system condition, serious head injury, or current drug use will be matched on an individual basis to schizophrenic participants and used as a control population.
11559460|NCT00937703|Placebo Comparator|Group1: Control group|face to face visit à T4mounths
11559461|NCT00937703|Active Comparator|Group2: IVS Group|face to face visit at T4mounths plus telephone visits each 2 weeks
11559462|NCT00937703|Active Comparator|Group3: PDAphone group|PDA system face to face visit at T4mounths plus telephone visits each 2 weeks
11559463|NCT00937690||infrared imaging of cutaneous lesions|patients and volunteers with cutaneous lesions, with and without clinically detectable melanoma, and with one or more palpable cutaneous lesions
11559464|NCT00937677||1|63 patients with relapsing-remitting Multiple Sclerosis who are enrolled in the TOUCH program and have been taking Tysabri monotherapy for 2 years.
11559465|NCT00937677||2|22 age- and sex-matched normal controls who completed 1 year follow-up.
11559466|NCT00937664|Other|AZD7762 + gemcitabine|AZD7762 administered alone and in combination with gemcitabine
11559467|NCT00937651|Placebo Comparator|Placebo|Placebo, 3 tablets
11559468|NCT00937651|Active Comparator|BR-A-657•K 20 mg group|Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
11559469|NCT00937651|Active Comparator|BR-A-657•K 60 mg group|Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
11559470|NCT00937651|Active Comparator|BR-A-657•K 180 mg group|Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
11559471|NCT00937638|Experimental|Modified-DASH Diet|
11559472|NCT00937638|Experimental|BOLD diet|
11559473|NCT00937638|Experimental|BOLD-X|
11559474|NCT00937612|Experimental|concurrent chemoradiation|patients who has 3 or more minor risk factors of recurrence, and will receive postoperative chemoradiation.
11559475|NCT00937599|Experimental|Brazil Nuts|The first group consumed the brazil nuts and the other group placebo (lactose pills)
11559476|NCT00937586||Newly diagnosed patients|Patients with newly diagnosed prostate cancer.
11559477|NCT00937573||Xience V|Percutaneous coronary intervention with Xience V stent placement
11559478|NCT00937573||Historical BMS|Percutaneous coronary intervention with bare metal stent placement prior to availability of Cypher, Taxus, or Xience V drug eluting stents at WFUBMC
11559479|NCT00937573||Historical DES|Percutaneous coronary intervention with drug eluting stent placement prior to availability of Xience V drug eluting stents at WFUBMC
11559480|NCT00937573||Contemporary BMS|Percutaneous coronary intervention with bare metal stent placement after Xience V drug eluting stents were available for use at WFUBMC
11559670|NCT00936260|Experimental|alendronate 4 years, uncontinued|No treatment during year 4th and 5th
11559481|NCT00937573||Contemporary DES|Percutaneous coronary intervention with Cypher or Taxus drug eluting stent placement after Xience V drug eluting stents were available for use at WFUBMC
11559482|NCT00937560|Experimental|Bevacizumab + paclitaxel + carboplatin|Participants received 6-8 (at the investigator's discretion) 3-week cycles of bevacizumab 7.5 mg/kg intravenously (iv) on Day 1 of each cycle, paclitaxel 80 mg/m^2 iv on Days 1, 8, and 15 of each cycle, and carboplatin iv to an area under the curve of 6 on Day 1 of each cycle. The initial dose of carboplatin was calculated according to the Calvert formula (mg = [glomerular filtration rate + 25] x 6). Following the combination treatments, participants received up to 17 3-week cycles of bevacizumab 7.5 mg/g iv alone.
11559483|NCT00937534|Active Comparator|Part A|Young male healthy volunteer
11559484|NCT00937534|Active Comparator|Part B|Elderly male healthy volunteer
11559485|NCT00937521|Other|1|Vaccine candidate formulation I
11559486|NCT00937521|Other|2|Vaccine candidate formulation II
11559487|NCT00937521|Other|3|Vaccine candidate formulation III
11559488|NCT00937521|Other|4|Vaccine candidate formulation IV
11559489|NCT00937521|Other|5|Vaccine candidate formulation V
11559490|NCT00937521|Other|6|Vaccine candidate formulation VI
11559491|NCT00937521|Other|7|Control
11559492|NCT00937521|Other|8|Vaccine candidate formulation I with antipyretic
11559493|NCT00937508|Placebo Comparator|Smoking counseling, Placebo|
11559494|NCT00937508|Experimental|Smoking counseling, Varenicline|
11559495|NCT00937495|Experimental|Treatment (vorinostat, bortezomib)|Patients receive 400 mg vorinostat orally once daily on days 1-14. Patients also receive 1.3 mg/m^2 bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11559496|NCT00937482|Experimental|Treatment (cediranib maleate and WBRT)|Patients receive oral cediranib maleate on day 1. Patients undergo whole-brain radiotherapy 5 days a week for 3 weeks beginning on day 3. Treatment continues treatment in the absence of disease progression or unacceptable toxicity.
11559497|NCT00937469|Experimental|Social sk. tr., parent tr.,standard tr.|
11559498|NCT00937469|Active Comparator|Standard treatment|
11559499|NCT00937456|Experimental|Laparoscopically-assisted esophagectomy|Laparoscopically-assisted esophagectomy: standard abdominal procedure of gastric mobilisation but through laparoscopic route. Right thoracotomy as usual.
11559500|NCT00937456|Active Comparator|Open esophagectomy|Conventional open esophagectomy: Esophagectomy with extended 2-field lymphadenectomy through laparotomy and right thoracotomy (Ivor-Lewis standard procedure)
11559501|NCT00937443||Walking Exercise Group|Walking Exercise Group versus Control Group
11559502|NCT00937430|Experimental|Bowel preparation group|Patients randomized to this arm will perform a bowel preparation prior to their pelvic organ prolapse surgery.
11559503|NCT00937430|No Intervention|No Bowel preparation group|Patients randomized to this group will not be performing a bowel preparation prior to their pelvic organ prolapse surgery.
11559504|NCT00937417|Experimental|Arm 1|vandetanib and docetaxel
11559505|NCT00937404|Experimental|IPV Group|Healthy male or female subjects between, and including, 60 and 90 days of age at the time of the first vaccination, receive 3 doses of Poliorix at 2 (Study Day 0, Visit 1), 3 (Study Month 1, Visit 2) and 4 (Study Month 2, Visit 3) months of age, administered intramuscularly into the upper right side of the thigh.
11559506|NCT00937391|Experimental|Gadopentetate dimeglumine (Magnevist, BAY86-6661)|For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
11559507|NCT00937378|Experimental|SER120|
11559508|NCT00937378|Placebo Comparator|Placebo|
11559509|NCT00937365|Active Comparator|Exercise|Specific strengthening exercises demonstrated to improve pregnancy-related low back pain are taught to participants of this arm. Additionally, each participant will be evaluated and additional exercises will be prescribed relevant to her particular needs. Study participants of this arm are asked to perform the exercises at home at least once a day. Exercise is recorded in a diary. Participants follow the same study visit schedule as the two other arms.
11559510|NCT00937365|Experimental|Spinal Manipulation|Women randomized to this arm will be evaluated for spinal subluxations and, if appropriate, treated with chiropractic manipulation. Type of manipulation is determined by presentation. Woman may be manipulated with high velocity low amplitude thrust, blocking, activator, or other appropriate means of manipulating.
11559511|NCT00937365|Experimental|Neuroemotional technique (NET)|"Neuroemotional technique (NET) is a mind-body technique which combines elements of chiropractic medicine, Chinese medicine, and behavioral psychology. Muscle response testing, a form of functional neurology, and visceral somatic reflexes are used to ascertain whether the pain or dysfunction experienced by the participant has an emotional component. If an emotional component is present, it is identified and the original triggering occurrence is identified. The participant creates a snapshot of that original occurrence and while she holds that image in her mind spinal levels which innervate the associated organ are adjusted."
11559512|NCT00937352|Active Comparator|Bapineuzumab 0.5 mg/kg|0.5 mg/kg
11559513|NCT00937352|Active Comparator|Bapineuzumab 1.0 mg/kg|1.0 mg/kg
11559514|NCT00937339|Active Comparator|Control|The control group will perform the same exercises on the vibration platform, as in the experimental group. However, the vibration device will be turned off during the exercises.
11559515|NCT00937339|Experimental|Whole body vibration|Subjects in the experimental group will undergo whole body vibration (1 session per day, 3 sessions per week) for 8 weeks. The vibration loading will be carried out using the Jet-Vibe System (Danil SMC Co., Ltd., Seoul, Korea). The vibration protocol used in this study will be 30Hz. While standing on the vibration platform, patients will be instructed to repeat the following set of light exercises: (1) light squatting,(2)deep squatting , (3) side-to-side weight-shift, (4) Forward and backward weight-shift, (5) forward lunge, (6) marching on the spot. The total duration of exposure of whole body vibration per session will be about 10 minutes.
11559661|NCT00936299|Placebo Comparator|Placebo + cognitive behavioral therapy|Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive placebo + CBT.
11559662|NCT00936286|Experimental|Respiratory Muscle Training|
11559516|NCT00937326|Placebo Comparator|Placebo|"The Placebo treatment group will be administered eight placebo capsules per day.
~Placebo will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
11559517|NCT00937326|Active Comparator|Arm1 - 0.25g|"The 0.25g SRT2104 treatment group will be administered one SRT2104 capsules with 7 placebo capsules, for a total of 8 capsules per day.
~0.25g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
11559518|NCT00937326|Active Comparator|Arm2 - 0.5g|"The 0.5g SRT2104 treatment group will be administered two SRT2104 capsules with 6 placebo capsules, for a total of 8 capsules per day.
~0.5g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
11559519|NCT00937326|Active Comparator|Arm3 - 1g|"The 1g SRT2104 treatment group will be administered four SRT2104 capsules with four placebo capsules, for a total of 8 capsules per day.
~1g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
11559520|NCT00937326|Active Comparator|Arm4 - 2g|"The 2g SRT2104 treatment group will be administered eight SRT2104 capsules per day.
~2g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
11559521|NCT00937313||Champagne wine|
11559522|NCT00937313||Placebo|alcohol with sparkling mineral water
11559523|NCT00937287||youth and caregivers|
11559524|NCT00937274|Experimental|Test product|
11559525|NCT00937274|Active Comparator|Commercial product|
11559526|NCT00937274|Placebo Comparator|Standard care|
11559527|NCT00937261|Experimental|Risperdal|Risperdal 2-8mg per day
11559528|NCT00937261|Experimental|Invega|Invega 6-12mg per day
11559529|NCT00937248|Experimental|Interventional|Patient randomized to be immobilized using a prone pillow and simple ankle fixation device with a CVID.
11559530|NCT00937248|Active Comparator|Standard Arm|Patient randomized to be immobilized using a prone pillow and simple ankle fixation device without a CVID
11559531|NCT00937235|Experimental|Integrated Treatment|Prolonged Exposure + Varenicline + Medication Management Counseling
11559532|NCT00937235|Active Comparator|Varenicline|Varenicline + Medication Management Counseling
11559533|NCT00937196|Active Comparator|Histaminum hydrochloricum globuli|To allow double-blind administration of the placebo pills going along with verbal suggestions of a blood-pressure-lowering effect
11559534|NCT00937196|Experimental|Placebo globuli|
11559535|NCT00937196|No Intervention|No treatment|
11559536|NCT00937170|Experimental|Gender Specific LPS flex|Participants in this arm will receive the Zimmer LPS flex Gender Specific Implant design
11559537|NCT00937170|Active Comparator|LPS flex|Participants in this arm will receive the Zimmer High Flex LPS implant
11559538|NCT00937170|Active Comparator|Triathlon|Participants in this arm will receive the Stryker Triathlon Implant design
11559539|NCT00937157|Other|1|Patients diagnosed with multiple sclerosis who have the presence of at least 1 or more Gd enhancing lesions and/or acute relapse.
11559540|NCT00937144|Experimental|viagra|viagra versus placebo will be given to patients with sickle cell anemia
11559541|NCT00937144|Placebo Comparator|placebo|viagra versus placebo will be given to patients with sickle cell anemia
11559542|NCT00937118||Injury Management|Patients with full thickness duodenal laceration undergoing laparotomy and surviving more then 72 hours at our level 1 trauma center in the years 1989-2009. Patients requiring pancreaticoduodenectomy were excluded.
11559543|NCT00937105|Active Comparator|ReNu Multiplus and lotrafilcon A lenses|ReNu Multiplus contact lens care solution
11559544|NCT00937105|Active Comparator|Clear Care solution and lotrafilcon A lenses|Clear Care Contact Lens Care Solution
11559545|NCT00937092|Active Comparator|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
11559546|NCT00937092|Active Comparator|low-dose dopamine + low-dose furosemide|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
11559547|NCT00937066||1|Adult patients 18-65 years with moderate to severe uncontrolled asthma
11559548|NCT00937053|Experimental|Hemoglobin below 120 g/dL|
11559549|NCT00937053|Active Comparator|Hemoglobin below 70 g/dL|
11559550|NCT00937040|Experimental|001|OROS MPH Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
11559551|NCT00937040|Placebo Comparator|002|Placebo Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
11559552|NCT00937027|Active Comparator|Aminopterin one 1.0 mg tablet|
11559553|NCT00937027|Active Comparator|Aminopterin 1 four 0.25 mg tablets|
11559554|NCT00937014|Active Comparator|Standard infant formula|
11559555|NCT00937014|Experimental|Test formula|
11559556|NCT00937001|Experimental|Biopsy/Ultrasound|
11559557|NCT00936988|Experimental|cinacalcet|
11559558|NCT00936975|Experimental|18F-Fluoride PET|Patients undergo fluorine F 18 sodium fluoride PET scan at baseline and then at 12 weeks after initiation of treatment with dasatinib. Dasatinib was administered under a concurrent protocol and was not considered part of the intervention on this protocol
11559559|NCT00936962|Experimental|Group 1 NeisVac C vaccine - 0 doses|NeisVac C (Meningococcal C) vaccine - 0 doses
11559560|NCT00936962|Experimental|Group 2 NeiscVac C - 2 doses|2 priming doses of NeisVac C vaccine at 2 and 4 mths of age
11559561|NCT00936962|Experimental|Group 3 NeiscVac C - 1 dose|1 priming dose of NeisVac C vaccine at 2 mths of age
11559663|NCT00936273||Suspected sleep apnea syndrome|Outpatients with suspected sleep apnea syndrome, age > 18 year
11559664|NCT00936260|Experimental|alendronate 6 years|
11559562|NCT00936949|Active Comparator|posterolateral approach|The posterolateral approach was described by many authors, but all share a common muscular interval in reference to the gluteus medius tendon. Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.
11559563|NCT00936949|Active Comparator|modified lateral approach|The operative technique described modified lateral approach as described by Mulliken et al.
11559564|NCT00936936|Experimental|Cycle # 1|"First Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)
~HD Cycle #1: Gemcitabine/Docetaxel/Melphalan/Carboplatin + PBPC"
11559565|NCT00936936|Experimental|Cycle #2|"Second Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)
~HD Cycle #2: Ifosfamide/Carboplatin/Etoposide + PBPC"
11559566|NCT00936923|Active Comparator|furosemide1|Patients will take furosemide 60mg per day for 1 years and undergo a study assessment at 3, 6, 12, 18, 24 months .
11559567|NCT00936923|Active Comparator|furosemide 2|Patients will take 120mg furosemide per day for 1 years and undergo a study assessment at 3, 6, 12, 18, 24 months .
11559568|NCT00936923|No Intervention|control|Patients in control group will not take furosemide
11559569|NCT00936910|Experimental|Antifungal lock-treated patients|Intestinal failure and other patients with poor IV access and central line fungal-related infections will receive intravenous systemic antifungal therapy plus the instillation of Ambisome locks into the infected catheter.
11559570|NCT00936897|Active Comparator|Ibandronate|Ibandronate 150mg PO QM (tablet)
11559571|NCT00936897|Experimental|Denosumab|denosumab 60mg Subcutaneous Q6M (pre-filled syringe)
11559572|NCT00936884|Experimental|Methylnaltrexone double-blind|Methylnaltrexone once every other day.
11559573|NCT00936884|Placebo Comparator|Placebo|Placebo once every other day.
11559574|NCT00936884|Other|Methylnaltrexone open-label|Subjects who completed the double-blind period had the option to receive methylnaltrexone once every other day during a 12-week, open-label extension period.
11559575|NCT00936871|Experimental|Part A|Lersivirine Tolerability
11559576|NCT00936871|Experimental|Part B|Thorough QTc
11559577|NCT00936858|Experimental|RAD001|RAD001 will be administered orally as once daily dose of 10 mg (one 10mg tablet or two 5mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity.
11559578|NCT00936845||Females with Hemophilia|Females with severe or moderate Hemophilia A or B.
11559579|NCT00936819|Placebo Comparator|Plasma-Lyte A and 25% autologous plasma|
11559580|NCT00936819|Experimental|Autologous EPCs|
11559581|NCT00936819|Experimental|Autologous EPCs Transfected with human eNOS|
11559582|NCT00936806||Unilateral intracranial tumor|Subjects with unilateral intracranial tumor
11559583|NCT00936806||Control group|Subjects without intracranial pathology
11559584|NCT00936780|Experimental|Infinnium-Core™ Paclitaxel eluting Coronary Stent|
11559585|NCT00936767|Experimental|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
11559586|NCT00936767|Active Comparator|Artesunate/Mefloquine (MAS3)|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
11559587|NCT00936754|Experimental|Treatment|Single administration of 500 mg of encapsulated brown seaweed powder, taken 30 minutes before test meal
11559588|NCT00936754|Placebo Comparator|Placebo|Single administration of encapsulated placebo, taken 30 minutes before test meal
11559589|NCT00936741|Experimental|Mifepristone|Mifepristone 300mg to 1200mg once daily
11559590|NCT00936728|Experimental|Arm A (white wine)|Patients consume white wine twice daily for 3-4 weeks.
11559591|NCT00936728|Active Comparator|Arm B (non-wine nutritional supplement)|Patients receive an oral non-wine nutritional supplement (e.g., Boost or Ensure) twice daily for 3-4 weeks.
11559592|NCT00936715|Experimental|FTC/TDF|
11559593|NCT00936702|Experimental|Treatment (carboplatin, paclitaxel, and everolimus)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Patients also receive everolimus PO QD on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11559594|NCT00936689|Sham Comparator|Traditional TACE|Chemoembolization by standard technique: epirubicin (maximum dose of 75 mg) conjugated with an oil-based contrast medium (Lipiodol) at the maximum dose of 15 ml + gelatin sponge particles(particles of transient embolization material, required to obstruct the treated vessel).
11559595|NCT00936689|Active Comparator|TACE with microsphere|
11559596|NCT00936676||Rasagiline mesylate|Enrollment by invitation to participates from the ADAGIO trial
11559597|NCT00936663|Experimental|Sitagliptin 100 mg daily|sitagliptin 100 mg daily
11559598|NCT00936663|Placebo Comparator|placebo|placebo
11559599|NCT00936650|Experimental|cinacalcet|
11559600|NCT00936650|Placebo Comparator|placebo|
11559601|NCT00936637|Experimental|Extensively hydrolyzed infant formula|
11559602|NCT00936624|Experimental|SOTB07 100mg|
11559603|NCT00936624|Experimental|SOTB07 200mg|
11559604|NCT00936624|Placebo Comparator|Placebo|
11559605|NCT00936624|Active Comparator|Montelukast 10mg|
11559606|NCT00936611|Experimental|LBH589|
11559607|NCT00936598|Experimental|zolpidem|Participants randomized to the zolpidem (intervention) group will receive the FDA approved dose of zolpidem, (10 mg for women <65; 5 mg for women > or = 65 years). For the purposes of this double-blind trial, zolpidem (e.g., Roxane Laboratories) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.
11559665|NCT00936260|Experimental|alendronate 5 years|No treatment during year 6th
11559666|NCT00936260|Experimental|alendronate 5 years, not continued|No treatment during year 5th
11559667|NCT00936260|Experimental|alendronate 4 years|No treatment during year 5th and 6th
11559668|NCT00936260|Experimental|alendronate 5 years, uncontinued|No treatment during year 4th
11559608|NCT00936598|Placebo Comparator|sugar pill|Participants randomized to the sugar pill (control) group will receive placebo. For the purposes of this double-blind trial, placebo (sugar) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.
11559609|NCT00936585|Other|Immunologic Monitoring|Blood draws and colonoscopy performed on patients enrolled in both intervention arms of the main study
11559610|NCT00936572|Experimental|high dose|high dose of probiotics (109 cfu)
11559611|NCT00936572|Experimental|low dose|low dose of probiotics (107 cfu)
11559612|NCT00936572|Placebo Comparator|probiotics|Maltodoxtrin
11559613|NCT00936559|Experimental|1|Arm A
11559614|NCT00936559|Experimental|2|Arm B
11559615|NCT00936559|Experimental|3|Arm C
11559616|NCT00936546|Experimental|Rituximab|
11559617|NCT00936520|Experimental|Dose 1|SAR 1118 dose 0.1%
11559618|NCT00936520|Experimental|Dose 2|SAR 1118 dose 1.0%
11559619|NCT00936520|Experimental|Dose 3|SAR 1118 dose 5.0%
11559620|NCT00936507|Experimental|Low-ED, small portion|
11559621|NCT00936507|Experimental|Low-ED, large portion|
11559622|NCT00936507|Experimental|High-ED, small portion|
11559623|NCT00936507|Experimental|High-ED, large portion|
11559624|NCT00936494|No Intervention|Control|No inferior turbinate surgery.
11559625|NCT00936494|Other|Intervention|Intervention group: Cold ablation inferior turbinate reduction utilizing radiofrequency ablation surgery (CITR).
11559626|NCT00936481||Healthy controls|18 years or older with body mass index between 25-45
11559627|NCT00936481||Obstructive Sleep Apnea Group|Age 18 years or older with body mass index between 25 and 45
11559628|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (3.75ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 3.75ug given by IM injection to the upper deltoid.
11559629|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (7.5ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 7.5ug given by IM injection to the upper deltoid.
11559630|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (25ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 25ug given by IM injection to the upper deltoid.
11559631|NCT00936468|Experimental|Fluzone® vaccine alone|One vaccination on Day 0 with Fluzone vaccine at 45 ug given by IM injection in the upper deltoid.
11559632|NCT00936455||Telemedicine|Telemedicine evaluated patients
11559633|NCT00936455||Telephone|Telephone evaluated patients
11559634|NCT00936442||Group A|Standard treatment: 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
11559635|NCT00936442||Group B|Standard treatment + educational material: 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice plus reception of educational material on regular basis.
11559636|NCT00936429|Experimental|10 µg DEN1-80E + 3.5 mg Alhydrogel|Administration of 10 µg DEN1-80E vaccine at Weeks 0, 4, and 8.
11559637|NCT00936429|Experimental|50 µg DEN1-80E + 3.5 mg Alhydrogel|Administration of 50 µg DEN1-80E vaccine at Weeks 0, 4, and 8.
11559638|NCT00936429|Placebo Comparator|Placebo|Administration of placebo vaccine at Weeks 0, 4, and 8.
11559639|NCT00936416|Experimental|GFR and RBF followed by MRI|Subjects will undergo GFR and renal blood flow estimation by Inulin and PAH clearance method, followed by a MRI test. The MRI examination will be performed on the same day as the inulin/PAH procedure.
11559640|NCT00936403|Experimental|NNC126-0083|
11559641|NCT00936403|Active Comparator|Norditropin NordiFlex®|
11559642|NCT00936390|Active Comparator|Arm I|Patients undergo external-beam radiation therapy (EBRT) once daily on days 1-5. Some patients instead receive EBRT with high-dose rate or low-dose rate brachytherapy implant.
11559643|NCT00936390|Experimental|Arm II|Patients receive androgen-deprivation therapy comprising luteinizing-hormone releasing-hormone (LHRH) agonist (leuprolide, goserelin, buserelin, or triptorelin) subcutaneously or as an injection every 1 to 3 months AND an oral antiandrogen therapy (flutamide 3 times daily or bicalutamide once daily) for 6 months. Beginning 8 weeks after the first LHRH injection, patients undergo radiotherapy as in arm I.
11559644|NCT00936377|Experimental|Dexmedetomidine, low dose|Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
11559645|NCT00936377|Experimental|Dexmedetomidine, high dose|Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
11559646|NCT00936377|Placebo Comparator|Placebo|Normal saline
11559647|NCT00936364|Experimental|Group I (Stage I of study)|Patients fast for 24 hours on day -1
11559648|NCT00936364|Experimental|Group II (Stage I of study)|Patients fast for 48 hours on days -2 and -1
11559649|NCT00936364|Experimental|Group III (Stage I of study)|Patients fast for 72 hours on days -3, -2, and -1
11559650|NCT00936364|Experimental|Group IV (Stage I of study)|Patients undergo a modified 48-hour fast with minimal caloric intake on day -2 and -1
11559651|NCT00936351|Experimental|Arm 1|Mindfulness Meditation
11559652|NCT00936351|Active Comparator|Arm 2|Support Group that involves discussion of work-related issues in which participants are facilitated to assist each other with problem solving and offer support
11559653|NCT00936338|Active Comparator|splint|
11559654|NCT00936338|Active Comparator|joint mobilization self exercise|
11559655|NCT00936325||Healthy volunteers|healthy volunteers to act as controls.
11559656|NCT00936325||Patients with SCLS|patients who have been diagnosed, or are suspected of having systemic capillary leak syndrome.
11559657|NCT00936325||Relatives|relatives of patients who have systemic capillary leak syndrome.
11559658|NCT00936312||Females with Hemophilia|Females with severe or moderate Hemophilia A or B
11559659|NCT00936312||Control group|Male subjects with severe Hemophilia A or B and female subjects with mild (20-60%) Hemophilia A or B.
11559660|NCT00936299|Active Comparator|Bupropion + cognitive behavioral therapy|Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive bupropion + CBT.
11559669|NCT00936260|Experimental|alendronate 4 years, not continued|No treatment during year 4th and 6th
11559671|NCT00936260|Experimental|Alendronato 3 years|No treatment during the last 3 years
11559672|NCT00936247|Experimental|1|HES 130/0.42 + Sterofundin ISO
11559673|NCT00936247|Active Comparator|2|Albumin + NaCl 0.9%
11559674|NCT00936234|Active Comparator|Vildagliptin|starting with vildagliptin for 30 days followed by placebo for 30 days
11559675|NCT00936234|Placebo Comparator|Placebo|starting with placebo for 30 days followed by vildagliptin for 30 days
11559676|NCT00936221|Active Comparator|1|AZD6244 in combination with dacarbazine
11559677|NCT00936221|Placebo Comparator|2|Placebo in combination with dacarbazine
11559678|NCT00936208||Essential hypertensive men and women|
11559679|NCT00936195|Active Comparator|Atripla (R)|
11559680|NCT00936195|Active Comparator|Combivir (R) + Kaletra (R) or Aluvia (R)|
11559681|NCT00936182|Experimental|Fluconazole|
11559682|NCT00936182|Placebo Comparator|Placebo|Placebo capsule daily for 30 days
11559683|NCT00936169|Experimental|IVUS optimised stent implantation|
11559684|NCT00936169|Active Comparator|angiographically guided DES implantation|
11559685|NCT00936156|Experimental|Chemotherapy|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
11559686|NCT00936143|Experimental|infliximab|200mg infliximab inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
11559687|NCT00936130||Lifestyle counseling|This group will be comprised of participants on a low calorie diet program.
11559688|NCT00936130||Weight Loss Surgery|This group will be comprised of participants having weight loss surgery: Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy.
11559689|NCT00936117|Experimental|Posaconazole|Posaconazole 200 mg (liquid) by mouth 3 times per day.
11559690|NCT00936104||SP in PDAC|Side population cells isolated from resection specimens obtained from patients with pancreatic cancer
11559691|NCT00936091|Placebo Comparator|placebo|125 schoolchildren were allocated randomly to receive placebo
11559692|NCT00936091|Active Comparator|vitamin A supplement|125 children received vitamin A supplements capsules (200 000 IU)
11559693|NCT00936078||Non-donors/controls|People who have not donated a kidney.
11559694|NCT00936078||Living Kidney Donors|
11559695|NCT00936065|Active Comparator|Group A|
11559696|NCT00936065|Experimental|Group B|
11559697|NCT00936065|Active Comparator|Group C|
11559698|NCT00936039|Experimental|unloading|2 weeks of unloading
11559699|NCT00936013|Experimental|oseltamivir|single antiviral treatment
11559700|NCT00936013|Experimental|oseltimivir and chinese medicinal herbs|combination treatment
11559701|NCT00936000|Active Comparator|protandim therapy for 7 days|
11559702|NCT00936000|Placebo Comparator|placebo arm|Individuals will receive a placebo equivalent in two equally divided doses for seven days
11559703|NCT00935987|Experimental|CYT387|
11559704|NCT00935961|Experimental|RAD001 + docetaxel + cisplatin|In this phase I trial, the primary endpoint will be considered to be reached when we have described a phase II recommended dose of RAD001 given with docetaxel + cisplatin as induction chemotherapy for head and neck cancer. Up to 3 dose levels of daily RAD001 will be studied. A standard 3 + 3 phase I dose escalation design will be used. The phase II recommended dose will be determined according to the dose escalation plan.
11559705|NCT00935948|Active Comparator|Imescard ointment|
11559706|NCT00935948|Placebo Comparator|Placebo|
11559707|NCT00935935||HIV older than 50 years|
11559708|NCT00935922|Placebo Comparator|Soybean oil bar|A nutrition bar enriched with soybean oil
11559709|NCT00935922|Experimental|Flaxseed bar with low lignans|A nutrition bar enriched with flaxseed oil
11559710|NCT00935922|Experimental|Flaxseed bars with high lignans|A nutrition bar enriched with flaxseed oil and high lignans
11559711|NCT00935896|No Intervention|high VT group|
11559712|NCT00935896|Experimental|Low tidal volume|
11559713|NCT00935883|Placebo Comparator|Saline|Randomized patients in the drusen or the GA cohort will receive placebo saline infusions as a comparator
11559714|NCT00935883|Active Comparator|Eculizumab|Randomized patients in the drusen or the GA cohort will receive active treatment with eculizumab
11559715|NCT00935870||A|DEPRESSED LATERAL CONDYLE FRACTURE
11559716|NCT00935870||B|BENIGN BONE TUMOR
11559717|NCT00935870||C|SPINAL FUSION
11559718|NCT00935857|Experimental|Balloon Colonoscopy|Colonoscopy using the single balloon colonoscopy system (novel endoscope to facilitate difficult colonoscopy).
11559719|NCT00935857|Active Comparator|Standard Colonoscopy|Colonoscopy using a standard adult colonoscope
11559720|NCT00935844|Experimental|TAK-901 Arm|
11559721|NCT00935831|Experimental|Subjects with renal impairment, non-dialysis|Subjects with moderate to severe renal impairment equivalent to National Kidney Foundation Kidney Disease Outcomes Quality Initiative stage 3 and stage 4 who are not undergoing dialysis will be included. Subjects will receive single 50 mg and 150 mg oral doses of GSK1278863A across two dosing periods in a single-blind, randomized sequence. Doses of GSK1278863A will be given as 25 mg and 100 mg tablets, with matching placebo tablets to maintain treatment blinding.
11559722|NCT00935831|Experimental|Healthy volunteers|Healthy subjects will be matched to the moderate and severe renally impaired subjects for gender, age, and BMI. Subjects will receive single 50 mg and 150 mg oral doses of GSK1278863A across two dosing periods in a single-blind, randomized sequence. Doses of GSK1278863A will be given as 25 mg and 100 mg tablets, with matching placebo tablets to maintain treatment blinding.
11559767|NCT00935493|Placebo Comparator|Placebo po qhs|
11559768|NCT00935480|Experimental|HAART+Raltegravir 12 months (+/-) Maraviroc|
11559769|NCT00935480|No Intervention|HAART|
11559723|NCT00935831|Experimental|Hemodialysis dependent subjects|The arm will consist of subjects with severe renal impairment (end-stage renal failure) who have been on stable hemodialysis treatment scheduled three times per week. Subjects will receive single oral doses of 150 mg GSK1278863A in each of 2 dosing periods in an open-label, fixed sequence. GSK1278863A will be administered just prior to receiving scheduled hemodialysis in Dosing Period 1. In Dosing Period 2, subjects will receive a single oral dose of GSK1278863 the morning after completion of a scheduled hemodialysis session.
11559724|NCT00935818|Active Comparator|varenicline and buproprion SR|Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
11559725|NCT00935818|Placebo Comparator|varenicline and placebo|Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
11559726|NCT00935805||Treatment|124 patients attending the primary care unit included after formal consent.
11559727|NCT00935792|Experimental|Arm I|Patients receive oral everolimus thrice weekly for 9 weeks and alemtuzumab subcutaneously thrice weekly for 8 weeks.
11559728|NCT00935779||Gastric cancer|patients with operable local gastric adenocarcinoma were studied
11559729|NCT00935779||Control group|patients operated on for benign diseases served as controls, randomly selected among patients with chronic gastro-esophageal reflux disease who were considered good candidates for antireflux surgery and properly matched in sex and age to study group
11559730|NCT00935766|Placebo Comparator|Sugar Pill|4 tabs of placebo dependent on randomization
11559731|NCT00935766|Active Comparator|Omega 3|omega-3-acid ethyl esters and instructed to take 4 1 mg capsules daily
11559732|NCT00935753|Experimental|Kuvan|10mg/kg Kuvan for 5 days followed by 20mg/kg Kuvan for a total of 60 days
11559733|NCT00935740||Age-Matched Healthy Controls|Age-Matched Healthy Controls
11559734|NCT00935740||Heart Failure|Subjects with LVEF < 40%
11559735|NCT00935727|Other|1|normally functioning transplanted kidneys
11559736|NCT00935727|Other|2|transplanted kidney undergoing known rejection or other known abnormality
11559737|NCT00935727|Other|3|transplanted kidney with unknown diagnosis
11559738|NCT00935714|Active Comparator|Muscle Group|Exercise
11559739|NCT00935714|Active Comparator|Sequence|Exercise
11559740|NCT00935701|Experimental|Acupuncture and Acupressure|In Phase 1, 10 children with ASD will receive acupressure for four weeks. At week 5, they will be introduced to acupuncture which will be continued throughout the rest of the study as tolerated. In Phase 2, 40 children with ASD will receive acupressure twice weekly for 12 weeks. Parents will be trained in the acupressure techniques and will be asked to do this daily, at bedtime, and/or as requested by the child or deemed needed by the parent. Children will begin to be assessed for their ability to participate in acupuncture treatment between weeks 5 and 7 at the discretion of the acupuncturist. By week 7, all children will have been introduced to acupuncture/needling. If needling is still refused at this time, acupressure will continue for the remainder of the study.
11559741|NCT00935688|Experimental|Rapid diagnostic tests|malaria diagnosis by rapid diagnostic test
11559742|NCT00935688|No Intervention|Clinic Microscopy|malaria diagnosed with field light-microscopy
11559743|NCT00935688|No Intervention|Clinical Diagnosis|Malaria diagnosed on the basis of clinical symptoms alone (i.e. not laboratory diagnosis)
11559744|NCT00935675|Active Comparator|Antidepressant treatment|
11559745|NCT00935675|Placebo Comparator|Placebo|
11559746|NCT00935662|Experimental|AZD8329|AZD8329 oral solution
11559747|NCT00935662|Placebo Comparator|Placebo|Placebo for AZD8329 oral solution
11559748|NCT00935649|Experimental|Randomized great toe|Subjects with both great toes infected. Right/left randomized to treatment / no treatment
11559749|NCT00935649|No Intervention|Untreated Toe|
11559750|NCT00935623|Experimental|Cohort 1|The first cohort will be challenged with 5 bites from P. vivax-infected mosquitoes each carrying at least a grade 2 sporozoite infection (>10 sporozoites in salivary gland).
11559751|NCT00935623|Experimental|Cohort 2|If the first cohort has less than 100% infectivity rate, the second cohort will be challenged with up to 10 grade 2 infective bites to ensure 100% infectivity rate.
11559752|NCT00935610|Active Comparator|Immunocal|20g of Immunocal
11559753|NCT00935610|Placebo Comparator|Casein|20g of Casein
11559754|NCT00935597|Experimental|Group 1|Patients with Minimal Residual Disease or Minimal Volume Relapse post allogeneic stem cell transplant will receive MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) by infusion
11559755|NCT00935597|Experimental|Group 2|Patients with greater than Minimal Residual Disease or Minimal Volume Relapse post allogeneic stem cell transplant will receive MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) by infusion in conjunction with donor lymphocyte infusion (DLI)
11559756|NCT00935584|Other|PACE Study|"The study utilized a quasi-experimental pre-post intervention design. The intervention provided was physician education to improve EMR use and communication.
~Physician training in patient-centered EMR use was developed. The conceptual model of patient-centered communication will provide the underlying framework for the training aimed at improving physicians interviewing and communication skills."
11559757|NCT00935571||Group I, Group II|"Group I: anesthetized with TIVA (Propofol + Remifentanil)
~Group II: anesthetized with inhalation (sevoflurane)"
11559758|NCT00935558|Experimental|Aromatase inhibitor and DC vaccination|the HLA-A2 positive patients will be treated with AI, DC vaccines, Zadaxin and IL-2
11559759|NCT00935558|Active Comparator|Aromatase inhibitor|the HLA-A2 negative patients will receive AI only
11559760|NCT00935545|Experimental|Open Label|
11559761|NCT00935532|Experimental|exenatide once weekly|
11559762|NCT00935532|Active Comparator|insulin glargine|
11559763|NCT00935519|Other|ceramic bearing|Survival rate of THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 5 years follow-up.
11559764|NCT00935506|Experimental|Clopidogrel + Aspirin|
11559765|NCT00935493|Experimental|Guanfacine 0.1 mg po qhs|
11559766|NCT00935493|Experimental|Guanfacine 0.5 mg po qhs|
11559770|NCT00935467|Other|Saxagliptin|
11559771|NCT00935441|Experimental|Telemonitoring|Case management with home telemonitoring for blood sugar and blood pressure plus home HbA1c measurement
11559772|NCT00935441|Active Comparator|Usual case management|Case management
11559773|NCT00935415|Active Comparator|Montelukast|capsules prepared in blindness
11559774|NCT00935415|Placebo Comparator|Placebo|matched placebo
11559775|NCT00935402|Experimental|Short Sleep|Subjects are permitted to spend 4 hours in bed per night for 5 consecutive nights. Subjects are inpatients for a period of 6 days.
11559776|NCT00935402|Active Comparator|Regular Sleep|Subjects are permitted to spend 9 hours in bed per night for 5 nights. Subjects are inpatients for a period of 6 days.
11559777|NCT00935389|Experimental|immunosuppressor|TW 30mg,q.d.*3 months and reduced into 20mg b.i.d
11559778|NCT00935376|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP)to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
11559779|NCT00935376|Experimental|Mindfulness Meditation Program|Mindfulness Meditation Program (MMP) is based on Mindfulness-Based Stress Reduction (MBSR), which teaches participants mindfulness skills such as meditation and yoga. Mindfulness may be defined as paying attention in a particular way, on purpose, in the present moment, and nonjudgmentally. The goal of MBSR is to provide participants with experiential tools and mindfulness practices to assist them to become more mindful of themselves, others and their external environment. The techniques are easy to learn and teach individuals to be aware of the present moment, with an open mind in which they can perceive their thoughts, physical sensations, and emotions nonjudgmentally.
11559780|NCT00935376|Active Comparator|Sleep Education Program|The Sleep Education Program (SEP) will serve as the control intervention in which participants will receive classes informing them how to change their habits to improve their sleep, and what to do if they have concerns about their sleep quality.
11559781|NCT00935363|Experimental|glyburide + fluconazole|
11559782|NCT00935363|Experimental|glyburide + rifampin|
11559783|NCT00935363|Active Comparator|glyburide|
11559784|NCT00935363|Experimental|glyburide + fluconazole + rifampin|
11559785|NCT00935350|Placebo Comparator|1|Control White bread containing 50g available carbohydrate
11559786|NCT00935350|Placebo Comparator|2|White bread and milk control
11559787|NCT00935350|Placebo Comparator|3|Granola control
11559788|NCT00935350|Placebo Comparator|4|Cornflakes and milk control
11559789|NCT00935350|Placebo Comparator|5|White rice control
11559790|NCT00935350|Placebo Comparator|6|Fruit yogurt control
11559791|NCT00935350|Placebo Comparator|7|Turkey dinner control
11559792|NCT00935350|Experimental|8|Granola
11559793|NCT00935350|Experimental|9|Cornflakes and milk
11559794|NCT00935350|Experimental|10|White Rice
11559795|NCT00935350|Experimental|11|Fruit yogurt
11559796|NCT00935350|Experimental|12|Turkey dinner
11559797|NCT00935350|Placebo Comparator|13|White Bread
11559798|NCT00935350|Placebo Comparator|14|White bread
11559799|NCT00935350|Experimental|15|Granola
11559800|NCT00935337|Experimental|Mind-Body Bridging Program|Mind Body Bridging subjects will be accessed with questionnaires and medical history evaluations for the impact of MBBP over the past 6 months since undertaking the program.
11559801|NCT00935337|Active Comparator|Sleep Hygiene|Sleep Hygiene subjects will be accessed with questionnaires and medical history evaluations for the impact of SH over the past 6 months since undertaking the program.
11559802|NCT00935324||Group A: patients following allo-SCT|Patients scheduled for allo-SCT fulfilling all inclusion criteria
11559803|NCT00935324||Group B - healthy controls|healthy voluntary blood donors
11559804|NCT00935311|Experimental|ABT-712|1 dose of 1 ABT-712 extended-release tablet plus 1 placebo tablet, followed by 1 dose of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
11559805|NCT00935311|Active Comparator|Hydrocodone/Acetaminophen|2 doses of 1 hydrocodone/acetaminophen immediate-release tablet plus 1 placebo tablet, administered once every 6 hours for 12 hours (for a total of 2 doses).
11559806|NCT00935311|Placebo Comparator|Placebo|2 doses of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
11559807|NCT00935298|Experimental|T|"The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation.After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5*1/*3 and *1/*1 ,expressors; CYP3A5*3/*3 nonexpressor）.
~The objective is to determine the initial dosage Range of tacrolimus in Chinese renal transplantation patients by genotyping of the cytochrome P450 3A5"
11559808|NCT00935272|Experimental|Treatment|Restylane® Treatment
11559809|NCT00935272|No Intervention|Non-Treatment|Non-Treatment Arm
11559810|NCT00935259|Experimental|Simvastatin 40 mg first, then placebo|Simvastatin 40 mg tablets once daily for 2 weeks followed by placebo for 2 weeks
11559811|NCT00935259|Placebo Comparator|Placebo first, then simvastatin 40 mg once daily|Placebo for 2 weeks followed by simvastatin 40 mg once daily for 2 weeks
11559812|NCT00935246|Experimental|Antidepressant treated group|Antidepressant treated group: depressed patients treated with Escitalopram
11559813|NCT00935246|No Intervention|other antidepressant treated group|other Antidepressant treated group: depressed patients treated with other antidepressant without escitalopram
11559814|NCT00935220|Experimental|linagliptin|Pharmacokinetic (PK)/Pharmacodynamic (PD) investigation
11559815|NCT00935207||Pediatric Pain Diary|Patients will be give a pain diary to complete.
11559816|NCT00935194|Experimental|blank|do not take antiviral therapy
11559817|NCT00935194|Experimental|Oseltamivir|antiviral therapy
11559818|NCT00935194|Experimental|chinese medicinary herbs|antiviral therapy
11559819|NCT00935194|Experimental|oseltalmivir and chinese medicinal herbs|combination antiviral therapy
11559906|NCT00934596|Experimental|Lund de-airing|Lund de-airing technique
11559907|NCT00934596|Active Comparator|Carbon-dioxide insufflation|carbon-dioxide insufflation will be provided to the open mediastinal wound in a standardized manner
11559820|NCT00935181|Experimental|exercise training program|The exercise training program consisted of three 90-minute sessions per week for eight weeks. Each session consisted of a stretching exercise, resistance that patients started at 70% of the initial one-repetition maximum (1RM: the maximum load which can be moved only once over the full range of motion without compensatory movements) in the first week (3x8 repetitions). Every week the load was increased by 5% of the 1RM, and endurance training (treadmill walking speed was set at 60% of the average speed obtained from the 6MWT (6MWTpeak) for 10 mins in the first week and was increased to 20 mins in week 8
11559821|NCT00935168|Experimental|Hydroxy-ethyl starch|Intravenous fluid resuscitation with 6% Hydroxy-ethyl starch (130/0.4)
11559822|NCT00935168|Active Comparator|Saline|Intravenous fluid resuscitation with saline (0.9% sodium chloride)
11559823|NCT00935155|Experimental|Acupuncture|Acupuncture in combination with exercise therapy
11559824|NCT00935155|Active Comparator|exercises|Coordination, mobilizing, endurance, strength
11559825|NCT00935129|Experimental|OmniPod system|At this arm patients will be treated with the OmniPod system for 12 weeks
11559826|NCT00935129|Active Comparator|patient's conventional pump|At this arm patients will be treated with their conventional pump for 12 weeks
11559827|NCT00935116|Active Comparator|etoricoxib|"G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.
~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery"
11559828|NCT00935103|Active Comparator|Psychoeducation|Psycheducation
11559829|NCT00935103|No Intervention|Control|The control group will not take any intervention
11559830|NCT00935090|Experimental|3'-deoxy-3'-[18F]fluorothymidine|The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body.
11559831|NCT00935077|Experimental|24 Month PPCM BP|A 24 month long physician/pharmacist collaborative intervention is implemented to manage hypertension
11559832|NCT00935077|Experimental|9 Month PPCM BP|A 9 month long physician/pharmacist collaborative intervention is implemented to manage hypertension
11559833|NCT00935077|Sham Comparator|PPCM Asthma|A 9 month long physician/pharmacist collaborative intervention is implemented to manage asthma
11559834|NCT00935077|No Intervention|BP Control Arm|No PPCM intervention
11559835|NCT00935064|Active Comparator|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
11559836|NCT00935064|Placebo Comparator|Placebo|
11559837|NCT00935051|Experimental|Arm 1|There is only one group of patients. Thus there is only one arm. Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. A numeric photograph of the wound will be taken at week 0, week 4 and week 12.
11559838|NCT00935025|Experimental|1, AZD1305|
11559839|NCT00935025|Placebo Comparator|2, Placebo|
11559840|NCT00935012|Experimental|Open-Label|
11559841|NCT00934999|Active Comparator|Burch|Patients will receive a Burch urethropexy at the time of an abdominal sacral colpopexy.
11559842|NCT00934999|Experimental|Mid-urethral sling|Patients will receive a mid-urethral sling at the time of an abdominal sacral colpopexy.
11559843|NCT00934973|Active Comparator|mebeverine + no website|Mebeverine 135mg tds for 6 weeks
11559844|NCT00934973|Active Comparator|methylcellulose + no website|methylcellulose 3 tablets twice a day for 6 weeks
11559845|NCT00934973|Placebo Comparator|placebo + no website|placebo tablets
11559846|NCT00934973|Active Comparator|mebeverine + CBT website minimal support|mebeverine 135mg tds and access to website
11559847|NCT00934973|Active Comparator|methylcellulose + CBT website|methylellulose 3 tablets twice a day and access to website
11559848|NCT00934973|Placebo Comparator|placebo + CBT website minimal support|placebo tablets and access to website
11559849|NCT00934973|Active Comparator|mebeverine + CBT website with support|mebeverine 135mg tds and access to website with nurse support session
11559850|NCT00934973|Active Comparator|methylcellulose + CBT website support|methylcellulose 3 tablets twice a day and access to website with nurse support
11559851|NCT00934973|Placebo Comparator|placebo + CBT website with support|placebo tablets and access to website with nurse support
11559852|NCT00934947|Placebo Comparator|Sugar pill|
11559853|NCT00934947|Experimental|Propranolol, Propanolol ER|
11559854|NCT00934934|Placebo Comparator|Placebo|Saline will serve as the placebo solution since the active comparator is clear and colourless.
11559855|NCT00934934|Active Comparator|Antifungal|Patient will receive a dose daily for a total of 14 days
11559856|NCT00934921|Experimental|Ondansetron|Ondansetron HCl 8 mg Orally Disintegrating Tablet (test) dosed in first period followed by Zofran® 8 mg ODT (reference) dosed in second period
11559857|NCT00934921|Active Comparator|Zofran®|Zofran® 8 mg ODT (reference) dosed in first period followed by Ondansetron HCl 8 mg Orally Disintegrating Tablet (test) dosed in second period
11559858|NCT00934908|Placebo Comparator|1|"Non-active sugar pill"
11559859|NCT00934908|Active Comparator|2|Green Tea Capsules
11559860|NCT00934895|Experimental|Phase I / Phase II|"Phase I:
~Abraxane will be given by IV for 30 minutes on the first day of the first three weeks of each 28 day cycle.
~RAD001 will be given by tablet. The first group of patients will receive RAD001 once daily depending on side effects seen drug could be increased later to twice a day for a 28 day cycle.
~Once a safe and effective drug range is established, the study moves into Phase II.
~Phase II:
~The maximum tolerated dose (established in Phase I) will be given as scheduled below and we will measure the effectiveness of the study drug combination.
~Abraxane will be given by IV (intravenous infusion) for 30 minutes on the first day of the first three weeks of each 28 day cycle (Day 1, Day 8, and Day 15 of each cycle).
~RAD001 will be given by tablet based on the dose established in the Phase I part of the study."
11559861|NCT00934882|Experimental|Arm 1|
11559862|NCT00934869||Metacarpal Shaft Fractures|
11559863|NCT00934856|Experimental|MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (over 2 days)|Participants with human epidermal growth factor receptor 2 (HER2)-positive MBC will receive docetaxel (Doc) 75 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Day 1 and T-DM1 2.4 milligrams per kilogram (mg/kg) IV infusion on Day 2 of Cycle 1 followed by T-DM1 75 mg/m^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 75 mg/m^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
11559864|NCT00934856|Experimental|MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (over 2 days)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m^2 IV infusion on Day 1 and T-DM1 2.4 mg/kg IV infusion on Day 2 of Cycle 1 followed by T-DM1 60 mg/m^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
11559865|NCT00934856|Experimental|MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (same day)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m^2 IV infusion and T-DM1 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
11559866|NCT00934856|Experimental|MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (same day)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m^2 IV infusion and T-DM1 3.6 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 will be stopped and T-DM1 3.6 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
11559867|NCT00934856|Experimental|LABC: T-DM1 + Doc (Doublet Regimen)|Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg IV infusion and docetaxel 60/75/100 mg/m^2 IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.
11559868|NCT00934856|Experimental|LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)|Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg Iv infusion, docetaxel 60/75 mg/m^2 IV infusion, and pertuzumab 840 mg (for Cycle 1) or 420 mg (for remaining cycles) IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.
11559869|NCT00934843|Experimental|Single dose steroid|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB) machine in the first month of life that receive ONE dose intravenous methylprednisolone (IVMP) prior to heart surgery.
11559870|NCT00934843|Experimental|Two Dose steroid|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB) machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
11559871|NCT00934830|Active Comparator|Antibiotic|
11559872|NCT00934830|Experimental|Therapeutic ultrasound|
11559873|NCT00934817|Experimental|TR sequential group|Amaryl-M 1/500 mg in period 1, Amaryl-M 2/500 mg in period 2
11559874|NCT00934817|Active Comparator|RT sequential group|Amaryl-M 2/500 mg in period 1, Amaryl-M 1/500 mg in period 2
11559875|NCT00934804|Experimental|Comparative Diagnostic system|Galilei dual Scheimpflug analyzer
11559876|NCT00934791|Active Comparator|Control Group|Tacrolimus, mycophenolate mofetil, and prednisone
11559877|NCT00934791|Active Comparator|Sirolimus Group|Sirolimus, mycophenolate mofetil, and prednisone
11559878|NCT00934778|Experimental|Bronchoscopy|
11559879|NCT00934752|Experimental|Lutonix Catheter|
11559880|NCT00934739|No Intervention|Control|Standard postoperative concurrent chemoradiotherapy
11559881|NCT00934739|Experimental|Thalidomide, Celebrex|Adjuvant anti-angiogenesis therapy
11559882|NCT00934739|Active Comparator|Cyclophosphamide, Dexamethasone|Adjuvant anti-angiogenesis therapy
11559883|NCT00934726||1 group, schizophrenia patients|Patients with schizophrenia according to ICD-10(diagnostic and statistical manual of mental disorders)
11559884|NCT00934713|Active Comparator|montelukast|montelukast 4 mg once per day for 8 weeks
11559885|NCT00934700|Experimental|Combination of hypothermia and xenon|Combination of hypothermia and inhaled xenon
11559886|NCT00934700|No Intervention|Hypothermia and standard intensive care|Hypothermia and standard intensive care
11559887|NCT00934687|Experimental|clostridium botulinum toxin type A neurotoxin complex|A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.
11559888|NCT00934687|Placebo Comparator|0.9% sodium chloride NaCl solution|0.9% NaCl solution will be injected like the experimental compound
11559889|NCT00934674|Experimental|1|Commercial Tablet manufactured by Excella
11559890|NCT00934674|Experimental|2|Clinical Tablet manufactured by Wyeth Montreal
11559891|NCT00934661|Experimental|Extended Release Epidural Morphine|Four mg (0.4 ml) of EREM will be delivered to the epidural space and flushed with 1 ml of saline
11559892|NCT00934661|Placebo Comparator|Placebo Group|The epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
11559893|NCT00934648|Experimental|1|
11559894|NCT00934635|Active Comparator|002|Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 2 hours
11559895|NCT00934635|Active Comparator|003|Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 2 hours
11559896|NCT00934635|Active Comparator|004|Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 2 hours
11559897|NCT00934635|Active Comparator|005|Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 24 hours
11559898|NCT00934635|Active Comparator|006|Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 24 hours
11559899|NCT00934635|Active Comparator|007|Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 24 hours
11559900|NCT00934635|Active Comparator|008|Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 24 hours
11559901|NCT00934635|Other|009|PET Scan PET Scan
11559902|NCT00934635|Active Comparator|001|Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 2 hours
11559903|NCT00934622|Experimental|AcrySof® ReSTOR® Aspheric IOL|AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL)
11559904|NCT00934609|Experimental|Training|12 weeks of endurance training on the cycle ergometer under supervision on a physician
11559905|NCT00934609|No Intervention|Control|Control condition
11559908|NCT00934583|Experimental|Image and Mood (IaM) program|Participants will participate in the IaM program.
11559909|NCT00934583|No Intervention|Wait-list control|Participants will be placed on a wait list until after participants in the IaM group have completed all assessments. After that, these participants will be offered the option to complete the IaM program.
11559910|NCT00934570|Active Comparator|Metformin, Standard exercise|Lifestyle intervention with metformin and standard exercise program.
11559911|NCT00934570|Placebo Comparator|Placebo, Standard exercise|Lifestyle intervention with placebo and standard exercise program
11559912|NCT00934570|Active Comparator|Metformin, Intensive exercise|Lifestyle intervention with metformin and intensive exercise
11559913|NCT00934570|Placebo Comparator|Placebo, Intensive exercise|Lifestyle intervention with placebo and intensive exercise program.
11559914|NCT00934557|Experimental|Good prognosis/mismatched donor/BM|
11559915|NCT00934557|Experimental|Good prognosis/mismatched donor/PB|
11559916|NCT00934557|Experimental|Poor prognosis/matched donor/BM|
11559917|NCT00934557|Experimental|Poor prognosis/matched donor/PB|
11559918|NCT00934557|Experimental|Poor prognosis/mismatched donor/BM|
11559919|NCT00934557|Experimental|Poor prognosis/mismatched donor/PB|
11559920|NCT00934557|Experimental|Good prognosis/matched donor/BM|
11559921|NCT00934557|Experimental|Good prognosis/matched donor/PB|
11559922|NCT00934544|Experimental|Ruxolitinib|5 mg tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule
11559923|NCT00934544|Active Comparator|Best Available Therapy (BAT)|"Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.
~Patients randomized to BAT were eligible to cross over to receive open-label ruxolitinib after a qualifying progression event, if they met the safety criteria. After the primary analysis in January 2011, patients randomized to receive BAT were allowed to cross over to receive ruxolitinib and move to the extension phase of the study without a qualifying progression event."
11559924|NCT00934531|Experimental|Donepezil|participants with MCI receiving donepezil
11559925|NCT00934531|Placebo Comparator|Placebo|Participants with MCI receiving placebo
11559926|NCT00934518|Experimental|Radiation and Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
11559927|NCT00934492|Active Comparator|Cotrimoxazole dispersible tablet|Children between 2-6 months will receive single dispersible tablet of 120mg,daily while children over 6 months to 5 years will receive 240 mg dispersible tablet daily for six months.
11559928|NCT00934492|Placebo Comparator|Placebo dispersible tablet|Children between 2-6 months will receive single dispersible Placebo tablet of 120mg,daily while children over 6 months to 5 years will receive 240 mg dispersible Placebo tablet daily for six months.
11559929|NCT00934479|No Intervention|Healthy Subjects|Healthy subjects completed a baseline 1-week diary of stool and defecatory characteristics, fasting breath for hydrogen and methane and a stool sample for pyrosequencing. Otherwise, the healthy subjects received no intervention.
11559930|NCT00934479|Experimental|Constipated Subjects|"Subjects with constipation included those with chronic constipation (CC) and those with constipation predominant irritable bowel syndrome (C-IBS). They completed a baseline 1-week diary of stool and defecatory characteristics, fasting breath for hydrogen and methane and a stool sample for pyrosequencing.
~Following baseline test and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.
~Following the 4-weeks treatment with lubiprostone, they completed another stool diary, fasting breath test, and stool sample for pyrosequencing."
11559931|NCT00934466|Experimental|1|MK2637 120 mg
11559932|NCT00934466|Experimental|2|MK2637 50 mg
11559933|NCT00934466|Placebo Comparator|3|Placebo
11559934|NCT00934466|Active Comparator|4|Dextromethorphan 220 mg
11559935|NCT00934466|Active Comparator|5|Dextromethorphan 110 mg
11559936|NCT00934453|Experimental|LGG|Lactobacillus rhamnosus GG (LGG) capsules containing 1x10^10 LGG per capsule will be given to volunteers with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis.
11559937|NCT00934453|Placebo Comparator|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis.
11559938|NCT00934440|Experimental|Dose Escalation: 5-azacitidine|A traditional 3+3 dose escalation trial was implemented. Successive cohorts of patients (3 participants/cohort) received bevacizumab at the standard dose of 10mg/kg in combination with escalating doses of 5-azacitidine. If no dose limiting toxicity (DLT) is seen, subsequent patients will be treated at the next dose level. If one DLT is seen, an additional three patients will be accrued at that dose level. If two or more DLTs are seen at one dose level, then the previous dose level will be chosen for phase IIA. If two DLT's are seen at dose level 1, the trial will end. The standard 5-azacitidine dose is 75mg/m2/day for 7 days. If no DLT is seen at dose level 3, then we will proceed with the phase IIA portion of the study.
11559939|NCT00934427|Active Comparator|Vascana|
11559940|NCT00934427|Placebo Comparator|Vehicle|
11559941|NCT00934414|Experimental|Smokers|
11559942|NCT00934414|Experimental|Non-Smokers|
11559943|NCT00934388|Experimental|Mesh placed in pre peritoneal plane|
11559944|NCT00934388|Active Comparator|No mesh placed|
11559945|NCT00934375|Experimental|1|
11559946|NCT00934375|Placebo Comparator|2|
11559947|NCT00934362|Other|Lucinactant first, then placebo|Active treatment first, then washout period, then placebo treatment
11559948|NCT00934362|Other|Placebo treatment first, then lucinactant treatment|0.9% NaCl vehicle treatment first, then washout period, then lucinactant treatment
11559949|NCT00934349||Patient|Native to the Comoro Archipelago (Grande Comore, Mayotte, Anjouan, Mohéli) fulfilling the clinical definition of the dry beriberi.
11559950|NCT00934349||Control|Native to the Comoro Archipelago, living in the same household as the patient, sharing the same meals. Free from beriberi and with normal neurological examination.
11559951|NCT00934336|Experimental|preprandial injection|pre-prandial injection of an ultra-fast-acting analog during 3 months, then post-prandial injection of an ultra-fast-acting analog during 3 other months.
11559952|NCT00934336|Experimental|post-prandial injection|post-prandial injection of an ultra-fast-acting analog during 3 months then pre-prandial injection of an ultra-fast-acting analog during 3 other months.
11559953|NCT00934323|Experimental|TR sequential group|Amaryl M SR 1/500 mg in period 1 and Amaryl M SR 2/500 mg in period 2
11559954|NCT00934323|Active Comparator|RT sequential group|Amaryl M SR 2/500 mg in period 1 and Amaryl M SR 1/500 mg in period 2
11559955|NCT00934310||Ambulatory Surgical Patients 1|"The nature of the operating room time out for ambulatory surgical patients will be examined before implementation of the World Health Organization's Surgical Safety Checklist."
11559956|NCT00934310||Ambulatory Surgical Patients 2|"The nature of the operating room time out for ambulatory surgical patients will be examined after implementation of the World Health Organization's Surgical Safety Checklist.Ambulatory surgical patients"
11559957|NCT00934297||Pilot group|Real-time US imaging with simultaneous display of dynamically corresponding MR images (from a previous MRI screening) will be used to re-locate the lesion previously reported as occult under a second-look ultrasound screening.
11559958|NCT00934284|Active Comparator|Injection only|Participants receive a therapeutic selective nerve root block and advice to return to normal activity as tolerated.
11559959|NCT00934284|Experimental|Injection plus physical therapy|Participants are referred to physical therapy within one week of receiving a therapeutic selective nerve root block. Physical therapy consists of end-range movements in a directional preference and/or mechanical traction to reduce radicular symptoms.
11559960|NCT00934271||Fractionated stereotactic radiotherapy|patients with active acromegaly
11559961|NCT00934245|Active Comparator|Inactivated Polio Vaccine (IPV)|Inactivated trivalent poliovirus vaccine (IPV) age Dose # doses/year 1 # doses year 2 and 3 6 mo -8y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
11559962|NCT00934245|Experimental|Inactivated Trivalent Influenza Vaccine|Inactivated split virion trivalent influenza vaccine (TIV) age Dose # doses year 1 # doses year 2 and 3 6-35 mo 0.25 ml 2 1 3-8 y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
11559963|NCT00934245|No Intervention|Surveillance arm|Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members.
11559964|NCT00934232|Experimental|Busulfan|Busulfex given to patients who are either ≥65 years or have renal insufficiency
11559965|NCT00934219|Active Comparator|High dose Lovaza|Lovaza 4 g twice a day, if not effective then 4 g 3 times a day
11559966|NCT00934219|Active Comparator|Standard Dose|2 g twice a day
11559967|NCT00934206|Experimental|Training|One month of endurance training (running / walking at 60 % heart rate reserve for 45 min 4 times per week)
11559968|NCT00934193|Active Comparator|Gabapentin|
11559969|NCT00934193|Placebo Comparator|Placebo|
11559970|NCT00934180|Experimental|Ondansetron|Ondansetron HCl 8 mg OD Tablet (test) dosed in first period followed by Zofran® 8 mg ODT (reference) dosed in second period
11559971|NCT00934180|Active Comparator|Zofran®|Zofran® 8 mg ODT (reference) dosed in first period followed by Ondansetron HCl 8 mg OD Tablet (test) dosed in second period
11559972|NCT00934167|Experimental|Test|Hipolabor
11559973|NCT00934167|Active Comparator|Comparator|5.000 USP/mL - APP
11559974|NCT00934154|Experimental|Thalidomide|MPT
11559975|NCT00934154|Active Comparator|Control|MP
11559976|NCT00934141|Experimental|Interest Circle Call + Website|Interest Circles are monthly teleconferences where agency change leaders discuss change-related issues and progress. Circles address how to improve timeliness, continuation, admissions, dropouts and transitions. They also address specialty topics (e.g., programs for women, adolescents). Participants discuss successes, failures, and challenges, and get advice and assignments for their improvement plans. Meeting summaries appear on the Web site. Interest Circles are inexpensive, but are they are sufficient? Should Interest Circles prove effective, they would provide a low-cost, convenient diffusion approach.
11559977|NCT00934141|Experimental|Coaching + Website|Coaching assigns an expert in process improvement to work with an agency to make, sustain, and spread process improvement efforts. Consultations focus on executive directors, change leaders and improvement teams. Coaches help agencies address key issues, but also broker relationships with other agencies, offer process improvement training, and promote the innovations to make and how to make them. Coaching takes place during site visits, monthly phone conferences, and via email.
11559978|NCT00934141|Experimental|Full: LS, Coaching, ICC, Website|Learning Session, Coaching, Interest Circle Calls, Website, see descriptions above
11559979|NCT00934141|Experimental|Learning Session + Website|Learning Sessions occur bi-annually as change teams convene to learn and gather support from each other and outside experts who offer advice on how best to adopt the innovations and learn about new directions for the collaborative (e.g., the need to create business cases for improvements). Learning Sessions and Interest Circles (see below) have similar objectives-to help agencies learn and gather support from each other and from outside experts.
11559980|NCT00934128|Experimental|Group 1: BiPAP then Vapotherm|Bilevel positive airway pressure device (BiPAP) then Vapotherm air delivery.
11559981|NCT00934128|Experimental|Group 2: Vapotherm then BiPAP|Vapotherm air delivery then BiPAP.
11559982|NCT00934102|Active Comparator|Lotrafilcon A|Lotrafilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
11559983|NCT00934102|Active Comparator|Narafilcon A|Narafilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
11559984|NCT00934102|Active Comparator|Galyfilcon A|Galyfilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
11559985|NCT00934089|Experimental|PF-04217329 + placebo|Active study drug + latanoprost vehicle
11559986|NCT00934089|Experimental|PF-04217329 + latanoprost|Active study drug + latanoprost
11559987|NCT00934076|Experimental|AT-101 plus Erlotinib|"Subjects will begin study treatment at 150 mg of erlotinib taken once daily in a continuous regimen expressed in 3 week cycles.
~Subjects will begin treatment with oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis."
11559988|NCT00934063||A|
11559989|NCT00934063||B|
11559990|NCT00934050|Experimental|ELND005|
11559991|NCT00934037|Other|Combined CT Angiography and Myocardial Perfusion|Single Arm study. All patients underwent combined CT Angiography and Myocardial Perfusion.
11559992|NCT00934024|Other|Abstinent|"All participants received varenicline. A priori determined analysis was between participants who quit smoking and those who continued to smoke.
~This arm was abstinent after 5 weeks of varenicline treatment.."
11559993|NCT00934024|Other|Non-abstinent|"All participants received varenicline. A priori determined analysis was between participants who quit smoking and those who continued to smoke.
~This arm was participants who continued to smoke after 5 weeks of varenicline treatment."
11559994|NCT00934011|Experimental|Group 1 - C-reactive protein (CRP) guided ab therapy|Intervention on antibiotic therapy will be based on circulating CRP levels
11559995|NCT00934011|Active Comparator|Group 2 - procalcitonin (PCT) guided ab therapy|Intervention on antibiotic therapy will be based on circulating PCT levels
11559996|NCT00933998|Experimental|Metanx|Metanx bid for 2 weeks then daily. Compare to non treated patient population
11559997|NCT00933985|Experimental|Treatment (obatoclax, vincristine, doxorubicin, dexrazoxane)|"STRATUM 1 (dose-escalation): Patients receive obatoclax mesylate IV over 3 hours on days 1 and 8 and vincristine sulfate IV, doxorubicin hydrochloride IV, and dexrazoxane hydrochloride IV on day 8 of course 1 (28 days). Drugs are administered on day 1 of subsequent courses and repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
~STRATUM 2: Patients receive obatoclax mesylate (at starting dose in stratum 1), vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride as in stratum 1.
~STRATUM 3: Patients receive obatoclax mesylate (at the MTD determined in stratum 1), vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride as in stratum 1."
11559998|NCT00933972|Experimental|1 (normal)|
11559999|NCT00933972|Experimental|2 (mild)|
11560000|NCT00933972|Experimental|3 (moderate)|
11560001|NCT00933972|Experimental|4 (severe)|
11560002|NCT00933959|Experimental|Mind-Body Bridging Program|"Subjects will undergo two approximately 1.5 hr training sessions using MBBP spaced one week apart at the VASLCHCS. Each training session will comprise a number of objectives:
~Session 1:
~The patient will discover the underlying cause of the insomnia.
~The patient will learn how to use easy to apply tools to quieten the mind to sleep soundly.
~Session 2:
~The patient will learn how to reduce daytime stress.
~The patient will experience a greater sense of self.
~To be maximally effective, the participant should master these objectives and practice MBBP on a daily basis. Bridging and all the other MBBP techniques can be implemented at any time throughout the day and right up to the onset of sleep."
11560003|NCT00933959|Active Comparator|Sleep Hygiene|Participants in the sleep hygiene arm will receive a 1 hr class directing them to the importance of following a list of up to 15 points (tips) for getting to sleep. These points include: limiting alcohol and caffeine intake before bed, using the bed only for sleeping, and having regular bedtimes. Once the instructor has gone over this list and has described in detail each of the 15 points, the class will have an opportunity to ask questions. The participant will be encouraged to learn and practice the objectives of the sleep hygiene class on a daily basis.
11560004|NCT00933946|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
11560005|NCT00933933|Experimental|ARCHITECT HIV Ag/Ab Combo Specificity|Specimens collected from normal apparently healthy individuals at low risk for HIV infection will be tested by the investigational HIV test and FDA-licensed HIV test.
11560006|NCT00933933|No Intervention|ARCHITECT HIV Ag/Ab Combo Sensitivity|Specimen with confirmed positive HIV Antigen, HIV-1 antibody, or HIV-2 antibody will be tested by the investigational HIV test.
11560007|NCT00933933|Experimental|ARCHITECT HIV Ag/Ab Combo Reactivity|Specimen collected from individuals at risk for HIV infection will be tested by the investigational HIV test.
11560008|NCT00933920|Active Comparator|Fed Group|
11560009|NCT00933920|Active Comparator|Fasted group|
11560010|NCT00933907|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Dermacyd PH_DESILSTY_FR (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
11560011|NCT00933881||Gestational Diabetes Mellitus (GDM)|
11560012|NCT00933868|Experimental|Magnesium infusion in patients breathing 100% oxygen|Patients will be given six infusions over three weeks. Each infusion will last between 4 and 10 minutes. They will then return to clinic in 1,2 and 3 months for the same tests (but no infusions will be given).
11560013|NCT00933868|Placebo Comparator|Placebo infusion|The patients will receive six placebo infusions after which they will return to clinic at one, two and three months. At the conclusion of the trial those patients who received placebo may elect to receive the active treatment in another (open label) trial that will begin shortly after this one concludes.
11560014|NCT00933855||communication training workshop|"The patient intervention is a 1 hour communication workshop entitled: Getting the Most out of your Doctor's Visit. The workshops will be offered to both patients and family members, but data will be collected only for patients. The workshops will be held on location at Queens Cancer Center."
11560015|NCT00933842|Experimental|Dermacyd PH_DESILSTY_FL (Lactic Acid)|Dermacyd PH_DESILSTY_FL (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample
11560016|NCT00933829|Placebo Comparator|Non-absorbable arm|uses non-absorbable suture such as Prolene to repair lacerations
11560017|NCT00933829|Active Comparator|Absorbable Suture Arm|uses absorbable sutures to repair lacerations
11560018|NCT00933816|Experimental|Sorafenib with Low-dose FP|
11560019|NCT00933790|Active Comparator|2EHRZ3/4HR3|Regimen 3. Intermittent - 2EHRZ3/4HR3 (E 1200mg, H 600 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg given thrice weekly)
11560020|NCT00933790|Experimental|2EHRZ7/4HR7|Regimen 1. Daily - 2EHRZ7/4HR7 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg daily)
11560021|NCT00933790|Experimental|2EHRZ7/4HR3|Regimen 2. Part Daily - 2EHRZ7/4HR3 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg daily in the intensive phase followed by H-600 mg ,R-450/600 mg in the continuation phase thrice weekly)
11560022|NCT00933777|Experimental|Therapy with everolimus and sorafenib|Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg
11560023|NCT00933751||Patients before emergent major abdominal surgery|
11560024|NCT00933725|Experimental|TCM intervention|Particle of compound Chinese herbs and TCM emotion treatment and tablet placebo of Tibolone
11560025|NCT00933725|Active Comparator|Western intervention|Tibolone and supportive psychotherapy and Particle placebo of compound Chinese herbs
11560026|NCT00933712|Experimental|Dermacyd Silver Floral (Lactic Acid)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
11560027|NCT00933699|Experimental|Dermacyd PH_DESILSTY_FL (Lactic Acid)|Treatment duration: 21 consecutive days
11560028|NCT00933686|Active Comparator|Saizen®|
11560029|NCT00933686|Active Comparator|Placebo + Saizen®|
11560030|NCT00933673|Experimental|L-DICE|
11560031|NCT00933660|Active Comparator|Control-1|ERC-training by instructor
11560032|NCT00933660|No Intervention|Control-2|No intervention
11560033|NCT00933660|Experimental|Experimental-1|Web-based training only
11560034|NCT00933660|Experimental|Experimental-2|Web-based training with a personal training manikin
11560035|NCT00933647|Experimental|Yerba Mate Tea|Subjects will drink 1000ml/day of yerba mate tea for 8 weeks.
11560036|NCT00933647|Active Comparator|Green Tea|Subjects will drink 1000ml/day of green tea for 8 weeks.
11560037|NCT00933647|Placebo Comparator|Apple Tea|Subjects will drink 1000ml/day of apple tea for 8 weeks.
11560038|NCT00933634|Experimental|electrical cardioversion|Patients were sedated with propofol and external cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula). Patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
11560039|NCT00933634|Active Comparator|propafenone|Propafenone (2 mg/kg bolus) was administered iv to obtain pharmacologic sinus rhythm conversion.
11560040|NCT00933621|Experimental|Autologous Bone Marrow infusion|Percutaneous intracoronary autologous bone marrow infusion
11560041|NCT00933608|Experimental|memantine|after a period of gradual dose increase from 5 mg/day, participants will be asked to take memantine (20mg/day) for 16 weeks 10 mg in the morning, 10 mg at night
11560042|NCT00933608|Placebo Comparator|Placebo|dose increase to match active drug, after that 1 tablet in the morning, 1 tablet at night, to match active drug
11560043|NCT00933595|Experimental|Smoking Cessation|The overall smoking cessation rate for the intervention is 18.8 at 3 months, 13.1 at 6 months and 10.0 at 12 months.
11560044|NCT00933569|Experimental|Dermacyd Silver Floral (Lactic Acid)|Aplication of Dermacyd Silver Floral (Lactic Acid) during 21 consecutive days
11560045|NCT00933556|Experimental|probiotic|subjects will be given a powder formulation of a probiotic VSL#3 to be taken once a day, at a dose of 6 gms
11560046|NCT00933556|Placebo Comparator|sugar pill|placebo identical to the active product will be given
11560047|NCT00933543|Experimental|Visonac cream with PDT|Active treatment, Light dose 37 J/cm2.
11560048|NCT00933543|Placebo Comparator|Vehicle cream with PDT|Placebo treatment, Light dose 37 J/cm2.
11560049|NCT00933530|Experimental|Cohort 1 - Dose Level A (0.03g/day)|"0.03g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.03g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.03g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.
~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
11560050|NCT00933530|Experimental|Cohort 2 - Dose Level B (0.1g/day)|"0.1g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.1g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.1g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.
~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
11560051|NCT00933530|Experimental|Cohort 3 - Dose Level C (0.25g/day)|"0.25g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.25g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.25g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.
~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
11560072|NCT00933361|Experimental|ghrelin|Ghrelin, a 28 amino acid peptide discovered in 1999, is predominantly secreted by gastric endocrine cells and is an endogenous ligand for the growth hormone secretagogue (GHS) receptor. When administered peripherally it stimulates growth hormone secretion, food intake, triggers a positive energy balance, produces weight gain through a central mechanism involving hypothalamic neuropeptides and has anti-inflammatory effects
11560073|NCT00933348|Active Comparator|OPAL A plus standard wound care|
11560074|NCT00933348|Placebo Comparator|Placebo plus standard wound care|
11560122|NCT00932919|Experimental|Thought field therapy|24 randomly selected patients will be treated with 5 sessions of standard Thought field therapy.
11560052|NCT00933530|Experimental|Cohort 4 - Dose Level D (0.5g/day)|"0.5g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.5g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.5g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.
~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
11560053|NCT00933530|Experimental|Cohort 5 - Dose Level E (1.0g/day)|"1.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 1.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 1.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.
~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
11560054|NCT00933530|Experimental|Cohort 6 - Dose Level F (2.0g/day)|"2.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 2.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 2.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.
~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
11560055|NCT00933530|Experimental|Cohort 7 - Dose Level G (3.0g/day)|"3.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 3.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 3.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.
~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period."
11560056|NCT00933504|Experimental|Dermacyd Silver Floral (Lactic Acid)|Lactic Acid sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample
11560057|NCT00933491||Diabetic|Type II Diabetes
11560058|NCT00933491||Control|Non-diabetics
11560059|NCT00933478||Patients with Patulous Eustachian Tube Dysfunction|
11560060|NCT00933465|Experimental|tablets first followed by syrup|first 6 weeks of study using tablets, then followed by assessment, and then the next 6 weeks using syrup, followed by assessment
11560061|NCT00933465|Experimental|Syrup first followed by tablets|first 6 weeks of study using syrup, then followed by assessment, and then the next 6 weeks using tablets, followed by assessment
11560062|NCT00933452|Experimental|low dose group|single oral administer 15mg duloxetine
11560063|NCT00933452|Experimental|moderate dose group/multiple dose group|single oral duloxetine 30mg, after that repeat 7 oral duloxetine 30mg/d
11560064|NCT00933452|Experimental|high dose group/crossover group|single oral duloxetine 60mg, after that single oral innovator duloxetine 60mg
11560065|NCT00933439|Experimental|Duloxetine|
11560066|NCT00933426|Experimental|Lenalidomide and Paclitaxel|"Phase I: Up to 5 differing doses of Lenalidomide tested plus fixed dose of Paclitaxel.
~Phase II: Lenalidomide at highest tolerated dose from Phase I plus Paclitaxel."
11560067|NCT00933413|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Application of Lactic acid during 21 consecutive days
11560068|NCT00933400|Active Comparator|Traditional Strategy (Group A)|In the traditional-care arm (Group A), all management and disposition decisions will be made by the healthcare providers caring for the participant. Participants will receive disposition (admit to hospital, admit to cardiac diagnostic unit, or discharge to home), diagnostic testing (none, stress testing, or cardiac catheterization), and treatment according to the team caring for the participant.
11560069|NCT00933400|Experimental|CT Coronary Angiography (Group B)|"In the study CT coronary angiography-based rapid rule out arm (Group B), participants will receive initial cardiac troponin and creatinine tests. Upon return of normal laboratory values (including a calculated creatinine clearance), the participants will receive a CT coronary angiography an estimated 90 minutes or as soon as the CT scanner is available following the initial values assessment. Participants with negative test results will be discharged unless other indications for admission per standard of care and follow up will comprise telephone interviews 30 days and 1 year after triage/presentation. Participants with positive test results will be admitted to the hospital for further management as dictated by the admitting team."
11560070|NCT00933387|Experimental|open label|an open-labelled, single-arm
11560071|NCT00933374|Experimental|Paclitaxel and RAD001|175 mg /m3 paclitaxel every 3 weeks and 10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
11560118|NCT00932945|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Treatment duration: 21 consecutive days
11560119|NCT00932932||PWS not receiving Growth Hormone|
11560120|NCT00932932||Control subjects healthy or obese|
11560121|NCT00932932||PWS subjects starting Growth Hormone|
11560075|NCT00933335|Experimental|Single Arm|Patients will first receive an abbreviated course of three cycles of fludarabine (25 mg/m2 for 5 days every 5 weeks). Iodine I 131 tositumomab will be initiated 6 to 8 weeks after completion of fludarabine. Patients will undergo dosimetry studies to determine the appropriate patient-specific activity of iodine I 131 tositumomab required to deliver a fixed dose of 75 cGy. The dose will be attenuated to 65 cGy for patients with platelet counts between 100,000 and 150,000/micoliter.
11560076|NCT00933322|Active Comparator|ruminant TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter containing ruminant TFA and with 15-20g rape oil for balancing the essential fatty acids.
11560077|NCT00933322|Active Comparator|industrial TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter containing TFA from PHVO and with 15-20g rape oil for balancing the essential fatty acids.
11560078|NCT00933322|Placebo Comparator|without TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter without TFA and with 15-20g rape oil for balancing the essential fatty acids.
11560079|NCT00933309|Experimental|Group 1|Exemestane alone
11560080|NCT00933309|Experimental|Group 2|Exemestane plus Avandamet
11560081|NCT00933296||A Patients with the Schnitzler syndrome|Patients with the Schnitzler syndrome
11560082|NCT00933296||B Control subjects:|B1 healthy B2 other diseases
11560083|NCT00933283|Experimental|Telaprevir + Methadone|Patients will receive telaprevir 750 mg orally, every 8 hours from Day 1 to Day 7, along with methadone 30 to 130 mg, once daily.
11560084|NCT00933270|Experimental|SUPERA® Nitinol Stent System|Implantation of SUPERA nitinol stent using the SUPERA® Nitinol Stent System
11560085|NCT00933257|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Dermacyd PH_DESILSTY_FR (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
11560086|NCT00933244|Other|High Dose Vitamin D3|"Loading Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take daily for 15 days and placebo gel-caps (white) to take daily for 15 days.
~Maintenance Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take two times a month for 350 days and placebo gel-caps (white) to take daily for 350 days."
11560087|NCT00933244|Other|Low Dose Vitamin D3|"Loading Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 15 days plus placebo gel-caps (yellow) to take daily for 15 days.
~Maintenance Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 350 days plus placebo gel-caps (yellow) to take two times a month for 350 days."
11560088|NCT00933244|Placebo Comparator|Placebo|"Loading Dose: Placebo gel-caps (yellow) to take daily for 15 days plus placebo gel-caps (white) to take daily for 15 days.
~Maintenance Dose: Placebo gel-caps (yellow) to take two times a month for 350 days plus placebo gel-caps (white) to take daily for 350 days."
11560089|NCT00933231|Active Comparator|Tacrolimus Standard Dose with ACEi/ARB|Participants receive a standard dose of tacrolimus with ACEi/ARB.
11560090|NCT00933231|Active Comparator|Tacrolimus Standard Dose without ACEi/ARB|Participants receive a standard dose of tacrolimus without ACEi/ARB.
11560091|NCT00933231|Experimental|Tacrolimus Low Dose with ACEi/ARB|Participants receive a low dose of tacrolimus with ACEi/ARB.
11560092|NCT00933231|Experimental|Tacrolimus Low Dose without ACEi/ARB|Participants receive a low dose of tacrolimus without ACEi/ARB.
11560093|NCT00933218|Active Comparator|polyphenols (non-alcoholic beer)|
11560094|NCT00933218|Placebo Comparator|beverage without polyphenols|
11560095|NCT00933192||Group 1: young healthy patients|
11560096|NCT00933192||Group 2: old healthy patients|
11560097|NCT00933179|Experimental|Arm 1|
11560098|NCT00933179|Active Comparator|Arm 2|
11560099|NCT00933166|Experimental|Lotrafilcon A|Investigational contact lens worn in both eyes for three months
11560100|NCT00933153|Active Comparator|Meals on Wheels|Participants will receive two meals daily from Meals on Wheels.
11560101|NCT00933153|Experimental|Meals on Wheels + Ensure Plus supplement|Participants will receive two meals from Meals on Wheels daily plus Ensure Plus supplements with meals.
11560102|NCT00933140||HIV infected women|HIV infected women between ages 18 - 64 years of age due for cervical cancer screening were enrolled.
11560103|NCT00933114||Functional Imaging|Functional imaging with MRI and PET
11560104|NCT00933101||HgbA1c <8|Adolescents with HgbA1c < or equal to 8% for the previous 12 months
11560105|NCT00933101||HgbA1c >10|Adolescents with HgbA1c > or equal to 10% for previous 12 months
11560106|NCT00933075|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also usedas a control sample.
11560107|NCT00933062|Active Comparator|SRT2104|Subjects will receive a dose of 2.0 g SRT2104 (administered as eight 250 mg capsules) on eight occasions during the study; once as a single dose (study day 1) during Treatment Period 1, and once per day for seven consecutive days (study days 15 to 21) during Treatment Period 2.
11560108|NCT00933062|Placebo Comparator|Placebo|Subjects will receive placebo on eight occasions during the study; once as a single dose (study day 1) during Treatment Period 1, and once per day for seven consecutive days (study days 15 to 21) during Treatment Period 2.
11560109|NCT00933049|Active Comparator|Cotrimoxazole|Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole) + Amoxicillin placebo
11560110|NCT00933049|Active Comparator|Amoxicillin|Amoxicillin (25 mg/kg/dose) + Cotrimoxazole placebo
11560111|NCT00933036|Experimental|Treatment arm|Crosstrees Pod System for PVA.
11560112|NCT00933023|Experimental|Mild steroid|1%hydrocortisone for 8 weeks
11560113|NCT00933023|Experimental|Potent Steroid|
11560114|NCT00932984|Experimental|Dermacyd Silver Floral (Lactic Acid)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
11560115|NCT00932971|Placebo Comparator|PEG-IFN alfa-2a plus placebo|Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus placebo once daily, orally
11560116|NCT00932971|Active Comparator|PEG-IFN alfa-2a plus Tenofovir|Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus Tenofovir disoproxilfumarat 245mg once daily, orally
11560117|NCT00932958||All comers >18 yrs old|This study is observational, studying patients who are already scheduled to undergo CCTA. Minors and those unable to consent to the study are excluded.
11560123|NCT00932919|Active Comparator|Cognitive therapy|Treatment with Cognitive therapy, 12 sessions with manualized therapy according to David Clark's model.
11560124|NCT00932919|Other|Wait list|24 patients will be randomly selected to 3 months on a wait list, thereafter randomly selected to either Cognitive therapy or Thought field therapy.
11560125|NCT00932906|Placebo Comparator|Instructor based training; <21 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
11560126|NCT00932906|Placebo Comparator|Instructor based training; 21-50 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
11560127|NCT00932906|Placebo Comparator|Instructor based training; >50 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
11560128|NCT00932906|Experimental|Video Skill Training; <21 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
11560129|NCT00932906|Experimental|Video Skill Training; 21-50 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
11560130|NCT00932906|Experimental|Video Skill Training; >50 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
11560131|NCT00932906|Experimental|Video scenario training; <21 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
11560132|NCT00932906|Experimental|Video scenario training; 21-50 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
11560133|NCT00932906|Experimental|Video scenario training; >50 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
11560134|NCT00932906|Experimental|Video demonstration training; <21 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
11560135|NCT00932906|Experimental|Video demonstration training; 21-50 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
11560136|NCT00932906|Experimental|Video demonstration training; >50 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
11560137|NCT00932893|Experimental|PF-02341066|
11560138|NCT00932893|Active Comparator|Pemetrexed or Docetaxel|Investigator selection of either pemetrexed or docetaxel as the active comparator
11560139|NCT00932867||Group 1|
11560140|NCT00932854|Experimental|EBUS|All patients in the trial will undergo EBUS for the diagnosis of isolated mediastinal lymphadenopathy. If this investigation is negative then the patient will be referred for mediastinoscopy.
11560141|NCT00932841|Placebo Comparator|Placebo|
11560142|NCT00932841|Active Comparator|VSL#3 90 billion bacteria|
11560143|NCT00932841|Active Comparator|VSL#3 900 billion bacteria|
11560144|NCT00932828|Experimental|Peanut oral immunotherapy|Newly diagnosed allergic children receiving peanut flour as oral immunotherapy for the treatment of peanut allergy.
11560145|NCT00932802||Group 1|
11560146|NCT00932776|Experimental|TBA|
11560147|NCT00932776|Active Comparator|Control|
11560148|NCT00932750|Placebo Comparator|MOS Weight maintenance|
11560149|NCT00932750|Placebo Comparator|MOS weight loss|
11560150|NCT00932737|Active Comparator|HBB 20mg 1-5 tablets per episode|patient to receive 1-5 tablets containing 20mg HBB per APC episode
11560151|NCT00932737|Placebo Comparator|Placebo|patient to receive a tablet identical to those containing HBB and take 1-5 tablets per episode
11560152|NCT00932724|Experimental|CY-503|
11560153|NCT00932724|Placebo Comparator|Placebo|
11560154|NCT00932711|Experimental|Educational intervention|Subjects in this group will receive educational brochures about management of COPD
11560155|NCT00932698|Experimental|Dose Escalation Cohort 1: Ixazomib 0.24 mg/m^2|Ixazomib 0.24 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 220 days).
11560156|NCT00932698|Experimental|Dose Escalation Cohort 2: Ixazomib 0.48 mg/m^2|Ixazomib 0.48 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 270 days).
11560180|NCT00932594|Active Comparator|3.Arthroscopic Treatment|Patient receives Arthroscopic treatments without adjusting the TMJ pressure
11560233|NCT00932321|Experimental|24 Day NA/EE|Norethindrone acetate 1 mg /ethinyl estradiol 20 mcg for 24 days of each 28 day cycle
11560157|NCT00932698|Experimental|Dose Escalation Cohort 3: Ixazomib 0.8 mg/m^2|Ixazomib 0.8 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 137 days).
11560158|NCT00932698|Experimental|Dose Escalation Cohort 4: Ixazomib 1.2 mg/m^2|Ixazomib 1.2 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1436 days).
11560159|NCT00932698|Experimental|Dose Escalation Cohort 5: Ixazomib 1.68 mg/m^2|Ixazomib 1.68 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 456 days).
11560160|NCT00932698|Experimental|Dose Escalation Cohort 6: Ixazomib 2.0 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1621 days).
11560161|NCT00932698|Experimental|Dose Escalation Cohort 7: Ixazomib 2.23 mg/m^2|Ixazomib 2.23 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 2434 days).
11560162|NCT00932698|Experimental|Relapsed and Refractory Expansion Cohort: Ixazomib 2 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months, Participants must also be refractory to their most recent therapy as evidenced by PD while on therapy or within 60 days after their last dose of therapy (Up to 1621 days).
11560163|NCT00932698|Experimental|Velcade-Relapsed (VR) Expansion Cohort: Ixazomib 2.0 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after >=1 prior therapy but have relapsed after previous Velcade exposure and were not treated with any other proteasome inhibitors (Up to 1573 days).
11560164|NCT00932698|Experimental|Proteasome Inhibitor-Naive Expansion Cohort: Ixazomib 2 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after >=1 prior therapy which must include thalidomide (or lenalidomide) and corticosteroid, but who never received a proteasome inhibitor (Up to 550 days).
11560165|NCT00932698|Experimental|Carfilzomib Expansion Cohort: Ixazomib 2.0 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants who previously received carfilzomib and had relapsed or refractory disease (Up to 123 days).
11560166|NCT00932685|Active Comparator|2. Video Game|
11560167|NCT00932685|Active Comparator|1. Midazolam 0.5mg/kg|
11560168|NCT00932672|Experimental|Atkins group|Men assigned to the Atkins diet will be asked to restrict carbohydrate intake to <20 grams/day. We will use an established clinical program directed by Dr. Eric Westman which implements this diet using a trained clinical nutritionist. No other dietary restrictions will be placed on the subjects. They will measure their urinary ketones at home weekly using urinary ketone strips. Subjects will meet with the nutritionist monthly during the 6 months of the study. Subjects in the Atkins arm will also be asked to walk at a brisk pace for 30 minutes a day, 5 days a week and will be provided a pedometer to measure the number of steps taken per day.
11560169|NCT00932672|No Intervention|Control group|Subjects assigned to the control group will be asked to make no changes in their dietary habits. At the completion of the study subjects will meet with the nutritionist and receive standard nutrition AHA recommendations.
11560170|NCT00932659||Hemodialysis patients|This is a single arm observational study. The single arm consists of adult hemodialysis patients without a prior history of cardiac arrhythmias who will be implanted with a continuous cardiac monitoring device (REVEAL, Medtronic) for an FDA approved indication.
11560171|NCT00932646|Experimental|BI1744 (Olodaterol)|Medium Dose once Daily
11560172|NCT00932646|Experimental|BI 1744 (Olodaterol)|Low Dose once Daily
11560173|NCT00932646|Placebo Comparator|Placebo|Placebo once Daily
11560174|NCT00932646|Active Comparator|Foradil|12 mcg twice daily
11560175|NCT00932620|Active Comparator|Simvastatin 40 mg|All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily
11560176|NCT00932620|Active Comparator|Simvastatin 10 mg plus ezetimibe 10 mg|All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily
11560177|NCT00932607|Active Comparator|Staloral Birch|"Start with 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.
~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
11560178|NCT00932607|Experimental|SUBLIVAC Birch|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily.
~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
11560179|NCT00932594|Active Comparator|1.Arthrocentesis only|Patients only have Arthrocentesis, but without adjusting the pressure of the TMJ
11560525|NCT00930215|Experimental|D961H 40 mg HPMC capsule|2 way crossover
11560181|NCT00932594|Active Comparator|4.Arthroscopic with Adjust Pressure|Arthroscopic Treatment with Adjust TMJ Pressure Treatment, during the Arthroscopic treatment adjust the pressure of TMJ to normal value
11560182|NCT00932594|Active Comparator|5.The TMJ Orperation Treatment|The TMJ Operation Treatment without adjusting the pressure of TMJ
11560183|NCT00932594|Active Comparator|6.The TMJ Operation with Adjust Pressure|The TMJ Operation with Adjust TMJ Pressure Treatment, during the treatments to adjust the TMJ pressure to normal value
11560184|NCT00932594|Active Comparator|7.Bite Plate Treatment|Bite Plate Treatment for Temporomandibular Disorders without adjusting the pressure of TMJ
11560185|NCT00932594|Active Comparator|8.Bite Plate with Adjust pressure|Bite Plate and Adjust Pressure Treatment for Temporomandibular Disorders, during the treatments adjust the pressure of TMJ to normal value
11560186|NCT00932594|Active Comparator|2.Arthrocentesis with adjust pressure|Arthrocentesis with adjust pressure according to the pressure of TMJ
11560187|NCT00932581||Full Exam|The first group will receive the full motor examination section in its original order.
11560188|NCT00932581||Subscale|The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
11560189|NCT00932555||Group 1|
11560190|NCT00932542|Experimental|Eutectic mixture|
11560191|NCT00932542|Placebo Comparator|placebo|
11560192|NCT00932542|Active Comparator|Medicaina|
11560193|NCT00932529|Active Comparator|Olanzapine|
11560194|NCT00932529|Active Comparator|Quetiapine|
11560195|NCT00932529|Active Comparator|Risperidone|
11560196|NCT00932529|Active Comparator|Ziprasidone|
11560197|NCT00932516|Active Comparator|South Beach Diet™ with SBD™ Products|
11560198|NCT00932516|Active Comparator|South Beach Diet™ alone|
11560199|NCT00932516|Active Comparator|Calorie restricted diet w/ SBD™ Products|
11560200|NCT00932516|Active Comparator|Calorie Restricted Diet alone|
11560201|NCT00932503|No Intervention|PDS II|PDS II® loop suture was used for abdominal wall closure
11560202|NCT00932503|Active Comparator|Vicryl plus|"antiseptic coated Vicryl plus was used for abdominal wall closure"
11560203|NCT00932490|Experimental|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and an advanced practice nurse will suggest individualized strategies to overcome barriers to adherence
11560204|NCT00932490|No Intervention|Control|
11560205|NCT00932477|Experimental|Artificial Tear Formulation 1|Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
11560206|NCT00932477|Experimental|Artificial Tear Formulation 2|Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
11560207|NCT00932477|Active Comparator|Glycerin and Polysorbate 80 based artificial tear|Glycerin and Polysorbate 80 based artificial tear
11560208|NCT00932464|Experimental|1|Neratinib Fasted
11560209|NCT00932464|Experimental|2|Neratinib Fed
11560210|NCT00932451|Experimental|PF-0231066|
11560211|NCT00932438|Experimental|Irinotecan Beads with FOLFOX6|
11560212|NCT00932438|Active Comparator|FOLFOX6/Avastin alone|
11560213|NCT00932425|Experimental|Outpatient cardiac monitoring|Patients will be assigned to wear a portable outpatient cardiac telemetry device for 21 days
11560214|NCT00932425|No Intervention|Control|Patients will be discharged home with standard clinical follow-up
11560215|NCT00932412|Experimental|CLARA|Clofarabine / Intermediate-Dose Cytarabine (CLARA) with G-CSF given during each sequence of chemotherapy in order to increase the blast priming.
11560216|NCT00932412|Active Comparator|HDAC|High-Dose Cytarabine (HDAC) with G-CSF given during each sequence of chemotherapy in order to increase the blast priming.
11560217|NCT00932399||Group 1|Underwent a procedure at a VA medical facility in VISN 20 for a lower limb amputation between 1997 and 2008
11560218|NCT00932399||Group 2|No history of lower limb amputation
11560219|NCT00932386|Experimental|dexmedetomidine Hcl infusion|Dexmedetomidine is a highly selective alpha-2 adrenoreceptor agonist, which possesses hypnotic, sedative, anxiolytic, sympatholytic and analgesic properties.
11560220|NCT00932386|Placebo Comparator|normal saline|
11560221|NCT00932373|Experimental|1|
11560222|NCT00932360|Experimental|Active TENS Placebo TENS No TENS|Active TENS: 100 Hz, 200 μs at maximal tolerable intensity Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor
11560223|NCT00932360|Experimental|Placebo TENS Active TENS No TENS|Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off Active TENS: 100 Hz, 200 μs at maximal tolerable intensity Participants wore a TENS unit that was turned off for blinding of the outcome assessor
11560224|NCT00932360|Experimental|No TENS Active TENS Placebo TENS|No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor Active TENS: 100 Hz, 200 μs at maximal tolerable intensity Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off
11560225|NCT00932360|Experimental|Active TENS No TENS Placebo TENS|Active TENS: 100 Hz, 200 μs at maximal tolerable intensity No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off
11560226|NCT00932360|Experimental|Placebo TENS No TENS Active TENS|Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off Participants wore a TENS unit that was turned off for blinding of the outcome assessor Active TENS: 100 Hz, 200 μs at maximal tolerable intensity
11560227|NCT00932360|Experimental|No TENS Placebo TENS Active TENS|No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off Active TENS: 100 Hz, 200 μs at maximal tolerable intensity
11560228|NCT00932347|Experimental|Mouthwash A|Mouthwash A: Camellia sinensis mouthwash
11560229|NCT00932347|Placebo Comparator|Mouthwash B|Mouthwash B: Placebo mouthwash
11560230|NCT00932334|Experimental|TALK Plus|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
11560231|NCT00932334|Experimental|TALK Standard|Participants receive and educational video and booklet about living kidney donation
11560232|NCT00932334|Other|Usual Care|Participants receive their usual medical care
11560234|NCT00932321|Active Comparator|21 Day NA/EE|Norethindrone acetate 1 mg/ethinyl estradiol 20 mcg for 21 days of each 28 day cycle
11560235|NCT00932308|Active Comparator|1|Western-style, high-fat, low-calcium diet (WD)
11560236|NCT00932308|Active Comparator|2|Prudent, low-fat, calcium sufficient diet (PD)
11560237|NCT00932295|Active Comparator|Own brand cigarette|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
11560238|NCT00932295|Sham Comparator|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
11560239|NCT00932295|Experimental|Electronic cigarette Version One C7|"10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)"
11560240|NCT00932295|Experimental|Electronic cigarette version 2: NJ|"10 puffs from a so-called electronic cigarette named NJOY (16 mg cartridge; 30 second inter puff interval)"
11560241|NCT00932282|Active Comparator|12 month maintenance of PnOIT|"Randomized subjects who will stay on the maintenance dose of oral peanut immunotherapy (PnOIT) for 12 months.
~The study has 4 phases: anti-IgE therapy before immunotherapy (Omalizumab), an initial desensitization day(s), a buildup period, and a daily home maintenance phase with a final dose of 8000mg peanut flour (~50% peanut protein). Then all subjects will be randomized to an additional 1 or 2 years (12 or 24 months) of maintenance OIT. An OFC will be performed at the end of the long-term maintenance in all groups."
11560242|NCT00932282|Active Comparator|24 month maintenance of PnOIT|"All subjects will be on the same intervention until Randomization. Randomized subjects who will stay on the maintenance dose of peanut oral immunotherapy (PnOIT) for 24 months.
~The study has 4 phases: anti-IgE therapy before immunotherapy (Omalizumab), an initial desensitization day(s), a buildup period, and a daily home maintenance phase with a final dose of 8000mg peanut flour (~50% peanut protein). Then all subjects will be randomized to an additional 1 or 2 years (12 or 24 months) of maintenance OIT. An OFC will be performed at the end of the long-term maintenance in all groups."
11560243|NCT00932269||Seroimmunity 2007|Cord blood from 400 newborns, 1800 children (2 - 18 years) and 2400 adults (above 18 years), randomly selected and stratified in age groups, from which blood samples are taken.
11560244|NCT00932269||Sub Study|800 immigrated children (14 - 16 years) from which blood samples are taken.
11560245|NCT00932256|Experimental|STAHIST for seasonal allergic rhinitis|STAHIST for seasonal allergic rhinitis: each white, scored tablet contains pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, and atropine sulfate .24mg
11560246|NCT00932230|Experimental|Group 1|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
11560247|NCT00932217|Active Comparator|filgrastim|patients mobilized with filgrastim
11560248|NCT00932217|Active Comparator|lenograstim|patients mobilized with lenograstim
11560249|NCT00932204|Experimental|Active stimulation|"For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).
~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d)."
11560250|NCT00932204|Sham Comparator|Sham stimulation|For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area.
11560251|NCT00932191|Active Comparator|Ultrasound phacoemulsification|Cataract nucleus is removed using standard amounts of ultrasound energy.
11560252|NCT00932191|Active Comparator|Reduced ultrasound phacoemulsification|Cataract nucleus removal using less ultrasound energy and more mechanical energy.
11560253|NCT00932178|Experimental|Calmer Life|Skills-based intervention to reduce anxiety and worry in adults age 50+.
11560254|NCT00932165||Exemestane|Patients taking Exemestane Tablets.
11560255|NCT00932152|Active Comparator|Arm B, Group 1|Best supportive care only: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support PRN
11560256|NCT00932152|Active Comparator|Arm B, Group 2|Best supportive care and Bevacizumab 15mg/kg every 21 days
11560257|NCT00932152|Experimental|Arm A, Group 1|Fulvestrant and anastrozole only
11560258|NCT00932152|Experimental|Arm A, Group 2|Fulvestrant, anastrozole and Bevacizumab
11560259|NCT00932139|Experimental|Electro-acupuncture control|"Blood pressure will be recorded before and after each EA treatment for 8 weeks. The course is a once a week 8-week treatment.
~Intervention is the Electro-acupuncture control treatment."
11560260|NCT00932139|Experimental|Electro-acupuncture test|"Blood pressure will be recorded before and after each EA treatment for 8 weeks. The course is a once a week 8-week treatment.
~Intervention is the active Electro-acupuncture treatment."
11560261|NCT00932126|Experimental|1|
11560262|NCT00932113|Active Comparator|Adalimumab|Dosing will be on day 1 and then weekly. For the injections, dosing will occur according to product recommendations. Patients will receive 80mg adalimumab (2 pre-filled syringes, each with 40mg) on day 1, and then 40mg on week 1 and then every 2 weeks (from week 1 through week 15).
11560263|NCT00932113|Active Comparator|Methotrexate (MTX)|Patients will be dosed according to the CHAMPION study in single weekly doses of methotrexate: 7.5mg at week 0, 10mg at week two, and 15mg at week 4 for all patients. For each subject if the PASI did not decrease by at least 50% from baseline (PASI-50) at week 8, dosing will be increased to 20mg per week; the dose will be maintained at 15mg per week if PASI-50 was achieved at week 8. If PASI-50 was not achieved at week 12, dosing will be increased to 25mg per week; the dose will be maintained at 20mg per week if the PASI-50 was achieved at week 12. All patients on methotrexate will also receive a dietary supplement of oral folate (5mg per week). Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study.
11560264|NCT00932100|Experimental|REG1-a|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
11560265|NCT00932100|Experimental|REG1-b|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
11560266|NCT00932100|Experimental|REG1-c|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
11560267|NCT00932100|Experimental|REG1-d|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
11560268|NCT00932100|Active Comparator|Heparin|Heparin per standard of care at the local institution
11560269|NCT00932087||type 2 diabetics with metabolic syndrome|
11560270|NCT00932087||metabolic syndrome without diabetes|
11560271|NCT00932087||type 1 diabetes|
11560272|NCT00932087||control|
11560273|NCT00932074|Experimental|3% KP-413 Ointment|
11560274|NCT00932074|Experimental|1% KP-413 Ointment|
11560275|NCT00932074|Placebo Comparator|Placebo|
11560276|NCT00932061|Active Comparator|Traditional Acupuncture|Acupuncture sites will be used for active intervention.
11560277|NCT00932061|Sham Comparator|Sham Treatment|Sham acupuncture is used.
11560278|NCT00932048|No Intervention|Control|
11560279|NCT00932048|Experimental|Atorvastatin|
11560280|NCT00932035|Experimental|Arm I (reverse mapping guided axillary lymph node dissection)|Patients receive isosulfan blue dye SC and then undergo reverse mapping-guided axillary lymph node dissection.
11560281|NCT00932035|Active Comparator|Arm II (control)|Patients undergo standard axillary lymph node dissection and then receive isosulfan blue dye SC.
11560282|NCT00932022|Experimental|trospium chloride XR 60 mg|Placebo capsule taken orally once daily for 2 weeks followed by trospium chloride extended release (XR) 60 mg capsule taken orally once daily for 12 weeks.
11560283|NCT00932022|Placebo Comparator|placebo|Placebo capsule taken orally once daily for 14 weeks.
11560284|NCT00932009||Human papillomavirus|Tanzanian men with HPV and Tanzanian men without
11560285|NCT00931996|Experimental|Antipsychotic|Antipsychotic
11560286|NCT00931970||Dialysis modality|
11560287|NCT00931957|Active Comparator|Etanercept-MTX-Prednisolone|Methotrexate + Prednisolone + Etanercept
11560288|NCT00931957|Other|B, MTX-Prednisolone|Methotrexate + Prednisolone
11560289|NCT00931944|Experimental|KNS-760704 300 mg/day|Open-label KNS-760704 (150 mg Q12H)
11560290|NCT00931931|Experimental|HSV1716 - Intratumoral route|Research participants with localized disease receiving HSV1716 as an intratumoral injection
11560291|NCT00931931|Experimental|HSV1716 - intravenous|Research participants with metastatic disease receiving HSV1716 intravenously
11560292|NCT00931918|Active Comparator|RCHOP|RCHOP [rituximab, cyclophosphamide, doxorubicin, prednisone] administered as follows: rituximab 375 mg/m^2 intravenous (IV) infusion, cyclophosphamide 750 mg/m^2 IV infusion, doxorubicin 50 mg/m^2 IV injection and vincristine 1.4 mg/m^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
11560293|NCT00931918|Experimental|Vc-RCHOP|Vc-RCHOP [bortezomib (VELCADE®), rituximab, cyclophosphamide, doxorubicin, prednisone] administered as follows: bortezomib (VELCADE ®) 1.3 mg/m^2 administered intravenous (IV) push on Days 1 and 4 of each cycle with RCHOP administered as follows: rituximab 375 mg/m^2 intravenous (IV) infusion, cyclophosphamide 750 mg/m^2 IV infusion, doxorubicin 50 mg/m^2 IV injection and vincristine 1.4 mg/m^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
11560294|NCT00931905|Experimental|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used, and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.
11560295|NCT00931905|Placebo Comparator|hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol.
11560296|NCT00931892|Experimental|Low gluten group|Subjects will eat 3g of gluten per day
11560297|NCT00931892|Experimental|High gluten group|Subjects will eat 10g of gluten per day
11560298|NCT00931879|Placebo Comparator|Placebo|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
11560299|NCT00931879|Active Comparator|omega-3-ethyl esters 4g|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
11560300|NCT00931866|Experimental|Diclofenac Sodium Patch|
11560301|NCT00931866|Placebo Comparator|Topical Placebo Patch|
11560302|NCT00931853|Experimental|SENNA + CASSIA (Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
11560303|NCT00931840|Experimental|EZN-2208|"EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
~PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL."
11560304|NCT00931840|Experimental|Cetuximab + EZN-2208|Cetuximab will be administered as an i.v. infusion on weekly basis. EZN-2208 administered as i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
11560305|NCT00931840|Active Comparator|Irinotecan + cetuximab|Cetuximab will be administered weekly as an i.v. infusion. Irinotecan will be administered as an i.v. infusion on Weeks 1 and 2 and repeated every 3 weeks.
11560306|NCT00931827||Group 1|
11560307|NCT00931827||Group 2|
11560308|NCT00931814|Other|exercise|
11560309|NCT00931801|Experimental|Intervention Arm No.1|
11560310|NCT00931801|Experimental|Intervention Arm No.2|
11560311|NCT00931801|Active Comparator|Control Arm|Continue baseline regimen
11560312|NCT00931788|Experimental|Intensive pharmacist case management|
11560313|NCT00931788|Active Comparator|Usual care|
11560314|NCT00931775|Placebo Comparator|Citalopram + placebo|Citalopram 20 mg/day t.i.d
11560315|NCT00931775|Experimental|Citalopram + pindolol|Citalopram 20 mg/day t.i.d Pindolol 15 mg/day t.i.d.
11560316|NCT00931762|Experimental|Panobinostat|Panobinostat will be administered orally once a day on Monday, Wednesday and Friday at a fixed dose of 40 mg.
11560317|NCT00931749|Experimental|Low intensity Ultrasound group|
11560318|NCT00931749|Sham Comparator|Sham ultrasound group|
11560319|NCT00931736|Active Comparator|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
11560320|NCT00931736|Active Comparator|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and < 50 kg, otherwise 300 mg for those weighing < 36 kg. Total duration of treatment is for 4 months.
11560321|NCT00931723|Active Comparator|1|Seroquel XR and Lithium
11560322|NCT00931723|Placebo Comparator|2|Seroquel XR and placebo
11560323|NCT00931710|Experimental|Valsartan/amlodipine/HCTZ|Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study.
11560324|NCT00931710|Active Comparator|Losartan/HCTZ|Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study.
11560325|NCT00931697|Experimental|AD 452 (+) mefloquine|
11560326|NCT00931697|Active Comparator|Racemic mefloquine|
11560327|NCT00931697|Placebo Comparator|Placebo|
11560328|NCT00931671|Other|Exercise|Exercise
11560329|NCT00931645|No Intervention|Complete responders|watch and wait policy
11560330|NCT00931645|Experimental|arm 2: complete responders patients|ABMT : TBI, 10 grays d-3-1 & cyclophosphamide 60 mg/sqm d-5-4
11560331|NCT00931645|Experimental|Non CR patients arm 3|Rescue chemotherapy and ABMT (see arm 2)
11560332|NCT00931645|Active Comparator|Non CR patients at random : arm 4|Rescue DHAP, F+C
11560333|NCT00931632|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide
11560334|NCT00931632|Placebo Comparator|Placebo|Nitrogen Placebo
11560335|NCT00931606|Experimental|1|ACE-011 Treatment Group (Dose Level 1)
11560336|NCT00931606|Experimental|2|ACE-011 Treatment Group (Dose Level 2)
11560337|NCT00931606|Experimental|3|ACE-011 Treatment Group (Dose Level 3)
11560338|NCT00931606|Placebo Comparator|4|Placebo
11560339|NCT00931593|Experimental|volunteers|"This is a descriptive study to compare two techniques (manometry with perfused dentsleeve probe vs high resolution manometry for the identification of tLESr). Each subject is his own control.
~The date of perfused manometry is randomized to avoid bias due to examinations' order."
11560340|NCT00931580|Placebo Comparator|Placebo|placebo tablet
11560341|NCT00931580|Experimental|400 IU|Vitamin D3 tablet, 400 IU
11560342|NCT00931580|Experimental|1,000 IU|Vitamin D3 tablet, 1,000 IU
11560343|NCT00931580|Experimental|2,000 IU|Vitamin D3 tablet, 2,000 IU
11560344|NCT00931580|Experimental|4,000 IU|Vitamin D3 tablet, 4,000 IU
11560345|NCT00931567|Active Comparator|Vaselitulle|after surgery, the loss of substance is treated using vaseline dressing
11560346|NCT00931567|Experimental|Autologous platelets gel|after surgery, the loss of substance is treated with Autologous platelets gel
11560347|NCT00931554|Active Comparator|Early drain removal|Drain removal in postoperative day 3
11560348|NCT00931554|Active Comparator|Standard drain removal|Drain removal on postoperative day 5
11560349|NCT00931541|Experimental|A|AZD6088 oral solution
11560350|NCT00931541|Experimental|B|Placebo oral solution
11560351|NCT00931528|Experimental|Tadalafil|Tadalafil
11560352|NCT00931528|Placebo Comparator|Placebo|Placebo
11560353|NCT00931515|Experimental|NuBac|NuBac device implanted at the L4/5 level
11560354|NCT00931515|Active Comparator|Prodisc-L|Prodisc-L implanted at the L4/5 level.
11560355|NCT00931489|Active Comparator|Wet AMD Patients Responders|Dilated eye exam once a month for 7 months; visual acuity and OCT once a month for 7 months; Lucentis(R)/ranibizumab injection once each month for the Baseline and Month 1-3 visits, then as needed at Month 4 and 5; 3 Tbls. blood draw at Baseline, Month 3 and Month 6 visits.
11560356|NCT00931489|No Intervention|Normal Population|Dilated eye exam and 3 Tbls. blood draw at first and only study visit.
11560357|NCT00931489|Active Comparator|Wet AMD Patients Acute Non-responders|Participants in this Group will have not responded to 4 prior injections of Lucentis(R)/ranibizumab or other anti-VEGF treatment. Dilated eye exam at Month 4; visual acuity and OCT at Months 4-6; injection of anti-VEGF treatment as needed at Months 4 and 5; 3 Tbls. blood draw at Month 4
11560358|NCT00931489|No Intervention|Dry AMD Population|Dilated eye exam and 3 Tbls. blood draw at first and only study visit.
11560359|NCT00931489|Active Comparator|Wet AMD Patients Chronic Non-responderes|Participants in this Group will have not responded to 4 or more prior injections of Lucentis(R)/ranibizumab or other anti-VEGF treatment. One visit at Month 4: Dilated eye exam with visual acuity and OCT; injection of anti-VEGF as needed; 3 Tbls. blood drawn
11560360|NCT00931463|Active Comparator|Ritonavir-boosted lopinavir and 2N(t)RTI|This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.
11560361|NCT00931463|Experimental|Ritonavir-boosted lopinavir and raltegravir|This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.
11560362|NCT00931450|Active Comparator|Group 1|Patients receive oral exemestane and oral placebo once daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
11560363|NCT00931450|Experimental|Group 2|Patients receive oral exemestane once daily and oral sunitinib malate once daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
11560364|NCT00931437|Experimental|vitamin K-rich dairy product|one single intake of a dairy product containing several K-vitamins: phylloquinone, menaquinone-7,8,9-and 10.
11560365|NCT00931424|Experimental|reconstruction|patients in this group will have both valve reconstruction and superficial vein surgery
11560366|NCT00931424|No Intervention|unreconstruction|patients in this group will only have superficial vein surgery
11560367|NCT00931411|Experimental|Formulation 609580 20 then 609209|Formulation 609580 20 cream is applied topically to the entire body twice a day, morning and evening, after bathing for 42 days. This is followed by the same application of formulation 609209 for 2 weeks. Dosage is at the discretion of the parent applying the cream to the child.
11560368|NCT00931411|Active Comparator|Formulation 609209 then 609580 20|Formulation 609209 cream is applied topically to entire body, twice a day, morning and evening, after bathing for 42 days. This is followed by the same application of formulation 609580 20 for 2 weeks. Dosage is at the discretion of the parent applying the cream to the child.
11560369|NCT00931398|Experimental|Methylphenidate HCl (Concerta)|
11560370|NCT00931398|Placebo Comparator|Placebo|
11560371|NCT00931385|Experimental|BI 1744 (Olodaterol) Low Dose|BI1744 Low Dose once daily
11560372|NCT00931385|Experimental|BI 1744 (Olodaterol) Med Dose|BI 1744 Med Dose once daily
11560373|NCT00931385|Placebo Comparator|Placebo|Placebo once daily
11560374|NCT00931385|Active Comparator|Foradil|Foradil 12 mcg twice daily
11560375|NCT00931372|Experimental|Sequence 1: AVE0010/Placebo|"Period 1: lixisenatide 20 µg in 200 µL, one single dose
~Period 2: placebo 200 µL, one single dose"
11560376|NCT00931372|Experimental|Sequence 2: Placebo/AVE0010|"Period 1: placebo 200 µL, one single dose
~Period 2: lixisenatide 20 µg in 200 µL, one single dose"
11560377|NCT00931359|Experimental|Treatment with DTS-G2 System|Subjects receive treatment with the DTS-G2 System (an energy-based medical device) in both axilla. Multiple treatment sessions may be used.
11560378|NCT00931359|Sham Comparator|Sham treatment|All elements of the treatment are given except that no energy is delivered. Multiple treatment sessions may be used.
11560379|NCT00931346|Experimental|FTC/TDF Daily|Daily dosing
11560380|NCT00931346|Experimental|FTC/TDF Intermittent|Dosed intermittently
11560381|NCT00931346|Placebo Comparator|Placebo Daily|Placebo dosed daily
11560382|NCT00931346|Placebo Comparator|Placebo Intermittent|Placebo dosed intermittently, orally.
11560383|NCT00931333|Experimental|1|
11560384|NCT00931320||3000 patients|Who have at least made 1 visit to the outpatient clinic within previous 6 months .
11560385|NCT00931307|Experimental|Lotrafilcon A|
11560386|NCT00931281|Active Comparator|1|ABT-450/ritonavir
11560387|NCT00931281|Placebo Comparator|2|Placebo for ABT-450/placebo for ritonavir
11560388|NCT00931268|Other|Macrolane VRF 30|Open label, baseline-controlled, one treatment session with injection of Macrolane VRF30 to each buttock, not exceeding 400 ml per subject.
11560389|NCT00931255|Active Comparator|Tacrolimus|Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
11560390|NCT00931255|Active Comparator|Sirolimus|5 mg, PO , daily
11560391|NCT00931242|Experimental|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
11560392|NCT00931229|Experimental|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines.
11560393|NCT00931216|Experimental|Integrated ANC, PMTCT and HIV Services|HIV care and treatment services are integrated into antenatal care (ANC) services for women testing positive within the ANC at this facility.
11560394|NCT00931216|No Intervention|Non-Integrated Services|Women testing positive in the ANC department are referred for care at the HIV clinic. HIV care and treatment services are not provided within the ANC at facilities randomized to this arm.
11560395|NCT00931177||Dehydrated children|children with dehydration
11560396|NCT00931164|Experimental|Sodium oxybate|"The study is an open-label, Phase I/II trial designed to obtain additional safety and pharmacokinetic parameters for use of sodium oxybate in children and adolescents afflicted with AHC.
~Given the limited number of children carrying the diagnosis of AHC, typical controls will not be available for our study. In lieu of this, the subjective recording of ictal episodes in the 6 week period prior to drug initiation will serve as reference in determining drug efficacy."
11560397|NCT00931151|Experimental|Casein|Protein source in the high fat meal is casein
11560398|NCT00931151|Experimental|Milk soluble protein|Protein source in the high fat meal are milk soluble protein
11560399|NCT00931151|Experimental|Alpha lactalbumin|Protein source in the high fat meal is alpha-lactalbumin
11560400|NCT00931138|Active Comparator|Arm1 = Aracytine + Daunorubicin|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
11560401|NCT00931138|Active Comparator|Arm 3 = Aracytine And Idarubicin|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
11560402|NCT00931138|Active Comparator|Arm 2 = Aracytine And Idarubicin|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
11560403|NCT00931125|Active Comparator|vitrectomy with ranibizumab|Patients receiving adjunct preoperative intravitreal ranibizumab (3±1 days) before vitrectomy surgery
11560404|NCT00931125|Placebo Comparator|vitrectomy without ranibizumab|Patients receiving sham treatment before vitrectomy as a comparator arm
11560405|NCT00931112|Other|exercise|
11560406|NCT00931099||Low risk pregnant women|300 women in the third trimester of a singleton uncomplicated pregnancy, who attend a low risk obstetric surveillance
11560407|NCT00931099||High risk pregnant women|100 women hospitalized at the Antenatal department due to pregnancy related hypertensive disorder, IUGR, diabetes mellitus or premature labor
11560408|NCT00931099||Pregnant women in labor|200 women of a singleton uncomplicated full term pregnancy will be recruited during labor at the delivery room
11560409|NCT00931099||Newborns|400 newborns belong to women in first two groups
11560410|NCT00931073|Experimental|Period 1|
11560411|NCT00931073|Experimental|Period 2|
11560412|NCT00931073|Experimental|Period 3|
11560413|NCT00931060|Experimental|Branched chain amino acids|Patients with cirrhosis. Healthy subjects age and sex matched
11560414|NCT00931034|Active Comparator|South Beach Diet with SBD Products|
11560415|NCT00931034|Active Comparator|ADA Diabetes meal plan|
11560416|NCT00931021|Active Comparator|Varenicline (Chantix)|
11560417|NCT00931021|Active Comparator|Nicotine Patch|
11560418|NCT00931008|Experimental|SID530|Study participants who meet eligibility criteria will be randomized to one of two treatment sequences, SID530 or Taxotere (i.e., SID530 on Day 1 followed by Taxotere on Day 21 or Taxotere on Day 1 followed by SID530 on Day 21)
11560419|NCT00931008|Active Comparator|Taxotere|Study participants who meet eligibility criteria will be randomized to one of two treatment sequences, SID530 or Taxotere (i.e., SID530 on Day 1 followed by Taxotere on Day 21 or Taxotere on Day 1 followed by SID530 on Day 21)
11560420|NCT00930995|Active Comparator|A|
11560421|NCT00930995|Placebo Comparator|B|
11560422|NCT00930982|Experimental|Ciprofloxacin Inhale (BAYQ3939)|32.5 mg ciprofloxacin hydrated corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice daily
11560423|NCT00930982|Placebo Comparator|Placebo|Inhalation of matching placebo twice a day
11560424|NCT00930956|Active Comparator|Dextrose|30 g of carbohydrate via Sun-Dex OGTT beverage
11560425|NCT00930956|Experimental|RS Type 2|30g Resistant Starch Type 2 (Hi-Maize 260, National Starch)
11560426|NCT00930956|Experimental|RS Type 4 (cross linked)|30g of cross linked RS type 4 (Fibersym RW, MGP Ingredients, Inc.)
11560427|NCT00930930|Experimental|Cisplatin and Paclitaxel + RAD001|Cisplatin 25 mg/m2 IV weekly + RAD001 5 mg PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + RAD001 5 mg PO daily for 11 weeks
11560428|NCT00930930|Active Comparator|Cisplatin and Paclitaxel + Placebo|Cisplatin 25 mg/m2 IV weekly + placebo PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + placebo PO daily for 11 weeks
11560429|NCT00930917|Experimental|cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
11560430|NCT00930917|Active Comparator|wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
11560431|NCT00930917|Other|conventional group|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
11560432|NCT00930891|Active Comparator|Arm A|4 additional cycles of chemotherapy
11560433|NCT00930891|Experimental|Arm B|4 additional cycles of chemotherapy + bevacizumab
11560434|NCT00930878||Promus|Patients intended to be treated with a Promus™ stent system
11560435|NCT00930878||Endeavor|Patients intended to be treated with an Endeavor™ stent system (excluded the Endeavor™ Resolute™ stent)
11560436|NCT00930878||Cypher|Patients intended to be treated with a Cypher™ stent system
11560437|NCT00930865|Active Comparator|Bumetanide|
11560438|NCT00930865|Active Comparator|Dapagliflozin|
11560439|NCT00930865|Active Comparator|Bumetanide + Dapagliflozin|
11560440|NCT00930839||Controls|Normal, healthy controls, males and females, ages 30-80
11560441|NCT00930813|Experimental|Lutonix Catheter|Paclitaxel coated Balloon Catheter
11560442|NCT00930813|Active Comparator|Standard uncoated Balloon Angioplasty Catheter|uncoated angioplasty balloon
11560443|NCT00930800|Other|Exercise|Dance Dance Revolution (DDR)
11560444|NCT00930787|Experimental|Strattice Reconstructive Tissue Matrix|Use of Strattice Reconstructive Tissue Matrix to support hernia repair
11560445|NCT00930787|Active Comparator|Proceed Surgical Mesh|Use of Proceed Surgical Mesh to support hernia repair
11560446|NCT00930774|Experimental|FM System|Provision of FM assistive device
11560447|NCT00930774|Experimental|Auditory Training|Provision of auditory training
11560448|NCT00930774|Experimental|FM System and Auditory Training|Provision of FM assistive device and auditory training
11560449|NCT00930774|No Intervention|Standard-of-Care|Standard-of-care informational counseling
11560450|NCT00930761|No Intervention|Control|
11560451|NCT00930761|Experimental|Music therapy|
11560452|NCT00930735||Myocardial fibrosis, outcomes|Groups with none and variable amounts of myocardial fibrosis
11560453|NCT00930722||quinapril|quinapril
11560454|NCT00930709|Active Comparator|Active strength training and stretching|Active strength training and stretching
11560455|NCT00930709|Active Comparator|Botulinum toxin type A injections|Botulinum toxin type A injections
11560456|NCT00930696|Experimental|Extensive Abdominal Lavage|women with full thickness excision of deep endometriosis involving the bowel
11560457|NCT00930696|Active Comparator|Standard Rinsing|women with full thickness excision of deep endometriosis involving the bowel
11560458|NCT00930683|Other|1|MEDI-546
11560459|NCT00930683|Other|2|MEDI-546
11560460|NCT00930683|Other|3|MEDI-546
11560461|NCT00930683|Other|4|MEDI-546
11560462|NCT00930683|Other|5|MEDI-546
11560463|NCT00930683|Other|6|MEDI-546
11560464|NCT00930683|Other|7|MEDI-546
11560465|NCT00930683|Other|8|MEDI-546
11560466|NCT00930683|Other|9|MEDI-546
11560467|NCT00930670|Experimental|Rosuvastatin-omeprazole|Rosuvastatin-omeprazole
11560468|NCT00930670|Experimental|Rosuvastatin-pantoprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
11560469|NCT00930670|Experimental|Rosuvastatin-esomeprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
11560470|NCT00930670|Active Comparator|Rosuvastatin-ranitidine|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300 mg for 11 months
11560471|NCT00930670|Experimental|Atorvastatin-omeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
11560472|NCT00930670|Experimental|Atorvastatin-pantoprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40mg for 11 months
11560473|NCT00930670|Experimental|Atorvastatin-esomeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
11560474|NCT00930670|Active Comparator|Atorvastatin-ranitidine|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
11560475|NCT00930644|Experimental|teduglutide|0.05 mg/kg/day
11560476|NCT00930631|Other|Single Arm|Single arm PK study
11560477|NCT00930618|Experimental|IMN|Isosorbide mononitrate
11560478|NCT00930618|Placebo Comparator|Placebo|Administration of placebo of IMN
11560761|NCT00928668|Experimental|Olodaterol (BI1744) Low|Single dosing of low dose Olodaterol inhaled orally from Respimat Device
11560479|NCT00930605|Experimental|Alemtuzumab combination with CHOP and ESHAP|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5. CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
11560480|NCT00930592||Children with Psoriasis|Children and adolescents from 10-17 years of age with moderate to severe psoriasis.
11560481|NCT00930592||Control: children with warts|Children and adolescents from 10-17 years of age with warts.
11560482|NCT00930579|Experimental|Metformin|
11560483|NCT00930566|Experimental|Extracorporal Photopheresis|
11560484|NCT00930553|Experimental|Previously treated with alemtuzumab|Alemtuzumab 12 mg per day administered through IV, once a day for 3 consecutive days (participants might receive additional cycles of alemtuzumab upon documented evidence of resumed disease activity, but not within same 12-month period)
11560485|NCT00930553|Experimental|Previously treated with interferon beta-1a (Rebif®)|Alemtuzumab 12 mg per day administered through IV, once a day for 5 consecutive days during the first cycle and 12 mg per day administered through IV, once a day for 3 consecutive days during the second cycle, 12 months later. Participants might qualify for as-needed retreatment (12 mg per day administered through IV, once a day for 3 consecutive days) after their second fixed annual cycle.
11560486|NCT00930514|Active Comparator|Rituximab IV 375 mg/m^2 (Stage 1: Cohort A)|
11560487|NCT00930514|Active Comparator|Rituximab IV 375 mg/m^2 (Stage 2: Cohort E)|
11560488|NCT00930514|Experimental|Rituximab SC 1400 mg (Stage 2: Cohort F)|
11560489|NCT00930514|Experimental|Rituximab SC 375 mg/m^2 (Stage 1: Cohort B)|
11560490|NCT00930514|Experimental|Rituximab SC 625 mg/m^2 (Stage 1: Cohort C)|
11560491|NCT00930514|Experimental|Rituximab SC 800 mg/m^2 (Stage 1: Cohort D)|
11560492|NCT00930501||Cancer patients|women 5-45 yr olf pre and post chemotherapy
11560493|NCT00930488||Group 1|
11560494|NCT00930462|No Intervention|Conventional colonoscopy|No cap fitted on the colonoscopes for this group.
11560495|NCT00930462|Experimental|Cap-assisted colonoscopy|
11560496|NCT00930449|Experimental|Cogmed Working Memory Training Program|
11560497|NCT00930449|Active Comparator|Academy of Math® program|
11560498|NCT00930449|Active Comparator|Special Education/Individualized Tutoring|
11560499|NCT00930436|Active Comparator|Saline infusion|Saline will be given as an active control agent to compare with sodium bicarbonate. Each bag of solution will be blinded, and given in the same manner.
11560500|NCT00930436|Experimental|Sodium Bicarbonate|Infusion of sodium bicarbonate will be given prior to,during and after the contrast agent for a total of 6 to 10 hours
11560501|NCT00930423||cases|patients with endstage renal failure due to atypical uraemic syndrome treated with hemodialysis.
11560502|NCT00930423||controls|patiënts with endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.
11560503|NCT00930410|Experimental|endomicroscopy|Utilisation of an intra-ductal confocal endomicroscopy during the endoscopic Retrograde Cholangio-Pancreatography
11560504|NCT00930397||Low risk women|Women without any personal risk.
11560505|NCT00930397||High risk women|Women at high risk for pre-eclampsia with personal of pre-eclampsia and/or IUGR in a previous pregnancy, diabetes, auto-immune syndrome such as lupus, hypertension, renal insufficiency and anti-phospholipid.
11560506|NCT00930384||Psoriasis group|All adult patients fulfilling inclusion criteria will be considered as cases in which psoriasis is detected and diagnosed by our principal investigator based on the clinical criteria accepted by American Academy of Dermatology. They will have an abdominal ultrasound performed by a radiologist to assess for the presence of nonalcoholic fatty liver disease. They will be referred to the research clinic to have a blood drawn.
11560507|NCT00930384||Control group|For every case an age, sex and body mass index (BMI range - kg/m2) matched control will be selected from the same dermatologic/radiologic clinic. The controls will be invited to voluntarily participate and informed consent will be obtained for performing ultrasonography and analytical tests to ensure the absence of manifest hepatic disease.
11560508|NCT00930358|Experimental|MEOPA|MEOPA : equimolar nitrous oxide/oxygen mixture
11560509|NCT00930358|Active Comparator|General anesthesia|Gold standard
11560510|NCT00930345|Other|SUTENT before nephrectomy|
11560511|NCT00930332|Active Comparator|Arm A: Methadone|"Level 1: 1 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA** per day)
~Level 2: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)
~Level 3: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)"
11560512|NCT00930332|Active Comparator|Arm B: Methadone|"Level 1: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)
~Level 2: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)
~Level 3: 4 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)"
11560513|NCT00930319||1|Patients with Advanced Hormone-dependent Prostate Carcinoma treated with Firmagon according to SPC
11560514|NCT00930306|Experimental|1|12 AZD2066 Capsule, 2 mg & 8 mg 2 Caffeine Tablet, 2 x 50 mg 2 Tolbutamide Tablet, half of 500 mg 2 Omeprazole Tablet, 20 mg 2 Midazolam Tablet, 7.5 mg 2 Metoprolol Tablet, 100 mg 2 Bupropion Tablet, 150 mg
11560515|NCT00930293|Experimental|Personalized Depression Care|Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication (citalopram) treatment.
11560516|NCT00930293|Active Comparator|Standard Depression Care|Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication (citalopram) treatment.
11560517|NCT00930280||Hemorrhagic stroke cases|People who have had a hemorrhagic stroke, specifically an intracerebral hemorrhage, and live within a 100 mile radius of the University of Cincinnati.
11560518|NCT00930280||Healthy Control Subjects|Healthy volunteers who are randomly identified in the same 100 mile radius of the University of Cincinnati and have not had a hemorrhagic stroke.
11560519|NCT00930254|Experimental|Ultrasound|Vascular puncture guided by vascular ultrasound
11560520|NCT00930241|Experimental|Advagraf|Advagraf® (one daily dose of Tacrolimus)
11560521|NCT00930241|Active Comparator|Prograf|Prograf® (two daily doses of Tacrolimus)
11560522|NCT00930228|Experimental|Flutamide|Flutamide 250 mg taken by mouth twice a day for 4 weeks. Flutamide is an androgen-receptor blocker.
11560523|NCT00930228|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
11560524|NCT00930215|Experimental|D961H 40 mg gelatin capsule|2 way crossover
11560526|NCT00930202|Experimental|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
11560527|NCT00930202|No Intervention|Standard Care|No intervention
11560528|NCT00930176|Experimental|Human Coagulation FACTOR X|
11560529|NCT00930163|Experimental|1|
11560530|NCT00930163|Placebo Comparator|2|
11560531|NCT00930150|Experimental|Posit Science Intervention|Participants will receive targeted cognitive training and participate in a bridging group.
11560532|NCT00930150|Active Comparator|Control|Participants will play commercially available computer games and participate in weekly groups to discuss health and wellness.
11560533|NCT00930137|Experimental|High dairy trans fat|a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal)
11560534|NCT00930137|Active Comparator|Low dairy trans fat diet|a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)
11560535|NCT00930124|Experimental|1|Group 1 will receive Conventional orthognathic surgery
11560536|NCT00930124|Active Comparator|2|Group 2 will receive distraction osteogenesis
11560537|NCT00930111|Active Comparator|2 weeks|Attending physicians are physician-of-records for traditional inpatient ward team (housestaff and medical students) for 2 weeks.
11560538|NCT00930111|Placebo Comparator|4 weeks|Attending physicians are physician-of-records for traditional inpatient ward team (housestaff and medical students) for 4 weeks.
11560539|NCT00930085|Experimental|SELDI-TOF MS|The proteic profiling is performed by SELDI-TOF mass spectroscopy.
11560540|NCT00930072|Experimental|Block|
11560541|NCT00930072|No Intervention|Standard Care|
11560542|NCT00930059|Experimental|PF-04447943|
11560543|NCT00930059|Placebo Comparator|Placebo|
11560544|NCT00930046|Active Comparator|Ropivacaine group|Patients in this group will receive ropivacaine via the wound catheter for the first 48hrs after surgery
11560545|NCT00930046|Placebo Comparator|Normal Saline Group|Will receive an infusion of normal saline for 48hrs post-operatively via the wound catheter.
11560546|NCT00930033|Active Comparator|A|Nephrectomy + sunitinib
11560547|NCT00930033|Experimental|B|Sunitinib alone
11560548|NCT00930020|Placebo Comparator|matching placebo pill|matching placebo
11560549|NCT00930020|Active Comparator|Oral minocycline|Minocycline 200mg
11560550|NCT00930007||Hyperandrogenemic|Girls with elevated free testosterone concentrations
11560551|NCT00930007||Controls|Girls with normal free testosterone concentrations
11560552|NCT00929994||Exercise|Following a 3 month non intervention period, participants will participate in Cardiac Rehabilitation, carrying out an exercise program which will last 6 months and combine both resistance and aerobic training.
11560553|NCT00929981||Oral Methylprednisolone|
11560554|NCT00929968|Placebo Comparator|Placebo to VAK694|
11560555|NCT00929968|Experimental|VAK694|
11560556|NCT00929968|Active Comparator|Fluticasone propionate|
11560557|NCT00929955|Active Comparator|Ondansetron|
11560558|NCT00929955|Active Comparator|Simvastatin|
11560559|NCT00929955|Placebo Comparator|Placebo|
11560560|NCT00929942|Experimental|DV Stent|"Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented."
11560561|NCT00929929|Experimental|L-Leucine|This arm receives a supplement of leucine along with a progressive resistance exercise program.
11560562|NCT00929929|Placebo Comparator|Maltodextrin|This arm receives a supplement of maltodextrin along with a progressive resistance exercise program.
11560563|NCT00929916||AM dosing of MoviPrep®|Take prep morning of exam
11560564|NCT00929916||PM/AM dosing of MoviPrep®|half of the volume of prep(1L) solution the evening prior, and half (1L) the morning of, colonoscopy.
11560565|NCT00929903|Experimental|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11560566|NCT00929890|Active Comparator|Lifestyle counseling|Patients will receive dietary counseling and a general advice on physical activity
11560567|NCT00929890|Experimental|Exercise training|patients will receive dietary counseling and will be enrolled in supervised exercise training
11560568|NCT00929877|Experimental|Ketoprofen lysinate 12.5 mg|
11560569|NCT00929877|Experimental|Ketoprofen lysinate 6.25 mg|
11560570|NCT00929877|Placebo Comparator|Matching placebo|
11560571|NCT00929864|Active Comparator|Abatacept|
11560572|NCT00929864|Active Comparator|Adalimumab|
11560573|NCT00929851|Experimental|BDP/FF|Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose inhaler
11560574|NCT00929851|Active Comparator|Formoterol fumarate|Formoterol fumarate 12 µg per metered dose
11560575|NCT00929838|Experimental|Diabetes Knowledge/Information Arm|Subjects randomized to the diabetes knowledge/information arm will complete 12 diabetes education modules over a 12-week period. The educational materials were developed based on guidelines for diabetes education by the American Diabetes Association. The content is based on the principles of the Adult Learning Theory. The information is designed to be relevant, person centered, and presented in a non-threatening manner. The modules are designed to be delivered via telephone in 10-15 minutes, so that the maximum contact time per telephone call including introduction and closing would not exceed 30 minutes.
11560576|NCT00929838|Experimental|Motivation/Behavioral Skills Arm|The motivation/behavioral skills intervention consists of patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions), patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools), and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks. The behavioral skills training will be focused on 4 behaviors - physical activity, diet, medication adherence, and glucose self-monitoring. Guided by subjects' current problem areas and preferences, subjects will be asked to choose 1 of 4 behaviors to focus on every 3 weeks (4 behaviors over 12 weeks).
11560762|NCT00928668|Experimental|Olodaterol (BI1744) Medium Low|Single dosing of medium low dose Olodaterol inhaled orally from Respimat Device
11560577|NCT00929838|Experimental|Combined Intervention Arm|The combined intervention group will receive weekly telephone-delivered diabetes knowledge/information, patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions), patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools), and behavioral skills training delivered via telephone. The behavioral skills training will be focused on 4 behaviors and guided by subjects' current problem areas and preferences, subjects will be asked to choose 1 of 4 behaviors to focus on every 3 weeks. The combined intervention group telephone sessions will last for 30 minutes.
11560578|NCT00929838|Sham Comparator|Usual Care Arm|The usual care group will receive weekly telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention. Patients in the usual care group will continue to receive any usual diabetes education provided by the clinic staff; however, they will not receive targeted diabetes knowledge/information, activation, empowerment, or behavioral skills training.
11560579|NCT00929825|Experimental|Elastomers|Patients will use hyperboloid as mechanical salivary stimuli. Patients will chew hyperboloid 3 times a day
11560580|NCT00929825|Experimental|TENS|TENS is a eletric stimuli that will be use in the skin near to parotid glands. Patients will receive TENS treatment as eletric salivary stimuli. Patients will receive TENS stimuli once a day for 15 days
11560581|NCT00929825|Experimental|Elastomers+TENS|Patients will receive TENS plus hyperboloid as eletric and mechanical treatment for salivary stimuli
11560582|NCT00929825|No Intervention|No therapy (control)|Patients will not receive intervention
11560583|NCT00929812|Active Comparator|Glucagon hydrochloride|GlucaGen® 1 mg/1 ml intramuscularly
11560584|NCT00929812|Placebo Comparator|Placebo|1 ml NaCl 0.9%
11560585|NCT00929799|Experimental|Growth Hormone|Therapy with recombinant human GH (Genotropin® 1 mg = 3 IU, Pfizer Inc., NY, USA) daily by subcutaneous injection using a Genotropin pen at maximal GH dose of 0.003 mg/kg/day in patients with severe GHD
11560586|NCT00929786||2|"Cases - those patients who develop DIH while on regular treatment with anti-TB drugs.
~Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs."
11560587|NCT00929773|Active Comparator|Erchonia PL2000 Laser|Low level laser light energy comprised of 1 milliWatts (mW) of red light (635 nm).
11560588|NCT00929773|Placebo Comparator|Placebo laser|inactive light
11560589|NCT00929760|Active Comparator|nephrologists|Combined management PCP: nephrologists (at least 4 nephrology visits/year)
11560590|NCT00929760|Active Comparator|Primary Care Physicians|Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG
11560591|NCT00929747|Active Comparator|Toric IOL|AcrySof IQ Toric IOL
11560592|NCT00929747|Active Comparator|Limbal Relaxing Incision|AcrySof IQ with Limbal Relaxing Incision
11560593|NCT00929734|Experimental|Rosuvastatin|
11560594|NCT00929734|Placebo Comparator|Placebo|
11560595|NCT00929721|Other|Subjects with Community-Acquired Pneumonia|Subjects with Community-Acquired Pneumonia
11560596|NCT00929708|Experimental|1|AZD3199 low dose
11560597|NCT00929708|Experimental|2|AZD3199 intermediate dose
11560598|NCT00929708|Experimental|3|AZD3199 high dose
11560599|NCT00929708|Active Comparator|4|Formoterol 2x4.5 microgram bid
11560600|NCT00929708|Placebo Comparator|5|Placebo
11560601|NCT00929695|Experimental|Arm I (Low-dose)|Patients receive low-dose prednisone or methylprednisolone once or twice daily in the absence of disease progression or unacceptable toxicity.
11560602|NCT00929695|Active Comparator|Arm II (Standard-dose)|Patients receive standard-dose prednisone or methylprednisolone once or twice daily in the absence of disease progression or unacceptable toxicity.
11560603|NCT00929682|Experimental|Levobupivacaine 0.568mg.mL|
11560604|NCT00929682|Other|Levobupivacaine 1.136mg.mL|
11560605|NCT00929669|Experimental|Pasireotide LAR|80 mg IM once monthly
11560606|NCT00929656|Experimental|Real rTMS|Real rTMS + unimanual paretic UE training
11560607|NCT00929656|Active Comparator|Sham rTMS|Sham rTMS + unimanual paretic UE training
11560608|NCT00929643||1|
11560609|NCT00929630|Experimental|glue (Tissucol ) treatment|patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
11560610|NCT00929630|Active Comparator|Seton treatment|patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
11560611|NCT00929617|Experimental|1: exercise with 2 counseling types|Patients will participate in 12 individual exercise sessions with an exercise specialist; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
11560612|NCT00929617|Other|2. Usual Care - written materials|Patients will receive written materials about exercise for cancer survivors
11560613|NCT00929604|No Intervention|Standard of care|Standard of care arm: utilizes the current standard of care per Zambian national guidelines to determine treatment failure and eligibility for second-line ART. HIV-1 viral load measurement is performed if the criteria for either immunologic (i.e., CD4+ lymphocyte count-based) or clinical treatment failure are fulfilled. If both immunologic and clinical treatment failure criteria are fulfilled, the ART regimen is changed to second-line without VL testing.
11560614|NCT00929604|Experimental|Routine HIV-1 viral load testing|Routine viral load testing arm: Routine HIV viral load testing at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30 and 36 months thereafter.
11560615|NCT00929591|Active Comparator|tamoxifen for five years|tamoxifen for five years
11560616|NCT00929591|Experimental|CAF followed by tamoxifen for five years|intermittent CAF X 6 courses followed by tamoxifen for five years
11560617|NCT00929591|Experimental|CAF with concurrent tamoxifen for five years|intermittent CAF X 6 courses with concurrent tamoxifen for five years
11560618|NCT00929578|Placebo Comparator|Placebo|The sterile placebo: Bacteriostatic Sodium Chloride for Injection.
11560702|NCT00928980|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy and withdrawal of antidepressant medication between the 4th and 5th session, patients being off medication until the end of study period (15 months).
11560703|NCT00928980|Experimental|Combination|Mindfulness Based Cognitive Therapy combined with the use of antidepressant medication during the study (15 months).
11560619|NCT00929578|Active Comparator|Fluphenazine|This will be an ascending dose study with the first cohort of 5 subjects dosed at 100 µg/mL, followed by cohorts at 500 and 2500 µg/mL. Dosing will be on Days 0, 7 and 14 and will consist of 5, or 10, 100 µL injections into the psoriatic lesion. The number of injections will depend on the lesion size. As this is a vehicle controlled study, subjects will receive intralesional injections of both drug and placebo, each into a separate target plaque, in a randomized fashion.
11560620|NCT00929565||Lung cancer|Comparison between individuals with and without pulmonary malignancy
11560621|NCT00929552|Experimental|Fish oil|Daily dose = 6g fish oil baked into rye bread and wheat rolls. Participants were asked to consume two slices of rye bread and one wheat roll pr day. The fish oil was micro-incapsulated.
11560622|NCT00929552|Active Comparator|Vegetable oil (Mix of canola, palm and soy oil)|Daily dose = 6g vegetable oil baked into rye bread and wheat rolls. Participants were asked to consume two slices of rye bread and one wheat roll pr day.
11560623|NCT00929539|Experimental|Dose 1 JTT-130|
11560624|NCT00929539|Experimental|Dose 2 JTT-130|
11560625|NCT00929539|Experimental|Dose 3 JTT-130|
11560626|NCT00929539|Placebo Comparator|Placebo|
11560627|NCT00929526|Experimental|Cervarix Group|subjects received 3 doses of Cervarix™ vaccine in primary vaccination study NCT00316693.
11560628|NCT00929526|Placebo Comparator|Aimmugen Group|subjects received 3 doses of Aimmugen ™ vaccine in primary vaccination study NCT00316693.
11560629|NCT00929500|Experimental|MAST program|Mixed Aerobic and Strength Training program (MAST): Each exercise session consisted of 10 minutes of warm-up, 15-30 minutes of interval aerobic training by cycle ergometer according to the program, 20 minutes of strength training exercises, and 10 minutes of cool-down by stretching.
11560630|NCT00929500|No Intervention|UC|Usual Care (UC) with Educational Lectures: No exercise sessions.
11560631|NCT00929487|Experimental|Contact lens solution #1|
11560632|NCT00929487|Experimental|Contact lens solution #2|
11560633|NCT00929487|Experimental|Contact lens solution #3|
11560634|NCT00929487|Experimental|Contact lens solution #4|
11560635|NCT00929487|Active Comparator|Saline/blister pack solution|
11560636|NCT00929474|Experimental|QuickOpt|
11560637|NCT00929474|Active Comparator|Control|
11560638|NCT00929461|Other|Omega-3 group|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
11560639|NCT00929461|Other|Omega 3 + Omega 6 group|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter.
11560640|NCT00929448||Immunoglobulin|
11560641|NCT00929435||MRSA surveillance|Newly recruited resident physicians will be monitored for a year with nasal swabs monthly.
11560642|NCT00929422||spinal cord injury 1|
11560643|NCT00929422||spinal cord injury 2|
11560644|NCT00929422||spinal cord injury 3|
11560645|NCT00929422||normal control|
11560646|NCT00929409|Active Comparator|Peroral iron - ferrous sulfate tablets|Peroral iron given as one tablet of ferrous sulfate 100 mg two times daily
11560647|NCT00929409|Active Comparator|Ferric carboxymaltose|Intravenous infusion of Ferric Carboxymaltose (Ferinject), the given dose is adapted according to the individual patient's requirement. No other form of iron supplementation is given.
11560648|NCT00929396|Experimental|Latent TB infection group|The latent TB group will receive two injections of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart.
11560649|NCT00929396|Experimental|BCG vaccinated group|The BCG vaccinated group will receive two vaccinations of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart
11560650|NCT00929370|Experimental|GSK1018921|Glycine Transporter-1 inhibitor to modulate the NMDA receptor.
11560651|NCT00929357||1|DMARDs
11560652|NCT00929357||2|Biologics
11560653|NCT00929344|Experimental|Duloxetine|
11560654|NCT00929344|Experimental|Pregabalin|
11560655|NCT00929344|Placebo Comparator|Placebo|
11560656|NCT00929331|Experimental|Fluviral Adult Group|Subjects aged between 18 and 60 years who received one dose of Fluviral® (2009-2010 season) intramuscularly in the deltoid region of the non-dominant arm
11560657|NCT00929331|Experimental|Fluviral Elderly Group|Subjects over 60 years of age who received one dose of Fluviral ® (2009-2010 season) intramuscularly in the deltoid region of the non-dominant arm
11560658|NCT00929318|Active Comparator|benign|patients after surgery because of a benign disease
11560659|NCT00929318|Active Comparator|DTC|Patients after thyroidectomy because of papillary carcinoma of the thyroid gland
11560660|NCT00929305|Placebo Comparator|Placebo laser|inactive laser light
11560661|NCT00929305|Active Comparator|Erchonia PL2000|The Erchonia PL2000 Laser emits 1 milliWatt (mW) of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
11560662|NCT00929292|Experimental|Modilac Dahlia 1|Formula enriched with alpha-lactalbumin and containing a probiotic
11560663|NCT00929292|Placebo Comparator|Modilac 1|Regular milk
11560664|NCT00929279|Active Comparator|Abciximab bolus plus infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen.
11560665|NCT00929279|Experimental|bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
11560666|NCT00929266|Experimental|1|"The choice of conducting the study in healthy volunteers and not in patients is based on the necessity to have a healthy physiological context avoiding any situation which could lead to hemolysis. As the protocol requires mobilization with a growth factor, the donors of peripheral stem cells (PSC) receive G-CSF.
~Direct intravenous injection of labeled cRBC in a volume of 1 mL will be administered to the subjects."
11560667|NCT00929253|Active Comparator|Computer delivered CRA + CM + Suboxone|"In this arm, participants are administered Suboxone and therapy is delivered by a computer. Fluency training is provided. The participant then listens through headphones and reads the information on the screen. They progress through various modules that involve education regarding high risk situations for potential use drug and skills to deal with those situations. In addition, skills for dealing with anxiety and anger are also provided. Videos are displayed that have examples of real-left situations. HIV/AIDS education is also provided. The program is interactive with the participant being required to answer short questions at the end of each module and prompts for homework worksheets are provided. These participants receive vouchers for providing drug negative urine samples."
11560668|NCT00929253|Active Comparator|Therapist delivered CRA + CM + Suboxone|In this arm of the study, the participants receive vouchers for providing a drug negative urine sample. These participants, however, do not have computer deliver therapy, only therapist delivered therapy.
11560669|NCT00929240|Active Comparator|Avastin (bevacizumab)|
11560670|NCT00929240|Experimental|Avastin (bevacizumab) + Xeloda (capecitabine)|
11560671|NCT00929227||1|Stress MRI perfusion, and cardiac CT will have observed sensitivity, specificity, and accuracyof at least 0.80 in predicting CAD in a patient population with prior equivocal stress testing.
11560672|NCT00929214|Experimental|Standard Therapy + Local Therapy|Systemic Standard Therapy (chemotherapy and/or endocrine therapy) + Local Therapy (surgery and/or radiation)
11560673|NCT00929201|Active Comparator|Sita + Met then Sita/Met FDC|Participants receive sitagliptin (Sita) 50 mg and metformin (Met) 500 mg individual tablets administered concomitantly as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin/metformin (Sita/Met) 50/500 mg FDC tablet administered as a single dose during Period 2.
11560674|NCT00929201|Active Comparator|Sita/Met FDC then Sita + Met|Participants receive sitagliptin/Metformin 50 mg/500 mg FDC tablet administered as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 2.
11560675|NCT00929188|Experimental|001|JNJ-42160443 Type=1 unit=mg number=10 form=solution for injection route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
11560676|NCT00929188|Placebo Comparator|002|Placebo Form=solution for injection route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
11560677|NCT00929175|Active Comparator|active CPAP|auto-PAP with therapeutic pressure
11560678|NCT00929175|Sham Comparator|sham-CPAP|auto-PAP with pressure less than 1cm H2O
11560679|NCT00929162|Experimental|ZD4054 + paclitaxel + carboplatin|ZD4054 10mg oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks
11560680|NCT00929162|Placebo Comparator|Placebo + paclitaxel + carboplatin|Placebo oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks
11560681|NCT00929136|Experimental|Endotoxin|
11560682|NCT00929123|Experimental|neural mobilization|manual therapy technique known to directly stress the median nerve
11560683|NCT00929123|Placebo Comparator|sham neural mobilization|manual therapy technique known to directly stress the median nerve without any stimulation.
11560684|NCT00929123|Active Comparator|Healthy Controls|People without carpal tunnel syndrome for comparison
11560685|NCT00929110|Experimental|Glycopyrronium bromide 50 μg|Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11560686|NCT00929110|Placebo Comparator|Placebo to glycopyrronium bromide|Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11560687|NCT00929110|Active Comparator|Tiotropium 18 μg|Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11560688|NCT00929097|Experimental|Implementation aids|
11560689|NCT00929097|Active Comparator|Control|
11560690|NCT00929084|Other|Survivor Stories Arm|Women in the Survivor Stories intervention arm will be given the Survivor Stories Tablet to take home for two weeks at three different time points over a two year period.
11560691|NCT00929084|Other|Control Arm|Women in the Control Arm will receive standard care.
11560692|NCT00929071|Experimental|Pain assessment for Evolence/topical anesthetic|Assess injection pain severity for a one time 1.0 mL injection of Evolence with 0.2 ml of topical anesthetic, applied 30 minutes prior to injection, to the left nasolabial fold of each participant .
11560693|NCT00929071|Experimental|Pain assessment for Evolence/Lidocaine|Assess injection pain severity for a one time 1.0 mL injection of Evolence mixed with 0.18 mL of 2% lidocaine (0.3% final lidocaine-HCl) in the right nasolabial fold of each participant.
11560694|NCT00929058|Experimental|Bevacizumab|
11560695|NCT00929045|Experimental|Growth Hormone|
11560696|NCT00929032||Liver transplant recipient|Liver transplant recipient
11560697|NCT00929019|Experimental|dendritic cell vaccination|HLA-A2.1 positive patient will receive 3 biweekly intradermal/intravenous vaccination with autologous mRNA transfected mature dendritic cells, followed by a DTH skin test for monitoring purposes. One such cycle is repeated every 6 months if no signs of progression, up to a total of 3 cycles.
11560698|NCT00929019|No Intervention|control arm|For comparison, HLA-A2.1 negative patients will be monitored for clinical response (secondary endpoint).
11560699|NCT00929006|Experimental|Micronized progesterone suspension|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
11560700|NCT00929006|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
11560701|NCT00928993||Main group|pediatric patients receiving overnight sleep study
11560760|NCT00928681|Other|0.3 mg/kg or placebo sc (multiple dose)|
11560998|NCT00927303||group 7|intervention 2 sequence of observers: 1,1,2,2
11560704|NCT00928980|Active Comparator|Optimal Medical Care|Treatment with optimal medical care: therapeutic dose of antidepressant medication during at least 15 months, administered in accordance with current guidelines.
11560705|NCT00928967||Group 1|
11560706|NCT00928954|Active Comparator|Gabapentin|Increasing dose to 300 mg four times per day (total of 1200 mg/day)
11560707|NCT00928954|Active Comparator|Memantine|Increasing dose over two weeks to 20 mg twice/day (total of 40 mg/day).
11560708|NCT00928941|Experimental|Arm 1|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units.
11560709|NCT00928941|Active Comparator|Arm 2|A computer game control condition will be implemented for 3-4 training exercises a week for 40 hours.
11560710|NCT00928928|Active Comparator|Open group|Group of patients operated with open approach for colorectal cancer
11560711|NCT00928928|Active Comparator|laparoscopic group|Group of patients operated with laparoscopic approach for colorectal cancer
11560712|NCT00928915|Experimental|Prothrombin complex concentrate (PCC)|intravenously, 30 IU/kg
11560713|NCT00928915|Experimental|Fresh frozen plasma (FFP)|intravenously, 20ml/kg
11560714|NCT00928902|Active Comparator|Peptides with GM-CSF-in-adjuvant, with upfront IL-2|Each of the peptides plus tetanus toxoid peptide, plus GM-CSF in adjuvant, administered subcutaneously and intradermally. Systemic low-dose IL-2 will be administered daily for 6 weeks, beginning at week 1 and ending at week 7.
11560715|NCT00928902|Active Comparator|Peptides plus GM-CSF-in-adjuvant, delayed IL-2|"Peptides plus GMCSF-in-adjuvant, with delayed IL-2.
~Each of the peptides plus tetanus toxoid peptide, plus GM-CSF in adjuvant, administered subcutaneously and intradermally. Systemic low-dose IL-2 will be administered daily for 6 weeks, beginning at week 4 and ending at week 10."
11560716|NCT00928889|Experimental|Nateglinide 120 mg|Nateglinide was taken orally 3 times daily, 10 minutes before meals for 4 weeks.
11560717|NCT00928889|Active Comparator|Acarbose 50 mg|Acarbose 50 mg was taken orally 3 times daily, with the first bite of food at meals for 4 weeks.
11560718|NCT00928876|Experimental|Anakinra group|Anakinra 150 mg/day during four weeks
11560719|NCT00928876|Placebo Comparator|Placebo|Placebo during four weeks
11560720|NCT00928863||Haemorrhagia post partum|Women with a high risk for haemorrhagia post partum.
11560721|NCT00928850|Active Comparator|urethral irrigation but no fascial suturing, QOL forms|The anterior two-thirds of the urethra is divided exposing a Foley catheter that was placed at the beginning of the procedure. Irrigation of the urethra may prevent spread of prostate cancer cells to tissue that is not removed during surgery. The urethra is irrigated with 60 cc of sterile water as it is withdrawn from the patient to 'wash' the urethra.
11560722|NCT00928850|Active Comparator|fascial suturing but no urethral irrigation, QOL forms|For patients undergoing fascial suturing only, after the initial placement of the suture through the urethra a second bite is taken deeply into the fascia of the lateral pelvic fascia.
11560723|NCT00928850|Active Comparator|both urethral irrigation and fascial suturing, QOL forms|
11560724|NCT00928850|Active Comparator|neither urethral irrigation nor fascial suturing, QOL forms|
11560725|NCT00928837|Active Comparator|flavocoxid 250 mg|Medical Food product
11560726|NCT00928837|Active Comparator|Naproxen|antiinflammatory
11560727|NCT00928837|Placebo Comparator|Placebo|Placebo
11560728|NCT00928837|Experimental|flavocoxid 500 mg|medical food product
11560729|NCT00928811|Other|Control|Standard of care administration with Simulect (basiliximab)being administered as per induction therapy on day of transplant and day 4.
11560730|NCT00928811|Experimental|Simulect|"Simulect (basiliximab) intravenously day of transplant and day 4.
~Chronic Simulect (basiliximab) administration monthly for one year duration.
~Concomitant decrease in Prograf administration."
11560731|NCT00928798|Experimental|rapamycin|one facial side rapamycin and one facial side placebo
11560732|NCT00928785|Experimental|REPEVAX|
11560733|NCT00928785|Active Comparator|Monovalent tetanus vaccine|
11560734|NCT00928772|Active Comparator|Alpha-Stim intervention|One hour Alpha-Stim intervention with sham midazolam
11560735|NCT00928772|Sham Comparator|Sham Alpha-Stim with midazolam|Sham Alpha-Stim intervention with real midazolam administration
11560736|NCT00928772|Placebo Comparator|Placebo|No Alpha-Stim and only topical anesthetics
11560737|NCT00928759||peripubertal obese girls|Peripubertal obese girls, aged 8 - 16 years, who are obese (BMI-for-age percentile greater or equal to 95)
11560738|NCT00928746|Other|ATROVENT 42mcg|
11560739|NCT00928733|Experimental|alcohol|Intraduodenal infusion of ethanol
11560740|NCT00928733|Other|Ethanol|
11560741|NCT00928733|Experimental|Placebo|Intraduodenal infusion of tap water
11560742|NCT00928720|Active Comparator|CES device|Participants will use the device for 60 minutes each day for 8 weeks.
11560743|NCT00928720|Sham Comparator|Sham device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device.
11560744|NCT00928720|No Intervention|Usual care alone|No intervention; participants will receive usual medical care
11560745|NCT00928707|Experimental|GIVINOSTAT + MTD Hydroxyurea (HU)_1|50 mg o.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy
11560746|NCT00928707|Experimental|GIVINOSTAT + MTD Hydroxyurea (HU)_2|50 mg b.i.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy
11560747|NCT00928694|Active Comparator|1|Fenofibrate U.S. Formulation
11560748|NCT00928694|Active Comparator|2|Fenofibrate UK Formulation
11560749|NCT00928681|Other|0.03 mg/kg or placebo iv|
11560750|NCT00928681|Other|0.1 mg/kg or placebo iv|
11560751|NCT00928681|Other|0.3 mg/kg or placebo iv|
11560752|NCT00928681|Experimental|1.0 mg/kg or placebo iv|
11560753|NCT00928681|Other|3.0 mg/kg or placebo sc|
11560754|NCT00928681|Other|10 mg/kg or placebo iv|
11560755|NCT00928681|Other|0.3 mg/kg or placebo sc|
11560756|NCT00928681|Other|0.1 mg/kg or placebo iv (multiple dose)|
11560757|NCT00928681|Other|0.3 mg/kg or placebo iv (multiple dose)|
11560758|NCT00928681|Other|3.0 mg/kg or placebo iv|
11560759|NCT00928681|Other|0.1 mg/kg or placebo sc|
11560763|NCT00928668|Experimental|Olodaterol (BI1744) Medium High|Single dosing of medium high dose Olodaterol inhaled orally from Respimat Device
11560764|NCT00928668|Experimental|Olodaterol (BI 1744) High|Single dosing of high dose Olodaterol inhaled orally from Respimat Device
11560765|NCT00928668|Placebo Comparator|Placebo|Single dosing of Olodaterol placebo inhaled orally from Respimat Device
11560766|NCT00928655|Experimental|acetazolamide|combination of acetazolamide and nocturnal continuous positive airway pressure ventilation
11560767|NCT00928655|Placebo Comparator|placebo capsules|combination of placebo and nocturnal continuous positive airway pressure ventilation
11560768|NCT00928642|Experimental|Oral Imatinib plus intravenous gemcitabine|"All research subjects receive oral imatinib 400mg days 1-5 and 8-12 of a 21 day cycle.
~All research subjects received IV gemcitabine 1000mg/m2 days 3 and 10 of a 21-day cycle. .
~All subjects had epithelial ovarian cancer or primary peritoneal carcinomatosis and had failed to respond to prior chemotherapy or progressed after prior chemotherapy."
11560769|NCT00928629|Other|All Subjects|ABI Screening Test Population: Subjects of either sex, any race, with at least two of the specified CVD risk factors, with no overt cardiovascular disease.
11560770|NCT00928616|Experimental|plant sterol esters|Participants consume plant sterol ester supplemented margarine (3 g/day)
11560771|NCT00928616|Placebo Comparator|Placebo|Placebo is a non-sterol ester supplemented margarine
11560772|NCT00928603|Experimental|cryotherapy|Focal Cryotherapy of localized tumor of prostate after spatial definition by in-house extended perineal core biopsy using a template biopsy strategy under local or general anesthesia
11560773|NCT00928590|Experimental|DuoTrav APS|Travoprost/Timolol Maleate Fixed Combination solution, 1 drop in the study eye(s) once daily, at 9 AM, for 12 months
11560774|NCT00928577||ACAM2000 Smallpox Vaccine Group|Participants are vaccinia vaccine-naive and have received ACAM2000 Smallpox vaccine as part of their Service Member readiness process.
11560775|NCT00928577||Other vaccinia vaccine Group|Participants did not receive ACAM2000 Smallpox vaccine as part of their Service Member readiness process because they are still protected by previous vaccinia vaccination or are ineligible for current ACAM2000 vaccination either because of recency of prior vaccinia vaccination or for reasons solely attributable to conditions or characteristics of their contacts (such as a healthy soldier who is married to someone with a contraindicated condition).
11560776|NCT00928564|Active Comparator|Pudendal Block|8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
11560777|NCT00928564|Placebo Comparator|Placebo|5ml of saline at each block site
11560778|NCT00928551|Experimental|1|
11560779|NCT00928538|No Intervention|Usual NFP Care|Usual NFP care includes pregnancy planning and contraceptive advice during nurse home visits, with the prescription and dispensing of contraceptives provided through the women's primary care settings.
11560780|NCT00928538|Experimental|Enhanced NFP Care|Enhanced NFP intervention includes usual NFP care plus the intervention that includes contraceptive administration and distribution in the home
11560781|NCT00928525|Experimental|Imatinib Mesylate|Patients affected by Desmoid Tumor and Chondrosarcoma will receive Imatinib Mesylate 800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
11560782|NCT00928512|Experimental|Secukinumab 25mg|Secukinumab 25mg s.c. q4wk
11560783|NCT00928512|Experimental|Secukinumab 75mg|Secukinumab 75mg s.c. q4wk
11560784|NCT00928512|Experimental|Secukinumab 150mg|Secukinumab 150mg s. c. q4wk
11560785|NCT00928512|Experimental|Secukinumab 300mg|Secukinumab 300mg s.c. q4wk
11560786|NCT00928512|Placebo Comparator|Secukinumab Placebo|Secukinumab Placebo s.c. q4wk
11560787|NCT00928499|Other|Interstim - continuous|Continuous stimulation
11560788|NCT00928499|Other|Interstim - cyclic|Cyclic stimulation
11560789|NCT00928486|Experimental|Lenalidomide and Dexamethasone|Lenalidomide 25mg by mouth (PO) once daily (QD) on Days 1-21 of each 28 day cycle; When creatinine (CrCl) clearance <60 mL/min, the initial dose was 10mg and the dose could be increased to 15mg after 2 cycles if the investigator judged therapeutic effect was insufficient and tolerability was acceptable. Dexamethasone 40 mg by PO once QD on days 1-4, 9-12 and 17-20 of each 28 day cycle for the first 4 cycles and Days 1-4 for the remaining cycles beginning at Cycle 5.
11560790|NCT00928473|Experimental|Lifestyle counseling|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
11560791|NCT00928460||Regular preanesthesia evaluation|Patients are evaluated by the anesthesiologist according to current protocol, including routine preoperative ECG.
11560792|NCT00928460||New preanesthesia evaluation|Patients are evaluated by the anesthesiologist according to a new protocol, in which a routine preoperative ECG is no longer provided.
11560793|NCT00928447|Active Comparator|1|Treatment effect of rHuPH20 injection on the exposure to topical nickel allergen
11560794|NCT00928447|Placebo Comparator|2|Treatment effect of placebo control injection on the exposure to topical nickel allergen
11560795|NCT00928434|Experimental|DI (Degarelix Intermittent)|"Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
~Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 were administered.
~During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered."
11560796|NCT00928434|Experimental|DC (Degarelix Continuous)|"Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.
~Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall"
11560847|NCT00928109|Active Comparator|Family Supportive Therapy|Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
11560848|NCT00928083|Experimental|Part A - 50 mg Single Dose|OZ439 Single doses of 50mg (capsules)
11560999|NCT00927303||group 8|intervention 2 sequence of observers: 2,2,1,1
11560797|NCT00928434|Active Comparator|LC (Leuprolide Continuous)|"Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0, administered intramuscular (i.m.) into a large muscle, as per manufacturer's labeling directions.
~One injection of 22.5 mg leuprolide 3-month depot was administered i.m. as per manufacturer's labeling directions at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).
~On Investigator's discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels."
11560798|NCT00928421|Experimental|Varisolve 0.125%|
11560799|NCT00928408||Cinacalcet|
11560800|NCT00928395|Active Comparator|Urgent PC|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
11560801|NCT00928356|Experimental|Hybrid CABG/PCI|Patients undergo hybrid, same sitting CABG/PCI as described.
11560802|NCT00928356|Other|Off-pump CABG|Standard of Care Off Pump CABG
11560803|NCT00928343|Experimental|GLPG0187|Single dose
11560804|NCT00928343|Placebo Comparator|Placebo|
11560805|NCT00928330|Experimental|A|
11560806|NCT00928330|Experimental|B|
11560807|NCT00928330|Experimental|C|
11560808|NCT00928317|Experimental|ART621 A|ART621 0.75mg/kg per week
11560809|NCT00928317|Experimental|ART621 B|ART621 1.5 mg/kg per week
11560810|NCT00928317|Experimental|ART621 C|ART621 3.0mg/kg per week
11560811|NCT00928317|Placebo Comparator|Placebo arm|
11560812|NCT00928304|Experimental|Florbetaben (BAY94-9172)|
11560813|NCT00928291|Experimental|Group 1 - PCT group|interventions on antibiotic therapy will be based on circulating PCT levels
11560814|NCT00928291|Active Comparator|Group 2 - Control group|antibiotic therapy will be guided by appropriate guidelines, and will be left at the discretion of caregivers.
11560815|NCT00928278|Experimental|Treatment A - PF-04764793|PF-04764793 using inhaler A
11560816|NCT00928278|Active Comparator|Treatment B - PF-04764793|PF-04764793 using inhaler B
11560817|NCT00928278|Experimental|Treatment C - PF-04764793|PF-04764793 using inhaler A
11560818|NCT00928278|Active Comparator|Treatment D - PF-04764793|PF-04764793 using inhaler B
11560819|NCT00928252|Experimental|Received 18F-fluorocholine PET/CT|IV fluorine-18 labeled methylcholine before PET/CT
11560820|NCT00928239|Experimental|1|Arm1: Laparoscopic repair of vaginal vault prolapse. Laparoscopic sacropexy procedure as described in previous publication(Sarlos D, Brandner S, Kots L, Gygax N, Schaer G. Laparoscopic sacrocolpopexy for uterine and post-hysterectomy prolapse: anatomical results, quality of life and perioperative outcome-a prospective study with 101 cases. Int Urogynecol JPelvic Floor Dysfunct. 2008 Oct;19(10):1415-22. Epub 2008 Jun 7. PubMed PMID: 18536861) with attachment to the caudal part of the vagina and the apex.
11560821|NCT00928239|Active Comparator|2|Arm 2: Laparoscopic repair of vaginal vault prolapse. Laparoscopic sacropexy procedure as described in previous publication(Sarlos D, Brandner S, Kots L, Gygax N, Schaer G. Laparoscopic sacrocolpopexy for uterine and post-hysterectomy prolapse: anatomical results, quality of life and perioperative outcome-a prospective study with 101 cases. Int Urogynecol JPelvic Floor Dysfunct. 2008 Oct;19(10):1415-22. Epub 2008 Jun 7. PubMed PMID: 18536861) with attachment of the dorsal mesh at distal end of vagina at dorsal vaginal wall
11560822|NCT00928226|Experimental|Arm 1 - 24 Grey SRS|24 Grey administered as 8 Gy x 3 fractions
11560823|NCT00928226|Experimental|Arm 2 - 27 Grey SRS|27 Grey administered as 9 Gy x 3 fractions
11560824|NCT00928226|Experimental|Arm 3 - 30 Grey SRS|30 Grey administered as 10 Gy x 3 fractions
11560825|NCT00928226|Experimental|Arm 4 - 33 Grey SRS|33 Grey administered as 11 Gy x 3 fractions
11560826|NCT00928213|Experimental|1|Control not treated, no placebo
11560827|NCT00928213|Experimental|2|Patient treated with low molecular weight heparin after repeated pregnancy loss
11560828|NCT00928213|Experimental|3|Patient super from first trimester bleeding treated with progesterone
11560829|NCT00928200|Experimental|Single Arm|All patients receive Vincristine, Dexamethasone, Doxorubicin, and Cytarabine. Dexrazoxane optional on Day 1. Erwinase is started between Days 3-5 and is given every M-W-F for a total of 10 doses. Patients with CNS 1 or 2 receive Methotrexate intrathecally on Day 15. Patients with CNS 3 receive Triple Intrathecal Therapy (Methotrexate, Cytarabine and Hydrocortisone) on Days 8, 15, and 22.
11560830|NCT00928187|Active Comparator|Arm A|emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
11560831|NCT00928187|Active Comparator|Arm B|abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
11560832|NCT00928187|Active Comparator|Arm C|emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
11560833|NCT00928174|Experimental|Single Arm|Fluorine-18 fluorocholine IV in conjunction with PET/CT imaging, up to 3 doses.
11560834|NCT00928161|No Intervention|Group 1|Patients with no acid reflux.
11560835|NCT00928161|Active Comparator|Group 2|Patients with acid reflux.
11560836|NCT00928148|Experimental|SPD465 (50 or 75 mg)|
11560837|NCT00928148|Active Comparator|Immediate Release Amphetamine salt (25 mg)|
11560838|NCT00928148|Placebo Comparator|Placebo|
11560839|NCT00928135|Active Comparator|7% Hypertonic saline|5 ml of 7% saline twice daily
11560840|NCT00928135|Experimental|Hypertonic xylitol|5 ml of 15% xylitol twice daily
11560841|NCT00928122|Experimental|1 / Presbyopia|Presbyopic patients, slightly hyperopes
11560842|NCT00928122|Experimental|2 / Myopia|Myopic patients without Astigmatism
11560843|NCT00928122|Experimental|3 / Hyperopia|Hyperope patients without Astigmatism
11560844|NCT00928122|Experimental|4 / Myopia with Astigmatism|Myopic patients incl. Astigmatism
11560845|NCT00928122|Experimental|5 / Hyperopia with Astigmatism|Hyperope patients incl. Astigmatism
11560846|NCT00928109|Experimental|Cognitive Behavioral Couples Therapy (CBCT)|CBCT is a 20-week program consisting of 1-hour sessions between a couple and a therapist. In this program, couples learn about ways to communicate about their relationship in the context of experiencing anorexia nervosa. CBCT focuses on couple-specific skills such as communication and targets relationship domains such as exercise, body image and sexuality, eating together as a couple, and broader relationship concerns outside of anorexia nervosa.
11560849|NCT00928083|Experimental|Part A - 100mg Single Dose|OZ439 Single doses of 100mg (capsules)
11560850|NCT00928083|Experimental|Part A - 200mg Single Dose|OZ439 Single doses of 200mg (capsules)
11560851|NCT00928083|Experimental|Part A - 400mg Single Dose|OZ439 Single doses of 400mg (capsules)
11560852|NCT00928083|Experimental|Part A - 400mg Single Dose + Food|OZ439 Single doses of 400mg (capsules) administered with food.
11560853|NCT00928083|Experimental|Part A - 400mg AD Single Dose|OZ439 Single doses of 400mg (aqueous dispersion)
11560854|NCT00928083|Experimental|Part A - 800mg Single Dose|OZ439 Single doses of 800mg (capsules)
11560855|NCT00928083|Experimental|Part A - 800mg AD Single Dose|OZ439 Single doses of 800mg (aqueous dispersion)
11560856|NCT00928083|Experimental|Part A - 1200mg Single Dose|OZ439 Single doses of 1200mg (capsules)
11560857|NCT00928083|Experimental|Part A - 1600mg AD Single Dose|OZ439 Single doses of 800mg (aqueous dispersion)
11560858|NCT00928083|Placebo Comparator|Part A - Placebo|Placebo control for Single rising Part A
11560859|NCT00928083|Experimental|Part B - 800mg AD Single Dose Fed|Single dose of OZ439 800mg aqueous dispersion administered under fed conditions
11560860|NCT00928083|Experimental|Part B - 800mg AD Single Dose Fast|Single dose of OZ439 800mg aqueous dispersion administered under fast conditions
11560861|NCT00928083|Experimental|Part C - 200mg AD Multiple Dose|200mg aqueous solution OZ439 or placebo once daily for 3 days fasted
11560862|NCT00928083|Experimental|Part C - 400mg AD Multiple Dose|400mg aqueous solution OZ439 or placebo once daily for 3 days fasted
11560863|NCT00928083|Experimental|Part C - 800mg AD Multiple Dose|800mg aqueous solution OZ439 or placebo once daily for 3 days fasted
11560864|NCT00928083|Placebo Comparator|Part C - Placebo|Placebo control for Multiple rising Part C
11560865|NCT00928070|Experimental|Fesoterodine|
11560866|NCT00928070|Placebo Comparator|Placebo|
11560867|NCT00928057|Experimental|4 mm / 8 mm PN|Subjects randomized to this study arm used either the 4mm PN or the 8mm PN for 3 weeks, then switched to the alternate PN for another 3 weeks. Order of PN use was randomly determined.
11560868|NCT00928057|Experimental|4 mm / 5 mm PN|Subjects randomized to this study arm used either the 4mm PN or the 5mm PN for 3 weeks, then switched to the alternate PN for another 3 weeks. Order of PN use was randomly determined.
11560869|NCT00928044||control groups|They had regular menstrual cycles and no history of pelvic surgery. None had any endocrine disorders (e.g. PCOS) and received any kind of medication that could affect the results within the preceding 6 months, and any woman who had a suspected pathologic lesion in the ovary or menopausal symptoms was excluded.
11560870|NCT00928044||operation group|1. They had regular menstrual cycles and no history of pelvic surgery. None had any endocrine disorders (e.g. PCOS) and received any kind of medication that could affect the results within the preceding 6 months, and any woman who had a suspected pathologic lesion in the ovary or menopausal symptoms was excluded. 2. Operations were performed for benign ovarian tumors, leiomyoma or adenomyosis
11560871|NCT00928018|Active Comparator|Sirolimus-Containing Regimen|"The Sirolimus containing arm will consist of the following drugs:
~Experimental Arm: tacrolimus + sirolimus + low-dose methotrexate
~Tacrolimus: Administered orally at a dose of 0.05 mg/kg based on ABW bid starting on day -3.
~Sirolimus:Given as a loading oral dose of 12 mg on day -3, then as a daily maintenance dose of 4 mg starting on day -2.
~Methotrexate: Administered by intravenous bolus infusion, per institutional standard, at a dose of 5 mg/m2 on days +1, +3 and +6."
11560872|NCT00928018|Active Comparator|Sirolimus-Free regimen|"There are two choices for the Sirolimus free arm:
~Control Arm 1: tacrolimus + methotrexate
~Tacrolimus:Administered orally at a dose of 0.05 mg/kg based on ABW bid starting on day -3.
~Methotrexate:Administered by intravenous bolus infusion at a dose of 5 mg/m2 on days +1, +3 and +6. For patients receiving stem cells from unrelated donors, an additional dose will be given on day +11.
~Control Arm 2: cyclosporine + MMF
~Cyclosporine: administered orally at a dose of 6 mg/kg based on ABW bid starting on day -3.
~MMF:administered at a dose of 3gm daily orally (or intravenously if the patient cannot tolerate oral administration) divided in 2 or 3 doses (bid or tid) depending on physician preference starting on day 3."
11560873|NCT00928005|Active Comparator|Weight loss diet|Participants will follow a low-calorie, low-fat weight loss diet for 6 months.
11560874|NCT00928005|Active Comparator|Weight loss diet plus exercise|Participants will follow a low-calorie, low-fat weight loss diet plus participate in a supervised exercise training program for 6 months.
11560875|NCT00927992||Patients with haemophilia who undergo liver transplantation|Patients with haemophilia who underwent liver transplantation and who have been followed up at any site in Spain.
11560876|NCT00927979|Experimental|Ropivacaine|
11560877|NCT00927979|Placebo Comparator|Water for injection|
11560878|NCT00927966|Experimental|RAD001 in combination with figitumumab|
11560879|NCT00927953|Experimental|MGAWN1|30 mg/kg single intravenous infusion of MGAWN1
11560880|NCT00927953|Placebo Comparator|Placebo - Normal Saline|single intravenous infusion of saline placebo
11560881|NCT00927940|Experimental|Drug Eluting Stent|All patients may have one or two lesions, if the two lesions are located in separate coronary arteries. A patient with one or two lesions treated with stents of diameter 2.5mm - 3.5mm will be designated in this study.
11560882|NCT00927927|Experimental|SD 0.0002 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.0002 mg/kg
11560883|NCT00927927|Experimental|SD 0.0012 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.0012 mg/kg
11560884|NCT00927927|Experimental|SD 0.007 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.007 mg/kg
11560885|NCT00927927|Experimental|SD 0.035 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.035 mg/kg
11560886|NCT00927927|Experimental|SD 0.175 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.175 mg/kg
11560887|NCT00927927|Experimental|SD 0.7 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.7 mg/kg
11560888|NCT00927927|Experimental|SD 2.5 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 2.5 mg/kg
11560889|NCT00927927|Experimental|SD 7.5 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 7.5 mg/kg
11560890|NCT00927927|Experimental|SD Placebo|Subjects were injected once with placebo
11560891|NCT00927927|Experimental|MD 0.02 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg
11560892|NCT00927927|Experimental|MD 0.3 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg
11560893|NCT00927927|Experimental|MD 1.0 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg
11560894|NCT00927927|Experimental|MD 1.6 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg
11560895|NCT00927927|Experimental|MD 4.0 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg
11560896|NCT00927927|Experimental|MD Placebo|Subjects were injected biweekly four times with placebo
11560897|NCT00927914|Experimental|Ranirestat 80 mg|Two 80 mg Ranirestat tablets, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
11560898|NCT00927914|Experimental|Ranirestat 40 mg|One 40 mg tablet of Ranirestat and a matching placebo, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
11560899|NCT00927914|Placebo Comparator|Placebo|Two placebo tablets, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
11560900|NCT00927901|Experimental|Indacaterol (ind) maleate-placebo-ind xinafoate-ind acetate|In treatment period 1, patients received indacaterol maleate 400 μg; in treatment period 2, patients received placebo to indacaterol; in treatment period 3, patients received indacaterol xinafoate 400 μg; and in treatment period 4, patients received indacaterol acetate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11560901|NCT00927901|Experimental|Indacaterol (ind) xinafoate-ind maleate-ind acetate-placebo|In treatment period 1, patients received indacaterol xinafoate 400 μg; in treatment period 2, patients received indacaterol maleate 400 μg; in treatment period 3, patients received indacaterol acetate 400 μg; and in treatment period 4, patients received placebo to indacaterol 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11560902|NCT00927901|Experimental|Indacaterol (ind) acetate-ind xinafoate-placebo-ind maleate|In treatment period 1, patients received indacaterol acetate 400 μg; in treatment period 2, patients received indacaterol xinafoate 400 μg; in treatment period 3, patients received placebo to indacaterol; and in treatment period 4, patients received indacaterol maleate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11560903|NCT00927901|Experimental|Placebo-indacaterol (ind) acetate-ind maleate-ind xinafoate|In treatment period 1, patients received placebo to indacaterol; in treatment period 2, patients received indacaterol acetate 400 μg; in treatment period 3, patients received indacaterol maleate 400 μg; and in treatment period 4, patients received indacaterol xinafoate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11560904|NCT00927888|Active Comparator|1 - Bupivacaine Block|3 ml of 0.25% Bupivacaine with Epi 1:100,000 (A block)
11560905|NCT00927888|Placebo Comparator|2 - Placebo|Normal saline with Epi 1:100,000 (B block)
11560906|NCT00927875|Experimental|All Subjects|
11560907|NCT00927862|Active Comparator|Standard IWPC warfarin dosing algorithm|Standard International Warfarin Pharmacogenetics Consortium (IWPC) warfarin dosing algorithm.
11560908|NCT00927862|Experimental|Modified IWPC warfarin dosing algorithm|Modified International Warfarin Pharmacogenetics Consortium (IWPC) warfarin dosing algorithm
11560909|NCT00927862|Other|Historical controls|The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records database of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic (PG)-guided cohorts (July 2008 through December 2010). Patients ≥18 years old initiating warfarin therapy with a baseline and at least 1 follow-up international normalized prothrombin time ratio (INR) level between days 3-14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG based.
11560910|NCT00927849|Active Comparator|surgical group lateral sphincterotomy|underwent closed lateral internal sphincterotomy (LIS) under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
11560911|NCT00927849|Active Comparator|Glycerin trinitrate group|all were instructed to apply the Glycerin trinitrate group (GTN) ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.
11560912|NCT00927849|Active Comparator|botulinum toxin injection|All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
11560913|NCT00927836|Experimental|AX200|
11560914|NCT00927836|Placebo Comparator|Placebo|
11560915|NCT00927823|Experimental|PF-04691502 Treatment|
11560916|NCT00927810|Experimental|canakinumab|
11560917|NCT00927797|Experimental|Immunochemotherapy, Maintencance|
11560918|NCT00927784|Sham Comparator|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media alone (placebo).
11560919|NCT00927784|Experimental|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs in sequential cohorts.
11560920|NCT00927771|Experimental|Azelaic Acid|
11560921|NCT00927771|Active Comparator|Hydroquinone|
11560997|NCT00927303||group 6|intervention 1 sequence of observers 2,2,1,1
11560922|NCT00927758|Active Comparator|Sequence 1: Flu/Sal- 250mcg/50mcg ->100mcg/50mcg->500mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.
~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.
~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.
~There were 14 days washout period between cycles."
11560923|NCT00927758|Active Comparator|Sequence 2: Flu/Sal- 500mcg/50mcg ->250mcg/50mcg->100mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.
~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.
~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.
~There were 14 days washout period between cycles."
11560924|NCT00927758|Active Comparator|Sequence 3: Flu/Sal- 100mcg/50mcg ->250mcg/50mcg->500mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.
~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.
~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.
~There were 14 days washout period between cycles."
11560925|NCT00927758|Active Comparator|Sequence 4: Flu/Sal- 250mcg/50mcg ->500mcg/50mcg->100mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.
~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.
~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.
~There were 14 days washout period between cycles."
11560926|NCT00927758|Active Comparator|Sequence 5: Flu/Sal- 500mcg/50mcg ->100mcg/50mcg->250mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.
~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.
~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.
~There were 14 days washout period between cycles."
11560927|NCT00927758|Active Comparator|Sequence 6: Flu/Sal- 100mcg/50mcg ->500mcg/50mcg->250mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.
~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.
~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.
~There were 14 days washout period between cycles."
11560928|NCT00927745|Experimental|With AutoFlow|Assist-controlled ventilation with activation of AutoFlow mode
11560929|NCT00927745|Active Comparator|Without AutoFlow|Assist-controlled ventilation without activation of AutoFlow mode
11560930|NCT00927732|Experimental|hydroquinidine|As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.
11560931|NCT00927732|Placebo Comparator|capsules of sugar|As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.
11560932|NCT00927719||ACAM2000® vaccinia vaccine Cohort|Participants had received ACAM2000®, vaccinia virus Smallpox vaccine.
11560933|NCT00927706|Experimental|Immediate intervention|Subjects and their caregivers randomized to this arm receive the intervention immediately after baseline data is collected.
11560934|NCT00927706|Experimental|Delayed Intervention|Subjects and their caregivers who are randomized to this group will receive the intervention after baseline measurements are administered twice (6 weeks apart).
11560935|NCT00927693|Experimental|Scan group|"Scan group undergoes complete cardiac risk assessment and CAC scanning at baseline."
11560936|NCT00927693|No Intervention|No scan group|"No scan group undergoes only complete cardiac risk assessment (without CAC scan) at baseline."
11560937|NCT00927680||Colorectal cancer cases|
11560938|NCT00927680||Controls|
11560939|NCT00927667|Experimental|Arm 1|
11560940|NCT00927667|Experimental|Arm 2|
11560941|NCT00927667|Experimental|Arm 3|
11560942|NCT00927667|Experimental|Arm 4|
11560943|NCT00927667|Experimental|Arm 5|
11560944|NCT00927654|Experimental|Iloprost|
11560945|NCT00927654|Placebo Comparator|Isotonic Sodium Chloride solution 0.9 %|
11560946|NCT00927641|Active Comparator|Ketoprofen Patch (HKT-500)|Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
11560947|NCT00927641|Placebo Comparator|Placebo Patch|Two placebo patches placed on target ankle once daily for 14 days
11560948|NCT00927628||Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular hole. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were >40-years-of-age.
11560949|NCT00927615|Experimental|intracoronary abciximab|intracoronary administration of abciximab (0.25 mg/kg body weight)
11560950|NCT00927615|Active Comparator|intravenous abciximab|intravenous administration of abciximab (0.25 mg/kg body weight)
11560951|NCT00927602|Experimental|fondaparinux|
11560952|NCT00927589|Experimental|1|
11560953|NCT00927576||Control subjects|Control subjects = 237. These subjects underwent extensive testing with computerized neuropsychological tests including digit span testing, spatial span testing, simple reaction time testing, choice reaction time testing, finger tapping, verbal fluency, design fluency, verbal list learning, questionnaire completion, and the trail making test.
11560954|NCT00927576||TBI patients|TBI patients N = 28. These patients underwent extensive testing with computerized neuropsychological tests including digit span testing, spatial span testing, simple reaction time testing, choice reaction time testing, finger tapping, verbal fluency, design fluency, verbal list learning, questionnaire completion, and the trail making test.
11560955|NCT00927563|Experimental|Tolcapone|Tolcapone 100-300mg/day
11560956|NCT00927550|Experimental|lithium plus usual care|
11560957|NCT00927550|Active Comparator|usual care without lithium therapy|
11560958|NCT00927537||Group 1|
11560959|NCT00927537||Group 2|
11560960|NCT00927524|Active Comparator|Apidra (insulin glulisine)|Administration of Apidra at three meals during a 24 hour period.
11560961|NCT00927524|Active Comparator|70/30 insulin|Administration of 73/30 insulin at three meals during a 24 hour period.
11560962|NCT00927511|Experimental|A - Dose Tritation|Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity
11560963|NCT00927511|Active Comparator|B- Control|Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
11560964|NCT00927498|Active Comparator|Arm A Daunorubicin and Cytarabine|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.
~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4."
11560965|NCT00927498|Experimental|Arm B Daunorubicin and Cytarabine and Mylotarg|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.
~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.
~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1."
11560966|NCT00927485|Experimental|Curcumin|Curcumin
11560967|NCT00927485|Placebo Comparator|Placebo|Placebo (sugar pills)
11560968|NCT00927472|Experimental|Malathion Gel|Malathion gel 0.5% 30 minute application
11560969|NCT00927472|Active Comparator|Nix Creme Rinse|Nix applied to scalp for 10 minutes
11560970|NCT00927459|Experimental|PRO-040201|PRO-040201 with placebo control in each cohort
11560971|NCT00927459|Placebo Comparator|Placebo|PRO-040201 with placebo control in each cohort
11560972|NCT00927446||Endoscopy screening|Patients with tissue diagnosis of head and neck cancer undergo endoscopy screening with conventional white light system first. Then the entire esophagus is examined under the NBI system by another endoscopist, who is blinded to the result of the conventional endoscopy.
11560973|NCT00927433|No Intervention|Standard care|Patients received standard education about fatigue by clinicians.
11560974|NCT00927433|Experimental|Education arm|Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions.
11560975|NCT00927420||1|Patients diagnosed with bipolar disorder I or II (DSM-IV) in ambulatory settings
11560976|NCT00927407|Experimental|Malathion gel 0.05%|Malathion gel 0.5% topical treatment for head lice
11560977|NCT00927407|Active Comparator|Malathion lotion 0.5%|Malathion lotion 0.5% treatment for head lice
11560978|NCT00927394|Experimental|Combination Therapy: Aliskiren + Valsartan|To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day)for 8 weeks. 1 tablet of Aliskiren 150 mg + 1 tablet of placebo Aliskiren 150 mg + 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg daily for 2 weeks. Forced titrated to: 2 tablets of Aliskiren 150 mg + 2 capsules of Valsartan 160 mg daily for 6 weeks
11560979|NCT00927394|Active Comparator|Monotherapy: Valsartan|To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day) for 8 weeks. 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg + 2 tablets of placebo Aliskiren 150 mg daily for 2 weeks. Forced titrated to: 2 capsules of Valsartan 160 mg + 2 tablets of placebo Aliskiren 150 mg daily for 6 weeks.
11560980|NCT00927381||Severe envenomation|Patients with a calculated severity score of 5 or 6 were included in this group.
11560981|NCT00927381||Minimal/Moderate Envenomation|Severity Score less than 5
11560982|NCT00927368|Active Comparator|Ultrasound guidance alone|The Tuohy needle was inserted in out-plane approach. Needle placement was considered adequate when the tip was visualized beneath the fascia iliaca; the catheter was then introduced 5 cm beyond the needle tip. Electrical stimulation was not used.
11560983|NCT00927368|Active Comparator|Ultrasound guidance needle stimulation|For the ultrasound guidance and needle stimulation arm, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA (2 Hz, pulse width 0.1 msec). Subsequently, the catheter was threaded 5 cm beyond the needle tip without additional electrical stimulation
11560984|NCT00927368|Active Comparator|Ultrasound guidance+catheter stimulation|For the ultrasound guidance and catheter stimulation group, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA. At that point, the peripheral nerve stimulator was then disconnected from the stimulating needle and connected to the proximal end of the catheter. The catheter was then advanced 5 cm past the needle tip. If the motor response disappeared during catheter advancement, the catheter was withdrawn slightly until the response returned. Needle orientation and catheter advancement were adjusted as necessary to elicit quadriceps contractions via the catheter with a stimulating current ≤0.5 mA.
11560985|NCT00927355|Active Comparator|Pioglitazone|half of the diabetic patients will be randomized to pioglitazone treatment for 6 months starting out with 15mg qd for 4 weeks and dose increased to 30mg (2 tablets) qday if no adverse effects noted at the four week mark by study physician.
11560986|NCT00927355|Placebo Comparator|Placebo|"The other half will be randomized to placebo for 6 months. The placebo pills also start out with one 15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician."
11560987|NCT00927342|Active Comparator|Vivostat|
11560988|NCT00927342|Active Comparator|BioGlue|
11560989|NCT00927329|Experimental|dust mite|
11560990|NCT00927316|Active Comparator|Active arm|E. coli 83972 bacteriuria
11560991|NCT00927316|Placebo Comparator|Placebo arm|Monitoring
11560992|NCT00927303||Group 1|Intervention 1 Sequence of observers: observer1, observer 2, observer 1, observer 2
11560993|NCT00927303||group 2|intervention 1 sequence of observers: observer 2, observer 1, observer 2, observer 1
11560994|NCT00927303||group 3|intervention 2 sequence of observers: 1,2,1,2
11560995|NCT00927303||group 4|intervention 2 sequence of observers: 2,1,2,1
11560996|NCT00927303||group 5|intervention 1 sequence of observers 1,1,2,2
11561000|NCT00927290|Active Comparator|1|Pioglitazone, 16 weeks before and during antiviral combination therapy
11561001|NCT00927290|Placebo Comparator|2|Pioglitazone placebo, 16 weeks before and during antiviral combination therapy
11561002|NCT00927277|Placebo Comparator|placebo laser|inactive light on the laser device.
11561003|NCT00927277|Active Comparator|Erchonia (R) LipoLASER PL|The Erchonia(R) LipoLASER PL is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
11561004|NCT00927264|Experimental|Behavioral|"Motivational Interviewing Intervention Plus Education
~Caregivers will receive a home-based motivational interviewing intervention for ETS reduction plus an educational program for ETS reduction."
11561005|NCT00927264|Active Comparator|Education Only|Caregivers will receive only educational program for ETS reduction.
11561006|NCT00927251|Experimental|Model 4296 LV Lead|Non-randomized study
11561007|NCT00927238|Experimental|XL TDR|The XL TDR is indicated for reconstruction of the disc following discectomy in skeletally mature subjects with symptomatic degenerative disc disease (DDD) of the lumbar spine at one level from L1-L5. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history radiographic studies.
11561008|NCT00927238|Other|Outcomes from lumbar fusion study|
11561009|NCT00927225|Active Comparator|active|subcutaneous wound infiltration with 50 mL ropivacaine 0.2%
11561010|NCT00927225|Placebo Comparator|placebo|subcutaneous wound infiltration with 50 mL saline
11561011|NCT00927212|Experimental|Group 1|2% AS101 ointment
11561012|NCT00927212|Experimental|Group 2|4% AS101 ointment
11561013|NCT00927199|Experimental|High-Oleic Canola Oil|
11561014|NCT00927199|Experimental|High-Oleic Canola/Flaxseed Oil Blend|
11561015|NCT00927199|Active Comparator|Western Diet|
11561016|NCT00927186|Experimental|Teriparatide|
11561017|NCT00927186|Active Comparator|Zoledronic Acid|
11561018|NCT00927173|Sham Comparator|Sham|Sham treatment
11561019|NCT00927173|Active Comparator|Active|Active Deep Transcranial Magnetic Stimulation treatment
11561020|NCT00927160||MACE group|Elderly patients admitted to the Mobile Acute Care of the Elderly Unit.
11561021|NCT00927160||Usual Care group|Elderly patients admitted to the general medicine service in the hospital
11561022|NCT00927147|Experimental|BNCT plus cetuximab|Patients treated with BNCT followed by cetuximab administration
11561023|NCT00927121|Active Comparator|Group 1 : G_1|G_1: stimulation for 4 - 6 hours a day, 4 tones per sequence
11561024|NCT00927121|Active Comparator|Group 2 :G_2|G_2: stimulation for 4 - 6 hours a day with 12-tone sequences
11561025|NCT00927121|Active Comparator|Group3 : G_3|G_3: stimulation for 4 - 6 hours a day, 4 tones per sequence with a signal controlled by EEG measurement
11561026|NCT00927121|Active Comparator|Group 4 : G_4|G_4: stimulation for 1 hour a day, 4 tones per sequence
11561027|NCT00927121|Placebo Comparator|Group5 : G_5|G_5: stimulation with placebo-tone
11561028|NCT00927095|Active Comparator|Continuous OC (EE/DROS)|Continuous daily oral drospirenone (DROS; 3mg) + ethinyl estradiol (EE; 20ug)
11561029|NCT00927095|Active Comparator|Intermittent OC (EE/DROS)|Interrupted (21 days active - 7 days placebo) oral DROS (20ug)/EE(3mg)
11561030|NCT00927095|Placebo Comparator|Placebo|Continuous daily oral placebo
11561031|NCT00927082|Experimental|PEG-IFN 90mcg 24 Wks|Participants received Pegasys (Pegylated interferon alfa-2a [PEG-IFN]) 90 micrograms (mcg) subcutaneously (SC) once a week for 24 weeks in Study WV19432 and entered follow-up (FU) Study MV22430.
11561032|NCT00927082|Experimental|PEG-IFN 180mcg 24 Wks|Participants received PEG-IFN 180 mcg SC once a week for 24 weeks in Study WV19432 and entered FU Study MV22430.
11561033|NCT00927082|Experimental|PEG-IFN 90mcg 48 Wks|Participants received PEG-IFN 90 mcg SC once a week for 48 weeks in Study WV19432 and entered FU Study MV22430.
11561034|NCT00927082|Experimental|PEG-IFN 180mcg 48 Wks|Participants received PEG-IFN 180 mcg SC once a week for 48 weeks in Study WV19432 and entered FU Study MV22430.
11561035|NCT00927069|Experimental|Group A|Patients who have shown an unsatisfactory response to 3 months of etanercept 50 mg twice a week without dose reduction prior to screening.
11561036|NCT00927069|Experimental|Group B|Patients who showed a satisfactory response to 3 months or more of etanercept 50 mg twice a week followed by a loss of response after dose reduction to 50 mg etanercept once a week prior to screening.
11561037|NCT00927069|Experimental|Group A dose increase at Week 12|Patients in group A who - after 12 weeks of adalimimab 40 mg every other week in this study - failed to reach a physician's global assessment (PGA) of clear or almost clear and had a dose increase to 40 mg adalimimab every week for another 12 weeks.
11561038|NCT00927069|Experimental|Group B dose increase at Week 12|Patients in group B who - after 12 weeks of adalimimab 40 mg every other week in this study - failed to reach a physician's global assessment (PGA) of clear or almost clear and had a dose increase to 40 mg adalimimab every week for another 12 weeks.
11561039|NCT00927056|Active Comparator|Minimally Invasive Microdiscectomy|
11561040|NCT00927056|Active Comparator|Conventional Open Microdiscectomy|
11561041|NCT00927043||1|
11561042|NCT00927030|Experimental|Pharmacokinetic|We hope to target 12 of the 30 children to be enrolled for this study to participate in a pharmacokinetic arm of the study. These 12 children would be receiving overnight sleep studies prior to receiving the first dose of melatonin and again at about every 3 week intervals each time the dose increases until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. During the sleep studies an intravenous catheter will be placed in the child's arm to sample small amounts of blood throughout the day (about 3 teaspoons of blood)to allow us to look at how melatonin is produced in children with autism who have sleep problems.
11561043|NCT00927030|Placebo Comparator|flavored inert liquid|Of the 30 targeted participants, 18 will be randomized at the first three week dosing period {1mg of melatonin}. The randomization will be single blind to the parent in a 5:1 ratio (15 children will receive melatonin, and 3 children will receive a flavored placebo at the first 3-week period only). After the initial 3-week dose cycle of 1 mg, all children randomized to placebo will begin 3 mg of melatonin and will continue in dose increase (6mg, 9 mg)until they meet the criteria of falling asleep within 30 minutes of bedtime 5/7 nights per week. No child will take more than 9 mg.
11561044|NCT00927017|Active Comparator|Liquorice 66 g/day|Liquorice given 66 grams per day for two weeks
11561045|NCT00927017|Active Comparator|Liquorice 102 g/day|Liquorice given 102 grams per day for two weeks
11561046|NCT00927004|Experimental|Etoricoxib 60 mg|
11561047|NCT00927004|Placebo Comparator|Sugar pill|
11561048|NCT00926991||traumatic rib fractures|
11561049|NCT00926978|Other|Radiopharmacokinetics|"1-2 mCi I-124 orally, once per day, twice total 0.9mg rhTSH intravenous injection, once per day, four total
~After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is < 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
11561050|NCT00926965|Experimental|Olanzapine group|randomized to Olanzapine group with dose range of 2.5-30mg/day
11561051|NCT00926965|Experimental|Amisulpiride group|the subjects were randomized to the amisulpiride group with dose range of 100 to 800mg/day
11561052|NCT00926965|Active Comparator|FGA group|The subjects were randomized to maintain the conventional antipsychotics
11561053|NCT00926952|Experimental|MAL-PDT 90 min incubation, no occlusion|Patients had 2-4 g of Methylaminolevulinate (MAL) spread on the entire face without occlusion and waited 90 minutes prior to photodynamic therapy (PDT) using red light.
11561054|NCT00926939|Experimental|Abstinence Contingent (AC)|This group will receive vouchers contingent on smoking reduction and smoking abstinence (confirmed through video submissions). Abstinence is defined as a CO sample of 4ppm or less.
11561055|NCT00926939|Experimental|Submission Contingent (SC)|This group receives vouchers for submitting videos of their CO breath test.
11561056|NCT00926926|Experimental|Active OTG|
11561057|NCT00926926|Placebo Comparator|Placebo|
11561058|NCT00926913||Group 1|
11561059|NCT00926900|Active Comparator|D-cycloserine|
11561060|NCT00926900|Placebo Comparator|Placebo|
11561061|NCT00926887|Sham Comparator|Placebo Laser|Placebo Laser is an inactive light
11561062|NCT00926887|Active Comparator|Erchonia EML Laser|Erchonia EML Laser uses two 7mW red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2.
11561063|NCT00926874||1|patients who presented an ischaemic stroke(full stroke or TIA)
11561064|NCT00926874||2|patients who present an acute coronary syndrome (ACS).
11561065|NCT00926861||Dry AMD|male or female persons aged over 50 years with dry age-related macular degeneration
11561066|NCT00926848|Experimental|PaTH intervention group|"The PaTH intervention group for patients and partners consisted of participation in a structured and formal cardiac rehabilitation program:
~18-36 exercise sessions
~18 educational sessions. The intervention consisted of patients and partners participating together in a formal cardiac rehabilitation program when typically just patients participate. In addition, partners were asked to make the same healthy eating and exercise changes that patients did to meet guidelines for health."
11561067|NCT00926848|Active Comparator|Usual care group|"The usual care group intervention for patients only consisted of participation in a structured and formal cardiac rehabilitation program:
~18-36 exercise sessions and 18 educational sessions
~Partners participated in the 18 educational sessions only."
11561068|NCT00926835|Experimental|Paroxetine|Paroxetine monotherapy
11561069|NCT00926835|Active Comparator|Escitalopram|Escitalopram monotherapy
11561070|NCT00926835|Active Comparator|Venlafaxine|Venlafaxine monotherapy
11561071|NCT00926835|Active Comparator|Paroxetine+Bupropion|
11561072|NCT00926835|Active Comparator|Paroxetine+Lamotrigine|
11561073|NCT00926835|Active Comparator|Paroxetine+Lithium|
11561074|NCT00926835|Active Comparator|escitalopram+mirtazapine|
11561075|NCT00926835|Active Comparator|Escitalopram+Aripiprazole|
11561076|NCT00926835|Active Comparator|Paroxetine + Venlafaxine|
11561077|NCT00926809|Active Comparator|Eradication|Helicobacter pylori eradication
11561078|NCT00926809|Placebo Comparator|No eradication|No eradication for Helicobacter pylori
11561079|NCT00926796|Experimental|Regimen B: gemifloxacin plus azithromycin|Gemifloxacin 320 mg by mouth one time plus azithromycin 2 gm by mouth one time.
11561080|NCT00926796|Experimental|Regimen A: gentamicin plus azithromycin|Gentamicin 240 mg intramuscular (IM) one time for patients greater than 45 kg or 5 mg/kg IM one time for patients less than or equal to 45 kg plus azithromycin 2 gm by mouth one time.
11561081|NCT00926783|Active Comparator|(1) targeted CFAE ablation|
11561082|NCT00926783|Active Comparator|(2) generalized CFAE ablation|
11561083|NCT00926770||Pretem infants (GG < 37+0)|
11561084|NCT00926757|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of chemotherapy, and will be continued until 3 months after completion of the chemotherapy.
11561085|NCT00926757|Active Comparator|Therapeutic arm|In patients with HBV reactivation and ALT flare > 100 U/L, entecavir 0.5mg daily will be prescribed for the cases till hepatitis remission
11561086|NCT00926744|Experimental|Intervention|Physically inactive participants receiving both physical activity and dietary counseling
11561087|NCT00926744|No Intervention|Active|Physically active participants receiving only dietary counseling
11561088|NCT00926744|No Intervention|Control|Physically inactive participants receiving only dietary counseling
11561089|NCT00926731|Experimental|1|AZD1152 variable dose in combination with 20 mg of LDAC. (The LDAC is given twice daily.)
11561090|NCT00926718|Experimental|Dose 1a|
11561091|NCT00926718|Experimental|Dose 2a|
11561092|NCT00926718|Experimental|Dose 3a|
11561093|NCT00926718|Experimental|Dose 1b|
11561094|NCT00926718|Experimental|Dose 2b|
11561095|NCT00926718|Experimental|Dose 3b|
11561096|NCT00926705|Active Comparator|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
11561097|NCT00926705|Experimental|Dexmedetomidine and Fentanyl|This group received a combination of Dexmedetomidine (1 ug/kg) and Fentanyl (1.79 ug/kg). Total number of patients in this group 24.
11561098|NCT00926692||Healthy Subjects|All subjects are considered healthy
11561099|NCT00926653||Depressed|Elderly participants with depression
11561100|NCT00926653||Control|Elderly participants who have never experienced depression
11561101|NCT00926640|Experimental|1|Belinostat dose escalation
11561102|NCT00926640|Experimental|2|Belinostat UGT1A1 wild type/*28 variant
11561103|NCT00926640|Experimental|3|Belinostat UGT1A1*60 or 2/3/4 variant
11561104|NCT00926627|Placebo Comparator|Placebo|placebo b.i.d.
11561105|NCT00926627|Experimental|Bosentan|62.5 mg/125 mg bosentan b.i.d.
11561106|NCT00926614|Experimental|Pioglitizone and Atorvastatin|Pioglitazone and Atorvastatin added to standard of care Pegasys and weight based ribavirin
11561107|NCT00926588|Experimental|Stepped Care|Patients received automated pain monitoring. A nurse care manager partnering with a physician pain specialist decide on treatment changes collaborating with primary care physicians. Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are used.
11561108|NCT00926588|No Intervention|Usual Care|Patients receive usual care for pain from their primary care physician
11561109|NCT00926575|Experimental|orBec®|Investigational drug
11561110|NCT00926575|Placebo Comparator|Placebo|Control
11561111|NCT00926562|Experimental|Iopromide|Drug: Ultravist 370 mgl/ml, injection of intra-artery during cardiac interventional operation
11561112|NCT00926562|Active Comparator|Iodixanol|Drug: Visipaque 320 mgl/ml, injection of intra-artery
11561113|NCT00926549|Experimental|spectral domain-OCT|Spectral domain-OCT scanning performed.
11561114|NCT00926536|Experimental|C-arm CT + DSA as needed'|In the group of subjects randomized in this group, the image guidance component of the procedure will be conducted by the acquisition of 3D CT-like images during a trans-hepatic arterial injection of iodinated contrast agent for road mapping the tumor feeding vessels and supplemented by DSA as needed by the operating physician as imaging guidance for planning tumor(s) treatment approach.
11561115|NCT00926536|Active Comparator|DSA only|In the group of subjects randomized in this group, present standard of care, i.e DSA imaging only will be used by the operating physician to map out the tumor vessels and used for treatment approach. Additional 3D CT-like images will be obtained, but only used if the operator cannot perform adequate planning using DSA alone.
11561116|NCT00926523||Healthy Controls|Subjects are made up of healthy adults
11561117|NCT00926523||Affected|Subjects have Pulmonary Hypertension
11561118|NCT00926510|Experimental|Language Toolkit|Language toolkit composed of simple tools that parents can use to interact with child and help language acquisition.
11561119|NCT00926510|Placebo Comparator|2|Safety counseling and smoke detector
11561120|NCT00926497|Experimental|Procalcitonin group|Antibiotic therapy is discontinued when two consecutive Procalcitonin values are below predefined age-adjusted cut-off values. Antibiotic therapy could be prolonged despite fulfilled Procalcitonin criteria at the discretion of the attending physician.
11561121|NCT00926497|No Intervention|Standard group|Standard treatment for suspected neonatal early-onset sepsis based on conventional laboratory parameters
11561122|NCT00926484||Tooth Mousse|
11561123|NCT00926484||fluoride varnish|
11561124|NCT00926484||Tooth Mousse + fluoride varnish|
11561125|NCT00926471|Experimental|Cognitive Behavioral Therapy (CBT) Program|Participants will receive a treatment program involving CBT plus adjunctive group counseling and parent training.
11561126|NCT00926471|No Intervention|Wait list control|Participants will be placed on a 12-week wait list with no active treatment
11561127|NCT00926445||Preterm (BW < 1500 grams)|
11561128|NCT00926445||Critically ill term newborn|ventilation > 48 hours
11561129|NCT00926445||Healthy term newborn|
11561130|NCT00926432|Other|Healthy volunteers|Small group of aged healthy volunteers
11561131|NCT00926432|Other|Patients|Patients consulting for spine disorders that may or may not have postural troubles
11561132|NCT00926419|Experimental|Varicella (1/5 dose) - ID - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
11561133|NCT00926419|Experimental|Varicella (1/5 dose) - ID - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
11561134|NCT00926419|Experimental|Varicella (2/5 dose) - ID - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.25 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
11561135|NCT00926419|Experimental|Varicella (2/5 dose) - ID - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.25 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
11561136|NCT00926419|Active Comparator|Varicella (full dose) - SC - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.5 ml Subcutaneous administration with Disposable Needle-free Syringe Jet Injector
11561137|NCT00926419|Active Comparator|Varicella (full dose) - SC - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.5 ml Subcutaneous administration with Disposable Needle Syringe
11561138|NCT00926419|Experimental|Hepatitis A (1/5 dose) ID - Injector|Hepatitis A virus vaccine, inactivated, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
11561139|NCT00926419|Experimental|Hepatitis A (1/5 dose) ID - Syringe|Hepatitis A virus vaccine, inactivated, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
11561140|NCT00926419|Active Comparator|Hepatitis A (full dose) IM - Injector|Hepatitis A virus vaccine, inactivated, Single dose, 0.5 ml Intramuscular administration with Disposable Needle-free Syringe Jet Injector
11561141|NCT00926419|Active Comparator|Hepatitis A (full dose) IM - Syringe|Hepatitis A virus vaccine, inactivated, Single dose, 0.5 ml Intramuscular administration with Disposable Needle Syringe
11561142|NCT00926393|Active Comparator|Quetiapine Immediate Release (IR)|Quetiapine 25, 100, 200 and 300 mg
11561143|NCT00926393|Active Comparator|Quetiapine Extended Release (XR)|Quetiapine 50, 200, 300
11561144|NCT00926380|Experimental|denosumab ONLY|
11561145|NCT00926380|Experimental|teriparatide (Forteo®) ONLY|
11561146|NCT00926380|Experimental|denosumab and teriparatide (Forteo®)|
11561147|NCT00926367|Experimental|Clinidamycin/ Benzoyl Peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide (BPO).
11561148|NCT00926367|Active Comparator|Benzoyl peroxide and adapalene|Once-daily applications, to the randomized side of the face either left or right, of benzoyl peroxide (BPO) and adapalene
11561149|NCT00926354|Experimental|AS101 infusion|Twenty patients who developed thrombocytopenia after a chemotherapy course will receive i.v. infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen, during the following 4 chemotherapy courses.
11561150|NCT00926354|No Intervention|Control group|Twenty patients who developed thrombocytopenia during chemotherapy course will be treated according to standard of care and will not receive the investigational product. Their medical condition will be followed and a complete blood count will be performed routinely once weekly.
11561151|NCT00926341|No Intervention|Active control|1. Active Control: (n=20), intervention: no intervention
11561152|NCT00926341|Active Comparator|PIO arm|PIO arm (n=30), Pioglitazone 30 mg/day, given for 24 weeks.
11561153|NCT00926341|Active Comparator|Telmi arm|Telmia arm (n=30): Tab. Telmisartan 40 mg/day given for 2 weeks.
11561154|NCT00926328|Active Comparator|A -Experimental toothpaste|triclosan/copolymer/fluoride toothpaste
11561155|NCT00926328|Placebo Comparator|B - control toothpaste|sodium fluoride only toothpaste (placebo)
11561156|NCT00926315|Experimental|calcitriol|calcitriol supplementation (0.25 mcg 2x/d)
11561157|NCT00926302|Experimental|Test drug|Levetiracetam one period
11561158|NCT00926302|Active Comparator|Reference drug|Keppra one period
11561159|NCT00926289|Active Comparator|Telmisartan|Telmisartan 80 mg
11561160|NCT00926289|Experimental|Telmisartan/hydrochlorothiazide|Telmisartan80mg/Hydrochlorothiazide25mg
11561161|NCT00926276|Active Comparator|Surgical Treatment Group-Fundoplication|Re-evaluated 1 month post-op Re-evaluated 2 months post-op
11561162|NCT00926276|Active Comparator|Medical Therapy|Treated by primary clinician for GERD Re-evaluated 1 month Proceed to Fundoplication if GERD persist by pH-MII Re-evaluated at 2 months (1 month post-op) Worsening BPD will be given option of immediate surgery
11561163|NCT00926263|Experimental|10 mg/kg cohort|
11561164|NCT00926263|Experimental|20 mg/kg cohort|
11561165|NCT00926263|Experimental|20/20 mg/kg cohort|
11561166|NCT00926250|Experimental|PS-IPC supplementation|
11561167|NCT00926250|Placebo Comparator|Placebo supplementation|
11561168|NCT00926237|Experimental|Sham followed by active 1Hz, then active 10Hz rTMS|Subjects assigned to this arm received sham rTMS followed by active rTMS at 1Hz and then active rTMS at 10 Hz. Each treatment consisted of a four-day trial with no less than 21 days separating each condition. Subjects receive sham stimulation first to prevent carry forward effects of the active treatment condition into the sham condition.
11561169|NCT00926237|Experimental|Sham followed by active 10Hz and active 1Hz rTMS|Subjects assigned to this arm received sham rTMS followed by active rTMS at 10 Hz and then active rTMS at 1 Hz. Each treatment consisted of a four-day trial with no less than 21 days separating each condition. Subjects receive sham stimulation first to prevent carry forward effects of the active treatment condition into the sham condition.
11561170|NCT00926211|Experimental|Computer-Assisted|Hair harvest using the computer-assisted system
11561171|NCT00926211|Active Comparator|Manual Harvest|Hair harvesting via manual technique
11561172|NCT00926185|Placebo Comparator|Placebo|Placebo Ophthalmic Solution
11561173|NCT00926185|Experimental|0.1% Lifitegrast|Lifitegrast
11561174|NCT00926185|Experimental|1.0% Lifitegrast|Lifitegrast
11561175|NCT00926185|Experimental|5.0% Lifitegrast|Lifitegrast
11561176|NCT00926159||ICD eligible|Patients with Ejection Fraction (EF) of 35% or less as determined by cardiac echocardiogram or cardiac nuclear scan.
11561177|NCT00926146|Experimental|NCMIT|Nurse Case Management Plus Contingency Management and Tracking and the HBV vaccine
11561178|NCT00926146|Active Comparator|SCMIT|Standard with Contingency Management and Tracking (SCMT) and HBV vaccine
11561179|NCT00926133||STEMI patients|Patients with acute STEMI treated by PCI without previously known type 2 diabetes.
11561180|NCT00926120|Experimental|Mogroside sweetener|All subjects will received Mogroside. Mogroside sweetener administered at a dosage level of 5 g every 6 hours for 14 days.
11561181|NCT00926094||1|
11561182|NCT00926094||2|
11561183|NCT00926081|No Intervention|Best medical treatment|Patients with peripheral artery disease receiving best medical treatment only
11561184|NCT00926081|Active Comparator|Supervised exercise training|Patients with peripheral artery disease receiving best medical treatment plus supervised exercise training
11561185|NCT00926068|Experimental|HO/03/03 10µg|
11561186|NCT00926068|Placebo Comparator|Placebo|
11561187|NCT00926055|No Intervention|Control|
11561188|NCT00926055|Active Comparator|Ezetimibe|
11561189|NCT00926055|Experimental|Ezetimibe/Simvastatin|
11561190|NCT00926042||Healthy Control|Healthy control group for research on autoimmune diseases
11561191|NCT00926029|Placebo Comparator|Fluoride control -A|Winterfresh Gel
11561192|NCT00926029|Active Comparator|Triclosan/Fluoride - B|Positive control (Total toothpaste)
11561193|NCT00926029|Experimental|Triclosan/fluoride/metal salt- C|test toothpaste
11561194|NCT00926016|Active Comparator|pioglitazone|Treatment with pioglitazone 45 mg a day for 3 months
11561195|NCT00926016|No Intervention|No intervention|Monitoring period without pioglitazone for 3 months
11561196|NCT00926003|Experimental|Full Computerized Cognitive Training|Intervention is a Computer Cognitive Rehabilitation Training delivered in 24 sessions over 8 weeks (3 times/week). A training session lasts about an hour and consists of 9 training games or programs, 3 pertaining to improving attention, 3 pertaining to improving visual-spatial memory, and 3 pertaining to improving reasoning/planning. Each training game become more difficult as the child gains proficiency.
11561197|NCT00926003|No Intervention|Control|Passive Control with no intervention training (computer cognitive games) for 8 weeks.
11561240|NCT00925691|Active Comparator|APICAL|implantation at the apex
11561241|NCT00925691|Experimental|SEPTAL|implantation at the interventricular septum
11561242|NCT00925678|Experimental|1|
11561198|NCT00926003|Active Comparator|Limited computerized cognitive training|"Intervention is a Computer Cognitive Rehabilitation Training delivered in 24 sessions over 8 weeks (3 times/week). A training session lasts about an hour and consists of 9 training games or programs, 3 pertaining to improving attention, 3 pertaining to improving visual-spatial memory, and 3 pertaining to improving reasoning/planning. In this arm, however, the training games do NOT become progressively more difficult as the child gains proficiency, but rotates randomly among simpler to moderate levels of difficulty for each game. The purpose to to give children int he limited CCRT arm comparable exposure to the cognitive games training as with the full CCRT arm, with the exception of the titrating nature of the game training."
11561199|NCT00925990|Experimental|CTS-1027 + ribavirin|Study drug plus ribavirin
11561200|NCT00925990|Experimental|CTS-1027 + placebo|Study drug plus placebo for ribavirin
11561201|NCT00925977|Active Comparator|insulin Glargine + insulin Apidra|insulin Glargine + insulin Apidra
11561202|NCT00925977|Active Comparator|Insulin NPH + Insulin Apidra|12 weeks treatment with Insulin NPH + Insulin Apidra
11561203|NCT00925964||Patients exposed|Patients with Systolic Pressure Index <0,9 ou >1,4.
11561204|NCT00925964||Patients not exposed|Patients with Systolic Pressure Index >0,9 ou <1,4.
11561205|NCT00925951|Experimental|Wet Cupping|
11561206|NCT00925951|No Intervention|Waiting Control|They can't use any other specific treatment except exercises and behavior modification (we'll offer a brochure which includes exercise method and directions about behavior modifications).
11561207|NCT00925938|Experimental|Misoprostol vaginal priming insert (MVPI)|One vaginal insert administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit. The initial dose is 400 mcg and dose will be adjusted between 100 - 1600 mcg after each study cohort based on safety and efficacy criteria as assessed by the Data and Safety Monitoring Board (DSMB).
11561208|NCT00925938|Placebo Comparator|MVPI Placebo|One vaginal insert of placebo administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit.
11561209|NCT00925925||Normal Birth Weight (NBW)|Term, healthy infants born at normal birth weights
11561210|NCT00925925||Low Birth Weight (LBW)|Infants born at > or equal to 34 0/7 weeks with a birth weight at < or equal to 10% for gestational age at birth (Small for Gestational Age, SGA)
11561211|NCT00925912|Active Comparator|1|"spinal anesthesia: Active Comparator
~The SA group were received a subarachnoid block with 1.5-2.0 ml of 0.5% bupivacaine."
11561212|NCT00925912|Experimental|2|Perianal block with 0.25% bupivacaine
11561213|NCT00925899|Experimental|Melatonin|20 mg
11561214|NCT00925899|Placebo Comparator|Placebo|
11561215|NCT00925886|Experimental|Acrysof Toric intraocular lens|A One piece, acrylic intraocular lens is implanted in the lens bag.
11561216|NCT00925873|Active Comparator|1|"Control arm without fludarabine
~Induction course: Ara-C 100mg/m2 days 1-7, idarubicin 8mg/m2 days 1-5, GM-CSF (molgramostim, Novartis) 5 microg/kg days 1 to neutrophil recovery;
~Consolidation course: Ara-C 1g/m2 q12h days 1-3, idarubicin 10mg/m2 days 2-3;
~and 3 quarterly reinduction courses during maintenance including Ara-C 80mg/m2 days 1-5, CCNU 40mg and mitoguazone 350mg/m2 day 1, ± fludarabine days 1-2."
11561217|NCT00925873|Experimental|2|"Fludarabine arm
~The same regimen with fludarabine 20 mg/m2/day IV for 30 minutes
~induction course + fludarabine days 2-7;
~consolidation course + fludarabine days 4-5;
~during reinduction courses + fludarabine days 1-2."
11561218|NCT00925860|Experimental|non invasive ventilation approach|pure hypoxemic patients admitted to ICU treated by non-positive pressure mechanical ventilation
11561219|NCT00925860|No Intervention|conventionally ventilated|pure hypoxemic patients treated by conventional ventilatory support
11561220|NCT00925847|Experimental|1|
11561221|NCT00925834|Placebo Comparator|Sodium chloride|"Control arm A: Hidden intracoronary infusion of 5ml sodium chloride"
11561222|NCT00925834|Experimental|Sodium chloride and verbal suggestions|"Experimental arm A: Open intracoronary infusion of 5ml sodium chloride plus the suggestion of a vasodilatory effect on coronary vessels"
11561223|NCT00925834|Active Comparator|Nitroglycerin|"Control arm B: Hidden intracoronary infusion of 0.01mg nitroglycerin in 5 ml sodium chloride"
11561224|NCT00925834|Experimental|Nitroglycerin and verbal suggestions|"Control arm B: Open intracoronary infusion of 0.01 mg nitroglycerin in 5 ml sodium chloride plus the suggestion of a vasodilatory effect on cardiac vessels"
11561225|NCT00925821|Experimental|Allogeneic stem cell transplant|Second scheduled transplantation performed from an HLA-matched MRD or MUD after conditioning with treosulfan and fludarabine
11561226|NCT00925821|Active Comparator|High-dose melphalan chemotherapy|Second high-dose melphalan therapy followed by transplantation of peripheral blood stem cells
11561227|NCT00925808||Unsuspected VTE|Prevalence of unsuspected VTE in oncology patients on routine staging CT scans of the thorax, abdomen and pelvis
11561228|NCT00925795|Active Comparator|Group A (1. EVOO; 2. ROO)|
11561229|NCT00925795|Active Comparator|Group B (1. ROO; 2. EVOO)|
11561230|NCT00925782|Other|Melphalan-Alkeran|Subjects begin with treatment Melphalan and crossover to treatment Alkeran
11561231|NCT00925782|Other|Alkeran-Melphalan|Subjects begin with treatment Alkeran and crossover to treatment Melphalan.
11561232|NCT00925769|Experimental|1|
11561233|NCT00925756|Experimental|Maraviroc 150 mg, 300 mg, or 600 mg twice daily|"This was a single arm study where Maraviroc was added for 24 weeks.
~Maraviroc was dose-adjusted for concomitantly administered HIV medications according to the manufacture's recommendations:
~150 mg twice daily with strong CYP3A4 inhibitors, including:
~Protease inhibitors (except tipranavir/ ritonavir)
~Delavirdine
~ketoconazole, itraconazole, clarithromycin, nefazadone, telithromycin
~Darunavir/r + etravirine
~300 mg twice daily with non-inducers/ non-inhibitors of CYP3A4, including:
~Tipranavir/ ritonavir
~Nevirapine
~All NRTIs
~Enfuvirtide
~600 mg twice daily with strong CYP3A4 inducers, including:
~Efavirenz, etravirine
~rifampin"
11561234|NCT00925743|Experimental|1|"5, 15, 20 or 25 mg/m2
~one injection of cabazitaxel on day 1 of each cycle (3 weeks)"
11561235|NCT00925730|Experimental|Pimecrolimus cream 1%|Pimecrolimus
11561236|NCT00925717||2500 patients|Who have records of clinic visit with endocrine internal medicines of nationwide secondary/tertiary hospitals within the last six months.
11561237|NCT00925704|Active Comparator|Calcitriol|
11561238|NCT00925704|Experimental|Lanthanum carbonate + calcitriol|
11561239|NCT00925704|Experimental|Sevelamer carbonate + calcitriol|
11561243|NCT00925678|Placebo Comparator|2|
11561244|NCT00925665||Glidescope|Patients intubated with the Glidescope technique
11561245|NCT00925665||Macintosh|Patients intubated via the conventional direct laryngoscopy with a Macintosh laryngoscope
11561246|NCT00925652|Experimental|1. Diet Intervention Arm|The dietary intervention will focus on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber.
11561247|NCT00925652|Experimental|2. Diet and exericise intervention arm|The dietary intervention will focus on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber. Patients randomized to the diet and exercise groups will also have a target physical activity goal of 180 minutes of moderate-intensity activity each week.
11561248|NCT00925652|Experimental|3. Bevicizumab, CM, and diet intervention|Participants will receive Bevacizumab treatment, cyclophosphamide and methotrexate treatment and well as the dietary intervention that will focus on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber.
11561249|NCT00925652|Experimental|4. Bevacizumab, CM, diet and exercise|Participants will receive bevacizumab, cyclophosphamide and methotrexate treatment and well as the dietary intervention that will focus on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber and will also have a target physical activity goal of 180 minutes of moderate-intensity activity each week.
11561250|NCT00925639|Experimental|Isoflavone|Patients will receive daily doses of 150 mg of concentrated extract of soy per os
11561251|NCT00925639|Placebo Comparator|Control|Patients will receive daily placebo pills
11561252|NCT00925626|Experimental|Sub - Vastus arthrotomy|Sub-vastus arthrotomy
11561253|NCT00925626|Active Comparator|Mid-Vastus arthrotomy|Mid-vastus arthrotomy
11561254|NCT00925613|No Intervention|Control|The double lumen tube is kept until extubation; there is no exchange with any tracheal tube or LMA.
11561255|NCT00925613|Active Comparator|Proseal|The double lumen tube is exchanged with a Proseal (LMA) before emergence according to the study protocol.
11561256|NCT00925613|Active Comparator|Tracheal tube|The double lumen tube is exchanged with a tracheal tube before emergence according to the study protocol.
11561257|NCT00925600|Placebo Comparator|Placebo|Participants received placebo administered by subcutaneous injection on Day 1 and at Month 6.
11561258|NCT00925600|Experimental|Denosumab|Participants received denosumab 60 mg administered by subcutaneous injection on Day 1 and at Month 6.
11561259|NCT00925587|Active Comparator|Q2W|Q2W administration of darbepoetin alfa.
11561260|NCT00925587|Active Comparator|QM|QM administration of darbepoetin alfa
11561261|NCT00925561||No treatment|
11561262|NCT00925548|Experimental|Investigational Arm|"Investigational Arm:
~Pretreatment (Single Dose): 300 milligrams per square meter (mg/m^2) up to a maximum dose of 600 mg of intravenous cyclophosphamide
~tecemotide (L-BLP25) plus Hormonal Therapy (Standard Dose)"
11561263|NCT00925548|Active Comparator|Control Arm|"Control Arm:
~Pretreatment (Single Dose): sodium chloride (NaCl) 9 grams per liter (g/L) infusion
~Placebo plus Hormonal Therapy (Standard Dose)"
11561264|NCT00925535|Active Comparator|Treatment A|Lersivirine
11561265|NCT00925535|Active Comparator|Treatment B|Rifabutin
11561266|NCT00925535|Experimental|Treatment C|Lersivirine and Rifabutin
11561267|NCT00925522|Experimental|Therapy Cool Path Duo Cardiac Ablation System|All patients who are eligible receive cardiac ablation procedure for Ischemic Ventricular Tachycardia
11561268|NCT00925496||Standard PROMOS prosthesis|Patients receiving a standard PROMOS prosthesis
11561269|NCT00925496||Reverse PROMOS prosthesis|Patients receiving a reverse PROMOS prosthesis
11561270|NCT00925483|Experimental|daily long|daily long (4 hours, 6 times weekly) dialysis for 6 months
11561271|NCT00925483|Experimental|daily short|daily short (2 hours 6 times weekly) dialysis for 6 months
11561272|NCT00925483|Experimental|alternate day conventional|alternate day conventional (4 hours, 3 times weekly) dialysis for 6 months
11561273|NCT00925483|Experimental|alternate day long|alternate day long (8 hours, 3 times weekly) dialysis for 6 months
11561274|NCT00925470||1|
11561275|NCT00925457||001|Current Domperidone Current domperidone at any dose regardless of proton pump inhibitor status
11561276|NCT00925457||002|Current proton pump inhibitor (PPI) Current PPI and not current dapoxetine
11561277|NCT00925457||003|No Intervention Neither current domperidone nor current PPI
11561278|NCT00925444|Experimental|FOREseal|
11561279|NCT00925444|Active Comparator|Stapling|
11561280|NCT00925431|Experimental|Lifestyle Modification|Behavioral: cognitive-motivational enhancement to lifestyle management plus nutritional education.
11561281|NCT00925431|Active Comparator|Supportive education|General fibromyalgia education plus nutritional education.
11561282|NCT00925418|No Intervention|Without Glove|Patients do not use frozen glove during chemotherapy with Taxotere®
11561283|NCT00925418|Experimental|With Glove|Patients use frozen glove during chemotherapy with Taxotere®
11561284|NCT00925405||Breast MRI Screening|
11561285|NCT00925392|Experimental|Doripenem 500 mg|
11561286|NCT00925392|Experimental|Doripenem 1000 mg|
11561287|NCT00925366|Other|Shoulder rotator cuff tear|Shoulder rotator cuff tear
11561288|NCT00925353|Experimental|lidocaine gel|
11561289|NCT00925340|Experimental|1 - Family Check Up|Brief family intervention that employs Motivational Interviewing.
11561290|NCT00925340|Active Comparator|2 - Psychoeducation|
11561291|NCT00925327|Experimental|Corneal collagen cross-linking with riboflavin and UVA light|
11561292|NCT00925314|Experimental|Transgenic Lymphocyte Immunization|Open Label, Single Arm
11561293|NCT00925301|Experimental|Migalastat|Migalastat 150-mg capsule taken orally every other day (QOD) for 6 months and an open-label 6-month treatment extension, followed by an optional, 12-month, open-label treatment extension.
11561294|NCT00925301|Placebo Comparator|Placebo|Placebo capsule taken orally QOD for 6 months.
11561295|NCT00925288|Active Comparator|Regular schedule|Duration: Gardasil HPV vaccine administered intramuscularly at 0,2,6 months
11561296|NCT00925288|Experimental|Modified Schedule|Duration: Gardasil HPV vaccine administered intramuscularly at 0,3,6 months
11561297|NCT00925275|Experimental|Dosimetric|
11561345|NCT00924950|Active Comparator|Taclonex Ointment Topically Once Daily|
11561298|NCT00925262|Experimental|Cognitive Processing Therapy|An adaptation of cognitive behavioral therapy, focusing on treatment for persons suffering mental health effects of trauma
11561299|NCT00925262|Experimental|Behavioral Activation|A form of counseling therapy that emphasizes enhancing pleasurable behaviors and minimizing negative behaviors as a means to reducing depression symptomatology.
11561300|NCT00925262|Experimental|non-specific counseling|a collection of counseling skills suitable for a broad range of mental health and psychosocial problems and not designed for specific disorders. This particular version was developed by a collaborator -Heartland Alliance - for use with torture survivors.
11561301|NCT00925262|No Intervention|wait control|persons in this study arm will not receive active treatment as part of the study but will be monitored during the study and offered treatment after 3-5 months of waiting.
11561302|NCT00925249||1|The study group will consist of RA patients of the Walter Reed Army Medical Center (WRAMC) rheumatology clinic being considered for treatment with anti-TNF alpha therapy. We will enter patients into the study over a projected course of 12-24 months or until we reach the statistical requirement of 60 subjects.
11561303|NCT00925249||2|The control group will consist of healthy subjects without known immune-dysregulation or history of treatment with biologic agents who present to the WRAMC Allergy- Immunology clinic for routine screening TST as a part of current WRAMC policy.
11561304|NCT00925223||irritable bowel syndrome|patients with diarrhea-predominant IBS will be enrolled in this group.
11561305|NCT00925223||control group|patients with colon cancer or colon polyp will be enrolled as control group.
11561306|NCT00925210|Experimental|Sequential pEBUS - ENB|
11561307|NCT00925184||medical students, graduate year,|medical students at graduate year will be invited to participate in this study.
11561308|NCT00925171|Experimental|Pulmonary Rehabilitation Group|Intervention with exercise management
11561309|NCT00925171|No Intervention|Control Group|"Patients will receive the standard advice to undertake strength and endurance exercises at home and invitation to attend the Norwich Breath Easy Group
~Patients will be stratified according to whether the initial programme took place in the outpatient hospital or community setting"
11561310|NCT00925158|Experimental|Surgical instrument (DAME)|Surgical dissector instrument created to malar elevation.
11561311|NCT00925145||1|
11561312|NCT00925132|Experimental|Temozolomide, Decitabine, Panobinostat|"Temozolomide - given each cycle.
~Decitabine - 6 cohorts with dose escalation.
~Panobinostat - 6 cohorts with dose escalation."
11561313|NCT00925119|Experimental|Atenolol|Participants will receive atenolol for 8 weeks.
11561314|NCT00925106|Active Comparator|Celebrex capsule|Commercial capsule
11561315|NCT00925106|Experimental|D1|Test formulation D1
11561316|NCT00925106|Experimental|D2|Test formulation D2
11561317|NCT00925106|Experimental|D3|Test formulation D3
11561318|NCT00925093|Active Comparator|Vancomycin|Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample
11561319|NCT00925093|Active Comparator|Teicoplanin|Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample
11561320|NCT00925093|Active Comparator|Linezolid|Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
11561321|NCT00925080||A|
11561322|NCT00925067|Experimental|lightweight TiMesh|
11561323|NCT00925067|Experimental|lightweight VyproII|
11561324|NCT00925067|Experimental|Heavyweight Marlex|
11561325|NCT00925054|Experimental|rAvPAL-PEG 0.001 mg/kg|Subjects will start on rAvPAL-PEG 0.001 mg/kg
11561326|NCT00925054|Experimental|rAvPAL-PEG 0.003 mg/kg|Subjects will start on rAvPAL-PEG 0.003 mg/kg
11561327|NCT00925054|Experimental|rAvPAL-PEG 0.01 mg/kg|Subjects will start on rAvPAL-PEG 0.01 mg/kg
11561328|NCT00925054|Experimental|rAvPAL-PEG 0.03 mg/kg|Subjects will start on rAvPAL-PEG 0.03 mg/kg
11561329|NCT00925054|Experimental|rAvPAL-PEG 0.1 mg/kg|Subjects will start on rAvPAL-PEG 0.1 mg/kg
11561330|NCT00925041|Experimental|Kxl Vedera|
11561331|NCT00925028|Experimental|Group A|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. After four months the groups will switch to the alternate management strategy.
11561332|NCT00925028|Experimental|Group B|Patients of group B will continue to be managed by their physician. After four months the groups will switch to the alternate management strategy.
11561333|NCT00925015|Experimental|Cetux/Irin - Dmab 10 mg/kg|After treatment with Cetuximab (Cetux) and Irinotecan (Irin), Dalotuzumab (Dmab) was administered as an intravenous infusion at 10 mg/kg in Cycle 1 on Days 22, 29 and 36; followed in subsequent cycles by treatment with 10 mg/kg on Days 1, 8, 15, 22, 29 and 36. Each cycle was 6 weeks long.
11561334|NCT00925015|Experimental|Cetux/Irin - Dmab 15/7.5 mg/kg|After treatment with Cetux/Irin, Dmab was administered as an intravenous infusion at 15 mg/kg in Cycle 1 on Days 8, 22 and 36; followed in subsequent cycles by treatment with 7.5 mg/kg on Days 8, 22 and 36. Each cycle was 6 weeks long.
11561335|NCT00925015|Experimental|Dmab 10 mg/kg - Cetux/Irin (DDI)|Dmab was administered in each cycle as an intravenous infusion at 10 mg/kg once weekly on Days 1, 22 and 29; followed by treatment with Cetux/Irin. For Drug-Drug Interaction (DDI). Each cycle was 6 weeks long.
11561336|NCT00925002|Active Comparator|Open-Label|
11561337|NCT00924989|Experimental|Arm A: OSI-906|150 mg twice daily
11561338|NCT00924989|Placebo Comparator|Arm B: Placebo|Matching placebo twice daily
11561339|NCT00924976|Experimental|1|Subjects will be offered the Steps for Achieving Financial Empowerment (SAFE) which helps facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
11561340|NCT00924976|No Intervention|2|Representative payeeship as usual
11561341|NCT00924963|Experimental|Jet injection lidocaine|J-Tip jet injection of 1% buffered lidocaine
11561342|NCT00924963|Placebo Comparator|Jet injection saline|J-Tip jet injection of sterile saline
11561343|NCT00924963|Active Comparator|Lidocaine cream|Lidocaine 4%cream applied for 30 minutes prior to IV insertion or venipuncture
11561344|NCT00924950|Active Comparator|Taclonex Ointment/Hydrogel Patch Applied Topically Once Daily|Taclonex ointment once daily used to treat one psoriatic plaque, along with the Hydrogel Patch used once daily.
11561346|NCT00924937|Active Comparator|Low Fat Diet|Dietary Intervention with a Low fat diet: <30% fat (12% monounsaturated fatty acids; 6-8%polyunsaturated fatty acids; <10% saturated fatty acids)
11561347|NCT00924937|Experimental|Mediterranean Diet|Dietary Intervention with a Mediterranean Diet: 35-38% fat (22% monounsaturated fatty acids; 6% polyunsaturated fatty acids; <10% saturated fatty acids).
11561348|NCT00924924|Experimental|Act Healthy!|Immediate treatment group of six-weeks of classes in self-management training for healthy behaviors
11561349|NCT00924924|Active Comparator|Delayed treatment control|Delayed self-management training group - begins following completion of the experimental group training
11561350|NCT00924911|Experimental|Part 1|A 4 way crossover of three GSK1322322 tablet formulations and GSK1322322 powder in bottle
11561351|NCT00924911|Experimental|Part 2|A 3 way crossover of a GSK1322322 tablet with a high fat meal, with Ranitidine, and with Ranitidine and Vitamin C.
11561352|NCT00924898|Experimental|Acute HIV Treatment Group|Single arm, open label study in which all participants received the same study treatment with efavirenz, emtricitabine, and tenofovir DF
11561353|NCT00924885|Experimental|Thin Follicle Aspiration Needle|
11561354|NCT00924885|Active Comparator|Standard Follicle Aspiration Needle|
11561355|NCT00924872|Experimental|intervention|receive wheelchair skills training
11561356|NCT00924872|No Intervention|control|no formalized wheelchair skills training provided
11561357|NCT00924859||1|Patients with clinical suspicion of CVT
11561358|NCT00924846|Active Comparator|HFOV plus iNO|HFOV plus iNO: high frequency oscillatory ventilation plus inhaled nitric oxide
11561359|NCT00924846|Active Comparator|CMV plus iNO|CMV (conventional mechanical ventilation) iNO (inhaled nitric oxide)
11561360|NCT00924833|Placebo Comparator|placebo|Placebo tablets. One tablet twice daily.
11561361|NCT00924833|Active Comparator|2: Carvedilol|Carvedilol 25 mg tablets. One tablet twice daily.
11561362|NCT00924833|Active Comparator|3: Nebivolol|Nebivolol 5 mg tablets. One nebivolo tablet daily. One placebo tablet daily.
11561363|NCT00924820|Experimental|Bevacizumab|Bevacizumab 10 mg/kg by vein over about 1 hour, every 2 weeks.
11561364|NCT00924807|Experimental|Androgen Depr, Radiotherapy, Sorafenib|Everyone will receive Leuprolide acetate, Bicalutamide,Sorafenib and radiotherapy.
11561365|NCT00924794||Cohort A|Women aged 18 years and above, diagnosed with high grade lesions or microinvasive cervical carcinomas in primary conization performed and registered in the Cancer Registry of Norway, and presenting with recurrent conization with high grade lesions or microinvasive cervical carcinoma or invasive cervical carcinoma.
11561366|NCT00924781|Experimental|MK2578 1 mcg for every 600 U of Epogen at Baseline|Participants were randomized to receive treatment every week (QW).
11561367|NCT00924781|Experimental|1 mcg of MK2578 for every 600 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
11561368|NCT00924781|Experimental|MK2578 1 mcg for every 350 U of Epogen at Baseline|Participants were randomized to receive treatment QW.
11561369|NCT00924781|Experimental|1 mcg of MK2578 for every 350 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
11561370|NCT00924781|Experimental|MK2578 1 mcg for every 200 U of Epogen at Baseline|Participants were randomized to receive treatment QW.
11561371|NCT00924781|Experimental|1 mcg of MK2578 for every 200 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
11561372|NCT00924768|Experimental|Endotoxin|Inhalation of 20K EU CCRE
11561373|NCT00924742|Experimental|Test drug|
11561374|NCT00924729|Active Comparator|Moxifloxacin 0.5% ophthalmic solution|
11561375|NCT00924729|Active Comparator|Besifloxacin 0.6% ophthalmic suspension|
11561376|NCT00924703|Experimental|rAvPAL-PEG|rAvPAL-PEG in varying doses dependent on safety and efficacy.
11561377|NCT00924690|Experimental|1|Behavioral Message Arm
11561378|NCT00924690|Active Comparator|2|Generic Message Arm
11561379|NCT00924677|Sham Comparator|lidocaine|Local injection with lidocaine through the RF cannula without activation of RF generator.
11561380|NCT00924677|Active Comparator|lidocaine, radiofrequency current|After lidocaine injection through the RF cannula, the temperature of the electrode tip was raised to 70℃ for 90 seconds by RF generator.
11561381|NCT00924664|Experimental|Tanezumab 20 mg|
11561382|NCT00924664|Experimental|Tanezumab 10 mg|
11561383|NCT00924651|Experimental|Standard Care + EXCAP|Personalized exercise prescription
11561384|NCT00924651|No Intervention|Standard Care|Wait list control
11561385|NCT00924638|Active Comparator|Continuous Monitoring|Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
11561386|NCT00924638|No Intervention|Control Arm|Follow-up at the same frequency, but with no Insertable Cardiac Monitor
11561387|NCT00924625|Experimental|Neuromuscular electrical stimulation|NMES will be used as in clinical practice based on an evidence-based approach. NMES will be applied at the participant's maximum tolerance. Participants will receive 3 treatments/week for 12 weeks with at least 48h between training sessions.
11561388|NCT00924625|Active Comparator|Volitional exercises|VE will be used as in clinical practice based on an evidence-based approach. VE program will be the one shown to positively affect muscle hypertrophy and will follow the resistance training principles. Participants will receive 3 treatments/week for 12 weeks with at least 48h between training sessions
11561389|NCT00924612|Experimental|Fasting|Single dose of oral testosterone undecanoate (containing 300 mg T) administered orally in a fasted state
11561390|NCT00924612|Experimental|Very low fat diet|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with very low fat (6-10% fat).
11561391|NCT00924612|Experimental|Low fat diet|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with low fat (20% fat).
11561392|NCT00924612|Experimental|Normal diet|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with normal fat (30% fat).
11561393|NCT00924612|Experimental|High fat diet|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with high fat (50% fat).
11561394|NCT00924599|Experimental|Intervention Group-English|Intervention Group will be learning how to lose weight through healthy eating and moderate exercise. The goal is to get participants to lose 7% of body weight and increase physical activity to 2 1/2 hours per week. This group will be meeting one time per week for twelve weeks, and then one time per month until conception.
11561395|NCT00924599|Experimental|Intervention Group-Spanish|Intervention Group will be learning how to lose weight through healthy eating and moderate exercise. The goal is to get participants to lose 7% of body weight and increase physical activity to 2 1/2 hours per week. This group will be meeting one time per week for twelve weeks, and then one time per month until conception.
11561396|NCT00924599|Active Comparator|Lifestyle education-English|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
11561397|NCT00924599|Active Comparator|Lifestyle education-Spanish|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
11561398|NCT00924586|Placebo Comparator|P|
11561399|NCT00924586|Experimental|E|
11561400|NCT00924573|Experimental|1|"Metformin on top of glimepiride
~Twice a day with 2-6 mg of daily dose for glimepiride and 500-750mg of daily dose for metformin for 24 weeks"
11561401|NCT00924573|Placebo Comparator|2|"Placebo on top of glimepiride
~Twice a day with 2-6 mg of daily dose for glimepiride and 2-3 tablets of placebo for 24 weeks"
11561402|NCT00924560|Experimental|91-day Levonorgestrel Oral Contraceptive|Participants received a 91-day regimen consisting of 84 consecutive days of active combination tablets containing 150 μg levonorgestrel (LNG)/30 μg ethinyl estradiol (EE), followed by 7 days of 10 μg EE tablets for a total of 52 weeks (4 consecutive 91-day cycles).
11561403|NCT00924560|Active Comparator|28-day Levonorgestrel Oral Contraceptive|Participants received a 28-day regimen consisting of 21 consecutive days of active combination tablets containing 100 μg LNG/20 μg EE followed by 7 days of placebo tablets for a total of 52 weeks (13 consecutive 28-day cycles).
11561404|NCT00924560|No Intervention|Untreated Control|Participants received no oral contraceptives during the study.
11561405|NCT00924547|Experimental|Docosahexanoic Acid Supplement|In this arm, participants took two different doses of a DHA supplement. Each dose of the DHA supplement was taken for 4 weeks.
11561406|NCT00924547|Placebo Comparator|Placebo|In this arm, participants took a placebo pill that did not contain any DHA.
11561407|NCT00924534|Placebo Comparator|1|
11561408|NCT00924534|Experimental|2|
11561409|NCT00924534|Experimental|3|
11561410|NCT00924534|Experimental|4|
11561411|NCT00924521|Active Comparator|Refined grain|Participants in this group will receive only refined grains as typically consumed in the average American diet.
11561412|NCT00924521|Experimental|Whole grain diet|Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
11561413|NCT00924508|Experimental|Patch + cream, patch alone, cream alone|This is a single arm study. Each subject will have 3 target lesions; one treated with TAC 0.1% cream and hydrogel patch (occlusion), the second treated with cream alone, and the third treated with occlusion alone.
11561414|NCT00924495|Active Comparator|Cortical function|Activity/inhibition of the cortex
11561415|NCT00924495|Active Comparator|Cortical regulation|
11561416|NCT00924482|Other|Single Arm - Device|Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery
11561417|NCT00924469|Experimental|Abiraterone plus leuprolide plus prednisone|Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day up to Week 24. Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks up to Week 24. Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks.
11561418|NCT00924469|Active Comparator|Leuprolide then abiraterone plus leuprolide plus prednisone|Leuprolide acetate will be administered at a dose of 22.5 mg as intramuscular injection once every 12 weeks up to Week 24. From Week 13 to 24, abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day with prednisone tablets administered orally as 5 mg once daily.
11561419|NCT00924456|Experimental|Transcendental Meditation program|a natural effortless mental technique practiced sitting quietly 20 minutes twice a day
11561420|NCT00924443|Experimental|Clofarabine|Clofarabine 30 mg/m^2/day intravenously over 1 hour for 5 days every 28 to 42 days (one cycle), then 20mg/m^2/day intravenously over 1 hour for 5 days every 29 to 43 days for the second and subsequent cycles, up to a maximum of 3 cycles.
11561421|NCT00924430|Other|1|
11561422|NCT00924430|Other|2|
11561423|NCT00924417|Experimental|Distraction|"Parent given brief teaching session on concept of distraction, and parent and child given 3 distraction toys/tools to assist with peripheral intravenous line placement."
11561424|NCT00924417|Other|Routine care|Patient managed as routine care.
11561425|NCT00924404|Experimental|Xylitol|isotonic xylitol for sinus rinse
11561426|NCT00924404|Active Comparator|Saline|saline for sinus rinse
11561427|NCT00924391|Active Comparator|dairy milk|Control phase with 1% milk.
11561428|NCT00924391|Experimental|phytosterol enhanced soy based beverage|Treatment phase where control-phase diets are provided with phytosterol enhanced soy based beverage.
11561429|NCT00924352|Experimental|Ixabepilone + Dasatinib|"Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.
~Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level - 1;100 mg QD,Dose Level - 2;70 mg QD."
11561430|NCT00924339|Placebo Comparator|Rapeseed oil|Control-Group (n = 15) : Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
11561431|NCT00924339|Experimental|Soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
11561432|NCT00924326|Experimental|1x10^9-1x10^10+ high dose Interleukin-2|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + cryopreserved anti-CD19-CAR PBL
11561433|NCT00924326|Experimental|1x10^9-1x10^10 + high dose Retreat|
11561434|NCT00924326|Experimental|0.5x10^7 cells/kg|
11561435|NCT00924326|Experimental|2.5x10^6 cells/kg|
11561436|NCT00924326|Experimental|1.0x10^6 cells/kg|
11561437|NCT00924326|Experimental|1.0x10^6 cells/kg (Reduced chemo)|
11561438|NCT00924326|Experimental|2.0x10^6 cells/kg (Reduced chemo)|
11561439|NCT00924326|Experimental|6.0x10^6 cells/kg (Reduced chemo)|
11561440|NCT00924326|Experimental|2.0x10^6 cells/kg (Moderate chemo)|
11561441|NCT00924326|Experimental|2.0x10^6 cells/kg (9-12 days culture)|
11561442|NCT00924313|Experimental|11C-acetate for Prostate Cancer Patients|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
11561443|NCT00924300||patients|children and/or adolescents with psychiatric disorder
11561444|NCT00924300||controls|typically-developing children/adolescents
11561445|NCT00924287|Experimental|Metastatic Cancer|Cancer that has invaded other parts of the body
11561446|NCT00924274|Experimental|Lifestyle counseling|
11561447|NCT00924274|Active Comparator|sunflower oil|
11561448|NCT00924261|Experimental|Hip Stretching|Kneeling Hip flexor stretch - 3 minutes a day, daily, for 10 weeks
11561449|NCT00924261|Experimental|Shoulder Stretch|Shoulder Stretch - 3 minutes daily for 10 weeks
11561450|NCT00924248||Group 1|
11561451|NCT00924222|Experimental|Sevoflurane|
11561452|NCT00924222|Experimental|Propofol|
11561453|NCT00924209|Experimental|Stage IIIA lung cancer patients|Non-squamous cell non small cell lung cancer treated with 1250 mg/m^2 gemcitabine dose for two doses on day 1 and day 8 every 21 days,80 mg/m^2 cisplatin day 1 every 21 days for 3 cycles, 7.5 mg/kg bevacizumab on day 1 every 21 days for first 2 cycles only, and 100 mg/m^2 intravenous, and 100 mg/m^2 etoposide intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
11561454|NCT00924196||Biologic parents of children and adults with NFI|Biologic parents of children and adults with NFI will be evaluated at one time point, using a Neuropsychological Test Batter and QOL Assessment.
11561455|NCT00924196||Children and adults with NFI|Children and adults with NFI whose tumor and non tumor related manifestations will be longitudinally evaluated.
11561456|NCT00924196||Unaffected siblings of children and adults with NFI|Unaffected siblings of children and adults with NFI will be evaluated at one time point using a Neuropsychogical Test Battery and QOL Assessment.
11561457|NCT00924183||Treatment-as-usual|All patients will receive treatment as usual: antidepressant medication and/or cognitive behavioral therapy (CBT). Patients' results will be compare to their own baseline measurements.
11561458|NCT00924170|Experimental|Fludarabine and Cyclophosphamide/LMB-2|Administer cycle 1 with Fludarabine and Cyclophosphamide (FC) alone. Two weeks after starting cycle 1, begin up to 6 cycles of FC plus LMB-2 at minimum 20-day intervals.
11561459|NCT00924118|Experimental|Sodium Nitrite|Dose escalation of sodium nitrite.
11561460|NCT00924118|No Intervention|Open Control|Standard therapy
11561461|NCT00924105|Experimental|1|
11561462|NCT00924105|Placebo Comparator|2|
11561463|NCT00924079|Experimental|nalbuphine|
11561464|NCT00924066|Experimental|Squamous and Nonsquamous participants|"Squamous cell carcinoma is a histologic subtype of cervical cancer. Squamous cell carcinoma of the cervix (80%) is much more common than adenocarcinoma of the cervix.
~Non squamous carcinoma is a histologic subtype of cervical cancer. It is the second most common form of cervical cancer; consists of adenocarcinoma, adenosquamous and non squamous (not otherwise specified) subtypes.
~All participants in both arms received ixabepilone 6 mg/m^2 x 5 days, each cycle."
11561465|NCT00924053|Experimental|EGT0001474|
11561466|NCT00924053|Placebo Comparator|Placebo|
11561467|NCT00924040|Experimental|BL22 Immunotherapy|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
11561468|NCT00924027|Experimental|1/Radiation Therapy|
11561469|NCT00924014|Active Comparator|Conivaptan|Conivaptan will be given via IV bolus
11561470|NCT00924014|Active Comparator|Furosemide|Furosemide will be given via IV bolus
11561471|NCT00924014|Active Comparator|conivaptan and furosemide|on day 3 subjects will receive both study drugs
11561472|NCT00924001|Experimental|Metastatic Melanoma|Melanoma that has invaded deep into the skin, lymph nodes, or other parts of the body.
11561473|NCT00923975|Other|Intended Users of the Software|Young adults, parents/guardians of young people under age 18, and healthcare professionals who work with this population would be intended users of the data management program. The DIDGET World Reports software is used to upload blood glucose results from the DIDGET Blood Glucose Monitoring System so that intended users can identify patterns in their diabetes management.
11561474|NCT00923962|Active Comparator|Type 2 Diabetes patients|
11561475|NCT00923962|Active Comparator|Healthy|
11561476|NCT00923962|Active Comparator|Artherosclerosis|
11561477|NCT00923949|Experimental|Pioglitazone|45 mg tablet daily by mouth for six weeks
11561478|NCT00923936|Active Comparator|KS;classic/HIV+not improved on antiviral|Kaposi's Sarcoma (KS) in patients who are Human immunodeficiency virus (HIV) Negative, HIV infected with stable disease for one year despite antiretroviral therapy or progressive disease despite 4 months of antiretroviral therapy.
11561479|NCT00923936|Active Comparator|All other advanced HIV-asociated KS|All other patients with advanced acquired immune deficiency syndrome (AIDS)-associated KS
11561480|NCT00923923|Experimental|levels of stress|
11561481|NCT00923910|Other|Donors|Related and unrelated donors undergo lymphapheresis to prepare cellular vaccines and to donate lymphocytes for infusion.
11561482|NCT00923910|Experimental|Recipients|Participants receive donor lymphocytes and vaccines prepared from donors.
11561483|NCT00923897|Experimental|RT for Liver Mets and HCC|
11561484|NCT00923871|Experimental|Cone Beam CT|
11561556|NCT00923104||2/patients|subjects with breast cancer, ductal carcinoma in situ, and adenocarcinoma of prostate
11561557|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 20mg/5mg/12.5mg|olmesartan medoxomil 20mg / amlodipine besylate 5 mg / hydrochlorothiazide 12.5mg
11561485|NCT00923858||Control - participants from cycles 1 & 2|no intervention. Control group is composed of participants from Cohort I (recruited during our first grant cycle) and from Cohort II (recruited during our second grant cycle). Continued observation is planned for those controls, partial tears and full tears who enrolled in study at age 65 years or younger and have less than 11 years of follow up.
11561486|NCT00923858||Cuff Tear Cohort III|These participants are being recruited from our clinical population and have been scheduled to undergo a standard of care rotator cuff repair and post op therapy. One shoulder has been indicated for rotator cuff repair and the contralateral shoulder is asymptomatic. Both shoulders will be monitored.
11561487|NCT00923845|Other|Donors|A sibling who is 6/6 HLA --matched with the recipient. Donors undergo donor lymphocyte harvest and stem cell mobilization and harvest.
11561488|NCT00923845|Other|Recipients|Recipients undergo induction therapy, allogeneic stem cell therapy and GVHD prophylaxis.
11561489|NCT00923819|Experimental|Group A|Laparoscopic Gastric Bypass
11561490|NCT00923819|Active Comparator|Group B|Standard conservative treatment. Patients from Child Obesity Registry of Vestfold.
11561491|NCT00923806|Experimental|Gene Therapy Treatment|
11561492|NCT00923793|Active Comparator|Titanium|Titanium implant for cranioplasty. Titanium implants are used since 10 years in Germany because of their high biocompatibility and accuracy of fit.
11561493|NCT00923793|Experimental|Hydroxylapatite|Hydroxylapatite (CustomBone) implant Hydroxylapatite implants are used since about 3 years in Germany. As this material is very similar to human bone structure an improved osteointegration has been observed.
11561494|NCT00923702|Other|2 doses of vaccine|The participants will receive two doses of the vaccine at Day 1 and Day 180.
11561495|NCT00923702|Other|3 doses of vaccine|The participants will receive three doses of the vaccine at Day 1, Day 60, and Day 180.
11561496|NCT00923676|Active Comparator|Fenofibrate|Fenofibrate pills
11561497|NCT00923676|Active Comparator|Rosuvastatin|Rosuvastatin pills
11561498|NCT00923676|Active Comparator|fenofibrate + rosuvastatin|fenofibrate pills + rosuvastatin pills
11561499|NCT00923663|Experimental|Lenalidomide|Lenalidomide administered orally at a dose of 25 mg daily
11561500|NCT00923624|Active Comparator|staff emails|Attention control that includes staff sending emails with information about using health information technology system.
11561501|NCT00923624|Experimental|study nurse messages|A series of 6 proactive secure messages and 3 proactive booster messages (for a total of 9 secure and personalized messages) sent by the study nurse via the EMR patient web portal.
11561502|NCT00923611|Placebo Comparator|Placebo|3 tablets of placebo will be taken 30minutes after breakfast for 8 weeks
11561503|NCT00923611|Active Comparator|Fimasartan 20mg|2 tablets of placebo and 1 tablets of fimasartan 20mg will be taken 30minutes after breakfast for 8 weeks
11561504|NCT00923611|Active Comparator|Fimasartan 60mg|3 tablets of fimasartan 20mg will be taken 30minutes after breakfast for 8 weeks
11561505|NCT00923611|Active Comparator|Fimasartan 120mg|3 tablets of fimasartan 40mg will be taken 30minutes after breakfast
11561506|NCT00923611|Active Comparator|Fimasartan 240mg|3 tablets of fimasartan 80mg will be taken 30minutes after breakfast for 8 weeks
11561507|NCT00923598|Active Comparator|1) 0.1% Ropivicaine on Right Leg|Patients will be randomized ot 0.1% Ropivicaine infusion on the right leg and therefore 0.4% Ropivicain in fusion for the left leg for pain due to bilateral TKA. The outcome measures will be measured on both legs, starting with the right leg each time. The infusion will last for the two days following surgery, that the patient is staying in the hospital.
11561508|NCT00923598|Active Comparator|2) 0.4% Ropivicaine on Right Leg|Patients will be randomized ot 0.4% Ropivicaine infusion on the right leg and therefore 0.1% Ropivicain in fusion for the left leg for pain due to bilateral TKA. The outcome measures will be measured on both legs, starting with the right leg each time. The infusion will last for the two days following surgery, that the patient is staying in the hospital.
11561509|NCT00923572||Group 1|
11561510|NCT00923559|Experimental|Mother-Infant Psychoanalytic treatment;MIP|MIP intervention
11561511|NCT00923559|Active Comparator|TAU|Treatment as usual
11561512|NCT00923533|Active Comparator|Part A|Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
11561513|NCT00923533|Active Comparator|Part B|Hydrochlorothiazide (7day) Hydrochlorothiazide + Fimasartan (7day)
11561514|NCT00923520|Experimental|1|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
11561515|NCT00923507||Patients|Patients with monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstr(SqrRoot)(Delta)m macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL).
11561516|NCT00923494|Active Comparator|Group R20|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
11561517|NCT00923494|Active Comparator|Group R30|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
11561518|NCT00923494|Active Comparator|Group R40|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
11561519|NCT00923481|Experimental|Multi-kinase inhibitor Fostamatinib Disodium (R935788)|200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
11561520|NCT00923442||1|Patients (from birth to 75 years old) diagnosed with any hematologic malignancy or pre malignant condition
11561521|NCT00923429|Active Comparator|S-A|
11561522|NCT00923429|Active Comparator|S-A+stretch|
11561523|NCT00923429|Experimental|S-A+stretch+manther|
11561524|NCT00923429|Experimental|S-A+stretch+manther+sterinject|
11561525|NCT00923416||Prostate Cancer|
11561526|NCT00923403|Placebo Comparator|Placebo Comparator|control dairy milk
11561527|NCT00923403|Experimental|experimental|plant sterol enriched soymilk
11561528|NCT00923364|Experimental|Recipients and Healthy Related Donors|Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.
11561558|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/12.5mg|
11561559|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/25mg|
11561529|NCT00923351|Experimental|Arm A - Participants who did not receive rhIL-7|Six patients with Ewings sarcoma family or tumors (ESFT) participants will receive cytotoxic/lympholytic therapy with cyclophosphamide and fludarabine (if cluster of differentiation 4 (CD4) count > 200 cells/mcl). Participant will receive Tumor lysate/keyhole limpet hemocyanin (KLH) pulsed dendritic cell vaccine followed by Infusion of 8H9/CD25 depleted autologous lymphocyte infusion on Day 1, followed by Tumor lysate/KLH pulsed dendritic cell vaccine on week 4, 6, 8, 10, and 12.
11561530|NCT00923351|Experimental|Arm B - Participants who received rhIL-7|"Eight patients with rhabdomyosarcoma, fifteen patients with Ewings sarcoma family or tumors (ESFT), two patients with desmoplastic small round cell tumor, and one patient with synovial cell sarcoma participants will receive CYT107 20 mcg/kg/dose subcutaneous (SQ) (approx. 48h prior to vaccine[Day 0]), Tumor lysate/KLH pulsed dendritic cell vaccine followed by Infuse 8H9/CD25 depleted autologous lymphocyte infusion on Day 2, followed by CYT107 20 mcg/kg/dose SQ on days 14, 28 and 42 (± 7 days), and Tumor lysate/KLH pulsed dendritic cell vaccine on Days 16, 30, 44, 56, and 70 (± 7 days).
~Apheresis/flow cytometry/delayed type of hypersensitivity (DTH) responses for immune endpoint monitoring (skin tests) will be performed on Week 8, 14, 20 (Arm A) and on Days 42, 84 and 126 (+/- 7 days) (Arm B); and radiographic studies for clinical restaging will be performed on Week 8 and 20 (Arm A) and Days 42 and 126 (+/- 7 days) (Arm B)."
11561531|NCT00923338|Experimental|Vesico-vaginal fistula plug|Vesico-vaginal fistula plug
11561532|NCT00923312|Experimental|CV9201|CV9201 is composed of five formulated mRNAs (drug product components) encoding antigens that are overexpressed or exclusively expressed in NSCLC cells.
11561533|NCT00923299|Other|cetuximab, trastuzumab|
11561534|NCT00923273|Experimental|Treatment level 1 - 3mg load|Sirolimus 3mg load/1mg/day; Pemetrexed 375mg/m^2
11561535|NCT00923273|Experimental|Treatment level 2 - 6 mg load|Sirolimus 6mg load/2mg/day; Pemetrexed 375mg/m^2
11561536|NCT00923273|Experimental|Treatment level 3 - 6mg load|Sirolimus 6mg load/2mg/day; Pemetrexed 375mg/m^2
11561537|NCT00923273|Experimental|Treatment level 4 - 10 mg load|Sirolimus 10mg load/3mg/day; Pemetrexed 500mg/m^2
11561538|NCT00923273|Experimental|Treatment level 5 - 15 mg load|Sirolimus 15mg load/5mg/day; Pemetrexed 500mg/m^2
11561539|NCT00923260|Experimental|Roux-en-Y Gastric Bypass/Omentectomy|Laparoscopic Roux-en-Y Gastric Bypass with omentectomy
11561540|NCT00923260|Active Comparator|Roux-en-Y Gastric Bypass alone|
11561541|NCT00923247|Experimental|Phase 1 - vandetanib and bortezomib|Patients will be treated with vandetanib and bortezomib to find the maximally tolerated dose
11561542|NCT00923247|Active Comparator|Phase 2 B - vandetanib alone|Patients will be treated with vandetanib alone.
11561543|NCT00923247|Active Comparator|Phase 2 A - vandetanib and bortezomib at the MTD|Patients will be treated with vandetanib and bortezomib at the maximally tolerated dose (MTD) of the Phase I study
11561544|NCT00923234|Experimental|Azacitidine and Lenalidomide|Azacitidine 75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles and Lenalidomide 10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
11561545|NCT00923221||1/Patient samples|blood samples from patients with diagnosed prostate cancer
11561546|NCT00923195|Experimental|TBI 600cGy + PBL + HD IL-2+gp100:154-162|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population). One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14. Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).Radiation: 2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute.
11561547|NCT00923195|Experimental|TBI 600cGy+PBL+HD IL-2+MART-1:26-35(27L)|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population). One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14. Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).Radiation: 2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute.
11561548|NCT00923182|Experimental|Alemtuzumab|The starting dose of alemtuzumab was 3 mg. The dose was gradually escalated on a daily basis (3 mg, 10 mg, and then 30 mg) until the patient tolerated a dose of 30 mg IV infusion over 2 hours. All subsequent doses of alemtuzumab were 30 mg IV 3 times a week (every other day).
11561549|NCT00923156|Experimental|Aliskiren|In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1. In double blind phase (Period 2), patients received aliskiren (150 mg once daily) up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site and matching placebo of ramipril capsules.
11561550|NCT00923156|Experimental|Ramipril|"In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1.
~In double blind phase (Period 2), patients received ramipril 10 mg capsule o.d and matching placebo of aliskiren tablet."
11561551|NCT00923156|Experimental|Aliskiren plus Ramipril|"In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1.
~In double blind phase (period 2), patients received ramipril (10 mg once daily capsule) and aliskiren (150 mg once daily tablet) up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site"
11561552|NCT00923130|Experimental|Bevacizumab with Ixabepilone|Bevacizumab 15mg/kg every 3 weeks Ixabepilone given on days 1,2,3,4 and 5 of each three week cycle at a dose of 6mg/m(2)/day
11561553|NCT00923117|Experimental|Bevacizumab resistant patients|Patients who had tumor progression while treated with bevacizumab.
11561554|NCT00923117|Experimental|Bevacizumab naive patients|Patients with progressive tumor who have not been treated with bevacizumab.
11561555|NCT00923104||1/healthy volunteers|healthy volunteers
11561560|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/12.5mg|
11561561|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/25mg|
11561562|NCT00923091|Experimental|olmesartan/amlodipine 20mg/5mg|olmesartan medoxomil 20mg / amlodipine besylate 5mg
11561563|NCT00923091|Experimental|olmesartan/amlodipine 40mg/5mg|
11561564|NCT00923091|Experimental|olmesartan/amlodipine 40mg/10mg|
11561565|NCT00923078|Experimental|Auditory-Visual Train Order|4 weeks (20 sessions) of auditory cognitive training (Brain Fitness) followed by 4 weeks (20 sessions) of visual cognitive training (Insight)
11561566|NCT00923078|Experimental|Visual-Auditory Train Order|4 weeks (20 sessions) of visual cognitive training (Insight) followed by 4 weeks (20 sessions) of auditory cognitive training (Brain Fitness)
11561567|NCT00923065||Consults|Patients being seen as a consult.
11561568|NCT00923065||Donors|Donors of cellular products.
11561569|NCT00923065||Genetic Follow-Up|Individuals with a known/suspected germline genomic research incidental pathogenic or likely pathogenic variant, and/or who require CLIA confirmation.
11561570|NCT00923065||Patients|Patients being enrolled for the treatment or follow-up of their disease.
11561571|NCT00923039||Exposed/ Not exposed|
11561572|NCT00923026||A/Gene Therapy|Patients who have received gene therapy
11561573|NCT00923026||B/Non-Gene Therapy|Patients who have not received gene therapy
11561574|NCT00923013|Experimental|1|Cladribine with immediate Rituximab
11561575|NCT00923013|Active Comparator|2|Cladribine with Rituximab delayed by at least 6 months after Cladribine if and when minimal residual disease is detected
11561576|NCT00923013|Experimental|3|Non-randomized group receving Cladribine with immediate Rituximab (before rather than after the 1st of the 5 daily doses of cladribine on day 1)
11561577|NCT00923000|Experimental|Nubian with Long dan xie gan tang 3g|
11561578|NCT00923000|Active Comparator|Nalbuphine|
11561579|NCT00923000|Active Comparator|Morphine|
11561580|NCT00923000|Experimental|Morphine with Long dan xie gan tang|
11561581|NCT00923000|Experimental|Nubian with Long dan xie gan tang 3g tid|
11561582|NCT00922987||Lyrica|Adult patients with partial seizures (type of epilepsy). Inclusion criteria according to Summary of Product Characteristics
11561583|NCT00922974|Experimental|Radiosurgery/SBRT|
11561584|NCT00922974|Active Comparator|External Beam Radiation Therapy|
11561585|NCT00922961|Experimental|cellular apoptosis|
11561586|NCT00922948|Experimental|Cryoablation|
11561587|NCT00922948|Active Comparator|Radiofrequency ablation|Radiofrequency ablation
11561588|NCT00922935|Experimental|Cresco early loading|The implants must be restored (loaded) with a permanent screw retained fixed partial denture (FPD) at 10 days of post surgery
11561589|NCT00922935|Experimental|Cresco late loading|"Healing caps will be placed until loading. The minimum waiting time is 4 weeks, but not before try ins to ensure a perfect fit. The implants must be restored (loaded) with a permanent screw retained fixed partial denture (FPD) within 42-56 days (6 to 8 weeks) of surgery."
11561590|NCT00922935|Active Comparator|Straumann system late loading|Straumann components loading at 6-8 weeks post surgery
11561591|NCT00922909|Active Comparator|2|Day 1 : morning : Medication on ; Stimulation : off afternoon : Medication : on ; Stimulation : on Day 2 : morning : Medication : off ; Stimulation : off afternoon : medication : off ; stimulation : on
11561592|NCT00922909|Active Comparator|3|Day 1 : morning : Medication off ; Stimulation : on afternoon : Medication : off ; Stimulation : off Day 2 : morning : Medication : on ; Stimulation : on afternoon : medication : on ; stimulation : off
11561593|NCT00922909|Active Comparator|4|Day 1 : morning : Medication off ; Stimulation : off afternoon : Medication : off ; Stimulation : on Day 2 : morning : Medication : on ; Stimulation : off afternoon : medication : on ; stimulation : on
11561594|NCT00922909|Active Comparator|1|Day 1 : morning : Medication on ; Stimulation on afternoon : Medication on ; Stimulation off Day 2 : morning : Medication off ; Stimulation on afternoon : Medication off ; Stimulation off
11561595|NCT00922896|Experimental|GPE|Gemcitabine-Cisplatin-Erlotinib
11561596|NCT00922883|Experimental|Eltrombopag|Eltrombopag (Promacta): Subjects commenced eltrombopag at a dose of 50 mg, which was increased by 25 mg every 2 weeks if the platelet count had not increased by 20 × 103/µL, to a maximum dose of 150 mg.
11561597|NCT00922870|Active Comparator|Standard treatment|
11561598|NCT00922870|Experimental|Cascade|
11561599|NCT00922857|Experimental|Respiratory rehabilitation|
11561600|NCT00922844|Active Comparator|Sevoflurane|Administration of the volatile anesthetic Sevoflurane.
11561601|NCT00922844|Active Comparator|Isoflurane|Administration of the volatile anesthetic Isoflurane.
11561602|NCT00922818||Radical perineal prostatectomy patients|Radical perineal prostatectomy patients
11561603|NCT00922805|Active Comparator|fiber-enriched formula then fiber-free formula|Subjects first receive a fiber-enriched formula for one week but then will be crossed over and receive a fiber-free formula
11561604|NCT00922805|Active Comparator|fiber-free formula then fiber-enriched formula|Subjects receive first formula only then will be crossed over and receive a fiber-enriched formula
11561605|NCT00922792|Experimental|A|
11561606|NCT00922792|Experimental|B|
11561607|NCT00922779|Experimental|1|
11561608|NCT00922766||1.0|
11561609|NCT00922753|Active Comparator|BiPAP6 assisted preoxygenation|
11561610|NCT00922753|Active Comparator|BiPAP4 assisted preoxygenation|
11561611|NCT00922753|Active Comparator|Standard preoxygenation (VS)|
11561612|NCT00922740|Placebo Comparator|Sugar pill|
11561613|NCT00922740|Experimental|VA106483 1 mg|
11561614|NCT00922740|Experimental|VA106483 2 mg|
11561615|NCT00922740|Experimental|VA106483 4 mg|
11561616|NCT00922727|Active Comparator|L. reuteri|Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment and maintenance of a well-functioning gastro-intestinal (GI) tract microflora and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment. The oil drops contain a dietary supplement of Lactobacillus reuteri DSM 17938.
11561734|NCT00921791|Active Comparator|Pharmaceutical care|Consultations with the pharmacists plus usual care.
11561617|NCT00922727|Placebo Comparator|Sunflower Oil|Placebo will be the equivalent number of drops of suspended sunflower oil (without LR), provided by Biogaia.
11561618|NCT00922714|Experimental|Glutamine|Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
11561619|NCT00922714|Placebo Comparator|Control|saline
11561620|NCT00922701|Experimental|Peritoneal Dialysis Solution|
11561621|NCT00922688|Active Comparator|Dipeptiven Arm Enteral|
11561622|NCT00922688|Placebo Comparator|Placebo Arm Enteral and Intravenously|
11561623|NCT00922688|Active Comparator|Dipeptiven ARM Intravenously|
11561624|NCT00922675|Experimental|Postconditioning|Active arm:Postconditioning protocol before routine PCI/stenting of an occluded coronary artery
11561625|NCT00922675|Other|Control|Control arm: Routine PCI/stenting of an occluded coronary artery without postconditioning
11561626|NCT00922649|Other|A|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen of ≥ 2 OAs
11561627|NCT00922649|Other|B|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen of basal insulin ± OAs
11561628|NCT00922649|Other|C|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen basal-bolus insulin ± OAs
11561629|NCT00922636|Active Comparator|Methylphenidate|Extended-release methylphenidate 18 milligrams per day (mg/day) to 54 mg/day, based on weight, given once daily (QD) and orally (po) as a capsule for the 8-week double-blind treatment phase, followed by 2 weeks of placebo in the taper phase.
11561630|NCT00922636|Placebo Comparator|Placebo|
11561631|NCT00922636|Experimental|LY2216684 (0.1 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of placebo in the taper phase.
11561632|NCT00922636|Experimental|LY2216684 (0.2 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of tapering in the taper phase.
11561633|NCT00922636|Experimental|LY2216684 (0.3 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of tapering in the taper phase.
11561634|NCT00922623|Experimental|Belotero®|
11561635|NCT00922610|Experimental|1|
11561636|NCT00922597||Group 1|
11561637|NCT00922584|Experimental|sorafenib|Patients with stage IIIB/IV NSCLC who failed EGFR-TKI therapy will receive oral sorafenib 400 mg twice daily until disease progression or unacceptable toxicity.
11561638|NCT00922571|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the OptiMedica Catalys™ Precision Laser System (Catalys System)
11561639|NCT00922558|No Intervention|normal children|Normal children ages 5-12 years.
11561640|NCT00922558|Experimental|postural control|
11561641|NCT00922532|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide
11561642|NCT00922532|Placebo Comparator|Nitrogen|Nitrogen Placebo
11561643|NCT00922519||1|
11561644|NCT00922506|Experimental|doxazosin plus tolterodine SR 2 mg|doxazosin plus tolterodine SR(2 mg, qd) for 12 weeks
11561645|NCT00922506|Experimental|doxazosin plus tolterodine SR 4 mg|doxazosin plus tolterodine SR(4 mg,qd) for 12 weeks
11561646|NCT00922480|Active Comparator|2|Losartan group
11561647|NCT00922480|Active Comparator|1|Fimasartan 60mg, 120mg
11561648|NCT00922467|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
11561649|NCT00922467|Experimental|Esmolol|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and esmolol
11561650|NCT00922454|Experimental|Talent Stent-Graft|
11561651|NCT00922454|Experimental|Cook Zenith Stent-Graft|
11561652|NCT00922441|Experimental|Fimasartan 1|Fimasartan 60 mg group
11561653|NCT00922441|Experimental|Fimasartan 2|Fimasartan 120 mg group
11561654|NCT00922441|Active Comparator|Valsartan|Reference (Valsartan 80 mg) group
11561655|NCT00922428||Observational group|Patients suffering from rheumatic disorders of different types and origins, especially those with arthralgia, myalgia, lumbago, or other diagnoses.
11561656|NCT00922415||cases|patients at least 18 years of age, with confirmed Crohn's disease undergoing intestinal resection for complicated Crohn's disease
11561657|NCT00922402|Experimental|Treatment|All patients will be submitted to a shared intensive protocol of insulin infusion supported by continuous glucose monitoring
11561658|NCT00922389|Experimental|G-CSF + Stem cells|
11561659|NCT00922389|Other|No stem cell group|
11561660|NCT00922389|Active Comparator|Standerd theraphy|Any therapy for diabetic foot CLI which is routinely practiced and accepted in India
11561661|NCT00922376|Active Comparator|T+ Intervention|The intervention group patients will use the T+ telemedicine application whilst completing repeated measures aiming to compare them to a control group receiving standard care.
11561662|NCT00922376|No Intervention|Usual care|The control group will be receiving the standard care offered by the NHS to patients suffering from diabetes.
11561663|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 alone|
11561664|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|
11561665|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|
11561666|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 + 625/125 µg CAF01|
11561667|NCT00922350|Experimental|heliox|The patients in this group underwent nebulization with heliox carried by the trunk erect
11561668|NCT00922350|Experimental|heliox+posture|The patients in this group carried out the mist carried by heliox and the trunk tilted forward
11561669|NCT00922350|Experimental|oxygen+posture|The patients in this group carried out the mist carried by oxygen and the trunk tilted forward
11561670|NCT00922350|Active Comparator|oxygen|The patients in this group carried out the mist carried by the oxygen and the trunk upright
11561671|NCT00922337||MGuard|eligible patients implanted with minimum one MGuard stent
11561672|NCT00922324|Experimental|STP206|STP206 administered either as a single dose or as a daily dose for seven consecutive days
11562183|NCT00918190|Active Comparator|Ondansetron-Dexa group|Use 2 different antiemetics
11561673|NCT00922324|Placebo Comparator|Vehicle Control|STP206 vehicle administered as either a single dose or as a daily dose for 7 consecutive days
11561674|NCT00922311|Experimental|Aliskiren|
11561675|NCT00922285|Experimental|Art Therapy|
11561676|NCT00922272|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
11561677|NCT00922272|Placebo Comparator|Placebo|Placebo
11561678|NCT00922259|Experimental|H7N7 Vaccine|Participants will be administered two doses of the candidate live influenza A H7N7 vaccine
11561679|NCT00922246|No Intervention|control group|Conscript used their own ankle boots instead of custom made insoles.
11561680|NCT00922246|Experimental|shoe insoles|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length. The insole was strong enough to fill the arch area thus providing support to the mid foot. It also influences the position of the foot. The insoles were individually customized by heating the polyethylene in form of individual foot with standing and walking in them. The conscripts were advised to use these insoles in their ankle boot.
11561681|NCT00922233|Experimental|Levonorgestrel|0.75 mg of levonorgestrel within 24 hours of sex
11561682|NCT00922220|Active Comparator|stationary bike|Participants rode a stationary bike for five minutes
11561683|NCT00922220|Active Comparator|lumbar extension exercises|Participants performed four sets of fifteen lumbar extension exercises over five minutes
11561684|NCT00922220|Experimental|spinal manipulative therapy|Participants received spinal manipulative therapy to the low back
11561685|NCT00922207|Experimental|1|
11561686|NCT00922207|Experimental|2|
11561687|NCT00922207|Placebo Comparator|3|
11561688|NCT00922181|Experimental|MWA|Patients undergoing MWA for hepatic metastases smaller than 3 cm, without underlying liver disease
11561689|NCT00922181|Active Comparator|RFA|Patients undergoing RFA for hepatic metastases smaller than 3 cm, without underlying liver disease
11561690|NCT00922168||Cardiac Surgeries: CABG, valve replacements|
11561691|NCT00922155|No Intervention|EBUS|After the PPLs been localized by endobronchial ultrasound(EBUS), patients in the EBUS group received transbronchial biopsy and bronchial washing at the bronchus located by EBUS.
11561692|NCT00922155|Active Comparator|EBUS-GS|After PPLs been localized by EBUS, the EBUS and guide sheath were then inserted to localize the lesion again. Transbronchial biopsy and brushing were done through the guide sheath after the probe been removed.
11561693|NCT00922129|Experimental|Conversion to sirolimus|
11561694|NCT00922129|Active Comparator|Calcineurim inhibitor reduction|
11561695|NCT00922116|Experimental|1|
11561696|NCT00922103|Experimental|INRA|Patients treated for medical refractory Ulcerative Colitis
11561697|NCT00922103|Active Comparator|IPAA|Patients treated for medical refractory Ulcerative Colitis
11561698|NCT00922064|Experimental|ECT|
11561699|NCT00922051|Experimental|Group 1|Application of Acu-TENS
11561700|NCT00922051|Placebo Comparator|Group 2|
11561701|NCT00922038|Experimental|High reward|
11561702|NCT00922038|Experimental|Low reward|
11561703|NCT00922038|No Intervention|Control|
11561704|NCT00922025||1|Male patients with non-small cell lung cancer (NSCLC) of adeno histology
11561705|NCT00922012|Experimental|Electromagnetic stimulation|Electromagnetic stimulation therapy
11561706|NCT00921986||Arrhythmias|Patients with arrhythmias
11561707|NCT00921986||Control Subjects|Subjects that do not have a history of cardiac arrhythmias.
11561708|NCT00921973|Active Comparator|VAX102|Simultaneous administration of VAX102 1 ug i.m. plus TIV
11561709|NCT00921973|Placebo Comparator|Placebo|
11561710|NCT00921960|No Intervention|Usual Care|Usual Care will involve ongoing management from the general practitioner, nurse-led assessment of cardiovascular risk at the general practice and referral to specialist services as deemed necessary.
11561711|NCT00921960|Other|Intervention|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate
11561712|NCT00921947|Experimental|VAX102 IM|VAX102 given as 1 µg intramuscular (i.m.)
11561713|NCT00921947|Experimental|VAX102 SC|VAX102 given as a 2 µg subcutaneous (s.c.) dose
11561714|NCT00921934||Vitamin C|Adult patients suffering from acute viral infection, especially herpes zoster, presenting themselves in Primary Care Centers or hospitals all over Germany, and who are treated with standard therapy and add-on vitamin C.
11561715|NCT00921921|Experimental|Extra-fine particle steroid inhaler|
11561716|NCT00921921|Placebo Comparator|Placebo control|
11561717|NCT00921908||epidural catheter|subfascial placement of a triple-orifice epidural catheter
11561718|NCT00921908||multiholed catheter|subfascial placement of a multi-orifice 15 cm catheter
11561719|NCT00921895|Experimental|Device Testing|Patients with conjunctivitis will be tested with the RPS Adeno Detector IV
11561720|NCT00921882||Oral glucose tolerance test|oral glucose tolerance test performed 48 hours post-partum and 8 weeks post-partum.
11561721|NCT00921869|Experimental|1|
11561722|NCT00921856|No Intervention|CAD|Patients admitted with suspicion of CAD and proof of CAD after coronary angiography.
11561723|NCT00921856|Experimental|No-CAD|Patients admitted with suspicion of CAD but without proof of CAD after coronary angiography will undergo intracoronary acetylcholine provocation test.
11561724|NCT00921843|Experimental|Methadone 0.1mg/kg|Methadone 0.1mg/kg
11561725|NCT00921843|Experimental|Methadone 0.2mg/kg|Methadone 0.2mg/kg
11561726|NCT00921843|Experimental|Methadone 0.3mg/kg|Methadone 0.3mg/kg
11561727|NCT00921843|Placebo Comparator|Control|No methadone
11561728|NCT00921830|Experimental|Ibuprofen|ibuprofen
11561729|NCT00921804|Experimental|1|AZD8529 40 mg
11561730|NCT00921804|Placebo Comparator|2|Placebo
11561731|NCT00921804|Other|3|Risperidone 4 mg (2mg on Day 1)
11561732|NCT00921791|Experimental|Home Blood Pressure Monitoring|Automatic oscillometric device for blood pressure measurement at home plus usual care.
11561733|NCT00921791|Experimental|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists plus usual care.
11561735|NCT00921791|Active Comparator|Control|Usual care: participants are instructed to keep on their current antihypertensive medication and receive non-pharmacological recommendations for hypertension treatment.
11561736|NCT00921765|Placebo Comparator|Placebo + Placebo|Saline single bolus dose iv + saline single bolus dose iv
11561737|NCT00921765|Active Comparator|Placebo + Ketamine|Saline single bolus dose followed by single bolus dose of ketamine 0.2 mg/kg bw
11561738|NCT00921765|Active Comparator|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
11561739|NCT00921765|Active Comparator|Naloxone + Ketamine|Single bolus dose of ketamine 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
11561740|NCT00921752||Patients at high cardiovascular risk|
11561741|NCT00921739|Experimental|IMRT concurrent with chemotherapy|6 fractions of esophageal sparing IMRT weekly for 5-6 weeks (dependent on dose cohort) concurrent with standard chemotherapy: Cisplatin 50 mg/m2 /d intravenously (IV) on days 1, 8, 29, and 36. Etoposide 50 mg/m2 /d IV on days 1 through 5 and 29 through 33.
11561742|NCT00921726|Experimental|1|Participants will receive treatment in the following order: Study Regimens A, B, C, D
11561743|NCT00921726|Experimental|2|Participants will receive treatment in the following order: Study Regimens B, A, C, D
11561744|NCT00921713|Active Comparator|Enhanced Usual Care|An extensive packet of information including cancer education materials and treatment resources will be mailed to patients.
11561745|NCT00921713|Experimental|Oncology Nurse Care Management|In addition to this mailed information packet, patients in OCNM will be contacted by an experienced Oncology nurse with additional training in self-management support and psychosocial care. The intervention nurse, supported by a Medical Oncologist and Clinical Psychologist, will work closely with patients, their primary care physicians, and other clinicians to assure that patient needs discussed are met. The nurses will be trained in and employ proven counseling and psychotherapeutic approaches-behavioral activation and problem-solving treatment. The multi-component intervention will be based on the Chronic Care Model's six elements (health care organization, community resources, self-management support, delivery system design, decision support, and clinical information system).
11561746|NCT00921700|Experimental|Ibuprofen + Paracetamol|Single oral dose of ibuprofen 400 mg + paracetamol (acetaminophen) 1000 mg
11561747|NCT00921700|Experimental|Ibuprofen + Paracetamol + Codeine|Single oral dose of ibuprofen 400 mg + paracetamol (acetaminophen) 1000 mg + codeine 60 mg
11561748|NCT00921700|Active Comparator|Paracetamol + Codeine|Single oral dose of paracetamol (acetaminophen) 1000 mg + codeine 60 mg
11561749|NCT00921700|Placebo Comparator|Placebo|Single oral dose of lactose as placebo
11561750|NCT00921687|Experimental|Multifactorial intervention|The multifactorial intervention will consist of a CKD lecture, the CKD reference card, academic detailing, and access to the CKD registry.
11561751|NCT00921687|Active Comparator|Education only|Providers in the education only arm will receive a CKD lecture and be given a CKD reference card.
11561752|NCT00921674|Experimental|Ivermectin|ivermectin
11561753|NCT00921661|Experimental|AVE0005 (aflibercept)|
11561754|NCT00921648||Mr Q, 40 years old|Dementia, sensory aphasia, irritability, hallucination MRI showed cortical lesion, mesial temporal lobe atrophy.
11561755|NCT00921648||Mr Guo,35 years old|Dementia, sensory aphasia, tremor, gait disturbance MRI showed cortical lesion, enlarged ventricle, white matter lesion, cerebral atrophy
11561756|NCT00921648||Mr Zhang,40 years old|Dementia, apraxia of speech, gatism , irritability, insomnia, gait disturbance MRI showed white matter lesion, cerebral atrophy.
11561757|NCT00921648||Mr Liu,40 years old|Dementia, apraxia of speech, irritability, insomnia MRI showed normal.
11561758|NCT00921648||Mr Zhang,54 years old|Dementia, apraxia of speech MRI showed white matter lesion, cerebral atrophy.
11561759|NCT00921635|Experimental|Maintain hemoglobin level above 120 g/L|Hemoglobin level from 120 g/L to 130 g/L
11561760|NCT00921635|Active Comparator|Maintain hemoglobin level above 100 g/L|Hemoglobin level from 100 g/L to 110 g/L
11561761|NCT00921622|Active Comparator|Vitamin D|1000 IU twice daily for up to 10 days
11561762|NCT00921622|Active Comparator|Vitamin C|500 mg twice daily for up to 10 days
11561763|NCT00921609||Acromegaly patients|All patients will undergo oral glucose tolerance test at postoperative day 1, 6 weeks, 3 months, and 1 year
11561764|NCT00921596|Other|Totally endoscopic cardiac operation|Patients with cardiac diseases undergo cardiac operations with totally endoscopic and cardiopulmonary bypass
11561765|NCT00921583||1|Examination of dental implants 20 years in function
11561766|NCT00921570|Experimental|Amlodipine|
11561767|NCT00921570|Experimental|Valsartan|
11561768|NCT00921570|Experimental|Valsartan+Amlodipine|
11561769|NCT00921557|Experimental|1A: Alendronate/Alendronate|Participants received alendronate for 96 weeks and calcium carbonate/vitamin D for 144 weeks
11561770|NCT00921557|Experimental|1B: Alendronate/Placebo|Participants received alendronate for 48 weeks followed by placebo for 48 weeks and calcium carbonate/vitamin D for 144 weeks
11561771|NCT00921557|Experimental|2: Placebo/Alendronate|Participants received placebo for 48 weeks followed by alendronate for 48 weeks and calcium carbonate/vitamin D for 144 weeks
11561772|NCT00921544|Active Comparator|Oral Sucrose|Oral sucrose administered 2 mins prior to eye exam
11561773|NCT00921544|Placebo Comparator|Sterile water|0.2 mls of sterile water
11561774|NCT00921531|Experimental|Thalidomide and TACE|Thalidomide is used for adjuvant therapy for TACE
11561775|NCT00921531|Active Comparator|TACE only|
11561776|NCT00921518|Placebo Comparator|Normal Saline|This group will receive isotonic saline at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
11561777|NCT00921518|Active Comparator|Sodium Bicarbonate|This arm two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
11561778|NCT00921505|Active Comparator|Ibuprofen 400 mg|Ibuprofen oral single dose
11561779|NCT00921505|Active Comparator|Ibuprofen 1200 mg|Ibuprofen oral single dose
11562835|NCT00913614|Experimental|Age Group 12-17 year old - Dose level 3|
11561780|NCT00921505|Active Comparator|Paracetamol (acetaminophen) 1000 mg|Paracetamol (acetaminophen) oral single dose
11561781|NCT00921505|Active Comparator|Ibuprofen 400 mg + paracetamol 1000 mg|Paracetamol (acetaminophen) + ibuprofen oral single dose
11561782|NCT00921492|Experimental|Low-frequency electro-acupuncture|
11561783|NCT00921492|Active Comparator|Meeting a therapist - attention|
11561784|NCT00921479||Females|Norwegian females Caucasian origin, between the age of 18 and 45, who are candidates for surgical removal of one mandibular 3. molar.
11561785|NCT00921479||Males|Norwegian males of Caucasian origin, between the age of 18 and 45, who are candidates for surgical removal of one mandibular 3. molar
11561786|NCT00921466||Hospital Patients/Hospital Employees|
11561787|NCT00921466||Hospital employees|A group of 10 hospital employees used as baseline
11561788|NCT00921453||Intervention 1|Participants using the prototype to receive expert system guided tailored internet information about the type of headache of a family member who provided anamnesis data for a common kind of headache.
11561789|NCT00921453||Control 1|Participants using search engines and portals to gather internet information about the type of headache of a family member who provided anamnesis data for a common kind of headache.
11561790|NCT00921453||Intervention 2|Participants using the prototype to receive expert system guided tailored internet information about the type of headache of a family member who provided anamnesis data for a less common kind of headache.
11561791|NCT00921453||Control 2|Participants using search engines and portals to gather internet information about the type of headache of a family member who provided anamnesis data for a less common kind of headache.
11561792|NCT00921427|Active Comparator|VRT and active tDCS|Patients will receive tDCS (noninvasive brain stimulation) concurrently with vision restoration therapy. TDCS is delivered using a small battery-operated device. Electrical leads from the device are connected to saline soaked sponges that are placed at strategic locations on the skull corresponding to areas of the brain that need to be stimulated (in this case, the visual cortex). The dosage will be set to 2 mA/min for 30 minutes, twice a day for 3 days a week for 12 weeks.
11561793|NCT00921427|Sham Comparator|VRT combined with sham tDCS|Patients will receive sham tDCS concurrently with vision restoration therapy. Electrical leads from the tDCS device will be connected to saline soaked sponges placed at strategic locations on the skull, in a similar maner as in the active tDCS group. Current will be turned on for 30 seconds but will be slowly ramped down and turned off. Treatment will continue for 3 days a week for 12 weeks.
11561794|NCT00921414|Active Comparator|1|observation : 3 years maintenance period with assesments and surveillance every 2 months
11561795|NCT00921414|Experimental|2|maintenance period infusions of Rituximab 375 mg/m2/2 months and assessement and surveillance
11561796|NCT00921401|Experimental|Asthma Feedback|Each month and before all visits with their asthma care provider, participants will be encouraged to go online and answer a series of questions regarding the types of asthma medications they use and how often they use them, asthma symptoms they have experienced, emergency department visits in the past year, the care they have received for their asthma (e.g., specialist visits) in the past year, and the planned date of their next visit with their asthma care provider. Participants will receive tailored feedback about what questions they should ask their doctor during a subsequent visit, whether or not they should schedule a visit sooner, and links to read more about each recommendation.
11561797|NCT00921401|Active Comparator|Preventive Feedback|Each month and before all visits with their primary care provider, participants will be encouraged to go online and answer a series of questions regarding their preventive care. They will receive tailored feedback regarding preventive services, such as pap testing, cancer screenings, and flu shots. Participants will receive tailored feedback regarding preventive services (e.g., cancer screening) that they should discuss with their primary care provider.
11561798|NCT00921388|Experimental|1|Exercise program
11561799|NCT00921388|Other|2|Relaxation program
11561800|NCT00921375|Experimental|Tuly, uric acid lowering drug|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
11561801|NCT00921362||1|Schizophrenia patients under Seroquel treatment
11561802|NCT00921349|Experimental|Ligation+Nadolol|"Multi-ligators were applied. Patients received regular ligation treatment at an interval of 3-4 weeks until variceal obliteration.
~Intervention; ligation of varices plus beta blockers (Nadolol)."
11561803|NCT00921349|Active Comparator|Nadolol only|
11561804|NCT00921336|Experimental|KW-2450|
11561805|NCT00921323|Placebo Comparator|Control|The control group will be advised to continue to be physically active and record daily steps
11561806|NCT00921323|Active Comparator|Goal-setting group|This intervention group would be instructed to increase their daily step count by at least 20% above their baseline gradually over 3 months.
11561807|NCT00921310|Experimental|Phase I Dose Level 1 (pemetrexed + temsirolimus)|"-Dose Level 1
~Pemetrexed 500mg/m^2 intravenous (IV) on Day 1 of each 21 day cycle
~Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle"
11561808|NCT00921310|Experimental|Phase I Dose Level -1 (pemetrexed + temsirolimus)|"Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle
~Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle"
11561809|NCT00921310|Experimental|Phase 2 (pemetrexed + temsirolimus)|"Phase 2 dose will be the maximum tolerated dose found in the Phase I portion of the study.
~Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle
~Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle"
11561810|NCT00921297|Active Comparator|Immediate Cataract Surgery|Subjects randomly selected into the Immediate Surgery group will have their cataract surgery scheduled one month from the time their initial study visits are completed. The subjects will be followed monthly for a period of 6 months for surgical and non-surgical adverse events. At the 6-month point, subjects will receive a final comprehensive eye exam and neuropsychological testing. The research partners will complete final activities of daily living and resource utilization questionnaires.
11561811|NCT00921297|No Intervention|Delayed Cataract Surgery|Subjects selected into the Delayed Surgery group will be asked to delay their surgery for 6 months after their initial study visits. At 6 months, this group will also undergo the same testing as the Surgery Group.
11561812|NCT00921284|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
11562082|NCT00919100|Experimental|Buzzy|Vibrating device with cold pack held to arm with tourniquet proximal to venipuncture site, optional distraction cards.
11561813|NCT00921284|Experimental|dexmedetomidine|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and dexmedetomidine
11561814|NCT00921271||At risk for compartment syndrome.|"Patients admitted to Selly Oak Hospital, Birmingham, Uk, meeting one or more of the following inclusion criteria:
~Patients with one or more of the following injuries:
~tibial fracture.
~crush injury/soft tissue injury to lower limb without fracture.
~pelvic fracture.
~major vascular injury below the aortic bifurcation.
~2 or more long bone fractures.
~Any patient sustaining a traumatic injury with a base deficit ≥ 6 mEq/L within 12 hours of Hospital admission.
~Any patient receiving ≥ 6 units packed red blood cells within 12 hours of hospital admission."
11561815|NCT00921258||control group|Patient with latent prostate cancer who agree to be controled instead of to be treated
11561816|NCT00921245||Group 1|
11561817|NCT00921232|Other|dyad|life-ending patient and its caregiver
11561818|NCT00921219|Experimental|Ivermectin|ivermectin
11561819|NCT00921206|Active Comparator|VAX102 given i.m.|Universal influenza candidate vaccine
11561820|NCT00921206|Active Comparator|VAX102 given s.c.|Universal influenza candidate vaccine
11561821|NCT00921180|Experimental|Entecavir and peginterferon|Entecavir 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52
11561822|NCT00921180|Active Comparator|Placebo and peginterferon|Placebo 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52
11561823|NCT00921167|Experimental|Bevacizumab/Irinotecan|
11561824|NCT00921154|Experimental|Ivermectin|Ivermectin
11561825|NCT00921141||study population|Patient with cancer requiring a long-term central venous catheter
11561826|NCT00921115|Experimental|Arimidex + Faslodex|"Patients will have an Oncotype Dx performed and if the RS is <25, they will receive Anastrazole and Fulvestrant for 16 weeks.
~On day 28, subjects will be evaluated for side effects and a needle core biopsy (optional) will be obtained. Response evaluation will occur every 28 days. All treatment will continue for 4 months followed by breast surgery. After surgery, patients will be off study and will receive additional breast cancer therapy per their treating physician. Patients who develop progressive disease on protocol will be removed from the study and treated by their treating physician. The protocol will be closed after the last accrued patient has had surgery."
11561827|NCT00921102|Placebo Comparator|Control|Patients in this group will receive both an intrathecal and intravenous injection of saline solution, as a placebo comparator.
11561828|NCT00921102|Experimental|Intrathecal Atropine|Patients in this group will receive intrathecal atropine as a prophylactic antiemetic agent. They will also receive intravenous saline solution to maintain blinding.
11561829|NCT00921102|Active Comparator|IV Atropine|Patients in this group will receive a small dose of atropine via the intravenous route to examine its possible antiemetic activity. They will also receive intravenous saline solution to maintain blinding.
11561830|NCT00921089||Hemodialysis group|End stage renal disease patients aged lower than 70 years, treated for more than 6 months with hemodialysis
11561831|NCT00921089||Control group|Normotensive healthy controls
11561832|NCT00921076|Active Comparator|Ankle Arthoplasty|Patients will undergo a Total Ankle Replacement procedure
11561833|NCT00921076|Active Comparator|Ankle fusion|Patients will undergo an Ankle Arthrodesis procedure
11561834|NCT00921063|Experimental|PD 0332334 250 mg|
11561835|NCT00921063|Experimental|PD 0332334 100 mg|
11561836|NCT00921063|Placebo Comparator|placebo|
11561837|NCT00921063|Active Comparator|Alprazolam extended release|
11561838|NCT00921050|Experimental|Levothyroxine|Half of participants randomly assigned, take a pill daily, bimonthly thyroid test
11561839|NCT00921050|Placebo Comparator|Placebo|Half of participants randomly assigned, take a pill daily, bimonthly thyroid test
11561840|NCT00921037|Experimental|Erbium YAG Laser|Patients with Neurofibromatosis Type 1 (Recklinghausen)
11561841|NCT00921024|Experimental|1|CXA-101
11561842|NCT00921024|Active Comparator|2|Ceftazidime
11561843|NCT00921011||Perimenopausal women|Women at the beginning stages of menopause
11561844|NCT00920998|Experimental|1. Z-338|3-way cross-over study (drug administration 3-times in fasted and 2 fed conditions)
11561845|NCT00920985|Experimental|Arm 1|
11561846|NCT00920985|Active Comparator|Arm 2|
11561847|NCT00920972|Experimental|Stratum 1|Recipients with non-malignant disorders, excluding thalassemia. Related or unrelated 8/8 HLA-matched bone marrow
11561848|NCT00920972|Experimental|Stratum 2|Recipient with transfusion dependent thalassemia. Related or unrelated. 8/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB
11561849|NCT00920972|Experimental|Stratum 3|Recipient with hemoglobinopathy Related or unrelated. 7/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB
11561850|NCT00920972|Experimental|Stratum 4|Recipient with non-malignant disorder, excluding hemoglobinopathy Related or unrelated. 7/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB
11561851|NCT00920959|Experimental|Fluticasone propionate/salmeterol combination|study drug
11561852|NCT00920959|Experimental|Fluticasone propionate|study drug
11561853|NCT00920959|Experimental|Placebo|placebo
11561854|NCT00920946|Placebo Comparator|Placebo|
11561855|NCT00920946|Experimental|Dimebon|
11561856|NCT00920933|Experimental|AIN457|
11561857|NCT00920933|Placebo Comparator|Placebo|
11561858|NCT00920933|Active Comparator|oral corticosteroid|
11561859|NCT00920907|Experimental|Ipilimumab (Process B)|Reference
11561860|NCT00920907|Experimental|Ipilimumab (Process C)|Test
11561861|NCT00920894|Experimental|yoghurt type minidrink containing plant stanol ester|
11561862|NCT00920894|Placebo Comparator|yoghurt type minidrink without plant stanol ester|
11561863|NCT00920881||Diabetes|
11561864|NCT00920868|Experimental|Dasatinib 50mg|Cohort 1
11561865|NCT00920855|Experimental|Bendamustine and Bortezomib|Bendamustine in escalating doses of 50, 70 or 90 mg/m^2 as combination therapy with bortezomib at 1.0 mg/m^2/dose administered for up to eight 28 day cycles.
11561866|NCT00920829|Active Comparator|A118G A/A with Naltrexone|Individuals with the OPRM1 genotype Asn40 are given naltrexone 50 mg after 2 days at 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
11562083|NCT00919074|Active Comparator|Pancreatic duct stent|Placement of a pancreatic duct stent to facilitate bile duct cannulation
11561867|NCT00920829|Placebo Comparator|A118G A/A with Placebo|Individuals with the OPRM1 genotype Asn40 are given Placebo for 16 weeks with Medication Management in 16 weeks
11561868|NCT00920829|Active Comparator|A118G Any G with Naltrexone|Individuals with the OPRM1 genotype Any G (Asp) are given naltrexone 50 mg after 2 days of naltrexone 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
11561869|NCT00920829|Placebo Comparator|A118G Any G with Placebo|Individuals with the OPRM1 genotype Any G (Asp) are given 50 mg naltrexone after 2 days at 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
11561870|NCT00920816|Experimental|A|
11561871|NCT00920816|Active Comparator|B|
11561872|NCT00920803|Active Comparator|5g SRT501|5.0 g of SRT501 will be administered once daily as an oral reconstituted powder, for 14 days at the same time each day. On Days 1 and 2, SRT501 will be administered approximately 15-30 minutes following the consumption of a standardized breakfast. On all other days, SRT501 will be administered approximately 15-30 minutes following the consumption of the evening meal. Following the course of SRT501 administration, subjects will undergo scheduled surgical removal of their metastatic liver disease as well as non-diseased tissue. Due to scheduling and surgical availability, subjects can receive SRT501 for a minimum of 10 days and a maximum of 21 days.
11561873|NCT00920803|Placebo Comparator|Placebo|Placebo will be administered once daily as an oral reconstituted powder, for 14 days at the same time each day. On Days 1 and 2, placebo will be administered approximately 15-30 minutes following the consumption of a standardized breakfast to allow for PK sample collection. On all other days, placebo will be administered approximately 15-30 minutes following the consumption of the evening meal. Following the course of placebo administration, subjects will undergo scheduled surgical removal of their metastatic liver disease as well as non-diseased tissue. Due to scheduling and surgical availability, subjects can receive placebo for a minimum of 10 days and a maximum of 21 days.
11561874|NCT00920790|Experimental|KW-0761|
11561875|NCT00920777|Experimental|8 weeks CBT|
11561876|NCT00920777|Active Comparator|Control group|
11561877|NCT00920777|Experimental|16 weeks CBT|
11561878|NCT00920764|Active Comparator|A|
11561879|NCT00920764|Active Comparator|B|
11561880|NCT00920764|Active Comparator|C|
11561881|NCT00920764|Placebo Comparator|D|
11561882|NCT00920751|Experimental|Water infusion|Water infusion in lieu of air insufflation during colonoscope insertion
11561883|NCT00920751|Active Comparator|Air insufflation|Conventional air insufflation colonoscopy
11561884|NCT00920738||Cancer Survivors|Subjects who are cancer survivors must have survived childhood cancer (diagnosed < or = 18 years) for a minimum of 5 years and be in remission.
11561885|NCT00920738||Healthy Siblings of Cancer Survivor|Healthy populations similar in age and gender distribution, derived from a frequency matched control population of 350 healthy siblings.
11561886|NCT00920725|Active Comparator|Subcutaneous Insulin|Aspart Insulin administered subcutaneously 0.2 units/kg/sq every 2 hours
11561887|NCT00920725|Active Comparator|IV Regular Insulin|Intravenous Regular Insulin 0.1 units/kg/hour
11561888|NCT00920725|Active Comparator|Intravenous Novolog Insulin|Intravenous Novolog Insulin 0.1 units/kg/hour
11561889|NCT00920712|Experimental|Weiqi decoction|
11561890|NCT00920712|Placebo Comparator|low dose of Weiqi decoction|
11561891|NCT00920699|Experimental|600 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day of CoQ10 in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
11561892|NCT00920699|Experimental|1200 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
11561893|NCT00920699|Experimental|2400 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
11561894|NCT00920686|Experimental|NXN-188|NXN-188, 600 mg, PRN
11561895|NCT00920686|Active Comparator|sumatriptan succinate 100 mg|Sumatriptan, 100 mg, PRN
11561896|NCT00920686|Placebo Comparator|placebo|matching, PRN
11561897|NCT00920660|Experimental|Treatment Group|"Subjects will be required to attend the research unit in a fasted state (at least 10 hours without food) on six separate occasions (treatment visits) during the study. At approximately the same time every morning, subjects will consume a standard, non-high-fat meal (approximately 650 kcal with 30% of calories derived from fat). Test material (per treatment) will be administered within 15-30 minutes following the meal. There will be at least a 7-day washout period between treatment visits.
~During the first five treatment visits, subjects will receive one of the following treatments in the form of 8 capsules: 0.25g SRT2104, 0.5g SRT2104, 1g SRT2104, 2g SRT2104, or placebo.
~During the last treatment visit, subjects will receive 30 mg of open-label prednisolone tablets."
11561898|NCT00920647|Other|Control|Untreated Patients
11561899|NCT00920647|Experimental|Idursulfase -IT (1 mg)|monthly using an intrathecal drug delivery device (IDDD)
11561900|NCT00920647|Experimental|Idursulfase-IT (10 mg)|monthly using an intrathecal drug delivery device (IDDD)
11561901|NCT00920647|Experimental|Idursulfase -IT (30 mg)|monthly using an intrathecal drug delivery device (IDDD)
11561902|NCT00920634||1|Patients with anovulation and oligoovulation due to hypothalamus-pituitary dysfunction (amenorrhea first grade, anovulatory cycle, polycystic ovary syndrome, oligoamenorrhea) who underwent ovulation induction
11561903|NCT00920621|Experimental|Vitamin D treatment|vitamin D treatment plus prenatal multivitamins
11561904|NCT00920621|Placebo Comparator|placebo|placebo plus prenatal multivitamins
11561905|NCT00920608|Experimental|A|AZD9056 400 mg and Methotrexate
11561906|NCT00920595|Experimental|1|CEP-9722 alone and in combination therapy with temozolomide.
11561907|NCT00920582|Experimental|1|
11561908|NCT00920582|Experimental|2|
11561909|NCT00920582|Experimental|3|
11561910|NCT00920582|Placebo Comparator|4|
11562084|NCT00919074|Active Comparator|Pancreatic wire|Placement of a guidewire into the pancreatic duct to facilitate bile duct cannulation.
11562090|NCT00918996|Experimental|No Bladder Flap Group|Uterine incision made 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
11561911|NCT00920556|Experimental|Treatment|"5.0 g SRT501 will be administered for 20 consecutive days in a 21 day cycle for a maximum of 12 cycles. SRT501 will be administered at the same time each morning (approximately 15-30 minutes after breakfast) on all dosing days. No SRT501 administration will occur on Day 21 of each cycle.
~After the first two cycles of SRT501, any subject who exhibits stable disease or better with SRT501 monotherapy (5.0 g/day) will continue for an additional two cycles. If, after the first two cycles, a subject exhibits PD, that subject will receive bortezomib (1.3 mg/m2 on Day 1, Day 4, Day 8, and Day 11 in a 21 day cycle) in conjunction with SRT501. Bortezomib will be administered prior to breakfast and SRT501 administration.
~If after two additional cycles of SRT501 monotherapy (4 cycles total), the subject exhibits a MR or better, they they will remain on SRT501 therapy. If PD or SD are exibited, they are to undergo bortezomib regiment listed above."
11561912|NCT00920543|Active Comparator|Fluticasone propionate|
11561913|NCT00920543|Active Comparator|Fluticasone propionate/salmeterol combination|
11561914|NCT00920530||Real time PCR monitoring|Women giving birth at the St Etienne Teaching Hospital
11561915|NCT00920517|Active Comparator|1|Participants will receive 1 injection of rDEN2/4delta30(ME) or placebo vaccine on Days 0 and 180
11561916|NCT00920517|Active Comparator|2|Participants will receive 1 injection of rDEN2/4delta30(ME) or placebo vaccine on Days 0 and 120
11561917|NCT00920504|Experimental|German PRO-SELF(c) Plus PCP|Group receives 10 weeks German PRO-SELF(c) Plus PCP intervention program
11561918|NCT00920504|Active Comparator|Standard Care|control group receives attention control and standard care
11561919|NCT00920491||patients with non-specific complaints|patients who do not have specific presenting symptoms (e.g. dyspnea, chest pain etc.)
11561920|NCT00920478|Active Comparator|Control Group|Inflammatory disease activity assessed using DAS28
11561921|NCT00920478|Experimental|Ultrasound Group|Inflammatory disease activity assessed using musculoskeletal ultrasound (gray scale and power doppler)
11561922|NCT00920465|Experimental|one-visit|
11561923|NCT00920465|Active Comparator|two-visit|
11561924|NCT00920439|Experimental|POLIORIX GROUP|Healthy male or female subjects between, and including, 18 and 24 months of age, received a single booster dose of Poliorix™ vaccine that was administrated into the upper right thigh by intramuscular injection (IM).
11561925|NCT00920426|Experimental|GSK1265744 30 mg|GSK1265744 30 mg
11561926|NCT00920426|Experimental|Placebo|Placebo to match GSK1265744
11561927|NCT00920426|Experimental|GSK1265744 5 mg|GSK1265744 5 mg
11561928|NCT00920413|Active Comparator|vitamin C|vitamin C 500mg orally once a day
11561929|NCT00920413|Placebo Comparator|placebo|
11561930|NCT00920387|Experimental|Experimental 200 mcg lysergic acid diethylamide|Administering 200 mcg LSD once during each of two LSD-assisted psychotherapy sessions scheduled two to four weeks apart.
11561931|NCT00920387|Active Comparator|Active Comparator 20 mcg Lysergic acid diethylamide|Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session
11561932|NCT00920374|Experimental|Fluarix Adult Group|Subjects who are 18-60 years of age received one dose of Fluarix™
11561933|NCT00920374|Experimental|Fluarix Elderly Group|Subjects who are > 60 years of age received one dose of Fluarix™
11561934|NCT00920361||1|Patients who underwent IVF
11561935|NCT00920348||Group 1|COPD moderate-severe(GOLD2-4)(post-BD FEV1/FVC<0.70 and FEV1<80% of pred.)
11561936|NCT00920348||Group 2|COPD mild (GOLD1)(post-BD FEV1/FVC<0.70 AND FEV1>=80% of pred.)
11561937|NCT00920348||Group 3|COPD at risk (ever smoker with post-BD FEV1/FVC>=0.70)
11561938|NCT00920348||Group 4|"Healthy control never smokers without respiratory disease (post-BD FEV1/FVC>=0.70."
11561939|NCT00920322|Active Comparator|five times weekly|Patients will receive rTMS on each weekday for 4 weeks (5 x weekly)
11561940|NCT00920322|Experimental|three times weekly|Patients will receive rTMS three times weekly for four weeks
11561941|NCT00920309|Experimental|Rapamycin|"Drug: Rapamycin
~Other Names:
~sirolimus The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml."
11561942|NCT00920309|Placebo Comparator|Standard of Care-Placebo|Standard of Care
11561943|NCT00920296|Experimental|Cohort 1|All subjects
11561944|NCT00920283|Experimental|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
11561945|NCT00920283|Active Comparator|Driver, Cobalt Alloy Coronary Stent|
11561946|NCT00920270|Active Comparator|antibiotic|conventional antibiotics
11561947|NCT00920270|Experimental|colistin group|nebulized colistin
11561948|NCT00920257|Experimental|GSK2141795|Oral GSK214179 given daily to patients with cancer. Groups of approximately three patients will receive GSK2141795 at increasing doses until a maximum tolerated dose is identified.
11561949|NCT00920231|Experimental|Arm 1 initial system|"8 blind subjects are asked to use a prototype computer vision system to determine the challenges facing computer vision based indoor navigation.
~Subjects are asked to travel through the hallways of a large hospital from the front entrance to a side entrance. The pathway consists of 9 segments including corners, four-way intersections, and doorways, and the total length of the route was approximately 200 meters. This challenging route was designed to stress the capabilities of the navigation system. It is a route that even sighted persons may find difficult to follow without practice. Pedestrian traffic was present throughout the route and lighting conditions could change in two of the segments where there were windows and doors."
11561950|NCT00920231|Experimental|Arm 2 modified system|The system is redesigned in response to problems identified from the first phase of the study. The redesigned system is tested by a second set of 8 blind subjects in the same indoor path as used in Arm 1.
11561951|NCT00920218|Experimental|GSK 1437173A F1 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 1 (F1) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
11561952|NCT00920218|Experimental|GSK 1437173A F2 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 2 (F2) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
11562091|NCT00918996|No Intervention|Bladder Flap Group|Standard cesarean section technique with incision and dissection of a bladder flap prior to uterine incision.
11562092|NCT00918983|Experimental|NX-1207|
11561953|NCT00920218|Experimental|Placebo-GSK 1437173A F1 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 1 dose of the placebo followed by 2 doses of GSK 1437173A F1 vaccine. For some safety analyses, this Group was split into Placebo 1D Group (results following placebo administration) and GSK 1437173A 2D Group (results following HZV administration). All vaccines were administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
11561954|NCT00920218|Placebo Comparator|Placebo Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of placebo, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
11561955|NCT00920192|Experimental|Foretinib|Phase I starting dose of 30 mg/day escalated to 45 mg/day, de-escalated to 30 mg/day; MTD for Phase II was 30 mg/day
11561956|NCT00920179||Dry eye group|Dry eye patients with Primary Sjogren's syndrome
11561957|NCT00920179||Controls|Healthy subjects without dry eyes
11561958|NCT00920166|Experimental|Modilac Pétunia 1|Formula with reduced total protein concentration, enriched in alpha-lactalbumin and containing a symbiotic
11561959|NCT00920166|Active Comparator|Modilac 1|Regular milk
11561960|NCT00920153|Experimental|Group 1 (favorable prognosis)|Patients receive ABVD and VABEM chemotherapy.
11561961|NCT00920153|Experimental|Group 2 (intermediate prognosis)|Patients receive ABVD and VABEM chemotherapy.
11561962|NCT00920153|Experimental|Group 3 (poor prognosis)|Patients receive VABEM, CEO, BEAM, and MINE chemotherapy. Patients also undergo allogeneic or autologous stem cell transplantation.
11561963|NCT00920140|Experimental|Phase I|"The proposed treatment schedule of GSK1120212 is continuous daily dosing. At the initiation of dosing, a loading dose will be given prior to starting continuous dosing (maintenance dose).
~Alterations to the dose and schedule will be based on emerging PK, PD, and tolerability data. The goal will be to define a regimen that is well tolerated and provides adequate PK and PD. This will be the recommended Phase II schedule."
11561964|NCT00920140|Experimental|Phase II|A dose determined by Phase I to further evaulate the safety profile, PK, PD, and clinical activity of GSK1120212.
11561965|NCT00920127|Placebo Comparator|Placebo|
11561966|NCT00920127|Active Comparator|AKL1|
11561967|NCT00920114|Experimental|Lupus disease|
11561968|NCT00920114|Active Comparator|Healthy witnesses|
11561969|NCT00920114|Active Comparator|Healthy witnesses with an other auto-immune disease|
11561970|NCT00920101|Active Comparator|Atorvastatin|
11561971|NCT00920101|Placebo Comparator|Lifestyle counseling|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
11561972|NCT00920088|Experimental|Cohort 1|GSK2248761 with LPV/RTV arm and probes
11561973|NCT00920088|Experimental|Cohort 2|GSK2248761 with DRV/RTV
11561974|NCT00920075||1 Alendronate for 12 months, post study|Participants earlier were treated with alendronate for 12 months either in an open label study (without control) or double blind study with placebo control. These studies were completed. In this post study evaluation, available participants will be scheduled for one clinic visit to assess their current status of the bone density and no treatment is involved.
11561975|NCT00920036|Experimental|Arm 1|Eight subjects were trained to utilize a handheld biofeedback device
11561976|NCT00920036|No Intervention|Arm 2|usual care
11561977|NCT00920023|Experimental|SPIO MRI|
11561978|NCT00919997||Specimen collection|Single group study. Blood, saliva, anal cytology, and penile cytology samples, and questionnaire responses will be collected from participants at a single study visit.
11561979|NCT00919984|Experimental|IP Chemotherapy|Patients with optimally debulked advanced (stage 3 or 4) epithelial ovarian cancer; IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
11561980|NCT00919958|Experimental|PLX-PAD low dose|
11561981|NCT00919958|Experimental|PLX-PAD intermediate dose|
11561982|NCT00919958|Experimental|PLX-PAD high dose|
11561983|NCT00919945|Experimental|1|The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed. Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms. Patients in arm 1 will receive continuous nasogastric formula feeding at time 1 and NPO at time 2 (12 hours later).
11561984|NCT00919945|Experimental|2|The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed. Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms. Patients in arm 2 will receive NPO at time 1 and crossover to continuous nasogastric formula feeding at time 2.
11561985|NCT00919932|Active Comparator|Paper and pen homework|Treatment as usual: therapy homework is completed by paper and pen.
11561986|NCT00919932|Experimental|Text-message homework|Experimental treatment: therapy homework is completed by text messaging.
11561987|NCT00919919|Experimental|Progesterone vaginal tablet|Group A - Daily use of Endometrin 100 mg progesterone vaginal tablet, and Estrofem orally.
11561988|NCT00919919|Other|Activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
11561989|NCT00919906|No Intervention|Handwriting without Tears|Standard practice
11561990|NCT00919906|Experimental|Haptic guidance|
11561991|NCT00919893|Active Comparator|Cernilton|Men with inflammatory chronic prostatitis-chronic pelvic pain syndrome (CP-CPPS)
11561992|NCT00919893|Placebo Comparator|Placebo|Men with inflammatory chronic prostatitis-chronic pelvic pain syndrome (CP-CPPS)
11561993|NCT00919880|Experimental|Experimental|
11561994|NCT00919880|Active Comparator|Active Comparator|
11561995|NCT00919867|Active Comparator|A: SPD503 (4mg)|
11561996|NCT00919867|Active Comparator|B: VYVANSE (50mg)|
11561997|NCT00919867|Active Comparator|C: SPD503 (4mg) + VYVANSE (50mg)|
11562089|NCT00919009|Experimental|Sorafeinb|Oral sorafenib (400 mg BID) will be start the 3 day after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination.
11561998|NCT00919854|Experimental|Darunavir (DRV)+Ritonavir (rtv)|Before dose adjustment, oral darunavir suspension (100 mg/mL): 20 mg per kg body weight twice daily for children weighing between 10 and <20 kg. After dose adjustment, 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg twice daily if weight more than or equal to 15 kg. Before dose adjustment, oral ritonavir solution (80 mg/mL): 3 mg per kg body weight twice daily and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
11561999|NCT00919841||Postpartum women|Women who deliver a singleton vaginally
11562000|NCT00919815|Experimental|ciclosporin arm|ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)
11562001|NCT00919815|Active Comparator|prednisolone|standard course of prednisolone given in a reducing regimen over 24 weeks
11562002|NCT00919802|Active Comparator|Oxytocin|Oxytocin, 40 IU intranasally, once
11562003|NCT00919802|Placebo Comparator|Saline as a nasal spray|Saline, 4ml intranasally, once
11562004|NCT00919776|Experimental|ciclosporin|ciclosporin reducing regimen lasting 16 weeks (additional prednisolone given for the first four weeks)
11562005|NCT00919776|Active Comparator|Prednisolone|standard course of prednisolone given in a reducing regimen over 16 weeks
11562006|NCT00919763|Experimental|CD 2027|Topical Ointment
11562007|NCT00919763|Placebo Comparator|CD 2027 Vehicle|Topical Ointment
11562008|NCT00919750||Ancillary-Correlative (tissue and blood sample collection)|Brain tumor tissue and blood specimens are collected from patients and banked for future study.
11562009|NCT00919737|Experimental|NPC-08|
11562010|NCT00919724||HIV-Infected|HIV-infected participants who are not currently receiving antiretroviral medications
11562011|NCT00919724||HIV-Uninfected|HIV-uninfected participants matched in age, sex, smoking status, and height to the HIV-infected participants
11562012|NCT00919711|Experimental|Denosumab 60 mg|
11562013|NCT00919711|Active Comparator|Risedronate 150 mg QM|
11562014|NCT00919698||Sedated mechanically ventilated patients|
11562015|NCT00919672|Active Comparator|Sacral nerve stimulation ON-OFF|As previously described the patients will be randomized in a blinded design to receive either ON-OFF or OFF-ON stimulation in a 2 month period.
11562016|NCT00919672|Active Comparator|Sacral nerve stimulation OFF-ON|As previously described the patients will be randomized in a blinded design to receive either ON-OFF or OFF-ON stimulation in a 2 month period.
11562017|NCT00919659|Experimental|parenteral nutrition|25kcal/kg/bw /day via parenteral support
11562018|NCT00919633|Experimental|Group 1: interferon alfa-2b (dose 1)|continuous subcutaneous infusion for 48 weeks
11562019|NCT00919633|Experimental|Group 2: interferon alfa-2b (dose 2)|continuous subcutaneous infusion for 48 weeks
11562020|NCT00919633|Experimental|Group 3: interferon alfa-2b (dose 3)|continuous subcutaneous infusion for 48 weeks
11562021|NCT00919633|Active Comparator|Group 4: peginterferon alfa-2b (1.5 μg/kg)|subcutaneous weekly for 48 weeks
11562022|NCT00919620|Experimental|case management (4 yrs)|4-year case management and standard care
11562023|NCT00919620|Active Comparator|case management (2 yrs) and standard care (2 yrs)|2-year case management and standard care
11562024|NCT00919620|No Intervention|standard care (4 yrs)|standard care for 4 years
11562025|NCT00919607|Active Comparator|1|quetiapine fumarate extended-release 300mg,administered once-daily Day1~5
11562026|NCT00919607|Experimental|2|quetiapine fumarate extended-release 300mg/Day1,600mg/Day2~6,administered once-daily
11562027|NCT00919607|Experimental|3|quetiapine fumarate extended-release 300mg/Day1,600mg/Day2,800mg/Day3~7,administered once-daily
11562028|NCT00919594|Experimental|Interpersonal Psychotherapy for Mothers|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.
11562029|NCT00919594|Active Comparator|Brief Supportive Psychotherapy|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
11562030|NCT00919581||Healthy controls|
11562031|NCT00919581||Subjects with spinal cord injury|
11562032|NCT00919555|Active Comparator|Tretionoin and Pioglitazone HCL|20 patients will be randomized blindedly to Tretinoin and Pioglitazone HCL
11562033|NCT00919555|Placebo Comparator|Sugar Pill|10 Patients will randomly receive placebo
11562034|NCT00919542|Active Comparator|prednisolone|standard course of prednisolone given in a reducing regimen over 16 weeks
11562035|NCT00919542|Experimental|Ciclosporin|ciclosporin reducing regimen lasting 16 weeks (additional prednisolone given for the first four weeks)
11562036|NCT00919516|Experimental|Stem Cell Implantation|
11562037|NCT00919503|Experimental|Regimen A (PBSCT and BMT)|"CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.
~TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.
~Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
11562085|NCT00919061|Experimental|Gemcitabine and Cisplatin plus Sorafenib|This is a non-randomized, open label, single institution, phase II study of gemcitabine and cisplatin plus sorafenib for the treatment of patients with advanced or biliary tract carcinomas naïve to systemic therapy.
11562086|NCT00919048||Urodynamic patients|Uroflow studies of patients who underwent urodynamics as part of an incontinence work-up.
11562087|NCT00919035|Experimental|Torisel|Single Agent Temsirolimus (Torisel®)
11562088|NCT00919022||Group 1|
11562038|NCT00919503|Experimental|Regimen B (UBCT)|"CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .
~TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.
~Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD."
11562039|NCT00919490|Experimental|Group 1|Single dose of 400 mg
11562040|NCT00919490|Experimental|Group 2|Single dose of 800 mg after safety evolution of Group I
11562041|NCT00919490|Experimental|Group 3|Single dose of 1200 mg after safety evolution of Group 2
11562042|NCT00919490|Experimental|Group 4|Single dose of 1600 mg after safety evolution of Group 3
11562043|NCT00919490|Placebo Comparator|Group 5|Single dose of placebo
11562044|NCT00919464|Other|Needle Insertion into Femur|Data gathering with monitoring of pressures in the thigh via via needle in femur.
11562045|NCT00919451|Experimental|Ciclosporin|ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)
11562046|NCT00919438||Dialysis|
11562047|NCT00919412||Preterm delivery (< 37 weeks)|
11562048|NCT00919412||Term delivery (>=37 weeks)|
11562049|NCT00919386||1 Direct ureteric measurement|This is determined by using a 5 French Pollack Open-Ended Flexi-Tip Ureteral catheter (Cook, Spencer, Indiana) to cannulate the ureteral orifice. A retrograde pyelogram will be done at the conclusion of the procedure and the Pollack will be advanced to the pyeloureteral junction (PUJ) under fluoroscopy. At this point the length of the distance between the PUJ and vesicoureteral junction (VUJ) will be recorded and stent length determined based on this measurement.
11562050|NCT00919386||2 Based on patient height|"We will use the height measurement criteria used by Lee et al in their study. Patients less than 5'2 will receive a 22 cm stent, 5'3-5'7 will get a 24 cm stent, 5'8-5'10 will get a 26 cm stent, 5'11 to 6'1 will get a 28 cm stent, and all patients greater than 6'2 will receive a 30 cm stent."
11562051|NCT00919386||3 Based on a predetermined formula|We will use the formula described by Wieder. Stent length in cm= patients height in inches - 42.
11562052|NCT00919373|Active Comparator|ICD-Implantation|Implantation of an Implantable Cardioverter Defibrillator (ICD) alone.
11562053|NCT00919373|Active Comparator|ICD + Ablation|Stratified Catheter Ablation of Ventricular Tachycardia and ICD Implantation
11562054|NCT00919360||Controls|Gravidas without history of hypertension of any kind, and matched to cases for parity, gestational age, labor status, mode of delivery, maternal age, and race.
11562055|NCT00919360||Preeclamptics|Gravidas at 32-42 weeks gestation, delivered by Caesarean Section, who have preeclampsia as defined by Sibai et al, 1997.
11562056|NCT00919334|No Intervention|single vision soft contact lens|Single vision soft contact lenses with same materials of the DISC lens
11562057|NCT00919334|Experimental|Defocus Incorporated Soft Contact (DISC) lens|The use of DISC lens to slow down the progression of myopia
11562058|NCT00919321|Other|PPV|
11562059|NCT00919308||Control, traditional bedside training|Postgraduate year 1 and 2 residents who are trained in central venous catheter insertion according to the traditional, bedside apprenticeship model.
11562060|NCT00919308||Simulation training|Postgraduate year 1 and 2 residents who complete a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by: the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous cannulator on a partial task training simulator with no technical errors.
11562061|NCT00919295|Placebo Comparator|placebo|placebo
11562062|NCT00919295|Placebo Comparator|mirtazapine 15|mirtazapine 15 mg
11562063|NCT00919295|Placebo Comparator|mirtazapine 30|mirtazapine 30mg
11562064|NCT00919282|Experimental|Gemcitabine/folinic acid/5-FU|Gemcitabine 1g/m² 5-FU 750mg/m² FS 500 mg/m²
11562065|NCT00919269||Ancillary-Correlative (specimen collection)|Surgical tissue, bone marrow, and blood specimens are collected at diagnosis (initial or relapse) and, if applicable, at the development of a second primary tumor. Specimens are used for research purposes. A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute.
11562066|NCT00919243|Experimental|prednisone|
11562067|NCT00919243|Active Comparator|allopurinol|
11562068|NCT00919230|No Intervention|no treatment|no iron given
11562069|NCT00919230|Experimental|ferrous sulphate|iron given
11562070|NCT00919217||Relapsing-remitting multiple sclerosis|Females with relapsing-remitting multiple sclerosis
11562071|NCT00919204|Experimental|Cohort 1|
11562072|NCT00919191|Experimental|Two interventions in split-face model|"Once daily use in a split face model:
~Tretinoin gel
~Adapalene Benzoyl peroxide"
11562073|NCT00919178|Experimental|1|Participants will receive a single immunization for Dengue virus serotype 4 (DEN4)
11562074|NCT00919178|Placebo Comparator|2|Participants will receive a single immunization in the form of placebo resembling vaccine for DEN 4
11562075|NCT00919165||control and study group|severe carotid artery stenosis in asymptomatic patients defined as greater than 80% stenosis angiographically or greater than 400 cm/sec peak systolic velocity on carotid doppler evaluation
11562076|NCT00919126|Experimental|Group A|Xenon 50% (45%-55%) in Oxygen (45%-55%),
11562077|NCT00919126|Experimental|Group B|Xenon 70% (65%-75%) in Oxygen (25%-35%)
11562078|NCT00919126|Active Comparator|Group C|Medical Air in Oxygen (45%-55%)
11562079|NCT00919113|Experimental|8 weekly bladder instillations of Uracyst|20 mL Uracyst (2% sodium chondroitin sulfate) per instillation; 8 instillations over a 7-week period
11562080|NCT00919113|Placebo Comparator|8 weekly bladder instillations of inactive control|20 mL inactive control buffer (phosphate-buffered saline); 8 instillations over a 7-week period
11562081|NCT00919100|Other|Standard Care|venipuncture with vapocoolant spray offered
11562093|NCT00918983|Placebo Comparator|Placebo|
11562961|NCT00912808|Placebo Comparator|Sugar Pill|
11562094|NCT00918970||SNA group|This group will have a real-time analysis of autonomic nervous system activity during its intensive care hospitalisation
11562095|NCT00918970||Clinical group|This group will have a conventional clinical analysis during its intensive care hospitalisation
11562096|NCT00918957|Experimental|TIP (Tobramycin Inhalation Powder)|Tobramycin 28 mg powder. The TIP dose of 112 mg twice a day (bis in diem = b.i.d.), given in a cycle of 28 days on treatment followed by 28 days off treatment.
11562097|NCT00918957|Placebo Comparator|Placebo|Placebo 20 mg powder capsules. The dose regimen for the reference product was inhaling the contents of four capsules twice a day (bis in diem = b.i.d.), in the morning and in the evening for 28 days (on treatment), followed by 28 days of no study treatment (off treatment).
11562098|NCT00918944|Other|Control arm|Practices with the EHR implemented will be randomized have the asthma disease management tools available passively (the control group).
11562099|NCT00918944|Other|Intervention arm|The intervention sites will have decision support alerts and reminders activated to guide providers toward these tools in the appropriate situations.
11562100|NCT00918931|Experimental|Obatoclax Mesylate|30 mg by vein over 3 hours Days 1-3, 14-day cycle
11562101|NCT00918918|Experimental|Treatment B|Vodka + orange juice
11562102|NCT00918918|Placebo Comparator|Treatment A|Orange juice
11562103|NCT00918905|Experimental|1 Telemonitor|Within 24 hours after the patient was discharged the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with a doctor. The patient was planned to have the equipment for approximately one week and had at least one follow-up phone call within the four weeks period. Telemonitoring video conferences could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period of time (hot-line).
11562104|NCT00918905|No Intervention|Control group|No tele-monitor at home. The COPD patients discharged after an acute exacerbation living outside Svendborg or Faaborg-Midtfyn municipalities in the recruiting area were included in the control group and assigned to conventional care.
11562105|NCT00918879|Experimental|1|Saxagliptin
11562106|NCT00918879|Placebo Comparator|2|
11562107|NCT00918866|Experimental|Low Pulmonary Arterial Pressure|Subjects with pulmonary arterial pressure (PAP) of < or = to 35 mmHg.
11562108|NCT00918866|Experimental|Elevated Pulmonary Arterial Pressure|Subjects with a PAP of > or = to 35 mmHg.
11562109|NCT00918853|Experimental|resection for adenocarcinoma|quality standard resection for adenocarcinoma of the head of the pancreas
11562110|NCT00918840||DermaVir + HAART|"Dosage: 0.4 mg DNA
~Dosage form: 3.2 mL DNA/PEIm nanomedicine
~Administration with 4 DermaPrep patches
~Frequency: every 4 weeks
~Duration: 8 weeks (3 DermaVir treatments)"
11562111|NCT00918840||Placebo + HAART|"Dosage form: 3.2 mL Placebo
~Administration with 4 DermaPrep patches
~Frequency: every four weeks
~Duration: 8 weeks (3 Placebo treatments)"
11562112|NCT00918814|Experimental|LIPO-102|LIPO-102
11562113|NCT00918814|Experimental|Placebo|Placebo
11562114|NCT00918801||Type 1 Diabetes Mellitus|Adolescents ages 13-18 with T1DM
11562115|NCT00918801||Non Controls|Healthy adolescents ages 13-18 without T1DM
11562116|NCT00918775||Observational (follow-up)|After metastasectomy, patients are followed up every 6 months for up to 5 years.
11562117|NCT00918762|Experimental|daVinci® Robotic Surgical System|Participants will undergo a planned surgical procedures via the robotic approach.
11562118|NCT00918749|Active Comparator|150 mg|150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.
11562119|NCT00918749|Experimental|75 mg|75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast
11562120|NCT00918749|Experimental|100 mg|100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast
11562121|NCT00918736|Experimental|hyaluronate injection|All patients with unilateral ankle OA received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
11562122|NCT00918723|Experimental|Treatment (induction and maintenance chemotherapy)|"INDUCTION THERAPY: Patients receive vorinostat PO once daily on days 1-5 and 8-12; cyclophosphamide IV over 30-60 minutes and fludarabine phosphate IV over 30-60 minutes on days 1-3; and rituximab IV on day 1, 2, 3, 4, or 5. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Beginning 3 months after the completion of induction therapy, patients receive vorinostat PO on days 1-14 and rituximab IV on day 1. Treatment repeats every 3 months for 2 years in the absence of disease progression or unacceptable toxicity."
11562123|NCT00918710||1|Patients with oropharyngeal squamous cell carcinomas
11562124|NCT00918697|Active Comparator|Mechanical debridment|In this arm, corneal epithelium was removed during PRK using conventional mechanical method.
11562125|NCT00918697|Experimental|Alcohol-asstisted debridement|In this arm, corneal epithelium was removed using ethanol 20% during PRK.
11562126|NCT00918684|Experimental|Escitalopram|12-week open label with 2 week placebo period (14 weeks total)
11562127|NCT00918671||Medication-overuse headache|Chronic daily headache combined with medication overuse
11562128|NCT00918658||Patients with hematologic cancer|Patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma
11562129|NCT00918658||Patients without cancer|Patients who do not have cancer.
11562130|NCT00918645|Experimental|41 Ca|
11562131|NCT00918632|Other|Sequence 1 (ABC)|"The following treatments will be administered in the following order A -> B-> C
~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting
~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.
~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
11562132|NCT00918632|Other|Sequence 2 (ACB)|"The following treatments will be administered in the following order A -> C -> B
~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting
~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.
~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
11562133|NCT00918632|Other|Sequence 3 (BCA)|"The following treatments will be administered in the following order B -> C -> A
~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting
~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.
~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
11562134|NCT00918632|Other|Sequence 4 (BAC)|"The following treatments will be administered in the following order B -> A -> C
~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting
~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.
~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
11562135|NCT00918632|Other|Sequence 5 (CAB)|"The following treatments will be administered in the following order C -> A -> B
~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting
~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.
~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
11562136|NCT00918632|Other|Sequence 6 (CBA)|"The following treatments will be administered in the following order C -> B -> A
~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting
~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.
~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
11562137|NCT00918619|Experimental|Sangustop|
11562138|NCT00918619|Active Comparator|Tachosil|
11562139|NCT00918606|Experimental|LIPO-102|
11562140|NCT00918593|Experimental|Electrochemotherapy|
11562141|NCT00918593|Active Comparator|radiotherapy|
11562142|NCT00918580|Experimental|1|
11562143|NCT00918567|Experimental|Combined therapy|atomoxetine plus behavior therapy
11562144|NCT00918567|Active Comparator|Drug therapy|atomoxetine alone
11562145|NCT00918554|Experimental|Methotrexate|
11562146|NCT00918554|Placebo Comparator|Placebo|
11562147|NCT00918541||A|asymptomatic patients with mild to moderate carotid artery stenosis
11562148|NCT00918528|Active Comparator|1. Internal urethrotomy|
11562149|NCT00918528|Experimental|2. Internal urethrotomy + mitomycin C|
11562150|NCT00918515|Experimental|AZD3043|Intravenous solution
11562151|NCT00918489|Experimental|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
11562152|NCT00918476|Experimental|1. filibuvir + Oral Contraceptives|
11562153|NCT00918463|Experimental|all patients|
11562154|NCT00918450|Experimental|1|
11562155|NCT00918437||RAUP treatment|Patients referred to the hospital for a snoring problem
11562156|NCT00918411|Experimental|Ramosetron group|oral
11562157|NCT00918411|Placebo Comparator|Placebo group|oral
11562158|NCT00918398|Experimental|1|AZD1981, 100 mg iv infusion
11562159|NCT00918398|Experimental|2|AZD1981, 514 mg oral solution
11562160|NCT00918398|Experimental|3|AZD1981, 500 mg oral tablet A
11562161|NCT00918398|Experimental|4|AZD1981, 500 mg oral tablet B
11562162|NCT00918385|Active Comparator|1|High Androgen Receptor (AR) activity
11562163|NCT00918385|Active Comparator|2|Low Androgen Receptor (AR) activity
11562164|NCT00918372||Extreme fitness|Female competitive long distance runners
11562165|NCT00918372||Control|Age and Risk matched controls
11562166|NCT00918359||HI|Subjects who experienced heat exhaustion or heat stroke in their past and will be identified by heat tolerance test (HTT) as Heat Intolerance .
11562167|NCT00918359||HT|Subjects who experienced heat exhaustion or heat stroke in their past and will be identified by heat tolerance test (HTT) as Heat Tolerance .
11562168|NCT00918346|Experimental|Tafluprost 0.0015% preserved formulation|
11562169|NCT00918346|Experimental|Tafluprost 0.0015% unpreserved formulation|
11562170|NCT00918333|Experimental|Treatment (panobinostat and everolimus)|Patients receive panobinostat PO QD or on days 1, 3, 5, 15, 17, and 19 and everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11562171|NCT00918320|Experimental|Toptecan + temozolomide|
11562172|NCT00918307|Experimental|Varenicline|Varenicline titrated to 2 x 0.5 mg twice daily for 12 weeks
11562173|NCT00918307|Placebo Comparator|Placebo|placebo titrated to 2 pills twice daily for 12 weeks
11562174|NCT00918294|Experimental|QuickOpt|QuickOpt is an optimization algorithm to program the AV, PV and VV delays
11562175|NCT00918281|Experimental|Fluciclatide Injection|Fluciclatide Injection
11562176|NCT00918268|Experimental|Influenza vaccine|
11562177|NCT00918255|Experimental|Adalimumab 40 mg qwk|Initial dose of adalimumab 160 mg at Week 0, adalimumab 80 mg at Week 2, followed by 40 mg weekly (qwk) starting at Week 4 through Week 15.
11562178|NCT00918255|Experimental|Adalimumab 40 mg eow|Initial dose of adalimumab 80 mg at Week 0, followed by adalimumab 40 mg eow (every other week) starting at Week 1 through Week 15.
11562179|NCT00918255|Placebo Comparator|Placebo|Matching placebo for adalimumab, administered weekly starting at Week 0 through Week 15.
11562180|NCT00918229|Other|balloon implantation|implantation of an absorbable perirectal spacer balloon
11562181|NCT00918203|Active Comparator|Paclitaxel + Carboplatin|"(Initial 4-6 cycles) Paclitaxel 200 milligram/square meter (mg/m2) over 3 hrs (Day 1) Carboplatin Area Under Concentration (AUC)=6 (Day 1) of each 21-day cycle (Initial 4-6 cycles) Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle
~Participants who experience progressive disease may cross over to olaratumab monotherapy."
11562182|NCT00918203|Experimental|Olaratumab + Paclitaxel + Carboplatin|"(Initial 4-6 cycles)
~Olaratumab 15 milligrams/kilogram (mg/kg) over 30 mins (Days 1 and 8) plus Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle
~Participants can remain on study after completing chemotherapy and receive olaratumab monotherapy on Days 1 and 8, provided there is ongoing evidence of clinical benefit."
11562184|NCT00918190|Active Comparator|Midazolam, Dexa group|use of midazolam and dexamethasone
11562185|NCT00918190|Placebo Comparator|Placebo|Saline will be given
11562186|NCT00918177|Experimental|Early patients|
11562187|NCT00918177|Experimental|Moderate Patients|
11562188|NCT00918164|Experimental|Healthy adult volunteers|Standard Phase 1 normal healthy adult volunteers, age range 21-55 years and of either sex
11562189|NCT00918151||A|
11562190|NCT00918138|Experimental|Saxagliptin + Metformin XR + matching Metformin XR placebo|(Saxagliptin 5 mg plus Metformin XR 1500 plus matching Metformin XR 500 mg placebo)
11562191|NCT00918138|Active Comparator|Metformin XR + Metformin XR + matching Saxagliptin placebo|(Metformin XR 500 mg plus Metformin XR 1500 mg plus matching Saxagliptin 5 mg placebo)
11562192|NCT00918125||White educational video|Patients will view an educational video that contains White physicians and patients.
11562193|NCT00918125||African-American educational video|Patients will view an educational video that contains African-American physicians and patients.
11562194|NCT00918125||Usual care|Patients will receive counseling about their condition and treatment options.
11562195|NCT00918112||Parkinson's Disease|Meets criteria for definite Parkinson's Disease
11562196|NCT00918112||Healthy Controls|- Must be in good health
11562197|NCT00918099|Active Comparator|Avaulta mesh|Avaulta mesh
11562198|NCT00918099|Active Comparator|Anterior repair|Anterior repair
11562199|NCT00918086|Experimental|Vitamin D pill|
11562200|NCT00918086|Placebo Comparator|Placebo|
11562201|NCT00918073||HIV positive smokers|50 HIV infected patients who enroll in a parent protocol to quit smoking and elect to participate in this sub-study.
11562202|NCT00918060|Experimental|gel a|
11562203|NCT00918060|Placebo Comparator|gel b|
11562204|NCT00918047|Experimental|SPN-804O 150mg/Day|Subjects who weighed 15.0 to 29.9 kg dosed with SPN-804O 150mg/Day
11562205|NCT00918047|Experimental|SPN-8040 300mg/Day|Subjects who weighed 30.0 to 44.9 kg dosed with SPN-8040 300mg/Day
11562206|NCT00918047|Experimental|SPN-8040 450mg/Day|Subjects who weighed 45.0 to 59.9 kg dosed with SPN-8040 450mg/Day
11562207|NCT00918047|Experimental|SPN-8040 600mg/Day|Subjects who weighed 60.0 kg and above dosed with SPN-8040 600mg/Day
11562208|NCT00918034|Experimental|LS11 (talaporfin sodium)|
11562209|NCT00918021|Active Comparator|olanzapine (B)|Group B: In addition to clozapine, the participants receive their normal dosage of olanzapine (=the same as on the hospital ward) for 12 weeks, next the decreasing dosage of olanzapine for four weeks and subsequently placebo for 8 weeks.
11562210|NCT00918021|Placebo Comparator|placebo (A)|Group A: : In addition to clozapine the participants receive the decreasing dosage of olanzapine for four weeks, next placebo for 8 weeks, after that the increasing dosage of olanzapine for four weeks and subsequently the normal dosage of olanzapine for 8 weeks.
11562211|NCT00918008||Blood sample|the blood sample only collected prior to surgery
11562212|NCT00917995|Experimental|Colostomy with a prophylactic mesh|
11562213|NCT00917995|No Intervention|Colostomy without a prophylactic mesh|
11562214|NCT00917982|Other|Vision therapy|
11562215|NCT00917943|Experimental|Tailored Counseling Intervention Arm|Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
11562216|NCT00917943|No Intervention|Control Arm|Women randomized to the control arm receive the booklet, Forever Free for Baby and Me: A Guide to Remaining Smoke Free and usual prenatal and postpartum care.
11562217|NCT00917930||physical training|
11562218|NCT00917904|Placebo Comparator|vehicle placebo gel|
11562219|NCT00917904|Experimental|dapivirine gel|
11562220|NCT00917891|Placebo Comparator|vehicle placebo gel|
11562221|NCT00917891|Experimental|dapivirine gel|
11562222|NCT00917878|Experimental|Milk|500 mL low-fat milk added to high-fat meal
11562223|NCT00917878|Experimental|Protein|Milk protein in 500 mL water added to high-fat meal
11562224|NCT00917878|Experimental|Calcium|Milk calcium in 500 mL water added to high-fat meal
11562225|NCT00917878|Experimental|Control|Lactose in 500 mL water added to high-fat meal (control condition)
11562226|NCT00917865|Experimental|FACBC Imaging|Dynamic FACBC PET of primary prostate carcinoma.
11562227|NCT00917852|Experimental|GORE Conformable TAG® Thoracic Endoprosthesis|
11562228|NCT00917839|Experimental|lamotrigine|7 weeks initial phase with increasing dose beginning with 25 mg oral 12 months treatment phase with fixed dose of 100 mg oral
11562229|NCT00917839|Placebo Comparator|Placebo|300mg Mannitol with 2% Aerosil
11562230|NCT00917826|Experimental|Arginine Butyrate + Ganciclovir/Valganciclovir|
11562231|NCT00917813|Experimental|KD-247|
11562232|NCT00917813|Placebo Comparator|Placebo|
11562233|NCT00917800||suspected coronary artery disease|patients referred to angiography because of suspected coronary artery disease
11562234|NCT00917787||Healthy, Non-asthmatic|
11562235|NCT00917787||Asthma|
11562236|NCT00917774|Active Comparator|Standard LPS Flex|Nexgen LPS-Flex total knee design used for TKA
11562237|NCT00917774|Experimental|Gender specific LPS-Flex|Gender specific LPS flex design used for TKA in female patients
11562238|NCT00917761|Experimental|Entecavir and peginterferon (52 weeks)|Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
11562239|NCT00917761|Experimental|Peginterferon (96 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-96
11562240|NCT00917761|Active Comparator|Peginterferon (48 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-48
11562241|NCT00917748|Experimental|1|docetaxel chemotherapy + modafinil 100 mg capsules
11562242|NCT00917748|Placebo Comparator|2|docetaxel chemotherapy + placebo (lactose) capsules (matched to modafinil drug)
11562243|NCT00917735|Experimental|Green tea extract|Green tea extract capsules containing 80.7 % total catechins (51.7 % EGCG)
11562244|NCT00917735|Placebo Comparator|Sugar pill|Placebo capsules containing 50% maltodextrin, 49.5 % cellulose, and 0.5 % magnesium stearate
11562245|NCT00917709|Experimental|DLB with extrapyramidal syndrome|patients dementia with Lewy bodies with extrapyramidal syndrome
11562246|NCT00917709|Other|DLB without extrapyramidal syndrome|patients dementia with Lewy bodies without extrapyramidal syndrome
11562247|NCT00917709|Sham Comparator|healthy volunteers|healthy volunteers
11562248|NCT00917696|Active Comparator|1|ATP
11562249|NCT00917696|Placebo Comparator|2|Saline
11562250|NCT00917683||1|Autistic patients.
11562251|NCT00917683||2|Matched controls
11562252|NCT00917644|Other|Reference|80 mg atorvastatin tablets
11562253|NCT00917644|Experimental|Test|New 80 mg atorvastatin tablets
11562254|NCT00917631|Experimental|Co-bedding|"Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.
~Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.
~Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes)."
11562255|NCT00917631|No Intervention|Standard care|For infants who are randomized to receive standard care, the twin pair will remain in separate incubators as per current NICU policy. The infant will be nested in boundaries consistent with neonatal care practices. The heelstick may occur at any time following randomization (within 10 days) to maintain consistency between groups.
11562256|NCT00917618|Active Comparator|Exercise intervention|Patients began the exercise intervention after randomization for 12 weeks
11562257|NCT00917618|Placebo Comparator|Control|Patients were asked not to change their baseline exercise program
11562258|NCT00917592|Experimental|Short intravenous amoxicillin plus clavulanic acid|Intravenous antibiotic 48 hours followed by oral antibiotic for 10 days
11562259|NCT00917592|Active Comparator|Long intravenous amoxicillin plus clavulanic acid|Intravenous antibiotic for 7 days followed by oral antibiotic for 5 days
11562260|NCT00917579|Other|Reference|10 mg atorvastatin
11562261|NCT00917579|Experimental|Test|New 10 mg atorvastatin tablet
11562262|NCT00917566|Active Comparator|Airtraq group|Use Airtraq for intubation
11562263|NCT00917566|Active Comparator|Macintoch gorup|Use Macintoch laryngoscope for intubation
11562264|NCT00917553|Experimental|doxycycline monohydrate|
11562265|NCT00917553|Placebo Comparator|Placebo|Placebo
11562266|NCT00917527|Placebo Comparator|Control|
11562267|NCT00917527|Experimental|Atorvastatin|
11562268|NCT00917501|Placebo Comparator|Placebo|Placebo to the Omega-3 given in other group taken twice a day.
11562269|NCT00917501|Active Comparator|Omega 3|Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA & will be taken twice a day.
11562270|NCT00917488|Experimental|A|Four concentrations of Glycyphagus domesticus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, was tested in every patient in duplicate on the volar surface of the forearm.
11562271|NCT00917475||Preterm infants|birth weight<1500 grams and gestational age<30 weeks
11562272|NCT00917462|Experimental|Sorafenib|Sorafenib for patients with metastatic or recurrent esophageal and gastroesophageal junction cancer.
11562273|NCT00917449|Active Comparator|L-arginine|L-arginine (3.2 gr bid) plus lifestyle counselling vs placebo plus lifestyle counselling
11562274|NCT00917449|Placebo Comparator|placebo|placebo plus lifestyle counselling for 18 months
11562275|NCT00917423||Inpatients with anorexia nervosa|Hospital inpatients with anorexia nervosa
11562276|NCT00917423||Normal weight controls|Healthy, normal-weight volunteers
11562277|NCT00917410|Experimental|SMS intervention|
11562278|NCT00917397|Experimental|psychotherapy|Trauma-focused cognitive behavioral therapy
11562279|NCT00917397|Experimental|Drug|drug treatment and psychoeducation
11562280|NCT00917397|No Intervention|Waiting list|subjects randomized to waiting list
11562281|NCT00917397|Experimental|Combination|Both drug and psychotherapy
11562282|NCT00917384|Experimental|ramucirumab|Participants receive ramucirumab, administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), and best supportive care (BSC) as determined appropriate by the investigator(s). Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
11562283|NCT00917384|Placebo Comparator|Placebo|Participants receive injection for intravenous infusion every 2 weeks plus BSC as determined appropriate by the investigator(s). Because investigators and ancillary medical personnel will be blinded as to assignment to active therapy versus placebo, the volume of placebo to be administered will be calculated as if it were active product with a dose of 8 mg/kg. Treatment will continue until there is evidence of PD, the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
11562284|NCT00917371||atomoxetine group|
11562285|NCT00917371||methylphenidate group|
11562286|NCT00917371||psychological counseling group|
11562287|NCT00917358|Experimental|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
11562288|NCT00917358|No Intervention|Observation|Retrospectively chart review of dialysis patients with acute hepatitis C who did not receive any intervention
11562289|NCT00917345||aldosteronism, hypertension|
11562290|NCT00917345||hypertension|
11562291|NCT00917332|Experimental|intervention|"55 third trimester women will receive a CD of relaxation and guided imagery (of safe place), to practice daily at home until childbirth"
11562292|NCT00917332|No Intervention|control|55 third trimester women who does not receive the relaxation and guided imagery CD.
11562293|NCT00917319|Experimental|Infection control measure|Bundling Infection Control Interventions
11562294|NCT00917306|Experimental|PEP005 gel|PEP005 gel, 0.05% administered once daily for 2 consecutive days
11562295|NCT00917293|Experimental|Pyridoxal 5'-Phosphate|Pyridoxal 5'-Phosphate, enteric-coated 2x 250mgs po bid.
11562296|NCT00917293|Placebo Comparator|Placebo|Placebo 2 pills, po bid.
11562297|NCT00917280||Parkinson's Disease|Parkinson Disease participants without dementia
11562298|NCT00917280||Control|Non-PD participants, matched for age, education and gender.
11562299|NCT00917267|Experimental|1|
11562300|NCT00917267|Active Comparator|2|
11562301|NCT00917254|Experimental|YM150 group-1|YM150 low dose group
11562302|NCT00917254|Experimental|YM150 group-2|YM150 high dose group
11562303|NCT00917254|Placebo Comparator|Placebo group|
11562304|NCT00917254|Active Comparator|Enoxaparin group|
11562305|NCT00917241|Experimental|MMI+IID group|MMI,methimazole；IID,intrathyroid injection of dexamethasone
11562306|NCT00917241|Active Comparator|MMI Group|MMI,methimazole
11562307|NCT00917228||Feedback|Subjects of this group are equipped with the biofeedback system
11562308|NCT00917228||Control|Subjects of this group are not equipped with the biofeedback system
11562309|NCT00917215|Experimental|Active acupuncture|
11562310|NCT00917215|Sham Comparator|Sham acupuncture|
11562311|NCT00917215|No Intervention|Waiting list control|
11562312|NCT00917202|Experimental|MB3|3 days
11562313|NCT00917202|Experimental|MB5|5 days
11562314|NCT00917202|Experimental|MB7|
11562315|NCT00917189|Experimental|Computerized Cognitive Skills Training|Participants will receive the Challenging Our Minds intervention, delivered in-person in Phase 1 and remotely in Phases 2 and 3.
11562316|NCT00917176|Experimental|Effective stimulation|Effective stimulation at sub-threshold level
11562317|NCT00917176|Placebo Comparator|Placebo stimulation|Stimulation at non-effective strength
11562318|NCT00917163|Experimental|Supralimus(R) Sirolimus Eluting Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
11562319|NCT00917163|Active Comparator|Xience V™ Everolimus Eluting Stent|The XIENCE V™ Everolimus Eluting Coronary Stent System consisting of the MULTI-LINK VISION® Coronary Stent System coated with a formulation containing everolimus, the active ingredient, embedded in a non-erodible polymer., Drug Load: 100 µg/cm2
11562320|NCT00917150|Experimental|OPC-6535 12.5mg|
11562321|NCT00917150|Experimental|OPC-6535 25mg|
11562322|NCT00917150|Experimental|OPC-6535 50mg|
11562323|NCT00917150|Placebo Comparator|placebo|
11562324|NCT00917137||Peripheral pulmonary lesions|
11562325|NCT00917124|Active Comparator|INVOS|INVOS : Cerebral oxygenation (rSO2) monitoring with INVOS. If rSO2 decreased for more than 20% from patient's baseline value, simple interventions were performed to prevent brain injury. These interventions included: repositioning of head or perfusion cannulae, increasing arterial carbon dioxide tension, increasing oxygen inspiration concentration, increasing arterial blood pressure, adjusting pump flow rate, temperature decreasing, increasing of anesthetic depth and blood transfusion.
11562326|NCT00917124|No Intervention|CONTROL|The CONTROL arm did not have INVOS or any other cerebral oxygenation monitoring, so interventions to control cerebral oxygenation were not performed.
11562327|NCT00917111|Experimental|CO2 Gas|
11562328|NCT00917111|Placebo Comparator|Inactive Placebo Gas|
11562329|NCT00917098|Experimental|Behavior Therapy|Participants will receive behavior therapy during Phases 1 and 2.
11562330|NCT00917098|Placebo Comparator|Supportive Counseling|Participants will receive supportive counseling during Phase 1 and will not participate in Phase 2.
11562331|NCT00917085|No Intervention|Control group|Control infants received the same standard care as infants who were not in the study. Infants were kept warm in incubators or warmer beds and were wrapped in blankets when held by their mothers. Hospital staff was responsible for providing standard care.
11562332|NCT00917085|Experimental|Skin-to-Skin group|
11562333|NCT00917072|Experimental|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
11562334|NCT00917072|Experimental|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center.
11562335|NCT00917072|Placebo Comparator|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
11562336|NCT00917059|Active Comparator|1|Participants will receive a 1-week treatment of escitalopram and then an 8-week treatment with escitalopram.
11562337|NCT00917059|Active Comparator|2|Participants will receive a 1-week treatment with escitalopram and then an 8-week treatment with bupropion XL.
11562338|NCT00917046|Experimental|1 Interval training|high-intensity Interval Training
11562339|NCT00917046|Experimental|2 Moderate Training|Moderate continuous training
11562340|NCT00917046|Active Comparator|3 Recommendation of exercise|Recommendation of regular exercise at moderate intensity at individual choice
11562341|NCT00917033|Experimental|GlideScope|Orotracheal intubation using the GlideScope videolaryngoscope
11562342|NCT00917033|Active Comparator|Macintosh|Orotracheal intubation using the Macintosh direct laryngoscope
11562343|NCT00917020|Experimental|Active: CO2 Gas|
11562344|NCT00917020|Placebo Comparator|Inactive Placebo Gas|
11562345|NCT00917007||ABO compatible|
11562346|NCT00917007||ABO incompatible, antiglobulin positive|
11562347|NCT00917007||ABO incompatible, antiglobulin negative|
11562348|NCT00916994|Experimental|SpaceGuard Balloon implantation|
11562349|NCT00916968|Active Comparator|Standard CR-Flex|
11562350|NCT00916968|Experimental|Gender specific CR-Flex|
11562351|NCT00916955||Individuals with 22q11.2 deletions|Individuals confirmed with the diagnosis of velo-cardio-facial syndrome by positive FISH or CGH microarray confirming the diagnosis and deletion of 22q11.2
11562352|NCT00916942|Experimental|NGX-4010 patch|
11562353|NCT00916942|Experimental|Lidocaine (2.5%)/Prilocaine (2.5%) Cream|Pre-treatment for NGX-4010
11563052|NCT00912171|Active Comparator|Anti-leukotrienes|
11562354|NCT00916929|Other|Implantable Cardioverter Defibrillator (ICD)|Impedance Monitoring Feature in an Implantable Cardioverter Defibrillator (ICD).
11562355|NCT00916929|Other|Cardiac Resynchronization Therapy (CRT-D)|Impedance Monitoring Feature in a Cardiac Resynchronization Therapy (CRT-D) device.
11562356|NCT00916916||Lanreotide|Patients taking lanreotide for the treatment of acromegaly.
11562357|NCT00916903||1|Patients with genetic condition being studied.
11562358|NCT00916903||2|Matched controls
11562359|NCT00916890|Active Comparator|Oral extended-release morphine|
11562360|NCT00916890|Active Comparator|Oral extended-release oxycodone|
11562361|NCT00916890|Active Comparator|Transdermal fentanyl|
11562362|NCT00916890|Active Comparator|Transdermal buprenorphine|
11562363|NCT00916851||Control group|Normally developing children and adolescents
11562364|NCT00916851||ADHD group|Children and adolescents with ADHD
11562365|NCT00916851||ASD group|Children and adolescents with ASD
11562366|NCT00916838||Type 1 Diabetes Mellitis|Children with Type 1 Diabetes Mellitis (T1DM) between 4 and 16 were recruited.
11562367|NCT00916838||Non diabetic Control|62 healthy siblings also enrolled in the study between the ages of 4 and 17.
11562368|NCT00916825|Experimental|3-week family oriented rehabprogramme|waiting control group
11562369|NCT00916799|Experimental|Oximeter arm and non-oximetry arm|
11562370|NCT00916786||OROS-methylphenidate|The patients will be randomly assigned to two treatment groups, the OROS-methylphenidate group (n=80) and the atomoxetine group (n=80), respectively.
11562371|NCT00916786||Atomoxetine group|The patients will be randomly assigned to two treatment groups, the OROS-methylphenidate group (n=80) and the atomoxetine group (n=80), respectively.
11562372|NCT00916786||Control group|Healthy controls matching for the distribution of age and sex of the case groups
11562373|NCT00916760|Experimental|1|A Subcutaneous Depigmented and Polymerized Allergen extract of Parietaria Judaica 1000 DPP/ml. Depigoid Parietaria judaica 1000 DPP/ml.
11562374|NCT00916760|Placebo Comparator|2|
11562375|NCT00916747|Experimental|Treatment arm|All patients will receive zoledronic acid, pravastatin and lonafarnib
11562376|NCT00916734|Experimental|Spinal Manipulation Group|Subjects who received spinal thrust manipulation as an intervention.
11562377|NCT00916734|Active Comparator|McKenzie MDT Group|
11562378|NCT00916721|Active Comparator|Propranolol|propranolol
11562379|NCT00916721|Placebo Comparator|Placebo|sugar pill
11562380|NCT00916708|Experimental|Intensive follow up|Intensive follow up in low-risk patients Intensive follow up in high-risk patients
11562381|NCT00916708|Experimental|Minimalist follow up|Minimalist follow up in low-risk patients Minimalist follow up in high-risk patients
11562382|NCT00916695|Active Comparator|Complex PCI strategy for bifurcation coronary lesions|Stenting main vessel and T-stenting for the side branch
11562383|NCT00916695|Active Comparator|Simple PCI strategies for bifurcation coronary lesions|Stenting main vessel, with provisional stenting for the side branch.
11562384|NCT00916682||Cystic Fibrosis|
11562385|NCT00916669|Active Comparator|Group A|Cisplatin and Etoposide
11562386|NCT00916669|Experimental|Group B|Cisplatin and etoposide, plus low-dose enoxaparin sodium
11562387|NCT00916669|Experimental|Group C|Cisplatin and etoposide, plus high-dose enoxaparin sodium
11562388|NCT00916656|Experimental|Prospective Arm|
11562389|NCT00916656|Other|Historical Control|
11562390|NCT00916643|Experimental|H.E.L.P. Secura|"The H.E.L.P. System is a device composed of multiple modules and their associated disposables which can selectively and continuously remove LDL-cholesterol from plasma by precipitating the LDL-cholesterol with high concentrations of heparin in an acidic buffer and returning the plasma to the patient. Procedure steps:
~Flushing the system with normal saline.
~Filtering whole blood through a 0.2 micron plasma filter for continuous plasma removal.
~Mixing the plasma with an equal volume of acetate buffer containing heparin.
~Precipitation of LDL as a complex with heparin.
~Removing the LDL-heparin precipitate by continuous circulation through a filter.
~Removing heparin with use of a heparin adsorber.
~Bicarbonate dialysis and ultrafiltration to produce an LDL-free plasma without excess heparin.
~Re-mixing the LDL-free plasma with blood coming from the plasma filter and returning the reconstituted blood to the patient."
11562391|NCT00916630|Other|Single-arm treatment|Dose finding study
11562392|NCT00916617|Experimental|1|5 mg/week
11562393|NCT00916604|Experimental|A|3 gradually increasing repeated oral doses of AZD1656 given to 3 groups (6 on active substance in each group)
11562394|NCT00916604|Placebo Comparator|B|Placebo oral suspension given to 3 groups (2 on placebo in each group)
11562395|NCT00916578|Experimental|Radiation Therapy + Capecitabine|"Capecitabine 825 mg/m2 twice a day. One of the two daily doses of capecitabine should be taken approximately 2 hours before receiving radiotherapy. The first day of Capecitabine is same day that radiotherapy is started, and last day that Capecitabine is given is last day of radiotherapy. Capecitabine administered only on days patient receives radiation therapy.
~Radiation therapy dose 50-57 Gy to initial clinical target volume (CTV, gross disease + tissue at risk for micrometastatic disease including margin around gross disease and draining regional lymphatics)."
11562396|NCT00916565||Experimental milk-based infant formula|
11562397|NCT00916565||Control milk-based infant formula|
11562398|NCT00916565||Breastfed Reference Group|
11562399|NCT00916552|Experimental|Erythropoeitin|40.000 IU, epoetin alfa; Janssen-Cilag
11562400|NCT00916539|Experimental|Cast that immobilizes the thumb|Cast that immobilizes the thumb
11562401|NCT00916539|Active Comparator|Cast that does not immobilize the thumb|Cast that does not immobilize the thumb
11562402|NCT00916526|Experimental|bronchial provocation test with mannitol|"Patients referred for evaluation of a chronic cough (without treatment or after stopping inhaled corticosteroids for 2 weeks) will perform a measure of FeNO, a bronchial provocation test with mannitol, will fill out a questionnaire of quality of life for the cough (Leicester Cough Questionnaire) and the intensity of coughing on a 10-cm visual scale.
~After 6 weeks after treatment with inhaled corticosteroids patients will perform the same tests."
11562403|NCT00916513||1|Patients ³ 40 years old, with T2DM diagnosed and followed up in the participating site at least 1 year prior to entry in the study, treated with diet, OADs and/or insulin for at least the past three months
11562404|NCT00916500|Experimental|CISPLATIN|Patients With Locally Advanced Cervical Cancer Who Underwent Concurrent Chemoradiation; Cisplatin 75mg/m2 IV Every 3 Week For 3 Cycles; External Pelvic Radiation 40 Gy; Brachytherapy Up to 85-90 Gy To Point A
11562405|NCT00916487|Experimental|Arm1|single arm of study in cross-over design
11562406|NCT00916474||Cohort A|Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time
11562407|NCT00916474||Cohort B|Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time
11562408|NCT00916461|Active Comparator|Minocycline|
11562409|NCT00916461|Placebo Comparator|Sugar Pill|
11562410|NCT00916448|Placebo Comparator|Placebo|placebo medication: 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously
11562411|NCT00916448|Active Comparator|Atazanavir|Atazanavir 150 mg, 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously
11562412|NCT00916422|Experimental|Depigoid Phleum pratense 1000DPP/Ml|Depigmented and Polymerized Allergen extract of Phleum Pratense.Subcutaneous Immunotherapy in an up-dosing cluster regimen for 4 weeks, followed by monthly injections for 2 years.
11562413|NCT00916422|Placebo Comparator|2|Placebo. Dosing regimen: An up-dosing cluster regimen for 4 weeks, followed by monthly injections for 2 years
11562414|NCT00916409|Experimental|NovoTTF-100A device in combination with Temozolomide|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
11562415|NCT00916409|Active Comparator|Temozolomide alone, as the best known standard of care|Patients will be treated with Temozolomide, as the best known standard of care for Glioblastoma Multiforme patients.
11562416|NCT00916396|Active Comparator|real drug|
11562417|NCT00916396|Placebo Comparator|placebo|
11562418|NCT00916383|Experimental|Upper Back|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of the upper back.
11562419|NCT00916383|Experimental|Upper Arm|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite arms.
11562420|NCT00916383|Experimental|Side of Torso|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of torso.
11562421|NCT00916370|Experimental|Core size registry (CSR)|Core size indicates the range of diameters of the stents used.
11562422|NCT00916370|Experimental|Long lesion registry (LLR)|Use of long lesion stents.
11562423|NCT00916357|Active Comparator|Humalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20|A subcutaneous (SC) injection of 0.3- to 0.5-units per kilogram (U/kg) of Humalog alone for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout period), followed by a SC injection of the appropriate dose of Humalog. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog + 3.75 nanograms/kilogram (ng/kg) recombinant human hyaluronidase PH20 (rHuPH20). The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 ng/kg rHuPH20 following a 3 to 14 day washout period.
11562424|NCT00916357|Active Comparator|Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog alone for up to 3 dose finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 nanograms/kilogram (ng/kg) recombinant human hyaluronidase PH20 (rHuPH20). The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
11562425|NCT00916357|Active Comparator|Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog + 3.75 nanograms per kilogram (ng/kg) recombinant human hyaluronidase PH20(rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog alone. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
11562426|NCT00916357|Active Comparator|Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then Humalog|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humulin-R + rHuPH20. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog following a 3- to 14-day washout period.
11562427|NCT00916357|Active Comparator|Humulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humulin-R + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humulin-R + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog alone. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
11562428|NCT00916357|Active Comparator|Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog|A subcutaneous (SC) injection of 0.3- to 0.5-units per kilogram (U/kg) of Humulin-R + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humulin-R + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog alone following a 3- to 14-day washout period.
11562429|NCT00916344|Experimental|Pacemaker therapy|
11562430|NCT00916331|Experimental|subcutaneous group|Vacuum drainage is indwelled in subcutaneous layer
11562431|NCT00916331|Experimental|intraarticular group|Vacuum drainage is indwelled in intraarticular space
11562432|NCT00916318|Experimental|A: experimental|"(A) internet based information and communication tool Sundabarn.se("
11562433|NCT00916318|Experimental|(B): experimental|(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A
11562434|NCT00916318|Experimental|(c): experimental|(C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A
11562435|NCT00916318|Active Comparator|(D): control group|
11562436|NCT00916305|Experimental|Modified Audio video|Participants will listen to an audio video modified to mimic noise induced hearing loss after one night at a loud club
11562437|NCT00916305|Active Comparator|Unmodified Audio video|Participants will listen to the same music as the other arm, but only the track with unaltered music.
11562438|NCT00916292|Experimental|Low dose|Four subjects will receive low dose FGF-1
11562439|NCT00916292|Experimental|High Dose|Four subjects will receive high dose FGF-1
11562440|NCT00916279|Experimental|Lutonix Catheter|
11562441|NCT00916266|Experimental|stem cell transplantation|Patients with refractory temporal lobe epilepsy that are transplanted with autologous bone marrow stem cells in order to provide seizure control.
11562442|NCT00916253|Experimental|Modafinil First|Treatment by Modafinil during first condition then placebo during second condition
11562443|NCT00916253|Experimental|Placebo First|Treatment by Placebo during first condition then Modafinil during second condition
11562444|NCT00916253|No Intervention|H|Healthy Volunteers
11562445|NCT00916240|Experimental|1|Participants will receive Multisystemic Therapy (MST).
11562446|NCT00916240|Active Comparator|2|Participants will receive home-based, non-directive family support.
11562447|NCT00916227|Experimental|ARRY-614|
11562448|NCT00916214|Experimental|Intervention|
11562449|NCT00916201|Experimental|Intranasal Insulin|Intranasal administered insulin
11562450|NCT00916201|Experimental|Cannabidiol CR|Cannabidiol is the main non psychoactive compound of the Cannabis sativa plant.
11562451|NCT00916201|Experimental|URB597|URB597 is a selective inhibitor of the Fatty acid amide hydrolase enzyme.
11562452|NCT00916188|Experimental|Black Tea-Four Doses|One, 2, 3 and 4 cups (150 ml/cup) of Black tea/day for week 1, 2, 3, and 4, respectively.
11562453|NCT00916188|Active Comparator|Black Tea-One Dose|One cup (150 ml) of Black tea/day during study.
11562454|NCT00916175|Placebo Comparator|P1&P2|Food product P1&P2 is composed of: placebo1(mimic aloe vera gel) 30ml and placebo2 (mimic Cnidoscolus chayamansa infusion) 200ml;
11562455|NCT00916175|Experimental|P1&CC|Food Product P1&CC contains: placebo1 (mimics liquified aloe vera gel) 30ml and Cnidoscolus Chayamansa infusion 200ml;
11562456|NCT00916175|Experimental|AG&P2|Food product AG&P2 contains (liquified aloe vera gel) 30ml and placebo2 (mimic CC infusion) 200ml.
11562457|NCT00916175|Experimental|AG&CC|Food product AG&CC is composed of: liquified aloe vera gel 30ml and Cnidoscolus Chayamansa infusion 200ml
11562458|NCT00916175|Experimental|TA (concentrated 5:1 aloe vera gel)|Food product TA contains concentrated 5:1 aloe vera gel by total process30 ml and purified water 200 ml.
11562459|NCT00916175|Placebo Comparator|P3|Food product Placebo 3 contains stabilizers and preservative used for TA 30 ml and purified water 200 ml.
11562460|NCT00916149|Active Comparator|Levetiracetam|12 individuals with epilepsy, 6 of whom experience infrequent focal epileptiform discharges and 6 of whom experience frequent focal discharges. These individuals will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.
11562461|NCT00916149|Active Comparator|Lamotrigine|12 individuals with epilepsy, 6 of whom experience infrequent generalized discharges and 6 of whom experience frequent generalized discharges. These individuals will be treated with lamotrigine (LMT). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LMT on discharge frequency, discharge duration, and cognitive task performance.
11562462|NCT00916149|No Intervention|No treatment|15 healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.
11562463|NCT00916136|Active Comparator|Cutaneous Traction|Applied by using a strap on boot that attaches to the leg. A rope is attached to the boot. Weight is attached to the rope to use gravity to pull traction. The traction is left in place until patient is taken to surgery for reduction of the femur fracture.
11562464|NCT00916136|Active Comparator|Skeletal Traction|A small incision is made on the inside of the knee and a pin is surgically inserted through the bone. Weights are then attached that will pull traction on the broken femur. This traction pin will stay in until patient is taken to surgery for reduction of the femur fracture.
11562465|NCT00916123|Experimental|Dose Level 1|177Lu-J591 at 20 mCi/dose
11562466|NCT00916123|Experimental|Dose Level 2|177Lu-J591 at 25 mCi/dose
11562467|NCT00916123|Experimental|Dose Level 3|177Lu-J591 at 30 mCi/dose
11562468|NCT00916123|Experimental|Dose Level 4|177Lu-J591 at 35 mCi/dose
11562469|NCT00916123|Experimental|Dose Level 5|177Lu-J591 at 40 mCi/dose
11562470|NCT00916110|Experimental|1.5mgSC|ATN-103
11562471|NCT00916110|Experimental|4mgSC|ATN-103
11562472|NCT00916110|Experimental|10mgSC|ATN-103
11562473|NCT00916110|Experimental|25mgSC|ATN-103
11562474|NCT00916110|Experimental|25mgIV|ATN-103
11562475|NCT00916110|Experimental|50mgSC|ATN-103
11562476|NCT00916110|Experimental|100mgSC|ATN-103
11562477|NCT00916110|Experimental|200mgSC|ATN-103
11562478|NCT00916110|Experimental|200mgIV|ATN-103
11562479|NCT00916097|Experimental|1|docetaxel 75mg/m2 in combination with cisplatin 75mg/m2 given every 3 weeks for 3 cycles
11562480|NCT00916084|Experimental|Group A|
11562481|NCT00916084|Experimental|Group B|
11562482|NCT00916071||Eating Disorders|Study subjects will be individuals with a history of eating disorder(s) diagnosis
11562483|NCT00916058|Experimental|Dose Level 1|Dose Level 1; Bendamustine 30 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
11562570|NCT00915460|Experimental|2|Patients previously enrolled in Biogen Idec study C96-823.
11562484|NCT00916058|Experimental|Dose Level 2|Dose Level 2; Bendamustine 60 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
11562485|NCT00916058|Experimental|Dose Level 3|Dose Level 3; Bendamustine 90 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
11562486|NCT00916058|Experimental|Dose Level 4|Dose Level 4; Bendamustine 120 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
11562487|NCT00916058|Experimental|Dose Level 5|Dose Level 5; Bendamustine 150 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
11562488|NCT00916058|Experimental|Dose Level 6|Dose Level 6; Bendamustine 225 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
11562489|NCT00916058|Experimental|Phase 2|Bendamustine 225 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
11562490|NCT00916045|Other|Myeloblative conditioning regimen|
11562491|NCT00916045|Other|Reduced intensity conditioning regimen - FluCyTBI|
11562492|NCT00916045|Other|Reduced intensity conditioning regimen - FluMel|
11562493|NCT00916032|Active Comparator|1|One infusion using a 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent followed by a second infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total)
11562494|NCT00916032|Active Comparator|2|One infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total) followed by a second infusion of one 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent
11562495|NCT00916019|Experimental|exercise|mild exercise training
11562496|NCT00916006|Experimental|PEP005 gel|PEP005 gel, 0.015% applied once daily for three consecutive days
11562497|NCT00916006|Placebo Comparator|Vehicle gel|Vehicle gel applied once daily for three consecutive days
11562498|NCT00915980||Patients without diabetes undergoing gastric bypass|
11562499|NCT00915967|Experimental|Vancomycin|Subjects in the experimental group will receive Vancomycin injected directly into the wound pocket.
11562500|NCT00915967|Placebo Comparator|Saline|Subjects in the saline group will receive a Saline injection directly into the wound pocket.
11562501|NCT00915954|Active Comparator|Active Acromegaly|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
11562502|NCT00915954|Active Comparator|Type 2 Diabetes Mellitus(DM)|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
11562503|NCT00915954|Active Comparator|Heathy Controls|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
11562504|NCT00915928|Active Comparator|ACE inhibitor|patients randomized to this arm will be treated with ACE inhibitors after surgery
11562505|NCT00915928|Placebo Comparator|Placebo|patients randomized to this arm will be treated with placebo after surgery
11562506|NCT00915915|Experimental|Arm 1|
11562507|NCT00915915|Experimental|Arm 2|
11562508|NCT00915902|Experimental|Omega-3-acid ethyl esters (Lovaza)|This randomized, double-blind, placebo, crossover trial consisted of two 8-week treatment periods, separated by a 4-week washout. Eligible patients were randomized to receive either fish oil 4 g daily or corn oil placebo during the first 8-week treatment period; patients received the alternate treatment during the next treatment period. GlaxoSmithKline supplied the study drug and the placebo. The study drug, Omega-3-acid ethyl esters (Lovaza) was given to patients PO daily as two, 1 g capsules taken twice daily during the duration of their 8-week treatment period. The study drug contained minimally 1.5 g DHA (docosahexaenoic acid) and 1.86 g EPA (eicosapentaenoic acid).
11562509|NCT00915902|Placebo Comparator|Placebo|This randomized, double-blind, placebo, crossover trial consisted of two 8-week treatment periods, separated by a 4-week washout. Eligible patients were randomized to receive either fish oil 4 g daily or corn oil placebo during the first 8-week treatment period; patients received the alternate treatment during the next treatment period. The corn oil placebo was given to patients PO daily as two, 1 g capsules taken twice daily during the duration of their 8-week non-treatment (placebo) period.
11562510|NCT00915889|Active Comparator|Group I|Patients receive a survivorship booklet in the mail that contains information about cervical cancer. Patients then receive a follow-up telephone call at 3 months to clarify any issues relevant to the survivorship booklet.
11562511|NCT00915889|Experimental|Group II|Patients are randomly assigned to receive either 6 or 8 weekly telephone sessions that address managing medical issues, health education, and cancer resources; balancing emotions and managing stress; coping skills and problem solving; family and social concerns; relational, intimacy, and sexual concerns; and financial and employment concerns. Patients also receive a survivorship booklet as in group I.
11562512|NCT00915876|Active Comparator|Paricalcitol|
11562513|NCT00915876|Placebo Comparator|Placebo|
11562514|NCT00915863|Active Comparator|Billroth-II-type|Billroth-II-type reconstruction after pancreaticoduodenectomy
11562515|NCT00915863|Experimental|Isolated Roux-en-Y|Isolated Roux-en-Y type reconstruction after pancreaticoduodenectomy
11562516|NCT00915850|Experimental|Anticancer drug|docetaxel, cisplatin and 5-FU
11562517|NCT00915837|Experimental|Slow release formulation|Slow release formulation, helical intravitreal triamcinolone implant
11562518|NCT00915837|Experimental|fast release formulation|fast release formulation, helical intravitreal triamcinolone implant
11562519|NCT00915824|Experimental|STOPP/START intervention|STOPP/START intervention group
11562520|NCT00915811|Experimental|FBATG|Haematopoietic stem cell transplantation utilising conditioning with Fludarabine, Busulphan and Thymoglobuline
11562521|NCT00915798||Smokers with ADHD|Smokers with ADHD participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
11562522|NCT00915798||Nonsmokers with ADHD|Nonsmokers with ADHD participated in one condition.
11562571|NCT00915460|Experimental|3|Patients previously enrolled in Biogen Idec study C97-830.
11562523|NCT00915798||Control smokers|Control smokers participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
11562524|NCT00915798||Control nonsmokers|Control nonsmokers participated in one condition.
11562525|NCT00915785|Experimental|5 azacytidine|
11562526|NCT00915772|Experimental|Linagliptin + metformin bid|Linagliptin low dose + metformin 500 mg, bid
11562527|NCT00915772|Experimental|Linagliptin+ metformin bid|Linagliptin low dose + metformin 1000 mg bid
11562528|NCT00915772|Active Comparator|Metformin bid|Metformin 1000 mg bid
11562529|NCT00915759|Active Comparator|ProKera|
11562530|NCT00915759|Placebo Comparator|Bandage contact lens|
11562531|NCT00915733|Active Comparator|triple group|"Additive cilostazol to dual antiplatelet therapy (triple antiplatelet therapy) in patients with acute myocardial infarction (AMI).
~Received cilostazol 100 mg twice daily in addition to aspirin 100 mg and clopidogrel 75 mg once daily."
11562532|NCT00915733|Active Comparator|high maintenance dose group|"High maintenance dose dual antiplatelet therapy in patients with acute myocardial infarction (AMI).
~Received clopidogrel 150 mg/day with aspirin 100 mg once daily."
11562533|NCT00915707|Experimental|Baseline|Subjects are tested under normal sleep conditions for carbohydrate metabolism and appetite regulation.
11562534|NCT00915707|Experimental|Sleep restriction|Subjects are tested under sleep restriction for carbohydrate metabolism and appetite regulation.
11562535|NCT00915707|Experimental|Reduced sleep quality|Subjects are tested under a poor sleep quality condition for carbohydrate metabolism and appetite regulation.
11562536|NCT00915694|Experimental|Single arm|NFV-RT-Tem
11562537|NCT00915681|Experimental|Legalon SIL|Silibinin: loading dose of one hour infusion of 5 mg/kg, followed by 20 mg/kg/day infused continuously via pump
11562538|NCT00915655|Experimental|DRV/rtv (darunavir/ritonavir)|Patients will receive darunavir tablets 2 x 400 mg in combination with ritonavir capsule 100 mg once daily for 48 weeks along with 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) ie, either zidovudine/lamivudine or abacavir/lamivudine
11562539|NCT00915642||Normal volunteers|Volunteers, body mass index 17 to 25
11562540|NCT00915642||Obese volunteers|Volunteers body mass index higher than 30
11562541|NCT00915629|Experimental|Probiotic|Dietary supplement
11562542|NCT00915616|No Intervention|control|9 healthy normal subjects.
11562543|NCT00915616|Active Comparator|Group II|Included 9 patients suffering from GERD; receiving melatonin alone for treatment of GERD in a dose of 3 mg once daily at the bed time.
11562544|NCT00915616|No Intervention|Group III, combined group|Included 9 patients suffering from GERD; receiving omeprazole alone for treatment of GERD in a dose of 20 mg twice daily.
11562545|NCT00915616|Active Comparator|Group IV|Included 9 patients suffering from GERD receiving omeprazole and melatonin for treatment of GERD in the same dose of each of them.
11562546|NCT00915603|Active Comparator|paclitaxel/bevacizumab/everolimus|Systemic Therapy
11562547|NCT00915603|Placebo Comparator|paclitaxel/bevacizumab/placebo|Systemic Therapy
11562548|NCT00915590|Experimental|Placebo first, then IL-1RA|It is our intent that 10 patients will complete a course of treatment with placebo, followed by a course of treatment with 5% custom made topical IL-1Ra.
11562549|NCT00915590|Experimental|IL-1RA first, then Placebo|It is our intent that 10 patients will complete a course of treatment with 5% custom made topical IL-1Ra, followed by a course of treatment with placebo
11562550|NCT00915577|Experimental|1st Injection|Manual injection with pre-filled syringe.
11562551|NCT00915577|Experimental|Single-use autoinjector|Single-use autoinjector with Avonex pre-filled syringe
11562552|NCT00915564|Experimental|TMC435 + methadone|Supervised intake of individualized methadone dose (range, 30 to 150 mg once daily) from Day -14 to Day -1; followed by addition of 150 mg dose of TMC435 once daily from Day 1 to Day 7 along with methadone; and later followed by continued intake of individualized methadone 30 to 32 days follow-up.
11562553|NCT00915551|Experimental|PEP005 (Ingenol Mebutate) gel|
11562554|NCT00915551|Placebo Comparator|Vehicle gel|
11562555|NCT00915538|Other|Group 1 / use of pMDI as approved|The intervention in this group will use inhalation from the pMDI containing budesonide/formoterol pMDI 160/4.5 2 inhalations as approved. (FDA approved product information) without a spacer. The pulmonary function tests (PFTs) will be collected at baseline and for a period of 12 hours post inhalation of 2 inhalation of budesonide /formoterol; pMDI160/5.
11562556|NCT00915538|Experimental|Group 2 / pMDI with Aerochamber Plus|The intervention in this group will use the pMDI budesonide/formoterol 160/4.5 with a valve holding chamber spacer device, Aerochamber Plus which is the intervention being studied The PFTs will be collected at baseline and for a period of 12 hours post inhalation of 2 inhalation of Symbicort 160/5. This is the intervention to be studied for comparison to the non-spacer inhalations..
11562557|NCT00915525|Experimental|botulinum toxin Type A 100U|Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
11562558|NCT00915525|Experimental|botulinum toxin Type A 150U|Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
11562559|NCT00915512|Experimental|Paliperidone extended-release (ER)|
11562560|NCT00915499|Active Comparator|ASV mode|
11562561|NCT00915499|Active Comparator|CPAP mode|
11562562|NCT00915486|Experimental|Good Standard of Care (GSoC)|Twice per week
11562563|NCT00915486|Experimental|GSoC + vehicle|Twice per week
11562564|NCT00915486|Experimental|GSoC + I-020201 (33microg)|Twice per week
11562565|NCT00915486|Experimental|GSoC + I-020201 (100microg)|Twice per week
11562566|NCT00915486|Experimental|GSoC + I-020201 (300microg)|Twice per week
11562567|NCT00915473|Experimental|Active Injection|Subjects randomized to this arm will receive 2.5 mL 0.5% bupivicaine plus 0.5 mL 20 mg methylprednisolone injected over the ipsilateral (unilateral headache) or bilateral (bilateral headache) occipital nerve.
11562568|NCT00915473|Placebo Comparator|Placebo Injection|Subjects randomized to this arm will receive 2.75 mL normal saline plus 0.25 mL 1% lidocaine injected over the ipsilateral (unilateral headache) or bilateral (bilateral headache) occipital nerve.
11562569|NCT00915460|Experimental|1|Patients previously enrolled in BIogen Idec study C95-812.
11562572|NCT00915447||Cat Allergic Rhinitis|Individuals with cat allergic rhinitis, yet without routine cat exposure
11562573|NCT00915421||Prehospital hypothermia group|All patients included to the study
11562574|NCT00915408|Experimental|CRD|
11562575|NCT00915382|Active Comparator|3 weekly regimen of S-1 and cisplatin|
11562576|NCT00915382|Active Comparator|5 weekly regimen of S-1 and cisplatin|
11562577|NCT00915356|Experimental|1|AZD1305 iv infusion
11562578|NCT00915356|Placebo Comparator|2|Placebo iv infusion
11562579|NCT00915343|Experimental|Novel once daily modified release|"Test drug: hydrocortisone (modified release), oral tablet, available as 20 mg and 5 mg.
~The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state"
11562580|NCT00915343|Active Comparator|Conventional TID hydrocortisone|Reference drug: hydrocortisone, oral tablet, 10 mg. The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM)in the same total daily dose as the experimental drug. The morning dose was administered in the fasting state.
11562581|NCT00915330|Active Comparator|TBNA alone|Arm A: TBNA alone.
11562582|NCT00915330|Experimental|TBNA with ROSE|Arm B: TBNA with ROSE.
11562583|NCT00915291|No Intervention|Usual education|"Participants randomized into the no intervention arm were not exposed to the web-based educational modules"
11562584|NCT00915291|Experimental|Web-based educational modules|Participants randomized into the intervention arm were exposed to the web-based educational modules
11562585|NCT00915278|Experimental|PF-04605412|
11562586|NCT00915252|Experimental|5-azacytidine|Patients enrolled in this arm will receive standard induction and consolidation chemotherapy preceded by 5-azacytidine. These patients will additionally receive maintenance therapy with 5-azacytidine for one year after start of induction therapy.
11562587|NCT00915252|Active Comparator|standard chemotherapy|Patients enrolled in this arm will receive standard chemotherapy treatment.
11562588|NCT00915239|Active Comparator|Pantoprazole|
11562589|NCT00915239|Placebo Comparator|Placebo|
11562590|NCT00915213||Repeat Prostate Biopsy|Men who undergo repeat prostate biopsy
11562591|NCT00915200|Placebo Comparator|Placebo|N-acetylcysteine placebo + silibin placebo
11562592|NCT00915200|Experimental|N-acetylcysteine|N-acetylcysteine active + silibin placebo
11562593|NCT00915200|Experimental|silibin|N-acetylcysteine placebo + silibin active
11562594|NCT00915200|Experimental|N-acetycysteine + silibin|N-acetylcysteine active + silibin active
11562595|NCT00915200|Experimental|N-acetylcysteine + high-dose silibin|N-acetylcysteine active + high-dose silibin active
11562596|NCT00915187|Active Comparator|Control|
11562597|NCT00915187|Experimental|CCS/C (Adjuvant Formulation)|
11562598|NCT00915148||Ultrasound examination|Women with prolonged Labour; Primi gravidae, single pregnancy, >37 weeks, fetus alive, cephalic presentation.
11562599|NCT00915135|Experimental|Ramelteon QD and Placebo QD (25 possible combinations total)|
11562600|NCT00915122|Experimental|IMRT in prostate cancer|
11562601|NCT00915109||vascular|People with a unilateral below-knee amputations due to a vascular reason
11562602|NCT00915109||nonvascular|People with a below-knee amputation due to nonvascular reasons
11562603|NCT00915109||Control|People with no gait impairments.
11562604|NCT00915096||High Tumor Burden Follicular Lymphoma|
11562605|NCT00915083|Experimental|Amrubicin 40mg/m^2|Amrubicin 40mg/m^2 given as a 5 minute IV infusion on Days 1, 2 & 3 of a 21 day cycle
11562606|NCT00915070|Active Comparator|BQ-123|
11562607|NCT00915070|Placebo Comparator|Physiological saline solution|
11562608|NCT00915057|Experimental|NRL972|Single 2mg intravenous dose of NRL972, administered on up to seven occasions
11562609|NCT00915044||IBD patients|Approximately 40 patients (adults and children) suffering from IBD will be enrolled.
11562610|NCT00915044||Controls|Approximately 100 healthy controls
11562611|NCT00915031|Active Comparator|Hypothermia Only OR|Use of Hypothermia Cooling device only in the operating room. Intervention is Hypothermia Cooling Device.
11562612|NCT00915031|Active Comparator|Hypothermia in OR + Recovery|Use of hypothermia cooling device in the operating room and up to five hours after surgery is intervention.
11562613|NCT00915018|Experimental|neratinib plus paclitaxel|
11562614|NCT00915018|Active Comparator|trastuzumab plus paclitaxel|
11562615|NCT00915005|Experimental|Group 1|"Group 1: Photon Therapy - 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.
~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.
~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
11562616|NCT00915005|Experimental|Group 2|"Group 2: Proton Therapy - 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.
~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.
~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
11562617|NCT00915005|Experimental|Group 3|"Group 3: Receives either photon or proton therapy, whichever participant's doctor decides is better, for for 6-7 1/2 weeks.
~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.
~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
11562618|NCT00915005|Experimental|Group 4|"Photon Therapy - Highest practical dose (74 CGE, 66 CGE) radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.
~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.
~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
11562619|NCT00914979|Experimental|1|Single Arm - Interventional
11562620|NCT00914966|Experimental|CINRYZE|"There were 3 potential dose escalation steps:
~Step 1: 1500 Units of CINRYZE (C1 inhibitor [human]) administered by IV infusion twice per week for 12 weeks
~Step 2: 2000 Units of CINRYZE (C1 inhibitor [human]) administered by IV infusion twice per week for 12 weeks
~Step 3: 2500 Units of CINRYZE (C1 inhibitor [human]) administered by IV infusion twice per week for 12 weeks"
11562621|NCT00914953|Experimental|oxytocin|
11562673|NCT00914589|Experimental|FXIII35IU/Kg|Recombinant factor XIII at a single dose of 35 IU/kg lean body mass (LBM) was administered via slow i.v. push at a rate not exceeding two mL per minute.
11562674|NCT00914589|Placebo Comparator|Placebo|Recombinant factor XIII placebo was administered as a single dose via slow i.v. push at a rate not exceeding two mL per minute.
11562675|NCT00914576|Active Comparator|1|
11562676|NCT00914576|Placebo Comparator|2|
11562622|NCT00914940|Experimental|Arm 1|"CONDITIONING: Patients undergo total-body irradiation twice daily on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine IV over 30 minutes on days -6 to -2. TRANSPLANTATION: Patients undergo infusion of CD34+ enriched allogeneic peripheral blood stem cells (PBSC) followed by CD45RA+ T-cell-depleted allogeneic PBSC on day 0.
~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Cohort A: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -1 and continuing until day 50 followed by standard taper in the absence of grade II-IV acute GVHD. Cohort B: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -1 and continuing until day 30 followed by rapid taper in the absence of grade II-IV acute GVHD."
11562623|NCT00914927|Experimental|1|
11562624|NCT00914927|Experimental|2|
11562625|NCT00914927|Placebo Comparator|3|
11562626|NCT00914914|Experimental|p28 Phase I Safety|A total of 15 patients were administered p28 i.v. as a short infusion three times per week for 4 weeks followed by a 2-week rest under an accelerated titration 3þ3 dose escalation design.
11562627|NCT00914901|Other|Healthy|10 healthy men
11562628|NCT00914901|Other|Asthmatics|10 male asthmatic subjects
11562629|NCT00914901|Other|Elite athletes with asthma|10 male elite athletes with asthma
11562630|NCT00914888|Experimental|A|Tigecycline
11562631|NCT00914888|Active Comparator|B|Ceftriaxone regimen
11562632|NCT00914875||group tramadol plus ketorolac|
11562633|NCT00914875||group tramadol plus dypirone|
11562634|NCT00914862|Experimental|Children Ramelteon 4 mg|Children 6 to 11 years of age who had insomnia associated with ADHD received a single 4 mg oral dose of ramelteon.
11562635|NCT00914862|Experimental|Children Ramelteon 8 mg|Children 6 to 11 years of age who had insomnia associated with ADHD received a single oral 8 mg dose of ramelteon.
11562636|NCT00914862|Experimental|Adolescents Ramelteon 4 mg|Adolescents 12 to 17 years of age with insomnia received a single oral dose of 4 mg ramelteon.
11562637|NCT00914862|Experimental|Adolescents Ramelteon 8 mg|Adolescents 12 to 17 years of age with insomnia received a single oral dose of 8 mg ramelteon.
11562638|NCT00914862|Active Comparator|Healthy Adult Ramelteon 8 mg|Healthy adults (18 to 50 years old) received a single oral dose of 8 mg ramelteon.
11562639|NCT00914849|Experimental|Arm 1 - Donor|"Day 1
~AMD3100 320 ug/kg IV
~Leukopheresis
~Day 2 (if peripheral blood stem cell (PBSC) collected is not sufficient)
~AMD3100 320 ug/kg IV
~Leukopheresis"
11562640|NCT00914849|Experimental|Arm 2 - Recipient|"Standard of care and physician choice myeloablative or non-myeloablative chemotherapy with or without total body irradiation (permitted = cyclophosphamide and single dose total body irradiation (TBI) / fludarabine and busulfan / fractionated TBI and cyclophosphamide / fractionated TBI, etoposide, and cyclophosphamide / busulfan and cyclophosphamide / fludarabine, busulfan, and ATGAM
~Day 0 = Stem Cell Transplant"
11562641|NCT00914836|Active Comparator|1 cc - Betamethasone Sodium Phosphate|1 cc - Betamethasone Sodium Phosphate
11562642|NCT00914836|Active Comparator|2 cc - Betamethasone Sodium Phosphate|2 cc - Betamethasone Sodium Phosphate
11562643|NCT00914823|Experimental|kisspeptin, GnRH|intravenous or subcutaneous administration of kisspeptin 112-121 and/or administration of GnRH
11562644|NCT00914810|Experimental|Vitamin D|Cholecalciferol (2000 I.U. daily)
11562645|NCT00914810|Placebo Comparator|Placebo|Placebo capsule (sugar pill daily)
11562646|NCT00914797|Active Comparator|asthmatics|10 male asthmatic subjects
11562647|NCT00914797|Active Comparator|healthy|10 male healthy volunteers
11562648|NCT00914797|Active Comparator|elite athletes with asthma|10 elite athletes with asthma.
11562649|NCT00914771|Active Comparator|H5N1 pandemic Influenza vaccine 3.75µg|
11562650|NCT00914771|Active Comparator|H5N1 pandemic Influenza vaccine 7.5µg|
11562651|NCT00914758||MS patients on Campath®|This group is comprised of patients diagnosed with relapsing remitting multiple sclerosis who were assigned to the Campath® treatment arm of the Care-MS II trial, for which this study is a sub-study
11562652|NCT00914758||MS patients on Rebif®|This group is comprised of patients diagnosed with relapsing remitting multiple sclerosis who were assigned to the Rebif® treatment arm of the Care-MS II trial, for which this study is a sub-study
11562653|NCT00914758||Control group|This group is comprised of non-MS, non-CNS compromised control participants matched in age, education level, and socioeconomic status to the participants in the 2 MS treatment groups
11562654|NCT00914732|Experimental|Group B, liquid, subcutaneous|Group B: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (1x10^8 TCID50/0.5 mL per dose) liquid formulation by the subcutaneous route on Day 0 and 28.
11562655|NCT00914732|Experimental|Group C, liquid, intradermal|Group C: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (2x10^7 TCID50/0.1mL per dose) liquid formulation by the intradermal route on Day 0 and 28.
11562656|NCT00914732|Experimental|Group A, lyophilized, subcutaneous|Group A: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (1x10^8 TCID50/0.5 mL per dose) lyophilized formulation by the subcutaneous route on Day 0 and 28.
11562657|NCT00914719|Active Comparator|Information only|
11562658|NCT00914719|Active Comparator|sexual risk reduction intervention|
11562659|NCT00914719|Experimental|SRRI+ETOH|
11562660|NCT00914693|Experimental|Arm 1|
11562661|NCT00914680|Experimental|MST|
11562662|NCT00914667|Experimental|Warfarin Alone|Reference treatment
11562663|NCT00914667|Experimental|Warfarin Concomitantly With Fesoterodine|Test treatment
11562664|NCT00914654|Other|Healthty|10 healthy men
11562665|NCT00914654|Other|Asthmatics|10 male asthmatic subjects
11562666|NCT00914654|Other|Elite asthmatics|10 male elite athletes with asthma
11562667|NCT00914641|Other|Apixaban Cross-over|
11562668|NCT00914628|Experimental|A|HSV-TK engineering donor Lymphocytes
11562669|NCT00914628|Active Comparator|B|T-cell depleted or T-cell replete strategies
11562670|NCT00914615|Experimental|SBRT for liver mets from colorectal cancer|
11562671|NCT00914602|Experimental|Single Arm (Treatment Period A and B)|"Treatment Period A: Sinemet® 25-100 treatment
~Treatment Period B: Multiple-Dose XP21279 (with Lodosyn®) treatment"
11562672|NCT00914589|Experimental|FXIII17.5IU/Kg|Recombinant factor XIII at a single dose of 17.5 IU/kg lean body mass (LBM) was administered via slow i.v. push at a rate not exceeding two mL per minute.
11562832|NCT00913614|Experimental|Age Group 6-11 year old - Dose Level 3|
11562677|NCT00914563|Experimental|LIDCO|The extensively burnt patients (age range 18-75 years) with second and the third degree burns, with TBSA above 15%, with or without inhalation injury will be included to the study. We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. We will use in the LIDCO group the continuous real-time hemodynamic monitoring through transpulmonal lithium dilution additionally. The monitor Lithium Dilution Cardiac Output (LIDCO) Plus permits, through analysis of the arterial blood pressure trace, to acquire items about CO, SVR and DO2. In fluid resuscitation, we will use a combination of the balanced crystalloids and synthetic colloids (of the middle molecular weight) in the ratio 2 ml/kg/% TBSA: 1 ml/kg/% TBSA.
11562678|NCT00914563|No Intervention|Standard care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
11562679|NCT00914550||Procalcitonin level, caregiver informed|Procalcitonin level for patients with lung infiltrates:caregivers know/ do not know results
11562680|NCT00914537||1|Human immunodeficiency virus (HIV) positive adult men who have sex with men that are members of KPNC (Kaiser Permanente Northern California) and do not have a current anal cancer diagnosis.
11562681|NCT00914524|Experimental|Treatment|16 weeks of treatment starting with 5 mg of olmesartan medoxomil. If tolerated, the dose was increased to the next higher dose at weeks 4, 8, and 12.
11562682|NCT00914511|Experimental|Healthy young males|Healthy young males age 18-45, inclusive
11562683|NCT00914511|Experimental|Elderly males|Elderly males 65 years of age and older
11562684|NCT00914498|Experimental|Xylocaine|Participants will receive local injection of 20 ml 1% Xylocaine to the skin incision site
11562685|NCT00914498|Placebo Comparator|Controls|Participants will receive injection of 0.9% NaCl 20 ml to the incision site
11562686|NCT00914485|Other|Provider Communication Skills Training|Provider clinical communication training intervention
11562687|NCT00914472|Experimental|Test|Heparin - Hipolabor
11562688|NCT00914472|Active Comparator|Ative comparator|Heparin - APP
11562689|NCT00914459|Other|Moroctocog alfa (AF-CC)|Open Label
11562690|NCT00914446|Other|morbid obese subject|
11562691|NCT00914446|Other|overweight and NASH subjects|
11562692|NCT00914446|Other|control subjects|
11562693|NCT00914433|Experimental|TPI 1100|Drug to be given by inhalation.
11562694|NCT00914420|Experimental|Intrepide|Group A- Primary stenting with Intrepide trapidil eluting stent
11562695|NCT00914420|Experimental|Taxus|Group B Stenting with Taxus DES
11562696|NCT00914407|Experimental|Healthy subjects|
11562697|NCT00914394|Active Comparator|NG-monomethyl-L-arginine (L-NMMA)|
11562698|NCT00914394|Active Comparator|Phenylephrine|
11562699|NCT00914394|Placebo Comparator|Physiological saline solution|
11562700|NCT00914381|Active Comparator|CRA + CM|Community Reinforcement Approach (CRA) combined with Contingency Management (CM)
11562701|NCT00914381|Active Comparator|TSF + CM|Twelve-Step Facilitation (TSF) combined with Contingency Management (CM)
11562702|NCT00914381|Active Comparator|CRA + VC|Community Reinforcement Approach (CRA) combined with Voucher Control (VC)
11562703|NCT00914381|Active Comparator|TSF + VC|Twelve-Step Facilitation (TSF) combined with Voucher Control (VC)
11562704|NCT00914368|Active Comparator|1|Patients with previously experienced stent thrombosis while on dual antiplatelet treatment within 6 months after coronary stenting for coronary artery disease
11562705|NCT00914368|Active Comparator|2|Patients with previously experienced myocardial infarction while on dual antiplatelet treatment within 6 months after coronary stenting for coronary artery disease
11562706|NCT00914368|Active Comparator|3|Patients without previously experienced myocardial infarction or stent thrombosis 6 within months after coronary stenting for coronary artery disease(matched controls for group 1 and 2)
11562707|NCT00914355|Experimental|SBRT for Hepatocellular Carcinoma|
11562708|NCT00914342||Upper-GI symptoms in primary-care patients|
11562709|NCT00914329|Experimental|Gelsemium 5CH|Globules of Gelsemium sempervirens 5CH
11562710|NCT00914329|Experimental|Gelsemium 15CH|Globules of Gelsemium Sempervirens 15CH
11562711|NCT00914329|Placebo Comparator|Placebo|Globules of placebo
11562712|NCT00914316|Active Comparator|Phase 1-Ranolazine, Phase 2-Ranolazine|This group will participate in the Phase 1 -12 week supervised exercise program and will additionally receive ranolazine 1000 mg orally, twice daily, by mouth. In Phase 2, the group will exercise independently and also receive ranolazine 1000 mg orally twice daily by mouth.
11562713|NCT00914316|Active Comparator|Phase 1 -Ranolazine, Phase 2 -Placebo|This group will participate in the Phase 1 -12 week supervised exercise program and will additionally receive ranolazine 1000 mg orally, twice daily, by mouth. In Phase 2, the group will exercise independently and will receive a sugar pill in place of the study drug.
11562714|NCT00914316|Active Comparator|Phase 1 -Placebo, Phase 2 -Ranolazine|This group will participate in the Phase 1 -12 week supervised exercise regimen and will receive a sugar pill in place of the study drug. In Phase 2, the group will exercise independently and also receive ranolazine 1000 mg orally twice daily by mouth.
11562715|NCT00914316|Placebo Comparator|Phase 1 -Placebo, Phase 2 -Placebo|This group will participate in the Phase 1 -12 week supervised exercise regimen and will receive a sugar pill in place of the study drug. In Phase 2, the group will exercise independently and will receive a sugar pill in place of the study drug.
11562716|NCT00914303|Experimental|AZD3241|AZD3241 Tablets
11562717|NCT00914303|Experimental|Placebo|Placebo Tablets
11562718|NCT00914290|Other|IPX056-Baclofen IR-IPX056|Following 2 weeks of run-in period, subjects were randomized to IPX056 and Placebo IR for 2 weeks and then to Baclofen IR and Placebo IPX056 for 2 weeks.
11562719|NCT00914290|Active Comparator|IPX056-IPX056-Baclofen IR|Following 2 weeks of run-in period, subjects were randomized to Baclofen IR and Placebo IPX056 for 2 weeks and then to IPX056 and Placebo IR for 2 weeks.
11562720|NCT00914277|Experimental|Sequence 1|"Period 1: placebo
~Period 2: sildenafil
~Period 3: SAR407899 dose level 2
~Period 4: SAR407899 dose level 1"
11562721|NCT00914277|Experimental|Sequence 2|"Period 1: sildenafil
~Period 2: SAR407899 dose level 1
~Period 3: placebo
~Period 4: SAR407899 dose level 2"
11562833|NCT00913614|Experimental|Age Group 12-17 year old - Dose level 1|
11562722|NCT00914277|Experimental|Sequence 3|"Period 1: SAR407899 dose level 1
~Period 2: SAR407899 dose level 2
~Period 3: sildenafil
~Period 4: placebo"
11562723|NCT00914277|Experimental|Sequence 4|"Period 1: SAR407899 dose level 2
~Period 2: placebo
~Period 3: SAR407899 dose level 1
~Period 4: sildenafil"
11562724|NCT00914264||COPD with OSA with CPAP treatment|COPD with OSA: CPAP treatment
11562725|NCT00914264||COPD without OSA|COPD without OSA, not treat with CPAP
11562726|NCT00914264||COPD with OSA but without CPAP treatment|COPD with OSA but patient refused CPAP treatment
11562727|NCT00914251|Active Comparator|Hesperidin, 500 mg per day|500 mg daily of oral Hesperidin for 3 weeks
11562728|NCT00914251|Placebo Comparator|Placebo|
11562729|NCT00914238|Experimental|5 year|5 years OPUS treatment
11562730|NCT00914238|Active Comparator|2 years of OPUS treatment|2 years OPUS treatment and 3 years of treatment as usual
11562731|NCT00914225||Intervention|Cohort 1 is the intervention group who received long-lasting insecticide treated bednets and a water filtration device
11562732|NCT00914225||Comparison|"Cohort 2 is the comparison group included from the control arm of the study, Empiric therapy of helminth coinfection to reduce HIV-1 disease progression ClinicalTrials.gov identifier: NCT00507221
~As part of the RCT (NCT00507221), we have enrolled 948 HIV infected ART naïve individuals to compare HIV disease progression in those receiving standard of care versus empiric deworming. Subjects are followed for 24 months and have serial measurements of HIV disease progression, and are evaluated serially for evidence of malaria, diarrhea and other co-morbidities. Participants in this study will have been consented for the collection of data on the frequency of malaria and diarrheal disease, their use of a bednet and water filtration and their compliance with TMP/SMX."
11562733|NCT00914212|Active Comparator|1|Sibutramine
11562734|NCT00914212|Placebo Comparator|2|Placebo
11562735|NCT00914199|Experimental|Kissing balloon post-dilatation|Percutaneous coronary intervention with implantation of stent using kissing balloon dilatation
11562736|NCT00914199|Experimental|No kissing balloon post-dilatation|Percutaneous coronary intervention with implantation of stent and not using kissing balloon postdilatation
11562737|NCT00914186|Placebo Comparator|Vehicle|
11562738|NCT00914186|Experimental|TS-022 0.005% lotion|
11562739|NCT00914186|Experimental|TS-022 0.010% lotion|
11562740|NCT00914186|Experimental|TS-022 0.020% lotion|
11562741|NCT00914173|Experimental|Pain/No Pain Stimuli|One Arm is used in this trial. The comparator is within the arm. The different types of stimuli levels and types are compared.
11562742|NCT00914160|Experimental|1|Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)
11562743|NCT00914160|Experimental|2|Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)
11562744|NCT00914160|Active Comparator|3|Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
11562745|NCT00914147|Other|Pulmonary Function Test (PFT)|After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization. PFT measurements will be reported as absolute values (e.g. liters) and percentage of predicted. The predicted normal values will be calculated according to sex, age, height and race using the Third National Health and Nutrition Examination Survey (NHANES III) reference equation. Predicted values for diffusion capacity will be calculated using the Morris/Polgar equation. DLCO values will be adjusted to anemia (hemoglobin levels)
11562746|NCT00914134|Experimental|Levodopa Infusion|Patients with advanced Parkinson's disease and motor fluctuations that cannot be adequately controlled with oral medication.
11562747|NCT00914121|Experimental|1|SKI-606 alone
11562748|NCT00914121|Placebo Comparator|2|Placebo
11562749|NCT00914121|Active Comparator|3|Moxifloxacin
11562750|NCT00914121|Experimental|4|SKI-606 plus ketoconazole
11562751|NCT00914121|Placebo Comparator|5|Placebo plus ketoconazole
11562752|NCT00914095|Active Comparator|methylphenidate|methylphenidate 10 mg tablets (1 mg /kg /day) 3 time a day
11562753|NCT00914095|Placebo Comparator|placebo|tablets of placebo 3 time a day
11562754|NCT00914082|Experimental|antenatal classes in self hypnosis|3 antenatal classes in self hypnosis. 3 audio compact discs for homework in self hypnosis and 1 audio compact disc for birth
11562755|NCT00914082|Active Comparator|relaxation and awareness|3 antenatal classes including training in relaxation methods and mindfulness.3 audio compact discs for homework and 1 for birth.
11562756|NCT00914082|Other|Control|Only receive ordinary antenatal care and no additional interventions
11562757|NCT00914069|Experimental|RIVS vascular access|RIVS vascular access
11562758|NCT00914069|Active Comparator|Conventional vascular access|Conventional vascular access
11562759|NCT00914056|Experimental|Lactulose withdrawal|Patients who were started on lactulose as a result of a precipitated HE episode underwent analysis while they were on lactulose; after this they underwent a controlled lactulose withdrawal with 3 visits post-withdrawal at 2 days, 14 days and 30 days after lactulose withdrawal
11562760|NCT00914030||A1|Patients with schizophrenia
11562761|NCT00914030||A2|Control subjects matched individually with patients with schizophrenia
11562762|NCT00914030||B1|Adult subjects with autism
11562763|NCT00914030||B2|Control subjects matched individually with adult subjects with autism
11562764|NCT00914030||C1|Children with autism
11562765|NCT00914030||C2|Control subjects matched individually with children with autism
11562766|NCT00914017|Experimental|Atorvastatin|40 mg of Lipitor (atorvastatin) daily for 1 year
11562767|NCT00914017|Placebo Comparator|Sugar Pill|Sugar pill daily for 1 year
11562768|NCT00914004|Experimental|1|Desipramine HCl 50 mg Tablets Cord Laboratories
11562769|NCT00914004|Active Comparator|2|Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc
11562770|NCT00913991|Experimental|Stress Management #1|8 weeks of individual stress management training sessions
11562771|NCT00913991|Active Comparator|Stress Management #2|8 weeks of individual stress management training sessions
11562772|NCT00913978|Active Comparator|Group 1: VitaHeat|Patients in group one will be warmed perioperatively with the VitaHeat mattress and IV fluid warmers once they are in the operating room.
11562834|NCT00913614|Experimental|Age Group 12-17 year old - Dose level 2|
11562773|NCT00913978|Active Comparator|Group 2: Bair Hugger|Patients in group two will be warmed perioperatively with the upper body bair hugger and IV fluid warmers once they are in the operating room.
11562774|NCT00913965|Experimental|1|Atenolol Tablets 100 mg (Cord Laboratories)
11562775|NCT00913965|Active Comparator|2|Atenolol Tablets 100 mg (Stuart Pharmaceutical)
11562776|NCT00913952|Experimental|1|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions.
11562777|NCT00913952|Experimental|2|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.
11562778|NCT00913952|Active Comparator|3|Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.
11562779|NCT00913939|Active Comparator|1: Salvage After EBRT|Patients with locally recurrent prostate cancer after radiotherapy will receive tumor-targeted salvage HDR brachytherapy. Arm 1 of the study will be coordinated and closely integrated with a separate concurrent study of MRI-guided prostate biopsy, which will be performed prior to accrual to Arm 1 of this trial (UHN 05-0641-C).
11562780|NCT00913939|Active Comparator|2: Boost to EBRT|Patients with locally advanced prostate cancer will receive a boost of prostate-targeted HDR brachytherapy during external beam radiotherapy.
11562781|NCT00913926||Group 1|
11562782|NCT00913913|Experimental|bevacizumab,IL-2, IFN, DC vaccine|Patients will be dosed with bevacizumab (10mg/kg) intravenously every two weeks beginning four weeks prior to the first vaccine. Each treatment week includes ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of continuous intravenous infusion of IL-2 (18 MiU/m2), and three subcutaneous injections of IFNa-2b (6 MiU) (every other day)
11562783|NCT00913900|Active Comparator|Autologous Stem cells (CD133+)|Intramuscular injection
11562784|NCT00913900|Placebo Comparator|Control|Intramuscular Injection
11562785|NCT00913887|Experimental|1|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)
11562786|NCT00913887|Experimental|2|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)
11562787|NCT00913887|Active Comparator|3|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
11562788|NCT00913874|Experimental|1|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
11562789|NCT00913874|Active Comparator|2|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
11562790|NCT00913861|Active Comparator|standard sedation|propofol and fentanyl
11562791|NCT00913861|Active Comparator|structured attention-standard sedation|structured attention
11562792|NCT00913861|Experimental|hypnosis-standard sedation|hypnosis
11562793|NCT00913848|Experimental|1|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
11562794|NCT00913848|Active Comparator|2|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
11562795|NCT00913835|Experimental|Olaratumab and Liposomal Doxorubicin|Olaratumab and Liposomal Doxorubicin
11562796|NCT00913835|Active Comparator|Liposomal Doxorubicin: Optional Olaratumab Monotherapy|Liposomal Doxorubicin Monotherapy until disease progression. Upon disease progression the participant had the option to receive Olaratumab monotherapy.
11562797|NCT00913822|Experimental|1|Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)
11562798|NCT00913822|Active Comparator|2|Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)
11562799|NCT00913809|Experimental|1|Desipramine HCL 100 mg Tablets Cord Laboratories
11562800|NCT00913809|Active Comparator|2|Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc
11562801|NCT00913796|Experimental|Postassium citrate|Aim: correction of metabolic acidosis
11562802|NCT00913796|Active Comparator|Potassium chloride|Potassium chloride is given to compensate for any possible effects of potassium in potassium citrate (primary treatment).
11562803|NCT00913783|Experimental|1|Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)
11562804|NCT00913783|Active Comparator|2|Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)
11562805|NCT00913770|No Intervention|SC|Standard Care
11562806|NCT00913770|Experimental|SBIRT|Screening, Brief Intervention and Facilitated Referral to Treatment
11562807|NCT00913770|Experimental|SBI+Bup|Screening, Brief Intervention and Buprenorphine initiation
11562808|NCT00913757||Group 1|400 patients with primary HCC (Hepatocellular carcinoma)
11562809|NCT00913757||Group 2|800 patients with chronic liver disease (high risk non-cancer cases)
11562810|NCT00913757||Group 3|800 population-based controls, identified through a OMV database that will match cases by age, gender, race, and county of residency
11562811|NCT00913744|Experimental|Ocriplasmin|
11562812|NCT00913744|Sham Comparator|Sham injection|
11562813|NCT00913731||psychotic patients|psychotic patients, acute ward, symptom rating scale.
11562814|NCT00913718|Experimental|1|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)
11562815|NCT00913718|Active Comparator|2|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
11562816|NCT00913705|Experimental|1|The patients will be randomized to receive taxol (Paclitaxel) and carboplatin as adjuvant or as neoadjuvant regimen or to surgery alone
11562817|NCT00913679|Active Comparator|Posterior approach|Posterior surgical approach in hip resurfacing arthroplasty
11562818|NCT00913679|Active Comparator|Anterolateral approach|Anterolateral surgical approach in hip resurfacing arthroplasty
11562819|NCT00913666|No Intervention|Group 1|Healthy Volunteers
11562820|NCT00913666|Experimental|Group 2|MS patients previously naïve to interferon therapy
11562821|NCT00913666|Experimental|Group 3|MS patients on Interferon beta-1a treatment with no history of breakthrough disease (clinically stable)
11562822|NCT00913666|Experimental|Group 4|MS patients on interferon beta-1a treatment with a history of breakthrough disease.
11562823|NCT00913653|Experimental|Stable heart failure patients|
11562824|NCT00913640||PD Group|
11562825|NCT00913640||Control Group|
11562826|NCT00913627|Experimental|1|1 x 600 mg ibuprofen IR/ER-roller compaction caplet
11562827|NCT00913627|Experimental|2|1 x 600 mg ibuprofen IR/ER-Wet granulation caplet
11562828|NCT00913627|Active Comparator|3|1x 220 mg naproxen sodium (Aleve caplet)
11562829|NCT00913627|Placebo Comparator|4|1 x placebo caplet
11562830|NCT00913614|Experimental|Age Group 6-11 year old - Dose level 1|
11562831|NCT00913614|Experimental|Age Group 6-11 year old - Dose Level 2|
11562836|NCT00913601|Experimental|Dextra|Unilateral sacral nerve stimulation dextra for 4 weeks
11562837|NCT00913601|Experimental|Sinistra|Unilateral sacral nerve stimulation sinistra 4 weeks
11562838|NCT00913601|Experimental|Bilateral|Bilateral sacral nerve stimulation 4 weeks
11562839|NCT00913588|Experimental|1|Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)
11562840|NCT00913588|Experimental|2|Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)
11562841|NCT00913588|Active Comparator|3|Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)
11562842|NCT00913575|Experimental|preoperative neuromuscular training|preoperative neuromuscular training
11562843|NCT00913575|Placebo Comparator|education|knee school
11562844|NCT00913562|Active Comparator|Patients with diabetes|Rosuvastatin
11562845|NCT00913562|Active Comparator|Patients with glaucoma|Rosuvastatin
11562846|NCT00913562|Placebo Comparator|Control patients with diabetes|Placebo
11562847|NCT00913562|Placebo Comparator|Control patients with glaucoma|Placebo
11562848|NCT00913549|Experimental|1|Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)
11562849|NCT00913549|Experimental|2|Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)
11562850|NCT00913536|Experimental|Cone beam CT in Bladder Cancer|
11562851|NCT00913523|Experimental|Tampon with GML|Regular and Super Tampon with GML added to the cover
11562852|NCT00913523|Sham Comparator|Tampon without GML|Regular and Super Tampon without GML
11562853|NCT00913523|Sham Comparator|Tampon Normally Used|Type and Size of Tampon Normally Used by Subjects
11562854|NCT00913510|Experimental|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
11562855|NCT00913510|Active Comparator|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, i.e. Drug.
11562856|NCT00913497|Active Comparator|insulin glulisine|
11562857|NCT00913497|Active Comparator|insulin aspart|
11562858|NCT00913484|Experimental|Disulfiram|Disulfiram 250 mg per day
11562859|NCT00913484|Placebo Comparator|Placebo|Placebo
11562860|NCT00913471||Acute-Longitudinal SCI|
11562861|NCT00913471||Chronic SCI|
11562862|NCT00913471||Healthy volunteers|
11562863|NCT00913458|Experimental|1|etanercept + methotrexate; etanercept + methotrexate
11562864|NCT00913445|Active Comparator|surgery, absorbable stitches|wound healing after absorbable and nonabsorbable stitches are compared
11562865|NCT00913445|Active Comparator|surgery, nonabsorbable stitches|
11562866|NCT00913432|Experimental|masitinib 3 mg|masitinib 3 mg/kg/day
11562867|NCT00913432|Experimental|masitinib 6 mg|masitinib 6 mg/kg/day
11562868|NCT00913419|Experimental|1|Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories
11562869|NCT00913419|Active Comparator|2|Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme
11562870|NCT00913406|Experimental|1|Experimental=Standard formula with lutein added to the formula
11562871|NCT00913406|Active Comparator|2|Active Comparator=Standard formula
11562872|NCT00913393|Placebo Comparator|1|Placebo IV
11562873|NCT00913393|Experimental|2|3 mg/kg FG-3019 IV
11562874|NCT00913393|Experimental|3|10 mg/kg FG-3019 IV
11562875|NCT00913380|Experimental|Low-dose CT|
11562876|NCT00913380|Active Comparator|Standard-dose CT|
11562877|NCT00913367|Active Comparator|Amaryl group|
11562878|NCT00913367|Experimental|Amaryl M group|
11562879|NCT00913354|Experimental|1|30 minutes of acupuncture just before and just after embryo replacement
11562880|NCT00913354|Placebo Comparator|2|Sham acupuncture for 30 minutes just before and just after embryo transfer
11562881|NCT00913341|Experimental|1|Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
11562882|NCT00913341|Active Comparator|2|Alprazolam Tablets, 1 mg (The Upjohn Company)
11562883|NCT00913328|Active Comparator|Montelukast|Oral montelukast 10 mg once daily for 12 weeks
11562884|NCT00913328|Placebo Comparator|Placebo|Oral placebo once daily for 12 weeks
11562885|NCT00913315|Experimental|tolterodine + tamsulosin|
11562886|NCT00913315|Active Comparator|tamsulosin + placebo|
11562887|NCT00913302|Experimental|Training|cardiovascular training
11562888|NCT00913289|Other|adipose tissue derived stromal cells|
11562889|NCT00913276|Other|Sevoflurane anesthesia|
11562890|NCT00913276|Other|Propofol anesthesia|
11562891|NCT00913263|Experimental|2-Hydroxyflutamide|Single injection of 2-Hydroxyflutamide (2-8mL ready-made paste)in one prostate lobe
11562892|NCT00913250|Experimental|Sequence 1|Serum containing Avonex followed by serum free Avonex
11562893|NCT00913250|Experimental|Sequence 2|Serum free Avonex followed by serum containing Avonex
11562894|NCT00913237|Experimental|1|Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)
11562895|NCT00913237|Active Comparator|2|Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)
11562896|NCT00913224|Experimental|1|Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)
11562897|NCT00913224|Active Comparator|2|Voltaren 50 mg Tablets (Geigy Pharmaceuticals)
11562898|NCT00913211|Experimental|rTMS only|brain stimulation to non-stroke primary motor area
11562899|NCT00913211|Experimental|Finger tracking training|Motor learning training using finger flexion/extension tracking movements toward a target.
11562900|NCT00913211|Experimental|rTMS and finger tracking|Combination of rTMS and tracking
11562901|NCT00913211|Placebo Comparator|Sham|Sham rTMS treatment
11562902|NCT00913198|Experimental|IV CP-4126|
11562903|NCT00913172||Intervention group|Directly Observed Treatment under Health Extension Workers
11562904|NCT00913172||Control group|Directly observed treatment under general health workers
11562905|NCT00913159|Active Comparator|Using HM3 lithotripter|This is an older generation lithotripter
11562906|NCT00913159|Active Comparator|F2 lithotripter|This is a newer generation lithotripter
11562907|NCT00913146||index|child with fever and a negative malaria RDT
11562908|NCT00913146||control|apparently healthy child with a negative RDT
11562909|NCT00913133|Experimental|Desirudin|desirudin 15 mg twice daily for a minimum of 5 days
11562910|NCT00913120|Experimental|YM150 group-1|YM150 low dose group
11562911|NCT00913120|Experimental|YM150 group-2|YM150 high dose group
11562912|NCT00913120|Placebo Comparator|Placebo group|
11562913|NCT00913120|Active Comparator|Enoxaparin group|
11562914|NCT00913107|Experimental|Lamictal®|"Lamictal® was used as the active medication in this study."
11562915|NCT00913107|Active Comparator|Tegretol®|"Tegretol® was employed as the control for comparative purposes in order to check and evaluate the efficacy (pain-relief) and occurrence of side- effects of Lamictal®."
11562916|NCT00913094||ICG|Group will have results blinded during observational phase of study. Results will be revealed at time of testing during the validation phase of the study.
11562917|NCT00913081|Experimental|Quercetin 500 mg|Quercetin 500 mg once, administered one hour before 500 mg immediate-release niacin
11562918|NCT00913081|Experimental|Quercetin 1000 mg|Quercetin 1000 mg once, administered one hour before 500 mg immediate-release niacin
11562919|NCT00913081|Experimental|Quercetin 2000 mg|Quercetin 2000 mg once, administered one hour before 500 mg immediate-release niacin
11562920|NCT00913081|Placebo Comparator|Placebo|Placebo once, administered one hour before 500 mg immediate-release niacin
11562921|NCT00913068|Experimental|TAP arm|in the experimental arm, the procedure will consist of the staff urologist injecting local anesthetic into the anterior abdominal wall bilaterally from the inside of the abdomen at the end of their surgery
11562922|NCT00913068|Active Comparator|standard post operative pain control|Our current post operative analgesic strategy involves a multi-modal approach, using local injectable anesthetic around the incision and systemic medications (i.e. non-steroidal anti-inflammatories, acetaminophen and break-through doses of opiates). Some of the more common adverse reactions are reparatory depression, sedation, confusion, delirium, nausea, pruritis, constipation, hypotension and bradycardia. Often it is these resulting side effects that extend the length of in hospital rehabilitation, and decrease a patient's overall satisfaction.
11562923|NCT00913055|Experimental|One hydrated 84mg Octreotide implant|hydrated implant
11562924|NCT00913055|Experimental|One non-hydrated 84mg Octreotide implant|
11562925|NCT00913042||1|febrile neutropenia patient
11562926|NCT00913029|Active Comparator|Stent|One hundred patients will be randomized to implantation of two G2 stents in at least one eye.
11562927|NCT00913029|Active Comparator|Medication|One hundred patients will be randomized to receive a fixed combination ocular hypotensive medication.
11562928|NCT00913016||letrozole (Femara)|
11562929|NCT00913003|Placebo Comparator|Placebo|Group B using saline as a placebo.
11562930|NCT00913003|Active Comparator|Lidocaine|Group A lidocaine infusion and bolus.
11562931|NCT00912990|Placebo Comparator|Normal saline|Normal saline volume calculated to be equal to the volume of cisatracurium 0.2mg/kg
11562932|NCT00912990|Active Comparator|Cisatracurium|Subjects in this arm will be given Cisatracurium 0.2mg/kg IV dose one time prior to intubation.
11562933|NCT00912977||Group 1|Groups are defined by another study
11562934|NCT00912977||Group 2|Groups are defined by another study
11562935|NCT00912977||Group 3|Groups are defined by another study
11562936|NCT00912964|Placebo Comparator|Placebo|Participants received matching mirabegron placebo tablets orally once a day for 12 weeks.
11562937|NCT00912964|Experimental|Mirabegron 25 mg|Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.
11562938|NCT00912964|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.
11562939|NCT00912938|Experimental|Zoledronic acid|Patients with advanced breast cancer with radiographic confirmation of bone metastases. This arm will be receiving zoledronic acid administration. The primary endpoint is to find the correlation between bone turnover markers and the frequency of skeletal-related-events for one year. Skeletal related events are defined as pathologic fractures, the need for radiation therapy, orthopaedic surgery, hypercalcemia of malignancy and spinal cord compression. A total of 237 patients will be included.
11562940|NCT00912925|Placebo Comparator|Placebo|Patients in the placebo-control group were administered a solution of 100 millimolar (mM) sodium phosphate, 150 mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over approximately 4 hours once weekly for 26 weeks.
11562941|NCT00912925|Active Comparator|Aldurazyme treatment|Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 Units/kg (approximately 0.58 mg/kg = labeled dose) administered intravenously over approximately 4 hours once weekly for 26 weeks.
11562942|NCT00912912|Experimental|Sunitinib Malate|Sunitinib Malate 50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
11562943|NCT00912899|Experimental|One|Noscapine HCl
11562944|NCT00912886||1: Case|Patients with early and moderate AD
11562945|NCT00912886||2: Controls|AD free volunteer-controls matched for gender and age
11562946|NCT00912873|Active Comparator|1. 0.1% Ropivicaine|Patients will be given 0.1% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.
11562947|NCT00912873|Experimental|2. 0.4% Ropivicaine|Patients will be given 0.4% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.
11562948|NCT00912860|Experimental|1|serum-free avonex given IM
11562949|NCT00912847||JHC|AFP > 20 ng/ml and USG positive
11562950|NCT00912847||Non JHC|patient without AFP > 20 or USG negative
11562951|NCT00912834||1|tract and field athletes
11562952|NCT00912834||2|swimming athletes
11562953|NCT00912834||3|tennis athletes
11562954|NCT00912834||4|football athletes
11562955|NCT00912834||5|basketball athletes
11562956|NCT00912834||6|Badminton athletes
11562957|NCT00912834||7|control group
11562958|NCT00912821|Active Comparator|8 L dialysate|8 L peritoneal dialysis solution
11562959|NCT00912821|Experimental|6 L dialysate|6 L peritoneal dialysis solution
11562960|NCT00912808|Experimental|Donepezil|
11562962|NCT00912795|Experimental|SMS Turkey|6-week smoking cessation program delivered via daily text messages
11562963|NCT00912795|No Intervention|Brochure control|7-page brochure that provided general information and tips on how to quit smoking
11562964|NCT00912782|Placebo Comparator|Placebo|Placebo one time per week for 3 weeks
11562965|NCT00912782|Experimental|Cholecalciferol|Vitamin D 200,000 IU per week for 3 weeks
11562966|NCT00912769||subvastus approach/ midvastus approach|subvastus: vastus medialis oblique was not cut during operation midvastus: vastus medialis oblique was cut during operation
11562967|NCT00912769||Cybex|Knee extension/ flexion isometric and isokinetic performance of all cases were tested using Cybex
11562968|NCT00912756|Experimental|1cilostazol|Cilostazol group: Treatment with cilostazol 200 mg/day BID (morning and evening) and aspirin at 100 mg/day will be started 3 to 7 days prior to EVT and continued until the end of the 2-year follow-up period.
11562969|NCT00912756|Active Comparator|2aspirin|Non-cilostazol group: Treatment with aspirin 100 mg/day will be started 3 to 7 days prior to EVT and continued until the end of the 2-year follow-up period.
11562970|NCT00912743|Experimental|1|MSI - H arm
11562971|NCT00912717||Pancreatic Cancer|individuals who have been diagnosed with pancreatic cancer
11562972|NCT00912717||Unaffected|individuals who have not been diagnosed with pancreatic cancer
11562973|NCT00912691|Experimental|1|CM-AT
11562974|NCT00912678|Active Comparator|MMF and Steroid Group|Group of Patients randomized to MMF and Steroid maintenance immunosuppression after 3 months (Tacrolimus withdrawal)
11562975|NCT00912678|Active Comparator|Low-Dose Tacrolimus Group|Patients randomized to withdrawal of MMF after 3 months and maintenance immunosuppression with low-dose tacrolimus and Steroids
11562976|NCT00912665|Experimental|Healthy Volunteer|
11562977|NCT00912652|Experimental|High Intensity Lifestyle Intervention|High intensity group will receive 48 sessions of lifestyle intervention over a two-year period
11562978|NCT00912652|Experimental|Mod. Intensity Lifestyle Intervention|Moderate intensity group will receive 32 sessions of lifestyle intervention over a two-year period.
11562979|NCT00912652|Experimental|Low Intensity Lifestyle Intervention|Low intensity group will receive 16 sessions of lifestyle intervention over a two-year period.
11562980|NCT00912652|Active Comparator|Health Education Control|Health education control group will receive 16 sessions of health education related to diet and exercise over a two-year period.
11562981|NCT00912639|Experimental|Genexol-PM|"All the patients are recurrent breast cancer after taxane treatment. Patients with a measurable lesion (at least 1 measurable lesion)
~Spiral CT : lesion ≥ 10mm (unidimension)
~X-ray, MRI, ultrasound : lesion ≥ 20 mm (unidimension)"
11562982|NCT00912626|Experimental|FU-1 feedback|
11562983|NCT00912626|No Intervention|control group|
11562984|NCT00912613|No Intervention|Discussion with nurse|Brief discussion with ICU follow-up nurse about the patients' critical illness
11562985|NCT00912613|Experimental|ICU Diary|Receipt of ICU Diary at 1 month post critical illness
11562986|NCT00912600||1|Elderly individuals presenting to one of 15 emergency departments and possibly qualifying for admission to an ICU
11562987|NCT00912574|Active Comparator|Saline|first of 4 arms: injection: 1 ml saline
11562988|NCT00912574|Active Comparator|GM-CSF|Second of 4 arms: injection: specified dose of GM-CSF in 1 ml saline
11562989|NCT00912574|Active Comparator|0.5 ml Montanide ISA-51 adjuvant and 0.5 ml saline|Third of 4 arms: injection: 0.5 ml Montanide ISA-51 adjuvant and 0.5 ml saline
11562990|NCT00912574|Active Comparator|GM-CSF in 0.5 ml slaine plus 0.5 ml Montanide ISA-51 adjuvant|Fourth of 4 arms: injection: specified dose of GM-CSF in 0.5 ml slaine plus 0.5 ml Montanide ISA-51 adjuvant
11562991|NCT00912561|No Intervention|Sedentary|patients who train after an 8 week observational period
11562992|NCT00912561|Active Comparator|patients who train immediately after enrollment|patients who train immediately after enrollment
11562993|NCT00912548|Experimental|TAM+OFS(E) group|"Patients should be premenopausal women ,prior to the start of chemotherapy, less than or equal to 45 years of age with oestrogen receptor positive ± progesterone receptor positive who have undergone a primary mass excision, received an neo-/adjuvant chemotherapy ± radiotherapy for their stage I, II or III breast cancer. This arm is ovarian suppression group which have a various starting time of ovarian function suppression after neo-/adjuvant chemotherapy.
~Ovarian function suppression will be done by administration of LHRH agonist (ZOLADEXTM) for 2 years. After that, the patients will complete taking tamoxifen 20mg/day for 5 years."
11562994|NCT00912548|Active Comparator|TAM(D) group|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 0, 6, 12, 18 and 24 months since the baseline asTsessment(0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized into the additional ovarian function suppression group or tamoxifen only group. The latter will complete taking tamoxifen 20mg/day for 5 years.
11562995|NCT00912548|No Intervention|Permanent postmenopausal(A) group|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. Eligible patients except for premenopausal status at the baseline will be followed up until 2 years after the baseline assessment for evaluating the menopausal status. This group still remains to postmenopausal status and will taking tamoxifen 20mg/day for 5 years if they remain in the study.
11562996|NCT00912548|Active Comparator|TAM(B)|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 6, 12, 18 and 24 months since the baseline assessment (0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized into the additional ovarian function suppression group or tamoxifen only group. This group, patients are premenopausal women, they will be randomized into tamoxifen only group, complete taking tamoxifen 20mg/day for 5 years.
11563053|NCT00912171|Active Comparator|Nasal steroid + anti-leukotrienes|
11563054|NCT00912158|Active Comparator|CPAP + ST|Continuous positive airway pressure (CPAP) and Standard medical therapy (ST)
11562997|NCT00912548|Experimental|TAM+OFS (C)|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 6, 12, 18 and 24 months since the baseline assessment (0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized. This group, patients are premenopausal women, they will be randomized into the additional ovarian function suppression group. Ovarian function suppression will be done by administration of LHRH agonist (ZOLADEXTM) for 2 years. Then, Patients will complete taking tamoxifen 20mg/day for 5 years.
11562998|NCT00912535|Active Comparator|Quetiapine extended release tablet|Quetiapine orally at a flexible dose fo 50-300mg/day according to the judgment by the investigator for 8 weeks, as adjunct to the same antidepressant at the same dose.
11562999|NCT00912535|Placebo Comparator|Placebo|Placebo orally, as adjunct to the same antidepressant at the same dose.
11563000|NCT00912522|Active Comparator|LT PFC HIGH FREQ TMS|
11563001|NCT00912522|Active Comparator|LT PFC LOW FREQ TMS|
11563002|NCT00912522|Active Comparator|RT PFC HIGH FREQ TMS|
11563003|NCT00912522|Active Comparator|RT PFC LOW FREQ TMS|
11563004|NCT00912522|Sham Comparator|SHAM STIMULATION|
11563005|NCT00912509|Active Comparator|30 minute light duration|30 minute treatment with UVX light
11563006|NCT00912509|Active Comparator|45 minute light duration|45 minute treatment with UVX light
11563007|NCT00912496|Experimental|Group 9: 2 dose prime|Received two doses of A/Vietnam/1203/04 90mcg vaccine as prime (on Days 0, 28 in DMID 07-0019), will receive a booster dose of A/Anhui/05 vaccine (A) with or without MF59 adjuvant in DMID 08-0013 on Day 0.
11563008|NCT00912496|Experimental|Group 8: 1 dose prime|Received A/Vietnam/1203/04 90mcg vaccine as prime (Day 0 in DMID 07-0019), will receive a booster dose of A/Anhui/05 vaccine (A) with or without MF59 adjuvant in DMID 08-0013 on Day 0.
11563009|NCT00912496|Experimental|Group 10: unprimed control/dose response group|Unprimed control and dose response group of H5 vaccine naive volunteers will be added in DMID 08-0013 to receive two doses of A/Anhui/05 vaccine (A) with or without MF59 adjuvant or placebo on Day 0 and Day 28.
11563010|NCT00912483|Experimental|Test|Heparin Sodium 5.000UI/0.25mL
11563011|NCT00912483|Active Comparator|Ative comparator|Heparin Sodium 5.000USP/mL
11563012|NCT00912457|Experimental|Donepezil|Donepezil-treated sleep apnea patients
11563013|NCT00912457|Placebo Comparator|Placebo|Placebo-treated sleep apnea patients
11563014|NCT00912444|Experimental|TAC Arm|six cycles of neoadjuvant Docetaxel, Anthracycline and Cyclophosphamide
11563015|NCT00912444|Experimental|TC Arm|six cycles of neoadjuvant Docetaxel and Cyclophosphamide
11563016|NCT00912431|Experimental|1|
11563017|NCT00912431|Placebo Comparator|2|
11563018|NCT00912405|Experimental|Sinexus Intranasal Splint|Patient receives a drug-coated intranasal splint
11563019|NCT00912392|Experimental|Etoposide-Carboplatin with Endostar|Endostar® 7.5mg/m2 on day 1 to day 14, etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
11563020|NCT00912392|Active Comparator|Etoposide-Carboplatin|Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
11563021|NCT00912379||hemoglobin determination|ICU and emergency unit patients
11563022|NCT00912366||Group A|VATS
11563023|NCT00912366||Group B|Open Surgery
11563024|NCT00912353|Experimental|AZD7268|
11563025|NCT00912353|Placebo Comparator|Placebo|
11563026|NCT00912340|Experimental|Trastuzumab|Patients receive trastuzumab IV over 30 minutes once every 3 weeks and continue to receive their most recent hormone therapy. Patients achieving disease progression receive everolimus PO daily in combination with trastuzumab and hormone therapy.
11563027|NCT00912340|Experimental|Everolimus|Patients receive everolimus PO daily and continue their most recent hormone therapy. Patients achieving disease progression receive trastuzumab IV over 30-90 minutes once every 3 weeks in combination with everolimus and hormone therapy.
11563028|NCT00912340|Experimental|Trastuzumab and everolimus (ARM REMOVED)|Patients receive trastuzumab IV over 30 minutes once every 3 weeks and everolimus PO daily while continuing to receive their most recent hormone therapy.
11563029|NCT00912327||Stage 1|
11563030|NCT00912327||Stage 2|
11563031|NCT00912314|Active Comparator|Monthly Maintenance PTNS|After 12 weeks of PTNS, patients will be randomized to either the monthly PTNS arm, or the no maintenance PTNS arm.
11563032|NCT00912314|No Intervention|No maintenance PTNS|After 12 weeks of PTNS, patients will either be randomized to the Monthly PTNS arm or the No maintenance PTNS arm.
11563033|NCT00912301|Experimental|NaCDC 500 mg|Participants randomized to this arm received 500 mg NaCDC per day for 4 days.
11563034|NCT00912301|Experimental|NaCDC 1000 mg|Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.
11563035|NCT00912301|Placebo Comparator|Placebo|Participants randomized to this arm received a placebo capsule each day for 4 days.
11563036|NCT00912288|Experimental|Dimebon|
11563037|NCT00912288|Placebo Comparator|Placebo|
11563038|NCT00912275|Experimental|Lapatinib plus Oral Vinorelbine|Oral vinorelbine on day 1 and day 8 q3w plus lapatinib 1000mg/day.
11563039|NCT00912262|Active Comparator|Low and High Concentration Capsaicin Topical Liquids|
11563040|NCT00912249|Experimental|Horticultural Therapy|
11563041|NCT00912236||1|BMI 20-25 kg/m2
11563042|NCT00912236||2|BMI > 30 kg/m2 with low TG (<150) and normal HDL (>50 for females, >40 for males)
11563043|NCT00912236||3|BMI > 30 kg/m2 with high TG (>150) and low HDL (<50 for females, <40 for males)
11563044|NCT00912223|Experimental|Hematopoietic Stem Cell Transplant|Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
11563045|NCT00912210|Active Comparator|Higher protein|
11563046|NCT00912210|Placebo Comparator|Higher carbohydrate|
11563047|NCT00912197|Experimental|Oligofructose|
11563048|NCT00912197|Placebo Comparator|Cellulose and maltodextrin|
11563049|NCT00912184|Experimental|1|CVVH with high cut-off polyamide membrane (P2SH) using standard continuous veno-venous hemofiltration (CVVH) settings
11563050|NCT00912184|Active Comparator|2|CVVH using standard high flux membrane with standard CVVH settings
11563051|NCT00912171|Active Comparator|Nasal steroid|
11563055|NCT00912158|Active Comparator|BiPAP + ST|Bilevel positive airway pressure (BiPAP) and standard medical therapy (ST)
11563056|NCT00912158|Active Comparator|ST|Standard Medical therapy (ST)
11563057|NCT00912145|Experimental|1|Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)
11563058|NCT00912145|Active Comparator|2|Alprazolam Tablets, 2 mg, Xanax (The Upjohn Company)
11563059|NCT00912132||Low risk singleton cohort|Women with singleton gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2009-2013) in this prospective cohort study. A sub-set of women with and without gestational diabetes were followed up to 6 weeks postpartum. Enrollment was based upon a predefined set of criteria including medical/reproductive history and pre-pregnancy body mass index. Women with a body mass index between 19.0-29.9 kg/m2 were in the low-risk cohort.
11563060|NCT00912132||Obese cohort|Women with singleton gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2009-2013) in this prospective cohort study. A sub-set of women with and without gestational diabetes were followed up to 6 weeks postpartum. Enrollment was based upon a predefined set of criteria including medical/reproductive history and pre-pregnancy body mass index. Women with a body mass index between 30.0-44.9 kg/m2 were in the obese cohort.
11563061|NCT00912119|Experimental|Group A|Group A - Low Dose
11563062|NCT00912119|Experimental|Group B|Group B - Intermediate Dose
11563063|NCT00912119|Experimental|Group C|Group C - High Dose
11563064|NCT00912119|Experimental|Group D|Group D - Extra Low
11563065|NCT00912106||HA injection|Patients with osteoarthritis of knee. They are going to received HA injection 1 vial per week for 5 weeks.
11563066|NCT00912093|Placebo Comparator|Placebo|Single subcutaneous injection of matching placebo
11563067|NCT00912093|Experimental|Icatibant|Single subcutaneous injection of icatibant, 30 mg
11563068|NCT00912080|Experimental|good signature|"Patients who have a good signature for the genomic analysis. They will receive the standard chemotherapy."
11563069|NCT00912067||hematopoietic stem cell transplantation|
11563070|NCT00912054|Experimental|1|DuoTrav APS
11563071|NCT00912054|Active Comparator|2|Xalacom
11563072|NCT00912041|Other|BrainGate|BrainGate Neural Interface System
11563073|NCT00912028|Active Comparator|senofilcon A|contact lens
11563074|NCT00912028|Active Comparator|lotrafilcon B|contact lens
11563075|NCT00912028|Active Comparator|balafilcon A|contact lens
11563076|NCT00912028|Active Comparator|methafilcon A|contact lens
11563077|NCT00912028|Active Comparator|vifilcon A|contact lens
11563078|NCT00912015|Experimental|Tramadol OAD 200mg|
11563079|NCT00912015|Experimental|Tramadol OAD 300mg|
11563080|NCT00912015|Experimental|Tramadol OAD 400mg|
11563081|NCT00912015|Other|Tramadol OAD 100mg|Despite provision in the protocol that the minimum daily dose was 200 mg, 2 patients took 100 mg against instructions.
11563082|NCT00912002|Experimental|MK-0941|MK-0941
11563083|NCT00911989|Other|Transvaginal Sleeve Gastrectomy|Transvaginal Sleeve Gastrectomy using Steerable Flex Trocar (SFT) for transvaginal endoscope placement (endoscopic visualization)
11563084|NCT00911976|Experimental|Xience V|Implantation of the Xience V stent in saphenous vein graft lesions
11563085|NCT00911963|Experimental|Part A|This will be a 4 dose escalation study comparing VCH-222 to placebo treatment.
11563086|NCT00911963|Experimental|Part B|VCH-222 + peginterferon alfa-2a + ribavirin (12 weeks) followed by peginterferon alfa-2a + ribavirin for 36 weeks
11563087|NCT00911937|Experimental|Fesoterodine|
11563088|NCT00911937|Placebo Comparator|Placebo|
11563089|NCT00911924|Experimental|iStent|
11563090|NCT00911911|Experimental|FEC 100 + TAXOTERE|"FEC 100 = Fluoro-uracile + Epirubicin + Cyclophosphamide Fluoro-uracile : 500 mg/m²/cycle Epirubicin : 100 mg/m²/cycle Cyclophosphamide : 500 mg/m²/cyle 1 cycle = 21 days. For a total of 6 cycles or 3 cycles followed by 3 cycles of TAXOTERE
~TAXOTERE 100 mg/m²/cycle
~1 cycle = 21 days. For a total of 3 cycles following 3 FEC 100"
11563091|NCT00911898|Experimental|MM-111|
11563092|NCT00911885|Experimental|High Fiber Diet|A single dietary change condition that focuses exclusively on increasing fiber.
11563093|NCT00911885|Active Comparator|AHA Diet|The AHA Diet is the current recommendation for patients with the metabolic syndrome.
11563094|NCT00911872|Experimental|aging|
11563095|NCT00911859|Experimental|Part 1: VMP+Siltuximab 11 mg/kg|Siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP (Velcade+Melphalan+Prednisone). Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally (by mouth).
11563096|NCT00911859|Experimental|Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg|Siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP. Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally
11563097|NCT00911859|Active Comparator|Part 2, Arm B: VMP|Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally
11563098|NCT00911846||Buprenorphine|opioid-dependent patients with buprenorphine substitution
11563099|NCT00911846||methadone|opioid-dependent patients substituted with methadone
11563100|NCT00911846||no substitution|opioid-dependent patients without substitution
11563101|NCT00911846||therapists|therapists of the patients
11563102|NCT00911820|Active Comparator|Arm A: PCA|Patients first received bevacizumab 10 mg/kg IV on day 1 of every cycle (cycle length=21 days) at approximately 0.5 mg/kg/minute. Additionally, on days 1 and 8 of each cycle, patients received cisplatin 30 mg/m2 IV over 30 minutes and then irinotecan 65 mg/m2 IV over 30 minutes of each 3-week cycle. Treatment could continue until disease progression or unacceptable toxicity.
11563103|NCT00911820|Active Comparator|Arm B: TPCA|Patients first received bevacizumab 10 mg/kg IV on day 1 of every cycle (cycle length=21 days) at approximately 0.5 mg/kg/minute. Additionally on days 1 and 8 of each cycle, patients received docetaxel 30 mg/m2 IV over 30 minutes followed by cisplatin 25 mg/m2 IV over 30 minutes and then irinotecan 50 mg/m2 IV over 30 minutes of each 3-week cycle.
11563104|NCT00911807|Experimental|Cerebrolysin + donepezil|
11563105|NCT00911807|Experimental|Cerebrolysin + placebo|
11563106|NCT00911807|Active Comparator|Donepezil + placebo|
11563107|NCT00911794|Experimental|Written Disclosure Therapy|
11563108|NCT00911794|Sham Comparator|Controls|
11563109|NCT00911781||Infants with infantile hemangiomas|
11563110|NCT00911768|Experimental|Korean Red Ginseng group|The brand name of experimental drug is 'Capsule of Korean Red Ginseng Powder'. It consists of the powder of steamed root of Panax ginseng made by Korean Ginseng Corp.
11563111|NCT00911768|Placebo Comparator|Corn-starch powder with ginseng flavor|The placebo of this study is corn-starch powder with Korean Red Ginseng flavor. It has the same shape, color and flavor like experimental drug.
11563112|NCT00911755|Other|Laryngoscopy|
11563113|NCT00911755|Other|Videolaryngoscopy|
11563114|NCT00911742|Experimental|1 Tramadol Contramid Once A Day|
11563115|NCT00911742|Active Comparator|2 Zytram (R)|
11563116|NCT00911716|Experimental|cyclophosphamide, Docetaxel, bevacizumab|
11563117|NCT00911703||Acute heart failure|Subjects with an ED diagnosis of acute decompensated heart failure .
11563118|NCT00911690||Cognitively Impaired|Patients in this cohort with be diagnosed with mild to moderate cognitive impairment, Alzheimers disease, Dementia, or any other form of cognitive impairment.
11563119|NCT00911690||Non-cognitively impaired|Patients in this cohort will be normal healthy adults over the age of 60 years that have no cognitive impairment.
11563120|NCT00911677||Open Aortic Repair|Patients 60 years of age and older undergoing open repair of the abdominal aorta
11563121|NCT00911664|Placebo Comparator|1|
11563122|NCT00911664|Experimental|2|
11563123|NCT00911664|Experimental|3|
11563124|NCT00911651|Active Comparator|salbutamol|6 patients with moderate (GOLD 2) and severe (GOLD 3) COPD
11563125|NCT00911651|Active Comparator|ipratropium bromide|COPD patients GOLD stage II and III
11563126|NCT00911638|Experimental|1: Patient decision aid|Patient decision aid focused on treatment options for osteoarthritis of the hip or knee and preference report for surgeons. The patient decision aid used is from the Informed Medical Decisions Foundation
11563127|NCT00911638|Active Comparator|2: Usual care|Usual patient educational resources for patients undergoing hip or knee replacement surgery.
11563128|NCT00911625|Active Comparator|0.5 units/kg|Participants randomized to this arm will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
11563129|NCT00911625|Experimental|0.25 units/kg|Participants randomized to this arm will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
11563130|NCT00911612|Experimental|Colesevelam|Participants received colesevelam 1.875 g twice daily
11563131|NCT00911612|Placebo Comparator|Placebo|Participants received an inert capsule matching the study drug twice daily, as prepared by the Mayo Clinic research pharmacy
11563132|NCT00911599|Active Comparator|Conserve Total Hip with BFH|CONSERVE® A-Class Total Hip with BFH technology. Blood and urine samples will be collected and blood metal ion levels will be analyzed and compared to samples from the other group.
11563133|NCT00911599|Active Comparator|Metal with Polyethylene Liner|Metal on polyethylene total hip replacement. Blood and urine samples will be collected and blood metal ion levels will be analyzed and compared to samples from the other group.
11563134|NCT00911573|Experimental|A|Tigecycline
11563135|NCT00911573|Active Comparator|B|Clindamycin (or Vancomycin if needed)
11563136|NCT00911560|Experimental|vaccine group one|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a inimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Patients assigned to in Group 1 will receive o ral β glucan (40 mg/kg/day) starting at week 6 or 7 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination .
11563137|NCT00911560|Experimental|vaccine group two|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a minimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Patients assigned to Group 2 will receive oral β glucan (40 mg/kg/day) starting week 1 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination .
11563138|NCT00911560|Experimental|vaccine group three|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a minimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Group 3 will include patients who have previously received vaccine and oral β glucanglucan. Patients in this group will not be randomized using the MSK CRDB system. They will be treated as patients in Group 1 and receive o ral β glucan (40 mg/kg/day) starting at week 6 or 7 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination . They will not be eligible for primary endpoint.
11563139|NCT00911547|Experimental|1|Montelukast + Beclomethasone
11563140|NCT00911547|Experimental|2|Montelukast + Placebo inhaler
11563141|NCT00911547|Experimental|3|Placebo tablet + Beclomethasone
11563142|NCT00911547|Placebo Comparator|4|Placebo tablet + Placebo inhaler
11563143|NCT00911534|Experimental|1|
11563144|NCT00911534|Placebo Comparator|2|
11563145|NCT00911521|Active Comparator|Vaccine arm|subjects receiving vaccination
11563146|NCT00911508|Active Comparator|Left Atrial Ablation|Pulmonary vein isolation using a circumferential ablative approach in the left atrium. Ablation may be performed using circular mapping catheter-guided ablation, antral isolation using a circular guided approach, or wide area circumferential ablation.
11563147|NCT00911508|Active Comparator|Rate or Rhythm Control Therapy|Current state-of-the-art drug therapy for atrial fibrillation (rate control or rhythm control). Treating physicians will be encouraged to follow the American College of Cardiology / American Heart Association / European Society of Cardiology Atrial Fibrillation Guidelines with regard to drug therapy for atrial fibrillation. The specific choice of rate control versus rhythm control drug therapy and the specific drugs to be used will ultimately be left to the discretion of the treating physician.
11563148|NCT00911495|Experimental|GMI-1070|
11563149|NCT00911482||Diabetes/weight loss|12 individuals with type 2 diabetes and hypertriglyceridemia
11563150|NCT00911482||Nondiabetic/hypertriglyceridemic|10 insulin resistant nondiabetic individuals with dyslipidemia
11563151|NCT00911482||Normotensive/nondiabetic|10 insulin resistant, normotensive, nondiabetic individuals
11563152|NCT00911482||Insulin resistant/dyslipidemic|14 insulin resistant nondiabetic individuals with dyslipidemia
11563153|NCT00911469|Experimental|1|
11563154|NCT00911469|Placebo Comparator|2|
11563155|NCT00911443|Experimental|Dacarbazine + Interferon alpha + thymosin-alpha-1 1.6 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
11563156|NCT00911443|Experimental|Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
11563157|NCT00911443|Experimental|Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
11563158|NCT00911443|Experimental|Dacarbazine + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
11563159|NCT00911443|Active Comparator|Dacarbazine + Interferon alpha|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
11563160|NCT00911404|Experimental|Low CHO|Diet with 40% total calories from carbohydrates.
11563161|NCT00911404|Active Comparator|High CHO|Diet with 55% total calories from carbohydrates.
11563162|NCT00911391|Active Comparator|Fluid restriction|Current best practice of intraoperative fluid restriction
11563163|NCT00911391|Experimental|Oesophageal Doppler|Oesophageal Doppler-guided fluid administration
11563164|NCT00911378|Active Comparator|Pressure support ventilation|Patients in this arm are weaned by gradual reduction of pressure support
11563165|NCT00911378|Active Comparator|Spontaneous breathing trials|Patients in this arm are weaned by T piece trials
11563166|NCT00911365|Placebo Comparator|normal saline|
11563167|NCT00911365|Experimental|autologous mesenchymal stem cells|
11563168|NCT00911352|Experimental|Frozen gel glove (Elasto-Gel Mitten)|Cryotherapy hand
11563169|NCT00911352|No Intervention|No frozen glove therapy|Usual care
11563170|NCT00911339|Active Comparator|Atorvastatin 10 mg|
11563171|NCT00911339|Active Comparator|Atorvastatin 80 mg|
11563172|NCT00911313|Experimental|Letrozole|
11563173|NCT00911313|Active Comparator|Metformin-CC|
11563174|NCT00911300|Active Comparator|Arm 1: fondaparinux|
11563175|NCT00911300|Active Comparator|Arm 2: unfractionated heparin + Vitamin-K-Antagonist|
11563176|NCT00911287|Experimental|Single Arm|
11563177|NCT00911274|Experimental|Test (mycophenolate mofetil) First|Mycophenolate Mofetil 250 mg Capsule dosed in first period followed by CellCept® 250 mg Capsule dosed in second period.
11563178|NCT00911274|Active Comparator|Reference (CellCept®) First|CellCept® 250 mg Capsule dosed in first period followed by Mycophenolate Mofetil 250 mg Capsule dosed in second period.
11563179|NCT00911261|Experimental|Single Arm|
11563180|NCT00911248|Experimental|PTC299|PTC299 administered at 100 mg/dose twice per day
11563181|NCT00911235|Experimental|Fesoterodine Alone|Reference treatment
11563182|NCT00911235|Other|fesoterodine plus fluconazole|Test treatment
11563183|NCT00911222||antiemetic treatment|epidemiological registry
11563184|NCT00911209|Experimental|Intervention|The Intervention group at each session will receive information on Heart healthy diet, lifestyle recommendations and diet and exercise counseling with a dietitian in order to achieve at least 7% weight loss (for example a person weighing 200 pounds will be encourage to lose at least 14 pounds).
11563185|NCT00911209|No Intervention|No Intervention|The standard of care group will receive information on Heart healthy diet at baseline visit and will return to a final visit about 28 weeks later.
11563186|NCT00911196||Group A|
11563187|NCT00911183|Experimental|Arm I (R-COP regimen)|Patients receive rituximab IV, cyclophosphamide IV, and vincristine sulfate IV on day 1. Patients also receive oral prednisone on days 1-5 and filgrastim subcutaneously (SC) on days 8-14 or pegfilgrastim SC on day 2. Treatment repeats every 21 days for at least 3 courses.
11563188|NCT00911183|Experimental|Arm II (R-COPY regimen)|Patients receive rituximab, cyclophosphamide, vincristine sulfate, prednisone, and filgrastim or pegfilgrastim as in arm I. Patients also receive liposome-encapsulated doxorubicin citrate IV on day 1. Treatment repeats every 21 days for at least 3 courses.
11563189|NCT00911170|Placebo Comparator|Placebo|Participants received standard chemotherapy (FOLFOX or FOLFIRI) on Days 1-2, and bevacizumab 5 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle plus placebo subcutaneous injection once per cycle, for a maximum of 4 cycles, 24 hours after chemotherapy (Day 4).
11563190|NCT00911170|Placebo Comparator|Pegfilgrastim|Participants received standard chemotherapy (FOLFOX or FOLFIRI) on Days 1-2 and bevacizumab 5 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle plus pegfilgrastim 6 mg administered as a single subcutaneous injection once per cycle, for a maximum of 4 cycles, 24 hours after chemotherapy (Day 4).
11563191|NCT00911157|Experimental|Fondaparinux|
11563192|NCT00911157|Other|unfractionated heparin|
11563193|NCT00911144|Experimental|Synflorix Group|Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.
11563194|NCT00911144|Active Comparator|Prevenar Group|Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.
11563279|NCT00910455|Experimental|Active|Single oral dose of SRX246 capsule
11563280|NCT00910455|Placebo Comparator|Placebo|Single oral dose of placebo capsule
11563195|NCT00911131|Active Comparator|Screening esophagoduodenoscopy (EGD)|"EGD will be performed utilizing conscious sedation. During EGD, the endoscopist will capture pictures of the esophageal body, Z-line, lower esophagus and proximal gastric folds. Grading of esophageal varices will be performed by all investigators using the Italian Liver cirrhosis project.
~Patients who are found to have small grade varices and meet the inclusion and exclusion criteria will be enrolled in the study."
11563196|NCT00911131|Active Comparator|Capsule Endoscopy|The capsule endoscope will be swallowed by the participant with 100cc of water and simethicone in the supine position. Recording is done for 2 minute in this position and then the head will be elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient will sip10cc of water and after 15 seconds, they will sit upright and sip water again. They can then walk and resume normal activity for 15 minutes. The videos will be reviewed and graded by a gastroenterologist experienced with capsule endoscopy and will be blinded to the patient's clinical and procedural history as well as the most recent EGD. The varices will be graded using the Given Imaging software that grades varices as no varices (C0), small varices or < 25% of esophageal circumference (C1), and large varices or > 25% of esophageal circumference (C2).
11563197|NCT00911131|Active Comparator|Capsule Endoscopy with abdominal binder|Before swallowing the capsule endoscope, an inflatable girdle is wrapped around the waist above the umbilicus and held in place by a an abdominal binder. The pressure is increased by 10mmHg for 10 minutes. The PillCam ESO is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.
11563198|NCT00911118|Experimental|Radiation|Patients enrolled in the study will undergo image-guided, intensity-modulated radiotherapy using the same equipment, techniques, and treatment-planning procedures as currently practiced as MSKCC. MSKCC patients will have the option of continued follow-up through MSKCC's established Prostate Survivorship Clinic for an indefinite period of time, meaning patients enrolled in the protocol will be encouraged to remain at MSKCC for life-long follow-up after their treatment. The standard assessments obtained in the Survivorship Clinic will not be altered. All protocol relevant data collected at these visits through month 60 will be used for protocol analysis.
11563199|NCT00911105||Patients with multiple myeloma|Patients with multiple myeloma receiving second line therapy or higher.
11563200|NCT00911079|Experimental|Hyperthermia with HDR brachytherapy|Hyperthermia will be delivered within approximately 2 hours of (HDR) brachytherapy associated with the implant session
11563201|NCT00911066|Experimental|MLN4924|
11563202|NCT00911066|Experimental|Azacitidine|
11563203|NCT00911053|No Intervention|Baseline|
11563204|NCT00911053|Experimental|Melatonin|Subjects will be administered melatonin.
11563205|NCT00911053|Experimental|Light|
11563206|NCT00911053|Experimental|Regular Sleep Schedule|
11563207|NCT00911053|No Intervention|Longitudinal Monitoring|Optional longitudinal study, an extension of the first study stage, for subjects whose rhythms are not clearly free-running.
11563208|NCT00911027|Experimental|SonoVue guided biopsy|
11563209|NCT00911027|Other|Systematic biopsy|
11563210|NCT00911014||Vesicovaginal fistula repair|Women undergoing repair of vesicovaginal fistula
11563211|NCT00911001||Group 1|
11563212|NCT00910988|Active Comparator|olanzapine|olanzapine injection in healthy control
11563213|NCT00910988|Active Comparator|ziprasidone|ziprasidone injection in healthy control
11563214|NCT00910988|Placebo Comparator|saline|saline injection in healthy control
11563215|NCT00910975|Active Comparator|Standard of care|Treatment with Pegasys 180 µg/week and ribavirin 1000/1200 mg per day. Treatment is given for 24, 48 or 72 weeks depending on the time point (week 4, 12 or 24) when HCV RNA becomes undetectable by the Cobas Taqman assay. If HCV RNA has not declined 2 logs by week 12 or is detectable at week 24, treatment is stopped.
11563216|NCT00910975|Experimental|Tailored treatment|Treatment with Pegasys 180 µg/week and ribavirin 1000/1200 mg per day. Treatment duration is flexible, 24-72 weeks, depending on the time point when the HCV RNA level is calculated to be 1 copy/mL. If the decline between day 14 and 28 is poor, treatment is stopped after 5 weeks.
11563217|NCT00910962|Experimental|Treatment A|7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg twice daily for 12 weeks
11563218|NCT00910962|Experimental|Treatment B|15 mg GW856553 starting dose, followed 12 hours later by 7.5mg twice daily for 12 weeks
11563219|NCT00910962|Placebo Comparator|Treatment C|Placebo twice daily for 12 weeks
11563220|NCT00910949||Painfree|Thoracotomy patients without chronic pain
11563221|NCT00910949||With Pain|Thoracotomy patients with chronic pain
11563222|NCT00910936|Experimental|Intervention|
11563223|NCT00910936|No Intervention|Control|
11563224|NCT00910910|Experimental|1 - Lenalidomide|1 - Lenalidomide
11563225|NCT00910910|Active Comparator|2- Chlorambucil|2- Chlorambucil
11563226|NCT00910897|Active Comparator|Velcade-Dexamethasone|
11563227|NCT00910897|Active Comparator|Velcade-Thalidomide-Dexamethasone|
11563228|NCT00910884||Arm I|Patients receive oral GRAS supplements daily for 12 months or as possible within the patient's parameters.
11563229|NCT00910884||Arm II|Patients do not receive supplements.
11563230|NCT00910871|Experimental|TMC207|TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks in addition to Background Regimen (BR) for the treatment of multi-drug resistant tuberculosis (MDR-TB).
11563231|NCT00910858|Experimental|10 mg Lenalidomide|"Participants in the Pharmacokinetic Phase received a single 10 mg oral dose of lenalidomide on Day -7. During the Monotherapy Phase participants received 10 mg oral lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or erythroid failure.
~During the Combined Treatment Phase participants who were erythroid nonresponders and erythroid responders who had developed an erythroid relapse continued treatment with 10 mg lenalidomide in conjunction with recombinant human erythropoietin (rhu EPO) 40,000 units administered weekly by subcutaneous injection for 8 weeks. Responding patients could continue combined treatment."
11563331|NCT00910052|No Intervention|Control|No fibrin sealant
11563709|NCT00907504|Active Comparator|Gemcitabine + Cisplatin|standard of care
11563710|NCT00907491||A|
11563232|NCT00910858|Experimental|15 mg Lenalidomide Non-del 5q|Following the enrollment of the first 25 patients into the Monotherapy Phase, a second group of 15 patients with low- or intermediate-1-risk MDS not associated with a del 5q (non-del 5q) cytogenetic abnormality were enrolled to receive 15 mg of lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or erythroid failure. During the Combined Treatment Phase participants who were erythroid nonresponders and erythroid responders who had developed an erythroid relapse continued treatment with 15 mg lenalidomide in conjunction with recombinant human erythropoietin (rhu EPO) 40,000 units administered weekly by subcutaneous injection for 8 weeks. Responding patients could continue combined treatment.
11563233|NCT00910845|Experimental|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
11563234|NCT00910845|Other|placebo/onabotulinumtoxinA|Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).
11563235|NCT00910832|Experimental|Eductyl suppository|
11563236|NCT00910832|Placebo Comparator|Placebo suppository|
11563237|NCT00910806|Experimental|TMC207, nevirapine|
11563238|NCT00910793|Other|Inuvair|
11563239|NCT00910780|Active Comparator|Staying on Risperdal|
11563240|NCT00910780|Active Comparator|Risperdal switched to Abilify|
11563241|NCT00910780|Active Comparator|Staying on Zyprexa|
11563242|NCT00910780|Active Comparator|Zyprexa switched to Abilify|
11563243|NCT00910767|Experimental|Closed loop (algorithm)|
11563244|NCT00910767|Placebo Comparator|Open loop|
11563245|NCT00910754|Experimental|Abiraterone acetate|Patients will take 1000 mg of abiraterone acetate once daily plus prednisone 5 mg twice daily orally (by mouth) until disease progression.
11563246|NCT00910741|Experimental|Nanoplatin|"Nanoplatin (NC-6004) had to be administered once every 3 weeks, on Day 1, Day 22 and Day 43 etc.
~Gemcitabine had to be administered to every patient 2 times on Day 1 and Day 8 every 3 weeks after the infusion of Nanoplatin (NC-6004)."
11563247|NCT00910728|Experimental|1|AZD1480
11563248|NCT00910715|Active Comparator|EM-10 days doxycycline|
11563249|NCT00910715|Active Comparator|EM-doxycycline 15 days|
11563250|NCT00910715|Placebo Comparator|controls|
11563251|NCT00910702|Experimental|FCVB team|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB)
11563252|NCT00910689|Placebo Comparator|1|Optimal Acute Therapy plus Beta Blocker Placebo
11563253|NCT00910689|Active Comparator|2|Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)
11563254|NCT00910689|Active Comparator|3|Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker placebo
11563255|NCT00910689|Active Comparator|4|Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)
11563256|NCT00910676|Experimental|DIPROSONE|
11563257|NCT00910663|Experimental|Test (mycophenolate mofetil) First|Mycophenolate Mofetil 250 mg Capsule dosed in first period followed by Cellcept® 250 mg Capsule dosed in second period.
11563258|NCT00910663|Active Comparator|Reference (CellCept®) First|CellCept® 250 mg Capsule dosed in first period followed by Mycophenolate Mofetil 250 mg Capsule dosed in second period.
11563259|NCT00910650|Experimental|F5 TCR transgenic cells|F5 TCR transgenic cell adoptive transfer therapy
11563260|NCT00910637|Experimental|Arm 1|
11563261|NCT00910624|Experimental|BOC + PEG/RBV|Participants who enrolled within 2 weeks after the last dose of PEG/RBV in previous protocol received boceprevir (BOC) + peginterferon/ribavirin (PEG/RBV) for up to 44 weeks followed by 24 weeks post-treatment follow-up. Participants who did not enroll within 2 weeks after the last dose of PEG/RBV in previous protocol received PEG/RBV for 4 weeks followed by BOC + PEG/RBV for up to 44 weeks, with 24 weeks post-treatment follow-up.
11563262|NCT00910598|Experimental|glatiramer acetate|glatiramer acetate 20 mg s.c. daily for 1 year
11563263|NCT00910598|No Intervention|no treatment|No disease modifying treatment allowed
11563264|NCT00910585|Experimental|Active coaching|Telephone and in person coaching
11563265|NCT00910585|Active Comparator|Usual care|Return to PCP for usual care
11563266|NCT00910546|Experimental|Implantation of gold marker|CT guided implantation of gold marker into early stage lung tumors. Extra 4DCT scans and fluoroscopies during planning and the 3 fraction radiotherapy course.
11563267|NCT00910533|Active Comparator|Early Lyme neuroborreliosis patients|
11563268|NCT00910533|No Intervention|control subjects|Control subjects without a history of Lyme borreliosis.
11563269|NCT00910520|Experimental|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
11563270|NCT00910520|Other|placebo/onabotulinumtoxinA|Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).
11563271|NCT00910507|Experimental|Exercise counseling|Each participant in the experimental group receives exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
11563272|NCT00910507|Active Comparator|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
11563273|NCT00910494|Experimental|12 Gray IORT|
11563274|NCT00910494|Experimental|15 Gray IORT|
11563275|NCT00910481|Experimental|Elective IABP Insertion|
11563276|NCT00910481|No Intervention|No Planned IABP Insertion|
11563277|NCT00910468||Robot Assisted Laparoscopic Myomectomy|
11563278|NCT00910468||Myomectomy via Laparotomy|
11563281|NCT00910442|Experimental|Patient Group|Dietary supplement:N-acetylcysteine 1g/day and Glutamine 20g/day for 7 consecutive days. The dietary supplements were intermediated by 7 days of washout with usual diet.
11563282|NCT00910442|Active Comparator|Control Group|Healthy HIV negative subjects submitted to the same dietary supplement than experimental group: N-acetylcysteine 1g/day and Glutamine 20g/day for 7 consecutive days. The dietary supplements were intermediated by 7 days of washout with usual diet.
11563283|NCT00910429|Experimental|Arm 1|
11563284|NCT00910416||patients receiving iv anesthesia|
11563285|NCT00910416||patients receiving balanced anesthesia|
11563286|NCT00910390|Placebo Comparator|Slow Freezing|Standard freezing protocol (slow freezing) of preimplantation embryos
11563287|NCT00910390|Experimental|VIT-Irvine|Vitrification with Irvine solution (rapid freezing) of preimplantation embryos
11563288|NCT00910390|Experimental|VIT-Vitrolife|Vitrification (rapid freezing) with Vitrolife solution
11563289|NCT00910377|Experimental|visit with grandmother|Teenagers mothers and their grandmothers receive counseling sessions about breastfeeding and complementary feeding.
11563290|NCT00910377|Experimental|visit without grandmother|Teenagers mothers don´t live with their grandmothers and receive counseling sessions about breastfeeding and complementary feeding.
11563291|NCT00910377|No Intervention|no visit with grandmother|Teenagers mothers live with their grandmothers and don´t receive counseling sessions about breastfeeding and complementary feeding.
11563292|NCT00910377|No Intervention|no visit without grandmother|Teenagers mothers don´t live with their grandmothers and don´t receive counseling sessions about breastfeeding and complementary feeding.
11563293|NCT00910364|Experimental|Exercise testing|Feasibility study; all participants receive intervention
11563294|NCT00910351|Experimental|Arm 1|
11563295|NCT00910338|Experimental|PFMT with Extracorporeal Biobeedback|
11563296|NCT00910312|Experimental|Breast Fibroadenoma|
11563297|NCT00910299|Experimental|Prasugrel|
11563298|NCT00910299|Active Comparator|Clopidogrel|
11563299|NCT00910286|Other|VENTILATOR WEANING|Two ventilators with different flow termination criteria (TC) were compared: Servo 300 (Siemens-Elema, Sweden) with fixed TC (5% of peak inspiratory flow) and Newport E500 (Newport Medical Instruments, CA) with automatic TC (varies between 5% to 55%). Each patient remained three hours in the protocol, one hour in each ventilator, after been randomized to one of two sequences of 3 steps: Fixed 5% / Automatic / Fixed 5% or Automatic / Fixed 5% / Automatic . The PS, the positive end expiratory pressure (PEEP), the inspiratory oxygen fraction (FiO2) and the pressure trigger sensitivity levels were unchanged during the protocol.
11563300|NCT00910273|Experimental|1|etanercept 50 mg/week
11563301|NCT00910247|Experimental|eslicarbazepine acetate|Open-label treatment with eslicarbazepine acetate will be at doses between 800 and 2400 mg QD
11563302|NCT00910234|Active Comparator|Drug: rhEpo, low dose|rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
11563303|NCT00910234|Active Comparator|Drug: rhEpo, high dose|rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
11563304|NCT00910234|Placebo Comparator|Control Normal saline|normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
11563305|NCT00910221|Active Comparator|1|
11563306|NCT00910221|Placebo Comparator|2|
11563307|NCT00910208|Experimental|Patient-controlled analgesia 1 mg demand dose|0.1 mg/kg morphine loading dose plus PCA with 1.0 mg morphine demand dosing every 6 minutes
11563308|NCT00910208|Experimental|Patient-controlled analgesia 1.5 mg demand dose|0.1 mg/kg morphine loading dose plus PCA with 1.5 mg morphine demand dosing every 6 minutes
11563309|NCT00910208|Active Comparator|Non-Patient-controlled analgesia comparison group|0.1 mg/kg morphine loading dose plus additional analgesia as needed
11563310|NCT00910195|Experimental|CPAP before Bi-Level-APAP|receiving CPAP treatment during the first night and then Bi-level-APAP treatment during second night
11563311|NCT00910195|Experimental|Bi-Level-APAP before CPAP|receiving Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
11563312|NCT00910182||1|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 and treated non-operatively
11563313|NCT00910182||2|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 who underwent emergency surgical treatment
11563314|NCT00910182||3|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 treated non-operatively plus transcatheter arterial embolisation
11563315|NCT00910169||inpatient treatment|naturalistic treatment no modification: observational study
11563316|NCT00910156|Active Comparator|Airtraq|
11563317|NCT00910156|Active Comparator|Glidescope|
11563318|NCT00910156|Active Comparator|Macintosh|
11563319|NCT00910143||1|patients operated before summer 1995, that is before the introduction of TME
11563320|NCT00910143||2|patients operated after summer 1995, that is after the introduction of TME.
11563321|NCT00910130||End Stage Renal Disease|Patients suffering from End Stage Renal Disease on Hemodialysis, without Diabetes
11563322|NCT00910130||Control|"Healthy people, with normal Renal Function and without Diabetes, matched with ESRD group for age, gender, BMI"
11563323|NCT00910117|Experimental|nimotuzumab|nimotuzumab plus PF regimen
11563324|NCT00910104|Experimental|Omegaven|1g/kg/day for duration of study participation for all participants
11563325|NCT00910091|Experimental|A- BN 83495- 40mg|After eligibility is confirmed, subjects will be randomised at baseline. The randomisation number and associated treatment for the total study will be allocated by an Interactive Voice Response System (IVRS) service
11563326|NCT00910091|Active Comparator|B- MA - 160mg|After eligibility is confirmed, subjects will be randomised at baseline. The randomisation number and associated treatment for the total study will be allocated by an Interactive Voice Response System (IVRS) service
11563327|NCT00910065|Experimental|Arm 1|
11563328|NCT00910065|Experimental|Arm 2|
11563329|NCT00910065|Active Comparator|Arm 3|
11563330|NCT00910052|Experimental|Fibrin sealant|received intraoperative fibrin sealant
11563332|NCT00910039|Experimental|Sunitinib malate|"Oral sunitinib malate once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
~Patients undergo neuropsychological battery testing at baseline and periodically during study to assess cognitive function (memory, verbal fluency, visual-motor speed, executive function, and motor dexterity), activities of daily living, and quality of life."
11563333|NCT00910026|Experimental|low tidal volume ventilation|6 ml/kg tidal volume ventilation
11563334|NCT00910026|Experimental|high tidal volume ventilation|12 ml/kg tidal volume ventilation
11563335|NCT00910013|Experimental|Ropivacaine + femoral block|After the surgery is proceeded and after the closure of the joint capsule, 20 cc of ropivacaine 0.5% is inserted intra-articular through a catheter.
11563336|NCT00910000|Experimental|Dose Level 1A|"Vorinostat: 200 mg taken orally once a day for the first two weeks of each three-week cycle
~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle
~Gemcitabine: 100 mg/m2, given intravenously on day 1 and day 8 of every three week cycle
~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
11563337|NCT00910000|Experimental|Dose Level 2A|"Vorinostat: 300mg, taken orally once a day for the first two weeks of each three-week cycle
~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle
~Gemcitabine: 1000 mg/m2, given intravenously on day 1 and day 8 of every three week cycle
~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
11563338|NCT00910000|Experimental|Dose Level 1B|"Vorinostat: 200mg, taken orally twice a day for days 1-3 and days 8-10 of every three week cycle
~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle
~Gemcitabine: 1000 mg/m2, given intravenously on day 1 and day 8 of every three week cycle
~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
11563339|NCT00910000|Experimental|Dose Level 1C|"Vorinostat: 200mg, taken orally twice a day for days 1, 2, 8 and 9 of every three week cycle
~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle
~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle
~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
11563340|NCT00910000|Experimental|Dose Level 1D|"Vorinostat: 300mg, taken orally once a day for days 1 and 2 of every three week cycle
~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle
~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle
~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
11563341|NCT00910000|Experimental|Dose Level 2D|"Vorinostat: 400mg, taken orally once a day for days 1 and 2 of every three week cycle
~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle
~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle
~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
11563342|NCT00909987|Experimental|Single arm|"Neoadyuvant chemotherapy with XELOX: Xeloda 1000mg/m2/12h dayly, day one in the afternoon until day 15 in the morning; plus oxaliplatin 130mg/m2 (day 1); and Bevacizumab 7.5 mg/kg (day 1)during 3 cycles (each cycle of 3 weeks).
~Followed by a selective use of chemoradiotherapy with radiotherapy (50.4Gy, 28 sesions of 1.8Gy during 5 weeks) plus Xeloda 825mg/m2/12h dayly."
11563343|NCT00909974|Experimental|Food supplement (FS)|Recipe of food supplement: 33% peanut butter, 32% soy flour, 15% vegetable oil, 20% sugar, UNIMMAP in powdered form Nutritional composition (per dose of 72g) Energy 1.56 MJ, protein 14.7 g, vitamin A 881 µg, vitamin E 13 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 21 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 461 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
11563344|NCT00909974|Active Comparator|UNIMMAP|UNIMMAPin tablet form: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
11563345|NCT00909961|Experimental|Zoledronic acid|
11563346|NCT00909948|Active Comparator|Fludarabine|The patients in this cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
11563347|NCT00909948|Active Comparator|TBI only|Patients will be given 200 centiGray (cGy) total body irradiation (TBI) in one fraction. TBI will be given on day 0, 4 to 6 hours prior to HCT.
11563348|NCT00909922||Lower Limb Amputees|Unilateral Above knee amputees
11563349|NCT00909909|Active Comparator|A|3DCRT/IMRT lumpectomy bed boost followed by accelerated whole breast irradiation (AWBI)
11563350|NCT00909909|Active Comparator|B|Accelerated whole breast irradiation (AWBI) followed by 3DCRT/IMRT lumpectomy bed boost
11563351|NCT00909896||Robotic Surgery candidates|Group of patients receive Robotic approach for endometrial cancer staging
11563352|NCT00909896||Open Laparotomy Surgical Candidates|Patients receiving open laparotomy for endometrial cancer surgical staging
11563353|NCT00909870|Experimental|1|Weekly applications of Dermagraft and compression dressings, in combination with systematic surgical wound debridement.
11563354|NCT00909870|Active Comparator|2|Weekly application of compression dressings only, in combination with systematic surgical wound debridement.
11563355|NCT00909857|Experimental|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one tablet SH T00658ID (BAY86-5027) plus one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles
11563356|NCT00909857|Active Comparator|Ethinyl estradiol, Levonorgestrel (Miranova)|Daily oral administration of one tablet placebo plus one tablet SH D593B (Miranova) for 28 days without tablet-free interval for 3 treatment cycles
11563357|NCT00909844|Experimental|Triptorelin|
11563358|NCT00909818|Active Comparator|standard fractionated radiotherapy|50 Gy/25 fractions, 2.00 Gy/fraction, 5 fractions per week
11563359|NCT00909818|Experimental|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
11563360|NCT00909805|Experimental|Cutaneous suture with glue|Inguinal surgical incision closing using Dermabond® glue instead of cutaneous suture with surjet
11563557|NCT00908427|Active Comparator|1|PVP group
11563361|NCT00909805|Active Comparator|Conventional suture|Inguinal surgical incision closing with conventional cutaneous suture (surjet)
11563362|NCT00909792|Other|Lotrafilcon B / Senofilcon A|Lotrafilcon B, followed by Senofilcon A
11563363|NCT00909792|Other|Senofilcon A / Lotrafilcon B|Senofilcon A, followed by Lotrafilcon B
11563364|NCT00909779|Experimental|Arformoterol 15 mcg twice daily|Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.
11563365|NCT00909779|Placebo Comparator|Placebo twice daily|Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.
11563366|NCT00909766|Active Comparator|Panel A|
11563367|NCT00909766|Active Comparator|Panel B|
11563368|NCT00909766|Active Comparator|Panel C|
11563369|NCT00909766|Active Comparator|Panel D|
11563370|NCT00909766|Active Comparator|Panel E|
11563371|NCT00909766|Active Comparator|Panel F|Low Dose
11563372|NCT00909766|Active Comparator|Panel G|High Dose
11563373|NCT00909766|Placebo Comparator|Panel H|
11563374|NCT00909753|Experimental|Ursodiol (test) First|Ursodiol Tablets, 500 mg
11563375|NCT00909753|Active Comparator|Urso Forte™ (reference) First|Urso Forte™ Tablets, 500 mg
11563376|NCT00909740|Experimental|1|
11563377|NCT00909727|Placebo Comparator|Placebo|Subjects who received placebo every 12 hours (q12h) for up to 48 weeks.
11563378|NCT00909727|Experimental|150 mg Ivacaftor q12h|Subjects who received 150 mg of ivacaftor q12h for up to 48 weeks.
11563379|NCT00909714|Experimental|Anodal tDCS|Direct Current (DC)-Stimulator to apply tDCS + Training
11563380|NCT00909714|Sham Comparator|Sham tDCS|Direct Current (DC)-Stimulator to apply Sham tDCS (Placebo) + Training
11563381|NCT00909701|Experimental|Test|PreOP Booster (Fresenius Kabi, Bad Homburg, Germany)
11563382|NCT00909701|Active Comparator|Comparator|PreOP (Nutricia Clinical Care, Trowbridge, UK)
11563383|NCT00909688|Experimental|1|BLI-489
11563384|NCT00909688|Placebo Comparator|2|placebo
11563385|NCT00909662||Patients|Female patients with operable breast cancer intending to undergo adjuvant chemotherapy
11563386|NCT00909662||Participants|Female control subjects will be recruited, consisting predominantly of age-matched (i.e.+/- 10 years of age) friends or family members of the patients.
11563387|NCT00909649|Active Comparator|1 fibrin glue|8 ml of fibrin glue was sprayed on the surgical area with Y canula ( doubleject application system).One milliliter of fibrin glue contains 70-100 mg. fibrinogen, 10-50 u factor 8 aprotinin 3000k iu/ml, 2-9 mg fibronectin,40-120 ug plasminogen ,4 Iu/ml thrombin, 40 mmol cocl2/L (immuno AG/austrial)
11563388|NCT00909649|No Intervention|2 non fibrin glue|after good haemostasis the same sized drain was applied in axillary and breast area and incision was closed. Followed by external compression for 10 minutes in both groups. Drains were left in places until the drainage for the preceding 24 h was less than 20 ml.
11563389|NCT00909636|Active Comparator|1. ABT-333 Tablet|Three 400mg ABT-333 Tablets, BID
11563390|NCT00909636|Active Comparator|2. ABT-333 Tablet|Four 400mg ABT-333 Tablets, BID
11563391|NCT00909636|Placebo Comparator|3. Placebo|Three or four placebo tablets, BID
11563392|NCT00909610|Experimental|Ursodiol (test) First|Ursodiol Tablets, 500 mg (test) dosed in first period followed by Urso Forte™ Tablets, 500 mg dosed in second period.
11563393|NCT00909610|Active Comparator|Urso Forte™ (reference) First|Urso Forte™ Tablets, 500 mg (reference) dosed in first period followed by Ursodiol Tablets, 500 mg (test) dosed in second period.
11563394|NCT00909597|Active Comparator|pioglitazone|
11563395|NCT00909597|Experimental|taspoglutide 10mg|taspoglutide 10mg sc weekly
11563396|NCT00909597|Experimental|taspoglutide 10mg/20mg|taspoglutide 20mg sc weekly after 4 weeks of taspoglutide 10mg sc weekly
11563397|NCT00909584|Experimental|1|4-Week dose equilibration period with Telintra followed by 4 month treatment period
11563398|NCT00909584|No Intervention|2|4 Month observation period with standard of care treatment and option to crossover to Telintra treatment for 4 week dose equilibration followed by 4 week treatment period
11563399|NCT00909571|Experimental|1. FK506E high dose group|
11563400|NCT00909571|Experimental|2. FK506E low dose group|
11563401|NCT00909545|Active Comparator|Isradipine CR 5mg|Isradipine CR 5mg/day
11563402|NCT00909545|Active Comparator|Isradipine CR 10mg|Isradipine CR 10mg/day
11563403|NCT00909545|Active Comparator|Isradipine CR 20mg|Isradipine CR 20mg/day
11563404|NCT00909545|Placebo Comparator|Placebo|Placebo
11563405|NCT00909532|Placebo Comparator|Placebo|Subjects who received placebo every 12 hours (q12h) for up to 48 weeks.
11563406|NCT00909532|Experimental|150 mg Ivacaftor q12h|Subjects who received 150 mg of ivacaftor q12h for up to 48 weeks.
11563407|NCT00909519|Active Comparator|naproxen|
11563408|NCT00909519|Experimental|naproxcinod|
11563409|NCT00909519|Placebo Comparator|placebo|
11563410|NCT00909506|Placebo Comparator|Placebo|Placebo
11563411|NCT00909506|Active Comparator|Metformin 500 mg/d|Metformin 500 mg/d
11563412|NCT00909506|Active Comparator|Metformin 1000 mg/d|Metformin 1000 mg/d
11563413|NCT00909493|Experimental|Access to Pain Specialist|Network
11563414|NCT00909480|Experimental|IDet|Individually adjusted insulin detemir once daily + metformin at least 1500 mg/day
11563415|NCT00909480|Active Comparator|IGlar|Individually adjusted insulin glargine once daily + metformin at least 1500 mg/day
11563416|NCT00909467||myeloproliferative, -dysplastic disease|
11563417|NCT00909454|Experimental|Daily 2000 IU vitamin D supplement|
11563418|NCT00909454|Active Comparator|Daily Vitamin D supplement 400 IU|
11563419|NCT00909441|Experimental|SNB + ALND|Intervention: Sentinel Lymph Node Biopsy followed by Axillary Node Dissection.
11563420|NCT00909428|Experimental|Solifenacin Succinate|The intervention for this study is 10mg daily solifenacin. Patients with overactive bladder syndrome will take this study drug for 30 days.
11563421|NCT00909402|Experimental|All Subjects|
11563422|NCT00909389||Filipino Patients with Hypercholesterolemia|
11563423|NCT00909376||1 - transabdominal sonography|Women who will have a transabdominal sonography done in the early second trimester.
11563424|NCT00909376||2 - transvaginal sonography|Women who will have a transvaginal sonography done in the early second trimester.
11563425|NCT00909363|Experimental|WAS patients receiving Promacta|Promacta® is commercially available in 12.5 mg, 25 mg, 50 mg, and 75 mg tablets. For this study, for young children unable to swallow a tablet, eltrombopag powder for oral suspension (Eltrombopag PfOS) will be used. PfOS is only available for investigational use at 20mg. Each sachet contains eltrombopag equivalent to 20mg per gm of powder and is reconstituted to a total of 10 ml so that the concentration is 2 mg/ml.
11563426|NCT00909363|Experimental|WAS patients for blood drawing only|WAS patients not receiving treatment to serve as subjects for platelet parameter studies blood drawing once only
11563427|NCT00909363|Placebo Comparator|healthy children for blood drawing only|healthy children having blood obtained once as controls for platelet parameters study
11563428|NCT00909350||No treatment|genetic research project; to meet inclusion criteria, participants must have normal upper GI tract upon upper endoscopy, for study biopsies to be taken
11563429|NCT00909337|Other|Bosentan|"In this study, all participants have normal pulmonary arterial pressure at rest and elevated pulmonary arterial pressure during exercise. First, they were followed up for a year and were controlled after 1 year without specific therapy for pulmonary hypertension. Then Bosentan was introduced. A second control showing the effects of the therapy was done after 6 months. The changes in the therapy period can be compared with the changes in the follow up period."
11563430|NCT00909324|Experimental|Pre-LASIK 0.3% hypromellose|
11563431|NCT00909324|Active Comparator|Post-LASIK 0.3% hypromellose|
11563432|NCT00909311|Active Comparator|1|Non-fasting
11563433|NCT00909311|Active Comparator|2|Fasting
11563434|NCT00909298|Experimental|1|TTP889 300 mg
11563435|NCT00909298|Placebo Comparator|2|TTP889 Placebo
11563436|NCT00909285|Experimental|Treatment Group (#1)|
11563437|NCT00909285|Sham Comparator|Control group (#2)|
11563438|NCT00909272||US-guided lumbar medial branch block|Patients who have low back pain and/or leg pain due to possible lumbar facet joint disease .
11563439|NCT00909272||Cadavers for Ultrasound landmarks|Cadavers donated to the Department of Anatomy in McMaster University will be used to determine the landmarks for ultrasound.
11563440|NCT00909259|Experimental|Phrenic Stimulation|
11563441|NCT00909233||Group 1|
11563442|NCT00909220||Current Major Depressive Disorder|Forty-one participants with a primary diagnosis of major depression using the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV) and scores > 24 on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-C; Rush et al., 1986) were enrolled into a treatment study at Northwestern University's Feinberg School of Medicine in Chicago, Illinois. This group will receive Behavioral Activation psychotherapy.
11563443|NCT00909220||Healthy Participants|Another 36 participants with no lifetime psychiatric symptoms and scores < 11 on the IDS-C were tracked prospectively, naturalistically, for 16 weeks.
11563444|NCT00909207||Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
11563445|NCT00909194|Experimental|Intervention|Educational Seminar on Juvenile Primary Fibromyalgia Syndrome and CD-guided total body relaxation technique
11563446|NCT00909194|No Intervention|Control|Control Arm consisted of an educational seminar on skin care
11563447|NCT00909181|Experimental|Oxybutynin Gel 56 mg/day|
11563448|NCT00909181|Experimental|Oxybutynin Gel 84 mg/day|
11563449|NCT00909181|Placebo Comparator|Placebo Gel|
11563450|NCT00909168|Experimental|Efficacy of FLAIMy|
11563451|NCT00909155|Active Comparator|Depressed; Venlafaxine treatment|Currently depressed subjects; Randomized medication treatment with Venlafaxine extended release tablets (Venlafaxine ERT). Dosage 75-300mg/day for up to 6 months.
11563452|NCT00909155|Active Comparator|Depressed; Fluoxetine treatment|Currently depressed subjects; Randomized medication treatment with Fluoxetine tablets. Dosage 20-80mg/day for up to 6 months.
11563453|NCT00909155|No Intervention|Control|Non-psychiatric subjects with no past or current history of depression. Subjects will receive no medication
11563454|NCT00909142||Group1|
11563455|NCT00909129|Experimental|HIV-1 HCV coinfected patients|HIV-1 HCV coinfected patients undergoing HCV therapy
11563456|NCT00909116||Chronic constipation - ODS|Adult Patients with ODS
11563457|NCT00909103||Pancreatic adenocarcinoma|Patients diagnosed with solid pancreatic adenocarcinoma masses, with cytological / histological confirmation
11563458|NCT00909103||Chronic pancreatitis|Patients diagnosed with solid pancreatic tumor masses with all the criteria fulfilled to exclude pancreatic cancer
11563459|NCT00909090|Active Comparator|Intervention|10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin
11563460|NCT00909090|Placebo Comparator|Placebo|visually identical placebo
11563461|NCT00909077|Active Comparator|1|Combination therapy with Dexamethasone and Rituximab
11563462|NCT00909077|Active Comparator|2|Dexamethasone as monotherapy
11563463|NCT00909064|Experimental|Arixtra|Effect of Arixtra on would drainage and length of stay for the patients with hip and knee replacement
11563464|NCT00909051||Group 1|
11563465|NCT00909025|Experimental|Claudiximab|
11563466|NCT00909012|Placebo Comparator|1|
11563467|NCT00909012|Experimental|2|
11563468|NCT00909012|Experimental|3|
11563469|NCT00909012|Experimental|4|
11563470|NCT00909012|Experimental|5|
11563471|NCT00908999||Controls|The control group have to be medically and cognitively healthy(MMSE ≥ 28; Hopkins Verbal Memory Test-Revised raw score within 1.5 SD of normative values for age and gender). These individuals are recruited from the community and all attempts will be made to match them on age and education to individuals recruited for groups of AD and aMCI.
11563472|NCT00908999||amnestic Mild Cognitive Impairment|Participants who have expressed interest to take part in the study. A consensus from the study clinicians regarding the diagnosis will be required before a subject is enrolled. The criteria for MCI include 1) observation of memory decline by informant, 2) Mini Mental Status Exam (MMSE) score between 24 and 30, 3) objective memory impairment on neuropsychological tests, 3) intact functional abilities, and 4) no diagnosis of dementia.
11563558|NCT00908427|Active Comparator|2|TURP group
11563473|NCT00908999||Alzheimer's disease|Patients with probable Alzheimer's disease according with the NINDS-ADRDA and DSM-IV diagnostic criteria. An additional criterion is a MMSE score between 16 and 27. All AD patients must have capacity to provide informed consent as judged by the referring physician.
11563474|NCT00908986|Experimental|Rituximab|Subjects receive rituximab in an open label manner
11563475|NCT00908973||Good responders|Excess weight loss of > 60% 1 year after gastric bypass surgery
11563476|NCT00908973||Poor responders|Excess weight loss of =< 50% 1 year after gastric bypass surgery
11563477|NCT00908973||Lean controls|Non-gastric bypass operated lean individuals, matched for age and sex
11563478|NCT00908960|Experimental|High TFMP: Enoxaparin|Patients received enoxaparin 40 mg subcutaneously once daily for 2 months (60 days).Only patients with high TFMP status at baseline were randomized to treatment or observation.
11563479|NCT00908960|No Intervention|High TFMP: Observation|Patients undergo observation until evaluation with a lower extremity ultrasound at 2 months (day 60). Only patients with high TFMP status at baseline were randomized to treatment or observation.
11563480|NCT00908960|No Intervention|Low TFMP: Observation|Patients undergo observation until evaluation with a lower extremity ultrasound at 2 months (day 60). Patients with low TFMP status at baseline were directly assigned to observation.
11563481|NCT00908947|Experimental|Overall Study|PTA plus stenting with the LifeStent® Vascular Stent System
11563482|NCT00908934|Experimental|1|50 or 400 mg AZD9056, Test formulation
11563483|NCT00908934|Experimental|2|50 or 400 mg AZD9056, Reference formulation
11563484|NCT00908921|Experimental|1|"The treatment period is 16 weeks with 5 visits: at weeks 2, 4, 8, 12, 16. At every visit if Fasting Blood Glucose (FBG) >7.0mmol/L the Glimepiride dosage is increased from 1mg to 2mg or 2mg to 4mg.
~At every visit if FBG<3.9mmol/L the Glimepiride dosage is decreased from 4mg to 2mg or 2mg to 1mg.
~Patients who have been on 4mg for 4 weeks and FBG>11.0mmol/L at visit, another treatment can be added at the physician's discretion."
11563485|NCT00908908|Experimental|1|
11563486|NCT00908895|Experimental|Radio-radial fixator|Patients are operated on using a radio-radial fixator (Distal radius fixator, Synthes)
11563487|NCT00908895|Active Comparator|Percutaneous pinning|Two K-wires inserted on a percutaneous way (dorsally and from the styloid), with a cast for 6 weeks
11563488|NCT00908882|Experimental|Enhanced PTSD Health Buddy and Motivational Interviewing|Veterans with PTSD who smoke are exposed to an intervention which included a 90-day smoking cessation curriculum that is integrated into the PTSD Health Buddy Program and weekly motivational interviewing counseling by a nurse plus usual smoking cessation care
11563489|NCT00908882|No Intervention|Usual PTSD Health Buddy Care|Veteran with PTSD who smoke randomly assigned to this arm received standard of care for smoking cessation and used the standard PTSD Health Buddy
11563490|NCT00908856|Placebo Comparator|Placebo|Placebo
11563491|NCT00908856|Active Comparator|autologous mononuclear cells|a single intravenous autologous bone marrow mononuclear cell transfusion
11563492|NCT00908856|Active Comparator|autologous marrow stromal cells|a single intravenous autologous marrow stromal cell transfusion
11563493|NCT00908843|Experimental|(I) BICARBONATE INTRAVENOUS INFUSION|Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
11563494|NCT00908843|Active Comparator|(II) ORAL SODIUM SOLUTION|Oral hydration with Sodium solution (Casen solution of rehydratation) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
11563495|NCT00908830||Cystic fibrosis|Lung transplant patients with cystic fibrosis. Measuring MPA levels in cystic fibrosis lung transplant patients for pharmacokinetic parameters.
11563496|NCT00908830||Non-cystic fibrosis lung transplant|Non-cystic fibrosis lung transplant patients. Non-cystic fibrosis lung transplant patients will have MPA levels drawn after their dose to determine pharmacokinetic parameters.
11563497|NCT00908817|Active Comparator|triamcinolone|
11563498|NCT00908817|Placebo Comparator|chlorhexidine|
11563499|NCT00908804|Active Comparator|open appendectomy|
11563500|NCT00908804|Active Comparator|laparoscopic appendectomy|
11563501|NCT00908791|Experimental|CLA|open-label, single-institution proof of principle study of oral CLA in patients with newly diagnosed adenocarcinoma of the breast.
11563502|NCT00908778|Experimental|Vitreosolve I|Intravitreal injection
11563503|NCT00908778|Experimental|Vitreosolve|Intravitreal injection
11563504|NCT00908765|Active Comparator|Aerobe Interval Training|High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.
11563505|NCT00908765|Active Comparator|Moderate Continous Training|Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks
11563506|NCT00908752|Active Comparator|Brivanib|Adjuvant treatment with TACE Therapy
11563507|NCT00908752|Placebo Comparator|Brivanib Placebo|Placebo adjuvant treatment with TACE Therapy
11563508|NCT00908726|Experimental|Microemulsion propofol|
11563509|NCT00908726|Active Comparator|Lipid emulsion propofol|
11563510|NCT00908713|Experimental|methylprednisolone|methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
11563511|NCT00908713|Placebo Comparator|Placebo|
11563512|NCT00908700|Experimental|Occlusion arm|Surgical intervention: Occlusion of the left atrial appendage (LAA) using 'cut-and-sew' technique appendage occlusion.
11563513|NCT00908700|Active Comparator|Medical arm|Medical arm: The comparator is best medical practice for atrial fibrillation related stroke prevention as per guidelines.
11563514|NCT00908687|Experimental|Group 1: 30 µg HA, no LT patch|A/H5N1 Vaccine 30 µg HA i.m. on Day 0
11563515|NCT00908687|Experimental|Group 2: 30 µg HA + 50 µg LT patch|A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
11563516|NCT00908687|Experimental|Group 3: 30 µg HA + 100 µg LT patch|A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
11563517|NCT00908687|Experimental|Group 4: 45 µg HA, no LT patch|A/H5N1 Vaccine 45 µg HA i.m. on Day 0
11563518|NCT00908687|Experimental|Group 5: 45 µg HA + 50 µg LT patch|A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
11563595|NCT00908154|Other|Cohort 4|
11563519|NCT00908687|Experimental|Group 6: 45 µg HA + 100 µg LT patch|A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
11563520|NCT00908674||Group 1|
11563521|NCT00908661|Active Comparator|Prophylactic mesh|All patients will have a permanent ostomy and a randomisation with prophylactic mesh
11563522|NCT00908661|No Intervention|without prophylactic mesh|All patients will have a permanent ostomy and a randomisation without prophylactic mesh
11563523|NCT00908648|No Intervention|1|standard white light
11563524|NCT00908648|Experimental|2|Narrow Band Imaging
11563525|NCT00908635||survivor|survivors of patients
11563526|NCT00908635||fatalities|non-survivors of patients
11563527|NCT00908622|Experimental|Skeletal myoblasts|Percutaneous autologous myoblast implantation
11563528|NCT00908622|Placebo Comparator|No cells|Percutaneous culture medium without cells implantation
11563529|NCT00908609||1|Patients who undergo routine ultrasound guided biopsy will be studied by optical imaging technique.
11563530|NCT00908609||2|Patients who have advanced breast cancers and are under neoadjuvant chemotherapy treatment will be studied by optical technique.
11563531|NCT00908596|Experimental|Gadoxetic acid disodium (Primovist/Eovist, BAY86-4873)|Participants received Primovist at a dose of 0.025 mmol/kg body weight (BW) intravenously.
11563532|NCT00908583|Experimental|Phase 1, two stages|Patients will receive 1 dose of rituximab, 4 doses of bortezomib and plasmapheresis. Rituximab will be given at a dose of 375 mg/m2 on day 32. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 32, 35, 39, 42. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
11563533|NCT00908583|Experimental|Phase 2, two stages|Patients will receive 1 dose of rituximab, 4 doses of bortezomib and plasmapheresis. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 32, 35, 39, 42. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
11563534|NCT00908583|Experimental|Phase 3, two stages|Patients will receive 1 dose of rituximab and 4 doses of bortezomib. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 23, 26, 30 and 33. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
11563535|NCT00908583|Experimental|Phase 4, single stage|Patients will receive 1 dose of rituximab and 6 doses of bortezomib. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered during the pre-transplant period on days 1, 4, 8, and 11, 14, and 17. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
11563536|NCT00908583|Experimental|Phase 5, single stage|Phase 5 evaluated even greater bortezomib dosing density by eliminating the inter-cycle dosing interval. Phase 5 evaluated eight consecutive doses of bortezomib with one dose of rituximab. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patient will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, 11, 14, 17, 20, and 23. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
11563537|NCT00908570|Experimental|1Topical estriol cream|
11563538|NCT00908570|Placebo Comparator|2Placebo cream|
11563539|NCT00908557|Experimental|1|Patients receiving an information and consent form that has been modified using the LISYCOM methods.
11563540|NCT00908557|Active Comparator|2|Patients receiving a standard information and consent form.
11563541|NCT00908544|Experimental|PHI-patients|"Patients with primary HIV infection (PHI) (see also Eligibility) are immediately treated with 2 NRTI + 1 PI/r + Maraviroc + Raltegravir"
11563542|NCT00908544|Experimental|CHI-patients|"Patients with chronic HIV infection (CHI) and with suppressed plasma viral load for at least three years under continuous HAART (2 NRTI + 1 PI/r see also Eligibility) intensified by Maraviroc + Raltegravir"
11563543|NCT00908531|Active Comparator|Postoperative letrozole|Definitive surgery without preoperative AI treatment
11563544|NCT00908531|Experimental|Preoperative letrozole|Treatment with letrozole for 4 months before definitive surgery.
11563545|NCT00908518||Total Intravenous Anesthesia|Propofol based anesthesia
11563546|NCT00908518||Inhaled anesthesia|Isoflurane based anesthesia
11563547|NCT00908505|Experimental|physiotherapy|
11563548|NCT00908492|Active Comparator|Education Control|
11563549|NCT00908492|Experimental|Environmental Skill Building|
11563550|NCT00908479|Experimental|LE|Leg Exercise group
11563551|NCT00908479|Experimental|LM|Leg Management (Control group)
11563552|NCT00908466|Experimental|Intravitreal Injection|Will receive intravitreal injections of sirolimus 352 µg in study eye on Days 0, 60, and 120.
11563553|NCT00908466|Experimental|Subconjunctival Injection|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
11563554|NCT00908453|Experimental|15mg/kg of loading dose|
11563555|NCT00908453|Experimental|18mg/kg of loading dose|
11563556|NCT00908453|Experimental|22.5mg/kg of loading dose|
11563559|NCT00908414|Experimental|Panel 1: Single Dose Escalation|Panel 1 will receive doses of 40 milligram (mg) (Session Ia), 100 mg (Session IIa), 200 mg (Session IIIa) and 400 mg (Session IVa) of TMC589337 or placebo.
11563560|NCT00908414|Experimental|Panel 2: Single Dose Escalation|Panel 2 will receive doses of 40 mg (Session Ib), 100 mg (Session IIb), 200 mg (Session IIIb) and 400 mg (Session IVb) of TMC589354 or placebo.
11563561|NCT00908414|Experimental|Panel 3: Multiple dosing|AA mg (Final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) b.i.d. (twice daily) during 7 days (Session Va) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session VIIIa).
11563562|NCT00908414|Experimental|Panel 4: Multiple dosing|BB mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589354 (n=6) b.i.d. during 7 days (Session Vb) ) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session VIIIb).
11563563|NCT00908414|Experimental|Panel 5: Multiple dosing|CC mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) b.i.d. during 7 days (Session VIa) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session IXa).
11563564|NCT00908414|Experimental|Panel 6: Multiple dosing|DD mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589354 (n=6) b.i.d. during 7 days (Session VIb) ) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session IXb).
11563565|NCT00908414|Experimental|Panel 7: Multiple dosing|EE mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) or YY mg TMC589354 (n=6) b.i.d. or q.d. during 7 days (Session VII) ) plus a single oral dose of 300 mg or 600mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg or 600 mg TMC310911, single dose (Session X).
11563566|NCT00908401|Active Comparator|sucrose|This group will receive oral sucrose for procedural pain
11563567|NCT00908401|Experimental|breastmilk|this group will receive breastmilk as analgesic product to avoid procedural pain
11563568|NCT00908388|Experimental|GORE Conformable TAG® Device Surgical Implant|
11563569|NCT00908375|Active Comparator|Pregabalin|A 75mg pregabalin capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
11563570|NCT00908375|Placebo Comparator|Surgar Pill|One Sugar pill capsule will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 Sugar pill capsules twice a day. The total duration of the treatment will be 3 weeks.
11563571|NCT00908362|Active Comparator|A|Inhalation of Fluticasone (via discus) twice daily for 28 days
11563572|NCT00908362|Active Comparator|B|Inhalation of Fluticasone and Salmeterol (via discus) twice daily for 28 days
11563573|NCT00908362|Placebo Comparator|C|Inhalation of Placebo (via discus) twice daily for 28 days.
11563574|NCT00908349|Other|Oxcarbazepine XR|Open Label Study
11563575|NCT00908336|Experimental|Docetaxel and Erlotinib|"Patients in the experimental arm will receive sequential treatment of intermittent erlotinib and docetaxel up to 4 cycles in the absence of disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.
~After 4 cycles, participants will receive 150 mg of erlotinib per day until disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment."
11563576|NCT00908336|Active Comparator|Erlotinib|Erlotinib (Tarceva®) 150 mg/day po daily until disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.
11563577|NCT00908323||A|Participants receiving the JS7 DNA and MVA/HIV62 vaccinations in HVTN 205
11563578|NCT00908323||B|Participants receiving the placebos of the JS7 DNA and MVA/HIV62 vaccines in HVTN 205
11563579|NCT00908310|Other|Omniscan|
11563580|NCT00908284|Active Comparator|Control Group|Participants will take part in a 12-week control group.
11563581|NCT00908284|Experimental|Exercise Program|Participants will take part in a 12-week exercise program.
11563582|NCT00908271|Other|Dapagliflozin|PO and IV
11563583|NCT00908245|Experimental|Preconditioning|Surgery with ischemic preconditioning
11563584|NCT00908245|Active Comparator|Control|Surgery without preconditioning ischemia
11563585|NCT00908232|Experimental|Stable Disease: VD|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8
11563586|NCT00908232|Experimental|Stable Disease: VDC|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and cyclophosphamide 500 mg, orally daily, days 1, 8 and 15 for cycle 5 to 8
11563587|NCT00908232|Experimental|Stable Disease: VDL|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and lenalidomide 10 mg orally daily from day 1 to day 14 for cycle 5 to 8
11563588|NCT00908232|Experimental|Complete to Partial Response: VD|Complete, very good partial or partial response after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8
11563589|NCT00908219|Experimental|Bevacizumab IV|All subjects will be treated with an intravenous infusion of the experimental drug (Bevacizumab 15 mg/kg) every 3 weeks for a total of twelve (12) weeks on study.
11563590|NCT00908206|Placebo Comparator|Placebo|Placebo to match GSK598809.
11563591|NCT00908193|Experimental|1|robot-assisted coelioscopy
11563592|NCT00908193|Active Comparator|2|conventional coelioscopy
11563593|NCT00908167|Other|Research Participants|Participants treated with sorafenib, cytarabine and clofarabine.
11563594|NCT00908154|Other|Cohort 1|
11563598|NCT00908141|Experimental|Arm I: sargramostim (days1-14)|Patients receive sargramostim (GM-CSF) subcutaneously (SC) on days 1-14. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11563599|NCT00908141|Experimental|Arm II: sargramostim (3xweek)|Patients receive GM-CSF SC three times weekly for 4 weeks. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11563600|NCT00908128|Experimental|Mycophenolate Mofetil (test) First|Mycophenolate Mofetil Tablets, 500 mg dosed in first period followed by CellCept® Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
11563601|NCT00908128|Active Comparator|CellCept® (reference) First|CellCept® Tablets, 500 mg dosed in first period followed by Mycophenolate Mofetil Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
11563602|NCT00908115||Infanrix Group|Subjects received one dose of Infanrix™ at 2, 4 and 6 months of age (primary vaccination), one dose at 15-18 months of age (booster vaccination) and one dose at 4-6 years of age (booster vaccination).
11563603|NCT00908102|Active Comparator|BB|"Subjects received the back book booklet, which is an self-information booklet about managing low back symptoms.
~Included in the Mild and Mild vs. NC interventions."
11563604|NCT00908102|Experimental|BB+A|"Subjects received a back book booklet and also oral advice based on the back book by the occupational health professional (OH Nurse or OH Physician in mild or moderate intervention, respectively).
~Included in the Mild and Mild vs. NC interventions. Arm was also used as a control at the Moderate and Moderate vs. NC interventions."
11563605|NCT00908102|Experimental|DBC|A graded activity back school program was carried out in a physiotherapy out-patient clinic that consisted of one-hour session twice or three times per week, lasting for 12 weeks, supervised by a specially trained physiotherapist. Arm is included in the MOderate and Moderate vs. NC interventions.
11563606|NCT00908102|Experimental|PMU|An intensive, multidisciplinary LBP rehabilitation program was carried out in a physical medicine out-patient unit at the local Central Hospital. The program included a 3-week pre-course of 1,5 hour session at 3 days per week, closely followed by a 3-week intensive rehabilitation course of 6.5 hours per day for 5 days per week. A personal graded activity training program was made for each subject and patients were later called for follow-up visit within 1 year of the initial course. Arm is included in the MOderate and Moderate vs. NC interventions.
11563607|NCT00908102|Placebo Comparator|NC|Natural course of low back pain
11563608|NCT00908089|Active Comparator|Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab|Combination therapy with 3 DMARDs (starting with methotrexate 10-25 mg/week, sulphasalazine 1-2 g/day and hydroxychloroquine 35 mg/kg/week)+ Prednisolon 7.5 mg/day + infliximab 3 mg/kg at weeks 4, 6, 10, 18, 26
11563609|NCT00908089|Placebo Comparator|Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo|Combination therapy with 3 DMARDs (starting with methotrexate 10-25 mg/week, sulphasalazine 1-2 g/day and hydroxychloroquine 25 mg/kg/week)+ Prednisolon 7.5 mg/day + placebo at weeks 4, 6, 10, 18, 26
11563610|NCT00908076|Active Comparator|amitiza|Amitiza
11563611|NCT00908076|Placebo Comparator|Placebo|Matching Placebo
11563612|NCT00908063|Experimental|Oxycyte|"Single intravenous infusion of Oxycyte (Perfluoro(t-butylcyclohexane) Intravenous Emulsion 60% w/v)
~One of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury."
11563613|NCT00908063|Placebo Comparator|Normal Saline|"Single intravenous infusion of Normal Saline
~One of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury."
11563614|NCT00908050|Placebo Comparator|Placebo|Placebo arm
11563615|NCT00908050|Active Comparator|botulinum toxin type A|Active arm
11563616|NCT00908037|Experimental|eltrombopag plus standard of care|eltrombopag
11563617|NCT00908037|Placebo Comparator|placebo plus standard of care|placebo
11563618|NCT00908024|Experimental|BMS-754807 + cetuximab|Combination
11563619|NCT00908011|Active Comparator|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)
11563620|NCT00908011|Active Comparator|Standard Care|Increased dose of rosuvastatin to 20mg/day
11563621|NCT00907998|Experimental|APL180 (first dose level)|
11563622|NCT00907998|Experimental|APL180 (second dose level)|
11563623|NCT00907998|Placebo Comparator|Placebo|
11563624|NCT00907985|Experimental|Treatment sequence A|Subjects on sequence A will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
11563625|NCT00907985|Experimental|Treatment sequence B|Subjects on sequence B will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
11563626|NCT00907985|Experimental|Treatment sequence C|Subjects on sequence C will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
11563627|NCT00907985|Experimental|Treatment sequence D|Subjects on sequence D will receive single dose of placebo in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
11563628|NCT00907985|Experimental|Treatment sequence E|Subjects on sequence E will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + placebo in session B of part 2.
11563629|NCT00907985|Experimental|Treatment sequence F|Subjects on sequence F will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
11563630|NCT00907985|Experimental|Treatment sequence G|Subjects on sequence G will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + placebo in session B of part 2.
11563757|NCT00907166|Experimental|Phase II, Arm A|CPI-613 + Gemcitabine
11563631|NCT00907985|Experimental|Treatment sequence H|Subjects on sequence H will receive single dose of placebo part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
11563632|NCT00907985|Experimental|Treatment sequence I|Subjects on sequence I will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
11563633|NCT00907985|Experimental|Treatment sequence J|Subjects on sequence J will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
11563634|NCT00907985|Experimental|Treatment sequence K|Subjects on sequence K will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
11563635|NCT00907985|Experimental|Treatment sequence L|Subjects on sequence L will receive single dose of placebo in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
11563636|NCT00907985|Experimental|Treatment sequence M|Subjects on sequence M will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + placebo in session B of part 2.
11563637|NCT00907985|Experimental|Treatment sequence N|Subjects on sequence N will receive single dose of vofopitant 10 milligrams capsule in part 1, placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
11563638|NCT00907985|Experimental|Treatment sequence O|Subjects on sequence O will receive placebo in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + placebo in session B of part 2.
11563639|NCT00907985|Experimental|Treatment sequence P|Subjects on sequence P will receive placebo in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
11563640|NCT00907985|Experimental|Treatment sequence Q|Subjects on sequence Q will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session A of part 2 and placebo + placebo in session B of part 2.
11563641|NCT00907985|Experimental|Treatment sequence R|Subjects on sequence R will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session B of part 2.
11563642|NCT00907985|Experimental|Treatment sequence S|Subjects on sequence S will receive placebo in part 1, single doses of lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session A of part 2 and placebo + placebo in session B of part 2.
11563643|NCT00907985|Experimental|Treatment sequence T|Subjects on sequence T will receive placebo in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session B of part 2.
11563644|NCT00907972|Experimental|Vitamin D3 supplementation|1000 IU/day of Vitamin D3
11563645|NCT00907972|Placebo Comparator|Placebo|Placebo
11563646|NCT00907946|Experimental|NT prior to PCNL|"A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one week prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:
~Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.
~If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol."
11563647|NCT00907946|No Intervention|NT at the surgery|A bladder urine culture will be obtained prior to surgery and appropriate antibiotic treatment will be initiated if necessary. The nephrostomy tract will be placed at the time of surgery under fluoroscopic guidance. All patients will receive empiric intravenous peri-operative antibiotics at induction. Renal pelvis urine and stone will be collected for culture and post-operative treatment will be initiated if necessary.
11563648|NCT00907933|Experimental|Part 1 - Arm 1|HVTs
11563649|NCT00907933|Placebo Comparator|Part 2 - Arm 3|HVTs
11563650|NCT00907933|Experimental|Part 1 - Arm 2|HVTs
11563651|NCT00907933|Experimental|Part 1 - Arm 3|HVTs
11563652|NCT00907933|Experimental|Part 1 - Arm 4|HVTs
11563653|NCT00907933|Experimental|Part 1 - Arm 5|HVTs
11563654|NCT00907933|Placebo Comparator|Part 1 - Arm 6|HVTs
11563655|NCT00907933|Experimental|Part 2 - Arm 1|HVTs
11563656|NCT00907933|Experimental|Part 2 - Arm 2|HVTs
11563657|NCT00907920||Correlative studies|"Tumor DNA samples are examined by mutation analysis for germline and somatic mutations in the ALK tyrosine kinase domain. Samples are analyzed by whole genome amplification using polymerase chain reaction and then sequenced for DNA alterations in the entire ALK coding sequence. Samples are also examined for SNPs by polymorphism analysis. Exploratory multivariable analysis is performed to test for the prognostic ability of ALK mutations in the presence of other known prognostic variables (i.e., age, International Neuroblastoma Staging System stage, MYCN status, International Neuroblastoma Pathology Classification, and diploidy).
~A subset of tumor DNA samples from high-risk patients will be resequenced for DNA alterations to determine whether or not additional regions in ALK, outside of the tyrosine kinase domain, are prone to mutations and should be sequenced in a larger panel."
11563658|NCT00907907|Experimental|Mycophenolate Mofetil (test) First|Mycophenolate Mofetil Tablets, 500 mg dosed in first period followed by CellCept® Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
11563659|NCT00907907|Active Comparator|Cellcept® (reference) First|CellCept® Tablets, 500 mg dosed in first period followed by Mycophenolate Mofetil Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
11563660|NCT00907894|Experimental|Stratum 1|
11563661|NCT00907894|Experimental|Stratum 2|
11563663|NCT00907881||All participants|Participants with type 2 diabetes mellitus (T2DM) who had sulfonylurea treatment added to an on-going regime of oral hypoglycemic agent(s).
11563664|NCT00907868|Active Comparator|Arm I|Patients undergo whole breast irradiation (WBI) once daily for 5 weeks (weekdays only).
11563665|NCT00907868|Experimental|Arm II|Patients undergo WBI as in arm I and a radiation tumor bed boost once daily for 8 days (weekdays only).
11563666|NCT00907842|Experimental|mesh placement|
11563667|NCT00907829|Active Comparator|Arm 1|persons with severe hand impairment following hemiparetic stroke
11563668|NCT00907829|Active Comparator|Arm 2|persons with severe hand impairment following hemiparetic stroke
11563669|NCT00907816||intervention|PCPs at MGH who receive display of utilization and quality during computer order entry
11563670|NCT00907816||control|
11563671|NCT00907803|Experimental|ST-246 400 mg|ST-246 400mg (2 x 200 mg Capsules) Orally Once Daily for 14 days
11563672|NCT00907803|Experimental|ST-246 600 mg|ST-246 600 mg (3 x 200 mg Capsules) Orally Once Daily for 14 days
11563673|NCT00907803|Placebo Comparator|Placebo|Matching Placebo capsules, Orally Once Daily for 14 days
11563674|NCT00907790|Experimental|Comprehensive Self-Management (CSM)|"Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS
~--------------------------------------------------------------------------------"
11563675|NCT00907790|Other|Usual Care (Control Group)|Includes the usual care provided by the person and their health care provider.
11563676|NCT00907777|Experimental|Pn Group|Subjects receiving GSK 1024850A vaccine.
11563677|NCT00907777|Active Comparator|Prev Group|Subjects receiving Prevenar™ vaccine.
11563678|NCT00907764|Experimental|Regadenoson alone|
11563679|NCT00907764|Experimental|Regadenoson with exercise|
11563680|NCT00907764|Experimental|Regadenoson with contrast agent|
11563681|NCT00907764|Experimental|Regadenoson with contrast agent (perfusion)|
11563682|NCT00907751|Experimental|1|Microangiopathic hemolytic anemia (< 12 g/dL) with thrombocytopenia (<50 G/L)
11563683|NCT00907738|Experimental|Vorinostat|
11563684|NCT00907725|Other|1|serum BhCG follow-up
11563685|NCT00907725|Other|2|ultrasonographic follow-up
11563686|NCT00907712|No Intervention|cardiovascular|cardiac echo
11563687|NCT00907686||LBWIs of CMV-positive mother|LBWIs born to CMV-positive mothers
11563688|NCT00907686||CMV Sero-negative & Sero-postive LBWIs|LBWIs of CMV sero-negative & sero-positive mothers
11563689|NCT00907673|Active Comparator|Patient condition pre-implant|
11563690|NCT00907660|Active Comparator|Full Dose|Provision of 8 weight loss counseling sessions, calorie guide, pedometer, meal plan, and 2 meals per day of portion-controlled foods (shakes and entrees)
11563691|NCT00907660|Experimental|Half dose|Provision of 8 weight loss counseling sessions, calorie guide, pedometer, meal plan, and 1 meal per day of portion-controlled foods (shakes and entrees)
11563692|NCT00907621|Experimental|Acupuncture|"Acupuncture with Seirin 020x15 mm sterile acupuncture needle:
~Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36 on infants born after 36th week of gestation and weighing over 2500 grams at birth, and who qualify according to Wessels definition:
~Paroxystical, uncontrolled crying in an otherwise healthy child under 3 months of age, and with more than 3 hours of crying 3 days per week for 3 weeks."
11563693|NCT00907621|No Intervention|Control|"Infants born after 36th week of gestation and weighing over 2500 grams at birth, and who qualify according to Wessels definition:
~Paroxystical, uncontrolled crying in an otherwise healthy child under 3 months of age, and with more than 3 hours of crying 3 days per week for 3 weeks.
~The Control group will have no intervention."
11563694|NCT00907608|Experimental|1|Receive Darbepoetin alfa
11563695|NCT00907608|No Intervention|2|
11563696|NCT00907595|Active Comparator|Ramelteon|Subjects randomized to Ramelteon
11563697|NCT00907595|Placebo Comparator|Placebo|Subjects randomized to placebo
11563698|NCT00907582|Experimental|ASCT in relapsed APL|autologous hematopoietic cell transplantation for patients with relapsed APL after achieving molecular remission
11563699|NCT00907543|Other|Neoadjuvant Treatment|Preoperative chemotherapy/radiotherapy treatment
11563700|NCT00907543|Experimental|Adjuvant Treatment|Postoperative chemotherapy/radiotherapy treatment
11563701|NCT00907530|Active Comparator|MULTIHANCE|gadobenate dimeglumine
11563702|NCT00907530|Active Comparator|GADOVIST|gadobutrol
11563703|NCT00907517|Experimental|MK-8776 10 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 10 mg/m^2 intravenously (IV) on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour continuous intravenous infusion (CIV) on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
11563704|NCT00907517|Experimental|MK-8776 20 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 20 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
11563705|NCT00907517|Experimental|MK-8776 40 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 40 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
11563706|NCT00907517|Experimental|MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 56 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
11563707|NCT00907517|Experimental|MK-8776 140 mg + Cytarabine 2 g/m^2|Participants received MK-8776 140 mg flat dose IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
11563708|NCT00907504|Experimental|CP-751,871 + Gemcitabine + Cisplatin|investigational arm
11563711|NCT00907478|Experimental|Romiplostim|"Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years.
~The starting dose of romiplostim was 1 μg/kg; weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L."
11563712|NCT00907465||Calibration study|These individuals were used to develop cut points for sedentary behavior using accelerometers and a metabolic chamber.
11563713|NCT00907452|Active Comparator|melphalan-prednisone-thalidomide|
11563714|NCT00907452|Active Comparator|lenalidomide-dexamethasone|
11563715|NCT00907426|Experimental|Bimatoprost 0.03% Followed by Bimatoprost 0.03%|Treatment period one (0-6 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin.
11563716|NCT00907426|Other|Bimatoprost 0.03% Followed by Vehicle|Treatment period one (0-6 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin.
11563717|NCT00907426|Other|Vehicle Followed by Bimatoprost 0.03%|Treatment period one (0-6 months), once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin.
11563718|NCT00907413|Experimental|ERCP and PDT|Endoscopic Retrograde Cholangio Pancreatography (ERCP) and stenting combined with Photodynamic Dynamic Therapy ERCP and PDT
11563719|NCT00907413|Active Comparator|ERCP alone|Endoscopic Retrograde Cholangio Pancreatography (ERCP) with stenting alone
11563720|NCT00907400|Experimental|1|PN400
11563721|NCT00907400|Active Comparator|2|Naprosyn E
11563722|NCT00907387|Active Comparator|Dose A|Dose A RT001
11563723|NCT00907387|Active Comparator|Dose B|Dose B RT001
11563724|NCT00907387|Placebo Comparator|Dose C|Dose C Placebo
11563725|NCT00907374|Active Comparator|Low dose inhibition of RAS|Standard low dose inhibition of the RAS with 10 mg of benazepril orally daily to treat microalbuminuria
11563726|NCT00907374|Experimental|Agressive inhibition of the RAS|40-80 mg benazepril plus 25-100 mg losartan both orally once or twice daily
11563727|NCT00907348|Experimental|Cohorts 1 - 2 - 3 - 4|Chemiotherapy
11563728|NCT00907335|Experimental|Retin-A Micro|Retin-A Micro 0.04% facial acne treatment used once daily
11563729|NCT00907335|Placebo Comparator|Vehicle Control|Color matched facial gel vehicle control used once daily
11563730|NCT00907322|Experimental|Dimbeon 20 mg|
11563731|NCT00907322|Experimental|Dimebon 40 mg|
11563732|NCT00907322|Experimental|Dimebon 60 mg|
11563733|NCT00907322|Experimental|Placebo|
11563734|NCT00907309|No Intervention|Treatment as usual|Participants will receive treatment as usual from their provider.
11563735|NCT00907309|Experimental|iMET|Participants will receive the iMET intervention.
11563736|NCT00907309|Experimental|iMET/TE|Participants will receive the iMET intervention and Technological Extenders (TEs).
11563737|NCT00907296|Placebo Comparator|Placebo|Participants received subcutaneous injections of matching placebo on day 1 and at weeks 2, 6, and 12.
11563738|NCT00907296|Experimental|Romosozumab 70 mg: 2 Doses|Participants received subcutaneous injections of 70 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
11563739|NCT00907296|Experimental|Romosozumab 70 mg: 3 Doses|Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
11563740|NCT00907296|Experimental|Romosozumab 70 mg: 4 Doses|Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2, 6, and 12.
11563741|NCT00907296|Experimental|Romosozumab 140 mg: 2 Doses|Participants received subcutaneous injections of 140 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
11563742|NCT00907296|Experimental|Romosozumab 140 mg: 3 Doses|Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
11563743|NCT00907296|Experimental|Romosozumab 140 mg: 4 Doses|Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2, 6, and 12.
11563744|NCT00907296|Experimental|Romosozumab 210 mg: 2 Doses|Participants received subcutaneous injections of 210 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
11563745|NCT00907296|Experimental|Romosozumab 210 mg: 3 Doses|Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
11563746|NCT00907296|Experimental|Romosozumab 210 mg: 4 Doses|Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2, 6, and 12.
11563747|NCT00907283|Experimental|deferiprone|15 mg/Kg/twice for 1 year
11563748|NCT00907270|Active Comparator|Cholecalciferol: 400 IU/day|Control: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D (Cholecalciferol: 400 IU/day)
11563749|NCT00907270|Experimental|Cholecalciferol 4000 IU/day|Experimental: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D
11563750|NCT00907257|Experimental|Same time of day|5% benzoyl peroxide wash and 0.04% tretinoin gel used at same time of day
11563751|NCT00907257|Active Comparator|Different times of day|5% benzoyl peroxide wash used in the morning and 0.04% tretinoin gel used in the evening
11563752|NCT00907218|Experimental|1|Adults who meet DSM-IV-TR criteria for ADHD and smoke cigarettes.
11563753|NCT00907205|Experimental|SF1126|Twice weekly IV infusion
11563754|NCT00907192||Opioids|Personal Interview and Questionnaire of Advanced cancer patients, taking narcotic pain drugs (opioids).
11563755|NCT00907179|Experimental|Dose escalation|"Phase I: Determine the highest and safest dosage of LBH589 (15 mg, 20 mg, and 30 mg). If the 15 mg dosage causes too many side effects, a back-up dosage of 10 mg will be used instead of the 15 mg.
~Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given"
11563756|NCT00907166|Experimental|Phase I, Arm A|CPI-613 + Gemcitabine
11563758|NCT00907166|Active Comparator|Phase II, Arm B|Gemcitabine
11563759|NCT00907153|Experimental|Vitamin D|
11563760|NCT00907153|Placebo Comparator|Placebo|
11563761|NCT00907140|Other|Chemoradiation therapy|
11563762|NCT00907127|Active Comparator|Mediterranean Diet and Exercise|Mediterranean Diet and Exercise
11563763|NCT00907114|Active Comparator|Ketorolac tromethamine|ocular topic ketorolac used 4 times a day during a week after panphotocoagulation
11563764|NCT00907114|Placebo Comparator|Polivynilic alcohol|ocular lubricant drops 4 times a day during one week after panphotocoagulation
11563765|NCT00907101|Experimental|Study Treatment|"Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)
~Other Names:
~Epiduo® Gel Apply once daily"
11563766|NCT00907088|Active Comparator|1|
11563767|NCT00907088|Experimental|2|
11563768|NCT00907075|Active Comparator|NES With Energy Restriction|
11563769|NCT00907075|Active Comparator|NES Without Energy Restriction|
11563770|NCT00907062|Experimental|Gingko biloba|60 mg of Ginkgo biloba (standardized to 15 mg ginkgofavonglycosides) given 2 times per day, with food, for 12 weeks.
11563771|NCT00907049||Subacute neck pain; chronic neck pain|Patients with subacute or chronic neck pain seen in the Primary Care Centers participating in the study.
11563772|NCT00907023||SOT|Patients that have had a solid organ transplant
11563773|NCT00907010||Group I|11 to 18 years - composed of 12 adolescent with six women and six men
11563774|NCT00907010||Group II|20 to 26 years - composed of 12 young with six women and six men
11563775|NCT00907010||Group III|45 to 60 years - composed of 12 adult with six women and six men
11563776|NCT00907010||Group IV|66 - 82 years - composed of 12 aged with six women and six men
11563777|NCT00906997|Active Comparator|Fecal occult blood testing|
11563778|NCT00906997|Active Comparator|Colonoscopy|
11563779|NCT00906984|Other|TheraSphere® treatment|TheraSphere® treatment will be performed in the outpatient setting. The effect on the tumor and any side effects of TheraSphere® HUD treatment will be examined. This is not a research study and there are no comparison or experimental treatments being used. Within 14 days of initial treatment, reverification of eligibility will be confirmed. If review of eligibility indicates an uncorrectable risk of flow to the gastrointestinal organs or risk of shunting to the lungs, treatment will not be administered. In this event, the patient will receive alternative treatment (chemoembolization) or no treatment. If the patient remains eligible, TheraSphere® will be administered within 14 days. All patients will be evaluated at 30 days post-treatment to assess clinical experience and adverse effects. Subsequently, patient status will be followed via communication with the referring oncologist to determine disease status and survival. Survival surveillance will continue up to 24 months.
11563780|NCT00906971|Active Comparator|Laxatives|Magnesium hydroxide for which the dosage varied according to individual needs (a minimum of 2 ml/kg), and received guidance regarding fiber-rich foods, water and toilet training. Patients attended weekly consultations with a pediatric gastroenterologist.
11563781|NCT00906945|Experimental|Dose Level 1|"G-CSF 10 mcg/kg SQ on Days 1-8
~Plerixafor 240 mcg/kg/d IV qd
~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8
~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8
~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
11563782|NCT00906945|Experimental|Dose Level 2|"G-CSF 10 mcg/kg SQ on Days 1-8
~Plerixafor 320 mcg/kg/d IV qd
~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8
~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8
~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
11563783|NCT00906945|Experimental|Dose Level 3|"G-CSF 10 mcg/kg SQ on Days 1-8
~Plerixafor 420 mcg/kg/d IV qd
~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8
~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8
~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
11563784|NCT00906945|Experimental|Dose Level 4|"G-CSF 10 mcg/kg SQ on Days 1-8
~Plerixafor 560 mcg/kg/d IV qd
~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8
~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8
~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
11563785|NCT00906945|Experimental|Dose Level 5|"G-CSF 10 mcg/kg SQ on Days 1-8
~Plerixafor 750 mcg/kg/d IV qd
~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8
~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8
~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
11563786|NCT00906945|Experimental|MTD - Phase II|"G-CSF MTD determined in Phase 1 SQ on Days 1-8
~Plerixafor MTD determined in Phase 1 mcg/kg/d IV qd
~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8
~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8
~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
11563787|NCT00906932||Trachview videoscope, direct laryngoscopy|Each subject served as their own control - the Trachview videoscope and direct laryngoscopy was performed on by all subjects in a sequential fashion.
11563788|NCT00906932||See above|See above
11563789|NCT00906919|Active Comparator|Regular diabetes patient education|Regular professionally-led diabetes patient education
11563790|NCT00906919|Experimental|Augmented Diabetes Patient Education|Regular professionally-led diabetes patient education augmented by participation in the Stanford Chronic Disease Self-Management Program
11563791|NCT00906906||1|Patient to receive CPB
11563792|NCT00906893|Experimental|1|
11563793|NCT00906867||Vocal cord dysfunction|Patients with suspicion of VCD
11563794|NCT00906854||Group I|practice of weight training exercises
11563795|NCT00906854||Group II|aerobic exercises as part of lessons jump, step and dance classes
11563796|NCT00906854||Group III|swimming (crawl mode)
11563797|NCT00906841|Experimental|90Y-DOTA-hLL2|Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)
11563798|NCT00906828|Active Comparator|1. Duodopa, optimised dose|
11563799|NCT00906828|Experimental|2. 80% Duodopa + entacapone|80% of optimised Duodopa dose + two tablets of entacapone at t=0 hours and at t= 6 hours
11563800|NCT00906828|Experimental|3. 80% Duodopa + tolcapone|80% of optimised Duodopa dose + two tablets of tolcapone at t=0 hours and at t= 6 hours
11563801|NCT00906802|Experimental|R-Y reconstruction|the reconstruction was performed by R-Y anastomosis
11563802|NCT00906802|No Intervention|conventional reconstruction|the anastomosis was performed by B-II
11563803|NCT00906789||Radiologists|Radiologists who have certification by the American Board of Radiology
11563804|NCT00906776|Active Comparator|Emdogain PLUS|Straumann Emdogain in combination with Straumann BoneCeramic
11563805|NCT00906776|Active Comparator|Autogenous bone|Autogenous bone from the patient
11563806|NCT00906763|Active Comparator|Dark Chocolate (85% cocoa)|Oral Intake of dark chocolate (85% cocoa) over 15 minutes.
11563807|NCT00906763|Active Comparator|White chocolate (0% cocoa)|Oral intake of 200 grams of white chocolate (0% cocoa) over 15 Minutes.
11563808|NCT00906750|Experimental|1|
11563809|NCT00906750|Active Comparator|2|
11563810|NCT00906737|Experimental|Ankle-Bot Training|Subjects in this group receive focused ankle training using the ankle-bot device.
11563811|NCT00906737|Active Comparator|Conventional Therapy|Subjects in this group will receive conventional focused ankle physical therapy.
11563812|NCT00906737|No Intervention|Control|Subjects in this group will not receive treatment; they will continue their usual care.
11563813|NCT00906724||aerobic exercise|Aerobic exercise in Insulin Resistant Minority Adolescents
11563814|NCT00906711||Group I|(G1): 10 - 18 years old
11563815|NCT00906711||Group II|(G2): 20 - 35 years old
11563816|NCT00906711||Group III|(G3): 45 - 60 years old
11563817|NCT00906711||Group IV|(G4): 65 - 85 years old
11563818|NCT00906698|Experimental|BIBW 2992 and vinorelbine i.v|Daily low (20mg), medium (40mg) and high (50mg) dosages of BIBW 2992 with standard dosage of vinorelbine i.v.
11563819|NCT00906698|Experimental|BIBW 2992 and vinorelbine per os|Daily low (20mg), medium (40mg) and high (50mg) dosages of BIBW 2992 with standard dosage of vinorelbine per os.
11563820|NCT00906685|Active Comparator|Intravitreal bevacizumab|
11563821|NCT00906685|Sham Comparator|Sham injection|
11563822|NCT00906672|Experimental|INTEGRA®|
11563823|NCT00906672|Active Comparator|Flap technique|
11563824|NCT00906659||diabetic macular edema|type 2 patients who had been treated with selective photocoagulation for clinically significant macular edema
11563825|NCT00906646|Experimental|Metabolic therapy|Metabolic therapy with antioxidants and cellular energisers
11563826|NCT00906646|Placebo Comparator|Placebo|Placebo tablets
11563827|NCT00906633||Outcome of combination antifungal therapy|
11563828|NCT00906620|Experimental|QPR intervention|"QPR intervention (Question, Persuade & Refer): The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
11563829|NCT00906620|Experimental|Awareness program|The awareness programme is comprised of a leaflet, six posters and four seminars. The seminars are made up of one introductory lesson, and two interactive follow-up lessons with role play and one final meeting as a closing/debriefing lesson.
11563830|NCT00906620|Experimental|ProfScreen|The program's primary objective is to help young people and their parents through the early identification of mental health problems, such as anxiety, depression, substance abuse, and suicide. Screening strategies are based on the valid premise that suicidal adolescents are under-identified, suffer from an active, often treatable mental illness such as depression and exhibit identifiable risk factors (Gould et al. 2003). A potential shortcoming of screening programs is that asking about suicide could increase suicidal ideation and behaviour. About this issue a recent study (Gould et al . 2005) on over 2300 students reported no evidence of iatrogenic effects of suicide screening and that screening in high schools is a safe component of youth suicide prevention efforts.
11563831|NCT00906620|Experimental|Control group|The control group will comprise 250 subjects. After the baseline assessment, subjects will be randomized in one of the three intervention arms or in the control group. Individuals in the control group will undergo the same baseline and follow-up evaluations as subjects in the intervention arms and will receive the same leaflet about healthy lifestyles with information about the possibility to seek help for unhealthy, suicidal behaviour and mental health problems. In this arm, no additional intervention will be performed although the possibility of seeking help from mental health resources will be available.
11563832|NCT00906607||Group I|10-18 years
11563833|NCT00906607||Group II|20-35 years
11563834|NCT00906607||Group III|45-60 years
11563835|NCT00906607||Group IV|65-75 years
11563836|NCT00906594|Active Comparator|Latanoprost|Latanoprost mono therapy
11563837|NCT00906594|Experimental|Latanoprost + Fixed combination|Latnoprost + Fixed combination
11563838|NCT00906581|Experimental|Behavioral|Behavioral
11563839|NCT00906581|No Intervention|Waitlist control|Waitlist control
11563840|NCT00906568||Sensitized vs non-sensitized|CF with and without SAD defined by MEF25 <50%
11563841|NCT00906555|No Intervention|1|hemodialysis patients with baseline Kt/V between 1.2 and 1.7 (1.2 ≤ Kt/V < 1.7)
11563842|NCT00906555|Experimental|2|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
11563843|NCT00906542||Acute ischemic stroke patients|Acute ischemic stroke patients admitted to the neurological intensive care unit or stroke unit within 24 hours after stroke onset in whom ischemic brain lesion was clearly assessed on CT and/or MRI
11563844|NCT00906529|Active Comparator|Conservative Blood Glucose Control|Goal Pre-prandial blood glucose <180 mg/dl.
11563845|NCT00906529|Active Comparator|Aggressive Blood Glucose Control|Pre-prandial goal blood glucose <110 mg/dl
11563846|NCT00906516|Experimental|Neuradiab in combination with Avastin|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.
~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
11563847|NCT00906503|Experimental|PET/Computed Tomography (CT)|Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan; Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
11563930|NCT00905866||Quality of life|All participants undergoing parathyroidectomy
11563848|NCT00906477|Experimental|Early intervention|Modified CI therapy starting between 7 and 28 days post stroke.
11563849|NCT00906477|Active Comparator|Delayed intervention|Modified CI Therapy starting 6 months post stroke
11563850|NCT00906451|No Intervention|No lipid-lowering|No lipid-lowering treatment during the first 7 days and then simvastatin 20 mg/day for three additional weeks, till the endothelial function assessment
11563851|NCT00906451|Experimental|Simvastatin 20 mg|Simvastatin 20 mg/day for 30 days, till the endothelial function assessment
11563852|NCT00906451|Experimental|Simvastatin 40 mg|Simvastatin 40 mg/day for 7 days and then switched to simvastatin 20mg/day for additional 3 weeks, till the endothelial function assessment
11563853|NCT00906451|Experimental|Simvastatin 80 mg|Simvastatin 80 mg/day for 7 days and then switched to simvastatin 20 mg/day for additional 3 weeks, till the endothelial function assessment
11563854|NCT00906438|Placebo Comparator|Control|
11563855|NCT00906438|Experimental|Treated|
11563856|NCT00906425|Active Comparator|Submerged healing|The Straumann Bone Level Implant(s) will be placed using a submerged healing treatment
11563857|NCT00906425|Active Comparator|Trans-mucosal healing|The Straumann Bone Level Implant(s) will be placed using a trans-mucosal healing treatment
11563858|NCT00906412||ET Group|Total of 25 participants with ET
11563859|NCT00906412||Controls|25 controls without ET
11563860|NCT00906399|Placebo Comparator|Placebo|Placebo every 2 weeks for 48 weeks followed by 125 µg peginterferon beta-1a subcutaneously every 2 or 4 weeks for 48 weeks.
11563861|NCT00906399|Experimental|Peginterferon Beta-1a Q2W|125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 96 weeks.
11563862|NCT00906399|Experimental|Peginterferon Beta-1a Q4W|125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 96 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).
11563863|NCT00906386|Experimental|1|
11563864|NCT00906386|Placebo Comparator|placebo|
11563865|NCT00906373|Active Comparator|Cohort 1, IMC A12 - 10 mg/kg|Treatment cycles will repeat until there is evidence of progressive disease (PD), toxicity, or withdrawal. If any participant experiences a dose-limiting toxicity (DLT), an additional 3 participants will be enrolled at this dose level (for a total of 6). If no further DLTs, enrollment into Cohort 2 will occur.
11563866|NCT00906373|Active Comparator|Cohort 2, IMC A12 20 - mg/kg|Treatment cycles will repeat until there is evidence of PD, toxicity, or withdrawal.
11563867|NCT00906360|Experimental|Treatment (enzyme inhibitor and monoclonal antibody therapy)|Patients receive sunitinib malate orally or by percutaneous gastrostomy tube once daily, cetuximab IV over 60-120 minutes once weekly, and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 7-9 weeks in the absence of disease progression or unacceptable toxicity. Patients with persistent disease undergo surgical resection.
11563868|NCT00906347|Active Comparator|Oxytocin augmentation|Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
11563869|NCT00906347|Active Comparator|Misoprostol augmentation|Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
11563870|NCT00906334|Experimental|800 mg/m^2 ON 01910.Na|800 mg/m^2 ON 01910.Na administered as a continuous intravenous infusion (CIV) over 24 hours for 48 hours (i.e. 2 consecutive 24-hour infusions) every week for the first 3 weeks of 4-week cycle.
11563871|NCT00906334|Experimental|1800 mg ON 01910.Na|1800 mg ON 01910.Na administered as a continuous intravenous infusion (CIV) over 24 hours for 72 hours (i.e., 3 consecutive 24-hour infusions) every 2 weeks for the first four 2-week cycles and every 4 weeks afterwards.
11563872|NCT00906308|Placebo Comparator|Placebo|
11563873|NCT00906308|Experimental|MF101 5 g/day|
11563874|NCT00906308|Experimental|MF101 10 g/day|
11563875|NCT00906295|Active Comparator|Allowed drop in hemoglobin to 4.5-5.5 mmol/L|Transfusion with red blood cells to level between 4.5-5.5 mmol/L
11563876|NCT00906295|Experimental|Allowed drop in hemoglobin to 5.6-6.5 mmol/L|Transfusion with red blood cells to level between 5.6-6.5 mmol/L
11563877|NCT00906282|Experimental|Pemetrexed/Carboplatin|"4 cycles of preoperative treatment (1 Cycle = 21 days):
~Pemetrexed: 500 mg/m2 intravenously (IV) for 10 minutes on Day 1 each cycle; Carboplatin: AUC 6.0 by IV on Day 1 each cycle."
11563878|NCT00906269|Active Comparator|1|
11563879|NCT00906269|Sham Comparator|2|
11563880|NCT00906256|Active Comparator|AZD7295|AZD7295
11563881|NCT00906256|Placebo Comparator|Placebo capsule|Placebo
11563882|NCT00906243|Experimental|CV9103|CV9103 will be applied intradermally on three (3) or five (5) time points. Treatment with CV9103 is administered over a period of either seven (7) or twenty-three (23) weeks.
11563883|NCT00906217||elderly patients|patients older than 70 years with normal renal function
11563884|NCT00906204|Experimental|Single-dose Thymoglobulin|Biological/Vaccine Single-dose rabbit Anti-thymocyte Globulin induction, 6 mg/kg IV infusion
11563885|NCT00906204|Active Comparator|Divided-dose Thymoglobulin|Biological/Vaccine Divided-dose rabbit Anti-thymocyte Globulin induction, 1.5 mg/kg IV infusion QD x 4
11563886|NCT00906191|Experimental|1|Single oral dose
11563887|NCT00906178|Experimental|CyberSenga|6-module HIV prevention program tailored for adolescents in Uganda
11563888|NCT00906178|No Intervention|Control|"treatment as usual - the sexual health education adolescents currently receive in secondary school"
11563889|NCT00906165|Active Comparator|1- Immediately provisionalized|The Straumann® Bone Level SLActive Implant (4.1mm diameter) will be immediately provisionalized upon placement, i.e. impressions will be taken directly after implant installation in order to fabricate screw-retained resin crowns within 48 hours after implant placement. At 16 weeks, the final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration.
11563890|NCT00906165|Active Comparator|2- Delayed Loading|The Straumann® Bone Level SLActive Implant (4.1mm diameter) will not be immediately provisionalized, instead there will be delayed implant loading. i.e. the patient will receive a removable prosthesis if necessary and the impressions for the final restoration will be taken 12-14 weeks after implant installation. At 16 weeks, the final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration.
11563931|NCT00905853|Active Comparator|Ventricular Tachycardia Ablation|Catheter ablation for Ventricular tachycardia will be performed within 14 days of randomization.
11563891|NCT00906152||Subacute low back pain; chronic low back pain|Patients with subacute or chronic low back pain seen in the Primary Care Centers participating in the study.
11563892|NCT00906139|Active Comparator|Propofol|To receive propofol (0.5 mg/kg up to 400 mg) and fentanyl (0.05 mg);
11563893|NCT00906139|Active Comparator|Midazolam|To receive midazolam (0.1 mg/kg) and fentanyl (0.05 mg).
11563894|NCT00906126|Experimental|Oral Misoprostol 1|Oral misoprostol 25 micrograms every 4 hours for up to two doses.
11563895|NCT00906126|Experimental|Oral Misoprostol 2|Oral misoprostol 50 micrograms every 4 hours for up to two doses.
11563896|NCT00906126|Experimental|Oral Misoprostol 3|Oral misoprostol 100 micrograms every 4 hours for up to two doses.
11563897|NCT00906126|Experimental|Oral Misoprostol 4|Oral Misoprostol 50 micrograms every 2 hours for up to two doses.
11563898|NCT00906126|Experimental|Oral Misoprostol 5|Oral Misoprostol 75 micrograms every 4 hours for up to two doses.
11563899|NCT00906113|Experimental|Intra-arterial melphalan|The patients will be treated by injection of chemotherapy (melphalan) into the ophthalmic artery of an eye affected by retinoblastoma
11563900|NCT00906087|Other|Cosopt|Intraocular pressure and blood pressure measurements will be compared under the following conditions: 1) after washout of clinical treatment, 2) after treatment with Cosopt, and 3) after another washout of Cosopt.
11563901|NCT00906074||Case|Cases will be defined as patients with elective or emergency abdominal surgery who develop severe surgical site infection (deep incisional or organ cavity type; see Center for Disease Control (CDC) criteria for definition in the Appendix), within 0-30 days of surgery.
11563902|NCT00906074||Control|Surgeon-matched controls will be patients with elective or emergency abdominal surgery who are free of surgical site infection (SSI) after 30 days from the surgery.
11563903|NCT00906061|Experimental|Gemcitabine and Docetaxel|Patients received biweekly docetaxel 50 mg/m2 iv, Gemcitabine 2000 mg/m2 iv days 1 and 14.
11563904|NCT00906048|Experimental|1|Levofloxacin and Rifampicin
11563905|NCT00906035|Active Comparator|Dipyridamole 200mg and Aspirin 25mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy. (NIRS) of the legs.
11563906|NCT00906035|Active Comparator|Dipyridamole 200 mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy. (NIRS) of the legs.
11563907|NCT00906035|Active Comparator|Aspirin 25 mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy (NIRS) of the legs.
11563908|NCT00906022|Experimental|Astron Pulsar Stent|Device: Astron Pulsar Stent
11563909|NCT00906022|Active Comparator|PTA alone|Device: Balloon angioplasty alone
11563910|NCT00905996|Active Comparator|Endoscopic Cyanoacrylate injection|Endoscopic injection of cyanoacrylate in the gastric varix until obturation
11563911|NCT00905996|No Intervention|No Intervention|No treatment offered for gastric varix
11563912|NCT00905996|Other|Beta-blocker (propranolol)|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was > 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure < 90 mm Hg or pulse rate < 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
11563913|NCT00905983|Experimental|Gemcitabine and Docetaxel|Patients received biweekly docetaxel 50 mg/m2 iv, Gemcitabine 2000 mg/m2 iv days 1 and 14.
11563914|NCT00905970||1|Patients with LTBI recently diagnosed under prophylactic chemotherapy treatment.
11563915|NCT00905970||2|Patients with LTBI recently diagnosed not following any prophylactic chemotherapy treatment.
11563916|NCT00905970||3|Patients with LTBI diagnosed time ago.
11563917|NCT00905970||4|Positive control for the Exhaled Breath condensate assay only. Patients with active TB will conform this group. The n of this group is determined, as it will only be used as a positive control to prove the bacilli's DNA can be detected in the exhaled breath condensate.
11563918|NCT00905957|Active Comparator|Transversus abdominis plane (TAP) Group|Patients will receive a TAP block using a local anaesthetic agent after induction of anaesthesia
11563919|NCT00905957|Placebo Comparator|Control Group|Patients will receive a TAP block using a placebo after induction of anaesthesia
11563920|NCT00905944|No Intervention|Control|
11563921|NCT00905944|Experimental|Intervention|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
11563922|NCT00905931|Experimental|Active|
11563923|NCT00905931|Placebo Comparator|Placebo|
11563924|NCT00905918|No Intervention|Arm I|Patients receive no intervention before undergoing planned surgery.
11563925|NCT00905918|Experimental|Arm II|Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 1 week before undergoing planned surgery.
11563926|NCT00905918|Experimental|Arm III|Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 2 weeks before undergoing planned surgery.
11563927|NCT00905905|Experimental|Ezetimibe-Simvastatin 10/40 mg|
11563928|NCT00905905|Active Comparator|Simvastatin 40 mg|
11563929|NCT00905879||Group 1|
11563932|NCT00905853|Active Comparator|Escalated Antiarrhythmic Drug Therapy|Patients are prescribed a loading dose of amiodarone or the addition of mexiletine to their current anti-arrhythmic medication which is stratified by the dose and type of antiarrhymic medication at the time of the index arrhythmic event.
11563933|NCT00905840|Active Comparator|Titanium Zircon implant|Intervention: each subject will receive two Straumann bone level implants, one implant is fabricated with Titanium Zircon and the other is a grade IV Titanium implant. Both implants will be randomly placed in the interforaminal region of the edentulous mandible, one on the right half and the other in the left part. Both implants will be treated the same way.
11563934|NCT00905840|Placebo Comparator|Titanium Grade IV implant|Intervention: each subject will receive two Straumann bone level implants, one implant is fabricated with Titanium Zircon and the other is a grade IV Titanium implant. Both implants will be randomly placed in the interforaminal region of the edentulous mandible, one on the right half and the other in the left part. Both implants will be treated the same way.
11563935|NCT00905827|Experimental|Intervention 1: in person CAMS|In person Collaborative Assessment and Management of Suicidality (CAMS) training for providers
11563936|NCT00905827|Experimental|Intervention 2: e-learning CAMS|Online Collaborative Assessment and Management of Suicidality (CAMS) training for providers
11563937|NCT00905827|No Intervention|Control: no training|Control Group: no training
11563938|NCT00905814|Other|Sequence 1 (BABA)|Treatment A: One 5-mg FCIR tablet Treatment B: Five 1-mg FCIR tablets Subjects in this sequence will participate in 4 periods in the following order: B -> A -> B -> A
11563939|NCT00905814|Other|Sequence 2 (ABAB)|Treatment A: One 5-mg FCIR tablet Treatment B: Five 1-mg FCIR tablets Subjects in this sequence will participate in 4 periods in the following order: A -> B -> A -> B
11563940|NCT00905801|Other|Arm A CT Perfusion|"Arm A Procedure
~On the first required study visit, subject will undergo one SOC CT scan followed by the research component:
~CTP imaging: Single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from clinical scan
~Subject will stand up and walk around, and then lay back down
~CT Perfusion imaging: Second single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from their clinical scan
~Procedures will be repeated at optional second study visit ~6-8 weeks later."
11563941|NCT00905801|Other|Arm B CT Perfusion|"Arm B Procedure
~On the first required study visit, subject will undergo one SOC CT scan followed by the research component:
~- CT Perfusion imaging: Single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from clinical scan
~Procedures will be repeated at optional second study visit ~6-8 weeks later."
11563942|NCT00905788|No Intervention|Control Group|Embryo transfer without any intervention
11563943|NCT00905788|Experimental|Embryo Expulsion|
11563944|NCT00905775||1 Isoflurane|The first group (G1) will be submitted to inhalational general anesthesia with isoflurane (1 CAM, evaluated by expired concentration of isoflurane)
11563945|NCT00905775||2 Propofol|The second group (G2) to targeted venous general anesthesia controlled with propofol. The targeted concentration of propofol will be kept at the predicted plasma concentration from 1 to 2 µg.ml-1 by means of a Diprifusor® infusion pump. During the interval from 10 minutes preceding ECC initiation to 10 minutes after ECC, the propofol concentration will be increased to 2 or 3 µg.ml-
11563946|NCT00905762|Experimental|Besifloxacin|Besifloxacin one drop instilled into study eye.
11563947|NCT00905762|Active Comparator|Gatifloxacin|Gatifloxacin one drop instilled into study eye.
11563948|NCT00905762|Active Comparator|Moxifloxacin|Moxifloxacin one drop instilled into study eye.
11563949|NCT00905736|Experimental|current controlled|a current controlled microcurent device providing a primarily monophasic waveform of typical amplitude 40 microamps
11563950|NCT00905736|Experimental|voltage controlled|constant voltage amplitude delivering high frequency AC waveform
11563951|NCT00905723|Experimental|Estrogen|Women randomized to this group will receive daily pills containing 1 mg of estradiol
11563952|NCT00905723|Experimental|Isoflavone|Women randomized to this group will receive daily pills of 150 mg isoflavone
11563953|NCT00905723|Placebo Comparator|Placebo|Women randomized to this group will be administered daily placebo pills
11563954|NCT00905710|No Intervention|1|Conventional colonoscopy
11563955|NCT00905710|Experimental|2|Colonoscopy using chromoendoscopy
11563956|NCT00905697||Living donor lung transplantation|Living lung transplantation donors
11563957|NCT00905684||Group 1|
11563958|NCT00905684||Group 2|
11563959|NCT00905671|Experimental|LCP+ Bifurcation Lesion|Bifurcating lesions that are positive for lipid core plaque, as detected by LipiScan Coronary Imaging, prior to angioplasty.
11563960|NCT00905671|Experimental|LCP- Bifurcation Lesion|Bifurcating lesions that are not positive for lipid core plaque, as detected by LipiScan Coronary Imaging, prior to angioplasty.
11563961|NCT00905658|No Intervention|Arm I|Patients are monitored via standard follow-up assessments every 3 weeks.
11563962|NCT00905658|Experimental|Arm II|Patients receive nutritional supplements and are monitored via standard follow-up assessments every 3 weeks.
11563963|NCT00905658|Experimental|Arm III|Patients receive nutritional supplements and are monitored via standard follow-up assessments every 3 weeks with additional biweekly assessments completed at home by a service provider.
11563964|NCT00905645|Experimental|Primary Augmentation|Silimed Gel-Filled Mammary Implant
11563965|NCT00905645|Experimental|Primary Reconstruction|Silimed Gel-Filled Mammary Implant
11563966|NCT00905645|Experimental|Revison|Silimed Gel-Filled Mammary Implant
11563967|NCT00905632|Experimental|BI 207127 low dose + SOC|BI 207127 low dose tid + SOC
11563968|NCT00905632|Experimental|BI 207127 middle dose +SOC|BI 207127 middle dose tid + SOC
11563969|NCT00905632|Experimental|BI 207127 high dose+SOC|BI 207127 high dose tid +SOC
11563970|NCT00905632|Placebo Comparator|Placebo + SOC|Placebo tid +SOC
11563971|NCT00905619||Control|No kidney disease
11563972|NCT00905619||PreHD kidney disease|Kidney disease stage 4 or below
11563973|NCT00905619||Hemodialysis|Kidney disease receiving hemodialysis
11563974|NCT00905606|Experimental|1|Topiramate Tablets, 25 mg
11563975|NCT00905606|Active Comparator|2|Topamax® Tablets, 25 mg
11564407|NCT00902460|Experimental|Treatment Sequence 1|
11563976|NCT00905580|Placebo Comparator|Placebo|Patients receive oral Placebo 150 mg 1 hour prior to surgery, and 12 hours later
11563977|NCT00905580|Experimental|Pregabalin|Patients receive oral pregabalin 150 mg 1 hour prior to surgery, and 12 hours later
11563978|NCT00905567|Experimental|Test First|Topiramate 2 x 25 mg Tablet
11563979|NCT00905567|Active Comparator|Reference First|Topamax® Tablet 2 x 25 mg
11563980|NCT00905554|Experimental|warm water|warm water irrigation during the insertion phase of colonoscopy
11563981|NCT00905554|Active Comparator|air|air insufflation during the insertion phase of colonoscopy
11563982|NCT00905541|No Intervention|No treatment|Phase A: No treatment
11563983|NCT00905541|Experimental|simvastatin chronic|Phase B: 40 mg/day simvastatin
11563984|NCT00905541|Experimental|simvastatin acute-on-chronic|Phase C: 80 mg simvastatin acute-on-chronic
11563985|NCT00905528||A|Subjects with type 2 diabetes mellitus, eGFR > 80, hypertension, no overt proteinuria
11563986|NCT00905528||B|Subjects with type 2 diabetes mellitus, eGFR > 80, hypertension, no overt proteinuria
11563987|NCT00905515|Active Comparator|1|Maintain on Cyclosporine (CsA) at target trough level of 50-250 ng/mL.
11563988|NCT00905515|Active Comparator|2|Convert to Prograf (TAC) at target trough levels of 3.0-5.9 ng/mL.
11563989|NCT00905515|Active Comparator|3|Convert to TAC at target trough levels of 6.0-8.9 ng/mL.
11563990|NCT00905502|Experimental|1: Restricted protocol (RG) group|Received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period.
11563991|NCT00905502|Active Comparator|2: Liberal protocol (LG) group|Received 10 ml/kg•hr of RL solution intraoperatively.
11563992|NCT00905489|Experimental|Nevirapine IR / Nevirapine XR|In this pharmaco-kinetic (PK) cross-over design trial, all patients initially receive nevirapine immediate release and then all patients are switched to nevirapine extended release 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).
11563993|NCT00905476||NPPV|Patients with chronic respiratory failure receiving domiciliary NPPV
11563994|NCT00905463||Transplantation|Lung transplantation candidates
11563995|NCT00905450|Experimental|BOL-303242-X|BOL-303242-X (Mapracorat)
11563996|NCT00905450|Placebo Comparator|Vehicle|Vehicle for BOL-303242-X (Mapracorat)
11563997|NCT00905437|Placebo Comparator|Placebo|Placebo as an adjunct to standard of care
11563998|NCT00905437|Active Comparator|Pregabalin|Pregabalin as an adjunct to standard of care
11563999|NCT00905424|Experimental|Active|Antidepressant + SPD489
11564000|NCT00905424|Placebo Comparator|Placebo|Antidepressant + placebo
11564001|NCT00905411|No Intervention|Attention Control / Usual Care|
11564002|NCT00905411|Experimental|Intervention|
11564003|NCT00905398|Experimental|nilotinib|single arm study
11564004|NCT00905385|Experimental|Low Dose: 3,200 CFU|5 subjects inoculated with 3,200 colony forming units (CFU).
11564005|NCT00905385|Experimental|High Dose: 32,000 CFU|5 subjects inoculated with 32,000 colony forming units (CFU).
11564006|NCT00905372|Experimental|LY2062430|
11564007|NCT00905372|Placebo Comparator|Placebo|
11564008|NCT00905359|Active Comparator|Aperius™ PercLID™ System|Aperius™ PercLID™ System arm. Patients randomized to this arm will undergo treatment with the Aperius™ PercLID™ System.
11564009|NCT00905359|Active Comparator|Standalone Decompressive Surgery|Patients randomized to this arm will receive Standalone Decompressive Surgery, defined as decompressive surgery without instrumentation or fusion.
11564010|NCT00905346|Experimental|Test First|Topiramate Capsules 25 mg
11564011|NCT00905346|Active Comparator|Reference First|Topamax® 25 mg Capsule
11564012|NCT00905333|Other|Single-arm|3 treatments, 6 sequences, 3 periods, cross-over, single dose arm (Willians' Plan)
11564013|NCT00905320|Active Comparator|Metallic Fasteners and Sutures|Laparoscopic ventral hernia repair with mesh fixation using both metallic fasteners and transabdominal sutures
11564014|NCT00905320|Experimental|Metallic Fasteners Alone|Laparoscopic ventral hernia repair with mesh fixation using metallic fasteners alone
11564015|NCT00905307|Experimental|1|OPC-34712 0.25 mg arm
11564016|NCT00905307|Experimental|2|OPC-34712 low-dose arm
11564017|NCT00905307|Experimental|3|OPC-34712 mid-dose arm
11564018|NCT00905307|Experimental|4|OPC-34712 high-dose arm
11564019|NCT00905307|Placebo Comparator|5|
11564020|NCT00905307|Active Comparator|6|Aripiprazole arm
11564021|NCT00905294||coronary artery disease|Subjects with coronary artery disease undergoing percutaneous coronary intervention
11564022|NCT00905281|Experimental|Action Group|
11564023|NCT00905281|Other|Standard care|
11564024|NCT00905268|Experimental|Group A: Idebenone|Patients under/equal 45 kg: idebenone 180 mg/day Patients over 45 kg: idebenone 360 mg/day
11564025|NCT00905268|Experimental|Group B: Idebenone|Patients under/equal 45 kg: idebenone 450 mg/day Patients over 45 kg: idebenone 900 mg/day
11564026|NCT00905268|Experimental|C: Idebenone|Patients under/equal 45 kg: idebenone 1350 mg/day Patients over 45 kg: idebenone 2250 mg/day
11564027|NCT00905268|Placebo Comparator|D: Placebo|placebo
11564028|NCT00905255|Experimental|Lixisenatide (Two-step Titration)|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
11564029|NCT00905255|Experimental|Lixisenatide (One-step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to end of treatment.
11564030|NCT00905229|Active Comparator|PO (by mouth)|2.5 mg P.O Vitamin K
11564031|NCT00905229|Active Comparator|IV (intravenous )|0.5 mg IV Vitamin K
11564032|NCT00905216|Experimental|Test|Heparin sodium - Bergamo
11564033|NCT00905216|Active Comparator|Comparator|Heparin APP
11564034|NCT00905203|Experimental|1|moderate exercise training (three times/ week including one home-based training and two supervised training)
11564035|NCT00905203|Experimental|2|intensive exercise training (four times/ week including one home-based training and three supervised training)
11564076|NCT00904852|Experimental|Tandutinib, bevacizumab, and temozolomide|tandutinib in combination with temozolomide and bevacizumab following concurrent radiation therapy and temozolomide treatment.
11564036|NCT00905190|Experimental|Fed|A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast
11564037|NCT00905190|Experimental|Fasting|A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.
11564038|NCT00905164|Experimental|Test First|Topiramate Capsules, 25 mg
11564039|NCT00905164|Active Comparator|Reference First|Topamax® Capsules, 25 mg
11564040|NCT00905151||HIV Positive|Across-sectional analysis of 200 HIV+ patients with varying levels of kidney function
11564041|NCT00905138|Experimental|1|single ascending doses
11564042|NCT00905138|Placebo Comparator|2|single dose placebo
11564043|NCT00905138|Experimental|3|multiple dose, 5 days, oral solution
11564044|NCT00905138|Placebo Comparator|4|multiple dose, 5 days, oral solution
11564045|NCT00905125|Experimental|Arm 2, Fluarix®|Single 0.5 mL intramuscular injection of Fluarix®.
11564046|NCT00905125|Experimental|Arm 1, Fluzone®|Single 0.5 mL intramuscular injection of Fluzone®.
11564047|NCT00905112|Experimental|MOMS|Receives manual therapy, stabilization exercise and patient education
11564048|NCT00905112|Active Comparator|STOB|Receive standard obstetrical care
11564049|NCT00905073|Experimental|cyclosporin+Methotrexate|cyclosporin treatment at 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for on year and methotrexate 5 mg/kg/day for one year.
11564050|NCT00905060|Experimental|protein peptide-complex (HSPPC-96)|autologous tumor-derived heat shock protein peptide-complex (HSPPC-96) administered at 25 μg per dose injected intradermally once weekly for 4 consecutive weeks and monthly following standard treatment with radiation and temozolomide.
11564051|NCT00905047|Other|XELODA|
11564052|NCT00905047|Other|UFT|
11564053|NCT00905034|Experimental|MOAD|Chemotherapy regimen of methotrexate, rituximab, vincristine, pegylated L-asparaginase and dexamethasone (MOAD).
11564054|NCT00905021|Experimental|Exemestane plus Sutent|"All patients enrolled on the study will receive treatment as follows:
~Exemestane 25 mg by mouth every day.
~Sunitinib 37.5 mg by mouth every day."
11564055|NCT00905008||DES|Patients underwent percutaneous coronary intervention and received at least one drug-eluting stent during their index hospitalisation.
11564056|NCT00905008||BMS|Patients underwent percutaneous coronary intervention and received at least one uncoated stent during their index hospitalisation.
11564057|NCT00904995|Experimental|Group 1 - Oral|Voriconazole Starting oral dose of 400 mg pills twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
11564058|NCT00904995|Experimental|Group 2 - IV + Oral|Voriconazole 6 mg/kg by vein (IV) first dose then 200 mg pills two times a day thereafter.
11564059|NCT00904982|Other|1 Usual Care Group/Control|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication. The MM can display messages to the participant and can confirm when medication is taken correctly.
11564060|NCT00904982|Experimental|2Med-eMonitor/Reminder|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication and will be set on active mode for this group. The MM will display messages of encouragement to participants and education on the importance of taking their warfarin medication. The Med-eMonitor also features an alarm that will sound to remind participants to take their medication as scheduled.
11564061|NCT00904982|Experimental|3 Incentive Group/Lottery|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication. The MM can display messages to the participant. This group will also be entered into a daily lottery in which he/she can win money. On any given study day, participants have a 1 in 10 chance of winning $10 and 1 in 100 chance of winning $100 when taking their warfarin as prescribed. Participants must take their dose correctly in order to be eligible for the daily lottery.
11564062|NCT00904982|Experimental|4 Combined Group/Lottery and Reminder|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication and will be set on active mode for this group. The MM will display messages of encouragement to participants and education on the importance of taking their warfarin medication. The Med-eMonitor also features an alarm that will sound to remind participants to take their medication as scheduled. Participants in this group will also be entered into a daily lottery. On any given study day, participants have a 1 in 10 chance of winning $10 and 1 in 100 chance of winning $100 when taking their warfarin medication as prescribed. Participants must take their dose correctly in order to be eligible for the daily lottery.
11564063|NCT00904969|Experimental|AMS Transobturator Male Sling System|
11564064|NCT00904943|Experimental|Test First|Topiramate Capsules, 25 mg
11564065|NCT00904943|Active Comparator|Reference First|Topamax® Capsules, 25 mg
11564066|NCT00904930||no periodontal disease|33 dental students (13 male, 20 female) with a mean age of 24.7 years (min. 19.8; max. 36.5) with no periodontal disease or dental trauma
11564067|NCT00904917|Experimental|Adapted PIP|"Participants (both mother and children) participated in an adapted cognitive family prevention program for the families of children with a depressed African American mother.
~The intervention was the Prevention Intervention Project."
11564068|NCT00904917|Active Comparator|Lecture|"Mothers received psychoeducation about depression.
~The intervention was psychoeducation."
11564069|NCT00904904|Experimental|Indomethacin|Indomethacin ophthalmic solution 0.1% for post-surgical inflammation
11564070|NCT00904904|Active Comparator|Ketorolac|Ketorolac ophthalmic solution 0.5% for post-surgical inflammation
11564071|NCT00904891|Experimental|1|Participants will receive a cognitive-behavioral group intervention.
11564072|NCT00904891|Active Comparator|2|Participants will receive cognitive-behavioral bibliotherapy.
11564073|NCT00904891|No Intervention|3|Participants will only complete study assessments.
11564074|NCT00904865|Other|1|SPA cholecystectomy
11564075|NCT00904865|Other|2|laparoscopic cholecystectomy
11564402|NCT00902486|Experimental|INCB028050 7 mg QD|INCB028050 7mg QD
11564077|NCT00904839|Experimental|BIBF 1120 + mFolfox6|BIBF1120 medium dose twice daily
11564078|NCT00904839|Active Comparator|Bevacizumab + mFolfox6|Bevacizumab 5mg/kg once daily every other week
11564079|NCT00904826|Experimental|Eculizumab|The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks. Subjects will receive therapy for a total of 12 months.
11564080|NCT00904813|Active Comparator|1. RT 5x5 Gy + surgery within 1 week|RT=Preoperative radiotherapy Gy=Gray
11564081|NCT00904813|Active Comparator|2.RT 5x5 Gy + surgery after 4-8 weeks|RT=radiotherapy Gy= Gray
11564082|NCT00904813|Active Comparator|3.RT 25x2 Gy + surgery after 4-8 weeks|RT= radiotherapy Gy= Gray
11564083|NCT00904800|Experimental|1|Low dose
11564084|NCT00904800|Experimental|2|Middle dose
11564085|NCT00904800|Experimental|3|High dose
11564086|NCT00904800|Placebo Comparator|4|placebo
11564087|NCT00904787|Experimental|1|
11564088|NCT00904774||premature neonates|gestational age less than 28 weeks
11564089|NCT00904761|Experimental|exercise|arm: intervention
11564090|NCT00904748|Experimental|Test 1|
11564091|NCT00904748|Experimental|Test 2|
11564092|NCT00904748|Active Comparator|Reference|
11564093|NCT00904735|Experimental|Arm I|Patients receive oral hydroxyurea twice daily and oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
11564094|NCT00904735|Experimental|Arm II|Patients receive oral hydroxyurea twice daily in the absence of disease progression or unacceptable toxicity.
11564095|NCT00904722|Experimental|CT-011 in combination with Rituximab|Combination of the immunotherapy drugs, CT-011 and rituximab.
11564096|NCT00904709|Experimental|Tranexamic acid, Menorrhagia, Bleeding|Tranexamic acid with titrated doses. All women with menorrhagia will take .
11564097|NCT00904683|Experimental|LY2062430|
11564098|NCT00904683|Placebo Comparator|Placebo|
11564099|NCT00904670|Experimental|Active|
11564100|NCT00904670|Placebo Comparator|Comparator|
11564101|NCT00904644||Salvage group|In this group patients are enrolled that have failed previous antiretroviral drug regimens and qualify for Raltegravir treatment according to the approved indication of this drug in Switzerland.
11564102|NCT00904644||Switch group|In this group, patients are enrolled which have to switch to Raltegravir due to drug toxicity or adverse events caused by other antiretroviral drugs.
11564103|NCT00904631|Experimental|Treatment|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
11564104|NCT00904618|Experimental|TVT-SECUR|This study arm consisted of 48 women operated from January 2007 to October 2008. All patients underwent the implantation of the TVT-SECUR for the treatment of stress urinary incontinence or stress predominant mixed urinary incontinence. The surgery was done under local anesthesia by one high-volume surgeon.
11564105|NCT00904605|Experimental|1- Lidoderm®|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
11564106|NCT00904605|Active Comparator|2-Celecoxib 200mg|Celecoxib (Celebrex®, G.D. Searle & Co., Chicago, IL), one 200 mg oral capsule QD
11564107|NCT00904592|Experimental|Qi ming granula|"Study group(combined therapy with Intervention of TCM): Basic therapy ＆ treating both on deficiency and stasis of blood.
~Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management, exercise and education.
~Qi ming granula, Usage: 4.5g，po，tid."
11564108|NCT00904592|Placebo Comparator|placebo comparator|"Control group: Basic therapy ＆ placebo
~Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.
~placebo,Usage: 4.5g，po，tid"
11564109|NCT00904579||1|Cancer patients who have had organ transplants identified through the transplant and cancer registries.
11564110|NCT00904553||Novalis Shaped Beam Surgery|Patients with limited brain metastases (mostly solitary brain metastasis) treated with Novalis Shaped Beam Surgery followed by planned craniotomy and resection of the metastases.
11564111|NCT00904540|Experimental|Lidoderm®|Commercially available Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain
11564112|NCT00904527|Experimental|Relaxation|Relaxation (Schultz)+ medical treatment (beta-bloquant or Oxetorone)+ patient's education
11564113|NCT00904527|No Intervention|without relaxation|Patients have no relaxation (only medical treatment+ education)
11564114|NCT00904501|Placebo Comparator|A|A bone marrow harvest (500 mL under general anaesthesia) is performed and BM-MNC are separated and concentrated (30mL). A placebo cell-product (30 mL saline with 4 ml peripheral blood) is implanted and the BM-MNC are cryo-conserved. Only the cell therapy unit, neither the patient, nor the clinician, know whether BM-MNC or placebo is implanted. After 6 months, it is possible to use previously cryo-conserved BM-MNC.
11564115|NCT00904501|Experimental|B|A bone marrow harvest (500 mL under general anaesthesia) is performed and BM-MNC are separated and concentrated (30mL) . The BM-MNC are implanted on the same day. Only the cell therapy unit, neither the patient, nor the clinician, know whether BM-MNC or placebo is implanted
11564116|NCT00904488|Active Comparator|Addition of PO Thiazide Diuretic|Addition of oral metolazone 5 mg daily to current intravenous bolus furosemide. All subjects will continue their current dose of intravenous bolus furosemide.
11564117|NCT00904488|Active Comparator|IV furosemide dose escalation|Current IV furosemide dose will be escalated to 2-2.5 x current dose, given as either IV bolus or continuous infusion over 24 hours.
11564118|NCT00904475|Experimental|1- Lidoderm®|Lidoderm (lidocaine patch 5%), up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain
11564119|NCT00904475|Placebo Comparator|2-Placebo|Matching placebo, up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain
11564120|NCT00904462|Experimental|Lidocaine 5% patch|Lidocaine 5% patch (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied on each affected knee once every 24 hours
11564121|NCT00904462|Placebo Comparator|Placebo patch|Matching placebo patch, 1⅓ patches applied on each affected knee once every 24 hours
11564122|NCT00904449|Experimental|Open Label|
11564123|NCT00904436|Experimental|1|Spinal Cord Injury: subjects who have cervical spinal cord injury and complaints of dyspnea
11564124|NCT00904436|No Intervention|2|Controls
11564125|NCT00904423|Experimental|Vitamin D|
11564126|NCT00904410|Experimental|1|
11564127|NCT00904397|Experimental|Lidoderm|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 2 patches applied once daily (q24h) directly to the most painful area of the low back
11564128|NCT00904397|Active Comparator|Celecoxib|Celecoxib (Celebrex®, G.D. Searle & Co., Chicago, IL), one 200 mg oral capsule QD
11564129|NCT00904384||HIV+|Patients with HIV infection living in the Autonomous Community of the Balearic Islands (CAIB), Spain
11564130|NCT00904384||Reference group|Same determinations as in HIV+ cases will be obtained in the control group of COPD patients without HIV infection as part of the study PAC-EPOC (FIS 05/2082)
11564131|NCT00904371||Patients with arterial hypertention|
11564132|NCT00904358||cross sectional area|internal jugular cross sectional area measured by ultrasound
11564133|NCT00904345|Experimental|Treatment|
11564134|NCT00904319|Experimental|Aquatic|Aquatic Power Training
11564135|NCT00904306|Placebo Comparator|Sugar pill|6 months treatment with placebo
11564136|NCT00904306|Active Comparator|low dose|600ug/day chromium picolinate for 6 months
11564137|NCT00904306|Active Comparator|high dose chromium picolinate|1000 ug/day
11564138|NCT00904293|Experimental|Genotype-guided warfarin dosing|A dosing algorithm including clinical factors and genotype information (VKORC1 and CYP2C9) will be used to determine initial warfarin doses.
11564139|NCT00904293|Active Comparator|Non-genotype guided warfarin dosing|Initial warfarin dosing will be determined using the same algorithm as in the experimental group, but only including the clinical factors and not including the genotype information
11564140|NCT00904280|Experimental|Oxymorphone ER|
11564141|NCT00904254|Experimental|1, diagnostic comparison|EP 1645/Solution For Injection
11564142|NCT00904241||Ancillary-Correlative (cytology specimen collection)|Patients undergo collection of blood, tissue, and bone marrow samples for analysis via RT-PCR, quantitative PCR, flow cytometry, and FISH.
11564143|NCT00904228|Experimental|Plastic Cap|Plastic lined stockinet cap (polyethylene bag)
11564144|NCT00904228|Active Comparator|Stockinet Cap|Usual practice
11564145|NCT00904202|Placebo Comparator|placebo capsules + placebo patch|Placebo to match lidocaine patch; up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing
11564146|NCT00904202|Experimental|placebo capsules + Lidoderm patch (Lidocaine Group)|Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing
11564147|NCT00904202|Active Comparator|Gabapentin capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules for oral dosing at a dose of 1800 mg/day AND Placebo patch to match lidocaine patch; up to four patches applied topically daily (q24h) to the area of maximal peripheral pain
11564148|NCT00904202|Other|Gabapentin capsules 1800 mg/day + Lidoderm patch|Gabapentin 1800 mg/day AND Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain
11564149|NCT00904189|No Intervention|Standard of care radiation therapy|Standard of care given for treatment of cancer. Subjects receiving incidental radiation dose to fingernails.
11564150|NCT00904176|Active Comparator|Dapagliflozin + Warfarin|
11564151|NCT00904176|Active Comparator|Warfarin|
11564152|NCT00904176|Active Comparator|Dapagliflozin + Digoxin|
11564153|NCT00904176|Active Comparator|Digoxin|
11564154|NCT00904150||1 Menstrual migraine|Caucasian women with a current or past history of menstrual migraine (MM = pure menstrual migraine or menstrually-related migraine) attending the City of London Migraine Clinic
11564155|NCT00904150||2 No migraine|Caucasian women with no personal history of migraine
11564156|NCT00904137|Active Comparator|Cast|Above elbow fiberglass cast with a collar-and-cuff
11564157|NCT00904137|Active Comparator|Splint|Long arm posterior plaster splint with a collar-and-cuff
11564158|NCT00904137|Active Comparator|Tape|Elastoplast tape applied to keep the elbow in flexion, with a collar-and-cuff
11564159|NCT00904124|Placebo Comparator|Control|No regular flour replaced
11564160|NCT00904124|Experimental|5% Cellulose|5% regular flour is replaced by cellulose
11564161|NCT00904124|Experimental|2.5% Alginate|2.5% regular flour is replaced by Alginate
11564162|NCT00904124|Experimental|5% Alginate|5% regular flour is replaced by Alginate
11564163|NCT00904124|Experimental|2.5% Guar gum|2.5% regular flour is replaced by Guar gum
11564164|NCT00904124|Experimental|1.25% Guar gum|1.25% regular flour is replaced by Guar gum
11564165|NCT00904111|Experimental|Lidocaine 5% Patch|Lidocaine 5% patch (Lidoderm®,Endo Pharmaceuticals Inc.), 2 patches applied directly to the most painful area of the low back once daily (q24h)
11564166|NCT00904111|Placebo Comparator|Placebo Topical Patch|Matching placebo patch, 2 patches applied directly to the most painful area of the low back once daily (q24h)
11564167|NCT00904098|Experimental|Frovatriptan|Frovatriptan 2.5 mg oral tablet
11564168|NCT00904098|Active Comparator|Usual Care|Usual care includes the current treatment used to treat all episodes of migraine headache
11564169|NCT00904085|Active Comparator|Oxymorphone|
11564170|NCT00904085|Placebo Comparator|Placebo|
11564171|NCT00904072||accepted|The suggestions provided by the CDSS which were accepted by the physicians.
11564172|NCT00904072||denied|The suggestions provided by the CDSS which were denied by the physicians.
11564173|NCT00904059|Experimental|Treatment Group A|
11564174|NCT00904059|Experimental|Treatment Group B|
11564175|NCT00904059|Experimental|Treatment Group C|Treatment Groups A and B are followed by Treatment Group C: A combination of BMS-650032 (200 mg) and BMS-790052 (30 mg)
11564176|NCT00904046|Experimental|Pioglitazone|For 60 Aim 2 Subjects Only - Pioglitazone (Actos)
11564177|NCT00904046|Placebo Comparator|Placebo|For 60 Subjects in Aim 2 Only - Placebo for Pioglitazone
11564178|NCT00904033|Active Comparator|Multivitamin|Multivitamin used as control group.
11564179|NCT00904033|Experimental|Exercise|Exercise consisting of progressive walking and resistance band training.
11564180|NCT00904033|Experimental|Calcitriol|Calcitriol pill taken once per week.
11564181|NCT00904033|Experimental|Calcitriol and Exercise|Calcitriol pill taken once per week plus Exercise consisting of progressive walking and resistance band training.
11564182|NCT00904020|Experimental|(1) Lidoderm|(1) Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
11564183|NCT00904007|Experimental|SE Game Cohort|Will receive ISE intervention.
11564184|NCT00904007|No Intervention|Control Cohort|The control cohort will receive identical content online (with no ISE)
11564185|NCT00903994|Other|Single Arm|Single Arm
11564186|NCT00903981|Experimental|Avanafil 100mg|
11564187|NCT00903981|Experimental|Avanafil 200mg|
11564188|NCT00903981|Placebo Comparator|Placebo|
11564189|NCT00903968|Experimental|Phase I Dose Level 1|Phase I Dose Level 1 patients received plerixafor 160ug/kg by injection on days 1-6 and bortezomib 1.0 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
11564190|NCT00903968|Experimental|Phase I Dose Level 2|Phase I Dose Level 2 patients received plerixafor 160ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
11564191|NCT00903968|Experimental|Phase I Dose Level 3|Phase I Dose Level 3 patients received plerixafor 240ug/kg by injection on days 1-6 and bortezomib 1.0 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
11564192|NCT00903968|Experimental|Phase I Dose Level 4|Phase I Dose Level 4 patients received plerixafor 240ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
11564193|NCT00903968|Experimental|Phase I Dose Level 5|Phase I Dose Level 5 patients received plerixafor 320ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
11564194|NCT00903968|Experimental|Phase I Dose Level 5B|Phase I Dose Level 5B patients received plerixafor 320ug/kg by injection on days 1, 2, 3, 6, 10, and 13 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
11564195|NCT00903968|Experimental|Phase I Dose Level 6|Phase I Dose Level 6 patients received plerixafor 400ug/kg by injection on days 1, 2, 3, 6, 10, and 13 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
11564196|NCT00903968|Experimental|All Phase I Participants|All Phase I participants received plerixafor by injection and bortezomib intravenously according to the established dose escalation schedule. Participants were treated until disease progression or unacceptable toxicity.
11564197|NCT00903968|Experimental|All Phase II Participants|All Phase I participants received plerixafor 320ug/kg by injection on days 1, 2, 3, 6, 10, and 13, bortezomib 1.3 mg/m2 intravenously or subcutaneously days 3, 6, 10, and 13, and dexamethasone 40mg orally days 3, 6, 10, and 13 of each 21 day cycle during induction. In maintenance, participants received plerixafor, bortezomib, and dexamethasone days 1, 8, 15, and 22 of each 35 day cycle. Participants were treated until disease progression or unacceptable toxicity.
11564198|NCT00903955||Chronic Obstructive Pulmonary Disease|Subjects diagnosed with COPD are classified according to standards set forth by the Global Initiative on Obstructive Lung Disease. This study recruits subjects in each of three GOLD categories.
11564199|NCT00903929|Experimental|Eltrombopag|
11564200|NCT00903903||1|RA patients with at least one active synovitis
11564201|NCT00903903||2|Non-RA patients with at least one active synovitis
11564202|NCT00903890||A|Individuals who have previously received radiation therapy and anthracycline chemotherapy for their Hodgkin's or non-Hodgkin's lymphoma.
11564203|NCT00903877|Experimental|Placebo followed by T3|Participants receive placebo for 4 weeks. Following placebo, participants begin T3 treatment at 25 mcg per day, for 4 weeks. Following this, participants begin T3 treatment at 50 mcg per day, for 4 more weeks.
11564204|NCT00903864||stethoscopy|
11564205|NCT00903864||BPM|blood pressure monitor
11564206|NCT00903851|Experimental|(1) Lidoderm|(1)Commercially available Lidoderm® (lidocaine patch 5%), up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain
11564207|NCT00903838|Experimental|1|
11564208|NCT00903838|Active Comparator|2|
11564209|NCT00903825|Active Comparator|Manual palpation|Local anesthetic before femoral artery puncture will be injected with the classic manual palpation technique
11564210|NCT00903825|Experimental|Ultrasound guidance|Local anesthetic before femoral artery puncture will be performed with the use of duplex ultrasound guidance
11564211|NCT00903812||A|No intervention - observational study
11564212|NCT00903799|Other|1|"Gastric electrical stimulation using Enterra Therapy. Device activated during 4 months then device in 'OFF' position the 4 following months.
~After the cross-over period, device activated until the end of the trial"
11564213|NCT00903799|Other|2|"Gastric electrical stimulation using Enterra Therapy. Device in 'OFF' position during 4 months then device activated the 4 following months.
~After the cross-over period, device activated until the end of the trial"
11564214|NCT00903786|Experimental|Perampanel|"Participants were treated with the perampanel dose that was administered in maintenance period of Study E2007-J081-231 (Study 231) [NCT00849212]. In some instances, a 1-step down-titration from the viewpoint of safety and up-titration to the maintenance dose of Study 231 was allowed. In general, 1 to 6 tablets of perampanel was administered orally as a 2-milligram (mg) tablet (2 mg to 12 mg) once daily before bedtime (under fed conditions as much as possible).
~The investigator, or subinvestigator, was allowed to complete the treatment by tapering the study drug after end of treatment or discontinuation (Follow-up Period), as appropriate. The taper period was 4 weeks at the longest."
11564215|NCT00903760|Experimental|Decitabine + Clofarabine|Drug delivery intravenously (IV) in alternating series of cycles (Decitabine 20 mg/m^2 for 5 days first 3 cycles, then Clofarabine 10 mg/m^2 five days for next 3 cycles), pattern repeats for up to 24 cycles.
11564216|NCT00903760|Experimental|Decitabine|Decitabine 20 mg/m^2 IV daily for 5 days for a total of 24 courses.
11564217|NCT00903747|Experimental|1|Prucalopride
11564218|NCT00903747|Placebo Comparator|2|Placebo/moxifloxacin
11564219|NCT00903734|Experimental|Erlotinib Hydrochloride|Those eligible for umbrella of studies and have not received Erlotinib hydrochloride in past, will first receive Erlotinib hydrochloride alone.
11564220|NCT00903721||1|Patients with perennial allergic rhinitis
11564221|NCT00903721||2|Patients with seasonal allergic rhinitis (including patients who also have perennial allergic rhinitis)
11564222|NCT00903708|Experimental|LY2275796|
11564223|NCT00903695|Experimental|Memory XL|"Subjects will take 2 Memory XL pills daily for 12 months (a vitamin nutriceutical developed by Thomas Shea, Ph.D.).
~Mild Cognitive Impairment (MCI) patients, who met inclusion/exclusion criteria, were assessed initially using 3 cognitive tests and 4 behavioral questionnaires, before they began ingesting pills assigned to them by VAMC Research Pharmacist. Each 3 months thereafter, they returned to lab to be reassessed using same instruments, and to receive the next batch of study pills from the Pharmacist. The last assessment was when the patient had just finished 12 months of pill ingestion."
11564224|NCT00903695|Placebo Comparator|placebo|"Subjects diagnosed with MCI took two placebo pills daily for 12 months; these pills are formulated to look and taste the same as the nutriceutical being studied, Memory XL, so study was double-blind. Procedures for this arm are exactly the same as the MEMORY XL arm.
~MCI subjects were assessed using 3 cognitive tests and 4 behavioral questionnaires, before they began ingesting the pills assigned to them by the Research Pharmacist at VAMC. Each 3 months thereafter, they returned to lab to be reassessed using the same instruments, and to receive next batch of study pills. Last assessment was when patient had completed 12 months of pill ingestion."
11564225|NCT00903682|Experimental|etravirine|etravirine (ETR TMC125) 400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
11564226|NCT00903682|Active Comparator|efavirenz|efavirenz (EFV) 600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
11564227|NCT00903669||Peripheral Facial Paralysis (PFP)|Patients who are diagnosed with peripheral facial paralysis.
11564228|NCT00903656|Experimental|Caelyx/Lapatinib|
11564229|NCT00903643||Healthy subjects|
11564230|NCT00903643||PBS subjects|
11564231|NCT00903630|Experimental|Phase 1 - Dose Level 1|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: 10 mg daily on Days 1-28 every 28 days
11564232|NCT00903630|Experimental|Phase I - Dose Level 2|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: 15 mg daily on Days 1-28 every 28 days
11564233|NCT00903630|Experimental|Phase 2|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: maximum tolerated dose from Phase I portion of the study (10mg) daily on Days 1-28 every 28 days
11564234|NCT00903617|Experimental|Part A Treatment A|5 mg of GSK256073
11564235|NCT00903617|Experimental|Part A Treatment B|50 mg of GSK256073
11564236|NCT00903617|Experimental|Part A Treatment C|150 mg of GSK256073
11564237|NCT00903617|Placebo Comparator|Part A Treatment D|placebo
11564238|NCT00903617|Placebo Comparator|Part B Treatment A|placebo
11564239|NCT00903617|Active Comparator|Part B Treatment B|1500 mg Niaspan
11564240|NCT00903617|Experimental|Part B Treatment C|x mg dose of GSK256073 based on data from Part A
11564241|NCT00903617|Experimental|Part B Treatment D|optional dose of GSK256073 based on data from Part A
11564242|NCT00903604|Experimental|AP214|Infusions of sequential ascending dosages of AP214
11564243|NCT00903604|Placebo Comparator|Placebo|Infusions of saline solution
11564244|NCT00903591||1|All women will be interviewed by telephone using the a similar questionnaire as used in the parent study. DNA samples will be obtained either via blood samples drawn during a home or clinic visits, or an Oragene Saliva DNA Self-Collection Kit sent to the participant's home.
11564245|NCT00903578||Kidney transplant recipients|
11564246|NCT00903552|Experimental|Low Dose|
11564247|NCT00903552|Placebo Comparator|PBS|
11564248|NCT00903552|Experimental|High Dose|
11564249|NCT00903526||candidemia|
11564250|NCT00903500|Experimental|1|Daily physical activity
11564251|NCT00903500|No Intervention|2|Usual care
11564252|NCT00903461|Experimental|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Subjects will receive a total of up to 7 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive a total EGFR AS dose of 1.92 milligrams in 1.78 milliliters on each weekly treatment. This dose may be delivered equally in the same tumor site per weekly session, the primary tumor or cervical lymph nodes.
11564253|NCT00903448|Experimental|A|Prilosec OTC
11564254|NCT00903448|Active Comparator|B|Prevacid
11564255|NCT00903422|Active Comparator|Eltrombopag|Eltrombopag
11564256|NCT00903422|Placebo Comparator|Placebo|Placebo
11564257|NCT00903409|Experimental|"Simvastatin + Lovaza® (Non-switchers)"|"Open label Simvastatin + Lovaza® (omega-3-acid ethyl esters) NOTE: this group was originally assigned to Simvastatin + Lovaza® in the double-blind trial, hence in this open-label extension, they are termed Non-switchers"
11564258|NCT00903409|Experimental|"Simvastatin + Lovaza® (Switchers)"|"Open label Simvastatin + Lovaza® (omega-3-acid ethyl esters) NOTE: this group was originally assigned to Simvastatin + placebo in the double-blind trial, hence in this open-label extension, they are termed Switchers"
11564259|NCT00903396|Experimental|Arm I|Patients receive palonosetron hydrochloride IV on day 1.
11564260|NCT00903396|Experimental|Arm II|Patients receive palonosetron hydrochloride IV on days 1 and 4.
11564261|NCT00903396|Placebo Comparator|Arm III|Patients receive placebo IV on day 1.
11564262|NCT00903396|Placebo Comparator|Arm IV|Patients receive placebo IV on days 1 and 4.
11564263|NCT00903383|Experimental|Low Dose|A low dose of LX3305; daily oral intake for 12 weeks
11564264|NCT00903383|Experimental|Mid Dose|A mid dose of LX3305; daily oral intake for 12 weeks
11564265|NCT00903383|Experimental|High Dose|A high dose of LX3305; daily oral intake for 12 weeks
11564266|NCT00903383|Placebo Comparator|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
11564267|NCT00903370|Active Comparator|MVS|All participants will undergo mitral valve surgery with ligation/excision of left atrial appendage.
11564268|NCT00903370|Experimental|Ablation|Participants will undergo mitral valve surgery with ligation/excision of left atrial appendage plus surgical ablation with pulmonary vein isolation or biatrial lesion set.
11564269|NCT00903357|Experimental|Montelukast first, then placebo|The group received active medication (montelukast 4 mg or 5mg once daily) for 8 weeks followed by a crossover to 8 weeks of placebo after 2-weeks washout period.
11564270|NCT00903357|Experimental|Placebo first, then Montelukast|The group received placebo medication (ascorbic acid) for 8 weeks followed by a crossover to 8 weeks of active medication (montelukast 4 mg or 5mg once daily) after 2-weeks washout period.
11564271|NCT00903344|Experimental|Vitamin D|4000IU Vitamin D3 in tablet taken daily with multivitamin
11564272|NCT00903344|Active Comparator|Multivitamin|Multivitamin with 400IU vitamin D tablet
11564273|NCT00903331|Experimental|ACT-064922|ACT-064922 tablet (macitentan), 10 mg, once daily
11564274|NCT00903331|Placebo Comparator|Placebo|Matching placebo, once daily
11564275|NCT00903318||Mexican American Men and Women|Rural and urban Mexican American men and women , aged 18 to 40, in urban Baytown, TX and rural Rio Grande Valley (Hidalgo County) communities along the Texas-Mexico border
11564276|NCT00903305|Experimental|Group II (SNIP)|Patients undergo SNIP comprising four visits over 2 months and four monthly telephone calls from the APN. The APN will provide 24 hour access during the study. Patients complete questionnaires about satisfaction with care, perceived preparedness with self-care, and helpfulness of patient teaching at baseline, 3 months and 6 months.
11564277|NCT00903305|Active Comparator|Group I (usual care intervention)|Patients undergo usual care and complete questionnaires about satisfaction with care, perceived preparedness with self-care, and helpfulness of patient teaching at baseline, 3 months and 6 months.
11564278|NCT00903292|Active Comparator|A, erlotinib|If EGFR mutation found then assigned to thyrosine kinase inhibitor (erlotinib)
11564279|NCT00903292|Active Comparator|B, pemetrexed|If EGFR wild type found then assigned to chemotherapy (pemetrexed)
11564280|NCT00903279|Placebo Comparator|Placebo|
11564281|NCT00903279|Experimental|Altabax|
11564282|NCT00903266|Experimental|MIT|Melodic Intonation Therapy
11564283|NCT00903266|Active Comparator|SRT|Speech-Repetition-Therapy
11564284|NCT00903266|No Intervention|NTC|No-Therapy Control; Patients in this arm will be re-randomized to the two active arms at the end of the NTC period.
11564285|NCT00903227|Experimental|Low Dose|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg) and 1 puff of inhaled Placebo twice a day with placebo intranasal spray 2 squirts each nostril once a day.
11564286|NCT00903227|Experimental|Combined|One puff of inhaled fluticasone propionate Evohaler pMDI 50 µg twice a day (Total daily FP dose 100 µg) and 1 puffs of Placebo twice a day with intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts each nostril once a day (i.e. total intranasal FP daily dose 200ug).
11564287|NCT00903227|Experimental|High dose|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg) and 1 puff of inhaled placebo twice a day with placebo intranasal spray 2 squirts each nostril once a day.
11564288|NCT00903201|Experimental|Treatment A|20 mg of SB656933
11564289|NCT00903201|Experimental|Treatment B|50 mg of SB656933
11564290|NCT00903201|Experimental|Placebo|Placebo
11564291|NCT00903188|Active Comparator|Cyclosporine|Simulect + cyclosporine + Myfortic + steroid stop at 3 months
11564292|NCT00903188|Active Comparator|Everolimus|Simulect + cyclosporine (decrease dose in one week at month 3 and replace by Everolimus (Certican)) + Myfortic + steroid maintenance
11564293|NCT00903175|Experimental|everolimus 1L/sunitinib 2L|everolimus First Line: 10 mg orally, once daily, (two 5 mg tablets), continuous treatment. sunitinib Second Line: 50 mg orally, once daily, 4 weeks on treatment followed by 2 weeks off (4/2)
11564294|NCT00903175|Active Comparator|sunitinib 1L/everolimus 2L|sunitinib First Line: 50 mg orally, once daily, 4 weeks on treatment followed by 2 weeks off (4/2) everolimus Second Line: 10 mg orally, once daily (two 5 mg tablets), continuous treatment
11564295|NCT00903162|Experimental|Letrozole-Leuprolide|Patients will receive 2.5mg oral letrozole daily and either 7.5mg monthly of Leuprolide IM or 22.5mg every three months of Leuprolide IM. Zoledronic acid 4mg IV every 6 months x 4 will also be offered optionally.
11564296|NCT00903149||MITP exposure or not|Mothers of children born preterm and term.
11564297|NCT00903084|Active Comparator|1|Participants will receive 7 doses per week, then 4 doses per week, then 2 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
11564298|NCT00903084|Active Comparator|2|Participants will receive 7 doses per week, then 2 doses per week, then 4 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
11564299|NCT00903084|Active Comparator|3|Participants will receive 4 doses per week, then 7 doses per week, then 2 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
11564300|NCT00903084|Active Comparator|4|Participants will receive 4 doses per week, then 2 doses per week, then 7 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
11564301|NCT00903084|Active Comparator|5|Participants will receive 2 doses per week, then 7 doses per week, then 4 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
11564302|NCT00903084|Active Comparator|6|Participants will receive 2 doses per week, then 4 doses per week, then 7 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
11564303|NCT00903071|Active Comparator|REAL PPL|REAL+PPL profiles PCP performance using real electronic medical record derived data to identify each PCP's specific failures of decision making in HT care antecedent to the personalized learning intervention.
11564304|NCT00903071|Active Comparator|SIM PPL|SIM+PPL, profiles PCP performance using simulated cases to identify each PCP's specific failures of decision making in HT care antecedent to the personalized learning intervention.
11564305|NCT00903071|No Intervention|Control|No intervention -control group
11564306|NCT00903045|Experimental|1|
11564307|NCT00903045|Placebo Comparator|2|
11564403|NCT00902486|Experimental|INCB028050 10 mg QD|INCB028050 10mg QD
11564408|NCT00902460|Experimental|Treatment Sequence 2|
11564441|NCT00902278|Active Comparator|Fluarix|
11564308|NCT00903032|Experimental|Arm 1|The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
11564309|NCT00903032|Active Comparator|Arm 2|Patients will receive usual care following ACS hospital discharge
11564310|NCT00903019|Experimental|1|Participants will receive problem-solving therapy (PST) delivered via teleconferencing (tele-PST).
11564311|NCT00903019|Active Comparator|2|Participants will receive problem-solving therapy (PST) delivered in-person.
11564312|NCT00903019|Placebo Comparator|3|Participants will receive monitoring phone calls.
11564313|NCT00903006|Active Comparator|Group 1: Fulvestrant|Group 1 will receive Fulvestrant only.
11564314|NCT00903006|Active Comparator|Group 2: Fulvestrant + Dasatinib|Group 2 will receive Fulvestrant and Dasatinib.
11564315|NCT00903006|Active Comparator|Group 3: Fulvestrant + MK-0646|Group 3 will receive Fulvestrant and MK-0646.
11564316|NCT00903006|Active Comparator|Group 4: Fulvestrant, MK-0646 + Dasatinib|Group 4 will receive Fulvestrant, MK-0646, and Dasatinib.
11564317|NCT00902993|Experimental|1|Part A single and multiple dose and part B fractionated dose
11564318|NCT00902993|Placebo Comparator|2|
11564319|NCT00902980||1. Community Based Clinics|Patient charts from community based nephrology clinics
11564320|NCT00902980||2. Regional Clinics|Patient charts from regional transplant clinics
11564321|NCT00902967|Active Comparator|1|Tablet Atorvastatin 10 mg once daily for 5 weeks (1 week before operation till 2 weeks after the operation)
11564322|NCT00902967|Placebo Comparator|2|Placebo tablets of similar shape and color given at night time dosing
11564323|NCT00902954|Experimental|A|anastrozole/letrozole 2-3 years switching to exemestane 3-2 years
11564324|NCT00902954|Active Comparator|B|anastrozole/letrozole 5 years
11564325|NCT00902941|Experimental|Rasagiline|
11564326|NCT00902941|Placebo Comparator|Placebo|
11564327|NCT00902928|Experimental|1. YM150, Dose X, twice daily|
11564328|NCT00902928|Experimental|2, YM150, Dose X, once daily|
11564329|NCT00902928|Experimental|3. YM150, Dose Y, twice daily|
11564330|NCT00902928|Experimental|4. YM150, Dose Y, once daily|
11564331|NCT00902928|Active Comparator|5. Enoxaparin|
11564332|NCT00902915|Experimental|Lenalidomide - Dexamethasone|
11564333|NCT00902902||1|
11564334|NCT00902902||2|
11564335|NCT00902889|Experimental|1|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation with GPE (upper cranial two contacts).
11564336|NCT00902889|Experimental|2|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
11564337|NCT00902876|Experimental|Mucograft + CAF|Mucograft in combination with coronally advanced flap (CAF)
11564338|NCT00902876|Experimental|CAF|Coronally advanced flap (CAF) alone
11564339|NCT00902863|Experimental|YOGA patients|Patients assessed for chronic pain at our Pain Management Centre
11564340|NCT00902850|Experimental|SofLens Daily Disposable|SofLens Daily Disposable Lenses
11564341|NCT00902850|Active Comparator|Marketed 1 Day Contact Lens|Marketed 1 Day Contact Lens
11564342|NCT00902837|Active Comparator|oxycodone Tablet|OxyCodone Prolonged release tablets
11564343|NCT00902837|Experimental|oxycodone naloxone tablet|Oxycodone naloxone prolonged release tablets (OXN)
11564344|NCT00902824|Active Comparator|Group A|"ADVAX at 0,1 and 2 months followed by TBC-M4 at 6 months
~Number of volunteers: 12"
11564345|NCT00902824|Active Comparator|Group B|"TBC-M4 at 0,1,6 months
~Number of volunteers: 12"
11564346|NCT00902824|Placebo Comparator|Placebo|Both Groups A and B will have 4 volunteers each (8 total) that will receive a placebo.
11564347|NCT00902811|Active Comparator|AM(LT)|Artesunate (Arsumax®, Sanofi)
11564348|NCT00902811|Experimental|AM(FDC)|Artesunate-mefloquine fixed dose combination
11564349|NCT00902811|Experimental|AL|artemether 20 mg - lumefantrine 120 mg co-formulated tabs
11564350|NCT00902811|Experimental|DP|40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/Piperaquine 160 mg tablets
11564351|NCT00902811|Experimental|AA (FDC)|Artesunate-amodiaquine fixed dose combination
11564352|NCT00902798|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.
~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
11564353|NCT00902798|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
~Time commitment: about 1 hour per week; Location: Pittsburgh, PA only"
11564354|NCT00902785||no drug|no drug
11564355|NCT00902772|Placebo Comparator|A|Placebo
11564356|NCT00902772|Active Comparator|B|Lorazepam
11564357|NCT00902772|Active Comparator|C|Lorazepam
11564358|NCT00902772|Active Comparator|D|Lorazepam
11564359|NCT00902772|Experimental|E|AZD7325
11564360|NCT00902772|Experimental|F|AZD7325
11564361|NCT00902772|Experimental|G|AZD7325
11564404|NCT00902486|Placebo Comparator|Placebo|Placebo group may 'cross-over' following 3 months of treatment to receive either active arm #2 (7mg QD) or active arm #3 (10mg QD) of INCB028050 capsules.
11564405|NCT00902473|Experimental|1|25 mg Topiramate tablets of Ranbaxy Laboratories, Ltd
11564406|NCT00902473|Active Comparator|2|(Topamax®) 25 mg Topiramate tablets of Ortho-McNeil Pharmaceutical, Inc. New jersey 08869
11564362|NCT00902759|No Intervention|Usual Care Group|"Participants randomized to the usual care group will be encouraged to return to their usual or pre-surgical levels of activity. Usual care of post-surgical PC and peri-ampullary patients typically includes encouragement to walk and be active as they can be by the surgeons, surgical nurses and the nurse practitioners. Participants in the usual care group will not receive an individual Exercise Prescription at the time of entry. The usual care group will perform a baseline walk. Participants in the usual care group will not receive an individual Exercise Prescription at the time of entry nor will they will a telephone call every month. Repeat questionnaires will be performed at 6 months."
11564363|NCT00902759|Experimental|Walking Program|Participants in the intervention arm will participate in a walking program consisting of a 6 week graduated walking program. There are three phases to the walking program, Phase 1 is Warm-up, Phase 2 is Brisk Walking and Phase 3 is Cool Down. Phase 1 is the same for all 6 weeks, and consists of a slow 5 minute walk. In Months 1 and 2, Phase 2 is a 10 minute brisk walk. In Months 3 and 4, Phase 2 is a 20 minute brisk walk. In Months 5 and 6, Phase 2 is a 25 - 30 minute brisk walk. Phase 3 is the same for all 6 weeks and consists of a 5 minute rest/cool down period.
11564364|NCT00902746|Experimental|NPC-01|Norethisterone, Ethinyl Estradiol
11564365|NCT00902720|Experimental|Cryopreservation|The ovarian tissue is frozen and banked at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
11564366|NCT00902707|Experimental|Mucinex 1200mg|Pill
11564367|NCT00902707|Placebo Comparator|Placebo|Pill
11564368|NCT00902694|Experimental|ACHIEVE Intervention|Group and individual weight counseling and group physical activity classes for 18 months.
11564369|NCT00902694|Other|Control|Control arm receives group health classes quarterly with topics not related to weight
11564370|NCT00902681|Other|Reference|a single dose of 8 mg fesoterodine (Toviaz™ 8 mg) tablet manufactured at Zwickau
11564371|NCT00902681|Other|Test|a single dose of 8 mg fesoterodine (Toviaz™ 8 mg) tablet manufactured at Vega Baja (Test)
11564372|NCT00902668|Experimental|Supportive care (lovastatin)|Patients undergo 25-28 fractions of standard whole-breast irradiation followed by a boost to the tumor bed or 10 fractions of accelerated partial-breast irradiation with balloon brachytherapy BID over 5-10 days. Patients also receive lovastatin PO QD for 12 months beginning on day 1 of radiation therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
11564373|NCT00902655|Experimental|Desmopressin|
11564374|NCT00902642|No Intervention|control group|
11564375|NCT00902642|Active Comparator|Course on psychosocial factors|an eight day university training course for physical therapists designed to integrating psychosocial factors in clinical practice on a patient level
11564376|NCT00902629|Experimental|Intervention|Intervention group contains the patients randomized for early treatment of their epiretinal fibrosis.
11564377|NCT00902629|No Intervention|Control|Control contains patients not randomized for early surgery.
11564378|NCT00902616|Active Comparator|1. L-arginine|3 gm TDS for 3 months
11564379|NCT00902616|Placebo Comparator|2. Placebo - Lactose powder|3 gm TDS for 3 months
11564380|NCT00902603||1|Patients with WHO Group I pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3 months.
11564381|NCT00902590||1|Patients with urothelial cancer
11564382|NCT00902590||2|unrelated adults accompanying patients to clinic
11564383|NCT00902577|Experimental|Diagnostic (MRI and PET using FMISO)|Two weeks before initiation of chemoradiotherapy with temozolomide, patients undergo MRI (DSC, DCE,DWI and MRS) and PET scan using FMISO. A subset of 15 patients undergo FMISO PET scans approximately 1 week before chemoradiotherapy.
11564384|NCT00902564|Experimental|Escitalopram|
11564385|NCT00902551||1|Subjects underwent cervical sample DNA image cytometry
11564386|NCT00902551||2|Subjects underwent cervical sample conventional cytology
11564387|NCT00902538|Experimental|Olmesartan (OLM) 40mg-Amlodipine (AML) 10mg|The participants in this arm received these 2 drugs for the 8-week, single-blind, run-in Period 1. Participants could then randomized to this same combination for an additional 8 weeks in the double-blind, Period 2.
11564388|NCT00902538|Experimental|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg|Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3.
11564389|NCT00902538|Experimental|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg|Participants could start receiving this combination in randomized, double-blind, 8- week Period 2.
11564390|NCT00902538|Experimental|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg (Responders)|Participants who meet their blood pressure goals in Period 3 and continued into the 8-week, double-blind Period 4 continued to receive this combination.
11564391|NCT00902538|Experimental|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg (Non-responders)|Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4
11564392|NCT00902538|Experimental|OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg (Non-responders)|Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4
11564393|NCT00902525|Experimental|90Y-Ibritumomab Tiuxetan double dose|90Y-Ibritumomab Tiuxetan administered at 0.4 mCi/kg at phase 2 and then at 0.2 mCi/kg at phase 3
11564394|NCT00902512|Active Comparator|Treatment A|Viagra® 100 mg tablet, administered with water
11564395|NCT00902512|Active Comparator|Treatment B|Sildenafil 100 mg CT administered with water
11564396|NCT00902512|Active Comparator|Treatment C|Sildenafil 100 mg CT administered without water
11564397|NCT00902499||NC|Normal older controls, not cognitively impaired; MMSE 27-30 and performance above education adjusted cutoff scores on the Logical Memory II subscale (LM-II Delayed Paragraph Recall) of the Wechsler Memory Scale
11564398|NCT00902499||vMCI|Very mild cognitive impairment; less severe objective memory deficit, scoring .5 to 1.5 S.D. (standard deviation) below education adjusted norms on the LM-II
11564399|NCT00902499||sMCI|significant mild cognitive impairment; objective cut off of 1.5 S.D. level below education adjusted norms on the LM-II
11564400|NCT00902499||AD|Mild Alzheimer's disease; meet NINCDS/ADRDA criteria for probable AD with mild dementia severity (CDR Total = 1), MMSE 20-26
11564401|NCT00902486|Experimental|INCB028050 4 mg QD|INCB028050 4mg Once daily (QD)
11564409|NCT00902447||Human Blood Cell Disorders|Human Blood Cell Disorders Tissue Bank
11564410|NCT00902421|Active Comparator|Antimuscarinics|
11564411|NCT00902421|Experimental|Selective serotonin reuptake inhibitors|Selective serotonin reuptake inhibitor
11564412|NCT00902408|Experimental|Lutein|Lutein enriched eggs
11564413|NCT00902408|Placebo Comparator|Placebo|Non enriched
11564414|NCT00902395|Active Comparator|Midazolam|Oral midazolam
11564415|NCT00902395|Experimental|Midazolam/ketamine|Combined midazolam and ketamine
11564416|NCT00902395|Other|Protective stabilization|No drug or placebo administered
11564417|NCT00902382||1|Infertile women who conceive spontaneously
11564418|NCT00902382||2|Infertile women who conceive on various ovulation stimulation medications
11564419|NCT00902369|Experimental|AK106-001616|
11564420|NCT00902369|Placebo Comparator|Placebo|Part1: AK106-001616 and Placebo
11564421|NCT00902369|Active Comparator|Active comparator|Part2: AK106-001616 and Active comparator
11564422|NCT00902356|Active Comparator|B|Six female subjects in each of cohorts 1 to 5 will receive AMG 167; six male subjects in each of cohorts 6 and 8; three female subjects in each of cohorts 7 and 9.
11564423|NCT00902356|Placebo Comparator|A|Two female subjects in each of cohorts 1 to 5 will receive placebo; two male subjects in each of cohorts 6 and 8; and 1 female subject in each of cohorts 7 and 9.
11564424|NCT00902343|Experimental|1|nomogram-based selection for acute normovolemic hemodilution
11564425|NCT00902343|Active Comparator|2|standard selection for ANH based on a planned resection of 3 or more segments.
11564426|NCT00902330|Experimental|Arm I (cranial microcurrent electrical stimulation [CES])|Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level), modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz, and to automatically turn off at the end of 1 hour. Patients use their CES unit once daily in weeks 1-18.
11564427|NCT00902330|Sham Comparator|Arm II (sham CES)|Patients receive a CES unit as in arm I, but the ear-lobe electrodes do not pass electrical current. Patients use their CES unit once daily in weeks 1-18.
11564428|NCT00902317|Active Comparator|Boston Scientific|The PolarCath peripheral balloon catheter (CryoVascular Systems, Inc., Los Gatos, CA) is a novel angioplasty system that simultaneously dilates and cools the plaque and vessel wall in the area of treatment. Cooling is achieved by inflating the balloon with nitrous oxide rather than the usual saline/contrast mixture.
11564429|NCT00902317|Active Comparator|Spectranetics|The excimer laser has unique properties that make it ideally suited to debulk atheromatous and thrombotic arterial blockages. LASER is an acronym for Light Amplification by Stimulated Emission of Radiation. However, there are many types of lasers, each distinguished by the wavelength of the emitted light, the effective power of the light beam, and whether the light is pulsed (like a flashbulb) or continuous (like a light bulb). The effectiveness of a given laser for intraarterial applications depends on how the light interacts with tissue inside an artery.
11564430|NCT00902317|Active Comparator|Fox Hollow|"The SilverHawk peripheral catheter system and cutter driver (FoxHollow Technologies, Redwood City, CA) are designed for the treatment of de novo and restenotic atherosclerotic lesions located in the native peripheral arteries. The catheter consists of a flexible shaft designed to track over a 0.014 guidewire. At the distal end of the catheter is a small cutting assembly comprised of a rotating inner blade contained within a tubular housing. The proximal end of the catheter contains a connector and Positioning Lever designed to fit into a small, disposable, battery-driven Cutter Driver which powers the device."
11564431|NCT00902317|Active Comparator|WL Gore|Viabahn Endoprosthesis (W.L. Gore & Associates, Flagstaff, AZ) is a flexible self-expanding endoluminal device consisting of expanded polytetrafluoroethylene (ePTFE) lining with an external Nitinol (NiTi=Nickel:Titanium) support extending along its entire length. The device is compressed and attached to a catheter delivery system. The Gore Viabahn Endoprosthesis is available in a wide range of diameters and lengths.
11564432|NCT00902317|Placebo Comparator|Control Group, Guidant|Balloon angioplasty is a treatment that uses a catheter with a tiny balloon mounted on the end. The balloon is positioned through the narrowing/blockage in your leg artery, and then it is inflated to push the narrowing apart and restore a channel for blood flow. The balloon is then deflated and removed from your body. A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface. The FDA has approved the use of certain stents for the treatment of narrowing in the leg arteries. Stents have been widely used in various parts of the body, including blocked blood vessels in the arms, legs, heart (coronary arteries), and kidneys (renal arteries).
11564433|NCT00902304|Active Comparator|Usual care|Physicians applied their usual pattern of patient visits and treatment strategies to achieve individualized blood pressure target
11564434|NCT00902304|Experimental|Monotherapy (initial monotherapy arm)|Physicians utilized valsartan 160mg per day for 6 weeks, followed by (if required) dose titrations every 4 weeks thereafter until week 14 (valsartan 320mg per day, then valsartan 320mg plus hydrochlorothiazide (HCTZ) 12.5mg per day, then valsartan 320mg plus HCTZ 25mg per day (maximal dose)). For patients not at blood pressure target at week 18, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
11564435|NCT00902304|Experimental|Combination (initial combination therapy arm)|Physicians initially utilized single tablet combination products of either valsartan plus hydrochlorothiazide (HCTZ) or valsartan plus amlodipine for an initial 6 weeks of therapy (based on the treating physician's preference), with dose titrations (if required) every 4 weeks thereafter until week 10. The maximum dose for the HCTZ combination was valsartan 160mg plus HCTZ 25mg per day. The maximum dose for the amlodipine combination was valsartan 160mg plus amlodipine 10mg per day. For patients who were not at blood pressure target at week 14, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
11564436|NCT00902291|Active Comparator|1. Gemcitabine monotherapy|
11564437|NCT00902291|Experimental|2. Gemcitabine plus AGS-1C4D4|
11564438|NCT00902278|Active Comparator|Flulaval|
11564439|NCT00902278|Active Comparator|Fluvirin|
11564440|NCT00902278|Active Comparator|Fluzone|
11564442|NCT00902278|Active Comparator|Affluria|
11564443|NCT00902265||desmopressin|"Participants with benign prostate syndrome suffering from nocturia associated with nocturnal polyuria.
~Drug given by prescription."
11564444|NCT00902252|Experimental|Usual/Natura®/Vitala™|All subjects will wear usual product for 21 days, followed by Natura® for 14 days and followed by Vitala™ for 159 days.
11564445|NCT00902226|Experimental|Escitalopram|
11564446|NCT00902213|No Intervention|Minimal movement|Minimal movement group with usual care non-intervention.
11564447|NCT00902213|Active Comparator|Physical Therapy|
11564448|NCT00902200|Placebo Comparator|Vehicle|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
11564449|NCT00902200|Experimental|AR-12286 0.05%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
11564450|NCT00902200|Experimental|AR-12286 0.1%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
11564451|NCT00902200|Experimental|AR-12286 0.25%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
11564452|NCT00902187|Other|Reference|fesoterodine (Toviaz™ 4 mg) tablet manufactured at Zwickau (Reference)
11564453|NCT00902187|Other|Test|fesoterodine (Toviaz™ 4 mg) tablet manufactured at Vega Baja (Test)
11564454|NCT00902174|Experimental|imatinib mesylate|Imatinib mesylate (QTI571) 200 mg once daily for two weeks, increased to 400 mg once daily if well tolerated. If 400 mg dose was not well tolerated, a down titration to 200 mg once daily was permitted.
11564455|NCT00902174|Placebo Comparator|Placebo|Placebo to imatinib mesylate taken once daily. Participants receiving placebo were allowed to receive already approved PAH treatments.
11564456|NCT00902161|Experimental|Propanolol + Placebo > Propanolol + MK0893|Participants received propanolol for 7 weeks. On Day -1 of Period 1 (Study Visit 6), single dose MK0893-matched placebo was added and propanolol was continued. After Period 1, participants underwent a 3-week wash-out while continuing to receive propanolol. Following the washout, participants were treated with a single dose of MK0893 on Day 21 (Visit 8).
11564457|NCT00902161|Placebo Comparator|Propanolol + MK0893 > Propanolol + Placebo|Participants received propanolol for 7 weeks. On Day -1 of Period 1 (Study Visit 6), single dose MK0893 was added and propanolol was continued. After Period 1, participants underwent a 3-week wash-out while continuing to receive propanolol. Following the washout, participants were treated with a single dose of MK0893-matched placebo on Day 21 (Visit 8).
11564458|NCT00902148|No Intervention|Control Group|Colorectal Surgery without use of SurgiWrapTM
11564459|NCT00902148|Active Comparator|Test Group|Colorectal Surgery with use of SurgiWrapTM film secured directly below the abdominal incision
11564460|NCT00902135||Group 1|
11564461|NCT00902135||Group 2|
11564462|NCT00902135||Group 3|
11564463|NCT00902122|Experimental|1|Five times of p53 gene intratumoral injection are given before surgery,then radical surgery will be conducted.
11564464|NCT00902122|Active Comparator|2|surgery
11564465|NCT00902122|Experimental|3|p53 gene therapy
11564466|NCT00902122|Active Comparator|4|p53 gene therapy plus radioactive iodine
11564467|NCT00902109||perimetry, HRT, OCT|perimetry, HRT, OCT
11564468|NCT00902096||Prenatal factors|Prenatal factors to predict cord blood IgE
11564469|NCT00902083|Experimental|surgery plus p53 gene|using p53 gene therapy before surgery
11564470|NCT00902083|Active Comparator|surgery alone|Surgery without pre-p53 gene therapy
11564471|NCT00902083|Experimental|p53 plus chemotherapy|p53 gene therapy with concurrent chemotherapy
11564472|NCT00902083|Experimental|p53 gene therapy alone|Intra-tumor injectio of rAd-p53 gene with no concurrent treatment
11564473|NCT00902070||1|Patients to whom Eslax has been administered to relax muscles at the time of anesthesia or tracheal intubation
11564474|NCT00902057|Active Comparator|desmopressin 1.5|
11564475|NCT00902057|Active Comparator|desmopressin 3|
11564476|NCT00902057|Active Comparator|desmopressin 15|
11564477|NCT00902057|Placebo Comparator|placebo|
11564478|NCT00902044|Experimental|Autologous HER2-specific T cells|"THIS ARM IS CLOSED
~Dose Level 1: 1x10^4 cells/m2
~Dose Level 2: 3x10^4 cells/m2
~Dose Level 3: 1x10^5 cells/m2 (NOT BEING USED)
~Dose Level 4: 3x10^5 cells/m2 (NOT BEING USED)
~Dose Level 5: 1x10^6 cells/m2
~Dose Level 6: 3x10^6 cells/m2
~Dose Level 7: 1x10^7 cells/m2
~Dose Level 8: 3x10^7 cells/m2
~Dose Level 9: 1x10^8 cells/m2"
11564479|NCT00902044|Experimental|HER2-specific T cells+fludarabine|"Autologous HER2-specific T cells+fludarabine:
~Dose Level 9A: fludarabine followed by 1x10^8 cells/m^2"
11564480|NCT00902044|Experimental|HER2-specific T cells+fludarab.+cycloph.|"Autologous HER2-specific T cells+fludarabine+cyclophosphamide:
~Dose Level 9B: fludarabine + cyclophosphamide followed by 1x10^8 cells/m^2"
11564481|NCT00902044|Experimental|CAR Positive cells|Dose Level 9C: fludarabine + cyclophosphamide followed by 1x10^8 cells/m^2 CAR positive cells/m^2
11564482|NCT00902031|Experimental|Docusate + Sennoside|
11564483|NCT00902031|Placebo Comparator|Sennoside + Placebo|
11564484|NCT00902018|Experimental|eltrombopag|10 ITP patients were treated with daily oral eltrombopag 75mg for 2 weeks and complete testing was done at weekly intervals 3 times they then were allowed to receive long-term eltrombopag
11564485|NCT00902018|Experimental|romiplostim|3 of the patients who received eltrombopag were also treated with romiplostim 10 micrograms/kg weekly for 2 weeks with the same complete testing done at weekly intervals three times after a washout period > 1 month they then resumed long-term eltrombopag
11564486|NCT00902018|Sham Comparator|healthy controls|no intervention single blood draw with complete studies
11564487|NCT00902005||Rheumatic patients|"Three groups:
~RA patients: 30 starting on Methotrexate, 30 starting on combination of Methotrexate and TNFalpha inhibitor.
~PSA patients: 20 starting on Methotrexate, 20 starting on combination of Methotrexate and TNFalpha inhibitor.
~AS patients: 20 starting on TNFalpha inhibitor"
11564488|NCT00901992|Experimental|MEDIAS 2 ICT|MEDIAS 2 ICT - education program for the initiation of intensive conventional insulin treatment (ICT) in type 2 diabetic patients
11564489|NCT00901992|Active Comparator|Current ICT program (ACC)|This education program consists of 10 lessons combining an insulin education program with an hypertension program
11564490|NCT00901979|Experimental|LCQ908 Dose 1|
11564491|NCT00901979|Experimental|LCQ908 Dose 2|
11564492|NCT00901979|Experimental|LCQ908 Dose 3|
11564493|NCT00901979|Experimental|LCQ908 Dose 4|
11564494|NCT00901979|Experimental|LCQ908 Dose 5|
11564495|NCT00901979|Placebo Comparator|Placebo|
11564496|NCT00901979|Active Comparator|Sitagliptin|
11564497|NCT00901966||Agricultural workers and spouses|Melanoma risk factors among Ag workers and spouses who use pesticides.
11564498|NCT00901953||1|migrainous vertigo
11564499|NCT00901953||2|migraine without vertigo
11564500|NCT00901940|Active Comparator|MenACWY Plain Polysaccharide (ACWY Vax)|The MenACWY Plain Polysaccharide Vaccine, which is already licensed and is used as a travel vaccine, is known as the MenACWY plain polysaccharide (ACWY Vax). Participants in this arm will receive 1 dose of the MenACWY plain polysaccharide (ACWY Vax) and 1 dose of the MenACWY conjugate (MenACWY).
11564501|NCT00901940|Active Comparator|MenACWY conjugate|The MenACWY conjugate vaccine was licensed in the UK in March 2010, and is known as the MenACWY conjugate vaccine (Menveo). Participants in this arm will receive 2 doses of the MenACWY conjugate vaccine.
11564502|NCT00901927|Experimental|Bendamustine + Mitoxantrone + Rituximab|Bendamustine starting dose 90 mg/m^2 intravenously (IV) over 30-60 minutes on Days 1 and 2 of each 8-day cycle. Mitoxantrone 10 mg/m^2 IV over 15 minutes on Day 2 of each cycle. Rituximab 375 mg/m^2 IV over several hours on Day 1 of each cycle.
11564503|NCT00901914|Placebo Comparator|1|Placebo
11564504|NCT00901914|Experimental|2|12.5 µg rBet v 1
11564505|NCT00901914|Experimental|3|25 µg rBet v 1
11564506|NCT00901914|Experimental|4|50 µg rBet v 1
11564507|NCT00901901|Experimental|Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)|Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)
11564508|NCT00901901|Active Comparator|Sorafenib (Nexavar, BAY43-9006) + Placebo|Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)
11564509|NCT00901888|Experimental|Angiotensin II infusion|Using forearm venous occlusion plethysmography angiotensin II will be infused to cause reduction in forearm blood flow. Infusion of apelin and sodium nitroprusside will given and vasodilatation will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
11564510|NCT00901888|Active Comparator|Noradrenaline|Using forearm venous occlusion plethysmography noradrenaline will be infused to cause reduction in forearm blood flow. Infusion of apelin and sodium nitroprusside will given and vasodilatation will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
11564511|NCT00901875|Experimental|Suboxone, maximum 8mg|
11564512|NCT00901875|Experimental|Buprenorphine + naloxone|
11564513|NCT00901875|Experimental|Buprenorphine + naloxone (Suboxone)|
11564514|NCT00901862|Active Comparator|1 Active PEFs|The pulsed electromagnetic fields were directed to the wrist. The model used has the form of a bracelet called Quantum MH-2MR which uses, as a source of power, an alkaline battery of 1.5 volts connected to an electronic circuit formed by two hybrid circuits of magnetic oscillation and a control system of all the generating frequency system.
11564515|NCT00901862|Sham Comparator|2 Sham|The sham machines were identical to the machines in actual operation in both phases of the study. The only difference was that the hybrid circuits crucial for the generation of the electromagnetic field had been removed.
11564516|NCT00901836|Experimental|Preoperative Proton Therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
11564517|NCT00901836|Active Comparator|Surgery|Standard of care surgery will be performed 4-6 weeks after the completion of radiation.
11564518|NCT00901823|Experimental|Sequence 1|Single dose of low dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
11564519|NCT00901823|Experimental|Sequence 2|Single dose of high dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
11564520|NCT00901810|Active Comparator|Apex Locator|Working length for cleaning and shaping of the canal is measured by Electronic Apex Locator in this group.
11564521|NCT00901810|Active Comparator|Radiography|Working length for cleaning and shaping of the canal is measured by Radiography in this group.
11564522|NCT00901797|Active Comparator|Arthroscopic Bankart repair|
11564523|NCT00901797|Active Comparator|ABR+ARIC|
11564524|NCT00901784|Experimental|1|25 mg Topiramate tablets of Ranbaxy Laboratories, Ltd
11564525|NCT00901784|Active Comparator|2|(Topamax®) 25 mg Topiramate tablets of Ortho-McNeil Pharmaceutical, Inc. New jersey 08869
11564526|NCT00901758|Placebo Comparator|2|Placebo solution was normal saline. After an initial 1mL dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL.
11564527|NCT00901758|Active Comparator|1|Treatment solution consisted of 100micrograms/mL of nitroglycerin. After an initial 1mL dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL.
11564528|NCT00901745|Experimental|Infusion of apelin|Using forearm venous occlusion plethysmography apelin will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
11564529|NCT00901745|Active Comparator|Sodium nitroprusside infusion|Using forearm venous occlusion plethysmography sodium nitroprusside will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
11564530|NCT00901719|Experimental|Sodium depletion|Subjects will be randomised to normal diet or sodium depleted diet. The sodium depletion protocol comprises of a single oral dose of 40 mg of furosemide followed by an out-patient diet containing >2000 kcal of energy, >60 g of protein, <12 mmol of sodium and <70 mmol of potassium per day for 3 days prior to study. This diet is know to increase the activity of the renin-angiotensin system.
11564531|NCT00901719|Placebo Comparator|Normal diet|Subjects will be randomised to a normal diet, with no restriction on sodium intake during the three days prior to the study.
11564532|NCT00901706|Experimental|CGA plus APS Usual Care|Comprehensive geriatric assessment coupled with Adult Protective Services (APS) usual care for elders with self-neglect.
11564533|NCT00901706|Active Comparator|APS Usual Care|APS usual care consisting of social, medical, and legal interventions.
11564534|NCT00901693|Experimental|AL-46383A|AL-46383A Ophthalmic Solution, 1 drop in each eye, 8 times a day for 10 days
11564535|NCT00901693|Placebo Comparator|Vehicle|AL-46383A Ophthalmic Solution Vehicle, 1 drop in each eye, 8 times a day, for 10 days
11564536|NCT00901654|Experimental|ACE527|
11564537|NCT00901654|Placebo Comparator|Placebo comparator|
11564538|NCT00901641|Experimental|cognitive training|CogniFit Personal Coach® computer cognitive training program. The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®). The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
11564539|NCT00901628|Experimental|Periarticular Injection group|Periarticular injection with ropivacaine, morphine, ketorolac, epinephrine, cefuroxime
11564540|NCT00901628|No Intervention|No Injection group|usual postoperative care without periarticular injection
11564541|NCT00901615|Experimental|Lenalidomide and R-CHOP|Escalating Lenalidomide dose from 2.5 to 25 mg Lenalidomide and R-CHOP
11564542|NCT00901589|Active Comparator|Premenopausal women-fishoil|
11564543|NCT00901589|Placebo Comparator|Premenopausal-placebo|
11564544|NCT00901589|Active Comparator|Postmenopausal women-fishoil|
11564545|NCT00901589|Placebo Comparator|Postmenopausal-placebo|
11564546|NCT00901576|Experimental|SPD503|
11564547|NCT00901576|Active Comparator|Concerta|
11564548|NCT00901576|Active Comparator|SPD503 + Concerta|
11564549|NCT00901563|Active Comparator|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
11564550|NCT00901563|Placebo Comparator|Saline|Saline will be infused through-out the study.
11564551|NCT00901550|Active Comparator|Methotrexate|A drug for RA patient
11564552|NCT00901550|Active Comparator|Infliximab|for RA treatment
11564553|NCT00901537|Experimental|Azacitidine and Cisplatin|Every 4 weeks, azacitidine is given daily as subcutaneous injection for 5 days from day 1 to day 5, and cisplatin is given as intravenous injection on day 8. The dose of azacitidine will be dose escalated among each group of 3-6 patients, and the dose of cisplatin is fixed.
11564554|NCT00901524|No Intervention|PegIFN- alpha 2a + RBV|
11564555|NCT00901511|Experimental|WLL/GM-CSF|Whole lung lavage followed by inhaled GM-CSF
11564556|NCT00901511|Active Comparator|WLL alone|
11564557|NCT00901498|Experimental|Treatment A (Reference)|
11564558|NCT00901498|Active Comparator|Treatment B|
11564559|NCT00901498|Active Comparator|Treatment C|
11564560|NCT00901498|Active Comparator|Treatment D|
11564561|NCT00901498|Active Comparator|Treatment E|
11564562|NCT00901485|Experimental|autotitrating NIV|approximately 6 weeks using domiciliary nocturnal autotitrating non-invasive ventilation
11564563|NCT00901485|Active Comparator|Standard non-invasive ventilation|approximately 6 weeks using domiciliary nocturnal standard non-invasive ventilation
11564564|NCT00901472||Stable type 2 Diabetes (ST2D)|Adults with Type 2 diabetes who receive medical care at the University of Chicago
11564565|NCT00901459|Active Comparator|rTMS 90% MT - Low frequency rTMS|Intervention type: device. Intervention description: low frequency rTMS was administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues using 90% MT (Motor Threshold) 1 Hz rTMS Dose on Superior Frontal Gyrus
11564566|NCT00901459|Active Comparator|Location Control|rTMS Dosing: 90% MT (Motor Threshold) 1 Hz rTNS Location: Motor Cortex
11564567|NCT00901459|Active Comparator|Frequency Control|rTMS Dosing: 90% MT (Motor Threshold) 10 Hz rTNS Location: Superior Frontal Gyrus
11564568|NCT00901446||Imaging|Subjects who receive intracoronary imaging with the investigative device.
11564569|NCT00901433||A|Usability study of the Personal Wheezometer
11564570|NCT00901420||Prostatectomy|
11564571|NCT00901420||Prostatectomy After Radiation Therapy|
11564572|NCT00901407|Experimental|1|lamotrigine
11564573|NCT00901407|Placebo Comparator|2|placebo
11564574|NCT00901394|Experimental|Treatment 1|B12-Folic acid, nitrous oxide
11564575|NCT00901394|Active Comparator|Treatment 2|Nitrous oxide (NO) and placebo
11564576|NCT00901394|Placebo Comparator|Control group|oxygen nitrogen
11564577|NCT00901381|Experimental|G-CSF|
11564578|NCT00901381|No Intervention|Control|
11564579|NCT00901368|Experimental|1|CHF1535 (beclometasone dipropionate plus formoterol, 400/24 µg daily)
11564580|NCT00901368|Active Comparator|2|Seretide® Diskus® (fluticasone plus salmeterol, 500/100 µg /daily)
11564581|NCT00901342|Experimental|Sipuleucel-T|Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
11564582|NCT00901329|Experimental|1: Gender prosthesis|
11564583|NCT00901329|Active Comparator|2: LPS flex prosthesis|
11564584|NCT00901316|Experimental|Routine Measures|
11564585|NCT00901316|Experimental|Bleach Baths|
11564586|NCT00901303|Other|Early Stage Disease|Group A
11564587|NCT00901303|Other|Advance Stage Disease|Group B
11564588|NCT00901290|Experimental|1|monophasic oral contraceptive
11564589|NCT00901290|Experimental|2|AZD7325
11564590|NCT00901277|No Intervention|Control|Usual Care
11564591|NCT00901277|Experimental|Web Intervention|Web-based: interactive web-based tool based on Microsoft's HealthVault technology for data transmission, tracking and communication of cardiac risk factors (e.g. home BP monitors for all in this intervention arm)
11564592|NCT00901277|Experimental|Nurse Intervention|Nurse: an interactive web-based tool based on Microsoft's HealthVault technology for data transmission, tracking and communication of cardiac risk factors (e.g. home BP monitors for all in this intervention arm)
11564593|NCT00901264||1|Patients with pathological diagnoses of cancer or leukemia
11564594|NCT00901264||2|3.1.3 Patients for whom chemotherapy is planned.
11564595|NCT00901251||1|
11564743|NCT00899379|Experimental|Treatment Sequence 2|Rizatriptan-Placebo-Rizatriptan-Rizatriptan
11564596|NCT00901225|Experimental|G-CSF plus Plerixafor|Patients who were unable to mobilize a minimum number of cells (CD34+ cell count <20 cells/ul)following 5 days of G-CSF mobilization.
11564597|NCT00901212|Active Comparator|LV Pacing|left univentricular pacing
11564598|NCT00901212|Active Comparator|BV Pacing|biventricular pacing
11564599|NCT00901199|Other|Child Cohort|This is the cohort in the study for children ages 8-18 years old. All subjects in this arm must have Liver Iron by SQUID of between 5-15mg/g dry liver and have a documented endocrinopathy or cardiac finding (low T2* or decreased cardiac function). All subjects in this arm will receive 7 days per week of Exjade and 3-5 days per week of Desferal.
11564600|NCT00901199|Other|Moderate Adult Cohort|Adults in this arm will have moderate iron overload,defined as SQUID of 5-15mg/g dry weight. They will also have to have a documented endocrinopathy or cardiac finding (low T2*). All subjects in this cohort will receive 7 days per week of Exjade (20-30mg/kg) and Desferal (50mg/kg)3-5 days per week.
11564601|NCT00901199|Other|Adults cohort with high iron overload|Adults with high iron overload defined as over 15mg/g dry liver. No cardiac finding or endocrinopathy necessary. Subjects in this cohort will receive Exjade 20-30mg/kg 7 days per week and Desferal (50mg/kg)5-7 days per week.
11564602|NCT00901186|Experimental|RFB002|RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.
11564603|NCT00901186|Active Comparator|Laser photocoagulation|At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.
11564604|NCT00901160||Surgical patients|Blood will be taken from patients who are on anti-platelet medication and are having surgery that requires an overnight stay. This is a pilot study to see if Thromboelastography® and Platelet Mapping Assay™ will be able to predict if a patient is at risk for a bleeding or a clotting problem after surgery.
11564605|NCT00901147|Experimental|panobinostat and bortezomib|Oral Panobinostat and intravenous bortezomib
11564606|NCT00901134||hypothermia|Patients with therapeutic hypothermia after cardiac arrest in hospitals
11564607|NCT00901121|Experimental|BoneCeramic|Straumann BoneCeramic is a fully synthetic bone graft substitute of medical grade purity in particulate form composed of biphasic calcium phosphate - a mixture of 60% hydroxylapatite and of 40% of the beta form of tricalcium phosphate (beta-TCP).
11564608|NCT00901121|Active Comparator|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
11564609|NCT00901108|Active Comparator|Trabectome-IOL|Combined Trabectome and cataract extraction with intraocular lens insertion
11564610|NCT00901108|Active Comparator|Trab-IOL|Combined Trabeculetomy with Mitomycin C and cataract extraction with intraocular lens insertion
11564611|NCT00901095|No Intervention|Control|Usual Care
11564612|NCT00901095|Experimental|Lifestyle intervention|The Lifestyle intervention group consists of in-person meetings co-led by an exercise specialist and dietician as well as follow-ups with an interventionist by phone.
11564613|NCT00901082|Active Comparator|information and relaxation|will receive the intervention that consist of information and relaxation
11564614|NCT00901082|No Intervention|No intervention|No specific intervention before the medial branch block.
11564615|NCT00901069|Other|Azacitidine|
11564616|NCT00901056|Active Comparator|Treated Group|This group will receive actual shockwave treatment
11564617|NCT00901043|Experimental|Walnut supplementation|Eight weeks with walnut supplementation to an ad lib diet
11564618|NCT00901043|Active Comparator|Ad lib diet|Eight weeks ad lib diet without walnut supplementation
11564619|NCT00901030||Patients with PCI on blood thinners|Patients have a coronary stent and are taking anti-clotting (anti-platelet) drug and are having non-cardiac surgery.
11564620|NCT00901017|Active Comparator|Straumann BoneCeramic|Straumann BoneCeramic
11564621|NCT00901017|Active Comparator|Bio-Oss|Geistlich Bio-Oss
11564622|NCT00901004||1|Reflux esophageal minimal change in the endoscopic finding
11564623|NCT00900991|Experimental|10 ug|10 microgram per dose
11564624|NCT00900991|Experimental|15 ug|15 microgram per dose
11564625|NCT00900978|Experimental|7v-PCV (Prevenar)|Biological/vaccine
11564626|NCT00900965|Active Comparator|Electroacupuncture treatment|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
11564627|NCT00900965|Sham Comparator|Sham acupunture treatment|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
11564628|NCT00900952||1|Infected elderly patients
11564629|NCT00900939|Experimental|Low-fat, vegan diet|
11564630|NCT00900939|Placebo Comparator|Control|
11564631|NCT00900900|Experimental|Dehydroepiandrosterone (DHEA)|
11564632|NCT00900900|Experimental|Pregnenolone|
11564633|NCT00900900|Placebo Comparator|Placebo|
11564634|NCT00900887|Active Comparator|Ketorolac|ocular topic ketorolac used 3 times a day for a week after the selective photocoagulation
11564635|NCT00900887|Active Comparator|Nepafenac|ocular topic nepafenac 3 times a day during one week after selective photocoagulation
11564636|NCT00900887|Placebo Comparator|Polietilenglicol 400, propilenglicol|ocular lubricant drops 3 times a day for a week after selective photocoagulation
11564637|NCT00900874|Active Comparator|1|Salbutamol + steroid
11564638|NCT00900874|Active Comparator|2|Formoterol + steroid
11564639|NCT00900861||1|Asthmatic patients above 18 y, treated with ICS or bronchodilators
11564640|NCT00900848||8|8 patients
11564641|NCT00900822|Experimental|Straumann Bone Ceramic|StraumannBone Ceramic is used as bone grafting material in sinus augmentation procedures
11564642|NCT00900822|Active Comparator|BioOss|BioOss is used as a bone grafting material in sinus augmentation procedure
11564643|NCT00900809|Experimental|Neukoplast™ (NK-92)|Neukoplast™ will be infused in three doses.1 x 10e9 cells/m2 dose, 3 x 10e9 cells/m2 dose, 5 x 10e9 cells/m2 dose.
11564870|NCT00897234||Healthy Volunteers|Non-smoking healthy volunteers
11564644|NCT00900796||1|Patients diagnosed with active AS who start anti-TNF therapy according to standard clinical practice.
11564645|NCT00900783|Experimental|2|FV-100, 400 mg once daily AND valacyclovir placebo, three times a day, for seven days
11564646|NCT00900783|Active Comparator|3|Valacyclovir, 1 gram, three times a day AND FV-100 placebo, once daily, for seven days
11564647|NCT00900783|Experimental|1|FV-100, 200 mg once daily AND valacyclovir placebo, three times a day, for seven days
11564648|NCT00900770||PIB+ NC|PIB positive, cognitively normal individuals with foci of elevated PIB retention in cortical regions typically affected in AD
11564649|NCT00900770||PIB- NC|PIB negative, cognitively normal individuals without amyloid deposition
11564650|NCT00900757|Experimental|Palonosetron|Single Arm trial of Palonosetron for the prevention of RINV in primary malignant glioma patients receiving radiation therapy (RT) and concomitant temozolomide (TMZ)
11564651|NCT00900744||Tamoxifen|20mg daily
11564652|NCT00900731|Experimental|Indacaterol 150 µg|Participants received indacaterol 150 μg delivered via a single-dose dry-powder inhaler (SDDPI) plus placebo to tiotropium delivered via the manufacturer's proprietary inhalation device (HandiHaler®) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.
11564653|NCT00900731|Active Comparator|Tiotropium 18 µg|Participants received tiotropium 18 μg delivered via the manufacturer's proprietary inhalation device (HandiHaler®) plus placebo to indacaterol delivered via a single-dose dry-powder inhaler (SDDPI) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.
11564654|NCT00900718|Experimental|Straumann Bone Ceramic|Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
11564655|NCT00900718|Active Comparator|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
11564656|NCT00900692|Experimental|Dynasplint Group|Along with the standard of care Botox and manual therapy, patients will use the Supination Dynasplint every day
11564657|NCT00900692|No Intervention|Standard of care|Patients in the standard of care group will have the standard Botox treatments and manual therapy with no additional interventions.
11564658|NCT00900666|Placebo Comparator|Saline injection|
11564659|NCT00900666|Experimental|Botulinum toxin injection|
11564660|NCT00900653|Experimental|Gynoflor|
11564661|NCT00900653|No Intervention|Control|
11564662|NCT00900640||ERCP group|All patients who have been scheduled for an ERCP due to medical necessity will be considered for this study.
11564663|NCT00900627|Experimental|1|AZD8931 plus Paclitaxel
11564664|NCT00900627|Placebo Comparator|2|Placebo plus Paclitaxel
11564665|NCT00900601|Experimental|Sacroilliac fusion|Pastient are treated with sacroiliac joint arthrodesis to the sacroiliac joint and symphysis
11564666|NCT00900588|Experimental|10 ug|10 microgram split-virion vaccine per dose
11564667|NCT00900588|Experimental|15 ug|15 microgram split-virion vaccine per dose
11564668|NCT00900588|Experimental|30 ug|30 microgram split-virion vaccine per dose
11564669|NCT00900588|Active Comparator|5 ug|5 microgram whole-virion vaccine per dose
11564670|NCT00900575|Experimental|Duke Arm|Patients referred for GYN procedures. Specifically, patients will be referred for Pap smear, colposcope or LEEP. The intervention for this arm is the use of the bench-top, miniature optical spectrometer or trans-vaginal colposcope
11564671|NCT00900562|Experimental|Arm 1|Zalypsis (PM00104)
11564672|NCT00900549|Experimental|CRT|
11564673|NCT00900549|Sham Comparator|No CRT|
11564674|NCT00900523||Known or suspected ovarian cancer|Women who have a diagnosis of ovarian cancer or who are suspected of having ovarian cancer
11564675|NCT00900510|Experimental|Drainage and placebo|Incision and drainage with placebo.
11564676|NCT00900510|Active Comparator|Drainage with TMP/SX|Drainage with Bactrim
11564677|NCT00900497|Experimental|White Blood Cells/Granulocytes|Fresh, non-irradiated granulocytes from ABO-Rh compatible, HLA-mismatched donors
11564678|NCT00900458|Active Comparator|1|formerly preeclamptic women with low plasma volume
11564679|NCT00900458|Active Comparator|2|formerly preeclamptic women with normal plasma volume
11564680|NCT00900458|Other|3|Healthy controls
11564681|NCT00900445||Basic science (pharmacokinetics)|Patients receive anticancer therapy as prescribed by their treating clinicians. Patients receive prednisone/prednisolone orally twice on either day 1 or day 8. Patients also receive daunorubicin hydrochloride IV over 30 minutes and vincristine IV once on the same day.
11564682|NCT00900406||Recipients of stem cells with graft versus host disease|
11564683|NCT00900406||Recipients of stem cells at risk of graft versus host disease|
11564684|NCT00900406||Donator of stem cells|
11564685|NCT00900328||Ancillary-Correlative (biomarkers in resected AC specimens)|Previously collected tissue samples from patients enrolled in CALGB 140202 are assessed for mutation analysis of c-Met, EGFR, Kras, p53, and c-CBL via standard PCR and sequencing; gene amplification of c-Met via real time quantitative PCR; LOH analysis of c-CBL; expression levels of met/HGF protein in serum via ELISA; and expression levels of c-Met, EGFR, p53, c-CBL, DUB3, ALK, and EMT via IHC.
11564686|NCT00900250||Ancillary-correlative (specimen collection and baking)|"Patients enrolled on HL therapeutic clinical trials undergo collection of tumor tissue samples at baseline and at relapse or disease progression. Serum and anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year after diagnosis, and at relapse or disease progression.
~Patients with relapsed or progressive disease who plan to enroll on HL relapse/retrieval clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral blood samples at relapse or disease progression.
~Patients enrolled more than 1 year after completion of treatment undergo collection of tumor specimens, serum, and anticoagulated peripheral blood samples at time of clinical evaluation."
11564687|NCT00900237|Active Comparator|Eslicarbazepine acetate|Eslicarbazepine acetate (ESL) 600 mg QD morning from Day 1-3 and 1200 mg ESL QD morning from Day 4-9
11564688|NCT00900237|Active Comparator|Oxcarbazepine|Oxcarbazepine 300 mg BID from Day 1-3 and oxcarbazepine 600mg BID from Day 4-9
11564744|NCT00899379|Experimental|Treatment Sequence 3|Rizatriptan-Rizatriptan-Placebo-Rizatriptan
11564689|NCT00900224||Group 1|Previously procured and archived bone marrow aspirate samples, blood and buccal cell samples, and bone marrow biopsy slides are analyzed for FLT3 ITD, MLL PTD, NPM1, KIT, KRAS, NRAS, CEBPA, WT1, JAK2, RUNX1, TET2, ASXL1, IDH1 and IDH2, CBL, and DNMT3A mutations, CBF fusion genes, levels of BAALC, ERG, EVI1, MN1, and APP microarray gene-expression, microRNA gene-expression signature, levels of methylation of genes silenced in AML, and genomic DNA by PCR amplification, RT-PCR, and denaturing high-performance liquid chromatography.
11564690|NCT00900198||1|Subjects being evaluated and/or treated for their malignancy at the NIH Clinical Center (adult and pediatric) and adult subjects at participating sites.
11564691|NCT00900159|Experimental|eszopiclone|Treatment with eszopiclone
11564692|NCT00900159|Placebo Comparator|matching placebo|Treatment with matching placebo
11564693|NCT00900146|Experimental|Canakinumab 5 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 5 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.
~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
11564694|NCT00900146|Experimental|Canakinumab 15 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 15 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.
~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
11564695|NCT00900146|Experimental|Canakinumab 50 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 50 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.
~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
11564696|NCT00900146|Experimental|Canakinumab 150 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 150 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.
~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
11564697|NCT00900146|Placebo Comparator|Placebo + Metformin|In 4 month dose finding period as well as during intermediate period, patients received one injection of canakinumab matching placebo monthly and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations).
11564698|NCT00900029||No HP802 Treatment|Treatment received in Study 802-247-09-015 was HP802
11564699|NCT00900029||No HP802 Vehicle Treatment|Treatment received in Study 802-247-09-015 was HP802 Vehicle
11564700|NCT00900003||pancreatic cancer patients|pancreatic cancer patients with excess tissue collected at the time of standard of care surgery
11564701|NCT00899990||Observational (biomarker sampling)|Patients undergo collection of tumor specimens, bone marrow, and peripheral blood at diagnosis. Associated demographic and clinical data are collected and archived. Patients who are not enrolled on a therapeutic clinical trial are followed annually.
11564702|NCT00899977|Placebo Comparator|Placebo|Subjects may receive a single, oral dose of placebo (capsule) in one of 4 crossover periods. Also, subjects may receive placebo orally, twice daily for 14 days in the last phase of the study.
11564703|NCT00899977|Experimental|1 mg TC-5214|Subjects may receive a single, oral capsule of 1 mg TC-5214 in one of 4 crossover periods.
11564704|NCT00899977|Experimental|2 mg TC-5214|Subjects may receive a single, oral capsule of 2 mg TC-5214 in one of 4 crossover periods.
11564705|NCT00899977|Experimental|4 mg TC-5214|Subjects may receive a single, oral capsule of 4 mg TC-5214 in one of 4 crossover periods. Also, subjects may receive 4 mg TC-5214 orally, twice daily for 14 days in the last phase of the study.
11564706|NCT00899977|Experimental|8 mg TC-5214|Subjects may receive a single, oral capsule of 8 mg TC-5214 in one of 4 crossover periods.
11564707|NCT00899964|Active Comparator|1|automated tailored feedback per E-mail
11564708|NCT00899964|Active Comparator|2|1 + active contact per E-mail possible
11564709|NCT00899964|Active Comparator|3|2 + active contact by trainer in case of exercise-related problems
11564710|NCT00899964|Active Comparator|4|3 + regular active contact by trainer
11564711|NCT00899951||Cohort 1|receiving fentaly citrate
11564712|NCT00899860||patients with renal cell cancer|
11564745|NCT00899379|Experimental|Treatment Sequence 4|Rizatriptan-Rizatriptan-Rizatriptan-Placebo
11564746|NCT00899379|Experimental|Treatment Sequence 5|Rizatriptan-Rizatriptan-Rizatriptan-Rizatriptan
11564747|NCT00899353|Experimental|Omega 3 supplement|Omega 3 supplement will be added to diet, 3 capsules per day for one month then 6 capsules per day for one month then 9 capsules per day as tolerated
11564748|NCT00899301||Patients with Breast Cancer|
11564749|NCT00899301||Patients without breast cancer|
11564828|NCT00898209||Patients at risk or already identified as having lung cancer|Blood and exhaled breath condensate will be collected.
11564713|NCT00899847|Experimental|Autologous-Allogeneic Peripheral Blood Stem Cell Transplant|Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.
11564714|NCT00899834||Tumor Samples|fresh-frozen and fixed tumor samples and correspondent normal tissue from patients affected with this tumor.(peripheral blood is applicable only to patients with focal brainstem gliomas and patients who undergo biopsy of a diffuse brainstem glioma at diagnosis)
11564715|NCT00899782||Ancillary-Correlative (lung cancer tissue bank)|Grossly viable tumor and grossly normal lung tissue are identified and removed from patient surgical specimens and cryopreserved until shipment to the CALGB Lung Cancer Tissue Bank for future use in research. Blood specimens are also collected prior to surgery and at 4-12 weeks post-surgery (before the start of adjuvant therapy) and shipped immediately to the Tissue Bank.
11564716|NCT00899717|Experimental|A|
11564717|NCT00899717|Placebo Comparator|B|
11564718|NCT00899704||Group 1|Patient tissue samples are screened using polymerase chain reaction (PCR) for human papilloma virus-specific primers. Samples are analyzed to identify a nodal-metastasis signature for oral squamous cell carcinoma. Samples also undergo microarray analysis to quantify expression levels for targeted genes. Initial data analysis is performed using Affymetrix® Microarray Suite 5.0 to quantify expression levels for targeted genes.
11564719|NCT00899678|Active Comparator|Maintenance High-Dose|Maintenance High-Dose group: 400 mg Certolizumab Pegol for subjects ≥ 40 kg or 200 mg Certolizumab Pegol for subjects 20 to < 40 kg
11564720|NCT00899678|Active Comparator|Maintenance Low-Dose|Maintenance Low-Dose group: 200 mg Certolizumab Pegol for subjects ≥ 40 kg or 100 mg Certolizumab Pegol for subjects 20 to < 40 kg
11564721|NCT00899652||All Patients|Completion of Telephone Study Entry Form, Additional On Study Form, and Specimen Transmittal Form.
11564722|NCT00899600|Placebo Comparator|Normal saline|
11564723|NCT00899600|Experimental|Ketamine|
11564724|NCT00899587|Experimental|Oxygen|
11564725|NCT00899587|Experimental|Enalapril|
11564726|NCT00899587|Placebo Comparator|Control|
11564727|NCT00899574|Experimental|Imiquimod|"Each treatment cycle consists of 8 weeks.
~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.
~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
11564728|NCT00899548||Metastatic breast cancer patients|DNA methylation analysis, microarray analysis, polymerase chain reaction, laboratory biomarker analysis
11564729|NCT00899535||Group 1|This research study is looking at the cancer genome using tumor samples from patients with stage I or stage II non-small cell lung cancer treated on clinical trial ACOSOG-Z0030. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
11564730|NCT00899483|Active Comparator|1|Administered with glucose potassium insulin solution to achieve euglycaemia 4.0-6.0 mmol/L
11564731|NCT00899483|No Intervention|2|Normal departmental practice using dextrose insulin infusion
11564732|NCT00899470|Experimental|S+ M, (fasted)> S/M (fed)> S/M (fasted)>S+M (fed)|Participants were randomized to receive oral co-administration of a 2.5 mg tablet of saxagliptin plus a 500 mg tablet of metformin immediate release (IR) under fasted conditions (S + M [fasted]) followed by a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions (S/M [fed]) followed by S/M under fasting conditions (S/M [fasted]) followed by S + M under fed conditions (S + M [fed])
11564733|NCT00899470|Experimental|S/M (fasted)> S+M (fasted)> S+M (fed)> S/M (fed)|Participants were randomized to receive S/M (fasted) followed by S + M (fasted) followed by S + M (fed) followed by S/M (fed)
11564734|NCT00899470|Experimental|S+M (fed)> S/M (fasted) >S/M (fed)> S+M (fasted)|Participants were randomized to receive S + M (fed) followed by S/M (fasted) followed by S/M (fed) followed by S+M (fasted)
11564735|NCT00899470|Experimental|S/M (fed)> S+M (fed)> S+M (fasted)> S/M (fasted)|Participants were randomized to receive S/M (fed) followed by S+M (fed) followed by S+M (fasted) followed by S/M (fasted)
11564736|NCT00899457||Healthy, non-smokers|
11564737|NCT00899431|Active Comparator|Group 1: Lenalidomide|Chemotherapy, Plus Lenalidomide - Lenalidomide starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months. Fludarabine 30 mg/m^2 intravenously daily on days -5, -4, -3. Rituximab 375 mg/m2 intravenously on day -13, and 1000 mg/m^2 on days -6, +1 and +8. Thymoglobulin 1.0 mg/kg intravenously over 4 hours (day -2 and -1). On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes. Bendamustine 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine). Allopurinol 300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
11564738|NCT00899431|Active Comparator|Group 2: No Lenalidomide|Chemotherapy Treatment, No Lenalidomide - Fludarabine 30 mg/m^2 intravenously daily on days -5, -4, -3. Rituximab 375 mg/m2 intravenously on day -13, and 1000 mg/m^2 on days -6, +1 and +8. Thymoglobulin 1.0 mg/kg intravenously over 4 hours (day -2 and -1). On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes. Bendamustine 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
11564739|NCT00899405||Patients with lung cancer|Collection of archival tumor specimen at the beginning of the study and collection of blood samples at the beginning of the study and then at regular intervals
11564740|NCT00899392|Experimental|Electronic Assisted Consent|Standard procedural consent performed by pediatric gastroenterologist plus assistance from computerized emmi module.
11564741|NCT00899392|No Intervention|Control Consent|Standard procedural consent as performed by pediatric gastroenterologists
11564742|NCT00899379|Experimental|Treatment Sequence 1|Placebo-Rizatriptan-Rizatriptan-Rizatriptan
11564750|NCT00899288|Experimental|tamoxifen and no bone fracture|Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have not had a bone fracture.
11564751|NCT00899288|Experimental|Letrozole and no bone fracture|Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have not had a bone fracture.
11564752|NCT00899288|Experimental|Tamoxifen and bone fracture|Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have had a bone fracture.
11564753|NCT00899288|Experimental|Letrozole and bone fracture|Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have had a bone fracture.
11564754|NCT00899275||Ancillary-correlative|After the initial submission of blood samples, patients may undergo open or closed biopsy in order to obtain fresh and frozen tissue samples as well as paraffin embedded material. Patients who are enrolled at the time of initial diagnosis but then have a definitive surgery or develop recurrent disease may submit additional samples (paraffin block, frozen and fresh tumor tissue, or slides together with blood samples). Autopsy tumor samples may also be submitted.
11564755|NCT00899223||Group 1|Previously untreated patients on a CALGB treatment protocol for leukemia (acute or chronic) or myelodysplasia are eligible. Patients must be registered to CALGB 9665 prior to receiving any therapy for their disease.
11564756|NCT00899145||Ancillary-Correlative (biomarker sampling and analysis)|Previously collected DNA samples and associated clinical information obtained from BRCA mutation-positive participants enrolled on GOG-0199 are studied. DNA samples are analyzed by mutation testing for variants (i.e., SNPs) in candidate genes of interest. Once genetic testing for a given set of variants has been completed, the coded laboratory data file is merged with selected demographic, clinical, and epidemiological data obtained from the GOG-0199 baseline questionnaire and submitted to the CIMBA Central Database to analyze and publish the data. The epidemiological and SNP data contributed to the central database are then distributed to the investigators responsible for analysis of a particular SNP or set of SNPs from a candidate gene or genetic pathway.
11564757|NCT00899093||Ancillary-Correlative (serum collection for YKL-40 and CA125)|Patients undergo collection of serum samples for analysis of YKL-40 via ELISA and CA125 via chemiluminometric sandwich immunoassay at the following time-points: at baseline; prior to beginning each course of chemotherapy (courses 1-6); at completion of chemotherapy; every 3 months during years 1-2 post-chemotherapy; every 6 months during years 3-5 post-chemotherapy; every year during years 6-10 post-chemotherapy; and at time of disease recurrence or progression.
11564758|NCT00899054|Experimental|P276-00 plus Radiation|"P276-00:
~Level 1:100 mg/m2/day x 5 q 3 weeks, level 2:140 mg/m2/day x 5 q 3 weeks, level 3: 185 mg/m2/day x 5 q 3 weeks.
~External beam radiotherapy (EBRT):
~2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 2 cycles (6 weeks)followed by upto 10 additional Gy if required"
11564759|NCT00899041|Active Comparator|Standard knee prosthesis|'standard' knee prosthesis (Sigma FB, J&J, UK).
11564760|NCT00899041|Active Comparator|High flexion knee prosthesis|'high flexion' knee prosthesis (Sigma RP-F, J&J, UK).
11564761|NCT00898989||Inclusion Body Myositis|
11564762|NCT00898989||Control|
11564763|NCT00898976||Group I|Immunohistochemistry is performed on tumor samples to analyze the following molecular markers: estrogen receptor, progesterone receptor, c-erbB2, p53, Ki-67, Bcl-2, Bax, cyclin D-1, and insulin-like growth factor-1R. PROJECTED ACCRUAL: A total of 300 tissue samples (150 from Native American women and 150 from Caucasian women) will be accrued for this study.
11564764|NCT00898950|Experimental|Aspirin low dose|Effects of using aspirin 75 mgs/day for 2 weeks.
11564765|NCT00898950|Experimental|Aspirin medium dose|Effects of using aspirin 300 mgs/day
11564766|NCT00898950|Experimental|aspirin high dose|aspirin 900mgs QID orally for 2 weeks
11564767|NCT00898950|Placebo Comparator|placebo|
11564768|NCT00898924||Group 1|Tissue samples were collected from patients on Day 1, Cycle 1. Whole blood and serum samples were collected on Day 1 (Cycle 1), Day 1 (Cycle 3), post-radiotherapy ZD1839 and at progression.
11564769|NCT00898898||Arm I|Tissue samples from protocol NCCTG-N9831 are obtained for immunohistochemistry and fluorescence in situ hybridization analysis of MYC, IGF- 1R, PTEN, and TOP2A genes. Exons 9 and 20 of PIK3CA gene are amplified via polymerase chain reaction; mutations in exons 9 and 20 of PIK3CA gene are identified.
11564770|NCT00898885||Bone Marrow Transplantation|
11564771|NCT00898859||1|Healthy, non-smoking
11564772|NCT00898859||2|healthy, ex-smoking
11564773|NCT00898859||3|healthy, current-smokers
11564774|NCT00898859||4|COPD, ex-smokers
11564775|NCT00898859||5|COPD, smokers
11564776|NCT00898846||UFT adjuvant therapy group|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year. During protocol treatment, clinical findings and laboratory values are evaluated every month. After the completion of protocol treatment, patients are followed-up, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
11564777|NCT00898846||Observation group|Patients are followed-up without adjuvant treatment, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
11564778|NCT00898833||Group 1|Previously collected plasma and urine samples are analyzed for VEGF via ELISA, plasma samples are analyzed for CgA and IL-6 via ELISA, hK2 via immunometric assay, plasma samples are analyzed for PSA via Tandem-R PSA kit, plasma samples are analyzed for TNF-alpha, sTNF-R1, and IL-8 via quantikine IL-8 immunoassay.
11564779|NCT00898807|Experimental|Citalopram and psychosocial intervention|Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention
11564780|NCT00898807|Placebo Comparator|Placebo and psychosocial intervention|Matching placebo, oral, and psychosocial intervention
11564781|NCT00898781||Metastatic Breast Cancer|
11564782|NCT00898781||Metastatic Ovarian Cancer|
11564783|NCT00898781||Metastatic Pancreatic Cancer|
11564784|NCT00898781||Metastatic Colon Cancer|
11564785|NCT00898781||Stage 3 Ovarian Cancer|
11564786|NCT00898781||Locally Advanced Pancreatic Cancer|
11564787|NCT00898768|Other|capsule endoscopy|capsule endoscopie at baseline and after 2 years
11564826|NCT00898222|Experimental|aspirin|Low dose daily aspirin in healthy volunteers for two weeks
11564827|NCT00898209||Health Volunteers|Blood and exhaled breath condensate will be collected.
11564869|NCT00897260|Experimental|1|
11564788|NCT00898755||Ancillary-Correlative (tissue sample collection)|"Leftover tissue from diagnostic procedures and/or surgery is cryopreserved and banked. Blood and/or bone marrow are also collected and banked. Cell lines are established and characterized via reverse-transcriptase polymerase chain reaction and/or flow cytometry for biomarkers and by DNA fingerprinting. Markers to be identified may include the following:
~NEUROBLASTOMA: tyrosine hydroxylase, protein gene product (PGP) 9.5, GD2, HLA class I, and HSAN 1.2 antigens EWING FAMILY OF TUMORS: EWS-FLI1, EWS-ERG, and PGP 9.5 RETINOBLASTOMA: interphotoreceptor retinoid-binding protein ACUTE LYMPHOBLASTIC LEUKEMIA: immunophenotype ALVEOLOR RHADOMYOSARCOMA: PAX3-FKHR, PAX7-FKHR, and MyoD1 ALL CELL TYPES: telomerase expression including hTR and hTERTMutations of TP53 gene are detected by flow cytometry and/or immunocytochemistry"
11564789|NCT00898742||head and neck cancer patients|
11564790|NCT00898716|Experimental|BMS-754807|
11564791|NCT00898677|Experimental|1|rizatriptan 5 mg
11564792|NCT00898677|Experimental|2|rizatriptan 10 mg
11564793|NCT00898677|Active Comparator|3|sumatriptan 100 mg
11564794|NCT00898677|Placebo Comparator|4|placebo
11564795|NCT00898638||Healthy Volunteers|Non-tumor volunteers will be asked to participate at the time that they are attending a head and neck cancer screening clinic or at the time they are accompanying a patient to their appointment at the head and neck clinic. Intake sheets and biological specimens contributed by volunteers will be coded at the time of collection so that no identifiers are obtained. These specimens will not be linked to identifiers.
11564796|NCT00898638||Head and Neck Tumor patients|Eligible patients will be identified at the Vanderbilt Head & Neck Clinic by clinical and research staff. An appropriately trained staff member will discuss the protocol with the patient (including, risks, benefits, alternatives, etc.).
11564797|NCT00898599|Placebo Comparator|Maltodextrin|
11564798|NCT00898599|Experimental|Prebiotic|Inulin type fructooligosaccharides
11564799|NCT00898560|Other|Microginon®|A single oral dose of a combined oral contraceptive containing 30ug ethinyloestradiol and 150ug levonorgestrel (Microginon ®).
11564800|NCT00898560|Experimental|ESL and Microginon®|15-day treatment with ESL 800 mg once daily, with co administration of a single oral dose of Microginin® on Day 14 of the relevant dosing period, to assess impact of ESL on pharmacokinetics of the combined oral contraceptive.
11564801|NCT00898547||Group 1|Serum samples previously obtained from patients on protocol CALGB-30107 are tested for levels of thrombospondin I serum, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked immunosorbent assays (ELISA).
11564802|NCT00898534|Experimental|Immediate Feedback|Subjects receive point-of-care hemoglobin A1c testing prior to their diabetes clinic visit, with results made available to the provider during the visit.
11564803|NCT00898534|No Intervention|Conventional Feedback|Subjects receive laboratory hemoglobin A1c testing at the clinic visit, with results made available to the provider several days later.
11564804|NCT00898521|Experimental|DGD|
11564805|NCT00898508||Normal benign breast disease or ductal carcinoma in situ|
11564806|NCT00898508||Invasive breast cancer|
11564807|NCT00898482||Healthy individuals|
11564808|NCT00898482||At risk individuals|
11564809|NCT00898482||Cancer patients|
11564810|NCT00898456||Group 1|Leukemia blast cells obtained from bone marrow aspirate or peripheral blood at diagnosis are used to study polymorphisms and haplotypes of ATP-binding cassette (ABC) B1, ABCC1, ABCG2, and other candidate genes. Multidrug resistance (MDR) protein expression and function are also analyzed using leukemia blast cells from patients enrolled on CALGB-9760.
11564811|NCT00898443|Other|Spinal Anesthetic Group|This group will receive spinal anesthetic for the surgical procedure and will serve as the control group for this study.
11564812|NCT00898443|Experimental|Epidural Anesthetic Group|This is the experimental group for this study.
11564813|NCT00898430||Head and neck squamous cell carcinoma patients (HNSCC)|
11564814|NCT00898404||Arm I|Tumor diagnostic specimens from patients who subsequently failed therapy within 4 years of diagnosis or who did not fail therapy within 4 years of diagnosis (control patients) are obtained from the Children's Oncology Group cellbank. Specimens are studied for molecular determinants of human reduced folate carrier (hRFC) gene expression and gene sequence alterations using reverse transcriptase-polymerase chain reaction (RT-PCR), thymidylate synthase inhibition assay, Rnase protection assay, or 5'RACE. Multidrug resistance proteins are also studied by RT-PCR.
11564815|NCT00898391||Ancillary-Correlative|Circulating DNA is extracted from serum. PCR amplification of MYCN is performed and analyzed by agarose gel electrophoresis. Real-time quantitative PCR is also performed.
11564816|NCT00898378||Colorectal Cancer Patients|Patients with stages I/II, III and IV colorectal cancer
11564817|NCT00898378||Colorectal Polyps Patients|Patients with adenomatous polyp(s) after colonoscopy.
11564818|NCT00898378||Healthy Controls|No abnormalities after colonoscopy.
11564819|NCT00898365||Ancillary-correlative (renal tumor classification, biology)|Tumor tissue, blood, and urine samples are collected for research studies, including immunohistochemistry. CT scans and MRIs are also performed. Loss of heterozygosity analyses (chromosome 1p and 16q) are performed by extraction of DNA. DNA polymorphisms are assayed by polymerase chain reaction using standard methodology. Leftover specimens are archived for future studies. (LOH and INI1 testing discontinued as of April 2014)
11564820|NCT00898326||Biopsy 36 month after breacchytherapy|Biopsy 36 month after breacchytherapy on protocol JUSMH-BRI-GU05-01.
11564821|NCT00898313||Sample Collection|
11564822|NCT00898300||Patients with confirmed or suspected head and neck cancer|
11564823|NCT00898287|Experimental|P276-00 plus Gemcitabine|"Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/m2/day x 5 q 3 weeks Level 2 - 140 mg/m2/day x 5 q 3 weeks Level 3 - 185 mg/m2/day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.
~Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity."
11564824|NCT00898274||High risk for developing prostate cancer|Male subjects age 45-65 at high risk for developing prostate cancer.
11564825|NCT00898274||Healthy participants|Aged matched healthy participants
11564829|NCT00898170|Experimental|myoma, with or without hypertension|those with myoma with or without hypertension in holter monitoring
11564830|NCT00898092||Group 1|Peripheral blood and bone marrow samples are analyzed to assess gene expression using polymerase chain reaction (PCR) or reverse transcriptase-PCR assays and microarray assays. Genes to be studied include BAALC, ERB, EVI1, MLL, FLT3, NPM1, and CEBPA.
11564831|NCT00898079||Observational|Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.
11564832|NCT00898053||Correlative studies|Previously archived tumor samples are analyzed for p53 mutations and p16 deletion by immunohistochemistry, FISH, PCR, and DNA sequencing.
11564833|NCT00897975|Experimental|red yeast rice (RYR) plus phytosterol|arm will take red yeast rice and phytosterol supplement
11564834|NCT00897975|Placebo Comparator|red yeast rice plus placebo|
11564835|NCT00897975|Active Comparator|TLC plus red yeast rice plus placebo|subjects attend 12 week therapeutic lifestyle program and take above supplement
11564836|NCT00897975|Experimental|TLC plus RYR plus phytosterol|Therapeutic lifestyle program for 12 weeks plus red yeast rice plus phytosterol
11564837|NCT00897962||Metastatic Breast Cancer|Patients with metastatic breast cancer receiving treatment with chemotherapy, endocrine therapy or targeted therapy
11564838|NCT00897962||Non-cancer medical illness|Patients with non-cancer medical condition
11564839|NCT00897962||Healthy Controls|Healthy patients being seen for an annual exam
11564840|NCT00897949|Experimental|Rizatriptan 10 mg|
11564841|NCT00897949|Experimental|Rizatriptan 5 mg|
11564842|NCT00897949|Placebo Comparator|Placebo|
11564843|NCT00897897|Other|Treated leiomyomas|Pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure receive a treatment with the Philips MRI-guided HIFU system. Patients must have completed child bearing prior to enrolling in this study.
11564844|NCT00897884|Experimental|Metformin|Patients will take metformin three times a day for two to three weeks prior surgery.
11564845|NCT00897858||Pediatric CNS tumor patients|Newly diagnosed pediatric patients with CNS tumor and no prior irradiation or chemotherapy
11564846|NCT00897832||pancreatic cancer|Patients with pancreatic cancer
11564847|NCT00897806||Genetic Markers|
11564848|NCT00897793||patients with epithelial cancers|Patients with head and neck cancer, and lung, breast, colorectal, and prostate cancers who are to undergo radiation therapy
11564849|NCT00897715|Active Comparator|Interleukin-1 receptor antagonist|active drug
11564850|NCT00897715|Placebo Comparator|Placebo|matching placebo
11564851|NCT00897676|Other|Vehicle first, then Exendin-(9-39)|An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). At time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. The following day, at time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, GLP-1, and glucagon will be measured every 30 minutes.
11564852|NCT00897676|Other|Exendin-(9-39) first then Vehicle.|"An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). . At time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. The following day, at time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, GLP-1, and glucagon will be measured every 30 minutes.
~."
11564853|NCT00897663||Single group|Tissue samples from patients enrolled on clinical trials NCCTG-N0177 or NCCTG-N0074 are analyzed by microarray analysis and immunohistochemistry for biological markers predicting progression-free survival and overall survival. Biological markers include epidermal growth factor expression, vIII mutant p53 gene, P-AKT, p7056k, S6, 4EBP1, STAT-3, PLC-g, Erk, ErbB2, ErbB3, ErbB4, platelet-derived growth factor receptor, IGF1R, interleukin-6, FADD, and MGMT.
11564854|NCT00897650||Lung cancer|Patients with a diagnosis of invasive lung cancer.
11564855|NCT00897637||Observational|Three hundred tumor specimens are analyzed for genetic expression profiles using Affymetrix assays. Specific genes are identified as classifiers and analyzed using tissue arrays. An additional 300 specimens are examined for gene expression and categorized according to the classifiers.
11564856|NCT00897468||breast cancer patients|
11564857|NCT00897442||Ancillary-Correlative (biomarker sampling and analysis)|Snap frozen tumor tissue, OCT molds of tumor tissue, formalin-preserved tumor tissue, buffy coat-prepared tumor tissue, and blood samples are collected and stored in the repository. Patient information is kept confidential, and patients are not informed of any research/test results from use of their tissues.
11564858|NCT00897429||Ancillary-Correlative (laboratory biomarker analysis)|Previously collected tissue samples are analyzed for K-ras mutations; COX-2, phospho-AKT, and VEGF overexpression; microvessel density; association of genomic instability with microsatellite instability and p53 mutations; and methylation status of MLH1, MGMT, and WRN and to identify prognostic biomarkers by LINE-1 hypomethylation, PIK3CA mutation, BRAF mutation, FASN expression, and VDR expression via immunohistochemistry, PCR, RT-PCR, and microarray.
11564859|NCT00897390|Other|Arm A|Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fasted conditions
11564860|NCT00897390|Other|Arm B|Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fasted conditions
11564861|NCT00897390|Other|Arm C|Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fed conditions with a standard meal
11564862|NCT00897390|Other|Arm D|Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fed conditions with a standard meal
11564863|NCT00897377|Experimental|Total resection with early radiation|Total resected LGGs treated with early radiation
11564864|NCT00897377|No Intervention|Total resection without radiation|Total resected LGGs treated without radiation
11564865|NCT00897377|Experimental|Residual LGGs with radiation|Residual LGGs treated with early radiation
11564866|NCT00897377|Experimental|Residual LGGs with chemo|Residual LGGS treated with temozolomide
11564867|NCT00897325||Ancillary-Correlative (Collecting and banking ALL specimens)|Patients undergo collection of bone marrow and peripheral blood at diagnosis of relapse and/or at the end of the first month of treatment.
11564868|NCT00897286||Tumor/Tissue Sample|Tumor material collected prospectively from a clinically well characterized patient cohort
11564871|NCT00897234||Non-Small Cell Lung Cancer|Patients with non-small cell lung cancer.
11564872|NCT00897221|Experimental|Dose 1|Deferiprone oral solution 20 mg/kg/day
11564873|NCT00897221|Experimental|Dose 2|Deferiprone oral solution 40 mg/kg/day
11564874|NCT00897182||Group 1|This is a CALGB Leukemia Tissue Bank project makes use of tissue from patients who have previously provided their consent. Diagnostic samples from patients enrolled on CALGB AML treatment studies (eg, CALGB 9621, 9710, and 19808) and who have been registered on the companion Leukemia Tissue Bank Protocol CALGB 9665 were used.
11564875|NCT00897169|Experimental|A|
11564876|NCT00897169|Experimental|B|
11564877|NCT00897130|Experimental|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted.
11564878|NCT00897117||Resectable non-small cell lung cancer|Patients with clinical stage I or II invasive lung cancer that can be completely removed by surgery and who have not undergone chemotherapy or radiotherapy before surgery
11564879|NCT00897104|Experimental|1|Rizatriptan
11564880|NCT00897104|Experimental|2|Sumatriptan
11564881|NCT00897104|Placebo Comparator|3|Placebo
11564882|NCT00897026||Group 1|Tissue samples are collected from patients. Tissue samples are analyzed by immunohistochemistry (Ki67, CK5/6, EGFR, ER) and fluorescence in situ hybridization (FISH).
11564883|NCT00896987|Experimental|1|lamotrigine
11564884|NCT00896987|Active Comparator|2|carbamazepine
11564885|NCT00896974|Experimental|Arm I|Participants receive a single dose of oral 9cUAB30 on day 1.
11564886|NCT00896961|Experimental|Observational (EF5)|Approximately 24-48 hours prior to surgical resection or biopsy, patients receive EF5 IV over no more than 2½ hours. Tissue samples are analyzed by immunohistochemistry for EF5 binding. Blood samples are analyzed for genetic markers and cytokines associated with hypoxia and EF5 concentration.
11564887|NCT00896883|Experimental|Middle Turbinate Implant|Subjects to receive Middle Turbinate Implant
11564888|NCT00896844|Experimental|emotional disclosure|writing about emotional events from the past
11564889|NCT00896844|Placebo Comparator|placebo writing|writing about how they spent their time the previous day
11564890|NCT00896831|Active Comparator|L-ornithine-L-aspartate|5 g L-ornithine-L-aspartate (1 sachet) three times per day for 60 days
11564891|NCT00896831|Placebo Comparator|placebo|5 g (1 sachet) of placebo comparator three times per day for 60 days
11564892|NCT00896779|Other|ranibizumab Group 1|Group 1: 3 monthly injections of 0.5mg then prn
11564893|NCT00896779|Other|ranibizumab Group 2|Group 2: 6 monthly injections of 0.5 mg then prn
11564894|NCT00896753||patients with metastatic colon cancer|
11564895|NCT00896714|Experimental|Closed loop anesthesia|
11564896|NCT00896701||Patient samples from C9621, C9720 and C19808|This is a CALGB Leukemia Tissue Bank project that makes use of tissue from patients who have previously provided their consent. Diagnostic and follow-up samples from acute myeloid leukemia (AML) patients treated on CALGB protocols 9621, 9720 and 19808, and who have been registered on the mandatory companion Leukemia Tissue Bank Protocol CALGB 9665 will be used.
11564897|NCT00896688||Healthy Volunteers|It will involve 5 volunteers and they will undergo C arm fluoroscopic guided cervical medial branch blocks (C2-C7) on unilateral position and then followed by the 3D ultrasound machine for visualization of needle position.
11564898|NCT00896688||Candidates for upper and lower cervial medical branch blocks|This will involve 25 patients and they will follow the same procedures as the healthy volunteers.
11564899|NCT00896675||patients treated with EGFR inhibitors and/or VEGF inhibitor|
11564900|NCT00896675||NOT treated with EGFR inhibitors and/or VEGF inhibitor|
11564901|NCT00896649|Experimental|positron emission mammography|questionnaire administration digital mammography positron emission mammography
11564902|NCT00896636||Luteal|Pre-menopausal women who undergo rFNA procedure during the luteal phase of their menstrual cycle.
11564903|NCT00896636||Follicular|Pre-menopausal women who undergo rFNA procedure during the follicular phase of their menstrual cycle.
11564904|NCT00896636||Menopause|Women who have entered menopause.
11564905|NCT00896610||Diabetes|Individuals who have been diagnosed with or are at risk for developing diabetes
11564906|NCT00896597|Experimental|NRL972|A single dose of 2 mg NRL972 will be administered on four occasions over a period of up to 6 weeks.
11564907|NCT00896571|Experimental|Arm 1|
11564908|NCT00896558|Experimental|Cohort A|A single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
11564909|NCT00896558|Experimental|Cohort B|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
11564910|NCT00896558|Experimental|Cohort C|Subjects in the probe cohort will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12. All subjects will receive a single dose of midazolam alone on Day -1, and co-administered with the morning dose of GSK1322322/placebo on Day 1 and Day 12.
11564911|NCT00896558|Experimental|Cohort D|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
11564912|NCT00896558|Experimental|Cohort E|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
11564913|NCT00896545|Experimental|5-keys feeding program|Counseling in small groups aimed at enhancing children's self control over eating
11564914|NCT00896545|Active Comparator|Healthy lifestyle counseling|Counseling in small groups aimed at achieving healthy eating patterns aimed at both the family and young children
11564915|NCT00896532|Placebo Comparator|Placebo|"Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously (SC) for up to 24 months.
~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
11564944|NCT00896298|Placebo Comparator|2 Sugar pill|Placebo for 4 months, then active comparator for 8 months.
11564945|NCT00896285|Active Comparator|1|
11564946|NCT00896285|Active Comparator|2|
11564947|NCT00896285|Active Comparator|3|
11564948|NCT00896285|Active Comparator|4|
11564916|NCT00896532|Active Comparator|Alendronate|"Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).
~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. At month 36 participants ended study participation."
11564917|NCT00896532|Active Comparator|Teriparatide|Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
11564918|NCT00896532|Experimental|Romosozumab 70 mg QM|"Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.
~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
11564919|NCT00896532|Experimental|Romosozumab 140 mg Q3M|"Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.
~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
11564920|NCT00896532|Experimental|Romosozumab 140 mg QM|"Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.
~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
11564921|NCT00896532|Experimental|Romosozumab 210 mg Q3M|"Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.
~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
11564922|NCT00896532|Experimental|Romosozumab 210 mg QM|"Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.
~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
11564923|NCT00896493|Experimental|Total lymphoid irradiation & anti-thymocyte immunoglobulin|TLI is administered from a 6 MeV linear accelerator in 80c- 120c Gy fractions. Anti-thymocyte-Globulin (ATG) is administered intravenously for a total dose of 7.5 mg/kg.
11564924|NCT00896480|Experimental|GSK2132231A Group|Subjects, male or female, 18 years of age or older, received up to 24 doses of GSK2132231A intramuscularly in 4 cycles. In Cycle 1 (ending Week 13) 6 doses were administered at 2-week intervals; in Cycle 2 (ending Week 32) 6 doses at 3-week intervals; in Cycle 3 (ending Week 54) 4 doses at 6-week intervals and in Cycle 4 4 doses at 12-week intervals, starting 12 weeks after end of Cycle 3, followed by, after an interruption of treatment of 6 months, 4 doses at 24-week intervals.
11564925|NCT00896454|Experimental|denosumab|Eligible subjects will receive denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
11564926|NCT00896441|Experimental|Depressed patients|Depressed patients assigned in an open-label study of citalopram
11564927|NCT00896441|No Intervention|Controls|Healthy controls used as a comparison (no intervention) group for change in resting-state fMRI over time
11564928|NCT00896428|Experimental|1|16 patients with a diagnosis of severe asthma under gallopamil treatment
11564929|NCT00896428|Placebo Comparator|2|16 patients with a diagnosis of severe asthma under placebo treatment
11564930|NCT00896402|Active Comparator|Chlorhexidine|skin antisepsis with chlorhexidine
11564931|NCT00896402|Active Comparator|Povidone-iodine|skin antisepsis with povidone-iodine
11564932|NCT00896389|Other|Salt-loading and thiazide diuretic (HCTZ)|Salt loading:2 L of 0.9% NaCl. HCTZ:12.5/ 25 mg of HCTZ for 1 week
11564933|NCT00896376|Experimental|trastuzumab|
11564934|NCT00896363|Active Comparator|Active|Parallel Group - High Dose Arm, Low Dose Arm
11564935|NCT00896363|Placebo Comparator|Placebo|Parallel Group
11564936|NCT00896350|Experimental|BOLD MRI|Determine the amount of oxygen supply to tumors.
11564937|NCT00896337|Experimental|ORION|All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with iliac artery stenting with the Epic™ Nitinol Stent System.
11564938|NCT00896324|Active Comparator|Cognitive Rehabilitation (Breast Cancer(BC) with chemotherapy)|Cognitive rehabilitation is a very low-risk method of treatment for cognitive deficits that involves restoring impaired function and/or training the individual to compensate for the area of deficit. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
11564939|NCT00896324|Active Comparator|Active Neurofeedback (BC pre-chemotherapy)|"In active Neurofeedback session subjects will be trained to increase brain activation in regions associated with executive function (EF) function deficits (as determined by neuroimaging measures) by viewing their own brain activation in real-time. The dose will be 2-3 sessions, each lasting approximately 30 minutes."
11564940|NCT00896324|Sham Comparator|Neurofeedback placebo (Sham) (BC pre-chemotherapy)|Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
11564941|NCT00896311|Active Comparator|1|Treatment solution consisted of 100 micrograms/mL of nitroglycerin. After an initial 1ml dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL
11564942|NCT00896311|Placebo Comparator|2|Placebo solution was saline. After an initial 1ml dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL
11564943|NCT00896298|Active Comparator|1 Leptin|Active Comparator for 4 months, then for 8 months.
11564949|NCT00896259||THA control|those with THA not participating in exercise and education program
11564950|NCT00896259||THA exercise|those with THA and participating in exercise and education program
11564951|NCT00896259||healthy control|Healthy control, people with no lower limb gait abnormalities
11564952|NCT00896246|Active Comparator|Klean-Prep®|1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Klean-Prep® (4 L) containing 99mTc-DTPA administered as a divided dose.
11564953|NCT00896246|Experimental|Moviprep®|1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Moviprep® (2 L) containing radiolabelled 99mTc-DTPA administered as a divided dose.
11564954|NCT00896233|Experimental|MRE|
11564955|NCT00896220||ICU Survivors and Their Family Caregiver|ICU Survivors who required one week or more of mechanical ventilation during their critical illness and their primary family caregiver
11564956|NCT00896207|Experimental|Arm I|Participants complete an overnight fast of ≥ 10 hours, eat a high-fat (approximately 50% of total caloric content of the meal) and high-calorie (approximately 800-1,000 calories) meal, and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.
11564957|NCT00896207|Experimental|Arm II|Participants complete an overnight fast of ≥ 10 hours and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.
11564958|NCT00896207|Experimental|Arm III|Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol® self-emulsifying solid dispersion capsule formulation.
11564959|NCT00896207|Experimental|Arm IV|Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol®/vitamin E TGPS self-emulsifying solid dispersion capsule formulation.
11564960|NCT00896207|Experimental|Arm V|Participants receive a single dose of oral Akt inhibitor SR13668 in a vitamin E TGPS self-emulsifying solid dispersion capsule formulation.
11564961|NCT00896207|Experimental|Arm VI|Participants receive a single dose of oral Akt inhibitor SR13668 in a Myrj 53 self-emulsifying solid dispersion capsule formulation.
11564962|NCT00896194|Active Comparator|1: Standard Behavioral Treatment (SBT)|This group receives standard behavioral treatment for weight loss as described below.
11564963|NCT00896194|Experimental|2: Modified SBT + Self-Efficacy|This group receives modified SBT with an additional self-efficacy component as described below.
11564964|NCT00896181|Experimental|Arm I|"INDUCTION THERAPY: Patients receive docetaxel IV over 60 minutes on day 1; cisplatin IV over 1-3 hours (or carboplatin IV over 30 minutes) on day 1; and fluorouracil IV continuously over 24 hours on days 1-5. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
~CONCURRENT CHEMORADIOTHERAPY: Beginning within 3-6 weeks after initiating the last course of induction chemotherapy, patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily for 6.5-7 weeks. Patients also receive cisplatin IV over 1 hour (or carboplatin IV over 30 minutes) once weekly in weeks 1-6 in the absence of disease progression or unacceptable toxicity."
11564965|NCT00896168|Experimental|Infliximab + Methotrexate (Moderate RA)|Participants with moderate RA (score greater than 3.2, but less than 5.1 on the disease activity score [DAS] 28) received infliximab 3 milligram per kilogram (mg/kg) intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) at Week 0, 2, 6, 14 and 22 along with oral MTX IN a stable dose of 7.5 to 20 mg per week (equal to the dose used before participation in the study) for 22 weeks.
11564966|NCT00896168|Experimental|Infliximab + Methotrexate (Severe RA)|Participants with severe RA (score greater than 5.1 on the DAS 28) received infliximab 3 mg/kg intravenous infusion at Week 0, 2, 6, 14 and 22 along with oral MTX in a stable dose of 7.5 to 20 mg per week (mg/week) equal to the dose used before participation in the study) for 22 weeks.
11564967|NCT00896155|Experimental|Concurrent Tamoxifen and Radiotherapy|ARM 1 will receive Tamoxifen given concurrently with radiotherapy. Tamoxifen will continue for a period of 5 years.
11564968|NCT00896155|Active Comparator|Sequential radiotherapy and tamoxifen|ARM-2 shall receive radiotherapy followed by tamoxifen sequentially. Again tamoxifen will continue for a period of 5 years.
11564969|NCT00896129||Study population|
11564970|NCT00896077|Active Comparator|Subcutaneous|Subcutaneous administration of LSF
11564971|NCT00896077|Active Comparator|IV|IV administration arm
11564972|NCT00896064|Experimental|Formulation 1|
11564973|NCT00896064|Experimental|Formulation 2|
11564974|NCT00896051|Experimental|ATV/rtv 300/100 mg (Treatment A)|Treatment-experienced human immunodeficiency virus - type 1 (HIV-1) infected participants will take by mouth atazanavir (ATV)/low-dose ritonavir (rtv) 300/100 mg once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 2 weeks pre-treatment followed by ATV/rtv 300/100 mg once daily + etravirine (ETR) 200 mg twice daily + 1 NRTI for 48 weeks. If particpating in an optional substudy to assess the effect of adding tenofovir disoproxil fumarate (TDF) for 7 days on ATV and ETR pharmacokinetics, participants will receive TDF 300 mg once daily for 7 days in addition to their antiretroviral regimen (ETR+ATV/rtv+NRTI).
11564975|NCT00896051|Experimental|ATV/rtv 400/100 mg (Treatment B)|Treatment-experienced human immunodeficiency virus - type 1 (HIV-1) infected participants will take by mouth atazanavir (ATV)/low-dose ritonavir (rtv) 300/100 mg once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 2 weeks pretreatment followed by ATV/rtv 400/100 mg once daily + etravirine (ETR) 200 mg twice daily + 1 NRTI for 48 weeks. If particpating in an optional substudy to assess the effect of adding tenofovir disoproxil fumarate (TDF) for 7 days on ATV and ETR pharmacokinetics, participants will take TDF 300 mg once daily for 7 days in addition to their antiretroviral regimen (ETR+ATV/rtv+NRTI).
11564976|NCT00896038|Experimental|Aprepitant|Following a 1-week placebo lead-in period subjects were given 125 mg of Aprepitant orally daily for 21 days
11564977|NCT00896038|Placebo Comparator|Placebo|Subjects received oral placebo during the 1-week placebo lead-in and then daily for 21 days
11564978|NCT00896025|Active Comparator|N-acetycylcysteine|Each eligible Acute Liver Failure patient will be given N-acetylcysteine (NAC), beginning at a dose of 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour, followed by 50 mg/kg in 500 ml 5% dextrose over four hours, and 125 mg/kg in 1000 ml 5% dextrose over 19 hours, then 150 mg/kg in 1000 ml 5% dextrose per 24 hours for an additional 48 hours. The patient will be on continuous N-acetylcysteine infusion for a total of 72 hours.
11565294|NCT00893841|Experimental|3|Quetiapine XR 300mg + Pramipexole 0.50mg
11564979|NCT00896025|No Intervention|Standard of care|Each eligible Acute Liver Failure patient for whom the investigator chooses not to utilize N-acetylcysteine may serve as a control and receives standard of care.
11564980|NCT00896012|Experimental|1. Low-dose tacrolimus arm|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months). All patients will undergo a second protocol biopsy at 12 months.
11564981|NCT00896012|Experimental|2. Rapamune conversion arm:|Patients in this group will undergo a gradual conversion from tacrolimus to Rapamune therapy. Tacrolimus will be withdrawn progressively over a period of 7-10 days. Dosage adjustments will be made with the aim of reducing the blood levels of tacrolimus by 25% every other day until tacrolimus is discontinued. Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
11564982|NCT00895999|Experimental|1|Female patients (n=30) who meet criteria for major depression and chronic pelvic pain will be randomly assigned to 8 individual sessions of IPT adapted for depression and pain.
11564983|NCT00895999|Other|2|Female patients (n=30) who meet criteria for major depression and chronic pelvic pain will be randomly assigned to Enhanced Support and Connection to Counseling (ESCC).
11564984|NCT00895986|Experimental|1|Conversation Maps Diabetes Education
11564985|NCT00895986|Experimental|2|Heart Healthy Living Diabetes Education
11564986|NCT00895973|Experimental|Stirrups delivery|Mom will be assigned to deliver with legs positioned in stirrups
11564987|NCT00895973|Experimental|Bed delivery|Mom will be assigned to deliver with the legs positioned in bed in the supine position
11564988|NCT00895960|Experimental|Dasatinib Plus RT + TMZ|Dasatinib (Sprycel) with Radiotherapy (RT) and 6 weeks of concomitant Temozolomide (TMZ)
11564989|NCT00895947|Experimental|Interferon-alpha|150 international units of interferon-alpha
11564990|NCT00895947|Placebo Comparator|placebo|placebo lozenges
11564991|NCT00895934|Experimental|Phase 1 - Dose Finding|Varying schedules and dose levels of vorinostat, azacitidine and gemtuzumab ozogamicin. Includes cohorts 1-3.
11564992|NCT00895934|Experimental|Phase 2 - Treatment at Selected Dose|Vorinostat 400 mg/day on days 1-9, azacitidine 75 mg/m2/day on days 1-7, gemtuzumab ozogamicin 3 mg/m2/day on days 4 and 8.
11564993|NCT00895921|Active Comparator|Aripiprazole|Participants will receive an injection of aripiprazole during the tracer-clamp study.
11564994|NCT00895921|Active Comparator|Olanzapine|Participants will receive an injection of olanzapine during the tracer-clamp study.
11564995|NCT00895908|Experimental|Friendship Group Intervention|"Participants will receive the Friendship Groups intervention."
11564996|NCT00895908|Active Comparator|Individual Tutoring|Participants will receive individual academic tutoring.
11564997|NCT00895895|Placebo Comparator|1|Placebo
11564998|NCT00895895|Experimental|2|SAM-531 1.5 mg
11564999|NCT00895895|Experimental|3|SAM-531 3.0 mg
11565000|NCT00895895|Experimental|4|SAM-531 5.0 mg
11565001|NCT00895895|Active Comparator|5|Donepezil
11565002|NCT00895882|Experimental|1|vaniprevir 300 mg b.i.d. + peg-IFN + RBV for 12 weeks, followed by placebo to vaniprevir + peg-IFN + RBV for 12 weeks
11565003|NCT00895882|Experimental|2|vaniprevir 300 mg b.i.d. + peg-IFN + RBV for 24 weeks
11565004|NCT00895882|Experimental|3|vaniprevir 600 mg b.i.d. + peg-IFN + RBV for 12 weeks, followed by placebo to vaniprevir + peg-IFN + RBV for 12 weeks
11565005|NCT00895882|Experimental|4|vaniprevir 600 mg b.i.d. + peg-IFN + RBV for 24 weeks
11565006|NCT00895882|Experimental|5|vaniprevir 600 mg q.d. + peg-IFN + RBV for 24 weeks
11565007|NCT00895882|Placebo Comparator|6|Placebo to vaniprevir + peg-IFN + RBV for 24 weeks, followed by peg-IFN + RBV for 24 weeks
11565008|NCT00895856||Old-aged people|
11565009|NCT00895843|Active Comparator|Conventional ibuprofen|
11565010|NCT00895843|Experimental|Brufen retard|
11565011|NCT00895830|Placebo Comparator|1|
11565012|NCT00895830|Experimental|2|0.3mg dose level
11565013|NCT00895830|Experimental|3|1mg dose level
11565014|NCT00895830|Experimental|4|2mg dose level
11565015|NCT00895830|Experimental|5|3mg dose level
11565016|NCT00895817|Active Comparator|Swallowed fluticasone|
11565017|NCT00895817|Active Comparator|Esomeprazole|
11565018|NCT00895804|Other|Pindolol, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
11565019|NCT00895804|Other|MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
11565020|NCT00895791|Active Comparator|1|AXXESS Biolimus A9-eluting bifurcation stent
11565021|NCT00895791|Active Comparator|2|culotte stenting with use of 2 drug eluting stents
11565022|NCT00895778|Experimental|NMB|muscle relaxation (neuromuscular block) during laparoscopic cholecystectomy
11565023|NCT00895778|Placebo Comparator|no NMB|no muscle relaxation (neuromuscular block) during laparoscopic cholecystectomy
11565024|NCT00895752|Experimental|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
11565025|NCT00895726|Experimental|APD209|
11565026|NCT00895713|Experimental|im HBIG Grifols|
11565027|NCT00895700|Experimental|Web-based behavioral intervention|
11565028|NCT00895700|No Intervention|Usual care|
11565029|NCT00895687|Experimental|Erlotinib + Bortezomib|Up to 4 dose levels of study drug combination tested with 3-6 participants enrolled at each dose level. Erlotinib beginning dose of 150 mg taken by mouth daily for 21-day cycle. Bortezomib beginning dose of 1. mg/m^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
11565030|NCT00895674||Group 1|
11565031|NCT00895661|Other|rituximab|single-arm, open-label, interventional
11565032|NCT00895648|Experimental|Alimta plus Cisplatin|
11565033|NCT00895635|Experimental|Treadmill Exercise Training|Participants will take part in a 12-week supervised treadmill exercise training program.
11565295|NCT00893815||1|HIV-Positive and Early HIV infection
11565034|NCT00895635|Experimental|Arm Ergometry Exercise Training|Participants will take part in a 12-week supervised aerobic arm ergometry exercise training program.
11565035|NCT00895635|Active Comparator|Usual Care Control Group|Participants will receive usual care for PAD from their doctor.
11565036|NCT00895622|No Intervention|Low Risk|No treatment given.
11565037|NCT00895622|Experimental|Intermediate Risk|54 Gy radiotherapy
11565038|NCT00895622|Experimental|High Risk|60 Gy radiotherapy
11565039|NCT00895609|Experimental|Sugammadex|Sugammadex in doses: 0 (placebo), 0.0625, 0.125, 0.25, 0.5 and 1 mg/kg
11565040|NCT00895609|Active Comparator|Neostigmine|Neostigmine in doses: 0 (placebo), 5, 8, 15, 25, 40 mg/kg
11565041|NCT00895596|Experimental|LB80380 30mg|LB80380 30mg
11565042|NCT00895596|Experimental|LB80380 60mg|LB80380 60mg
11565043|NCT00895596|Experimental|LB80380 90mg,|LB80380 90mg
11565044|NCT00895596|Experimental|LB80380 150mg|LB80380 150mg
11565045|NCT00895596|Experimental|LB80380 240mg|LB80380 240mg
11565046|NCT00895583|Experimental|Group I - Planned transition to sirolimus from tacrolimus|
11565047|NCT00895583|Active Comparator|Group II - Continuation of tacrolimus|
11565048|NCT00895570|Experimental|Modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
11565049|NCT00895570|Placebo Comparator|Placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
11565050|NCT00895557|Active Comparator|chantix|
11565051|NCT00895544|Experimental|1|Day 0: Single priming vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Vietnam strain) - Day 360: Randomization to booster vaccination with Dose B of whole virion, Vero cell-derived influenza vaccine (Indonesia strain)
11565052|NCT00895544|Experimental|2|Day 0: Single priming vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Vietnam strain) - Day 360: Randomization to booster vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Indonesia strain)
11565053|NCT00895531|Active Comparator|Peripheral Nerve group|Group will receive sciatic catheter placed before or after surgery by subgluteal approach with the use of ultrasound. The ischial tuberosity will be identified with the ultrasound probe and its midpoint marked. A catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
11565054|NCT00895531|Experimental|Depodur Group|patients will have an L2-L3 epidural placed while they are in the sitting position before or after femoral catheter placement. They will receive 7.5 mg Depodur via the epidural catheter. All of these patients will receive Singular 10 mg and Claritin 10 mg before the epidural Depodur is placed, as per our protocol of patients receiving EREM.
11565055|NCT00895518|No Intervention|1|Participants will receive assessments only.
11565056|NCT00895518|Experimental|2|Participants will receive prolonged exposure therapy.
11565057|NCT00895505|Active Comparator|oral anticoagulants|Experimental intervention: Extension of OAT in VTE patients showing high plasma levels of D-Dimer after end of routine secondary prophylaxis.
11565058|NCT00895505|No Intervention|2|Control: Withdrawal of OAT in VTE patients after end of routine secondary prophylaxis and receiving low molecular weight heparin in risk situations.
11565059|NCT00895492||Sotero del Rio|Emergency Room and Hospital based surveillance
11565060|NCT00895492||Van Buren|Emergency Room and Hospital based surveillance
11565061|NCT00895479|Experimental|Trinam|Graft placement plus Trinam therapy
11565062|NCT00895479|No Intervention|Control|Graft placement surgery alone
11565063|NCT00895453|Active Comparator|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid).
11565064|NCT00895453|Active Comparator|itraconazole + lactobacilli agent|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid). Additionally, Lactobacillus vaginal tablets monthly given through 6 days.
11565065|NCT00895453|Active Comparator|classic homeopathy (CH)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
11565066|NCT00895440||1|Diabetic patients without neuropathy
11565067|NCT00895440||2|Diabetic patients with painless neuropathy
11565068|NCT00895440||3|Diabetic patients with painful neuropathy
11565069|NCT00895440||4|Diabetic patients with Charcot neuroarthropathy
11565070|NCT00895440||5|Control non-diabetic subjects
11565071|NCT00895427||1|Male ages 45-54, without diabetes, CAC score from 0 to >1000
11565072|NCT00895427||2|Male ages 55-64, without diabetes, CAC score from 0 to >1000
11565073|NCT00895427||3|Male ages 65+, without diabetes, CAC score from 0 to >1000
11565074|NCT00895427||4|Male ages 45-54, with diabetes and CAC score from 0 to >1000
11565075|NCT00895427||5|Male ages 55-64, with diabetes, CAC score from 0 to >1000
11565076|NCT00895427||6|Male ages 65+, with diabetes, CAC score from 0 to >1000
11565077|NCT00895427||7|Female ages 50-59, without diabetes, CAC score from 0 to >1000
11565078|NCT00895427||8|Females ages 60-69, without diabetes and CAC score from 0 to >1000
11565079|NCT00895427||9|Females ages 70 +, without diabetes, CAC score from 0 to >1000
11565080|NCT00895427||10|Female ages 50- 59, with diabetes, CAC score from 0 to >1000
11565081|NCT00895427||11|Female ages 60-69, with diabetes, CAC score from 0 to >1000
11565082|NCT00895427||12|Female age 70+, with diabetes, CAC score from 0 to >1000
11565083|NCT00895414|Experimental|Doxorubicin alone first, then Doxorubicin with Enalapril|Patients receive doxorubicin hydrochloride IV over 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2.
11565131|NCT00895063|Experimental|Vocal Exercise|Subject will speak continually for one hour following injection of botulinum toxin.
11565296|NCT00893815||2|HIV-Positive and Late HIV-infection
11565084|NCT00895414|Experimental|Doxorubicin with Enalapril first, then Doxorubicin alone|Patients receive doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
11565085|NCT00895401|Active Comparator|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
11565086|NCT00895401|Experimental|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available nutritional supplement designed to meet the nutritional needs of malnourished hemodialysis patients. The serving size is 8 oz which provides 425 kcal and 19 g protein
11565087|NCT00895388|Other|Structured Rehabilitation program|
11565088|NCT00895388|No Intervention|Controls|
11565089|NCT00895375||Psoriasis patients|40 subjects (male or female) age 18 or older with psoriasis covering >10% BSA and without a diagnosis of depression.
11565090|NCT00895375||Patients without psoriasis|40 subjects without psoriasis matched for age, sex and BMI, as a control population.
11565091|NCT00895362|Experimental|Erlotinib + Cetuximab|Erlotinib in Combination with Cetuximab
11565092|NCT00895349|Experimental|1|CT Abdomen and Pelvis + whole body PET-CT
11565093|NCT00895349|Active Comparator|2|CT Abdomen and Pelvis
11565094|NCT00895310|Experimental|Ketoconazole and Hydrocortisone|Ketoconazole 200mg PO TID + Hydrocortisone 20mg PO Qam, 10mg PO Qpm
11565095|NCT00895284|Experimental|Robot|Robotic hysterectomy
11565096|NCT00895284|Active Comparator|Standard|Standard hysterectomy
11565097|NCT00895271||Healthy Volunteers|Up to 50 subjects as healthy controls
11565098|NCT00895271||Immunodeficiency|Up to 150 subjects with poorly defined, rare inherited immunodeficiency or immunodysregulation disorders
11565099|NCT00895258|Experimental|IPS-CT|Participants will receive individual placement and support (IPS) plus cognitive training (CT).
11565100|NCT00895258|Active Comparator|IPS-ES|Participants will receive individual placement and support (IPS) plus enhanced support (ES).
11565101|NCT00895245|Experimental|Arm I|"Patients receive cisplatin IV on day 1. Treatment repeats every 21 days for up to 3 courses. Patients also undergo radiotherapy once daily 5 days a week for up to 7 weeks.
~Patients receive fosaprepitant dimeglumine IV, palonosetron hydrochloride IV, and dexamethasone IV on day 1.Patients then receive oral dexamethasone on days 2-4. Patients with no emesis or requirement for rescue anti-emetics in the first 120 hours after cisplatin infusion continue to receive the anti-emetic regimen as above with the second and third courses of cisplatin.
~Patients complete an emesis diary daily for 5 days after each cisplatin infusion. Patients also complete a Functional Living Index-Emesis Questionnaire on day 8 after each cisplatin infusion."
11565102|NCT00895232|Experimental|Cohort I|500 mg dose Venofer over 4 hours
11565103|NCT00895232|Experimental|Cohort II|500 mg Venofer infusion over 4-6 hours on Day 0 and repeated on Day 2 to 7
11565104|NCT00895232|Experimental|Cohort III|500 mg Venofer over 6 hours, followed within 24 hours by 500 mg Venofer over 6 hours
11565105|NCT00895219|Active Comparator|1|Breathing re-training
11565106|NCT00895219|Active Comparator|2|Breathing re-training and musculoskeletal physiotherapy techniques
11565107|NCT00895206|Experimental|1|individual adapted immunosuppression
11565108|NCT00895206|Active Comparator|2|golden standard therapy
11565109|NCT00895193|Active Comparator|Apple-pectin 2000mg|Participant receives Apple pectin 2000mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
11565110|NCT00895193|Active Comparator|Regular Non-enteric coated aspirin 325mg|Participant receives aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
11565111|NCT00895193|Active Comparator|Apple pectin + aspirin|Participant receives apple pectin 2000mg and aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
11565112|NCT00895193|Placebo Comparator|Placebo Comparator|Participant receives placebo 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
11565113|NCT00895180|Experimental|Group 1|Patients receive ramucirumab IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11565114|NCT00895180|Experimental|Group 2|Patients receive olaratumab IV over 60-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11565115|NCT00895167|Experimental|curcumin|every subject receives 12 g of oral curcumin
11565116|NCT00895154|Active Comparator|General Tutoring Group|Participants will receive general tutoring in the subject of his/her choice.
11565117|NCT00895154|Experimental|Tutoring + Memory Training Group|Participants will receive tutoring and memory training.
11565118|NCT00895141|Experimental|Low saturated fat diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 8%E saturated fat
11565119|NCT00895141|Experimental|High saturated fat diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
11565120|NCT00895128|Experimental|Erlotinib + Dasatinib|Erlotinib starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients. Dasatinib starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
11565121|NCT00895115|Sham Comparator|Arm I|Patients receive no supplementation.
11565122|NCT00895115|Experimental|Arm II|Patients receive oral high γ-tocopherol vitamin E supplementation once daily for 1 week.
11565123|NCT00895115|Experimental|Arm III|Patients receive oral high γ-tocopherol vitamin E supplementation once daily for 2 weeks.
11565124|NCT00895102|Active Comparator|1. ABT-333 Capsule vs ABT-333 Tablet|400mg ABT-333 Tablet, QD, single dose vs eight 50mg ABT-333 Capsules, QD, single dose
11565125|NCT00895102|Active Comparator|2. ABT-333 Tablet|ABT-333 400mg Tablet, QD, single ascending doses (1200mg, 1600mg, 2400mg)
11565126|NCT00895102|Placebo Comparator|3. Placebo|Placebo tablets, QD, single ascending doses
11565127|NCT00895089|Experimental|A: Moxifloxacin|Moxifloxacin 400mg IV once daily for 14 days, then 400mg PO once daily for 7 days.
11565128|NCT00895089|Active Comparator|B: Ceftriaxone|Ceftriaxone 2gm IV every 12 hours for 14 days, then cephalexin 1gm PO every 6 hours for 7 days.
11565129|NCT00895076|Experimental|1|dexamethasone iontophoretic patch
11565130|NCT00895076|Active Comparator|2|dexamethasone intramuscular injection
11565235|NCT00894296||1|schizophrenia patients
11565132|NCT00895063|Placebo Comparator|Silence|Subject will remain silent for one hour following injection of botulinum toxin.
11565133|NCT00895050||1|Patients diagnosed with RA
11565134|NCT00895037||1|Patients treated with Refacto AF
11565135|NCT00895024||Caregivers|
11565136|NCT00895011|Placebo Comparator|Placebo|
11565137|NCT00895011|Experimental|Avanafil 100 mg|
11565138|NCT00895011|Experimental|Avanafil 200 mg|
11565139|NCT00894998|Experimental|1|Heparin sodium 5.000 UI - Cristália
11565140|NCT00894998|Active Comparator|2|Heparin Sodium 5.000 USP - APP
11565141|NCT00894985|Experimental|1|Heparin 5.000UI
11565142|NCT00894985|Active Comparator|2|Heparin 5.000USP - APP
11565143|NCT00894972|Active Comparator|1|General exercise. Participants in this group will perform aerobic exercise, range of motion exercise and general strengthening exercise.
11565144|NCT00894972|Experimental|2|Specific exercise. Participants in this group will perform aerobic exercise, range of motion exercise, and specific motor control exercises.
11565145|NCT00894959|Experimental|1|Heparin Sodium Blausiegel 1
11565146|NCT00894959|Experimental|Active Comparator|heparin sodium - APP 5.000 USP
11565147|NCT00894946|Experimental|Recurrent IVF implantation failure|
11565148|NCT00894946|Experimental|Endometriosis|
11565149|NCT00894933|Experimental|Continuum|Verify the consistency of performance of the AMS CONTINUUM device in facilitating a sustainable anastomosis following a radical prostatectomy using updated Device design elements and Physician training materials on Device implant technique.
11565150|NCT00894920|Placebo Comparator|placebo|
11565151|NCT00894920|Active Comparator|biotin|
11565152|NCT00894907|Experimental|PiCCO-group|Insertion of an arterial PiCCO catheter. Resuscitation using crystalloids and/or colloids according to PiCCO-parameter-guided algorithm
11565153|NCT00894907|Other|2|Control: Haemodynamic management without ITBI and ELWI using any other haemodynamic monitoring tool, with the exception of the PiCCO-system.
11565154|NCT00894881||1 group|patients before colonoscopy
11565155|NCT00894868|Experimental|Vildagliptin|
11565156|NCT00894868|Placebo Comparator|Placebo|
11565157|NCT00894855|Active Comparator|education only|This comprehensive education program included a health educator visit, on the education van, who gave education about sun safety.
11565158|NCT00894855|Experimental|education plus dermatologist skin exam|"In addition to the education program, participants received free skin exams by board certified dermatologists from Brigham and Women's Hospital. The van was equipped with a private clinical setting conducive to carry out such examinations. Based on the recommendations of the American Academy of Dermatology (AAD), a visual full body exam was provided to participants. At the end of each skin exam the dermatologist provided a presumptive diagnosis to the participant, and made appropriate recommendations and referrals for follow up with the participants' physician/dermatologist (if and when necessary). All participants undergoing the skin exam were required to complete an AAD Skin Cancer Screening Registration and Report form."
11565159|NCT00894855|Experimental|educ, biometric fb, and derm skin exam|Participants received the active components of the other three conditions.
11565160|NCT00894855|Experimental|education plus biometric feedback|In addition to the educational program, participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
11565161|NCT00894842|Active Comparator|Pregnenolone|
11565162|NCT00894842|Placebo Comparator|Sugar pill|
11565163|NCT00894829|Experimental|1|Heparin sodium - Eurofarma
11565164|NCT00894829|Active Comparator|2|Heparin APP
11565165|NCT00894816|Active Comparator|1|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19) 10E8 CFU per serving
11565166|NCT00894816|Placebo Comparator|2|Placebo (infant cereals without any additions)
11565167|NCT00894803|Active Comparator|rt-PA only|Subject will receive the standard dose (0.9mg/kg) of IV rt-PA given over 60 minutes. One out of 6 subjects will be in this group.
11565168|NCT00894803|Experimental|rt-PA and Eptifibatide|Subject will receive the standard dose (0.9mg/kg) of IV rt-PA. This IV dose will be discontinued at 40 minutes. The subject will immediately receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours. Five out of six subjects will be in this group.
11565169|NCT00894790|Experimental|1|
11565170|NCT00894790|Active Comparator|2|
11565171|NCT00894777||1|Patients with moderate and severe psoriasis under treatment with topical and/or systemic drugs
11565172|NCT00894764||Routine Follow Up|Monthly nasopharyngeal swab for infant. Seen during acute illness.
11565173|NCT00894764||Immunology|Monthly nasopharyngeal swab for mother and infant. Serum sample taken from Infant. Seen during acute illness.
11565174|NCT00894751|Active Comparator|dexmedetomidine|Determine if there is a significant difference in the quality of care between our two standard anesthesia techniques for children undergoing a MRI of the body and/or extremity MRI.
11565175|NCT00894751|Active Comparator|propofol|Determine if there is a significant difference in the quality of care between our two standard anesthesia techniques for children undergoing a MRI of the body and/or extremity MRI.
11565176|NCT00894738||antipsychotic treated|Children with psychiatric diagnoses who are currently treated with antipsychotic medications.
11565177|NCT00894738||healthy control|Age- and gender-matched children who do not have a psychiatric diagnosis, are not taking antipsychotic medications, and are otherwise healthy.
11565178|NCT00894725|Experimental|LPS|laparoscopic left colonic resection
11565179|NCT00894725|Active Comparator|Open|open left colonic resection
11565180|NCT00894699|Active Comparator|1|single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
11565181|NCT00894699|Placebo Comparator|2|single dose of sublingual Placebo NanoTab™
11565236|NCT00894296||2|healthy control
11565297|NCT00893815||3|HIV-negative
11565182|NCT00894686|Experimental|All subjects|Assessment of seropersistence of TBE antibodies at yearly intervals from approximately 3 years (38 months) to 10 years (118 months) after the first booster vaccination (in Study 700401), as well as antibody response to a second booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5 mL, depending on the subject´s age. Timing of the second booster vaccination will depend on the level of serum TBE antibodies detected at the defined assessment time points. Subjects who are not protected against TBE for an entire further season (NT titer <= 20 and/or ELISA value <=126 VIE U/mL) will be invited to receive the second booster vaccination at either the 40, 48, 60, 72, 84, 96, 108, or 120-month time point.
11565183|NCT00894673|Experimental|1|Heparin sodium Hipolabor
11565184|NCT00894673|Active Comparator|2|Heparim Sodium APP 5.000 USP
11565185|NCT00894660|Experimental|Amodiaquine (Pfizer)|
11565186|NCT00894660|Active Comparator|Amodiaquine tablets (Arsuamoon-Guilin China)|
11565187|NCT00894647|Placebo Comparator|2|placebo cream in 250mg/packet, up to 2 packets applied daily
11565188|NCT00894647|Active Comparator|imiquimod cream|Imiquimod 3.75% cream, 250 mg single-use packets, up to 2 packets applied daily
11565189|NCT00894634|Experimental|Brompheniramine maleate|Brompheniramine maleate oral solution 1 mg/5 mL, single dose
11565190|NCT00894621|Experimental|Norepinephrine|
11565191|NCT00894621|Placebo Comparator|Placebo|
11565192|NCT00894608|Experimental|letrozole protocol|patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
11565193|NCT00894608|Experimental|long GnRHa protocol|patients in long GnRHa protocol for ovarian stimulation with Gnrha and gonadotropins
11565194|NCT00894595|Experimental|Intervention group|The clubs in the intervention group are instructed to perform a warm-up program at two training sessions per week throughout the entire 2009 competitive season.
11565195|NCT00894595|Active Comparator|Control group|The clubs in the control group are instructed to train and play as usual throughout the 2009 season
11565196|NCT00894569|Active Comparator|A|6 cycles of carboplatin/paclitaxel
11565197|NCT00894569|Experimental|B|carboplatin/paclitaxel plus cetuximab until disease progression
11565198|NCT00894556|Experimental|Treatment Sequence A|Rizatriptan - Rizatriptan - Placebo
11565199|NCT00894556|Experimental|Treatment Sequence B|Rizatriptan - Placebo - Rizatriptan
11565200|NCT00894556|Experimental|Treatment Sequence C|Placebo - Rizatriptan - Rizatriptan
11565201|NCT00894556|Other|Baseline Phase|Sumatriptan
11565202|NCT00894543|Active Comparator|Escitalopram|Escitalopram is a selective serotonin reuptake inhibitor (SSRI)
11565203|NCT00894543|Placebo Comparator|Placebo|Inactive pill
11565204|NCT00894530|Experimental|1|
11565205|NCT00894530|Placebo Comparator|2|
11565206|NCT00894517|Experimental|Botulinum Toxin Type A|OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
11565207|NCT00894517|Placebo Comparator|Placebo (saline)|Placebo (saline) injected into the prostate on Day 1.
11565208|NCT00894504|Experimental|Panitumumab/Gemcitabine/Carboplatin|Systemic therapy
11565209|NCT00894478||1|12 children with MRI-negative partial epilepsy who are being worked-up for epilepsy surgery
11565210|NCT00894478||2|12 children with MRI-visible FCD who are being worked-up for epilepsy surgery
11565211|NCT00894478||3|Control Group- Healthy Volunteers
11565212|NCT00894465|Experimental|Versed|Both patients who are VCUG naive and patients who have had a previous VCUG are given oral midazolam prior to undergoing the VCUG.
11565213|NCT00894465|Placebo Comparator|Placebo|Both patients who are VCUG naive and patients who have had a previous VCUG are given an oral placebo prior to undergoing the VCUG.
11565214|NCT00894439|Experimental|1|
11565215|NCT00894426||1|Morning Symptoms (+)
11565216|NCT00894426||2|Morning Symptoms (-)
11565217|NCT00894413|Placebo Comparator|Placebo|
11565218|NCT00894413|Experimental|Tadalafil|Tadalafil 20 mg once per day
11565219|NCT00894400|Experimental|Targeting of most fractionated electrograms first|During catheter ablation of AF patients will have fractionated electrograms targeted. In the experimental group the fractionated electrograms believed to be most critical will be targeted first.
11565220|NCT00894400|Active Comparator|Targeting least fractionated electrograms first|During catheter ablation of AF fractionated electrograms are targeted. In this arm the least fractionated electrograms will be targeted first.
11565221|NCT00894387|Experimental|Aliskiren|Randomized patients in this arm received, Aliskiren 150 mg once daily for 2 weeks. From week 2 upto 6 months , patients who could tolerate study medication were up-titrated to aliskiren 300 mg once daliy.
11565222|NCT00894387|Placebo Comparator|Placebo|Randomized patients in this arm received matching placebo of Aliskiren. At week 2, Patients who could tolerate study medication were up-titrated to matching placebo of 300 mg aliskiren.
11565223|NCT00894374|Experimental|Artesunate (Pfizer)|
11565224|NCT00894374|Active Comparator|Artesunate (Arsuamoon® Tablets Guilin-China)|
11565225|NCT00894361|Active Comparator|rotating-platform design TKA|patients who were randomized to receive the rotating platform mobile-bearing TKA design
11565226|NCT00894361|Active Comparator|all-polyethylene tibia design TKA|patients who were randomized to receive the all-polyethylene tibial component design
11565227|NCT00894335||1|Pheochromocytoma
11565228|NCT00894335||2|Conn-Syndrome
11565229|NCT00894335||3|Cushing disease
11565230|NCT00894335||4|Metastasis
11565231|NCT00894335||5|Non-functional tumor
11565232|NCT00894322|Experimental|Cohort 1: Healthy Participants|A single 10-mg dose of exenatide once weekly suspension given to healthy participants via 3 subcutaneous (SC) injections at Day 1.
11565233|NCT00894322|Experimental|Cohort 2: Diabetes Participants|On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, thiazolidinedione (TZD), or a combination of metformin or TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks.
11565234|NCT00894322|Placebo Comparator|Cohort 2: Diabetes Participants Placebo|On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, thiazolidinedione (TZD), or a combination of metformin or TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks.
11565237|NCT00894283|Active Comparator|Enoxaparin|Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.
11565238|NCT00894283|Active Comparator|Fondaparinux|Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.
11565239|NCT00894257||HCV/HIV infected pregnant women|
11565240|NCT00894244|Experimental|Treatment|Treatment using a non-invasive skin tightening radiofrequency device to observe skin shrinkage in the arms
11565241|NCT00894231|Placebo Comparator|placebo|Sugar tablet
11565242|NCT00894231|Active Comparator|Xyzal|
11565243|NCT00894218|Active Comparator|Conventional arthroplasty|Total hip or knee conventional arthroplasty
11565244|NCT00894218|Experimental|Mini-invasive arthroplasty|Total hip or knee mini-invasive arthroplasty
11565245|NCT00894218|Experimental|Mini-invasive and computer-assisted arthroplasty|Mini-invasive and computer-assisted total hip or knee arthroplasty
11565246|NCT00894205|Experimental|strengthening exercise|"A low intensity strengthening exercise program based on the Tufts University Strong Bones program. Utilizes small free weights and chair exercises."
11565247|NCT00894192|Active Comparator|Wavefront guided lenses|
11565248|NCT00894192|Placebo Comparator|Conventional lenses|
11565249|NCT00894166|Active Comparator|Nicotine Replacement Therapy Responder|Nicotine Responders
11565250|NCT00894166|Active Comparator|Pre-Quit Rescue to Bupropion & Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 2 to use of Zyban (bupropion) in combination with nicotine patches
11565251|NCT00894166|Active Comparator|Pre-Quit Rescue to Varenicline|Participants not responsive to nicotine patches who are randomly assigned at week 2 to use of Chantix (varenicline)
11565252|NCT00894166|Active Comparator|Pre-Quit Rescue to Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 2 to continued use of nicotine patches
11565253|NCT00894166|Active Comparator|Post-Quit Rescue to Bupropion & Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 4 to use of Zyban (bupropion) in combination with nicotine patches
11565254|NCT00894166|Active Comparator|Post-Quit Rescue to Varenicline|Participants not responsive to nicotine patches who are randomly assigned at week 4 to use of Chantix (varenicline)
11565255|NCT00894166|Active Comparator|Post-Quit Rescue to Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 4 to continued use of nicotine patches
11565256|NCT00894153|Experimental|chemo plus p53|chemotherapy plus p53
11565257|NCT00894153|Active Comparator|chemo only|chemotherapy group
11565258|NCT00894153|Active Comparator|radio|radiotherapy
11565259|NCT00894140|Other|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
11565260|NCT00894127|Experimental|CyPath Assay of Deep-Lung Sputum Sample|Deep-lung sputum was obtained from two cohorts, including (1) high-risk control group comprised of individuals not diagnosed but at high risk for lung cancer (n=102) and, (2) cancer group comprised of individuals with confirmed lung cancer diagnosis (n=26), was labeled in exact manner with TCPP and evaluated to detect red fluorescent [ie, cancer] cells (RFCs) from deep-lung sputum samples.
11565261|NCT00894114|Other|Stratum 1|Placebo recipients in the parent protocol (Merck V520 Protocols 007 or 012) will receive ALVAC-HIV Vaccine
11565262|NCT00894114|Experimental|Stratum 2|Nonresponders who received active vaccine in parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
11565263|NCT00894114|Experimental|Stratum 3|Low responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
11565264|NCT00894114|Experimental|Stratum 4|High responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
11565265|NCT00894101|Experimental|[F-18] FLT and FDG|
11565266|NCT00894062|Active Comparator|1|ZES resolute (Endeavor® resolute)
11565267|NCT00894062|Active Comparator|2|EES (Xience®)
11565268|NCT00894049|Experimental|Flu-Bu-ATG|Fludarabine (30mg/m²/5 days) Oral Busulfan (8 mg/kg over 2 days) Thymoglobuline (2.5 mg/m²/1day).
11565269|NCT00894049|Experimental|Fluda-TBI|Fludarabine (25mg/m²/ 3 days) 2 Gy TBI
11565270|NCT00894023|Experimental|Abciximab|IC bolus of abciximab
11565271|NCT00894023|Active Comparator|IV Abciximab|IV abciximab + infusion
11565272|NCT00893997|Experimental|PR-1 vaccine|4 injections of 0.5 mg PR1 peptide vaccine every 3 weeks.
11565273|NCT00893984|Experimental|Nebivolol|Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
11565274|NCT00893971|Experimental|1|Inhaled PT001 18 μg
11565275|NCT00893971|Experimental|2|Inhaled PT005 2.4 μg
11565276|NCT00893971|Experimental|3|Inhaled PT003 (PT001 18 μg / 2.4 μg PT005)
11565277|NCT00893971|Experimental|4|PT001 18 μg + PT005 2.4 μg
11565278|NCT00893945|Experimental|DC/AAT vaccine|Intradermal injection of 3 Autologous dendritic cell vaccines (DC/AAT, DC/AAT-flu, DC/KLH) that have been co-cultured with autologous apoptotic tumor specimens.
11565279|NCT00893932||SIRS|
11565280|NCT00893906|Experimental|TIV|Children living in villages randomized to influenza vaccine
11565281|NCT00893906|Experimental|IPV|Children living in villages randomized to polio vaccine
11565282|NCT00893893||1|Lean premenopausal women
11565283|NCT00893893||2|Visceral obese premenopausal women
11565284|NCT00893880|Experimental|1|(1) 30min treatment
11565285|NCT00893880|Experimental|2|(1) 60min treatment
11565286|NCT00893880|Experimental|3|(2) 30min treatments over two consecutive days.
11565287|NCT00893880|Experimental|4|(2) 60min treatments over two consecutive days.
11565288|NCT00893867|Experimental|DP-b99|
11565289|NCT00893867|Placebo Comparator|Mannitol|
11565290|NCT00893854|Experimental|Diclophenac|
11565291|NCT00893854|Experimental|Triamcinolone|
11565292|NCT00893841|Placebo Comparator|1|Quetiapine XR 300mg + Placebo
11565293|NCT00893841|Experimental|2|Quetiapine XR 300mg + Pramipexole 0.25mg
11565298|NCT00893802|Experimental|Periodontal treatment|Scaling and root planning
11565299|NCT00893802|No Intervention|Control|
11565300|NCT00893789|Experimental|1|Armodafinil 50 mg/day
11565301|NCT00893789|Experimental|2|Armodafinil 150 mg/day
11565302|NCT00893789|Experimental|3|Armodafinil 250 mg/day
11565303|NCT00893789|Placebo Comparator|4|Placebo
11565304|NCT00893776|Active Comparator|1 Unilateral Group|This group will wear the SaeboFlex orthosis on their affected extremity and do exercises with that extremity only. SaeboFlex exercises include moving the ball in high repetition of grasp and release while wearing the SaeboFlex orthosis to various positions individualized to each participant based on movement deficits, as well as Task Training (using the affected arm during specific functional activities to use newly acquired movement patterns)
11565305|NCT00893776|Experimental|2 Bilateral training|Members of this group will wear the SaeboFlex orthosis on the affected extremity and do exercises with the affected extremity and the non-affected extremity at the same time. SaeboFlex exercises include moving the ball in high repetition of grasp and release while wearing the SaeboFlex orthosis to various positions individualized to each participant based on movement deficits, as well as Task Training (using the affected arm during specific functional activities to use newly acquired movement patterns)
11565306|NCT00893763|Experimental|Pre-intubation CHX|Chlorhexidine applied to oral cavity prior to intubation
11565307|NCT00893763|Active Comparator|Control|No chlorhexidine applied to oral cavity prior to intubation
11565308|NCT00893750|Experimental|NET Truth Education|
11565309|NCT00893750|Experimental|Conflict Resolution Trainings|
11565310|NCT00893750|Experimental|Traditional Methods|
11565311|NCT00893737|Experimental|Treximet|Treximet (a combination of sumatriptan 85 mg and naproxen sodium 500 mg) 1 tablet to be administered as soon as patient has headache indicative of migraine. Patient may treat up to 16 migraine attacks in 2 month study period.
11565312|NCT00893724|Placebo Comparator|P (Placebo)|
11565313|NCT00893724|Active Comparator|S (Supplement)|
11565314|NCT00893724|Active Comparator|SM (Supplement with Minocycline)|
11565315|NCT00893711|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938 is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops of a commercially available oil suspension, 30 min before feeding, once a day for 30 days.
11565316|NCT00893711|Placebo Comparator|Placebo|Placebo is administered in V drops once a day for 30 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
11565317|NCT00893711|Active Comparator|L.reuteri + vit D|L. reuteri DSM 17938 (10^8 CFU) plus vitamin D3 (400 UI) five drops/day for 3 months
11565318|NCT00893711|Placebo Comparator|Vit D Placebo|vitamin D3 (400 UI) five drops/day for 3 months
11565319|NCT00893685|Experimental|Home telemonitoring|
11565320|NCT00893685|No Intervention|Usual care (control group)|
11565321|NCT00893672||1|Routine strategy of chest radiograph prescription
11565322|NCT00893672||2|On-demand strategy of chest radiograph prescription
11565323|NCT00893659|Experimental|wheat bread with beta-glucan supplementation|
11565324|NCT00893659|Placebo Comparator|wheat bread without beta-glucan|
11565325|NCT00893646|Experimental|weight loss counseling|individual monthly counseling on diet, physical activity and sleep
11565326|NCT00893646|No Intervention|control|no lifestyle advice, yearly assessments
11565327|NCT00893620|Other|1|Treatment
11565328|NCT00893607|Experimental|Intra-anal|The first 12 subjects were administered 10mg NRL001 as a slow release suppository into the anal canal.
11565329|NCT00893607|Experimental|Rectal|The second 12 subjects were administered 10mg NRL001 as a slow release rectal suppository.
11565330|NCT00893594|Placebo Comparator|1|Placebo taken at onset of aura associated with migraine.
11565331|NCT00893594|Active Comparator|2|Sumatriptan with naprosyn taken at onset of aura associated with migraine.
11565332|NCT00893581|Active Comparator|1--Quetiapine & Placebo|Quetiapine & Placebo in the place of Lithium
11565333|NCT00893581|Active Comparator|2-- Lithium & Placebo|Lithium & Placebo in the place of Quetiapine
11565334|NCT00893581|Placebo Comparator|Placebo|Sugar Pill (Placebo) given to mimic drug
11565335|NCT00893568|Active Comparator|Healthy volunteers|Healthy volunteers without treatment
11565336|NCT00893568|Experimental|CBT|Psychotraumatized patients treated by Cognitive and Behavioral Therapies (CBT)
11565337|NCT00893568|Experimental|EMDR|Psychotraumatized patients treated by Eye Movement Desensitization and Reprocessing (EMDR)
11565338|NCT00893555|Active Comparator|control|Voriconazole dosing based on SPC
11565339|NCT00893555|Experimental|TDM|Voriconazole serum concentration based dosing
11565340|NCT00893529|Experimental|dietary intervention 1|
11565341|NCT00893529|Experimental|dietary intervention 2|
11565342|NCT00893516|Experimental|1|CHOP chemo therapy + CD4 therapy
11565343|NCT00893516|Active Comparator|2|CHOP chemotherapy
11565344|NCT00893490|Experimental|Ahmed Glaucoma Valve (AGV) alone|
11565345|NCT00893490|Experimental|AGV plus MMC|
11565346|NCT00893490|Experimental|AGV plus amniotic membrane coverage|
11565347|NCT00893464|Experimental|IXAZOMIB|
11565348|NCT00893451|Active Comparator|A|Vitamin D3 1600 IU orally twice daily
11565349|NCT00893451|Placebo Comparator|B|Placebo orally twice daily
11565350|NCT00893438|Experimental|FitNet treatment|FitNet treatment: web-based cognitive behaviour therapy
11565351|NCT00893438|Active Comparator|Usual care|waiting list for FitNet intervention (usual care allowed)
11565352|NCT00893412|Active Comparator|Tramadol + Metal cannula|Fast-release Orodispersible Tramadol Tablet + Metal cannula
11565353|NCT00893412|Placebo Comparator|Placebo + Metal cannula|Placebo + Metal cannula
11565354|NCT00893412|Active Comparator|Tramadol + Balloon|Fast-release Orodispersible Tramadol Tablet + balloon catheter
11565355|NCT00893412|Placebo Comparator|Placebo + Balloon|Placebo + balloon catheter
11565356|NCT00893399|Experimental|1|chemotherapy in combination with ATRA with gemtuzumab ozogamicin
11565357|NCT00893399|Active Comparator|2|chemotherapy in combination with ATRA without gemtuzumab ozogamicin
11565419|NCT00892996|No Intervention|1|Metoclopramide 10 mg intravenous
11565358|NCT00893386||Non-4195 Lead, 181 days|Patients with a Medtronic LV Lead, other than Model 4195, implanted at least 181 days
11565359|NCT00893386||4195 Lead, 181 days|Patients with a Medtronic Model 4195 LV Lead implanted at least 181 days
11565360|NCT00893386||4195 Lead, 90-180 days|Patients with Medtronic Model 4195 LV Lead implanted for 90-180 days
11565361|NCT00893373|Experimental|Sorafenib|Induction, Consolidation and Maintenance plus Sorafenib 2x 400 mg/d
11565362|NCT00893373|Placebo Comparator|Placebo|Induction, Consolidation and Maintenance plus Placebo
11565363|NCT00893360|Experimental|Cardiac Stem Cell Treatment - Group 1|Autologous stem cell infusion of 12.5 MIL CDCs via intracoronary infusion.
11565364|NCT00893360|Experimental|Cardiac Stem Cell Treatment -Group 2|Autologous stem cell infusion of 25 MIL CDCs via intracoronary infusion.
11565365|NCT00893360|No Intervention|Observation (Control Group)|Observation of myocardial recovery after usual medical management.
11565366|NCT00893347|Active Comparator|I|Treatment as usual
11565367|NCT00893347|Experimental|II|Treatment as usual + cognitive-behavioural therapy
11565368|NCT00893334||BMD:|Patients diagnosed with Becker Muscular Dystrophy
11565369|NCT00893334||LGMD2A|patient diagnosed with Limb-Girdle Muscular Dystrophy, type 2A Calpain-3 deficiency
11565370|NCT00893334||LGMD2B|Patients diagnosed with Limb-Girdle Muscular Dystrophy, type 2B Miyoshi myopathy Dysferlin deficiency
11565371|NCT00893334||LGMD2I|Patients diagnosed with Limb-Girdle Muscular Dystrophy, type 2I FKRP-deficiency
11565372|NCT00893334||Control|Healthy Controls
11565373|NCT00893321|Other|Inferior Oblique Muscle Recession and Myectomy|
11565374|NCT00893282|Experimental|BackStop|Intracorporeal lithotripsy with the use of an anti-retropulsion device.
11565375|NCT00893282|Active Comparator|Control|No anti-retropulsion device will be used during lithotripsy.
11565376|NCT00893269|Experimental|Active Medication|Participants receive active hypnotic medication prior to sleep
11565377|NCT00893269|Placebo Comparator|Placebo|Participants receive placebo prior to sleep
11565378|NCT00893256|Experimental|Risperidone and citalopram|24 patients were randomized to receive add-on citalopram (20 mg/day) in a double-blind fashion to open-label risperidone (4-8 mg/day)
11565379|NCT00893256|Placebo Comparator|Risperidone and placebo|24 patients were randomized to receive add-on placebo in a double-blind fashion to open-label treatment with risperidone (4-8 mg/day)
11565380|NCT00893243||1Tears Again/Control|
11565381|NCT00893243||2Opticol/Control|
11565382|NCT00893243||3Optive/Control|
11565383|NCT00893243||4Tears Again/Opticol|
11565384|NCT00893243||5Tears Again/Optive|
11565385|NCT00893243||6Opticol/Optive|
11565386|NCT00893230|Experimental|Lactobacillus sakei KCTC 10755BP|
11565387|NCT00893230|Placebo Comparator|microcrystalline cellulose|
11565388|NCT00893217|Active Comparator|Arm 1|
11565389|NCT00893217|Experimental|Arm 2|
11565390|NCT00893191||Sildenafil|Treated with 50 mg of Sildenafil at night
11565391|NCT00893191||Placebo|Treated with placebo at night
11565392|NCT00893178||CHF with elevated PAP|CHF patients (LVEF > 35%) with elevated mean pulmonary pressure( > 20 mmHg ) measured by pa catheter
11565393|NCT00893178||CHF patient without elevated PAP|CHF patients (LVEF > 35%) with normal mean pulmonary pressure
11565394|NCT00893178||Normal EF with elevated PAP|Patients with normal LVEF < 60% with elevated mean pulmonary pressure
11565395|NCT00893165||hemodialysis patients|chronic hemodialysis patients with elevated inflammation markers
11565396|NCT00893152||Group 1|Male veterans (focus groups and individual interviews)
11565397|NCT00893152||Group 2|Female veterans (focus groups and individual interviews)
11565398|NCT00893152||Group 3|Family members of participating veterans (focus groups and individual interviews)
11565399|NCT00893139|Experimental|AL-38583 0.05%|AL-38583 ophthalmic solution 0.05%, 1 drop per eye, 3 times a day, for 35 days
11565400|NCT00893139|Experimental|AL-38583 0.10%|AL-38583 ophthalmic solution 0.10%, 1 drop per eye, 3 times a day, for 35 days
11565401|NCT00893139|Placebo Comparator|AL-38583 vehicle|Inactive ingredients used as a placebo comparator, 1 drop per eye, 3 times a day, for 35 days
11565402|NCT00893126||Subjects with severe psoriasis|Subjects 18 to 55 with severe psoriasis. Subject will undergo a CCTA (Coronary CT Angiogram) scan.
11565403|NCT00893126||Subjects without psoriasis|Subjects 18 to 55 who do not have psoriasis or rheumatologic conditions, including rheumatoid arthritis and systemic lupus erythematosus. This group of subjects will complete a CCTA (Coronary CT Angiogram)scan.
11565404|NCT00893113|Placebo Comparator|Placebo, Then Alfuzosin|Participants first received 1 Placebo tablet once daily for 12 weeks. Participants then received a 10 mg tablet of Alfuzosin daily for 12 weeks.
11565405|NCT00893113|Experimental|Alfuzosin, Then Placebo|Participants first received a 10 mg tablet of Alfuzosin once daily for 12 weeks. Participants then received 1 Placebo tablet once daily for 12 weeks.
11565406|NCT00893100|Experimental|Diltiazem|
11565407|NCT00893087|Active Comparator|1|Flow triggering
11565408|NCT00893087|Active Comparator|2|Pressure triggering
11565409|NCT00893087|Active Comparator|3|NAVA triggering
11565410|NCT00893074|Other|0, 30, 60, and 120mg dronabinol|0, 30, 60, and 120mf dronabinol was administered in a randomized within-subjects crossover study to compare the medication dose effects of cannabis withdrawal, cognitive performance, and response to acute cannabis dosing
11565411|NCT00893061|Experimental|Arm I|Patients receive oral tamoxifen citrate once daily for 1 year in the absence of disease progression or unacceptable toxicity.
11565412|NCT00893061|Experimental|Arm II|Patients receive an oral aromatase inhibitor (letrozole, anastrozole, or exemestane) once daily for 1 year in the absence of disease progression or unacceptable toxicity.
11565413|NCT00893048|Experimental|Prednisone|Use of prednisone to decrease LOS and overall treatment time of cellulitis
11565414|NCT00893048|Experimental|Placebo|
11565415|NCT00893035||Intermediate prognosis prostate cancer|Intermediate prognosis prostate cancer
11565416|NCT00893035||Breast cancer|conservative treatment and age<60 Boost irradiation and age>60
11565417|NCT00893009|Placebo Comparator|Placebo|
11565418|NCT00893009|Active Comparator|Theophylline|100 twice a day
11565420|NCT00892996|No Intervention|2|Ondansetron 8 mg intravenous
11565421|NCT00892996|Active Comparator|3|dexamethasone 5 mg and metoclopramide 10 mg
11565422|NCT00892996|Active Comparator|4|dexamethasone 5 mg and ondansetron 8 mg IV
11565423|NCT00892983|No Intervention|Standard well child care|Standard Well Child Care (SWCC) - 8 Core visits at 2-4 weeks, 6 weeks, 3, 5, 8-10 and 15 months, 2 and 3 years.
11565424|NCT00892983|Experimental|Food Activity Breast feeding support|FAB (Food Activity Breast feeding support) 8 extra parent contacts for augmented education and support around breast feeding, food and activity
11565425|NCT00892983|Experimental|Sleep|Prevention of sleep problems in first 6 months and then active early intervention for sleep problems from 6 months to 24 months
11565426|NCT00892983|Experimental|FAB + Sleep|combination of interventions used in arms 2 and 3
11565427|NCT00892970|Experimental|1|
11565428|NCT00892970|Placebo Comparator|2|
11565429|NCT00892957|Experimental|FS VH S/D 500 s-apr|FS VH S/D 500 s-apr will be applied to the study suture line.
11565430|NCT00892957|Active Comparator|Manual compression with surgical gauze pads|Dry gauze pads will be positioned to cover the complete study suture line.
11565431|NCT00892944|Experimental|1|AZD2516
11565432|NCT00892918|Active Comparator|Moxifloxacin|About 20 patients treated by Moxifloxacin ophthalmic solution 0.5% (Vigamox) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.
11565433|NCT00892918|Active Comparator|Gatifloxacin|About 20 patients treated by Gatifloxacin ophthalmic solution 0.3% (Zymar) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.
11565434|NCT00892905||POC INR and APTT Hemochron|Adult patients undergoing elective on pump coronary artery bypass grafting surgery who have not received anticoagulants or clopidogrel within 5 days preoperatively.
11565435|NCT00892892|Experimental|Arm 1|Rilmenidine as a sympatholytic agent for three months
11565436|NCT00892892|Active Comparator|Arm 2|Nitrendipine as a non-sympatholytic agent for three months
11565437|NCT00892879|Experimental|1|Single port laparoscopic device
11565438|NCT00892879|Active Comparator|2|Four-port laparoscopic device
11565439|NCT00892866||Ancillary-Correlative (biomarkers in cervical cancer)|Patients undergo liquid-based cytology specimen sample collection for analysis of CA-IX, p16, Ki-67, and MCM2 expression via IHC and for the presence of high risk HPV DNA and HPV genotyping.
11565440|NCT00892853|Other|Bone Density Scanning|To acquire high resolution images of the bones and aid in determining bone density.
11565441|NCT00892840|Experimental|Panels 1 to 7 (BMS-820836 or Placebo)|
11565442|NCT00892827|Experimental|Single Arm Study|Rituximab
11565443|NCT00892814|Experimental|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
11565444|NCT00892814|Active Comparator|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
11565445|NCT00892801|Experimental|Treatment|RAD001 + radiation therapy
11565446|NCT00892788|Active Comparator|A|Participants assigned to Group A will receive the LEARN (Lifestyle, Exercise, Attitudes, Relationships, Nutrition) Program weight loss manual and will be instructed to read a section of the manual each week and complete suggested activities. They will also meet with the research staff once a week for weigh-in and supportive counseling.
11565447|NCT00892788|Experimental|B|Participants assigned to Group B will receive the LEARN manual and will meet with research staff each week for weigh-in and supportive counseling. They will also receive contingency management or the opportunity to earn draws with the chance of winning prizes for losing weight and completing healthy activities.
11565448|NCT00892775|Experimental|Priorix-Tetra new WS Group|Subjects received 2 doses of Priorix-Tetra vaccine formulated with new measles and rubella working seeds at Day 0 and Week 12.
11565449|NCT00892775|Experimental|Priorix-Tetra current WS Group|Subjects received 2 doses of Priorix-Tetra vaccine manufactured with current working seed virus at Day 0 and Week 12.
11565450|NCT00892762|Experimental|Travoprost APS|Travoprost APS 40 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days
11565451|NCT00892762|Active Comparator|XALATAN|Latanoprost 50 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days
11565452|NCT00892749|Experimental|1. ASP1585|
11565453|NCT00892736|Experimental|Treatment (veliparib)|"Patients receive veliparib PO BID* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~NOTE: *Patients receive veliparib once on day 1 of course 1 for pharmacokinetic and pharmacodynamic studies."
11565454|NCT00892723|Experimental|Low Dose|
11565455|NCT00892723|Experimental|High Dose|
11565456|NCT00892723|Placebo Comparator|Placebo|
11565457|NCT00892710|Experimental|Pemetrexed/Bevacizumab|"Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days
~Bevacizumab 15 mg/kg IV every 21 days"
11565458|NCT00892710|Experimental|Pemetrexed/Bevacizumab/Carboplatin|"Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days
~Bevacizumab 15 mg/kg IV every 21 days
~Carboplatin AUC=5 IV every 21 days"
11565459|NCT00892710|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days
11565460|NCT00892697|Experimental|Arm|15 subjects will receive Telaprevir in combination with pegylated interferon alfa-2a and ribavirin
11565461|NCT00892671||medical students|
11565462|NCT00892658|Experimental|Sorafenib + RT|
11565463|NCT00892632|Experimental|1|1. To compare confocal image characteristics of benign vs. malignant biliary strictures
11565464|NCT00892619|Experimental|ILM forceps|Using ILM forceps to initiate and complete peel
11565465|NCT00892619|Active Comparator|Other|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
11565466|NCT00892606|Experimental|Methadone|Patients received 2 µg/kg fentanyl, 0.2 mg/kg ketamine and 0.2 mg/kg of methadone IV with induction of general anesthesia.
11565467|NCT00892606|Active Comparator|Control|Patients received 2 µg/kg fentanyl, 0.2 mg/kg ketamine, and 0.2 mg/kg morphine (standard of care)
11565468|NCT00892593|Experimental|1 Fecal Immunochemical Testing-Surveillance|Fecal Immunochemical Testing performed at yearly intervals.
11565469|NCT00892593|No Intervention|2 Usual Care - Surveillance|
11565470|NCT00892593|No Intervention|3 Usual Care - Screening|
11565471|NCT00892593|Experimental|4 Fecal Immunochemical Testing-Screening|Fecal Immunochemical Testing yearly, beginning at year 6.
11565472|NCT00892567|Experimental|9 Peptide Vaccine|
11565473|NCT00892554|Experimental|DHA supplementation|
11565474|NCT00892554|Placebo Comparator|corn/soy capsule, no DHA|
11565475|NCT00892515|Experimental|exercise|
11565476|NCT00892502|Active Comparator|1|Bismuth tablets
11565477|NCT00892502|Placebo Comparator|2|Placebo tablets, containing no active substance
11565478|NCT00892476|Experimental|1|Infants receive supplemental calcium in their 24 cal/oz formula or fortified breast milk.
11565479|NCT00892476|Active Comparator|2|Infants will receive fortified breast milk or 24 cal/oz formula
11565480|NCT00892450|Experimental|Arm 1|crossover design
11565481|NCT00892437|Experimental|ATV+COBI+FTC/TDF|COBI + RTV placebo +ATV+FTC/TDF for 48 weeks
11565482|NCT00892437|Active Comparator|ATV+RTV+FTC/TDF|RTV + COBI placebo +ATV+FTC/TDF for 48 weeks
11565483|NCT00892424|Experimental|Sorafenib + RT|
11565484|NCT00892411||All study participants|Patients With Acute Low Back Pain
11565485|NCT00892398|Experimental|ranibizumab|Trabeculectomy with mitomycin C associated with 2 subconjunctival injections of ranibizumab: 1 intraoperatively and 1 at 2 weeks post-operatively
11565486|NCT00892398|Active Comparator|standard care|Trabeculectomy with mitomycin C and standard post-operative care
11565487|NCT00892385|Experimental|Non-CNS Disease|A traditional 3 + 3 dose escalation design will be implemented. Successive cohorts of participants (3 participants/cohort) will be entered sequentially to each dose level. If 0/3 participants at a dose level experience dose limiting toxicity (DLT) new participants may be entered at the next higher dose level. If 1 participant has a DLT, 3 more will be enrolled at the same dose level. If the 1st participant in the expanded cohort (4th at the given DL), experiences no DLT, the remaining 2 participants can start treatment. If 2 or more experience DLT in the first cycle, no further participants are started at that dose and the MTD is the highest dose level in which <2 (of 6) participants develop DLT. If the final dose level is deemed the MTD, 6 participants will be treated at this dose level even if a DLT has not been observed.
11565488|NCT00892385|Experimental|CNS Disease|A traditional 3 + 3 dose escalation design with successive cohorts of 3 participants will be entered sequentially to each dose level. If 0/3 participants experience DLT, new participants may be entered at the next higher dose level. If 1 participant has a DLT, 3 more will be enrolled at the same dose level. If the 1st participant in the expanded cohort (4th at the given DL), experiences no DLT, the remaining 2 participants can start treatment. If 1/3 participants experience a non-CNS DLT in Cohort B dose level 6, dose escalation will continue to dose level 7, as 3 subjects have already been treated in Cohort A dose level 6 and 7 subjects in Cohort A dose level 7, none of whom experienced non-CNS toxicities. If 2 or more experience DLT in cycle 1, no more participants are started at that dose and the MTD is the highest dose where <2/6 participants develop DLT. If the final dose level is deemed the MTD, 6 participants will be treated at this dose level even if no DLT has been observed.
11565489|NCT00892372||1 (type 2 diabetes, body weight, HbA1c)|The investigators analyzed the recorded data (body weight and glycohemoglobin) of 70 type 2 diabetic patients treated with the diet therapy. Recorded values at 0, 2 and 4 months for body weight (BW) and glycohemoglobin (HbA1c) were used. And changes from baseline (0 month) in BW (ΔBW) were plotted against those of HbA1c (ΔHbA1c).
11565490|NCT00892372||2 (type 2 diabetes, pioglitazone, HbA1c)|The investigators analyzed the recorded data (body weight and glycohemoglobin) of 23 type 2 diabetic patients treated with pioglitazone. Recorded values at 0, 2 and 4 months for body weight (BW)and glycohemoglobin (HbA1c) were used. And changes from baseline (0 month) in BW (ΔBW) were plotted against those of HbA1c (ΔHbA1c).
11565491|NCT00892359|Experimental|Anidulafungin|
11565492|NCT00892346|Experimental|Single ASCT with Thalidomide maintenance|"Single ASCT followed by Thalidomide maintenance:
~patients recieved 4-6 cycles of standard VAD chemotherapy or Thalidomide/dexamethasone as induction therapy
~CTX+G-SCF mobilization to collecetd PBSC
~Patiens recieved Mel 200 as conditioning followed by Thalidomide 100mg maintenance"
11565493|NCT00892281|Other|Oracea® as monotherapy|Oracea as monotherapy
11565494|NCT00892281|Other|Oracea® as add-on therapy|Oracea® as add-on Therapy (Oracea® + Metronidazoles and/or Azelaic Acids and/or Sodium Sulfacetamides
11565495|NCT00892268|Experimental|Arm I|Patients undergo acupuncture for 20-30 minutes, on the appropriate pain points on the anterior portion of the body alternating with posterior portion of the body, thrice weekly for 2 weeks and then twice weekly for 3 weeks.
11565496|NCT00892268|Active Comparator|Arm II|Patients receive standard-of-care analgesics (i.e., NSAIDs, narcotics, acetaminophen, or other) for 5 weeks. Patients not responding to analgesia may cross over to arm I.
11565497|NCT00892242|Experimental|Neoadjuvant Zoledronic Acid|"Zoledronic acid 4 mg IV prior to pancreatic resection (approximately 2 weeks prior to resection)
~Pancreatic resection
~Zoledronic acid 4 mg IV monthly for two additional doses"
11565498|NCT00892229|Active Comparator|Buccal Misoprostol|Group one: 50 patients with first trimester missed abortion received buccal misoprostol
11565499|NCT00892229|Active Comparator|Vaginal Misoprostol|Group two: 5 patients received vaginal misoprostol
11565500|NCT00892229|Active Comparator|Buccal and Vaginal Misoprostol|"50 primiparous and 50 multiparous women: one hundred patients have been administered the medication buccally (25 primigravida and 25 multigravida), and vaginally (25 primigravida and 25 multigravida), three hours before dilation and curettage. They were admitted to the hospital one day before the surgical evacuation, and preparation of cross matched blood done for all recruited subjects.
~Each group was randomly allocated (1,3,5,... for the buccal group & 2,4,6,... for the vaginal group) to receive 400 microgram misoprostol."
11565501|NCT00892216|Experimental|Acupressure Band|A band with bead attachment will be used to produce Acupressure and applied to the P6 (three fingers breath from the wrist crease on th ventral surface of the upper limb). The application will be done 20 minutes prior to anesthesia and explanation as to usage after surgery will be given. The patient of caregiver will apply pressure on the bead for three minutes and repeat this four times a day for the next five days. None of the protocol for prevention of PONV in this group of patients will be changed. The postoperative therapy for nausea and vomiting will be on a PRN (as required) basis. Nausea and vomiting scores and VAS scores for pain estimation will be carried out according to hospital protocol in the PACU amd twice a day thereafter for their period of stay in the hospital. The amount of analgesics and antiemetics used and the number of days spent in the hospital will be registered.
11565601|NCT00891475|Experimental|Arm 3|38 patients
11565502|NCT00892216|Sham Comparator|Sham Acupressure|The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
11565503|NCT00892203|Experimental|Active|
11565504|NCT00892203|Active Comparator|Comparator|
11565505|NCT00892203|Placebo Comparator|Placebo|
11565506|NCT00892190|Experimental|dasatinib (SPRYCEL) and all trans retinoic acid (VESANOID)|"Dasatinib DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours
~ATRA 22.5mg/m2 every 12 hours"
11565507|NCT00892177|Experimental|Arm I|Patients receive bevacizumab on Day 1 and dasatinib on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11565508|NCT00892177|Active Comparator|Arm II|Patients receive bevacizumab on Day 1 and placebo on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11565509|NCT00892164|Active Comparator|FOCUS (Group A)|Patients submitted to total thyroidectomy with the use of the FOCUS harmonic scalpel device
11565510|NCT00892164|Active Comparator|LIGASURE (Group Β)|Patients submitted to total thyroidectomy with the use of the electrothermal bipolar vessel sealing device
11565511|NCT00892151|Experimental|Intended Users of the Software|10 Healthcare Professionals and 40 persons with diabetes (of which 6 were parents/legal guardians of children with diabetes) using a diabetes data management program.
11565512|NCT00892138|Experimental|Mindfulness training|Mindfulness training
11565513|NCT00892138|No Intervention|Control|Study program as usual
11565514|NCT00892112|Active Comparator|intravenous immunoglobulins|IV, 40 ml/kg over 4 days
11565515|NCT00892112|Placebo Comparator|plasma volume expander Albuman|IV, 40 ml/kg over 4 days
11565516|NCT00892099|Experimental|High Dose Ergocalciferol|Receives 50,000 IU of ergocalciferol weekly
11565517|NCT00892099|Experimental|Low Dose Ergocalciferol|Receives 50,000 IU of ergocalciferol per month
11565518|NCT00892099|Placebo Comparator|Placebo|Receives no ergocalciferol
11565519|NCT00892073|Experimental|Diazoxide and Metformin Therapy|
11565520|NCT00892047|Experimental|1: venlafaxine plus aripiprazole|antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
11565521|NCT00892047|Experimental|2: Placebo Comparator|antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
11565522|NCT00892021|Experimental|NSA-789|Active study drug
11565523|NCT00892021|Placebo Comparator|Placebo|Inactive study drug
11565524|NCT00892008||Open-Label|This study was open-label with only one treatment group. Pregabalin was prescribed in accordance with usual clinical practice.
11565525|NCT00891995|Experimental|Intensive Treatment|closed loop therapy (4-6 days), insulin pump (2 years), continuous glucose monitoring (2 years), home glucose monitoring (2 years)
11565526|NCT00891995|Active Comparator|Standard Treatment|home glucose monitoring (2 years)
11565527|NCT00891982|Experimental|CTGel plus BPO wash|Benzoyl peroxide (BPO) Wash in the morning and CTGel in the evening
11565528|NCT00891982|Active Comparator|CTGel|Soap Free Cleanser in the morning and CTGel in the evening
11565529|NCT00891943|Other|Structured lifestyle support|Intervention group-structured lifestyle support.
11565530|NCT00891943|No Intervention|Usual care for weight management|"This is the control group, and they will receive usual care for weight management at their GP practice."
11565531|NCT00891930|Experimental|Panitumumab|Participants received panitumumab (6 mg/kg starting dose) with irinotecan (starting dose of 180 mg/m²) every 2 weeks (Q2W) during Part 1. Upon radiographically confirmed disease progression, participants proceeded to Part 2 of the study and received treatment with panitumumab (6 mg/kg starting dose) and ganitumab (12 mg/kg starting dose) Q2W.
11565532|NCT00891917|Placebo Comparator|Syrup|identical placebo formulation to be administered twice a day.
11565533|NCT00891917|Active Comparator|Ubiquinol-10 Syrup|CoQ (LiQ-NOL®) 10.0 mg/kg/d to be administered twice a day
11565534|NCT00891904|Experimental|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once weekly in weeks 1-5
11565535|NCT00891891||Spina Bifida|140 children with spina bifida (ages 8-15)
11565536|NCT00891878|Experimental|Arm I|Patients receive oral capecitabine twice daily on days 1-14. Patients experiencing disease progression may crossover to arm II at the physician's discretion.
11565537|NCT00891878|Experimental|Arm II|Patients receive oral capecitabine as in arm 1 and oral sunitinib malate once daily on days 1-21.
11565538|NCT00891865||Pediatric lung transplantation|
11565539|NCT00891839|Experimental|Bendamustine+Rituximab|Patients receive bendamustine at 90 mg/m^2 intravenously (iv) on days 1 and 2, and 375 mg/m^2 of rituximab by iv on day 1 of each 28-day cycle. Six 28-day cycles were planned and up to 8 cycles permitted for patients who do not have progressive disease and who have not achieved a complete response (CR).
11565540|NCT00891826|Placebo Comparator|Corn oil|
11565541|NCT00891826|Experimental|Omega-3 fatty acids|
11565542|NCT00891813|Experimental|Zemplar (paracalcitol)|
11565543|NCT00891800|Experimental|1|All patients will be treated with SIR-Sphere therapy.
11565544|NCT00891774|Experimental|Device|Treatment with EVOLENCE®
11565545|NCT00891761|Active Comparator|Active Comparator|Patients receive IV casopitant (active), IV ondansetron and oral dexamethasone on Day 1 as well as oral dexamethasone on Days 2-4 of each cycle of cisplatin-based highly emetogenic chemotherapy for the prevention of chemotherapy induced nausea and vomiting.
11565546|NCT00891761|Placebo Comparator|Placebo Comparator|Patients receive IV casopitant (placebo), IV ondansetron and oral dexamethasone on Day 1 as well as oral dexamethasone on Days 2-4 of each cycle of cisplatin-based highly emetogenic chemotherapy for the prevention of chemotherapy induced nausea and vomiting.
11565547|NCT00891748|Experimental|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter.
11565548|NCT00891735|Experimental|Ranibizumab 0.5 mg monthly|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 24 months.
11565549|NCT00891735|Experimental|Ranibizumab 2.0 mg monthly|Patients received ranibizumab 2.0 mg monthly administered intravitreally for 24 months.
11565602|NCT00891462|Experimental|1|Aclidinium bromide dose, inhaled, for 12 weeks of treatment
11565603|NCT00891462|Experimental|2|Aclidinium bromide dose, inhaled, for 12 weeks of treatment
11565604|NCT00891462|Placebo Comparator|3|Inhaled placebo for 12 weeks
11565550|NCT00891735|Experimental|Ranibizumab 0.5 mg as-needed (pro re nata [PRN])|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.
11565551|NCT00891735|Experimental|Ranibizumab 2.0 mg as-needed (pro re nata [PRN])|Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.
11565552|NCT00891709|Experimental|1|LEO 29102 2.5 mg/g cream
11565553|NCT00891709|Placebo Comparator|2|LEO 29102 cream vehicle
11565554|NCT00891696|Active Comparator|Exp 1: AA + Rap|Participants will receive amino acid supplementation and rapamycin.
11565555|NCT00891696|Placebo Comparator|Exp 1: AA|Participants will receive amino acid supplementation and placebo rapamycin.
11565556|NCT00891696|Active Comparator|Exp 1: HEx + Rap|Participants will receive rapamycin and placebo amino acid supplementation, and they will undergo high-intensity resistance exercise.
11565557|NCT00891696|Placebo Comparator|Exp 1: HEx|Participants will receive placebo amino acid supplementation and placebo rapamycin, and they will undergo high-intensity resistance exercise.
11565558|NCT00891696|Active Comparator|Exp 1: HEx + AA + Rap|Participants will receive amino acid supplementation and rapamycin, and they will undergo high-intensity resistance exercise.
11565559|NCT00891696|Placebo Comparator|Exp 1: HEx + AA|Participants will receive amino acid supplementation and placebo rapamycin, and they will undergo high-intensity resistance exercise.
11565560|NCT00891696|Active Comparator|Exp 2: LExFR + Rap|Participants will receive rapamycin and will undergo low-intensity resistance exercise with blood flow restriction.
11565561|NCT00891696|Placebo Comparator|Exp 2 and 3: LExFR|Participants will receive placebo rapamycin and will undergo low-intensity resistance exercise with blood flow restriction.
11565562|NCT00891696|Active Comparator|Exp 2: SNP|Participants will receive sodium nitroprusside in a resting state.
11565563|NCT00891696|Active Comparator|Exp 2: FR|Participants will undergo blood flow restriction in a resting state.
11565564|NCT00891696|Active Comparator|Exp 2: LEx + SNP|Participants will receive sodium nitroprusside and undergo low-intensity resistance exercise.
11565565|NCT00891696|Placebo Comparator|Exp 3: LEx|Participants will undergo low-intensity resistance exercise.
11565566|NCT00891696|Active Comparator|Exp 3: HEx|Participants will undergo high-intensity resistance exercise.
11565567|NCT00891696|Active Comparator|Exp 3: HEx + AA|Participants will receive amino acid supplementation and will undergo high-intensity resistance exercise.
11565568|NCT00891683|Placebo Comparator|Placebo|4 Capsules of Placebo
11565569|NCT00891683|Active Comparator|100 mg|One 100 mg capsule and 3 placebo capsules of AEG33773
11565570|NCT00891683|Active Comparator|200 mg|Two 100 mg capsules and two placebo capsules
11565571|NCT00891683|Active Comparator|400 mg|Four 100 mg AEG33773 capsules
11565572|NCT00891670|Active Comparator|triple group|received cilostazol 100 mg twice daily in addition to aspirin 100mg and clopidogrel 75mg once daily
11565573|NCT00891670|Active Comparator|high maintenance dose group|received clopidogrel 150 mg/day with aspirin 100mg once daily
11565574|NCT00891657|Experimental|SprayShield™|SprayShield™
11565575|NCT00891657|No Intervention|Control|No adhesion barrier administered.
11565576|NCT00891644||1|HIV positive adolescents who never initiated care within 6 months of receipt of HIV positive results.
11565577|NCT00891644||2|HIV positive adolescents who initiated care, but did not follow up with care within 12 months of the initial care visit. Also included in this group are those who initiated and followed-up with care, but have dropped out of care for 12 or more months.
11565578|NCT00891644||3|HIV positive adolescents who initiated care and maintained care. These youth are currently in care.
11565579|NCT00891631|Experimental|iSBIRT|Participants will complete the iSBIRT system.
11565580|NCT00891631|Experimental|iSBIRT/TE|Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system and technological extenders
11565581|NCT00891631|No Intervention|TAU|Participants will receive Treatment as Usual from their primary care provider.
11565582|NCT00891618|Experimental|Acupuncture|3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
11565583|NCT00891605|Experimental|Paclitaxel and ABT-263|
11565584|NCT00891592|Experimental|Dose Escalation Arm|Subjects with cord blood stored in more than one fraction will be enrolled into Dose Escalation Arm. Subjects will receive Cord Blood Stem Cell Transplant followed by expanded Cord Blood T cells on Day 0.
11565585|NCT00891592|Active Comparator|Observation Arm|Subjects with cord blood stored in one fraction will be enrolled into the Observation Arm. Subjects will receive Cord Blood Stem Cell Transplant on Day 0.
11565586|NCT00891579|Active Comparator|Alimta|Treatment of Alimta
11565587|NCT00891579|Active Comparator|IRESSA|Treatment of IRESSA
11565588|NCT00891553||Ronacaleret|Subjects receiving ronacaleret (200mg,300mg or 400mg) in study CR9108963 will be enrolled into this study.
11565589|NCT00891553||Placebo|Subjects receiving placebo in study CR9108963 will be enrolled into this study.
11565590|NCT00891540|Active Comparator|1|Local infiltration with Ropivacaine
11565591|NCT00891540|Active Comparator|2|Local infiltration with Ropivacaine
11565592|NCT00891540|Placebo Comparator|3|Local infiltration with NaCl
11565593|NCT00891527|Experimental|Avastin and/or Gleevec|Patients were all treated with Gleevec (imatinib mesylate) and those without congenital heart disease and those who progressed were also treated with Avastin (bevacizumab).
11565594|NCT00891514|Experimental|Aerobic Exercise|Treadmill training
11565595|NCT00891514|Active Comparator|Stretch Control|Stretching exercises
11565596|NCT00891501|Experimental|Single|Clinical case series
11565597|NCT00891488||Fit|
11565598|NCT00891488||Unfit|
11565599|NCT00891475|Experimental|Arm 1|38 patients
11565600|NCT00891475|Experimental|Arm 2|38 patients
11565605|NCT00891436|Placebo Comparator|Placebo nasal spray|
11565606|NCT00891436|Active Comparator|Fluticasone furoate nasal spray|
11565607|NCT00891423|Active Comparator|Meropenem short infusion|"Meropenem 1g infused over 30 minutes
~every 8 hours if calculated CrCL greater than or equal to 50 mL/min OR
~every 12 hours if calculated CrCL less than 50 mL/min or hemofiltration"
11565608|NCT00891423|Experimental|Meropenem extended infusion|"Meropenem 500mg infused over 3 hours
~every 8 hours if calculated CrCL greater than or equal to 50 mL/min OR
~every 12 hours if calculated CrCL less than 50 mL/min or hemofiltration"
11565609|NCT00891397|Experimental|1|Pregabalin group is made up of 20 patients. Patients will receive 150mg/day in two divided does. The patients will be assessed weekly and the dose can be increased to 300mg/day, if the patient does not report any decrease in pain. The following week the dose may be increased to 600mg/day if once again the patient reports no decrease in pain. This is also the maximum permissible does that will be given to the patient. If patient reports any side effects then the dose can be decreased once. The time period of 2 to 5 weeks will be the dose adjustment period. After which the drug maintenance period extends from week 5 to 12. All doses will be given in two divided doses/day.
11565610|NCT00891397|Placebo Comparator|2|Ten patients will be be in the placebo group.
11565611|NCT00891384|Experimental|1|25 mg lenalidomide
11565612|NCT00891384|Experimental|2|5 mg lenalidomide
11565613|NCT00891371|Experimental|lanreotide (Autogel formulation) Autogel 120mg|lanreotide (Autogel formulation) Autogel 120mg
11565614|NCT00891358|Experimental|Focus Group|Participants in focus groups will meet and discuss their intervention needs.
11565615|NCT00891332|Experimental|1|S-1 plus LV
11565616|NCT00891319|Experimental|CCFES|"CCFES - Contralaterally Controlled Functional Electrical Stimulation
~Electrical stimulator
~Stimulation to finger and thumb extensors only in response to, and with an intensity proportional to, opening of the contralateral unimpaired hand.
~A glove instrumented with sensors and worn on the unimpaired hand detects the degree of hand opening and determines stimulation intensity.
~Therapy sessions are done with the subject being assisted by the CCFES system."
11565617|NCT00891319|Active Comparator|cNMES|"cNMES - Cyclic NeuroMuscular Electrical Stimulation
~Electrical stimulator
~Preprogrammed cycles of finger and thumb extensor stimulation repeatedly and automatically open the hand.
~Subject instructed to not move the contralateral arm/hand during stimulation.
~Therapy sessions are done without the stimulation system."
11565618|NCT00891306|Experimental|Treatment arm|Gene Therapy
11565619|NCT00891293|Experimental|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
11565620|NCT00891267|Experimental|Olmesartan medoxomil low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
11565621|NCT00891267|Experimental|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
11565622|NCT00891267|Active Comparator|Amlodipine|Amlodipine taken once daily for 6 weeks
11565623|NCT00891254|Active Comparator|1. Intraperitoneal repair|Patients with incisional hernia, 5 cm in diameter or with an area of 25 cm2, submitted to elective surgery
11565624|NCT00891254|Active Comparator|2. On-Lay repair|Patients with incisional hernia, with a diameter of 5 cm or an area of 25 cm2, submitted to elective surgery
11565625|NCT00891241|Experimental|Cohort 1|Healthy Population
11565626|NCT00891241|Experimental|Cohort 2|Heart Failure Subjects with a documented ejection fraction of 35% or less, and a diagnosis of NYHA Class II-III heart failure, history of ventricular arrhythmia and ICD placement
11565627|NCT00891228|Placebo Comparator|Testosterone Gel 10 g and Nestorone® 0 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
11565628|NCT00891228|Experimental|Testosterone Gel 10 g and Nestorone® 8 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg NES mL gel) by pressing two times with 2 mL dispenser head.
11565629|NCT00891228|Experimental|Testosterone Gel 10 g plus Nestorone® Gel 12 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
11565630|NCT00891202|Experimental|Active|Eliglustat
11565631|NCT00891202|Placebo Comparator|Placebo|Placebo
11565632|NCT00891189||1 Control|Healthy participants without asthma
11565633|NCT00891189||2 Non-nocturnal asthma|Participants with non-nocturnal asthma
11565634|NCT00891189||3 Nocturnal asthma|Participants with nocturnal asthma
11565635|NCT00891176|Experimental|Synflorix-Meningitec Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age. 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.
11565636|NCT00891176|Experimental|Synflorix-NeisVac-C Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age and 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.
11565673|NCT00890942|Experimental|naloxone|
11565637|NCT00891176|Experimental|Synflorix-Menitorix Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.
11565638|NCT00891176|Active Comparator|Prevenar-Menitorix Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.
11565639|NCT00891163|Experimental|Synera|
11565640|NCT00891163|Placebo Comparator|Placebo|
11565641|NCT00891150|Active Comparator|oxytocin|group 1 will receive oxytocin solutions with 20U/500ml during cesarean section
11565642|NCT00891150|Active Comparator|oxytocin2|group 2 will receive oxytocin solutions with 30U/500ml during cesarean section
11565643|NCT00891150|Active Comparator|oxytocin3|group 3 will receive oxytocin solutions with 40U/500ml during cesarean section
11565644|NCT00891137|Experimental|Group A|Low dose, single donor CLT-008 (human myeloid progenitor cells)
11565645|NCT00891137|Experimental|Group B|Low dose, multiple donor CLT-008 (human myeloid progenitor cells)
11565646|NCT00891137|Experimental|Group C|Intermediate dose, multiple donor CLT-008 (human myeloid progenitor cells)
11565647|NCT00891137|Experimental|Group D|High dose, multiple donor CLT-008 (human myeloid progenitor cells)
11565648|NCT00891124||1|Type II DM and Hypertension and/or Hyperlipidemia
11565649|NCT00891111|Experimental|Direct Payment|Direct Payment: Employees receive a $25 gift card upon completion of a Health Risk Assessment
11565650|NCT00891111|Experimental|Regret Lottery|Regret Lottery: Employees are divided into work units of about 5 employees. Employees in the lottery-linked incentive condition will be eligible for a weekly lottery drawing only if they have already completed their health risk assessment. The lotteries will work as follows. Participants will be assigned to work units of about 10 people. Each week, one work group is drawn at random. If a participants group was drawn and that participant already completed the health risk assessment, then that person will win a $100 cash prize. If all of the members of his or her work group also filled out the health risk assessment, then the prize will be boosted.
11565651|NCT00891098|Active Comparator|Imaginal exposure|
11565652|NCT00891098|Experimental|Imagery rescripting|
11565653|NCT00891085||Open Lung Ventilation|within 24 hours of arrival trauma patients with ISS >25 will be randomized to BiVent (APRV)
11565654|NCT00891085||SIMV|within 24 hours of arrival trauma patients with ISS >25 will be randomized to either SIMV or BiVent
11565655|NCT00891072|Experimental|Treatment|Patients receive oral R-(-)-gossypol acetic acid twice daily on days 1-3. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
11565656|NCT00891059||Placebo Diskus Inhaler|
11565657|NCT00891046|Experimental|Canakinumab|Canakinumab
11565658|NCT00891033|Experimental|Cohort 1|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 5 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
11565659|NCT00891033|Experimental|Cohort 2|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 10 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
11565660|NCT00891033|Experimental|Cohort 3|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 15 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
11565661|NCT00891033|Experimental|Cohort 4|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 20 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
11565662|NCT00891020|Experimental|Tocilizumab 8 mg/kg Monotherapy|Participants received Tocilizumab 8 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions for 24 weeks. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
11565663|NCT00891020|Experimental|Tocilizumab 4 mg/kg + DMARD|Participants received Tocilizumab (TCZ) 4 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions plus non-biologic disease-modifying antirheumatic drug (DMARD) of the investigator's choice for 24 weeks. Participants not achieving a 20% improvement from baseline in tender and swollen joint counts at Week 8 were to have their dosage increased to 8 mg/kg, per protocol. Beginning at Week 12 dosage increase to 8 mg/kg was at the discretion of the investigator. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
11565664|NCT00891020|Experimental|Tocilizumab 8 mg/kg + DMARD|Participants received Tocilizumab (TCZ) 8 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions plus non-biologic disease-modifying antirheumatic drug (DMARD) of the investigator's choice for 24 weeks. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
11565665|NCT00891007|Experimental|Group 1|
11565666|NCT00891007|Experimental|Group 2|
11565667|NCT00891007|Active Comparator|Group 3|
11565668|NCT00890994||Suspected breast cancer|
11565669|NCT00890981|Other|Arm 1|Participants who were randomized to either denosumab or placebo in Study 20050179 and at least 12 months had elapsed from their 20050179 end-of-study visit had dual energy X-ray absorptiometry (DXA) of the forearm and HR-pQCT of the tibia and radius on Day 1 of this study. No study drug was administered.
11565670|NCT00890968|Experimental|Triamcinolone Acetonide (TAC) DuraPeel|
11565671|NCT00890968|Placebo Comparator|Placebo|
11565672|NCT00890955|Experimental|1|"Amrubicin + Cyclophosphamide 3+3 design with the following dose levels:
~Dose Level -1: Amrubicin 20mg/m2, Cyclophosphamide 500mg/m2
~Dose Level 1: Amrubicin 25mg/m2, Cyclophosphamide 500mg/m2
~Dose Level 2: Amrubicin 30mg/m2, Cyclophosphamide 500mg/m2
~Dose Level 3: Amrubicin 35mg/m2, Cyclophosphamide 500mg/m2
~Dose Level 4: Amrubicin 40mg/m2, Cyclophosphamide 500mg/m2"
11565674|NCT00890942|Placebo Comparator|normal saline|
11565675|NCT00890929|Experimental|Azacitidine followed by lenalidomide|Dose escalation then dose expansion
11565676|NCT00890916|Experimental|Neuroprosthesis System|Receives implanted device for hand function.
11565677|NCT00890903||NSCLC|Patients with advanced non-small cell lung cancer
11565678|NCT00890903||MBC|Female patients with metastatic, Anthracycline-resistent breast cancer
11565679|NCT00890890|Experimental|Avagacestat (50 mg)|
11565680|NCT00890890|Placebo Comparator|Placebo|
11565681|NCT00890877|Experimental|1|
11565682|NCT00890877|Experimental|2|
11565683|NCT00890877|Experimental|3|
11565684|NCT00890877|Experimental|4|
11565685|NCT00890864|Active Comparator|1|Women aged 47-49 invited for breast screening
11565686|NCT00890864|Active Comparator|2|Women aged 71-73 invited for breast screening
11565687|NCT00890851|Other|Procedure TUNA|
11565688|NCT00890838|Active Comparator|Omegaven|will receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperatively
11565689|NCT00890838|No Intervention|Without Omegaven|will not receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperativel
11565690|NCT00890825|Active Comparator|AZD6244 + Docetaxel|AZD6244 75 mg bd + Docetaxel 75 mg/m^2
11565691|NCT00890825|Placebo Comparator|Placebo + Docetaxel|Placebo + Docetaxel 75 mg/m^2
11565692|NCT00890812||Factors VIII, IX and XI levels measured|Case group
11565693|NCT00890812||Non Stroke patients|This is the control group. This group represents patients who were initially evaluated for stroke.
11565694|NCT00890799|Experimental|occluders|Shanghai pmVSD occluder (LEPU Medical Tech-nology Co, Ltd, Beijing, China) was used in this study.
11565695|NCT00890786|Experimental|HGG|Temozolomide, Bevacizumab, and Irinotecan according to the treatment schedule in the intervention section.
11565696|NCT00890786|Experimental|DIPG|Temozolomide, Bevacizumab, and Irinotecan according to the treatment schedule in the interventions section.
11565697|NCT00890760|Experimental|Group 1|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 3 weeks after boost
11565698|NCT00890760|Experimental|Group 2|AdCh63 ME-TRAP alone followed by sporozoite challenge 3 weeks later
11565699|NCT00890760|Experimental|Group 3|Non-vaccinated Control for Groups 1 and 2 challenged with sporozoite
11565700|NCT00890760|Experimental|Group 4|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 11 weeks after boost
11565701|NCT00890760|Experimental|Group 5|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 3 weeks after boost
11565702|NCT00890760|Experimental|Group 6|Protected volunteers from Group 1 re-challenged with sporozoite after 6 months
11565703|NCT00890760|Experimental|Group 7|Non vaccinated control for Groups 4-6, 8-10 challenged with sporozoite
11565704|NCT00890760|Experimental|Group 8|3 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 8 weeks interval each followed by sporozoite challenge 3 weeks after last vaccination
11565705|NCT00890760|Experimental|Group 9|2 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 8 weeks interval followed by sporozoite challenge 3 weeks after last vaccination
11565706|NCT00890760|Experimental|Group 10|3 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 4 weeks interval each followed by sporozoite challenge 3 weeks after last vaccination
11565707|NCT00890747|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11565708|NCT00890734|Experimental|1|
11565709|NCT00890734|Placebo Comparator|2|
11565710|NCT00890721|Experimental|SKY0402|During the hemorrhoidectomy, 30cc of SKY0402 is injected into the wound.
11565711|NCT00890721|Placebo Comparator|Placebo|During the hemorrhoidectomy, 30cc Placebo injected into the wound.
11565712|NCT00890708|No Intervention|non-TDM of voriconazole|conventional dose
11565713|NCT00890708|Experimental|TDM of voriconazole|
11565714|NCT00890695|Active Comparator|Ready to use supplementary food (RUSF)|The RUSF intervention consists of a food paste made of maize, soya, sorghum, vegetable oil, sugar, dried skim milk and vitamin/mineral premix, prepared by VALID Nutrition in collaboration with Insta Products, Kenya in accordance with composition specified by the latest WHO expert consultation in 2008. Children in the intervention arm receive 4 weeks supply of RUSF. The amount supplied is based on the child's weight to give energy supplement of 100kcal per kg per day, equivalent to 25g RUSF per kg per day.
11565715|NCT00890695|No Intervention|Normal diet (standard of care)|For equity, parents or guardians of children in the usual diet arm will be given 2 bags of maize meal(4Kg) for family consumption instead of RUSF. All parents and carers in both arms will also receive standard nutritional advice as specified in the current WHO IMCI handbook.
11565716|NCT00890682|Experimental|Sky0402|Injection of Study Drug
11565717|NCT00890682|Placebo Comparator|Placebo|Injection of study drug
11565718|NCT00890669|Experimental|PD Group|Nine subjects with idiopathic PD, previously diagnosed by one specialist physician participated in this study.
11565719|NCT00890656|Experimental|Augmented Hyper-CVAD|Hyper-CVAD (courses 1, 3, 5, and 7) alternated with high-dose methotrexate/ara-C (courses 2, 4, 6, and 8) administered on day 21; Hyper-CVAD = Cyclophosphamide, Vincristine, Doxorubicin, Decadron + Pegaspargase.
11565720|NCT00890643|Experimental|Arm 1|Persons with PTSD
11565721|NCT00890643|Placebo Comparator|Arm 2|Persons with PTSD
11565722|NCT00890630|Active Comparator|Oxytocin|Induction of Labour with Oxytocin Alone
11565723|NCT00890630|Experimental|Intracervical Catheter|Insertion of an Intracervical Balloon Catheter plus administration of oxytocin for labour induction.
11565724|NCT00890617|Experimental|Prednisone & Cryotherapy|"Prednisone taken:
~20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure"
11565725|NCT00890604|Other|1|Usual Care
11565726|NCT00890604|Experimental|2|Normothermia Protocol
11565727|NCT00890591|Experimental|Treatment|
11565728|NCT00890578||1-abdominal|half abdominal surgeries (20 patients out of 40)
11565729|NCT00890578||2-breast|half breast surgeries (20 out of 40)
11565730|NCT00890565|Experimental|Treatment A: Sancuso® patch|Treatment A: Sancuso® patch (Day 1) and placebo IV (Day 3)
11565731|NCT00890565|Experimental|Treatment B: IV Granisetron 10 mcg/kg|Treatment B: placebo patch (Day 1) and granisetron IV (Day 3)
11565732|NCT00890565|Placebo Comparator|Treatment C: Matching placebo patch|Treatment C: placebo patch (Day 1) and placebo IV (Day 3)
11565733|NCT00890565|Active Comparator|Treatment D: Oral Moxifloxacin 400 mg|Treatment D: placebo patch (Day 1) and oral moxifloxacin (Day 3).
11565734|NCT00890552|Experimental|Lenalidomide+Melphalan+Dexamethasone|Patients received lenalidomide 10 mg/day orally on days 1-21, melphalan 0.18 mg/kg orally on days 1-4, and dexamethasone 40 mg orally once weekly of a 28-day cycle (MDR treatment).
11565735|NCT00890539|Experimental|Quadrupling|methacholine challenge using quadrupling concentrations
11565736|NCT00890539|Active Comparator|doubling|doubling concentrations of methacholine
11565737|NCT00890526|Experimental|1|Full treatment = Counseling + sound therapy.
11565738|NCT00890526|Experimental|2|Counseling + placebo sound therapy.
11565739|NCT00890526|Experimental|3|No Counseling + Sound Therapy
11565740|NCT00890526|Placebo Comparator|4|No counseling + Placebo sound therapy.
11565741|NCT00890500|Active Comparator|Group 1|2 umbilical cord units: Second cord blood unit modulated with ProHema
11565742|NCT00890500|Active Comparator|Group 2|2 umbilical cord units: First cord blood unit modulated with ProHema
11565743|NCT00890487|Other|hyaluroni acid pill|
11565744|NCT00890474|Experimental|Moxibustion|
11565745|NCT00890474|No Intervention|Control|
11565746|NCT00890461||Defibrillator|The subject population will be obtained by approaching the Principal and Co- Investigators' patients who have been referred for ICD implantation or who already have an ICD. This population ranges in age from 18 years on, and includes both males and females. A maximum of 50 subjects will be enrolled in this study.
11565747|NCT00890448||Lapaquistat acetate participants|
11565748|NCT00890422|Experimental|1FSME vaccination|2 vaccination on day 0
11565749|NCT00890422|Experimental|2 FSME vaccination|1 vaccination on day 0 and one vaccination on day 4
11565750|NCT00890422|Experimental|3 FSME vaccination|2 vaccinations on day 0 and 1 vaccination on day 4
11565751|NCT00890409|No Intervention|Normothermia|Rectal temperature was maintained at 36.0-37.5 degree C.
11565752|NCT00890409|Experimental|Hypothermia|The group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
11565753|NCT00890396||Active Follow-up|An active follow-up involved the performance of many of the laboratory tests and procedures done during BABY HUG clinical trials study. These included, but not limited to, serial laboratory parameters that were not part of routine clinical care such as Hgb F levels, pitted cell count, Howell-Jolly Body determination, a liver-spleen scan, diethylenetriaminepentaacetic acid (DTPA) glomerular filtration rate (GFR) measurement, creatinine clearance, Cystatin C, urine concentrating ability, transcranial Doppler, and neuropsychological testing.
11565754|NCT00890396||Passive Follow-up|A passive follow-up involved the abstraction of clinical data from the medical record. Results of physical examinations and laboratory tests performed as part of routine clinical care were recorded.
11565755|NCT00890383|No Intervention|Crystalloid only|patients will receive crystalloid fluids only for volume therapy of severe trauma
11565756|NCT00890383|Active Comparator|Colloid + Crystalloid arm|Goal directed volume therapy for severe trauma resuscitation
11565757|NCT00890370|Other|1|Active cycle of breathing techniques
11565758|NCT00890370|Other|2|Autogenic drainage
11565759|NCT00890370|Other|3|R-C Cornet
11565760|NCT00890370|Other|4|Flutter
11565761|NCT00890370|Other|5|PEP
11565762|NCT00890357||Triptan User|
11565763|NCT00890357||Triptan Discontinued|
11565764|NCT00890331|Active Comparator|Diabetes Education|
11565765|NCT00890331|Experimental|TeamWork CS Sessions|
11565766|NCT00890318|Other|1|Healthy volunteers, receiving daily dose of 80 mg ABT-072 or placebo, QD for 10 days; and on Study Day 11 receiving a single dose of 80 mg ABT-072 or placebo + 400 mg ketoconazole
11565767|NCT00890318|Other|2|Healthy volunteers, receiving 160 mg ABT-072 or placebo, QD for 10 days.
11565768|NCT00890318|Other|3|Healthy volunteers, receiving 320 mg ABT-072 or placebo, QD for 10 days.
11565769|NCT00890305|Experimental|CT-011 in combination with FOLFOX|"CT-011 (3 mg/kg) administered intravenously every 4 weeks for 4 weeks and every 12 weeks thereafter until disease progression or maximum tolerance.
~FOLFOX (FOLFOX4 or mFOLFOX6) administered 7 days after the first administration of CT-011 and repeated every 14 days for up to 24 cycles. At the end of FOLFOX therapy, patients who have not progressed will be eligible for maintenance chemotherapy with 5-FU/leucovorin at the same dose and schedule until disease progression or study drug discontinuation."
11565770|NCT00890305|Active Comparator|FOLFOX|FOLFOX (FOLFOX-4 or mFOLFOX6) administered every 14 days for up to 24 cycles. At the end of FOLFOX therapy, patients who have not progressed will be eligible for maintenance chemotherapy with 5-FU/leucovorin at the same dose and schedule until disease progression or study drug discontinuation.
11565771|NCT00890279|Experimental|Cilnidipine|The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group A, blood pressure is controlled by Candesartan plus Cilnidipine.
11565772|NCT00890279|Active Comparator|Imidapril|The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group B, blood pressure is controlled by Candesartan plus Imidapril.
11565773|NCT00890253|Experimental|CNI-free Immunosuppression|Immunosuppression after OLT including basiliximab, enteric-coated mycophenolate sodium (EC-MPS), and everolimus.
11565774|NCT00890227|Active Comparator|Traditional technique|All level open instrumented posterior spinal fusions
11565901|NCT00889122|Experimental|Lifestyle Counseling|
11565775|NCT00890227|Active Comparator|Minimally invasive technique|Open surgery for all the levels except the proximal segment (most proximal instrumented level) where minimally invasive technique will be used.
11565776|NCT00890214|Active Comparator|1 prostacyclin group|prostacyclin analogue (PGIA) used as circuit anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in acute kidney failure patients
11565777|NCT00890214|Active Comparator|2 heparin group|unfractionated heparin used as circuit anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in acute kidney failure patients
11565778|NCT00890201||Normal Gallbladder|"Patients with normal gallbladder (without gallstones) evidenced by preoperative ultrasonography (and postoperative biopsy) submitted to elective gastroesophageal surgery (gastrectomy for gastric cancer, bariatric surgery or esophageal surgery such as Nissen plicature or miotomy for achalasia).
~The pancreaticobiliary junction must be normal as evidenced by intraoperative cholangiography. Preoperative values of amylase and lipase must be normal."
11565779|NCT00890201||Gallbladder with gallstones|"Patients submitted to elective cholecystectomy for diseased gallbladders (gallbladder with gallstones evidenced by preoperative ultrasound).
~The pancreaticobiliary junction must be normal as evidenced by intraoperative cholangiography and the preoperative amylase and lipase levels must also be normal."
11565780|NCT00890188|Experimental|THALIDOMIDE and UFUR|
11565781|NCT00890175|Experimental|Inhaled loxapine @ 0 & 10 h|Inhalation of 10 mg of loxapine at 0 and 10 hours
11565782|NCT00890175|Placebo Comparator|Inhaled placebo @ 2 & 10 hours|Inhalation of 0 mg of loxapine (placebo) at 0 and 10 hours
11565783|NCT00890162|Active Comparator|Omalizumab|Subjects will receive two doses of Omalizumab while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months.
11565784|NCT00890162|Placebo Comparator|Placebo|Subjects will receive two doses of placebo while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months.
11565785|NCT00890149|Experimental|Ondansetron|Ondansetron + BASICS Plus
11565786|NCT00890149|Placebo Comparator|Placebo|Placebo + BASICS Plus
11565787|NCT00890123|Active Comparator|Omegaven|Patients in this arm will receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperatively.
11565788|NCT00890123|No Intervention|Without Omegaven|Patients will not receive IV Omega 3 fatty acids
11565789|NCT00890110|Experimental|Autologus vaccination with suntinib|Combination of autologous dnp irradiated modified cells with sunitinib treatments
11565790|NCT00890097|Experimental|AL-8309B 1.0%|AL-8309B 1.0% Ophthalmic Solution, 1 drop in each eye twice daily for 30 months, up to a maximum of 36 months
11565791|NCT00890097|Experimental|AL-8309B 1.75%|AL-8309B 1.75% Ophthalmic Solution, 1 drop in each eye twice daily, for 30 months up to a maximum of 36 months
11565792|NCT00890097|Placebo Comparator|Vehicle|AL-8309B Vehicle, 1 drop in each eye twice daily, for 30 months up to a maximum of 36 months
11565793|NCT00890084||Group1|
11565794|NCT00890071||Acute circulatory failure|Patients for whom the decision to give fluids was taken because the presence of one or more clinical signs of acute circulatory failure.
11565795|NCT00890058||Cases|Postmenopausal breast cancer patients with hand pain receiving aromatase inhibitors
11565796|NCT00890058||Controls|Postmenopausal breast cancer patients with hand pain not receiving aromatase inhibitors
11565797|NCT00890045|Active Comparator|Control graft|Conventional ePTFE hemodialysis graft
11565798|NCT00890045|Experimental|HeRO Vascular Access Device|HeRO Vascular Access Device
11565799|NCT00890032|Experimental|BTSC mRNA-loaded DCs|BTSC mRNA-loaded DCs administered intradermally weekly for first 3 vaccines, then monthly until progression or withdrawal.
11565800|NCT00890019|Experimental|1A, 2A, 3A, 4A, 5A, 6A, 7A|AdCh63 ME-TRAP
11565801|NCT00890019|Experimental|1B, 2B, 3B, 4B, 6B, 7B, 7C|AdCh63 ME-TRAP; MVA ME-TRAP
11565802|NCT00890006|Experimental|MRI + CBCT in prostate cancer|
11565803|NCT00889980||Melanoma|Patients with primary melanoma
11565804|NCT00889967|Experimental|1|Ciprofloxacin for Inhalation 100 mg/day by inhalation
11565805|NCT00889967|Experimental|2|Ciprofloxacin for inhalation 150 mg/day by inhalation
11565806|NCT00889967|Placebo Comparator|Placebo|Placebo by inhalation
11565807|NCT00889954|Experimental|TGFBeta resistant HER2/EBV-CTLs|"The following dose levels will be evaluated:
~Dose Level 1: 1 x 10^4 cells/m^2
~Dose Level 2: 3 x 10^4 cells/m^2
~Dose Level 5: 1 x 10^6 cells/m^2
~Dose Level 6: 3 x 10^6 cells/m^2
~Dose Level 7: 1 x 10^7 cells/m^2
~Dose Level 8: 3 x 10^7 cells/m^2
~Dose Level 9:1 x 10^8 cells/m^2"
11565808|NCT00889941|Active Comparator|small|
11565809|NCT00889941|Active Comparator|medium|
11565810|NCT00889941|Active Comparator|large|
11565811|NCT00889928|Experimental|cholecystectomy|transvaginal cholecystectomy
11565812|NCT00889915|Active Comparator|1|Participants will receive methylphenidate transdermal system.
11565813|NCT00889915|Active Comparator|2|Participants will receive lisdexamfetamine dimesylate.
11565814|NCT00889915|Active Comparator|3|Participants will receive osmotic-release oral system methylphenidate (OROS MPH).
11565815|NCT00889915|Active Comparator|4|Participants will receive mixed amphetamine salts extended release.
11565816|NCT00889889|Experimental|1|
11565817|NCT00889889|Placebo Comparator|2|
11565818|NCT00889876|Experimental|Metformin|
11565819|NCT00889876|Experimental|Exercise|
11565820|NCT00889863|Experimental|Canakinumab|In Part I participants received open label 4 mg/kg canakinumab subcutaneous injection every 4 weeks for up to 32 weeks. For the first 8 weeks Part Ia (4 weeks) and Ib (4 weeks) patients maintained a stable oral steroid dose (prednisone or equivalent) followed by Ic an up to 20 week steroid tapering period and then Id a 4 week stable steroid dose period. Participants were then randomized to receive either 4 mg/kg canakinumab subcutaneous injection or placebo comparator in Part II and remained on the stable oral steroid dose for 24 weeks. At 24 weeks in Part II participants with a >0.2 mg/kg and ≤ 0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤ 0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.
11565821|NCT00889863|Placebo Comparator|Placebo|Participants in Part II received placebo matching canakinumab subcutaneous injection every 4 weeks. At 24 weeks in Part II participants with a >0.2 mg/kg and ≤0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.
11565822|NCT00889850|Active Comparator|1|Oral fasted administration of one capsule of 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
11565823|NCT00889850|Active Comparator|2|Oral fasted administration of one tablet of INexium 40 mg MUPS tablets (AstraZeneca, France)
11565824|NCT00889850|Active Comparator|3|Oral fed administration of one capsule of 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
11565825|NCT00889850|Active Comparator|4|Oral fed administration of one tablet of INexium 40 mg MUPS tablets (AstraZeneca, France)
11565826|NCT00889837|Experimental|Inhaled Loxapine|Staccato Loxapine, 10 mg doses x 2, 10 hours apart
11565827|NCT00889837|Placebo Comparator|Inhaled Placebo|Staccato Placebo,inhalations x 2, 10 hours apart
11565828|NCT00889824|Experimental|prosthesis group|balance prosthesis
11565829|NCT00889785|Active Comparator|1 (Usual Care)|Patients will continue to review usual care in the diabetes clinic. Patients will receive monthly phone calls as an active control condition.
11565830|NCT00889785|Experimental|Intervention|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
11565831|NCT00889720|Other|Smoking cessation tratment including varenicline|
11565832|NCT00889707|Experimental|Active Drug|PRX302
11565833|NCT00889707|Placebo Comparator|Placebo|Placebo
11565834|NCT00889681|Experimental|Ablation|All study subjects will be receive cryo ablation with the experimental devices and, optionally, an Atrial Fibrillation Drug.
11565835|NCT00889668|Experimental|Experimental|subjects with a diagnosis of type 1 or 2 diabetes; GlucoTrack results will be compared with the readings from approved invasive glucose meter device.
11565836|NCT00889655|Active Comparator|Golytely|216 patients at random will provided a prescription for the standard 4 L golytely preparation as the bowel cleanser for their colonoscopy
11565837|NCT00889655|Experimental|MiraLax|216 patients will be randomized to take 238 gm of miralax mixed with 64 oz of gatorade for their bowel cleanser
11565838|NCT00889642|Active Comparator|Active|Contains Lidocaine and Epinephrine
11565839|NCT00889642|Placebo Comparator|Placebo|Contains Epinephrine
11565840|NCT00889629|Experimental|Doxercalciferol|Patients are randomized using an A B C D randomization scheme in which the patient and the primary investigator are blinded but the study staff is not. Active group receives doxercalciferol (Hectorol) 1mcgwith active titration based on intact PTH plus 25-OH Vitamin D3 (cholecalciferol) 400 IU. Safety labs and end point labs are monitored as per protocol, with the opportunity to increase the dose of doxercalciferol if target PTH value is not achieved by the predetermined midpoint.
11565841|NCT00889629|Placebo Comparator|Cholecalciferol|Patients are randomized using an A B C D randomization scheme in which the patient and the primary investigator are blinded but the study staff is not. Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol) plus 25-OH Vitamin D3 (cholecalciferol) 400IU. Safety labs and end point labs are monitored as per protocol, with the opportunity to increase the dose of doxercalciferol placebo if target PTH value is not achieved by the predetermined midpoint.
11565842|NCT00889603||1|
11565843|NCT00889590|Experimental|Zoledronic acid|Adjuvant zoledronic acid
11565844|NCT00889590|No Intervention|Control|Standard care
11565845|NCT00889538|Placebo Comparator|Placebo|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
11565846|NCT00889538|Active Comparator|Glutathione|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
11565847|NCT00889538|Active Comparator|Glutathione, Vit C and NAC|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
11565848|NCT00889525|Experimental|Cabergoline|
11565849|NCT00889512|Active Comparator|Luveris Fixed dose|Participants in this arm will take Gonal F® and the same dose of Luveris® throughout the cycle. Their dose of Gonal F® will be adjusted throughout the cycle based on their response to the medication. The Luveris® dose will remain constant throughout.
11565850|NCT00889512|Experimental|Luveris increasing dose|Patients assigned to this group will gradually reduce the Gonal F® dose while increasing the Luveris® dose during the cycle, which more closely mimics the natural menstrual cycle.
11565851|NCT00889499|Placebo Comparator|Crossover study|Crossover study
11565852|NCT00889499|Placebo Comparator|2|Crossover Study
11565853|NCT00889499|Placebo Comparator|3|Crossover Study
11565854|NCT00889486|Placebo Comparator|Placebo|Four placebo capsules taken orally once per day for 28 days
11565855|NCT00889486|Experimental|10 mg TZP-102|One 10 mg TZP-102 Capsule and three placebo capsules taken orally once per day for 28 days
11565856|NCT00889486|Experimental|20 mg TZP-102|Two 10 mg TZP-102 Capsules and two placebo capsules taken orally once per day for 28 days
11565857|NCT00889486|Experimental|40 mg TZP-102|Four 10 mg TZP-102 Capsules taken orally once per day for 28 days
11565858|NCT00889473|Experimental|Larazotide acetate 1 mg|larazotide acetate 1 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
11565859|NCT00889473|Placebo Comparator|Placebo|placebo capsules TID + 900 mg gluten capsules TID for 6 weeks
11565860|NCT00889460|Placebo Comparator|1|Placebo group
11565861|NCT00889460|Experimental|2|rBet v 1 tablets
11565862|NCT00889434|Active Comparator|EGCG|Two cycles comprising 28 days of continuous daily treatment with EGCGgiven 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
11565863|NCT00889434|Active Comparator|Tocotrienol|
11565864|NCT00889434|Other|EGCG + Tocotrienol|Combination of both arms
11565865|NCT00889421|Experimental|Treatment|Patients receiving apremilast.
11565866|NCT00889408|Experimental|Treatment|DT2219ARL at assigned dose IV over 4 hours in the outpatient setting on day 1, 3, 5, and 8
11565867|NCT00889395|No Intervention|Home visit|Patients will have monthly home visits during which health educational talks will be given
11565868|NCT00889382|Experimental|Phase 1 Arm A|Intermittent OSI-906 Once Daily (QD) on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15 (except Treatment Period 1 (TP 1); in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22)
11565902|NCT00889109||1|Open Capsular Shift
11565869|NCT00889382|Experimental|Phase 1 Arm B1|Continuous OSI-906 Twice Daily (BID) (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15;(except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15 and 22)
11565870|NCT00889382|Experimental|Phase 1 Arm B2|Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 (except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 5 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22); (additional PK sampling on Days 9 or 13 0r 14 for TP 1)
11565871|NCT00889382|Experimental|Phase 1 Arm B3|Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 with no separation in OSI-906 and paclitaxel dosing (except TP 1; in TP 1 continuous OSI-906 dosing 2 hours prior to the initiation of paclitaxel infusion on Day 8 only, with paclitaxel on Days 8, 15, and 22, and additional PK sampling on Day 9 or 13 or 14)
11565872|NCT00889382|Experimental|Phase 2 Arm A|Intermittent OSI-906 QD on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15
11565873|NCT00889382|Experimental|Phase 2 Arm B|Continuous OSI-906 BID from Day 1 onwards with paclitaxel on Days 1, 8, and 15
11565874|NCT00889382|Experimental|Phase 2 Arm C|Paclitaxel on Days 1, 8, and 15
11565875|NCT00889382|Experimental|Phase 2 Arm C Roll-over|Continuous OSI-906 BID from Day 1 onwards
11565876|NCT00889369|Experimental|A|Use of duloxetine, flexible dose (60-120mg/day) for 8 weeks, following a 2-week placebo lead-in phase
11565877|NCT00889356|Experimental|Clindamycin 100mg and Ketoconazole 400mg|
11565878|NCT00889356|Active Comparator|Tetracycline 100mg and Amphotericin B 50mg|
11565879|NCT00889343|Experimental|1|
11565880|NCT00889343|Placebo Comparator|2|
11565881|NCT00889330|Experimental|alcaftadine ophthalmic solution|active treatment: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).
11565882|NCT00889330|Placebo Comparator|inactive ophthalmic solution vehicle|Placebo, vehicle: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).
11565883|NCT00889317||healthy adults|
11565884|NCT00889304||A|HTO cohort
11565885|NCT00889265|Experimental|CopiOs Pericardium Membrane|Subject's study site must exhibit a partially edentulous ridge of the maxilla or mandible with at least one tooth-span in length and less than 5.5mm in its smallest buccolingual dimension as measured by ridge-mapping calipers.
11565886|NCT00889252|Experimental|K-Lens|Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug
11565887|NCT00889252|Placebo Comparator|Placebo Lens|Placebo lens
11565888|NCT00889239|Experimental|A|ceramic crown
11565889|NCT00889226|Experimental|Pitavastatin Group|
11565890|NCT00889226|Active Comparator|Atorvastatin Group|
11565891|NCT00889213|Experimental|Patch and glue arm|Randomized patients to the patch and glue arm will undergo placement of a falciform ligament tissue patch and fibrin glue to the resection margin of the remnant pancreas following distal pancreatectomy
11565892|NCT00889213|Active Comparator|stapled /sutured pancreatic closure|
11565893|NCT00889200|Experimental|Open-label Eszopiclone|Standard dosing of drug for 6 weeks for insomnia
11565894|NCT00889187|Experimental|Phase 1 Cohort 1: Photon Rad (30 Gy/12 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:
~At dose level 1, a total dose of 30 Gy in 10 fractions (3 Gy/day) was prescribed to the 95% isodose and administered 5 days per week over 12 days.
~Chemotherapy:
~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.
~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
11565895|NCT00889187|Experimental|Phase I Cohort 2: Photon Rad (25 Gy/11 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:
~At dose level 2, a total dose of 25 Gy in 5 fractions was prescribed to the 95% isodose and administered at 5 Gy per fraction over 11 days.
~Chemotherapy:
~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.
~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
11565896|NCT00889187|Experimental|Phase I Cohort 3: Photon Rad (25 Gy/5 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:
~At dose level 3, a total dose of 25 Gy in 5 fractions was prescribed to the 95% isodose and administered at 5 Gy per fraction over 5 days.
~Chemotherapy:
~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.
~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
11565897|NCT00889187|Experimental|All Phase I: Photon Rad+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:
~All Phase I participants received the radiation regimen according to the established dose escalation schedule.
~Chemotherapy:
~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.
~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
11565898|NCT00889187|Experimental|Phase II: Photon Rad (MTD)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:
~Phase II participants received the radiation regimen established in the Phase I study (MTD).
~Chemotherapy:
~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.
~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
11565899|NCT00889148|Experimental|Gabapentin|600mg of gabapentin will be given orally two hours preoperatively and 200mg for 3 times a day after surgery for three days.
11565900|NCT00889148|Placebo Comparator|Placebo|
11565903|NCT00889109||2|Arthroscopic Bankart Repair
11565904|NCT00889109||3|Healthy controls
11565905|NCT00889096|Active Comparator|study day 1 propanolol|Oral administration of 80 mg propranolol (1 capsule containing two Obsidan® tablets: 2 x 40 mg propranolol) according to randomization list with 240 ml. Determination of blood pressure, heart rate over 4 hours and until return to the initial baseline values.
11565906|NCT00889096|Placebo Comparator|study day 1 placebo|Oral administration of placebo (1 capsule containing two placebo tablets) according to randomization list with 240 ml. Determination of blood pressure, heart rate over 4 hours and until return to the initial baseline values.
11565907|NCT00889083||Control|Non septic patients needing hepatic surgery
11565908|NCT00889083||Sepsis|Septic patients needing surgery for peritonitis
11565909|NCT00889070||1|Stage 1 (Pilot Study) All infants enrolled in the pilot stage and completing baseline screening will be evaluated as the analyzable set.
11565910|NCT00889057|Experimental|sorafenib|
11565911|NCT00889044|Experimental|clopidogrel by chewing|
11565912|NCT00889044|Placebo Comparator|Placebo|
11565913|NCT00889031||No Treatment|
11565914|NCT00889018|Active Comparator|group 1|chemotherapy using carboplatin 560mg/m2
11565915|NCT00889018|Experimental|group 2|chemotherapy using 750mg/m2 carboplatin
11565916|NCT00889005|Experimental|Cognitive Behavioral Therapy|Five sessions of trauma-focused, telephone based cognitive behavioral therapy, followed by assessment and referral to clinical treatment if needed.
11565917|NCT00889005|No Intervention|Waitlist control group|Five weeks without active intervention, followed by assessment and referral to clinical treatment if needed.
11565918|NCT00888992|No Intervention|Group A|Receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls.
11565919|NCT00888992|Experimental|Group B|
11565920|NCT00888992|Experimental|Group C|
11565921|NCT00888979|Experimental|Nicotrol with Behavioral Counseling|Nicotrol Inhaler: 10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
11565922|NCT00888966||Out of hospital cardiac arrest|Out of hospital cardiac patients successfully resuscitated and admitted to ICU
11565923|NCT00888953|Experimental|Intervention|Residents living in nursing homes allocated to intervention group. Assessment of risk factors. Implementation of a multifactorial tailored program to prevent falls.
11565924|NCT00888953|Other|Control|Residents living in nursing homes allocated to control group. Assessment of risk factors. Receive the usual attention.
11565925|NCT00888940|Experimental|ecallantide|
11565926|NCT00888940|Active Comparator|Cyklokapron(R)|
11565927|NCT00888927|Experimental|KW-0761|open label, dose escalation(0.1, 0.3, 1.0 mg/kg)
11565928|NCT00888914|Active Comparator|Dose A|RT001 Dose A; Active Comparator
11565929|NCT00888914|Active Comparator|Dose B|RT001 Dose B; Active Comparator
11565930|NCT00888914|Active Comparator|Dose C|RT001 Dose C; Active Comparator
11565931|NCT00888914|Active Comparator|Dose D|RT001 Dose D; Active Comparator
11565932|NCT00888914|Placebo Comparator|Dose E|RT001 Dose E; Vehicle Comparator
11565933|NCT00888901|Experimental|1|Patients on eltrombopag
11565934|NCT00888901|Active Comparator|2|Patients on corticosteroids
11565935|NCT00888901|No Intervention|3|Untreated patients
11565936|NCT00888888||Cohort: Patients with colonic resections|Colonic resections in patients submitted to appendicectomy for suspected acute appendicitis
11565937|NCT00888875|Experimental|1|Computer randomized insertion of the i-gel. Intubation fiberoptically of a tracheal tube
11565938|NCT00888875|Active Comparator|2|Computer randomized insertion of the i-gel. Intubation fiberoptically of a tracheal tube
11565939|NCT00888862|Experimental|A|Use of desvenlafaxine succinate, flexible dose (50-100mg/day)
11565940|NCT00888849|Experimental|Stapling|
11565941|NCT00888849|Active Comparator|Suturing|4 layered hand-sutured anastomosis
11565942|NCT00888836|Active Comparator|GBP|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 years undergo gastric bypass
11565943|NCT00888836|Active Comparator|BPD 2|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 years undergo bilio-pancreatic diversion
11565944|NCT00888836|Active Comparator|Med Ter3|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 yearsundergo medical therapy
11565945|NCT00888797|Active Comparator|1|Perioperative Propranolol and Etodolac
11565946|NCT00888797|Placebo Comparator|2|Placebo
11565947|NCT00888784|Active Comparator|1. Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in the gastric varix
11565948|NCT00888784|Placebo Comparator|2. Beta-blocker|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
11565949|NCT00888771||1|
11565950|NCT00888771||2|
11565951|NCT00888771||3|
11565952|NCT00888771||4|
11565953|NCT00888758|Experimental|1|
11565954|NCT00888758|Active Comparator|2|
11565955|NCT00888745|Experimental|1|
11565956|NCT00888745|Placebo Comparator|2|
11565957|NCT00888732|Experimental|Insulin therapy|Insulin Aspart, Biphasic Insulin Aspart 70 and 50 & Fast-acting Human Insulin
11565958|NCT00888719|Experimental|CWP-0403 50mg|
11565959|NCT00888719|Experimental|CWP-0403 100mg|
11565960|NCT00888719|Placebo Comparator|placebo|
11565961|NCT00888706|Active Comparator|1|
11565962|NCT00888706|Active Comparator|2|
11565963|NCT00888706|Active Comparator|3|
11565964|NCT00888706|Experimental|4|
11566516|NCT00884663|Placebo Comparator|3 Placebo|
11565965|NCT00888693|Experimental|1|ABT-288 vs placebo capsules administered orally once daily for 14 days
11565966|NCT00888693|Experimental|2|ABT-288 vs placebo capsules administered orally once daily for 14 days
11565967|NCT00888693|Experimental|3|ABT-288 vs placebo capsules administered orally once daily for 14 days
11565968|NCT00888693|Experimental|4|ABT288 vs placebo administered orally once daily for 14 days
11565969|NCT00888693|Experimental|5|ABT-288 vs placebo administered orally once daily for 14 days
11565970|NCT00888693|Experimental|6|ABT-288 vs placebo administered orally once daily for 14 days
11565971|NCT00888693|Experimental|7|ABT-288 vs placebo administered orally once daily for 14 days
11565972|NCT00888693|Experimental|8|ABT-288 vs placebo administered orally once daily for 14 days
11565973|NCT00888693|Experimental|9|ABT-288 vs placebo administered orally once daily for 14 days
11565974|NCT00888680|Experimental|BGC20-1531 200 mg|
11565975|NCT00888680|Experimental|BGC20-1531 400mg|
11565976|NCT00888680|Placebo Comparator|Lactose|
11565977|NCT00888667||ICD patient with frequent PVCs|
11565978|NCT00888654|Experimental|B-Dim, Radical Prosatectomy|"B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
~Radical Prostatectomy"
11565979|NCT00888641|No Intervention|Normothermia|After arterial clamping, no ice slush will be used
11565980|NCT00888641|Experimental|Hypothermia|After arterial clamping, the kidney will be surrounded in ice slush for 10 minutes
11565981|NCT00888628|Experimental|Islet transplant|"Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.
~For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.
~Induction therapy for subsequent transplants will be 2 doses of basiliximab.
~All patients will receive Etanercept to promote engraftment."
11565982|NCT00888615|Experimental|Treatment (paclitaxel, elesclomol sodium)|Patients receive paclitaxel IV over 1 hour and elesclomol sodium IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients who are currently on treatment must not be dosed with elesclomol sodium after 12/31/2015. All other study procedures, with the exception of elesclomol sodium administration and paclitaxel administration, should continue in accordance with protocol requirements. Any treatment given after 12/31/2015, including continuation of paclitaxel, will be considered off study. The body surface area (BSA) formula was used to determine the total dose of elesclomol equivalent to be administered. The elesclomol sodium dosing solution should be administered over one hour, using an administration set with a 0.22 micron end filter.
11565983|NCT00888602|Experimental|MM1 - Meal|3.4g psyllium served with a meal
11565984|NCT00888602|Experimental|MM2 - Meal|6.8 g psyllium served with a meal
11565985|NCT00888602|Experimental|MM2 (no Meal)|6.8 g psyllium consumed with no meal
11565986|NCT00888602|Sham Comparator|Meal Only|meal only
11565987|NCT00888576||1|Non-intervention
11565988|NCT00888550|Experimental|1. Splinting|
11565989|NCT00888550|Active Comparator|2. No Splinting|
11565990|NCT00888537|Experimental|Decision Aid|Patients in this arm will discuss medications to help the heart heal after a heart attack with the clinician and the help of the acute myocardial infarction (AMI) Choice Decision Aid.
11565991|NCT00888537|Active Comparator|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
11565992|NCT00888524|Experimental|General Practice (GP) in Physio plus Deep water running|A supplementation of Deep Water running exercises of 20 minutes in high intensity around aerobic thresholds estimated in individual land and water test
11565993|NCT00888524|Experimental|General Practice in Physio|A procedure of evidence-based physiotherapy is usual care in pragmatic trial
11565994|NCT00888511|Experimental|1|
11565995|NCT00888498|Placebo Comparator|Hands-On Control|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the experimental groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
11565996|NCT00888498|Experimental|Fast Stretching|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
11565997|NCT00888498|Experimental|Slow Stretching|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
11565998|NCT00888485|Experimental|Behavioral intervention|Group exposed to behavioral intervention program
11565999|NCT00888485|Active Comparator|Standard treatment|
11566000|NCT00888472|Experimental|1|
11566001|NCT00888459|Active Comparator|active|Self-help counseling material and 4 mg nicotine lozenges
11566002|NCT00888459|Placebo Comparator|2|self help counseling material and placebo nicotine lozenges
11566003|NCT00888446|Experimental|Group A|"Number of Vaccine Recipients: 10
~Dosage level 3 x 10^10 DRP
~Month 0 + 6"
11566004|NCT00888446|Experimental|Group B|"Number of Vaccine Recipients: 10
~Dosage level 3 x 10^10 DRP
~Month 0+12"
11566005|NCT00888446|Experimental|Group C|"Number of Vaccine Recipients: 10
~Dosage level 3 x 10^11 DRP
~Month 0+6"
11566006|NCT00888446|Experimental|Group D|"Number of Vaccine Recipients: 10
~Dosage level 3 x 10^11 DRP
~Month 0+12"
11566007|NCT00888446|Experimental|Group E|"Number of Vaccine Recipients: 10
~Dosage level 3 x 10^12 DRP
~Month 0+6"
11566008|NCT00888446|Experimental|Group F|"Number of Vaccine Recipients: 10
~Dosage level 3 x 10^12 DRP
~Month 0+12"
11566609|NCT00883896|Experimental|Arm 2|Part 1: 100 mg ILV-094 SC Q4W
11566009|NCT00888446|Experimental|Group G|"Number of Vaccine Recipients: 10
~Preselected for baseline AAV neutralization titers of <1/8
~Dosage level 3 x 10^12 DRP
~Month 0+6"
11566010|NCT00888446|Placebo Comparator|Placebo|3 volunteers will receive placebo matched to each experimental group.
11566011|NCT00888433|Experimental|Renal Denervation|Renal Denervation and maintenance of anti-hypertensive medications
11566012|NCT00888433|No Intervention|Control|Maintenance of anti-hypertensive medications with option for cross-over treatment after 6-months
11566013|NCT00888420||Medical Management|Patient satisfaction under current operational conditions
11566014|NCT00888420||Interventional Management|Patient satisfaction under the PSDA (Plan, do, study, act) performance improvement measures
11566015|NCT00888407|Experimental|HBV Screening|Small group educational session with HBV screening resources provided.
11566016|NCT00888407|Sham Comparator|Nutrition|Small group educational discussion, diet & nutrition resources provided.
11566017|NCT00888394|Experimental|1|
11566018|NCT00888394|Experimental|2|
11566019|NCT00888394|Experimental|3|
11566020|NCT00888394|Experimental|4|
11566021|NCT00888381|Experimental|Adults|Healthy volunteers aged 18 to 59 years
11566022|NCT00888381|Experimental|Older Adults|Healthy volunteers aged 60 years or older
11566023|NCT00888368|Experimental|Transpatellar Approach|
11566024|NCT00888368|Active Comparator|Suprapatellar Approach|
11566025|NCT00888355|Placebo Comparator|1|Placebo
11566026|NCT00888355|Experimental|2|Losartan 50 q.a.m.
11566027|NCT00888355|Experimental|3|Losartan 25 b.i.d.
11566028|NCT00888355|Experimental|4|Losartan 25 q.a.m.
11566029|NCT00888342|Active Comparator|1 supplementary oxygen|participant receives supplementary oxygen one night, polysomnography with capnography will be compared to no treatment another night
11566030|NCT00888342|Active Comparator|2 Zopiclone|participant receives 5 mg zopiclone one night, polysomnography with capnography will be compared to no treatment another night
11566031|NCT00888342|Active Comparator|3 Alcohol|participant receives 0,5 mg alcohol /kg body weight before sleep one night, polysomnography with capnography will be compared to no intervention another night
11566032|NCT00888329|Experimental|Aprepitant|40 mg aprepitant
11566033|NCT00888329|Placebo Comparator|Placebo|Placebo
11566034|NCT00888316||Without Iron Overload|Patients entering study without pre-HSCT iron-overload. Iron overload will be defined as liver ion concentration (LIC above normal (>1.8 mg/g) on R2 magnetic resonance imaging (MRI) of the liver.
11566035|NCT00888316||With Iron-Overload|Patients entering study with pre-HSCT iron-overload. Iron overload will be defined as liver ion concentration (LIC above normal (>1.8 mg/g) on R2 magnetic resonance imaging (MRI) of the liver.
11566036|NCT00888303|Active Comparator|A (dexamethasone)|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
11566037|NCT00888303|Placebo Comparator|B (Control)|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
11566038|NCT00888290|Experimental|Single arm|Crossover design. Participants will be getting either placebo or different doses of sodium bicarbonate during the study.
11566039|NCT00888251||Comprehensive weight management program|
11566040|NCT00888238|Experimental|Sitagliptin/Sitagliptin/Placebo|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
11566041|NCT00888238|Experimental|Sitagliptin/Placebo/Sitaglipitin|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
11566042|NCT00888238|Experimental|Placebo/Sitagliptin/Sitagliptin|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
11566043|NCT00888225|Experimental|Eccentric exercise|Group exposed to eccentric exercise treatment
11566044|NCT00888225|Active Comparator|Concentric exercise|Group exposed to concentric exercise treatment
11566045|NCT00888212|Experimental|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
11566046|NCT00888199|Experimental|Congenital/Traumatic|Individuals who were born with a limb deficiency or who have had a traumatic amputation.
11566047|NCT00888199|Experimental|Dysvascular/Diabetic|Individuals who have had an amputation as a result of vascular disease.
11566048|NCT00888186|Active Comparator|1. Duodopa optimal dose|
11566049|NCT00888186|Experimental|2. Duodopa 20% too high dose|
11566050|NCT00888186|Experimental|3. Duodopa 10% too low dose|
11566051|NCT00888186|Experimental|4. Duodopa 20% too low dose|
11566052|NCT00888186|Experimental|5. Duodopa 10% too high dose|
11566053|NCT00888173|Experimental|Treatment (brivanib alaninate)|Patients receive brivanib alaninate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11566054|NCT00888147||Fiber formula|This group will receive tube feeding formula that contains fiber.
11566055|NCT00888134|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID for 3 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11566056|NCT00888108|Experimental|docetaxel +ABT-263|
11566057|NCT00888095|Experimental|1|caudal Zona incerta (cZI)
11566058|NCT00888095|Experimental|2|Nucleus subthalamicus (STN)
11566059|NCT00888082|No Intervention|A|Patients receiving only adjuvant chemotherapy
11566060|NCT00888082|Experimental|B|Patient receiving goserelin acetate along with adjuvant chemotherapy
11566061|NCT00888069|Experimental|Low Dose CTAP101 Capsules|CTAP101 Capsules, 450 mcg dose
11566062|NCT00888069|Experimental|High Dose CTAP101 Capsules|CTAP101 Capsules, 900 mcg dose
11566063|NCT00888069|Experimental|CTAP101 Injection|IV injection, 448 mcg dose
11566064|NCT00888056|Experimental|ARM A|Bilateral chronic electrical stimulation of the hypothalamus/fornix
11566065|NCT00888043|Other|I|CNTO 95 and avastin
11566066|NCT00888030||2|CKD patients with normal p-cresol
11566067|NCT00888030||3|CKD patient with normal indoxyl sulfate
11566068|NCT00888030||4|CKD patients with high indoxyl sulfate
11566069|NCT00888030||1|CKD patients with high p cresol
11566070|NCT00888017||PPI group|This group of infants have received treatment with a PPI as ordered by their neonatologist during their hospital stay.
11566071|NCT00888017||non-PPI group|These infants did not receive PPIs during their hospital stay.
11566072|NCT00888004|Experimental|Active|
11566073|NCT00888004|Placebo Comparator|Placebo|
11566074|NCT00887991||Electric Pump 1 (ISIS Duo iQ Electric Breast Pump)|This is a parallel trial where subjects (mother of preterm infants) will be allocated to use one of two electric breast pumps to express milk. The use of electric breast pumps is routine practice on neonatal units in the UK.
11566075|NCT00887991||Electric Pump 2 (Medela Symphony Electric Breast Pump)|This is a parallel trial where subjects (mother of preterm infants) will be allocated to use one of two electric breast pumps to express milk. The use of electric breast pumps is routine practice on neonatal units in the UK.
11566076|NCT00887978|Placebo Comparator|Placebo|Identical placebo tablets to UT-15C, doses were titrated in the same manner
11566077|NCT00887978|Experimental|UT-15C SR|Doses were initiated at 0.25 mg BID and increased by 0.25 mg BID every three days (as clinically indicated based on tolerability and symptoms of PAH), to a max dose of 16 mg BID.
11566078|NCT00887965|Other|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
11566079|NCT00887952|Experimental|1|Partial removal of carious dentine. Carious dentine partial removal plus restoration in one session. The group is divided according to the filling material: amalgam or resin.
11566080|NCT00887952|Active Comparator|2|Stepwise excavation: Carious dentine removal performed in 2 steps: partial removal of carious dentine, indirect pulp capping (calcium hydroxide cement); temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling (amalgam or resin).
11566081|NCT00887939||1|Affected physical urticaria
11566082|NCT00887939||2|Healthy volunteer
11566083|NCT00887939||3|Unaffected relative
11566084|NCT00887926|Experimental|IMC-EB10 5 milligrams/kilogram (mg/kg)|All participants will receive intravenous infusions of IMC-EB10, with the dose depending on which cohort they are enrolled into.
11566085|NCT00887900|Experimental|1|Submitted to deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
11566086|NCT00887900|Active Comparator|2|Submitted to regular penetrating keratoplasty
11566087|NCT00887887||liver surgery|patients with benign or malignant hepatobiliary disease requiring partial hepatic resection
11566088|NCT00887874||A|
11566089|NCT00887861|Experimental|BGG492|
11566090|NCT00887861|Placebo Comparator|Placebo|
11566091|NCT00887848|Experimental|Lokomat training|Lokomat training
11566092|NCT00887848|Other|Waiting list|Lokomat training after waiting phase of 5 weeks
11566093|NCT00887835|Experimental|PERPOS™ PLS|Minimally invasive transfacet fixation with PERPOS™ PLS as an aid to fusion
11566094|NCT00887822|Experimental|Bevacizumab, Capecitabine and Cisplatin|Participants will receive bevacizumab 7.5 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every 3-week cycle in combination with capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily (total daily dose 2000 mg/m^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
11566095|NCT00887822|Placebo Comparator|Placebo, Capecitabine and Cisplatin|Participants will receive placebo matched to bevacizumab on Day 1 of every 3-week cycle in combination with capecitabine 1000 mg/m^2 orally twice daily (total daily dose 2000 mg/m^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
11566096|NCT00887809|Experimental|gemcitabine and docetaxel with bevacizumab|Patients will receive bevacizumab at 15 mg/kg on day 1 of each 21-day cycle intravenously over 30 minutes followed by a one hour (+30/-15 min) break. For cycles 1 through 6, gemcitabine will be administered at 900 mg/m2 over 90 minutes on day 1 and 8 of a 21-day cycle. Docetaxel will be administered at 75 mg/m2, over 60 minutes, on day 8. This will be followed by either 5 days of filgrastim or a single injection of pegfilgrastim. For cycles 7 and beyond, gemcitabine will be given at 800 mg/m2 over 30 minutes on day 1 and 8; docetaxel will be given at 35 mg/m2 over 30 minutes, also on days 1 and 8.
11566097|NCT00887783|Experimental|B|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)
11566098|NCT00887783|Active Comparator|A|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)
11566099|NCT00887770|Experimental|A|600mg AZD5672 + Moxifloxacin placebo
11566100|NCT00887770|Experimental|B|100mg AZD5672 + Moxifloxacin placebo
11566101|NCT00887770|Active Comparator|C|AZD5672 placebo + Moxifloxacin 400mg
11566102|NCT00887770|Placebo Comparator|D|AZD5672 placebo + Moxifloxacin placebo
11566103|NCT00887757|Experimental|gemcitabine +ABT-263|
11566104|NCT00887744|Other|Aperius Treatment Arm|Single Arm
11566105|NCT00887731||Part 1 group|Observational study with a convenience sample of ten (10) patients. PART 1 will end when at least 3 of 4 consecutive patients achieve the goal of less than six (6) operator required interruptions per hour for oxygen saturation deviations from study guidelines, or at ten (10) patients.
11566106|NCT00887731||Part 2 group|(After successful completion of PART 1) Within patient cross-over study with a randomized cross-over sequence. Sequential data analysis methods will be used to help minimize the patient sample size which will be no more than twenty (20) patients plus up to a maximum of seven (7) who might be eligible from PART 1.
11566107|NCT00887731||Part 3 Group|(After successful completion of PART 2) Within patient cross-over study with a randomized cross-over sequence. Studies will last 4 to 12 hours divided in two (2) equal time blocks with one cross-over to either automatic or manual control modes.
11566108|NCT00887718|Experimental|PET scan for lymphoma assessment|
11566109|NCT00887705|No Intervention|1: Standard rehabilitation programme|
11566110|NCT00887705|Experimental|2. Additional ADL training|
11566153|NCT00887406|Experimental|Cohort 1, period 4|GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg, Placebo
11566610|NCT00883896|Experimental|Arm 3|Part 1: 100 mg ILV-094 SC Q2W
11566111|NCT00887679|Experimental|Escitalopram|Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Open label, rater-blinded, prospective, 6-week trial of escitalopram.Subjects received escitalopram 10-20mg. Escitalopram was started at 10mg per day and augmented weekly in 10mg per day increments, the maximum dose being 20mg per day.
11566112|NCT00887653|Experimental|Raltegravir|This is a single arm study where HIV-infected individuals virologically suppressed on current regimen will be switched to raltegravir +optimized back ground regimen for 6 months
11566113|NCT00887640|Experimental|Temsirolimus 25 mg|Temsirolimus 25mg was administered by IV infusion each week (days 1, 8, 15, and 22 of each 28 day cycle). The infusion was to be administered over a period not less than 30 minutes and was to be completed within 60 minutes. Subjects were premedicated with 25 to 50 mg IV or PO diphenhydramine (or an alternative antihistamine in case of allergies) 30 minutes prior to the infusion.
11566114|NCT00887627|Experimental|1. Mild Renal Function Impaired Subjects|
11566115|NCT00887627|Experimental|2. Moderate Renal Function Impaired Subjects|
11566116|NCT00887627|Experimental|3. Subjects with Normal Renal Function|
11566117|NCT00887614|Experimental|MBSR|Participation will involve online completion of a questionnaire survey before and after the Mindfulness-Based Stress Reduction (MBSR) intervention. Specifically, research study participants will complete validated self-report measures to assess mindfulness, cognitive-emotional processes, sleep quality, symptoms of stress, sense of spirituality, and quality of life before and after the MBSR intervention.
11566118|NCT00887601|Experimental|Part I|Subjects will receive placebo, MK3134, and donepezil in one of four treatment sequences.
11566119|NCT00887601|Experimental|Part II|Subjects will receive placebo and three different doses of MK3134 (1 mg, 5 mg, and 25 mg) in one of four treatment sequences.
11566120|NCT00887588|Experimental|LCZ696|During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid.
11566121|NCT00887588|Active Comparator|Valsartan|During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid.
11566122|NCT00887575|Experimental|Dose Level I|"Neoadjuvant - Paclitaxel IV (70 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 5) day 1 of every cycle and Sunitinib PO (25mg) daily.
~Maintenance - Sunitinib PO (25mg) daily"
11566123|NCT00887575|Experimental|Dose Level II|Paclitaxel IV (80 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 5) day 1 of every cycle and Sunitinib PO (25mg) daily.
11566124|NCT00887575|Experimental|Dose Level III|Paclitaxel IV (80 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 6) day 1 of every cycle and Sunitinib PO (25mg) daily.
11566125|NCT00887562|Experimental|Idebenone 900 mg/day|Idebenone 900 mg/day
11566126|NCT00887562|Experimental|Idebenone 2250 mg/day|Idebenone 2250 mg/day
11566127|NCT00887562|Placebo Comparator|placebo|Placebo
11566128|NCT00887549|Experimental|Pemetrexed|
11566129|NCT00887536|Active Comparator|Group 1: TAC then pegfilgrastim|docetaxel, doxorubicin, cyclophosphamide, and pegfilgrastim/filgrastim
11566130|NCT00887536|Active Comparator|Group 2: TC|docetaxel and cyclophosphamide
11566131|NCT00887536|Experimental|Group 3: TC + bevacizumab|docetaxel, cyclophosphamide, and bevacizumab
11566132|NCT00887523|Experimental|1|prone intensity-modulated radiotherapy
11566133|NCT00887523|Active Comparator|2|supine intensity-modulated radiotherapy
11566134|NCT00887510|Active Comparator|Thiazide First|Participants will receive 25 mg of hydrochlorothiazide (HCTZ) each day for 6 weeks, followed by 25 mg of HCTZ every day plus 4 mg of trandolapril each day for 6 weeks, followed by 4 mg trandolapril each day for 6 weeks.
11566135|NCT00887510|Active Comparator|Trandolapril First|Participants will receive 4 mg of trandolapril each day for 6 weeks, followed by 4 mg of trandolapril for 6 weeks plus 25 mg of HCTZ each day for 6 weeks, followed by 25 mg of HCTZ each day for 6 weeks.
11566136|NCT00887497|Experimental|Catheterization|Patients receive angioembolization prior to surgery
11566137|NCT00887484|Experimental|Clindoxyl Gel|Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.
11566138|NCT00887484|Active Comparator|Epiduo gel|Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.
11566139|NCT00887471||Children who underwent PITA|Children who underwent partial intracapsular tonsillectomy and adenoidectomy between July 2003 and January 2008 for treatment of pediatric sleep-disordered breathing documented by positive preoperative polysomnography.
11566140|NCT00887471||Children who underwent T&A|Children who underwent total tonsillectomy and adenoidectomy between July 2003 and January 2008 for treatment of pediatric sleep-disordered breathing documented by positive preoperative polysomnography.
11566141|NCT00887458|Active Comparator|Low Dose|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
11566142|NCT00887458|Active Comparator|High Dose|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
11566143|NCT00887445|Experimental|A|
11566144|NCT00887445|Placebo Comparator|B|
11566145|NCT00887432|Experimental|Arm I (cholecalciferol and placebo)|Patients receive cholecalciferol PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm II.
11566146|NCT00887432|Experimental|Arm II (placebo and cholecalciferol)|Patients receive placebo PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm I.
11566147|NCT00887419|Experimental|Coping Skills Training|Coping Skills Training in pain management
11566148|NCT00887419|Active Comparator|Education|Chronic Pain Education
11566149|NCT00887419|No Intervention|Usual Care|Patients receive no study intervention, continue with usual medical care.
11566150|NCT00887406|Experimental|Cohort 1, Period 2|GSK961081 3mcg, Placebo, GSK961081 15mcg, GSK961081 50mcg
11566151|NCT00887406|Experimental|Cohort 1, period 1|Placebo, GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg
11566152|NCT00887406|Experimental|Cohort 1, period 3|GSK961081 3mcg, GSK961081 15mcg, Placebo, GSK961081 50mcg
11566154|NCT00887406|Experimental|Cohort 2, period 1|Placebo, GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg,
11566155|NCT00887406|Experimental|Cohort 2, period 2|GSK961081 100mcg, Placebo, GSK961081 200mcg, GSK961081 300mcg
11566156|NCT00887406|Experimental|Cohort 2, period 3|GSK961081 100mcg, GSK961081 200mcg, Placebo, GSK961081 300mcg
11566157|NCT00887406|Experimental|Cohort 2, period 4|GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg, Placebo
11566158|NCT00887406|Experimental|Cohort 3|GSK961081 100mcg or Placebo
11566159|NCT00887406|Experimental|Cohort 4|GSK961081 300mcg or Placebo
11566160|NCT00887393|Other|Low carbohydrate|Low carbohydrate pre-bariatric surgery diet
11566161|NCT00887393|Other|Low fat|Low fat pre-bariatric surgery diet
11566162|NCT00887380|Active Comparator|Arm A: Concurrent|Investigational treatment: Anastrozole commenced before (Pre-radiotherapy commencement of anastrozole) and continued during radiotherapy.
11566163|NCT00887380|Active Comparator|Arm B: Sequential|Standard Treatment: Anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy (Post radiotherapy commencement of anastrozole)
11566164|NCT00887367|Placebo Comparator|Placebo to match GSK598809|Placebo to match GSK598809.
11566165|NCT00887367|Placebo Comparator|Placebo to match ethanol infusion|Glucose solution to be given in the same way as ethanol.
11566166|NCT00887354|Experimental|Teriparatide|"20 micrograms (mcg) a day by subcutaneous injection throughout study.
~Placebo oral tablets once a week, to match the active comparator weekly dose, during the double-blind, double-dummy phase only."
11566167|NCT00887354|Active Comparator|Risedronate|"35 milligrams (mg) risedronate sodium orally once weekly throughout study.
~Daily placebo injection, to match the daily experimental drug dose, during the double-blind, double-dummy phase only."
11566168|NCT00887341|Experimental|1|
11566169|NCT00887341|Active Comparator|2|
11566170|NCT00887328|Experimental|IV tPA|intravenous tissue plasminogen activator
11566171|NCT00887328|Placebo Comparator|Placebo|
11566172|NCT00887315|Active Comparator|Group 1|Chemotherapy only
11566173|NCT00887315|Active Comparator|2|Chemotherapy and hypofractionated image guided radiotherapy
11566174|NCT00887302||1|Gastric Band
11566175|NCT00887302||2|Gastric Sleeve
11566176|NCT00887302||3|Gastric Bypass with PEG tube
11566177|NCT00887276|Active Comparator|Moxifloxacin|
11566178|NCT00887276|Active Comparator|Ampicillin; Amoxicillin|
11566179|NCT00887263|Experimental|A|
11566180|NCT00887263|Placebo Comparator|B|
11566181|NCT00887250|Placebo Comparator|1|Placebo
11566182|NCT00887250|Experimental|2|Losartan 50 mg for 12 weeks
11566183|NCT00887250|Experimental|3|Losartan 50 mg titrated to 100 mg after 6 weeks
11566184|NCT00887237|Experimental|TRIV|Cardiac resynchronization with triple site ventricular stimulation (2 RV leads and 1 LV lead)
11566185|NCT00887237|Active Comparator|BIV|Conventional cardiac resynchronization
11566186|NCT00887224|Experimental|Desvenlafaxine succinate sustained release 50 mg|
11566187|NCT00887224|Placebo Comparator|Placebo|
11566188|NCT00887211|Active Comparator|ProStent|implant ProStent drug-eluting stents
11566189|NCT00887211|Active Comparator|Firebird|implant Firebird drug-eluting stents
11566190|NCT00887198|Placebo Comparator|Placebo + prednisone|Placebo plus prednisone
11566191|NCT00887198|Experimental|Abiraterone + prednisone|Abiraterone acetate plus prednisone
11566192|NCT00887185|Active Comparator|1 - Traditional training|Temporal bone dissection training in cadaveric laboratory. Subjects are provided 2 cadaveric temporal bones and asked to spend 2 weeks practicing the surgical technique of complete mastoidectomy with facial recess approach.
11566193|NCT00887185|Experimental|2 Simulator training|Subjects perform temporal bone surgical dissection training on a simulator.
11566194|NCT00887172|Experimental|1|Wind-cold syndrome group were patients classified by Chinese Medicine practitioner of Wind-cold syndrome and took treatment of Jing Fang Bai Du san.
11566195|NCT00887172|Placebo Comparator|2|Wind-cold syndrome group were patients classified by Chinese Medicine practitioner of Wind-cold syndrome and took placebo of Jing Fang Bai Du san.
11566196|NCT00887172|Experimental|3|Wind-heat syndrome group were patients classified by Chinese Medicine practitioner of Wind-heat syndrome and took treatment of Ying Qiao san.
11566197|NCT00887172|Placebo Comparator|4|Wind-heat syndrome group were patients classified by Chinese Medicine practitioner of Wind-heat syndrome and took placebo of Ying Qiao san.
11566198|NCT00887159|Active Comparator|Arm A (CE)|Patients receive cisplatin IV over 1-2 hours on day 1 and etoposide IV over 1-2 hours on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11566199|NCT00887159|Experimental|Arm B (CE + GDC-0449)|Patients receive cisplatin and etoposide as in Arm A and vismodegib PO QD on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive vismodegib alone QD in the absence of disease progression or unacceptable toxicity.
11566200|NCT00887159|Experimental|Arm C (CE + IMC-A12)|Patients receive cisplatin and etoposide as in Arm A and cixutumumab IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cixutumumab alone once weekly in the absence of disease progression or unacceptable toxicity.
11566201|NCT00887146|Experimental|Arm A (RT, procarbazine, lomustine, vincristine)|Patients undergo 3D-CRT or IMRT on days 1-5 for 5-7 weeks. Patients also receive procarbazine hydrochloride PO on days 8-21, lomustine PO on day 1 and vincristine sulfate IV on days 8 and 29 of courses 3-8. Treatment repeats every 6-7 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11566202|NCT00887146|Experimental|Arm B (RT, temozolomide)|Patients undergo RT as in arm I and receive temozolomide PO QD on days 1-5 for 5-7 weeks. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients receive adjuvant temozolomide PO QD days 1-5. Treatment with adjuvant temozolomide repeats every 4 weeks for 6-12 courses in the absence of disease progression and unacceptable toxicity.
11566203|NCT00887133||1|Patients consulting Western Medicine outpatient clinics for a new episode of illness
11566204|NCT00887120|Active Comparator|1|Lopinavir/ritonavir standard dose + zidovudine and lamivudine
11566611|NCT00883896|Placebo Comparator|Arm 4|
11566205|NCT00887120|Active Comparator|2|Lopinavir/ritonavir low dose (70% of standard dose) + zidovudine and lamivudine
11566206|NCT00887107|Experimental|sorafenib|30 patients with non-radioiodine avid differentiated thyroid carcinoma
11566207|NCT00887094|Experimental|Aerobic exercise|One bout of aerobic physical training will be performed on a cycle ergometer for 50 min
11566208|NCT00887094|Experimental|Aerobic-resistance exercise|One bout of aerobic-resistance physical training will be performed on a cycle ergometer added by a strenght training for 50 min (total)
11566209|NCT00887081|Experimental|Interferon and Ribavirin|Patients with hemoglobinopathy will receive Interferon and Ribavirin
11566210|NCT00887068|Experimental|Azacitidine|Azacitidine 32 mg/m^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
11566211|NCT00887068|No Intervention|No Azacitidine|Standard treatment post allogeneic transplant is supportive care only.
11566212|NCT00887042|Experimental|Fludarabine|
11566213|NCT00887029|Active Comparator|DuoTrav|
11566214|NCT00887029|Active Comparator|Xalacom|
11566215|NCT00887003|Experimental|LV/LD 1|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
11566216|NCT00887003|Experimental|LV/HD 2|Low Volume, High Dose (5cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
11566217|NCT00887003|Experimental|HV/LD 3|High Volume, Low Dose (10cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
11566218|NCT00887003|Experimental|HV/HD 4|High Volume, High Dose (10cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
11566219|NCT00886990||1|Receiving a single PI boosted by low dose ritonavir
11566220|NCT00886990||2|Receiving two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
11566221|NCT00886964|Active Comparator|1|HBV ID
11566222|NCT00886964|Active Comparator|2|HBV IM
11566223|NCT00886951|Experimental|Access I123MNI388/I123MNI390 and brain imaging|
11566224|NCT00886938|Experimental|rTMS to DLPF, pilot study|rTMS to the dorsolateral prefrontal cortex for patients with tinnitus
11566225|NCT00886925|Active Comparator|Albumin|
11566226|NCT00886925|Placebo Comparator|Saline|
11566227|NCT00886912|Active Comparator|Hypoxia|training in simulated altitude
11566228|NCT00886912|Placebo Comparator|Normoxia|training under normoxic conditions
11566229|NCT00886899|Experimental|BridgePoint Medical System|Attempt to cross CTO with the BridgePoint Medical System after an attempt to cross the CTO with a currently marketed guidewire
11566230|NCT00886886|Other|Reboxetine, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
11566231|NCT00886873|Experimental|Group 1|Oral administration of mifepristone 5 mg daily for six months.
11566232|NCT00886873|Experimental|Group 2|Oral administration of mifepristone 10 mg daily for six months.
11566233|NCT00886860|Active Comparator|conventional oral misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 centimeters
11566234|NCT00886860|Experimental|titrated oral misoprostol|misoprostol 20 micrograms oral every hour until cervical dilatation 3 centimeters
11566235|NCT00886847|Experimental|EBUS FNA vs FNC|
11566236|NCT00886834|Experimental|Misoprostol|Misoprostol 400 micrograms inserted vaginally or buccally, per the participants desire.
11566237|NCT00886834|Placebo Comparator|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
11566238|NCT00886821|Experimental|1|
11566239|NCT00886808|Experimental|1|110 microgram dose of iCo-007 Intravitreal Injection
11566240|NCT00886808|Experimental|2|350microgram dose of iCo-007 Intravitreal Injection
11566241|NCT00886808|Experimental|3|700microgram dose of iCo-007 Intravitreal Injection
11566242|NCT00886808|Experimental|4|1,000microgram dose of iCo-007 Intravitreal Injection
11566243|NCT00886795|Experimental|Abatacept|4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 weeks, and 8 weeks.
11566244|NCT00886782|Experimental|Cdc7-inhibitor|
11566245|NCT00886769|Experimental|Canakinumab|Patients received a single dose of subcutaneous(sc) injection of canakinumab (4 mg/kg) on Day 1. Maximal total single dose of canakinumab allowed was 300 mg. Any patient who required a dose greater than 150 mg (patients>37.5 kg) received two sc injections.
11566246|NCT00886769|Placebo Comparator|Placebo|Patients received a single dose matching placebo of canakinumab on day 1.
11566247|NCT00886756|Experimental|1|
11566248|NCT00886756|Placebo Comparator|2|
11566249|NCT00886743|Other|Oprelvekin as subcutaneous injection (50 mg/kg once daily)|Open label treatment with oprelvekin
11566250|NCT00886730|Experimental|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
11566251|NCT00886730|Experimental|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
11566252|NCT00886730|Experimental|Physicians endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
11566253|NCT00886704|Active Comparator|Convenience drink with EPA and DHA|Daily consumption of 200 ml convenience drink, containing 0.5 g EPA and DHA (Omega-3 Fatty Acids)
11566254|NCT00886704|Placebo Comparator|Convenience drink without EPA and DHA|Daily consumption of 200 ml convenience drink, not containing 0.5 g EPA and DHA (Omega-3 Fatty Acids), but containing 1.0 g of Omega-6 Fatty Acids (e.g. corn oil)
11566255|NCT00886691|Experimental|Arm I (bevacizumab and everolimus)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and everolimus PO QD on days 1-28.
11566256|NCT00886691|Experimental|Arm II (bevacizumab and placebo)|Patients receive bevacizumab as in Arm I and placebo PO QD on days 1-28.
11566257|NCT00886678|Experimental|1|patients receiving pemetrexed, carboplatin and radiation therapy.
11566258|NCT00886665|Placebo Comparator|Placebo|
11566259|NCT00886665|Experimental|JWHGWT|
11566260|NCT00886652|Experimental|Exercise|"The patients of the Exercise group were submitted to a four-month physiotherapy protocol, with three weekly sessions of 60 minutes each, accompanied by a physiotherapist, and consisting of warm-up, aerobic exercise on an electric treadmill, and then winding down and relaxation.
~Each patient in this group was therefore submitted to an average of 48 sessions of exercises, always carried out at the same physiotherapy center."
11566261|NCT00886652|No Intervention|2|The patients of the control group were not submitted to any type of physical exercises. Like the patients submitted to the protocol, they were evaluated at the beginning, and again after four months.
11566262|NCT00886639|Other|First of 2 6-minute-walking test with oxygen|Continuous flow of 2 liters per minute First with oxygen, second with medical air
11566263|NCT00886639|Other|First of 2 6-minute-walking tests with medical air|Medical air is compressed room air. First test with medical air, second with oxygen
11566264|NCT00886626|Experimental|Exenatide|Exenatide
11566265|NCT00886626|No Intervention|Control|Control - no intervention
11566266|NCT00886613|Experimental|V212|Participants randomized to receive V212 (heat treated VZV Vaccine)
11566267|NCT00886613|Active Comparator|Zostavax™|Participants randomized to receive Zostavax™ (Zoster Vaccine, live)
11566268|NCT00886613|Placebo Comparator|Placebo|Participants randomized to receive placebo
11566269|NCT00886600|Placebo Comparator|1|Placebo
11566270|NCT00886600|Experimental|2|losartan 50 mg q.d.
11566271|NCT00886600|Experimental|3|losartan 100 mg q.d.
11566272|NCT00886600|Experimental|4|losartan 50 mg b.i.d.
11566273|NCT00886587|Experimental|11054-010|F# 11054-010 Investigational Device
11566274|NCT00886587|Active Comparator|10495-053|F# 10495-053 Atopiclair
11566275|NCT00886574|Active Comparator|Aspirin|Aspirin 100 mg once a day
11566276|NCT00886574|Active Comparator|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
11566277|NCT00886561|Experimental|HIV risk reduction intervention|Behavioral intervention designed to reduce HIV risk behaviors and enhance enhance HIV-preventive behaviors among female sex workers (FSWs) in Armenia
11566278|NCT00886561|Active Comparator|Wait list control|Will receive behavioral intervention after completion of study upon request.
11566279|NCT00886548||Ultrasound performed|Single arm study.
11566280|NCT00886522|Experimental|Intrabone cord blood infusion|All adults patients with hematological malignancies, lacking a HLA matched donor but with a HLA compatible CB unit, fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
11566281|NCT00886509|Experimental|Collateral promotion; PCI after 6 months|First pegGCSF or placebo; PCI after 6 months
11566282|NCT00886509|Experimental|Collateral promotion after PCI at baseline|Collateral promotion with pegGCSF after PCI at baseline
11566283|NCT00886483|Active Comparator|Active neurofeedback|In the active neurofeedback condition, the intervention is active neurofeedback (actual neurofeedback) either twice weekly or three times a week (randomized to frequency), with the same amount of total treatment over 40 sessions, varying only in frequency. Neurofeedback will be via the CyberLearning technology, using videogame race car speed and steering as feedback governed by EEG theta-beta ratio through the interface. the game controller is used in the usual fashion, but maximal speed is capped by the threshold theta-beta ratio, which changes from minute-to-minute by fuzzy logic based on the previous minute's ratio. If theta power exceeds a threshold, the rumble function of the controller comes on as a warning. The feedback is transparent to the patient, who just plays the videogame.
11566284|NCT00886483|Sham Comparator|Sham Neurofeedback|The sham condition will appear identical to the neurofeedback in all aspects: equipment, duration, frequency, and videogame choices. The only difference is that the interface module will be pre-programmed to give random feedback rather than contingent on the participant's brainwave power spectrum.
11566285|NCT00886470|Experimental|ST266 1|Topical treatment every other day
11566286|NCT00886470|Experimental|ST266 2|Topical treatment every 4th day
11566287|NCT00886470|Experimental|ST266 3|Topical treatment every 7th day
11566288|NCT00886457|Experimental|Decitabine plus PEG Interferon-alfa 2B|3.7 mg/m**2 decitabine plus 0, 0.5, 1.5, 3, or 6 mcg/kg PET-Intron
11566289|NCT00886444|Experimental|Ferucarbotran|
11566290|NCT00886431|Experimental|Vitrification|The embryos of patients allocated to this arm will be cryopreserved by vitrification.
11566291|NCT00886431|No Intervention|Slow cooling|The embryos of patients allocated to this arm will be cryopreserved by the slow cooling method, which is the standard method (=no intervention)
11566292|NCT00886418|Active Comparator|1|Total intravenous anesthesia (propofol and remifentanil) is provided using the close-loop system. A muscle relaxant is used to facilitate tracheal intubation; its administration is continued throughout anesthesia.
11566293|NCT00886418|Experimental|2|Total intravenous anesthesia (propofol and remifentanil) is provided using the close-loop system. No muscle relaxant is used and a placebo is infused throughout anesthesia.
11566294|NCT00886405|Experimental|Nytroglicerin|
11566295|NCT00886392||diabetic macular edema|Type 2 diabetes patients who had clinically significant macular edema by the criterion of the ETDRS
11566296|NCT00886379|Active Comparator|1|Mongolian milk without D
11566297|NCT00886379|Experimental|2|Mongolian milk with vitamin D
11566298|NCT00886379|Experimental|3|UHT milk
11566299|NCT00886379|Experimental|4|Milk Substitute
11566300|NCT00886379|Experimental|5|Seasonal D
11566301|NCT00886379|Experimental|6|Daily D
11566302|NCT00886366|Experimental|1|AZD6714 in 8 increasing oral single doses a-h given to 8 groups (3 on active and 1 on placebo in each group)
11566303|NCT00886366|Experimental|2|2 oral single doses d and g suspensions of AZD6714 given to 2 groups (3+1) together with food
11566304|NCT00886366|Experimental|3|Two increasing oral doses of AZD6714 and one placebo given to 2 groups with 3 type 2 diabetic patients.
11566305|NCT00886353|Active Comparator|APN01|Healthy volunteers will receive APN01
11566306|NCT00886353|Placebo Comparator|Placebo|Physiological saline administrated i.v.
11566307|NCT00886340|Active Comparator|Enhanced standard care|
11566308|NCT00886340|Experimental|Lifestyle counseling|
11566309|NCT00886327||Postoperative patients|Patients with CD who recently underwent bowel resection
11566310|NCT00886314|Active Comparator|midazolam|
11566311|NCT00886314|Active Comparator|clown doctor|
11566312|NCT00886301|Other|1|obese or overweight patients with fatty liver or ectopic fat
11566313|NCT00886288||Telmisartan|
11566314|NCT00886288||Telmisartan + hydrochlorothiazide|
11566315|NCT00886275|Experimental|Dexmedetomidine|
11566316|NCT00886275|Active Comparator|Midazolam|
11566317|NCT00886275|Experimental|Dexmedetomidine, Midazolam|Combination
11566318|NCT00886262|Experimental|Vasopressin|
11566319|NCT00886262|Placebo Comparator|Normal saline placebo|
11566320|NCT00886236|Active Comparator|1 Preoperative Gabapentin Liquid|Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)
11566321|NCT00886236|Experimental|2 Preoperative and Postoperative Gabapentin Liquid|Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Gabapentin Elixir (300 mg x 6 doses)
11566322|NCT00886236|Placebo Comparator|3 Preoperative and Postoperative Placebo Liquid|Preoperative Placebo Liquid (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)
11566323|NCT00886223|Experimental|1|
11566324|NCT00886210|Active Comparator|1LC with drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
11566325|NCT00886210|Active Comparator|2LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. no drain at the end of operation.
11566326|NCT00886197||GERD|"Symptomatic reflux subjects who receive esophagogastroscopy, aged from 20 to 70 years old.
~Patients with typical reflux symptoms (heartburn and/or acid regurgitation) at least 3 times per week in recent 4 months."
11566327|NCT00886184|Experimental|1|Induction of pre hospital early hypothermia in patients having a cardiac .
11566328|NCT00886184|Active Comparator|2|Induction of hypothermia only at hospital arrival.
11566329|NCT00886171|Experimental|Social Skills Training|
11566330|NCT00886171|Experimental|Physical Activity Training|
11566331|NCT00886158||Solid Organ Transplant Recipients|Solid organ transplant recipients receiving their care at Seattle Children's Hospital
11566332|NCT00886145|Other|Vibration and No Vibration|Vibration: Right Leg and No Vibration: Left Leg.
11566333|NCT00886132|Experimental|Sunitinib|Patients with progressive, recurrent and/or metastatic ACC treated with sunitinib 37.5 mg daily in this single-arm, two-stage phase II trial.
11566334|NCT00886119|Other|Lotrafilcon B / Omafilcon A|Lotrafilcon B, followed by Omafilcon A
11566335|NCT00886119|Other|Omafilcon A / Lotrafilcon B|Omafilcon A, followed by Lotrafilcon B
11566336|NCT00886106|Experimental|1|Remifentanil
11566337|NCT00886106|Active Comparator|2|Midazolam
11566338|NCT00886093|Experimental|Sequence 1|
11566339|NCT00886093|Experimental|Sequence 2|
11566340|NCT00886080|Experimental|Add-on arrhythmia surgery|"Adjuvant anti-arrhythmic surgery consists of a beating heart epicardial box isolation of all pulmonary veins using microwave energy (Flex 4 or Flex 10 ablation probes and Microwave generator by Guidant/Afix, Fremont, CA, USA). The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. In addition excision or exclusion of the left atrial appendage is performed in both the treated as the control group."
11566341|NCT00886067|Experimental|2-[18F]-F-A85380|Single microdose
11566342|NCT00886067|Experimental|AZD1446|Single oral administration
11566343|NCT00886054||Neurocritical patients|Neurocritical patients including those sustaining head injury, cerebrovascular events (such as intracerebral hemorrhage, subarachnoid hemorrhage, etc.), brain tumor, or hydrocephalus.
11566344|NCT00886041|Other|laparoscopy group|laparoscopy
11566345|NCT00886041|Active Comparator|ovarian stimulation group|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
11566346|NCT00886028|Experimental|Liposomal doxorubicin|Thirty patients with MPM who received liposomal doxorubicin 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles.
11566347|NCT00886015|Experimental|TT Clamp|The TT clamp will be used in trichiasis surgery.
11566348|NCT00886015|Active Comparator|Standard BLTR Technique|Standard BLTR technique will be used in trichiasis surgery.
11566349|NCT00885989|Experimental|1|
11566350|NCT00885989|Placebo Comparator|2|
11566351|NCT00885963|Experimental|sapacitabine|
11566352|NCT00885950||Colorectal liver metastases|Patients with colorectal liver metastases undergoing partial hepatic resection who were preoperatively treated with either neoadjuvant chemotherapy or not and/or anticoagulants or not
11566353|NCT00885937|Experimental|Arm 1|
11566354|NCT00885937|Active Comparator|Arm 2|
11566355|NCT00885937|Placebo Comparator|Arm 3|
11566356|NCT00885924|Active Comparator|Active treatment|Desmopressin 0.3 microgram/kg
11566357|NCT00885924|Placebo Comparator|Placebo|NaCl 0.9%
11566358|NCT00885911||Extraglottic device|The laryngeal mask airway (LMA) used during pediatric anesthesia for routine and difficult airway management.
11566359|NCT00885898|Active Comparator|1|"Non-invasive ventilation"
11566360|NCT00885898|Active Comparator|2|"Conventional"
11566361|NCT00885885|Experimental|1|Panitumumab+FOLFOX 4
11566362|NCT00885885|Experimental|2|Panitumumab+FOLFIRI
11566363|NCT00885872|Experimental|Treat|At visit 2 each eligible subject will be allocated to rosuvastatin. Subjects who reach the criteria at visit 3, dosage of rosuvastatin will be titrated. The subjects will be encouraged to take the study drug at the same time each day for 104 weeks.
11566665|NCT00883480|Experimental|1|
11566364|NCT00885859||1|responders: patients who have a pain reduction of 30% or more after two weeks TENS-treatment
11566365|NCT00885859||2|non-responders: patient who have a pain reduction smaller than 15% after two weeks TENS-treatment
11566366|NCT00885846|Active Comparator|Qigong Therapy|
11566367|NCT00885846|Active Comparator|PRT|
11566368|NCT00885846|No Intervention|Control|
11566369|NCT00885833|Experimental|Fludarabine|
11566370|NCT00885820|Experimental|1|Protocol biopsies at 1, 2 and 3 months
11566371|NCT00885820|Active Comparator|2|No protocol biopsies
11566372|NCT00885794|Experimental|0.5 mg Ranibizumab|3 intravitreal injections of 0.5 mg Ranibizumab every 5 weeks
11566373|NCT00885794|Experimental|1.0 mg of Ranibizumab|3 intravitreal injections of 1.0mg Ranibizumab every 5 weeks
11566374|NCT00885781|Experimental|SMOFlipid|
11566375|NCT00885781|Active Comparator|Lipovenoes MCT|
11566376|NCT00885768||A|patients with renal artery stenosis
11566377|NCT00885755|Experimental|1|
11566378|NCT00885742|Experimental|FXIII|All subjects who received a dose of Factor XIII (FXIII) Concentrate (Human).
11566379|NCT00885729|Experimental|Stem cells|Cartilage defect are treated surgical either with chondrocytes or stem cells
11566380|NCT00885729|Active Comparator|Rehabilitation|Active rehabilitation program
11566381|NCT00885716|Experimental|communication skills training|group training in shared decision making.
11566382|NCT00885716|Active Comparator|cognitive training|standard group training of cognitive skills (Konzentrationstraining)
11566383|NCT00885703|Experimental|Stage 1, Fluconazole 1200mg|Participants receive Fluconazole 1200mg induction dose in Stage 1
11566384|NCT00885703|Experimental|Stage 1, Fluconazole 1600mg|Participants receive Fluconazole 1600mg induction dose in Stage 1
11566385|NCT00885703|Experimental|Stage 1, Fluconazole 2000mg|Participants receive Fluconazole 2000mg induction dose in Stage 1
11566386|NCT00885703|Active Comparator|Stage 1, Ampho B|Participants receive Amphotericin B followed by Fluconazole in Stage 1
11566387|NCT00885703|Experimental|Stage 2, Fluconazole 1600mg|Participants receive Fluconazole 1600mg induction dose in Stage 2
11566388|NCT00885703|Experimental|Stage 2, Fluconazole 2000mg|Participants receive Fluconazole 2000mg induction dose in Stage 2
11566389|NCT00885703|Active Comparator|Stage 2, Ampho B|Participants receive Amphotericin B followed by Fluconazole in Stage 2
11566390|NCT00885690|Active Comparator|Sertindole|Sertindole 16-24 mg
11566391|NCT00885690|Active Comparator|Olanzapine|Olanzapine 10-20 mg
11566392|NCT00885677|Active Comparator|Study Group|Patients of the study arm are CRT-D patients followed-up by means of a remote disease management system (Medtronic Carelink® Network), for which an automatic alerting system is enabled for fluid accumulation, AT/AF episodes and system integrity.
11566393|NCT00885677|No Intervention|Control Group|Patients are CRT-D patients managed according to current standard clinical practice, based on routinely performed in-office visits.
11566394|NCT00885664|Active Comparator|Truvada|
11566395|NCT00885664|Active Comparator|Kaletra|
11566396|NCT00885651|Experimental|1|Metoprolol for 10 days followed by placebo for 7 days.
11566397|NCT00885651|Placebo Comparator|2|Placebo for 7 days followed by Metoprolol for 10 days
11566398|NCT00885638|Placebo Comparator|Placebo|A placebo tablet is given before ingestion of macronutrients
11566399|NCT00885638|Active Comparator|Sitagliptin|Sitagliptin is given before ingestion of macronutrients
11566400|NCT00885599|Experimental|PERIORINSE|naturopathic remedy
11566401|NCT00885599|Active Comparator|CPC|Cepacol, standard anti-bacterial mouthwash
11566402|NCT00885599|Active Comparator|Listerine|standard anti-bacterial mouthwash
11566403|NCT00885599|Placebo Comparator|placebo|colored water
11566404|NCT00885586|Sham Comparator|Sham-laser acupuncture|Sham laser acupuncture (c) is applied at equivalent points as needle acupuncture. Laser irradiation is faked.
11566405|NCT00885586|Active Comparator|gabapentine|standard analgesic treatment
11566406|NCT00885586|Active Comparator|Acupuncture|Acupuncture treatment is semi-standardized, i.e. beside a scheme of basic points, individual points can be chosen according to the TCM diagnostic pattern.
11566407|NCT00885573|Other|Sleep apnea subjects|"Patients with suspected sleep apnea syndrome will have nocturnal polysomnography. According to the number of respiratory events per hour of sleep, patients will be classified as sleep apnea or controls. All the patients will be blindly assessed for pharyngeal sensitivity the morning following the nocturnal recording."
11566408|NCT00885547|Experimental|immunosuppressor|
11566409|NCT00885534|Experimental|Chemotherapy|This is a single institution phase II trial in stage III or IV melanoma patients with measurable disease but no prior cytotoxic chemotherapy and not thought to be curable by surgery.Before starting the chemotherapy, you may need to have a fresh biopsy of your tumor. If you have already had a tumor biopsy that we can use, you may not need another biopsy. Your study doctor will review with you the biopsies you have had. We will try to obtain biopsy material that already exists but if we cannot, you will need another biopsy.
11566410|NCT00885521|Experimental|Exercise|8 week, twice weekly exercise program with both endurance and upper and lower limb strength training
11566411|NCT00885521|No Intervention|2|No exercise, twice weekly phone calls
11566412|NCT00885508|Experimental|Aracytidine, Daunaurubicine, Lenalidomide|
11566413|NCT00885495|Active Comparator|B|Darunavir+ritonavir x 7 days; Rosuvastatin x 7 days; Combination x 7 days
11566414|NCT00885495|Active Comparator|A|Rosuvastatin x 7 days; darunavir+ritonavir x 7 days; Combination x 7 days
11566415|NCT00885482|Experimental|Single arm|"Treatment simplification from a standard combined antiretroviral therapy including 2 NRTIs and Atazanavir with Ritonavir to Lamivudine plus Atazanavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy."
11566416|NCT00885469||1|Patients with known Barrett's Esophagus or chronic GERD
11566417|NCT00885456|Experimental|PREVENT program|12-week program of exercise and education to induce physiological and behavioral changes needed to reduce vascular risk factors.
11566512|NCT00884676|Experimental|Schedule A|Schedule A: Ixabepilone - Weekly for 3 weeks each cycle (Days 1, 8 and 15) For both Schedules A and B, Sunitinib daily, orally, starting on Day 8 of Cycle 1
11566418|NCT00885456|Active Comparator|Usual Care|Average of three visits to the Neurovascular Clinic for a neurological and health assessment, counseling regarding stroke/TIA and diagnostic test results, and assessment, modification and education of secondary prevention factors
11566419|NCT00885443|Active Comparator|1|
11566420|NCT00885443|Active Comparator|2|
11566421|NCT00885430|Experimental|Pico-Salax|
11566422|NCT00885417|Experimental|Cravit-based sequential therapy|Cravit-based sequential therapy Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
11566423|NCT00885404|Other|Intravenous fluids|
11566424|NCT00885378|Active Comparator|Saxagliptin plus metformin IR|
11566425|NCT00885378|Placebo Comparator|Placebo plus metformin IR|
11566426|NCT00885365|Experimental|Bramitob|tobramycin / Bramitob administered 300mg twice a day for 4 weeks
11566427|NCT00885365|Active Comparator|TOBI|tobramycin / TOBI administered 300mg twice a day for 4 weeks
11566428|NCT00885352|Experimental|Sitagliptin|Sitagliptin 100 mg tablet orally once daily for 26 weeks.
11566429|NCT00885352|Placebo Comparator|Placebo|Placebo to sitagliptin orally once daily for 26 weeks.
11566430|NCT00885339||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases.
11566431|NCT00885326|Other|Treatment|"Bevacizumab: Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.
~Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).
~Zoledronic acid will be administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first."
11566432|NCT00885313|Experimental|DHA250|DHA 250 mg/kg/d plus lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
11566433|NCT00885313|Experimental|DHA500|DHA 250 mg/kg/d plus lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
11566434|NCT00885313|Placebo Comparator|PLA|placebo and lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
11566435|NCT00885300|Experimental|1|cloxacillin 100 mg/ml + heparin 1000iu/ml as catheter lock at the end of hemodialysis
11566436|NCT00885300|Active Comparator|2|heparin 1000iu/ml as catheter lock at the end of hemodialysis
11566437|NCT00885287|Active Comparator|HIV-positives on ARVs receiving AL for malaria|HIV-positive patients on first-line ARVs receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
11566438|NCT00885287|Active Comparator|HIV-positives receiving AL for malaria|HIV-positive patients not receiving antiretrovirals but receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
11566439|NCT00885287|Active Comparator|HIV-negatives receiving AL for malaria|HIV-negative patients receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
11566440|NCT00885274|Experimental|Split Dose|Doses of Pico-Salax split: one dose administered the night prior to colonoscopy and the other dose administered the day of the procedure.
11566441|NCT00885274|Active Comparator|Traditional Dose|Both doses of Pico-Salax taken the evening prior to colonoscopy.
11566442|NCT00885235||A|Subjects that are indicated for colonoscopy who are suspected or known to suffer from large bowel diseases.
11566443|NCT00885222|Active Comparator|1|PD patient that were treated with STN DBS and developed depression after the surgery (n=5).
11566444|NCT00885222|Active Comparator|2|PD patients with depression that are candidates for STN DBS (n=5).
11566445|NCT00885222|Active Comparator|3|PD patients without depression that are candidates for STN DBS (n=10).
11566446|NCT00885209||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases.
11566447|NCT00885196|Experimental|AEB071 200 mg BID|
11566448|NCT00885196|Experimental|AEB071 400 mg OD|
11566449|NCT00885196|Experimental|AEB071 300 mg BID|
11566450|NCT00885196|Placebo Comparator|Placebo BID|
11566451|NCT00885183|Experimental|acupuncture therapy|Breast cancer patients are randomised to additional 12 acupuncture treatment sessions while undergoing standard chemotherapy
11566452|NCT00885183|Other|Usual care|Control group (usual care) receives standard chemotherapy alone
11566453|NCT00885170|Experimental|Odanacatib 50 mg|Odanacatib 50 mg tablets once weekly for 24 months. Vitamin D3 (dietary supplement), two 2800 IU tablets, taken once weekly for 24 months. Participants received calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
11566454|NCT00885170|Placebo Comparator|Placebo|Placebo to odanacatib 50 mg tablets once weekly for 24 months. Vitamin D3 (dietary supplement), two 2800 IU tablets, taken once weekly for 24 months. Participants received calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
11566455|NCT00885157|Experimental|Group A|Will receive fractional doses of IPV Intradermally
11566456|NCT00885157|Active Comparator|Group B|Will receive full doses of IPV Intramuscularly
11566457|NCT00885118|Experimental|BI 10773 low dose quaque die (QD)|patient to receive a BI 10773 low dose tablet and a placebo tablet once daily
11566458|NCT00885118|Experimental|BI 10773 mid-low dose QD|patient to receive a BI 10773 middle dose tablet and a placebo tablet once daily
11566459|NCT00885118|Experimental|BI 10773 mid-high dose QD|patient to receive two tablets of BI 10773 middle dose once daily
11566460|NCT00885118|Experimental|BI 10773 high dose QD|patient to receive a BI 10773 high dose tablet and a placebo tablet once daily
11566461|NCT00885118|Placebo Comparator|Placebo|patient to receive two tablets of placebo once daily
11566462|NCT00885105|Experimental|Fluzone® Vaccine-Primed Group|Participants received 2 doses of Fluzone® vaccine at 2 months (in Study GRC 27)
11566463|NCT00885105|Active Comparator|Influenza Vaccine-Naive Group|Participants who have never received influenza vaccine (and not in Study GRC27)
11566513|NCT00884676|Experimental|Schedule B|Ixabepilone - Day 1 of each 3-week cycle For both Schedules A and B, Sunitinib daily, orally, starting on Day 8 of Cycle 1.
11566514|NCT00884663|Experimental|1 Candesartan|
11566464|NCT00885092|Other|FID 114675A / RepleniSH|FID 114675A in Period 1; RepleniSH in Period 2. Each solution was used for 7 days for cleaning, rinsing, conditioning, disinfecting, and storing silicone hydrogel contact lenses, per protocol-specified instructions. A new pair of silicone hydrogel contact lenses was dispensed at the start of each period and worn bilaterally on a daily wear basis.
11566465|NCT00885092|Other|RepleniSH / FID 114675A|RepleniSH in Period 1; FID 114675A in Period 2. Each solution was used for 7 days for cleaning, rinsing, conditioning, disinfecting, and storing silicone hydrogel contact lenses, per protocol-specified instructions. A new pair of silicone hydrogel contact lenses was dispensed at the start of each period and worn bilaterally on a daily wear basis.
11566466|NCT00885079|Experimental|Rebamipide|Instillation,4 times/day for 4 weeks
11566467|NCT00885079|Active Comparator|Hyaluronate|Instillation,6 times/day for 4 weeks
11566468|NCT00885066|Experimental|gemcitabine, capecitabine, erlotinib|
11566469|NCT00885053|Experimental|Fish oil|
11566470|NCT00885053|Placebo Comparator|Olive oil|
11566471|NCT00885014|Experimental|CBT|Telephone cognitive-behavioral therapy
11566472|NCT00885014|Active Comparator|TAU|Treatment as usual through the Employees Assistance Program
11566473|NCT00885001|Experimental|Short Arc Banding Group|Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
11566474|NCT00884988|Active Comparator|Lymphomyosot|homeopathic remedy
11566475|NCT00884988|Placebo Comparator|Placebo remedy|identical in color, constituency and taste to true remedy
11566476|NCT00884962|Experimental|PLVR|
11566477|NCT00884949|Experimental|BMN 110|Within-patient Dose-Escalation
11566478|NCT00884936||Group 1|Young age: 20 to 30 years old
11566479|NCT00884936||Group 2|Middle Age: 38 to 48 years old (pre-menopausal only)
11566480|NCT00884936||Group 3|Elderly Age: 60 to 75 years old (Post-menopausal only)
11566481|NCT00884897|Experimental|Oxytocin|We will purchase OT from PharmaWorld, an international pharmacy located in Switzerland; the preparation of intranasal OT is manufactured by Novartis and sold under the trade name: Syntocinon. We have obtained an IND (number 78,246) for Syntocinon (intranasal oxytocin) manufactured by Novartis.
11566482|NCT00884897|Placebo Comparator|Placebo|We will be purchasing oxytocin placebo nasal spray through LABOSWISS located in Davos, Switzerland and distributed through PharmaWorld. LABOSWISS will manufacture the matching the placebo under GDP guidelines. The placebo will be in every way identical to the oxytocin formulation but will not contain OT.
11566483|NCT00884884|Placebo Comparator|Double Placebo|Placebo, Placebo
11566484|NCT00884884|Experimental|Aripiprazole 15, Placebo|15 mg Aripiprazole, Placebo
11566485|NCT00884884|Experimental|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
11566486|NCT00884884|Experimental|Topiramate 100mg, Placebo|Topiramate 100 mg daily plus Placebo daily
11566487|NCT00884884|Experimental|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
11566488|NCT00884884|Experimental|Topiramate 100, Aripiprazole 5|Topiramate 100 daily plus, Aripiprazole 5mg daily
11566489|NCT00884884|Experimental|Topiramate 200, Aripiprazole 15|Topiramate 200 mg daily plus Aripiprazole 15mg daily
11566490|NCT00884884|Experimental|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily, Aripiprazole 7.5 mg daily
11566491|NCT00884884|Experimental|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
11566492|NCT00884871||Laparoscopic adjustable gastric banding|100 obese women undergoing laparoscopic adjustable gastric banding
11566493|NCT00884858|Experimental|Maraviroc|Subjects in this group will add Maraviroc to their current HAART.
11566494|NCT00884858|No Intervention|2|Subjects in this group will continue their current HAART without adding Maraviroc.
11566495|NCT00884845|Experimental|Arm 1|Administration of i.v. infusions of PM02734 (on Days 1, 8 and 15) every three weeks and a daily oral dose of erlotinib
11566496|NCT00884832|Experimental|Oral Clonidine|Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
11566497|NCT00884832|Placebo Comparator|Oral Placebo|Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
11566498|NCT00884819|Experimental|1|fenofibrate 200mg/daily for 6 months
11566499|NCT00884819|Placebo Comparator|2|Placebo match for 6 months
11566500|NCT00884806|Experimental|FID 114675A|FID 114675A used for 7 days, per protocol-specified instructions. Silicone hydrogel or hydrogel contact lenses worn bilaterally on a daily wear basis, one brand only.
11566501|NCT00884793|Experimental|intensification with raltegravir +/- NNRTI or PI|Intensification with raltegravir 400mg PO BID +/- a study PI or NNRTI
11566502|NCT00884780||Pediatric Pain|Children between the ages of 8 and 17 experiencing pain.
11566503|NCT00884754|Experimental|rigid GlideScope Specific Stylet|
11566504|NCT00884754|Active Comparator|90º curvature, malleable stylet|
11566505|NCT00884741|Active Comparator|Arm I (radiation therapy, temozolomide, placebo)|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks and receive temozolomide PO QD for up to 7 weeks. Beginning 4 weeks after completion of chemotherapy and radiation therapy, patients receive temozolomide PO QD on days 1-5. Treatment with temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients also receive placebo IV over 30-90 minutes once every 2 weeks beginning in week 4 of chemotherapy and radiation therapy and continuing until the completion of temozolomide.
11566506|NCT00884741|Experimental|Arm II (radiation therapy, temozolomide, bevacizumab)|Patients undergo radiation therapy and receive temozolomide as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes once every 2 weeks beginning in week 4 of chemoradiotherapy and continuing until the completion of adjuvant temozolomide.
11566507|NCT00884728||Indigenous children aged <15 years|Indigenous children aged <15 years within participating communities of the Northern Territory
11566508|NCT00884715|Experimental|1 implant|117 mg Octreotide implant
11566509|NCT00884715|Experimental|2 implants|234 mg Octreotide implant
11566510|NCT00884689||1|Asthma patient with specific treatment
11566511|NCT00884689||2|Asthma patient on different specific treatment compared to the other group
11566515|NCT00884663|Active Comparator|2 propranolol|
11566517|NCT00884650|Active Comparator|Group 1|Group 1 will receive oral analgesia only
11566518|NCT00884650|Active Comparator|Group 2|Group 2 will have an anesthetic continuous-infusion device with supplemental oral analgesia
11566519|NCT00884637||CNV subjects|
11566520|NCT00884624||A|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
11566521|NCT00884611|Experimental|Predictive Low Glucose Suspend|The pump suspension system consists of the Revel CGM device communicating with a laptop computer that contains the hypoglycemia prediction algorithm. During the 21 night study period, the laptop is placed at the bedside and turned on by the participant at bedtime and off on arising in the morning.The laptop contains a randomization schedule (2:1) that indicats whether the hypoglycemia prediction algorithm will be in operation that night (Predictive Low Glucose Suspend Algorithm ON) or will not be activated (Predictive Low Glucose Suspend Algorithm OFF), to which the participant is blinded.
11566522|NCT00884585|Experimental|Cyclosporine Ophthalmic Solution (COS) followed by COS|Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
11566523|NCT00884585|Other|Placebo followed by COS|Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months followed by cyclosporine ophthalmic solution 0.010% up to 9 additional months; at Month 9 the dose may be adjusted to 2 times a day.
11566524|NCT00884559|Active Comparator|Technical|Technical Instructions
11566525|NCT00884559|Experimental|Leadership|Leadership-Instructions
11566526|NCT00884546|Experimental|Arm 1|BMS-833923 (Starting dose is a loading dose of 60 mg for 7 days with a 30 mg daily dose thereafter)
11566527|NCT00884546|Active Comparator|Arm 2|"BMS-833923 (MTD or below)
~Lenalidomide (at or below the recommended prescribing dose)
~Dexamethasone (40 mg)"
11566528|NCT00884546|Active Comparator|Arm 3|"BMS-833923 (MTD or below)
~Bortezomib (at or below the recommended prescribing dose)"
11566529|NCT00884533|Experimental|Group 1|Group 1 - placebo on Day -1, rosi XR 8mg from Days 1-20, rosi XR 20mg on Day 21
11566530|NCT00884533|Placebo Comparator|Group 3|Placebo on Day -1, Days 1-20 and Day 21
11566531|NCT00884533|Active Comparator|Group 2|Placebo for Day -1, placebo on Days 1-20 and moxifloxacin active comparator 400 mg on Day 21
11566532|NCT00884520|Experimental|VM4-037|Approximately sixteen (16) adult subjects including four (4) healthy volunteers and twelve (12) cancer subjects who have confirmed or highly suspected diagnosis of head & neck, lung, large solitary hepatic and renal cell cancer, as defined by protocol criteria
11566533|NCT00884507|Placebo Comparator|Placebo|
11566534|NCT00884507|Experimental|RO5313534 15mg|
11566535|NCT00884507|Experimental|RO5313534 1mg|
11566536|NCT00884507|Experimental|RO5313534 5mg|
11566537|NCT00884494|Experimental|Roux-en-Y gastric bypass|
11566538|NCT00884494|Experimental|Lean|
11566539|NCT00884481||Natalizumab|Participants with MS treated with Tysabri over 12 months
11566540|NCT00884468||1|Patients with PsA that fulfill the eligibility criteria of the study
11566541|NCT00884442|Active Comparator|1|One tablet of Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL, fasted state
11566542|NCT00884442|Active Comparator|2|One tablet of Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL, fed state
11566543|NCT00884442|Active Comparator|3|One tablet of Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, fasted state
11566544|NCT00884442|Active Comparator|4|One tablet of Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, fed state
11566545|NCT00884429|Active Comparator|1- Conventional Chest Physiotherapy|Percussion , thorax compression and Postural Drainage/suction if necessary
11566546|NCT00884429|Active Comparator|2- Chest physiotherapy- Actual techniques|slow prolonged expiration and clearance rhinopharynx and suction if necessary
11566547|NCT00884429|Active Comparator|3- Airway Suction|Suction superior airways. Only in admission.
11566548|NCT00884416|Experimental|Sorafenib dose titration|
11566549|NCT00884390|Experimental|ReFacto AF|
11566550|NCT00884377|Active Comparator|Sodium stibogluconate intravenous|20 mg/kg/day Sodium stibogluconate intravenous
11566551|NCT00884377|Experimental|ThermoMed device|ThermoMed device, single heat treatment at 50 degrees Celsius
11566552|NCT00884364|Active Comparator|Control|
11566553|NCT00884364|Experimental|Exercise|
11566554|NCT00884338|Experimental|Exercise|
11566555|NCT00884338|Active Comparator|Control group|
11566556|NCT00884325|Experimental|Xyzal|
11566557|NCT00884325|Placebo Comparator|Placebo|
11566558|NCT00884312|Experimental|Carfilzomib|Participants received carfilzomib administered intravenously, using the same method, frequency, and dose level as in the last cycle of the participant's previous carfilzomib study. Treatment was continued until confirmation of disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or commercial availability of carfilzomib.
11566559|NCT00884299|No Intervention|1|Free diet
11566560|NCT00884299|Experimental|Diet rich in antioxidants|Diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients in this arm will be seen regularly in the outpatient clinic where there will be informed for the potential beneficial effects of fruits and vegetables in health status by two members of the study team (attending physician and specialist nurse). At baseline and at each visit it is clearly explained to them that the dietary goal is to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the 3-year study period.
11566561|NCT00884286|Experimental|Arm One|Aplidin® given as a 1-hour weekly IV infusion
11566562|NCT00884273|Experimental|Degarelix 240 mg/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
11566607|NCT00883909||observational|A follow-up study in adult male subjects who have received investigational
11566608|NCT00883896|Placebo Comparator|Arm 1|Part 1: Placebo
11566563|NCT00884273|Active Comparator|Goserelin (3.6 mg) + bicalutamide (50 mg)|"Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.
~On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin."
11566564|NCT00884260|Experimental|Arm 1|
11566565|NCT00884234|Experimental|1|RT001 (Botulinum Toxin Type A Topical Gel)
11566566|NCT00884234|Placebo Comparator|2|Vehicle Control
11566567|NCT00884221|Experimental|Highly Purified Menotrophin|
11566568|NCT00884221|Active Comparator|Recombinant FSH|
11566569|NCT00884208||Group 1|Recommend assistive device
11566570|NCT00884208||Group 2|Consultation for PT assessment
11566571|NCT00884195|Experimental|1|Gratitude Journaling
11566572|NCT00884195|Placebo Comparator|2|Neutral Journaling
11566573|NCT00884182|Experimental|Group 1|Participants on vaccination schedule 1 (Day 0 and Day 21)
11566574|NCT00884182|Experimental|Group 2|Participants on vaccination schedule 2 (Day 0 and Day 14)
11566575|NCT00884182|Experimental|Group 3|Participants on vaccination schedule 3 (Day 0 and Day 42)
11566576|NCT00884130||Laparoscopic|Patients having a laparoscopic colorectal resection
11566577|NCT00884130||Open|Patients having an open colorectal resection
11566578|NCT00884117||Participants Infected with Influenza|Participants with a positive diagnostic test of influenza and/or displaying symptoms suggestive of influenza-like illness will be enrolled and followed for up to 10 days after informed consent for virological surveillance and assessment of clinical outcomes. Participants may receive treatment including oseltamivir, other treatment/medication, or no treatment.
11566579|NCT00884104|Experimental|1.tamsulosin + solifenacin|
11566580|NCT00884091||Healthy Adults|"Chinese in origin
~Healthy
~No medication at least two weeks before the study"
11566581|NCT00884078|Experimental|1|C-MAPS (Culturally adapted manualized problem solving training) will be a brief problem focused therapy comprising of 8 sessions within three months after a self-harm episode. We will have two engagement sessions before the actual therapy. The adapted therapy/training will be delivered by therapists/trained counselors in the patient's home/GP practice depending upon patient's choice. Sessions will be offered weekly in the first month and than fortnightly and will last 50 minutes.
11566582|NCT00884078|No Intervention|2 Control group|"Patients who will be randomized to the treatment as usual arm will receive routine care. In most cases this consists of an assessment by a casualty doctor or a junior psychiatrist in the emergency department, on the basis of which about one third patients are referred for follow up as a psychiatry outpatient, a small number are referred to addiction services, and the remainder are advised to consult their own general practitioner (Kapur 1998) this is particularly so in case of Asian females (Cooper et al, 2006). No patients are routinely referred to psychotherapy or psychology services. Participants will receive an initial assessment along with treatment as usual (TAU) as ascertained by the general practitioner or mental health professional any type of treatment apart from C-MAPS will be permitted. We will record the degree of patient adherence to standard care."
11566583|NCT00884065|Experimental|Intervention Group|The intervention group was treated with a single session of DF following the procedure as described by the authors.
11566584|NCT00884065|Placebo Comparator|Control Group|The control group was treated with a single placebo session of DF.
11566585|NCT00884052|Experimental|levetiracetam dose escalation|6 Babies in Phase 1-Received Dose 1: 20 mg/kg; 5 mg/kg daily 12 Babies in Phase 2-Received Dose 2: 40 mg/kg; 10 mg/kg/day
11566586|NCT00884039|Active Comparator|30 mg anecortave acetate|
11566587|NCT00884039|Active Comparator|15 mg anecortave acetate|
11566588|NCT00884026|Active Comparator|1|Subjects that experience hypotension after spinal anesthesia.
11566589|NCT00884026|Active Comparator|2|Subjects that do not experience hypotension after spinal anesthesia.
11566590|NCT00884013||1|Quality Payment and all clinical reminders turned on
11566591|NCT00884013||2|Quality Payment and ABCS measures reminders turned on
11566592|NCT00884013||3|Quality Payment and non-ABCS measures reminders turned on
11566593|NCT00884013||4|Quality Reporting and Recognition with all clinical reminders turned on
11566594|NCT00884013||5|Quality Reporting and Recognition with ABCS measures reminders turned on
11566595|NCT00884013||6|Quality Reporting and Recognition with non-ABCS measures reminders turned on
11566596|NCT00884000|Active Comparator|1|
11566597|NCT00884000|Experimental|2|
11566598|NCT00883987||Back Pain|"Patients with chronic mechanical low back pain (Chronic low back pain is defined as having pain between the lower ribs and gluteal folds, with minimal radiation to the thigh and never below the knee, present for a minimum of seven weeks)"
11566599|NCT00883974|Experimental|1|
11566600|NCT00883974|No Intervention|2|Standard Neonatal Intensive Care Unit (NICU) procedures for the care of pre-term infants
11566601|NCT00883961|Experimental|Supervised exercise|
11566602|NCT00883961|No Intervention|Control group|The patients will not carry out a structured exercise program.
11566603|NCT00883948|Experimental|1|Participants will receive initial minimal (trophic) enteral feeding.
11566604|NCT00883948|Experimental|2|Participants will receive initial full-calorie enteral feeding.
11566605|NCT00883935|Experimental|Sequence 2|In the first treatment period, all subjects will receive GSK1349572 30mg q24h for 5 days (treatment A). In period two, subjects will receive GSK1349572 30mg q24h in combination with ATV 400mg q24h (treatment C) for 14 days. There will be no washout between treatment periods. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
11566606|NCT00883935|Experimental|Sequence 1|In the first treatment period, all subjects will receive GSK1349572 30mg q24h for 5 days (treatment A). In period two, subjects will receive GSK1349572 30mg q24h in combination with ATV/RTV 300/100mg q24h (treatment B) for 14 days. There will be no washout between treatment periods. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
11566612|NCT00883896|Experimental|Arm 5|Part 2: 200 mg ILV-094 SC Q2W
11566613|NCT00883883|Experimental|1|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)
11566614|NCT00883883|Active Comparator|2|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)
11566615|NCT00883870|Experimental|mesenchymal stem cells|Intramuscular injection
11566616|NCT00883870|Experimental|Placebo|Intramuscular injection
11566617|NCT00883844|Experimental|1|Continuation of any Nucleos(t)ide analogue treatment and add-on of peginterferon for 24 weeks
11566618|NCT00883844|Active Comparator|2|Continuation of Nucleos(t)ide analogue mono-therapy
11566619|NCT00883831|Experimental|Individualized manual acupuncture|
11566620|NCT00883818|Experimental|Antibiotics therapy|
11566621|NCT00883805||Metal-on-Metal Articulations|Subjects will be people who have had metal-on-metal total hip arthroplasties
11566622|NCT00883805||Ceramic-on-Metal Articulations|Subjects will be people who have had ceramic-on-metal total hip arthroplasties
11566623|NCT00883792|Experimental|Colonoscopy screening|One-time colonoscopy is the screening tool used in this trial. All individuals in the screening group will be offered a full colonoscopy. At colonoscopy, all detected CRC precursor lesions will be removed, whenever possible.
11566624|NCT00883792|No Intervention|Control|"The control group will not be offered any screening or intervention within the trial, but follow usual care in the participating countries. Individuals assigned to the control group will not be informed about their status as controls in the trial. This approach facilitates a truly population-based study, which will be used to estimate the effect of the screening intervention in the general population, mimicking national CRC screening programs.
~All ethics committees at the participating centres have approved the study protocol before recruiting individuals to the trial. In Sweden, the national ethics committee particularly reviewed the non-information of the control group and found it ethically acceptable."
11566625|NCT00883779|Experimental|1|
11566626|NCT00883779|Placebo Comparator|2|
11566627|NCT00883766|Active Comparator|Long agonist protocol|
11566628|NCT00883766|Experimental|Antagonist protocol|
11566629|NCT00883753|Experimental|tocilizumab|Participants received tocilizumab 8 mg/kg intravenous (IV), maximum dose not exceeding 800 mg in a single infusion, every 4 weeks for up to 104 weeks or up to 4 weeks after tocilizumab became commercially available in the respective country whichever occurred first.
11566630|NCT00883740|Experimental|Lyrica|flexible dosing Lyrica 300-450mg/day
11566631|NCT00883740|Placebo Comparator|Placebo|Placebo
11566632|NCT00883727|Experimental|stem cells|
11566633|NCT00883727|Placebo Comparator|Placebo|
11566634|NCT00883714|Experimental|Supervised exercise|
11566635|NCT00883714|Active Comparator|Control group|
11566636|NCT00883701||COPD patients|COPD patients who undergo exacerbation
11566637|NCT00883701||Non COPD patients (controls)|Subjects who undergo respiratory infection (acute bronchitis) without COPD or other respiratory illness
11566638|NCT00883688|Experimental|Bevacizumab + Lapatinib|"Bevacizumab 10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week study cycle). Lapatinib Pills of 700 mg/m^2/dose given orally 2 times each day."
11566639|NCT00883675|Experimental|Treatment|Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin Area Under the Curve 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
11566640|NCT00883662||Group 1|
11566641|NCT00883649|Placebo Comparator|1|
11566642|NCT00883649|Active Comparator|2|
11566643|NCT00883636||Focal Segmental Glomerulosclerosis|
11566644|NCT00883636||Non-Focal Segmental Glomerulosclerosis|
11566645|NCT00883623|Experimental|Treatment Arm|Treatment Arm
11566646|NCT00883597||Controls|Patients with ileostomy.
11566647|NCT00883597||Standard Sepsis Treatment|Patients with ileostomy and sepsis
11566648|NCT00883584|Active Comparator|1|IMD-1041
11566649|NCT00883584|Placebo Comparator|2|
11566650|NCT00883571|Active Comparator|house advancement flap|house advancement flap
11566651|NCT00883571|Active Comparator|Rhomboid flap|rhomboid flapa was incised in the ischiorectal fossa. Without undermining of its fatty base, the flap was then mobilized into the anal canal so that the tip could be sutured to the top of the strictured area using Vicryl 3/0 sutures
11566652|NCT00883571|Active Comparator|Y-V anoplasty|Y-V anoplasty
11566653|NCT00883558|Experimental|INSULIN-PH20 NP / Insulin Lispro|"All enrolled participants underwent a 1-month dose titration period and received 100 units per milliliter (U/mL) insulin lispro, injected subcutaneously (SC) pre-meals, with doses titrated to each participant individually.
~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.
~INSULIN-PH20 NP (Treatment A): 100 U/mL non-preserved (NP) formulation of regular human insulin with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, doses titrated to each participant individually.
~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, doses titrated to each participant individually.
~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine or maintained their usual regimen through an insulin pump."
11566654|NCT00883545|Experimental|Woman endoscopist|
11566655|NCT00883545|Active Comparator|Usual care|
11566656|NCT00883532|Experimental|budesonide|The treatment group will receive surfactant and budesonide.
11566657|NCT00883532|Placebo Comparator|surfactant and air|The placebo group will receive surfactant and air as control.
11566658|NCT00883519|Active Comparator|IPT-A|
11566659|NCT00883519|Active Comparator|IPT-AP|
11566660|NCT00883506|Experimental|1|Lisinopril 40 mg Tablet under fed conditions.
11566661|NCT00883506|Active Comparator|2|Lisinopril 40 mg Tablet (Zestril)
11566662|NCT00883506|Experimental|3|Lisinopril 40 mg Tablet under fasting conditions.
11566663|NCT00883493|Experimental|Quetiapin fumarate XR|Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
11566664|NCT00883493|Experimental|Quetiapin fumarate XR+Lithium carbonate|Quetiapine XR will be administered like monotherapy arm. Lithium will be administered twice daily from Day 1 to Day 56.
11566666|NCT00883467|Other|1|baseline MR signal prior to, during and 30 minutes after an ischemic period of 20 minutes
11566667|NCT00883467|Other|2|baseline MR signal prior to, during and 30 minutes after an ischemic period of 20 minutes with additional 5 minutes of cuff stenosis directly after cuff release
11566668|NCT00883467|Other|3|short time preconditioning, other details according arm 2
11566669|NCT00883467|Other|4|long time preconditioning, other details according arm 2
11566670|NCT00883441|Experimental|VM|implementation of new vector control tools (insecticide treated curtains and jar covers) through the existing routine vector control programme
11566671|NCT00883441|Experimental|PM|implementation of new vector control tools (insecticide treated covers and curtains) through partnerships
11566672|NCT00883428||Pergnant women|Pregnant women, of 28 weeks or more of gestation, who are seen in the Health Centers participating in the study.
11566673|NCT00883402|Active Comparator|CEA|Carotid endarterectomy
11566674|NCT00883402|Active Comparator|CAS|Carotid Artery Stenting
11566675|NCT00883389||Safe Kidney Care|Patients with Chronic Kidney Disease (eGFR < 60 ml/min/1.732)and not expected to need dialysis within 6 months of enrollment
11566676|NCT00883376||1|OSAS patients
11566677|NCT00883376||2|no OSAS patients
11566678|NCT00883363|Experimental|Precondition|Induction of precondition at start of operation on a arm
11566679|NCT00883363|No Intervention|Control|No precondition
11566680|NCT00883350|Experimental|RIDE|Participants randomized to utilize the RIDE e-health application for the duration of the 12 week intervention.
11566681|NCT00883350|No Intervention|Control|Participants assigned to the Health-Ed (control) group will receive health information via the cell phone throughout the 84-day study. We have generated numerous health information tips for other studies on a variety of topics, including stress management, the benefits of eating fruits and vegetables, etc. [6-9]. These lessons will be modified for delivery via cell phone. We have found that participants assigned to these health information control groups report being satisfied with the information and their assignment. Importantly, our data also indicate that such health information results in very little behavior change or weight loss, e.g., [6].
11566682|NCT00883337|Experimental|Teriflunomide 7 mg / 14 mg|Teriflunomide 7 mg once daily (core treatment period) and teriflunomide 14 mg once daily (extended treatment period).
11566683|NCT00883337|Experimental|Teriflunomide 14 mg / 14 mg|Teriflunomide 14 mg once daily (core treatment period) and teriflunomide 14 mg once daily (extension treatment period).
11566684|NCT00883337|Active Comparator|IFN-β-1a / 14 mg|Interferon β-1a 3 times a week (core treatment period) and teriflunomide 14 mg once daily (extended treatment period).
11566685|NCT00883324||1|fetal fibronectin specimens collected with a speculum
11566686|NCT00883324||2|fetal fibronectin specimens collected without a speculum
11566687|NCT00883298|Experimental|Open Label|temozolomide plus bevacizumab administered as open label single arm treatment
11566688|NCT00883285||1|conventional aortic valve replacement
11566689|NCT00883285||2|transfemoral aortic valve replacement
11566690|NCT00883285||3|transapical aortic valve replacement
11566691|NCT00883272||Normal Controls|25 women with CADP-CT > 66 seconds were treated with Femarelle
11566692|NCT00883272||Thrombophilic|Seven women in cohort of a previous study were found to have shortened closure times (CADP-CT < 61s) at time of enrollment. They all underwent genetic testing for a hypercoagulable state.
11566693|NCT00883259|Experimental|Experimental|Metformin treatment
11566694|NCT00883259|Placebo Comparator|Placebo|Placebo tablets
11566695|NCT00883246|Other|Atherectomy|All patients enrolled in this single-arm study were treated with directional atherectomy.
11566696|NCT00883233|Experimental|1|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks
11566697|NCT00883233|Experimental|2|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks
11566698|NCT00883233|Experimental|3|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
11566699|NCT00883233|Active Comparator|4|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week
11566700|NCT00883220|Experimental|Self-management of urinary catheter|Intervention: Self-management group--teaching behavioral approaches(awareness, self-monitoring, and self-management) to prevent or minimize urinary catheter complications.
11566701|NCT00883220|No Intervention|Usual care 2|Usual care for urinary catheter. Home care and/or clinic care is the usual care for people with long-term urinary catheters.
11566702|NCT00883194|Experimental|1|PRF-108 Gel, 4% ropivacaine
11566703|NCT00883194|Placebo Comparator|2|PRF-108 Gel, Vehicle
11566704|NCT00883194|Active Comparator|3|Ropivacaine Solution 0.5%
11566705|NCT00883194|Experimental|PRF-110, 4%|PRF-110, 4% ropivacaine
11566706|NCT00883168|Placebo Comparator|placebo|
11566707|NCT00883168|Active Comparator|azelastine Hcl|
11566708|NCT00883168|Active Comparator|fluticasone propionate|
11566709|NCT00883168|Experimental|azelastine Hcl /fluticasone propionate|
11566710|NCT00883155|Experimental|1|Bupropion HCl 100 mg Tablets (Invamed Inc.)
11566711|NCT00883155|Active Comparator|2|Wellbutrin 100 mg Tablets (Glaxo Wellcome)
11566712|NCT00883142||Group 1|
11566713|NCT00883129|Experimental|Mycophenolate Arm|Participants will receive oral mycophenolate mofetil for 2 years.
11566714|NCT00883129|Experimental|Cyclophosphamide Arm|Participants will receive oral cyclophosphamide for 1 year, followed by placebo for 1 year.
11566715|NCT00883116|Experimental|Ixabepilone, 40 mg/m^2, intravenously (IV)|Participants received ixabepilone, 40 mg/m^2, given IV over 3 hours every 21 days until unacceptable toxicity or disease progression
11566864|NCT00882141|Experimental|1|Weight loss
11566865|NCT00882141|Experimental|2|Exercise plus weight loss
11566866|NCT00882128||1|
11566868|NCT00882102|Experimental|Decitabine + Gemtuzumab Ozogamicin|Decitabine 20 mg/m^2 by vein (IV) over 1-1/2 hours daily for 5 days. Gemtuzumab ozogamicin 3 mg/m^2 by vein on day 5.
11566716|NCT00883116|Active Comparator|Control chemotherapy (Paclitaxel or Doxorubicin)|Participants received either paclitaxel, 175 mg/m^2 given IV over 3 hours, or per institutional guidelines but not exceeding 3 hours, every 21 days until disease progression or unacceptable toxicity or doxorubicin, 60 mg/m^2 given IV per institutional guidelines every 21 days, depending on the prior therapy received, until disease progression, unacceptable toxicity, or cumulative dose of 500 mg/m^2.
11566717|NCT00883103|Active Comparator|Lidocaine|2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
11566718|NCT00883103|Placebo Comparator|Aqueous gel|Plain aqueous gel as placebo will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
11566719|NCT00883090|Experimental|FXIII|All subjects treated with Factor XIII Concentrate (Human) (FXIII)
11566720|NCT00883077||Inflammation|Patients with long standing history or short onset of ulcerative colitis.
11566721|NCT00883077||Healthy controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
11566722|NCT00883077||Irritable bowel syndrome|Patients admitted to outpatient department with symptoms meeting ROME III criteria of irritable bowel syndrome.
11566723|NCT00883064|Experimental|1|Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)
11566724|NCT00883064|Active Comparator|2|Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)
11566725|NCT00883051|Experimental|50 mg Lasmiditan|50 mg lasmiditan administered orally (PO)
11566726|NCT00883051|Experimental|100 mg Lasmiditan|100 mg lasmiditan administered orally (PO)
11566727|NCT00883051|Experimental|200 mg Lasmiditan|200 mg lasmiditan administered orally (PO)
11566728|NCT00883051|Experimental|400 mg Lasmiditan|400 mg lasmiditan administered orally (PO)
11566729|NCT00883051|Placebo Comparator|Placebo|Placebo administered orally (PO)
11566730|NCT00883038|Active Comparator|Active Comparator|Diabetic diet following the DNSG guidelines
11566731|NCT00883038|Experimental|Experimental|Low-fat vegetarian diet
11566732|NCT00883025||1|OSAS patients
11566733|NCT00883025||2|no OSAS Patient
11566734|NCT00883012|Experimental|Influenza vaccine|Two doses of trivalent sub-unit influenza vaccine (2009) to be administered one month apart
11566735|NCT00883012|Placebo Comparator|Placebo|Two doses of saline administered one month apart
11566736|NCT00882999|Placebo Comparator|Placebo|Injection: Every 4 weeks in the placebo arm for 24 weeks (Weeks 0, 4, 8, 12, 16, and 20) for a total of 6 doses. Every 4 weeks in the LY2127399 arms [4 milligrams (mg) LY2127399 / 12 weeks and 120 mg LY2127399 / 12 weeks] for 24 weeks (except Week 0 and Week 12).
11566737|NCT00882999|Experimental|4 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
11566738|NCT00882999|Experimental|40 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
11566739|NCT00882999|Experimental|120 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
11566740|NCT00882999|Experimental|4 mg LY2127399 / 12 weeks|"Drug: LY2127399 Injection: 2 doses, one every 12 weeks for 24 weeks.
~Drug: Placebo Injection: Every 4 weeks for 24 weeks (except Week 0 and Week 12)."
11566741|NCT00882999|Experimental|120 mg LY2127399 / 12 weeks|"Drug: LY2127399 Injection: 2 doses, one every 12 weeks for 24 weeks.
~Drug: Placebo Injection: Every 4 weeks for 24 weeks (except Week 0 and Week 12)."
11566742|NCT00882999|Experimental|12 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
11566743|NCT00882986||1|Men with high fitness (above VO2max of 60)
11566744|NCT00882986||2|Men with average fitness (below VO2max of 50)
11566745|NCT00882973|Experimental|Cohort 1|Genexol-PM 220 mg/m2 + Gemcitabine 1,250 mg/m2
11566746|NCT00882973|Experimental|Cohort 2|Genexol-PM 260 mg/m2 + Gemcitabine 1,250 mg/m2
11566747|NCT00882973|Experimental|Cohort 3|Genexol-PM 300 mg/m2 + Gemcitabine 1,250 mg/m2
11566748|NCT00882960|Active Comparator|1|patients who are randomized to receive intravenous fentanyl for control of their pain
11566749|NCT00882960|Active Comparator|2|patients who are randomized to receive intra-nasal fentanyl for control of their pain
11566750|NCT00882947||Group 1|
11566751|NCT00882934|Experimental|A1|Arm 1 received an informative letter explaining that they were allocated to receive a substance for Erectile Dysfunction treatment.
11566752|NCT00882934|Placebo Comparator|A2|Arm 2 (A2) was written informed that they could or could not receive an active drug for ED treatment.
11566753|NCT00882934|Experimental|A3|Arm 3 (A3) was properly written informed to be using no effective drug for ED treatment.
11566754|NCT00882921||Elaprase|Idursulfase 0.5 mg/kg Weekly
11566755|NCT00882908|Experimental|TMC435 75 mg 12 Wks + PR 24/48|Participants will receive TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
11566756|NCT00882908|Experimental|TMC435 75 mg 24 Wks + PR 24/48|Participants will receive TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
11566757|NCT00882908|Experimental|TMC435 150 mg 12 Wks + PR 24/48|Participants will receive TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
11566758|NCT00882908|Experimental|TMC435 150 mg 24 Wks + PR 24/48|Participants will receive TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
11566759|NCT00882908|Placebo Comparator|Placebo 24 Wks + PR48|Participants will receive Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.
11566867|NCT00882115|Experimental|DEP challenge in subjects consuming BSE|DEP will be administered in nostrils of participants who received BSE intervention by drinking 1 cup of liquid containing 1.25 g BSE daily for 4 days, or without consuming BSE.
11567017|NCT00881023|Active Comparator|1|Randomized to Microfracture
11566760|NCT00882895|Experimental|Allogeneic Transplant|"TLI - 80 cGy on days -14, -11, -10, -9, -8, -7, -4, -3, -2, -1
~Anti-thymocyte globulin (ATG) 1.5 mg/kg on days -11, -10, -8, -7
~Solumedrol - 1 mg/kg on days -11, -10, -9, -8, -7
~Tacrolimus - beginning on day -3 with starting dose of 0.3 mg/kg PO BID. Will be continued per institutional guidelines.
~Stem cell infusion - day 0
~Mycophenolate mofetil (MMF) - beginning on day 0 with dose of 15 mg/kg PO (5-10 hours after transplant)"
11566761|NCT00882882|Experimental|1|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
11566762|NCT00882882|Experimental|2|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
11566763|NCT00882882|Active Comparator|3|GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb
11566764|NCT00882882|Active Comparator|4|GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb
11566765|NCT00882856|Active Comparator|Bisoprolol-washout -placebo|Bisoprolol - wash out - placebo
11566766|NCT00882856|Active Comparator|Placebo - wash out - bisoprolol|Placebo - wash out - bisoprolol
11566767|NCT00882843||Group 1|Healthy Able bodied Control
11566768|NCT00882843||Group 2|Spinal Cord Injury
11566769|NCT00882830|Experimental|EMS group|
11566770|NCT00882830|No Intervention|control group|
11566771|NCT00882817|Active Comparator|1|Pulmonary Rehabilitation
11566772|NCT00882817|No Intervention|2|
11566773|NCT00882804|Experimental|Hemin|
11566774|NCT00882804|Placebo Comparator|placebo|
11566775|NCT00882791||Historical Arm|266 cases of BCC treated with Mohs surgery approximately 2-5 years ago will be assessed for recurrence.
11566776|NCT00882791||Prospective Arm|300 cases of BCC will be followed annually for 3 years after Mohs surgery to assess for recurrence.
11566777|NCT00882778||activated recombinant human factor VII|Male patients diagnosed with haemophilia A or B with inhibitors, who were prescribed activated recombinant human factor VII (rFVIIa) for at least 30 days. All direction for rFVIIa medication usage was at the sole discretion of the physician in accordance within their usual practice. Data was collected for approximately 6 months of pre-prophylaxis, while the prophylaxis period had no limits.
11566778|NCT00882765|Experimental|Arm I|Patients receive neoadjuvant oral genistein once daily for 2 weeks in the absence of disease progression or unacceptable toxicity.
11566779|NCT00882765|No Intervention|No intervention|Patients receive no specific neoadjuvant therapy.
11566780|NCT00882752||Ulcerative colitius|The method used to identify the microbes in the sample was chosen because it had the potential to provide more exhaustive identification of the bacteria present in the sample as compared to culturing methodology.
11566781|NCT00882739|Other|no pre-treatment|No pre-treatment at first medical contact - Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
11566782|NCT00882739|Experimental|600 mg loading dose|600 mg clopidogrel loading dose at first medical contact
11566783|NCT00882739|Experimental|900 mg loading dose|900 mg clopidogrel loading dose at first medical contact
11566784|NCT00882726|Experimental|CNTO 3649 IV (Healthy participants)|
11566785|NCT00882726|Experimental|CNTO 3649 SC (Healthy participants)|
11566786|NCT00882726|Experimental|CNTO 3649 SC (Diabetic patients)|
11566787|NCT00882713|Experimental|C.E.R.A.|Eligible participants will be administered continuous erythropoietin receptor activator (C.E.R.A.[Mircera]) intravenously (IV) every 4 weeks for 44 weeks. The starting dose of 120, 200, or 360 micrograms (mcg) will be based on the dose of epoetin alfa or beta administered in the week preceding the switch to C.E.R.A. Subsequent doses will be adjusted to maintain the individual participant's hemoglobin (Hb) within a range of +/- 1.0 grams per deciliter (g/dL) of the reference hemoglobin (Hb) concentration and between 10.50 and 12.50 g/dL.
11566788|NCT00882700|Experimental|1|Cefdinir 300 mg Capsule (Sandoz, Austria)
11566789|NCT00882700|Active Comparator|2|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
11566790|NCT00882687|Experimental|0.1% Lifitegrast|
11566791|NCT00882687|Experimental|1.0% Lifitegrast|
11566792|NCT00882687|Experimental|5.0% Lifitegrast|
11566793|NCT00882687|Placebo Comparator|Placebo|
11566794|NCT00882674|Experimental|1|
11566795|NCT00882661|Experimental|SECURE-C Cervical Artificial Disc|Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc
11566796|NCT00882661|Active Comparator|ASSURE Cervical plate and an allograft interbody spacer|Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
11566797|NCT00882648||Drug dependent women|All drug dependent women enrolled in comprehensive substance abuse treatment at the Center for Addiction and Pregnancy of Johns Hopkins University between 2004 and 2009; retrospective chart review.
11566798|NCT00882635|Experimental|Enoxaparin|
11566799|NCT00882635|Active Comparator|Unfractionated heparin|
11566800|NCT00882622|Active Comparator|RIPC|
11566801|NCT00882622|Sham Comparator|CONTROL|
11566802|NCT00882609|Active Comparator|TC-MDP Bone Scan|Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan
11566803|NCT00882609|Experimental|F18-Fluoride PET/CT|Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan
11566804|NCT00882596|Experimental|1|Contura accelerated partial breast irradiation. Following a lumpectomy, a Contura balloon catheter is placed in the lumpectomy cavity. Later that morning, accelerated partial breast irradiation begins.
11566805|NCT00882583|Experimental|Dasatinib/Cetuximab/RT|"In Cohort A , there will be an initial run-in period of single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8 and oral dasatinib at specific dose level from day 8-14.
~Cohort A will consist of patients with AJCC stage II (T2N0) and III (T1-2N1) SCCHN of oral cavity, oropharynx, T2N0 hypopharynx, T2N0-1 supraglottic larynx. Treatment will be dasatinib at specific dose level in combination with cetuximab 250mg/m2 IV and radiation therapy (RT) 70Gy at 2Gy/fn."
11566869|NCT00882089|Experimental|1|A Contura balloon catheter is placed in the lumpectomy cavity. Later that morning, accelerated partial irradiation begins.
11566806|NCT00882583|Experimental|Dasatinib/Cetuximab/cisplatin/RT|"In Cohort B, there will be an initial run-in period of single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8 and oral dasatinib at specific dose level from day 8-14.
~Cohort B will include patients with AJCC stage III (T3N0-1) and IV (T1-4N2-3M0, T4N0-1M0) squamous cell carcinoma of Oral Cavity, Oropharynx, Hypopharynx, and Larynx. Treatment will be daily dasatinib at specific dose level, in combination with q 3 week cisplatin 75mg/m2, weekly cetuximab 250mg/m2 IV and RT 70Gy ( 2gy per fraction)."
11566807|NCT00882570|Experimental|1|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)
11566808|NCT00882570|Active Comparator|2|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)
11566809|NCT00882557|Experimental|A|9 mg/kg of daptomycin administered during the last 30 minutes of a hemodialysis session.
11566810|NCT00882557|Experimental|B|Post dialysis dosing
11566811|NCT00882544||Diagnosed Pediatric Hydronephrosis|Children diagnosed with hydronephrosis who are to receive robotic pyeloplasty surgery
11566812|NCT00882531|Experimental|Isotretinoin|
11566813|NCT00882531|Placebo Comparator|placebo|
11566814|NCT00882518|Experimental|1-Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)|Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) extended-release (300 mg/1st day, 600 mg/2nd day, 400 or 600 or 800 mg/3-42 day)
11566815|NCT00882518|Active Comparator|2-Chlorpromazine|Chlorpromazine (50 or 100 mg/1st day; 100-200 mg/2nd day; 150-300 mg/3rd day; 200-400 mg/4th day; 300 or 400 or 500 or 600 mg/5-42 days)
11566816|NCT00882505|Experimental|Vitamin D supplement|Receive vitamin D supplements.
11566817|NCT00882505|Placebo Comparator|Placebo|Receive placebo pills
11566818|NCT00882505|No Intervention|Tanning bed user|Regular tanning bed users will be assessed for their vitamin D levels.
11566819|NCT00882492|Active Comparator|1|This active arm is a continuous infusion of GLP-1 during cardiac surgery
11566820|NCT00882492|Placebo Comparator|2|This is a continuous infusion of normal saline solution infusion as placebo at (1.5 pmol/kg/min)
11566821|NCT00882466|No Intervention|PCI only|primary PCI only
11566822|NCT00882466|Experimental|EPO|
11566823|NCT00882453||Group 1|
11566824|NCT00882440|Placebo Comparator|1|Placebo
11566825|NCT00882440|Experimental|2|Losartan 10 mg
11566826|NCT00882440|Experimental|3|Losartan 25 mg
11566827|NCT00882440|Experimental|4|Losartan 50 mg
11566828|NCT00882440|Experimental|5|Losartan 100 mg
11566829|NCT00882440|Experimental|6|Losartan 150 mg
11566830|NCT00882440|Active Comparator|7|Enalapril 20 mg
11566831|NCT00882427|Experimental|eMPC|improved model predictive control algorithm (eMPC) for glycaemic control in ICU patients
11566832|NCT00882414|Placebo Comparator|ThromboVIT Placebo|Patients will receive 1 placebo infusion of 100ml 0.9% sodium chloride every 7 days for a total of 3 infusions.
11566833|NCT00882414|Experimental|ThromboVIT 1000|ThromboVIT 1000: Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride every 7 days for a total of 2 infusions (1000 mg) followed by 1 placebo infusion of 100ml 0.9% sodium chloride.
11566834|NCT00882414|Experimental|ThromboVIT 1500|Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride every 7 days for a total of 3 infusions (1500 mg).
11566835|NCT00882414|Experimental|ThromboVIT 500|ThromboVIT 500: Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride (500 mg) followed by 2 placebo infusions of 100ml 0.9% sodium chloride every 7 days.
11566836|NCT00882401|Active Comparator|Ergocalciferol (oral)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
11566837|NCT00882401|Placebo Comparator|Placebo|Matching placebo at same dose schedule as ergocalciferol
11566838|NCT00882388|Active Comparator|ASA|aspirin only
11566839|NCT00882388|Active Comparator|Cele|
11566840|NCT00882388|Experimental|ASA + Cele|
11566841|NCT00882388|Active Comparator|ASA + Clo|
11566842|NCT00882388|Experimental|ASA + Clo + Cele|
11566843|NCT00882375|Experimental|Nicotine|Nicotine
11566844|NCT00882375|Placebo Comparator|Placebo|Placebo
11566845|NCT00882362|Experimental|1|
11566846|NCT00882336||1|Patients 50+ years old, with at least one additional CV risk factor (with no previous CV event or hospitalization for a CV event)
11566847|NCT00882323|Experimental|Fludarabine|
11566848|NCT00882310|Experimental|Gemcitabine, Docetaxel, Capecitabine GTX|GTX - A two week regimen of Gemcitabine at 600 mg/m2 on days 4 and 1, infused over 60 minutes, Docetaxel at 30 mg/m2 on days 4 and 11, infused over 60 minutes and Capecitabine at 1000 mg/m2 (capped at 1000 mg BID days 1-14) followed by one week off for a total of a 21 day cycle. This is repeated for a total of 6 months.
11566849|NCT00882297|Active Comparator|1|Transversal approach guided placement
11566850|NCT00882297|Active Comparator|2|Longitudinal approach guided placement
11566851|NCT00882271|Experimental|1|Traditional Chinese Acupuncture
11566852|NCT00882271|Placebo Comparator|2|Placebo Acupuncture
11566853|NCT00882258|Experimental|12.5 mg Proellex|Proellex 12.5 mg daily
11566854|NCT00882258|Experimental|25 mg Proellex daily|Proellex 25 mg
11566855|NCT00882258|Placebo Comparator|Placebo|Placebo daily
11566856|NCT00882245|Placebo Comparator|Vehicle ointment|
11566857|NCT00882245|Experimental|SRD441 Ointment|
11566858|NCT00882232|Experimental|1|Cross-linked hyaluronan gel and radiotherapy. Cross-linked hyaluronan gel is injected under anesthesia between the prostate and rectum prior to the start of radiotherapy. The gel pushes the prostate away from the rectum over several months, thereby reducing the dose of radiation delivered to the rectum. Hyaluronic acid is a naturally-occurring substance that is gradually absorbed by the body.
11566859|NCT00882219|Experimental|Xience V®|
11566860|NCT00882206|Experimental|Decitabine / Vorinostat|This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.
11566861|NCT00882167||1|Patients with laparotomy in history
11566862|NCT00882154|Experimental|1|Cefdinir 300 mg Capsule (Sandoz, Austria)
11566863|NCT00882154|Active Comparator|2|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
11566870|NCT00882076|Experimental|Treatment Cohort 1|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2 (3 doses); Clofarabine (Days 2-6) 20 mg/m2
11566871|NCT00882076|Experimental|Treatment Cohort 2|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 25 mg/m2
11566872|NCT00882076|Experimental|Treatment Cohort 3|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 30 mg/m2
11566873|NCT00882076|Experimental|Treatment Cohort 4|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-5) 8 mg/m2; Clofarabine (Days 2-6) 30 mg/m2
11566874|NCT00882076|Experimental|Treatment Cohort 0|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 10 mg/m2 (In the event of a DLT in Treatment Cohort 1)
11566875|NCT00882063|Experimental|P276-00|Starting dose level of P276-00 is 50 mg/m2/day. The drug will be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min. Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.
11566876|NCT00882050|Active Comparator|1|Exenatide to be infused by intravenous method at 0.27 ng/kg/min (0.066 pmol/kg/min)
11566877|NCT00882050|Active Comparator|2|IV Exenatide to be infused by intravenous method at0.41 ng/kg/min (0.099 pmol/kg/min)
11566878|NCT00882050|Placebo Comparator|3|Placebo of normal saline solution
11566879|NCT00882037||Meth Dependence|Methamphetamine Dependence in residential Substance Abuse Treatment Program
11566880|NCT00882024|Experimental|1 Tranilast|Tranilast, 300 mg/day
11566881|NCT00882024|Experimental|2 Tranilast|Tranilast, 150 mg/day
11566882|NCT00882024|Placebo Comparator|3|Placebo
11566883|NCT00882011||Arm 1|Adult patients with T-lymphoblastic lymphoma treated with intensive chemo/radiotherapy or intensive chemotherapy followed by transplant.
11566884|NCT00881998|Active Comparator|1|Minimally invasive total hip arthroplasty
11566885|NCT00881998|Active Comparator|2|
11566886|NCT00881985|Active Comparator|continuous positive airway pressure|
11566887|NCT00881985|No Intervention|observation|
11566888|NCT00881972|Experimental|exercise|
11566889|NCT00881959|Experimental|Group 1: Puros Dermis|Experimental treatment group of subjects who each have a single non-adjacent Miller's Class I or II gingival recession defect, greater than or equal to 2 mm, located on the buccal aspect of the maxillary incisor, canine, or premolar.
11566890|NCT00881959|Active Comparator|Group 2: Alloderm|Control group of subjects who each have a single non-adjacent Miller's Class I or II gingival recession defect, greater than or equal to 2 mm, located on the buccal aspect of the maxillary incisor, canine, or premolar.
11566891|NCT00881946|Experimental|GSK2119183|
11566892|NCT00881933|Experimental|Fludarabine|
11566893|NCT00881920|Experimental|Kappa CD28 T cells for B-CLL|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
11566894|NCT00881920|Experimental|Kappa CD28 T cells for B-cell lymphoma|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
11566895|NCT00881920|Experimental|Kappa CD28 T cells for myeloma|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
11566896|NCT00881907|Experimental|Group A|Group A subjects will be asked to attend a recall visit 2 months following completion of the treatment visits.
11566897|NCT00881907|Experimental|Group B|Group B subjects will be asked to attend a recall visit at 4 months following completion of the treatment visits.
11566898|NCT00881907|Experimental|Group C|Group C subjects will be asked to attend a recall visit at 6 months following completion of the treatment visits.
11566899|NCT00881894|Experimental|Sequence A-B (Test: PR2.1.1 - Reference: PR1.0)|Two single applications of rotigotine patches from two different manufacturing processes in the order A-B separated by a washout phase of at least 5 days
11566900|NCT00881894|Experimental|Sequence B-A (Reference: PR1.0 - Test: PR2.1.1)|Two single applications of rotigotine patches from two different manufacturing processes in the order B-A separated by a washout phase of at least 5 days
11566901|NCT00881881||1|Patients with early RA
11566902|NCT00881868|Active Comparator|Clobex Spray|
11566903|NCT00881868|Placebo Comparator|Vehicle spray|
11566904|NCT00881855|Experimental|1|Cefprozil 500 mg Tablets (Sandoz, GmbH)
11566905|NCT00881855|Active Comparator|2|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)
11566906|NCT00881842|Experimental|1|
11566907|NCT00881829||Healthy volunteer|Smoker or non-smoker
11566908|NCT00881816|Experimental|Liposomal paclitaxel plus capecitabine|
11566909|NCT00881803||Group 1|Ascorbic Acid Supplementation Only
11566910|NCT00881803||Group 2|Iron Supplementation Only
11566911|NCT00881803||Group 3|Concurrent Ascorbic Acid & Iron Supplementation
11566912|NCT00881790||Fluoride application|
11566913|NCT00881777|Experimental|RF Heating + CABG|Radiofrequency heating of the myocardial infarct scar plus Coronary Artery Bypass Grafting (CABG) surgery
11566914|NCT00881777|Active Comparator|CABG Alone|Coronary Artery Bypass Grafting (CABG) surgery only, without radiofrequency heating of the myocardial infarct scar
11566915|NCT00881764||Exposed Cohort|Children who had inguinal hernia surgery and general anesthesia before 36 months of age (n=500). These children should be ages 8 yr, 0 mo to 15 yr, 0 mo at the time of the study period.
11566916|NCT00881764||Unexposed Cohort|Children who are siblings of the exposed children (inguinal hernia surgery and general anesthesia) and differ in age from the exposed children by less than 36 months and have no history of surgery or exposure to volatile and intravenous anesthetics or sedatives including barbiturates, benzodiazepines and chloral hydrate less than 36 months of age. These children should also be ages 8 yr, 0 mo to 15 yr, 0 mo at the time of the study period.
11566917|NCT00881751|Experimental|Arm 1: bevacizumab and erlotinib|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28.
11566918|NCT00881751|Active Comparator|Arm 2: sorafenib tosylate|Patients receive oral sorafenib tosylate twice daily on days 1-28.
11566919|NCT00881738|Experimental|1|Clarithromycin 250 mg Tablets (Geneva, USA)
11566920|NCT00881738|Active Comparator|2|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)
11566921|NCT00881725|Experimental|Metformin|500mg t.i.d. for 4-12 weeks prior to Radical Prostatectomy
11566922|NCT00881712|Experimental|PET positive nodal disease measuring 15 mm or greater|Proton radiation with concomitant chemotherapy
11566923|NCT00881712|Experimental|PET positive nodal disease measuring less than 15 mm|Proton radiation
11566924|NCT00881712|Experimental|Patients considered resectable|Proton radiation plus surgery
11566925|NCT00881699|Experimental|1|Participants will complete HIV risk reduction group meetings.
11566926|NCT00881699|Active Comparator|2|Participants will complete health promotion group meetings.
11566927|NCT00881686|Experimental|adenosine|Adenosine will be administered intravenously before surgery
11566928|NCT00881673|Experimental|1|
11566929|NCT00881673|Active Comparator|2|
11566930|NCT00881673|Placebo Comparator|3|
11566931|NCT00881660|Experimental|Fetal Endotracheal Occlusion|Placement and retrieval of the GoldBAL4 or GoldBal2 Detachable balloon using the plug/unplug method, using BALTACCIDBPE100 Delivery Catheter.
11566932|NCT00881647|Experimental|1|Participants will receive an 8-week course of cognitive behavioral therapy for insomnia.
11566933|NCT00881647|No Intervention|2|Participants will be placed on a waitlist for 8 weeks.
11566934|NCT00881634|Experimental|1|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)
11566935|NCT00881634|Active Comparator|2|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
11566936|NCT00881621|Experimental|Lapatinib and Capecitabine|Treatment
11566937|NCT00881608|Placebo Comparator|Placebo|Initiation-Placebo Cycle-Five (5) placebo capsules will be dispensed to subjects to self-administer for five days starting on cycle day 18.
11566938|NCT00881608|Experimental|3 mg Proellex|First Cycle (3 mg)- Five (5) 3 mg capsules of Proellex will be dispensed to subjects to self-administer for five days starting on cycle day 18.
11566939|NCT00881608|Experimental|6 mg Proellex|Second Cycle (6 mg)-Subjects, who have not experienced menses, will have their dose of Proellex escalated, and be dispensed ten (10) 3 mg capsules of Proellex to self-administer 2, 3 mg capsules each day for five days starting on cycle day 18.
11566940|NCT00881608|Experimental|12 mg Proellex|Third Cycle (12 mg)-Subjects, who have not experienced menses, will have their dose of Proellex escalated, and be dispensed twenty (20) 3 mg capsules of Proellex to self-administer 4, 3 mg capsules for five days starting on cycle day 18.
11566941|NCT00881608|Experimental|25 mg Proellex|Fourth Cycle (25 mg)-Subjects, who have not experienced menses, will be dispensed five (5) 25 mg capsules of Proellex to self-administer for five days starting on cycle day 18.
11566942|NCT00881595|Other|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Temozolomide five days per week during radiotherapy for 5 weeks. Proton radiation five days per week for 5 weeks Standard surgery will take place 4-6 weeks after completion of chemoradiation.
11566943|NCT00881595|Active Comparator|Chemoradiotherapy Temozolomide|Chemoradiotherapy Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
11566944|NCT00881595|Active Comparator|Proton Therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
11566945|NCT00881582|Experimental|Pegylated interferon alfa-2a plus ribavarin|Pegylated interferon alfa-2a plus ribavarin for 48 weeks
11566946|NCT00881569|Experimental|1|CS-7017 tablets twice daily at strength ranging from 0.5 mg to 0.75 mg
11566947|NCT00881556|Experimental|group 1|Reduced Intensity
11566948|NCT00881543|Placebo Comparator|1|This arm will begin taking the placebo by a month, after a month will be tested the diets (the same caloric amount with different composition on fat, protein and carbohydrates)making curves of insulin, glucagon, C peptide and glp 1 and lipid when diets are tested (three acute tests with diets). After that, the patient will begin the drug by month (Januvia, 100 mg a day)and repeat all the three curves using the prepared diets to compare with the first month.
11566949|NCT00881543|Active Comparator|2|Since the beginning they will use the drug. Then will make the three tests and after will stop the drug by 1 month and come back to do the tests. We objective to demonstrate the washout of the drug clinically.
11566950|NCT00881530|Active Comparator|Sitagliptin|100 mg
11566951|NCT00881530|Active Comparator|Metformin|2000 mg
11566952|NCT00881530|Experimental|BI 10773 X mg|lower dose
11566953|NCT00881530|Experimental|BI 10773 Y mg|higher dose
11566954|NCT00881517|Experimental|Cytotect|
11566955|NCT00881517|Placebo Comparator|placebo|
11566956|NCT00881504|Experimental|"FOLFOX6 and Bevacizumab"|"Intervention = bevacizumab in combination with chemotherapy
~Treatment of biliary system carcinoma using Bevacizumab in combination with modified FOLFOX6."
11566957|NCT00881491|Experimental|Group A|Group A - Double antibiotic paste: intracanal medicament consisting of ciprofloxacin and metronidazole
11566958|NCT00881491|Experimental|Group B|Group B - Triple Antibiotic Paste: intracanal medicament consisting of ciprofloxacin, metronidazole, minocycline
11566959|NCT00881491|Active Comparator|Group C|Group C - Mineral trioxide aggregate: used as an apical barrier
11566960|NCT00881478|Active Comparator|Nutrition counselling alone|Nutrition counseling session with registered dietician
11566961|NCT00881478|Experimental|Nutrition counselling + portion control|Nutrition counseling with registered dietician in addition to teaching about use of a portion control tool
11566962|NCT00881465|Experimental|Cognitive-behavioral therapy|Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks. The first session will be held face-to-face to foster rapport. Sessions 1-4 will be held twice weekly; thereafter sessions will be held weekly. Sessions 1-3 are devoted to psychoeducation, treatment discussion, and hierarchy development. Sessions 4-10 involve CBT exercises specific to each youth.
11567016|NCT00881062|Experimental|25 mg Proellex|25 mg (100 µCi) [14C]-Proellex
11566963|NCT00881465|Placebo Comparator|Waitlist|Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
11566964|NCT00881452|Active Comparator|CM-AT|CM-AT (Luminenz-AT)- 900mg CM-AT, pancreatic enzyme concentrate (720mg)
11566965|NCT00881452|Placebo Comparator|Placebo|Placebo 900mg (Sucanate (98% w/w), Citric Acid (2% w/w)
11566966|NCT00881439|Placebo Comparator|Placebo|
11566967|NCT00881439|Active Comparator|Aliskiren|
11566968|NCT00881426|Experimental|1|Cefprozil 500 mg Tablets (Sandoz GmbH)
11566969|NCT00881426|Active Comparator|2|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)
11566970|NCT00881413|Experimental|Esomeprazole|High-dose esomeprazole
11566971|NCT00881413|Active Comparator|Pantoprazole|High-dose pantoprazole
11566972|NCT00881400|Experimental|1|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)
11566973|NCT00881400|Active Comparator|2|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)
11566974|NCT00881387|Experimental|Group 1 (eligible for SCT)|Patients receive rituximab IV, vinorelbine ditartrate IV over 6-10 minutes, and gemcitabine hydrochloride IV over 30 minutes on day 1 and pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response (CR) or partial response (PR) undergo SCT.
11566975|NCT00881387|Experimental|Group 2 (ineligible for SCT)|Patients receive rituximab, vinorelbine ditartrate, gemcitabine hydrochloride, and pegfilgrastim as in group 1. Patients with CR, PR, or stable disease after 3 courses continue to receive therapy in the absence of disease progression or unacceptable toxicity.
11566976|NCT00881374|Experimental|Dermacyd Infantile (Lactic Acid)|six weeks treatment
11566977|NCT00881361|Other|Study cohort|Patients who plan to receive or have received neoadjuvant chemotherapy are eligible. Patients undergo examination for breast and axilla lymph adenopathy and then undergo ultrasound of the axillary nodes at baseline and after completion of neoadjuvant chemotherapy. Within 12 weeks of completing neoadjuvant chemotherapy, patients undergo a mastectomy or lumpectomy (per surgeon discretion) including both sentinel lymph node surgery and axillary lymph node dissection.
11566978|NCT00881348|Experimental|Dermacyd infantile (Lactic Acid)|5 weeks treatment
11566979|NCT00881335|No Intervention|control group|
11566980|NCT00881335|Experimental|intervention|Intervention group were given flutter valve mucus clearance devices to do pulmonary function exercise
11566981|NCT00881322|Experimental|BC-130|Active Arm
11566982|NCT00881322|Placebo Comparator|Sugar Pill|Placebo
11566983|NCT00881309|Experimental|immunosuppressor|
11566984|NCT00881296|Experimental|1|"Gemcitabine 1000mg/m2 Day 1,15
~Carboplatin AUC=3 Day 1, 15 every 4 weeks"
11566985|NCT00881296|Active Comparator|2|Gemcitabine 1000mg/m2 Day 1, 8, 15
11566986|NCT00881283||cured Cushing's disease|
11566987|NCT00881270|Experimental|Dermacyd infantile (Lactic Acid)|treatment duration 21 consecutive days
11566988|NCT00881257|Experimental|1|GRST Peripheral Catheter System
11566989|NCT00881244|Experimental|1|AS1411
11566990|NCT00881231|Experimental|1|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)
11566991|NCT00881231|Active Comparator|2|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)
11566992|NCT00881218|Experimental|Regadenoson CMR|Images in the cardiac short axis will be obtained using a gradient recalled echo sequence, TR 2.3 msec/TE 1.1 msec, 80*256 matrix, slice thickness 10 mm. Images will be obtained during power injection of 0.075 mmol/Kg of a conventional gadolinium based MR contrast agent at a rate of 5 mL/sec followed by a 15 mL saline flush into an antecubital vein. Perfusion imaging will be performed at stress and rest. Stress: Regadenoson 400 mcg will be administered IV bolus via an antecubital cannula. Immediately after injection, MR scanning will begin and contrast will be given. Rest: After 10 minutes, rest imaging will be performed identically, but without regadenoson injection. To identify late enhancement of myocardial tissue inversion recovery prepared images will be obtained.
11566993|NCT00881205|Experimental|Rivastigmine|Rivastigmine patch arm with the application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size.
11566994|NCT00881205|Placebo Comparator|Placebo|Placebo patch arm with the application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size.
11566995|NCT00881192|No Intervention|Control|No preoperative IABP; if needed, postoperative IABP placement
11566996|NCT00881192|Active Comparator|IABP|Preoperative IABP placement
11566997|NCT00881179|Experimental|1|Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)
11566998|NCT00881179|Active Comparator|2|Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)
11566999|NCT00881166|Experimental|1|oral MP-470 + paclitaxel/carboplatin
11567000|NCT00881166|Experimental|2|oral MP-470 + carboplatin/etoposide
11567001|NCT00881166|Experimental|3|oral MP-470 + topotecan
11567002|NCT00881166|Experimental|4|oral MP-470 + docetaxel
11567003|NCT00881166|Experimental|5|oral MP-470 + Erlotinib
11567004|NCT00881153|Experimental|1|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)
11567005|NCT00881153|Active Comparator|2|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)
11567006|NCT00881140|Experimental|antiprogestin|Daily use of 10 mg administrated per vagina
11567007|NCT00881127|Experimental|1|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)
11567008|NCT00881127|Active Comparator|2|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
11567009|NCT00881114|Experimental|Cetuximab|patients with 2 or fewer genetic variants will receive cetuximab
11567010|NCT00881114|Experimental|Cisplatin|Subjects with 3 to 8 genetic variants will receive cisplatin
11567011|NCT00881101|Experimental|1|Liposomal paclitaxel
11567012|NCT00881088|No Intervention|1|Patients randomized to the no intervention group
11567013|NCT00881088|Experimental|Nadroparin|Subjects randomized to group receiving nadroparin 0,3 cc daily during immobilization
11567014|NCT00881088|Experimental|Fondaparinux|Subjects randomized to fondaparinux 2,5 mg daily group during immobilization
11567015|NCT00881075|Experimental|SeeMore(TM)|intravenous imaging agent for enhanced magnetic resonance imaging.
11567018|NCT00881023|Experimental|2|Randomized to Device
11567019|NCT00881023|Experimental|3|Non-randomized with lesion greater than 6cmˆ2
11567020|NCT00881010||Telephone Intervention|
11567021|NCT00881010||Usual Care|
11567022|NCT00880997|Experimental|Doxazosin|"Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:
~Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)
~Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)
~Both groups were tapered off doxazosin or placebo over study weeks 14-17."
11567023|NCT00880997|Placebo Comparator|placebo|A sugar pill to mimic the experiment drug, doxazosin, will be administered in the same manner as the experimental drug through the study duration.
11567024|NCT00880971|Experimental|PORT|Patients undergo thoracic radiotherapy using 3D-CRT or IMRT (50 Gy, 2 Gy once daily over 5 weeks) after postoperative chemotherapy.
11567025|NCT00880971|No Intervention|Non-PORT|Patients undergo postoperative chemotherapy.
11567026|NCT00880958|Experimental|1|
11567027|NCT00880958|Placebo Comparator|2|
11567028|NCT00880945||36-40 patients|patients with small peripheral lesions who need bronchoscopy for diagnostic purposes
11567029|NCT00880932|Experimental|customized electronic alert|"This intervention was not targeted to patients with a disease but to the providers. The intervention was not a drug but a customized electronic alert, requesting the prescriber to specify a reason for override whenever the combination drugs of warfarin and NSAID were ordered together."
11567030|NCT00880932|No Intervention|Standard practice|The control group was not patients but the providers. Providers in the control group continued with the standard practice of receiving passive alerts in the form of message boxes warning the provider not to prescribe the combination drugs warfarin and NSAID.
11567031|NCT00880919|Active Comparator|1|Seroquel XR 150mg oral tablets taken daily for 8 weeks.
11567032|NCT00880919|Active Comparator|2|Seroquel XR 300mg oral tablets taken daily for 8 weeks.
11567033|NCT00880919|Placebo Comparator|3|Equivalent number of placebo oral tablets taken daily for 8 weeks.
11567034|NCT00880906|Active Comparator|A|Group A receives steroids and PPI, (SOC) and esophageal dilation.
11567035|NCT00880906|Sham Comparator|B|Receives steroids and PPI only- Does not have esophageal dilation.
11567036|NCT00880893|Experimental|CYD Dengue Vaccine Group|Participant's received the CYD Dengue Vaccine at 0, 6, and 12 months as first, second, and third vaccinations, respectively.
11567037|NCT00880893|Sham Comparator|Placebo Group|All participants received a placebo at first vaccination (Month 0). Participants <12 years received hepatitis A at second (Month 6) and third (Month 12) vaccinations. Participants >= 12 years received influenza vaccine of Northern and Southern hemisphere formulations at second (Month 6) and third (Month 12) vaccinations.
11567038|NCT00880880|Experimental|pre-visit e-PAQ-PF|Participants assigned to fill out the e-PAQ-PF prior to their clinic visit. Participants will arrive early to clinic appointment and fill out e-PAQ-PF. Results will be given to clinician and participant. After their visit they will complete the post visit questionnaire.
11567039|NCT00880880|No Intervention|post-visit e-PAQ-PF|Participants assigned to complete the e-PAQ-PF after their clinic visit. Pre-visit participants will sign consent form - but otherwise will receive no study interventions. Post-visit they will fill out e-PAQ-PF and post visit questionnaire.
11567040|NCT00880867|Experimental|Poly-ICLC|Poly-ICLC plus low dose local radiation.
11567041|NCT00880854|Experimental|1|BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 in combination with CP-675,206 I.V. week 3, week 1
11567042|NCT00880841||no treatment|phase 1a study for healthy normals
11567043|NCT00880828|Experimental|A|FIR cervical collar plus Acetaminophen
11567044|NCT00880828|Active Comparator|B|Conservative cervical collar plus Acetaminophen
11567045|NCT00880828|Placebo Comparator|C|Acetaminophen only
11567046|NCT00880815|Experimental|Treatment (chemotherapy, stem cell transplant, rituximab)|Participants receive rituximab IV over 5-7 hours on days -13 and -6, fludarabine IV over 1 hour and bendamustine IV over 1 hour on days -5 to -3, and tacrolimus IV starting on day -2 and PO after hospital discharge for 6 to 8 months. Participants with MUD receive thymoglobulin on days -2 and -1. Participants undergo allogenic stem cell transplant over 30-45 minutes on day 0. Participants receive rituximab IV over 5-7 hours on days 1 and 8 and methotrexate IV over 30 minutes on days 1, 3, and 6. Participants with MUD also receive methotrexate IV on day 11. Participants receive G-CSF SC once daily starting on day 7 until white blood cell counts recover.
11567047|NCT00880789|Experimental|Dose Level One: 5x10^6/m2|CTL Dose Given from Day +30 post SCT (stem cell transplant). For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs. A maximum 18 patients will be accrued into each group. The final MTD will be the dose with probability closest to the target toxicity rate at these termination points. The trial continues until a minimum of 12 patients have been treated. The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD. We therefore expect to enroll between 12-18 patients into this trial.
11567048|NCT00880763|Experimental|Vaniprevir 200 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 100 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
11567049|NCT00880763|Experimental|Vaniprevir 600 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 300 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
11567050|NCT00880763|Experimental|Vaniprevir 1200 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 600 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
11567051|NCT00880763|Placebo Comparator|Placebo + peg-IFN + ribavirin|Participants will receive placebo twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
11567052|NCT00880750|Experimental|Lanthanum carbonate granules|Lanthanum carbonate granulated formulation crossover to chewable tablet formulation
11567053|NCT00880750|Experimental|Lanthanum carbonate chewable tablets (Fosrenol)|Lanthanum carbonate chewable table formulation crossover to granulated formulation
11567054|NCT00880737||Stable PE patients|Hemodynamically stable patients with acute symptomatic pulmonary embolism
11567055|NCT00880724|No Intervention|Medical management|
11567056|NCT00880711||1|Patient with advanced BC, already receiving Faslodex therapy
11567057|NCT00880698|Experimental|HIV-uninfected RotaTeq|HIV-1 uninfected participants receiving 3 doses of RotaTeq vaccine at intervals of 4-10 weeks with the third dose administered by 32 weeks of age.
11567058|NCT00880698|Placebo Comparator|HIV-uninfected Placebo|HIV-1 uninfected participants receiving 3 doses of placebo at intervals of 4-10 weeks with the third dose administered by 32 weeks of age
11567059|NCT00880698|Experimental|HIV-infected RotaTeq|HIV-1 infected participants receiving 3 doses of RotaTeq vaccine at intervals of 4-10 weeks with the third dose administered by 32 weeks of age.
11567060|NCT00880698|Placebo Comparator|HIV-1 infected Placebo|HIV-1 infected participants receiving 3 doses of placebo at intervals of 4-10 weeks with the third dose administered by 32 weeks of age
11567061|NCT00880685|Experimental|Memantine|Memantine 10-30mg
11567062|NCT00880672|Active Comparator|dutasteride|oral, 5mg, once per day, 2 weeks
11567063|NCT00880672|Placebo Comparator|placebo|oral, 5mg, once per day, 2 weeks
11567064|NCT00880659|Experimental|1|Promotion of handwashing with soap and maintenance of a fully stocked handwashing station.
11567065|NCT00880659|No Intervention|2|Practice of routine handwashing among the household members
11567066|NCT00880646|Experimental|1|
11567067|NCT00880646|Placebo Comparator|2|
11567068|NCT00880620|Placebo Comparator|Placebo|One Placebo capsule was given TID for the first 21 days. Two placebo capsules were given TID on days 22 till end of study (week 30).
11567069|NCT00880620|Experimental|IPX066 145 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-21. One IPX066 145 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).
11567070|NCT00880620|Experimental|IPX066 245 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. One IPX066 245 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).
11567071|NCT00880620|Experimental|IPX066 390 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. Two IPX066 195 mg LD capsules were given TID on days 22 till end of study (week 30).
11567072|NCT00880607|Active Comparator|Intrathecal morphine|Receives a single dose of intrathecal morphine
11567073|NCT00880607|Experimental|Extended Release Epidural Morphine|Receives DepoDur extended release epidural morphine for pain management
11567074|NCT00880594|Experimental|Open label desipramine|
11567075|NCT00880581|Experimental|PF-3512676|Patients will be treated with 18 mg PF-3512676 by intratumoral injection on day 2 following local radiotherapy, then weekly for a total of 10 injections over 10 weeks.
11567076|NCT00880568|Experimental|MK-1496 20 mg (21-Day Cycle)|Participants receiving MK-1496 20 mg on Day 1 of each 21-day cycle
11567077|NCT00880568|Experimental|MK-1496 40 mg (21-Day Cycle)|Participants receiving MK-1496 40 mg on Day 1 of each 21-day cycle
11567078|NCT00880568|Experimental|MK-1496 80 mg (21-Day Cycle)|Participants receiving MK-1496 80 mg on Day 1 of each 21-day cycle
11567079|NCT00880568|Experimental|MK-1496 120 mg (21-Day Cycle)|Participants receiving MK-1496 120 mg on Day 1 of each 21-day cycle
11567080|NCT00880568|Experimental|MK-1496 20 mg (28-Day Cycle)|Participants receiving MK-1496 20 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
11567081|NCT00880568|Experimental|MK-1496 40 mg (28-Day Cycle)|Participants receiving MK-1496 40 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
11567082|NCT00880568|Experimental|MK-1496 80 mg (28-Day Cycle)|Participants receiving MK-1496 80 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
11567083|NCT00880568|Experimental|MK-1496 100 mg (28-Day Cycle)|Participants receiving MK-1496 100 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
11567084|NCT00880568|Experimental|MK-1496 120 mg (28-Day Cycle)|Participants receiving MK-1496 120 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
11567085|NCT00880555||Arm 1: Non-Dementia Memory Disorder|Elderly patients with non-dementia memory disorder (mild cognitive impairment)
11567086|NCT00880555||Arm 2: Control|Elderly controls without memory impairment
11567087|NCT00880555||Arm 3: Mild Alzheimer Disease|Patients with mild Alzheimer disease (but preserved routine activities of daily living)
11567088|NCT00880542|Experimental|Sorafenib + Ifosfamide|"* Neoadjuvant therapy: Patients receive oral sorafenib tosylate twice daily on days 1-14 in course 1. Patients then receive oral sorafenib tosylate twice daily on days 1-28 and ifosfamide IV continuously on days 1-7 in courses 2 and 3. Treatment repeats every 14-28 days* for 3 courses.
~NOTE: *Course 1 is 14 days in duration; courses 2 and 3 are 28 days in duration.
~Surgery: At least 1 week after the completion of neoadjuvant therapy, patients undergo surgery.
~Adjuvant therapy: Beginning ≥ 3 weeks after surgery, patients who respond to neoadjuvant therapy receive oral sorafenib twice daily for 6 months. Patients also receive 2 courses of ifosfamide as in courses 2 and 3 of neoadjuvant therapy."
11567089|NCT00880529|Experimental|ON-Q|Subcutaneous bupivicaine administration and IV opioid medication if necessary
11567090|NCT00880529|Active Comparator|IV opioids alone|Standard therapy with IV opioid administration
11567091|NCT00880516||control|Adults with normal sinuses
11567092|NCT00880516||case|Adults with chronic sinusitis and positive findings on imaging.
11567093|NCT00880490|Experimental|1|Inhaled PT005 2.4 mcg
11567094|NCT00880490|Experimental|2|Inhaled PT005 4.8 mcg
11567095|NCT00880490|Experimental|3|Inhaled PT005 9.6 mcg
11567096|NCT00880490|Placebo Comparator|4|Inhaled Placebo
11567097|NCT00880490|Active Comparator|5|Formoterol Fumarate 12 mcg (Foradil Aerolizer)
11567098|NCT00880477|Experimental|Group A|
11567099|NCT00880477|Experimental|Group B|
11567100|NCT00880464|Experimental|Vaccine|Biological/Vaccine: Autologous, Lethally Irradiated Breast Cancer Cells Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
11567101|NCT00880425||Participants with continuous headache|
11567102|NCT00880425||Participnts with non-continuous headache|
11567103|NCT00880412|Experimental|EHT 0202 40 mg bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
11567104|NCT00880412|Experimental|EHT 0202 80 mg bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
11567105|NCT00880412|Placebo Comparator|placebo bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
11567106|NCT00880399|Placebo Comparator|Placebo|inactive placebo to match orvepitant 30 and 60 mg dosage forms
11567107|NCT00880399|Experimental|Orvepitant 30 mg|30 mg/day (low dose)
11567108|NCT00880399|Experimental|Orvepitant 60 mg|60 mg/day (high dose)
11567109|NCT00880386|Experimental|Losartan Group|50 mg Losartan tablet taken daily for 24 weeks
11567110|NCT00880373|Active Comparator|1|Diamorphine or Morphine by PCA and oral ibuprofen
11567111|NCT00880373|Placebo Comparator|2|Diamorphine or Morphine by PCA and oral placebo
11567112|NCT00880360|Experimental|Ontak|Administration of Ontak IV for treatment of epithelial ovarian cancer
11567113|NCT00880347|Other|Alzheimer's Disease|Group of patients clinically diagnosed with probable AD
11567114|NCT00880347|Other|Non-AD dementia|Group of patients clinically diagnosed with one of the 5 most frequent non-AD dementia : vascular dementia, mixed dementia, frontotemporal dementia, Lewy bodies dementia, Parkinson's disease dementia.
11567115|NCT00880347|Other|control subjects|Group of control subjects without any clinical cognitive impairment.
11567116|NCT00880334|Experimental|vandetanib & Docetaxel|vandetanib orally and Docetaxel intravenously
11567117|NCT00880334|Active Comparator|Placebo and Docetaxel|Placebo orally and docetaxel intravenously
11567118|NCT00880321|Experimental|Part 1|Part 1 will identify the recommended Part 2 dose using a dose-escalation procedure. Escalation may proceed until either a maximum tolerated dose is established, or the toxicokinetic safety limit is reached. Subjects may dose up to three times a day.
11567119|NCT00880321|Experimental|Part 2|Part 2 will explore further the safety, tolerability, and clinical activity of GSK2118436 in subjects with BRAF mutation-positive tumors using the recommended part 2 dose identified during Part 1. Biologically active doses will be identified by measurement of pharmacodynamic markers in tumor tissue and blood across a range of doses and these doses may be explored in Part 2.
11567120|NCT00880308|Experimental|LDE225|
11567121|NCT00880295|Active Comparator|endoscopic surgery|
11567122|NCT00880295|Active Comparator|open surgery|
11567123|NCT00880282|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 60 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.
11567124|NCT00880269|Experimental|Stratum A|patients with refractory acute myelogenous leukemia (AML) initially diagnosed as de novo AML received 60 mg of panobinostat per day on three discontinuous days per week.
11567125|NCT00880269|Experimental|Stratum B|patients with refractory AML initially diagnosed as AML secondary to myelodysplastic syndrome (MDS)/antecedent hematologic disorder (AHD) received 60 mg of panobinostat per day on three discontinuous days per week.
11567126|NCT00880256|Experimental|MBSR|Patients who undergo mindfulness-based stress reduction will fill out measures of IBS severity before and after the mindfulness course.
11567127|NCT00880243|Experimental|EMA+GM-CSF|"Daunorubicine (CérubidineR) : 80 mg/m2/jour IV over 30 min from day 1 to day 3,
~AraC (AracytineR) : 500 mg/m2/jour IV from day 1 to day 3,
~Mitoxantrone (NovantroneR) : 12 mg/m2/jour IV over 30 min from day 8 to 9
~AraC (AracytineR) : 500 mg/m2/12h IV over 3 hours from day 8 to day10.
~GM-CSF (LeucomaxR): 5 µg/kg/jour IV over 6 hours from day 1 to day 10."
11567128|NCT00880243|Active Comparator|EMA without GM-CSF|"Daunorubicine (CérubidineR) : 80 mg/m2/jour IV over 30 min from day 1 to day 3,
~AraC (AracytineR) : 500 mg/m2/jour IV from day 1 to day 3,
~Mitoxantrone (NovantroneR) : 12 mg/m2/jour IV over 30 min from day 8 to 9
~AraC (AracytineR) : 500 mg/m2/12h IV over 3 hours from day 8 to day10."
11567129|NCT00880243|Experimental|HD AraC+ GM-CSF|"AraC (Aracytine) : 3 g/m2/12h IV (3 hours) on days 1, 3 , 5
~GM-CSF :5 µg/kg/d IV (6 hours) from day1 to day 5"
11567130|NCT00880243|Active Comparator|HD-AraC without GM-CSF|- AraC (Aracytine) : 3 g/m2/12h IV (3 hours) on days 1, 3 , 5
11567131|NCT00880230|Experimental|Scuba Iliac Stent System|Device: Scuba™ iliac stent
11567132|NCT00880217|Experimental|001|JNJ-31001074 1 mg/d 1-mg capsule once daily for 42 days
11567133|NCT00880217|Experimental|002|JNJ-31001074 3 mg/d 3-mg capsule once daily for 42 days
11567134|NCT00880217|Experimental|003|JNJ-31001074 10 mg/d 10-mg capsule once daily for 42 days
11567135|NCT00880217|Active Comparator|004|Atomoxetine 80 mg/d 40-mg capsule for 3 days followed by 80-mg capsule once daily for 39 days
11567136|NCT00880217|Active Comparator|005|OROS methylphenidate HCl 54 mg/d 36-mg capsule for 3 days followed by 54-mg capsule once daily for 39 days
11567137|NCT00880217|Placebo Comparator|006|Placebo capsule once daily for 42 days
11567138|NCT00880204|Experimental|Trained doctors|ESS-EMCH Training will be provided to doctors working in general emergency, pediatrics and obstetrics department in district hospitals.
11567139|NCT00880204|No Intervention|No Training|No training will be given to doctors (act as controls)
11567140|NCT00880191|Experimental|Arm I|Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral gabapentin once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral gabapentin either two or three times daily on days 2-5 of chemotherapy.
11567141|NCT00880191|Experimental|Arm II|Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral placebo once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral placebo either two or three times daily on days 2-5 of chemotherapy.
11567142|NCT00880178||Simvastatin|Participants in the main AIM-HIGH study who are receiving simvastatin.
11567143|NCT00880178||Simvastatin and Extended-Release Niacin|Participants in the main AIM-HIGH study who are receiving simvastatin and extended-release niacin.
11567144|NCT00880165|Active Comparator|Arm 1|In-laboratory testing followed by continuous positive airway pressure treatment
11567145|NCT00880165|Active Comparator|Arm 2|Home unattended testing followed by continuous positive airway pressure treatment
11567146|NCT00880152|Experimental|MBSR|An 8-week course in mindfulness-based stress reduction (MBSR)
11567147|NCT00880152|No Intervention|2|Treatment as usual
11567148|NCT00880126|Experimental|CDT|Community Development Teams bring together counties who are implementing a new practice
11567149|NCT00880113||Acute stroke|Patients over 18 years of age with acute stroke symptoms of less then 9 hours duration and no hemorrhage on non-contrast CT.
11567150|NCT00880100|Experimental|Ultrase® MT12|
11567151|NCT00880087|Experimental|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia after experiencing cardiac arrest.
11567152|NCT00880087|Active Comparator|Therapeutic Normothermia|Participants will receive therapeutic normothermia after experiencing cardiac arrest.
11567153|NCT00880074|Experimental|FLT-PET Scan|FLT solution is administered through a peripheral intravenous catheter approximately 60 minutes before the PET scan. 3 Positron Emission Tomography (PET) scans performed 60-90 minutes after intravenous injection of FLT: 1) within 2 weeks before day 1 of chemotherapy treatment; 2) day 6-7 of chemotherapy treatment; and,3) at end of chemotherapy treatment, day 19-20.
11567154|NCT00880048|Experimental|orvepitant 30 mg|orvepitant 30 mg (low dose)
11567155|NCT00880048|Experimental|orvepitant 60 mg|orvepitant 60 mg (high dose)
11567156|NCT00880048|Placebo Comparator|Placebo|inactive placebo to match orvepitant 30 mg and 60 mg dosage forms
11567157|NCT00880035|Experimental|Group A|Group A: day 1 = music, day 2 = washout, day 3 = headphone without music
11567158|NCT00880035|Experimental|Group B|Group B: day 1 = headphone without music, day 2 = washout, day 3 = music
11567159|NCT00880022|Active Comparator|arm compression only|Intervention of arm compression only by Flexitouch System
11567160|NCT00880022|Experimental|arm, trunk and chest compression|Intervention of arm, trunk and chest compression by Flexitouch System
11567161|NCT00880009|Experimental|1|Combination of Bosutinib and Letrozole
11567162|NCT00880009|Active Comparator|2|Letrozole
11567163|NCT00879996|Active Comparator|1|Methadone 10-60 mg per day in 2-4 divided doses for 6 months
11567164|NCT00879996|Experimental|2|Buprenorphine 4-16 mg per day in 2-4 divided doses for 6 months (using tablets of buprenorphine/naloxone:4/1 mg)
11567165|NCT00879983|Other|Group 1|Will accept azithromycin ER first, after at least 14 days washout, then accept azithromycin tablet.
11567166|NCT00879983|Other|Group 2|Will accept azithromycin tablet first, after at least 14 days washout, then accept azithromycin ER .
11567167|NCT00879970|Active Comparator|pioglitazone|PIO tablet was administered in the dose of 30 milligrams (mg) OD initially and could be titrated to a maximum dose of 45 mg at or after the 6-month visit. After 1 year of treatment, the dose of PIO was increased to 45 mg OD for the duration of 5.5 years.
11567168|NCT00879970|Active Comparator|rosiglitazone|RSG tablet was administered in the dose of 4 mg OD initially and could be titrated to a maximum dose of 8 mg at or after the 6-month visit. After 1 year of treatment, the dose of RSG was increased to 8 mg OD for the duration of 5.5 years.
11567169|NCT00879970|Placebo Comparator|TZD placebo|Matching placebo tablet was administered once a day (OD) for the duration of 5.5 years
11567170|NCT00879970|Active Comparator|Vitamin D|Active comparator
11567171|NCT00879970|Placebo Comparator|Vitamin D placebo|Placebo Comparator
11567172|NCT00879957|Active Comparator|Heparin group|The heparin group is the arm of the study in which all of the subjects will be treated according to current standard medical therapy. All fluids to be infused through their PICCs will have 0.5 units heparin per milliliter of intravenous fluid.
11567173|NCT00879957|Experimental|No heparin group|This group will only receive the prescribed fluids to infuse through their PICCs. No heparin will be added to the intravenous infusions.
11567174|NCT00879944||Psoriasis|Children ages 5-17 years old with moderate or severe plaque type psoriasis. Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
11567175|NCT00879944||Atopic Dermatitis Controls|Children ages 5 to 17 years old with moderate to severe atopic dermatitis. Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
11567176|NCT00879944||Healthy Controls|"Children 5-17 years of age who are healthy and seen in dermatology clinic for a non-systemic skin condition.
~Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm"
11567177|NCT00879931|Experimental|1|methylprednisolone
11567178|NCT00879931|Placebo Comparator|2|Placebo (NaCl 0.9%)
11567179|NCT00879918|Experimental|Nicotine pharmacokinetics|circadian smoking protocol and IV pharmacokinetic protocol
11567180|NCT00879905|Experimental|once weekly dosing schedule|
11567181|NCT00879905|Experimental|twice weekly dosing schedule|
11567182|NCT00879892|Active Comparator|Hypothermia and xenon|
11567183|NCT00879892|Active Comparator|Hypothermia|
11567184|NCT00879879|Experimental|Losartan|50 mg tablets of losartan taken daily by mouth for 1 year
11567185|NCT00879866|Experimental|1|
11567186|NCT00879853|Experimental|Interpersonal Therapy|
11567187|NCT00879853|No Intervention|Wait List Control|
11567188|NCT00879840||Females|With endometrial cancer, ovarian cancer, and women undergoing hysterectomy for benign reasons.
11567189|NCT00879827|Experimental|Single Group|
11567190|NCT00879814|Experimental|1|rLP2086 vaccine 60 mcg
11567191|NCT00879814|Experimental|2|rLP2086 vaccine 120 mcg
11567192|NCT00879814|Experimental|3|rLP2086 vaccine 200 mcg
11567193|NCT00879814|Active Comparator|4|Tdap vaccine - normal saline - normal saline
11567194|NCT00879801||Subjects with IGR|Subjects at high risk of diabetes, such as those with impaired glucose regulation (IFG and or IGT)
11567195|NCT00879788|Experimental|1|Ramipril capsules 10 mg (containing Ramipril 10 mg)of of OHM Laboratories Inc., USA (a subsidiary of Ranbaxy Pharmaceuticals Inc), USA
11567196|NCT00879788|Active Comparator|2|ALTACE® capsule 10 mg (containing Ramipril 10 mg)of King Pharmaceuticals Inc., Bristol, TN 37620, USA
11567197|NCT00879775|Experimental|Caffeine|Intravenous injections of 200mg of caffeine with 100ml of normal saline over 1 hour
11567198|NCT00879775|Placebo Comparator|Placebo|Intravenous injections of 100ml of normal saline over 1 hour
11567199|NCT00879762|Experimental|Group A: High Dose|Single high dose of IMVAMUNE® (5x10^8 TCID50, consisting of two 0.5 mL injections) vaccine on Day 0 and a single saline placebo dose (single 0.5 mL injection) on Day 28 to match the two dose regimen of Group B.
11567200|NCT00879762|Active Comparator|Group B: Standard Dose|Standard two dose regimen of IMVAMUNE® (1x10^8 TCID50) vaccine on Day 0 (consisting of 0.5 mL injection of vaccine and 0.5 mL injection of saline placebo) and Day 28 (single 0.5 mL injection of vaccine).
11567201|NCT00879749|Placebo Comparator|Saline|
11567202|NCT00879749|Experimental|Nexvax2|
11567203|NCT00879736|Active Comparator|THT PACE eLearning module|The PACE (prepare, ask, check, express) training methodology will be available to patients before their 2nd doctor visit
11567204|NCT00879736|Active Comparator|THT PACE eLearning module & nurse-led workshop training|THT PACE eLearning and then nurse-led workshop for training on PACE methodology
11567205|NCT00879736|Placebo Comparator|Usual care|Patients just go to their doctor as they normally would but get some disease specific information in the form of brochures as do intervention arms
11567206|NCT00879723|Experimental|Vitamin and mineral supplementation|Intravenous micronutrient solution or an oral micronutrient supplementation twice per day for 14 days. Treatment is determined by percent total body surface area burned.
11567207|NCT00879723|No Intervention|Control|current vitamin regimen as listed on the Memorial medical Center Order Set for burn unit admission.
11567208|NCT00879710|Other|Subjects with type 1 diabetes mellitus, option 1|"Half the subjects will start with arm (i.e. every other subject in order)
~Simvastatin 40 mg tablet by month daily for 6 weeks,
~4 weeks washout period
~Half the subjects will start with arm (i.e. every other subject in order)
~Ezetimibe 10 mg by month for 6 weeks
~4 weeks washout period
~Simvastatin 40 mg tablet by month daily for 6 weeks"
11567209|NCT00879710|Other|Subjects with type 2 diabetes mellitus option 1|"Half the subjects will start with arm (i.e. every other subject in order)
~Simvastatin 40 mg tablet by month daily for 6 weeks,
~4 weeks washout period
~Half the subjects will start with arm (i.e. every other subject in order)
~Ezetimibe 10 mg by month for 6 weeks
~4 weeks washout period
~Simvastatin 40 mg tablet by month daily for 6 weeks"
11567210|NCT00879710|Other|Subjects with type 1 diabetes mellitus, option 2|"Half the subjects will start with arm (i.e. every other subject in order)
~Ezetimibe 10 mg by month for 6 weeks,
~4 weeks washout period"
11567211|NCT00879710|Other|Subjects with type 2 diabetes mellitus option 2|"Half the subjects will start with arm (i.e. every other subject in order) Ezetimibe 10 mg by month for 6 weeks,
~•4 weeks washout period"
11567212|NCT00879697|Active Comparator|Strength training|Patients who performed strength training. The strength training program was composed by 8 exercises for whole body performed at sub-maximal intensity prescribed according to the patients self-perceived effort
11567213|NCT00879697|Active Comparator|Walking training|Patients who performed walking training. The walking training was performed in a treadmill using sub-maximal intensity prescribed based in patients self perceived effort
11567214|NCT00879684|Experimental|1|
11567215|NCT00879671|Active Comparator|1|Lutamax
11567216|NCT00879671|Placebo Comparator|2|Placebo
11567217|NCT00879658|Experimental|BAF312 10mg (period 1)|
11567218|NCT00879658|Experimental|BAF312 2 mg (period 1)|
11567219|NCT00879658|Experimental|BAF312 0.5 mg (period 1)|
11567220|NCT00879658|Experimental|BAF312 dose between 0.1 to 8 mg period 2|
11567221|NCT00879658|Experimental|BAF312 dose between 0.1 - 8 mg period 2|
11567222|NCT00879658|Placebo Comparator|Placebo (period 1, 2)|
11567223|NCT00879645|Experimental|Sodium Sulfide - Mild Cohort|Mild renal impairment (RI) Cohort administered 1.5 mg/kg/hr infusion of Sodium sulfide intravenously for 3 hours.
11567224|NCT00879645|Experimental|Sodium Sulfide - Healthy Cohort|Healthy subjects received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
11567225|NCT00879645|Experimental|Sodium Sulfide - Moderate Cohort|Moderate RI cohort received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
11567226|NCT00879645|Experimental|Sodium Sulfide - Severe Cohort|Severe RI cohort received sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
11567227|NCT00879632||1|TREATMENT AS USUAL
11567228|NCT00879632||2|CONTROLS
11567229|NCT00879619|Experimental|Chemotherapy and enzyme inhibitor|Patients receive docetaxel IV over 60 minutes on day 1, prednisone PO BID on days 1-21, and sunitinib malate PO QD on days 2-15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sunitinib malate PO QD on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11567230|NCT00879606|Experimental|1|Participants will be randomized to receive ALT-836.
11567231|NCT00879606|Placebo Comparator|2|Patients will be randomized to receive placebo.
11567232|NCT00879593|Experimental|PtcCO2|
11567233|NCT00879580||Non-ruptured aneurysms|Patients with intracranial aneurysm(s) requiring an endovascular treatment with a Codman ENTERPRISE stent who have one or more non-ruptured or late ruptured (>30days), intracranial aneurysm.
11567234|NCT00879580||Acute ruptured Aneurysms|Patients with intracranial aneurysm(s) requiring an endovascular treatment with a Codman ENTERPRISE stent who have a on or more acute ruptured (<30Days) aneurysms
11567235|NCT00879554|Experimental|1|
11567236|NCT00879541|Other|PK Biostate® [SP]|"Part 1: PK subjects are randomized to receive Biostate® [SP] either on Day 1 or Day 8.
~Part 3: All PK subjects receive Biostate® [SP] on Day 180."
11567237|NCT00879541|Other|PK Biostate® [RP]|Part 1: PK subjects are randomized to receive Biostate® [RP] either on Day 1 or Day 8.
11567238|NCT00879541|Experimental|Efficacy|Part 2: This arm includes all subjects during the efficacy component of the study.
11567239|NCT00879515||1|Males and females with fragile X syndrome, ages 5 to 25 years old
11567240|NCT00879515||2|Males and females with the FMR1 premutation, ages 5 to 25 year old
11567241|NCT00879515||3|Males and females with Down syndrome, ages 5 to 25 years old
11567242|NCT00879515||4|Males and females with normal development, ages 5 to 25 years old
11567243|NCT00879502||1|Men with the fragile X premutation
11567244|NCT00879502||2|Healthy men
11567245|NCT00879502||3|Brothers of men with the fragile X premutation
11567246|NCT00879476|Experimental|1|Ramipril capsules 10 mg (containing Ramipril 10 mg)of of OHM Laboratories Inc., USA (a subsidiary of Ranbaxy Pharmaceuticals Inc), USA
11567247|NCT00879476|Active Comparator|2|ALTACE® capsule 10 mg (containing Ramipril 10 mg)of King Pharmaceuticals Inc., Bristol, TN 37620, USA
11567248|NCT00879463|Active Comparator|GROUP A|Brain tissue oxygen saturation monitoring
11567249|NCT00879463|Active Comparator|GROUP B|CONTROL GROUP
11567250|NCT00879450|Experimental|1 Booklet|
11567251|NCT00879450|Active Comparator|2 standard|
11567252|NCT00879437|Experimental|1|
11567253|NCT00879424|Experimental|1|
11567254|NCT00879424|Placebo Comparator|2|
11567255|NCT00879411||arterial hypertension|
11567256|NCT00879398||OAB-Toviaz|All patients who enrolled in this study
11567257|NCT00879385|Experimental|All patients|All participants enrolled.
11567258|NCT00879372|Placebo Comparator|1|Placebo
11567259|NCT00879372|Active Comparator|2|Tianeptine
11567260|NCT00879359|Experimental|I|
11567261|NCT00879346|Experimental|1|160mg oral dose of AZD8931
11567262|NCT00879333|Experimental|Everolimus + BSC|All patients were randomized to receive everolimus + BSC. All patients orally took two 5 mg tablets of everolimus once daily. Therefore, all patients in the everolimus arm took a total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
11567263|NCT00879333|Placebo Comparator|Placebo + BSC|All patients were randomized to receive placebo + BSC. All patients orally took two 5 mg tablets of matching placebo once daily. Therefore, all patients in the placebo receive matching tablets of total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
11567264|NCT00879320||1|Adults with ADHD
11567265|NCT00879320||2|Healthy adults without ADHD
11567266|NCT00879307|Experimental|1|Use of quetiapine
11567267|NCT00879294|Sham Comparator|1 Wristband|Some patients will be randomized to wear a motion sickness wristband which does not have any drug effect.
11567268|NCT00879294|Experimental|Chewing Gum|Patients will be randomized to use chewing gum after surgery.
11567269|NCT00879294|No Intervention|Control|Usual post-operative care.
11567270|NCT00879281|No Intervention|1 Care as usual|Regular care
11567271|NCT00879281|Experimental|2 Intervention|"Regular Care + individualized written action plan to enhance self-mananagement and early detection/treatment of an exacerbation."
11567272|NCT00879255|Experimental|Videoteleconferencing CPT|"The experimental arm is the group condition that received the CPT treatment via videoteleconferencing modality as compared to the experimental condition which is via face-to-face traditional modality.
~Cognitive Processing Therapy Group Videoteleconference is delivered to male combat veterans who have been diagnosed with PTSD, through videoteleconference."
11567273|NCT00879255|Active Comparator|Face-to-Face CPT|"The control arm is the group condition that received the CPT treatment via face-to-face traditional modality as compared to the experimental condition which is via videoteleconferencing modality.
~Cognitive Processing Therapy Group In-Person is delivered to male combat veterans who have been diagnosed with PTSD, in-person, rather than through videoteleconference."
11567274|NCT00879242|Experimental|Deferasirox|30 mg/kg/day. The daily dose can be increased to 40 mg/kg in case of unsatisfactory response after 12 weeks of treatment.
11567275|NCT00879229|Experimental|Ambrisentan|Participants were randomized to receive ambrisentan treatment at an initial dose of 5 mg for 4 weeks, followed by ambrisentan at the target dose of 10 mg for an additional 52 weeks
11567276|NCT00879229|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match ambrisentan for 48 weeks, then transition to ambrisentan treatment at the initial dose of 5 mg for 4 weeks, followed by ambrisentan at the target dose of 10 mg for an additional 4 weeks.
11567277|NCT00879216|Placebo Comparator|Sugar pill|
11567278|NCT00879216|Experimental|VA106483|
11567279|NCT00879203||Type 1 Diabetes (T1DM)|Youth and young adults with T1DM
11567280|NCT00879203||Non diabetic siblings|Non diabetic, young siblings of T1DM participants
11567281|NCT00879190|Active Comparator|Unasyn (ampicillin/sulbactam)|
11567282|NCT00879190|Active Comparator|Ampicillin/gentamicin|
11567283|NCT00879177|Active Comparator|Group A|Study drug (varenicline) for 12 weeks, brief smoking cessation counseling for 5 weeks, and ambulatory blood pressure monitoring at Weeks 6 and 24.
11567284|NCT00879177|Experimental|Group B|Study drug (varenicline) for 12 weeks, brief smoking cessation counseling for 5 weeks, ambulatory blood pressure monitoring at Weeks 6 and 24, and behavioral therapy for Weeks 2-5.
11567285|NCT00879151|Experimental|Psychotherapy|Patients are randomized to one of three different types of psychotherapy: Cognitive-Behavioral Therapy for adolescents, Family-Based Therapy for Bulimia Nervosa, and Supportive Psychotherapy. All treatments consist of 18 sessions over a period of approximately 6 months.
11567286|NCT00879138|Placebo Comparator|Sugar pill|
11567287|NCT00879138|Experimental|VA106483 2 mg|
11567288|NCT00879138|Experimental|VA106483 4 mg|
11567289|NCT00879138|Experimental|VA106483 8 mg|
11567290|NCT00879112|Experimental|1|MB07811 Cohort 1
11567291|NCT00879112|Experimental|2|MB07811 Cohort 2
11567292|NCT00879112|Experimental|3|MB07811 Cohort 3
11567293|NCT00879112|Placebo Comparator|4|Cohort 4
11567294|NCT00879099|Active Comparator|Paroxetine|
11567295|NCT00879099|Placebo Comparator|Gelatine capsule|
11567343|NCT00878774|Experimental|Cohort 4|ToleroMune Ragweed or placebo comparator
11567296|NCT00879099|Experimental|Timolol 0.5 % eye drops|The plasm levels of timolol will be measured after one drop of timolol has been administered into both eyes.
11567297|NCT00879099|Experimental|Timosan 0.1% eye gel|The plasm levels of timolol will be measured after one drop of timolol has been administered into both eyes.
11567298|NCT00879086|Active Comparator|1|
11567299|NCT00879086|Active Comparator|2|
11567300|NCT00879073|Experimental|A - Cohort 1 Treatment|Cohort 1: Bendamustine 60 mg/m² x 4 weeks
11567301|NCT00879073|Experimental|B - Cohort 2 Treatment|Cohort 2: Bendamustine 80 mg/m² x 4 weeks
11567302|NCT00879073|Experimental|C - Cohort 3 Treatment|Cohort 3: Bendamustine 100 mg/m² x 4 weeks
11567303|NCT00879060|Experimental|spironolactone|
11567304|NCT00879047|Experimental|HIV+, Ritonavir-regimen|10 subjects will be HIV+ and will begin receiving Ritonavir-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
11567305|NCT00879047|Experimental|HIV+/HCV+ Co-infected, Ritonavir-regimen|10 subjects will be HIV+/HCV+ co-infected and will begin receiving Ritonavir-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
11567306|NCT00879047|Experimental|HIV+, Efavirenz-regimen|10 subjects will be HIV+ and will begin receiving Efavirenz-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
11567307|NCT00879047|Experimental|HIV+/HCV+ Co-infected, Efavirenz-regimen|10 subjects will be HIV+/HCV+ co-infected and will begin receiving Efavirenz-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
11567308|NCT00879047|Experimental|Maraviroc in Healthy Subjects|10 healthy subjects will begin receiving maraviroc, and their PK interactions with alcohol/placebo will be evaluated.
11567309|NCT00879034|Experimental|Zoledronic Acid,Pravastatin,and Lonafarnib|Lonafarnib;Zoledronic acid;Pravastatin
11567310|NCT00879021|Placebo Comparator|Pregabalin, (other name) Lyrica|Study subjects wil be randomized to either the Pregabalin or Placebo group. There is a 5o ,50 chance of being in either group.
11567311|NCT00879021|Placebo Comparator|pregabalin, drug|study subjects that are randomized to the placebo group will receive matching placebo
11567312|NCT00879008||Group 1|
11567313|NCT00878995|Placebo Comparator|Standard of Care Therapy + Placebo Testosterone|Patients receive standard of care chemotherapy and/or radiation plus placebo testosterone intramuscularly (IM) weekly for 7 weeks.
11567314|NCT00878995|Active Comparator|Standard of Care Therapy + Testosterone|Patients receive standard of care chemotherapy and/or radiation plus testosterone (Testosterone Enanthate 100mg/ml) intramuscularly (IM) weekly for 7 weeks.
11567315|NCT00878969|Active Comparator|Valsartan|80 mg of valsartan (ARB) taken orally on a daily basis for 1 week followed by 160 mg of valsartan taken orally on a daily basis for 18 months
11567316|NCT00878969|Active Comparator|Ramipril|2.5 mg of ramipril (ACE inhibitor) taken orally on a daily basis for 1 week followed by 5 mg of ramipril taken orally on a daily basis for 18 months
11567317|NCT00878969|Placebo Comparator|Placebo|matching placebo taken orally on a daily basis for 1 week followed by matching placebo taken orally on a daily basis for 18 months
11567318|NCT00878956|Active Comparator|1|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
11567319|NCT00878956|Placebo Comparator|2|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
11567320|NCT00878917|Experimental|Dorzolamide|
11567321|NCT00878904|Experimental|treatment with Panobinostat and Epirubicin|
11567322|NCT00878891|Active Comparator|1. Conventional glucose monitoring|Discontinuous glucose monitoring - GlucoDay Device with Continue record blinded
11567323|NCT00878891|Experimental|2. Conventional glucose monitoring + Glucoday|Continuous glucose monitoring - GlucoDay device with Continue record displayed
11567324|NCT00878878|Experimental|Arm A|
11567325|NCT00878878|Experimental|Arm B|
11567326|NCT00878865|Experimental|Alprazolam 1 mg tablet|Alprazolam 1 mg tablet
11567327|NCT00878865|Active Comparator|Xanax 1 mg tablet|Xanax 1 mg tablet
11567328|NCT00878852|Active Comparator|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of a 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001)
11567329|NCT00878852|Experimental|Experimental|Participants randomly assigned to this group will received standard treatment (including 12 session therapy program) supplemented with an intervention with a contingency management program, designed to improve adherence and efficacy of the treatment program.
11567330|NCT00878839|Other|Toric|AcrySof Toric IOL to assess corneal aberration
11567331|NCT00878826|Active Comparator|Enoxaparin 40 mg per day|
11567332|NCT00878826|Active Comparator|Enoxaparin 1 mg per kg daily|
11567333|NCT00878826|Active Comparator|Pre prescribed regimen of Enoxaparin|Current enoxaparin dose at time of first prenatal visit.
11567334|NCT00878813||1|All consecutive stroke patients undergoing acute intra-arterial revascularisation therapy
11567335|NCT00878813||2|All consecutive stroke patients undergoing acute intra-venous revascularisation therapy
11567336|NCT00878813||3|All consecutive stroke patients treated conservatively
11567337|NCT00878813||4|All consecutive TIA patients
11567338|NCT00878800|Experimental|Experimental: PXD101 and doxorubicin (BelDox)|5-day PXD101 IV schedule with dose escalation combined with 1 day doxorubicin dose escalation IV
11567339|NCT00878787|Experimental|Theta-burst Trancranial Magnetic Stim|
11567340|NCT00878774|Experimental|Cohort 1|ToleroMune Ragweed, subjects to receive either active or placebo comparator
11567341|NCT00878774|Experimental|Cohort 2|ToleroMune Ragweed or placebo comparator
11567342|NCT00878774|Experimental|Cohort 3|ToleroMune Ragweed or placebo comparator
11567344|NCT00878774|Experimental|Cohort 5|ToleroMune Ragweed or placebo comparator
11567345|NCT00878761|Experimental|STX-100 (0.03mg/kg)|8 patients (6 active and 2 placebo)
11567346|NCT00878761|Experimental|STX-100 (0.1mg/kg)|8 patients (6 active and 2 placebo)
11567347|NCT00878761|Experimental|STX-100 (0.3mg/kg)|16 patients (12 active and 4 placebo)
11567348|NCT00878761|Experimental|STX-100 (1mg/kg)|16 patients (12 active and 4 placebo)
11567349|NCT00878748|Experimental|A|Effexor XR
11567350|NCT00878748|Other|B|Effexor XR discontinue
11567351|NCT00878735|Experimental|1|Zen meditation
11567352|NCT00878735|No Intervention|2|No meditation (no intervention; keep regular activities) or a resting group (this group stays at the same place of the retreat group, but only to rest)
11567353|NCT00878722|Experimental|Arm A|"PXD101 administered as a 30-minute intravenous (IV) infusion of 1000 mg/m²/d for five consecutive days every 3 weeks.
~Idarubicin administered on day 5 (first steps) or days 4 and 5 (later steps). Patients will be treated in a 21-day cycle for a minimum of 2 cycles and a maximum of 6 cycles (depending on cumulated idarubicin dose)."
11567354|NCT00878722|Experimental|Arm B|PXD101 administered by continuous intravenous infusion over 24-48 hours and idarubicin (in the later steps) added after the first 24 hours. The second cycle will start on day 15 but under observation of possible toxicity. Further cycles will be administered q 14 d for up to 6 cycles. The first dose steps will be carried out with PXD101 alone for safety reasons.
11567355|NCT00878709|Experimental|Neratinib|240 mg orally daily for one year
11567356|NCT00878709|Placebo Comparator|Placebo|orally daily for one year
11567357|NCT00878696||Tinnitus|Tinnitus patients
11567358|NCT00878683|Experimental|1|Device and standard catheter
11567359|NCT00878683|No Intervention|2|Standard catheter
11567360|NCT00878657|Experimental|Radiotherapy plus gemcitabine|"Drug: gemcitabine hydrochloride
~Radiation: intensity-modulated radiation therapy"
11567361|NCT00878644|Experimental|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia after experiencing cardiac arrest.
11567362|NCT00878644|Active Comparator|Therapeutic Normothermia|Participants will receive therapeutic normothermia after experiencing cardiac arrest.
11567363|NCT00878631|Active Comparator|1 Normal Saline|infusion of 250 ccs of Normal Saline within 4 hours of the accident
11567364|NCT00878631|Experimental|2 - hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 infused within 4 hours of the accident
11567365|NCT00878618|Experimental|HAB|AZD0837 test- (in session 1) and reference- (in session 2) formulation with heavy breakfast
11567366|NCT00878618|Experimental|HBA|AZD0837 reference- (in session 1) and test- (in session 2) formulation with heavy breakfast
11567367|NCT00878618|Experimental|LAB|AZD0837 test- (in session 1) and reference- (in session 2) formulation with light breakfast
11567368|NCT00878618|Experimental|LBA|AZD0837 reference- (in session 1) and test- (in session 2) formulation with light breakfast
11567369|NCT00878605|Experimental|Cyclo-Z (minimally effective)|3mg CHP plus 20mg zinc containing gel capsule;
11567370|NCT00878605|Experimental|Cyclo-Z (maximally effective)|9mg CHP plus 20mg zinc containing gel capsule;
11567371|NCT00878605|Experimental|Cyclo-Z (not additionally effective)|15mg CHP plus 20mg zinc containing gel capsule
11567372|NCT00878605|Placebo Comparator|Placebo (for CHP)|Placebo capsules containing no zinc or CHP
11567373|NCT00878592|No Intervention|Control group|The first group (Group 1) will include the control subjects. They will receive one session of dietary and behavioral education.
11567374|NCT00878592|Experimental|Dietary and Lifestyle counseling|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of ~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
11567375|NCT00878579|Experimental|PDS System|
11567376|NCT00878579|Active Comparator|Fusion|
11567377|NCT00878566|Active Comparator|Usual Care|
11567378|NCT00878566|Experimental|Enhanced pharmacist care|
11567379|NCT00878553|Placebo Comparator|Placebo|Two placebo tablets administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
11567380|NCT00878553|Experimental|10 mg SKP-1041|One 10 mg SKP-1041 controlled release zaleplon tablet plus one placebo tablet administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
11567381|NCT00878553|Experimental|15 mg SKP-1041|One 15 mg SKP-1041 controlled release zaleplon tablet plus one placebo tablet administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
11567382|NCT00878553|Experimental|20 mg SKP-1041|Two 10 mg SKP-1041 controlled release zaleplon tablets administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
11567383|NCT00878540|Experimental|mirtazapine|
11567384|NCT00878527|Experimental|Treatment with the pump|Treatment with the CircuLite Synergy Pocket Circulatory Assist Device
11567385|NCT00878514|Experimental|Alprazolam|Alprazolam 1 mg tablet
11567386|NCT00878514|Active Comparator|Xanax|Xanax 1 mg tablet
11567387|NCT00878501|Experimental|AZD1386, 90 mg|
11567388|NCT00878501|Experimental|AZD1386, 30 mg|
11567389|NCT00878501|Placebo Comparator|Placebo|
11567390|NCT00878475||Group with obstructive causes of dyspnea|Criteria for clinical assessment of severe asthma (diffuse polyphonic bilateral and particular expiratory wheezes, chest tightness, shortness of breath, using accessory muscles of breathing, signs of hyperinflation, atopic condition, personal or family history of asthma, tachypnea, previous asthma and asthma medications, and the value of modified Boston criteria for HF ≤ 5) and criteria for chronic obstructive pulmonary disease (COPD) exacerbation (history of COPD, COPD medications, cough, worsening dyspnea, increased sputum production and volume, increased sputum purulence, rhonchi and rales, modified Boston criteria for HF ≤ 5)
11567491|NCT00877864|Active Comparator|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
11567391|NCT00878475||Heart failure group|The investigators protocol for clinical assessment of HF-related acute dyspnea (the prehospital clinical assessment for HF) was designed based on Boston (13) and Framingham criteria for HF (14) (Table 1). The investigators did not use certain criteria from the original protocols, which were not available in the prehospital setting (e.g., chest radiography).
11567392|NCT00878462|Experimental|Sequence 1|Subjects randomly assigned to this sequence receive in order: Treatment A, C, B, A, C, B. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
11567393|NCT00878462|Experimental|Sequence 2|Subjects randomly assigned to this sequence receive in order: Treatment A, B, C, A, B, C. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
11567394|NCT00878462|Experimental|Sequence 3|Subjects randomly assigned to this sequence receive in order: Treatment B, C, A, B, C, A. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
11567395|NCT00878462|Experimental|Sequence 4|Subjects randomly assigned to this sequence receive in order: Treatment B, A, C, B, A, C. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
11567396|NCT00878462|Experimental|Sequence 5|Subjects randomly assigned to this sequence receive in order: Treatment C, B, A, C, B, A. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
11567397|NCT00878462|Experimental|Sequence 6|Subjects randomly assigned to this sequence receive in order: Treatment C, A, B, C, A, B. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
11567398|NCT00878449|Experimental|ABT-263 + etoposide/cisplatin|
11567399|NCT00878436|Experimental|Arm A (120 mg/week)|"Each treatment cycle has 21 days:
~Bicalutamide (Casodex®) 50mg P.O. daily, continuously, with the addition of:
~40 mg Panobinostat 3 times per week (120 mg per week) for 2 consecutive weeks with one week rest"
11567400|NCT00878436|Experimental|Arm B (60 mg/week)-Closed to accrual|"Each treatment cycle has 21 days:
~Bicalutamide (Casodex®) 50mg P.O. daily, continuously, with the addition of:
~20 mg Panobinostat 3 times per week (60 mg per week) for 2 consecutive weeks with one week rest"
11567401|NCT00878397|Experimental|1|Free distribution of long lasting insecticide nets to school children and their younger siblings
11567402|NCT00878397|Experimental|2|No school-based delivery of long lasting insecticide nets in the first year, followed by free delivery in the second year
11567403|NCT00878384|Active Comparator|Rate control|Strategy of 'rate-control': acceptance of atrial fibrillation, and dose-adjusted drug therapy as needed to control ventricular rate.
11567404|NCT00878384|Active Comparator|Catheter Ablation|Strategy of 'rhythm control' by catheter ablation: patients will undergo catheter ablation with the intention of restoring sinus rhythm.
11567405|NCT00878371|Other|morphine|All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
11567406|NCT00878358|Active Comparator|Physiotherapy|
11567407|NCT00878358|Experimental|Hydrotherapy|
11567408|NCT00878345|Active Comparator|1|Dexmedetomidine sedation protocol
11567409|NCT00878345|Active Comparator|2|Pentobarbital sedation protocol
11567410|NCT00878332||partially edentulous patients|"Adult (post growth period) patients who are interested in fixed dental rehabilitation (non- removable denture) by dental implants.
~Partially edentulous patients with insufficient bone height for dental implant insertion."
11567411|NCT00878319|Active Comparator|Surgical|Surgical intervention: open reduction and internal fixation (ORIF)
11567412|NCT00878319|Active Comparator|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
11567413|NCT00878306|Active Comparator|Disulfiram|Disulfiram
11567414|NCT00878306|Experimental|Disulfiram + Efavirenz|Efavirenz alone, then in addition with Disulfiram
11567415|NCT00878306|Experimental|Disulfiram + Atazanavir|Atazanavir alone, then in addition with Disulfiram
11567416|NCT00878306|Experimental|Disulfiram + Ritonavir|Ritonavir alone, then in addition with Disulfiram
11567417|NCT00878293|Experimental|A|Dose 1, 40 µg
11567418|NCT00878293|Experimental|B|Dose 2, 120 µg
11567419|NCT00878293|Experimental|C|Dose 3
11567420|NCT00878293|Experimental|D|Dose 4
11567421|NCT00878293|Experimental|E|Dose 5
11567422|NCT00878293|Experimental|F|Dose 6
11567423|NCT00878293|Experimental|G|Dose 7
11567424|NCT00878293|Active Comparator|H|Morphin
11567425|NCT00878293|Placebo Comparator|I|Placebo
11567426|NCT00878280||1|1:control(healthy subjects)
11567427|NCT00878280||2|2:case(dementia patients)
11567428|NCT00878267||Interview|
11567429|NCT00878254|Experimental|R-MACLO/IVAM|"Four 21-day cycles, followed by Maintenance Therapy as follows:
~Cycles 1 and 3: Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Methotrexate, Leucovorin, and G-CSF per study protocol.
~Cycles 2 and 4: Rituximab, Cytarabine, Ifosfamide, Mesna, Etoposide, and G-CSF per study protocol.
~Maintenance Therapy: Rituximab: For study participants in complete remission. Every 6 months for up to 3 years, per study protocol."
11567430|NCT00878228|Experimental|Study Group|The study group will receive intraoperative IV ondansetron and also postoperative oral ondansetron tablets (8 mg each day for two days).
11567431|NCT00878228|Placebo Comparator|Control Group|The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days).
11567432|NCT00878215|Experimental|Phase 1:Localize Anatomical Points on Liver Surface|-The surgeon will use image-guided surgery equipment to create the mapping with 3-D pictures of the participants liver. Laser range scanning will also be used to take 3-D pictures of the liver surface. The participant will then have planned standard surgery.
11567433|NCT00878215|Experimental|Phase 2: Ceramic bead|-The surgeon will use image-guided surgery to create the mapping with 3-D pictures of the liver. During the surgery, a ceramic bead will be placed in a pre-operatively determined target location within the tumor using image-guided surgery. Standard surgical procedures will then be used to remove the tumors. Magnetic resonance (MR) images of the resected liver will confirm targeting accuracy.
11567489|NCT00877877|Other|Cervarix Group|Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.
11567434|NCT00878215|Experimental|Phase 3: Ablative therapy|-The surgeon will use image-guided surgery to create the mapping with 3-D pictures of the liver. The liver tumors will be ablated using image-guided surgery. Standard surgical procedures will then be used to remove the portion of the liver that has the ablated tumors. The accuracy of the ablation will be confirmed via pathology sectioning.
11567435|NCT00878215|Experimental|Phase 4: Ablative therapy (not liver resection candidates)|-This phase is for patients who otherwise do not qualify to have a portion of their liver to be surgically removed. The surgeon will use image-guidance to create the mapping with 3-D pictures of the liver. The tumors will be ablated using image-guided therapy.
11567436|NCT00878202|No Intervention|Control|Optimal medical treatment of Heart failure and therapeutic education
11567437|NCT00878202|Experimental|Telemedicine|Optimal medical treatment of heart failure disease and therapeutic education
11567438|NCT00878189|Experimental|1|
11567439|NCT00878176|Experimental|1|(Crossover study)
11567440|NCT00878163|Experimental|Treatment (vismodegib, erlotinib hydrochloride, gemcitabine)|Patients receive Hedgehog antagonist GDC-0449 PO QD and erlotinib hydrochloride PO QD on days 1-28. Some patients also receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11567441|NCT00878150|Experimental|Telephone-based CBT|- 12 counseling sessions over 16 weeks over the telephone
11567442|NCT00878150|Experimental|In-person CBT|- 12 counseling sessions over 16 weeks at either Harborview Medical Center or the University of Washington Medical Center in Seattle, WA
11567443|NCT00878150|No Intervention|3: Usual care|- No counseling sessions as part of this study, however you are free to pursue regular medical care and counseling outside of this study
11567444|NCT00878137||APLA|Patients with antiphospholipid antibody syndrome.
11567445|NCT00878137||Control|Patients on warfarin therapy but without antiphosphilipid antibody syndrome.
11567446|NCT00878124|Experimental|CoQ10|Coenzyme Q10 co-treatment
11567447|NCT00878124|Placebo Comparator|Placebo control|Placebo Co-treatment
11567448|NCT00878111|Experimental|A: escalating dose levels of NGR-hTNF|NGR-hTNF administered at high doses
11567449|NCT00878085|Experimental|1|Robot Therapy with activities of daily living (ADLs)
11567450|NCT00878085|Active Comparator|2|Standard Occupational Therapy
11567451|NCT00878072|Experimental|Famciclovir|
11567452|NCT00878059||Proxies|A family member-caregiver (the medical decision-maker) for someone with Alzheimer's Disease. Must be the person who would be able to make decisions for someone with Alzheimer's disease about being in medical research.
11567453|NCT00878046|Experimental|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
11567454|NCT00878033||1|Diabetic Dialysis Patients
11567455|NCT00878033||2|Non-Diabetic Dialysis Patients
11567456|NCT00878033||3|Healthy Controls
11567457|NCT00878020|Active Comparator|Arm 1|BMS-830216 (10 mg)
11567458|NCT00878020|Active Comparator|Arm 2|BMS-830216 (30 mg)
11567459|NCT00878020|Active Comparator|Arm 3|BMS-830216 (100 mg)
11567460|NCT00878020|Active Comparator|Arm 4|BMS-830216 (300 mg)
11567461|NCT00878020|Active Comparator|Arm 5|BMS-830216 (600 mg)
11567462|NCT00878020|Active Comparator|Arm 6|BMS-830216 (1200 mg)
11567463|NCT00878007|Experimental|1|"Intermittent screening and treatment (IST) for malaria.
~This intervention is a change from a previous intervention based on intermittent preventive treatment for malaria owning to the withdrawal of amodiaquine (one of the previous IPT drugs) in Kenya in 2009."
11567464|NCT00878007|Experimental|2|Enhanced teacher training on literacy instruction.
11567465|NCT00878007|Experimental|3|Intermittent screening and treatment (IST) for malaria and enhanced teacher training on literacy instruction
11567466|NCT00878007|No Intervention|4|
11567467|NCT00877994|Active Comparator|Immediate|This group will receive the nurture group therapy immediately after enrolling in the study.
11567468|NCT00877994|Active Comparator|Delayed|This group will receive the nurture group therapy 16 weeks after enrolling in the study.
11567469|NCT00877981|Active Comparator|Videoassited surgery|"In patients randomized to a video-assisted approach, the surgeon has the option to choose either the lateral- (VAPLA) or medial (MIVAP) techniques, both initiated with a 15 mm transverse skin incision. The lateral approach is performed as described by Henry.
~The medial approach is performed using the gasless procedure developed by Miccoli."
11567470|NCT00877981|Active Comparator|Open surgery|Open surgery, a 15 mm transverse skin incision is made close to the site of the parathyroid adenoma indicated by sestamibi scintigraphy.
11567471|NCT00877968|Placebo Comparator|Whole wheat banana bread|Banana bread made with whole wheat flour
11567472|NCT00877968|Active Comparator|Whole pea flour banana bread|Banana bread made with whole pea flour
11567473|NCT00877968|Placebo Comparator|Whole wheat biscotti|Biscotti made with whole wheat flour
11567474|NCT00877968|Active Comparator|Whole pea biscotti|Biscotti made with whole pea flour
11567475|NCT00877968|Placebo Comparator|Whole wheat pasta|Pasta made with whole wheat durum
11567476|NCT00877968|Active Comparator|Whole pea flour|Pasta made with 30% whole pea flour and 70% white wheat durum
11567477|NCT00877968|Placebo Comparator|White bread|
11567478|NCT00877968|Placebo Comparator|Boiled yellow peas|
11567479|NCT00877955|Active Comparator|alprazolam sublingual tablet reference|
11567480|NCT00877955|Experimental|alprazolam sublingual tablet test|
11567481|NCT00877942||1|Typically developing children drawn from the general population
11567482|NCT00877942||2|Children with Turner Syndrome
11567483|NCT00877929|Experimental|Telmisartan 80 / Amlodipine 10|Telmisartan 80 / Amlodipine 5 for two weeks, then forced titration to Telmisartan 80 / Amlodipine 10 Fixed Dose Combination
11567484|NCT00877929|Active Comparator|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
11567485|NCT00877903|Experimental|Prochymal®|200 million cells (M) Mesenchymal Stem Cell (MSC) administered via IV infusion
11567486|NCT00877903|Placebo Comparator|Placebo|Placebo via IV infusion
11567487|NCT00877890|Experimental|1|
11567488|NCT00877890|Active Comparator|2|
11567490|NCT00877864|Active Comparator|High volume combined aerobic/resistance exercise|
11567492|NCT00877864|Active Comparator|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
11567493|NCT00877864|Active Comparator|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
11567494|NCT00877864|Active Comparator|Printed PA information, pedometers and step log group|Printed physical activity information, pedometers and step log group
11567495|NCT00877864|Placebo Comparator|Control|
11567496|NCT00877851|Experimental|1 CD-ROM|Use of CD-ROM for 12 weeks
11567497|NCT00877851|No Intervention|2 Control|Usual care and list of useful websites
11567498|NCT00877812|Experimental|Arm 1 glycine and leucine infusion|Determine in healthy, adequately pyridoxine nourished humans using a protocol based on amino acid glycine tracer methods: (a) the postprandial rates of in vivo glycine turnover, glycine-based generation of one-carbon units, thymidylate and purine synthesis, and the impact of vitamin B6 deficiency on the rates of these processes and (b) the effect of vitamin B6 deficiency on the postprandial rate of glutathione synthesis. 14 subjects will be chosen after screening is complete and will begin a B6 deficient diet for 30 days. At the beginning and end of the 30 days they will receive an infusion of leucine and glycine then they will begin the four week diet. At the end of four weeks the infusion will be repeated.
11567499|NCT00877812|Experimental|Arm 2 Intervention of Serine and methionine infusion|This arm will allow investigation of total Hcy remethylation and remethylation from serine-derived 1C units, kinetics of serine and the methionine cycle and kinetics of transsulfuration reactions. 14 healthy subjects will be selected and screened. Prior to starting a B6 deficient diet for four weeks an infusion of serine and methionine will commence. Following the first infusion the diet will begin and after four weeks another infusion will be done.
11567500|NCT00877799|Experimental|CR845|CR845 administered as a single 15-min i.v. infusion at doses of 0.008 or 0.024 mg/kg on the day after surgery (Cohort 1), or at a dose of 0.040 mg/kg immediately after surgery (Cohort 2)
11567501|NCT00877799|Placebo Comparator|Placebo|Matched placebo administered as a single 15-min i.v. infusion on the day after surgery (Cohort 1), or the immediately after surgery (Cohort 2)
11567502|NCT00877786|Active Comparator|Face-to-face group therapy|
11567503|NCT00877786|Active Comparator|Online chat group therapy|
11567504|NCT00877773|Experimental|Temsirolimus|Temsirolimus 25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
11567505|NCT00877760|Experimental|ETV + pegIFN|Patients receive Entecavir in a dosage of 0.5 mg once daily per os from day 0, up to week 48. From week 24 to week 48, they also receive pegylated-interferon a-2a in a dose of 180 μg per week s.c. At week 48, response will be assessed. Responders will continue to take Entecavir until week 72, and quit subsequently. Non-responders at week 48 will continue on Entecavir up to week 96.
11567506|NCT00877760|Active Comparator|ETV|Patients receive Entecavir in a dosage of 0.5 mg once daily per os from day 0, up to week 48. At week 48, response will be assessed. Responders will continue to take Entecavir until week 72, and quit subsequently. Non-responders at week 48 will continue on Entecavir up to week 96.
11567507|NCT00877747||PET2 negative|Patients with negative early interim PET after 2 courses of ABVD who continued therapy with ABVD
11567508|NCT00877747||PET2 positive|Patients with positive early interim PET after 2 courses of ABVD who changed their therapy to BEACOPP
11567509|NCT00877734|Experimental|1|Baclofen
11567510|NCT00877734|Placebo Comparator|2|Placebo
11567511|NCT00877721|Experimental|balance treatment|
11567512|NCT00877695|Experimental|Motive8 2 Change FtF|This arm of the motivational enhancement intervention (MEI) will be delivered face to face (FtF) using a real-time, dynamic implementation approach. The intervention consisted of 2 sessions lasting approximately 60 to 90 minutes. The sessions focused on increasing participants' awareness of the multiple influences on behaviors from self, family, culture and community and how these influences impact the way we think and behave including sexually. Through a series of exercises the participant develops strategies for understanding and managing his own triggers that helps them to make healthy life choices. Both Motiv8 2Change arms used the exact same intervention, with the exception that one was delivered face to face and the other through the internet.
11567513|NCT00877695|Experimental|Motive8 2Change -Internet|This arm of the motivational enhancement intervention (MEI) will be delivered via the Internet face to face (FtF) using a real-time, dynamic implementation approach.The intervention consisted of 2 sessions lasting approximately 60 to 90 minutes. The sessions focused on increasing participants' awareness of the multiple influences on behaviors from self, family, culture and community and how these influences impact the way we think and behave including sexually. Through a series of exercises the participant develops strategies for understanding and managing his own triggers that helps them to make healthy life choices. Both Motiv8 2Change arms used the exact same intervention, with the exception that one was delivered face to face and the other through the internet.
11567514|NCT00877695|No Intervention|delayed|
11567515|NCT00877695|Active Comparator|Motiv8 2Change Careers|Comparable in number of sessions and duration to the experimental arms, but focused on resume development and interviewing skills. This arm consisted of 2 sessions. In the first session participants reviewed different career choices and created a winning resume. The second session focused on job interviewing skills. It included role plays with feedback. It also contains ethically mandated information regarding HIV prevention. It was delivered on line by a trained facilitator.
11567516|NCT00877682|Experimental|Cryotherapy|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
11567517|NCT00877669|Active Comparator|Transurethral resection of the prostate|TURP group
11567518|NCT00877669|Experimental|Holmium Laser Enucleation of Prostate|HoLEP group
11567519|NCT00877656|Experimental|CD4|Open label treatment arm
11567520|NCT00877643|Experimental|Upstream rhythm control|
11567521|NCT00877643|Active Comparator|Conventional rhythm control|
11567522|NCT00877630||1:endoscopic group|patients underwent endoscopic thyroidectomy
11567523|NCT00877630||2:conventional group|patients underwent open thyroidectomy
11567524|NCT00877617||QOL Questionnaire|
11567525|NCT00877604|Experimental|TUDCA|tauroursodeoxycholic acid di-hydrate
11567526|NCT00877604|Placebo Comparator|placebo|excipient lactose
11567527|NCT00877591|Experimental|1|Buprenorphine + Fosamprenavir/Ritonavir
11567528|NCT00877591|Active Comparator|2|Control Fosamprenavir/Ritonavir
11567529|NCT00877591|Experimental|3|Buprenorphine + Darunavir/Ritonavir
11567530|NCT00877591|Active Comparator|4|Control Darunavir/Ritonavir
11567531|NCT00877591|Experimental|5|Buprenorphine + Rifampin
11567532|NCT00877591|Experimental|6|Buprenorphine + Rifabutin
11567533|NCT00877578|Experimental|1|Nutri-Energie ®, a cake of high caloric density and palatability, twice a day for 4 weeks, in addition to an enriched diet.
11567534|NCT00877578|Active Comparator|2|Clinutren 1.5 ® standard isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet.
11567535|NCT00877552||Control|Typically developing
11567536|NCT00877552||Mild ventriculomegaly (MVM)|Fetal isolated mild ventriculomegaly
11567537|NCT00877552||Schizophrenia High Risk|Offspring of mothers with schizophrenia
11567538|NCT00877552||Bipolar High Risk|Offspring of mothers with schizophrenia
11567539|NCT00877539|Experimental|PF-03526299|
11567540|NCT00877539|Placebo Comparator|Placebo|
11567541|NCT00877539|Active Comparator|Fluticasone propionate|
11567542|NCT00877526||A|
11567543|NCT00877513|Experimental|Smokers|Cigarette smokers wishing to quit
11567544|NCT00877500|Experimental|Group I (ixabepilone)|Participants receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11567545|NCT00877500|Active Comparator|Group II (standard of care)|Participants receive standard of care for 18 weeks.
11567546|NCT00877487|Experimental|SPD489|
11567547|NCT00877487|Placebo Comparator|Placebo|
11567548|NCT00877474|Experimental|Arm 1|PM01183 administered i.v. over one hour, on Day 1, every three weeks, at a starting dose of 20 µg/m2.
11567549|NCT00877448|Experimental|Multimeric-001 250 Mcg|Multimeric-001 250 Mcg in PBS
11567550|NCT00877448|Experimental|Adjuvanted Multimeric-001 250 Mcg|250 Mcg in montanide
11567551|NCT00877448|Placebo Comparator|Phosphate Buffered saline|Non-adjuvanted placebo
11567552|NCT00877448|Placebo Comparator|Adjuvanted PBS|Adjuvant was montanide
11567553|NCT00877448|Experimental|Multimeric-001 500 Mcg|Multimeric-001 in PBS
11567554|NCT00877448|Experimental|Adjuvanted Multimeric-001 500 Mcg|Adjuvant was montanide
11567555|NCT00877448|Experimental|Multimeric-001 125 Mcg|Multimeric-001 in PBS
11567556|NCT00877435|Experimental|1|Cognitive behavioral therapy (CBT) + prize-based contingency management (prizeCM)
11567557|NCT00877435|Active Comparator|2|Cognitive behavioral therapy (CBT)
11567558|NCT00877422|No Intervention|Group A|Group A is identified as serum vitamin D level more than 16 ng/dl.
11567559|NCT00877422|Active Comparator|Group B|Group B is identified as serum vitamin D level less than 16 ng/dl and is supplemented with vitamin D3.
11567560|NCT00877422|No Intervention|Group C|Group C is identified as serum vitamin D less than 16 ng/dl and is not supplemented with vitamin D3.
11567561|NCT00877409|Active Comparator|Acnase|
11567562|NCT00877409|Placebo Comparator|Vehicle|
11567563|NCT00877396|Experimental|Influenza|Inactivated Influenza vaccination
11567564|NCT00877396|Placebo Comparator|Control|Hepatitis A vaccine
11567565|NCT00877383|Experimental|Indacaterol 150 μg and tiotropium 18 μg|Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single-dose dry-powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11567566|NCT00877383|Active Comparator|Tiotropium 18 μg|Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single-dose dry-powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11567567|NCT00877370|Experimental|ertapenem|subjects will receive ertapenem while receiving CVVHD
11567568|NCT00877357|Experimental|Shan 5 Lot No 1|
11567569|NCT00877357|Experimental|Shan 5 Lot No 2|
11567570|NCT00877357|Experimental|Shan 5 Lot No 3|
11567571|NCT00877344|Experimental|1|Immediate insertion of either a LNG-IUC or a Copper T380 IUD after 12-24 week abortion
11567572|NCT00877344|Experimental|2|Interval insertion (two to four weeks post abortion) of either a LNG-IUC or a Copper T380 IUD after 12-24 abortion
11567573|NCT00877331|Experimental|1|Brief intervention using motivational interviewing. One in-person session (30-45 minutes) with a brief phone follow-up one week later.
11567574|NCT00877331|No Intervention|2|Enhanced care as usual.
11567575|NCT00877318|No Intervention|Control|Program of cardiac rehabilitation introduced in complete hospitalization pursued in day hospital during 3 months
11567576|NCT00877318|Experimental|telemedicine|Program of cardiac rehabilitation introduced in complete hospitalization pursued at home via a terminal during 3 months
11567577|NCT00877305|Active Comparator|RIPC|Remote Ischemic Preconditioning
11567578|NCT00877305|Placebo Comparator|CONTROL|Control
11567579|NCT00877292||Down syndrome|Women having CVS or amniocentesis who, as a group, have a high prevalence of Down syndrome.
11567580|NCT00877279|Experimental|Belotero® Soft|Comparator will be given into the opposite side of the face that Belotero® Soft was administered for facial wrinkles, such as nasolabial folds.
11567581|NCT00877279|Active Comparator|CosmoDerm1|
11567582|NCT00877266|Active Comparator|1. Ultrasound|Ultrasound is randomly chosen by use of a computer program. The time for catheter placement will begin with the ultrasound probe touches the patient. Patients will be asked their discomfort on a 0-10 scale (0=no discomfort and 10=worst discomfort imaginable) and will be called the next day by the research staff.
11567661|NCT00876694|Experimental|Indacaterol 300 µg|Indacaterol 300 μg once a day (o.d.) delivered via single dose dry powder inhaler (SDDPI). Daily ICS monotherapy, if needed, was allowed to remain stable throughout study. Salbutamol was available for rescue use throughout study.
11567583|NCT00877266|Active Comparator|2. Electrical Stimulation|Nerve Stimulation (electrical stimulation) is randomly chosen using a computer program. Time of placement begins when the catheter-placement first touches the patient. After catheter placement patient is asked their discomfort on a 0-10 scale (0=no discomfort and 10=worst discomfort imaginable) and called the day after surgery by the research staff.
11567584|NCT00877253|Experimental|Dose Level One|
11567585|NCT00877253|Experimental|Dose Level Two|
11567586|NCT00877253|Experimental|Dose Level Three|
11567587|NCT00877240|Other|Lifestyle counseling|
11567588|NCT00877227|Experimental|folinic acid|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns
11567589|NCT00877227|No Intervention|2|control subjects admitted at the Neonatal Intensive Care Unit (NICU)
11567590|NCT00877214|Experimental|Rituximab|Follicular Lymphomas: Rituximab 375 mg/m² for additional 2 years after 2 years of standard maintainance All other lymphomas: Rituximab 375 mg/m² for 2 years as maintainance. From 2014 only Morbus Waldenstroem: Rituximab 1.400 mg absolute s. c. injection
11567591|NCT00877214|Active Comparator|Standard|Rituximab / Observation
11567592|NCT00877188|Experimental|exercise|supervised combined aerobic and resistance training for 12 weeks
11567593|NCT00877188|No Intervention|control|waist list control with usual care
11567594|NCT00877175|Experimental|1|Lower conjunctival fornix packing arm. For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix.
11567595|NCT00877175|Active Comparator|2|Conventional instillation arm. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
11567596|NCT00877162|Experimental|1|Providing parents with a group teaching intervention (2 hours long). The teaching session is followed by 2 weeks of phone calls twice a week to offer parents support for their use of the strategies described in the teaching session and to clarify any questions about the teaching session content. The arm will have baseline data collected one week prior to the teaching session. Follow-up data will be collected at 6 and 24 weeks post intervention. A pamphlet on infant safety will be distributed to the intervention arm following the 6 week data collection point. A pamphlet on managing behavioural sleep problems will distributed to the control group following the 6 week data collection point.
11567597|NCT00877149|Experimental|A|
11567598|NCT00877123|Experimental|Vitamin D|Intervention arm: Oral vitamin D 100,000 IU once a month for three consecutive months.
11567599|NCT00877123|Placebo Comparator|Placebo|
11567600|NCT00877110|Experimental|chemotherapy, allogeneic NK cells, 3F8|This is a phase I study to assess the safety and feasibility of combining HLA-mismatched (KIR ligand incompatible) NK cells with 3F8 in high-risk NB patients. Following chemotherapy, patients will be treated in sequential groups of 3 patients/dose of NK cells. Four dose levels of NK cells, starting at dose level I, will be evaluated in this treatment protocol. In the unlikely case toxicity is encountered at dose level I, patients will then be treated at the lower dose level 0. Patients can receive up to 3 cycles of treatment on protocol. For subsequent cycles, patients will be treated at either less than or at the same dose level of NK cells as their first cycle.
11567601|NCT00877097|Experimental|1|Clodronate 800 mg / day + estradiol 2 mg + norethisterone acetate 1 mg / day for five years.
11567602|NCT00877097|Placebo Comparator|2|Placebo 2 tablets/ day + estradiol 2 mg + norethisterone acetate 1 mg / day for five years.
11567603|NCT00877097|Active Comparator|3|Clodronate 800 mg / day for five years.
11567604|NCT00877084|Experimental|1|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
11567605|NCT00877084|Placebo Comparator|2|Usual care according to clinical pathway for COPD exacerbations + NO training
11567606|NCT00877071|Experimental|LC Drug Eluting Bead, Regional Chemoembolization|Use of LC Drug-Eluting Beads for chemoembolization will provide a method for downstaging patients with hepatocellular carcinoma which is not amenable to surgical resection or local ablative therapy to liver transplant eligibility
11567607|NCT00877058|Experimental|1.Preventive home visit|Preventive home visits: This intervention included a single home visit made by either a nurse, a physiotherapist, a qualified social worker or an occupational therapist. Participants received verbal and written information/advice about what the districts could provide. The preventive home visit was guided by a protocol, which included an opportunity for individuals to further elaborate on certain elements. The visit lasted between one and a half to two hours.
11567608|NCT00877058|Experimental|2. Senior meetings|The senior meetings comprised four weekly meetings with about six participants in each group. The main purpose was to focus on two different topics: 1) information about the ageing process and its consequences and 2) provision of tools and strategies for solving problems that can arise in the home environment. A follow-up home visit took place two to three weeks after the group sessions were completed. The group meetings were led either by an occupational therapist, a registered nurse, a physiotherapist or a qualified social worker, all of whom spoke about their particular dimension of aging.
11567609|NCT00877058|No Intervention|3. Control group|The control group had access to the ordinary range of services if requested from the urban districts for the aged. The aim of the municipal provision of care for the older persons is to ensure the ability to live as independently as possible. This includes remaining in their homes. When an older person in Sweden has difficulties managing independently, she or he can apply for assistance from the district. The extent of such support is subject to an assessment of needs and includes meals on wheels, help with cleaning and shopping, assistance with personal care, safety alarms and transportation service. The older person are also offered healthcare, provided either by municipal home help or home medical care services.
11567610|NCT00877032|Experimental|Arm 1|
11567611|NCT00877006|Experimental|Bendamustine and Rituximab (BR)|Participants received the investigational bendamustine and rituximab regimen for 6 to 8 28-day cycles: bendamustine 90 mg/m^2 intravenous (IV) on Days 1 and 2; rituximab 375 mg/m^2 IV on Day 1
11567612|NCT00877006|Active Comparator|R-CHOP/R-CVP|"Participants received the standard regimen (R-CHOP or R-CVP) for 6 to 8 21-days cycles.
~R-CHOP: rituximab 375 mg/m^2 IV on Day 1; vincristine 1.4 mg/m^2 (up to 2 mg/m^2 maximum dose) IV on Day 1; doxorubicin 50 mg/m^2 IV Day 1; cyclophosphamide 750 mg/m^2 IV Day 1; prednisone 100 mg oral on Days 1 to 5
~R-CVP: rituximab 375 mg/m^2 IV on Day 1; cyclophosphamide 750 mg/m^2 IV on Day 1 or cyclophosphamide 1000 mg/m^2 IV on Day 1; vincristine 1.4 mg/m^2 (up to 2 mg/m^2 maximum dose) IV on Day 1; prednisone 100 mg oral on Days 1 to 5"
11567613|NCT00876993|Experimental|Dose Level 0|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 75 mg/m^2 PO
11567614|NCT00876993|Experimental|Dose Level 1|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 125 mg/m^2 PO
11567615|NCT00876993|Experimental|Dose Level 2|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 175 mg/m^2 PO
11567616|NCT00876993|Experimental|Dose Level 3|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 200 mg/m^2 PO
11567617|NCT00876993|Experimental|Dose Level 4|Bevacizmuab 10 mg/kg IV Irinotecan 150 mg/m^2 IV Temozolomide 200 mg/m^2 PO
11567618|NCT00876980|Active Comparator|1|nasal Continuous Positive Airway Pressure treatment for 3 months
11567619|NCT00876980|No Intervention|2|controls have no treatment, being observed for 3 months
11567620|NCT00876967|Experimental|1|metallic single use blade
11567621|NCT00876967|Experimental|2|plastic single use blade
11567622|NCT00876967|Active Comparator|3|metallic reusable blade
11567623|NCT00876954|Placebo Comparator|Placebo|Warming without increase in core temperature
11567624|NCT00876954|Active Comparator|Hyperthermia|Hyperthermia for 2,5 hours (39 °C core temperature)
11567625|NCT00876941|Experimental|Standard Brief Intervention|
11567626|NCT00876941|Experimental|Enhanced Brief Intervention|
11567627|NCT00876941|Active Comparator|Control|
11567628|NCT00876928|Placebo Comparator|Placebo|Subjects with low vitamin D levels and pre-diabetes
11567629|NCT00876928|Experimental|vitamin D|Subjects with low vitamin D levels and pre-diabetes
11567630|NCT00876915|Experimental|High Risk for VTE recieving dalteparin|Patients assigned at random to receive prophylactic dalteparin injections
11567631|NCT00876915|No Intervention|High Risk for VTE No therapy|No prophylactic therapy for VTE prevention given (Subjects receiving standard of care)
11567632|NCT00876915|No Intervention|Low Risk for VTE|Used as a control for the secondary outcome of evaluating tissue factor in collected blood samples
11567633|NCT00876902|Experimental|1|Active Group: (18 subjects) YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient PRIOR to arterial reperfusion of the liver. One extra IV dose of 1 mg/kg will be given at the end of the procedure only to patients that have experienced an intraoperative blood loss of greater than 10 units.
11567634|NCT00876902|Placebo Comparator|2|Placebo Control: (18 subjects) Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient PRIOR to arterial reperfusion of the liver. One additional infusion of 0.1 mL/kg placebo control (saline) will be given at the end of the procedure to patients that have experienced an intraoperative blood loss of greater than 10 units.
11567635|NCT00876876|Placebo Comparator|Placebo QD or BID|Placebo QD or BID
11567636|NCT00876876|Experimental|Lixivaptan QD or BID|Lixivaptan QD or BID
11567637|NCT00876863|Experimental|CERE-110|CERE-110: Adeno-Associated Virus Delivery of NGF
11567638|NCT00876863|Sham Comparator|Placebo|Placebo Surgery
11567639|NCT00876850|Experimental|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
11567640|NCT00876850|Active Comparator|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
11567641|NCT00876837||Adults with pediatric-onset SCI|
11567642|NCT00876824|Experimental|Amphotericin B lipid emulsion|Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A Drug: Amphotericin B lipid emulsion
11567643|NCT00876824|Active Comparator|Liposomal Amphotericin B|Liposomal Amphotericin B in visceral leishmaniasis - 15mg/kg on day 1 in Group B
11567644|NCT00876811|Experimental|one-cup|
11567645|NCT00876811|Experimental|two-cups|
11567646|NCT00876811|Experimental|four-cups|
11567647|NCT00876798|Experimental|1|Lixivaptan
11567648|NCT00876798|Placebo Comparator|2|Placebo
11567649|NCT00876785|Active Comparator|1|Reference wheat bread breakfast
11567650|NCT00876785|Experimental|2|Rye bread breakfast
11567651|NCT00876759|Active Comparator|WBRT|standard WBRT to a total dose of 30 Gy in 10 fractions
11567652|NCT00876759|Experimental|WBRT with simulatneous boost|The experimental group will be treated with helical tomotherapy giving 3 Gy per fraction to the whole brain up to a total dose of 30 Gy in 10 fractions and raising the prescribed dose to the brain metastases to 5 Gy per fraction. The dose fall off to the normal brain should be as steep as possible around each brain metastasis. The optic chiasm and the optic nerves should not receive more than 3.5 Gy per fraction.
11567653|NCT00876746|Active Comparator|1. Supraclavicular|Patients will be randomized to placement of a nerve block in the supraclavicular position. After the catheter has been placed, sensory and motor deficit will be assessed and following surgery, for the next three days, the patient will be contacted by research staff to assess pain scores and other outcome measures.
11567654|NCT00876746|Active Comparator|2. Infraclavicular|Patients will be randomized to placement of a nerve block in the infraclavicular position. After the catheter has been placed, sensory and motor deficit will be assessed and following surgery, for the next three days, the patient will be contacted by research staff to assess pain scores and other outcome measures.
11567655|NCT00876733||HIV treatment|
11567656|NCT00876720|Experimental|1|Combined frontal and temporal transcranial magnetic stimulation
11567657|NCT00876720|Experimental|2|Temporal transcranial magnetic stimulation
11567658|NCT00876707|Active Comparator|Tecnis|
11567659|NCT00876707|Active Comparator|ReSTOR|
11567660|NCT00876707|Active Comparator|ReZoom|
11567715|NCT00876252|Active Comparator|IC43 100 mcg w/o|IC43 100 mcg without Aluminum hydroxide
11568360|NCT00871572|Placebo Comparator|Placebo|
11567662|NCT00876694|Active Comparator|Salmeterol 50 µg|Salmeterol 50 μg twice a day (b.i.d.) delivered via Diskus®. Daily ICS monotherapy, if needed, was allowed to remain stable throughout study. Salbutamol was available for rescue use throughout study.
11567663|NCT00876681|Active Comparator|1. Ultrasound|Ultrasound method of placement is selected randomly, using a computer program. The patient is asked their pain and discomfort using a 0-10 scale where 0=no pain/discomfort and 10=worst pain/discomfort imaginable. The patient is asked this question prior to surgery, but after catheter placement and then again the first day after surgery. Time of placement is also measured and begins when the ultrasound probe first touches the skin. Patients are also asked the numbness of their foot and toes based on a 0-10 scale where 0=no numbness and 10=completely numb.
11567664|NCT00876681|Active Comparator|2. Electrical Stimulation|Electrical stimulation (nerve stimulation) method of placement is selected randomly, using a computer program. The patient is asked their pain and discomfort using a 0-10 scale where 0=no pain/discomfort and 10=worst pain/discomfort imaginable. The patient is asked this question prior to surgery, but after catheter placement, and then again the first day after surgery. Time of placement is also measured and begins when the nerve stimulation needle first touches the skin. Patients are also asked the numbness of their foot and toes based on a 0-10 scale where 0=no numbness and 10=completely numb.
11567665|NCT00876655|Experimental|free acid|TR-701 free acid phosphate powder in capsule formulation (equivalent to 150 mg TR-700)
11567666|NCT00876655|Experimental|di-sodium phosphate salt|One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)
11567667|NCT00876642|Experimental|1|
11567668|NCT00876642|No Intervention|2|
11567669|NCT00876616|Experimental|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d+MMF 1.0g/d
11567670|NCT00876616|Active Comparator|Cyclophosphamide|CTX iv 0.75 g/m2 body surface area (BSA)
11567671|NCT00876603||1|
11567672|NCT00876603||2|
11567673|NCT00876603||CSM - ACDF|Cervical spondylotic myelopathy treated with anterior cervical decompression and fusion
11567674|NCT00876603||CSM - Cervical laminoplasty|Cervical spondylotic myelopathy treated with cervical laminoplasty
11567675|NCT00876577||Group 1|
11567676|NCT00876564|Other|Trauma patients|Included in trauma registry
11567677|NCT00876551|Experimental|E-V.A.C.|Patients that are treated with E-V.A.C.
11567678|NCT00876538|Experimental|TRO19622|2 capsules of TRO19622 (330mg) once day with the noon meal
11567679|NCT00876538|Placebo Comparator|Control|2 capsules of placebo once day with the noon meal
11567680|NCT00876525|Experimental|Freedom SOLO stentless valve|
11567681|NCT00876499||Questionnaire|
11567682|NCT00876486|Experimental|Genexol®-PM|This is a open-labeled, randomized, parallel, phase III Trial. Up to 106 elgible patients will be enrolled in each treatment arm(Total 212 subjects will recruited) according to the trial design. Patients will be randomly allocated to arm A (Genexol-PM) or arm B (Paclitaxel).
11567683|NCT00876486|Active Comparator|Genexol®|This is a open-labeled, randomized, parallel, phase III Trial. Up to 106 elgible patients will be enrolled in each treatment arm(Total 212 subjects will recruited) according to the trial design. Patients will be randomly allocated to arm A (Genexol-PM) or arm B (Paclitaxel).
11567684|NCT00876473||1|Acute Respiratory Failure patients
11567685|NCT00876460|Experimental|BIBF 1120 + docetaxel|Low, medium and high dose of BIBF 1120 and 60 mg/m2, 75 mg/m2 docetaxel every 3 weeks
11567686|NCT00876447|Experimental|Botulinum Toxin Type A 300U|Botulinum toxin Type A 300U injections into the detrusor > 12 weeks as needed for up to 3 years.
11567687|NCT00876447|Experimental|Botulinum Toxin Type A 200U|Botulinum toxin Type A 200U injections into the detrusor > 12 weeks as needed for up to 3 years.
11567688|NCT00876421|Placebo Comparator|P|
11567689|NCT00876421|Active Comparator|A|
11567690|NCT00876421|Experimental|E1|
11567691|NCT00876421|Experimental|E2|
11567692|NCT00876421|Experimental|E3|
11567693|NCT00876395|Experimental|Everolimus + Paclitaxel + Trastuzumab|Everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22
11567694|NCT00876395|Placebo Comparator|Placebo + Paclitaxel + Trastuzumab|Placebo of everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22
11567695|NCT00876369||Urticaria/Angioedema|Subjects with chronic urticaria and/or angioedema
11567696|NCT00876369||allergy control|Subjects with physician diagnosed allergic rhinitis
11567697|NCT00876356|Active Comparator|1|Conjugated Linoleic Acid 4.5g/day in three divided doses p.o. for 12 weeks
11567698|NCT00876356|Placebo Comparator|2|Olive oil 4.5g/day x 12 weeks.
11567699|NCT00876343|Experimental|1|Fixed dose
11567700|NCT00876343|Experimental|2|Titration dose
11567701|NCT00876343|Placebo Comparator|3|Placebo
11567702|NCT00876330|Experimental|1|Receives Hypertension and Hyperlipidemia Intervention using Clinical Decision Support.
11567703|NCT00876330|Experimental|2|Receives Hypertension and Hyperlipidemia Intervention with automated telephone outreach.
11567704|NCT00876317|Active Comparator|1|Etoricoxib 60 mg per oz for 14 days
11567705|NCT00876317|Active Comparator|2|Etoricoxib 90 mg per oz for 14 days
11567706|NCT00876304|Experimental|PF-04802540|
11567707|NCT00876304|Placebo Comparator|Placebo|
11567708|NCT00876291|Placebo Comparator|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
11567709|NCT00876291|Active Comparator|Probiotic|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
11567710|NCT00876278|Other|*AT.Smart 46LC|The *AT.Smart 46LC is indicated for primary implantation for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the *AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
11567711|NCT00876265|Experimental|Belotero|
11567712|NCT00876265|Active Comparator|Zyplast|
11567713|NCT00876252|Active Comparator|IC43 100 mcg|IC43 100 mcg with Aluminum hydroxide
11567714|NCT00876252|Active Comparator|IC43 200 mcg|IC43 200 mcg with Aluminum hydroxide
11567716|NCT00876252|Placebo Comparator|Placebo|phosphate-buffered saline solution containing 0,9 % NaCl and 400 mcg Aluminum hydroxide as an adjuvant
11567717|NCT00876200|Experimental|Minoxidil|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.
~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
11567718|NCT00876200|Placebo Comparator|Placebo|Placebo = lactose
11567719|NCT00876187|Experimental|Tanezumab 20 mg IV|
11567720|NCT00876187|Experimental|Tanezumab 10 mg IV|
11567721|NCT00876187|Experimental|Tanezumab 5 mg IV|
11567722|NCT00876187|Active Comparator|Naproxen|
11567723|NCT00876187|Placebo Comparator|Placebo|
11567724|NCT00876174||Patients|20 patients with genotype 1, chronic hepatitis C who are to undergo standard antiviral therapy
11567725|NCT00876174||control|Group 2, (control): 10 healthy family members or significant others of patients who are to undergo standard antiviral therapy
11567726|NCT00876161|Experimental|DAS181|
11567727|NCT00876161|Placebo Comparator|Lactose|
11567728|NCT00876135|Placebo Comparator|Inhaled Bronchodilator|
11567729|NCT00876122|Experimental|1|
11567730|NCT00876109|Experimental|Group A: GDC-0941 QD Dose Escalation|Participants will receive GDC-0941 for up to 1 year, administered orally QD at a starting dose of 15 milligrams (mg).
11567731|NCT00876109|Experimental|Group B: GDC-0941 BID Dose Escalation|Participants will receive GDC-0941 for up to 1 year, administered orally BID at a starting dose determined from Group A assessments.
11567732|NCT00876109|Experimental|Group C: GDC-0941 QD or BID Expansion|Participants will receive GDC-0941 for up to 1 year, administered orally QD or BID. The dose/regimen will be determined on the basis of data from Groups A and B.
11567733|NCT00876096|Other|1|precocious diagnosis and taken care therapeutics of the systematic athlete's feet
11567734|NCT00876083||Group 1|
11567735|NCT00876057|Active Comparator|TH|Total hysterectomy
11567736|NCT00876057|Active Comparator|SH|Subtotal hysterectomy
11567737|NCT00876044|Experimental|1|4 mg/kg every 2 weeks
11567738|NCT00876044|Placebo Comparator|2|matching placebo
11567739|NCT00876031|Experimental|O-TIE|oral maintenance therapy with trofosfamide, idarubicin, and etoposide
11567740|NCT00876031|No Intervention|control|
11567741|NCT00876018|No Intervention|No intervention|No intervention
11567742|NCT00876018|Experimental|Nutritional supplement|Fortified nutritional powder
11567743|NCT00876018|Placebo Comparator|Placebo|Un-fortified nutritional powder
11567744|NCT00876005|Active Comparator|1|80% oxygen during cesarean section
11567745|NCT00876005|Active Comparator|2|30% oxygen during cesarean section
11567746|NCT00875992|Experimental|ETN with ASLS|Angle stable locking of the Expert Tibial Nail using ASLS
11567747|NCT00875992|Active Comparator|ETN with conventional locking|Conventional locking of the Expert Tibial Nail using conventional locking bolts
11567748|NCT00875979|Experimental|Trastuzumab emtansine 3.0 mg/kg + pertuzumab 420 mg|Patients received trastuzumab emtansine 3.0 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer therapy, or patient discontinuation. Patients also received a loading dose of 840 mg of pertuzumab IV on Day 1 of Cycle 1 followed by pertuzumab 420 mg IV on Day 1 of every subsequent 3 week cycle.
11567749|NCT00875979|Experimental|Trastuzumab emtansine 3.6 mg/kg + pertuzumab 420 mg|Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer therapy, or patient discontinuation. Patients also received a loading dose of 840 mg of pertuzumab IV on Day 1 of Cycle 1 followed by pertuzumab 420 mg IV on Day 1 of every subsequent 3 week cycle.
11567750|NCT00875966|Experimental|1|Azithromycin for oral suspension 200mg/5mL
11567751|NCT00875966|Active Comparator|2|Zithromax (azithromycin for oral suspension) 200mg/5mL
11567752|NCT00875953|Active Comparator|Standard dissection|standard neck dissection technique: scalpel and cautery.
11567753|NCT00875953|Experimental|Harmonic Scalpel|Harmonic scalpel used in neck dissection.
11567754|NCT00875940||Group 1|Patients having both Tc-99m perfusion scan and echocardiogram.
11567755|NCT00875927|Active Comparator|1 - control|candy not including scraping microcapsules
11567756|NCT00875927|Active Comparator|2 - Scraping|candy including scraping TCP microcapsules
11567757|NCT00875927|Active Comparator|3 - Scraping plus Propolis|candy including scraping Propolis microcapsules
11567758|NCT00875927|Active Comparator|4 - Scraping plus Zinc|candy including scraping Zinc microcapsules
11567759|NCT00875927|Active Comparator|5 - Scraping plus Propolis and Zinc|candy including scraping Propolis and Zinc microcapsules
11567760|NCT00875914|Experimental|Manually guided|Treatment with manually guided RF-catheter
11567761|NCT00875914|Experimental|Magnetically navigated|Treatment with magnetically navigated RF-catheter.
11567762|NCT00875901|Experimental|Peripherally located lung tumor|12 cobalt gray equivalent per fraction to a total of 48 cobalt gray equivalent
11567763|NCT00875901|Experimental|Centrally located lung tumor|6 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent
11567764|NCT00875888|Experimental|HCO|High cut-off filters HCO1100
11567765|NCT00875888|Active Comparator|control|conventional high-flux filters
11567766|NCT00875875|Active Comparator|1|This is the approved treatment regimen for travelers' diarrhea (600 mg)
11567767|NCT00875875|Active Comparator|2|This is the same dose as the standard dose, given once daily (200 mg)
11567768|NCT00875862|Active Comparator|1. 0.2% Ropivicaine perinueral infusion|Patients will receive normal standard of care post-manipulation (single-injection brachial plexus nerve block, oral analgesics, and cold therapy). They will then be randomized to 0.2% Ropivicaine attached to the perineural catheter and an infusion will be initiated. The outcome measures will be assessed by study staff on the phone and at regular visits to the surgeon's office.
11567813|NCT00875524|Experimental|CYD Dengue Vaccine Group|Participants who received CYD dengue vaccine as first (Day 0), second (Day 0 + 6 months), and third (Day 0 + 12 months) injections. Participants were followed for 4 years after the third injection.
11568361|NCT00871572|Experimental|LY2409021 10 milligrams (mg)|
11567769|NCT00875862|Placebo Comparator|2. Normal Saline perineural infusion|Patients will receive normal standard of care post-manipulation (single-injection brachial plexus nerve block, oral analgesics, and cold therapy). They will then be randomized to normal saline attached to the perineural catheter and an infusion will be initiated. The outcome measures will be assessed by study staff on the phone and at regular visits to the surgeon's office.
11567770|NCT00875849|Experimental|Cetuximab|
11567771|NCT00875836|Experimental|Buspirone|Buspirone
11567772|NCT00875836|Placebo Comparator|Placebo|Placebo
11567773|NCT00875823||PH Patients|"Patients with:
~Primary Hyperoxaluria Type I Primary Hyperoxaluria Type II Primary Hyperoxaluria NonI-NonII"
11567774|NCT00875797|Active Comparator|parentral glutamine|parenteral glutamine given in central venous line in dose up to 30 g par day
11567775|NCT00875797|Experimental|entral glutamine|enteral glutamine given through gastric tube in a dose up to 30 g per day
11567776|NCT00875784|Experimental|TREXIMA tablet followed by IMITREX injection (4mg)|TREXIMA™ (sumatriptan succinate / naproxen sodium) Tablet followed by IMITREX® (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System®
11567777|NCT00875784|Experimental|TREXIMA tablet followed by IMITREX injection (6mg)|TREXIMA tablet followed by IMITREX® (sumatriptan succinate) Injection 6mg administered using the IMITREX STATdose System®
11567778|NCT00875784|Active Comparator|IMITREX tablet (100mg)|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
11567779|NCT00875771|Experimental|1|"Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks
~Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks
~Bevacizumab: 5 mg/kg day 1, every 2 Weeks"
11567780|NCT00875758|Active Comparator|Standard threshold|
11567781|NCT00875758|Experimental|Low-threshold|
11567782|NCT00875745|Experimental|Sorafenib-Vorinostat|This is a single-arm, non-randomized feasibility and safety Phase I trial of a combination of Sorafenib and Vorinostat, both administered orally.
11567783|NCT00875732|Experimental|1|Biventricular Pacing
11567784|NCT00875732|Active Comparator|2|Right Ventricular Pacing
11567785|NCT00875719|Active Comparator|continuous v intermittent Oxygen therapy|intermittent oxygen compared to constant flow oxygen as regards walking distance
11567786|NCT00875706|Other|Training Feasibility|"4 sites will receive the training intervention to determine the feasibility of the train-the trainer approach.
~The educational intervention is included in this arm."
11567787|NCT00875706|Other|Data Collection - Survey|Survey data collection tools will be piloted to assess feasibility of survey administration and development of the survey for future studies. This tools were piloted in sites where the educational intervention was administered.
11567788|NCT00875706|Other|Data Collection - Interview|Interview data collection tools will be piloted to assess feasibility of interview administration and development of the interview protocol for future studies. This tools were piloted in sites where the educational intervention was administered.
11567789|NCT00875693|Experimental|Arm A dose of CPX - 351|Dose level 1A: 60 units/m2 days -28, -26 and -24 Dose level 2A: 80 units/m2 days -28, -26 and -24 Dose level 3A: 100 units/m2 days -28, -26 and -24 Dose level 4A: 120 units/m2 days -28, -26 and -24 Dose level 5A: 140 units/m2 days -28, -26 and -24 Dose level 6A: 160 units/m2 days -28, -26 and -24
11567790|NCT00875693|Experimental|Arm B dose of CPX-351|Dose level 1B: 60 units/m2 days -21, -19 and -17 Dose level 2B: 80 units/m2 days -21, -19 and -17 Dose level 3B: 100 units/m2 days -21, -19 and -17 Dose level 4B: 120 units/m2 days -21, -19 and -17 Dose level 5B: 140 units/m2 days -21, -19 and -17
11567791|NCT00875680|Experimental|autoPPC|
11567792|NCT00875667|Experimental|Lenalidomide|Lenalidomide
11567793|NCT00875667|Active Comparator|Investigators choice single agent|Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, Fludarabine
11567794|NCT00875654|No Intervention|1|Control group without intervention nor placebo
11567795|NCT00875654|Experimental|2|First dose of stem cells
11567796|NCT00875654|Experimental|3|Second dose of stem cells
11567797|NCT00875641||HRV cohort|HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).
11567798|NCT00875641||Concurrent Control cohort|Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).
11567799|NCT00875641||Recent Historical Control cohort|Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.
11567800|NCT00875628|Other|Cohort 1|PF-00868554 100 mg or placebo
11567801|NCT00875628|Other|Cohort 2|PF-00868554 300 mg or placebo
11567802|NCT00875628|Other|Cohort 3|PF-00868554 600 mg or placebo
11567803|NCT00875615|Experimental|Cisplatin or Carboplatin + Sorafenib|
11567804|NCT00875602|No Intervention|control|before-after (retrospective) and concurrent controls as comparators with a prospective intervention group
11567805|NCT00875602|Active Comparator|Study unit|Hospitalized patients in the study group will be continously monitored / supervised by the contact-free device
11567806|NCT00875589||Control|Control subjects with no Mild Traumatic Brain Injury (MTBI) and no Post-Traumatic Stress Disorder (PTSD)
11567807|NCT00875589||MTBI|Subject with a diagnosis for Mild Traumatic Brain Injury (MTBI)
11567808|NCT00875563|Experimental|1|Zenith(R) Fenestrated AAA Endovascular Graft
11567809|NCT00875550|Active Comparator|Dexmedetomidine Low Dose|
11567810|NCT00875550|Active Comparator|Dexmedetomidine High dose|
11567811|NCT00875537|Active Comparator|Capsaicin oral gel 0.01%|
11567812|NCT00875537|Active Comparator|Capsaicin oral gel 0.025%|
11567868|NCT00875108|Experimental|VIAject™|Single injection
11567909|NCT00874861|Experimental|Vaccine + Poly-ICLC|Peptide Vaccine + Poly-ICLC
11567814|NCT00875524|Sham Comparator|Control Vaccine Group|Participants who received the Meningococcal Polysaccharide Vaccine A + C, placebo, and Typhoid Vi polysaccharide vaccine as the first (Day 0), second (Day 0 + 6 months), and third (Day 0 + 12 months) injections, respectively. Participants were followed for 4 years after the third injection.
11567815|NCT00875498|Active Comparator|active iTBS|iTBS active intensity = 80%MT during 6 minutes. 20 sessions, 2 per day
11567816|NCT00875498|Placebo Comparator|sham iTBS|iTBS placebo (placebo coil)with same parameters than active
11567817|NCT00875485|Experimental|Twinrix Adult Group|Subjects received 2 doses of Twinrix™ Adult intramuscularly according to a 0, 6 month schedule in the primary study
11567818|NCT00875485|Experimental|Twinrix Junior Group|Subjects received 3 doses of Twinrix™ Junior (= half dose Twinrix™ Adult) intramuscularly according to a 0, 1, 6 month schedule in the primary study
11567819|NCT00875459|Experimental|VIAject™|Single injection
11567820|NCT00875446|Experimental|Subjects receiving GSK1223249|"Eligible subjects will receive sequential dose of intravenous infusion of GSK1223249 with a starting dose of 0.01 milligram per kilogram followed by 0.1, 0.5,
~1, 2.5, 5, 7.5, and 15 milligrams per kilograms."
11567821|NCT00875446|Placebo Comparator|Subjects receiving placebo|Eligible subjects will receive intravenous infusion of placebo.
11567822|NCT00875433|Experimental|Monotherapy|BIBW 2992 high dose, once daily, continuous, monotherapy
11567823|NCT00875420|Experimental|RAD1901 10 mg|Oral once a day for 28 days
11567824|NCT00875420|Experimental|RAD1901 25 mg|Oral once a day for 28 days
11567825|NCT00875420|Experimental|RAD1901 50 mg|Oral once a day for 28 days
11567826|NCT00875420|Experimental|RAD1901 100 mg|Oral once a day for 28 days
11567827|NCT00875420|Placebo Comparator|Placebo|Oral once a day for 28 days
11567828|NCT00875394|Experimental|1|sitagliptin + metformin
11567829|NCT00875394|Active Comparator|2|metformin + any other oral antidiabetic drug
11567830|NCT00875394|Active Comparator|3|metformin
11567831|NCT00875368|Active Comparator|Maraviroc|
11567832|NCT00875368|Placebo Comparator|Placebo|Placebo drug
11567833|NCT00875355|Experimental|Arm I|Patients undergo isocentric radiotherapy to the brain 5 times a week for 2 weeks.
11567834|NCT00875355|Experimental|Arm II|Patients undergo radiotherapy as in arm I and receive oral temozolomide once daily for 2 weeks.
11567835|NCT00875342|Experimental|D-cycloserine|
11567836|NCT00875342|Placebo Comparator|Placebo|
11567837|NCT00875329||Group 1|A convenience sample of 97VHA patients who served during the OEF or OIF era, who are targeted in CPRS as requiring the TBI Clinical reminder will be included. This includes all ages, both sexes, and all races and ethnicities.
11567838|NCT00875316|Experimental|Cohort A|
11567839|NCT00875316|Experimental|Cohort B|
11567840|NCT00875316|Experimental|Cohort C|
11567841|NCT00875316|Experimental|Cohort D (Optional)|
11567842|NCT00875303|Placebo Comparator|Control|Routine primary care.
11567843|NCT00875303|Experimental|Multimedia intervention|
11567844|NCT00875290|No Intervention|Control|Observational arm
11567845|NCT00875290|Experimental|Real-time glucose sensor|Subjects wear real-time glucose sensor
11567846|NCT00875277|Experimental|LEO 29102 cream|LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks
11567847|NCT00875277|Placebo Comparator|LEO 29102 Cream Vehicle|LEO 29102 cream vehicle applied topically twice daily for 4 weeks.
11567848|NCT00875277|Experimental|Betamethasone Dipropionate Cream|Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.
11567849|NCT00875277|Experimental|LEO 29102 Plus Calcipotriol Cream|LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.
11567850|NCT00875277|Experimental|LEO 29102 Plus Betamethasone Dipropionate|LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.
11567851|NCT00875277|Active Comparator|Daivobet® Ointment|Daivobet® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.
11567852|NCT00875264|Experimental|1|At least one 6-week (42-day) cycle in which patients will be treated daily with CEP-11981 for 28 days, followed by a treatment-free period of 14 days.
11567853|NCT00875251||term infants body composition|Term infants from 2 days of life to 7 days of life without IUGR
11567854|NCT00875251||preterm infants body composition|very low birth weight infants before discharge
11567855|NCT00875225|Active Comparator|Control DVD|Control DVD with usual care information
11567856|NCT00875225|Active Comparator|Intervention DVD|Intervention group will receive DVD with patient stories and information from health care professionals
11567857|NCT00875212|Experimental|dentifrice intervention|4 types of dentifrices were used in 4 different periods in a crossover study design.
11567858|NCT00875199|Active Comparator|A|Participants assigned to Group A will receive the DPP manual (Wing & Gillis, 1996), a behavioral weight-loss program with demonstrated efficacy in facilitating weight loss. Participants in Group A will be instructed to read a section of the manual each week and complete suggested activities. They will also meet with the research staff once a week for weigh-in and supportive counseling.
11567859|NCT00875199|Experimental|B|Participants assigned to Group B will receive the DPP manual and will meet with research staff each week for weigh-in and supportive counseling. They will also receive contingency management or the opportunity to earn draws with the chance of winning prizes for losing weight and completing healthy activities.
11567860|NCT00875186||multiple-exercise group (ME)|participants exercised 2 times weekly for 1 hour (aerobic endurance training)
11567861|NCT00875186||Low-exercise group (LE)|participants exercises 1 time weekly for 1 hour (aerobic endurance training)
11567862|NCT00875173|Experimental|Selenium|Sodium selenite 100 micrograms in capsugel by mouth diary for 365 consecutive days
11567863|NCT00875173|Active Comparator|Placebo|Capsugel for placebo (selenium 100 micrograms capsugel) by mouth diary for 365 consecutive days
11567864|NCT00875160|Experimental|AT2101|
11567865|NCT00875147||with bevacizumab|Neoadjuvant chemotherapy with bevacizumab
11567866|NCT00875147||without Bevacizumab|Neoadjuvant chemotherapy without Bevacizumab
11567867|NCT00875134|Experimental|Verbal prompt, cutaneous stimulation|Patient receives either or both a verbal stimulus or cutaneous stimulus
11567869|NCT00875095||IUI patients|Patients undergoing routine semen analysis as part of their infertility treatment pertaining to success or failure with intrauterine insemination, based upon their sperm DNA integrity
11567870|NCT00875095||IVF patients|Couples undergoing routine screening prior to IVF retrievals to assess their reproductive treatment outcomes as compared to the sperm DNA integrity
11567871|NCT00875082|Active Comparator|Montelukast|Montelukast chewing tablets once daily per os, plus inhaled short acting beta2 agonist as needed
11567872|NCT00875082|Placebo Comparator|placebo|placebo chewing tablets per os once daily, plus inhaled short acting beta 2 agonist as needed
11567873|NCT00875069|Experimental|ethanol|
11567874|NCT00875069|Placebo Comparator|placebo|
11567875|NCT00875056|Experimental|Follicular Lymphoma (FL)|Participants with relapsed/refractory FL received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol.
11567876|NCT00875056|Experimental|Indolent non-FL B-NHL or MCL|Participants with indolent non-follicular lymphoma (FL) B-cell non-Hodgkin's lymphoma (B-NHL), or with mantle cell Lymphoma (MCL) received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol.
11567877|NCT00875056|Experimental|Other Disease|Participants with disease other than relapsed/refractory follicular lymphoma (FL), non-FL B-cell non-Hodgkin's lymphoma (B-NHL), or mantle cell Lymphoma (MCL), as assessed by the Independent Central Pathological Committee, received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol. This group was created to include participants who enrolled, but whose later diagnoses by the Independent Central Pathological Committee excluded them from analysis in the FL and non-FL B-NHL/MCL groups because they had different disease than those prespecified in the protocol.
11567878|NCT00875043||1. flat Jackson table|All measurements previously described will be done with the patient in the prone postion and Jackson table flat.
11567879|NCT00875043||2. Elevated Jackson tablet|All measurements previously described will be performed with subjects placed prone on the elevated Jackson table.
11567880|NCT00875030|Experimental|1.0|
11567881|NCT00875030|Active Comparator|2.0|
11567882|NCT00875017|Experimental|Meal + Lanthanum|
11567883|NCT00875017|Active Comparator|Meal + Sevelamer|
11567884|NCT00875017|No Intervention|Meal Only|
11567885|NCT00875017|No Intervention|Fasting|
11567886|NCT00874978|Experimental|lenalidomide|
11567887|NCT00874965|Active Comparator|ES|Electrostimulation
11567888|NCT00874965|Placebo Comparator|Sham ES|Sham stimulation
11567889|NCT00874939|Experimental|PBO→MK-7.5→DON→MK-25|Treatment by single oral dose with Placebo (PBO) in the first crossover period; MK-0249 7.5 mg (MK-7.5) in the second crossover period; Donepezil 5 mg (DON) in the third crossover period; and MK-0249 25 mg (MK-25) in the fourth crossover period.
11567890|NCT00874939|Experimental|MK-7.5→PBO→MK-25→DON|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; Placebo in the second crossover period; MK-0249 25 mg in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
11567891|NCT00874939|Experimental|DON→MK-25→PBO→MK-7.5|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; MK-0249 25 mg in the second crossover period; Placebo in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
11567892|NCT00874939|Experimental|MK-25→DON→MK-7.5→PBO|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; Donepezil 5 mg in the second crossover period; MK-0249 7.5 mg in the third crossover period; and Placebo in the fourth crossover period.
11567893|NCT00874939|Experimental|PBO→MK-25→MK-7.5→DON|Treatment by single oral dose with Placebo in the first crossover period; MK-0249 25 mg in the second crossover period; MK-0249 7.5 mg in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
11567894|NCT00874939|Experimental|MK-7.5→DON→PBO→MK-25|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; Donepezil 5 mg in the second crossover period; Placebo in the third crossover period; and MK-0249 25 mg in the fourth crossover period.
11567895|NCT00874939|Experimental|DON→MK-7.5→MK-25→PBO|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; MK-0249 7.5 mg in the second crossover period; MK-0249 25 mg in the third crossover period; and Placebo in the fourth crossover period.
11567896|NCT00874939|Experimental|MK-25→PBO→DON→MK-7.5|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; Placebo in the second crossover period; Donepezil 5 mg in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
11567897|NCT00874939|Experimental|PBO→DON→MK-25→MK-7.5|Treatment by single oral dose with Placebo in the first crossover period; Donepezil 5 mg in the second crossover period; MK-0249 25 mg in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
11567898|NCT00874939|Experimental|MK-7.5→MK-25→DON→PBO|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; MK-0249 25 mg in the second crossover period; Donepezil 5 mg in the third crossover period; and Placebo in the fourth crossover period.
11567899|NCT00874939|Experimental|DON→PBO→MK-7.5→MK-25|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; Placebo in the second crossover period; MK-0249 7.5 mg in the third crossover period; and MK-0249 25 mg in the fourth crossover period.
11567900|NCT00874939|Experimental|MK-25→MK-7.5→PBO→DON|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; MK-0249 7.5 mg in the second crossover period; Placebo in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
11567901|NCT00874926||Group 1|
11567902|NCT00874913|Experimental|Laser Doppler Flowmetry|
11567903|NCT00874900|Experimental|Game|
11567904|NCT00874900|Experimental|Game + Activation|
11567905|NCT00874900|No Intervention|Booklet|
11567906|NCT00874900|Experimental|Booklet + Activation|
11567907|NCT00874887|Active Comparator|Vigamox®|moxifloxacin 0.5% (m mg/mL), boric acid, sodium chloride, and purified water
11567908|NCT00874887|Active Comparator|Zymar®|gatifloxacin 0.3% (3 mg/mL), benzalkonium chloride 0.005%, edetate disodium; purified water and sodium chloride
11567910|NCT00874848|Experimental|Imprime PGG|Imprime PGG Injection + Cetuximab + Paclitaxel/Carboplatin
11567911|NCT00874848|Active Comparator|Control|Cetuximab + Paclitaxel/Carboplatin
11567912|NCT00874822||Berlin|Patients diagnosed with obstructive sleep apnea by polysomnography after being screened with the Berlin questionnaire.
11567913|NCT00874809|Other|Insulin Treatment|There is only one arm for this study using lispro insulin administered by insulin pump.
11567914|NCT00874796|Experimental|GS-9450 10 mg/day|GS-9450 taken as one 10 mg capsule by mouth once daily
11567915|NCT00874796|Experimental|GS-9450 40 mg/day|GS-9450 taken as one 40 mg capsule by mouth once daily
11567916|NCT00874796|Placebo Comparator|Placebo|Placebo taken as one placebo capsule by mouth once daily
11567917|NCT00874770|Experimental|Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A)|Active Comparator
11567918|NCT00874770|Experimental|Daclatasvir, Peginterferon alpha-2a, ribavirin (B)|Active Comparator
11567919|NCT00874770|Experimental|Daclatasvir, Peginterferon alpha-2a, ribavirin (C)|Active Comparator
11567920|NCT00874770|Active Comparator|Placebo, Peginterferon alpha-2a, ribavirin (D)|
11567921|NCT00874744|Experimental|bevacizumab|
11567922|NCT00874744|Experimental|Triamcinolone|
11567923|NCT00874731|Experimental|Pt 1. Placebo/Ridaforolimus 100 mg; Pt 2. Ridaforolimus 40 mg|[Pt 1, Day 1]: Participants received a single dose of placebo (10 oral tablets) on Day 1 of Part 1. [Pt 1, Day 2]: Following completion of Part 1 / Day 1, participants received a single dose of ridaforolimus 100 mg (10 x 10 mg oral tablets) on Day 2 of Part 1. Following completion of Part 1 / Day 2, participants entered a washout period of ≥5 days before the first dose Part 2. [Pt 2]: Following completion of Part 1, participants received ridaforolimus 40 mg (4 x 10 mg oral tablets) given once daily (QD) for 5 consecutive days followed by 2 days off-drug.
11567924|NCT00874718|Active Comparator|Action group|
11567925|NCT00874718|Other|Control group|Non-specific educational program for general health.
11567926|NCT00874692|Experimental|BMS and sterilisation|BMS and sterilisation programme will be delivered
11567927|NCT00874692|No Intervention|BMS standard water heating|
11567928|NCT00874679||Group 1|
11567929|NCT00874666|Active Comparator|1|Positive control with 100% allicin bioavailability
11567930|NCT00874666|Experimental|2|garlic powder tablet
11567931|NCT00874653||Group 1|
11567932|NCT00874640||Group 1|
11567933|NCT00874627|Experimental|Experimental|Administration of Milk
11567934|NCT00874627|Placebo Comparator|Placebo|meals without milk
11567935|NCT00874614|Experimental|Ultratrace® Iobenguane I 131 Treatment|
11567936|NCT00874601|Experimental|valsartan group|The valsartan group will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.
11567937|NCT00874601|No Intervention|control group|Patients on control group will not receive any other antihypertensive medication for first 7 days after stroke onset. However, rescue therapy with antihypertensive agents can be permitted for episodes with severely elevated blood pressures during acute periods.
11567938|NCT00874588|Experimental|Phase I study|
11567939|NCT00874575|Placebo Comparator|1|Control
11567940|NCT00874575|Experimental|2|Beta-hydroxy-Beta-methylbutyrate, 3 g/d
11567941|NCT00874575|Experimental|3|Vitamin D, 2000 IU/d
11567942|NCT00874575|Experimental|4|Beta-hydroxy-Beta-methylbutyrate (3 g/d) + Vitamin D (2000 IU/d)
11567943|NCT00874562|Active Comparator|Steroid Only|Corticosteroid Alone
11567944|NCT00874562|Active Comparator|Steroid plus Rapamycin|Corticosteroid plus Rapamycin
11567945|NCT00874549|Active Comparator|Group 1: Menomune Day 0|Participants received a single dose of Menomune® vaccine on Day 0.
11567946|NCT00874549|Experimental|Group 2: Menactra® Day 0 x 2|Participants received two single-dose injections of Menactra® vaccine on Day 0
11567947|NCT00874549|Experimental|Group 3: Menactra® Day 0 and 14|Participants received a single dose of Menactra® vaccine on Day 0 and on Day 14
11567948|NCT00874549|Experimental|Group 4: Menactra® Day 0 and 28|Participants received a single dose of Menactra® vaccine on Day 0 and on Day 28.
11567949|NCT00874536|Experimental|ALA|This group will receive the ALA supplement
11567950|NCT00874536|Placebo Comparator|Placebo|This group will receive the placebo supplement
11567951|NCT00874523|Active Comparator|Arm A|
11567952|NCT00874523|Active Comparator|Arm B|
11567953|NCT00874510|No Intervention|Standard Schedule|interns work standard schedule, being on duty for 30 continuous hours
11567954|NCT00874510|Experimental|Mandatory Naps|interns on overnight extended duty shifts have mandatory sign out of cell phones and cross-coverage responsibilities for 5 hours roughly between 12 and 5 am. For Year 2, this will be two 3 hour shifts, the first between 12am-3am and the 2nd between 3am-6am.
11567955|NCT00874497|Experimental|1 Tetomilast|
11567956|NCT00874497|Placebo Comparator|2 Placebo|
11567957|NCT00874484|Experimental|1|
11567958|NCT00874484|Placebo Comparator|2|
11567959|NCT00874471||sarcoidosis|
11567960|NCT00874471||ankylosing spondylitis|
11567961|NCT00874471||Behcet's disease|
11567962|NCT00874471||toxoplasmosis|
11567963|NCT00874471||herpetic acute retinal necrosis|
11567964|NCT00874471||idiopathic uveitis|
11567965|NCT00874471||ankylosing spondylitis (no uveitis)|
11567966|NCT00874471||sarcoidosis (no uveitis)|
11567967|NCT00874471||Behcet's disease (no uveitis)|
11567968|NCT00874471||normal control|
11567969|NCT00874458|Experimental|MRI|
11567970|NCT00874445||ICD shocks programmed to Tuned Waveform|ICD shocks programmed to Tuned Waveform
11567971|NCT00874445||ICD shocks programmed to Fixed Tilt Waveform|ICD shocks programmed to Fixed Tilt Waveform
11567972|NCT00874432|Active Comparator|Chronic Kidney Disease-ACE-I|ace inhibitor
11567973|NCT00874432|Placebo Comparator|Chronic Kidney Disease|
11567974|NCT00874432|Active Comparator|Age matched control-ACE-I|ace-inhibitor
11567975|NCT00874432|Placebo Comparator|Age matched control|Placebo
11568362|NCT00871572|Experimental|LY2409021 30 mg|
11567976|NCT00874419|Experimental|erlotinib|Arm 1 receive erlotinib 150 mg oral, once a day until progression or unacceptable toxicity
11567977|NCT00874419|Active Comparator|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
11567978|NCT00874406|Experimental|1|transhepatic arterial chemotherapy (TAC) were given 7 days before liver metastasis resection. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
11567979|NCT00874406|Active Comparator|2|Liver metastasis resection was done without TAC. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
11567980|NCT00874393|Active Comparator|Dopamine and hydrocortisone|Dopamine AND hydrocortisone
11567981|NCT00874393|Active Comparator|Dopamine and placebo|Dopamine AND normal saline placebo
11567982|NCT00874393|Active Comparator|Placebo and hydrocortisone|Dextrose (D5W) placebo AND hydrocortisone
11567983|NCT00874393|Placebo Comparator|Placebo and Placebo|Dextrose (D5W) placebo AND normal saline placebo
11567984|NCT00874380||1|First describe the diet of a cohort of dialysis patients with focus on fiber content.
11567985|NCT00874354|Experimental|Autologous bone marrow stem cells|Patients within 3 to 14 days from percutaneous coronary intervention (PCI) and stent implantation for Acute Myocardial Infarction (AMI) will receive either 50 cc's or 100 cc's of autologous bone marrow mononuclear cells through an intracoronary tranplantation of stem cells into the infarct-related coronary artery.
11567986|NCT00874341|No Intervention|1|
11567987|NCT00874341|Active Comparator|2|4 portions fruit and vegetables daily for 12 weeks
11567988|NCT00874341|Active Comparator|3|7 portions of fruit and vegetables daily for 12 weeks
11567989|NCT00874328|Experimental|study arm|Irinotecan /IV D1 Cisplatin 60mg/m2 iv D1 S-1 bid, P.o. D1 ~ 14 q 3 weeks until maximum 6 cycles
11567990|NCT00874302|Experimental|25 mg|25 mg Proellex
11567991|NCT00874302|Experimental|50 mg|50 mg Proellex
11567992|NCT00874289||Acute heart failure patients|
11567993|NCT00874289||Chronic heart failure patients|
11567994|NCT00874276|Experimental|No EGT Allele, slow metabolizers for DCA|Individuals were genotyped at the beginning of the study and their haplotypes were defined. Dichloroacetate 2.5.ug/kg (non-clinical dose) will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
11567995|NCT00874276|Experimental|1+ EGT Allele, fast metabolizers for DCA|Individuals were genotyped at the beginning of the study and their haplotypes were defined. Dichloroacetate 2.5.ug/kg (non-clinical dose) will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
11567996|NCT00874250|Experimental|GORE CTAG Device|The primary endpoint of this study is freedom from a Major Device Event (MDE) through 1 month post-treatment in subjects treated with the GORE® Conformable TAG® Thoracic Endoprosthesis.
11567997|NCT00874237|Other|Treatment sequence ABC|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
11567998|NCT00874237|Other|Treatment sequence ACB|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
11567999|NCT00874237|Other|Treatment sequence BCA|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
11568000|NCT00874237|Other|Treatment sequence BAC|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
11568001|NCT00874237|Other|Treatment sequence CAB|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
11568002|NCT00874237|Other|Treatment sequence CBA|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
11568003|NCT00874224|Active Comparator|1|patients undergoing open left lateral hepatic sectionectomy
11568004|NCT00874224|Active Comparator|2|patients undergoing a laparoscopic left lateral hepatic sectionectomy
11568005|NCT00874224|Active Comparator|3|Prospective registry of patients that cannot be randomized (both open and laparoscopic left lateral hepatic sectionectomy)
11568006|NCT00874211||Observation|Patients will be observed and will undergo assessment of therapy complications.
11568007|NCT00874185||Questionnaire|filling in questionnaires
11568008|NCT00874172|Active Comparator|2|Combination of acetaminophen, morphine
11568009|NCT00874172|Experimental|1|Combination of acetaminophen, nitrous oxide, nefopam, morphine
11568010|NCT00874159||A|
11568011|NCT00874146||1|HER2-positive advanced breast cancer
11568012|NCT00874133|Active Comparator|Motillium|20 mg motilium thrice daily for 12 weeks.
11568013|NCT00874133|Active Comparator|Acupuncture|Acupuncture treatment.
11568014|NCT00874120|Experimental|Phenylephrine HCl Extended-Release tablets 30 mg|Phenylephrine HCl Extended Release tablets 30 mg
11568015|NCT00874120|Placebo Comparator|Placebo|Placebo
11568016|NCT00874107|Experimental|1|Imprime PGG + bevacizumab + paclitaxel/carboplatin
11568017|NCT00874107|Other|2|bevacizumab + paclitaxel/carboplatin
11568018|NCT00874094|Active Comparator|platelet rich fibrin matrix|Both nasolabial folds treated with 0-2 cc of autologous platelet rich fibrin matrix,sufficient to efface nasolabial fold
11568019|NCT00874068|Active Comparator|Standard vegetable oil formula|
11568020|NCT00874068|Active Comparator|InFat|
11568021|NCT00874068|No Intervention|Breast-fed|
11568022|NCT00874042|Experimental|ARQ 197 in combination with gemcitabine|
11568023|NCT00874029|Experimental|Halt Procedure|In this single-arm study, subjects who have symptomatic uterine fibroids will have the Halt Procedure in which intra-abdominal ultrasound will guide RF ablation of uterine fibroids using the Halt System.
11568024|NCT00874016|Active Comparator|Airtraq|Intubation with the use of the Airtraq
11568025|NCT00874016|Active Comparator|Direct Laryngoscopy|Intubation using direct laryngoscopy
11568026|NCT00874003|Experimental|mirtazapine, tablet, 30 mg|n=29
11568027|NCT00874003|Placebo Comparator|sugar pill|n=30
11568028|NCT00873990|Active Comparator|1|application of total etch bonding agent ( 5th generation) for placement of resing based pit and fissure sealants.
11568029|NCT00873990|Experimental|2|Self etch bonding agent (7th generation) application for placement of resin based pit and fissure sealant
11568030|NCT00873977|Active Comparator|C-flex|
11568031|NCT00873977|Active Comparator|A-flex|
11568032|NCT00873977|No Intervention|Auto-CPAP|
11568033|NCT00873951|Experimental|Intact casein|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as 15N-labelled intact casein
11568034|NCT00873951|Experimental|Hydrolyzed casein|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
11568035|NCT00873951|Experimental|AA|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
11568036|NCT00873938||1-supervised|
11568037|NCT00873938||2 -unsupervised|
11568038|NCT00873925|Experimental|Autologous UCB Plus Vit D Omega 3 FA|A single autologous (self) intravenous umbilical cord blood infusion followed by 1 year of daily Vitamin D and Omega 3 Fatty Acid supplementation give as liquid drops and gel capsules that can be swallowed or added to food
11568039|NCT00873925|No Intervention|Control|Subjects randomized to be controls will continue to use intensive insulin therapy in order to compare c-peptide production at 1 year in those receiving combination therapy vs those who do not
11568040|NCT00873912|Experimental|Monovalent influenza virus vaccine|Frozen monovalent vaccine containing new strain
11568041|NCT00873912|Placebo Comparator|Placebo|Placebo
11568042|NCT00873899||Remote Arm|The patients in Remote arm will receive a Medtronic CareLink Monitor to perform remote interrogation and transmission of ICD data. The remote arm ICD will be programmed to transmit over the CareLink Network.
11568043|NCT00873899||Implantable defibrillator patients|Heart failure patients implanted with a wireless-transmission-enabled ICD.
11568044|NCT00873886|Experimental|Oseltamivir (Tamiflu)|
11568045|NCT00873886|Other|Esterase|
11568046|NCT00873873||Persistent obstruction|(pattern of asthma progression)
11568047|NCT00873873||Late obstruction|(pattern of asthma progression)
11568048|NCT00873873||Late normal|(pattern of asthma progression)
11568049|NCT00873873||Persistent normal|(pattern of asthma progression)
11568050|NCT00873860|Placebo Comparator|Placebo|Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
11568051|NCT00873860|Experimental|CAT-354 150 mg|CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
11568052|NCT00873860|Experimental|CAT-354 300 mg|CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
11568053|NCT00873860|Experimental|CAT-354 600 mg|CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
11568054|NCT00873834|Experimental|Fluoxetine arm|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.
~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
11568055|NCT00873834|Placebo Comparator|placebo arm|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
11568056|NCT00873821|Experimental|1|MK-0941
11568057|NCT00873821|Placebo Comparator|2|Placebo Comparator
11568058|NCT00873795|Experimental|aripiprazole and sertraline|The patients of this arm receive ten weeks of treatment with a combination of sertraline 50mg/day and aripiprazole 2.5mg/day.The effect of this arm is assessed for HAM-D17, CGI, SF-36 and BSRS-50.
11568059|NCT00873795|Placebo Comparator|sertraline and placebo|The patients of this arm receive ten weeks of treatment with a combination of sertraline 50mg/day and placebo.The effect of this arm is assessed for HAM-D17, CGI, SF-36 and BSRS-50.
11568060|NCT00873782|Experimental|1|Participants will undergo retrograde high pressure transvenous limb perfusion with normal saline.
11568061|NCT00873769|Experimental|Healthy smokers|Healthy smokers, male and female
11568062|NCT00873769|Experimental|Healthy nonsmokers|Healthy nonsmokers, Healthy smokers, male and female
11568063|NCT00873756|Experimental|A|
11568064|NCT00873743||1|60 women after elective cesarian section
11568065|NCT00873743||2|60 women after elective cesarian section
11568066|NCT00873730|Experimental|1|
11568067|NCT00873730|Active Comparator|2|
11568068|NCT00873717|Experimental|Dentary|Intervention: trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.
11568069|NCT00873717|Experimental|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
11568070|NCT00873717|Experimental|Dentary + nutrition|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed) associated with control of the administration of dietary prescriptions, incitement to eat.
11568071|NCT00873717|No Intervention|Control|usual care
11568072|NCT00873704|Active Comparator|1|recieves supplemental oxygen postoperatively
11568073|NCT00873704|No Intervention|2|treated as usual without supplemental oxygen
11568074|NCT00873691||1|ICD shocks programmed to Tuned Waveform
11568075|NCT00873691||2|ICD shocks programmed to 50% Tilt waveform
11568076|NCT00873678||1|Children or adult patients affected with JS/CORS
11568077|NCT00873665|Experimental|Aerobic exercise|"To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.
~The test of the arm effect of incidence of ED will be made with the Wald chi-square test from the logistic regression model. A dichotomous variable indicating whether the patient received PDE-5 inhibitor therapy will be used as a covariate in the model. The arm effect will be summarized by giving arm-specific covariate-adjusted proportions and their 80% confidence intervals, and the p-value."
11568363|NCT00871572|Experimental|LY2409021 60 mg|
11568078|NCT00873665|Other|Wait-list control|"To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.
~For the analyses of arm differences in erectile dysfunction (IIEF) score, sexual functioning, urinary incontinence, and QOL, the primary endpoints will be the change across time in these continuous variables. Specifically, change across time for LTF patients will be imputed to be zero for all these analyses."
11568079|NCT00873639||A|
11568080|NCT00873626|Active Comparator|1|fluoroquinolones 5 days
11568081|NCT00873626|Active Comparator|2|fluoroquinolones 10 days
11568082|NCT00873613|No Intervention|Direct ophthalmoscopy|
11568083|NCT00873613|Experimental|Non-dilated retinal photography|
11568084|NCT00873587|Other|Inspiration|
11568085|NCT00873587|Other|Expiration|
11568086|NCT00873574||1|2 patients with MPD for each family. One case for each family will be randomised ; the cohort will be of 120 patients.
11568087|NCT00873574||2|1 control for each family
11568088|NCT00873561|Active Comparator|1 Experimental|NBI-6024 0.1 mg
11568089|NCT00873561|Active Comparator|2 Experimental|NBI-6024 0.5 mg
11568090|NCT00873561|Active Comparator|3 Experimental|NBI-6024 1 mg
11568091|NCT00873561|No Intervention|4 placebo|Placebo injection
11568092|NCT00873548||PFNA_Asia treated|
11568093|NCT00873535|Active Comparator|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
11568094|NCT00873535|Placebo Comparator|Placebo|This group (N=40) will receive placebo in the same dosing regimen as for Varenicline. The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
11568095|NCT00873522||Community acquired pneumonia|
11568096|NCT00873522||Health-Care-Associated pneumonia|
11568097|NCT00873509|Experimental|1|Buspirone 2.5 mg
11568098|NCT00873509|Experimental|2|Buspirone 5.0 mg
11568099|NCT00873509|Placebo Comparator|3|Placebo match
11568100|NCT00873496||Sjögren|Pre and post treatment establishment of salivary flow rate, objective and subjective clinical oral complications' severity of the patients using hydroxychloroquine
11568101|NCT00873483|Experimental|Arm 1|
11568102|NCT00873470|Experimental|Stimulation|All patients included have the stimulation
11568103|NCT00873457|Experimental|Perifosine|Perifosine 50 mg twice a day for a total of six 28-day cycles.
11568104|NCT00873444|Active Comparator|1) Ceramic-on-Metal Bearing|A cementless acetabular cup with ceramic liner for use in total hip replacement
11568105|NCT00873444|Active Comparator|2) Metal-on-Metal Bearing|A cementless acetabular cup with metal liner for use in total hip replacement
11568106|NCT00873431|Experimental|IC47 30 mcg|30 mcg with Alum
11568107|NCT00873431|Experimental|IC47 30 mcg w/o|30 mcg without Alum
11568108|NCT00873431|Experimental|IC47 150 mcg|150 mcg with Alum
11568109|NCT00873431|Experimental|IC47 150 mcg w/o|150 mcg without Alum
11568110|NCT00873418|Experimental|Coping Skills Training|16 week telephone intervention using coping skills training to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
11568111|NCT00873418|Active Comparator|Educational Control|16 weekly telephone calls for extended (standardized) care on heart failure education.
11568112|NCT00873405|Active Comparator|SRSG|Silastic® ring sleeve gastrectomy (SRSG).
11568113|NCT00873405|Other|SRGB|Silastic® ring gastric bypass.
11568114|NCT00873392|Experimental|1|Experimental drug
11568115|NCT00873392|Active Comparator|2|Usual treatment
11568116|NCT00873379|Active Comparator|melatonin|.5 mg (one half of a 1 mg tablet of GNC rapid dissolving Melatonin, natural product number (NPN) 80001380)
11568117|NCT00873379|Placebo Comparator|placebo|half a white placebo tablet
11568118|NCT00873353|Experimental|Unique arm|"6 cycles (3 weeks each one) of :
~capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks
~erlotinib (Tarceva®) 150mg/day, oral. Days: every days"
11568119|NCT00873340||Group 1|
11568120|NCT00873327|Active Comparator|1|Open label -- 6 interval doses
11568121|NCT00873314|Experimental|Bed rest|
11568122|NCT00873314|Placebo Comparator|Activity restriction|
11568123|NCT00873301|Experimental|vulvodynia|
11568124|NCT00873275|Experimental|Treatment (ursodiol, combination chemotherapy, bevacizumab)|Patients receive oral ursodiol twice daily on days 1-28 (days -6 to 28 of course 1), leucovorin calcium IV over 2 hours on days 1 and 15, fluorouracil IV over 46 hours on days 1-2 and 15-16, and oxaliplatin IV over 2 hours and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11568125|NCT00873262|Active Comparator|Hormones|
11568126|NCT00873262|Placebo Comparator|Solvent|
11568127|NCT00873236|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks.
11568128|NCT00873236|Experimental|Arm II|Patients receive bevacizumab as in arm I and low-dose recombinant interferon alpha-2a subcutaneously (SC) 3 times weekly beginning on day 0.
11568129|NCT00873236|Experimental|Arm III|Patients receive bevacizumab as in arm I and standard-dose recombinant interferon alpha-2a SC 3 times weekly beginning on day 0.
11568130|NCT00873223|Experimental|A|
11568131|NCT00873210||Patients treated with Sutent|125 consecutive patients in outpatient care with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
11568132|NCT00873197|Experimental|Sancuso® patch/IV granisetron|Subjects will receive 1 Sancuso® patch worn for 7 days (168 hours). Immediately after the patch has been applied on Day 1, IV granisetron will be administered over 30 seconds. Following patch removal at 168 hours, a new patch will be immediately applied to the opposite arm and will remain in place for a further 7 days (168 to 336 hours).
11568260|NCT00872274|Active Comparator|2|IMITREX® 100 mg tablets (containing sumatriptan succinate equivalent to 100 mg of sumatriptan)
11568576|NCT00870038|Experimental|2|Uncoated balloon + Genous stent
11568133|NCT00873184|Other|1|A prospective, single-arm intervention study, potential participants will be identified and screened for eligibility via medical record review of patient scheduled for their post surgical primary adjuvant treatment consultation at DUMC.
11568134|NCT00873171||1. OMT|This procedure consist of Sacral rocking is performed by placing the heel of the practitioner's hand over the sacrum and by using the palpatory skills of an osteopathic physician; rock the sacrum into a position with no restriction. Myofascial release will utilize various physical motions to place the patients lumbosacral region in a position of maximal comfort and tissue release.
11568135|NCT00873171||2. Attention control OMT|The procedure consist of light pressure applied to certain painful areas of the body and back to decrease pain and help patient relax. The physician will look for areas of the body that hurt, lay his/her hands on the those places, and apply light pressure.
11568136|NCT00873171||3. Standard of Care|This procedure consists of various conservative treatments that can help reduce stress. Those include dietary modifications, pharmaceuticals, bladder training, and neuromodulation. If these treatments are not successful, minimally invasive surgical procedures is performed.
11568137|NCT00873158|No Intervention|Physical Therapy Group|Patient's in the Physical Therapy Group will have the standard manual treatments during their usual physical therapy visits with no additional intervention
11568138|NCT00873158|Experimental|Dynasplint Group|Along with standard manual physical therapy, patients will have a stretching device (Dynasplint) used in rehabilitation to regain ROM in stiff joints. Patients will use this device 20-30 minutes 2 times per day at home.
11568139|NCT00873145||1|Patients with major bone defects around the elbow.
11568140|NCT00873132||Data Collection|Collect data both retrospectively and prospectively on subjects seen at the Preston Robert Tisch Brain Tumor Center
11568141|NCT00873119|Experimental|Arm A - BelCaP|Group A: belinostat 1000 mg/m² administered as a 30 minute IV infusion once daily on days 1, 2 and 3, with at least 18 hours between infusions, followed by belinostat 2000 mg administered orally once daily on days 4 and 5, every 3-weeks, in combination with paclitaxel 175 mg/m² administered as an IV infusion following the infusion of belinostat on cycle day 3, and carboplatin (AUC 6) administered as a 30-60 minute IV infusion directly after the paclitaxel administration on cycle day 3.
11568142|NCT00873119|Active Comparator|Arm B - CaP|Group B: paclitaxel 175 mg/m² administered as an IV infusion directly followed by carboplatin (AUC 6) administered as a 30-60 minute IV infusion on cycle day 1 of a 3-weekly cycle.
11568143|NCT00873093|Experimental|Pre-B ALL Relapse<18 mths from diagnosis (chemo) age<=21 yrs|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
11568144|NCT00873093|Experimental|Pre-B ALL Relapse 18-36 mths from diagnosis (chemo) age<=21 yr|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
11568145|NCT00873093|Experimental|Pre-B ALL Relapse<36 mths from diagnosis (chemo) age>21 yrs|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
11568146|NCT00873093|Experimental|T-cell ALL (Chemotherapy)|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
11568147|NCT00873093|Experimental|T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy)|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
11568148|NCT00873067|Active Comparator|ACVP plus roof line|Standard procedure for atrial fibrillation ablation, including pulmonary vein isolation plus roof line ablation. All ablation lines will be tested.
11568149|NCT00873067|Active Comparator|Additional CFAEs ablation|Atrial fibrillation ablation with pulmonary vein ablation and roof line. In addition, complex fractionated atrial electrograms ablation will be performed, lasting at most 30 minutes.
11568150|NCT00873054||1 ESWL|In this procedure,scope will be placed inside bladder and a plastic tube (stent) will be left to drain the kidney on the affected side in a routine manner. Next the patient will be transferred to a separate room and sound waves will be aimed at the center of the stone until the stone is broken into pieces.
11568151|NCT00873054||2 PCNL|In this procedure,scope will be placed inside bladder and a plastic tube (stent) will be left to drain the kidney on the affected side in a routine manner. Next, a small (1cm) cut will be made in the back and a tube will be placed into the kidney. Through this tube a small camera will be placed inside the kidney and break the stone into many pieces and remove them through the same tube. All fragments that can be seen will be removed. A different plastic tube (drain) will be placed through the cut and into the kidney and left in place for 5-7 days.
11568152|NCT00873041|Experimental|5 mg/kg/day deferasirox|Participants received a starting dose of 5 mg/kg/day deferasirox tablets orally each day in the morning for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
11568153|NCT00873041|Experimental|10 mg/kg/day deferasirox|Participants received a starting dose of 10 mg/kg/day deferasirox tablets orally each day in the morning for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
11568154|NCT00873041|Placebo Comparator|5 mg/kg/day placebo|Placebo tablet matching 5 mg/kg/day orally in the morning each day for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
11568210|NCT00872677||Dietitian & Weight Watchers + Spirituality Counseling|Dietitian wkly for the 1st-3 months, every other week for the next 3 months and monthly thereafter; Spiritual counselor weekly in months 6-9, every other week in months 9-12 and monthly thereafter.
11568155|NCT00873041|Placebo Comparator|10 mg/kg/day placebo|Placebo tablet matching 10 mg/kg/day orally in the morning each day for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
11568156|NCT00873028|Experimental|1|
11568157|NCT00873028|No Intervention|2|Those patients assigned to Control were followed by their own physicians, received routine nursing assistance, were visited daily by the one of the investigators (CPM), but were not exposed to any specific respiratory or motor physical intervention.
11568158|NCT00873015|Experimental|Nitrite|Continuous intravenous infusion of Sodium Nitrite
11568159|NCT00873015|Placebo Comparator|Vehicle control|Continuous intravenous infusion of saline
11568160|NCT00873002|Active Comparator|LBH589|This study utilizes a sequential dose-escalation design to define the MTD of LBH589 when combined with standard doses of sorafenib.
11568161|NCT00872989|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who progress also receive oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of a second disease progression or unacceptable toxicity.
11568162|NCT00872989|Experimental|Arm II|Patients receive docetaxel IV over 1 hour on day 1 and oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11568163|NCT00872976|Experimental|Cohort #1|
11568164|NCT00872976|Experimental|Cohort #2|
11568165|NCT00872963||RABIES VACCINE|Those subjects who received the active comparator
11568166|NCT00872963||RTS,S/AS01E|The subjects who received investigational product
11568167|NCT00872950|Other|Open label|Open label
11568168|NCT00872924|Experimental|1|sumatriptan succinate 100 mg tablets (containing 140 mg of sumatriptan succinate equivalent to 100 mg sumatriptan) of OHM laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA).
11568169|NCT00872924|Active Comparator|2|IMITREX® 100 mg tablets (containing 140 mg of sumatriptan succinate equivalent to 100 mg sumatriptan)
11568170|NCT00872911|Experimental|Nutritional supplement|
11568171|NCT00872911|Experimental|Placebo + Exercise|
11568172|NCT00872911|Experimental|Nutritional Supplement + Exercise|
11568173|NCT00872911|No Intervention|Placebo|
11568174|NCT00872898|Experimental|1|Once daily oral administration of memantine for 12 weeks.
11568175|NCT00872898|Placebo Comparator|2|Once daily oral administration of placebo for 12 weeks.
11568176|NCT00872885|Experimental|A|Dose 1
11568177|NCT00872885|Experimental|B|Dose 2
11568178|NCT00872885|Experimental|C|Dose 3
11568179|NCT00872885|Active Comparator|D|Morphine
11568180|NCT00872885|Placebo Comparator|E|Placebo
11568181|NCT00872872|Active Comparator|AZT/3TC 1 week after delivery|AZT/3TC 1week after delivery
11568182|NCT00872872|Experimental|AZT/3TC 2 weeks after delivery|AZT/3TC 2 weeks after delivery
11568183|NCT00872859|Experimental|1|Dermamatrix with radiation
11568184|NCT00872859|Experimental|2|Dermamatrix without radiation
11568185|NCT00872859|Experimental|3|Alloderm with radiation
11568186|NCT00872859|Experimental|4|Alloderm without radiation
11568187|NCT00872833||age 18-29|People age groups 18-29 with transfusion-dependent thalassemia who have reported at least mild degrees of pain during the main Assessment of Pain study.
11568188|NCT00872833||age 30+|People age groups 30+ years with transfusion-dependent thalassemia who have reported at least mild degrees of pain during the main Assessment of Pain study.
11568189|NCT00872820|Active Comparator|1|Participants will receive standard cognitive behavioral therapy.
11568190|NCT00872820|Experimental|2|Participants will receive acceptance- and commitment-based behavioral therapy.
11568191|NCT00872820|No Intervention|3|Participants will be placed on a waitlist for 3 months before being offered treatment.
11568192|NCT00872807|Experimental|Group intervention|Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality. They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months.
11568193|NCT00872807|Active Comparator|Individual intervention|Lifestyle counseling for each separate family practiced by single health professionals both in hospital and municipality. A more conventional model.
11568194|NCT00872794|Other|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
11568195|NCT00872781|Experimental|1|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc (a subsidiary of Ranbaxy pharmaceuticals Inc)
11568196|NCT00872781|Active Comparator|2|ACCURETICTM tablets (containing fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg)
11568197|NCT00872755|Active Comparator|Nissen|Laparoscopic Nissen Fundoplication
11568198|NCT00872755|Active Comparator|Gastropexy|Procedure/Surgery Laparoscopic Nissen Fundoplication combined with posterior gastropexy
11568199|NCT00872742|Experimental|1|Participants will receive acceptance enhanced behavior therapy (AEBT) for trichotillomania (TTM).
11568200|NCT00872742|Active Comparator|2|Participants will receive psychoeducation and supportive therapy (PST) for TTM.
11568201|NCT00872729|Active Comparator|Cystagon®|Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg
11568202|NCT00872729|Experimental|RP103|Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg
11568203|NCT00872716|Experimental|Quetiapine XR|100 mg single-dose Quetiapine XR
11568204|NCT00872716|Placebo Comparator|Placebo|
11568205|NCT00872703||1|
11568206|NCT00872703||2|
11568207|NCT00872690||Group 1|OEF/OIF veterans with polytrauma who have been referred by the Tampa VA Polytrauma Rehabilitation Center (PRC) to the VA VR&E Regional Office in St. Petersburg, Florida for Chapter 31 (IL) services.
11568208|NCT00872690||Group 2|Caregivers of the veterans who enroll in the study
11568209|NCT00872677||Dietitian-led counseling and Weight Watchers|Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.
11568211|NCT00872664|Active Comparator|formula with added carotenoids|Both arms are double-blinded. Infant will be assigned to receive preterm formula with added carotenoids. If infant is receiving human milk then the study formula will only be used as a supplement.
11568212|NCT00872664|Active Comparator|formula without added carotenoids|Both arms are double-blinded. This arm will use preterm formula as it is currently available, which is without any carotenoids. If the infant is receiving human milk, then the formula will be used as a supplement as needed.
11568213|NCT00872651|Experimental|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
11568214|NCT00872651|Active Comparator|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
11568215|NCT00872638|Active Comparator|1|
11568216|NCT00872638|Active Comparator|2|
11568217|NCT00872625|Experimental|Cyberknife|
11568218|NCT00872612|Experimental|A|Endosonography arm
11568219|NCT00872612|Active Comparator|B|Conventional bronchoscopy arm
11568220|NCT00872599|Placebo Comparator|Placebo, then fenofibrate|Randomized study of fenofibrate versus placebo during high salt diet
11568221|NCT00872599|Placebo Comparator|Fenofibrate, then placebo|Randomized study of fenofibrate versus placebo during high salt intake.
11568222|NCT00872586|Experimental|1|Olmesartan medoxomil and hydrochlorothiazide
11568223|NCT00872586|Active Comparator|2|olmesartan medoxomil
11568224|NCT00872573|Other|C-Stem™ AMT Femoral Component|
11568225|NCT00872547|Active Comparator|1|Resurfacing system
11568226|NCT00872547|Active Comparator|2|Large Metal-on-Metal Total Hip Replacement
11568227|NCT00872534|Experimental|PL-2200|PL-2200 is an NSAID product containing 325mg of acetylsalicylic acid and phosphatidylcholine in a neutral lipid matrix.
11568228|NCT00872534|Active Comparator|Aspirin|Immediate release 325mg aspirin
11568229|NCT00872521|Experimental|bortezomib; doxorubicin; dexamethasone|PAD induction Open Label Treatment: Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1 4 8 & 11) Doxorubicin 20 mg/m2 i.v. (D1 & 4) Dexamethasone 20 mg p.o. (D1 2 4 5 8 9 11 & 12)
11568230|NCT00872495||1|"Bladder Cancer Group:
~Patients scheduled to have a cystectomy or cystoscopy of their bladder with possible removal or biopsy of bladder tumor or tissue.
~Two urine samples collected at the time of the scheduled procedure:
~One sample collected through voiding. The other sample collected from atheterized urine in the operating room. Additional urine samples may be collected at each follow up visit over two years. These samples will be obtained via voiding, standard urine sample collection."
11568231|NCT00872495||2|Control Group: Patients with no known evidence of bladder cancer. One urine sample will be collected through voiding, as with standard urine sample collection at the time of clinic visit.
11568232|NCT00872482|Experimental|1|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT. Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
11568233|NCT00872482|Placebo Comparator|2|"A placebo will be administered by the intravenous route weekly during WBRT and following WBRT.
~Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day."
11568234|NCT00872469|Active Comparator|Tranexamic acid|
11568235|NCT00872469|Placebo Comparator|placebo|
11568236|NCT00872443||FOP|Patients who already have an occlusion of POF secondary to a cryptogenic CVA and younger than 55 years old and without characterized thromboembolic events.
11568237|NCT00872430|Active Comparator|Placebo/Laxative tea crossover|This arm received placebo in the first period and laxative tea in the second period (after washout period of 9 days).
11568238|NCT00872430|Active Comparator|Laxative tea/Placebo crossover|This arm received laxative tea in the first intervention period and placebo in the second intervention period (after washout period of 9 days).
11568239|NCT00872417|Experimental|Treatment-naive|To explore the efficiency and safety of generic antiretroviral drugs for 520 treatment-naive HIV/AIDS patients
11568240|NCT00872417|No Intervention|TREATMENT-EXPERIENCED|To explore the long term ARV of treatment-experienced patients who have no sign of drug resistance; to explore the long term efficiency and safety and drug sife effects of ARV in HIV/AIDS patients. These patients have taken ARV for approximately 3 years already.
11568241|NCT00872417|Experimental|drug resistance|To explore the second line drugs for those drug resistance patients
11568242|NCT00872404|Experimental|1|CP-751,871 will be administered as an open-label intravenous solution. Patients will remain under clinical observation for one hour post-infusion
11568243|NCT00872391|Experimental|Hypofractionated LINAC radiotherapy|
11568244|NCT00872378|Active Comparator|Exenatide|Laparoscopic adjustable gastric banding group: twice daily exenatide therapy plus a standard diet and exercise program
11568245|NCT00872378|Placebo Comparator|Placebo|Laparoscopic adjustable gastric banding group: twice daily placebo therapy plus a standard diet and exercise program
11568246|NCT00872365|Other|1|Regular aerobic physical exercise + placebo
11568247|NCT00872365|Other|2|Activities of daily living + Micronutrients
11568248|NCT00872365|Other|3|Regular aerobic exercise + micronutrients
11568249|NCT00872365|Placebo Comparator|4|Activities of daily living + placebo
11568250|NCT00872339||transfusion-dependant|People with transfusion-dependant thalassemia who received at least 8 transfusions in the past year.
11568251|NCT00872339||non-transfusion-dependant|People with non-transfusion-dependant thalassemia who received no transfusions in the past year.
11568252|NCT00872339||intermittently transfused|Intermittently transfused patients- individuals who received at least one but fewer than eight transfusions in the last year
11568253|NCT00872326|Experimental|Autologous Bone Marrow Mononuclear Cells|Consecutive inclusion among diabetic patients with critical limb ischemia. Intraarterial infusion of autologous bone marrow mononuclear cells
11568254|NCT00872313||1|Psychoses within the first 3 months postpartum
11568255|NCT00872313||2|Psychoses > 3 months to 6 months postpartum
11568256|NCT00872300|Experimental|1|
11568257|NCT00872287|Active Comparator|Laparoscopic Cholecystectomy|Four ports classic laparoscopic cholecystectomy
11568258|NCT00872287|Active Comparator|SILS|Single transumbilical incision laparoscopic cholecystectomy
11568259|NCT00872274|Experimental|1|sumatriptan succinate tablets 100 mg (containing sumatriptan succinate equivalent to 100 mg of sumatriptan) manufactured by OHM Laboratories In
11568355|NCT00871598|Experimental|Single 0.3|
11568261|NCT00872261||Proxy microbicide product|Use of vaginal lubricant as a proxy microbicide gel; use of multivitamin as proxy pre-exposure prophylaxis (PrEP) product
11568262|NCT00872248|Experimental|1|Parturients received spinal anesthesia
11568263|NCT00872248|Active Comparator|2|Parturients received epidural anesthesia
11568264|NCT00872235|Experimental|1|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc.(division of Ranbaxy Laboratories Limited)
11568265|NCT00872235|Active Comparator|2|Accuretic tablets (fixed dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg)
11568266|NCT00872235|Experimental|3|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc.(division of Ranbaxy Laboratories Limited)
11568267|NCT00872235|Active Comparator|4|Accuretic tablets (fixed dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg)
11568268|NCT00872222|Other|Ceramic-on-Ceramic|Pinnacle™ Acetabular System with ceramic liner
11568269|NCT00872209|Active Comparator|Ciloxan Ear Drops|Ciloxan (Alcon, Inc.) Sterile Ophthalmic and Ear Drops
11568270|NCT00872209|Experimental|Foam Otic Cipro|Patients randomized to this study arm will receive the experimental product
11568271|NCT00872196|Other|1 - Follow-up Study|This is a follow-up study with no treatment and only samples being collected.
11568272|NCT00872170|Active Comparator|Intervention|Participants with thalassemia who have pulmonary hypertension will receive sildenafil for 12 weeks.
11568273|NCT00872170|No Intervention|Control|Participants with thalassemia who do not have pulmonary hypertension will be part of a control group and will only be undergoing screening/baseline assessments.
11568274|NCT00872157|Experimental|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
11568275|NCT00872144|Active Comparator|Sativex|
11568276|NCT00872131||Generalized social anxiety disorder participants|Participants with generalized social anxiety disorder will undergo MRI scanning and sertraline treatment.
11568277|NCT00872131||Healthy control participants|Healthy control participants will undergo MRI scanning.
11568278|NCT00872118|Experimental|1|Brief Intervention for Socially Anxious Drinkers
11568279|NCT00872118|Active Comparator|2|Enhanced Alcohol Skills and Education Program
11568280|NCT00872105|Other|Non-operative treatment|The first treatment strategy will involve conservative (nonoperative) management of the clavicle fracture.
11568281|NCT00872105|Active Comparator|Operative treatment|The second treatment strategy will involve operative fixation (i.e. ORIF) of the fracture with a plate and screws.
11568282|NCT00872092||Breath test|Subjects with suspected SBBO
11568283|NCT00872079|Active Comparator|Genomics|"Aim 1: Collect historical data on warfarin dosing in subjects at the VA. Aim 2: Collect genotype information on up to 300 subjects receiving warfarin anticoagulation.
~Aim 3: Develop a computer model incorporating the information from Aim 1 and 2. Aim 4: Conduct randomized clinical trial."
11568284|NCT00872066|Active Comparator|1) SmartSet® HV Bone Cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
11568285|NCT00872066|Active Comparator|2) SmartSet® GHV Bone Cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
11568286|NCT00872053|Experimental|Arm 1|Focused Ankle Training
11568287|NCT00872053|Experimental|Arm 2|Combination Therapy
11568288|NCT00872040||Nuliparous women and their husbands|Women in their first pregnancy with their husbands
11568289|NCT00872027|Experimental|1|Participants will receive 8 weeks of escitalopram treatment.
11568290|NCT00872027|Placebo Comparator|2|Participants will receive 8 weeks of placebo pills.
11568291|NCT00872014|Experimental|15mg/ kg cohort|AMG 386 15mg/kg intravenously once weekly and Sorafenib 400mg orally twice daily in an every 4 weeks dosing schedule.
11568292|NCT00872014|Experimental|10 mg/kg cohort|AMG 386 10mg/kg intravenously once weekly and Sorafenib 400mg orally twice daily in an every 4 weeks dosing schedule.
11568293|NCT00872001|Active Comparator|Acadesine|Acadesine intravenous (IV) infusion, plus cardioplegia solution with acadesine, and priming solution with acadesine in the heart lung machine during cardiopulmonary bypass (CPB)
11568294|NCT00872001|Placebo Comparator|Placebo|Normal saline, IV infusion, plus cardioplegia solution with added normal saline, and priming solution with added normal saline in the heart lung machine during CPB
11568295|NCT00871975|Experimental|Urodynamics + Tetra|All patients were recruited to the same arm and receive Urodynamics testing as part of the routine diagnostic work-up, plus the Tetra-NIRS intervention.
11568296|NCT00871962||1|COPD patients on necessity of long-term oxygen therapy
11568297|NCT00871949|Experimental|Cohort 1, Sequence 1|Period 1- Placebo Period 2- 100 mg Period 3- 300 mg
11568298|NCT00871949|Experimental|Cohort 1, Sequence 2|Period 1- 35 mg Period 2- Placebo Period 3- 300 mg
11568299|NCT00871949|Experimental|Cohort 1, Sequence 3|Period 1- 35 mg Period 2- 100 mg Period 3- Placebo
11568300|NCT00871949|Experimental|Cohort 2, Sequence 1|Period 1- Placebo Period 2- 1000 mg Period 3- 1500 mg Period 4- 600 mg (Fed conditions)
11568301|NCT00871949|Experimental|Cohort 2, Sequence 2|Period 1- 600 mg Period 2- Placebo Period 3- 1500 mg Period 4- 600 mg (Fed conditions)
11568302|NCT00871949|Experimental|Cohort 2, Sequence 3|Period 1- 600 mg Period 2- 1000 mg Period 3- Placebo Period 4- 600 mg (Fed conditions)
11568303|NCT00871936|Experimental|1|SLx-4090 in combination with Metformin
11568304|NCT00871936|Other|2|Placebo
11568305|NCT00871923|Experimental|Tarceva + RT|Tarceva (Erlotinib hydrochloride) + Radiation Therapy. Tarceva 150 mg by mouth every day beginning Day 1. Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
11568306|NCT00871910|Experimental|2 Hour SCH 727965 infusion|Participants treated with 2 hour SCH 727965 IV infusion
11568307|NCT00871910|Experimental|8 Hour SCH 727965 infusion|Participants treated with 8 hour SCH 727965 IV infusion.
11568308|NCT00871910|Experimental|24 Hour SCH 727965 infusion|Participants treated with 24 hour SCH 727965 IV infusion.
11568309|NCT00871910|Experimental|2 Hour SCH 727965 infusions plus aprepitant in Cycle 1|Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 1 only.
11568356|NCT00871598|Experimental|Repeat 1.0|
11568357|NCT00871598|Experimental|Repeat 2.0|
11568310|NCT00871910|Experimental|2 Hour SCH 727965 infusion plus aprepitant in Cycle 2|Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 2 only.
11568311|NCT00871897||Cardiac Rehabilitation|People with heart failure who elect to participate in cardiac rehabilitation.
11568312|NCT00871897||No Cardiac Rehabiliation|People with heart failure who elect NOT to participate in cardiac rehabilitation.
11568313|NCT00871884|Active Comparator|Treatment As Usual|
11568314|NCT00871884|Experimental|Experimental|
11568315|NCT00871871|Experimental|Part I, Placebo-HCTZ|Placebo in Period 1 followed by HCTZ in Period 2
11568316|NCT00871871|Experimental|Part I, HCTZ-Placebo|HCTZ in Period 1, followed by placebo in Period 2
11568317|NCT00871871|Experimental|Part II, Placebo-ISMN|Placebo in Period 1, followed by ISMN in Period 2
11568318|NCT00871871|Experimental|Part II, ISMN-Placebo|ISMN in Period 1, followed by placebo in Period 2
11568319|NCT00871858|Active Comparator|Arm I|Patients receive oral anastrozole once daily for 6 months.
11568320|NCT00871858|Experimental|Arm II|Patients receive fulvestrant intramuscularly on days 1, 14, and 28 and then once a month at 2-6 months.
11568321|NCT00871845|No Intervention|LEAN (non obese, naive)|Patients naive to hepatitis C therapy with body mass index (BMI) <25
11568322|NCT00871845|Other|OVERWEIGHT (obese, naive, control)|Patients naive to hepatitis C therapy with BMI ≥ 25, received Dietary and Lifestyle modification educational sessions (one-time 15 minute weight loss instruction and pamphlet and enrolled into weight management program with 5 weekly one-hour nutrition and physical exercise education sessions after initial evaluation followed by monthly follow up.)
11568323|NCT00871819|Other|Spinal Cord Stimulation Group|Spinal Cord Stimulation (SCS) Treatment Group
11568324|NCT00871806|Active Comparator|Eletriptan commercial tablet with water|Eletriptan commercial tablet given with water
11568325|NCT00871806|Experimental|Eletriptan oral disintegrating tablet (ODT) #1 without water|Oral disintegrating tablet formulation #1 without water
11568326|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #2 without water|Oral disintegrating tablet formulation #2 without water
11568327|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #1 with water|Oral disintegrating tablet formulation (ODT) #1 with water
11568328|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #2 with water|Oral disintegrating tablet formulation (ODT) #2 with water
11568329|NCT00871793|Active Comparator|1|Occupational therapy
11568330|NCT00871793|No Intervention|2|watchful waiting
11568331|NCT00871780|Experimental|Natalizumab|natalizumab 300 mg IV every 4 weeks for 48 weeks
11568332|NCT00871767|Experimental|1|40 or 100mg AZD5672, Reference formulation
11568333|NCT00871767|Experimental|2|40 or 100mg AZD5672, Test formulation
11568334|NCT00871741|Experimental|GSK2202083A GROUP|Subjects in this group were to receive three doses of GSK2202083A vaccine at 3, 5 and 11 months of age, as an intramuscular injection in the anterolateral quadrant of the right thigh.
11568335|NCT00871741|Active Comparator|INFANRIX + MENJUGATE GROUP|Subjects in this group were to receive three doses of Infanrix™ hexa vaccine at 3, 5 and 11 months of age, and two doses of Menjugate® vaccine at 3 and 5 months of age, as an intramuscular injection in the anterolateral quadrant of the right thigh.
11568336|NCT00871728|Experimental|Itraconazole|
11568337|NCT00871715|Experimental|ASAP|A focused, intense, evidence-based, upper extremity rehabilitation program, administered during the early post-acute outpatient interval. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence.
11568338|NCT00871715|Active Comparator|DEUCC|Dose-equivalent usual and customary arm therapy administered early post-acutely in the outpatient setting. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
11568339|NCT00871715|Other|UCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group with treatment dose administered in accordance with usual and customary practices.
11568340|NCT00871702|Experimental|Donor lymphocyte infusion|CD34-TK75 transduced T lymphocytes from donors matched at a 5/6 or 6/6 antigen level at a dose of 1.0 x 105 cells/kg recipient weight.
11568341|NCT00871689|Experimental|UCBT With Post-Transplant IL-2|Patients receive cyclophosphamide, fludarabine phosphate, total-body irradiation, T cell depleted umbilical cord blood transplantation (UCBT), followed by interleukin-2 (IL-2, aldesleukin) every other day beginning day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
11568342|NCT00871676|Active Comparator|1|Overweight/obese individuals being treated with lifestyle modification to facilitate weight loss.
11568343|NCT00871676|Experimental|2|Lifestyle modification plus use of chewing gum to facilitate weight loss in overweight/obese persons.
11568344|NCT00871663|Experimental|Advanced solid tumors|Participants with advanced solid tumors treated with SCH 727965 in dose-escalation cohorts
11568345|NCT00871663|Experimental|Non-Hodgkin's lymphoma and multiple myeloma|Participants with non-Hodgkin's lymphoma or multiple myeloma treated with SCH 727965
11568346|NCT00871663|Experimental|B cell chronic lymphocytic leukemia|Participants with B-cell chronic lymphocytic leukemia treated with SCH 727965 in dose-escalation cohorts
11568347|NCT00871650||Combat Veterans with PTSD|Male Veterans of Operation Iraqi Freedom (OIF) and/or Operation Enduring Freedom (OEF), ages 18-50, with Combat Exposure Scale score > 17, who are not on medication and do not have trauma history before age 18.
11568348|NCT00871650||Combat Veterans without PTSD|Male Veterans of Operation Iraqi Freedom (OIF) and/or Operation Enduring Freedom (OEF), ages 18-50, with combat experience, who are not suffering from PTSD, and who are not on medication.
11568349|NCT00871637||Group One|Healthy non-smoking controls
11568350|NCT00871637||Group Two|Smoking adults with chronic bronchitis/chronic obstructive pulmonary disease
11568351|NCT00871637||Group Three|Non-smoking adults with chronic bronchitis/chronic obstructive pulmonary disease
11568352|NCT00871624|Active Comparator|Dexmedetomidine|Subjects received active dexmedetomidine 0.2 -0.7 mcg/kg/hr
11568353|NCT00871624|Placebo Comparator|Placebo|Subjects received placebo saline solution 0.2-0.7 mcg/kg/hr
11568354|NCT00871598|Placebo Comparator|Placebo|
11568364|NCT00871559|Experimental|Q2W|REGN421 (SAR153192) taken once every two weeks (Q2W)
11568365|NCT00871546|Experimental|Participants with MCL randomized to SCH 727965|
11568366|NCT00871546|Active Comparator|Participants with MCL randomized to bortezomib|
11568367|NCT00871546|Experimental|MCL treated w/SCH 727965 after progression on bortezomib|
11568368|NCT00871546|Experimental|Participants with B-CLL randomized to SCH 727965|
11568369|NCT00871546|Active Comparator|Participants with B-CLL randomized to alemtuzumab|
11568370|NCT00871546|Experimental|B-CLL treated w/ SCH 727965 after progression on alemtuzumab|
11568371|NCT00871533|Experimental|1|"REGIONAL PEG IFN MAINTENANCE: Regional PEG IFN-a2b given subcutaneously at MAINTENANCE dose level. (This arm has completed enrollment; non-evaluable subjects as defined in section 9.5 may be replaced at any point during study."
11568372|NCT00871533|Experimental|2|No intervention / no injection control.
11568373|NCT00871533|Experimental|3|"PEG IFN INDUCTION: System PEG IFN-a2b given subcutaneously at INDUCTION dose level"
11568374|NCT00871533|Experimental|4|"REGIONAL HDI MAINTENANCE: Regional HDI given subcutaneously at MAINTENANCE dose level per standard HDI regimen"
11568375|NCT00871533|No Intervention|5|"HDI Induction: Systemic HDI given intravenously at INDUCTION dose level per the standard HDI regimen."
11568376|NCT00871520||Palliative Therapy|Patients referred to the oncology / radiation oncology departments for palliative therapy.
11568377|NCT00871507|Experimental|001|
11568378|NCT00871507|Experimental|002|
11568379|NCT00871507|Placebo Comparator|003|
11568380|NCT00871507|Active Comparator|004|
11568381|NCT00871494|Experimental|Azithromycin switch therapy (switch from intravenous to oral).|
11568382|NCT00871481|Experimental|Treatment (laboratory-treated T cells and ipilimumab)|Patients receive cyclophosphamide IV on day -2, therapeutic cytotoxic T lymphocytes IV over 30-60 minutes on day 0, low-dose aldesleukin SC BID on days 0-13, and ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
11568383|NCT00871468|Active Comparator|superior plate|Clavicle plate on the superior surface of the bone
11568384|NCT00871468|Experimental|anterior inferior plate|plate placed on anterior inferior surface of bone
11568385|NCT00871455|Experimental|1|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
11568386|NCT00871442|Active Comparator|No Basal Infusion|"PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml
~Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)"
11568387|NCT00871442|Active Comparator|Basal Infusion|"PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml
~Group 2: Basal Infusion: 10 ml/hr; Bolus 5 ml q 30min prn (5ml demand dose with 30min lockout)"
11568388|NCT00871403|Experimental|Arm 1|Investigational treatment (pazopanib and pemetrexed)
11568389|NCT00871403|Active Comparator|Arm 2|Standard treatment (pemetrexed and cisplatin)
11568390|NCT00871377|Placebo Comparator|Placebo|Corn Oil Placebo (n-6 fatty acids)
11568391|NCT00871377|Experimental|High Dose Fish Oil|2160 mg of EPA + DHA
11568392|NCT00871377|Experimental|Low Dose Fish Oil|1060 mg of EPA + DHA
11568393|NCT00871364|Experimental|A|VENLAFAXINE TABLETS 50 mg, single dose
11568394|NCT00871364|Active Comparator|B|Effexor® (venlafaxine HCl) Tablets equivalent to 50 mg venlafaxine, single dose
11568395|NCT00871351|Experimental|Ezetimibe + Atorvastatin|Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
11568396|NCT00871351|Active Comparator|Atorvastatin|Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
11568397|NCT00871351|Active Comparator|Rosuvastatin|Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
11568398|NCT00871338|Experimental|GSK2197870A Group|Subjects aged between and including 6 and 12 weeks of age at the time of first vaccination received 3 doses of GSK2197870A vaccine at Months 0, 1 and 2, 2 doses of Prevenar™ vaccine at Months 0 and 2 and a booster dose of Menitorix™ vaccine at Month 10. All vaccines were administered intramuscularly. GSK2197870A and Menitorix™ vaccines were administered in the right upper anterolateral thigh and Prevenar™ vaccine in the left upper anterolateral thigh.
11568399|NCT00871338|Active Comparator|Pediacel Group|Subjects aged between and including 6 and 12 weeks of age at the time of first vaccination received 3 doses of Pediacel™ vaccine at Months 0, 1 and 2, 2 doses of Prevenar™ vaccine at Months 0 and 2, 2 doses of Menjugate™ vaccine at Months 1 and 2 and a booster dose of Menitorix™ at Month 10. All vaccines were administered intramuscularly. Pediacel™ and Menitorix™ vaccines were administered in the right upper anterolateral thigh and Prevenar™ vaccine in the left upper anterolateral thigh and Menjugate™ vaccine in the left lower anterolateral thigh.
11568400|NCT00871325|Experimental|Daikenchuto (TU-100) 7.5g/day|Daikenchuto (TU-100) 2.5g TID (7.5g/day)
11568401|NCT00871325|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID (15g/day)
11568402|NCT00871325|Placebo Comparator|Placebo|Placebo TID
11568403|NCT00871312|Active Comparator|Topical Wound Oxygen Therapy|Subjects will receive four 90 minute treatments of two2 therapy per week
11568404|NCT00871312|Placebo Comparator|Placebo Therapy|Subjects will receive four 90 minute treatments of Placebo two2 therapy per week
11568405|NCT00871299|Experimental|1|Mindfulness Based Cognitive Therapy (MBCT) + medication management
11568406|NCT00871299|Active Comparator|2|The Health Enhancement Program (HEP) + medication management
11568407|NCT00871286|Experimental|CT scan (sinus) pre-tx|Sinus CT scan performed at initial otolaryngology (ear, nose, and throat)visit
11568408|NCT00871286|Other|CT scan (sinus) post-tx|Sinus CT scan performed after 3-4 weeks of antibiotic treatment and any other indicated medical treatment(s), per insurance company guidelines
11568409|NCT00871260|Other|Open Label|Approximately 25 healthy volunteers will be recruited as controls, and approximately 500 patients with suspected coronary artery disease be recruited. Scan will be done with regadenoson contrast.
11568410|NCT00871247|Experimental|A|Finasteride 5 mg single dose tablet, single dose
11568411|NCT00871247|Active Comparator|B|Proscar® 5 mg Tablet, single dose
11568577|NCT00870038|Active Comparator|3|Drug eluting stent (Taxus stent)
11568412|NCT00871208|Experimental|1|Altabax (R) and Locoid Lipocream (R):Patients will apply both drugs sequentially to active lesions of atopic dermatitis. Physical examination, skin cultures, photos and quality of life scores will be performed at baseline, week 1, week 2 and week 4.
11568413|NCT00871208|Active Comparator|2|Vehicle and Locoid Lipocream (R):Patients will apply both drugs sequentially to active lesions of atopic dermatitis. Physical examination, skin cultures, photos and quality of life scores will be performed at baseline, week 1, week 2 and week 4.
11568414|NCT00871182|Experimental|PT001 18 mcg|Inhaled PT001 18 mcg
11568415|NCT00871182|Experimental|PT001 36 mcg|Inhaled PT001 36 mcg
11568416|NCT00871182|Experimental|PT001 72 mcg|Inhaled PT001 72 mcg
11568417|NCT00871182|Experimental|PT001 144 mcg|Inhaled PT001 144 mcg
11568418|NCT00871182|Placebo Comparator|Inhaled Placebo|Inhaled Placebo
11568419|NCT00871182|Active Comparator|Tiotropium Handihaler|Tiotropium 18 mcg administered via Handihaler
11568420|NCT00871169|Experimental|Irinotecan, oxaliplatin, and cetuximab|The goal is to administer at least 4 cycles to each patient, but treatment may stop earlier if the treating physician deems stopping to be in the best interest of the patient. Repeated treatment may be given to patients who benefit (either complete or partial response or stabilization of disease)
11568421|NCT00871156|Active Comparator|Part 1|Tafenoquine + Chloroquine vs. Chloroquine alone
11568422|NCT00871156|Placebo Comparator|Part 2|Chloroquine alone, Tafenoquine alone or Chloroquine+Tafenoquine
11568423|NCT00871143|Experimental|CBT specific for BDD|This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.
11568424|NCT00871143|Active Comparator|Non Specific CBT|Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
11568425|NCT00871117|Experimental|Kinrix + M-M-R II + Varivax|Subjects received at Day 0 one dose of Kinrix, intramuscularly in the deltoid region of the left upper arm, co-administered with one dose of M-M-R II and Varivax each, subcutaneously in the deltoid of the right upper and lower arm, respectively.
11568426|NCT00871117|Active Comparator|Kinrix + M-M-R II -> Varivax|Subjects received at Day 0 one dose of Kinrix, intramuscularly in the deltoid region of the left upper arm, co-administered with one dose of M-M-R II, subcutaneously in the deltoid of the right upper arm. At Day 30 they received one dose of Varivax subcutaneously in the deltoid region of the right upper arm.
11568427|NCT00871104|Experimental|1|IV fosfomycin and imipenem adjusted to renal function
11568428|NCT00871104|Active Comparator|2|IV Vancomycin twice a day with valley leves higher than 15 mcg/kg
11568429|NCT00871091|Experimental|1|CAD/CAM group, customized archwires
11568430|NCT00871091|Active Comparator|2|prefabricated archwires (superelastic)
11568431|NCT00871091|Active Comparator|3|prefabricated archwires with manual adjustments
11568432|NCT00871078||A|HIV-positive patients with CD4 cell counts below 100 cells/mm³ at some point of time in their medical history lasting for at least 6 months
11568433|NCT00871078||B|HIV-positive patients with CD4 cell counts never below 100 cells/mm³ in their medical records
11568434|NCT00871078||C|HIV-negative patients (control group)
11568435|NCT00871065|Experimental|A|Trial Arm (single arm study)
11568436|NCT00871039|Experimental|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
11568437|NCT00871039|Experimental|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
11568438|NCT00871026|Experimental|1|CAD/CAM group, customized archwires
11568439|NCT00871026|Active Comparator|2|prefabricated archwires (superelastic)
11568440|NCT00871013|Experimental|MEL-VTD-PACE|Melphalan, Velcade, Thalidomide, Dexamethasone, CisPlatin, Adriamycin, Cyclophosphamide, Etoposide
11568441|NCT00871000|Experimental|BOOSTRIX POLIO GROUP|Healthy male or female children, between and including 5 to 6 years of age, who were primed with three doses of Infanrix™ vaccine according to the Italian 3-5-11 month vaccination schedule, additionally received a single booster dose of Boostrix Polio™ vaccine co-administered with a single dose of Priorix Tetra™ vaccine at Day 0. Boostrix Polio™ vaccine was administered intramuscularly in the deltoid region of the left upper arm, while the Priorix Tetra™ vaccine was administered subcutaneously in the deltoid region of the right upper arm.
11568442|NCT00871000|Active Comparator|TETRAVAC GROUP|Healthy male or female children, between and including 5 to 6 years of age, who were primed with three doses of Infanrix™ vaccine according to the Italian 3-5-11 month vaccination schedule, additionally received a single booster dose of Tetravac™ vaccine co-administered with a single dose of Priorix Tetra™ vaccine at Day 0. Tetravac™ vaccine was administered intramuscularly in the deltoid region of the left upper arm, while the Priorix Tetra™ vaccine was administered subcutaneously in the deltoid region of the right upper arm.
11568443|NCT00870987|Experimental|1|DNA vaccine prime Given at 0, 4, and 8 weeks
11568444|NCT00870987|Experimental|2|adenovirus type 5 vaccine boost Given at 24 weeks
11568445|NCT00870974|Experimental|Assess [18F]FPEB and PET imaging|To assess [18F] FPEB and PET imaging in subjects with neuropsychiatric conditions.
11568446|NCT00870961|Experimental|Arm I|Patients receive oral cholecalciferol (vitamin D3) supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
11568447|NCT00870961|Placebo Comparator|Arm II|Patients receive oral placebo supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
11568448|NCT00870948|Experimental|Regimen A|One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
11568449|NCT00870948|Experimental|Regimen B|One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected IV in an arm vein
11568450|NCT00870948|Experimental|Regimen C|One 100 mg ABT 874 (reconstituted lyophilized powder from the 3000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
11568451|NCT00870948|Experimental|Regimen D|One 100 mg ABT-874 (reconstituted lyophilized powder from the 1000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
11568452|NCT00870948|Experimental|Regimen E|700 mg ABT-874 (reconstituted lyophilized powder from the 3000 L process) in 100 mL 5% dextrose solution IV infusion in an arm vein
11568453|NCT00870935|Active Comparator|Balloon catheter|Hysterosalpingography using intrauterine Balloon catheter
11568454|NCT00870935|Active Comparator|Cervical vacuum cup|Hysterosalpingography using cervical vacuum cup
11568455|NCT00870935|Experimental|Operator choice|Hysterosalpingography is performed using either balloon catheter or cervical vacuum cup on the basis of the operator's choice
11568456|NCT00870922|Experimental|TMD group|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
11568457|NCT00870909|Active Comparator|active tDCS|"tDCS active; - Intensity = 2 milliamps (mA) during 20 minutes. ramp up/ramp down 30sec anodal tDCS applied over the left DLPFC combined with cathodal tDCS applied over the left temporoparietal junction (TPJ).
~10 sessions, 2 per day"
11568458|NCT00870909|Placebo Comparator|sham tDCS|tDCS placebo same electrode montage than in the active group. 30 sec of active tDCS in the beginning of the stimulation sessions; ramp up/ramp down 30 sec
11568459|NCT00870896|Experimental|Tiotropium|Cough reflex measured by capsaicin Inhalation Challenge will follow Dicpinigaitis performed at 1 and 3 months. Solutions prepared to make a stock solution of 0.01 Mol diluted with physiologic saline to yield 11 doubling concentrations from 0.98 to 1,000 uMol/L. Final diluted capsaicin concentrations are: 0.98, 1.95, 3.9, 7.8, 15.6, 31.2, 62.5, 125, 250, 500, and 1000 uMol/L. Then, place 1 ml of the first concentration into nebulizer. Subjects inhale single breath of capsaicin aerosol. Single breaths are delivered in ascending order, with normal saline randomly interspersed to increase blindness, until two or more coughs (C2) and five or more coughs (C5) are reached. The different concentrations are delivered at 2 minute intervals.
11568460|NCT00870883|Experimental|N-acetylcysteine plus deferoxamine|
11568461|NCT00870870|Experimental|GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)|"Cycles repeat every 3 weeks for first 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met
~*Cisplatin will replace Carboplatin. Gemcitabine/Carboplatin/Cetuximab (GCC) plus cixutumumab will change to Gemcitabine/Cisplatin/Cetuximab (GCiC) plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)"
11568462|NCT00870870|Active Comparator|GCiC (Gemcitabine/Cisplatin/Cetuximab)|"Cycles repeat every 3 weeks for 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met
~*Cisplatin will replace Carboplatin. GCC plus cixutumumab will change to GCiC plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)"
11568463|NCT00870857||1|Subjects will be 300 HIV+ subjects and 300 HIV- controls selected by random sampling stratified by age and smoking history. Subjects will be recruited from the University of Pittsburgh and the University of Washington (UW) MACS sites. The University of California San Francisco (UCSF) will serve as the recruiting center for the WIHS cohort
11568464|NCT00870844|Experimental|Lu AA24493 (CEPO): 0.5 mcg/kg|
11568465|NCT00870844|Experimental|Lu AA24493 (CEPO): 5.0 mcg/kg|
11568466|NCT00870844|Experimental|Lu AA24493 (CEPO): 50.0 mcg/kg|
11568467|NCT00870844|Placebo Comparator|Placebo|
11568468|NCT00870831||Islet Recipient|Subjects that have successfully received and maintained an Islet transplant at Washington University Center for Islet Transplantation
11568469|NCT00870831||Control|subjects that were similar in height, weight and age that did NOT have diabetes to act as the comparative group
11568470|NCT00870818|Experimental|1 Active|"Protege had 4 study arms, 3 were dosed with different doses of teplizumab, and 1 was a control group given placebo. This Extension study will continue to assess the subjects from these 4 arms.
~In Protege: Experimental Drug: Teplizumab, IV dosing daily for 14 days times 2 courses"
11568471|NCT00870818|Experimental|2 Active|In Protege: Experimental Drug: Teplizumab, IV dosing daily for 14 days times 2 courses
11568472|NCT00870818|Experimental|3 Active|In Protege: Experimental Drug: Teplizumab, IV dosing daily for 14 days times 2 courses
11568473|NCT00870818|Placebo Comparator|1 controlled|In Protege: Placebo Comparator: IV dosing daily for 14 days times 2 courses
11568474|NCT00870805|Experimental|bilateral-ultrabrief ECT|Patients will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 3-4 times seizure threshold.
11568475|NCT00870805|Active Comparator|bilateral standard ECT|Patients will be treated with a standard (1.0ms) pulse with a bilateral placement at 1.5 times seizure threshold.
11568476|NCT00870805|Experimental|right-unilateral ultrabrief ECT|Patients will be treated with an ultrabrief (0.3ms) pulse with a right unilateral placement at 8 times seizure threshold.
11568477|NCT00870805|Active Comparator|right-unilateral standard ECT|Patients will be treated with a standard (1.0ms) pulse with a right unilateral placement at 5 times seizure threshold.
11568478|NCT00870792|Active Comparator|Received report|
11568479|NCT00870792|Placebo Comparator|Routine care|Patients receive usual, routine, care.
11568480|NCT00870779|Experimental|5-aminolevulinic acid|
11568481|NCT00870766|Active Comparator|CT|All patients in the CT arm undergo abdominal CT scanning within 24 hours of admission to the ER.
11568482|NCT00870766|No Intervention|Current practice|The patients in the current practice arm are referred to radiological examinations, such as US, plain radiography or CT, based on the clinical need only.
11568483|NCT00870753|Experimental|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
11568484|NCT00870753|No Intervention|Controls|Control group are offered the yoga intervention after finishing the study
11568921|NCT00867698|Placebo Comparator|Placebo B|4 grams TID
11568485|NCT00870740|Experimental|Group 1: DAC HYP 150 mg|Participants who received placebo in 205MS201 receive DAC HYP 150 mg subcutaneous (SC) injection every 4 weeks for a total of 13 doses.
11568486|NCT00870740|Experimental|Group 1: DAC HYP 300 mg|Participants who received placebo in 205MS201 receive DAC HYP 300 mg SC injection every 4 weeks for a total of 13 doses.
11568487|NCT00870740|Experimental|Group 2: Washout then DAC HYP 150 mg|Participants who received DAC HYP 150 mg SC injection in 205MS201 undergo a washout period (placebo SC every 4 weeks for a total of 5 doses) and then receive DAC HYP 150 mg SC every 4 weeks for a total of 8 doses.
11568488|NCT00870740|Experimental|Group 2: DAC HYP 150 mg|Participants who received DAC HYP 150 mg SC injection in 205MS201 receive DAC HYP 150 mg SC every 4 weeks for a total of 13 doses.
11568489|NCT00870740|Experimental|Group 3: Washout then DAC HYP 300 mg|Participants who received DAC HYP 300 mg SC in 205MS201 undergo a washout period (placebo SC every 4 weeks for a total of 5 doses) and then receive DAC HYP 300 mg SC every 4 weeks for a total of 8 doses.
11568490|NCT00870740|Experimental|Group 3: DAC HYP 300 mg|Participants who received DAC HYP 300 mg SC in 205MS201 receive DAC HYP 300 mg SC every 4 weeks for a total of 13 doses.
11568491|NCT00870727|Experimental|Arm 1. Aripiprazole oral product|Participants will receive Aripiprazole oral product with a minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.
11568492|NCT00870727|Placebo Comparator|Arm 2. Placebo oral capsule|Participants will receive matching (identical in size and appearance to study drug) placebo oral capsules over 8-weeks of treatment.
11568493|NCT00870714|Experimental|A|Eligible patients with high-risk prostate cancer who are scheduled to undergo radical prostatectomy will receive four cycles of therapy with ketoconazole and docetaxel prior to surgery resection
11568494|NCT00870701|Experimental|Absence of Radiotherapy|No Radiotherapy; Simple monitoring without active treatment
11568495|NCT00870701|Active Comparator|Radiotherapy|Radiotherapy
11568496|NCT00870688||1|epilepsy patients
11568497|NCT00870675||ventriculomegaly|Pregnant women carrying a fetus with the ultrasound finding of enlarged ventricles (ventriculomegaly).
11568498|NCT00870662|Experimental|Automatic Fluid Shunt|
11568499|NCT00870649|Experimental|Bilhvax vaccine (Sh28GST)|Arm 1 : S. haematobium infected children pretreated by two doses of PZQ (at Week-9 and W-8)receiving 3 injections of candidate vaccine at D0, W4, W8 and a boost at W52, and then treated by a third dose of PZQ at W44.
11568500|NCT00870649|Placebo Comparator|Placebo|Arm 2 : S. haematobium infected children pretreated by two doses of PZQ (at Week-9 and W-8)receiving 3 injections of placebo at D0, W4, W8 and a boost at W52, and then treated by a third dose of PZQ at W44.
11568501|NCT00870597|Experimental|1|Multifocal IOL implant associated with vitreous opacities that underwent 25-gauge vitrectomy were prospectively analyzed.
11568502|NCT00870597|Experimental|2|Multifocal IOL implantation without transconjunctival vitrectomy
11568503|NCT00870584|Experimental|Omalizumab|The determined dose (at least 0.016 mg/kg/IgE (IU/mL) was administered subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used.
11568504|NCT00870584|Placebo Comparator|Placebo|Placebo was administered subcutaneously every 2 weeks or every 4 weeks depending on the dosing schedule in the protocol.
11568505|NCT00870571|Experimental|A|AMLODIPINE (as BESILATE) TABLETS 10 mg, single dose
11568506|NCT00870571|Active Comparator|B|NorvasC® 10 mg Tablets, single dose
11568507|NCT00870558|Experimental|Arm I|Patients receive an intra-arterial infusion of iodine I 131 ethiodized oil.
11568508|NCT00870558|Placebo Comparator|Arm II|Patients receive an intra-arterial infusion of unlabeled ethiodized oil.
11568509|NCT00870545|Experimental|Telephone support|12 telephone support group sessions based on the letters of the word BATTLEMIND
11568510|NCT00870532|Experimental|1|60 mg/week of vinorelbine + sorafenib
11568511|NCT00870532|Experimental|2|90 mg/week of vinorelbine + sorafenib
11568512|NCT00870532|Experimental|3|120 mg/week of vinorelbine + sorafenib
11568513|NCT00870519|Experimental|I 123-MNI-168|
11568514|NCT00870519|Experimental|I123 MNI168|brain imaging using I123MNI168
11568515|NCT00870506|No Intervention|2|No intervention (control)
11568516|NCT00870506|Experimental|1|5-minute video on donation and transplantation
11568517|NCT00870493|Experimental|I|each subject will receive oral aliskiren 300 mg/day for 16 weeks, followed by a washout period of 4 weeks, then crossed over to placebo for another 16 weeks
11568518|NCT00870493|Active Comparator|II|each subject will receive placebo for 16 weeks, followed by a washout period of 4 weeks, then crossed over to oral aliskiren 300 mg/day for another 16 weeks
11568519|NCT00870480|Experimental|A|Finasteride 5 mg single dose tablet, single dose
11568520|NCT00870480|Active Comparator|B|Proscar® 5 mg Tablet, single dose
11568521|NCT00870467|Placebo Comparator|DB Placebo|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
11568522|NCT00870467|Experimental|DB adalimumab|Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
11568523|NCT00870467|Experimental|DB Adalimumab/OL Adalimumab|Participants received double-blind adalimumab administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
11568524|NCT00870467|Experimental|DB Placebo/OL Adalimumab|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
11568525|NCT00870467|Experimental|DB Adalimumab/RE OL Adalimumab|Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
11568578|NCT00870025|Active Comparator|hCG|200 IU rec hCG s.c./5 days, 4 doses prior to onset of COH
11568526|NCT00870467|Experimental|DB Placebo/RE OL Adalimumab|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
11568527|NCT00870454|Experimental|001|Carisbamate 800 mg/d 200 mg/d twice daily titrated up to 400 mg twice daily as tolerated by Week 3
11568528|NCT00870454|Experimental|002|Carisbamate 1 200 mg/d 200 mg/d twice daily titrated up to 600 mg twice daily as tolerated by Week 3
11568529|NCT00870454|Active Comparator|003|Pregabalin 300 mg/d 75 mg/d twice daily for Week 1 followed by 150 mg twice daily for the remainder
11568530|NCT00870454|Placebo Comparator|004|Placebo Placebo capsules twice daily
11568531|NCT00870441|Experimental|1. ASP2151|
11568532|NCT00870441|Active Comparator|2. Valacyclovir|
11568533|NCT00870441|Placebo Comparator|3. Placebo|
11568534|NCT00870428||Preeclampsia Evaluation|Patients who are admitted for the evaluation of preeclampsia
11568535|NCT00870415|Experimental|Surgerie|
11568536|NCT00870402|Experimental|1|
11568537|NCT00870402|Placebo Comparator|2|
11568538|NCT00870376||urodynamic studies|
11568539|NCT00870363|Active Comparator|1|maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
11568540|NCT00870363|Active Comparator|2|maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
11568541|NCT00870363|Active Comparator|3|efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
11568542|NCT00870363|No Intervention|4|HIV-negative
11568543|NCT00870350|Active Comparator|Td5ap|Group 1 receiving Td5ap as a single intramuscular injection.
11568544|NCT00870350|Active Comparator|Td1aP|Group 2 receiving Td1aP as a single intramuscular injection
11568545|NCT00870337|Experimental|Single arm|
11568546|NCT00870324||1. Control|Patients will receive the Tendril (wide-spaced) lead as part of their ICD implant
11568547|NCT00870324||2. Experimental|Patients will receive the OptiSense (narrow-spaced) lead as part of their ICD implant
11568548|NCT00870311|Experimental|Blinded Lithium|Bipolar Disorder patients
11568549|NCT00870298|Experimental|computerized alert|An automatic electronic stop of the tmp/sulfa or warfarin order whenever a resident or nurse practitioner places an order for tmp/sulfa with an already active warfarin order, or when ordering both simultaneously
11568550|NCT00870298|Other|2 Current practice|Current practice of the pharmacist recommending cessation of concurrent warfarin and tmp/sulfa orders
11568551|NCT00870272|Active Comparator|1|400mcg sublingual misoprostol
11568552|NCT00870272|Active Comparator|2|400mcg buccal misoprostol
11568553|NCT00870246||1|High mobility
11568554|NCT00870246||2|Lower mobility
11568555|NCT00870233||GYN pts undergoing surgery|This study will assess patient use of WEBCORE, an online system designed for cancer patients to self-record toxicity-related symptoms based on NCI Common Terminology Criteria for Adverse Events and global quality of life (QoL) by European Organization for Research and Treatment of Cancer (EORTC QLQ-C30).
11568556|NCT00870220|Experimental|GH alone, Low dose E2 patch, Very Low-dose E2 patch|"Group 1: Growth hormone alone, no E2. Group 2: Growth Hormone plus Estradiol patch dose A(14 mcg/d x 10 d) x 6 months then Estradiol patch dose B(25 mcg/d x 10 d) x 6 months.
~Group 3: Growth Hormone plus Estradiol patch dose B(25 mcg/d x 10 d) x 6 months then Estradiol patch dose C(25 mcg/d x 3 w) x 6 months."
11568557|NCT00870207|Other|Immediate Intervention Group|The immediate intervention group will receive the TSSC pilot worksite intervention in the initial 12 week period from the pre-test/enrollment visit.
11568558|NCT00870207|Other|Delayed Intervention Group|The delayed intervention group will receive the TSSC pilot worksite intervention beginning in month 6 of the study (6 months from the enrollment/pre-test visit).
11568559|NCT00870194|Experimental|1|
11568560|NCT00870194|Placebo Comparator|2|
11568561|NCT00870181|Experimental|ADV-TK/GCV|ADV-TK was administered via intraarterial cerebral infusion. Systemic GCV therapy was delivered at a dose of 5mg/kg intravenous, every 12 h at 36 hours after ADV-TK therapy.
11568562|NCT00870181|Active Comparator|Control group|Patients received surgery or systemic chemotherapy or palliative care.
11568563|NCT00870155|Experimental|Dirucotide|
11568564|NCT00870142|Experimental|A|AMLODIPINE (as BESILATE) TABLETS 10 mg, single dose
11568565|NCT00870142|Active Comparator|B|Norvasc® 10 mg Tablets, single dose
11568566|NCT00870129|Experimental|MRI|The advanced MRI studies will be obtained at the time of the routinely scheduled preoperative planning MRI and/or the routinely scheduled pre-RT planning MRI at approximately 3±2 weeks after surgery. The routine sequences obtained for the planning MRI are standard of care. The advanced MRI sequences may or may not be additional as some have already been adopted into the standard of care imaging at MSKCC.
11568567|NCT00870116|Other|1 - SBRT using cyberknife|SBRT using cyberknife: treatment = 2x15 Gy during 2 weeks
11568568|NCT00870116|Other|2 - SBRT using linear accelerator|SBRT using linear accelerator: treatment = 2x15 Gy during 2 weeks
11568569|NCT00870116|Other|3 - Conformational radiotherapy|Conformational radiotherapy: treatment = 5x2 Gy during 7 weeks
11568570|NCT00870103|Experimental|Vigadexa eye drops|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
11568571|NCT00870077|Experimental|1|
11568572|NCT00870064|Other|Formal Operative Treatment|Children randomized to the formal operative management arm will be taken to the Operating Room within 24 hours for irrigation and debridement and appropriate bone management.
11568573|NCT00870064|Other|Emergency Department Treatment|Children in the Emergency Department Treatment arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
11568574|NCT00870051||AAA patients|Subjects diagnosed with an AAA who are considered candidates for endovascular repair with Endurant Stent Graft, and who meet the inclusion/exclusion criteria are intended to participate in this registry
11568575|NCT00870038|Experimental|1|Paclitaxel eluting balloon (Elutax) + Genous stent
11568579|NCT00870025|Placebo Comparator|placebo|similar injection at same time points with similar diluent but no hCG
11568580|NCT00870012|Active Comparator|Lepicol probiotic & prebiotic formula+simple lifestyle advice|
11568581|NCT00870012|Placebo Comparator|Simple lifestyle advice alone|
11568582|NCT00869986|Experimental|Dirucotide|
11568583|NCT00869986|Placebo Comparator|Placebo|
11568584|NCT00869973|Experimental|1|Aprepitant
11568585|NCT00869973|Active Comparator|2|dexamethasone
11568586|NCT00869960|Experimental|Antiretroviral therapy|Healthy volunteers received two doses of Tenofovir, Emtricitabine, Atazanavir and Ritonavir administered twice (on day 6 - 10 and day 20 - 25 after day of Follicular phase); with pharmacokinetic measurements at 6 - 10 days after menses and then again at day 20 - 25 after menses.
11568587|NCT00869947|Experimental|Prosthesis|Powered ankle-foot prosthesis and passive-elastic prosthesis
11568588|NCT00869947|Experimental|Non-amputee|Non-amputee
11568589|NCT00869934|Active Comparator|1. Cognitive-Behavior Therapy|
11568590|NCT00869934|Experimental|2. Behavior Therapy|
11568591|NCT00869934|Experimental|3. Cognitive Therapy|
11568592|NCT00869908||A|
11568593|NCT00869895|Experimental|1|
11568594|NCT00869882|Experimental|1|Posterolateral fusion with instrumentation combined to transforaminal lumbar interbody fusion
11568595|NCT00869882|Active Comparator|2|Posterolateral fusion with instrumentation
11568596|NCT00869869|Experimental|melatonin|melatonin
11568597|NCT00869869|Placebo Comparator|placebo|placebo
11568598|NCT00869856|Experimental|1|HX575, EPO Hexal
11568599|NCT00869843|Other|Single group|
11568600|NCT00869830|Experimental|biofeedback|
11568601|NCT00869817||1|Mutation Positive
11568602|NCT00869817||2|Mutation Negative
11568603|NCT00869804|Experimental|Exercise|combination aerobic (walking) and resistance (strength training) exercise
11568604|NCT00869804|Sham Comparator|attention control|attention control with daily journal and cancer-related education
11568605|NCT00869791|Other|Sequence 1|"Treatment Period 1:
~IPX066 - 7 days; Washout Period - 7 days;
~Treatment Period 2:
~IR CD-LD- 7 days"
11568606|NCT00869791|Other|Sequence 2|"Treatment Period 1:
~IR CD-LD - 7 days; Washout period - 7 days;
~Treatment Period 2:
~IPX066- 7 days"
11568607|NCT00869778|Experimental|εPA-44 900μg|Inject εPA-44 900μg at week 0, 4, 8, 12, 20, 28.
11568608|NCT00869778|Experimental|εPA-44 600μg+Placebo 300μg|Inject εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.
11568609|NCT00869778|Placebo Comparator|Placebo 900μg|Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.
11568610|NCT00869765|Experimental|tDCS and D-CYC|Major Depression tDCS and D-cyc
11568611|NCT00869752|Experimental|Arm 1|MK-0646, a monoclonial antibody in combination with etoposide and cisplatin.
11568612|NCT00869726|Experimental|Dirucotide|
11568613|NCT00869726|Placebo Comparator|Placebo|
11568614|NCT00869713|Other|primary vaccination with boost|Inactivated, Dried (TSI-GSD 200), RVF Vaccine
11568615|NCT00869687|Other|Poly-L-Lactic Acid Injection|
11568616|NCT00869674|No Intervention|Routine pathologic method|Half of each sentinal lymph node will have rountine pathologic examination as normal practice.
11568617|NCT00869674|Experimental|GeneSearch BLN Assay|Half of each sentinal lymph node will have GeneSearch BLN testing.
11568618|NCT00869661|Experimental|Group 1|RO5024048 500 mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 12 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
11568619|NCT00869661|Experimental|Group 2|RO5024048 1000mg bid + Pegasys + Copegus for 8 weeks, followed by SOC for 16 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
11568620|NCT00869661|Experimental|Group 3|RO5024048 1000mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 12 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
11568621|NCT00869661|Experimental|Group 4|Group 4 will receive RO5024048 1000mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 36 weeks
11568622|NCT00869661|Active Comparator|Group 5|Group 5 will receive SOC for 48 weeks
11568623|NCT00869661|Experimental|Group 6|Group 6 provides retreatment on an open-label basis for patients of Group 5 who failed treatment. Patients will receive RO5024048 1000mg bid + Pegasys + Copegus for 24 weeks, followed by SOC for 24 weeks.
11568624|NCT00869648|Active Comparator|Neutralposition|Head placed in neutral position
11568625|NCT00869648|Active Comparator|Extension|Head placed in extension
11568626|NCT00869648|Active Comparator|Anaesthesiologist's position|Head placed in position deemed optimal by an anaesthesiologist
11568627|NCT00869635|Experimental|1|"Treatment by combination of photodynamic therapy and S-1
~PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
~S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, <1.25m2: 80mg/day, 1.25~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment"
11568628|NCT00869635|Active Comparator|2|"Treatment by photodynamic therapy only
~PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
~Other managements except systemic chemotherapy were added freely."
11568629|NCT00869635|Other|3|Treatment by photodynamic therapy only or combined chemotherapy with photodynamic therapy: Open label
11568630|NCT00869622|Active Comparator|Risedronate|Active drug
11568631|NCT00869622|Placebo Comparator|Placebo + Calcium and Vitamin D|All patients both on placebo and active bisphosphonate to receive calcium and vitamin D
11568632|NCT00869609|Active Comparator|GLB Traditional Maintenance (TM)|Group Lifestyle Balance (GLB) program Traditional Maintenance: After completion of the GLB 12 core sessions, participants who are randomly assigned to GLB program Traditional Maintenance (TM) will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions.
11568682|NCT00869310|Experimental|1|Dexamethasone plus Aprepitant
11568683|NCT00869310|Active Comparator|2|dexamethasone plus metoclopramide
11568684|NCT00869297|Active Comparator|Control|
11569022|NCT00866944|Experimental|2|FOLFOX 4 followed by Adecatumumab
11568633|NCT00869609|Active Comparator|GLB-Carb-focused Maintenance (CF)|Group Lifestyle Balance (GLB) program Carb-focused Maintenance: After completion of the GLB 12 core sessions, participants randomly assigned to GLB Carb-focused Maintenance (CF) will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information regarding healthy carbohydrate intake and hunger management.
11568634|NCT00869596|Placebo Comparator|1|Placebo
11568635|NCT00869596|Active Comparator|2|Fluticasone 440 mcg
11568636|NCT00869596|Active Comparator|3|Fluticasone 1980 mcg
11568637|NCT00869583|Experimental|1|Participants will immediately take part in the physical activity program.
11568638|NCT00869583|No Intervention|2|
11568639|NCT00869570|Experimental|Arm A: Sorafenib & Capecitabine & RT|"Sorafenib: day 1 to 33 (5 weeks, including Saturday and Sunday) every 24 hours, immediately or within two hours after RT according to the dose escalation table during phase I, and the recommended dose during phase IIa. The intake stops at the last day of RT. On nonradiotherapy days (e.g. Saturday, Sunday), the tablets have to be taken at the same time as during the week.
~Capecitabine: day 1 to 33 (5 weeks, including Saturday and Sunday) according to dose escalation table during phase I, and at the recommended dose during phase IIa. The intake stops in the evening of the last day of RT.
~External beam RT: Monday through Friday for 5 weeks starting on day 1 (daily fraction 1.8 Gy, final dose 45 Gy) each day at the same time (e.g. 11:00 a.m. daily).
~Surgery: 6 weeks (± 1 week) after radiochemotherapy (RCT) has been completed"
11568640|NCT00869557|Experimental|Stribild|
11568641|NCT00869557|Active Comparator|Atripla|
11568642|NCT00869544||HIV|Those positive for HIV and those negative but at high risk for HIV. Both positive and negative for HIV who smoke and those who do not smoke. Both HIV positive and negative with and without asthma and/or COPD
11568643|NCT00869531|Experimental|WW|wholegrain wheat
11568644|NCT00869531|Active Comparator|RW|refined wheat
11568645|NCT00869518|Active Comparator|Rifabutin|Subjects will be assigned to 7 days of treatment with rifabutin plus trimethoprim-sulfamethoxazole
11568646|NCT00869518|Placebo Comparator|Placebo|Subjects will be assigned to 7 days of treatment with placebo plus trimethoprim-sulfamethoxazole
11568647|NCT00869505||Case Group|Intensive Residential Treatment with memantine augmentation
11568648|NCT00869505||Control Group|Intensive Residential Treatment without memantine augmentation
11568649|NCT00869492|Other|A|instructed nadifloxacine 1% cream twice dailly, and placebo for benzoyl peroxide 5% solution once dailly
11568650|NCT00869492|Other|B|instructed nadifloxacine 1% cream twice dailly, and active benzoyl peroxide 5% solution once dailly
11568651|NCT00869479||1|subjects with a histologically-proven diagnosis of NSF
11568652|NCT00869479||2|subjects with other fibrosing skin diseases
11568653|NCT00869479||3|subjects with non-fibrosing skin diseases
11568654|NCT00869479||4|subjects without skin diseases
11568655|NCT00869453||1|Healthy volunteers
11568656|NCT00869440|Experimental|1: Remimazolam (CNS 7056) 0.10 mg/kg|Remimazolam (CNS 7056) 0.10 mg/kg iv
11568657|NCT00869440|Experimental|2: Remimazolam (CNS 7056) 0.15 mg/kg|Remimazolam (CNS 7056) 0.15 mg/kg iv
11568658|NCT00869440|Experimental|3: Remimazolam (CNS 7056) 0.20 mg/kg|Remimazolam (CNS 7056) 0.20 mg/kg iv
11568659|NCT00869440|Experimental|4: Midazolam 0.075 mg/kg|Midazolam 0.075 mg/kg iv
11568660|NCT00869427|Active Comparator|1 vitamin C|Vitamin C 1g bid
11568661|NCT00869427|No Intervention|2|Usual Care
11568662|NCT00869414|Active Comparator|insulin glargine only in morning|Morning only administration of insulin glargine
11568663|NCT00869414|Active Comparator|insulin glargine only at evening|Evening only administration of insulin glargine
11568664|NCT00869414|Active Comparator|split dose insulin glargine|Split dose administration of insulin glargine, half dose in morning, half dose in evening
11568665|NCT00869401|Experimental|Group 1 (Phase II) dasatinib + radiation + temozolomide|Patients receive concomitant chemotherapy and radiation for cycle one for a total of 42 days, then patients receive adjuvant chemotherapy 28-42 days post cycle one treatment. Patients receive only dasatinib post cycle 8 until progressive disease, unacceptable adverse events or refusal.
11568666|NCT00869401|Active Comparator|Group 2 (Phase II) placebo + radiation + temozolomide|Patients receive concomitant chemotherapy and radiation for cycle one for a total of 42 days, then patients receive adjuvant chemotherapy 28-42 days post cycle one treatment. Patients receive only placebo post cycle 8 until progressive disease, unacceptable adverse events or refusal.
11568667|NCT00869388|Experimental|Arm 1|rBBX-01 1.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
11568668|NCT00869388|Experimental|Arm 2|rBBX-01 2.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
11568669|NCT00869388|Experimental|Arm 3|rBBX-01 4.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
11568670|NCT00869388|Experimental|Arm 4 (optional)|rBBX-01 8.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
11568671|NCT00869375|Active Comparator|CLEARWAY GROUP|Endovascular peripheral intervention - Percutaneous transluminal angioplasty with simultaneous in situ thrombolysis (local thrombolytic plus low pressure balloon angioplasty) with Clearway balloon
11568672|NCT00869375|Active Comparator|ANGIOJET GROUP|Endovascular peripheral intervention - Percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy with AngioJet Rheolytic Thrombectomy System
11568673|NCT00869362|Experimental|Diabetes Management Team|Evaluation and management by diabetes management team
11568674|NCT00869362|No Intervention|Control|Patients receive usual care for diabetes
11568675|NCT00869349|Experimental|IFS Intervention Group|
11568676|NCT00869349|Active Comparator|Education Group|
11568677|NCT00869336|Experimental|Luliconazole Cream 1% - 2 wks|Daily treatment with Luliconazole Cream 1% for 2 weeks
11568678|NCT00869336|Experimental|Luliconazole Cream 1% - 4 wks|Daily treatment with Luliconazole Cream 1% for 4 weeks
11568679|NCT00869336|Placebo Comparator|Placebo Comparator - 2 wks|Daily treatment with Vehicle Cream for 2 weeks
11568680|NCT00869336|Placebo Comparator|Placebo Comparator - 4 wks|Daily treatment with Vehicle Cream for 4 weeks
11568681|NCT00869323|Experimental|Treated Patients|This group includes patients receiving Bortezomib and Rituximab for post-transplant lymphoproliferative disorders (PTLD).
11568685|NCT00869297|Experimental|Intervention|These patients receive fluid boluses based on measurements from the FloTrac
11568686|NCT00869271|Experimental|1|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.
11568687|NCT00869271|Active Comparator|2|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle.
11568688|NCT00869258|Experimental|GTX and Radiation Therapy with Gemzar|"Chemotherapy Treatment with Gemcitabine, Docetaxel, and Capecitabine:
~A cycle of chemotherapy is made up of 21 days. During each cycle patients will take Xeloda® twice a day for 14 days followed by a rest period of 7 days. On day 4 and 11 (+/- 2 days) of each 21-day cycle patients will also receive Gemzar and Taxotere.
~Weekly Radiation Therapy with Low-Dose Gemzar Chemotherapy:
~After completing a total of 3 cycles of GTX chemotherapy each patient will receive 5 weeks of standard radiation therapy in combination with low-dose Gemzar chemotherapy."
11568689|NCT00869245|Experimental|1|Cardiac MRI Protocol. Patients will be transferred to the observation unit and undergo a stress cardiac MRI evaluation.
11568690|NCT00869245|Experimental|2|Conventional care cardiac testing. Patients will be transferred to the observation unit and undergo cardiac testing as determined by their treating physician.
11568691|NCT00869232|Experimental|MEL--VTD-PACE|Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide and Etoposide
11568692|NCT00869219|Active Comparator|Nevanac|
11568693|NCT00869219|Active Comparator|Acular LS|
11568694|NCT00869206|Experimental|Arm I (zoledronic acid every 4 weeks)|Patients receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
11568695|NCT00869206|Experimental|Arm II (zoledronic acid every 12 weeks)|Patients receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
11568696|NCT00869193|Active Comparator|Grape seed|Grape seed extract
11568697|NCT00869193|Placebo Comparator|Placebo|Microcrystalline cellulose
11568698|NCT00869180|Experimental|Diclofenac Sodium Patch|
11568699|NCT00869180|Placebo Comparator|Topical Placebo Patch|
11568700|NCT00869167|Experimental|1: Ramelteon|
11568701|NCT00869167|Placebo Comparator|2: Placebo|
11568702|NCT00869154|Active Comparator|Primary care follow up|Multidisciplinary examination and follow up by the family doctor.
11568703|NCT00869154|Experimental|Multidisciplinary follow up|Multidisciplinary examination and follow up by a multidisciplinary outpatient team.
11568704|NCT00869141|Experimental|Research arm (postop IOP>10)|Receive glaucoma medications if the eye pressure more than 10 mmHg after AHmed valve implantation
11568705|NCT00869141|Active Comparator|Standard of care arm (postop IOP>17)|Receive glaucoma medication if eye pressure more than 17 mmHg after Ahmed valve implantation
11568706|NCT00869128|Other|Placebo First|Subjects were treated for 3 weeks with 1 tablet per night of Placebo and then with 2 mg melatonin (Circadin).
11568707|NCT00869128|Other|Circadin first|Subjects were treated for 3 weeks with 1 tablet per night of 2 mg melatonin (Circadin) and then with placebo.
11568708|NCT00869115|Experimental|1|TREATMENT 0.5 μg/kg/min
11568709|NCT00869115|Experimental|2|TREATMENT 1.0 μg/kg/min
11568710|NCT00869115|Experimental|3|TREATMENT 1.5 μg/kg/min
11568711|NCT00869115|Placebo Comparator|4|PLACEBO
11568712|NCT00869102|Experimental|GLP-1|
11568713|NCT00869089|Experimental|CC-10004|"CC-10004 treament:
~30mg,oral medication, BID, for 24 weeks (60mg total DAILY)"
11568714|NCT00869076|Experimental|Pharmacist Management|In this arm the Pharmacist managed the Diabetes in collaboration with the primary care physician
11568715|NCT00869076|Active Comparator|Usual Care|The patient was managed by the primary care physician
11568716|NCT00869063|Experimental|Diclofenac Sodium Patch|
11568717|NCT00869063|Placebo Comparator|Placebo Patch|
11568718|NCT00869050|Experimental|Capecitabine and Temozolomide|Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg and Temozolomide 150-200 mg/m2/day (PO divided BID).
11568719|NCT00869037|Active Comparator|Periarticluar Multimodal Technique|
11568720|NCT00869037|Active Comparator|CFNB plus Posterior Capsular Injection|
11568721|NCT00869024|Experimental|Stem Cell therapy|Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells in Patients with Severe LV Dysfunction and LVAD Support
11568722|NCT00869024|Placebo Comparator|Placebo|Intramyocardial Delivery Placebo solution into Patients with Severe LV Dysfunction and LVAD Support
11568723|NCT00869011|Experimental|1|Exercise
11568724|NCT00869011|No Intervention|2|No structured exercise program
11568725|NCT00868998|Experimental|Treatment|Gemcitabine, docetaxel, and capecitabine
11568726|NCT00868985|Experimental|PEG 3350 plus electrolytes|Patients were dosed with PEG 3350 with electrolytes
11568727|NCT00868985|Experimental|PEG 3350 without electrolytes|Patients were dosed with PEG 3350 without electrolytes
11568728|NCT00868972|Active Comparator|Embolic protection|Percutaneous renal stenting using a distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
11568729|NCT00868972|Sham Comparator|No embolic protection|Percutaneous renal stenting intervention without embolic protection
11568730|NCT00868959|Experimental|lurasidone|
11568731|NCT00868946|Experimental|Treatment with IND Ribavirin|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with IND Virazole (Ribavirin) for 7 days with multiple dosing regime based on weight and dosage day.
11568732|NCT00868933|Active Comparator|Low glycemic index dietary intervention program|The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
11568733|NCT00868933|Placebo Comparator|Simple lifestyle advice|The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
11568860|NCT00868101|Experimental|Preconditioning|Children who received the preconditioning stimulus
11568861|NCT00868101|No Intervention|Control|Children who did not receive the preconditioning stimulus
11568922|NCT00867685|Experimental|Treatment A|Single oral dose of 40 mg AZD2624 liquid suspension in a fasted state.
11568734|NCT00868920|Experimental|1|"The Graseby 3300 PCA pump will be loaded with a mixture of propofol 10 mg/cc containing 10 µg/cc remifentanil. The loading and demand doses will be individualized based on patient weight, height, age, and gender.
~The initial loading phase of sedation will be performed by the anesthesiologist to permit estimation of patient sensitivity. Following the initial loading dose, a series of button presses will be issued by the anesthesiologist to achieve a state of moderate sedation, as determined by a decrease in BIS to the range of 75-80. Once this state has been reached, the button will be transferred to the patient for Patient C0ntrolled Sedation."
11568735|NCT00868920|Experimental|2|"The Graseby 3300 PCA pump will be loaded with a mixture of propofol 10 mg/cc containing 10 µg/cc remifentanil. The loading and demand doses will be individualized based on patient weight, height, age, and gender.
~The initial loading phase of sedation will be performed by the anesthesiologist to permit estimation of patient sensitivity. Following the initial loading dose, a series of button presses will be issued by the anesthesiologist to achieve a state of moderate sedation, as determined by a decrease in BIS to the range of 75-80. Once this state has been reached,the anesthesiologist will control the sedation."
11568736|NCT00868907|Experimental|Treatment A|35 mg risedronate DR tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
11568737|NCT00868907|Experimental|Treatment B|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
11568738|NCT00868907|Active Comparator|Treatment C|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
11568739|NCT00868894|Experimental|1|
11568740|NCT00868894|Experimental|2|
11568741|NCT00868894|Placebo Comparator|3|
11568742|NCT00868894|Active Comparator|4|
11568743|NCT00868881||1|Blood Pressure poorly controlled in the previous year and poorly controlled at the inclusion in the study
11568744|NCT00868881||2|Blood Pressure poorly controlled in the previous year and well controlled at the inclusion in the study.
11568745|NCT00868881||3|Blood Pressure well controlled in the previous year and well controlled at the inclusion in the study
11568746|NCT00868881||4|Blood Pressure well controlled in the previous year and poorly controlled at the inclusion in the study
11568747|NCT00868881||5|Blood Pressure well controlled in the previous year independently of the level of control at the inclusion.
11568748|NCT00868881||6|Blood Pressure poorly controlled in the previous year independently of the level of control at the inclusion.
11568749|NCT00868855|Experimental|1|Bradykinin
11568750|NCT00868829|Experimental|Firebird2|
11568751|NCT00868816|Experimental|1|12 cycles of oxaliplatine based adjuvant chemotherapy
11568752|NCT00868816|Active Comparator|2|8 cycles of oxaliplatine based adjuvant chemotherapy
11568753|NCT00868790|Experimental|PLA→MK-3577 QD AM→MK-3577 QD PM→MK-3577 BID (Arm 1)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
11568754|NCT00868790|Experimental|MK-3577 QD AM→PLA→MK-3577 BID→MK-3577 QD PM (Arm 2)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
11568755|NCT00868790|Experimental|MK-3577 QD PM→MK-3577 BID→PLA→MK-3577 QD AM (Arm 3)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed MK- 3577 25 mg BID for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4.
11568756|NCT00868790|Experimental|MK-3577 BID→MK-3577 QD PM→MK-3577 QD AM→PLA (Arm 4)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
11568757|NCT00868790|Experimental|PLA→MK-3577 BID→MK-3577 QD AM→MK-3577 QD PM (Arm 5)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 25 mg BID for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4.
11568758|NCT00868790|Experimental|MK-3577 QD AM→MK-3577 QD PM→PLA→MK-3577 BID (Arm 6)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4.
11568759|NCT00868790|Experimental|MK-3577 QD PM→MK-3577 QD AM→MK-3577 BID→PLA (Arm 7)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
11568760|NCT00868790|Experimental|MK-3577 BID→PLA→MK-3577 QD PM→MK-3577 QD AM (Arm 8)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4.
11568761|NCT00868790|Experimental|PLA→MK-3577 QD PM→MK-3577 BID→MK-3577 QD AM (Arm 9)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
11568762|NCT00868790|Experimental|MK-3577 QD AM→MK-3577 BID→MK-3577 QD PM→PLA (Arm 10)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by MK-3577 25 mg BID for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
11568923|NCT00867685|Experimental|Treatment B|Single oral dose of 40 mg (2x20mg tablets)AZD2624 in a fasted state.
11568763|NCT00868790|Experimental|MK-3577 QD PM→PLA→MK-3577 QD AM→MK-3577 BID (Arm 11)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
11568764|NCT00868790|Experimental|MK-3577 BID→MK-3577 QD AM→PLA→MK-3577 QD PM (Arm 12)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4.
11568765|NCT00868790|Experimental|PLA→METF→MK-3577 QD AM→MK-3577 QD PM (Arm 13)|Domiciled participants were to receive oral treatment with dose-matched placebo to metformin (METF) for 4 weeks during Period 1, followed by metformin 1000 mg BID for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4. Participants in this arm were administered metformin placebo during Period 1 and active metformin during Period 2.
11568766|NCT00868790|Experimental|METF→PLA→MK-3577 QD PM→MK-3577 QD AM (Arm 14)|Domiciled participants were to receive oral treatment with metformin 1000 mg BID for 4 weeks during Period 1, followed by dose-matched placebo to metformin for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4. Participants in this arm were administered active metformin during Period 1 and metformin placebo during Period 2.
11568767|NCT00868777|Experimental|Sinus grafting using allogenic bone|
11568768|NCT00868764|Experimental|Sancuso® patch|Subjects receiving 1 Sancuso® patch worn for 7 days
11568769|NCT00868751|Experimental|Tocilizumab|Single arm study - treatment only
11568770|NCT00868738|Active Comparator|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU), given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
11568771|NCT00868738|Placebo Comparator|Placebo|Subjects will be provided a placebo, given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
11568772|NCT00868725||possible oral cancer|Patients reporting for oral cavity examination with the possibility or certainty of oral lesions
11568773|NCT00868712||1|Warfarin use < 6 months
11568774|NCT00868712||2|Warfarin use 6-24 months
11568775|NCT00868712||3|Warfarin use >24 months
11568776|NCT00868699|Experimental|lurasidone low arm|
11568777|NCT00868699|Placebo Comparator|Placebo|
11568778|NCT00868699|Experimental|lurasidone high arm|
11568779|NCT00868686|Active Comparator|Volar aluminum splint|
11568780|NCT00868686|Active Comparator|Dorsal aluminum splint|
11568781|NCT00868686|Active Comparator|Custom thermoplastic|
11568782|NCT00868673|Active Comparator|Low fructose arm|"Overweighted or obese previously healthy adults (with no other comorbidities, defined as: Diabetes (DM1 or DM2), hypertension, chronic kidney disease (CKD), hepatic damage, dyslipidemia medication, anemia, malignancy or pregnancy), with a Body Mass Index (BMI) of >25 kilograms(weight)/ squared meters (height).
~They will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and rest energy (without exercise).
~This group will be assigned to a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of less than 20 grams/day fructose diet levels.
~Total Time of intervention 6 weeks for each patient"
11568783|NCT00868673|Active Comparator|Normal fructose arm|"Overweighted or obese previously healthy adults (with no other comorbidities; defined as: Diabetes Mellitus (DM1 or DM2), hypertension, chronic kidney disease (CKD), hepatic damage, dyslipidemia medication, anemia, malignancy or pregnancy), with a Body Mass Index (BMI) of >25 kilograms(weight)/ squared meters (height).
~Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet (of 15% proteins, 30% lipids and 55% carbohydrates); calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise).
~This group will receive a controlled fructose diet between 50 and 70 grams/day of fructose intake.
~Total time of intervention:6 weeks for each patient"
11568784|NCT00868660|Experimental|ZP1848|Healthy Subjects or Crohn's Disease patients
11568785|NCT00868660|Placebo Comparator|Placebo|Healthy subjects or Crohn's Disease patients
11568786|NCT00868647|Other|Radiofrequency Ablation|
11568787|NCT00868634|Active Comparator|A|Capecitabine / Bevacizumab
11568788|NCT00868634|Experimental|B|Capecitabine / Bevacizumab / Vinorelbine
11568789|NCT00868621||1|Control
11568790|NCT00868621||2|Overactive Bladder Patients
11568791|NCT00868621||3|Urinary Tract Infection
11568792|NCT00868608|Experimental|inotuzumab ozogamicin|inotuzumab ozogamicin
11568793|NCT00868595|Experimental|Dose escalation|"Cohort 1: BPX-101, 4 x 10*6 cells administered every other week for 6 cycles Cohort 2: BPX-101, 12.5 x 10*6 cells administered every other week for 6 cycles Cohort 3: BPX-101, 25 x 10*6 cells administered every other week for 6 cycles Cohort 4: BPX-101, 25 x 10*6 cells administered every 4 weeks for 3 cycles
~At 24 hours after each vaccination, a single dose of the activating agent, AP1903 for Injection, will be administered at a fixed dose of 0.4 mg/kg via intravenous (IV) infusion over 2 hours."
11568794|NCT00868582||FDG-PET|F-18 fluorodeoxyglucose (FDG-PET)
11568795|NCT00868582||NaF-18 PET|F-18 sodum-fluoride (NaF-18 PET)
11568796|NCT00868569|Experimental|1|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemoembolision (TACE) using oxaliplatin, fudr, mmc and iodine. Then begin folfox4 again.
11568797|NCT00868569|Active Comparator|2|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy (TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.
11568798|NCT00868556||1 episodic migraine sufferers|
11568799|NCT00868556||2 chronic migraine sufferers|
11568800|NCT00868556||3 non migraine sufferers (controls)|
11568862|NCT00868088|Active Comparator|ALA + PDT|Topical ALA will be applied to the entire lip surface and allowed to incubate for 60 minutes plus or minus 30 minutes. Blue light at a wavelength of 405-420 nm will be used for treatment at a dose of 1000 seconds.
11569021|NCT00866944|Experimental|1|Adecatumumab alone
11568801|NCT00868543|Active Comparator|Long limb|Hospitalized male or female subjects 18-65 years of age,obese with body mass index (BMI= kg/m²)>50.Patients without mental or nervous disorders interfering with adequate evaluation of one's health condition, who read the informed consent form and gave a written consent to participate in the study. Gastric bypass was performed with long (150 cm) alimentary Roux limb
11568802|NCT00868543|Active Comparator|Very long limb|Hospitalized male or female subjects 18-65 years of age,obese with body mass index (BMI= kg/m²)>50.Patients without mental or nervous disorders interfering with adequate evaluation of one's health condition, who read the informed consent form and gave a written consent to participate in the study. Gastric bypass was performed with very long (250 cm) alimentary Roux limb
11568803|NCT00868530|Experimental|Xyntha|This trial was an open-label and included assessments of safety, clinical efficacy, and Factor VIII (FVIII) recovery in Chinese subjects with hemophilia A. Subjects received on-demand treatments with Xyntha over a 6-month (calendar day) period.
11568804|NCT00868517|Experimental|True Group Auricular Acupuncture|Received true group auricular acupuncture twice weekly for a period of two months.
11568805|NCT00868517|Sham Comparator|Sham Group Auricular Acupuncture|Received sham group auricular acupuncture twice weekly for a period of two months.
11568806|NCT00868517|Other|Wait-List Control Group|Served as wait list control. Did not receive any acupuncture during the study period.
11568807|NCT00868504||examined by endoscopy|Patients, examined by endoscopy, being screened for GI tract tumors
11568808|NCT00868465|Active Comparator|1|Artemether-lumefantrine; currently the first line treatment in Tanzania
11568809|NCT00868465|Experimental|2|Dihydroartemisinin-piperaquine, alternative ACT
11568810|NCT00868452|Experimental|Lurasidone|
11568811|NCT00868452|Placebo Comparator|Placebo|
11568812|NCT00868439|Active Comparator|patiromer|
11568813|NCT00868439|Placebo Comparator|placebo|
11568814|NCT00868426|Experimental|1|Budesonide/Formoterol Batch 1
11568815|NCT00868426|Experimental|2|Budesonide/Formoterol Batch 2
11568816|NCT00868426|Experimental|3|Budesonide/Formoterol Batch 1 and charcoal
11568817|NCT00868413|Active Comparator|A|FCR+ABT-263
11568818|NCT00868413|Active Comparator|B|BR+ABT-263
11568819|NCT00868400|Experimental|1|High-carbohydrate
11568820|NCT00868400|Placebo Comparator|2|Placebo
11568821|NCT00868400|No Intervention|3|Control
11568822|NCT00868387|Experimental|energy-restricted, CHO-restricted diet|Interventions: carbohydrate restriction of diet: 40% Frequency: daily Duration: 12 months
11568823|NCT00868387|Active Comparator|energy-restricted, CHO-rich diet|Comparator: carbohydrate content of diet: > 55% Frequency: daily Duration: 12 months
11568824|NCT00868374|Experimental|1|Quetiapine XR
11568825|NCT00868374|Placebo Comparator|2|
11568826|NCT00868361|Experimental|Slow and rapid N-acetyl transferase genotypes|
11568827|NCT00868348|Placebo Comparator|Saline|
11568828|NCT00868348|Active Comparator|Ketorolac|
11568829|NCT00868335|Active Comparator|1|Anterior cervical discectomy, no disc prosthesis
11568830|NCT00868335|Experimental|2|Anterior cervical discectomy, with disc prosthesis
11568831|NCT00868309|Experimental|Anavip|The initial dose of study drug was administered in a total volume of 500 mL (initial doses only) IV over 30 minutes for Anavip
11568832|NCT00868309|Active Comparator|CroFab|The initial dose of study drug was administered in a total volume of 500 mL (initial doses only) IV over 60 minutes for CroFab, or as permitted by IV access.
11568833|NCT00868296|Active Comparator|Low dose|
11568834|NCT00868296|Active Comparator|High dose|
11568835|NCT00868283|Experimental|Cerebrolysin|
11568836|NCT00868283|Placebo Comparator|0.9% Saline Solution|
11568837|NCT00868270||Children with UTIs|
11568838|NCT00868257||CHARTA study cohort|Primarily 5- to 10-year-old Ugandan children with HIV or AIDS who are taking ART, with some 1- to 4-year-olds included because of recent trends in treating younger children
11568839|NCT00868231|Experimental|Aclidinium 400 μg bid|Aclidinium bromide 400 μg twice-daily by inhalation
11568840|NCT00868231|Active Comparator|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily by inhalation
11568841|NCT00868231|Placebo Comparator|Placebo|Placebo
11568842|NCT00868218|Active Comparator|1|30µg HA vaccine Intramuscularly administered
11568843|NCT00868218|Active Comparator|2|1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
11568844|NCT00868218|Active Comparator|3|7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
11568845|NCT00868218|Active Comparator|4|30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
11568846|NCT00868205|Experimental|low coffee dose|3 cups of coffee daily for 8 weeks
11568847|NCT00868205|Experimental|high coffee dose|5 cups of coffee daily for eight weeks
11568848|NCT00868205|No Intervention|Control|Consumption of water instead of coffee daily for eight weeks
11568849|NCT00868192|Experimental|Pemetrexed and bevacizumab|"Pemetrexed 500 mg/m2 IV on Day 1 of each 21 day cycle
~Bevacizumab 15 mg/kg IV on Day 1 of each 21 day cycle"
11568850|NCT00868179|Experimental|Pradax|This is the only arm in the study and all will follow the same protocol for the study which is taking the pradax after total knee replacement
11568851|NCT00868166|Experimental|Olesoxime|2 Capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzole 50mg bid
11568852|NCT00868166|Placebo Comparator|Placebo Comparator|2 Capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
11568853|NCT00868153||Group 1|
11568854|NCT00868140|Experimental|1/Pioglitazone|Pioglitazone in pill form at 45mg twice per day for 6 months
11568855|NCT00868140|Placebo Comparator|2/Placebo|Placebo control to arm 1 in pill form identical to treatment form also twice per day for 6 months
11568856|NCT00868127|Experimental|Lapaquistat Acetate 100 mg QD|
11568857|NCT00868127|Experimental|Lapaquistat Acetate 100 mg QD + Added Therapy|
11568858|NCT00868114|Experimental|1|3 weekly injections of intratumoral TNFerade plus radiation and 3 weekly intratumoral injections of dendritic cell vaccine
11568859|NCT00868114|Experimental|2|Radiation Only with 3 weekly intratumoral injections of dendritic cell vaccine
11568863|NCT00868088|Placebo Comparator|placebo + PDT|Topical placebo will be applied to the entire lip surface and allowed to incubate for 60 minutes plus or minus 30 minutes. Blue light at a wavelength of 405-420 nm will be used for treatment at a dose of 1000 seconds.
11568864|NCT00868075|Experimental|Chest Physiotherapy|Twice daily chest physiotherapy
11568865|NCT00868075|Experimental|Chest Physiotherapy + Exercise Program|Chest Physiotherapy + Exercise Program
11568866|NCT00868062|Experimental|1|
11568867|NCT00868049||1|Obese subjects
11568868|NCT00868049||2|Normal-weight subjects
11568869|NCT00868036||Patch testing|Patch testing on patients with chronic idiopathic dermatitis.
11568870|NCT00868023|Experimental|1|CHF 1535 DPI : BDP/Formo 400/24 µg
11568871|NCT00868023|Active Comparator|2|CHF 1535 pMDI HFA : BDP/Formo 400/24 µg
11568872|NCT00868023|Experimental|3|CHF 1535 DPI : BDP/Formo 100/6 µg
11568873|NCT00868023|Active Comparator|4|CHF 1535 pMDI HFA : BDP/Formo 100/6 µg
11568874|NCT00868023|Placebo Comparator|5|Placebo
11568875|NCT00868010|Experimental|1: donepezil|Participants will receive treatment for 12 weeks on donepezil 10 mg (or 5 mg if unable to tolerate 10 mg). Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
11568876|NCT00868010|Placebo Comparator|2. placebo|Participants will receive treatment for 12 weeks with placebo pill. Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
11568877|NCT00867997|Active Comparator|Dentifrice|Chemoactive (remineralizing, neuroactive) dentifrice treatment
11568878|NCT00867997|Active Comparator|Sealant|DBA/sealant application
11568879|NCT00867997|Active Comparator|Resin-based composite|Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
11568880|NCT00867984|Experimental|1|Torsion-guided VV optimization plus AV optimization.
11568881|NCT00867984|Active Comparator|2|AV optimization only.
11568882|NCT00867971||RGH treated|
11568883|NCT00867971||Starting treatment with RGH|
11568884|NCT00867945||1. Pregnant Women|
11568885|NCT00867945||2. Non-Pregnant Controls|
11568886|NCT00867945||3. IVF controls|
11568887|NCT00867932|Experimental|Eculizumab|Eculizumab was administered as an IV infusion for 12 weeks. All participants weighed more than 45 kg and received the following weight-based dosing regimen: induction/loading = 600 milligram (mg) weekly x 4; maintenance = 900 mg at Week 5; 900 mg every 2 weeks.
11568888|NCT00867919|Experimental|1|Participants will receive a cognitive behavioral family therapy for adolescent depression to be developed in this study.
11568889|NCT00867919|Active Comparator|2|Participants will receive treatment as usual 1 year prior to the experimental treatment group.
11568890|NCT00867906|Other|Cohort 1|Asthmatics using salbutamol only, subjects to receive either Cat-PAD or placebo comparator
11568891|NCT00867906|Other|Cohort 2|Asthmatics using inhaled corticosteroid, subjects to receive either Cat-PAD or placebo comparator
11568892|NCT00867906|Other|Cohort 3|Asthmatics using inhaled corticosteroid and LABA, subjects to receive either Cat-PAD or placebo comparator
11568893|NCT00867893||DA group|RLS patients started treatment on dopamine agonists within the past year
11568894|NCT00867893||NonDA|RLS patients started treatment on medication other than dopamine agonists within the past year
11568895|NCT00867880|Experimental|1|
11568896|NCT00867880|Active Comparator|2|
11568897|NCT00867867|Active Comparator|1|Ferrous Fumarate with Ferrous Sulphate
11568898|NCT00867867|Active Comparator|2|Ferric pyrophosphate with ferrous sulphate
11568899|NCT00867867|Placebo Comparator|3|Ferrous sulphate
11568900|NCT00867854||Experimental|25 evaluable subjects from the experimental arm of ATN 061 who undergo de-intensification to boosted atazanavir (ATV) with VL suppression of < 100 copies/ml and CD4+ T cells > 350 cells/mm3 at week 48 and maintain VL suppression to < 400 copies/ml with stable CD4+ T cell counts after week 48.
11568901|NCT00867854||Control|25 evaluable subjects from ATN 071 will also be enrolled. These subjects will have initiated HAART according to current DHHS guidelines (CD4+ T cells < 350 cells/mm3), had viral load suppression to < 100 copies/ml at 24 through 48 weeks on HAART and maintained suppression to < 400 copies/ml through week 80.
11568902|NCT00867841||Pneumonia|Children diagnosed with community-acquired pneumonia by the emergency department physician
11568903|NCT00867828|Experimental|1|Neptune Krill Oil(TM)softgels (1g QD). Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
11568904|NCT00867828|Active Comparator|2|Fish oil softgels (1g QD). Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
11568905|NCT00867828|Placebo Comparator|3|Placebo (soy oil) softgels (1g QD. The soy oil placebo will provide neither EPA nor DHA.
11568906|NCT00867815|Other|Arm 1|
11568907|NCT00867802|Experimental|Mindfulness- Based Stress Reduction: Active Comparator|Mindfulness-Based Stress Reduction program
11568908|NCT00867789|Experimental|Trimethoprim-sulfamethaxazole|Incision and drainage of the abscess and treatment with oral TMP-SMX (100 patients)
11568909|NCT00867789|Placebo Comparator|Sugar pill|Incision and drainage of the abscess and treatment with oral placebo (100 patients)
11568910|NCT00867776|Experimental|AAHC Excercise Program Support Group|Participants taking part in the AAHC Exercise Program Support Group (the intervention).
11568911|NCT00867763|Experimental|IVM|Early egg retrieval, in vitro maturation, then IVF
11568912|NCT00867763|Active Comparator|Mild IVF|Mild gonadotropin and conventional IVF
11568913|NCT00867750|Experimental|RE|Device: Radioembolisation with yttrium-90 labelled SIR-Spheres microspheres
11568914|NCT00867750|Active Comparator|TACE|Transarterial Chemoembolisation with embolising agent Embospheres and chemotherapeutic agent epirubicin
11568915|NCT00867737|Experimental|Advair 115/21 MDI|Advair HFA 115/21 MDI Intervention = initiate intervention after screening
11568916|NCT00867737|Active Comparator|2 = Symbicort 160/4.5|Symbicort initiated after screening
11568917|NCT00867724|Experimental|Aer-O-Scope Colonoscopy|Screening Colonoscopy
11568918|NCT00867698|Experimental|AST-120 (6g)|2 grams TID
11568919|NCT00867698|Placebo Comparator|Placebo A|2 grams TID
11568920|NCT00867698|Experimental|AST-120 (12g)|4 grams TID
11568924|NCT00867685|Experimental|Treatment C|Single oral dose of 40 mg (2x20mg tablets) in a fed state.
11568925|NCT00867672|Experimental|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
11568926|NCT00867672|Experimental|Decitabine+VPA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks, and VPA (p.o.) from day 6 of first cycle continuously throughout all treatment cycles
11568927|NCT00867672|Experimental|Decitabine+ATRA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
11568928|NCT00867672|Experimental|Decitabine+VPA+ATRA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and VPA (p.o.) from day 6 continuously throughout all treatment cycles and ATRA (45 mg/m² p.o.), from day 6 to day 28 of each treatment cycle
11568929|NCT00867659|Experimental|Cetrotide acetate|oocyte donors will receive cetrotide acetate on the day of oocyte retrieval. The incidence of OHSS will be assessed.
11568930|NCT00867633||Urothelial carcinoma|The DNA samples extracted from the urothelial carcinoma tissue
11568931|NCT00867633||RCC|the DNA sample extracted from RCC
11568932|NCT00867633||Non-cancer|The DNA sample extracted from the non-cancerous kidney tissue
11568933|NCT00867620||1|case group: patients with urothelial carcinoma
11568934|NCT00867620||2|control group: those without previous history of any malignancy
11568935|NCT00867607|Experimental|MRX-6 (2%)|
11568936|NCT00867607|Experimental|MRX-6 (1%)|
11568937|NCT00867607|Experimental|MRX-6 (0.2%)|
11568938|NCT00867607|Active Comparator|Steroid|
11568939|NCT00867581||1|chronic-stage patients after infarction in the territory of unilateral middle cerebral artery
11568940|NCT00867581||2|age, sex and risk factor matched volunteers without ischemic stroke
11568941|NCT00867568|Experimental|TPI 287|
11568942|NCT00867555|Experimental|EGCG|"Double blind randomized, placebo-controlled cross-over design with two arms:
~the green tea extract TEAVIGO, high in EGCG and
~placebo"
11568943|NCT00867555|Placebo Comparator|placebo|
11568944|NCT00867542||past IUGR|3-4 y old children with past IUGR
11568945|NCT00867542||control|3-4 y old healthy children
11568946|NCT00867529|Experimental|Treatment (rituximab pre- and post-transplant)|Patients receive rituximab IV, pre- and post-transplant, on days -3, 10, 24, and 38. Patients undergo donor peripheral blood stem cell transplant on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity.
11568947|NCT00867516|Experimental|1|ALD518 80 mg
11568948|NCT00867516|Experimental|2|ALD518 160 mg
11568949|NCT00867516|Experimental|3|ALD518 320 mg
11568950|NCT00867516|Placebo Comparator|4|No ALD518
11568951|NCT00867503|Experimental|bendamustine|bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
11568952|NCT00867490|Experimental|Candesartan+HCTZ, aliskiren+HCTZ, aliskiren+HCTZ+amlodipine|
11568953|NCT00867477|Experimental|Cohort 1: Esophagus Cancer|Breathing Test + Respiratory Symptoms Questionnaire
11568954|NCT00867477|Experimental|Cohort 2: Lung Cancer|Breathing Test + Respiratory Symptoms Questionnaire
11568955|NCT00867451|Experimental|Immediate Treatment|Children will receive behavioral sleep interventions and, if needed, melatonin, to improve sleep functions.
11568956|NCT00867451|Experimental|Delayed Treatment|Children will only receive sleep behavior interventions for the first four weeks of the trial. Treatment with study drug will be delayed to the 5th week.
11568957|NCT00867438|Placebo Comparator|1|
11568958|NCT00867438|Experimental|2|
11568959|NCT00867425|Experimental|Intervention|
11568960|NCT00867412||Conventional staging|Staging with CT, mediastinoscopy and bronchoscopy
11568961|NCT00867412||Conventional staging and PET/CT|Staging with CT, mediastinoscopy and bronchoscopy, and PET/CT performed prior to mediastinoscopy
11568962|NCT00867399|Active Comparator|20mg of ABT-126 QD|20 mg of ABT-126 QD for 10 days
11568963|NCT00867399|Active Comparator|30mg and 45mg ABT-126 QD|30 mg and 45mg of ABT-126 QD for 21 days
11568964|NCT00867373|Experimental|Education Intervention|"The intervention used in the randomized controlled trial consists of 1) measuring the parents' height and weight and 2) providing the parents with feedback on their calculated BMI on an educational handout (included in Appendix V). The purpose of the handout is to convey the following 5 messages:
~Definition of BMI
~How BMI is calculated
~What the parent's BMI is based on the measurements taken
~What weight category the parent is in (underweight, normal weight, overweight, or obese)
~Children with overweight or obese parents are at higher risk of becoming overweight themselves.
~The Research Assistant will verbally review the educational handout with the parent. The handout will be available in both English and Spanish."
11568965|NCT00867373|No Intervention|Control Group|Parents assigned to the control group will proceed to their child's well child visit after their baseline data are collected.
11568966|NCT00867360|Experimental|Mifepristone|Receive mifepristone for 8 days
11568967|NCT00867360|Placebo Comparator|Placebo|Receive placebo rather than mifepristone
11568968|NCT00867347|Active Comparator|Arm I|"Patients undergo a radical cystectomy, including pelvic lymphadenectomy,
~between 4 and 6 weeks after initiating course 4 of chemotherapy."
11568969|NCT00867347|Experimental|Arm II|Patients with no visible residual tumor (cT0 or pT0) or residual but superficial tumor (pTa, pT1) undergo radiotherapy beginning within 4-6 weeks of day 1 of course 4 and continuing for 6.5 weeks.
11568970|NCT00867334|Experimental|Imatinib mesylate and panitumumab|Subjects whose initial liver biopsy samples meet certain lab values will be placed in Arm 1. Each participant assigned to Arm 1 will receive imatinib mesylate for 28 days, followed by a combination of imatinib mesylate and panitumumab.
11568971|NCT00867334|Active Comparator|Panitumumab (standard-of-care)|Subjects whose initial liver biopsy samples meet certain lab values will be placed in Arm 2. Participants in Arm 2 will receive standard-of-care treatment with panitumumab.
11568972|NCT00867321|Experimental|Arm I (Phase II)|Patients receive oral sorafenib tosylate on days 1-28 twice daily and bevacizumab IV on days 1 and 15.
11568973|NCT00867321|Experimental|Arm II (Phase II)|Patients receive oral sorafenib tosylate twice daily on days 1-28.
11568974|NCT00867308|Experimental|Lenalidomide 15 mg|"Patients diagnosed with high risk Myelodysplastic syndrome (MDS), regardless of 5q deletion status, will receive lenalidomide 15 mg per day orally, on days 1-28 of a 42 day cycle for 2 cycles. At this point, patients meeting protocol specified response criteria will proceed to Continuing Therapy on a reduced dose of lenalidomide until progression.
~Patients not achieving response will receive 2 additional cycles of treatment, whereupon response will again be assessed. Patients achieving response at this point will proceed to Continuing Therapy as described.
~Patients without evidence of response after 4 cycles will be taken off-study."
11568975|NCT00867308|Experimental|Lenalidomide 50 mg|"Patients diagnosed with high risk Myelodysplastic syndrome (MDS), regardless of 5q deletion status, will receive lenalidomide 50 mg per day orally, on days 1-28 of a 42 day cycle for 2 cycles. At this point, patients meeting protocol specified response criteria will proceed to Continuing Therapy on a reduced dose of lenalidomide until progression.
~Patients not achieving response will receive 2 additional cycles of treatment, whereupon response will again be assessed. Patients achieving response at this point will proceed to Continuing Therapy as described.
~Patients without evidence of response after 4 cycles will be taken off-study."
11568976|NCT00867295|Placebo Comparator|placebo|no antibiotic is used
11568977|NCT00867295|Active Comparator|drug|cefazolin Sodium 1g i.v. before the operation
11568978|NCT00867282|Experimental|Treatment A|
11568979|NCT00867282|Active Comparator|Treatment B|
11568980|NCT00867269||Blood Relatives|Blood Relatives of ICL subjects
11568981|NCT00867269||Household Contacts|Household contacts of ICL subjects
11568982|NCT00867269||ICL Subjects|Patients with confirmed idiopathic CD4 lymphocytopenia
11568983|NCT00867256|Experimental|Large Diameter Metal on Metal|
11568984|NCT00867243||Group 1: HCV Positive|50 patients whom are HCV positive
11568985|NCT00867243||Group 2: HCV Negative|50 patients whom are HCV negative.
11568986|NCT00867230|Experimental|FTS (S-trans, trans-farnesylthiosalicylic acid)|
11568987|NCT00867217|Experimental|High Dose Vitamin D|High Dose Vitamin D3 capsule (3 x 10,000 IU capsules weekly). All subjects also received standard dose vitamin D3 (600 IU daily) and letrozole (2.5 mg daily).
11568988|NCT00867217|Placebo Comparator|Placebo|Placebo matched for High Dose Vitamin D3 capsules. All subjects also received standard dose vitamin D3 (600 IU daily) and letrozole (2.5 mg daily).
11568989|NCT00867204||Short-wire device|The Fusion Short-wire ERCP device was used
11568990|NCT00867204||Long-wire device|The traditional Long-wire ERCP device was used
11568991|NCT00867191|Placebo Comparator|1|Placebo, 1 tablet daily, per os
11568992|NCT00867191|Active Comparator|2|Desloratadine, one 5 mg tablet daily, per os
11568993|NCT00867178|Experimental|Treatment (vorinostat, isotretinoin, chemotherapy)|See Detailed Description
11568994|NCT00867165|Experimental|Ezetimibe|Ezetimibe 10-mg tablet once daily for 12 weeks
11568995|NCT00867165|Placebo Comparator|Placebo|Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks
11568996|NCT00867152|Experimental|Cohort 2|All subjects will receive GSK1349572 50mg q24h (Treatment A) from Day 1 to Day 5 in Period 1. There will be no washout between treatment Periods 1 and 2. Subjects will receive GSK1349572 50mg q24h and ETV/DRV/RTV 200/600/100mg q12h from Day 1 to Day 14 in Period 2. Day 1 of Period 3 will be approximately 3 weeks after the last dose in Period 2. Subjects will receive GSK1349572 50mg q12h and ETV/DRV/RTV 200/600/100mg q12h from Day 1 to Day 14. Period 3 will not be performed if there is no significant interaction in Period 2.
11568997|NCT00867152|Experimental|Cohort 1|All subjects will receive GSK1349572 50mg q24h (Treatment A) from Day 1 to Day 5 in Period 1. There will be no washout between treatment Periods 1 and 2. Subjects will receive GSK1349572 50mg q24h and ETV/LPV/RTV 200/400/100mg q12h from Day 1 to Day 14 in Period 2. Day 1 of Period 3 will be approximately 3 weeks after the last dose in Period 2. Subjects will receive GSK1349572 50mg q12h and ETV/LPV/RTV 200/400/100mg q12h from Day 1 to Day 14. Period 3 will not be performed if there is no significant interaction in Period 2.
11568998|NCT00867139|Experimental|TCAD-Randomized Arm|TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
11568999|NCT00867139|Active Comparator|Neuraminidase Monotherapy Arm|Zanamivir or Oseltamivir
11569000|NCT00867139|Other|TCAD Open Label Arm|TCAD for subjects who cannot tolerate or are ineligible to receive zanamivir
11569001|NCT00867113|Experimental|Imatinib|All subjects received in tablet form imatinib (STI571) 400 mg once daily.
11569002|NCT00867100|Placebo Comparator|Placebo|Placebo treatment
11569003|NCT00867100|Experimental|140 mg SC|140 mg SC PsO
11569004|NCT00867100|Active Comparator|350 mg SC|350 mg SC PsO
11569005|NCT00867100|Experimental|700 mg IV|700 mg IV PsO
11569006|NCT00867087|Experimental|Rituximab 375 mg/m^2 + Inotuzumab Ozogamicin 1.8 mg/m^2|Inotuzumab ozogamicin, in combination with rituximab, will be administered to patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma prior to an autologous stem cell transplant (aSCT).
11569007|NCT00867048|Experimental|Early ART|Initiate ART immediately following randomization
11569008|NCT00867048|Active Comparator|Deferred ART|Defer ART until the CD4+ count declines to <350 cells/cu mm or AIDS develops
11569009|NCT00867035|Active Comparator|Chlorhexidine gluconate and scraper|The intervention was accomplished by subject after instructions from investigator: twice a day a tongue scraper was used with 4 or more strokes, followed by 20ml of 0.12% chlorhexidine gluconate mouthwash used for 30 sec, for one week.
11569010|NCT00867035|Experimental|Chlorine dioxide and scraper|The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.1% stabilized chlor8ine dioxide rinse for 30sec, for one week.
11569011|NCT00867022||1|Women with gestational diabetes
11569012|NCT00867022||2|Pregnant women without gestational daibetes
11569013|NCT00867022||3|Women with gestational diabetes and hypertension
11569014|NCT00867022||4|Non pregnant women
11569015|NCT00867009|Experimental|Induction/maintenance Therapy|pemetrexed, cisplatin and cetuximab followed by pemetrexed and cetuximab
11569016|NCT00866970|Experimental|1|ALD518
11569017|NCT00866970|Experimental|2|ALD518
11569018|NCT00866970|Experimental|3|ALD518
11569019|NCT00866970|Placebo Comparator|4|No ALD518
11569020|NCT00866957||Patients with liver cancer|Patients diagnosed with liver cancer
11569023|NCT00866944|Active Comparator|3|FOLFOX 4 alone
11569024|NCT00866918|Experimental|Standard Risk (WBC < 10000/uL)|See Detailed Description
11569025|NCT00866918|Active Comparator|High Risk (WBC > 10000/uL)|See Detailed Description
11569026|NCT00866905|Experimental|Ixabepilone/Cyclophosphamide|Systemic Therapy followed by surgery and possible radiation therapy
11569027|NCT00866892|Active Comparator|irrigation|
11569028|NCT00866892|Experimental|no irrigation|
11569029|NCT00866879|Active Comparator|Control|Group 1 will continue immunosuppression medication per standard of care (SOC) at Northwestern by taking mycophenolate mofetil and tacrolimus.
11569030|NCT00866879|Experimental|Transition to Sirolimus Group|Group 2 will switch immunosuppression medication to taking mycophenolate mofetil and sirolimus
11569031|NCT00866879|Other|Donors|Data and blood samples from the donors are collected in this study to contribute to the general knowledge to be used in assessing the two donor recipient groups, which are the target of this study.
11569032|NCT00866866|Experimental|N-Acetyl Cysteine|
11569033|NCT00866866|Placebo Comparator|Placebo|
11569034|NCT00866840|Experimental|Riluzole|100 mg orally twice daily
11569035|NCT00866814||Ventrio Group|Patients diagnosed with a ventral hernia requiring an open surgery for repair.
11569036|NCT00866801||Healthy|Healthy subjects scheduled for general anesthesia
11569037|NCT00866801||Healthy with thoracic epidural anelgesia|Healthy subjects scheduled for general anesthesia and thoracic epidural analgesia
11569038|NCT00866801||Diabetes|Subjects with diabetes scheduled for general anesthesia
11569039|NCT00866801||Diabetes with autonomic neuropathy|Subjects with diabetes and cardiovascular autonomic neuropathy scheduled for general anesthesia
11569040|NCT00866788|Experimental|Omalizumab 75 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.).
11569041|NCT00866788|Experimental|Omalizumab 300 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
11569042|NCT00866788|Experimental|Omalizumab 600 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
11569043|NCT00866788|Placebo Comparator|Placebo|Participants received a single subcutaneous placebo injection on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
11569044|NCT00866775|Experimental|Eslicarbazepine 1600 mg QD|"Subjects randomized to 1600 mg QD of eslicarbazepine acetate will titrate from 600 mg QD (Day 0) to 1200 mg QD (Week 1) to 1600 mg QD (Weeks 2-18)
~Subjects may continue in an open-label extension study with a starting dose of 1600 mg QD, or taper off study drug at the completion of this study The treatment period for subjects entering the open label extension study is up to 9 study visits over 18 weeks. The treatment period for subjects not entering the open-label extension study is up to 10 study visits over 19 weeks."
11569045|NCT00866775|Experimental|Eslicarbazepine 1200 mg QD|"Subjects randomized to 1200 mg QD eslicarbazepine acetate will titrate from 400 mg QD (Day 0) to 800 mg QD (week 1) to 1200 mg QD (weeks 2-18)
~Subjects may continue in an open-label extension study with a starting dose of 1600 mg QD, or taper off study drug at the completion of this study The treatment period for subjects entering the open label extension study is up to 9 study visits over 18 weeks. The treatment period for subjects not entering the open-label extension study is up to 10 study visits over 19 weeks."
11569046|NCT00866762|Experimental|1|Treatment with study drug approximately 6 months and follow-up for 3 months
11569047|NCT00866749|Experimental|Augmented BFM Therapy|Induction + Maintenance: Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Doxorubicin, Thioguanine
11569048|NCT00866736|Experimental|dasatinib|
11569049|NCT00866723|Experimental|bevacizumab|Bevacizumab was administered at 15 mg/kg intravenously every 3 weeks. Treatment continued until disease progression or unacceptable toxicity.
11569050|NCT00866697|Placebo Comparator|Placebo|matched placebo tablet administered orally once daily for up to 24 months
11569051|NCT00866697|Experimental|Pazopanib|Pazopanib tablet administered orally at 800 mg once daily for up to 24 months
11569052|NCT00866684|Experimental|1|Patients will receive Sirolimus in addition to their previous immunosuppressive therapy.
11569053|NCT00866684|Active Comparator|2|Patients will stay on their previous immunosuppressive regimen.
11569054|NCT00866671||Nelarabine|nelarabine 650mg/m2 IV daily for 5 days. repeat every 21 days.
11569055|NCT00866658|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
11569056|NCT00866658|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
11569057|NCT00866645|Experimental|1|Intramuscular Levosulpiride
11569058|NCT00866645|Active Comparator|2|Intramuscular Haloperidol
11569059|NCT00866632|Experimental|Group Cognitive Behavioural Therapy|
11569060|NCT00866632|Experimental|Telephone Cognitive Behavioural Therapy|
11569061|NCT00866632|No Intervention|Group Education|
11569062|NCT00866632|No Intervention|Telephone Education|
11569063|NCT00866619|Experimental|GSK257049 [5-17M] Group|Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.
11569359|NCT00864461||Control|Siblings of the same gender of the case, between 7-24 years old.
11569064|NCT00866619|Experimental|GSK257049 [6-12W] Group|Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin vaccines or a booster dose of Menjugate and Polio Sabin vaccines, at Month 20. All vaccines have been administered intramuscularly in the interolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.
11569065|NCT00866619|Active Comparator|VeroRab Comparator [5-17M] Group|Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.
11569066|NCT00866619|Experimental|Menjugate Comparator [6-12W] Group|Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate and Polio Sabin vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.
11569067|NCT00866606|Experimental|Benefix|Subjects received on-demand treatments with BeneFIX over a 6-month (calendar day) period.
11569068|NCT00866593|Experimental|1|Generic Escitalopram Oxalate Tablets
11569069|NCT00866593|Active Comparator|2|Innovator Escitalopram(Lexapro®)
11569070|NCT00866580|Experimental|Group A|
11569071|NCT00866580|Experimental|Group B|
11569072|NCT00866567||1|Premature infants of less than 28 weeks of gestational age
11569073|NCT00866567||2|Premature infants of more than 28 weeks and less than 32 weeks of gestational age
11569074|NCT00866567||3|Term newborns
11569075|NCT00866567||4|Adults
11569076|NCT00866554|Active Comparator|LHRH agonist|Administration of a 3-month treatment with an LHRH agonist (chosen by the treating radiation oncologist) and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
11569077|NCT00866554|Experimental|Dutasteride, Bicalutamide, Tamoxifen|"Administration of Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.
~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride
~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."
11569078|NCT00866541|Experimental|volunteers|artificial increased respiratory resistance
11569079|NCT00866528|Experimental|Phase I|oral pazopanib once daily (Phase I starting dose 800 mg) and paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
11569080|NCT00866515|Experimental|Active|Ketoconazole 400mg OD days 1-6
11569081|NCT00866515|Placebo Comparator|Placebo|Placebo OD for 1 to 6 days
11569082|NCT00866502|Experimental|sNN0031|Continuous ICV infusion for two weeks at one of three dose levels
11569083|NCT00866502|Placebo Comparator|Placebo|Continuous ICV infusion
11569084|NCT00866489|No Intervention|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min.
11569085|NCT00866489|Experimental|RIPC|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
11569086|NCT00866476|Experimental|Vaccine-recipients|
11569087|NCT00866476|Placebo Comparator|Placebo|
11569088|NCT00866463|Active Comparator|Conventional Oral Tablet With Water|
11569089|NCT00866463|Experimental|Experimental Tablet With Water|
11569090|NCT00866463|Experimental|Experimental Tablet Without Water|
11569091|NCT00866450|Active Comparator|Western style diet|high-fat, low-calcium diet
11569092|NCT00866450|Active Comparator|Prudent diet|low-fat, calcium-sufficient diet
11569093|NCT00866437|Experimental|Healthy Control group|
11569094|NCT00866437|Experimental|PMS|
11569095|NCT00866424|Experimental|A,2, II|
11569096|NCT00866398||1 DES|Patients receiving drug-eluting stent
11569097|NCT00866398||2 BMS|Patients receiving bare metal stent
11569098|NCT00866359|Active Comparator|A. Apremilast|
11569099|NCT00866359|Placebo Comparator|B. Placebo Comparator|
11569100|NCT00866346|Experimental|PR1-CTL|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.
~Starting infusion dose 1 x 106 nucleated cells/kg."
11569101|NCT00866333|Experimental|Entinostat|"Regimen determined by protocol version.
~Regimen 1: entinostat 10 mg (two 5 mg tablets) orally, once every two weeks (Days 1 and 15) in a 28-day cycle until disease progression or unacceptable toxicity.
~Regimen 2: entinostat 10 mg (two 5 mg tablets) orally on Day 1, increased to 15 mg (three 5 mg tablets) beginning on Day 15 of Cycle 1 for participants who had not experienced treatment-related adverse events with severity grade ≥2 (moderate), then continue 15 mg every two weeks (Days 1 and 15) in a 28-day cycle until disease progression or unacceptable toxicity.
~Regimen 3: entinostat 15 mg (three 5 mg tablets), orally, once weekly for 3 weeks followed by a 1-week break in a 4-week (28-day) cycle until disease progression or unacceptable toxicity."
11569102|NCT00866320|Experimental|Sorafenib|Chemotherapy single agent systemic. Sorafenib given up to 600mg orally every 12 hours for up to 10 months (40 weeks).
11569134|NCT00866034|Experimental|CD6|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6. As in the other arm of the study, exogenous gonadotropins will commence on cycle day 2.
11569135|NCT00866021|Experimental|1|Lopinavir/ritonavir (LPV/r) as single antiretroviral administered concomitantly with peg-interferon and ribavirin
11569136|NCT00866021|Active Comparator|2|Lopinavir/ritonavir (LPV/r) with 2 NRTIs, administered concomitantly with peg-interferon and ribavirin
11569137|NCT00866008|Experimental|1|Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment.
11569360|NCT00864448|Experimental|A|Ramipril10 mg Capsules, single dose
11569103|NCT00866307|Experimental|High Risk - Average (Day 29 MRD < 0.01%)|Cyclophosphamide IV days 1 & 29; cytarabine IV subcutaneously (SC) days 1-4, 8-11, 29-32, & 36-39; mercaptopurine PO once daily (QD) days 1-14 & 29-42; vincristine sulfate IV days 15, 22, 43, & 50; methotrexate IT days 1, 8, 15, & 22; & pegaspargase IV days 15 & 43. Int. Maint.: Vincristine sulfate IV days 1, 11, 21, 31, & 41; methotrexate IV days 1, 11, 21, 31, & 41; methotrexate IT days 1 & 31; and pegaspargase IV days 2 & 22. Delayed Intensification: Vincristine sulfate IV days 1, 8, 15, 43, & 50; dexamethasone IV or PO days 1-7 & 15-21; doxorubicin hydrochloride IV days 1, 8, & 15; cyclophosphamide IV day 29; cytarabine IV or SC days 29-32 & 36-39; thioguanine PO days 29-42; methotrexate IT days 1, 29, & 36; and pegaspargase IV days 4 & 43. Maint. begins day 57 of DI: Vincristine sulfate IV days 1, 29, & 57; prednisone PO days 1-5, 29-33, & 57-61; mercaptopurine PO days 1-84; methotrexate IT day 1; and methotrexate PO days 8, 15, 22, 29*, 36, 43, 50, 57, 64, 71, & 78.
11569104|NCT00866307|Experimental|High Risk - High (Day 29 MRD ≥ 0.01%) or other factors|Cyclophosphamide, cytarabine, mercaptopurine, vincristine sulfate, and methotrexate as in group A. Beginning on day 1, pegaspargase IV every 2 weeks. Patients with CNS3 disease undergo cranial radiotherapy QD for 10 days and patients with testicular disease undergo testicular radiotherapy QD for 12 days, beginning on day 1 of consolidation. Interim Maintenance: Patients receive vincristine sulfate and methotrexate as in group A. Beginning on day 1, pegaspargase IV every 2 weeks. Delayed Intensification: Vincristine sulfate, dexamethasone, doxorubicin hydrochloride, cyclophosphamide, cytarabine, thioguanine, and methotrexate as in group A. Beginning on day 1, pegaspargase IV over 1-2 hours every 2 weeks. Maint. begins day 57 of DI: Vincristine sulfate IV days 1, 29, & 57; prednisone PO days 1-5, 29-33, & 57-61; mercaptopurine PO days 1-84; methotrexate IT day 1; and methotrexate PO days 8, 15, 22, 29*, 36, 43, 50, 57, 64, 71, & 78.
11569105|NCT00866294|Experimental|paroxetine CR group|controlled-release (CR) of paroxetine 12.5 to 50mg/day
11569106|NCT00866294|Other|paroxetine IR group|Immediate-release (IR) of paroxetine 10 to 40mg/day as a reference arm
11569107|NCT00866294|Placebo Comparator|placebo group|matched placebo to both paroxetine CR and paroxetine IR
11569108|NCT00866281|Experimental|30 mg/m^2 bid|Participants received bodyweight and body surface area (BSA) stratified dose of midostaurin 30 mg/m^2 twice daily (bid) through oral route. The total daily dose in 30 mg/m^2 bid cohort was 60 mg/m^2.
11569109|NCT00866281|Experimental|60 mg/m^2 bid|Participants received bodyweight and BSA stratified dose of midostaurin 60 mg/m^2 bid through oral route. The total daily dose in 60 mg/m^2 bid cohort was 120 mg/m^2.
11569110|NCT00866268|Experimental|Low suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter.
11569111|NCT00866268|Active Comparator|High suction drainage|The standard DRENOFAST® system was used in the control group, and the initial negative pressure was 700 mmHg.
11569112|NCT00866242|Experimental|Challenge-recipients|
11569113|NCT00866216|Experimental|1|Azithromycin Monohydrate 600mg Tablets
11569114|NCT00866216|Active Comparator|2|Zithromax (Azithromycin Dihydrate) 600mg Tablets
11569115|NCT00866203|Experimental|HDS|modified high dose sequential therapy
11569116|NCT00866203|Active Comparator|ProMECE/CytaBOM|four additional courses of standard ProMECE/CytaBOM
11569117|NCT00866190|Experimental|Cohort 1|SQ109 dose 75 mg or placebo once daily for 14 days.
11569118|NCT00866190|Experimental|Cohort 3|SQ109 dose 150 mg or placebo once daily for 14 days.
11569119|NCT00866190|Experimental|Cohort 2|SQ109 dose 150 mg or placebo once daily on Days 1-5, 9, and 14.
11569120|NCT00866177|Experimental|Arm I|Patients receive oral MEK inhibitor AZD6244 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11569121|NCT00866151||1|"Previously enrolled subjects in the Benefits and Risks of Alternative Weight Loss Strategies - a Clinical Trial, which was run at Stanford 2003-2005. (A to Z Study)"
11569122|NCT00866138|Experimental|1|masitinib (AB1010)
11569123|NCT00866112|Experimental|1|Intervention group to promote physical activity
11569124|NCT00866112|Other|2|Minimal contact control group
11569125|NCT00866099|No Intervention|"Normal Care"|Primary care practices randomly allocated will be given a summary of the NICE/SCIE dementia guidelines (2006) and offered workshop training and software at the end of the study.
11569126|NCT00866099|Experimental|Training|Practices randomly allocated to the intervention arm will be asked to participate in tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.
11569127|NCT00866073|Experimental|A|Decitabine 15 mg/m2 i.v. - single arm
11569128|NCT00866060|Active Comparator|1|"10mg donepezil plus 20mg memantine
~Participants in this arm will continue with their current donepezil 10mg/day regimen and immediately commence active memantine at a dose of 5mg per day, increasing in 5mg increments weekly until 20mg per day is achieved from week 4 onwards"
11569129|NCT00866060|Placebo Comparator|2|"Placebo donepezil plus 20mg memantine
~Participants in this arm will immediately commence active memantine at a dose of 5mg per day, increasing in 5mg increments weekly until 20mg per day is achieved from week 4 onwards. Donepezil dose will be reduced to 5mg daily in weeks 1 to 4 and replaced with placebo donepezil in week 5."
11569130|NCT00866060|Placebo Comparator|3|"10mg donepezil plus placebo memantine
~Participants in this arm will continue with their current donepezil 10mg/day regimen and immediately commence placebo memantine."
11569131|NCT00866060|Placebo Comparator|4|"Placebo donepezil plus placebo memantine
~Participants in this arm will immediately commence placebo memantine dose escalation and will switch to donepezil 5mg daily in weeks 1 to 4, and replaced with placebo donepezil in week 5."
11569132|NCT00866047|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion
11569133|NCT00866034|Experimental|CD2|Early fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2, together with the initiation of daily treatment with exogenous gonadotropins.
11569138|NCT00866008|Experimental|2|Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG.
11569139|NCT00865995||1|patients undergoing elective procedures with intubation and no known respiratory pathology
11569140|NCT00865995||2|patients with tracheostomy
11569141|NCT00865995||3|patients with chronic lung disease or respiratory symptoms undergoing bronchoscopy
11569142|NCT00865969|Experimental|Belinostat|Belinostat (PXD101) 1000 mg/m²administered as a 30 minute IV infusion
11569143|NCT00865956|Experimental|Care Management|Care Management plus voucher incentives for adherence to primary care appointments.
11569144|NCT00865956|No Intervention|Usual care|Usual care
11569145|NCT00865943|Experimental|A|Citalopram HBr eq. 10 mg tablets, single dose
11569146|NCT00865943|Active Comparator|B|CELEXATM 10 mg tablets, single dose
11569147|NCT00865917|Active Comparator|1|beta-blocker
11569148|NCT00865917|Experimental|2|I(f)-blocker
11569149|NCT00865917|Placebo Comparator|3|Placebo
11569150|NCT00865904|Placebo Comparator|Placebo|Placebo matched to VX-809 capsule orally once daily for 28 days.
11569151|NCT00865904|Experimental|VX-809, 25 mg|VX-809, 25 milligram (mg) capsule orally once daily for 28 days.
11569152|NCT00865904|Experimental|VX-809, 50 mg|VX-809, 50 mg capsule orally once daily for 28 days.
11569153|NCT00865904|Experimental|VX-809, 100 mg|VX-809, 100 mg capsule orally once daily for 28 days.
11569154|NCT00865904|Experimental|VX-809, 200 mg|VX-809, 200 mg capsule orally once daily for 28 days.
11569155|NCT00865891|Experimental|A|Nifedipine Extended Release tablets 60 mg, single dose
11569156|NCT00865891|Active Comparator|B|ADALAT® CC Extended Release Tablets 60 mg
11569157|NCT00865878|Active Comparator|1|Topical Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA) will be applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to blue light treatment for 16 minutes and 40 seconds.
11569158|NCT00865878|Placebo Comparator|2|Kerastick containing vehicle ingredients only (VEH) will be applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to blue light treatment for 16 minutes 40 seconds.
11569159|NCT00865865|Other|1|Conventional total knee arthroplasty
11569160|NCT00865865|Active Comparator|2|Computer aided total knee arthroplasty
11569161|NCT00865852|Experimental|A|Metformin HCl 750 mg Extender Release tablets, single dose
11569162|NCT00865852|Active Comparator|B|GLUCOPHAGE® XR 750 mg tablets, single dose
11569163|NCT00865839|Experimental|A|Metformin HCl 500 mg tablets, single dose
11569164|NCT00865839|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
11569165|NCT00865826||1|HIV-infected males and females who are not currently receiving ART
11569166|NCT00865813|Experimental|Punch Biopsy|
11569167|NCT00865787||Olive Oil A|
11569168|NCT00865787||Olive Oil B|
11569169|NCT00865774|Experimental|1|Arm number 1 focuses on the traditional quantity frequency model.
11569170|NCT00865774|Experimental|2|Arm number 2 targets subjective drunkenness.
11569171|NCT00865761|Experimental|A|Alprazolam 3 mg Extended Release Tablets, single dose
11569172|NCT00865761|Active Comparator|B|XANAX XR® 3 mg tablets, single dose
11569173|NCT00865748|Experimental|A|Metformin HCl 500 mg tablets, single dose
11569174|NCT00865748|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
11569175|NCT00865722|Active Comparator|RemotePostConditioning|Patients will receive pPCI and treatments according to guidelines for STEMI PLUS extrinsic cuff compression to the lower limb for 5 ' followed by 5' reperfusion for three cycles (30' in total) starting with myocardial reperfusion
11569176|NCT00865722|Sham Comparator|Controls|pPCI and treatments according to guidelines for STEMI
11569177|NCT00865709|Experimental|Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6|Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease (PD)
11569178|NCT00865709|Placebo Comparator|Matching placebo + mFOLFOX6|Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease
11569179|NCT00865696|Experimental|A|Mirtazapine 15 mg tablets, single dose
11569180|NCT00865696|Active Comparator|B|REMERON® 15 mg tablets, single dose
11569181|NCT00865683|Active Comparator|1|Participants will receive DHA supplements.
11569182|NCT00865683|Placebo Comparator|2|Participants will receive placebo capsules of corn oil.
11569183|NCT00865670|Experimental|1|Azithromycin Monohydrate 600mg Tablets
11569184|NCT00865670|Active Comparator|2|Zithromax (azithromycin dihydrate)600mg Tablets
11569185|NCT00865657|Experimental|A|Alprazolam 3 mg Extended Release Tablets, single dose
11569186|NCT00865657|Active Comparator|B|XANAX XR® 3 mg tablets, single dose
11569187|NCT00865644|Experimental|Imiquimod|
11569188|NCT00865631|Experimental|A|Gabapentin 800 mg tablets, single dose (1 tablet)
11569189|NCT00865631|Active Comparator|B|NEURONTIN® 400 mg capsules, single dose (2 capsules)
11569190|NCT00865618|Experimental|1|Eplerenone 50mg Tablets
11569191|NCT00865618|Active Comparator|2|INSPRA 50mg Tablets
11569192|NCT00865605|Experimental|A|Halobetasol Propionate 0.05% Ointment, single exposure
11569193|NCT00865605|Active Comparator|B|Ultravate® 0.05% ointment, single exposure
11569194|NCT00865579|Experimental|1|All subjects to receive first 50mg/d Safinamide with an increase of target dose of 100mg/d after 14 days of taper period until end of treatment visit. In case of any intolerance the daily dose of 100mg might be decreased to 50mg/d. Patients permanently discontinuing treatment will enter a 7day taper phase before treatment discontinuation at a dose of 50mg/day. Subjects already taking 50mg/d may stop Safinamide immediately.
11569195|NCT00865566|Experimental|1|Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
11569196|NCT00865566|Placebo Comparator|2|Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
11569197|NCT00865540|Experimental|prednisolone acetate 1%|one drop every 8h two days before surgery
11569198|NCT00865540|Experimental|ketorolac tromethamine 0.4%|one drop every 8h two days before surgery
11569199|NCT00865540|Experimental|nepafenac 0.1%|one drop every 8h two days before surgery
11569200|NCT00865540|Placebo Comparator|placebo|one drop every 8h two days before surgery
11569201|NCT00865527|Active Comparator|Fecal Occult Blood Test|fecal occult blood test
11569202|NCT00865527|Active Comparator|Virtual Colonoscopy|virtual colonoscopy
11569203|NCT00865527|Active Comparator|Optical Colonoscopy|optical (conventional / endoscopic) colonoscopy
11569204|NCT00865514|Experimental|Haplotypes and DCA metabolism|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
11569205|NCT00865501|Experimental|1|spironolactone
11569206|NCT00865501|Placebo Comparator|2|placebo
11569207|NCT00865488|No Intervention|1|patients who will be treated in accordance with standard of care
11569208|NCT00865488|Experimental|2|patients for which Adhexil will be applied to prevent/reduce adhesions
11569209|NCT00865475|No Intervention|TZV (Trizivir)|Keeping on TZV in patients with viral suppression
11569210|NCT00865475|Experimental|2|Switching to LPV/r monotherapy
11569211|NCT00865462|Experimental|A|Abrika Bupropion 150 mg XL Tablet, single dose
11569212|NCT00865462|Active Comparator|B|Wellbutrin XL® 150 mg Tablet, single dose
11569213|NCT00865449|Active Comparator|1|Peritoneal Dialysis patients on aldactone for 6 months
11569214|NCT00865449|Placebo Comparator|2|Peritoneal dialysis Patients on the placebo arm for 6 months
11569215|NCT00865436|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
11569216|NCT00865436|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
11569217|NCT00865423|Experimental|A|Gabapentin 800 mg Tablets, single dose
11569218|NCT00865423|Active Comparator|B|NEURONTIN® 800 mg Tablets, single dose
11569219|NCT00865410|Experimental|A|Abrika Bupropion 150 mg Extended-Released Tablet, single dose
11569220|NCT00865410|Active Comparator|B|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
11569221|NCT00865397||A|
11569222|NCT00865384|Experimental|A|Mirtazapine 15 mg tablets, single dose
11569223|NCT00865384|Active Comparator|B|REMERON® 15 mg tablets, single dose
11569224|NCT00865371|Experimental|A|Abrika Bupropion 150 mg Extended-Released Tablet, single dose
11569225|NCT00865371|Active Comparator|B|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
11569226|NCT00865358|Experimental|Yoga Group|A standardized hatha yoga protocol delivered in 12 weekly classes.
11569227|NCT00865358|No Intervention|Usual care|Participants continue to receive their usual medical care for their back pain
11569228|NCT00865319|Experimental|99 m Tc-EC-DG|99m Tc-Ec-DG injection followed by SPECT/CT imaging (range 20-30 mCi) 1mg EC-DG
11569229|NCT00865319|Active Comparator|18F-FDG|18 F FDG injection followed by PET/CT imaging
11569230|NCT00865306|Experimental|Active CBT|"Seven parent-only and 8-13 child-only sessions focusing on CBT for anxiety disorders using the Being Brave protocol."
11569231|NCT00865306|No Intervention|No intervention (wait-list controls)|Control children received no intervention.
11569232|NCT00865293||Obesity|Subjects with obesity, defined as BMI > 30, aged 25-60
11569233|NCT00865293||Control|Subjects with a BMI 18,5-25, aged 25-60
11569234|NCT00865280|Experimental|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet, 150 mg
11569235|NCT00865280|Active Comparator|Linezolid|Gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; Gram negative treatment: moxifloxacin 400 mg tablet and moxifloxacin 400 mg IV infusion solution
11569236|NCT00865267|Experimental|A|Ultravate® 0.05% ointment, single exposure
11569237|NCT00865254|Experimental|Traditional Contingency Management|Standard treatment plus prize based contingency management.
11569238|NCT00865254|Experimental|Early Enhanced Contingency Management|Prize based contingency management with enhanced magnitude early in treatment and reduced magnitude later in treatment.
11569239|NCT00865254|Active Comparator|Standard Treatment|Counseling and monitoring of smoking cessation.
11569240|NCT00865241|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
11569241|NCT00865241|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
11569242|NCT00865228|Experimental|Lapaquistat Acetate 100 mg QD (morning)|
11569243|NCT00865228|Experimental|Lapaquistat Acetate 100 mg QD (evening)|
11569244|NCT00865228|Experimental|Lapaquistat Acetate 50 mg BID|
11569245|NCT00865228|Placebo Comparator|Placebo BID|
11569246|NCT00865215|Experimental|A|Propranolol Hydrochloride Extended Release Capsules 160 mg, single dose
11569247|NCT00865215|Active Comparator|B|INDERAL® LA 160 mg Capsules, single dose
11569248|NCT00865202|Experimental|L-Tryptophan|L-tryptophan supplementation (1 gram enterally three times per day) starting post-operatively and continuing for a maximum of 9 doses or the time of discharge from ICU (whichever occurs first)
11569249|NCT00865202|Placebo Comparator|Placebo|Similar appearing placebo administered post-operatively (1 enterally three times per day) for a total of nine doses or discharge from ICU (whichever occurs first)
11569303|NCT00864825|Experimental|Allopurinol|
11569304|NCT00864825|Placebo Comparator|Placebo|
11569305|NCT00864812|Experimental|1|tiotropium with fluticasone propionate/salmeterol (FSC)
11569306|NCT00864812|Active Comparator|2|tiotropium
11569361|NCT00864448|Active Comparator|B|Atlace® 10 mg capsules, single dose
11569362|NCT00864435|Experimental|A|Carvedilol 12.5 mg Tablets, single dose
11569250|NCT00865189|Experimental|Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)|In this arm, participants will undergo 3 phases of treatment. During the Phase 1, participants will receive induction chemotherapy with 6 two-week cycles of bevacizumab + Folfox-4 (5-FU + oxaliplatin + folinic acid) for 12 weeks followed by a treatment-free interval of 3 to 4 weeks. The Phase 2 will include 7 weeks of bevacizumab + chemoradiotherapy (intravenous [IV] infusion of bevacizumab alone, 2 weeks before administration of the first cycle of chemoradiotherapy, then 5 one-week cycles of chemoradiotherapy [5-FU + radiotherapy], with administration of bevacizumab every two weeks [Cycles 1, 3 and 5]) followed by a treatment-free interval of 6 to 8 weeks. The Phase 3 will be surgery involving a radical rectal excision using the total mesorectal excision (TME) technique.
11569251|NCT00865189|Experimental|Arm B (Bevacizumab, Chemoradiotherapy)|In this arm, participants will receive the Phase 2 and Phase 3 treatments only. The phase 2 will include 7 weeks of bevacizumab + chemoradiotherapy (IV infusion of bevacizumab alone, 2 weeks before administration of the first cycle of chemoradiotherapy, then 5 one-week cycles of chemoradiotherapy [5-FU + radiotherapy], with administration of bevacizumab every two weeks [Cycles 1, 3 and 5]) followed by a treatment-free interval of 6 to 8 weeks. The phase 3 will be surgery involving a radical rectal excision using the TME technique.
11569252|NCT00865176|Experimental|1|Eplerenone 50mg Tablets
11569253|NCT00865176|Active Comparator|2|INSPRA 50mg Tablets
11569254|NCT00865137|Experimental|1 FK506E|
11569255|NCT00865124|Experimental|Spironolactone (mineralocorticoid receptor [MR] blockade)|
11569256|NCT00865124|Active Comparator|Hydrochlorothiazide + potassium|
11569257|NCT00865124|Placebo Comparator|Placebo capsule|
11569258|NCT00865111|Experimental|A|Bupropion 150 mg Extended-Released Tablet, single dose
11569259|NCT00865111|Active Comparator|B|Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
11569260|NCT00865098|Experimental|Cetuximab With Radiotherapy|
11569261|NCT00865085|Experimental|A|Citalopram HBr 40 mg tablets, single dose
11569262|NCT00865085|Active Comparator|B|CelexaTM 40 mg tablets, single dose
11569263|NCT00865072|Experimental|A|Metformin HCl 750 mg Extender Release tablets, single dose
11569264|NCT00865072|Active Comparator|B|GLUCOPHAGE® XR 750 mg tablets, single dose
11569265|NCT00865059|Experimental|A|Gabapentin 800 mg Tablets, single dose
11569266|NCT00865059|Active Comparator|B|NEURONTIN® 800 mg Tablets, single dose
11569267|NCT00865046|Experimental|PST + PST boosters|PST once a week for 10 weeks, then tapering over 6 months
11569268|NCT00865046|Active Comparator|PST + control-PST boosters|PST once a week for 10 weeks, then control-PST tapering over 6 months
11569269|NCT00865046|Placebo Comparator|Control-PST|control-PST for 10 weeks
11569270|NCT00865033|Experimental|1|Metformin HCL Tablets, 1000 mg
11569271|NCT00865033|Active Comparator|2|Glucophage 1000 mg Tablets
11569272|NCT00865020|Experimental|Aliskiren 300 mg|Aliskiren tablets starting at a dose of 150 mg taken orally daily for 2 weeks followed by a dose of 300 mg taken orally for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Aliskiren: 1 tablet for the first 2 weeks and 2 tablets during the one week withdrawal period.
11569273|NCT00865020|Active Comparator|Telmisartan 80 mg|Telmisartan capsules starting at a dose of 40 mg taken orally daily for 2 weeks followed by a dose of 80 mg taken orally daily for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Telmisartan: 1 capsule for the first 2 weeks and 2 capsules during the one week withdrawal period.
11569274|NCT00865007|Experimental|Monotherapy group|Lopinavir/ritonavir (LPV/r).
11569275|NCT00865007|Active Comparator|Triple arm|Lopinavir/ritonavir (LPV/r)+ ABC/3TC
11569276|NCT00864994||1|• 30 healthy subjects with 20 pack years smoking who have no signs of COPD (age 40-75 years)
11569277|NCT00864994||2|• 30 COPD patients with GOLD stage II (age 40-75 years)
11569278|NCT00864981|Experimental|1|Bupropion HCI ER Tablets, 150 mg
11569279|NCT00864981|Active Comparator|2|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg
11569280|NCT00864968|Experimental|A|Nabumetone 750 mg tablets, single dose
11569281|NCT00864968|Active Comparator|B|Nabumetone 750 mg tablets, single dose
11569282|NCT00864955|Experimental|phototype 2|Volunteers with cutaneous phototype 2
11569283|NCT00864955|Experimental|phototype 4|Volunteers with cutaneous phototype 4
11569284|NCT00864942|Experimental|BL-NHL|Bendamustine and lenalidomide for NHL
11569285|NCT00864942|Experimental|BLR-CLL|Bendamustine, lenalidomide, rituximab for CLL
11569286|NCT00864942|Experimental|BLR-NHL|Bendamustine, lenalidomide, and rituximab for NHL
11569287|NCT00864942|Experimental|BL-CLL|bendamustine and lenalidomide in patients with CLL
11569288|NCT00864929||1|Appropriate antimicrobial treatment
11569289|NCT00864929||2|Inappropriate antimicrobial treatment
11569290|NCT00864916|Experimental|1|Participants will receive pentoxifylline and combination antiretroviral therapy (cART).
11569291|NCT00864916|Active Comparator|2|Participants will receive placebo and cART.
11569292|NCT00864903||pediatric ER|any child undergoing a spinal tap due to suspected meningitis
11569293|NCT00864890|Experimental|A|Citalopram HBr 40 mg tablets, single dose
11569294|NCT00864890|Active Comparator|B|CelexaTM 40 mg tablets, single dose
11569295|NCT00864864|Experimental|Sunitinib|
11569296|NCT00864851|Active Comparator|Replagal 0.2 mg/kg, IV, every other week|Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every other week for 52 weeks.
11569297|NCT00864851|Active Comparator|Replagal 0.2 mg/kg, IV, weekly|Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every week for 52 weeks.
11569298|NCT00864851|Active Comparator|Replagal 0.4 mg/kg, IV, weekly|Patients randomized to receive Replagal 0.4 mg/kg via intravenous infusion every week for 52 weeks.
11569299|NCT00864838|No Intervention|1|Patients submitted to 1,5 mg/0,06 ml intravitreal injection of bevacizumab and no treatment for intraocular pressure elevation
11569300|NCT00864838|Experimental|2|Acetazolamide: 250 mg of oral acetazolamide 1 hour before intravitreal bevacizumab injection
11569301|NCT00864838|Experimental|3|topic brimonidine tartarate: one drop of brimonidine tartarate 1 hour before intravitreal bevacizumab injection
11569302|NCT00864838|Experimental|4|anterior chamber paracentesis: anterior chamber paracentesis immediately after intravitreal bevacizumab
11569307|NCT00864799|Active Comparator|Vaginal misoprostol|"Women allocated to the vaginal misoprostol management protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 4 hours by 400 mcg vaginal misoprostol, the latter repeated every 4 hours for a maximum of 4 doses.
~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.
~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
11569308|NCT00864799|Active Comparator|Oral misoprostol|"Women allocated to the standard management protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 3 hours by 400 mcg misoprostol orally, the latter repeated every 3-hours to a maximum of 4 oral doses.
~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.
~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
11569309|NCT00864799|Active Comparator|Sublingual misoprostol|"Women allocated to the sublingual misoprostol protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 3 hours by 400 mcg sublingual misoprostol, the latter repeated every 3 hours for a maximum of 4 doses.
~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.
~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
11569310|NCT00864786|Experimental|Cohort 1|200 mcg
11569311|NCT00864786|Experimental|Cohort 2|600 mcg
11569312|NCT00864786|Experimental|Cohort 3|1000 mcg
11569313|NCT00864786|Experimental|Cohort 4|Dose to be decided
11569314|NCT00864786|Experimental|Cohort 5|Dose to be decided
11569315|NCT00864760|Experimental|A|Gabapentin 800 mg tablets, single dose (1 tablet)
11569316|NCT00864760|Active Comparator|B|NEURONTIN® 400 mg capsules, single dose (2 capsules)
11569317|NCT00864747|Experimental|A|Propranolol Hydrochloride Extended Release Capsules 160 mg, single dose
11569318|NCT00864747|Active Comparator|B|INDERAL® LA 160 mg Capsules, single dose
11569319|NCT00864734|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
11569320|NCT00864734|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
11569321|NCT00864721|Experimental|Sunitinib Malate|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
11569322|NCT00864708|Experimental|Arm 1|radio frequency-controlled (RF) Microstimulator (RFM) Gait System
11569323|NCT00864695||Surgical patients|Individuals who were hospitalized in the Botucatu Medical School Hospital to undergo surgery under anesthesia administered by the Anesthesiology Service of BMS Department of Anesthesiology.
11569324|NCT00864682|Placebo Comparator|Placebo|Saline pretreatment, saline admixture
11569325|NCT00864682|Active Comparator|Lidocaine pretreatment|Lidocaine pretreatment / saline-propofol admixture
11569326|NCT00864682|Active Comparator|Lidocaine-Propofol admixture|saline pretreatment / Lidocaine-propofol admixture
11569327|NCT00864669|Experimental|A|Metformin HCl 500 mg tablets, single dose
11569328|NCT00864669|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
11569329|NCT00864656||1|Patients submitted to application of 1 drop of 10% phenylephrine
11569330|NCT00864656||2|Patients submitted to application of 2 drops of 10% phenylephrine
11569331|NCT00864656||3|Patients submitted to application of 4 drops of 10% phenylephrine
11569332|NCT00864643|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin QD|
11569333|NCT00864643|Active Comparator|Atorvastatin QD|
11569334|NCT00864630|No Intervention|Wait list|
11569335|NCT00864630|Experimental|Computer-based problem solving therapy|
11569336|NCT00864617|Experimental|A|Nifedipine Extended Release tablets 60 mg, single dose
11569337|NCT00864617|Active Comparator|B|ADALAT® CC Extended Release Tablets 60 mg
11569338|NCT00864604|Experimental|A|Nabumetone 750 mg tablets, single dose
11569339|NCT00864604|Active Comparator|B|Nabumetone 750 mg tablets, single dose
11569340|NCT00864591||SPECT and stress CMR patients|"patients undergoing SPECT stress imaging, for the evaluation of myocardial ischemia.
~The study group will include patients with either normal undergoing SPECT stress imaging or with mild to severe ischemia, to include the entire spectrum of coronary artery disease.
~Patients will be pre selected and evaluated by a non-dependent cardiologist in order to verify that patients in whom the repeat stress might pose a serious risk will be excluded from the study."
11569341|NCT00864565|Experimental|A|Fentanyl 25 μg/h transdermal system, single application
11569342|NCT00864565|Active Comparator|B|Duragesic 25 μg/h transdermal system single application
11569343|NCT00864552||Group 1|
11569344|NCT00864539|Experimental|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 mL
11569345|NCT00864539|Active Comparator|plain milk|daily intake of 200 mL plain milk
11569346|NCT00864539|Experimental|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium
11569347|NCT00864539|Active Comparator|plane juice|subjects receiving plain orange juice
11569348|NCT00864539|Experimental|vitamin D-Ca supplement|Subjects receiving daily supplement containing 500 mg + 200 IU vitamin D
11569349|NCT00864539|Placebo Comparator|Placebo|Subjects receiving daily placebo containing 1g starch
11569350|NCT00864526|Experimental|A|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
11569351|NCT00864526|Active Comparator|B|COMBONOX® tablets, single dose
11569352|NCT00864513|Experimental|chemotherapy|pemetrexed
11569353|NCT00864500|Experimental|A|Clobetasol Propionate 0.05% lotion, single exposure
11569354|NCT00864500|Active Comparator|B|Clobex TM 0.05% Lotion, single exposure
11569355|NCT00864487|Experimental|1|Neratinib alone
11569356|NCT00864487|Experimental|2|Neratinib plus rifampin
11569357|NCT00864474||Maraviroc Tablets|Patients administered.
11569358|NCT00864461||Case|Patients with clinical and cytogenetics diagnosis of Down syndrome, between 7 - 24 years old.
11569363|NCT00864435|Active Comparator|B|Coreg® 12.5 mg Tablets , single dose
11569364|NCT00864422|Experimental|1|
11569365|NCT00864422|Active Comparator|2|
11569366|NCT00864409|Active Comparator|Hip 1|high volume local anesthetic infiltration
11569367|NCT00864409|Placebo Comparator|Hip 2|
11569368|NCT00864396|Experimental|Prevacid|
11569369|NCT00864383|Placebo Comparator|Regimen 1 - 2EHRZ/4HR (control regimen)|"Eight weeks of chemotherapy with Ethambutol, Isoniazid, Rifampicin and Pyrazinamide plus the Moxifloxacin placebo, followed by
~Nine weeks of Isoniazid and Rifampicin plus the Moxifloxacin placebo, followed by
~Nine weeks of Isoniazid and Rifampicin only."
11569370|NCT00864383|Experimental|Regimen 2 - 2MHRZ/2MHR|"Eight weeks of chemotherapy with Moxifloxacin, Isoniazid, Rifampicin and Pyrazinamide plus the Ethambutol placebo, followed by
~Nine weeks of Moxifloxacin, Isoniazid and Rifampicin, followed by
~Nine weeks of the Isoniazid placebo and the Rifampicin placebo."
11569371|NCT00864383|Experimental|Regimen 3 - 2EMRZ/2MR|"Eight weeks of chemotherapy with Ethambutol, Moxifloxacin, Rifampicin and Pyrazinamide plus the Isoniazid placebo, followed by
~Nine weeks of Moxifloxacin and Rifampicin plus the Isoniazid placebo, followed by
~Nine weeks of the Isoniazid placebo and the Rifampicin placebo"
11569372|NCT00864357|Experimental|A|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
11569373|NCT00864357|Active Comparator|B|COMBONOX® tablets, single dose
11569374|NCT00864344|Experimental|A|Sertraline HCl 100 mg tablets, single dose
11569375|NCT00864344|Active Comparator|B|Zoloft® 100 mg tablets, single dose
11569376|NCT00864331|Active Comparator|Radiotherapy|For patients in Group A (Stage IIIA or IIIB), EBRT 39 Gy in 13 daily fractions over, with no chemotherapy.
11569377|NCT00864331|Experimental|Chemotherapy and radiotherapy|For patients in Group A (either stage IIIA or IIIB) receive a course of up to 3 cycles of chemotherapy followed by EBRT of 10 Gy in a single fraction or 16 Gy in 2 fractions 1 week apart.
11569378|NCT00864331|Active Comparator|Chemotherapy|For patients in Group B (either stage IIIB (wet) or IV) receive up to 3 cycles of chemotherapy, and no radiotherapy.
11569379|NCT00864331|Experimental|Palliative radiotherapy and chemotherapy|For patients in Group B (either stage IIIB (wet) or IV) receive EBRT of 10 Gy in a single fraction or 16 Gy in two fractions 1 week apart, followed by up to 3 cycles of chemotherapy.
11569380|NCT00864305|Experimental|A|Gabapentin 400 mg capsules
11569381|NCT00864305|Active Comparator|B|Neurontin 400 mg capsules
11569382|NCT00864292||HIV-infected, no dementia|Patients with HIV-infection but no dementia
11569383|NCT00864292||HIV-infected, dementia|Patients with HIV-infection and dementia
11569384|NCT00864279|Experimental|A|Cetirizine Hydrochloride 10 mg tablets, single dose
11569385|NCT00864279|Active Comparator|B|Zyrtec® 10 mg tablets, single dose
11569386|NCT00864266|Experimental|1|After obtaining the biopsy, patients will be treated by standard chemotherapy (the regimen has to be in agreement with the ELCWP guidelines, available on the website www.elcwp.org)
11569387|NCT00864253|Experimental|ABI-007|Treatment Arm A (ABI-007): Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
11569388|NCT00864253|Active Comparator|Dacarbazine|Treatment Arm B (dacarbazine): Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
11569389|NCT00864240|Experimental|A|Clobex TM 0.05% Lotion, single exposure
11569390|NCT00864227|Experimental|Umbilical Cord Blood Transplantation|Participants will receive a double unit Hematopoietic Umbilical Cord Blood Stem Cell Transplantation using a non-myeloablative preparative regimen, GVHD prophylaxis.
11569391|NCT00864214|Experimental|1|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
11569392|NCT00864214|Experimental|2|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
11569393|NCT00864214|Experimental|3|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
11569394|NCT00864214|Experimental|4|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
11569395|NCT00864201|Experimental|bosentan|
11569396|NCT00864188|Placebo Comparator|1|Glucono-Delta-Lactone acidified milk containing no bacterial strains
11569397|NCT00864188|Experimental|2|Glucono-Delta-Lactone acidified milk containing one probiotic strain called Lactobacillus paracasei NCC2461.
11569398|NCT00864188|Placebo Comparator|3|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii subsp.bulgaricus.
11569399|NCT00864188|Experimental|4|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii and one probiotic strain called Lactobacillus paracasei NCC2461.
11569400|NCT00864188|Experimental|5|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii, one probiotic strain called Lactobacillus paracasei NCC2461 and Vitamin B2,B3, C and E, Beta Carotene and an Oil.
11569401|NCT00864175|Experimental|Treatment A - INCB007839 and Trastuzumab|"INCB007839 100 mg BID and trastuzumab
~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
11569402|NCT00864175|Experimental|Treatment B - INCB007839 and Trastuzumab|"INCB007839 200 mg BID and trastuzumab
~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
11569403|NCT00864175|Experimental|Treatment C - INCB007839 and Trastuzumab|"INCB007839 300 mg BID and trastuzumab
~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
11569404|NCT00864175|Experimental|Treatment D - INCB007839 and Docetaxel|INCB007839 300mg BID with docetaxel
11569405|NCT00864162|Experimental|A|Ramipril10 mg Capsules, single dose
11569406|NCT00864162|Active Comparator|B|Atlace® 10 mg capsules, single dose
11569407|NCT00864149|Experimental|A|Carvedilol 12.5 mg Tablets, single dose
11569408|NCT00864149|Active Comparator|B|Coreg® 12.5 mg Tablets , single dose
11569409|NCT00864136||Group 1|
11569410|NCT00864136||Group 2|
11569411|NCT00864136||Group 3|
11569412|NCT00864123|Active Comparator|Cognitive-behavioral therapy + placebo|Involves receiving cognitive-behavioral treatment of OCD symptoms for 10 sessions. One hour prior to sessions 4-10, the child will take either 1 or 2 pills containing 25mg of placebo. The number of pills depends on the child's weight (e.g., about 46kgs takes 2 capsules).
11569413|NCT00864123|Experimental|Cognitive-behavioral therapy + D-cycloserine|Involves receiving cognitive-behavioral treatment of OCD symptoms for 10 sessions. One hour prior to sessions 4-10, the child will take either 1 or 2 pills containing 25mg of D-cycloserine. The number of pills depends on the child's weight (e.g., about 46kgs takes 2 capsules).
11569414|NCT00864110|Experimental|99mTc EC-DG|99mTc-EC-DG with SPECT/CT imaging
11569415|NCT00864110|Active Comparator|18F FDG|18F FDG with PET/CT imaging
11569416|NCT00864097|Experimental|Tanezumab 10 mg + diclofenac|IV tanezumab 10 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
11569417|NCT00864097|Experimental|Tanezumab 5 mg + diclofenac|IV tanezumab 5 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
11569418|NCT00864097|Experimental|Tanezumab 2.5 mg + diclofenac|IV tanezumab 2.5 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
11569419|NCT00864097|Placebo Comparator|IV placebo + diclofenac|IV placebo to match tanezumab every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
11569420|NCT00864084|Experimental|Pulmonary rehabilitation|People with respiratory disease
11569421|NCT00864071|Experimental|A|Griseofulvin 125 mg/5 mL Suspension, single dose
11569422|NCT00864071|Active Comparator|B|Grifulvin V® 125 mg/5 mL Suspension, single dose
11569423|NCT00864058|Experimental|A|Gabapentin 400 mg capsules
11569424|NCT00864058|Active Comparator|B|Neurontin 400 mg capsules
11569425|NCT00864045|Experimental|Sertindole|
11569426|NCT00864045|Active Comparator|Olanzapine|
11569427|NCT00864032|Experimental|Phase I|
11569428|NCT00864019|Experimental|A|Sertraline HCl 100 mg tablets, single dose
11569429|NCT00864019|Active Comparator|B|Zoloft® 100 mg tablets, single dose
11569430|NCT00864006|Experimental|1|Divalproex Sodium 125 MG Delayed Release Tablets Sandoz
11569431|NCT00864006|Active Comparator|2|Depakote 125 MG DR Tablets Abbott Laboratories USA
11569432|NCT00863980|Experimental|Telmisartan|Treatment with Telmisartan
11569433|NCT00863980|Active Comparator|Candesartan|Treatment with Candesartan
11569434|NCT00863967||1|no cardiovascular events
11569435|NCT00863967||2|proven cardiovascular events
11569436|NCT00863967||3|possible cardiovascular events
11569437|NCT00863954|Active Comparator|Output A|
11569438|NCT00863954|Active Comparator|Output B|
11569439|NCT00863954|Active Comparator|Output C|
11569440|NCT00863954|Active Comparator|Output D|
11569441|NCT00863954|Active Comparator|Output E|
11569442|NCT00863954|Active Comparator|Output F|
11569443|NCT00863941|Experimental|A|Abrika Bupropion 150 mg XL Tablet, single dose
11569444|NCT00863941|Active Comparator|B|Wellbutrin XL® 150 mg Tablet, single dose
11569445|NCT00863928|No Intervention|Control Arm|No suppository given
11569446|NCT00863928|Experimental|B & O suppository|B & O suppository, belladonna 16.2 mg and opium 60 mg suppository (Paddock Laboratories, Minneapolis, MN)
11569447|NCT00863915|Experimental|A|Ramipril10 mg Capsules, single dose
11569448|NCT00863915|Active Comparator|B|Atlace® 10 mg capsules, single dose
11569449|NCT00863902|Experimental|Cetirizine Hydrochloride|Cetirizine Hydrochloride 10 mg tablets, single dose
11569450|NCT00863902|Active Comparator|Zyrtec|Zyrtec® 10 mg tablets, single dose
11569451|NCT00863889|Experimental|1|1cc Depomedrol, 4 cc 1% Lidocaine, 4 cc 0.25% Marcaine
11569452|NCT00863889|Placebo Comparator|2|4 cc 1% Lidocaine, 4 cc 0.25% Marcaine
11569453|NCT00863876||1|non-operated healthy eyes
11569454|NCT00863876||2|eyes 1 months following LASIK
11569455|NCT00863876||3|eyes 3-6 months following LASIK
11569456|NCT00863876||4|eyes with spherical monofocal IOLs more than 3 months postop
11569457|NCT00863876||5|eyes with aspherical monofocal IOLs more than 3 months postop
11569458|NCT00863876||6|eyes with toric monofocal IOLs more than 3 months postop
11569459|NCT00863876||7|eyes with diffractive multifocal IOLs more than 3 months postop
11569460|NCT00863876||8|eyes with phakic IOLs more than 3 months postop
11569461|NCT00863876||9|eyes with keratoconus
11569462|NCT00863863|Experimental|A|Griseofulvin 125 mg/5 mL Suspension, single dose
11569463|NCT00863863|Active Comparator|B|Grifulvin V® 125 mg/5 mL Suspension, single dose
11569464|NCT00863850|Experimental|1|
11569465|NCT00863837|Active Comparator|Arm A|add pantoloc to reduce ulcer bleeding after banding ligation
11569466|NCT00863837|Placebo Comparator|Arm B: ligation + terlipressin 1mg q6h|Arm B, intervention: ligation + terlipressin 1mg q6h
11569467|NCT00863811||2|POAG patients with IOP under control by prostaglandins eye drops treatment and assuming two tablets per day of the food supplement KRONEK
11569468|NCT00863811||1|POAG patients compensated by the treatment of betablockers eye drops and taking two tablets per day of KRONEK
11569469|NCT00863798|Experimental|Desvenlafaxine succinate sustained release 10 mg|
11569470|NCT00863798|Experimental|Desvenlafaxine succinate sustained release 50 mg|
11569471|NCT00863798|Placebo Comparator|Placebo|
11569472|NCT00863785|Experimental|Corticoids plus N Acetyl Cysteine|40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
11569473|NCT00863772|Experimental|Tanezumab 5 mg|
11569474|NCT00863772|Experimental|Tanezumab 10 mg|
11569475|NCT00863772|Placebo Comparator|Placebo|
11569476|NCT00863759|Active Comparator|1|Patients will receive an aspheric intraocular lenses (IOL) Akreos AO in the right eye and an spheric IOL Akreos Fit in the left eye, during cataract surgery.
11569477|NCT00863759|Active Comparator|2|Patients will receive an spheric intraocular lens (IOL) Akreos Fit in the right eye and an aspheric IOL Akreos AO in the left eye, during cataract surgery.
11569478|NCT00863746|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (BID)
11569479|NCT00863746|Placebo Comparator|Placebo|Participants received 2 tablets of placebo orally twice daily (BID)
11569480|NCT00863707|Placebo Comparator|Placebo|Matching intravenous (IV) bolus injection
11569481|NCT00863707|Experimental|Regadenoson|0.4 mg/5 mL intravenous bolus injection
11569482|NCT00863681|Experimental|Arm 1|
11569483|NCT00863668|Active Comparator|Efavirenz|
11569484|NCT00863668|Experimental|Raltegravir|
11569485|NCT00863655|Experimental|Everolimus + Exemestane|Everolimus 10 mg daily in combination with exemestane 25 mg daily
11569486|NCT00863655|Active Comparator|Placebo + Exemestane|Placebo of everolimus in combination with exemestane 25 mg daily
11569487|NCT00863642|Experimental|Early|In patients who present with mild to moderate gallstone pancreatitis, those randomized to the early arm will undergo laparoscopic cholecystectomy within 48 hours of admission, regardless of laboratory values normalization and resolution of abdominal pain.
11569488|NCT00863642|Other|Control|In patients in the control arm, laparoscopic cholecystectomy is delayed until laboratory values normalize and abdominal pain resolves.
11569489|NCT00863629|No Intervention|1|25 normoglycemic patients as control group
11569490|NCT00863629|Active Comparator|2|20 hyperglycemic patients (glucose >140 mg/dl) randomized to conventional glycemic control by insulin (CGC group; glucose goal 180-200 mg/dl)
11569491|NCT00863629|Experimental|3|20 hyperglycemic patients (glucose >140 mg/dl) were randomized to intensive glycemic control by insunin (IGC group; glucose goal 80-140 mg/dl)
11569492|NCT00863616|Experimental|HFCWO|HFCWO twice a day delivered by SmartVest device at 13Hz FOR 20min x2. Duration 4 weeks in each phase with a 2week washout.
11569493|NCT00863616|No Intervention|Placebo/Control|Self-administered breathing exercises
11569494|NCT00863603|No Intervention|1|No exposure to supplemental oxygen
11569495|NCT00863603|Other|Oxygen, treatment, supplement|6 weeks of supplemental oxygen delivered by nasal cannula post hemodialysis graft placement
11569496|NCT00863590|Experimental|A|Panel A
11569497|NCT00863590|Experimental|B|Panel B
11569498|NCT00863590|Experimental|C|Panel C
11569499|NCT00863590|Experimental|D|Panel D
11569500|NCT00863564|Active Comparator|Whey Isolate|
11569501|NCT00863564|Active Comparator|Caseine|
11569502|NCT00863564|Active Comparator|Cod|
11569503|NCT00863564|Active Comparator|Gluten|
11569504|NCT00863551|Experimental|Trospium Chloride Extended Release, 60 mg|Trospium Chloride Extended Release, 60 mg
11569505|NCT00863538|Experimental|1|
11569506|NCT00863525|Experimental|1|Odanacatib
11569507|NCT00863525|Placebo Comparator|2|Placebo
11569508|NCT00863512|Experimental|Arm I|Patients receive cisplatin IV on day 1 and vinorelbine ditartrate IV on days 1 and 8 OR docetaxel IV and cytarabine IV on day 1 OR gemcitabine hydrochloride IV on days 1 and 8 and cytarabine IV on day 1 OR pemetrexed disodium IV and cisplatin IV on day 1.. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11569509|NCT00863512|Experimental|Arm II|Patients receive standard care (observation).
11569510|NCT00863499|Active Comparator|A|Short Acting methylphenidate
11569511|NCT00863499|Active Comparator|B|Long Acting Methylphenidate
11569512|NCT00863499|No Intervention|C|Healthy Controls
11569513|NCT00863473|No Intervention|Conservative /Physiotherapy|Active training protocol with instructed physiotherapy and self excercises
11569514|NCT00863473|Active Comparator|Surgery with LCP T plate|Surgical treatment with interlocking plate
11569515|NCT00863460|Active Comparator|A|MTX-based chemotherapy followed by WBRT
11569516|NCT00863460|Experimental|B|MTX-based chemotherapy followed by intensive chemotherapy and hematopoietic stem cell rescue
11569517|NCT00863434|Experimental|Treatment (colony stimulating factor and chemotherapy)|Patients receive G-CSF SC QD on days 1-5 and clofarabine IV over 1 hour and cytarabine IV on days 2-5. Beginning approximately 1 month later, patients may receive one additional course of treatment in the absence of disease progression or unacceptable toxicity.
11569518|NCT00863395|Experimental|Skin Biopsy|
11569519|NCT00863382|Active Comparator|1|Standard Event Monitor
11569520|NCT00863382|Active Comparator|2|Sleuth recorder
11569521|NCT00863369|Experimental|Treatment (bortezomib, gemcitabine hydrochloride, rituximab)|Patients receive bortezomib IV, gemcitabine hydrochloride IV over 3-4 hours, and rituximab IV on days 1 and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
11569522|NCT00863356|Experimental|Epistaxis Group|"Subjects presenting with epistaxis that have not been controlled by traditional nasal packing, or that recurred immediately upon removal of the nasal packing will be included in this study. Subject will be evaluated during the packing period to determine the effect of hemostasis. Chitosan coated packing will be removed after 48 hours. Subjects' nasal cavities will be examined endoscopically to evaluate bleeding control, morphological changes induced by the chitosan coated packing.
~One week after the removal of the packing, the patients will be endoscopically examined to assess the healing of the packed area, to monitor control of bleeding, and observe any potential delayed reaction to the packing material."
11569523|NCT00863343||All|Anyone presenting with influenza-like-illness
11569524|NCT00863330|Experimental|Determine toxicity of treatment regimen.|
11569525|NCT00863317|Experimental|montelukast sodium|4mg granules PO QD for 14 days
11569526|NCT00863317|Placebo Comparator|Placebo|Sucrose granules PO QD for 14 days
11569527|NCT00863304|Experimental|1|
11569528|NCT00863304|Experimental|2|
11569529|NCT00863304|Active Comparator|3|
11569530|NCT00863304|Placebo Comparator|4|
11569531|NCT00863291|Active Comparator|1|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
11569532|NCT00863291|Placebo Comparator|2|Placebo given in a manner similar to he active comparator
11569533|NCT00863278|Active Comparator|Arm A|"All patients will be treated by stabilized Kligman's trio with daily application during 4 months.
~After one month, the left side of the face will be treated with pulsed dye laser at the rate of 3 sessions (one every weeks).
~Applications of cream will be stopped on both side of the face for the 3 days following each laser session. Final visit will be scheduled 1 month after the end of applications of stabilized Kligman's trio.
~All the patients will used a sunscreen indication 50 + for the duration of the entire study.
~The patient is her own witness. They compare the hemiface treated without laser and the hemiface treated with the laser."
11569534|NCT00863278|Active Comparator|Arm B|"All patients will be treated by stabilized Kligman's trio at the rate of application in the evening during 4 months.
~After one month, the side of the right face will be treated by pulsed dye laser at the rase of 3 sessions spaced out by 3 weeks each.
~Applications will be stopped in the 3 days which will follow every session by laser with blown colouring agent. The patients will be seen again 1 month after the stopping of applications of stabilized Kligman's trio
~All patients will be used a sunscreen indication 50 + for the duration of study.
~The patient is her own witness. They compare the cheek treated without laser and the cheek treated with the laser."
11569535|NCT00863265|Experimental|Crossover order ABC|The order of treatments is A (phytosterols + ezetimibe), B (double placebo), and C (active ezetimibe and phytosterol placebo).
11569536|NCT00863265|Experimental|Crossover order BCA|The order of treatments is B (double placebo), C (active ezetimibe and phytosterol placebo), and A (phytosterols + ezetimibe).
11569537|NCT00863265|Experimental|Crossover order BAC|The order of treatments is B (double placebo), A (phytosterols + ezetimibe), and C (active ezetimibe and phytosterol placebo)
11569538|NCT00863265|Experimental|Crossover order ACB|The order of treatments is A (phytosterols + ezetimibe), C (active ezetimibe and placebo phytosterols, and B (double placebo).
11569539|NCT00863265|Experimental|Crossover order CAB|The order of treatments is C (active ezetimibe and placebo phytosterols), A (phytosterols + ezetimibe), and B (double placebo).
11569540|NCT00863265|Experimental|Crossover order CBA|The order of treatments is C (active ezetimibe and placebo phytosterols), B (double placebo), and A (phytosterols and ezetimibe).
11569541|NCT00863252|Experimental|1|MMF
11569542|NCT00863252|Active Comparator|2|Control
11569543|NCT00863239|Experimental|1|Locteron™ (controlled-release interferon alpha 2b) 320 µg as biweekly subcutaneous injection
11569544|NCT00863239|Experimental|2|Locteron™ (controlled-release interferon alpha 2b) 480 µg as biweekly subcutaneous injection
11569545|NCT00863239|Experimental|3|Locteron™ (controlled-release interferon alpha 2b) 640 µg as biweekly subcutaneous injection
11569546|NCT00863239|Active Comparator|4|PEG-Intron™ (12 kDalton pegylated interferon alpha 2b) 1.5 µg/kg body weight weekly subcutaneous injection
11569547|NCT00863213|Experimental|Atrial Fibrillation Ablation|
11569548|NCT00863213|Active Comparator|Drug therapy|
11569549|NCT00863200||Telephone Intervention Group|
11569550|NCT00863200||Standard Care Group|
11569551|NCT00863187|Experimental|rituximab|b cell depletion drug
11569552|NCT00863174|Experimental|1|SPARC147709
11569553|NCT00863174|Active Comparator|2|Reference147709
11569554|NCT00863161|Experimental|1|AZD3355 65 + 65 mg capsule
11569555|NCT00863135|Experimental|Continuous Positive Airway Pressure|nocturnal continuous positive airways pressure
11569556|NCT00863135|Other|Control|Waiting list,3 months without any change in their treatment, come into the CPAP procedure after that time
11569557|NCT00863122|Experimental|lapatinib|Subjects will receive lapatinib for 10 days prior to surgery for vestibular schwannoma resection.
11569558|NCT00863122|No Intervention|control|Control subjects will not receive any intervention prior to surgery for vestibular schwannoma resection.
11569559|NCT00863109||PEG + RBV (Standard Clinical Practice)|Participants receive peginterferon alfa-2b (PEG) and ribavirin (RBV) in combination therapy for 48 weeks according to standard clinical practice followed by 24 weeks of observation.
11569560|NCT00863096||Gardasil|
11569561|NCT00863083|Active Comparator|1|Multifamily group weight management intervention plus rewards for program attendance
11569562|NCT00863083|Active Comparator|2|Multifamily group weight management intervention plus rewards for attendance and goal attainment
11569563|NCT00863070||Bladder Exstrophy Patients|Patients who receive follow-up care at Connecticut CMC urology clinic for bladder exstrophy.
11569564|NCT00863057|Experimental|1|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine and methadone placebo, (Period 2, Weeks 6 to 9) duloxetine placebo and methadone, (Period 3, Weeks 11 to 14) duloxetine and methadone, (Period 4, Weeks 16 to 19) duloxetine placebo and methadone placebo
11569565|NCT00863057|Experimental|2|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine placebo and methadone, (Period 2, Weeks 6 to 9) duloxetine placebo and methadone placebo, (Period 3, Weeks 11 to 14) duloxetine and methadone placebo, (Period 4, Weeks 16 to 19) duloxetine and methadone
11569566|NCT00863057|Experimental|3|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine and methadone, (Period 2, Weeks 6 to 9) duloxetine and methadone placebo, (Period 3, Weeks 11 to 14) duloxetine placebo and methadone placebo, (Period 4, Weeks 16 to 19) duloxetine placebo and methadone
11569567|NCT00863057|Experimental|4|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine placebo and methadone placebo, (Period 2, Weeks 6 to 9) duloxetine and methadone, (Period 3, Weeks 11 to 14) duloxetine placebo and methadone, (Period 4, Weeks 16 to 19) duloxetine and methadone placebo
11569568|NCT00863044|Active Comparator|High frequency ventilation|high frequency ventilation
11569569|NCT00863044|Placebo Comparator|Apnea|lung ventilation will be stopped during distal anastomosis as is commonly done
11569570|NCT00863031|Experimental|problem-solving therapy|Three sessions of brief problem-solving counselling at week 1, 3 and 5 by a family doctor.
11569571|NCT00863031|Placebo Comparator|viewing video|Three sessions of health education viewing video in groups of 3 to 5 people
11569572|NCT00863018||Control|Eyes with glaucoma and on anti-glaucoma medication but without glaucoma surgery
11569573|NCT00863018||Implant surgery|Eyes underwent Ahmed glaucoma valve implantation
11569734|NCT00861939|Active Comparator|2|WELLBUTRIN XL 300mg Tablets
11569574|NCT00863018||Trabeculectomy|Eyes underwent conventional trabeculectomy with mitomycin-C
11569575|NCT00863005|Experimental|1. K201|
11569576|NCT00863005|Active Comparator|2.|
11569577|NCT00862992|Experimental|1|
11569578|NCT00862992|Experimental|2|
11569579|NCT00862992|Experimental|3|
11569580|NCT00862979|Active Comparator|CNI-regimen|CNI-regimen: cyclosporine A (CyA) or tacrolimus (TAC) with everolimus (EVR) with corticosteroids
11569581|NCT00862979|Experimental|CNI-free-regimen|CNI-free regimen: everolimus (EVR) with MPA (either MMF or enteric coated mycophenolate sodium (EC-MPS)) and corticosteroids
11569582|NCT00862966|Experimental|citrate|
11569583|NCT00862966|Active Comparator|heparin|
11569584|NCT00862953|Active Comparator|Normal protein normal carbohydrate|Normal protein normal carbohydrate calory restricted nutrition
11569585|NCT00862953|Experimental|Normal protein low carbohydrates|Normal protein low carbohydrate energy-restricted diet
11569586|NCT00862953|Experimental|High protein normal carbohydrates|High protein normal carbohydrates
11569587|NCT00862953|Experimental|High protein low carbohydrate|High protein low carbohydrate nutrition
11569588|NCT00862940|Experimental|Memantine|
11569589|NCT00862940|Placebo Comparator|Placebo|
11569590|NCT00862927||Cue reactivity in virtual reality|Breath Scan + Saliva Sample + Questionnaires + View Virtual Reality Scenes
11569591|NCT00862914||1|benign melanocytic naevi
11569592|NCT00862914||2|dysplastic melanocytic naevi
11569593|NCT00862914||3|cutaneous malignant melanoma
11569594|NCT00862901|Experimental|1|100 J / cm2 over 24 hours
11569595|NCT00862901|Experimental|2|200 J / cm2 over 24 hours
11569596|NCT00862901|Experimental|3|400 J / cm2 over 24 hours
11569597|NCT00862901|Experimental|4|800 J / cm2 over 24 hours
11569598|NCT00862888|Placebo Comparator|Cohort 1; Study Period 1, 2, 3 or 4|Cohort 1: Exploring two single doses of PF-00446687 200 mg as well as sildenafil 100mg and placebo (double dummy design)
11569599|NCT00862888|Placebo Comparator|Cohort 2; study periods 1, 2, 3 or 4|Cohort 2: Exploring single doses of PF-00446687 20 mg - 175 mg. Subjects to receive two of 3 possible doses of PF-00446687 as well as a single dose of sildenafil 100mg and placebo (double dummy design).
11569600|NCT00862875|Experimental|1:Insulin detemir|Insulin detemir (Levemir® - Novolin® 4 pen)
11569601|NCT00862875|Active Comparator|2:Insulin Glargin|Insulin glargine (Lantus® - Solostar®)
11569602|NCT00862849|Experimental|Insulin Lispro, Regular Human Insulin, rHuPH20|"All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C).
~Intervention A: a single, subcutaneous (SC) injection of 0.15 units per kilogram (U/kg) insulin lispro with 3.75 nanograms per kilogram (ng/kg) recombinant human hyaluronidase (rHuPH20)
~Intervention B: a single, SC injection of 0.15 U/kg regular human insulin (RHI) with 3.75 ng/kg rHuPH20
~Intervention C: a single, SC injection of 0.15 U/kg insulin lispro alone
~There was a washout period of 3 to 14 days between interventions.
~The treatment sequence (ABC, ACB, BAC, BCA, CAB, or CBA) was repeated once so that each participant received up to 6 injections."
11569603|NCT00862836|Experimental|1|Vandetanib added to standard therapy (pegliposomal doxorubicin)
11569604|NCT00862823|Active Comparator|Atripla Tablet|Drug exposure after administration of Atripla Tablet
11569605|NCT00862823|Experimental|Atripla Liquid|Drug exposure after administration of an extemporaneously prepared liquid formulation of Atripla
11569606|NCT00862810|Other|Received HPV vaccine first|
11569607|NCT00862810|Other|Received concomitant vaccines first|
11569608|NCT00862797||endotracheal tube|Patients intubated with cuffed endotracheal tubes
11569609|NCT00862784|Experimental|IMC-1121B (ramucirumab) + mFOLFOX-6|This regimen will be repeated every 2 weeks until disease progression, unacceptable toxicity, or withdrawal.
11569610|NCT00862745|Experimental|Active|fesoterodine 4 mg (1 tablet) for 2 weeks with the option to increase to fesoterodine 8 mg or stay at fesoterodine 4 mg for 10 weeks for a total of 12 weeks of study medication.
11569611|NCT00862745|Placebo Comparator|Control|placebo (an identical pill that contains no medication) 1 tablet daily for 2 weeks followed by the option to increase the placebo pill daily for 10 weeks for a total of 12 weeks of study placebo medication.
11569612|NCT00862732|Active Comparator|1 Cognitive Behavioural Therapy|Intervention group will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
11569613|NCT00862732|Active Comparator|2 Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
11569614|NCT00862719|Experimental|Sitagliptin once per day|600 mg sitagliptin once per day orally starting on Day -1 for a total of 4 doses
11569615|NCT00862719|Experimental|Sitagliptin twice per day|600 mg sitagliptin twice per day orally starting on Day -1 for a total of 8 doses
11569616|NCT00862719|Experimental|Sitagliptin three times per day|600 mg sitagliptin three times per day orally starting on Day -1 for a total of 12 doses
11569617|NCT00862706|Experimental|A|
11569618|NCT00862693|Experimental|1 calcitriol|calcitriol 0.5ug/BIW for 12 months
11569619|NCT00862693|No Intervention|2|no intervention
11569620|NCT00862680||Diagnostic (4D PET/CT)|Participants undergo 4D PET/CT scan over up to 12 minutes.
11569621|NCT00862667|Experimental|Treatment A|PF-00241939 300ug using Inhaler A
11569622|NCT00862667|Active Comparator|Treatment B|PF-00241939 300ug using Inhaler B
11569623|NCT00862667|Active Comparator|Treatment C|PF-00241939 300ug using Inhaler C
11569624|NCT00862654|Experimental|C propionate 4/week + Ketoconasole 2/week|Clobetasol propionate shampoo 0.05% (4/week) + Ketoconazole shampoo 2% (2/week)
11569625|NCT00862654|Experimental|C propionate 2/week + Ketoconasole 2/week|Clobetasol propionate shampoo 0.05% (2/week) + Ketoconazole shampoo 2% (2/week)
11569626|NCT00862654|Experimental|C propionate 2/week|Clobetasol propionate shampoo 0.05% (2/week)
11569627|NCT00862654|Active Comparator|Ketoconazole 2/week|Ketoconazole shampoo 2% (2/week)
11569628|NCT00862641|Placebo Comparator|Placebo - Asthma|Matching intravenous (IV) bolus injection, subjects with Asthma
11569629|NCT00862641|Experimental|Regadenoson - Asthma|0.4mg / 5mL intravenous bolus injection, subjects with Asthma
11569630|NCT00862641|Placebo Comparator|Placebo - COPD|Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)
11569631|NCT00862641|Experimental|Regadenoson - COPD|0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)
11569632|NCT00862628|Experimental|Rebamipide|
11569633|NCT00862602|Experimental|1|Stepping Up to Health
11569634|NCT00862602|No Intervention|2|Usual care group
11569635|NCT00862576||1|Burning Mouth Syndrome Group
11569636|NCT00862576||2|Control Group
11569637|NCT00862563|Experimental|Zonisamide|Encapsulated zonisamide with a target maintenance doses of 400 mg/day administered as 4 capsules per day.
11569638|NCT00862563|Experimental|Levetiracetam|Encapsulated levetiracetam with a target maintenance doses of 2000 mg/day administered as 4 capsules per day .
11569639|NCT00862563|Active Comparator|Topiramate|Encapsulated topiramate with a target maintenance doses of 300 mg/day administered as 4 capsules per day .
11569640|NCT00862563|Placebo Comparator|Sugar Pill|Encapsulated sugar pill with a target maintenance dose administered as 4 capsules per day.
11569641|NCT00862550|Experimental|Group 1|Acupuncture (Areas known to help dry mouth)
11569642|NCT00862550|Experimental|Group 2|Acupuncture (Areas not known to help dry mouth)
11569643|NCT00862537||Active Resonator magnetic field therapy|Administration of active magnetic fields with the Resonator Device
11569644|NCT00862524|Experimental|ARRY-334543 + gemcitabine|
11569645|NCT00862511|Experimental|Coated Total Knee Arthroplasty|allergy coated TKA
11569646|NCT00862511|Active Comparator|Standard Total Knee Arthroplasty|normal TKA
11569647|NCT00862498|Experimental|Group 1 Treatment in Clinic|Participants will complete the written disclosure treatment in a clinic setting.
11569648|NCT00862498|Experimental|Group 2 Treatment via telephone|Participants will complete the written disclosure treatment in their homes via telephone.
11569649|NCT00862498|No Intervention|Group 3 Waitlist|Individuals will be placed on a waitlist for a period of 4 months, during which they will receive a phone call every other week to assess their suicidal ideation and post-traumatic stress disorder symptom severity.
11569650|NCT00862485||StudyGroup|
11569651|NCT00862472|Experimental|DuoTrav APS|DuoTrav APS QD AM
11569652|NCT00862472|Active Comparator|DuoTrav|DuoTrav QD AM
11569653|NCT00862459|Experimental|Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.03 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg body weight (BW) of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
11569654|NCT00862459|Experimental|Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.1 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
11569655|NCT00862459|Experimental|Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.3 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
11569656|NCT00862446|Experimental|Treatment|All infants will receive Omegaven
11569657|NCT00862433|Experimental|Arm 1|Determine optimal fat content of meal for optimal absorption of vitamin E
11569658|NCT00862433|Experimental|Arm 2|Determine optimal dose of vitamin E.
11569659|NCT00862433|Experimental|Arm 3|Investigate the relationship between vitamin C status and vitamin E turnover
11569660|NCT00862433|Experimental|NAFLD sub-study|Investigate the relationship between fatty liver disease and vitamin E turnover.
11569661|NCT00862420|Experimental|Clopidogrel|75 mg clopidogrel once daily from Day 1 to Week 12
11569662|NCT00862420|Active Comparator|Ticlopidine|200 mg ticlopidine once daily from Day 1 to Week 12
11569663|NCT00862407||1|Non-pulsatile Group (conventional)
11569664|NCT00862407||2|Pulsatile group (Alternate)
11569665|NCT00862394|Experimental|1|CHF 1535 Next DPI : BDP/Formoterol : 200/12 µg
11569666|NCT00862394|Active Comparator|2|CHF 1535 HFA pMDI : BDP/Formoterol : 200/12 µg
11569667|NCT00862394|Experimental|3|CHF 1535 Next DPI : BDP/Formoterol : 400/24 µg
11569668|NCT00862394|Active Comparator|4|CHF 1535 HFA pMDI : BDP/Formoterol : 400/24 µg
11569669|NCT00862381|Experimental|1|Hydrocortisone
11569670|NCT00862381|Placebo Comparator|2|Placebo
11569671|NCT00862368|Experimental|PAM -Enhanced/Asthma|The PAM-Enhanced/Asthma group: 2 in-home visits that included asthma education consistent with NIH recommendations (NIH, NAEPP, 1997) and smoking cessation counseling. Consistent with Motivational Interviewing (MI), smoking was broached in a non-judgmental manner and as another trigger for asthma. Feedback was given on expired air Carbon Monoxide (CO) levels of the smoker (to increase personal perception of risk) and the amount of smoke exposure to the child (to increase risk perception to the child). 6 phone calls were then provided over the next 4 months that focused on asthma education, a second round of feedback on the child's ETS exposure, and smoking cessation counseling. MI was used at all contacts. Free nicotine patch tx was given if they were ready to quit within 30 days.
11569672|NCT00862368|Active Comparator|PAM-Asthma|The PAM-Asthma arm received the same in-home counseling visits as PAM-Enhanced/Asthma. The 6 counseling phone calls were different from those received by PAM-Enhanced/Asthma, and included only an asthma follow-up and discussion of a child wellness topic. Smoking cessation was not discussed and additional feedback on ETS samplers was not provided. Motivational Interviewing approaches were used in all in-home and phone counseling. Free nicotine patch tx was given if they were ready to quit within 30 days.
11569735|NCT00861926|Experimental|Beclometasone/formoterol (100/6 µg)|Foster : fixed combination of BDP extrafine 100 µg plus formoterol fumarate 6 µg administered via a pMDI standard actuator
11569736|NCT00861926|Active Comparator|salbutamol|Ventolin : salbutamol sulphate 100 µg per metered dose
11569673|NCT00862368|Active Comparator|PAM-Healthy|The PAM-Healthy arm received the same in-home counseling visits as PAM and PAM Enhanced but asthma information was replaced with child wellness topics. The 6 counseling phone calls were the same timing and duration as the other two groups (six, 15 minutes calls, over four months) focused on a child wellness topic. Smoking cessation or sampler feedback was not discussed. Motivational Interviewing approaches were used in all in-home and phone counseling. Free nicotine patch tx was given if they were ready to quit within 30 days.
11569674|NCT00862355|Experimental|1|SPARC147609
11569675|NCT00862355|Active Comparator|2|Reference147609
11569676|NCT00862342|Experimental|Bevacizumab|Bevacizumab continuation plus chemotherapy in patients who have failed previous bevacizumab plus other chemotherapy
11569677|NCT00862329|Experimental|Casein|
11569678|NCT00862329|Experimental|MSP|
11569679|NCT00862329|Experimental|Casein/MSP|
11569680|NCT00862329|Experimental|Soy protein|
11569681|NCT00862316|Experimental|Computer Navigational Unit Assistance|Oxford Unicompartmental Knee arthroplasty will be performed with the assistance of a computer navigational unit.
11569682|NCT00862316|Active Comparator|Non- Computer Navigational Unit Assisted|Oxford Unicompartmental Knee arthroplasty will be performed traditionally (without the assistance of a computer navigational unit).
11569683|NCT00862303|Placebo Comparator|IL-2/IFN-α|
11569684|NCT00862303|Experimental|DC-CIK|
11569685|NCT00862290||sepsis group|Patients who develop sepsis in the ICU
11569686|NCT00862290||SIRS group|Patients who develop SIRS after cardiac surgery with cardiopulmonary bypass
11569687|NCT00862290||control group|normal healthy volunteers
11569688|NCT00862277||Group 1: Menactra® from Previous Studies|Subjects previously received only one dose of meningococcal vaccine, Menactra® in Study MTA04, MTA12, MTA19, or MTA21.
11569689|NCT00862277||Group 2: Menomune® from Previous Study|Subjects previously received only one dose of meningococcal vaccine, Menomune® in Study MTA04
11569690|NCT00862277||Group 3: Control|Meningococcal vaccine-naive age matched subjects
11569691|NCT00862264|Experimental|CHF 1535 pMDI|CHF 1535 HFA pMDI aerosol (100 µg/unit dose of beclomethasone dipropionate plus 6 µg of formoterol/unit dose
11569692|NCT00862264|Active Comparator|BDP pMDI|Beclomethasone dipropionate-CFC pMDI, 250 µg/unit dose
11569693|NCT00862251|Experimental|Ezetimibe/simvastatin|
11569694|NCT00862251|Active Comparator|Doubling statin dose|
11569695|NCT00862251|Active Comparator|Rosuvastatin|
11569696|NCT00862238|Experimental|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, & C
11569697|NCT00862238|Other|Health Promotion|4-session education offering basic information about the prevention of hepatitis A, B & C
11569698|NCT00862225|Placebo Comparator|1|
11569699|NCT00862225|Active Comparator|2|
11569700|NCT00862225|Experimental|3|
11569701|NCT00862212|Experimental|Brief Alcohol Intervention|Half of the subjects will be randomly assigned to receive a brief physician-delivered alcohol intervention designed by the NIAAA to be delivered by primary care and mental health providers.
11569702|NCT00862212|No Intervention|Control Group|
11569703|NCT00862186|Other|Self-Management Arm|Behavioral: 'Fatigue Facts & Fixes'
11569704|NCT00862173||Patients with NSCLC with CNS Metastasis|Patients who developed CNS metastasis of NSCLC during the treatment.
11569705|NCT00862173||Patients with NSCLC without CNS Metastasis|Patients with NSCLC that does not develop CNS metastasis during the treatment.
11569706|NCT00862160|Active Comparator|1|using minimized cardiopulmonary bypass circuit ROCsafeTM
11569707|NCT00862160|No Intervention|2|using standard cardiopulmonary bypass circuit
11569708|NCT00862147|Experimental|ICDP|International Child Development Program
11569709|NCT00862147|Active Comparator|Treatment as usual|Treatment as usual
11569710|NCT00862134|Active Comparator|Docetaxel 75 mg/m^2|Subjects randomized to the docetaxel arm will be administered 75 mg/m^2, IV, every 21 days (an approved dose and schedule)
11569711|NCT00862134|Experimental|PR104 + 60 mg/m^2 docetaxel|Subjects randomized to the PR104/docetaxel arm will be administered 60 mg/m^2 docetaxel, IV, every 21 days plus 770 mg/m^2 PR104, IV, every 21 days and prophylactic G-CSF.
11569712|NCT00862121|Experimental|Mesalazine|Mesalazine (Mesalamine) 2 g sachet; 6 g daily
11569713|NCT00862121|Placebo Comparator|Placebo|Placebo to Mesalazine (Mesalamine) 2 g sachet; 6 g daily
11569714|NCT00862108|Experimental|Methylphenidate|
11569715|NCT00862095|Placebo Comparator|Placebo|Placebo group
11569716|NCT00862095|Experimental|Propranolol|Propranolol (target dose 80 mg a day)
11569717|NCT00862095|Experimental|Topiramate|Topiramate (target dose 100 mg a day)
11569718|NCT00862095|Experimental|Amitriptyline|Amitriptyline (target dose 50 mg a day)
11569719|NCT00862082|Experimental|PR104 + Sorafenib|PR104 will be administered IV once every four weeks, in addition to 400mg sorafenib PO twice daily
11569720|NCT00862056||Cardiac CT|All participants will undergo a coronary artery CT angiogram
11569721|NCT00862043|Experimental|Sildenafil Citrate|Sildenafil Citrate 40 mg t.i.d. oral
11569722|NCT00862043|Placebo Comparator|Placebo|Sildenafil-matched oral placebo 40 mg t.i.d
11569723|NCT00862030||1|Study Cohort
11569724|NCT00862017|Experimental|MSG|Subjects receive a 6-d supplementation of MSG and are studied on the 7th day in the postprandial period following a standard meal ingestion with 2g MSG
11569725|NCT00862017|Placebo Comparator|Control|
11569726|NCT00861991|Experimental|Perspective taking intervention|Students were given an instruction to take the perspectives of their standardized patients
11569727|NCT00861991|Active Comparator|Control|Students given standard instructions
11569728|NCT00861978|Placebo Comparator|1|
11569729|NCT00861978|Experimental|2|
11569730|NCT00861965|Experimental|Treatment|AlloStim-8
11569731|NCT00861952|Experimental|Neuragen|Ad lib use of Neuragen (a natural health product) applied topically 2-3 times per day in 2-3 drops per application
11569732|NCT00861952|Sham Comparator|Mineral oil|Mineral oil, scent and color matched to intervention
11569733|NCT00861939|Experimental|1|Bupropion HCl 300mg Extended Release Tablet
11569737|NCT00861913|Experimental|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11569738|NCT00861887|Active Comparator|Vancomycin|Vancomycin 125 mg every 6 hours x 4 weeks
11569739|NCT00861887|Placebo Comparator|Placebo|Vancomycin 125 mg every 6 hours x 2 weeks, followed by placebo every 6 hours x 2 weeks
11569740|NCT00861874|Experimental|Treatment|
11569741|NCT00861861|Active Comparator|1|pitavastatin group
11569742|NCT00861861|Active Comparator|2|atorvastatin group
11569743|NCT00861848||12-50 with heart disease|12-50 with heart disease
11569744|NCT00861848||12-50 normal controls|12-50 normal controls
11569745|NCT00861835|Experimental|ROSE for TBNA|
11569746|NCT00861835|No Intervention|NR|no on-site cytopathology assessment (NR)
11569747|NCT00861822|Active Comparator|RBC|Advance RBC transfusion' (ART) group
11569748|NCT00861822|Other|Standard Care|Standard-of-care RBC transfusion (SRT) group
11569749|NCT00861809|Experimental|Cohort 1 Period 1|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
11569750|NCT00861809|Experimental|Cohort 1 Period 2|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
11569751|NCT00861809|Experimental|Cohort 1 Period 3|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
11569752|NCT00861796|Experimental|1|
11569753|NCT00861796|Placebo Comparator|2|
11569754|NCT00861783|Experimental|Group A - irinotecan|"Note: As of Amendment 2 (March 2009), treatment in the irinotecan arm of the study (Group A) is closed to enrollment.
~Treatment with escalating doses of ON 01910.Na in combination with irinotecan."
11569755|NCT00861783|Experimental|Group B - oxaliplatin|Treatment with escalating doses of ON 01910.Na in combination with oxaliplatin.
11569756|NCT00861770|Other|1 - Control|All subjects will receive blood volume measurement immediately before and 30 minutes after ultrafiltration is completed. In the control group, the treating physician will not see the blood volume measurement results and treat according to standard of care.
11569757|NCT00861770|Experimental|2 - BVM|Ultrafiltration will be guided by blood volume measurement results.
11569758|NCT00861757|Placebo Comparator|Placebo|
11569759|NCT00861757|Experimental|2.5 mg Tadalafil|
11569760|NCT00861757|Experimental|5.0 mg Tadalafil|
11569761|NCT00861757|Active Comparator|0.2 mg Tamsulosin|
11569762|NCT00861744|Experimental|Priorix 1 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 1) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
11569763|NCT00861744|Experimental|Priorix 2 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 2) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
11569764|NCT00861744|Experimental|Priorix 3 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 3) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
11569765|NCT00861744|Active Comparator|MMR-II Group|Subjects between 12 and 15 months of age at the time of study vaccination who randomly received one dose of one of three different commercially-available lot of M-M-R II (Merck and Co.) vaccine subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
11569766|NCT00861731|Active Comparator|1|hypolipidemic treatment
11569767|NCT00861731|Sham Comparator|2|hypolipidemic treatment
11569768|NCT00861731|Sham Comparator|3|hypolipidemic treatment
11569769|NCT00861718|Experimental|AZD7268|
11569770|NCT00861718|Placebo Comparator|Placebo|
11569771|NCT00861705|Active Comparator|Arm I (paclitaxel, doxorubicin, cyclophosphamide)|Patients receive paclitaxel IV over 60 minutes once weekly in weeks 1-12. Patients then receive dose-dense doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 5-30 minutes (ddAC) once in weeks 13, 15, 17, and 19.
11569772|NCT00861705|Experimental|Arm II (paclitaxel, ddAC, bevacizumab)|Patients receive paclitaxel and ddAC as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes in weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17.
11569773|NCT00861705|Experimental|Arm III (paclitaxel, ddAC, carboplatin)|Patients receive paclitaxel and ddAC as in Arm I. Patients also receive carboplatin IV over 30 minutes once in weeks 1, 4, 7, and 10.
11569774|NCT00861705|Experimental|Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin)|Patients receive paclitaxel and ddAC as in Arm I, bevacizumab as in Arm II, and carboplatin as in Arm III.
11569775|NCT00861692|Experimental|Argatroban|
11569776|NCT00861666|Other|Forgiveness-based Writing|
11569777|NCT00861640|Experimental|Intravenous Omeprazole|100 cases of Intravenous Omeprazole
11569778|NCT00861640|Experimental|Oral Rabeprazole|100 cases of oral rabeprazole
11569779|NCT00861614|Active Comparator|Ipilimumab|
11569780|NCT00861614|Placebo Comparator|Placebo|
11569781|NCT00861601|Experimental|low dose|eltrombopag 12.5 mg/day
11569782|NCT00861601|Experimental|middle dose|eltrombopag 25 mg/day
11569783|NCT00861601|Experimental|high dose|eltrombopag 37.5 mg/day
11569784|NCT00861588|Experimental|isoflavones|Subjects who met the inclusion and exclusion criteria would be randomly assigned (concealment of allocation) to receive isoflavones
11569785|NCT00861588|Placebo Comparator|starch|Subjects who met the inclusion and exclusion criteria would be randomly assigned (concealment of allocation) to receive placebo
11569786|NCT00861562|Active Comparator|Imescard pills/Placebo crossover|Patients received Imescard water smartweed composed pills during the first intervention period and placebo during the second, after a 10-day washout period.
11569787|NCT00861562|Active Comparator|Placebo/Imescard pills crossover|Patients received placebo during the first intervention period and Imescard water smartweed composed pills during the second, after a 10-day washout period.
11569788|NCT00861549|Experimental|cohort 1|1mg / 0.5 tablet
11569789|NCT00861549|Experimental|cohort 2|2mg / 1 tablet; crossover with Phencynonate hydrochloride (2mg/1 tablet) made in China
11569790|NCT00861549|Experimental|cohort 3|4mg / 2 tablets
11569791|NCT00861536|Experimental|ATG Fresenius|
11569792|NCT00861536|Active Comparator|Thymoglobuline Genzyme|
11569793|NCT00861523|Active Comparator|1. thiamine|Pregnant women until 12 week of gestation who refer to the ER because of nausea and vomiting and didn't improve after hydration, will receive thiamine IV
11569794|NCT00861523|Active Comparator|2. promethazine|Pregnant women until 12 week of gestation who refer to the ER because of nausea and vomiting and didn't improve after hydration, will receive promethazine IV
11569795|NCT00861497|Experimental|Bifeprunox|
11569796|NCT00861484|Experimental|GSK958108 3 mg|Experimental
11569797|NCT00861484|Placebo Comparator|Placebo of GSK958108|Placebo
11569798|NCT00861471|Experimental|Docetaxel +Gleevec|
11569799|NCT00861458|Experimental|PF-00868554|
11569800|NCT00861445|Experimental|1|
11569801|NCT00861445|Placebo Comparator|2|
11569802|NCT00861432|Active Comparator|additive homeopathic treatment|These patients receive additive homeopathic treatment during conventional cancer treatment.
11569803|NCT00861432|No Intervention|no additive homeopathic treatment|These patients do not receive additive homeopathic treatment during conventional cancer treatment.
11569804|NCT00861419|Experimental|D|3 mg/kg AMG 386 IV (QW) / 125 mg AMG 706 PO (QD)
11569805|NCT00861419|Experimental|A|3 mg/kg AMG 386 IV (QW) / 15 mg/kg bevacizumab IV (Q3W)
11569806|NCT00861419|Experimental|B|3 mg/kg AMG 386 IV (QW) / 75 mg AMG 706 PO (QD)
11569807|NCT00861419|Experimental|E|3 mg/kg AMG 386 IV (QW) / 400 mg sorafenib PO (BID)
11569808|NCT00861419|Experimental|H|10 mg/kg AMG 386 IV (QW) / 50 mg sunitinib PO (QD - 4 weeks on/2 weeks off)
11569809|NCT00861419|Experimental|G|3 mg/kg AMG 386 IV (QW) / 50 mg sunitinib PO (QD - 4 weeks on/2 weeks off)
11569810|NCT00861419|Experimental|C|10 mg/kg AMG 386 IV (QW) / 15 mg/kg bevacizumab IV (Q3W)
11569811|NCT00861419|Experimental|F|10 mg/kg AMG 386 IV (QW) / 400 mg sorafenib PO (BID)
11569812|NCT00861406|Experimental|Group 1|Pegylated Interferon alfa-2b (Once week x 4 weeks) + GP-100 Peptide
11569813|NCT00861406|Experimental|Group 2|Pegylated Interferon alfa-2b (Once week x 8 weeks) + GP-100 Peptide
11569814|NCT00861406|Experimental|Group 3|Pegylated Interferon alfa-2b (Once week x 12 weeks) + GP-100 Peptide
11569815|NCT00861393|Other|CBT|
11569816|NCT00861393|Other|Waitlist|
11569817|NCT00861380|Experimental|10Pn3+1-6W- 6M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
11569818|NCT00861380|Experimental|10Pn2+1-6W-6M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
11569819|NCT00861380|Active Comparator|Ctrl-6W-6M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B vaccine (called also HBV vaccine) according to either a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule), or according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
11569820|NCT00861380|Experimental|10Pn7-11M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 7 to 11 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
11569872|NCT00860925|Experimental|Clonidine placebo and active ASA|
11569873|NCT00860925|Placebo Comparator|Clonidine placebo and ASA placebo|
11569874|NCT00860912|Experimental|Intervention: Collagen matrix|Cystocele repair: Veritas reinforcing material implanted for reinforcement of cystocele repair with collagen matrix
11570438|NCT00856973|Experimental|High dose eszopiclone|2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
11569821|NCT00861380|Active Comparator|Ctrl7-11M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 7 to 11 months at enrolment. Subjects received the Engerix B (called also HBV) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
11569822|NCT00861380|Experimental|10Pn12-18M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 12 to 18 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
11569823|NCT00861380|Active Comparator|Ctrl12-18M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 12 to 18 months at enrolment. Subjects received the Havrix (called also HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
11569824|NCT00861367|Active Comparator|1|aspirin 100mg
11569825|NCT00861367|Placebo Comparator|2|empty capsule
11569826|NCT00861341|Experimental|Pioglitazone with or without Aspirin|Blood samples will be taken at time 0 to measure platelet aggregation. 30mg Pioglitazone will be ingested and another blood sample will be obtained 90-180 minutes later for platelet aggregation. After 6-9 days, subjects will ingest 81mg of aspirin. Another blood sample will be obtained 2-24 hours later for baseline determination of platelet aggregation and activation after taking aspirin. Subjects will then ingest 30mg pioglitazone and a final blood sample will be obtained 90-180 minutes later to measure platelet aggregation.
11569827|NCT00861328|Experimental|A|Treatment of escalating doses of ON 01910.Na in combination with irinotecan
11569828|NCT00861328|Experimental|B|Treatment of escalating doses of ON 01910.Na in combination with oxaliplatin
11569829|NCT00861315|Experimental|Nebulized amikacin|Patients receive nebulized amikacin once a day during three days. Placebo is administered intravenousely
11569830|NCT00861315|Active Comparator|Intravenous amikacin|
11569831|NCT00861302|Experimental|Treatment group|This is the only group in the study. It consists of patients with chronic musculoskeletal pain who are receiving the treatment program
11569832|NCT00861276|Experimental|1|Arm instructed to use spray at least once an hour when awake.
11569833|NCT00861276|Active Comparator|2|Ad libitum: patients were instructed to use NNS when craving appears.
11569834|NCT00861263|Other|spiral overtube|Any subject that has been referred for spiral enteroscopy will be asked to participate in this study. The purpose is to gather data about the technical aspects of the procedure,diagnostic capability and treatment as well as long term follow up.
11569835|NCT00861250|Experimental|Vel/Dex|
11569836|NCT00861237|Placebo Comparator|Placebo globules group|Patients receive Placebo globules made out of sugar and looking similar to active drug sublingually before surgery.
11569837|NCT00861237|Active Comparator|Nux vomica group|Patients receive Nux vomica globules made out of sugar sublingually before surgery.
11569838|NCT00861224||Observed Subjects|Subjects that submitted bone marrow biopsy and aspirates.
11569839|NCT00861211|Experimental|Active treatment arm|
11569840|NCT00861211|Placebo Comparator|Placebo|
11569841|NCT00861198||ERCP|Patients who have a medical indication for ERCP with cholangioscopy and/or pancreatoscopy and are referred for the procedure as part of their standard medical care will be considered for the study.
11569842|NCT00861185|Experimental|Senicapoc|
11569843|NCT00861185|Placebo Comparator|Placebo|
11569844|NCT00861172|Experimental|1|
11569845|NCT00861159||1|
11569846|NCT00861146|Experimental|1 concurrent smoking cessation|smoking cessation delivered concurrent with intensive alcohol treatment
11569847|NCT00861146|Active Comparator|2 deferred smoking cessation|smoking cessation delivered 12 weeks after intensive alcohol treatment
11569848|NCT00861094|Experimental|FOLFOX and radiotherapy|Oxaliplatin (85mg/m2); Folinic Acid (200mg/m2); 5-FU (400mg/m2-Bolus and 1600mg/m2 over 46h)- once every two weeks for six cycles
11569849|NCT00861094|Experimental|5-FU / cisplatin and radiotherapy|5-FU (100mg/m2); Cisplatin (75mg/m2)
11569850|NCT00861081|Experimental|1: Care management|
11569851|NCT00861081|Active Comparator|2: Written Materials|
11569852|NCT00861068|Experimental|1|
11569853|NCT00861068|Placebo Comparator|2|
11569854|NCT00861055||Infants|Infants less than 7 days of age with clinical signs of sepsis
11569855|NCT00861055||Mothers|Mothers following antenatal care at SMRU antenatal clinic, Maela camp who are 28 - 30 weeks gestation
11569856|NCT00861042|Experimental|1|
11569857|NCT00861029|Experimental|Pazopanib|Subjects will receive pazopanib during study
11569858|NCT00861029|Other|Placebo|Placebo as a comparator to pazopanib
11569859|NCT00861016|Experimental|1|The patients with mild to moderate essential hypertension
11569860|NCT00861003||Schizophrenia, antipsychotics|Stable outpatient status of schizophrenia or schizoaffective disorder currently taking a single oral antipsychotic
11569861|NCT00860990||1|SCI or disabled
11569862|NCT00860990||2|Able-bodied
11569863|NCT00860977|Placebo Comparator|Placebo|Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
11569864|NCT00860977|Experimental|Valacyclovir|oral valacyclovir 500mg twice daily
11569865|NCT00860964|Placebo Comparator|Placebo|
11569866|NCT00860964|Experimental|estradiol valerate|
11569867|NCT00860951|Other|Brain Computer Interface Keyboard|What effect does the environment (BCI, AT device, Computer) have on the accuracy of typing using a BCI keyboard?
11569868|NCT00860938|Active Comparator|Budesonide|
11569869|NCT00860938|Placebo Comparator|Placebo|
11569870|NCT00860925|Experimental|active clonidine and active ASA|
11569871|NCT00860925|Experimental|active clonidine and ASA placebo|
11569875|NCT00860912|Other|Native tissue repair|Intervention: Cystocele repair performed: No reinforcing material used and routine performance of a cystocele repair using native tissues.
11569876|NCT00860899|Active Comparator|clonidine|Clonidine is an alpha2-adrenergic agonist with sedative, analgesic and hemodynamic properties. It inhibits transmission of nociceptive stimuli in the dorsal horn of the spinal cord, acting on the inhibitory descending pathways.
11569877|NCT00860899|Active Comparator|levobupivacaine|Levobupivacaine is long-acting local anesthetic, S-enantiomer of bupivacaine, with identical anesthetic potency.
11569878|NCT00860886||1|Mongolian Women
11569879|NCT00860886||2|Women in other parts of the world other than Mongolia.
11569880|NCT00860873|Experimental|Test 1|Oral Powder EMS
11569881|NCT00860873|Experimental|Test 2|Hard Capsules EMS
11569882|NCT00860873|Active Comparator|Comparator 1|Oral Powder Zodiac
11569883|NCT00860873|Active Comparator|Comparator 2|Hard capsules - Zodiac
11569884|NCT00860847|Active Comparator|Aged Garlic Extract and Coenzyme Q10|"AGE (1200 mg) and CoQ10 (120 mg)
~This is a combination of aged garlic extract and co-enzyme Q10"
11569885|NCT00860847|No Intervention|Placebo|placebo pills will be given
11569886|NCT00860834|Experimental|1|Pediatricians and parents of children with asthma will participate in the asthma coaching program.
11569887|NCT00860834|Active Comparator|2|Children of parents enrolled in the study will receive usual asthma care from their pediatrician.
11569888|NCT00860821|Experimental|1|AZD8309
11569889|NCT00860821|Placebo Comparator|2|Placebo
11569890|NCT00860808|Experimental|1 AM-101|low dose
11569891|NCT00860808|Experimental|2 AM-101|high dose
11569892|NCT00860808|Placebo Comparator|3 Placebo|
11569893|NCT00860795|Active Comparator|Echinacea|
11569894|NCT00860795|Placebo Comparator|placebo|
11569895|NCT00860782|Experimental|Low Frequency Support|Parent Educational Support (once/year for 2 years)
11569896|NCT00860782|Experimental|High Frequency Support|Parent Educational Support (4 times/year for 2 years)
11569897|NCT00860769|Experimental|ASHA Life|6-session educational group discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills.
11569898|NCT00860769|Active Comparator|Usual Care|3-session educational group focusing on HIV prevention, anti-retroviral therapy (ART) and parenting.
11569899|NCT00860756|Experimental|1|Intervention Group
11569900|NCT00860743|No Intervention|Arm 1|"We plan to study 10 males and 10 females with moderate obstructive sleep apnea (OSA), and 10 healthy males and 10 healthy females. The males and the females will be matched based on age, race, sex and body mass index. The OSA and control participants will be exposed to intermittent hypoxia and sham intermittent hypoxia during wakefulness and sleep."
11569901|NCT00860743|Experimental|ANTIOXIDANT COCKTAIL|We plan to study 10 male participants with moderate obstructive sleep apnea (OSA) and 10 male control participants matched for age, race and body mass index. The OSA and control participants will be exposed to intermittent hypoxia during wakefulness and sleep following administration of an antioxidant or a placebo cocktail that will be presented in a randomized fashion.
11569902|NCT00860730|Experimental|Perceval S|
11569903|NCT00860717|Active Comparator|1|Subjects from the arm number 1 received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
11569904|NCT00860717|Experimental|2|Subjects from the arm number 2 received low level laser therapy 3 times per week for 12 weeks, in addition to the same treatment as patients from the arm number 1.
11569905|NCT00860704|Active Comparator|Ringerlactate lean|fluidtherapy with crystalloids in lean patients
11569906|NCT00860704|Active Comparator|Ringerlactate overweight|fluidtherapy with crystalloids in overweight patients
11569907|NCT00860704|Active Comparator|Ringerlactate obese|fluidtherapy with crystalloids in obese patients
11569908|NCT00860691|Active Comparator|ARM I - Open colorectal surgery|Open colorectal surgery
11569909|NCT00860691|Experimental|ARM II - Laparoscopic colorectal surgery|Laparoscopic colorectal surgery
11569910|NCT00860691|Other|Control - reference value|Blood samples from healthy volunteers will be obtained at one time point.Peripheral blood samples will be obtained into tubes with no additive (BD Vacutainer System, Plymouth, UK).Samples will be processed to serum. Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA)using specific anti-Fas MoAbs, Human sFas Immunoassay. Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay. Serum concentration of IL - 17 will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using Human IL-17 Immunoassay. . Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube. burst neutrophil production will be determined quantitatively by flow cytometry as described by Rothe using a commercial kit Bursttest Kit.
11569911|NCT00860678|Active Comparator|A|Training group
11569912|NCT00860678|Other|B|Controls
11569913|NCT00860665||1|Observational study on consecutive persons over the age of 55 years presenting for screening colonoscopy
11569914|NCT00860652|Experimental|Adjuvant Radiotherapy (RT)|Adjuvant Radiotherapy (64Gy in 32 Fractions to the prostate bed)
11569915|NCT00860652|Experimental|Active Surveillance with Early SalvageRT|Active Surveillance with Early Salvage Radiotherapy
11569916|NCT00860639|Active Comparator|gemtuzumab ozogamycin|Initial randomization will be completed upon receipt of karyotype results and will determine the administration of gemtuzumab ozogamycin (MYLOTARG ®) in combination with chemotherapy during the induction course and the first intensive consolidation course.
11569917|NCT00860639|No Intervention|without Mylotarg|
11569918|NCT00860626|Experimental|1|At the twelfth week of interferon α treatment, HBV DNA is detectable(>1000 copies/ml), or HBeAg is still positive. And nucleoside analogue is added for 12 weeks.
11569919|NCT00860626|Active Comparator|2|At the twelfth week of interferon α treatment, HBV DNA is detectable (>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
11569920|NCT00860626|Active Comparator|3|At the twelfth week of interferon α treatment, HBV DNA is undetectable (<1000 copies/ml), or HBeAg is negative. And interferon is continued for another 9 months.
11569921|NCT00860613|Experimental|1|women in this group received usual medical treatment and counseling from a nutritionist and diabetes educator. They received a specific diet using carbohydrate counting (40-45% of carbohydrates)and a moderate energy restriction. Weight gain, adequacy of diet, results of the self glucose monitoring, and ketonuria were evaluated every two weeks. They also received education on diabetes, diet and glucose monitoring.
11569922|NCT00860613|Experimental|2|Women in this group received usual medical treatment and counseling from a nutritionist and diabetes educator. The diet they received was based on carbohydrate counting (40-45% of carbohydrates), but recommended only low-moderate glycemic index foods. Weight gain, adequacy of diet, results of the self glucose monitoring, and ketonuria were evaluated every two weeks. They also received education on diabetes, diet and glucose monitoring.
11569923|NCT00860613|No Intervention|3|women in this group received the current hospital treatment. They did not receive any intervention except for the self glucose monitoring that they did every two weeks. Weight gain and the results of the self glucose monitoring, were evaluated every two weeks.
11569924|NCT00860600|Experimental|1. PG2 Treatment: 5 days/week|Powder for Injection, 500 mg PG2/500 ml normal saline, 5 days/week, 2 to 4 weeks
11569925|NCT00860600|Experimental|2. PG2 Treatment: 3 days/week|Powder for Injection, 500 mg PG2/500 ml normal saline, 3 days/week, 2 to 4 weeks
11569926|NCT00860574|Experimental|Treatment (allogeneic transplantation)|CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.
11569927|NCT00860561||1|Postmenopausal women with locally advanced or metastatic breast cancer who have failed 2 or more prior hormone therapies, or were intolerant to prior hormone therapy and have no endocrine therapeutic options.
11569928|NCT00860535|Experimental|Ph+ CML or Ph+ ALL|GFS biomarker evaluation
11569929|NCT00860522|Experimental|Phase I|Three patients will be enrolled at dose Level 1. If the patient does not completed the three infusion of JVRS-100 during cycle 1 for reason other than toxicity, another patient will be accrued at the same dose level.
11569930|NCT00860522|Experimental|Phase II|3 patients will be enrolled at a given dose level. If one of these patients experiences a dose limiting toxicity, an additional 3 patients will be enrolled at the given dose level. If the 1st 2 subjects enrolled and treated at a given dose experience dose limiting toxicities, no additional subjects will be enrolled at that dose. Dose escalation may proceed if < 2/6 patients at a given dose level experience a LDT. If ≥ 2/6 patients experience a DLT at a given dose level, the next lower dose level will be considered the RP2D. If a patient does not complete the 3 infusions of JVRS-100 during Cycle 1 for reasons other than toxicity, another patient will be accrued at the same dose level. Once the RP2D is established, the cohort will be expanded to a total of 12 patients.
11569931|NCT00860509|Placebo Comparator|Low Phytosterol Diet|Diet with 100 mg of daily phytosterols
11569932|NCT00860509|Active Comparator|High Phytosterol Diet|Diet with 600 mg of daily phytosterols
11569933|NCT00860496|Other|1|Treatment Arm 1 will receive one single dose of CP-690,550 on Day 1, Tacrolimus on Days 1-8, and one single dose of CP-690,550 on Day 8.
11569934|NCT00860496|Other|2|Treatment Arm 2 will receive one single dose of CP-690,550 on Day 1, Cyclosporine on Days 1-6, and one single dose of CP-690,550 on Day 6.
11569935|NCT00860483|No Intervention|observational|This is an observational study. no intervention occurs in subjects. their performance in a laparoscopic trainer is observed and correlated with brain activity
11569936|NCT00860470|Active Comparator|1|Iron (27 mg) and folic acid (600 ug)
11569937|NCT00860470|Experimental|2|Multiple micronutrient
11569938|NCT00860457|Experimental|Chemotherapy|Fludarabine/Rituximab followed by Lenalidomide
11569939|NCT00860444|Active Comparator|1|Participants will take part in the basic educational and counseling program through their community health care center.
11569940|NCT00860444|Experimental|2|Participants will take part in the comprehensive educational and counseling program through their community health care center.
11569941|NCT00860431|No Intervention|1|Standard-of-care (conservative treatment)
11569942|NCT00860431|Experimental|2|AST-120 6g/day (3 times a day)
11569943|NCT00860418|Active Comparator|1|Standard asthma education delivered during 2 home visits by a nurse.
11569944|NCT00860418|Experimental|2 PAAL|PAAL
11569945|NCT00860405|Experimental|1|Investigational drug: HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion)
11569946|NCT00860405|Active Comparator|2|Control drug: Human serum albumin (HSA 50g/L)
11569947|NCT00860392|Experimental|1|Biomarker evaluation
11569948|NCT00860379|Placebo Comparator|Placebo|Placebo
11569949|NCT00860379|Experimental|Selenium1|Subject will receive 2 ug/kg of IV selenium per day
11569950|NCT00860379|Experimental|Selenium2|Subject will receive 4 ug/kg of IV selenium per day
11569951|NCT00860366|Experimental|Uric Acid|Single intravenous infusion of 1 gram of Uric Acid dissolved in vehicle (500 ml of 0'1% Lithium Carbonate and 5% Mannitol).
11569952|NCT00860366|Placebo Comparator|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
11569953|NCT00860353|Experimental|1|
11569954|NCT00860353|Placebo Comparator|2|
11569955|NCT00860340|Experimental|1|Study patient will take 100mg tablet of Spironolactone
11569956|NCT00860327||Newborns|Newborns with hypoplastic left heart syndrome who are receiving a right ventricle to pulmonary artery shunt as first stage palliation.
11569957|NCT00860327||Infants|Infants who are undergoing complete repair for tetralogy of Fallot or similar pathology.
11569958|NCT00860314|Active Comparator|AP Position|Cardioversion with antero-posterior electrode position
11569959|NCT00860314|Active Comparator|AL Position|Cardioversion with antero-lateral electrode position
11569960|NCT00860301|Experimental|Acupuncture group|
11570439|NCT00856973|Placebo Comparator|Placebo|Placebo 6-17 years
11569961|NCT00860301|No Intervention|Control group|Infants come to the clinic six times, are left alone for five minutes with the acupuncture nurse who hold its hand and talks to it.
11569962|NCT00860288|Experimental|Vildagliptin Dose 1|
11569963|NCT00860288|Experimental|Vildagliptin Dose 2|
11569964|NCT00860288|Placebo Comparator|Placebo|
11569965|NCT00860288|Active Comparator|Sitagliptin|
11569966|NCT00860275|Active Comparator|BMS-708163 / Ketoconazole|
11569967|NCT00860275|Active Comparator|BMS-708163 / Fluconazole|
11569968|NCT00860262|Experimental|telmisartan and amlodipine|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
11569969|NCT00860262|Active Comparator|amlodipine|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
11569970|NCT00860262|Active Comparator|telmisartan|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
11569971|NCT00860249|No Intervention|Usual Care|Usual Care. Participants in this arm will receive Usual care until outcome assessment is performed at 6 months following randomization. At that time, they will be sent a letter reminding them to obtain the ordered preventative service test, however no further outcomes will be assessed. Thus, during the course of the study, all participants in this arm will have solely received usual care.
11569972|NCT00860249|Experimental|Behavioral: Letter Only|Behavioral: Letter Only Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
11569973|NCT00860249|Experimental|Behavioral: Letter and Educational DVD|Behavioral: Letter and Educational DVD Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
11569974|NCT00860236|Active Comparator|Psycoeducation/counseling|
11569975|NCT00860236|Active Comparator|Cognitive behavioural therapy|
11569976|NCT00860223|Experimental|1|Digoxin alone
11569977|NCT00860223|Experimental|2|Digoxin plus neratinib
11569978|NCT00860197|No Intervention|Control|No coffee
11569979|NCT00860197|Experimental|Group 1|Fully torrefied coffee
11569980|NCT00860197|Experimental|Group 2|Partially torrefied coffee
11569981|NCT00860184||50-79% stenosis|Subjects with 50-79% stenosis of the carotid artery Absence of prior ischemic neurological symptoms Age 18 or older
11569982|NCT00860171|Experimental|Treatment (iodine I 131 monoclonal antibody B, autologous HCT)|Patients receive a dosimetric dose of iodine I 131 monoclonal antibody BC8 IV on day -20 and a therapeutic dose on day -11. Before day -20, patients may also receive up to 2 additional dosimetric doses of iodine I 131 monoclonal antibody BC8 IV approximately 1-2 weeks apart. Patients then undergo autologous stem cell transplantation on day 0.
11569983|NCT00860158|Experimental|Single Arm Assignment|Neoadjuvant dasatinib plus leuprolide acetate followed by radical prostatectomy
11569984|NCT00860145|Experimental|radiosurgery|Radiosurgical treatment of the medial temporal lobe
11569985|NCT00860145|Active Comparator|temporal lobectomy|Resection of medial temporal lobe
11569986|NCT00860132||2|a group of consecutive hip fracture patients admitted to a dedicated comprehensive orthogeriatric ward and a group of similar patients admitted to an orthopedic ward and later on transferred to geriatric rehab center
11569987|NCT00860119|Experimental|Sublingual tablet|Test treatment
11569988|NCT00860119|Experimental|Oral tablet|Reference treatment
11569989|NCT00860106|Other|Follow up|"ED score and DDimer level of patients who have stopped their VKA treatment (after the first or the second previous proximal VTE).
~Phone follow up for 2 years."
11569990|NCT00860093|Experimental|1|MPC-5971
11569991|NCT00860093|Placebo Comparator|2|placebo identical in appearance to study drug
11569992|NCT00860080|Experimental|PXL01|Four Subjects per cohort will receive 10, 20, or 40 mg PXL01 respectively.
11569993|NCT00860080|Placebo Comparator|Placebo|One subject per cohort will receive 10, 20, or 40 mg Placebo respectively.
11569994|NCT00860067|Experimental|Q/LAIV (MEDI3250)|Q/LAIV (quadrivalent influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson (BD) Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 temperature-sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], B/Victoria [B/Malaysia/2506/2004], and B/Yamagata [B/Florida/4/2006]).
11569995|NCT00860067|Active Comparator|FluMist/B/Yamagata|FluMist/B/Yamagata (trivalent influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature-sensitive, cold-adapted, attentuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Yamagata [B/Florida/4/2006])a B strain of the Yamagata lineage.
11569996|NCT00860067|Active Comparator|FluMist/B/Victoria|FluMist/B/Victoria(trivalent influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature-sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Victoria [B/Malaysia/2506/2004])a B strain of the Victoria lineage.
11569997|NCT00860054|Experimental|Medium Phytosterols|Diets with daily 400 mg of phytosterols
11569998|NCT00860054|Experimental|High Phytosterols Diet|Diet with 2000 mg of daily phytosterols
11569999|NCT00860054|Placebo Comparator|Low Phyto Diet|Diet with less than 100 mg of daily phytosterols
11570000|NCT00860041||Group I|Patients complete pain questionnaires at baseline, 2-8 days after each weekly paclitaxel treatment given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
11570043|NCT00859807|Experimental|Sequence 2 (19 subjects)|Period 1: treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis Period 2: treatment A (15.3 mL (50 mg/5 mL) AQ suspension (Pfizer); test treatment
11570440|NCT00856960|Active Comparator|1|Aliskiren 600 mg
11570001|NCT00860041||Group II|Patients complete pain questionnaires at baseline, 2-8 days after each weekly paclitaxel treatment not given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
11570002|NCT00860041||Group III|Patients complete pain questionnaires at baseline, 2-8 days after each 2-4 week paclitaxel treatment given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
11570003|NCT00860041||Group IV|Patients complete pain questionnaires at baseline, 2-8 days after each 2-4 week paclitaxel treatment not given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
11570004|NCT00860028|Experimental|Extended Varenicline Pretreatment|Arm 1 (Experimental) = 4 weeks varenicline (Chantix) titrated to 1 mg oral tablet twice per day before the smoking quit date followed by 4 weeks varenicline (Chantix) 1 mg oral tablet twice per day treatment.
11570005|NCT00860028|Experimental|Short-term Varenicline Pretreatment|Arm 2 (Experimental) = 3 weeks placebo + 1 week varenicline (Chantix)pretreatment + 4 weeks varenicline 1 mg oral tablet twice per day treatment following the smoking quit date.
11570006|NCT00860015|Experimental|Alimta/Gemcitabine|IV administration of drugs for 14 days for up to 4 cycles
11570007|NCT00860002||1|Ultramini laparotomy (UMLT) myomectomy (UMLT-M) versus laparoscopic myomectomy (LM)
11570008|NCT00860002||2|Laparoscopically aided myomectomy (LAM) versus LM
11570009|NCT00860002||3|LAM versus UMLT-M
11570010|NCT00860002||4|Mini laparotomy myomectomy (ML-M) versus UMLT-M
11570011|NCT00860002||5|Laparoscopic uterine artery occlusion with blockage of anastomosis between the uterine and ovarian vessels (LUVO) versus laparoscopic uterine artery occlusion without blockage of anastomosis between the uterine and ovarian vessels (LUAO)
11570012|NCT00860002||6|LUVO+LAM versus LUAO+LAM
11570013|NCT00860002||7|LUVO+LM versus LUAO+LM
11570014|NCT00860002||8|LUVO+UMLT-M versus LUAO+UMLT-M
11570015|NCT00860002||9|LUVO versus UMLT-UVO
11570016|NCT00860002||10|UMLT-UVO versus UMLT-UAO
11570017|NCT00860002||11|LUAO versus UMLT-UAO
11570018|NCT00860002||12|UMLT-UVO+UMLT-M versus UMLT-UAO+UMLT-M
11570019|NCT00860002||13|LUVO versus LM
11570020|NCT00860002||14|LUVO versus LAM
11570021|NCT00860002||15|LUVO versus LUAO+LM
11570022|NCT00860002||16|LUVO versus LUAO+UMLT-M
11570023|NCT00860002||17|LUVO versus LUAO+LAM
11570024|NCT00859976|Active Comparator|Plasma-sprayed shell|Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
11570025|NCT00859976|Experimental|BoneMaster coated shell|Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
11570026|NCT00859950|Active Comparator|Sleep Apnea|Subjects found to have Obstructive Sleep Apnea (OSA) with Intermittent Hypoxemia (IH). This arm will undergo a pre-treatment blood draw, one month of Continuous Positive Airway Pressure (CPAP) to treat OSA, and a post-treatment blood draw.
11570027|NCT00859950|No Intervention|Normal Control|Subject found to have no evidence of Obstructive Sleep Apnea (OSA) after Nocturnal Polysomnography (NPSG). These subjects will only undergo a blood draw and will not have the Continuous Positive Airway Pressure (CPAP) treatment.
11570028|NCT00859937|Experimental|Arm I|Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11570029|NCT00859911|Active Comparator|2|Thiamine Mononitrate 5mg, Riboflavin 2 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg
11570030|NCT00859911|Experimental|1|Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocobalamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
11570031|NCT00859898|Experimental|Dapagliflozin + Metformin XR|"Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks
~Metformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"
11570032|NCT00859898|Experimental|Dapagliflozin + Placebo|"Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks.
~Placebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks."
11570033|NCT00859898|Active Comparator|Metformin XR + Placebo|"Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks
~Placebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"
11570034|NCT00859885||1|Patients who receive antithrombotic treatment only
11570035|NCT00859885||2|Patients who undergo percutaneous device closure
11570036|NCT00859872|Experimental|oral group|risperidone oral solution combination clonazepam oral
11570037|NCT00859872|Active Comparator|IM group|haloperidol IM injection
11570038|NCT00859846|Experimental|Long Axis arterial line placement|Twenty four patients will undergo arterial line placements using long axis arterial line placement under ultrasound.
11570039|NCT00859846|Experimental|Short Axis arterial line placement|Twenty four patients will undergo arterial line placements using short axis arterial line placement under ultrasound.
11570040|NCT00859846|Active Comparator|Palpation arterial line placement|Twenty four patients will undergo arterial line placements using Traditional palpation arterial line placement.
11570041|NCT00859833|Experimental|myocardial perfusion reserve|Myocardial perfusion reserve will be measured by quantifying myocardial blood flow using MRI at rest and then with each of 2 coronary vasodilators. Measurements are performed with first pass gadolinium perfusion (i.v. bolus injection of 0.02 or 0.03 mmol/kg of gadolinium). Each of the 2 drugs is given sequentially (30 minutes apart) in the same sequence in every patient. The shorter acting drug (adenosine) is given first so it has time to wear off before giving the second drug. It is ideal to measure MPR with each drug during the same imaging session so that there are no other clinical variables that change between the administration of the 2 agents. See below.
11570042|NCT00859807|Experimental|Sequence 1 (19 subjects)|"Period 1: treatment A (15.3 mL (50 mg/5 mL) AQ suspension (Pfizer); test treatment.
~Period 2: treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis); reference treatment)."
11570044|NCT00859781|Experimental|1. 177Lu-J591+Ketoconzole|Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 177Lu-J591 Infusion, continue ketoconazole and hydrocortisone
11570045|NCT00859781|Placebo Comparator|2. 111In-J591 + ketoconazole|Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 111In-J591 (placebo) Infusion, continue ketoconazole and hydrocortisone
11570046|NCT00859768|Experimental|Intervention group 1|Pre-test measures are assessed. The patient receives the SIPP twice during their RT period. The first time is before the first consultation with the radiotherapist and the second time is before the last consultation at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
11570047|NCT00859768|Experimental|Intervention group 2|No pre-test measures are assessed. The patient receives the SIPP twice during their RT period. The first time is before the first consultation with the radiotherapist and the second time is before the last consultation at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
11570048|NCT00859768|No Intervention|Control group 1|Pre-test measures are assessed. Enhanced usual care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
11570049|NCT00859768|No Intervention|Control group 2|No pre-test measures are assessed. Enhanced usual care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
11570050|NCT00859755|Experimental|ARRY-403|
11570051|NCT00859755|Placebo Comparator|Placebo|
11570052|NCT00859742|Experimental|EBUS-TBNA|
11570053|NCT00859729|Experimental|Cohort I|50 µg DNA/dose, 3 patients
11570054|NCT00859729|Experimental|Cohort II|150 µg DNA/dose, 3 patients
11570055|NCT00859729|Experimental|Cohort III|400 µg DNA/dose, 3 patients
11570056|NCT00859729|Experimental|Cohort IV|1000 µg DNA/dose, 3 patients
11570057|NCT00859729|Experimental|Cohort V|Optimal dose to be determined, 6 patients
11570058|NCT00859716|Experimental|1|vaccination with ACE393 followed by challenge with campylobacter jejuni
11570059|NCT00859716|Placebo Comparator|2|Placebo vaccination followed by challenge with campylobacter jejuni
11570060|NCT00859703|Placebo Comparator|2|"Patients receive placebo 35 mg once a week plus a calcium and vitamin D supplementation.
~Measure of bone density, bone markers, clinical examination and questionnaire regarding fractures will be assessed at 12 and 24 months of treatment"
11570061|NCT00859703|Active Comparator|1|"Patients receive risedronate 35 mg once a week plus a calcium and vitamin D supplementation.
~Measure of bone density, bone markers, clinical examination and questionnaire regarding fractures will be assessed at 12 and 24 months of treatment"
11570062|NCT00859690||Sleep Disorder - Sleep Apnea|Subjects determined by a clinically indicated overnight sleep study (Nocturnal Polysomnography) to have Obstructive Sleep Apnea (OSA).
11570063|NCT00859690||Sleep Disorder - Not Sleep Apnea|Subjects determined by a clinically indicated overnight sleep study (Nocturnal Polysomnography) to have a sleep disorder other than Obstructive Sleep Apnea (OSA).
11570064|NCT00859677||1|HIV-positive and MRSA negative
11570065|NCT00859677||2|HIV-positive and MRSA infected (skin/soft tissue)
11570066|NCT00859677||3|HIV-positive and MRSA colonized
11570067|NCT00859677||4|HIV-negative and MRSA negative
11570068|NCT00859677||5|HIV-negative and MRSA infected (skin/soft tissue)
11570069|NCT00859677||6|HIV-negative and MRSA colonized
11570070|NCT00859664||Neuroleptics|Children with autistic spectrum disorder, treated with neuroleptics
11570071|NCT00859651|Active Comparator|20,000 IU weekly|"Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 20,000 IU weekly, for one year.
~Cholecalciferol 20,000 IU (2 active capsules + 1 matching placebo capsule)"
11570072|NCT00859651|Active Comparator|30,000 IU weekly|"Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 30,000 IU weekly, for one year.
~Cholecalciferol 30,000 IU (3 active capsules)"
11570073|NCT00859638|Experimental|Intervention Group|Rehabilitation self-management group, on-line self monitoring of physical function, and organizational capacity building.
11570074|NCT00859638|No Intervention|Case matched controls|Usual care in primary health care.
11570075|NCT00859625|Experimental|1|Nurse participation during colonoscope withdrawal
11570076|NCT00859625|No Intervention|2|usual colonoscopy practice
11570077|NCT00859599|Active Comparator|1|"At the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A & B, E & F, X & Y) the randomised patient shall receive.
~Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed."
11570078|NCT00859599|Placebo Comparator|2|"At the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A & B, E & F, X & Y) the randomised patient shall receive.
~Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed."
11570169|NCT00858884|No Intervention|No intevention|No intervention
11570170|NCT00858871|Active Comparator|Brivanib|
11570171|NCT00858871|Active Comparator|Sorafenib|
11570441|NCT00856960|Active Comparator|2|Aliskiren 150 mg
11570079|NCT00859586|Experimental|Miltenyi Magnetic cell sorter for CD3|"Miltenyi Magnetic cell sorter device will be used for CD3 selection of granulocyte colony stimulating factor mobilized allogeneic PBSCT. In stage 1, subjects will receive 1 x 10 to the eight power CD3 cells/kg. In stage II, the dose of CD3+ cells will be increased to 2 x 10 to the eight power cells/kg.
~This phase II clinical trial is designed to evaluate a novel non-myeloablative but highly immunosuppressive disease specific conditioning regimen and infusion of unmanipulated lymphocytes from a haplo-identical familial donor in subjects with relapsed disease following matched sibling stem cell transplantation who are not candidates for alternative treatment options. The clinical trial will evaluate recipient survival at six months post-relapse of disease."
11570080|NCT00859573|Active Comparator|1. Modafinil|
11570081|NCT00859573|Placebo Comparator|2: Placebo|Placebo
11570082|NCT00859547|Experimental|Recombinant thrombin (rThrombin), 1000 IU/mL|
11570083|NCT00859521|Experimental|Levetiracetam|Levetiracetam 1000 mg Tablet (test) dosed in first period followed by Keppra® 1000 mg Tablet (reference) dosed in second period
11570084|NCT00859521|Active Comparator|Keppra®|Keppra® 1000 mg Tablet (reference) dosed in first period followed by Levetiracetam 1000 mg Tablet (test) dosed in second period
11570085|NCT00859508|Experimental|SyntheCel|
11570086|NCT00859508|Active Comparator|other FDA cleared dura replacements|
11570087|NCT00859495|Experimental|Multimodal lung sparing regimen|"Intrapleural chemotherapy plus systemic chemotherapy:
~Thoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy."
11570088|NCT00859469|Experimental|Oxaliplatin and Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 90 minutes, then Oxaliplatin 100 mg/m² IV infusion over 2 hours repeated for 14 days up to 6 cycles
11570089|NCT00859456|Experimental|Sunitinib|Patients with unresectable or metastatic angiosarcoma, epithelioid sarcoma-like hemangioendothelioma and Kaposi's sarcoma, either receiving Sunitinib as first-line therapy or failure after no more than 2 prior chemotherapy regimens.
11570090|NCT00859430|Experimental|Levetiracetam|Levetiracetam 1000 mg Tablet (test) dosed in first period followed by Keppra® 1000 mg Tablet (reference) dosed in second period
11570091|NCT00859430|Active Comparator|Keppra®|Keppra® 1000 mg Tablet (reference) dosed in first period followed by Levetiracetam 1000 mg Tablet (test) dosed in second period
11570092|NCT00859417|Active Comparator|1|Traditional surgical method without prosthesis
11570093|NCT00859417|Experimental|2|Surgical method with Perigee prosthesis
11570094|NCT00859404|Experimental|1. oglemilast|
11570095|NCT00859404|Experimental|2. oglemilast|
11570096|NCT00859404|Experimental|3. oglemilast|
11570097|NCT00859404|Placebo Comparator|4. placebo|
11570098|NCT00859391||1 - Active|This group received gluten pre-treated with ALV003
11570099|NCT00859391||2 - Placebo|This group received Gluten pre-treated with placebo.
11570100|NCT00859378|Active Comparator|1 - cemented|Patients are treated with a cemented semiendoprosthesis
11570101|NCT00859378|Active Comparator|2 - non-cemented|Patients are treated with a non-cemented semiendoprosthesis
11570102|NCT00859365|Experimental|Acupuncture|Real Acupuncture
11570103|NCT00859365|Placebo Comparator|2 Placebo acupuncture|
11570104|NCT00859365|No Intervention|3 No treatment|No treatment performed
11570105|NCT00859352|Experimental|1|AZD1981 100mg and Midazolam
11570106|NCT00859352|Experimental|2|AZD1981 500mg and Midazolam
11570107|NCT00859339|Experimental|Experimental Treatment|Neoadjuvant cisplatin, gemcitabine and sunitinib malate followed by radical cystectomy
11570108|NCT00859313|Experimental|Sufentanil NanoTab PCA System/15 mcg|
11570109|NCT00859300||1|500 patients with ventricular fibrillation at the acute phase of myocardial infarct
11570110|NCT00859300||2|500 patients without ventricular fibrillation at the acute phase of myocardial infarct.
11570111|NCT00859274|Experimental|Budesonide|All patients receive this treatment to induce a change in asthma control
11570112|NCT00859261|Experimental|Breast imaging using Ultrasound and Photoacoustic|Evaluating 3D ultrasound for breast abnormalities/masses/cysts. This includes ultrasound imaging and possibly photoacoustic imaging.
11570113|NCT00859235|Active Comparator|1|
11570114|NCT00859235|Placebo Comparator|2. Plain water|
11570115|NCT00859222|Experimental|Phase I Cohort 1: Bevacizumab +LBH589 20 mg every week|Phase I Cohort 1 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the original starting LBH589 dose of 20 mg/day orally, 3x per week, every week (days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26). Participants were treated until disease progression or unacceptable toxicity.
11570116|NCT00859222|Experimental|Phase I Cohort 2: Bevacizumab + LBH589 20 mg every other week|Phase I Cohort 2 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the amended starting LBH589 dose of 20 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
11570117|NCT00859222|Experimental|Phase I Cohort 3: Bevacizumab + LBH589 30 mg every other week|Phase I Cohort 3 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
11570118|NCT00859222|Experimental|All Phase I Participants|All phase I participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 according to the established dose escalation schedule. Participants were treated until disease progression or unacceptable toxicity.
11570119|NCT00859222|Experimental|Phase II GBM: Bevacizumab + LBH589 30 mg every other week|Phase II glioblastoma (GBM) participants received the regimen established in the Phase I study (Feb 2011). Phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
11570285|NCT00857961|Experimental|3 mL (60 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days to both axilla (1.5 mL to each axilla). All study participants are randomized to each of the 4 study treatments.
11570120|NCT00859222|Experimental|Phase II AG: Bevacizumab + LBH589 30 mg every other week|Phase II Anaplastic Glioma (AG) participants received the regimen established in the Phase I study (Feb 2011). Phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
11570121|NCT00859222|Experimental|All Phase II Participants|All phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
11570122|NCT00859196|Experimental|Arm 1|
11570123|NCT00859196|Placebo Comparator|Arm 2|
11570124|NCT00859183|Active Comparator|1|cumulative loading dose of 8 mg of sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
11570125|NCT00859183|Active Comparator|2|cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
11570126|NCT00859183|Placebo Comparator|3|oral placebo
11570127|NCT00859170|Experimental|Accordion use|Use of an Accordion device during the lithotripsy.
11570128|NCT00859170|No Intervention|Control Group|Patients who will not have an Accordion device used during lithotripsy.
11570129|NCT00859157||Group 1|Patients undergo standard mastectomy.
11570130|NCT00859157||Group 2|Patients undergo tumescent mastectomy.
11570131|NCT00859144|Experimental|BART|Participants will complete the Becoming a Responsible Teen (BART) program.
11570132|NCT00859144|Experimental|Reducing the Risk|Participants will complete the Reducing the Risk program.
11570133|NCT00859144|Active Comparator|Be Proud Be Responsible|Participants will complete the Be Proud! Be Responsible! program.
11570134|NCT00859131|Active Comparator|Thymoglobulin|Subjects receiving Thymoglobulin as induction agent in renal transplantation
11570135|NCT00859131|Active Comparator|Zenapax|subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
11570136|NCT00859118|Experimental|Schedule A Cohort 1|"Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.
~Scan#1: Baseline (days -3 to 0) Scan#2: Week 2 (between days 12-14) Scan#3: Week 3 (7 days after axitinib held) Up to 10 patients will receive 2 DCE-CT scans at week 2 and 3, coinciding with the FLT-PET scans."
11570137|NCT00859118|Experimental|Schedule A: Cohort 2|"Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.
~Scan#1: Week 2 (between days 12-14) Scan#2: Week 3 (2 days after axitinib held) Scan#3: Week 3 (7 days after axitinib held) Up to 10 patients will receive 2 DCE-CT scans at week 2 and 3, coinciding with the FLT-PET scans."
11570138|NCT00859105|Experimental|Imiquimod 5%|Manufactured by Apotex
11570139|NCT00859105|Active Comparator|Adara 5 % Cream US|Manufactured by 3M, US.
11570140|NCT00859105|Active Comparator|Adara 5% Cream Canada|Manufactured by 3M, Canada
11570141|NCT00859105|Placebo Comparator|Vehicle|Manufactured by Apotex
11570142|NCT00859092|Experimental|Thickening of feeds|
11570143|NCT00859092|No Intervention|Removal of thickener|
11570144|NCT00859079|Active Comparator|GLP-1|Intravenously administered GLP-1
11570145|NCT00859079|Active Comparator|Insulin intravenously|Insulin intravenously according to the Munich registry
11570146|NCT00859066||Control Group|"First year University of Michigan Radiology residents will take call as scheduled without a buddy call experience.
~(Enrollment completed for the control group)"
11570147|NCT00859066||Experimental Group|2009 class of first year Radiology residents who will be assigned two 5 hour shifts working side by side with a more senior resident (who has experience taking call).
11570148|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh A|
11570149|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh B|
11570150|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh C|
11570151|NCT00859053|Active Comparator|BMS-790052 in Healthy Subjects|
11570152|NCT00859040|Experimental|SOM230C|Monthly SOM230C (pasireotide LAR) - 60 mg intramuscularly (Single-Arm Trial)
11570153|NCT00859027|Experimental|Risedronate|35 mg by mouth every week as directed
11570154|NCT00859027|Placebo Comparator|risedronate placebo tablet|Calcium and vitamin D
11570155|NCT00859014|Experimental|Autologous Bone Marrow Mononuclear Cells|Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg.
11570156|NCT00859001|Experimental|FM+R|4 cycles of FM+R plus Zevalin
11570157|NCT00858988|Experimental|Rifaximin|
11570158|NCT00858988|Placebo Comparator|Placebo|
11570159|NCT00858975|Experimental|Cryotherapy|The patients who receive cryotherapy for their renal tumors
11570160|NCT00858962|Experimental|Bup/Ral|Buprenorphine and Raltegravir co-administration
11570161|NCT00858949||Post surgery monitored group|Outpatients undergoing elective surgery with anesthesia that is expected to last one hour and to require significant postoperative opioids
11570162|NCT00858936|Experimental|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
11570163|NCT00858936|Placebo Comparator|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
11570164|NCT00858910|Experimental|EG1: embedded MI|"Experimental group 1:
~Participants receive motor imagery (MI) training included in 45min physiotherapy, 3 times per week for 2 weeks."
11570165|NCT00858910|Experimental|EG2: added MI|"Experimental group 2:
~Participants receive a 15 minutes motor imagery (MI) training added to a 30 min physiotherapy session, 3 times a week for two weeks."
11570166|NCT00858910|Placebo Comparator|CG|"Control group:
~Participants receive a 15 min control intervention added to their 30 min physiotherapy session, 3 times a week for two weeks."
11570167|NCT00858897|Experimental|1|Normoglycemia (80-140 mg/dL)
11570168|NCT00858897|Experimental|2|Hyperglycemia (200-250 mg/dL)
11570172|NCT00858858|Experimental|Arm 1|All patients are treated with DCA and UDCA perfusion of the esophagus, one year apart, followed by 8 weeks of treatment with oral ursodeoxycholic acid 10 mg/kg qd. Then a final DCA perfusion of the esophagus.
11570173|NCT00858845|Experimental|Clonidine patch|Participants assigned to wear a clonidine patch.
11570174|NCT00858845|Placebo Comparator|Placebo|Participants assigned to wear a matching placebo patch.
11570175|NCT00858832|Experimental|Methergine|Methergine group received Methergine 0.2mg po every 6 hours for two days, plus routine postpartum care.
11570176|NCT00858832|No Intervention|No treatment|No treatment group received only routine postpartum care.
11570177|NCT00858819||AS|Patients with AS attending three different rheumatology clinics in Western Sweden have been invited to participate.
11570178|NCT00858806|Experimental|Intermittent Imatinib|"Imatinib will be given with the following schedule:
~1 week on / 1 week off for the 1st month(weeks 1-4)
~2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)
~1 month on / 1 month off from the 4th month thereafter (weeks 13 on)"
11570179|NCT00858793|Experimental|A|
11570180|NCT00858780|Active Comparator|1|50mg once weekly + methotrexate
11570181|NCT00858780|Active Comparator|2|25mg once weekly + methotrexate
11570182|NCT00858780|Placebo Comparator|3|once weekly + methotrexate
11570183|NCT00858767|Active Comparator|1|2 casein capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks
11570184|NCT00858767|Active Comparator|2|2 arabic gum capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks
11570185|NCT00858767|Active Comparator|3|2 linseed capsules existing of 90 µg menaquinone-7 per day for 8 weeks
11570186|NCT00858754|Experimental|Group 1 Active Drug|Methylnaltrexone
11570187|NCT00858754|Placebo Comparator|Group 2 Non-Active Drug|Placebo
11570188|NCT00858741|Experimental|8 Gy arm|8.0 Gy in 1 fraction to 8.0 Gy total dose.
11570189|NCT00858741|Active Comparator|30 Gy arm|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
11570190|NCT00858728|Experimental|1|5 portions fruit and vegetables/day
11570191|NCT00858728|Other|2|2 portions fruit and vegetables/day
11570192|NCT00858715|Active Comparator|1|75 mg clopidogrel + 100 mg aspirin
11570193|NCT00858715|Active Comparator|2|150 mg clopidogrel + 100 mg aspirin
11570194|NCT00858702|Experimental|1|olmesartan medoxomil tablets and a CCB tablet (of the dihydropyridine class), once daily for 8 weeks
11570195|NCT00858702|Experimental|2|olmesartan medoxomil and a diuretic tablet (of the thiazide class)
11570196|NCT00858689|Experimental|minocyline 50 mg or 100 mg PO BID|open label treatment with minocycline low or high dose, 50 mg or 100 mg PO (by mouth) BID (twice a day), added to existing medication regimen for 8 weeks
11570197|NCT00858676|Active Comparator|Acarbose|
11570198|NCT00858663|Experimental|Chemoradiation|"IMRT, 1 fraction/day, over approximately 33 treatment days
~RAD001 per oral or PEG, per dose escalation scheme (Days 1 - 42)
~Cisplatin IV weekly, per dose escalation scheme (Days 1, 8, 15, 22, 29, 36)"
11570199|NCT00858650||Standard of Care|Hypogonadal males treated by standard of care, with or without testosterone replacement therapy
11570200|NCT00858637|Experimental|1 MCI-196|
11570201|NCT00858637|Placebo Comparator|2 Placebo of MCI-196|
11570202|NCT00858637|Active Comparator|3 Simvastatin|
11570203|NCT00858637|Placebo Comparator|4 Placebo of Simvastatin|
11570204|NCT00858624|Active Comparator|Chronic Cough Patients|
11570205|NCT00858624|Active Comparator|Healthy Volunteers|
11570206|NCT00858598||Pro Osteon|All patients in this pilot study will receive pro osteon as a bone void filler and will be enrolled according to the same inclusion / exclusion criteria.
11570207|NCT00858572|Experimental|Cohort|
11570208|NCT00858559|Experimental|1|Home Monitoring
11570209|NCT00858559|Active Comparator|2|Home Monitoring not used
11570210|NCT00858546|Experimental|Active repetitive transcranial Stimulation|Active repetitive transcranial Stimulation
11570211|NCT00858533|Other|workplace health advice|The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances.
11570212|NCT00858533|No Intervention|GP sickness absence consultation|Routine general practitioner care for workplace sickness absence.
11570213|NCT00858520||Smoking controls|Smokers without lung cancer and without COPD
11570214|NCT00858520||COPD patients|Smokers with COPD but without lung cancer
11570215|NCT00858520||Lung cancer patients|smokers - never smokers with lung cancer
11570216|NCT00858507|Experimental|Personal Health Assessment/RN Brief Intervention|RN-based medical outreach, administration of a personal health assessment and brief intervention
11570217|NCT00858507|Placebo Comparator|Social Work-Administered Outreach|Social work based outreach (usual care)
11570218|NCT00858494|Experimental|homeopathic cold remedy|
11570219|NCT00858481|Placebo Comparator|1|Vehicle control
11570220|NCT00858481|Active Comparator|2|0.5% Spinosad creme rinse
11570221|NCT00858481|Active Comparator|3|1.0% Spinosad Creme Rinse
11570222|NCT00858481|Active Comparator|4|2.0% Spinosad Creme Rinse
11570223|NCT00858468|Experimental|Group 1|Participants aged 6 to 12 Weeks at enrollment
11570224|NCT00858468|Experimental|Group 2|Participants aged 24 to 36 Weeks at enrollment
11570225|NCT00858455|Experimental|Healthy Volunteers|4 period cross over
11570226|NCT00858442|Experimental|With PRP|Each patient received a single dose of 5cc PRP before the graft.
11570227|NCT00858442|No Intervention|Without PRP|Control patients did not receive any intervention before the graft.
11570228|NCT00858429|Experimental|Cohort 1 (capecitabine, Y90)|2,000mg/m2 capecitabine +110 Y90
11570229|NCT00858429|Experimental|Cohort 2 (capecitabine , Y90)|2,000mg/m2 capecitabine + 130 Y90
11570230|NCT00858429|Experimental|Cohort 3 (capecitabine, Y90)|2,000mg/m2 Capecitabine + 150 Y90
11570231|NCT00858429|Experimental|Cohort 4 (capecitabine, Y90)|2,000 mg/m2 capecitabine = 170 Y90
11570232|NCT00858416|Experimental|AB|First active then Sham
11570233|NCT00858416|Sham Comparator|BA|First sham then active
11570349|NCT00857558|Experimental|3|OPC-262 5mg
11570350|NCT00857558|Placebo Comparator|4|
11570234|NCT00858403|Experimental|Treatment with Dasatinib|Dasatinib 140 mg orally (po) every day starting Day #1, continuous dosing. This dose was chosen based on the current experience in patients with solids tumors who have had prior chemotherapy.
11570235|NCT00858390|No Intervention|1 standard care|organ donors receiving standard care
11570236|NCT00858390|Experimental|2 Enteral Feeding|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
11570237|NCT00858377|Experimental|Arm 1- Dose Expansion|The dose expansion part of the study will begin after completion of the dose escalation phase and will consist of 3 cohorts of 14 subjects each. One taxane-resistant tumor type will be evaluated in each cohort.
11570238|NCT00858377|Experimental|Arm 1- Dose Escalation|The dose escalation part of the study is aimed at determining the maximum tolerated dose (MTD) of AMG 900 and if necessary, the MTD with prophylactic GCSF support (MTD-G).
11570239|NCT00858364|Placebo Comparator|Placebo|Participants received placebo once every 3 weeks (Q3W) administered subcutaneously until 3 weeks after the completion of chemotherapy or upon determination of disease progression, whichever occurred first.
11570240|NCT00858364|Experimental|Darbepoetin alfa|Participants received darbepoetin alfa 500 µg once every 3 weeks (Q3W) administered subcutaneously until 3 weeks after the completion of chemotherapy or upon determination of disease progression, whichever occurred first.
11570241|NCT00858351|Experimental|Thermal Biofeedback Assisted Relaxation|
11570242|NCT00858351|Active Comparator|Discussion|
11570243|NCT00858312|Experimental|1|Diet with 3-4 servings of dairy-rich foods/day
11570244|NCT00858312|Placebo Comparator|2|Low Dairy < 1 serving of dairy food/day
11570245|NCT00858299|Experimental|valsartan|
11570246|NCT00858286|Experimental|Stable dosing with SERETIDE, short acting B-2agonist as needed|Regular treatment with SERETIDE in a stable dosing with short acting beta-2 agonists as needed
11570247|NCT00858286|Experimental|Maintenance treatment with SYMBICORT and SYMBICORT as needed|Maintenance treatment with SYMBICORT and using the same inhaler with SYMBICORT as needed
11570248|NCT00858273|Active Comparator|Antioxidant Supplement|Vitamin C 250 mg; beta-carotene 6 mg; vitamin E 30 mg; selenium 100 mcg; zinc 20 mg
11570249|NCT00858273|Placebo Comparator|Placebo|
11570250|NCT00858260||hemodialysis patients|Adult patients undergoing maintenance dialysis since at leat three months
11570251|NCT00858247|Experimental|Vitamin D3-low dose|Vitamin D3 400 IU capsule, one capsule daily for 12 weeks.
11570252|NCT00858247|Experimental|Vitamin D3-high dose|Vitamin D3 2000 IU capsule, one capsule daily for 12 weeks.
11570253|NCT00858234|Experimental|1|MK0683
11570254|NCT00858208||Patients with neovascular Age-Related Macula Degeneration|
11570255|NCT00858195|Experimental|1|Indomethacin 75mg ER Capsules
11570256|NCT00858195|Active Comparator|2|Indocin 75mg SR Capsules
11570257|NCT00858182|Experimental|Group A|
11570258|NCT00858182|Experimental|Group B|
11570259|NCT00858143||1|
11570260|NCT00858130|Experimental|Veinoplus|Every subject enrolled in study will be in this experimental arm. VeinoPlus device will be used by all enrolled subjects.
11570261|NCT00858117|Experimental|Alemtuzumab and Rituximab|Administration of Alemtuzumab combined with Rituximab to test the feasibility of combining these two monoclonal antibodies as a first line therapy in patients with B-cell chronic lymphocytic leukemia.
11570262|NCT00858104|Active Comparator|1|Laser thermal ablation
11570263|NCT00858104|No Intervention|2|Follow-up
11570264|NCT00858078||Previously referred|Previously-enrolled subjects from NCI Protocol 01-C-0009
11570265|NCT00858078||Self-referred|Self-referred women at increased familial risk of breast and ovarian cancer were recruited through an hereditary breast/ovarian cancer advocacy group
11570266|NCT00858065|Active Comparator|RCT FM|Random control trial- Family Matters. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to Family Matters program.
11570267|NCT00858065|Active Comparator|Choice SFP|Half the families were assigned to the choice condition in which they can choose between two prevention programs. This arm chose the Strengthening Families Program (SFP).
11570268|NCT00858065|Active Comparator|RCT SFP|Random control trial- Strengthening Families Program. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to Strengthening Families Program.
11570269|NCT00858065|No Intervention|RCT Control|Random control trial- Control Group. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to the control group and received no prevention program. However, this group and all groups received an informational pamphlet about youth alcohol and other drug use.
11570270|NCT00858065|Active Comparator|Choice FM|Half the families were assigned to the choice condition in which they can choose between two prevention programs. This arm chose the Family Matters (FM) program.
11570271|NCT00858052|Experimental|breast augmentation|breast implant
11570272|NCT00858039||Her-2 positive ESBC|
11570273|NCT00858026|Other|1|Breastfed babies
11570274|NCT00858026|Active Comparator|2|Weaning with the standard milk
11570275|NCT00858026|Experimental|3|Weaning with the fermented milk
11570276|NCT00858013|Active Comparator|Nateglinide|Nateglinide 90~120mg three times a day
11570277|NCT00858013|Active Comparator|Glimepiride|Glimepiride 1~2mg once a day
11570278|NCT00858000||Group A|No intervention
11570279|NCT00857987|Experimental|1|Guaifenesin, doxylamine succinate and hydrochloride etafedrine syrup
11570280|NCT00857987|Placebo Comparator|2|Vehicle
11570281|NCT00857974|No Intervention|Usual Care|No physical activity intervention will be prescribed for the Usual Care Arm.
11570282|NCT00857974|Active Comparator|Physical Activity|
11570283|NCT00857961|Experimental|3 mL (30 mg) of 1% Testosterone MD-Lotion|Applied once daily for 7 days to both axilla (1.5 mL to each axilla). All study participants are randomized to each of the 4 study treatments.
11570284|NCT00857961|Experimental|1.5 mL (30 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days to one axilla. All study participants are randomized to each of the 4 study treatments.
11570442|NCT00856960|Active Comparator|3|Losartan 100 mg
11570443|NCT00856960|Placebo Comparator|4|Placebo
11570286|NCT00857961|Experimental|4.5 mL (90 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days by three doses to both axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla). All study participants are randomized to each of the 4 study treatments.
11570287|NCT00857948|Experimental|0.15% ivermectin|Participant on 0.15% ivermectin treatment conditioner
11570288|NCT00857948|Experimental|0.25% ivermectin|Participants on 0.25% ivermectin treatment conditioner
11570289|NCT00857948|Experimental|0.50% ivermectin|Participants on 0.50% ivermectin treatment conditioner
11570290|NCT00857948|Placebo Comparator|Placebo|participants on Placebo (Vehicle control)
11570291|NCT00857935|Experimental|1|NatrOVA Creme Rinse - 1%
11570292|NCT00857935|Active Comparator|2|NIX Creme Rinse
11570293|NCT00857922||Neurosurgical patient|Neurosurgical patient of the Mischer Neuroscience Institute, 18 years and over
11570294|NCT00857922||Family members|Family members of specific vascular, trauma, brain tumor and functional disorder cohorts
11570295|NCT00857909|Active Comparator|Randomisation 1|Amiloride 5 mg twice daily for 28 days, later compared with spironolactone and placebo
11570296|NCT00857909|Active Comparator|Randomisation 2|Spironolactone 25 mg twice daily, to be compared with placebo and amiloride
11570297|NCT00857909|Placebo Comparator|Placebo|calcium tablet
11570298|NCT00857896|Experimental|Fesoterodine once daily|
11570299|NCT00857883|Placebo Comparator|Part A|Part A: This part of the study will start with a very low dose of study drug, which will then be gradually increased in subsequent doses. This is known as dose-rising and is the way to assess safety and tolerability (i.e. possible presence of any side effects that make taking the drug unpleasant) of increasing doses of the study drug. Effects will be compared to those seen when a placebo is taken. Up to 4 groups of 6-9 healthy male or female volunteers will be enrolled.
11570300|NCT00857883|Active Comparator|Part B|Part B: A dose selected from Part A that was well tolerated will be used to check if there is a difference in the pharmacokinetics (blood levels) of the study drug when taken without food in liquid form, or as a capsule, or as a capsule together with a high fat meal to assess the effect of food. One group of 12 healthy male or female volunteers will be enrolled.
11570301|NCT00857883|Placebo Comparator|Part C|Part C: A well tolerated dose selected from Parts A & B will be used to test whether the drug has an effect on individual preferences for sugary and high fat food, when compared to placebo. Up to 32 healthy overweight male volunteers will be enrolled.
11570302|NCT00857870|Active Comparator|Metformin|
11570303|NCT00857870|Active Comparator|Insulin glargine|
11570304|NCT00857857|Experimental|13 day repeat dose|
11570305|NCT00857844||Group 1|Normal GFR (>90ml/min/1.73m2). Stage I CKD
11570306|NCT00857844||Group 2|GFR between 30-59ml/min/1.73m2. Stage III CKD
11570307|NCT00857844||Group 3|GFR between 15-29ml/min/1.72m2. Stage IV CKD
11570308|NCT00857831|Experimental|Arm 1|Vitamin D & Calcium supplementation in FES
11570309|NCT00857818|Experimental|Aripiprazole|
11570310|NCT00857818|Active Comparator|Control group (Oanzapine, risperidone, or quetiapine)|
11570311|NCT00857805|Active Comparator|Transarterial Chemoembolization|Transarterial Chemoembolization
11570312|NCT00857805|Active Comparator|Proton Beam Radiotherapy|Proton Beam Radiotherapy
11570313|NCT00857792|Other|Open Label|
11570314|NCT00857779|Active Comparator|subcutaneous immunotherapy|subcutaneous immunotherapy using a slow updosing schedule
11570315|NCT00857779|Active Comparator|subcutaneous injections|subcutaneous immunotherapy using a fast updosing schedule
11570316|NCT00857766|Active Comparator|ADVAIR DISKUS|Subjects receive blinded Fluticasone Propionate/Salmeterol. At 4 months subjects will receive open label SPIRIVA HANDIHALER
11570317|NCT00857766|Placebo Comparator|Placebo|Subjects will receive placebo ADVAIR DISKUS. At 4 months subjects will receive open label SPIRIVA HANDIHALER
11570318|NCT00857753|Experimental|1|Fentanyl patch 25 ug/hr Sandoz
11570319|NCT00857753|Active Comparator|2|Duragesic Patch 25 ug/hr
11570320|NCT00857727|Experimental|Drug|Dexmedetomidine
11570321|NCT00857727|Placebo Comparator|Control|Normal Saline IV solution
11570322|NCT00857701|No Intervention|1|Patient will receive post-surgical standard of care treatment with standard Physical therapy and NSAIDs.
11570323|NCT00857701|Experimental|2|Patients will be treated with the Standard of Care physical therapy and NSAIDs as well as a Knee Extension Dynasplint that includes tension chambers.
11570324|NCT00857688|Experimental|1 - Test|Patients will recieve the association.
11570325|NCT00857688|Placebo Comparator|2|Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
11570326|NCT00857675|Experimental|Adefovir Dipivoxil|ADV 10mg tablets once daily
11570327|NCT00857675|Placebo Comparator|Adefovir Dipivoxil matched placebo|Adefovir Dipivoxil matched placebo one tablet once daily
11570328|NCT00857662|Experimental|Onyx|
11570329|NCT00857662|Active Comparator|TRUFILL|
11570330|NCT00857649|Experimental|Memantine|
11570331|NCT00857649|Placebo Comparator|Placebo|
11570332|NCT00857636|Experimental|Health Literacy|
11570333|NCT00857623|Experimental|1|
11570334|NCT00857623|Placebo Comparator|2|
11570335|NCT00857610||1|Subjects using 0.1% retinol one day per week
11570336|NCT00857610||2|Subjects using 0.1% retinol three days per week
11570337|NCT00857610||3|Subjects using 0.1% retinol seven days per week
11570338|NCT00857610||4|Subjects using 0.5% retinol one day per week
11570339|NCT00857610||5|Subjects using 0.5% retinol three days per week
11570340|NCT00857610||6|Subjects using 0.5% retinol seven times per week
11570341|NCT00857597|Experimental|EsophyX|
11570342|NCT00857597|Active Comparator|Proton Pump Inhibitors|
11570343|NCT00857584|Experimental|Quetiapine Extended Release|Lithium or valproate at stable doses within seric therapeutic levels
11570344|NCT00857584|Active Comparator|Sertraline|Lithium or valproate at stable doses within seric therapeutic levels
11570345|NCT00857571|Experimental|Suspension|PF-02413873 suspension
11570346|NCT00857571|Experimental|Tablet|PF-02413873 Phase 2 Tablets
11570347|NCT00857558|Experimental|1|OPC-262 1mg
11570348|NCT00857558|Experimental|2|OPC-262 2.5mg
11570351|NCT00857545|Experimental|Arm I (vaccine therapy and adjuvant)|Patients receive polyvalent antigen-KLH conjugate vaccine and immunological adjuvant OPT-821 subcutaneously (SC) once in weeks 1, 2, 3, 7, 11, 23, 35, 47, 59, 71, and 83 in the absence of disease progression or unacceptable toxicity.
11570352|NCT00857545|Experimental|Arm II (adjuvant)|Patients receive immunological adjuvant OPT-821 SC as in arm I.
11570353|NCT00857532|Experimental|Normal cognitive performance|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores of ≥9, indicating normal cognitive performance.
11570354|NCT00857532|Experimental|Mild cognitive deficits|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores between 6 and 8, inclusive, indicating mild cognitive deficits.
11570355|NCT00857532|Experimental|Severe cognitive impairment|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores below 5, indicating moderate to severe cognitive impairment.
11570356|NCT00857519|Experimental|Chemotherapy|Chemotherapy using Melphalan, Carboplatin.
11570357|NCT00857493|Experimental|Group 1|
11570358|NCT00857493|Experimental|Group 2|
11570359|NCT00857480|Experimental|Reference|No pre-treatment
11570360|NCT00857480|Experimental|T1|Cloxacillin pre- and co-treatment
11570361|NCT00857480|Experimental|T2|UDCA pre-treatment
11570362|NCT00857467|Experimental|1 g suppository|Subjects receive 5 mg NRL001, 10 mg NRL001 and placebo in a 1g rectal suppository
11570363|NCT00857467|Experimental|2 g suppository|Subjects receive 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository.
11570364|NCT00857454|Experimental|Testosterone MD-lotion|"In this open-label extension of the MTE08 trial, participants received Testosterone Metered Dose (MD)-Lotion for 60 days (dosing from Day 121 of the MTE08 trial to Day 180 of the MTE09 trial). Participants in MTE08 initially received 3.0 milliliters (mL) (60 micrograms [mg]) of 2% Testosterone MD-Lotion, and may have had their dose of testosterone adjusted upwards or downwards.
~Doses could be titrated to one of the following:
~1.5 mL (30 mg) of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to one axilla).
~3.0 mL (60 mg)of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to each axilla).
~4.5 mL (90 mg)of 2% Testosterone MD-Lotion applied daily by 3 doses to the axilla (2 x 1.5 mL to one axilla and 2 x 1.5 mL to the other axilla).
~6.0 (120 mg)of 2% Testosterone MD-Lotion applied daily by 4 doses to the axilla (2 x 1.5 mL to each axilla)."
11570365|NCT00857441|Experimental|1|Use of Dior balloon and implant of Liberté Bare Metal Stent
11570366|NCT00857441|Active Comparator|2|Use of standard balloon and implant of Liberté Bare Metal Stent
11570367|NCT00857441|Active Comparator|3|Use of standard balloon and implant of Taxus Liberté Drug Eluting Stent
11570368|NCT00857428|Experimental|1|Oxymorphone ER 40 mg tablets Sandoz
11570369|NCT00857428|Active Comparator|2|Opana ER 40 mg tablets Eon Pharmaceuticals
11570370|NCT00857415|Experimental|Autopsy Cohort|End-of-life subjects (life expectancy < 6 months) consenting to brain donation at autopsy.
11570371|NCT00857415|Experimental|Specificity Cohort|Younger healthy controls presumed to be devoid of beta-amyloid plaques.
11570372|NCT00857402|Active Comparator|Peanuts|
11570373|NCT00857402|Active Comparator|Daboqolo|
11570374|NCT00857389|Experimental|Thio-Clo-Bu with Allo SCT|"Pre-transplant conditioning regimen:
~Thiotepa (Thio) + Clofarabine (Clo) + Busulfan (Blu) + Allogeneic Stem Cell Transplantation (Allo SCT) + ATG + G-CSF
~Post haploidentical stem cell transplant participants:
~Cyclophosphamide 50 mg/kg by vein on Days + 3 and + 4. Mesna 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses."
11570375|NCT00857376|Placebo Comparator|placebo|Placebo 2 tabs three times daily
11570376|NCT00857376|Experimental|Alpha lipoic acid 1|Alpha lipoic acid 600 mg daily
11570377|NCT00857376|Experimental|Alpha lipoic acid 2|Alpha Lipoic acid 1200 mg daily
11570378|NCT00857376|Experimental|Alpha lipoic acid 3|Alpha lipoic acid 1800 mg daily
11570379|NCT00857363||Constipated|Adult subjects with functional constipation as define by Rome II criteria
11570380|NCT00857350||HIV+, opiod dependent|
11570381|NCT00857324|Experimental|ZMP|Combination with Vorinostat, Melphalan and Prednisone
11570382|NCT00857311|Experimental|MRKAd5 HIV-1 gag vaccine 1x10^9 vp/dose|Participants administered MRKAd5 HIV-1 gag vaccine 1x10^9 viral particles (vp)/dose (V520), on Day 1, Week 4, and Week 26.
11570383|NCT00857311|Experimental|MRKAd5 HIV-1 gag vaccine 1x10^10 vp/dose|"Participants were to be administered MRKAd5 HIV-1 gag 1x10^10 vp/dose (V520) on Day 1, Week 4, and Week 26.
~Per a letter dated 30-Aug-2005 all sites were notified that due to recruitment challenges enrollment would be halted as of 01-Oct-2005. Consequently, no participants were enrolled in the group MRKAd5 HIV-1 gag 1x10^10 vp/dose."
11570384|NCT00857311|Experimental|Placebo|Participants administered placebo to MRKAd5 HIV-1 gag vaccine (V520) on Day 1, Week 4, and Week 26.
11570385|NCT00857311|Sham Comparator|Open Label Tetanus and Diptheria Toxoids Adsorbed|"Participants were to be administered open label tetanus and diptheria toxoids adsorbed (Td) at Day 1 only.
~Per a letter dated 30-Aug-2005 all sites were notified that due to recruitment challenges enrollment would be halted as of 01-Oct-2005. Consequently, no participants were enrolled in this group."
11570386|NCT00857298|Active Comparator|HIV-MS|HIV-positive obese women with metabolic syndrome will be studied before and after losing 6-8% of body weight
11570387|NCT00857298|Active Comparator|MS only|HIV-negative obese women with metabolic syndrome will be studied before and after losing 6-8% of body weight
11570388|NCT00857285|Experimental|1|olmesartan medoxomil
11570389|NCT00857285|Active Comparator|2|losartan potassium
11570390|NCT00857272|Active Comparator|HalfLytely with 10mg bisacodyl|Active control
11570391|NCT00857272|Experimental|HalfLytely with 5mg bisacodyl|Investigational dose
11570392|NCT00857259|Experimental|Everolimus 5 mg|5 mg orally once daily plus sham ocular injection on Day 1 (Baseline) until Day 28
11570393|NCT00857259|Active Comparator|Ranibizumab 0.5 mg|Ranibizumab intra-vitreal therapy (IVT) 0.5 mg on Day 1 (baseline)
11570394|NCT00857259|Active Comparator|Oral Everolimus (5mg) and Ranibizumab (0.5mg)|Everolimus orally 5 mg once daily plus Ranibizumab Intra-vitreal therapy (IVT) 0.5 mg on day 1 (baseline)
11570436|NCT00856986|Other|Intensified group|Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c ≥ 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group.
11570395|NCT00857246|Experimental|Induction/ surgery/ chemoRT|"Induction treatment (3 weeks/cycle x 4 cycles): Cisplatin and Irinotecan on days 1 and 8; Cetuximab on days 1, 8, and 15.
~Surgery (starts 3-4 weeks after induction treatment).
~Chemoradiation treatment (starts 4-6 weeks after surgery):
~weeks 1-19: Cetuximab on day 1 of every week; week 1: 5-FU and Leucovorin (LV) x 5 days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU+ LV on days 1-4; week 9: 5-FU+ LV on days 1-3; weeks 14 and 19: 5-FU+LV x 5days"
11570396|NCT00857233|Experimental|Memantine|
11570397|NCT00857220|Experimental|2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs)|
11570398|NCT00857207|Experimental|Arm 1: Treatment Goal Management Training|Treatment Goal Management Training
11570399|NCT00857207|No Intervention|Arm 2: Control-Brain Health Workshop|Control-Brain Health Workshop
11570400|NCT00857194||Group 2|Chronic, stable spinal cord injury
11570401|NCT00857181||Liver Cirrhosis|Single cohort of patients with liver cirrhosis to be investigated in the study. Two-monthly measurements of serum cytokines.
11570402|NCT00857168|Active Comparator|Group 1|
11570403|NCT00857168|Active Comparator|Group 2|
11570404|NCT00857168|Active Comparator|Group 3|
11570405|NCT00857168|Active Comparator|Group 4|
11570406|NCT00857168|Active Comparator|Group 5|
11570407|NCT00857168|Active Comparator|Group 6|
11570408|NCT00857155|No Intervention|Aspirin only|Continue aspirin until surgery
11570409|NCT00857155|Other|Clopidogrel and Aspirin|
11570410|NCT00857142|Experimental|1|Oxymorphone hydrochloride 40 mg extended release tablets (Sandoz)
11570411|NCT00857142|Active Comparator|2|Opana 40 mg extended release tablets
11570412|NCT00857129|No Intervention|1|Low risk women with expected normal birth are being Randomized to The Midwife-led Unit, with low amount of intervention, No epidural is offered, no medical augmentation available, unless for the active phase of the second stage. If extended surveillance is necessary or if the birth no longer is considered to be normal and needs to be taken over by a doctor, the woman will be transferred to either the Normal Unit or the Special Unit
11570413|NCT00857129|Experimental|2|Low-risk women are randomised to this Low-risk maternal unit, The Normal Unit.The unit is organised for low-risk women with expected normal birth. The unit has access to extended surveillance, epidural and operative vaginal deliveries. If extended surveillance is necessary for a woman randomised to this unit, she does not have to be transferred to a higher level of care. Instrumental vaginal deliveries can be carried out at this unit.
11570414|NCT00857129|Experimental|3|Women with expected normal births are being randomised to this Special birth unit designed to take care of women before, under and after birth. The Special Unit cares for women with extended need for surveillance, but does also handle low-risk women.
11570415|NCT00857116|Active Comparator|Albendazole|Albendazole 400mg per os once daily for three consecutive days
11570416|NCT00857116|Placebo Comparator|Placebo|Placebo 400mg per os for three consecutive days
11570417|NCT00857103|No Intervention|1|Standard care
11570418|NCT00857103|Experimental|2|Use of Choice intervention to support consultations
11570419|NCT00857090|Experimental|1|Drug
11570420|NCT00857090|Placebo Comparator|2|Vehicle
11570421|NCT00857077|Placebo Comparator|1 Placebo|
11570422|NCT00857077|Active Comparator|2 Sulfadoxine-pyrimethamine (SP)|
11570423|NCT00857051|Experimental|1|A 22 minute DVD that discusses common stressor in the early postpartum.
11570424|NCT00857051|Experimental|2|A 24 hour hotline available for the first 3 months postpartum.
11570425|NCT00857051|Experimental|3|Both the film and the hotline will be given to this arm.
11570426|NCT00857051|No Intervention|4|A CD of children's music will be given to mothers in this arm.
11570427|NCT00857038|Experimental|1|Doxycycline 100mg daily
11570428|NCT00857038|Placebo Comparator|2|Placebo
11570429|NCT00857025|Experimental|Treatment (beta-glucan MM-10-001)|Patients receive oral beta-glucan MM-10-001 once or twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11570430|NCT00857012||All patients|treated with Anastrozole as per SPC
11570431|NCT00856999|Experimental|Botox|Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
11570432|NCT00856986|Experimental|Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%
11570433|NCT00856986|Experimental|Insulin detemir + Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%
11570434|NCT00856986|Experimental|Non-Randomised Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%
11570435|NCT00856986|Other|Early Withdrawals Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial
11570437|NCT00856973|Experimental|Low dose eszopiclone|1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
11570561|NCT00856271|Experimental|1|olmesartan medoxomil
11570444|NCT00856947|Active Comparator|Vitamin D|Dietary supplement: 2400 IU Vitamin D3 (2 tablets of 1200 IU) from week 24 of gestation to 1 week after delivery
11570445|NCT00856947|Placebo Comparator|Placebo|Placebo: 2 placebo tablets with no active substance, identical to the active tablets, from week 24 of gestation to 1 week after delivery
11570446|NCT00856934|No Intervention|Control|Wounds covered with standard dressings: three layers of paraffin gauze, standard bandages, elastic bandage.
11570447|NCT00856934|Experimental|PRP|PRP sprayed onto the wound bed with Calcium Choride. Wounds covered with same standard dressings used in control group.
11570448|NCT00856934|Experimental|PRP+K|Keratinocytes suspended in PRP sprayed onto the wound bed with Calcium Choride. Wounds covered with same standard dressings used in control group.
11570449|NCT00856908|Experimental|1|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
11570450|NCT00856908|Placebo Comparator|2|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
11570451|NCT00856895||Hispanic|
11570452|NCT00856895||Non-Hispanic|
11570453|NCT00856882|Experimental|soy protein and isoflavones|
11570454|NCT00856882|Experimental|milk protein and isoflavones|
11570455|NCT00856882|Placebo Comparator|milk protein only|
11570456|NCT00856869|Experimental|1 YM|Healthy young males
11570457|NCT00856869|Experimental|2 EM|Healthy elderly males
11570458|NCT00856869|Experimental|3 YF|Healthy young females
11570459|NCT00856869|Experimental|4 EF|Healthy elderly females
11570460|NCT00856869|Experimental|5 NASH|Patients with presumed NASH
11570461|NCT00856869|Experimental|6 CTP-A|Patients with hepatic cirrhosis CTP-class A
11570462|NCT00856869|Experimental|7 CTP-BC|Patients with hepatic cirrhosis CTP-class B and C
11570463|NCT00856856|Experimental|Absorb stent|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)
11570464|NCT00856843|Active Comparator|Polyethylene glycol 3350 based bowel preparation|Polyethylene glycol 3350 based bowel preparation
11570465|NCT00856843|Experimental|BLI800|BLI800
11570466|NCT00856830|Experimental|Novel Drug Combination|"This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin.
~This study has only one arm but it incorporates two phases. Phase I utilizes a combination of bendamustine and irinotecan for Regimen A followed by etoposide and carboplatin for Regimen B."
11570467|NCT00856817|Experimental|1|L-arginine treatment first, heme arginate treatment second
11570468|NCT00856817|Experimental|2|Heme arginate treatment first, L-arginine treatment second
11570469|NCT00856804|Experimental|1|thalidomide added to peg-interferon + ribavirina
11570470|NCT00856791|Experimental|ON 01910.Na|3200 mg ON 01910.Na administered intravenously over 2 hours on days 1, 4, 8, 11, 15, and 18 of 28-day cycle
11570471|NCT00856778|Other|Virtue® Male Sling|Subjects implanted with Virtue® Male Sling
11570472|NCT00856765|Experimental|1|Drug eluting balloon followed immediately by implantation of bare metal stent
11570473|NCT00856765|Active Comparator|2|Drug eluting stent
11570474|NCT00856765|Active Comparator|3|Bare metal stent
11570475|NCT00856752|Experimental|T1|Pre-treatment with rifampicin
11570476|NCT00856752|Experimental|T2|Pre-treatment with cyclosporin
11570477|NCT00856752|Experimental|Reference|Administration of NRL001 alone: no pre-treatment
11570478|NCT00856739||Group 1|
11570479|NCT00856726|Experimental|PTH infusion|(1-34) PTH infusion at a rate of 0.055 ug/kg/hour for six hours
11570480|NCT00856713|Experimental|1 YM|Healthy young males
11570481|NCT00856713|Experimental|2 EM|Healthy elderly males
11570482|NCT00856713|Experimental|3 YF|Healthy young females
11570483|NCT00856713|Experimental|4 EF|Healthy elderly females
11570484|NCT00856713|Experimental|5 CTP-A|Patients with hepatic cirrhosis CTP-class A
11570485|NCT00856713|Experimental|6 CTP-BC|Patients with hepatic cirrhosis CTP-class B and C
11570486|NCT00856700|Experimental|GLP-1 infusion|Patients with metabolic syndrome
11570487|NCT00856687|Experimental|PF-03893787|
11570488|NCT00856687|Placebo Comparator|Placebo|
11570489|NCT00856687|Active Comparator|Montelukast|
11570490|NCT00856661|Experimental|Desmoteplase|
11570491|NCT00856661|Placebo Comparator|Placebo|
11570492|NCT00856648||Group 1|SCI
11570493|NCT00856648||Group 2|Able-bodied
11570494|NCT00856635|Experimental|Glatiramer acetate|Participants received glatiramer acetate 20 mg subcutaneous injection once a day for up to 6 months.
11570495|NCT00856635|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once a day for up to 6 months.
11570496|NCT00856622|Experimental|Fixed combination of latanoprost 0.005% and timolol 0.5%|
11570497|NCT00856622|Active Comparator|timolol 0.5% ophthalmic solution|one drop in the morning and evening
11570498|NCT00856622|Active Comparator|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
11570499|NCT00856609|Active Comparator|Exenatide|10 micrograms subcutaneously twice
11570500|NCT00856609|Placebo Comparator|Placebo|Twice daily
11570501|NCT00856596|Other|Males and females with athlete's foot|Male and female subjects with athlete's foot inbetween their toes without nail involvement
11570502|NCT00856583|Experimental|Sertindole|Normally in the range of 4 to 20 mg/day
11570503|NCT00856583|Active Comparator|Risperidone|Normally in the range of 2 to 8 mg/day
11570504|NCT00856557|Experimental|Seminar and Practicum|Seminar and practicum that occurs over 4 week period for internal medicine residents, designed to provide a systematic approach to identifying and addressing contextual factors essential to planning patient care.
11570505|NCT00856557|No Intervention|No intervention|No educational intervention.
11570506|NCT00856544|Experimental|Active 5 mg|
11570507|NCT00856544|Experimental|Active 10 mg|
11570508|NCT00856544|Placebo Comparator|Placebo Sequence 1|Placebo non-responders advance to 5 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 5 mg CP-690,550 at Month 6 visit.
11570562|NCT00856271|Active Comparator|2|losartan potassium
11570509|NCT00856544|Placebo Comparator|Placebo Sequence 2|Placebo non-responders advance to 10 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 10 mg CP-690,550 at Month 6 visit.
11570510|NCT00856531||1|
11570511|NCT00856531||2|
11570512|NCT00856531||3|
11570513|NCT00856531||4|
11570514|NCT00856531||5|
11570515|NCT00856531||6|
11570516|NCT00856531||7|
11570517|NCT00856531||8|
11570518|NCT00856531||9|
11570519|NCT00856531||10|
11570520|NCT00856531||11|
11570521|NCT00856531||12|
11570522|NCT00856531||13|
11570523|NCT00856531||14|
11570524|NCT00856531||15|
11570525|NCT00856518|Active Comparator|Arm 1: EMST|The experimental group receives five weeks of expiratory muscle strength training (EMST) using a positive pressure threshold device
11570526|NCT00856518|Sham Comparator|Arm 2: Sham group|The Sham group undergoes the same 5-week EMST exercise as the experimental group using the same device but without a spring for minimal pressure load
11570527|NCT00856505|Experimental|Everolimus and mycophenolate sodium|Combination of experimental immunosuppressants for GvHD prophylaxis
11570528|NCT00856492|Experimental|Arm 1|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 and bevacizumab IV over 30- to 90-minutes on day 1 of weeks 1-12. Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 14, 16, 18, 20, 22, and 24.
11570529|NCT00856492|Active Comparator|Arm 2|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 of weeks 1-12, and then receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 14, 16, 18, 20, 22, and 24.
11570530|NCT00856492|Active Comparator|Arm 3|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 1, 3, 5, 7, 9, and 11, and then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 of weeks 14-25.
11570531|NCT00856479|Active Comparator|1 Infuse|The patient will receive BMP 2 with allograft
11570532|NCT00856479|Active Comparator|2 Iliac crest autograft|Autograft from Patients Iliac Crest and allograft
11570533|NCT00856453|Experimental|Yoga classes plus home yoga practic|
11570534|NCT00856453|Experimental|home yoga practice alone|
11570535|NCT00856440||1|SCI
11570536|NCT00856440||2|Able-bodied
11570537|NCT00856427|Experimental|Diagnostic|Patients undergo implantation of radio-opaque markers into the primary lesion and affected lymph nodes by bronchoscopy. Patients then undergo routine 4D CT, 4D CBCT, fluoroscopy, and x-ray imaging during standard stereotactic radiation therapy (early stage tumors) or conventionally fractionated radiation therapy (advanced stage tumors).
11570538|NCT00856414|Experimental|1|botulinum toxin Type A 20U
11570539|NCT00856401|Experimental|PTH1-84 in parent study|In the RELAY, RACE, and HEXT study participants utilize PTH1-84. In the REPLACE Study participants utilize PTH1-84 or placebo of PTH1-84.
11570540|NCT00856388|Experimental|Treatment (Reduced intensity allogeneic stem cell transplant)|"Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.
~Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan."
11570541|NCT00856375|Experimental|NKTR-102|NKTR-102
11570542|NCT00856375|Active Comparator|irinotecan|IV every 3 weeks
11570543|NCT00856362|Experimental|1|
11570544|NCT00856349||Analysis cohort|Enrolled subjects who met study eligibility criteria and contributed data toward study endpoints.
11570545|NCT00856323|Experimental|PEP/CM|Participants are provided contingency management vouchers for methamphetamine abstinence, and can initiate postexposure prophylaxis (Truvada; 1 pill daily for 28 days) after non-occupational exposure to HIV.
11570546|NCT00856310|Active Comparator|Cohort 1|Dose 1 REGN475
11570547|NCT00856310|Active Comparator|Cohort 2|Dose 2 of REGN475
11570548|NCT00856310|Active Comparator|Cohort 3|Dose 2 of REGN475
11570549|NCT00856310|Active Comparator|Cohort 4|Dose 1 of REGN475
11570550|NCT00856310|Active Comparator|Cohort 5|Dose 2 of REGN475
11570551|NCT00856310|Active Comparator|Cohort 6|Dose 1 REGN475 subcutaneous administration
11570552|NCT00856310|Active Comparator|Cohort 7|Dose 2 REGN475 subcutaneous administration
11570553|NCT00856297|Experimental|MenACWY-CRM|Subjects received one primary dose of MenACWY-CRM conjugate vaccine in the parent study and were followed for persistence in the present study.
11570554|NCT00856297|Active Comparator|Licensed comparator|Subjects received one primary dose of a quadrivalent meningococcal conjugate vaccine with diphtheria toxoid as the protein carrier in the parent study and were followed for persistence in the present study at 5 years postvaccination.
11570555|NCT00856297|Other|Naive|Subjects who were age-matched to the other study groups and had not received any previous meningococcal vaccinations.
11570556|NCT00856297|Experimental|MenACWY-CRM/MenACWY-CRM|Subjects received one primary dose of the MenACWY-CRM conjugate vaccine in the parent study and one booster dose of MenACWY-CRM conjugate vaccine at 3 years after primary vaccination.
11570557|NCT00856297|Experimental|Licensed comparator/MenACWY-CRM|Subjects received one primary dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine in the parent study and one booster dose of MenACWY-CRM conjugate vaccine at 3 years after primary vaccination.
11570558|NCT00856284|Experimental|Metformin + Alogliptin 12.5 mg|Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.
11570559|NCT00856284|Experimental|Metformin + Alogliptin 25 mg|Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.
11570560|NCT00856284|Active Comparator|Metformin + Glipizide|Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.
11570563|NCT00856258|Placebo Comparator|Cohort 1|Cohort 1 completed.
11570564|NCT00856258|Placebo Comparator|Cohort 2|Cohort 2 not studied
11570565|NCT00856258|Placebo Comparator|Cohort 3|Cohort 3 not studied
11570566|NCT00856258|Placebo Comparator|Cohort 4|Cohort 4 not studied
11570567|NCT00856245|Other|Rituximab|Patients will be treated IV with rituximab at the rate of 50 milligrams per hour (mg/hour) for 1 hour. If patient tolerates the infusion, the rate is increased by increments of 50 mg/hour every 30 minutes to a maximum of 400 mg/hour. If patient has a severe reaction, the infusion is stopped temporarily and the infusion rate is decreased by 50%. Subsequent infusions are started at the rate of 100 mg/hour, increased by 100 mg/hour every 30 minutes to a maximum of 400 mg/hour if tolerated. Vital signs are monitored every 15 minutes for 2 hours and every 30 minutes thereafter.
11570568|NCT00856232|No Intervention|Standard therapy|Standard emergency department evaluation and treatment for headache
11570569|NCT00856232|Placebo Comparator|Medical Air|Air inhalation at 15L / min x 15 minutes followed by standard emergency department evaluation and treatment for headache
11570570|NCT00856232|Experimental|Oxygen|Oxygen inhalation at 15 L/min for 15 minutes followed by standard emergency department evaluation and treatment for headache
11570571|NCT00856219|Active Comparator|Enteral Continuous|Continuous tube feeding for 72 hours.
11570572|NCT00856219|Active Comparator|Enteral Intermittent|Intermittent tube feedings for 72 hours
11570573|NCT00856219|Active Comparator|Parenteral|Parenteral continuously for 72 hours
11570574|NCT00856206|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
11570575|NCT00856206|Experimental|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
11570576|NCT00856193|Placebo Comparator|Placebo then NVA237 50μg|Placebo 50 μg capsules followed by NVA237 50 μg capsules for inhalation once daily with Concept 1 device.
11570577|NCT00856193|Experimental|NVA237 50μg then placebo|NVA237 50 μg capsules followed by matching placebo 50 μg capsules for inhalation once daily with Concept 1 device.
11570578|NCT00856180|Experimental|Bevacizumab then Cyclophosphamide with Bevacizumab|Patients were given a regimen of sequential antiangiogenic blockade and disease assessed serologically and radiologically every 2 cycles/6 weeks. Patients started with bevacizumab 15 mg/kg IV every 3 weeks until they experienced progressive disease (PD) [RECIST 1.0 or Rustin criteria] or significant toxicity. If clinically stable as assessed by their treating physician, patients then received cyclophosphamide 50 mg orally (PO) daily continuously with bevacizumab treatment. If second PD occurred, patients discontinued the combination treatment.
11570579|NCT00856167|Active Comparator|TCM|Whole systems traditional Chinese medicine, including individually tailored herbal formulas, acupuncture, tuna (Chinese massage), lifestyle recommendations
11570580|NCT00856167|Active Comparator|Self-care|Self-care for TMD developed by Dworkin, LeResche et al.
11570581|NCT00856141|Experimental|1. High fluidic parameters|Bottle height varied from 90-110cms, fixed aspiration flow rate 40cc/min, vacuum upto 650mmHg depending on the grade of cataract
11570582|NCT00856141|Active Comparator|2. Low fluidic parameters|Bottle height varied from 70-90cms, fixed aspiration flow rate of 25cc/min, vacuum upto 400mmHg, depending on the grade of cataract
11570583|NCT00856115||African American Female|
11570584|NCT00856115||African American Male|
11570585|NCT00856115||Caucasian Female|
11570586|NCT00856115||Caucasian Male|
11570587|NCT00856102|Experimental|Exercise|
11570588|NCT00856102|No Intervention|Control|
11570589|NCT00856089|Experimental|Retapamulin|
11570590|NCT00856076||VTE case group 1/2|Women with first time venous thromboembolism in pregnancy. VTE data validated from medical records.
11570591|NCT00856076||VTE control group 1|All pregnancies of source population - clinical data from the Norwegian Birth Registry and the Norwegian Patient Registry.
11570592|NCT00856076||VTE control group 2|Randomly drawn from group 1 (using the Norwegian Birth Registry), but matched for time of delivery. Without history of venous thromboembolism, and with validated data from medical records.
11570593|NCT00856076||VTE case group 3|Subjects from VTE case group 1/2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
11570594|NCT00856076||VTE control group 3|Subjects from VTE control group 2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
11570595|NCT00856076||IUFD group 1|Women who have experienced IUFD - data verified from medical records.
11570596|NCT00856076||IUFD group 2|Subjects from IUFD group 2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
11570597|NCT00856076||IUFD control group 1|All pregnancies of source population - clinical data from the Norwegian Birth Registry and the Norwegian Patient Registry.
11570598|NCT00856076||IUFD control group 2|Subjects from VTE control group 1/2 with validated data from medical records.
11570599|NCT00856076||IUFD control group 3|Subjects from VTE control group 3 invited to answer a disease specific questionnaire for IUFD.
11570600|NCT00856050|Experimental|letrozole|single arm trial - all patients received letrozole 2.5mg by mouth per day
11570601|NCT00856037|Experimental|Treatment (doxorubicin hydrochloride, topotecan hydrochloride)|Patients receive doxorubicin hydrochloride IV over 3-5 minutes on day 6 of course 1 and on days 6, 13, and 20 of courses 2-5. Patients also receive topotecan hydrochloride PO on days 1-5. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
11570602|NCT00856024||Group 1: Naïve patients|Patients, from Brazil, with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin and who previous to this treatment had not been treated with peginterferon alfa-2b.
11570603|NCT00856024||Group 2: Re-treatment|Patients, from Brazil, with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin and who previous to this treatment had been considered nonresponders or relapsing to prior treatment for chronic hepatitis C.
11570604|NCT00856024||Group 3: HIV/HCV co-infected patients|Patients, from Brazil, with confirmed chronic hepatitis C and infected with Humman Immunodeficiency Virus (HIV) who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin.
11570605|NCT00856011||1|Diabetic patients with carpal tunnel syndrome
11570606|NCT00856011||2|Non-diabetic patients with carpal tunnel syndrome
11570607|NCT00855998||1|With BRCA1 or BRCA2 mutations
11570608|NCT00855998||2|Without BRCA1 or BRCA2 mutations
11570609|NCT00855985|Active Comparator|1|Pancreaticojejunostomy for reconstruction after pancreaticoduodenectomy
11570610|NCT00855985|Active Comparator|2|Pancreaticogastrostomy for reconstruction after pancreaticoduodenectomy
11570611|NCT00855959|Experimental|1|Four weeks treatment with either Pulmicort Turbuhaler at a dose of 400 μg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily
11570612|NCT00855959|Experimental|2|Pulmicort Turbuhaler at a dose of 200 μg twice daily and Pulmicort Respules at a dose of 0.5 mg twice daily or 1.0 mg once daily (low dose)
11570613|NCT00855933|No Intervention|Control - no flossing|Subjects brushed thoroughly for one minute with Crest® Cavity Protection toothpaste and an Oral-B® Indicator soft, manual toothbrush once daily.
11570614|NCT00855933|Experimental|Experimental Floss|Subjects brushed thoroughly for one minute with Crest® Cavity Protection toothpaste and an Oral-B® Indicator soft, manual toothbrush once daily. Subjects flossed once daily with the experimental floss.
11570615|NCT00855920|Active Comparator|Placebo (for Rilonacept) and Indomethacin|Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 with Indomethacin orally thrice a day (TID) for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
11570616|NCT00855920|Active Comparator|Rilonacept and Indomethacin|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 with Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
11570617|NCT00855920|Active Comparator|Rilonacept and Placebo (for Indomethacin)|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 with Placebo (for Indomethacin) orally TID for 12 days.
11570618|NCT00855907||cases|IBD patients above the age of 18 years old, suffering from the disease for at least one year.
11570619|NCT00855894|Experimental|Pertuzumab + erlotinib|Patients received pertuzumab 840 mg intravenously (IV) 1 time (loading dose) followed by 420 mg IV (maintenance dose) every 3 weeks (q3w) plus erlotinib 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.
11570620|NCT00855881|Experimental|Treatment arm|Treated with tegafur-uracil for 1 year
11570621|NCT00855855||Hib vaccine|Participants has received at least one dose of an Hib vaccine
11570622|NCT00855842|Experimental|osmotic dilator|osmotic dilator
11570623|NCT00855829|Active Comparator|Miniature Actilady device active|one miniature Actilady device tested for all patients during a 4 months period. The device is active in 3 months out of the 4, and the patients are blinded to the action of the device (sham comparator).
11570624|NCT00855829|Sham Comparator|Miniature Actilady device not active|Sham Comparator: one miniature Actilady device tested for all patients during a 4 months period. The device is active in 3 months out of the 4, and the patients are blinded to the action of the device (sham comparator).
11570625|NCT00855816|Experimental|Breathing training|relaxation training
11570626|NCT00855816|No Intervention|Treatment as usual|treatment as usual
11570627|NCT00855803|Experimental|Group 1 radiation|"Intervention:
~Patients had prior radiotherapy will undergo 5 fractions of stereotactic body radiotherapy (SBRT) over 30-90 minutes each."
11570628|NCT00855803|Experimental|Group 2 radiation|"Intervention:
~Patients has no prior radiotherapy will undergo 1 fraction of SBRT over 30-90 minutes."
11570629|NCT00855790|Active Comparator|RJ3 Biopsy Forcep|use of RJ3 Biopsy forcep for the polypectomy
11570630|NCT00855790|Active Comparator|RJ4 Biopsey Forcep|Use of RJ$ biopsy forcep for polypectomy
11570631|NCT00855777|Experimental|Etoricoxib|Etoricoxib 120 mg/day x 3 days
11570632|NCT00855777|Active Comparator|Ibuprofen|Ibuprofen 1800 mg/day x 3 days
11570633|NCT00855764|Experimental|Paclitaxel|
11570634|NCT00855738|Other|1.0|
11570635|NCT00855712|Experimental|Organ Care System|
11570636|NCT00855712|Active Comparator|Cold cardioplegia solution|
11570637|NCT00855686|Experimental|Memantine|
11570638|NCT00855686|Placebo Comparator|Placebo|
11570639|NCT00855673|Experimental|Active|Active group receiving intermittent compression
11570640|NCT00855673|Active Comparator|Control|Standard Medical Treatment
11570641|NCT00855660|Active Comparator|Riociguat|Subjects received multiple doses of riociguat (thrice a day) with concomitant administration of ranitidine (once daily) for 14 days
11570642|NCT00855660|Placebo Comparator|Placebo|Subjects received placebo (thrice a day) with concomitant administration of ranitidine (once daily) for 14 days
11570643|NCT00855634|Active Comparator|1|"COHORT 1 (minimal metastatic disease):
~Arm 1 (intervention): resection of the primary tumor, followed by resection of the liver metastasis/metastases
~Arm 2 (control): exploration and/or gastroenterostomy and/or hepaticojejunostomy/choledochojejunostomy"
11570644|NCT00855634|Active Comparator|2|"COHORT 2 (venous infiltration):
~Arm 1 (intervention): resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV)
~Arm 2 (control): resection of the primary tumor with dissection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV) plus tumor masses adjacent to these veins; no venous resection"
11570645|NCT00855621|Active Comparator|Single microelectrode|Surgical procedure performed using single microelectrode recording guidance intraoperatively
11570646|NCT00855621|Active Comparator|Multiple microelectrode|Surgical procedure performed using multiple microelectrode recording guidance intraoperatively
11570647|NCT00855608|Experimental|adalimumab arm|intravitreal mode of delivery
11570648|NCT00855595|Experimental|Azelaic acid (Finacea, BAY39-6251) plus Doxycycline (Oracea)|Participants received topical azelaic acid gel 15% twice daily and doxycycline 40 mg once daily for 12 weeks
11570649|NCT00855595|Active Comparator|Metronidazole (Metrogel) plus Doxycycline (Oracea)|Participants received topical metronidazole 1% gel once daily and doxycycline 40 mg once daily for 12 weeks
11570650|NCT00855582|Experimental|Tadalafil 2.5 mg|
11570651|NCT00855582|Experimental|Tadalafil 5 mg|
11570652|NCT00855582|Placebo Comparator|Placebo|
11570732|NCT00854828|Active Comparator|Non-Operative Intervention|
11570653|NCT00855569||1|Each donor site will act as it own control - both dressings will be applied to the donor site and assessments will be made
11570654|NCT00855530|Experimental|1|
11570655|NCT00855517|Experimental|Punctal Plug|
11570656|NCT00855504||Subjects|All the consecutive primigravidae who register in the antenatal clinic before 20 weeks of gestation
11570657|NCT00855491|Experimental|1. MYOPIA|axial length > 26.00 mm
11570658|NCT00855491|Active Comparator|2. Emmetropia|emmetropic eyes- eyes with an axial length of 21.00 to 23.99 mm
11570659|NCT00855478|Experimental|1|Cypher drug-eluting stent
11570660|NCT00855465|Experimental|Riociguat (Adempas, BAY63-2521)_individual dose titration|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 16 weeks
11570661|NCT00855465|Placebo Comparator|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 16 weeks
11570662|NCT00855439|Experimental|Exenatide|Subjects will take exenatide by subcutaneous injection twice daily for 18 months
11570663|NCT00855439|Active Comparator|glargine|Subjects will take 1 daily injection of insulin glargine for 18 months.
11570664|NCT00855413|Other|Darunavir/Ritonavir and Etravirine|"Darunavir/Ritonavir 800 mg/100 mg orally once daily.
~ETR will be given 200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen."
11570665|NCT00855400|Experimental|Transplant|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
11570666|NCT00855387||Costs|Patients collected consecutively for undergoing major surgical procedures(liver, bile duct, pancreas, small bowel, colo-rectal, gastric bypass resections).
11570667|NCT00855361|Experimental|Rabeprazole sodium|
11570668|NCT00855348||Adults > 50 Years Scheduled for Colonscopy|Average to increased risk adults older than 50 years without symptoms indicative of CRC and designated for colonoscopy.
11570669|NCT00855335|Experimental|Group 1: Darunavir 600 /Ritonavir 100|TMC114 (darunavir) Two 300 milligram (mg) or one 600 mg tablet twice daily up to 12 weeks postpartum / ritonavir one 100 mg tablet twice daily with darunavir up to 12 weeks postpartum.
11570670|NCT00855335|Experimental|Group 2: Darunavir 800/Ritonavir 100|TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum/ ritonavir one 100 mg tablet once daily with darunavir up to 12 weeks postpartum.
11570671|NCT00855335|Experimental|Group 3: Etravirine|TMC125 (etravirine) 200 mg (1*200 mg/2*100 mg) tablets twice daily up to 12 weeks postpartum.
11570672|NCT00855335|Experimental|Group 4: Rilpivirine|TMC278 (rilpivirine) One 25 mg tablet once daily up to 12 weeks postpartum.
11570673|NCT00855335|Experimental|Group 5: Darunavir 800/Cobicistat 150|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
11570674|NCT00855322|Experimental|1|Gym group exercise intervention
11570675|NCT00855322|Experimental|2|Hydrotherapy group exercise intervention
11570676|NCT00855322|No Intervention|3|Control group
11570677|NCT00855309|Experimental|Arm I|Patients receive weight-based IV acyclovir sodium every 8 or 12 hours.
11570678|NCT00855309|Experimental|Arm II|Patients receive low-dose IV acyclovir sodium every 8 or 12 hours.
11570679|NCT00855283|Experimental|Arm 1|SCI
11570680|NCT00855270|Placebo Comparator|saline|An IV injection of saline will be administered to the control group in a double blind, randomized manner.
11570681|NCT00855270|Experimental|Hydrocortisone|IV hydrocortisone will be given in a double blind random manner as the active treatment group
11570682|NCT00855257|Experimental|1|treatment by acid nicotinique
11570683|NCT00855257|Placebo Comparator|2|Treatment by placebo
11570684|NCT00855244|Other|BMT survivors|Diagnostic exams
11570685|NCT00855218|Experimental|Sorafenib (Nexavar, BAY43-9006) + TACE|Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Patients were then also treated with Transarterial Chemoembolization (TACE) performed with DC Bead (300 to 500 microns) and doxorubicin (150 mg) between 3 to 7 days after the first dose of sorafenib, TACE was also performed on Days 1 (+ 4 days) of cycle 1, 3, 7, 13 and then every 6 cycles thereafter (an optional TACE procedure could be performed between Day 1 of Cycle 7 and Cycle 13 and between Day 1 of Cycles 13 and 19, if deemed necessary by the Investigator.)
11570686|NCT00855218|Placebo Comparator|Placebo + TACE|Placebo was to be orally administered as 2 tablets bid (twice daily). Patients were then also treated with TACE performed with DC Bead (300 to 500 microns) and doxorubicin (150 mg) between 3 to 7 days after the first dose of placebo, TACE was also performed on Days 1 (+ 4 days) of cycle 1, 3, 7, 13 and then every 6 cycles thereafter (an optional TACE procedure could be performed between Day 1 of Cycle 7 and Cycle 13 and between Day 1 of Cycles 13 and 19, if deemed necessary by the Investigator.)
11570687|NCT00855205|Experimental|Treatment|Treatment with rituximab
11570688|NCT00855192|Experimental|mindfulness-based therapy|mindfulness-based meditation
11570689|NCT00855192|Experimental|interpersonal therapy|psycho-educational
11570690|NCT00855179|Active Comparator|Antistax film-coated tablets 360 mg|Patient to receive 2 tablets daily as a morning dose, each containing 360 mg Antistax
11570691|NCT00855179|Placebo Comparator|Placebo|Patient to receive 2 tablets identical to those containing 360 mg Antistax daily as a morning dose
11570692|NCT00855166|Experimental|A|Dapagliflozin 10 mg plus Metformin
11570693|NCT00855166|Placebo Comparator|B|Placebo plus Metformin
11570694|NCT00855153|Experimental|treatment|Subjects receive 50mg DCS prior to 90 min session with graded VRE treatment
11570695|NCT00855140|Placebo Comparator|Sham acupuncture|Sham acupuncture at non-active acupuncture points, using the Park Sham Device
11570696|NCT00855140|Experimental|Verum Acupuncture|Acupuncture following a specific TCM-based protocol
11570697|NCT00855127||Liver transplant recipients|
11570698|NCT00855114|Experimental|Patients Treated with Everolimus|Breast cancer patients treated with Everolimus by mouth, 5 mgs/day x 7 days, followed by surgery.
11570699|NCT00855101|Experimental|voriconazole|
11570700|NCT00855088|Experimental|Darunavir, ritonavir, etravirine|Single arm trial looking at the pharmacokinetics of darunavir, ritonavir, etravirine in healthy volunteers.
11570733|NCT00854815|Active Comparator|Irrigation|Irrigation of the area with at least 500ml normal saline using the power suction/irrigator
11570701|NCT00855075||Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
11570702|NCT00855062|Active Comparator|Minocycline|Minocycline 100 mg orally every 12 hours
11570703|NCT00855062|Placebo Comparator|Placebo|Placebo minocycline capsules every 12 hours
11570704|NCT00855049|Experimental|1|Intranasal acetaminophen administration
11570705|NCT00855049|Active Comparator|2|Oral acetaminophen administration
11570706|NCT00855036||Renal Injury|All patients who have a discernable injury to the renal parenchyma on CT scan from blunt trauma
11570707|NCT00855023||Asymptomatic Volunteers|healthy volunteer athletes and excluded those who had any of the following criteria: 1) counter-indications to magnetic resonance imaging (e.g., pregnancy or postsurgical hardware [plates, screws, aneurysm clip, implanted cardiac pacemaker, etc.]); (2) relevant medical problems (e.g., connective tissue problems, paralyzed hemidiaphragm, morbid obesity, claustrophobia, etc.); (3) clinical signs of an impairment or abnormality in the knee (e.g., abnormal range of motion, muscle weakness, or malalignment); (4) injury to the knee that required medical attention; (5) previous surgery on the knee; or (6) current pain in the knee.
11570708|NCT00855010|Experimental|pioglitazone|pioglitazone tablet 45 mg once daily
11570709|NCT00855010|Placebo Comparator|placebo pill|placebo pill once daily (look-alike pill which contains no active ingredients)
11570710|NCT00854997||1|AMI with OSA
11570711|NCT00854997||2|AMI without OSA
11570712|NCT00854984|Experimental|Self-help CBT|A nurse supported self-help CBT intervention in addition to usual care.
11570713|NCT00854984|No Intervention|Usual care|
11570714|NCT00854971|No Intervention|control|Oxaliplatin infusion (85mg/m2) on days 1 and 15 (every 2 weeks) 5-FU bolus + infusions (400 mg/m2) on days 1, 2, 15 and 16 LV infusions (200 mg/m2) on days 1, 2, 15 and 16
11570715|NCT00854971|Active Comparator|Active|FOLFOX-4 regimen + Infusion of TKCell(autologous activated lymphocyte) over 2x10^9 cells, IV route, 7 times
11570716|NCT00854945|Experimental|ON 01910.Na|1800 mg/day of ON 01910.Na administered as a 24-hour continuous intravenous infusion on days 1, 2 and 3 of 14-day cycle.
11570717|NCT00854932|Experimental|PCT group|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PCT values are within the normal range.Antibiotic therapy can be continued despite fulfilled criteria at the discretion of the attending physician. These divesions from the stopping rules will be reported for further analysis.
11570718|NCT00854932|No Intervention|Standard group|The duration of antibiotic treatment in the standard group is based on the attending physician's assessment of the risk of classification: infection unlikely for 36-72 hours, infection possible for 5-7 days, infection probable of proven for 7-21 days depending on clinical course, laboratory values and positive cultures.
11570719|NCT00854919|Experimental|CBT|All subjects received cognitive-behavioral therapy (CBT) during the study period.
11570720|NCT00854919|Experimental|1|Drug; Paroxetine (30-50mg/D)or Fluvoxamine (150-250mg/D), 1-year administration
11570721|NCT00854919|Active Comparator|2|Either risperidone (1-5mg/D), olanzapine (1-5mg/D) or quetiapine (25-100mg/D) was added to ongoing SSRI, the combination trial was continued at least for half a year.
11570722|NCT00854906||Keratometric Tear Breakup Time|These are the study participants whose tear break up times were measured with a keratometer.
11570723|NCT00854906||Fluorescein Break Up Time|These are the study participants whose tear break up times were measured with with fluorescein dye.
11570724|NCT00854893|Experimental|anodal|anodal stimulation: 20 min during language learning, intensity: 1 mV, anodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
11570725|NCT00854893|Experimental|cathodal|anodal stimulation: 20 min during language learning, intensity: 1 mV, cathodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
11570726|NCT00854893|Experimental|sham (placebo)|sham stimulation (placebo condition): 30 seconds during language learning, intensity: 1 mV, anodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
11570727|NCT00854867|Experimental|Whole brain radiotherapy (WBRT) with concomitant Depocyte|Subjects will receive a total of 38.4 Gray (Gy) WBRT given over 4 weeks. Subjects will receive 3 GyWBRT on Days 1 and 2 and then 1.8 Gy on the third fourth and fifth days of WBRT treatment during Week 1. Subjects will then receive 1.8 Gy WBRT per day; 5 days out of seven, each week for the next 3 weeks. A total of 4 doses of DepoCyte (50 mg of liposomal ARA-C) will be administered intrathecally. The first dose will be administered on Day 3 (or Day 4 or 5) of Week 1, i.e. the third day of radiotherapy treatment when the dosage is reduced to 1.8 Gy. The second dose will be administered on Day 17(+2 days); the third dose will be administered on Day 31 (+2 days); the fourth dose will be administered on Day 45 (+2 days) to complete the induction phase of the protocol. Subjects will continue to receive an additional 6 doses of DepoCyte one dose every 28 days (+2 days) during the maintenance period. The first dose will be given 28 days after the last dose in the induction phase.
11570728|NCT00854867|Active Comparator|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|Subjects will receive a total of 38.4 Gy WBRT given over 4 weeks. Subjects will receive 3 Gy (WBRT on Day 1 and Day 2) and then 1.8 Gy on the third fourth and fifth days of WBRT treatment during Week 1. Subjects will then receive 1.8 Gy WBRT per day; 5 days out of seven, each week for the next 3 weeks. A total of 4 doses of DepoCyte (50 mg of liposomal ARA-C) will be administered intrathecally. The first dose will be administered on Day 29 (+2 days); the second dose will be administered on Day 43(+2 days); the third dose will be administered on Day 57 (+2 days); the fourth dose will be administered on Day 71 (+2 days) to complete the induction phase of the protocol. DepoCyte should never be administered more frequently than every 14th day. Subjects will continue to receive an additional 6 doses of DepoCyte one dose every 28 days (+2 days) during the maintenance period. The first dose will be given 28 days after the last dose in the induction phase.
11570729|NCT00854854|No Intervention|Control|"Oxaliplatin infusion (100mg/m2) on days 1 and 15 (every 2 weeks)
~5-FU bolus + infusions (400 mg/m2) on days 1, 2, 15 and 16
~LV infusions (200 mg/m2) on days 1, 2, 15 and 16"
11570730|NCT00854854|Active Comparator|Active|"Infusion of TKCell(autologous activated lymphocyte) over 2x10^9 cells, IV route, 7 times
~and chemotherapy schedule"
11570731|NCT00854828|Active Comparator|Surgical Intervention|
11570734|NCT00854815|Active Comparator|No Irrigation|Only suction with the power suction/irrigator without saline attached
11570735|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 48 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 47 weeks + peg-IFNα2a 180 µg subcutaneously (sc) once weekly for 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 48 weeks.
11570736|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 24 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 23 weeks + peg-IFNα2a 180 µg sc once weekly for 24 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 24 weeks.
11570737|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 24 or 48 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 23 or 47 weeks + peg-IFNα2a 180 µg sc once weekly for 24 or 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 24 or 48 weeks. Participants who achieve a rapid viral response, defined as having undetectable hepatitis C virus RNA at week 4, are treated for 24 weeks; other patients are treated for 48 weeks.
11570738|NCT00854802|Placebo Comparator|Debio 025 placebo + peg-IFNα2a + ribavirin - 48 weeks|Participants receive Debio 025 placebo orally twice daily for 7 days followed by Debio 025 placebo orally once daily for 47 weeks + peg-IFNα2a 180 µg subcutaneously (sc) once weekly for 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 48 weeks.
11570739|NCT00854789|Experimental|Vaccine|HLA-A2+ and HLA-A3+ patients are administered the E75+GM-CSF vaccine.
11570740|NCT00854789|No Intervention|Control/observation|HLA-A2- and HLA-A3- patients are prospectively followed for disease recurrence. Control patients are not vaccinated.
11570741|NCT00854776|Active Comparator|1|Upper GI tract symptoms are evaluated. Patients are asked to report to gastroenterologist if they have persistent ulcer symptoms and to report to the emergency room if they have evidence of GI bleeding or ulcer complications (melena, hematemesis, or sudden onset of severe epigastric pain). Endoscopy will be undergone to document any gastroduodenal ulcers with or without ulcer complications. If the hemoglobin level has decreased by 2g/dL or more, or stool check shows occult blood at each visit, endoscopy will be undergone to check the presence of gastroduodenal ulcers with or without bleeding. Patients without persistent ulcer symptoms or without evidence of ulcer complications will be invited to undergone scheduled endoscopy at the 3-month end of follow-up in each subjective.
11570742|NCT00854776|Placebo Comparator|2|Upper GI tract symptoms are evaluated at each visit. Patients are asked to report to gastroenterologist if they have persistent ulcer symptoms and to report to the emergency room if they have evidence of GI bleeding or ulcer complications (melena, hematemesis, or sudden onset of severe epigastric pain). Endoscopy will be undergone to document any gastroduodenal ulcers with or without ulcer complications. An ulcer is defined as a circumscribed mucosal break at least 3 mm in diameter. If the hemoglobin level has decreased by 2g/dL or more, or stool check shows occult blood at each visit, endoscopy will be undergone to check the presence of gastroduodenal ulcers with or without bleeding. Patients without persistent ulcer symptoms or without evidence of ulcer complications will be invited to undergone scheduled endoscopy at the 3-month end of follow-up in each subjective.
11570743|NCT00854763||Hypertension|
11570744|NCT00854750|Experimental|ACTHAR- placebo first|Placebo, 20 mg, 40 mg, 80 mg
11570745|NCT00854750|Experimental|ACTHAR- placebo second|20mg, Placebo, 40 mg, 80mg
11570746|NCT00854750|Experimental|ACTHAR- placebo third|20 mg, 40 mg, Placebo, 80 mg
11570747|NCT00854750|Experimental|ACTHAR- placebo fourth|20 mg, 40 mg, 80 mg, Placebo
11570748|NCT00854737|Active Comparator|1|Omega-3 fatty acid and cytidine supplementation
11570749|NCT00854737|Active Comparator|2|omega-3 fatty acid supplementation
11570750|NCT00854737|Placebo Comparator|placebo|placeno or sugar pill
11570751|NCT00854724|Active Comparator|Puerarin|
11570752|NCT00854724|Placebo Comparator|Placebo|Sugar beet filler in capsule
11570753|NCT00854711|Experimental|nitric oxide|inhaled nitric oxide 80 ppm and oxygen
11570754|NCT00854711|Placebo Comparator|standart of care|no intervention
11570755|NCT00854698|Experimental|Group with MVA|
11570756|NCT00854698|Other|group without MVA|
11570757|NCT00854685|Experimental|1|
11570758|NCT00854685|Experimental|2|
11570759|NCT00854685|Experimental|3|
11570760|NCT00854685|Experimental|4|
11570761|NCT00854685|Placebo Comparator|5|
11570762|NCT00854685|Placebo Comparator|6|
11570763|NCT00854672||sarcoidosis patients|Sarcoidosis patients referred to the ild care team of the outpatient clinic of the department of Respiratory Medicine of the MUMC and also participated in the baseline study between November 2008 and September 2009 will be included in this study
11570764|NCT00854659|Active Comparator|1|ABT-102 Tablets, 4 mg BID
11570765|NCT00854659|Active Comparator|2|ABT-102 Tablets BID, escalating dose
11570766|NCT00854659|Active Comparator|3|ABT-102 Tablets BID, escalating dose
11570767|NCT00854659|Placebo Comparator|4|Placebo Tablets, BID
11570768|NCT00854646|Experimental|ON 01910.Na|The starting dose is 650 mg/m2 per day for 3 continuous days every 2 weeks. In successive courses, infusion time may be increased by 1 day up to 7 days every two weeks and/or drug dose may be increased (650, 1050, 1700 mg/m2/day, etc.). After 4 2-week cycles, cycle length may be extended to 3 or 4 weeks. Treatment continues until evidence of disease progression, intolerable adverse events or withdraw of consent.
11570769|NCT00854633|Experimental|1|Talactoferrin
11570770|NCT00854633|Placebo Comparator|2|Placebo
11570771|NCT00854620|Experimental|Sorafenib|"Cycle 1: 400 mg BID sorafenib
~Cycle 2: 600 mg BID sorafenib
~Cycle 3+: 800 mg BID sorafenib"
11570772|NCT00854607||Invasive Aspergillosis|Observational
11570773|NCT00854594|No Intervention|Control|Control sites will receive the baseline measures pre and post. These sites will receive traditional diabetes education, which includes teleconsultation.
11570774|NCT00854594|Experimental|ReSPECT Intervention|Intervention sites will receive baseline measures pre and post, but also in-depth Shared Medical Appointments (SMA)(The Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT) intervention) and at 15 months SMA video conferences. At the end of the 18 months the randomly selected patients and providers will be asked to take part in a qualitative interview.
11570775|NCT00854581|Experimental|Induction (Up to Day 21)|"For one cycle, up to Day 21. All participants are enrolled to induction therapy phase, then move to the maintenance therapy phase if they achieve complete response (PR) or partial response (PR). Participants who achieve a clinical CR at Day 14 response assessment will go on to Part 1 maintenance therapy. Patients who achieve a PR will receive 7 more days of induction therapy and then go on to Part 1 Maintenance Therapy.:
~Zidovudine:
~Days 1-2: 1.5 grams intravenously (IV) twice daily
~Days 3-21: 1.5 grams IV twice daily
~Interferon alfa-2b (IFN):
~5 10 million units (mu) intravenously twice daily"
11570776|NCT00854581|Experimental|Part 1 Maintenance (Up to Day 60)|"From Treatment Day 14 or 21 to start of Month 3 (Day 60). Study participants move on to Part 1 Maintenance Therapy only if they achieve complete response (CR) or partial response (PR) after induction therapy. Restaging and molecular evaluation of disease at start of Month 3:
~Zidovudine: 600 mg orally twice daily in all phases of Maintenance Therapy
~PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly
~Participants then proceed to Part 2 maintenance."
11570777|NCT00854581|Experimental|Part 2A Maintenance (Up to 12 Months)|"Participants achieving a CR with undetectable clonal disease. Participants will receive therapy for as long as response is maintained:
~Zidovudine: 600 mg orally twice daily
~PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly"
11570778|NCT00854581|Experimental|Part 2B Maintenance (Up to 12 Months)|"Participants achieving a CR with minimal residual disease (by multiplex PCR) or PR in Part 1:
~Zidovudine: 600 mg or 300 mg orally twice daily, per protocol
~PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly, per protocol
~Valproic acid, 250 mg orally twice daily, per protocol"
11570779|NCT00854568|Experimental|CEOP regimen|CEOP regimen
11570780|NCT00854568|Active Comparator|CHOP regimen|CHOP regimen
11570781|NCT00854555|Experimental|robot|30 persons with incomplete SCI who live within driving distance to Oslo and who meet the inclusion/exclusion criteria will be selected for randomization to robotic assisted training or control (conventional treatment). Intervention consists of locomotor training with robot for 60 days during 6 months period in an out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
11570782|NCT00854555|Experimental|manual assistance|30 persons with incomplete SCI who live outside driving distance to Oslo and who meet inclusion/exclusion criteria will be selected for manually assisted training in Tromsø or control (conventional treatment). Intervention consists of 60 days locomotor training with manual assistance during 6 months period in an in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
11570783|NCT00854542|Active Comparator|TCSCT|
11570784|NCT00854542|Placebo Comparator|Usual Care|
11570785|NCT00854529|Experimental|1|20 patients who had an uneventful trabeculectomy with usage of mitomycin C, will receive subconjunctival bevacizumab 1 week after the surgery
11570786|NCT00854529|Active Comparator|2|20 patients who had an uneventful trabeculectomy with usage of mitomycin C, will receive subconjunctival bevacizumab 2 weeks after the surgery
11570787|NCT00854529|No Intervention|3|20 patients after an uneventful trabeculectomy with usage of mitomycin C, will not receive any bevacizumab injection.
11570788|NCT00854503|Active Comparator|Simvastatin|Simvastatin 20 mg/day
11570789|NCT00854503|Active Comparator|Rosuvastatin|Rosuvastatin 20 mg/day
11570790|NCT00854451|Active Comparator|1 omeprazole plus amoxicillin|omeprazole 20mg bid 2wk + amoxicillin 500mg qid 2wk
11570791|NCT00854451|Active Comparator|2 omeprazole plus amoxicillin|omeprazole 20mg bid 2wk + amoxicillin 250mg qid 2wk
11570792|NCT00854451|Active Comparator|3 omeprazole plus amoxicillin|omeprazole 20mg qd 2wk + amoxicillin 500mg qid 2wk
11570793|NCT00854451|Active Comparator|4 omeprazole plus amoxicillin|omeprazole 20mg qd 2wk + amoxicillin 250mg qid 2wk
11570794|NCT00854438|Experimental|Active treatment arm|Reduction of anticholinergic drug effects by pharmacist review
11570795|NCT00854438|No Intervention|Control|No intervention
11570796|NCT00854425|Experimental|L-asp|
11570797|NCT00854386|Active Comparator|1|liberal fluid administration group
11570798|NCT00854386|Experimental|2|Restrictive fluid administration group
11570799|NCT00854373|Experimental|1|Bravelle
11570800|NCT00854373|Placebo Comparator|2|Saline
11570801|NCT00854360|Experimental|BDP HFA 80 µg/day|During the 2-week double-blind Treatment Period participants self-administered two actuations (one per nostril) of 40 micrograms (µg) BDP HFA and two actuations of placebo HFA once daily.
11570802|NCT00854360|Experimental|BDP HFA 160 µg/day|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of 40 µg BDP HFA once daily.
11570803|NCT00854360|Experimental|BDP HFA 320 µg/day|During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.
11570804|NCT00854360|Placebo Comparator|Placebo|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.
11570805|NCT00854334||1.|Children with both obesity and obstructive sleep apnea
11570806|NCT00854334||2|Children without the presence of both obesity and obstructive sleep apnea
11570807|NCT00854321||patients with active RA|drug, follow-up
11570808|NCT00854308|Experimental|MetMAb + Erlotinib|MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity.
11570809|NCT00854308|Placebo Comparator|Placebo + Erlotinib|Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity.
11570810|NCT00854295|Other|1|Follow-up of existing IDE study subjects
11570811|NCT00854295|Other|2|Newly enrolled study subjects
11570812|NCT00854256|Experimental|Canaloplasty|
11570813|NCT00854256|Active Comparator|Trabeculectomy with mitomycin C|
11570814|NCT00854230|Experimental|1|Naltrexone
11570815|NCT00854230|Placebo Comparator|2|
11570816|NCT00854217|Placebo Comparator|placebo, hemodilution|
11570817|NCT00854191|Experimental|1|4 half-day of simulator ERCP practice and usual training
11570818|NCT00854191|Active Comparator|2|Usual training
11570819|NCT00854178|Experimental|2|
11570820|NCT00854152|Experimental|1|
11570882|NCT00853736|Active Comparator|B|Roxicodone™ tablet 30 mg
11570821|NCT00854139|Experimental|Bone marrow and renal transplant|Cyclophosphamide, anti-thymocyte globulin, thymic irradiation conditioning and kidney transplant and bone marrow transplant from a related donor for patients with multiple myeloma and end stage renal disease with cyclosporine for graft versus host disease prophylaxis
11570822|NCT00854126|Experimental|1|
11570823|NCT00854113|Experimental|EGT0001474|Ascending doses of EGT0001474
11570824|NCT00854113|Placebo Comparator|Placebo|Placebo
11570825|NCT00854100|Placebo Comparator|Placebo|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo
11570826|NCT00854100|Experimental|Cariprazine 0.1 - 0.3 mg|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR)+ cariprazine low dose
11570827|NCT00854100|Experimental|Cariprazine 1.0 - 2.0 mg|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine high dose
11570828|NCT00854087|Active Comparator|Fuzheng Huayu|Pill with Fuzheng Huayu
11570829|NCT00854087|Placebo Comparator|Placebo|Pill without Fuzheng Huayu (sugar pill)
11570830|NCT00854074|No Intervention|2|Subject will be observed until recovery of normal GI function
11570831|NCT00854074|Experimental|1|Spinal neurostimulation
11570832|NCT00854061|Experimental|T-Pred|Tobramycin prednisolone acetate combination
11570833|NCT00854061|Active Comparator|Pred Forte|Prednisolone acetate
11570834|NCT00854035|Experimental|E|
11570835|NCT00854035|Placebo Comparator|P|
11570836|NCT00854022||Healthy|Healthy adults, of any ethnicity, or sex, and with no previous history of cancer, except for non-melanoma skin cancer
11570837|NCT00854022||RCC|Adult patients with newly diagnosed (diagnosed within the year of enrollment) renal carcinoma (RCC) any ethnicity, or sex, who have not received prior chemotherapy or radiotherapy.
11570838|NCT00854009|Experimental|1|BLI-489
11570839|NCT00854009|Placebo Comparator|2|Placebo
11570840|NCT00853996|Experimental|Prevention (acolbifene hydrochloride)|Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
11570841|NCT00853970|Experimental|Bromfenac ophthalmic solution 0.09%|dosed 1 drop daily in study eye for 2 weeks
11570842|NCT00853970|Placebo Comparator|Placebo|dosed 1 drop daily in study eye for 2 weeks
11570843|NCT00853957|Experimental|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
11570844|NCT00853957|Active Comparator|Amlodipine|Amlodipine 5mg titrated to 10 mg
11570845|NCT00853944|No Intervention|P|subjects take 1 tablet of placebo daily
11570846|NCT00853944|Experimental|S|subjects take 1 tablet of sitagliptin 100 mg daily
11570847|NCT00853931|Experimental|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 [i.e. Cycles 1, 2, 3, etc.]) until disease progression or intolerance panitumumab as determined by the investigator.
11570848|NCT00853918|Experimental|$20 Cash|
11570849|NCT00853918|Experimental|$50 Cash|
11570850|NCT00853918|Experimental|$50 Check|
11570851|NCT00853918|Experimental|$100 Check|
11570852|NCT00853905|Experimental|Treatment 1(Triesence)|glaucoma surgery with 0.2cc Triesence adjunct.
11570853|NCT00853905|Active Comparator|Treatment 2 (balanced salt solution BSS)|glaucoma surgery with balanced salt solution, the standard technique.
11570854|NCT00853892|Experimental|A|Controlled-Release Oxycodone Hydrochloride 40 mg tablet
11570855|NCT00853892|Active Comparator|B|OxyContin® 40 mg tablet
11570856|NCT00853879|Active Comparator|Arm 1. B6, B12, folate|Triple therapy with folate. Intervention #1.
11570857|NCT00853879|Active Comparator|Arm 2. B6, B12, L-methylfolate|Triple therapy with L-methylfolate. Intervention #2
11570858|NCT00853879|Placebo Comparator|Arm 3. B6, B12, Placebo|Triple therapy with placebo. Intervention #3.
11570859|NCT00853866|Experimental|1|reboxetine + tDCS verum
11570860|NCT00853866|Experimental|2|reboxetine + sham tDCS
11570861|NCT00853866|Experimental|3|placebo drug + verum tDCS
11570862|NCT00853866|Experimental|4|placebo drug + sham tDCS
11570863|NCT00853853|Active Comparator|1. EnSeal Device|The EnSeal device cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding. The device is able to seal blood vessels up to 7mm and hemorrhoidal vessels are much smaller than this size.
11570864|NCT00853853|Active Comparator|2. Ferguson Hemorrhoidectomy|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced.
11570865|NCT00853840|Experimental|1.|Maraviroc + Vardenafil
11570866|NCT00853840|Placebo Comparator|2.|Maraviroc + Placebo
11570867|NCT00853827|Placebo Comparator|1|
11570868|NCT00853827|Experimental|2|Aliskiren 300 mg
11570869|NCT00853814|Experimental|Reduced access to sedentary behaviors, High park access|
11570870|NCT00853814|Experimental|Usual access to sedentary behaviors, High park access|
11570871|NCT00853814|Experimental|Reduced access to sedentary behaviors, Low park access|
11570872|NCT00853814|Experimental|Usual access to sedentary behaviors, Low park access|
11570873|NCT00853801|Experimental|1|Lifestyle modification education and counseling for intervention patients. Diagnosis and treatment education and feedback on performance for providers of intervention patients.
11570874|NCT00853775||African American Families|Families with 2 parents and 2 children - no intervention, observational study
11570875|NCT00853775||Caucasian Families|Families with 2 parents and 2 children - no intervention, observational study
11570876|NCT00853762|Experimental|Atacicept 25 mg (With Loading)|
11570877|NCT00853762|Experimental|Atacicept 75 mg (With Loading)|
11570878|NCT00853762|Experimental|Atacicept 150 mg (With Loading)|
11570879|NCT00853762|Experimental|Atacicept 150 mg (Without Loading)|
11570880|NCT00853749|Other|Single|All subjects will receive a single dose of 13vPnC
11570881|NCT00853736|Experimental|A|Oxycodone hydrochloride tablet 30 mg
11570883|NCT00853723|Experimental|PTHrP 400 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months.
11570884|NCT00853723|Experimental|PTHrP 600 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months.
11570885|NCT00853723|Active Comparator|PTH 20 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months.
11570886|NCT00853710|Experimental|rapid PSA assay on whole blood|
11570887|NCT00853697|Experimental|testosterone with the 5α-reductase inhibitor dutast|This trial is a multi-center, open-label, phase II trial of the combination of exogenous testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride in patients with castration-resistant metastatic prostate cancer.
11570888|NCT00853684|Experimental|oxaliplatin, capecitabine plus endostar|
11570889|NCT00853671|Experimental|Adenosine Stress Dual-source CTP|A multiphase adenosine Stress Dual-source stress perfusion computed tomography imaging test, as described above, will be performed in all patients.
11570890|NCT00853658|Experimental|Combination Aliskiren / Enalapril|Aliskiren / Enalapril combination therapy-150 mg/10 mg titrated to 300 mg/ 10 mg film-coated tablets and administered orally.
11570891|NCT00853658|Experimental|Aliskiren|Aliskiren monotherapy - 150 mg titrated to 300 mg film-coated tablets and administered orally.
11570892|NCT00853658|Active Comparator|Enalapril|Enalapril monotherapy -10 mg film-coated tablet and administered orally.
11570893|NCT00853645|Experimental|S-ICD System|Single-arm with 6 patients implanted with an S-ICD System
11570894|NCT00853632|Other|Device - CEP Mitral Valve|
11570895|NCT00853619|Experimental|Services Demo at PHS and RI|Service based CDS intervention at PHS.
11570896|NCT00853619|Active Comparator|Normal CDS interventions at PHS and RI|Normal CDS intervention at both PHS and RI hospitals
11570897|NCT00853606|Experimental|avanafil|
11570898|NCT00853593|Experimental|Model 4396 LV Lead|Non-randomized study.
11570899|NCT00853580|Placebo Comparator|2|This is a prospective multi-centre randomized, placebo-controlled Phase II study to determine the efficacy of Lovastatin ™ on visual spatial learning and/or attention abilities of children with NF1 aged between 8 and less than 16 years. In addition, the effect of Lovastatin ™ on secondary measures of executive function, visual spatial skills, behavior and quality of life will be assessed. Participants will be randomized to 16-weeks of treatment with Lovastatin ™ or a matched placebo.
11570900|NCT00853580|Experimental|1|This is a prospective multi-centre randomized, placebo-controlled Phase II study to determine the efficacy of Lovastatin ™ on visual spatial learning and/or attention abilities of children with NF1 aged between 8 and less than 16 years. In addition, the effect of Lovastatin ™ on secondary measures of executive function, visual spatial skills, behavior and quality of life will be assessed. Participants will be randomized to 16-weeks of treatment with Lovastatin ™ or a matched placebo.
11570901|NCT00853567|Active Comparator|25 g Proellex|25 mg oral daily dose of Proellex
11570902|NCT00853567|Active Comparator|50 mg Proellex|50 mg oral daily dose of Proellex
11570903|NCT00853567|Placebo Comparator|Placebo|Placebo treatment
11570904|NCT00853554|Experimental|A|Hydromorphone Hydrochloride tablet 8 mg
11570905|NCT00853554|Active Comparator|B|Dilaudid® tablet 8 mg
11570906|NCT00853541||heart failure with renal impairment|Heart Failure patients with renal impairment
11570907|NCT00853528|Experimental|Single-fraction radiosurgery; 16 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 16 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
11570908|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 21 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 21 Gray
11570909|NCT00853528|Experimental|Single-fraction radiosurgery; 18 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 18 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
11570910|NCT00853528|Experimental|Single-fraction radiosurgery; 20 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 20 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
11570911|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 24 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 24 Gray
11570912|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 27 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 27 Gray
11570913|NCT00853515|Experimental|1|Goal-directed fluid resuscitation with lactated Ringer's solution
11570914|NCT00853515|Experimental|2|Goal-directed fluid resuscitation with normal saline
11570915|NCT00853515|No Intervention|3|Standard fluid resuscitation with lactated Ringer's solution
11570916|NCT00853515|No Intervention|4|Standard fluid resuscitation with normal saline
11570917|NCT00853502|Active Comparator|testosterone cypionate|
11570918|NCT00853502|No Intervention|bone monitoring|
11570919|NCT00853489|Experimental|recombinant bone morphogenetic protein 2|The patient will receive rhBMP-2 plus allograft chips in the bone defect site. Intervention type: surgical
11570920|NCT00853489|Active Comparator|Autogenous iliac crest bone graft|Bone will be harvested from the iliac crest and placed in the bone defect.
11571057|NCT00852618||A|Participants undergoing treatment with raltegravir (RAL) in the main study
11570921|NCT00853463|No Intervention|No Alert|The responsible physician of a patient randomized to the control arm will not be contacted regarding the increased VTE risk of the patient.
11570922|NCT00853463|Other|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
11570923|NCT00853450|Experimental|1|AZD6482 on top of ASA
11570924|NCT00853450|Active Comparator|2|Clopidogrel on top of ASA
11570925|NCT00853424|Active Comparator|M|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
11570926|NCT00853424|Experimental|I|subjects receive an islet cell transplant in addition to all recommended medical treatment for diabetes and diabetic eye disease
11570927|NCT00853398|Experimental|Minimal Invasive Surgery,|
11570928|NCT00853398|Active Comparator|Standard Surgical Technique|
11570929|NCT00853385|Experimental|5mg|
11570930|NCT00853385|Experimental|10 mg|
11570931|NCT00853385|Placebo Comparator|Placebo Sequence 1|
11570932|NCT00853385|Placebo Comparator|Placebo Sequence 2|
11570933|NCT00853385|Active Comparator|adalimumab|
11570934|NCT00853372|Experimental|Trebananib 10 mg/kg + Sunitinib|Trebananib 10 mg/kg intravenously (IV) once weekly (QW) plus sunitinib 50 mg orally (PO) once daily (QD) 4 weeks on/2 weeks off
11570935|NCT00853372|Experimental|Trebananib 15 mg/kg + Sunitinib|Trebananib 15 mg/kg IV QW plus sunitinib 50 mg PO QD 4 weeks on/2 weeks off
11570936|NCT00853346|Experimental|1|Patients randomized to the immediate arm will be given 12 weeks of CBT starting one week after randomization
11570937|NCT00853346|Active Comparator|2|Patients in the delayed arm will receive 12 weeks of CBT, starting 12 weeks after randomization.
11570938|NCT00853333|Active Comparator|Propofol|Administration via an IV
11570939|NCT00853333|Active Comparator|Midazolam|Administration via an IV
11570940|NCT00853333|Active Comparator|Dexmedetomidine|Administration via an IV
11570941|NCT00853320|Experimental|A|Oxycodone hydrochloride tablet 15 mg
11570942|NCT00853320|Active Comparator|B|Roxicodone™ tablet 15 mg
11570943|NCT00853307|Experimental|Alisertib 50 mg|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).
11570944|NCT00853294|Active Comparator|B|Tussionex® Pennkinetic® Extended Release Oral Suspension
11570945|NCT00853294|Experimental|A|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule
11570946|NCT00853281|Experimental|Hammocks with LLIN|Locally-made hammocks covered with long-lasting insecticidal net (LLIN)- Olyset(R), used in addition to the standard vector control measures
11570947|NCT00853281|Active Comparator|ITN|Standard vector control measures (insectice-treated net or ITN)
11570948|NCT00853268|Experimental|A|Controlled-Release Oxycodone Hydrochloride 40 mg tablet
11570949|NCT00853268|Active Comparator|B|OxyContin® 40 mg tablet
11570950|NCT00853255|Experimental|1|Participants will receive 0.5 mL of vaccine intranasally via an Accuspray device (0.25 mL in each nostril)
11570951|NCT00853242|Placebo Comparator|Placebo|Placebo matched to Genz-644470 tablet orally three times a day (TID) with meals for 3 weeks.
11570952|NCT00853242|Experimental|Genz-644470 2.4 Grams Per Day (g/day)|Genz-644470 2.4 g/day tablets dosed orally TID with meals for 3 weeks.
11570953|NCT00853242|Experimental|Genz-644470 4.8 g/day|Genz-644470 4.8 g/day tablets dosed orally TID with meals for 3 weeks.
11570954|NCT00853242|Experimental|Genz-644470 7.2 g/day|Genz-644470 7.2 g/day tablets dosed orally TID with meals for 3 weeks.
11570955|NCT00853242|Active Comparator|Sevelamer Carbonate 2.4 g/day|Sevelamer Carbonate 2.4 g/day tablets dosed orally TID with meals for 3 weeks.
11570956|NCT00853242|Active Comparator|Sevelamer Carbonate 4.8 g/day|Sevelamer Carbonate 4.8 g/day tablets dosed orally TID with meals for 3 weeks.
11570957|NCT00853242|Active Comparator|Sevelamer Carbonate 7.2 g/day|Sevelamer Carbonate 7.2 g/day tablets dosed orally TID with meals for 3 weeks.
11570958|NCT00853229|Experimental|pregabalin/placebo|pregabalin and placebo given using a cross-over design
11570959|NCT00853229|Experimental|placebo/pregabalin|placebo and pregabalin given using a cross-over design
11570960|NCT00853216|Experimental|A|Oxycodone hydrochloride tablet 30 mg
11570961|NCT00853216|Active Comparator|B|Roxicodone™ tablet 30 mg
11570962|NCT00853203||Part 1|Interviews + Questionnaire + Electronically Activated Recorder (EAR)
11570963|NCT00853203||Part 2, Expressive Disclosure Group|Group Meetings + Written Materials
11570964|NCT00853203||Part 2, Standard Care Control Group|Written Materials
11570965|NCT00853190|Experimental|A|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule
11570966|NCT00853190|Active Comparator|B|Tussionex® Pennkinetic® Extended Release Oral Suspension
11570967|NCT00853177|Experimental|nitrous oxide|"N2O of 50% and 50% O2
~MEOPA"
11570968|NCT00853177|Active Comparator|lidocaine|Injection solution 1%
11570969|NCT00853164|Experimental|aerobic exercise|Subjects who are randomly assigned to this arm will be assigned a walking program to participate in 3 times a week for eight weeks
11570970|NCT00853164|Experimental|resistence training|Subjects who are randomly assigned to this arm will be assigned a weight training program to participate in 3 times a week for eight weeks
11570971|NCT00853164|Active Comparator|Usual Care|Subjects who are randomly assigned to this arm will not participate in any exercise program and will continue with usual care treatment
11570972|NCT00853151|Experimental|LY2428757 plus TT223 3 milligrams (mg)|Weekly LY2428757 plus 3 milligrams (mg) daily TT223
11570973|NCT00853151|Experimental|LY2428757 plus TT223 2mg|Weekly LY2428757 plus 2 mg daily TT223
11570974|NCT00853151|Experimental|LY2428757 plus placebo|Weekly LY2428757 plus daily TT223 placebo
11570975|NCT00853151|Placebo Comparator|Placebo plus Placebo|Weekly LY2428757 placebo plus daily TT223 placebo
11571012|NCT00852943||Patients|Subjects, ages birth to 99 years old, known to have or suspected of having an inherited disorder of allergic inflammation or mast cell homeostasis or activation, will be eligible for enrollment.
11571259|NCT00851227|Experimental|2. Moderately Hepatic Impaired Subjects|
11570976|NCT00853138|Experimental|CBT|Cognitive-behavioral therapy delivered via the internet in eight treatment modules for children (education, stress and negative emotions, deep breathing and relaxation, distraction, cognitive skills, sleep hygiene and lifestyle, staying active, relapse prevention) and eight treatment modules for parents (education, stress and negative emotions, operant strategies I, operant strategies II, modeling, sleep hygiene and lifestyle, communication, relapse prevention).
11570977|NCT00853138|No Intervention|SMC|The standard medical care wait-list control group continued with the treatment recommendations proscribed by their pain care team.
11570978|NCT00853125|Experimental|Sunitinib plus Irradiated Allogeneic Lymphocytes|
11570979|NCT00853112|Experimental|PF-00489791 1 mg|
11570980|NCT00853112|Experimental|PF-00489791 2 mg|
11570981|NCT00853112|Experimental|PF-00489791 4 mg|
11570982|NCT00853112|Experimental|PF-00489791 10 mg|
11570983|NCT00853112|Experimental|PF-00489791 20 mg|
11570984|NCT00853112|Placebo Comparator|Placebo|
11570985|NCT00853112|Active Comparator|Sildenafil|Observational comparator arm
11570986|NCT00853099|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections every 2 weeks for 52 weeks. From Week 8, participants with an inadequate response could switch to rescue therapy, where they initially received adalimumab 160 mg, 80 mg 2 weeks later, and then 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
11570987|NCT00853099|Experimental|Adalimumab 80 mg/40 mg|Participants received adalimumab 80 mg on Day 1, 40 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
11570988|NCT00853099|Experimental|Adalimumab 160 mg/80 mg|Participants received adalimumab 160 mg on Day 1, 80 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
11570989|NCT00853086||A|
11570990|NCT00853073|Active Comparator|Bevacizumab|subjects will receive 1.0mg (0.04cc of 25 mg/ml) subconjunctival bevacizumab either temporal or nasal to the bleb following bleb needling procedure in addition to 0.1 cc mitomycin C.
11570991|NCT00853073|Placebo Comparator|balanced salt solution|patients randomized to treatment B are given 0.04cc of balanced salt solution injected in identical fashion either temporal or nasal to the bleb following bleb needling procedure in addition to 0.1 cc mitomycin C.
11570992|NCT00853047|Experimental|Telotristat Etiprate 150 mg Core Phase|Telotristat etiprate capsules,150 mg orally 3 times daily for 28 days in the double-blind treatment period (core phase) in combination with stable-dose octreotide long-acting release (LAR) depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
11570993|NCT00853047|Experimental|Telotristat Etiprate 250 mg Core Phase|Telotristat etiprate capsules, 250 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
11570994|NCT00853047|Experimental|Telotristat Etiprate 350 mg Core Phase|Telotristat etiprate capsules, 350 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
11570995|NCT00853047|Experimental|Telotristat Etiprate 500 mg Core Phase|Telotristat etiprate capsules, 500 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with a stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
11570996|NCT00853047|Experimental|Placebo Core Phase|Placebo-matching telotristat etiprate capsules, orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to receive telotristat etiprate in the optional open-label extension period.
11570997|NCT00853047|Experimental|Telotristat Etiprate Open-Label Extension Phase|Telotristat etiprate at assigned dose level for 8 weeks in combination with stable-dose octreotide LAR depot therapy given once per month in the open-label extension period. Upon completion of the 8-week period, participants could enter an additional extension period of 172 weeks, receiving telotristat etiprate at the assigned dose or maximum tolerated dose (500 mg 3 times daily).
11570998|NCT00853034|Active Comparator|FOS-IN|prebiotic fructo-oligosaccharide enriched inulin
11570999|NCT00853034|Experimental|AXOS|arabinoxylan-oligosaccharides (AXOS)
11571000|NCT00853021|Experimental|Bevacizumab and Aldesleukin|
11571001|NCT00852995|Experimental|A - Low Q7D|Low dose HP802-247, applied at each visit
11571002|NCT00852995|Experimental|B - Low Q14D|Low dose HP802-247 applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
11571003|NCT00852995|Experimental|C - High Q7D|High dose HP802-247, applied at each visit
11571004|NCT00852995|Experimental|D - High Q14D|High dose HP802-247, applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
11571005|NCT00852995|Placebo Comparator|E - Vehicle|Placebo (Vehicle), applied at each visit
11571006|NCT00852982|Experimental|Exercise|Five hours of Nordic walking per week, during four months
11571007|NCT00852982|No Intervention|Control|Control group asked not to alter lifestyle during study
11571008|NCT00852969|Active Comparator|Niacin|
11571009|NCT00852969|Placebo Comparator|Placebo|
11571010|NCT00852956|Experimental|Treatment|Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total)and Olanzapine (10 mg/day)
11571011|NCT00852956|Active Comparator|Control|Matching placebo TID; 08:00, 13:00 and 18:00 and Olanzapine (10 mg/day).
11571260|NCT00851227|Experimental|3. Subjects with Normal Hepatic Function|
11571013|NCT00852930|Experimental|laser alone|The intervention was therapist administered low level laser therapy using low level laser, number of sessions based upon patient response
11571014|NCT00852930|Active Comparator|mld alone|The intervention was therapist administered manual lymphatic drainage (mld) using standard massage techniques,number of sessions based upon patient response
11571015|NCT00852930|Experimental|laser and mld combined|The intervention was therapist administered low level laser and mld using low level laser and standard massage techniques, number of sessions based upon patient response
11571016|NCT00852917|Experimental|1: Tramadol Once A Day 100mg|
11571017|NCT00852917|Experimental|2: Tramadol Once A Day 200mg|
11571018|NCT00852917|Experimental|3: Tramadol Once A Day 300mg|
11571019|NCT00852917|Placebo Comparator|4: Placebo|
11571020|NCT00852904||NCS Vanguard cohort|Women of child bearing potential, children born to women enrolled in the study, the children s biological and/or social fathers, and primary caregivers (if other than parent)
11571021|NCT00852878|Active Comparator|Biofeedback|heart rate variability biofeedback
11571022|NCT00852878|Active Comparator|Behavioral|Behavioral intervention will provide parent and child with a variety of pain management techniques such as relaxation, distraction, contingency management, and coping statements
11571023|NCT00852865|Experimental|1|24 healthy volunteers consuming L.farciminis during three weeks
11571024|NCT00852865|Placebo Comparator|2|24 healthy volunteers consuming placebo during three weeks
11571025|NCT00852852|Experimental|Intervention|Patient participants in the intervention arm can access educational information about self-care strategies, track and share reports of their symptoms and quality of life issues over time, and receive coaching on how to discuss these issues with their care team.
11571026|NCT00852852|No Intervention|Control|Participants in the control arm access the ESRA-C from home or clinic to self-assess only.
11571027|NCT00852839|Experimental|552-02|
11571028|NCT00852839|Placebo Comparator|Placebo|
11571029|NCT00852826|Sham Comparator|1|Standard axillary lymphadenectomy
11571030|NCT00852826|Experimental|2|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
11571031|NCT00852800|Active Comparator|Standard regimen|Albumin in standard regimen (1.5 g/Kg IV on day 1 and 1 g/kg IV on day 3)with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3
11571032|NCT00852800|Experimental|Dose reduced regimen|Albumin in dose reduced regimen (1 g/kg IV on day 1 and 0.5 g/kg IV on day 3) with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3
11571033|NCT00852787|Experimental|Low|0.1mg/kg
11571034|NCT00852787|Experimental|Medium|0.4mg/kg
11571035|NCT00852787|Experimental|High|1.6 mg/kg
11571036|NCT00852787|Placebo Comparator|Placebo|
11571037|NCT00852774||1|Endometrial Cancer Patients Hysterectomy Robotic Surgery
11571038|NCT00852774||2|Endometrial Cancer Patient Hysterectomy Laparotomy Surgery
11571039|NCT00852761|Experimental|Olux-E Foam|Olux-E (clobetasol propionate 0.05%) foam
11571040|NCT00852761|Active Comparator|Clobex lotion|Clobex (clobetasol propionate 0.05%) lotion.
11571041|NCT00852722|Experimental|1. Low fat study diet|The low fat study diet arm will receive low fat diet training and followed for 12 months on the diet.
11571042|NCT00852722|No Intervention|2. Regular diet group|The regular diet arm will be a wait-listed group that will receive no training in diet and will be advised to continue their regular (usual) diet as was prior to entry into the study, for the duration of the study. They will have a similar clinic follow up schedule as the treatment group. The regular diet group will be given identical instructions to exercise regularly similar to the treatment group.
11571043|NCT00852696|Placebo Comparator|Placebo Group|Placebo Orally 9 weeks once daily.
11571044|NCT00852696|Experimental|Solifenacin Group|Solifenacin Orally 9 weeks once daily.
11571045|NCT00852683|Active Comparator|A|
11571046|NCT00852683|Placebo Comparator|B|
11571047|NCT00852670|Experimental|A|
11571048|NCT00852670|Placebo Comparator|B|
11571049|NCT00852657|Active Comparator|Surgical treatment|Open or mini-open tendon repair with acromioplasty
11571050|NCT00852657|Active Comparator|Physiotherapy|Physiotherapy by exercises
11571051|NCT00852644|Experimental|56 Gray (LESS than 3 centimeter cohort)|"Intervention:
~Procedure/Surgery: computed tomography Standard CT scans
~Intervention:
~Radiation: fludeoxyglucose F 18 standard doses with CT scans
~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray
~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
11571052|NCT00852644|Experimental|62 Gray (LESS than 3 centimeter cohort)|"Intervention:
~Procedure/Surgery: computed tomography Standard CT scans
~Intervention:
~Radiation: fludeoxyglucose F 18 standard doses with CT scans
~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray
~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
11571053|NCT00852644|Experimental|68 Gray (LESS than 3 centimeter cohort)|"Intervention:
~Procedure/Surgery: computed tomography Standard CT scans
~Intervention:
~Radiation: fludeoxyglucose F 18 standard doses with CT scans
~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray
~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
11571054|NCT00852644|Experimental|56 Gray (MORE than 3 centimeter cohort)|"Intervention:
~Procedure/Surgery: computed tomography Standard CT scans
~Intervention:
~Radiation: fludeoxyglucose F 18 standard doses with CT scans
~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray
~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
11571055|NCT00852644|Experimental|62 Gray (MORE than 3 centimeter cohort)|"Intervention:
~Procedure/Surgery: computed tomography Standard CT scans
~Intervention:
~Radiation: fludeoxyglucose F 18 standard doses with CT scans
~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray
~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
11571056|NCT00852644|Experimental|68 Gray (MORE than 3 centimeter cohort)|"Intervention:
~Procedure/Surgery: computed tomography Standard CT scans
~Intervention:
~Radiation: fludeoxyglucose F 18 standard doses with CT scans
~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray
~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
11571509|NCT00849446||Activity monitoring in CVA patients|
11571058|NCT00852618||B|Participants undergoing treatment with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in the main study
11571059|NCT00852605|No Intervention|Oxygen|Conventional Treatment including Oxygen-support
11571060|NCT00852605|Experimental|NIV|Conventional Treatment plus intermittent Non-Invasive-Ventilation
11571061|NCT00852592|Active Comparator|Active Comparator|7000lux broad-spectrum light
11571062|NCT00852592|Placebo Comparator|Inactive Comparator|50lux dim red light
11571063|NCT00852579|Experimental|1|Active treatment.
11571064|NCT00852579|Placebo Comparator|2|Placebo control group.
11571065|NCT00852566|Active Comparator|Imatinib|Standard treatment Imatinib 400mg OD
11571066|NCT00852566|Experimental|dasatinib|Dasatinib 100mg OD
11571067|NCT00852540|Experimental|Retapamulin|
11571068|NCT00852540|Active Comparator|Linezolid|
11571069|NCT00852527||Subjects with mild TBI|Presence of mild TBI defined by positive reference test
11571070|NCT00852527||Subjects without mild TBI|Absence of mild TBI defined by negative reference test
11571071|NCT00852514|Experimental|Monthly BIA|monthly BIA to monitor fluid status
11571072|NCT00852501||Non-functioning pituitary macroadenoma|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
11571073|NCT00852488|Experimental|Catheter|Cohort undergoing catheter placement using the new technique being studied
11571074|NCT00852475|Placebo Comparator|MUFA|Assignment to monounsaturated enriched diet with exercise. This represents the MUFA MOVE! program
11571075|NCT00852475|Active Comparator|PUFA|Assignment to polyunsaturated enriched diet with exercise. This represents the PUFA MOVE! program
11571076|NCT00852462|Experimental|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
11571077|NCT00852462|No Intervention|Usual Care|Symptom assessment and management follows customary procedures in each study site.
11571078|NCT00852449|Experimental|restrictive fluid|Restrictive fluid administration: 6 ml kg-1 h-1 of crystalloids (lactated Ringer's solution)
11571079|NCT00852449|Experimental|liberal fluid|Liberal fluid administration: 12 ml kg-1 h-1 of crystalloids (lactated Ringer's solution)
11571080|NCT00852436|Active Comparator|1|Pregabalin capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.
11571081|NCT00852436|Placebo Comparator|2|Placebo capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.
11571082|NCT00852423|Experimental|DHAPQ|Three-day treatment with dihydroartemisinin-piperaquine
11571083|NCT00852423|Experimental|MQAS|Three-day treatment with mefloquine artesunate
11571084|NCT00852423|Active Comparator|AQAS|Three-day treatment with artesunate-amodiaquine
11571085|NCT00852423|Active Comparator|AL|Three day treatment with artemether-lumefantrine (Coartem(R)
11571086|NCT00852410|Active Comparator|1% lidocaine with 1:100000 adrenaline|high dose adrenaline
11571087|NCT00852410|Active Comparator|1% lidocaine with 1:200,000 adrenaline|low dose
11571088|NCT00852397|Experimental|Apixaban 2.5 mg|
11571089|NCT00852397|Experimental|Apixaban 5.0 mg|
11571090|NCT00852397|Placebo Comparator|Placebo|
11571091|NCT00852371|Active Comparator|Combination of Amodiaquine +sulfadoxine-pyrimethamine|Combination of Amodiaquine (Camoquin, Parke-Davis, 200 mg tablets, 10 mg/kg on days 0 and 1, and 5 mg/kg on day 2) + sulfadoxine-pyrimethamine (Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine per treatment as a single dose) given as oral tablets
11571092|NCT00852371|Active Comparator|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets targeting a total dose of 6.4 and 51.2 mg/kg of dihydroartemisinin and piperaquine, respectively, given in 3 equally divided daily doses to the nearest ¼ tablet)
11571093|NCT00852371|Placebo Comparator|Placebo|Placebo (had no active ingredients, produced by Cosmos Limited, Nairobi, Kenya)
11571094|NCT00852371|Active Comparator|Sulfadoxine-pyrimethamine alone|sulfadoxine-pyrimethamine (Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine per treatment as a single dose) given as oral tablets
11571095|NCT00852358|Experimental|intrathecal laronidase|The Experimental treatment group will receive study assessments and intrathecal laronidase (1.74 mg laronidase) treatments every 1-3 months beginning at start of study.
11571096|NCT00852358|Other|Control Group|During the first 11 months, the control group will receive study assessments but will be unblinded with no intrathecal treatment or placebo administered. Beginning at month 12, the control group will receive intrathecal laronidase (1.74 mg) treatment every 3 months (months 12, 15, 18, and 21).
11571097|NCT00852332|Experimental|Curcumine|With curcumin capsules
11571098|NCT00852332|Active Comparator|Drug taxotere only|Without curcumin
11571099|NCT00852319|Experimental|Central Mississippi group|Participants from central Mississippi are provided with 24 months of interpregnancy care. The results from this arm are compared to a historical control group (who were not given interpregnancy care) from the same geographical area in Mississippi.
11571100|NCT00852319|Experimental|Mississippi Delta group|Participants from 18 counties of the Mississippi delta are provided with 24 months of interpregnancy care. The results from this arm are compared to a historical control group (who were not given interpregnancy care) from the same geographical area in Mississippi.
11571101|NCT00852306|Experimental|slow freeze|these recipients will have their first embryo transfer with oocytes frozen via the slow freeze method.
11571102|NCT00852306|Experimental|vitrification|these recipients will have their first attempt at an embryo transfer with oocytes frozen via the vitrification method.
11571103|NCT00852293||study group|Patients with liver disease followed at the liver unit at Hadassah Medical Center.
11571104|NCT00852267|Active Comparator|High CHO, High SatFat Diet|
11571105|NCT00852267|Experimental|Low CHO, High SatFat Diet|
11571106|NCT00852267|Experimental|Low CHO, Low SatFat Diet|
11571107|NCT00852241|Experimental|Restalyne and Perlane|One syringe of Perlane® (1.0cc) and one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
11571108|NCT00852228|Experimental|chronomodulated HAI chemotherapy|
11571109|NCT00852228|Experimental|conventional HAI chemotherapy|
11571110|NCT00852215|Active Comparator|1|Taxus stent group
11571111|NCT00852215|Active Comparator|2|Vision stent group
11571112|NCT00852202|Experimental|1|0.25 - 0.75 mg/day cariprazine capsules, oral administration, once daily dosing.
11571113|NCT00852202|Experimental|2|1.5 - 3.0 mg/day cariprazine capsules, oral administration, once daily dosing.
11571114|NCT00852202|Placebo Comparator|3|Matching placebo capsules, oral administration, once daily dosing.
11571115|NCT00852176||On-label treatment|"Patients treated in routine clinical practice following FDA Pre-Market Approval of the Beta-Cath(TM) 3.5F System within the parameters of the approved indications for use for the System (on-label)."
11571116|NCT00852163|Experimental|Clofarabine with Busulfan|Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days
11571117|NCT00852137|Experimental|PEP005 (ingenol mebutate) Gel, 0.05%|
11571118|NCT00852137|Placebo Comparator|Vehicle Gel|
11571119|NCT00852124|Placebo Comparator|Placebo|Packets similar to VSL#3 will be taken 2 X daily but not containing active bacteria
11571120|NCT00852124|Active Comparator|VSL#3|Packets of VSL#3 (powder containing 8 bacteria believed to be beneficial) will be taken 2 x daily in food or a cool beverage.
11571121|NCT00852111||Patients|Prostate cancer patients
11571122|NCT00852098|Active Comparator|1|dividing short gastric vessels
11571123|NCT00852098|Active Comparator|2|non-dividing short gastric vessels
11571124|NCT00852085|Experimental|Group MI|Four group counseling sessions and a directed observational visit to the emergency department of a busy urban hospital
11571125|NCT00852085|Active Comparator|Enhanced community service|
11571126|NCT00852072|Active Comparator|Single-operator cholangioscopy guided laser lithotripsy|Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy
11571127|NCT00852072|Active Comparator|Balloon sphincteroplasty|Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
11571128|NCT00852059|Experimental|Immediate release|Treatment with immediate release (IR) methylphenidate (Medikinet®) in the morning and 3-4 h later (twice a day)
11571129|NCT00852059|Active Comparator|Extended release|Treatment with extended release (ER) methylphenidate (Medikinet reatard®) applied with breakfast(once daily)
11571130|NCT00852046|Experimental|1. Low dose dexmedetomidine|Dexmedetomidine 0.2 mcg/kg/hr added to fentanyl & propofol.
11571131|NCT00852046|Experimental|2. High dose dexmedetomidine|Dexmedetomidine 0.6 mcg/kg/hr added to fentanyl & propofol.
11571132|NCT00852046|Placebo Comparator|3. Placebo|Placebo added to fentanyl & propofol.
11571133|NCT00852033|No Intervention|1|Assessment Group (no intervention)
11571134|NCT00852033|Active Comparator|2|Brief Motivational Intervention (BMI)
11571135|NCT00852033|Active Comparator|3|Parent Based Intervention (PBI)
11571136|NCT00852033|Active Comparator|4|BMI and TBI
11571137|NCT00852020|Experimental|1|oral nutritional supplement containing n-3-fatty acids, amino acids and antioxidants
11571138|NCT00852020|Placebo Comparator|2|oral nutritional supplement (isocaloric, isonitrogenous)
11571139|NCT00852007|Experimental|DC-Tn-MUC|DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1. 1.2 x 10e7 dendritic cells per dose. 5 administrations (doses)may be given in total.
11571140|NCT00851994||1|Patients having surgery
11571141|NCT00851981|Placebo Comparator|1|
11571142|NCT00851981|Active Comparator|SAMe|
11571143|NCT00851968|Active Comparator|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
11571144|NCT00851968|Experimental|Hemihepatic vascular Clamping|Patients with HCC received Hemihepatic vascular Clamping in hepatectomy
11571145|NCT00851968|Experimental|portal vein occlusion|Patients with HCC received portal vein occlusion in hepatectomy
11571146|NCT00851955||1. Normal pancreas patients|Patients with no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test (EUS, CT scan or MRI).
11571147|NCT00851955||2. Chronic pancreatitis patients|Patients with documented diagnosis of moderate to advanced chronic pancreatitis supported by at least 1 positive imaging test (EUS,CT scan or MRI).
11571148|NCT00851955||3. Pancreatic cancer patients|Patients with documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.
11571149|NCT00851942|Experimental|Synacthen 250 micrograms|IV injection of 250 micrograms of Synacthen in 1m
11571150|NCT00851929|Experimental|sarcoidosis associated pulmonary hypertension|sarcoidosis associated pulmonary hypertension
11571151|NCT00851916|Other|CyberKnife Radiosurgery|Single arm study using CyberKnife radiosurgery to treat recurrent prostate cancer patients that have already received external beam radiotherapy.
11571152|NCT00851903|Experimental|Combination insulin glargine and sitagliptin|"Insulin glargine administered once a day, in the evening, at dinner or at bedtime. Starting dose: - last dose administered in the core study for patients previously treated with insulin glargine, - 0.2 U/Kg of body weight for patients previously treated with sitagliptin. Monitoring of blood glucose and titration: all patients, irrespective of their previous treatment group in the core study were empowered to adjust their insulin doses, under strict investigator's supervision. The goal was to achieve through a force titration 70 < Fasting Plasma Glucose (FPG) ≤ 100 mg/dL (3.9 <FPG ≤ 5.5 mmol/L).
~Sitagliptin: stable dose of 100 mg once a day administered with or without food."
11571153|NCT00851890|Experimental|ABT-333 (300 mg) twice daily (BID) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 300 mg ABT-333 BID for 2 days followed by 300 mg ABT-333 BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
11571201|NCT00851643|Experimental|Octavalent HPV with 120 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 120 mcg IMX.
11571202|NCT00851630|Experimental|Early|Initiation of fixed dose combination zidovudine/lamivudine/abacavir 2 weeks after commencing antituberculous therapy
11571154|NCT00851890|Experimental|ABT-333 (600 mg) twice daily (BID) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 600 mg ABT-333 BID for 2 days followed by 600 mg ABT-333 BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
11571155|NCT00851890|Experimental|ABT-333 (1200 mg) once daily (QD) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 1200 mg ABT-333 QD for 2 days followed by 1200 mg ABT-333 QD with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
11571156|NCT00851890|Placebo Comparator|Placebo + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naïve participants received matching placebo once daily (QD) or twice daily (BID) for 2 days followed by placebo QD or BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
11571157|NCT00851877|Experimental|arm one|Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy
11571158|NCT00851864|Experimental|A|Women requiring therapeutic anticoagulation, singleton pregnancy,<30weeks
11571159|NCT00851838|Experimental|PD solution|
11571160|NCT00851812|Other|Arm 1|Usual Care: Standard care monitoring
11571161|NCT00851812|Experimental|Arm 2|Progressive walking and resistance exercise treatment
11571162|NCT00851799||Cohort A|"ATV/RTV + FTC/TDF
~Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily."
11571163|NCT00851799||Cohort B|"RAL + FTC/TDF
~FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily."
11571164|NCT00851799||Cohort C|"DRV/RTV + FTC/TDF
~FTC/TDF, darunavir (DRV), and RTV, orally, once daily."
11571165|NCT00851786|Experimental|1|Participants with CD4 cell counts of 200 cells/uL or greater in Stages 1 and 2, stratified by CD4 cell counts (200-349 cells/uL vs. >=350 cells/uL), will be given one dose of ZOSTAVAX (Zoster Vaccine Live) at Day 0 and Week 6 and will be followed for at least 42 days after each vaccination after which a safety assessment will be conducted.
11571166|NCT00851786|Placebo Comparator|2|Participants with CD4 cell counts of 200 cells/uL or greater in Stages 1 and 2, stratified by CD4 cell counts (200-349 cells/uL vs. >=350 cells/uL), will be given one dose of placebo at Day 0 and Week 6 and will be followed for at least 42 days after each vaccination after which a safety assessment will be conducted
11571167|NCT00851773|Experimental|A|
11571168|NCT00851773|Experimental|B|
11571169|NCT00851773|Experimental|C|
11571170|NCT00851773|Experimental|D|
11571171|NCT00851773|Experimental|E|
11571172|NCT00851773|Placebo Comparator|F1|
11571173|NCT00851773|Placebo Comparator|F2|
11571174|NCT00851773|Placebo Comparator|F3|
11571175|NCT00851773|Placebo Comparator|F4|
11571176|NCT00851773|Placebo Comparator|F5|
11571177|NCT00851760|Experimental|1 Combined Surgery|
11571178|NCT00851760|Active Comparator|2 consecutive surgery|
11571179|NCT00851747|Experimental|C Phosphatidylcholine Deoxycholate|Phosphatidylcholine Deoxycholate Injections. Group C will receive only study drug injections
11571180|NCT00851747|Placebo Comparator|A Saline|Group A will serve as a control and will receive only injections of saline as a placebo.
11571181|NCT00851747|Active Comparator|B PhosphatidylcholineDeoxycholate/Saline|Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side.
11571182|NCT00851734|Experimental|LX214 0.02%|LX214 ophthalmic solution 0.02%
11571183|NCT00851734|Experimental|LX214 0.2%|
11571184|NCT00851734|Placebo Comparator|placebo|placebo
11571185|NCT00851721|Experimental|Prophylaxis arm|
11571186|NCT00851721|Active Comparator|On-demand arm|
11571187|NCT00851708|Active Comparator|NAC|treatment
11571188|NCT00851708|No Intervention|control|
11571189|NCT00851695||Asthma|All 1024 participants of the Childhood Asthma Management Program, who provided blood samples.
11571190|NCT00851695||Asthma in Hispanics|All 616 subjects in the Genetic Epidemiology of Asthma in Costa Rica who have serum.
11571191|NCT00851695||Lung function and lung function decline|626 subjects from the Normative Aging Study who have serum and lung function.
11571192|NCT00851682|Other|Radical prostatectomy patients|Patients who have been diagnosed with prostate cancer and are scheduled to undergo radical prostatectomy and have not received any preoperative treatment for prostate cancer.
11571193|NCT00851682|Other|Brachytherapy patients|Patients who have been diagnosed with prostate cancer and are scheduled to undergo brachytherapy and have not received any preoperative treatment for prostate cancer.
11571194|NCT00851669|Experimental|IPT|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
11571195|NCT00851669|Active Comparator|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
11571196|NCT00851643|Active Comparator|qHPV (GARDASIL™) - Phase A Control|Quadrivalent Human Papillomavirus (qHPV) (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™). This is the control for the Octavalent HPV with 15 mcg ISCOMATRIX™ (IMX) / Aluminum Hydroxyphosphate Sulfate (AAHS) and Octavalent HPV with 30 mcg IMX / AAHS during Phase A.
11571197|NCT00851643|Experimental|Octavalent HPV with 15 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg AAHS and 15 mcg IMX.
11571198|NCT00851643|Experimental|Octavalent HPV with 30 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 30 mcg IMX.
11571199|NCT00851643|Active Comparator|qHPV (GARDASIL™) - Phase B Control|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™). This is the control for the Octavalent HPV with 60 mcg IMX / AAHS and Octavalent HPV with 120 mcg IMX / AAHS during Phase B.
11571200|NCT00851643|Experimental|Octavalent HPV with 60 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 60 mcg IMX.
11571203|NCT00851630|Experimental|Delayed|Initiation of fixed dose combination zidovudine/lamivudine/abacavir 8 weeks after commencing antituberculous therapy
11571204|NCT00851617|Experimental|IMT Group|The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
11571205|NCT00851617|No Intervention|Control Group|Patients were evaluated until weaning without interventions
11571206|NCT00851604||1|Patients with malignant neuroendocrine tumors
11571207|NCT00851591|Experimental|Fenugreek category 1|receive fenugreek
11571208|NCT00851591|Placebo Comparator|Placebo Category 2|receive placebo
11571209|NCT00851578|Experimental|WATCHMAN|non-valvular atrial fibrillation patients contraindicated to warfarin
11571210|NCT00851565|Active Comparator|1|Patients with Crohn's disease with secondary loss of response to infliximab.
11571211|NCT00851565|Active Comparator|2|Patients with Crohn's disease with secondary loss of response to infliximab.
11571212|NCT00851539|No Intervention|Control|Participants received counseling from a live counselor.
11571213|NCT00851539|Experimental|Video|Behavioral Intervention Video
11571214|NCT00851526||Coronary bifurcation lesion|
11571215|NCT00851513|Experimental|Group B|local anesthetics (lidocaine) associated with local steroids (depo-medrol)
11571216|NCT00851513|Experimental|Group C|local anesthetics (lidocaine) associated with local steroids (depomedrol) and important volumes of physiological serum
11571217|NCT00851513|Active Comparator|Group A|only local anesthetic (lidocaine)
11571218|NCT00851500|Experimental|low dose K-604|
11571219|NCT00851500|Experimental|high dose K-604|
11571220|NCT00851500|Placebo Comparator|placebo|
11571221|NCT00851487|Experimental|Amoxicillin|Oral amoxicillin in the dose of 15 mg/kg/dose 8 hourly was given as an active drug
11571222|NCT00851487|Placebo Comparator|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
11571223|NCT00851448|Experimental|1|Oral nutritional supplement containing n-3 fatty acids, amino acids, antioxidants
11571224|NCT00851448|Placebo Comparator|2|isocaloric, isonitrogenous
11571225|NCT00851435|Experimental|KBPA-101, a monoclonal antibody|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
11571226|NCT00851409|Other|Recombinant Human C1 Inhibitor|Weekly administration of 50 IU/kg Recombinant Human C1 Inhibitor
11571227|NCT00851396||Obese female adolescents|Obese adolescents will be screened for vitamin D deficiency through an existing study. Those found to be vitamin D deficient will be given standard treatment of vitamin D deficiency. In this study, patients who self report that they had taken the treatment for vitamin D will be screened for serum 25 OH D level and will undergo OGTT. The OGTT results as well as insulin resistance indices will be compared to their initial values.
11571228|NCT00851383|Experimental|Group A|Ad35-GRIN/ENV: 2x10^9 vp
11571229|NCT00851383|Experimental|Group B|Ad35-GRIN/ENV: 2x10^10 vp
11571230|NCT00851383|Experimental|Group C|Ad35-GRIN/ENV: 2x10^11 vp
11571231|NCT00851383|Experimental|Group D|Ad35-GRIN at 1x10^10 vp
11571232|NCT00851370|Experimental|Omalizumab|
11571233|NCT00851370|Placebo Comparator|Placebo|
11571234|NCT00851357|Experimental|Active patches and telephone counseling|Proactive Telephone Counseling and 8-weeks of nicotine patches
11571235|NCT00851357|Placebo Comparator|Placebo patches and telephone counseling|Proactive Telephone Counseling and 8-weeks of placebo patches
11571236|NCT00851357|Active Comparator|Telephone counseling|Proactive Telephone Counseling
11571237|NCT00851357|Active Comparator|Active patches and materials|8-weeks of nicotine patches and materials
11571238|NCT00851357|Active Comparator|Placebo patches and materials|8-weeks placebo patches and materials
11571239|NCT00851357|Active Comparator|Materials|Self-help materials
11571240|NCT00851344|Active Comparator|GSK835726 (10mg)|10mg oral dose
11571241|NCT00851344|Active Comparator|GSK835726 (50mg)|50mg oral dose
11571242|NCT00851344|Active Comparator|GSK835726 (100mg)|50mg oral dose
11571243|NCT00851344|Active Comparator|Cetirizine 10mg|10mg cetirizine as active comparator
11571244|NCT00851344|Placebo Comparator|placebo|placebo tablet
11571245|NCT00851318|Experimental|Certolizumab pegol 200 mg|Participants received 200 mg certolizumab pegol by subcutaneous injection once every 2 weeks in combination with methotrexate for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
11571246|NCT00851318|Experimental|Certolizumab pegol 400 mg|Participants received 400 mg certolizumab pegol by subcutaneous injection once every 4 weeks in combination with methotrexate for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
11571247|NCT00851305|Experimental|1 confocal laser endomicroscopy|Targeted biopsies are performed when the lesion was considered as IM, dysplasia or carcinoma by confocal laser endomicroscopy.
11571248|NCT00851305|Active Comparator|2 Conventional endoscopy|Routine biopsies are performed when the lesion was considered as IM, dysplasia or carcinoma by conventional endoscopy.
11571249|NCT00851292|Active Comparator|Side-firing|prostate biopsies obtained with side-firing probe
11571250|NCT00851292|Active Comparator|End-firing|
11571251|NCT00851279|Experimental|Magnetic irrigated ablation catheter|Patients with documented VT and prior MI, in whom an ICD was implanted either for primary or secondary prevention, were recruited for endocardial mapping/ablation during VT (entrainment mapping, activation mapping) and/or substrate mapping in sinus rhythm (elimination of fractionated/late potentials, endocardial scar homogenization) with remote magnetic navigation (Niobe, Stereotaxis Inc.,St Louis, USA) and irrigated RF ablation (NaviStar RMT ThermoCool, Biosense Webster,California, USA).
11571252|NCT00851266|Experimental|1|V512
11571253|NCT00851266|Placebo Comparator|2|Placebo to V512
11571254|NCT00851253|Experimental|Group 1 (CK SRS boost therapy)|Radiation: CyberKnife Stereotactic Radiosurgery boost (2 fractionated doses) beginning 4-8 weeks after completion of standard therapy.
11571255|NCT00851253|Experimental|Group 2 (CK SRS salvage therapy)|Radiation : CyberKnife® stereotactic radiosurgery salvage therapy (5 fractions) 3 times weekly.
11571256|NCT00851240|Experimental|BTT1023|
11571257|NCT00851240|Placebo Comparator|Placebo|
11571258|NCT00851227|Experimental|1. Mildly Hepatic Impaired Subjects|
11571261|NCT00851214||Acute CHF/COPD|Patients presenting with shortness of breath secondary to acute exacerbation of CHF/COPD
11571262|NCT00851214||Acute Trauma|Acute trauma patients with a trauma ISS>15
11571263|NCT00851214||Sepsis|Patients presenting with a suspicion of acute sepsis (fever, tachycardia, tachypnea)
11571264|NCT00851214||Stroke|Patients presenting with symptoms and signs of acute stroke (thrombotic or hemorrhagic)
11571265|NCT00851201|Active Comparator|Standard Intervention|
11571266|NCT00851201|Experimental|Intensive lifestyle|
11571267|NCT00851188|Experimental|internet CBT self-help|CBT via the internet
11571268|NCT00851188|Experimental|CBT self-help booklet|
11571269|NCT00851188|Active Comparator|Waiting list|
11571270|NCT00851175|No Intervention|1|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia
11571271|NCT00851175|Active Comparator|2|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia with concommitant administration of caffeine (90 ug/min/100ml forearm volume) into the brachial artery of the experimental (=non dominant) arm
11571272|NCT00851175|Experimental|3|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia after 7 days oral treatment with rosuvastatin 1dd 20mg
11571273|NCT00851175|Active Comparator|4|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia after 7 days oral treatment with rosuvastatin 1dd 20mg with concommitant administration of caffeine (90 ug/min/100ml forearm volume) into the brachial artery of the experimental (=non dominant) arm
11571274|NCT00851162|Experimental|Trinity|Trinity multipotent stem cells
11571275|NCT00851162|Active Comparator|Demineralized bone matrix|Demineralized bone matrix
11571276|NCT00851149||1/10|Abdominal aortic surgery patients
11571277|NCT00851149||2/10|Total hip replacement patients
11571278|NCT00851136|Experimental|1|
11571279|NCT00851123|Experimental|1. Modified Constraint-Induced Movement therapy|Modified Constraint-Induced Movement Therapy at the rehabilitation unit or in an outpatient clinic.
11571280|NCT00851123|Experimental|2.Task-specific bimanual training|Task-specific bimanual training at the rehabilitation unit or in an outpatient clinic.
11571281|NCT00851084|Active Comparator|mFOLFOX6 only|modified FOLFOX6 chemotherapy regimen
11571282|NCT00851084|Experimental|mFOLFOX6 + aflibercept|modified FOLFOX6 chemotherapy regimen in combination with aflibercept
11571283|NCT00851071|Active Comparator|Cognitive Behavioral Therapy|Three individual 45 minute cognitive behavioral therapy sessions over a 3 month period
11571284|NCT00851071|No Intervention|Usual Care Arm|The Usual Care Arm will be the control arm. These patients will not be scheduled with any CBT sessions.
11571285|NCT00851058|Experimental|Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
11571286|NCT00851058|Active Comparator|Community Counseling|Four session of group counseling and six hours of volunteering in a local not for profit community agency.
11571287|NCT00851058|Placebo Comparator|Prototypic Community Service|Four hours of education about road safety and 16 hours volunteering at a local not for profit community service.
11571288|NCT00851045|Active Comparator|Arm 1|Irinotecan/5-Fluorouracil (bolus)/5-Fluorouracil (infusional)/Leucovorin calcium/CT-322
11571289|NCT00851045|Active Comparator|Arm 2|Irinotecan/5-Fluorouracil(bolus)/5-Fluorouracil(infusional)/Leucovorin calcium /Bevacizumab/Bevacizumab Placebo(saline solution)
11571290|NCT00851032||Molecular Profiling Analyses|Participants seen in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center in Houston, Texas
11571291|NCT00851019|Experimental|DDR|"Dance Dance Revolution (DDR) Exergaming"
11571292|NCT00851019|Active Comparator|Treadmill|Treadmill exercise
11571293|NCT00851006|Experimental|Open-Label Creatine|Creatine Monohydrate 4 grams daily by mouth
11571294|NCT00850993|Experimental|Cohort 1: Stannsoporfin 1.5 mg/kg|Participants receive a single dose of 1.5 mg/kg by intramuscular (IM) injection, along with PhotoTherapy (PT) if and when needed.
11571295|NCT00850993|Experimental|Cohort 2: Stannsoporfin 3.0 mg/kg|Participants receive a single dose of 3.0 mg/kg by intramuscular (IM) injection, along with PT if and when needed.
11571296|NCT00850993|Experimental|Cohort 3: Stannsoporfin 4.5 mg/kg|Participants receive a single dose of 4.5 mg/kg by intramuscular (IM) injection, along with PT if and when needed.
11571297|NCT00850993|Placebo Comparator|Cohort 4: Placebo|Participants receive a single dose of placebo (sterile saline solution) by IM injection, along with PT if and when needed.
11571298|NCT00850954|Experimental|Group I (smoking cessation)|Participants receive smoking cessation intervention materials based on TTM.
11571299|NCT00850954|Experimental|Group II (informational)|Participants receive fotonovelas and other materials on secondhand smoking and how to assist the smoker in quitting.
11571300|NCT00850941||Questionnaire|Prognostic factors and outcome for patients treated with radiation with curative intent for rising Prostate Specific Antigen (PSA) post-prostatectomy.
11571301|NCT00850928||Subjects|65 years and older scheduled for spine surgery will be undergoing serial assessments preoperatively and postoperatively over 6 time-points.
11571302|NCT00850915|Other|1|in this arm contacts of enrolled TB-HIV index cases were actively approached and screened for TB and offered HIV testing by CHW at their homes
11571303|NCT00850915|Other|2|no interventation was done in this group, they received the regulare care and follow up following NTP guidelines
11571304|NCT00850902|Active Comparator|Moderate Humidity (MH)|
11571305|NCT00850902|Experimental|High Humidity|
11571306|NCT00850889|Active Comparator|1|Juvederm Ultra Injectable Gel with Lidocaine
11571307|NCT00850889|Active Comparator|2|Restylane Injectable Gel
11571308|NCT00850863||A|20 healthy individuals not susceptible for COPD (age 18-40 years, 0 < pack years > 10, FEV1/FVC >70% , FEV1 >85% predicted)
11571309|NCT00850863||B|30 healthy individuals susceptible for COPD (age 40-75years, pack years >20, FEV1/FVC > 70%, FEV1 > 85% predicted)
11571310|NCT00850863||C|20 healthy individuals very susceptible for COPD (age 18-40 year, 0 < pack years > 10, FEV1/FVC > 70%, FEV1 > 85% predicted)and high prevalance of COPD in smoking family members older than 45 years
11571311|NCT00850863||D1|30 COPD patients with GOLD stage I (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 > 80% predicted)
11571312|NCT00850863||D2|30 COPD patients with GOLD stage II (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 50-80 predicted)
11571313|NCT00850863||D3|30 COPD patients with GOLD stage III (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 30-50% predicted)
11571314|NCT00850863||D4|30 COPD patients with GOLD stage IV (age 40-75 years,Pack years > 10, FEV1/FVC ≤ 70%, FEV1 30% predicted)
11571315|NCT00850863||E|20 healthy individuels very susceptible for COPD ( Age 18-40 years,0 < Pack years > 10, FEV1/FVC >70%, FEV1 > 85% predicted, and one of the smoking family members has severe early onset COPD or mild COPD with very low smoke exposure
11571316|NCT00850863||F|30 COPD patients who are highly susceptible (age > 53 years with Pack years > 10 , FEV1/FVC ≤ 70% and FEV1 < 40% predicted) or (age >18 years with 0 < pack years > 5, FEV1/FVC ≤ 70% and FEV1 < 80% predicted)
11571317|NCT00850850|Active Comparator|Physostigmine|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 mg of physostigmine.
11571318|NCT00850850|Placebo Comparator|NaCl|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo).
11571319|NCT00850837|Experimental|1|Participants will apply Acidform lubricant twice daily for 14 consecutive days between menses
11571320|NCT00850837|Placebo Comparator|2|Participants will apply HEC gel twice daily for 14 consecutive days between menses
11571321|NCT00850824|Experimental|Behavioral|Community Health Worker home visits
11571322|NCT00850824|Active Comparator|Usual Care|Usual Care, Wait List Control
11571323|NCT00850811|Experimental|1|
11571324|NCT00850798|Experimental|1|Fasting plasma glucose (mg/dL) 90 to 130 Glycated hemoglobin (%) 6.0 to 7.0
11571325|NCT00850798|Active Comparator|2|Fasting plasma glucose (mg/dL) 90 to 180 Glycated hemoglobin (%) 7.0 to 9.0
11571326|NCT00850772|Experimental|Early post-operative enteral feeding|Standard post-operative care and diet together with early post-operative enteral feeding
11571327|NCT00850772|No Intervention|Standard post-operative care and diet|Standard post-operative care and diet only
11571328|NCT00850759|Experimental|virtual reality|street-crossing training in a virtual pedestrian environment
11571329|NCT00850759|Active Comparator|computer and video|exposure to training in pedestrian safety via computer software, internet games, and television videos
11571330|NCT00850759|Active Comparator|streetside training|one-on-one training in street-crossing skills by an adult, at a streetside location
11571331|NCT00850759|No Intervention|no-contact control|no-contact control group.
11571332|NCT00850746|Placebo Comparator|A. Placebo|
11571333|NCT00850746|Experimental|B. Ym443 Lower Dose|
11571334|NCT00850746|Experimental|C. YM443 Higher Dose|
11571335|NCT00850746|Active Comparator|D. Moxiflocxacin|
11571336|NCT00850720||Cardiac Surgery|Infants with congenital defects.
11571337|NCT00850707||1|220 hemodialysis patients with Arterovenous fistula (AVF group)
11571338|NCT00850707||2|58 hemodialysis patients with Arterovenous graft (AVG group)
11571339|NCT00850707||3|180 hemodialysis patients with Tunneled cuffed catheters (TCC group)
11571340|NCT00850707||4|60 healthy subjects as controls
11571341|NCT00850694||1|Obese female adolescents
11571342|NCT00850681|Experimental|1|PEP005 (ingenol mebutate) Gel
11571343|NCT00850668|Active Comparator|EMP-123|Participants who are not allergic to peanuts will receive four escalating doses of study product on a weekly basis
11571344|NCT00850668|Experimental|EMP-123 in Peanut Allergics|Participants who are allergic to peanuts will receive weekly dose escalation of the study product for 10 weeks followed by administration every 2 weeks for 6 weeks
11571345|NCT00850642|Placebo Comparator|Placebo|12 day repeat dosing with placebo
11571346|NCT00850642|Experimental|GSK2190915 100mg|12 day repeat dosing treatment phase with 100mg GSK2190915.
11571347|NCT00850629|Placebo Comparator|placebo|Placebo
11571348|NCT00850629|Experimental|lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
11571349|NCT00850616|Experimental|1|MRKAd6 Trigene 0.5x10^9 Ad6 vg
11571350|NCT00850616|Experimental|2|MRKAd6 Trigene 0.5x10^10 Ad6 vg
11571351|NCT00850616|Experimental|3|MRKAd6 Trigene 0.5x10^11 Ad6 vg
11571352|NCT00850616|Experimental|4|MRKAd5 Trigene 0.5x10^10 Ad5 vg
11571353|NCT00850616|Experimental|5|MRKAd5 Trivalent 1.5x10^10 Ad5 vg
11571354|NCT00850616|Experimental|6|MRKAd5+6 Trigene 1x10^9 Ad vg
11571355|NCT00850616|Experimental|7|MRKAd5+6 Trigene 1x10^10 Ad vg
11571356|NCT00850616|Placebo Comparator|8|Placebo
11571357|NCT00850603|Active Comparator|Group 1|0.5 mL Subcutaneous arm (Menomune® )
11571358|NCT00850603|Experimental|Group 2|0.1 mL Subcutaneous arm (Menomune®)
11571359|NCT00850603|Experimental|Group 3|0.05 mL Intradermal arm (Menomune®)
11571360|NCT00850603|Experimental|Group 4|0.1 mL Intradermal arm (Menomune®)
11571361|NCT00850603|Experimental|Group 5|0.15 mL Intradermal arm (Menomune®)
11571362|NCT00850590|Experimental|Low Dose|NRL001 at 5, 7.5, and 10 mg administered in a dose escalating manner with placebo in a random position in the sequence. NRL001 is contained in either a 1 g or a 2 g slow release rectal suppository.
11571363|NCT00850590|Experimental|High Dose|NRL001 at 10, 12.5, and 15 mg administered in a dose escalating manner with placebo in a random position in the sequence. NRL001 is contained in either a 1 g or a 2 g slow release rectal suppository.
11571364|NCT00850577|Active Comparator|Paclitaxel/Carboplatin/CT-322|
11571365|NCT00850577|Active Comparator|Paclitaxel/Carboplatin/Bevacizumab/Placebo|
11571366|NCT00850564|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone (Tesamorelin) 2mg by subcutaneous injection once daily
11571367|NCT00850551|Active Comparator|Usual Care|Usual Care
11571368|NCT00850551|Other|Intervention|Twice weekly home spirometry and symptom assessment
11571369|NCT00850512|Experimental|CHOP21|4 cycles CHOP21-R plus Zevalin
11571370|NCT00850499|Experimental|VELCADE and fludarabine (Group A)|VELCADE 1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 and fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
11571510|NCT00849446||Activity monitoring in healthy persons|
11571511|NCT00849433||1|30 patients with asthma
11571371|NCT00850499|Active Comparator|fludarabine and rituximab (Group B)|fludarabine 40mg/m2/day orally on Days 1 to 5 and rituximab 375mg/m2 on Day 1 of every 35-day cycle
11571372|NCT00850473|Experimental|Positron Emitting Image|Patient will have a PET/CT imaging study to determine cardiac stenosis, F-18 FDG and heparin/intralipid infusion and Contrast Dye.will be administered.
11571373|NCT00850460|Placebo Comparator|Placebo|Lactose placebo pill
11571374|NCT00850460|Active Comparator|Statins|Statin medications
11571375|NCT00850447|Experimental|Cognitive Remediation Therapy|
11571376|NCT00850447|Placebo Comparator|Videogames|
11571377|NCT00850421|Other|Botulinum Toxin Type A|
11571378|NCT00850408|Experimental|Real rTMS|Real rTMS - subjects receiving real repetitive TMS - 1Hz over unaffected hemisphere
11571379|NCT00850408|Sham Comparator|Sham rTMS|Sham rTMS
11571380|NCT00850395||1|Non-Interventional
11571381|NCT00850382|Experimental|Dasatinib|"Induction cycle(s):
~Patients will receive in cycle 1 induction therapy with daunorubicin 60 mg/m2/day administered on days 1 through 3 and cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7). Patients will receive dasatinib 100 mg QD on days 8-21. Patients not achieving CR or CRi at the end of cycle 1 will be evaluable to receive a second induction cycle identical in schedule and dosage to the first induction cycle.
~Consolidation Cycles 1, 2, 3, 4:
~Patients achieving CR or CRi at the end of cycle 1 will receive consolidation therapy for 4 cy-cles. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours. Patients will receive dasatinib 100 mg QD on days 6-28.
~Maintenance therapy:
~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
11571382|NCT00850369|Experimental|1|All subjects wil receive monthly RBC transfusions for 6 months
11571383|NCT00850356||Bariatric Surgery Patient (Sx)|Participants who are patients in an Adult Weight Management Clinic (AWMC) and undergo bariatric surgery.
11571384|NCT00850356||Medical Treamtent (Mx)|Participants who are patients in the same AWMC as above and are currently undergoing a medical treatment program that includes intensive lifestyle counseling (diets, exercise, behavioral modification).
11571385|NCT00850356||Wait-List (Wx)|Participants who are on the Wait-List for the AWMC, and waiting to undergo medical treatment program and/or bariatric surgery.
11571386|NCT00850343|Experimental|Certolizumab pegol 200 mg|Participants received 200 mg certolizumab pegol by subcutaneous injection once every 2 weeks for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
11571387|NCT00850343|Experimental|Certolizumab pegol 400 mg|Participants received 400 mg certolizumab pegol by subcutaneous injection once every 4 weeks for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
11571388|NCT00850330||Hospitalized patients|Patients elder than 65 years old hospitalized for any reason.
11571389|NCT00850304|Experimental|Arm one|
11571390|NCT00850291||1|Electrosurgical vessel sealing device
11571391|NCT00850291||2|traditional surgical methods:stitches and ligations
11571392|NCT00850278|Experimental|FLT-PET imaging|Prior to surgical resection, patient will undergo [11C]MET PET imaging, [18F]FLT PET imaging, MRI, and spectroscopy imaging.
11571393|NCT00850265|Experimental|Spacer|Extrafine formoterol plus beclomethasone with spacer
11571394|NCT00850265|No Intervention|No Spacer|Extrafine formoterol plus beclomethasone without spacer
11571395|NCT00850252|Experimental|Lifeline blood vessel|
11571396|NCT00850239|Experimental|1|dutogliptin/PHX1149T
11571397|NCT00850239|Placebo Comparator|2|Plabeco
11571398|NCT00850226|Experimental|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
11571399|NCT00850226|Experimental|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
11571400|NCT00850213||Endeavor Resolute Stent|Patients implanted with the Medtronic Endeavor Resolute stent
11571401|NCT00850200|Experimental|Proton Radiation Plan|
11571402|NCT00850200|Active Comparator|Conventional Photon Radiation Plan|
11571403|NCT00850200|Active Comparator|Intensity Modulated Radiation Plan|
11571404|NCT00850187|Experimental|Bone marrow mesenchymal stem cells|
11571405|NCT00850174|Experimental|Oxcarbazepine|Oxcarbazepine 600 mg Tablet (test) dosed in first period followed by Trileptal® 600 mg Tablet (reference) dosed in second period
11571406|NCT00850174|Active Comparator|Trileptal®|Trileptal® 600 mg Tablet (reference) dosed in first period followed by Oxcarbazepine 600 mg Tablet (test) dosed in second period
11571407|NCT00850161|Experimental|Nasulin™|Intranasal insulin spray
11571408|NCT00850161|Active Comparator|aspart|Subcutaneous administration
11571409|NCT00850148|Experimental|Melles|
11571410|NCT00850148|Experimental|Anwar|
11571411|NCT00850135|Other|Continuous Glucose Monitor in pregnancy|The Seven Continuous Glucose Monitoring System: Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
11571412|NCT00850122|Experimental|Cefazolin|"Dosage Number of Infants
~≤28 days of age 25 mg/kg IV q12 6 29-120 days of age 25 mg/kg IV q8 6"
11571413|NCT00850096|Placebo Comparator|Placebo for Nasulin|Placebo for Nasulin Spray
11571414|NCT00850096|Active Comparator|Nasulin|Nasulin (intranasal insulin spray 1%)
11571415|NCT00850083||Children in the ED|
11571512|NCT00849433||2|30 patients with COPD
11571416|NCT00850070|Experimental|sapropterin, 100 mg capsules|Sapropterin was supplied as a 100 mg tablet and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks.
11571417|NCT00850070|Placebo Comparator|Placebo, matching active drug|The placebo was supplied as a 100 mg tablet, and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks.
11571418|NCT00850044|Active Comparator|1|ABT-450
11571419|NCT00850044|Placebo Comparator|2|Placebo for ABT-450
11571420|NCT00850044|Active Comparator|3|ABT-450/ritonavir
11571421|NCT00850044|Placebo Comparator|4|Placebo for ABT-450/placebo for ritonavir
11571422|NCT00850031|Experimental|AcuFocus Corneal Inlay|Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.
11571423|NCT00850018|Experimental|1|Participants will receive monthly blood transfusions.
11571424|NCT00850018|Active Comparator|2|Participants will receive usual care.
11571425|NCT00850005|Experimental|IVIG|Active treatment will be intravenous immunoglobulin G (Gamunex, immune globulin intravenous [human], 10%), at a dose of 2 g/kg divided over five days (0.4 g/kg/day).
11571426|NCT00850005|Placebo Comparator|Placebo|The placebo treatment will be intravenous normal saline and will be infused in a similar manner.
11571427|NCT00849992|Other|Imiquimod 5%|Patients randomized to this arm will receive treatment with imiquimod 5%
11571428|NCT00849992|Other|Photodynamic therapy|Patients will be randomized to receive photodynamic therapy twice at a 2 week interval to the affected area.
11571429|NCT00849979|Other|Questionnaire|
11571430|NCT00849979|Other|Questionnaire + Interview|
11571431|NCT00849966|Experimental|A|Celebrex suspension
11571432|NCT00849966|Placebo Comparator|B|Placebo
11571433|NCT00849953||FinESS Treatment|Subjects undergoing treatment with the FinESS Sinus Treatment System
11571434|NCT00849940|Experimental|CAS NIRS FORE-SIGHT oximeter|Pediatric patients presenting for cardiac catheterization.
11571435|NCT00849914||1|Patients with actinic keratoses of the skin
11571436|NCT00849914||2|Patients with basal cell carcinoma of the skin
11571437|NCT00849914||3|Patients with squamous cell carcinoma of the skin
11571438|NCT00849901|Placebo Comparator|Placebo|
11571439|NCT00849901|Active Comparator|Fluoxetine|
11571440|NCT00849901|Experimental|Duloxetine|
11571441|NCT00849888|Experimental|Atypical Complete DiGeorge|Thymus Transplantation with Immunosuppression
11571442|NCT00849888|Experimental|Typical Complete DiGeorge|Thymus Transplantation without Immunosuppression
11571443|NCT00849875|Experimental|Group A|All patients are to receive the same treatment consisting of 24 injections of the immunotherapeutic GSK2132231A combined with a course of 8 cycles of dacarbazine given at the beginning of the treatment
11571444|NCT00849862|Experimental|Levetiracetam|Levetiracetam 750 mg Tablet (test) dosed in first period followed by Keppra 750 mg Tablet (reference) dosed in second period
11571445|NCT00849862|Active Comparator|Keppra®|Keppra® 750 mg Tablet (reference) dosed in first period followed by Levetiracetam 750 mg Tablet (test) dosed in second period
11571446|NCT00849849||Postpartum GDM OGTT|200 women with prior GDM in their index pregnancies will undergo postpartum screening assessment. This program will follow these women who are at a high risk of developing DM2 after delivery for 1 year.
11571447|NCT00849836||Acute exacerbation|
11571448|NCT00849836||Stable disease|
11571449|NCT00849836||Healthy control|
11571450|NCT00849823|Active Comparator|Male Sexual Health Program|
11571451|NCT00849823|Experimental|Focus on the Future Program|
11571452|NCT00849810|Experimental|Metoprolol to nebivolol|metoprolol 25-200mg at a stable daily dose for 4 weeks, then change to nebivolol at a comparable stable dose (5-20 mg) for 4 -5 weeks.
11571453|NCT00849797|Experimental|Oxcarbazepine|Oxcarbazepine 600 mg Tablet (test) dosed in first period followed by Trileptal® 600 mg Tablet (reference) dosed in second period
11571454|NCT00849797|Active Comparator|Trileptal®|Trileptal® 600 mg Tablet (reference) dosed in first period followed by Oxcarbazepine 600 mg Tablet (test) dosed in second period
11571455|NCT00849771||1|Operative Treatment (Open Reduction Internal Fixation)
11571456|NCT00849771||2|Non-operative/Conservative Care
11571457|NCT00849758||1|chemotherapy: elderly patients receiving 4x adjuvant taxotere cyclophosphamide adjuvant for breast cancer
11571458|NCT00849758||2|adjuvant hormone therapy: 40 patients receiving adjuvant aromatase inhibitor without chemotherapy
11571459|NCT00849745|Experimental|Systemic Lupus Erythematosus|"Nonmyeloablative allogeneic stem cell transplant
~Patients must:
~Satisfy the American College of Rheumatology (ACR) criteria for the diagnosis of SLE
~Have Lupus nephritis, refractory and severe seizures or encephalopathy, severe pulmonary involvement, transfusion-dependent cytopenias, catastrophic antiphospholipid syndrome or vasculitis and/or immune complex deposition causing end-organ signs or symptoms.
~Have received a trial of corticosteroids equivalent to prednisone greater than or equal to 0.5 mg/kg/d for at least one month
~Have received a trial of IV cyclophosphamide pulse greater than 500 mg/square meter at least once within the previous 6 months, unless contraindicated because of severe cytopenias or intolerance."
11571460|NCT00849745|Experimental|Systemic Sclerosis|"Nonmyeloablative allogeneic stem cell transplant
~Patients must:
~Have diagnosis of SSc as defined by American College of Rheumatology and at high-risk for fatal outcome.
~Have (1) both a and b below and (2) at least one of c, d, or e.
~Diffuse cutaneous scleroderma with skin score of >= 16
~Duration of systemic sclerosis <= 3 years from the onset of first non-Raynaud's symptom.
~Presence of interstitial or pulmonary vascular lung involvement (FVC or DLCO <70% of predicted) especially with evidence of alveolitis (abnormal bronchoalveolar lavage or high-resolution chest CT scan).
~Presence of myocardial disease
~History or presence of proteinuria > 500 mg/24 hrs or serum creatinine > the upper limit of normal."
11571461|NCT00849732|Experimental|1|V520 (1x10^9 vp/d)
11571462|NCT00849732|Experimental|2|V520 (1x10^10 vp/d)
11571463|NCT00849732|Placebo Comparator|3|Placebo to V520
11571513|NCT00849407||1|melanoma patients
11571514|NCT00849407||2|controls
11571515|NCT00849394||1|Shortened infusions of bevacizumab
11571464|NCT00849719|Experimental|1|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient.
11571465|NCT00849719|Active Comparator|2|Patients in this arm will be administered with only boluses of 1.5 mg/bolus of MO, by request.
11571466|NCT00849706||Study group|Medical staff personal, doctors and nurses, working night shifts.
11571467|NCT00849693|Placebo Comparator|Placebo|
11571468|NCT00849693|Active Comparator|Fluoxetine|
11571469|NCT00849693|Experimental|Duloxetine 60 mg|
11571470|NCT00849693|Experimental|Duloxetine 30 mg|
11571471|NCT00849680|Placebo Comparator|Placebo|Participants receiving 1.0 ml of placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine or the placebo to the MRKAd5 HIV-1 gag vaccine injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26 or a 2-dose regimen at Day 1 and Week 26 or Day 1 and Week 4.
11571472|NCT00849680|Experimental|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)|Participants receiving 1.0 ml of the Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
11571473|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
11571474|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
11571475|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
11571476|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
11571477|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26, or in a 2-dose regimen at Day 1 and Week 4 (with no vaccine administered at Week 26) or Day 1 and Week 26 (with placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine administered at Week 4)
11571478|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
11571479|NCT00849667|Active Comparator|1|Carboplatin and taxane with MORAb-003 1.25 mg/kg
11571480|NCT00849667|Active Comparator|2|Carboplatin and taxane with MORAb-003 2.5 mg/kg
11571481|NCT00849667|Placebo Comparator|3|Carboplatin and taxane with Placebo
11571482|NCT00849654|Experimental|PCI-32765|
11571483|NCT00849641||1|patients with decompensated liver cirrhosis admitted to the medical ICU
11571484|NCT00849641||2|critically ill patients without liver cirrhosis, matched to group 1
11571485|NCT00849641||3|healthy control group
11571486|NCT00849628||1|Constipation
11571487|NCT00849615|Experimental|FLOT|
11571488|NCT00849602|Placebo Comparator|1|
11571489|NCT00849602|Active Comparator|2|
11571490|NCT00849589|No Intervention|1|Treatment as Usual (TAU)
11571491|NCT00849589|Experimental|2|Computerized Screening and Brief Physician Advice (SBA)
11571492|NCT00849589|Experimental|3|Computerized screening and brief physician advice with technological extenders (SBA/TE)
11571493|NCT00849576|Active Comparator|Regular Human Insulin|Single Injection
11571494|NCT00849576|Active Comparator|Inuslin Lispro (90%)|Single Injection
11571495|NCT00849576|Experimental|Insulin VIAject™ (75%)|Single Injection
11571496|NCT00849576|Experimental|Insulin VIAject™ (90%)|Single injection
11571497|NCT00849563|Active Comparator|SRA+genetic test|patients randomized to receive genetic test for type 2 diabetes risk will be followed and surveyed and will be counseled based on SAR and genetic risk for type 2 diabetes
11571498|NCT00849563|No Intervention|SRA only|Patients randomized to not get genetic testing will be followed and surveyed and will be counseled based on SRA only
11571499|NCT00849563|No Intervention|no testing control|Patients not interested in genetic testing will be followed and surveyed. Counseling will be based on SRA only
11571500|NCT00849550|Experimental|XELOX-A-Ev|
11571501|NCT00849537|Experimental|Triamcinolone|Injection of intravitreal Triamcinolone
11571502|NCT00849524|Experimental|Ad-ISF35|Ad-ISF35, intranodal injection, 3.3 x 10^10 ISF35 viral particles, every 2-4 weeks up to six total injections.
11571503|NCT00849511|Active Comparator|Placebo first|Placebo 8 weeks, 6 weeks washout, extended-release melatonin 2 mg vesper for 8 weeks
11571504|NCT00849511|Active Comparator|Melatonin first|Extended-release melatonin 2 mg vesper for 8 weeks, 6 weeks washout, placebo 8 weeks
11571505|NCT00849485|Experimental|Levetiracetam|Levetiracetam 750 mg Tablet (test) dosed in first period followed by Keppra® 750 mg Tablet (reference) dosed in second period
11571506|NCT00849485|Active Comparator|Keppra®|Keppra® 750 mg Tablet (reference) dosed in first period followed by Levetiracetam 750 mg Tablet (test) dosed in second period
11571507|NCT00849472|Experimental|Treatment Arm|"Preoperative
~Cycles 1-4 Doxorubicin 60 mg/m2 IV over 15 minutes + Cyclophosphamide 600 mg/m2 IV over 30 minutes of Day 1 every 21 days
~followed by:
~Cycles 5-8 Paclitaxel 80 mg/m2 IV over 60 minutes (Days 1, 8, and 15) every 28 days in combination with pazopanib (800 mg) PO once daily (2 tablets taken at the same time each day either 1 hour before or 2 hours after a meal) Daily beginning on Day 1 of the first paclitaxel cycle Until 7 days before surgery
~Followed by Surgery
~Postoperative Pazopanib 800 mg PO once daily (2 tablets taken at the same time each day either 1 hour before or 2 hours after a meal) Daily beginning 4-6 weeks after surgery 6 months from first postoperative dose"
11571508|NCT00849459|Experimental|adenovirus-mediated human interleukin-12|starting dose of ADV-hIL12 - 1 x 10 to the 10th power vp (virus particles) per patient, escalating in half-log increments up to 1 x 10 to the 13th power vp per patient, after which dose escalation will be at lower increments of 2 x 10 to the 13th power vp, to a maximum of 3.0 x 10 to the 13th power vp per patient.
11571516|NCT00849381|Experimental|Cervarix Compliance Issue Centre Group|Subjects from one centre where compliance issues were discovered, who received the Hepatitis A control vaccine in the primary study (NCT00122681) and the Cervarix vaccine in the current study
11571517|NCT00849381|Experimental|Cervarix All Centres Group|Subjects from all study centres who received the Hepatitis A control vaccine in the primary study (NCT00122681) and the Cervarix vaccine in the current study.
11571518|NCT00849368|Experimental|Azathioprine / Allopurinol|Single arm study: Dose escalations as described.
11571519|NCT00849355|Experimental|unique|RCOMP-14 with Rituximab
11571520|NCT00849342||A|
11571521|NCT00849329|Experimental|Period 1|1250mg lapatinib once daily in the morning
11571522|NCT00849329|Experimental|Period 2|1250mg lapatinib once daily in the morning in combination with esomeprazole 40mg once daily at bedtime.
11571523|NCT00849316||A|
11571524|NCT00849303|Experimental|earlier gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.
11571525|NCT00849303|Active Comparator|later gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.
11571526|NCT00849290|Experimental|APC8015F|
11571527|NCT00849264|Experimental|A|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with endostar
11571528|NCT00849264|Active Comparator|B|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with CBP and 5-FU
11571529|NCT00849264|Experimental|C|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with endostar, CBP and 5-FU
11571530|NCT00849251|Experimental|Treatment (chemotherapy and enzyme inhibitor)|Patients receive cyclophosphamide IV or PO over 1 hour, bortezomib IV over 3 minutes, and dexamethasone IV or PO on days 1, 8, and 15. Patients also receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11571531|NCT00849212|Experimental|1|
11571532|NCT00849199||High risk of breast or ovarian cancer|
11571533|NCT00849186|Experimental|Arm 1|
11571534|NCT00849160|Experimental|Darunavir/r|
11571535|NCT00849147|Experimental|Haploidentical Bone Marrow Transplant|Participants will receive a human leucocyte antigen (HLA) haploidentical bone marrow transplantation using a non-myeloablative preparative regimen, GVHD prophylaxis.
11571536|NCT00849134|Placebo Comparator|Cohort 1,2 & 3|This part of the study will start with a very low dose of study drug, which will then be gradually increased in subsequent doses. This is known as dose-rising and is the way to assess safety and tolerability (i.e. possible presence of any side effects that make taking the drug unpleasant) of increasing the study drug. Effects will be compared to those seen when a placebo is taken. Up to 3 groups of 8 healthy male and female volunteers may be enrolled.
11571537|NCT00849134|Active Comparator|Cohort 4|If an investigation of food effect is not possible in Cohorts 2 or 3, this Cohort will be used to check if there is a difference in the blood levels of the study drug when taken with or without a high fat meal.
11571538|NCT00849121|Experimental|1|Intradermal vaccinations of a DNA vaccine encoding PAP, with GM-CSF as an adjuvant given every 2 weeks for the first 12 weeks, then every 12 weeks until disease progression.
11571539|NCT00849121|Experimental|2|Intradermal vaccinations of a DNA vaccine encoding PAP, with GM-CSF as an adjuvant given every 2 weeks for the first 12 weeks, then given every 2-week, 4-week, or 3-month intervals as dictated by cellular immune response measurement.
11571540|NCT00849108|Experimental|Cohort 1: dose range and dose interval|Patients to receive either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during pharmacological or exercise stress, over a 1-day or 2-day period.
11571541|NCT00849108|Experimental|Cohort 2: Pharm&exercise stress Efficacy|"Patients to receive 2 IV bolus injections of BMS747158:1 at rest and 1 at stress
~For the Pharmacologic (Adenosine) Stress:
~Doses at rest to range between 2.9 and 3.4 mCi.
~Doses under stress to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.
~For the Exercise Stress:
~Doses at rest were to range between 1.7 and 2.0 mCi.
~Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi."
11571542|NCT00849095|Experimental|as needed medication|patients assigned to this arm will take bid inhaled placebo plus prn inhaled 160/4.5 mcg budesonide/formoterol combination
11571543|NCT00849095|Active Comparator|guideline treatment|bid inhaled 160/4.5 mcg budesonide/formoterol combination plus prn 500 mcg terbutaline
11571544|NCT00849069|Experimental|Group A|
11571545|NCT00849069|Active Comparator|Group B|
11571546|NCT00849056|Placebo Comparator|placebo + pioglitazone (with or without metformin)|Placebo albiglutide weekly injection + pioglitazone (with or without metformin)
11571547|NCT00849056|Experimental|albiglutide + pioglitazone (with or without metformin)|albiglutide weekly injection + pioglitazone (with or without meformin)
11571548|NCT00849043||Provent|Provent Professional Sleep Apnea Therapy device
11571549|NCT00849030|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
11571550|NCT00849030|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
11571551|NCT00849030|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
11571552|NCT00849017|Experimental|albiglutide|albiglutide weekly injection
11571553|NCT00849017|Placebo Comparator|placebo|albiglutide matching placebo
11571554|NCT00849017|Experimental|albiglutide up-titration|albiglutide weekly injection uptitration at week 12
11571555|NCT00849004|Active Comparator|Gel vs. Sheet|One group will act to compare the effectiveness between silicone gel and silicone sheet.
11571556|NCT00849004|Active Comparator|sheet vs. paper tape|The second group between silicone sheet and paper tape.
11571557|NCT00849004|Active Comparator|gel vs. paper tape|One group will act to compare the effectiveness between silicone gel and paper tape.
11571612|NCT00848588||1|Full and part-time 9-1-1 call takers employed at Ambulance Communication Centres in the Canadian provinces of Ontario, Nova Scotia, New Brunswick, as well as the city of Montreal, Quebec, Canada.
11571665|NCT00848211|Experimental|TUTI-16 0.1 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
11571558|NCT00848991|Active Comparator|Precedex|In the operating room routine anesthesia monitors will be placed and vital signs will be recorded continuously using data collection software. A routine propofol anesthetic will be administered to subjects randomized to the control group or a Precedex infusion with propofol for subjects randomized to the treatment group. Precedex infusion will be started after induction of general anesthesia. Vital signs (SBP, DBP, MAP) will be recorded continuously throughout the surgery. At the end of the case subjects will be extubated and the blinded observer will assess emergence from anesthesia based on hemodynamic stability and tolerance of the endotracheal tube. Videotaping of emergence will be used to assist in the evaluation of emergence of anesthesia and extubation.
11571559|NCT00848991|Active Comparator|Propofol|Propofol for emergence from anesthesia
11571560|NCT00848978|Experimental|2|The experimental group will participate in the aerobic and strength training program.
11571561|NCT00848978|No Intervention|1|The usual care group will receive general physical activity guidelines.
11571562|NCT00848965|Placebo Comparator|Placebo|
11571563|NCT00848965|Experimental|Fluticasone propionate 25ug|
11571564|NCT00848965|Experimental|Fluticason propionate 50ug|
11571565|NCT00848965|Experimental|Fluticasone propionate 100ug|
11571566|NCT00848965|Experimental|Flutciasone propionate 200ug|
11571567|NCT00848939|Experimental|treprostinil diethanolamine|
11571568|NCT00848926|Experimental|Brentuximab vedotin|
11571569|NCT00848913|Active Comparator|Rehabilitation without strength training|Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
11571570|NCT00848913|Experimental|Rehabilitation with strength training|Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of fractured limb every day during admission.
11571571|NCT00848900|No Intervention|Control|
11571572|NCT00848900|Experimental|Outdoor activity|Adding 1 hour outdoor time into school curricula
11571573|NCT00848887|Experimental|1|
11571574|NCT00848874|Experimental|PVGS User|
11571575|NCT00848861|Active Comparator|1 propofol|
11571576|NCT00848861|Active Comparator|2 midazolam plus meperidine|
11571577|NCT00848848|Active Comparator|1|
11571578|NCT00848848|Active Comparator|2|
11571579|NCT00848848|Active Comparator|3|
11571580|NCT00848848|Active Comparator|4|
11571581|NCT00848848|Active Comparator|5|
11571582|NCT00848848|Active Comparator|6|
11571583|NCT00848848|Active Comparator|7|
11571584|NCT00848848|Active Comparator|8|
11571585|NCT00848848|Active Comparator|9|
11571586|NCT00848848|Active Comparator|10|
11571587|NCT00848835||control|all patients in the control group
11571588|NCT00848809||1|Slow-low efficiency daily dialysis group
11571589|NCT00848809||2|Intermittent Hemodialysis group
11571590|NCT00848796|Other|Heparin|Compare two market brands of Heparin
11571591|NCT00848783|Experimental|A-with IP Floxuridine|"Induction treatment:
~Cisplatin 25 mg/m^2 and Irinotecan 75 mg/m^2 once a week for 4 weeks, both intravenous; Two weeks without treatment; Repeat the course once.
~Re-evaluation, surgery if complete response, partial response or stable disease, or off the protocol if progression of disease.
~Randomization
~Surgery.
~Postoperative IP treatment:
~Day 1,2,3: Floxuridine 3 gm/day, IP; Day 3: Cisplatin 60 mg/m^2, IP; 2 weeks without treatment; repeat the course once
~Postoperative systemic treatment: courses 1-9: Capecitabine 2,000 mg/m^2/day x14 every 3 weeks/course, Oral"
11571592|NCT00848783|Experimental|B-Without IP Floxuridine|Same as Arm A except no postoperative IP treatment.
11571593|NCT00848770|Active Comparator|1, 140 to 160 mmHg|Esmolol, NPS or NOR
11571594|NCT00848770|Active Comparator|2, 161 to 180 mmHg|Esmolol, NPS or NOR
11571595|NCT00848770|Active Comparator|3, 181 to 200 mmHg|Esmolol, NPS or NOR
11571596|NCT00848757|Experimental|Lifestyle Counseling|"Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the DPP Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population."
11571597|NCT00848757|No Intervention|Usual Care Control|Women with pre-diabetes randomized to usual care will be offered 30 minute appointments with a medical provider to review their diagnosis, risk for diabetes, and stress the importance of lifestyle changes to prevent diabetes, including weight loss and exercise and setting individual goals for these. Usual care participants will be encouraged to achieve goals equivalent to the ILI group: to reduce their weight by 7%, and to increase their physical activity to approximately 150 minutes moderate intensity exercise per week. They will be offered a consultation with an FHCHC nutritionist to achieve dietary/weight loss objectives. Participants are offered printed educational materials which are language and literacy-appropriate.
11571598|NCT00848744|Experimental|topical salicylic acid 1.0% cream|
11571599|NCT00848731|Experimental|iNO|gaseous NO is delivered by facemask
11571600|NCT00848718|Experimental|MK-2206 + carboplatin + paclitaxel|MK-2206 combined with carboplatin and paclitaxel
11571601|NCT00848718|Experimental|MK-2206 + docetaxel|MK-2206 combined with docetaxel plus pretreatment with a corticosteroid
11571602|NCT00848718|Experimental|MK-2206 + erlotinib|MK-2206 combined with erlotinib
11571603|NCT00848705|Active Comparator|Measurement Only|
11571604|NCT00848705|Experimental|Internet Intervention|
11571605|NCT00848692|Experimental|1|Rituximab
11571606|NCT00848692|Placebo Comparator|2|Placebo (saline)
11571607|NCT00848679|Active Comparator|Epidural lidocaine|30 women to receive 5 x 5mL boluses of epidural lidocaine 2%. 10 pre-eclampsia, 10 term pregnancy, 10 non-pregnant.
11571608|NCT00848679|Placebo Comparator|Epidural saline|30 women to receive 5 x 5 mL boluses of epidural saline. 10 pre-eclamptics, 10 normal term pregnancy, 10 non-pregnant
11571609|NCT00848666|Experimental|I|Patients with tinea pedis
11571610|NCT00848640|Experimental|Sorafenib|
11571611|NCT00848627||Males|60 years of age or older Smokers or history of smoking
11571664|NCT00848211|Experimental|TUTI-16 0.03 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
11571613|NCT00848575||Group 1 - Device|The principal Investigator and sub-investigators of this study will identify potential participants that attend the gynecologic oncology or gynecology clinics of UAMS. These subjects will have been scheduled for diagnostic or therapeutic laparoscopy. Based on the Inclusion Criteria and Exclusion Criteria of this study, women who are eligible for the study will be approached to participate.
11571614|NCT00848562|Experimental|Nicorandil|
11571615|NCT00848549|Active Comparator|ZNS|
11571616|NCT00848549|Active Comparator|CBZ|
11571617|NCT00848536|Experimental|TRAVATAN APS|One drop once daily in the evening for 3 months
11571618|NCT00848536|Active Comparator|TRAVATAN|One drop once daily in the evening for 3 months
11571619|NCT00848510|Experimental|EMD 525797|
11571620|NCT00848497|Active Comparator|Testim® + Viagra®|Testim® gel (50 mg of testosterone) once daily + Viagra® 25 mg tablet every night
11571621|NCT00848497|Placebo Comparator|Placebo Testim® + Viagra®|Placebo Testim® gel once daily + Viagra® 25 mg tablet every night
11571622|NCT00848484|Experimental|1|MK5757
11571623|NCT00848484|Placebo Comparator|2|Placebo
11571624|NCT00848471|Experimental|1|Quark RMR calorimeter (Cosmed)
11571625|NCT00848471|Active Comparator|2|Deltatrac II (GE health Care Clinical Systems)
11571626|NCT00848458|Experimental|Azelaic Acid Iontophoresis|
11571627|NCT00848458|Active Comparator|Azelaic acid topical|
11571628|NCT00848445|Experimental|APP and VRR on|APP and VRR turned on at 2 week visit
11571629|NCT00848445|Active Comparator|APP and VRR off|APP and VRR turned off
11571630|NCT00848432|Experimental|1|Optimal therapeutic doses of risperidone continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months in clinically stable schizophrenia patients
11571631|NCT00848432|Experimental|2|Optimal therapeutic doses of risperidone continued for 26 weeks followed by a 50% dose reduction for at least another 6 months in clinically stable schizophrenia patients
11571632|NCT00848432|Experimental|3|Optimal therapeutic doses of risperidone continued for at least 1 year in clinically stable schizophrenia patients
11571633|NCT00848419|Active Comparator|Methadone|Epidural methadone bolus 4mg
11571634|NCT00848419|Active Comparator|Morphine|Epidural morphine 4mg bolus
11571635|NCT00848419|Active Comparator|Fentanyl|Epidural fentanyl 200 microgram bolus
11571636|NCT00848419|Placebo Comparator|Saline|Epidural saline bolus
11571637|NCT00848406||1|30 individuals ≤ 40 years, who currently smoke ≥ 10 cigarettes/day and > 10 packyears
11571638|NCT00848406||2|30 individuals ≤ 40 years, who have not smoked during the last year, have never smoked for as long as a year (i.e. at least one cigarette per day or one cigar per week, AND have < 0.5 packyear.
11571639|NCT00848406||3|30 individuals above 40 years, who currently smoke ≥ 10 cigarettes per day, and > 20 packyears.
11571640|NCT00848406||4|30 individuals above 40 years, who have not smoked during the last year, have never smoked for as long as a year, and have < 0.5 packyear.
11571641|NCT00848393|Active Comparator|Fentanyl (High Dose)|This arm will receive a total of 25 mcg/kg of Fentanyl (High Dose) in two divided doses. First half-dose given at induction and second half-dose given before incision.
11571642|NCT00848393|Active Comparator|Fentanyl (Low Dose)|This arm will receive a total of 10 mcg/kg of Fentanyl (Low Dose). First half-dose will be given at induction and second half -dose given before incision.
11571643|NCT00848393|Active Comparator|Fentanyl (Low Dose) + Dexmedetomidine|This arm will receive10 mcg/kg of Fentanyl (Low Dose) -2 divided doses. Dexmedetomidine (Dex) loading dose-1 mcg/kg over 10 min, then Dex infusion at 0.5mcg/kg/hr.
11571644|NCT00848380||1|Patients with hypertension and hyperlipidemia and other CV risk factors
11571645|NCT00848367|Experimental|High attachment anxiety condition|16 weeks of Group Psychodynamic Interpersonal Psychotherapy for patients with Binge Eating Disorder, matching them by attachment anxiety dimensions in order to enhance the impact of the therapy. It is hypothesized that by optimally matching patients to groups, they will have better clinical and health outcomes.
11571646|NCT00848367|Experimental|Low attachment anxiety condition|16 weeks of Group Psychodynamic Interpersonal Psychotherapy for patients with Binge Eating Disorder, matching them by attachment anxiety dimensions in order to enhance the impact of the therapy. It is hypothesized that by optimally matching patients to groups, they will have better clinical and health outcomes.
11571647|NCT00848354|Experimental|Phase 1 Etanercept + methotrexate|Phase 1: Etanercept + methotrexate
11571648|NCT00848354|Active Comparator|Phase 1 Conventional DMARD (SSZ or HCQ) + MTX|Phase 1: Sulfasalazine (SSZ) + methotrexate (MTX) OR Phase 1: Hydrocholoquine (HCQ) + methotrexate
11571649|NCT00848341||Control|
11571650|NCT00848328|Experimental|Lenalidomide and Rituximab|Rituximab 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15. Lenalidomide 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
11571651|NCT00848315|No Intervention|1|Usual Care that the Type 2 Diabetes Patients usually receive at the health centers.
11571652|NCT00848315|Experimental|2|Cognitive Behavioral Intervention
11571653|NCT00848302|Experimental|L-arginine|Assess the effects of regional L-arginine supplementation in patients with chronic lower extremity occlusive disease undergoing angiography
11571654|NCT00848289||Participants with Bladder Cancer|Patients diagnosed with superficial or muscle-invasive bladder cancer. Specimens, personal and follow-up telephone interviews will be collected and conducted.
11571655|NCT00848276||1|Hypogonadal Men before and after starting testosterone replacement therapy
11571656|NCT00848276||2|Post-menopausal women before and after starting Estrogen Replacement Therapy
11571657|NCT00848263|Active Comparator|DVR|Volar plate
11571658|NCT00848263|Active Comparator|DNP|Dorsal nail plate
11571659|NCT00848250|Experimental|ACE inhibitor|Patients already on an ACE inhibitor will continue it until the day of surgery
11571660|NCT00848250|Experimental|No ACE inhibitor|Patients on ACE inhibitors who are randomized to stop their ACE inhibitor 48 hours prior to surgery
11571661|NCT00848237|Experimental|Treatment|All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
11571662|NCT00848224|Experimental|2|
11571663|NCT00848211|Placebo Comparator|Placebo|
11571782|NCT00847613|Experimental|Sequence 2|
11571666|NCT00848211|Experimental|TUTI-16 0.6 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
11571667|NCT00848198||Normal|Subjects with no objective signs of Dry Eye Disease
11571668|NCT00848198||Dry Eye Disease|Subjects with objective signs of Dry Eye Disease
11571669|NCT00848185||Antagonist-hCG for triggering|Protocol with antagonist and hCG to trigger oocyte maturation
11571670|NCT00848185||Antagonist-aGnRH for triggering|Protocol with antagonist and 0,2 mg triptorelin to trigger oocyte maturation
11571671|NCT00848185||Long protocol-hCG for triggering|Long Protocol and hCG to trigger oocyte maturation
11571672|NCT00848172|Active Comparator|Octanoic Acid|
11571673|NCT00848172|Placebo Comparator|Placebo|
11571674|NCT00848159||1|Group 1 was composed of six women with a densitometric diagnosis of osteoporosis in column (DP =- 2.70 to -4.97), with an average weight of 57.5 (+6.9) kg, mean height of 1 , 4 (+ 0.07) my body mass index (BMI) of 26.1 (+1.8) Kg/m2
11571675|NCT00848159||2|Group 2 consists of six women with a densitometric diagnosis of osteopenia in column (DP =- 1.07 to -2.09), with an average weight of 62.1 (+9.9) kg, mean height of 1, 5 (+0.03) I BMI 25.3 (3.3) kg/m2, both compared with young adults
11571676|NCT00848146|Experimental|NOTES-Assisted Lap Chole|These patients will undergo an experimental surgical procedure that uses a combination of laparoscopic instruments (i.e., inserted through the skin into the abdominal cavity) and flexible endoscopic instruments (i.e., inserted through the mouth).
11571677|NCT00848133|Active Comparator|mini-midvastus|
11571678|NCT00848133|Active Comparator|mini-subvastus|
11571679|NCT00848120|Experimental|1|
11571680|NCT00848107|Experimental|Treprostinil|Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose (MTD).
11571681|NCT00848094|Other|arm 1|Arm I: tumor diameter more than 5 cm and less than 10 cm.
11571682|NCT00848094|Other|arm 2|Arm II: tumor diameter no less than 10 cm.
11571683|NCT00848081|Placebo Comparator|Placebo|
11571684|NCT00848081|Experimental|Tadalafil|
11571685|NCT00848068|Other|OD (Right Eye)|FID 114657 or OPTIVE
11571686|NCT00848068|Other|OS (Left eye)|FID 114657 or OPTIVE
11571687|NCT00848055|Experimental|arm 1|AbGn168 cohort 1
11571688|NCT00848055|Experimental|arm 2|AbGn168 cohort 2
11571689|NCT00848055|Experimental|arm 3|AbGn168 cohort 3
11571690|NCT00848055|Experimental|arm 4|AbGn168 cohort 4
11571691|NCT00848055|Experimental|arm 5|AbGn168 cohort 5
11571692|NCT00848055|Experimental|arm 6|AbGn168 cohort 6
11571693|NCT00848055|Experimental|arm 7|AbGn168 cohort 7
11571694|NCT00848055|Experimental|arm 8|AbGn168 cohort 8
11571695|NCT00848042|Active Comparator|AuroShell-3.5|Group treated with the lowest treatment level with 4.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 3.5 watts. Device: AuroLase Therapy
11571696|NCT00848042|Active Comparator|AuroShell-4.5|Group treated with up to 7.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 4.5 watts. Device: AuroLase Therapy
11571697|NCT00848042|Active Comparator|AuroShell-5.0|Group treated with up to 7.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 5.0 watts. Device: AuroLase Therapy
11571698|NCT00848029|Experimental|1|
11571699|NCT00848016|Experimental|Treatment (R-(-)-gossypol acetic acid)|Patients receive 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11571700|NCT00848003|Active Comparator|1. Active|"Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12)
~Probiotic, BB-12, supplemented yogurt, 4 ounces taken orally for 10 days"
11571701|NCT00848003|Placebo Comparator|2. Placebo|Strawberry flavored yogurt
11571702|NCT00847990||Pregnant women|Pregnant women who are scheduled to undergo an amniocentesis or CVS procedure and will receive the fetal FISH and/or karyotype results from the procedure.
11571703|NCT00847977|Active Comparator|1|Heafusine - Physiologic serum
11571704|NCT00847977|Experimental|2|Isofundine - Tetraspan
11571705|NCT00847964|Experimental|Algisyl-LVR implants|Algisyl-LVR implants to the left ventricular wall
11571706|NCT00847951|Other|Renal perfusion in Neonates|Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys.
11571707|NCT00847938|Active Comparator|1|neostigmine 0.04 mg.kg associated with atropine 0.02 mg/kg
11571708|NCT00847938|Active Comparator|2|neostigmine 0.02 mg.kg associated with atropine 0.01 mg/kg
11571709|NCT00847938|Active Comparator|3|neostigmine 0.1 mg.kg associated with atropine 0.05 mg/kg
11571710|NCT00847938|No Intervention|4|no injection of neostigmine
11571711|NCT00847925|Other|A|50ng Avotermin/100ul
11571712|NCT00847925|Other|B|20ng Avotermin/100ul
11571713|NCT00847925|Other|C|5ng Avotermin/100ul
11571714|NCT00847925|Other|D|100ng Avotermin/100ul
11571715|NCT00847925|Other|E|500ng Avotermin/100ul
11571716|NCT00847925|Other|F|0.25ng Avotermin/100ul
11571717|NCT00847925|Other|G|1ng Avotermin/100ul
11571718|NCT00847925|Other|H|20ng Avotermin/100ul
11571719|NCT00847925|Other|I|50ng Avotermin/100ul
11571720|NCT00847912|Experimental|Arm 1: 5-fluorouracil|Group assigned to blinded 5-FU (5-fluorouracil) cream applied to face and ears twice daily for maximum of 56 doses
11571721|NCT00847912|Placebo Comparator|Arm 2: Placebo|Group assigned to blinded placebo, vehicle control cream applied to face and ears twice daily for maximum of 56 doses
11571722|NCT00847899|Active Comparator|1|AR9281
11571723|NCT00847899|Active Comparator|2|AR9281
11571724|NCT00847899|Placebo Comparator|3|Placebo
11571725|NCT00847899|Placebo Comparator|4|Placebo
11571726|NCT00847886|Experimental|LX3305|Daily oral intake of LX3305 for 14 days.
11571727|NCT00847886|Placebo Comparator|LX3305 Placebo|Matching placebo dosing with daily oral intake for 14 days.
11571728|NCT00847873|Experimental|Combined SU/IPV treatment|A combined treatment containing cognitive behavioral therapy addressing partner violence and cognitive behavioral therapy addressing substance abuse
11571729|NCT00847873|Active Comparator|control condition|Cognitive behavioral therapy addressing substance abuse
11571730|NCT00847860|Experimental|1|Cilostazol
11571731|NCT00847860|Active Comparator|2|Asprin
11571732|NCT00847847|Other|2|control subjects with muscle biopsy
11571733|NCT00847847|Other|1|ALS patients with muscle biopsy
11571734|NCT00847834|Experimental|1|"4 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg followed by:
~If DBP<85mmHg: 4 weeks of one tablet of Irbesartan 150mg / Hydrochlorothiazide 12.5mg
~If DBP≥85mmHg: 4 weeks of one tablet of Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet of Irbesartan 150mg"
11571735|NCT00847834|Experimental|2|"2 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg followed by 2 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet Irbesartan 150mg followed by:
~If DBP<85mmHg: 4 weeks of of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet Irbesartan 150mg
~If DBP≥85mmHg: 4 weeks of two tablets Irbesartan 150mg / Hydrochlorothiazide 12.5mg"
11571736|NCT00847821||Bazedoxifene 10 mg/CE 0.625 mg|
11571737|NCT00847821||Bazedoxifene 20 mg/CE 0.625 mg|
11571738|NCT00847821||Bazedoxifene 40 mg/CE 0.625 mg|
11571739|NCT00847821||Bazedoxifene 10 mg/CE 0.45 mg|
11571740|NCT00847821||Bazedoxifene 20 mg/CE 0.45 mg|
11571741|NCT00847821||Bazedoxifene 40 mg/CE 0.45 mg|
11571742|NCT00847821||Raloxifene 60 mg|
11571743|NCT00847821||Placebo|
11571744|NCT00847808|Experimental|1|
11571745|NCT00847795|Experimental|1|5ng Avotermin
11571746|NCT00847795|Experimental|2|50ng Avotermin
11571747|NCT00847795|Experimental|3|100ng Avotermin
11571748|NCT00847795|Placebo Comparator|4|Placebo
11571749|NCT00847795|No Intervention|5|Standard Care
11571750|NCT00847782|Other|Blood draw (Group 1)|"Normocholesterolemic Subjects
~Normal Healthy Volunteers"
11571751|NCT00847782|Other|Blood draw (Group 2)|Hypercholesterolemic Subjects
11571752|NCT00847782|Other|Blood draw (Group 3)|Hypercholesterolemic Subjects with Statin Treatment
11571753|NCT00847769|Experimental|High velocity, low amplitude stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
11571754|NCT00847769|Active Comparator|Slow, mobilization stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
11571755|NCT00847769|Sham Comparator|Passive positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
11571756|NCT00847756||rAOM|Children 0-5 years of age suffering from recurrent acute otitis media and waiting for tympanostomy tube insertion.
11571757|NCT00847756||COME|Children 0-5 years of age suffering from chronic otitis media with effusion and waiting for tympanostomy tube insertion.
11571758|NCT00847756||CSOM|Children 0-5 years of age suffering from chronic suppurative otitis media and waiting for tympanostomy tube insertion. Note: Only 3 patients with CSOM were recruited and therefore not suitable for publication.
11571759|NCT00847730|Experimental|VAC GranuFoam Bridge Dressing|This is a medical device foam dressing allowing placement away from wound site. It is designed to simplify the bridging application. It is used in combination with the V.A.C. Negative Pressure Wound Therapy System. For each subject, the dressing was applied in compliance with the IFU for 48-72 hours.
11571760|NCT00847717|Experimental|1|IIb preserving neck dissection
11571761|NCT00847717|Other|2|Conventional neck dissection
11571762|NCT00847704|Experimental|Test treatment group|Device: Assisted movement and enhanced sensation
11571763|NCT00847691||Sarcoma|patients with biopsy or excision of sarcoma (suspected or diagnosed)
11571764|NCT00847678|Experimental|1|Mycograb + Amphotericin B + 5 flucytosine
11571765|NCT00847678|Placebo Comparator|2|Placebo + Amphotericin B + 5 flucytosine
11571766|NCT00847678|Experimental|3|Mycograb + Amphotericin B
11571767|NCT00847665|Active Comparator|Turning every 4 hours|The four-hours repositioning group patients were turned every four hours following the next sequence: left side, back with a 30º elevation of the head end and the foot end of the bed, right side using the 30º tilt, back.
11571768|NCT00847665|Experimental|Turning every 2 hours|The two-hours repositioning group patients, were turned every two hours following the next sequence: left side, back with a 30º elevation of the head end and the foot end of the bed, right side using the 30º tilt, back.
11571769|NCT00847639|Experimental|Lenalidomide|Lenalidomide maintenance therapy will start within 60 to 180 days after allogeneic HCT at a starting dose of 10mg PO once daily. Dose escalation and de-escalation are performed depending on tolerability of lenalidomide. The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days).
11571770|NCT00847626|Experimental|Azilsartan medoxomil 20 mg/chlorthalidone 12.5 mg QD|
11571771|NCT00847626|Experimental|Azilsartan medoxomil 20 mg/chlorthalidone 25 mg QD|
11571772|NCT00847626|Experimental|Azilsartan medoxomil 40 mg/chlorthalidone 12.5 mg QD|
11571773|NCT00847626|Experimental|Azilsartan medoxomil 40 mg/chlorthalidone 25 mg QD|
11571774|NCT00847626|Experimental|Azilsartan medoxomil 80 mg/chlorthalidone 12.5 mg QD|
11571775|NCT00847626|Experimental|Azilsartan medoxomil 80 mg/chlorthalidone 25 mg QD|
11571776|NCT00847626|Active Comparator|Chlorthalidone 12.5 mg QD|
11571777|NCT00847626|Active Comparator|Chlorthalidone 25 mg QD|
11571778|NCT00847626|Experimental|Azilsartan medoxomil 20 mg QD|
11571779|NCT00847626|Experimental|Azilsartan medoxomil 40 mg QD|
11571780|NCT00847626|Experimental|Azilsartan medoxomil 80 mg QD|
11571781|NCT00847613|Experimental|Sequence 1|
11571783|NCT00847613|Placebo Comparator|Sequence 3|
11571784|NCT00847613|Placebo Comparator|Sequence 4|
11571785|NCT00847600|Experimental|1 Pregnenolone|50 mg/day
11571786|NCT00847600|Placebo Comparator|2 Placebo|1 caps.
11571787|NCT00847587|Experimental|1|Early postpartum insertion
11571788|NCT00847587|Active Comparator|2|Standard postpartum insertion
11571789|NCT00847574|Experimental|Moderate-fat|35% of calories from fat
11571790|NCT00847574|Experimental|Lower-fat|20% of calories from fat
11571791|NCT00847561|Experimental|Family-based CBT|Family-based CBT. Participants will receive family-based cognitive behavioral therapy. Families in this group will learn about how to identify the signs and symptoms of anxiety, ways to cope with anxiety, relaxation techniques, and problem-solving skills. They will participate in 8, one-hour sessions, once/week with trained clinicians and 3 monthly booster sessions to reinforce what they learned.
11571792|NCT00847561|Placebo Comparator|Information Monitoring|Information Monitoring. Participants will receive a packet of information about anxiety. Participants in this group will be called monthly to monitor symptoms of anxiety.
11571793|NCT00847548|Experimental|combined treatment|A combined treatment containing cognitive behavioral therapy addressing partner violence and cognitive behavioral therapy addressing substance abuse
11571794|NCT00847548|Active Comparator|control condition|Cognitive behavioral therapy addressing partner violence
11571795|NCT00847535|Other|1|Transurethral dose escalation
11571796|NCT00847535|Other|2|Periurethral dose escalation
11571797|NCT00847522|Experimental|All patients|All participants enrolled.
11571798|NCT00847509|Experimental|FLT PET scan|Open label, nonrandomized, uncontrolled, single group assignment, multi-center clinical trial to evaluate [F-18] FLT as a PET imaging tool in cancer patients clinically scheduled for treatment with radiation or radiation - chemotherapy. Standard [F-18] FDG PET will be the active comparator.
11571799|NCT00847496|Experimental|1|AWBAT
11571800|NCT00847496|Active Comparator|2|BIOBRANE(R)
11571801|NCT00847483|Active Comparator|Latanoprost|
11571802|NCT00847483|Active Comparator|Travoprost|
11571803|NCT00847483|Active Comparator|Bimatoprost|
11571804|NCT00847457|Experimental|Aerobic exercise|Participants will perform aerobic exercise regularly for 12 weeks.
11571805|NCT00847457|Active Comparator|Stretch|Participants will stretch regularly for 12 weeks.
11571806|NCT00847444|Active Comparator|AA|Drug intervention
11571807|NCT00847444|Active Comparator|BA|Lifestyle intervention
11571808|NCT00847444|No Intervention|BB|No individualized lifestyle intervention program.
11571809|NCT00847431||STN DBS Group|PD patients with deep brain stimulators in the subthalamic nucleus. Subjects within this group will be placed into either a 1 contact group, or 2 contact group, depending on contact location requirements for this study.
11571810|NCT00847431||Control Group|PD patients without deep brain stimulator surgery, with similar symptoms to the study group.
11571811|NCT00847418|Experimental|Esketamine|
11571812|NCT00847405|Experimental|1|
11571813|NCT00847405|Active Comparator|2|
11571814|NCT00847392|Experimental|Ultrasound|Bladder ultrasound prior to catheterization
11571815|NCT00847392|No Intervention|Standard catheterization|No ultrasound prior to bladder catheterization
11571816|NCT00847379|Experimental|Overall Participants: High-Dose Ataluren|All participants will receive ataluren suspension orally three times a day (TID), 20 mg/kg at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for up to 96 weeks in this study. Any participant who was receiving a reduced dose of ataluren at the end of treatment visit in study PTC124-GD-007-DMD, will be initiated ataluren therapy in this extension study at the 5-, 5-, and 10-mg/kg dose level; dose will be increased to 10, 10, and 20 mg/kg at Week 6 and to 20, 20, and 40 mg/kg at Week 12, if the preceding dose level is well tolerated.
11571817|NCT00847366|Experimental|Perifosine 201|"Perifosine 201: A Phase 1/2 trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer.
~Perifosine dosage:
~Arm A: 50 mg p.o. 3 times daily with meals. Arm B: 150 mg p.o. daily at bedtime. Arm C: 300 mg p.o. 3 times a day (900 mg) once a week."
11571818|NCT00847366|Experimental|Perifosine 206|"Perifosine 206: A Randomized Phase II Trial of Three Doses of Perifosine in Combination with Trastuzumab.
~Arm A: Perifosine 50 mg p.o. daily + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle.
~Arm B: Perifosine 50 mg p.o three times a day + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle.
~Arm C: Perifosine 300 mg three times on one day + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle."
11571819|NCT00847366|Experimental|Perifosine 207|Perifosine 207: a Phase IIA Trial of Two Schedules of Perifosine Arm A: 50 mg daily with food. Arm B: 50 mg twice daily with food.
11571820|NCT00847366|Experimental|Perifosine 208|Perifosine 208: A Phase II Trial of Two Schedules of Perifosine in Combination with Endocrine Therapy (Tamoxifen) for Patients with Estrogen Receptor or Progesterone Receptor Positive Metastatic Breast Cancer Dosage: Arm A: 50 mg Perifosine /day p.o. .Endocrine therapy continued at same dose and schedule. Arm B: 900 Perifosine weekly. Endocrine therapy continued at same dose and schedule.
11571821|NCT00847366|Experimental|Perifosine 209|Perifosine 209: A Phase II Trial of Perifosine in Patients with Sarcomas. Perifosine 900 mg weekly (This dose should be divided so that the maximum dose rate is 300 mg in any 4-hour interval).
11571822|NCT00847327|Experimental|Parental Support|
11571823|NCT00847327|Active Comparator|Diabetes Education|
11571824|NCT00847314||Group 1|
11571825|NCT00847301||Renal Impairment|
11571826|NCT00847288|Experimental|Monthly Review Arm|Patients enrolled at centers that are assigned to the monthly review arm will have their device data reviewed monthly
11571827|NCT00847288|Active Comparator|Quarterly Review Arm|Patients enrolled at centers that are assigned to the quarterly review arm will have their device data reviewed every 3 months
11571828|NCT00847275|Placebo Comparator|1|"Exclusive nephrology follow-up arm"
11571829|NCT00847275|Experimental|2|"Geriatric follow-up arm"
11571830|NCT00847262|Experimental|Telmisartan Group|Telmisartan intervention group
11571831|NCT00847262|Active Comparator|Amlodipine Group|Amlodipine intervention group
11571832|NCT00847249|Experimental|1|Solution for nebulisation, inhaled
11571833|NCT00847249|Placebo Comparator|2|Solution for nebulisation, inhaled
11571834|NCT00847236||Subjects with Polymyalgia Rheumatica|50 subjects with Polymyalgia Rheumatica, both acute and chronic
11571835|NCT00847236||Subjects w/o Polymyalgia Rheumatica|50 subjects with Rheumatic Disease other than polymyalgia Rheumatica
11571836|NCT00847236||Subjects w/o Rheumatic Disease|50-Non Rheumatic disease subjects
11571837|NCT00847223|Experimental|ZARNESTRA (Tipifarnib)|
11571838|NCT00847210|Experimental|Dexlansoprazole MR 30 mg QD|
11571839|NCT00847210|Experimental|Dexlansoprazole MR 60 mg QD|
11571840|NCT00847197|Experimental|1|MK1903
11571841|NCT00847197|Placebo Comparator|2|Placebo to MK1903
11571842|NCT00847184|Active Comparator|1. Airtraq|Intubation with the use of the Airtraq technique
11571843|NCT00847184|Active Comparator|2. MacIntosh|Intubation using the standard MacIntosh blade
11571844|NCT00847171|Experimental|Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine|Participants receive Trastuzumab (T), Cyclophosphamide (CY), and an allogeneic GM-CSF-secreting whole cell breast cancer vaccine
11571845|NCT00847158|Active Comparator|1|phacoemulsification alone
11571846|NCT00847158|Active Comparator|2|phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
11571847|NCT00847145|Experimental|12B12M (1a)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age,respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
11571848|NCT00847145|Experimental|12B13M (1b)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.
11571849|NCT00847145|Experimental|12M13B15B (2a)|Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.
11571850|NCT00847145|Experimental|12M12B14B (2b)|Previously in the parent study subjects ahd received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.
11571851|NCT00847145|Experimental|12B12M (3a)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ at 2, 4 and 6 months of age respectively. These subjects had received one booster (fourth) dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
11571852|NCT00847145|Experimental|12B13M (3b)|Previously in the present study subjects had received three doses of rMenB+OMV NZ at 12 months of age respectively. These subjects one booster (fourth) dose of rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.
11571853|NCT00847145|Experimental|12B12M_C (4a)|Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age respectively. These subjects had received one single dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
11571854|NCT00847145|Experimental|12B13M_C (4b)|Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age. These subjects received one single dose o rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.
11571855|NCT00847132|Experimental|Collaborative Care|Collaborative Care Treatment: A study care manager provides depression education, consults with study psychiatrist to develop individualized treatment recommendations, and collaborates with patient and medical team to implement those recommendations
11571856|NCT00847132|Active Comparator|Usual Care|Usual Care Treatment: Primary medical providers are informed that the patient has depression and that treatment is recommended.
11571857|NCT00847119|Experimental|Bevacizumab & capecitabine & radiotheraphy|"Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.
~Radiotherapy 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.
~Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period."
11571858|NCT00847093|Experimental|Cream|Experimental group receiving either medicated topical cream or placebo cream
11571859|NCT00847080|Experimental|Sitagliptin|
11571860|NCT00847080|Placebo Comparator|Placebo|
11571861|NCT00847067|Active Comparator|Block|
11571862|NCT00847067|Sham Comparator|Sham injection|Skin injections with Normal Saline
11571863|NCT00847054|Experimental|MORAb-004|
11571864|NCT00847028|Experimental|1|glucose 10%
11571865|NCT00847028|Experimental|2|glucose 20%
11571866|NCT00847028|Experimental|3|glucose 30%
11571867|NCT00847028|Placebo Comparator|4|placebo: sterile water
11571868|NCT00847015|Experimental|Gemcitabine, Cisplatin, and Sunitinib|This is a phase II study of GCS (Gemcitabine, Cisplatin, and Sunitinib) as neoadjuvant chemotherapy in patients with muscle-invasive urothelial carcinoma of the bladder. Patients with muscle invasive urothelial carcinoma who are candidates for radical cystectomy will be enrolled.
11571869|NCT00847002|Active Comparator|Standard Wound Care|Gentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment.
11571870|NCT00847002|Active Comparator|Flexitouch system with Standard Wound Care|In addition to standard wound care, patients who have been randomized to this group will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis (FarrowWrap will be removed during the time they are using Flexitouch). The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action.
11571871|NCT00846989|Experimental|1|
11571872|NCT00846989|Experimental|2|
11571873|NCT00846989|Active Comparator|3|
11571874|NCT00846976|Experimental|200 mg Casodex|
11571913|NCT00846625|Active Comparator|2|Triamcinolone (4 mg/0.1 ml)
11571875|NCT00846963|Experimental|Ursodiol|Participants assigned in this arm receive an ursodiol suspension at 20mg/ml.
11571876|NCT00846963|Placebo Comparator|placebo|A placebo suspension that looks like the ursodiol suspension used.
11571877|NCT00846950|Experimental|healthy volunteers|
11571878|NCT00846924|Active Comparator|repeat 24-hour Holter monitor|
11571879|NCT00846924|Experimental|30-day ambulatory cardiac event monitor|
11571880|NCT00846911||Group 1|
11571881|NCT00846898|Experimental|cinnamon|Subjects in this group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
11571882|NCT00846898|Placebo Comparator|Control|Subjects in this group will receive placebo capsules (starch flour) for 12 weeks period. The 2 g dose of starch capsules will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
11571883|NCT00846885|Experimental|1|
11571884|NCT00846885|Active Comparator|2|
11571885|NCT00846872|Active Comparator|Low dose GHRP-3|Subjects will receive the infusion for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
11571886|NCT00846872|Active Comparator|High dose GHRP -3|Subjects will receive the infusion for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
11571887|NCT00846872|Placebo Comparator|Saline Infusion|Subjects will receive Placebo for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
11571888|NCT00846859|Experimental|varenicline|
11571889|NCT00846859|Placebo Comparator|placebo|
11571890|NCT00846846|Experimental|Endeavor® Zotarolimus Eluting Coronary Stent|Endeavor® Zotarolimus Eluting Coronary Stent System
11571891|NCT00846833|Experimental|Cyclophosphamide, high-dose interleukin-2, NK cell|
11571892|NCT00846807||Patients 75 years or younger|
11571893|NCT00846794||1 Asymptomatic|students with conditions being studied
11571894|NCT00846794||2 Symptomatic|students without conditions being studied
11571895|NCT00846781|Experimental|Denufosol tetrasodium Inhalation Solution|
11571896|NCT00846755|Active Comparator|Levothyroxine, Propylthiouracil|Drugs for the treatment of thyroid disease, are administered, when necessary, in high risk women, either in case finding, or in Universal Screening Group
11571897|NCT00846755|No Intervention|clinical checks|Low risk women whose sera are tested postpartum. Then patients with undiagnosed thyroid disease, are not treated
11571898|NCT00846742|Experimental|Treatment|Participants receive Stanford V Chemotherapy with or without radiation therapy. Patients receive doxorubicin hydrochloride IV and vinblastine IV on day 1 of weeks 1, 3, 5, and 7; mechlorethamine hydrochloride IV on day 1 of weeks 1 and 5; vincristine sulfate IV and bleomycin IV on day 1 of weeks 2, 4, 6, and 8; etoposide IV on day 1 of weeks 3 and 7; and prednisone orally (PO) three times daily every other day of weeks 1-8. Beginning 2-3 weeks after completion of chemotherapy, patients not achieving complete response undergo radiation therapy to individual nodal sites (tailored fields)
11571899|NCT00846716|Experimental|Pioglitazone add on to SU or biguanide|
11571900|NCT00846716|Active Comparator|SU or Biguanide|
11571901|NCT00846703|Active Comparator|Protocol A (MM)|
11571902|NCT00846703|Experimental|Protocol B (MM/VD)|
11571903|NCT00846690|Active Comparator|Benzocaine|"serves as active control"
11571904|NCT00846690|Experimental|TAC|serves as comparator
11571905|NCT00846677|Experimental|1|Vitamin D quick dissolve strip
11571906|NCT00846677|Active Comparator|2|Vitamin D syrup
11571907|NCT00846664|Experimental|Group 1|Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
11571908|NCT00846651|Experimental|colloid, then phenylephrine infusion|colloid administration; with 0.5 L Hydroxyethylstarch solution at a rate of 17 ml/min and completed over 30 min. A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
11571909|NCT00846651|Active Comparator|crystalloid, then phenylephrine infusion|crystalloid administration; The patients received 1.5 L Ringer's lactate infusion at a rate of 50 ml/min and completed over 30 min prior to spinal anesthesia for cesarean section. A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
11571910|NCT00846638|Experimental|1|Diagnostic assessment with brief intervention and 3, 6, and 12 month follow-up
11571911|NCT00846638|Active Comparator|2|Diagnostic assessment with 12 month follow-up
11571912|NCT00846625|Experimental|1|Ranibizumab (0.5 mg)
11571914|NCT00846612|Experimental|Avastin-Doxil|
11571915|NCT00846599||1|High omega-3
11571916|NCT00846599||2|High saturated fat
11571917|NCT00846586|Experimental|Indacaterol 150 μg and tiotropium 18 μg|Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11571918|NCT00846586|Active Comparator|Tiotropium 18 μg|Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11571919|NCT00846573|Experimental|Asthmatic Participants|This population is made up of only confirmed asthmatics. Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
11571920|NCT00846573|Experimental|Healthy|"This population is made up of subjects who are considered clinically healthy. This means that there are no records of any chronic disorders or pulmonary history.
~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
11571921|NCT00846573|Experimental|COPD Patients|"This population is made up of only confirmed COPD patients. Diagnosis must be confirmed through their doctor prior to enrollment.
~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
11571922|NCT00846573|Experimental|Cystic Fibrosis Patients|"This population is made up entirely of confirmed cystic fibrosis patients. Diagnosis must be confirmed through their physician.
~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
11571923|NCT00846560||1 ALS patients|
11571924|NCT00846560||2 Healthy subjects|
11571925|NCT00846547|Experimental|Arbaclofen|
11571926|NCT00846534||Post operative atrial fibrillation|To evaluate the ability of oxidative stress markers to predict postoperative atrial fibrillation in subjects undergoing cardiac surgery.
11571927|NCT00846521|Experimental|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
11571928|NCT00846508|Experimental|ciaplantin,cancer,survival|
11571929|NCT00846495|Active Comparator|topiramate|Subjects randomized to Group A at Visit 2 were provided with topiramate, titrated over 4 weeks to a maximum dose of 100 mg daily. One dosage adjustment was allowed with a minimum dose of 50 mg daily.
11571930|NCT00846495|Active Comparator|frovatriptan|Subjects randomized to Group B at Visit 2 were provided with frovatriptan 5 mg to treat during prodrome at the point they were confident a disabling migraine would occur (before the onset of headache).
11571931|NCT00846482|Experimental|Resected or metastatic CRC|All patients with advanced or stage II or III colorectal cancer being treated with oxaliplatin
11571932|NCT00846469|Experimental|chest pain|CCTA (Coronary computed tomography angiography)
11571933|NCT00846443|Experimental|1|pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
11571934|NCT00846443|Experimental|2|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
11571935|NCT00846443|Experimental|3|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions
11571936|NCT00846443|Experimental|4|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
11571937|NCT00846430|Experimental|Open-Label Intervention|This is a phase II single arm study with sequential treatments available by response where all participants begin therapy with a combination of celecoxib and interferon alpha-2b (CI, treatment-1). Response to CI therapy will be assessed at six months by clinical and radiographic evaluations. Those patients who have achieved a partial response (improvement in pain, improvement in functioning, or ≥50% reduction in tumor size) or complete response (resolution of pain, and normalization of functioning with a ≥ 90% reduction in tumor size) will continue with the same CI therapy for up-to two years on study.
11571938|NCT00846417||Case|Patients with ICDs who attend the ICD Support Groups.
11571939|NCT00846417||Control|Patients with ICDs who do not attend the ICD support groups.
11571940|NCT00846404||Case|Patients with Diastolic Dysfunction
11571941|NCT00846404||Control|Patients without Diastolic Dysfunction
11571942|NCT00846391|Experimental|MK8245 5 mg b.i.d.|MK8245
11571943|NCT00846391|Experimental|MK8245 50 mg b.i.d.|MK8245
11571944|NCT00846391|Placebo Comparator|Placebo|Placebo
11571945|NCT00846378|Experimental|Post conditioning|After 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. The balloon should be inflated to only occlude the coronary artery. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.
11571946|NCT00846378|Active Comparator|Usual Care|Usual care for treatment of thrombolysis in myocardial infarction (TIMI) 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
11571947|NCT00846365|Experimental|Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD|(dependant on blood pressure)
11571948|NCT00846365|Experimental|Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD|(dependant on blood pressure)
11571949|NCT00846365|Active Comparator|Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD|(dependant on blood pressure)
11571950|NCT00846352|Active Comparator|Early Bronch|This group will receive bronchoscopy within 36 hours of enrollment into the study.
11571951|NCT00846352|Active Comparator|Late bronch|This group will receive bronchoscopy within 5 days of enrollment.
11571952|NCT00846339|Experimental|1|DRD2 Taq1A1 allele
11571953|NCT00846339|Experimental|2|DRD Taq1 A2 homozygote2
11571954|NCT00846326|Experimental|Oxymetazoline-Fluticasone Propionate|Combination nasal spray with oxymetazoline 0.05% and fluticasone propionate 0.05%
11571955|NCT00846326|Placebo Comparator|Oxymetazoline-placebo|oxymetazoline 0.05% w/v and placebo fluticasone propionate
11571956|NCT00846313|Active Comparator|Dietary counseling|Patients receive dietary advice at an individual level and are offered contact with clinical dietitian every second week if necessary.
11571957|NCT00846313|No Intervention|Control|
11571958|NCT00846287|Active Comparator|Drug Subjects|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. BROVANA (arformoterol tartrate) Inhalation Solution is supplied as 2 mL of arformoterol tartrate solution packaged in 2.1 mL unit-dose, low-density polyethylene (LDPE) unit-dose vials. Each unit-dose vial contains 15 mcg of arformoterol (equivalent to 22 mcg of arformoterol tartrate) in a sterile, isotonic saline solution, pH-adjusted to 5.0 with citric acid and sodium citrate. After administration of the drug, three additional bags of hyperpolarized helium-3 will be administered, again with five to ten minutes between each bag.
11571959|NCT00846287|Placebo Comparator|Saline|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the placebo (nebulized saline solution) will be administered (2.1 mL). After administration of the placebo, three additional bags of hyperpolarized helium-3 will be administered, again with five to ten minutes between each bag.
11571960|NCT00846274|Active Comparator|Antithrombin III|
11571961|NCT00846274|Experimental|SK Antithrombin III|
11571962|NCT00846261|Experimental|Ilzarov|
11571963|NCT00846248|Active Comparator|1|Chromium picolinate
11571964|NCT00846248|Placebo Comparator|2|2 sugar pills taken twice daily
11571965|NCT00846235|Experimental|Moisturising cream|
11571966|NCT00846222|Experimental|Mild theraputic hypothermia|
11571967|NCT00846196|Experimental|2|one commercial risedronate 35 mg DR tablet
11571968|NCT00846196|Active Comparator|1|one Phase III risedronate 35 mg DR tablet
11571969|NCT00846183|Active Comparator|local ingury|In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed.
11571970|NCT00846183|No Intervention|control|in 60 patients routine IVF are performed
11571971|NCT00846170|Active Comparator|probiotics|patients with IBS that will receive investigational treatment for 4 weeks
11571972|NCT00846170|Placebo Comparator|Placebo|cross over of patients from arm 1
11571973|NCT00846157|No Intervention|control|Rituximab 375mg/m2 IV administered on day 1. Cyclophosphamide 750mg/m2 IV for 2hours,Adriamycin 50mg/m2 ,Vincristine 1.4mg/m2 IV respectively. Prednisone 60mg P.O. per day for 5 days.
11571974|NCT00846157|Active Comparator|Active|R-CHOP plus Natural Killer Cell therapy
11571975|NCT00846131|Active Comparator|A: Y-90 alone|Patients randomized to Arm A will proceed to Y-90 treatment alone in the Northwestern standard of care procedure
11571976|NCT00846131|Experimental|B: Sorafenib + Y-90|Patients randomized to Arm B will start sorafenib at a dose of 400 mg twice daily for bilirubin ≤ 1.5 x ULN and 200 mg twice daily for bilirubin > 1.5 x ULN to ≤ 3 x ULN. After 14 days of sorafenib therapy (+/- 3 days) patients will proceed to Y-90 in the Northwestern standard of care procedure
11571977|NCT00846118|Active Comparator|Pitavastatin|Pitavastatin in addition to optimal standard care
11571978|NCT00846118|No Intervention|optimal standard care|
11571979|NCT00846105|Experimental|Rapid PCR screen|Rapid PCR screen test for detection of MRSA carriers upon hospital admission
11571980|NCT00846105|Active Comparator|Conventional culture|Conventional culture screen for detection of MRSA carriers upon hospital admission
11571981|NCT00846092|Experimental|Device|"The study will require 20 subjects.
~Each subject will have one study eye that will be designated for treatment.
~Subjects will be exposed to light emitted from Warp 10 LED's (Quantum Devices, Barneveld, WI) at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.
~Treatments involve application of the LED-generated light for 80 seconds, twice daily.
~Primary efficacy and toxicity outcomes are determined by measuring excess retinal thickness via Ocular Coherence Tomography at 1 month, 3 months, and 6 months, prior to conclusion of the study.
~• This protocol will be stopped if, at any point in the study, a 50% increase in excess retinal thickness is demonstrated via OCT in 25% of subjects in the experimental group."
11571982|NCT00846066|Experimental|Hands on Training|Hands on Training by a pediatric dentist
11571983|NCT00846066|Active Comparator|Web Based Training|Web Based Training for all residents before randomization
11571984|NCT00846053|Other|Stable lung function|* Group S (n = 14) will consist of CF patients, aged 12-21 years old, who underwent FDG-PET with stable lung function during the past 4 years, defined as less than 2% decline per year. There is no therapeutic intervention and FDG-PET scan will be performed in both cohorts.
11571985|NCT00846053|Other|Rapidly deteriorating lung function|* Group R (n = 14) will contain CF patients, aged 12-21 years old, who underwent FDG-PET with rapidly deteriorating lung function during the past 4 years with greater than 4% per year decline. There is no therapeutic intervention and FDG-PET scan will be performed in both cohorts.
11572044|NCT00845598|Active Comparator|Fluticasone propionate|
11572045|NCT00845585|Active Comparator|Owniflow II|
11571986|NCT00846040|Experimental|isocaloric selective reduction of dietary fat|determine the effects of two isocaloric, reduced energy diets for 6 days, selectively restrictive in either fat or carbohydrate calories, on 24-hour respiratory quotient, macronutrient utilization and energy balance in obese subjects.
11571987|NCT00846027|Experimental|Bevacizumab + paclitaxel + gemcitabine|Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m^2 IV, and gemcitabine 2000 mg/m^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
11571988|NCT00846014|Experimental|Asthmatics|All subjects will be asthmatics that have had an exacerbation (asthma attack) no more than 48 hours before the imaging session.
11571989|NCT00846001|Active Comparator|CABG alone|Standard coronary artery bypass grafting according guidelines
11571990|NCT00846001|Experimental|CABG+CRT|Standard coronary artery bypass grafting according guidelines with concomitant three bipolar epicardial leads implantation for cardiac resynchronization therapy
11571991|NCT00845988|Active Comparator|treatment as usual|patients showing weight gain while receiving treatment with risperidone, olanzapine, quetiapine, or clozapine
11571992|NCT00845988|Experimental|switch to aripiprazole|aripiprazole
11571993|NCT00845975|Active Comparator|Erchonia Hearing Lasers #1 & #2|"Erchonia Hearing Laser #1 is a dual laser system composed of a pulsed red 7.5 milliwatts (mW) laser of 635 nm +/- 5 nm and a pulsed green 7.5 mW laser of 532 nm, both lasers in simultaneous operation when the laser is activated.
~Erchonia Hearing Laser #2 is a single diode laser that in pulsed mode emits 4.9 mW of red 635 nm +/- 5 nm light."
11571994|NCT00845975|Placebo Comparator|Placebo Lasers|Inactive lasers that do not emit any therapeutic light.
11571995|NCT00845962|Active Comparator|Chloroprocaine|
11571996|NCT00845962|Active Comparator|Bupivacaine|
11571997|NCT00845936|Experimental|1|850 mg of Metformin bid
11571998|NCT00845936|Placebo Comparator|placebo|Tablets Identical to Metformin, bid
11571999|NCT00845923|Other|Civamide Patch 0.015%|All subjects in study will receive the Civamide Patch 0.015%
11572000|NCT00845910|Experimental|1|
11572001|NCT00845897|Placebo Comparator|1|Placebo (saline) injections into 6 sites in the calf muscle
11572002|NCT00845897|Active Comparator|2|Total 200 units of Botulinum Toxin injected into 6 sites into the calf muscles.
11572003|NCT00845897|Active Comparator|3|300 units of botulinum toxin injected into 6 sites in the calf muscle
11572004|NCT00845884|Experimental|AVDCF|Drug: Docetaxel, Cisplatin, Capecitabine, Bevacizumab
11572005|NCT00845871|Experimental|deferasirox|Patients will have five general options for taking Deferasirox including with or without meals, crushed and added to a soft food or mixed in a liquid of choice.
11572006|NCT00845858|Active Comparator|Metoclopramide Nasal Spray 10 mg|
11572007|NCT00845858|Active Comparator|Metoclopramide Nasal Spray 14 mg|
11572008|NCT00845858|Placebo Comparator|Placebo Nasal Spray|
11572009|NCT00845845|Active Comparator|Omega-3-acid ethyl esters (Lovaza)|Participants receive 4 milligrams (mg) daily of omega-3-acid ethyl esters (Lovaza) and dietary counseling for 24 weeks
11572010|NCT00845845|Placebo Comparator|Placebo|Participants receive daily placebo and dietary counseling for 24 weeks
11572011|NCT00845832|Experimental|1|
11572012|NCT00845832|Active Comparator|2|
11572013|NCT00845819|Active Comparator|EGF|rhEGF + povidone iodine, chlorhexidine, & nystatin
11572014|NCT00845819|Placebo Comparator|Placebo|Placebo + povidone iodine, chlorhexidine, & nystatin
11572015|NCT00845806||Arabic Speakers|All subjects must be male native arabic speakers who can read and speak english.
11572016|NCT00845780|Experimental|withdrawal amiodarone|withdrawal amiodarone afer at least 6 months of sinus rhythm maintenance on amiodarone therapy
11572017|NCT00845780|Active Comparator|continuation amiodarone|continuation of amiodarone after 6 months of sinus rhythm maintenance on amiodarone therapy
11572018|NCT00845767|Experimental|Diesel Exposure|1 hour exposure to dilute diesel exhaust at a concentration of 300 µg/m3 with intermittent exercise
11572019|NCT00845767|Experimental|Air Exposure|1 hour exposure to filtered air during intermittent exercise
11572020|NCT00845754|Placebo Comparator|1|Placebo
11572021|NCT00845754|Active Comparator|2|Ketorolac
11572022|NCT00845728|Experimental|Indacaterol|Indacaterol 150 µg o.d. delivered via single-dose dry powder inhaler (SDDPI)
11572023|NCT00845728|Active Comparator|Tiotropium|Tiotropium 18 µg o.d. delivered via the handihaler®
11572024|NCT00845715|Other|Early motion|
11572025|NCT00845715|Other|Standard motion|
11572026|NCT00845702|Experimental|Dotarem|Each subject will receive one injection of Dotarem 0.2 ml/kg.
11572027|NCT00845702|Other|Time Of Flight Magnetic Resonance Angiography|Each subject undergo a TOF MRA
11572028|NCT00845689|Placebo Comparator|1|liver resection with Pringle + placebo
11572029|NCT00845689|Active Comparator|2|liver resection with Pringle + adenosine preconditiong
11572030|NCT00845689|Active Comparator|3|liver resection with Pringle + adenosine pre- and postconditioning
11572031|NCT00845676|Experimental|Pegylated interferon alfa-2a + Ribavirin|Pegylated interferon alfa-2a + Ribavirin
11572032|NCT00845663|Active Comparator|Pre-filled Syringe|pre-filled syringe (reference)
11572033|NCT00845663|Experimental|Auto-injection Device|Auto-injection device (test)
11572034|NCT00845650|Experimental|AIGIV 3.5 mg/kg (Cohort A)|AIGIV containing 3.5 mg/kg anti-PA IgG as a single intravenous infusion.
11572035|NCT00845650|Other|Gamunex 90 mg/kg (Cohort A)|Gamunex 90 mg/kg total IgG as a single intravenous infusion.
11572036|NCT00845650|Experimental|AIGIV 7.0 mg/kg (Cohort B)|AIGIV containing 7.0 mg/kg anti-PA IgG as a single intravenous infusion.
11572037|NCT00845650|Other|Gamunex 180 mg/kg (Cohort B)|Gamunex 180 mg/kg total IgG as a single intravenous infusion.
11572038|NCT00845650|Experimental|AIGIV 14.0 mg/kg (Cohort C)|AIGIV containing 14.0 mg/kg anti-PA IgG as a single intravenous infusion.
11572039|NCT00845650|Other|Gamunex 360 mg/kg (Cohort C)|Gamunex 360 mg/kg total IgG as a single intravenous infusion.
11572040|NCT00845637|Active Comparator|Eggplant extract|
11572041|NCT00845637|Placebo Comparator|Placebo|
11572042|NCT00845624||1|Preterm infants <1500 grams or 32 weeks gestation.
11572043|NCT00845598|Experimental|Azelastine Fluticasone|
11572047|NCT00845572|Experimental|Consta Club|
11572048|NCT00845559|Experimental|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide.
11572049|NCT00845559|No Intervention|No Treatment|
11572050|NCT00845546|Experimental|1|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets of Ranbaxy
11572051|NCT00845546|Active Comparator|2|(Claritin_D® 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets
11572052|NCT00845520|Experimental|Lens implantation +1.00 diopter (D) postop target|Lens implant power calculated for postoperative MRSE target of +1.00 D
11572053|NCT00845520|Experimental|Lens implantation -1.00 D postop target|Lens implant power calculated for postoperative MRSE target of -1.00 D
11572054|NCT00845520|Experimental|Lens implantation 0.00 D postop target|Lens implant power calculated for postoperative MRSE target of 0.00 D
11572055|NCT00845507|Experimental|Exenatide Group|Exenatide dstarted at 5 mcg subcutaneously twice daily within one hour before the morning and evening meals, and increased (as tolerated) to 10 mcg.
11572056|NCT00845507|Placebo Comparator|Placebo Group|Placebo: Sterile solution in equivalent doses as Exenatide
11572057|NCT00845494|Other|medication history education|Four hospital unit nurses asked to participate in the study. Two nursing units will receive the cognitive behavioral intervention.
11572058|NCT00845481|Experimental|all patients apply all products|
11572059|NCT00845468||No treatment|
11572060|NCT00845455||1. Harm Avoidance|Personality type
11572061|NCT00845455||2. Reward Dependence|Personality type
11572062|NCT00845455||3. Novelty Seeking|Personality type
11572063|NCT00845429|Experimental|Group 1: Standard-dose Cell-based Influenza Vaccine|Participants will receive a single dose of standard-dose cell-based influenza virus vaccine.
11572064|NCT00845429|Experimental|Group 2: High-dose Cell-based Influenza Vaccine|Participants will receive a single dose of high-dose cell-based influenza virus vaccine.
11572065|NCT00845429|Active Comparator|Group 3: Licensed Fluzone® Influenza Vaccine|Participants will receive a single dose of licensed Fluzone® influenza vaccine.
11572066|NCT00845390||ICD Patients|ICD patients
11572067|NCT00845377|Experimental|Counseling|
11572068|NCT00845364|Experimental|Perhexiline|Pre-operative administration of Perhexiline tablets according to dosing schedule
11572069|NCT00845364|Placebo Comparator|Placebo|Pre-operative administration of placebo tablets according to dosing schedule
11572070|NCT00845351|Experimental|Bexarotene|Bexarotene 300 mg/m2/day times 5 days
11572071|NCT00845338|Experimental|Arm 1|
11572072|NCT00845325|Active Comparator|Group One|"The first group (early motion) will have a bulky dressing placed at the time of surgery. They will be instructed to remove the dressing on the first postoperative day and to place a band-aid over the incision. A set of non-weight bearing stretching exercises will be explained on the day of surgery and instructions with diagrams sent home with the patient. They will begin these exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work."
11572073|NCT00845325|Other|Behavorial Control Group Two|The second group will have wrist immobilization splints placed at the time surgery. The thumb and fingers will not have limited motion in this splint. Due to the splint placement, the patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
11572074|NCT00845312||Complicated hospitalization|"Patients 60 years old or younger, who were diagnosed with community acquired pneumonia (CAP) between March 1, 2005 and December 31, 2008 were retrospectively analyzed for risk factors for severe morbidity or mortality.
~was defined as at least one of the following parameters: hospitalization longer than ten days, admission to intensive care unit and in- hospital mortality. Otherwise, the hospitalization was defined uncomplicated .The Rambam hospital Institutional Review Board approved the study."
11572075|NCT00845299|Experimental|1|Latanoprost punctal plug and use of artificial tears containing Benzalkonium Chloride
11572076|NCT00845299|Experimental|2|Latanoprost punctal plug only
11572077|NCT00845273||Pegaptanib sodium|Patients administered Pegaptanib sodium.
11572078|NCT00845260|Experimental|Internet CBT|Internet-based cognitive behavior therapy (CBT).
11572079|NCT00845260|Experimental|Group CBT|Group cognitive behavior therapy (CBT).
11572080|NCT00845247|Placebo Comparator|Control|Control group patients will receive usual medical plus usual supportive treatment.
11572081|NCT00845247|Active Comparator|Case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
11572082|NCT00845234|No Intervention|Standard of Care Group|Received the current standard of care as operationally defined by the investigators- Q&A session + Video
11572083|NCT00845234|Experimental|Intervention Group|Intervention group- Patients will receive the brief educational CBT intervention + video and Q&A session
11572084|NCT00845221|Experimental|Imatinib|
11572085|NCT00845208|Active Comparator|Case Management|
11572086|NCT00845208|Experimental|Network Support|12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
11572087|NCT00845208|Experimental|Network Support + Contingency Mgmnt|12 weekly sessions intended to help patients change their social networks to be more supportive of abstinence. Contingency management component added to reinforce efforts to make network changes.
11572088|NCT00845195|Experimental|Olopatadine HCl Nasal Spray, 0.6%|
11572089|NCT00845195|Active Comparator|Azelastine HCl Nasal Spray, 0.1%|
11572090|NCT00845182|Active Comparator|Pioglitazone|Pioglitazone: 15 Patients will be randomized to Pioglitazone only arm
11572091|NCT00845182|Experimental|Exenatide|Exenatide: 15 subjects will be randomized to receive Exenatide
11572092|NCT00845182|Experimental|Drug Pioglitazone and Drug Exentatide|Pioglitazone and Exenatide: 15 subjects will be randomized to Pioglitazone and Exenatide
11572093|NCT00845169|Experimental|Diesel Exposure|1 hour exposure to diesel exhaust at 300 µg/m3 during intermittent exercise
11572094|NCT00845169|Experimental|Air Exposure|1 hour exposure to filtered air during intermittent exercise
11572095|NCT00845156|Active Comparator|Anti-Oxidant|Alpha Lipoic Acid
11572096|NCT00845156|Placebo Comparator|Placebo|Placebo
11572097|NCT00845130|Experimental|Diabetic Type II Subjects|Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm
11572098|NCT00845130|Experimental|Healthy Subjects|Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm
11572099|NCT00845117|Experimental|Limbal Stem Cell Transplant|The cornea is debrided of all superficial fibrovascular tissue and the cultivated stem cell graft is glued onto the cornea.
11572100|NCT00845104|Experimental|Arm I|See Detailed Description
11572101|NCT00845091|Experimental|Exercise|moderate-intensity, low-impact, supervised, aerobic exercise
11572102|NCT00845091|Active Comparator|Heart Healthy Education|Educational topics on heart health (e.g., nutrition, smoking, sleep)
11572103|NCT00845078||1|Immediate reconstruction followed by radiation therapy
11572104|NCT00845078||2|Radiation therapy followed by delayed reconstruction
11572105|NCT00845065|Placebo Comparator|Arm 1 (Control Arm)|Peginterferon alfa-2a (180 μg/week subcutaneously [SC]) plus ribavirin (1000 to 1200 mg/day orally [PO]) for 4 weeks followed by placebo (800 mg three times a day [TID] PO, using placebo matching SCH 503034 200-mg capsules) + peginterferon alfa-2a 180 μg/week SC plus ribavirin 1000 to 1200 mg/day PO divided twice daily (BID) for 48 weeks with 24 weeks post-treatment follow-up.
11572106|NCT00845065|Experimental|Arm 2 (Boceprevir Arm)|"Peginterferon alfa-2a (180 μg/week subcutaneously [SC]) plus ribavirin (1000 to 1200 mg/day orally [PO]) for 4 weeks followed by boceprevir (800 mg three times a day [TID] PO, using SCH 503034 200-mg capsules) + peginterferon alfa-2a 180 μg/week SC plus ribavirin 1000 to 1200 mg/day PO divided twice daily (BID) for 48 weeks
~with 24 weeks post-treatment follow-up."
11572107|NCT00845052||First group of house staff|First group of house staff to be surveyed
11572108|NCT00845052||Second group of house staff|Second group of house staff to be surveyed
11572109|NCT00845052||Thirst group of house staff|Third group of house staff to be surveyed
11572110|NCT00845039|Active Comparator|Cetuximab + Irinotecan|Participants in Treatment Group 1 will receive intravenous infusions of Cetuximab 500 milligrams per square meter (mg/m²) and Irinotecan 180 mg/m².
11572111|NCT00845039|Experimental|Cetuximab + IMC-A12 + Irinotecan|Participants in Treatment Group 2 will receive intravenous infusions of Cetuximab 500 mg/m², IMC-A12 10 milligrams/kilogram (mg/kg) and Irinotecan 180 mg/m².
11572112|NCT00845026|Experimental|LY2140023|
11572113|NCT00845026|Active Comparator|aripiprazole|
11572114|NCT00845026|Active Comparator|olanzapine|
11572115|NCT00845026|Active Comparator|risperidone|
11572116|NCT00845013||HIV Infection|HIV-infected individuals with the clinical diagnosis of pulmonary hypertension or HIV-infected individuals who have mildly elevated pulmonary arterial pressures
11572117|NCT00845000|Experimental|SCH 420814 10 mg→SCH 420814 100 mg→Placebo|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
11572118|NCT00845000|Experimental|SCH 420814 100 mg→Placebo→ SCH 420814 10 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
11572119|NCT00845000|Experimental|Placebo→SCH 420814 10 mg→SCH 420814 100 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
11572120|NCT00845000|Experimental|SCH 420814 10 mg→ Placebo→ SCH 420814 100 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
11572121|NCT00845000|Experimental|SCH 420814 100 mg→ SCH 420814 10 mg→Placebo|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
11572122|NCT00845000|Experimental|Placebo→ SCH 420814 100 mg→SCH 420814 10 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
11572123|NCT00844974|Other|1|
11572124|NCT00844961|Experimental|Internet CBT|10 weeks of internet delivered cognitive behaviour therapy
11572125|NCT00844961|No Intervention|Waiting list|Waiting list which is offered treatment after completion of post intervention assessments
11572167|NCT00844649|Active Comparator|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks followed by a week of rest (Cycle 2 onward).
11572168|NCT00844636|Active Comparator|Sharp Needles|Sharp needles to close uterus, fascia and skin during cesarean section
11572169|NCT00844636|Active Comparator|Blunt Needles|Assignment to blunt needles to close uterus, fascia and skin during cesarean section
11572126|NCT00844948||Young adults (18-25 years old)|Young adults (18-25 years old). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started treatment or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
11572127|NCT00844948||Elderly (60-80 years old)|Elderly (60-80 years old). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started treatment or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
11572128|NCT00844948||Chinese speakers|Chinese speakers (Mandarin or Cantonese). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
11572129|NCT00844922|Experimental|Org 34517|Org 34517 titrated to 900 mg daily for 2 weeks
11572130|NCT00844922|Placebo Comparator|Placebo|
11572131|NCT00844896|Active Comparator|DEF-only|Distress Emotional Support and Family Assessment Treatment
11572132|NCT00844896|Experimental|DEF + COPE|Distress Emotional Support and Family Assessment Treatment and Creating Opportunities for Parent Empowerment Treatment
11572133|NCT00844883|Experimental|sorafenib and drug eluting beads|single arm
11572134|NCT00844870|Active Comparator|1|stabilization training group
11572135|NCT00844870|Experimental|2|auditory response training group
11572136|NCT00844857|Experimental|Olanzapine/Fluoxetine Combination|
11572137|NCT00844857|Placebo Comparator|Placebo|
11572138|NCT00844844|Experimental|Eculizumab|
11572139|NCT00844831|Experimental|Treatment with lubiprostone|Subjects receive lubiprostone and bacteria is measured before and after
11572140|NCT00844818|No Intervention|Control|Moms and dads who were current smokers (1 cigarette, even a puff, in past 30 days) or recent quitters (smoked since one month prior to conception)
11572141|NCT00844818|Experimental|Intervention Group|Moms and dads who were current smokers (1 cigarette, even a puff, in past 30 days) or recent quitters (smoked since one month prior to conception)
11572142|NCT00844805|Experimental|Infliximab + Naproxen|Infliximab administered at a dose of 5 mg/kg intravenously on Day 1 of Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks during the 28-week treatment phase.
11572143|NCT00844805|Placebo Comparator|Placebo + Naproxen|Placebo administered intravenously on Day 1 at Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks, during the 28-week treatment phase.
11572144|NCT00844805|Experimental|Naproxen Only (Follow-Up)|For participants who achieved partial remission during 28-week treatment phase, naproxen was continued at a daily dose of 1000 mg administered orally for an additional 24 weeks in the follow-up phase.
11572145|NCT00844805|No Intervention|No Treatment (Follow-Up)|For participants who achieved partial remission during Treatment phase, no treatment was administered for an additional 24 weeks in the follow-up phase.
11572146|NCT00844792|Experimental|1|This group of men will be on active treatment (antioxidants)for 6-8 weeks prior to their radical prostatectomy.
11572147|NCT00844792|Placebo Comparator|2|This group of men will be on placebo for 6-8 weeks prior to their radical prostatectomy.
11572148|NCT00844779||T|(n=30): without central adiposity, without insulin resistance, operated for cholecystectomy or a benign liver tumor.
11572149|NCT00844779||A|(n=30): with central adiposity, insulin resistance and hepatic steatosis (histology).
11572150|NCT00844779||B|(n=30): with central adiposity, insulin resistance and steatohepatitis ± hepatic fibrosis (histology).
11572151|NCT00844753|Active Comparator|1|Atomoxetine + Parent Management Training
11572152|NCT00844753|Active Comparator|2|Atomoxetine without Parent Management Training
11572153|NCT00844753|Placebo Comparator|3|Placebo + Parent Management Training
11572154|NCT00844753|Placebo Comparator|4|Placebo without Parent Management Training
11572155|NCT00844740|Experimental|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood and urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
11572156|NCT00844727|Active Comparator|1|Rofexocib 25 mg OD, 1 year treatment
11572157|NCT00844727|Placebo Comparator|2|Placebo
11572158|NCT00844714|Experimental|Rituxan|
11572159|NCT00844701||Non-smoker|Non-smoking control
11572160|NCT00844701||Nicotine Dependent Smoking Group|current smokers
11572161|NCT00844688|Other|sorafenib/gemcitabine|
11572162|NCT00844675|Experimental|rabeprazole|rabeprazole
11572163|NCT00844675|Experimental|placebo|placebo
11572164|NCT00844662|Experimental|1|
11572165|NCT00844662|Active Comparator|2|
11572166|NCT00844649|Experimental|Albumin-bound paclitaxel (ABI-007)/Gemcitabine|ABI-007 125 mg/m2 administered in combination with gemcitabine 1000 mg/m2 weekly for 3 weeks followed by one week of rest.
11572219|NCT00844272|No Intervention|Treatment as usual|Control group did not received no intervention.
11572170|NCT00844597|Experimental|Cohort 1 - 0.5 mg/kg/wk|Subjects in this group will receive a 0.5 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
11572171|NCT00844597|Experimental|Cohort 2 - 1.0 mg/kg/wk|Subjects in this group will receive a 1.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
11572172|NCT00844597|Experimental|Cohort 3 - 2.0 mg/kg/wk|Subjects in this group will receive a 2.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
11572173|NCT00844597|Experimental|Cohort 4 - 4.0 mg/kg/wk|Subjects in this group will receive a 4.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
11572174|NCT00844597|Experimental|Cohort 5 - 10.0 mg/kg/wk|Subjects in this group will receive a 10.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
11572175|NCT00844597|Experimental|Cohort 6 - 20.0 mg/kg/wk|Subjects in this group will receive a 20.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
11572176|NCT00844584|Other|ablation|patients with atrial fibrillation underwent radiofrequency ablation with totally thoracoscope.
11572177|NCT00844571||E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
11572178|NCT00844571||control group|
11572179|NCT00844558|Experimental|Gait Training|Gait Training Intervention Group Participants
11572180|NCT00844558|Placebo Comparator|Control|Gait Training Control Group Participants
11572181|NCT00844545|Experimental|Eculizumab|
11572182|NCT00844532|Experimental|Absolute Pro™ Peripheral Self-Expanding Stent System|Arm includes both Absolute Pro™ and Absolute Pro™ Long Lesion (LL) Peripheral Self-Expanding Stent Systems
11572183|NCT00844519|Active Comparator|Maraviroc|For subjects assigned to the maraviroc group, subjects will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medication. For subjects on ritonavir, the dose of maraviroc will be 150mg by mouth twice daily.
11572184|NCT00844519|Placebo Comparator|Placebo|
11572185|NCT00844493|Experimental|H10407 challenge 1|7 or 8 logs of E. coli strain H10407 with CeraVacx buffer
11572186|NCT00844493|Experimental|H10407 challenge 2|7 or 8 logs of E. coli strain H10407 with bicarbonate buffer
11572187|NCT00844493|Experimental|H10407 challenge 3|6 logs of E. coli H10407 with bicarbonate buffer
11572188|NCT00844493|Experimental|H10407 challenge 4|5 logs of E. coli H10407 with bicarbonate buffer
11572189|NCT00844480|Experimental|zoledronic acid|
11572190|NCT00844480|Placebo Comparator|placebo|
11572191|NCT00844454|Experimental|QFEA|multi-pronged ethanol ablation
11572192|NCT00844454|Active Comparator|RFA|radiofrequency ablation
11572193|NCT00844428|Experimental|Eculizumab|
11572194|NCT00844415|Experimental|dabigatran etexilate|open label; patient to receive dabigatran etexilate BID for three days
11572195|NCT00844402|Experimental|Atorvastatin|Atorvastatin 10 mg per day for 48 weeks
11572196|NCT00844389|Active Comparator|NIR light|Group of patients stimulated with near to infrared light daily stimulation
11572197|NCT00844389|Placebo Comparator|Green light|Group of patients stimulated with green light.
11572198|NCT00844376|Other|Test|Extemporaneous preparation suspension Atorvastatin prototype formulation
11572199|NCT00844376|Other|Reference|Commercial atorvastatin tablet (Lipitor®)
11572200|NCT00844363|Other|NB-UVB|Regular, monitored NB-UVB treatment. Patients will be treated 3 times per week, and a full course of therapy is 12 weeks. NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
11572201|NCT00844350|No Intervention|letrozole+hCG|
11572202|NCT00844350|No Intervention|letrozole+oxytocin|
11572203|NCT00844350|No Intervention|letrozole+oxytocin+hCG|
11572204|NCT00844350|No Intervention|clomiphene citrate +oxytocin|
11572205|NCT00844350|No Intervention|clomiphene citrate +oxytocin+hCG|
11572206|NCT00844337|Active Comparator|1|One study arm will receive injectable gentamicin once daily and oral amoxicillin twice daily for seven days by comparison to other study arms.
11572207|NCT00844337|Active Comparator|2|Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days
11572208|NCT00844337|Active Comparator|3|Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days (COMPARISON ARM)
11572209|NCT00844324|Experimental|A|Candesartan cilexetil 1mg/mL
11572210|NCT00844324|Experimental|B|Candesartan cilexetil 1.6mg/mL
11572211|NCT00844311|Active Comparator|Control arm|150 iu/day of rFSH alone
11572212|NCT00844311|Experimental|hCG low dose|150 iu/day of rFSH + 50 iu/day of hCG from stimulation day 1
11572213|NCT00844311|Experimental|hCG medium dose|150 iu/day of rFSH + 100 iu/day of hCG from stimulation day 1
11572214|NCT00844311|Experimental|hCG high dose|150 iu/day of rFSH + 150 iu/day of hCG from stimulation day 1
11572215|NCT00844298|Experimental|Nilotinib+mVPD|Patients who were Philadelphia-positive, newly-diagnosed adult ALL and treated with nilotinib + mVPD treatment plan
11572216|NCT00844285||Cimzia Cohort:|Patients about to receive treatment with Cimzia® as part of pre-existing management plan for Crohn's disease or has already been receiving treatment with Cimzia® for ≤12 months. Patients must also receive a Cimzia dose within 2 months following enrollment.
11572217|NCT00844285||Comparison cohort|Patient must be about to receive treatment with any other medication as part of a pre-existing management plan for Crohn's disease or has already been receiving treatment (previous Cimzia® treatment is prohibited).
11572218|NCT00844272|Experimental|Psychoeducation|"PE group sessions lasted 60 minutes and were carried out under continuous supervision. The manualised program was especially tailored to (former) IDUs in HCV treatment, containing the following aspects:
~Module 1: HCV infection and symptoms, course of illness, interaction with opioid dependence, further problems and risk factors
~Module 2: HCV treatment, side effects, psychiatric and somatic comorbidities, reinfection and drug use, risk behaviour
~Module 3: Coping strategies, resources and self-help, effective use of health-care support, the role of social environment, healthy living & nutrition"
11572220|NCT00844259||Research Group|15 children with Down syndrome, observed in two interaction conditions: playing with their therapist (A) and playing with their caregiver (B).
11572221|NCT00844246|Experimental|SRS|School Readiness Specialist (SRS) will administer the screening questionnaire to the subject during the intervention period, at the subject's 9, 18, 24 and 30 month visits. They will then see their PCP for a well child visit in which the results of the test will be interpreted, developmental counseling and/or anticipatory guidance provided as per usual care. EI (Early intervention) referral will be completed, at the discretion of the providers, if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
11572222|NCT00844246|Experimental|Provider|Primary Care Physician (PCP) will do the developmental screening at the subject's 9, 18, 24 and 30 month well child visits. Once the screening questionnaire is complete the PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI (Early intervention) referral will be completed, at the discretion of the providers, if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
11572223|NCT00844246|No Intervention|Routine|Subjects randomized to routine surveillance will receive routine preventive care as well as developmental surveillance at all well child visits, including the 9, 18, 24 and 30 month visits. EI referral will be completed, at the discretion of the provider, if the PCP observes a developmental delay during surveillance or the caregivers raise a specific concern about the child's development.
11572224|NCT00844233|Experimental|1|Irinotecan Bead
11572225|NCT00844220|Experimental|CT/MR|CT/MRI-directed clinical management strategy
11572226|NCT00844220|Active Comparator|Catheterization|Standard clinical management
11572227|NCT00844207|Experimental|Treatment A|Two of the fixed combination tablets each containing 250 mg of azithromycin and 155 mg of chloroquine base.
11572228|NCT00844207|Active Comparator|Treatment B|A single tablet containing 500 mg of azithromycin and a single tablet containing 300 mg of chloroquine base.
11572229|NCT00844194|Other|DPNP with depression (1)|Patients that have diabetic polyneuropathy and depression and are responder to 60 mg duloxetine QD (>30% pain reduction after week 6)
11572230|NCT00844194|Other|DPNP with depression (2)|Patients that have diabetic polyneuropathy and depression and are non-responder to 60 mg duloxetine QD (<30% pain reduction after week 6)
11572231|NCT00844194|Other|DPNP without depression (1)|Patients that have diabetic polyneuropathy and no depression and are responder to 60 mg duloxetine QD (>30% pain reduction after week 6)
11572232|NCT00844194|Other|DPNP without depression (2)|Patients that have diabetic polyneuropathy and no depression and are non-responder to 60 mg duloxetine QD (<30% pain reduction after week 6)
11572233|NCT00844181||0|white women
11572234|NCT00844181||1|Black women
11572235|NCT00844168|Experimental|Treatment (adjuvant sorafenib tosylate after liver transplant)|Patients receive sorafenib tosylate PO twice daily on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11572236|NCT00844155|Active Comparator|A.Oseltamivir 75 mg dose|Patients will be randomized to two groups (group A) to receive oseltamivir at 75 mg, or (group B) to receive the drug at 150 mg in the fasting or fed state.
11572237|NCT00844155|Active Comparator|B. Oseltamivir 150mg|Patients will be randomized to groups (group A) to receive oseltamivir at 75 mg, or group B to receive the drug at 150 mg in the fasting or fed state.
11572238|NCT00844142|Other|1|etanercept 25mg twice weekly
11572239|NCT00844142|Active Comparator|2|Sulfasalazine 2000- 3000mg daily
11572240|NCT00844129||Neurofibromatosis Type 1|Children with Neurofibromatosis Type 1
11572241|NCT00844116|Active Comparator|Conventional Spirometry|personal spirometry
11572242|NCT00844116|Experimental|Telematic Spirometry|"performed remotely on line"
11572243|NCT00844103|Experimental|1|
11572244|NCT00844103|Placebo Comparator|2|
11572245|NCT00844090|Placebo Comparator|Arm 1|placebo tablets
11572246|NCT00844090|Experimental|Arm 2|methylphenidate tablets
11572247|NCT00844077||Barrett's metaplasia|Barrett's intestinal metaplasia, confirmed via pathology, undergoing standard of care endoscopic screening.
11572248|NCT00844064|Experimental|AP 12009|
11572249|NCT00844051|No Intervention|No Intervention|No school-based influenza vaccination program
11572250|NCT00844051|Active Comparator|Intervention|School-based Influenza Vaccination Program
11572251|NCT00844038||1|Sick
11572252|NCT00844025|Experimental|Pharmacist intervention|Patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including medication review, medication reconciliation, patient education and recommended actions.
11572253|NCT00844025|No Intervention|Usual care|Patients randomized to usual care group will receive routine review of medication by ward-based pharmacist and nurse.
11572254|NCT00844012|Experimental|Experimental group|
11572255|NCT00844012|Active Comparator|Control|
11572256|NCT00843986|Placebo Comparator|Placebo|Matching loading dose and continuous intravenous infusion for 48 hours
11572257|NCT00843986|Experimental|Conivaptan|20mg loading dose followed by a 20mg/ day continuous intravenous infusion for 48 hours
11572258|NCT00843973||iliac crest bone graft|Bone graft harvested via iliac crest bone graft procedure
11572259|NCT00843973||Reamer Irrigator Aspirator|Bone graft harvested via the Reamer Irrigator Aspirator (RIA) Procedure
11572260|NCT00843960|Active Comparator|1|intervention group
11572261|NCT00843960|No Intervention|2|control group
11572262|NCT00843934|Experimental|anti-cancer agent|
11572263|NCT00843921|Experimental|Carbaglu|Investigate whether a 3-day treatment with NCG can improve or restore urea genesis capacity in patients with NAGS, CPSI, or OTC deficiency or PA or MMA using surrogate markers: [13C] label incorporation into urea and plasma levels of ammonia, urea nitrogen (BUN) and amino acids
11572264|NCT00843908|Active Comparator|TVT|Women in this arm will undergo the Tension Free Vaginal Tape procedure
11572265|NCT00843908|Experimental|Miniarc|Women in this group will undergo the Miniarc suburethral sling procedure
11572266|NCT00843882|Active Comparator|Arm A (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21.
11572367|NCT00843063|Active Comparator|famotidine|Famotidine 40 mg om and nocte
11572267|NCT00843882|Experimental|Arm B (lenalidomide, epoetin alfa)|Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa SC once weekly.
11572268|NCT00843869||Chronic Rhinosinusitis|Participants with chronic rhinosinusitis
11572269|NCT00843856|Active Comparator|tacrolimus|Intervention type -drug tacrolimus therapy 2mg bd adjust to obtain levels of 5-12ng/L
11572270|NCT00843856|Active Comparator|tacrolimus and mycophenolate mofetil|tacrolimus 2mgs bd (adjusted to obtain levels 5-12mg/L and mycophenolate mofetil 500mg bd adjusted to obtain levels 1.5-3mg/L
11572271|NCT00843843|Active Comparator|9 hour sleep, then 3 hour nap and 6 hour sleep|
11572272|NCT00843843|Active Comparator|3 hour nap and 6 hour sleep, then 9 hour sleep|
11572273|NCT00843830|Experimental|Treatment Arm|Participants will receive tumoral irradiation and dendritic cell vaccination.
11572274|NCT00843817|Experimental|DRUG|PULMOZYME
11572275|NCT00843791|Placebo Comparator|Placebo|Treatment with placebo for 3 months before spectroscopy, hyperinsulinemic-euglycemic clamp, control diet, blood sampling.
11572276|NCT00843791|Active Comparator|2|Treatment with pioglitazone for 3 months before hyperinsulinemic-euglycemic clamp, control diet with blood sampling and spectroscopy.
11572277|NCT00843778|Experimental|Certolizumab Pegol|Certolizumab Pegol 200 mg every two weeks at the hospital by a nurse. Certolizumab Pegol 200 mg every two weeks at the patient's home done by patient (self-injection).
11572278|NCT00843765|Active Comparator|TCM integrated group|800 patients with acupuncture, massage and basic Chinese medicine treatment
11572279|NCT00843765|Active Comparator|Western Medicine group|400 patients with modern rehabilitation techniques and Western Medicine basic treatment
11572280|NCT00843739|Experimental|EMST|Four week device driven strength training program
11572281|NCT00843739|Sham Comparator|sham|Four week sham device driven training program
11572282|NCT00843739|No Intervention|Control|Four weeks of no intervention
11572283|NCT00843726|Experimental|Arm I|Patients undergo 1 high-dose fraction of stereotactic body radiotherapy (SBRT).
11572284|NCT00843726|Experimental|Arm II|Patients undergo 3 high-dose fractions (approximately 1 week apart) of SBRT.
11572285|NCT00843713|Placebo Comparator|Placebo|For subjects assigned to the placebo group, patients will take a matching placebo pill of 400 mg by mouth twice daily for 24 weeks in addition to taking their current HIV medication
11572286|NCT00843713|Active Comparator|Raltegravir|For subjects assigned to the active comparator group, they will receive raltegravir at 400 mg by mouth twice daily for 24 weeks in addition to continuing to take their current HIV medication
11572287|NCT00843700|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy, 16 individual sessions within 32 weeks
11572288|NCT00843700|Active Comparator|Individual Psychotherapy|Individual Psychotherapy, 16 individual sessions within 32 weeks
11572289|NCT00843661|Experimental|Ezetimibe and fenofibrate|
11572290|NCT00843661|Active Comparator|Pravastatin|
11572291|NCT00843648||preterms|mother and preterm babies
11572292|NCT00843648||term-bfing|term breastfed babies and mothers
11572293|NCT00843648||term-PIF|term non breastfed babies and mothers
11572294|NCT00843648||c-section|c-section babies and their mothers
11572295|NCT00843635|Experimental|Arm A - Tadalafil 10mg|Patients will receive 10mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
11572296|NCT00843635|Experimental|Arm B - Tadalafil 20mg|Patients will receive 20mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
11572297|NCT00843635|Placebo Comparator|Arm C - Placebo|Patients receive oral placebo once daily on days 1-20 in the absence of unacceptable toxicity.
11572298|NCT00843622|Experimental|1|Tobacco-based, smokefree product in pouch format for oral use, pouch size 1.0 or 0.5 g to be used ad libitum by participants
11572299|NCT00843622|Placebo Comparator|2|Non-tobacco, non-nicotine placebo product in pouch format for oral use, pouch size 1.0 g or 0.5 g, to be used ad libitum by the participants
11572300|NCT00843609|Experimental|Continuous glucose monitoring|Continuously wearing the FreeStyle Navigator continuous glucose monitor, displaying real-time glucose values and sounding alarms
11572301|NCT00843609|No Intervention|Control|Using SMBG with standard routine instructions
11572302|NCT00843596|Experimental|vacuum device - suction cup|
11572303|NCT00843583||resistant hypertension subjects|subjects with resistant hypertension
11572304|NCT00843570|No Intervention|1|Natural FER (frozen embryo replacement)
11572305|NCT00843570|Active Comparator|2|HRT-FER (Down regulated frozen embryo replacement)
11572306|NCT00843557||all ICU admissions|patients admitted to the ICU for greater then 72hrs
11572307|NCT00843544|Experimental|Integrative Medicine|
11572308|NCT00843544|No Intervention|Control|
11572309|NCT00843531|Experimental|RAD001 and erlotinib|"Each 28 day cycle:
~RAD001: 5 mg per day by mouth (self-administered) Erlotinib: 100 mg per day by mouth (self-administered)"
11572310|NCT00843518|Experimental|LY451395|3 milligram (mg) LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate
11572311|NCT00843518|Placebo Comparator|Placebo|Placebo orally twice daily for 12 weeks
11572312|NCT00843505|Experimental|1|Participants will take part in a telemedicine smoking cessation program.
11572313|NCT00843505|Active Comparator|2|Participants will take part in a telephone quitline smoking cessation program.
11572314|NCT00843492|Active Comparator|Nadroparin|After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days. Patients will then be followed up to five weeks (± one week) after the cast or brace removal.
11572315|NCT00843492|Experimental|Fondaparinux|After randomization (Day 1), subjects will receive subcutaneously, once daily, fondaparinux 2.5 mg (1.5 mg in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days. Patients will then be followed up to five weeks (± one week) after the cast or brace removal.
11572316|NCT00843479||Elderly NGT|Normoglycemic subjects 65-80 years old
11572317|NCT00843479||Middle-age NGT|Middle-age normoglycemic subjects 35 to 50 years old.
11572738|NCT00840450|Experimental|Paclitaxel + Imatinib Mesylate (Gleevec)|
11572318|NCT00843466|Active Comparator|Mild moisturizing Hand Cleanser|The test group will be provided with a mild moisturizing hand cleanser for all hand cleansing needs during the duration of the study.
11572319|NCT00843466|No Intervention|Current Hand Cleanser|The control group will continue to use their current cleanser for all hand washing.
11572320|NCT00843453|Other|1|Comparison of serum vitamin and B12 concentrations of PPI and non-PPI groups
11572321|NCT00843453|Experimental|2|Comparison of baseline and end of treatment serum vitamin B12 and MMA concentrations.
11572322|NCT00843440|Experimental|Bevacizumab|Study using a Gehan design, 7 patients will be included in the first phase and 18 additional patients will enter the second phase.
11572323|NCT00843427|Experimental|Aphasia - CIAT|Patients with aphasia >1 year after left MCA stroke who will be randomized to receive CIAT
11572324|NCT00843427|No Intervention|Aphasia - observation|Patients with aphasia >1 year after left MCA stroke who will be randomized to no intervention (observation)
11572325|NCT00843388|Active Comparator|1|60 days treatment with tablet hexalacton 25 mg OD.
11572326|NCT00843388|Placebo Comparator|2|Inactive drug of 25 mg OD
11572327|NCT00843375||Normal|Subjects who have had a colonoscopy and no adenomas or cancer was found.
11572328|NCT00843375||Adenomas|Subjects who had an adenoma found on colonoscopy. All samples must be collected before the adenoma is removed.
11572329|NCT00843375||Colorectal Adenocarcinoma|Subjects who have confirmed colorectal carcinoma. All samples must be collected before the cancer is removed.
11572330|NCT00843375||High Risk Normal|Subjects who had a colonoscopy without adenomas or cancer AND have a history of adenomas, colorectal cancer (greater than 3 years ago) or a family history of cancer or adenomas.
11572331|NCT00843362|Experimental|1|24-hours vaginal dinoprostone pessary
11572332|NCT00843362|Active Comparator|2|Vaginal dinoprostone gel
11572333|NCT00843349|Active Comparator|900 mg Phosphate Diet-LC|dietary phosphorus restriction (900 mg/day of phosphorus) + phosphorus binder (Lanthanum Carbonate)
11572334|NCT00843349|Active Comparator|Ad Libitum Diet-LC|no dietary intervention + phosphorus binder (Lanthanum Carbonate)
11572335|NCT00843349|Active Comparator|900 mg Phosphate Diet-LC Placebo|dietary phosphorus restriction (900 mg/day of phosphorus) + placebo
11572336|NCT00843349|Placebo Comparator|Ad Libitum Diet-LC Placebo|no dietary intervention + placebo
11572337|NCT00843336|Experimental|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that measures urinary estrogen and LH and provides users with low, high, or peak fertility readings.
11572338|NCT00843336|Active Comparator|Cervical mucus monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
11572339|NCT00843310|Experimental|ReMeDex|"Treatment phase (28 days/cycle x 6 cycles):
~Lenalidomide: 10 mg/day orally on days 1-21, followed by 7 days of rest. Melphalan: 4 mg/m2 daily on days 1-4. Dexamethasone: 40 mg daily on days 1, 8, 15 and 22.
~Maintenance Phase (for subjects who achieve partial response or better at the end of the treatment phase):
~lenalidomide: 10 mg/day orally on days 1-21 followed by 7 days of rest (28 days/cycle) for a maximum of 24 cycles."
11572340|NCT00843297|Active Comparator|CG|Coolgard: invasive Cooling
11572341|NCT00843297|Active Comparator|AS|ArcticSun: Surface-Cooling
11572342|NCT00843297|Sham Comparator|UnCOOL|No Cooling-Therapy due to non-operational cooling-devices
11572343|NCT00843284||Patients with neuropathic pain|
11572344|NCT00843271||MESA Lung|MESA-Lung is an ancillary study of the Multi-Ethnic Study of Atherosclerosis (MESA). MESA, established in 1999, is well characterized, multi-ethnic (white, Black, Hispanic and Chinese), and multi-center (Columbia, Johns Hopkins, Northwestern, UCLA, Minnesota,and Wake Forest) prospective cohort study. MESA-Lung included a 60% random sample of the MESA cohort at the six Field Centers in Exam 3 and Exam 4, stratified on race/ethnicity.
11572345|NCT00843258|No Intervention|Active Sonographic surveillance|Follow-up at 1.5 and 3 months (Ultrasound,Clinical examination), at 6 and 12 months (clinical examination, pelvic X-ray)
11572346|NCT00843258|Experimental|Abduction treatment|Treatment (abduction splint) from 0-6 weeks, follow-up at 1.5 and 3 months (clinical examination and ultrasound) and at 6 and 12 months (clinical examination and pelvic x-ray)
11572347|NCT00843245||heart failure|Heart failure attending a HF clinic with or without clinical decompensation
11572348|NCT00843232||Elderly T2DM|Elderly T2DM subjects 65 to 80 years old
11572349|NCT00843232||Middle-age T2DM|Middle-age T2DM subjects 35 to 50 years old
11572350|NCT00843219||PET/CT Scan|
11572351|NCT00843193|Experimental|GSK679586|Subjects will receive three, once monthly intravenous administration of 10 mg/kg of GSK679586, according to randomization
11572352|NCT00843193|Placebo Comparator|PLACEBO|Subjects will receive three, once monthly intravenous administration of saline, according to randomization
11572353|NCT00843180|Experimental|massage|
11572354|NCT00843180|No Intervention|control|usual care only as control arm
11572355|NCT00843167|Experimental|Sulforaphane Supplement|Patients receive oral broccoli sprout extract supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.
11572356|NCT00843167|Placebo Comparator|Placebo|Patients receive oral placebo supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.
11572357|NCT00843154|Experimental|Candesartan QD|
11572358|NCT00843154|Active Comparator|Standard chronic heart disease therapy|
11572359|NCT00843141|Experimental|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
11572360|NCT00843141|Active Comparator|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
11572361|NCT00843128|Experimental|1: RAGT|Following randomization, 20 patients will be treated with RAGT, 12 sessions over three weeks
11572362|NCT00843128|Active Comparator|2: Control|The control group will be treated by CWT, 12 sessions in three weeks.
11572363|NCT00843115||Observational|This study was non-interventional and simply followed for 3 months patients initiating a treatment with donepezil
11572364|NCT00843089|No Intervention|1|Standard care
11572365|NCT00843089|Experimental|2|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
11572366|NCT00843063|Active Comparator|pantoprazole|pantoprazole 20 mg om and matching placebo nocte
11572368|NCT00843050|Experimental|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
11572369|NCT00843037|Experimental|Open label - Sunitinib|Sunitinib, 50mg daily, once daily for 4 weeks followed by a 2-week break
11572370|NCT00843024|Experimental|Sumatriptan and Naproxen 1|Sumatriptan succinate and naproxen sodium combination 10mg/60mg
11572371|NCT00843024|Experimental|Sumatriptan and Naproxen 2|Sumatriptan succinate and naproxen sodium combination 30mg/180mg
11572372|NCT00843024|Experimental|Sumatriptan and Naproxen 3|Sumatriptan succinate and naproxen sodium combination 85mg/500mg
11572373|NCT00843024|Placebo Comparator|Placebo|Placebo to match
11572374|NCT00843011|Experimental|Arm 1|Orvepitant 60 mg
11572375|NCT00842998|Experimental|1 - Trastuzumab|Day1 Week1: 8 mg/kg iv in 90 min. Following 1st week: 2 mg/kg once/weekly for 8 weeks
11572376|NCT00842998|Experimental|2 - Lapatinib|1500 mg/die orally
11572377|NCT00842985|Other|drug condition|Participants received each drug condition in sequential order across 4 test days. Not all participants received the interventions in the same order.
11572378|NCT00842959|Other|ZO|XL Stabi ZO or Invent ZO
11572379|NCT00842946|Experimental|Exposure w/ Acceptance-Based Rationale|Behavioral exposure within the context of psychological acceptance.
11572380|NCT00842946|Active Comparator|Exposure w/ Habituation-Based Rationale|Behavioral exposure within the context of habituation.
11572381|NCT00842933|Experimental|Experimental group|Corticosteroids discontinued 24 hours after cessation of vasopressor therapy or 7 days, which ever comes first.
11572382|NCT00842933|Active Comparator|Standard of care group|Standard corticosteroid therapy given for 7 days as treatment for adrenal insufficiency during septic shock.
11572383|NCT00842920|Placebo Comparator|Placebo|Placebo or 20 mg Simvastatin (stratified by prior use of statins)
11572384|NCT00842920|Experimental|Simvastatin 60 mg|Simvastatin 60 mg once daily
11572385|NCT00842920|Experimental|Simvastatin 20 mg|Simvastatin 20 mg once daily
11572386|NCT00842907|Active Comparator|oral isotretinoin|Twelve subjects will be treated with oral isotretinoin 20.0 mg, once a day, every other day, for 24 weeks.
11572387|NCT00842907|Active Comparator|tretinoin|Twelve patients will be treated with 0,05% tretinoin cream applied on face and forearms at night and moisturizer broad-spectrum sunscreen twice a day.
11572388|NCT00842894||Insulin detemir|
11572389|NCT00842894||Biphasic insulin aspart 30|
11572390|NCT00842881|No Intervention|a|healingstone
11572391|NCT00842881|No Intervention|b|stone powder
11572392|NCT00842855||1|274 GERD patients, partial responders to PPI treatment
11572393|NCT00842842|Active Comparator|1: tacks|mesh fixation with tacks
11572394|NCT00842842|Experimental|2: glue|mesh fixation with glue
11572395|NCT00842829|Experimental|FBT 100 mcg|During the Titration Period, participants took fentanyl buccal tables (FBT) with a starting dose of 100 mcg until they reached an effective dose, with a maximum dose of 800 mcg and a maximum timeframe of 7 days. Participants who reached an effective dose entered the Open-label Treatment Period, whose length depended on how long was needed to treat up to 8 episodes of breakthrough pain (BTP) with FBT (maximum of 8 days). The length of the Continuation Period (when applicable) varied from country to country, up to until FBT was commercially available in that country.
11572396|NCT00842829|Active Comparator|FBT 200 mcg|During the Titration Period, participants took fentanyl buccal tables (FBT) with a starting dose of 200 mcg until they reached an effective dose, with a maximum dose of 800 mcg and a maximum timeframe of 7 days. Participants who reached an effective dose entered the Open-label Treatment Period, whose length depended on how long was needed to treat up to 8 episodes of breakthrough pain (BTP) with FBT (maximum of 8 days). The length of the Continuation Period (when applicable) varied from country to country, up to until FBT was commercially available in that country.
11572397|NCT00842816|Experimental|1|10 mg ST101
11572398|NCT00842816|Experimental|2|60 mg ST101
11572399|NCT00842816|Experimental|3|120 mg ST101
11572400|NCT00842816|Placebo Comparator|4|Placebo
11572401|NCT00842803|No Intervention|Control Group|Patients in this group will not be allowed albumin or any other colloids fluid for the first 7 days post-operative
11572402|NCT00842803|Experimental|Albumin group|Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
11572403|NCT00842777|Experimental|Parent group treatment|Manualized group treatment of parents. Allocation of 4-6 parental couples of children with similar age.
11572404|NCT00842777|Active Comparator|Parent self-help groups|Professionals initiate and organize the self-help groups initially. The groups will not receive any teaching or counseling concerning eating and physical activity.
11572405|NCT00842764|Experimental|Holmium: YAG laser|Subjects will go under minimally invasive Holmium: YAG laser blepharoplasty
11572406|NCT00842751|Placebo Comparator|Testosterone Undecanoate + placebo finasteride|Acyline 300mcg/kg subcutaneous on days 1, 15 and 29 + Testosterone Undecanoate (TU)200mg twice daily, orally for 7 days + placebo finasteride twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)
11572407|NCT00842751|Experimental|Testosterone Undecanoate + Finasteride 0.5mg|Acyline 300mcg/kg subcutaneous on days 1, 15 & 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 0.5mg twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)
11572408|NCT00842751|Experimental|Testosterone Undecanoate + Finasteride 1mg|Acyline 300mcg/kg subcutaneous on days 1, 15 & 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 1mg twice daily, orally for 7 days during one of the three intervention periods ((First Intervention, Second Intervention or Third Intervention)
11572409|NCT00842738|Active Comparator|Mindfulness meditation|Women with mild dysplasia offered mindfulness meditation
11572410|NCT00842738|Other|No meditation|Women with mild dysplasia offered health care services as usual
11572411|NCT00842738|Other|Controls|Women with normal cervical cells
11572412|NCT00842712|Experimental|Safety run-in part: Cil (1000 mg) + Cetuximab + Cis + Gem|
11572413|NCT00842712|Experimental|Safety run-in part: Cil (1000 mg) + Cetuximab + Cis + Vin|
11572414|NCT00842712|Experimental|Safety run-in part: Cil (2000 mg) + Cetuximab + Cis + Gem|
11572415|NCT00842712|Experimental|Safety run-in part: Cil (2000 mg) + Cetuximab + Cis + Vin|
11572416|NCT00842712|Experimental|Randomized part: Cil (Once Weekly) + Cetuximab + Chemotherapy|
11572417|NCT00842712|Experimental|Randomized part: Cil (Twice Weekly) + Cetuximab + Chemotherapy|
11572418|NCT00842712|Active Comparator|Randomized part: Cetuximab + Chemotherapy|
11572419|NCT00842699||1|patients receiving IL-2 receptor antagonist (Simulect) as induction treatment
11572420|NCT00842699||2|patients receiving Thymoglobulin as induction treatment
11572421|NCT00842673|Experimental|1|30 mg ST101
11572422|NCT00842673|Experimental|2|90 mg ST101
11572423|NCT00842673|Experimental|3|180 mg ST101
11572424|NCT00842673|Placebo Comparator|4|Placebo
11572425|NCT00842660|Experimental|Gemzar,survival|
11572426|NCT00842634|Experimental|Cohort 1|Patients who have failed two more HAART regimens
11572427|NCT00842634|Experimental|Cohort 2|Patients doing well on a stable antiretroviral medication
11572428|NCT00842634|Experimental|Cohort 3|Patients who have an undetectable viral load on HAART who have exhibited suboptimal CD4+ T cell gains during long term antiretroviral therapy. This group will not participate in the structured treatment interruption.
11572429|NCT00842621||1|Pediatric participants with severe sickle cell disease (HbSS or Hb S/β°-thalassemia) who are not receiving treatment, e.g., hydroxyurea or chronic transfusions
11572430|NCT00842621||2|Pediatric participants with other forms of SCD or severe sickle cell disease patients (HbSS or Hb S/β°-thalassemia) being treated with hydroxyurea or chronic transfusions
11572431|NCT00842621||3|Pediatric and adult participants with other non-sickling hematological disorders
11572432|NCT00842608|Experimental|Haloperidol Eligible Intervention|0.5-1mg Haloperidol Q8h for 7 days, reduced exposure to anticholinergics, reduced exposure to benzodiazepines
11572433|NCT00842608|Active Comparator|Haloperidol Eligible Usual Care|Usual care
11572434|NCT00842608|Experimental|Haldol-Ineligible Arm|"Haldol-Ineligible arm for patients with contraindications for Haldol, unresolvable prolonged QTc, history of torsades de pointes, or history of seizures.
~Patients are randomized and will still receive:
~reduced exposure to anticholinergics, reduced exposure to benzodiazepines"
11572435|NCT00842608|Active Comparator|Haldol Ineligible Usual Care|Usual Care
11572436|NCT00842595|Experimental|R NIMP|(Mabthera®) Rituximab IV 375 mg/m²day 1 (Navelbine ®)Vinorelbine IV 25mg/m² day 1 and day 5 (Novantrone®)Mitoxantrone IV 10 mg/m² day 1 (Holoxan®)Ifostamide IV 1000 mg/m²day 1 to day 5 (Cortancyl®)prednisone oral day 1 to day 5
11572437|NCT00842582|Experimental|Single group assignment|Patients will receive Azacitidine at 20, 40, or 75 milligrams per meter squared subcutaneous once daily for 7 days.
11572438|NCT00842569||Normal weighted|BMI<25
11572439|NCT00842569||Obese|BMI>30
11572440|NCT00842556|Active Comparator|Dapagliflozin|
11572441|NCT00842556|Active Comparator|Glimepiride|
11572442|NCT00842556|Active Comparator|Dapagliflozin + Glimepiride|
11572443|NCT00842556|Active Comparator|Sitagliptin|
11572444|NCT00842556|Active Comparator|Dapagliflozin + Sitagliptin|
11572445|NCT00842543|Experimental|Overweight|Overweight Boys receiving either Fruit and Vegetable Juice Concentrate (FVJC) or Placebo, 1 capsule, twice a day, for 6 months
11572446|NCT00842543|Experimental|Lean|Lean Boys receiving either Fruit and Vegetable Juice Concentrate (FVJC) or Placebo, 1 capsule, twice a day, for 6 months
11572447|NCT00842530|Experimental|CYD Dengue Vaccine Group|Participants (both Cohort 1 and 2) received 3 injections of the CYD Dengue vaccine, 1 injection each at 0, 6, and 12 months.
11572448|NCT00842530|Placebo Comparator|Control Group|Participants (Cohort 1) received rabies vaccine at Month 0 and placebo at 6 and 12 months. Participants (Cohort 2) received placebo at 0, 6, and 12 months.
11572449|NCT00842517|Experimental|Extended|36-week duration contingency management program
11572450|NCT00842517|Active Comparator|Standard|12-week duration contingency management program
11572451|NCT00842504|Other|Micafungin|3 mg/kg given once
11572452|NCT00842491|Experimental|endostar+chemotherapy|
11572453|NCT00842478|Experimental|Raspall|
11572454|NCT00842478|No Intervention|Control|
11572455|NCT00842465||1|benign breast diseases
11572456|NCT00842465||2|breast cancer
11572457|NCT00842465||3|control
11572458|NCT00842452|Experimental|Oral Topotecan|
11572459|NCT00842439|Experimental|Cognitive Behavioral Intervention (CBI)|Participants will meet with an interventionist once a week for 12 weeks. They will discuss the child's behavior, will learn coping skills and how to deal with other people.
11572460|NCT00842439|Experimental|Nutritional Supplements (NUT)|Participants will be asked to take omega-3 supplements, multivitamin tablets, and calcium tablets every day for 12 weeks.
11572461|NCT00842439|Experimental|CBI + NUT|Participants will receive both the cognitive behavioral intervention and the nutritional supplements.
11572462|NCT00842439|No Intervention|No intervention|Participants will not be asked to come for sessions or any other intervention. They will receive a list of the types of help that are available if they are interested in following up on their own.
11572463|NCT00842426|No Intervention|Usual Care|Usual Care
11572464|NCT00842426|Experimental|Self-Management Program|Online Self-Management.
11572465|NCT00842426|Experimental|Care Management Program|Care management lifestyle modification program with intensive intervention phase with exercise and nutrition specialist. Followed by a online self-management phase.
11572466|NCT00842413||1|The study compares brain-damaged patients with healthy ones on two psychophysical tasks.
11572467|NCT00842413||2|The study does not intervene on the brain-damaged patients, it merely compares their behaviour with that of healthy patients on a range of psychophysical tasks.
11572468|NCT00842387||1|Patients with symptoms suggestive of GERD, managed according to a new structured and implemented pathway
11572469|NCT00842387||2|Patients with symptoms suggestive of GERD, managed according to usual clinical practice.
11572470|NCT00842374||Non-STEMI ACS|
11572471|NCT00842361|Active Comparator|Mix30|
11572472|NCT00842361|Experimental|SIAC|
11572569|NCT00841620|Active Comparator|1|Haemorrhoidectomy a.m. Milligan for grade 3-4 haemorrhoids
11572473|NCT00842348|Experimental|Lanreotide (Autogel formulation)|Patients from the preceding DB study (Study 726) were treated with open label lanreotide Autogel 120 mg by deep subcutaneous injections every 28 days. Patients were included if they had been treated with lanreotide (Autogel formulation) or placebo in DB Study 726 and had stable disease at the end of the 96-week treatment period, or if they had received placebo and had disease progression at any time during Study 726. Safety data were based on the safety population patients who received lanreotide in Study 729). The main efficacy analysis was based on the ITT population (patients randomised in Study 726 regardless of whether they continued into Study 729).
11572474|NCT00842335|Experimental|JI-101|
11572475|NCT00842322|Experimental|High fluid intake|fluid intake of 4 litres per day
11572476|NCT00842322|Experimental|normal fluid intake|Fluid intake of 2 litres per day
11572477|NCT00842309|Active Comparator|D-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
11572478|NCT00842309|Placebo Comparator|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
11572479|NCT00842296|Experimental|Seg. RF Ablation with CLF catheter|Single Arm with CLF Catheter
11572480|NCT00842283||dermatologic diseases|skin tissue sample
11572481|NCT00842270|Experimental|2|4,5 mg/kg/day
11572482|NCT00842270|Experimental|3|6 mg/kg/day
11572483|NCT00842270|Placebo Comparator|4|matching placebo for AB1010 3, 4,5 and 6 mg/kg/day
11572484|NCT00842270|Experimental|1|AB1010 3 mg/kg/day
11572485|NCT00842257|Experimental|Panitumumab|Panitumumab administered by a central line infusion on days 1 and 15 of each 4 week cycle.
11572486|NCT00842244|Experimental|A|
11572487|NCT00842231||Visual performance measures|Collection of visual performance measures in subjects with low levels of astigmatism.
11572488|NCT00842205|Active Comparator|1 HCV positive pts|"Patients with chronic HCV infection undergoing liver biopsy followed by antiviral treatment.
~peg-IFN alfa 2a 180ug s.c. QW + ribavirin 1000-1200mg p.o. daily 48weeks or peg-IFN alfa 2b 1.5 ug/kg s.c. QW + ribavirin 100-1200mg p.o. daily 48 weeks"
11572489|NCT00842205|No Intervention|2 Other liver disease|pts. with NASH (or other liver disease) undergoing liver biopsy.
11572490|NCT00842192||A|
11572491|NCT00842179||Manual Closure|Patients who received vascular closure with manual compression after percutaneous coronary intervention (PCI)
11572492|NCT00842179||Perclose Device|Patients who received vascular closure with the Perclose VCD after percutaneous coronary intervention (PCI)
11572493|NCT00842153|Experimental|Clobetasol Propionate Foam|Topical foam formulation that includes clobetasol propionate (Steroid)
11572494|NCT00842153|Placebo Comparator|Vehicle Foam|Vehicle foam is the same as the clobetasol propionate foam except it does not include the active drug.
11572495|NCT00842140|Active Comparator|1|This group will receive an oral contraceptive containing 0,03mg ethynylestradiol and 2mg chlormadinone acetate
11572496|NCT00842140|Experimental|2|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
11572497|NCT00842140|Experimental|3|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg metformin.
11572498|NCT00842114|Experimental|R+CVP+IFN|8 cycles of Rituximab plus CVP chemotherapy (Bagley's et al) associated with Interferon for 12 weeks
11572499|NCT00842101||pressure monitor|Tibial Fracture
11572500|NCT00842088|Experimental|Active|
11572501|NCT00842088|Placebo Comparator|Placebo|
11572502|NCT00842075|Experimental|1 Symlin|Subcutaneous injection of pramlintide prior to each meal with reduction of mealtime bolus insulin
11572503|NCT00842075|No Intervention|2 Usual Regimen|Usual bolus insulin dose at each meal
11572504|NCT00842062|Experimental|MyoScience Tissue Remodeling Device|
11572505|NCT00842049|Experimental|Study|Insertion of lumbar drain
11572506|NCT00842049|Other|Control|Normal clinical management without lumbar drain
11572507|NCT00842036|Active Comparator|ANft|12- step Al/Nar-Anon Facilitation
11572508|NCT00842036|Experimental|TEnT|Treatment Entry Training
11572509|NCT00842036|Experimental|CRAFT|Community Reinforcement and Family Training
11572510|NCT00842023|Experimental|Nesiritide Infusion|Nesiritide: 2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours.
11572511|NCT00842023|Active Comparator|Nitroglycerin Infusion|Nitroglycerin was initiated at 10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP<or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment.
11572512|NCT00842010||HND|Patients with hyperglycemia, without previous diagnosis of diabetes
11572513|NCT00842010||DH|Patients that have previous diagnosis of Diabetes Mellitus
11572514|NCT00842010||NHND|Patient with NO previous diagnosis of diabetes, and no hyperglycemia
11572515|NCT00841984||1|patients with complex neurological disease of unknown cause
11572516|NCT00841984||2|positive controls : patients with already known metabolic disease for whom we already have CSF or urines
11572517|NCT00841984||3|negative controls: patients with non metabolic neurological disorders of known cause hospitalized for a lumbar puncture
11572518|NCT00841971|Experimental|anidulafungin|anti-fungal agent
11572519|NCT00841971|Active Comparator|Fluconazole|anti-fungal agent
11572520|NCT00841945|Active Comparator|1|"Chemotherapy + Radiotherapy
~- 4 or 6 R CHOP courses regimen every 14 days R CHOP = Rituximab, Doxorubicin, Vincristine and prednisone
~Radiotherapy 40 gray on initial nodes"
11572521|NCT00841945|Experimental|2|"Chemotherapy
~- 4 or 6 R CHOP courses regimen every 14 days R CHOP = Rituximab, Doxorubicin, Vincristine and prednisone"
11572522|NCT00841932||Fractional Flow Reserve|Patients with suspected coronary artery disease undergoing FFR to assess physiological significance of stenosis
11572565|NCT00841659|Active Comparator|Paxil®|Paxil® 40 mg Tablet (reference) dosed in first period followed by Paroxetine HCl 40 mg Tablet (test) dosed in second period
11572566|NCT00841646|Other|1|
11572567|NCT00841633|No Intervention|1|No induced hypertension (reference group)
11572568|NCT00841633|Experimental|2|Induced hypertension with a MAP of 30 mmHg above the average MAP on the previous day; during 24-36 hours, until a perfusion CT scan has been performed
11572523|NCT00841919|Active Comparator|2|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
11572524|NCT00841919|Experimental|1|"The study group will receive Insulin Glargine as basal insulin and bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff"
11572525|NCT00841906|Other|Alice PDx with only written instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device.
11572526|NCT00841906|Other|Alice PDx with written and verbal instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device.
11572527|NCT00841893|Experimental|1|Mustard
11572528|NCT00841893|Experimental|2|Placebo
11572529|NCT00841880|Experimental|1|2 weeks run-in of Ramipril 5 mg followed by 8 weeks of Ramipril + Felodipine
11572530|NCT00841880|Active Comparator|2|2 weeks run-in of Ramipril 5 mg followed by 8 weeks of Ramipril 10 mg
11572531|NCT00841867||1|Subjects 18-80 years of age who have previously undergone partial pancreatectomy due to a benign lesion
11572532|NCT00841867||2|Healthy control subjects, 18-80 years of age, who have not had partial pancreatectomy.
11572533|NCT00841854|Active Comparator|PBMT7|pantoprazole 40mg bid, bismuth 300mg qid, metronidazole 500mg tid,tetracycline 500mg qid for 7 days
11572534|NCT00841854|Active Comparator|PBMT14|pantoprazole 40mg bid, bismuth 300mg qid, metronidazole 500mg tid,tetracycline 500mg qid for 14 days
11572535|NCT00841841|Experimental|Dipyrone|"Analgesic affectiveness using Dipyrone (500mg) as a postoperative drug for pain relief.
~Intervention: Drug: dipyrone and acetaminophen"
11572536|NCT00841841|Experimental|Acetaminophen|"Analgesic affectiveness using Acetaminophen (750mg) as a postoperative drug for pain relief.
~Intervention: Drug: dipyrone and acetaminophen"
11572537|NCT00841828|Experimental|Experimental|Epirubicin + Cyclophosphamide -> Docetaxel + Lapatinib
11572538|NCT00841828|Active Comparator|Control|Epirubicin + Cyclophosphamide -> Docetaxel + Trastuzumab
11572539|NCT00841815|Experimental|Amlodipine Besylate|Amlodipine Besylate 10 mg tablet (test) dosed in first period followed by Norvasc® 10 mg tablet (reference) dosed in second period
11572540|NCT00841815|Active Comparator|Norvasc®|Norvasc® 10 mg tablet (reference) dosed in first period followed by Amlodipine Besylate 10 mg tablet (test) dosed in second period
11572541|NCT00841802|Experimental|Prednisone|Steroid medication
11572542|NCT00841802|No Intervention|No Intervention|No Intervention
11572543|NCT00841789|Experimental|Arm 1 -Etanercept|Drug - Treatment with Etanercept as adjunct to standard treatment with IVIG and aspirin
11572544|NCT00841789|Placebo Comparator|2|Placebo
11572545|NCT00841776|Active Comparator|Duac gel|Clindamycin and benzoyl peroxide gel
11572546|NCT00841776|Active Comparator|Ziana gel|Clindamycin and tretinoin gel
11572547|NCT00841763|Experimental|TIV + aH5N1|First dose of the non-adjuvanted trivalent influenza virus vaccine(TIV) followed by two doses of the adjuvanted monovalent influenza virus vaccine (aH5N1)
11572548|NCT00841763|Active Comparator|PL + aTIV|First dose of placebo (PL-saline) followed by two doses of the adjuvanted trivalent influenza virus vaccine (aTIV)
11572549|NCT00841750|Experimental|No chest tube|No chest tube left in the pleural cavity at the end of a VATS pulmonary wedge resection.
11572550|NCT00841750|Active Comparator|Chest tube|Chest tube left in the pleural cavity at the end of a VATS pulmonary wedge resection.
11572551|NCT00841737|Experimental|Psychoeducational group intervention|Psychoeducational group received weekly a psychoeducational intervention during a period of 12 weeks run by a nurses.
11572552|NCT00841737|Active Comparator|Control group|Individual conventional care
11572553|NCT00841724|Active Comparator|Busilvex, Fludara, Thymoglobuline|D-6: Fludara D-5: Fludara + Busilvex D-4: Fludara + Busilvex D-3: Fludara + Busilvex D-2: Fludara + Thymoglobuline D-1: Thymoglobuline D0: graft infusion
11572554|NCT00841711|Other|Behavioral counseling|
11572555|NCT00841698|Experimental|Paroxetine|Paroxetine HCl 40 mg Tablet (test) dosed in first period followed by Paxil® 40 mg Tablet (reference) dosed in second period
11572556|NCT00841698|Active Comparator|Paxil®|Paxil 40 mg Tablet (reference) dosed in first period followed by Paroxetine HCl 40 mg Tablet (test) dosed in second period
11572557|NCT00841685|Experimental|1|Goldlock
11572558|NCT00841685|Active Comparator|2|Visicoil smallest size
11572559|NCT00841685|Active Comparator|3|Visicoil larger size
11572560|NCT00841685|Active Comparator|4|Bard goldmarker smallest size
11572561|NCT00841685|Active Comparator|5|Bard goldmarker larger size
11572562|NCT00841672|Experimental|Aliskiren/amlodipine 300/10 mg tablet|Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg.
11572563|NCT00841672|Active Comparator|Amlodipine 10 mg capsule|Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg.
11572564|NCT00841659|Experimental|Paroxetine|Paroxetine HCl 40 mg Tablet (test) dosed in first period followed by Paxil® 40 mg Tablet (reference) dosed in second period
11572570|NCT00841620|Active Comparator|2|Stapled anopexy for grade 3-4 haemorrhoids
11572571|NCT00841607|Experimental|Pancreaticojejunostomy|Pancreaticojejunostomy reconstruction used following Whipple surgery.
11572572|NCT00841607|Active Comparator|Pancreaticogastomy|Pancreaticogastomy reconstruction used following Whipple surgery.
11572573|NCT00841594|Active Comparator|1|"MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
~Applied to the hand."
11572574|NCT00841594|Active Comparator|2|"MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
~Applied to the chest."
11572575|NCT00841581|Experimental|Lucentis|"All patients receive iL for for first 6 months of study. At 6 months - patients are classified as responders or non-responders. Responders receive iL PRN based on OCT,clinical exam etc. Non-responders are seen again at 12 months for repeat investigations."
11572576|NCT00841568|Experimental|1|
11572577|NCT00841555|Experimental|Hypofractionation Radiotherapy+Temozolomide|Patients will receive temozolomide PO daily for 5 weeks. Beginning week 1 after initiation of temozolomide therapy, patients undergo HIMRT times a week for a total of 15 fractions.
11572578|NCT00841542|Experimental|Amlodipine Besylate|Amlodipine Besylate 10 mg tablet (test) dosed in first period followed by Norvasc® 10 mg tablet (reference) dosed in second period
11572579|NCT00841542|Active Comparator|Norvasc®|Norvasc® 10 mg tablet (reference) dosed in first period followed by Amlodipine Besylate 10 mg tablet (test) dosed in second period
11572580|NCT00841516|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
11572581|NCT00841516|Experimental|80 µg rBet v1-FV Immunotherapy|All randomized patients were treated with either placebo or 80 µg rBet v1-FV (maintenance dose) for 2 years.
11572582|NCT00841503||12 healthy volunteers|Healthy volunteers are randomized to 1 of 4 products over 4 weekly visits: i)buckwheat crackers;ii)crackers without buckwheat; iii)oral glucose; iv) oral sugar substitute, followed by 7 days of buckwheat crackers.
11572583|NCT00841503||12 Participants with Type 2 diabetes|Volunteers with type 2 diabetes are randomized to 1 of 4 products over 4 weekly visits: i)buckwheat crackers;ii)crackers without buckwheat; iii)oral glucose; iv) oral sugar substitute, followed by 7 days of buckwheat crackers.
11572584|NCT00841490||1|Intellectually & Developmentally Disabled Adults
11572585|NCT00841490||2|Control Group of Adults without Intellectual & Developmental Disabilities
11572586|NCT00841477|No Intervention|A1|standard behavioral intervention, standard HB vaccine schedule (0,1,6month)
11572587|NCT00841477|Active Comparator|A2|standard behavioral intervention, accelerated HB vaccine schedule (0,1,2month)
11572588|NCT00841477|Active Comparator|B1|enhanced behavioral intervention, standard vaccine schedule
11572589|NCT00841477|Active Comparator|B2|enhanced behavioral intervention, accelerated vaccine schedule (0,1,2MONTH)
11572590|NCT00841438|Active Comparator|Provisional use of Clotinab|Provisional use of clotinab
11572591|NCT00841438|Experimental|Upstream use of clotinab|early upstream use of clotinab
11572592|NCT00841425||Swimmers|
11572593|NCT00841412|Experimental|Immediate Intervention Group|Immediate Intervention: Long term care units assigned to the Immediate Intervention group were first to receive the staff training and management intervention to improve nutritional care processes.
11572594|NCT00841412|Active Comparator|Delayed Intervention Group|Delayed Intervention: Long term care units assigned to the Delayed Intervention group were monitored under usual care conditions to serve as a control for the Immediate Intervention group. Then, these units received the staff training and management intervention at a later date.
11572595|NCT00841399|Experimental|E75 + GM-CSF vaccine|The dose escalation scheme is for three patients to receive each of the doses, 100, 500, and 1,000 mcg of peptide + 250 mcg GM-CSF each month for 6 months until the maximum tolerated dose is determined. Patients who receive the vaccine are HLA-A2+ and/or HLA-A3+. Responses to the vaccine are measured via immunologic assays.
11572596|NCT00841399|No Intervention|Control/observation|HLA-A2- and HLA-A3- patients do not receive the E37 + GM-CSF vaccine, but are instead enrolled to the control arm for observation.
11572597|NCT00841386|Experimental|Cross-linking treatment|Topical anesthesia (lidocaine jelly 2%) will be used. The central 9 mm of corneal epithelium will be removed cautiously with an Amoils brush. Riboflavin 0.1% solution will be applied (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) to the cornea every 2-3 minutes for 15 minutes and then every 5 minutes thereafter. The UV source will be from the CBM VEGA X-linker (CSO, Florence, Italy). A wavelength of 370 nm will be used to direct 5.4 J/cm2 to the area of cornea debrided for 30 minutes. The distance from the UV source to the cornea will be 1.5 to 5.4 cm.
11572598|NCT00841386|Sham Comparator|Sham treatment group|Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and a 2% methylcellulose solution combined with 1% fluorescein dye will be applied to the cornea every 5 minutes for 30 minutes. The patient will be placed under the UV device, but instead of the UV light, the LED aiming beam will be applied for 30 minutes.
11572599|NCT00841373|Active Comparator|1|Panretinal Photocoagulation
11572600|NCT00841373|Active Comparator|2|Ranibizumab Supplementing Panretinal Laser Photocoagulation
11572601|NCT00841360||HIV Positive|"Participant self-discloses as HIV positive.
~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
11572602|NCT00841360||HIV Negative|"Participant self-discloses as HIV negative (based on receiving a negative HIV test within 12 months prior to study consent).
~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
11572603|NCT00841360||HIV Status Unknown|"Participant self-discloses as HIV negative (no history of prior HIV testing, or HIV screening more than 12 months prior to date of study consent).
~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
11572665|NCT00840996|Placebo Comparator|Placebo|Perioperative placebo IV infusion besides the standard anesthesia care, including general anesthesia and postoperative patient controlled analgesia.
11572604|NCT00841360||Friendship Network Members|Friendship network members will also consist of sexually experienced females, aged 13 years and older. Although most members are expected to be of African American race and/or Hispanic/Latina ethnicity, all races and ethnicities will be included.
11572605|NCT00841347|No Intervention|1|Study of habitual sleep length on non obese teen group
11572606|NCT00841347|Experimental|2|Study of habitual sleep length period followed by extended sleep length period on obese teen group
11572607|NCT00841347|Experimental|3|Study of extended sleep length period followed by habitual sleep length period on obese teen group
11572608|NCT00841334|Experimental|1|ACTION
11572609|NCT00841334|Active Comparator|2|Usual care
11572610|NCT00841321|Active Comparator|Arm 1|Subjects with multiple sclerosis and documented cognitive impairment will be randomized to take the intervention or placebo.
11572611|NCT00841321|Placebo Comparator|Arm 2|Subjects with multiple sclerosis and documented cognitive impairment will be randomized to receive the placebo.
11572612|NCT00841308|Active Comparator|Usual care|
11572613|NCT00841308|Active Comparator|Home blood pressure monitoring|
11572614|NCT00841295|Experimental|Carnitine|Intervention 'Parenteral L-carnitine supplementation' Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
11572615|NCT00841295|Placebo Comparator|Controle|Intervention 'Parenteral supplementation with sterile water'
11572616|NCT00841282|Active Comparator|1|Water Infusion in lieu of Air Insufflation Colonoscopy
11572617|NCT00841282|Placebo Comparator|2|Air Insufflation Colonoscopy
11572618|NCT00841269|Experimental|Uridine|Uridine 500 mg by mouth twice daily for 6 weeks
11572619|NCT00841269|No Intervention|Healthy Comparison|Healthy comparison participants were seen for baseline and week 6 MRI scans. No treatment was administered to participants enrolled as healthy comparisons.
11572620|NCT00841256|Experimental|Immunotherapy|Grass pollen allergens in a water/glycerol solution
11572621|NCT00841256|Placebo Comparator|Placebo|Water/glycerol solution with phosphate buffered saline
11572622|NCT00841243|Active Comparator|nutritional advise/support|Nutritional advise and support
11572623|NCT00841243|No Intervention|control|Control
11572624|NCT00841230|Placebo Comparator|Lactose placebo|1x/day
11572625|NCT00841230|Experimental|Deanxit|
11572626|NCT00841217|Placebo Comparator|1|placebo group
11572627|NCT00841217|Active Comparator|2|GW501516, 2.5mg
11572628|NCT00841204|Experimental|Arm I|Participants receive oral sulindac twice daily for 8 weeks
11572629|NCT00841204|Placebo Comparator|Arm II|Participants receive oral placebo twice daily for 8 weeks
11572630|NCT00841191|Experimental|Siltuximab 2.8 mg/kg (Cohort 1)|
11572631|NCT00841191|Experimental|Siltuximab 5.5 mg/kg (Cohort 2)|
11572632|NCT00841191|Experimental|Siltuximab 11 mg/kg (Cohort 3)|
11572633|NCT00841191|Experimental|Siltuximab 15 mg/kg (Cohort 4)|
11572634|NCT00841191|Experimental|Siltuximab 15 mg/kg (Expansion Cohort 5)|
11572635|NCT00841191|Experimental|Siltuximab 15 mg/kg (Ovarian Cancer Cohort 6)|
11572636|NCT00841191|Experimental|Siltuximab 15 mg/kg (KRAS Mutant Tumors Cohort 7)|
11572637|NCT00841178|Active Comparator|Surgery|Patients undergo Surgery under a general anaesthetic.
11572638|NCT00841178|Experimental|EVLT|Patients undergo EVLT under a local anaesthetic.
11572639|NCT00841165|Experimental|1|Participants in this arm are treated with Continuous Positive Airway Pressure at 5cm H2O and 100% oxygen
11572640|NCT00841165|Active Comparator|2|Participants in this arm receive standard of care therapy- oxygen via a non-rebreather mask
11572641|NCT00841152||Hand lesions|Stratum I: comparison of three interventions (autograft, bioactive glass and beta-tricalcium phosphate)
11572642|NCT00841152||Long-bone lesions|Stratum II: comparison of three interventions (bioactive glass, beta-tricalcium phosphate, allograft)
11572643|NCT00841139|Experimental|Perhexiline|perhexiline 100mg bd for 1 month duration
11572644|NCT00841139|Placebo Comparator|Placebo|placebo one tablet bd for 1 month duration
11572645|NCT00841126|Experimental|Magnesium iron hydroxycarbonate|
11572646|NCT00841126|Active Comparator|Lanthanum carbonate|
11572647|NCT00841126|Placebo Comparator|Placebo|
11572648|NCT00841113|Experimental|1 Abarelix|Investigative drug
11572649|NCT00841113|Active Comparator|2 Goserelin plus bicalutamide|Standard therapy
11572650|NCT00841100|Experimental|Acute 24 Hour Component|Participants will receive one dose of Kuvan 20 mg/kg on Day 1 and assessed for Acute 24 hour Kuvan response.
11572651|NCT00841100|Experimental|Phase 1 Group|After completion of acute 24 hour component, participants can enroll in Phase 1 and will receive Kuvan 20 mg/kg by mouth once daily for 28 consecutive days
11572652|NCT00841100|Experimental|Phase 2 Group|Participants in Phase 1 that was not responsive will continue on to the Phase 2 of the study. Positive response is defined as a decrease of blood phenylalanine of 30% or greater from baseline taken from morning blood serum. The Phase 2 component of the study will be a 2 week period of dietary restriction.
11572653|NCT00841100|Experimental|Phase 3 Group|Participants in Phase 2 that achieves a fasting blood phenylalanine of less than 600 umol/l after 2 week dietary restriction will be retreated with Kuvan 20 mg/kg by mouth once daily for a period of 28 consecutive days.
11572654|NCT00841087|Experimental|SIBA|
11572655|NCT00841087|Active Comparator|Insulin Detemir|
11572656|NCT00841074|Experimental|1|Peridex mouthwash
11572657|NCT00841074|Placebo Comparator|2|Placebo mouthwash
11572658|NCT00841061|Active Comparator|Cereal L|Rice cereal with electrolytic iron
11572659|NCT00841061|Active Comparator|Cereal M|Rice cereal with ferrous fumarate
11572660|NCT00841048|Experimental|1|AZD4017 in ascending doses (start dose 75mg od)
11572661|NCT00841048|Placebo Comparator|2|Placebo
11572662|NCT00841035|Experimental|Eroltinib added to standard of care|150 mg of erlotinib for 7 days prior to surgery,then in the adjuvant stage the subject will receive 100mg of erlotinib and gemcitabine 1000mg/2 for 6 cycles
11572663|NCT00841022|Experimental|1|Information of children with comic leaflet
11572664|NCT00841022|No Intervention|2|
11572739|NCT00840411|Experimental|Clarithromycin (test) First|
11572666|NCT00840996|Active Comparator|Lidocaine|Perioperative intravenous lidocaine infusion besides the standard anesthesia care, including general anesthesia plus and post operative patient controlled analgesia.
11572667|NCT00840983|No Intervention|1-Immediate Cord Clamping|infants received the routine care of immediate clamping of the umbilical cord
11572668|NCT00840983|Experimental|2-Delayed Cord Clamping|after birth, cord clamping was delayed 30 to 45 seconds while infant was held lower than the level of the placenta.
11572669|NCT00840970|Active Comparator|Efficacy Unilateral Control|Non-coated splint placed unilaterally in the ethmoid sinus opening randomized to receive the active comparator following FESS (control arm)
11572670|NCT00840970|Experimental|Efficacy Unilateral Treatment|Drug-coated splint placed unilaterally in the ethmoid sinus opening randomized to receive the intervention following FESS (treatment arm)
11572671|NCT00840970|Experimental|Safety/PK Bilateral Treatment|Drug-coated splints placed bilaterally in both ethmoid sinus openings following FESS
11572672|NCT00840957||A|Rhumatoid arthritis patient currently receiving infliximab
11572673|NCT00840944|Experimental|ZOMATRIP|GnRH agonist triptorelin plus somatropin
11572674|NCT00840931|Experimental|Immunotherapy|Participants will take two 5 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Participants will receive 4 treatment cycles with 28 days in each cycle. Those participants showing a clinical response after 4 cycles of treatment may continue to receive lenalidomide as a single agent for additional cycles at the treating Physicians discretion. During each 28 day cycle participants will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
11572675|NCT00840918|Active Comparator|1|Intravenous Lidocaine group
11572676|NCT00840918|Placebo Comparator|Placebo|Intravenous placebo Group - Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
11572677|NCT00840905||1|HIV seropositive women from an HIV Antiretroviral therapy clinic in Johannesburg South Africa
11572678|NCT00840905||2|A cohort of HIV seropositive women from Gabarone Botswana
11572679|NCT00840905||3|A cohort of HIV seropositive women from Rio De Janeiro Brasil
11572680|NCT00840892|Experimental|Intercom|INTERdisciplinary COMmunity-based COPD management (INTERCOM)
11572681|NCT00840892|No Intervention|Usual Care|
11572682|NCT00840879|Experimental|Meloxicam|Meloxicam 15 mg Tablet (test) dosed in first period followed by Mobic® 15 mg Tablet (reference) dosed in second period
11572683|NCT00840879|Active Comparator|Mobic®|Mobic® 15 mg Tablet (reference) dosed in first period followed by Meloxicam 15 mg Tablet (test) dosed in second period
11572684|NCT00840866|Experimental|1|
11572685|NCT00840866|Active Comparator|2|
11572686|NCT00840853|Experimental|Group A with disease|"CD19+ B-ALL undergoing allogeneic HSCT, with minimal residual disease or relapse post-HSCT
~Patients will receive one of the following dose levels of CD19CAR/virus specific T cells:
~Dose Level 1: 1.5 x 10^7/m2
~Dose Level 2: 4.5 x 10^7/m2
~Dose Level 3: 1.2 x 10^8/m2
~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.
~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.
~If patients with relapse have a partial response or have stable disease they will be eligible to receive up to 6 further doses of CTLs, each of which will consist of the same number or less than as their first injection."
11572687|NCT00840853|Experimental|Group A without disease|"CD19+ B-ALL undergoing allogeneic HSCT, without detectable disease post-HSCT.
~Patients will receive CD19CAR/virus specific T cells - Dose Level 1: 1.5 x 10^7/m2
~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.
~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells."
11572688|NCT00840853|Experimental|Group B with disease|"CD19+ B cell CLL or NHL undergoing allogeneic HSCT, with minimal residual disease or relapse post-HSCT
~Patients will receive one of the following dose levels of CD19CAR/virus specific T cells:
~Dose Level 1: 1.5 x 10^7/m2
~Dose Level 2: 4.5 x 10^7/m2
~Dose Level 3: 1.2 x 10^8/m2
~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.
~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.
~If patients with relapse have a partial response or have stable disease they will be eligible to receive up to 6 further doses of CTLs, each of which will consist of the same number or less than as their first injection."
11572689|NCT00840853|Experimental|Group B without disease|"CD19+ B cell CLL or NHL undergoing allogeneic HSCT, without detectable disease post-HSCT
~Patients will receive CD19CAR/virus specific T cells -
~Dose Level 1: 1.5 x 10^7/m2
~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.
~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells."
11572690|NCT00840840|Experimental|1|
11572691|NCT00840840|Active Comparator|2|
11572692|NCT00840827|Experimental|all patients|Lenalidomide 10mg po daily/ CSA 250mg orally twice daily
11572693|NCT00840801|Experimental|1|Subjects receive three vaccinations with a paediatric TBE vaccine according to the conventional vaccination schedule.
11572694|NCT00840801|Experimental|2|Subjects receive three vaccinations with a paediatric TBE vaccine according to the conventional vaccination schedule.
11572695|NCT00840788|Experimental|Skin adhesive|perineal skin repair with octyl-2-cyanoacrylate skin adhesive
11572696|NCT00840788|Active Comparator|subcuticular suture|continuous subcuticular suture of perineal skin using rapidly absorbable polyglactin 910
11572697|NCT00840775|Other|Presillion™ Stent System|
11572698|NCT00840762|Experimental|VircoType HIV-1|Genotypic HIV resistance testing results interpreted by VircoType HIV-1 algorithm
11572699|NCT00840762|Active Comparator|Local Expert review|Local Expert HIV genotypic review, as per Badri, S. et al CID 2003
11572700|NCT00840749|Experimental|CyberKnife Stereotactic Radiotherapy|
11572701|NCT00840749|Active Comparator|Surgery|
11572702|NCT00840736|Active Comparator|1|Laparoscopic adjustable gastric banding
11572703|NCT00840736|Active Comparator|2|vertical banded gastroplasty
11572704|NCT00840723||Current smokers|Current cigarette smokers with no other illness
11572705|NCT00840723||Healthy controls|Healthy non smokers
11572735|NCT00840476|Active Comparator|Mobic®|Mobic® 15 mg Tablet (reference) dosed in first period followed by Meloxicam 15 mg Tablet (test) dosed in second period
11572706|NCT00840697|Active Comparator|Work related rehabilitation|"work related rehabilitation and exercises
~The workplace intervention includes two steps:
~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.
~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks.
~Exercises comprises of treatment in groups. The treatment includes exercises, both strength and fitness, in addition to cognitive intervention of how to manage pain and work."
11572707|NCT00840697|Active Comparator|Brief intervention|1 consultation at the physiotherapist, which give advise and a summary talk with the physician
11572708|NCT00840697|Active Comparator|Multidisciplinary exercise group|10 days of exercise and cognitive treatment group
11572709|NCT00840671|Experimental|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
11572710|NCT00840671|Placebo Comparator|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
11572711|NCT00840658|Placebo Comparator|Group A|Didactic safer injection & sexual activity education: In each city, 75 women will participate in a 60 minute lecture-format presentation and printed materials on safer sex and safer injection based on CDC guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). In this component, there will be no theory-driven active skill building elements oriented towards safer sex or safer injection.
11572712|NCT00840658|Active Comparator|Group B|"Interactive injection risk intervention and didactic safer sex education: In each city, 75 women will participate in the 60 minute Di No a las Jeringas Contaminadas ['Say No to Contaminated Syringes'] counseling session. This one-on-one intervention incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared. In addition, participants will be provided a lecture-format presentation on safer sex. However, in this component, there will be no theory-driven active skill building elements oriented towards safer sex."
11572713|NCT00840658|Active Comparator|Group C|"Interactive sexual risk intervention and didactic safer injection education: In each city, 75 women will participate in the 60 minute Di No Al Sexo Inseguro [Say No to Unsafe Sex'] counseling session. This one on one intervention incorporates elements of MI and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of unsafe sex and condom use with clients. In addition, participants will be provided a lecture format presentation on safer injection sharing. However, in this component, there will be no theory-driven active skill building elements oriented towards safer injection behavior."
11572714|NCT00840658|Experimental|Group D|"Interactive injection and sexual risk intervention: In each city, 75 women will participate in the 60 minute Di No a las Jeringas Contaminadas ['Say No to Contaminated Syringes'] and Di No Al Sexo Inseguro [Say No to Unsafe Sex'] counseling session. This one-on-one intervention incorporates elements of MI and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy)."
11572715|NCT00840645|Experimental|1. YM178|
11572716|NCT00840632|Experimental|Trandolapril|Trandolapril 4 mg Tablet (test) dosed in first period followed by Mavik® 4 mg Tablet (reference) dosed in second period
11572717|NCT00840632|Active Comparator|Mavik®|Mavik® 4 mg Tablet (reference) dosed in first period followed by Trandolapril 4 mg Tablet (test) dosed in second period
11572718|NCT00840606|Experimental|1|
11572719|NCT00840606|Active Comparator|2|
11572720|NCT00840593|Active Comparator|1. Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
11572721|NCT00840593|Active Comparator|2 Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
11572722|NCT00840580|Experimental|Vigamox|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
11572723|NCT00840580|Active Comparator|Cravit|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
11572724|NCT00840567|Other|Healthy Volunteers|To obtain a one time skin sample (4 ml skin punch biopsy) and one time blood sample (1 teaspoon)
11572725|NCT00840567|Other|Patients with benign, inherited hematologic disease|To obtain a one time skin sample (4 ml skin punch biopsy) and one time blood sample (1 teaspoon)
11572726|NCT00840554|Active Comparator|Physical Therapy|
11572727|NCT00840554|Experimental|Home Exercise|
11572728|NCT00840541||DR|Type-2 diabetic subjects diagnosed with diabetic retinopathy (DR).
11572729|NCT00840528|Experimental|Ozone exposure|Exposure to ozone at 0.4ppm
11572730|NCT00840515||Emulsion|
11572731|NCT00840502||Pregnant women|Pregnant women who present at the SMRU antenatal clinics on the Thai Burmese border.
11572732|NCT00840489|Experimental|Ribavirin|Ribavirin 1000-1200 mg qd
11572733|NCT00840489|Active Comparator|Colchicine|Colchicine 0.5 mg bd
11572734|NCT00840476|Experimental|Meloxicam|Meloxicam 15 mg Tablet (test) dosed in first period followed by Mobic® 15 mg Tablet (reference) dosed in second period
11572740|NCT00840411|Active Comparator|Biaxin® XL (reference) First|
11572741|NCT00840398|Experimental|1|
11572742|NCT00840398|Active Comparator|2|
11572743|NCT00840385|Experimental|A|
11572744|NCT00840372||1|Chronic hemodialysis patients, native arterio-venous fistula
11572745|NCT00840372||2|Chronic hemodialysis patients, native arterio-venous fistula
11572746|NCT00840359|Experimental|1 PDT|Leishmania lesion
11572747|NCT00840359|Active Comparator|Cryo|Leishmania lesion
11572748|NCT00840346|Experimental|1|The first patients enrolled in the trial will be successively distributed into three cohorts of patients for each dose level of panobinostat (20 mg, 30 mg, 40 mg) in combination with idarubicin and cytarabine, according to the classical 3+3 schedule
11572749|NCT00840333|Experimental|1|CF PATIENTS 6-11 YEARS OF AGE
11572750|NCT00840333|Experimental|2|CF PATIENTS 12-16 YEARS OF AGE
11572751|NCT00840320|Experimental|1|Repeat doses of active at escalating doses
11572752|NCT00840320|Placebo Comparator|2|Repeat doses of placebo
11572753|NCT00840294|No Intervention|Observation|Observation only for 2 weeks
11572754|NCT00840294|Active Comparator|Antibiotic|Ciprofloxacin 500 mg twice daily for 2 weeks
11572755|NCT00840281|Experimental|1|
11572756|NCT00840281|Active Comparator|2|
11572757|NCT00840268|Experimental|HPGG 0.25%|Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel, 1 drop per eye twice daily (BID) (in the morning upon awakening and in the evening prior to bedtime) for 21 days (Treatment phase).
11572758|NCT00840268|Placebo Comparator|HPGG Vehicle|Hydroxypropyl Guar Galactomannan Vehicle, 1 drop per eye twice daily (BID) (in the morning upon awakening and in the evening prior to bedtime) for 21 days (Treatment phase).
11572759|NCT00840255|Active Comparator|Breif Behavioral Treatment of Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
11572760|NCT00840255|Other|Information Control|This arm of the study does not receive the Brief Behavioral Treatment for Insomnia. This arm will act as the control arm.
11572761|NCT00840242|Experimental|Nicotine gum|Nicotine gum
11572762|NCT00840242|Placebo Comparator|Placebo gum|Placebo gum
11572763|NCT00840242|Active Comparator|Nicotine inhaler|Nicotine inhaler
11572764|NCT00840242|Placebo Comparator|Placebo inhaler|Placebo inhaler
11572765|NCT00840229|Experimental|1 capsular & intra-articular|corticosteroid injection (Triamcinolone) in capsule/rotator interval and intra-articular
11572766|NCT00840229|Active Comparator|2 intra-articular|corticosteroid injection (Triamcinolone) intra-articular placebo injection (Lidocaine) in capsule
11572767|NCT00840229|Placebo Comparator|3 placebo|placebo injections (Lidocaine) in capsule and intra-articular
11572768|NCT00840216|Experimental|1|
11572769|NCT00840216|Active Comparator|2|
11572770|NCT00840203|Experimental|Mesalamine|Mesalamine 4gm/60mL Rectal Enema (test) dosed in first period followed by Rowasa® 4gm/60mL Rectal Enema (reference) dosed in second period
11572771|NCT00840203|Active Comparator|Rowasa®|Rowasa® 4gm/60mL Rectal Enema (reference) dosed in first period followed by Mesalamine 4gm/60mL Rectal Enema (test) dosed in second period
11572772|NCT00840190|Experimental|P1446A-05|
11572773|NCT00840177|Experimental|treatment|"Induction (1 cycle):
~pravastatin 1280 mg/d PO D 1-8 idarubicin 12 mg/m2/d IV D 4-6 AraC 1.5 g/m2/d contIV D 4-7
~Consolidation (up to 2 cycles):
~pravastatin 1280 mg/d PO D 1-6 idarubicin 12 mg/m2/d IV D 4-5 AraC 1.5 g/m2/d contIV D 4-5"
11572774|NCT00840151|No Intervention|Treatment Group A|Individuals randomized to Treatment Group A will receive standard treatment for study weeks 1-6.
11572775|NCT00840151|Experimental|Treatment Group B|Individuals randomized to Treatment Group B will receive contingency management plus standard treatment for study weeks 1-6.
11572776|NCT00840151|No Intervention|Aftercare Group A|All participants will be re-randomized after study week 6. Those participants assigned to Aftercare Group A will receive standard treatment for study weeks 7-12.
11572777|NCT00840151|Experimental|Aftercare Group B|All participants will be re-randomized after study week 6. Those participants assigned to Aftercare Group B will receive contingency management treatment plus standard treatment for weeks 7-12.
11572778|NCT00840138||1|Patients with common bile duct injury after open cholecystectomy
11572779|NCT00840138||2|Patients with common bile duct injury after laparoscopic cholecystectomy
11572780|NCT00840125|Experimental|1|docetaxel + erlotinib
11572781|NCT00840112|Experimental|LCHAD/TFP with peripheral neuropathy|Subjects diagnosed with LCHAD or TFP and with documented peripheral neuropathy
11572782|NCT00840099|Experimental|1|
11572783|NCT00840099|Active Comparator|2|
11572784|NCT00840086|Experimental|rFVIII|
11572785|NCT00840073|Experimental|Trandolapril|Trandolapril 4 mg Tablet (test) dosed in first period followed by Mavik® 4 mg Tablet (reference) dosed in second period
11572786|NCT00840073|Active Comparator|Mavik®|Mavik® 4 mg Tablet (reference) dosed in first period followed by Trandolapril 4 mg Tablet (test) dosed in second period
11572787|NCT00840060|Experimental|AMALS|Addressing multiple aspects of language simultaneously
11572788|NCT00840060|Experimental|DTA|Discrete Trial Approach
11572789|NCT00840047|Experimental|Participants|Participants who meet the eligibility criteria in the study will receive methionine.
11572790|NCT00840034|Experimental|LY2216684|
11572791|NCT00840034|Placebo Comparator|Placebo|
11572792|NCT00840008|Experimental|Educational intervention|see protocol
11572793|NCT00840008|No Intervention|Standard care|distribution of guidelines and a published algorithm
11572794|NCT00839995||Patients undergoing multi-level spine surgery|
11572795|NCT00839982|Experimental|Treatment (chemotherapy)|Patients receive clofarabine PO QD on days 1-5 and low-dose cytarabine SC BID on days 1-10 or SC QD on days 1-14. Treatment repeats every 21-28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11572796|NCT00839969|Sham Comparator|Cystoscopy alone|Women in this arm will undergo saline cystoscopy under general anaesthesia only.
11572797|NCT00839969|Active Comparator|Cystoscopy and urethral dilatation|Women in this group will undergo cystoscopy and urethral dilatation under general anaesthesia
11572798|NCT00839956|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive bortezomib IV on days 2 and 5 and vorinostat PO QD on days 1-14. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
11572799|NCT00839943|Active Comparator|ozone|obese vs non-obese women
11572800|NCT00839943|Active Comparator|air|obese vs non obese women
11572801|NCT00839930|Experimental|Cilostazol (test)|Cilostazol 50 mg Tablet (test) dosed in first period followed by Pletal® 50 mg Tablet (reference) dosed in second period
11572802|NCT00839930|Active Comparator|Pletal® (reference)|Pletal® 50 mg Tablet (reference) dosed in first period followed by Cilostazol 50 mg Tablet (test) dosed in second period.
11572803|NCT00839917|Experimental|ProQuad™|
11572804|NCT00839917|Active Comparator|M-M-R™ II and Varivax™|
11572805|NCT00839904|Experimental|exercise|two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
11572806|NCT00839904|No Intervention|control|no intervention
11572807|NCT00839891|Placebo Comparator|3|"Group 1: 56 subjects to receive active study drug (VI-0521) at steady state, PHEN/TPM 7.5/46 (a potential therapeutic dose), escalating to PHEN/TPM 22.5/138 (a supra-therapeutic dose);
~Group 2: 28 subjects to receive placebo preceded by a single oral dose of moxifloxacin on Day 2;
~Group 3: 28 subjects to receive placebo followed by a single oral dose of moxifloxacin on Day 24;"
11572808|NCT00839878||A|
11572809|NCT00839865|Experimental|herb ointment dressing change group|This group of patients in the ointment dressing every 2 days until Wound Healing or 6 months
11572810|NCT00839865|No Intervention|Conventional dressing change group|This group of patients in the Conventional dressing every 2 days until Wound Healing or 6 months
11572811|NCT00839852|Experimental|Cariprazine 1.5mg|Participants received cariprazine 1.5 mg capsule once, twice or three times a day depending on their response and tolerability
11572812|NCT00839839|Experimental|Oocyte Vitrification|
11572813|NCT00839826|Active Comparator|Arm 2|
11572814|NCT00839826|Experimental|Arm 1|
11572815|NCT00839813|Experimental|Yoga|10 week trauma-sensitive yoga classes
11572816|NCT00839813|No Intervention|Women's Health Education|10 weeks of women's health education classes as an attentional control group
11572817|NCT00839800|Experimental|1|Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + Symbicort Turbuhaler 160/4.5 µg as needed
11572818|NCT00839800|Active Comparator|2|Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + terbutaline Turbuhaler 0.4 mg as needed
11572819|NCT00839787|Experimental|Morphine|Morphine Sulfate: If weight is <50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given.
11572820|NCT00839787|Placebo Comparator|Placebo|Normal saline
11572821|NCT00839774|Experimental|1|Whole yellow pea flour
11572822|NCT00839774|Experimental|2|Fractionated yellow pea flour
11572823|NCT00839774|Experimental|3|White wheat flour
11572824|NCT00839761|Experimental|iron fortified rice group|
11572825|NCT00839761|Placebo Comparator|iron drop group|
11572826|NCT00839748||asthmatics|asthmatics registry for those interested in future asthma studies
11572827|NCT00839735||COPD|Chronic obstructive pulmonary disease
11572828|NCT00839735||Asthma|
11572829|NCT00839735||Healthy controls|
11572830|NCT00839722|Experimental|1|fertility after embolization
11572831|NCT00839709||depletion immunosuppression|
11572832|NCT00839709||no depletion immunosuppression|
11572833|NCT00839683|Active Comparator|simvastatin|
11572834|NCT00839683|Active Comparator|Dapagliflozin + simvastatin|
11572835|NCT00839683|Active Comparator|Dapagliflozin|
11572836|NCT00839683|Active Comparator|valsartan|
11572837|NCT00839683|Active Comparator|Dapagliflozin + valsartan|
11572838|NCT00839670|Active Comparator|Modified Therapy|
11572839|NCT00839670|Active Comparator|Standard Therapy|
11572840|NCT00839657|Experimental|1|Genotype-guided dosing algorithm for warfarin
11572841|NCT00839657|Active Comparator|2|Clinical-guided dosing algorithm for warfarin
11572842|NCT00839644|Active Comparator|2|
11572843|NCT00839644|Active Comparator|3|
11572844|NCT00839644|Active Comparator|1|
11572845|NCT00839605||Dexmedetomidine|Those requiring thoracic surgery and receiving dex
11572846|NCT00839605||placebo|Group having thoracic surgery and not receiving dex drug
11572847|NCT00839592|Experimental|Electroacupuncture|"Acupoints will be treated at bilateral Ear Shenmen, Sishencong (EX-HN1), Anmian, and unilateral Yintang (EX-HN3) and Baihui (GV20).
~Acupuncture will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (CEFAR Acus II, Lund, Sweden) will be connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.45 ms square wave pulses and constant current. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
11572848|NCT00839592|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the same acupoints as stated in the electroacupuncture group. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
11572849|NCT00839579|Experimental|4x4min|4x4minutes interval group
11572850|NCT00839579|Experimental|1x4min|
11572851|NCT00839566|Experimental|AV ablation|
11572852|NCT00839566|Active Comparator|Rate control|Rate control by drugs
11572853|NCT00839566|No Intervention|Sinus rhythm|
11572854|NCT00839540|Active Comparator|micafungin 100|Patients receive Micafungin 100 mg qd
11572855|NCT00839540|Active Comparator|micafungin 200|Patients receive 200 mg Micafungin qd
11572856|NCT00839540|Active Comparator|Caspofungin|Patients receive caspofungin 70 mg LD followed by 50 mg qd
11572857|NCT00839527|Active Comparator|metformin + glimepiride + pioglitazone + albiglutide placebo|Metformin + glimepiride + pioglitazone + matching albiglutide placebo
11572858|NCT00839527|Experimental|metformin + glimepiride + pioglitazone placebo + albiglutide|Metformin + open-label glimepiride + pioglitazone matching placebo + albiglutide
11572859|NCT00839527|Active Comparator|met + glimepiride + pioglitazone placebo + albiglutide placebo|metformin + open-label glimepiride + pioglitazone placebo + albiglutide placebo
11572860|NCT00839501|Experimental|1|Participants will receive either potassium or placebo during six 3-week-long treatments, as randomly determined. Participants will then continue to receive potassium, if tolerated, and also either acetazolamide or placebo during another six 3-week-long treatments, as randomly determined.
11572861|NCT00839488|Active Comparator|I|pantoprazole 40 mg iv qd
11572862|NCT00839488|Active Comparator|II|famotidine 20 mg q12h
11572863|NCT00839462|Experimental|Arm 1|
11572864|NCT00839462|Active Comparator|Arm 2|
11572865|NCT00839449|Experimental|A|Patients in the group A are orally administered eicosapentaenoic acid ethyl ester.
11572866|NCT00839449|No Intervention|B|Patients in the group B (control) are not administered eicosapentaenoic acid ethyl ester.
11572867|NCT00839436|Experimental|3 microgram/kg CYT107|3 microgram/kg CYT107
11572868|NCT00839436|Experimental|10 microgram/kg CYT107|10 microgram/kg CYT107
11572869|NCT00839436|Experimental|20 microgram/kg CYT107|20 microgram/kg CYT107
11572870|NCT00839423|Placebo Comparator|Placebo|
11572871|NCT00839423|Experimental|Vortioxetine (Lu AA21004) 5 mg|
11572872|NCT00839423|Experimental|Vortioxetine (Lu AA21004) 10 mg|
11572873|NCT00839423|Other|Venlafaxine XL 225 mg|Active Reference
11572874|NCT00839397|Other|Paroxetine|A 52-week, non-comparative, uncontrolled study (However, the baseline phase is single blind)
11572875|NCT00839384|Experimental|Implant Advisa IPG|Advisa IPG implant
11572876|NCT00839371|Active Comparator|Midazolam|i.v. midazolam titration until adequate depth of sedation
11572877|NCT00839371|Active Comparator|Propofol|i.v. propofol titration until adequate depth of sedation
11572878|NCT00839358|Active Comparator|Albumin plus midodrine|Albumin 40 g every 15 days during 1 year or until liver transplantation. Midodrine 5mg/8h. It can be increased according the value of mean arterial pressure. If there is no increase (defined as at least 10mmHGin MAP)midodrine can be increased at a dose of 10mg/8h. This treatment will be given during 1 year or until liver transplantation.
11572879|NCT00839358|Placebo Comparator|salin solution plus pills|Placebo of albumin in the same schedule thats in arm 1; placebo of midodrine in the same schedule thats in arm 1.
11572880|NCT00839332|Experimental|LY2603618 + Gemcitabine|"Participants participated in Phase 1 or 2.
~LY2603618 (Phase 1): 70 to 250 milligrams/meter squared (mg/m^2) LY2603618 as a 1-hour continuous intravenous (IV) infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until disease progression (DP). Participants received LY2603618 as part of the dose escalation cohort (dose of 70, 105, 150, 200, or 250 mg/m^2) or the expansion cohort (flat dose of 200 mg or 230 mg).
~LY2603618 (Phase 2): 230 mg LY2603618 as a 1-hour continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until DP.
~Gemcitabine (Phase 1 and 2): 1000 mg/m^2 gemcitabine as a 30-minute continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until DP. Participants received gemcitabine 24 hours prior to LY2603618 administration."
11572881|NCT00839332|Active Comparator|Gemcitabine|"Participants participated in Phase 2 only.
~Gemcitabine (Phase 2): 1000 mg/m^2 gemcitabine as a 30-minute continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until disease progression."
11572882|NCT00839319|Experimental|Acyline plus Placebo|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous placebo hCG injection (inj) every other day (5 doses) for 10 days
11572883|NCT00839319|Experimental|Acyline plus 15 IU hCG|Acyline 300 ug/kg (SQ) inj(s) on Day 1 plus subcutaneous 15 IU hCG injection (inj) every other day (5 doses) for 10 days
11572884|NCT00839319|Experimental|Acyline plus 60 IU hCG|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 60 IU hCG injection (inj) every other day (5 doses) for 10 days
11572885|NCT00839319|Experimental|Acyline plus 125 IU hCG|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 125 IU hCG injection (inj) every other day (5 doses) for 10 days
11572886|NCT00839319|Experimental|Acyline plus Testosterone gel|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus Testosterone gel 75 mg/day daily for 10 days
11572887|NCT00839306|Experimental|1|
11572888|NCT00839306|Active Comparator|2|
11572889|NCT00839293|Experimental|A|ABT -335 capsules 135mg
11572890|NCT00839293|Experimental|B|ABT-335 capsules 45mg
11572891|NCT00839280|Experimental|Arm 1|
11572892|NCT00839280|Active Comparator|Arm 2|
11572893|NCT00839267||Unstable|Patient with acute myocardial infarction plus severe hemodynamical instability. It means, on mechanical ventilation and catecholamine support
11572894|NCT00839267||Stable|Patients with myocardial infarction hemodynamically completely (Killip I)stable.
11572895|NCT00839254|Experimental|10Pn3+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
11573064|NCT00838227|Experimental|One arm|Study withdrawn due to lack of funds.
11573065|NCT00838214|Experimental|budesonide|3mg capsules 3x/day for 6 months
11573112|NCT00837954|Active Comparator|2|distal Anastomosis Surgicel®, proximal Anastomosis Lyostypt®
11572896|NCT00839254|Experimental|10Pn2+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
11572897|NCT00839254|Active Comparator|Ctrl3+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B vaccine (called also HBV vaccine) according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
11572898|NCT00839254|Active Comparator|Ctrl2+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B vaccine (called also HBV vaccine) according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
11572899|NCT00839254|Experimental|10Pn7-11M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
11572900|NCT00839254|Active Comparator|Ctrl7-11M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Engerix B (called also HBV) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
11572901|NCT00839254|Active Comparator|10Pn12-18M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
11572902|NCT00839254|Experimental|Ctrl12-18M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Havrix (called also HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
11572903|NCT00839241|Experimental|Autologous Blood Transfusion|
11572904|NCT00839241|Active Comparator|Allogenic Blood Transfusion|
11572905|NCT00839228|Experimental|Perhexiline|perhexiline 100mg o bd for 3 months
11572906|NCT00839228|Placebo Comparator|Placebo|Placebo one tablet bd for 3 months
11572907|NCT00839202|Experimental|FVIII immuno-assay|The study is not designed as a therapeutic evaluation, but an assessment of clotting factor VIII timed responses after the infusion of specified doses of licensed clotting factor VIII concentrates. The purpose of the study is to measure the levels of infused licensed clotting factor VIII by standard assay techniques and comparing these standard assays with an experimental assay. Measurements of possible co-factors that might impact the results were also carried out.
11572908|NCT00839176|Placebo Comparator|Placebo|Placebo (w/o API)
11572909|NCT00839176|Experimental|2|5mg dose of RX-10100
11572910|NCT00839176|Experimental|3|10mg dose of RX-10100
11572911|NCT00839176|Experimental|4|15 mg dose of RX-10100
11572912|NCT00839163|Experimental|Arm 1|
11572913|NCT00839163|Experimental|Arm 2|
11572914|NCT00839163|Experimental|Arm 3|
11572915|NCT00839163|Experimental|Arm 4|
11572916|NCT00839163|Active Comparator|Arm 5|
11572917|NCT00839150||1|Diabetic patients without diabetic retinopathy : No intervention
11572918|NCT00839150||2|Sex and age-matched control subjects : No intervention
11572919|NCT00839137||no exercise program group|group will continue with current level of activity and will be asked not to start an exercise program. They will be seen in the clinic three times a week for 12 weeks. These visits will be very brief; blood pressure, heart rate, oxygen level and peak flow will be measured at each visit
11572920|NCT00839137||exercise group|will meet three times a week for 12 weeks, following specific exercise program
11572921|NCT00839124|Active Comparator|Allergic asthma|subjects with allergic asthma will undergo challenge with 20,000 EU CCRE
11572922|NCT00839124|Active Comparator|healthy control|Healthy volunteers will undergo challenge with 20,000 EU CCRE
11572923|NCT00839111|Experimental|A|Sorafenib plus FOLFIRI regimen
11572924|NCT00839098|No Intervention|Control Group|Control Group
11572925|NCT00839098|Experimental|Instruction Group|Instruction Group
11572926|NCT00839098|Experimental|Instruction and Virtual Coach Group|Instruction and Virtual Coach Group
11572927|NCT00839085|No Intervention|1|normal procedure of CABG
11572928|NCT00839085|Active Comparator|2: GSE|100 mg GSE every 6h /Po, starting one day before surgery (4 doses in 24h)
11572929|NCT00839085|Active Comparator|3: Vit C|25 mg/kg through pump
11572930|NCT00839072|Experimental|Trazodone Contramid OAD|
11572931|NCT00839072|Active Comparator|Desyrel|
11572932|NCT00839059|Experimental|Lenalidomide|
11573113|NCT00837954|Active Comparator|3|distal and proximal Anastomosis Lyostypt®
11572933|NCT00839046|Active Comparator|1 Community Health Worker Intervention|This is the active control group, which all 150 participants will receive. It consists of visits from trained community health workers, who will provide asthma education, as well as provision of equipment and supplies to reduce indoor environmental exposures for asthma. These will include: vacuum cleaners, mattress and pillow covers, cleaning supplies.
11572934|NCT00839046|Experimental|2 Air Filter|The 50 families in the Air Filter Arm will receive an air filter in addition to the standard community health worker intervention. The Air Filter will be installed right after baseline measurements in the home.
11572935|NCT00839046|Experimental|3 Air Filter and Air Conditioner|"Fifty families will be assigned to the Air Filter and Air Conditioner Arm. In addition to the standard community health worker intervention, they will receive an air filter and an air conditioner (for the warmer months)."
11572936|NCT00839033|Experimental|1|patients treated with standard treatment and a mechanical insufflation-exsufflation
11572937|NCT00839033|Active Comparator|2|Patients with standard treatment and standard respiratory physiotherapy
11572938|NCT00839020|Active Comparator|1|Navigated total knee arthroplasty with a minimally invasive approach
11572939|NCT00839020|Active Comparator|2|Navigated total knee arthroplasty with a conventional approach
11572940|NCT00839007|Experimental|A|Dose 1 of CD-NP
11572941|NCT00839007|Experimental|B|Dose 2 of CD-NP
11572942|NCT00839007|Experimental|C|Dose 3 of CD-NP
11572943|NCT00839007|Experimental|D|Dose 4 of CD-NP
11572944|NCT00839007|Experimental|E|Dose 5 of CD-NP
11572945|NCT00839007|Experimental|F|Dose 6 of CD-NP
11572946|NCT00839007|Placebo Comparator|G|Placebo
11572947|NCT00838994|Experimental|Traditional Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (CEFAR Acus II, Lund, Sweden) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.45 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
11572948|NCT00838994|Active Comparator|Minimal Acupuncture|"Patients will be treated superficially at points away from classic acupoints. The points include bilateral Deltoideus [in the middle of the line insertion of Binao LI 14 and acromion], Forearm [1 inch laterally of the middle point between Shaohai HE3 and Shenmen HE7], Upper arm [1 inch laterally of Tianfu LU 3] and Lower leg [0.5 inch dorsally of Xuanzhong GB39]. De qi is avoided during needling. The treatment procedure, electric-stimulation, frequency, duration and number of treatment sessions will be the same for the Traditional Acupuncture group."
11572949|NCT00838994|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the site 1 inch beside the acupoints in order to avoid the acupressure effect. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
11572950|NCT00838981|Active Comparator|Modafinil Plus Contingency Magagement|Modafinil from 200mg up to 400mg plus Contingency Management
11572951|NCT00838981|Placebo Comparator|Sugar Pill Plus Contingency Management|Placebo: sugar pill
11572952|NCT00838981|Active Comparator|Modafinil Plus Voucher Control|
11572953|NCT00838981|Placebo Comparator|Sugar Pill Plus Voucher Control|
11572954|NCT00838968|Active Comparator|interferon-alpha (IFN-alpha)|the interferon-alpha is intramuscular injected 3,000,000U three times a week for 18 months
11572955|NCT00838968|No Intervention|control|no interventions were assigned
11572956|NCT00838955|Experimental|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
11572957|NCT00838942||1|Patients suffering from both Alzheimer's disease and low vision due to a bilateral impeding cataract.
11572958|NCT00838929|Experimental|Vorinostat (200 mg) and radiation|Cohort 1: Patients receive 200 mg of Vorinostat and radiation
11572959|NCT00838929|Experimental|Vorinostat (300 mg) and radiation|Cohort 2: Patients receive 300 mg of vorinostat and radiation
11572960|NCT00838929|Experimental|Vorinostat (400 mg) and radiation|Cohort 3: Patients receive 400 mg of vorinostat and radiation
11572961|NCT00838916|Experimental|albiglutide weekly injection|albiglutide weekly subcutaneous injection
11572962|NCT00838916|Active Comparator|insulin glargine|insulin glargine daily injection
11572963|NCT00838903|Experimental|albiglutide + metformin|Albiglutide + metformin + placebo sitagliptin + placebo glimepiride
11572964|NCT00838903|Active Comparator|sitagliptin + metformin|Sitagliptin + metformin + placebo albiglutide + placebo glimepiride
11572965|NCT00838903|Active Comparator|glimepiride + metformin|Glimepiride + metformin + placebo albiglutide + placebo sitagliptin
11572966|NCT00838903|Active Comparator|metformin + placebo|Metformin + placebo albiglutide + placebo sitagliptin + placebo glimepiride
11572967|NCT00838890|Active Comparator|Cdc7-inhibitor (A)|
11572968|NCT00838890|Active Comparator|Cdc7-inhibitor (B)|
11572969|NCT00838877|Experimental|1|
11572970|NCT00838864|Active Comparator|1|ceftrioxone 500mg q12h for 3 days
11572971|NCT00838864|Active Comparator|2|ceftrioxone 500 mg q12h for 7 days
11572972|NCT00838851|Experimental|CCRE|
11572973|NCT00838838||Group 1|
11572974|NCT00838825|No Intervention|traditional|The traditional arm is composed of primary care physicians who continue the health care delivery model existing for the 5 years prior to the study. The traditional includes the physician, a pool of resources including random assignment of diabetic educators and includes the entire panel of patients assigned to the PCP.
11573066|NCT00838214|Active Comparator|prednisone|5mg tablet, 40mg starting dose titrated to 10mg over 3 months
11573067|NCT00838201|Experimental|Arm 1|
11572975|NCT00838825|Experimental|care management|The care management group is composed of primary care physicians who have been assigned a specific physician extender, the care manager, and an additional medical assistant and form a care manager team working together with registry support, team meetings and instruction in self-management and includes the entire panel of patients assigned to the PCP.
11572976|NCT00838812|Other|clindamicin and tretinoin gel|
11572977|NCT00838799|Experimental|1|
11572978|NCT00838799|Experimental|2|
11572979|NCT00838799|Experimental|3|
11572980|NCT00838799|Active Comparator|4|
11572981|NCT00838799|Placebo Comparator|5|
11572982|NCT00838773|Experimental|YMSM|Young Men Who Have Sex with Men
11572983|NCT00838773|Experimental|YHA|Young Heterosexual Adults
11572984|NCT00838773|Experimental|ROMA|Gypsies (Bulgarian)
11572985|NCT00838773|No Intervention|Control|All study participants (including those in control condition networks) receive HIV/AIDS/STD risk reduction counseling at baseline, as well as testing and treatment or treatment referral for STDs and HIV infection. STD/HIV testing and treatment or treatment referral are provided at each followup point. This constitutes the control intervention.
11572986|NCT00838747||Gynaecological Cancer|Gynaecological Cancer
11572987|NCT00838734||1|Pre-LASIK
11572988|NCT00838734||2|Post-LASIK
11572989|NCT00838708|Placebo Comparator|Vehicle cream|
11572990|NCT00838708|Experimental|SRD174 Cream|
11572991|NCT00838695|Experimental|African Americans|Subjects' hand veins will be measured for maximum constriction while being infused with phenylephrine, and then mental stress and cold pressor testing
11572992|NCT00838695|Experimental|Caucasians|Subjects' hand veins will be measured for maximum constriction while being infused with phenylephrine, and then mental stress and cold pressor testing
11572993|NCT00838682|Experimental|rabeprazole sodium|Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
11572994|NCT00838682|Active Comparator|Omeprazole|Intravenous Omeprazole 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
11572995|NCT00838656|Experimental|Arm I|Patients receive carboplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo treatment with paclitaxel and may also receive 6 more courses of neoadjuvant chemotherapy. Patients may then undergo surgery. After surgery, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11572996|NCT00838656|Experimental|Arm II|Patients receive carboplatin IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo treatment with paclitaxel and may also receive 6 more courses of neoadjuvant chemotherapy. Patients may then undergo surgery. After surgery, patients receive paclitaxel IV over 3 hours and gemcitabine hydrochloride IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11572997|NCT00838643||Allogeneic pts|Adult allogeneic HSCT recipients
11572998|NCT00838630|Experimental|1|
11572999|NCT00838630|Active Comparator|2|
11573000|NCT00838617||Participants with ALS|Participants diagnosed with ALS.
11573001|NCT00838591|Experimental|1|MN-221 given i.v. 1-hour infusion a total dose of 1200 μg (40 μg/min for 15 min [600 μg] + 13.3 μg/min for 45 min [600 μg]) as an adjunct to the standard of care for acute exacerbation of asthma.
11573002|NCT00838591|Placebo Comparator|Placebo|Placebo (Lot #CLO-095) was packaged in identical vials containing only excipients and administered as an i.v. 1-hour infusion with a regimen as described for MN-221.
11573003|NCT00838578|Experimental|KRN330 + Irinotecan|open label, single arm
11573004|NCT00838565|Placebo Comparator|Placebo|
11573005|NCT00838565|Experimental|PF-04236921|
11573006|NCT00838552||1 Asthma subjects|Children with asthma undergoing clinically indicated bronchoscopy at National Jewish Health.
11573007|NCT00838552||2 Non-asthma subjects|Children with other respiratory diseases than asthma undergoing clinically indicated bronchoscopy at National Jewish Health.
11573008|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 1)|Neratinib 120 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
11573009|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 2)|Neratinib 120 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
11573010|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 3)|Neratinib 120 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
11573011|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 4)|Neratinib 120 mg and Temsirolimus 75 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
11573012|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 5)|Neratinib 160 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
11573013|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 6)|Neratinib 160 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
11573068|NCT00838188||1|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
11573069|NCT00838188||2|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
11573014|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 7)|Neratinib 160 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
11573015|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 8)|Neratinib 160 mg and Temsirolimus 75 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
11573016|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 9)|Neratinib 200 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
11573017|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 10)|Neratinib 200 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
11573018|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 11)|Neratinib 200 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
11573019|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 12)|Neratinib 240 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
11573020|NCT00838526|Experimental|1|
11573021|NCT00838526|Active Comparator|2|
11573022|NCT00838513|Experimental|eculizumab|
11573023|NCT00838500|Active Comparator|Immediate SPA treatment|Immediate spa treatment during 18 days soon after randomization (1 year)
11573024|NCT00838500|Sham Comparator|Late SPA treatment|Late spa treatment during 18 days soon after 12 months visit (2nd year)
11573025|NCT00838487|Active Comparator|condroflex and exercise|assent arm
11573026|NCT00838487|Placebo Comparator|sugar pill and exercise|sugar pill arm
11573027|NCT00838474|Other|music therapy|Each infant was randomized to receive music therapy or no music over 2 consecutive days
11573028|NCT00838461|Active Comparator|1|HSD-016
11573029|NCT00838461|Placebo Comparator|2|placebo
11573030|NCT00838448|Experimental|Cannabis users|Cannabis users
11573031|NCT00838448|Experimental|Cannabis no-users|Cannabis no-users
11573032|NCT00838435|Experimental|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
11573033|NCT00838422||FD-OCT, ORA, USP|
11573034|NCT00838409||1|
11573035|NCT00838396|Experimental|XP19986 CR|On either study Day 1 or study Day 5 (after completion of the minimum 3-day washout period), participants received a single dose of XP19986 10, 20, 40 or 60 mg.
11573036|NCT00838396|Placebo Comparator|Placebo for XP19986 CR|On either study Day 1 or study Day 5 (after completion of the minimum 3-day washout period), participants received a single dose of placebo.
11573037|NCT00838383|Experimental|sitaxsentan (1.0 mg/kg)|
11573038|NCT00838383|Experimental|sitaxsentan (2.0 mg/kg)|
11573039|NCT00838383|Placebo Comparator|Placebo|
11573040|NCT00838370|Experimental|DPYD*2A|Patients are screened for a DPD-deficiency. Patients with a DPYD*2A mutation are eligible for intervention with capecitabine/5-FU .
11573041|NCT00838357|Experimental|Plerixafor|Plerixafor added to a G-CSF Mobilisation regimen
11573042|NCT00838344|No Intervention|Usual care|Usual prescription refill system and pharmacy care.
11573043|NCT00838344|Experimental|Intervention|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
11573044|NCT00838331|Experimental|Fresh blood, then aged blood|
11573045|NCT00838318||Arm 1 Hispanic CRC Patients|
11573046|NCT00838318||Arm 2 FDRs of Hispancic CRC Patients|First-Degree Relatives (FDRs) of Hispanic CRC Patients
11573047|NCT00838318||Arm 3 Key Informants|Key informants from Houston Hispanic Health Coalition.
11573048|NCT00838305|Placebo Comparator|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
11573049|NCT00838305|Experimental|mdma|drug: mdma subjects also get citalopram and placebo in a 2x2 crossover design
11573050|NCT00838292|Active Comparator|ART: food|ART + food supplementation + nutrition counseling
11573051|NCT00838292|Active Comparator|ART: no food|ART + nutrition counseling
11573052|NCT00838292|Active Comparator|pre-ART: food|no ART (cotrimoxazole provided) + food supplementation + nutrition counseling
11573053|NCT00838292|Active Comparator|pre-ART: no food|no ART (cotrimoxazole provided) + nutrition counseling
11573054|NCT00838279|Experimental|Lamotrigine|Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in first period followed by Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in second period
11573055|NCT00838279|Active Comparator|Lamictal®|Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in first period followed by Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in second period
11573056|NCT00838266|Experimental|1|Antiplaque mouthrinse containing active component (Grape Seed Extract + nicométhanol fluorhydrate)
11573057|NCT00838266|Placebo Comparator|2|Antiplaque mouthrinse containing non-active component
11573058|NCT00838253|Experimental|1|
11573059|NCT00838253|Experimental|2|
11573060|NCT00838253|Experimental|3|
11573061|NCT00838253|Placebo Comparator|4|
11573062|NCT00838240|Experimental|Arm I|Patients receive idarubicin IV over 5 minutes on days 1, 3, and 5, cytarabine IV continuously on days 1-10, and clofarabine IV over 1 hour on days 2, 4, 6, 8, and 10.
11573063|NCT00838240|Experimental|Arm II|Patients receive idarubicin IV and cytarabine IV as in arm I. Patients also receive clofarabine IV by push injection over 10 minutes on days 2, 4, 6, 8, and 10.
11573070|NCT00838188||Breast - feeding first|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
11573071|NCT00838188||Bottle first|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
11573072|NCT00838188||Way of feeding|Each infant is evaluated twice, once after breastfeeding and once after bottle feeding of breast milk using a Premature Nipple & Ring (Ross Products Division, Columbus OH, USA). In this way, each infant serves as its own control. REE is recorded for 20 minutes after each meal
11573073|NCT00838175||1|All pts. who have undergone percutaneous intervention who received a suture-mediated closure of the venous access site will be screened for eligibility for this research trial.
11573074|NCT00838162|Experimental|TMC310911/rtv 75/100 mg twice daily|TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14
11573075|NCT00838162|Experimental|TMC310911/rtv 150/100 mg twice daily|TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14
11573076|NCT00838162|Experimental|TMC310911/rtv 300/100 mg twice daily|TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14
11573077|NCT00838162|Experimental|TMC310911/rtv 300/100 mg once daily|TMC310911 300 mg + ritonavir 100 mg once daily on Days 1 to 14
11573078|NCT00838149|Active Comparator|Glutamine|Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
11573079|NCT00838149|Placebo Comparator|Whey Protein|"Whey Protein:
~Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
11573080|NCT00838136|Experimental|Lamotrigine|Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in first period followed by Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in second period
11573081|NCT00838136|Active Comparator|Lamictal®|Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in first period followed by Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in second period
11573082|NCT00838110|Experimental|Dimebon 20 mg TID (Cohort 1)|
11573083|NCT00838110|Placebo Comparator|Placebo TID (Cohort 1)|
11573084|NCT00838110|Experimental|Dimebon 20 mg TID (Cohort 2)|
11573085|NCT00838110|Placebo Comparator|Placebo TID (Cohort 2)|
11573086|NCT00838097||Darbepoetin alfa|Participants with chronic kidney disease who received darbepoetin alfa for the treatment of anaemia as part of routine clinical practice.
11573087|NCT00838084|Experimental|LY2811376 Part 1|LY2811376 (5 mg up to 500 mg); once a day or twice a day for 1 day in up to 3 periods.
11573088|NCT00838084|Placebo Comparator|Placebo Part 1|once a day or twice a day for 1 day in up to 3 periods.
11573089|NCT00838084|Experimental|LY2811376 - Part 2 low dose|Single dose of LY2811376, dose determined by part 1
11573090|NCT00838084|Experimental|LY2811376 - Part 2 high dose|Single dose of LY2811376, dose determined by part 1
11573091|NCT00838084|Placebo Comparator|Placebo Part 2|single dose
11573092|NCT00838071|Experimental|IGIV-HB Grifols|
11573093|NCT00838058|Experimental|Part1; controlled release formulation 4; 250 mg|one 250 mg controlled release tablet, once in the morning, in fasted state
11573094|NCT00838058|Experimental|Part1; controlled release formulation 4; 500 mg|2x250 mg, once in the morning, in fasted state
11573095|NCT00838058|Experimental|Part 1; controlled release formula 4; 1000 mg|4x250 mg tabs, once in the morning, in fasted state
11573096|NCT00838058|Experimental|Part 1; controlled release formulation 4; 500 mg FED|2x250 mg, once in the morning , in fed state
11573097|NCT00838058|Experimental|Part 2; IR formulation 500mg|4x125 mg tab of current formulation , once in the morning in the fasted state. This arm will occur as Part 2, only as needed, pending results of Part 1
11573098|NCT00838058|Experimental|Part 2; IR formulation, 500 mg FED|4x125 mg once in the morning in the fed state. This arm will occur as part of Part 2,only as needed, pending results of Part 1.
11573099|NCT00838058|Experimental|Part 2; controlled release formulation 5;500 mg, FASTED|2x250 controlled release formulation 5 tabs once in the morning in the fasted state. This arm will only occur as part of Part 2, pending results of Part 1.
11573100|NCT00838058|Experimental|Part 2; controlled release formulation 5;500 mg, FED|2x250 mg controlled release formulation 5 tabs once in the morning in the fed state. This arm will only occur as part of Part 2 pending results of Part 1
11573101|NCT00838045|Experimental|Akreos TL intraocular lens|Bausch & Lomb Akreos TL intraocular lens
11573102|NCT00838032|Experimental|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
11573103|NCT00838032|Active Comparator|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
11573104|NCT00838019|Experimental|Cord blood|
11573105|NCT00838006|Experimental|Biofeedback training|Heart rate variability biofeedback training and iPod with Breath Pacer app
11573106|NCT00838006|Experimental|Cognitive bias modification training|Cognitive bias modification training and iPod with cognitive bias training app
11573107|NCT00838006|Sham Comparator|Control Group|No additional resilience training and iPod with no resilience training apps
11573108|NCT00837993||Survival Analysis|Survival Analysis Based on Reclassification to a Two-tier Grading System: Review of Pathology Slides for Patients participating on Protocol COG 158.
11573109|NCT00837967|Experimental|First Symbicort, then Terbutaline|Symbicort Turbuhaler 160/4.5μg for 3 days First , then Terbutaline Turbuhaler 0.4 mg for 3 days
11573110|NCT00837967|Experimental|First Turbuhaler, then Symbicort|Terbutaline Turbuhaler 0.4 mg for 3 days First, then Symbicort Turbuhaler 160/4.5μg for 3 days,
11573111|NCT00837954|Active Comparator|1|distal Anastomosis Lyostypt®, proximal Anastomosis Surgicel®
11573114|NCT00837954|Active Comparator|4|distal and proximal Anastomosis Surgicel®
11573115|NCT00837941|Experimental|1|sequence 1 - Pregabalin, Duloxetine hydrochloride, Diphenhydramine hydrochloride
11573116|NCT00837941|Experimental|2|sequence 2 - Duloxetine hydrochloride, Pregabalin, Diphenhydramine hydrochloride
11573117|NCT00837941|Experimental|3|sequence 3 - Diphenhydramine hydrochloride, Duloxetine hydrochloride, Pregabalin
11573118|NCT00837941|Experimental|4|sequence 4 - Pregabalin, Diphenhydramine hydrochloride, Duloxetine hydrochloride
11573119|NCT00837941|Experimental|5|sequence 5 - Duloxetine hydrochloride, Diphenhydramine hydrochloride, Pregabalin
11573120|NCT00837941|Experimental|6|sequence 6 - Diphenhydramine hydrochloride, Pregabalin, Duloxetine hydrochloride
11573121|NCT00837928|Experimental|Bendamustine and Fractionated stereotactic radiotherapy|Bendamustine 40 mg/m2 and will be administered IV on days 1,2,and 3 prior to surgery on each day of SRT (Sterotactic radiation therapy). Laboratory biomarker analysis will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. Pharmacokinetic samples will not be collected from patients who begin SRT on day 1). Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine) Stereotactic fractionated radiation therapy starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri). Concurrent Bendamustine is administered on Days of Stereotactic Radiotherapy (Arm 1: 40 mg/m2/ Day; Arm 2: 50 mg/m2/day).
11573122|NCT00837915|Experimental|1|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets of Ranbaxy
11573123|NCT00837915|Active Comparator|2|(Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets
11573124|NCT00837902|Experimental|Atenolol|"There is only 1 arm to this study. Intervention: All participants received atenolol. Genotyping for GRK5 was performed to identify if participants were GLN/GLN, GLN/LEU, or LEU/LEU.
~Heart rates were measured at rest, and as participants performed graded incremental exercise on a supine bicycle ergometer (at 25, 50, and 75 W for 2 minutes each) twice, once before and once 2.5 hours after taking 25 mg of atenolol."
11573125|NCT00837889||decompensated heart failure patients|
11573126|NCT00837889||chronic heart failure patients|
11573127|NCT00837889||healthy controls|
11573128|NCT00837876|Experimental|Treatment|Sorafenib + Erlotinib
11573129|NCT00837863|Experimental|1|ALTU-238
11573130|NCT00837863|Experimental|2|ALTU-238
11573131|NCT00837863|Experimental|3|ALTU-238
11573132|NCT00837863|Active Comparator|4|Nutropin AQ
11573133|NCT00837850|Active Comparator|1|
11573134|NCT00837850|Active Comparator|2|
11573135|NCT00837837|Experimental|Chlorpheniramine|Chlorpheniramine dose by body weight.
11573136|NCT00837824|Experimental|Fabrazyme 1mg/kg every 2 weeks|Fabrazyme 1.0 mg/kg every 2 weeks
11573137|NCT00837824|Experimental|Fabrazyme 3mg/kg every 2 weeks|Fabrazyme 3.0 mg/kg every 2 weeks
11573138|NCT00837811|Experimental|LY2127399|
11573139|NCT00837798||No history of AF|Patient should not have had a documented history of AF for a period of 3 months prior to enrollment.
11573140|NCT00837785|Experimental|1|240 mg (two 120 mg capsules) twice a day
11573141|NCT00837785|Experimental|2|240 mg (two 120 mg capsules) three times a day
11573142|NCT00837772|Active Comparator|Arm 1|Usual standard cutting guide for TKA (Total Knee Arthroscopy)
11573143|NCT00837772|Experimental|Arm 2|Otismed MRI generated cutting guide for TKA
11573144|NCT00837759|Other|T1D group|This study was terminated prior to full subject accrual because of changes to study personnel. The original study design was changed from a double-blind, placebo-controlled study to an open-label pilot study in order to collect safety data on enrolled subjects prior to study termination.
11573145|NCT00837746||1|Women taking risedronate for 5 years
11573146|NCT00837733|Experimental|Biopsy catheter|Biopsy catheter (Pipelle de Cornier, Prodimed, Neuilly-en-Thelle, France
11573147|NCT00837694||1|Non-obese/0 kcal
11573148|NCT00837694||2|Non-obese/100 kcal
11573149|NCT00837694||3|Non-obese/300 kcal
11573150|NCT00837694||4|Obese/0 kcal
11573151|NCT00837694||5|Obese/100 kcal
11573152|NCT00837694||6|Obese/300 kcal
11573153|NCT00837681||lung disease|hematopoietic stem cell transplantation (HSCT)
11573154|NCT00837668||sarcoidosis|sarcoidosis patients undergoing clinical bronchoscopy
11573155|NCT00837655|Experimental|1|Sevelamer intervention
11573156|NCT00837655|Active Comparator|2|Calcium carbonate
11573157|NCT00837642||ART (Assited reproductive technologies)|In participants born after IVF will be performed a transthoracic echocardiography
11573158|NCT00837642||Control|In participants naturally conceived will be performed a transthoracic echocardiography
11573159|NCT00837616|Active Comparator|Group A|Group A will receive the oral estradiol for 12 months
11573160|NCT00837616|Active Comparator|Group B|Group B will receive the transdermal estradiol for 12 months
11573161|NCT00837603|Active Comparator|Training|Ergometer Training
11573162|NCT00837603|No Intervention|2|Counseling
11573163|NCT00837590|Experimental|Acute Salsalate|Nondiabetic lean and obese subjects will be studied in this arm. Subjects will be studied at baseline and after a single dose of oral salsalate.
11573164|NCT00837590|Experimental|Chronic Salsalate - Obese|Obese subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate.
11573165|NCT00837590|Experimental|Chronic Salsalate - Lean|Lean subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate. The effects of an acute fatty acid infusion on vascular function will be measured on both occasions.
11573166|NCT00837577|Experimental|Sitagliptin/Sitagliptin|
11573167|NCT00837577|Experimental|Placebo/Sitagliptin|
11573168|NCT00837564|Experimental|CBASP|CBASP psychotherapy
11573169|NCT00837564|Experimental|Escitalopram|Escitalopram pharmacotherapy and clinical management
11573170|NCT00837551|Placebo Comparator|1 Placebo cream|0% cream 12 patients
11573171|NCT00837551|Active Comparator|2. Cream|0.5% WBI-1001 cream 12 patients
11573172|NCT00837551|Active Comparator|3. Cream|1.0% WBI-1001 cream 12 patients
11573173|NCT00837538||Back pain|Persons with back pain and supposed instability of lumbar spine
11573543|NCT00834912|Experimental|2: Tramadol HCl (Confab Laboratories) fed|
11573174|NCT00837512|Experimental|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
11573175|NCT00837512|Active Comparator|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
11573176|NCT00837499||Mexican Women from Mexico|
11573177|NCT00837499||Mexican-American Women in U.S.|
11573178|NCT00837499||African-American Women in U.S.|
11573179|NCT00837486|Active Comparator|Active Group - Active Stimulation|Receive active stimulation with Reclaim™ DBS System
11573180|NCT00837486|Sham Comparator|Control Group - Sham Stimulation|Receive sham stimulation with Reclaim™ DBS System
11573181|NCT00837473|Other|Plexur-P Bone Void Filler|Single arm. Open Label.
11573182|NCT00837460|Experimental|rehabilitation|Bilateral and unilateral prehension oriented rehabilitation to enhance prehension.
11573183|NCT00837447|Active Comparator|NexGen CR knee prosthesis|side of knee operated with total knee replacement with Nexgen CR prosthesis
11573184|NCT00837447|Active Comparator|NexGen CR-Flex knee prosthesis|side of knee operated with total knee arthroplasty using Nexgen CR-flex prosthesis
11573185|NCT00837434|Experimental|Etanercept|Participants receive a subcutaneous injection of etanercept once every week for 24 weeks
11573186|NCT00837434|Experimental|Adalimumab|Participants receive a subcutaneous injection of adalimumab once every 2 weeks for 24 weeks
11573187|NCT00837421||sepsis|sepsis survivors
11573188|NCT00837408||Cases|Individuals with Type 2 Diabetes
11573189|NCT00837408||Controls|Individuals without Type 2 Diabetes
11573190|NCT00837395||premenstual asthma|women with asthma have an increase in asthma symptoms during the premenstrual or menstrual period
11573191|NCT00837382|Experimental|1|MEDVAMC Nightmare Treatment
11573192|NCT00837382|Experimental|2|Videoconferencing nightmare Treatment
11573193|NCT00837369|Experimental|1|RTPE studies (resting and following Regadenoson 400 ug IV bolus injection) will be performed during a continuous infusion of lipid encapsulated microbubbles (Definity, Lantheus Medical Imaging) to qualitatively and quantitatively examine wall motion and myocardial contrast enhancement.
11573194|NCT00837356|Experimental|Advate®/turoctocog alfa|
11573195|NCT00837343|Experimental|Quetiapine Fumarate arm|Quetiapine Fumarate arm
11573196|NCT00837330|Experimental|Ranibizumab 0.5 mg/ 0.05 cc|Intraocular injection of 0.5 mg/ 0.05 cc ranibizumab
11573197|NCT00837330|Experimental|Ranibizumab 0.3 mg/ 0.05 cc|Intraocular injection of 0.3 mg/ 0.05 cc ranibizumab
11573198|NCT00837317|Experimental|1|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
11573199|NCT00837304||UC|Patients with known ulcerative colitis
11573200|NCT00837291|Experimental|CF101 1 mg BID|
11573201|NCT00837291|Placebo Comparator|Placebo|Placebo tablets BID
11573202|NCT00837278||1 IVF|Pregnancies conceived with the use of assisted reproductive technologies. This is defined as a pregnancy conceived with all gametes being handled outside of the body.
11573203|NCT00837278||2 Control|Spontaneously conceived pregnancies.
11573204|NCT00837265|Experimental|Neugranin Dose Level 1|
11573205|NCT00837265|Experimental|Neugranin Dose Level 2|
11573206|NCT00837265|Active Comparator|Pegfilgrastim|
11573207|NCT00837252|Experimental|Finasteride|
11573208|NCT00837239|Experimental|Gemcitabine + HuaChanSu|Gemcitabine 1,000 mg/m2 once a week for 3 weeks then 1 week off + HuaChanSu 20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
11573209|NCT00837239|Experimental|Gemcitabine + Placebo|Gemcitabine 1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle) + Placebo 500 ml saline only administered as a 2 hour infusion by central line.
11573210|NCT00837226||Study group-Bariatric procedure performed|
11573211|NCT00837226||Control group: No bariatric procedures|
11573212|NCT00837213|Active Comparator|BPO with clindamycin foam|Benzoyl peroxide (BPO) wash with clindamycin foam
11573213|NCT00837213|Active Comparator|BPO + clindamycin foam + doxycycline|Benzoyl peroxide (BPO) wash with clindamycin foam and doxycycline capsules
11573214|NCT00837200|Experimental|Oncaspar, Doxil, Decadron Regimen|Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
11573215|NCT00837187|Active Comparator|Intravenous dexmedetomidine|Dexmedetomidine is administered intravenously
11573216|NCT00837187|Experimental|Intranasal administration|Dexmedetomidine is administered intranasally
11573217|NCT00837174|Experimental|Combination Vorinostat + Bortezomib|Six cycle combination therapy with vorinostat and bortezomib.
11573218|NCT00837161|Experimental|Philips MR guided HIFU system|Patient receiving HIFU treatment
11573219|NCT00837148|Experimental|Sorafenib and Dacarbazine|This study is an open label, single arm, Simon two stage, phase 2 trial of continuous, daily oral sorafenib, with intravenous dacarbazine administered every three weeks for patients with synovial sarcoma, leiomyosarcoma and malignant peripheral nerve sheath tumor.
11573220|NCT00837135|Experimental|All Subjects|Screening for Eligibility into Trial
11573221|NCT00837135|Experimental|ARM A|GI-4000 Vaccine
11573222|NCT00837135|Experimental|ARM B|GI-4000 Vaccine + Activated T Cells
11573223|NCT00837135|Experimental|After GI-4000 Vaccine #4|GI-4000 Monthly - For those with incomplete removal of tumor GI-4000 Monthly + Chemotherapy - For those with complete removal of tumor
11573224|NCT00837122||Control|Control subjects are nondiabetics ethnically matched to patients
11573225|NCT00837122||T2D|Patients with confirmed T2D who are newly diagnosed or on treatment in Ibadan, Nigeria
11573226|NCT00837109|Experimental|1|Imagery Rescripting Nightmare Treatment
11573227|NCT00837109|Active Comparator|2|Treatment-as-usual in the Trauma Recovery Program
11573228|NCT00837096|Experimental|V.A.C. Therapy|Negative Pressure Wound Therapy (NPWT) distrubtes negative pressre across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
11573276|NCT00836719|Experimental|Polyphenon E|Standarized green tea extract containing 50% EGCG
11573229|NCT00837096|Active Comparator|Moist Wound Therapy (MWT)|t wound therapy (MWT) is a widely used treatment modality that demonstrates benefit through the facilitation of a moist wound environment, which is known to promote faster relative wound healing compared to wounds exposed to air.
11573230|NCT00837070|Experimental|1|Percutaneous zygapophyseal cyst rupture
11573231|NCT00837057|Other|early crrt, late crrt|
11573232|NCT00837044|Active Comparator|1|Treximet, cognitive testing
11573233|NCT00837044|Placebo Comparator|2|Placebo, Cognitive testing
11573234|NCT00837031|Experimental|Intervention|"The study began with a lead-in portion to confirm the tolerability of lenalidomide (25mg PO days 1-21) in combination with gemcitabine (1000mg/m2 IV days 1, 8, and 15).
~After completion of the lead-in phase, all subsequent patients received lenalidomide 25mg PO on days 1-21 and gemcitabine 1000mg/m2 IV days 1, 8, and 15 of 28-day treatment cycles. Patients were instructed to take lenalidomide at approximately the same time each morning. Patients were permitted to continue treatment until disease progression or intolerable toxicity occurred."
11573235|NCT00837018|Experimental|Physical exercise program|45 min, 3 times a week
11573236|NCT00837005||1|Patients with suspected CAD
11573237|NCT00837005||2|Patients with known CAD and suspected ischemia.
11573238|NCT00836992||Control|Patient's QOL assessments data is not shared with the physician, nurse, and/or nurse practitioner and the patient
11573239|NCT00836992||Active|Patient's QOL assessments data is shared with the physician, nurse, and/or nurse practitioner and the patient immediately prior to the on-treatment visit.
11573240|NCT00836953|Experimental|Study Group|Participants received 2 doses of Fluzone® vaccine
11573241|NCT00836940|Placebo Comparator|1|
11573242|NCT00836940|Experimental|2|GRC 8200-25mg OD
11573243|NCT00836940|Experimental|3|GRC 8200-50mg OD
11573244|NCT00836940|Experimental|4|GRC 8200-50mg BD
11573245|NCT00836940|Experimental|5|GRC 8200-100mg OD
11573246|NCT00836927|Experimental|Ridaforolimus 10 mg Days 1-5|Ridaforolimus 10 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus intravenous (IV) infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
11573247|NCT00836927|Experimental|Ridaforolimus 10 mg Days 1-6|Ridaforolimus 10 mg administered orally once daily on Days 1-6 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
11573248|NCT00836927|Experimental|Ridaforolimus 20 mg Days 1-5|Ridaforolimus 20 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
11573249|NCT00836927|Experimental|Ridaforolimus 30 mg Days 1-5|Ridaforolimus 30 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
11573250|NCT00836927|Experimental|Ridaforolimus 40 mg Days 1-5|Ridaforolimus 40 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
11573251|NCT00836914|Active Comparator|CAL-101|
11573252|NCT00836914|Placebo Comparator|Placebo|
11573253|NCT00836901|Experimental|Amoxicillin Calvulanic Acid|Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in first period followed by Augmentin® 40-57 mg Chewable Tablet (reference) dosed in second period
11573254|NCT00836901|Active Comparator|Augmentin®|Augmentin® 400-57 mg Chewable Tablet (test) dosed in first period followed by Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (reference) dosed in second period
11573255|NCT00836888|Experimental|Cohort|
11573256|NCT00836875|Experimental|1|Children from 2 to 17 years who have possible, probable or proven invasive aspergillosis, or other rare mold infection (eg, Scedosporium and Fusarium).
11573257|NCT00836862||Arteriovenous Fistula|
11573258|NCT00836849|Experimental|1|
11573259|NCT00836849|Active Comparator|2|
11573260|NCT00836836|Experimental|1|Modified Atkins diet arm-In this arm, the children will start the modified Atkins diet after a 4-week baseline period, during which daily seizure log will be maintained. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided.
11573261|NCT00836836|No Intervention|2|"No Intervention arm- After the 4-week baseline period, this group will receive their normal diet with no dietetic input, and remain on the same on-going antiepileptic medication for the 3 months. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided.
~At the end of three months, patients in this arm will be offered the option of the modified Atkins diet treatment.
~This group will not receive any dietetic input"
11573262|NCT00836823|Experimental|Alpha blocker|Alfuzosin 10mg
11573263|NCT00836810|Experimental|Timed Release Tablet Prednisone|12 patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
11573264|NCT00836810|Active Comparator|Standard Prednisolone|12 patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.
11573265|NCT00836797||1 Case with scaffold|This group of patients will be having a placement of PLGA bioscaffold in the alveolar socket after teeth extraction
11573266|NCT00836797||2 Control without scaffold|The Alveolar socket will be left to heal and no treatment/scaffold placement will be done
11573267|NCT00836784|Experimental|1|
11573268|NCT00836784|Experimental|2|
11573269|NCT00836771|Placebo Comparator|Materna infant formula 1|milk based infant formula powder
11573270|NCT00836771|Experimental|Materna infant formula 2|Probiotic supplemented infant formula
11573271|NCT00836771|Experimental|Materna infant formula 3|Prebiotic supplemented infant formula
11573272|NCT00836771|Experimental|Materna infant formula 4|Prebiotic+ Probiotic supplemented infant formula
11573273|NCT00836771|Other|Human milk|Human Milk
11573274|NCT00836758|Experimental|CPAP Device|Breathing event detection (AED) by the CPAP device will be compared to breathing event detection by a simultaneous PSG (manual PSG scoring).
11573275|NCT00836745||1|Non Interventional
11573277|NCT00836706|Experimental|Clarithromycin (test)|Clarithromycin 500 mg Tablet (test) dosed in first period followed by Biaxin® 500 mg Tablet (reference) dosed in second period
11573278|NCT00836706|Active Comparator|Biaxin®|Biaxin® 500 mg Tablet (reference) dosed in first period followed by Clarithromycin 500 mg Tablet (test) dosed in second period
11573279|NCT00836693|Experimental|Tadalafil|
11573280|NCT00836693|Placebo Comparator|Placebo|
11573281|NCT00836667|Experimental|1|
11573282|NCT00836667|Active Comparator|2|
11573283|NCT00836654|Active Comparator|1 Catumaxomab|Patient received Catumaxomab and paracentesis
11573284|NCT00836654|No Intervention|2:|Patient treated by paracentesis alone, but after the second paracentesis the patient is able to cross-over in the Catumaxomab-arm
11573285|NCT00836641|Active Comparator|pneumococcal immunization (2 mo)|one dose of pneumococcal conjugate vaccine (prevenar) followed after 2 months by one dose of pneumococcal polysaccharide vaccine (pneumovax)
11573286|NCT00836641|Active Comparator|pneumococcal immunization (10 mo)|one dose of pneumococcal conjugate vaccine (prevenar) followed after 10 months by one dose of pneumococcal polysaccharide vaccine (pneumovax)
11573287|NCT00836628|Experimental|experimental|
11573288|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 1)|
11573289|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 2)|
11573290|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 3)|
11573291|NCT00836589||Data Collection Group|
11573292|NCT00836576|Experimental|1|
11573293|NCT00836576|Active Comparator|2|
11573294|NCT00836563||Forearm Arteriovenous Loop Graft|
11573295|NCT00836550|Active Comparator|Control|The participants spoke with a live counselor prior to answering the knowledge measure
11573296|NCT00836550|Experimental|Video|
11573297|NCT00836537|Experimental|1|
11573298|NCT00836537|Active Comparator|2|
11573299|NCT00836524||1|Pregnant women are included when they attend nuchal transcluency examination and will during their pregnancy be examined 4 times with ultrasound
11573300|NCT00836498|Experimental|Part I, RotaTeq|3 doses of RotaTeq
11573301|NCT00836498|Placebo Comparator|Part I, placebo|3 doses of placebo
11573302|NCT00836498|Experimental|Part II, RotaTeq|3 doses of RotaTeq
11573303|NCT00836498|Experimental|Part II, RotaTeq and placebo|1 dose of RotaTeq and 2 doses of placebo
11573304|NCT00836498|Placebo Comparator|Part II, placebo|3 doses of placebo
11573305|NCT00836485|Experimental|1|Ketotifen 4.0% Patch
11573306|NCT00836485|Placebo Comparator|2|Placebo Patch
11573307|NCT00836485|Active Comparator|3|Pataday(TM)
11573308|NCT00836485|Placebo Comparator|4|Placebo eye drops
11573309|NCT00836472|Experimental|Glyburide Metformin|Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in first period followed by Glucovance® 5/500 mg Tablet (reference) dosed in second period
11573310|NCT00836472|Active Comparator|Glucovance®|Glucovance® 5/500 mg Tablet (reference) dosed in first period followed by Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in second period
11573311|NCT00836459|No Intervention|Control|
11573312|NCT00836459|Experimental|Mini Booster|
11573313|NCT00836459|Experimental|Full Booster|
11573314|NCT00836446|Active Comparator|Group 1|20 min. physical activity routine
11573315|NCT00836446|Experimental|Group 2|40 min. aerobic physical activity routine
11573316|NCT00836433|Active Comparator|FALLS only|Traditional falls educational intervention, including self-study modules, audit and feedback, falls team training, academic detailing, and toolkit.
11573317|NCT00836433|Experimental|CONNECT and FALLS|CONNECT educational intervention is designed to improve relationship-building and communication. The intervention includes 2 in-class session, group mapping exercise, individual relationship mapping exercises, Self-monitoring of interactions, individual staff coaching sessions. FALLS is a traditional falls educational intervention, including self-study modules, audit and feedback, falls team training, academic detailing, and toolkit.
11573318|NCT00836420||liver|patients with acute liver failure
11573319|NCT00836407|Experimental|Arm 1: Ipilimumab Alone|Ipilimumab alone
11573320|NCT00836407|Experimental|Arm 2: Ipilimumab + Pancreatic Cancer Vaccine|Ipilimumab + Pancreatic Cancer Vaccine
11573321|NCT00836394|Experimental|Intervention Group|Will undergo whole body vibration (WBV) therapy (6 minutes of training on 5 days a week for 3 months)
11573322|NCT00836394|No Intervention|Control|Will follow daily habitual activities
11573323|NCT00836381|Experimental|Tolterodine ER|Tolterodine ER 4mg once daily
11573324|NCT00836381|Placebo Comparator|Placebo|Placebo once daily
11573325|NCT00836368|Experimental|MaxiGamma|
11573326|NCT00836355|Experimental|Enoxaparin|
11573327|NCT00836355|Experimental|Minocycline|Minocycline 200 mg orally once daily for 5 days
11573328|NCT00836355|Experimental|Enoxaparin and minocycline|
11573329|NCT00836355|No Intervention|Control|
11573330|NCT00836342||Previous history of SCC|Participants had previous history of SCC
11573331|NCT00836342||Previous history of BCC|Participants had previous history of BCC
11573332|NCT00836342||Control|Participants had no previous history of squamous cell carcinoma or basal cell carcinoma
11573333|NCT00836329|Experimental|Intensive Glucose Management|Participants will receive intensive glucose management.
11573334|NCT00836329|Active Comparator|Traditional Glucose Management|Participants will receive a traditional method of glucose management.
11573335|NCT00836303|No Intervention|Control|Patients of physicians randomly assigned to the control group received usual care
11573336|NCT00836303|Experimental|Intervention Group|This group will receive the behavioral intervention.
11573337|NCT00836290|Experimental|Pre-release|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
11573338|NCT00836290|Experimental|Post-release|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
11573536|NCT00834964|Experimental|Venlafaxine|Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period
11573339|NCT00836290|No Intervention|Control|Participants in the control group do not receive education sessions during their term in the study. However, these sessions are available to them after completing the study.
11573340|NCT00836277|Experimental|Irinotecan plus panitumumab|"Irinotecan 100 mg/m2 IV Day 1 and Day 8
~+ Panitumumab 9mg/kg IV Day 1 Cycle = 21 days"
11573341|NCT00836264||Morphine T & A|"Subjects ages 4-18 years of age who have a Tonsillectomy and Adenoidectomy and receive morphine for pain control and who have also enrolled in the CAG study at CHOP, A Study of the Genetic Causes of Complex Pediatric Disorders (GCPD study), as approved by the CHOP IRB, 2006-7-4886."
11573342|NCT00836251||H218O and 2H2O|schizophrenia
11573343|NCT00836238||Questionnaire + Fall Risk Assessment|Physical Function Interview + Physical Function Tests + Symptom Assessment Interview
11573344|NCT00836225|Experimental|A|50 mg ISIS 388626 vs Placebo, s.c. injection
11573345|NCT00836225|Experimental|B|100 mg ISIS 388626 vs Placebo, s.c. injection
11573346|NCT00836225|Experimental|C|200 mg ISIS 388626 vs Placebo, s.c. injection
11573347|NCT00836225|Experimental|D|400 mg ISIS 388626 vs Placebo, s.c. injection
11573348|NCT00836225|Experimental|AA|50 mg ISIS 388626, 3x over 1 week s.c. injection, weekly s.c. injection for 5 weeks vs Placebo
11573349|NCT00836225|Experimental|BB|100 mg ISIS 388626, 3x over 1 week s.c. injection, weekly s.c. injection for 5 weeks vs Placebo
11573350|NCT00836225|Experimental|AAA|50 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
11573351|NCT00836225|Experimental|BBB|100 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
11573352|NCT00836225|Experimental|CCC|200 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
11573353|NCT00836225|Experimental|FFF|50 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
11573354|NCT00836212|Experimental|LPV|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
11573355|NCT00836212|Experimental|EFV|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
11573356|NCT00836199|Placebo Comparator|Placebo vaccine|
11573357|NCT00836199|Experimental|NicVAX vaccine|
11573358|NCT00836186|Other|Radiation therapy|Women with non-metastatic breast cancer status post lumpectomy to negative margins and who are receiving whole breast irradiation as per standard treatment plan.
11573359|NCT00836173|Experimental|RICE followed by GARD|"RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, for 3 cycles.
~GaRD treatment: After RICE treatment, gallium nitrate will be given continuously over a 7 day period. In addition rituximab will be given on day 1 of each cycle. Dexamethasone will be given for the first 4 days of each cycle. The length of each cycle is 21 days."
11573360|NCT00836160||1|
11573361|NCT00836160||2|
11573362|NCT00836147|Placebo Comparator|1|250 ng dose
11573363|NCT00836147|Active Comparator|2|250 ng dose
11573364|NCT00836134|Experimental|1|rectus sheath block
11573365|NCT00836134|Active Comparator|2|local anesthetic infiltration
11573366|NCT00836121||tumor|
11573367|NCT00836108|Sham Comparator|1|spontaneous
11573368|NCT00836108|Experimental|2|coordinating arm elevation with inspiration
11573369|NCT00836108|Experimental|3|coordinating arm elevation with expiration
11573370|NCT00836095|Other|Supreme LMA|"Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant.
~The choice of the airway device will be randomized by opening a sealed envelope immediately before induction. The airway device will be blindly inserted by an experienced attending anesthesiologist."
11573371|NCT00836095|Active Comparator|Proseal LMA|"Proseal is a multiple use, variant of the laryngeal mask airway.
~The choice of the airway device will be randomized by opening a sealed envelope immediately before induction. The airway device will be blindly inserted by an experienced attending anesthesiologist."
11573372|NCT00836082|Experimental|Cohort 1 (N=10)|Placebo-controlled, escalating multiple doses of 0.5mg per day for 14 days.
11573373|NCT00836082|Experimental|Cohort 2 (N=10)|Placebo-controlled, escalating multiple doses of 1mg per day for 14 days.
11573374|NCT00836082|Experimental|Cohort 3 (N=10)|Placebo-controlled, escalating multiple doses of 4mg per day for 14 days.
11573375|NCT00836082|Experimental|Cohort 4 (N=10)|Placebo-controlled, escalating multiple doses of 8mg per day for 14 days.
11573376|NCT00836069|Experimental|PD 0332334-α2δ ligand (450mg)|PD 0332334, 450mg/day, for 8 weeks and then 2 weeks of dose tapering.
11573377|NCT00836069|Experimental|PD 0332334-α2δ ligand (600mg)|PD 0332334, 600mg/day, for 8 weeks and then 2 weeks of dose tapering.
11573378|NCT00836069|Active Comparator|Paroxetine|Paroxetine, 20mg/daym for 8 weeks and then 2 weeks of dose tapering.
11573379|NCT00836069|Placebo Comparator|Placebo|Inactive Substance (placebo) for 10 weeks.
11573380|NCT00836056|Experimental|Clindamycin (test)|Clindamycin 300 mg Capsule (test) dosed in first period followed by Cleocin® 300 mg Capsule (reference) dosed in second period
11573381|NCT00836056|Active Comparator|Cleocin® (reference)|Cleocin® 300 mg Capsule (reference) dosed in first period followed by Clindamycin 300 mg Capsule (test) dosed in second period
11573382|NCT00836043||Group 1|
11573383|NCT00836030||A|
11573384|NCT00836017||BOTOX®|Patients received BOTOX® (onabotulinumtoxinA) treatment as standard of care in clinical practice as prescribed by the physician. No intervention was administered as part of the study.
11573385|NCT00836004|Experimental|Clindamycin (test)|Clindamycin 300 mg Capsule (test) dosed in first period followed by Cleocin® 300 mg Capsule (reference) dosed in second period
11573386|NCT00836004|Active Comparator|Cleocin® (reference)|Cleocin® 300 mg Capsule (reference) dosed in first period followed by Clindamycin 300 mg Capsule (test) dosed in second period
11573542|NCT00834912|Experimental|1: Tramadol HCl (Confab Laboratories) fasting|
11573387|NCT00835991|Experimental|Glyburide Metformin|Glyburide Metformin 5/500 Film-Coated Tablet (test) dosed in first period followed by Glucovance® 5/500 mg Tablet (reference) dosed in second period
11573388|NCT00835991|Active Comparator|Glucovance®|Glucovance® 5/500 mg Tablet (reference) dosed in first period followed by Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in second period
11573389|NCT00835978|Other|A|Randomized arm
11573390|NCT00835978|Other|B|Randomized arm
11573391|NCT00835978|Other|C|Non-randomized arm
11573392|NCT00835965|Active Comparator|Active Comparator|Patients receive aprepitant and dexamethasone for prevention of postoperative nausea and vomiting
11573393|NCT00835965|Placebo Comparator|Placebo Comparator|Patients receiving aprepitant and placebo dexamethasone for prevention of postoperative nausea and vomiting
11573394|NCT00835952|Experimental|ATX-101|
11573395|NCT00835939|Active Comparator|25% Dextrose and 1% Lidocaine|
11573396|NCT00835939|Placebo Comparator|Lidocaine|
11573397|NCT00835926|Experimental|Fluzone® Vaccine Group 1|Participants aged 18 to 59 years at enrollment - Fluzone® Group
11573398|NCT00835926|Experimental|Fluzone® Vaccine Group 2|Participants aged 60 years and older at enrollment - Fluzone® Group
11573399|NCT00835900|Experimental|varenicline|drug plus counseling.
11573400|NCT00835900|Active Comparator|placebo|placebo plus counseling
11573401|NCT00835887|Experimental|1|Treatment with low dose flavanoids
11573402|NCT00835887|Experimental|2|Treatment with high dose flavanoids
11573403|NCT00835861|Experimental|Metformin|Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation. After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.
11573404|NCT00835861|Active Comparator|Insulin|Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation. After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.
11573405|NCT00835848|Active Comparator|Exenatide|25 μg Byetta (Lilly, Exenatide) is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
11573406|NCT00835848|Placebo Comparator|Saline|Isotonic saline infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
11573407|NCT00835835|Placebo Comparator|Control group|The placebo group did not receive treatment during the matched period yet did undergo all assessments. The MS Placebo group received equal treatment following the study intervention period.
11573408|NCT00835835|Experimental|Combination Treadmill training group|Subjects randomized to Combination therapy received 20 minutes of Lokomat assisted treadmill training followed by up to 20 minutes of BWS treadmill training (without robotic assistance) twice a week.
11573409|NCT00835822|Experimental|A|Arm treated with Investigational product.
11573410|NCT00835822|Placebo Comparator|B|Arm treated with placebo.
11573411|NCT00835809||Acute respiratory diseases.|Patient admit in emergency or intensive care unite with acute respiratory insufficiency.
11573412|NCT00835796|Experimental|Finasteride|Finasteride 5 mg Tablet (test) dosed in first period followed by Proscar® 5 mg Tablet (reference) dosed in second period
11573413|NCT00835796|Active Comparator|Proscar®|Proscar® 5 mg Tablet (reference) dosed in first period followed by Finasteride 5 mg Tablet (test) dosed in second period
11573414|NCT00835783||FUO|Patients with fever of unknown origin undergoing FDG-PET/CT as part of work-up.
11573415|NCT00835783||BUO|Patients with bacteremia of unknown origin undergoing FDG-PET/CT as part of work-up.
11573416|NCT00835783||VGI|Patients with vascular graft infections undergoing FDG-PET/CT as part of work-up.
11573417|NCT00835770|Experimental|BG00012 plus placebo|In the first phase, participants will receive BG00012 240 mg (two 120 mg capsules) twice a day (BID) and 2 placebo capsules once a day. In the second phase participants will receive open-label BG00012 240 mg BID, for atleast 8 years.
11573418|NCT00835770|Experimental|BG00012|In the first phase participants will receive BG00012 240 mg (two 120 mg capsules) three times a day (TID). In the second phase participants will receive open-label BG00012 240 mg BID for atleast 8 years.
11573419|NCT00835757||1|Diabetic peripheral neuropathy
11573420|NCT00835757||2|Healthy controls
11573421|NCT00835744|Placebo Comparator|A|Patients undergo a standard treatment with clomiphene citrate from day 3 until day 7 of the cycle at a dose of 50 mg daily. If no reaction on day 13 of the cycle, an increased dose of 100 mg of clomiphene citrate is administered from day 13 until day 17 of the cycle.
11573422|NCT00835744|Active Comparator|B|Patients undergo a standard treatment with clomiphene citrate from day 3 until day 7 of the cycle at a dose of 50 mg daily. If no reaction on day 13 of the cycle, gonadotropins (75IU) are administered from day 13 until day 17 of the cycle.
11573423|NCT00835731|Experimental|1|400mcg buccal misoprostol
11573424|NCT00835731|Experimental|2|Dilapan-S, control: vitamin B-12 administered sublingually
11573425|NCT00835718|Experimental|Stage I, Arm 1|MK0594 5 mg/day
11573426|NCT00835718|Placebo Comparator|Stage I, Arm 2|Placebo
11573427|NCT00835718|Experimental|Stage II, Arm 2|MK0594 1 mg/day
11573428|NCT00835718|Experimental|Stage II, Arm 3|MK0594 1 mg/week
11573429|NCT00835718|Placebo Comparator|Stage II, Arm 4|Placebo
11573430|NCT00835705|Experimental|Amoxicillin Clavulanic Acid|Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in first period followed by Augmentin® 400-57 mg Chewable Tablet (reference) dosed in second period
11573431|NCT00835705|Active Comparator|Augmentin®|Augmentin® 400-57 mg Chewable Tablet (reference) dosed in first period followed by Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in second period
11573432|NCT00835692|Experimental|Clarithromycin Tablets|Clarithromycin 500 mg Tablet (test) dosed in first period followed by Biaxin® 500 mg Tablet (reference) dosed in second period
11573433|NCT00835692|Active Comparator|Biaxin® Tablets|Biaxin® 500 mg Tablet (reference) dosed in first period followed by Clarithromycin 500 mg Tablet (test) dosed in second period
11573434|NCT00835679|Experimental|Cohort A (no systemic neoadjuvant therapy)|Patients receive no systemic neoadjuvant therapy between enrollment and the time of definitive surgical resection of liver metastases. Liver biopsies were performed at surgery since this cohort received no systemic therapy.
11573435|NCT00835679|Experimental|Cohort B (cetuximab)|Patients receive 400 mg/m^2 cetuximab IV over 120 minutes on day 1 and 250 mg/m^2 cetuximab IV over 60-120 minutes on day 8. Definitive surgical resection of liver metastases will take place on day 15.
11573436|NCT00835679|Experimental|Cohort C (dasatinib)|Patients receive dasatinib 100 mg orally once daily on days 1-14. Definitive surgical resection of liver metastases will take place on day 15.
11573437|NCT00835679|Experimental|Cohort D (cetuximab, dasatinib)|Patients receive 400 mg/m^2 cetuximab IV over 120 minutes on day 1 and 250 mg/m^2 cetuximab IV over 60-120 minutes on day 8 AND dasatinib 100 mg orally once daily on days 1-14. Definitive surgical resection of liver metastases will take place on day 15.
11573438|NCT00835666|Experimental|Finasteride|Finasteride 5 mg Tablet (test) dosed in first period followed by Proscar® 5 mg Tablet (reference) dosed in second period
11573439|NCT00835666|Active Comparator|Proscar®|Proscar® 5 mg Tablet (reference) dosed in first period followed by Finasteride 5 mg Tablet (test) dosed in second period
11573440|NCT00835653||1|patients with a carpal tunnel syndrome
11573441|NCT00835653||2|patients without a carpal tunnel syndrome
11573442|NCT00835640|Experimental|1|
11573443|NCT00835640|Active Comparator|2|
11573444|NCT00835627|Active Comparator|sertraline|flexible dose sertraline
11573445|NCT00835627|Active Comparator|CBT-ip|cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual, 1 hour therapy sessions
11573446|NCT00835627|Active Comparator|Combined (sertraline + CBT-ip)|flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12 individual, 1 hour therapy sessions
11573447|NCT00835627|Active Comparator|Standard care|community care / treatment as usual: routine follow up with existing providers
11573448|NCT00835614|Experimental|1|
11573449|NCT00835614|Active Comparator|2|
11573450|NCT00835588|Experimental|Pantoprazole|Pantoprazole Sodium 40 mg DR Tablet (test) dosed in first period followed by Protonix® 40 mg DR Tablet (reference) dosed in second period
11573451|NCT00835588|Active Comparator|Protonix®|Protonix 40 mg DR Tablet (reference) dosed in first period followed by Pantoprazole Sodium 40 mg DR Tablet (test) dosed in second period
11573452|NCT00835575|Experimental|1|
11573453|NCT00835575|Active Comparator|2|
11573454|NCT00835562|Experimental|Osteosynthesis|
11573455|NCT00835562|Experimental|Non-surgical|
11573456|NCT00835562|Experimental|Hemiarthroplasty|
11573457|NCT00835549|Experimental|1|
11573458|NCT00835549|Active Comparator|2|
11573459|NCT00835536|Experimental|1|
11573460|NCT00835536|Active Comparator|2|
11573461|NCT00835523||OHSS risk|
11573462|NCT00835510|Experimental|Butenafine cream 1% (Taro)|Butenafine cream manufactured by Taro applied for 7 days
11573463|NCT00835510|Active Comparator|Lotrimin Ultra (butenafine) 1%|Lotrimin Ultra (butenafine) applied for 7 days
11573464|NCT00835510|Placebo Comparator|Vehicle|Butenafine vehicle applied for 7 days
11573465|NCT00835497|Experimental|Glipizide Metformin|Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in first period followed by Metaglip® 5/500 mg Tablet (reference) dosed in second period
11573466|NCT00835497|Active Comparator|Metaglip®|Metaglip® 5/500 mg Tablet (reference) dosed in first period followed by Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in second period
11573467|NCT00835484|Experimental|1|
11573468|NCT00835484|Active Comparator|2|
11573469|NCT00835471|Experimental|1|Erlotinib plus docetaxel (squamous cell NSCLC) or pemetrexed (non-squamous cell NSCLC)
11573470|NCT00835471|Active Comparator|2|Erlotinib
11573471|NCT00835445||1|Asthmatics with polyps
11573472|NCT00835445||2|Non-asthmatics with polyps
11573473|NCT00835419|Experimental|1|P276-00 investigational product (small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor)
11573474|NCT00835406|Experimental|Alendronate Sodium First|70 mg Alendronate Sodium Tablets test product dosed in first period followed by 70 mg Fosamax® Tablets reference product dosed in second period
11573475|NCT00835406|Active Comparator|Fosamax® First|70 mg Fosamax® Tablets reference product dosed in first period followed by 70 mg Alendronate Sodium Tablets test product dosed in second period.
11573476|NCT00835393|Experimental|1|
11573477|NCT00835393|Active Comparator|2|
11573478|NCT00835380|Experimental|1|VAQTA™
11573479|NCT00835367|Experimental|Amlodipine Benazepril|Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period
11573480|NCT00835367|Active Comparator|Lotrel®|Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in second period
11573481|NCT00835354|Experimental|1|
11573482|NCT00835354|Active Comparator|2|
11573483|NCT00835341||p16-methylated|patients with mild or moderate oral epithelial dysplasia containing methylated p16 CpG island.
11573484|NCT00835341||p16-unmethylated|patients with mild or moderate oral epithelial dysplasia NOT containing methylated p16 CpG island.
11573485|NCT00835328|Experimental|Exendin (9-39) 0.02 mg/kg/hr|Cohort 1: Participants will be administered 0.02 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
11573537|NCT00834964|Active Comparator|Effexor®|Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period
11573538|NCT00834938||1|Patients with DM2 undergoing RYGB with remission of DM2
11573539|NCT00834938||2|Patients with DM2 undergoing RYGB without remission of DM2
11573540|NCT00834925|No Intervention|standard dose diltiazem|
11573541|NCT00834925|Experimental|low dose diltiazem|
11573486|NCT00835328|Experimental|Exendin (9-39) 0.04 mg/kg/hr|Cohort 2: Participants will be administered 0.04 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
11573487|NCT00835328|Experimental|Exendin (9-39) 0.10 mg/kg/hr|Cohort 3: Participants will be administered 0.10 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 6 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
11573488|NCT00835328|Experimental|Exendin (9-39) 0.20 mg/kg/hr|Cohort 4: Participants will be administered 0.20 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
11573489|NCT00835315||3|patients with psoriasis , patients with atopic dermatitis and healthy patients.
11573490|NCT00835302|Experimental|Manipulation + Exercise Group|Cervicothoracic manipulation and ROM exercises
11573491|NCT00835289|Placebo Comparator|Placebo (corn oil)|Each participant will be taking 3 capsules of a matching placebo (corn oil).
11573492|NCT00835289|Experimental|PUFA (Omax3)|Omax3[TM] (Cenestra Health), or dietary supplement: n-3 polyunsaturated fatty acids, is a 1 gram softgel capsule containing 94.5% omega-3 fatty acids. Each participant will be taking 3 capsules of Omax3[TM].
11573493|NCT00835276|Experimental|1|
11573494|NCT00835276|Active Comparator|2|
11573495|NCT00835263|Experimental|Lamotrigine|Lamotrigine 200 mg Tablet (test) dosed in first period followed by Lamictal® 200 mg Tablet (reference) dosed in second period
11573496|NCT00835263|Active Comparator|Lamictal®|Lamictal® 200 mg Tablet (reference) dosed in first period followed by Lamotrigine 200 mg Tablet (test) dosed in second period
11573497|NCT00835250|Active Comparator|Laparoscopy|Laparoscopic cholecystectomy
11573498|NCT00835250|Experimental|Transumbilical|Transumbilical endoscopic cholecystectomy
11573499|NCT00835250|Experimental|Transvaginal|Transvaginal endoscopic cholecystectomy
11573500|NCT00835237|Experimental|Boostrix Group|Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)
11573501|NCT00835237|Active Comparator|Decavac Group|Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)
11573502|NCT00835224|Experimental|Midodrine|A drug to treat low blood pressure.
11573503|NCT00835224|Experimental|L-Name|L-Name: A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
11573504|NCT00835224|Placebo Comparator|Placebo|Placebo: A pill with an inactive substance that looks like the study drug.
11573505|NCT00835211|Experimental|1|
11573506|NCT00835211|Active Comparator|2|
11573507|NCT00835198|Active Comparator|1|Dapsone gel 5% and Tretinoin gel 0.025%
11573508|NCT00835198|Active Comparator|2|Tretinoin gel 0.025%
11573509|NCT00835185|Experimental|IMC-11F8 (necitumumab) /mFOLFOX-6 regimen|Participants will receive IMC-11F8 (necitumumab) once every 2 weeks in combination with the mFOLFOX-6 regimen (oxaliplatin/5-FU/FA)
11573510|NCT00835172|Experimental|Glimepiride|Glimepiride 4 mg Tablet (test) dosed in first period followed by Amaryl® 4 mg Tablet (reference) dosed in second period
11573511|NCT00835172|Active Comparator|Amaryl®|Amaryl® 4 mg Tablet (reference) dosed in first period followed by Glimepiride 4 mg Tablet (test) dosed in second period
11573512|NCT00835159|Experimental|Rivastigmine Patch|Group receiving Rivastigmine Patch
11573513|NCT00835159|Placebo Comparator|Placebo Patch|A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
11573514|NCT00835146|Experimental|1|
11573515|NCT00835146|Active Comparator|2|
11573516|NCT00835120|Experimental|Pioglitazone|Pioglitazone has been approved by the U.S. Food and Drug Administration (FDA) to help people who are diagnosed with diabetes
11573517|NCT00835107|Experimental|Ziprasidone|
11573518|NCT00835107|Placebo Comparator|Sugar pill|
11573519|NCT00835094|Experimental|Morning|
11573520|NCT00835094|Experimental|Evening|
11573521|NCT00835081|Experimental|1|
11573522|NCT00835081|Active Comparator|2|
11573523|NCT00835068||BeneFIX|
11573524|NCT00835042|Experimental|1|
11573525|NCT00835042|Active Comparator|2|
11573526|NCT00835029|Active Comparator|Clotrimazole varnish|Clotrimazole in a slow release varnish treatment
11573527|NCT00835029|Active Comparator|Clotrimazole troches|Clotrimazole troches 10 mgx5 day for treatment of denture associated candiad infection
11573528|NCT00835016|Experimental|Early psychosocial stimulation (LTP)|The 10 session of Early psychosocial stimulation (LTP)will be delivered to depressed mothers in the intervention group
11573529|NCT00835016|Active Comparator|Waiting group|Waiting group will receive standard follow-up by their own LHWs. This group intervention will be documented at baseline, 3 months (end of the trial) and at 6 months. Similar training of Learning through Play will be provided to the mothers in this group at the end of the study.
11573530|NCT00835003|Active Comparator|1|Elective caesarean section at 38 weeks and 3 days of gestation
11573531|NCT00835003|Active Comparator|2|Elective caesarean section at 39 weeks and 3 days of gestation
11573532|NCT00834990|Experimental|1|
11573533|NCT00834990|Active Comparator|2|
11573534|NCT00834977|Experimental|Amlodipine Benazepril|Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period
11573535|NCT00834977|Active Comparator|Lotrel®|Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsules (test) dosed in second period
11573544|NCT00834912|Experimental|3: Tramadol HCl (Trillium Healthcare) fasting|
11573545|NCT00834899|Experimental|1|As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the eptifibatide arm will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
11573546|NCT00834899|Placebo Comparator|2|As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
11573547|NCT00834886|Active Comparator|Combination|Bright light 10.000 lux + melatonin 3 mg
11573548|NCT00834886|Active Comparator|Melatonin|Melatonin 3 mg + placebo red light 400 lux
11573549|NCT00834886|Active Comparator|Bright light|Bright light 10.000 lux + placebo capsule 3 mg rice flour
11573550|NCT00834886|Placebo Comparator|Placebo|Placebo Red light 400 lux + placebo capsule 3 mg rice flour
11573551|NCT00834873|Experimental|Carvedilol|Carvedilol 25 mg Tablet (test) dosed in first period followed by Coreg® 25 mg Tablet (reference) dosed in second period
11573552|NCT00834873|Active Comparator|Coreg®|Coreg® 25 mg Tablet (reference) dosed in first period followed by Carvedilol 25 mg Tablet (test) dosed in second period
11573553|NCT00834860|Active Comparator|CHC, HCC|100 naïve CHC patients concomitant with hepatocellular carcinoma without clinical evidence of HCC recurrence more than 3 months after curative treatments.
11573554|NCT00834860|Active Comparator|CHC, LC|100 naïve CHC patients without malignancy
11573555|NCT00834847|Experimental|Pravastatin fast|Test product under fasting conditions dosed in first period followed by either test or reference product dosed under fed conditions in second and third periods
11573556|NCT00834847|Experimental|Pravastatin|Test product under fed conditions dosed in first period followed by either test product dosed under fasting conditions or reference product dosed under fed conditions in second and third periods
11573557|NCT00834847|Active Comparator|Pravachol®|Reference product under fed conditions dosed in first period followed by test product dosed under either fed or fasted conditions in second and third periods
11573558|NCT00834834|Active Comparator|Fluoxetine|Participants will receive fluoxetine with clinical management, which may involve switching medication to citalopram, another SSRI.
11573559|NCT00834834|Active Comparator|Dialectical behavior therapy|Participants will receive dialectical behavioral therapy (DBT).
11573560|NCT00834821|Experimental|1|Participants will undergo the Child Life and Attention Skills (CLAS) Program.
11573561|NCT00834821|Active Comparator|2|Participants will undergo parent focused training (PFT).
11573562|NCT00834821|No Intervention|3|Participants will receive a list of referrals for clinical services as needed, including professional organizations, support groups, and the community mental health system.
11573563|NCT00834808|Experimental|1: Tramadol HCl 100mg|
11573564|NCT00834808|Experimental|2: Tramadol HCl 200mg|
11573565|NCT00834808|Experimental|3: Tramadol HCl 300mg|
11573566|NCT00834795|Experimental|Carvedilol|Carvedilol 25 mg Tablet (test) dosed in first period followed by Coreg® 25 mg Tablet (reference) dosed in second period
11573567|NCT00834795|Active Comparator|Coreg®|Coreg® 25 mg Tablet (reference) dosed in first period followed by Carvedilol 25 mg Tablet (test) dosed in second period
11573568|NCT00834782||IOP|Measuring IOP
11573569|NCT00834756|Experimental|Azithromycin|Azithromycin 600 mg tablet (test) dosed in first period followed by Zithromax® 600 mg tablet (reference) dosed in second period
11573570|NCT00834756|Active Comparator|Zithromax®|Zithromax® 600 mg tablet (reference) dosed in first period followed by Azithromycin 600 mg tablet (test) dosed in second period
11573571|NCT00834743|Experimental|1|
11573572|NCT00834743|Active Comparator|2|
11573573|NCT00834730|Active Comparator|Ketamine|Ketamine 2mg/kg IV
11573574|NCT00834730|Experimental|N2O gas|50%-70% N2O gas inhalation
11573575|NCT00834717|Experimental|Granisetron|Granisetron 1 mg Tablet (test) dosed in first period followed by Kytril® 1 mg Tablet (reference) dosed in second period
11573576|NCT00834717|Active Comparator|Kytril®|Kytril 1 mg Tablet (reference) dosed in first period followed by Granisetron 1 mg Tablet (test) dosed in second period
11573577|NCT00834704|Other|1|Dose determination
11573578|NCT00834691||1|Patients with anemia and systolic heart failure
11573579|NCT00834691||2|Patients with systolic heart failure but without anemia
11573580|NCT00834691||3|Patients with at least moderate chronic renal failure, with or without anemia and without systolic heart failure.
11573581|NCT00834678|Experimental|Bendamustine and Erlotinib|Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 - 21 of each 28 day cycle.
11573582|NCT00834665|Experimental|hTERT/GM-CSF+PCV, T cell infusion|ARM A = hTERT/GM-CSF+PCV, T cell infusion
11573583|NCT00834665|Experimental|GM-CSF+PCV, T cell infusion,GM-CSF+PVC|ARM B GM-CSF+PCV, T cell infusion,GM-CSF+PVC
11573584|NCT00834652|Experimental|1|Participants will receive sertraline and metformin.
11573585|NCT00834652|Placebo Comparator|2|Participants will receive sertraline and placebo.
11573586|NCT00834639|Experimental|1|
11573587|NCT00834639|Active Comparator|2|
11573588|NCT00834626|Other|Surgery group|Interventional study of the effects of a novel metabolic procedure of Ileal Interposition with Sleeve Gastrectomy
11573589|NCT00834613|Experimental|1|
11573590|NCT00834613|Active Comparator|2|
11573591|NCT00834600|Experimental|HCTZ , ARB|Patients randomized to the Experimental Arm have initial drug choice determined by Plasma Renin Activity level. Low renin subjects are assigned to the diuretic hydrochlorothothiazide. Those with PRA >.65 ng/hr are assigned to the angiotensin receptor blocker, olmesartan.
11573592|NCT00834600|Active Comparator|Conventional antihypertensive therapy|All patients randomized to Active Comparator Arm received hydrochlorothiazide 25 mg, which is increased to 50 mg at 3-4 weeks. At 6 weeks, olmesartan may be added if BP > 140 mmHg
11573593|NCT00834587|Experimental|Glipizide Metformin|Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in first period followed by Metaglip™ 5/500 mg Tablet (reference) dosed in second period
11573658|NCT00834171||2|Loteprednol etabonate (0.5%) and tobramycin (0.3%)
11573659|NCT00834158|Active Comparator|TACE|perform TACE only
11573594|NCT00834587|Active Comparator|Metaglip™|Metaglip™ 5/500 mg Tablet (reference) dosed in first period followed by Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in second period
11573595|NCT00834574|Experimental|1|
11573596|NCT00834574|Active Comparator|2|
11573597|NCT00834561|Experimental|Lamotrigine|Lamotrigine 200 mg Tablet (test) dosed in first period followed by Lamictal® 200 mg Tablet (reference) dosed in second period
11573598|NCT00834561|Active Comparator|Lamictal®|Lamictal® 200 mg Tablet (reference) dosed in first period followed by Lamotrigine 200 mg Tablet (test) dosed in second period
11573599|NCT00834548||1|WB-MRA standard protocol
11573600|NCT00834548||2|WB-MRA hybrid protocol
11573601|NCT00834535|Experimental|1|
11573602|NCT00834535|Active Comparator|2|
11573603|NCT00834522|Experimental|Granisetron|Granisetron 2 x 1 mg Tablet (test) dosed in first period followed by Kytril® 2 x 1 mg Tablet (reference) dosed in second period
11573604|NCT00834522|Active Comparator|Kytril®|Kytril® 2 x 1 mg Tablet (reference) dosed in first period followed by Granisetron 2 x 1 mg Tablet (test) dosed in second period
11573605|NCT00834509||Obstructive Sleep Apnea (OSA)|OSA participants will be treated with a CPAP/APAP treatment, per standard clinical care.
11573606|NCT00834509||Control|Control participants will not receive APAP/CPAP treatment, if not diagnosed with OSA.
11573607|NCT00834496||1|"Our experience with the use of Sirolimus is delineated below. About 15% to 20% of our patients are currently switched to Sirolimus.Indications for conversion from calcinurin inhibitors (CNIs) to Sirolimus more than 90 days post liver transplantation include:
~CNI renal toxicity.
~Hepatic fibrosis on biopsy.
~CNI neurologic toxicity.
~Post transplant diabetes. Any of the above 4 indications makes a patient a candidate for conversion from CNIs to Sirolimus at or > 90 days after liver transplantation."
11573608|NCT00834483|Experimental|1|Knotless suture for wound closure
11573609|NCT00834483|Active Comparator|2|Layered traditional wound closure (monocryl)
11573610|NCT00834470|Experimental|Atropine|Atropine 0.01mg/kg IV
11573611|NCT00834470|Placebo Comparator|Normal saline|Same volume of atropine
11573612|NCT00834457|Active Comparator|2A|co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg po(Trizivir)one tablet twice daily(BID)for 96 weeks
11573613|NCT00834457|Active Comparator|2B|co-formulated abacavir 600mg/3TC 300mg orally (as Kivexa) one tablet daily plus fixed dose lopinavir 133.3mg/ritonavir 33.3mg orally (as Aluvia) four tablets daily for 96 weeks
11573614|NCT00834444|Experimental|1|
11573615|NCT00834444|Active Comparator|2|
11573616|NCT00834431|Experimental|1|
11573617|NCT00834431|Active Comparator|2|
11573618|NCT00834418|Experimental|Leflunomide|Leflunomide 20 mg Tablet
11573619|NCT00834418|Active Comparator|Arava™|Arava™ 20 mg Tablet
11573620|NCT00834405|Experimental|Leflunomide|Leflunomide 20 mg Tablet
11573621|NCT00834405|Active Comparator|Arava®|Arava® 20 mg Tablet
11573622|NCT00834392|No Intervention|Control|
11573623|NCT00834392|Experimental|Exercise|
11573624|NCT00834379|Experimental|Pravastatin|Pravastatin 40 mg Tablet (test) dosed in first period followed by Pravachol® 40 mg Tablet (reference) dosed in second period
11573625|NCT00834379|Active Comparator|Pravachol®|Pravachol® 40 mg Tablet (reference) dosed in first period followed by Pravastatin 40 mg Tablet (test) dosed in second period
11573626|NCT00834366|Experimental|Tramadol HCl 200 mg Film-coated Tablets|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet based on randomization schedule.
11573627|NCT00834366|Experimental|Tramadol HCl 200 mg Uncoated Tablets|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Uncoated Tablet based on randomization schedule.
11573628|NCT00834353||Pulmonary tuberculosis patients|Freshly diagnosed pulmonary tuberculosis patients who are started with antituberculosis drugs
11573629|NCT00834340|Experimental|Glimepiride|Glimepiride 4 mg Tablet (test) dosed in first period followed by Amaryl® 4 mg Tablet (reference) dosed in second period
11573630|NCT00834340|Active Comparator|Amaryl®|Amaryl® 4 mg Tablet (reference) dosed in first period followed by Glimepiride 4 mg Tablet (test) dosed in second period
11573631|NCT00834327|Experimental|1|aplindore 0.05 mg MR total daily dose
11573632|NCT00834327|Experimental|2|aplindore 0.1 mg MR total daily dose
11573633|NCT00834327|Experimental|3|aplindore 0.25 mg MR total daily dose (to include short titration)
11573634|NCT00834327|Experimental|4|aplindore 0.5 mg MR total daily dose (to include short titration)
11573635|NCT00834327|Placebo Comparator|5|Placebo
11573636|NCT00834314|Experimental|Vacuum-pack|see Interventions
11573637|NCT00834314|Active Comparator|Abdominal dressing|see Interventions
11573638|NCT00834301|Experimental|Treatment Arm|
11573639|NCT00834288|Experimental|1: 1x200 mg Tramadol HCl OAD tablet daily|
11573640|NCT00834288|Active Comparator|2: 1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly|
11573641|NCT00834275|Experimental|1|
11573642|NCT00834275|Active Comparator|2|
11573643|NCT00834262||A|
11573644|NCT00834249|Experimental|Venlafaxine|Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period
11573645|NCT00834249|Active Comparator|Effexor®|Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period
11573646|NCT00834236|Experimental|gastric cancer|gastric cancer patients
11573647|NCT00834236|Active Comparator|normal subject|healthy subject
11573648|NCT00834223|Other|Aquashunt|Open label, all subjects receive device.
11573649|NCT00834210|Active Comparator|1|Dapsone Gel 5% and Tazarotene Cream 0.1%
11573650|NCT00834210|Active Comparator|2|Tazarotene Cream 0.1%
11573651|NCT00834197|Experimental|1|
11573652|NCT00834197|Active Comparator|2|
11573653|NCT00834184|Experimental|A|nikkomycin Z 250 mg BID versus placebo BID x 14 days
11573654|NCT00834184|Experimental|B|nikkomycin Z 500 mg BID versus placebo BID x 14 days
11573655|NCT00834184|Experimental|C|nikkomycin Z 750 mg BID versus placebo BID x 14 days
11573656|NCT00834184|Experimental|D|nikkomycin Z 750 mg TID versus placebo TID x 14 days
11573657|NCT00834171||1|Loteprednol etabonate ophthalmic suspension 0.5%
11573660|NCT00834158|Experimental|TACE+PVE|perform TACE and PVE sequentially
11573661|NCT00834145|Experimental|1|Patients will receive a NormaTec pump and perform active pumping twice daily during hospitalization and thereafter once daily in addition to routine medical therapy.
11573662|NCT00834145|No Intervention|2|Routine medical treatment
11573663|NCT00834132|Experimental|Azithromycin|Azithromycin 600 mg tablet (test) dosed in first period followed by Zithromax® 600 mg tablet (reference) dosed in second period
11573664|NCT00834132|Active Comparator|Zithromax®|Zithromax® 600 mg tablet (reference) dosed in first period followed by Azithromycin 600 mg tablet (test) dosed in second period
11573665|NCT00834119|Experimental|Mometasone furoate|
11573666|NCT00834119|Experimental|Mometasone furoate plus an oral antihistamine|
11573667|NCT00834106|Experimental|qHPV|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6
11573668|NCT00834106|Placebo Comparator|Placebo|Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6
11573669|NCT00834093|Experimental|Biological/Vaccine|'Epstein-Barr Virus Specific Immunotherapy' given intravenously on Days 1 and 14
11573670|NCT00834080|Experimental|Medisorb naltrexone 380 mg (VIVITROL)|
11573671|NCT00834067|Experimental|1|
11573672|NCT00834067|Active Comparator|2|
11573673|NCT00834054||Double-lung transplanted patients|
11573674|NCT00834041|Experimental|Aliskiren 2 mg/kg|Oral mini-tablets (3.125 mg) of aliskiren dosed at 2 mg/kg body weight once each morning
11573675|NCT00834041|Experimental|Aliskiren 6 mg/kg|Oral mini-tablets (3.125 mg) of aliskiren dosed at 6 mg/kg body weight once each morning
11573676|NCT00834028||1|patients with hepatocellular carcinoma receive transcatheter arterial chemoembolization
11573677|NCT00834015|Other|Experimental|combined strength and aerobic training
11573678|NCT00833989|Placebo Comparator|PLACEBO|
11573679|NCT00833989|Experimental|ACTIVE|
11573680|NCT00833976|Experimental|open-label Lovaza (omega-3 fatty acids)|4g per day (4g once a day or 2g two times a day) for 16 weeks
11573681|NCT00833963||Participants Treated With Trastuzumab|Participants who are being treated with trastuzumab during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
11573682|NCT00833963||Participants Treated With Trastuzumab and Pertuzumab|Participants who are being treated with the combination of trastuzumab and pertuzumab during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
11573683|NCT00833963||Participants Treated With Ado-Trastuzumab Emtansine|Participants who are being treated with ado-trastuzumab emtansine during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
11573684|NCT00833950|Experimental|narrow band noise|Phase out in narrow band noise tinnitus patients
11573685|NCT00833937|Experimental|Zolpidem|Zolpidem Tartrate 10 mg Tablet (test) dosed in first period followed by Ambien® 10 mg Tablet (reference) dosed in second period
11573686|NCT00833937|Active Comparator|Ambien®|Ambien® 10 mg Tablet (reference) dosed in first period followed by Zolpidem Tartrate 10 mg Tablet (test) dosed in second period
11573687|NCT00833924|Other|1|Treatment with Endovascular Graft
11573688|NCT00833911|Experimental|Tramadol Contramid® OAD|
11573689|NCT00833898|No Intervention|Caregiver Control|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care.
11573690|NCT00833898|Experimental|Caregiver Intervention|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation Paced Respiration and Relaxation (PEPRR), which included one-on-one psychoeducation, stress management intervention, with paced respiration.
11573691|NCT00833885|Other|1|Control
11573692|NCT00833885|Other|2|Masks
11573693|NCT00833885|Other|3|Masks and Hygiene
11573694|NCT00833872|Experimental|LEO 22811 solution|
11573695|NCT00833872|Placebo Comparator|placebo solution|
11573696|NCT00833859|Experimental|Chemotherapy followed by Radiation Treatment|GTX-SRS: Gemcitabine, Taxotere, Xeloda (GTX)-Stereotactic Radiosurgery (SRS)
11573697|NCT00833833|Experimental|Phase 1: 2 mg pomalidomide|Pomalidomide 2 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
11573698|NCT00833833|Experimental|Phase 1: 3 mg pomalidomide|Pomalidomide 3 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
11573699|NCT00833833|Experimental|Phase 1: 4 mg pomalidomide|Pomalidomide 4 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
11573700|NCT00833833|Experimental|Phase 1: 5 mg pomalidomide|Pomalidomide 5 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
11573701|NCT00833833|Experimental|Phase 2: pomalidomide + dexamethasone|Combination therapy of 4 mg pomalidomide given once per day on Days 1-21 of each 28-day cycle and the starting dose of dexamethasone (determined by age) on days 1, 8, 15, and 22 of each 28-day cycle. The starting dose of dexamethasone was 40 mg for participants who were ≤ 75 years of age and 20 mg for participants who were > 75 years of age. Dose reduction steps for dexamethasone were provided for drug-related toxicities.
11573702|NCT00833833|Experimental|Phase 2: pomalidomide|4 mg pomalidomide was given once per day on Days 1-21 of each 28-day cycle until PD. Participants in the single agent pomalidomide treatment arm who developed confirmed PD at any time had the option to receive oral dexamethasone on days 1, 8, 15, and 22 of each 28-day cycle at the starting dose of 20 or 40 mg depending on age in addition to their current dose of pomalidomide, or to discontinue treatment.
11573703|NCT00833820|Active Comparator|A|Patients receiving real rTMS
11573704|NCT00833820|Sham Comparator|B|patients receiving sham stimulation
11573705|NCT00833807|Experimental|Nab-paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.
~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
11573706|NCT00833794|Experimental|1 Tramadol Once A Day|
11573707|NCT00833794|Placebo Comparator|2 Placebo|
11573708|NCT00833781|Active Comparator|mRNA-transfected dendritic cells|Participants in this arm/group received mRNA-transfected autologous dendritic cells
11573709|NCT00833781|Placebo Comparator|Dendritic cells without mRNA|Participants in this arm/group received autologous dendritic cells with no mRNA transfection
11573710|NCT00833768|Active Comparator|Sevelamer carbonate|
11573711|NCT00833768|Placebo Comparator|Placebo|
11573712|NCT00833755|Active Comparator|Opioid - Ketamine|This group consists of 16 subjects who have chronic pain conditions treated with an opioid regimen. Subjects were randomized to receive a ketamine treatment during the study. They were given an intravenous infusion of ketamine (0.05mg/kg) diluted in 50 ml normal saline over 30 minutes.
11573713|NCT00833755|Active Comparator|Non-opioid - Ketamine|This group consists of 22 subjects who have chronic pain conditions but were not on an opioid regimen over the last 3 months. Subjects were randomized to receive a ketamine treatment during the study. They were given an intravenous infusion of ketamine (0.05mg/kg) diluted in 50 ml normal saline over 30 minutes.
11573714|NCT00833755|Placebo Comparator|Opioid - Placebos|This group consists of 18 subjects who have chronic pain conditions treated with an opioid regimen. Subjects were randomized to receive a placebo treatment during the study. They were given an intravenous infusion of 50 ml normal saline over 30 minutes.
11573715|NCT00833755|Placebo Comparator|Non-opioid - Placebos|This group consists of 23 subjects who have chronic pain conditions but were not on an opioid regimen over the last 3 months. Subjects were randomized to receive a placebo treatment during the study. They were given an intravenous infusion of 50 ml normal saline over 30 minutes.
11573716|NCT00833742|Experimental|1|ISTDP therapy was provided
11573717|NCT00833742|No Intervention|2|People referred but never seen
11573718|NCT00833729|Experimental|etanercept|Single armed study
11573719|NCT00833716|Experimental|A|
11573720|NCT00833703|Placebo Comparator|Placebo|0.2 mL/kg/day matching placebo solution once daily.
11573721|NCT00833703|Experimental|Clopidogrel 0.2 mg/kg/day|0.2 mL/kg/day Clopidogrel reconstituted solution at 1mg/mL once daily.
11573722|NCT00833690|Placebo Comparator|[A:]|Placebo to produce no urate elevation
11573723|NCT00833690|Experimental|[B:]|"Inosine to produce a mild urate elevation
~500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL"
11573724|NCT00833690|Experimental|[C.]|"Inosine to produce a moderate urate elevation
~500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL"
11573725|NCT00833664|Experimental|Terbinafine|Terbinafine 250 mg Tablet (test) dosed in first period followed by Lamisil® 250 mg Tablet (reference) dosed in second period
11573726|NCT00833664|Active Comparator|Lamisil®|Lamisil® 250 mg Tablet (reference) dosed in first period followed by Terbinafine 250 mg Tablet (test) dosed in second period
11573727|NCT00833651||tacrolimus|Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus
11573728|NCT00833651||sirolimus|Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing sirolimus
11573729|NCT00833651||Healthy controls|Age, gender- and race-matched individuals, not on immunosuppressive medications
11573730|NCT00833638|Experimental|Tadalafil 2.5 mg|No drug during baseline period, 2.5 mg for 14 days, then will continue at 5 mg for 14 days.
11573731|NCT00833638|Experimental|Tadalafil 5 mg|No drug during baseline period, 5 mg for 14 days, then will continue at 5 mg for 14 days.
11573732|NCT00833638|Placebo Comparator|Placebo|No drug during baseline period, placebo for 14 days, then will continue tadalafil at 5 mg for 14 days.
11573733|NCT00833625|Experimental|PET/CT Scan + Biomarkers Testing|"PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).
~Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis."
11573734|NCT00833612|No Intervention|Control arm of study|
11573735|NCT00833599||1: NIRFLI with ICG|1) Persons affected with lymphatic or lympho-vascular disorders, 2) Family members (affected or unaffected) of persons affected with lymphatic or lympho-vascular disorders and 3) Health, normal persons (Controls) that participate at one of the clinical sites in both the lymphatic function imaging with indocyanine green and the Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) system, as well, as the genetic analysis portion of the study.
11573736|NCT00833599||2: Genetic Analysis Only|Family members of an affected subject from Group 1. Subjects in Group 2 can be either affected or unaffected and will provide a blood or saliva sample for the genetic analysis portion of the study, but will not undergo lymphatic function imaging with ICG and the NIRFLI system. Group 2 individuals are not required to travel to one of the clinical sites in order to participate in the study.
11573737|NCT00833586|Experimental|Terbinafine|Terbinafine HCl 250 mg Tablet (test) dosed in first period followed by Lamisil® 250 mg Tablet (reference) dosed in second period
11573738|NCT00833586|Active Comparator|Lamisil®|Lamisil® 250 mg Tablet (reference) dosed in first period followed by Terbinafine 250 mg Tablet (test) dosed in second period
11573739|NCT00833573||1|For GP : the first 3 consecutive adult patients and the first children seen during the GP's visit with a diagnosis of GERD.
11573740|NCT00833573||2|For Paediatrics : the first 2 consecutive children seen during the Paediatric's visit with a diagnosis of GERD.
11573741|NCT00833560|Experimental|Cyclophosphamide + Bortezomib + Dexamethasone|Part 1 will be the dose titration part for cyclophosphamide. Participants will receive cyclophosphamide, bortezomib, and dexamethasone for 3 cycles. In Part 2, participants will receive cyclophosphamide (dose determined in Part 1) with pre-defined dose of bortezomib and dexamethasone for 3 cycles.
11573742|NCT00833547|Experimental|Eszopiclone|3mg of eszopiclone on two consecutive nights
11573743|NCT00833547|Placebo Comparator|placebo|placebo capsule that looks identical to eszopiclone capsule on two consecutive nights
11573744|NCT00833534|Experimental|Group I (consolidation phase)|Patients receive oral lenalidomide once daily on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
11573745|NCT00833534|Experimental|Group II (consolidation phase)|Patients receive lenalidomide as in group I. Patients also receive rituximab IV once on the day before the start of lenalidomide and then once between days 25-30, 50-55, and 75-80 for a total of 4 doses in the absence of disease progression or unacceptable toxicity.
11573746|NCT00833521|Experimental|Zolpidem|Zolpidem Tartrate 10 mg Tablet (test) dosed in first period followed by Ambien® 10 mg Tablet (reference) dosed in second period
11573747|NCT00833521|Active Comparator|Ambien®|Ambien® 10 mg Tablet (reference) dosed in first period followed by Zolpidem Tartrate 10 mg Tablet (test) dosed in second period
11573748|NCT00833508|Experimental|Test arm|Patients undergoing preoperative chemoradiotherapy will have their exercise capacity measured before and after chemoradiotherapy.
11573749|NCT00833495|Experimental|1|FOV1101-00 concentration 1 and Prednisolone Acetate 0.12% (Pred Mild®)
11573750|NCT00833495|Experimental|2|FOV1101-00 concentration 2 and Prednisolone Acetate 0.12% (Pred Mild®)
11573751|NCT00833495|Experimental|3|Vehicle of FOV1101-00 and Prednisolone Acetate 1% (Pred Forte®)
11573752|NCT00833495|Placebo Comparator|4|Vehicle of FOV1101-00 and vehicle of FOV1101-00
11573753|NCT00833482|Active Comparator|Voriconazole, 200 mg BID (EM)|
11573754|NCT00833482|Active Comparator|Atazanavir/Ritonavir, 300/100 QD (EM & PM)|
11573755|NCT00833482|Active Comparator|Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)|
11573756|NCT00833482|Active Comparator|Voriconazole, 50 mg BID (PM)|
11573757|NCT00833482|Active Comparator|Atazanavir/ritonavir, 300/100mgQD+voriconazole, 50mgBID (PM)|
11573758|NCT00833469|Experimental|Escitalopram|Flexible dose escitalopram 10mg
11573759|NCT00833456||1|Seroquel SR: Patients whose symptoms are controlled with Seroquel SR and started with the therapy up to 1 month before the inclusion
11573760|NCT00833456||2|Atypical antipsychotics: Patients whose symptoms are controlled with atypical antipsychotic in once daily formulation (excluding Seroquel SR) and started with the therapy up to 1 month before the inclusion
11573761|NCT00833443|Active Comparator|Bupropion|Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days.
11573762|NCT00833443|Placebo Comparator|Sugar Pill|
11573763|NCT00833417|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.
11573764|NCT00833404|Experimental|Smoking Cessation|8-week nicotine patch regimen
11573765|NCT00833404|No Intervention|Wait List Control|Smoking as usual
11573766|NCT00833391|Experimental|GSK1838262 arm|Each subject will participate in five dosing sessions separated by at least seven days. Subjects will receive a single dose of current formulation of GSK1838262 or one of the four new formulations of GSK1838262 at each dosing session in random sequence.
11573767|NCT00833378|Active Comparator|Period 2|Treatment B
11573768|NCT00833378|Active Comparator|Period 1|Treatment A
11573769|NCT00833378|Active Comparator|Period 3|Treatment C
11573770|NCT00833365|Active Comparator|Early treatment|Infants randomized to this group will receive their initial dose of ibuprofen prior to reaching 96 hrs old
11573771|NCT00833365|Active Comparator|Late treatment|Infants randomized to this group will receive their initial dose of ibuprofen after infant has reached 96 hrs old but before the infant reaches 10 days old.
11573772|NCT00833352|Experimental|1|Right ventricular lead located in Mid Septum
11573773|NCT00833352|Active Comparator|2|Right ventricular lead located in Apex
11573774|NCT00833339|Experimental|1|mifepristone
11573775|NCT00833339|Placebo Comparator|2|
11573776|NCT00833326|Experimental|ARRY-334543 + docetaxel + prophylactic growth factors|
11573777|NCT00833300|Active Comparator|1|Haloperidol
11573778|NCT00833300|Active Comparator|2|Olanzapine
11573779|NCT00833274|Experimental|1|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
11573780|NCT00833261|Experimental|Single Arm: Chemotherapy with Concurrent Radiation therapy|Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy intensity-modulated radiation therapy
11573781|NCT00833248|Experimental|Degarelix 240 mg/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
11573782|NCT00833248|Active Comparator|Goserelin (3.6 mg) + bicalutamide (50 mg)|"On Day 0, the participants began once-daily oral (p.o.) treatment with bicalutamide as anti-androgen flare protection. This treatment continued for 2 weeks after the first dose of goserelin (i.e. 17 days in total).
~On Day 3, the first goserelin implant was inserted s.c. into the abdominal wall. The second and third doses of goserelin were administered on Days 31 and 59, respectively."
11573783|NCT00833235||Patients with dry eye|No treatment is prescribed for the study. Patient dry eye progression will be followed for up to 60 months. Patients may use artificial tears to treat their dry eye symptoms.
11573784|NCT00833235||Patients with no history of dry eye|No treatment is prescribed for this control group. Patients will be followed for up to 60 months. If needed, patients may use artificial tears.
11573785|NCT00833222||Full Term Infants|Infants born between 37 4/7 weeks and 42 3/7 weeks gestation.
11573786|NCT00833222||Preterm Infants|Infants born between 32 4/7 weeks and 35 3/7 weeks gestation.
11573787|NCT00833209|Experimental|1|Patients with Medication Overuse Headache (MOH)
11573788|NCT00833209|Sham Comparator|2|controls suffering from migraine
11573789|NCT00833209|Sham Comparator|3|controls without any neurological disease
11573790|NCT00833183|Active Comparator|25 J/cm2, with occlusion on right side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to either 25 J/cm2 of red light starting with the occluded side first.
11573791|NCT00833183|Active Comparator|37 J/cm2, with occlusion on right side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to 37 J/cm2 of red light starting with the occluded side first.
11573792|NCT00833183|Active Comparator|25 J/cm2 , with occlusion on left side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to either 25 J/cm2 of red light starting with the occluded side first.
11573793|NCT00833183|Active Comparator|37 J/cm2 , with occlusion on left side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to 37 J/cm2 of red light starting with the occluded side first.
11573794|NCT00833157|Experimental|Glucosamine|
11573795|NCT00833157|Experimental|Ibuprofen|
11573796|NCT00833157|Placebo Comparator|Placebo|
11573797|NCT00833144||1|Congestive Heart Failure
11573798|NCT00833144||2|Patients without congestive heart failure
11573799|NCT00833131|Experimental|1|25 Gy in 5 fractions of 5 Gy over 5 days. One week interval. Consolidating chemotherapy of 3 courses of FOLFOX4. Surgery 10-11 weeks from beginning of radiation and at least 4 weeks from the last dose of fluorouracil.
11573800|NCT00833131|Active Comparator|2|Conventionally fractionated chemoradiation with 50.4 Gy total dose in 28 fractions of 1.8 Gy over 5.5 weeks. Surgery 10-11 weeks from beginning of radiation and at least 4 weeks from the last dose of radiation.
11573801|NCT00833118||Intubation|
11573802|NCT00833105|Experimental|AMES treatment|The subject will receive 25 treatment sessions, conducted 2-3 times per week on the AMES device. Each session will consist of testing followed by 30 minutes of wrist and finger rehabilitation using the AMES device.
11573803|NCT00833092|Placebo Comparator|Sugar pill|Sugar Pill
11573804|NCT00833092|Active Comparator|magnesium|300 milligrams of magnesium daily
11573805|NCT00833079|Experimental|Tacrolimus 0.1% Taro|Tacrolimus 0.1% manufactured by Taro applied for 14 days
11573806|NCT00833079|Active Comparator|Protopic - Tacrolimus 0.1%|Protopic, Tacrolimus 0.1% applied for 14 days
11573807|NCT00833079|Placebo Comparator|Vehicle|Tacrolimus vehicle applied for 14 days
11573808|NCT00833066|Placebo Comparator|Placebo|
11573809|NCT00833066|Experimental|gpASIT 25|
11573810|NCT00833066|Experimental|gpASIT 100|
11573811|NCT00833066|Experimental|gpASIT 400|
11573812|NCT00833053|Experimental|IFX q 6 weeks|
11573813|NCT00833053|Experimental|IFX + MTX|
11573814|NCT00833040|Experimental|Titration of sufentanil, the DBL sufentanil & PBO|"During the Titration Phase, patients titrated to the effective dosage of sublingual sufentanil NanoTab™(20, 30, 40, 60 or 80 mcg). One sublingual sufentanil NanoTab™ was taken as needed for breakthrough pain.
~During the Double-Blind Phase, patients were then randomized to one of six treatment sequences, each of which included seven active doses of sublingual sufentanil (dosage determined in Titration Phase) and three placebo doses taken in random order. One NanoTab™ was taken as needed for breakthrough pain."
11573815|NCT00833027|Experimental|1|Sitagliptin
11573816|NCT00833014|Experimental|I|
11573817|NCT00833001||1|GYNECARE PROLIFT+M* Pelvic Floor Repair System
11573818|NCT00832988||Pacemaker patients|Patients who are implanted with a SJM Zephyr™ DR device for a standard pacing indication will be eligible
11573819|NCT00832962||1|Adult Rh negative pregnant patients from 7 selected centers (SAINT ANTOINE hospital, CHU Marseille, CHU Nantes, CHU Lille, LOUIS MOURIER Hospital, SAINT VINCENT-PAUL Hospital, CH POISSY)
11573820|NCT00832962||2|Adult Rh negative pregnant patients from 6 selected centers (Tenon hospital, Jean VERDIER Hospital, La Pitie-Salpetriere Hospital, Cochin Hospital, Robert Debre Hospital, BICHAT Hospital)
11573821|NCT00832923|No Intervention|Routine IMPACT DC care|Participants receive standard asthma education as routine for IMPACT DC
11573822|NCT00832923|Experimental|Enhanced care PEPAC Intervention|
11573823|NCT00832910||Rheumatoid Arthritis group1|This group had patients with rheumatoid arthritis
11573824|NCT00832910||2|
11573825|NCT00832897|Sham Comparator|Eyedrop|
11573826|NCT00832897|Active Comparator|Crosslinking|The patients will be submitted to corneal collagen crosslinking, by use riboflavin eyedrop with UVA light.
11573827|NCT00832884|Active Comparator|Group 1A|Lacosamide, IV, 50 mg, once, 30 minutes
11573828|NCT00832884|Active Comparator|Group 2A|Lacosamide, IV, 100 mg, once, 30 min
11573829|NCT00832884|Active Comparator|Group 3A|Lacosamide, IV, 150 mg, once, 30 min
11573830|NCT00832884|Active Comparator|Group 4A|Lacosamide, IV, 200 mg, once, 30 min
11573831|NCT00832884|Active Comparator|Group 1B|Lacosamide, IV, 50 mg, once, 15 min
11573832|NCT00832884|Active Comparator|Group 2B|Lacosamide, IV, 100 mg, once, 15 min
11573833|NCT00832884|Active Comparator|Group 3B|Lacosamide, IV, 150 mg, once, 15 min
11573834|NCT00832884|Active Comparator|Group 4B|Lacosamide, IV, 200 mg, once, 15 min
11573835|NCT00832871|Experimental|Mifepristone|200 mg RU-486 (Mifepristone) daily
11573836|NCT00832845|Experimental|CBSST plus treatment as usual|Subject randomized to the CBSST Group arm will attend 2 hour weekly Cognitive Behavioural Social Skills therapy sessions for 9 months. They will also be attending follow-up assessments q 4 months.
11573837|NCT00832845|Active Comparator|Treatment as Usual Group|Subjects randomized to the Treatment as Usual Group Arm will continue with their regular psychiatric treatment for 1 year. Like the CBSST Group Arm, they will have follow up assessments q 4 months. After completing the Treatment as Usual Group arm, they will automatically continue on with the CBSST Group Arm.
11573838|NCT00832832|Experimental|Eyelid closure|Eyelids will be closed after administration of eye drop
11573839|NCT00832832|Active Comparator|No eyelid closure|Eyelids will not be closed after eye drop instillation
11573840|NCT00832819|Experimental|E7080 (Dose Escalation Cohort)|This will be a dose-escalation evaluation of 12-18 participants to determine the maximum tolerated dose of E7080 in combination with paclitaxel and carboplatin.
11573841|NCT00832819|Experimental|E7080 (Expansion Cohort)|Dosage of E7080 for Expansion Cohort will be determined based on the maximum tolerated dose in the Dose-Escalation Cohort.
11573842|NCT00832806|Active Comparator|1|Extended IVR (integrated voice response technology) vs. no extended IVR
11573843|NCT00832806|Active Comparator|2|Extended IVR (integrated voice response technology) vs. no extended IVR
11573844|NCT00832780|Experimental|Stereotactic Body Radiation (SBRT)|60 Gy using 12 Gy per fraction over 5 fractions, to be given within 10 calendar days
11573845|NCT00832767|Active Comparator|SILS Port|SILS™ Port Laparoscopic Cholecystectomy
11573846|NCT00832767|Active Comparator|Four Port|Four Port Laparoscopic Cholecystectomy
11573847|NCT00832754|Experimental|RDT+ACT group|RDT+ACT group (ACT offered to RDT positive cases only)
11573848|NCT00832754|Active Comparator|Clinical judgement+ACT group|Clinical judgement+ACT group (ACT offered to all suspected cases of malaria by clinical judgement)
11573849|NCT00832728|Active Comparator|ELAD|ELAD Therapy + Standard of Care
11573850|NCT00832728|Other|Standard of Care|Hospital based standard of care for acute liver failure
11573851|NCT00832715|Experimental|EBUS-TBNA|Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA)
11573852|NCT00832689|Experimental|1|
11573853|NCT00832663|Experimental|NSAID|receive NSAID
11573854|NCT00832663|Placebo Comparator|Placebo|receive placebo
11573855|NCT00832650|Experimental|Fesoterodine|Tablets
11573856|NCT00832650|Placebo Comparator|Placebo|Tablets
11573857|NCT00832650|Active Comparator|Solifenacin|Tablets
11573858|NCT00832637|Experimental|Gemcitabine, Cisplatin, Erlotinib|A combination of Cisplatin at 40 mg/m2 + Gemcitabine at 1000 mg/m2, every 28 days + Erlotinib 100 mg daily, orally. Cycles will be repeated every four weeks.
11573859|NCT00832624|Experimental|1|sitagliptin
11573860|NCT00832611|Experimental|Experimental: Group A Anastomotic Coupler|Device: ROX Anastomotic Coupler System (ACS). The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
11573861|NCT00832598|Experimental|PET imaging|We will perform [18F]FACBC PET and [18F]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc.
11573862|NCT00832585|Experimental|Alefacept|"Amevive® has been shown to be a safe and effective agent in the treatment of psoriasis but may prove useful in treating atopic dermatitis at a dose of 15mg IM every week for 12 weeks. Unlike other biologics for the treatment of skin diseases, the use of alefacept is not associated with increased infection, congestive heart failure, demyelinating disorders or lupus- like syndromes."
11573863|NCT00832572|Experimental|Placebo-Ranolazine|Participants were randomized to receive placebo to match ranolazine during Weeks 1 to 6, then ranolazine during Weeks 7 to 12.
11573864|NCT00832572|Experimental|Ranolazine-Placebo|Participants were randomized to receive ranolazine during Weeks 1 to 6, then placebo to match ranolazine during Weeks 7 to 12.
11573865|NCT00832559|Experimental|CVA21|CVA21
11573866|NCT00832546|Placebo Comparator|1|Placebo
11573867|NCT00832546|Experimental|2|Powder in solution
11573868|NCT00832546|Experimental|3|
11573869|NCT00832520|Experimental|Remeron (Mirtazapine)|Mirtazapine 15 mg orally at bed time for 8 weeks
11573870|NCT00832507|Experimental|Cicletanine 150 mg QD|Cicletanine 150 mg administered once daily (QD)
11573871|NCT00832507|Experimental|Cicletanine 150 mg BID|Cicletanine 150 mg administered twice daily (BID)
11573872|NCT00832507|Experimental|Cicletanine 300 mg QD|Cicletanine 300 mg administered once daily (QD)
11573873|NCT00832507|Placebo Comparator|Placebo|Placebo to match cicletanine administered once daily
11573874|NCT00832481|Active Comparator|Repaglinide,tablet|
11573875|NCT00832481|Active Comparator|Metformin, tablet|
11573876|NCT00832468|Placebo Comparator|sham ear acupressure|
11573877|NCT00832468|Experimental|ear acupressure|
11573878|NCT00832455|Experimental|Montelukast|
11573879|NCT00832442||Beta blocker|
11573880|NCT00832442||Placebo|
11573881|NCT00832429|Experimental|Lymphatic Mapping + SLN Mapping/Biopsy|SLN mapping and biopsy done in OR under general anesthesia. Injection of Tc99m-Sulfur colloid again around eyelid tumor(s) or removed tumor site(s). Lymph nodes visible from injection removed and tested for signs of metastatic disease.
11573882|NCT00832416|Experimental|1 Tramadol Once A Day 100mg|
11573883|NCT00832416|Experimental|2: Tramadol Once A Day 200mg|
11573884|NCT00832416|Experimental|3: Tramadol Once A Day 300mg|
11573885|NCT00832416|Experimental|4: Placebo|
11573886|NCT00832403||polytetrafluoroethylene|
11573887|NCT00832390|Experimental|1|sitagliptin
11573888|NCT00832377|Experimental|Timolol/Dorzolamide|Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks
11573889|NCT00832364|Experimental|1|U0279 and Injectable Biologic
11573890|NCT00832364|Placebo Comparator|2|Placebo and Injectable Biologic
11573891|NCT00832351|Experimental|1|Early mobilisation within 24 hours after admittance to hospital
11573892|NCT00832351|No Intervention|2|Mobilisation after 24 but within 48 hours from admittance to hospital
11573893|NCT00832338|Experimental|Docetaxel with Cytoxan|Patients will be treated with docetaxel at 75 mg/m² concomitantly with cytoxan 600 mg/m² (TC) IV D1 every 3 weeks for 6 cycles. Due to known toxicity of docetaxel, all patients require dexamethasone 4 mg twice daily (BID) PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel to minimize hypersensitivity reactions and fluid retention.
11573894|NCT00832325||1 individual interviews|The patient will be asked to come in to the Counseling Center at MSKCC (641 Lexington Avenue, 7th Floor) and participate in an individual interview at their convenience.
11573895|NCT00832325||2 Focus Groups|The patient will be asked to come in to the Counseling Center at MSKCC (641 Lexington Avenue, 7th Floor) and participate in a focus group at their convenience.
11573987|NCT00831662|Experimental|Arm 1|
11573896|NCT00832325||3 Questionnaire|The patient will be asked to participate in three 60-90 minute telephone interviews scheduled at their convenience.
11573897|NCT00832312|Experimental|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml) injected into the knee joint
11573898|NCT00832312|Placebo Comparator|Saline|Injection of 1cc of saline into the knee joint
11573899|NCT00832299|Experimental|6 cycles of FOLFOX pre and post TME|
11573900|NCT00832286|Experimental|Cipro|At Week 12, subjects will receive a 3-day course of oral Ciprofloxacin 500 mg every 12h.
11573901|NCT00832234|Experimental|BDR|
11573902|NCT00832221|Active Comparator|1|
11573903|NCT00832221|Active Comparator|2|
11573904|NCT00832208|Active Comparator|Ambisome control:|Ambisome, Total dose 21.0 mg given as 7 x 3mg on days 1,2,3,4,5, and 14 and 21
11573905|NCT00832208|Experimental|Ambisome test|Single dose Ambisome in sequence(7.5 / 10.0/ 12.5 / 15.0mg)
11573906|NCT00832195|Experimental|1|Footwear with motion controlling elements built into construction in order to reduce pronation of the foot and ankle during running.
11573907|NCT00832195|Active Comparator|2|Footwear with standard neutral stabilization elements for the foot and ankle during running.
11573908|NCT00832182|Experimental|Insulin aspart and neutral protamine Hagedorn insulin|
11573909|NCT00832169|Experimental|1|
11573910|NCT00832156|Experimental|1|wound 1: the placement of keratinocytes onto a collagen/elastin support after the application of the meshed split skin autograft.
11573911|NCT00832156|Other|2|control wound site; application of mesh graft alone
11573912|NCT00832143|No Intervention|1|Usual Care
11573913|NCT00832143|Experimental|2|Referral Card with one-to-one counseling
11573914|NCT00832130|Experimental|Manual Mini System|Treatment with experimental Manual Mini System
11573915|NCT00832130|Active Comparator|Warm Compress Therapy|Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase
11573916|NCT00832117|Experimental|Escalation and Expansion|
11573917|NCT00832091|Active Comparator|1|There are 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were 3 concentrations used for topical administration to the active drug groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
11573918|NCT00832091|Placebo Comparator|2|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
11573919|NCT00832078|Other|Group A|SCCM (SpeediCath Compact Male catheter) then SC (SpeediCath cathter) on test day 1. SC then SCCM on test day 2
11573920|NCT00832078|Other|Group B|SC (SpeediCath cathter)then SCCM (SpeediCath Compact Male catheter) on test day 1. SCCM then SC on test day 2
11573921|NCT00832065||Patients With Sleep Apnea and Low Testosterone|Adult male patients between 18-70 years of age with nely diagnosed OSAS documented by all night polysomnography(PSG)
11573922|NCT00832052|Experimental|Cohort 1|Subjects will be randomized to receive either experimental drug (n=6) or placebo (n=2).
11573923|NCT00832052|Experimental|Cohort 2|Subjects will be randomized to receive either experimental drug (n=6) or placebo (n=2).
11573924|NCT00832052|Experimental|Cohort 3a|Subjects will be randomized to receive either experimental drug (n=3) or placebo (n=1).
11573925|NCT00832052|Experimental|Cohort 3b|Subjects will be randomized to receive either experimental drug (n=3) or placebo (n=1).
11573926|NCT00832052|Experimental|Cohort 4|
11573927|NCT00832039|Active Comparator|SelPCT|Patient receives sodium-selenite; causal therapy is guided by a PCT based algorithm.
11573928|NCT00832039|Active Comparator|SelKon|Patient receives sodium-selenite; causal therapy is not guided by a PCT based algorithm.
11573929|NCT00832039|Placebo Comparator|PlacPCT|Patient receives placebo; causal therapy is guided by a PCT based algorithm.
11573930|NCT00832039|Placebo Comparator|PlacKon|Patient receives placebo; causal therapy is not guided by a PCT based algorithm.
11573931|NCT00832026||Sleep apnea|Patients with diagnosed obstructive sleep apnea
11573932|NCT00832013|Active Comparator|1|"Propofol 1 % at a dose of 4mg/kg will be administered intravenously via a standard Medex Protégé® 3010 (Medex-A Furon. Healthcare Company, Duluth, GA, USA) infusion pump at a constant rate determined by the randomization schedule. Fresh gas flow will be maintained at 6 l/min throughout the induction procedure with the FiO2 increased to 0.5. Full cardiovascular, respiratory and EEG monitoring will continue during induction of anesthesia.
~Once the loading dose of propofol has been delivered the propofol infusion will be maintained at a rate of 200mcg/kg/min or as determined by the attending anesthesiologist whilst the end-point respiratory responses are observed."
11573933|NCT00832013|Active Comparator|2|Same procedure as above. These subjects will be stratified by age and randomized, using the Biased Coin Design (BCD) principle to determine the infusion rate of propofol for delivery of the induction dose.
11573934|NCT00832000|Experimental|1|Participants will receive mexiletine for 4 weeks, then no intervention for 1 week, and finally placebo for 4 weeks.
11573935|NCT00832000|Experimental|2|Participants will receive placebo for 4 weeks, then no intervention for 1 week, and finally mexiletine for 4 weeks.
11573936|NCT00831987|Experimental|Fluzone® Vaccine Group - Age 18-59 Years|Participants aged 18 to 59 years at enrollment and received 1 dose of Fluzone® Vaccine
11573937|NCT00831987|Experimental|Fluzone® Vaccine Group - Age ≥ 60 Years|Participants aged at least 60 years or older at enrollment and received 1 dose of Fluzone® Vaccine
11573938|NCT00831974|Experimental|2|masitinib (AB1010) 6 mg/kg/day
11573939|NCT00831974|Experimental|1|masitinib (AB1010) 3 mg/kg/day
11573940|NCT00831961||1|Patients randomized to gatifloxacin (Zymar)
11573941|NCT00831961||2|Patients randomized to moxifloxacin (Vigamox)
11573942|NCT00831961||3|Patients randomized to ofloxacin (Ocuflox)
11573943|NCT00831961||4|Patients randomized to azithromycin (AzaSite)
11573944|NCT00831948||Mitochondrial disease|Patients already diagnosed for mitochondrial pathology without mtDNA mutations yet detected by current diagnostic techniques
11573945|NCT00831935||Depressed|Depressed individuals, as identified by their referring physician.
11573946|NCT00831935||Non-depressed|Non-depressed individuals, confirmed to be non-depressed by the Centers for Epidemiological Studies Depression Scale (CES-D).
11573947|NCT00831922|Experimental|1|masitinib (AB1010) 3 mg/kg/day
11573948|NCT00831922|Experimental|2|masitinib (AB1010) 6 mg/kg/day
11573949|NCT00831909||1|All NSCLC patients attending the responsible department of treating this type of patients (e.g. Oncology Department, Pneumology Department) for the first time (regardless of whether the patient is diagnosed with locally, advanced or metastatic disease) at the participating sites from the first of January 2009 to the end of March 2009. Patients diagnosed, or even treated, in other departments within the same hospital or in another hospital are susceptible to be included in the study if full access to the patient's medical record is made available.
11573950|NCT00831896|Experimental|1|TAK-701
11573951|NCT00831883|Experimental|Partner Specific IMB|partner-specific HIV risk reduction intervention
11573952|NCT00831883|Placebo Comparator|HLS|5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
11573953|NCT00831857||Group A|Treatment with sunitinib.
11573954|NCT00831857||Group B|Treatment with bevacizumab and interferon
11573955|NCT00831844|Experimental|Group 1 - Recurrent or Refractory Hepatoblastoma|Group 1 - Recurrent or Refractory Hepatoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11573956|NCT00831844|Experimental|Group 2 - Recurrent or Refractory Synovial Sarcoma|Group 2 - Recurrent or Refractory Synovial Sarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11573957|NCT00831844|Experimental|Group 3 - Recurrent or Refractory Rhabdomyosarcoma|Group 3 - Recurrent or Refractory Rhabdomyosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11573958|NCT00831844|Experimental|Grp 4-Recurrent or Refractory Adrenocortical Carcinoma|Group 4 - Recurrent or Refractory Adrenocortical Carcinoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11573959|NCT00831844|Experimental|Grp 5-Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Group 5 - Recurrent or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11573960|NCT00831844|Experimental|Grp 6 - Neuroblastoma-MIBG Positive Without Measurable Disease|Group 6 - Recurrent or Refractory Neuroblastoma -meta-iodobenzylguanidine (MIBG) Positive Without Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11573961|NCT00831844|Experimental|Grp 7-Neuroblastoma with measurable disease|Group 7 - Recurrent or Refractory Neuroblastoma -With Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11573962|NCT00831844|Experimental|Group 8 - Recurrent Osteosarcoma|Group 8 - Recurrent Osteosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11573963|NCT00831844|Experimental|Group 9 - Recurrent or Refractory Wilms Tumor|Group 9 - Recurrent or Refractory Wilms Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11573964|NCT00831844|Experimental|Group 10 - Recurrent or Refractory Retinoblastoma|Group 10 - Recurrent or Refractory Retinoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11573965|NCT00831818||1|Mothers of healthy infants who breastfeed on demand
11573966|NCT00831818||2|Mothers of healthy infants who do not breastfeed
11573967|NCT00831792|Experimental|TK1258|4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day). Following an initial 4-week cycle at a starting dose of 400 mg 5 days- on and 2 days off, TKI258 may be escalated to 500 mg/day 5 days-on/2 days off if no significant Grade3/4 AEs or laboratory abnormalities are observed.
11573968|NCT00831779|Experimental|Dapagliflozin|
11573969|NCT00831779|Placebo Comparator|Placebo|
11573970|NCT00831766|Experimental|Phase I: Dose Escalation|"Induction: A dose escalation plan for induction therapy using a standard 3x3 design with dose escalation of Lenalidomide only, to determine maximum tolerated dose (MTD). Idarubicin and cytarabine doses will be fixed.
~Idarubicin: 12 mg/m^2.
~Cytarabine: 200 mg/m^2.
~Lenalidomide: According to dose escalation levels. Level 1: 5 mg/d; Level 2: 10 mg/d; Level 3: 15 mg/d; Level 4: 20 mg/d; Level 5: 25 mg/d."
11573971|NCT00831766|Experimental|Phase II: Treatment at MTD|"Idarubicin: 12 mg/m^2.
~Cytarabine: 200 mg/m^2.
~Lenalidomide: Maximum Tolerated Dose (MTD)."
11573972|NCT00831753|Experimental|Group 1|DTaP-IPV-Hep B-PRP~T vaccine group
11573973|NCT00831753|Active Comparator|Group 2|Infanrix® Hexa vaccine group
11573974|NCT00831740|Experimental|Speech Therapy|
11573975|NCT00831740|Active Comparator|ACT NoW Visitor|
11573976|NCT00831727|Experimental|Expressive Writing|
11573977|NCT00831727|Placebo Comparator|Control|
11573978|NCT00831714||Group 1|
11573979|NCT00831714||Group 2|
11573980|NCT00831701|Active Comparator|Tamsulosin|Tamsulosin treatment
11573981|NCT00831701|Placebo Comparator|Placebo|Placebo treatment
11573982|NCT00831688|Active Comparator|1|Local overpressure treatment
11573983|NCT00831688|Placebo Comparator|2|Placebo treatment
11573984|NCT00831675|Experimental|Infants <12 Months|Participants aged ≥ 6 to < 12 months at enrollment and received 2 doses of Fluzone® Vaccine
11573985|NCT00831675|Experimental|Toddlers ≥12 Months|Participants aged ≥ 12 to < 36 months at enrollment and received 2 doses of Fluzone® vaccine
11573986|NCT00831662|Placebo Comparator|Arm 2|
11573988|NCT00831649|Experimental|natalizumab|
11573989|NCT00831636|Experimental|Open label CP-4055|Phase I: Dose escalation Phase II: Fixed dose
11573990|NCT00831623|Experimental|Proton radiation therapy|Single arm
11573991|NCT00831610|Other|STUDY|"Female healthy volunteers (25 to 55 years old) with normal weight.
~Morbid Obese women waiting for bariatric surgery.
~Post-bariatric female patients, 25 to 55 years old, MORE than 12 months of weight stability, pendular abdominal wall, clinical conditions to anchor-line abdominoplasty without flap undermining. Skin Evaluation before the abdominoplasty.
~Group 3, submitted to anchor-line abdominoplasty without flap undermining."
11573992|NCT00831610|Other|CONTROL|Group 3: Post-bariatric female patients, 25 to 55 years old, LESS than 12 months of weight stability, pendular abdominal wall, clinical conditions to anchor-line abdominoplasty without flap undermining. Who will be submitted to abdominoplasty after the study period.
11573993|NCT00831597|Experimental|Bendamustine with rituximab|All patients received combination bendamustine with rituximab
11573994|NCT00831571||All Participants|Patients receiving Oxaliplatin
11573995|NCT00831571||Desensitization|Patients that have experienced a moderate to severe hypersensitivity reaction to oxaliplatin
11573996|NCT00831545|Experimental|Subjects with melanoma|
11573997|NCT00831545|Experimental|Subjects with breast cancer|
11573998|NCT00831545|Experimental|Subjects with non-small cell lung cancer|
11573999|NCT00831532|Experimental|Normal|Healthy Volunteers
11574000|NCT00831532|Experimental|Mild Hepatic Impairment|Mild hepatic impairment patients
11574001|NCT00831532|Experimental|Moderate hepatic Impairment|Moderate Hepatic Impairment Patients
11574002|NCT00831532|Experimental|Severe Hepatic Impairment|Severe Hepatic Impairment Patients
11574003|NCT00831519||Macrosomial, GD|
11574004|NCT00831519||Macrosomial, control|
11574005|NCT00831506|Experimental|A|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
11574006|NCT00831506|Experimental|B|digoxin once daily (0.125 mg QD) plus Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
11574007|NCT00831493|Experimental|Vorinostat + Radiation Therapy|Vorinostat starting dose 200 mg orally once daily, Monday to Friday, Weeks 1 to 6; Radiation Therapy Dose of 50.4 Gray (Gy) in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.
11574008|NCT00831480|Experimental|1|All subjects will take everolimus
11574009|NCT00831467|Experimental|CV9103|CV9103 is applied intradermally into the thigh and upper arm of either side of the body at week 1, week 3, week 7, week 15, week 23
11574010|NCT00831441|Active Comparator|Apixaban|
11574011|NCT00831441|Placebo Comparator|Placebo|
11574012|NCT00831428||Scottish swimming team|
11574013|NCT00831415|Experimental|1|DVS SR
11574014|NCT00831402|No Intervention|Arm without iodized vitamin (VITAMIN OLIGOBS PREGNANCY)|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
11574015|NCT00831402|Active Comparator|Arm with iodized vitamin|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
11574016|NCT00831389|Experimental|Closed Loop (CL) Phase|Closed Loop (CL) Phase
11574017|NCT00831389|No Intervention|Standard of Care (OL) Phase|Standard of Care (OL) Phase or Open Loop Phase
11574018|NCT00831376|Experimental|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
11574019|NCT00831376|Active Comparator|2: racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
11574020|NCT00831376|Placebo Comparator|3: Placebo|Patients will be asked to take two puffs four times a day for 2 weeks
11574021|NCT00831363||1|minimal invasive approach
11574022|NCT00831363||2|traditional transgluteal approach
11574023|NCT00831350|Experimental|ranibizumab|
11574024|NCT00831337|Experimental|Liver cirrhosis compensated|VSL3 supplemented twice daily for 28 days
11574025|NCT00831337|Experimental|Liver cirrhosis decompensated|VSL3 supplemented twice daily for 28 days
11574026|NCT00831337|Experimental|Control group|VSL3 supplemented twice daily for 28 days
11574027|NCT00831311|Experimental|1|DTaP IPV HB-PRP~T vaccine group
11574028|NCT00831311|Active Comparator|2|PENTAXIM™ and ENGERIX B® vaccines group
11574029|NCT00831298|Other|1|Behavioral Questionnaire Sleep Recordings Genetic analysis
11574030|NCT00831285|Experimental|tortilla with high amylose flour|
11574031|NCT00831285|Experimental|barley tortilla with low amylose flour|
11574032|NCT00831285|Experimental|barley tortilla with low amylose flour and soluble fibre|
11574033|NCT00831285|Experimental|barley tortilla with low amylose flour and insoluble fibre|
11574034|NCT00831285|Active Comparator|glucose|
11574035|NCT00831285|Experimental|barley tortilla with low amylose flour and low soluble fibre|
11574036|NCT00831272|Experimental|Naltrexone|50mg/day of naltrexone
11574037|NCT00831272|Placebo Comparator|Placebo|Placebo
11574038|NCT00831259||1|Incidence of silent stroke in patients with PFO
11574039|NCT00831259||2|Incidence of silent stroke in patients without PFO
11574040|NCT00831246|Experimental|1|Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
11574041|NCT00831246|Sham Comparator|2|Patients are given standard post-op care with clear liquid diet as tolerated .
11574042|NCT00831233|Experimental|Degarelix 240 mg/80 mg|Degarelix 240 mg (40 mg/mL) + 80 mg (20 mg/mL)
11574043|NCT00831233|Active Comparator|Goserelin (3.6 mg) + bicalutamide (50 mg)|Goserelin (3.6 mg) + bicalutamide (50 mg)
11574044|NCT00831220||1|Patients with a COPD exacerbation
11574045|NCT00831220||2|Patients with stable COPD
11574046|NCT00831220||3|Smokers or former smokers
11574047|NCT00831220||4|Never smokers
11574048|NCT00831207||G1|15 HIV-1+ individuals, previously untreated or without HAART for at least six months and CD4+ < 350 cells/mm3.
11574049|NCT00831207||G2|31 HIV-1+ individuals undergoing HAART without virological therapeutic failure (TF).
11574050|NCT00831207||G3|43 HIV-1+ individuals undergoing HAART with TF.
11574051|NCT00831207||G4|20 normal individuals who served as controls for serum cytokines.
11574052|NCT00831194|Experimental|Diet plan and PDA|
11574053|NCT00831181|Experimental|Preoperative Chemoradiation|Preoperative Chemoradiation with oxaliplatin/5-FU followed by mesorectal excision and 5-FU / leucovorin (FOLFOX 6)
11574054|NCT00831155|Active Comparator|1|Extinction Based Group (EBT): switch to smoking denicotinized cigarettes while wearing a 21mg/day nicotine patch for one month prior to their quit date.
11574055|NCT00831155|No Intervention|2|Nicotine Replacement Group (NRT): smoke their usual brand of cigarettes up to the quit date.
11574056|NCT00831142||Prostate Cancer|Males with prostate cancer, referred for biopsy or radical prostatectomy
11574057|NCT00831129|Active Comparator|Simvastatin + Placebo Rosiglitazone|Subjects will receive 40 mg Simvastatin + 1 tab Placebo Rosiglitazone daily
11574058|NCT00831129|Active Comparator|Simvastatin + rosiglitazone|Subjects will receive 40 mg Simvastatin + 4 mg Rosiglitazone once daily
11574059|NCT00831116||LipiScan|Subjects who have at least one native coronary artery imaged with the LipiScan CIS.
11574060|NCT00831103|Experimental|EPB-348 1000 mg|EPB-348 1000 mg dosed once daily for seven days
11574061|NCT00831103|Experimental|EPB-348 2000 mg|EPB-348 2000 mg dosed once daily for seven days
11574062|NCT00831103|Experimental|EPB-348 3000 mg|EPB-348 3000 mg dosed once daily for seven days
11574063|NCT00831103|Active Comparator|Valacyclovir|Valacyclovir 1000 mg dosed three times daily for seven days
11574064|NCT00831077|Active Comparator|14C-ORM-14540|
11574065|NCT00831077|Active Comparator|14C-ORM-12741|
11574066|NCT00831064|Active Comparator|1. 4L PEG only|4L PEG PO
11574067|NCT00831064|Active Comparator|2. 2L PEG plus bisacodyl|2L PEG PO + 4 tablets bisacodyl PO
11574068|NCT00831064|Active Comparator|3. NaP|90 cc NaP PO
11574069|NCT00831064|Active Comparator|4. PSMC plus Mg-citrate|PSMC plus 300 cc Mg-citrate PO
11574070|NCT00831051|Experimental|Q8003 12mg/8mg|Combination
11574071|NCT00831051|Active Comparator|Morphine sulfate 12 mg|Single component
11574072|NCT00831051|Active Comparator|Oxycodone HCl 8mg|Single component
11574073|NCT00831051|Experimental|Q8003 6mg/4mg|Combination
11574074|NCT00831051|Active Comparator|Morphine sulfate 6mg|Single component
11574075|NCT00831051|Active Comparator|Oxycodone HCl 4mg|Single component
11574076|NCT00831025|Experimental|1|Depigmented and polymerized allergen extract of Olea europaea pollen for subcutaneous injection.
11574077|NCT00831025|Placebo Comparator|2|Placebo for subcutaneous injection.
11574078|NCT00831012|Experimental|Group 1|Group 1 will consist of healthy participants receiving an immunization of 10^3 PFU rDEN3delta30/31-7164
11574079|NCT00831012|Experimental|Group 2|"Group 2A will consist of healthy participants who will receive an immunization of 10^5 PFU of rDEN3delta30/31-7164 vaccine or placebo. Group 2A participants will be enrolled if less that 90% of Group 1 participants seroconvert to DEN3 by Study Day 42.
~Group 2B will consist of healthy participants who will receive an immunization of 10^1 PFU of rDEN3delta30/31-7164 vaccine or placebo. Group 2B participants will be enrolled if more that 90% of Group 1 participants seroconvert to DEN3 by Study Day 42."
11574080|NCT00830999|Experimental|Positive energy balance|Comparison between isocaloric and hypercaloric diets with no exercise performed in any trials
11574081|NCT00830999|Experimental|Energy balance with exercise|Comparison between an isocaloric diet without exercise and a hypercaloric diet with a sufficient amount of exercise performed to match the excess calories consumed resulting in both trials being in net energy balance.
11574082|NCT00830999|Experimental|Negative energy balance|Comparison between isocaloric and hypocaloric diets with no exercise performed in any trials
11574083|NCT00830999|Experimental|Negative energy balance with exercise|Comparison between consuming an isocaloric diet without exercise and consuming the same amount of calories as in the isocaloric trial but with exercise performed resulting in net negative energy balance in the exercise trial.
11574084|NCT00830986||1|Computer Assisted Total Knee Arthroplasty
11574085|NCT00830986||2|Conventional Instrumented Total Knee Arthroplasty
11574086|NCT00830973||Active Study Group|The active study group consists of 50 year or older postmenopausal women taking tamoxifen for the prevention of reoccurrence of breast cancer, do not meet exclusion criteria, meet all inclusion criteria, and are enrolled members for Medco clients agreeing to participate.
11574087|NCT00830960|Experimental|Prasugrel 60/10 Primary|Loading dose 60 mg followed by maintenance dose 10 mg/day
11574088|NCT00830960|Experimental|Prasugrel 30/7.5 Primary|Loading dose 30 mg followed by maintenance dose 7.5 mg/day
11574089|NCT00830960|Experimental|Prasugrel 30/5 Primary|Loading dose 30 mg followed by maintenance dose 5 mg/day
11574090|NCT00830960|Active Comparator|Clopidogrel 300/75 Primary|Loading dose 300 mg followed by maintenance dose 75 mg/day
11574091|NCT00830960|Experimental|Prasugrel 30/5 Low Weight/Elderly|Loading dose 30 mg followed by maintenance dose 5 mg/day
11574092|NCT00830960|Active Comparator|Clopidogrel 300/75 Low Weight/Elderly|Loading dose 300 mg followed by maintenance dose 75 mg/day
11574093|NCT00830947|Experimental|OrthoAccel Device|Device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
11574094|NCT00830947|Sham Comparator|Sham Device (inactive device)|Sham device will look identical to active devices but will not deliver vibration to the patient.
11574095|NCT00830934|Active Comparator|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
11574096|NCT00830934|Experimental|Group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
11574097|NCT00830921||1|"Patients will be identified from the Oxford Pleural Clinic and from referrals within the multi-disciplinary team including palliative care and oncology services.
~Screening criteria are based on normal practice and consecutive eligible patients will be offered trial entry. The principal investigator or a nominated member of staff will approach participants who fulfil the criteria for inclusion in the study. Screening logs will be kept."
11574207|NCT00830154|Experimental|1|0.30 mg pagoclone BID
11574098|NCT00830908|Experimental|LaserComb|Patients aged 18 years and older with a diagnosis of seborrheic dermatitis of the scalp
11574099|NCT00830895|Experimental|RAD001|RAD001 10mg/day
11574100|NCT00830882|Experimental|1:levosalbutamol|2 puffs four times a day for 2 weeks
11574101|NCT00830882|Active Comparator|2: racemic salbutamol|2 puffs four times a day for 2 weeks
11574102|NCT00830882|Placebo Comparator|3: Placebo|2 puffs four times a day for 2 weeks
11574103|NCT00830869|Experimental|Part 1: Ixazomib 0.125 milligram per square meter (mg/m^2)|Ixazomib (MLN9708) 0.125 mg/m^2, injection, intravenously (IV), once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
11574104|NCT00830869|Experimental|Part 1: Ixazomib 0.25 mg/m^2|Ixazomib (MLN9708) 0.25 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
11574105|NCT00830869|Experimental|Part 1: Ixazomib 0.5 mg/m^2|Ixazomib (MLN9708) 0.5 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
11574106|NCT00830869|Experimental|Part 1: Ixazomib 1 mg/m^2|Ixazomib (MLN9708) 1 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
11574107|NCT00830869|Experimental|Part 1: Ixazomib 1.33 mg/m^2|Ixazomib (MLN9708) 1.33 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
11574108|NCT00830869|Experimental|Part 1: Ixazomib 1.76 mg/m^2|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
11574109|NCT00830869|Experimental|Part 1: Ixazomib 2.34 mg/m^2|Ixazomib (MLN9708) 2.34 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study. Once the MTD will be established, participants with NSCLC, Head and Neck Cancer (H&N), Soft Tissue Sarcoma (STC) or Prostate Cancer (PC) will be included in MTD disease expanded cohort. An additional tumor pharmacodynamics expansion cohort (TPEC) will enroll participants with any type of solid tumor that can be biopsied for tissue analysis before and after treatment with ixazomib.
11574110|NCT00830869|Experimental|Part 2:Ixazomib 1.76 mg/m^2-NSCLC|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with NSCLC during Part 2 of the study.
11574111|NCT00830869|Experimental|Part 2: Ixazomib 1.76 mg/m^2-H&N|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with H&N during Part 2 of the study.
11574112|NCT00830869|Experimental|Part 2: Ixazomib 1.76 mg/m^2-STC|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with STC during Part 2 of the study.
11574113|NCT00830869|Experimental|Part 2: Ixazomib 1.76 mg/m^2-PC|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with PC during Part 2 of the study.
11574114|NCT00830869|Experimental|Part 2: Ixazomib 1.76 mg/m^2-TPEC|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with various types of solid tumors suitable for biopsy in tumor pharmacodynamic expansion cohort (TPEC) during Part 2 of the study.
11574115|NCT00830856|Experimental|1|Early initiation of antiretroviral therapy. Patients in this treatment group were started on Fluconazole 800mg by mouth every day for Cryptococcal Meningitis, and within 72hrs of diagnosis were started on First line antiretroviral therapy per Zimbabwe treatment guidelines which is Stavudine, Lamivudine and Nevirapine.
11574116|NCT00830856|Experimental|2|Delayed initiation of antiretroviral therapy. Patients in this treatment group were started on Fluconazole 800mg by mouth every day for Cryptococcal Meningitis, and after completion of high dose fluconazole for 10 weeks, the patients in this group were started on First line antiretroviral therapy per Zimbabwe treatment guidelines which is Stavudine, Lamivudine and Nevirapine.
11574117|NCT00830843|Active Comparator|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
11574118|NCT00830843|Experimental|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
11574119|NCT00830804|Experimental|RAL + DRV/RTV|Raltegravir (400 mg BID) plus Darunavir/Ritonavir (800 mg/100 mg QD) for 52 weeks
11574120|NCT00830791|Experimental|MK-0941 20 mg Mild Renal Insufficiency|MK-0941 20 mg administered to participants with mild renal insufficiency and type 2 diabetes.
11574121|NCT00830791|Experimental|MK-0941 20 mg Moderate Renal Insufficiency|MK-0941 20 mg administered to participants with moderate renal insufficiency and type 2 diabetes.
11574122|NCT00830791|Experimental|MK-0941 5 mg Severe Renal Insufficiency|MK-0941 5 mg administered to participants with severe renal insufficiency and type 2 diabetes.
11574123|NCT00830791|Experimental|MK-0941 20 mg Matched Controls|MK-0941 20 mg administered to age-, gender-, race-, body mass index (BMI)-, and hemoglobin A1C (HbAIc)-matched control subjects with normal renal function and type 2 diabetes.
11574124|NCT00830791|Experimental|MK-0941 5 mg Matched Controls|MK-0941 5 mg administered to age-, gender-, race-, body mass index (BMI)-, and HbAIc-matched control subjects with normal renal function and type 2 diabetes.
11574125|NCT00830778|Experimental|PG anastomosis|Pancreaticogastrostomy (PG) reconstruction/anastomosis after pancreaticoduodenectomy (PD)
11574126|NCT00830778|Active Comparator|PJ anastomosis|Pancreaticojejunostomy (PJ) reconstruction/anastomosis after pancreaticoduodenectomy (PD)
11574208|NCT00830154|Experimental|2|0.60 mg pagoclone BID
11574127|NCT00830765|Placebo Comparator|1 Placebo|The participant will receive a weekly injection of placebo from the time of enrollment up until 34 weeks' gestation or delivery, whichever occurs first.
11574128|NCT00830765|Active Comparator|Progesterone|The participant will receive weekly injections of 100mg of OHP17 from the time of enrollment until 34 weeks' gestation or delivery, whichever occurs first.
11574129|NCT00830726||1|Healthy volunteers
11574130|NCT00830726||2|Patients with symptomatic heart failure and EF < 40%
11574131|NCT00830726||3|Patients with symptomatic aortic valve stenosis
11574132|NCT00830726||4|Patients with Acute Coronary syndromes prior to surgical intervention
11574133|NCT00830726||5|Patients with refractory stable angina requiring surgical intervention.
11574134|NCT00830726||6|Patients with pulmonary hypertension and preserved systolic left ventricular function.
11574135|NCT00830713|Experimental|MKTP treatment|subject will undergo MKTP
11574136|NCT00830700|Experimental|CATMH intervention|Child telemental health service delivery intervention
11574137|NCT00830700|No Intervention|augmented TAU/PCP|Augmented treatment as usual with primary care physician
11574138|NCT00830687|Other|Targon FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
11574139|NCT00830674|Experimental|KRN23|Single IV or SC administration on day 1
11574140|NCT00830674|Placebo Comparator|Placebo|Single IV or SC administration on day 1
11574141|NCT00830661|Active Comparator|LIFT|those subjects receiving the Ligation of Intersphincteric Fistula Track procedure
11574142|NCT00830661|Active Comparator|Plug|those subjects randomized to the receive the placement of the porcine anal fistula plug
11574143|NCT00830648|Experimental|1|
11574144|NCT00830622|Experimental|1|Cell Phone Intervention: participant receives weekly SMS text message from the health care worker.
11574145|NCT00830622|No Intervention|2|SOC: Participant receives standard of care support but not weekly SMS text messages from the health care worker.
11574146|NCT00830609|Active Comparator|A|Patients in this arm will receive standard of care (Peginterferon alfa 2A 180 mcg/weeks SC plus ribavirin 800 mg/day for 24 weeks).
11574147|NCT00830609|Experimental|B1|After a period of 4 weeks with peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day (Induction phase), these patients will be allocated according to negativity or positivity of RNA-HCV at week 4. If RNA-HCV negative, treatment with peginterferon alfa 2 a 180 mcg/week plus RBV 800 mg/day (SOC) will be continued over 20 additional weeks (Arm B1). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin > 12g/dL.
11574148|NCT00830609|Experimental|B2|If RNA-HCV at week 4 remains positive after the induction phase, then peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day will be continued for 20 additional weeks (Arm B2). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin > 12g/dL.
11574149|NCT00830596|Active Comparator|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
11574150|NCT00830596|Active Comparator|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
11574151|NCT00830596|Placebo Comparator|Sham Intervention|Light effleurage and a sham mechanically-assisted chiropractic treatment for 2 weeks followed by full spine manipulation for 4 weeks
11574152|NCT00830583|Other|1|pompe's disease suspected patient
11574153|NCT00830570||1|Historical control group. Patients in this group are drawn from the same plan populations as the intervention group, but they are identified during the 1-year period prior to the start of patient enrollment in the intervention group. The historical control group is closely matched with the intervention group on demographic characteristics, practice patterns, and benefit plan features that may affect resource utilization.
11574154|NCT00830570||2|Concurrent control group. Patients in this group are drawn from different set of plan populations, but they initiate warfarin treatment during the same time period as patients in the intervention group. Outcomes data for the concurrent control group will be used to evaluate whether any differences between the intervention group and the historical control group can be attributed to changes in clinical practice over time. Baseline data for the concurrent control group will help validate the incidence assumptions used in the calculation of statistical power. This use of baseline population norms is an effective means of limiting bias in quasi-experimental studies.
11574155|NCT00830570||3|Active study group. For plans participating in the active arm of the study, enrollment is offered to every patient who initiates warfarin therapy during the enrollment period (beginning in July 2007) and who meets the eligibility criteria. Patients are identified for the active study group if they have a warfarin pharmacy claim and no prior warfarin claims during the preceding 180 days. Only patients who remain eligible for the pharmacy benefit throughout the study period are included in the final sample.
11574156|NCT00830544|Experimental|1|Experimental chemotherapy using neoadjuvant approach
11574157|NCT00830531|Experimental|1|Standard phenobarbital combined with either 0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the status of the dose escalation design.
11574158|NCT00830531|Placebo Comparator|2|Standard phenobarbital therapy combined with normal saline as placebo for bumetanide
11574159|NCT00830518|Experimental|Alisertib|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period, in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).
11574160|NCT00830505|Experimental|1: fluticasone/salmeterol|2 puffs twice a day for 2 weeks
11574161|NCT00830505|Active Comparator|2: fluticasone|2 puffs twice a day for 2 weeks
11574162|NCT00830492|Active Comparator|2|In group A (n=100), the patients were stimulated conventional. They desensitized with buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg and ovarian stimulation would commence with 150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
11574209|NCT00830154|Placebo Comparator|3|placebo
11574163|NCT00830492|Experimental|clomiphen/gonadotropin/GnRH antagonist|Patients in group B ( n=100 ) were stimulated clomiphene citrate ( ) 100 mg from cycle day three through seven and continuous gonadotropin stimulation with of r_FSH 75 IU daily from cycle day 5. Ultrasound in two group was performed on 8 cycle day. In group B 0.25 mg GnRH antagonist (Ganirelix , Organon ,Netherland ) daily was started with dominant follicle ≥14mm and in this day 75 IU human menopoasl gonadotropin (HMG) (Menogon, ferring, pharmacenticals , Germany ) increased to the initial gonadotropin . LH assessment on the day of starting antagonist was performed and if LH was >15 IU/L , cycle was cancelled. Human chorionic gonadotropin 10000 IU ((pregnyl, Organon, Oss, the Netherlands ) was given when 1 to 3 follicles reached 18 mm
11574164|NCT00830479|Active Comparator|Open Surgery|
11574165|NCT00830479|Active Comparator|Endoscopic Surgery|
11574166|NCT00830466|Experimental|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
11574167|NCT00830440|Experimental|EndoBarrier Device|EndoBarrier Device and Diet & Lifestyle Counseling
11574168|NCT00830440|Active Comparator|Control|Diet & Lifestyle Counseling
11574169|NCT00830427|Experimental|PF-00610355|
11574170|NCT00830427|Experimental|PF - 00610355|
11574171|NCT00830427|Placebo Comparator|Placebo|
11574172|NCT00830414|Experimental|1|
11574173|NCT00830414|Active Comparator|2|DEPO-PROVERA®
11574174|NCT00830401|No Intervention|1|One or more of the predefined minor intra-uterine abnormalities have been detected, but not treated during hysteroscopy.
11574175|NCT00830401|Active Comparator|2|One or more of the predefined minor intra-uterine abnormalities have been detected and treated during hysteroscopy.
11574176|NCT00830388|Experimental|Ketoconazole 2% Foam|Open-label study
11574177|NCT00830375|Experimental|Memantine|10-30mg, memantine
11574178|NCT00830362|Active Comparator|Propranolol 40mg|
11574179|NCT00830362|Placebo Comparator|Placebo|
11574180|NCT00830349|Experimental|1|Risperidone 1 mg Tablets
11574181|NCT00830349|Active Comparator|2|Risperdal® 1 mg Tablets
11574182|NCT00830336|Experimental|Azithromycin (test)|Azithromycin for Oral Suspension 200 mg/5 mL (test) dosed in first period followed by Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in second period
11574183|NCT00830336|Active Comparator|Zithromax® (reference)|Zithromax® for Oral Suspension 200 mg/5 mL (reference) dosed in first period followed by Azithromycin for Oral Suspension 200 mg/5 mL (test) dosed in second period
11574184|NCT00830323|Experimental|1|
11574185|NCT00830323|Experimental|Arm 2|
11574186|NCT00830323|Active Comparator|Arm 3|
11574187|NCT00830310|Experimental|Customized Adherence Enhancement (CAE)|"Participants will be assigned to receive one or more of the study interventions based upon the participant's responses on the Attitudes toward Mood Stabilizers Questionnaire (AMSQ) and reasons for non-adherence on the Rating of Medication Influences (ROMI).
~Individuals will participate in a series of 4 60-minute sessions over a 4-week period, with the study therapist who will implement the module-based intervention. The number of modules may differ depending on the baseline adherence profile of the participant.
~An intervention manual developed by the investigators will provide explicit guidelines regarding how modules may be co-administered in single or multiple sessions to minimize redundancy as well as time and effort burden on study participants. The manual for each module will specifically address how any module could be combined with the other modules."
11574188|NCT00830297|Active Comparator|1 Insulatard (long-acting insulin)|
11574189|NCT00830297|Active Comparator|2 Conventional treatment|
11574190|NCT00830284|Experimental|Recruitment|Patients with hypoxic respiratory failure
11574191|NCT00830271|Experimental|Vicryl plus/Monocryl plus|"Vicryl plus and Monocryl plus is the active comparator arm. These are the active sutures, coated with triclosan antiseptic, being used in the closure of skin and subcutaneous tissues after breast cancer surgery."
11574192|NCT00830271|Placebo Comparator|vicryl/monocryl|"Plain Vicryl or Monocryl suture currently the standard which are not coated with triclosan, serve as the control."
11574193|NCT00830258|Experimental|Pravastatin|Pravastatin 80 mg Tablet (test) dosed in first period followed by Pravachol® 80 mg Tablet (reference) dosed in second period
11574194|NCT00830258|Active Comparator|Pravachol®|Pravachol® 80 mg Tablet (reference) dosed in first period followed by Pravastatin 80 mg Tablet (test) dosed in second period
11574195|NCT00830245|Experimental|Erlotinib|Erlotinib 150mg/day (if no negative conversion --> increment to 250mg/day)
11574196|NCT00830232|Active Comparator|Closed-cell stent (Xact stent)|For patients randomized to the closed-cell stent group, the Xact closed-cell stents were used. The Xact stent is a FDA approved device.
11574197|NCT00830232|Active Comparator|Open-cell stent (Acculink carotid)|For patients randomized to the open-cell stent group, the Acculink carotid stent was used. The Acculink stent is a FDA approved device.
11574198|NCT00830219|Experimental|1|
11574199|NCT00830219|Active Comparator|2|
11574200|NCT00830206|Experimental|Azithromycin (test)|Azithromycin Oral Suspension 200 mg/5 mL (test) dosed in first period followed by Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in second period
11574201|NCT00830206|Active Comparator|Zithromax® (reference)|Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in first period followed by Azithromycin Oral Suspension 200 mg/5 mL (test) dosed in second period
11574202|NCT00830193|Active Comparator|N-acetylcysteine|Intravenous fluid administration was administered as soon as possible following randomization (not to exceed 12 hours prior to anticipated contrast exposure) and continued for 12 hours post CT. Patients randomized to the experimental arm received intravenous normal saline plus NAC 10 grams IV (5 g pre and 2.5 g at 6 and 12 hours post-exposure) for a total of 3 doses.
11574203|NCT00830193|Placebo Comparator|Placebo|Intravenous fluid administration was administered as soon as possible following randomization (not to exceed 12 hours prior to anticipated contrast exposure) and continued for 12 hours post CT. Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g in 100 cc D5W (pre-CT dose) or 2.5 g in 50 cc D5W (post-CT doses). The placebo was D5W and was colour and consistency matched by pharmacy. Patients randomized to placebo received intravenous normal saline plus 3 doses of placebo.
11574204|NCT00830180|Experimental|Anti-NGF AB|
11574205|NCT00830167|Placebo Comparator|Placebo|
11574206|NCT00830167|Experimental|Pregabalin|
11574210|NCT00830141||1|50 children with GH deficiency
11574211|NCT00830141||2|50 children with ISS
11574212|NCT00830141||3|50 children with FTT
11574213|NCT00830141||4|50 children with obesity
11574214|NCT00830141||5|50 children without short stature or obesity will serve as controls
11574215|NCT00830128|Experimental|pregabalin (Lyrica)|
11574216|NCT00830115||Pantoprazole|All patients enrolled
11574217|NCT00830102|Active Comparator|1|"Period 1 Treatment Regimen A: FlutiForm 100/10 ug
~Period 2 Treatment Regimen B: FlutiForm 250/10 ug
~Period 3 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug
~Period 4 Treatment Regimen D: Flixotide Evohaler 250 ug"
11574218|NCT00830102|Active Comparator|2|"Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug
~Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug
~Period 3 Treatment Regimen B: FlutiForm 250/10 ug
~Period 4 Treatment Regimen A: FlutiForm 100/10 ug"
11574219|NCT00830102|Active Comparator|3|"Period 1 Treatment Regimen B: FlutiForm 250/10 ug
~Period 2 Treatment Regimen A: FlutiForm 100/10 ug
~Period 3 Treatment Regimen F: Placebo
~Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug"
11574220|NCT00830102|Active Comparator|4|"Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug
~Period 2 Treatment Regimen F: Placebo
~Period 3 Treatment Regimen A: FlutiForm 100/10 ug
~Period 4 Treatment Regimen B: FlutiForm 250/10 ug"
11574221|NCT00830102|Active Comparator|5|"Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug
~Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug
~Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug
~Period 4 Treatment Regimen F: Placebo"
11574222|NCT00830102|Active Comparator|6|"Period 1 Treatment Regimen F: Placebo
~Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug
~Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug
~Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug"
11574223|NCT00830089|Experimental|TAP block|40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
11574224|NCT00830089|No Intervention|Standard care|No TAP block is given. Care is otherwise identical to arm 1
11574225|NCT00830076|Experimental|Sitagliptin + placebo metformin|
11574226|NCT00830076|Experimental|Metformin + placebo sitagliptin|
11574227|NCT00830076|Experimental|Sitagliptin + metformin|Co-administration of sitagliptin and metformin
11574228|NCT00830076|Placebo Comparator|Placebo sitagliptin + placebo metformin|Co-administration of placebo to sitagliptin and placebo to metformin
11574229|NCT00830063|Experimental|1|
11574230|NCT00830063|Experimental|2|
11574231|NCT00830063|Active Comparator|3|
11574232|NCT00830063|Placebo Comparator|4|
11574233|NCT00830050|Experimental|Arm 1|
11574234|NCT00830050|Placebo Comparator|Arm 2|
11574235|NCT00830037|Experimental|IV Iron|
11574236|NCT00830037|Active Comparator|Oral Iron|
11574237|NCT00830024|Experimental|Alprazolam (test)|Alprazolam 3 mg ER Tablet (test) dosed in first period followed by Xanax XR® 3 mg Tablet (reference) dosed in second period
11574238|NCT00830024|Active Comparator|Xanax XR®|Xanax XR® 3 mg Tablet (test) dosed in first period followed by Alprazolam 3 mg ER Tablet (test) dosed in second period
11574239|NCT00830011|Active Comparator|standard care|Medical care including medication for neuropathic pain
11574240|NCT00830011|Active Comparator|CBT|
11574241|NCT00829998|Experimental|Zaleplon|Zaleplon 10 mg Capsule (test) dosed in first period followed by Sonata® 10 mg Capsule (reference) dosed in second period
11574242|NCT00829998|Active Comparator|Sonata®|Sonata® 10 mg Capsule (reference) dosed in first period followed by Zaleplon 10 mg Capsule (test) dosed in second period
11574243|NCT00829985|Experimental|Glycerinated German Cockroach Allergenic Extract|Participants with German cockroach allergy and mild to moderate asthma, rhinitis, or both self-administered concentrated (1:20 weight per volume [w/v]) daily doses of glycerinated German cockroach allergenic extract (50% glycerin) placed under the tongue (sublingually) to dissolve. The treatment course and study duration was 6 months. Note: The extract was also administered during the preliminary dosing visits, up to five escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
11574244|NCT00829985|Placebo Comparator|Placebo|Participants with German cockroach allergy and mild to moderate asthma, rhinitis, or both self-administered daily doses of placebo placed under the tongue (sublingually) to dissolve. The treatment course and study duration was 6 months. Note: The placebo was also administered during the preliminary dosing visits, up to five escalating doses, or until the maximum study dose (420 microliters, 1:20 weight per volume [w/v]) was achieved.
11574245|NCT00829972||1|children undergoing adenotonsillectomy
11574246|NCT00829972||2|children undergoing elective procedures other than adenotonsillectomy
11574247|NCT00829959||Genetic Counseling|Women referred to the Clinical Cancer Genetics Program for discussion of Hereditary Breast And Ovarian Syndrome (HBOC).
11574248|NCT00829946|Experimental|2|
11574249|NCT00829933|Experimental|1|DU-176b low dose
11574250|NCT00829933|Experimental|2|DU-176b intermediate dose
11574251|NCT00829933|Experimental|3|DU-176b high dose
11574252|NCT00829933|Active Comparator|4|Warfarin
11574253|NCT00829920||Bladder cancer|Patients with muscle invasive or metastatic bladder cancer who will be planning for treatment with surgery or chemotherapy.
11574254|NCT00829907|Experimental|1|Orm-12741
11574255|NCT00829894|Experimental|1|Risperidone 1 mg Tablet
11574256|NCT00829894|Active Comparator|2|Risperdal® 1 mg Tablet
11574257|NCT00829881|Placebo Comparator|1|Participants will receive a placebo capsule, administered orally, once per study visit.
11574258|NCT00829881|Experimental|2|Participants will receive a betahistine capsule, administered orally, once per study visit.
11574259|NCT00829868|Experimental|Zaleplon|Zaleplon 10 mg Capsule (test) dosed in first period followed by Sonata® 10 mg Capsule (reference) dosed in second period
11574260|NCT00829868|Active Comparator|Sonata®|Sonata® 10 mg Capsule (reference) dosed in first period followed by Zaleplon 10 mg Capsule (test) dosed in second period
11574261|NCT00829855||1|Patients with hypertensive (systolic blood pressure ≥160 mmHg) acute pulmonary edema, evaluated within 120 minutes after admittance.
11574262|NCT00829855||2|The same patients from group 1 followed-up at 48 to 96 hours.
11574263|NCT00829842|Placebo Comparator|1|Placebo
11574265|NCT00829829|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
11574266|NCT00829829|Active Comparator|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.
11574267|NCT00829829|Active Comparator|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
11574268|NCT00829816|Experimental|Dimebon|20 mg dimebon by mouth 3 times per day
11574269|NCT00829816|Placebo Comparator|Placebo|20 mg placebo by mouth 3 times per day
11574270|NCT00829803|Experimental|SNAP Monitor EEG signals|
11574271|NCT00829803|Active Comparator|BIS Monitor EEG signals (VISTA)|
11574272|NCT00829790|Experimental|1|Doxycycline Monohydrate
11574273|NCT00829790|Active Comparator|2|Vibramycin Monohydrate®
11574274|NCT00829764|Experimental|1|Doxycycline Monohydrate
11574275|NCT00829764|Active Comparator|2|Vibramycin Monohydrate®
11574276|NCT00829751|Active Comparator|ReNu Multiplus|Purevision lenses will be soaked in ReNu Multiplus
11574277|NCT00829751|Active Comparator|OptiFree RePlenish|PureVision lenses will be soaked in OptiFree RePlenish
11574278|NCT00829738||Group 1|All patients enrolled
11574279|NCT00829725|Active Comparator|screws-internal fixation|3-4-screws-internal fixation
11574280|NCT00829725|Experimental|TARGON FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
11574281|NCT00829712|Experimental|1|
11574282|NCT00829712|Active Comparator|2|Focalin®
11574283|NCT00829699|Experimental|1|Euinsulinemic (low insulin infusion) Euglycemic (normal blood glucose levels) glucose clamp with lipid (fat) infusion
11574284|NCT00829699|Experimental|2|Euinsulinemic Hyperglycemic (high glucose levels) glucose clamp with lipid infusion
11574285|NCT00829699|Experimental|3|Hyperinsulinemic (High dose insulin) euglycemic glucose clamp with lipid infusion
11574286|NCT00829699|Experimental|4|Hyperinsulinemic hyperglycemic (high glucose level) glucose clamp with lipid infusion
11574287|NCT00829686|No Intervention|No intervention|No antibiotic
11574288|NCT00829686|Active Comparator|Septra DS|Septra DS (800/160) two pills PO BID x 7 days
11574289|NCT00829673|Experimental|1|
11574290|NCT00829673|Active Comparator|2|Focalin®
11574291|NCT00829660|Active Comparator|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
11574292|NCT00829660|Placebo Comparator|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
11574293|NCT00829647|Experimental|combination dasatinib plus lenalidomide|dasatinib 70 mg po daily plus lenalidomide 2.5 md po daily
11574294|NCT00829634|Other|l-methamphetamine|
11574295|NCT00829621|Active Comparator|75 mmHg suction|IVAC suction 75 mmHg
11574296|NCT00829621|Experimental|125 mmHg suction|IVAC suction 125 mmHg
11574297|NCT00829608|Experimental|Human Papillomavirus Vaccine|There are 9 participants currently being followed in the faculty sponsor's clinic that carry the clinical and histologic diagnosis of RRP. The 9 participants meet one or more of the following criteria: Surgery requirement of more than 4 procedures per year, distal multisite spread of disease, and rapid regrowth of papilloma disease with airway compromise.
11574298|NCT00829595|Experimental|1|IBD, on both an anti-TNF agent and an immunomodulator
11574299|NCT00829595|Experimental|2|IBD, not on any immunosuppressive medications
11574300|NCT00829595|Active Comparator|3|Healthy, non-IBD, not on immunosuppressive medications (control arm)
11574301|NCT00829582|Experimental|ETI-204|ETI-204, Anthim
11574302|NCT00829582|Sham Comparator|placebo|
11574303|NCT00829569|Experimental|Intralipid with/without Omegaven|Lipid infusion with/without marine n-3 fatty acids
11574304|NCT00829556|Experimental|1|
11574305|NCT00829556|No Intervention|2|Standard Surgical skin preparation
11574306|NCT00829543|Experimental|sacroiliac injection|an open label study designed to evaluate the efficacy and safety of guide-free sacroiliac injection in refractory sacroiliac pain due to spondyloarthropathies
11574307|NCT00829530|Experimental|1|
11574308|NCT00829530|Active Comparator|2|
11574309|NCT00829517|Active Comparator|STI kiosk|computer-assisted provision of screening for chlamydia
11574310|NCT00829517|Experimental|contraceptive kiosk|computer-assisted provision of hormonal contraception
11574311|NCT00829504|Experimental|1|
11574312|NCT00829504|Active Comparator|2|
11574313|NCT00829478|Placebo Comparator|1|Usual Care
11574314|NCT00829478|Experimental|2|Intervention
11574315|NCT00829465|Active Comparator|control|
11574316|NCT00829465|Experimental|therapy|
11574317|NCT00829452|Experimental|1|
11574318|NCT00829452|Active Comparator|2|
11574319|NCT00829439|Experimental|Levodopa/Carbidopa|"Other Names:
~Sinemet L-dopa
~Dosages are based on levodopa.
~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.
~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
11574320|NCT00829426|Experimental|Alprazolam|Alprazolam 3mg ER Tablet (test) dosed in first period followed by Xanax XR® 3 mg Tablet (reference) dosed in second period
11574321|NCT00829426|Active Comparator|Xanax XR®|Xanax XR® 3 mg Tablet (reference) dosed in first period followed by Alprazolam 3 mg ER Tablet (test) dosed in second period
11574322|NCT00829413|Other|Patients who received SonoVue|"Patients with at least one target lesions requiring work-up for characterization to undergo
~Unenhanced ultrasound of the target lesion (UE-US): gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion using commercially available ultrasound equipment and standard techniques (B-mode or Harmonic imaging) to study the anatomy of the target lesion and surrounding parenchyma;
~SonoVue-enhanced ultrasound of the target lesion (CE-US):procedures described in protocol Section 7.5.1.2, to study the lesion vascularity in comparison to the surrounding parenchyma; and
~Truth standard
~2.4 mL of sulfur hexafluoride microbubbles (SonoVue®) will be administered as a bolus injection in a peripheral vein."
11574323|NCT00829400|Experimental|Posit Science|Brain Fitness, Insight, and Aristotle Cognitive Software Training Suites Targeting 100 hours of training
11574324|NCT00829400|Active Comparator|Nintendo Brain Age|Brain Age 2 Nintendo DS Portable Device for home or office use, targeting 100 hours of training
11574325|NCT00829387|Experimental|Behavioral|Cognitive behavioral therapy - Ten sessions of individual treatment delivered by a doctoral level psychologist.
11574326|NCT00829387|Active Comparator|Educational|Diabetes Education - Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator
11574327|NCT00829374|Experimental|1|Dimebon, 5 mg orally three times daily
11574328|NCT00829374|Experimental|2|Dimebon, 20 mg orally three times daily
11574329|NCT00829374|Placebo Comparator|3|Placebo orally three times daily
11574330|NCT00829361|Other|Telemedicine|
11574331|NCT00829348|No Intervention|Statins, counseling|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
11574332|NCT00829348|Experimental|Statins, Counselling, SMS|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
11574333|NCT00829335||HCC patients|According with the investigators previously reported selection flow-chart , patients suitable for surgical approach were those with HCC without ascites, without or with esophageal varices for which preoperative endoscopic eradication could be carried out successfully, and with serum bilirubin level lower than 1.5 mg/dl. Potential candidates to systematic segmental or subsegmental resection by IOUS-guided finger compression were considered patients with single HCC located in one or 2 adjacent segments without portal thrombosis, and anyway not demanding for its complete removal a sectional resection or wider.
11574334|NCT00829322|Experimental|Treatment group|
11574335|NCT00829322|Placebo Comparator|Control group|
11574336|NCT00829309|Experimental|Pravastatin|Pravastatin 80 mg Tablet (test) dosed in first period followed by Pravachol® 80 mg Tablet (reference) dosed in second period
11574337|NCT00829309|Active Comparator|Pravachol®|Pravachol® 80 mg Tablet (reference) dosed in first period followed by Pravastatin 80 mg Tablet (test) dosed in second period
11574338|NCT00829296|Experimental|nebivolol|Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
11574339|NCT00829296|Active Comparator|Metoprolol|Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
11574340|NCT00829283|Active Comparator|1|Standard Care
11574341|NCT00829283|Experimental|2|Stepped-care
11574342|NCT00829270||mitochondrial diseases diagnosis|
11574343|NCT00829257|Experimental|Fine particle steroid inhaler|HFA-BDP plus Fluticasone/Salmeterol Combination
11574344|NCT00829257|Active Comparator|Coarse Particle Inhaler|FP plus Fluticasone/Salmeterol combination
11574345|NCT00829244|Experimental|CONSORT Dosing|GONAL-f® dose based on subject baseline characteristics determined according to the CONSORT calculator
11574346|NCT00829244|Active Comparator|Standard Dosing|GONAL-f® at a standard dose of 150 IU per day
11574347|NCT00829231|Experimental|Arm 1|
11574348|NCT00829231|Experimental|Arm 2|
11574349|NCT00829231|Experimental|Arm 3|
11574350|NCT00829218|Active Comparator|1 - Glutamate challenge|Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 1 is the 5 grams of glutamate which will be given in a mixed juice.
11574351|NCT00829218|Placebo Comparator|2- Placebo|Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 2 is the placebo arm, which will be juice with nothing added.
11574352|NCT00829192|Experimental|1|Afamelanotide (CUV1647) implant administered subcutaneously every 60 days for 24 months
11574353|NCT00829192|Placebo Comparator|2|Placebo implant administered subcutaneously every 60 days for 24 months
11574354|NCT00829166|Experimental|Trastuzumab emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
11574355|NCT00829166|Active Comparator|Lapatinib + Capecitabine|Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.
11574356|NCT00829153|Experimental|U clip|Anastomosis with U clips
11574357|NCT00829153|Active Comparator|2|Prolene anastomosis
11574358|NCT00829140|Placebo Comparator|Placebo BID|
11574359|NCT00829140|Experimental|Lorcaserin 10mg BID|
11574360|NCT00829127|Experimental|1|
11574361|NCT00829127|Placebo Comparator|2|
11574362|NCT00829114|Active Comparator|1|ART/COC group
11574363|NCT00829114|Active Comparator|2|COC group
11574364|NCT00829101||1 One-stage repair|A consecutive group of children born with unilateral cleft lip and palate from the south region of Sweden, in all 10 children, who have had a primary palatal surgery at 12 months of age.
11574387|NCT00828932|Experimental|Lorcaserin 10mg|
11574365|NCT00829101||2 Two-stage repair, early closure|A consecutive group of children born with unilateral cleft lip and palate from the western region of Sweden, in all 10 children, who have had a two-stage palatal surgery, with soft palate closure at 4-6 months and repair of the hard palate at 12 months of age.
11574366|NCT00829101||3 Two-stage repair, delayed closure|A consecutive group of children born with unilateral cleft lip and palate from the western region of Sweden, in all 10 children, who have have had a two-stage palatal surgery, with soft palate closure at 4-6 months and repair of the hard palate at 36 months of age.
11574367|NCT00829075|Experimental|I|only r-FSH TREATMENT
11574368|NCT00829075|Experimental|II|only HP-hMG TREATMENT
11574369|NCT00829075|Experimental|III|r-FSH plus HP-hMG TREATMENT
11574370|NCT00829062|No Intervention|Glucose sensor|Children who have assented to wear a 72 hour physician ordered continuous glucose monitor.
11574371|NCT00829049|Active Comparator|Tazarotene Cream 0.1%|1 pea-size amount, QD x 16 weeks
11574372|NCT00829049|Active Comparator|Adapalene Gel 0.3%|1 pea-size amount, QD x 16 weeks
11574373|NCT00829036|Experimental|Wayfinding Prototype|A Wayfinding Prototype is evaluated in terms of the time it takes subjects to use this device to walk to specific indoor locations versus baseline walking time.
11574374|NCT00829023|Experimental|betadine, DuraPrep, ChloraPrep|surgical skin preparation solution
11574375|NCT00829010|Experimental|HIV+/+ Group|Infants born from a HIV positive mother and confirmed as HIV infected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered intramuscularly in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
11574376|NCT00829010|Experimental|HIV+/- Group|Infants born from a HIV positive mother and confirmed as HIV exposed uninfected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
11574377|NCT00829010|Experimental|HIV- (3+1) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
11574378|NCT00829010|Experimental|HIV- (EPI) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected.Subjects received 3 primary doses of Synflorix™ vaccine (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
11574379|NCT00829010|Experimental|HIV- (2+1) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected.Subjects received 2 primary doses (at 6 & 14 weeks of age at study Months 0 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
11574380|NCT00828997|Other|Prevenar vaccine|all participants are immunized with a dose of pneumococcal conjugate vaccine
11574381|NCT00828984|Experimental|Arm A (high-dose PEG 3350)|Patients receive high-dose macrogol 3350-based oral osmotic laxative PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
11574382|NCT00828984|Experimental|Arm B (low-dose polyethylene glycol)|Patients receive low-dose macrogol 3350-based oral osmotic laxative PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
11574383|NCT00828984|Placebo Comparator|Arm C (placebo)|Patients receive placebo PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
11574384|NCT00828971|Experimental|Arm 1|
11574385|NCT00828971|Active Comparator|Arm 2|
11574386|NCT00828945||Hyperlipidemic Patients|
11574388|NCT00828919|Experimental|Treatment|Patients continue the same treatment (axitinib monotherapy or in combination with crizotinib) as in prior axitinib study
11574389|NCT00828906|Experimental|1|DuoTrav
11574390|NCT00828880||DRX9000|
11574391|NCT00828867|Experimental|Cohort 1|100mg
11574392|NCT00828867|Experimental|Cohort 2|200mg
11574393|NCT00828867|Experimental|Cohort 3|400mg
11574394|NCT00828867|Experimental|Cohort 4|800mg
11574395|NCT00828867|Experimental|Cohort 5|1500mg
11574396|NCT00828867|Experimental|Cohort 6|2000mg
11574397|NCT00828867|Experimental|Cohort 7|800mg with food
11574398|NCT00828867|Experimental|Cohort 8|3000mg
11574399|NCT00828867|Experimental|Cohort 9|4000mg
11574400|NCT00828854|Experimental|treatment|Continued treatment with same AI at labeled dose and schedule, plus Entinostat (5mg PO every week)
11574401|NCT00828841|Active Comparator|Paclitaxel, Carboplatin, Cetuximab (Arm A)|Patients with squamous or non-squamous histologies will receive carboplatin and paclitaxel for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion.
11574402|NCT00828841|Active Comparator|Platinum, Gemcitabine, Cetuximab (Arm B)|Patients with squamous or non-squamous histologies will receive gemcitabine with either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion.
11574403|NCT00828841|Active Comparator|Platinum, Pemetrexed, Cetuximab (Arm C)|Patients with squamous histology will receive pemetrexed and either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion. Patients with non-squamous histology are not eligible for this arm.
11574404|NCT00828828||Sarcoidosis|Sarcoidosis patients who are assigned to receive influenza vaccine
11574405|NCT00828828||Healthy Controls|Healthy controls who are assigned to receive influenza vaccine
11574406|NCT00828802|Experimental|Cohort 1|Lenalidomide (5mg) and Decitabine
11574407|NCT00828802|Experimental|Cohort 2|Lenalidomide (10 mg) and Decitabine
11574408|NCT00828802|Experimental|Cohort 3|Lenalidomide (15 mg) and Decitabine
11574409|NCT00828802|Experimental|Cohort 4|Lenalidomide (20 mg) and Decitabine
11574410|NCT00828802|Experimental|Cohort 5|Lenalidomide (25 mg) and Decitabine
11574411|NCT00828776|Experimental|1|Heparin Cristália
11574412|NCT00828776|Active Comparator|2|Heparin - Roche
11574413|NCT00828763|Experimental|1|[14C]-GSK1349572 administered as a single oral dose
11574414|NCT00828750|Experimental|Treatment|Eltrombopag oral tablets once daily
11574415|NCT00828737|Experimental|Arm 1|
11574416|NCT00828724|Experimental|Lorcaserin 10mg|
11574417|NCT00828711|Experimental|MVI 100|MVI 100 mcg vaginal insert
11574418|NCT00828711|Experimental|MVI 150|MVI 150 mcg vaginal insert
11574419|NCT00828711|Experimental|MVI 200|MVI 200 mcg vaginal insert
11574420|NCT00828698||Acute Myocardial Infarction patients|
11574421|NCT00828685|Active Comparator|Operative (CRPP)|If indicated, the wrist fracture would be treated with surgery-the specific operative procedure would be randomized.
11574422|NCT00828685|Active Comparator|Operative (ORIF)|If indicated, the wrist fracture would be treated with surgery-the specific operative procedure would be randomized
11574423|NCT00828672|Active Comparator|AXE (ARM 1)|Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.
11574424|NCT00828672|Active Comparator|AX (ARM 2)|Bevacizumab and Capecitabine concurrently with radiotherapy
11574425|NCT00828659|Placebo Comparator|Placebo|
11574426|NCT00828659|Active Comparator|Active Comparator #1|
11574427|NCT00828659|Active Comparator|Active Comparator #2|
11574428|NCT00828659|Active Comparator|Active Comparator #3|
11574429|NCT00828659|Experimental|Lorcaserin Dose #1|
11574430|NCT00828659|Experimental|Lorcaserin Dose #2|
11574431|NCT00828659|Experimental|Lorcaserin Dose #3|
11574432|NCT00828646|Experimental|BMS-708163 - Panel 1|(Age 20-45 years)
11574433|NCT00828646|Experimental|BMS-708163 - Panel 2|(Age 20-45 years)
11574434|NCT00828646|Experimental|BMS-708163 - Panel 3|(age 65 or above)
11574435|NCT00828646|Experimental|BMS-708163 - Panel 4|(age 65 or above)
11574436|NCT00828620||PET-CT|Patients with Unresectable stage IV colorectal cancer; eligible for 3rd line Irinotecan and Cetuximab
11574437|NCT00828607||liver mass|The group will comprise any patients with an unknown liver mass at the time of diagnostic imaging.
11574438|NCT00828594|Experimental|Phase 1: RAD001 plus sorafenib|
11574439|NCT00828581|Experimental|Lorcaserin|
11574440|NCT00828568|Experimental|Imiquimod 5% Taro|Imiquimod 5% manufactured by Taro applied for 16 weeks
11574441|NCT00828568|Active Comparator|Aldara - Imiquimod 5%|Aldara, Imiquimod 5% applied for 16 weeks
11574442|NCT00828568|Placebo Comparator|Vehicle|Imiquimod vehicle applied for 16 weeks
11574443|NCT00828542|Experimental|etonogestrel implant|Etonogestrel releasing contraceptive implant (Implanon®, NV Organon, Oss, The Netherlands) inserted 24-48 h after delivery. It is compounded by 68mg of etonogestrel, 3years of duration.
11574444|NCT00828542|Active Comparator|depot medroxyprogesterone acetate|At the 6th week postpartum, this group received intramuscular 150 mg of depot medroxyprogesterone acetate (Contracept®, EMS Sigma Pharma, Hortolandia, Brazil).
11574587|NCT00827411|Experimental|1: Monitoring Arm|"First randomization:
~Monitoring Arm: dose adjustment of both aspirin and clopidogrel in suboptimal responders identified based on a point of care assay (VerifyNow)."
11574445|NCT00828516|Experimental|Usual treatment plus acupuncture|Acupuncture and moxibustion, individualised according to participant priorities, delivered once weekly for 7 treatments (Series 1) followed by 6 treatments (Series 2) if participant wishes to continue treatment
11574446|NCT00828503|Active Comparator|1 Certican + Valganciclovir|Valganciclovir will be administered and Certican (everolimus) will be added as immunosuppression
11574447|NCT00828503|Active Comparator|2 Valganciclovir alone|Valganciclovir will be added alone.
11574448|NCT00828490||Pediatric Asthmatics|Medicaid beneficiaries ≤21 years of age who meet the HEDIS criteria for persistent asthma
11574449|NCT00828490||Antipsychotic Therapy|Medicaid beneficiaries ≥18 years of age and enrolled ≥6 months of the past 12 months with enrollment in at least one of the past 3 months and ≥3 antipsychotic Rx within past 12 months
11574450|NCT00828490||Bipolar Therapy|Medicaid beneficiaries ≥18 years of age and enrolled ≥6 months of the past 12 months with enrollment in at least one of the past 3 months and a diagnosis of Bipolar in past 3 years, and ≥ 1 antidepressant Rx in past 6 months, and no mood stabilizer in past 6 months.
11574451|NCT00828490||Opioid Therapy|"Medicaid beneficiaries ≥18 years and enrolled ≥6 of prior 12 months with enrollment in ≥1 of prior 3 months and ≥1 opioid fill in prior 3 months and none of the following in prior 12 months:
~Hospice CPT code or Primary diagnosis of cancer or Oncology CPT code"
11574452|NCT00828490||Fraud and Abuse|Medicaid beneficiaries who filled at least 3 opioid Rx in the last 12 months
11574453|NCT00828490||Pediatric Antipsychtotic Therapy|Medicaid beneficiaries <18 years of age with at least 3 antipsychotic Rx's in the past year.
11574454|NCT00828477|Active Comparator|1|Xibrom (bromfenac)
11574455|NCT00828477|Active Comparator|2|Nevanac (nepafenac)
11574456|NCT00828464|Experimental|clobetasol propionate foam|All subjects receive clobetasol propionate
11574457|NCT00828451|Experimental|Preterm Infants for EGF Profiles|Premature infants born at < 32 weeks gestation who are 7 days old or less. Infants received and intravenous infusion of [5,5,5-2H3]leucine (stable isotope labeled leucine) with sampling of blood, urine and saliva.
11574458|NCT00828438|Experimental|Lorcaserin 10mg|
11574459|NCT00828425||1|Diabetic patients with retinopathy
11574460|NCT00828412|Active Comparator|1|EpiCeram Skin Barrier Emulsion
11574461|NCT00828412|Active Comparator|2|Desonide Cream 0.05%
11574462|NCT00828399|Experimental|Glutamine|
11574463|NCT00828399|Placebo Comparator|Whole protein|
11574464|NCT00828386|Experimental|Induction chemotherapy + concurrent chemoradiotherapy|"Induction chemotherapy (Docetaxel + Cisplatin + 5-FU):
~Docetaxel 75 mg/m² administered on D1 of each course, every 3 weeks, via one-hour IV infusion
~Cisplatin 75 mg/m² administered on D1 via one-hour infusion followed by
~5-Fluorouracil (as a continuous infusion): 750 mg/m²/d administered as a continuous infusion from D1 to D5.
~The cycles will be repeated every 3 weeks up to a total of 3 courses. Followed by concurrent chemoradiotherapy with Cisplatin : weekly Cisplatin 40 mg/m2 starting on D1 of the radiation therapy (70 Gy/7 weeks)."
11574465|NCT00828386|Active Comparator|Concurrent radiochemotherapy alone|Concurrent chemoradiotherapy with Cisplatin : weekly Cisplatin 40 mg/m2 starting on D1 of the radiation therapy (70 Gy/7 weeks).
11574466|NCT00828373|Placebo Comparator|Placebo|
11574467|NCT00828373|Active Comparator|Lidocaine|
11574468|NCT00828347|Other|1.0 μg/day Alfacalcidol|Alfacalcidol 1.0 μg capsule by mouth, every day for 6 months
11574469|NCT00828347|Other|0.25 μg/day Alfacalcidol|Alfacalcidol 0.25 μg capsule by mouth, every day for 6 months
11574470|NCT00828334|Experimental|Transcatheter PDA Coil|Transcatheter occlusion of Patent Ductus Arteriosus (PDA) with the flex and medium Nit-Occlud PDA.
11574471|NCT00828321|Experimental|1|
11574472|NCT00828321|Active Comparator|2|
11574473|NCT00828308|Experimental|Ixabepilone|"Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.
~Prostatectomy 2-8 weeks after completion ***this was standard of care and not a part of the study***"
11574474|NCT00828295|Experimental|1 mcg/kg arm|Single dose IV Palonosetron 1 mcg/kg (up to a maximum total dose of 0.075 mg)
11574475|NCT00828295|Experimental|3 mcg/kg arm|Single dose IV Palonosetron 3 mcg/kg (up to a maximum total dose of 0.25 mg)
11574476|NCT00828282|Experimental|1|
11574477|NCT00828269|No Intervention|1|Liver tissue biopsy
11574478|NCT00828243||Case-control|Infants with varying degrees of neonatal respiratory distress syndrome
11574479|NCT00828243||Nutrient|Infants up to 6 months of age with varying severity of respiratory distress receive stable isotopically labeled nutrients (precursors of surfactant phospholipids or proteins) to permit mass spectrometry-based measurement of surfactant kinetics.
11574480|NCT00828230|Experimental|1|2mg rectal budesonide per day for 8 weeks
11574481|NCT00828230|Placebo Comparator|2|One application of placebo foam once daily for 8 weeks
11574482|NCT00828217|Experimental|with APA|Children have adapted physical activity during their hospitalization
11574483|NCT00828217|No Intervention|without APA|Children don't have adapted physical activity during their hospitalization
11574484|NCT00828204|Experimental|Avonex Single-Use Autoinjector|"Participants received open label weekly treatment with Avonex 30 mcg intramuscular (IM) injections, provided in Avonex prefilled syringes.
~In the Main Study, injection #1: administration of Avonex prefilled syringe via manual IM injection on Day 1. Injections #2, #3, and #4: administration of Avonex prefilled syringe using the single-use autoinjector on Days 8, 15, and 22, respectively. In the Extension Study, participants were to continue treatment with the Avonex single-use autoinjector for up to an additional 12 weeks."
11574485|NCT00828191|Experimental|Progesterone SC|
11574486|NCT00828191|Active Comparator|Progesterone Tablets|
11574487|NCT00828178|Active Comparator|Omega-3|3 g of Omega-3 (1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid ethyl esters); flow-mediated dilation of the brachial artery
11574488|NCT00828178|Placebo Comparator|corn starch|corn starch; flow-mediated dilation of the brachial artery
11574489|NCT00828165|Experimental|ARRY-300|
11574490|NCT00828165|Placebo Comparator|Placebo|Placebo
11574491|NCT00828152|Experimental|1|Internet-delivered CBT. Contact with therapist thru an e-mail system. 12 weeks.
11574492|NCT00828152|Placebo Comparator|2|On line discussion group.
11574636|NCT00826995|Active Comparator|Written education arm:|Subjects receiving the written educational material
11574493|NCT00828139|Experimental|Arm I (ziv-aflibercept, topotecan hydrochloride)|Patients receive ziv-aflibercept IV over 1 hour on day 1 and topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after 4 courses may then receive ziv-aflibercept IV on day 1 and topotecan hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11574494|NCT00828139|Active Comparator|Arm II (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after 4 courses may then receive topotecan hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11574495|NCT00828126||PET-CT Scan|
11574496|NCT00828113|Experimental|Extended treatment|52-week varenicline therapy + individual smoking cessation counseling
11574497|NCT00828113|Active Comparator|Standard treatment|13 weeks of varenicline therapy + individual smoking cessation counseling
11574498|NCT00828087|Experimental|Everolimus Arm|Everolimus Eluting Coronary Stent System
11574499|NCT00828087|Active Comparator|non drug eluting stent Arm|cobalt chromium balloon expandable stent
11574500|NCT00828074|Experimental|Treatment (vinorelbine tartrate and sorafenib tosylate)|Patients receive sorafenib tosylate PO twice daily on days 1-28 and vinorelbine ditartrate IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11574501|NCT00828061|Placebo Comparator|A|placebo
11574502|NCT00828061|Active Comparator|B|10 mg prednisone
11574503|NCT00828061|Active Comparator|C|25 mg prednisone
11574504|NCT00828048||Pancreatic Cyst|Pancreatic Cyst
11574505|NCT00828035|Other|1, REL|rel group : patients with light endoscopic robot
11574506|NCT00828035|Active Comparator|2, AO|AO group : Patients with surgery assistant
11574507|NCT00828009|Experimental|Tecemotide/bevacizumab after chemoradiation|"Concomitant Chemoradiotherapy: Patients (pts) receive paclitaxel intravenously (IV) over 1 hour and carboplatin IV over 15-30 minutes weekly for 6 weeks. Pts also receive radiotherapy 5 days a week for 6½ weeks. Pts with CR, PR, or SD proceed to consolidation chemotherapy.
~Consolidation chemotherapy: Pts receive paclitaxel IV over 3 hours and carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression (PD) or unacceptable toxicity. Pts with CR, PR, or SD proceed to maintenance therapy.
~Maintenance therapy: Pts receive a single dose of cyclophosphamide IV over 15-30 minutes 3 days before the first dose of bevacizumab and tecemotide. Pts then receive bevacizumab IV over 30-90 minutes on day 1 and tecemotide subcutaneously on days 1, 8, and 15 of courses 1 and 2 and on day 1 of every other course beginning in course 4. Treatment repeats every 21 days for up to 34 courses in the absence of PD or unacceptable toxicity."
11574508|NCT00827983|Experimental|Progesterone SC|
11574509|NCT00827983|Active Comparator|Progesterone Vaginal gel|
11574510|NCT00827970|Experimental|1 Screening|Individuals receiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
11574511|NCT00827970|No Intervention|2 Control|Control group receiving usual care
11574512|NCT00827957|Active Comparator|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
11574513|NCT00827957|Active Comparator|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
11574514|NCT00827944|Active Comparator|1|Parietex ProGrip
11574515|NCT00827944|Active Comparator|2|Low weight polypropylene mesh
11574516|NCT00827931|Experimental|A|end of the operation and on the mornings of the first, second, fourth and seventh postoperative days.
11574517|NCT00827931|Other|B|Standard of Care
11574518|NCT00827918|Experimental|MK-8998|MK-8998, 6 mg twice a day (BID) for Days 1 to 7, and 8 mg BID thereafter for a 4-week total treatment period
11574519|NCT00827918|Active Comparator|Olanzapine|Olanzapine, 5 mg BID for Day 1 to 7, and 15 mg (5 mg in the morning and 10 mg in the evening) thereafter for a 4-week total treatment period
11574520|NCT00827918|Placebo Comparator|Placebo|Placebo Comparator to MK-8998 or olanzapine
11574521|NCT00827905||Hospitalized|Patients admitted to the hospital
11574522|NCT00827892|Experimental|1|
11574523|NCT00827892|Placebo Comparator|2|
11574524|NCT00827879|Experimental|Strength at Home Couples Group|PTSD-Focused Cognitive Behavioral Therapy for Couples
11574525|NCT00827879|Placebo Comparator|Supportive Group Therapy|Supportive therapy for couples
11574526|NCT00827866|Other|1|Counselor-Initiated Tobacco Quit Line Group QL where the counselor contacts the client with a standardized intervention protocol)
11574527|NCT00827866|Other|2|Self-Paced Tobacco Quit Line Group which leaves the calling up to participants
11574528|NCT00827853|Experimental|1|Conventional angioplasty balloon post-dilation of nitinol self expanding stents
11574529|NCT00827853|Experimental|2|Cryoplasty balloon post-dilation
11574530|NCT00827840|Experimental|1. Paliperidone ER|New antipsychotics
11574531|NCT00827840|Active Comparator|2 Risperidone|
11574532|NCT00827827|Experimental|Arm 1|Participants in this group undergo lower-extremity strength training on three pneumatic resistance machines (Keiser Leg Press, Keiser Leg Extension, and Keiser Leg Curl). Training sessions happen 3 times per week (M,W,F) and last approximately 45 minutes to 1 hour. Participants in this group exercise each limb individually to account for the large discrepancies in strength between legs in stroke survivors.
11574637|NCT00826982||Pancreatic Cancer|
11574638|NCT00826969|Active Comparator|1|Ciclesonide 320µg
11574533|NCT00827827|Active Comparator|Arm 2|Participants in this group receive equal exposure to study staff compared with the experimental ST group (approximately 45 minutes to 1 hour 3 times per week). Exercise sessions for this group involve a full battery of active and passive...upper and lower body...stretching and range of motion exercises performed on raised padded tables.
11574534|NCT00827814|Experimental|Dutasteride|
11574535|NCT00827801||Group 1|MDASI-HF questionnaire provided to Doctor for symptom management.
11574536|NCT00827801||Group 2|MDASI-HF questionnaire collected not provided to Doctor.
11574537|NCT00827788|Active Comparator|iodixanol|Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
11574538|NCT00827788|Active Comparator|iopromide|Low-osmolar contrast medium (Iopromide) will be administered during PCI
11574539|NCT00827775|No Intervention|Control|Patients without intradialytic hypertension defined as average pre to post hemodialysis SBP falling >10 mmhg for more than 4/6 of the last dialysis treatment sessions
11574540|NCT00827775|Active Comparator|Intervention|Patients with intradialytic hypertension defined as average pre to post hemodialysis SBP elevation of >10 mmhg for more than 4/6 of the last dialysis treatment sessions
11574541|NCT00827762||Phenylketonuria|Individuals with mild phenylketonuria/hyperphenylalanemia who are beginning treatment with Kuvan.
11574542|NCT00827736|Experimental|Botox injection|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline. In addition, a placebo ointment has to be applied to the anoderm six times a day
11574543|NCT00827736|Active Comparator|ISDN ointment|application of ISDN 1% ointment 6 times a day. injection of placebo into internal anal sphincter
11574544|NCT00827723||Alcoholic|Alcoholic cirrhotic patient with resectable hepatocellular carcinoma
11574545|NCT00827723||Viral|Viral cirrhotic patient with resectable hepatocellular carcinoma
11574546|NCT00827710|Active Comparator|1|patients who received point-of-care report cards and were listed on provider performance report card
11574547|NCT00827710|Active Comparator|2|Patients who received point-of-care diabetes report cards but were not listed on provider performance report card
11574548|NCT00827710|Active Comparator|3|Patients who did not receive point-of-care report card but who were listed on provider performance report card
11574549|NCT00827710|No Intervention|4|Patients who did not receive point of care report card and who did were not listed on provider performance report card
11574550|NCT00827684|Active Comparator|Response or stable disease|will receive Temsirolimus
11574551|NCT00827684|Experimental|Progression|Will receive a combination of Temsirolimus and Irinotecan
11574552|NCT00827671|Other|Pre-operative chemotherapy|
11574553|NCT00827658|Active Comparator|Hypothenar Palm block|Hypothenar Palmar block group. Local anesthetic is placed at this location in this study group. The same local composition (Intervention) is used for both study groups. The trial is a comparison of location not the Intervention.
11574554|NCT00827658|Active Comparator|Volar Wrist Block|Volar Wrist block group. Local anesthetic is placed at this location in this study group. The same local composition (Intervention) is used for both study groups. The trial is a comparison of location not the Intervention.
11574555|NCT00827645||Uterine artery embolization|Women with symptomatic uterine fibroids scheduled for uterine artery embolization
11574556|NCT00827632|Active Comparator|Normal Weight group|Participants with a BMI of 19-24.9 kg/m^2
11574557|NCT00827632|Active Comparator|Obese group|Participants with a BMI of 30-39.9 kg/m^2
11574558|NCT00827619|Other|1|single arm non-randomized post-market study
11574559|NCT00827606|Experimental|Atorvastatin|All subjects will be treated with atorvastatin
11574560|NCT00827593|Active Comparator|Standard behavioral weight loss|University-based behavioral weight loss treatment
11574561|NCT00827593|Active Comparator|Weight Watchers|Weight Watchers program
11574562|NCT00827593|Active Comparator|Combined Treatment|University-based behavioral weight loss treatment followed by Weight Watchers
11574563|NCT00827580|Experimental|Eniluracil|
11574564|NCT00827567|Experimental|RAD 001|RAD001-10 mg by mouth once everyday
11574565|NCT00827554|Experimental|LMWH plus TACE|50 HCC patients will be allocated to receive Nadroparin 4100 AXa iu twice daily 3 days after TACE which lasted for 6 weeks
11574566|NCT00827554|Active Comparator|TACE alone|50 HCC patients randomly assigned to receive TACE without LMWH
11574567|NCT00827541||1|Patients hospitalized because of cIAI or cSSTI
11574568|NCT00827528|Experimental|SIS graft|this group will use a biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.
11574569|NCT00827528|Active Comparator|2|this group will use a traditional repair on correction of anterior vaginal wall prolapse.
11574570|NCT00827515|Experimental|One|
11574571|NCT00827515|Experimental|Two|
11574572|NCT00827515|Experimental|Three|
11574573|NCT00827515|Experimental|Four|
11574574|NCT00827489|Experimental|HTC-867|
11574575|NCT00827489|Placebo Comparator|Placebo|
11574576|NCT00827476|Experimental|ovarian transplantation|tissue will be used for xenotransplantation or in vitro culture
11574577|NCT00827463|Experimental|NFS and iron in the first quater|first arm: dosage NFS and iron during the beginning of the pregnancy then in the sixth month of pregnancy then in th delivery.
11574578|NCT00827463|Experimental|No NFS and iron in the first quater|second arm: dosage NFS and iron during the sixth month of pregnancy then in th delivery. No dosage of NFS and iron during the beginning of the pregnancy
11574579|NCT00827450|Placebo Comparator|Ctl|control isocaloric diet; no coffee
11574580|NCT00827450|Placebo Comparator|HF|Hypercaloric. high fructose diet; no coffee
11574581|NCT00827450|Experimental|C1|Hypercaloric, high fructose diet; caffeine-free, torrefied coffee
11574582|NCT00827450|Experimental|C2|Hypercaloric, high fructose diet; caffeine-free, partially torrefied coffee
11574583|NCT00827450|Experimental|C3|Hypercaloric, high fructose diet; caffeinated, partially torrefied coffee
11574584|NCT00827437|Other|1|
11574585|NCT00827424|Experimental|1|This arm will receive Lifestyle counseling by applying a modified PACE protocol
11574586|NCT00827424|No Intervention|2|Subject in this arm will be recruited but will receive no intervention
11574639|NCT00826969|Placebo Comparator|2|Placebo
11574588|NCT00827411|Active Comparator|2: Conventional Arm|"First randomization:
~Conventional Arm: fixed dose regiment of both aspirin and clopidogrel in all patients following DES implantation according to international guidelines"
11574589|NCT00827411|Experimental|3: Pursuit Arm|"Second randomization after one year of follow-up:
~Pursuit Arm: Pursuit of a dual oral antiplatelet therapy (aspirin and clopidogrel) beyond one year"
11574590|NCT00827411|Active Comparator|4: Interruption Arm|"Second randomization after one year of follow-up:
~Interruption Arm: Interruption of clopidogrel therapy."
11574591|NCT00827385||hypertensive|
11574592|NCT00827385||normotensive|
11574593|NCT00827372|Experimental|Pazopanib Treatment|Pazopanib 800 mg orally once each day (maximum total duration of treatment = 24 weeks)
11574594|NCT00827359|Experimental|Treatment|This is a single-arm study. All patients will receive everolimus.
11574595|NCT00827346|Active Comparator|Group 1|600-mg double dose
11574596|NCT00827346|Active Comparator|Group 2|600/600-mg double loading dose (first dose 600 mg given immediately upon arrival at the hospital and the second dose 600 mg, 3 hours after the first loading dose for a total of 900 mg
11574597|NCT00827346|Active Comparator|Group 3|Clopidogrel 900mg
11574598|NCT00827346|Active Comparator|Group 4|First dose 600 mg given immediately upon arrival at the hospital and the second dose 300 mg, 3 hours after the first loading dose for a total of 900 mg
11574599|NCT00827333|No Intervention|Phase I-Usual Care|
11574600|NCT00827333|Active Comparator|Phase 2 - Intervention|
11574601|NCT00827307|Experimental|Combination|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg.
11574602|NCT00827307|Active Comparator|Conctrol|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
11574603|NCT00827294|Experimental|Self-delivered mirror therapy|All participants were directed to self-deliver mirror therapy for 20 minutes per day.
11574604|NCT00827281|Experimental|1|DCS-augmented CBT for smoking cessation
11574605|NCT00827281|Placebo Comparator|2|Placebo-augmented CBT for smoking cessation
11574606|NCT00827268|Other|Arm 1|Repeated probes every 8 hours of treatment (1/week)
11574607|NCT00827255||Patients who received Restasis®|Patients who received Restasis® (cyclosporine ophthalmic emulsion 0.05%)
11574608|NCT00827242|Experimental|Tadalafil|
11574609|NCT00827242|Placebo Comparator|Placebo|
11574610|NCT00827229|Other|LaborPro, active Labor, Vaginal Examination|
11574611|NCT00827216|Placebo Comparator|Physiologic saline|
11574612|NCT00827216|Active Comparator|Erythromycine|
11574613|NCT00827203|Experimental|Cohort|
11574614|NCT00827190|Experimental|1|ILS-920
11574615|NCT00827177|Experimental|ARQ 197 in combination with sorafenib|
11574616|NCT00827164|Experimental|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
11574617|NCT00827164|Other|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
11574618|NCT00827151|Active Comparator|Estrogen and lifestyle|
11574619|NCT00827151|No Intervention|Lifestyle|
11574620|NCT00827138|Experimental|DCC-2036|This is a single arm study
11574621|NCT00827112|Experimental|Arm A|maraviroc (Selzentry, Celsentri) 150 mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100mg QD Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, but expressing cosmetic concerns because of the jaundice or scleral icterus (associated with bilirubin elevations) and wish to discontinue atazanavir (Reyataz) in spite of reassurances by the investigator, will be permitted on a single occasion only to switch to another protease inhibitor either darunavir (Prezista)/ritonavir (Norvir)((800/100 mg) QD or lopinavir/ritonavir (Kaletra, Aluvia)(400/100mg) BID and remain in the study. If the investigator decides to switch to a protease inhibitor other than darunavir (Prezista)/ritonavir (Norvir) or lopinavir/ritonavir (Kaletra, Aluvia)(, then the subject must be discontinued from the study.
11574622|NCT00827112|Experimental|Arm B|"emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD
~Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, but expressing cosmetic concerns because of the jaundice or scleral icterus (associated with bilirubin elevations) and wish to discontinue atazanavir in spite of reassurances by the investigator, will be permitted on a single occasion only to switch to another protease inhibitor either darunavir/ritonavir (800/100 mg) QD or lopinavir/ritonavir (400/100mg) BID and remain in the study. If the investigator decides to switch to a protease inhibitor other than darunavir/ritonavir or lopinavir/ritonavir, then the subject must be discontinued from the study."
11574623|NCT00827086||1|Patients with non-infectious Uveitis
11574624|NCT00827086||2|Patients with scleritis
11574625|NCT00827073|Active Comparator|Tetracaine 0.5% drop|Tetracaine 0.5% drop of betadine will be used on the operative eye after Tetracaine has been administered
11574626|NCT00827073|Active Comparator|Lidocaine 2% Jelly|Lidocaine 2% Jelly drop of betadine will be used on the operative eye after Lidocaine 2% Jelly has been administered
11574627|NCT00827047|Active Comparator|Total Hemihepatic Vascular Exclusion|Patients with HCC received Total Hemihepatic Vascular Exclusion in hepatectomy.
11574628|NCT00827047|Experimental|Hemihepatic vascular Clamping|Patients with HCC received Hemihepatic vascular Clamping in hepatectomy.
11574629|NCT00827047|Experimental|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
11574630|NCT00827034|Other|A|A: Warfarin alone
11574631|NCT00827034|Other|B|B: Dimebon and Warfarin co-administration
11574632|NCT00827021|Experimental|ESAs 1 low dose|
11574633|NCT00827021|Active Comparator|ESAs 2 high dose|
11574634|NCT00827008|Experimental|1, verum|
11574635|NCT00826995|Experimental|Video-based education arm:|Subjects receiving the video-based educational material
11574640|NCT00826943|Active Comparator|Levocetirzine|5 mg daily x 7 days (note = cross over = all participants receive active comparators and placebo)
11574641|NCT00826943|Active Comparator|cetirizine|10 mg daily x 7 days. Note = crossover study, so all participants recieve all active comparators and placebo.
11574642|NCT00826943|Placebo Comparator|placebo|one tablet daily x 7 days; note that this is a crossover study so all participants receive all active comparators and placebo
11574643|NCT00826930|Experimental|1A|0.5 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
11574644|NCT00826930|Experimental|2A|0.75 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
11574645|NCT00826930|Experimental|3A|1.0 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
11574646|NCT00826930|Experimental|4A|Dose of TSC either 0.5 mg/kg, 0.75 mg/kg, or 1.0 mg/kg based on the Data Monitoring Committee decision, anticonvulsants at Baseline - phenytoin only or none
11574647|NCT00826930|Experimental|1B|0.5 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
11574648|NCT00826930|Experimental|2B|0.75 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
11574649|NCT00826930|Experimental|3B|1.0 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
11574650|NCT00826930|Experimental|4B|Dose of TSC either 0.5 mg/kg, 0.75 mg/kg, or 1.0 mg/kg based on the Data Monitoring Committee decision, anticonvulsants at Baseline - any except phenytoin-only or none
11574651|NCT00826917||Objective 1: XI VOCALTM in 3D fetal volumetry measurement|group 1: multiplanar; group 2: VOCALTM; group 3: XI VOCALTM
11574652|NCT00826917||Objective 2: XI VOCALTM in 3D placental volumetry measurement|group 1: multiplanar; group 2: VOCALTM; group 3: XI VOCALTM
11574653|NCT00826917||Objective 3: Comparison between 2 ultrasound machine|"intramachine reliability for (i)fetal, (ii)gestational sac and (iii)placenta volumetry measurement for (a)multiplanar and (b)VOCALTM:- group 1:Accuvix; group 2:Voluson 730
~intermachine reliability for fetal, gestational sac and placenta volumetry measurement for (a)multiplanar and (b)VOCALTM for Accuvix and Voluson 730"
11574654|NCT00826917||Objective 4:3D volumetry in fetuses at risk of Hb Bart's|Measurement of fetal, gestational sac and placenta volume per CRL quotient using multiplanar technique:- group 1: affected; group 2: unaffected
11574655|NCT00826904||Lean|Healthy, pregnant women with BMI of 20 - 26 kg/m2
11574656|NCT00826904||Obese|Healthy, obese pregnant women with BMI 30 - 38 kg/m2
11574657|NCT00826878|Experimental|Tivozanib (AV-951)|
11574658|NCT00826839|Experimental|OCP/MDL|Oral contraceptive pills/microdose lupron
11574659|NCT00826839|Experimental|E2/antagonist|Estradiol patch/gonadotropin-releasing hormone antagonist
11574660|NCT00826826|Active Comparator|Amiodarone|
11574661|NCT00826826|Placebo Comparator|Placebo|
11574662|NCT00826813|Experimental|stenting|The conventional esophageal stent or 125I radiation stent is placed in the patients with dysphagia who are enrolled to the study.
11574663|NCT00826800|Experimental|Neoadjuvant FOLFOX Plus Bevacizumab|FOLFOX and bevacizumab will be given to colon cancer patients for 4 cycles over 8 weeks; an additional 2 cycles of FOLFOX without bevacizumab will be given for a total of 12 weeks of pre-operative chemotherapy.Restaging will be performed within 3 weeks of the 6th chemotherapy cycle. Colon surgery will be performed between weeks 3 and 6 subsequent to the 6th cycle of FOLFOX. Patients receiving preoperative chemotherapy without radiation will wait a minimum of 3 weeks from their last dose of chemotherapy, and 6 weeks from their last dose of bevacizumab, before proceeding to surgery. Specifically, it is intended that patients will undergo surgery between 3-6 weeks from completion of their neoadjuvant therapy as deemed clinically appropriate by their surgeon and medical oncologist. This permits a 7-10 week interval between the 4th bevacizumab administration and colon surgery.
11574664|NCT00826774|Active Comparator|Ususal Care|
11574665|NCT00826774|Experimental|Breif Lifestyle Counseling|
11574666|NCT00826774|Experimental|Enhanced Brief Lifestyle Counseling|
11574667|NCT00826761|Active Comparator|1|High dose Lb. casei
11574668|NCT00826761|Active Comparator|2|Low dose Lb. Casei
11574669|NCT00826761|Placebo Comparator|3|
11574670|NCT00826748|Experimental|Treated Smokers|The treatment with inhaled beclomethasone will be administered to this cohort from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days.
11574671|NCT00826748|No Intervention|Non-Treated Smokers|This cohort will act as control and include healthy smokers who receive no treatment.
11574672|NCT00826748|No Intervention|Non-Smokers|This cohort will act as control and include healthy non-smokers who receive no treatment.
11574673|NCT00826735|Experimental|Guided imagery|The experimental group received a relaxation focused guided imagery intervention to use through the remainder of pregnancy plus a physiologic guided imagery intervention during the third stage of labor. These interventions were scripted and prerecorded on CDs.
11574674|NCT00826709|Experimental|Arm 1|2 Nasal swabs
11574675|NCT00826709|Experimental|Arm 2|2 Nasopharyngeal swabs
11574676|NCT00826709|Experimental|Arm 3|Nasal wash or aspirate
11574677|NCT00826683|Other|Control group of healthy subjects|Control group of healthy subjects : simple blood analysis of EPCs
11574678|NCT00826683|Active Comparator|COPD|COPD: one initial blood sample and simple clinical follow-up
11574679|NCT00826683|Active Comparator|NSCLC|NSCLC: one initial blood sample and usual clinical follow-up
11574680|NCT00826670|Experimental|Topical decolonization|
11574681|NCT00826670|Placebo Comparator|Placebo|
11574682|NCT00826657|Placebo Comparator|placebo|Receive placebo (sugar pill) during the intervention. Received a 1000 mg vitamin B12 injection at the end of the study.
11574683|NCT00826657|Active Comparator|Vitamin B12|Received 500 micrograms vitamin B12 per day during the study Received a 1000 mg vitamin B12 injection at the start of the study
11574684|NCT00826644|Experimental|Belotecan|
11574685|NCT00826644|Active Comparator|Etoposide|
11574686|NCT00826631|Active Comparator|1|Fast food intake, doubling of caloric intake, in combination with sedentary behavior (no exercise)
11574687|NCT00826631|No Intervention|2|Control group, parallel
11574688|NCT00826618|Experimental|Ranibizumab|
11574926|NCT00824850|Experimental|1|Subjects received Prevnar in study D118-P8
11574689|NCT00826605||Urobilinogen increase|Increase in urobilinogen increase on routine dipstick test at prenatal appointment after 37 weeks gestation
11574690|NCT00826605||Weight Loss at Term|Weight loss since previous prenatal appointment after 37 weeks gestation
11574691|NCT00826592|Experimental|Video-based education arm|Subjects receiving the video-based educational material
11574692|NCT00826592|Active Comparator|Written education arm:|Subjects receiving the written educational material
11574693|NCT00826579|Experimental|Colon cancer|Colon cancer patients of all stages
11574694|NCT00826566|Active Comparator|1|500 mg caffeine capsules per day
11574695|NCT00826566|Placebo Comparator|2|500 mg placebo capsules
11574696|NCT00826553|Experimental|GABA agonist|
11574697|NCT00826553|Experimental|Alpha 2 agonist|
11574698|NCT00826540|Experimental|Treatment (sorafenib tosylate and bevacizumab)|Patients receive sorafenib tosylate orally twice daily on days 1-5 and 8-12 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Blood samples are collected at baseline and then periodically during study treatment for laboratory biomarker and pharmacogenetic studies
11574699|NCT00826514|Experimental|Tanezumab|
11574700|NCT00826514|Placebo Comparator|Placebo|
11574701|NCT00826501|Active Comparator|1|Endoscopic cyst-gastrostomy with a neurolytic block along with oral/transdermal analgesic therapy
11574702|NCT00826501|Active Comparator|2|Surgical cyst-gastrostomy with neurolytic block and pain managed by only oral/transdermal analgesic
11574703|NCT00826488|Other|observational|Observational
11574704|NCT00826475|Experimental|Mindfulness|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
11574705|NCT00826475|Active Comparator|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
11574706|NCT00826462|Experimental|1|"Corticosteroid injection in combination with physical therapy
~Injection with triamcinolone 10 mg and 10 mg of lidocaine at start and at 3 weeks in combination with physiotherapy for 6 weeks (12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises) Naprosyn Entero 500 mg bid for 14 days"
11574707|NCT00826462|Placebo Comparator|2|"Placebo injection in combination with physical therapy
~Injection with sodium chloride and 10 mg of lidocaine at start and at 3 weeks in combination with physiotherapy for 6 weeks (12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises) Naprosyn entero 500 mg bid for 14 days"
11574708|NCT00826462|Active Comparator|3|Control group: wait-and-see treatment Naprosyn entero 500 mg bid for 14 days
11574709|NCT00826449|Experimental|Phase I|Dasatinib + Erlotinib
11574710|NCT00826436||8 subjects for Cohort 1|
11574711|NCT00826436||8 subjects for Cohort 2|
11574712|NCT00826410|Experimental|subcutaneous drain|"Use of subcutaneus suction drain (Redon) after laparotomy"
11574713|NCT00826397|Experimental|Acupuncture Arm|Patients in the treatment arm will receive acupuncture administered twice weekly for six weeks and will be allowed to take pain medication as necessary.
11574714|NCT00826397|Sham Comparator|Control Arm|The control patients will receive a form of sham acupuncture, which will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks.
11574715|NCT00826371|Experimental|1|
11574716|NCT00826358|Experimental|A|ABT-143 capsules 5/45mg
11574717|NCT00826358|Active Comparator|B|ABT-335 45mg and rosuvastatin 5mg
11574718|NCT00826345|Experimental|Acupuncture/Moxibustion|Diagnostic Acupuncturists assessments will inform acupuncture/moxibustion treatment prescriptions for persons with HIV/AIDS experiencing distal peripheral neuropathy. This protocol is tailored specifically for the subject's unique diagnosis according to the symptoms being reported at each diagnostic acupuncture (DA) session.
11574719|NCT00826345|Placebo Comparator|Placebo Acupuncture / Moxibustion|Sham/placebo Arm: Points will be administered away from the classic/traditional true point location.
11574720|NCT00826332|Active Comparator|Abdominal|Transabdominal ultrasound guided embryo transfer
11574721|NCT00826332|Active Comparator|Vaginal|Transvaginal ultrasound guided embryo transfer
11574722|NCT00826319||Bioimpedance sub-study cohort|Funded by a grant from Kidney Foundation of Canada, Dr. Catherine Clase initiated a bioimpedance sub-study across 7 centres and recruited n=416 within the CANPREDDICT population. The study uses bioimpedance measurements to assess volume status to determine the multivariable relationship between baseline volume overload and subsequent cardiovascular events. Subjects are followed at 6 months intervals for 2 years.
11574723|NCT00826319||Ethnic enrichment cohort|Additional recruitment initiated and funded by the Principal Investigator, Adeera Levin for enriching the ethnic representation within the Canadian cohort on South Asian and Oriental Asian was completed from Sept 2012 to June 2013, n=53.
11574724|NCT00826319||Original CanPreddict cohort|The original CanPreddict cohort was recruited from Jun 2008 - Oct 2009 has 2544 CKD patients across Canada.
11574725|NCT00826306|Experimental|Video-based education arm|Subjects receiving the video-based educational material
11574726|NCT00826306|Active Comparator|Written education arm|Subjects receiving the written educational material
11574727|NCT00826293|Active Comparator|True Stabilization Group|Patients will be randomized to one of the two treatment groups (true stabilization vs. sham stabilization). Patients will be exercising with a belt that is expected to reduce impingement of the rotator cuff tendons.
11574728|NCT00826293|Sham Comparator|Sham Stabilization|Patients receive sham stabilization. The sham procedure imitates the treatment without any true effect.
11574729|NCT00826280|Placebo Comparator|Placebo plus Regadenoson|Two placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection
11574730|NCT00826280|Experimental|Caffeine 200 mg plus Regadenoson|One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection
11574731|NCT00826280|Experimental|Caffeine 400 mg plus Regadenoson|Two 200 mg Caffeine capsules plus 0.4 mg regadenoson per 5mL intravenous bolus injection
11574732|NCT00826267|Experimental|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
11574733|NCT00826267|Active Comparator|Lapatinib|Lapatinib tablets 1500 mg daily.
11574734|NCT00826267|Active Comparator|Trastuzumab|Trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly.
11574735|NCT00826241|Experimental|Temozolomide + Lapatinib|Temozolomide starting dose 125 mg/m^2 daily by mouth on days 1-7 & 15-21 of a 28 day cycle. Lapatinib starting dose 1250 mg daily by mouth.
11574736|NCT00826228|Experimental|PTH/Weight-Bearing|
11574737|NCT00826215|Experimental|1|Electroacupuncture treatment
11574738|NCT00826215|Sham Comparator|2|Sham laser acupuncture
11574739|NCT00826202|Experimental|D serine|60 mg/kg/day
11574740|NCT00826202|Placebo Comparator|Placebo|
11574741|NCT00826176|Experimental|Sugammadex in Caucasian Subjects|At 1-2 post-tetanic counts (PTC) after the last dose of rocuronium, 4.0 mg.kg-1 sugammadex was to be administered. Caucasian subjects living in Europe.
11574742|NCT00826176|Experimental|Sugammadex in Chinese Subjects|At 1-2 post-tetanic counts (PTC) after the last dose of rocuronium, 4.0 mg.kg-1 sugammadex was to be administered. Chinese subjects living in China.
11574743|NCT00826163|Active Comparator|stable COPD|Postbronchodilator FEV1> or = 50% predicted
11574744|NCT00826163|Sham Comparator|Asthma|Postbronchodilator FEV1 > or = 50% predicted
11574745|NCT00826150|Experimental|BC-819|BC-819 60, 120 and 240 mg IP administration
11574746|NCT00826137|Experimental|A|Treated with prebiotics.
11574747|NCT00826137|Placebo Comparator|B|Placebo treated.
11574748|NCT00826124|Active Comparator|I|Two epidural steroid injections two weeks apart based on history and physical exam alone
11574749|NCT00826124|Active Comparator|II|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
11574750|NCT00826111|Active Comparator|Eszopiclone|Lexapro for 10 weeks together with eszopiclone.
11574751|NCT00826111|Placebo Comparator|Placebo|Lexapro for 10 weeks together with placebo.
11574752|NCT00826098|Experimental|1 (PRP)|Total knee replacement with PRP
11574753|NCT00826098|No Intervention|2 (non-PRP)|Total knee replacement without PRP
11574754|NCT00826085|Experimental|Thermodox in combination with hyperthermia|Single arm study
11574755|NCT00826072||ALI|patients with acute lung injury at 24h after cardiac surgery
11574756|NCT00826072||Control|patients without acute lung injury 24h after cardiac surgery
11574757|NCT00826059|Active Comparator|Active Stimulation|"Implantation/ISS Stimulation during 5 consecutive days & Standard of Care (SoC).
~Day 1: First stimulation initiated within 24 hours from stroke onset, following implantation completion. All subjects will be treated according to SoC for treatment of Acute Ischemic Stroke.
~Day 2-4: ISS Stimulation treatment sessions repeated daily. Each treatment will be initiated within 18-26 hours from the preceding treatment.
~Day 5: Following completion of the last ISS Stimulation treatment session, imaging performed for assessing Injectable Neuro Stimulator (INS) positioning and/or lesion. Implant removal procedure will then be performed. Subsequently, patients will be evaluated for safety and effectiveness.
~Subjects will continue with SoC as needed and discharged from the hospital based on the judgment of the study investigator."
11574758|NCT00826059|Sham Comparator|Sham Stimulation|"Sham Implantation and Sham Stimulation during 5 consecutive days & Standard of Care (SoC).
~Day 1: First Sham stimulation initiated within 24 hours from stroke onset, following Sham implantation procedure. All subjects will be treated according to SoC for treatment of Acute Ischemic Stroke.
~Day 2-4: Sham Stimulation sessions repeated daily. Each Sham Stimulation will be initiated within 18-26 hours from the preceding treatment.
~Day 5: Following completion of the last Sham Stimulation session, imaging performed for lesion assessment. Sham Implant removal will then be performed. Subsequently, patients will be evaluated for safety and effectiveness.
~Subjects will continue with SoC as needed and discharged from the hospital based on the judgment of the study investigator."
11574759|NCT00826033||Therapy monitoring|
11574760|NCT00826020|Experimental|Omegaven™|This study will be a prospective, non-randomized, open-label study of Omegaven™ for provision of parenteral lipid calories. The study cohort, receiving the parenteral nutrition (PN) lipid at 1g/kg/day, will be compared to historical controls at University of Nebraska Medical Center (UNMC) where parenteral lipid calories were provided exclusively through soybean-based formulations. The study is planned to enroll 100 patients. The Intestinal Rehabilitation Program at UNMC sees between 20 and 30 new pediatric patients per year, with almost all being PN-dependent and over 75% presenting with a bilirubin ≥ 2mg/dL. Based on these calculations, we estimate 4-5 years to enroll 100 patients.
11574761|NCT00825994|Experimental|Omega-3|omega-3 fatty acids, 2grams qd [every day] (2 x 1 gram tablets), PO [by mouth]
11574762|NCT00825981||coronary artery bypass graft|patients undergoing elective coronary artery bypass graft with or without cardiopulmonary bypass
11574763|NCT00825968||Data collection group|Patients having procedures done at the electrophysiology Laboratories at the Ross Heart Hospital at The Ohio State University Medical Center.
11574764|NCT00825955|Experimental|Brivanib|
11574765|NCT00825955|Placebo Comparator|Placebo|
11574766|NCT00825942|Experimental|C-KAD Ophthalmic Solution|
11574767|NCT00825929||1|Treated with one of the antiretroviral agents under study, PK parameters during pregnancy will be compared with PK parameters after pregnancy (within the same woman)
11574768|NCT00825916|Experimental|High Dose|
11574769|NCT00825916|Placebo Comparator|Placebo|
11574770|NCT00825916|Experimental|Low Dose|
11574771|NCT00825903|Experimental|1|Aquatic based exercise
11574772|NCT00825864|Active Comparator|1diclofenac drops treatment|four times a day for 3 months
11574773|NCT00825864|Active Comparator|2dexamethasone drops|
11574774|NCT00825851|Active Comparator|continuous smoking|subjects smoke 20 cigarettes per day
11574775|NCT00825851|Active Comparator|smoking cessation and NRT|subjects quit smoking and use transdermal nicotine patch
11574776|NCT00825851|Placebo Comparator|smoking cessation and placebo patch|subjects quit smoking and use placebo patch
11574777|NCT00825851|No Intervention|never smokers|subjects being never smokers and who refrain from smoking
11574778|NCT00825838|Experimental|1|Oral ingestion of 6mg chili pepper extract
11574779|NCT00825838|Placebo Comparator|2|Oral ingestion of 0 mg chili pepper extract (matching placebo)
11574780|NCT00825825|Active Comparator|Escitalopram|One week of escitalopram at 10 mg followed by one week at 20 mg in healthy volunteers.
11574781|NCT00825825|Active Comparator|Citalopram|One week of citalopram at 20 mg followed by one week at 40 mg in healthy volunteers.
11574782|NCT00825825|Placebo Comparator|Placebo|Two weeks of placebo in healthy volunteers.
11574783|NCT00825812|Experimental|Sugammadex in Caucasian Subjects|At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
11574784|NCT00825812|Active Comparator|Neostigmine in Caucasian Subjects|At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
11574785|NCT00825812|Experimental|Sugammadex in Chinese Subjects|At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
11574786|NCT00825812|Active Comparator|Neostigmine in Chinese Subjects|At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
11574787|NCT00825799||Major Depressive Disorder|Adults with major depressive disorder who are experiencing a current depressive episode.
11574788|NCT00825799||Healthy controls|Individuals without any Axis I psychiatric diagnosis who are matched to depressed subjects by age and sex.
11574789|NCT00825786|Active Comparator|Group 1|combined group: ropivacaine and mepivacaine mixture: 1:1 volume mixture of 1.5% mepivacaine and 0.5% ropivacaine in 2 syringes (labeled 1 and 2) with 15 mL in each (total, 30 mL) injected in immediate sequence;
11574790|NCT00825786|Active Comparator|Group 2|sequential group: mepivacaine followed by ropivacaine: syringe 1 containing 15 mL of 1.5% mepivacaine, syringe 2 containing 15 mL of 0.5% ropivacaine (total, 30 mL); syringe 2 was injected with a 90-sec delay after injection of syringe 1.
11574791|NCT00825773|Active Comparator|Excel|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
11574792|NCT00825773|Sham Comparator|Cypher|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
11574793|NCT00825760|Other|1|Single treatment
11574794|NCT00825760|Other|2|12 treatments, once weekly
11574795|NCT00825734|Experimental|Dose Level 1|Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (40mg/m^2)
11574796|NCT00825734|Experimental|Dose Level -1|Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (32mg/m^2)
11574797|NCT00825734|Experimental|Dose Level 1a|Sorafenib PO BID (400mg), Ixabepilone IV every 21 days (32mg/m^2)
11574798|NCT00825721|Active Comparator|1.3% (low dose)|
11574799|NCT00825721|Active Comparator|2% (medium dose)|
11574800|NCT00825721|Active Comparator|2.6% (high dose)|
11574801|NCT00825721|Placebo Comparator|Placebo|
11574802|NCT00825708|Active Comparator|rTMS|rTMS session
11574803|NCT00825708|Sham Comparator|SHAM|sham session
11574804|NCT00825695|Active Comparator|flavanol-rich cocoa|
11574805|NCT00825695|Placebo Comparator|flavanol-poor cocoa|
11574806|NCT00825682|Experimental|1|20 breast cancer patients scheduled for adjunctive radiation treatment will be recruited for this study to receive reflexology treatment initiated at the beginning of radiation therapy, once a week, for 10 weeks.
11574807|NCT00825682|No Intervention|2|20 breast cancer patients, scheduled for adjunctive radiation treatment, matched by age to the intervention group will receive treatment as usual, and will be evaluated by the same measures as the intervention group.
11574808|NCT00825669|Active Comparator|survival rate (TACE)|to compare the effects of TACE and TACE plus laser ablation for treating patients with PVTT
11574809|NCT00825669|Active Comparator|survival rate (TACE plus laser ablation)|to compare the effects of TACE and TACE plus laser ablation for treating patients with PVTT
11574810|NCT00825656|Experimental|1|Sinol-M
11574811|NCT00825656|Active Comparator|2|Sinol
11574812|NCT00825643||Insulin detemir|
11574813|NCT00825630|Active Comparator|Lansoprazole (Lanton)|Patients with H.pylori infection will take one tablet a day of 20 mg Lansoprazole for 14 days orally in the morning
11574814|NCT00825630|Active Comparator|Omeprazole (Losec)|Patients with H.pylori infection will take one tablet of 30 mg a day of Omeprazole for 14 days orally in the morning
11574815|NCT00825630|Active Comparator|Pantoprazole (Controloc)|Patients with H.pylori infection will take one tablet a day of 40 mg of Pantoprazole for 14 days orally in the morning
11574816|NCT00825630|Active Comparator|Esomeprazole(Nexium)|Patients with H.pylori infection will take one tablet a day of 20 mg Esomeprazole for 14 days orally on the morning
11574817|NCT00825617|Experimental|HRT|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
11574818|NCT00825604|No Intervention|Without PCI|Optimized medical treatment, physical training and smoking cessation
11574819|NCT00825604|Active Comparator|With PCI|optimized medical treatment, physical training and smoking cessation with complimentary treatment with percutaneous coronary intervention(PCI)
11574820|NCT00825591|Active Comparator|1|Individuals with abnormal rhythmicity will be treated with melatonin to assess if sleep patterns are improved.
11574821|NCT00825591|Placebo Comparator|2|
11574822|NCT00825578|Active Comparator|1|Upper-lobe predominant emphysema
11574823|NCT00825578|Active Comparator|2|Non-upper lobe predominant emphysema
11574824|NCT00825565|Experimental|Alwextin cream|8 subjects enrolled in this single study arm. All 8 subjects completed the study.
11574825|NCT00825539|Placebo Comparator|Placebo|
11574826|NCT00825539|Experimental|AQW051|
11574827|NCT00825526|Experimental|Early Intervention, MBSR therapy|Group that receives Mindfulness Based Stress Reduction Therapy immediately after randomization
11574828|NCT00825526|Active Comparator|Delayed Treatment Arm, MBSR Therapy|Group that receives Mindfulness Based Stress Reduction Therapy within 3 months of randomization
11574829|NCT00825513|Experimental|Akreos Toric|Akreos Toric Intraocular Lens
11574927|NCT00824850|Experimental|2|Subjects received MnCC in study D118-P8
11574830|NCT00825513|Active Comparator|Akreos Advanced|Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)
11574831|NCT00825500|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo (0 mg)
11574832|NCT00825500|Active Comparator|Inhaled Loxapine 1.25 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
11574833|NCT00825500|Experimental|Inhaled Loxapine 2.5 mg|Inhaled Staccato Loxapine 2.5 mg, single dose
11574834|NCT00825487|Experimental|ARQ 621 treatment|
11574835|NCT00825474|Experimental|survival rate|therapeutic effect of partial hepatectomy or TACE plus PEI for small hepatocellular carcinoma
11574836|NCT00825461||1|Anorexia with tube feeding
11574837|NCT00825461||2|Anorexia without tube feeding
11574838|NCT00825461||3|Control
11574839|NCT00825448|Experimental|2|patient in hospital a week before the date of surgery for the treatment of his addiction alcohol
11574840|NCT00825448|No Intervention|1|no treatment of his addiction alcohol during a week before the date of surgery
11574841|NCT00825435|Experimental|1|Coronary CT angiogram plus Standard of care (CTA+SOC)
11574842|NCT00825435|No Intervention|2|Standard of Care (SOC)
11574843|NCT00825422|Experimental|A|first bolus of 20 ml of ropivacaine(5mg/ml) and continuous infiltration (8ml/h)of ropivacaine (2mg/ml)
11574844|NCT00825422|Placebo Comparator|B|first bolus of 20 ml of physiological saline solution(9%) and continuous infiltration (8ml/h)of physiological saline solution(9%)
11574845|NCT00825396|Experimental|C-KAD Ophthalmic Solution|
11574846|NCT00825383|Active Comparator|1|High Fiber Diet
11574847|NCT00825383|Active Comparator|2|Moderate Fiber Diet
11574848|NCT00825370|Experimental|Protocolized|"1 mg IV hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
11574849|NCT00825370|Active Comparator|Discretionary Care|Patients receive an IV opioid the type and dose of which is determined by the treating physician
11574850|NCT00825344|Experimental|1|Etanercept 50 mg preoperatively
11574851|NCT00825344|Placebo Comparator|2|Subcutaneous saline preoperatively
11574852|NCT00825331||1|patients for elective catheterization without special risks
11574853|NCT00825331||2|patients for elective catheterization with special risks
11574854|NCT00825331||3|patients for PCI without GP IIb/IIIa
11574855|NCT00825331||4|Patients for PCI with GPIIb/IIIa and emergencies
11574856|NCT00825318|Experimental|Daily ultrafiltration|During the treatment phase of the study, the subject will undergo ultrafiltration 6 times a week and hemodialysis 2 times a week.
11574857|NCT00825305|Experimental|Zagreb (2-1-1)|Rabies PCEC vaccine was applied according Zagreb schedule with 2 vaccinations on day 0, 1 vaccination on day 7 and day 21, respectively
11574858|NCT00825305|Active Comparator|Essen (1-1-1-1-1)|Rabies PCEC vaccine was applied according Essen schedule, i.e. 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.
11574859|NCT00825292|Active Comparator|2|HDNBI colonoscopy followed by standard white light colonoscopy
11574860|NCT00825292|Active Comparator|1|standard white light colonoscopy followed by HDNBI colonoscopy
11574861|NCT00825279|Active Comparator|1-BMS|Bare Metal Stent (Euca STS Flex)
11574862|NCT00825279|Experimental|2-DES|Drug Eluting Stent (Euca STS Flex DE), Paclitaxel Eluting stent with biodegradable polymer
11574863|NCT00825266|Active Comparator|bosentan|Bosentan 62.5 twice daily for 4 weeks, then 125 mg twice daily.
11574864|NCT00825266|Active Comparator|Pioglitazone|Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration of the study.
11574865|NCT00825240||Cancer Survivorship Study|Survey of colorectal cancer patients within one year from treatment end.
11574866|NCT00825227|Active Comparator|Patient responses to 150 mg/day armodafinil|"150 mg/day armodafinil
~taxane chemotherapy treatment alone or in combination with other agents"
11574867|NCT00825227|Placebo Comparator|Patient responses to placebo|"placebo
~taxane chemotherapy treatment alone or in combination with other agents"
11574868|NCT00825214|Active Comparator|1|Use of zapperclick on mosquito bite
11574869|NCT00825214|Placebo Comparator|2|use of inactivated zapperclick on mosquito bite
11574870|NCT00825201|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation given IP on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11574871|NCT00825188|Active Comparator|eplerenone|
11574872|NCT00825188|Active Comparator|amlodipine|Amlodipine 5-10mg daily times 8 weeks
11574873|NCT00825175|Active Comparator|1|Treadmill Training in infants with Down syndrome only
11574874|NCT00825175|Experimental|2|Treadmill Training and supramalleolar orthoses use for infants with Down syndrome
11574875|NCT00825162|Experimental|Cohort A|Participants aged 6 months to less than 3 years
11574876|NCT00825162|Experimental|Cohort B|Participants aged 3 years to less than 9 years
11574877|NCT00825162|Experimental|Cohort C|Participants aged 9 years to less than 18 years
11574878|NCT00825149|Experimental|A: R/R FL: Obinutuzumab Low Dose + CHOP|Participants with Relapsed/Refractory (R/R) FL will receive obinutuzumab 400 milligrams (mg) intravenous (IV) infusion on Days 1 and 8 of Cycle 1 and every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 milligrams per square-meter (mg/m^2), vincristine 1.4 mg/m^2 capped at 2 mg, and cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 400 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
11574879|NCT00825149|Experimental|B: R/R FL: Obinutuzumab High Dose + CHOP|Participants with R/R FL will receive obinutuzumab 1600 mg IV infusion on Days 1 and 8 of Cycle 1 and 800 mg IV infusion every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 capped at 2 mg, and cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 800 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
11574928|NCT00824837|Experimental|A|New larger pore membrane
11574880|NCT00825149|Experimental|C: R/R FL: Obinutuzumab Low Dose + FC|Participants with R/R FL will receive obinutuzumab 400 mg IV infusion on Days 1 and 8 of Cycle 1 and every 4 weeks on Day 1 of subsequent cycles (for 46 cycles) in the induction period; Fludarabine 25 mg/m^2/day and cyclophosphamide 250 mg/m^2/day IV infusion every 4 weeks on Days 13 of each cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 400 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
11574881|NCT00825149|Experimental|D: R/R FL: Obinutuzumab High Dose + FC|Participants with R/R FL will receive obinutuzumab 1600 mg IV infusion on Days 1 and 8 of Cycle 1 and 800 mg IV infusion every 4 weeks on Days 1 of subsequent cycles (for 46 cycles) in the induction period; Fludarabine 25 mg/m^2/day and cyclophosphamide 250 mg/m^2/day IV infusion every 4 weeks on Days 13 of each cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 800 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
11574882|NCT00825149|Experimental|E: First-Line FL: Obinutuzumab + Bendamustine|Participants with first-line FL will receive obinutuzumab 1000 mg IV infusion on Days 1 and 8 of Cycle 1 and every 4 weeks on Day 1 of subsequent cycles (for 46 cycles) in the induction period; Bendamustine 90 mg/m^2 IV infusion on Days 2 and 3 of Cycle 1 and every 4 weeks on Days 1 and 2 of each subsequent cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 1000 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
11574883|NCT00825149|Experimental|F: First-Line FL: Obinutuzumab + CHOP|Participants with first-line FL will receive obinutuzumab 1000 mg IV infusion on Days 1 and 8 of Cycle 1 and every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 capped at 2 mg, cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 1000 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
11574884|NCT00825136|Active Comparator|relaxation|The patients of this arm practice on-line muscle relaxation for 8 weeks.
11574885|NCT00825136|Experimental|relaxation & biofeedback|The patients of this arm practice on-line muscle relaxation plus finger temperature biofeedback for 8 weeks.
11574886|NCT00825123|Experimental|Ivabradine|
11574887|NCT00825123|Active Comparator|Metoprolol|
11574888|NCT00825123|Placebo Comparator|Placebo|
11574889|NCT00825110||No treatment|confirmed diagnosis of colorectal carcinoma
11574890|NCT00825097|Experimental|Neurotomy Group|8 patients undergoing a selective tibial neurotomy under general anesthesia
11574891|NCT00825097|Active Comparator|BTX Group|8 patients undergoing a botulinum toxin injection in the calf muscles under EMG-control
11574892|NCT00825084|Experimental|single dose cohort-Japanese group|Japanese healthy subjects
11574893|NCT00825084|Experimental|single dose cohort-Western group|Western healthy subjects
11574894|NCT00825084|Experimental|multiple dose cohort-Japanese group|Japanese healthy subjects
11574895|NCT00825084|Experimental|multiple dose cohort-Western group|Western healthy subjects
11574896|NCT00825071|Active Comparator|Group D|Dexamethasone group : This group received 8 mg dexamethasone
11574897|NCT00825071|Active Comparator|Group O|Ondansetron Group: received 4 mg ondansetron
11574898|NCT00825071|Placebo Comparator|Group P|(Group P) received normal saline (Placebo)
11574899|NCT00825058|Experimental|1|
11574900|NCT00825058|Placebo Comparator|2|
11574901|NCT00825058|Active Comparator|3|
11574902|NCT00825045|Experimental|Treatment with risperidone|Gradual titration of risperidone according to clinical response
11574903|NCT00825032|Active Comparator|1: comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
11574904|NCT00825032|Experimental|2: UEET + PR|Experimental program consisting in additional 15 daily sessions of unsupported UEET over and above the same PR program used for control patients.
11574905|NCT00825019|Experimental|1|
11574906|NCT00825019|Placebo Comparator|2|
11574907|NCT00825019|Active Comparator|3|paroxetine
11574908|NCT00825006|No Intervention|Control|Dual site pacing (LV tip electrode and RV tip electrode)
11574909|NCT00825006|Experimental|Triple site pacing|Triple site pacing(LV tip electrode,RV tip electrode and RV ring electrode)
11574910|NCT00824993|Experimental|Ibandronate + Calcium + Vitamin D|Ibandronate infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant. Calcium 500 mg by mouth everyday for 12 months. Vitamin D 400 units by mouth 2 times a day for 12 months.
11574911|NCT00824993|Experimental|Calcium + Viatmin D|Calcium 500 mg by mouth everyday for 12 months. Vitamin D 400 units by mouth 2 times a day for 12 months.
11574912|NCT00824980|Experimental|IP10.C8 Gel|
11574913|NCT00824980|Placebo Comparator|Placebo Gel|
11574914|NCT00824967|No Intervention|1- The reference group|one will take care of the patient in a habitual way: no consultation additional, step of exam on top of that...
11574915|NCT00824967|Other|2- The intervention group|Training and valuation of the treating personnel
11574916|NCT00824928||Observational|Patients with locally recurrent prostate cancer that have chosen salvage cryotherapy
11574917|NCT00824902|Experimental|Tissue Elastography Imaging|Using special elastography software, probe pressed gently against prostate during routine ultrasound before prostate surgery, 10-15 minutes process.
11574918|NCT00824889|Other|1|Healthy volunteer
11574919|NCT00824889|Other|2|atopic dermatitis patient
11574920|NCT00824889|Other|3|contact dermatitis patient
11574921|NCT00824889|Other|4|psoriasis patient
11574922|NCT00824889|Other|5|lichen planus patient
11574923|NCT00824889|Other|6|GVH patient
11574924|NCT00824889|Other|7|melanoma patient
11574925|NCT00824863|Experimental|one arm|All 10 patients receive ketoconazole 2% foam in the uncontrolled study.
11574929|NCT00824837|Active Comparator|B|Standard haemodialysis membrane
11574930|NCT00824824|Experimental|Brimonidine 0.2%-timolol 0.5% arm|Patients using timolol were switched to brimonidine tartrate / timolol maleate 0.2%/05% 1 get BID OU for six weeks.
11574931|NCT00824824|Active Comparator|Dorzolamide 2%-timolol 0.5% arm|Patients using timolol were switched ti dorzolamide hydrochloride / timolol 0.5% 2%/0.5% bid OU for six weeks
11574932|NCT00824811|Experimental|Group 1: Cyclosporine eye drops|Cyclosporine Eye Drops (Restasis) 1 drop twice/day for 84 days to both eyes + Fluorometholone Eye Drops (FML Forte) on declining dose schedule.
11574933|NCT00824811|Experimental|Group 2: Lubricant Eye Drops|Lubricant Eye Drops (Refresh Endura) 1 drop twice/day for 84 days to both eyes + Fluorometholone Eye Drops (FML Forte) on declining dose schedule.
11574934|NCT00824798||haemophiliacs A and B|haemophiliacs A and B mild, moderate or severe from 4 to 80 years old, with or without inhibitors.
11574935|NCT00824785|Active Comparator|Arm A EOX|EOX chemotherapy (epirubicin, oxaliplatin and capecitabine)
11574936|NCT00824785|Active Comparator|Arm B EOX + panitumumab.|EOX chemotherapy with the addition of panitumumab 9mg/kg every 21 days
11574937|NCT00824759|Placebo Comparator|placebo|
11574938|NCT00824759|Active Comparator|oxygen|
11574939|NCT00824746|Experimental|Gefitinib retreatment group|Gefitinib retreatment
11574940|NCT00824733|Experimental|Arm I: Treatment (PF03512676 in combination with Trastuzumab)|12 weekly treatments. Week 1-12 patients will receive Trastuzumab 2mg/kg IV(intervenous infusion). Patients who have not been treated wih Trastuzumab within 4 weeks will receive a loading dose of 4 mg/kg on week 1 and PF-03512676-0.16 mg/kg subcutaneous injection.Correlative studies will be drawn on week 1, 2, 6, 12 and 18.
11574941|NCT00824720|Experimental|High Dose Device|device worn continuously for 14 days
11574942|NCT00824720|Experimental|Low Dose Device|device worn continuously for 14 days
11574943|NCT00824720|Placebo Comparator|Placebo Device|device worn continuously for 14 days
11574944|NCT00824707|Experimental|anti-virus therapy|100 HCC patients will be allocated to receive anti-virus therapy.
11574945|NCT00824707|Active Comparator|conventional therapy|100 patients will undergo conventional therapy
11574946|NCT00824694|Active Comparator|Intervention|The intervention will consist of targeted SMBG, provider training and patient education-all of which are focused on normalizing the most significant glucose abnormalities at any given time. SMBG will alternate between 2 strategies: glucose profiling and target monitoring. Intervention PCP's will use 380 View to identify a patient's most significant glucose elevations(s) and devise a treatment plan that includes drug type, dose increases, monitoring times, goal for the target, and stop criteria.
11574947|NCT00824694|Active Comparator|Control Arms|Subjects will repeat the dose titration cycle under the guidance of a case manager until the target is reached, maximal recommended doses of medications are used, or a stop criterion is met. They will then resume glucose profiling to identify the next target. This process is repeated until all targets reach their optimal value. Control patients will monitor and be treated in the customary manner.
11574948|NCT00824681|Experimental|1|Sound Of Family Together (S.O.F.T.) Music Program
11574949|NCT00824681|Active Comparator|2|Non-Therapy Related Activities (NTRA)
11574950|NCT00824655|Experimental|Group 1|
11574951|NCT00824655|Experimental|Group 2|
11574952|NCT00824642|Experimental|Group 1|Applied Acu-TENS prior to exercise
11574953|NCT00824642|Experimental|Group 2|Applied Acu-TENS prior to and during exercise
11574954|NCT00824642|Placebo Comparator|Group 3|Applied placebo TENS prior to exercise
11574955|NCT00824629|Experimental|1|Afterloading embryo transfer procedure
11574956|NCT00824629|Active Comparator|2|Direct embryo transfer procedure
11574957|NCT00824616|Placebo Comparator|Placebo|Participants receiving placebo tablets three times daily plus insulin injection once daily
11574958|NCT00824616|Experimental|MK-0941|Participants receiving MK-0941 tablets three times daily plus insulin injection once daily
11574959|NCT00824603||primary care provider|attending insulin CME Training
11574960|NCT00824590|Experimental|Severe renal impairment group|Subjects with severe renal impairment defined by creatinine clearance of less than 30 mL/min but not yet on dialysis
11574961|NCT00824590|Experimental|normal renal function|Subjects with normal renal function defined by creatinine clearance of greater than 80 mL/min and demographically comparable to subjects with impaired renal function
11574962|NCT00824577||250~300 patients|heart rate variability, heart function and Kt/V
11574963|NCT00824564|Experimental|A|Tranexamic Acid plus standard of care
11574964|NCT00824564|Other|B|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss.
11574965|NCT00824551|Experimental|Hyperbaric Oxygen Therapy|2 HBOT treatments
11574966|NCT00824551|Active Comparator|2|Standard care and treatment
11574967|NCT00824538|Experimental|sunitinib|Study to evaluate the effect of sunitinib (37.5 mg/day orally for 6 months) on occult tumor cells in the bone marrow of patients with high risk early stage breast cancer
11574968|NCT00824512|Experimental|EGb 761® 120 mg|
11574969|NCT00824512|Placebo Comparator|Placebo|
11574970|NCT00824499|Experimental|DPA|Regional complex intervention based on the Chronic Care Model
11574971|NCT00824499|No Intervention|VR|
11574972|NCT00824486|Active Comparator|TIPP|Injury prevention education using TIPP materials
11574973|NCT00824486|Experimental|Safe Home Model|Injury prevention education using safe home model
11574974|NCT00824473|Placebo Comparator|1|Placebo
11574975|NCT00824473|Active Comparator|2|0.15% azelastine hydrochloride
11574976|NCT00824460|Experimental|1.25 g PA21|
11574977|NCT00824460|Experimental|5.0 g PA21|
11574978|NCT00824460|Experimental|7.5 g PA21|
11574979|NCT00824460|Experimental|10.0 g PA21|
11574980|NCT00824460|Experimental|12.5 g PA21|
11574981|NCT00824460|Experimental|Sevelamer hydrochloride - active control|
11574982|NCT00824447|Placebo Comparator|Placebo control|Placebo control
11574983|NCT00824447|Active Comparator|Grass pollen extract, twice weekly|Grass pollen extract, 9,500 BU, given twice weekly
11574984|NCT00824447|Active Comparator|Grass pollen extract daily|Grass pollen extract, 9,500 BU, given daily
11574985|NCT00824447|Active Comparator|Increased dose of grass pollen extract|Increased dose of grass pollen extract, 19,000 BU, given daily
11574986|NCT00824434|Experimental|Experimental Stent|
11574987|NCT00824421|Experimental|UK- 453,061 Dose One|UK 453,061 Dose One plus Truvada
11574988|NCT00824421|Experimental|UK-453,061 Dose Two|UK 453,061 Dose Two plus Truvada
11574989|NCT00824421|Active Comparator|Efavirenz + Truvada|Efavirenz + Truvada
11574990|NCT00824408|Experimental|BI 6727 +pemetrexed|BI 6727 plus 500 mg/^m2 pemetrexed i.v. on day 1 of 21 day cycle
11574991|NCT00824408|Active Comparator|pemetrexed|500 mg/m^2 i.v. on day 1 of a 21 day cycle
11574992|NCT00824395||1|Individuals with diabetes
11574993|NCT00824395||2|Individuals without diabetes
11574994|NCT00824382|Experimental|BI 1744 CL 5 Âµg|2 puffs of 2.5 Âµg/actuation
11574995|NCT00824382|Experimental|BI 1744 CL 10 Âµg|2 puffs of 5 Âµg/actuation
11574996|NCT00824382|Placebo Comparator|Placebo|2 puffs
11574997|NCT00824382|Experimental|BI 1744 CL 2 Âµg|2 puffs of 1 Âµg/actuation
11574998|NCT00824369|No Intervention|Anti-retroviral therapy|Anti-retroviral therapy
11574999|NCT00824356|Active Comparator|GSK1004726 (1000mg)|1000mg aqueous suspension
11575000|NCT00824356|Placebo Comparator|Placebo|Intranasal spray
11575001|NCT00824356|Active Comparator|GSK1004723 (200mg)|200 mg aqueous suspension
11575002|NCT00824343|Experimental|Single P276-00 arm|This is a single experimental arm study
11575003|NCT00824330|Other|Control Phase; Exercise Phase|"Participants act as their own control.
~Control Phase:
~Participants will not change their activity during the 3 month control phase (defined as no strength training and less than 30 minutes brisk walking/moderate exercise per week, no vigorous exercise) Baseline measures will be obtained.
~Exercise Phase:
~This phase will consist of a Titration phase followed by an Intervention Phase. During the Titration phase, under the guidance of a trainer, subjects will increase their number of steps by 20% per week until they have reached 10,000 steps or 3 months have passed. During the Intervention Phase subjects will continue to walk 10,000 steps (or the number of steps they reached in the Titration phase)."
11575004|NCT00824317|Placebo Comparator|1|Placebo
11575005|NCT00824317|Experimental|2|methylphenidate
11575006|NCT00824304||Fe, Zn, Fe+Zn, Placebo|placebo comparator
11575007|NCT00824291|Placebo Comparator|1|
11575008|NCT00824291|Experimental|2|
11575009|NCT00824265|Experimental|Ofatumumab, Fludarabine, Cyclophosphamide|Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
11575010|NCT00824265|Active Comparator|Fludarabine, Cyclophosphamide|Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
11575011|NCT00824252||Spousal Support|Questionnaire for Head and Neck Cancer Patients + Spouses
11575012|NCT00824239|Active Comparator|1. Intermittent sedation|
11575013|NCT00824239|Active Comparator|2. Daily interruption of sedation|
11575014|NCT00824200|Experimental|Behavioral and Exercise Therapy (M-BET)|Multicomponent behavior and exercise therapy program (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene & non-pharmacological management of peripheral edema. M-BET alone will be given with placebo capsules.
11575015|NCT00824200|Active Comparator|Drug Therapy w/ Behavioral Placebo|alpha-adrenergic antagonist medication with a placebo behavioral intervention
11575016|NCT00824200|Active Comparator|Combination Therapy|Combination therapy: MBET and alpha-adrenergic antagonist medication
11575017|NCT00824187|Experimental|Arm 1|
11575018|NCT00824187|Placebo Comparator|Arm 2|
11575019|NCT00824174||Questionnaire|1 questionnaire, about 15-20 minutes.
11575020|NCT00824161|Experimental|1|TAS-109
11575021|NCT00824148|Experimental|Real-time glucose monitoring|Use of Guardian REAL-Time Continuous Glucose Monitoring System, (Medtronic Minimed, Northridge, CA) for 1 month, followed by observation for 2 months.
11575022|NCT00824148|Active Comparator|Self-monitoring of plasma glucose|Conventional self-monitoring of plasma glucose by finger-prick sampling for 1 month, followed by 1 month observation.
11575023|NCT00824135|Experimental|1|
11575024|NCT00824122||1|Children greater than 6 months receiving at least one dose of Vancomycin and Red Man Syndrome
11575025|NCT00824122||2|Children greater than 6 months receiving at least one dose of Vancomycin and has not had Red Man Syndrome
11575026|NCT00824109|Other|Single Arm Study|Consecutive patients meeting the selection criteria
11575027|NCT00824083||1|sarcoma survivors
11575028|NCT00824083||2|healthy subjects
11575029|NCT00824070|Experimental|Besifloxacin|Besifloxacin ophthalmic suspension
11575030|NCT00824070|Active Comparator|Moxifloxacin|Vigamox (moxifloxacin ophthalmic solution, 0.5%)
11575031|NCT00824070|Active Comparator|Gatifloxacin|Zymar (gatifloxacin ophthalmic solution, 0.3%)
11575032|NCT00824057|Experimental|1|
11575033|NCT00824044|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a manualized therapeutic treatment for depression based on principles of cognitive restructuring and behavioral changes.
11575034|NCT00824044|Active Comparator|Escitalopram|Escitalopram or Lexapro is a Selective Serotonin Reuptake Inhibitor (SSRI) used to treat depression
11575035|NCT00824005|Placebo Comparator|Placebo Injections|Participants will receive placebo injections.
11575036|NCT00824005|Experimental|Active Stem Cell Injections|Participants will receive active stem cell injections.
11575037|NCT00823992|Placebo Comparator|placebo|
11575038|NCT00823992|Experimental|taspoglutide|
11575039|NCT00823979|Experimental|UK- 453,061 Dose One|
11575040|NCT00823979|Experimental|UK- 453,061 Dose Two|
11575041|NCT00823979|Active Comparator|Comparator|
11575042|NCT00823966||Delavirdine Mesilate|Patients administered.
11575043|NCT00823953|Placebo Comparator|Placebo|placebo powder (wheat flour) The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
11575103|NCT00823550|Experimental|A|entecavir 0.5 mg QD
11575104|NCT00823550|Active Comparator|B|lamivudine 100 mg QD
11575044|NCT00823953|Active Comparator|Momordica charantia|"Thirty patients will be assigned to each arm in a double blind manner. The active arm will be administered capsules containing a total of 500 mg of Momordica charantia freeze dried powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
~The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3."
11575045|NCT00823940|Placebo Comparator|Cohort A1|Dose escalation: 5 - 100mg and placebo in 4 planned doses
11575046|NCT00823940|Placebo Comparator|Cohort A2|Dose escalation: 100-600mg and placebo in 4 planned doses
11575047|NCT00823940|Other|Cohort B1|Glucagon challenge test
11575048|NCT00823940|Active Comparator|Cohort B3|Glucagon challenge test + selected dose of GSK1362885
11575049|NCT00823927||1|HIV smokers with emphysema
11575050|NCT00823927||2|HIV smokers without emphysema
11575051|NCT00823901|Experimental|Clindamycin/Tretinoin Gel|Participants applied Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel on entire face (forehead, nose, chin, cheeks) once daily at night for 12 weeks
11575052|NCT00823901|Placebo Comparator|Placebo gel|Participants applied Placebo gel with no active medication on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks.
11575053|NCT00823875|Experimental|1|
11575054|NCT00823875|Experimental|2|
11575055|NCT00823875|Experimental|3|
11575056|NCT00823875|Other|4|Control Group
11575057|NCT00823862|Experimental|Active (SD-101)|SD-101 in cohorts of escalating doses
11575058|NCT00823849|Experimental|1|
11575059|NCT00823849|Experimental|2|
11575060|NCT00823849|Experimental|3|
11575061|NCT00823849|No Intervention|4|Control Group
11575062|NCT00823836|Experimental|ropinirolePR-PR group|
11575063|NCT00823836|Active Comparator|ropiniroleIR-PR group|
11575064|NCT00823823|Active Comparator|Bivalved cast|Patients with a displaced distal radius or mid-diaphyseal forearm fracture requiring closed reduction will be immobilized in a bivalved cast
11575065|NCT00823823|Active Comparator|Circumferential cast|Patients with a displaced distal radius or mid-diaphyseal forearm fracture requiring closed reduction will be immobilized in a circumferential cast
11575066|NCT00823810|Experimental|Colorectal cancer|
11575067|NCT00823797|Experimental|Treatment (bendamustine hydrochloride)|Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
11575068|NCT00823784|Experimental|1THD group|Series of 135 patients with 3rd degree Hemorrhoids treated by THD device under spinal anaesthesia
11575069|NCT00823784|Active Comparator|2 stapler group|135 patients with 3rd degree hemorrhoids will be treated by staple hemorrhoidopexy
11575070|NCT00823771||Reviewed by radiation oncologist|
11575071|NCT00823771||Reviewed by general practitioner|
11575072|NCT00823758||1|Parents of children under 8 years of age who have ever given their children an over- the-counter medication.
11575073|NCT00823758||2|Adolescents who are 13 to 20 years of age who have ever heard of over-the-counter medication.
11575074|NCT00823758||3|Adults (21 years of age or older) who have used over-the-counter medication in the past 2 years.
11575075|NCT00823758||4|Primary care physicians will be Family Practitioners or General Internist, with an active Texas license, who devote at least 50% of their time to clinical practice.
11575076|NCT00823758||5|Pharmacists holding a PharmD degree and licensure in the state of Texas and work at least half-time in a community pharmacy setting.
11575077|NCT00823745|Experimental|1|[14C]-PF-00868554
11575078|NCT00823732|Active Comparator|Phase 2 Intervention|GROUP II (palliative care intervention): Patients receive an individualized interdisciplinary palliative care intervention comprising learner-centered, knowledge-centered, assessment-centered, and community-centered concepts. Patients undergo 4 teaching sessions, focused on physical, psychological, social, and spiritual well-being, once weekly in weeks 3-6. Patients then receive 4 follow-up phone calls in weeks 9, 13, 17, and 21.
11575079|NCT00823732|No Intervention|Phase I Usual Care|GROUP I (usual care): Patients receive standard care.
11575080|NCT00823719|Experimental|ofatumumab + DHAP or ICE chemotherapy regimen|This study is a single arm study, but the Investigators are required to prospectively choose to treat all of their subjects with either ICE or DHAP chemotherapy regimens in combination with ofatumumab. Regardless of whether the subject receives ICE or DHAP chemotherapy, all subjects will receive the same ofatumumab regimen and dose.
11575081|NCT00823693|Active Comparator|Bimosiamose Cream|
11575082|NCT00823693|Placebo Comparator|Placebo Cream|
11575083|NCT00823680|Placebo Comparator|Placebo|
11575084|NCT00823680|Experimental|RO5027838 200mg|
11575085|NCT00823680|Experimental|RO5027838 50mg|
11575086|NCT00823680|Experimental|RO5093151 10mg|
11575087|NCT00823680|Experimental|RO5093151 400mg|
11575088|NCT00823667|Active Comparator|Phase 1 Usual care|
11575089|NCT00823667|Active Comparator|Phase 2 Intervention|
11575090|NCT00823654||Premenopausal Women with Early Stage Breast Cancer|
11575091|NCT00823654||Unaffected High Risk Women with BRCA mutations|
11575092|NCT00823641|Experimental|Infliximab|Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
11575093|NCT00823628|Active Comparator|iopromide|
11575094|NCT00823628|Experimental|iodixanol|
11575095|NCT00823615|Other|Lotrafilcon B / Senofilcon A|Lotrafilcon B, followed by Senofilcon A
11575096|NCT00823615|Other|Senofilcon A / Lotrafilcon B|Senofilcon A, followed by Lotrafilcon B
11575097|NCT00823602|Experimental|1|"GnRH antagonist ganirelix 0.25 mg fromm 6th ovarian stimulation"
11575098|NCT00823602|Active Comparator|2|GnRH agonist, suprefact, stimulation with a standard long protocol
11575099|NCT00823589|Experimental|pathological group|pathological group
11575100|NCT00823589|Experimental|healthy aged|healthy aged
11575101|NCT00823576|Active Comparator|1|"Group witness: one receiving a single bolus of analgesic
~Seepage simple person the end of intervention of 200mg of ropivacaïne 0,5 % at the level of zones it"
11575102|NCT00823576|Active Comparator|2|Group catheter: receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.
11575105|NCT00823524|Experimental|donor NK cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
11575106|NCT00823511||Female Partners|Female partners of HIM Study participants
11575107|NCT00823498||African American Parents|
11575108|NCT00823498||African American Youth|African American Youth between ages of 12-15 Years Old
11575109|NCT00823485|Active Comparator|2|drainage of hemorraghia
11575110|NCT00823485|Experimental|1|Actylise
11575111|NCT00823472|Experimental|Start rFSH cycle day 2|
11575112|NCT00823472|Experimental|Start rFSH on cycle day 5|
11575113|NCT00823459|Experimental|Single-Arm Everolimus|Single-arm study with patients receiving Everolimus orally once daily dosing of 10 mg continuously from Day 1 of study until progression of disease or unacceptable toxicity. In addition archival tissue will be analysed for markers of P13K/mTOR pathway activation.
11575114|NCT00823446|Experimental|Revera Wound Care|
11575115|NCT00823446|Placebo Comparator|Normal Saline|
11575116|NCT00823433|Experimental|Oral Penicillin|2 grams of oral penicillin V given within 4 hours of delivery
11575117|NCT00823420|Experimental|in-vitro maturation of oocytes|
11575118|NCT00823407|Other|MDA|
11575119|NCT00823394||Windsor Village United Methodist Church|Questionnaire + Body Measurements + Self-help Materials
11575120|NCT00823381|Experimental|Resveratrol|
11575121|NCT00823381|Placebo Comparator|Placebo|
11575122|NCT00823381|Active Comparator|Calorie Restriction|
11575123|NCT00823368||Arbaclofen followed by Placebo|
11575124|NCT00823368||Placebo followed by Arbaclofen|
11575125|NCT00823355|Experimental|BCX1777|
11575126|NCT00823342|Placebo Comparator|Group A|CLEVUDINE 30 mg qd + TENOFOVIR Placebo
11575127|NCT00823342|Active Comparator|Group B|TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
11575128|NCT00823342|Placebo Comparator|Group C|TENOFOVIR 300 mg qd + CLEVUDINE Placebo
11575129|NCT00823316|Experimental|1|at a dose of 1x1,000,000 hMSC/kg
11575130|NCT00823316|Experimental|2|at a dose of 5x1,000,000 hMSC/kg
11575131|NCT00823303|Experimental|Paricalcitol|titrated to achieve 40-60% PTH suppression
11575132|NCT00823303|Active Comparator|Calcitriol|titrated to achieve 40-60% PTH suppression
11575133|NCT00823277||1|Overweight and obese Children (BMI SDS > 90th percentile according to Danish BMI sheets) 5-20 Years of age. Recruited from the Paediatric department, University Hospital Holbaek, Region Zealand, Denmark, University of Copenhagen
11575134|NCT00823264|Experimental|Multiple Doses of Activated Charcoal|Patients will receive 50 grams of activated charcoal by mouth every 4 hours until phenytoin levels drop below 25 ug/cc
11575135|NCT00823264|No Intervention|Control|Will not receive activated charcoal. Serum levels will be followed.
11575136|NCT00823251|Experimental|IlluminOss device|IlluminOss bone-pin device
11575137|NCT00823238|Active Comparator|systemic|
11575138|NCT00823238|Active Comparator|inhaled|
11575139|NCT00823225|Other|A: Standard therapy|
11575140|NCT00823225|Experimental|B: Urokinase|
11575141|NCT00823212|Active Comparator|PROMUS|Patients who received the PROMUS (XIENCE V) Everolimus-Eluting Coronary Stent
11575142|NCT00823212|Experimental|PROMUS Element|Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent
11575143|NCT00823199|Experimental|Allopurinal treatment|Allopurinal 300mg once daily by mouth for four weeks
11575144|NCT00823186|Experimental|Phyxol,cancer,intra vascular flow|weekly cisplatin plus paclitaxel for 3 cycles as neoadjuvant chemotherapy (NAC) for FIGO IB2 and bulky IIA, squamous cell cervical cancer followed by radical hysterectomy and pelvic lymphedectomy
11575145|NCT00823173|Experimental|Topical ESBA105|ESBA105 applied as eye drops
11575146|NCT00823160|Active Comparator|1: Sternotomy|Patients who are randomized to a sternotomy after the finding of blood in the pericardial sac.
11575147|NCT00823160|Active Comparator|2: Subxyphoid window|Patients who receive a subxyphoid window after the finding of blood in the pericardial sac.
11575148|NCT00823147|Experimental|Pain Catastrophizing Induction Group|"Collect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest.
~Catastrophizing group: 10-minute catastrophizing induction. Participants self-rate their level of emotional distress.
~Subsequent blood draws occur per protocol time points:
~25 minutes following IV placement (BASELINE)
~15 minutes post catastrophizing induction (stress experiment)
~90 minutes (1.5 hours) post-induction
~150 minutes (2.5 hours) post-induction
~210 minutes (3.5 hours) post-induction
~270 minutes (4.5 hours) post-induction"
11575149|NCT00823147|No Intervention|Control Group|"Collect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest.
~Control group: Persons in this group will rest, complete puzzles, read emotionally-neutral material or watch videos provided to them.
~Blood draws and saliva samples gathered per protocol time points:
~25 minutes following IV placement (BASELINE- T1)
~25 minutes following baseline T2
~115 minutes (1 hour 55 min) post baseline T3
~175 minutes (2 hours 55 min) post baseline T4
~235 minutes (3 hours 55 min) post baseline T5
~295 minutes (4 hours 55 min) post baseline T6"
11575150|NCT00823134|Other|AL + polysomnography|Participant wears an Apnea Link sleep apnoea screening device during the polysomnography to detect apnoeas (obstructive, central).
11575151|NCT00823121|Active Comparator|frozen-embryo transfer|In this group all embryos are cryopreserved and two months later embryo transfer will perform.
11575152|NCT00823121|Active Comparator|fresh embryo transfer|In this arm fresh embryo transfers are performed on day 2 or 3.
11575153|NCT00823108|Experimental|1|Glucose-insulin-potassium
11575154|NCT00823108|No Intervention|2|Control
11575155|NCT00823095|Experimental|Topically applied Nitric Oxide|Topically applied Nitric Oxide for 8 hours daily for 2 weeks.
11575156|NCT00823082|Experimental|Antithrombin III treatment group|Preoperative ATIII supplementation administered immediately after anesthesia induction
11575157|NCT00823082|No Intervention|Control group|No preoperative ATIII supplementation administered
11575207|NCT00822705|Active Comparator|Oral PYY3-36|
11575208|NCT00822705|Active Comparator|Oral GLP-1 plus oral PYY3-36|
11575158|NCT00823069|Other|Perlane and Perlane-L|This is a split-face design injecting both Perlane and Perlane-L injectable gels, administered once. Each subject received Perlane-L on one side of the face, and Perlane on the other. Subjects were blinded to which side of their face receive Perlane or Perlane-L. The study was randomized and treatments successive.
11575159|NCT00823056|Placebo Comparator|1|
11575160|NCT00823056|Active Comparator|2|
11575161|NCT00823043||Timolol hemihydrate|Subjects currently prescribed timolol hemihydrate 0.5% solution.
11575162|NCT00823043||Timolol maleate|Subjects currently prescribed timolol maleate in sorbate.
11575163|NCT00823030|Placebo Comparator|Placebo|Placebo instillation: 20 ml of normal saline instilled intravesically
11575164|NCT00823030|Experimental|experimental arm|The experimental instillation will include 8 ml of 2% lidocaine, 3 ml of sodium bicarbonate, and 9 ml of normal saline.
11575165|NCT00823017|Experimental|1|Patient-preferred music
11575166|NCT00823017|Experimental|2|Relaxation Music
11575167|NCT00823017|Placebo Comparator|3|Standard of Care
11575168|NCT00823004|Active Comparator|1|A/L: Poor responders who will receive letrozole and GnRH antagonist for ovarian stimulation
11575169|NCT00823004|Active Comparator|2|MF: In this arm poor responders are treated by microdose GnRH agonist flare protocol
11575170|NCT00822991|Active Comparator|Group of CE-US|screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
11575171|NCT00822991|Active Comparator|Group of B-mode US|screening by conventional B-mode US every 3-5 months
11575172|NCT00822978|Active Comparator|ACHN-490 Injection|ACHN-490 Injection in escalating doses
11575173|NCT00822978|Placebo Comparator|2|Placebo is normal saline
11575174|NCT00822965||Patient Knowledge Assessments|Questionnaires + Phone Interview
11575175|NCT00822926|Experimental|Placebo then Botox|Injection 1: Saline- Subcutaneous injection of saline into scar tissue Injection 2: Botulinum Toxin Type A- Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue
11575176|NCT00822926|Experimental|Botox then Placebo|Injection 1: Botulinum Toxin Type A- Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue Injection 2: Saline- Subcutaneous injection of saline into scar tissue
11575177|NCT00822913|Experimental|Botulinum A toxin|Botulinum A toxin intravesical injection
11575178|NCT00822900|Experimental|Progesterone|Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 72 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone will be combined with a 20% Intralipid mixture for infusion.
11575179|NCT00822900|Placebo Comparator|Placebo|"Placebo stock solution was the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid was based on the same mg/kg/hr volume that would be required if PROG had been in the vial. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid was administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table was used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 72 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The placebo will be combined with a 20% Intralipid mixture for infusion."
11575180|NCT00822887|Experimental|Vandetanib|Dose level 1:100 mg qd, 2:200 mg qd, 3:300 mg qd. Fractionated Stereotactic Radiotherapy: all patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
11575181|NCT00822874|Experimental|in-vitro maturation of oocytes|
11575182|NCT00822861|Experimental|Dose level No.1|TPI ASM8 1 mg BID
11575183|NCT00822861|Experimental|Dose level No.2|TPI ASM8 2 mg BID
11575184|NCT00822861|Experimental|Dose level No.3|TPI ASM8 4mg BID
11575185|NCT00822861|Experimental|Dose level No.4|TPI ASM8 8 mg Die
11575186|NCT00822848|Experimental|Sorafenib, Epirubicin, Ifosfamide|
11575187|NCT00822835|Active Comparator|ILV-095|6 SC single dose injections
11575188|NCT00822835|Placebo Comparator|Placebo|Placebo
11575189|NCT00822822||A|Health History Process
11575190|NCT00822809|Experimental|A|"Patients will receive premedication of 25 mg (i.v.) prednisolone 30 minutes prior start of infusion of catumaxomab.
~Catumaxomab will be infused i.p. with 3 hour constant rate infusions via an indwelling catheter."
11575191|NCT00822809|Other|B|Catumaxomab will be administered in a dosage identical to Arm A but without the prednisolone premedication.
11575192|NCT00822796|Experimental|A|Burn patients with >20% TBSA burns scheduled to undergo debridement and grafting who will have placed the Thermogard™ central venous warming catheter by Alsius
11575193|NCT00822796|Active Comparator|B|Burn patients with >20% TBSA burns scheduled to undergo debridement and grafting who will have placed a central venous catheter as a part of their routine burn management
11575194|NCT00822783|Active Comparator|Omalizumab|
11575195|NCT00822783|Placebo Comparator|Placebo|
11575196|NCT00822770|Experimental|Phase I|ATG + Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant
11575197|NCT00822770|Experimental|Phase II|ATG + MTD Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant
11575198|NCT00822757|Experimental|1|V710
11575199|NCT00822757|Placebo Comparator|2|Placebo
11575200|NCT00822744|Experimental|SSR411298 10 mg|SSR411298 10 mg, one capsule once daily for 8 weeks
11575201|NCT00822744|Experimental|SSR411298 50 mg|SSR411298 50 mg, one capsule once daily for 8 weeks
11575202|NCT00822744|Experimental|SSR411298 200 mg|SSR411298 200 mg, one capsule once daily for 8 weeks
11575203|NCT00822744|Active Comparator|Escitalopram 10 mg|Escitalopram 10 mg, one capsule once daily for 8 weeks
11575204|NCT00822744|Placebo Comparator|Placebo|Placebo (for SSR411298), one capsule once daily for 8 weeks
11575205|NCT00822731|Experimental|Lymphoma|patients diagnosed as lymphoma
11575206|NCT00822705|Active Comparator|ORAL GLP-1, TABLET|
11575210|NCT00822692|Active Comparator|Bactrim DS|Trim/sulfa (800/160) two tablets orally (PO) twice a day (BID) x 7 days
11575211|NCT00822692|Placebo Comparator|matched placebo|matched placebo 2 pills orally (PO) twice a day (BID) x 7 days
11575212|NCT00822679|Experimental|1: Eszopiclone|Subjects receive Eszopiclone for three consecutive nights to observe changes in sleep measures, and inflammatory and coagulation factors
11575213|NCT00822679|Placebo Comparator|2: Placebo|Subjects given placebo for 3 consecutive nights to observe changes in sleep measures, and inflammatory and coagulation factors
11575214|NCT00822666|Active Comparator|1|patients homozygous for the 2C19*1 genetic variant
11575215|NCT00822666|Experimental|2|carriers of the 2C19*2 genetic variant (homozygous or heterozygous)
11575216|NCT00822653|Experimental|Calf Muscle Pump Stimulation|Subjects serve as self-control. Six weeks of dialysis data without intervention will be compared to six weeks post intervention
11575217|NCT00822640|Experimental|1|Columbus Knee Prosthesis with rotating Platform
11575218|NCT00822640|Active Comparator|2|Columbus Knee Prosthesis with fixed platform
11575219|NCT00822627|Experimental|Vaccination group|Vaccination group
11575220|NCT00822627|Experimental|Education/referral|Education/referral
11575221|NCT00822614|Active Comparator|Active Comparator|Current BTP Medication
11575222|NCT00822614|Experimental|Fentanyl TAIFUN|Titration for dose confirmation followed by observation period
11575223|NCT00822601|Experimental|1|
11575224|NCT00822601|Placebo Comparator|2|
11575225|NCT00822588|Experimental|1|
11575226|NCT00822588|No Intervention|2|
11575227|NCT00822575|Active Comparator|A|
11575228|NCT00822575|Sham Comparator|B|
11575229|NCT00822562|Active Comparator|Procedure/Surgery|surgery
11575230|NCT00822562|Experimental|Procedure|PRFA or PMCT
11575231|NCT00822549||1|all the patients included in the study received intravenous morphine in PACU and in the wards
11575232|NCT00822536|Active Comparator|1|Bi therapy : aspirin/ clopidogrel
11575233|NCT00822536|Active Comparator|2|Monotherapy: aspirin
11575234|NCT00822523|Experimental|Botulinum toxin type A, 20 units|Single intramuscular (into extensor digitorum brevis muscle of the foot) dose of Botulinum toxin type A, 20 units
11575235|NCT00822523|Experimental|Botulinum toxin, type A, 2 units|Single intramuscular (into extensor digitorum brevis muscle of the foot) dose of Botulinum toxin type A, 2 units
11575236|NCT00822523|Placebo Comparator|Placebo|Saline, Single dose, Intramuscular injection into right EDB
11575237|NCT00822510|Experimental|Telephone Interpersonal Counseling|Telephone delivered interpersonal counseling support intervention. Intervention was for 8 weeks. Participants were called on the telephone each week for about 30 minutes.
11575238|NCT00822510|Active Comparator|Telephone delivered education only|Telephone delivered education only. Educational topics included prostate cancer health, side effects, physical activity, diet. Participants were called on the telephone each week for about 30 minutes.
11575239|NCT00822497|Experimental|1|Music-Based Imagery
11575240|NCT00822497|Experimental|2|Music Alternate Engagement
11575241|NCT00822497|No Intervention|Control|Debridement under standard care with no music therapy interventions
11575242|NCT00822484|Active Comparator|ILV-095|6 SC single dose injections
11575243|NCT00822484|Placebo Comparator|Placebo|Placebo
11575244|NCT00822471|Other|Diabetes Self-Management Education|Education intervention with historic self-controls.
11575245|NCT00822458|Experimental|Arm I|"Patients receive oral hedgehog antagonist GDC-0449 once daily on days 1 and 4-28 in course 1 and on days 1-28 in all subsequent courses. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
~Blood samples are collected periodically for pharmacokinetic studies. Archival tumor tissue samples are collected and analyzed for the expression of genes that activate the SHH (e.g., Gli1, Gli2, SFRP1, ATOH1, and PTCH2) or WNT (e.g., DKK2 and DKK4) cell signal pathways by in situ hybridization and reverse transcriptase real time-PCR."
11575246|NCT00822432||1|
11575247|NCT00822419|Active Comparator|lidocaine|Lidocaine 5% cream 5 gr will be double blindly put on the skin preoperatively
11575248|NCT00822419|Experimental|ketamine|ketamine cream 5% 5gr will be put on the skin preoperatively
11575249|NCT00822419|Sham Comparator|placebo|non-drug similar cream will be put on the skin preoperatively
11575250|NCT00822406|Active Comparator|1|This arm received individualized homeopathic medicine during 6 months (initial phase), and completed three years (second phase)
11575251|NCT00822406|Placebo Comparator|2|This arm received placebo during 6 months. After this period, all patients received individualized homeopathic medicine for three years.
11575252|NCT00822393|Active Comparator|1|Busulfan
11575253|NCT00822393|Experimental|2|Treosulfan
11575254|NCT00822380|Experimental|Anemic children|
11575255|NCT00822367|Experimental|Nutritional suplements|
11575256|NCT00822354|Experimental|1|Subjects will receive tadalafil 20mg every other day for the first month, and then placebo for the second month.
11575257|NCT00822354|Experimental|2|Subjects will receive placebo for the first month, and tadalafil 20mg orally every other day for the second month.
11575258|NCT00822328|Experimental|1|Fermented milk with Lactobacillus casei strain Shirota 100ml per day
11575259|NCT00822328|Placebo Comparator|2|Unfermented milk without Lactobacillus casei strain Shirota 100ml per day
11575260|NCT00822315|Active Comparator|1|efavirenz
11575261|NCT00822315|Experimental|2|raltegravir 400 mg
11575262|NCT00822315|Experimental|3|raltegravir 800 mg
11575263|NCT00822302|Placebo Comparator|1.Saline Infusion|Patients randomised to this arm will receive an infusion of saline
11575264|NCT00822302|Active Comparator|2.recHDL|Patients randomised to the active comparator arm of the study will receive 40mg/kg reconstituted High density lipoproteins (lot nos 05422-00006) over a period of 4 hours, 24 hours prior to carotid endarterectomy.
11575265|NCT00822276||ADEH+ participants colonized with MSSA|
11575266|NCT00822276||ADEH+ participants colonized with MRSA|
11575267|NCT00822276||Uncolonized ADEH+ participants|
11575268|NCT00822276||ADEH- participants colonized with MSSA|
11575269|NCT00822276||ADEH- participants colonized with MRSA|
11575270|NCT00822276||Uncolonized ADEH- subjects|
11575271|NCT00822276||Non-atopic uncolonized S. aureus participants|
11575272|NCT00822263|Placebo Comparator|2|control
11575273|NCT00822263|Experimental|1|Active medicine
11575274|NCT00822250|Other|1|cutting hair, skin phenotype description
11575275|NCT00822237|Experimental|VARIVAX 2007 process + M-M-R II|
11575276|NCT00822237|Active Comparator|VARIVAX 1999 process + M-M-R II|
11575277|NCT00822224|Experimental|1|Use of MEOPA during the painful care
11575278|NCT00822211|Experimental|Vildagliptin Dose 1|
11575279|NCT00822211|Experimental|Vildagliptin Dose 2|
11575280|NCT00822211|Placebo Comparator|Placebo|
11575281|NCT00822198|Experimental|plantar vibration|Subject will use Juvent plantar vibration device daily in the home or office for six months.
11575282|NCT00822185|Experimental|vatreptacog alfa, 5 mcg/kg|
11575283|NCT00822185|Experimental|vatreptacog alfa, 10 mcg/kg|
11575284|NCT00822185|Experimental|vatreptacog alfa, 20 mcg/kg|
11575285|NCT00822185|Experimental|vatreptacog alfa, 30 mcg/kg|
11575286|NCT00822172|Active Comparator|Cilostazol + L-Carnitine|1 tablet cilostazol 100 mg PO BID and 3 capsules L-carnitine 334 mg PO BID
11575287|NCT00822172|Placebo Comparator|Cilostazol + Placebo|1 tablet cilostazol 100 mg PO BID and 3 capsules placebo PO BID
11575288|NCT00822146|Experimental|1|
11575289|NCT00822133|Active Comparator|lodocaine|lidocaine 5% cream will be put on the skin
11575290|NCT00822133|Experimental|ketamine|ketamine 5% will be put on the skin
11575291|NCT00822133|Placebo Comparator|placebo|non-active cream will be put on the skin
11575292|NCT00822120|Experimental|HIV Positive, PET Positive: BEACOPP standard|Etoposide 100 mg/m2 IV Days 1, 2, 3 Dox 25 mg/m2 IV Day 1 Cyclo 650mg/m2 IV Day 1 Procarb 100 mg/m2 PO Days 1-7 Pred 40 mg/m2 PO Days 1-14 Bleo 10u/m2 IV Day 8 Vincristine 1.4 mg/m2 IV Day 8 Q 21 Days x 6 cycles
11575293|NCT00822120|Experimental|HIV Negative, PET Positive: BEACOPP escalated|Etoposide 200 mg/m2 IV Days 1, 2, 3 Dox 35 mg/m2 IV Day 1 Cyclo 1,250 mg/m2 IV Day 1 Procarb 100 mg/m2 PO Days 1-7 Pred 40 mg/m2 PO Days 1-14 Bleo 10u/m2 IV Day 8 Vincristine 1.4 mg/m2 IV Day 8 G-CSF 5mcg/kg/day SQ Days 8-14 Q 21 Days x 6 cycles
11575294|NCT00822120|Active Comparator|HIV Positive, PET Negative: ABVD|Doxorubicin 25 mg/m2 IV Bleomycin 10u/m2 IV Vinblastine 6mg/m2 IV Dacarbazine 375 mg/m2 IV Days 1, 15 Q 28 Days x 2
11575295|NCT00822120|Active Comparator|HIV Negative, PET Negative: ABVD|Doxorubicin 25 mg/m2 IV Bleomycin 10u/m2 IV Vinblastine 6mg/m2 IV Dacarbazine 375 mg/m2 IV Days 1, 15 Q 28 Days x 2
11575296|NCT00822107|Experimental|Thiazide Response|Hydrochlorothiazide 50 mg will be administered by mouth once.
11575297|NCT00822094|Experimental|CPX-351 (Arm A)|First induction: 100 units/m2 on Days 1, 3, and 5 by 90-minute IV infusion Second induction: 100 units/m2 on Days 1 and 3 by 90-minute IV infusion Consolidation(s): 100 units/m2 on Days 1 and 3 by 90-minute IV infusion
11575298|NCT00822094|Active Comparator|Salvage Therapy (Arm B)|First induction: Investigator's choice salvage therapy administered according to local practice Second induction: Investigator's choice salvage therapy administered according to local practice Consolidation(s): Investigator's choice consolidation therapy administered according to local practice
11575299|NCT00822081|Active Comparator|1|brimonidine/timolol. Fixed-combination monotherapy.
11575300|NCT00822081|Active Comparator|2|dorzolamide/timolol. Fixed-combination monotherapy.
11575301|NCT00822081|Active Comparator|3|prostaglandin analogue+ brimonidine/timolol fixed combination.
11575302|NCT00822081|Active Comparator|4|prostaglandin analogue+dorzolamide/timolol fixed combination.
11575303|NCT00822068|Experimental|anodal tDCS|
11575304|NCT00822068|Active Comparator|2|cathodal tDCS
11575305|NCT00822068|Placebo Comparator|3|sham stimulation
11575306|NCT00822055|Active Comparator|1|brimonidine/timolol Fixed-combination monotherapy
11575307|NCT00822055|Active Comparator|2|dorzolamide/timolol fixed-combination monotherapy
11575308|NCT00822055|Active Comparator|3|prostaglandin analogue + brimonidine/timolol fixed combination
11575309|NCT00822055|Active Comparator|4|prostaglandin analogue + dorzolamide/timolol fixed combination
11575310|NCT00822042||1|Patients with corticotherapy lasting more than 3 months
11575311|NCT00822029|Experimental|1|FOSAMAX (oral bisphosphonate)
11575312|NCT00822029|Placebo Comparator|2|PLACEBO
11575313|NCT00822003|Active Comparator|1|Human GLP-1
11575314|NCT00822003|Placebo Comparator|2|Placebo tablet
11575315|NCT00821990|Active Comparator|Chemotherapy|Eligible patients will be first offered randomization. If willing to participate RCT, the patient will be randomized to chemotherapy or best supportive care. If patients refuse to participate in RCT, but nevertheless agree to receive treatment of their preferences, they are offered their treatment of choice (chemotherapy or supportive care).
11575316|NCT00821990|Active Comparator|Supportive care|Eligible patients will be first offered randomization. If willing to participate RCT, the patient will be randomized to chemotherapy or best supportive care. If patients refuse to participate in RCT, but nevertheless agree to receive treatment of their preferences, they are offered their treatment of choice (chemotherapy or supportive care).
11575317|NCT00821977|Experimental|Vildagliptin Dose 1|
11575318|NCT00821977|Experimental|Vildagliptin Dose 2|
11575319|NCT00821977|Placebo Comparator|Placebo|
11575320|NCT00821964|Experimental|Treatment (biological therapy, chemo)|Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
11575321|NCT00821951|Experimental|Vorinostat and Radiotherapy|
11575322|NCT00821938|Active Comparator|CRT-ICD|
11575323|NCT00821938|Placebo Comparator|DDD-ICD|
11575324|NCT00821912|Experimental|Taxotere Xeloda|"Taxotere i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule.
~Xeloda orally day 1-14 every 3 weeks."
11575325|NCT00821886|Experimental|Ixabepilone/Trastuzumab/Carboplatin|Neoadjuvant treatment with Ixabepilone, Trastuzumab and Carboplatin, followed by surgery, peri-operative treatment and post-operative (adjuvant) treatment if patient deemed to be a surgical candidate
11575326|NCT00821873|Experimental|CR Plug BackFill|Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site
11575327|NCT00821860|Experimental|Arm I|Patients undergo video-assisted thoracoscopic cytoreductive pleurectomy either at the time of biopsy or after confirmation of biopsy results.
11575328|NCT00821860|Active Comparator|Arm II|Patients undergo talc pleurodesis via an indwelling intercostal chest drain or via thoracoscopy either at the time of biopsy or after confirmation of biopsy results.
11575329|NCT00821847||1:experimental|male, caucasian, HIV infected patients with glomerular filtration rate between 60 and 30 ml/min (estimated with cockcroft and Gault formulae)
11575330|NCT00821834|Experimental|Clopidogrel|"Patients received:
~clopidogrel 300 mg as a loading dose, then 75 mg once daily as a maintenance dose,
~ticlopidine matching placebo twice daily."
11575331|NCT00821834|Active Comparator|Ticlopidine|"Patients received:
~ticlopidine 100 mg twice daily,
~clopidogrel matching placebo once daily."
11575332|NCT00821821|Experimental|MCI-186|
11575333|NCT00821821|Placebo Comparator|Placebo Group|
11575334|NCT00821795|Active Comparator|NPH/Regular 70/30 mix|transition insulin therapy with NPH/Regular 70/30 mix for outpatient glycemic control following a hospitalization for non-critical acute illness
11575335|NCT00821795|Active Comparator|Aspart insulin analog biphasic mix|transition insulin therapy with Aspart insulin analog 70/30 mix for outpatient glycemic control following a hospitalization for non-critical acute illness
11575336|NCT00821756|Experimental|1|Assertive intervention in OPAC-style: Outreach,problem solving,adherence,continuity
11575337|NCT00821756|No Intervention|2|Control arm: Treatment as usual
11575338|NCT00821743|Other|1|The DBS electrodes (model 3389, Medtronic) will be stereotactically implanted bilaterally in the PPN, according to the technique usually used for STN-DBS, and connected to the subcutaneously implanted stimulator (Kinetra, Medtronic).
11575339|NCT00821717|Experimental|1:|
11575340|NCT00821717|Placebo Comparator|2|
11575341|NCT00821691|Other|1|"Amantadin - Placebo: 5 amantadin caps - 4 days wash out - 5 placebo caps
~5 amantadin caps (100mg); 2 caps a day during 3 days; after wash out period (4 days): 5 placebo caps (2 caps a day during 3 days)"
11575342|NCT00821691|Other|2|"Placebo - Amantadin: 5 placebo caps - 4 days wash out - 5 amantadin caps
~5 placebo caps: 2 caps a day during 3 days after wash out period (4 days): 5 amantadin caps(100mg) (2 caps a day during 3 days)"
11575343|NCT00821678|Experimental|Arm 1 Telemedicine Outreach for PTSD|Telemedicine-Based Collaborative Care
11575344|NCT00821678|No Intervention|Arm 2 Treatment as usual|Usual Care
11575345|NCT00821665|Experimental|Sucrose|Sucrose
11575346|NCT00821665|Placebo Comparator|Water|Water
11575347|NCT00821652|Other|Dose-esclation|Part I represents a dose-escalation part with topical resiquimod in an open-label fashion.
11575348|NCT00821652|Experimental|2|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I.
11575349|NCT00821626|Active Comparator|Rapid test|Returning travelers with fever will have a rapid flu test
11575350|NCT00821626|Sham Comparator|Comparator|Returning travelers with fever will benefit of the usual medical care, without rapid flu test
11575351|NCT00821600|Experimental|001|risperidone IR and LAI formulation 1 mg risperidone IR single injection followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
11575352|NCT00821587|Active Comparator|Tacrolimus|Tacrolimus
11575353|NCT00821587|Active Comparator|Cyclosporine|Cyclosporine
11575354|NCT00821574|Experimental|1|Fluvastatin: daily 80 mg, oral
11575355|NCT00821574|Experimental|2|Valsartan
11575356|NCT00821574|Experimental|3|Hydrochlorothiazide
11575357|NCT00821548|Experimental|1|Electrostimulation of the muscles of the scapular belt and the femoris quadristocks
11575358|NCT00821535|Other|Active group|maraviroc dosing group
11575359|NCT00821522|Active Comparator|Preconditioning|
11575360|NCT00821522|No Intervention|Control|Standard clinical management during cardiac surgery.
11575361|NCT00821509|Active Comparator|Hand washing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent hand washing in office and at home
11575362|NCT00821509|Active Comparator|Disinfectant rubbing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
11575363|NCT00821509|No Intervention|Control|No change in hygiene behaviour
11575364|NCT00821496|Experimental|Oral Contraceptive|
11575365|NCT00821483|Placebo Comparator|1: placebo|
11575366|NCT00821483|Active Comparator|2 Frovatriptan|
11575367|NCT00821470|Experimental|bone marrow graft group|core decompression + bone marrow implantation into the necrotic lesion
11575368|NCT00821470|Active Comparator|control|core decompression
11575369|NCT00821457|Active Comparator|Group 1|250ng Juvista vs placebo
11575370|NCT00821457|Active Comparator|Group 2|500 ng Juvista vs placebo
11575371|NCT00821444|Active Comparator|Geodon fed|Commercial Geodon (ziprasidone) capsules given with food
11575372|NCT00821444|Experimental|B16 Fasted|Experimental reduced food effect formulation given without food
11575373|NCT00821444|Experimental|B16 Fed|Experimental reduced food effect formulation given with food
11575374|NCT00821431|Experimental|Compression device|The electrical compression device is operated from battery or a main adaptor. It is based upon the use of inflatable pneumatic cuffs that apply controlled compression to the foot, ankle and calf.
11575375|NCT00821431|Active Comparator|Profore, 4-layer bandage|A high compression 4-layer bandage (Profore, Trademark of Smith and Nephew). This is a four-layer system that can be purchased either separately or as a package: a wound contact layer (Knitted viscose), a sub-compression wadding bandage, two layers of elastane bandage plus a top cohesive layer.
11575376|NCT00821418|Experimental|PulsHaler first|
11575377|NCT00821418|Placebo Comparator|Placebo first|
11575378|NCT00821405||peritoneal dialysis|peritoneal dialysis patient lasting for more than 3 months
11575379|NCT00821392|Active Comparator|1 Febuxostat 40mg|
11575380|NCT00821392|Active Comparator|2 Febuxostat 80mg|
11575381|NCT00821392|Active Comparator|3 Febuxostat 120mg|
11575382|NCT00821392|Sham Comparator|4 Allopurinol 300mg|
11575383|NCT00821392|Placebo Comparator|5 Placebo|
11575384|NCT00821366|Active Comparator|1|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment only group
11575385|NCT00821366|Active Comparator|2|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment and ARV peer adherence support group
11575386|NCT00821366|Active Comparator|3|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment, ARV peer adherence support and nutritional support group
11575387|NCT00821366|No Intervention|4|Randomly selected households from the general community served by the selected health facility, excluding households where someone is known to receive ARV treatment - comparison/control group
11575388|NCT00821353|Active Comparator|RFCA|
11575389|NCT00821353|Active Comparator|Drug|
11575390|NCT00821340|Experimental|rAAV2-hRPE65|
11575391|NCT00821327|Experimental|Study Arm|Gemcitabine, Cisplatin, Sunitinib
11575392|NCT00821288|Experimental|Survivorship Intervention|Latina and Caucasian breast cancer survivors treated in an urban academic medical center receiving Survivorship Intervention
11575393|NCT00821288|Active Comparator|Facing Forward|Latina and Caucasian breast cancer survivors treated in an urban academic medical center receiving Survivorship Intervention Facing Forward: Life after Cancer Treatment manual
11575394|NCT00821275|Active Comparator|pregnancy expectation|The patients who desire for future pregnancy will enroll into this arm , and will be divided into UAE group and SURGERY group.
11575395|NCT00821275|Active Comparator|No pregnancy expectation|The patients who don't desire for reserving uterus and/ or future pregnancy will enroll into this arm , and will be divided into UAE group and SURGERY group.
11575396|NCT00821262|Experimental|sevoflurane|The study group will receive Sevoflurane for a 4-6 hours period (from anesthesia induction to transfer to ICU).
11575397|NCT00821262|Active Comparator|propofol|The control group will receive propofol for the same 4-6 hours period.
11575398|NCT00821249|Experimental|ARRY-520|
11575399|NCT00821249|Experimental|ARRY-520 + G-CSF support|
11575400|NCT00821249|Experimental|ARRY-520 + dexamethasone + G-CSF support|
11575401|NCT00821236|Active Comparator|Wavelight|WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment
11575402|NCT00821236|Active Comparator|AMO/VISX CustomVue|AMO/VISX CustomVue™
11575403|NCT00821236|Active Comparator|LADARVision 4000 excimer laser|LADARVision 4000 excimer laser
11575404|NCT00821223|Active Comparator|manual small incision cataract surgery|surgical intervention by small incision cataract surgery
11575405|NCT00821223|Other|phacoemulsification|surgical intervention by phacoemulsification
11575406|NCT00821210|Sham Comparator|2|
11575407|NCT00821210|Active Comparator|1|
11575408|NCT00821197|Active Comparator|long-limb bypass|Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)
11575409|NCT00821197|Active Comparator|Distal gastric bypass|Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)
11575410|NCT00821184|Active Comparator|Vesicare|Vesicare alone
11575411|NCT00821184|Active Comparator|Vesicare/behavioral modification|Vesicare plus behavioral modification
11575412|NCT00821158|Placebo Comparator|1|Placebo tablet and iv
11575413|NCT00821158|Experimental|2|Placebo tablet and intervention iv
11575414|NCT00821158|Experimental|3|Intervention tablet and placebo iv
11575415|NCT00821145|Active Comparator|1|50 patients operated using a conventional open surgery to exclude an abdominal aortic aneurysm
11575416|NCT00821145|Experimental|2|50 patients operated using a total laparoscopic aortic aneurysm resection
11575417|NCT00821145|Active Comparator|3|25 patients using a laparoscopic approach for AAA resection with a stapled proximal anastomosis
11575418|NCT00821132||ALS families|Patients with either inherited or sporadic ALS or PLS and selected family members
11575419|NCT00821119|Active Comparator|NCPAP|preterm infants with nasal positive pressure ventilation as a primary mode of respiratory support in preterm infants with respiratory distress syndrome will be compared to preterm infants with nasal intermittent positive pressure ventilation
11575420|NCT00821119|Experimental|NIPPV|preterm with nasal intermittent positive pressure ventilation as a primary mode of respiratory support in preterm infants with respiratory distress syndrome
11575421|NCT00821106|Experimental|Right transradial approach|Coronary diagnostic or interventional procedures performed through right radial approach
11575422|NCT00821106|Experimental|Left transradial approach|Diagnostic or interventional procedures performed through left radial approach
11575423|NCT00821093|Experimental|Indacaterol 150 µg|Patients inhaled indacaterol 150 μg once daily in the morning between 8:00 and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Patients also inhaled placebo to salmeterol twice daily, once in the morning between 8:00 and 11:00 AM and once in the evening between 8:00 and 11:00 PM via the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11575424|NCT00821093|Active Comparator|Salmeterol 50 µg|Patients inhaled salmeterol 50 μg twice daily, once in the morning between 8:00 and 11:00 AM and once in the evening between 8:00 and 11:00 PM via the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]) for 12 weeks. Patients also inhaled placebo to indacaterol once daily in the morning between 8:00 and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11575425|NCT00821080|Experimental|Vandetanib and Sirolimus|Single arm study
11575426|NCT00821067|Active Comparator|1|A 6 gm/day (3 gm/bid) dose of D-ribose
11575427|NCT00821067|Placebo Comparator|2|A 6 gm/day (3 gm/bid) dose of dextrose.
11575428|NCT00821054|Experimental|Period 1|Treatment A, B or C
11575429|NCT00821054|Experimental|Period 2|Treatment A, B or C
11575430|NCT00821054|Experimental|Period 3|Treatment A, B or C
11575431|NCT00821041|No Intervention|Waiting list control|
11575432|NCT00821041|Experimental|CBT|A 6 weeks online course. Each week participants log on to view videos and read information that focus on a variety of intervention techniques. These include relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training. Participants also monitor their sleep using an online sleep diary and respond to questions regarding their adherence to the program.
11575433|NCT00821028|Experimental|Paclitaxel|Participants will receive Paclitaxel.
11575434|NCT00821015|Experimental|Experimental|All study subjects will undergo cryoablation. This is a non-randomized trial.
11575435|NCT00821002|Experimental|Plug placement|
11575436|NCT00820989|Experimental|A|Time points after IV Endotoxin administration compared to baseline (immediately before Endotoxin administration).
11575437|NCT00820976|No Intervention|control|remission induction with cytosine arabinoside amd idarubicine
11575438|NCT00820976|Experimental|G-CSF|G-CSF was administered starting on Day 8 until neutrophil recovery
11575439|NCT00820963|Experimental|Arm I|Patients undergo standard radiotherapy 5 days a week for 6 weeks.
11575440|NCT00820963|Experimental|Arm II|Patients undergo hypofractionated radiotherapy 5 days a week for 2 weeks.
11575441|NCT00820963|Experimental|Arm III|Patients receive oral temozolomide on days 1-5. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11575442|NCT00820950|Experimental|Treatment 1: Ruxolitinib|Ruxolitinib -- 0.5%
11575443|NCT00820950|Experimental|Treatment 2: Ruxolitinib|Ruxolitinib -- 1.0%
11575444|NCT00820950|Experimental|Treatment 3: Ruxolitinib|Ruxolitinib -- 1.5%
11575445|NCT00820950|Placebo Comparator|Treatment 4: Placebo|Placebo Cream
11575446|NCT00820950|Active Comparator|Treatment 5: Dovonex® calcipotriene|Dovonex® calcipotriene 0.005% cream
11575447|NCT00820950|Active Comparator|Treatment 6: Diprolene® AF betamethasone diproprionate|
11575448|NCT00820924|Experimental|LAPATINIB|LAPATINIB 1500MG ORAL ONCE DAILY
11575449|NCT00820911|Active Comparator|cyclosporine (reduced exposure) / everolimus|
11575450|NCT00820911|Experimental|AEB071 300 mg b.i.d. / everolimus|
11575451|NCT00820911|Experimental|AEB071 200 mg b.i.d. / everolimus|
11575452|NCT00820898|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11575453|NCT00820885|Other|cohort A|20 mg dose 20 mg/ML concentration and placebo
11575454|NCT00820885|Other|Cohort AR|20 mg in 50 mg/ml concentration and placebo
11575455|NCT00820885|Other|Cohort C|25 mg in 50mg/ml concentration and placebo
11575456|NCT00820885|Other|Cohort D|15 mg in 50mg/ml concentration and placebo
11575457|NCT00820885|Other|Cohort E|10 mg in 50mg/ml concentration and placebo
11575458|NCT00820885|Other|Cohort F|30mg in 50mg/ml concentration and placebo
11575459|NCT00820885|Other|Cohort H|50mg in 50mg/ml concentration and placebo
11575460|NCT00820885|Other|cohort I|80mg in 50mg/ml concentration and placebo
11575461|NCT00820872|Experimental|docetaxel + carboplatin + trastuzumab + lapatinib|"Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes on day 1, trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15, and oral lapatinib ditosylate on days 1-21 (TCHL). Treatment with TCHL repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30-90 minutes on day 1 and oral lapatinib ditosylate on days 1-21 (days 1-7 of course 12 only) (LT). Treatment with LT repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
~After completion of study treatment, patients are followed every 6 months for 2 years and then annually for up to 8 years."
11575462|NCT00820859|Experimental|1|
11575463|NCT00820859|Active Comparator|2|
11575464|NCT00820846|Experimental|Part A, Group 1|Participants will receive two injections of the pGA2/JS7 DNA vaccine and then two injections of the MVA/HIV62 vaccine
11575465|NCT00820846|Placebo Comparator|Part A, Group 2|Participants will receive four placebo injections
11575466|NCT00820846|Experimental|Part B, Group 3|Participants will receive two injections of the pGA2/JS7 DNA vaccine and then two injections of the MVA/HIV62 vaccine
11575467|NCT00820846|Experimental|Part B, Group 4|Participants will receive three injections of the MVA/HIV62 vaccine and one injection of the placebo
11575468|NCT00820846|Placebo Comparator|Part B, Group 5|Participants will receive four placebo injections
11575469|NCT00820833|Placebo Comparator|1|Standard infant formula
11575470|NCT00820833|Experimental|2|Test formula
11575471|NCT00820833|No Intervention|3|Breastfeeding reference group
11575472|NCT00820820|Active Comparator|Rouvax|
11575473|NCT00820820|Placebo Comparator|Placebo|Sub cutaneous injection of vehicle
11575474|NCT00820807|Experimental|1|3g/day
11575475|NCT00820807|Experimental|2|6g/day
11575476|NCT00820807|Placebo Comparator|Placebo beverage|0g/day
11575477|NCT00820794|Experimental|Cohort 1a|Subjects are treated with single dose lithium first. Then after at least 7 day washout, the subjects start PD 0332334 treatment from day 1 to day 9. At day 4 of PD 0332334 treatment, single dose lithium is given to subjects.
11575478|NCT00820794|Experimental|Cohort 1b|Subjects are treated with PD 0332334 from day 1 to 9 and a single dose of lithium is given at day 4. After at least 7 day washout, the subjects are treated with single dose of lithium.
11575479|NCT00820781|Active Comparator|Portacaval shunt|Undergo portacaval shunt surgery
11575480|NCT00820781|Active Comparator|Sclerotherapy|Undergo endoscopic sclerotherapy
11575481|NCT00820768|Experimental|ABI-010|
11575482|NCT00820755|Active Comparator|Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy|
11575483|NCT00820755|Active Comparator|Cetuximab 500 mg/m^2 every 2 weeks|
11575484|NCT00820755|Active Comparator|Cetuximab 250 mg/m^2 weekly|
11575485|NCT00820742||Phase IV Post Marketing Surveillance Study|Open-label, observational study
11575486|NCT00820729||1|Patients with interstitial pulmonary disease
11575487|NCT00820716|Experimental|CA|Exercise training with alternate load
11575488|NCT00820716|Active Comparator|CC|Exercise training with constant load
11575489|NCT00820690||Clinical stage III|Women with invasive breast cancer; clinical stage III, condition to receive neoadjuvant chemotherapy based in doxorubicin/ cyclophosphamide and paclitaxel followed by surgery (mastectomy and axillary lymph node dissection)
11575490|NCT00820677|Experimental|DVD/Video|Parents of newborns in the experimental group attending their first baby visit will be shown a video about newborn care.
11575491|NCT00820664|Active Comparator|17β-estradiol 2.0 milligrams|Estrace 2.0 mg tablet
11575492|NCT00820664|Active Comparator|17β-estradiol 0.5 milligrams|Estrace 0.5 mg tablet
11575493|NCT00820664|Placebo Comparator|3|Placebo
11575494|NCT00820651|Placebo Comparator|Placebo|
11575495|NCT00820651|Experimental|Diamel|
11575496|NCT00820638|Experimental|1|observational
11575497|NCT00820625|Active Comparator|1|ablation: pulmonary vein isolation
11575498|NCT00820625|Active Comparator|2|ablation: pulmonary vein isolation with additional ablation of fragmented potentials
11575499|NCT00820612|Active Comparator|1|Indomethacin suppository
11575500|NCT00820612|Placebo Comparator|2|Placebo suppository
11575501|NCT00820599|Experimental|TAVR|Transaortic Valve Replacement
11575502|NCT00820586|Experimental|Mononuclear bone marrow derived cells|Intramyocardial injection of total mononuclear bone marrow derived cells
11575503|NCT00820586|Experimental|Selected CD34+ bone marrow derived cells|Intramyocardial injection of selected CD34+ bone marrow derived cells
11575504|NCT00820573|Placebo Comparator|Placebo|Placebo to be provided for 6 weeks
11575505|NCT00820573|Experimental|Sitagliptin|Sitagliptin to be provided for 6 weeks
11575506|NCT00820573|Experimental|Metformin|Metformin to be provided for 6 weeks
11575507|NCT00820573|Experimental|Sitagliptin+Metfromin|Sitagliptin + Metformin combined will be provided for 6 weeks
11575508|NCT00820560|Experimental|INCB07839 100mg, immediate release (IR) capsules|
11575509|NCT00820560|Experimental|INCB07839 200 mg IR capsules|
11575510|NCT00820547|Experimental|(FEC / Docetaxel) + Bevacizumab|Neoadjuvant treatment: 4 cycles FEC + Bevacizumab followed by 4 cycles Docetaxel + Bevacizumab Adjuvant: Bevacizumab for 1 year
11575511|NCT00820534|Experimental|Penciclovir|Penciclovir
11575512|NCT00820534|Placebo Comparator|Placebo|Placebo
11575513|NCT00820521|Experimental|active|
11575514|NCT00820521|Placebo Comparator|placebo|
11575515|NCT00820508|Experimental|1|Oral, once daily administration of CHR-2845 to determine safety and tolerability
11575516|NCT00820495|Experimental|Web + Phone|Highly interactive tailored Web-based smokeless tobacco cessation program plus phone counseling
11575517|NCT00820495|Experimental|Web Only|Highly interactive tailored Web-based smokeless tobacco cessation program
11575518|NCT00820495|Experimental|Phone Only|Phone counseling intervention for smokeless tobacco cessation
11575519|NCT00820495|Experimental|Control|Usual care (initial call plus self-help materials)
11575520|NCT00820482|Active Comparator|Group A|Group A: 75 UI/day of Hp-hMG (Menopur®, Ferring, Copenhaghen, Dinamarca)
11575521|NCT00820482|Experimental|Group B|75UI/day of rFSH (Gonal®, Serono, Ginebra, Suiza) + 75UI/day of rLH (Luveris®, Serono, Ginebra, Suiza)
11575522|NCT00820469|Experimental|1|Patients treated by rituximab
11575523|NCT00820469|Experimental|2|Patients treated by rituximab and plasma exchange
11575524|NCT00820456||Colorectal Cancer, Hepatic Metastasis|Eligible participants in Arm A enrolled in this imaging study will: be older than 18, have metastatic colorectal cancer with at least one hepatic lesion, and be treated with FOLFOX in combination with bevacizumab.
11575525|NCT00820456||Primary Tumor Undefined, Hepatic Metastasis|Eligible participants in Arm B enrolled in this imaging study will: be older than 18, must have prior histological documentation of any types of cancer with metastasis to the liver, and must be in stable treatment conditions prior to and between scans.
11575526|NCT00820443|Experimental|Ceramic on metal prosthesis|Ceramic on metal prosthesis
11575527|NCT00820430||Control--Non-Osteoporotic Knee|Kellgren-Lawrence (KL) scale score of 0, Age: 18-35 years
11575528|NCT00820430||Minimal Osteoarthritis, Knee|Kellgren-Lawrence (KL) scale score of 1 or 2, Age: Older than 18; no upper limit
11575529|NCT00820430||Moderate Osteoarthritis, Knee|Kellgren-Lawrence (KL) scale score of 3, Age: Older than 18; no upper limit
11575530|NCT00820417|Experimental|a|Dose-escalation
11575531|NCT00820417|Experimental|B|Maximum tolerated dose (MTD)
11575532|NCT00820404|Experimental|1|BLI-489
11575533|NCT00820404|Placebo Comparator|2|Placebo
11575534|NCT00820391|Experimental|KIDNET|Narrative Exposure Therapy for Children
11575535|NCT00820391|Experimental|Meditation/Relaxation|
11575536|NCT00820378||atherosclerosis|Patients With Clinically Evident Arterial Disease or Cardiovascular Risk Factors
11575537|NCT00820352|Active Comparator|bosentan|Patients in this arm receive bosentan twice a day for 12 weeks
11575538|NCT00820352|Placebo Comparator|placebo|patients in this arm receive 12 placebo twice a day for 12 weeks
11575539|NCT00820339|Active Comparator|Selective Hepatic Vascular Exclusion|Patients with HCC received Selective Hepatic Vascular Exclusion in hepatectomy.
11575540|NCT00820339|Experimental|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
11575541|NCT00820326|Active Comparator|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
11575542|NCT00820326|Placebo Comparator|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
11575543|NCT00820313|Other|Lifestyle Intervention|Comprehensive lifestyle intervention for reversal of heart disease
11575544|NCT00820300|Experimental|Punctal plug|
11575545|NCT00820274|Experimental|amniotic membranes|
11575546|NCT00820261||Diarrhea|children and infants (less than 5 years of age) presenting with severe diarrhea will be enrolled
11575547|NCT00820248|Active Comparator|Arm I|Patients undergo standard fractionation radiotherapy (IMRT or 3D CRT) once daily, 5 days a week, for 7 weeks. Patients receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
11575548|NCT00820248|Experimental|Arm II|Patients undergo accelerated fractionation radiotherapy (IMRT or 3D CRT) once or twice daily, 5 days a week, for 6 weeks. Patients receive panitumumab IV over 30-90 minutes 1 week prior to and on days 15 and 36 of radiotherapy.
11575552|NCT00820222|Experimental|Lapatinib plus capecitabine|Lapatinib 1250 mg once daily and capecitabine 2000mg/m2/day, days 1-14, every 21 days
11575553|NCT00820222|Active Comparator|Trastuzumab plus capecitabine|trastuzumab loading dose of 8mg/kg followed by 6mg/kg q3weekly infusions, and capecitabine 2500mg/m2/day, days 1-14, every 21 days
11575554|NCT00820183|Experimental|quality improvement plan|It will be the group of primary health care teams who will undertake the quality improvement plan for hypertensive patients
11575555|NCT00820183|No Intervention|non intervention|It will be the group of primary health care teams that will not undertake the quality improvement plan for hypertension control
11575556|NCT00820170|Experimental|dasatinib and paclitaxel|"The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel.
~The phase II portion of this trial has a Simon two-stage design to determine the efficacy of dasatinib when administered in combination with paclitaxel."
11575557|NCT00820157|Active Comparator|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE
11575558|NCT00820157|Experimental|TACE|TACE alone
11575559|NCT00820144|Experimental|1|voie nasale 0.25 mg
11575560|NCT00820144|Experimental|2|0.5mg of CTB by oral way
11575561|NCT00820144|Experimental|3|1mg of dukoral by oral way
11575562|NCT00820144|Experimental|4|0.25mg of CTB by sublingual way
11575563|NCT00820144|Experimental|5|1mg of CTB by sublingual way
11575564|NCT00820131|Experimental|1|
11575565|NCT00820131|Active Comparator|2|
11575566|NCT00820118|Experimental|Intermittent treatment|6 months on antiretroviral treatment and 6 months off treatment
11575567|NCT00820105|Experimental|ADX10059 25 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
11575568|NCT00820105|Experimental|ADX10059 50 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
11575569|NCT00820105|Experimental|ADX10059 100 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
11575570|NCT00820105|Placebo Comparator|ADX10059 Matching Placebo|Weeks 1-2: once daily Weeks 3-12: twice daily
11575571|NCT00820092|Active Comparator|Xerecept 1.0|1.0 ug/kg/hr hCRF -24 hour IV infusion
11575572|NCT00820092|Active Comparator|Xerecept 2.0|2.0 ug/kg/hr-24 hour IV infusion
11575573|NCT00820092|Active Comparator|Xerecept 3.0|3.0 ug/kg/hr-24 hour infusion
11575574|NCT00820079|Experimental|ADX10059 120 mg|Twice-daily
11575575|NCT00820079|Placebo Comparator|ADX10059 Matching Placebo|twice-daily
11575576|NCT00820053|No Intervention|no adjuvant TACE|controll group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive adjuvant TACE after liver resection
11575577|NCT00820053|Experimental|adjuvant TACE|patients who adjuvant TACE after liver resection
11575578|NCT00820027|Experimental|Etoricoxib 90 mg|Participants received etoricoxib 90 mg once daily, matching placebo to etoricoxib 120 mg once daily, and matching placebo to ibuprofen 600 mg every 8 hours for 7 days.
11575579|NCT00820027|Experimental|Etoricoxib 120 mg|Participants received etoricoxib 120 mg once daily, matching placebo to etoricoxib 90 mg once daily, and matching placebo to ibuprofen 600 mg every 8 hours for 7 days.
11575580|NCT00820027|Active Comparator|Ibuprofen 1800 mg|Participants received ibuprofen 600 mg every 8 hours, matching placebo to etoricoxib 120 mg once daily, and matching placebo to etoricoxib 90 mg once daily for 7 days.
11575581|NCT00820027|Placebo Comparator|Placebo|Participants received matching placebo to etoricoxib 90 mg and matching placebo to etoricoxib 120 mg once daily, and matching placebo to ibuprofen every 8 hours for 7 days.
11575582|NCT00820014|Experimental|1|ESBA105 eye drops
11575583|NCT00820014|Placebo Comparator|2|Placebo control (vehicle)
11575584|NCT00820001|Experimental|Acute Treatment Protocol Booster|Child participants in this arm were initial participants enrolled in the parent study and randomized to receive the specialty treatment from study clinicians in either the clinic or community setting. In this continuation study, the participants were enrolled at the 36 month assessment and randomized to participate in the booster dose of treatment. The treatment provided in this arm includes specific booster treatment based on the 8 modules of the initial treatment study. Saliva samples were also collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
11575585|NCT00820001|Experimental|Acute Treatment Protocol No-Booster|Child participants in this arm were initial participants enrolled in the parent study and randomized to receive the specialty treatment from study clinicians in either the clinic or community setting. In this continuation study, the participants were enrolled at the 36 month assessment and randomized to participate in assessments only thus not receiving any additional booster treatment. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
11575586|NCT00820001|Active Comparator|Treatment As Usual|Child participants in this arm were initial participants enrolled in the parent study in the clinically referred Treatment As Usual comparison group. These participants were initially enrolled in treatment services with identified providers and received treatment services as provided in that community agency. In this continuation study, the participants were enrolled at the 36 month assessment and participated in the ongoing follow-up assessments only. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
11575587|NCT00820001|Other|No Intervention Healthy Comparison|The Healthy Control subjects enrolled initially in the parent study are incorporated in a related project designed to evaluate the role of biological measures in differentiating antisocial and normal children. All Healthy Control participants were initially matched to cases in the clinical sample (both the acute treatment and the clinically referred Treatment as Usual).
11575588|NCT00819988|Placebo Comparator|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
11575589|NCT00819988|Experimental|Pregabalin|Single dose of 75 mg given 30-60 minutes preoperatively, then 50 mg every 8 hours for 3 days postoperatively if creatinine clearance > 60 ml/min OR 25 mg every 8 hours for 3 days postoperatively if creatinine clearance 30-60 ml/min
11575590|NCT00819975|Active Comparator|Casein|
11575591|NCT00819975|Active Comparator|Whey Isolate|
11575592|NCT00819975|Active Comparator|Whey Hydrolysate|
11575593|NCT00819975|Active Comparator|Alphalact-Albumin|
11575594|NCT00819962|Other|TAP|ksu
11575595|NCT00819949|Experimental|Arm 1|Potential eligible subjects for the trial will be individuals between ages 18-85, with a confirmed diagnosis of PD that experience freezing.
11575596|NCT00819936|Experimental|2|Backward walking,
11575597|NCT00819936|Active Comparator|1|Forward walking
11575598|NCT00819923|Experimental|1|Patients receiving bio-active stent during the intervention
11575599|NCT00819923|Active Comparator|2|Patients receiving everolimus-eluting stent during the intervention
11575600|NCT00819910|Active Comparator|Rosiglitazone + Placebo|Rosiglitazone 8 mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks
11575601|NCT00819910|Active Comparator|Fenofibrate + Placebo|Fenofibrate 145mg daily + Placebo (Rosiglitazone) 8mg daily for 12weeks
11575602|NCT00819910|Experimental|Rosiglitazone +Fenofibrate|Rosiglitazone 8mg daily + Fenofibrate 145mg daily for 12 weeks
11575603|NCT00819910|Placebo Comparator|Placebo Therapy Daily|Placebo (Rosiglitazone) 8mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks
11575604|NCT00819884|Experimental|1|twice daily during 4 days
11575605|NCT00819884|Experimental|2|once daily during 4 days
11575606|NCT00819871||PLI|patients with postoperative lung injury
11575607|NCT00819871||without PLI|patients without postoperative lung injury
11575608|NCT00819871||PLI/PKI|patients with at least one organ injury of lung or kidney after surgery
11575609|NCT00819871||without PLI/PKI|patients without lung or kidney injury after surgery
11575610|NCT00819858|Experimental|RUTF|RUTF supplement (Plumpynut®) of 500 kcal/day for 2 weeks
11575611|NCT00819858|No Intervention|control|no supplement given
11575612|NCT00819845|Experimental|Ramipril|
11575613|NCT00819845|Experimental|Carvedilol|
11575614|NCT00819832|Experimental|Phase 1 Group 1 Vertebroplasty|Vertebroplasty
11575615|NCT00819832|Experimental|Phase 1 Group 2 Kyphoplasty|Kyphoplasty
11575616|NCT00819832|Active Comparator|Phase 2 Group 1 Vertebroplasty|Vertebroplasty
11575617|NCT00819832|Active Comparator|Phase 2 Group 2 Vertebroplasty + Cavity SpineWand|Vertebroplasty with Cavity SpineWand
11575618|NCT00819832|Active Comparator|Phase 2 Group 3 Kyphoplasty|Kyphoplasty
11575619|NCT00819832|Active Comparator|Phase 2 Group 4 Kyphoplasty + Cavity SpineWand|Kyphoplasty with Cavity SpineWand
11575620|NCT00819819|Active Comparator|1 Gluten containing diet|Gluten added to diet at 6 months per American Academy of Pediatrics recommendations
11575621|NCT00819819|Active Comparator|2 Gluten free diet|Non gluten containing food starch added to diet from 6-12 months
11575622|NCT00819806|Experimental|A|PF-3512676, and three MHC class I Montanide ISA 720 VG and the peptides NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102 will be administered in three separate subcutaneous (under the skin) injections.
11575623|NCT00819806|Experimental|B|This vaccine injection contains all the same components of Arm A and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm). Cyclophosphamide is an agent that is thought to increase the anti-tumor response of vaccines.
11575624|NCT00819806|Experimental|C|PF-3512676, Montanide ISA 720 VG and the peptides NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102, NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-1 157-170 will be administered in three separate subcutaneous injections.
11575625|NCT00819806|Experimental|D|This vaccine injection contains all the same components of Arm C and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm).
11575626|NCT00819806|Experimental|E|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein will be administered in three separate subcutaneous injections.
11575627|NCT00819806|Experimental|F|This vaccine injection contains all the same components of Arm E and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm).
11575628|NCT00819793|Experimental|CentriMag Ventricular Assist System|All patients meeting the patient selection criteria will be treated with the CentriMag Ventricular Assist System.
11575629|NCT00819780|Experimental|Panitumumab Plus mFOLFOX6|Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and modified FOLFOX6 (mFOLFOX6) chemotherapy regimen consisting of oxaliplatin (85 mg/m^2), leucovorin (400 mg/m^2) and 5-fluorouracil (5-FU) (2400 mg/m^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
11575630|NCT00819780|Active Comparator|Bevacizumab Plus mFOLFOX6|Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 regimen consisting of oxaliplatin (85 mg/m^2), leucovorin (400 mg/m^2), followed by 5-FU (2400 mg/m^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
11575631|NCT00819767|Experimental|Aliskiren|For the first week of the 8 week treatment period, patients received aliskiren 150 mg, placebo to aliskiren, and 2 capsules of placebo to valsartan. For the remaining 7 weeks of the study, patients received aliskiren 300 mg (two 150 mg tablets) and 2 capsules of placebo to valsartan. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
11575632|NCT00819767|Active Comparator|Valsartan|For the first week of the 8 week treatment period, patients received valsartan 160 mg, placebo to valsartan, and 2 tablets of placebo to aliskiren. For the remaining 7 weeks of the study, patients received valsartan 320 mg (two 160 mg capsules) and 2 tablets of placebo to aliskiren. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
11575633|NCT00819754|Experimental|IXO regimen + bevacizumab|This is phase I/II safety and efficacy study. There is only one arm of Irinotecan, Xeloda and Oxaliplatin (IXO) regimen with Avastin (bevacizumab)
11575634|NCT00819741|Experimental|Repaglinide + metformin|Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily.
11575635|NCT00819741|Active Comparator|Repaglinide|Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily.
11575636|NCT00819728|Experimental|Taxotere/Irinotecan|
11575637|NCT00819715||1|Small for gestational age preterm infants
11575638|NCT00819715||2|Appropriate for gestational preterm infants
11575639|NCT00819702|Experimental|Model Care|The Model Care approach was implemented in 7 practices, where PCPs were trained to address major risk factors for CM, including maternal depression, alcohol/substance abuse, intimate partner violence, food insecurity, harsh punishment and major stress. We taught how they can be briefly assessed and initially addressed. The initial training consisted of one 4-hour in-person session. Use of the Parent Screening Questionnaire (PSQ) was discussed, as was the importance of applying it universally during regular checkups. PCPs SEEK Parent Handouts on each targeted problem. We held 1-hour booster sessions every 6 months over the subsequent 2.5 years.
11575640|NCT00819702|No Intervention|Standard Care|PCPs in Standard Care group served as the controls. They continued to practice as usual.
11575641|NCT00819676||subjects with asthma|
11575642|NCT00819676||healthy subjects|
11575643|NCT00819663||Crohns patients|Established Crohn's disease patients who underwent CTE imaging before and after initiating infliximab therapy
11575644|NCT00819650|Experimental|Licartin|patients who receive Licartin therapy after liver resection
11575645|NCT00819650|No Intervention|placebo|control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive Licartin therapy after liver resection
11575646|NCT00819637|Experimental|Arformoterol 3 doses|
11575647|NCT00819637|Experimental|Arformoterol 1 dose, placebo 2 doses|
11575648|NCT00819637|Active Comparator|Levalbuterol 3 doses|
11575649|NCT00819624|Other|Interactive Voice Response System|
11575650|NCT00819624|Other|Personal Digital Assisstant|
11575651|NCT00819611|Experimental|Working memory training|
11575652|NCT00819611|Sham Comparator|Control version of working memory training|
11575653|NCT00819598||SUSPECTED ARTERIAL DISEASE|
11575654|NCT00819585|Experimental|Core study: Canakinumab 25 mg|Canakinumab 25 mg subcutaneously (sc) once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
11575655|NCT00819585|Experimental|Core study: Canakinumab 50 mg|Canakinumab 50 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
11575656|NCT00819585|Experimental|Core study: Canakinumab 100 mg|Canakinumab 100 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
11575657|NCT00819585|Experimental|Core study: Canakinumab 200 mg|Canakinumab 100 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
11575658|NCT00819585|Experimental|Core study: Canakinumab 300 mg|Canakinumab 300 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
11575659|NCT00819585|Experimental|Core study: Canakinumab q4wk|Canakinumab 50 mg sc at Days 1, and 29 followed by canakinumab 25 mg sc on Days 57, and 85 plus daily placebo capsules for 16 weeks, repeated every 4 week (q4wk). Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
11575660|NCT00819585|Active Comparator|Core study: Colchicine 0.5 mg|Colchicine 0.5 mg capsule orally once daily throughout the whole treatment phase of 16 weeks plus placebo matching canakinumab s.c. at Days 1, 29, 57, and 85. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
11575661|NCT00819585|Experimental|Extension study: Group A|Participants who were randomized to canakinumab in the core study and were treated with canakinumab for at least 1 flare in the extension study.
11575662|NCT00819585|Experimental|Extension study: Group B|Patients who were randomized to canakinumab in the core study but did not receive treatment with canakinumab in the extension study.
11575663|NCT00819585|Experimental|Extension study: Group C|Patients who were randomized to colchicine in the core study and were treated with canakinumab for at least 1 flare in the extension study.
11575664|NCT00819585|Experimental|Extension study: Group D|Patients who were randomized to colchicine in the core study but did not receive treatment with canakinumab in the extension study.
11575665|NCT00819572|Experimental|1|DLX105 low dose
11575666|NCT00819572|Experimental|2|DLX105 high dose
11575667|NCT00819572|Placebo Comparator|3|
11575668|NCT00819559|Active Comparator|Open PCRT group|Patients who underwent preoperative chemoradiotherapy and open resection
11575669|NCT00819559|Experimental|Open no PCRT group|Patients who did not undergo preoperative chemoradiotherapy and open resection
11575670|NCT00819559|Active Comparator|LAP PCRT group|Patients who underwent preoperative chemoradiotherapy and laparoscopic resection
11575671|NCT00819559|Experimental|LAP no PCRT group|Patients who did not undergo preoperative chemoradiotherapy and laparoscopic resection
11575672|NCT00819546|Other|Only one arm on this study.|
11575673|NCT00819533|Experimental|sensor|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
11575674|NCT00819520|Experimental|Ivermectin|ivermectin Stromectol®)
11575675|NCT00819520|Active Comparator|Malathion|malathion(Prioderm®)
11575676|NCT00819507|Experimental|Vanos Cream|glucocorticoid cream
11575677|NCT00819494|Sham Comparator|Healthy controls|
11575678|NCT00819494|Active Comparator|Patients with immediate reactions|
11575679|NCT00819481||3DKnee|Post Market Study
11575680|NCT00819468|Experimental|Participants with Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh score of 7-9) will receive 20 mg of teduglutide.
11575681|NCT00819468|Active Comparator|Healthy Volunteers|Healthy volunteers with normal hepatic function matched to hepatic impaired participants by age, gender, BMI, and renal function as measured by creatinine will receive 20 mg of teduglutide.
11575682|NCT00819455|Active Comparator|2|In person lifestyle advice at baseline, 6, 12, 18 months.
11575683|NCT00819455|Experimental|1|In person lifestyle advice at baseline, 6, 12, 18 months. Receive reminders by internet based, mobile phone text messaging (Frequency, time and number(s) of messages according to participants requirement)
11575684|NCT00819442|Placebo Comparator|1|patients without heart failure, with cardiobiopsy
11575685|NCT00819442|Experimental|2|patients with heart failure in NYHA class I, II
11575686|NCT00819442|Experimental|3|Patients with heart failure in NYHA class III, IV
11575687|NCT00819429|Experimental|1|"Omega-3 + Standard treatment
~Children in this group will be given 400 mg of DHA and 600 mg of EPA. Caregivers will be instructed to give two 500mg Omega-3 capsules twice a day, at breakfast and at the evening meal for 6 months. Parents will be seen by the attending on a monthly basis for standard treatment procedure."
11575688|NCT00819429|Experimental|2|"Social skills + Omega-3 placebo + Standard treatment
~Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months. They will also undergo a manualised group social problem solving skills training protocol of 12 weekly 1-hour sessions (Ang & Ooi, 2003a, 2003b). There will be booster sessions scheduled at 3-week intervals after the initial treatment period of 12 weeks, for a total of 4 booster sessions."
11575689|NCT00819429|Experimental|3|"Omega-3 + Social skills + Standard treatment
~Children in this group will receive omega-3 supplement and social skills training on top of standard treatment. Procedures for administration of Omega-3 supplement are similar to those stated in (1) and (2)."
11575690|NCT00819429|Placebo Comparator|4|"Omega-3 placebo + Standard treatment.
~Children in this group will receive placebo as well as a course of the standard treatment. Procedure for administering the placebo capsules is similar to that outlined in (2)."
11575691|NCT00819416|Experimental|1|5% albumin
11575692|NCT00819416|Other|2|Normal saline
11575693|NCT00819403|Active Comparator|simvastatin|Simvastatin 40 mg daily
11575694|NCT00819403|Active Comparator|simvastatin/ezetimibe|Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
11575695|NCT00819390|Experimental|A: Chloroquine then Placebo for Off-ART Participants|Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
11575696|NCT00819390|Experimental|B: Placebo then Chloroquine for Off-ART Participants|Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
11575697|NCT00819390|Experimental|C: Chloroquine then Placebo for On-ART Participants|Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
11575698|NCT00819390|Experimental|D: Placebo then Chloroquine for On-ART Participants|Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
11575699|NCT00819377|Placebo Comparator|Normal saline|Normal saline by inhalation over 15 min
11575700|NCT00819377|Active Comparator|Milrinone|Inhaled milrinone 5 mg(as for the injectable solution)
11575701|NCT00819364|Experimental|1|Participants with autism will receive BCRI intervention program.
11575702|NCT00819364|Active Comparator|2|Participants with autism will receive standard care available in the community.
11575703|NCT00819351|Experimental|PEG-asparaginase 6 weeks intervals|"PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (from week 13 after diagnosis to week 33).
~All additional therapy (High Dose Methotrexate, Vincristin, Dexamethasone, 6-Mercaptopurine, doxorubicin, intrathecal chemotherapy) is the same in both arms."
11575704|NCT00819351|Active Comparator|PEG-Asparaginase 2 weeks intervals|"PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (from week 13 after diagnosis to week 33).
~All additional therapy (High Dose Methotrexate, Vincristin, Dexamethasone, 6-Mercaptopurine, doxorubicin, intrathecal chemotherapy) is the same in both arms."
11575705|NCT00819338|Active Comparator|polyunsaturated|5g per day of polyunsaturated fatty acids (3.5g EPA and DHA).
11575706|NCT00819338|Placebo Comparator|monounsaturated|5g a day of oleic enriched sunflower oil
11575707|NCT00819325|Experimental|Intensive glycemic control|Included routine use of pioglitazone (30 mg/d) for 6 months in addition to titration of their other oral hypoglycemic agents in order to get the HbA1c<6%.
11575708|NCT00819325|Active Comparator|conservative glycemic control|Included titration of oral hypoglycemic agents to get HbA1c<7% without the use of a thiazolidinedione.
11575709|NCT00819312|Active Comparator|Arm 1|
11575710|NCT00819299|Experimental|AcuFocus Corneal Inlay|Implantation of the AcuFocus Corneal Inlay ACI 7000PDT in emmetropic presbyopic patients.
11575711|NCT00819286|Active Comparator|wire (control)|patients will have their sternum closed using wire (stainless steel surgical wire).
11576063|NCT00817024|Placebo Comparator|Placebo|
11575712|NCT00819286|Experimental|SternaLock Rigid Fixation Plates|patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates.
11575713|NCT00819273||1|patients who have records of clinic visit with circulatory and endocrine internal medicines of nationwide tertiary hospitals within the last one year.
11575714|NCT00819260|Experimental|Harmonic Reduced Breast|harmonic scalpel used to reduce breast on that side
11575715|NCT00819260|Active Comparator|Electrocautery Reduced Breast|Electrocautery (current practice = control) used to reduce breast on that side
11575716|NCT00819247|Experimental|Degarelix 80/80 + 40|Loading doses of Degarelix 80 mg (20 mg/mL) on Days 0 and 3. Maintenance doses of 40 mg (20 mg/mL) given on days 28, 56, 84, 112 and 140.
11575717|NCT00819247|Experimental|Degarelix 40/40 + 40|Loading doses of Degarelix 40 mg (20 mg/mL) on Days 0 and 3. Maintenance doses of 40 mg (20 mg/mL) given on days 28, 56, 84, 112 and 140.
11575718|NCT00819247|Experimental|Degarelix 80 + 20|Loading dose of Degarelix 80 mg (20 mg/mL) on Day 0. Maintenance doses of 20 mg (10 mg/mL) given on days 28, 56, 84, 112 and 140.
11575719|NCT00819234|Placebo Comparator|1|
11575720|NCT00819234|Experimental|2|Pramlintide and 1.25mg Metreleptin
11575721|NCT00819234|Experimental|3|Pramlintide and 2.5mg Metreleptin
11575722|NCT00819234|Experimental|4|Pramlintide and 5.0mg Metreleptin
11575723|NCT00819221|Experimental|1|
11575724|NCT00819208|Active Comparator|Physical Activity Program + General Health Education Materials|Intervention Arm
11575725|NCT00819208|Active Comparator|General Health Education Materials|Control Arm
11575726|NCT00819195||RRMS|Relapsing-remitting multiple sclerosis patients who have not yet received glatiramer acetate (Copaxone) therapy recommended as part of clinical care
11575727|NCT00819195||HC|Healthy control volunteers
11575728|NCT00819182|Experimental|Paced respiration|The paced respiration intervention group received a compact disc with paper booklet. The booklet reinforced instructions on the first audio track for how to accomplish a target breath rate of 6-8 breaths per minute, practice twice per day for 15 minutes, and apply the breathing at the onset of each hot flash. Women were instructed to do slow, deep, abdominal breathing in through the nose and out through the mouth as per international recommendations (4). They were also instructed to practice twice per day for 15 minutes as per the small, laboratory-based studies (5, 6). The second and third tracks contained specially composed, digitally recorded music to help entrain the breath rate and structure the length of practice.
11575729|NCT00819182|Sham Comparator|Sham comparator: Fast, shallow breathing|The sham comparator group received a digital videodisc with paper booklet. The booklet reinforced voice-over and video demonstration to practice twice per day and apply the fast shallow breathing at the onset of each flash. A previously published report provides additional details and data indicating this program was a suitable attention control.
11575730|NCT00819182|No Intervention|Control: Usual Care|The usual care group received an investigator-signed letter explaining they were not selected to receive any study materials during the 16-week follow-up. These participants received paced respiration materials by mail after study completion.
11575731|NCT00819169|Experimental|Part 1 Cohort 3|AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg IV (day 1 of each Q3W cycle)
11575732|NCT00819169|Experimental|Part 1 Cohort 1|AMG 479 18 mg/kg IV plus AMG 655 1 mg/kg IV (day 1 of each Q3W cycle)
11575733|NCT00819169|Experimental|Part 1 Cohort 2|AMG 479 18 mg/kg IV plus AMG 655 3 mg/kg IV (day 1 of each Q3W cycle)
11575734|NCT00819169|Experimental|Part 2|AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg Q3W, or the MTD, as determined in Part 1 of the study
11575735|NCT00819156|Experimental|Degarelix 200/80|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.
11575736|NCT00819156|Experimental|Degarelix 200/120|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.
11575737|NCT00819156|Experimental|Degarelix 200/160|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.
11575738|NCT00819156|Experimental|Degarelix 240/80|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.
11575739|NCT00819156|Experimental|Degarelix 240/120|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.
11575740|NCT00819156|Experimental|Degarelix 240/160|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.
11575741|NCT00819117|Active Comparator|Transvenous Lead (TVN CRT)|Control group: resynchronization via a transvenous left ventricular lead (TVN CRT)
11575742|NCT00819117|Experimental|Epicardial Lead (EPI CRT)|Treatment group: resynchronization via an epicardial left ventricular lead (EPI CRT)
11575743|NCT00819104|Experimental|1|FDC of Metoprolol XL 50mg + Amlodipine 5mg
11575744|NCT00819104|Experimental|2|FDC of Metoprolol XL 25mg + Amlodipine 2.5mg
11575745|NCT00819104|Active Comparator|3|Extended release Metoprolol succinate
11575746|NCT00819104|Active Comparator|4|Extended release Metoprolol succinate
11575747|NCT00819104|Active Comparator|5|Amlodipine 5mg in immediate release formulation
11575748|NCT00819091|Active Comparator|BI 1356|5 mg orally (po) once daily
11575749|NCT00819091|Placebo Comparator|Placebo|one tablet once daily
11575750|NCT00819078|Active Comparator|Bupropion Sr|40 adolescent patients
11575751|NCT00819078|Placebo Comparator|Placebo (sugar pill)|40 adolescent patients will receive placebo
11575752|NCT00819065|Active Comparator|1-BTA Lanzhou/Allergan|Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Lanzhou at allocation and after twelve weeks will receive the same drug from laboratory Allergan.
11575753|NCT00819065|Active Comparator|2. BTA Allergan/Lanzhou|Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Allergan at allocation and after twelve weeks will receive the same drug from laboratory Lanzhou.
11575754|NCT00819052|Active Comparator|NVP IR|200 mg orally twice a day (po BID)
11575755|NCT00819052|Experimental|NVP XR|400 mg orally once a day (po QD)
11575756|NCT00819039|Experimental|Part 1: Oral Aprepitant|In Study Part 1, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.
11575757|NCT00819039|Experimental|Part 2: Oral Aprepitant|In Study Part 2, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.
11575758|NCT00819039|Active Comparator|Part 2: Intravenous Ondansetron|In Study Part 2, participants aged 6 months to 17 years received a single intravenous dose of ondansetron on Day 1.
11575759|NCT00819013|Experimental|Study Group 1|ACAM-FLU-A low dose + Adjuvant 1
11575760|NCT00819013|Experimental|Study Group 2|ACAM-FLU-A low dose + Adjuvant 2
11575761|NCT00819013|Experimental|Study Group 3|ACAM-FLU-A low dose
11575762|NCT00819013|Placebo Comparator|Study Group 4|Saline placebo
11575763|NCT00819000||Treated MS Subjects|Subjects who are treated with Glatiramer Acetate or Interferon (IFN)-β and receive their therapy from one of the participating Specialty Pharmacies
11575764|NCT00818987|Other|Operative|Treatment arm - intervention = Open Reduction Internal Fixation or Reduction & Immobilization
11575765|NCT00818987|No Intervention|Non Operative|Placebo arm
11575766|NCT00818961|Other|Hematopoietic Stem Cell Transplantation|All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on donor type
11575767|NCT00818948|Placebo Comparator|Placebo|2 subjects of each cohort (cohort 1 to 6) will receive placebo
11575768|NCT00818948|Other|AMG811|Six subjects in each cohort (cohort 1 to 6) will receive AMG 811
11575769|NCT00818935|Experimental|Low-Intermediate-Glycemic Index diets|
11575770|NCT00818935|Active Comparator|High GI diet|
11575771|NCT00818909|Experimental|Systane|Systane ocular product
11575772|NCT00818883|Experimental|Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD|
11575773|NCT00818883|Experimental|Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD|
11575774|NCT00818870|Active Comparator|Omeprazole 20 mg|
11575775|NCT00818870|Experimental|Vecam 20/300|
11575776|NCT00818870|Experimental|Vecam 40/300|
11575777|NCT00818857|Active Comparator|1|Early intervention.
11575778|NCT00818857|Active Comparator|2|Delayed intervention
11575779|NCT00818844|Experimental|Nepafenac|Nepafenac 0.1% dosed topically TID for 3 months after Epiretinal Membrane (ERM) Surgery
11575780|NCT00818844|Placebo Comparator|BSS|BSS dosed topically TID for 3 months after Epiretinal Membrane (ERM) Surgery
11575781|NCT00818818|Experimental|Meglumine antimoniate|Treated with 5mg/kg/d of pentavalent antimony (meglumine antimoniate) intravenously for 20 consecutive days.
11575782|NCT00818805|Experimental|Olopatadine 0.1% one eye|Patients received one drop Olopatadine 0.1% in one eye and 1 drop Olopatadine placebo in contralateral eye
11575783|NCT00818805|Experimental|Tranilast 0.5% one eye|Patients received one drop Tranilast ophthalmic solution 0.5% in one eye and 1 drop tranilast placebo in contralateral eye
11575784|NCT00818805|Placebo Comparator|Placebo (Olopatadine)|Patients received one drop Olopatadine 0.1% in one eye and 1 drop Olopatadine placebo in contralateral eye
11575785|NCT00818805|Placebo Comparator|Placebo (Tranilast)|Patients received one drop Tranilast ophthalmic solution 0.5% in one eye and 1 drop tranilast placebo in contralateral eye
11575786|NCT00818792|Active Comparator|Drug-eluting stent Xience V|
11575787|NCT00818792|Active Comparator|Bare-metal stent Vision|
11575788|NCT00818779|Experimental|Aliskiren|Aliskiren 150-300 mg once daily
11575789|NCT00818779|Active Comparator|Amlodipine|5-10 mg amlodipine once daily
11575790|NCT00818766|Active Comparator|Antibiotic|Participants received intravenous (IV) cefazolin or vancomycin (for participants allergic to cephalosporin) immediately following surgery for 48 hours or until all chest tubes were removed, whichever occurred first.
11575791|NCT00818766|Placebo Comparator|Placebo|Participants received IV placebo-matching antibiotics immediately following surgery for 48 hours or until all chest tubes were removed, whichever occurred first.
11575792|NCT00818753|Experimental|Dabigatran 110 mg|experimental drug therapy in this indication
11575793|NCT00818753|Experimental|Dabigatran 150 mg|experimental drug therapy in this indication
11575794|NCT00818753|Active Comparator|Unfractionated Heparin|standard therapy in this indication as comparator
11575795|NCT00818740|Experimental|ORM-12741 i.v.|
11575796|NCT00818740|Experimental|ORM-12741 oral solution|
11575797|NCT00818740|Experimental|ORM-12741 oral capsule with food|
11575798|NCT00818740|Experimental|ORM-12741 oral capsule without food|
11575799|NCT00818714|Experimental|1|Dose escalation study to define the maximum tolerated boost dose of stereotactic body radiation therapy (SBRT) to the residual primary tumor after definitive therapy with concurrent chemotherapy and external beam radiation.
11575800|NCT00818701|Placebo Comparator|1: low dose BNP alone|low dose BNP with placebo
11575801|NCT00818701|Active Comparator|2: low dose BNP + PDEVI|low dose BNpo + PDEVI
11575802|NCT00818688||1|Patients eligible for enrolment were all consecutive patients aged 18 years or over, with a symptomatic ST of the lower limbs at least 5 cm long on compression ultrasonography. Patients who had undergone surgery under general or loco-regional anaesthesia in the previous 10 days, those in whom ST had occurred after sclerotherapy within the previous 30 days and those whose follow-up was not considered to be feasible were ineligible.
11575803|NCT00818688||2|Patients eligible for enrolment were all consecutive patients aged 18 years or over, with a symptomatic ST of the lower limbs at least 5 cm long on compression ultrasonography. Patients who had undergone surgery under general or loco-regional anaesthesia in the previous 10 days, those in whom ST had occurred after sclerotherapy within the previous 30 days and those whose follow-up was not considered to be feasible were ineligible.
11575804|NCT00818675|Experimental|Ridaforolimus|
11575805|NCT00818675|Placebo Comparator|Placebo|
11575806|NCT00818662|Experimental|IGIV, 10% 400mg/kg|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
11575807|NCT00818662|Experimental|IGIV, 10% 200mg/kg|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
11575808|NCT00818662|Placebo Comparator|Human Albumin 0.25% Solution - 4 mL/kg|0.25% human albumin solution infused at 4 mL/kg/2weeks
11575809|NCT00818662|Placebo Comparator|Human Albumin 0.25% Solution - 2 mL/kg|0.25% human albumin solution infused at 2 mL/kg/2weeks
11575810|NCT00818649|Experimental|Velcade + Vorinostat|This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.
11575811|NCT00818636|Experimental|Expressive Writing|In addition to attending group therapy as usual, participants write about their feelings about an issue of their choosing three times during a two week period for at least 20 minutes each time.
11575812|NCT00818636|Active Comparator|Treatment as Usual|Participants attend group therapy as usual only.
11575813|NCT00818623|Experimental|Degarelix 120 mg (20 mg/mL)|Degarelix 120 mg (20 mg/mL)
11575814|NCT00818623|Experimental|Degarelix 120 mg (40 mg/mL)|Degarelix 120 mg (40 mg/mL)
11575815|NCT00818623|Experimental|Degarelix 160 mg (40 mg/mL)|Degarelix 160 mg (40 mg/mL)
11575816|NCT00818623|Experimental|Degarelix 200 mg (40 mg/mL)|Degarelix 200 mg (40 mg/mL)
11575817|NCT00818623|Experimental|Degarelix 200 mg (60 mg/mL)|Degarelix 200 mg (60 mg/mL)
11575818|NCT00818623|Experimental|Degarelix 240 mg (40 mg/mL)|Degarelix 240 mg (40 mg/mL)
11575819|NCT00818623|Experimental|Degarelix 240 mg (60 mg/mL)|Degarelix 240 mg (60 mg/mL)
11575820|NCT00818623|Experimental|Degarelix 320 mg (60 mg/mL)|Degarelix 320 mg (60 mg/mL)
11575821|NCT00818610|Experimental|Monotherapy|
11575822|NCT00818610|Active Comparator|Bi-therapy|
11575823|NCT00818597|Experimental|EISS-treatment|In this arm patients receive additional treatment with the EISS-bioreactor
11575824|NCT00818584|Experimental|1. micafungin lower dose|
11575825|NCT00818584|Experimental|2. micafungin higher dose|
11575826|NCT00818571|Experimental|Vildagliptin 25 mg qd in Renal Impaired (RI) patients|
11575827|NCT00818571|Experimental|Vildagliptin 50 mg qd in RI Patients|
11575828|NCT00818571|Experimental|Vildagliptin 25 mg qd in matched Healthy Volunteer (HV)|
11575829|NCT00818571|Experimental|Vildagliptin 50 mg qd in matched HV|
11575830|NCT00818558|Experimental|1|stade IA [pT1 N0M0]
11575831|NCT00818558|Experimental|2|stade IB [pT2 N0M0]
11575832|NCT00818558|Experimental|3|stade IIA [pTI N1M0]
11575833|NCT00818558|Experimental|4|stade IIB [pT2 N1 et T3N0M0]
11575834|NCT00818558|Experimental|5|control groupe [tabagic subject]
11575835|NCT00818558|Experimental|6|Control group B [intervention for a pulmonaire non tumoral pulmonary lesion]
11575836|NCT00818545|Placebo Comparator|2|
11575837|NCT00818545|Experimental|hydroxypropyltetrahydropyrantriol|
11575838|NCT00818532||1|Measurement device
11575839|NCT00818519|Experimental|EE20/Drospirenone (YAZ, BAY86-5300)|In the active treatment group, participants received 24 consecutive days of active tablets followed by 4 consecutive days of inactive tablets. The active tablet contained 3 mg DRSP (Drospirenone) and 20µg EE (Ethinyl estradiol).
11575840|NCT00818519|Placebo Comparator|Placebo|The participants of the placebo group received inert but identical-appearing, color-matched tablets.
11575841|NCT00818506||Late onset MDD|Patients with major depressive disorder between 50 and 70 years of age that did not suffer from depression before the age of 50.
11575842|NCT00818506||Controls|Healthy controls (matched for age, sex, and tobacco use status)
11575843|NCT00818493|Experimental|1|Q8003, flexible ascending dose
11575844|NCT00818493|Experimental|2|Low dose Q8003
11575845|NCT00818493|Active Comparator|3|Percocet (oxycodone and acetaminophen)
11575846|NCT00818480|Experimental|1. YM155|
11575847|NCT00818467|Experimental|Tanning spray|To characterize the 25(OH)D response to 4 weeks of thrice weekly 40 mJ of UV-B light in a group of normal subjects with skin types I and II while using multiple applications of 3% DHA for five weeks.
11575848|NCT00818467|Active Comparator|UVB|To characterize the 25(OH)D response to 4 weeks of thrice weekly 40 mJ of UV-B light in a control group of normal subjects with skin types I and II who are not using 3% DHA applications.
11575849|NCT00818441|Experimental|Cohort A|Dacomitinib (PF-00299804) in patients with EGFR mutated NSCLC or clinical characteristics defined above to enhance for EGFR mutated NSCLC
11575850|NCT00818441|Experimental|Cohort B|Dacomitinib in patients with HER2 mutated or amplified NSCLC
11575851|NCT00818428|Active Comparator|1|Speech Production Intervention + Articulation Parent Group
11575852|NCT00818428|Experimental|2|Speech Production Intervention + Dialogic Reading Parent Group
11575853|NCT00818428|Experimental|3|Speech Perception Intervention + Articulation Parent Group
11575854|NCT00818428|Experimental|4|Speech Perception Intervention + Dialogical Reading Parent Group
11575855|NCT00818415|Experimental|Arm 1|
11575856|NCT00818415|Active Comparator|Arm 2|
11575857|NCT00818402||Non-small cell lung cancer patients|
11575858|NCT00818389|Active Comparator|1|Participants randomized to lithium/riluzole (randomization is 1:1 lithium/riluzole to placebo/riluzole, i.e., participants have an equal chance of getting randomized to lithium vs. placebo).
11575859|NCT00818389|Placebo Comparator|2|Participants randomized to placebo/riluzole (randomization is 1:1 lithium/riluzole to placebo/riluzole, i.e., participants have an equal chance of getting randomized to lithium vs. placebo).
11575860|NCT00818363|Experimental|Group 1: SABER™-Bupivacaine|5.0 mL SABER™-Bupivacaine/Once
11575861|NCT00818363|Placebo Comparator|Group 2: SABER™-Placebo|5.0 mL SABER™-Placebo/Once
11575862|NCT00818350|Experimental|SUNITINIB|
11575863|NCT00818337|Active Comparator|Aspirin 81mg|Resistant
11575864|NCT00818324|Experimental|OPC-12759 Ophthalmic suspension|Instillation, 4times/day
11575865|NCT00818311|Other|5|
11575866|NCT00818298|Experimental|1|ziprasidone
11575867|NCT00818285|No Intervention|1|Physicians in this arm will be using the standard electronic prescription interface.
11575868|NCT00818285|Experimental|2|In addition to the standard electronic prescription module, physicians in this arm will receive targeted drugs alert and decision support for psychotropic drug management
11575869|NCT00818272||Remicade (infliximab)|Participants with confirmed diagnosis of active Crohn's disease.
11575955|NCT00817713|No Intervention|HIV care, no anthelminthic treatment|HIV care as per Tanzanian National AIDS Control Program (NACP) guidelines
11575956|NCT00817700|No Intervention|Normal (8 hours) sleep time|Subjects are studied under normal sleep time conditions.
11575870|NCT00818259|Experimental|Part IA-fosaprepitant 115 mg/aprepitant|Day 1, fosaprepitant intravenous (IV) at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg orally (PO), prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
11575871|NCT00818259|Experimental|Part IB-fosaprepitant 150 mg|Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
11575872|NCT00818259|Experimental|Part IIA-aprepitant 80 mg equiv.|Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to <12 years of age - 47 mg/m^2; 4 months to <6 months of age - 2.0 mg/kg; 1 month to <4 months of age - 1.0 mg/kg; birth to <1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
11575873|NCT00818259|Experimental|Part IIB-aprepitant 125 mg equiv.|Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to <12 years of age - 74 mg/m^2; 6 months to <2 years of age - 1.3 mg/kg; 4 months to <6 months of age - 3.0 mg/kg; 1 month to <4 months of age - 1.5 mg/kg; birth to <1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
11575874|NCT00818259|Active Comparator|Part III-ondansetron|Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to <12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.
11575875|NCT00818259|Experimental|Part IV-aprepitant regimen|Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to <12 years of age - 3.0 mg/kg; 1 month to <4 months of age - 1.5 mg/kg; Birth to <1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to <12 years of age - 2.0 mg/kg; 1 month to <4 months of age - 1.0 mg/kg; Birth to <1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.
11575876|NCT00818259|Experimental|Part V-fosaprepitant regimen|Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to <12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
11575877|NCT00818246|Sham Comparator|Sham light|one side of the face was treated three times weekly for four consecutive weeks (12 treatments) with a Sham light on the experimental periorbital area
11575878|NCT00818246|Experimental|LED-treated|one side of the face was treated three times weekly for four consecutive weeks (12 treatments) with 660 nm Light emitting diode (LED) on the experimental periorbital area
11575879|NCT00818233||Observation|Variability will be assessed between each examiner.
11575880|NCT00818220|Experimental|1-Delayed Cord Clamping (DCC)|Immediately after birth, the infant is placed in a warm blanket and held lower than the placenta. The research nurse counts out 30 to 45 seconds for the obstetrician. The cord is milked once and then clamped at 30 to 45 seconds after birth.
11575881|NCT00818220|Active Comparator|2-Immediate Cord Clamping (ICC)|Routine care which is immediate cord clamping
11575882|NCT00818207|Other|Full Smoking Cessation Treatment Coverage (100%)|A subject randomized to the intervention group will be eligible for smoking cessation treatment (SCT) reimbursement during the 26-week period following the randomization.
11575883|NCT00818207|Other|No Smoking Cessation Treatment Coverage (0%)|Subjects in the control group choosing to quit using an SCT method will not be eligible for smoking cessation treatment (SCT) reimbursement and, thus, will have to purchase their treatment out of pocket.
11575884|NCT00818194|Experimental|A. tacrolimus first|Subjects receive extended release tacrolimus in first dosing interval then cross over to cyclosporine A for second dosing interval
11575885|NCT00818194|Experimental|B. cyclosporine first|Subjects receive cyclosporine A in first dosing interval then cross over to extended release tacrolimus for second dosing interval
11575886|NCT00818181|Experimental|Solution of birch pollen allergen extract|In total up to 4 drops (dose for maintainace therapy)are administered under the tongue.
11575887|NCT00818168||Infliximab|Subjects with ankylosing spondylitis who were treated with infliximab. The dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC)
11575888|NCT00818155|Experimental|desvenlafaxine succinate SR|desvenlafaxine succinate SR
11575889|NCT00818155|Placebo Comparator|Placebo|
11575890|NCT00818142||eating disorder, type 1 diabetes|Individuals diagnosed with type 1 diabetes and an eating disorder who withhold their insulin.
11575891|NCT00818129|Experimental|1|
11575892|NCT00818129|Placebo Comparator|2|
11575893|NCT00818116|Experimental|ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL)
11575894|NCT00818103|Experimental|Atorvastatin, β-interferon, EPO|
11575895|NCT00818090|Experimental|TP|paclitaxel and cisplatin every 3 weeks
11575896|NCT00818077||Metformin, Type 2 Diabetes|
11575897|NCT00818064|Experimental|A, HV|Dose cohort 1 (3 subjects active, 1 placebo)
11575898|NCT00818064|Experimental|B, HV|Dose cohort 2 (3 subjects active, 1 placebo)
11575899|NCT00818064|Experimental|C, HV|Dose cohort 3 (3 subjects active, 1 placebo)
11575900|NCT00818064|Experimental|D, HV|Dose cohort 4 (3 subjects active, 1 placebo)
11575901|NCT00818064|Experimental|E, HV|Dose cohort 5 (3 subjects active, 1 placebo)
11575902|NCT00818064|Experimental|A, RA|Dose cohort 1 (3 subjects active, 1 placebo)
11575903|NCT00818064|Experimental|B, RA|Dose cohort 2 (3 subjects active, 1 placebo)
11575904|NCT00818064|Experimental|C, RA|Dose cohort 3 (3 subjects active, 1 placebo)
11575905|NCT00818051|Active Comparator|Arm I (control)|Patients undergo sequential boost dose intensity-modulated radiotherapy (IMRT) 5 days a week for 4.6 weeks (23 fractions; 56 Gy).
11575906|NCT00818051|Experimental|Arm II|Patients undergo concurrent boost dose IMRT 5 days a week for 3 weeks (15 fractions; 48 Gy).
11575907|NCT00818051|Experimental|Arm III|Patients undergo concurrent boost dose IMRT 5 days a week for 3 weeks (15 fractions; 53 Gy).
11575908|NCT00818038||TYSABRI|Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
11576115|NCT00816673|Placebo Comparator|placebo|
11575909|NCT00818025|No Intervention|Standard of Care|All subjects will receive standard care to prepare for discharge that consists of a one-on-one, pre-discharge educational session delivered by the transplant coordinator prior to hospital discharge and provision of a reference binder for each lung transplant recipient to take home.
11575910|NCT00818025|Experimental|Pocket PATH hand-held device|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
11575911|NCT00817999|Experimental|Loading Dose|Participants received a 300 mg dose of clopidogrel with or without GFJ.
11575912|NCT00817999|Experimental|Maintenance Dose|Participants received clopidogrel 75 mg/day for 7 days with or without GFJ
11575913|NCT00817986|Experimental|Arbaclofen placarbil 20 mg|Arbaclofen placarbil 20 mg, BID, for 14 days including the taper period.
11575914|NCT00817986|Placebo Comparator|Placebo for Arbaclofen placarbil|Placebo for 14 days
11575915|NCT00817986|Experimental|Arbaclofen placarbil 30 mg|Arbaclofen placarbil 30 mg, BID, for 14 days including the taper period.
11575916|NCT00817986|Experimental|Arbaclofen placarbil 40 mg|Arbaclofen placarbil 40 mg, BID, for 14 days including the taper period.
11575917|NCT00817973|Active Comparator|Casein|
11575918|NCT00817973|Active Comparator|Whey|
11575919|NCT00817973|Active Comparator|Cod|
11575920|NCT00817973|Active Comparator|Gluten|
11575921|NCT00817960|Experimental|Methylphenidate|
11575922|NCT00817947|Active Comparator|Usual airway clearance technique|Airway clearance using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure or oscillating positive expiratory pressure
11575923|NCT00817947|Other|HFCWO|High frequency chest wall oscillation
11575924|NCT00817934||PREVENTION AND TREATMENT|PATIENTS 50 YEARS AND OLDER REQUIRE SCREENING COLONOSCOPY. PATIENTS WITH FAMILY HISTORY OF COLON CANCER WILL REQUIRE IT BEFORE THE AGE OF 50.
11575925|NCT00817921||1|former premature children treated by ibuprofen
11575926|NCT00817921||2|former premature children not treated by ibuprofen
11575927|NCT00817921||3|former term children (control)
11575928|NCT00817908||1|Patients at high risk for CMV infection (CMV serostatus: D+/R-) who are expected to receive three months of antiviral prophylaxis.
11575929|NCT00817895|Experimental|5-FU+Cisplatin|50 HCC patients will be implanted 600mg sustained released 5-FU and 60mg sustained released cisplatin into liver incisal margin after tumor is resected.
11575930|NCT00817895|Active Comparator|5-FU|50 HCC patients will be implanted 600mg sustained released 5-FU into liver incisal margin after tumor is resected.
11575931|NCT00817895|Experimental|control|
11575932|NCT00817882|Experimental|1|individually targeted vocational rehabilitation
11575933|NCT00817882|Active Comparator|2|routine back pain rehabilitation
11575934|NCT00817869|Experimental|New Flooring|Will receive 8.3mm thick floor covering (Omnisports EXCEL) to replace previous floor covering.
11575935|NCT00817869|No Intervention|Standard Flooring|Ward will remain with standard floor covering. The overlay will have a comparable slip resistance rating to the new flooring. The sub-floor will also be comparable.
11575936|NCT00817843|Experimental|First Simva 80mg then Simvai/Eze10/10mg|First 6 weeks of Simvastatin 80mg, then 6 weeks of Simvastatin/Ezetimibe 10/10mg after 6 weeks of placebo washout
11575937|NCT00817843|Experimental|First Simva/Eze 10/10mg then Simva 80mg|First 6 weeks of Simvastatin/Ezetimibe 10/10mg, then 6 weeks of Simvastatin 80mg after 6 weeks of placebo washout
11575938|NCT00817830|Experimental|lodenafil carbonate|Evaluate cardiovascular safety of lodenafil carbonate in patients with coronary artery disease undergoing physical effort, before and after using lodenafil carbonate.
11575939|NCT00817817|Experimental|Group 1|
11575940|NCT00817817|Experimental|Group 2|
11575941|NCT00817804|Experimental|V60 then Conventional|Study device first
11575942|NCT00817804|Experimental|Conventional then V60|Conventional device first
11575943|NCT00817791|Experimental|HBO|
11575944|NCT00817778|Experimental|AZD1656|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
11575945|NCT00817778|Placebo Comparator|Placebo|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
11575946|NCT00817765|Active Comparator|Posaconazole alone|400mg posaconazole BID for 10 days (start on day 1 with 200mg QD, day 2 200mg BID; from day 3 onwards 400mg BID)
11575947|NCT00817765|Active Comparator|Fosamprenavir ritonavir|Fosamprenavir 700mg / ritonavir 100mg BID for 10 days
11575948|NCT00817765|Experimental|Fosamprenavir posaconazole|Fosamprenavir 700mg / posaconazole 400mg BID for 10 days (start on day 1 with 200mg QD, day 2 200mg BID; from day 3 onwards 400mg BID)
11575949|NCT00817752|Experimental|1|Receives Ashwagandha herb.
11575950|NCT00817739|Active Comparator|Continuous Therapy|Continuous complete androgen suppression therapy with leuprorelin 3.75 mg sustained release (SR), injection, subcutaneously once every 28 days and flutamide, 250 mg, tablet, orally thrice daily until there are signs of disease progression.
11575951|NCT00817739|Experimental|Intermittent therapy|Intermittent complete androgen suppression therapy starting at randomization with interruption of treatment given in the induction period until PSA levels reach >=10 ng/mL or other signs of progression appear. Upon treatment resumption, leuproreline 3.75 mg SR, injection, subcutaneously once every 28 days and flutamide 250 mg, tablet, orally thrice daily, until PSA levels are <normal (that is, <4 ng/mL) and no signs of disease progression appear. The intermittent therapy will be continued similarly until the study end or the appearance of signs of disease progression under treatment.
11575952|NCT00817726||1- RBD|polysomnographically diagnosed RBD patients. RBD is a sleep disorder diagnosed by a sleep lab in which the individual has muscle movements during the phase of deep sleep during which the muscles should be relaxed. Suspicion of RBD by history will be confirmed during screening.
11575953|NCT00817726||2 - control|"control:
~must not have any neurological degenerative diagnosis.
~must NOT have RBD.
~must be able to age and/or gender-match to RBD and PD subjects already enrolled."
11575954|NCT00817713|Active Comparator|anthelminthic treatment|Albendazol plus fix-dose Praziquantel plus Ivermectin
11576116|NCT00816673|Experimental|Circadin|
11575957|NCT00817700|Experimental|Sleep restriction|"Sleep restriction to 4 hours of sleep per night.
~Overnight sleep recording, measures of endocrine and metabolic (from blood), cardiovascular (measures of blood pressure and heart rate), performance ( before and after sleep restriction and after sleep recovery."
11575958|NCT00817687|Experimental|1|
11575959|NCT00817687|No Intervention|2|
11575960|NCT00817674||1|CKD subjects
11575961|NCT00817674||2|Healthy Controls
11575962|NCT00817661|Experimental|1|Vitamin A group
11575963|NCT00817661|Placebo Comparator|2|Placebo group
11575964|NCT00817648|Experimental|1|Quetiapine fumarate, flexible doses(600-750 mg/d)
11575965|NCT00817648|Active Comparator|2|risperidone, flexible doses(3-6 mg/d)
11575966|NCT00817635|Placebo Comparator|Placebo|
11575967|NCT00817635|Experimental|LCI699 dosing regimen 1|
11575968|NCT00817635|Experimental|LCI699 dosing regimen 2|
11575969|NCT00817635|Experimental|LCI699 dosing regimen 3|
11575970|NCT00817635|Active Comparator|Eplerenone 50 mg BID|
11575971|NCT00817622|Placebo Comparator|A|"Placebo, Placebo :
~Placebo pearls,500 mg QID for 12 Weeks (2000 mg corn oil per day) Placebo pearl + corn oil 400 mg per day for 12 weeks"
11575972|NCT00817622|Active Comparator|B|"EPA, Placebo :
~EPA pearls,500 mg QID for 12 Weeks (2000 mg per day),From MINAMINUTRITION Company(Belgium)+ Placebo pearl ,corn oil 400 mg per day for 12 weeks"
11575973|NCT00817622|Placebo Comparator|C|"Placebo ,Vitamin E :
~Placebo pearls,500 mg QID for 12 Weeks (2000 mg corn oil per day)+ Vitamin E pearls, 400 mg from DANA Company(IRAN) per day for 12 weeks"
11575974|NCT00817622|Active Comparator|D|"EPA, Vitamin E :
~EPA pearls,500 mg QID From MINAMINUTRITION Company(Belgium) for 12 Weeks (2000 mg EPA per day)+ Vitamin E pearls, 400 mg from DANA Company ( IRAN) per day for 12 weeks"
11575975|NCT00817609|Experimental|A|
11575976|NCT00817609|Placebo Comparator|B|
11575977|NCT00817583|Experimental|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous intravenous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of two cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.The radiation dose is 66-76Gy to the GTV, 60Gy to CTV1, and 54Gy to CTV2.
11575978|NCT00817570||1|Transfemoral Amputees using the C- Leg knee.
11575979|NCT00817570||2|Transfemoral Amputees using a Multiaxial Knee.
11575980|NCT00817570||3|Able bodied.
11575981|NCT00817557|Active Comparator|Loteprednol|Loteprednol BID
11575982|NCT00817557|Placebo Comparator|Rewetter|Rewetter BID
11575983|NCT00817544|Experimental|ORM-12741|ORM-12741
11575984|NCT00817531|Experimental|All subjects take open label Dasatinib|Dasatinib / Sprycel 100 mg
11575985|NCT00817518|Experimental|1|
11575986|NCT00817518|Experimental|2|
11575987|NCT00817505|Active Comparator|1|AZD1656 tablet + food
11575988|NCT00817505|Active Comparator|2|AZD1656 susp. without food
11575989|NCT00817505|Active Comparator|3|AZD1656 tablet
11575990|NCT00817492||1|Subjects with mild to moderate kidney disease
11575991|NCT00817492||2|Healthy Control Subjects
11575992|NCT00817479|Active Comparator|Dexamethasone|20 mg of dexamethasone
11575993|NCT00817479|Placebo Comparator|Placebo [Saline]|Saline
11575994|NCT00817466|Experimental|Racemic adrenaline, fixed intervals|Active drug with fixed intervals of inhalation, adjusted at least every 24h.
11575995|NCT00817466|Experimental|Racemic adrenalin, on demand|Racemic adrenaline, inhalations on demand (max every 2 hrs)
11575996|NCT00817466|Active Comparator|Saline, fixed intervals|Saline inhalation fixed intervals, adjusted at least every 24 hrs
11575997|NCT00817466|Active Comparator|saline on demand|Saline inhalations on demand, max every 2 hrs, adjusted every 12 hrs
11575998|NCT00817453||1|Clinically diagnosed Early iPD
11575999|NCT00817453||2|Age/gender matched controls without neurodegenerative diagnosis
11576000|NCT00817453||atypical or late Parkinsonian Syndromes|Includes subjects facing or having undergone DBS, diagnoses of MSA, PSP or other atypical syndromes.
11576001|NCT00817440|No Intervention|Control|control: muscle and fat biopsies and basal aminoacid and glucose turnover
11576002|NCT00817440|Experimental|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
11576003|NCT00817440|Experimental|Fasting|3 days of fasting and then the same as arm 1
11576004|NCT00817427|No Intervention|Baseline|CKD subjects and healthy, matched controls will have measures of cardiovascular function (BP, HR) measure of hormonal fluid balance (renin/aldosterone) measure and measures of glucose metabolism (response to glucose load and over 24 hr profile) with 3 days of habitual sleep time
11576005|NCT00817427|Experimental|CKD- Sleep extension|Measures as in baseline but with bed time increased by 2 hours
11576006|NCT00817427|Experimental|Controls short sleep|Measures as in baseline but with sleep disruption
11576007|NCT00817414|Placebo Comparator|Cohort A, Placebo|
11576008|NCT00817414|Experimental|Cohort A, LCI699 dosing regimen 1|
11576009|NCT00817414|Experimental|Cohort A, LCI699 dosing regimen 2|
11576010|NCT00817414|Placebo Comparator|Cohort B, Placebo|
11576011|NCT00817414|Experimental|Cohort B, LCI699 dosing regimen 3|
11576012|NCT00817414|Experimental|Cohort B, LCI699 dosing regimen 4|
11576013|NCT00817388||1|patients will be asked to provide a urine specimen and complete a questionnaire.
11576014|NCT00817375|Experimental|SSRI treated group|SSRI treated group is depressive patients treated with fluoxetine, paroxetine, or sertraline
11576015|NCT00817375|Active Comparator|non-SSRI treated group|non-SSRI treated group is depressive patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine
11576059|NCT00817037|Placebo Comparator|Placebo|"Once daily oral placebo tablet given over a period of 6 weeks.
~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
11576060|NCT00817037|Active Comparator|Nifedipine|"Open labeled active comparator
~Once daily oral nifedipine 30mg given over a period of 6 weeks.
~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
11576061|NCT00817024|Experimental|Xuefu Zhuyu Capsules|
11576117|NCT00816660|Experimental|1|
11576016|NCT00817362|Experimental|IPI-504 and Trastuzumab|"IPI-504 IV infusion 300 mg/m2 once weekly in combination with trastuzumab infusion every 3 weeks. (Continuous schedule)
~Three week cycle with IPI-504 twice per week for 2 weeks and trastuzumab once per cycle followed by one week without treatment.
~Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was <4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.
~IPI-504 and trastuzumab will be administered for all cycles. Until progression or unacceptable toxicity develops."
11576017|NCT00817336|Experimental|D-serine|60 mg/kg/day
11576018|NCT00817336|Placebo Comparator|Placebo|
11576019|NCT00817323|Experimental|Quetiapine fumurate (Seroquel)|See Detailed description
11576020|NCT00817310||Severe IVH|Infants born at less than 1500g with diagnosis of Grade II or IV IVH
11576021|NCT00817310||control|infants born at less than 1500g without IVH on HUS
11576022|NCT00817297|Other|V60 Mask, Then Conventional Mask|Experimental V60 Mask Ventilator for treating adult patients with COPD, then Comparator Conventional Mask Ventilator for treating adult patients with COPD
11576023|NCT00817297|Other|Conventional Mask, Then V60 Mask|Comparator Conventional Mask noninvasive Ventilator for treating adult patients with COPD, then Experimental V60 Mask noninvasive Ventilator for treating adult patients with COPD.
11576024|NCT00817284|Experimental|arm I|Bevacizumab + Irinotecan and concomitant radiotherapy
11576025|NCT00817284|Experimental|Arm II|Bevacizumab and Temozolomide and concomitant radiotherapy
11576026|NCT00817271|Experimental|1|
11576027|NCT00817271|Experimental|2|
11576028|NCT00817258|Other|1|All patients will receive radical radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
11576029|NCT00817245|Active Comparator|1|Oral Amoxicillin Capsule Metronidazole Tablet Omeprazole Capsule
11576030|NCT00817245|No Intervention|2|No medical treatment
11576031|NCT00817232|Experimental|Treatment 1|50 microamp amplitude
11576032|NCT00817232|Experimental|Treatment 2|500 microamp amplitude
11576033|NCT00817219|Experimental|TACLONEX ointment|
11576034|NCT00817206|Experimental|LCP-Tacro|LCP-Tacro tablets™, once daily (LifeCycle Pharma A/S, Hoersholm DK)
11576035|NCT00817206|Active Comparator|Prograf (tacrolimus)|Prograf® capsules, twice daily (Astellas Pharma US, Deerfield IL)
11576036|NCT00817193|Experimental|Physical Activity|Participants will begin to participate in walking sessions and strength building classes that will be offered at each location. Participants will be asked to attend a minimum of 1 strength class per week, with a target of doing 150 minutes of moderate exercise each week. The exercise classes will include stretching and counseling to help participants understand and address the barriers to becoming and staying involved in regular exercise.
11576037|NCT00817193|Active Comparator|Wellness|Participants will begin to participate in a wellness program that will meet at each site twice per month. The first meeting will involve a lecture or presentation on a wellness-related topic. The second meeting will follow-up on concepts that were introduced in the first meeting, and will also to provide participants an opportunity to share experiences. Participants will be asked to attend both wellness sessions each month for whole year that the program is running.
11576038|NCT00817180|Active Comparator|A|Positive Expiratory Pressure (PEP) - an airway clearance technique
11576039|NCT00817180|Active Comparator|B|High Frequency Chest Wall Oscillation (HFCWO) also known as the 'Vest technique' - an airway clearance technique.
11576040|NCT00817167|Experimental|inReach (A)|Bronchoscopy procedure is planned using inReach planning software
11576041|NCT00817167|Active Comparator|Control (B)|Bronchoscopy procedure is planned using standard CT viewer software
11576042|NCT00817154|Experimental|Hopes-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
11576043|NCT00817141||Without urinary catheter|
11576044|NCT00817128|Experimental|1|PEPT after randomization
11576045|NCT00817128|Experimental|2|CBO after randomization
11576046|NCT00817115|No Intervention|1|Subjects undergoing routine cardiac catheterization or interventional procedures using the standard fluoroscopy system.
11576047|NCT00817115|Experimental|2|Subjects undergoing routine cardiac catheterization or interventional procedures using the region-of-interest fluoroscopy (x-ray fovea imaging) system.
11576048|NCT00817102|Other|CorCTA|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures
11576049|NCT00817089|Placebo Comparator|Group 1 Asn40 Placebo Placebo|Each alcohol session preceded by pretreatment with placebo oral tablet
11576050|NCT00817089|Active Comparator|Group 2 Asn40 Placebo Naltrexone|The first alcohol session preceded by pretreatment with placebo oral tablet. The second alcohol session preceded by pretreatment with naltrexone 50 mg as a single dose.
11576051|NCT00817089|Placebo Comparator|Group 3 Asp40 Placebo Placebo|Each alcohol session preceded by pretreatment with placebo oral tablet
11576052|NCT00817089|Active Comparator|Group 4 Asp40 Placebo Naltrexone|The first alcohol session preceded by pretreatment with placebo oral tablet. The second alcohol session preceded by pretreatment with naltrexone 50 mg as a single dose.
11576053|NCT00817076|Experimental|1|
11576054|NCT00817063|Experimental|Alitretinoin|Patients will receive alitretinoin 30mg capsule for up to 24 weeks
11576055|NCT00817063|Experimental|Placebo|Patients will receive placebo 30mg capsule for up to 24 weeks
11576056|NCT00817050|Active Comparator|Nasonex Followed by Flonase|
11576057|NCT00817050|Active Comparator|Flonase Followed by Nasonex|
11576058|NCT00817037|Experimental|Sitaxsentan|"Once daily oral sitaxsentan 100mg given over a period of 6 weeks.
~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
11576062|NCT00817024|Active Comparator|Sheng Mai Capsules|
11576064|NCT00817011|Experimental|SSRI treated group|SSRI treated group are depressive patients treated with fluoxetine, paroxetine, citalopram or sertraline
11576065|NCT00817011|Active Comparator|non-SSRI treated group|non-SSRI treated group are depressive patients treated with venlafaxine, nortriptyline, bupropion, duloxetine, trazodone or mirtazapine
11576066|NCT00816998|Other|Early|Participants randomized to this arm will begin physical therapy of their fractured wrist approximately one week following surgery
11576067|NCT00816998|Other|Delayed|Participants randomized to this group will begin physical therapy of their fractured wrist approximately 6 weeks from their surgery. This is the approximate time frame in which therapy begins for patients not involved in the study. The term Delayed refers to therapy being delayed in starting from those in the study who begin therapy at one week post-operatively, not a delay in current care practice.
11576068|NCT00816985|Experimental|Liposuction + Questionnaires|Liposuction, followed by Quality of Life Questionnaires and extended follow-up period.
11576069|NCT00816972|Active Comparator|DL 2.5 mg|Desloratadine 2.5 mg twice daily (BID) + Placebo for Oxybutynin 2.5 mg BID for 7 days
11576070|NCT00816972|Active Comparator|OXY 5 mg|Placebo for Desloratadine 2.5 mg BID + Oxybutynin 5 mg BID for 7 days
11576071|NCT00816972|Experimental|DL 2.5 mg + OXY 2.5 mg|Desloratadine 2.5 mg BID + Oxybutynin 2.5 mg BID + Placebo for Oxybutynin 2.5 mg BID for 7 days
11576072|NCT00816972|Experimental|DL 2.5 mg + OXY 5 mg|Desloratadine 2.5 mg BID + Oxybutynin 5 mg BID for 7 days
11576073|NCT00816972|Placebo Comparator|Placebo|Placebo for Desloratadine 2.5 mg BID + Placebo for Oxybutynin 2.5 mg BID for 7 days
11576074|NCT00816959|Active Comparator|Arm I: R-mabHDI and ABVD|
11576075|NCT00816959|Active Comparator|Arm II: ABVD|
11576076|NCT00816946|No Intervention|Routine LHW Advice|Arm receiving routine advice by their local Lady Health Workers (LHWs)
11576077|NCT00816946|Active Comparator|Enhanced LHW Advice|Arm receiving enhanced nutrition and health advice from the local Lady Health Workers (LHWs)during their routine community visits.
11576078|NCT00816933|Experimental|one port|Patients undergo one port appectomy. Skin incision about 2cm size is made upon umbilicus and dissection is performed to make opening. Then, wound retractcor(Alexis) is iserted on opening site and wound is extended. Rubber glove built-in three 5mm trocars is applied over wound retractor. Pneumoperitoneum is achieved via trocar and appendectomy is performed. After appendectomy, wound is repaired.
11576079|NCT00816933|Active Comparator|Three ports|"Paitents will undergo three port appendectomy. 10 mm trocar is inserted on umbilicus, and two 5mm trocas is inserted low abdomen, left flank respectively.
~Appendectomy is performed vis these trocas. After operation, wounds are repaired."
11576080|NCT00816920||1|Outpatients with suspected leg DVT after exclusion of proximal DVT
11576081|NCT00816907|Experimental|Metformin|Encapsulated metformin 1000-2000 mg/day
11576082|NCT00816907|Placebo Comparator|Placebo|Matching placebo capsules 2-4 daily
11576083|NCT00816894|Experimental|D-serine arm|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes.
11576084|NCT00816894|Active Comparator|Olanzapine arm|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
11576085|NCT00816881|Experimental|1|flutter mucus clearance device
11576086|NCT00816881|No Intervention|2|Observation
11576087|NCT00816868|Experimental|non-small cell lung cancer (NSCLC)|erlotinib in combination with capecitabine as first-line treatment in elderly patients with stage IIIB/IV adenocarcinoma non-small cell lung cancer (NSCLC)
11576088|NCT00816855|Other|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of three cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
11576089|NCT00816829|Placebo Comparator|1|Fenofibrate-matching placebo tablet
11576090|NCT00816829|Experimental|2|145 mg NanoCrystal fenofibrate tablet
11576091|NCT00816816|Other|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of three cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
11576092|NCT00816803|Experimental|BM transplant with physiotherapy|Autologous BM transplant
11576093|NCT00816803|Active Comparator|Physiotherapy only|conventional physical therapy for chronic spinal cord injury.
11576094|NCT00816790|Active Comparator|Dose Adjusted|This arm will receive their broad spectrum antibiotic as an adjusted dose based on their renal function as measured when sepsis is diagnosed and antimicrobials are initiated
11576095|NCT00816790|Experimental|Unadjusted Dose|This arm will receive their broad spectrum antibiotic as an unadjusted dose regardless of their renal function
11576096|NCT00816777|Experimental|Chemoembolization|Chemoembolization with Irinotecan Bead in combination with Intravenous Chemotherapy Group (test arm)
11576097|NCT00816777|Active Comparator|Chemotherapy|Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks
11576098|NCT00816764|Experimental|1. AGS-8M4 Dose 1|
11576099|NCT00816764|Experimental|2. AGS-8M4 Dose 2|
11576100|NCT00816764|Experimental|3. AGS-8M4 Dose 3|
11576101|NCT00816764|Experimental|4. AGS-8M4 Dose 4|
11576102|NCT00816751|Active Comparator|1|
11576103|NCT00816751|Experimental|2|
11576104|NCT00816725|Experimental|Self-help course and information|
11576105|NCT00816712|Active Comparator|A|Testosterone - 300 mg IM
11576106|NCT00816712|Active Comparator|B|Testosterone - 100 mg IM
11576107|NCT00816712|Placebo Comparator|C|Placebo - IM
11576108|NCT00816699|Placebo Comparator|1|Routine anesthetic risk information
11576109|NCT00816699|Active Comparator|2|Preprint preoperative risk information
11576110|NCT00816686|Experimental|1. AGS-16M18 Dose 1|
11576111|NCT00816686|Experimental|2. AGS-16M18 Dose 2|
11576112|NCT00816686|Experimental|3. AGS-16M18 Dose 3|
11576113|NCT00816686|Experimental|4. AGS-16M18 Dose 4|
11576114|NCT00816686|Experimental|5. AGS-16M18 Dose 5|
11576119|NCT00816647|Active Comparator|1|Medial patellofemoral ligament reconstruction
11576120|NCT00816647|Active Comparator|2|Medial reefing
11576121|NCT00816634|Active Comparator|1|"Chemotherapy regimen (XP):
~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr repeat every 3 weeks"
11576122|NCT00816634|Active Comparator|2|"XT Regimen:
~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs Repeat every 3 weeks"
11576123|NCT00816621|Experimental|ABC for Children Adopted Internationally|ABC for Children Adopted Internationally: 10 session in home intervention that targets parent nurturance, synchrony, pseudo-autistic behaviors, and indiscriminate sociability
11576124|NCT00816621|Active Comparator|DEF for Children Adopted Internationally|DEF for Children Adopted Internationally: 10 session in home intervention that targets cognitive and motor delays
11576125|NCT00816608||type 2 diabetes|
11576126|NCT00816595|Experimental|Arm A: Pentostatin, Cyclophosphamide, Rituximab, and Avastin|Patients receive 15 mg/kg bevacizumab IV over 30-90 minutes on day 1 of courses 1-5 and on days 1, 22, and 43 of course 6; 375 mg/m^2 rituximab IV over 2-4 hours on days 2 and 3 of course 1 and on day 1 of courses 2-6; and 2 mg/m^3 pentostatin IV over 30 minutes and 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 2 of course 1 and on day 1 of courses 2-6. Patients also receive 6 mg pegfilgrastim subcutaneously (SC) on day 3 of course 1 and on day 2 of courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11576127|NCT00816595|Experimental|Arm B: Pentostatin, Cyclophosphamide, and Rituximab|Patients receive 100 mg rituximab IV over 2-4 hours on day 1 and 375 mg/m^2 on day 2 of course 1 and 375 mg/m^2 on day 1 of courses 2-6. They receive 2 mg/m^2 pentostatin IV over 30 minutes and 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1. Patients also receive 6 mg pegfilgrastim SC on day 2. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11576128|NCT00816582|Experimental|PET/CT Guided FES Therapy|All subjects will be seen at baseline and then monthly until month 6 of fulvestrant therapy unless clinical or radiological progression or unacceptable toxicity earlier than month 6.
11576129|NCT00816569|Experimental|Keratoconus|One eye of Keratoconus patient
11576130|NCT00816556|Active Comparator|Estriol|Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
11576131|NCT00816556|Active Comparator|Estradiol|Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
11576132|NCT00816556|Placebo Comparator|Vanicream Lite|Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
11576133|NCT00816543|Experimental|1|3 cycles of neoadjuvant chemotherapy of Docetaxel, Oxaliplatin and S-1. Surgery 5 to 6 weeks after completion of the chemotherapy.
11576134|NCT00816530||Asymptomatic Women who have Dense Breast Tissue|Women who have no signs or symptoms of breast cancer who have > 50% parenchymal density on mammography.
11576135|NCT00816517|Experimental|botulinum toxin|injection of botulinum toxin type A
11576136|NCT00816504|Experimental|1|Galactose
11576137|NCT00816491|Active Comparator|A|Conventional white light colonoscopy
11576138|NCT00816491|Experimental|B|Chromoendoscopy
11576139|NCT00816478|Experimental|1|Galactose
11576140|NCT00816465|Experimental|1|Patients receiving Hoodia
11576141|NCT00816465|Placebo Comparator|2|Patients receiving placebo
11576142|NCT00816426|Other|1|Dosing 2 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
11576143|NCT00816426|Other|2|Dosing 4 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
11576144|NCT00816426|Other|3|Dosing 8 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
11576145|NCT00816426|Other|4|Dosing 12 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
11576146|NCT00816426|Other|5|Dosing 24 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
11576147|NCT00816400|Experimental|MEDI-575, 3.0 mg/kg QWk Escalation Phase (Cohort 1)|Single lead-in dose of MEDI-575 at 0.5 mg/kg as a 60-minute intravenous (IV) infusion administered 7 days prior to first dose at 3.0 mg/kg; MEDI-575 administered at 3.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (once every 7 days [QWk]) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
11576148|NCT00816400|Experimental|MEDI-575, 6.0 mg/kg QWk Escalation Phase (Cohort 2)|MEDI-575 administered at 6.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
11576149|NCT00816400|Experimental|MEDI-575, 9.0 mg/kg QWk Escalation Phase (Cohort 3)|MEDI-575 administered at 9.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
11576237|NCT00815815|Active Comparator|Continued inpatient treatment|Participants will undergo inpatient hospital treatment until they have gained enough weight to be discharged.
11576393|NCT00814671|Experimental|RPT 600|Rifapentine 600mg daily
11576150|NCT00816400|Experimental|MEDI-575, 12 mg/kg QWk Escalation Phase (Cohort 4)|MEDI-575 administered at 12.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
11576151|NCT00816400|Experimental|MEDI-575, 15 mg/kg QWk Escalation Phase (Cohort 5)|MEDI-575 administered at 15.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
11576152|NCT00816400|Experimental|MEDI-575, 25 mg/kg Q3Wk Escalation Phase (Cohort 6)|MEDI-575 administered at 25.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (once every 21 days [Q3Wk]) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
11576153|NCT00816400|Experimental|MEDI-575, 35 mg/kg Q3Wk Escalation Phase (Cohort 7)|MEDI-575 administered at 35.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (Q3Wk) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
11576154|NCT00816400|Experimental|MEDI-575, 9.0 mg/kg QWk Expansion Phase|MEDI-575 administered at 9.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
11576155|NCT00816400|Experimental|MEDI-575, 25 mg/kg Q3Wk Expansion Phase|MEDI-575 administered at 25.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (Q3Wk) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
11576156|NCT00816387|Active Comparator|IUI|Intrauterine insemination using standard catheter
11576157|NCT00816387|Experimental|FSP|Fallopian tube sperm perfusion using a commercial device for hysterosalpingography and tubal hydropertubation
11576158|NCT00816374|Other|1|Group I
11576159|NCT00816374|Other|2|Group II
11576160|NCT00816361|Experimental|MEDI-573 0.5 mg/Kg QWk Dose Escalation|Participants received MEDI-573 0.5 milligram per kilogram (mg/kg) as a 60-minute intravenous (IV) infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
11576161|NCT00816361|Experimental|MEDI-573 1.5 mg/Kg QWk Dose Escalation|Participants received MEDI-573 1.5 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
11576162|NCT00816361|Experimental|MEDI-573 5 mg/Kg QWk Dose Escalation|Participants received MEDI-573 5 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
11576163|NCT00816361|Experimental|MEDI-573 10 mg/Kg QWk Dose Escalation|Participants received MEDI-573 10 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
11576164|NCT00816361|Experimental|MEDI-573 15 mg/Kg QWk Dose Escalation|Participants received MEDI-573 15 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
11576165|NCT00816361|Experimental|MEDI-573 30 mg/Kg Q3Wk Dose Escalation|Participants received MEDI-573 30 mg/kg as a 90-minute IV infusion once every 21 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
11576166|NCT00816361|Experimental|MEDI-573 45 mg/Kg Q3Wk Dose Escalation|Participants received MEDI-573 45 mg/kg as a 90-minute IV infusion once every 21 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
11576167|NCT00816361|Experimental|MEDI-573 5 mg/Kg QWk Dose Expansion|Participants received MEDI-573 5 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
11576168|NCT00816361|Experimental|MEDI-573 15 mg/Kg QWk Dose Expansion|Participants received MEDI-573 15 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
11576169|NCT00816348|Other|Omegaven|All subjects will receive Omegaven
11576170|NCT00816335|Experimental|Arm 1|F-FDG-directed surgery for known or suspected malignancy using gamma detection probes.
11576171|NCT00816322|Active Comparator|omega-3 fatty acids|EPA 2.1 g/d+DHA 1.1 g/d
11576172|NCT00816322|Placebo Comparator|Placebo|high oleic oil
11576173|NCT00816309|Experimental|Acapella Physiotherapy|Physiotherapy with acapella versus no physiotherapy
11576174|NCT00816309|No Intervention|No physiotherapy|Physiotherapy with acapella versus no physiotherapy
11576175|NCT00816296||Controls|Obese (BMI>30) and normal AST and ALT. Between the ages of 5 and 18 years old.
11576176|NCT00816296||Liver Disease|Obese (BMI>30) and elevated AST and/or ALT (evidence of NAFLD). Between the ages of 5 and 18 years old.
11576177|NCT00816270|Experimental|1|Experimental operatory wound closure with liquid bandage (Johnson & Johnson, Skillman, NJ, USA).
11576178|NCT00816244|Experimental|Atorvastatin|
11576179|NCT00816231|Experimental|Alcohol and Nicotine Group|Alcohol and Nicotine Drug/Cue Interactions
11576180|NCT00816231|Active Comparator|Alcohol Only Group|Alcohol Only Drug/Cue Interactions
11576181|NCT00816231|Active Comparator|Nicotine Only Group|Nicotine Only Drug/Cue Interactions
11576182|NCT00816231|Placebo Comparator|Placebo and Placebo Group|Placebo Only Drug/Cue Interactions
11576183|NCT00816218|Experimental|Pioglitazone|Fifty type 2 diabetic patients (25 diet-treated and 25 treated with diet plus sulfonylurea) will have pioglitazone, 45 mg daily; added to their therapeutic regimen. All patients will be closely monitored and, in addition to periodic contacts and clinical visits, metabolic and vascular parameters will be assessed at the beginning and after 3 and 6 months of therapy. Euglycemic hyperinsulinemic clamp with muscle biopsies will be performed at the beginning and after 6 months of treatment.
11576184|NCT00816205|Experimental|Single Arm|This is an open label, dose-finding study. After detrminig baseline resting anal pressure with a manometric test, coated Suppositories will be administered intra rectally. Subjects will take rectally a total of 3 Coated Suppositories per study.
11576292|NCT00815334|Experimental|Patients with decreased bladder compliance|Patients who have decreased bladder compliance
11576185|NCT00816192|Active Comparator|1|"The externally irrigated-tip catheter is an open system in which saline is continuously infused and empties into the blood pool. For the externally irrigated-tip catheter, RF energy delivery settings were: power ≤ 35 watts and temperature ≤ 43°C with a variable flow-rate to obtain a temperature around 40°C."
11576186|NCT00816192|Experimental|2|"For the internally irrigated tip catheter (reference catheter), radiofrequency (RF) energy delivery settings will be: power ≤ 35 watts, temperature ≤ 47◦C and a fixed flow rate of 0.6 ml/s.
~The advantage of the Chili thermo-cooled tip system is that no saline solution leaves the catheter system and flows into the patient."
11576187|NCT00816166|Experimental|Stent Group|"Medical therapy + PHAROS Vitesse neurovascular stent (Stent Group)"
11576188|NCT00816166|Active Comparator|Medical Therapy Group|"Medical therapy alone (Medical Therapy Group)"
11576189|NCT00816153|Experimental|PVI|PVI guided fluid management
11576190|NCT00816153|No Intervention|Control|
11576191|NCT00816140|Active Comparator|Klaricid, triple therapy|Klaricid based triple therapy
11576192|NCT00816140|Experimental|Cravit, triple therapy|Cravit based triple therapy
11576193|NCT00816127|Experimental|1|DDAVP
11576194|NCT00816127|Active Comparator|2|Standard Treatment
11576195|NCT00816114||Chronic Myelogenous Leukemia|All CML patients in any phase of the disease that received imatinib treatment outside of MDACC clinical trials and has had at least one MDACC clinic visit.
11576196|NCT00816101|Experimental|PROCELLERA™Antimicrobial Dressing|Dressing changes every 3 days, more frequently if needed
11576197|NCT00816101|Active Comparator|Mepilex® Border Lite|Dressing changes every 2-3 days, more frequently if needed
11576198|NCT00816101|Active Comparator|Band-Aid® Adhesive Bandage|Dressing changes every 2-3 days, more frequently if needed.
11576199|NCT00816088||neutropenia|Patients undergoing stem cell transplantation or chemotherapy likely to lead to prolonged neutropenia.
11576200|NCT00816075|Experimental|1, Distilled water|the group of patients with superficial bladder cancer in the intermediate risk group who had their first recurrence after 6 months from the initial TUR. We plan to administer 200 ml of distilled water as immediate instillation for 2 hours
11576201|NCT00816062|Experimental|Treatment|Patients diagnosed with an abdominal aortic or aorto-iliac aneurysm that are considered candidates for endovascular repair, per the FDA approved IFU.
11576202|NCT00816049|Active Comparator|6MPfixed|Fixed dose 6-mercaptopurine days 30-85
11576203|NCT00816049|Experimental|6MPindividualized|Individualized dose increments of 6-mercaptopurine days 30-85
11576204|NCT00816036|No Intervention|Arm 1|Baseline Period
11576205|NCT00816036|Experimental|Arm 2|Intervention Period
11576206|NCT00816023|Experimental|Ecallantide Low Dose|target steady state concentration of 0.15 mg/L
11576207|NCT00816023|Experimental|Ecallantide Medium Dose|target steady state concentration of 0.75 mg/L
11576208|NCT00816023|Experimental|Ecallantide High Dose|target steady state concentration of 2.25 mg/L
11576209|NCT00816023|Placebo Comparator|Placebo|placebo
11576210|NCT00816010|Experimental|1|Lifestyle and compliance counseling via telephone contact with structured set of questions and reinforcements provided
11576211|NCT00816010|No Intervention|2|Control arm with usual care as per local hospital practice
11576212|NCT00815997|Sham Comparator|6-Fr TRI (transradial coronary intervention)|TRI will be performed using a 6-Fr guiding catheter.
11576213|NCT00815997|Active Comparator|4-Fr TRI|TRI will be performed using a 4-Fr guiding catheter.
11576214|NCT00815984||Schoolchildren with asthma.|Schoolchildren with asthma.
11576215|NCT00815971||NSCLC|Patients with non-small cell lung cancer carcinoma treated with erlotinib
11576216|NCT00815958|Experimental|A|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)
11576217|NCT00815958|Active Comparator|B|Reaming with conventional reamer
11576218|NCT00815945|Experimental|PegLiposomal Doxorubicin + Carboplatin|Subjects will receive PegLiposomal Doxorubicin (40mg/m²) and Carboplatin (AUC6) every 28 days. Treatment period up to 6 months (therapy can be continued in case of tumor response and benefit for the patient)
11576219|NCT00815932|Experimental|1-CRPS|10 tDCS naïve patients with CRPS-related neuropathic pain in upper limb
11576220|NCT00815932|Experimental|2-DN|20 tDCS naïve patients with diabetic neuropathy
11576221|NCT00815932|Experimental|3-RPNP|20 tDCS naïve patients with resistant peripheral neuropathic pain
11576222|NCT00815932|Experimental|4-CIPN|10 tDCS naïve patients with CIPN-Chemotherapy Induced Pain Neuropathy patients
11576223|NCT00815919|Experimental|Velcade (bortezomib)|
11576224|NCT00815906|Experimental|SBI-087 0.15 mg IV|
11576225|NCT00815906|Experimental|SBI-087 0.5 mg IV|
11576226|NCT00815906|Experimental|SBI-087 100 mg SC|
11576227|NCT00815906|Experimental|SBI-087 200 mg SC|
11576228|NCT00815893|Experimental|1 dex group|received dexmedetomidine (1.0 mcg/kg) infusion
11576229|NCT00815893|Placebo Comparator|2 control group|received 0.9% saline
11576230|NCT00815893|Active Comparator|3 Propofol group|received 1% propofol using effect-site TCI(Base Primea, Fresenius, France)
11576231|NCT00815880|Active Comparator|Implantable Counterpulsation Therapy|The study is a single arm study with 20 patients being treated with implantable counterpulsation. Patients that meet eligibility will be enrolled and implanted into the treatment arm of the study. These patients will receive the C-Pulse System Implant as intervention therapy. There is not a control arm in this feasibility study.
11576232|NCT00815867|Experimental|A|Patient will receive Epoetin Beta
11576233|NCT00815867|No Intervention|B|
11576234|NCT00815854|Experimental|Folate|"During Phase 1, participants will undergo screening for metabolic syndrome and have genetic makeup, body size, and endothelial functioning measured. During Phase 2, participants will receive daily folic acid as a treatment for metabolic syndrome.
~Phase 2B participants will receive either daily folic acid or placebo as a treatment for metabolic syndrome."
11576235|NCT00815854|Placebo Comparator|Placebo|"During Phase 1, participants will undergo screening for metabolic syndrome and have genetic makeup, body size, and endothelial functioning measured. During Phase 2, participants will receive daily folic acid as a treatment for metabolic syndrome.
~Phase 2B participants will receive either daily folic acid or placebo as a treatment for metabolic syndrome."
11576236|NCT00815828|Other|1|Group that don't do the resistance exercises
11576238|NCT00815815|Experimental|Sequenced treatment|Participants will begin with inpatient treatment, transition to day patient treatment, and then transition to outpatient treatment.
11576239|NCT00815789|Experimental|Intervention|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
11576240|NCT00815789|No Intervention|Control|Receive educational material about CVD reduction at baseline
11576241|NCT00815776|Experimental|1|Treatment group receiving the CID
11576242|NCT00815776|Active Comparator|2|Group assigned a mouth splint
11576243|NCT00815776|Active Comparator|Exercise Control Group|Group who received no device but were instead assigned a study-specified jaw exercise program
11576244|NCT00815763|Experimental|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg once a day and continued for 14 days
11576245|NCT00815763|Placebo Comparator|placebo|infusion placebo (group B)once a day and continued for 14 days
11576246|NCT00815750|Other|Phase I - Information Gathering|
11576247|NCT00815750|Other|Phase 2 - Decision Aid|
11576248|NCT00815737|Experimental|A|
11576249|NCT00815737|Placebo Comparator|B|
11576250|NCT00815724|Experimental|1|Participants will take part in a distance learning group.
11576251|NCT00815724|No Intervention|2|Participants in the control group will not receive any study materials or take part in any study activities.
11576252|NCT00815698|Active Comparator|no suture|self-adhesive mesh, i.e. no suture for mesh fixation
11576253|NCT00815698|Experimental|Suture|Suture for mesh fixation
11576254|NCT00815685|Experimental|Eicosapentaenoic Acid|
11576255|NCT00815672|No Intervention|Treatment Arm 1|Usual Care: Standard care monitoring
11576256|NCT00815672|Experimental|Treatment arm 2|Home-based Exercise: Progressive walking and resistance exercise treatment.
11576257|NCT00815659|Experimental|Rosuvastatin|medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
11576258|NCT00815646|Experimental|Sildenafil|Measurements of pulmonary and systemic pressures during cold water immersion before and after sildenafil 50 mg orally.
11576259|NCT00815633|Experimental|Alefacept|Treatment Group (only one group)
11576260|NCT00815620||1|patients undergoing local ablative therapy such as transcatheter-arterial chemoembolization or selective interal radiotherapy
11576261|NCT00815620||2|patients undergoing surgery or radiofrequency ablation
11576262|NCT00815620||3|patients undergoing peptide receptor radiotherapy
11576263|NCT00815581|Other|photorefraction|
11576264|NCT00815568|Experimental|Regimen|Conditioning regimen for AML with FLT3 mutation, AML/MDS unfavorable cytogenetic risk group, chemorefractory NHL or HD, or ALL/CML
11576265|NCT00815555||1|Women diagnosed with receptor positive breast cancer, treated with Tamoxifen
11576266|NCT00815542|Active Comparator|double balloon catheter|Cervical ripening by double balloon catheter
11576267|NCT00815542|Placebo Comparator|prostaglandins E2|cervical ripening using prostaglandins E2
11576268|NCT00815516|Experimental|Micafungin|Infants received micafungin at a dose of 10 mg/kg per day by intravenous infusion for a minimum of 21 days to a maximum of 28 days for infants without end-organ dissemination or for a maximum of 42 days for infants with end-organ dissemination.
11576269|NCT00815516|Active Comparator|Amphotericin B deoxycholate|Infants received amphotericin B deoxycholate (CAB) at a dose of 1.0 mg/kg per day by intravenous infusion for a minimum of 21 days to a maximum of 28 days for infants without end-organ dissemination or for a maximum of 42 days for infants with end-organ dissemination.
11576270|NCT00815503|Active Comparator|Ropivacaine|
11576271|NCT00815503|Placebo Comparator|Saline|
11576272|NCT00815490|Experimental|Desaturation|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
11576273|NCT00815477|Active Comparator|1|Waitlist control with generic Information about lifestyle and hypertension
11576274|NCT00815477|Experimental|2|Web-based intervention of lifestyle counseling messages based on the transtheoretical model of readiness for change.
11576275|NCT00815464|Experimental|Antiviral Therapy|Liquid Acupuncture(Herb Acupoints Injection) Therapeutics was researched and developed by Herbalist Yu Ru Lin in early of 1950s and used by Yu Medical Garden till now. It is an integrated therapeutics,according to individual condition, select the Acupoints(not limit to current used common acupoints) and proper herbs made individually.It is a special medical treatment conception, which theory is utilizing patients' condition, mobilizing their individual internal curability,therefore the final efficacy can be retrieved.
11576276|NCT00815451|Placebo Comparator|placebo dark chocolate|polyphenol-poor dark chocolate
11576277|NCT00815451|Experimental|polyphenol-rich dark chocolate|
11576278|NCT00815438|Experimental|Surgical Procedure|Laparoscopic transvaginal cholecystectomy with endoscopic assistance.
11576279|NCT00815425||African Americans with RA|1063 participants with RA
11576280|NCT00815425||African-Americans without RA|550 participants without RA
11576281|NCT00815412|Active Comparator|Counseling in use of health care|
11576282|NCT00815412|Active Comparator|Counseling in diet, exercise|
11576283|NCT00815412|Placebo Comparator|Contol group|
11576284|NCT00815399|Experimental|1|
11576285|NCT00815399|Active Comparator|2|
11576286|NCT00815386|Experimental|PTMA implanted|Enrolled patients receiving a PTMA implant
11576287|NCT00815373|Active Comparator|1|Cosopt* b. i. d. (dosed morning and bedtime) will be administered topically
11576288|NCT00815373|Active Comparator|2|Xalacom* q.d.(dosed bedtime) and placebo vehicle q.d. (dosed morning) topically in the other group
11576289|NCT00815360|Experimental|Treatment group|"single intravitreal injection of ranibizumab (0.5 mg in 0.1 cc)
~peripheral laser to areas of retinal nonperfusion on ultra-widefield fluorescein angiography"
11576290|NCT00815360|Active Comparator|Control Group|"single intravitreal injection of triamcinolone acetonide (4.0 mg in 0.1 cc)
~macular laser per treatment criteria"
11576291|NCT00815347|Other|1 Crossover|
11576392|NCT00814671|Active Comparator|RIF 600|Rifampin 600mg daily
11576293|NCT00815334|Active Comparator|Patients with normal bladder compliance|Patients who have normal bladder compliance
11576294|NCT00815308|Experimental|cetuximab, concurrent chemo-radiotherapy|Cetuximab, injection, loading dose400 mg/m^2,(Day1 in Week1) followed by 250 mg/m^2(Day1, every week for Weeks 2-8) Paclitaxel, injection,45 mg/m^2 (Day 1, every week for Weeks 2-8) Cisplatin, injection,20 mg/m^2 (Day 1, every week for Weeks 2-8) radiation therapy, 59.4 Gy, 1.8 Gy/33 fractions,1 fraction daily, Days 1-5 every week for Weeks 2-7, and Days 1-3 for Week 8
11576295|NCT00815295|Experimental|Cetuximab + sorafenib|Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly. Sorafenib will be given at 200mg/m2 twice daily.
11576296|NCT00815282|Other|Patients|patients were girls aged 15 to 18 immunised with the HPV vaccine according to dutch vaccination guidelines
11576297|NCT00815269|Active Comparator|1|Halothane anesthesia: induction and maintenance with different doses
11576298|NCT00815269|Experimental|2|Isoflurane anesthesia: induction and maintenance with different doses
11576299|NCT00815269|Experimental|3|Sevoflurane anesthesia: induction and maintenance with different doses
11576300|NCT00815269|Experimental|4|Desflurane anesthesia: induction and maintenance with different doses
11576301|NCT00815269|Experimental|5|Enflurane anesthesia: induction and maintenance with different doses
11576302|NCT00815256|Experimental|Cross linking (CXL)|Patients with progressive mild and moderate grades of ketatoconus are randomized and allocated to this group and submitted to the treatment with riboflavin and ultraviolet -A light. They do not match any of the exclusion criterion: pregnancy, corneal thickness less than 400 μm, history of corneal surgery, herpes ocular infection, other corneal disease or scarring, chemical injuries and riboflavin allergy.
11576303|NCT00815243|Experimental|Telemed|Group of trauma&orthopedic patients - for determination of clinical strategy and treatment plan telemedicine will be used
11576304|NCT00815243|Active Comparator|InternalControl|Group of trauma&orthopedic patients from 3rd level trauma center - for determination of clinical strategy and treatment plan usual clinical approaches will be used
11576305|NCT00815243|Active Comparator|ExternalControl|Group of trauma&orthopedic patients from 1-2rd level trauma centers (in rural and small municipal hospitals) - for determination of clinical strategy and treatment plan personal arriving of the expert by the car (so-called Urgent Expert Care) will be used
11576306|NCT00815217|Experimental|1 lipoaspirate|wounds which have received the lipoaspirate
11576307|NCT00815217|Placebo Comparator|2 control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
11576308|NCT00815204||posttraumatic stress disorder|
11576309|NCT00815204||history of trauma exposure but no PTSD|
11576310|NCT00815204||healthy controls|
11576311|NCT00815191|Active Comparator|Vital Heat|Vital HEAT (vH2) Temperature Management System
11576312|NCT00815191|Active Comparator|Forced air|Forced-air warming
11576313|NCT00815178|Experimental|Inspiratory muscle training|
11576314|NCT00815178|Placebo Comparator|Placebo|
11576315|NCT00815165||Protocol 04-039 subjects|At least 50 and maximum of 100 healthy adolescent female subjects aged 12-17 years who were vaccinated in protocol 04-039 will be enrolled.
11576316|NCT00815165||Positive and Negative Controls|Approximately 100 screened subjects will be enrolled to serve as positive and negative controls.
11576317|NCT00815152|Experimental|1|Twenty five caregivers will randomly be assigned to receive active coping skills training and 25 caregivers will randomly receive usual care at The Preston Robert Tisch Brain Tumor Center at Duke.
11576318|NCT00815152|Placebo Comparator|2|Caregivers that will receive ususal care.
11576319|NCT00815139||ZES group|Groups who were treated with zotarolimus eluting stent
11576320|NCT00815126|Active Comparator|Mucocutaneous symptoms from NSAIDs|
11576321|NCT00815126|Active Comparator|Respiratory symptoms from NSAIDs|
11576322|NCT00815126|Active Comparator|NSAIDs tolerant individuals|
11576323|NCT00815113||1|First degree relative of gastric cancer patient
11576324|NCT00815113||2|Consecutive gastro-esophageal reflux patients
11576325|NCT00815100|Placebo Comparator|Placebo|
11576326|NCT00815100|Active Comparator|Ivabradine|
11576327|NCT00815087|Experimental|Functional Electrical Stimulation (FES)|Functional electrical stimulation: Experimental
11576328|NCT00815087|Active Comparator|Home Rehabilitation Program (HRP)|Exercise home program
11576329|NCT00815074||1|Women in the military who have returned from deployment within the past 12 months.
11576330|NCT00815048|Active Comparator|Remifentanil|"Atropine
~Remifentanil"
11576331|NCT00815048|Placebo Comparator|Fentanyl|"Atropine
~Fentanyl
~Succinylcholine"
11576332|NCT00815035|Active Comparator|Peanut OIT|Subjects randomized to receive active treatment with peanut protein flour.
11576333|NCT00815035|Placebo Comparator|Placebo|Subjects randomized to receive placebo in the form of oat flour.
11576334|NCT00815022|Active Comparator|1|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 20 degree celsius
11576335|NCT00815022|Experimental|2|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 10 degree celsius
11576336|NCT00815022|Experimental|3|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 15 degree celsius
11576337|NCT00815022|Experimental|4|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 25 degree celsius
11576338|NCT00815022|Experimental|5|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 30 degree celsius
11576339|NCT00815022|Experimental|6|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 35 degree celsius
11576340|NCT00815009|No Intervention|A (Std of Care)|Standard of Care/Control, including Lifestyle Advice (attend a basic healthy nutrition class as well as follow up appointments with GI MD).
11576341|NCT00815009|Experimental|B (Low Fat)|Standard of Care, plus Low Fat Diet and Moderate Exercise
11576342|NCT00815009|Experimental|C (Mod Fat)|Standard of Care, plus Moderate Fat/Low Processed Carbohydrate Diet and Moderate Exercise
11576343|NCT00815009|Experimental|D (Exercise only)|Standard of Care plus Moderate Exercise only
11576344|NCT00814996||1: employment|
11576345|NCT00814996||2: unemployment|
11576346|NCT00814983|Experimental|Naive T-cell Depleted Stem Cell Transplant|Experimental: Cohort 2 will receive a T-cell depleted peripheral blood stem cell graft. All other aspects of this stem cell transplantation are in line with the standard of care.
11576347|NCT00814983|Active Comparator|Stem Cell Transplant No Manipulation|Control: Cohort 1 Stem Cell Transplant No Manipulation will receive the currently accepted standard approach to myeloablative allogeneic stem cell transplantation
11576348|NCT00814970|Experimental|Complete SE Vascular Stent System|COMPLETE SE Vascular Stent System - implantation of study device in native SFA and/or PPA for subjects with symptomatic ischemic peripheral arterial disease in the superficial femoral artery or proximal popliteal arteries with an occlusion or lesion greater or equal to 50 percent with lesions located above the knee and amenable to percutaneous treatment with angioplasty and vascular stent implantation.
11576349|NCT00814957|Experimental|Open-label|D3 receptor antagonist
11576350|NCT00814944|Experimental|Dose Group 1|
11576351|NCT00814944|Experimental|Dose Group 2|
11576352|NCT00814944|Experimental|Dose Group 3|
11576353|NCT00814944|Placebo Comparator|Dose Group 4|
11576354|NCT00814931|Experimental|1|Treatment Group
11576355|NCT00814931|Placebo Comparator|2|
11576356|NCT00814918|Experimental|1|5-ALA Application and exposure using Blu-U light to 1/2 of face.
11576357|NCT00814918|Experimental|2|5-ALA Application and exposure using Candela V-beam Pulse Dye Laser to 1/2 of face.
11576358|NCT00814905|Placebo Comparator|vaginal delivery 1|no further antibiotics after delivery (the patient will receive a saline infusion instead of antibiotics)
11576359|NCT00814905|Active Comparator|vaginal delivery antibotics2|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following vaginal delivery
11576360|NCT00814905|Other|cesarean delivery one dose3|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
11576361|NCT00814905|Other|cesarean multiple antibiotics 4|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
11576362|NCT00814892|Experimental|DC-APCC|Patients undergo standard leukapheresis to harvest peripheral blood mononuclear cells for dendritic cell vaccine preparation. Patients receive the APCC vaccine and autologous dendritic cells derived from CD14-positive myeloid peripheral blood cells ID on days 0, 14, and 28 and then every 28 days for up to 14 courses in the absence of disease progression or unacceptable toxicity.
11576363|NCT00814879|Active Comparator|a.|N(t)RTI(s) based backbone & PI/r
11576364|NCT00814879|Experimental|b.|Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID
11576365|NCT00814866|Other|Adalimumab|Open label
11576366|NCT00814853||Extubation readiness testing|Patients who pass the ERT.
11576367|NCT00814840|Active Comparator|Triple-site group|Triple-site resynchronization group
11576368|NCT00814840|Active Comparator|Standard resynchronization group|Standard (double-site) resynchronization group
11576369|NCT00814827||Group 1|Patients with nontuberculous mycobacteria (NTM) alone.
11576370|NCT00814827||Group 2|Patients with non-NTM opportunistic infection, either with or without concurrent NTM infection.
11576371|NCT00814827||Group 3|Patients with pulmonary mycobacterium tuberculosis (MTB).
11576372|NCT00814827||Group 4|Patients with disseminated mycobacterium tuberculosis (MTB).
11576373|NCT00814827||Group 5|Blood Specimen Donors.
11576374|NCT00814814||Cardiopulmonary arrest|
11576375|NCT00814801|Placebo Comparator|Placebo|
11576376|NCT00814801|Experimental|Galantamine 16 mg/day|
11576377|NCT00814801|Experimental|Galantamine 24 mg/day|
11576378|NCT00814788|Experimental|Bicalutamide + Everolimus|Patients receive oral bicalutamide and oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11576379|NCT00814775|Active Comparator|Group 1|Fastrach Laryngeal Mask Airway intubation
11576380|NCT00814775|Active Comparator|Group 2|Intubation of difficult airway using CTrach Laryngeal Mask
11576381|NCT00814762|Experimental|HIV 732462 Group|Subjects received 2 doses of the HIV Vaccine 732462 into the deltoid muscle of the dominant arm, on a 0, 1 Month schedule.
11576382|NCT00814762|Placebo Comparator|Placebo Group|Subjects received 2 doses of the placebo vaccine into the deltoid muscle of the dominant arm, on a 0, 1 Month schedule.
11576383|NCT00814749|Active Comparator|surgical therapy|
11576384|NCT00814749|Active Comparator|individual management|
11576385|NCT00814736|Experimental|UK369,003 + Placebo or sildenafil|All subjects will receive 17 days daily dosing of UK-369,003 100 mg MR Subjects will receive single oral doses of the following interactant treatments in a randomized order On Day 14, a single dose of sildenafil-matching placebo or 100 mg sildenafil and on Day 17 a single dose of 100 mg sildenafil or a sildenafil matching placebo
11576386|NCT00814723|Active Comparator|Fluvastatin|Fluvastatin 80 mg MR
11576387|NCT00814723|Active Comparator|Fluvastatin + Ezetimibe|Fluvastatin MR 80 mg plus Ezetimibe 10 mg
11576388|NCT00814710|Experimental|Synflorix & Tritanrix-HebB/Hib Group|Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
11576389|NCT00814710|Active Comparator|Hiberix group & Tritanrix-HebB Group|Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
11576390|NCT00814697|Experimental|Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Coil Stimulation (rTMS) treatment in Alzheimer's disease. The Magstim Rapid2 stimulator with a peak magnetic field of 0.5-3.5 Tesla at 100% output was used over the right and left dorsolateral prefrontal cortex. Patients received 4 sessions of rTMS over 2 weeks, lasting approximately 30 minutes, 2 consecutive days a week for 2 weeks.
11576391|NCT00814671|Experimental|RPT450|Rifapentine 450mg daily
11576394|NCT00814658|Experimental|Galantamine + Nimodipine|
11576395|NCT00814658|Experimental|Galantamine + Placebo|
11576396|NCT00814645|Active Comparator|Dose level 1|a single dose (5 mg sodium nitrite)of AIR001 Inhalation Solution administered by inhalation following nebulization
11576397|NCT00814645|Active Comparator|Dose level 2|a single dose(15 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
11576398|NCT00814645|Active Comparator|Dose level 3|a single dose(45 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
11576399|NCT00814645|Active Comparator|Dose level 4|a single dose(113 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
11576400|NCT00814645|Placebo Comparator|Expansion arm|On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
11576401|NCT00814632|Experimental|Study Drug CC 10004|Study drug CC-10004 20mg taken orally twice a day.
11576402|NCT00814619|Experimental|Arm I|Patients receive panitumumab IV over 30-90 minutes on days 1, 15, 29, 43, and 57 and oral capecitabine twice daily on days 8-40. Beginning on day 8, patients undergo daily fractions of 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning approximately 6 weeks after completion of panitumumab and chemoradiotherapy, patients undergo surgery.
11576403|NCT00814619|Active Comparator|Arm II|Patients receive oral capecitabine twice daily on days 1-33. Patients undergo concurrent 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning 6 weeks after completion of chemoradiotherapy, patients undergo surgery.
11576404|NCT00814606|Experimental|Single Group|8 weeks period of escalating doses of fluvastatin to a goal dose of 80mg daily, then patients will start treatment of HCV at week 9 with the usual standard of care protocol for medication dose, office visits and laboratories. Peginterferon alfa2a 180 mcg/ml SQ injection once a week for 48 weeks and ribavirin 1000-1200 mg daily orally in two divided doses for 48 weeks. Patients weighing < 75 kg will receive 1000mg per day (400mg in the morning and 600mg in the evening). Patients weighing ≥ 75 kg will receive 1200 mg per day (600mg in the morning and 600 mg in the evening).
11576405|NCT00814593|Experimental|Arm I|Patients undergo intracranial placement of polifeprosan 20 with carmustine implant (Gliadel® wafer) at the time of therapeutic craniotomy.
11576406|NCT00814593|Experimental|Arm II|Patients undergo leukapheresis to obtain autologous lymphokine-activated killer (LAK) cells, followed 3-7 days later by therapeutic craniotomy. The autologous LAK cells are then instilled into the tumor bed cavity at the time of therapeutic craniotomy.
11576407|NCT00814580|Experimental|001|Tapentadol IR First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1 if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
11576408|NCT00814580|Active Comparator|002|Oxycodone IR First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1 if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
11576409|NCT00814567|Active Comparator|Arm I (control)|Patients undergo standard whole breast radiotherapy once daily on days 1-5 for 3 weeks.
11576410|NCT00814567|Experimental|Arm II|Patients undergo reduced whole breast radiotherapy and standard partial breast radiotherapy once daily on days 1-5 for 3 weeks.
11576411|NCT00814567|Experimental|Arm III|Patients undergo standard partial breast radiotherapy once daily on days 1-5 for 3 weeks.
11576412|NCT00814554|No Intervention|control|no intervention was carried out in high school
11576413|NCT00814554|Experimental|Educational strategy|Educational strategy was carried out in high school.
11576414|NCT00814554|Experimental|Screening strategy|Screening strategy was carried out in high school.
11576415|NCT00814554|Experimental|Environmental strategy|Environmental strategy was carried out in high school.
11576416|NCT00814554|Experimental|Educational and Screening strategies|Educational strategy and Screening strategy were carried out in high school
11576417|NCT00814554|Experimental|Screening and Environmental strategies|Screening strategy and Environmental strategy were carried out in high school
11576418|NCT00814554|Experimental|Educational and Environmental strategies|Educational strategy and Environmental strategy were carried out in high school
11576419|NCT00814554|Experimental|the three strategies|Educational strategy, Screening strategy and Environmental strategy were carried out in high school.
11576420|NCT00814541|Experimental|1|Relapsed patients, previously treated with VAD or VAD like regimen (VAMP, C-VAMP and Z-Dex are examples of VAD like therapy) and who have had autologous transplants at least 1 year previously.Patients may proceed directly to PAD therapy or have had a maximum of one other line of therapy before PAD.
11576421|NCT00814541|Experimental|2|Relapsed patients, previously treated with VAD or VAD-like regimen who have not had autologous transplantation and achieved at least PR (Appendix A). Patients may proceed directly to PAD therapy or have had a maximum of two other lines of therapy before PAD.
11576422|NCT00814541|Experimental|3|Patients refractory (MR, NC or PD) to VAD or VAD-like therapy. Patients should proceed directly to PAD therapy. Patients with NC or PD may proceed to PAD after a minimum of two cycles of VAD or VAD-like therapy or a minimum of 4 cycles, if MR.
11576423|NCT00814528|Experimental|1|"Application of 5-ALA PDT to some lesions on skin with Blue U light source (417 nm)."
11576424|NCT00814528|Experimental|2|5-FU, Imiquimod or treatment with cryotherapy to lesions on the skin.
11576425|NCT00814515|Active Comparator|1|Ciclosporin 0.1%
11576426|NCT00814515|Placebo Comparator|2|Vehicle
11576427|NCT00814502|Active Comparator|Zolpidem CR|Subjects randomized to Zolpidem CR
11576428|NCT00814502|Placebo Comparator|Placebo|Subjects randomized to Placebo
11576429|NCT00814489|Experimental|GSK2254233A Group|Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11576430|NCT00814489|Experimental|GSK2254232A Group|Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11576431|NCT00814489|Active Comparator|Engerix Group|Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11576432|NCT00814476|Active Comparator|2|Regular treated group in the first segment and CareLink treated group in the second segment
11576433|NCT00814476|Experimental|1. CareLink team supported group|CareLink team supported group
11576434|NCT00814463|Active Comparator|Post-operative SRS|All patients will undergo SRS with the planned target volume (PTV) defined as the resection cavity plus a 3-mm margin after surgical resection of a single brain metastasis. Dose will be prescribed to the maximum isodose line completely encompassing the PTV using the guidelines established in RTOG 9005. All patients will be evaluated for neurocognitive function via Mini-Mental State Examination (MMSE), Quality of Life (QOL) via FACT-Br, and for local recurrence via MRI every 3 months over the course of the study.
11576435|NCT00814437||Donors|Oocyte donor
11576436|NCT00814424|Active Comparator|1|ERCP patients monitored using currently marketed smart biteblock o2
11576437|NCT00814424|Experimental|2|ERCP patients monitored using experimental biteblock delivering up to 10 lit/min oxygen
11576438|NCT00814411|Experimental|Group Counseling|Group family planning counseling
11576439|NCT00814411|Active Comparator|Individual Counseling|Individual family planning counseling with gynecological patients who have unmet need
11576440|NCT00814398|Experimental|SET on day 3|Single embryo transfer on day 3 of embryo development
11576441|NCT00814398|Experimental|DET on day 3|Double embryo transfer on day 3 of embryo development
11576442|NCT00814398|Experimental|SET on day 5|Single embryo transfer on day 5 of embryo development
11576443|NCT00814398|Experimental|DET on day 5|Double embryo transfer on day 5 of embryo development
11576444|NCT00814385|Active Comparator|Vaccine arm 1|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by non-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
11576445|NCT00814385|Active Comparator|Vaccine arm 2|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
11576446|NCT00814385|Active Comparator|Vaccine arm 3|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by non-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
11576447|NCT00814385|Active Comparator|Vaccine arm 4|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
11576448|NCT00814385|Active Comparator|Vaccine arm 5|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by non-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
11576449|NCT00814385|Active Comparator|vaccine arm 6|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
11576450|NCT00814385|Active Comparator|Vaccine arm 7|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by non-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
11576451|NCT00814385|Active Comparator|Vaccine arm 8|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
11576452|NCT00814385|Active Comparator|Vaccine arm 9|No priming dose and single dose MF59 adjuvanted H5N1 vaccine at 52 weeks
11576453|NCT00814372|Experimental|MBX-102 400|
11576454|NCT00814372|Experimental|MBX-102 600|
11576455|NCT00814372|Placebo Comparator|Placebo|
11576456|NCT00814372|Active Comparator|Actos|30-45 mg
11576457|NCT00814359|Experimental|Magic Mouthwash Plus Sucralfate|
11576458|NCT00814359|Active Comparator|Benzydamine HCl|
11576459|NCT00814346|Active Comparator|EGb 120 mg|
11576460|NCT00814346|Placebo Comparator|Placebo|
11576461|NCT00814333|Experimental|1|Thrombin-JMI
11576462|NCT00814333|Active Comparator|2|Merocel pack
11576463|NCT00814320|Experimental|1|Efficacy and tolerability of subcutaneous (SC) infusions of immune globulin intravenous (IGIV), 10% with hyaluronidase (rHuPH20) after ramp-up
11576464|NCT00814320|Experimental|2|Pharmacokinetics of intravenous (IV) infusions of immune globulin intravenous (IGIV), 10% and efficacy and tolerability of subcutaneous (SC) infusions of immune globulin intravenous (IGIV), 10% with hyaluronidase (rHuPH20) after ramp-up
11576465|NCT00814307|Experimental|Active 5mg|
11576466|NCT00814307|Experimental|Active 10 mg|
11576467|NCT00814307|Placebo Comparator|Placebo Sequence 1|
11576468|NCT00814307|Placebo Comparator|Placebo Sequence 2|
11576469|NCT00814294|Placebo Comparator|1|Patients on metformin will remain on their stable dose and receive a sugar pill.
11576470|NCT00814294|Experimental|2; Oral HDV-Insulin|Patients on a stable dose of metformin will receive Oral HDV-I.
11576471|NCT00814294|Experimental|3; Oral HDV-Insulin|Patients on a stable dose of metformin will receive Oral HDV-I.
11576472|NCT00814281|Placebo Comparator|1|Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.
11576473|NCT00814281|Placebo Comparator|2|Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.
11576474|NCT00814281|Experimental|3|Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.
11576475|NCT00814281|Experimental|4|Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.
11576476|NCT00814268|Experimental|Combination therapy|Administration of Aspirin + Clopidogrel for 30 days
11576477|NCT00814268|Active Comparator|Monotherapy|Administration of Aspirin + Clopidogrel placebo for 30 days
11576478|NCT00814255|Experimental|2|Conservative medical therapy plus adalimumab
11576479|NCT00814255|Active Comparator|1|Conservative medical therapy (lisinopril, losartan, atorvastatin)
11576480|NCT00814255|Experimental|conservative medical therapy plus galactose|drug: galactose 0.2 g /kg/dose (maximum dose 15g) po BID
11576582|NCT00813670|Experimental|Cohort 3: Single dose of XPF-001|
11576481|NCT00814242|Active Comparator|hepatectomy|Patients with HCC adjacent to major blood vessels recieved radical resection.
11576482|NCT00814242|Experimental|percutaneous radiationfrequency ablation|CT or Ultrasound-guided percutaneous radiofrequency ablation
11576483|NCT00814229|Active Comparator|Vaccine 1|influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
11576484|NCT00814229|Active Comparator|vaccine 2|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
11576485|NCT00814229|Active Comparator|Vaccine 3|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
11576486|NCT00814229|Active Comparator|Vaccine 4|influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
11576487|NCT00814229|Active Comparator|Vaccine 5|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
11576488|NCT00814229|Active Comparator|Vaccine 6|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
11576489|NCT00814229|Active Comparator|Vaccine 7|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
11576490|NCT00814229|Active Comparator|Vaccine 8|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
11576491|NCT00814229|Active Comparator|Vaccine 9|influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
11576492|NCT00814229|Active Comparator|Vaccine 10|influenza H9N2 vaccine virosomal containing 5microg haemagglutinin by intramuscular injection
11576493|NCT00814229|Active Comparator|Vaccine 11|influenza H9N2 vaccine virosomal containing 15microg haemagglutinin by intramuscular injection
11576494|NCT00814229|Active Comparator|Vaccine 12|influenza H9N2 vaccine virosomal containing 45microg haemagglutinin by intramuscular injection
11576495|NCT00814229|Active Comparator|Vaccine 13|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
11576496|NCT00814229|Active Comparator|Vaccine 14|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
11576497|NCT00814216|Experimental|QAV680|
11576498|NCT00814216|Placebo Comparator|Placebo|
11576499|NCT00814216|Active Comparator|Fluticasone Propionate Inhaler|
11576500|NCT00814203||Chronic obstructive lung disease|those with a condition
11576501|NCT00814190|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
11576502|NCT00814190|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
11576503|NCT00814177|Experimental|No change|Intervention Drug warfarin no change in the dose is performed
11576504|NCT00814177|Active Comparator|Change|Intervention Drug Warfarin One dose increased if subtherapeutic level; one dose deleted or reduced if supratherapeutic level
11576505|NCT00814164|Experimental|Clorafarbine with daunorubicin|Patients receive clofarabine IV over 1 hour on days 1-5 and daunorubicin hydrochloride IV over 5 minutes on days 1, 3, and 5.
11576506|NCT00814151||MicroPhage|Blood Culture positive specimens available within 24 hours of alarm.
11576507|NCT00814151||Standard of Care|Blood Culture positive specimens.
11576508|NCT00814138|Active Comparator|1|Methotrexate
11576509|NCT00814138|Placebo Comparator|2|Placebo
11576510|NCT00814125|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
11576511|NCT00814125|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
11576512|NCT00814125|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
11576513|NCT00814112||1 septic shock|septic shock, ICU
11576514|NCT00814112||2 controls|matched controls
11576515|NCT00814099|Active Comparator|1|Participants will receive care at a pediatric ICU that is continuing the usual approach to sedation management.
11576516|NCT00814099|Experimental|2|Participants will receive care at a pediatric ICU that is implementing the team approach to sedation management.
11576517|NCT00814086|Experimental|Treatment (paclitaxel, cisplatin)|Patients receive paclitaxel IV over 3 hours and cisplatin intraperitoneally (IP) on day 1 and paclitaxel IP on day 8. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11576518|NCT00814073|Experimental|Masitinib & BSC|Masitinib (6 mg/kg/day) administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)
11576519|NCT00814073|Placebo Comparator|Placebo & BSC|Matching placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)
11576520|NCT00814060|Experimental|1|40-mg tablet
11576521|NCT00814060|Experimental|2|240-mg tablet
11576522|NCT00814060|Experimental|3|80-mg capsule
11576523|NCT00814034||1:Tamoxifen|
11576524|NCT00814034||2:Steroidal Aromatase Inhibitor|
11576525|NCT00814034||3:Non-steroidal Aromatase Inhibitor|
11576526|NCT00814021|Experimental|sunitinib,|
11576527|NCT00813995|Experimental|Sitagliptin|
11576528|NCT00813995|Placebo Comparator|Placebo|
11576529|NCT00813982|Experimental|Experimental Lotrafilcon A Contact Lens|Lotrafilcon A experimental contact lens randomly assigned to one eye
11576530|NCT00813982|Active Comparator|Commercial Lotrafilcon A Contact Lens|Lotrafilcon A commercial contact lens randomly assigned to one eye
11576531|NCT00813969|Experimental|Autologous MSC transplantation|
11576532|NCT00813956|Experimental|1|standard chemotherapy plus BSI-201
11576533|NCT00813943|Experimental|Cilengitide (2-times weekly) + Temozolomide + Radiotherapy|
11576534|NCT00813943|Experimental|Cilengitide (5-times weekly) + Temozolomide + Radiotherapy|
11576535|NCT00813943|Active Comparator|Temozolomide + Radiotherapy|
11576583|NCT00813670|Experimental|Cohort 4: Single dose of XPF-001|
11576584|NCT00813670|Experimental|Cohort 5: Single dose of XPF-001|
11576536|NCT00813930|Experimental|INTERxVENT Program|Participants in INTERxVENT will complete a 'Baseline Assessment' and 'Follow-up' questionnaire, and will have a health professional visit his/her home for an initial assessment (BP,height,weight,waist measurement) and blood collection (blood glucose and cholesterol levels). As part of the program, each participant will also complete a self-reported 'Health History Questionnaire' (HHQ); a follow-up HHQ will be completed about 12 weeks into the program to monitor progress. Each participant randomized to INTERxVENT receives educational articles which address diabetes management issues. A structured, individualized program, consisting of educational materials and 12 live mentoring/coaching telephone calls will take place over 6 months. The mentors consist of allied health professionals. The sequence by which educational content is administered will be both self-directed and guided by the mentors using an algorithmic approach according to the participant's readiness-to-change scores.
11576537|NCT00813930|No Intervention|Usual medical care|Each participant randomized to this group will not receive any formal intervention but will receive the same care over the 6-month period as he/she usually receives from his/her health care team. Participants in this group will undergo the same baseline and outcome assessment as those in the intervention group, including blood pressure (BP) measurement, physical assessment (height, weight, waist measurement) and blood collection (blood glucose and cholesterol levels), as well as completion of the 'Baseline Assessment' and 'Follow-up' questionnaires.
11576538|NCT00813917|Active Comparator|varenicline|
11576539|NCT00813917|Placebo Comparator|Placebo|
11576540|NCT00813904|Experimental|rThrombin, 1000 IU/mL|
11576541|NCT00813891|Active Comparator|Pre-PDT|Participants in this group will receive an intraocular Ranibizumab injection one week prior to the first PDT with verteporfin.
11576542|NCT00813891|Active Comparator|Post-PDT|Participants in this group will receive an intraocular Ranibizumab injection one week post the first PDT with verteporfin.
11576543|NCT00813891|Active Comparator|No PDT|Participants in this group will receive an intraocular Ranibizumab injection with no accompanying PDT with verteporfin.
11576544|NCT00813878||Normal participants|
11576545|NCT00813878||Breast Cancer Patients|
11576546|NCT00813865|Experimental|Afegostat Tartrate Treatment Regimen 1|Afegostat tartrate was administered orally at a dose of 225 mg QD for 3 or 7 consecutive days followed by no study medication for 4 or 7 consecutive days (consecutive 3-days-on/4-days-off or 7-days-on/7-days-off, respectively). Amendment 2 added a MWF 3-days-on/4-days-off regimen. After Amendment 2 was implemented, all participants were assigned to one of the two 3-days-on/4-days-off regimens. Amendment 4 removed the consecutive 3-days-on/4-days-off regimen, and all participants were assigned to the MWF 3-days-on/4-days-off regimen. Participants were to receive afegostat tartrate for 30 months and be followed for 6 months after EOT.
11576547|NCT00813852|Experimental|2|exercise training, CPAP, and inspiratory muscle strengthening program
11576548|NCT00813839|Experimental|1 SmartCare|automated ventilator controlled adjustment of pressure support
11576549|NCT00813839|Active Comparator|2 spontaneous breathing Trial|daily SBT on minimum pressure support
11576550|NCT00813826|Experimental|SLC022|300mg TID
11576551|NCT00813826|Placebo Comparator|Placebo|Matching placebo capsule
11576552|NCT00813813|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
11576553|NCT00813800|Experimental|Varenicline|Open-label; subjects will receive a behavioral intervention in addition to Varenicline.
11576554|NCT00813787||A. glioma|A. glioma population
11576555|NCT00813787||B. Normal brain|B. Normal brain
11576556|NCT00813774|Active Comparator|Reference|Lyophilized formulation (reference)
11576557|NCT00813774|Experimental|Liquid|Liquid Formulation (test)
11576558|NCT00813774|Experimental|Pre-filled Syringe|Pre-filled syringe (test)
11576559|NCT00813761|Other|02Optix CL and ReNu MPS with SICS|O2Optix contact lens and ReNu MultiPlus Multi-Purpose Solution
11576560|NCT00813761|Other|Proclear CL and ReNu MPS with SICS|Proclear contact lens and ReNu MultiPlus Multi-Purpose Solution
11576561|NCT00813761|Other|02Optix CL and Clear Care LCS with SICS|O2Optix contact lens and Clear Care lens care solution subject
11576562|NCT00813761|Other|Proclear CL and Clear Care LCS with SICS|Proclear contact lens and Clear Care lens care solution
11576563|NCT00813761|Other|02Optix CL and ReNu MPS without SICS|O2Optix contact lens and ReNu MultiPlus Multi-Purpose Solution
11576564|NCT00813761|Other|Proclear CL and ReNu MPS without SICS|Proclear contact lens and ReNu MultiPlus Multi-Purpose Solution
11576565|NCT00813761|Other|02Optix CL and Clear Care LCS without SICS|O2Optix contact lens and Clear Care lens care solution
11576566|NCT00813761|Other|Proclear CL and Clear Care LCS without SICS|Proclear contact lens and Clear Care lens care solution
11576567|NCT00813735|Experimental|Eszopiclone|Drug: Eszopiclone 2mg, Drug: Escitalopram 10mg or 20mg
11576568|NCT00813735|Placebo Comparator|Placebo|Drug: Placebo, Drug: Escitalopram 10mg or 20mg
11576569|NCT00813722|Active Comparator|phone calls|patients received phone calls
11576570|NCT00813722|Placebo Comparator|no phone calls|patients received no phone calls
11576571|NCT00813722|Active Comparator|current treatment|calcium chanel blocker and at1 antagonist
11576572|NCT00813722|Active Comparator|tradittional treatment|beta blocker and diuretic
11576573|NCT00813709|Active Comparator|RNF 44 mcg thrice weekly|
11576574|NCT00813709|Active Comparator|RNF 44 mcg once weekly and placebo|
11576575|NCT00813709|Active Comparator|Placebo/RNF 44 mcg thrice weekly|
11576576|NCT00813696|Experimental|A|cisplatin + gemcitabine
11576577|NCT00813696|Active Comparator|B|gemcitabine
11576578|NCT00813683|Experimental|1|"Stimulation of 67 Bladder point"
11576579|NCT00813683|Sham Comparator|2|"Stimulation of 45 Stomach point (sham)"
11576580|NCT00813670|Experimental|Cohort 1: Single dose of XPF-001|
11576581|NCT00813670|Experimental|Cohort 2: Single dose of XPF-001|
11576585|NCT00813670|Experimental|Cohort A: Repeated doses of XPF-001|
11576586|NCT00813670|Experimental|Cohort B: Repeated doses of XPF-001|
11576587|NCT00813670|Experimental|Cohort C: Repeated doses of XPF-001|
11576588|NCT00813657|Experimental|Lifestyle counseling|
11576589|NCT00813644||1|uromentor training
11576590|NCT00813644||2|non uromentor training
11576591|NCT00813631|Experimental|silver-releasing dressings|Silver, in its common ionic (active) form (Ag+), is particularly attractive as an antibacterial agent because it can be readily incorporated into dressing materials. Silver-dressing are wound products designed to control infection and provide a wound environment conducive to management exudates, pain, and malodour.
11576592|NCT00813618|Experimental|1|MEDI-507
11576593|NCT00813618|Experimental|2|MEDI-507
11576594|NCT00813618|Experimental|3|MEDI-507
11576595|NCT00813605|Experimental|Arm A|AMG 655 10 mg/kg plus AMG 479 placebo in combination with FOLFIRI every 14 days
11576596|NCT00813605|Active Comparator|Arm C|AMG 479 Placebo plus AMG 655 Placebo in combination with FOLFIRI every 14 days
11576597|NCT00813605|Experimental|Arm B|AMG 479 12 mg/kg plus AMG 655 placebo in combination with FOLFIRI every 14 days
11576598|NCT00813592|Experimental|All participants|
11576599|NCT00813566||Diagnostic|
11576600|NCT00813553|Placebo Comparator|beta-alanine 0|
11576601|NCT00813553|Experimental|beta-alanine 1|
11576602|NCT00813553|Experimental|beta-alanine 2|
11576603|NCT00813540|Experimental|1|Exercise
11576604|NCT00813540|Other|2|Usual Care, no intervention
11576605|NCT00813527|Experimental|Lapaquistat Acetate 100 mg QD + Fenofibrate 145 mg QD|
11576606|NCT00813527|Active Comparator|Fenofibrate 145 mg QD|
11576607|NCT00813514|Experimental|1|Open longitudinal study with observer masked analysis
11576608|NCT00813488|Experimental|Fentanyl buccal tablet first then immediate release oxycodone|This crossover study includes a screening period, two titration periods, two double-blind treatment periods during which subjects will be randomized to receive fentanyl buccal tablet (FBT) plus placebo during the first treatment period and then immediate release oxycodone plus placebo during the second treatment period or vice versa, then followed by a 12-week open-label treatment period with FBT or an alternative short acting opioid.
11576609|NCT00813488|Experimental|Immediate Release Oxycodone first then FBT|This crossover study includes a screening period, two titration periods, two double-blind treatment periods during which subjects will be randomized to receive fentanyl buccal tablet (FBT) plus placebo during the first treatment period and then immediate release oxycodone plus placebo during the second treatment period or vice versa, then followed by a 12-week open-label treatment period with FBT or an alternative short acting opioid.
11576610|NCT00813475|Experimental|tight control|
11576611|NCT00813475|Experimental|standard control|basal bolus insulin regimen
11576612|NCT00813449|Experimental|A|Experimental group : Endostar combined with dacarbazine
11576613|NCT00813449|Placebo Comparator|2|Control group : Dacarbazine combined with placebo
11576614|NCT00813436|Experimental|1|Oxytocin
11576615|NCT00813436|Placebo Comparator|2|Placebo
11576616|NCT00813423|Experimental|Treatment (sunitinib malate, hydroxychloroquine)|Patients receive sunitinib malate PO QD on days 1-28 and hydroxychloroquine PO QD or BID on days 1-42 (beginning day 4 of course 1). Treatment repeats every 42 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11576617|NCT00813397|Experimental|Sepraspray|Receive Sepraspray
11576618|NCT00813397|No Intervention|Control|No Treatment, No Placebo
11576619|NCT00813384|Experimental|Dose Escalation|The dose escalation part of the study is aimed at determining the maximum tolerated dose (MTD), if feasible, and evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 208.
11576620|NCT00813384|Experimental|Dose Expansion|The dose expansion will consist of up to 30 subjects and the dose level of AMG 208 will be dependent upon emerging safety and PK data from the dose escalation part of the study.
11576621|NCT00813371|Active Comparator|1|Airway Pressure Release Ventilation Arm
11576622|NCT00813371|Active Comparator|2|ARDSnet protocol
11576623|NCT00813358|Experimental|Endovascular repair|treatment
11576624|NCT00813345|Experimental|A - Light therapy|Light therapy (1500 lux)
11576625|NCT00813345|Placebo Comparator|B - identical control lamp|identical control lamp
11576626|NCT00813332|Experimental|1|Endostar combined with Docetaxel for Advanced NSCLC: All eligible patients will receive Endostar in combination with Docetaxel chemotherapy for 2 cycles (21 days for each cycle) and cases of good response(CR+PR+SD) will continue treatment for 2 cycles. Endostar treatment will continue after completion of first 4 cycles until disease progression.
11576627|NCT00813332|Placebo Comparator|2|Docetaxel combined with placebo for Advanced NSCLC: All eligible patients will receive placebo in combination with Docetaxel chemotherapy for 2 cycles (21 days for each cycle) and cases of good response(CR+PR+SD) will continue treatment for 2 cycles. Placebo will continue after completion of first 4 cycles until disease progression.
11576628|NCT00813319|Experimental|1 - Girls OnGuard/HPV awareness|Adolescents will watch a short (10 min), interactive DVD designed to promote HPV awareness and initial GARDASIL vaccination and receive a keepsake to help them remember to return to the clinic for their second and third vaccine doses.
11576629|NCT00813319|No Intervention|2 - General health promotion|Adolescents will watch an equally short (10 min) DVD on healthy lifestyles and behaviors. HPV awareness and vaccination will not be addressed.
11576630|NCT00813306|Experimental|A|AZD2066
11576631|NCT00813306|Placebo Comparator|B|Placebo
11576632|NCT00813306|Experimental|C|AZD2066
11576633|NCT00813306|Experimental|D|AZD2066
11576634|NCT00813306|Placebo Comparator|E|Placebo
11576635|NCT00813293|Experimental|Sorafenib|Participants received a nine-day course of oral sorafenib 400 mg twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip, 70 ± 2º C, 5 min).
11576636|NCT00813293|Placebo Comparator|Placebo|Participants received a nine-day course of placebo pills twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip, 70 ± 2º C, 5 min).
11576637|NCT00813280||hyperglycemia|hospitalized patients with BG >300 ml/dL
11576638|NCT00813267|Experimental|stem cell|mesenchymal stem cell infusion and bone marrow mononuclear cell infusion
11576639|NCT00813254||Questionnaire|Longitudinal measure of QOL, sexual functioning and symptoms in women with recurrent, platinum-resistant ovarian cancer receiving multiple second-line treatment regimens
11576640|NCT00813241|Active Comparator|A|A single dose of 200 mg celecoxib capsule administered as 1 x 200 mg celecoxib capsule, (Reference Formulation)
11576641|NCT00813241|Experimental|B|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet formulation containing granule type A1
11576642|NCT00813241|Experimental|C|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet containing granule type B2
11576643|NCT00813241|Experimental|D|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet containing granule type C1
11576644|NCT00813215|Experimental|1|Relatives to patients with type 2 diabetes.
11576645|NCT00813215|Active Comparator|2|Controls with no family history of type 2 diabetes.
11576646|NCT00813202|Experimental|Nesiritide|
11576647|NCT00813189|Experimental|1 : early start (GH treatment) group|in the early start group, patients were treated with growth hormone for one year immediately after randomisation
11576648|NCT00813189|No Intervention|2 :delayed start (GH treatment) group|in the delayed start group patients took GH treatment for 1 year , 6 months after randomisation
11576649|NCT00813176|Active Comparator|Double Lumen Endotracheal Tube|We used a device called a double lumen tube ( DLT Broncho-Cath®). It is a bifurcated endotracheal tube designed to independently collapse the operated lung.
11576650|NCT00813176|Active Comparator|Arndt Bronchial Blocker|We used a device called a bronchial blocker (9 Fr Arndt® blocker) along with a standard single-lumen tracheal tube (8.0-9.0 mm ID). The Arndt bronchial blocker is a single device, with a distal balloon that is passed thru the single lumen endotracheal once the patient is intubated. The Arndt bronchial blocker is designed to collapse the operated lung.
11576651|NCT00813163|Experimental|PEP02|Liposome Irinotecan
11576652|NCT00813150|Experimental|Vd (bortezomib + dexamethasone)|"Participants received bortezomib at a dose of 1.3 mg/m² body surface area (BSA) for eight 3-week cycles. Within each cycle it was administered twice weekly (on Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 through 21). They received single oral doses of 20 mg dexamethasone on Days
~1 and 2, 4 and 5, 8 and 9, and 11 and 12 of each cycle."
11576653|NCT00813150|Active Comparator|Vcd (bortezomib + low-dose dexamethasone + cyclophosphamide)|Participants received bortezomib at a dose of 1.3 mg/m² body surface area (BSA) for eight 3-week cycles. Within each cycle it was administered twice weekly (on Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 through 21). They received single oral doses of 20 mg dexamethasone on Days 1 and 2, 4 and 5, 8 and 9, and 11 and 12 of each cycle and single oral doses of 50 mg cyclophosphamide on a once daily basis from Day 1, Cycle 1 continuously until Day 21, Cycle 8.
11576654|NCT00813137|Experimental|Folfox4 plus Endostar|
11576655|NCT00813124|Experimental|Azacytidine Maintenance after allotx|Busulfan + Fludarabine + ATG + Azacytidine after allogeneic stem cell transplantation (allotx)
11576656|NCT00813111|Experimental|SKY0402|A single local administration of 300 mg in a 20-mL volume into each breast implant pocket for a total dose of 600 mg (i.e., a total of 40 mL)
11576657|NCT00813111|Active Comparator|Bupivacaine HCl|A single local administration of 100 mg in a 20-mL volume into each breast implant pocket for a total dose of 200 mg (i.e., a total of 40 mL)
11576658|NCT00813098|Experimental|High dose|A high dose of LX1031; daily oral intake for 28 days
11576659|NCT00813098|Experimental|Low Dose|A low dose of LX1031; daily oral intake for 28 days
11576660|NCT00813098|Placebo Comparator|Placebo|Matching placebo dosing with daily oral intake
11576661|NCT00813085|Other|Electronic disease management decision support|An electronic Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS).
11576662|NCT00813085|No Intervention|2|Usual care by Family Physician
11576663|NCT00813072|Experimental|1. PEP02|liposome irinotecan
11576664|NCT00813072|Active Comparator|2. irinotecan|
11576665|NCT00813072|Active Comparator|3. docetaxel|
11576666|NCT00813059|Experimental|1|
11576667|NCT00813046|Experimental|gpASIT+TM|
11576668|NCT00813033|Other|patient decision aid|
11576669|NCT00813020|Experimental|A|
11576670|NCT00813020|Experimental|B|
11576671|NCT00813020|Experimental|C|
11576672|NCT00813007||Questionnaire|Radical trachelectomy outcomes for cervical cancer
11576673|NCT00812994|Placebo Comparator|Placebo|
11576674|NCT00812994|Experimental|Escitalopram|
11576675|NCT00812981|Experimental|1562902A NP GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the new-processed (NP) 1562902A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Days 0 and 21.
11576676|NCT00812981|Experimental|1562902A CP GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the comparative-processed (CP) 1562902A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Days 0 and 21.
11576677|NCT00812968|Experimental|Lenalidomide|Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
11576678|NCT00812955|Experimental|A - ABT-143 capsules 5/135 mg|ABT-143 capsules 5/135 mg - ABT-143 (rosuvastatin 5 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
11576679|NCT00812955|Experimental|B - ABT-143 capsules 10/135 mg|ABT-143 capsules 10/135 mg - ABT-143 (rosuvastatin 10 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
11576680|NCT00812955|Experimental|C - ABT-143 capsules 20/135 mg|ABT-143 capsules 20/135 mg - ABT-143 (rosuvastatin 20 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
11576681|NCT00812955|Active Comparator|D - Simvastatin capsules 40 mg|Simvastatin capsules 40 mg daily for 8 weeks
11576682|NCT00812942|Active Comparator|fobt|faecal occult blood test
11576683|NCT00812942|Active Comparator|colonoscopy|colonoscopy screening
11576684|NCT00812929|Placebo Comparator|Placebo|
11576685|NCT00812929|Experimental|GSK2190915 10 mg|
11576686|NCT00812929|Experimental|GSK2190915 50 mg|
11576687|NCT00812929|Experimental|GSK2190915 100 mg|
11576746|NCT00812461|Experimental|Nalmefene|
11576688|NCT00812929|Experimental|GSK2190915 200 mg|
11576689|NCT00812916||RF ablation|RF Ablation using specialized CFAE software
11576690|NCT00812903|No Intervention|Control|Control group
11576691|NCT00812903|Experimental|Exercise|Intervention group
11576692|NCT00812877|Active Comparator|Mineral Trioxide Aggregate|Pulp capping agent, Mineral Trioxide Aggregate used as a direct pulp cap
11576693|NCT00812877|Active Comparator|Calcium Hydroxide|Pulp capping agent, Calcium Hydroxide used as a direct pulp cap
11576694|NCT00812864|Experimental|Capecitabine|
11576695|NCT00812838|Experimental|100 units of Botulinum Toxin Type A|Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline
11576696|NCT00812838|Placebo Comparator|Normal saline|"Injection solution will consist of 10 cc preservative free normal saline
~Subjects had the choice of crossing over to ARM 1 at the end of 16 weeks.
~Cross-over: For subjects in Arm 2, crossover to BOTOX treatment will begin after the Week 16 Visit by repeating the study schedule as for Week 0 to Week 16."
11576697|NCT00812825|Experimental|PF-04173127|
11576698|NCT00812825|Active Comparator|Prednisolone|
11576699|NCT00812825|Placebo Comparator|Placebo|
11576700|NCT00812825|Sham Comparator|Solution Placebo|
11576701|NCT00812825|Experimental|PF-04171327 Tablet|
11576702|NCT00812812|Experimental|paroxetine group|paroxetine 10-40mg/day
11576703|NCT00812812|Placebo Comparator|placebo group|matched placebo to paroxetine
11576704|NCT00812799|Active Comparator|Grass pollen extract|Subjects will receive 19.000 BU grass pollen extract daily sublingually
11576705|NCT00812799|Placebo Comparator|Placebo control|Subjects will receive matching placebo control daily sublingually
11576706|NCT00812773|Experimental|3 day repeat dose|
11576707|NCT00812760|Experimental|1|
11576708|NCT00812747||1|
11576709|NCT00812734||surgery|
11576710|NCT00812721|Placebo Comparator|1|Preservative Free Saline
11576711|NCT00812721|Active Comparator|2|Optive (TM)
11576712|NCT00812721|Active Comparator|3|Refresh Moderate/Severe (TM)
11576713|NCT00812721|Active Comparator|4|Systane (TM)
11576714|NCT00812721|Active Comparator|5|Systane Ultra (TM)
11576715|NCT00812708|Experimental|Morcher iris diaphragm implantation|This is a non-randomized, non-comparative interventional surgical series. Patients will undergo Morcher iris diaphragm implantation in their affected eye(s). After surgery, patients will complete 5 postoperative examinations. At each examination, they will be evaluated for changes in light and glare sensitivity and visual acuity. They will also be monitored for adverse reactions.
11576716|NCT00812695|No Intervention|1|
11576717|NCT00812695|Active Comparator|2|CPAP
11576718|NCT00812669|Experimental|Fludarabine, Cylophosphamide and Rituximab|
11576719|NCT00812656||Stroke Panel group|Patients undergoing cardiac surgery with the use of cardiopulmonary bypass
11576720|NCT00812630|Experimental|1|In the second part of the trial, subjects will apply MENT or placebo gel transdermally for 12 weeks and will have 24-hour blood pressure monitoring at baseline, Week 6 and Week 12.
11576721|NCT00812617|Experimental|Mineral water 1|
11576722|NCT00812617|Experimental|Mineral water 2|
11576723|NCT00812604|Experimental|Ping On Ointment|Ping On Ointment
11576724|NCT00812604|Placebo Comparator|Vaseline|Vaseline with minor trace of Ping On ointment to give medicinal smell
11576725|NCT00812578|Active Comparator|Cholecalciferol|
11576726|NCT00812578|Placebo Comparator|Placebo pill|
11576727|NCT00812565|Placebo Comparator|Placebo every 2 weeks|Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).
11576728|NCT00812565|Experimental|0.1 g/kg octagam 10% every 2 weeks|Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).
11576729|NCT00812565|Experimental|0.25 g/kg octagam 10% every 2 weeks|Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).
11576730|NCT00812565|Experimental|0.4 g/kg octagam 10% every 2 weeks|Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).
11576731|NCT00812565|Placebo Comparator|Placebo every 4 weeks|Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).
11576732|NCT00812565|Experimental|0.2 g/kg octagam 10% every 4 weeks|Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).
11576733|NCT00812565|Experimental|0.5 g/kg octagam 10% every 4 weeks|Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).
11576734|NCT00812565|Experimental|0.8 g/kg octagam 10% every 4 weeks|Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).
11576735|NCT00812552||Case|Late or very late drug-eluting stent thrombosis
11576736|NCT00812552||Control|No drug-eluting stent thrombosis
11576737|NCT00812539|Experimental|"Diabetes Connected Health Tool Deluxe"|Subjects enrolled into the intervention arm will measure their glucose levels by using a glucometer. An iMetrikus modem will upload the blood glucose readings to a secure, web-based portal. Participants will be given login information to access this portal, where they can view their glucose readings and detailed graphical representation of their blood glucose levels over time, read educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to these subjects' information on the web portal).
11576738|NCT00812539|Active Comparator|"Diabetes Connected Health Tool Basic"|Control group will measure their glucose levels by using a glucometer. An iMetrikus modem will upload the blood glucose readings to a secure, web-based portal. Participants will be given login information to access this portal. where they can view their glucose readings in tabular form. Their physicians will not have access to this information.
11576739|NCT00812500|Experimental|1|Young men, age 21-46 years.
11576740|NCT00812500|Experimental|2|Old Men, age 63-81 years.
11576741|NCT00812500|Experimental|3|Young women, age 21-46 years.
11576742|NCT00812500|Experimental|4|Old women, age 63-81 years.
11576743|NCT00812487|Experimental|Intravenous insulin|
11576744|NCT00812487|Active Comparator|Subcutaneous Insulin|4 injections of insulin/day
11576745|NCT00812461|Placebo Comparator|Placebo|
11576747|NCT00812448|Experimental|tea catechin extracts containing mask|wearing the tea catechin extracts containing mask
11576748|NCT00812435|Experimental|Eptifibatide|PCI with administration of eptifibatide
11576749|NCT00812422|Experimental|Dexibuprofen 1|Dexibuprofen 2.5 or 5 mg/kg
11576750|NCT00812422|Experimental|Dexibuprofen 2|Dexibuprofen 3.5 or 7 mg/kg
11576751|NCT00812422|Active Comparator|Ibuprofen|Ibuprofen 5 or 10 mg/kg
11576752|NCT00812409|Experimental|1|Control group: non-protein supplement with resistance and aerobic exercise.
11576753|NCT00812409|Experimental|2|Low protein supplement with resistance and aerobic exercise.
11576754|NCT00812409|Experimental|3|Moderate protein supplement with resistance and aerobic exercise.
11576755|NCT00812409|Experimental|4|High protein supplement with resistance and aerobic exercise.
11576756|NCT00812396|Active Comparator|1|Low dose testosterone
11576757|NCT00812396|Active Comparator|2|High dose testosterone
11576758|NCT00812396|Placebo Comparator|3|Placebo
11576759|NCT00812383|Experimental|Bivalirudin|
11576760|NCT00812383|Active Comparator|Heparin|
11576761|NCT00812370|Experimental|open label|
11576762|NCT00812357||1|Patients treated with Symbicort basic treatment
11576763|NCT00812357||2|Patients treated with Symbicort basic treatment + treatment of symptoms as needed
11576764|NCT00812344|Experimental|1|
11576765|NCT00812344|Active Comparator|2|AZD0837 + Ketoconazole
11576766|NCT00812331|Experimental|Genotype 2|Participants with chronic genotype 2 hepatitis C virus (HCV) infection
11576767|NCT00812331|Experimental|Genotype 3|Participants with chronic genotype 3 HCV infection
11576768|NCT00812331|Experimental|Genotype 4|Participants with chronic genotype 4 HCV infection
11576769|NCT00812331|Experimental|Genotype 5|Participants with chronic genotype 5 HCV infection
11576770|NCT00812331|Experimental|Genotype 6|Participants with chronic genotype 6 HCV infection
11576771|NCT00812318|Experimental|Treatment A|GSK1265744 10mg oral solution
11576772|NCT00812318|Experimental|Treatment B|GSK1265744 5mg tablet, fasted
11576773|NCT00812318|Experimental|Treatment C|GSK1265744 5mg tablet, fed
11576774|NCT00812305|Experimental|Low dose in healthy patients|
11576775|NCT00812305|Experimental|Low dose in hepatically impaired patients|
11576776|NCT00812279|Experimental|1. SMAR|Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times.
11576777|NCT00812279|Active Comparator|2 Conventional cigarette (CC)|Subjects will be allowed to smoke without any limit on consumption during the designated smoking times.
11576778|NCT00812279|Active Comparator|3. smoking cessation (SC)|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
11576779|NCT00812266|Experimental|A|Topotecan + cisplatin
11576780|NCT00812266|Active Comparator|B|Etoposide + carboplatin
11576781|NCT00812253|Experimental|Intravenous Insulin|
11576782|NCT00812253|Active Comparator|Subcutaneous Insulin|Basal bolus insulin (4 injections per day)
11576783|NCT00812240|Experimental|Masitinib (7.5)|Participants receive masitinib (7.5 mg/kg/day), given orally twice daily.
11576784|NCT00812240|Experimental|Masitinib (6.0)|Participants receive masitinib (6.0 mg/kg/day), given orally twice daily
11576785|NCT00812240|Active Comparator|Active Comparator (7.5)|Participants receive imatinib at 400 or 600 mg per day
11576786|NCT00812240|Active Comparator|Active Comparator (6.0)|Participants receive imatinib at 400 or 600 mg per day
11576787|NCT00812227|Experimental|Psychodynamic psychotherapy|
11576788|NCT00812214|Experimental|1|
11576789|NCT00812214|Placebo Comparator|2|
11576790|NCT00812201||1|
11576791|NCT00812188|Active Comparator|Medium Dose UVA-1|Medium dose (60 J/cm2) UVA-1 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream to another morphea plaque twice daily for twelve weeks.
11576792|NCT00812188|Active Comparator|High Dose UVA-1|High dose UVA-1 treatment 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream twice daily for 12 weeks to another morphea plaque.
11576793|NCT00812175||Group 1|
11576794|NCT00812162|Experimental|1|High protein diet.
11576795|NCT00812162|Experimental|2|Lower protein diet.
11576796|NCT00812123|Experimental|Calcineurin free|Immunosuppression with Sirolimus, Mycophenolate and Steroids
11576797|NCT00812123|Active Comparator|Calcineurin|Immunosuppressive therapy with Cyclosporin A, Mycophenolate and Steroids
11576798|NCT00812097|Other|Primary Augmentation|The Primary Augmentation cohort will include patients who wish general breast enlargement receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants.
11576799|NCT00812097|Other|Primary Reconstruction|The Primary Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants.
11576800|NCT00812097|Other|Revision Augmentation|The Revision Augmentation cohort will include patients receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants during a revision surgery to correct or improve the result of a primary breast augmentation surgery.
11576801|NCT00812097|Other|Revision Reconstruction|The Revision Reconstruction cohort will include patients receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants during a revision surgery to correct or improve the result of a primary breast reconstruction surgery.
11576802|NCT00812084||CAP cohort|Includes cases that were hospitalized because of a community-acquired pneumonia during the study period, and for which we had a baseline EQ-5D score from the start of the study period. These CAP cases are prospectively followed for up to one year using questionnaires for health status and (health) resources.
11576803|NCT00812084||Controls cohort|For each CAP cases, two controls are matched based on age, sex and baseline EQ-5D score measured at the start of the study. These controls are prospectively followed for up to one year using questionnaires for health status and (health) resources.
11576804|NCT00812058|Experimental|RG2417|Oral RG2417 taken twice daily for 8 weeks
11576805|NCT00812058|Placebo Comparator|Placebo|Oral placebo taken twice daily for 8 weeks
11576808|NCT00812019|Experimental|3.75_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
11576809|NCT00812019|Experimental|3.75_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
11576810|NCT00812019|Experimental|3.75_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
11576811|NCT00812019|Experimental|3.75_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
11576812|NCT00812019|Experimental|7.5_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
11576813|NCT00812019|Experimental|7.5_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
11576814|NCT00812019|Experimental|7.5_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
11576815|NCT00812019|Experimental|7.5_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
11576816|NCT00812019|Experimental|15_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
11576817|NCT00812019|Experimental|15_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
11576818|NCT00812019|Experimental|15_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
11576819|NCT00812019|Experimental|15_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
11576820|NCT00812006|Experimental|A|Treatment Sequence A: rizatriptan, rizatriptan, placebo
11576821|NCT00812006|Experimental|B|Sequence B: rizatriptan, placebo, rizatriptan
11576822|NCT00812006|Experimental|C|Sequence C: placebo, rizatriptan, rizatriptan
11576823|NCT00811993|Experimental|1|
11576824|NCT00811993|Experimental|10|
11576825|NCT00811993|Experimental|11|
11576826|NCT00811993|Experimental|12|
11576827|NCT00811993|Experimental|13|
11576828|NCT00811993|Experimental|2|
11576829|NCT00811993|Experimental|3|
11576830|NCT00811993|Experimental|4|
11576831|NCT00811993|Experimental|5|
11576832|NCT00811993|Experimental|6|
11576833|NCT00811993|Experimental|7|
11576834|NCT00811993|Experimental|8|
11576835|NCT00811993|Experimental|9|
11576836|NCT00811980||Heathy Subjects|
11576837|NCT00811967|Experimental|Treatment Arm|
11576838|NCT00811967|No Intervention|Control Arm|
11576839|NCT00811954|Experimental|Arm A: ATV/RTV + FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
11576840|NCT00811954|Experimental|Arm B: RAL + FTC/TDF|FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
11576841|NCT00811954|Experimental|Arm C: DRV/RTV + FTC/TDF|FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
11576842|NCT00811941|Placebo Comparator|Placebo|
11576843|NCT00811941|Experimental|Nalmefene|
11576844|NCT00811928|Active Comparator|Posaconazole|Posaconazole oral suspension 200 mg three times a day (TID)
11576845|NCT00811928|Active Comparator|Fluconazole|Fluconazole 400 mg once daily (QD)
11576846|NCT00811915|Experimental|Sirolimus|"Group A : Sirolimus introduction and tacrolimus withdrawal
~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14.
~Sirolimus daily dose according to CYP3A5 genotype CYP3A5*1/*1 or *1/*3: 4 mg/d CYPY3A5*3/*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml"
11576847|NCT00811915|Active Comparator|B|Tacrolimus (Advagraf) dose to obtain a trough level between 4 and 10 ng/ml
11576848|NCT00811902|Experimental|Nerispirdine 50mg|Nerispirdine 50mg once daily for 14 weeks
11576849|NCT00811902|Experimental|Nerispirdine 100mg|Nerispirdine 100mg once daily for 14 weeks
11576850|NCT00811902|Experimental|Nerispirdine 200mg|Nerispirdine 200mg once daily for 14 weeks
11576851|NCT00811902|Placebo Comparator|Placebo|Placebo for Nerispirdine once daily for 14 weeks
11576852|NCT00811889|Placebo Comparator|Placebo|
11576853|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 75mg|
11576854|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 150mg|
11576855|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 25mg|
11576856|NCT00811863||1|Subjects with moderate renal insufficiency defined as an eGFR 30-60 mL/min/1.73 m2
11576857|NCT00811863||2|Subjects with severe renal insufficiency defined as an eGFR <30 mL/min/1.73 m2 and ESRD defined as requiring dialysis
11576858|NCT00811850|Active Comparator|Combigan®|Combigan® (fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution). One drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks.
11576859|NCT00811850|Active Comparator|Cosopt®|Cosopt® (fixed combination of dorzolamide hydrochloride - timolol maleate ophthalmic solution). One drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks.
11576860|NCT00811837|Experimental|Remifentail|Remifentanil Infusion
11576861|NCT00811837|Active Comparator|Midazolam|Active Placebo
11576862|NCT00811824|Active Comparator|1|Immediate physical activity and dietary change intervention
11576863|NCT00811824|Other|2|Delayed physical activity and dietary change intervention
11576864|NCT00811811|Experimental|1|Behavioral neurocardiac training
11576865|NCT00811811|Active Comparator|2|Autogenic relaxation training
11576866|NCT00811798|Experimental|Cervarix Group|
11576867|NCT00811772|Active Comparator|Bare metal stent|Implantation of one or more bare metal stent(s) to to treat coronary artery stenosis
11577327|NCT00808522|No Intervention|routine care|Patients receiving routine care will be followed
11576868|NCT00811772|Experimental|Drug eluting stent|Implantation of one or more drug eluting stent(s) to treat coronary artery stenosis
11576869|NCT00811746|Experimental|1|Rozerem (Ramelteon) 8 mg taken orally 30 minutes before a split-night PSG
11576870|NCT00811746|Active Comparator|2|Lunesta (Eszopiclone) 3 mg taken 30 minutes before the start of split-night PSG
11576871|NCT00811746|Other|3|Historical controls (chart review) matched for demographics and comorbidities of the study drug groups.
11576872|NCT00811733|Experimental|Ofatumumab|Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.
11576873|NCT00811720|Placebo Comparator|Placebo|
11576874|NCT00811720|Experimental|Nalmefene|
11576875|NCT00811707||1: volunteers|non-pregnant female
11576876|NCT00811707||2: parturients|parturients was scheduled to receive lumbar epidurals for elective cesaeran delivery labor analgesia
11576877|NCT00811694||a|15 male and 15 female patients with glaucoma
11576878|NCT00811694||b|30 sex matched healthy volunteers
11576879|NCT00811681|Experimental|Pioglitazone|pioglitazone
11576880|NCT00811681|Placebo Comparator|Control|placebo
11576881|NCT00811668|Experimental|CPAP before SOMNOVentCR|started with CPAP and continued with SOMNOvent CR
11576882|NCT00811668|Experimental|SOMNOVentCR before CPAP|began with SOMNOvent CR and ended with CPAP
11576883|NCT00811655|Experimental|Pre-Operative SRS|SRS pre-operatively with the planned target volume defined as the tumor plus a 3-mm margin.
11576884|NCT00811642|Experimental|Posaconazole|Posaconazole 400 mg twice a day (BID) oral suspension for 12 weeks
11576885|NCT00811629||control group|
11576886|NCT00811603|Active Comparator|1|Patients who receive antibiotic prophylaxis after clamping of the umbilical cord
11576887|NCT00811603|Experimental|2|Patients who receive antibiotic prophylaxis prior to skin incision
11576888|NCT00811590|Experimental|All patients|All participants enrolled.
11576889|NCT00811577|Experimental|AZX100-placebo|Three trocar sites designated as anterior, lateral and posterior were randomized on each patient to receive one low dose of AZX100 3 mg/linear cm, one high dose of AZX100 10 mg/linear cm, or placebo (saline).
11576890|NCT00811577|Placebo Comparator|Placebo-only|Three trocar sites on each patient received one dose of placebo (saline).
11576891|NCT00811564|Active Comparator|1|Fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution
11576892|NCT00811564|Active Comparator|2|Latanoprost 0.005% ophthalmic solution
11576893|NCT00811538||1 1 (Liv*)|i.v. thrombolysis with rtPA
11576894|NCT00811538||2 (L*)|intraarterial thrombolysis
11576895|NCT00811499|Experimental|ARRY-371797 (Schedule 1)|
11576896|NCT00811499|Experimental|ARRY-371797 (Schedule 2)|
11576897|NCT00811499|Placebo Comparator|Placebo|
11576898|NCT00811486|No Intervention|Usual care|Group II
11576899|NCT00811486|Experimental|Spironolactone and conivaptan|Group I
11576900|NCT00811473|Experimental|Quetiapine XR|
11576901|NCT00811473|Placebo Comparator|Placebo|
11576902|NCT00811460|Experimental|1|
11576903|NCT00811447|Experimental|1|Administration of docetaxel 60 mg/m² on Day 1, Cisplatin 60 mg/m² after the end of the docetaxel infusion and 5-fluorouracil (5-FU) 600 mg/m²/day from Day 1 after the end of the cisplatin infusion to Day 5.
11576904|NCT00811447|Active Comparator|2|Cisplatin 75 mg/m² on Day 1, 5-FU 600 mg/m²/day from Day 1 after the end of the cisplatin infusion to Day 5.
11576905|NCT00811434|Active Comparator|Lactulose|3 months of Lactulose therapy based on pt. weight
11576906|NCT00811434|Placebo Comparator|placebo|1.5 ml/kg day po of sugar water placebo for three months
11576907|NCT00811421|Active Comparator|Trial 1: IPTp-SP+LLITNs|HIV-negative pregnant women receiving 2 doses of IPTp (500mg of sulfadoxine and 25 mg of pyrimethamine) in the context of long lasting Insecticide Treated Nets (LLITNs)
11576908|NCT00811421|Experimental|Trial 1: IPTp-MQ (full dose) + LLITNs|HIV-negative pregnant women receiving 2 full doses of IPTp (15 mg/Kg) in the context of long lasting Insecticide Treated Nets (LLITNs)
11576909|NCT00811421|Experimental|Trial 1: IPTp-MQ (split dose)+LLITNs|HIV-negative pregnant women receiving 2 doses of MQ as IPTp split dose over 2 days (15mg/kg) in the context of long lasting Insecticide Treated Nets (LLITNs
11576910|NCT00811421|Experimental|Trial 2: CTX+IPTp-Placebo+LLITNs|HIV-positive pregnant women receiving 3 doses of IPTp (placebo) in the context of long lasting Insecticide Treated Nets (LLITNs)
11576911|NCT00811421|Experimental|Trial 2: CTX + IPTp-MQ+ LLITNs|HIV-positive pregnant women receiving 3 doses of IPTp (15 mg/Kg) in the context of long lasting Insecticide Treated Nets (LLITNs)
11576912|NCT00811395|Placebo Comparator|Placebo + IFN-β|Placebo (for teriflunomide) once daily concomitantly with interferon-β [IFN-β] for 24 additional weeks
11576913|NCT00811395|Experimental|Teriflunomide 7 mg + IFN-β|Teriflunomide 7 mg once daily concomitantly with interferon-β [IFN-β] for 24 additional weeks
11576914|NCT00811395|Experimental|Teriflunomide 14 mg + IFN-β|Teriflunomide 14 mg once daily concomitantly with interferon-β [IFN-β] for 24 additional weeks
11576915|NCT00811395|Placebo Comparator|Placebo + GA|Placebo (for teriflunomide) once daily concomitantly with glatiramer acetate [GA] for 24 additional weeks
11576916|NCT00811395|Experimental|Teriflunomide 7 mg + GA|Teriflunomide 7 mg once daily concomitantly with glatiramer acetate [GA] for 24 additional weeks
11576917|NCT00811395|Experimental|Teriflunomide 14 mg + GA|Teriflunomide 14 mg once daily concomitantly with glatiramer acetate [GA] for 24 additional weeks
11576918|NCT00811382|Experimental|1: Access to HMSC (Home Monitoring Service Center)|Full functionality of the Home Monitoring System for an early optimization of CRT and management of AF with a full access for the treating physician to the HMSC
11576919|NCT00811382|Active Comparator|2: No access to HMSC|Limited access of the treating physician to the HMSC where only events regarding implant and lead status will be generated and sent to the physician.
11576920|NCT00811369|Experimental|1|Fulvestrant + ZACTIMA Group
11576921|NCT00811369|Placebo Comparator|2|Fulvestrant + Placebo Group
11576971|NCT00810979|Experimental|1|SLx-4090 dose #1 in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
11577368|NCT00808262|Experimental|TNFa Kinoid dose 1|
11576922|NCT00811356|Experimental|Single Dose, Repeat Dose, Drug-Drug Interaction|"GSK932121 or placebo will be administered as a single dose with or without food in a dose escalation manner. Once the results from the single dose is obtained and reviewed, GSK932121 or placebo will be administered as a repeat dose. The results from each repeat dose level will be reviewed prior to determining the next repeat dose level.
~To better understand the effect of GSK932121 on rosiglitazone and rosuvastatin, a drug-drug interaction arm will also be investigated in this study. Rosiglitazone and rosuvastatin will be administered alone, then GSK932121 will be given as a repeat dose. Rosiglitazone and rosuvastatin will then be administered in combination with GSK932121."
11576923|NCT00811343|Experimental|1|
11576924|NCT00811330|Experimental|1: Atorvastatin 80 mg.|Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
11576925|NCT00811330|No Intervention|2: No Atrovastatine|
11576926|NCT00811317|Experimental|Closed-loop|Type 1 diabetic subjects under closed-loop blood glucose control
11576927|NCT00811304||US group|All patients admitted to the labor and delivery suite who request an epidural for labor analgesia.
11576928|NCT00811291|Placebo Comparator|1|
11576929|NCT00811291|Active Comparator|2|folic acid and B-vitamin supplement
11576930|NCT00811278||step1|asthma patients on step 1 therapy
11576931|NCT00811278||step 2|asthma patients on step 2 therapy
11576932|NCT00811278||healthy|non-asthmatics
11576933|NCT00811265|Experimental|Simulated ExAblate MRgFUS|Patients undergoing simulated ExAblate MRgFUS device use
11576934|NCT00811252|Placebo Comparator|Placebo|
11576935|NCT00811252|Experimental|Vortioxetine 5 mg|
11576936|NCT00811252|Other|Duloxetine 60 mg|Active reference
11576937|NCT00811239|Other|control group|As the antivenom was not yet clinically available until 2006, all patients included during the first two years (2004-2005) received supportive therapy only.
11576938|NCT00811239|Active Comparator|antivenom group|The patients included during the third year (2006) were treated with antivenom therapy and supportive care.
11576939|NCT00811226||Patients|Patients with arterial hypertension Stade I or Stade II
11576940|NCT00811213|Experimental|1|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
11576941|NCT00811213|Active Comparator|2|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
11576942|NCT00811200|Active Comparator|1: Lucentis|
11576943|NCT00811200|Active Comparator|2: Kenalog|
11576944|NCT00811200|Sham Comparator|3: No treatment|
11576945|NCT00811187|Experimental|Lidocaine paracervical block|5cc 1% lidocaine injection in each paracervical region
11576946|NCT00811187|Placebo Comparator|Saline placebo injection|5cc Normal Saline injection in each paracervical region
11576947|NCT00811174|Experimental|Octagam 10%|
11576948|NCT00811161|Experimental|needle free injector of HA|
11576949|NCT00811148||Tissue Bank|Collection of clinical data and tumor tissue removed during brain surgeries for future research.
11576950|NCT00811135|Experimental|1|
11576951|NCT00811109|No Intervention|Standard|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity
11576952|NCT00811109|Active Comparator|2|With Blood Volume on-line monitoring only
11576953|NCT00811109|Active Comparator|3|With Blood volume and Blood temperature on-line monitoring
11576954|NCT00811096|Experimental|Treatment Arm|
11576955|NCT00811096|Active Comparator|Comparator Arm|Comparator Arm
11576956|NCT00811083|Active Comparator|DMSA- 1 round|Subjects receive 1 round of DMSA (10 mg/kg-dose, 9 doses over 3 days), followed by 3 months of placebo
11576957|NCT00811083|Active Comparator|DMSA-7 rounds|Participants receive 7 rounds of DMSA over 4 months; each round consists of 3 days of DMSA (10 mg/kg-dose, 9 doses over 3 days), followed by 11 days off (no treatment), and then repeating.
11576958|NCT00811070|Experimental|1|
11576959|NCT00811057|Active Comparator|1 Magnesium Sulfate|
11576960|NCT00811057|Active Comparator|2 Nifedipine|Participants randomized to this group will receive the medication nifedipine orally.
11576961|NCT00811057|Active Comparator|3 Indomethacin|Participants randomized to this arm will receive the medication indomethacin per rectum and orally.
11576962|NCT00811044||Entry|This group is just entering the study and will need to be genotyped.
11576963|NCT00811044||Affected|This group has been genotyped and has the gene undergoing study at that time.
11576964|NCT00811044||Control|This group has been genotyped and does not have the gene currently under study.
11576965|NCT00811031|Experimental|Taxotere + Prednisone|
11576966|NCT00811018|Experimental|Sitaxsentan|Sitaxsentan
11576967|NCT00811005|Active Comparator|Acitretin-PUVA combination|"Acitretin-PUVA combination:
~Acitretin monotherapy: Patients randomized to the acitretin group will receive acitretin in a dose of 1mg /kg daily two weeks prior to additional PUVA treatment.
~PUVA treatment (see below) will be applied thrice weekly in addition to acitretin until (near) complete clearance or over a maximum period of 12 weeks. (Near) complete clearance is defined by improvement of the clinical baseline score (see below) by ≥90%.
~PUVA treatment:
~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation."
11576968|NCT00811005|Experimental|Fumaric acid ester -PUVA combination|"FAE monotherapy:
~Patients randomized to this group will receive FAE in weekly incremental doses (initial daily dose: 30 mg dimethylfumarate (DMF), highest daily dose: 720 mg DMF) starting two weeks prior to additional PUVA treatment.
~FAE-PUVA combination:
~PUVA treatment will be applied thrice weekly in addition to FAE until (near) complete clearance or over a maximum period of 12 weeks. (Near) complete clearance is defined by improvement of the clinical baseline score (see below) by ≥90%.
~PUVA treatment:
~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation."
11576969|NCT00810992|Active Comparator|1 Program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
11576970|NCT00810992|Experimental|2 Program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
11576972|NCT00810979|Experimental|2|SLx-4090 dose #2 in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
11576973|NCT00810979|Other|3|Placebo in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
11576974|NCT00810953|Experimental|single arm|Use of pentamidine in locally advanced or metastatic pancreatic cancer
11576975|NCT00810940|Active Comparator|1|Control: Standard treatment for severe head trauma including mannitol
11576976|NCT00810940|Experimental|2|Study drug plus standard treatment
11576977|NCT00810927|Active Comparator|1|Phenylephrine (Neosynephrine®, Abbott Laboratories, North Chicago, IL, USA) dose: 1µg/(kg.min), infusion period 20 minutes
11576978|NCT00810927|Active Comparator|2|NG-monomethyl-L-arginine (L-NMMA, Clinalfa, Läufelfingen, Switzerland) dose: bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/(kg.min) over 15 minutes
11576979|NCT00810927|Placebo Comparator|3|Physiologic saline solution
11576980|NCT00810914|Experimental|1|Continuous epidural infusion of medication for method of pain relief
11576981|NCT00810914|Experimental|2|continuous epidural infusion in conjuction with patient controlled anesthesia (PCA)
11576982|NCT00810914|Experimental|3|patient controlled anesthesia only this arm has pt controlled medication delivery. (PCA)
11576983|NCT00810901|Experimental|Organ Donor|Intervention used a DVD, text messaging, emails, a website, US Mail, and telephone calls to educate teens about their choice to become a designated organ donor on their first driver's license application.
11576984|NCT00810901|Active Comparator|Alcohol Prevention|Intervention used a DVD and text messages, to educate teens about the laws that prohibit underage minors purchasing and consuming alcohol
11576985|NCT00810888|Active Comparator|Group 1-Recombinant activated factor VII|"Participants with ICH determined by CTA to be high risk for hemorrhage growth (spot sign positive for contrast leakage within the brain hematoma) randomized to receive rFVIIa at 80 mcg/kg (max dose 21.3 mL)."
11576986|NCT00810888|Placebo Comparator|Group 2 - Placebo|"Participants with ICH determined by CTA to be high risk for hemorrhage growth (spot sign positive for contrast leakage within the brain hematoma) will be randomized to receive placebo."
11576987|NCT00810888|No Intervention|Group 3 - Observation Only Arm|"Participants with ICHdetermined by CTA not to be at high risk for hemorrhage growth (CTA spot sign negative) enrolled into a prospective observational group."
11576988|NCT00810875||hepatitis C|pregnant women with hepatitis C virus infection and their infants
11576989|NCT00810875||controls|pregnant women without hepatitis C infection and their infants
11576990|NCT00810862|Experimental|Pimecrolimus|Pimecrolimus 1% cream
11576991|NCT00810862|Placebo Comparator|2|Placebo cream over affected study area
11576992|NCT00810849|Placebo Comparator|Prednisolone|Six-week tapering course of prednisolone and those assigned to the prednisolone control arm will receive the same number of identically-coated placebo tablets.
11576993|NCT00810849|Placebo Comparator|Mycobacterium w|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months).
11576994|NCT00810836|Active Comparator|1|BG00012 480 mg/day
11576995|NCT00810836|Active Comparator|2|BG00012 720 mg/day
11576996|NCT00810836|Placebo Comparator|3|
11576997|NCT00810823||1:Gastric bypass/diabetes|Patients undergoing gastric bypass surgery, and who are diagnosed with type 2 diabetes.
11576998|NCT00810823||2:Gastric bypass/not Diabetic|Patients undergoing gastric bypass surgery, not diagnosed with diabetes.
11576999|NCT00810810|Active Comparator|1|Blood components with no additional treatment
11577000|NCT00810810|Experimental|2|Blood components leukoreduced
11577001|NCT00810810|Experimental|3|Blood components leukoreduced and irradiated
11577002|NCT00810797|Experimental|Treatment (exemestane)|Patients receive oral exemestane once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11577003|NCT00810784||1|Patients cared for before our intervention.
11577004|NCT00810784||2|Patients cared for after our intervention.
11577005|NCT00810771|Experimental|Preference-tailored (PT) intervention|"Intervention:
~Behavioral: Standard Information Behavioral: Preference-tailored Information"
11577006|NCT00810771|Active Comparator|Standard information (SI) intervention|Behavioral: Standard Information
11577007|NCT00810771|No Intervention|Usual Care|Due to budget and time constraints this group was not powered as a true study arm but was used to assess the impact of our baseline physician information letter and to control for any other interventions of system-wide initiatives that may occur during the study timeframe and impact rated of CRC screening. Data was not collected on every participant in this arm.
11577008|NCT00810758|Experimental|PF-04878691|
11577009|NCT00810745|Experimental|rectal resection|
11577010|NCT00810732|Experimental|Sitaxsentan|Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
11577011|NCT00810732|Active Comparator|Nifedipine|Nifedipine 30 mg extended release tablets, orally administered once daily (open label arm)
11577012|NCT00810732|Placebo Comparator|Placebo|Placebo for sitaxsentan, orally administered once daily (double blind arm)
11577013|NCT00810719|Experimental|Gemcitabine and Erlotinib|The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.Erlotinib will be dosed at 150mg orally (tablets) on days 2-5, 9-12, and 16-26 of a 28 day cycle.
11577014|NCT00810706|No Intervention|1: observation only|Patients have completed at least 5 years and not more than 7 years of continued treatment with tamoxifen (20 mg/day). Tamoxifen could have been discontinued up to 6 months prior to study entry.
11577015|NCT00810706|Active Comparator|2: Exemestane|Patients randomised to receive exemestane (25 mg/day) for 5 years, following completion of 5-7 years of Tamoxifen treatment
11577016|NCT00810693|Experimental|Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks
11577171|NCT00809653|Experimental|Visit 2|2 hour walk in city centre location in Beijing China
11577017|NCT00810693|Experimental|Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 1.5mg three times daily (tid) (titration between 1.0 mg and 1.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks
11577018|NCT00810693|Placebo Comparator|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 12 weeks
11577019|NCT00810680|Experimental|Valproic acid|
11577020|NCT00810667|Experimental|Lu AE58054|
11577021|NCT00810667|Placebo Comparator|Placebo|
11577022|NCT00810654|Experimental|ANPEP|Aspergillus niger prolyl endoprotease (AN-PEP), a microbial-derived prolyl endoprotease which cleaves gluten
11577023|NCT00810654|Placebo Comparator|Placebo|
11577024|NCT00810641|Active Comparator|Gufoni maneuver|Gufoni maneuver for apogeotropic HC-BPPV
11577025|NCT00810641|Active Comparator|Headshaking maneuver|headshaking maneuver for apogeotropic HC BPPV
11577026|NCT00810641|Sham Comparator|sham maneuver|sham maneuver for apogeotropic HC BPPV
11577027|NCT00810628|Experimental|1|All subjects in same investigative group with same CBT intervention.
11577028|NCT00810615|Sham Comparator|Sham treatment|Subject will breathe air at less than 1.3 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at less that 1.3 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
11577029|NCT00810615|Experimental|Hyperbaric oxygen 2.4 ATA|Subject will breathe 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
11577030|NCT00810602|Experimental|Vorinostat prophylaxis|Vorinostat,combined with standard GVHD prevention medications(tacrolimus, mycophenolate) for adults who received a reduced intensity, related donor stem cell transplant
11577031|NCT00810589|Experimental|1|
11577032|NCT00810589|Active Comparator|2|
11577033|NCT00810576|Experimental|Vorinostat + Bortezomib|Vorinostat 200 mg orally twice on Days 1-14 + Bortezomib 1.3 mg/m^2 intravenous (IV) on Days 1, 4, 8, 11.
11577034|NCT00810563|Placebo Comparator|1|Saline solution 0.9% 5mL in each portal
11577035|NCT00810563|Active Comparator|2|Bupivacaine 0.5% 5mL in each portal
11577036|NCT00810550|Other|LV systolic dysfunction|Diagnostic Testing
11577037|NCT00810524|Experimental|A|120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).
11577038|NCT00810524|Active Comparator|B|120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).
11577039|NCT00810524|Experimental|C|180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).
11577040|NCT00810524|Active Comparator|D|180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).
11577041|NCT00810511|Experimental|Lotrafilcon A|Investigational, spherical, silicone hydrogel contact lenses
11577042|NCT00810511|Active Comparator|Comfilcon A|Commercially marketed, spherical, silicone hydrogel contact lenses
11577043|NCT00810485|Experimental|ADX10059 50 mg|twice-daily
11577044|NCT00810485|Experimental|ADX10059 100 mg|twice-daily
11577045|NCT00810485|Experimental|ADX10059 150 mg|twice-daily
11577046|NCT00810485|Placebo Comparator|ADX10059 Matching Placebo|twice-daily
11577047|NCT00810472|Experimental|HLA Matching|HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial [8]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method [6]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
11577048|NCT00810472|Placebo Comparator|Random graft assignment|
11577049|NCT00810446||rifabutin|Patients administered Rifabutin.
11577050|NCT00810433|Experimental|Arm 1|
11577051|NCT00810407||rifabutin|Patients administered Rifabutin.
11577052|NCT00810394|Experimental|Sorafenib|Dose Re-Escalation Following a Dose Reduction
11577053|NCT00810381|Active Comparator|1|"Nitroglycerin: (Perlinganit, Nycomet Heilmittelwerke, Vienna, Austria):
~0, 0.25, 0.5, 1, 1.5 and 2 µg/kg/min, each infusion step for 20 minutes"
11577054|NCT00810381|Active Comparator|2|"Isosorbide-Dinitrate: (Isoket 0,1 %, Gebro Broschek, Fieberbrunn, Austria):
~0, 0.5, 1, 2, 4 and 6 µg/kg/min , each infusion step for 20 minutes"
11577055|NCT00810381|Active Comparator|3|"Sodium-Nitroprusside: (Nipruss, Sanol-Schwarz, Monheim, Germany):
~0, 0.25, 0.5, 1, 2 and 4 µg/kg/min, each infusion step for 20 minutes"
11577056|NCT00810381|Placebo Comparator|4|Physiologic saline solution
11577057|NCT00810368|Active Comparator|Carnosine treatment group|Carnosine treatment group
11577058|NCT00810368|Placebo Comparator|Placebo control group|Placebo control group
11577059|NCT00810355|Active Comparator|Arm 1|Support group
11577060|NCT00810355|Experimental|Arm 2|Cognitive Behavior Therapy
11577061|NCT00810355|Experimental|Arm 3|Cognitive Behavior Therapy and Cognitive Remediation
11577062|NCT00810342|Experimental|1- physical activity tailored|Tailored telephone counseling about how to become more physically active and goal setting. Email feedback on physical activity progress. Website listing resources new mothers can use to become more active.
11577063|NCT00810342|Active Comparator|2 - physical activity standard|Standard Website resources / information on physical activity
11577064|NCT00810329||1|This group consists of patients with Chronic fatigue syndrome, Fibromyalgia and other conditions like Multiple chemical sensitivity, Irritable bowel syndrome, Interstitial Cystitis, Gulf War Illness.
11577065|NCT00810329||2|The healthy control group
11577066|NCT00810316|Other|Treatment A|
11577067|NCT00810316|Other|Treatment B|
11577068|NCT00810316|Other|Treatment C|
11577069|NCT00810303|Experimental|whole study group|A study with a duration of 34 days with 4 periods (= 4 pharmakokinetics) on 12 healthy subjects.
11577070|NCT00810277|Experimental|1|
11577071|NCT00810264||Data Collection Group|
11577072|NCT00810251||MatrixRIB|
11577073|NCT00810238|Experimental|1|Optimal standard of care + C-Cure
11577074|NCT00810238|No Intervention|2|Optimal standard of care
11577075|NCT00810225||1|GWI: veterans of the 1990-1991 Persian Gulf War who have autonomic, neurological and other symptoms
11577076|NCT00810225||2|HC: healthy veterans of the 1990-1991 Persian Gulf War
11577077|NCT00810212|Active Comparator|1|Autograft
11577078|NCT00810212|Experimental|2|Low Dose MPCs
11577079|NCT00810212|Experimental|3|Medium Dose MPCs
11577080|NCT00810212|Experimental|4|High Dose MPCs
11577081|NCT00810199|Experimental|Tocilizumab + Methotrexate|Tocilizumab 8 mg/kg (up to 800 mg) intravenous (IV) once every 4 weeks + weekly oral methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drugs (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded methotrexate if a flare occurred.
11577082|NCT00810199|Placebo Comparator|Tocilizumab + Placebo|Tocilizumab 8 mg/kg (up to 800 mg) IV once every 4 weeks + weekly oral placebo to methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and placebo to methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drug (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded placebo to methotrexate if a flare occurred.
11577083|NCT00810186||Newborns needing respiratory monitoring|Premature and term newborn infants (male/female)
11577084|NCT00810173|Experimental|1|This group received call phone support to incentive the increase of the number of steps during 6 weeks
11577085|NCT00810173|No Intervention|2|This group just received a pedometer to register the number of steps for 6 weeks but this group don´t received a phone call.
11577086|NCT00810160|Active Comparator|1|Permeate
11577087|NCT00810160|Active Comparator|2|GOS
11577088|NCT00810160|Active Comparator|3|Bifidobacterium infantis
11577089|NCT00810160|Active Comparator|4|Bifidobacterium animalis
11577090|NCT00810147|Active Comparator|A1|
11577091|NCT00810147|Active Comparator|A2|
11577092|NCT00810147|Active Comparator|A3|
11577093|NCT00810147|Active Comparator|A4|
11577094|NCT00810147|Placebo Comparator|A5|
11577095|NCT00810134|Other|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
11577096|NCT00810134|Other|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
11577097|NCT00810121|Experimental|1|Ketoprofen 100 mg b.i.d. for 5 days
11577098|NCT00810121|Experimental|2|Ketoprofen 150 mg b.i.d. for 5 days
11577099|NCT00810108|Experimental|Whole Then Crushed Tablets|These subjects will take whole lopinavir tablets at Study Visit 1, and crushed tablets at Study Visit 2.
11577100|NCT00810108|Experimental|Crushed Then Whole Tablets|These subjects will take crushed tablets at Study Visit 1, and whole tablets at Study Visit 2.
11577101|NCT00810095|Experimental|Treatment Arm|
11577102|NCT00810082|Active Comparator|Group A|Standard physical therapy for fall prevention
11577103|NCT00810082|Experimental|Group B|Physical therapy for fall prevention that includes ActiveStep
11577104|NCT00810069|Experimental|Early Intervention|Escitalopram 10 milligrams per day for 4 weeks (one 10 milligram [mg]-capsule) followed by Duloxetine flexible dose (60 or 120 mg daily) for 12 weeks.
11577105|NCT00810069|Experimental|Delayed Intervention|Escitalopram 10 mg per day for 4 weeks (one 10 mg-capsule) followed by Escitalopram 10 to 20 mg per day for 4 weeks (one or two 10 mg capsule[s]). Then, non-responders switched to Duloxetine 60 or 120 mg per day for 8 weeks , and responders continued on Escitalopram 10 to 20 mg per day for 8 weeks.
11577106|NCT00810056|Active Comparator|Assessment only|Cognitive, academic achievement and mental health screening assessment and report.
11577107|NCT00810056|Experimental|Assessment + FHF|Cognitive, academic achievement and mental health screening assessment and report. Fostering Healthy Futures program (FHF) including weekly therapeutic skill groups and mentoring over a 9-month period.
11577108|NCT00810043|Active Comparator|Curette-First|All of patients in the study were treated with Balloon Kyphoplasty. During Balloon Kyphoplasty, two inflatable bone tamps (IBTs) are placed into the vertebral body bilaterally via a transpedicular or extrapedicular approach under fluoroscopic guidance. In this arm, curettage was performed prior to use of inflatable bone tamps.
11577109|NCT00810043|Active Comparator|IBT-First|All of patients in the study were treated with Balloon Kyphoplasty. During Balloon Kyphoplasty, two inflatable bone tamps (IBTs) are placed into the vertebral body bilaterally via a transpedicular or extrapedicular approach under fluoroscopic guidance. In this arm, inflatable bone tamps were used prior to curettage, then followed by a second inflation of the bone tamps.
11577110|NCT00810030|Experimental|FERINJECT® (Ferric carboxymaltose)|
11577111|NCT00810030|Active Comparator|VENOFER® (Iron Sucrose)|
11577112|NCT00810017|Experimental|Single arm study|Etoposide 100mg/m2 daily x 3 days Q3W and Trastuzumab 8mg/kg loading dose then 6mg/kg, then single agent until disease progression
11577113|NCT00810004|Experimental|Ferinject|Intravenous infusion of iron
11577114|NCT00810004|Placebo Comparator|Placebo|NaCL 0,9%
11577369|NCT00808262|Experimental|TNFa Kinoid dose 2|
11577370|NCT00808262|Experimental|TNFa Kinoid dose 3|
11577115|NCT00809991|Experimental|Hypofractionated radiation therapy in prostate adenocarcinoma|Participants with histologically confirmed, locally confined adenocarcinoma of the prostate receive 3.6 Gy per day to a total dose of 57.6 Gy (16 fractions).
11577116|NCT00809965|Experimental|Rivaroxaban 2.5 mg bid|One 2.5 mg rivaroxaban tablet twice daily for up to 6 months
11577117|NCT00809965|Experimental|Rivaroxaban 5 mg bid|One 5 mg rivaroxaban tablet twice daily for up to 6 months
11577118|NCT00809965|Placebo Comparator|Placebo|One placebo tablet twice daily for up to 6 months
11577119|NCT00809952||Recombinat FSH|
11577120|NCT00809939|Active Comparator|1|previous preterm delivery, treatment with weekly injections of 17 alfa hydroxyprogesterone caproate.
11577121|NCT00809939|Active Comparator|2|previous preterm delivery, treatment with daily vaginal natural progesterone
11577122|NCT00809939|Active Comparator|3|short cervical length, treatment with weekly injections of 17 alfa hydroxyprogesterone caproate.
11577123|NCT00809939|Active Comparator|4|short cervical length, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
11577124|NCT00809926|Experimental|Valsartan/aliskiren|
11577125|NCT00809926|Active Comparator|Valsartan|
11577126|NCT00809913|Experimental|Short treatment|7 days of standard antibiotic treatment (preferably ciprofloxacin) followed by 7 days of placebo
11577127|NCT00809913|Active Comparator|Standard treatment|14 days of standard antibiotic treatment (initial b-lactam or fluoroquinolone followed by ciprofloxacin through the 8th till 14th day)
11577128|NCT00809900||Dietary Supplement|Cranberry Juice Consumption
11577129|NCT00809887|Placebo Comparator|1|ALT with placebo with systemic Micafungin therapy
11577130|NCT00809887|Experimental|2|ALT with Micafungin and heparin with systemic Micafungin therapy
11577131|NCT00809874|Active Comparator|Casein|
11577132|NCT00809874|Active Comparator|Whey Isolate|
11577133|NCT00809874|Active Comparator|Whey Hydrolysate|
11577134|NCT00809874|Active Comparator|Alphalact-Albumin|
11577135|NCT00809861|Active Comparator|1|volar locking plating of distal radius fractures
11577136|NCT00809861|Active Comparator|2|
11577137|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
11577138|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
11577139|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
11577140|NCT00809848|Active Comparator|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
11577141|NCT00809848|Placebo Comparator|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
11577142|NCT00809835|No Intervention|Standard Treatment As Usual (TAU)|Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals. This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment. The counseling program's theoretical orientation is described as client-centered.
11577143|NCT00809835|Experimental|TAU Plus Galantamine|Standard treatment plus Galantamine. In this study, we will use 8 mg galantamine extended release (ER). Galantamine ER is used once daily. The recommended initial dose is 8 mg/day and the maintenance dose is 16-24 mg/day.
11577144|NCT00809835|Experimental|TAU plus Computer Assisted Cognitive Behavioral Therapy (CBT)|TAU plus computer assisted CBT plus placebo. All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project. Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.
11577145|NCT00809835|Experimental|TAU plus CBT plus galantamine|Standard treatment, plus computer assisted cognitive behavioral therapy, plus galantamine.
11577146|NCT00809822|Active Comparator|1|Intravenous immunoglobulin
11577147|NCT00809822|Placebo Comparator|2|Physiological saline
11577148|NCT00809809|Active Comparator|Zinc gluconate|Oral swabs containing homeopathic Zinc gluconate
11577149|NCT00809809|Placebo Comparator|Placebo|placebo
11577150|NCT00809796|Experimental|single arm|Use of pentamidine in second and/or third line metastatic colon cancer
11577151|NCT00809783|Experimental|Tanezumab 10 mg|Tanezumab 10 mg
11577152|NCT00809783|Experimental|Tanezumab 5 mg|Tanezumab 5 mg
11577153|NCT00809783|Experimental|Tanezumab 2.5 mg|Tanezumab 2.5 mg
11577154|NCT00809770|Experimental|1|Contingency management
11577155|NCT00809770|Other|2|Non Contingent Control Condition
11577156|NCT00809757|Experimental|1|90 ug Levalbuterol (2 actuations)
11577157|NCT00809757|Active Comparator|2|0.31 ug Levalbuterol UDV TID
11577158|NCT00809757|Placebo Comparator|3|Placebo
11577159|NCT00809731||Observational Group|All commercially available 2nd-generation antipsychotic with an indication of treating schizophrenia will be prescribed by the physician according to normal practices
11577160|NCT00809718|Other|raltegravir and rifapentine|Concomitant administration of raltegravir and rifapentine in healthy volunteers
11577161|NCT00809705|Experimental|1|
11577162|NCT00809705|Experimental|2|
11577163|NCT00809705|Placebo Comparator|3|
11577164|NCT00809692|Active Comparator|1|50 subjects with allergic disease receiving histamine challenges by the prick test and iontophoresis technique (serial assessment of blood flow using validated Doppler technique)
11577165|NCT00809692|Experimental|2|150 additional subjects with allergic disease; undergo genotyping; laser Dopper assessment
11577166|NCT00809679|Experimental|T-62 100 mg bid|
11577167|NCT00809679|Experimental|T-62 200 mg bid|
11577168|NCT00809679|Placebo Comparator|Placebo|
11577169|NCT00809666|No Intervention|Mercury|All subsequent blood pressure recording done using mercury sphygmomanometry
11577170|NCT00809653|Experimental|Visit 1|2 hour walk in city centre location in Beijing China
11577172|NCT00809640|Active Comparator|1|The intervention group will receive prevention of low back pain education through a Back Comic-Book, and their beliefs/knowledge will be tested twice after intervention.
11577173|NCT00809640|No Intervention|2|The control group will receive no intervention, and their beliefs/knowledge on low back pain will be tested twice after the first assessment.
11577174|NCT00809627|Experimental|1|IV caffeine with saline and opiate
11577175|NCT00809627|Placebo Comparator|2|IV saline with opiate
11577176|NCT00809614|Experimental|AIN457 (2x 10mg/kg)|Each patient received 10 mg/kg AIN457 intravenously, on Day 1 and Day 22.
11577177|NCT00809614|Placebo Comparator|Placebo|Each patient received 10 mg/kg of matching placebo intravenously, on Day 1 and Day 22.
11577178|NCT00809601|Experimental|1|
11577179|NCT00809588|Experimental|Melanoma Vaccine|GM-CSF Vaccine
11577180|NCT00809562|Experimental|1|
11577181|NCT00809562|Placebo Comparator|2|
11577182|NCT00809549|Placebo Comparator|Normal Saline|
11577183|NCT00809549|Experimental|Filgrastim|
11577184|NCT00809536|Other|Cohort 1|This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults
11577185|NCT00809536|Other|Cohort 2|This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults
11577186|NCT00809523|Experimental|Inactivated negative ion generator|Equivalent exposure to inactivated Negative Ion Generator
11577187|NCT00809523|Experimental|LED light treatment device|Light-emitting photodiode light treatment device, used for 30 min before 8 am
11577188|NCT00809510|Experimental|1|
11577189|NCT00809484||1: Low risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily
11577190|NCT00809484||2:Moderate risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, +/- Risedronate 35mg orally once a week
11577191|NCT00809484||3:High risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, Risedronate 35mg orally once a week
11577192|NCT00809471|Placebo Comparator|placebo|
11577193|NCT00809471|Experimental|avanafil 100 mg|
11577194|NCT00809471|Experimental|avanafil 200 mg|
11577195|NCT00809458|Experimental|Arm 1 (Vitamin E)|Vitamin E
11577196|NCT00809458|Placebo Comparator|Arm 2|Placebo (same vehicle as used for vitamin E)
11577197|NCT00809445|Experimental|HIV rapid test & counseling|Participants will be offered an oral fluid HIV rapid test (via oral swab) and brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach (Project RESPECT-2 counseling). Prior to receiving testing, study participants must first provide consent for HIV testing. Consent for testing will be obtained through a second consent form required of all participants who wish to proceed with the HIV test.
11577198|NCT00809445|Experimental|HIV rapid test and info|Participants will be offered an oral fluid HIV rapid test (via oral swab). Prior to receiving testing, study participants must first provide consent for HIV testing. Again, consent for testing will be obtained through a second consent form required of all participants who wish to proceed with the HIV test. Participants will receive rapid HIV testing and test results after signing the consent to be tested. In both Groups 1 and 2, participants who test reactive (preliminary positive) will be counseled on the sexual risk behaviors associated with transmission of HIV and the acquisition of STDs, as is current clinical practice with those testing HIV positive. Confirmed positives will be linked to HIV primary care.
11577199|NCT00809445|Active Comparator|HIV testing referral|Participants randomized to group 3 will receive a referral list for HIV community-testing agencies. Each CTP site will have previously prepared an extensive referral list of testing sites in the surrounding geographic area. By virtue of their status as patients in the CTPs, they will receive whatever HIV testing and HIV education referrals the CTPs normally provide to their patients. This is the standard of care at CTPs that do not provide on-site testing.
11577200|NCT00809432|Experimental|Visit 1|2 hour city centre kerbside walk in Beijing China
11577201|NCT00809432|Experimental|Visit 2|2 hour city centre kerbside walk in Beijing China
11577202|NCT00809419|Experimental|A|NeoVista Ophthalmic System procedure + Lucentis
11577203|NCT00809393|Active Comparator|low dose|low dose tranexamic acid
11577204|NCT00809393|Experimental|high dose|
11577205|NCT00809380|Experimental|Parental presence|Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
11577206|NCT00809380|Active Comparator|Control|One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
11577207|NCT00809367|Other|Collection of Leukemia Cells|Other: Collection of Leukemia Cells Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
11577208|NCT00809354|Active Comparator|IV Placebo + NSAID|Oral NSAID
11577209|NCT00809354|Experimental|Tanezumab 5 mg|IV tanezumab 5 mg every 8 weeks (through Week 48)
11577210|NCT00809354|Experimental|Tanezumab 10 mg|IV tanezumab 10 mg every 8 weeks (through Week 48)
11577211|NCT00809354|Experimental|Tanezumab 5 mg + NSAID|IV doses of tanezumab 5 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
11577212|NCT00809354|Experimental|Tanezumab 10 mg + NSAID|IV doses of tanezumab 10 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
11577213|NCT00809341|Active Comparator|PET Negative|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or an equivalent anthracycline-containing regimen for 3 cycles, followed by PET scan. Participants with a negative PET scan will complete their chemotherapy regimen as prescribed by their oncologist.
11577272|NCT00808912|Active Comparator|1|Subjects will exercise in a high air pollutant environment after ingesting a standard dose of sildenafil.
11577214|NCT00809341|Active Comparator|PET Positive|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or an equivalent anthracycline-containing regimen for 3 cycles, followed by PET scan. Participants with a positive PET scan will receive two cycles of R-ICE (rituximab, ifosfamide, carboplatin, etoposide) followed by HiCy (high-dose cyclophosphamide).
11577215|NCT00809328|Experimental|Azithromycin|Azithromycin switch therapy (switch from intravenous to oral)
11577216|NCT00809315|Active Comparator|Assessment only|Cognitive, academic achievement and mental health screening assessment and report.
11577217|NCT00809315|Experimental|Fostering Healthy Futures (FHF) Assessment + FHF|Cognitive, academic achievement and mental health screening assessment and report. Weekly therapeutic skill groups and mentoring over a 9-month period.
11577218|NCT00809302|Experimental|1|aplindore 2 mg MR total daily dose
11577219|NCT00809302|Experimental|2|aplindore 6 mg MR total daily dose
11577220|NCT00809302|Experimental|3|aplindore 12 mg MR total daily dose
11577221|NCT00809302|Placebo Comparator|4|Placebo
11577222|NCT00809289|Experimental|One|
11577223|NCT00809289|Placebo Comparator|Two|
11577224|NCT00809289|Active Comparator|Three|Administration of a single oral dse of 400mg moxifloxacin
11577225|NCT00809250|Experimental|GM-K562/leukemia cell vaccine|Biological/Vaccine: GM-K562/leukemia cell vaccine Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
11577226|NCT00809237|Experimental|Gefitinib, Hydroxychloroquine|"For the lead in phase I study, recruited patients will receive one week of 250 mg of Gefitinib, before HCQ at the assigned dose is introduced in addition to Gefitinib 250 mg om.
~After the MTD of HCQ is determined, the phase II study will proceed with the combination of 250 mg of Gefitinib and the MTD dose of HCQ."
11577227|NCT00809224||ALS|ALS group should have ALS.
11577228|NCT00809224||Control|The control group should not have ALS or any other neurological/psychiatric disorder, and must be over the age of 40.
11577229|NCT00809211|Experimental|Nilotinib|
11577230|NCT00809198|Experimental|Sodium Hyaluronate|Sodium Hyaluronate (Kynex)
11577231|NCT00809198|Active Comparator|Carboxymethylcellulose sodium|Carboxymethylcellulose sodium (Refresh Plus)
11577232|NCT00809185|Experimental|RAD001 (everolimus)|RAD001 (everolimus) at 10mg/day with Bone marrow aspirate/biopsy and other laboratory biomarker analysis
11577233|NCT00809172|Active Comparator|1|Ciclosporin
11577234|NCT00809172|Experimental|2|Methotrexate
11577235|NCT00809159|Experimental|Part 1 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as a single dose.
11577236|NCT00809159|Placebo Comparator|Part 1 - Placebo|Placebo to AIN457A was administered intravenously as a single dose
11577237|NCT00809159|Experimental|Parts 1 and 2 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
11577238|NCT00809159|Experimental|Part 1 and 2 - AIN457 0.1 mg/kg|AIN457A 0.1 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
11577239|NCT00809159|Experimental|Part 1 and 2 - AIN457 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
11577240|NCT00809146|Active Comparator|Intramuscular (IM) anticonvulsant|This group gets active treatment with an anticonvulsant by the intramuscular route of administration.
11577241|NCT00809146|Active Comparator|Intravenous (IV) anticonvulsant|This group gets active treatment with an anticonvulsant by the intravenous route of administration.
11577242|NCT00809133|Experimental|Part A|BIBW2992 + Paclitaxel
11577243|NCT00809133|Experimental|Part B|BIBW2992 + Paclitaxel + Bevacizumab
11577244|NCT00809133|Experimental|Part C|BIBW2992 + Carboplatin
11577245|NCT00809133|Experimental|Part D|BIBW2992 +Paclitaxel + Carboplatin
11577246|NCT00809107|Experimental|1|HCG GROUP
11577247|NCT00809107|No Intervention|2|LH pick
11577248|NCT00809094|Placebo Comparator|Placebo|Placebo was administered oral tablet TID for 24 weeks.
11577249|NCT00809094|Active Comparator|N-Acetylcysteine|Participants received 900 mg of oral N-acetylcysteine TID for 24 weeks.
11577250|NCT00809081|Other|1|1. Enteral Feeding
11577251|NCT00809081|No Intervention|2|Total Parental support
11577252|NCT00809068|Active Comparator|1|fenofibrate and tibolone
11577253|NCT00809068|Sham Comparator|2|tibolone
11577254|NCT00809055|Experimental|High dose caffeine|Loading dose 40mg/kg IV caffeine citrate, followed 12 hours later by 20mg/kg IV caffeine citrate, followed 12 hours later by 10mg/kg IV caffeine citrate, followed 12 hours later by 10mg/kg IV caffeine citrate.
11577255|NCT00809055|Active Comparator|Standard dose caffeine|Loading dose 20mg/kg IV caffeine citrate, followed 12 hours later with D5W placebo, followed 12 hours later with 10mg/kg IV caffeine citrate, followed 12 hours later with D5W placebo.
11577256|NCT00809042|Experimental|1|Hydroxyurea
11577257|NCT00809042|Active Comparator|2|L-carnitine and hydroxyurea
11577258|NCT00809042|Active Comparator|4|L-carnitine , magnesium chloride and hydroxyurea
11577259|NCT00809042|Active Comparator|3|magnesium chloride and hydroxyurea
11577260|NCT00809003||Sjogren's group|
11577261|NCT00809003||Dry eye|
11577262|NCT00809003||Normals|
11577263|NCT00808990|Experimental|OSA and NAFLD patients using CPAP|OSA and NAFLD patients using CPAP being followed for 6 months.
11577264|NCT00808990|No Intervention|control|OSA and NAFLD patients not using CPAP being followed for 6 months.
11577265|NCT00808977|Experimental|Dersalazine|
11577266|NCT00808977|Active Comparator|Mesalazine|
11577267|NCT00808977|Placebo Comparator|Placebo|
11577268|NCT00808951|Experimental|Artemether -lumefantrine|Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso
11577269|NCT00808951|Experimental|Artesunate-amodiaquine|Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso
11577270|NCT00808938|Experimental|Active Treatment|
11577271|NCT00808925|Experimental|research arm|
11577273|NCT00808912|Active Comparator|2|Subjects will exercise in a low pollutant environment after ingesting a standard dose of sildenafil.
11577274|NCT00808912|Placebo Comparator|3|Subjects will exercise in a high pollutant environment after ingesting a placebo.
11577275|NCT00808912|Placebo Comparator|4|Subjects will exercise in a low pollutant environment after ingesting a placebo.
11577276|NCT00808899|Experimental|1|Fixed doses of IV temsirolimus concomitantly with two courses of fixed dosages of irinotecan, 2 days off, repeated daily 5 times.If initial dosages are not tolerable, subsequent patients will be given a reduced dosage of temsirolimus with irinotecan.If this dosage combination is not tolerable,irinotecan dosage will be decreased.If this dosage combination is not tolerable.Further enrollment to initial six week treatment will be terminated.Second course of irinotecan will begin on day 22, response will be determined after six weeks. Resection of primary tumor will be attempted after initial therapy.Following initial treatment children will undergo alternating courses of induction chemotherapy with cyclophosphamide,doxorubicin,etoposide,topotecan, and cisplatin.First cohort of 17 patients will receive Block 2 with temsirolimus for all three courses, weekly 2 times.If this is not tolerated subsequent patients will receive Block 2 chemotherapy with reduced dosages of temsirolimus.
11577277|NCT00808873|Experimental|1|brief education and 6 follow-up visits
11577278|NCT00808873|No Intervention|2|treatment-as-usual
11577279|NCT00808860|Placebo Comparator|Placebo group|Gliclazide + Placebo tea
11577280|NCT00808860|Active Comparator|GP group|Gliclazide + Gynostemma pentaphyllum tea
11577281|NCT00808834|Other|Senofilcon A / Lotrafilcon A|Senofilcon A, followed by Lotrafilcon A
11577282|NCT00808834|Other|Lotrafilcon A / Senofilcon A|Lotrafilcon A, followed by Senofilcon A
11577283|NCT00808808||Arm A (Control)|A control arm of usual care offering TIV with baseline advertisement
11577284|NCT00808808||Arm B (Choice)|An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
11577285|NCT00808808||Arm C (Choice Plus)|An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
11577286|NCT00808795|Experimental|N-acetylcysteine|
11577287|NCT00808795|Placebo Comparator|Placebo|
11577288|NCT00808782|Sham Comparator|Sham rTMS|Sham 5Hz rTMS.
11577289|NCT00808782|Experimental|rTMS|Active 5Hz deep TMS.
11577290|NCT00808769|Active Comparator|1|Zegerid®
11577291|NCT00808769|Experimental|2|Prilosec OTC®
11577292|NCT00808756|Experimental|1: Intervention|This group will be fed a diet enriched with fermentable carbohydrates.
11577293|NCT00808756|Placebo Comparator|2: Placebo.|The placebo group will be fed a diet without addition of fermentable carbohydrates. This placebo formula will have the same nutritional values than the intervention (energy, proteins, carbohydrates, fat, vitamins & minerals).
11577294|NCT00808756|No Intervention|BF|The 2 intervention groups will be compared with a breast-fed infants control group.
11577295|NCT00808743|Active Comparator|Group 1|Patients receive oral celecoxib twice daily and oral placebo twice daily
11577296|NCT00808743|Experimental|Group 2|Patients receive oral celecoxib twice daily and oral ursodeoxycholic acid twice daily
11577297|NCT00808730|Experimental|1|fiberoptic fibroscopy
11577298|NCT00808717|Experimental|High dose Atorvastatin 80 mg|Administered Atorvastatin 80 mg before intervention
11577299|NCT00808717|Active Comparator|Control|Administered Atorvastatin 10 mg before intervention
11577300|NCT00808691||1|Patients with sepsis
11577301|NCT00808691||2|Patient admitted for postoperative care
11577302|NCT00808691||3|Patients with ARDS
11577303|NCT00808691||4|Patients with ARF
11577304|NCT00808691||5|Patients who receive liver support treatment
11577305|NCT00808691||6|Patients wiht brain death
11577306|NCT00808678|Experimental|1|ABT-143 capsules 20/135 mg
11577307|NCT00808678|Active Comparator|2|ABT-335 135 mg and rosuvastatin 20 mg
11577308|NCT00808665|Experimental|Dexmedetomidine|At the beginning of spinal surgery, patients will receive 1 hour dexmedetomidine intravenous bolus of 0.7 mcg/kg, followed by infusion of dexmedetomidine at a rate of 0.5 mcg/kg/hour for 2 hours, followed by an infusion of dexmedetomidine at a rate of 0.2 mcg/kg/hour for the duration of the procedure and for 4 hours after the procedure.
11577309|NCT00808665|Placebo Comparator|Saline|Since this is a blinded study, at the beginning of spinal surgery, patients will receive a 1 hour 0.9% saline intravenous bolus at a rate and volume commensurate with a 0.7 mcg/kg/hour bolus of dexmedetomidine. Similarly, this will be followed with a saline infusion at a rate of 0.5 mcg/kg/hour for 2 hours, followed by an infusion of saline at a rate of 0.2 mcg/kg/hour for the duration of the procedure and for 4 hours after the procedure.
11577310|NCT00808639|Experimental|Dose Dense MVAC|Chemo therapy with methotrexate, vinblastine, Adriamycin, Cisplatin
11577311|NCT00808626|Experimental|99mTc-rBitistatin|
11577312|NCT00808613|Active Comparator|1|Optetrak Posterior Stabilized
11577313|NCT00808613|Active Comparator|2|Optetrak Hi-Flex
11577314|NCT00808600|Other|resource-activating training, intensified exercise training|combination of the two interventions: resource-activating behavioural training and intensified exercise training
11577315|NCT00808600|Other|resource-activating training, moderate exercise training|combination of the two interventions: resource-activating training and moderate exercise training
11577316|NCT00808600|Other|relaxation training, intensified exercise training|combination of the two interventions: relaxation training and intensified exercise training
11577317|NCT00808600|Other|relaxation training, moderate exercise training|combination of the two interventions: relaxation training and moderate exercise training
11577318|NCT00808587||No Treatment|
11577319|NCT00808574|Experimental|Intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
11577320|NCT00808574|No Intervention|Control|No risk assessment or presentation
11577321|NCT00808561|Active Comparator|1 Alternative Fistula|
11577322|NCT00808561|Active Comparator|2 Forearm AV Graft|
11577323|NCT00808548||Lifestyle counseling|
11577324|NCT00808535||diabetics|
11577325|NCT00808535||healthy controls|
11577326|NCT00808522|Experimental|hCG|Patients at high risk for breast cancer will be treated with hCG
11577328|NCT00808509|Active Comparator|Adalimumab + MTX|Participants continued treatment with adalimumab 40 mg subcutaneously every other week plus methotrexate (at least 10 mg/week orally or subcutaneously) for 52 weeks. After Week 52 an observational extension period ensued where participants were treated at the discretion of the investigator.
11577329|NCT00808509|Experimental|Methotrexate|Participants discontinued adalimumab and continued to receive methotrexate (at least 10 mg/week orally or subcutaneously) for 52 weeks. Participants with a significant increase in RA disease activity were re-instituted to adalimumab 40 mg every other week (rescue arm). After Week 52 an observational extension period ensued where participants were treated at the discretion of the investigator.
11577330|NCT00808496|Experimental|MRI|Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline.
11577331|NCT00808496|Active Comparator|Radiography|Biannual disease progression monitoring with radiography of both hands and wrists.
11577332|NCT00808496|Placebo Comparator|Standard of Care|Diagnostic imaging results (MRI or radiography) reported to upon requisition.
11577333|NCT00808483|Experimental|Walking skill training group|Participation in the supervised walking skill training program.
11577334|NCT00808483|No Intervention|Control group|No participation in the supervised walking skill training program
11577335|NCT00808470|Experimental|Nutrients|Subjects in University of Florida music player study who are assigned to nutrient condition(beta-carotene, vitamins C and E, magnesium). Nutrient tablets are consumed for 4 days.
11577336|NCT00808470|Placebo Comparator|Placebo for nutrients|Subjects in University of Florida music player study who are assigned to control (placebo) condition. Placebo tablets are consumed for 4 days.
11577337|NCT00808457||patients with suspected pneumonia|
11577338|NCT00808444|Experimental|Synflorix Clinical Lot & Infanrix Group|Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).
11577339|NCT00808444|Experimental|Synflorix Commercial Lot Infanrix Group|Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).
11577340|NCT00808431|Experimental|Lifestyle counseling|Lifestyle counseling
11577341|NCT00808418|Experimental|Cohort|
11577342|NCT00808405|Active Comparator|acyclovir|
11577343|NCT00808405|Placebo Comparator|placebo|
11577344|NCT00808392|Experimental|1|
11577345|NCT00808392|Active Comparator|2|
11577346|NCT00808379|Other|Arm 2 (Radiation + boost )|"Radiation dose to pelvis will be delivered at 1.8 Gy per day, five days per week, to give a total of 25 fractions over a period of five weeks for a total of 45 Gy.
~Boost Field - Will be given to all the patients in the radiotherapy alone followed by surgery arm.
~The boost will be given with by 3dimensional conformal radiotherapy to a dose of 15-20 Gy. After 45Gy the boost will be planned on the original tumor volume."
11577347|NCT00808379|Active Comparator|Arm 1 (standard) Chemoradiation|"The Radiation dose will be delivered at 1.8 Gy per day, five days per week, to give a total of 25 fractions over a period of five weeks for a total of 45 Gy.
~Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles."
11577348|NCT00808366|Experimental|RV4104A ointment|
11577349|NCT00808366|Active Comparator|bifonazole-urea ointment|
11577350|NCT00808340|Active Comparator|senofilA test/senofilA prod/balafilconA|Subjects wear 3 multifocal contact lenses: senofilcon A test worn first, senofilcon A production worn second, and balafilcon A worn third.
11577351|NCT00808340|Active Comparator|senofilcon A test/balafilcon A/senofilcon A prod|Subjects wear 3 multifocal contact lenses: senofilcon A test worn first, balafilcon A worn second, and senofilcon A production worn third.
11577352|NCT00808340|Active Comparator|senofilcon A prod/senofilcon A test/balafilcon A|Subjects wear 3 multifocal contact lenses: senofilcon A production worn first, senofilcon A test worn second, and balafilcon A worn third.
11577353|NCT00808340|Active Comparator|senofilcon A prod/ balifilcon A/ senofilcon A test|Subjects wear 3 multifocal contact lenses: senofilcon A production worn first, balafilcon A worn second, and senofilcon A test worn third.
11577354|NCT00808340|Active Comparator|balafilcon A/senofilcon A test/senofilcon A prod|Subjects wear 3 multifocal contact lenses: balafilcon A worn first, senofilcon A test worn second, and senofilcon A production worn third.
11577355|NCT00808340|Active Comparator|balafilcon A/senofilcon A prod/senofilcon A test|Subjects wear 3 multifocal contact lenses: balafilcon A worn first, senofilcon A production worn second, senofilcon A test worn third.
11577356|NCT00808327|Active Comparator|1|Bupivacaine alone
11577357|NCT00808327|Active Comparator|2|Bupivacaine plus Fentanyl
11577358|NCT00808314|Active Comparator|LL for CAD|Subjects with <5% pre-test low likelihood for CAD based on Diamond and Forrester criteria will be recruited to undergo both rest/stress dipyridamole PET followed by a rest/stress Lexiscan(TM) PET with 30 days.
11577359|NCT00808314|Active Comparator|CAD|Subjects with existing mild-moderate ishemia demonstrated by a recent (< 1 month) rest/stress dipyridamole PET will undergo a rest/stress Lexiscan(TM) PET.
11577360|NCT00808301|Other|A/B|This is a cross-over design, i.e. each patient is treated with either oat or control products in different times.
11577361|NCT00808288|Experimental|PF-00610355|
11577362|NCT00808288|Experimental|PF- 00610355|
11577363|NCT00808288|Experimental|PF - 00610355|
11577364|NCT00808288|Placebo Comparator|Placebo|
11577365|NCT00808288|Active Comparator|Salmeterol|
11577366|NCT00808275|Experimental|Dairy calcium|Diet with dairy calcium sources
11577367|NCT00808275|Experimental|Non-dairy calcium|Diet with non-dairy calcium sources
11577371|NCT00808249|Experimental|A-AZD7325 2mg|AZD7325 2mg BID
11577372|NCT00808249|Experimental|B-AZD7325 5mg|AZD7325 5mg BID
11577373|NCT00808249|Experimental|C-AZD7325 10mg|AZD7325 10mg QD
11577374|NCT00808249|Experimental|D-Placebo|Placebo
11577375|NCT00808236|Experimental|RhinoChill|Intra-arrest cooling with the RhinoChill during advanced cardiac life support
11577376|NCT00808236|Other|Control|Advanced cardiac life support, only
11577377|NCT00808223|Experimental|1. alefacept|
11577378|NCT00808210|Experimental|Ocrelizumab 200mg|Participants received two intravenous (IV) infusions of 200 mg ocrelizumab administered on Day 1 and Day 15 and placebo IV infliximab infusions administered on Day 1, Day 15, Week 6, and Week 14. In addition to the study medication, all patients were to receive methotrexate at a stable dose of 7.5-25 mg/week and folic acid or equivalent at a dose of 5 mg/week to minimize methotrexate toxicity.
11577379|NCT00808210|Active Comparator|Infliximab 5mg/kg|Participants received four IV infusions of 5 mg/kg infliximab administered on Day 1, Day 15, Week 6, and Week 14 and placebo ocrelizumab infusions administered on Day 1 and Day 15. In addition to the study medication, all patients were to receive methotrexate at a stable dose of 7.5-25 mg/week and folic acid or equivalent at a dose of 5 mg/week to minimize methotrexate toxicity.
11577380|NCT00808197|Experimental|1|Observatory, longitudinal, 3-years follow up study
11577381|NCT00808184|Active Comparator|CPT-11|
11577382|NCT00808171|Experimental|EMLA and Livopan|Administered EMLA and Livopan
11577383|NCT00808171|Experimental|EMLA and gas placebo|Administered EMLA and oxygen
11577384|NCT00808171|Experimental|Livopan and placebo cream|Administered Livopan and placebo cream
11577385|NCT00808158||1|Children ages 9 to 10 years old, with a body mass index (BMI) in the 50th to 98th percentile range
11577386|NCT00808145|Experimental|Gemcitabine/Cisiplatin/Sorafenib|All eligible patients will receive intravenous gemcitabine/cisplatin + daily oral sorafenib until disease progression occurs
11577387|NCT00808132|Experimental|1|bazedoxifene 20 mg/conjugated estrogens 0.45 mg
11577388|NCT00808132|Experimental|2|bazedoxifene 20 mg/conjugated estrogens 0.625 mg
11577389|NCT00808132|Experimental|3|bazedoxifene 20 mg
11577390|NCT00808132|Active Comparator|4|Prempro
11577391|NCT00808132|Placebo Comparator|5|Placebo
11577392|NCT00808106||Albinism|Patients with albinism
11577393|NCT00808093|Other|fixed sequence|fixed sequence (14 days fasted followed by 14 days either high fat or standard meal
11577394|NCT00808080|Experimental|Biologic|AML_CTL cells
11577395|NCT00808067|Experimental|dabigatran dose 1|dabigatran high dose twice daily
11577396|NCT00808067|Experimental|dabigatran dose 2|dabigatran low dose twice daily
11577397|NCT00808054|Experimental|Glucose and EMLA|Received glucose oral and topical EMLA
11577398|NCT00808054|Experimental|Glucose and placebo|Received glucose and no EMLA
11577399|NCT00808054|Experimental|Oral placebo and EMLA|Received oral placebo and EMLA
11577400|NCT00808041||Treatment|Breast cancer patients undergoing hormonal therapy before surgery.
11577401|NCT00808028|Experimental|1|dose level 1 rLP2086 vaccine
11577402|NCT00808028|Experimental|2|dose level 2 rLP2086 vaccine
11577403|NCT00808028|Experimental|3|dose level 3 rLP2086 vaccine
11577404|NCT00808028|Placebo Comparator|4|normal saline (placebo)
11577405|NCT00808015||Patients in routine practice|Patients prescribed Champix by treating physician and then entered into trial
11577406|NCT00808002|Experimental|1|From Baseline to Week48: Raltegravir BID + Tenofovir/Emtricitabine QD + Maraviroc BID From W48 to W72: Raltegravir BID + Tenofovir/Emtricitabine QD
11577407|NCT00808002|Active Comparator|2|Start ARV treatment with : Raltegravir BID + Tenofovir/Emtricitabine
11577408|NCT00807989|Active Comparator|Carbamazepine|Carbamazepine
11577409|NCT00807989|Experimental|Lamotrigine/Valproate|Lamotrigine and Valproate combination therapy
11577410|NCT00807976||Study group|Type 2 diabetic patients aged 70 years and older.
11577411|NCT00807976||Control group|Patients aged 70 years and older, with no history of type 2 diabetes mellitus.
11577412|NCT00807963|Experimental|Stage 1: rHuPH20 plus ZA|Participants will receive one of several dose/concentrations of recombinant human hyaluronidase PH20 (rHuPH20) with zoledronic acid (ZA).
11577413|NCT00807963|Experimental|Stage 2: ZA|Participants will receive a dose/concentration of ZA administered without rHuPH20.
11577414|NCT00807963|Experimental|Stage 3: rHuPH20 plus ZA|Participants will receive one of several dose/concentrations of rHuPH20 with ZA.
11577415|NCT00807963|Experimental|Stage 4: ZA|Participants will receive an intravenous (IV) dose of 5 milligrams (mg) ZA.
11577416|NCT00807963|Experimental|Stage 4: ZA with rHuPH20|Participants will receive a subcutaneous (SC) dose of ZA with rHuPH20.
11577417|NCT00807937|Experimental|A|AZD7325 5mg twice daily
11577418|NCT00807937|Experimental|B|AZD7325 15mg twice daily
11577419|NCT00807937|Active Comparator|C|Lorazepam 2mg twice daily
11577420|NCT00807937|Placebo Comparator|D|Placebo
11577421|NCT00807911|Active Comparator|Adjuvant FL|FL (5-FU 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles)
11577422|NCT00807911|Experimental|Adjuvant FOLFOX|FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-FU bolus 400 mg/m2 on D1, 5-FU infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles)
11577423|NCT00807885|Experimental|Tegaderm-secured 24 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, Teflon angiocatheter secured with Tegaderm
11577424|NCT00807885|Experimental|Tape-secured 24 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, Teflon angiocatheter secured with a tape double chevron
11577425|NCT00807885|Experimental|Tegaderm-secured 24 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, polyurethane angiocatheter secured with Tegaderm
11577504|NCT00807352||level 5|patients triaged level 5
11577426|NCT00807885|Experimental|Tape-secured 24 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, polyurethane angiocatheter secured with a tape double chevron
11577427|NCT00807885|Experimental|Tegaderm-secured 20 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, Teflon angiocatheter secured with Tegaderm
11577428|NCT00807885|Experimental|Tape-secured 20 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, Teflon angiocatheter secured with a tape double chevron
11577429|NCT00807885|Experimental|Tegaderm-secured 20 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, polyurethane angiocatheter secured with Tegaderm
11577430|NCT00807885|Experimental|Tape-secured 20 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, polyurethane angiocatheter secured with a tape double chevron
11577431|NCT00807885|Experimental|SC button with 27 ga X 9 mm needle|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a button-type subcutaneous delivery system (with a 27-gauge, 9 mm long metal needle)
11577432|NCT00807872|Other|I-124 Mu 11-1F4 sterile injection|Single arm study
11577433|NCT00807859|Experimental|Cohort A1|
11577434|NCT00807859|Experimental|Cohort A3|
11577435|NCT00807859|Experimental|Cohort B1|
11577436|NCT00807859|Experimental|Cohort B3|
11577437|NCT00807846|Experimental|Celecoxib|
11577438|NCT00807846|Experimental|Naproxen|
11577439|NCT00807833||CBF measurement|"It is a proof of concept study, aimed to evaluate whether the optimal CPP, defined by the best PRx, corresponds to the acceptable CBF values.
~Patients admitted with the diagnosis of TBI and SAH in for whom ICP and CPP needs to be monitored on clinical ground will be also monitored with a TD probe and routinely tested for cerebral autoregulation, thus obtaining the CBF corresponding at a given the best CPP and autoregulation status."
11577440|NCT00807807|Placebo Comparator|1|Participants will receive placebo folic acid.
11577441|NCT00807807|Experimental|2|Participants will receive 100 mcg of folic acid.
11577442|NCT00807807|Experimental|3|Participants will receive 400 mcg of folic acid.
11577443|NCT00807807|Experimental|4|Participants will receive 1000 mcg of folic acid.
11577444|NCT00807807|Experimental|5|Participants will receive 2000 mcg of folic acid.
11577445|NCT00807794|Experimental|1|MEDI-507
11577446|NCT00807794|Experimental|2|MEDI-507
11577447|NCT00807794|Experimental|3|MEDI-507
11577448|NCT00807794|Experimental|4|MEDI-507
11577449|NCT00807794|Experimental|5|MEDI-507
11577450|NCT00807781|Experimental|Mammaglobin-A DNA vaccine|"Patients will receive vaccine day 1 (week 1), week 4 (day 29 +/- 7), week 8 (day 57 +/- 7) with at least 21 days between injection days.
~All injections will be given intramuscularly using a jet delivery device.
~Patients will be administered the vaccine in lateral shoulder and buttocks positions that will be rotated with each administration in the above order."
11577451|NCT00807768|Active Comparator|Arm I (pelvic radiation therapy)|Patients undergo conventional or intensity-modulated pelvic radiation therapy once daily, 5 days a week, for 5-6 weeks (total of 25-28 fractions) in the absence of disease progression or unacceptable toxicity. Patients with stage II disease or stage I disease with a confirmed diagnosis of clear cell and/or papillary serous histology may also undergo 1 or 2 intravaginal (i.e., vaginal cuff) brachytherapy boost treatments.
11577452|NCT00807768|Experimental|Arm II (brachytherapy, paclitaxel, carboplatin)|Patients undergo vaginal cuff brachytherapy comprising 3-5 high-dose rate brachytherapy treatments over approximately 2 weeks or 1 or 2 low-dose rate brachytherapy treatments over 1-2 days. Beginning within 3 weeks after initiating brachytherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Chemotherapy repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11577453|NCT00807755|Experimental|Phase I Dose-Escalation|This is a phase I dose escalation study of RAD001 and carboplatin/etoposide. Patients will be accrued in a standard 3 + 3 design based on toxicities experienced during the first cycle. Ten additional chemotherapy naive extensive stage small cell lung cancer (ES-SCLC) patients will be accrued at the Maximum Tolerated Dose (MTD) for further toxicity and response assessment.
11577454|NCT00807742|Experimental|Contingency Management (CM)|Condition provides contingent monetary reinforcement for smoking reductions (first 5 days) then for smoking abstinence (subsequent 14 days). Expired carbon monoxide (CO) levels will be the basis for determining reductions and abstinence.
11577455|NCT00807742|Active Comparator|Noncontingent Reinforcement (NR)|Controls for effects of receiving payments, providing daily breath samples for CO level, and degree of interaction between patient and research staff. NR will allow them to earn an amount which is matched in amount to the expected average earned in CM contingent only on providing breath samples independent of the CO level attained.
11577456|NCT00807729|Active Comparator|ERCP|All ERCP's were performed by one of the authors (JPC), a fulltime faculty member and gastroenterology fellowship instructor in the presence and concurrence of the principal author/ surgeon (SJR). Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
11577505|NCT00807339|Experimental|1|Phase I dose escalation
11577506|NCT00807326|Experimental|Loperamide/simeticone Caplets|Drug (including placebo)
11577507|NCT00807326|Active Comparator|Loperamide/simeticone Chewable Tablets|Drug (including placebo)
11577457|NCT00807729|Active Comparator|Lap CBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
11577458|NCT00807716|Experimental|walking skill group|weight-bearing 12 times, 70 minutes
11577459|NCT00807716|Active Comparator|usual physiotherapy care|partial weight-bearing, 12 times, 40 minutes
11577460|NCT00807703|Experimental|1|Select Stim: see summary
11577461|NCT00807677|Experimental|1|TAK-901
11577462|NCT00807664|Experimental|1|Biatain Ag dressing
11577463|NCT00807664|Active Comparator|2|Biatain dressing
11577464|NCT00807651|Active Comparator|insulin therapy|The participants not accepted written informed consent will receive insulin therapy
11577465|NCT00807651|Experimental|AHSCT|The participants accepted written informed consent will receive the therapy of autologous hematopoietic stem cell transplantation(AHSCT)
11577466|NCT00807625|Active Comparator|IUCD|Assigned to use a copper intrauterine device
11577467|NCT00807625|Active Comparator|DMPA|Assigned to use Depo Provera
11577468|NCT00807612|Experimental|Part 1 Cohort 1|AMG 479 at 18 mg/kg in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 at 18 mg/kg monotherapy for 24 months from study day 1
11577469|NCT00807612|Experimental|Part 1 Cohort 2|AMG 479 at 12 mg/kg in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 at 12 mg/kg monotherapy for 24 months from study day 1
11577470|NCT00807612|Experimental|Part 2|"AMG 479 in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 monotherapy for 24 months from study day 1
~(AMG 479 dose in Part 2 will be the final AMG 479 dose from Part 1)"
11577471|NCT00807599|Experimental|Stem cell transplant x 1 or x 2|"All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :
~stem cell transplant right after collection
~continue lenalidomide and dexamethasone, saving stem cell transplant for a later time."
11577472|NCT00807599|Experimental|Continue lenalidomide and dexamethasone|"All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :
~stem cell transplant right after collection
~continue lenalidomide and dexamethasone
~saving stem cell transplant for a later time."
11577473|NCT00807586|Experimental|Steroid|
11577474|NCT00807586|Placebo Comparator|Placebo|
11577475|NCT00807573|Experimental|Paclitaxel, Bevacizumab & Pemetrexed|During each 28-day cycle, paclitaxel, pemetrexed and bevacizumab will be given intravenously on days 1 and 15. Paclitaxel will be administered at 90mg/m^2 over 60 minutes on days 1 and 15. Pemetrexed 500mg/m^2 will be administered over 10 minutes on days 1 and 15. Bevacizumab will be given at 10mg/kg over 20 minutes on days 1 and 15
11577476|NCT00807560|Experimental|FBT-PO|Family Based Therapy for Pediatric Overweight.
11577477|NCT00807560|Active Comparator|NEC-control|Nutritional Educational Control Condition (NEC).
11577478|NCT00807547|Active Comparator|Allergy vaccination|Allergy vaccination by 6 subcutaneous injections to 10,000 SQ-U with 1-3 days intervals, continuation by 2 injections with 10,000 SQ-U with 2-4 weeks intervals
11577479|NCT00807547|Placebo Comparator|Subcutaneous injections|Placebo injections
11577480|NCT00807534|Active Comparator|ipratropium bromide|acute bronchodilation: ipratropium bromide
11577481|NCT00807534|Placebo Comparator|placebo|placebo nebulization
11577482|NCT00807521|Active Comparator|1|High dose bolus of dexamethasone before surgery
11577483|NCT00807521|Placebo Comparator|2|Placebo control
11577484|NCT00807508|Experimental|1|daily leucine supplementation
11577485|NCT00807508|Placebo Comparator|2|daily placebo supplementation
11577486|NCT00807495|Experimental|Alisertib 50 mg|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 24 months or longer with Sponsor approval).
11577487|NCT00807482||1|People who have been definitively diagnosed with primary ciliary dyskinesia (PCD).
11577488|NCT00807469||1|20 healthy individuals not susceptible for COPD (age 18-40 years, >0>10 packyears, FEV1/VC >70%, FEV1 >85% predicted)
11577489|NCT00807469||2|20 healthy individuals susceptible for COPD (age 18-40 years >20 packyears, FEV1/VC >70%, FEV1 >85% predicted) and high prevalence of COPD in smoking family members older than 45 years
11577490|NCT00807469||3|20 healthy individuals very susceptible for COPD (age 18-40 years, > 0 > 10 packyears, FEV1/VC >70%, FEV1 >85% predicted), and one of the smoking family members has severe early onset COPD or mild COPD with very low smoke exposure
11577491|NCT00807469||4|30 healthy individuals not susceptible for COPD (age 40-75 years, >20 packyears, FEV1/VC >70%, FEV1 >85% predicted)
11577492|NCT00807469||5|30 COPD patients with GOLD stage II (age 40-75 years, >10 packyears, FEV1/VC <_70%, FEV1 50-80% predicted)
11577493|NCT00807456|Experimental|ASTRA TECH Implant System, OsseoSpeed™|
11577494|NCT00807443|Experimental|Raltegravir|
11577495|NCT00807430|Experimental|1|24 patients receiving active treatment
11577496|NCT00807430|Placebo Comparator|2|Placebo treatment
11577497|NCT00807391|Other|TBCA/TBNA|Under fluoroscopy first transbronchial forceps biopsy is performed, afterwards in random order transbronchial catheter aspiration(TBCA) and transbronchial needle aspiration (TBNA).
11577498|NCT00807378||1|AIDS PATIENTS
11577499|NCT00807378||2|NON-AIDS PATIENTS
11577500|NCT00807365|Experimental|GHRH|Growth Hormone-Releasing Hormone
11577501|NCT00807352||level 2|Patients triaged level 2
11577502|NCT00807352||level 3|patients triaged level 3
11577503|NCT00807352||level 4|patients triaged level 4
11577508|NCT00807326|Active Comparator|Probiotic Capsules|Drug (including placebo)
11577509|NCT00807313||At best response|Patients with oligometastatic colorectal cancer, who presents at best response under chemotherapy, will receive stereotactic body radiotherapy on their residual disease
11577510|NCT00807313||No indication for chemotherapy|Patients with oligometastatic colorectal cancer, who are progressive under chemotherapy or who are no candidates for (further) chemotherapy, will receive stereotactic body radiotherapy on the sites of disease.
11577511|NCT00807300|Active Comparator|brachytherapy|
11577512|NCT00807300|Other|TACE|transarterial chemoembolization
11577513|NCT00807287|Experimental|1|Placement of jejunal feeding tube using the unguided frictional method
11577514|NCT00807287|Active Comparator|2|Jejunal tube placement using the endoscopic method
11577515|NCT00807248|Placebo Comparator|Escitalopram placebo and gaboxadol placebo|
11577516|NCT00807248|Active Comparator|Escitalopram 20 mg and gaboxadol placebo|
11577517|NCT00807248|Experimental|Escitalopram 20 mg and gaboxadol 5 mg|
11577518|NCT00807248|Experimental|Escitalopram 20 mg and gaboxadol 10 mg|
11577519|NCT00807235|Experimental|Regimen 1|
11577520|NCT00807235|Experimental|Regimen 2|
11577521|NCT00807222|Active Comparator|lisdexamfetamine dimesylate|30, 50, or 70 mg
11577522|NCT00807222|Placebo Comparator|placebo|
11577523|NCT00807209|Experimental|High Dose SKY0402|
11577524|NCT00807209|Active Comparator|Standard of Care|
11577525|NCT00807209|Experimental|Low Dose SKY0402|
11577526|NCT00807196|Experimental|T|
11577527|NCT00807183|Placebo Comparator|Tx1|Inactive air filter
11577528|NCT00807183|Experimental|Tx2|New EPA-certified woodstove
11577529|NCT00807183|Experimental|Tx3|Active air filter
11577530|NCT00807170|Experimental|ZACTIMA TM|
11577531|NCT00807157|Placebo Comparator|2|Every morning subjects will consume a stick of placebo during 30 days
11577532|NCT00807157|Experimental|1|Every morning subjects will consume a stick of PROBIOSTICK® during 30 days
11577533|NCT00807144|Experimental|Prolonged-Release Tacrolimus|Transplant maintenance immunosuppression with Prolonged-release Tacrolimus monotherapy
11577534|NCT00807144|Active Comparator|Standard-Release tacrolimus|Transplant maintenance immunosuppression with Standard-release Tacrolimus monotherapy
11577535|NCT00807131|Experimental|1|Patient follow-up
11577536|NCT00807131|Experimental|2|Counseling
11577537|NCT00807131|Experimental|3|Drug dispensing
11577538|NCT00807131|Active Comparator|4|pharmacy usual care
11577539|NCT00807118|Experimental|A (Cohort I)|
11577540|NCT00807118|Experimental|B (Cohort I)|
11577541|NCT00807118|Experimental|C (Cohort I)|
11577542|NCT00807118|Experimental|B (Cohort II)|
11577543|NCT00807118|Experimental|D (Cohort II)|
11577544|NCT00807118|Experimental|E (Cohort II)|
11577545|NCT00807105|Experimental|depressive patients|patients suffering from deppresion
11577546|NCT00807092|Experimental|BIAsp 30|BIAsp 30 (biphasic insulin aspart 30) administered subcutaneously (under the skin) twice daily (before breakfast and dinner) + metformin. Initial total daily dose of 0.3 U or IU/kg body weight followed by individual dose adjustment for BIAsp 30 was performed over the first 4 weeks (titration period) to achieve the pre-meal blood glucose target of 4.4-6.1 mmol/l. The achieved dose was maintained for the last 2 weeks of treatment unless hypoglycaemia occurred.
11577547|NCT00807092|Experimental|BHI 30|BHI 30 (biphasic human insulin 30) administered subcutaneously (under the skin) twice daily (30 minutes before breakfast and dinner) + metformin. Initial total daily dose of 0.3 U or IU/kg body weight followed by individual dose adjustment for BHI 30 was performed over the first 4 weeks (titration period) to achieve the pre-meal blood glucose target of 4.4-6.1 mmol/l. The achieved dose was maintained for the last 2 weeks of treatment unless hypoglycaemia occurred.
11577548|NCT00807079|Experimental|single arm|
11577549|NCT00807066|Experimental|A|Gefitinib
11577550|NCT00807066|Active Comparator|B|Platinum based chemotherapy
11577551|NCT00807053|Active Comparator|1|Ciclesonide HFA 75 mcg (37,5 mcg / actuation, 1 actuation/nostril), once daily
11577552|NCT00807053|Active Comparator|2|Ciclesonide HFA 150 mcg (75 mcg / actuation, 1 actuation/nostril), once daily
11577553|NCT00807053|Active Comparator|3|Ciclesonide HFA 300 mcg (150 mcg / actuation, 1 actuation/nostril), once daily
11577554|NCT00807053|Placebo Comparator|4|Placebo
11577555|NCT00807040|Active Comparator|Mitral Valve Repair with Annuloplasty|Participants will undergo mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.
11577556|NCT00807040|Active Comparator|Mitral Valve Replacement|Participants will undergo mitral valve replacement and complete preservation of the sub-valvular apparatus.
11577557|NCT00807027|No Intervention|Control Group|The study subjects randomly assigned to the control group is given Temozolomide chemotherapy and radiation therapy for 6 weeks according to the clinical test plans, and then administers Temozolomide only for 6 weeks.
11577558|NCT00807027|Experimental|Test Group|The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after surgery by administering Temozolomide chemotherapy and radiation therapy same as control group with Immuncell-LC (14 times).
11577559|NCT00807014|Experimental|Duac Gel|Duac Gel
11577560|NCT00807014|Active Comparator|Differin gel|Differin gel
11577561|NCT00807001|Experimental|Cohort A|Subjects randomized 8:2 (active:placebo) to receive one 25 milligrams (mg) capsule of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
11577562|NCT00807001|Experimental|Cohort B|Subjects randomized 8:2 (active:placebo) to receive two 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
11577563|NCT00807001|Experimental|Cohort C|Subjects randomized 8:2 (active:placebo) to receive three 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
11577661|NCT00806299|Experimental|1|Drug (including placebo)
11577564|NCT00807001|Experimental|Cohort D|Subjects randomized 8:2 (active:placebo) to receive four 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
11577565|NCT00806988|Active Comparator|Mitral Valve Repair|Participants will undergo CABG and a mitral valve repair procedure.
11577566|NCT00806988|Active Comparator|CABG|Participants will undergo CABG.
11577567|NCT00806975|Other|usability and preference|
11577568|NCT00806962|Experimental|Vaccine Arm 1|50 µg Norwalk VLP Vaccine + Adjuvant/Excipients
11577569|NCT00806962|Experimental|Vaccine Arm 2|100 µg Norwalk VLP Vaccine + Adjuvant/Excipients
11577570|NCT00806962|Active Comparator|Adjuvant/Excipients (MPL)|14 mg chitosan, 3 mg mannitol, 3 mg sucrose, and 50 mcg MPL
11577571|NCT00806962|Sham Comparator|Empty device|Empty device that contains no dry powder formulation. Actuation of the empty intranasal delivery device will deliver a puff of air per device.
11577572|NCT00806936||A|
11577573|NCT00806936||B|
11577574|NCT00806923|Experimental|1|
11577575|NCT00806923|Experimental|2|
11577576|NCT00806923|Placebo Comparator|3|
11577577|NCT00806910|Active Comparator|Treatment|Subjects will be treated with Intravenous Vaprisol along with Nesiritide infusion and intravenous Furosemide (either continuous infusion or bolus injections - total dose of Furosemide received will be calculated at the end of the study).
11577578|NCT00806910|Placebo Comparator|Placebo|Subjects will be given Placebo (at the same rate of Vaprisol given in the treatment arm) along with Nesiritide infusion and intravenous Furosemide (either continuous infusion or bolus injections - total dose of Furosemide received will be calculated at the end of the study).
11577579|NCT00806897||A|
11577580|NCT00806884|Other|Control Arm1|Normal optimal medical and physiotherapy treatment
11577581|NCT00806884|Experimental|Treatment Arm 2|Physiotherapy musculoskeletal interventions in addition to normal optimal medical and physiotherapy care
11577582|NCT00806871|Active Comparator|A|
11577583|NCT00806871|Active Comparator|B|
11577584|NCT00806871|Placebo Comparator|C|
11577585|NCT00806858||A|
11577586|NCT00806845||HIV infected individuals, HIV controllers|CD4+ T cell count > 350/µl, HIV load < 1000 copies/ml
11577587|NCT00806845||HIV infected individuals, early progressors|CD4+ T cell count > 350/µl, HIV load > 1000 copies/ml
11577588|NCT00806845||HIV infected individuals, late progressors|CD4+ T cell count < 200/µl
11577589|NCT00806845||HIV infected individuals, late progressors with therapy|CD4+ T cell count < 200/µl, under ART
11577590|NCT00806845||Healthy individuals|Uninfected
11577591|NCT00806832||Medical clowns treatment|Patients scheduled for an elective cataract surgery will receive pre-operative conventional treatment and in addition will be exposed to medical clowns effect
11577592|NCT00806832||Conventional treatment only|Patients scheduled for elective cataract surgery will receive only conventional pre-operative treatment
11577593|NCT00806819|Experimental|nintedanib (BIBF1120) plus pemetrexed|nintedanib (BIBF1120) along with standard therapy of pemetrexed
11577594|NCT00806819|Placebo Comparator|Placebo plus pemetrexed|Pemetrexed standard therapy
11577595|NCT00806819|Experimental|nintedanib (BIBF1120) monotherapy|nintedanib (BIBF1120) monotherapy only for patients who discontinue pemetrexed
11577596|NCT00806819|Active Comparator|pemetrexed monotherapy|pemetrexed monotherapy only for patients who discontinue nintedanib (BIBF1120) or placebo
11577597|NCT00806819|Placebo Comparator|placebo monotherapy|placebo monotherapy only for patients who discontinue pemetrexed
11577598|NCT00806806|Placebo Comparator|Placebo|
11577599|NCT00806806|Experimental|SKY0402|
11577600|NCT00806780|No Intervention|1|routine surgery with cholangiography
11577601|NCT00806780|Experimental|2|routine cholangiography
11577602|NCT00806754|Active Comparator|1|Ciclesonide nasal spray (50 mcg/spray, one spray per nostril) and placebo azelastine nasal spray ( two sprays per nostril) administered twice daily approximately 1 minute apart, once in the morning and 12 hours later, in the evening.
11577603|NCT00806754|Active Comparator|2|Ciclesonide nasal spray (50 mcg/spray, one spray per nostril) and azelastine nasal spray (137 mcg/spray, two sprays per nostril) administered twice daily approximately 1 minute apart, once in the morning and 12 hours later, in the evening.
11577604|NCT00806741|Active Comparator|1|NG-monomethyl-L-arginine (L-NMMA)
11577605|NCT00806741|Active Comparator|2|Phenylephrine
11577606|NCT00806741|Placebo Comparator|3|Physiological saline solution
11577607|NCT00806728|Experimental|1|MEDI-507
11577608|NCT00806728|Experimental|2|MEDI-507
11577609|NCT00806689||Cardiac surgery patients|Patients in atrial fibrillation being scheduled for cardiac surgery and concomitant ablation procedure
11577610|NCT00806676|Other|1. Chronic Kidney Disease, NKF Stage 1-4|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with chronic kidney disease will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
11577611|NCT00806676|Other|2. ESRD (dialysis)|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with ESRD will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
11577612|NCT00806676|Other|3. Kidney Transplant Recipient|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with a kidney transplant will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
11577613|NCT00806663|Experimental|Sunitinib Arm|Sutent sunitinib 37 mg once daily (4 weeks on/2 weeks off)
11577614|NCT00806650||Blood draw for diagnosis testing|
11577662|NCT00806299|Experimental|2|Drug (including placebo)
11577663|NCT00806299|Experimental|3|Drug (including placebo)
11577615|NCT00806637|Experimental|1|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
11577616|NCT00806637|Active Comparator|2|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
11577617|NCT00806624|Experimental|2|DU-176b tablets: high-dose
11577618|NCT00806624|Active Comparator|3|Warfarin tablets
11577619|NCT00806624|Experimental|1|DU-176b tablets: low-dose
11577620|NCT00806611|Experimental|50% Ethanol|Operating surgeon injects 20 ml of 50% ethanol on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
11577621|NCT00806611|Placebo Comparator|Placebo|Operating surgeon injects 20 ml of saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
11577622|NCT00806598|Experimental|Thymoglobulin + Cyclosporin|Combination of Thymoglobulin 3.5 or 2.5 mg/kg/day intravenous (IV) for 5 days + Methylprednisone 1 mg/kg/day IV for 5 days, before each dose Thymoglobulin + Cyclosporin 5 mg/kg orally for 6 months following Thymoglobulin + Granulocyte - Colony Stimulating Factor (G-CSF) 5 microgram/kg subcutaneously daily up to 3 months
11577623|NCT00806585|Experimental|MK-0736 0.5 mg|One MK-0736 0.5 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will then be switched to MK-0736 8.0 mg, once daily for an additional 52 weeks (Phase B).
11577624|NCT00806585|Experimental|MK-0736 2.0 mg|One MK-0736 2.0 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will then be switched to MK-0736 8.0 mg, once daily for 52 weeks (Phase B).
11577625|NCT00806585|Experimental|MK-0736 8.0 mg|One MK-0736 8.0 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will continue to receive MK-0736 8.0 mg, once daily for 52 weeks (Phase B).
11577626|NCT00806585|Active Comparator|HCTZ 12.5 mg → MK-0736 8.0 mg|one 12.5 mg hydrochlorothiazide (HCTZ) tablet daily, orally, for 12 weeks. Participant then switched to MK-0736 8.0 mg for 12 weeks (Phase A). Participant will continue to receive MK-0736 8.0 mg, once daily for an additional 52 weeks (Phase B).
11577627|NCT00806585|Placebo Comparator|Placebo|One placebo tablet daily, orally, for 24 weeks (Phase A). Participant will continue to receive placebo, once daily for 52 weeks (Phase B)
11577628|NCT00806572|Experimental|Treatment|
11577629|NCT00806572|No Intervention|Control|
11577630|NCT00806559|Active Comparator|Usual room|Patients in this arm will see their clinician in the usual clinical exam room
11577631|NCT00806559|Experimental|Re-designed room|Patients assigned to this arm will see the physician in a redesigned clinical exam room
11577632|NCT00806546|Experimental|NP101|sumatriptan iontophoretic transdermal patch
11577633|NCT00806533||HES 130 / 0.42|paediatric patients aged up to 12 years requiring non-emergency volume replacement therapy with HES 130/0.42
11577634|NCT00806507||Echocardiogram + Blood Test|Additional Echocardiogram views performed in 5-10 minutes of regularly scheduled echocardiograms plus blood tests measuring of hormones and metabolic proteins (such as sugars and acids).
11577635|NCT00806494|Experimental|Treatment Arm|Fesoterodine 4mg, escalating to 8mg as required
11577636|NCT00806481|Active Comparator|1|Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
11577637|NCT00806481|Placebo Comparator|2|Treatment group: treatment with tablets of placebo three times daily for 36 weeks
11577638|NCT00806468|Experimental|Desmopressin|Desmopressin 0,2 mg once daily and Desmopressin 0,2 mg bid for one week each.
11577639|NCT00806442|Experimental|1: Borage Seed Oil and Echium Seed Oil|Borage/Echium plant seed oils: 2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
11577640|NCT00806442|Placebo Comparator|2: Placebo Comparator|Placebo comparator: 9 g/day corn oil
11577641|NCT00806429|Experimental|1|transvaginal appendectomy
11577642|NCT00806429|No Intervention|2|
11577643|NCT00806416|Experimental|Sequence 1|alendronate/vitamin D combination then alendronate
11577644|NCT00806416|Experimental|Sequence 2|alendronate then alendronate/vitamin D combination
11577645|NCT00806416|Experimental|Sequence 3|alendronate/vitamin D combination then vitamin D
11577646|NCT00806416|Experimental|Sequence 4|vitamin D then alendronate/vitamin D combination
11577647|NCT00806403|Active Comparator|thrombolysis|
11577648|NCT00806403|Active Comparator|invasive|
11577649|NCT00806390|Active Comparator|Metoprolol|Receiving metoprolol
11577650|NCT00806390|No Intervention|Control|Not receiving metoprolol
11577651|NCT00806364||1|Blood, skin, stool/rectal swabs, buccal mucosa and bone marrow aspirate samples from approximately 250 healthy volunteer donors
11577652|NCT00806351|Experimental|Anidulafungin Arm|Subjects were randomized 2:1 (anidulafungin:caspofunin).
11577653|NCT00806351|Experimental|Caspofungin Arm|Subjects were randomized 2:1 (anidulafungin:caspofunin).
11577654|NCT00806338|Experimental|Trodusquemine (MSI-1436) 3mg/m2|
11577655|NCT00806338|Experimental|Trodusquemine (MSI-1436) 6mg/m2|
11577656|NCT00806338|Experimental|Trodusquemine (MSI-1436) 10mg/m2|
11577657|NCT00806338|Placebo Comparator|Placebo|
11577658|NCT00806325||AML|Adult patients with AML admitted for treatment of the same
11577659|NCT00806312||1 PAH|Patients who are ≥ 18 years of age, not pregnant, and undergoing right heart catheterization for PAH diagnosis as part of their clinical care will be approached for consent and participation in this study.
11577660|NCT00806312||2. Control|Patients who present with symptoms of PAH and whose clinical right heart catheterization doesn't support this diagnosis will be enrolled as control subjects.
11577664|NCT00806286|Experimental|CS-7017 with Paclitaxel and Carboplatin|
11577665|NCT00806286|Placebo Comparator|Paclitaxel and Carboplatin|
11577666|NCT00806273|Active Comparator|Group 2|For Group II, the ultrasonic irrigation system involves using an initial irrigation with a conventional syringe followed by ultrasonic irrigation.
11577667|NCT00806273|Active Comparator|Group 1|For Group I, needle irrigation will be delivered into the pulp chamber using a syringe tip placed above the access opening and removed with high volume suction.
11577668|NCT00806260|Experimental|Treatment 1|Dosed first with alcohol, then active VI-0521, and last, VI-0521 placebo
11577669|NCT00806260|Experimental|Treatment 2|First dosed with alcohol placebo (fruit juice), then active VI-0521, and last, placebo VI-0521
11577670|NCT00806260|Experimental|Treatment 3|First dosed with alcohol, then VI-0521 placebo, and last, active VI-0521
11577671|NCT00806260|Experimental|Treatment 4|First dosed with alcohol placebo, then VI-0521 placebo, and last, active VI-0521
11577672|NCT00806234|Active Comparator|1|Participants will continue on current antipsychotic medication.
11577673|NCT00806234|Experimental|2|Participants will undergo a staggered switch from current antipsychotic medication to aripiprazole or perphenazine.
11577674|NCT00806234|Experimental|3|Participants will add metformin to current antipsychotic medication treatment.
11577675|NCT00806221|Experimental|Emollient|Skin barrier protection from birth
11577676|NCT00806208|Active Comparator|1|MEDI 507 and Methylprednisolone
11577677|NCT00806208|Active Comparator|2|MEDI-507 and Methylprednisolone
11577678|NCT00806208|Active Comparator|3|MEDI-507 and Methylprednisolone
11577679|NCT00806208|Active Comparator|4|MEDI-507 and Methylprednisolone
11577680|NCT00806208|Placebo Comparator|5|Placebo
11577681|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (Non-Detailed)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR: 12 months.
~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.
~Non-Detailed - infants who only provided SAEs (Serious Adverse Events) and medically attended AEs (Adverse Events)."
11577682|NCT00806195|Active Comparator|Routine Vaccines (Non-Detailed)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6 months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR: 12 months.
~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.
~Non-Detailed - subjects who only provided SAEs and medically attended AEs."
11577683|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (Detailed)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.
~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.
~Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs."
11577684|NCT00806195|Active Comparator|Routine Vaccines (Detailed)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6 months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, and Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.
~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.
~Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs."
11577685|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (All)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.
~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.
~All (Detailed and Non-Detailed subjects): Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs; Non-Detailed - subjects who only provided SAEs and medically attended AEs."
11577686|NCT00806195|Active Comparator|Routine Vaccines (All)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, and Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.
~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.
~All (Detailed and Non-Detailed subjects): Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs; Non-Detailed - subjects who only provided SAEs and medically attended AEs."
11577687|NCT00806182||Pediatric case-controls|These are children who underwent lumbar puncture and blood drawing for diagnostic testing for non-inflammatory neurological or non-neurological disorders, and whose samples were retrieved from the clinical lab under a linked Institutional Review Board (IRB) protocol.
11577688|NCT00806182||Pediatric OMS|These are patients treated by the P.I. based on clinical decision making, not a clinical trial (this is an observational study). The types of treatments are varied, and, on the initial evaluation, the patients may be untreated or already tried on various immunotherapies. They range from monotherapy with steroids, ACTH, or IVIg, to disease modifying agents, such as rituximab, cyclophosphamide, and other chemotherapy, typically adjunctively or as combination therapy.
11577689|NCT00806169|Experimental|1|group I (n=17) nonproliferative DR and ischemic maculopathy
11577690|NCT00806169|Experimental|2|group II (n=38) nonproliferative DR without ischemic maculopathy
11577691|NCT00806169|Experimental|3|group III (n=18) proliferative DR with or without ischemic maculopathy
11577692|NCT00806156|Experimental|1|NKTR-102
11577693|NCT00806156|Experimental|2|NKTR-102
11577694|NCT00806143|Active Comparator|1|patients will undergo sequential bilateral rTMS treatment
11577695|NCT00806143|Active Comparator|2|patients will undergo unilateral low frequency right sided DLPFC rTMS
11577696|NCT00806117|Active Comparator|Radiotherapy (RT)|Radiotherapy
11577697|NCT00806117|Experimental|Concurrent chemoirradiation (CCRT)|"Concurrent chemoirradiation:
~External beam radiation with concurrent weekly platinum chemotherapy"
11577698|NCT00806117|Experimental|Sequence chemo and radiation (SCRT)|"Sequence chemotherapy and radiotherapy:
~2 cycles chemotherapy of Paclitaxel and Cisplatin before and after the irradiation"
11577699|NCT00806104|Experimental|1|Fructo-oligosaccharides
11577700|NCT00806104|Placebo Comparator|2|Maltodextrins
11577701|NCT00806091||COPD subjects|healthy subjects
11577702|NCT00806078|Experimental|1|Single dose intact capsules 2 x 324 mg
11577703|NCT00806078|Experimental|2|Single dose contents of two capsules (2 x 324 mg) opened and mixed in 120 mL of chocolate pudding
11577704|NCT00806065|Experimental|1|
11577705|NCT00806039|Other|1|Early renal involvement
11577706|NCT00806039|No Intervention|2|control
11577707|NCT00806026|Experimental|PBO/PGB 300 mg|
11577708|NCT00806026|Active Comparator|PBO/PPX 0.25 mg|
11577709|NCT00806026|Active Comparator|PBO/PPX 0.5 mg|
11577710|NCT00806026|Experimental|PGB 300 mg|
11577711|NCT00806026|Active Comparator|PPX 0.25 mg|
11577712|NCT00806026|Active Comparator|PPX 0.5 mg|
11577713|NCT00806013||1|CYP2C9*1/*1 and CYP2C19*1/*1 alleles carrier
11577714|NCT00806013||2|CYP2C19 PMs (CYP2C19*2/*2, CYP2C19*2/*3 or CYP2C19*3/*3)
11577715|NCT00806013||3|CYP2C9*1/*3 and CYP2C19*1/*1 alleles carrier
11577716|NCT00806000||Athletes|
11577717|NCT00805961|Experimental|Intervention|"Combined Modality Treatment and Systemic Therapy
~Combined Modality Therapy - Radiation Therapy: 2 Gy/fraction, single daily fractions Monday-Friday, to total of 60 Gy Temozolomide: 75 mg/m2 by mouth daily Bevacizumab: 10 mg/kg IV every 2 weeks (Weeks 1, 3, 5, and 7)
~After the last dose of radiation, patients exhibiting an objective response, stable disease on MRI scan, or have stable/improved tumor-related symptoms will begin systemic therapy
~Systemic Therapy - Bevacizumab: 10 mg/kg IV every 2 weeks Everolimus: 10 mg by mouth daily"
11577718|NCT00805948|Experimental|DeNovo|Prospectively enrolled subjects treated with the Talent Thoracic Stent Graft System following U.S. market approval of the device.
11577719|NCT00805948|No Intervention|Valor|Historical control arm, consisting of 195 subjects from the VALOR Test Group (PMA P070007) that were followed for 5 years per the VALOR protocol. The data from these subjects will be combined with the data from the subjects implanted after commercial release (DeNovo) to comprise the final analysis cohort for the THRIVE Study
11577720|NCT00805935|Experimental|Menotropin/Progesterone vaginal insert|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.
~Progesterone vaginal insert (Endometrin®) 100 mg starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
11577721|NCT00805935|Experimental|Menotropin/Progesterone in oil|"Menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.
~Progesterone in oil 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
11577722|NCT00805935|Active Comparator|Follitropin beta/Progesterone vaginal insert|"Follitropin beta (Follistim Pen®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.
~Progesterone vaginal insert (Endometrin®) 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
11577723|NCT00805935|Active Comparator|Follitropin beta/Progesterone in oil|"Follitropin beta (Follistim Pen®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.
~Progesterone in oil 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
11577724|NCT00805922||A|
11577725|NCT00805909|Experimental|NI-0401|5 daily infusions of escalating doses of NI-0401
11577726|NCT00805896|Experimental|1|Songyou Granule
11577727|NCT00805896|Placebo Comparator|2|
11577728|NCT00805883|Experimental|1|
11577729|NCT00805870|Experimental|Fish Oil|Lovaza, 3 grams/day for 65 days
11577730|NCT00805870|Placebo Comparator|Control|Wheat Germ Oil, 3 grams/day for 65 days
11577731|NCT00805844||1|Spine surgery with Motor Evoked Potential monitoring without SedLine monitoring visible.
11577732|NCT00805844||2|Spine surgery with Motor Evoked Potential Monitoring with SedLine monitoring visible.
11577733|NCT00805831|Experimental|A|Aortic anastomosis surgery will be conducted using HDH device.
11577734|NCT00805818|Experimental|NNZ-2566|20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1 mg/kg/h (Cohort 1, n=20), 3 mg/kg/h (Cohort 2, n=20) or 6 mg/kg/h (Cohort 3, n=133) intravenous infusion for a total of 72 consecutive hours.
11577735|NCT00805818|Placebo Comparator|Sodium Chloride (0.9%) for Injection|Intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion (Cohort 1, n=10), (Cohort 2, n=10) or (Cohort 3, n=67) intravenous infusion for a total of 72 consecutive hours.
11577736|NCT00805805|Experimental|1|Tetrathiomolybdate with ursodiol
11577737|NCT00805805|Placebo Comparator|2|Placebo with ursodiol
11577738|NCT00805792|Experimental|Donepezil|Participants received treatment with donepezil within 24 hours after the onset of ischemic stroke symptoms. Participants received donepezil 5 mg/day for 30 days, followed by an increase to 10 mg/day for 60 days.
11577739|NCT00805766|Experimental|TA-650|
11577740|NCT00805753|Active Comparator|Arm 1 ACTH 40 units|Receive ACTH at the dose of 40 units sub-cutaneously for up to 12 weeks. If at day 91 no response has been shown, you will have the option to increase the dose of ACTH to 80 units for up to an additional 120 days.
11577741|NCT00805753|Active Comparator|Arm 2 ACTH 80 units|Receive ACTH at the dose of 80 units sub-cutaneously for up to 12 weeks.
11577742|NCT00805740|Experimental|Anidulafungin arm|
11577743|NCT00805740|Experimental|Caspofungin arm|
11577744|NCT00805714||Acute myocardial infarction|AMI patients who are in need to be treated by statins
11577745|NCT00805701|Active Comparator|0.5mg Avodart|.5mg avodart capsule orally once a day during 13 months
11577746|NCT00805701|Placebo Comparator|Placebo|placebo capsule orally daily for 13 months
11577747|NCT00805688||Symptom Study|Questionnaires + Blood Draw + Pedometer used to learn about symptoms related to chemotherapy and the disease, in patients with advanced pancreatic cancer.
11577748|NCT00805675|Experimental|Telbivudine 600 mg monotherapy|All patients in this arm were randomized to receive Telbivudine (LDT) 600 mg QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
11577749|NCT00805675|Active Comparator|Tenofovir disproxil fumarate 300 mg monotherapy|All patients in this arm were randomized to receive Tenofovir disoproxil fumarate 300 mg(equivalent to tenofovir disoproxil 245 mg)QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
11577750|NCT00805675|Active Comparator|Telbivudine 600 mg and Tenofovir 300 mg|All patients in this arm were randomized to receive Telbivudine (LDT) 600 mg QD and Tenofovir (TDF) 300 mg (equivalent to Tenofovir disoproxil 245 mg)QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
11577751|NCT00805662|Experimental|Oxytocin|Intranasal oxytocin during IUI
11577752|NCT00805649|Experimental|1|eyes with predominately classic lesions
11577753|NCT00805649|Experimental|2|eyes with occult lesions
11577754|NCT00805623|No Intervention|AW|no pacifier , no sucrose
11577755|NCT00805623|Active Comparator|AS|sucrose without pacifier
11577756|NCT00805623|No Intervention|PW|
11577757|NCT00805623|Experimental|PS|Pacifier and sucrose interventional
11577758|NCT00805610|Experimental|Hepatocyte Transplantation|Hepatocyte Transplantation through single donor will be transplanted into the liver via intraportal or intrasplenic routes.
11577759|NCT00805597|Experimental|radiotherapy|radiotherapy of 50Gy/25/f/5w to the ipsilateral chest wall and supraclavicular region
11577760|NCT00805597|Active Comparator|no radiotherapy|no radiotherapy
11577761|NCT00805584|Experimental|Arm 1|
11577762|NCT00805571||Adult|Adult patients with end-stage kidney disease awaiting kidney transplantation.
11577763|NCT00805571||Pediatric|Children with end-stage kidney disease awaiting kidney transplantation.
11577764|NCT00805558|Experimental|Moxifloxacin|Scaling and root planing plus 400 mg moxifloxacin once daily for 7 days.
11577765|NCT00805558|Active Comparator|Ciprofloxacin plus metronidazole|Scaling and root planing plus ciprofloxacin 1000 mg once daily for 7 days and metronidazole 500 mg twice daily for 7 days
11577766|NCT00805545|Experimental|A|Group of patients that will receive antibiotics 30-60 minutes prior to incision
11577767|NCT00805545|Active Comparator|B|Group of patients that will receive antibiotics immediately after clamping the umbilical cord
11577768|NCT00805532|Experimental|Behavioral Activation|Behavioral Activation (BA), modified to be delivered in 6-8, 60 minute sessions to address PTSD-related problems.
11577769|NCT00805532|Active Comparator|Treatment as Usual|Treatment As Usual for PTSD (TAU) within VA PTSD specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system.
11577770|NCT00805519|Active Comparator|Glucosamine and chondroitin sulfate|in this group patients will receive Glucosamine and chondroitin sulfate oral dietary supplementation
11577771|NCT00805519|Experimental|P :glucosa, chondroitin, Prednis|in this group patients will receive glucosamine and chondroitin sulfate plus Prednisolone oral administration
11577772|NCT00805519|Experimental|Glucosa, Chondroitin, Chloroquine|in this group pateints will orally receive Glucosamine and Chondroitin sulfate plus Chloroquine.
11577773|NCT00805519|Experimental|Glucosa, Chondro, Prednis,Chloroq|in this group patients will receive Glucosamine and Chondroitin sulfate plus Prednisolone and Chloroquine
11577774|NCT00805506||Diabetes Insulin Treated|People with type 1 or type 2 diabetes on insulin.
11577775|NCT00805493|No Intervention|Medication Taper|All participants begin with gradual tapering to the point of discontinuing medication
11577776|NCT00805493|No Intervention|Random assignment to placebo|Once they are medication-free, 50% of participants are randomized to placebo
11577777|NCT00805493|Active Comparator|Random assignment to riluzole|One they are medication-free, 50% of participants are randomized to riluzole
11577778|NCT00805480|Experimental|AIN457 3 mg/kg|Participants randomized to this arm received AIN457 3 mg/kg on day 1, and then matching placebo on days 15 and 29.
11577779|NCT00805480|Experimental|AIN457 10 mg/kg|Participants randomized to this arm received AIN457 10 mg/kg on day 1, and then matching placebo on days 15 and 29.
11577780|NCT00805480|Experimental|AIN457 10 mg/kg x3|Participants randomized to this arm received AIN457 3 mg/kg on days 1, 15 and 29.
11577781|NCT00805480|Placebo Comparator|Placebo|Participants randomized to this arm received matching placebo to AIN457 on days 1, 15 and 29
11577782|NCT00805467|Experimental|1|R935788 50 mg tablet, orally, twice-a-day
11577783|NCT00805467|Experimental|2|R935788 100 mg tablet, orally, twice-a-day
11577784|NCT00805467|Experimental|3|R935788 100 mg tablet, orally, once-a-day
11577785|NCT00805467|Experimental|4|R935788 150 mg tablet, orally, once-a-day
11577786|NCT00805441|Placebo Comparator|Placebo|
11577787|NCT00805441|Experimental|LY686017|
11577788|NCT00805428||2|control group
11577789|NCT00805428||patients with UC|patients with UC, without corticosteroid or immunosuppressive therapy
11577790|NCT00805415|Experimental|Arm 1|
11577791|NCT00805415|Experimental|Arm 2|
11577792|NCT00805402|Experimental|1 flow cytometry|flow cytometry
11577833|NCT00805155||Cohort Group 2|Subjects number 21 to 50
11577834|NCT00805155||Cohort Group 3|Subject Numbers 51 to 80
11577793|NCT00805389|Experimental|GSK223192A 1 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
11577794|NCT00805389|Experimental|GSK223192A 2 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
11577795|NCT00805389|Experimental|GSK223192A 3 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
11577796|NCT00805389|Experimental|Fendrix Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
11577797|NCT00805389|Active Comparator|Engerix-B Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
11577798|NCT00805376|Experimental|Group A: DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
11577799|NCT00805376|Experimental|Group B: DNX-2401 + Surgery|DNX-2401 injection + Tumor removal
11577800|NCT00805350|Experimental|Eplivanserin|Eplivanserin 5 mg/day
11577801|NCT00805350|Placebo Comparator|Placebo|Placebo of Eplivanserin 5 mg/day
11577802|NCT00805324|Experimental|Arm 1|
11577803|NCT00805311|Experimental|CEA Group|Patients will undergo carotid endarterectomy (CEA) and receive medical treatment including medical therapy with statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.
11577804|NCT00805311|Active Comparator|OMT Group|Patients will receive conservative therapy - optimal medical treatment (OMT) including statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.
11577805|NCT00805298|Active Comparator|methylprednisolone|
11577806|NCT00805298|Placebo Comparator|placebo|
11577807|NCT00805298|Active Comparator|lidocaine|
11577808|NCT00805298|Active Comparator|bupivacaine|
11577809|NCT00805285|Experimental|Combination Oral Budesonide and Rectal Hydrocortisone|See intervention
11577810|NCT00805272|Experimental|1|
11577811|NCT00805259|Active Comparator|1. Atomistic|payment for own work
11577812|NCT00805259|Active Comparator|2. Altruistic|payment for partner's work
11577813|NCT00805259|Active Comparator|3. Team-based|payment for relative performance of combined effort of each team
11577814|NCT00805259|No Intervention|4. Control|access to software but no financial incentives
11577815|NCT00805246||Pulmonary Embolism (PE)|Subjects diagnosed with PE by CT will be recruited.
11577816|NCT00805233|Experimental|1|Combination Ranibizumab intravitreal injection plus bromfenac ophthalmic drops
11577817|NCT00805233|Active Comparator|2|ranibizumab injection alone.
11577818|NCT00805220|Active Comparator|1|Regular overground walking without poles
11577819|NCT00805220|Experimental|2|Nordic Walking
11577820|NCT00805207|Experimental|Progesterone - PCOS|Women with obesity and polycystic ovary syndrome
11577821|NCT00805207|Experimental|Testosterone - premenopausal women|Healthy premenopausal women.
11577822|NCT00805207|Experimental|Continuous positive airway pressure|Women and men with obesity and obstructive sleep apnea
11577823|NCT00805207|Experimental|Glucocorticoid|Lean and obese healthy women, and obese men
11577824|NCT00805207|Experimental|Estrogen|Postmenopausal women
11577825|NCT00805207|Other|control|Postmenopausal women - tested before and after no treatment. Duration between before and after testing ranged from 31 to 78 days with an average of 46 days between visits
11577826|NCT00805207|No Intervention|control - baseline testing only|Healthy men and women
11577827|NCT00805207|Experimental|Progesterone - Postmenopausal women|Postmenopausal women
11577828|NCT00805207|Experimental|Testosterone - Postmenopausal women|Postmenopausal women
11577829|NCT00805194|Experimental|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
11577830|NCT00805194|Placebo Comparator|Placebo plus docetaxel|Placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
11577831|NCT00805181||Acute uncomplicated pyelonephritis|
11577832|NCT00805155||Cohort Group 1|Subjects number 1 to 20
11577835|NCT00805142|Experimental|Opioid-Naive Participants (Tapentadol PR)|Opioid-naive participants are defined as those who had moderate to severe cancer pain that is not controlled sufficiently with non-opioid medications. Treatment period comprises of Titration and Maintenance period. Titration period (3-14 days) is duration between start of treatment to day before initial dose in the maintenance period. Treatment will be initiated with tapentadol prolonged release (JNS024PR, PR) 25 milligram (mg) oral tablet twice daily. Dose will be increased or decreased as per Investigator's discretion up to Day 14. Maximum dose limit will be 500 mg per day. Participants will then be assigned to the treatment in the maintenance period (15-19 days). The maintenance period is duration between the first dose and the final assessment in the maintenance period. Participants will receive tapentadol PR oral tablet twice daily for 5 days at the same dose used on last day of titration period.
11577836|NCT00805142|Experimental|Opioid-Switch Participants (Tapentadol PR)|Opioid-switching participants are defined as those who had moderate to severe cancer pain that is controlled sufficiently with opioid therapy. Treatment period comprises of Titration and Maintenance period. Titration period (3-14 days) is duration between start of treatment to day before initial dose in maintenance period. Initial dose of tapentadol PR is selected according to daily dose of opioid (morphine sustained release [SR] preparation, oxycodone hydrochloride [HCl] SR tablet or fentanyl patch). Equivalent dose of tapentadol PR oral tablet twice daily is given depending on daily dose of opioid at completion of Screening period. Maximum dose limit is 500 mg per day. Participants will then be assigned to treatment in maintenance period (15-19 days). Maintenance period is defined as duration between first dose and final assessment in maintenance period. Participants will receive tapentadol PR oral tablet twice daily for 5 days at same dose used on last day of titration period.
11577837|NCT00805129|Experimental|Everolimus|Everolimus will be administered at a dose of 10 mg orally once daily continuously.
11577838|NCT00805116|Experimental|1|Whale blubber oil
11577839|NCT00805116|Active Comparator|2|Cod liver oil
11577840|NCT00805103|Experimental|(HFA-SRT) in Large-Volume Brain Metastases|
11577841|NCT00805090|Active Comparator|Sporanox|Active arm approved as an anti-fungal being used to compare HPβCD when administered in DIC075V compared to Sporanox.
11577842|NCT00805090|Experimental|Dyloject|Diclofenac Sodium
11577843|NCT00805077|Experimental|1|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
11577844|NCT00805077|Other|2|tidal volume of 10 ml/kg of ideal body weight without PEEP
11577845|NCT00805064|Active Comparator|ischemic CRVO|treatment was applied to this entity
11577846|NCT00805064|Active Comparator|non ischemic CRVO|treatment was applied to this entity
11577847|NCT00805064|Active Comparator|BRVO|treatment was applied to this entity
11577848|NCT00805051||Severe aortic stenosis|Patients undergoing aortic valve replacement because of severe aortic stenosis
11577849|NCT00805038|Placebo Comparator|Control|Usual care
11577850|NCT00805038|Experimental|Intervention|Navigator will assist patients in completing steps in transplant process
11577851|NCT00805025|Experimental|AZLI|Participants were evaluated beginning 14 days prior to starting a 28-day course of AZLI (Day 0 to Day 28), followed by post-treatment assessments every 14 days through Day 56, for a total of 70 days of participation in the study.
11577852|NCT00805012|Active Comparator|1|docetaxel+CDDP
11577853|NCT00805012|Experimental|2|docetaxel+S-1
11577854|NCT00804999|Placebo Comparator|Placebo 1|Subjects that have never worn contacts with no ocular problems were selected. A baseline HRT was performed. Trial contact lenses were soaked in clear care solution for 10 hours. After 10 hours of the lenses soaking in clear care the subject returned. The contacts lenses that were soaked in clear care were inserted onto the patients eyes. The patient then wore the contacts for two hours. After two hours the contact lenses were removed. An HRT was performed immediately after removing the contact lenses. The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
11577855|NCT00804999|Active Comparator|Renu|Subjects that had worn contacts for at least two weeks without incident were selected. A baseline HRT was performed.Trial contacts lenses were soaked in ReNu contact solution for 10 hours. After 10 hours of the lenses soaking in ReNu the subject returned. The contacts were inserted onto the patients eyes. The patient then wore the contacts for two hours. After two hours the contacts lenses were removed. An HRT both with and without sodium fluorescein was performed immediately after removing the contact lenses.The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
11577856|NCT00804999|Active Comparator|Optifree|Subjects that had worn contacts for at least two weeks without incident were selected. A baseline HRT was performed.Trial contacts lenses were soaked in Optifree Replenish contact solution for 10 hours. After 10 hours of the lenses soaking in Optifree Replenish the subject returned. The contacts were inserted onto the patients eyes. The patient wore contacts the for two hours. After two hours the contacts were removed. An HRT both with and without sodium fluorescein was performed immediately after removing the contact lenses.The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
11577857|NCT00804986|Experimental|0.5 mg LY2428757|Once weekly, subcutaneous injection of 0.5 milligram (mg) LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
11577858|NCT00804986|Experimental|2.0 mg LY2428757|Once weekly, subcutaneous injection of 2.0 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
11577859|NCT00804986|Experimental|6.2 mg LY2428757|Once weekly, subcutaneous injection of 6.2 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
11577860|NCT00804986|Experimental|12.0 mg LY2428757|Once weekly, subcutaneous injection of 12.0 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
11577861|NCT00804986|Experimental|17.6 mg LY2428757|Once weekly, subcutaneous injection of 17.6 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
11577862|NCT00804986|Placebo Comparator|Placebo|Once weekly, subcutaneous injection of placebo for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
11577863|NCT00804973|Experimental|1|
11577864|NCT00804973|Placebo Comparator|2|
11577865|NCT00804973|Active Comparator|3|
11577866|NCT00804960|Experimental|Letrozole|1) Letrozole/ Recombinant FSH
11577867|NCT00804960|Active Comparator|Standard IVF|luteal phase GnRHa suppression/gonadotropin
11577868|NCT00804947|Experimental|Intravenous busulfan and melphalan|
11577869|NCT00804934||0|
11577870|NCT00804908|Placebo Comparator|Placebo for ABT-888 BID + TMZ QD|Placebo for ABT-888 twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
11577871|NCT00804908|Active Comparator|ABT-888 20 mg BID + TMZ QD|ABT-888 20 mg twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
11577872|NCT00804908|Active Comparator|ABT-888 40 mg BID + TMZ QD|ABT-888 40 mg twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
11577873|NCT00804895|Experimental|1|subcutaneous injection of Cortivazol ALTIM, 3,375mg
11577874|NCT00804895|Placebo Comparator|2|PROAMP, subcutaneous serum physiological saline
11577875|NCT00804882||1|Mexican Americans with heart failure and metabolic syndrome
11577876|NCT00804882||2|Mexican Americans with heart failure without metabolic syndrome
11577877|NCT00804882||3|Non-Hispanic White Americans with heart failure and metabolic syndrome
11577878|NCT00804882||4|Non-Hispanic White Americans with heart failure without metabolic syndrome
11577879|NCT00804869||1|PalmScan biometric group
11577880|NCT00804869||2|A-mode ultrasonography biometric group
11577881|NCT00804856|Experimental|Schedule A|BI 6727 (d1 and 15 - one hour iv.) + LD ARA C 2x20 mg/d s.c.
11577882|NCT00804856|Experimental|Schedule B|BI 6727 (d1 and 15 - one hour iv.)
11577883|NCT00804856|Active Comparator|Schedule C|LD-ARA C monotherapy (2 x 20 mg/d s.c.)
11577884|NCT00804843|Experimental|Statin 80 mg + Niacin extended-release (ER)|Participants in Russia and Brasil will receive 80 mg Simvastatin + niacin. All other participants will receive 80 mg Atorvastatin + niacin.
11577885|NCT00804843|Active Comparator|Statin 10 mg|Participants in Russia and Brasil will receive 10 mg Simvastatin. All other participants will receive 10 mg Atorvastatin.
11577886|NCT00804830|Experimental|chemotherapy|Treatment with Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w for 6 months.
11577887|NCT00804817|Active Comparator|Care as usual|Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
11577888|NCT00804817|Experimental|SCION-HSCT program|"Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.
~The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects."
11577889|NCT00804804|Experimental|Y1|young volunteers (20-30 years), morningness chronotype
11577890|NCT00804804|Experimental|Y2|young volunteers (20-30 years), eveningness chronotype
11577891|NCT00804804|Experimental|O1|Aged volunteers (65-75 years), morningness chronotype
11577892|NCT00804804|Experimental|O 2|aged volunteers (65-75 years), eveningness chronotype
11577893|NCT00804791|Active Comparator|Systane|One drop dispensed into each eye
11577894|NCT00804791|Active Comparator|Unisol|One drop dispensed into each eye
11577895|NCT00804778||CABG,general anesthesia|their CO and CI was measured with USCOM and Swan-ganz cco respectively.
11577896|NCT00804778||group 1|co measured with swan-ganz cco combined with vigilance
11577897|NCT00804765|Experimental|1|Therapeutic education
11577898|NCT00804765|Placebo Comparator|2|
11577899|NCT00804752|Experimental|Vitamin D|An addition of Vitamin D to the standard treatment
11577900|NCT00804739|Experimental|MITT|Mothers will be assigned to the Mother-Infant Treatment Team (MITT)and will receive either psychotherapy or sertraline or both as well as outreach.
11577901|NCT00804726|Experimental|Akreos MI Five-O|Accommodating intraocular lens
11577902|NCT00804713|Experimental|All study participants|Subjects administered the TB skin test, Battey skin test, QFT-GIT, and T-Spot
11577903|NCT00804700|Active Comparator|Control Group|Subjects will be given a 60 minute lecture on the benefits of regular exercise and how music can enhance the exercise experience. Subjects will be individually instructed how to use the Precor elliptical trainer at the Yates fitness center while listening to music. Subjects are instructed to exercise using the elliptical trainer for periods of 45 -55 minutes at a time as frequently as they like with a minimum frequency of once per week. Subjects will also be encouraged to exercise regularly by walking, jogging or engaging in other forms of physical activity during the intervention period. A fitness attendant will be on hand to supervise their exercise activity, but will not give specific advice how to exercise, other than to make sure they are exercising safely.
11577904|NCT00804700|Experimental|Intervention Arm|Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
11577905|NCT00804687|Experimental|JNJ-39220675 then Pseudoephedrine then Placebo|Single-dose of JNJ-39220675 will be administered as 1 milliliter (ml) of 10 milligram/milliliter (mg/ml) solution orally along with placebo tablet in first treatment period; after that in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with 60 milligram (mg) pseudoephedrine tablet; and then single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
11577938|NCT00804479||no treatment|Available 301 subjects enrolled in CALM-PD Available 82 subjects enrolled in CALM-PD imaging substudy
11577939|NCT00804466|Experimental|Women referred to colposcopy clinic|Triage tests for diagnosis of cervical pre-cancer amongHPV positive women
11577940|NCT00804453|Active Comparator|1|Standard blood line
11577906|NCT00804687|Experimental|JNJ-39220675 then Placebo then Pseudoephedrine|Single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
11577907|NCT00804687|Experimental|Placebo then JNJ-39220675 then Pseudoephedrine|Single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
11577908|NCT00804687|Experimental|Placebo then Pseudoephedrine then JNJ-39220675|Single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet; and then single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
11577909|NCT00804687|Experimental|Pseudoephedrine then JNJ-39220675 then Placebo|Single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in first treatment period; after that, in second treatment period, single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
11577910|NCT00804687|Experimental|Pseudoephedrine then Placebo then JNJ-39220675|Single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with placebo tablet; and then single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
11577911|NCT00804674|Active Comparator|1 bupivacain|
11577912|NCT00804674|Placebo Comparator|2 placebo|
11577913|NCT00804661||1|Children and adults with cystic fibrosis
11577914|NCT00804648|Active Comparator|hemihydrate/maleate/maleate gel|Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate 0.5% Period three - Timolol maleate gel forming solution 0.5%
11577915|NCT00804648|Active Comparator|maleate/maleate gel/hemihydrate|Period one - Timolol maleate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol hemihydrate 0.5%
11577916|NCT00804648|Active Comparator|maleate gel/hemihydrate/maleate|Period one - Timolol maleate gel forming solution 0.5% Period two - Timolol hemihydrate 0.5% Period three - Timolol maleate 0.5%
11577917|NCT00804648|Active Comparator|hemihydrate/maleate gel/maleate|Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol maleate 0.5%
11577918|NCT00804648|Active Comparator|maleate/hemihydrate/maleate gel|Period 1 - Timolol maleate 0.5% Period 2 - Timolol hemihydrate 0.5% Period 3 - Timolol maleate gel forming solution 0.5%
11577919|NCT00804648|Active Comparator|maleate gel, maleate, hemihydrate|Period 1 - Timolol maleate gel forming solution 0.5% Period 2 - Timolol maleate 0.5% Period 3 - Timolol hemihydrate 0.5%
11577920|NCT00804622|Active Comparator|1|tenofovir disproxil fumarate 300 mg monotherapy
11577921|NCT00804622|Active Comparator|2|telbivudine 600 mg monotherapy
11577922|NCT00804622|Active Comparator|3|telbivudine 600 mg and tenofovir disproxil fumarate 300 mg
11577923|NCT00804609|Active Comparator|DepoDur following epidural lidocaine|Epidural DepoDur was administered 60 minutes after an epidural Lidocaine top-up for surgical anesthetic in cesarean section patients.
11577924|NCT00804609|Active Comparator|DepoDur following spinal anesthetic|Epidural DepoDur was administered 60 minutes after a standard spinal anesthetic. No prior epidural local anesthetic was used prior to DepoDur in this group assignment.
11577925|NCT00804596|Other|Subjects with diabetes|Subjects with diabetes use a new blood glucose monitoring system with subject capillary blood.
11577926|NCT00804570|Experimental|LY2196044|
11577927|NCT00804570|Placebo Comparator|Placebo|
11577928|NCT00804557||Uro-Ease Spirus Catheter|10 patients randomized to the Uro-Ease Catheter group for 1 week. In clinic, patients will be instructed in the use of the Uro-Ease Catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to a standard, non-helical urinary catheter. Patients will be followed up to 1 month.
11577929|NCT00804557||Standard Urinary Catheter|10 patients randomized to a Standard Urinary Catheter group for 1 week. In clinic, patients will be instructed in the use of the catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to the UroEase Spirus Catheter. All patients will be followed up to 1 month.
11577930|NCT00804544|Experimental|1|Mammoscintigraphy with SPECT-CT optimized 99mTc-MIBI imaging (experimental arm) will be compared to conventional planar imaging. Mammoscintigraphy results before and after chemotherapy and radiation therapy, will be compared to the histopathological results after surgery.
11577931|NCT00804531|Experimental|Visipaque - Hydrocortancyl|Administration of two treatments for the experimental arm
11577932|NCT00804531|Placebo Comparator|Visipaque|Administration of only one treatment in intra discal of visipaque
11577933|NCT00804518|Experimental|Exercise intervention|
11577934|NCT00804505|Experimental|1|Test arm daily wear hybrid contact lens.
11577935|NCT00804505|Other|2|Control: SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Hybrid Contact Lens
11577936|NCT00804492|Experimental|1|To establish an integrated intervention model for prevention of elderly fall
11577937|NCT00804492|Experimental|2|To perform a RCT to investigate the effectiveness of the multicenter, multifaceted intervention program
11577941|NCT00804453|Experimental|2|Cartridge blood line
11577942|NCT00804440|Active Comparator|Test Product|
11577943|NCT00804440|Active Comparator|Reference Product|
11577944|NCT00804427|Experimental|Fish oil (90% triglycerides)|Fish oil (4 grams/day of combined EPA and DHA) as 90% triglyceride formulation, taken in two divided doses with main meals.
11577945|NCT00804427|Experimental|Fish oil (60% triglycerides)|Fish oil (4 grams/day of combined EPA and DHA) as 60% triglyceride formulation, taken in two divided doses with main meals.
11577946|NCT00804427|Experimental|Fish oil (ethyl esters)|Fish oil (4 grams/day of combined EPA and DHA) as ethyl esters formulation (0% triglycerides), taken in two divided doses with main meals.
11577947|NCT00804427|Placebo Comparator|Soy oil|Soy oil supplement with identical total fat content, taken in two divided doses with main meals.
11577948|NCT00804414|Experimental|1|
11577949|NCT00804414|Placebo Comparator|2|
11577950|NCT00804401|Active Comparator|Test Product|
11577951|NCT00804401|Active Comparator|Reference Product|
11577952|NCT00804388|Active Comparator|1|Uncemented total hip replacement, 32 mm caput
11577953|NCT00804388|Active Comparator|2|Uncemented total hip replacement, 36 mm caput
11577954|NCT00804375|Experimental|2PX|Pain medication
11577955|NCT00804375|Placebo Comparator|placebo|placebo
11577956|NCT00804349|No Intervention|Control|Patients will receive standard medical therapy for heart failure only and will not receive Autotitrating Positive Airway Pressure therapy.
11577957|NCT00804349|Active Comparator|Autotitrating Positive Airway Pressure|Patients will receive Autotitrating Positive Airway Pressure therapy in addition to standard medical care for heart failure.
11577958|NCT00804336|Experimental|Pasireotide and RAD001|RAD001 was administered orally as a once-daily dose. Pasireotide s.c. was self-administered s.c. twice daily for 4 weeks. If pasireotide s.c. was tolerated, patients received pasireotide LAR i.m. at the corresponding dose level. Pasireotide s.c. was continued for an additional 2 weeks after administration of pasireotide LAR until anticipated steady-state levels of pasireotide LAR were achieved. Pasireotide LAR was administered every 28 days. Cycles for everolimus and pasireotide LAR were repeated every 28 days.
11577959|NCT00804323|Experimental|Group 1|Patients with open-angle glaucoma
11577960|NCT00804310|Experimental|Lapatinib and Ixabepilone|
11577961|NCT00804284||Pentacel Group|Infants initiated on PENTACEL® vaccine
11577962|NCT00804284||Other DTap vaccines Group|Infants initiated on other DTaP vaccines
11577963|NCT00804271|Other|Memantine|
11577964|NCT00804245|Experimental|radiolabeled choline tracer scans|PET-CT scans supplemented with Choline 11 tracer
11577965|NCT00804232|Experimental|1|effects on child health of family-based home care compared to traditional hospital-based care,
11577966|NCT00804232|Experimental|2|effects on child health of family-based psychological treatment compared to traditional hospital-based treatment
11577967|NCT00804219|Experimental|TBE low responder|
11577968|NCT00804219|Experimental|FSME responder|
11577969|NCT00804219|Experimental|hepatitis B non-responder|
11577970|NCT00804206|Experimental|Group A|Bevacizumab before panretinal photocoagulation.
11577971|NCT00804206|Experimental|Group B|Bevacizumab after panretinal photocoagulation
11577972|NCT00804193|Experimental|Test Product|Ciclopirox Olamine Topical Suspension
11577973|NCT00804193|Active Comparator|Reference Product|Loprox® Topical Suspension 0.77%
11577974|NCT00804193|Placebo Comparator|Vehicle Product|placebo of test product
11577975|NCT00804180|Other|Coping skills intervention|Self-Injection Anxiety Counseling: Evaluation of a group treatment for injection-related anxiety. The intention of the study is to obtain basic evaluation of a clinical treatment offered in a natural clinic setting, and does not include a control group, or procedure for random assignment of participants.
11577976|NCT00804154|Experimental|Single Arm|advanced cancer patients with pain
11577977|NCT00804141|Experimental|MOA-728 12 mg QD|Participants will receive MOA-728 12 milligrams (mg) SC once daily (QD) for 48 weeks. Dosing could be adjusted to an as needed (PRN) basis with a minimum 1 dose per week and maximum 1 dose per day.
11577978|NCT00804115|No Intervention|1|Latanoprost in combination with Pilocarpine
11577979|NCT00804115|No Intervention|2|Timolol or Cosopt
11577980|NCT00804102|Active Comparator|Retinitis pigmentosa|
11577981|NCT00804102|Active Comparator|Macula off|condition after treatment of retinal detachment
11577982|NCT00804102|Active Comparator|Primary open angle Glaucoma|
11577983|NCT00804102|Active Comparator|Hereditary Macular Degeneration|
11577984|NCT00804102|Active Comparator|Treated Retina detachment|
11577985|NCT00804102|Active Comparator|Retinal Artery Occlusion|
11577986|NCT00804102|Active Comparator|Retinal Vein Occlusion|
11577987|NCT00804102|Active Comparator|Non-Arteriitic-Anterior-Ischemic Optic-Neuropathy|
11577988|NCT00804102|Active Comparator|Hereditary autosomal dominant Optic atrophy|
11577989|NCT00804102|Active Comparator|dry Age-related Macular Degeneration|
11577990|NCT00804102|Active Comparator|Ischemic Macula edema|
11577991|NCT00804102|Sham Comparator|Non-stimulated|
11577992|NCT00804089|Experimental|1|Traditional needle acupuncture
11577993|NCT00804089|Active Comparator|2|Myofascial trigger point dry needling
11577994|NCT00804089|Active Comparator|3|Myofascial trigger point acupressure
11577995|NCT00804076|Experimental|NP2|Intradermal injection
11577996|NCT00804063||1|glaucoma patients
11577997|NCT00804063||2|non-glaucoma controls
11577998|NCT00804050|Experimental|Infusion A: rEPO|rEPO for 4 mounths consequently
11577999|NCT00804050|Experimental|Infusion B combined r-EPO|rEPO in association with acid 13-cis-retinoic acid and Dihydroxyvitamin D3 for 4 mounths consequently
11578000|NCT00804037|Active Comparator|Ethanol|
11578001|NCT00804037|Active Comparator|Ethanolamine Oleate|
11578002|NCT00804024||ClearWay™ RX|
11578003|NCT00804011|Experimental|1|Automatic tube compensation plus pressure support
11578004|NCT00804011|Active Comparator|2|Pressure support alone
11578005|NCT00803985|Active Comparator|Lichtenstein|Open operation with onlay light weight polypropylene mesh
11578514|NCT00800475|Active Comparator|Reference Drug|
11578006|NCT00803985|Active Comparator|Total Extraperitoneal repair (TEP)|Laparoscopic operation with preperitoneal nonfixated mesh
11578007|NCT00803972|Experimental|Stage 1: 3 U insulin plus rHuPH20|Participants will receive 3 Units (U) of regular insulin (100 U/milliliter [mL]), coadministered with sequential concentrations of 0, 1.25, 5, 10, 20, and 80 micrograms (μg)/mL recombinant human hyaluronidase (rHuPH20).
11578008|NCT00803972|Experimental|Stage 1: 12 U insulin plus rHuPH20|Participants will receive 12 U of regular insulin (100 U/mL), coadministered with sequential concentrations of 0, 1.25, 5, 10, 20, and 80 μg/mL rHuPH20.
11578009|NCT00803972|Experimental|Stage 2: insulin plus rHuPH20|Participants will receive 6, 12, and 24 U regular insulin (100 U/mL) in a randomly assigned order, with each insulin dose administered once with and once without 5 μg/mL rHuPH20.
11578010|NCT00803972|Experimental|Stage 3: 1.5 U insulin lispro plus rHuPH20|Participants will receive 1.5 U of insulin lispro (50 U/mL), coadministered with sequential concentrations of 0, 0.0625, 0.3125, 1.25, 5, and 20 μg/mL rHuPH20.
11578011|NCT00803972|Experimental|Stage 3: 6 U insulin lispro plus rHuPH20|Participants will receive 6 U of insulin lispro (50 U/mL), coadministered with sequential concentrations of 0, 0.0625, 0.3125, 1.25, 5, and 20 μg/mL rHuPH20.
11578012|NCT00803972|Experimental|Stage 4: 95 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 95 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
11578013|NCT00803972|Experimental|Stage 4: 50 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 50 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
11578014|NCT00803972|Experimental|Stage 4: 25 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 25 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
11578015|NCT00803959|Active Comparator|No UDS|Women desiring surgery for diagnosed, uncomplicated predominant stress urinary incontinence (UI) who receive a basic office evaluation only.
11578016|NCT00803959|Active Comparator|UDS|Women desiring surgery for diagnosed, uncomplicated predominant stress urinary incontinence (UI) who receive a basic office evaluation with preoperative urodynamic studies prior to surgery.
11578017|NCT00803946|Active Comparator|Test Product|
11578018|NCT00803946|Active Comparator|Reference Product|
11578019|NCT00803933|Experimental|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
11578020|NCT00803933|Active Comparator|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
11578021|NCT00803920||Exenatide|
11578022|NCT00803920||Exenatide LAR|
11578023|NCT00803907|Experimental|nodular BCC of the eyelid|Patients with nodular BCC of the eyelid
11578024|NCT00803894|Active Comparator|A|MK0752 1000 mg
11578025|NCT00803894|Active Comparator|B|MK0752 350 mg
11578026|NCT00803894|Placebo Comparator|C|Placebo
11578027|NCT00803881||CF patients of all age groups|Longitudinal prospective assessment of upper and lower airway colonization in all patients attended in the Jena University CF centre
11578028|NCT00803868|Experimental|1|Varenicline
11578029|NCT00803868|Placebo Comparator|2|Placebo
11578030|NCT00803855|Experimental|AZD1446 Oral or placebo|Single oral administration of AZD1446 or placebo
11578031|NCT00803855|Experimental|AZD1446 Oral, with or without food|Single oral administration of AZD1446 with or without food
11578032|NCT00803816|Other|Addition of everolimus to standard care|refractive to cyclosporine A (CsA) received additional everolimus.
11578033|NCT00803803|Experimental|Pilocarpine Concentration|Varying concentration 0.5 to 8% - 22 patients were examined regarding: visual acuity, iris color, pupil size, chamber angle, C/D ratio, visual field (VF), coefficient of aqueous outflow and Goldmann tonometry. After a one month washout period, pilocarpine was used 4 times daily, in concentrations from 0.5 to 8%. The amount of IOP change was compared with various clinical findings
11578034|NCT00803803|Experimental|Pilocarpine Frequency|Varying frequency, once to four times daily - 15 patients were included in a crossover study: IOP was checked daily for 3 days and for 9 hours on fourth day. Pilocarpine was started on day 5 once daily OD and BID OS; on day 9 once daily OD and QID OS; on day 12 QID OD and once daily OS; on day 16 once daily OD and QID OS; and on day 19 QID OD and once daily OS. No medications were used on days 23-25. IOP was measured on days 4, 8, 11, 15, 18, 22 and 25.
11578035|NCT00803790|Experimental|Sequence 1- alendronate+vitamin D combination then alendronate|Participants in Part 1 received 70mg alendronate+5600 International Units (IU) vitamin D combination tablet in Period 1 followed by 70mg alendronate tablet in Period 2. A washout of at least 12 days separated each treatment period.
11578036|NCT00803790|Experimental|Sequence 2 alendronate then alendronate+vitamin D combination|Participants in Part 1 received 70mg alendronate tablet in Period 1 followed by 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.
11578037|NCT00803790|Experimental|Sequence 3 alendronate+vitamin D combination then vitamin D|Participants in Part 2 received 70mg alendronate+5600 IU vitamin D combination tablet in Period 1 followed by a single dose of 5600 IU vitamin D, administered as two 2800 IU tablets in Period 2. A washout of at least 12 days separated each treatment period.
11578038|NCT00803790|Experimental|Sequence 4- vitamin D then alendronate+vitamin D combination|Participants in Part 2 received a single dose of 5600 IU vitamin D, administered as two 2800 IU tablets in Period 1 followed by a 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.
11578039|NCT00803777|Experimental|Intended Users of the Monitoring System|Subjects with type 1 diabetes and healthcare professionals (HCP) used a new blood glucose monitoring system (BGMS) with subject capillary blood. Any subject under age 18 was accompanied by a parent or guardian, who assisted subject if applicable.
11578040|NCT00803764|Active Comparator|Test Product|
11578041|NCT00803764|Active Comparator|Reference Product|
11578042|NCT00803751|Experimental|Truview intubation|Receive laryngoscopy with Truview first and is immediately followed by laryngoscopy and intubation with Macintosh
11578043|NCT00803751|Active Comparator|Macintosh intubation|Macintosh blade will be used first followed by laryngoscopy and intubation with the truview
11578642|NCT00799591||1|Intensive Care
11578044|NCT00803738|Experimental|Test Product|Terconazole Vaginal Suppository
11578045|NCT00803738|Active Comparator|Reference Product|Terazol Vaginal Suppository
11578046|NCT00803725|Active Comparator|1|Mepivicaine for spinal anesthesia
11578047|NCT00803725|Experimental|2|Mepivacaine with Fentanyl for spinal anesthesia
11578048|NCT00803712|Experimental|Cinacalcet Group|Cinacalcet plus low dose active Vitamin D (if prescribed)
11578049|NCT00803712|Active Comparator|Control Group|Flexible active vitamin D dosing
11578050|NCT00803699|Placebo Comparator|Placebo|Capsule contains no selenium
11578051|NCT00803699|Active Comparator|Selenium as L-selenomethionine|50, 100, or 200 micrograms of selenium
11578052|NCT00803686|Experimental|Part 1 Double Blind Oral rsCT Tablet|Intervention: Oral rsCT tablet given once 4 hours after evening meal.
11578053|NCT00803686|Placebo Comparator|Part 1, Double-blind Oral Placebo Tablet|Intervention: Oral placebo tablet matching the oral rsCT tablet, given once 4 hours after evening meal
11578054|NCT00803686|Experimental|Part 2 Open label, Oral rsCT tablet|Intervention: Oral rsCT tablet given once 2 hours after evening meal.
11578055|NCT00803686|Active Comparator|Part 2, Open Label Fortical Nasal Spray|Intervention: Part 2 Open label. Fortical (rsCT) nasal spray given once 2 hours after evening meal
11578056|NCT00803673|Experimental|Active|100mcg 719
11578057|NCT00803673|Experimental|Active 2|500mcg '719
11578058|NCT00803673|Experimental|Active 3|1000mcg '719
11578059|NCT00803673|Placebo Comparator|Placebo|Placebo '719
11578060|NCT00803647|Experimental|treatment|mFOLFOX7 (5-FU, leucovorin, oxaliplatin) + cetuximab
11578061|NCT00803634|Experimental|Clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was administered intravenously via a single dedicated line to all patients randomized to the clevidipine arm. Clevidipine was infused at an initial rate of 2 mg/h for the first 3 minutes. If blood pressure was not in the target range at 3 minutes, clevidipine was titrated to effect thereafter by doubling the dose every 3 min, per physician discretion and as tolerated by the patient until the desired effect until the SBP target range was attained. Once target range was achieved, the infusion rate could be increased or decreased as needed to maintain blood pressure for minimum of 30 minutes and a maximum duration of 96 hours. The minimum infusion rate was 1 mg/h and maximum infusion rate was 32 mg/h.
11578062|NCT00803634|Active Comparator|Standard of Care IV antihypertensive|For patients randomized to standard of care (SOC) IV antihypertensive treatment, a continuous infusion of an intravenous antihypertensive agent represented standard of care. The selection of treatment was at the discretion of the investigator. The infusion was to be administered according to the institution's treatment practice.
11578063|NCT00803608|Active Comparator|02|Current standard of care insole
11578064|NCT00803608|Experimental|01|TrueContour® insole
11578065|NCT00803595|Experimental|CS-8958 Low Dose|CS-8958 powder to be inhaled - low-dose arm
11578066|NCT00803595|Experimental|CS-8958 High Dose|CS-8958 powder to be inhaled - high-dose arm
11578067|NCT00803595|Active Comparator|Oseltamivir phosphate|oseltamivir phosphate oral capsules
11578068|NCT00803582|Experimental|Experimental|Traditional acupuncture
11578069|NCT00803582|Sham Comparator|Placebo|Placebo acupuncture
11578070|NCT00803582|No Intervention|No-treatment|no treatment
11578071|NCT00803569|Experimental|ALVAC(2)-NY-ESO-1(M)/TRICOM + GM-CSF|Patients received SC injections with ALVAC(2)-NY-ESO-1(M)/TRICOM (0.5 mL) on Day 1 and the GM-CSF sargramostim (100 μg) on Days 1 through 4 in continuous 28-day cycles for up to 6 cycles.
11578072|NCT00803556|Experimental|Arm 1|"Patients whose last dose is > 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin
~Patients whose last dose is < 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin"
11578073|NCT00803556|Experimental|Arm 2|"Patients whose last dose is > 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of paclitaxel and 60 min of infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin
~Patients whose last dose is < 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin"
11578074|NCT00803543|Active Comparator|Valacyclovir|This is the arm taking Valacyclovir
11578075|NCT00803543|Placebo Comparator|Placebo|This is the arm taking the placebo
11578076|NCT00803530|Experimental|1|"Loading phase (week 1): ATO 0.3 mg/Kg/die for 5 consecutive days.
~Subsequent phase (from week 2 to week 16): ATO 0.25 mg/kg twice a week (day 2 and 5 of every week).
~Ascorbic acid 1000 mg IV within 30 minutes after each arsenic trioxide infusion for 16 consecutive weeks."
11578077|NCT00803517||Photodynamic therapy (PDT)|
11578078|NCT00803517||Focal laser photocoagulation (focal)|
11578079|NCT00803491|Experimental|Problem based learning program|PBL intervention - a self-promoting PBL program for patients with rheumatic diseases.
11578080|NCT00803491|Active Comparator|Control group|Traditional rheumatological care.
11578081|NCT00803478|Active Comparator|Hinge position|superior vs. temporal
11578082|NCT00803478|Active Comparator|Hinge width|45 vs 90 degrees
11578083|NCT00803478|Active Comparator|Flap Thickness|110 vs 130 microns
11578084|NCT00803465||Cohort Group 1|Subjects number 1 to 24
11578085|NCT00803465||Cohort Group 2|Subjects number 25 to 44
11578086|NCT00803465||Cohort Group 3|Subjects number 45 to 68
11578087|NCT00803465||Cohort Group 4|Subjects number 69 to 91
11578088|NCT00803465||Cohort Group 5|Subjects Number 92 to 115
11578089|NCT00803452|Active Comparator|Doxycycline|Oral doxycycline
11578090|NCT00803452|Active Comparator|azithromycin|Topical azithromycin daily to the conjunctival culdesac
11578091|NCT00803439||Cohort Group 1|Subjects number 1 to 20
11578092|NCT00803439||Cohort Group 2|Subjects number 21 to 40
11578093|NCT00803439||Cohort Group 3|Subjects number 41 to 60
11578094|NCT00803439||Cohort Group 4|Subjects number 61 to 80
11578095|NCT00803426|Active Comparator|1|Local anesthetic will be injected above the division of the sciatic nerve.
11578096|NCT00803426|Experimental|2|Local anesthetic will be injected below the division of the sciatic nerve, around the common peroneal and tibial nerves.
11578097|NCT00803413|Other|Back School|Participants received weekly sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)
11578098|NCT00803413|Other|Supervised Walking|Participants received weekly sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group
11578099|NCT00803413|Other|Back School and Walking|Participants received weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening); 30 minutes of on-place supervised walking in group
11578100|NCT00803413|Other|Control Group|Participants received weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
11578101|NCT00803400|Active Comparator|Alprazolam|
11578102|NCT00803400|Active Comparator|Alprazolam + Aerobic exercise|
11578103|NCT00803387||Patients taking Xalatan with ocular dryness or irritation|"patient must already be using xalatan for at least 1 month prior to study enrollment in both eyes and have complaints of dry eye and/or irritation.
~any race and of either sex, diagnosed with open angle glaucoma (OAG) (with or without pseudoexfoliation or pigment dispersion components) or ocular hypertension (OHT)"
11578104|NCT00803374|Experimental|0.1 mg/kg|
11578105|NCT00803374|Experimental|0.3 mg/kg|
11578106|NCT00803374|Experimental|1.0 mg/kg|
11578107|NCT00803374|Experimental|3.0 mg/kg|
11578108|NCT00803374|Experimental|10 mg/kg|
11578109|NCT00803361|Experimental|Duloxetine|
11578110|NCT00803361|Placebo Comparator|Placebo|
11578111|NCT00803348|Active Comparator|1|Initial Bolus dose of 0.2% ropivicaine followed by 0.2% ropivicaine infusion until day 2 post-op
11578112|NCT00803348|Experimental|2|Initial Bolus dose of 0.2% ropivicaine followed by 0.1% ropivicaine infusion until day 2 post-op
11578113|NCT00803348|Placebo Comparator|3|Initial Bolus dose of 0.375% ropivicaine followed by saline infusion until day 2 post-op
11578114|NCT00803335|Active Comparator|Premarin cream 0.5gm|Application of 0.5gm of vaginal estrogen cream nightly until surgery.
11578115|NCT00803335|Active Comparator|Premarin cream 1.0gm|Application of 1.0gm of vaginal estrogen cream nightly until surgery.
11578116|NCT00803335|No Intervention|No intervention|Women in this arm will not apply any cream or moisturizers to the vagina until surgery, ie no intervention.
11578117|NCT00803322||1|communities where tuberculosis patients followed the conventional health facility based tuberculosis case finding and treatment
11578118|NCT00803322||2|community where suspects of pulmonary tuberculosis were identified by community health workers and received treatment in the community
11578119|NCT00803309|Active Comparator|A|PegIntron® 1.5 µg/kg once weekly (QW) subcutaneous (sc) plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 24 weeks beyond standard treatment with 24 weeks follow-up
11578120|NCT00803309|Active Comparator|B|PegIntron® 1.5 µg/kg QW sc plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 12 weeks beyond standard treatment with 24 weeks follow-up
11578121|NCT00803296||Obese patients with type 2 diabetes|Patients with type 2 diabetes and BMI>33
11578122|NCT00803296||Obese subjects with normal glucose tolerance|Subjects with normal glucose tolerance and BMI>33
11578123|NCT00803296||Lean subjects with type 2 diabetes|Patients with type 2 diabetes and BM<25
11578124|NCT00803296||Lean subjects with normal glucose tolerance|Subjects with normal glucose tolerance and BM<25
11578125|NCT00803283|Experimental|Hydromprphone Hydrochloride (HCl) OROS|Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
11578126|NCT00803283|Active Comparator|Morphine Sustain Release (SR)|Participants will receive morphine SR 8 mg every 24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
11578127|NCT00803270|Active Comparator|Surgical Treatment|Surgical treatment will consist of the following evidence-based stress incontinence procedures: mid-urethral slings (TVT, TOT, TVT-O), fascial slings, and Burch colposuspension.
11578128|NCT00803270|Active Comparator|Non Surgical Treatment|"The non-surgical treatment will include two components:
~Pharmacological therapy with any FDA approved overactive bladder (OAB) drug in approved doses; and
~Behavioral therapy."
11578129|NCT00803257|Experimental|1|Lumbrical splint and lumbrical stretches
11578130|NCT00803257|Active Comparator|2|Lumbrical Splint and regular exercises
11578131|NCT00803257|Active Comparator|3|Regular splint and lumbrical exercises
11578132|NCT00803257|Active Comparator|4|Regular splint and regular exercises
11578133|NCT00803244|Experimental|300 IR|300 IR grass pollen allergen extract tablet
11578134|NCT00803244|Placebo Comparator|Placebo|Placebo tablet
11578135|NCT00803231||Retrospective cohort|Patient treated with Xigris between January 2006 and November 2008.
11578136|NCT00803231||Prospective cohort|Patient treated with Xigris between November 2008 and November 2009.
11578137|NCT00803218||Cohort Group 1|Subjects number 1 to 26
11578138|NCT00803218||Cohort Group 2|Subjects number 27 to 56
11578139|NCT00803205|Experimental|Ataluren|Participants will receive ataluren 3 times per day (TID): 10 milligrams (mg)/kilogram (kg) of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total daily dose 40 mg/kg). Treatment will continue for 48 weeks, after which participants will be followed for 4 weeks.
11578140|NCT00803205|Placebo Comparator|Placebo|Participants will receive placebo TID: 10 mg/kg of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total daily dose 40 mg/kg). Treatment will continue for 48 weeks, after which participants will be followed for 4 weeks.
11578141|NCT00803192|Active Comparator|Test Drug|
11578142|NCT00803192|Active Comparator|Reference Drug|
11578143|NCT00803179|Experimental|Growth Hormone Therapy|"Nutropin Aqueous (AQ):
~Initiation treatment for adult males is 0.2mg/d and for women 0.4mg/d"
11578144|NCT00803166||Cohort Group 1|Subjects number 1 to 30
11578145|NCT00803166||Cohort Group 2|Subjects number 31 to 60
11578146|NCT00803140|Active Comparator|Cautery Arm|Cautery to make skin incision
11578147|NCT00803140|Active Comparator|Scalpel Incision|Scalpel to make skin incision
11578148|NCT00803127||no treament|
11578149|NCT00803114|Experimental|Epidural Morphine|2.5 mg dose of epidural morphine given within one hour following vaginal delivery
11578150|NCT00803114|Placebo Comparator|Placebo|5 ml of epidural preservative-free saline given within one hour following vaginal delivery
11578151|NCT00803101|Experimental|Beriplex® P/N|
11578152|NCT00803101|Active Comparator|Fresh frozen plasma|
11578153|NCT00803088|Experimental|1|Treatment of airways with the Alair System
11578154|NCT00803062|Active Comparator|Arm I (paclitaxel and cisplatin)|Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV on day 1 or 2.
11578155|NCT00803062|Experimental|Arm II (paclitaxel, cisplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV and bevacizumab IV over 30-90 minutes on day 1 or 2.
11578156|NCT00803062|Experimental|Arm III (topotecan hydrochloride and paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
11578157|NCT00803062|Experimental|Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab)|Patients receive paclitaxel IV over 3 hours and bevacizumab IV over 30-90 minutes on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
11578158|NCT00803049|Experimental|Placebo/Teriflunomide 7 mg|Participants who completed treatment of placebo (for teriflunomide) tablet once daily (QD) for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.
11578159|NCT00803049|Experimental|Teriflunomide 7 mg/7 mg|Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.
11578160|NCT00803049|Experimental|Placebo/Teriflunomide 14 mg|Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.
11578161|NCT00803049|Experimental|Teriflunomide 14 mg/14 mg|Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.
11578162|NCT00803023|Experimental|1|Sodium Oxybate Oral Solution (4.5 grams)
11578163|NCT00803023|Experimental|2|Sodium Oxybate taken as a combination of an Oral Solution and Placebo Tablets (4.5 grams)
11578164|NCT00803023|Experimental|3|Sodium Oxybate Oral Solution (6 grams)
11578165|NCT00803023|Experimental|4|Sodium Oxybate taken as a combination of an Oral Solution and Placebo Tablets (6 grams)
11578166|NCT00803010|Active Comparator|Tacrolimus / Rapamycin (TAC/RAPA)|"Tacrolimus: beginning 3 days before transplant and given for at least 50 days.
~Rapamycin: given the day before transplant and continued daily for at least one year."
11578167|NCT00803010|Active Comparator|Tacrolimus / Methotrexate (TAC/MTX)|"Tacrolimus: beginning 3 days before transplant and given for at least 50 days.
~Methotrexate: given on days 1, 3, 6 and 11, after transplant."
11578168|NCT00802997|Active Comparator|1|Treatment with Sinergy system
11578169|NCT00802997|Placebo Comparator|2|placebo controlled
11578170|NCT00802971|Experimental|1: FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
11578171|NCT00802971|No Intervention|2: Control|
11578172|NCT00802958||Cohort Group 1|Subjects number 1 to 30
11578173|NCT00802958||Cohort Group 2|Subjects number 31 to 56
11578174|NCT00802958||Cohort Group 3|Subject Numbers 57 to 76
11578175|NCT00802945|Experimental|NKTR-102 q14d|NKTR-102
11578176|NCT00802945|Experimental|NKTR-102 q21d|NKTR-102
11578177|NCT00802932||Partial Breast Radiation|1. Patients receiving Partial breast radiation
11578178|NCT00802932||Whole Breast Radiation|2. Patients receiving whole breast radiation
11578179|NCT00802919|Experimental|Varenicline|Varenciline 1-2 mg/day
11578180|NCT00802919|Placebo Comparator|Matched Placebo|placebo for varenicline
11578181|NCT00802906|Active Comparator|1|1.5 mg bevacizumab single injection and on demand if leakage is persistent or recurs
11578182|NCT00802906|Active Comparator|2|initial selective subthreshold micropulselasercoagulation and on demand if leakage is persistent or recurs
11578183|NCT00802906|No Intervention|3|control
11578184|NCT00802893|Experimental|Experimental Drug|
11578185|NCT00802893|Placebo Comparator|Placebo Comparator|
11578186|NCT00802880|Experimental|Dacarbazine|Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.
11578187|NCT00802867|Experimental|1|Subjects in Study 494-01 and Study 494-03 who had received 4 doses of Pentacel™ vaccine.
11578188|NCT00802841|Experimental|Nilotinib|Participants received 400 mg nilotinib twice daily (BID).
11578189|NCT00802841|Active Comparator|Imatinib|Participants received 600 mg imatinib once daily (QD).
11578190|NCT00802828|Active Comparator|Test Product|
11578191|NCT00802828|Active Comparator|Reference Product|
11578192|NCT00802815|Experimental|Etanercept|
11578193|NCT00802802|Experimental|Cohort I, Step 1|HIV-infected children 3 months to 36 months of age, receiving EFV and two NRTIs
11578194|NCT00802802|Experimental|Cohort II|HIV/TB-coinfected children 3 months to 36 months of age, receiving EFV, two NRTIs, and rifampin-containing anti-tuberculosis (anti-TB) therapy
11578272|NCT00802256|Experimental|B|teeth which are treated with new Endodontic Cement (NEC) material
11578273|NCT00802230|Active Comparator|1|Carvedilol IR
11578195|NCT00802802|Experimental|Cohort I, Step 2|HIV-infected children from Cohort I who become coinfected with TB during the study. They will receive EFV, two NRTIs, and rifampin-containing anti-TB therapy
11578196|NCT00802789||1|Mild to moderate adult asthmatics (≥18years of age) insufficiently treated with ICS or ICS + LABA.
11578197|NCT00802776|Active Comparator|FLAK|Femtosecond laser assisted keratoplasty
11578198|NCT00802776|Active Comparator|PKP|Penetrating Keratoplasty
11578199|NCT00802763||vaginitis|
11578200|NCT00802737|Experimental|Ofatumumab|Eight once weekly infusions (1 x 300 mg + 7 x 2000 mg), then 2000 mg once monthly for two years
11578201|NCT00802724|Experimental|1 Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
11578202|NCT00802724|Active Comparator|2 Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
11578203|NCT00802711|Experimental|Arm I|Patients undergo accelerated partial breast irradiation (APBI) using 3-dimensional conformal radiation therapy twice daily over 5-10 days (total of 10 fractions) in the absence of disease progression or unacceptable toxicity.
11578204|NCT00802711|Experimental|Arm II|Patients undergo APBI using multi-catheter interstitial brachytherapy twice daily over 5-10 days (total of 10 fractions) in the absence of disease progression or unacceptable toxicity.
11578205|NCT00802698|Experimental|Group 1|
11578206|NCT00802685|Experimental|early ibuprofen|"Drug: Early ibuprofen
~IBUPROFEN DOSING SCHEDULE: At the diagnosis of PDA, infants randomized to early treatment will receive blinded ibuprofen initial dose 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy will be blinded. This group will then be eligible to receive unblinded, open label ibuprofen for a hemodynamically significant PDA include: SIGNS OF PDA + Presence of significant pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (not due to something other than PDA) defined as at least two of the following respirator settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV."
11578207|NCT00802685|Other|Late Ibuprofen expectant group (placebo)|"Late ibuprofen expectant group (placebo): Ibuprofen schedule: At PDA diagnosis, infants randomized to late expectant group will receive blinded placebo. If hemo-dynamically significant PDA develops, infants now receive open label ibuprofen, initial dose of 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA: Signs of PDA + pulmonary hemorrhage alone or Signs of PDA + Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following respirator settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV. Infants who had received placebo will ibuprofen for the first time (thus, late ibuprofen or expectant)."
11578208|NCT00802672|Experimental|Test Product|Ciclopirox Olamine Cream 0.77%
11578209|NCT00802672|Active Comparator|Reference Product|Loprox Cream 0.77%
11578210|NCT00802672|Placebo Comparator|Vehicle Product|placebo of test product
11578211|NCT00802659|Experimental|Group -1|1000 cGY radiation
11578212|NCT00802659|Experimental|Group 1|1200 cGY radiation
11578213|NCT00802659|Experimental|Group 2|1400 cGY radiation
11578214|NCT00802659|Experimental|Group 3|1600 cGY radiation
11578215|NCT00802646|Experimental|1|When it is time for the epidural catheter, the mother will receive 2.5 mcg fentanyl spinally and then a bag of preservative-free normal saline will be administered through the epidural pump. When additional pain medication is requested, the mother will receive a known combined spinal epidural solution.
11578216|NCT00802646|Active Comparator|2|When it is time for the epidural catheter, the mother will receive 2.5 mcg fentanyl spinally and then a bag of combined spinal epidural anesthetic through the epidural pump. When additional pain medication is requested, the mother will receive a known combined spinal epidural solution.
11578217|NCT00802633|Active Comparator|Stapling device|Efficacy of stapling device during radical cystectomy
11578218|NCT00802633|Active Comparator|Ligasure Device|Efficacy of ligasure tissue sealing device during radical cystectomy
11578219|NCT00802594|Experimental|DB289|
11578220|NCT00802581|Experimental|1|Ensuring circumferential spread of local anesthetic around the sciatic nerve.
11578221|NCT00802581|Active Comparator|2|Single shot injection of local anesthetic near the sciatic nerve will be performed, without ensuring circumferential spread.
11578222|NCT00802555|Experimental|ARQ 197|
11578223|NCT00802542||1|Adult patients with mild or moderate essential hypertension who do not tolerate ACE inhibitors because of cough, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal and the doctor has decided to increase the Atacand dose to 16mg as per SmPC.
11578224|NCT00802529|Experimental|Steroid (Methylprednisolone)|Steroid (Methylprednisolone)
11578225|NCT00802529|Active Comparator|Gentamicin|Gentamicin
11578226|NCT00802516|Placebo Comparator|1. placebo|placebo margarine
11578227|NCT00802516|Experimental|2. stanol ester|margarine with plant stanol ester
11578228|NCT00802516|Experimental|3. sterol ester|margarine with plant sterol ester
11578274|NCT00802230|Active Comparator|2|Metoprolol Succinate
11578275|NCT00802217|Active Comparator|Cohort 1|Civamide liquid filled softgel capsule 5 mg
11578276|NCT00802217|Active Comparator|Cohort 2|Civamide liquid filled soft gel capsules 2 x 5 mg
11578277|NCT00802204|Active Comparator|Lean controls|Lean complete baseline outcome measures only
11578229|NCT00802503|Experimental|SPN group|"experimental arm: Supplemental Parenteral Nutrition (SPN) is added to enteral nutrition (EN) to reach 100% of their predicted energy needs from ICU day 4.
~In the treated group, SPN is started if at day 4 energy input by EN is < 60% of energy target in order to reach 100% of energy target by peripheral or central line. Nutritional products as currently used in our institution. SPN is composed of EN and PN, both techniques being currently used in our institution."
11578230|NCT00802503|No Intervention|Control gr|EN : start EN at 20-30 ml/h per day up to maximal 150 ml/h per day; or day1: 500 ml, day2: 1000 ml, day3: 1500 ml of EN dependant on gastrointestinal tolerance (gastric residue volume more than 500ml). Nutritional products as currently used in our institution.
11578231|NCT00802490|Active Comparator|Intervention|20 sessions of EEG biofeedback training
11578232|NCT00802490|Placebo Comparator|Control|Only 1 session of EEG biofeedback training
11578233|NCT00802477|Experimental|1|Application of Autologous Blood Products to surgical site during mastectomy.
11578234|NCT00802477|Active Comparator|2|Standard Modified Radical Mastectomy
11578235|NCT00802464|Experimental|GSK1437173A formulation 1 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
11578236|NCT00802464|Experimental|GSK1437173A formulation 2 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) GSK1437173A formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
11578237|NCT00802464|Experimental|GSK1437173A formulation 3 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
11578238|NCT00802464|Placebo Comparator|Control Group|Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
11578239|NCT00802451|Active Comparator|Test Drug|
11578240|NCT00802451|Active Comparator|Reference Drug|
11578241|NCT00802438|Experimental|Mepolizumab|up to 3 monthly doses of 750mg i.v. mepolizumab
11578242|NCT00802425|Experimental|2|AM-111 low dose
11578243|NCT00802425|Placebo Comparator|1|
11578244|NCT00802425|Experimental|3|AM-111 high dose
11578245|NCT00802412|Other|Topiramate|The subjects for the proposed study will be 180 currently smoking, treatment-seeking male veterans with alcohol and nicotine dependence. Ninety subjects will be randomized to the topiramate arm and 90 subjects will be randomized to the placebo group.
11578246|NCT00802412|Placebo Comparator|Placebo|90 participants, will receive matching placebo
11578247|NCT00802399|Other|Partial Lacrimal Punctual Occlusion|Cauterization of the edge of all lacrimal punctum was carried out in all patients
11578248|NCT00802373|Experimental|I|Solifenacin succinate 5/10mg
11578249|NCT00802373|Experimental|II|Tolterodine 4mg
11578250|NCT00802360|Experimental|Menopur/Endometrin|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.
~Progestrone vaginal insert (Endometrin®) starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
11578251|NCT00802360|Experimental|Menopur/Progesterone in Oil|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.
~Progesterone in Oil injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
11578252|NCT00802360|Active Comparator|Follistim/Endometrin|"Follitropin beta (Follistim®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.
~Progestrone vaginal insert (Endometrin®) starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
11578253|NCT00802360|Active Comparator|Follistim/Progesterone in Oil|"Follitropin beta (Follistim®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.
~Progesterone in Oil injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
11578254|NCT00802347|Experimental|I5NP|
11578255|NCT00802347|Placebo Comparator|Saline|
11578256|NCT00802334|Experimental|1|
11578257|NCT00802321|Experimental|dutasteride|
11578258|NCT00802308|Experimental|Treatment A|Single dose administration of Egalet® morphine with alcohol
11578259|NCT00802308|Experimental|Treatment B|Single dose administration of Egalet® morphine with alcohol
11578260|NCT00802308|Experimental|Treatment C|Single dose administration of Egalet® morphine with alcohol
11578261|NCT00802308|Placebo Comparator|Treatment D|Single dose administration of Egalet® morphine with water
11578262|NCT00802295|Active Comparator|standard dosis protocol|Administration of standard dosis of gonadotrophins for ovarian stimulation.
11578263|NCT00802295|Experimental|2|Administration of low dosis of Gonadotrophins for ovarian stimulation
11578264|NCT00802282|Experimental|1|First of 5 groups, as described in the protocol and to which volunteers are blinded
11578265|NCT00802282|Experimental|2|Second of 5 groups, as described in the protocol and to which volunteers are blinded
11578266|NCT00802282|Experimental|3|Third of 5 groups, as described in the protocol and to which volunteers are blinded
11578267|NCT00802282|Experimental|4|Fourth of 5 groups, as described in the protocol and to which volunteers are blinded
11578268|NCT00802282|Experimental|5|Fifth of 5 groups as described in the protocol and to which volunteers are blinded
11578269|NCT00802269|Experimental|Reduced Fluence Parameters|Eyes receiving retinal photocoagulation with reduced fluence parameters (time 20-50 msec, power 400-700 mW)
11578270|NCT00802269|Active Comparator|Traditional parameters|Eyes receiving retinal photocoagulation with traditional parameters (time 100-200 msec, power 200-400 mW)
11578271|NCT00802256|Experimental|A|teeth which are treated with Mineral Trioxide Aggregate (MTA) material
11578278|NCT00802204|Experimental|Obese|Obese completing baseline and post-VLCD outcome measures
11578279|NCT00802191||Control Group|Participants with no movement disorders.
11578280|NCT00802191||Movement Disorders Participants|Participants have a movement disorder
11578281|NCT00802165|Experimental|Electroacupuncture Treatment Group|Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness
11578282|NCT00802165|Sham Comparator|Sham Treatment Group|Sham electroacupuncture treatment gives comparison to the experimental group
11578283|NCT00802152|Experimental|Home Monitoring|100 eligible subjects identified as (HbA1c >= 8% OR SBP > 130 mm Hg)
11578284|NCT00802152|No Intervention|Usual Care|100 eligible subjects identified as (HbA1c >= 8% OR SBP > 130 mm Hg)
11578285|NCT00802139|Experimental|venoferrum group|
11578286|NCT00802139|Active Comparator|Bolgre group|
11578287|NCT00802126|Experimental|Bevacizumab and verteporfin|
11578288|NCT00802113|Experimental|Arm A - Family Donor|Fludarabine and Busulfan: Patients who have a matched family (allogeneic) donor will go on to receive non-ablative therapy, followed by an infusion of donor stem cells; this is called an allogeneic peripheral blood stem cell transplant. The non-ablative therapy will be busulfan and ﬂudarabine, Usually large (myeloablative) doses of these drugs are used for an allogeneic transplant. However, in this study lower doses (non-ablative) of chemotherapy will be given. In patients who still have evidence of disease after allogeneic transplant, additional donor immune cells (donor lymphocyte infusion) (DLI) will be given twice to further treat the lymphoma.
11578289|NCT00802113|Experimental|Arm B - Unrelated Cord Blood or Adult|Fludarabine, Busulfan and ATG: For patients who don't have a matched family donor, a cord blood search and unrelated adult search will be done at all of the cord blood banks and adult donor registries in the world. If a closely matched cord blood donor or unrelated adult donor is found, non-ablative chemotherapy with busulfan, ﬂudarabine and antithymocyte globulin (ATG) followed by the infusion of matched unrelated cord blood cells or adult donor stem cells or bone marrow to restore the bone marrow will be given.
11578290|NCT00802100|Experimental|Olanzapine|Participants will receive treatment with olanzapine and metformin, with the possible addition of simvastatin or benztropine, depending on side effects.
11578291|NCT00802100|Experimental|Perphenazine|Participants will receive treatment with perphenazine and benztropine, with the possible addition of simvastatin or metformin, depending on side effects.
11578292|NCT00802100|Experimental|Aripiprazole|Participants will receive treatment with aripiprazole, with the possible addition of simvastatin, metformin, or benztropine, depending on side effects.
11578293|NCT00802087|Experimental|Egalet® hydrocodone treatment A|Single Dose administration
11578294|NCT00802087|Experimental|Egalet® hydrocodone Treatment B|Single Dose Administration
11578295|NCT00802087|Experimental|Egalet® hydrocodone Treatment C|Single Dose Administration
11578296|NCT00802087|Experimental|Egalet® hydrocodone Treatment D|Single Dose Administration
11578297|NCT00802087|Active Comparator|Active Comparator|Single Dose Administration
11578298|NCT00802074|Active Comparator|Group A|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 1400mg BID Period 3- Fosamprenavir 1400mg BID + Raltegravir 400mg BID
11578299|NCT00802074|Active Comparator|Group B|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg BID + Raltegravir 400mg BID Period 3 Fosamprenavir 1400mg BID
11578300|NCT00802074|Active Comparator|Group C|Period 1-Raltegravir 400mg BID Period2- Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3- Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID
11578301|NCT00802074|Active Comparator|Group D|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID
11578302|NCT00802074|Active Comparator|Group E|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3- Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID
11578303|NCT00802074|Active Comparator|Group F|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
11578304|NCT00802048|Experimental|1|48h postoperative infusion of ropivacaine
11578305|NCT00802048|Placebo Comparator|2|48h postoperative infusion of NaCl.
11578306|NCT00802035|Active Comparator|IR am|30 mg, single dose, morning administration (immediate release [IR])
11578307|NCT00802035|Experimental|ER am|30 mg; single dose; morning administration (extended release [ER])
11578308|NCT00802035|Experimental|ER pm|30 mg; single dose; evening administration
11578309|NCT00802035|Active Comparator|IR pm|30 mg; single dose; evening administration
11578310|NCT00802009|Experimental|1|Dexamethasone 8mg added to routine local anesthetic during brachial plexus blockade.
11578311|NCT00802009|Active Comparator|2|Routine anesthetic solution (30 cc 1.5% mepivicaine) used during brachial plexus blockade.
11578312|NCT00801996||1. Prostate Cancer|"Inclusion Criteria:
~All study subjects should be able to provide informed consent
~Males ages 40 years or older
~Individuals from the Qatari Peninsula whose ancestors up to three generations back were natives of Qatar.
~Individuals undergoing Trans Rectal Ultrasound (TRUS) biopsy as dictated by their standard clinical care
~Ultrasound OR digital rectal examination consistent with prostate disease OR A level of PSA (Prostatic Specific Antigen) greater than 3.0
~Exclusion Criteria:
~• Patient refuses consent"
11578313|NCT00801996||2. Normal Healthy Controls|"Inclusion Criteria:
~All study subjects should be able to provide informed consent
~Males or females ages 40 years or older (see section A8 for the rationale for the inclusion of females)
~Individuals of Arab descent from Qatari peninsula without any personal or family history of prostate cancer
~Exclusion Criteria:
~Individuals with family history of prostate cancer
~Individuals not deemed in good overall health by the investigator will not be accepted into the study"
11578314|NCT00801983|Experimental|A|Subject receives typical keyboard first for 6 months and alternative keyboard second for 6 months
11578315|NCT00801983|Experimental|B|Subject receives alternative keyboard first for 6 months and typical keyboard second for 6 months
11578316|NCT00801970|Experimental|1 - Pregnant - Tokophobic|Psychoanalysis treatment.
11578317|NCT00801970|Experimental|2 - Pregnant - Tokophobic|Cognitive-Behavioral treatment.
11578318|NCT00801970|Experimental|3 - Non-pregnant - Tokophobic|Group Therapy
11578319|NCT00801970|No Intervention|4 - Control|Pregnant and non-pregnant non-tokophobic women will answer questionnaires. Won't receive therapy.
11578320|NCT00801957|Experimental|1|tacrolimus ointment 0.03%
11578321|NCT00801957|Active Comparator|2|hydrocortisone acetate 1% and butyrate 0.1%
11578322|NCT00801957|Other|3|Control group vaccination and challenge dose only
11578323|NCT00801944|Experimental|I|Solifenacin succinate 5/10mg
11578324|NCT00801944|Experimental|II|Placebo
11578325|NCT00801931|Experimental|A: Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated total body irradiation (TBI) will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5 and-4, Cyclophosphamide on Days -3 and -2 and- rabbit antithymocyte globulin on Days -4, -3, -2 and -1.The double cord blood infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/mycophenolate mofetil (MMF).
11578326|NCT00801931|Experimental|B: Full intensity without TBI|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with double cord blood infusion on Day 0. Granulocyte-macrophage colony-stimulating factor (GM-CSF) hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
11578327|NCT00801931|Experimental|C: Moderate Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -8. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
11578328|NCT00801931|Experimental|D: Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -6. Patients will receive busulfan twice daily on Days -6, and-5; fludarabine on Days -6, -5, -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
11578329|NCT00801931|Experimental|E: Fanconi's Anemia|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and horse antithymocyte globulin on Days -5, -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
11578330|NCT00801931|Experimental|F: Regimen for non-malignant diseases|Patients will begin fosphenytoin or phenytoin prophylaxis on Day -10. Patients will receive busulfan on days -9, -8, -7 and -6, cyclophosphamide on days -5, -4, -3, and -2 and rabbit antithymocyte globulin on days -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
11578331|NCT00801918|Other|DD Alone|Patients will get Denileukin Diftitox for 5 days every 3 weeks for a total of 4 cycles.
11578332|NCT00801918|Experimental|DD with ICE Chemotherapy|For patients who show a response to DD alone after 4 cycles or for patients who show progressive disease after 2 cycles, DD will be given with ICE chemotherapy for 2 cycles.
11578333|NCT00801905|Active Comparator|1: Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
11578334|NCT00801905|Placebo Comparator|2: placebo|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
11578335|NCT00801892|Active Comparator|1 subjects treated with CPAP|Continuous Positive Airway Pressure treatment (CPAP)
11578336|NCT00801892|Sham Comparator|2 subjects treated with sham-CPAP|Sham Continuous Positive Airway Pressure treatment (sham-CPAP)
11578337|NCT00801879|Active Comparator|Mupirocin ointment|0.25g mupirocin calcium ointment, 2% in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
11578338|NCT00801879|Placebo Comparator|Placebo ointment|0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
11578339|NCT00801866|Experimental|Group 1|Panretinal Photocoagulation + Bevacizumab
11578340|NCT00801866|Experimental|Group 2|Panretinal Photocoagulation
11578341|NCT00801853|Experimental|Aerovant 1|Aerovant 1mg bid
11578342|NCT00801853|Experimental|Aerovant 2|Aerovant 3mg bid
11578343|NCT00801853|Experimental|Aerovant 3|Aerovant 10mg bid
11578344|NCT00801853|Placebo Comparator|Placebo Control|Placebo Control
11578345|NCT00801827|Experimental|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET) scans of their brains using F-18 (fallypride), a dopamine type 2/3 (DA D2/3) receptor radioligand whose binding is sensitive to competition with endogenous dopamine, before and after the operation.
11578346|NCT00801814|Placebo Comparator|1|White Bread
11578347|NCT00801814|Placebo Comparator|2|White Bread and Margarine Control
11578348|NCT00801814|Placebo Comparator|3|Glucose drink control
11578349|NCT00801814|Experimental|4|"White bread and margarine
~or
~Glucose drink"
11578350|NCT00801814|Experimental|5|"White bread and margarine
~or
~Glucose drink"
11578351|NCT00801814|Experimental|6|"White bread and margarine
~or
~Glucose drink"
11578352|NCT00801801|Experimental|Metronomic Docetaxel + Sorafenib|"Subjects with advanced non-squamous cell non-small cell lung cancer with poor performance status will receive treatment in this non-randomized, open-label Phase II Study of Metronomic Chemotherapy (docetaxel) plus sorafenib as first-line therapy.
~Subjects will be treated with metronomic chemotherapy with low dose docetaxel weekly for 3 out of 4 weeks, and sorafenib will be administered continuously 400 mg bid on a 28 day cycle. Treatment with metronomic chemotherapy will be expressed as a 4-week cycle."
11578353|NCT00801788|Experimental|Egalet® oxycodone Treatment A|Single Dose Administration
11578354|NCT00801788|Experimental|Egalet® oxycodone Treatment B|Single Dose Administration
11578355|NCT00801788|Experimental|Egalet® oxycodone Treatment C|Single Dose Administration
11578356|NCT00801788|Active Comparator|Active comparator|Single Dose Administration
11578357|NCT00801736|Experimental|Platinum Arm|Cisplatin (IMP) / Pemetrexed (IMP)
11578358|NCT00801736|Experimental|Non Platinum Arm|Paclitaxel (IMP) / Pemetrexed (IMP)
11578416|NCT00801307|Active Comparator|3|Medical Air
11578359|NCT00801723|Experimental|1: Budesonide MMX® 6 mg|One Budesonide-MMX® 6 mg tablet self-administered by the patients with a glass of water, in the morning after breakfast.
11578360|NCT00801723|Placebo Comparator|2: Placebo|One placebo tablet self-administered by the patients with a glass of water, in the morning after breakfast.
11578361|NCT00801710|Experimental|BridgePoint Medial System|
11578362|NCT00801697|Experimental|1A|rAD5-naive participants will receive rAd35 intramuscularly at study entry and rAd5 intramuscularly at Month 6
11578363|NCT00801697|Placebo Comparator|1B|Participants will receive rAd35 placebo intramuscularly at study entry and rAd5 placebo intramuscularly at Month 6
11578364|NCT00801697|Experimental|2A|rAD5-naive participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd5 intramuscularly at Month 6
11578365|NCT00801697|Placebo Comparator|2B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd5 placebo intramuscularly at Month 6
11578366|NCT00801697|Experimental|3A|Participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd35 intramuscularly at Month 6
11578367|NCT00801697|Placebo Comparator|3B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd35 placebo intramuscularly at Month 6
11578368|NCT00801697|Experimental|4A|Participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd35 intramuscularly at Month 6
11578369|NCT00801697|Placebo Comparator|4B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd35 placebo intramuscularly at Month 6
11578370|NCT00801684|Placebo Comparator|Placebo|Represents Dose A in the Dosing Sequence assignments.
11578371|NCT00801684|Experimental|TrIP-2D (100mcg)|Represents Dose B
11578372|NCT00801684|Experimental|TrIP-2SS (100mcg)|Represents Dose C
11578373|NCT00801684|Experimental|TrIP-2D (400mcg)|Represents Dose D
11578374|NCT00801684|Experimental|TrIP-2SS (100mcg) + Foradil (12mcg)|Represents Dose E. All subjects received Dose E as their final (5th) dose, after completing their initial 4 single doses according to their sequence assignment.
11578375|NCT00801671|Active Comparator|1|
11578376|NCT00801671|Sham Comparator|2|
11578377|NCT00801645|Experimental|Obese exercise|
11578378|NCT00801645|No Intervention|Obese Control|
11578379|NCT00801645|Experimental|Lean Exercise|
11578380|NCT00801645|No Intervention|Lean Control|
11578381|NCT00801632|Experimental|Kidney and Marrow Recipients|Combined kidney and bone marrow transplant
11578382|NCT00801619||Intervention|Receive decision support when reviewing bilirubin results in the clinical information systems/electronic health record
11578383|NCT00801619||Control|No decision support
11578384|NCT00801606|Experimental|Study drug containing zinc alone|Zinc 20 mg daily
11578385|NCT00801606|Experimental|Study drug Micronutrient without zinc|micronutrients (vitamin A, thiamine, riboflavin, vitamins B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, and copper) without zinc.
11578386|NCT00801606|Experimental|Study drug Micronutrient with zinc|micronutrients in combination with zinc (vitamin A, thiamine, riboflavin, vitamin B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, copper, and 20 mg elemental zinc).
11578387|NCT00801606|Placebo Comparator|Placebo|Placebo only
11578388|NCT00801593||Children with JIA|
11578389|NCT00801580|Experimental|1|The patient receive 2 different drug combinations on this study. The first combination will consist of an intensive chemotherapy regimen (cyclophosphamide, mesna, methotrexate, doxorubicin liposomal or doxorubicin, vincristine, ARA-C (cytarabine) and dexamethasone). The second combination will consist of another intensive chemotherapy regimen (methotrexate and Ara-C [cytarabine]).
11578390|NCT00801567|Experimental|1|All subjects will receive the intervention (MRS scan).
11578391|NCT00801554||ASD|Children and adults with Autism Spectrum Disorders.
11578392|NCT00801554||Non-ASD|Healthy volunteers who have never been diagnosed with an Autism Spectrum Disorder in their lifetime.
11578393|NCT00801541||AMD|Patients with wet AMD in one eye and dry AMD in the other eye (study eye).
11578394|NCT00801528|Active Comparator|Ropivacaine|Continuous wound instillation of ropivacaine 0.2 % at a rate set of 10 mL/hr
11578395|NCT00801528|Active Comparator|Diclofenac|Continuous wound instillation of diclofenac (300 mg/240 ml water for injection) at a rate set of 10 mL/hr
11578396|NCT00801528|Placebo Comparator|Water for injection|Continuous wound instillation of water for injection at a rate set of 10 mL/hr
11578397|NCT00801502|Other|Control|No change in diet
11578398|NCT00801502|Active Comparator|Oily fish|Two portions of salmon per week from week 20 of pregnancy until giving birth
11578399|NCT00801489|Experimental|Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)|See Detailed Description
11578400|NCT00801463|Experimental|Large pred|Prednisone 60mg/d*8 wks
11578401|NCT00801463|Experimental|small pred|Pred 30mg/d*8wks
11578402|NCT00801450|Experimental|Intravitreal (IVI)|
11578403|NCT00801450|Experimental|SubTenon´s (STI)|
11578404|NCT00801437||Xalacom treatment|patients with primary glaucoma
11578405|NCT00801424|Experimental|standard heating|Standard intraoperative warming measures including heated sheets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
11578406|NCT00801411|Experimental|Arm I|Patients receive cyclophosphamide IV and docetaxel IV over 1 hour on day 1.
11578407|NCT00801411|Active Comparator|Arm II|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1.
11578408|NCT00801398|Experimental|Oxymorphone IR|Open-Label, 2 part ascending-dose multicenter study
11578409|NCT00801372||Pre-existing Fibroblast MCB|Pre-existing fibroblast donors for hESC derivation project
11578410|NCT00801359|Active Comparator|BSSplus|
11578411|NCT00801359|Experimental|Ringer|
11578412|NCT00801320|Experimental|Cohort 1|Patients with either primary ovarian carcinoma or ovarian carcinoma in first relapse treated with DC/Ovarian tumor cells + GM-CSF
11578413|NCT00801320|Experimental|Cohort 2|Patients with either primary ovarian carcinoma or ovarian carcinoma in first relapse treated with DC/Ovarian tumor cells + GM-CSF and topical Imiquimod at site of vaccination
11578414|NCT00801307|Experimental|1|He/O2 78:22
11578415|NCT00801307|Experimental|2|He/O2 65:35
11578417|NCT00801281|Active Comparator|R-CVP|Standard arm 1. R-CVP - Rituximab, Cyclophosphamide, Vincristine, Prednisone 2
11578418|NCT00801281|Experimental|R-CHOP|Study arm 2. R-CHOP - Rituximab, Cyclophosphamide, Hydroxyldaunorubicine (doxorubicin), Oncovin (vincristine), Prednisone 1
11578419|NCT00801268|Active Comparator|emodin|
11578420|NCT00801268|Experimental|Triptolide Woldifii|TW60mg/d
11578421|NCT00801255|Experimental|Cohort A|
11578422|NCT00801255|Experimental|Cohort B|
11578423|NCT00801255|Experimental|Cohort C|
11578424|NCT00801255|Experimental|Cohort D|
11578425|NCT00801255|Experimental|Cohort E|
11578426|NCT00801255|Experimental|Cohort F|
11578427|NCT00801255|Experimental|Cohort G|
11578428|NCT00801242|Experimental|Degarelix 240 mg / 80 mg|
11578429|NCT00801229|Active Comparator|Vyvanse|Patients may be randomized to the active comparator arm. Participants randomized to this arm will receive 30, 50, or 70mg Vyvanse daily.
11578430|NCT00801229|Placebo Comparator|Placebo|Patients may be randomized to the placebo comparator arm. Those randomized to this arm will receive 30, 50, or 70mg placebo daily.
11578431|NCT00801216|Experimental|High-dose sequential chemoimmunotherapy|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 & 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
11578432|NCT00801203|Experimental|1|Induced Reflex Cough Test (IRCT) followed by Voluntary Cough Test (VCT)
11578433|NCT00801203|Experimental|2|Voluntary Cough Test (VCT) followed by Induced Reflex Cough Test (IRCT)
11578434|NCT00801190|Active Comparator|HES (130/0.4)|33 ml/kg i.v. HES (130/0.4)
11578435|NCT00801190|Placebo Comparator|Ringer's Lactate|33 ml/kg i.v. Rigner's Lactate
11578436|NCT00801177|Experimental|IMC-11F8 (Every week)|Cycle of therapy administered intravenously, once a week for 6 weeks, for a total of six doses per cycle.
11578437|NCT00801177|Experimental|IMC-11F8 (Every other week)|Cycle of therapy administered intravenously, every other week for 6 weeks, for a total of three doses per cycle.
11578438|NCT00801164|Experimental|Frio Oral Rinse|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
11578439|NCT00801164|Experimental|Placebo|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
11578440|NCT00801151|Experimental|Vorinostat, vinorelbine|Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.
11578441|NCT00801138|Placebo Comparator|Group 1|Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block
11578442|NCT00801138|Placebo Comparator|Group 2|Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline
11578443|NCT00801138|Active Comparator|Group 3|Group 3 Ropivacaine and dexamethasone: 30 ml 0.5% ropivacaine mixed with dexamethasone 8 mg (2 ml)
11578444|NCT00801138|Active Comparator|Group 4|Group 4 Bupivacaine and steroid: 30 ml 0.5% bupivacaine mixed with dexamethasone 8 mg (2 ml).
11578445|NCT00801112||1|PD patients with residual renal function >200ml with BIA monitor.
11578446|NCT00801112||2|PD patients with residual renal function <200ml with BIA monitor.
11578447|NCT00801112||3|PD patients with residual renal function >200ml without BIA monitor
11578448|NCT00801112||4|PD patients with residual renal function <200ml without BIA monitor
11578449|NCT00801099|Experimental|Abx|single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
11578450|NCT00801086|Experimental|1|MTS-01 (7% Tempol gel)
11578451|NCT00801086|Placebo Comparator|2|Vehicle
11578452|NCT00801073|Experimental|Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
11578453|NCT00801060|Experimental|Treatment Group A|"FCR + Lumiliximab (L)
~L (Lumiliximab): Day 2 50 mg/m2, Day 4 450 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks.
~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks
~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks
~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
11578454|NCT00801060|Active Comparator|Treatment Group B|"FCR
~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks
~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks
~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
11578455|NCT00801047|Experimental|1|Epidural group
11578456|NCT00801047|Active Comparator|2|Remifentanil iv PCA
11578457|NCT00801034|Placebo Comparator|1|Calcium tablets
11578458|NCT00801034|Active Comparator|2|Potassium tablets
11578459|NCT00801021|Experimental|Frio Oral Rinse|Prescription Mouth Rinse
11578460|NCT00801008|Experimental|Exercise and Relaxation Intervention|Participants in this arm will receive a 12 week exercise and relaxation intervention
11578461|NCT00801008|No Intervention|Wait List Control Condition|Participants in this arm will be offered the exercise and relaxation intervention after a 12 week delay.
11578462|NCT00800995|Sham Comparator|Control|
11578463|NCT00800995|Experimental|SOD|
11578464|NCT00800982|Active Comparator|1 (Etanercept only)|Subjects will only be treated with etanercept. This is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months. No UVB will be given. Sham UVB will not be used because the subjects are not blinded because they often know they are receiving sham UVB due to differences in light intensity and heat.
11578508|NCT00800527|Active Comparator|1|Gabapentin
11578509|NCT00800527|Active Comparator|2|Diclofenac
11578510|NCT00800514|Experimental|active|
11578511|NCT00800501|Experimental|sNN0029|
11578512|NCT00800501|Placebo Comparator|Placebo|
11578513|NCT00800475|Active Comparator|Test Drug|
11578465|NCT00800982|Experimental|2 (Etanercept + nb-UVB)|"Subjects will receive etanercept. This is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.
~In addition, for months 3-6, subjects will receive Narrow Band Ultraviolet B phototherapy three times a week for 12 weeks in addition to the etanercept maintenance dose. The safety and efficacy of the combination therapy will be evaluated by the registered phototherapy nurses at each phototherapy visit and by the study investigator at monthly visits. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff."
11578466|NCT00800969|Other|all patients|all patients with Adenocarcinoma
11578467|NCT00800956|Experimental|Single oral dose of [14C]-esreboxetine|
11578468|NCT00800943|Experimental|Campath-1H|
11578469|NCT00800930|Active Comparator|1|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
11578470|NCT00800930|Placebo Comparator|2|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
11578471|NCT00800865|Other|Biomarker Evaluation Group I|Biomarker evaluation before and after dosing with cytotoxic agent(s)
11578472|NCT00800865|Other|Biomarker Evaluation Group II|Biomarker evaluation before and after dosing with cytotoxic agent(s)
11578473|NCT00800839|Experimental|Busulfan + Fludarabine + Cyclophosphamide|Busulfan starting dose of 32 mg/m^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3. Fludarabine dose of 40 mg/m^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan. Cyclophosphamide dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
11578474|NCT00800813||open, laparoscopic, or robotic-assisted lap|Patients will also be assessed for penile length and the presence of Peyronie's Disease at these specified times.
11578475|NCT00800800|Active Comparator|1|Rosuvastatin 40 mg
11578476|NCT00800800|Placebo Comparator|2|placebo
11578477|NCT00800787|Experimental|Arm One: Nabi-HB|All subjects will be administered Nabi HB Subcutaneously
11578478|NCT00800774|Experimental|1|Nine eyes of nine patients (3 male and 6 female) with high anisometropia (>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
11578479|NCT00800761|Active Comparator|Deferoxamine alone|comparison of deferoxamine subcutaneous 40mg/kg/die alone versus combined therapy deferoxamine-deferiprone
11578480|NCT00800761|Active Comparator|Deferoxamine plus Deferiprone|comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
11578481|NCT00800748|Experimental|Group A|Participants with genotype 1, 4, 5 or 6 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 1000-1200 mg PO daily (dependent on body weight) for 48 weeks.
11578482|NCT00800748|Experimental|Group B|Participants with genotype 2 or 3 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 24 weeks.
11578483|NCT00800748|Experimental|Group C|Participants with HIV co-infection received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 48 weeks.
11578484|NCT00800735|Experimental|Pegylated-interferon alfa-2a plus ribavirin|Participants received pegylated-interferon alfa-2a 180 µg/week subcutaneously plus ribavirin 1000 mg/day orally for patients weighing < 75 kg or 1200 mg/day for patients weighing ≥ 75 kg for 48 weeks.
11578485|NCT00800722|Experimental|Treatment of Port Wine Stain|Rapamycin Treatment of Port Wine Stain
11578486|NCT00800709|Experimental|Memantine|
11578487|NCT00800696|Experimental|oral care|intervention: The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx.
11578488|NCT00800696|No Intervention|control|continue to receive oral care as performed today.
11578489|NCT00800683|Experimental|BI 1356|patient to receive a tablet containing BI 1356 once daily
11578490|NCT00800683|Placebo Comparator|placebo|patient to receive a tablet identical to BI 1356 once daily
11578491|NCT00800670|Experimental|Lower dose|Lower dose of Ad5Ag85A: 10^8pfu
11578492|NCT00800670|Experimental|Higher dose|Higher dose of vaccine Ad5Ag85A: 10^9pfu
11578493|NCT00800644||Evaluation Group|Bone Mineral Density Test + MRI or CT + Blood Test
11578494|NCT00800618|Experimental|PF-02413873|PF-2413873 active treatment
11578495|NCT00800618|Placebo Comparator|Placebo|Placebo
11578496|NCT00800605|Experimental|1|Vero cell-derived, trivalent, seasonal influenza vaccine
11578497|NCT00800605|Placebo Comparator|2|Phosphate-buffered saline
11578498|NCT00800592|Active Comparator|10 mg sildenafil bolus|10 mg sildenafil bolus
11578499|NCT00800579|Experimental|1|GS-9411 0.6 mg
11578500|NCT00800579|Experimental|2|GS-9411 1.2 mg
11578501|NCT00800579|Experimental|3|GS-9411 2.4 mg
11578502|NCT00800579|Placebo Comparator|4|Inhaled volume-matched sterile saline placebo
11578503|NCT00800566|Experimental|Oral Clofarabine|
11578504|NCT00800553|Experimental|donepezil|donepezil, 5 mg p.o. for approx 2 weeks
11578505|NCT00800553|Placebo Comparator|placebo|placebo
11578506|NCT00800540|Other|AZARGA/COMBIGAN|AZARGA, followed by COMBIGAN, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
11578507|NCT00800540|Other|COMBIGAN/AZARGA|COMBIGAN, followed by AZARGA, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
11578515|NCT00800462|Active Comparator|Oxybutynin Cl|
11578516|NCT00800462|Active Comparator|Trospium Cl|
11578517|NCT00800462|Active Comparator|Darifenacin Hydrogren Bromide (HBr)|
11578518|NCT00800436|Experimental|Part 1: Cohort 1|Healthy male participants will receive Herceptin 6 mg/kg IV on Day 1.
11578519|NCT00800436|Experimental|Part 1: Cohort 2|Female participants with HER2-positive breast cancer will receive Herceptin 6 mg/kg IV on Day 1.
11578520|NCT00800436|Experimental|Part 1: Cohort 3|Healthy male participants will receive Herceptin 6 mg/kg SC on Day 1.
11578521|NCT00800436|Experimental|Part 1: Cohort 4|Healthy male participants will receive Herceptin 10 mg/kg SC on Day 1.
11578522|NCT00800436|Experimental|Part 1: Cohort 5|Healthy male participants will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohorts 1, 2, 3, and 4.
11578523|NCT00800436|Experimental|Part 2: Cohort A|Female participants with HER2-positive breast cancer will receive Herceptin SC at the dose level determined in Part 1.
11578524|NCT00800436|Experimental|Part 2: Cohort B|Female participants with HER2-positive breast cancer will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohort A.
11578525|NCT00800423|Experimental|brimonidine|"50 patients receiving Brimonidine Tartrate drops in the operated eye: 1 drop X2 a day for 1 month.
~they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)"
11578526|NCT00800423|Active Comparator|2 tmolol|"50 patients receiving timolol maleate 0.5% drops in the operated eye
~1 drop X2 a day for 1 month. they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)"
11578527|NCT00800423|No Intervention|3|50 patients will not receive any additional drug to the usual medications after cataract surgery (corticosteroids and antibiotics drops)
11578528|NCT00800410|No Intervention|Information on community resources|Participants received information about free and publicly available community resources on healthy lifestyle activities
11578529|NCT00800410|Experimental|Community Health Worker services|
11578530|NCT00800384|Experimental|1|ICD implant without defibrillation testing
11578531|NCT00800384|Active Comparator|2|ICD implant with defibrillation testing
11578532|NCT00800371||JIA|Patients with JIA
11578533|NCT00800358|Experimental|1|Oral Paricalcitol in varying doses
11578534|NCT00800358|Active Comparator|2|Calcitriol
11578535|NCT00800345|Experimental|Experimenal|Metronomic oral topotecan and oral pazopanib will be administered by mouth beginning on Cycle 1 Day 1. Patients will be enrolled and observed for dose limiting toxicity (DLT) for 1 cycle of treatment. Dose modification of the combination will depend on the number of patients experiencing DLT(s) at each dose level.
11578536|NCT00800332|Experimental|1|
11578537|NCT00800332|Experimental|2|
11578538|NCT00800332|Placebo Comparator|3|
11578539|NCT00800319|Experimental|RDC-0313, 5mg|5 mg of RDC-0313; single dose
11578540|NCT00800319|Experimental|RDC-0313, 15 mg|15 mg RDC-0313; single dose
11578541|NCT00800319|Experimental|RDC-0313, 25mg|25 mg RDC-0313; single dose
11578542|NCT00800319|Experimental|RDC-0313, 50 mg|50 mg RDC-0313; single dose
11578543|NCT00800319|Experimental|RDC-0313, 75 mg|75 mg RDC-0313; single dose
11578544|NCT00800319|Placebo Comparator|Placebo|volume-match placebo; single dose
11578545|NCT00800306|Experimental|levosimendan|
11578546|NCT00800306|Active Comparator|Control|
11578547|NCT00800293||Cohort Group 1|Subject Numbers 1 to 29
11578548|NCT00800293||Cohort Group 2|Subject Numbers 20 to 59
11578549|NCT00800293||Cohort Group 3|Subject Numbers 60 to 89
11578550|NCT00800293||Cohort Group 4|Subject Numbers 90 to 116
11578551|NCT00800280|Experimental|Single dose PD 0332334|
11578552|NCT00800280|Experimental|Single dose PD 0332334 with steady-state cimetidine|
11578553|NCT00800267|Experimental|Fixed combination of latanoprost 0.005% and timolol 0.5%|
11578554|NCT00800267|Active Comparator|latanoprost 0.005%|
11578555|NCT00800267|Active Comparator|Timolol - 0.5%|
11578556|NCT00800254|Experimental|Neuromuscular Electrical Stimulation (NMES)|
11578557|NCT00800254|Active Comparator|Standard Rehabilitation Protocol|
11578558|NCT00800228||1|Eight men and eight women to define the time course of changes in MBG \ and OLC accompanying sodium loading
11578559|NCT00800228||2|32 additional women to determine whether breathing pattern is predictive of sodium sensitivity in that gender. Women are being studied in the second experiment because they, but not men, have been shown to have an association of breathing pattern with high perceived stress11 and an association of high resting end tidal CO2 with high resting blood pressure.
11578560|NCT00800215|Experimental|1|
11578561|NCT00800215|Placebo Comparator|2|
11578562|NCT00800215|Experimental|3|
11578563|NCT00800215|Placebo Comparator|4|
11578564|NCT00800202|Experimental|1|
11578565|NCT00800202|Experimental|2|
11578566|NCT00800176|Placebo Comparator|Placebo|"During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast.
~During the 12-week double-blind treatment period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test."
11578567|NCT00800176|Experimental|RO4998452 10mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 10 mg of RO4998452.
11578568|NCT00800176|Experimental|RO4998452 2.5mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 2.5 mg of RO4998452.
11578643|NCT00799578|Experimental|Cystagon-EC|
11578644|NCT00799565|Experimental|1|Subject with a Mitral Valvular Prolapse
11578645|NCT00799565|Experimental|2|Healthy Volunteers
11578646|NCT00799552|Placebo Comparator|Placebo|
11578647|NCT00799552|Experimental|RX-10045|
11578569|NCT00800176|Experimental|RO4998452 20mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 20 mg of RO4998452.
11578570|NCT00800176|Experimental|RO4998452 40mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 40 mg of RO4998452.
11578571|NCT00800176|Experimental|RO4998452 5mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 5 mg of RO4998452.
11578572|NCT00800163|Experimental|ED Physician Activation/Immediate Transfer|
11578573|NCT00800137|Active Comparator|Bridging anti-coagulation|Low Molecular Weight Heparin or IV unfractionated Heparin
11578574|NCT00800137|Experimental|Continued oral anti-coagulation|Coumadin
11578575|NCT00800124|No Intervention|1|Cemented hemiprosthesis
11578576|NCT00800124|Active Comparator|2|Non-cemented hemiprosthesis
11578577|NCT00800111|Other|Treatment|Endothelial keratoplasty procedure is performed.
11578578|NCT00800098|Placebo Comparator|Placebo|Placebo cream matched on consistency, color, and smell
11578579|NCT00800098|Active Comparator|Active|AARP active arthritis cream
11578580|NCT00800085|No Intervention|FDR of type 1 diabetes patients receiving glucose 20%|First Degree Relatives of diabetes type 1 patient with a high, intermedian or low risk (accoring to the criteria of the protocol), for developing diabetes type 1.
11578581|NCT00800072|Experimental|oxygen therapy|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
11578582|NCT00800059|Experimental|Treatment|Treatment with TMI and autologous Stem Cell transplant
11578583|NCT00800046|Experimental|AccuCinch® Ventriculoplasty System|Patients meeting the enrollment criteria will be treated with the AccuCinch® Ventriculoplasty System.
11578584|NCT00800033|Experimental|Aerobic exercise training|
11578585|NCT00800033|Placebo Comparator|Resistance exercise training|
11578586|NCT00800033|Experimental|pulse diet|Pulse based diet containing peas, lentils, and beans
11578587|NCT00800033|No Intervention|Regular diet|
11578588|NCT00800007|Active Comparator|ANZ-521|
11578589|NCT00800007|Placebo Comparator|Placebo|
11578590|NCT00799994||1|Patients that have medical intervention in an attempt to lower intraocular pressure (oral or topical)
11578591|NCT00799994||2|Patients who have received no intervention
11578592|NCT00799968|Active Comparator|Group 1|UK-12h group
11578593|NCT00799968|Experimental|Group 2|UK-2h group
11578594|NCT00799955|Placebo Comparator|1|Subjects will receive 100 micrograms of spinal morphine, at the time of spinal needle insertion (standard care at BCW). At the end of the case, one of two investigators, using ultrasound, will visualize the transversus abdominis plane. A capped needle will be pushed against the skin to mimic the pressure sensation of the TAP block. The needle will not break the skin and nothing will be injected in this control group. The procedure will then be repeated on the other side. A dressing will be applied on each side to blind the subject and researcher to which group she is in.
11578595|NCT00799955|Active Comparator|2|No additional spinal medications will be given. At the end of the case, one of the two investigators, under sterile conditions, and using ultrasound, will visualize the tip of a blunt regional anaesthesia needle entering the transversus abdominis plane. After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected, under vision, into the transversus abdominis plane, on each side. The subjects will still have spinal anesthesia of the abdomen and therefore will not feel needle insertion as sharp although most will have a sensation of pressure. A dressing will be applied over the needle's entry points.
11578596|NCT00799929|Active Comparator|ARM A - Mini IVF|The Mini IVF method entails pre-treatment with oral contraceptive pills. Ovarian stimulation is achieved using an oral anti-estrogen in conjunction with injections of gonadotropin (225IU-600IU per cycle), with initial dose of 75IU-150IU per injection. Ovulation is induced by a GnRH (gonadotropin-releasing hormone) agonist nasal spray/hCG (human chorionic gonadotropin) injection. Retrieved oocytes following in vitro fertilization (IVF/ICSI) are cultured to the blastocyst stage. Blastocyst stage embryos are vitrified using the CryoTop method. No fresh embryo transfer is conducted. Subsequently, SET of a thawed blastocyst is performed in a natural cycle/HRT that does not involve ovarian stimulation. SETs are conducted until pregnancy is achieved or all vitrified blastocysts have been used.
11578597|NCT00799929|Active Comparator|Arm B - Conventional IVF|The standard IVF method entails pre-treatment with a GnRH analog injections in the midluteal phase. Controlled ovarian hyperstimulation is achieved with injections of gonadotropin (150IU-300IU/day). Ovulation is induced by hCG injection and retrieved oocytes following in vitro fertilization (IVF/ICSI) are cultured to the blastocyst stage. If this occurs on day 5, then fresh SET/DET (single embryo transfer/double embryo transfer) is performed. Remaining blastocysts are cryopreserved and transferred in subsequent natural cycles/HRT (hormone replacement therapy) that does not involve ovarian stimulation.
11578598|NCT00799916|Active Comparator|Voluven|Resuscitation fluid: Voluven (R)
11578599|NCT00799916|Active Comparator|Saline|Resuscitation fluid: Saline solution
11578600|NCT00799903|Experimental|Darapladib|Single daily oral tablet
11578601|NCT00799903|Placebo Comparator|Placebo|Single daily oral tablet
11578602|NCT00799890|Experimental|Sunphenon|
11578603|NCT00799890|Placebo Comparator|Placebo|
11578604|NCT00799877||1|This registry will evaluate the long-term safety and effectiveness of HUMIRA® as used in routine clinical practice.
11578648|NCT00799526|Experimental|Ex Vivo Transplantation|Autologous Ex Vivo Conjunctival Epithelial Cell Expansion for Symblepharon Transplantation
11578649|NCT00799513|Experimental|Lenalidomide|single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
11578605|NCT00799864|Experimental|Rilpivirine (TMC278)|The patients received rilpivirine with 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) as a background regimen in cohort 1 [aged greater than or equal to (> =) 12 to less than (<) 18 years] for up to 240 weeks which is already completed and recruitment closed and will receive this treatment in cohort 2 (children aged > = 6 to < 12 years) for up to 48 weeks. The NRTIs include zidovudine, abacavir, or tenofovir disoproxil fumarate in combination with lamivudine or emtricitabine.
11578606|NCT00799851|Active Comparator|Variceal band ligation|VBL was performed with a multiband ligation device (Euroligator System®). The first band was placed at or close to the gastroesophageal junction, with subsequent bands being placed proximally in a slightly spiral pattern. All visible varices within the distal esophagus were treated, with a maximum of 10 bands being placed in each session. There was a 3-week interval between each treatment session. When VBL was technically impossible due to scarring, sclerotherapy with ethanolamine oleate was performed on thin vessels.
11578607|NCT00799851|Active Comparator|cyanoacrylate injection|"CI group received intravariceal injections of 0.5 ml of N-butyl-2-cyanoacrylate (Histoacryl®) diluted in 0.5 ml of Lipiodol (Lipiodol®). Before injection of the Histoacryl-Lipiodol mixture, the catheter was filled up with 1 ml of Lipiodol. After puncturing the EV, the mixture was injected inside it and followed by injection of 1 ml of distilled water. Finally the catheter was retracted. To minimize the risk of embolism, a maximum of two medium or large vessels, in opposite walls, were treated in each session and not more than 0.5 ml of Histoacryl® was injected into each vessel.
~A second injection was performed in any EV that maintained blood flow (medium or large size, blue, depressive at palpation with the catheter), in a bi-weekly interval basis. A chest x-ray was performed to evaluate the location of the Histoacryl-Lipiodol solution. Small vessels were treated with ethanolamine oleate sclerotherapy."
11578608|NCT00799838|Experimental|Ketoprofen + Amoxicillin|Ketoprofen + Amoxicillin for 3 days, then Amoxicillin alone for 7 days
11578609|NCT00799838|Placebo Comparator|Amoxicillin|Placebo (for ketoprofen) + Amoxicillin for 3 days, then Amoxicillin alone for 7 days
11578610|NCT00799825|Experimental|Cervarix group|Female subjects who previously received the active control i.e. Hepatitis A vaccine in the primary study (NCT00122681) and who received the Cervarix vaccine in the current study. The Cervarix vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1 and 6 months schedule.
11578611|NCT00799812|Experimental|CHG Swabstick (3 @ once)|Chlorhexidine(CHG)2% CHG/isopropyl alcohol (IPA)70%-3 swabsticks applied @ same time
11578612|NCT00799812|Experimental|CHG Swabstick sequential|Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v--3 swabsticks applied one-at-a-time
11578613|NCT00799812|Active Comparator|Hibiclens|Chlorhexidine gluconate 4% w/v in an aqueous base
11578614|NCT00799812|Placebo Comparator|Sterile water swab (3 @ once)|Sterile swabstick wetted with sterile water--3 swabsticks applied at the same time.
11578615|NCT00799812|Placebo Comparator|Sterile water swabstick (sequential)|Sterile swabstick wetted with sterile water--3 swabsticks applied one-at-a-time.
11578616|NCT00799799|Experimental|NK|patient treated as per protocol
11578617|NCT00799773|Experimental|1|Participants will receive rituximab in addition to plasma exchange and corticosteroids.
11578618|NCT00799773|Active Comparator|2|Participants will receive plasma exchange and corticosteroids.
11578619|NCT00799760|Experimental|1|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
11578620|NCT00799760|Active Comparator|2|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 days
11578621|NCT00799760|Active Comparator|3|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
11578622|NCT00799747|Experimental|1|AZD4017 in ascending doses (start dose 2mg)
11578623|NCT00799747|Placebo Comparator|2|Placebo
11578624|NCT00799734|Active Comparator|alternative medicine|Intake of prepacked Chinese herbal medicine (EXD), one sachet of granules (15g extracted granules) twice a day
11578625|NCT00799734|Placebo Comparator|placebo|placebo therapy of 15g granules with similar colour and taste.
11578626|NCT00799721||1|VLBW infants with erythropoietin therapy
11578627|NCT00799721||2|VLBW infants without erythropoietin therapy.
11578628|NCT00799708|Placebo Comparator|1|Placebo
11578629|NCT00799708|Active Comparator|2|Estrace 0.5 mg
11578630|NCT00799708|Active Comparator|3|Estrace 2 mg
11578631|NCT00799682|Active Comparator|Xalatan®|
11578632|NCT00799682|Active Comparator|Travatan Z®|
11578633|NCT00799669||MAPS+|"MAPS+ (Motivation and Problem-Solving Plus):
~Counseling using specific treatment approach that focuses on combined smoking cessation and the reduction of at-risk alcohol use."
11578634|NCT00799669||MAPS|"MAPS (Motivation and Problem-Solving):
~Counseling treatment approach with a focus on smoking cessation."
11578635|NCT00799656|Experimental|1|First period: Ataciguat - Second period: Placebo
11578636|NCT00799656|Experimental|2|First period: Placebo - Second period: Ataciguat
11578637|NCT00799643|Active Comparator|1|Salsalate, 3.5 g/d orally, divided dosing
11578638|NCT00799643|Placebo Comparator|2|Salsalate Placebo, orally, divided dosing
11578639|NCT00799617|Active Comparator|AndroGel® (testosterone gel)|The initial dose of AndroGel will be 5.0 g (containing 50 mg of testosterone) once a day. Participants will apply AndroGel once daily to the shoulders, abdomen or upper arms. The serum testosterone concentration will be measured monthly for the first three months, then at months 6, 9 and 12. If the testosterone concentration is not between 500 and 800 ng/dL at any time point, the dose will be either increased by increments of 1.25-2.5 g/day, up to a maximum of 15 g/day or decreased by increments of 1.25-3.75 ng/day. Participants will be taught how to apply the gel and they will be provided with written instructions and precautions. This information will be reviewed at each contact and visit.
11578640|NCT00799617|Placebo Comparator|Placebo gel|Placebo gel is identical to the testosterone gel and is supplied in an identical pump bottle container. It is applied to the shoulders, abdomen or upper arms once a day. Participants will be taught how to apply the gel and they will be provided with written instructions and precautions. This information will be reviewed at each contact and visit.
11578641|NCT00799604|Experimental|clevidipine|"Patients were sequentially assigned to one of following three planned dose cohorts for Bolus 1 within the clevidipine arm:
~Cohort 1: clevidipine 250 µg (0.5 mL)
~Cohort 2: clevidipine 500 µg (1 mL)
~Cohort 3: clevidipine 125 µg (0.25 mL or 0.5 mL of a 1:1 solution)"
11578650|NCT00799500|Experimental|Weekly screening|Screening and treatment of bacterial vaginosis during pregnancy through self-administered weekly vaginal pH determination.
11578651|NCT00799500|No Intervention|Observation|Usual care
11578652|NCT00799487|Experimental|1|CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
11578653|NCT00799487|Experimental|2|CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
11578654|NCT00799461|Experimental|Arm I (full website access w/ PST; first study only)|Patients receive full access to INSPIRE website for 6 months, which offers an individually tailored greeting home page with links to information on each of the target areas identified as being elevated on baseline assessment and how to manage the complications; a bulletin board with input from other survivors that is solicited, edited, and posted weekly; resource pages; and an opportunity to send secure messages with questions or comments. Patients also undergo 4-8 phone-based PST sessions with a behavioral health specialist.
11578655|NCT00799461|Experimental|Arm II (full website access without PST)|Patients receive full access to INSPIRE website for 6 months as in arm I.
11578656|NCT00799461|Sham Comparator|Arm III (delayed website access)|Patients do not have access to INSPIRE website for 6 months. After 6 months, patients receive full access to INSPIRE website for 3 months.
11578657|NCT00799435|No Intervention|1|Participants will receive usual care for 12 weeks. The care will be dictated by the primary physician and/or diabetologist caring for the participant. Efforts will be made to ensure that all participants receive standard measures as indicated by guidelines, with a particular emphasis on blood pressure control and glucose control.
11578658|NCT00799435|Experimental|2|Participants will receive exenatide for 12 weeks.
11578659|NCT00799422|Active Comparator|ReNu MultiPlus|ReNu MultiPlus used as specified in the protocol for contact lens care. In this crossover study, ReNu MultiPlus was dispensed in randomized order with Complete Easy Rub and Clear Care. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
11578660|NCT00799422|Active Comparator|Complete Easy Rub|Complete Easy Rub used as specified in the protocol for contact lens care. In this crossover study, Complete Easy Rub was dispensed in randomized order with ReNu MultiPlus and Clear Care. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
11578661|NCT00799422|Active Comparator|Clear Care|Clear Care used as specified in the protocol for contact lens care. In this crossover study, Clear Care was dispensed in randomized order with Complete Easy Rub and ReNu MultiPlus. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
11578662|NCT00799409|Experimental|1|CONCERTA (methylphenidate HCl) / Placebo Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
11578663|NCT00799409|Experimental|2|Placebo/ CONCERTA (methylphenidate HCl) Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
11578664|NCT00799396|Experimental|Overall Study|Participants will receive clopidogrel treatment alone, followed by clopidogrel plus aspirin treatment on the last day of treatment.
11578665|NCT00799383|Experimental|Calcium and Vitamin D|Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
11578666|NCT00799383|Placebo Comparator|Placebo|Placebo
11578667|NCT00799370|Experimental|1|Early weight bearing: immediate in postoperative
11578668|NCT00799370|Experimental|2|Delayed weight bearing: 2 months after surgery
11578669|NCT00799344||Stent|Catania Stent
11578670|NCT00799331|Experimental|A|AZD5985
11578671|NCT00799331|Experimental|B|placebo
11578672|NCT00799305||COPD patients|
11578673|NCT00799292|No Intervention|No injection|Patients did not receive an injection at cervix prior to beginning the procedure
11578674|NCT00799292|Experimental|Injection of vasopressin|Patients will be randomized to receive 20cc of dilute vasopressin (20units in 50cc normal saline)injected at cervix at beginning of the hysterectomy
11578675|NCT00799279|Experimental|Follow-up Counseling Arm|smoking cessation training for providers,practice tools for providers, patient quit plan, and follow-up telephone counselling for smokers
11578676|NCT00799279|Active Comparator|Practice Support Arm|smoking cessation training for providers,practice tools for providers, patient quit plan for smokers.
11578677|NCT00799266|Experimental|Zoledronic acid|Twice yearly 0.05 mg/kg (max 5 mg) i.v infusion (at least 30 minutes) of zoledronic acid
11578678|NCT00799266|Placebo Comparator|Placebo|Twice yearly i.v of infusion of Placebo (similar dosing as active drug)
11578679|NCT00799240|Active Comparator|Arm A Pemetrexed Cisplatin|Arm A: Pemetrexed, cisplatin: pemetrexed and cisplatin chemotherapy at standard doses given IV every 21 days. Patients will be treated for a maximum of 6 cycles.
11578680|NCT00799240|Experimental|Arm B Permetrexed, Cisplatin, MK-0646|Pemetrexed and cisplatin chemotherapy at standard doses given IV every 21 days in combination with MK-0646 given IV, 10 mg/Kg, Days 1, 8 and 15 weekly
11578681|NCT00799227|Experimental|700 µg Dexamethasone Implant|700 µg dexamethasone implant in the study eye at Day 1
11578682|NCT00799214|Placebo Comparator|1|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
11578683|NCT00799214|Experimental|2|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
11578684|NCT00799214|Active Comparator|3|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
11578685|NCT00799201|Experimental|Control|Sennosides liquid 5mL (8.8mg) every 6 hours plus docusate sodium liquid 10mL (100mg) every 12 hours
11578686|NCT00799188|No Intervention|1|reduction of immunosuppression
11578687|NCT00799188|Experimental|2|switch to Everolimus : 50% reduction of calcineurin inhibitors (ciclosporine or tacrolimus)
11578688|NCT00799175|Active Comparator|1 Group A(Active)|Group A (Active) receives a multimodal injection intra- and postoperatively
11578833|NCT00798239|Experimental|Prefix 150|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
11578689|NCT00799175|Placebo Comparator|2 Group P (Placebo)|Group P (Placebo) receives no injection intraoperatively and a saline injection postoperatively
11578690|NCT00799162||Women with a scheduled cesarean section|
11578691|NCT00799149|Active Comparator|Gabapentin|Gabapentin (1200 mg) administered 30-90 min before the patient entered the operating room; Subsequent doses of Gabapentin (1200 mg)were administered on the mornings (08H00) of the first, second, and third postoperative days.
11578692|NCT00799149|Active Comparator|Etoricoxib|Etoricoxib (120 mg)administered 30-90 min before the patient entered the operating room; Subsequent doses of etoricoxib (120 mg)were administered on the mornings (08H00) of the first, second, and third postoperative days.
11578693|NCT00799149|Placebo Comparator|Sugar pill|Sugar pill administered 30-90 min before the patient entered the operating room. Subsequent doses of Sugar pill were administered on the mornings (08H00) of the first, second, and third postoperative days.
11578694|NCT00799136|Other|One|Rituxan with EPOCH and Antiretrovirals
11578695|NCT00799110|Experimental|Group 2|Vaccine, GM-CSF and imiquimod,
11578696|NCT00799110|Experimental|Group 1|Vaccination plus GM-CSF
11578697|NCT00799097||Endoscopic Sinus Surgery|Subjects who have failed maximum medical management and have elected for endoscopic sinus surgery
11578698|NCT00799084|Experimental|Nurse|Receives symptom management assistance from an oncology nurse via the telephone
11578699|NCT00799084|Experimental|AVR|Receives symptom management assistance from an Automated telephone system
11578700|NCT00799071|Experimental|posaconazole|posaconazole as antifungal prophylaxis
11578701|NCT00799058|Active Comparator|dapivirine gel 4789|will be applied by participants once daily for 12-weeks treatment period
11578702|NCT00799058|Active Comparator|dapivirine gel 4759|Will be applied by participants once daily for12-weeks treatment period
11578703|NCT00799058|Placebo Comparator|HEC-based placebo gel, 2.5g containing no Dapivirine|Will be applied once daily for 12-weeks treatment period
11578704|NCT00799045|Experimental|Aspirin + clopidogrel|Aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
11578705|NCT00799045|Active Comparator|Aspirin|Aspirin (80 mg/day) for 3 months following ASD closure.
11578706|NCT00799032|Other|Stent|Catania Stent
11578707|NCT00799006|Placebo Comparator|Placebo|
11578708|NCT00799006|Experimental|PF-04620110|
11578709|NCT00798993|Active Comparator|Structured exercise program|Participants will be randomised at 3 months into either this group or the comparator of usual exercise.
11578710|NCT00798993|Experimental|Vitamin D|Cholecalciferol 2000U per day will be given to all participants for the duration of the study
11578711|NCT00798993|Placebo Comparator|Usual exercise|Participants randomised to this arm, at 3 months, will continue on their usual exercise routine
11578712|NCT00798980||Arm 1|
11578713|NCT00798967|Experimental|Teduglutide|0.05 mg/kg/day sc dose of teduglutide
11578714|NCT00798967|Placebo Comparator|Placebo|Matching subcutaneous dose of placebo to teduglutide
11578715|NCT00798954|Active Comparator|TAXUS|
11578716|NCT00798954|Active Comparator|Cypher|
11578717|NCT00798941|Experimental|pain intervention|music and massage for 30 minutes
11578718|NCT00798941|Experimental|thirst intervention|sterile water mouth spray, lip moisturizer,mouth swab
11578719|NCT00798941|No Intervention|control|
11578720|NCT00798915|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
11578721|NCT00798915|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
11578722|NCT00798915|Experimental|Type 2 diabetes mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
11578723|NCT00798902|Active Comparator|Control|Iliac Crest Autograft
11578724|NCT00798902|Experimental|Prefix 150|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
11578725|NCT00798889|Experimental|Sunitinib|
11578726|NCT00798876|Placebo Comparator|Standard Western Diet|Subjects will be asked to consume a standard Western Diet for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages. Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
11578727|NCT00798876|Experimental|Low-Fat Diet|Subjects will be asked to consume a low fat diet with fish oil and vitamin E supplements for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages. Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
11578728|NCT00798863|Experimental|operative group|The patients of the group will have the operation of two step video assisted submandibular sialadenectomy.
11578729|NCT00798850|Active Comparator|PTA|
11578730|NCT00798850|Active Comparator|SEP|
11578731|NCT00798850|Active Comparator|PTA+SEP|
11578732|NCT00798837|Other|IMAX|"There is only one arm in this study.
~Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.
~Doses of radiotherapy are as follows:
~The prescription dose will be 73.7 Gy in 28 fractions.
~A simultaneous intraprostatic maximal simultaneous boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
11578733|NCT00798824|Active Comparator|Indwelling nasogastric tube placement|
11578734|NCT00798824|Active Comparator|Intermittent orogastric tube placement|
11578735|NCT00798811|Other|KSPNO-S-081|Reduced-dose Craniospinal Radiotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Rescue in Children with Newly Diagnosed High-risk Brain Tumor
11578736|NCT00798811|Other|KSPNO-S-082|High-dose Chemotherapy and Autologous Stem Cell Rescue in Infants and Young Children with Newly Diagnosed High-risk Brain Tumor To Avoid or Reduce Craniospinal Radiation
11578737|NCT00798811|Other|KSPNO-S-083|High-dose Chemotherapy and Autologous Stem Cell Rescue in Children with Recurrent Brain Tumor or Non-germinomatous Germ Cell Tumor with Inadequate Response to Conventional Treatment
11578738|NCT00798798|Experimental|Implantable Tissue Expansion Device|Will apply externally implantable tissue expansion device for 2 days
11579403|NCT00793832|Active Comparator|1|Supervised exercise.
11578739|NCT00798785|Experimental|group I ATG-MMF-TAC|"Two clinical implants in the liver:
~First implant: ATG-fresenium Maintained immunosuppression: MMF-TAC n=30"
11578740|NCT00798785|Experimental|group II ATG-Rituximab-MMF-TAC|"Two clinical implants in the liver:
~First Implant: ATG fresenium + Rituximab Maintained immunosuppression: MMF-TAC n=5"
11578741|NCT00798785|Experimental|group III ATG-Basilixumab-MMF-TAC|"Two clinical implants in the liver:
~First implant: ATG-fresenium Second implant: basilixumab Maintained immunosuppression: MMF-TAC n=5"
11578742|NCT00798785|Experimental|group IV omentum|"Two clinical implants: first in the omentum followed by a clinical implant in the liver:
~First implant: ATG-fresenium Maintained immunosuppression: MMF-TAC n=10"
11578743|NCT00798772|Experimental|A: Broad spectrum micronutrients|"The experimental treatment medications (micronutrients and antioxidants) will be taken as one packet (8 capsules) twice a day with meals. Because of the presence of calcium, iron and zinc in the study medication, any other medication must be taken at least two hours before or after taking it. Participants may initiate the intervention at half dose (one packet of 8 capsules once a day) and increase to full dose after one week.
~The intervention will last for two years."
11578744|NCT00798772|Active Comparator|B: Identical appearing multivitamins|"The active comparator/control medications (identical appearing RDA multivitamins and minerals) will be taken as one packet (8 capsules) twice a day with meals. Because of the presence of calcium, iron and zinc in the study medication, any other medication must be taken at least two hours before or after taking it. Participants may initiate the intervention at half dose (one packet of 8 capsules once a day) and increase to full dose after one week.
~The intervention will last for two years."
11578745|NCT00798759|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
11578746|NCT00798759|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
11578747|NCT00798746||Pyloric Drainage Procedure|Esophagectomy with pyloric drainage procedure
11578748|NCT00798746||No Pyloric Drainage Procedure|Esophagectomy without pyloric drainage procedure
11578749|NCT00798733||Non-Operative|Surgeon treated the patient non-operatively
11578750|NCT00798733||Operative|Surgeon treated the patient operatively
11578751|NCT00798720|Experimental|Vorinostat + Bortezomib|Vorinostat 400 mg + Bortezomib 1.3 mg/m2
11578752|NCT00798707|Experimental|Desvenlafaxine succinate sustained-release 25 mg|
11578753|NCT00798707|Experimental|Desvenlafaxine succinate sustained-release 50 mg|
11578754|NCT00798707|Placebo Comparator|Placebo|
11578755|NCT00798694|Other|New to Meds|Naive to glaucoma therapy medical or surgical. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
11578756|NCT00798694|Other|Currently on Xalatan|Patients currently on Xalatan at least one month. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
11578757|NCT00798681|Experimental|1|Patients will receive RTU TPN with olive-oil as the primary source of lipids
11578758|NCT00798681|Active Comparator|2|CNF parenteral nutrition made with olive oil as the primary source of lipids
11578759|NCT00798681|Active Comparator|3|CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
11578760|NCT00798668|Experimental|1|participants continue current exercise and take liquid supplement
11578761|NCT00798668|Experimental|2|Participants continue current exercise and take solid supplement
11578762|NCT00798668|Experimental|3|Participants continue current sedentary behavior and take liquid supplements
11578763|NCT00798668|Experimental|4|Participants continue current sedentary behavior and take solid supplements
11578764|NCT00798655|Experimental|Panitumumab, Cisplatin plus radiation|Standard radiation 60-66 Gy with 200 cGy daily fractions in 6-7 weeks Cisplatin* 30 mg/m2 IV, weekly during radiation (total of 6-7 doses based upon radiation therapy dose requirements) Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses based upon radiation therapy dose requirements)
11578765|NCT00798642|Active Comparator|Hypnotherapy|
11578766|NCT00798642|Placebo Comparator|Standard care|
11578767|NCT00798642|Placebo Comparator|Mind Body Therapy|
11578768|NCT00798629|Experimental|Vaccine Dose Escalation|Dose Escalation: Intradermal DC Injection. Level 1: Cell Dose: 2 x 10^6 Level 2: Cell Dose: 1 x 10^7 Level 3: Cell Dose: 2 x 10^7
11578769|NCT00798616|Placebo Comparator|Responders/Placebo|Albuterol responders being given placebo
11578770|NCT00798616|Active Comparator|Responders/Steroids|albuterol responders being given steroids
11578771|NCT00798616|Placebo Comparator|Non-responders/placebo|non-albuterol responders being given placebo
11578772|NCT00798616|Active Comparator|non-responders/steroids|non-albuterol responders being given steroids
11578773|NCT00798603|Experimental|pemetrexed + carboplatin + bevacizumab|Patients receive pemetrexed disodium IV over 10 minutes, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease or partial or complete response after 6 courses may continue to receive pemetrexed disodium and bevacizumab every 21 days in the absence of disease progression or unacceptable toxicity.
11578774|NCT00798590|Experimental|GLP-1|
11578775|NCT00798590|Placebo Comparator|Saline|
11578776|NCT00798577|Experimental|Vigamox|Vigamox Ophthalmic Solution (Moxifloxacin 5mg/mL)
11578777|NCT00798577|Placebo Comparator|BSS Placebo|Balanced Salt Solution
11578778|NCT00798551|Other|Risk counseling|Risk counseling regarding elevated blood pressure
11578779|NCT00798538|Active Comparator|Integrated|Provision of buprenorphine induction and management, substance abuse counseling and HIV care at one clinic.
11578780|NCT00798538|Placebo Comparator|Non-integrated|Buprenorphine induction, substance abuse counseling and HIV care will be managed at multiple locations, respectively: the Community Health Care Van, the Yale AIDS Program, and individuals' HIV clinics.
11578781|NCT00798525|Active Comparator|PR1|Patients treated with Argatroban (Argatra®), a direct thrombin inhibitor
11578782|NCT00798525|Active Comparator|PR2|Patients treated with Lepirudin (Refludan®), a direct thrombin inhibitor
11578834|NCT00798239|Experimental|Prefix 750|Prefix (AMPLEX) B2A Enhanced Ceramic Granules
11578835|NCT00798226|Active Comparator|1|n-3 fatty acid
11578836|NCT00798226|Placebo Comparator|2|Olive oil
11578783|NCT00798512|Experimental|1|Single arm Study in which 120 patients fulfilling eligibility criteria will be screened and undergo carotid stenting with the Cristallo ideale™ carotid stent after placement of the Mo.Ma device as cerebral protection system. The technique of diffusion-weighted magnetic resonance imaging (DW-MRI) will be used to identify new ischemic lesions.
11578784|NCT00798499||1|Laboratory variables
11578785|NCT00798486|Other|Subjects with and without Diabetes|Subjects participating in this study included 93 who had diabetes and 17 who did not have diabetes.
11578786|NCT00798473|Experimental|1|Zoledronic acid, 0.06 mg/kg IV in a single infusion, maximum of 4 mg
11578787|NCT00798473|Placebo Comparator|2|IV saline infusion
11578788|NCT00798460|Active Comparator|Lamivudine plus adefovir|
11578789|NCT00798460|Active Comparator|Clevudine plus adefovir|
11578790|NCT00798447|Experimental|lipid emulsion with n-3 FA|
11578791|NCT00798447|Active Comparator|lipid emulsion without n-3 FA|
11578792|NCT00798434|Active Comparator|Placebo|Flexible dose regimen of placebo once daily. The dose can be increased after 4 weeks if clinically indicated. Subsequently the dose can be reduced to the original dose if clinically indicated.
11578793|NCT00798434|Active Comparator|Fesoterodine|Flexible dose regimen of fesoterodine fumarate 4mg once daily. The dose can be increased to 8mg once daily after 4 weeks if clinically indicated. Subsequently the dose can be reduced to 4mg if clinically indicated.
11578794|NCT00798421||Heathcare worker|health care worker exposed to patient with influenza
11578795|NCT00798408|Experimental|1|Participants will maintain current physical activity and take a fluid supplement.
11578796|NCT00798408|Experimental|2|Participants will maintain current physical activity and take a solid supplement.
11578797|NCT00798395|Experimental|Treatment 1|
11578798|NCT00798395|Experimental|Treatment 2|
11578799|NCT00798395|Placebo Comparator|Treatment 3|
11578800|NCT00798395|Active Comparator|Treatment 4|
11578801|NCT00798382|Experimental|1: Soy formula|experimental soy formula #1
11578802|NCT00798382|Active Comparator|2: Soy Formula|Commercially available soy formula
11578803|NCT00798382|Experimental|3: Soy formula|experimental soy formula #2
11578804|NCT00798369|Experimental|Canakinumab 10 mg|Canakinumab 10 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
11578805|NCT00798369|Experimental|Canakinumab 25 mg|Canakinumab 25 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
11578806|NCT00798369|Experimental|Canakinumab 50 mg|Canakinumab 50 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
11578807|NCT00798369|Experimental|Canakinumab 90 mg|Canakinumab 90 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
11578808|NCT00798369|Experimental|Canakinumab 150 mg|Canakinumab 150 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
11578809|NCT00798369|Active Comparator|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg intramuscularly (i.m) once. The i.m. injection was recommended to be administered deeply into the gluteal muscle. Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
11578810|NCT00798356|Other|1|Yoga training
11578811|NCT00798343|Active Comparator|Seasonal vaccine|Seasonal influenza vaccination
11578812|NCT00798343|Experimental|Pandemic vaccine|MF59-adjuvanted H5N1 monovalent vaccine
11578813|NCT00798317|Experimental|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
11578814|NCT00798317|Placebo Comparator|Placebo|Intravitreal injection of placebo
11578815|NCT00798304|Experimental|1|Dose level 1 of meningococcal B rLP2086 vaccine and routine childhood vaccines
11578816|NCT00798304|Experimental|2|Dose level 2 of meningococcal B rLP2086 vaccine and routine childhood vaccines
11578817|NCT00798304|Experimental|3|Control group
11578818|NCT00798291|Placebo Comparator|Ad lib diet/placebo|Ad lib diet and control product placebo
11578819|NCT00798291|Experimental|Ad lib diet/AN 777|Ad lib diet and AN 777
11578820|NCT00798291|Active Comparator|Ad lib diet/placebo/exercise|Diet ad lib; exercise; and placebo
11578821|NCT00798291|Experimental|Ad lib diet/ AN 777/ exercise|Diet ad lib; AN 777; exercise
11578822|NCT00798278|Experimental|Urokinase|urokinase infusion for 3 days
11578823|NCT00798278|Active Comparator|Thoracoscopic|Video-Assisted Thoracoscopic
11578824|NCT00798265|Experimental|1|.5 mL dose injected IM at 0, 2 and 6 months (+/- 2 weeks) and knowledge survey at week 0
11578825|NCT00798265|Experimental|2|.5 mL dose injected IM at 0, 2 and 6 months (+/- 2 weeks) and knowledge survey at week 0
11578826|NCT00798265|Active Comparator|3|.5 mL dose injected IM at 0, 2 and 6 months (+/- 2 weeks) and knowledge survey at week 0
11578827|NCT00798252|Experimental|Arm A (Capecitabine + Brivanib alaninate)|
11578828|NCT00798252|Experimental|Arm B (Doxorubicin + Brivanib alaninate)|
11578829|NCT00798252|Experimental|Arm C (Ixabepilone + Brivanib alaninate)|
11578830|NCT00798252|Experimental|Arm D (Docetaxel + Brivanib alaninate)|
11578831|NCT00798252|Experimental|Arm E (Paclitaxel + Brivanib alaninate)|
11578832|NCT00798239|Active Comparator|Control|The control arm is Iliac Crest Autograft
11578837|NCT00798213|Experimental|Participants with AML randomized to SCH 727965|
11578838|NCT00798213|Active Comparator|Participants with AML randomized to gemtuzumab ozogamicin|
11578839|NCT00798213|Experimental|AML treated w/ SCH 727965 after prog. on gemtuzumab ozogamicin|
11578840|NCT00798213|Experimental|Participants with ALL treated with SCH 727965|
11578841|NCT00798200|Other|Exercise|All participants will take part in a supervised, structured, exercise program
11578842|NCT00798187||Homogeneous Support Group|
11578843|NCT00798187||Heterogeneous Support Group One|
11578844|NCT00798187||Heterogeneous Support Group Two|
11578845|NCT00798174|Experimental|Standard configuration vs. azygos coil|"The DFT with the standard Superior Vena Cava (SVC) coil vs. DFT with the azygos coil.
~In this crossover study, each patient serves and own control, with defibrillation testing performed with and with the azygos coil"
11578846|NCT00798161|Experimental|BI 1356 + metformin|BI 1356 low dose + metformin 500 mg, twice daily
11578847|NCT00798161|Placebo Comparator|matching placebo|matching placebo
11578848|NCT00798161|Experimental|BI 1356+ Metformin|BI 1356 low dose + metformin 1000 mg, twice daily
11578849|NCT00798161|Active Comparator|Metformin|Metformin 500 mg, twice daily
11578850|NCT00798161|Active Comparator|metformin|Metformin 1000 mg, twice daily
11578851|NCT00798161|Experimental|BI 1356|BI 1356 high dose, once daily
11578852|NCT00798148|Experimental|MIBG|
11578853|NCT00798135|Experimental|itraconazole|Patients will receive oral itraconazole 200mg a day until disease progression.
11578854|NCT00798122|Experimental|Women|IVUS and MRI performed in women with no obstructive CAD at angiography
11578855|NCT00798109|Experimental|Motivational Therapy|Four motivational interview for cannabis abuse in schizophrenia population during one month
11578856|NCT00798109|Other|Usual Care|Usual care with intensive psychotherapy
11578857|NCT00798096|Experimental|1|
11578858|NCT00798070|Experimental|Arm A: dtEC→dtT|Individually tailored and two weekly dosed epirubicin + cyclophosphamide followed by a three weeks break followed by biweekly and tailored docetaxel (dtEC→dtT) given every second week
11578859|NCT00798070|Active Comparator|Arm B: FEC→T|Fixed dosed and three weekly epirubicin, cyclophosphamide and 5-fluorouracil, followed by fixed dosed and three weekly docetaxel
11578860|NCT00798057||Proton Radiation|
11578861|NCT00798044|Experimental|Feedback to counselors|substance abuse counselors received feedback reports on their average performance and on the average performance of the clinic as a whole. Feedback reports contained information on average alliance, treatment satisfaction, and drug/alcohol use.
11578862|NCT00798044|No Intervention|Treatment as Usual|No feedback reports were provided in this arm.
11578863|NCT00798031|Other|1|a minimum of two dental implants, but up to 3 dental implants, will be placed in each of 20 subjects. All surgical procedures will be performed as outpatient procedures at the College of Dentistry and implant placement will follow a one-stage procedure under local anesthesia. Placement of the 2-3 dental implants is the only intervention.
11578864|NCT00798018|Placebo Comparator|Air|air was used to inflate the cuff.
11578865|NCT00798018|Placebo Comparator|Normal Saline|Normal saline was used to inflate the cuff.
11578866|NCT00798018|Active Comparator|lidocaine|2% lidocaine was used to inflate the cuff.
11578867|NCT00798018|Experimental|tetracaine|1% tetracaine was used to inflate the cuff.
11578868|NCT00797992|Experimental|1|Myopic eyes with retinal neovascularization
11578869|NCT00797979|Experimental|1|Skull Grip bone fixation
11578870|NCT00797979|Active Comparator|2|Standard skull bon flap fixation, sutures
11578871|NCT00797966|Experimental|1|OPC-34712 + ADT
11578872|NCT00797966|Placebo Comparator|2|Placebo + ADT
11578873|NCT00797953|Experimental|Low dose|2 capsules of T89 with 1 placebo capsule each time, twice daily. The daily dose is 250 mg.
11578874|NCT00797953|Experimental|High dose|3 capsules of T89 each time, twice daily. The daily dose is 375 mg
11578875|NCT00797953|Placebo Comparator|Placebo|3 placebo capsules (PC) each time, twice per day. The daily dose is 0 mg.
11578876|NCT00797940|Experimental|Single Arm|Up to 42 subjects with first recurrence or progression of GBM
11578877|NCT00797927|Experimental|1. quetiapine|quetiapine would replace the original conventional antipsychotic agent
11578878|NCT00797927|No Intervention|2. conventional antipsychotics|
11578879|NCT00797914||Patients undergoing colonoscopy|Patients who are undergoing outpatient colonoscopy for colorectal cancer screening or for symptoms suggestive of colonic diseases.
11578880|NCT00797901|Experimental|Collaborative Care, Treatment as Usual|
11578881|NCT00797888|Experimental|Telephonic|Tailored telephonic intervention to improve HbA1c for participants in the diabetes registry
11578882|NCT00797888|Active Comparator|Standard registry|People with diabetes who are in the A1c registry may receive letters from the DOHMH to promote improved A1c and also give lists of bronx resources for healther foof and activites
11578883|NCT00797875|Experimental|1|PNF stretching x 5 repetitions for 3 days
11578884|NCT00797875|Active Comparator|2|passive stretching
11578885|NCT00797862|Experimental|Aliskiren + Amlodipine|Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.
11578886|NCT00797862|Experimental|Aliskiren Start - Amlodipine Add-On|Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.
11578915|NCT00797680|Experimental|24 hours hypothermia|24 hours hypothermia
11578887|NCT00797862|Experimental|Amlodipine Start- Aliskiren Add-On|Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks.
11578888|NCT00797849|Active Comparator|1|Wear prosthetics laminated with Farabloc surrounding the liner. If not wearing prosthetics, subject needs to wear Farabloc sock or glove over shrinker.
11578889|NCT00797849|Sham Comparator|2|Wear prosthetics laminated with sham material surrounding the liner. If not wearing prosthetics, subject needs to wear sock or glove over shrinker.
11578890|NCT00797836|Experimental|Quantiferon Gold|
11578891|NCT00797823|Placebo Comparator|Insulin + Placebo|Glycemic control of subject participants was managed by the closed-loop system which delivered insulin and normal saline (instead of glucagon) as a placebo, based upon algorithm calculations.
11578892|NCT00797823|Active Comparator|Insulin + Glucagon|Glycemic control of subject participants was managed by the system which delivered insulin and glucagon based upon algorithm calculations.
11578893|NCT00797823|Experimental|Pilot Study|Pilot studies designed to assess safety of the system. Includes 6 participants undergoing 7 studies.
11578894|NCT00797810|Experimental|therapy|
11578895|NCT00797797|Experimental|Milnacipran Added|
11578896|NCT00797797|Experimental|No Treatment Added|
11578897|NCT00797771|Experimental|A|"Adi insulin pump users"
11578898|NCT00797758|Experimental|1|Umbilical cord blood transplantation after reduced intensity conditioning
11578899|NCT00797745|Active Comparator|Standard of Care|"PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily for 48 weeks.
~Subjects with >= 1 log decrease from baseline in HCV-RNA levels after 12 weeks, but still above the lower limit of quantitation, have the option of crossing over to PegIntron, ribavirin plus SCH 900518 400 mg and ritonavir 100 mg daily for 12 weeks. This is followed by standard of care, PegIntron and ribavirin, for a total treatment duration of up to 48 weeks."
11578900|NCT00797745|Experimental|2|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
11578901|NCT00797745|Experimental|3|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 400 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
11578902|NCT00797745|Experimental|4|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
11578903|NCT00797745|Experimental|5|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 400 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
11578904|NCT00797745|Experimental|6|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 100 mg twice daily plus ritonavir 100 mg twice daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
11578905|NCT00797745|Experimental|7|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 600 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
11578906|NCT00797732|Active Comparator|Active Acupuncture|The active intervention used a three-phase step-up protocol to gradually increase the body areas treated and needling intensity. Acupuncture needles (0.20x25mm) were inserted with a depth of 5-10 mm into predefined points based on a systematic literature review following the STRICTA guideline. Needles were stimulated to obtain the de qi sensation. An electroacupuncture (EA) device was connected at two acupoints. All needles remained in place for 30 minutes. The active acupuncture was administered once every 2 weeks for 24 weeks, starting 2 weeks into CRT and ending at 20 weeks after CRT. [Refs: Lu W, Wayne PM et al. Contemp Clin Trials 2012; 33; 700-711; MacPherson H, Altman DG et al. PLoS Med 2010;7:e1000261]
11578907|NCT00797732|Sham Comparator|Sham Acupuncture|The sham intervention was designed to be maximally inert and minimally invasive, while simulating most aspects of the active protocol. Sham needles (0.12x30mm) were inserted at 14 locations paralleling the same body regions needled in the active group; however, all sham point locations were off the pathways of traditional Chinese medicine acupuncture meridians and points. An identical but deactivated EA device was used following sham protocols previously used. The sham acupuncture was administered once every 2 weeks for 24 weeks, starting 2 weeks into CRT and ending at 20 weeks after CRT. [Refs: Lu W, Wayne PM et al. Contemp Clin Trials 2012; 33; 700-711; Wayne PA, Krebs DE et al. Arch Phys Med Rehabil 2005;86:2248-2255]
11578908|NCT00797719|Experimental|All|This is a single arm study. All patients enrolled will be in this arm.
11578909|NCT00797706|Placebo Comparator|Vehicle|
11578910|NCT00797706|Experimental|Low dose|
11578911|NCT00797706|Experimental|High dose|
11578912|NCT00797693|Experimental|Vaginal Misoprostol|A drug is given vaginally and to compare this with an oral administration of the same drug to find it is effect on it is effect on the cervix
11578913|NCT00797693|Experimental|Oral Misoprostol|A drug is given vaginally and to compare this with an oral administration of the same drug to find it is effect on it is effect on the cervix
11578914|NCT00797680|Experimental|72 hours hypothermia|72 hours hypothermia
11578916|NCT00797667|Experimental|Telcagepant 140 mg|Participants receive one telcagepant 140 mg tablet and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks
11578917|NCT00797667|Experimental|Telcagepant 280 mg|Participants receive one telcagepant 280 mg tablet and one 140 mg telcagepant placebo, orally, twice daily for 12 weeks
11578918|NCT00797667|Placebo Comparator|Placebo|Participants receive one 140 mg telcagepant placebo and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks
11578919|NCT00797654|Experimental|1|Participants will receive pre and post HIV-test counseling and an information-motivation-behavior skills training combined with cognitive processing therapy
11578920|NCT00797654|Active Comparator|2|Participants will receive pre and post HIV-test counseling
11578921|NCT00797641||1|Patients admitted to the hospital, or inpatients admitted for another reason, presenting with overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia, as well as other clinical or laboratory evidence of acute blood loss from the upper gastrointestinal tract
11578922|NCT00797628|Experimental|Information Prescription|"Providers will give usual care to patients who smoke and a paper prescription with the name and url of the Smoking Coach website. The smoking coach website is a tailored, public health intervention for smoking cessation."
11578923|NCT00797628|Experimental|QUIT-PRIMO|Providers will give usual care to patients who smoke and then refer patients to the online smoking cessation system electronically.
11578924|NCT00797615|Placebo Comparator|Alternative Intervention|12-week alternate intervention program focused on building self-esteem and social self-efficacy
11578925|NCT00797615|Active Comparator|Active Intervention|12-week intervention program focused on dietary intake and physical activity
11578926|NCT00797602||Proton Radiation|
11578927|NCT00797589|Experimental|Ringer lactate|Crystalloid solution
11578928|NCT00797589|Experimental|HES solution (Tetraspan®)|Balanced colloid solution
11578929|NCT00797576||1/Cases|Subjects whom had cardioversion aborted due to LAA thrombus or suspicion of LAA thrombus on TEE.
11578930|NCT00797576||2/Controls|Subjects with underlying atrial fibrillation undergoing elective TEE as clinically indicated for any reason.
11578931|NCT00797563|Other|Subjects with diabetes|Subjects with diabetes use a new blood glucose monitoring system (BGMS) Apollo Blood Glucose Monitoring System with capillary blood; healthcare professionals use the new BGMS with subject capillary and venous blood.
11578932|NCT00797550|Active Comparator|Control|The Control arm of the study will receive bone autograft.
11578933|NCT00797550|Experimental|Treatment|The Treatment arm of the study will receive single level posterolateral spinal fusion between L1 to S1 levels with implantation of BRC product.
11578934|NCT00797524||DR|Diabetic Retinopathy
11578935|NCT00797524||ARMD|Age-Related Macular Degeneration
11578936|NCT00797524||ME|Macular Edema
11578937|NCT00797511|Experimental|Study Group|Participants will receive one dose of Tetanus, diphtheria (reduced antigen content), pertussis (acellular components) vaccine (TdcP-IPV, ADACEL Polio) on Day 0
11578938|NCT00797498||Xerostomia Questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
11578939|NCT00797485|Active Comparator|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive FOLFIRI chemotherapy comprising irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11578940|NCT00797485|Experimental|Arm II|Patients receive bevacizumab and FOLFIRI chemotherapy (B-FOLFIRI) as in arm I. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes on day 1 and oral capecitabine once every 12 hours on days 1-14. Treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11578941|NCT00797472|Active Comparator|Arm I: R-mabHD|Anti-hodgkin disease agent
11578942|NCT00797472|Active Comparator|Arm II: ABVD|
11578943|NCT00797459|Experimental|Restylane and Restylane with Lidocaine|This is a split-face design injecting both Restylane and Restylane-L injectable gels, administered once. Each subject received Restylane on one side of the face, and Restylane-L on the other. Subjects were blinded to which side of their face received Restylane or Restylane-L. The study was randomized and treatments successive.
11578944|NCT00797446||Photon/Proton Radiation Therapy|Data collection will be obtained from the patient's medical records including initial evaluation, pathology report, dosimetry information, radiotherapy completion records and follow-up.
11578945|NCT00797433||Mechanical ventilation|All male patients with acute respiratory failure requiring mechanical ventilation
11578946|NCT00797420|Other|Loading Dose|Loading Dose
11578947|NCT00797420|Other|Loading & high dose|Loading dose & high dose Fluconazole
11578948|NCT00797394|Experimental|Treated|
11578949|NCT00797394|Active Comparator|Control|
11578950|NCT00797381||1|
11578951|NCT00797381||2|
11578952|NCT00797368|Experimental|Manual Therapy and Exercise|Manual Therapy and Exercise
11578953|NCT00797368|Active Comparator|Home Exercise|Home Exercise
11578954|NCT00797342|Other|first of three dosing cohorts|
11578955|NCT00797342|Other|second of three dosing cohorts|
11578956|NCT00797342|Other|third of three dosing cohorts|
11578957|NCT00797329||observation|adult men with alcohol and polydrug use according to DSM-IV criteria, hospitalized in maximum security department between 2002 - 2008
11578958|NCT00797316|Experimental|Aliskiren plus Hydrochlorothiazide|Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.
11578959|NCT00797316|Active Comparator|Aliskiren|Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.
11578960|NCT00797303|Experimental|1|A single intraoperative subconjunctival application of bevacizumab and 2 months follow-up
11578961|NCT00797290||Photon/Proton Radiation Therapy|Photon/Proton Radiation Therapy
11578962|NCT00797277|Experimental|IM olanzapine|Patients of this arm received 10 mg IM olanzapine after randomization
11578963|NCT00797277|Active Comparator|IM haloperidol plus lorazepam|Patients of this arm received 5 mg IM haloperidol plus 2 mg IM lorazepam after randomization
11578964|NCT00797264|Experimental|A|Ketamine pre and per operative, and morphine postoperative
11578965|NCT00797264|Active Comparator|B|NaCl pre and per operative, and morphine postoperative
11578966|NCT00797264|Experimental|C|Ketamine and morphine postoperative
11578967|NCT00797251||Right posterior section group|Patients with tumors in the right posterior section of the liver (segments 6-7)
11578968|NCT00797238||NSCLC stage III|Taiwanese NSCLC patients with stage III
11578969|NCT00797225|Placebo Comparator|Placebo|Participants received placebo tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
11578970|NCT00797225|Experimental|Elagolix 150 mg|Participants received elagolix 150 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg for an additional 12 weeks.
11578971|NCT00797225|Experimental|Elagolix 250 mg|Participants received elagolix 250 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.
11578972|NCT00797225|Other|Leuprorelin|Participants received placebo tablets once a day and leuprorelin acetate 1-month depot 3.75 mg intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
11578973|NCT00797212|Other|Subjects with diabetes|Subjects with diabetes use a new Apollo Blood Glucose Monitoring System with blood obtained from the palm and forearm
11578974|NCT00797199||1-Treatment Group 1|Women receiving HRT treatment of Premarin.
11578975|NCT00797199||2-Treatment Group 2|Women receiving combination HRT treatment of Premarin + Provera.
11578976|NCT00797199||3- Treatment Group 3|Women receiving combination HRT treatment of Premarin + Prometrium.
11578977|NCT00797199||4- Controls|Women not on HRT or healthy controls.
11578978|NCT00797186|Other|Intensive therapy|There is one arm in this trial. All patients receive the same therapy. The goal is to compare a noninvasive and invasive imaging technique in the same population.
11578979|NCT00797134||DR|Diabetic Retinopathy
11578980|NCT00797121|Experimental|Preoperative biliary drainage|
11578981|NCT00797121|No Intervention|Controlled group|
11578982|NCT00797108|Experimental|1|Loading dose of IV sulopenem with switch to oral PF-03709270
11578983|NCT00797108|Experimental|2|IV sulopenem with switch to oral PF-03709270
11578984|NCT00797108|Active Comparator|3|IV ceftriaxone with switch to oral amoxicillin/clavulanate potassium comparator
11578985|NCT00797082|Experimental|1|"MRI = Myocardial Perfusion Stress and MPS = Myocardial Perfusion Scintigraphy
~Diabetic patients
~Coronary insufficiency"
11578986|NCT00797069|Active Comparator|standard nutritional product|Standard nutritional product not specific for diabetes
11578987|NCT00797069|Active Comparator|diabetes specific product|Diabetes specific nutritional product
11578988|NCT00797069|Experimental|Experimental diabetes specific product|Diabetes specific experimental nutritional product
11578989|NCT00797056|Experimental|G-CSF|
11578990|NCT00797056|Placebo Comparator|Placebo|
11578991|NCT00797043||Photon/Proton Radiation Therapy|Data consolidation and analysis
11578992|NCT00797030|Active Comparator|1|Ten HIV-positive-patients with dry eye diagnosis received sodium carboxymethylcellulose 0.5% drops (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) for six months.
11578993|NCT00797030|Other|2|Ten HIV-positive-patients with dry eye received sodium carboximethylcelullose 0.5% (1 drop 4 times per day) during six months
11578994|NCT00797017||001|
11578995|NCT00797017||002|
11578996|NCT00797017||003|
11578997|NCT00797017||004|
11578998|NCT00797017||005|
11578999|NCT00797017||006|
11579000|NCT00797017||007|
11579001|NCT00797004||endoscopic sinus procedure candidates|
11579002|NCT00796991|Active Comparator|Arm A|
11579003|NCT00796991|Active Comparator|Arm B|
11579004|NCT00796991|Active Comparator|Arm C|
11579005|NCT00796978|Experimental|trastuzumab|
11579006|NCT00796965|Experimental|1|
11579007|NCT00796965|Placebo Comparator|2|
11579008|NCT00796952|Active Comparator|Usual Care|"Patient management by the attending Radiation oncologist as usual."
11579009|NCT00796952|Experimental|Pharyngocise|Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their chemo-radiation treatment (up to a maximum of 6 weeks)
11579010|NCT00796952|Sham Comparator|Valchuff|"Standardised sham swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of chemo-radiation treatment."
11579011|NCT00796939|Active Comparator|Green Light Mask|
11579012|NCT00796939|Placebo Comparator|Red light mask|
11579013|NCT00796926|Experimental|Systane Ultra|Used four times a day topically to each eye
11579014|NCT00796926|Active Comparator|Refresh|Used four times a day topically to each eye
11579015|NCT00796913|Active Comparator|Stop of medication after remission|"After enetering remission patients are randomised to continue low dose medication or to stop medication: Overview of study described in:
~Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487."
11579016|NCT00796913|No Intervention|Medication for 2 yrs after remission|See Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.
11579017|NCT00796913|Experimental|Se-yeast 200 Microgr/day + arm A|Additional arm where patients have been taking Se supplements during RISG1 therapy, and for 2 years after ATD withdrawal.
11579018|NCT00796900|Experimental|Dantrolene|
11579019|NCT00796900|Placebo Comparator|Placebo|
11579020|NCT00796887|Experimental|Niaspan® 500mg|
11579021|NCT00796887|Experimental|Niaspan® 1000mg|
11579022|NCT00796887|Placebo Comparator|Placebo|
11579023|NCT00796861|Experimental|Single Arm|Sunitinib (50mg PO daily x 4 wks + 2 wks rest x 3 cycles if able to tolerate tx
11579024|NCT00796822|Experimental|1|Participants will receive pentoxifylline.
11579025|NCT00796822|Placebo Comparator|2|Participants will receive placebo.
11579026|NCT00796809||Biologics|Patients receiving TNF inhibitors or biologic agents
11579027|NCT00796809||DMARD|Patients receiving methotrexate without any biologic
11579028|NCT00796796|Experimental|Cohort 1 (Starting Dose)|"Temsirolimus 20 mg IV weekly for 4 weeks
~Radiation therapy will begin on Day 2, one day after the initial dose of temsirolimus. Treatment will consist of daily fractions of 250 cGy, 5 days per week to a total cumulative dose of 3500 cGy for a total of 14 days."
11579029|NCT00796796|Experimental|Cohort 2|"Temsirolimus 25 mg IV weekly for 4 weeks
~Radiation therapy will begin on Day 2, one day after the initial dose of temsirolimus. Treatment will consist of daily fractions of 250 cGy, 5 days per week to a total cumulative dose of 3500 cGy for a total of 14 days."
11579030|NCT00796783||1|Patients with presumed Cushing's disease who have failed pituitary surgery and/or radiation and require medical treatment for recurrent or persistent Cushing's syndrome.
11579031|NCT00796770|Experimental|Dendritic Cell Vaccine|Autologous dendritic cells generated using GM-CSF and interferon alpha, loaded with HIV lipopeptides and activated with lipopolysaccharide
11579032|NCT00796757|Experimental|1|
11579033|NCT00796744|Placebo Comparator|Placebo Vehicle Control|control placebo vehicle gel
11579034|NCT00796744|Active Comparator|0.03% DSC127|0.03 % DSC127 in Vehicle Control
11579035|NCT00796744|Active Comparator|0.01% DSC127|0.01% DSC127 in Vehicle Control
11579036|NCT00796718|Experimental|Capecitabine|Capecitabine orally twice daily plus standard radiotherapy for 5 weeks, followed by surgery within 6 weeks after completion of treatment.
11579037|NCT00796705|Experimental|Adalimumab / Adalimumab Placebo|1 sub-cutaneous (SQ) injection of adalimumab or 1 SQ injection of placebo will be given in a blinded and alternating fashion for a total of 12 weeks
11579038|NCT00796705|Experimental|Etanercept|Participants will receive 1 SQ injection of etanercept each week for 12 weeks
11579039|NCT00796692|Experimental|Group 2|Low molecular weight heparin
11579040|NCT00796692|Active Comparator|Group 1|Unfractionated heparin(UFH)
11579041|NCT00796679|Experimental|1|paricalcitol
11579042|NCT00796679|Placebo Comparator|2|placebo
11579043|NCT00796666|Experimental|Sitaxsentan and Placebo|Monotherapy arm
11579044|NCT00796666|Experimental|Sitaxsentan and Sildenafil|Combination treatment
11579045|NCT00796653|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
11579046|NCT00796653|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
11579047|NCT00796653|Active Comparator|Formoterol 12mcg|12mcg inhaled twice daily from the Aerolizer inhaler
11579048|NCT00796653|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
11579049|NCT00796627|Sham Comparator|Healthy volunteers|"Healthy volunteers with no burn wounds Volunteers donate blood that will be studied in comparison to patients who have sustained burns. The circulating bone marrow stem cells will be counted and compared to the levels in burn patients. Six 12 ml tubes will be taken for the study. You will not be compensated. But you will be helping to advance science if you join the study."
11579050|NCT00796627|Active Comparator|Burn volunteer|To recruit burn wound patients with defined clinical criteria for study. A second-degree burn of at least 10 cm2 to up to 95% BSA; age = 14-75 years; BP > 100 mm Hg systolic; heart rate < 100 beats/minute; urine output > 30 ml/hour; area of burn < 20% of BSA; body temperature = 98.5-101 degrees Fahrenheit; serum albumin > 3 mg/ml; and informed consent. We will also obtain a history regarding the presence or absence of risk factors that may affect CAC numbers: hypertension > 1 year; smoking > 2 pack-years or within the last year; diabetes mellitus; and family history of premature coronary artery disease (men < 55 and women < 65 years of age).Six 12 ml tubes will be taken at 5 time points
11579051|NCT00796614|Placebo Comparator|Placebo|Participants received matching placebo to tamsulosin hydrochloride via opened capsules every day for 14 weeks
11579052|NCT00796614|Experimental|Low dose|Participants received 0.001 - 0.002 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
11579053|NCT00796614|Experimental|Medium dose|Participants received 0.002 - 0.004 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
11579054|NCT00796614|Experimental|High dose|Participants received 0.004 - 0.008 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
11579055|NCT00796601|Experimental|Esreboxetine|
11579056|NCT00796601|Placebo Comparator|Placebo|
11579057|NCT00796588|No Intervention|Control group|Patients undergoing liver surgery without the designated intervention
11579058|NCT00796588|Other|RIPC|application of pneumatic tourniquet in patients undergoing liver surgery
11579059|NCT00796575|Experimental|CS-8080|3 mg CS-8080, 10mg CS-8080, 20 mg CS-8080
11579060|NCT00796575|Placebo Comparator|placebo|placebo
11579061|NCT00796562|Experimental|Myeloablative haploidentical BMT|"All participants except those with acute lymphoblastic leukemia and lymphoblastic lymphoma: Busulfan will be administered 1 mg/kg oral (or 0.8 mg/kg IV) four times per day for four days, followed by cyclophosphamide 50 mg/kg once per day for two days.
~Participants with acute lymphocytic leukemia or lymphoblastic lymphoma: Cyclophosphamide will be administered 50 mg/kg once per day for two days, followed by total body irradiation at 300 cGy per day for four days."
11579062|NCT00796549|Experimental|BIBW 2992|BIBW 2992 in EGFR FISH positive NSCLC patients
11579063|NCT00796536|Experimental|1|Participants will undergo 12 weeks of group cognitive behavioral therapy (CBT) and a pre- and post-intervention MRI brain scan.
11579217|NCT00795262|Placebo Comparator|placebo comparator|Quinapril 40 mg (Accupril)plus placebo will be given for 8 weeks.
11579064|NCT00796536|Active Comparator|2|Participants will received 12 weeks of pain education and a pre- and post-intervention MRI brain scan.
11579065|NCT00796523|Experimental|Happiest Baby videotape|videotape describing the Happiest Baby on the Block technique
11579066|NCT00796523|Placebo Comparator|control videotape|videotape with normal newborn instruction
11579067|NCT00796510|Experimental|Sitaxsentan|Monotherapy arm
11579068|NCT00796510|Experimental|Sitaxsentan and Sildenafil|Combination treatment
11579069|NCT00796497|Experimental|ondansetron|
11579070|NCT00796484|Experimental|1|
11579071|NCT00796458|Active Comparator|Arm I|Patients continue to receive LHRH-A therapy until disease progression.
11579072|NCT00796458|Experimental|Arm II|Patients receive LHRH-A therapy as in arm I. Patients also receive docetaxel IV on day 1. Treatment with docetaxel repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11579073|NCT00796445|Experimental|MAGE-A3 Group|Patients who received up to 13 doses of recMAGE-A3 + AS15 ASCI. Study products were administered as intramuscular (IM) injections in the deltoid or the lateral region of the thigh (not in anatomical regions where lymph nodes had been excised): 5 doses of ASCI product at 3-week intervals, followed by 8 doses of ASCI product at 12-week intervals.
11579074|NCT00796445|Placebo Comparator|Placebo Group|Patients who received up to 13 doses of placebo. Study products were administered as intramuscular (IM) injections in the deltoid or the lateral region of the thigh (not in anatomical regions where lymph nodes had been excised): 5 doses of placebo at 3-week intervals, followed by 8 doses of placebo at 12-week intervals.
11579075|NCT00796419|Experimental|1|Intravenous 5% human albumin
11579076|NCT00796419|Experimental|2|Intravenous 6% hetastarch
11579077|NCT00796393|Experimental|2|Subject with active product, not vaccinated against influenza.
11579078|NCT00796393|Placebo Comparator|3|Subject with placebo, vaccinated against influenza.
11579079|NCT00796393|Placebo Comparator|4|Subject with placebo, not vaccinated against influenza.
11579080|NCT00796393|Experimental|1|Subject with active product, vaccinated against influenza
11579081|NCT00796367|Placebo Comparator|Placebo|Placebo
11579082|NCT00796367|Experimental|VI-0521 Mid|7.5 mg phentermine and 46 mg topiramate
11579083|NCT00796367|Experimental|VI-0521 Top|15 mg phentermine and 92 mg topiramate
11579084|NCT00796354|Active Comparator|NRL920|
11579085|NCT00796354|Placebo Comparator|Placebo|
11579086|NCT00796341|Experimental|1|
11579087|NCT00796341|No Intervention|2|
11579088|NCT00796328|Experimental|1|
11579089|NCT00796315|Experimental|Doxylamine Succinate (USP)|Doxylamine Succinate United States Pharmacopeia (USP)
11579090|NCT00796302|Experimental|1|Children will receive active methylphenidate HCl and active risperidone. Parents will receive parent management training.
11579091|NCT00796302|Active Comparator|2|Children will receive methylphenidate HCl and placebo instead of the active risperidone. Parents will receive parent management training.
11579092|NCT00796289|Experimental|GnRH High Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
11579093|NCT00796289|Experimental|GnRH Medium Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a medium target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
11579094|NCT00796289|Experimental|GnRH Low Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a low target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
11579095|NCT00796289|Active Comparator|Clomiphene Citrate|Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral 50 mg clomiphene citrate for 5 days
11579096|NCT00796289|Placebo Comparator|Placebo|Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
11579097|NCT00796263|Other|HAART|"The proposed HAART regimen consists of:
~2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications
~Dolutegravir(DTG) 50 mg orally once daily"
11579098|NCT00796250|Experimental|Group A|
11579099|NCT00796250|Active Comparator|Group B|
11579100|NCT00796237|Experimental|WBV|In their regular physiotherapy sessions, the subjects in the experimental group will receive whole body vibration therapy for a duration of 4 weeks during their stay in the Tung Wah Hospital.
11579101|NCT00796237|Active Comparator|CON|The subjects in this group will not receive whole body vibration therapy.
11579102|NCT00796224|Active Comparator|1.|60 mg/kg azithromycin ER (Extended Release)arm
11579103|NCT00796224|Active Comparator|2.|30 mg/kg azithromycin IR (Immediate Release) arm
11579104|NCT00796211|Experimental|1|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
11579105|NCT00796211|Experimental|2|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
11579106|NCT00796211|Active Comparator|3|0.1% nortriptyline HCl topical cream
11579107|NCT00796211|Active Comparator|4|0.005% calcipotriol topical cream
11579108|NCT00796211|Placebo Comparator|5|Vehicle of CRx-197 topical cream (placebo)
11579109|NCT00796198|Active Comparator|Xalatan+Cosopt|Cosopt will be added to Xalatan when Xalatan is effective but not sufficient to reach the target pressure (Add group) (n = 25)
11579110|NCT00796198|Active Comparator|Xalatan|when Xalatan is effective and sufficient to reach the target pressure no other medication will be added (control group) (n = 25)
11579111|NCT00796172|Experimental|1|Medication adherence system (MAS) plus counseling from doctors
11579112|NCT00796172|Active Comparator|2|Usual care
11579113|NCT00796159||Olmesartan medoxomil + HCTZ|
11579114|NCT00796133|Active Comparator|1|0.5 ml of NES/E2 equaling 0.45 g and contains 1.5 mg NES/0.5 mg E2
11579115|NCT00796133|Active Comparator|2|1.0 ml of NES/E2 gel equaling 0.9 g and contains 3.0 mg NES/1.0 mg E2
11579116|NCT00796133|Active Comparator|3|1.5 ml of NES/E2 gel equaling 4.5 mg NES/1.5 mg E2
11579117|NCT00796120|Experimental|Trabectedin|Trabectedin 1.5 milligram per square meter (mg/m^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
11579118|NCT00796120|Active Comparator|Doxorubicin plus Ifosfamide|Doxorubicin (as a monotherapy) 75 mg per m^2 will be given intravenously every 3 weeks or Doxorubicin 60 mg per m^2 will be given intravenously every 3 weeks followed by ifosfamide 6 to 9 gram (g)/m^2 every 3 weeks until disease progression.
11579119|NCT00796107|Experimental|R1507 in Combination With Letrozole|Participants received a full daily dose of 2.5 mg of orally administered Letrozole along with 16 mg/kg of intravenous R1507 administered q3w, and observed for dose limiting toxicity for the first 2 cycles of treatment.
11579120|NCT00796094||Evaluation of tissue elasticity|Evaluate the potential importance of tissue elasticity in the assessment soft tissue structures.
11579121|NCT00796068|Experimental|Arm I (low risk for graft failure)|"Patients receive a conditioning regimen comprising fludarabine phosphate IV over 1 hour QD on days -6 to -2 and treosulfan IV over 120 minutes on days - 6 to -4. Patients undergo TBI on day -1. Patients then undergo donor UCBT on day 0.
~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour or PO 2-3 times daily on days -3 to 100, followed by a taper in the absence of GVHD. Patients also receive mycophenolate mofetil IV 3 times daily on days 0 to 40, followed by a taper in the absence of GVHD."
11579122|NCT00796068|Experimental|Arm II (high risk for graft failure)|Patients receive a conditioning regimen, TBI, donor UCBT, GVHD prophylaxis, and mycophenolate mofetil as in Arm I.
11579123|NCT00796055|Experimental|1|MEDI-547
11579124|NCT00796042|Active Comparator|1|Usual Care
11579125|NCT00796042|Experimental|2|Individualized, Community-based, Pressure management and Mobility program:
11579126|NCT00796003|Experimental|Phase I: JNJ-30979754 15 mg/m2|JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
11579127|NCT00796003|Experimental|Phase I: JNJ-30979754 20 mg/m2|JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
11579128|NCT00796003|Experimental|Phase II: JNJ-30979754 20 mg/m2|JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles
11579129|NCT00795977|Experimental|dendritic cells|
11579130|NCT00795964|Experimental|1|intraoperative mechanical ventilation with 6 ml/kg predicted body weight
11579131|NCT00795964|Active Comparator|2|intraoperative mechanical ventilation with 12 ml/kg predicted body weight
11579132|NCT00795951|Experimental|TRUE Test panels 1.1, 2.1, 3.1|All subjects were patched with 3 T.R.U.E. Test panels containing 28 allergens and 1 negative control.
11579133|NCT00795938|Active Comparator|Conventional Oral Tablet With Water|
11579134|NCT00795938|Experimental|Experimental Tablet With Water|
11579135|NCT00795938|Experimental|Experimental Tablet Without Water|
11579136|NCT00795925|Experimental|propiverine hydrochloride|
11579137|NCT00795912|Active Comparator|1|Atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
11579138|NCT00795912|No Intervention|2|Usual medical care of heart failure
11579139|NCT00795899|Experimental|1|Epirubicin/Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab in patients with HER-2 overexpression
11579140|NCT00795886|Experimental|All participants|
11579141|NCT00795860|Active Comparator|Weight loss - diet only|
11579142|NCT00795860|Experimental|Weight loss plus exercise|
11579143|NCT00795847|Experimental|1. Preminent|Patients with blood pressure self-measurement-proven morning hypertension are treated with Preminent 1T qd for 3 months.
11579144|NCT00795847|Active Comparator|2. High-dose losartan|Patients with blood pressure self-measurement-proven morning hypertension are treated with losartan 100 mg qd for 3 months.
11579145|NCT00795834|Placebo Comparator|Beverage|
11579146|NCT00795834|Active Comparator|High Polyphenol Beverage|
11579147|NCT00795821|Experimental|LY2216684|"10-week Acute Treatment Phase: Day after Week 0=start of 6 milligram (mg) once daily (QD) dosing; Week 1=all participants titrated to 9 mg QD; After Week 1=dose increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.
~1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of acute treatment phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62)."
11579148|NCT00795821|Placebo Comparator|Placebo|"10-week Acute Treatment Phase: 3 tablets QD for 10 weeks
~1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684 dose; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62)."
11579149|NCT00795808|Experimental|BMI > 32|Women with BMI > 32
11579150|NCT00795808|Experimental|BMI </= 32|Women with BMI </= 32
11579151|NCT00795795|Active Comparator|with PGS|IVF cycles with Preimplantation Genetic Screening (PGS)
11579152|NCT00795795|Active Comparator|Without PGS|IVF cycle without Preimplantation Genetic Screening
11579153|NCT00795782|Experimental|UniCND|Limited/ipsilateral central lymph node dissection
11579154|NCT00795782|Active Comparator|BiCND|Comprehensive/bilateral central lymph node dissection
11579155|NCT00795782|No Intervention|NoCND|No central lymph node dissection
11579156|NCT00795769|Experimental|Ondansetron therapy|Patients receive ondansetron IV once 30-60 minutes before undergoing autologous peripheral blood stem cell transplantation.
11579157|NCT00795756|Experimental|Intrathecal DepoCyte|I.t. DepoCyte 50 mg admninistered x6-8 (depending on immunophenotypic disease subset) during induction/consolidation/eraly maintenance phases
11579158|NCT00795756|Active Comparator|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg injected intrathecally x12 during indiction/consolidation phases
11579159|NCT00795730|Placebo Comparator|placebo|
11579160|NCT00795730|Experimental|NSA-789|
11579161|NCT00795717|Active Comparator|Lovaza|Lovaza, dietary counseling
11579162|NCT00795717|Placebo Comparator|Placebo|Placebo, dietary counseling
11579163|NCT00795704|Placebo Comparator|Placebo|Control Group
11579164|NCT00795704|Active Comparator|Mulberry Leaf Extract|
11579401|NCT00793858|Active Comparator|5|isotonic ciclesonide in left nostril and hypotonic ciclesonide in right
11579165|NCT00795691|Experimental|Low-carbohydrate diet|The low-carbohydrate diet was based on the Atkins weight loss diet. The daily intake goals were to restrict intake of carbohydrate to 20-25 grams for the first 2-week phase. If body weight decreased, the daily goal for carbohydrate was increased by 5 grams. If body weight increased, the daily goal for carbohydrate intake was decreased by 5 grams. The minimum goal for carbohydrate intake was 20 grams per day and the maximum goal was 50 grams per day.
11579166|NCT00795691|Active Comparator|Low-fat diet|The low-fat diet was based on the algorithm used to restrict fat and calorie intake in the Diabetes Prevention Program. The daily goals for fat intake was based on an algorithm to reduce total calorie intake to achieve a one pound weight loss per week with 25% of calories from fat.
11579167|NCT00795665|Experimental|Bevacizumab and Carmustine|
11579168|NCT00795652|Experimental|Distance Treatment|50% randomized to receive Distance Treatment for postpartum depression
11579169|NCT00795652|No Intervention|Usual Care Services|50% randomized to receive usual care services for postpartum depression
11579170|NCT00795639|Experimental|Sitaxsentan|Monotherapy
11579171|NCT00795639|Placebo Comparator|Sitaxsentan Placebo|Monotherapy
11579172|NCT00795626|Experimental|Lifestyle counseling|"Two groups:
~control - conventional care
~intervention - systematic education in the reduction of the risk estimate to cardiovascular events"
11579173|NCT00795613|Experimental|PET pos|Patients With Interim Pet Positive Proceed To Escalated Beacopp Regimen
11579174|NCT00795613|Other|PET negative|Patients With Interim-Pet Negative Continue The Conventional ABVD Regimen
11579175|NCT00795600|Experimental|insulin detemir|Insulin detemir injected subcutaneously (s.c.) in the evening in combination with insulin aspart injected s.c. as mealtime insulin for 26 weeks
11579176|NCT00795600|Active Comparator|insulin NPH|Insulin isophane (Neutral Protamine Hagedorn, NPH) injected subcutaneously (s.c.) in the evening in combination with insulin aspart injected s.c. as mealtime insulin for 26 weeks
11579177|NCT00795587|Active Comparator|mannitol high dose|mannitol 20% 0,8 g/ kg on minutes
11579178|NCT00795587|Active Comparator|mannitol low dose|mannitol 20% 0,4 g/ kg on minutes
11579179|NCT00795574|Experimental|infliximab|Double blind placebo cross-over
11579180|NCT00795574|Placebo Comparator|Placebo|Double blind placebo controlled cross-over
11579181|NCT00795561|Experimental|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
11579182|NCT00795561|Active Comparator|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
11579183|NCT00795548|Experimental|5-Azacitidine|5-Azacitidine in addition to standard donor lymphocyte infusions.
11579184|NCT00795522|Experimental|Arm 1|Desloratadine
11579185|NCT00795509||Tolterodine tartrate.|Patients taking Tolterodine tartrate.
11579186|NCT00795496||AD patients|AD patients who fulfill the inclusion criteria for the study
11579187|NCT00795483|Experimental|1-ANNUAL|1. Zoledronic acid + Lifestyle modifications (experimental)
11579188|NCT00795483|Other|2-CONTROL|2. Lifestyle modifications (control)
11579189|NCT00795483|Experimental|3-BIENNIAL|3. Zoledronic acid + Lifestyle modifications (experimental)
11579190|NCT00795470|No Intervention|No catheter change no antimicrobial|Urinary catheter will not be changed and no antimicrobials will be prescribed
11579191|NCT00795470|Active Comparator|Antimicrobial and catheter change|
11579192|NCT00795470|Active Comparator|Catheter change and NO antimicrobial|
11579193|NCT00795470|Active Comparator|Antimicrobial and NO catheter change|
11579194|NCT00795457|Experimental|1|Patients must have undergone surgery or biopsy alone ≤16 weeks prior to study entry (no postoperative radiation or chemotherapy).
11579195|NCT00795457|Experimental|2|Patients received surgery or biopsy and radiation therapy (RT) (including fractionated external beam radiation therapy and/or stereotactic radiosurgery), which was completed ≥6 months prior to enrollment, and have a baseline MRI scan (within 4 weeks of the first vaccine) that shows stable disease or regression.
11579196|NCT00795444|Experimental|Maraviroc|Adult patients with HIV infection and a viral load that has been suppressed for a long period (less than 50 copies/mL for at least 2 years) while on antiretroviral therapy.The treatment group will maintain the habitual antiretroviral therapy combined with maraviroc.
11579197|NCT00795418|Experimental|CAD106|
11579198|NCT00795418|Placebo Comparator|Placebo|
11579199|NCT00795405|Sham Comparator|1|No exposure to sporting events
11579200|NCT00795405|Experimental|2|Exposure to sporting events
11579201|NCT00795392||1|Patients assessed with ASA physical status scale
11579202|NCT00795392||2|Patients assessed with full-scale psychological factors
11579203|NCT00795379|Experimental|IE|Participants will complete an at home four-week, intervention targeting their negative cognitions triggered by physical sensations. The goal of IE is to purposefully induce bodily sensations related to autonomic arousal so that participants can learn that those sensations are not harmful. IE and Cognitive restructuring have been found to be superior to progressive muscle relaxation as a way to avoid aversive autonomic sensations.
11579204|NCT00795379|No Intervention|2|waitlist control
11579205|NCT00795366|Active Comparator|AVP, arginine vasopressin|Vasopressin
11579206|NCT00795366|Active Comparator|Standard Catecholamine|levophed, dopamine, phenylephrine)
11579207|NCT00795353||1. Amevive Exposure|Canadian subjects with moderate to severe chronic plaque psoriasis
11579208|NCT00795340|Experimental|Arm I Cediranib|Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
11579209|NCT00795340|Placebo Comparator|Arm II Placebo|Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.
11579210|NCT00795327|Experimental|1|single arm study
11579211|NCT00795314|Active Comparator|1|Propofol-fentanyl combined anesthesia
11579212|NCT00795314|Experimental|2|Propofol-butorphanol combined anesthesia
11579213|NCT00795288|Experimental|Simvastatin, 80 mg/day|Simvastatin, 80 mg/day for 21 days
11579214|NCT00795288|Placebo Comparator|Placebo|Placebo
11579215|NCT00795275|Experimental|IFG|people with impaired fasting glucose
11579216|NCT00795275|Experimental|NGT|people with normal glucose tolerance
11579218|NCT00795262|Active Comparator|Active comparator|Quinapril 40 mg plus Alpha Lipoic Acid (ALA)on vascular effects of patients with diabetes and hypertension
11579219|NCT00795249|Experimental|smoker|Individuals who have a habit of chronic smoking without any coronary risk factors
11579220|NCT00795249|No Intervention|non-smoker|the age-matched healthy volunteers
11579221|NCT00795236|No Intervention|Observational|Observe to determine free-running versus entrained status.
11579222|NCT00795236|Experimental|Melatonin|Subjects with free-running rhythms will take melatonin.
11579223|NCT00795223|Active Comparator|1|Injection of 0.3 mg morphine with spinal block and perform femoral nerve block with 0.5% bupivacaine
11579224|NCT00795223|Active Comparator|2|Injection of 0.3 mg morphine with spinal block and perform femoral nerve block with 0.25% bupivacaine
11579225|NCT00795223|Active Comparator|3|Injection of 0.2 mg morphine with spinal block and perform femoral nerve block with 0.5% bupivacaine
11579226|NCT00795223|Active Comparator|4|Injection of 0.2 mg morphine with spinal block and perform femoral nerve block with 0.25% bupivacaine
11579227|NCT00795210|Experimental|GH 6mcg/kg/d|Recombinant human growth hormone 6mcg/kg SC once daily
11579228|NCT00795210|Experimental|GH 2mg daily|Recombinant human growth hormone 2mg SC once daily
11579229|NCT00795210|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks
11579230|NCT00795197||Screening Group|Screening Group
11579231|NCT00795184|Other|Imaging Procedures HDWLE first NBI second and pCLE|All patients undergo both endoscopic imaging procedures and then the endomicroscopy procedure; the endoscopic imaging procedures being performed back to back by two endoscopists, blinded to each other.
11579232|NCT00795184|Other|Imaging Procedures NBI first HDWLE second and pCLE|All patients undergo both endoscopic imaging procedures and then the endomicroscopy procedure; the endoscopic imaging procedures being performed back to back by two endoscopists, blinded to each other.
11579233|NCT00795171|Experimental|Docetaxel + Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
11579234|NCT00795171|Active Comparator|Taxotere|docetaxel 75mg/m2 day1 q 21d x 4 cycles
11579235|NCT00795158|Experimental|Arm 1|
11579236|NCT00795145|Placebo Comparator|Cohort 1: Placebo|
11579237|NCT00795145|Experimental|Cohort 1: 900 mg linezolid|
11579238|NCT00795145|Experimental|Cohort 1: 1200 mg linezolid|
11579239|NCT00795145|Placebo Comparator|Cohort 2: Placebo|
11579240|NCT00795145|Experimental|Cohort 2: 600 mg linezolid|
11579241|NCT00795145|Experimental|Cohort 2: 1200 mg linezolid|
11579242|NCT00795145|Active Comparator|Cohort 2: 400 mg Moxifloxacin|
11579243|NCT00795132|Active Comparator|Related BM PBSC|Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor related to the participant/recipient
11579244|NCT00795132|Active Comparator|Unrelated BM PBSC|Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor unrelated to the participant/recipient
11579245|NCT00795132|Active Comparator|Unrelated Blood Cord|Blood Cord donated from a donor unrelated to the participant/recipient
11579246|NCT00795119|Experimental|NIRS|Children who undergo NIRS
11579247|NCT00795106|Active Comparator|Capsaicin patch|Patches will contain capsaicin 0.1% (500 mcg)
11579248|NCT00795106|Placebo Comparator|Placebo patch|Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing.
11579249|NCT00795093||1|552 GERD patients, partial responders to PPI treatment
11579250|NCT00795080||1|Normal volunteers who do not have malformations in their cerebral spinal fluid (CSF)
11579251|NCT00795080||2|Patients with incidentally discovered Chiari 1 DVS malformation of the cerebral spinal fluid (CSF)
11579252|NCT00795080||3|Patients with known Chiari or any other CVJ malformations undergoing a workup prior to surgery. Research images will be added to the clinically ordered exams ordered at 3 months and 1 year after surgery.
11579253|NCT00795067||Carotid atherosclerosis group|Patients who undergo carotid ultrasound examination for carotid atherosclerosis screening
11579254|NCT00795054||allogeneic stem cell recipients|Pediatric and adult allogeneic stem cell transplant recipients and their care givers.
11579255|NCT00795041||1|10 women with indication for ART with ICSI or IVF
11579256|NCT00795028|Active Comparator|1|Standard Care for people after a hip fracture
11579257|NCT00795028|Experimental|2|Standard Care + exercise intervention
11579258|NCT00795015|Active Comparator|leuven|these patients had their IV insulin controlled by using the protocol adapted from van den Berghe et al. University of Leuven, Belgium, NEJM Nov. 2001
11579259|NCT00795015|Active Comparator|glucommander|these subjects had IV insulin controlled by a computer program called the glucommander described by Davidson, P et al Diabetes Care Oct. 2005
11579260|NCT00795002|Experimental|Arm I|Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 60-120 minutes on day 9.
11579261|NCT00795002|Experimental|Arm II|Patients receive alvocidib IV over 30 minutes followed by alvocidib IV over 4 hours on days 1-3. Patients also receive cytarabine and mitoxantrone hydrochloride as in arm I.
11579262|NCT00794989|Experimental|Arm 1: Intervention|Patients ingest ground flaxseed daily, with already prepared foods, for 6 months.
11579263|NCT00794989|Other|Arm 2: Observational|Patients do not receive ground flaxseed.
11579264|NCT00794976|Experimental|1|Dexamethasone Iontophoretic Patch (low dose)
11579265|NCT00794976|Experimental|2|Dexamethasone Iontophoretic Patch (high dose)
11579266|NCT00794976|Experimental|3|Dexamethasone Passive Patch
11579267|NCT00794976|Placebo Comparator|4|Placebo Patch
11579268|NCT00794963|Experimental|Integrated care|Provide on-site internal medicine evaluation, treatment and follow up of metabolic syndrome for patients in Clozapine Clinic
11579269|NCT00794963|Other|Usual Care|Follow the 8-month outcome of schizophrenia patients with metabolic syndrome treated in the community
11579270|NCT00794950|Experimental|Sunitinib treatment|Intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma.
11579404|NCT00793832|Active Comparator|2|Diet Advice
11579405|NCT00793819|Experimental|1 Silodosin|
11579271|NCT00794924|Experimental|Probiotics, VSL#3|Acutely hospitalized elderly patients in a geriatric orthopedic rehabilitation department received commercially available probiotics (VSL#3) for 45 days.
11579272|NCT00794924|Placebo Comparator|Placebo|Acutely hospitalized elderly patients in a geriatric orthopedic rehabilitation department received placebo sachets for 45 days.
11579273|NCT00794911|Experimental|QOLT|Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions.
11579274|NCT00794911|Active Comparator|ST|Supportive Therapy (ST) 8 weekly individual counseling sessions
11579275|NCT00794911|No Intervention|Standard Care|
11579276|NCT00794898|Experimental|Arm 1|Remicade in the treatment of patients with active RA despite treatment with MTX.
11579277|NCT00794885|Experimental|Enalapril/folic acid|A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
11579278|NCT00794885|Active Comparator|Enalapril|Enalapril maleate 10 mg per day is given
11579279|NCT00794872||1|Patients with stage 3 CKD
11579280|NCT00794872||2|Patients with stage 4 CKD
11579281|NCT00794872||3|Patients without evidence for CDK
11579282|NCT00794846|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
11579283|NCT00794846|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
11579284|NCT00794820|Experimental|FCR-Multiple Dose Rituximab|Fludarabine phosphate + Cyclophosphamide + Rituximab
11579285|NCT00794807|Experimental|Alefacept|
11579286|NCT00794794|Experimental|Desloratadine and Cetirizine Crossover|To compare the preference in taste between desloratadine and cetirizine.
11579287|NCT00794781|Experimental|1|
11579288|NCT00794768|Experimental|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
11579289|NCT00794768|Experimental|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
11579290|NCT00794755|Active Comparator|Vitamin K|
11579291|NCT00794755|Placebo Comparator|Placebo|
11579292|NCT00794742||Burn Wounds|Patients with burn wounds
11579293|NCT00794716|Experimental|NRL972|
11579294|NCT00794703|Experimental|1. Micafungin|
11579295|NCT00794703|Active Comparator|2. Itraconazole|
11579296|NCT00794690|Experimental|black cohosh extract, liver|100 postmenopausal women
11579297|NCT00794677|Placebo Comparator|Sugar Pill|Placebo medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
11579298|NCT00794677|Experimental|ezetimibe|10 mg medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
11579299|NCT00794664|Placebo Comparator|Placebo|Weekly subcutaneous injections for 26 weeks
11579300|NCT00794664|Experimental|Mipomersen|200 mg weekly subcutaneous injections for 26 weeks
11579301|NCT00794651||OA|moderate to severe osteoarthritis of the knee
11579302|NCT00794625|Experimental|1|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add valproate and behavioral family counseling to their treatment during Phase 2. If they do not respond to valproate, they will be switched to risperidone.
11579303|NCT00794625|Experimental|2|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add risperidone and behavioral family counseling to their treatment during Phase 2. If they do not respond to risperidone, they will switch to valproate.
11579304|NCT00794625|Placebo Comparator|3|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add placebo and behavioral family counseling to their treatment during Phase 2.
11579305|NCT00794612|Experimental|1|Dermacyd Femina Pocket BR (Lactic Acid)
11579306|NCT00794599|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
11579307|NCT00794599|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
11579308|NCT00794586|Experimental|FTI 80mg/20mg BID|Fosfomycin/Tobramycin combination 80mg/20 mg inhaled twice daily
11579309|NCT00794586|Experimental|FTI 160mg/40mg BID|Fosfomycin/Tobramycin combination 160 mg/40 mg inhaled twice daily
11579310|NCT00794586|Placebo Comparator|Placebo A BID|Placebo A inhaled twice daily
11579311|NCT00794586|Placebo Comparator|Placebo B BID|Placebo B inhaled twice daily
11579312|NCT00794573|Experimental|Varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
11579313|NCT00794573|Placebo Comparator|Sugar pill|placebo for 0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
11579314|NCT00794560|Experimental|clinical setting: intervention|"Recruitment of patients in the hospital into the randomized intervention group. Intervention is done by a trained pharmacist/Doctor of Philosophy-student in the study center (a pharmacy) or at patient's bedside in the hospital.
~Intervention: patient education"
11579315|NCT00794560|No Intervention|clinical setting: standard care|Recruitment of patients in the hospital into the randomized control group (standard care in community pharmacy)
11579316|NCT00794560|Experimental|daily life setting: intervention|"Recruitment of patients in trained community pharmacies into the intervention group. Intervention is done by trained pharmacists.
~Intervention: patient education"
11579317|NCT00794560|No Intervention|daily life setting: standard care|Recruitment of patients in community pharmacies into control group (standard care in community pharmacy)
11579318|NCT00794547|Experimental|1|In the Phase I part of the study, we will test the safety of calcitriol along with standard chemotherapy. In addition, the goal is to see what effects (good and bad) it has on you and your type of Non-Small Cell Lung Cancer. This study is ongoing. In this portion of the study, we are testing increasing doses of calcitriol in combination with standard chemotherapy. If 2/3 patients at any dose level experience side effects that are limiting, we will call the dose level below that dose the maximum tolerated dose.
11579319|NCT00794547|Experimental|2|In the Phase II part of the study, we will find out the response of subjects' cancer has to the combination of a fixed dose of calcitriol (determined in the phase I study) with standard chemotherapy.
11579320|NCT00794508|Experimental|Retroviral-mediated ADA gene transfer|Transfer of the human ADA gene to isolated CD34+ cells from the bone marrow.
11579321|NCT00794495|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
11579322|NCT00794495|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
11579323|NCT00794469||Water|obese children (body mass index > 95th percentile for age and sex) that will drink cold water
11579324|NCT00794456|Experimental|1|Association of Passiflora incarnata L; Crataegus Oxyacantha L and Salix alba L.
11579325|NCT00794456|Active Comparator|2|Valeriana officinalis 50 mg
11579326|NCT00794443|Experimental|1. Monthly - Dose 1|Monthly intermittent administration, dose 1
11579327|NCT00794443|Experimental|2. Monthly - Dose 2|Monthly intermittent administration, dose 2
11579328|NCT00794443|Active Comparator|3. Daily|Daily administration
11579329|NCT00794430|Experimental|V3381|V3381: titrated from 100 mg bid to maximum 400 mg bid over 4 weeks followed by maintenance phase at highest tolerated dose. Total duration of treatment 13 weeks.
11579330|NCT00794430|Placebo Comparator|Placebo|Placebo to match V3381, 100 mg, given according to the same regimen.
11579331|NCT00794417|Experimental|1|
11579332|NCT00794391|Experimental|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller & Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
11579333|NCT00794391|Active Comparator|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
11579334|NCT00794378|Experimental|Desloratadine and Cetirizine Crossover|To compare the preference in taste between desloratadine and cetirizine.
11579335|NCT00794365||Open-label|
11579336|NCT00794352||Healthy Volunteer|Healthy patients with NO inflammatory and/or demyelinating/dysmyelinating diseases of theCN
11579337|NCT00794352||Patient Cohort|Patients who present with CNS white matter injury (including inflammatory and/or demyelinating/dysmyelinating diseases of the CNS)
11579338|NCT00794339|Experimental|Copper ATSM|pre-therapy pelvic 64Cu-ATSM-PET/CT with Pre- and post- therapy FDG PET/CT
11579339|NCT00794326|Experimental|PDsol 12|Treatment with a peritoneal dialysis solution containing a low concentration of sodium.
11579340|NCT00794326|Active Comparator|Gambrosol trio 40|Treatment with the peritoneal dialysis solution Gambrosol trio 40 isotonic bag (1.5%)
11579341|NCT00794313|Experimental|Amantadine|
11579342|NCT00794313|Experimental|Amantadine plus Topiramate|
11579343|NCT00794313|Placebo Comparator|Sugar Pill|
11579344|NCT00794300||Acute myocardial infarction patients|
11579345|NCT00794287||1|Hymenoptera allergic patients before allergen specific immunotherapy
11579346|NCT00794287||2|Hymenoptera allergic patients after allergen specific immunotherapy
11579347|NCT00794274|Experimental|Open label drug|"Drug: CC-100004
~After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis"
11579348|NCT00794261|Experimental|Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
11579349|NCT00794261|Active Comparator|Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN > 0.5 G/L)
11579350|NCT00794248|Experimental|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
11579351|NCT00794248|Experimental|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
11579352|NCT00794235|Other|Sorafenib and Dacarbacine|
11579353|NCT00794222|Experimental|Mood monitoring|The mobiletype monitoring intervention group will monitor their current activities, current mood, responses to negative mood, any recent stressors and coping strategies. Other activities monitored include eating patterns, exercise patterns, quantity and quality of sleep and alcohol and cannabis use.
11579354|NCT00794222|No Intervention|Comparison monitoring program|"The mobiletype monitoring comparison group will monitor their current activities, eating patterns, exercise patterns, quantity and quality of sleep and alcohol and cannabis use.
~This program excludes questions about mood, stress and coping strategies."
11579355|NCT00794209|Experimental|1|
11579356|NCT00794196|No Intervention|Usual Care|The control group will be receiving usual medical and pharmaceutical care.
11579357|NCT00794196|Experimental|Intervention Group|Intervention group will be receiving usual medical and pharmaceutical care plus a pharmaceutical support program.
11579358|NCT00794183|Active Comparator|1|AVD set by taking the larger of 0.50ms or A-V interval 0.30
11579359|NCT00794183|Active Comparator|2|AVD set by taking the larger of 0.50ms or A-V interval 0.50
11579360|NCT00794183|Active Comparator|3|AVD set by taking the larger of 0.50ms or A-V interval 0.70
11579402|NCT00793845|Experimental|High risk neuroblastoma|"Conventional chemotherapy (9 cycles)
~Surgery conventional chemotherapy (after 6 cycles of chemotherapy)
~Tandem HDCT/autoSCT
~First HDCT (cyclophosphamide, etoposide, carboplatin)
~Second HDCT (total body irradiation, thiotepa, melphalan)
~Local radiotherapy
~Retinoic acid, interleukin-2"
11579361|NCT00794170|Experimental|Telephone and print based intervention|The I-SIGHT intervention consists of twelve interactive voice recognition (IVR) phone calls over a nine-month period and accompanying printed materials that are mailed to participants following each call. The phone call messages and print materials are tailored to individuals' circumstances using data from the screening and baseline interviews. The intervention is based on theoretical constructs from Social Cognitive Theory and the Health Belief Model, and emphasizes self-efficacy, medication taking skills, outcome expectancies, facilitators and barriers to compliance, and social support. The treatment group receives the tailored telephone intervention and mailed, printed materials.
11579362|NCT00794170|No Intervention|Usual care|The control group received usual care at each clinical site and interacted with study personnel only for data collection.
11579363|NCT00794157|Experimental|Indacaterol 150 µg|Patients received indacaterol 150 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11579364|NCT00794157|Experimental|Indacaterol 300 µg|Patients received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11579365|NCT00794157|Placebo Comparator|Placebo|Patients received placebo delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11579366|NCT00794144|Experimental|1|Olopatadine Hydrochloride Nasal Spray 0.6%
11579367|NCT00794144|Placebo Comparator|2|Olopatadine Hydrochloride Nasal Spray Vehicle
11579368|NCT00794118||1.0|As per routinary clinical practice
11579369|NCT00794105||Normal ears|
11579370|NCT00794105||Otitis media ears.|
11579371|NCT00794092|Experimental|Sinerem|MRI scanning of patients with AAA before and 24hrs +/- 4hrs after administration of Sinerem
11579372|NCT00794079|Experimental|A|omega-3 fatty acids
11579373|NCT00794079|Placebo Comparator|B|corn oil
11579374|NCT00794066||1|TIA
11579375|NCT00794066||2|Ischemic stroke
11579376|NCT00794066||3|Hemorrhagic stroke
11579377|NCT00794053|Experimental|study group|The members in this group will undergo intervention by having surgery and lymph node detection by dye staining
11579378|NCT00794040|Active Comparator|Add-on citalopram following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
11579379|NCT00794040|Placebo Comparator|Add-on placebo after optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
11579380|NCT00794027|Other|Yoga group|Patients with heart failure
11579381|NCT00794014|Experimental|Conservative strategy|
11579382|NCT00794014|Experimental|Aggressive strategy|
11579383|NCT00794001|Experimental|Data Feedback|The intervention is systematic feedback on performance (using predefined quality indicators) to cardiology, ED, and EMS-stakeholders and staff.
11579384|NCT00793988|Active Comparator|1|Group receiving vibration-assisted anaesthesia
11579385|NCT00793988|Placebo Comparator|2|Group receiving switched-off vibrating device
11579386|NCT00793975|Experimental|IMC-1121B|"All patients will receive intravenous infusions of IMC-1121B with the dose depending on which cohort they are enrolled into. A minimum of three patients will be enrolled in each cohort.
~A completed patient will be either a patient who completes the 4-week treatment cycle and 2-week observation period (for a total of 6 weeks), or a patient who discontinues therapy for an IMC-1121B-related toxicity. Toxicity data for each cohort will be reviewed prior to dose escalation.
~When all patients complete a cohort, dose escalation to the next cohort will occur."
11579387|NCT00793962|Experimental|hypofractionation radiotherapy|breast cancer women with mastectomy high-risk: T3-4 and/or 4 or more axillary nodes involvement postmastectomy hypofractionation radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
11579388|NCT00793962|Active Comparator|conventional fractionation radiotherapy|breast cancer women with mastectomy high-risk with T3-4 and/or 4 or more axillary nodes postmastectomy conventional fractionation radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
11579389|NCT00793923|Experimental|Combination Therapy|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
11579390|NCT00793923|Active Comparator|Monotherapy|intravitreal injection of 0.5 mg ranibizumab
11579391|NCT00793910|Active Comparator|Gabapentin|oral medication
11579392|NCT00793910|Placebo Comparator|placebo|
11579393|NCT00793897|Experimental|Sequential allocation of patients in two dosing schedules|
11579394|NCT00793884||Diabetes Education|Latino individuals with diabetes who are attending the Emory Latino Diabetes Education Program (ELDEP) will be followed in order to collect outcomes on clinical measurements. The class curriculum follows the American Association of Diabetes Educators (AADE) seven self-care behaviors: healthy eating, being active, monitoring, medication use, problem-solving and healthy coping. Program participants attend an initial 3 hour diabetes education class conducted in Spanish and then are invited to return to monthly follow-up sessions covering topics of meal planning, exercise, medications and complications. The follow-up sessions include activities such as dance lessons, cooking demonstrations, and sharing.
11579395|NCT00793871|Experimental|sunitinib|single agent sunitinib, single arm
11579396|NCT00793858|Active Comparator|1|placebo in left nostril, isotonic ciclesonide in right
11579397|NCT00793858|Active Comparator|2|hypotonic ciclesonide in left nostril, placebo in right
11579398|NCT00793858|Active Comparator|3|hypotonic ciclesonide in right and left nostrils
11579399|NCT00793858|Active Comparator|4|isotonic ciclesonide in both right and left nostrils
11579400|NCT00793858|Placebo Comparator|6|placebo in both right and left nostrils
11579406|NCT00793819|Placebo Comparator|2 Placebo|
11579407|NCT00793806||Medical Tool|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
11579408|NCT00793793|Experimental|20mg|patient to receive 20mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
11579409|NCT00793793|Experimental|48mg|patient to receive 48mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
11579410|NCT00793793|Experimental|120mg|patient to receive 120mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
11579411|NCT00793793|Experimental|240mg|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
11579412|NCT00793793|Placebo Comparator|Placebo|
11579413|NCT00793780|Active Comparator|Naltrexone 25mg|
11579414|NCT00793780|Placebo Comparator|Placebo|
11579415|NCT00793767|Placebo Comparator|placebo|placebo
11579416|NCT00793767|Experimental|Erythropoietin|acute administration of erythropoietin
11579417|NCT00793754|No Intervention|1|
11579418|NCT00793754|Experimental|2|Aspirin 100 mg / day
11579419|NCT00793754|Experimental|3|Atorvastatin 40 mg / day
11579420|NCT00793754|Experimental|4|Aspirin 100 mg / day + Atorvastatin 40 mg / day
11579421|NCT00793741||1|Type 1 Diabetes Hypoglycemia unawareness Islet transplant candidate
11579422|NCT00793741||2|Healthy control subjects
11579423|NCT00793728|Active Comparator|Antrectomy|
11579424|NCT00793728|Active Comparator|Without antrectomy|
11579425|NCT00793715|Active Comparator|1|Decompressive laparotomy with temporary abdominal closure
11579426|NCT00793715|Active Comparator|2|Patients who will receive percutaneous puncture with placement of abdominal catheter
11579427|NCT00793702|Experimental|A|two injections 0.01 µg rdESAT-6 + rCFP-10 (6 weeks interval)
11579428|NCT00793702|Experimental|B|two injections 0.01 µg rdESAT-6 + rCFP-10 (12 weeks interval)
11579429|NCT00793702|Experimental|C|two injections 0.1 µg rdESAT-6 + rCFP-10 (6 weeks interval)
11579430|NCT00793702|Experimental|D|two injections 0.1 µg rdESAT-6 + rCFP-10 (12 weeks interval)
11579431|NCT00793702|Experimental|E|one injection 1.0 µg rdESAT-6 + rCFP-10
11579432|NCT00793689||total thyroidectomy|patients undergoing total thyroidectomy
11579433|NCT00793676|Other|A= Asthma|
11579434|NCT00793676|Other|B= COPD|
11579435|NCT00793676|Other|C= Control|
11579436|NCT00793663|Experimental|1|The effect of xenon as an anaesthetic on the depth of hypnosis.
11579437|NCT00793663|Active Comparator|2|The effect of sevoflurane as an anesthetic on the depth of hypnosis
11579438|NCT00793663|Experimental|3|Dexamethasone as prevention of postoperative nausea and vomiting after xenon or sevoflurane anesthesia
11579439|NCT00793663|Placebo Comparator|4|
11579440|NCT00793663|Experimental|5|Ondansetron, to determine the onset-time of ondansetron when used as rescue medication for postoperative nausea and vomiting
11579441|NCT00793663|Placebo Comparator|6|
11579442|NCT00793650|Active Comparator|Bortezomib before Melphalan|Enrolled patients were randomized to receive a single escalating dose of bortezomib (1.0, 1.3, or 1.6 mg/m2) 24 hours before melphalan.
11579443|NCT00793650|Active Comparator|Bortezomib after Melphalan|Enrolled patients were randomized to receive a single escalating dose of bortezomib (1.0, 1.3, or 1.6 mg/m2) 24 hours after melphalan.
11579444|NCT00793637||Surgical|Patients with proximal and/or distal tibial, femoral and/or humeral fractures treated with intramedullary nails and the Angular Stable Locking System(ASLS)
11579445|NCT00793624|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
11579446|NCT00793624|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
11579447|NCT00793624|Active Comparator|Formoterol 12mcg|12mcg inhaled twice daily from the Aerolizer inhaler
11579448|NCT00793624|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
11579449|NCT00793611|Active Comparator|Behavioral therapy|"Behavioral Therapy standard of care (which consists of bladder drills, voiding diaries, timed voiding and pelvic floor exercises)"
11579450|NCT00793611|Experimental|hypnotherapy|patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatments for overactive bladder
11579451|NCT00793598|Experimental|CMX001|Cohort 3A 40 mg of CMX001 given on Days 0, 7, 14, 21, and 28 Cohort 4A 100 mg of CMX001 given twice weekly for a total of 9 doses Cohort 4B 200 mg of CMX001 given once or twice weekly Cohort 4C 300 mg of CMX001 given once or twice weekly
11579452|NCT00793598|Placebo Comparator|Placebo|Cohort 3A once weekly for a total of 5 doses Cohort 4A twice weekly for a total of 9 doses Cohort 4B once or twice weekly Cohort 4C once or twice weekly
11579453|NCT00793585|Experimental|Allopurinol|Allopurinol group:allopurinol, 100-300mg/d according to the levels of Scr(serum creatinine) and UA(uric acid), for those Scr < 1.5mg/dl (133 umol/L) at the baseline, allopurinol was given 100 mg three times daily.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
11579454|NCT00793585|Other|Control group|Control group:(patient in this group were received health education and were encouraged to adhere to a low-purine diet and continue their usual therapy.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
11579455|NCT00793572|Experimental|Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy|See Detailed Description
11579456|NCT00793559|Active Comparator|terlipressin bolus|1 mg of terlipressin received one time only
11579457|NCT00793559|Experimental|terlipressin drip|
11579458|NCT00793546|Experimental|1|combination of bosutinib and exemestane
11579459|NCT00793546|Active Comparator|2|exemestane
11579460|NCT00793520|Experimental|1|Twice daily oral administration of milnacipran for 5 weeks, placebo for 2 weeks, and crossover to placebo for 5 weeks.
11579461|NCT00793520|Experimental|2|Twice daily oral administration of placebo for 5 weeks, placebo for 2 weeks, and crossover to milnacipran for 5 weeks.
11579609|NCT00792389|Experimental|1|Patients receiving warmed, humidified gas
11579462|NCT00793507|Experimental|1: Intervention Group|All participants in the intervention group will be receiving standard preventive dental care received by children in their dental providers' office. These intervention children will receive dental scaling, cleaning and fluoride varnish at visits every three to six months. All participants in the intervention group will receive active reminder/recall from the hygienist, encouraging the participants to return every three to six months for the oral exam, cleaning, scaling and fluoride application.
11579463|NCT00793507|Active Comparator|2: Control Group|The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist.
11579464|NCT00793494|Experimental|Probaclac|Administration of Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™) b.i.d.
11579465|NCT00793494|Placebo Comparator|Placebo|
11579466|NCT00793481||Diagnostic tool|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
11579467|NCT00793468|Placebo Comparator|Placebo Arm|Subjects in placebo arm will be taking placebo once daily for 12 weeks from week 5 to 16.
11579468|NCT00793468|Experimental|GSK598809 Arm|Subjects in GSK598809 arm will be taking GSK598809 once daily for 12 weeks from weeks 5 to 16.
11579469|NCT00793455|Experimental|Intervention Group|Received Educational Outreach
11579470|NCT00793455|No Intervention|Usual Care Control Group|Participants in this arm will receive normal care until outcome assessment is performed at 6 months following the placement of the order for the preventive service. They will be sent a letter reminding them to obtain the ordered preventive service test.
11579471|NCT00793442||Novel Endothelial Markers Derivation|"Our study participants will come from the Protocolized Care for Early Severe Sepsis (ProCESS) trial will be eligible participants.
~From the ProCESS subjects, the researchers will include those who were: 1) recruited by participating centers who participated in other components of this ancillary study or 2) who were sequentially enrolled from periods derived from the beginning, middle, and end of the ProCESS study."
11579472|NCT00793442||Novel Endothelial Marker Validation|Our study participants will come from the Protocolized Care for Early Severe Sepsis (ProCESS) trial will be eligible participants; the researchers will recruit a sequential 300 patient validation set.
11579473|NCT00793416|Experimental|ShuntCheck measure|All patients will have ShuntCheck measurements along with radionuclide shunt patency testing.
11579474|NCT00793403||1|As per routine clinical care
11579475|NCT00793390||inflammatory breast cancer cases|inflammatory breast cancer cases
11579476|NCT00793390||non-inflammotory breast cancer cases|non-inflammatory breast cancer cases
11579477|NCT00793390||visitor controls without cancer|visitor controls without breast cancer- those visiting cancer patients
11579478|NCT00793377|Experimental|ADOC x 4 + Tam 20|Adriamycin will be given at a dose of 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles. Adriamycin will be administered as a short i.v. infusion over 15 minutes, followed immediately by a 1-hour infusion of docetaxel diluted in 250 mL NaCl. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
11579479|NCT00793377|Experimental|AC x 4 - Doc x 4 + Tam 20|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy
11579480|NCT00793364|Active Comparator|Stanol ester|Stanol-ester administration group
11579481|NCT00793364|Placebo Comparator|Placebo spread|Placebo spread group
11579482|NCT00793364|Other|Mediterranean diet group|Mediterranean diet group
11579483|NCT00793338|Experimental|Sildenafil|All patients will receive open-label treatment with sildenafil.
11579484|NCT00793325||Somatropin|Patients administered Somatropin.
11579485|NCT00793299|Experimental|Video Illness Narrative|single arm pilot study
11579486|NCT00793286|Other|A|Mesh fixation by staples
11579487|NCT00793286|Other|B|Mesh fixation by glue
11579488|NCT00793273||A|
11579489|NCT00793260|Active Comparator|Usual Support Group|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
11579490|NCT00793260|Experimental|Enhanced Support Group|The Enhanced-Support Group intervention used more sophisticated predictive models, more extensive outreach to engage individuals, and provided tighter feedback loops to inform the care support process.
11579491|NCT00793234|Experimental|1|0.3 mg/kg TB-402
11579492|NCT00793234|Experimental|2|0.6 mg/kg TB-402
11579493|NCT00793234|Experimental|3|1.2 mg/kg TB-402
11579494|NCT00793234|Active Comparator|4|
11579495|NCT00793221|Other|Sirolimus-eluting stent|Implantation of sirolimus-eluting coronary stent
11579496|NCT00793221|Active Comparator|Everolimus-eluting stent|Implantation of everolimus-eluting coronary stent
11579497|NCT00793208|Experimental|Vaccine|vaccine composed of lethally irradiated semi-allogeneic human fibroblasts transfected with genomic tumor DNA from the patient's own tumor
11579498|NCT00793195|Active Comparator|1) Intralipid|Fat Emulsions for Intravenous Nutrition
11579499|NCT00793195|Experimental|2) SMOFlipid|Fat Emulsions for Intravenous Nutrition
11579500|NCT00793182|Active Comparator|1|Ioversol 320 mgI/mL
11579501|NCT00793182|Active Comparator|2|Iodixanol 320 mgI/mL
11579502|NCT00793169||lidocane|Patients undergoing Mohs micrographic surgery of the face or neck will have their blood drawn before, during, and after the procedure.
11579503|NCT00793156|Placebo Comparator|Placebo|Patients will be randomized into Placebo group
11579504|NCT00793156|Active Comparator|2|2.5 µg group randomized
11579505|NCT00793156|Active Comparator|3|5.0 µg group randomized
11579506|NCT00793143||Sleeve|
11579507|NCT00793143||Bypass|
11579610|NCT00792389|Active Comparator|2|Patients receiving cool, day gas
11579611|NCT00792376|Experimental|etoricoxib|etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
11579508|NCT00793130|Other|Coltect|Coltect contains natural compounds: curcumin, green tea and selenium which are approved as food supplements by the Ministry of Health in Israel. Curcumin and green tea are widely used in the food industry.
11579509|NCT00793117|Experimental|1|poly vinil chloride packing
11579510|NCT00793104|Other|CR Plug|Placement of allograft CR Plug in primary injury site
11579511|NCT00793091|Active Comparator|1|
11579512|NCT00793091|Placebo Comparator|2|
11579513|NCT00793065||1|Physicians that are using paper-based medical charts and who are not receiving Medical Home redesign incentives.
11579514|NCT00793065||2|Physicians that are using Electronic Health Records (EHRs) and who are not undergoing Medical Home redesign.
11579515|NCT00793065||3|Physicians that are using Electronic Health Records (EHRs) and undergoing Medical Home redesign.
11579516|NCT00793052|Experimental|A|
11579517|NCT00793026|Experimental|1|Dermacyd Breeze Pocket BR (Lactic Acid)
11579518|NCT00793013|Experimental|ARDS Net Low Tidal Volume|
11579519|NCT00793013|Experimental|APRV Ventilation|
11579520|NCT00793000|Experimental|Cohort 1|
11579521|NCT00793000|Experimental|Cohort 2|
11579522|NCT00793000|Experimental|Cohort 3|
11579523|NCT00793000|Experimental|Cohort 4|
11579524|NCT00793000|Experimental|Cohort 5|
11579525|NCT00793000|Experimental|Cohort 6|
11579526|NCT00793000|Experimental|Cohort 7|
11579527|NCT00793000|Experimental|Cohort 8|Japanese volunteers, low dose previously tested (based on PK)
11579528|NCT00793000|Experimental|Cohort 9|Japanese volunteers, intermediate dose previously tested (based on PK)
11579529|NCT00793000|Experimental|Cohort 10|Japanese volunteers, high dose previously tested (based on safety)
11579530|NCT00792974||COPD by GOLD-criteria III and IV|
11579531|NCT00792961|Experimental|Endomicroscopy|Endomicroscopy is performed in addition to the patient's indicated robot-assisted prostate surgery
11579532|NCT00792948|Experimental|Treatment (chemotherapy, transplant, maintenance)|See Detailed Description
11579533|NCT00792935|Experimental|MK-0941|
11579534|NCT00792935|Active Comparator|Glimepiride|
11579535|NCT00792922|Active Comparator|≥90% coverage with azithromycin target|Selected communities will receive mass treatment annually for three years.
11579536|NCT00792922|Active Comparator|80%-89% coverage with azithromycin target|Selected communities will receive mass treatment annually for three years.
11579537|NCT00792922|Active Comparator|≥90% coverage with azithromycin , treatment based|"Treatment to be administered at baseline then continued yearly if trachoma prevalence is greater than 5%
~In Niger, treatment will be every 6-months for children ages twelve and under."
11579538|NCT00792922|Active Comparator|80%-89% coverage with azithromycin : treatment based|"Treatment to be administered at baseline then continued yearly if trachoma prevalence is greater than 5%
~In Niger, treatment will be every 6-months for children ages twelve and under."
11579539|NCT00792909|Experimental|Synflorix™ Group 1|Subjects previously vaccinated with the Synflorix™ vaccine according to a 2+1 schedule, receiving one dose of Synflorix™ at 36-46 months of age.
11579540|NCT00792909|Experimental|Synflorix™ Group 2|Subjects previously vaccinated with the Synflorix™ vaccine according to a 3+1 schedule, receiving one dose of Synflorix™ at 36-46 months of age.
11579541|NCT00792909|Active Comparator|Unprimed Group|Age-matched subjects not previously vaccinated with any pneumococcal vaccine receiving two doses of Synflorix™ at 36-46 and 38-48 months of age. Age-matching was ensured by the enrolment of subjects 36-46 months of age.
11579542|NCT00792896|Experimental|1|Family conference + education materials
11579543|NCT00792896|No Intervention|2|education materials
11579544|NCT00792883||patients ARDS|142 Patients in respiratory failure with a diagnosis of ARDS hospitalized at the ICU.
11579545|NCT00792883||Patients non ARDS|432 patients in respiratory failure from other causes (ARDS being formally excluded), hospitalized at the same ICU.
11579546|NCT00792883||Healthy controls|626 healthy patients undergoing elective surgery at the Pediatric Surgery Department or recruited from the pediatric ambulatory.
11579547|NCT00792870|Experimental|SURI Enhanced|
11579548|NCT00792870|Active Comparator|SURI Standard|
11579549|NCT00792857|Experimental|CTAP201 Injection at dose a|CTAP201 at dose a
11579550|NCT00792857|Experimental|CTAP201 Injection|CTAP201 at dose b or dose c
11579551|NCT00792857|Active Comparator|Doxercalciferol at dose a|Active at dose a
11579552|NCT00792857|Active Comparator|Doxercalciferol|Active at dose b or dose c
11579553|NCT00792844|Experimental|Bio-K capsule|1 capsule of lactobacillus acidophilus and lactobacillus casei (50 billion live bacteria) daily for duration of antibiotic therapy and 7 days after or until discharge, whichever comes first
11579554|NCT00792844|Active Comparator|Bio-K liquid|98 g of lactobacillus acidophilus and lactobacillus casei (50 billion live bacteria) daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever comes first
11579555|NCT00792844|No Intervention|no Bio-K|No lactobacillus product - standard infection control procedures (i.e. handwashing, etc.)
11579556|NCT00792831|Experimental|ITF2357|
11579557|NCT00792818|Experimental|curcuma domestica|1,500 mg/day (oral) divided into 3 times for 28 days
11579558|NCT00792818|Active Comparator|Ibuprofen|1,200 mg/day (oral) divided into 3 times for 28 days
11579559|NCT00792805|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11579560|NCT00792805|Experimental|Indacaterol 300 μg|Patients inhaled indacaterol 300 μg via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11579612|NCT00792376|Active Comparator|diclofenac|diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
11579613|NCT00792350||Group 1|
11579874|NCT00790426|Experimental|FGFR3 wild type|
11579561|NCT00792805|Placebo Comparator|Placebo to indacaterol|Patients inhaled placebo to indacaterol via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11579562|NCT00792792||Tissue transfer skin flap|Modulated Imaging Spectroscopy
11579563|NCT00792766|Experimental|RAD001|
11579564|NCT00792753|Experimental|1. DESyne DES|Test arm: Intervention with DESyne Novolimus-Eluting Coronary Stent DESyne Novolimus Stent System
11579565|NCT00792753|Active Comparator|2. Medtronic Endeavor DES|Control arm: Intervention with Medtronic Endeavor Zotarolimus-Eluting Coronary Stent Medtronic Endeavor Coronary Stent System
11579566|NCT00792753|Experimental|3. DESyne BD DES|Test arm: Intervention with DESyne BD Novolimus-Eluting Coronary Stent DESyne BD Novolimus Stent System
11579567|NCT00792740|Placebo Comparator|Placebo capsules|"oral ITF2357 50 mg b.i.d.
~matching placebo Two parallel groups (1:1)"
11579568|NCT00792740|Experimental|ITF2357|"oral ITF2357 50 mg b.i.d.
~matching placebo Two parallel groups (1:1)."
11579569|NCT00792727|Experimental|Ketoprofen Patch|Treatment with experimental drug
11579570|NCT00792727|Placebo Comparator|Placebo Patch|Treatment with placebo drug
11579571|NCT00792701|Experimental|Arm II|Beginning within 84 days after surgery, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11579572|NCT00792688|Experimental|1|GLYC-101 Gel, 0.1% on one eyelid and Placebo Gel on the other eyelid
11579573|NCT00792688|Experimental|2|GLYC-101 Gel, 1.0% on one eyelid and Placebo Gel on the other eyelid
11579574|NCT00792688|Experimental|3|GLYC-101 Gel, 0.1% on one eyelid and GLYC-101 Gel, 1.0% on the other eyelid
11579575|NCT00792675|Experimental|Exercise|
11579576|NCT00792662|Experimental|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
11579577|NCT00792662|Placebo Comparator|Placebo|Standard inactive pill.
11579578|NCT00792649||1|screening colonoscopy with HD+ endoscopes
11579579|NCT00792649||2|screening colonoscopy with standardvideoendoscopes
11579580|NCT00792636|Experimental|sumatriptan and naproxen sodium combination|
11579581|NCT00792636|Active Comparator|sumatriptan|
11579582|NCT00792636|Active Comparator|naproxen sodium|
11579583|NCT00792623|Experimental|Varilrix Group|Subjects with autologous peripheral stem cell/bone marrow transplants, who received 2 doses of Varilrix vaccine subcutaneously in the deltiod region of the non-dominant upper arm, at 4.5 and 6.5 months post-transplantation.
11579584|NCT00792610|Experimental|Hepatitis B booster|They receive 3 doses of hepatitis B vaccine (Engerix-B Injection, recombinant HBsAg, 20mcg/ml/vial, GSK) at 0, 1st, 6th month during follow-up. Their anti-HBs status were checked at baseline, one week, one month, sixth month, and seven months later after the first dose of hepatitis B vaccine.
11579585|NCT00792597||spine or hip surgery|
11579586|NCT00792584|Experimental|1|patients treats with etravirine for 6 weeks
11579587|NCT00792584|Experimental|2|patients treats with efavirenz for 6 weeks
11579588|NCT00792571|Experimental|B.I.D|Beraprost Sodium Modified Release Tablets, 60mcg, b.i.d (twice a day dosing)
11579589|NCT00792571|Experimental|Q.I.D|Beraprost Sodium Modified Release Tablets, 60mcg, q.i.d (four times a day dosing)
11579590|NCT00792558|Experimental|Single Arm|
11579591|NCT00792532||iMRI|
11579592|NCT00792519|Experimental|CBT|group cognitive behavioral treatment
11579593|NCT00792519|Active Comparator|HIV support group|group support
11579594|NCT00792506|Experimental|ITF2357|
11579595|NCT00792493|Experimental|ORM-12741|
11579596|NCT00792493|Placebo Comparator|Placebo|
11579597|NCT00792480|Experimental|Intensive Counseling Group|
11579598|NCT00792480|No Intervention|Routine care group|"The routine care group took part in an initial physical exam and history, routine labs, and routine visits per American College of Obstetrics & Gynecology (ACOG) standards. The only counseling on diet and exercise during pregnancy was that included in our standard prenatal booklet What to do When You're Having a Baby by Gloria Mayer (Institute for Health Advancement, 2003, La Habra, CA). At each routine obstetric appointment, the participant's weight was measured recorded in the medical chart. The healthcare provider did not counsel the participant regarding any changes in diet or lifestyle."
11579599|NCT00792467|Experimental|ITF2357|"Patients will receive the following therapy cycle
~ITF2357, 50 mg every 6 hours, per os, days 1 - 3;
~Mechlorethamine, 6 mg/sqm, intravenously , day 4. Therapy will be administered every 21 days as long as there is no evidence of progressive disease or unacceptable toxicity, but in any case for a maximum of 12 cycles."
11579600|NCT00792454|Experimental|exercise training/renal rehabilitation|Experimental arm will undergo 12 weeks of training in exercise, meditation, and nutrition education.
11579601|NCT00792454|No Intervention|control|Control co-hort will receive usual chronic kidney disease care and no exercise, meditation or dietary education intervention.
11579602|NCT00792441|No Intervention|intervention group|Patients with mechanical ventilated who met the criteria for weaning from medical doctor in Srinagarind hospital, Khon Kaen University
11579603|NCT00792428|Active Comparator|Real-tDCS + PT-OT|Each subject will receive up to 5 days of traditional physical-occupational therapy for at least 1 hour per day in the stroke recovery laboratory in combination with real transcranial direct current stimulation (tDCS) over the motor region for up to 30 min.
11579604|NCT00792428|Sham Comparator|Sham-tDCS + PT-OT|Each subject will receive up to 5 days of traditional physical-occupational therapy for at least 1 hour per day in the stroke recovery laboratory in combination with sham (pretend) tDCS for up to 30 min. over the motor region.
11579605|NCT00792415||1|Limited continuous opioid exposure (at least 120 and less than 156 hours)
11579606|NCT00792415||2|Extended continuous opioid exposure (156 hours or more)
11579607|NCT00792402||1 control group|Computerized data collection of outcome measures in usual care
11579608|NCT00792402||2 intervention group|Computerized data collection of outcome measures and interviews to clinicians which are using a computerized Heart Failure guideline in their daily practice.
11579614|NCT00792337|Active Comparator|simvastatin|simvastatin in combination with budesonide
11579615|NCT00792337|Placebo Comparator|B1-6-12|Budesonide in combination with B1-6-12
11579616|NCT00792324|Active Comparator|Group 1|Four 100mg Etravirine tablets plus one Efavirenz (EFV) placebo tablet once daily
11579617|NCT00792324|Active Comparator|Group 2|One 600mg EFV tablet plus four Etravirine placebo tablet tablets once daily
11579618|NCT00792311|Experimental|Tsui test|Tsui test administration.
11579619|NCT00792298|Experimental|Suvorexant 10 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 10 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
11579620|NCT00792298|Experimental|Placebo → Suvorexant 10 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 10 mg suvorexant daily prior to bedtime during Treatment Period 2.
11579621|NCT00792298|Experimental|Suvorexant 20 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 20 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
11579622|NCT00792298|Experimental|Placebo → Suvorexant 20 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 20 mg suvorexant daily prior to bedtime during Treatment Period 2.
11579623|NCT00792298|Experimental|Suvorexant 40 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 40 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
11579624|NCT00792298|Experimental|Placebo → Suvorexant 40 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 40 mg suvorexant daily prior to bedtime during Treatment Period 2.
11579625|NCT00792298|Experimental|Suvorexant 80 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 80 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
11579626|NCT00792298|Experimental|Placebo → Suvorexant 80 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 80 mg suvorexant daily prior to bedtime during Treatment Period 2.
11579627|NCT00792285|Experimental|Automated Telephone Outreach|Automated Telephone Outreach with Speech Recognition
11579628|NCT00792285|No Intervention|Usual Care|Usual Care
11579629|NCT00792259||1|Patients with Retinal Disease
11579630|NCT00792259||2|Patients without Retinal Disease
11579631|NCT00792259||3|Normal Subjects
11579632|NCT00792246|Experimental|graft versus host disease|Patients receiving oral voriconazole will be switched to intravenous voriconazole. Pharmacokinetics will be determined after each formulation.
11579633|NCT00792246|Experimental|No graft versus host disease|Patients receiving oral voriconazole will be switched to intravenous voriconazole. Pharmacokinetics will be determined after each formulation.
11579634|NCT00792233|Experimental|1|Participants taking anti-TNF medications will be monitored for signs of their disease for 6 months. If, after 6 months, their disease has become inactive, they will stop taking anti-TNF medications for up to 8 months. If participants who are no longer taking anti-TNF medications have a disease flare-up, they will begin treatment again.
11579635|NCT00792220|Experimental|MSU|
11579636|NCT00792220|Active Comparator|OCCM|
11579637|NCT00792207|Experimental|Intervention|"Intervention Group:
~The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data recorded by an activity monitor."
11579638|NCT00792207|Active Comparator|Control|The control group will use an activity monitor and will have access to a website to monitor activity, but will not receive the Virtual Coach program.
11579639|NCT00792194|Experimental|training group|supervised training program 3 times a week with coach.
11579640|NCT00792194|No Intervention|group without training|a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.
11579641|NCT00792181|Experimental|1|Medical intervention - with benzodiazepines (Midazolam).
11579642|NCT00792181|Experimental|2|Course intervention - a professional development course for caregivers.
11579643|NCT00792181|Experimental|3|Combination of both medical interventions and a professional development course for caregivers.
11579644|NCT00792181|No Intervention|4|No intervention at all = a control group
11579645|NCT00792168|Active Comparator|1. Venlafaxine|
11579646|NCT00792168|Placebo Comparator|2. Placebo|
11579647|NCT00792142|Experimental|Treatment (stem cell transplant, maintenance treatment)|Patients receive high-dose melphalan IV over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation on day 0. Patients receive filgrastim IV or SC beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive oral thalidomide once daily until disease progression.
11579648|NCT00792129||Control|Posterior unilateral interbody fusion using an open approach midline incision (TLIF)
11579649|NCT00792129||Experimental|MiLIF procedure with specialized Atavi instrumentation and minimally invasive visualization capabilities
11579650|NCT00792116|Experimental|Gum Chewing|
11579651|NCT00792116|No Intervention|Non-gum chewing|
11579652|NCT00792103|Experimental|NP101|sumatriptan iontophoretic transdermal patch
11579653|NCT00792090|Experimental|1|Fermented milk
11579654|NCT00792090|Active Comparator|2|Standard milk
11579655|NCT00792077|Experimental|Sleep time|"Assessment of patients with chronic lymphocytic leukemia (CLL) experience severe cancer related fatigue (CRF):
~Lenalidomide + Actigraph + Questionnaire + Sleep Test"
11579656|NCT00792064||1|Kidney-Tx-recipients
11579657|NCT00792064||2|Liver-Tx-recipients
11579658|NCT00792064||3|Heart-Tx-recipients
11579659|NCT00792064||4|Lung-Tx-recipients
11579660|NCT00792051|Active Comparator|1|Influenza vaccine
11579661|NCT00792051|Placebo Comparator|2|
11579662|NCT00792038||1|OCD patients
11579663|NCT00792038||2|Normal Controls
11579664|NCT00792012|Experimental|Glioblastoma Multiforme Patients|Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining with Temozolomide (TMZ) Chemotherapy
11579665|NCT00791999|Experimental|CDP870 100mg|200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks
11579666|NCT00791999|Experimental|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks
11579667|NCT00791999|Experimental|CDP870 400mg|400mg CDP870 given every 2 weeks
11579668|NCT00791999|Placebo Comparator|Placebo|Placebo given every 2 weeks
11579669|NCT00791986|No Intervention|control|The patients in this control group do not conduct any breathing training.
11579670|NCT00791986|Experimental|ULB|The patients conduct controlled slow breathing training using the WPTB device without inspiratory resistance.
11579671|NCT00791986|Experimental|LB|The patients breath in against resistance using WPTB device.
11579672|NCT00791973|Active Comparator|Veramyst, then Placebo|fluticasone furoate (Veramyst) nasal spray once daily for a week, then one week washout period followed by placebo nasal spray once daily for a week
11579673|NCT00791973|Active Comparator|Placebo, then Veramyst|placebo nasal spray once daily for a week, then one week washout period followed by fluticasone furoate (veramyst) nasal spray once daily for a week
11579674|NCT00791960|Active Comparator|Dimenhydrinate|Dimenhydrinate
11579675|NCT00791960|Placebo Comparator|Placebo|Placebo
11579676|NCT00791934|Experimental|Stratus Microflow Ethmoid Spacer|Temporary implantation of Ethmoid spacer with Triamcinolone Acetonide for 28 days.
11579677|NCT00791921|Experimental|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks
11579678|NCT00791921|Placebo Comparator|Placebo|Placebo of CDP870
11579679|NCT00791908|Experimental|electrodessication (ED)|Treatment over 6 weeks using electrodessication (ED) to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
11579680|NCT00791908|Experimental|pulsed dye laser (PDL)|Treatment over 6 weeks using pulsed dye laser (PDL) to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
11579681|NCT00791908|Experimental|potassium titanyl phosphate (KTP) laser|Treatment over 6 weeks using potassium titanyl phosphate (KTP) laser to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
11579682|NCT00791895|Experimental|A|
11579683|NCT00791882|Experimental|1|"Group of behaviors by which someone express feelings, attitudes, wishes,opinions and rights , in an adequate manner regarding situation and context.
~Social skills are the substrate for social competence, which is the ability to find and legitimate relevant and personal goals"
11579684|NCT00791882|No Intervention|2|Control group will attend the same number of sessions, but without intervention of the therapists
11579685|NCT00791856|Active Comparator|1|28 cm2 testosterone patch
11579686|NCT00791856|Experimental|2|14 cm2 testosterone patch
11579687|NCT00791843|Experimental|GHRH and placebo|Everyone will receive 12 weeks of GHRH and 12 weeks of Placebo
11579688|NCT00791830|Active Comparator|Irbesartan|
11579689|NCT00791830|Placebo Comparator|Placebo|
11579690|NCT00791817|Experimental|200 mg PG 760564, Subjects Fasted|200 mg PG 760564, Subjects Fasted, single dose
11579691|NCT00791817|Experimental|200 mg PG 760564, Subjects Fed|200 mg PG 760564, Subjects Fed high fat meal
11579692|NCT00791804|Experimental|Single Arm|
11579693|NCT00791791|Other|1|increasing remifentanil administration
11579694|NCT00791791|Other|2|decreasing remifentanil concentration
11579695|NCT00791778|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)
11579696|NCT00791778|Placebo Comparator|Placebo|Participants received 2 matching placebo tablets per oral twice daily
11579697|NCT00791765|Experimental|Placebo BIW/Etanercept 50 mg BIW|Participants received placebo subcutaneous injections twice per week (BIW) for the first 12 weeks of the study. From Week 12 to Week 24, participants received etanercept 50 mg BIW.
11579698|NCT00791765|Experimental|Etanercept 50 mg BIW/Etanercept 50 mg QW|Participants received etanercept 50 mg by subcutaneous injection twice per week (BIW) for the first 12 weeks of the study. From Week 12 to Week 24, participants received etanercept 50 mg once per week (QW) and placebo once per week.
11579699|NCT00791752|Experimental|1|AZD4017 in ascending doses (start dose 2mg)
11579700|NCT00791752|Placebo Comparator|2|Placebo
11579701|NCT00791739|Experimental|one arm study|
11579702|NCT00791726||1|Patients with noninfectious uveitis and macular edema
11579703|NCT00791700|Experimental|Maraviroc|"Subjects will be stratified by age and formulation into one of the following cohorts:
~Cohort 1: ≥2-<6 years of age, maraviroc liquid formulation; Cohort 2: ≥6-<12 years of age, maraviroc tablet formulation; Cohort 3: ≥6-<12 years of age, maraviroc liquid formulation and Cohort 4: ≥12-<18 years of age, maraviroc tablet formulation."
11579872|NCT00790439|Experimental|LMW-SD|18 participants randomized to immunosuppression with Low Molecular Weight Sulfated Dextran (LMW-SD)
11579704|NCT00791687||PRENATAL CORTICOSTEROIDS|Extremely low gestational age neonates (<28 weeks gestation) whose mothers received full course of betamethasone before delivery.
11579705|NCT00791687||NON PRENATAL CORTICOSTEROIDS|Extremely low gestational age neonates (<28 weeks gestation) whose mothers did not receive full course of betamethasone before delivery.
11579706|NCT00791661|Experimental|Panel A: MK-1006 15/30/45|Participants received a single rising dose of MK-1006 (dosed at 15 mg, 30 mg, and 45 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
11579707|NCT00791661|Experimental|Panel B: MK-1006 60/80/60 fed|Participants received a single rising dose of MK-1006 (dosed at 60 mg, 80 mg, and 60 mg fed state) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
11579708|NCT00791661|Experimental|Panel C: MK-1006 100/140/170|Participants received a single rising dose of MK-1006 (dosed at 100 mg, 140 mg, and 170 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
11579709|NCT00791648|Experimental|statin|"Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.
~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1."
11579710|NCT00791648|Placebo Comparator|placebo|"Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.
~Aim 2 control: placebo the day of cardiac surgery and postop day 1."
11579711|NCT00791635||Observational (questionnaires)|"RETROSPECTIVE PORTION: Patients who have undergone pelvic exenteration complete one set of QOL questionnaires.
~PROSPECTIVE PORTION: Patients undergoing pelvic exenteration complete questionnaires over 20-40 minutes within 2 weeks before surgery, and at 4-12 weeks, 6 months, and 1, 2, 3, 4, 5, and 10 years after surgery regarding feelings, abilities, depression, coping, social support, sexual function and body image. Patients with cervical cancer may complete 1 additional questionnaire during each of these visits."
11579712|NCT00791596|Experimental|1|The first Arm received the intervention between baseline and the first follow-up, whereas the second Arm was the Control group
11579713|NCT00791596|Experimental|2|The second Arm received the intervention between the third and the fourth follow-up, whereas the first Arm was the Control group
11579714|NCT00791570|Experimental|A|
11579715|NCT00791557|Experimental|Infliximab|Single arm open label IV Infliximab given at weeks 1,2,14,22
11579716|NCT00791544|Experimental|Dose Level -1|0.5 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
11579717|NCT00791544|Experimental|Dose Level 1|1 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
11579718|NCT00791544|Experimental|Dose Level 2|3 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
11579719|NCT00791544|Experimental|Dose Level 3|6 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
11579720|NCT00791544|Experimental|Dose Level 4|12 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
11579721|NCT00791544|Experimental|Dose Level 5|18 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
11579722|NCT00791544|Experimental|Combination cohort 1|AVE1642 selected dose in combination with sorafenib
11579723|NCT00791544|Experimental|Combination cohort 2|AVE1642 selected dose in combination with erlotinib
11579724|NCT00791531|Experimental|Methotrexate|Oral methotrexate 5mg once daily for 5 consecutive days
11579725|NCT00791518||No group|No group
11579726|NCT00791505|Active Comparator|Ciprofloxacin|750 mg a day during 10 days
11579727|NCT00791505|Active Comparator|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
11579728|NCT00791492|Experimental|Fx-1006A|
11579729|NCT00791479|Experimental|0.1 milligram (mg) LY2189265|LY2189265: 0.1 milligram (mg), subcutaneous (SC), once weekly (QW)
11579730|NCT00791479|Experimental|0.5 milligram (mg) LY2189265|LY2189265: 0.5 milligram (mg), subcutaneous (SC), once weekly (QW)
11579731|NCT00791479|Experimental|1.0 milligram (mg) LY2189265|LY2189265: 1.0 milligram (mg), subcutaneous (SC), once weekly (QW)
11579732|NCT00791479|Experimental|1.5 milligram (mg) LY2189265|LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
11579733|NCT00791479|Placebo Comparator|Placebo|Placebo: subcutaneous (SC) once weekly (QW)
11579734|NCT00791466|Experimental|1|
11579735|NCT00791466|Placebo Comparator|2|
11579736|NCT00791453||I|Established patients at the Clarksdale Diabetes and Metabolism Center
11579737|NCT00791440|Experimental|1|Up to 26 sessions (over a 30 week period) of weekly, individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
11579738|NCT00791440|Active Comparator|2|30 weeks of standard psychiatric treatment.
11579739|NCT00791427||AMD Patients|
11579740|NCT00791388|Placebo Comparator|placebo|placebo capsule
11579741|NCT00791388|Experimental|50 mg PG 760564|50 mg PG 760564 active
11579742|NCT00791388|Experimental|100 mg PG 760564|100 mg PG 760564 active
11579743|NCT00791388|Experimental|200 mg PG 760564|200 mg PG 760564 active
11579744|NCT00791388|Experimental|400 mg PG 760564|400 mg PG 760564 active
11579745|NCT00791375|Experimental|Physical Activity Intervention|Participants in this arm will be given access to a website designed to help them increase their levels of physical activity
11579746|NCT00791375|Placebo Comparator|Cancer Website Control Group|Participants in this arm will be given information on cancer-related websites (that do not provide information on physical activity)
11579747|NCT00791362|Other|improvement programme CVD|
11579748|NCT00791362|Other|improvement programme other conditions|
11579749|NCT00791336|Experimental|Nelfinavir|
11579750|NCT00791323|Active Comparator|1|Ketorolac 0.4%
11579751|NCT00791323|Active Comparator|2|Mineral Oil Emollient
11579752|NCT00791310|Experimental|TEP|Performance of of TEP coupled to scanner X
11579753|NCT00791297|Active Comparator|1|Contraceptive Vaginal Ring delivering a daily dose of 1500 μg of CDB-2914
11579754|NCT00791297|Active Comparator|2|Contraceptive Vaginal Ring delivering a daily dose of 2500 μg of CDB-2914
11579875|NCT00790426|Experimental|FGFR3 mutant|
11579755|NCT00791271|Experimental|Decitabine + Peginterferon Alfa-2b|Decitabine starting dose of 10mg/m^2 given daily via intravenous infusion on days 1-5 of 28 day cycle. Peginterferon Alfa-2b starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
11579756|NCT00791258|Experimental|1|Azor tablets and hydrochlorothiazide tablets (if necessary) will be administered for up to 20 weeks
11579757|NCT00791245||1|DeNovo NT
11579758|NCT00791219|Experimental|Test|100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
11579759|NCT00791219|Active Comparator|Reference|200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).
11579760|NCT00791219|Placebo Comparator|Placebo|Two placebo capsules taken approximately 30 minutes prior to breakfast
11579761|NCT00791206|Experimental|1|
11579762|NCT00791206|Other|2|
11579763|NCT00791154|Active Comparator|ARM B|Blinded AMG 102 study drug and carboplatin or cisplatin and etoposide
11579764|NCT00791154|Placebo Comparator|ARM C|Blinded placebo and carboplatin or cisplatin and etoposide
11579765|NCT00791154|Active Comparator|ARM A|Blinded AMG 479 study drug and carboplatin or cisplatin and etoposide
11579766|NCT00791141|Experimental|Cetuximab|Cetuximab in combination with radiotherapy, cisplatin and 5-FU. After chemoradiotherapy all patients receive a cetuximab maintenance therapy.
11579767|NCT00791128|Experimental|EndoBarrier GI Liner|22 patients were implanted with the GI Liner for a 52-week duration. Assessments were performed during the 6 months post-explant period.
11579768|NCT00791115|Experimental|prostatectomy after radiotherapy|
11579769|NCT00791102|Active Comparator|1|Topical ASP-1001
11579770|NCT00791102|Placebo Comparator|2|Placebo for Topical ASP-1001
11579771|NCT00791089|Experimental|Fish Oil, Ablation, Sinus Rhythm|Patients in the treatment arm will receive omega-3 fatty acids (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
11579772|NCT00791089|Placebo Comparator|placebo, Ablation, sinus rhythm|Patients in the control arm will not receive any omega-3 fatty acids. However they will receive placebo.
11579773|NCT00791076|Placebo Comparator|Saline Placebo|Saline
11579774|NCT00791076|Active Comparator|Pancreatic Polypeptide|Pancreatic Polypeptide
11579775|NCT00791063|Experimental|18F ML-10|Intervention - 18F ML-10 PET/CT imaging for early detection of response of brain metastases to WBRT
11579776|NCT00791050|Experimental|1 Thermo|
11579777|NCT00791050|No Intervention|2 Control|
11579778|NCT00791037|Experimental|Treatment (vaccine therapy)|"Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2 weeks later, patients undergo leukapheresis to isolate and collect peripheral blood mononuclear cells for T-cell expansion.
~Patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10 days for up to three immunizations. Patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion, followed by 2 additional booster vaccines at 2-month intervals."
11579779|NCT00791024|Experimental|single arm|
11579780|NCT00791011|Experimental|Cohort 4|AMG 655 (intermediate dose) with Vorinostat
11579781|NCT00791011|Experimental|Cohort 1|AMG 655 (low dose) with Bortezomib
11579782|NCT00791011|Experimental|Cohort 2|AMG 655 (low dose) with vorinostat
11579783|NCT00791011|Experimental|Cohort 5|AMG 655 (high dose) with Bortezomib
11579784|NCT00791011|Experimental|Cohort 6|AMG 655 (high dose) with Vorinostat
11579785|NCT00791011|Experimental|Cohort 7|Part 2 - Mantle Cell Lymphoma subjects only: AMG 655 at dose TBD with Bortezomib
11579786|NCT00791011|Experimental|Cohort 3|AMG 655 (intermediate dose) with Bortezomib
11579787|NCT00790998|Experimental|Moxidectin|Moxidectin 8mg
11579788|NCT00790998|Active Comparator|Ivermectin|Ivermectin 150 mcg/kg
11579789|NCT00790985|Experimental|flavocoxid 500 mg|flavonoid mixture
11579790|NCT00790985|Active Comparator|naproxen|nonsteroidal anti-inflammatory drug
11579791|NCT00790972|Placebo Comparator|2|Identical-appearing placebo
11579792|NCT00790972|Active Comparator|1|two sprays in each nostril three times daily for one week
11579793|NCT00790959|Experimental|SASA!|
11579794|NCT00790959|Active Comparator|Control|
11579795|NCT00790946|Active Comparator|Valsartan|Valsartan 80 to 160mg
11579796|NCT00790946|No Intervention|standard therapy|
11579797|NCT00790933|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, 30-minute intravenous (IV) infusion every 4 weeks, starting at Week 0 for approximately up to 510 weeks.
11579798|NCT00790920|Experimental|Desmoteplase|
11579799|NCT00790920|Placebo Comparator|Placebo|
11579800|NCT00790907|Experimental|Open label fondaparinux background and standard dose UFH|Subjects indicated for PCI and randomized to receive standard dose UFH
11579801|NCT00790907|Experimental|Open label fondaparinux background and low dose UFH|Subjects indicated for PCI and randomized to receive low dose UFH
11579802|NCT00790907|Other|Open label fondapaparinux|Subjects not indicated for PCI and not randomized
11579803|NCT00790894|Active Comparator|1|
11579804|NCT00790894|Experimental|2|
11579805|NCT00790881|Other|Antiretroviral-naive|Antiretroviral-naive included as control group
11579806|NCT00790881|Active Comparator|Nevirapine-based antiretroviral therapy|Nevirapine-based antiretroviral therapy
11579807|NCT00790868|Experimental|D-cycloserine|DCS-augmented CBT
11579808|NCT00790868|Placebo Comparator|Placebo|placebo-augmented CBT
11579809|NCT00790855|Experimental|Bendamustine|Starting dose 50 mg/m^2 intravenously over 2 hours twice on Days 1-4 of every 4 week study cycle.
11579810|NCT00790842|Experimental|Group A - CrCl 30-60 mL/min|Creatinine clearance 30 - 60 mL/min, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
11579811|NCT00790842|Experimental|Group B, CrCl < 30 mL/min|Creatinine clearance < 30 mL/min, not on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
11579873|NCT00790439|Active Comparator|Control Group, Standard of Care|18 participants randomized to immunosuppression without Low Molecular Weight Sulfated Dextran (LMW-SD)
11579812|NCT00790842|Experimental|Group C, CrCl < 30 mL/min, on dialysis|Creatinine clearance < 30 mL/min and on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
11579813|NCT00790829|Experimental|A, B|Group B received a seven-milligram transdermal patch and Group A received a placebo patch.
11579814|NCT00790816|Experimental|Group 1|Study Drug
11579815|NCT00790816|Experimental|Group 2|Study Drug
11579816|NCT00790803|Other|Pegaptanib (Macugen)|Open label, non randomized, interventional controlled injection of 0.3mg of Pegaptanib (Macugen) every 6weeks with max of 5 injections over 30weeks.
11579817|NCT00790790|Placebo Comparator|Placebo|Participants randomized to LY545694 placebo were given LY545694 placebo twice daily (BID) oral (po) for 5 weeks.
11579818|NCT00790790|Experimental|LY545694 49 mg|Participants randomized to LY545694 49 milligrams (mg) BID po were first administered LY545694 21 mg BID po at Visit 3. After 1 week of dosing, participants were escalated to LY545694 49 mg BID po at Visit 4. Participants who were intolerant of this dose were titrated back down to 21 mg BID po for the remainder of study treatment.
11579819|NCT00790790|Experimental|LY545694 105 mg|Participants randomized to LY545694 105 mg BID po were first administered LY545694 21 mg BID po at Visit 3. After 1 week of dosing, participants were escalated to LY545694 49 mg BID po at Visit 4. At Visit 5, participants were titrated to the final dose of LY545694 105 mg BID po. Participants who were intolerant of this dose were titrated back down to LY545694 49 mg BID po for the remainder of study treatment.
11579820|NCT00790764|Placebo Comparator|Placebo|20 individuals will receive placebo.
11579821|NCT00790764|Experimental|MESENDO|"Active combination autologous stem cell therapy. 40 individuals will receive MESENDO in either the high or low dose treatment groups."
11579822|NCT00790751|Placebo Comparator|placebo|
11579823|NCT00790751|Experimental|avanafil 50 mg|
11579824|NCT00790751|Experimental|avanafil 100 mg|
11579825|NCT00790751|Experimental|avanafil 200 mg|
11579826|NCT00790738|Experimental|1|liothyronine (T3)
11579827|NCT00790738|Placebo Comparator|2|placebo
11579828|NCT00790725|Other|PAV|Proportional Assist Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
11579829|NCT00790725|Other|PS|Pressure Support Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
11579830|NCT00790699|Active Comparator|I-PORT|Treatment group
11579831|NCT00790699|Active Comparator|standard injections|control group
11579832|NCT00790686|Experimental|1|Memokath 051
11579833|NCT00790673|Experimental|1|CF102 1 mg qd
11579834|NCT00790673|Experimental|2|CF102 1 mg bid
11579835|NCT00790673|Experimental|3|CF102 1 mg bid; 16 weeks
11579836|NCT00790673|Placebo Comparator|5|
11579837|NCT00790660|Experimental|ASP1941 Lowest Dose|Oral
11579838|NCT00790660|Experimental|ASP1941 Low Dose|Oral
11579839|NCT00790660|Experimental|ASP1941 Medium Dose|Oral
11579840|NCT00790660|Experimental|ASP1941 High Dose|Oral
11579841|NCT00790660|Placebo Comparator|Placebo|Oral
11579842|NCT00790647|Experimental|Stem Cell Transplant with Bortezomib and Melphalan|Mobilization with Filgrastim Stem Cell Collection Bortezomib Melphalan Stem Cell infusion
11579843|NCT00790634||Parkinson's Disease|Patients with idiopathic Parkinson's disease
11579844|NCT00790634||Obsessive-compulsive disorder|Individuals with a diagnosis of obsessive-compulsive disorder
11579845|NCT00790634||OCD controls|Healthy controls, matched in age and number to obsessive-compulsive group
11579846|NCT00790634||PD controls|Healthy controls, matched in age and number to Parkinson's disease group
11579847|NCT00790595|Experimental|Group A|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
11579848|NCT00790595|Experimental|Group B|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
11579849|NCT00790595|Experimental|Group C|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
11579850|NCT00790595|Experimental|Group D|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
11579851|NCT00790595|Experimental|Group E|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
11579852|NCT00790582|Experimental|lithium carbonate|
11579853|NCT00790569|Experimental|Arm I|Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
11579854|NCT00790569|Placebo Comparator|Arm II|Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
11579855|NCT00790569|Active Comparator|Arm III|Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
11579856|NCT00790556|Experimental|1|MK8245
11579857|NCT00790556|Placebo Comparator|2|Placebo Comparator
11579858|NCT00790543||Observation|Children newly diagnosed with Crohn's disease.
11579859|NCT00790530|Experimental|ATO-SR|Automated Telephone Outreach with Speech Recognition
11579860|NCT00790530|No Intervention|Usual Care|Usual Care
11579861|NCT00790517|Experimental|1|Premier Lifestyle Intervention with Dash Diet, adapted for populations with mental illnesses
11579862|NCT00790517|No Intervention|2|Usual care
11579863|NCT00790504||1 study group|Women with multiple gestations recruited from the prenatal care or high risk pregnancy units
11579864|NCT00790504||2 control group|Women with singleton gestation recruited from the prenatal care or high risk pregnancy units
11579865|NCT00790491|Experimental|Lifestyle counseling|
11579866|NCT00790478|Placebo Comparator|Placebo|
11579867|NCT00790478|Active Comparator|Melatonin|
11579868|NCT00790465|Active Comparator|1|dark chocolate consumption during manometry and 2 weeks treatment with dark chocolate
11579869|NCT00790465|Other|2|placebo comparator: 7 grams of placebo-chocolate at day 1 during manometry, and than crossover to treatment with dark chocolate for 2 weeks.
11579870|NCT00790452|Active Comparator|Group 1 (Aspirin)|Aspirin 325 mg/day orally
11579871|NCT00790452|Placebo Comparator|Group 2 (Placebo)|Tablet/day orally
11579876|NCT00790413|Experimental|High-dose MIBG with haploidentical stem cell transplantation|High-dose MIBG followed by Fludarabine, Thiotepa and Melfalan as conditioning Before haploidentical transplantation of T-cell depleted graft
11579877|NCT00790400|Experimental|Everolimus|Study drug was given by continuous oral daily dosing of two 5 mg tablets.
11579878|NCT00790400|Placebo Comparator|Placebo|Placebo was given by continuous oral daily dosing of two 5 mg tablets.
11579879|NCT00790387|Experimental|1 High dose tirofiban and enoxaparin|"Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg .
~Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours."
11579880|NCT00790387|Active Comparator|2 tirofiban and unfractionated heparin|"Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours.
~UFH heparin was administered as a bolus of 70 U/kg and additional heparin was given to maintain the activated clotting time (ACT) at 250"
11579881|NCT00790374|Experimental|Cohort 1|6 patients have been enrolled, the cohort has been completed.
11579882|NCT00790374|Experimental|Cohort 2|6 patients have been enrolled in cohort 2, the cohort has been completed.
11579883|NCT00790374|Experimental|Cohort 3|5 patients have been enrolled in cohort 3. The cohort was closed after the 5th patient enrolled.
11579884|NCT00790361||Control|"Controls (healthy volunteers) will have two scans (fMRI, MRS and DTI) six months apart to determine reproducibility.
~A blinded investigator will administer JOA, ASIA/ISCOS, NDI and SF-36 prior to the scan at all time points."
11579885|NCT00790361||CCS Participants|"CCS participants will have three scans (fMRI, MRS and DTI), one acutely (up to 48 hours after injury), one subacutely (15 days after injury), and one late (6 months after injury).
~A blinded investigator will administer JOA, ASIA/ISCOS, NDI and SF-36 prior to the scan at all time points."
11579886|NCT00790348||1|Patients who on Januvia
11579887|NCT00790348||2|Patients on Janumet (Combination of Januvia and Metformin)
11579888|NCT00790348||3|Patients on Metformin
11579889|NCT00790335|Experimental|A-Intervention|PCDT with intrathrombus delivery of recombinant tissue plasminogen activator (rt-PA, maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
11579890|NCT00790335|No Intervention|B-Control|Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target international normalized ratio 2.0 - 3.0). Elastic compression stockings will be prescribed
11579891|NCT00790322|Experimental|Active|
11579892|NCT00790322|Placebo Comparator|Placebo|
11579893|NCT00790309||Weight loss surgery|This group will be comprised of people having weight loss surgery: Roux-en Y gastric bypass, vertical sleeve gastrectomy, or adjustable gastric banding
11579894|NCT00790309||Abdominal surgery|This group will be comprised of people having abdominal surgeries such as nissen fundoplication or cholecystectomy.
11579895|NCT00790309||Lean|This group will be comprised of normal weight healthy volunteers.
11579896|NCT00790296|Experimental|Thyrotropin releasing hormone (TRH)|TRH
11579897|NCT00790296|Placebo Comparator|Saline|Placebo
11579898|NCT00790283|Experimental|Numen|
11579899|NCT00790283|Active Comparator|Vision/MiniVision|
11579900|NCT00790270|Active Comparator|Cyclobenzaprine|
11579901|NCT00790270|Active Comparator|Ibuprofen|
11579902|NCT00790270|Experimental|Ibuprophen plus Cyclobenzaprine|
11579903|NCT00790257|Experimental|Monolayer Cellular Device|Encapsulated human islets allotransplantation transplanted in subcutaneous tissue in Type 1 diabetes patient
11579904|NCT00790244|Experimental|Arm 2|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and 4.
~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
11579905|NCT00790244|Experimental|Arm 3|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 45Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and 4.
~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
11579906|NCT00790244|Experimental|Group B|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.
~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
11579907|NCT00790244|Experimental|Arm 1|<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle (>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)
11579908|NCT00790231||men|observation of the urinary function with and without thoracic epidural anesthesia
11579909|NCT00790231||women|observation of the urinary function with and without thoracic epidural anesthesia
11579910|NCT00790218|Experimental|CF102|An open-label trial (1, 5, and 25 mg BID) in 28-day cycles.
11579911|NCT00790205|Experimental|Sitagliptin|Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
11579912|NCT00790205|Placebo Comparator|Placebo|Placebo to sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
11579913|NCT00790192|Experimental|Lurasidone 80mg|
11579914|NCT00790192|Experimental|Lurasidone 160mg|
11579915|NCT00790192|Active Comparator|Quetiapine XR|
11579916|NCT00790192|Placebo Comparator|Placebo|
11579917|NCT00790179|Active Comparator|PCA;active comparator|Patients with intravenous PCA hydromorphone alone
11579918|NCT00790179|Active Comparator|CFB|Patients with a continuous femoral block (CFB) + PCA hydromorphone
11579919|NCT00790179|Active Comparator|CLPB|Patients with a continuous lumbar plexus block + PCA hydromorphone
11579920|NCT00790166|Active Comparator|CPAP + ThermoSmart™ humidity|
11579921|NCT00790166|Active Comparator|CPAP + Conventional humidity|
11579922|NCT00790166|Active Comparator|CPAP + No added humidity|
11579923|NCT00790153|Active Comparator|1|AZD1656
11579924|NCT00790153|Active Comparator|2|Insulin
11579925|NCT00790140|Active Comparator|Immunonutrition Prosure|This group of patients are to be given a tube feed enriched with 2.2 g Eicosapentaenoic Acid (EPA) per day for 5 days pre surgery and 21 days post surgery
11579926|NCT00790140|Placebo Comparator|Standard enteral nutrition Ensure Plus|This group are to be given a standard enteral tube feed without EPA for 5 days pre op and 21 days post surgery
11579927|NCT00790127|Placebo Comparator|Placebo|Placebo
11579928|NCT00790127|Experimental|HQK-1001|HQK-1001
11579929|NCT00790114|Experimental|1|
11579930|NCT00790101|Experimental|1|Risedronate 35mg once a week
11579931|NCT00790101|Active Comparator|2|Raloxifene 60mg daily
11579932|NCT00790101|Placebo Comparator|3|
11579933|NCT00790062|Active Comparator|Oxytocin 10 units/500cc|1 dose only for prophylaxis given over 1 hour
11579934|NCT00790062|Experimental|Oxytocin 40 units/500cc|One dose only given over 1 hour. Per DSMB recommendations, this intermediate arm was stopped Jan 2010.
11579935|NCT00790062|Experimental|Oxytocin 80U/500cc|1 dose only given over 1 hour
11579936|NCT00790049|Experimental|ARRY-371797|
11579937|NCT00790049|Placebo Comparator|Placebo|
11579938|NCT00790036|Experimental|Everolimus|Participants who received Everolimus 10 mg (two 5 mg tablets), daily for 12 months
11579939|NCT00790036|Placebo Comparator|Placebo|Participants who received Everolimus placebo 10 mg (two 5 mg tablets), daily for 12 months
11579940|NCT00790023|Experimental|80 mcg Ciclesonide|80 mcg Ciclesonide once daily
11579941|NCT00790023|Experimental|160 mcg Ciclesonide|160 mcg Ciclesonide once daily
11579942|NCT00790023|Placebo Comparator|Placebo|Placebo once daily
11579943|NCT00790010|Experimental|Bevacizumab Plus Ipilimumab Cohort 1|5 subjects for this cohort
11579944|NCT00790010|Experimental|Bevacizumab Plus Ipilimumab Cohort 2|17 subects for this cohort
11579945|NCT00790010|Experimental|Bevacizumab Plus Ipilimumab Cohort 3|12 subjects
11579946|NCT00790010|Experimental|Bevacizumab Plus Ipilimumab Cohort 4|12 subjects
11579947|NCT00789997|Experimental|Etanercept|etanercept 50 mg subcutaneous given on the day of randomization and one week later prednisone placebo po daily for 10 days Levofloxacin 750 mg po daily for 10 days.
11579948|NCT00789997|Active Comparator|Prednisone|prednisone 40 mg daily for 10 days etanercept placebo subcutaneous given on the day of randomization and one week later Levofloxacin 750 mg daily for 10 days.
11579949|NCT00789958|Experimental|Adjuvant Chemo+ Chemoradiotherapy|"Adjuvant Chemotherapy
~Capecitabine, 1500 mg/m^2/day, PO, Every 12 hrs on Days 1-14 of each cycle
~Gemcitabine hydrochloride, 1000 mg/m^2, IV, Days 1 & 8 of each cycle
~Chemoradiotherapy
~-Capecitabine, 1330 mg/m^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT
~Radiation (RT):
~3-dimensional conformal radiation therapy - 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.
~intensity-modulated radiation therapy: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions."
11579950|NCT00789945|Placebo Comparator|Study Arm A|Study Arm A will be the primary control arm.
11579951|NCT00789945|Experimental|Study Arm B|Study Arm B will serve as the intervention arm.
11579952|NCT00789932|Experimental|CBT|
11579953|NCT00789932|Active Comparator|Usual Care|
11579954|NCT00789919|No Intervention|1|Study participants (those diagnosed with mild preeclampsia) are admitted to hospital for standard inpatient management of their disease.
11579955|NCT00789919|Experimental|2|Study participants (those diagnosed with mild preeclampsia) are admitted to hospital and their infant is delivered as soon as possible after 34 weeks gestation. As there is no determined optimal time of delivery in these patients, delivery is the intervention.
11579956|NCT00789906||1|350 healthy women , aged from 18 to 89
11579957|NCT00789906||2|350 healthy men, aged from 18 to 89
11579958|NCT00789893||Women with cervical, endometrial, rectal or anal cancer|Women seen in the radiation oncology clinic with cervical, endometrial, rectal or anal cancer who will receive external beam pelvic radiation or brachytherapy
11579959|NCT00789880|Experimental|Vitamin D3|Subjects received a 21-day course of oral vitamin D3 (cholecalciferol, 4,000 international units [IU]
11579960|NCT00789880|Placebo Comparator|Placebo|Subjects received a 21-day course of oral vitamin D3-placebo
11579961|NCT00789867|Experimental|20ml pGM169/GL67A|Received a nebulized dose 20ml via an breath-actuated nebulizer
11579962|NCT00789867|Experimental|10ml pGM169/GL67A|Received a nebulized dose 10ml via an breath-actuated nebulizer
11579963|NCT00789867|Experimental|5ml pGM169/GL67A|Received a nebulized dose 5ml via an breath-actuated nebulizer
11579964|NCT00789854|Active Comparator|Add-on Quetiapine XR+SSRI/Venlafaxine|"Selective serotonin reuptake inhibitors (SSRI) or Venlafaxine from previous therapy + add-on treatment with quetiapine XR, 300mg tablet once daily (od).
~From previous anti-depressant treatment 64% of the patients had SSRI and 35% had Venlafaxine at baseline."
11579965|NCT00789854|Active Comparator|Add-on Lithium+SSRI/Venlafaxine|"Selective serotonin reuptake inhibitors (SSRI) or venlafaxine from previous therapy + add-on treatment with lithium, approximately 900mg tablet once daily (od).
~From previous anti-depressant treatment 67% of the patients had SSRI and 33% had Venlafaxine at baseline."
11579966|NCT00789854|Active Comparator|Monotherapy Quetiapine XR|Switch from previous treatment with SSRI or venlafaxine to quetiapine XR monotherapy, 300mg tablet once daily (od)
11579967|NCT00789841||Patients with NET and diarrhea.|
11579968|NCT00789828|Experimental|Everolimus|Everolimus was administered orally at a starting dose of 4.5mg/m^2 daily and subsequently titrated to attain whole blood trough concentration of 5 to 15 ng/mL. Dose adjustments were permitted based on safety and whole blood trough concentrations.
11579969|NCT00789828|Placebo Comparator|Placebo|Matching Placebo administered orally.
11579970|NCT00789815|Active Comparator|BIS-guided propofol infusion|In the study group, induction was started using alfentanil 4~5μg/kg bolus following repeated propofol boluses (0.5~1.5 mg/kg) until the BIS level reached 70. During maintenance, propofol infusion (3~12 mg/kg/hour) was given using a syringe pump (Injectomat Agilia, Fresenius Kabi, France), which was titrated to keep the BIS level between 65 and 75.
11580013|NCT00789542|Experimental|Intermittent Pneumatic Compression|SCD Express device applied with thigh length sleeves for up to 30 days
11580471|NCT00786188|Placebo Comparator|Placebo - Sugar Pill|Eligible subjects will be randomized to receive a sugar pill.
11579971|NCT00789815|Active Comparator|Clinical-judged midazolam administration|In the control group, induction was started using alfentanil 4~5μg/kg bolus following 2 mg midazolam bolus. After 2 minutes, if the patient was not well sedated, midazolam boluses were repeat by increments of 2 mg/2min until conscious sedation was achieved
11579972|NCT00789802|Experimental|transdermal estradiol|participants will be randomized to transdermal estradiol
11579973|NCT00789802|Experimental|oral naproxen|participants will be randomized to oral naproxen
11579974|NCT00789802|Placebo Comparator|oral placebo|participants will be randomized to oral placebo
11579975|NCT00789789||1|
11579976|NCT00789776|Experimental|Treatment (non-myeloablative transplant)|"CONDITIONING: Patients receive fludarabine IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total-body irradiation on day -1.
~DONOR BONE MARROW TRANSPLANTATION: Patients undergo donor bone marrow transplantation on day 0.
~POST-TRANSPLANTATION IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3 and mycophenolate mofetil PO TID on days 4 to 40, followed by a taper until day 84 in the absence of GVHD. Patients also receive tacrolimus IV continuously or IV QD over 1-2 hours or PO BID on days 4 to 84, followed by a taper until day 180 in the absence of GVHD.
~NK CELL INFUSION: Patients undergo donor lymphocyte infusion of NK cells on day 7."
11579977|NCT00789763|Experimental|Sorafenib + gemcitabine + radiotherapy|
11579978|NCT00789750|Experimental|Colesevelam|Participants receive six colesevelam tablets (3.8 grams/day) in addition to pioglitazone-based therapy (30 mg or 45 mg)
11579979|NCT00789750|Placebo Comparator|Placebo|Participants receive six placebo tablets in addition to pioglitazone-based therapy (30 mg or 45 mg)
11579980|NCT00789737|Experimental|Welchol|Welchol 625mg tablets
11579981|NCT00789737|Placebo Comparator|placebo|placebo
11579982|NCT00789724|Experimental|Anakinra|Anakinra 100 mg given daily by subcutaneous injection for 14 days
11579983|NCT00789724|Placebo Comparator|Placebo|0.67 ml of NaCl 0.9% solution
11579984|NCT00789711||A|
11579985|NCT00789711||B|
11579986|NCT00789698|Experimental|Lurasidone HC1|
11579987|NCT00789698|Active Comparator|Quetiapine|
11579988|NCT00789685|Experimental|Interferon Beta|Interferon Beta
11579989|NCT00789672|Active Comparator|Lower Dose (3-1) levodopa/carbidopa|Oral levodopa 0.51 mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation) combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam 9 weeks after starting medication.
11579990|NCT00789672|Active Comparator|Higher Dose (4.5-1) levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation) combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam 9 weeks after starting medication.
11579991|NCT00789659|Experimental|VAC dressing|The patients whose postoperative wound will be dressed with a negative pressure (V.A.C.) dressing.
11579992|NCT00789646|Experimental|NSS/Lidocaine|First injection: Normal saline Second injection: 2% Lidocaine without adrenaline
11579993|NCT00789646|Experimental|Lidocaine/NSS|First injection: 2% Lidocaine without adrenaline Second injection: Normal saline
11579994|NCT00789633|Experimental|Masitinib & gemcitabine|Participants receive masitinib (9 mg/kg/day), given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
11579995|NCT00789633|Placebo Comparator|Placebo & gemcitabine|Participants receive matching placebo, given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
11579996|NCT00789620|Active Comparator|1|Lidocaine 1% administrated as a bolus of 1.5 mg/kg, then intraoperative 2mg/kg/h and postoperative 1.3mg/kg/h during 24 h
11579997|NCT00789620|Placebo Comparator|2|NaCl 0.9% as a bolus 1.5mg/kg, then intraoperative 2mg/kg/h and postoperative 1.3mg/kg/h during 24h
11579998|NCT00789607|Active Comparator|MRI-guided FM|
11579999|NCT00789607|Active Comparator|TRUS-guided FM|
11580000|NCT00789594|Experimental|Laboratory Monitoring|Laboratory Monitoring
11580001|NCT00789594|Experimental|Result management|Result management
11580002|NCT00789594|Experimental|Both interventions|Both laboratory monitoring and result management interventions
11580003|NCT00789594|No Intervention|Usual care|Usual care
11580004|NCT00789581|Experimental|Doxorubicin/cyclophosphamide, ixabepilone|Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by ixabepilone at 40 mg/m2 given for 4 cycles of 21 days each.
11580005|NCT00789581|Active Comparator|Doxorubicin/cyclophosphamide, paclitaxel|Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by paclitaxel at 80 mg/m2 weekly for 12 weeks.
11580006|NCT00789568|Experimental|Sapropterin Dihydrochloride 100mg/kg and placebo Moxifloxacin|A single dose of 100mg/kg of Sapropterin Dihydrochloride taken along with placebo Moxifloxacin.
11580007|NCT00789568|Experimental|Sapropterin Dihydrochloride 20mg/kg and placebo Moxifloxacin|A single dose of 20mg/kg of Sapropterin Dihydrochloride taken along with a placebo Moxifloxacin.
11580008|NCT00789568|Active Comparator|Sapropterin Dihydrochloride placebo and Moxifloxacin|No placebo tablets for Sapropterin Dihydrochloride will be administered, but instead will be apple juice only, taken along with 400mg of Moxifloxacin.
11580009|NCT00789568|Placebo Comparator|Sapropterin Dihydrocholide placebo and Moxifloxacin placebo|No placebo tablets for Sapropterin Dihydrochloride will be administered, but instead will be apple juice only, taken along with placebo of Moxifloxacin.
11580010|NCT00789555|Experimental|PATANASE|Olopatadine hydrochloride 0.6% nasal spray (PATANASE), two sprays in each nostril twice a day (morning and evening) for up to 12 months
11580011|NCT00789555|Placebo Comparator|Patanase Vehicle, pH 3.7|Olopatadine nasal spray vehicle, pH 3.7, two sprays in each nostril twice a day (morning and evening) for up to 12 months
11580012|NCT00789555|Placebo Comparator|Patanase Vehicle, pH 7.0|Olopatadine nasal spray vehicle, pH 7.0, two sprays in each nostril twice a day (morning and evening) for up to 12 months
11580014|NCT00789542|Other|Routine care|Routine care which might include: early mobilisation, adequate hydration, aspirin if ischaemic stroke and graduated compression stockings according to local protocols.
11580015|NCT00789529|Active Comparator|1|Opti-Free® RepleniSH® MPDS
11580016|NCT00789529|Active Comparator|2|Renu MultiPlus®
11580017|NCT00789516||1|Normal control
11580018|NCT00789516||2|B thalassemia regular transfusion
11580019|NCT00789516||3|B thalassemia post transplantation
11580020|NCT00789503|Experimental|Bread fortified with vitamin D3 and calcium|
11580021|NCT00789477|Experimental|Intravitreal Aflibercept Injection .5Q4|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) .5 mg every 4 weeks
11580022|NCT00789477|Experimental|Intravitreal Aflibercept Injection 2Q4|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2 mg every 4 weeks
11580023|NCT00789477|Experimental|Intravitreal Aflibercept Injection 2Q8|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2mg every 4 weeks for 3 visits followed by every 8 weeks
11580024|NCT00789477|Experimental|Intravitreal Aflibercept Injection 2PRN|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2mg every 4 weeks for 3 visits followed by PRN (as-needed) dosing according to the re-treatment criteria
11580025|NCT00789477|Active Comparator|Laser Photocoagulation|Focal laser at week 1, and one week after visits at which the participant met laser re-treatment criteria to the end of the study (week 52) starting at week 16; laser re- treatment was permitted no more than once every 16 weeks.
11580026|NCT00789464|Other|ARM A|Probiotics drops plus placebo elixir
11580027|NCT00789464|Other|ARM B|TMP/SMZ elixir plus placebo drops
11580028|NCT00789451|Sham Comparator|1|no ischaemia - only sham. Blood pressure cuff inflation up till 10 mmHg on the upper arm for 20 mins.
11580029|NCT00789451|Active Comparator|2|Ischaemia 20 minutes. Blood pressure cuff will be inflated around the upper arm for 20 minutes to induce ischaemia.
11580030|NCT00789438||General Anesthesia|Patients undergoing short-term surgery (30-90 min) under general anesthesia
11580031|NCT00789438||Spinal|Patients undergoing short-term surgery (30-90 min) under spinal anesthesia
11580032|NCT00789438||Spinal + Sedation|Patients undergoing short-term surgery (30-90 min) under spinal anesthesia with sedation
11580033|NCT00789425|Active Comparator|1|a standardized extract of olive polyphenols at 250 mg per day + 1000 mg of calcium per day.
11580034|NCT00789425|Placebo Comparator|2|Placebo (starch) + 1000 mg of calcium per day.
11580035|NCT00789412||Expected ICU|Patients with expected postoperative admission to the ICU. Baseline measurement of SSI. Exploration prior to weaning.
11580036|NCT00789412||Unexpected ICU|Patients with unexpected stay at the ICU. No baseline measurement of SSI. Exploration in 'steady state' of analgosedation.
11580037|NCT00789399|Active Comparator|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
11580038|NCT00789399|Placebo Comparator|Placebo|
11580039|NCT00789386|Experimental|Remifentanil|
11580040|NCT00789386|Placebo Comparator|Midazolam|Active Placebo
11580041|NCT00789373|Experimental|pemetrexed + cisplatin followed by pemetrexed|pemetrexed plus cisplatin followed by pemetrexed plus best supportive care
11580042|NCT00789373|Placebo Comparator|pemetrexed + cisplatin followed by placebo|pemetrexed plus cisplatin followed by placebo plus best supportive care
11580043|NCT00789360|Experimental|Inhaled Placebo crossed over to Inhaled Loxapine|Inhaled Staccato Placebo, 2 inhalations, 8 hours apart; washout of at least 4 days; Inhaled Staccato Loxapine, 10 mg oses x 2, 8 hours apart
11580044|NCT00789360|Experimental|Inhaled Loxapine crossed over to Inhaled Placebo|Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart; washout of at least 4 days; Inhaled Staccato Placebo, 2 inhalations, 8 hours apart;
11580045|NCT00789347||1|Healthy volunteers
11580046|NCT00789347||2|Patient with neuropathic pain
11580047|NCT00789347||3|patients without neuropathic pain
11580048|NCT00789321|Experimental|1|amlodipine
11580049|NCT00789321|Placebo Comparator|2|Placebo to amlodipine
11580050|NCT00789308|Active Comparator|Standard of Care|18 participants randomized to protocol immunosuppression (Daclizumab OR Basiliximab; Tacrolimus OR Cyclosporine; Mycophenolate Mofetil OR Sirolimus; and heparin) without LMW-DS
11580051|NCT00789308|Experimental|LMW-DS|18 participants randomized to protocol immunosuppression (Daclizumab OR Basiliximab; Tacrolimus OR Cyclosporine; Mycophenolate Mofetil OR Sirolimus; and heparin) and LMW-DS
11580052|NCT00789295|Active Comparator|Mediterranean diet|The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%)
11580053|NCT00789295|Active Comparator|Low-Carbohydrates diet|Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)
11580054|NCT00789282|Active Comparator|Usual Care Group|The 'usual care' study arm (control) will reflect current patterns of care for patients with thpe 2 diabetes in the Capital Health region
11580055|NCT00789282|Experimental|Enhanced Care Group|In the enhanced care group(intervention arm) the participants will receive a multifactorial intervention with three main components that include: optimized medical management, 2) support for development of enhanced patient self management skills, and 3) organized proactive follow-up by chronic disease management teams to support improvement in care.
11580056|NCT00789269|Experimental|1|rhubarb
11580057|NCT00789269|Placebo Comparator|2|
11580058|NCT00789256|Experimental|Study treatment|All patients will receive the following regimen: 1) Melphalan 2 mg orally, once daily. 2) Bortezomib 1.0 mg/M2 IV on days 1, 4, 8, 11.
11580059|NCT00789243|Active Comparator|1|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, local ischaemic preconditioning will be induced by inflating a cuff around the non-dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
11580060|NCT00789243|Active Comparator|2|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
11580737|NCT00784277|Active Comparator|003|oxycodone IR 10mg for 14 days
11580061|NCT00789243|Placebo Comparator|3|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, sham will be performed by inflating a cuff to 10 mmHg for 5 mins followed by 5 mins of deflation. This cycle will be repeated 3 times.
11580062|NCT00789230|Active Comparator|primary suture|
11580063|NCT00789230|Active Comparator|mesh enforced closure|
11580064|NCT00789217|Active Comparator|In-house penicillin testing preparation|In-house penicillin testing prepared from alkali-treated penicillin G
11580065|NCT00789217|Active Comparator|Commercial penicillin test kit|Commercial penicillin test kit order from Diater company
11580066|NCT00789217|Active Comparator|Penicillin G Sodium|Penicillin G Sodium from routine clinical use
11580067|NCT00789204|Experimental|GPR|Global Postural Re-Education
11580068|NCT00789204|Active Comparator|SEP|Standard Exercise Programm
11580069|NCT00789191|Experimental|Comb|Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment
11580070|NCT00789191|Active Comparator|Sita|Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment
11580071|NCT00789178||patients with fibromyalgia|
11580072|NCT00789178||patients with active RA|
11580073|NCT00789165|Experimental|Quinidine|Patients with type I Brugada electrocardiogram (either spontaneous or following a drug challenge with sodium channel blocker) who never experienced arrhythmia-related symptoms. Patients will receive quinidine therapy at the discretion of the attending physician.
11580074|NCT00789165|Active Comparator|no therapy|Patients with asymptomatic Brugada syndrome who opted to receive no therapy following the recommendation of their attending physician
11580075|NCT00789152|Experimental|desloratadine followed by levocetirizine|Subjects in this arm received desloratadine 5 mg daily for 8 days, followed by 10 day washout period, then followed by levocetirizine 5 mg daily for 8 days
11580076|NCT00789152|Experimental|levocetirizine followed by desloratadine|Subjects in this arm received levocetirizine 5 mg daily for 8 days, followed by 10 day washout period, then followed by desloratadine 5 mg daily for 8 days
11580077|NCT00789139|Other|AF monitoring by ICM|Only one arm
11580078|NCT00789113|Experimental|Extended Release Lamotrigine|Extended Release Lamotrigine
11580079|NCT00789100||1|Group provided with home-based monitor
11580080|NCT00789100||2|Group receives no home-based monitor
11580081|NCT00789087|Active Comparator|1. Videothoracoscopic talc poudrage (VT)|
11580082|NCT00789087|Active Comparator|2. Talc slurry through a chest tube (DT)|
11580083|NCT00789074|Experimental|Varenicline pre-treatmemt|Participants will use varenicline (1mg BD) 4-weeks prior to quitting
11580084|NCT00789074|Placebo Comparator|Placebo|Participants will use 3 weeks of placebo, followed by 1 week of varenicline, prior to quitting
11580085|NCT00789048|No Intervention|Surgeon doesn't see|The surgeon doesn't see the radiograph prior to surgery
11580086|NCT00789048|Experimental|Surgeon does see|The surgeon can see the radiograph prior to surgery
11580087|NCT00789022||1|40 subjects in a First Psychotic Episode
11580088|NCT00789022||2|20 First Degree relatives
11580089|NCT00789022||3|20 Healthy subjects
11580090|NCT00789009||Group 1|Consist of HIV positive patients recruited from the Washington DC metropolitan area who will receive long-term care for their HIV infection through the NIAID/CCMD HIV clinic
11580091|NCT00789009||Group 2|Patients with known or suspected HIV infection, referred to a NIAID/CCMD investigator for reasons such as testing to diagnose or exclude HIV disease or assistance with HIV-related problems.
11580092|NCT00788996|Experimental|Lifestyle counseling|Usual care
11580093|NCT00788970|Experimental|Acupressure|Acupressure adjuvant therapy
11580094|NCT00788970|Placebo Comparator|Placebo acupressure|Sham acupressure adjuvant therapy
11580095|NCT00788970|No Intervention|No treatment|Wait list group (no treatment)
11580096|NCT00788957|Experimental|Part 1: Panitumumab + Rilotumumab|Participants received panitumumab 6 mg/kg and rilotumumab 10 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
11580097|NCT00788957|Active Comparator|Part 2: Panitumumab Alone|Participants received panitumumab 6 mg/kg and placebo by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
11580098|NCT00788957|Experimental|Part 2: Panitumumab + Rilotumumab|Participants received panitumumab 6 mg/kg and rilotumumab 10 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
11580099|NCT00788957|Experimental|Part 2: Panitumumab + Ganitumab|Participants received panitumumab 6 mg/kg and ganitumab 12 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
11580100|NCT00788944|Other|1|
11580101|NCT00788931|Experimental|IV LBH589 + trastuzumab + paclitaxel|i.v. panobinostat
11580102|NCT00788931|Experimental|Oral LBH589 + trastuzumab + paclitaxel|oral panobinostat
11580103|NCT00788918|Experimental|Chronic hepatitis C treatment|30 Chronic HCV patients with pending antiviral treatment. A majority will have pending treatment with interferon and ribavirin, and the treated patients will be assessed 8-12 weeks after starting treatment for interferon-induced depression.
11580104|NCT00788918|No Intervention|Healthy Controls|50 age, sex and education matched controls (matched 1:1 to participants in the HCV patient groups (+/- treatment)
11580105|NCT00788918|No Intervention|Former HCV infected|20 Subjects with prior HCV infection identified through positive HCV antibodies, but negative HCV RNA.
11580106|NCT00788918|No Intervention|Chronic HCV patient - no treatment|20 chronic HCV patients without pending antiviral treatment.
11580107|NCT00788905|Experimental|A|"Subject will continue conventional hemodialysis therapy for one week (no intervention phase) and then swtich to the Allient system for two weeks (active comparator phase)."
11580108|NCT00788892|Experimental|Arm A: CPX-351|First induction: CPX-351 at 100u/m2 administered on days 1, 3 and 5 Second induction: CPX-351 at 100u/m2 administered on days 1 and 3 Consolidation: CPX-351 at 100u/m2 administered on days 1 and 3
11580158|NCT00788541|Experimental|48 mg Anecortave Acetate, high volume low dose|Anecortave Acetate Sterile Suspension, 60 mg/mL, one injection of 0.8 mL in the study eye monthly for 6 months.
11580109|NCT00788892|Active Comparator|Arm B: Cytarabine + Daunorubicin|First induction: Cytarabine at a dose of 100mg/m2/day on days 1-7, Daunorubicin at dose of 45 or 60mg/m2 on days 1-3 Second induction: Cytarabine at a dose of 100mg/m2/day on days 1-5, Daunorubicin at a dose of 45 or 60 mg/m2/day on days 1 and 2 Consolidation: Investigator's Choice
11580110|NCT00788879|Experimental|1|This study arm is located in Brownsville, Texas. This community is exposed to the TSSC media messages as well as may be visited by the lay health workers and see the built environment changes
11580111|NCT00788879|No Intervention|2|The control group is located in Laredo. This community is not exposed to the TSSC messages nor does the campaign work to actively change the built environment or use lay health workers to share physical activity and nutrition information.
11580112|NCT00788866|Experimental|Pomegranate juice|This arm with receive 8oz of pomegranate juice per day.
11580113|NCT00788866|Placebo Comparator|Placebo|This group will take 8oz of placebo juice that lacks pomegranate daily
11580114|NCT00788853||A|
11580115|NCT00788840|Active Comparator|1. Insulatard|
11580116|NCT00788840|Active Comparator|2. Detemir|
11580117|NCT00788827|Experimental|Autologous CD34+ stem cells|Up to 5 x 10 log 8 of autologous stem cells on a single occasion
11580118|NCT00788814|Other|Control|Control group
11580119|NCT00788801|Experimental|Baseline|
11580120|NCT00788801|Experimental|ABT-614 Low Dose|
11580121|NCT00788801|Experimental|ABT-614 High Dose|
11580122|NCT00788788|Active Comparator|1|Study subjects where breathing Heliox with a fraction of Helium of 25% followed by 50% and 75% with larger external resistor in comparison to medical air
11580123|NCT00788788|Active Comparator|2|Study subjects where breathing Heliox with a fraction of Helium of 50% followed by 75% and 25% with larger external resistor in comparison to medical air
11580124|NCT00788788|Active Comparator|3|Study subjects where breathing Heliox with a fraction of Helium of 25% followed by 50% and 75% with larger external resistor in comparison to medical air
11580125|NCT00788775|Experimental|Nilotinib|Nilotinib was given at a dose of 400 mg orally daily (200 mg pills twice per day). Patients received treatment up to 12 months as long as they were receiving clinical benefit.
11580126|NCT00788762||Villagers in Taxiarchis|
11580127|NCT00788749|Placebo Comparator|Placebo|Placebo tablets for 2 weeks followed by fluticasone nasal drops 800mcg/d for 2 months followed by fluticasone nasal spray 400 mcg/d for 4 months
11580128|NCT00788749|Experimental|Prednisolone|25 mg Prednisolone OD for 2 weeks followed by Fluticasone nasal drops 800 mcg/d for 2 months, followed by fluticasone nasal spray 400mcg/day for 4 months
11580129|NCT00788723|Experimental|1|Patients with severe brain injury, awake, but have cognitive problems
11580130|NCT00788723|Experimental|2|Patients with severe brain injury and disorders of consciousness ( in minimally conscious or in vegetative state)
11580131|NCT00788723|Experimental|3|Healthy volunteers
11580132|NCT00788710|Experimental|Etoricoxib 120 mg|etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.
11580133|NCT00788710|Experimental|Etoricoxib 90 mg|etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.
11580134|NCT00788710|Placebo Comparator|Placebo|Placebo- 3 tablets once daily
11580135|NCT00788697|Other|Patients who received SonoVue|"Patients with at least 1 target lesion requiring work-up for characterization to undergo
~Unenhanced ultrasound of the target lesion (UE-US): gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion using commercially available ultrasound equipment and standard techniques (B-mode or Harmonic imaging) to study the anatomy of the target lesion and surrounding parenchyma;
~SonoVue-enhanced ultrasound of the target lesion (CE-US): procedures described in protocol Section 7.5.1.2, to study the lesion vascularity in comparison to the surrounding parenchyma; and
~Truth standard"
11580136|NCT00788684|Experimental|ABT-263 + rituximab|
11580137|NCT00788671|Experimental|Treatment (levonorgestrel-releasing intrauterine system)|Patients undergo placement of a levonorgestrel-releasing intrauterine system.
11580138|NCT00788658|Placebo Comparator|Diet modifications|Diet consultation and life style modifications for 6 sessions
11580139|NCT00788658|Active Comparator|Cognitive therapy|6 sessions of cognitive behavioral therapy
11580140|NCT00788645|Experimental|Forecast|COPD patients receiving advice and poor weather warning
11580141|NCT00788645|Experimental|No Forecast|COPD patients receiving advice and poor weather warning
11580142|NCT00788645|No Intervention|Control|Age matched non - COPD subjects
11580143|NCT00788632|Experimental|educational materials|Patient educational DVD and brochure
11580144|NCT00788632|Other|physician education|Physician web modules
11580145|NCT00788632|Experimental|System intervention|Self-referral letter with toll-free number provided
11580146|NCT00788619|Active Comparator|Day 3 transfer|Subjects in this arm will have two embryos transferred three days after fertilization. Embryos will be selected based on the concentration of nitric oxide metabolites in the culture medium.
11580147|NCT00788619|Active Comparator|Day 5 transfer|Subjects will have two embryos transferred on day 5 after fertilization with selection of embryos based on morphologic criteria.
11580148|NCT00788606|Experimental|bevacizumab and Rituximab|This study evaluates the feasibility using the anti-VEGF drug, bevacizumab, in combination with the standard treatment Rituximab in patients with stage II, III and IV diffuse large B cell lymphoma (DLBCL)
11580149|NCT00788593|Placebo Comparator|Placebo|
11580150|NCT00788593|Experimental|EUR-1008 (APT-1008) High Dose|
11580151|NCT00788593|Experimental|EUR-1008 (APT-1008) Low Dose|
11580152|NCT00788567|Experimental|1|
11580153|NCT00788554|Active Comparator|1|
11580154|NCT00788554|Active Comparator|2|
11580155|NCT00788541|Experimental|3 mg Anecortave Acetate, low volume high dose|Anecortave Acetate Sterile Suspension, 6 mg/mL, one injection of 0.5 mL in the study eye monthly for 6 months.
11580156|NCT00788541|Experimental|3 mg Anecortave Acetate, high volume low dose|Anecortave Acetate Sterile Suspension, 3.75 mg/mL, one injection of 0.8 mL in the study eye monthly for 6 months.
11580157|NCT00788541|Experimental|48 mg Anecortave Acetate, low volume high dose|Anecortave Acetate Sterile Suspension, 96 mg/mL, one injection of 0.5 mL in the study eye monthly for 6 months.
11580159|NCT00788541|Placebo Comparator|Anecortave Acetate Vehicle, low volume|Anecortave Acetate Vehicle, one injection of 0.5 mL in the study eye monthly for 6 months.
11580160|NCT00788541|Placebo Comparator|Anecortave Acetate Vehicle, high volume|Anecortave Acetate Vehicle, one injection of 0.8 mL in the study eye monthly for 6 months.
11580161|NCT00788528|Experimental|Arm A|1600 mg S-2367 (velneperit)
11580162|NCT00788515|Experimental|1|
11580163|NCT00788515|Active Comparator|2|
11580164|NCT00788476||Childhood Cancer Survivors|
11580165|NCT00788476||Primary Caregivers|
11580166|NCT00788463|Experimental|Aerosol|
11580167|NCT00788463|Active Comparator|Spray|
11580168|NCT00788424|Experimental|AS101 Cream|Twice daily topical application of AS101 cream on the psoriatic lesions for approx. 12 weeks is expected to clear the treated area.
11580169|NCT00788424|Experimental|Placebo|Twice daily topical application on the psoriatic lesions for 8 weeks will serve as control group.
11580170|NCT00788398|Active Comparator|Saline, gravity flow|
11580171|NCT00788398|Active Comparator|Saline, Low Pressure|
11580172|NCT00788398|Active Comparator|Saline, High Pressure|
11580173|NCT00788398|Active Comparator|Soap, Gravity Flow|
11580174|NCT00788398|Active Comparator|Soap, low pressure|
11580175|NCT00788398|Active Comparator|Soap, high pressure|
11580176|NCT00788372|Experimental|Fentanyl|Fentanyl transdermal patch will be applied once daily up to 4 weeks in Treatment period 1, releasing at the rate of 12.5 microgram per hour (mcg/hr), maintained for 2 days and for another 48 weeks in Treatment period 2. The dose will be increased as per Investigators' discretion in both treatment periods and the maximum applied dose will be 300 mcg/hr. Total duration of treatment is 52 weeks.
11580177|NCT00788346|Experimental|Computerized Alerts|Computerized Clinical Decision Support to clinician at the time of prescribing
11580178|NCT00788346|Experimental|Alerts PLUS Detailing|Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
11580179|NCT00788346|No Intervention|Usual Care|Usual Care
11580180|NCT00788333|Experimental|A|Combination
11580181|NCT00788320|Placebo Comparator|Placebo|Placebo three times a week for 8 weeks
11580182|NCT00788320|Experimental|Cholecalciferol|Vitamin D3 50,000 IU three times a week for 8 weeks
11580183|NCT00788307|Experimental|Experimental Arm|
11580184|NCT00788294|Active Comparator|10 mg IV|
11580185|NCT00788294|Active Comparator|5 mg SC|
11580186|NCT00788294|Active Comparator|10 mg SC|
11580187|NCT00788294|Active Comparator|19 mg SC|
11580188|NCT00788281|Experimental|A|laparoscopic surgery plus postsurgery adjuvant chemotherapy of FOLFOX4
11580189|NCT00788281|Active Comparator|B|open surgery plus postsurgery adjuvant chemotherapy of FOLFOX4
11580190|NCT00788255||All participants|"For each patient, 1 solution with citrated whole blood (control) and 3 solutions with citrated whole blood and exogenous oxytocin were prepared in separate vials using micropipettes as follows:
~Citrated whole blood 1mL + 23μU oxytocin: final exogenous oxytocin concentration=22.5 μU/mL Citrated whole blood 1mL + 31μU oxytocin: final exogenous oxytocin concentration=30.1μU/mL Citrated whole blood 1mL + 34μU oxytocin: final exogenous oxytocin concentration=32.9μU/mL
~After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation."
11580191|NCT00788242|Experimental|1|Administration of glucose-insulin-potassium
11580192|NCT00788242|Placebo Comparator|2|
11580193|NCT00788229|Experimental|1. Study Drugs|
11580194|NCT00788229|Experimental|2. Study Drug|
11580195|NCT00788229|Experimental|3. Study Drug|
11580196|NCT00788229|Placebo Comparator|4. Placebo|
11580197|NCT00788216||Healthy Volunteers|Women over the age of 18 without the diagnosis of cervical cancer.
11580198|NCT00788216||Cervical Cancer Patients|Women over the age of 18 with a history of cervical cancer treated with surgery or chemoradiation.
11580199|NCT00788203||5-keys program|Counseling re family feeding behaviors.
11580200|NCT00788203||Lifestyle counseling|Counseling re healthy eating for child and family
11580201|NCT00788190|Other|Surgery|Surgical intervention to reduce Distal Radius Fracture
11580202|NCT00788190|Other|Conservative Treatment|Conservative treatment of Distal Radius Fractures
11580203|NCT00788164|Experimental|Groups 1-3|Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine intramuscularly (IM) on days 1 and 29 and TA-HPV vaccine IM on day 57.
11580204|NCT00788164|Experimental|Group 4|Patients receive topical imiquimod on days 1, 29, and 57.
11580205|NCT00788164|Experimental|Group 5|Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and TA-HPV vaccine as in groups 1-3, and imiquimod as in group 4.
11580206|NCT00788151|Experimental|CYD Dengue vaccine group|Participants received three injections of the CYD Dengue vaccine at 0, 6, and 12 months. Participants were followed for 6 months after the last vaccination (up to 18 months).
11580207|NCT00788151|Placebo Comparator|Control group|Participants received two injections of placebo, and one injection of pneumococcal polysaccharide vaccine (Pneumo23®) at 0, 6, and 12 months, respectively. Participants were followed for 6 months after the last vaccination (up to 18 months).
11580208|NCT00788138|Experimental|1|Vitamin D3 250,000 PO Once
11580209|NCT00788138|Placebo Comparator|2|Matching Placebo
11580210|NCT00788125|Experimental|Dasatinib with Ifosfamide, Carboplatin, Etoposide|
11580211|NCT00788112|Experimental|Vorinostat|
11580212|NCT00788099|Experimental|1|Plitidepsin and Sorafenib
11580213|NCT00788099|Experimental|2|Gemcitabine and Plitidepsin
11580214|NCT00788073|Active Comparator|STX209|STX209 variable dose from 1mg bid to 10mg tid, capsule, oral, 4 weeks
11580215|NCT00788073|Placebo Comparator|Placebo|variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
11580216|NCT00788060|Experimental|RAD001|
11580217|NCT00788047|Other|Regimen A (Reference)|
11580218|NCT00788047|Experimental|Regimen B (Test)|
11580219|NCT00788034|Experimental|Lu AA21004|
11580220|NCT00788034|Placebo Comparator|Placebo|
11580221|NCT00788021||Tacrolimus|Recipients of deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus
11580222|NCT00788021||Sirolimus|Recipients of deceased or living donor renal transplants maintained on immunosuppressive regimen using sirolimus
11580223|NCT00788021||Healthy controls|Age, race and gender-matched individuals not on immunosuppressive regimens. Whenever possible an transplant recipient's donor may be recruited to serve as healthy control
11580224|NCT00788008|Active Comparator|1|Inhalational anesthesia with isoflurane
11580225|NCT00788008|Active Comparator|2|total intravenous anesthesia with propofol
11580226|NCT00787995||MPS IVA|Subjects with mucopolysaccharidosis IVA (Morquio Syndrome)
11580227|NCT00787969|Experimental|Treatment (rituximab, cladribine, temsirolimus)|Patients receive rituximab IV on day 1 and cladribine IV over 2 hours on days 1-5. Patients then receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive filgrastim SC on days 6-15 or pegfilgrastim SC on day 6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11580228|NCT00787943|Experimental|Left side of face|Topical benzoyl peroxide 10.0% cream - Formulation 2 or Topical benzoyl peroxide 10.0% cream - Formulation 1 is to be applied to left side of the face.
11580229|NCT00787943|Experimental|Right side of face|Topical benzoyl peroxide 10.0% cream - Formulation 2 or Topical benzoyl peroxide 10.0% cream - Formulation 1 is to be applied to right side of the face.
11580230|NCT00787930||Manic Subject with DWM Hyperintensities >2|Subjects with acute mania who were treated with naturalistic protocol (starting with valproic acid) who had a BOYKO DWM Hyperintensity rating >2 and a YMRS <15 at week 3.
11580231|NCT00787930||Manic Subjects with DWM Hyperintensities <3|Subjects with acute mania who were treated with naturalistic protocol (starting with valproic acid)who had a BOYKO DWM Hyperintensity rating <3 and a YMRS <15 at week 3.
11580232|NCT00787917|Experimental|Omalizumab|"Eligible participants received a maximum dose of 600 mg omalizumab via subcutaneous injection for 6 months in the double-blind phase of the study. The study medication was to be administered at the same time of day. Study medication was injected subcutaneously into the upper arm in the area of the deltoid or to the thigh. A maximum 600 mg dose required 4 injections. All participants who entered the study received itraconazole twice daily, while receiving oral corticosteroids, with a maximum daily dose of 400 mg.
~Participants who completed double-blinded phase, entered open-label treatment period of 6 months and continued the same regimen of omalizumab of double-blinded phase."
11580233|NCT00787917|Placebo Comparator|Placebo|Eligible participants received placebo comparator via subcutaneous injection for 6 months in the double-blind phase of the study. The study medication was to be administered at the same time of day. Study medication was injected subcutaneously into the upper arm in the area of the deltoid or to the thigh. All participants who entered the study received itraconazole twice daily, while on oral corticosteroids, with a maximum daily dose of 400 mg.
11580234|NCT00787904||Surgical Menopause|Pre-menopausal women undergoing total hysterectomy with oophorectomy rendering them post-menopausal
11580235|NCT00787904||Surgical Control|Pre-menopausal women undergoing abdominal surgery but without ovary removal
11580236|NCT00787904||Healthy|Healthy matched pre-menopausal controls
11580237|NCT00787891|Experimental|Rabeprazole 0.5 mg/kg|rabeprazole 0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
11580238|NCT00787891|Experimental|Rabeprazole 1.0 mg/kg|rabeprazole 1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
11580239|NCT00787878||A|
11580240|NCT00787878||B|
11580241|NCT00787878||C|
11580242|NCT00787865||Krabbe Disease|Children with infantile Krabbe disease
11580243|NCT00787865||Low Enzyme/No Krabbe Disease|Children without disease who have low enzyme levels
11580244|NCT00787865||Control|Children with no disease and normal enzyme levels
11580245|NCT00787865||Motor Disability|Children at risk of developing motor disability
11580246|NCT00787852|Experimental|Group 1: Radiation, Paclitaxel, Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43
~Dasatinib is to be taken 1x daily
~50 mg daily 100 mg daily
~70 mg daily 100 mg daily
~100 mg daily 100 mg daily
~Maintenance x 2 years*"
11580247|NCT00787852|Experimental|Group 2: Radiation, Paclitaxel, carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36
~Dasatinib is to be taken 1x daily
~50 mg daily 100 mg daily
~70 mg daily 100 mg daily
~100 mg daily 100 mg daily Maintenance x 2 years*"
11580248|NCT00787839||Group 1|Atlanta VA Medical Center patients who meet criteria for screening for prediabetes and early diabetes based on standard guidelines of the VA, the American Diabetes Association, and the National Institutes of Health
11580249|NCT00787826|Experimental|Vaccination|Live Francisella Tularensis Vaccine
11580250|NCT00787813|Active Comparator|1|N-Acetyl Cysteine
11580251|NCT00787813|Placebo Comparator|2|placebo
11580252|NCT00787800|Active Comparator|Dual Chamber ICD|Dual chamber Implantable Cardioverter-Defibrillator (ICD): Atrial therapies and minimized ventricular pacing will be programmed on along with Ventricular Tachycardia/Ventricular Fibrillation (VT/VF) detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation.
11580253|NCT00787800|Active Comparator|Single Chamber ICD|Single chamber Implantable Cardioverter-Defibrillator: Optimally programmed Ventricular Tachycardia/Ventricular Fibrillation (VT/VF) detection and therapies will be programmed on including use of detection enhancements.
11580254|NCT00787787|Experimental|Treatment (sunitinib malate and capecitabine)|Patients receive sunitinib malate PO QD on days 1-21 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence or disease progression or unacceptable toxicity.
11580255|NCT00787761|Experimental|ATG, Cytoxan, Bu/Flu based Allogeneic Transplant|All patients will receive an ATG, Cyclosphosphamide, Busulfan and Fludarabine based Allogeneic Transplant
11580256|NCT00787735|Experimental|Integrated Care|Integrated Substance Abuse and Psychiatric Care (ISAP). Subjects received both their substance abuse and psychiatric care within the ATS clinic. Counseling compliance will be measured over time.
11580257|NCT00787735|Active Comparator|Parallel Care|Parallel Substance Abuse and Psychiatric Care (PSAP). Subjects received their substance abuse treatment at the ATS clinic. Their psychiatric care was received at Community Psychiatry. Counseling compliance will be measured over time.
11580258|NCT00787722|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.
11580259|NCT00787709|Experimental|1|Receives Pathways universal school-based health promotion curriculum from 4th-6th grade
11580260|NCT00787709|No Intervention|2|Control group of students who do not receive the intervention
11580261|NCT00787696|Experimental|Skills Training|intervention group received information, motivation and skills training: condom application, assertive communication & problem solving
11580262|NCT00787696|Active Comparator|Health Education|Comparsion group received information and motivation
11580263|NCT00787683|Experimental|Home-monitoring|Patients receive an additional home-monitoring (remote-monitoring) device (CardioMessengerII) following Biotronik Lumax ICD implantation. The device enables regular transmission and examination of ICD information via home-monitoring. Follow-up appointments in outpatient clinic are changed compared to standard care. While follow-up 1, 12, and 24 months after ICD implantation consist of outpatient clinic appointments, follow-up 3, 6, and 18 months after ICD implantation are conducted remotely.
11580264|NCT00787683|No Intervention|Standard care|Patients randomised to the standard care group receive no home-monitoring device (CardioMessengerII) following Lumax ICD implantation. Patients have scheduled follow-up appointments at the ICD outpatient clinics at 1, 3, 6, 12, 18, and 24 months after ICD implantation.
11580265|NCT00787670|Experimental|Gastric Bypass Surgery|Gastric Bypass Surgery consists of a laparoscopic approach and includes the creation of an isolated 10-15-ml proximal gastric pouch, a retro-colic, retro-gastric Roux-en-Y gastrojejunostomy with linear stapler technique, a 100-cm Roux-limb, a 30-cm biliopancreatic limb, and a stapled end-side enteroenterostomy.
11580266|NCT00787670|Active Comparator|Diabetes Support and Education|Diabetes Support and Eduction. Subjects attend three educational/social support sessions for 1 year after enrollment. The educational sessions offered for diabetes support and education including informational sessions on diet/nutrition and exercise. These sessions are informational only and do not teach behavioral self-regulation skills. Different nutrition and exercise topics are covered each session. Education
11580267|NCT00787670|Active Comparator|Tissue Control Group|Tissue control group includes subjects who are undergoing other non-gastric bypass abdominal surgery. A pea size piece of omentum and subcutaneous fat will be collected.
11580268|NCT00787657||Arm 1|
11580269|NCT00787644|Active Comparator|1|
11580270|NCT00787644|Placebo Comparator|2|
11580271|NCT00787618|Active Comparator|50 mg Proellex Mild impairment|50 mg Proellex single dose Female subjects with mild renal impairment function.
11580272|NCT00787618|Active Comparator|50 mg Proellex Moderate|50 mg Proellex, Female subjects with moderate renal impairment function.
11580273|NCT00787618|Active Comparator|50 mg Proellex, Normal|50 mg Proellex, Female subjects with normal renal function.
11580274|NCT00787605|Active Comparator|Amlodipine|Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
11580275|NCT00787605|Experimental|Aliskiren / HCTZ|Aliskiren / HCTZ 150/12.5 mg for 1 week followed by 300/25 mg for 7 weeks
11580276|NCT00787592||1|"SSD:
~Patients that receive SSD as the topical debriding agent"
11580277|NCT00787592||2|"Collagenase:
~Patients that receive collagenase as the debriding agent."
11580278|NCT00787579|Active Comparator|Bifocal spectacles|
11580279|NCT00787579|Active Comparator|Prismatic bifocals|
11580280|NCT00787579|No Intervention|Single vision spectacles|
11580281|NCT00787566|Experimental|0.5 mg of TRG (intranasal granisetron)|0.5 mg dose, intranasal powder, single spray, administered once
11580282|NCT00787566|Experimental|1.0 mg of TRG (intranasal granisetron)|1.0 mg dose, intranasal powder, songle spray, administered once
11580283|NCT00787566|Experimental|2.0 mg of TRG (intranasal granisetron)|2.0 mg dose, intranasal powder, single spray, administered once
11580284|NCT00787553|Active Comparator|cefazolin|
11580285|NCT00787553|Active Comparator|tinidazole|
11580286|NCT00787553|Active Comparator|cefazolin plus tinidazole|
11580287|NCT00787540||I|Coronary Slow Flow Patients
11580288|NCT00787540||II|Coronary Artery Occlusion Patients
11580289|NCT00787527|Experimental|Zolinza + CHOP|Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
11580290|NCT00787501|Active Comparator|SSRIs|Selective Serotonin Reuptake Inhibitors
11580291|NCT00787501|Active Comparator|CBT|Cognitive Behavior Therapy
11580292|NCT00787488|Experimental|1|Chemotherapy plus Hyperthermia
11580293|NCT00787475|Experimental|1|CHW intervention
11580294|NCT00787475|No Intervention|2|Enhanced usual care (brochure mailings)
11580295|NCT00787462|Active Comparator|Active|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
11580401|NCT00786721||Diffuse Optical Spectroscopy|muscle properties scanning
11580402|NCT00786708||NGAL|Urine that would otherwise be discarded will be obtained from a convenience sample of patients admitted to the hospital through the emergency room who meet the inclusion / exclusion criteria for this study.
11580403|NCT00786695|Placebo Comparator|Placebo|Identical looking Placebo
11580404|NCT00786695|Experimental|esomeprazole|esomeprazole (40 mg o d) for 14 days
11580472|NCT00786162|Experimental|Intervention|Internet-based hypertension self-management platform
11580296|NCT00787462|Placebo Comparator|Placebo|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
11580297|NCT00787436|No Intervention|1|Standard of care with normal treatment
11580298|NCT00787436|Active Comparator|Thalidomide|Standard of care and treatment using Thalidomide
11580299|NCT00787423||COHORT 1|Individuals from 18 to 75 years of age who are current heroin users seeking treatment for addiction and who spend most of their time in Baltimore city.
11580300|NCT00787410|Experimental|1|
11580301|NCT00787397|Experimental|1. Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy-Sleep
11580302|NCT00787384|Experimental|Imatinib|Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib was discontinued after 12 total weeks of therapy.
11580303|NCT00787371|Experimental|0.25 Dose Group|PegIntron 0.25 mcg/kg SC QW for 12 weeks
11580304|NCT00787371|Experimental|0.5 Dose Group|PegIntron 0.5 mcg/kg SC QW for 12 weeks
11580305|NCT00787371|Experimental|1.0 Dose Group|PegIntron 1.0 mcg/kg SC QW for 12 weeks
11580306|NCT00787371|No Intervention|No-treatment Control|No treatment (no placebo)
11580307|NCT00787358|Active Comparator|ZT-031|
11580308|NCT00787358|Placebo Comparator|Placebo|
11580309|NCT00787345|Other|Surgery residents|general surgery residents undergoing evaluation and training in MBP during CVC placement as per department policy are eligible for the study.
11580310|NCT00787332|Experimental|Desirudin|Patients with suspected HIT without thrombosis syndrome (HIT/TS), randomized to SC Desirudin
11580311|NCT00787332|Active Comparator|Argatroban®|Patients randomized to IV Argatroban®
11580312|NCT00787319||AMD|
11580313|NCT00787306|Experimental|Multi-faceted Cardiovascular Decision Support|Risk factor active surveillance, multi-disciplinary disease management and decision aid intervention
11580314|NCT00787306|Other|Control Usual Care|Usual care in a wait-list control arm that receives the experimental intervention after 6 months.
11580315|NCT00787293|Experimental|1|Patient is screened for study and given baseline assessments. Pending fulfillment of study eligibility criteria, patient is implanted with PTMA system.
11580316|NCT00787280|Experimental|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
11580317|NCT00787280|Experimental|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
11580318|NCT00787267|Experimental|Dasatinib|"After a biopsy is done to obtain fresh frozen tumor tissue (Stage I), dasatinib is to be administered as an oral dose of 70 mg twice daily on a continuous basis for 6 weeks. Every 6 weeks radiologic exam will be done to assess response. Treatment will continue until progression of disease, intolerable toxicity or patient withdrawal.
~For Stage II, a biopsy to obtain fresh frozen tumor tissue will also be done. Depending on results from Stage I and results of biopsy, treatment with dasatinib will be determined."
11580319|NCT00787254|Experimental|Lansoprazole 15 mg QD|
11580320|NCT00787254|Active Comparator|Gefarnate 50 mg BID|
11580321|NCT00787241||Mild preeclampsia|Preeclampsia without eclampsia or HELLP syndrome
11580322|NCT00787241||Severe preeclampsia|Severe preeclampsia with eclampsia and/or HELLP syndrome
11580323|NCT00787241||Mild preeclampsia superimposed on chronic hypertension|Mild preeclampsia in association with chronic hypertension
11580324|NCT00787215||no treatment|observational: no treatment involved
11580325|NCT00787202|Experimental|15 mg BID|
11580326|NCT00787202|Experimental|10 mg BID|
11580327|NCT00787202|Experimental|3 mg BID|
11580328|NCT00787202|Experimental|0.5 mg BID|
11580329|NCT00787202|Placebo Comparator|Placebo|
11580330|NCT00787189|Active Comparator|The Hearing Laser|Active low level laser light therapy of 635 nanometers (nm)
11580331|NCT00787189|Placebo Comparator|Placebo Laser|inactive low level laser light therapy with no therapeutic output
11580332|NCT00787176|Active Comparator|Group A|An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient was positioned for epidural placement. Oxytocin management continued as per protocol.
11580333|NCT00787176|Experimental|Group B|An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement was halved and not increased for 60 minutes until after placement.
11580334|NCT00787176|Active Comparator|Group C|The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. Oxytocin management continued per protocol.
11580335|NCT00787176|Experimental|Group D|The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement was halved and not increased for 60 minutes until after placement.
11580336|NCT00787163|Experimental|1|amnioinfusion
11580337|NCT00787163|No Intervention|2|expectant management
11580338|NCT00787150|Experimental|Apixaban 5mg BID|
11580339|NCT00787150|Experimental|Apixaban 2.5mg BID|
11580340|NCT00787150|Active Comparator|Warfarin|
11580341|NCT00787137|Experimental|PG102 0.3 mg/kg|Lowest dose PG102
11580342|NCT00787137|Experimental|PG102 1 mg/kg|Second dose PG102
11580343|NCT00787137|Placebo Comparator|Placebo (phosphate-buffered saline)|Control
11580344|NCT00787124||1|< 28 weeks gestation, < 30 days of age, < 3 previous transfusions
11580345|NCT00787124||2|< 28 weeks gestation, >=30 days of age, >= 3 previous transfusions
11580346|NCT00787111|Experimental|Fluoxetine ODT|Fluoxetine ODT ranging from 2mg to 54mg
11580405|NCT00786682|Experimental|Docetaxel and Hydroxychloroquine|"Drug: Docetaxel 75 mg/m2 intravenously every 21 days on Day 1 of the treatment cycle
~Drug: hydroxychloroquine 200 mg twice daily
~A cycle is defined as an interval of 21 days."
11580347|NCT00787098|No Intervention|1|RA begins data collection with chart review for demographic and explanatory variables, collects data for baseline muscle strength. During standard care period, PM will obtain information about the plan for activity for enrolled patients (turning, complete or partial weight-bearing i.e., reverse Trendelenberg positioning, ROM, sitting and walking) through discussion with the direct providers. RA will interview one provider about factors which influence the decision to implement activity or provide bedrest, including the presence of orders for bedrest or physical therapy. If activity is planned, the PM will observe and record the type and duration of activity, drawing serum biomarkers 20 minutes before and 20 minutes after the activity. If no activity is planned or activity duration is less than 10 minutes, serum for only baseline inflammatory biomarkers will be drawn. The RA will collect outcomes data within 24 hours of discharge from the ICU.
11580348|NCT00787098|Experimental|2|Identical procedures for date recruitment, consent and data collection will occur. In this phase, the Project Manager will promote the use of the ETM protocol through coaching (e.g., reminding staff of benefits of mobility, identification of available resources, or suggesting cessation of bedrest orders) and by participating in planning at least one 20-minute activity.
11580349|NCT00787085||Case|Patients hospitalized with a urine or blood culture positive for fungi
11580350|NCT00787085||Control|Patients hospitalized with a urine culture negative for fungi
11580351|NCT00787072|Experimental|1|
11580352|NCT00787072|Placebo Comparator|2|
11580353|NCT00787059|Experimental|Ad5.hAC6|Will receive intracoronary adenovirus encoding human adenylyl cyclase type 6
11580354|NCT00787059|Placebo Comparator|sucrose solution|Will receive intracoronary sucrose solution
11580355|NCT00787033|Experimental|1|Dose escalation study with Expansion Cohorts at RP2D and Schedule
11580356|NCT00787020||Ventriculostomy Open|Subjects are treated with near continuous cerebrospinal fluid (CSF) diversion by positioning the stopcock in the open position and the intracranial pressure (ICP) is monitored once each hour: CSF drains into an external ventricular drainage bag.
11580357|NCT00787020||Ventriculostomy Monitored|Subjects are treated with intermittent cerebrospinal fluid (CSF) diversion. Intracranial pressure (ICP) is monitored and CSF is drained only when the ICP exceeds a threshold dictated by the attending physician.
11580358|NCT00787007|Experimental|1|10 mg
11580359|NCT00787007|Experimental|2|20 mg, fasted and fed
11580360|NCT00787007|Experimental|3|40 mg
11580361|NCT00787007|Experimental|4|80 mg
11580362|NCT00787007|Experimental|5|160 mg
11580363|NCT00787007|Experimental|6|320 mg
11580364|NCT00787007|Placebo Comparator|7|placebo capsule
11580365|NCT00786994|Experimental|1|Oleogel-S10 100 mg/g ointment for three months once a day (54 patients)
11580366|NCT00786994|Experimental|2|Oleogel-S10 100 mg/g ointment for three months twice a day (54 patients)
11580367|NCT00786994|Placebo Comparator|3|Placebo (petroleum jelly) for three months once a day (27 patients)
11580368|NCT00786994|Placebo Comparator|4|Placebo (petroleum jelly) for three months twice a day (27 patients)
11580369|NCT00786981|Other|Epidural steroid injection and physical therapy|
11580370|NCT00786981|Other|Epidural steroid injection|
11580371|NCT00786968|Experimental|intrathecal laronidase|drug laronidase, dose 1.74 mg, route intrathecal, frequency every 30-90 days, duration 1 year
11580372|NCT00786942|Active Comparator|1|autologous bone graft
11580373|NCT00786942|Experimental|2|without bone graft
11580374|NCT00786929|Experimental|drainage|
11580375|NCT00786929|Active Comparator|2|Conservative treatment
11580376|NCT00786916|Placebo Comparator|Group A|Saline
11580377|NCT00786916|Active Comparator|Group B|Lidocaine 0.25 mg/kg
11580378|NCT00786916|Active Comparator|Group C|Lidocaine 0.5 mg/kg
11580379|NCT00786890||no treatment|observational, no treatment needed
11580380|NCT00786877|Experimental|Improved biomass cookstove with exterior ventilation|"In phase 1, installation of an improved cookstove with ventilation to exterior is the active arm.
~In phase 2, this improved biomass cookstove is the control arm."
11580381|NCT00786877|No Intervention|Traditional cookstove|In phase 1, the control arm is the traditional standard open burning cookstove in house.
11580382|NCT00786877|Experimental|Phase 2 invervention arm (LPG stove)|In phase 2 of this project, households are individually randomized to either continuation of the improved biomass stove from phase 1, or a new LPG stove and gas for 12 months.
11580383|NCT00786864|Experimental|1. Experimental Group|Exercise Intervention Group
11580384|NCT00786864|No Intervention|2. Control Group|Control group - no intervention
11580385|NCT00786851|Experimental|1|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
11580386|NCT00786838|Experimental|Trabectedin|3-hour placebo intravenous infusion on Day 1 and trabectedin 1.3 mg/m2 3-hour intravenous infusion on Day 2 (single-blind). Patients may continue treatment with trabectedin until clinical benefit or drug is commercially available (open-label).
11580387|NCT00786825|Experimental|somatostatin|Type 1 diabetes and Hypoglycemia unawareness
11580388|NCT00786825|No Intervention|2|Healthy control subjects
11580389|NCT00786812|Other|CAMN107A2109 Extension Patients|
11580390|NCT00786812|Other|AMN107 Naive|
11580391|NCT00786799|Active Comparator|Omega-3 Fatty Acids|
11580392|NCT00786799|Placebo Comparator|Placebo|
11580393|NCT00786786||1|Spinal Cord Injury
11580394|NCT00786773||1|GERD patients who will be treated for GERD with PPI, H2RA, antacid, prokinetics, combination therapy
11580395|NCT00786760||1. Men ages 18 - 44 years|
11580396|NCT00786760||2. Men ages 45 - 70 years|
11580397|NCT00786747|Experimental|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
11580398|NCT00786747|Active Comparator|Non-tailored control computer program|This program provides non-tailored, generic information about colorectal cancer screening, in the user's preferred language (English or Spanish).
11580399|NCT00786734|Experimental|Pitavastatin Group|
11580400|NCT00786734|Other|Usual Care Group|
11580406|NCT00786669|Experimental|Bevacizumab+TEM/VCR/IRN/CEF|"Bevacizumab(IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles
~Temozolomide (TEM) 100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.
~Vincristine (VCR) 1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients <0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).
~Irinotecan (IRN) 90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles
~Cefexime (CEF) 8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity"
11580407|NCT00786643|Experimental|Stratum 1|Patients in stratum 1 have not received prior chemotherapy in the metastatic setting.
11580408|NCT00786643|Experimental|Stratum 2|Patients in stratum 2 have received 1-2 prior chemotherapy regimens in the metastatic setting.
11580409|NCT00786630|Experimental|Case Management|
11580410|NCT00786630|Experimental|Facilitated Treatment Alliance|
11580411|NCT00786617||Nurse-driven|Mechanically ventilated patients weaned by nurse-driven ventilator weaning protocol
11580412|NCT00786617||Physician-initated|Mechanically ventilated patients weaned by physician-initiated, non-protocol methods
11580413|NCT00786604||1|Those with a cervical spinal cord injury
11580414|NCT00786604||2|Those with a thoracic spinal cord injury
11580415|NCT00786604||3|Healthy, control group
11580416|NCT00786591||Acute Pancreatitis Patients|Patients presenting with clinical features compatible with acute pancreatitis
11580417|NCT00786591||Control|Preoperative patients going for elective cholecystectomy
11580418|NCT00786578||1|overweight runners (BMI>25)
11580419|NCT00786578||2|lean runners (BMI<24)
11580420|NCT00786565|Experimental|Advanced Akreos Adapt|Advanced Akreos Adapt Aspheric Intraocular Lens (IOL).
11580421|NCT00786565|Experimental|Akreos Adapt|Akreos Adapt Spherical Intraocular Lens (IOL).
11580422|NCT00786552|Experimental|chemotherapy|
11580423|NCT00786513|Active Comparator|Control Arm|
11580424|NCT00786513|Experimental|Intervention Arm|
11580425|NCT00786500|Active Comparator|Gynostemma pentaphyllum tea|
11580426|NCT00786500|Placebo Comparator|Placebo tea|
11580427|NCT00786487|Experimental|lipid trained|20% lipid infusion in trained subjects
11580428|NCT00786487|Active Comparator|glycerol trained|glycerol infusion into trained subjects
11580429|NCT00786487|Experimental|lipid untrained|lipid infusion into untrained subjects
11580430|NCT00786487|Active Comparator|glycerol untrained|glycerol infusion into untrained subjects
11580431|NCT00786474|Placebo Comparator|Placebo|
11580432|NCT00786474|Experimental|Dalteparin|
11580433|NCT00786448||Group 1|
11580434|NCT00786435||1|Those with a cervical spinal cord injury
11580435|NCT00786435||2|Those with a thoracic spinal cord injury
11580436|NCT00786435||3|Healthy, control group
11580437|NCT00786422|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|
11580438|NCT00786409|Other|Gardasil|30 patients will receive 0.5 ml Gardasil vaccine at months 0,2, and 6.
11580439|NCT00786396|Experimental|DAART|Group that will be observed daily taking their medications for a period of six months. Followed by the remaining six months of the intervention in which the subject will take medications on their own.
11580440|NCT00786396|No Intervention|2|SAT (standard of care) group will take their medications as directed by their physicians for the period of one year.
11580441|NCT00786383|Experimental|IMC-1121B|IMC-1121B injectable solution at a concentration of 5 mg/mL in single-use vials containing 100 mg/20 mL or 250 mg/50 mL of product, administered intravenously at an initial dose of 6 mg/kg.A minimum of three patients will be enrolled into each cohort. When all patients complete a cohort, dose escalation to the next cohort will occur.
11580442|NCT00786370|Active Comparator|Propofol|
11580443|NCT00786370|Experimental|Dexmedetomidine|
11580444|NCT00786357|Experimental|Intervention|
11580445|NCT00786344|Experimental|Lifestyle Redesign|
11580446|NCT00786344|No Intervention|No Treatment Control|The no treatment control arm did not receive the intervention during the first six-month period. However the intervention, which has been proven to be beneficial, was administered to the control arm immediately following the 6 month assessment.
11580447|NCT00786331|Active Comparator|A|Monochemotherapy
11580448|NCT00786331|Experimental|B|Combination chemotherapy
11580449|NCT00786318|Experimental|ziprasidone|
11580450|NCT00786318|Active Comparator|Standard therapy|
11580451|NCT00786305|Experimental|1: nebulized ceftazidime and amikacin|
11580452|NCT00786305|Active Comparator|2: intravenous ceftazidime and amikacin|
11580453|NCT00786292|Other|Noisy PSV|Assisted mechanical ventilation with noisy PSV
11580454|NCT00786292|Other|PSV|Assisted mechanical ventilation with PSV
11580455|NCT00786279|Placebo Comparator|1|150 cc daily of flavored, calorie-free beverage without alcohol
11580456|NCT00786279|Experimental|2|150 cc flavored, calorie-free beverage with 15 gm ethanol daily
11580457|NCT00786266|Active Comparator|NIOSH shiftwork booklet|
11580458|NCT00786266|Experimental|Sleep Enhancement Training System|
11580459|NCT00786253|Experimental|Arm 1|
11580460|NCT00786253|Experimental|Arm 2|
11580461|NCT00786240|Experimental|A|
11580462|NCT00786240|Experimental|B|
11580463|NCT00786227||Legacy HAQ-DI first, PROMIS 20-item short form first|To eliminate effects due to order of administration, patients with RA will be randomized to complete either the Legacy measure HAQ-DI first in the assessment battery or the PROMIS 20-item short forms first.
11580464|NCT00786214|Experimental|Acupuncture|Patients given acupuncture treatment
11580465|NCT00786214|Sham Comparator|Sham acupuncture|Patients given sham acupuncture treatment
11580466|NCT00786201|Placebo Comparator|Placebo|
11580467|NCT00786201|Experimental|CNTO 888 1 mg/kg|
11580468|NCT00786201|Experimental|CNTO 888 5 mg/kg|
11580469|NCT00786201|Experimental|CNTO 888 15 mg/kg|
11580470|NCT00786188|Experimental|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg.
11580473|NCT00786162|Active Comparator|Control|Installation of BP cuff for communal use at the worksite
11580474|NCT00786149|Experimental|1|Participants will receive NRT and Motivational Interviewing counseling
11580475|NCT00786149|Active Comparator|2|Varenicline plus brief advice
11580476|NCT00786136|Experimental|1|perioperative rosuvastatin administration for at least 5 dosages
11580477|NCT00786136|Placebo Comparator|control|blank control of perioperative statin administration
11580478|NCT00786123|Experimental|VSL#3|Patients taking probiotics (VSL#3)
11580479|NCT00786123|Placebo Comparator|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
11580480|NCT00786110|Experimental|1 arm only|"One arm only with Sorafenib plus Paclitaxel Patients enrolled will undergo strict follow-up
~Intervention: Sorafenib plus Paclitaxel"
11580481|NCT00786097|Experimental|1|Dermacyd PH_DETINLYN (Lactic Acid)
11580482|NCT00786084||1|Phase I patients who had a paraesophageal hernia repair with synthetic mesh.
11580483|NCT00786084||2|Phase I patients who had a paraesophageal hernia repair with small intestine submucosa mesh.
11580484|NCT00786071||Rett syndrome girls|The study population consists of a well-defined group of Dutch RTT thirteen girls with complete clinical, molecular and neurophysiological work-up.
11580485|NCT00786045|Experimental|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
11580486|NCT00786045|No Intervention|Control|The investigators have devised a series of mobility-related tasks that can be easily and safely carried out at home without ongoing professional supervision
11580487|NCT00786032||BCI Device|All participants will use the BCI System as a means of communication.
11580488|NCT00786019|Experimental|Ascorbic acid|All study subjects have ascorbic acid infusion during one exercise visit as well as a three month exercise training intervention.
11580489|NCT00786006|Experimental|Arm 1|FOLFIRI.3
11580490|NCT00786006|Active Comparator|Arm 2|FOLFOX
11580491|NCT00785993|Active Comparator|Control Group|Fresh donor oocytes
11580492|NCT00785993|Experimental|Group I|vitrified donor oocytes
11580493|NCT00785980|Active Comparator|Quinine Sulfate|Baseline quinine sulfate pharmacokinetics
11580494|NCT00785980|Experimental|Quinine Sulfate with Ciprofloxacin|Quinine sulfate pharmacokinetics in the presence of steady state ciprofloxacin
11580495|NCT00785967|Experimental|1|raltegravir 400mg bid + Truvada 1 tab qd
11580496|NCT00785967|Active Comparator|2|efavirenz 600mg qhs + Truvada 1 tab qd (or Atripla 1 tab qhs)
11580497|NCT00785954|Experimental|A1: KAI-9803|
11580498|NCT00785954|Experimental|A2: KAI-9803|
11580499|NCT00785954|Experimental|A3: KAI-9803|
11580500|NCT00785954|Placebo Comparator|A4: Placebo|
11580501|NCT00785941|Experimental|IMC-A12|"All patients will receive intravenous infusions of IMC-A12, with the dose depending on which cohort they are enrolled into a minimum of three patients will be enrolled in each Cohort. When all patients complete a cohort, dose escalation to the next Cohort will occur.
~A treatment cycle will consist of IMC-A12 administered intravenously, once every other week for 4 weeks, for a total of 2 doses; followed by a 2-week observation period."
11580502|NCT00785928|Experimental|Placebo|
11580503|NCT00785928|Experimental|1 mg LY2127399|
11580504|NCT00785928|Experimental|3 mg LY2127399|
11580505|NCT00785928|Experimental|10 mg LY2127399|
11580506|NCT00785928|Experimental|30 mg LY2127399|
11580507|NCT00785928|Experimental|60 mg LY2127399|
11580508|NCT00785928|Experimental|120 mg LY2127399|
11580509|NCT00785915|Experimental|1|
11580510|NCT00785915|Placebo Comparator|2|given (2 subjects in each ethnic/dose group)
11580511|NCT00785876|No Intervention|1|Control Sites
11580512|NCT00785876|Experimental|2|Intervention Sites
11580513|NCT00785863|Placebo Comparator|Placebo|
11580514|NCT00785863|Active Comparator|Remifentanil|
11580515|NCT00785863|Active Comparator|Ketorolac and remifentanil|
11580516|NCT00785863|Active Comparator|Parecoxib and remifentanil|
11580517|NCT00785850|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower
11580518|NCT00785837|No Intervention|Before Hidrotherapy|
11580519|NCT00785837|Experimental|Hidrotherapy|
11580520|NCT00785824||1 A-A Breastfeeding Mothers|Group 1: Postpartum African-American breastfeeding women at 6-8 weeks post childbirth, and again at 12-14 weeks post childbirth
11580521|NCT00785824||2 - AA Bottlefeeding Mothers|Group 2: Postpartum African-American bottlefeeding women at 6-8 weeks post childbirth and again at 12-14 weeks post childbirth.
11580522|NCT00785824||3 - AA Normal Controls|Group 3: Normal African-American non-pregnant controls who are age-matched to Group 1
11580523|NCT00785811|Experimental|1|L-arginine aspartate (Targifor)
11580524|NCT00785811|Placebo Comparator|2|Placebo
11580525|NCT00785798|Experimental|vorinostat doxil|Escalating doses of vorinostat 200mg to 400mg twice daily on days 1-7, and fixed-dose IV PLD 30mg/m2 on day 3 of a 21-day cycle
11580526|NCT00785785|Experimental|Nilotinib|nilotinib 400 mg twice a day
11580527|NCT00785785|Active Comparator|Imatinib|imatinib 400 mg once daily
11580528|NCT00785772|Experimental|1: Patients with Cleatinine Clearance (CLcr) 5-14 mL/min|
11580529|NCT00785772|Experimental|2: Patients with CLcr 15-29 mL/min|
11580530|NCT00785772|Experimental|3: Patients with CLcr 30-59 mL/min|
11580531|NCT00785746|Experimental|core|strength training of the core muscles.
11580532|NCT00785746|No Intervention|stretch and strength|This program consists of general stretching exercises and peripheral muscle strengthening exercises with a special emphasis on strengthening the upper extremity muscles because of their importance for ADL but not necessarily balance.
11580738|NCT00784277|Placebo Comparator|004|placebo 1 capsule for 14 days
11580533|NCT00785733||1|Moderate and severe asthma patients stabilized on Symbicort SMART
11580534|NCT00785720|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid)
11580535|NCT00785707||cochlear implant|children less than 24 months at time of cochlear implantation
11580536|NCT00785694|Experimental|B|One instillation of mitomycin C after transurethral resection in white and blue fluorescence light with Hexvix.
11580537|NCT00785694|No Intervention|A|Multiple instillations of mitomycin C after transurethral resection in white light alone.
11580538|NCT00785681|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid)
11580539|NCT00785655|Experimental|1|Dermacyd PH_DETINLYN (Lactic Acid)
11580540|NCT00785642|Experimental|1|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)
11580541|NCT00785629|Active Comparator|Calcium Acetate|667 mg with meals
11580542|NCT00785629|Active Comparator|Lanthanum Carbonate|500 mg with meals
11580543|NCT00785629|Active Comparator|Sevelamer Carbonate|800 mg with meals
11580544|NCT00785629|Placebo Comparator|Placebo|with meals
11580545|NCT00785590|Experimental|1|Dermacyd PH_DETINLYN (Lactic Acid)
11580546|NCT00785577|Placebo Comparator|Placebo|LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules thrice daily (TID) po for 6 weeks
11580547|NCT00785577|Active Comparator|Pregabalin|"Pregabalin thrice daily (TID) oral for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6
~LY545694 placebo BID po for 5 weeks"
11580548|NCT00785577|Experimental|LY545694 21 mg|"LY545694 21 milligrams (mg) BID po for 1 week
~Pregabalin placebo TID po for 6 weeks"
11580549|NCT00785577|Experimental|LY545694 49 mg|"LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.
~Pregabalin placebo TID po for 6 weeks"
11580550|NCT00785577|Experimental|LY545694 105 mg|"LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.
~Pregabalin placebo TID po for 6 weeks"
11580551|NCT00785551|Experimental|1|quinine sulfate 648mg in subjects with normal renal function (CLcr > 80mL/min)
11580552|NCT00785551|Experimental|2|quinine sulfate 648mg in subjects with mildly impaired renal function (CLcr > 50 to 80 mL/min)
11580553|NCT00785551|Experimental|3|quinine sulfate 648mg in subjects with moderately impaired renal function (CLcr 30 to 50mL/min)
11580554|NCT00785538|Experimental|IMC-A12|All participants will receive intravenous (I.V.) infusions of IMC-A12, with the dose depending on which cohort they are enrolled into. A minimum of three participants will be enrolled in each cohort. When all participants complete a cohort, dose escalation to the next cohort will occur.
11580555|NCT00785512|Active Comparator|1|Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
11580556|NCT00785512|Placebo Comparator|2|Matching placebo tablets, oral administration
11580557|NCT00785499|Experimental|skim milk|skim milk
11580558|NCT00785499|Experimental|whey|Whey milk drink
11580559|NCT00785499|Experimental|casein|casein milk drink
11580560|NCT00785499|Active Comparator|water|Danish mineral water
11580561|NCT00785486|Other|Midazolam alone|Baseline midazolam and 1-hydroxy-midazolam pharmacokinetics. One day 1 after a fast of at least 10 hours patients received a single oral dose of midazolam 2 mg. Blood was drawn at times sufficient to characterize the pharmacokinetics of midazolam and its main metabolite.
11580562|NCT00785486|Other|Qualaquin (quinine) alone steady state|On the morning of day 9 after taking Qualaquin (quinine) capsules 324 mg orally every 8 hours for the prior 5 days, and following a fast of at least 10 hours all study participants received their usual morning dose of Qualaquin (quinine) 324 mg. Blood was drawn at times sufficient to determine the steady state Cmax and AUC 0-tau for Qualaquin (quinine).
11580563|NCT00785486|Experimental|Midazolam with Qualaquin (quinine)|On day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen, all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg. Blood was drawn sufficient to characterize the steady state kinetics of quinine and the kinetics of midazolam and 1-hydroxy-midazolam in the presence of each other.
11580564|NCT00785473|Active Comparator|1|cholecalciferol, calcium carbonate
11580565|NCT00785473|Placebo Comparator|2|capsules not containing cholecalciferol, otherwise identical to Active comparator; calcium carbonate
11580566|NCT00785460|Experimental|Benfotiamine and Smoking|
11580567|NCT00785460|Placebo Comparator|Smoking alone|
11580568|NCT00785447|Other|1|Twenty healthy subjects between 18 to 59 years of age meeting ASA I-II criteria, undergoing elective surgery, requiring general anesthesia and being able to breathe through both their nose and mouth.
11580569|NCT00785434|Experimental|Active|Active escitalopram
11580570|NCT00785421|Experimental|A|"Patients with KPS > 80% and normal kidney function receive GFFC + LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.).
~Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) + Enoxaparin 1mg/kg daily s.c.
~After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) + Enoxaparin 40mg/d s.c."
11580571|NCT00785421|Active Comparator|B|"Patients with KPS > 80% and normal kidney function receive GFFC - LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w - Enoxaparin 1mg/kg daily s.c.).
~Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) - Enoxaparin 1mg/kg daily s.c.
~After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) - Enoxaparin 40mg/d s.c."
11580572|NCT00785408|Experimental|1|
11580573|NCT00785408|Experimental|2|
11580574|NCT00785408|Experimental|3|
11580575|NCT00785408|Placebo Comparator|4|
11580576|NCT00785408|Placebo Comparator|5|
11580577|NCT00785408|Placebo Comparator|6|
11580578|NCT00785395|Experimental|A|
11580579|NCT00785382|Placebo Comparator|1|
11580580|NCT00785382|Experimental|2|
11580581|NCT00785369|Other|1|Device: In vivo reflectance confocal microscopy of pigmented lesions in vivo
11580582|NCT00785356|Experimental|25 mg Proellex|Proellex 25 mg
11580583|NCT00785356|Experimental|Proellex 50 mg|Proellex 50 mg
11580584|NCT00785356|Placebo Comparator|Placebo|Placebo
11580585|NCT00785343|Active Comparator|Conventional Treatment|
11580586|NCT00785343|Experimental|Robotic and Conventional Therapy|
11580587|NCT00785330|Other|A|Patients receiving no rituximab as GVHD prophylaxis after allogeneic SZT and only standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
11580588|NCT00785330|Experimental|B|rituximab in addition to standard GVHD prophylaxis
11580589|NCT00785317|Experimental|Angemin|1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP
11580590|NCT00785317|Active Comparator|Activelle|1 mg of oral E2 in continuous combination with 0.5 mg of NETA
11580591|NCT00785304||Traumatic Brain Injury|Active Duty military blast-related TBI patients
11580592|NCT00785304||Other Injury Control|Active duty military patients with other injuries but no TBI
11580593|NCT00785291|Active Comparator|Arm A (Paclitaxel)|Patients receive 90 mg/m^2 paclitaxel IV over 1 hour on days 1, 8, and 15. Patients may receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15.
11580594|NCT00785291|Experimental|Arm B (Nab-paclitaxel)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Patients may also receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15.
11580595|NCT00785291|Experimental|Arm C (Ixabepilone)|Patients receive ixabepilone IV over 60 minutes on days 1, 8, and 15. Patients may also receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. (closed to accrual as of 7/18/11)
11580596|NCT00785278||1|Able-bodied participants: Able-bodied individuals will be asked to propel a wheelchair at a self-selected speed for a period of time during which data will be collected on their propulsion biomechanics. It is assumed, for the purpose of the study, that un-learned able-bodied individuals learning to propel a wheelchair reflect newly injured individuals who are just getting accustomed to a new chair.
11580597|NCT00785278||2|Participants with paraplegia: Individuals who are at least 1-year post injury and have used a manual wheelchair as their primary means of locomotion during this time, will be assumed to be, for the purpose of this study, experienced wheelchair users.
11580598|NCT00785265|Experimental|Group Based|60-minute group session involving other study patients who have been assigned to this condition and their guests.
11580599|NCT00785265|Active Comparator|Home-Based|60-minute educational intervention in their home, which will be delivered by an African American health educator.
11580600|NCT00785265|No Intervention|Standard Care|60-minute individual session with an African American health educator.
11580601|NCT00785252|Experimental|1|EZIO
11580602|NCT00785252|Experimental|2|Central line
11580603|NCT00785226|Experimental|RDEA119 with Sorafenib|Total daily doses of RDEA119 from 10 mg/day to 100 mg/day and sorafenib from 400 mg/day to 800 mg/day.
11580604|NCT00785213|Active Comparator|Rosiglitazone Alone|Baseline rosiglitazone pharmacokinetics.
11580605|NCT00785213|Experimental|Rosiglitazone with Steady State Quinine Sulfate|Rosiglitazone pharmacokinetics in the presence of steady state quinine sulfate.
11580606|NCT00785200|Experimental|Chlorhexidine|Approximately 500 detainees housed in approximately 23 detention tanks will be enrolled and receive 2% chlorhexidine-soaked disposable wash cloths (Sage Products, Inc.) to clean their skin on Mondays, Wednesdays, and Fridays for 6 months. Newly arrived detainees in the tanks will be offered enrollment in the study on a biweekly schedule.
11580607|NCT00785200|Placebo Comparator|Water|Approximately 500 detainees in approximately 23 detention tanks will receive water-soaked wash cloths to clean their skin each Monday, Wednesday, and Friday for a 6-month period. If detainees newly arrive to these study tanks, they will be offered enrollment on a biweekly schedule.
11580608|NCT00785200|No Intervention|Usual care|Approximately 500 detainees in approximately 23 detention tanks will be enrolled. These detainees will not receive any intervention. They will be followed for 6 months, and newly arrived detainees will be offered enrollment on a biweekly schedule.
11580609|NCT00785174|Active Comparator|continuous positive airway pressure|respiratory assistance
11580610|NCT00785174|Active Comparator|NIPSV|respiratory assistance using face mak and ventilator to provide inspiratory pressure support and positive end expiratory pressure
11580611|NCT00785148|Experimental|1|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)
11580612|NCT00785135|Active Comparator|Standard (Treatment)|
11580613|NCT00785135|Sham Comparator|Placebo (control)|
11580614|NCT00785109|Experimental|1|100 patients daily additional intake of 2mg vitamin k1
11580615|NCT00785109|Placebo Comparator|2|100 patients no additional intake of vitamin K
11580616|NCT00785096||Patients|Patients who admit for a minor or major surgical intervention
11580617|NCT00785096||Nurses|Medical staff of the University Hospital of Zurich
11580618|NCT00785096||Physicians|Medical staff of the University Hospital of Zurich and other institutions
11580619|NCT00785083|Experimental|1|
11580620|NCT00785083|Placebo Comparator|2|
11580621|NCT00785070||1|Perioperative
11580622|NCT00785057||1|Hypertension patients with history of stroke
11580623|NCT00785057||2|Hypertension patients without history of stroke
11580624|NCT00785044||Group|No participants received any drug administration. No intervention conducted.
11580625|NCT00785031|Active Comparator|internet based intervention|
11580626|NCT00785031|No Intervention|usual care|Patients receive their usual care from their specialist or general practitioner.
11580627|NCT00785018|Active Comparator|C1-esterase inhibitor|Endotoxin 2ng/kg followed by C1- esterase inhibitor 100 U/kg infusion
11580628|NCT00785018|Placebo Comparator|Placebo|Endotoxin 2ng/kg followed by saline 0.9%(placebo) infusion
11580629|NCT00785005||1|Females with Type 2 Diabetes
11580630|NCT00785005||2|Females without Type 2 Diabetes
11580631|NCT00784992|No Intervention|1|Endonasal DCR with silicone tubes (this is the control group since it is the standard procedure / gold standard, although the evidence base for the use of tubes is lacking, hence the need for this trial)
11580686|NCT00784615||2|Women with polycystic ovaries and oligo or anovulation without hyperandrogenism
11580632|NCT00784992|Active Comparator|2|Endonasal DCR without silicone tubes (this is the 'intervention' arm)
11580633|NCT00784979|No Intervention|CMVIG followed by PP|MMF or rapamycin was given with CMVIG for 4 weeks followed by plasmapheresis
11580634|NCT00784966|Active Comparator|1|Two weeks etanercept post islet transplant
11580635|NCT00784966|Active Comparator|2|Two months etanercept treatment post islet transplant
11580636|NCT00784953||1|Asthma patients who were partly controlled or uncontrolled, need to step up, or adjust dose of the controller medications to ICS/LABA
11580637|NCT00784940|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
11580638|NCT00784940|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
11580639|NCT00784940|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
11580640|NCT00784927|Experimental|Treatment|"Participants with symptomatic untreated low grade NHL will be treated according to a 28 day schedule for up to a maximum of 12 consecutive cycles:
~375 mg/m^2 Rituximab IV on day 1. 20 mg Lenalidomide taken orally on days 1-21. 250 mg/m^2 Cyclophosphamide orally on days 1, 8, 15. 40 mg Dexamethasone orally on days 1, 8, 15, 22."
11580641|NCT00784914|Active Comparator|Cohort 1|Patients do not receive temsirolimus.
11580642|NCT00784914|Experimental|Cohort 2|48 hours after surgery, patients receive one 200 mg dose of temsirolimus IV.
11580643|NCT00784888||Aromatase inhibitors|Early stage postmenopausal breast cancer patients under tamoxifen treatment who are switching to aromatase inhibitor treatment
11580644|NCT00784875|Experimental|Period A|2-week double-blind placebo lead-in period. Period A is the first of four 2-week treatment periods.
11580645|NCT00784875|Experimental|Period B|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period B is the second of four 2-week treatment periods.
11580646|NCT00784875|Experimental|Period C|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period C is the third of four 2-week treatment periods.
11580647|NCT00784875|Experimental|Period D|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period D is the fourth of four 2-week treatment periods.
11580648|NCT00784862|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
11580649|NCT00784862|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
11580650|NCT00784862|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
11580651|NCT00784849|Experimental|1|One arm diagnostic
11580652|NCT00784836|Experimental|Avonex|Avonex 30 mcg given subcutaneously, once weekly, for 18 months.
11580653|NCT00784823|Experimental|Combined dose intense Melphalan with bortezomib (MTD)|"The purpose of this study is to determine the tolerance and potential efficacy of combining dose intense melphalan with escalating doses of bortezomib in patients with multiple myeloma undergoing autologous stem cell transplantation.
~Combined dose intense Melphalan with maximum tolerated dose of bortezomib (MTD)"
11580654|NCT00784810|Experimental|Oxycodone/Naloxone Tablets|Oxycodone/Naloxone combination
11580655|NCT00784810|Active Comparator|Codeine/Paracetamol Tablets|Codeine/Paracetamol combination
11580656|NCT00784797|Active Comparator|pitocin|high dose pitocin drip 48 hours after mifepristone preparation.
11580657|NCT00784797|Active Comparator|misopristol|vaginal and oral misopristol 48 hours after mifepristone preparation.
11580658|NCT00784784|Experimental|Influenza vaccine|Influenza vaccine, using Fluviral trivalent split virus vaccine
11580659|NCT00784784|Experimental|Antiviral prophylaxis|Zanamivir antiviral prophylaxis
11580660|NCT00784758|Experimental|Fenzian Device|Subjects randomized to this arm will receive treatment with the Fenzian Device
11580661|NCT00784758|Sham Comparator|Sham Device|Subjects randomized to this arm will receive treatment with the sham device.
11580662|NCT00784745|Experimental|Dexamethasone|
11580663|NCT00784732|Experimental|1|
11580664|NCT00784732|Experimental|2|
11580665|NCT00784732|Active Comparator|3|
11580666|NCT00784719|Experimental|Treatment 1|
11580667|NCT00784719|Experimental|Treatment 2|
11580668|NCT00784719|Experimental|Treatment 3|
11580669|NCT00784719|Experimental|Treatment 4|
11580670|NCT00784719|Active Comparator|Active comparator|
11580671|NCT00784719|Placebo Comparator|Placebo|
11580672|NCT00784706|Experimental|CIT with eye-patching|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log. Participants were also asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
11580673|NCT00784706|Experimental|constraint-induced therapy|The intervention in this group resembled the intervention of the CIT+EP group, except participants did not wear the EP glasses.
11580674|NCT00784706|Active Comparator|conventional therapy|traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
11580675|NCT00784693|Experimental|Tanezumab|
11580676|NCT00784693|Placebo Comparator|Placebo|
11580677|NCT00784680|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
11580678|NCT00784680|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
11580679|NCT00784680|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
11580680|NCT00784654|Experimental|Lisdexamfetamine dimesylate (LDX)|Open-label 30, 50, or 70mg
11580681|NCT00784654|Placebo Comparator|Placebo|
11580682|NCT00784641|Experimental|Novel Bausch & Lomb Contact Lens|Novel Bausch & Lomb daily disposable contact lenses
11580683|NCT00784641|Active Comparator|SofLens|Bausch & Lomb SofLens daily disposable contact lenses
11580684|NCT00784641|Active Comparator|Acuvue|Johnson and Johnson 1-Day Acuvue Moist contact lenses
11580685|NCT00784615||1|Women with polycystic ovaries, oligo or anovulation and hyperandrogenism.
11580687|NCT00784615||3|Women with normal ovaries, oligo or anovulation and hyperandrogenism
11580688|NCT00784615||4|Women with normal ovaries, oligo or anovulation and hyperandrogenism
11580689|NCT00784615||5|Women with out polycystic ovary syndrome
11580690|NCT00784589|Experimental|Rituximab|
11580691|NCT00784589|Active Comparator|Corticotherapy|General Corticotherapy
11580692|NCT00784576||Cardiac surgery patients|Individuals consecutively scheduled for cardiac surgery
11580693|NCT00784563|Active Comparator|Continuous training|Aerobic walking using continuous heart rate training.
11580694|NCT00784563|Active Comparator|Interval training|Aerobic walking using interval heart rate training
11580695|NCT00784550|Experimental|ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler|Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID Plus Tiotropium Bromide 18 mcg QD
11580696|NCT00784550|Active Comparator|SPIRIVA® HANDIHALER® inhaler|Tiotropium Bromide 18mcg QD plus Placebo DISKUS BID
11580697|NCT00784537|Other|Arm A|"Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)
~The subsequent treatment will be as it follows:
~PET-2 positive patients will be high-dose salvage treatment;
~PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).
~The following restaging procedures are planned as it follows:
~Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.
~Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).
~PET-6 negative patients will be randomized to first arm:
~No radiotherapy."
11580698|NCT00784537|Other|Arm B|"Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)
~The subsequent treatment will be as it follows:
~PET-2 positive patients will be high-dose salvage treatment;
~PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).
~The following restaging procedures are planned as it follows:
~Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.
~Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).
~PET-6 negative patients will be randomized to second arm:
~Adjuvant radiotherapy (30 Gy) on sites of initial bulky disease."
11580699|NCT00784524|Experimental|LMI Vaccination + IL-2|Patients receiving allogeneic large multivalent immunogen breast cancer vaccine and aldesleukin.
11580700|NCT00784511|Experimental|1 vitamin D3|vitamin D3, 4000 IU/d
11580701|NCT00784511|Placebo Comparator|2|placebo
11580702|NCT00784498|Active Comparator|midazolam/ketamine|Patients with orthopedic injuries requiring painful manipulation
11580703|NCT00784498|Active Comparator|propofol|Patients with orthopedic injuries requiring painful manipulation
11580704|NCT00784485|Experimental|Xolair injections|All subjects receive active drug (Xolair-see 'interventions').
11580705|NCT00784472|Active Comparator|oxycodone|
11580706|NCT00784472|Active Comparator|morphine|
11580707|NCT00784459|Experimental|Treatment with Abatacept|Administration of Abatacept intravenously 10 mg/kg every 2 weeks for 3 doses, followed by every 4 weeks for 2 doses.
11580708|NCT00784459|Placebo Comparator|Placebo|Administration of placebo (normal saline) intravenously 10 mg/kg every 2 weeks for 3 doses, followed by every 4 weeks for 2 doses.
11580709|NCT00784446|No Intervention|XELOX, Bevacizumab, Imatinib|
11580710|NCT00784433|Experimental|alcohol 1|
11580711|NCT00784433|Experimental|alcohol 2|
11580712|NCT00784433|Placebo Comparator|control|
11580713|NCT00784420|Active Comparator|UK-453,061|
11580714|NCT00784420|Active Comparator|Raltegravir|
11580715|NCT00784420|Experimental|UK-453,061 plus Raltegravir|
11580716|NCT00784407|Active Comparator|FOCUS (group A)|Patients submitted to total thyroidectomy with the use of the FOCUS harmonic scalpel device
11580717|NCT00784407|Active Comparator|HARMONIC ACE (group B)|Patients submitted to total thyroidectomy with the use of the HARMONIC ACE harmonic scalpel device
11580718|NCT00784394|Experimental|Arm I (diindolylmethane)|Participants receive a single dose of diindolylmethane PO on day 1.
11580719|NCT00784394|Placebo Comparator|Arm II (placebo)|Participants receive a single dose of placebo orally (PO) on day 1.
11580720|NCT00784381||1|
11580721|NCT00784381||2|These units use the same electronic prescribing system, but had no counselling software
11580722|NCT00784368|Experimental|SFI (ITCZ Oral Solution Monotherapy)|Participants with deep-seated mycosis (Systemic Fungal Infection [SFI]) received itraconazole (ITCZ) oral solution in the dose range of 20 milliliter (ml) per day to 40 ml per day for 12 weeks as per Investigator's discretion.
11580723|NCT00784368|Experimental|SFI (Switched Treatment)|Participants with SFI received 200 milligram (mg) twice daily itraconazole intravenous (into the vein) infusion (ITCZ-IV) for first 2 days followed by 200 mg per day ITCZ-IV up to 14 days. Participants then received ITCZ oral solution in the dose range of 20 ml per day to 40 ml per day for 12 weeks as per Investigator's discretion.
11580724|NCT00784368|Experimental|FN (Switched treatment)|Participants with febrile neutropenia (FN) with suspected fungal infection received 200 mg twice daily ITCZ-IV for first 2 days followed by 200 mg per day ITCZ-IV up to 14 days. Participants then received ITCZ oral solution in the dose range of 20 ml per day to 40 ml per day for 12 weeks as per Investigator's discretion.
11580725|NCT00784355|Experimental|1:Laparoscopic cholecystectomy|Surgery
11580726|NCT00784355|No Intervention|2:controls|non-surgical control group
11580727|NCT00784342||Stable|Patients who are stable have not had a COPD exacerbation in the past 2 months.
11580728|NCT00784342||Exacerbation|Patients with an exacerbation have been diagnosed and started on treatment for an exacerbation within the past 3 days.
11580729|NCT00784329|Experimental|Optical Frequency Domain Imaging|Optical Frequency Domain Imaging System used during Lung and Bronchial biopsies to detect cancerous tissue. Tissue imaging results will be compared to tissue biopsy results.
11580730|NCT00784316|Active Comparator|metoprolol|
11580731|NCT00784316|Active Comparator|amiodarone|
11580732|NCT00784303|Experimental|DTC cohort|This arm will enroll participants with radioiodine (131 I)-refractory/resistant differentiated thyroid cancer.
11580733|NCT00784303|Experimental|MTC cohort|This arm will enroll participants with medullary thyroid cancer.
11580734|NCT00784290|Experimental|1|Orantinib
11580735|NCT00784277|Experimental|001|Tapentadol IR (CG5503) 50mg for 14 days
11580736|NCT00784277|Experimental|002|Tapentadol IR (CG5503) 75mg for 14 days
11580739|NCT00784277|Experimental|005|Tapentadol ER (CG5503) flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
11580740|NCT00784277|Active Comparator|006|oxycodone CR flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
11580741|NCT00784277|Placebo Comparator|007|placebo Tablets and capsules 2 x a day for 28 days
11580742|NCT00784238|Experimental|Paliperidone|Paliperidone Extended-Release (ER) oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
11580743|NCT00784225|Experimental|Vitamin E + selenium placebo|vitamin E and selenium placebo daily for 7-12 years
11580744|NCT00784225|Experimental|Selenium + vitamin E placebo|selenium and vitamin E placebo daily for 7-12 years
11580745|NCT00784225|Experimental|Vitamin E + selenium|vitamin E and selenium placebo daily for 7-12 years
11580746|NCT00784225|Placebo Comparator|Vitamin E placebo + selenium placebo|vitamin E placebo and selenium placebo daily for 7-12 years
11580747|NCT00784212|Experimental|Cohort 1|
11580748|NCT00784212|Experimental|Cohort II|
11580749|NCT00784212|Experimental|Cohort III|
11580750|NCT00784186|Experimental|mifepristone+misoprostol|200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
11580751|NCT00784186|Experimental|misoprostol|800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
11580752|NCT00784160|Experimental|1|Lactic Acid
11580753|NCT00784147|Active Comparator|Ibalizumab 800 mg|every 2 weeks, combined with an Optimized Background Regimen
11580754|NCT00784147|Active Comparator|Ibalizumab 2000 mg|every 4 weeks, combined with an Optimized Background Regimen
11580755|NCT00784134|Experimental|Alteplase|administration of alteplase via the intraventricular catheter
11580756|NCT00784134|Placebo Comparator|Saline Placebo|1 ml of normal saline administered via the intraventricular catheter
11580757|NCT00784121|Experimental|1|Lactic Acid (Dermacyd Breeze)
11580758|NCT00784108|Other|Diagnostic tool|Modulated Imaging measure effect of Photodynamic therapy treatment
11580759|NCT00784108|Other|Photodynamic therapy|Modulated Imaging measure effect of Photodynamic therapy treatment
11580760|NCT00784095|Experimental|Preparation and Completion|"Subjects in the first group (treatment) met with the facilitator three times for a period of forty-five minutes to one hour to discuss issues of life completion and preparation. In the first session, subjects were asked to discuss issues related to life review. In session two, participants spoke about issues of regret and forgiveness. In the final session, subjects discussed issues of heritage and legacy."
11580761|NCT00784095|Active Comparator|Attention Control|"The subjects in the second group (attention control) met with a facilitator three times for 45 minutes and listened to a non-guided relaxation CD."
11580762|NCT00784095|No Intervention|True Control|"Subjects in the third group (true control) were exposed to no intervention or attention control."
11580763|NCT00784082||Homozygous SS sickle cell children|"Hydroxycarbamide, Hydroxyurea (drug):
~Homozygous SS sickle cell children, aged > 3 years, of sub-Saharian Africa extraction, in a steady-state of disease , taken no drug except penicillin-V, folate or iron supplementation, hydroxyurea, divided into three groups :
~children treated with hydroxyurea 20-25 mg/kg/day since at least 3 months with clinical efficacy on vaso-occlusive events
~untreated children with major vaso-occlusive events
~children > 5 year-old without a history of vaso-occlusive events
~Controls : heterozygous AS parents or siblings of the patients, and AA siblings or healthy African unrelated subjects, aged > 3 years, taken no drug on the day of blood sampling."
11580764|NCT00784082||Homozygous SS children|"Hydroxycarbamide, Hydroxyurea (drug):
~Homozygous SS children, aged > 3 years, of sub-Saharian Africa extraction, in a steady-state of disease, taken no drug except penicillin-V, folate or iron supplementation, hydroxyurea, divided into three groups :
~children treated with hydroxyurea 20-25 mg/kg/day since at least 3 months with clinical efficacy on vaso-occlusive events
~untreated children with major vaso-occlusive events
~children > 5 year-old without a history of vaso-occlusive events
~Controls : heterozygous AS parents or siblings of the patients, and AA siblings or healthy African unrelated subjects, aged > 3 years, taken no drug on the day of blood sampling."
11580765|NCT00784069|Experimental|1|Lactic Acid (Dermacyd Breeze)
11580766|NCT00784056|Experimental|1|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)
11580767|NCT00784043|Experimental|Bilateral|Bilaterally implanted simultaneously
11580768|NCT00784043|Experimental|Unilateral|Unilaterally implanted
11580769|NCT00784030|Other|Polycystic Kidney Disease Patients|Patients who present with polycystic kidney disease (PKD)
11580770|NCT00784030|Other|Healthy Patients|
11580771|NCT00784017|Active Comparator|asparaginase medac|
11580772|NCT00784017|Experimental|recombinant asparaginase|
11580773|NCT00784004|Other|Volunteers|Ten healthy volunteers
11580774|NCT00784004|Other|Patients|Sixteen patients with respiratory insufficiency
11580775|NCT00783991||IVR-PC|This group will have instruments administered through interactive voice response (IVR) and personal computer (PC).
11580776|NCT00783991||PP-PC|This group will have instruments administered through paper and pencil (PP) and PC.
11580777|NCT00783991||PDA-PC|This group will have instruments administered by personal digital assistant (PDA) and PC.
11580778|NCT00783991||PC-PC|This group will have all instruments administered through PC.
11580779|NCT00783978||1|Children with chronic lung disease
11580780|NCT00783965|Experimental|Arm I|Patients apply 0.1% tazarotene cream on months 0-12 and vehicle (placebo) on months 13-36 once daily to the chest.
11580781|NCT00783965|Experimental|Arm II|Patients apply, vehicle (placebo) on months 0-12 and 0.1% tazarotene cream on months 13-36 once daily to the chest.
11580782|NCT00783952|Other|1|Mixed venous oxygen saturation measurement obtained from blood drawn from a pulmonary artery catheter.Calculation of mixed venous oxygen saturation from the measurement of peripheral oxygen saturations using multiple Cerebral/Somatic Tissue Oximeter device probes
11580783|NCT00783939|Experimental|1|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
11580784|NCT00783926|Experimental|Cohort 1|60 subjects randomized in an equal number to six different vaccine doses
11580785|NCT00783926|Experimental|Cohort 2|Following review of safety data of Cohort 1, approximately 360 additional subjects randomized in an equal number to the six different vaccine doses
11580786|NCT00783900|Active Comparator|metoprolol|
11580787|NCT00783900|Active Comparator|biatrial pacing|
11580788|NCT00783887||1|Patients with suspected or confirmed primary ciliary dyskinesia after ciliary investigations who accepted to participate to the genetic studies
11580789|NCT00783861|Experimental|1|Lactic Acid (Dermacyd Femina)
11580790|NCT00783835|Experimental|Methylphenidate|
11580791|NCT00783822|Other|intervention|rapid genetic counseling and testing
11580792|NCT00783822|No Intervention|control|usual care
11580793|NCT00783796|Experimental|2.25mm XIENCE V®|Patients receiving the 2.25 mm XIENCE V® stent
11580794|NCT00783783||Poor metabolizers|Patients with CYP2D6 genotypes predictive of poor metabolizer phenotype
11580795|NCT00783783||Non poor metabolizers|Patients with CYP2D6 genotypes predictive of intermediate, extensive, or ultra-rapid metabolizer phenotypes
11580796|NCT00783770||30-33 weeks|mother infant pairs with gestation of 30-33 weeks
11580797|NCT00783770||34-37 weeks|mother infant pairs with gestation of 34-37 weeks
11580798|NCT00783770||38-42 weeks|mother infant pairs with gestation of 38-42 weeks
11580799|NCT00783757|Experimental|Optical Imaging|Tomographic Optical Imaging Arm
11580800|NCT00783744|Experimental|1|Insulin Glargine + Glimepiride + Metformin
11580801|NCT00783744|Active Comparator|2|Insulin monotherapy with premixed insulin NPH 30/70
11580802|NCT00783731|Experimental|Low dose midazolam|
11580803|NCT00783718|Experimental|Vedolizumab|"In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).
~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase."
11580804|NCT00783718|Placebo Comparator|Placebo|In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.
11580805|NCT00783705|Experimental|Arm I (inositol)|Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.
11580806|NCT00783705|Experimental|Arm II (placebo)|Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.
11580807|NCT00783692|Experimental|Vedolizumab|"In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).
~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase."
11580808|NCT00783692|Placebo Comparator|Placebo|In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.
11580809|NCT00783679|Other|1|Twenty adult spontaneously breathing patients without intubation and mechanical ventilation recruited from the cardiac catheterization laboratory. All will be post-heart-transplant patients coming for yearly evaluation.
11580810|NCT00783666|Experimental|1|Lactic Acid
11580811|NCT00783640|Experimental|1|Lactic Acid
11580812|NCT00783627||1|Patient with sickle cell disease
11580813|NCT00783627||2|Healthy volunteers
11580814|NCT00783614|Active Comparator|1|Start antiretroviral therapy (ART) immediately and initiate aspirin 325mg po daily
11580815|NCT00783614|Placebo Comparator|2|Start antiretroviral therapy (ART) immediately and initiate placebo pill daily
11580816|NCT00783614|Active Comparator|3|Defer antiretroviral therapy (ART) for 1 month and immediately initiate aspirin 325mg po daily
11580817|NCT00783614|Placebo Comparator|4|Defer antiretroviral therapy (ART) for 1 month and immediately initiate placebo pill daily
11580818|NCT00783601|Experimental|1|Treatment Sequence 1: MK0524 + placebo, MK0524 + montelukast, placebo, placebo, placebo + montelukast
11580819|NCT00783601|Experimental|2|Treatment sequence 2: Placebo, montelukast, placebo, MK0524, MK0524 + montelukast
11580820|NCT00783575||Inflammatory Bowel Disease|Crohn's disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel disease (IBD) are chronic, life-long, destructive inflammatory conditions of the gastrointestinal tract.
11580821|NCT00783562|Experimental|1|
11580822|NCT00783562|Active Comparator|2|
11580823|NCT00783549|Experimental|Cohort 1|6 active 2 placebo
11580824|NCT00783549|Experimental|Cohort 2|9 active 3 placebo
11580825|NCT00783549|Experimental|Cohort 3|Optional cohort
11580826|NCT00783549|Experimental|Cohort 4|12 active
11580827|NCT00783549|Experimental|Cohort 5|12 active
11580828|NCT00783536|Experimental|1|"Clinical and demographic information
~Clinical and Laboratory information"
11580829|NCT00783536|Active Comparator|2|"Clinical and demographic information
~Clinical and Laboratory information"
11580830|NCT00783523|Active Comparator|Doxycycline|Patients undergoing elective vascular malformation surgery will receive doxycycline100 mg twice a day, a dose shown to effectively decrease MMP or placebo, treatment for two weeks prior to surgery
11580831|NCT00783523|Placebo Comparator|Placebo|Patients undergoing elective vascular malformation surgery will receive doxycycline100 mg twice a day, a dose shown to effectively decrease MMP or placebo, treatment for two weeks prior to surgery
11580832|NCT00783510||HUMIRA® Treatment Arm|For patients taking HUMIRA®
11580833|NCT00783510||Methotrexate Treatment Arm|For patients taking Methotrexate
11580834|NCT00783497||1|Caucasian Americans
11580835|NCT00783497||2|African Americans
11580836|NCT00783484|Experimental|Cohort 1|PF-03716539 crossover, single dose escalation (doses subject to change).
11580837|NCT00783484|Experimental|Cohort 2|PF-03716539 crossover, single dose escalation (doses subject to change).
11580838|NCT00783484|Experimental|Cohort 3|Midazolam-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
11580839|NCT00783484|Experimental|Cohort 4|Darunavir-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
11580840|NCT00783484|Experimental|Cohort 5|Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
11580841|NCT00783484|Experimental|Cohort 6|Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 200 mg).
11580842|NCT00783471|Experimental|1|Erlotinib followed by Docetaxel
11580843|NCT00783471|Experimental|2|Docetaxel followed by Erlotinib
11580844|NCT00783458|Active Comparator|Nasonex Followed by Flonase|
11580845|NCT00783458|Active Comparator|Flonase Followed by Nasonex|
11580846|NCT00783445|Experimental|1|Exercise in a community setting while supervised by a coach
11580847|NCT00783445|Active Comparator|2|Self-exercise plan based on an individualized prescription after an initial fitness evaluation
11580848|NCT00783432|Experimental|1|Astepro Nasal Spray (0.1% azelastine hydrochloride)
11580849|NCT00783432|Active Comparator|2|Astelin Nasal Spray (0.1% azelastine hydrochloride)
11580850|NCT00783406|Experimental|PF- 00610355|
11580851|NCT00783406|Experimental|PF-00610355|
11580852|NCT00783406|Experimental|PF -00610355|
11580853|NCT00783406|Placebo Comparator|Placebo|
11580854|NCT00783393|Experimental|Single arm|"The study consists of two steps:
~Step 1, the therapeutic study phase, comprising six cycles of treatment with temozolomide, and
~Step 2, the long-term treatment phase, where subjects with at least disease stabilization at the end of Step 1 may continue temozolomide treatment until unacceptable toxicity or disease progression occur, up to a maximum of 2 years from the start of treatment in Cycle 1."
11580855|NCT00783380|Experimental|Virosomal influenza vaccine|
11580856|NCT00783380|Active Comparator|Subunit influenza vaccine|
11580857|NCT00783367|Experimental|Lenalidomide plus rituximab with dexamethasone|Lenalidomide-low dose dexamethasone plus rituximab
11580858|NCT00783354|Active Comparator|Continuous Treatment|
11580859|NCT00783354|Experimental|PRN regimen|
11580860|NCT00783341|Experimental|GAP-134|
11580861|NCT00783341|Placebo Comparator|placebo|
11580862|NCT00783328|Experimental|1|Open label single arm trial
11580863|NCT00783315|Active Comparator|1|Self-Directed Weight Loss Program (Control Group)
11580864|NCT00783315|Experimental|2|Call-Center Directed (CCD) Weight Loss Program
11580865|NCT00783315|Experimental|3|In-Person Directed (IPD) Weight Loss Program
11580866|NCT00783289|Placebo Comparator|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
11580867|NCT00783289|Experimental|Benralizumab 25 mg|Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
11580868|NCT00783289|Experimental|Benralizumab 100 mg|Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
11580869|NCT00783289|Experimental|Benralizumab 200 mg|Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
11580870|NCT00783276|Placebo Comparator|Sugar Pill|Placebo
11580871|NCT00783276|Active Comparator|SYN115|
11580872|NCT00783263|Experimental|Rosuvastatin 5 mg + Ezetimibe 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
11580873|NCT00783263|Active Comparator|Rosuvastatin 10 mg|Participants who received rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
11580874|NCT00783263|Experimental|Rosuvastatin 10 mg + Ezetimibe 10 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
11580875|NCT00783263|Active Comparator|Rosuvastatin 20 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
11580876|NCT00783250|Experimental|Salbutamol+Tiotropium|Salbutamol will be given at the dose of 400 micrograms and Tiotropium at the dose of 18 micrograms
11580877|NCT00783250|Placebo Comparator|placebo + Tiotropium|Placebo using MDI + administration of Tiotropium after 20 minutes
11580878|NCT00783237|Experimental|Mometasone Furoate Nasal Spray|
11580879|NCT00783237|Placebo Comparator|Placebo Nasal Spray|
11580880|NCT00783224|Placebo Comparator|Mometasone Furoate Placebo (PLAMF)|Placebo to mometasone furoate nasal spray, made to be indistinguishable from mometasone furoate nasal spray
11580881|NCT00783224|Placebo Comparator|Fluticasone Propionate Placebo (PLAFP)|Placebo to fluticasone propionate nasal spray, made to be indistinguishable from fluticasone propionate nasal spray
11580882|NCT00783224|Experimental|Mometasone Furoate (MF)|Mometasone furoate nasal spray 200 μg/day(QD)
11580883|NCT00783224|Active Comparator|Fluticasone Propionate (FP)|Fluticasone Propionate nasal spray 200 μg/day, twice per day (BID)
11580884|NCT00783211|Experimental|1|desloratadine
11580885|NCT00783211|Active Comparator|2|fexofenadine
11580886|NCT00783211|Placebo Comparator|3|placebo
11580887|NCT00783198|Experimental|SCH 39641 6 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 6 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
11580888|NCT00783198|Experimental|SCH 39641 12 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 12 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
11580889|NCT00783198|Placebo Comparator|Placebo|Participants receive placebo matching ambrosia artemisiifolia allergen extract, rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
11580890|NCT00783185|Experimental|ACT|Anti-Cannabis-Consumption-Training
11580891|NCT00783185|Active Comparator|CG|Control group
11580892|NCT00783172|Experimental|OGF & Gemcitabine|Opioid Growth factor 250 ug/kg IV once a week. Gemcitabine 1000 mg/m2 weekly for 7 out of 8 weeks induction then every 3 out of 4 week cycles.
11580893|NCT00783159|Experimental|A|Training I
11580894|NCT00783159|Experimental|B|Training II
11580895|NCT00783159|Active Comparator|C|Control
11580896|NCT00783146|Experimental|1|desloratadine
11580897|NCT00783146|Active Comparator|2|fexofenadine
11580898|NCT00783146|Placebo Comparator|3|placebo
11580899|NCT00783133|Experimental|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
11580900|NCT00783133|Experimental|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
11580901|NCT00783120|Experimental|1|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold).
11580902|NCT00783120|Sham Comparator|2|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session)
11580903|NCT00783107|Experimental|Cyclosporine|
11580904|NCT00783107|Placebo Comparator|Placebo|Subjects will be randomly assigned to Cyclosporine or placebo, in a ratio of 2:1.
11580905|NCT00783094|Experimental|Tadalafil 2.5 milligrams (mg)|2.5 mg tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.
11580906|NCT00783094|Experimental|Tadalafil 5 mg|5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.
11580907|NCT00783094|Placebo Comparator|Placebo|"Placebo tablet taken by mouth once a day for 12 weeks.
~Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks."
11580908|NCT00783081|Experimental|low dose K-134|
11580909|NCT00783081|Experimental|mid dose K-134|
11580910|NCT00783081|Experimental|high dose K-134|
11580911|NCT00783081|Active Comparator|Comparator|
11580912|NCT00783081|Placebo Comparator|Placebo|
11580913|NCT00783068|Active Comparator|GTS-21|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0).
11580914|NCT00783068|Placebo Comparator|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
11580915|NCT00783055|Experimental|Treatment|12 weeks of individually tailored intervention programmes based on participants individual wishes for daily activities e.g.ADL, mobility, social, mental or creative that they want to improve, conserve - and/or to revive.
11580916|NCT00783042|Active Comparator|1|
11580917|NCT00783042|Placebo Comparator|2|
11580918|NCT00783029||Healthy Subjects|Healthy participants between the ages of 21 and 65 years old.
11580919|NCT00783016|Experimental|Morphine|
11580920|NCT00783016|No Intervention|Placebo|
11580921|NCT00783003|Experimental|Long acting muscarinic receptor antagonist (LAMA)|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
11580922|NCT00783003|Experimental|Long acting Beta 2 agonist (LABA)|Inhaled Long Acting Beta 2 agonist (LABA) which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
11580923|NCT00783003|Experimental|LAMA with LABA|Inhaled Long Acting Muscarinic receptor Antagonist (LAMA) and a inhaled Long Acting Beta 2 Agonist (LABA), both in development for treatment of Chronic Obstructive Pulmonary Disease and taken in combination.
11580924|NCT00783003|Placebo Comparator|Placebo|Matching placebo, no intervention.
11580925|NCT00782990|Active Comparator|tvt group|Surgical treatment for incontinence: TVT
11580926|NCT00782990|Active Comparator|Burch group|Surgical treatment for incontinence: Colposuspension
11580927|NCT00782977|Sham Comparator|1|Nasal cannulae with no oxygen flow
11580928|NCT00782977|Active Comparator|2|Nasal cannulae with oxygen flow at 5 L/minute
11580929|NCT00782977|Active Comparator|3|Nasal cannulae with oxygen flow at 10 L/minute
11580930|NCT00782964||1|Outpatient with major depressive disorder, who has a change in pharmacological therapeutical plan after an incomplete response or intolerance to a treatment with an adequate dosage of an antidepressant (SSRI/NSRI) (20-40 mg fluoxetine, 75-225 mg venlafaxine or equivalent) for at least 6 weeks.
11580931|NCT00782951|Experimental|Org 28611|
11580932|NCT00782951|Active Comparator|morphine sulfate|
11580933|NCT00782951|Placebo Comparator|Placebo|
11580934|NCT00782938||low SAA|
11580935|NCT00782938||high SAA|
11580936|NCT00782925|Experimental|1|"Study intervention:
~A face/profile X-ray of their entire spine at baseline
~Educational program
~Exercise program
~Self-led exercises
~A follow-up at 12 and 24 months with their occupational therapist.
~A follow-up at 18 months with a physical therapist.
~Workers received also at the end of the educational program written standardized information about back pain (the back book, an information booklet) 1.
~Coudeyre E., Tubach F., Rannou F. & all, Effect of simple information booklet on pain persistance after an acute episode of low back pain: a non- randomised trial in a primary care setting. PLoS ONE. 2007 ; 2 : e706"
11580937|NCT00782925|No Intervention|2|"Control intervention :
~No intervention
~A face/profile X-ray of their entire spine at baseline
~A follow-up at 12 and 24 months with their occupational therapist,
~A follow-up at 18 months with a physical therapist."
11580938|NCT00782899||1|Schizophrenic patients with a acute episode treated in outpatients clinics
11580939|NCT00782873||obese subjects|BMI > 35
11580940|NCT00782860||unsuccessful termination|unsuccessful termination of early pregnancy failure with Misoprostol
11580941|NCT00782860||successful termination|successful termination of early pregnancy failure with Misoprostol
11580942|NCT00782847|Active Comparator|with DiaNe program|study subjects which participated in the DiaNe consultation and support program
11580943|NCT00782847|No Intervention|without DiaNe program|study subjects which received standard care by diabetologist and/or nephrologist
11580944|NCT00782821|Active Comparator|Rabbit Antithymocyte Globulin (rATG)|Rabbit Antithymocyte Globulin (rATG) 1.5mg/kg per dose x 6 doses rATG was administered on post-op day 0, 2, 4, 6, 8 and 10.
11580997|NCT00782457|Active Comparator|OPEN SURGERY|
11580998|NCT00782457|Experimental|LAPAROSCOPIC SURGERY|
11580945|NCT00782821|Experimental|RATG/Rituxan|Rabbit Antithymocyte Globulin (rATG)/Rituxan 1.5mg/kg per dose x 5 doses of rATG. 375mg/m2 x 1 dose of rituxan. rATG was administered on post-op day 0, 2, 4, 6 and 8. Rituxan was given on post-op day 1.
11580946|NCT00782821|Experimental|RATG/Velcade|Rabbit Antithymocyte Globulin (rATG) /Velcade 1.5mg/kg per dose x 5 doses of rATG. 1.3mg/m2 per dose x 4 doses of velcade. rATG was administered on post-op day 0, 2, 4, and 6. Velcade was administered on post-op day 0, 3, 7 and 10.
11580947|NCT00782821|Experimental|RATG/Rituxan/Velcade|"Rabbit Antithymocyte Globulin (RATG) / Rituxan / Velcade 1.5mg/kg per dose x 4 doses of rATG. 200mg/m2 for 1 dose of rituxan. 1.3mg/m2 per dose x 4 doses of velcade.
~rATG was administered on post-op day 0, 2, 4, and 6. Velcade was administered on post-op day 0, 3, 7 and 10. Rituxan was given on post-op day 1."
11580948|NCT00782808||1 HIV DNA will be stratified by high|
11580949|NCT00782808||2 HIV DNA will be stratified by low|
11580950|NCT00782795|Active Comparator|Pioglitazone|30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
11580951|NCT00782795|Placebo Comparator|sugar pill (placebo)|1 sugar pill (placebo) taken once daily for 48 weeks.
11580952|NCT00782769|Experimental|Oxybutinyn Vaginal Ring 4mg|inserted daily and replaced every 4 weeks
11580953|NCT00782769|Experimental|Oxybutinyn Vaginal Ring 6mg|inserted daily and replaced every 4 weeks
11580954|NCT00782756|Experimental|RT, with temozolomide and bevacizumab|This treatment regimen is novel in that it delivers the initial course of RT over 2 weeks instead of 6 weeks; also, the addition of bevacizumab during and after RT is a new approach.
11580955|NCT00782743||1|patients with required new anticoagulation with phenprocoumon 1/2 of them with a GFR< 60 ml/min and >15 ml/min
11580956|NCT00782743||2|patients with required therapy with ASS, 1/2 of them with a GFR <60 ml/min and >15 ml/min
11580957|NCT00782730||Bladder Scan Group|Patients who agree to enroll in the trial and allow their known bladder volumes and residual bladder volumes to be measured by actual volumes retrograde instilled, and also by bladder scanner ultrasound.
11580958|NCT00782717|Experimental|NEVANAC|One drop three times a day starting on the day prior to cataract surgery (Day -1) and continuing on the day of surgery (Day 0) and for 90 days thereafter.
11580959|NCT00782717|Placebo Comparator|Nepafenac Vehicle|One drop three times a day starting on the day prior to cataract surgery (Day -1) and continuing on the day of surgery (Day 0) and for 90 days thereafter.
11580960|NCT00782704||1|questionnair for Patients
11580961|NCT00782704||2|questionnaire for Nurses
11580962|NCT00782704||3|questionnaire for Physicians
11580963|NCT00782691||Head-and-neck cancer patients.|Head-and-neck cancer patients eligible for therapeutic lymph node dissection of cervical nodes.
11580964|NCT00782665|Active Comparator|Group 1|Patients who have labored and subsequently delivered by cesarean section
11580965|NCT00782665|Placebo Comparator|2|Patients who electively select cesarean section
11580966|NCT00782652|Active Comparator|1|inhaled nitric oxide at 40 or 80ppm
11580967|NCT00782652|Placebo Comparator|2|inhaled nitrogen at either 40 or 80ppm
11580968|NCT00782639|Active Comparator|Iopamiro-370|
11580969|NCT00782639|Active Comparator|Visipaque 320|
11580970|NCT00782626|Experimental|everolimus|Patients rcvd oral everolimus 5.0 mg/m2/day for a 28-day treatment course up to a total of 12 courses (48 weeks) if a patient had stable disease except if toxicity was unacceptable. Two dose reductions were permitted (3.0 5.0 mg/m2/day and 2.0 mg/m2/day).
11580971|NCT00782613|Active Comparator|1|Two psoriatic plaques of similar surface area and severity will be identified for each subject. ALT-2074 will be applied topically twice daily to 1 of the 2 target plaques, and the placebo control to the other plaque for a period of 28 days in amounts sufficient to cover the entire surface area of the target plaque, extending to 1 cm outside of the plaque border.
11580972|NCT00782613|Placebo Comparator|2|Placebo
11580973|NCT00782600|Experimental|50 mg oral suspension|once daily for one day
11580974|NCT00782600|Experimental|50 mg CR Type 1|once daily for one day
11580975|NCT00782600|Experimental|50 mg CR Type 2|once daily for one day
11580976|NCT00782600|Experimental|50 mg SR Type 3|once daily for one day
11580977|NCT00782587|Experimental|Arm 1|Single arm, open label, single dose, intravesical instillation of Chemophase (combination of rHuPH20 and mitomycin) for appropriate superficial bladder cancer patients within 6 hours of TURBT.
11580978|NCT00782574|Experimental|1|AZD2281 + Cisplatin combination therapy
11580979|NCT00782561|Experimental|FG-3019|FG-3019 5 mg/kg
11580980|NCT00782548|Active Comparator|1|Test product A (1 x 30 mg KADIAN)
11580981|NCT00782548|Active Comparator|2|Reference product B (1 x 30 mg Avinza)
11580982|NCT00782535|Experimental|Treatment A|Single therapeutic dose of CHF 4226 pMDI
11580983|NCT00782535|Experimental|Treatment B|Single therapeutic dose of CHF 4226 pMDI
11580984|NCT00782535|Experimental|Treatment C|Single supratherapeutic dose of CHF 4226 pMDI
11580985|NCT00782535|Experimental|Treatment D|Single supratherapeutic dose of CHF 4226 pMDI
11580986|NCT00782535|Placebo Comparator|Treatment E|Single dose of placebo
11580987|NCT00782522|Experimental|1|Eccentric training program
11580988|NCT00782522|Active Comparator|2|Traditional training program
11580989|NCT00782509|Experimental|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
11580990|NCT00782509|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
11580991|NCT00782509|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
11580992|NCT00782496|Experimental|Level1 Basic Meter Features|Adults with type 1 and type 2 diabetes use only basic features (Level 1) to test their blood. The CONTOUR meter has the basic features such as small meter size, easy to use , No Coding™ technology, 5-second test time, small sample size (0.6 µL), automatic control solution marking, 480 reading memory capacity.
11580993|NCT00782496|Experimental|Level 2 Advanced Meter Features|Adults with type 1 and type 2 diabetes additionally access and use more advanced meter features(Level 2)during blood glucose testing. The advanced features include ability to mark blood glucose values as obtained before or after meals or to set an audible reminder to test.
11580994|NCT00782470||Group 1|
11580995|NCT00782470||Group 2|
11580996|NCT00782470||Group 3|
11580999|NCT00782444|Active Comparator|Computer navigated knee replacement|Computer navigation system from Brainlab, vector vision, kolibri.
11581000|NCT00782444|Placebo Comparator|Conventional knee replacement|Conventional total knee replacement is performed with intramedullary guides in the traditional way.
11581001|NCT00782431|Experimental|1|Vero cell-derived, trivalent, seasonal influenza vaccine
11581002|NCT00782431|Active Comparator|2|Licensed egg-derived, trivalent seasonal influenza vaccine
11581003|NCT00782418|Active Comparator|1|exenatide 5mcg
11581004|NCT00782418|Active Comparator|2|exenatide 1.5mcg
11581005|NCT00782418|Placebo Comparator|3|Placebo
11581006|NCT00782405|Experimental|1|quetiapine
11581007|NCT00782405|Active Comparator|2|mirtazapine
11581008|NCT00782379|Experimental|Myeloablative Haploidentical Transplant|All patients will receive treatment using Fludarabine, Busulfan and Cyclophosphamide prior to receiving a haploidentical transplant followed by post-transplant cyclosphosphamide.
11581009|NCT00782366||Genetic Testing Group|Those who will receive predictive genetic risk assessments
11581010|NCT00782366||Control|Those who will receive standard of care
11581011|NCT00782353|Experimental|Cohort 1|Subjects randomized 8:2 (active:placebo) to receive ANA598 200 mg bid
11581012|NCT00782353|Experimental|Cohort 2|Subjects randomized 8:2 (active:placebo) to receive ANA598 400 mg bid
11581013|NCT00782353|Experimental|Cohort 3|Subjects randomized 8:2 (active:placebo) to receive ANA598 800 mg bid
11581014|NCT00782340|Active Comparator|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
11581015|NCT00782340|Placebo Comparator|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
11581016|NCT00782327|Experimental|1|Losartan
11581017|NCT00782327|Placebo Comparator|2|Placebo
11581018|NCT00782314||1|patients with maintenance only treatment with Symbicort Turbuhaler for at least 1 month
11581019|NCT00782314||2|patients with SMART treatment with Symbicort Turbuhaler for at least 1 month
11581020|NCT00782301|Active Comparator|Maraviroc|
11581021|NCT00782301|Active Comparator|Etravirine|
11581022|NCT00782288|Active Comparator|1|low dose 0.05mg digitoxin given once daily for 28 days
11581023|NCT00782288|Active Comparator|2|higher dose 0.1mg digitoxin daily for 28 days
11581024|NCT00782288|Placebo Comparator|3|placebo given daily for 28 days
11581025|NCT00782275|Experimental|bevacizumab and temsirolimus|"bevacizumab: given intravenously at a dose of 10mg/kg every 2 weeks (days 1 and 15)
~temsirolimus: given intravenously at a dose of 25mg weekly on days 1, 8, 15, and 22
~1 cycle=28-days
~There were no dose reductions for bevacizumab allowed. If bevacizumab was held, the same dose would be used if treatment were resumed. If temsirolimus was held, the same or a reduced dose (15mg IV weekly) could be used upon resumption of therapy. Treatment was continued until the development of unacceptable toxicity or progression."
11581026|NCT00782262|Other|Group 1 (n=20)|BP < 140/90, no diabetes mellitus and fasting glucose < 5.5
11581027|NCT00782262|Other|Group 2 (n=20)|BP > 140/100, no diabetes mellitus and fasting glucose < 5.5
11581028|NCT00782262|Other|Group 3 (n=20)|BP <140/100, no diabetes mellitus, fasting glucose 5.5 - 6.9
11581029|NCT00782249|Experimental|1|Vagus nerve stimulation paradigm #1
11581030|NCT00782249|Experimental|2|Vagus nerve stimulation paradigm #2
11581031|NCT00782249|Experimental|3|Vagus nerve stimulation paradigm #3
11581032|NCT00782236|Active Comparator|Straumann BoneCeramic|In the test group, the subjects will receive the Bone Graft Material Straumann BoneCeramic in combination with a collagen membrane for preservation of the alveolar ridge after tooth extraction.
11581033|NCT00782236|Active Comparator|Freeze Dried Allograft Bone|In the control group, the subjects will receive Bone Graft Material Freeze Dried Allograft Bone in combination with a collagen membrane for preservation of the alveolar ridge after tooth extraction.
11581034|NCT00782223||1|Hip X-rays DDH
11581035|NCT00782223||2|Hip X-rays, CP
11581036|NCT00782223||3|Long standing lower Limb X-rays
11581037|NCT00782223||4|Scoliosis, AP X-rays
11581038|NCT00782223||5|Scoliosis Lateral X-rays
11581039|NCT00782210|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
11581040|NCT00782210|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
11581041|NCT00782210|Placebo Comparator|Placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
11581042|NCT00782197|Experimental|1|PRGF
11581043|NCT00782197|Active Comparator|2|Hyaluronic Acid
11581044|NCT00782184|Experimental|ezetimibe/simvastatin 10/40|Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, ezetimibe/simvastatin 10/40 was administered once daily in tablet form during the 6-week double-blind treatment period
11581045|NCT00782184|Active Comparator|atorvastatin 40 mg|Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, 40 mg atorvastatin was administered once daily in tablet form during the 6-week double-blind treatment period
11581046|NCT00782171|Active Comparator|Immediate Loading|SLActive dental implant(s) will be restored with a temporary restoration on the day of surgery.
11581047|NCT00782171|Active Comparator|Early Loading|Healing caps will be placed on the SLActive dental implant(s) immediately after surgery. A provisional restoration will be placed between day 28 to day 34 post surgery
11581089|NCT00781794|Placebo Comparator|3|
11581090|NCT00781781|Experimental|1|"High risk patients (at least one GVHD high risk criterion):
~Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive)."
11581091|NCT00781781|Experimental|2|"Low Risk patients (no GVHD high risk criterion):
~Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive)."
11581092|NCT00781768|Placebo Comparator|Standard PO (Zofran + Dexamethasone)|Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron (Zofran) 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion.
11581836|NCT00776594|Experimental|Group 2|Androgen Deprivation Therapy Alone
11581048|NCT00782145|Experimental|Arm I|"Each dyad receives institution-specific care for 6 months, which typically includes psychosocial support for the HSCT recipient and individualized or group education and support for the accompanying parent during the peri-transplant period. They also receive the Web-based Hematopoietic Stem Cell Transplantation (HSCT-) Comprehensive Health Enhancement Support System (HSCT-CHESS) intervention for 6 months. Accompanying parents also identify a companion to receive access to the HSCT-CHESS Web Site.
~The HSCT-CHESS Web site provides ready access to accurate information and resources about pediatric HSCT, practical tips, organizational tools, and other supporting services for use during the transplant process. In addition to collecting data for later analysis, the Web site tracking system allows for further tailoring of information and support for the user, principally by time post transplant."
11581049|NCT00782145|Active Comparator|Arm II|Each dyad receives institution-specific usual care for 6 months as described in arm I. Accompanying parents also receive a book from the Blood and Marrow Transplant Information Network (BMT Infonet).
11581050|NCT00782106|Experimental|1|Tolerability of subcutaneous infusions
11581051|NCT00782106|Experimental|2|Tolerability of subcutaneous infusions and pharmacokinetics
11581052|NCT00782080|Experimental|Sedariston|Sedariston (100 mg St. John´s Wort and 50 mg Valerian extract) capsule given orally in capsules (size 1) twice daily for eight weeks in children (6-11): 1 - 0 -1 In Adolescents (12-17 years) two capsules (size 1) twice daily: 2 - 0 - 2.
11581053|NCT00782080|Placebo Comparator|Placebo campsule|Placebo provided by the company given orally in capsules (size 1 )twice daily
11581054|NCT00782067|Experimental|Midostaurin (PKC412)|Midostaurin was administered at a dose of 100 mg twice daily (bid) in continuous cycles of 28 days until disease progression, intolerable toxicity or withdrawal due to any cause, whichever occurred first.
11581055|NCT00782054|Active Comparator|Active|moisturizer with endopeptidases
11581056|NCT00782054|Placebo Comparator|Placebo|moisturizer without endopeptidases
11581057|NCT00782041|Experimental|1|Oxaliplatin 85 mg/m² over 3 hours at Day 1 and Day 15. 5-FU 2,000 mg/m² over 4 hours at Day 1. Folinic acid 20 mg/m² Bolus at Day 1.
11581058|NCT00782028|No Intervention|Standard Care|No intervention consists of routine well child care
11581059|NCT00782028|Other|Centering parenting/Group well child care|
11581060|NCT00782015|Active Comparator|almonds|3 oz/d almonds
11581061|NCT00782015|Placebo Comparator|Placebo|NCEP Step 2 diet
11581062|NCT00782002|Experimental|IMC-18F1|
11581063|NCT00781989||Rheumatoid Arthritis patients|Patients with seropositive Rheumatoid Arthritis with symptom onset of less than three years
11581064|NCT00781976|Placebo Comparator|1|
11581065|NCT00781976|Active Comparator|2|
11581066|NCT00781963|Experimental|CBT-I|Manual-based cognitive behavioral therapy for insomnia (CBT-I) provided in 5 individual or group sessions by a non-clinician sleep coach.
11581067|NCT00781963|Active Comparator|Control|Non-directive sleep education provided in 5 group sessions by a health educator.
11581068|NCT00781950|Placebo Comparator|Placebo|Randomized, Blinded Controlled Arm of patients receiving placebo food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing a mixture of wheat and wheat bran to replace the flaxseed daily for one year.
11581069|NCT00781950|Experimental|Flaxseed|Randomized, Blinded group of patients that will be given food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing 30 g of milled flaxseed daily for one year
11581070|NCT00781937|Experimental|Lira 3.0 mg|A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liraglutide 3.0 mg, once daily, injected subcutaneously and instructed to follow a standard energy-restricted diet in the 56-week main trial period. Subjects discontinued treatment in the 12-week follow-up period. The starting dose of liraglutide was 0.6 mg, with weekly increments of 0.6 mg every 7 days until the target dose of 3.0 mg was reached
11581071|NCT00781937|Placebo Comparator|Placebo|A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liraglutide placebo, once daily, injected subcutaneously for 56 weeks and instructed to follow a standard energy-restricted diet in the 56-week main trial period. Subjects discontinued treatment in the 12-week follow-up period
11581072|NCT00781924||biopsy|
11581073|NCT00781911|Experimental|Carcinoid tumor|Participants with carcinoid tumor will receive cixutumumab 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
11581074|NCT00781911|Experimental|Islet cell carcinoma|Participants with islet cell carcinoma will receive cixutumumab 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
11581075|NCT00781898|Active Comparator|Depot Naltrexone|
11581076|NCT00781898|Placebo Comparator|Placebo|
11581077|NCT00781872|Experimental|open|a group of patients with active multiple sclerosis, failures to respond to other treatments
11581078|NCT00781859|Experimental|125µg Ocriplasmin|125µg intravitreal injection of ocriplasmin
11581079|NCT00781859|Placebo Comparator|Placebo|placebo intravitreal injection
11581080|NCT00781846|Experimental|1|30mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks
11581081|NCT00781846|Experimental|2|40mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks
11581082|NCT00781846|Experimental|3|40mg QDx5/wk ridaforolimus plus 15mg/kg Q3wks bevacizumab for 3 weeks
11581083|NCT00781833|Experimental|Treatment|Intramuscular Electrical Stimulation
11581084|NCT00781820|Placebo Comparator|Arm 2|
11581085|NCT00781820|Experimental|Arm 1|
11581086|NCT00781807|Experimental|1|The prospective intervention group with nutrition management, home-based bicycle ergometer training program and psychosocial support
11581087|NCT00781794|Experimental|1|Dose 1
11581088|NCT00781794|Experimental|2|Dose 2
11581093|NCT00781768|Active Comparator|Aprepitant (MK-869) + Standard PO|Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO [blinded] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO [blinded] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
11581094|NCT00781755|Experimental|1|VAR-MI: This group will receive 1mg/day varenicline (titrated from .5mg/day) and two sessions of a motivational interviewing platform CBT treatment over the course of two weeks.
11581095|NCT00781755|Placebo Comparator|2|PLA-MI: VAR-MI: This group will receive a daily placebo pill and two sessions of a motivational interviewing platform CBT treatment over the course of two weeks.
11581096|NCT00781742|Experimental|1|100 mg iv once per dosing day
11581097|NCT00781742|Experimental|2|150 mg iv once per dosing day
11581098|NCT00781742|Placebo Comparator|3|
11581099|NCT00781729|Experimental|1|Yoga, one hour class, 3 times per week, for 24 weeks
11581100|NCT00781729|Placebo Comparator|2|Luncheon Seminar Series, once per month, for 24 weeks
11581101|NCT00781716|Active Comparator|Cypher Stent|Cypher Sirolimus-Eluting Coronary Stent System
11581102|NCT00781716|Active Comparator|Endeavor Stent|Endeavor Zotarolimus-Eluting Coronary Stent System
11581103|NCT00781703|Other|DIAMOND Care Model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the Patient Health Questionnaire-9 (PHQ9), treatment adjustment as indicated, psychiatric consultation, relapse prevention.
11581104|NCT00781690|Experimental|1|Treatment with Evodial with reduction of heparin across study period
11581105|NCT00781677||MDD|
11581106|NCT00781664|Experimental|A|AN2718 Cream SF Vehicle
11581107|NCT00781664|Experimental|B|AN2718 Cream SF, 0.3%
11581108|NCT00781664|Experimental|C|AN2718 Cream SF, 1%
11581109|NCT00781664|Experimental|D|AN2718 Gel Vehicle
11581110|NCT00781664|Experimental|E|AN2718 Gel, 1.5%
11581111|NCT00781664|Experimental|F|AN2718 Gel, 2.5%
11581112|NCT00781664|Experimental|G|AN2718 Gel, 5%
11581113|NCT00781664|Experimental|H|AN2718 Gel, 7.5%
11581114|NCT00781664|Active Comparator|I|Sodium Lauryl Sulfate, 0.5%
11581115|NCT00781625|Active Comparator|Probiotic vaginal capsules|Probiotic vaginal capsule, placebo oral capsule
11581116|NCT00781625|Placebo Comparator|placebo|placebo oral capsule, placebo vaginal capsule
11581117|NCT00781625|Active Comparator|Probiotic oral capsules|Probiotic oral capsules, placebo vaginal capsules
11581118|NCT00781612|Experimental|Trastuzumab Emtansine|Participants will receive trastuzumab emtansine either as a single agent or in combination with other anti-cancer therapy (atezolizumab, paclitaxel, trastuzumab and docetaxel). Participants will receive the same dose and schedule on Cycle 1, Day 1 at which it was given at the end of the parent study. Study drug will be administered in 21-day cycles or weekly, depending on the schedule used in the parent study. Participants will receive study treatment until disease progression or unacceptable toxicity.
11581119|NCT00781599|Active Comparator|1|Chantix for 3 months and Standard Counseling
11581120|NCT00781599|Experimental|2|Chantix for 3 months and Adherence Counseling
11581121|NCT00781586|Experimental|Arm 1|
11581122|NCT00781586|Active Comparator|Arm 2|
11581123|NCT00781586|Placebo Comparator|Arm 3|
11581124|NCT00781573|Experimental|1|Clopidogrel (75 mg/day) is continued for another year at the completion of the initial year of clopidogrel and aspirin administration post DES implantation
11581125|NCT00781573|No Intervention|2|Clopidogrel (75 mg/day) is stopped at the completion of the initial year of clopidogrel and aspirin administration post DES implantation
11581126|NCT00781560||1|patients being diagnosed as dyslipidemia but not receiving Crestor®
11581127|NCT00781560||2|hypercholesterolemia or mixed dyslipidemia and have been initiated treatment with Crestor®
11581128|NCT00781547|Experimental|Recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
11581129|NCT00781547|Placebo Comparator|Placebo|
11581130|NCT00781534|Active Comparator|1. Ginseng|Ginseng group
11581131|NCT00781534|Active Comparator|2. Ginsenosdie RE|Ginsenoside RE (a metabolite of ginseng) group
11581132|NCT00781534|Placebo Comparator|3. Placebo|"placebo (sugar pill) group"
11581133|NCT00781521|Experimental|1|Floxin otic solution twice a day for 7 days
11581134|NCT00781508|Experimental|sildenafil|Effect of oral administration of a single dose of sildenafil 50 mg on left ventricular filling pressures as evaluated 1 hr after sildenafil administration in patients with heart failure
11581135|NCT00781508|Placebo Comparator|placebo|Inactive placebo prepared to mimic the appearance of sildenafil.
11581136|NCT00781495||type 2 diabetes mellitus|
11581137|NCT00781482|Experimental|1|This is a crossover study. Each study drug will be administered (one at a time and in random order) to each subject on separate occasions over the course of the study.
11581138|NCT00781469||A|12 treatment naive patients who fulfil the American College of Rheumatology (ACR) criteria for RA with active disease defined by a Disease Activity Score (DAS)28 score of more than 3.2.
11581139|NCT00781469||B|6 RA patients in remission on a stable dose of methotrexate with a DAS28 score lower than 2.6
11581140|NCT00781469||C|12 patients who fulfill the ACR criteria for RA and are being treated with methotrexate but still have active disease, defined as a DAS28 score of more than 3.2
11581141|NCT00781456|Experimental|91-day Levonorgestrel Oral Contraceptive|Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10 µg EE monotherapy, for a total of 13 weeks.
11581245|NCT00780520|Experimental|1|
11581246|NCT00780520|Placebo Comparator|2|
11581247|NCT00780507||1|Patients are in a state of remission
11581142|NCT00781456|Placebo Comparator|Placebo|Participants received placebo, 12 weeks (84 consecutive days) of inactive tablets, followed by an additional 7 days of inactive tablets, for a total of 13 weeks.
11581143|NCT00781443|Experimental|A|
11581144|NCT00781443|Placebo Comparator|B|
11581145|NCT00781430|Experimental|1|
11581146|NCT00781417|Active Comparator|1|Cholecalciferol 50,000 IU once a week for 12 weeks then every other week for 40 weeks
11581147|NCT00781417|Placebo Comparator|Placebo|Placebo
11581148|NCT00781391|Active Comparator|Warfarin/placebo edoxaban|Warfarin tablets plus placebo Edoxaban tablets
11581149|NCT00781391|Experimental|high dose edoxaban/placebo warfarin|Edoxaban tablets (60mg) plus warfarin placebo tablets
11581150|NCT00781391|Experimental|low dose edoxaban/placebo warfarin|Edoxaban tablets (30mg) plus warfarin placebo tablets
11581151|NCT00781378|Active Comparator|Group 1|rt-PA 100 mg continuous intravenous infusion for 2 hours
11581152|NCT00781378|Experimental|group 2|rt-PA 50 mg continuous intravenous infusion for 2 hours
11581153|NCT00781365|No Intervention|Control|Patients in the control group will receive usual care from their primary care physicians at HealthPartners Medical Group clinics.
11581154|NCT00781365|Experimental|Telemonitors and pharmacy management|The telemonitoring intervention (TI) patients will receive a home blood pressure telemonitor and will work with a clinical pharmacist case manager to control elevated blood pressure. Patients will use their home telemonitors to read and send their blood pressures to their Pharmacist case manager, who will use phone meetings with the patient to make medication adjustments.
11581155|NCT00781352|Active Comparator|group 1|Colorectal surgery with 65% nitrous oxide administration
11581156|NCT00781352|Active Comparator|group 2|Colorectal surgery with nitrogen administration
11581157|NCT00781339|Experimental|Active|
11581158|NCT00781326|Other|Open Label Antidepressant|In Phase 1, all participants will be placed on antidepressant medication. In Phase 2, participants will continue with their antidepressant medication and also receive receive either nimodipine or placebo.
11581159|NCT00781300|Active Comparator|Loteprednol|
11581160|NCT00781300|Active Comparator|Dexamethasone|
11581161|NCT00781287|Experimental|Raltegravir + 3-drug anti-HIV therapy|
11581162|NCT00781287|Active Comparator|3-drug anti-HIV therapy|
11581163|NCT00781274|Experimental|MP-424|
11581164|NCT00781261|Placebo Comparator|Control|Subjects in the control group will receive a placebo drug for a 1 year period
11581165|NCT00781261|Active Comparator|Zoledronic Acid|Subjects in this intervention group will be given 5mg Zoledronic acid as a single injection
11581166|NCT00781248|Experimental|1|starting with active NG Shield
11581167|NCT00781248|Experimental|2|Starting with inactive NG Shield
11581168|NCT00781209|Experimental|Exp|Posterior Fossa Irradiation 37.5 Gy in 2.5 Gy fractions+Radiosurgical boost; Follow up:Contrast enhanced MRI & Mini Mental Status Examination
11581169|NCT00781196|Experimental|1|Oral folic acid
11581170|NCT00781196|Placebo Comparator|2|placebo
11581171|NCT00781183|Experimental|pulmonary rehabilitation|patients that are enrolled in pulmonary rehabilitation
11581172|NCT00781157|Experimental|1|
11581173|NCT00781144||1|first year osteopathic students
11581174|NCT00781144||2|fourth and fifth year osteopathic students
11581175|NCT00781144||3|experienced osteopathic clinicians
11581176|NCT00781131|Placebo Comparator|1|
11581177|NCT00781131|Experimental|2|Pregabalin 75 mg
11581178|NCT00781131|Experimental|3|Pregabalin 150 mg
11581179|NCT00781118|Experimental|Treatment|The Treatment arm has alerting enabled in their device during the 6-month randomization period. Treatment arm patients also have alerting enabled in the post-randomization period. Once a patient arrives at the ER, the standard of care triage process for MI is followed and that is outside of the ALERTS Study protocol. With Amendment the Treatment arm was re-defined as an ALARMS_ON group which included A) Control patients after the randomization period and until database lock (4/1/2014); and, b) Treatment patients both during the randomization period and after the randomization period until database lock (4/1/2014).
11581180|NCT00781118|Other|Control|The Control arm has alerting disabled in their device during the 6-month randomization period. Control arm patients also have alerting enabled in the post-randomization period. Once a patient arrives at the ER, the standard of care triage process for MI is followed and that is outside of the ALERTS Study protocol. With Amendment the Control arm was re-defined as an ALARMS_OFF group which included A) Control patients during the randomization period when the Guardian did not have alarms enabled.
11581181|NCT00781105|Experimental|1|
11581182|NCT00781092|Experimental|1|Systane Ultra
11581183|NCT00781092|Active Comparator|2|Bausch and Lomb Sensitive Eyes
11581184|NCT00781079|Experimental|Consumer Provider|Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
11581185|NCT00781079|No Intervention|Care as Usual|Care as usual
11581186|NCT00781066|Experimental|1|Controlled cord traction (CCT)
11581187|NCT00781066|Active Comparator|2|No CCT
11581188|NCT00781053|Experimental|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months.
11581189|NCT00781040||Neutropenic patients|Adult AML and ASCT patients with neutropenic fever.
11581190|NCT00781027|Active Comparator|1|Torsional phacoemulsification
11581191|NCT00781027|Active Comparator|2|Longitudinal phacoemulsification
11581192|NCT00781001|Placebo Comparator|1|Placebo cannabis
11581193|NCT00781001|Experimental|2|Active cannabis - 1% THC by weight
11581194|NCT00781001|Experimental|3|Active cannabis - 4% THC by weight
11581195|NCT00781001|Experimental|4|Active cannabis - 7% THC by weight
11581196|NCT00780975|Experimental|Arm 1|Aplidin (Plitidepsin)
11581248|NCT00780507||2|Patients are in a flare
11581249|NCT00780494|Experimental|bevacizumab+ carboplatin +capecitabine|Participants receive bevacizumab 15 mg/kg intravenously followed by carboplatin AUC 6 intravenously on Day 1 of a 21-day cycle, concurrently with capecitabine 850 mg/m2 twice-daily by mouth on Cycle Days 1-to-14, followed by a 1-week break.
11581293|NCT00780195|Experimental|1|Single 2 hour hyperinsulinemic euglycemic clamp study at ~90 mg/dl.
11582416|NCT00772226|Placebo Comparator|Pillow without music|
11581197|NCT00780962|Experimental|N-Acetylcysteine group|Subjects in this group will receive 3 grams of N-acetylcysteine in 500 cc normal saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, they will receive a continuous infusion of 200 mg N-acetylcysteine per hour. This dose will be administered as an infusion of 67 cc per hour of a solution of 3 grams of N-acetylcysteine in 1000 cc of normal saline. The infusion will be administered for a minimum of two hours and then stopped after 24 hours, or when the patient is discharged from the Emergency Department or the hospital, whichever comes first.
11581198|NCT00780962|Placebo Comparator|0.9% Sodium-chloride group|Subjects in this group will receive 500 cc Normal Saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, they will receive a continuous infusion of 67 cc per hour of normal saline. The infusion will be administered for a minimum of two hours and then stopped after 24 hours, or when the patient is discharged from the Emergency Department or the hospital, whichever comes first.
11581199|NCT00780949|Experimental|1: Crohn's disease patient|intestinal biopsies
11581200|NCT00780923|Experimental|CPAP|
11581201|NCT00780910|Experimental|MP-424|
11581202|NCT00780897||1|POF patients; 18 years <Age> 40 years; Hormonal sampling; FMR1 analysis; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy; Bone Mineral Density; Pelvic Ultrasonography;
11581203|NCT00780897||2|Control Group No POF patients; Benign ovarian pathology; 18 years <Age> 40 years; Hormonal sampling; FMR1 analyze; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy under specific conditions; Bone Mineral Density; Pelvic Ultrasonography
11581204|NCT00780884|Experimental|acupuncture needles|Acupuncture needles named acuzone needles. The acuzone needles are sterile and single use, manufactured by DONG BANG MEDICAL CO.,LTD.
11581205|NCT00780858||Ganirelix|Patients with premature lutenization (progesterone >1,2 ng/ml) who did not get pregnant during the first IUI underwent a second IUI.
11581206|NCT00780858||Control|Patients without premature lutenization (progesterone >1,2 ng/ml) underwent a only one IUI.
11581207|NCT00780845||AKI (-)|Patients without acute kidney injury after on-pump CABG
11581208|NCT00780845||AKI (+)|Patients with acute kidney injury after on-pump CABG
11581209|NCT00780832|Active Comparator|1|Caffeine reduction through diet and beverage counselling
11581210|NCT00780832|Active Comparator|2|Anticholinergic medication
11581211|NCT00780819|Experimental|PoleStar N20 intraoperative MRI|PoleStar N20 intraoperative MRI
11581212|NCT00780806|Experimental|1|Immunization with one dose of MnB rLP2086 vaccine at 0, 1 and 6 months
11581213|NCT00780793|Active Comparator|1-M : Maintenance|Usual care
11581214|NCT00780793|Experimental|2 -S : Spacing of TNF-blocker injections|Spacing of TNF-blocker injections
11581215|NCT00780780|Active Comparator|1|Triamcinolone intravitreal injection + Nepafenac eye drops
11581216|NCT00780780|Other|2|Triamcinolone intravitreal injection
11581217|NCT00780767|Experimental|Thrombectomy arm|
11581218|NCT00780754|Experimental|dutasteride|treatment group
11581219|NCT00780754|Active Comparator|watchful waiting strategy|
11581220|NCT00780741|Active Comparator|Immediate Office Probing|Probing to be performed in the office setting using topical anesthesia and infant restraint. Probing to be performed either the same day as randomization or within two weeks.
11581221|NCT00780741|Active Comparator|Deferred Facility Probing|Probing to be performed in a surgical facility under general anesthesia within four weeks after completion of the 26-week visit if any of the clinical signs persist.
11581222|NCT00780728|Active Comparator|Sildenafil|
11581223|NCT00780715|Active Comparator|Gliclazide MR|
11581224|NCT00780715|Active Comparator|Sitagliptin|
11581225|NCT00780715|Active Comparator|Pioglitazone|
11581226|NCT00780715|Experimental|Metformin|
11581227|NCT00780702|Experimental|Arm 1|
11581228|NCT00780702|Placebo Comparator|Arm 2|
11581229|NCT00780676|Experimental|Dasatinib sensitivity signature|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
11581230|NCT00780676|Experimental|SRC pathway activity signature|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
11581231|NCT00780676|Experimental|Dasatinib target index|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
11581232|NCT00780676|Experimental|Selumetinib pathway predictor|Participants predicted to respond to selumetinib/AZD6244 by predictive gene signature (either MEK pathway activity predictor positive or MEK pathway predictor negative) receive selumetinib 75 mg by mouth twice daily (BID).
11581233|NCT00780663|Experimental|Quarfloxin|Single arm study - open label.
11581234|NCT00780650|Experimental|1|
11581235|NCT00780650|Placebo Comparator|2|
11581236|NCT00780637|Experimental|Bradykinin|Patients receive 0, 10, 20, and 40 ng/min/100cc forearm volume of intrabrachial bradykinin, for 5 minutes at each dose. Forearm blood flow will be measured by strain gauge plethysmography, blood samples will be obtained to measure t-PA, PAI-1 at each dose. FMD and Radial artery tonometry will also be performed under resting conditions.
11581237|NCT00780624|Active Comparator|NIPPV|The NIPPV group receiving NIPPV treatment.
11581238|NCT00780624|Active Comparator|Control|The Control group receiving nCPAP treatment.
11581239|NCT00780598|Experimental|Tosedostat|oral, once daily administration of tosedostat to evaluate its efficacy, safety and tolerability
11581240|NCT00780585||1|Subjects who participated in previous Org 24448 trials
11581241|NCT00780572|Experimental|Arm 1: ADE Alerts|Arm 1 is a random intervention group in which half of the patients admitted to the VASLCHCS during study time period will be randomly selected. Providers will see ADE alerts for all patient in the randomly selected experimental group
11581242|NCT00780572|No Intervention|Arm 2: Control/No Alerts|The second arm is the control. Alerts will not be displayed for these patients.
11581243|NCT00780559|Other|Tailored Diet and Physical Activity|Subjects will receive an individually tailored diet and physical activity enhancement program
11581244|NCT00780559|Other|Standard of Care|Subjects will be told to reduce their baseline weight by 7% and exercise for 150 minutes/week. There is no tailored, directed program.
11581250|NCT00780481|Experimental|Bradykinin|Patients will have flow mediated vasodilation and radial artery tonometry performed. They will then receive 0, 10, 20, 40 ng/100cc/min of intrabrachial bradykinin. Strain gauge plethysmography and blood sampling at each dose will be done to evaluate t-PA release. Blood will also be drawn for other biomarkers.
11581251|NCT00780468|Active Comparator|1|Existing diet plan
11581252|NCT00780468|Experimental|2|New diet plan
11581253|NCT00780455|Experimental|Interferon beta-1b, FRP within 15 days after randomization|Interferon beta-1b (Betaseron, BAY86-5046) 250 microgram (8 MUI), sub-cutaneous, administration every other day, Participants starting the 6 weeks functional rehabilitation protocol (FRP) within 15 days after randomization
11581254|NCT00780455|Experimental|Interferon beta-1b, FRP about 6 weeks after randomization|Interferon beta-1b (Betaseron, BAY86-5046) 250 microgram (8 MUI), sub-cutaneous, administration every other day, Participants starting the 6 weeks functional rehabilitation protocol (FRP) about 6 weeks after randomization
11581255|NCT00780442|Experimental|DCS|D-Cycloserine 50 mg is a partial glutamate agonist. Participants received DCS prior to cocaine cue exposure sessions.
11581256|NCT00780442|Placebo Comparator|Placebo|Saline comparator. Participants received placebo prior to cocaine cue exposure sessions.
11581257|NCT00780429||1|MMF+cyclosporine
11581258|NCT00780429||2|MMF+tacrolimus
11581259|NCT00780429||3|MMF+sirolimus
11581260|NCT00780416|Experimental|TRV/PEG/RBV|
11581261|NCT00780416|Active Comparator|PEG/RBV|
11581262|NCT00780403|Active Comparator|RediTab/Zyrtec|Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
11581263|NCT00780403|Active Comparator|Zyrtec/RediTab|Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.
11581264|NCT00780390|Placebo Comparator|CRPS patients without spinal cord stimulation|CRPS patients declining spinal cord stimulation therapy. Autonomic Function will be assessed at baseline and again within 2 years.
11581265|NCT00780390|Experimental|CRPS patients: candidates for spinal cord stimulator|CRPS patients who are candidates for spinal cord stimulator implant. These patients will have Autonomic Function assessments before and after the Standard of Care spinal cord stimulation implant
11581266|NCT00780377|Experimental|Bradykinin|Patients have holter monitoring. Patients receive intracoronary bradykinin (0.2, 0.6, 2.0 ug/min) and have coronary sinus and coronary artery blood sampling for t-PA and O2 content.
11581267|NCT00780351||SLEDD-f, vanco|Surgical ICU patients who is on slow low efficiency daily hemodiafiltration (SLEDD-f) and requires vancomycin therapy
11581268|NCT00780338|Experimental|1|Cohort 1: receives the Assets Getting To Outcomes intervention first. The AGTO intervention includes three types of assistance which are adapted to fit the needs and priorities of the individuals involved, as well as the inner and outer setting: (1) a manual of text and tools; (2) face-to-face training, and (3) onsite technical assistance (TA). These three types of assistance aim to improve the implementation process for each program. Two full-time, Maine-based staff, one with a master's and one with a bachelor's degree, provided AGTO tools, training, and TA to the intervention coalitions and programs during the two year intervention period. The tools are in the Search Institute-published manual, Getting To Outcomes with Developmental Assets: Ten steps to measuring success in youth programs and communities, which all intervention participants received.
11581269|NCT00780338|Active Comparator|2|Cohort 2: receives the Assets Getting To Outcomes intervention second, after Cohort 1 is done receiving the intervention.
11581270|NCT00780325|Experimental|1|CG100649, single oral dose of 2 mg
11581271|NCT00780325|Experimental|2|CG100649, single oral dose of 8 mg
11581272|NCT00780325|Active Comparator|3|Celecoxib, single oral dose of 200 mg
11581273|NCT00780325|Active Comparator|4|Naproxen, single oral dose of 500 mg
11581274|NCT00780325|Active Comparator|5|Acetazolamide, single oral dose of 250 mg
11581275|NCT00780325|Placebo Comparator|6|Placebo, single oral administration
11581276|NCT00780312|No Intervention|2|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse before onset of radiotherapy treatment.
11581277|NCT00780312|Experimental|1|physiotherapy
11581278|NCT00780299|Active Comparator|2|control
11581279|NCT00780299|Experimental|1|HDHP
11581280|NCT00780286|Experimental|1|
11581281|NCT00780286|Active Comparator|2|
11581282|NCT00780273|Experimental|Ankylos dental implants.|"3 Ankylos dental implants placed in platform switch configuration on one side of the mandible in support of a fixed restoration.
~A total number of 19 subjects participated in this randomized, split mouth, masked, prospective, open, comparison, monocenter study. Participants were subjects with an edentulous mandible who recieved 3 implants on each side which were splinted for the delivery of a fixed prosthesis."
11581283|NCT00780273|Active Comparator|3i Prevail dental implants.|"Three 3i Prevail dental implants placed on the opposite side of the mandible from the Ankylos implants in support of fixed dental restoration.
~After a baseline phase of 1 month the mandible sides of subjects were randomly assigned to one of the 2 parallel treatment groups: one side received ANKYLOS plus implants. The contralateral sde recieved Certain PREVAIL Implants. Abutments were installed and loaded immediately by a fixed temporary bridge. After 3 months the final prosthesis was incorporated."
11581284|NCT00780260|Experimental|1|5 session strengths-based case management intervention delivered by a professional case manager and a peer support specialist team
11581285|NCT00780260|Active Comparator|2|5 session strengths-based case management intervention delivered by a professional case manager.
11581286|NCT00780247||Alaska residents|"50 healthy community dwelling males or females."
11581287|NCT00780247||Hawaiian residents|"50 healthy community dwelling males or females at each site"
11581288|NCT00780234|Experimental|Arm 1: pioglitazone|Current or former smokers receive 6 months of treatment with pioglitazone
11581289|NCT00780234|Placebo Comparator|Arm 2: placebo|Current or former smokers receive 6 months of treatment with placebo
11581290|NCT00780221||control|patients without coronary artery disease
11581291|NCT00780221||case|patients with coronary artery disease
11581292|NCT00780208|Other|Daytrana (methylphenidate patch)|Methylphenidate patch
11581294|NCT00780195|Experimental|2|Single 2 hour hyperinsulinemic hypoglycemic clamp study at ~70 mg/dl.
11581295|NCT00780195|Experimental|3|Single 2 hour hyperinsulinemic hypoglycemic clamp at ~60 mg/dl.
11581296|NCT00780195|Experimental|4|Single, 2 hour hyperinsulinemic hypoglycemic clamp at ~50 mg/dl.
11581297|NCT00780182|Experimental|1|All subjects will receive three 40mg doses of CMX001 as 1)solution fasted, 2)tablet fasted and 3)tablet following a high-fat breakfast. The order in which each subject receives each of the doses will be determined by a randomization code.
11581298|NCT00780169|Experimental|sorafenib +FOLFIRI|This is a Phase I safety study. There is only one arm of FOLFIRI administered every 14 days (2 week schedule) and sorafenib administered orally, twice daily continuously. First cycle sorafenib began at day +2 to FOLFIRI.
11581299|NCT00780143|Experimental|Arm 1|Plitidepsin in combination with Cytarabine
11581300|NCT00780130||Group 1|male & female college students ages 20 to 50, asymptomatic normals
11581301|NCT00780104|Experimental|Rapamycin + MEC|
11581302|NCT00780091||1|classical monitoring strategy
11581303|NCT00780091||2|optimized monitoring strategy
11581304|NCT00780078||1|Patients intubated orotracheally for over 6 days
11581305|NCT00780052|Experimental|1|c-myb AS ODN as a 24-hour continuous infusion over 7 days
11581306|NCT00780039|Experimental|Single Arm|Caelyx 30 mg/m2 in combination with carboplatin dosed to target AUC of 5 mg/mL.min.
11581307|NCT00780026|Experimental|Strict Glycemic Control|strict glycemic control (80 to 110 mg/dl)
11581308|NCT00780026|No Intervention|Standard of Care Control|standard of care insulin dosing
11581309|NCT00780013|Experimental|1|metformin hydrochloride (HCI) liquid 500 mg/5 mL of Ranbaxy
11581310|NCT00780013|Active Comparator|2|Glucophage® 1000 mg tablets
11581311|NCT00780000|Experimental|A1|
11581312|NCT00779987|Other|Autologous serum -Systane|Crossover arm starting with autologous serum for 2 weeks. After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using artificial tears (Systane)
11581313|NCT00779987|Other|Systane- Autologous serum|Crossover arm starting with artificial tears (Systane) for 2 weeks. After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using autologous serum.
11581314|NCT00779974||s/p Total Shoulder Arthroplasty|The subject population for this study consists of adult patients with a primary diagnosis of osteoarthritis who have had a total shoulder arthroplasty preformed by the PI between September 2003 through December 2007.
11581315|NCT00779961|Experimental|Group A|Early Cleft Palate Repair (Age group 6-10 months)
11581316|NCT00779961|Active Comparator|Group B|Sick Kids Routine cleft palate repair (age group 10-14 months)
11581317|NCT00779948||Targon FN|
11581318|NCT00779948||DHS|
11581319|NCT00779935|Experimental|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
11581320|NCT00779922|Experimental|group 1 to 5|
11581321|NCT00779909|Placebo Comparator|1- Placebo|placebo capsule once per day
11581322|NCT00779909|Experimental|2- Vitamin D3, 500 IU|vitamin D3, 500 IU capsule once per day
11581323|NCT00779909|Experimental|3- Vitamin D3, 2500 IU|vitamin D3, 2500 IU capsule once per day
11581324|NCT00779909|Experimental|4- Vitamin D3, 5000 IU|vitamin D3, 5000 IU capsule once per day
11581325|NCT00779870||1|healthy volunteers
11581326|NCT00779870||2|mild asthmatics
11581327|NCT00779870||3|moderately-severe asthmatics
11581328|NCT00779870||4|severe asthmatics
11581329|NCT00779857|Experimental|AtriCure LAA Exclusion System|AtriCure LAA Exclusion System
11581330|NCT00779844|Experimental|1|obese patients
11581331|NCT00779844|Active Comparator|2|lean patients
11581332|NCT00779831|Experimental|1|120 mg Pseudoephedrine hydrochloride extended release tablets of ranbaxy
11581333|NCT00779831|Active Comparator|2|(Sudafed ® 12 hour) 120 mg Pseudoephedrine hydrochloride extended - release tablets
11581334|NCT00779818|Experimental|Group 1|Treatment by electrical acupuncture
11581335|NCT00779818|Experimental|Group 2|Treatment by laser
11581336|NCT00779805|Experimental|1|Pseudoephedrine hydrochloride 120 mg ER tablets of Ranbaxy
11581337|NCT00779805|Active Comparator|2|Sudafed 120 mg ER tablets
11581338|NCT00779779||Rotarix Group|Subjects received 2 oral doses of Rotarix vaccine at an interval of at least 4 weeks between doses. The first dose was given from the age of 6 weeks and vaccination with both doses was to be completed by 24 weeks of age.
11581339|NCT00779766|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ vaccine. Cervarix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
11581340|NCT00779766|Placebo Comparator|Placebo Group|Subjects received 3 doses of placebo. Placebo was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
11581341|NCT00779753|Experimental|Neonates|Sixteen neonates admitted to the Neonatal Intensive Care Unit (NICU) at the Hospital for Sick Children (SickKids) will be required for this study. The diagnoses will include, but are not limited to, the following: Trachea-esophageal fistula and/or esophageal atresia, Congenital diaphragmatic hernia, imperforate anus, Hirschsprung's disease, Malrotation with or without volvulus, Intestinal atresias, Gastroschisis, Omphalocele, Necrotizing enterocolitis, Respiratory distress syndrome.
11581342|NCT00779740|Experimental|New Formulation Group|
11581343|NCT00779740|Active Comparator|Old Formulation Group|
11581344|NCT00779714|Experimental|A (individualized combined chemotherapy)|
11581345|NCT00779714|Active Comparator|B (DTIC monochemotherapy)|
11581346|NCT00779701|Other|A|All subjects placed on insulin infusion.
11581347|NCT00779675||Infliximab 5 mg/kg|
11581348|NCT00779649|Active Comparator|MoviPrep|
11581349|NCT00779649|Active Comparator|HalfLytely|
11581350|NCT00779636|Experimental|Desloratadine 10 mg|
11581351|NCT00779636|Placebo Comparator|Placebo|
11581352|NCT00779610|Experimental|Active|Vibration with forearm flexion (active contraction)
11581353|NCT00779610|Sham Comparator|Passive|Vibration without forearm flexion (passive)
11581354|NCT00779597|No Intervention|Care as usual|Care as usual, i.e. standard pain treatment and standard care
11581355|NCT00779597|Experimental|SCION-PAIN program|SCION-PAIN program - Additionally to standard pain treatment, patients from the intervention wards received, the SCION-PAIN program consisting of 3 modules: pharmacologic pain management, non-pharmacologic pain management and discharge management.
11581356|NCT00779584|Experimental|MK-8776 10mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 10 mg/m^2 given as monotherapy as an intravenous (IV) infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
11581357|NCT00779584|Experimental|MK-8776 20mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 20 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
11581358|NCT00779584|Experimental|MK-8776 40mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 40 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
11581359|NCT00779584|Experimental|MK-8776 80mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 80 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
11581360|NCT00779584|Experimental|MK-8776 112mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 112 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
11581361|NCT00779584|Experimental|MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 80 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
11581362|NCT00779584|Experimental|MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 112 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
11581363|NCT00779584|Experimental|MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 150 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
11581364|NCT00779584|Experimental|MK-8776 200mg+Gemcitabine 1000mg/m^2|Participants received MK-8776 200 mg given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
11581365|NCT00779571|Experimental|Crispbread|Intervention: Crispbread LCD
11581366|NCT00779571|Active Comparator|Liquid meal replacement|Intervention: LMR LCD
11581367|NCT00779558|Active Comparator|Study drug|Heparin sulfate infusion at 10 units/kg/hour
11581368|NCT00779558|Placebo Comparator|Placebo|Placebo - normal saline infusion
11581369|NCT00779545|Placebo Comparator|Placebo|The placebo group was divided into 3 groups receiving 1, 2 or 4 sprays/nostril. The regimen of each placebo group was BID
11581370|NCT00779545|Experimental|Mometasone furoate nasal spray 100 mcg QD|
11581371|NCT00779545|Experimental|Mometasone furoate nasal spray 200 mcg QD|
11581372|NCT00779545|Experimental|Mometasone furoate nasal spray 400 mcg QD|
11581373|NCT00779545|Experimental|Mometasone furoate nasal spray 100 mcg BID|
11581374|NCT00779545|Experimental|Mometasone furoate nasal spray 200 mcg BID|
11581375|NCT00779532|Active Comparator|Group A|"Once daily intake (orally) of 5 NOMAC-E2 placebo tablets from Day -1 to Day 14.
~Once daily intake (orally) of one moxifloxacin placebo capsule at Day -1.
~Once daily intake (orally) of one moxifloxacin capsule of 400 mg at Day 14."
11581376|NCT00779532|Experimental|Group B|"Once daily intake (orally) of 4 NOMAC-E2 placebo tablets and 1 NOMAC-E2 (2.5/1.5 mg) tablet from Day 1 to Day 14.
~Once daily intake (orally) of 5 NOMAC-E2 placebo tablets and 1 moxifloxacin placebo capsule at Day -1.
~Once daily intake (orally) of 1 moxifloxacin placebo capsule at Day 14."
11581377|NCT00779532|Experimental|Group C|"Once daily intake (orally) of 5 NOMAC-E2 (2.5/1.5 mg) tablets from Day 1 to Day 14.
~Once daily intake (orally) of 5 NOMAC-E2 placebo tablets and 1 moxifloxacin placebo capsule at Day -1.
~Once daily intake (orally) of 1 moxifloxacin placebo capsule at Day 14"
11581378|NCT00779532|Placebo Comparator|Group D|"Once daily intake (orally) of 5 NOMAC-E2 placebo tablets from Day -1 to Day 14.
~Once daily intake (orally) of 1 moxifloxacin placebo capsule at Days -1 and 14."
11581379|NCT00779519|Placebo Comparator|Placebo|
11581380|NCT00779519|Experimental|TTP435|
11581381|NCT00779506|Experimental|Quetiapine Fumarate XR|Seroquel XR 400-800mg
11581382|NCT00779493|Active Comparator|A|Curcumin 900mg twice daily by mouth
11581383|NCT00779493|Placebo Comparator|B|Placebo capsule to be made by Swanson Vitamins to simulate the capsule.
11581384|NCT00779480|Experimental|KW-2449|Sequential dose escalation in separate cohorts of 3+3 design from 450 mg/day to 800 mg/day total daily dose.
11581385|NCT00779467|Experimental|Bupivacaine with Neostimgine 8 mcg/ml|STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
11581386|NCT00779467|Experimental|Bupivacaine and Neostigmine 4 mcg/ml|STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
11581387|NCT00779467|Experimental|Bupivacaine with Neostigmine 2 mcg/ml|STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
11581388|NCT00779467|Active Comparator|BUPIVACAINE WITH FENTANYL 2 MCG/ML|Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
11581389|NCT00779454|Other|KRAS wildtype|
11581390|NCT00779454|Other|KRAS mutation|Inclusion has been completed in the KRAS mutation arm.
11581391|NCT00779441|Experimental|1|Zolpidem 10mg tablets of ranbaxy
11581392|NCT00779441|Active Comparator|2|AmbienÂ® 10mg tablets
11581393|NCT00779428|Experimental|A1|
11581394|NCT00779415||Partial Rotator Cuff Tear|Patients who presented from 1/1/02 to 12/31/06 to Hershey Medical Center with complaint of shoulder pain and were treated by the Orthopaedic Department
11581395|NCT00779402|Experimental|Sipuleucel-T|Subjects received infusion of Sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
11581396|NCT00779402|Placebo Comparator|Control|Subjects received infusion of control (autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen) at 2-week intervals, for a total of 3 infusions.
11581397|NCT00779389|Experimental|Arm A|Erlotinib 150 mg
11581398|NCT00779389|Experimental|Arm B|Dasatinib + placebo
11581399|NCT00779389|Experimental|Arm C|Erlotinib (150 mg) plus Dasatinib (100 mg) for 14-21 days.
11581400|NCT00779389|Placebo Comparator|Arm D|Placebo for 14-21 days
11581401|NCT00779376|Experimental|1|Zidovudine 300mg tablets of Ranbaxy
11581402|NCT00779376|Active Comparator|2|Retrovir ®) 300 mg Zidovudine tablets of Glaxosmithkline
11581403|NCT00779363|Experimental|Implanted Device|
11581404|NCT00779350|Experimental|1|sertraline 100 mg tablets of ranbaxy
11581405|NCT00779350|Active Comparator|2|Zoloft® 100 mg tablets
11581406|NCT00779337|Experimental|Single group study|Autologous AdE1- Latent Membrane Protein (LMP) Cytotoxic T Lymphocytes.
11581407|NCT00779324|Experimental|Amantadine|Amantadine 100 mg every morning and Noon
11581408|NCT00779324|Placebo Comparator|Placebo|Placebo tablets
11581409|NCT00779311|Experimental|Experimenal|All eligible patients will receive the mFOLFOX6 regimen at full dose followed by IV bevacizumab 5mg/kg on Day 1 of each treatment cycle. Sorafenib will be administered daily throughout treatment beginning on day 1
11581410|NCT00779298||Healthy subjects|Healthy subjects, without symptoms or a prior history of gastrointestinal disease, abdominal surgery or diabetes mellitus
11581411|NCT00779285|Experimental|Single-arm|Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles
11581412|NCT00779272||1|Without preoperative chemotherapy
11581413|NCT00779272||2|With preoperative chemotherapy
11581414|NCT00779259|Active Comparator|Theophylline alone|baseline theophylline pharmacokinetics
11581415|NCT00779259|Active Comparator|Quinine alone|baseline quinine pharmacokinetics at steady state
11581416|NCT00779259|Experimental|Theophylline with steady state quinine|Theophylline pharmacokinetics in the presence of steady state quinine and quinine pharmacokinetics in the presence of theophylline.
11581417|NCT00779246|Active Comparator|1|Active surveillance cultures (ASC) (via nasal swabs) will be performed for all patients admitted to the medical intensive care unit (ICU) during the designated study period. All patients will be placed in contact isolation until nasal swabs return negative; otherwise will remain in isolation.
11581418|NCT00779246|Active Comparator|2|Chlorhexidine gluconate (CHG) cloths will be used to bathe patients daily instead of standard soap and water. Active surveillance cultures (ASC) will also be used in this arm, but results will be blinded and not used to determine whether patients should be in contact isolation.
11581419|NCT00779233|Experimental|1|Zidovudine tablets 300 mg of Ranbaxy
11581420|NCT00779233|Active Comparator|2|RETROVIR ® 300 mg tablets (GlaxoSmithKline)
11581421|NCT00779220|Placebo Comparator|1|
11581422|NCT00779220|Experimental|2|
11581423|NCT00779220|Experimental|3|
11581424|NCT00779220|Experimental|4:|
11581425|NCT00779207|Experimental|1|weight loss
11581426|NCT00779207|Experimental|2|Weight loss and exercise
11581427|NCT00779194|Experimental|1|SLE subjects receiving the study drug, Rapamune.
11581428|NCT00779194|No Intervention|2|Healthy control group donating blood for the main study.
11581429|NCT00779194|No Intervention|3|SLE subjects donating blood for Genetic sub-study
11581430|NCT00779194|No Intervention|4|Healthy control subjects donating blood for the Genetic sub-study
11581431|NCT00779181|Experimental|ADX415 (high dose)|A high dose of ADX415
11581432|NCT00779181|Experimental|ADX415 (mid level dose)|A mid level dose of ADX415
11581433|NCT00779181|Experimental|ADX415 (low dose)|A low dose of ADX415
11581434|NCT00779181|Placebo Comparator|Placebo|
11581435|NCT00779168|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive white button mushroom extract PO twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
11581436|NCT00779155|Placebo Comparator|Inactive Resonator Therapy|Inactive magnetic resonance therapy
11581437|NCT00779155|Active Comparator|Active Resonator Therapy|active magnetic resonance therapy
11581438|NCT00779142|Other|Methotrexate 25mg/ml|Methotrexate intravenous 25mg/ml: Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose to subjects with diabetic macular edema resistant to conventional therapies.
11581439|NCT00779129|Experimental|Single Arm|Caelyx 35 mg/m2 and Cyclophosphamide 600 mg/m2
11581440|NCT00779116|Active Comparator|RediTab/Zyrtec|Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
11581441|NCT00779116|Active Comparator|Zyrtec/RediTab|Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.
11581442|NCT00779103|Experimental|Histrelin Subcutaneous Implant (50 mg)|Subcutaneous implant designed to deliver histrelin continously for 12 months.
11581443|NCT00779090|Experimental|Group A_RM|Patients with FRC after open endotracheal suctioning of more than 94% of baseline randomized to receive an alveolar recruitment manoeuvre.
11581444|NCT00779090|No Intervention|Group A_NRM|Patients with FRC after open endotracheal suctioning of more than 94% of baseline randomized to receive no alveolar recruitment manoeuvre.
11581445|NCT00779090|Experimental|Group B_RM|Patients with FRC after open endotracheal suctioning of less than 94% of baseline randomized to receive an alveolar recruitment manoeuvre.
11581446|NCT00779090|No Intervention|Group B_NRM|Patients with FRC after open endotracheal suctioning of less than 94% of baseline randomized to receive no alveolar recruitment manoeuvre.
11581447|NCT00779077||cystic fibrosis|adults and children with cystic fibrosis
11581448|NCT00779064|Experimental|Arm 1|
11581449|NCT00779064|Experimental|Arm 2|
11581450|NCT00779051|Experimental|1|Zolipidem 10mg tablets of Ranbaxy
11581451|NCT00779051|Active Comparator|2|Ambien® 10mg tablets
11581452|NCT00779038|Experimental|Fentanyl ITS|40 microgram (mcg) per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an Iontophoretic Transdermal System (ITS). Total duration of treatment will be 72 hours.
11581453|NCT00779025|Active Comparator|MINE Alone|Female Personal Lubricant (PD-F-5254)
11581513|NCT00778622|Experimental|A3|Obese by Body Weight Index
11581454|NCT00779025|Experimental|YOURS and MINE|Male Personal Lubricant (10855-096) used in conjunction with Female Personal Lubricant (PD-F-5254)
11581455|NCT00779012|Experimental|Remicade|
11581456|NCT00778999|Active Comparator|Oral Contraceptive|Use of oral contraceptive pills prior to controlled ovarian stimulation
11581457|NCT00778999|No Intervention|Non-Oral Contraceptive|No use of oral contraceptive pills prior to controlled ovarian stimulation
11581458|NCT00778986|Experimental|remote monitoring|group of patients that will be using the heart failure remote patient monitoring system in addition to the usual care they receive at the University Health Network Heart Failure Clinic
11581459|NCT00778986|No Intervention|control|group of patients provided with usual care at the University Health Network Heart Failure Clinic
11581460|NCT00778973|Experimental|1|sertraline 100 mg tablets of Ranbaxy
11581461|NCT00778973|Active Comparator|2|Zoloft® 100 mg tablets
11581462|NCT00778960|Experimental|Slow Breathing Group|
11581463|NCT00778960|Experimental|Meditation Group|
11581464|NCT00778960|Experimental|Meditation and Slow Breathing Group|
11581465|NCT00778960|Placebo Comparator|Sitting Quietly Group|
11581466|NCT00778947|Active Comparator|1|
11581467|NCT00778947|Active Comparator|2|
11581468|NCT00778934|Experimental|1|Intimate Health Gel
11581469|NCT00778921|Experimental|Amlodipine 10 mg|Amlodipine 10 mg
11581470|NCT00778921|Experimental|Aliskiren/Amlodipine 150/10 mg|Aliskiren/Amlodipine 150/10 mg
11581471|NCT00778921|Experimental|Aliskiren/Amlodipine 300/10 mg|Aliskiren/Amlodipine 300/10 mg
11581472|NCT00778908|Experimental|A|Late-course accelerated hyperfractionated IMRT with concomitant cisplatin chemotherapy
11581473|NCT00778908|Other|B|Conventionally fractionated IMRT with concomitant cisplatin chemotherapy
11581474|NCT00778895|Experimental|Fluviral F1 Group|Subjects 6 months to 3 years of age received if primed, 1 dose of formulation 1 of Fluviral vaccine at Day 0 and if unprimed, 2 doses of formulation 1 of Fluviral vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
11581475|NCT00778895|Experimental|Fluviral F2 Group|Subjects 6 months to 3 years of age received if primed, 1 dose of formulation 2 of Fluviral vaccine at Day 0 and if unprimed, 2 doses of formulation 1 of Fluviral vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
11581476|NCT00778895|Active Comparator|Vaxigrip Group|Subjects 6 months to 3 years of age received if primed, 1 dose of Vaxigrip vaccine at Day 0 and if unprimed, 2 doses of Vaxigrip vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
11581477|NCT00778882|Experimental|VM106|
11581478|NCT00778869|Experimental|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
11581479|NCT00778856|Experimental|Hand Transplant|
11581480|NCT00778843|Experimental|Viusid|
11581481|NCT00778843|Placebo Comparator|Placebo|Placebo three oral sachets daily during 24 weeks
11581482|NCT00778830|Experimental|Cetuximab plus FOLFIRI|
11581483|NCT00778830|Experimental|Cetuximab plus FOLFOX|
11581484|NCT00778817|Experimental|Arm II (Mitotane + IMC-A12)|Patients receive mitotane as in arm I and anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once every 2 weeks in the absence of disease progression or unacceptable toxicity.
11581485|NCT00778804|Experimental|telemedicine|Web-based monitoring in addition to usual clincial care with quarterly visits
11581486|NCT00778804|No Intervention|Control|Ususal care with quarterly visits
11581487|NCT00778791|Experimental|1|metformin HC1 750 mg extended-release tablets
11581488|NCT00778791|Experimental|2|Glucophage® XR 750 mg tablets
11581489|NCT00778778|Experimental|1|Cefprozil 500mg tablets of ranbaxy
11581490|NCT00778778|Active Comparator|2|CEFZIL ® 500 mg cefprozil tablets of BMS, USA
11581491|NCT00778778|Active Comparator|3|CEFZIL ® 500 mg tablets, BMS Canada
11581492|NCT00778765|Experimental|1|400 mg Gabapentin Capsules of Ranbaxy
11581493|NCT00778765|Active Comparator|2|Neurontin® 400 mg Gabapentin Capsules
11581494|NCT00778752|Experimental|A|"Lenalidomide-treatment starts between 100 and 180 days after allogeneic stem cell transplantation. Three dose-levels will be investigated.
~Dose-level -1: 2.5 mg/d if 2.5mg capsules are available, day 1-21, otherwise 5 mg every other day, day 1-21
~Dose-level 0: 5 mg/d, day 1-21
~Dose-level 1: 10 mg/d, day 1-21
~Dose-level 2: 15 mg/d, day 1-21"
11581495|NCT00778739|Experimental|1|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
11581496|NCT00778739|Active Comparator|2|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
11581497|NCT00778726|Experimental|1|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets of Ranbaxy
11581498|NCT00778726|Active Comparator|2|Lotensin® HCT tablets
11581499|NCT00778713|Experimental|1|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets of Ranbaxy laboratories Limited
11581500|NCT00778713|Active Comparator|2|Monopril ® - HCT 20-12.5 mg tablets by Bristol Meyers Squibb following a single oral dose (1 x 20/12.5 mg tablet)
11581501|NCT00778700|Experimental|Treatment 1: Ruxolitinib|Ruxolitinib -- 0.5 percent phosphate cream
11581502|NCT00778700|Experimental|Treatment 2: Ruxolitinib|Ruxolitinib -- 1.0 percent phosphate cream
11581503|NCT00778700|Experimental|Treatment 3: Ruxolitinib|Ruxolitinib -- 1.5 percent phosphate cream
11581504|NCT00778700|Placebo Comparator|Treatment 4: Placebo|Placebo cream
11581505|NCT00778674|Experimental|1|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
11581506|NCT00778674|Active Comparator|2|Lotensin® HCT tablets
11581507|NCT00778661|Experimental|1|amoxicillin 400mg + clovalunic acid 57.5mg tablets of Ranbaxy
11581508|NCT00778661|Active Comparator|2|Augmentin® tablets of glaxosmithkline
11581509|NCT00778648|Experimental|Juice Plus|
11581510|NCT00778648|Placebo Comparator|Placebo|
11581511|NCT00778622|Experimental|A1|Normal Weight by Body Weight Index
11581512|NCT00778622|Experimental|A2|Overweight by Body Weight Index
11581514|NCT00778609|Experimental|Arm 1|
11581516|NCT00778596|Experimental|Prednisolone priming|Prednisolone priming 4 weeks, then treated with telbivudine.
11581517|NCT00778596|Placebo Comparator|Placebo priming|Placebo priming for 4 weeks, then followed a telbivudine treatment for 2 years.
11581518|NCT00778583|Experimental|1|Nitrofurantoin 100 mg capsules of Ranbaxy
11581519|NCT00778583|Active Comparator|2|Macrobid 100 mg capsules
11581520|NCT00778570||ASA|Participants treated for Excimer laser vision correction using Advanced Surface Ablation (ASA).
11581521|NCT00778570||LASIK|Participants treated for Excimer laser vision correction using Laser-Assisted In Situ Keratomileusis (LASIK)
11581522|NCT00778557|Experimental|1|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL (Ranbaxy Laboratories Limited, India)
11581523|NCT00778557|Active Comparator|2|Cefzil TM (CEFPROZIL) for oral suspension equivalent to 250mg/5mL anhydrous, cefprozil (Bristol-Myers Squibb Company, New Jersey USA)
11581524|NCT00778557|Active Comparator|3|Cefzil TM (CEFPROZIL) for oral suspension equivalent to 250mg/5mL anhydrous, cefprozil (Bristol-Myers Squibb Company, New Jersey USA)
11581525|NCT00778544|Experimental|1|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension of Ranbaxy
11581526|NCT00778544|Active Comparator|2|Augmentin ES-600
11581527|NCT00778518|Active Comparator|1|low dose
11581528|NCT00778518|Active Comparator|2|Medium dose
11581529|NCT00778518|Active Comparator|3|High Dose
11581530|NCT00778505|Experimental|1|closed-loop administration of propofol and remifentanil using bispectral index as the controller
11581531|NCT00778505|Active Comparator|2|manual administration of propofol and remifentanil according to bispectral index values
11581532|NCT00778492||No Treatment|Patients with the history of ingestion of aspirin and/or ADP receptor antagonist (clopidogrel or ticlopidine) for at least 7 days prior the surgery. All patients undergoing cardiac surgery with the use of cardiopulmonary bypass on elective and urgent basis.
11581533|NCT00778479|Experimental|Sepraspray|Receive Sepraspray
11581534|NCT00778479|No Intervention|Control|no treatment
11581535|NCT00778466|Experimental|1|metformin hydrochloride 1000 mg tablets of ranbaxy
11581536|NCT00778466|Active Comparator|2|GLUCOPHAGE® (metformin hydrochloride) 1000 mg tablets
11581537|NCT00778453|Experimental|Hospital-based mCIT|Hospital-based modified constraint-induced therapy(mCIT)
11581538|NCT00778453|Experimental|Hospital-based BIT|Hospital-based bilateral isokinematic training (BIT)
11581539|NCT00778453|Experimental|Hospital-based TR|Hospital-based traditional rehabilitation (TR)
11581540|NCT00778453|Experimental|Home-based BAT|Home-based bilateral arm training(BAT)
11581541|NCT00778453|Experimental|Home-based TR|Home-based traditional rehabilitation (TR)
11581542|NCT00778453|Experimental|Home-based mCIT|Home-based modified constraint-induced therapy (mCIT)
11581543|NCT00778427|Experimental|1|metformin hydrochloride 1000 mg tablets of Ranbaxy
11581544|NCT00778427|Active Comparator|2|GLUCOPHAGE® (metformin hydrochloride) 1000 mg tablets
11581545|NCT00778414|Experimental|1|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension of ranbaxy
11581546|NCT00778414|Active Comparator|2|Augmentin ES - 600
11581547|NCT00778401|Experimental|1|Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited
11581548|NCT00778401|Active Comparator|2|Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd.
11581549|NCT00778388|Active Comparator|IC43 50|IC43 50 mcg with AI(OH)3
11581550|NCT00778388|Active Comparator|IC43 100 with|IC43 100 mcg with AI(OH)3
11581551|NCT00778388|Active Comparator|IC43 100 w/o|IC43 100 mcg w/o AI(OH)3
11581552|NCT00778388|Active Comparator|IC43 200|IC43 200 mcg with AI(OH)3
11581553|NCT00778388|Placebo Comparator|Placebo|Placebo (0,9% NaCl)
11581554|NCT00778375|Experimental|Clofarabine + Cytarabine + Decitabine|Clofarabine 20 mg/m^2 by vein (IV) as a 1- to 2-hour intravenous infusion daily for 5 days. Cytarabine 20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions. Decitabine 20 mg/m^2 as a 1- to 2-hour infusion daily for 5 days.
11581555|NCT00778362||Splenectomy|all patients received splenectomy (patient list will be applied from Dept. of Pathology) at National Taiwan University Hospital in the last 20 years.
11581556|NCT00778349|Experimental|1|Metformin solution 100 mg/mL under fasting condition
11581557|NCT00778349|Experimental|2|Metformin solution 100 mg/mL, after low fat meal
11581558|NCT00778349|Experimental|3|Metformin solution 100 mg/mL, after high fat meal
11581559|NCT00778336||Limb Ischemia|Patients presenting with limb ischemia for treatment
11581560|NCT00778336||Deep Vein Thrombosis|Patients presenting with deep vein thrombosis for treatment
11581561|NCT00778336||Hemodialysis Access|Patients presenting with thrombosed hemodialysis access for treatment
11581562|NCT00778336||Other Thrombotic Conditions|Patients presenting with thrombosed conditions other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment.
11581563|NCT00778323|Experimental|A,2, II|
11581564|NCT00778310|Experimental|Concerta|The subject will be administered their usual dose of Concerta the morning of the FMRI scan in a double blind fashion
11581565|NCT00778310|Placebo Comparator|Placebo|The subject will be administered a placebo the morning of the FMRI scan in a double blind fashion
11581566|NCT00778297|Experimental|Group 1|
11581567|NCT00778297|Active Comparator|Group 2|
11581568|NCT00778284|Experimental|1|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets of Ranbaxy
11581569|NCT00778284|Active Comparator|2|Augumentin chewable tablets of Glaxosmithkline
11581570|NCT00778271|Experimental|1|Gabapentin 400mg capsules
11581571|NCT00778271|Active Comparator|2|Neurontin® 400 mg capsules
11581572|NCT00778258|Experimental|Milk-allergic; Non-consumption|Subjects in this arm reacted to the lowest baseline dose of baked milk (muffin) and will continue strict milk avoidance, returning for re-evaluation with laboratory tests at 12 and 24 months and baked milk challenge at 36 months. Individual participants may be challenged at 12 and or 24 months.
11581622|NCT00777998|Experimental|A|Auto-Allo Tandem Stem cell Transplantation plus maintenance therapy with Thalidomide and DLI
11581623|NCT00777998|Active Comparator|B|Auto-Auto Tandem stem cell Transplantation plus maintenance therapy with Thalidomide
11581573|NCT00778258|Experimental|Tolerated Muffin, Reacted to Pizza|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin but react to ingesting the amount of baked milk in a standardized portion of pizza. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
11581574|NCT00778258|Experimental|Reacted to Rice Pudding|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin and a standardized portion of pizza but react to a standardized dose of baked milk in rice pudding. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
11581575|NCT00778258|Experimental|Reacted to Non-baked Milk|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin, pizza and rice pudding but react to a standardized dose of non-baked milk. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
11581576|NCT00778258|Experimental|Tolerant to Baked and Non-baked Milk|"Biological/Vaccine: Baked Milk At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.
~Biological/Vaccine: Non-baked Milk Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk."
11581577|NCT00778258|No Intervention|Non-Interventional Comparison|Thirty subjects who fulfill inclusion criteria but are unwilling to participate in the full protocol will be enrolled as a comparison group to the active arms.
11581578|NCT00778245|Experimental|1|cefprozil 500mg tablets of Ranbaxy
11581579|NCT00778245|Active Comparator|2|CEFZIL ® 500 mg tablets of Bristol-Myers Squibb Company, USA
11581580|NCT00778232|Experimental|1|Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited
11581581|NCT00778232|Active Comparator|2|Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd
11581582|NCT00778219||A|Patients needing intubation of single lumen tracheal tube and performed using laryngoscope
11581583|NCT00778219||B|Patients needing intubation of single lumen tracheal tube and performed using lightwand
11581584|NCT00778219||C|Patients needing intubation of double lumen endobronchial cath and performed using laryngoscope
11581585|NCT00778206||1. PKUDOS Registry|Patients with a confirmed diagnosis of Phenylketonuria (PKU) with hyperphenylalaninemia who have either received Kuvan therapy, or currently receive Kuvan therapy, or intend to begin receiving Kuvan therapy within 90 days of entering the registry.
11581586|NCT00778206||2. PKU MOMS Subregistry|Patients with PKU who are pregnant at enrollment in the registry or who become pregnant while participating in the registry.
11581587|NCT00778193|Placebo Comparator|Placebo|
11581588|NCT00778193|Active Comparator|Naproxen|
11581589|NCT00778193|Experimental|Aspirin|
11581590|NCT00778193|Experimental|Clopidogrel|
11581591|NCT00778193|Experimental|Celecoxib|
11581592|NCT00778180|Experimental|1|furosemide 80 mg tablets of Ranbaxy
11581593|NCT00778180|Active Comparator|2|Lasix® (furosemide) 80 mg tablets
11581594|NCT00778167|Experimental|Arm I (Enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO once daily on days 1-21. Patients with documented disease progression may cross over and receive treatment on arm II.
11581595|NCT00778167|Experimental|Arm II (Enzyme inhibitor and monoclonal antibody therapy)|Patients receive erlotinib hydrochloride PO as in arm I and cixutumumab IV over 1 hour on days 1, 8, and 15.
11581596|NCT00778154||Alendronate 3 to < 5 years|Alendronate (any combination of 10 mg daily or 70 mg once weekly) 3- 5 years.
11581597|NCT00778154||Risedronate 3 to < 5 Years|Risedronate (any combination of 5 mg daily or 35 mg once weekly) 3-5 years.
11581598|NCT00778154||Alendronate ≥ 5 Years|Alendronate (any combination of 10 mg daily or 70 mg once weekly) for greater than or equal to 5 years.
11581599|NCT00778154||Risedronate ≥ 5 Years|Risedronate (any combination of 5 mg daily or 35 mg once weekly) for greater than or equal to 5 years.
11581600|NCT00778141|Experimental|1|metformin HC1 750 mg extended-release tablets
11581601|NCT00778141|Active Comparator|2|Glucophage® XR 750 mg tablets
11581602|NCT00778128|Experimental|1|"Step 1: Dose escalation - oral CP-4126
~Step 2: Oral CP-4126 on day 1 and 15 in a 4 week schedule. One dose (only) gemcitabine IV on day 8."
11581603|NCT00778128|Experimental|2|"Step 1: Dose escalation - oral CP-4126
~Step 2: Oral CP-4126 on day 8 and 15 in a 4 week schedule. One dose (only) gemcitabine IV on day 1."
11581604|NCT00778115|Experimental|1|Loperamide HCl 2 mg and simethicone 125 mg tablets of ranbaxy
11581605|NCT00778115|Active Comparator|2|Imodium® Advanced caplets
11581606|NCT00778102|Experimental|1|
11581607|NCT00778102|Active Comparator|2|
11581608|NCT00778089|Other|Open Label Single Arm|All enrolled subjects will have a skin test composed of Bovine Collagen and Lidocaine.
11581609|NCT00778076|Active Comparator|HAG|Patients that will receive a Hyaluronic acid treatment course consisting of 3 consecutive injections one week apart.
11581610|NCT00778076|Placebo Comparator|PG|Those patients that receive 3 consecutive placebo injections one week apart.
11581611|NCT00778063|Placebo Comparator|saline|intranasal saline will be given 30 minutes prior to surgery
11581612|NCT00778063|Experimental|dexmedetomidine|2 mcg/kg dexmedetomidine will be given intranasally 30 minutes prior to surgery
11581613|NCT00778050|Experimental|1|amoxicillin tablets for oral suspension 600 mg by Ranbaxy Laboratories Limited
11581614|NCT00778050|Active Comparator|2|Amoxil ® for oral suspension 400 mg/ 5 mL by SmithKline Beecham Pharmaceuticals (600mg dose)
11581615|NCT00778037|Experimental|1|Cyclobenzaprine hydrochloride 10 mg tablet of ranbaxy
11581616|NCT00778037|Active Comparator|2|Flexeril® 10 mg tablets
11581617|NCT00778024|Experimental|1|fluoxetine HCL 40 mg capsules of ranbaxy
11581618|NCT00778024|Active Comparator|2|PROZAC® 40 mg capsules
11581619|NCT00778011|Active Comparator|1|
11581626|NCT00777972|Experimental|1|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets by Ranbaxy Laboratories Limited
11581627|NCT00777972|Active Comparator|2|Monopril ®.-HCT 20-12.5 mg tablets by Bristol-Meyers Squibb following a single oral dose (1 x 20-12.5 mg tablet
11581628|NCT00777959|Experimental|Open Label|ridaforolimus (MK8669)+ bicalutamide
11581629|NCT00777959|Experimental|Ridaforolimus|ridaforolimus (MK8669)+ bicalutamide
11581630|NCT00777959|Placebo Comparator|Placebo|Placebo + bicalutamide
11581631|NCT00777946|Experimental|Aliskiren 300 mg/Amlodipine 5 mg|Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.
11581632|NCT00777946|Experimental|Aliskiren 300 mg/Amlodipine 10 mg|Participants received 1 Aliskiren/Amlodipine 300/10 mg tablet + 1 Placebo to Aliskiren tablet orally once daily in the morning for 8 weeks.
11581633|NCT00777946|Active Comparator|Aliskiren 300 mg|Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.
11581634|NCT00777933|Active Comparator|cyclosporine|
11581635|NCT00777933|Experimental|Tacrolimus|
11581636|NCT00777920|Experimental|Ambrisentan|Participants will receive ambrisentan 2.5 mg, 5 mg or 10 mg tablet orally once daily until such time as the investigator or participant chooses to stop ambrisentan treatment, ambrisentan becomes commercially available, or the sponsor stops the study.
11581637|NCT00777907|Active Comparator|Coil embolization|Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed. Stents are not allowed in this arm.
11581638|NCT00777907|Experimental|Pipeline|Placement of 1 or more Pipeline Embolization Device(s)(PED) into the parent artery at the target aneurysm.
11581639|NCT00777894|Experimental|Radiation: 3-dimensional conformal radiation therapy|
11581640|NCT00777868|Experimental|1|
11581641|NCT00777868|Experimental|2|
11581642|NCT00777868|Experimental|3|
11581643|NCT00777868|Placebo Comparator|4|
11581644|NCT00777855|Experimental|warfarin then warfarin plus rifampin|
11581645|NCT00777842|Experimental|1|Device
11581646|NCT00777829|Experimental|Low-dose sodium oxybate|
11581647|NCT00777829|Experimental|High-dose sodium oxybate|
11581648|NCT00777829|Experimental|Low-dose zolpidem|
11581649|NCT00777829|Experimental|High-dose zolpidem|
11581650|NCT00777829|Placebo Comparator|Placebo|
11581651|NCT00777816|Active Comparator|1|
11581652|NCT00777816|Placebo Comparator|2|
11581653|NCT00777803|Experimental|IncobotulinumtoxinA (Xeomin®/Bocouture®)|IncobotulinumtoxinA (Xeomin®/Bocouture®), 24 units; mode of administration: intramuscular injection.
11581654|NCT00777803|Active Comparator|OnabotulinumtoxinA (Vistabel®)|OnabotulinumtoxinA (Vistabel®), 24 units; mode of administration: intramuscular injection.
11581655|NCT00777790|Experimental|Menactra® Group|Received Menactra® vaccine in Study MTA02
11581656|NCT00777790|Experimental|Menomune® Group|Received Menomune® vaccine in Study MTA02
11581657|NCT00777790|Experimental|Control Group|Meningococcal vaccine-naïve Control Group.
11581658|NCT00777777|Experimental|1|Either the Circumflex Coronary Artery or the Right Coronary Artery will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
11581659|NCT00777764|Experimental|Healthy Volunteers|Healthy participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and 1:1000, 1:100, 1:10 dilution and full concentrations of both omalizumab and omalizumab excipients.
11581660|NCT00777764|Experimental|Allergic Asthma Participants|Allergic asthma participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and a succession of 1:1000, 1:100, 1:10 dilutions and full concentration of both omalizumab and omalizumab excipients.
11581661|NCT00777738|Experimental|bortezomib|bortezomib
11581662|NCT00777725||1|Chronic stable left sided HF patients
11581663|NCT00777725||2|Predominant right sided HF patients secondary to valvular heart disease, pulmonary artery hypertension (PAH), chronic obstructive pulmonary disease (COPD), or thrombotic disease and etc
11581664|NCT00777725||3|Acute decompensated left sided heart failure patients who have volume overload and have been admitted for diuresis
11581665|NCT00777725||4|Control subjects with no evidence of heart disease.
11581666|NCT00777712||Diabetics (HbA1c level >8%) with infection|Poorly controlled diabetes in patients with HbA1c level >8% who have wound (s) 4 weeks or longer with infection. N=50
11581667|NCT00777712||Normoglycemic- with infection|Non-Diabetic patients with wound(s) 4 weeks or longer with infection. N=50
11581668|NCT00777712||Diabetics (HbA1c level >8%) without infection|Poorly controlled diabetes in patients with HbA1c level >8% who have wound (s) 4 weeks or longer without infection. N=50
11581669|NCT00777712||Normoglycemic- without infection|Non-Diabetic patients with wound(s)4 weeks or longer without infection. N=50
11581670|NCT00777712||Diabetics (HbA1c level<8%) with infection|Patients with controlled diabetes with HbA1c level<8% who have wound (s) 4 weeks or longer and also with infection. N=50
11581671|NCT00777712||Diabetics (HbA1c level <8%) without infection|Patients with controlled diabetes with HbA1c level <8% who have wound (s) 4 weeks or longer and also without infection. N=50
11581672|NCT00777699|Experimental|1|
11581673|NCT00777686||MRI/MRS Scanning|Magnetic resonance imaging with magnetic resonance spectroscopy (MRI/MRS Scanning)
11581674|NCT00777647|Experimental|Sugar-sweetened soft drink|54g sugar/L, 180kJ/100mL
11581675|NCT00777647|Experimental|Aspartame-sweetened soft drink|1.5kJ/100mL
11581676|NCT00777647|Active Comparator|Semi-skimmed milk|202kJ/100mL
11581677|NCT00777647|Placebo Comparator|Water|0kJ/100mL
11581678|NCT00777634||Binge eating disorder (BED)|Individuals who meet criteria for binge eating disorder.
11581679|NCT00777634||Without BED|Individuals who do not meet criteria for binge eating disorder.
11581680|NCT00777621|Active Comparator|Calorie restriction|
11581681|NCT00777621|Active Comparator|Exercise|
11581682|NCT00777621|Experimental|Calorie restriction and exercise|
11581782|NCT00777023|Placebo Comparator|Sugar Pill|Placebo 1200 mg or 1800 mg
11581835|NCT00776594|Experimental|Group 1|Androgen Deprivation Therapy Plus Bevacizumab
11581683|NCT00777608|Experimental|Donepezil 5-10 mg|There will be a 14 day period when all participants will receive placebo, followed by 5 mg donepezil, once daily for 14 days then titrated to 10 mg donepezil once daily for 70 days. Participants may then receive open-label donepezil for an additional 24 weeks.
11581684|NCT00777608|Placebo Comparator|Placebo|There will be a 14 day period when all participants will receive placebo. Participants will take placebo capsules orally, once daily for 84 days. Participants may then receive open-label donepezil for an additional 24 weeks.
11581685|NCT00777595|Experimental|Treatment A|Single therapeutic dose of CHF 4226 pMDI
11581686|NCT00777595|Experimental|Treatment B|Single supratherapeutic dose of CHF 4226 pMDI
11581687|NCT00777595|Placebo Comparator|Treatment C|Single dose of placebo
11581688|NCT00777595|Active Comparator|Treatment D|Single dose of moxifloxacin
11581689|NCT00777582|Experimental|Treatment A|300mg bid (twice daily) tablet dose
11581690|NCT00777582|Experimental|Treatment B|400 mg twice daily (bid) capsule dose
11581691|NCT00777582|Experimental|Treatment C|400mg bid (twice daily) tablet dose
11581692|NCT00777569|Experimental|Extra-low nicotine cigarettes|
11581693|NCT00777569|Experimental|Nicotine-free cigarettes|
11581694|NCT00777569|Active Comparator|Medicinal Nicotine|
11581695|NCT00777556|Experimental|DR-104|One tablet for emergency contraception
11581696|NCT00777543|Other|Control|The control is the wholegrain bread enriched with bran that has not been pretreated.
11581697|NCT00777543|Experimental|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
11581698|NCT00777530|Experimental|1|
11581699|NCT00777517|Other|Reference|Commercial 10 mg Lipitor formulation tablet
11581700|NCT00777517|Other|Test|Atorvastatin pediatric formulation
11581701|NCT00777504|Active Comparator|A|When PD is being determined the patient will continue with the oral angiogenesis inhibitors for 2 more weeks. After 2 weeks, an Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI). After evaluating these scans patients in group A now stop the orale angiogenesis inhibitor.
11581702|NCT00777504|Active Comparator|B|When PD is being determined the patient will continue with the oral angiogenesis inhibitors for 2 more weeks. After 2 weeks, an Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI). After evaluating these scans patients in group B continue with angiogenesis inhibitors for 2 more weeks. After these 2 weeks(so 4 weeks after inclusion) another Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI) and a FDG-PET-scan.
11581703|NCT00777491|Experimental|5-FU and Cisplatin + BID Irradiation|Within 8 weeks following pre-study transurethral resection (TUR) patients receive 2.5 weeks of induction chemoradiotherapy (induction 5-fluorouracil, induction cisplatin, induction BID radiation therapy). Consolidation chemoradiotherapy begins 7-14 days following post-induction chemoradiotherapy endoscopic response evaluation. Patients achieving a complete response receive 1.5 weeks of consolidation chemoradiotherapy (consolidation 5-fluorouracil, consolidation cisplatin, consolidation BID radiation therapy). Patients without a complete response undergo radical cystectomy. Outpatient adjuvant chemotherapy (adjuvant gemcitabine, adjuvant cisplatin) begins 4-5 weeks following the post-consolidation endoscopic evaluation or 8-12 weeks following radical cystectomy, and continues for 12 weeks.
11581704|NCT00777491|Experimental|Gemcitabine + QD Irradiation|Within 8 weeks following pre-study transurethral resection (TUR) patients receive 2.5 weeks of induction chemoradiotherapy (induction gemcitabine and induction QD radiation therapy). Consolidation chemoradiotherapy begins 7-14 days following post-induction chemoradiotherapy endoscopic response evaluation. Patients achieving a complete response receive 1.5 weeks of consolidation chemoradiotherapy (consolidation gemcitabine and consolidation QD radiation therapy). Patients without a complete response undergo radical cystectomy. Outpatient adjuvant chemotherapy (adjuvant gemcitabine and adjuvant cisplatin) begins 4-5 weeks following the post-consolidation endoscopic evaluation or 8-12 weeks following radical cystectomy, and continues for 12 weeks.
11581705|NCT00777465||KDIGO 0|Patients with no acute kidney injury after cardiac surgery
11581706|NCT00777465||KDIGO 1|Patients with acute kidney injury KDIGO stage 1 after cardiac surgery (Increase in SCr by ≥ 0.3 mg/dL (≥ 26.5 lmol/L) or 1.5 to 1.9 times baseline)
11581707|NCT00777465||KDIGO 2|Patients with acute kidney injury KDIGO stage 2 after cardiac surgery (2.0 to 2.9 times baseline SCr)
11581708|NCT00777465||KDIGO 3|Patients with acute kidney injury KDIGO stage 3 after cardiac surgery (3.0 times baseline or more; or increase in SCr to ≥ 4.0 mg/dL; or initiation of renal replacement therapy)
11581709|NCT00777452||1|active surveillance
11581710|NCT00777452||2|radical prostatectomy
11581711|NCT00777452||3|external beam radiotherapy
11581712|NCT00777452||4|high intensity focused ultrasound
11581713|NCT00777439|Other|Domperidone|All eligible subjects will receive domperidone in an open label, single group assignment.
11581714|NCT00777426||Thai HAD individuals (25 cases)|
11581715|NCT00777426||Thai Non-HAD individuals (25 cases)|
11581716|NCT00777426||Thai Non-infected individuals (10 cases)|
11581717|NCT00777413|Experimental|1|Minocycline 100 mg tablets of Ranbaxy
11581718|NCT00777413|Active Comparator|2|Minocin 100mg tablets
11581719|NCT00777400|Experimental|1|Efalizumab will be started on Day 0 until the end of the study at Week 24. At the end of the first week, after efalizumab is started, cyclosporine or tacrolimus will be decreased by 50% and at 2 weeks the dose of cyclosporine or tacrolimus will be completely discontinued. At 12 weeks Cellcept or myfortic will be discontinued and the patient will be converted to sirolimus for the remainder of the study.
11581720|NCT00777387|Active Comparator|1|slow-freeze
11581721|NCT00777387|Active Comparator|2|vitrification
11581722|NCT00777374|Experimental|1|Allergen containing patch
11581723|NCT00777374|Placebo Comparator|2|Placebo patch
11581724|NCT00777361|Experimental|AZD3480 iv|Single iv infusion AZD3480
11581725|NCT00777361|Experimental|Oral [14C] AZD3480|Single oral dose [14C]AZD3480
11581726|NCT00777348|Experimental|1|DSCG + Reproterol
11581727|NCT00777348|Active Comparator|2|DSCG
11581728|NCT00777348|Active Comparator|3|Reproterol
11581729|NCT00777348|Placebo Comparator|4|Placebo
11581730|NCT00777335|Experimental|Panobinostat i.v.|
11581731|NCT00777335|Experimental|Panobinostat oral|
11581732|NCT00777322|Experimental|Interventional study|Patients with known keratoconus or pellucid marginal degeneration will be invited to join the study. The study is partly a continuation in the management of patients who have had previous keratophakia, who will have near-normal or supra-physiological levels of corneal thickness. It is also intended for patients with relatively mild keratoconus who have sufficient corneal thickness to allow a limited laser ablation whilst still leaving a residual stromal bed of at least 350μ.
11581733|NCT00777309|Experimental|1|Erlotinib (150 mg) once daily plus ARQ 197 (360 mg) twice daily.
11581734|NCT00777309|Active Comparator|2|Erlotinib (150 mg) once daily plus ARQ 197 placebo twice daily
11581735|NCT00777296|Experimental|Cohort 1 - 280 mg ARIKACE™|Subjects in this cohort will receive 280 mg of ARIKACE™
11581736|NCT00777296|Placebo Comparator|Cohort 1 - Placebo|Subjects in this arm of cohort 1 will receive matching placebo
11581737|NCT00777296|Experimental|Cohort 2 - 560 mg ARIKACE™|Subjects in this cohort will receive 560 mg of ARIKACE™
11581738|NCT00777296|Placebo Comparator|Cohort 2 - Placebo|Subjects in this arm of cohort 2 will receive matching placebo
11581739|NCT00777270|Experimental|1 continuous|continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
11581740|NCT00777270|Experimental|2 interrupted|interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
11581741|NCT00777257|Experimental|Study Group A|Tdap vaccine + placebo concomitantly on Day 0; Menactra® vaccine 28 days later
11581742|NCT00777257|Experimental|Study Group B|Tdap vaccine + Menactra® vaccine concomitantly on Day 0; placebo 28 days later
11581743|NCT00777257|Experimental|Study Group C|Menactra® vaccine + placebo concomitantly on Day 0; Tdap vaccine 28 days later
11581744|NCT00777244|No Intervention|Follow-up|Arm B
11581745|NCT00777244|Experimental|Mitotane|Arm A
11581746|NCT00777231|Experimental|Sickle Cell Disease|Recipients treated with an enriched hematopoetic stem cell infusion
11581747|NCT00777231|Experimental|Non-Malignant Disorders|Recipients treated with an enriched hematopoetic stem cell infusion
11581748|NCT00777231|Experimental|Aplastic Anemia|Recipients treated with an enriched hematopoetic stem cell infusion
11581749|NCT00777231|Experimental|Sickle Cell Disease : Extended Protocol|Recipients treated with an enriched hematopoetic stem cell infusion and Campath 1H conditioning
11581750|NCT00777218|Active Comparator|1|
11581751|NCT00777218|Active Comparator|2|
11581752|NCT00777218|Active Comparator|3|
11581753|NCT00777205|Active Comparator|Enhanced Usual Care|Patients in the enhanced usual care arm received their usual mental health care, a copy of the Depression Helpbook, and bi-weekly study mailings with depression management tips.
11581754|NCT00777205|Experimental|Telephone-based peer support|Participants in the intervention arm received usual mental health care and biweekly study mailings. In addition, they had access to a telephone platform over which they could make free calls to their peer partner for mutual peer support over a 6-month period of time.
11581755|NCT00777192||Symptoms in Colorectal Cancer|Colorectal Cancer Patients Receiving Oxaliplatin Chemotherapy
11581756|NCT00777179|Experimental|Vandetanib|
11581757|NCT00777179|Placebo Comparator|Placebo|
11581758|NCT00777166|Active Comparator|1|oxytocin 5 units
11581759|NCT00777166|Active Comparator|2|oxytocin, 10 units
11581760|NCT00777153|Experimental|Cediranib 30mg|Cediranib 30mg
11581761|NCT00777153|Other|Cediranib 20mg + lomustine|Cediranib 20mg + lomustine
11581762|NCT00777153|Active Comparator|Lomustine and Placebo Cediranib|Lomustine and Placebo Cediranib
11581763|NCT00777140|Active Comparator|1. Deferoxamine|Intravenous deferoxamine: bolus of 10mg/Kg (initiated during tPA infusion) and perfusion of 20/40/60 mg/Kg/day during 72h. Three different doses (3 steps), 15 patient in the active arm for each dose.
11581764|NCT00777140|Placebo Comparator|2. Placebo|Saline solution: Bolus and perfusion during 72h. 5 patients in the placebo arm in each step (randomization 3:1)
11581765|NCT00777127|Experimental|1|Aldara 5% Cream
11581766|NCT00777127|Active Comparator|2|Solaraze 3% Gel
11581767|NCT00777114|Experimental|All patients|
11581768|NCT00777101|Experimental|Neratinib|
11581769|NCT00777101|Active Comparator|Lapatinib plus Capecitabine|
11581770|NCT00777088|Experimental|Pipeline|Placement of Pipeline Embolization Device in the parent artery at the aneurysm location
11581771|NCT00777075|Active Comparator|L-arginine|
11581772|NCT00777075|Placebo Comparator|placebo|
11581773|NCT00777062|Experimental|1|VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6
11581774|NCT00777062|Placebo Comparator|2|Placebo injection, 380 mg injection at the start of weeks 2 and 6.
11581775|NCT00777049|Experimental|ER+ and/or PgR+ (Arm I)|Panobinostat oral 40 mg (3 times a week) given every other week as part of a 28 day cycle.
11581776|NCT00777049|Experimental|ER- and PgR- (Arm II)|Panobinostat oral 40 mg (3 times a week) given every other week as part of a 28 day cycle.
11581777|NCT00777036|Experimental|Cohort 1: Imatinib-resistant/intolerant CP-CML|"Dasatinib 60 mg/m² tablet every day (QD) [with a maximum dose of 100 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit
~OR
~Dasatinib 72 mg/m² powder for oral suspension (PFSO) QD [with a maximum dose of 120 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
11581778|NCT00777036|Experimental|Cohort 2: Ph+ALL or AP- or BP-CML|"Dasatinib 80 mg/m² tablet QD [with a maximum dose of 140 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit
~OR
~Dasatinib 96 mg/m² PFSO QD [with a maximum dose of 170 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
11581779|NCT00777036|Experimental|Cohort 3: Newly diagnosed, treatment naïve CP-CML|"Dasatinib 60 mg/m² tablet QD [with a maximum dose of 100 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit
~OR
~Dasatinib 72 mg/m² PFSO QD [with a maximum dose of 120 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
11581780|NCT00777023|Experimental|G-ER 1200 mg|Gabapentin extended-release (G-ER) 1200 mg
11581781|NCT00777023|Experimental|G-ER 1800 mg|Gabapentin extended-release (G-ER) 1800 mg
11581783|NCT00777010|Active Comparator|Healthy high carbohydrate diet|Participants will follow a typical, higher carbohydrate dietary intervention with emphasis on lower glycemic carbohydrate foods and monounsaturated fatty acid consumption
11581784|NCT00777010|Experimental|Carbohydrate restricted, ketogenic diet|Paricipants will follow a carbohydrate restricted dietary intervention designed to induce ketone metabolism
11581785|NCT00776997|Other|Magnetic Sphincter Augmentation|Single-arm study: all subjects were treated with magnetic sphincter augmentation. A subject's baseline measurements prior to sphincter augmentation were compared to post-sphincter augmentation measurements. Subjects served as their own control.
11581786|NCT00776984|Experimental|tiotropium 5mcg/day|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
11581787|NCT00776984|Experimental|placebo|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
11581788|NCT00776971|Experimental|Sugar-sweetened soft drink|54g sugar/L, 180kJ/100mL
11581789|NCT00776971|Experimental|Aspartame-sweetened soft drink|1.5kJ/100mL
11581790|NCT00776971|Active Comparator|Semi-skimmed milk|202kJ/100mL
11581791|NCT00776971|Placebo Comparator|Water|0kJ/100mL
11581792|NCT00776958||Ovarian or Breast Cancer Study Registry|
11581793|NCT00776932||Knee OA|Those over the age of 50 who have frequent pain in their knee that has lasted for at least six months.
11581794|NCT00776919|Experimental|1|clindamycin / benzoyl peroxide gel
11581795|NCT00776919|Active Comparator|2|Clindamycin gel
11581796|NCT00776919|Active Comparator|3|BPO gel
11581797|NCT00776919|Placebo Comparator|4|vehicle gel
11581798|NCT00776906|Experimental|1|PTX-coated balloon
11581799|NCT00776906|Active Comparator|2|Bare balloon
11581800|NCT00776880||1|Patients assessed with ASA physical status scale
11581801|NCT00776880||2|Patients assessed with PPS scale
11581802|NCT00776867|Experimental|perifosine|This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level.
11581803|NCT00776841|Placebo Comparator|Placebo|Placebo control single dose
11581804|NCT00776841|Experimental|Dose 1|Dose 30 mg
11581805|NCT00776841|Experimental|Dose 2|Dose 100 mg
11581806|NCT00776841|Experimental|Dose 3|Dose 300 mg
11581807|NCT00776841|Experimental|Dose 4|Dose 900 mg
11581808|NCT00776841|Experimental|Dose 1 repeated|Dose 30 mg for 4 days
11581809|NCT00776841|Experimental|Dose 2 repeated|Dose high for 4 days
11581810|NCT00776828|Active Comparator|TAT|triple antiplatelet therapy : aspirin, clopidogrel and cilostazol
11581811|NCT00776828|Placebo Comparator|DAT|dual antiplatelet therapy : aspirin, clopidogrel
11581812|NCT00776802|Experimental|GCS-10|
11581813|NCT00776789|Experimental|skin to skin contact|Infants randomized to this group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. Mothers in both the groups received support for initiating breastfeeding, if required. All mothers, regardless of the group allocation, were advised to give exclusive breastfeeding to their infants during the hospital stay. They were discouraged from giving supplemental feeds to their infants unless indicated by the duty registrar. All the mothers were counseled regarding the duration of exclusive breastfeeding at the time of discharge.
11581814|NCT00776789|Experimental|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC. All mothers, regardless of the group allocation, were advised to give exclusive breastfeeding to their infants during the hospital stay. They were discouraged from giving supplemental feeds to their infants unless indicated by the duty registrar. All the mothers were counseled regarding the duration of exclusive breastfeeding at the time of discharge.
11581815|NCT00776763|Experimental|Avastin|
11581816|NCT00776750|Experimental|influenza vaccination|All participants received a standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection. The vaccine contained 15 μg hemagglutinin of each of the following influenza strains: A/ New Caledonia/20/99 (H1N1), A/ Panama/2007/99 (H3N2), and B/Shangdong/7/97, recommended by WHO as components of the influenza vaccine for the epidemic season 2003/2004.
11581817|NCT00776724|Active Comparator|1|docetaxel-epirubicin for 4 cycles before surgery
11581818|NCT00776724|Experimental|2|Tailored regimens, base on immunohistochemical study of the tumor biopsy tissue, for 4 cycles before surgery.
11581819|NCT00776698|Experimental|1|
11581820|NCT00776685|Experimental|learning to cope with your impulsivity|Cognitive-behavioural intervention targeting impulsive personality
11581821|NCT00776685|Experimental|learning to cope with your sensation seeking|cognitive behavioural intervention designed to help sensation seeking youth manage their need for stimulation and excitement.
11581822|NCT00776685|Experimental|learning to cope with your anxiety sensitivity|cognitive behavioural intervention teaching anxiety sensitive youth to manager their sensitivity to threat and anxiety.
11581823|NCT00776685|Experimental|learning to manage your negative thinking|cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
11581824|NCT00776672|Experimental|1|fosinopril sodium 40 mg tablets of Ranbaxy
11581825|NCT00776672|Active Comparator|2|Monopril® 40mg tablets
11581826|NCT00776659||Observational|
11581827|NCT00776646|Experimental|1|hydrochlorothiazide 50 mg tablet
11581828|NCT00776646|Active Comparator|2|hydrochlorothiazide 50 mg tablet
11581829|NCT00776633|Experimental|Short triple|6 weeks triple therapy
11581830|NCT00776633|Active Comparator|Long triple|6 months triple therapy
11581831|NCT00776620|Experimental|1|Glimepiride 1 MG Tablets of Ranbaxy
11581832|NCT00776620|Active Comparator|2|AMARYL® 1 mg tablets
11581833|NCT00776607|Experimental|Insulin|Insulin: NovoMix 30. Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal.
11581834|NCT00776607|Active Comparator|Tablet|Patients will progress from lifestyle modification to metformin, to metformin with Rosiglitazone and finally insulin depending on HbA1c levels.
11581837|NCT00776581||1|Records regarding combined spinal-epidural analgesia (CSEA) with patient-controlled analgesia (PCA) pump
11581838|NCT00776581||2|Records regarding combined spinal-epidural analgesia with intermittent bolus injection (IBI)
11581839|NCT00776581||3|Records regarding epidural analgesia (EA) with patient-controlled pump
11581840|NCT00776581||4|Records regarding epidural analgesia with intermittent bolus injection
11581841|NCT00776568|Active Comparator|2|
11581842|NCT00776568|Experimental|1|
11581843|NCT00776555|Experimental|Vyvanse™|50mg capsule that has been emptied and made into solution
11581844|NCT00776555|Experimental|ADDERALL XR®|20mg capsule that has been emptied, crushed, and made into solution
11581845|NCT00776542|Experimental|1|Minocycline 100 mg tablets of ranbaxy
11581846|NCT00776542|Active Comparator|2|Minocin 100mg tablets
11581847|NCT00776529|Experimental|A Sensorimotor first|In each of nine sessions: first sensorimotor exercises, then strengthening exercises
11581848|NCT00776529|Experimental|B Sensorimotor & strength alternated|In each of nine sessions: Strength and sensorimotor exercises alternated
11581849|NCT00776516|Experimental|1|mirabegron alone
11581850|NCT00776516|Experimental|2|mirabegron and rifampin
11581851|NCT00776503|Experimental|B|Cytarabine 10mg/m2 day 1-14 Vorinostat 400mg/d day 1-(7 or 10 or 14)
11581852|NCT00776503|Experimental|A|Cytarabine 10mg/m2 day 1-14 Vorinostat 400mg/d day 15-(21 or 24 or 28)
11581853|NCT00776490|Experimental|1|Glimepiride 1 MG Tablets of ranbaxy
11581854|NCT00776490|Active Comparator|2|AMARYL® 1 mg tablets
11581855|NCT00776477|Experimental|1|
11581856|NCT00776477|Active Comparator|2|
11581857|NCT00776451||1|Subjects diagnosed with Dry AMD
11581858|NCT00776438|Experimental|Study Group 1|Adult, age 18 to 40 years
11581859|NCT00776438|Experimental|Study Group 2|Adult, age 18 to 40 years
11581860|NCT00776438|Experimental|Study Group 3|Elderly, age 60 to 85 years
11581861|NCT00776438|Experimental|Study Group 4|Elderly, age 60 to 85 years
11581862|NCT00776425|Experimental|Epoetin Beta 150 IU/kg|Participants with solid and lymphoid malignancies will receive subcutaneous or intravenous epoetin beta at a dose of 150 IU per kg of body weight thrice weekly.
11581863|NCT00776425|Experimental|Epoetin Beta 30000 IU|Participants with lymphoid malignancies will receive subcutaneous or intravenous epoetin beta at a dose of 30000 IU once weekly.
11581864|NCT00776412||HIV Negative|Healthy Volunteer Cohort
11581865|NCT00776412||HIV Positive INR|HIV Positive INR Cohort
11581866|NCT00776412||HIV Positive Standard|HIV Positive Standard Cohort
11581867|NCT00776399|Experimental|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
11581868|NCT00776373|Experimental|Arm 1|Rapamycin in combination with High Dose Etoposide and Cytarabine (HiVAC)
11581869|NCT00776360|Experimental|oxytocin, gastric emptying|Oxytocin is given to study the gastric emptying rate
11581870|NCT00776360|Placebo Comparator|oxytocin|sodium chloride is given to study gastric emptying rate
11581871|NCT00776347|Experimental|donepezil|
11581872|NCT00776334|Experimental|1|fosinopril sodium 40 mg tablets of Ranbaxy
11581873|NCT00776334|Active Comparator|2|Monopril® 40mg tablets
11581874|NCT00776321|Placebo Comparator|1|
11581875|NCT00776321|Experimental|Eprotirome dose 1|
11581876|NCT00776321|Experimental|Eprotirome dose 2|
11581877|NCT00776295|Experimental|adeno virus vectored p53|Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes
11581878|NCT00776282|Experimental|1|loratadine 10 mg orally disintegrating tablets
11581879|NCT00776282|Active Comparator|2|loratadine 10 mg orally disintegrating tablets
11581880|NCT00776269|Experimental|argon laser|
11581881|NCT00776256|Active Comparator|1|effect of beta-glucan
11581882|NCT00776256|Active Comparator|2|effect of fructo-oligosaccharide
11581883|NCT00776256|Active Comparator|3|effect of beta-glucan and fructooligosaccharide
11581884|NCT00776256|Placebo Comparator|4|no beta-glucan nor fructooligosaccharide
11581885|NCT00776243||wDM|Early diabetes
11581886|NCT00776243||pDM|Poorly controlled diabetic patients
11581887|NCT00776230|Active Comparator|IC51 (~12 months post filling)|6 mcg (~12 months post filling)
11581888|NCT00776230|Active Comparator|IC51 (~18 months post filling)|6 mcg (~18 months post filling)
11581889|NCT00776230|Active Comparator|IC51 (~24 months post filling)|6 mcg (~24 months post filling)
11581890|NCT00776217|Experimental|1|loratadine 10 mg orally disintegrating tablets
11581891|NCT00776217|Active Comparator|2|loratadine 10 mg orally disintegrating tablets
11581892|NCT00776204|Active Comparator|1|Drug Eluting Stent
11581893|NCT00776204|Active Comparator|2|Drug Eluting Stent
11581894|NCT00776204|Active Comparator|3|Drug Eluting Stent
11581895|NCT00776191|Active Comparator|Physioneal 35 vs. 40|Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks, followed by Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks.
11581896|NCT00776191|Active Comparator|Physioneal 40 vs. 35|Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks followed by Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks
11581897|NCT00776165|Experimental|1|Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF)(Shantha) Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
11581898|NCT00776165|Active Comparator|2|Neupogen (rhG-CSF) Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
11581899|NCT00776139|Experimental|1|Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc.
11581900|NCT00776139|Experimental|2|Zyrtec® Cetirizine Hydrochloride, 10 mg tablet of Pfizer Labs
11581901|NCT00776126||1|All enrolled subjects will undergo digital breast tomosynthesis.
11581902|NCT00776113|Active Comparator|2|Carvedilol 12.5 mg tablets
11581903|NCT00776113|Experimental|1|Carvedilol 12.5 mg tablets
11581904|NCT00776100|Other|Arm I|Patients undergo observation for 6 weeks.
11581905|NCT00776100|Experimental|Arm II|Patients undergo radiotherapy 5 days a week for 6 weeks to all sites of gross disease.
11581906|NCT00776087|Experimental|1 = Home Monitoring|Remote monitoring of ICD and CRT-D function and patient status
11581907|NCT00776087|Active Comparator|2 = No Home Monitoring|Home Monitoring option is switched off
11581908|NCT00776074|Experimental|Leuprorelin (GF)|
11581909|NCT00776074|Experimental|Leuprorelin (GC)|
11581910|NCT00776048||ABI|Acquired brain injury with lower limb spasticity
11581911|NCT00776048||Healthy Controls|Age matched healthy controls
11581912|NCT00776035||heart failure|Obesity related Heart failure population
11581913|NCT00776022|Experimental|1|Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories
11581914|NCT00776022|Active Comparator|2|Cetirizine Hydrochloride 10 mg tablet of Pfizer Labs
11581915|NCT00776009|Experimental|Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg|Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg dose (one 20 mg capsule and one 10 mg capsule) orally once a day for 7 days.
11581916|NCT00776009|Active Comparator|Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg|Dex-Methylphenidate hydrochloride (Focalin® XR) one 20 mg capsule orally once a day for 7 days.
11581917|NCT00776009|Placebo Comparator|Placebo|Two Capsules taken orally once a day for 7 days
11581918|NCT00775996|Experimental|1|15 mg clorazepate dipotassium tablets of ranbaxy
11581919|NCT00775996|Active Comparator|2|(TranxeneeT-Tab®) 15 mg clorazepate dipotassium tablets
11581920|NCT00775983|Active Comparator|laminaria|laminaria placed for cervical dilation; usual standard of care in study clinic
11581921|NCT00775983|Experimental|Dilapan-S|experimental treatment
11581922|NCT00775957||1|FLT-PET Scan
11581923|NCT00775957||2|FDG-PET Scan
11581924|NCT00775944|Active Comparator|Standard support|Standard 'Together Programme' telephone support for smoking cessation & advice to obtain nicotine addiction treatment
11581925|NCT00775944|Active Comparator|Proactive telephone support|Proactive support & advice to obtain nicotine addiction treatment
11581926|NCT00775944|Active Comparator|Standard support & offer NRT|Reactive telephone support (i.e. Together Programme) and offer of voucher for cost free Nicotine Replacement Therapy
11581927|NCT00775944|Active Comparator|Proactive support & offer NRT|Proactive telephone support and offer of voucher for cost free NRT
11581928|NCT00775931|Active Comparator|marrow graft transplant conditioning|Pre-transplant conditioning using Campath-1H, Busulfan, Fludarabine monophosphate, and total lymphoid irradiation followed by unrelated or matched related donor marrow graft transplantation (both peripheral blood and marrow) and a second CD34 cell infusion on Day 42.
11581929|NCT00775931|Active Comparator|cord blood transplant conditioning|Pre-transplant conditioning using Campath-1H, Busulfan and Cyclophosphamide followed by unrelated umbilical cord blood transplantation and a second smaller portion cord blood graft infusion on Day 42.
11581930|NCT00775918|Experimental|1|Doxycycline monohydrate 100mg tablets of Ranbaxy
11581931|NCT00775918|Active Comparator|2|Adoxa ® 100 mg tablets of Bradley Pharmaceuticals Inc
11581932|NCT00775905|Experimental|1|amlodipine 10 mg tablets of Ranbaxy
11581933|NCT00775905|Active Comparator|2|Norvasc® 10 mg tablets
11581934|NCT00775879|Experimental|A|2.5% target concentration
11581935|NCT00775879|Active Comparator|B|2.5% manually selected
11581936|NCT00775866|Experimental|MRI guided prostate biopsy|
11581937|NCT00775853||PD Risk Individuals|Individuals who may be at risk for developing PD, because of genetic risk; olfactory dysfunction; symptomatic rapid eye movement (REM) sleep behavior disorder (RBD); or orthostatic hypotension.
11581938|NCT00775840|Experimental|Candesartan QD + Heart Failure Therapy|(with angiotensin-converting enzyme-inhibitors/beta-blockers)
11581939|NCT00775840|Placebo Comparator|Placebo QD + Heart Failure Therapy|(with angiotensin-converting enzyme-inhibitors/beta-blockers)
11581940|NCT00775827|Experimental|1|fenofibrate 160 mg tablets of Ranbaxy Laboratories
11581941|NCT00775827|Active Comparator|2|Tricor 160 mg tablets
11581942|NCT00775814|Experimental|Candesartan + Hydrochlorothiazide QD|
11581943|NCT00775814|Active Comparator|Hydrochlorothiazide QD|
11581944|NCT00775801|Experimental|Treatment|FLD
11581945|NCT00775801|Active Comparator|Control|
11581946|NCT00775788|Experimental|Implant Failure|
11581947|NCT00775788|Experimental|Post mastectomy breast reconstruction|
11581948|NCT00775788|Experimental|Congenital malformations|
11581949|NCT00775788|Experimental|Breast Ptosis|
11581950|NCT00775788|Experimental|Micromastia|
11581951|NCT00775788|Experimental|Asymmetric Breasts|
11581952|NCT00775775||TBI|Patients with moderate to severe TBI
11581953|NCT00775762|Active Comparator|aspirin|
11581954|NCT00775762|Active Comparator|clopidogrel|
11581955|NCT00775762|Active Comparator|clopidogrel plus aspirin|
11581956|NCT00775749|Experimental|1|The nicotine patch will be applied prior to surgery and remain on the right upper back for 24 hours.
11581957|NCT00775749|Placebo Comparator|2|The placebo patch has no active ingredients and the same inactive ingredients as the nicotine patch. It will be administered the same fashion as the nicotine patch.
11581958|NCT00775736||A|
11581959|NCT00775710|Active Comparator|1|Non-invasive ventilation is maintained during three nights after recovery of an episode of hypercapnic respiratory failure.
11581960|NCT00775710|No Intervention|2|Discontinuation of NIV after the recovery of hypercapnic respiratory failure, without prolong it during night.
11581961|NCT00775697|Experimental|Montelukast|the single arm will receive montelukast
11581962|NCT00775684|Experimental|Exenatide|Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
11581963|NCT00775684|Experimental|Sitagliptin|Sitagliptin (Januvia®)-100 mg by mouth every morning
11581964|NCT00775684|Active Comparator|Glimepiride|Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose < 110mg/dl
11581965|NCT00775671|Active Comparator|Nebivolol|Nebivolol 5mg by mouth daily for 12 weeks.
11581966|NCT00775671|Active Comparator|Metoprolol|Metoprolol ER 100mg by mouth daily for 12 weeks.
11581967|NCT00775658|Active Comparator|olopatadine then placebo|participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
11581968|NCT00775658|Active Comparator|placebo then olopatadine|participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
11581969|NCT00775645|Experimental|Arm I|Patients receive oral acetyl-L-carnitine hydrochloride 3 times daily for 24 weeks.
11581970|NCT00775645|Placebo Comparator|Arm II|Patients receive oral placebo 3 times daily for 24 weeks.
11581971|NCT00775632|Active Comparator|Standard of Care|The current standard of care for GVHD prophylaxis at Princess Margaret Hospital is cyclosporine and Mycophenolate or cyclosporine and methotrexate.
11581972|NCT00775632|Experimental|Cyclosporine and Campath|The efficacy of experimental arm will be tested against standard of care for prevention of Chronic extensive GVHD.
11581973|NCT00775619|Active Comparator|2|Coreg® 12.5 mg tablets
11581974|NCT00775619|Experimental|1|Carvedilol 12.5 mg tablets
11581975|NCT00775606|Active Comparator|ARM A/Lopinar/ritonavir|Subjects randomized to Arm A initiated Lopinavir 400 mg/ritonavir 100 mg BID + emtricitabine 200 mg/tenofovir 300 mg QD
11581976|NCT00775606|Active Comparator|ARM B/Efavirenz|Subjects randomized to Arm B initiated Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg QD
11581977|NCT00775580|Experimental|1|atenolol 100 mg Capsules of Ranbaxy
11581978|NCT00775580|Active Comparator|2|Tenormin 100mg capsules
11581979|NCT00775567|Active Comparator|1|30g fructose dissolved in water twice a day
11581980|NCT00775567|No Intervention|No Intervention|
11581981|NCT00775554|Other|traditional hematoma block|people will receive traditional hematoma block for closed forearm fractures
11581982|NCT00775554|Other|ultrasound guided hematoma block|pts. will receive a hematoma block using bedside ultrasound to guide the placement
11581983|NCT00775541|Experimental|Vitamin C|2 gms vitamin C
11581984|NCT00775528|Experimental|A|
11581985|NCT00775515|Experimental|one|laparoscopic prostatectomy
11581986|NCT00775502|Experimental|BIW-8962, monoclonal antibody|
11581987|NCT00775489|Active Comparator|1|Steroid nasal spray (beclomethasone)
11581988|NCT00775489|Placebo Comparator|2|Normal saline nasal spray
11581989|NCT00775476|Active Comparator|NAC|2.4 g - 4.8 g of NAC daily starting after 3 month open label titration period.
11581990|NCT00775476|Placebo Comparator|Placebo|2.4 g - 4.8 g of placebo per day after 3 month open label titration period.
11581991|NCT00775463|Experimental|treprostinil diethanolamine|Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
11581992|NCT00775463|Placebo Comparator|placebo (sugar pill)|Matching placebo sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
11581993|NCT00775450|Experimental|Group 1a: Fluzone ID After Fluzone ID|
11581994|NCT00775450|Experimental|Group 1b: Fluzone IM After Fluzone ID|
11581995|NCT00775450|Active Comparator|Group 2a: Fluzone IM After Fluzone IM|
11581996|NCT00775450|Experimental|Group 2b: Fluzone ID After Fluzone IM|
11581997|NCT00775450|Active Comparator|Group 3: Fluzone HD After Fluzone HD|
11581998|NCT00775437|Experimental|Adalimumab|Adalimumab 24 mg/m^2 body surface area (BSA) up to a total dose of 20 mg administered every other week (eow) by parent or designee as a single dose via subcutaneous injection at approximately the same time of day, for a minimum of 24 weeks. Participants could continue in the study until age 4 and 15 kg (US and Puerto Rico) or for up to 1 additional year after reaching age 4 and 15 kg (EU). Visits beyond Week 24 occurred every 12 weeks for those participants who continued in the study.
11581999|NCT00775424|Experimental|PENNVAX-B alone|PENNVAX-B alone
11582000|NCT00775424|Experimental|PENNVAX-B+IL12|PENNVAX-B+IL12
11582001|NCT00775424|Experimental|PENNVAX-B+IL15|PENNVAX-B+IL15
11582002|NCT00775424|Placebo Comparator|PLACEBO|PLACEBO
11582003|NCT00775411|Experimental|700 µg dexamethasone and ranibizumab|700 µg dexamethasone intravitreal injection at Day 1 in the study eye. Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
11582004|NCT00775398||A|Subjects with anti-topical bovine thrombin antibodies pre-surgery, who received topical THROMBIN-JMI® during the study surgery.
11582005|NCT00775398||B|Subjects with anti-topical bovine thrombin antibodies pre-surgery, who did not received THROMBIN-JMI® during the study surgery.
11582006|NCT00775398||C|Subjects with no anti-topical bovine thrombin antibodies pre-surgery and who did receive THROMBIN-JMI® during the study surgery.
11582007|NCT00775398||D|Subjects with no anti-topical bovine thrombin antibodies pre-surgery and who did not receive THROMBIN-JMI® during the study surgery.
11582008|NCT00775385|Active Comparator|A|Standard chemotherapy
11582009|NCT00775385|Experimental|B|Customized treatment
11582010|NCT00775372|Experimental|1|clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories
11582011|NCT00775372|Active Comparator|2|Biaxin® granules 250 mg/5 mL oral suspension
11582012|NCT00775359|Experimental|1|Fenofibrate 160mg Tablets of Ranbaxy
11582013|NCT00775359|Active Comparator|2|TriCor® 160 mg Fenofibrate Tablets
11582014|NCT00775346||Polysomnography (PSG) Subjects|Subjects who have been prescribed with needing a polysomnography (PSG) will be enrolled into the study.
11582015|NCT00775333||1|Patients with diabetes and carpal tunnel syndrome
11582016|NCT00775333||2|Non-diabetic patients with carpal tunnel syndrome
11582530|NCT00771563|Active Comparator|Arm A|Chemotherapy without LMWH
11582017|NCT00775320||Brain tumor FLT-PET|Those diagnosed with a brain tumor and are to undergo surgery
11582018|NCT00775307|Placebo Comparator|B|Placebo 400 mg/day (24 weeks)
11582019|NCT00775307|Experimental|A|Pazopanib 400 mg/day (24 weeks)
11582020|NCT00775294|Experimental|maraviroc|Single arm trial looking at the pharmacokinetics of maraviroc in healthy volunteers.
11582021|NCT00775281||1|
11582022|NCT00775281||2|
11582023|NCT00775281||3|
11582024|NCT00775268|Experimental|Group A|Patients undergo 3'-deoxy-3'-[18F] fluorothymidine (FLT) and fludeoxyglucose F 18 (FDG) PET/CT scans at baseline, after 2 courses of chemotherapy, and after completion of chemotherapy. Patients with residual FDG-positive mass after completion of therapy may be enrolled in group B.
11582025|NCT00775268|Experimental|Group B|Patients undergo an FLT PET/CT scan within 2 weeks after completion of chemotherapy. Patients also undergo a biopsy or fine-needle aspiration, if clinically indicated.
11582026|NCT00775255|Experimental|1|clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories
11582027|NCT00775255|Active Comparator|2|Biaxin® granules 250 mg/5 mL oral suspension
11582028|NCT00775242|Experimental|Estradiol and progesterone injection|Comparison of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P
11582029|NCT00775229|Active Comparator|1|Naltrexone
11582030|NCT00775229|Placebo Comparator|2|Placebo
11582031|NCT00775216|No Intervention|Standard care|Standard behavioral counseling
11582032|NCT00775216|Experimental|Intervention|"Behavioral counseling intervention augmented with an interactive health promotion telephone helpline"
11582033|NCT00775203|Experimental|Trazodone Contramid Once A Day (OAD)|
11582034|NCT00775203|Placebo Comparator|Placebo|
11582035|NCT00775190|Active Comparator|Ortho tricyclen™|Participant Randomized to Ortho tricyclen 1 tablet by mouth Daily
11582036|NCT00775190|Active Comparator|Trinessa™|Participant Randomized to Trinessa 1 tablet by mouth Daily
11582037|NCT00775177|Experimental|1|Doxycycline monohydrate 100mg tablets of Ranbaxy
11582038|NCT00775177|Active Comparator|2|Adoxa ® 100mg tablets of Bradley Pharmaceuticals, Inc
11582039|NCT00775164|Experimental|pioglitazone|Pioglitazone: 15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
11582040|NCT00775164|Active Comparator|Metformin|Metformin XR; 1000 mg once daily for 16 weeks.
11582041|NCT00775151|Experimental|1|amlodipine 10 mg tablet of Ranbaxy
11582042|NCT00775151|Active Comparator|2|Norvasc® 10 mg tablets
11582043|NCT00775138|Experimental|Cohort 1 - 280 mg Arikayce™|Subjects in this arm of the cohort 1 will receive 280 mg of Arikayce™
11582044|NCT00775138|Placebo Comparator|Cohort 1 - Placebo|Subjects in this arm of the cohort 1 will receive matching placebo.
11582045|NCT00775138|Experimental|Cohort 2 - 560 mg Arikayce™|Subjects in this arm of the cohort 2 will receive 560 mg of Arikayce™
11582046|NCT00775138|Placebo Comparator|Cohort 2 - Placebo|Subjects in this arm of the cohort 2 will receive matching placebo
11582047|NCT00775112|Experimental|1|with pillow
11582048|NCT00775112|No Intervention|2|without pillow
11582049|NCT00775099|Experimental|Filtered Air Exposure|1 hour exposure to filtered air during intermittent exercise
11582050|NCT00775099|Experimental|Diesel Exhaust Exposure|1 hour exposure to dilute diesel exhaust at a concentration of 300 µg/m3 during intermittent exercise
11582051|NCT00775099|Experimental|Filtered Diesel Exposure|1 hour exposure to diesel exhaust with all particulates filtered out using teflon filter with intermittent exercise
11582052|NCT00775099|Experimental|PALAS Exposure|1 hour exposure to pure carbon particles produced by PALAS generator during intermittent exercise
11582053|NCT00775073|Experimental|Treatment|Bevacizumab (Avastin) & Everolimus (RAD001)
11582054|NCT00775047|Experimental|Pharmacy|Women receive their second and third depot-medroxyprogesterone acetate injections at the pharmacy by clinical pharmacists
11582055|NCT00775047|Active Comparator|Planned Parenthood clinic|Women receive their second and third depot-medroxyprogesterone acetate injections per usual care at their Planned Parenthood clinic.
11582056|NCT00775034|Experimental|1|Study group (Tisseel®)
11582057|NCT00775034|Other|2|Control group
11582058|NCT00775021|Active Comparator|etafilcon A/nelfilcon A|etafilcon A contact lens worn first and nelfilcon A contact lens worn second
11582059|NCT00775021|Active Comparator|nelfilcon A/etafilcon A|nelfilcon A contact lens worn first and etafilcon A contact lens second.
11582060|NCT00775008|Experimental|podcast|
11582061|NCT00775008|Active Comparator|Web group|
11582062|NCT00774995|Experimental|Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig)|Subjects who previously received HBV vaccine at 0, 1, 6 and 60 months (4 doses) and HBIg concomitantly at Month 0, and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
11582063|NCT00774995|Experimental|Engerix(3-dose)+HBIg|Subjects who previously received HBV vaccine at 0, 1, 6 months (3 doses) and HBIg concomitantly at Month 0, and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
11582064|NCT00774995|Experimental|Engerix(4-dose)|Subjects who previously received HBV vaccine at 0, 1, 6 and 60 months (4 doses) and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
11582065|NCT00774995|Experimental|Engerix(3-dose)|Subjects who previously received HBV vaccine at 0, 1, 6 months (3 doses) and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
11582066|NCT00774982|Experimental|1 6MP Test Formulation|1 x 40 mg Oral Tablet, 6 MP Delayed Release Test Formulation, for targeted ileal delivery
11582067|NCT00774982|Active Comparator|2. 6MP Reference Formulation|2 x 50 mg oral tablet, PURINETHOL
11582068|NCT00774969|Experimental|All|6 patients with Perianal Crohn's Disease and 10 healthy Volunteers
11582069|NCT00774956|Experimental|1|Subject with shoulder impingement
11582070|NCT00774956|Active Comparator|2|Healthy persons
11582071|NCT00774943|Active Comparator|AMG 557|
11582072|NCT00774943|Placebo Comparator|Placebo|
11582123|NCT00774579||2|Patients with growth hormone (GH) deficiency not starting GH replacement.
11582073|NCT00774930|Experimental|Lanreotide Autogel (Somatuline Depot) 120 mg|"Subjects received deep s.c. lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).
~After completing the DB phase (or if they met criteria for early roll over [ERO]) the subjects entered the IOL phase during which they received lanreotide Autogel 120 mg deep s.c. every 4 weeks for 32 weeks. During the LTOLE phase, subjects continued treatment with lanreotide Autogel 120 mg deep s.c. every 4 weeks until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained [whichever occurred first])."
11582074|NCT00774930|Placebo Comparator|Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE|"Subjects received deep s.c. placebo every 4 weeks (±3 days) for 16 weeks (DB phase).
~After completing the DB phase (or if they met criteria for ERO) the subjects entered the IOL phase during which they received lanreotide Autogel 120 mg deep s.c. every 4 weeks for 32 weeks. During the LTOLE phase, subjects continued treatment with lanreotide Autogel 120 mg deep s.c. every 4 weeks until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained [whichever occurred first])."
11582075|NCT00774917|Experimental|Numen|
11582076|NCT00774878|Experimental|Arm A|
11582077|NCT00774878|Active Comparator|Arm B|
11582078|NCT00774865||Surgical|Patients who have previously undergone robotic bypass surgery
11582079|NCT00774852|Experimental|Treatment|Abatacept plus Euro-lupus regimen
11582080|NCT00774852|Placebo Comparator|Control|Abatacept placebo plus Euro-lupus regimen
11582081|NCT00774839||Newly diagnosed stage II-III colon cancer 65 years or older|Medicare-eligible (≥ or = to 65 years) patients diagnosed with stage II - III colon cancer, are at least 4 months into chemotherapy and up to 7 months post-chemotherapy.
11582082|NCT00774826|Experimental|1|R-CVP x 3; Restaging if> RP then R-CVP x 5
11582083|NCT00774826|Experimental|2|R-CHOP x 3; Restaging if > RP then R-CHOP x 3 plus 2 Rituximab
11582084|NCT00774826|Experimental|3|R-FM x 3; Restaging if > RP then R-FM x 3 plus 2 Rituximab
11582085|NCT00774813|Active Comparator|A|Nexalin 1.3mA device + placebo antidepressant
11582086|NCT00774813|Active Comparator|B|Nexalin 15mA device + placebo antidepressant
11582087|NCT00774813|Placebo Comparator|C|Placebo device + SSRI (Citalopram or similar)
11582088|NCT00774800|Experimental|First Humalog+PH20, then Humalog, Humulin-R+PH20, Humulin-R|"Humalog + Recombinant human hyaluronidase PH20 (rHuPH20) (Intervention 1): 24 units (U) of rHuPH20 per unit of Humalog, injected subcutaneously (SC), for up to 3 visits until an appropriate dose was identified.
~Humalog alone (Intervention 2): a single SC injection of the appropriate identified dose of Humalog, delivered before a liquid meal.
~Humulin-R + rHuPH20 (Intervention 3): 24 U of rHuPH20 per unit of Humulin-R, injected SC, for up to 2 visits until an appropriate dose was identified.
~Humulin-R alone (Intervention 4): a single SC injection of the appropriate identified dose of Humulin-R, delivered before a liquid meal.
~Appropriate dose of either Humalog or Humulin-R was that at which blood glucose following a liquid meal was <160 milligrams per deciliter (mg/dL) for more than 30 minutes during the first 4 hours after injection and never fell below 60 mg/dL.
~All dose finding visits and interventions were separated by 3-10 days."
11582089|NCT00774787|Experimental|Imiquimod, treatment, topical cream|Imiquimod 5% cream, 1 packet (250 mg cream), applied to left or right treatment area on the face and/or balding scalp
11582090|NCT00774787|No Intervention|Control, Untreated|No treatment of treatment area on the other half of the face and/or balding scalp
11582091|NCT00774774|Placebo Comparator|2|No intervention
11582092|NCT00774774|Experimental|1|Mask
11582093|NCT00774761|Experimental|1|
11582094|NCT00774761|Experimental|2|
11582095|NCT00774761|Active Comparator|3|
11582096|NCT00774761|Active Comparator|4|
11582097|NCT00774761|Active Comparator|5|
11582098|NCT00774748|Experimental|I|All participants in the study will use the subcutaneous catheter twice for a period of one week each to inject the enoxaparin. For the remainder of the study the participants will inject subcutaneously.
11582099|NCT00774735|Experimental|Sequence 1|
11582100|NCT00774735|Experimental|Sequence 2|
11582101|NCT00774722|Experimental|Metronidazole|
11582102|NCT00774722|Placebo Comparator|Placebo|
11582103|NCT00774709||1|
11582104|NCT00774696|Experimental|1|Clarithromycin 500 mg Tablets
11582105|NCT00774696|Active Comparator|2|BIAXIN® 500 mg tablets
11582106|NCT00774683||Sub-study Group A|Six HIV-positive African American women from the main study, CID 0706
11582107|NCT00774644|Experimental|1|clarithromycin 500 mg tablets of Ranbaxy Laboratories Limited
11582108|NCT00774644|Active Comparator|2|BIAXIN® 500 mg tablets containing clarithromycin 500mg tablets
11582109|NCT00774631|Experimental|Hypothermia|mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming
11582110|NCT00774631|Active Comparator|No hypothermia|no hypothermia, according to local recommendations and guidelines of medical societies and literature
11582111|NCT00774618|Experimental|Resection|Those subjects undergoing resection with or without plate fixation
11582112|NCT00774618|No Intervention|Nonoperative|These patients were not considered candidates for surgical intervention by the investigators, declined surgical intervention, or did not receive insurance approval for surgery
11582113|NCT00774605|Experimental|Varenicline free base solution|
11582114|NCT00774605|Experimental|Varenicline transdermal delivery system|
11582115|NCT00774592|Experimental|1|Focus on Youth in the Caribbean (FOYC) plus Caribbean Informed Parents and Children Together (CImPACT)
11582116|NCT00774592|Experimental|2|FOYC plus Goal For It (GFI)
11582117|NCT00774592|Active Comparator|3|Wonderous Wetlands plus GFI
11582118|NCT00774592|Experimental|Grade 10-BFOOY+CImPACT|Youth receives HIV intervention; parents receive parental monitoring intervention
11582119|NCT00774592|Experimental|Grade 10 BFOOY+GFI|Youth receive HIV prevention intervention and parents receive attention control intervention on career planning
11582120|NCT00774592|Experimental|BFOOYand no parent intervention|Youth receive HIV prevention intervention; parents receive no intervention
11582121|NCT00774592|Placebo Comparator|Health and FAmily life|Youth receive standard of care (current curriculum); parents receive no intervention
11582122|NCT00774579||1|Patients with growth hormone (GH) deficiency starting GH replacement.
11582124|NCT00774566|Active Comparator|1|segmental PVI using an irrigated tip catheter
11582125|NCT00774566|Active Comparator|2|PVI using the Cryo-Balloon
11582126|NCT00774553|Experimental|1|AZD1656
11582127|NCT00774553|Placebo Comparator|2|Placebo
11582128|NCT00774540|Experimental|1|Ketorolac
11582129|NCT00774540|Placebo Comparator|2|saline
11582130|NCT00774527|No Intervention|ArmI(CyATG)|•Conditioning therapy will start on day -5 in patients who are randomized to receive Cy+ATG. Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter
11582131|NCT00774514|Experimental|Air exposure|1 hour exposure to filtered air during intermittent exercise
11582132|NCT00774514|Experimental|NO2 exposure|1 hour exposure to nitrogen dioxide at 4ppm during intermittent exercise
11582133|NCT00774501|Experimental|treatment of metastatic liver disease|The intervention is the use of image guidance with general anesthesia and suspended ventilation during treatment delivery. This will allow precise localization and delivery of dose to the tumor.
11582134|NCT00774475|Placebo Comparator|1: standard therapy|clopidogrel 75 mg/day
11582135|NCT00774475|Active Comparator|2: doubled therapy|clopidogrel 150 mg/day
11582136|NCT00774462|Experimental|1|
11582137|NCT00774449||1|individuals, who have undergone double (DLTx) or heart and lung transplantation (HLTx) at Hannover Medical School 6 months prior to inclusion
11582138|NCT00774436|Experimental|Patients scheduled to receive Focal Cryotherapy|After enrollment, patients will undergo a repeat transrectal ultrasound- guided prostate biopsy (minimum of 12 cores) to confirm the low-risk nature of their cancer. For study purposes, patients must meet the original entry crieteria on this repeat biopsy. If the patient meets the repeat-biopsy enrollment criteria, they will be treated with focal cryotherapy, meaning cryoablation of the regions of the prostate containing cancer. Efficacy is defined as all negative biopsy cores at the site of the focal ablation on a repeat transrectal biopsy 6 months after cryoablation. At baseline (prior to the re-staging biopsy), 3 months after focal cryotherapy, and at 6 months after focal cryotherapy (prior to the repeat prostate biopsy used to define efficacy), the patient will complete quality of life questionnaires as standard for all patients in the Urology Service.
11582139|NCT00774423|Placebo Comparator|Placebo|MAIN EXCIPIENT OF THE RILUTEK
11582140|NCT00774423|Active Comparator|Riluzole|RILUTEK
11582141|NCT00774397|Experimental|240 mg QD TN|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
11582142|NCT00774397|Experimental|240 mg QD / LI-TN|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
11582143|NCT00774397|Placebo Comparator|Placebo|Placebo once daily combined with PegIFN/RBV for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
11582144|NCT00774397|Experimental|120 mg QD / LI-TN|120 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in (LI) phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), followed by an additional 24 weeks of PegIFN/RBV in treatment naive (TN) patients
11582145|NCT00774397|Experimental|240 mg QD TE|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV in treatment experienced (TE) patients
11582146|NCT00774397|Experimental|240 mg QD / LI-TE|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-experienced (TE) patients
11582147|NCT00774397|Experimental|240 mg BID / LI-TE|240mg BI 201335 NA (Faldaprevir) twice daily combined with PegIFN/RBV for 24 or 48 weeks, with 3-day lead-in phase of PegIFN/RBV, in treatment-experienced patients
11582148|NCT00774384|Active Comparator|1|Immunisation with NZ MenB OMV vaccine (NZ98/254)
11582149|NCT00774384|No Intervention|2|No vaccine
11582150|NCT00774371|Experimental|1|The intervention program consists of group sessions provided according to the following schedule: weekly for 4 months, every other week for two months, and follow-up monthly sessions through 18 months of active subject participation. The time points for data collection from all subjects are baseline, 6 months, and 18 months. The group sessions offered to the treatment study arm are closed-group contingents with an average of 12-15 women assigned to each group.
11582151|NCT00774358|Experimental|Interleukin-2|We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
11582152|NCT00774345|Experimental|1|Lenalidomide po qd on days 1-28 of a 28 day cycle
11582153|NCT00774345|Placebo Comparator|2|Placebo capsules given orally on days 1-28 of a 28 day cycle
11582154|NCT00774319|Active Comparator|1|Induction Chemotherapy with TPF Then: cisplatin 100 mg/m2 on day 1, 22 and 43 combined with conventional radiotherapy
11582155|NCT00774319|Active Comparator|2|Induction chemotherapy with TPF Then cisplatin 40mg/m2 on day 1,8,15,22,29 and 35 combined with accelerated radiotherapy
11582156|NCT00774306|Active Comparator|1|Participants randomized to Group 1 will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
11582157|NCT00774306|Active Comparator|2|Participants randomized to Group 2 will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses or in a once-daily extended release formulation.
11582158|NCT00774306|Active Comparator|3|Participants randomized to Group 3 will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
11582159|NCT00774306|No Intervention|4|Participants randomized to Group 4 will receive no drug intervention.
11582160|NCT00774293|Experimental|1|Arnica 5CH and Bryonia 9CH (homeopathic drugs)
11582161|NCT00774293|Placebo Comparator|2|placebo Arnica 5CH and Bryonia 9CH
11582214|NCT00773825||2|Pregnancy after ovarian stimulation
11582215|NCT00773825||3|natural pregnancy
11582162|NCT00774280|No Intervention|ArmI(BuCy)|"Intravenous busulfan (Busulfex®; Orphan Medical, Minnetonka, MN) 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4
~Cyclophosphamide 60 ㎎/㎏ in D5W 200 ㎖ i.v. over 1-2 hours on days -3 and -2"
11582163|NCT00774280|No Intervention|Arm II (BuFlu)|"Intravenous busulfan 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4.
~Fludarabine (Fludara®, Schering AG, Berlin, Germany) 30 ㎎/㎡ i.v. over 30 minutes in D5W 100 ㎖ on days -6 to -2"
11582164|NCT00774267||1|
11582165|NCT00774267||2|
11582166|NCT00774267||3|
11582167|NCT00774267||4|
11582168|NCT00774254|Experimental|A|
11582169|NCT00774241|Experimental|1|
11582170|NCT00774228|Experimental|I-ZIP Ocular Bandage|
11582171|NCT00774228|Active Comparator|Oasis 24 hour Soft Shield Collagen Corneal Shield|
11582172|NCT00774202|Active Comparator|Rituximab, Cyclophosphamide, Vincristine, Prednisone|"'Standard Dose of Rituximab administered with C, V, P (CVP)'
~Interventions: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses at standard rates and use of premedication. The schedule will be to give the first rituximab infusion 5 days (± 3 days) prior to first administration of CVP, and the following 3 infusions will be given on the same day as the 3 cycles of C, V, P. On those days, the IV Cyclophosphamide and Vincristine will be given first so that the administration of fluids with the rituximab can be used as post-cyclophosphamide hydration, Cyclophosphamide dosing will be 750mg/m2 (maximum 2000mg), vincristine 1.4 mg/m2 (up to 1.6 mg), prednisone 100mg po daily for 5 days."
11582173|NCT00774202|Active Comparator|Higher Dose of Rituximab|In this arm, Rituximab will be administered at a dose of 750 mg/m2 once a week x 4 consecutive weeks (4 infusions in total). We will perform EKG monitor tracings before, during and after Rituxan infusions. This will be a single-lead tracing that will allow us to look at the Q-T interval.
11582174|NCT00774189|Experimental|1|clarithromycin 250 mg tablets of Ranbaxy Laboratories
11582175|NCT00774189|Active Comparator|2|Biaxin 250 mg tablets
11582176|NCT00774176||1|Phase 1 & Gene Expression:Hospitalized COPD exacerbators
11582177|NCT00774176||2|Phase 2: COPD group
11582178|NCT00774176||3|Genetic Association Studies: COPD and Healthy Controls
11582179|NCT00774163|Experimental|1|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
11582180|NCT00774163|Placebo Comparator|2|Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
11582181|NCT00774150|Experimental|1. Cognitive Behavioral Therapy|
11582182|NCT00774150|Active Comparator|2. Client Centered Therapy|
11582183|NCT00774124|Experimental|1 Telemedicine|Usual care plus telemonitoring
11582184|NCT00774124|Active Comparator|2 Standard of Care|Standard of care - women will monitor and record blood glucose levels four times a day.
11582185|NCT00774111|Experimental|Sequence 1|
11582186|NCT00774098|Placebo Comparator|Control Group|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
11582187|NCT00774098|Experimental|GICP|
11582188|NCT00774085||Patients with Schizophrenia|Patients with Schizophrenia are treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
11582189|NCT00774072|Active Comparator|Tobramycin 80 mg|applied once daily via Pari Sinus nebulizer
11582190|NCT00774072|Placebo Comparator|isotonic saline|applied once daily via Pari Sinus nebulizer
11582191|NCT00774046|Experimental|Induction chemotherapy followed by stem cell transplant|Ara-C Mitoxantrone Etoposide Stem cell mobilization Autologous transplant
11582192|NCT00774033|Experimental|1|Treatment of acute burn in adults and children by epidermal cell spray
11582193|NCT00774033|Active Comparator|2|Treatment of acute burn in adults and children by classic skin grafts
11582194|NCT00774020|Experimental|1|
11582195|NCT00774007|Placebo Comparator|Placebo|Placebo
11582196|NCT00774007|Active Comparator|Mesalazine|mesalazine 800 mg t.i.d.
11582197|NCT00773994|Other|Normal velopharyngeal mechanism|All participants in this study are normal healthy adults, who have agreed to undergo to a videofluoroscopic Televex. These participants are acceptable control subjects because they are not diagnosed with VPI and/or submucous cleft palate (SMCP) and the velopharyageal mechanism functions the same in adults as it does in children. This procedure will take approximately 3 minutes to 5 minutes.
11582198|NCT00773981|Active Comparator|1|Endoluminal vacuum therapy.
11582199|NCT00773981|No Intervention|2|Patients not receiving vacuum therapy should be treated with a catheter with daily rinsing for a minimum of 7 days.
11582200|NCT00773968|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants will receive methoxy polyethylene glycol-epoetin beta once monthly by subcutaneous (SC) injection for 28 weeks.
11582201|NCT00773955|Experimental|Treatment (R-(-)-gossypol)|Patients receive oral R-(-)-gossypol once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11582202|NCT00773942|No Intervention|Usual care|Study subjects receive usual care, without the intervention.
11582203|NCT00773942|Experimental|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
11582204|NCT00773942|Experimental|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and a brief chart synopsis including patient medical history, medication history, and relevant laboratory information.
11582205|NCT00773929|Experimental|1|3-6 subjects each cohort. Escalate dose after safety evaluation of subjects in cohort
11582206|NCT00773890|Experimental|TRF-1101|Daily treatment with TRF-1101
11582207|NCT00773890|Placebo Comparator|Placebo|Daily treatment with placebo
11582208|NCT00773877||1|Primary open angle glaucoma
11582209|NCT00773877||2|Normal Controls
11582210|NCT00773851|Other|A|transfacial sutures
11582211|NCT00773851|Other|B|staples
11582212|NCT00773838|Experimental|1|vorinostat and bortezomib
11582213|NCT00773825||1|Pregnancy after ICSI or IVF
11582216|NCT00773812|Experimental|Active Mecamylamine|There will be 12 children in this arm. These children will receive the active medication (mecamylamine).
11582217|NCT00773812|Placebo Comparator|Placebo|There will be 8 children in this arm. These children will receive placebo instead of the active medication.
11582218|NCT00773799||rehabilitation center's hospitalized patients|
11582219|NCT00773786|Experimental|Arformoterol|Arformoterol twice daily for 1 week via nebulizer
11582220|NCT00773786|Placebo Comparator|Placebo|Placebo twice daily for 1 week
11582221|NCT00773773|Experimental|Patients undergoing prostatic biopsy|This study will enroll two groups of 250 patients who are to undergo prostatic biopsy as part of their routine medical care because of suspicion of prostate cancer (elevated PSA between 2 and 10 ng/ml, abnormal rectal examination, or both). The first group will contain 250 patients of African-American descent and the second will contain 250 Caucasian men.
11582222|NCT00773760||dosing|
11582223|NCT00773747|Experimental|Vorinostat + bortezomib arm|
11582224|NCT00773747|Placebo Comparator|Placebo + bortezomib arm|
11582225|NCT00773734|Experimental|Apremilast 10mg|Apremilast 10 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 10 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
11582226|NCT00773734|Experimental|Apremilast 20mg|Apremilast 20 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 20 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
11582227|NCT00773734|Experimental|Apremilast 30 mg|Apremilast 30 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
11582228|NCT00773734|Placebo Comparator|Placebo|Oral Placebo tablets administered twice daily (BID) for 16 weeks during the placebo-controlled phase.
11582229|NCT00773734|Experimental|Placebo/Apremilast 20 mg|Participants initially randomized to receive placebo twice daily during the 16 week placebo controlled phase are re-randomized to 20 mg apremilast BID during the 8 week active treatment phase
11582230|NCT00773734|Experimental|Placebo/Apremilast 30mg|Participants initially randomized to receive placebo twice daily during the 16 week placebo controlled phase are re-randomized to 30 mg apremilast BID during the 8 week active treatment phase
11582231|NCT00773708|Experimental|1|intensify their triple-drug therapy with Raltegravir (RAL)
11582232|NCT00773708|No Intervention|2|Continue with the same antiretroviral therapy
11582233|NCT00773695|Active Comparator|Chemotherapy|Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks.
11582234|NCT00773695|Experimental|Chemotherapy and Bevacizumab|Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks. Participants will also receive concurrent treatment with bevacizumab every 3 weeks for 24 weeks.
11582235|NCT00773695|Active Comparator|Endocrine Therapy|Participants will receive aromatase inhibitor therapy at discretion of the investigator for a period of 24 weeks.
11582236|NCT00773695|Experimental|Endocrine Therapy and Bevacizumab|Participants will receive aromatase inhibitor therapy at discretion of the investigator and concurrent treatment with bevacizumab for a period of 24 weeks.
11582237|NCT00773656||1|patients treated for a prostate adenocarcinoma
11582238|NCT00773643|Experimental|Tissue Sample|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
11582239|NCT00773630|Active Comparator|A|Intake of Pletal 100 mg tablets dose together with 200 ml water
11582240|NCT00773630|Experimental|B|Intake of Pletal 100 mg ODT dose without water
11582241|NCT00773630|Experimental|C|Intake of Pletal 100 mg ODT dose together with 200 ml water
11582242|NCT00773630|Active Comparator|D|Intake of Pletal 100 mg ODT dose without water
11582243|NCT00773617|Experimental|1|Integrative cognitive affective therapy (ICAT)
11582244|NCT00773617|Active Comparator|2|Cognitive behavioral therapy (CBT)
11582245|NCT00773604|Other|Treatment|Deep Brain Stimulation
11582246|NCT00773591|Active Comparator|Botulinum Toxin Typ A|
11582247|NCT00773591|Placebo Comparator|Placebo|
11582248|NCT00773578||1|atopic asthmatic children exposed to environmental tobacco smoke
11582249|NCT00773578||2|atopic asthmatic children unexposed to environmental tobacco smoke
11582250|NCT00773565|Other|Optifast|Patients included take part at a weight reduction program over one year.
11582251|NCT00773552|Experimental|solifenacin succinate|Group randomized into solifenacin succinate treatment
11582252|NCT00773552|Placebo Comparator|placebo|Group randomized into placebo
11582253|NCT00773539|Active Comparator|1|
11582254|NCT00773539|Active Comparator|2|
11582255|NCT00773539|Active Comparator|3|
11582256|NCT00773526|Experimental|1|
11582257|NCT00773513|Active Comparator|Erythropoiesis Stimulating Agents|Participants will receive reference ESA according to approved label. The approved reference ESA compounds in the study will be darbepoetin alfa, epoetin alfa and epoetin beta.
11582258|NCT00773513|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants not currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta iv or sc once every 2 weeks for correction of renal anemia (target Hb 10-12 g/dL). Once corrected and in participants currently being treated with an ESA, methoxy polyethylene glycol-epoetin beta will be administered once monthly.
11582259|NCT00773500||1|Providers adopting electronic prescribing in New York City, New York
11582260|NCT00773500||2|Providers adopting electronic prescribing in the Taconic region of New York
11582261|NCT00773474|Experimental|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
11582262|NCT00773461|Experimental|1|
11582263|NCT00773461|Placebo Comparator|2|
11582264|NCT00773448|Active Comparator|Limited Malignancy Screening|
11582265|NCT00773448|Experimental|Extensive Malignancy Screening|Limited screen as described above in combination with comprehensive computed tomography of the abdomen/pelvis
11582266|NCT00773435|Active Comparator|1. Echinacea purpurea|
11582267|NCT00773435|Placebo Comparator|2. placebo|
11582268|NCT00773422|Experimental|naltrexone + varenicline|naltrexone (25mg) + varenicline (2mg)
11582269|NCT00773422|Experimental|varenicline|varenicline 2mg
11582270|NCT00773422|Placebo Comparator|placebo|placebo control
11582271|NCT00773383|Experimental|1|
11582272|NCT00773370|Experimental|APA-Stroke|The APA-stroke exercise program designed specifically for individuals with hemiparetic gait deficits due to stroke. These progressive exercises focus on walking, balance and weight shifting and include an exercise homework component.
11582273|NCT00773370|Active Comparator|Sittercise|Sittercise is not stroke specific. This less vigorous exercise program consists of seated exercise, focusing on stretching to improve general range of motion and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework associated with this group.
11582274|NCT00773357|Experimental|Guanfacine|guanfacine 3mg/day
11582275|NCT00773357|Placebo Comparator|Placebo|placebo control
11582276|NCT00773357|Experimental|Carvedilol|Carvedilol 50 mg/day
11582277|NCT00773344|Experimental|A1|
11582278|NCT00773331|Experimental|1|
11582279|NCT00773331|Active Comparator|2|
11582280|NCT00773318|Experimental|A|"Patients with histologically proven AJCC stages I - II - III prostate cancer including men with clinical T3N0M0 disease, men with PSA > 10 mg/ml, and men with Gleason score of 8-10. Prostate cancer patients scheduled for prostatectomy and pelvic lymph node dissection (CLND).
~Arm A = SPECT/CT guided LM/SL versus CLND"
11582281|NCT00773292|Experimental|ciclosporin|48 weeks treatment with ciclosporin
11582282|NCT00773279|Experimental|PDS290 --> FlexPen®|Subjects will receive trial drug with PDS290 for 12 weeks (treatment sequence 1) followed by FlexPen® for 12 weeks (treatment sequence 2)
11582283|NCT00773279|Experimental|FlexPen® --> PDS290|Subjects will receive trial drug with FlexPen® for 12 weeks (treatment sequence 1) followed by PDS290 for 12 weeks (treatment sequence 2)
11582284|NCT00773253|Active Comparator|standard EMG-guided Botox injection|All patients will undergo injection using conventional single channel EMG-guided technique. This will be used as a baseline for multi-channel mapping-based injections. Patients will be randomized to undergo single-channel vs. multi-channel assessment upon study entry and will then cross over to the alternate arm.
11582285|NCT00773253|Experimental|Multi-channel EMG-guided Botox injection|Patients will receive multi-channel EMG-guided Botox injection before or after they have been treated with single-channel EMG-guided Botox, depending on which group they are assigned in the cross-over design.
11582286|NCT00773240|Experimental|1|Grazax
11582287|NCT00773240|Placebo Comparator|2|
11582288|NCT00773227|Experimental|1|All patients included
11582289|NCT00773214|Experimental|exercise|
11582290|NCT00773201|Experimental|1|Healthy subjects
11582291|NCT00773188|Experimental|1|
11582292|NCT00773175|Active Comparator|Subcutaneous|Isotonic fluid rehydration by SC administration with hylenex (150 Units in 1 mL)
11582293|NCT00773175|Active Comparator|Intravenous|Isotonic fluid rehydration by IV
11582294|NCT00773162|Placebo Comparator|1|
11582295|NCT00773162|Active Comparator|2|
11582296|NCT00773149|Experimental|1|all included patients
11582297|NCT00773136|Active Comparator|Bimatoprost Suspension|Intervention to be administered: Each subject was given two suspensions, one mixed with Bimatoprost and one mixed with normal saline. They were instructed to use each suspension to a pre-determined eyelash (prepared prior to study enrollment in double blind fashion and marked after randomization with right and left). The intervention was the one eye with the Bimatoprost.
11582298|NCT00773123||1|Primary open angle glaucoma
11582299|NCT00773123||2|Normal controls
11582300|NCT00773110|Experimental|1 Albumin|Priming of the cardiopulmonary bypass circuit with 20% human albumin solution prior to surgery
11582301|NCT00773110|Placebo Comparator|2 Gelofusin|Priming of the cardiopulmonary bypass circuit with gelofusin prior to surgery
11582302|NCT00773097|Experimental|MUC1 Poly-ICLC|
11582303|NCT00773084|Active Comparator|Drug|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone
11582304|NCT00773071|Experimental|A|"Single photon emission computed tomography/computed tomography (SPECT/CT) guided lymphatic mapping and sentinel lymphadenectomy (LM/SL) vs. complete lymph node dissection (CLND)
~All cervical cancer and vulvar cancer patients will undergo CLND according to the standard of care in gynecologic cancers as recommended by the International Federation of Gynecology and Obstetrics (FIGO).
~Patients with FIGO IA2 and IB1 cervical cancers will be scheduled for radical hysterectomy and pelvic lymph node dissection.
~Patients with FIGO IB and II vulvar cancers and those of patients with FIGO III with clinically negative regional lymph nodes will be scheduled for vulvectomy and inguinal lymph node dissection."
11582305|NCT00773058|Active Comparator|glucocorticoid+RAI|stress-dose glucocorticoid treatment, compared to placebo group and ACTH test hints RAI
11582306|NCT00773058|Placebo Comparator|placebo + RAI|no glucocorticoid But ATCH test hints RAI
11582307|NCT00773058|Active Comparator|glucocorticoid|stress-dose glucocorticoid treatment, compared to placebo group and ACTH test does not hint RAI
11582308|NCT00773058|Placebo Comparator|placebo|no glucocorticoid But ATCH test does not hint RAI
11582309|NCT00773045||pain training program|ICU Patients treated with or without pain management protocol
11582310|NCT00773006||A|Stable/elective PCI patients
11582311|NCT00773006||B|NSTEMI PCI patients
11582312|NCT00773006||C|STEMI PCI patients
11582313|NCT00772993||1|Primary open angle glaucoma
11582314|NCT00772993||2|Normal Control
11582315|NCT00772993||3|Myopia with no evidence of glaucoma
11582316|NCT00772993||4|Myopia with evidence og glaucoma
11582317|NCT00772980|Experimental|1|Drug: Neramexa mesylate Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
11582318|NCT00772980|Placebo Comparator|2|Drug: Placebo Double-blind treatment period of 17 weeks placebo
11582412|NCT00772252||1|patient with hepatic failure undergoing liver support treatment in surgical intensive care unit
11582319|NCT00772967|Experimental|Placebo, Naproxen, Ultracet|Participants were treated with Placebo for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
11582320|NCT00772967|Experimental|Naproxen, Ultracet, Placebo|Participants were treated with Naproxen for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
11582321|NCT00772967|Experimental|Ultracet, Placebo, Naproxen|Participants were treated with Ultracet for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
11582322|NCT00772967|Experimental|Placebo, Ultracet, Naproxen|Participants were treated with Placebo for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
11582323|NCT00772967|Experimental|Naproxen, Placebo, Ultracet|Participants were treated with Naproxen for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
11582324|NCT00772967|Experimental|Ultracet, Naproxen, Placebo|Participants were treated with Ultracet for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
11582325|NCT00772954|Placebo Comparator|Placebo vaccine group|Participants scheduled to receive a dose of placebo vaccine on Day 0, Day 28, and Day 56, respectively.
11582326|NCT00772954|Experimental|Clostridium Difficile Vaccine Group 1|Participants scheduled to receive a dose of 50 μg Clostridium Difficile vaccine on Day 0, Day 28, and Day 56, respectively.
11582327|NCT00772954|Experimental|Clostridium Difficile Vaccine Group 2|Participants scheduled to receive a dose of 100 μg Clostridium Difficile vaccine on Day 0, Day 28, and Day 56, respectively.
11582328|NCT00772941||Varenicline|Patients taking Varenicline.
11582329|NCT00772928|Experimental|Pentacel™ concurrently with Prevnar®|Participants had Pentacel™ concurrently administered with Prevnar®
11582330|NCT00772928|Experimental|Pentacel™ staggered schedule with Prevnar®|Participants had Pentacel™ given at different times from Prevnar® (using a standardized, staggered schedule).
11582331|NCT00772915|Experimental|Lenalidomide with On-Demand Dexamethasone|"Lenalidmoide: 25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.
~Dexamethasone: 10-40 mg once weekly (days 1, 8, 15, & 22) orally with food until progression."
11582332|NCT00772902|Experimental|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg) once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
11582333|NCT00772902|Active Comparator|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
11582334|NCT00772889|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.
11582335|NCT00772889|Active Comparator|Fluarix elderly Group|Subjects aged ≥66 years received one dose of Fluarix vaccine.
11582336|NCT00772889|Active Comparator|Fluarix young Group|Subjects aged 19-43 years received one dose of Fluarix vaccine.
11582337|NCT00772876|Experimental|P1446A-05|Single arm of the study drug. This being a dose escalation study, patient will receive a dose depending on the stage of the trial.
11582338|NCT00772850||Antegrade nailing, humeral fractures|We included patient's age and gender, fracture location, fracture cause, presence of nail removal, post-operative period and comorbidity or associated disease as independent variables. Fracture location was either humeral neck or humeral shaft. Humeral neck fractures were defined as fractures above surgical neck of the humerus. Meanwhile, humeral shaft fractures were defined as fractures below surgical neck of the humerus and 5 cm above the olecarnon fossa. Humeral shaft fractures were separated into three groups: proximal third shaft fractures, middle third shaft fractures and distal third shaft fractures. Fracture causes included simple falls and traffic accidents.
11582339|NCT00772837|Experimental|1.H.Pylori Eradication Group|The eradication group will receive triple therapy (omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BID and Amoxycillin 1g BID) for 1 week for the eradication of H. pylori
11582340|NCT00772837|Placebo Comparator|2.Control Placebo Group|The control group will receive omeprazole 20 mg BID for 1 week along with placebo antibiotics for 1 week
11582341|NCT00772824|No Intervention|1|10 patients (30 cycles) of chemotherapy will receive placebo
11582342|NCT00772824|Active Comparator|2|Intravenous glutamine
11582343|NCT00772824|Experimental|3|Oral Glutamine
11582344|NCT00772811|No Intervention|Flu-Mel|Conditioning chemotherapy before infusion of allogeneic stem cells will include fludarabine 30 mg/m2/day for 5 consecutive days (days -6 to -2) and melphalan 100 mg/m2 at day -2.
11582345|NCT00772785|Experimental|Probuphine|buprenorphine implant
11582346|NCT00772772|Experimental|Vitamin D3|Vitamin D3 30,000 international units orally per week for 8 weeks
11582347|NCT00772759|Experimental|1|Dry powder for oral inhalation
11582348|NCT00772759|Placebo Comparator|2|Dry powder for oral inhalation
11582349|NCT00772746||exercise|Respiratory and cognitive exercises in panic disorder patients.
11582350|NCT00772707|Experimental|Opti-Free Replenish|Multi-purpose contact lens solution for cleaning and disinfecting study contact lenses used on a daily basis for 30 days.
11582351|NCT00772694|Experimental|sorafenib|drug
11582352|NCT00772681|Experimental|1|
11582353|NCT00772668|Experimental|RCVELP|"Rituximab, Cyclophosphamide, Bortezomib, Prednisone (RCVELP):
~Rituximab
~Induction: 375 mg/m2 IV infusion on Day 1 of every 21 days cycle for 8 cycles
~Maintenance: 375/m2 Days 1, 8, 15, 22 every 6 months for up to 4 cycles
~Cyclophosphamide: 750 mg/m2 intravenous piggyback (IVPB) on Day 1 of every 21 day cycle for 8 cycles
~Bortezomib: 1.6 mg/m2 IV push on Days 1 and 8 of every 21 days cycle for 8 cycles
~Prednisone: 100 mg PO daily on Days 1-5 of every 21 day cycle for 8 cycles"
11582413|NCT00772239|Experimental|Rotem|ROTEM: Rotation thromboelastometry
11582414|NCT00772239|Active Comparator|S|Standard coagulation managment procedure
11582354|NCT00772655|Experimental|Study Therapy|Induction therapy with a single course of 90Yttrium-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111Indium-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 up to a maximal dose of 12.000 MBq [if platelets are below 150000/µl only 11 MBq/kg are administered). Observation for patients achieving complete clinical and molecular response or partial clinical response. Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2 (t14;18)-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
11582355|NCT00772629|Experimental|Group 1|Subjects naïve to any meningococcal vaccination
11582356|NCT00772629|Experimental|Group 2|Subjects who previously received unconjugated polysaccharide vaccine (either bivalent A and C or tetravalent A, C, Y, and W 135)
11582357|NCT00772616|Experimental|1|Patients will receive propofol and remifentanil automatically administered (closed-loop administration using bispectral index as the single input for the controller).
11582358|NCT00772616|Active Comparator|2|Patients will receive propofol automatically administered (closed-loop administration using bispectral index as the single input for the controller) and sufentanil according to usual criteria
11582359|NCT00772603|Placebo Comparator|Placebo|Placebo - four identical tablets taken orally once daily
11582360|NCT00772603|Active Comparator|2400 mg SPN-804|2400mg OXC XR taken orally once daily as four identical tablets
11582361|NCT00772603|Active Comparator|1200mg SPN-804|1200mg OXC XR taken orally once daily as four identical tablets
11582362|NCT00772590|Experimental|Raltegravir, bovine colostrum|Raltegravir and hyper-immune bovine colostrum
11582363|NCT00772590|Experimental|Hyper-immune bovine colostrum|Hyper-immune bovine colostrum and Raltegravir placebo
11582364|NCT00772590|Experimental|Raltegravir|Raltegravir and Hyper-immune Bovine Colostrum Placebo
11582365|NCT00772590|Placebo Comparator|Placebo|Raltegravir placebo and hyper-immune bovine colostrum placebo
11582366|NCT00772577|Experimental|1|Aliskiren Hydrochlorothiazide(HCTZ)
11582367|NCT00772577|Active Comparator|2|Ramipril
11582368|NCT00772564|Experimental|Atorvastatin 80 mg|
11582369|NCT00772564|Experimental|Atorvastatin 10 mg|
11582370|NCT00772551|Active Comparator|1|
11582371|NCT00772551|Active Comparator|2|
11582372|NCT00772538|Experimental|tiotropium 5mcg/day|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
11582373|NCT00772538|Experimental|placebo|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
11582374|NCT00772525|Experimental|Sequence 1|"placebo,1 day treatment period 1
~50 mg Nerispirdine, 1 day treatment period 2
~400 mg Nerispirdine, 1 day treatment period 3"
11582375|NCT00772525|Experimental|Sequence 2|"placebo,1 day treatment period 1
~400 mg Nerispirdine, 1 day treatment period 2
~50 mg Nerispirdine, 1 day treatment period 3"
11582376|NCT00772525|Experimental|Sequence 3|"50 mg Nerispirdine, 1 day treatment period 1
~placebo, 1 day treatment period 2
~400 mg Nerispirdine, 1 day treatment period 3"
11582377|NCT00772525|Experimental|Sequence 4|"50 mg Nerispirdine, 1 day treatment period 1
~400 mg Nerispirdine, 1 day treatment period 2
~placebo, 1 day treatment period 3"
11582378|NCT00772525|Experimental|Sequence 5|"400 mg Nerispirdine, 1 day treatment period 1
~placebo, 1 day treatment period 2
~50 mg Nerispirdine, 1 day treatment period 3"
11582379|NCT00772525|Experimental|Sequence 6|"400 mg Nerispirdine, 1 day treatment period 1
~50 mg Nerispirdine, 1 day treatment period 2
~placebo, 1 day treatment period 3"
11582380|NCT00772512|Experimental|A|
11582381|NCT00772512|Experimental|B|
11582382|NCT00772512|Placebo Comparator|C|
11582383|NCT00772499|Experimental|1|olmesartan medoxomil tablets with added doses of hydrochlorothiazide, amlodipine, or hydralazine, if required to maintain target blood pressure
11582384|NCT00772499|Active Comparator|2|Atenolol tablets with added doses of hydrochlorothiazide, amlodipine, or hydralazine, if required to maintain target blood pressure
11582385|NCT00772473||1 group, usual acute triptan treatment|
11582386|NCT00772460|Active Comparator|Forced Air|Warming with forced air (BairHugger)
11582387|NCT00772460|Experimental|Conductive Warming|Warming with the conductive device (HotDog)
11582388|NCT00772447|Experimental|AZ drug|Daptomycin
11582389|NCT00772447|Active Comparator|Comparator|Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin
11582390|NCT00772421||Responder|A subject having at least a 50% reduction in total seizure frequency compared to the SANTE study 3-month Baseline Phase
11582391|NCT00772421||Non-responder|A subject with a less than 50% reduction in total seizure frequency compared to the SANTE study 3-month Baseline Phase.
11582392|NCT00772408||TB|patients with pulmonary TB
11582393|NCT00772408||control|healthy controls
11582394|NCT00772395|Active Comparator|Risedronate|
11582395|NCT00772395|Placebo Comparator|Placebo|
11582396|NCT00772382|Experimental|MCI-196|
11582397|NCT00772356|Experimental|A|
11582398|NCT00772356|Active Comparator|B|
11582399|NCT00772343|Placebo Comparator|Placebo Vaccine|0.9% Normal saline
11582400|NCT00772343|Experimental|Low dose|Low dose vaccine with adjuvant
11582401|NCT00772343|Experimental|High dose 1|High-dose vaccine with adjuvant
11582402|NCT00772343|Experimental|High dose 2|High-dose vaccine without adjuvant
11582403|NCT00772330|Experimental|MIDI Arrow|Ab externo glaucoma drainage device with no reservoir
11582404|NCT00772317|Experimental|HIFU|High Intensity Focused Ultrasound
11582405|NCT00772304|Experimental|1|Olopatadine 0.6% / Azelastine 137 mcg
11582406|NCT00772291|Placebo Comparator|placebo|
11582407|NCT00772291|Active Comparator|pregabalin|
11582408|NCT00772278|Active Comparator|CAS|carotid artery stenting
11582409|NCT00772278|Active Comparator|CEA|carotid endarterectomy
11582410|NCT00772265|Experimental|Wosulin N|Wosulin N, Isophane insulin for injection (Recombinant Human Insulin)(100 IU/mL), cartridges 3.0 mL
11582411|NCT00772265|Active Comparator|Novolin N|Novolin N, Isophane insulin for injection (Recominant Human Insulin)(100IU/ml),cartridges 3.0ml.
11582415|NCT00772226|Active Comparator|music|
11582417|NCT00772213|Experimental|MIGTS treatment|controlled trial (quasi-randomized) versus controls (=conventional treatment not in the MIGTS)
11582418|NCT00772213|No Intervention|controls (=conventional treatment not in the MIGTS)|
11582419|NCT00772200||Observational (neuropsychological and behavioral tests)|Parent and child participants complete the COG Standard Neuropsychological and Behavioral Battery at approximately 9, 30, and 60 months post-diagnosis in a 1-2 hour testing session conducted by a neuropsychologist or psychologist. The Battery consists of measures of intelligence, processing speed, attention, memory, language preference, behavioral/social/emotional function, executive function, adaptive function, and quality of life.
11582420|NCT00772187|Experimental|1|General anesthesia + I.V pca
11582421|NCT00772187|Experimental|2|General anesthesia + spinal analgesia + I.V pca
11582422|NCT00772174|Experimental|Pioglitazone + Metformin|
11582423|NCT00772174|Active Comparator|Metformin|
11582424|NCT00772161|Experimental|Sequence 1|First treatment week (day 1 to day 7) 20mg Ritalin LA; second treatment week (day 8 to day 14) 20mg Medikinet retard.
11582425|NCT00772161|Experimental|Sequence 2|First treatment week (day 1 to day 7) 20mg Medikinet retard; second treatment week (day 8 to day 14) 20mg Ritalin LA.
11582426|NCT00772148|Experimental|LCP-Tacro|LCP - Tacro™ tablets, once daily (LifeCycle Pharma A/S, Hørsholm DK)
11582427|NCT00772148|Active Comparator|Prograf (tacrolimus)|Prograf® capsules, twice daily (Astellas Pharma US, Deerfield IL)
11582428|NCT00772122|Experimental|Granulocyte colony stimulating factor|The G-CSF group of 35 women, underwent a daily sub-cutaneous administration of the filgrastim (Neupogen, Dompe', Italy), the recombinant G-CSF, at a dosage of 1 micro gram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
11582429|NCT00772122|Placebo Comparator|placebo (saline solution)|The placebo group consisting of 33 subjects, was given a treatment with saline solution at the 0.2ml/day subcutaneously/, from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
11582430|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 1|Participants will receive a dose of Influenza intradermal vaccine Lot 1
11582431|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 2|Participants will receive a dose of Influenza intradermal vaccine Lot 2
11582432|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 3|Participants will receive a dose of Influenza intradermal vaccine Lot 3
11582433|NCT00772109|Active Comparator|Fluzone Intramuscular Vaccine|Participants will receive a dose of influenza intramuscular vaccine
11582434|NCT00772096|Experimental|Verum|
11582435|NCT00772096|No Intervention|No treatment|
11582436|NCT00772083|Experimental|1|
11582437|NCT00772083|Active Comparator|2|standard approach currently being used
11582438|NCT00772070|Experimental|Previously received TetraMenD|Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.
11582439|NCT00772070|Experimental|Meningococcal vaccine-naїve|Participants have never received a Meningococcal vaccine in the past.
11582440|NCT00772057|Active Comparator|Propranolol group|
11582441|NCT00772057|Placebo Comparator|Placebo group|
11582442|NCT00772044|Active Comparator|Provent|Those receiving the active device
11582443|NCT00772044|Sham Comparator|Sham|Those receiving sham device
11582444|NCT00772031|Active Comparator|1|Participants will receive propranolol and topiramate.
11582445|NCT00772031|Placebo Comparator|2|Participants will receive a placebo and topiramate.
11582446|NCT00772005|Active Comparator|150 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
11582447|NCT00772005|Active Comparator|200 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
11582448|NCT00772005|Active Comparator|250 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
11582449|NCT00772005|Placebo Comparator|Matching Placebo|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
11582450|NCT00771979|Experimental|1|
11582451|NCT00771966|Placebo Comparator|Standard treatment|
11582452|NCT00771966|Active Comparator|SV maximization|
11582453|NCT00771953|Experimental|Apricoxib|Apricoxib 400mg once a day
11582454|NCT00771953|Placebo Comparator|Placebo|Placebo once a day
11582455|NCT00771940|Active Comparator|Ghrelin|
11582456|NCT00771927||Lacosamide|Epilepsy patients with partial-onset seizures who are uncontrolled on current therapy and are treated with add-on Vimpat
11582492|NCT00771719|Experimental|Ceftobiprole|Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
11582457|NCT00771927||Other AED|Epilepsy patients with partial-onset seizures who are uncontrolled on current therapy and are treated with other approved AED as add-on therapy
11582458|NCT00771914|Experimental|Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza|First Placebo, then 4 grams of Lovaza, then 81mg of Aspirin, then both 4 grams of Lovaza and 81 mg of Aspirin
11582459|NCT00771914|Experimental|Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo|First 81mg of Aspirin, then 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo
11582460|NCT00771914|Experimental|Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin|First 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 81mg of Aspirin
11582461|NCT00771914|Experimental|Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin|First both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 4 grams of Lovaza, then 81mg of Aspirin
11582462|NCT00771901|Placebo Comparator|Placebo|Subjects will be given a placebo rather than tauroursodeoxycholic acid.
11582463|NCT00771901|Experimental|tauroursodeoxycholic acid|Subjects will receive tauroursodeoxycholic acid for four weeks.
11582464|NCT00771901|Experimental|PBA|Subjects will receive sodium phenylbutyrate for four weeks.
11582465|NCT00771888|Other|1|lanreotide
11582466|NCT00771875|Active Comparator|Rabbit Antithymocyte Globulin (RATG)|Rabbit Antithymocyte Globulin (RATG) All patients will receive RATG (Thymoglobulin) dosed based on CD3 count. Patients will be redosed when the cluster of differentiation 3 (CD3) count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily. 1.5mg/kg/day over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels > 25 cells/mm3); Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
11582467|NCT00771875|Experimental|RATG/Rituximab|Rabbit Antithymocyte Globulin (RATG) + Rituximab Subjects will be given 1.5mg/kg/day of RATG over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels > 25 cells/mm3); Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
11582468|NCT00771875|Experimental|RATG/Bortezomib|Rabbit Antithymocyte Globulin (RATG) + Bortezomib -Subjects will be given 1.5mg/kg/day of RATG over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels > 25 cells/mm3). Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Bortezomib will be given at a dose of 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Methylprednisolone will be administered prior to each bortezomib dose. On days 2 and 5, administer methylprednisolone 100 mg intravenous push (IVP). On days 9 and 12, administer methylprednisolone 50 mg intravenous push (IVP). If thymoglobulin is administered the same day as bortezomib, the order of administration is- methylprednisolone, then bortezomib, then thymoglobulin.
11582469|NCT00771862|Placebo Comparator|1. standard care|1 day of perineural ropivacaine 0.2% infusion followed by 4-5 days of normal saline infusion.
11582470|NCT00771862|Active Comparator|2: experimental care|4-5 days of perineural ropivacaine 0.4% infusion.
11582471|NCT00771849|Experimental|Menactra® Vaccine Group|Participants receiving the tetravalent (A, C, Y, and W 135) meningococcal diphtheria toxoid conjugate vaccine
11582472|NCT00771849|Active Comparator|Hiberix® Vaccine Group|Participants receiving Haemophilus Influenzae Type b (Hib) vaccine
11582473|NCT00771823|Active Comparator|2|
11582474|NCT00771823|Active Comparator|1|"Maraviroc 300 mg twice daily for the first 14 days of the study.
~Placebo twice daily for the last 14 days of the study"
11582475|NCT00771810|Placebo Comparator|Placebo|Combination gemcitabine and platinum-based chemotherapy with concurrent placebo
11582476|NCT00771810|Experimental|TXA127 100 ug/kg|Combination gemcitabine and platinum-based chemotherapy with concurrent 100 ug/kg/day TXA127
11582477|NCT00771810|Experimental|TXA127 300 ug/kg|Combination gemcitabine and platinum-based chemotherapy with concurrent 300 ug/kg/day TXA127
11582478|NCT00771797|Experimental|1|Treatement with low dose flavanoids over 60 days
11582479|NCT00771797|Experimental|2|Treatment with high dose flavanoids over 60 days
11582480|NCT00771784||1|Short term endotracheal intubation.
11582481|NCT00771784||2|Long term endotracheal intubation.
11582482|NCT00771771|Active Comparator|Day unit rehabilitation|Discharge from the hospital to the patients' homes as soon as possible, supported by an out-patient ambulatory coordinating multidisciplinary team. The patients will be offered rehabilitation in a day unit, and multidisciplinary policlinical follow-ups will be performed 3 and 6 months after inclusion.
11582483|NCT00771771|Active Comparator|Home rehabilitation|Discharge from the hospital to the patients' homes as soon as possible, supported by an out-patient ambulatory coordinating multidisciplinary team. The patients will be offered rehabilitation treatment in their homes, and multidisciplinary policlinical follow-ups will be performed 3 and 6 months after inclusion.
11582484|NCT00771771|No Intervention|Treatment as usual|Patients will receive rehabilitation treatment after today's principles and routines.
11582485|NCT00771758|Experimental|001|tapentadol IR 50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days maximum daily dose 450 mg
11582486|NCT00771758|Experimental|002|oxycodone IR 5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days maximum daily dose 60 mg
11582487|NCT00771758|Placebo Comparator|003|placebo 1 capsule every 4 - 6 hr as needed for up to 10 days
11582488|NCT00771745|Active Comparator|rATG 4 doses|Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
11582489|NCT00771745|Active Comparator|rATG 3 doses|Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
11582490|NCT00771732|Experimental|1|Light therapy
11582491|NCT00771732|Sham Comparator|2|"6 minute session given with machine off"
11582493|NCT00771706|Experimental|Proton Pump Inhibitor|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
11582494|NCT00771706|Placebo Comparator|Sugar Pill|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough
11582495|NCT00771680||A|
11582496|NCT00771667|Placebo Comparator|Placebo (IP)|
11582497|NCT00771667|Experimental|Ustekinumab 1mg/kg (IP)|
11582498|NCT00771667|Experimental|Ustekinumab 3 mg/kg (IP)|
11582499|NCT00771667|Experimental|Ustekinumab 6 mg/kg (IP)|
11582500|NCT00771667|Placebo Comparator|Placebo IV - Responder - Placebo SC (MP)|
11582501|NCT00771667|Placebo Comparator|Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC|
11582502|NCT00771667|Placebo Comparator|Ustekinumab IV - Responder - Placebo SC (MP)|
11582503|NCT00771667|Experimental|Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|
11582504|NCT00771667|Placebo Comparator|Ustekinumab IV - Nonresponder - Placebo SC (MP)|
11582505|NCT00771667|Experimental|Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|
11582506|NCT00771654|Placebo Comparator|Placebo|Subjects will be randomized to the daily dosing of either oral Phentermine 37.5mg or placebo to commence at their 2 week follow-up appointment following their gastric band procedure
11582507|NCT00771654|Experimental|Phentermine|Subjects will be randomized to the daily dosing of either oral Phentermine 37.5mg or placebo to commence at their 2 week follow-up appointment following their gastric band procedure
11582508|NCT00771641|Active Comparator|Standard Fractionation|Standard Fractionation: 2 Gy/Fx, Q.D. 5 Days/wk, Total Dose: 70 Gy/35 Fx x 7 wks
11582509|NCT00771641|Experimental|Hyperfractionation|Hyperfractionation: 1.2 Gy/Fx, b.i.d. (> 6 hours apart, 5 days/wk) Total Dose: 81.6 Gy/68 Fx/7 weeks
11582510|NCT00771641|Experimental|Accelerated Hyperfractionation with split|Accelerated Hyperfractionation with split: 1.6 Gy/Fx b.i.d. (> 6 hours apart), 5 days/wk, Total Dose: 67.2 Gy/42 Fx/6 wks with a 2 week rest after 38.4 Gy
11582511|NCT00771641|Experimental|Accelerated fractionation with concomitant boost|Accelerated fractionation with concomitant boost
11582512|NCT00771628|Experimental|Flex-It Stylet|Patients will be intubated using the GlideScope with an ETT fitted with a Flex-It stylet.
11582513|NCT00771628|Active Comparator|2 Malleable|
11582514|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation A Group|Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11582515|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation B1 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11582516|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation B2 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11582517|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation C1 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11582518|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation C2 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11582519|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation D1 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11582520|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation D2 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11582521|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation E1 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11582522|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation E2 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11582523|NCT00771602|Experimental|Rituximab|Group 1: 375 mg/m^2 IV Rituximab Alone
11582524|NCT00771602|Experimental|Alemtuzumab|Group 2: 30 mg SQ Alemtuzumab Alone
11582525|NCT00771602|Experimental|Rituximab + Alemtuzumab|Group 3: 375 mg/m^2 Rituximab + 30 mg SQ Alemtuzumab
11582526|NCT00771589|Experimental|Prosthesis|Motorized External Knee prosthesis for above knee amputees. Comprised of agonist and antagonist actuators to mimic behavior of knee joint during locomotion.
11582527|NCT00771576||A. Healthy Controls|subjects w/ predicted normal BCM (healthy, normalweight, nondiabetic individuals who have stimulated insulin and cpeptide levels within the normal range);
11582528|NCT00771576||B. Longstanding T1D|subjects with predicted reduced beta cell mass (subjects with established T1DM who have low or not measurable stimulated insulin and c peptide levels);
11582529|NCT00771576||C. Obese Subjects|subjects with predicted increased beta cell mass (euglycemic obese subjects with fasting hyperinsulinemia).
11582531|NCT00771563|Experimental|Arm B|Chemotherapy with LMWH
11582532|NCT00771537|No Intervention|Arm 1. Control PLUS Control|
11582533|NCT00771537|Experimental|Arm 2. Control PLUS 1-Sided|No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
11582534|NCT00771537|Experimental|Arm 3. Control PLUS 2-Sided Trivial|No message intervention control condition regarding HIV testing AND 2-Sided trivial message experimental intervention condition regarding HIV vaccine clinical trial participation.
11582535|NCT00771537|Experimental|Arm 4. Control PLUS 2-Sided Major|No message intervention control condition regarding HIV testing AND 2-Sided Major message experimental intervention condition regarding HIV vaccine clinical trial participation.
11582536|NCT00771537|Experimental|Arm 5. 1-Sided PLUS Control|1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
11582537|NCT00771537|Experimental|Arm 6. 1-Sided PLUS 1-Sided|1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
11582538|NCT00771537|Experimental|Arm 7. 1-Sided PLUS 2-Sided Trivial|1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
11582539|NCT00771537|Experimental|Aim 8. 1-Sided PLUS 2-Sided Major|1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Major message intervention experimental condition regarding HIV vaccine clinical trial participation.
11582540|NCT00771537|Experimental|Arm 9. 2-Sided Trivial PLUS Control|2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
11582541|NCT00771537|Experimental|Arm 10. 2-Sided Trivial PLUS 1-Sided|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
11582542|NCT00771537|Experimental|Arm 11. 2-Sided Trivial PLUS 2-Sided Trivial|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
11582543|NCT00771537|Experimental|Arm 12. 2-Sided Trivial PLUS 2-Sided Major|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
11582544|NCT00771537|Experimental|Arm 13. 2-Sided Major PLUS Control|2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
11582545|NCT00771537|Experimental|Arm 14. 2-Sided Major PLUS 1-Sided|2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
11582546|NCT00771537|Experimental|Arm 15. 2-Sided Major PLUS 2-Sided Trivial|2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
11582547|NCT00771537|Experimental|Arm 16. 2-Sided Major PLUS 2-Sided Major|2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
11582548|NCT00771524|Experimental|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
11582549|NCT00771524|No Intervention|Control|Standard of care antibiotics prior to hip replacement surgery
11582550|NCT00771511|Experimental|1|Capsaicin cream applied to cervix after lidocaine gel
11582551|NCT00771511|Placebo Comparator|2|only lidocaine applied to the cervix
11582552|NCT00771498|Other|lopinavir|Patients with HIV/TB co-infection will receive treatment for both infection, and PK of lopinavir 800mg + ritonavir 200mg (PO BID) during 5 months will be performed
11582553|NCT00771485|Experimental|1|
11582554|NCT00771485|Other|2|
11582555|NCT00771472|Experimental|Vorinostat|
11582556|NCT00771459|Active Comparator|Ropivacaine|
11582557|NCT00771459|Placebo Comparator|Placebo|
11582558|NCT00771446|Experimental|ELAD (plus Standard of Care)|Treatment with ELAD in addition to standard of care therapy Standard of care therapy defines uniform treatment for ascites, esophageal varices, dietary recommendations, etc.
11582559|NCT00771446|Other|Standard of Care (Control)|Standard of care treatment Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
11582560|NCT00771433|Experimental|Group 1|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 6-11 of each course of chemotherapy as primary prophylaxis. Chemotherapy courses repeat every three weeks for 3-6 courses.
11582561|NCT00771433|Experimental|Group 2|Patients receive G-CSF SC once daily on days 6-11 of each course of chemotherapy as primary prophylaxis. Chemotherapy courses repeat every three weeks for 3-6 courses. Patients may also receive secondary prophylaxis with G-CSF if they experience an episode of neutropenia.
11582562|NCT00771420|Active Comparator|1|0.01mg/kg and 0.03mg/kg CAM-3001
11582563|NCT00771420|Active Comparator|2|0.1mg/kg CAM-3001
11582564|NCT00771420|Active Comparator|3|0.3mg/kg CAM-3001
11582565|NCT00771420|Active Comparator|4|1.0mg/kg CAM-3001
11582566|NCT00771420|Active Comparator|5|3.0mg/kgCAM-3001
11582567|NCT00771420|Active Comparator|6|10.0mg/kg CAM-3001
11582568|NCT00771420|Placebo Comparator|7|Placebo
11582569|NCT00771407|Active Comparator|Strattice fascial inlay|Strattice will be placed as a fascial inlay to support the ostomy site
11582570|NCT00771407|Other|Standard ostomy construction|Ostomy will be created in the standard fashion
11582571|NCT00771394|Placebo Comparator|1. Tamsulosin alone|
11582572|NCT00771394|Experimental|2. Tamsulosin + solifenacin (low dose)|
11582573|NCT00771394|Active Comparator|3. Tamsulosin + solifenacin (high dose)|
11582574|NCT00771381|Experimental|1|18F-FAZA + FluGlucoScan Injection
11582797|NCT00769769|Experimental|Telephone-based psychotherapy|
11582575|NCT00771368|Experimental|Nitric Oxide|gaseous nitric oxide delivered topically for 30 minutes
11582576|NCT00771355||1|Subjects with vitiligo.
11582577|NCT00771355||2|Subjects with melasma.
11582578|NCT00771355||3|Subjects with post-inflammatory hyper-pigmentation.
11582579|NCT00771355||4|Subjects with post-inflammatory hypo-pigmentation.
11582580|NCT00771342|Experimental|1|1% gasoue nitric oxide, delivered topically for 40 minutes daily for three consecutive days
11582581|NCT00771342|Placebo Comparator|2|Nitrogen gas delivered topically for 40 minutes, daily, for 3 consecutive days
11582582|NCT00771329|Experimental|1|BIIB023
11582583|NCT00771329|Placebo Comparator|2|
11582584|NCT00771316|Experimental|Group 1|MK0826 (ertapenem)
11582585|NCT00771316|Active Comparator|Group 2|meropenem
11582586|NCT00771303||Ct scan|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer measurement, lower limb compression ultrasonography and multi-slice computed tomography.
11582587|NCT00771277|Experimental|Arm 1|Use of volunteer support teams to provide services
11582588|NCT00771264|Active Comparator|Urgent PC|
11582589|NCT00771264|No Intervention|Sham / Placebo|
11582590|NCT00771251|Experimental|CNTO 148 50 mg|
11582591|NCT00771251|Experimental|CNTO 148 100 mg|
11582592|NCT00771251|Experimental|Placebo|
11582593|NCT00771238|Experimental|P500 Mattress|The new P500 Low Air Loss mattress will be used to replace the standard mattress for this study arm.
11582594|NCT00771238|No Intervention|Standard of Care Mattress|Cardiovascular ICU patients that receive standard of care mattress (Total Care Treatment Mattress) and standard pressure ulcer prevention care. All patients had daily skin assessments, as per normal care.
11582595|NCT00771225|Other|prolapse surgery with fascial repair|
11582596|NCT00771225|Other|prolapse surgery with mesh repair|
11582597|NCT00771212||001|
11582598|NCT00771199|Experimental|Transdermal Therapeutic System (TTS)-Fentanyl|
11582599|NCT00771186||children with vocal fold immobility|
11582600|NCT00771173|Active Comparator|Study Medication Group|Participants that are randomized to the phenazopyridine HCl group will receive the study medication (200 mg of phenzopyridine HCl orally) after leaving the operating room. We anticipate the first dose to be given after the patient has left the recovery area. We will continue use of study medication until it has been given up to 24 hours after the first VAS collection or catheter removal, whichever occurs first
11582601|NCT00771173|Placebo Comparator|Placebo tablet Group|For participants randomized to the placebo group will follow the same dosing schedule for the study medication, although they will receive an inert placebo tablet.
11582602|NCT00771160|Experimental|1|MK0476 5mg
11582603|NCT00771160|Experimental|2|MK0476 10mg
11582604|NCT00771147||Group 1|
11582605|NCT00771134|Experimental|Lu AA39959|
11582606|NCT00771134|Placebo Comparator|Placebo|
11582607|NCT00771134|Active Comparator|Quetiapine|
11582608|NCT00771121|Active Comparator|new emulsion|
11582609|NCT00771121|Placebo Comparator|new emulsion placebo|
11582610|NCT00771108|No Intervention|control|Subjects will serve as controls, continuing current diet and activity levels. Subjects will get monthly weights by the investigator at the research center.
11582611|NCT00771108|Experimental|Exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
11582612|NCT00771095|Active Comparator|Control (available) podcast|
11582613|NCT00771095|Experimental|Enhanced podcast|
11582614|NCT00771069||1|Type II Diabetes Mellitus patients with Complication and Hypertension
11582615|NCT00771056|Experimental|Hydroxychloroquine|Hydroxychloroquine 400 mg po daily for up to one year.
11582616|NCT00771043|No Intervention|TYSABRI|
11582617|NCT00771043|No Intervention|AVONEX|
11582618|NCT00771030|Experimental|Rheumatoid Arthritis|"The arm will enroll sequentially in two parts:
~Part A - Dose escalation at different dose levels with AMG 827 Part B - Dose expansion at selected dose level from part 1 with AMG 827"
11582619|NCT00771030|Placebo Comparator|Rheumatoid Arthritis (Placebo)|"The arm will enroll sequentially in two parts:
~Part A - Dose escalation at different dose levels with placebo Part B - Dose expansion at selected dose level from part 1 with placebo"
11582620|NCT00771017|Active Comparator|Arm I|Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment comprising leuprolide acetate or goserelin intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
11582621|NCT00771017|Experimental|Arm II|Patients receive androgen ablation as in arm I. Patients receive GVAX prostate cancer vaccine (CG1940 and CG8711) intradermally (ID) on day 1. Beginning on day 1 of week 3, patients receive booster doses of CG1940 and CG8711 ID every 2 weeks for 24 weeks.
11582622|NCT00771004|Experimental|Pioglitazone 30 mg to 45 mg QD|
11582623|NCT00771004|Placebo Comparator|Placebo QD|
11582624|NCT00770991|Experimental|Black Raspberry (BRB) Slurry plus BRB suppositories|20 grams BRB Slurry BID plus two, 730 mg BRB suppositories HS
11582625|NCT00770991|Experimental|Black Raspberry (BRB) Placebo Slurry plus BRB suppositories|20 grams BRB Placebo Slurry BID plus two, 730 mg BRB suppositories HS
11582626|NCT00770978|Experimental|Ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
11582627|NCT00770978|Experimental|Ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
11582628|NCT00770965|Experimental|AIN457 0.3 mg/kg|Participants received AIN457 0.3 mg/kg IV on Day 1.
11582629|NCT00770965|Experimental|AIN457 1.0 mg/kg|Participants received AIN457 1.0 mg/kg IV on Day 1.
11582630|NCT00770965|Experimental|AIN457 3.0 mg/kg|Participants received AIN457 3.0 mg/kg IV on Day 1.
11582631|NCT00770965|Placebo Comparator|Placebo|Participants received placebo to AIN457A IV on day 1.
11582632|NCT00770952|Experimental|Pioglitazone 30 mg to 45 mg QD + Glimepiride 2 mg to 4 mg QD|
11582633|NCT00770952|Active Comparator|Glimepiride 4 mg to 6 mg QD|
11582634|NCT00770926|Experimental|Program immediately|Receives the lifestyle program as soon as possible after randomization
11582798|NCT00769769|Active Comparator|Face-to-face psychotherapy|
11582635|NCT00770926|No Intervention|Wait list control|Wait one year and at the end of the year, is offered the option of participating in the program
11582636|NCT00770913|Active Comparator|1|
11582637|NCT00770913|Experimental|2|
11582638|NCT00770913|Experimental|3|
11582639|NCT00770900|Experimental|Montelukast|Asthmatic children and teenagers took montelukast daily.
11582640|NCT00770900|Placebo Comparator|Placebo|Placebo to montelukast tablet daily.
11582641|NCT00770887||Study participants|This study will enroll 50 English-speaking/literate women at least 18 years of age of any race who have sought contraception with DMPA at the Planned Parenthood of Southwest and Central Florida clinics in Tampa and Fort Myers. Patients who choose to begin DMPA or who have already been using DMPA will be approached regarding voluntary participation in the study. Because DMPA is contraindicated in pregnancy, women with a positive urine pregnancy will not be eligible. Should a woman become pregnant during the study, she will receive no further DMPA injections
11582642|NCT00770874|Experimental|1|S-1 + Cisplatin (arm A)
11582643|NCT00770874|Active Comparator|2|Cisplatin (arm B)
11582644|NCT00770861|Active Comparator|Nebivolol|Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets, oral administration
11582645|NCT00770861|Placebo Comparator|Placebo|Matching placebo tablets, oral administration
11582646|NCT00770848|Other|Phase 1b - AMG 102|Phase 1b is an open-label study with AMG 102 at 15mg/kg de-escalating to 7.5mg/kg and 5mg/kg if needed, will be administered by IV Q3W in combination with MP.
11582647|NCT00770848|Experimental|Phase 2 Arm A - AMG 102 + MP|AMG 102 safe dose level in phase 1b in combination with MP, will be administered by IV Q3W.
11582648|NCT00770848|Placebo Comparator|Phase 2 Arm C- PLACEBO|Placebo in combination with MP, will be administered by IV Q3W.
11582649|NCT00770848|Experimental|Phase 2 Arm B - AMG 102 + MP|Safe dose level in phase 1b of AMG 102 + MP will be administered by Q3W
11582650|NCT00770835|Experimental|Pioglitazone and Metformin QD|(along with lifestyle modification)
11582651|NCT00770835|Active Comparator|Glibenclamide and Metformin QD|(along with lifestyle modification)
11582652|NCT00770822|Experimental|Device, HIFU|High Intensity Focused Ultrasound
11582653|NCT00770822|Active Comparator|Device, brachytherapy|Brachytherapy
11582654|NCT00770809|Experimental|Arm I (THL)|Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m^2 IV over 1 hour once weekly and lapatinib ditosylate 750 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity.
11582655|NCT00770809|Active Comparator|Arm II (TH)|Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m^2 IV over 1 hour once weekly for 16 weeks in the absence of disease progression or unacceptable toxicity.
11582656|NCT00770809|Experimental|Arm III (TL)|Patients receive paclitaxel 80 mg/m^2 IV over 1 hour once weekly and lapatinib ditosylate 15000 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity. (Discontinued as of 6-15-11)
11582657|NCT00770796|Placebo Comparator|Placebo|placebo
11582658|NCT00770796|Active Comparator|Atorvastatin|80 mg die of Atorvastatin given at least two days before elective angiography or angioplasty and continued for two days after.
11582659|NCT00770783|Experimental|Magnetic Seizure Therapy (MST)|
11582660|NCT00770783|Active Comparator|Electroconvulsive Therapy (ECT)|
11582661|NCT00770770|Experimental|Fluocinolone Acetonide 0.2 µg/day|0.2 µg/day
11582662|NCT00770770|Experimental|Fluocinolone Acetonide 0.5 µg/day|0.5 µg/day
11582663|NCT00770757|Experimental|CC-4047 Arm|CC-4047 2 mg orally every day for 1 course (12 weeks or 84 days). Every 28 days of treatment are considered as 1 cycle and every 3 cycles are are considered as 1 course of treatment. A total of 4 courses of treatment are planned (12 months).
11582664|NCT00770744|Experimental|Zicronapine|
11582665|NCT00770744|Active Comparator|Olanzapine|
11582666|NCT00770731|Experimental|Torisel + Hycamtin + Velcade|"Torisel starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle.
~Hycamtin starting Dose 0.8 mg/m^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle.
~Velcade starting Dose 0.3 mg/m^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle."
11582667|NCT00770731|Experimental|Expansion Group|"Torisel + Hycamtin + Velcade Expansion Group
~Addition of 10 participants at highest tolerated dose level"
11582668|NCT00770718|Experimental|Recombinant Activated Factor VII|The first five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is >1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given. If a maximum total of 80mcg/kg has been administered without successful correction of INR, then FFP infusions will be utilized to complete correction.
11582669|NCT00770718|Experimental|Prothrombin Complex Concentrate (PCC)|5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is >1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered before FFP will be used to complete the correction.
11582718|NCT00770380|Active Comparator|Behavioral relapse prevention counseling|In the behavioral relapse prevention counseling, participants were taught coping strategies for resisting the urge to smoke. This intervention focused on relapse prevention (i.e., maintenance stage of change) and was based on the theoretical concepts and treatment procedures advocated by Marlatt and Gordon and recent smoking relapse data.
11582752|NCT00770146|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
11582827|NCT00769522|Experimental|FCR|
11582670|NCT00770718|Active Comparator|Fresh Frozen Plasma (FFP)|The last five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is >4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to >1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
11582671|NCT00770705|Experimental|1|Group receiving phenoxybenzamine
11582672|NCT00770705|Other|2|Historical control
11582673|NCT00770692|Experimental|Eszopiclone 1 mg- Elderly|
11582674|NCT00770692|Experimental|Eszopiclone 2 mg- Elderly|
11582675|NCT00770692|Experimental|Eszopiclone 2 mg- Non-elderly|
11582676|NCT00770692|Experimental|Eszopiclone 3 mg- Non-elderly|
11582677|NCT00770679|Experimental|High-Dose Statin|80 mg atorvastatin daily for 3 weeks
11582678|NCT00770666|Experimental|1|Nicotine patch, nicotine inhaler, bupropion
11582679|NCT00770666|Active Comparator|2|Nicotine patch
11582680|NCT00770653|Experimental|Pioglitazone 15 mg and Metformin 850 mg BID|
11582681|NCT00770653|Active Comparator|Glimepiride 2 mg and Metformin 850 mg BID|
11582682|NCT00770640|Experimental|Pioglitazone 30mg QD|(and variable insulin therapy)
11582683|NCT00770640|Placebo Comparator|Placebo QD|(and variable insulin therapy)
11582684|NCT00770627|Placebo Comparator|Placebo caps|
11582685|NCT00770627|Active Comparator|Omega 3 caps|
11582686|NCT00770614|Active Comparator|1|Sodium Bicarbonate (154 mEq/L in dextrose and H2O) 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
11582687|NCT00770614|Active Comparator|2|Isotonic Saline (0.9% sodium chloride) 1 mL/kg/h for 12 hours after the procedure
11582688|NCT00770614|Placebo Comparator|3|Placebo
11582689|NCT00770601|Experimental|Canakinumab|
11582690|NCT00770588|Experimental|gefitinib|Gefitinib (Iressa® 250 mg) 1 tablet daily
11582691|NCT00770588|Placebo Comparator|placebo|placebo 1 tablet daily
11582692|NCT00770575|Experimental|Pioglitazone 30mg to 45 mg QD + Atorvastatin 20 mg to 40 mg QD|
11582693|NCT00770575|Active Comparator|Atorvastatin 20mg to 40 mg QD|
11582694|NCT00770562|Active Comparator|Dexamethasone|Participants received 40 milligrams (mg) dexamethasone, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4). Participants in this treatment arm who failed to achieve a sustained response and had a platelet count of less than or equal to (≤)20 x 10^9 platelets per liter (L; from Day 30 up to end of 6 months) were treated with salvage treatment of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg per square meter (mg/m^2), intravenously (IV), with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28.
11582695|NCT00770562|Experimental|Dexamethasone plus Rituximab|Participants received dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m^2, IV, with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28. Nonresponsive participants with platelets less than (<) 20 x10^9/L or with active bleeding could have also received an additional treatment course of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m^2, IV on Days 7, 14, 21, and 28 administered with immunoglobulin (IgG) IV (at investigator discretion) and/or low/medium dose steroids (at investigator discretion) on Days 7, 14, 21, and 28.
11582696|NCT00770536|Experimental|Part 1|In part 1, six subjects will be assigned to each cohort A or B. This is a dose escalation/de escalation study with a 6 + 3 design based on the incidence of DLTs (dose limiting toxicities) during the first 4 weeks of combined therapy [(cohort A: AMG 386 and pegylated liposomal doxorubicin) or (cohort B: AMG 386 and topotecan)].
11582697|NCT00770536|Experimental|Part 2|The decision on declaration of a safe and tolerable dose during part 1 will lead to part 2 (cohort A: liposomal doxorubicin + AMG 386 MTD (max tolerated dose) of part 1, cohort B: Topotecan + AMG 386 MTD (max tolerated dose) of part 1
11582698|NCT00770510|Experimental|Eszopiclone 1 mg|
11582699|NCT00770510|Experimental|Eszopiclone 2 mg|
11582700|NCT00770510|Experimental|Eszopiclone 3 mg|
11582701|NCT00770510|Placebo Comparator|Placebo|
11582702|NCT00770510|Active Comparator|Zolpidem Tartrate 10 mg|
11582703|NCT00770497|Experimental|Pioglitazone 15 mg to 30 mg QD|
11582704|NCT00770497|Active Comparator|Pioglitazone 15 mg to 30 mg QD + Ramipril 2.5 mg to 5 mg QD|
11582705|NCT00770497|Active Comparator|Ramipril 2.5 mg to 5 mg QD|
11582706|NCT00770484|Experimental|Propranolol then placebo|Active treatment
11582707|NCT00770484|Placebo Comparator|Placebo then propranolol|Placebo Treatment
11582708|NCT00770471|Experimental|Dose Escalation|
11582709|NCT00770458||Pregnant women|Pregnant women that will undergo standard of care procedures to evaluate fetus for Down Syndrome
11582710|NCT00770445|Experimental|Pioglitazone 15mg BID|Insulin therapy added
11582711|NCT00770445|Experimental|Pioglitazone 15mg + Metformin 850mg BID|Insulin Therapy Added
11582712|NCT00770445|Active Comparator|Metformin 850mg BID|Insulin therapy added
11582713|NCT00770432|Active Comparator|Polyethylene glycol 3350 powder for solution|MiraLAX® (polyethylene glycol 3350 powder for solution)
11582714|NCT00770432|Placebo Comparator|Placebo|MALTRIN 500® M500 (maltodextrin 500)
11582715|NCT00770393|Experimental|1|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging.
11582716|NCT00770393|Active Comparator|2|Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.
11582717|NCT00770380|Experimental|Hypnosis for relapse prevention|The hypnosis intervention was conducted in two face-to-face visits with hypnosis recorded for home practice. Learning, practicing, and employing hypnotic skills in resisting the urge to smoke are core components of this intervention.
11582719|NCT00770367|Experimental|Pioglitazone then Placebo|18 volunteers that are Diabetic adults, 40-75 years that have higher ADMA levels as well as increased inflammation will take Pioglitazone for the first 12 week period of the study and then take the placebo for the final 12 weeks of the study.
11582720|NCT00770367|Experimental|Placebo then Pioglitazone|18 (other half of participants) volunteers that are Diabetic adults, 40-75 years that have higher ADMA levels as well as increased inflammation will take the placebo for the first 12 week period of the study and then take the Pioglitazone for the final 12 weeks of the study.
11582721|NCT00770354|Experimental|1|AS1402 plus letrozole
11582722|NCT00770354|Active Comparator|2|Letrozole
11582723|NCT00770341|Experimental|MK-3009 (daptomycin) 4 mg/kg|
11582724|NCT00770341|Active Comparator|Vancomycin|
11582725|NCT00770341|Experimental|MK-3009 (daptomycin) 6 mg/kg|
11582726|NCT00770328|Experimental|Pentoxifylline|Patients receive Pentoxifylline 400 mg po TID for 8 weeks.
11582727|NCT00770328|Placebo Comparator|Placebo|Patients take a placebo TID for 8 weeks.
11582728|NCT00770315|Experimental|SCH 39641 1.5 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
11582729|NCT00770315|Experimental|SCH 39641 6 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
11582730|NCT00770315|Experimental|SCH 39641 12 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
11582731|NCT00770315|Placebo Comparator|Placebo|Participants receive matching placebo rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
11582732|NCT00770289||Single group|
11582733|NCT00770276||Bariatric surgery|Bariatric surgery
11582734|NCT00770276||conservative Therapie|diet and exercise
11582735|NCT00770263|Experimental|Dose Level 1A|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.
~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.
~Temsirolimus 10 mg IV on days 8, 15, 22, and 29 during the first cycle.
~Temsirolimus 10 mg IV on days 8, 15, and 22 during subsequent cycles."
11582736|NCT00770263|Experimental|Dose Level 1|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.
~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.
~Temsirolimus 15 mg IV on days 8, 15, 22, and 29 during the first cycle.
~Temsirolimus 15 mg IV on days 8, 15, and 22 during subsequent cycles."
11582737|NCT00770263|Experimental|Dose Level 2|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.
~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.
~Temsirolimus 20 mg IV on days 8, 15, 22, and 29 during the first cycle.
~Temsirolimus 20 mg IV on days 8, 15, and 22 during subsequent cycles."
11582738|NCT00770263|Experimental|Dose Level 3|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.
~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.
~Temsirolimus 25 mg IV on days 8, 15, 22, and 29 during the first cycle.
~Temsirolimus 25 mg IV on days 8, 15, and 22 during subsequent cycles."
11582739|NCT00770263|Experimental|Dose Expansion Phase|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.
~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.
~Temsirolimus 25 mg IV on days 8, 15, 22, and 29 during the first cycle.
~Temsirolimus 25 mg IV on days 8, 15, and 22 during subsequent cycles."
11582740|NCT00770237|Experimental|Cues|Outcome Measures During cue trials, primary measures include craving (TCQ-SF, VAS), mood (mood form, VAS), and autonomic (heart rate, blood pressure, skin conductance and temperature) responsivity. During self-administration trials, primary measures include breakpoint (final ratio completed), total number of responses, and number of cigarette puffs earned and taken. Secondary measures include baseline smoking history, mood form, TCQ-SF, CO, FTND, and urinary cotinine and 3-hydroxycotinine (3-HC).
11582741|NCT00770224|Experimental|R-CHOP, tositumomab and rituximab|"Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 IV Day 1 Prednisone 100 mg PO Days 1-5 Rituximab 375 mg/m2 IV Day 1 Q 21 Days x 6 Cycles
~Patients are restaged by CT scan. Unlabeled tositumomab antibody 450 mg IV within 12 after Cycle 6 of CHOP. Dosimetric dose 35 mg IV after infusion of unlabeled tositumomab antibody. Unlabeled tositumomab antibody 450 mg IV 7-14 days after dosimetric dose. Therapeutic dose 35 mg IV after infusion of unlabeled tositumomab antibody.
~Rituximab 375 mg/m2 IV q 3 months x 4 years beginning 1 year after registration."
11582742|NCT00770211|Experimental|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
11582743|NCT00770211|Placebo Comparator|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
11582744|NCT00770198||alcoholic liver disease|alcoholic liver disease patients undergoing a transjugular liver biospy in our institution
11582745|NCT00770198||chronic HCV hepatitis|chronic HCV hepatitis patients undergoing a transjugular liver biopsy in our institution
11582746|NCT00770185|Experimental|Ridaforolimus|oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
11582747|NCT00770172|Experimental|Arm I|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily for 6 days beginning 1 week after the start of chemotherapy (days 7-12). If chemotherapy begins on day 8, patients receive G-CSF SC on days 9-14.
11582748|NCT00770172|Experimental|Arm II|Patients receive G-CSF SC every 2 days on days 10-20 for up to 6 injections.
11582749|NCT00770159|Experimental|1|MK0822
11582750|NCT00770159|Placebo Comparator|2|Placebo to MK0822
11582751|NCT00770146|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once a week for 26 weeks.
11582828|NCT00769522|Experimental|BR|
11582753|NCT00770133|Experimental|Ketotifen/naphazoline|Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
11582754|NCT00770133|Placebo Comparator|Vehicle|Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
11582755|NCT00770133|Active Comparator|Naphazoline|Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
11582756|NCT00770133|Active Comparator|Ketotifen|Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
11582757|NCT00770120|Experimental|Everolimus|Daily oral Everolimus 10 mg/day
11582758|NCT00770107|Active Comparator|Thiamine|
11582759|NCT00770107|Placebo Comparator|Placebo|
11582760|NCT00770094|Active Comparator|Group 1|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment in one eye of the subject and the AMO/VISX CustomVue™ wavefront guided Excimer Laser System performed on the contralateral eye
11582761|NCT00770094|Active Comparator|Group 2|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment in one eye of the subject and the Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System performed on the contralateral eye
11582762|NCT00770094|Active Comparator|Group 3|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment in one eye of the subject and the Bausch and Lomb Planoscan™ Excimer Laser System performed on the contralateral eye
11582763|NCT00770081|Experimental|1|50mg qd vildagliptin
11582764|NCT00770081|Active Comparator|2|sitagliptin (25mg qd)
11582765|NCT00770068||Experimental group|All participants testing positive for tree and ragweed pollen allergies, as determined by levels of immunoglobulin E (IgE) antibodies
11582766|NCT00770068||Control group|All participants testing negative for tree and ragweed pollen allergies, as determined by levels of IgE antibodies
11582767|NCT00770042|Experimental|Group 1|Ketoconazole 400 mg qd for 5 days (Days 2-6) plus a single dose of 50 mg avanafil on Days 1 and 6
11582768|NCT00770042|Experimental|Group 2|Erythromycin 500mg every 12 hours for 5 days (Days 2-6) plus a single dose of 200 mg Avanafil on Days 1 and 6.
11582769|NCT00770042|Experimental|Group 3|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8) plus a single dose of 50 mg avanafil on Days 1 and 8
11582770|NCT00770029|Experimental|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
11582771|NCT00770029|Placebo Comparator|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
11582772|NCT00770016|Experimental|1|the aim of the present study is to characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic - intramyocellular lipids in 12 adult patients, recently diagnosed with hypothyroidism
11582773|NCT00770003|Experimental|1|
11582774|NCT00770003|Placebo Comparator|2|
11582775|NCT00769990|Experimental|Genistein|Patients treated with Genistein who are going to undergo palliative radiation treatments for painful boney metastases.
11582776|NCT00769938|Active Comparator|Aspirin + clopidogrel + oral anticoagulation|
11582777|NCT00769938|Active Comparator|Oral anticoagulants + clopidogrel|
11582778|NCT00769925|Experimental|Therapist Assisted Bibliotherapy-Primary Care (TAB-PC)|
11582779|NCT00769925|Experimental|Cognitive Behavior Therapy-Primary Care (CBT-PC)|
11582780|NCT00769912|Experimental|1|50% N2O- 50%O2 mixture administration during the intervention
11582781|NCT00769912|Placebo Comparator|2|Placebo (air) during the intervention
11582782|NCT00769899|Experimental|1|
11582783|NCT00769899|Placebo Comparator|2|
11582784|NCT00769886|Experimental|KetoNaph|KetoNaph (ketotifen fumarate 0.025%, naphazoline HCl 0.05%) ophthalmic solution
11582785|NCT00769886|Active Comparator|Naphazoline|Naphazoline HCl 0.05% ophthalmic solution
11582786|NCT00769886|Active Comparator|Ketotifen|Ketotifen fumarate 0.025% ophthalmic solution
11582787|NCT00769886|Placebo Comparator|Vehicle|Vehicle of KetoNaph ophthalmic solution
11582788|NCT00769873|Active Comparator|Lovenox|Patients receive Lovenox 40mg SC daily (30mg SC daily if creatinine clearance < 30) for 21 days after laparoscopic splenectomy
11582789|NCT00769873|No Intervention|No Lovenox|Patients do NOT receive Lovenox post laparoscopic splenectomy
11582790|NCT00769860|Active Comparator|1|Arimoclomol
11582791|NCT00769860|Placebo Comparator|2|
11582792|NCT00769847||Sagittal synostosis|Male and female infants from 1-6 months of age with isolated, single suture sagittal craniosynostosis.
11582793|NCT00769834||CKD|The cohort comprises of patients who are diagnosed to have chronic kidney disease as defined by the K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease-2002.
11582794|NCT00769808|Experimental|Technolas 217z Excimer Laser|Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism.
11582795|NCT00769795|Experimental|Experimental|Bicalutamide 50 mg daily for 12 weeks Goserelin 10.8 mg SC once IMC-A12 10 mg/kg IV every three weeks for 12 weeks
11582796|NCT00769782|Experimental|therapeutic conventional surgery|All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
11582799|NCT00769756||2|"Financial incentive
~For the parents the financial incentive was 5 euros for every kilogram of weight-loss. For children the weight loss was calculated differently, taking into account the individual need of each child to lose weight. Children with a body mass index between the 90th and 97th age-adjusted BMI-percentile were asked to maintain their weight, and were paid in dependence on how well they managed to achieve this goal. Children with age-adjusted BMI-percentiles between 97 and 99, or above the 99th age-adjusted BMI-percentile received 5 euros per weight losses of respectively 500 g or 1 kg."
11582800|NCT00769756||1|The telemedical equipment consisted of a weighing scale for each family, an accelerometer for each participant, and a Homebox for each family which received the data from the scale and the accelerometers via bluetooth and transfered them via a telephone link to a server in Munich.
11582801|NCT00769756||3|The basic diet for all participants was supported by a list giving the calorie contents of a large variety of food-stuffs. The dual diet group received a second list giving the glycemic index (GI) for a large variety of carbohy-drates. Emphasis was placed on a preference for low-GI carbohydrates but not on avoidance of carbohydrates as required by the Atkins diet.
11582802|NCT00769730||1|Patients with hepatocellular carcinoma caused by hepatitis B virus who will be treated by transcatheter arterial chemoembolization were included.
11582803|NCT00769717|Experimental|Wellness-Centered|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
11582804|NCT00769717|Active Comparator|Weight-Centered|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
11582805|NCT00769704|Active Comparator|GM-CSF|Granulocyte macrophage colony-stimulating factor (GM-CSF) was administered at a dose of 125 μg/m²/day subcutaneously for 14 days, followed by a 14-day rest period for 24 weeks. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, or lack of response by 12 months, for a maximum of 18 months.
11582806|NCT00769704|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec on Days 1 and 15 of each 28-day cycle for 24 weeks. The initial dose of talimogene laherparepvec was at a concentration of 10⁶ plaque forming units (PFU)/mL, injected into 1 or more skin, subcutaneous or nodal tumors. Subsequent doses began at least 3 weeks after the first dose and consisted of talimogene laherparepvec at a concentration of 10⁸ PFU/mL. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, lack of response by 12 months, or disappearance of all injectable lesions, for a maximum of 18 months.
11582807|NCT00769691||Group A|Adult patients undergoing cardiac surgery
11582808|NCT00769678|Active Comparator|Stimulation of diaphragm|
11582809|NCT00769665||Systane Ultra|Systane Ultra
11582810|NCT00769665||Sensitive Eyes|Sensitive Eyes
11582811|NCT00769652|Experimental|Medical nutrition therapy|Medical nutrition therapy
11582812|NCT00769652|Active Comparator|Standard care|Standard care
11582813|NCT00769626|Experimental|Early Treatment|
11582814|NCT00769626|Active Comparator|Usual Care|
11582815|NCT00769600|Active Comparator|Itraconazole with Pemetrexed|Pemetrexed IV every 21 days with oral Itraconazole 200mg daily.
11582816|NCT00769600|Active Comparator|Single agent pemetrexed|Pemetrexed IV on day 1 of 21-day cycle.
11582817|NCT00769587|Experimental|Thalidomide|Use of thalidomide
11582818|NCT00769574|Experimental|1|Patients with coronary syndrome
11582819|NCT00769574|Other|2|Subjects without coronary syndrome
11582820|NCT00769561|Experimental|BFB-CBT|"Biofeedback-based cognitive-behavioral treatment:
~The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits."
11582821|NCT00769561|Active Comparator|Occlusal Splint (OS)|"Dental treatment with occlusal splints:
~Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment."
11582822|NCT00769548|Experimental|Arm 1|Neoadjuvant total androgen suppression (TAS) given 2 months before and during radiation therapy (RT) to the whole pelvis followed by a prostate boost.
11582823|NCT00769548|Experimental|Arm 2|Neoadjuvant TAS given 2 months before and during RT to the prostate only.
11582824|NCT00769548|Experimental|Arm 3|RT to the whole pelvis followed by a boost to the prostate followed by 4 months of TAS.
11582825|NCT00769548|Experimental|Arm 4|RT to the prostate only followed by 4 months of TAS.
11582826|NCT00769535|Experimental|HSP70 and TNF polymorphisms|
11582829|NCT00769509|Experimental|preterm formula|Assessment of energy expenditure of preterm infant during fed with preterm formula
11582830|NCT00769509|Active Comparator|human milk with fortifier|Assessment of energy expenditure by indirect calorimetry during fed with human milk with fortifier
11582831|NCT00769496|Experimental|Arm 1|
11582832|NCT00769483|Experimental|Phase I, Arm A|MK-0646 + Gemcitabine
11582833|NCT00769483|Experimental|Phase I, Arm B|MK-0646 + Gemcitabine + Erlotinib
11582834|NCT00769483|Experimental|Phase II, Arm A|Gemcitabine + Erlotinib
11582835|NCT00769483|Experimental|Phase II, Arm B|MK-0646 + Gemcitabine + Erlotinib
11582836|NCT00769483|Experimental|Phase II, Arm C|Gemcitabine + Erlotinib
11582837|NCT00769470|Active Comparator|Arm I|Patients receive trastuzumab IV over 90 minutes on day in course 1. Patients receive docetaxel IV, carboplatin IV, and trastuzumab IV over 30 minutes on day 1 in course 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11582838|NCT00769470|Experimental|Arm II|Patients receive oral lapatinib ditosylate once daily on days 1-21 in course 1. Patients receive docetaxel IV and carboplatin IV on day 1 and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7.Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11582839|NCT00769470|Experimental|Arm III|Patients receive trastuzumab IV over 90 minutes on day 1 and oral lapatinib ditosylate daily on days 1-21. Starting on day 22, patients receive docetaxel IV, carboplatin IV, and trastuzumab IV three times a week and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11582840|NCT00769457|Experimental|1|Arm with activated OptiVol / Carelink-system, event-triggered physician alert and physician access to Cardiac Compass data
11582841|NCT00769457|No Intervention|2|Arm with standard ICD - CRT-D therapy, no OptiVol and no Carelink
11582842|NCT00769431|No Intervention|Focus group|
11582843|NCT00769418|Experimental|1|odanacatib (MK0822)
11582844|NCT00769418|Placebo Comparator|2|placebo to odanacatib (MK0822)
11582845|NCT00769405|Experimental|Arm I|Patients undergo surgery and receive standard systemic chemotherapy comprising leucovorin calcium IV followed by fluorouracil IV over 30 minutes. Systemic chemotherapy will continue for at least 6 months (before and after surgery). Patients also undergo CHIP comprising oxaliplatin intraperitoneally during surgery and hyperthermia for 30 minutes.
11582846|NCT00769405|Experimental|Arm II|Patients undergo surgery and receive standard systemic chemotherapy comprising leucovorin calcium IV followed by fluorouracil IV over 30 minutes. Systemic chemotherapy will continue for at least 6 months (before and after surgery).
11582847|NCT00769392|Other|All Participants|All Participants will be randomized to receive a unique sequence of one of the 4 anesthetic agents per month, prior to a standard of care monthly intravitreal injection (1 injection per month for a total of 4 months). At the end of study participation, each patient will have received each of the 4 anesthetic agents once prior to one of the 4 intravitreal injections (ex. Randomization to sequence: Proparacaine Ophthalmic drops used prior to Injection 1; Tetracaine Ophthalmic drops used prior to Injection 2; Lidocaine 4% sponge used prior to Injection 3; Lidocaine 2% injectable solution (subconjunctival) used prior to Injection 4).
11582848|NCT00769379|Experimental|Arm I (standard WBI)|Patients undergo standard WBI over 5-6 weeks.
11582849|NCT00769379|Experimental|Arm II (WBI, trastuzumab)|Patients receive trastuzumab IV over 30-90 minutes once in weeks 1 and 4. Patients also undergo WBI as in Arm I.
11582850|NCT00769366|Experimental|Psychotherapy|Psychotherapy and medical therapy
11582851|NCT00769366|Active Comparator|Control|Optimal medical therapy
11582852|NCT00769353|Experimental|Cognitive Behavioral Therapy-PASCET|Primary and Secondary Coping Enhancement Training (PASCET)
11582853|NCT00769353|Active Comparator|Supportive Non-Directive Therapy (SNDT)|Supportive Non-Directive Therapy (SNDT)
11582854|NCT00769314|Experimental|1|Acyclovir Lauriad 50mg
11582855|NCT00769314|Placebo Comparator|2|
11582856|NCT00769301||1|Not hospitalized cancer patients under active treatment
11582857|NCT00769301||2|Caregivers of these cancer patients
11582858|NCT00769288|Experimental|I|Patients will receive a 1-hour infusion of FAU on days 1-5.
11582859|NCT00769275||1|Screening at start study with Adenosine vasodilator stress Tc-99m Sestamibi SPECT imaging
11582860|NCT00769275||2|No screening
11582861|NCT00769262|Active Comparator|Aggressive Weaning|Infants will be weaned from the isolette using our current NICU standard of care.
11582862|NCT00769262|Experimental|Conservative Weaning|Infants will be weaned from the isolette using a modified conservative weaning schedule.
11582863|NCT00769236|Other|1|Patients with crohn disease
11582864|NCT00769236|Other|2|Patients reached by hemorrhagic first side-colitis
11582865|NCT00769236|Other|3|Patients controls
11582866|NCT00769210|Experimental|A|
11582867|NCT00769197||1|Children with birth/time of neurologic insult less than 28 weeks of gestation
11582868|NCT00769197||2|Children with birth/time of neurologic insult at more than 28 weeks of gestation
11582869|NCT00769184|Experimental|Corticosteroid + LCD|corticosteroid and LCD treatment (2 weeks), LCD alone treatment (4 weeks)
11582870|NCT00769184|Placebo Comparator|Corticosteroid + Placebo|corticosteroid and placebo treatment (2 weeks), placebo alone treatment (4 weeks)
11582871|NCT00769171|Active Comparator|Arm 2|
11582872|NCT00769171|Experimental|Arm 1|
11582873|NCT00769158|Experimental|Topiramate + Naltrexone|Combination of Topiramate and Naltrexone
11582874|NCT00769158|Placebo Comparator|Placebo|
11582875|NCT00769145|Experimental|Ranibizumab|Patients to receive two injections of 0.5 mg ranibizumab subconjunctivally
11582876|NCT00769132|Experimental|A|ER niacin/laropiprant + Placebo to laropiprant
11582877|NCT00769132|Active Comparator|B|ER niacin + Placebo to laropiprant
11582878|NCT00769132|Experimental|C|laropiprant + Placebo to ER niacin/laropiprant
11582879|NCT00769132|Placebo Comparator|D|Placebo
11582880|NCT00769119|Experimental|AZD9668 active treatment|
11582881|NCT00769119|Placebo Comparator|AZD9668 placebo treatment|
11582882|NCT00769106|No Intervention|B (control group)|regular treatment and follow up
11582997|NCT00768287|Experimental|IB1001|
11582998|NCT00768287|Active Comparator|nonacog alfa|
11582883|NCT00769106|Experimental|A (CIK group)|cytokine-induced killer cell treatment plus regular treatment and follow up
11582884|NCT00769093|Active Comparator|Group 1|Both groups will receive an intravenous chemotherapeutic drug (carboplatin). The first study group (n=6) will receive bevacizumab, the antiangiogenic agent for three weeks, then dexamethasone for three weeks.
11582885|NCT00769093|Active Comparator|Group 2|Both groups will receive an intravenous chemotherapeutic drug (carboplatin). The second study group (n=6) will receive dexamethasone for 3 weeks, then switch to bevacizumab, the antiangiogenic agent, for 3 weeks.
11582886|NCT00769080||1|Standard Treatment plus PSP
11582887|NCT00769080||2|Standard Treatment
11582888|NCT00769067|Active Comparator|A|
11582889|NCT00769067|Experimental|B|
11582890|NCT00769054|Active Comparator|1|Local Infiltration with Ropivacaine
11582891|NCT00769054|Placebo Comparator|2|Local Infiltration with Placebo
11582892|NCT00769041|Placebo Comparator|placebo|
11582893|NCT00769041|Active Comparator|moxifloxacin|
11582894|NCT00769041|Experimental|avanafil therapeutic|avanafil 100mg - therapeutic dose
11582895|NCT00769041|Experimental|avanafil supratherapeutic|avanafil 800mg - supratherapeutic dose
11582896|NCT00769028|Experimental|AIMSPRO|
11582897|NCT00769028|Placebo Comparator|Placebo|
11582898|NCT00769015|Experimental|BA-LVR|In BA-LVR, a low vision occupational therapist (OT) will deliver Behavior Activation (BA), a psychological treatment to prevent depression. This will be administered in the context of the standard of low vision care for OTs as defined by the American Occupational Therapy Association (AOTA). The OTs will collaborate with low vision optometrists, who will deliver the standard of low vision care as defined by the American Optometric Association. The optometrists will evaluate remaining vision and magnification needs, prescribe optical devices, and provide the OTs with initial care plans. The OTs will subsequently meet with subjects in their homes 6 times over 12 weeks to enhance device use, home modifications, and compensatory strategies.
11582899|NCT00769015|Placebo Comparator|ST-LVR|Subjects randomized to ST-LVR will receive clinic-based low vision optometry, in addition to 6 in-home Supportive Therapy (ST) sessions. ST is a placebo condition that controls for the attention that subjects in the active treatment arm will receive.
11582900|NCT00769002|Active Comparator|Natural Infection|previously naturally infected
11582901|NCT00769002|Active Comparator|FluShield - influenza positivity|prior FluShield ipsilateral vaccinated
11582902|NCT00769002|Active Comparator|FluShield - influenza positivity2|prior FluShield contralateral vaccinated
11582903|NCT00769002|Active Comparator|FluMist|prior FluMist vaccinated.
11582904|NCT00768989|Experimental|Atazanavir + Raltegravir|Atazanavir 300 mg twice daily + Raltegravir 400 mg twice daily
11582905|NCT00768989|Active Comparator|Atazanavir + Ritonavir + Tenofovir /Emtricitabine|Atazanavir, 300 mg once daily, + Ritonavir, 100 mg once daily, + Tenofovir 300 mg/Emtricitabine, 200 mg once daily
11582906|NCT00768963|Experimental|1|Patients will receive one injection of ranibizumab 3 days prior to surgery
11582907|NCT00768963|Experimental|2|Patients will undergo one injection of ranibizumab at the time of surgery
11582908|NCT00768950||Spondyloarthropathies|Patients with spondyloarthropathies (ankylosing spondylitis, reactive arthritis, psoriatic arthritis and spondylitis, enteropathic arthritis and spondylitis, juvenile-onset spondyloarthritis, and undifferentiated spondyloarthritis) as defined by the AMOR criteria
11582909|NCT00768937|Experimental|Treatment arm|all patients will be treated with sorafenib
11582910|NCT00768924||1|Spinal fusion patients
11582911|NCT00768911|Experimental|1|
11582912|NCT00768898||2.5 microliters lissamine green|
11582913|NCT00768898||5.0 microliters lissamine green|
11582914|NCT00768898||10.0 microliters lissamine green|
11582915|NCT00768885|Active Comparator|PureVision 1|PureVision soft contact lens design #1.
11582916|NCT00768885|Experimental|PureVision 2|PureVision soft contact lens design #2
11582917|NCT00768859|Experimental|1|paclitaxel, trastuzumab and carboplatin
11582918|NCT00768846|Active Comparator|1|Endeavor Resolute Stent
11582919|NCT00768846|Active Comparator|2|Xience V Stent
11582920|NCT00768820|Experimental|1|
11582921|NCT00768807|Sham Comparator|Sham CPAP|Patients submitted to SHAM CPAP use for 06 months
11582922|NCT00768807|Active Comparator|CPAP|OSA patients submitted to 06 months of CPAP treatment
11582923|NCT00768794|Active Comparator|Acidolphilus|In the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.
11582924|NCT00768781|Active Comparator|Mindfulness-Based Stress Reduction|
11582925|NCT00768781|Active Comparator|Mindfulness-Based Therapy for Insomnia|
11582926|NCT00768781|Other|Behavioral Therapy for Insomnia (Delayed treatment condition)|
11582927|NCT00768768|Active Comparator|1|Iontophoretic Dose Level 1
11582928|NCT00768768|Active Comparator|2|Iontophoretic Dose Level 2
11582929|NCT00768768|Active Comparator|3|Iontophoretic Dose Level 3
11582930|NCT00768768|Active Comparator|4|Iontophoretic Dose Level 4
11582931|NCT00768768|Active Comparator|5|Iontophoretic Dose Level 5
11582932|NCT00768755|Experimental|I|Axitinib (continuous) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
11582933|NCT00768755|Experimental|II|Axitinib (modified) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
11582934|NCT00768755|Active Comparator|III|pemetrexed and cisplatin
11582935|NCT00768755|Experimental|IV|Axitinib interrupted before each chemo cycle (Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
11582936|NCT00768755|Active Comparator|V|pemetrexed and cisplatin
11582999|NCT00768274|Experimental|Arm A|Low-dose apabetalone (RVX000222) or placebo
11583000|NCT00768274|Experimental|Arm B|apabetalone (RVX000222) Dose-escalation or placebo
11583001|NCT00768274|Experimental|Arm C|high-dose apabetalone (RVX000222) or placebo
11583057|NCT00767793|Placebo Comparator|Arm 1|One drop in each eye every 12 hours for seven days
11582937|NCT00768729|Experimental|1|"Participants who have been maintained on MMF at study entry will start the study on 600 mg/m2 MMF orally daily. Participants who have been maintained on Azathioprine due to MMF intolerance will receive 1 mg/kg Azathioprine orally daily.
~Participants will continue receiving sirolimus throughout the study. However, MMF or Azathioprine will be withdrawn gradually over a period of at least 6 months. Dosage will be reduced by 25% initially and by 25% every subsequent 2 months resulting in complete withdrawal by 6 months."
11582938|NCT00768716|Experimental|White subjects|2 x 500 mg acetaminophen by mouth once
11582939|NCT00768716|Experimental|Black subjects|2 x 500 mg acetaminophen by mouth once
11582940|NCT00768690|Other|1|Healthy volunteers, receiving daily doses of 200 mg ABT-333 or placebo, BID for 10 days; and on Study Day 11 receiving a single dose of 200 mg ABT-333 or placebo + 400 mg ketoconazole
11582941|NCT00768690|Other|2|Healthy volunteers, receiving 400 mg ABT-333 or placebo, BID
11582942|NCT00768690|Other|3|Healthy volunteers, receiving 600mg ABT-333 or placebo, BID
11582943|NCT00768690|Other|4|Healthy volunteers, receiving 1000mg ABT-333 or placebo, BID
11582944|NCT00768690|Other|5|"Healthy volunteers, receiving 1600mg ABT-333 or placebo, BID*
~*After review of the data from previous groups, and in accordance with the protocol, this arm was not dosed."
11582945|NCT00768664|Experimental|A|
11582946|NCT00768651|Experimental|One arm: Sitagliptin + Pantoprazole|"Intervention Details:
~Sitagliptin 100 mg daily and Pantoprazole 40 mg bid for 6 months, followed by a three-month washout."
11582947|NCT00768638|Active Comparator|Atorvastatin 10mg|
11582948|NCT00768638|Active Comparator|Atorvastatin 40mg|
11582949|NCT00768612|Experimental|1|Lowest dose
11582950|NCT00768612|Experimental|2|Middle dose
11582951|NCT00768612|Experimental|3|Highest dose
11582952|NCT00768612|Active Comparator|4|Positive Control
11582953|NCT00768599|Active Comparator|1|Econazole Nitrate Cream 1%
11582954|NCT00768599|Experimental|2|Econazole Nitrate Foam 1%
11582955|NCT00768599|Placebo Comparator|3|Vehicle Foam
11582956|NCT00768586||1|Extreme premature infants under the 28th week of gestation.
11582957|NCT00768573||1. Taste test|
11582958|NCT00768560|Active Comparator|Nifedipine (Adalat CR, BAYA1040) 40 mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
11582959|NCT00768560|Experimental|Nifedipine (Adalat CR, BAYA1040) 40 mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
11582960|NCT00768560|Experimental|Nifedipine (Adalat CR, BAYA1040) 80 mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
11582961|NCT00768547||By protocol|Where the test are predefined
11582962|NCT00768547||By degression|The group where the doctor decided which test are to be taken.
11582963|NCT00768521|Experimental|1|Part I, Sequence 1: tolterodine tartrate crossing over to matching placebo
11582964|NCT00768521|Experimental|2|Part I, Sequence 2: placebo crossing over to study drug 4 mg once a Day (qd)
11582965|NCT00768521|Experimental|3|Part II, Sequence 1: study drug crossing over to placebo
11582966|NCT00768521|Experimental|4|Part II, Sequence 2: placebo crossing over to study drug
11582967|NCT00768508|Experimental|Ondansetron|Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy
11582968|NCT00768508|Experimental|Naltrexone|Naltrexone 50 mg/day + Cognitive Behavioral Therapy
11582969|NCT00768508|Experimental|Ondansetron + Naltrexone|Ondansetron 4 ug/kg b.i.d. + Naltrexone 50 mg/day + Cognitive Behavioral Therapy
11582970|NCT00768508|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy
11582971|NCT00768495||One Cohort|
11582972|NCT00768482|Experimental|Probuphine|Patients are first inducted on SL BPN, and then switched to 4 Probuphine implants
11582973|NCT00768469|Experimental|Nera 160 + Pac|Neratinib 160 mg + Paclitaxel 80 mg/m^2
11582974|NCT00768469|Experimental|Nera 240 + Pac|Neratinib 240 mg + Paclitaxel 80 mg/m^2
11582975|NCT00768456|Active Comparator|1|Local infiltration with Ropivacaine
11582976|NCT00768456|Placebo Comparator|2|Local infiltration with Placebo (NaCl)
11582977|NCT00768430|Experimental|1|Ketamine
11582978|NCT00768430|Active Comparator|2|Midazolam
11582979|NCT00768417||Participants|Participants completed all 3-arms of this cross-over design study.
11582980|NCT00768404|Experimental|A|
11582981|NCT00768391|Experimental|IMC-3G3|All patients will receive intravenous infusions of IMC-3G3, with the dose depending on which cohort they are enrolled into.
11582982|NCT00768378|Experimental|Perceived stimulation|When subjects assigned to the perceived stimulation group increase the intensity of the stimulus, they will feel a tingling sensation on the tongue. The tingling will move on the tongue in relation to where the head/body moves.
11582983|NCT00768378|Experimental|Subliminal stimulation|When subjects assigned to the subliminal stimulation group increase the intensity of the stimulus, the device provides a stimulus that is below their conscious awareness, so they will not be able to perceive it. The stimulus will move on the tongue in relation to where the head/body moves.
11582984|NCT00768365||group 1|patients with adrenal incidentaloma
11582985|NCT00768365||group 2|Thirty-five subjects comparable for sex, age, and BMI were enrolled as a control group (group 2).
11582986|NCT00768365||group 3|The other control group (group 3) of 35 healthy individuals matched for sex, age, BMI, metabolic syndrome criteria, cardiovascular risk parameters, menopausal status, smoking status, consumption of alcohol, usage of antihypertensive drugs, insulin or oral hypoglycaemic agents to perform a 1:1 case-control analysis.
11582987|NCT00768352|Other|Education Intervention|
11582988|NCT00768339|Experimental|1|Single agent AEG35156 as 2hr IV infusion, weekly dosing in Patients with relapsed or refractory chronic lymphocytic leukemia and indolent B-cell lymphomas
11582989|NCT00768326|Experimental|Zicronapine. Study Part A|
11582990|NCT00768326|Experimental|Zicronapine. Study Part B|
11582991|NCT00768326|Experimental|Zicronapine. Study Part C|
11582992|NCT00768326|Experimental|Zicronapine. Study Part D|
11582993|NCT00768326|Experimental|Zicronapine. Study Part E|
11582994|NCT00768326|Placebo Comparator|2A, 2B, 2C, 2D, 2E|
11582995|NCT00768300|Experimental|Ambrisentan|
11582996|NCT00768300|Placebo Comparator|Placebo|
11583002|NCT00768261|No Intervention|Very Mild to Mild DAT Untreated|Group 1) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are untreated with either cholinesterase inhibitors or memantine
11583003|NCT00768261|Active Comparator|Very Mild-Mild DAT Treated W/ Donepezil|Group 2) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with Donepezil (Aricept®).
11583004|NCT00768261|Active Comparator|Very Mild-Mild DAT Treated W/Combination|Group 3) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with the combination of Donepezil (Aricept®) and Memantine (Namenda®)
11583005|NCT00768261|No Intervention|Nondemented Comparison Subjects|Group 4) nondemented comparison subjects.
11583006|NCT00768248|Active Comparator|Active|3-7 days of perineural local anesthetic infusion
11583007|NCT00768248|Placebo Comparator|Placebo|3-7 days of perineural normal saline infusion
11583008|NCT00768235|Experimental|1: yoga group|Yoga group
11583009|NCT00768235|No Intervention|2: control group|
11583010|NCT00768222|Active Comparator|Chinese Silk Suture|Natural, non-absorbable silk suture made from entwined thread from silkworm larva, commercially available in China, used in a simple interrupted transdermal suture pattern
11583011|NCT00768222|Experimental|VICRYL* Plus Suture|Synthetic absorbable surgical suture composed of a copolymer of 90% glycolide and 10% L-lactide and containing triclosan antibacterial, used in a subcuticular closure technique
11583012|NCT00768209|Experimental|Treatment A|
11583013|NCT00768183|Experimental|Regimen A|KADIAN Capsule + alcohol (under fasting conditions)
11583014|NCT00768183|Experimental|Regimen B|KADIAN Capsule + alcohol (under fed conditions)
11583015|NCT00768183|Experimental|Regimen C|KADIAN Capsule + water (under fasting conditions)
11583016|NCT00768183|Experimental|Regimen D|Morphine sulfate IR oral solution + water (under fasting conditions)
11583017|NCT00768170|Experimental|1|MK0633
11583018|NCT00768157|Experimental|antiviral group|Drug: antiviral treatment(lamivudine or entecavir) after the Procedure/Surgery (radical resection of HBV-related HCC)
11583019|NCT00768157|Active Comparator|control group|Procedure/Surgery (radical resection of HBV-related HCC) without Drug of antiviral treatment - close observation without antiviral treatment
11583020|NCT00768144|Experimental|Sunitinib|Patients received oral Sunitinib at the daily dose of 37.5 mg continuously over a 28- day treatment cycle. Treatment continued until clinical or radiological evidence of progressive disease or excessive toxicity.
11583021|NCT00768131|Experimental|A1 FISH (+)|
11583022|NCT00768131|Active Comparator|B1 FISH (+)|
11583023|NCT00768131|Experimental|A2 FISH (-)|
11583024|NCT00768131|Active Comparator|B2 FISH (-)|
11583025|NCT00768118|Experimental|Curcumin, Green Tea extract, Polygonum Cuspidatum & Soybean|Total number of visits: 2, pre-intervention blood draw and urine sample collection, post-intervention blood draw and urine sample collection and interview Length of each visit: 15-30 minutes Total expected duration of participants' involvement: 15 days During the two-week intervention, volunteers will take two 1/2g capsules of the combination capsule, twice daily immediately after morning and evening meals.
11583026|NCT00768105|Experimental|1|
11583027|NCT00768105|Placebo Comparator|2|
11583028|NCT00768079|Placebo Comparator|Placebo|A single dose of placebo matched to benralizumab (MEDI-563) intravenous infusion over at least 30 minutes on Day 0.
11583029|NCT00768079|Experimental|Benralizumab 0.3 mg/kg|A single dose of benralizumab (MEDI-563) 0.3 milligram per kilogram (mg/kg) of body weight intravenous infusion over at least 30 minutes on Day 0.
11583030|NCT00768079|Experimental|Benralizumab 1.0 mg/kg|A single dose of benralizumab (MEDI-563) 1.0 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.
11583031|NCT00768066|Experimental|1|Participants will receive an injection of 100 million or 200 million autologous human mesenchymal stem cells (hMSCs).
11583032|NCT00768066|Experimental|2|Participants will receive an injection of 100 million or 200 million autologous human bone marrow cells (hBMCs).
11583033|NCT00768066|Placebo Comparator|3|Participants will receive a placebo injection of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS).
11583034|NCT00768053|Experimental|1|
11583035|NCT00768040|Experimental|Aliskiren 300 mg|Aliskiren 300 mg once daily for 12 weeks
11583036|NCT00768040|Placebo Comparator|Placebo|Matching placebo once daily for 12 weeks
11583037|NCT00768014||1|Healthy term pregnant women in labor without any pain relief
11583038|NCT00768014||2|Healthy term pregnant women received TENS
11583039|NCT00768014||3|Healthy term pregnant women received epidural anesthesia
11583040|NCT00767988|Active Comparator|A|Urex-cap-5 capsules (2x10^9 cfu each of RC-14 and GR-1) 1:1 ratio
11583041|NCT00767988|Placebo Comparator|B|Capsule 1:1
11583042|NCT00767975|No Intervention|2|For patients who diagnosed with LTBI, they choose to receive LTBI treatment depends on their willingness; if they choose not, then they are in no intervention arm.
11583043|NCT00767975|Experimental|1|Provided INH 6m or RMP 4 m; whether enter treatment arm is determined by patient's willingness
11583044|NCT00767962|Other|1|talc pleurodesis under medical thoracoscopy
11583045|NCT00767962|Other|2|pleurodesis under video-assisted thoracoscopy surgery
11583046|NCT00767949|Experimental|1|iSONEP
11583047|NCT00767897||CKD stage 3 or 4|Girls and Boys age 9-18 with CKD stage 3 or 4
11583048|NCT00767897||On dialysis|Girls and Boys age 9-18 who are on dialysis
11583049|NCT00767897||Transplanted|Girls and Boys age 9-18 who have had a functioning kidney transplant for longer than 6 months and are on the same immunosuppression regimen.
11583050|NCT00767897||Healthy|Girls and Boys age 9-18
11583051|NCT00767871|Experimental|Escitalopram|escitalopram (10-20mg) to panic patients
11583052|NCT00767819|Experimental|Arm 1|Progressive or metastatic bone or soft tissue sarcomas
11583053|NCT00767819|Experimental|Arm 2|Progressive gastrointestinal stromal tumors (GIST) after failure of prior imatinib and sunitinib 1st and 2nd line
11583054|NCT00767819|Experimental|Arm 3|Progressive or metastatic alveolar soft part sarcoma (ASPS)
11583055|NCT00767806|Experimental|Duloxetine|Participants received duloxetine 60 milligram by mouth once daily for 12 weeks of double-blind treatment
11583056|NCT00767806|Placebo Comparator|Placebo|Patients received placebo by mouth once daily for 12 weeks of double-blind treatment
11583058|NCT00767793|Experimental|Arm 2|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
11583059|NCT00767793|Experimental|Arm 3|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
11583060|NCT00767793|Experimental|Arm 4|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
11583061|NCT00767780||3|Patients suffering from ankle fractures and instability
11583062|NCT00767780||4|Patients suffering from hip osteoarthritis
11583063|NCT00767780||5|Patients who underwent total knee replacement or total hip replacement
11583064|NCT00767780||1|Patients suffering from bilateral knee osteoarthritis
11583065|NCT00767780||2|Patients suffering fron non specific low back pain
11583066|NCT00767767|Placebo Comparator|Placebos|Saline Infusion
11583067|NCT00767767|Active Comparator|Propofol 0.45mcg/mL|Anesthetic Drug Infusion
11583068|NCT00767767|Active Comparator|Propofol 0.90mcg/mL|Anesthetic Drug Infusion
11583069|NCT00767767|Active Comparator|Thiopental 1.5mcg/mL|Anesthetic Drug Infusion
11583070|NCT00767767|Active Comparator|Thiopental 3mcg/mL|Anesthetic Drug Infusion
11583071|NCT00767754|Other|paroxetine cr|single arm
11583072|NCT00767741|Experimental|with treatment|
11583073|NCT00767728|Active Comparator|1|Mesalamine pellets
11583074|NCT00767728|Placebo Comparator|2|Placebo
11583075|NCT00767715|Experimental|A|Patients will be given olanzapine
11583076|NCT00767715|Active Comparator|B|Patients will be given either haloperidol or zuclopentixol
11583077|NCT00767689|Experimental|vitamin B6|patient receiving xeloda and vitamin B6
11583078|NCT00767689|Placebo Comparator|2 placebo|patient receiving xeloda and placebo
11583079|NCT00767676|Other|1|
11583080|NCT00767663|Experimental|1|dipyridamole
11583081|NCT00767663|Placebo Comparator|2|placebo
11583082|NCT00767637|Experimental|Arm 1|
11583083|NCT00767624|Other|antidepressant + desensitization|Combined antidepressant medication (determined by an algorithm) plus desensitization therapy
11583084|NCT00767624|Other|antidepressant + cognitive behavioral|Combined antidepressant medication (determined by algorithm) plus cognitive behavioral therapy
11583085|NCT00767598|Active Comparator|A|Vardenafil
11583086|NCT00767598|Active Comparator|B|Sildenafil
11583087|NCT00767598|Active Comparator|C|Udenafil
11583088|NCT00767585||A:|70 women with hormone-dependent or hormone-independent early breast cancer that have completed their chemo- and/or radiotherapy just recently (up to 6 months after completion of therapy)
11583089|NCT00767585||B|70 women with hormone-independent early breast cancer, 24-36 months after completion of chemo- and/or radiotherapy
11583090|NCT00767585||C|70 women with hormone-independent early breast cancer, 54-66 months after completion of chemo- and/or radiotherapy
11583091|NCT00767585||D|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of tamoxifen therapy
11583092|NCT00767585||E|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy
11583093|NCT00767585||F|70 women with hormone-dependent early breast cancer, 54-66 months after initiation of tamoxifen therapy
11583094|NCT00767585||G|70 women with hormone-dependent early breast cancer, 54-66 months after initiation of aromatase inhibitors therapy
11583095|NCT00767585||H|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy following 24-36 months of initial tamoxifen therapy
11583096|NCT00767572|Experimental|atorvastatin|Patients are randomized to either atorvastatin or placebo once daily for 12 weeks. There is a 4 week washout, and then the groups are switched for 12 weeks. Brachial artery assessment will be performed before and after each 12 week period on therapy.
11583097|NCT00767572|Placebo Comparator|sugar pill|See above. Patients will be randomized to atorvastatin vs. placebo for 12 weeks and after a 4 week washout period the groups will be switched.
11583098|NCT00767559|Active Comparator|1|"Variable dose warfarin: 5 mg beginning the night before surgery, followed by 5mg the PM of surgery*, and then variable daily dose,until day 30 follow-up.
~(target INR 2.0-2.5)"
11583099|NCT00767559|Active Comparator|2|"Fondaparinux:
~2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day*,or 6-8 hours after epidural catheter removal, and continued until follow-up (28 days +/-2) from day of surgery."
11583100|NCT00767559|Active Comparator|3|"Fixed Low Dose warfarin
~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily follow-up at Day 28 (+/-2 days from surgery)."
11583101|NCT00767520|Active Comparator|A|
11583102|NCT00767520|Placebo Comparator|B|
11583103|NCT00767507|Experimental|Cangrelor|Cangrelor was administered as a continuous IV infusion of 0.75µg/kg/min for a minimum of 48 hours and a maximum of 7 days.
11583104|NCT00767507|Placebo Comparator|Placebo|A placebo infusion was administered as a continuous IV infusion of 0.75µg/kg/min for a minimum of 48 hours and a maximum of 7 days, to maintain the blind.
11583105|NCT00767494|Experimental|1|Travoprost/Brinzolamide AM, Vehicle PM
11583106|NCT00767494|Experimental|2|Travoprost/Brinzolamide PM, Vehicle AM
11583107|NCT00767494|Active Comparator|3|AZOPT AM and PM
11583108|NCT00767494|Active Comparator|4|TRAVATAN PM, Vehicle AM
11583109|NCT00767481|Experimental|Travoprost/Brinzolamide PM, Vehicle AM|Travoprost/Brinzolamide PM, Vehicle AM
11583110|NCT00767481|Experimental|Travoprost/Brinzolamide AM, Vehicle PM|Travoprost/Brinzolamide AM, Vehicle PM
11583111|NCT00767481|Active Comparator|Cosopt|Cosopt BID
11583112|NCT00767468|Experimental|Bilirubin Normal to 3x Upper Limit of Normal|
11583113|NCT00767468|Experimental|Bilirubin >3x to 6x Upper Limit of Normal|
11583114|NCT00767455|Sham Comparator|Positive, Negative Controls|
11583115|NCT00767442||1|Health volunteer
11583116|NCT00767442||2|Patient with suspected oral mucosa lesion
11583117|NCT00767429|Experimental|1|subjects with fall risk
11583118|NCT00767416|Experimental|Cohort 1 MEDI-559|MEDI-559
11583119|NCT00767416|Placebo Comparator|Cohort 1 Placebo|Placebo
11583120|NCT00767403|Experimental|1|
11583121|NCT00767403|Active Comparator|2|
11583124|NCT00767377|Experimental|EOF5 Group|The regimen of 5-day Continuous infusion of FU combined with Epirubicin and Oxaliplatin will be used in the patients recruited in this trial.
11583125|NCT00767364|Experimental|Infants with bowel resection|Infants with bowel resection who will receive the oral rotavirus vaccine, RotaTeq(R).
11583126|NCT00767364|Active Comparator|Healthy Infants|Healthy infants that are gest. age and age-matched controls within 14 days will be given the oral rotavirus vaccine, RotaTeq(R).
11583127|NCT00767338|Active Comparator|No surgery + IUI|No microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with intrauterine insemination.
11583128|NCT00767338|Active Comparator|No Surgery + TI|No microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with timed intercourse.
11583129|NCT00767338|Active Comparator|Surgery + IUI|Microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with intrauterine insemination.
11583130|NCT00767338|Active Comparator|Surgery + TI|Microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with timed intercourse.
11583131|NCT00767325|Experimental|Abatacept, 10 mg/kg|
11583132|NCT00767312||Patients|HIV-infected patients who are 18 years of age or older, have been enrolled in another NIH protocol.
11583133|NCT00767299|Experimental|1|
11583134|NCT00767299|Placebo Comparator|2|
11583135|NCT00767260|Experimental|BM-MNC+HOT|Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
11583136|NCT00767260|Experimental|BM-MNC|Autologous Bone Marrow mononuclear cell Infusion
11583137|NCT00767260|Experimental|HOT|hyperbaric oxygen therapy
11583138|NCT00767260|Active Comparator|Control|stand medical therapy (enhanced hemoglucose monitor, health and diet counseling and insulin injection)
11583139|NCT00767247||1|Male or female with arterial hypertension
11583140|NCT00767221|Experimental|A|The patient is his own control. Endpoint variables are measured before, during and after treatment.
11583141|NCT00767208|Experimental|type 2 diabetic subjects|
11583142|NCT00767208|Experimental|overweight healthy subjects|
11583143|NCT00767195||1. Control group|Patients in the intensive care unit who have no pulmonary edema
11583144|NCT00767195||2. Study group 1|Patients with cardiogenic pulmonary edema in the intensive care unit
11583145|NCT00767195||3. Study group 2|Patients with non-cardiogenic pulmonary edema in the intensive care unit
11583146|NCT00767182||Pregnant patients with VPP antecedent|Pregnancy women consulting for an scan during their 12th week of amenorrhea at the University Hospital of Saint Etienne will be studied in this clinical trial. They have an history of VPP (Vascular Placental Pathology). They will have to give a blood sample.
11583147|NCT00767169|Experimental|coated implant and control|
11583148|NCT00767156|Active Comparator|SBA24 capsule plus Omega7 cream|the subjects took SBA24 sea buckthorn oil capsule and apply Omega7 cream
11583149|NCT00767156|Active Comparator|SBA24 capsule plus base cream|the subjects took SBA24 sea buckthorn oil capsule and apply a base cream
11583150|NCT00767156|Active Comparator|Omega7 Cream|The subjects Omega 7 Sea Buckthorn Oil Cream, twice per day
11583151|NCT00767156|Placebo Comparator|Base cream|The subjects use base cream on the face, twice per day
11583152|NCT00767130||1|receiving atorvastatin
11583153|NCT00767130||2|receiving simvastatin
11583154|NCT00767130||3|receiving rosuvastatin
11583155|NCT00767104|Experimental|Silk-Like Pillowcase|Silk- Like pillowcase-One-half of subjects will be assigned to sleep on the study product, which is a standard size pillowcase made of a silk-like fabric every night for 12 weeks. The study pillowcases are fabricated from a light-weight plain-weave fabric woven of 100 percent synthetic yarns. The fabric is comprised of approximately 50% polyester and 50% nylon. The yarns in the fabric are formed from continuous-filament fibers, with no fibers projecting beyond the planar surface of the fabric. The antimicrobial technology used in the fabric is incorporated into the fibers during the finishing process and does not migrate out of the fabric or cause adverse reactions with skin contact.
11583156|NCT00767104|Placebo Comparator|Cotton Pillowcase|Placebo Comparator-One-half of subjects will be assigned to sleep on the placebo pillow case every night for 12 weeks. Placebo pillowcase is made of 100% cotton
11583157|NCT00767091|Active Comparator|Active treatment|A: transdermal rivastigmine at 4.6 mg per day during one month then 9.5 mg per day during 5 months.
11583158|NCT00767091|Placebo Comparator|placebo|transdermal patch of placebo
11583159|NCT00767065|Active Comparator|Cardiac Computed Tomography (CCT)|Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. CCT will be available Monday to Friday from 9am until 5pm. Patients will be entered into the study provided CCT can be undertaken within 24 hours of troponin result. Therefore, the only period during which a patient will be ineligible for inclusion will be between 5pm on a Friday and 9am the following Sunday. Studies will be reported at CWH by one of 2 experienced radiologists trained in CCT and results passed to the referring team on the same day.
11583160|NCT00767065|Active Comparator|Standard Care Arm|Patients randomised to the standard care arm will undergo further care as dictated by the responsible clinician. Except for CCT, all standard investigations will be available to the responsible clinician and may be used at their discretion. CCT does not form part of current in-patient management at our hospital.
11583161|NCT00767052|Experimental|Active|AZD1236 tablet
11583162|NCT00767052|Placebo Comparator|Placebo|Placebo tablet
11583163|NCT00767052|Other|Relative bioavailability|AZD1236 Oral suspension
11583164|NCT00767052|Other|Relative bioavailability tablet|AZD1236 tablet
11583165|NCT00767039|Active Comparator|1|Surfactant (beractant, Survanta initial dose 100 mg/kg and subsequent doses 100 mg/kg phospholipids every 6-12 hours, as needed for up to 4 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation
11583166|NCT00767039|Experimental|2|Surfactant (poractant, Curosurf initial dose 200 mg/kg and subsequent doses 100 mg/kg phospholipids every 12-24 hours as needed for up to 3 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation
11583167|NCT00767026|Experimental|1|
11583168|NCT00767026|Active Comparator|2|
11583169|NCT00767013|Experimental|AVS, CAD|DSCT
11583170|NCT00767000|Experimental|MK-0941 10 mg|
11583171|NCT00767000|Experimental|MK-0941 20 mg|
11583172|NCT00767000|Experimental|MK-0941 30 mg|
11583173|NCT00767000|Experimental|MK-0941 40 mg|
11583174|NCT00767000|Placebo Comparator|Placebo|
11583175|NCT00766974|Active Comparator|1|Anti-embolism Knee High compression stocking
11583176|NCT00766974|Active Comparator|2|20-30mmHg Knee High Jobst Compression Stocking
11583177|NCT00766961|Active Comparator|TAE group|Trans-catheter arterial embolization
11583178|NCT00766961|Active Comparator|Surgery group|Surgery
11583179|NCT00766948||No Treatment|
11583180|NCT00766935||1|Females with previously diagnosed unilateral Lymphoedema of the arm, who have had a mastectomy or breast conservation surgery with axillary sampling or dissection, with or without adjuvant therapy.
11583181|NCT00766935||2|Healthy females aged between 18-75 years chosen randomly from the population of Queensland, Australia.
11583182|NCT00766909|Experimental|CsA|Cyclosporine
11583183|NCT00766909|Experimental|Tac|Tacrolimus
11583184|NCT00766909|Placebo Comparator|Placebo|placebo/saline
11583185|NCT00766896|Active Comparator|Aspirin Sensitive|"For PFA-100 using a cartridge with C-EPI (collagen-epinephrine): occlusion time >= 150 seconds
~Chrono-Log Model 700 Whole-Blood: < 1Ω with 0.75 mM of arachidonic acid
~Chrono-Log Model 700 Whole-Blood: with collagen at 1 mg/L and 5 mg/L, according to the formula 1 - (Rate of aggregation with 1 mg / Rate of aggregation with 5 mg) > 0.50
~Chrono-Log Model 700 Whole-Blood: with collagen at 1 mg/L < 10Ω
~Plateletworks: aggregation <60% with arachidonic acid will be considered sensitive
~VerifyNow Aspirin Assay (Accumetrics): < 550 aspirin reaction units (ARUs)
~Impact-R (Diamed) < 3.2% platelet aggregates on the surface of the plate after incubation with arachidonic acid"
11583186|NCT00766896|Active Comparator|Platelet with hyperreactivity to aspirin|"For PFA-100 using a cartridge with C-EPI (collagen-epinephrine): occlusion time < 150 s
~Chrono-Log Whole-Blood: above or = 1Ω with 0.75 mM of AA
~Chrono-Log Whole-Blood: with collagen at 1 mg/L and 5 mg/L, according to the formula 1 - (Rate of aggregation with 1 mg / Rate of aggregation with 5 mg) below 0.50
~Chrono-Log Whole-Blood: with collagen 1 mg/L above or = 10Ω
~Plateletworks: aggregation of more than 60% with arachidonic acid will be considered resistant
~VerifyNow Aspirin Assay (Accumetrics): ≥ 550 aspirin reaction units (ARUs)
~Impact-R (Diamed) > 3.2% platelet aggregates on the surface of the plate after incubation with arachidonic acid"
11583187|NCT00766870|Experimental|1|
11583188|NCT00766870|Experimental|2|
11583189|NCT00766870|Experimental|3|
11583190|NCT00766870|Other|4|
11583191|NCT00766870|Placebo Comparator|5|
11583192|NCT00766857|Experimental|1. Exenatide|
11583193|NCT00766857|Active Comparator|2. Insulin glargine|
11583194|NCT00766844|Experimental|Active|Spinal cord stimulation
11583195|NCT00766831|Experimental|Hydromorphone OROS|Participants will receive hydromorphone OROS (8 milligram [mg] up to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
11583196|NCT00766818|Experimental|1|Kaletra
11583197|NCT00766805|Active Comparator|EVL + Drugs|Patients randomized to the EVL plus drugs therapy received EVL plus beta-blocker (propranolol) and nitrate (ISMN).
11583198|NCT00766805|Placebo Comparator|EVL alone|Patients assigned to the EVL group underwent variceal band ligation alone till variceal obliteration.
11583199|NCT00766792|Experimental|1|Nocturnal dialysis
11583200|NCT00766792|Active Comparator|2|Standard dialysis
11583201|NCT00766779|Experimental|Transplant Arm|Hematopoietic cell transplantation after Reduced Intensity Conditioning
11583202|NCT00766779|Active Comparator|Conventional Chemotherapy|The non-transplant treatment approach for consolidation
11583203|NCT00766766|Experimental|1|Experimental Intervention Group
11583204|NCT00766766|No Intervention|2|Standard Care Control
11583205|NCT00766753|Experimental|Single|All consenting, eligible subjects receive the intervention
11583206|NCT00766740|Active Comparator|1|thrombectomy
11583207|NCT00766740|Active Comparator|2|Standard PCI
11583208|NCT00766714|Experimental|1|Cook K-SOFT-5100 catheter
11583209|NCT00766714|Active Comparator|2|Frydman classical catheter
11583210|NCT00766688|Experimental|25 mg/day AVE5530|
11583211|NCT00766688|Experimental|50 mg/day AVE5530|
11583212|NCT00766688|Placebo Comparator|Placebo|
11583213|NCT00766675|Experimental|Tramadol hydrochloride/acetaminophen|Tramadol hydrochloride/acetaminophen oral tablet will be administered as 37.5 /325 milligram respectively once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
11583214|NCT00766649|Experimental|Sirolimus|Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
11583215|NCT00766636|Experimental|Gemcitabine + Erlotinib Without Radiation|"Gemcitabine + Erlotinib without radiation - Arm A: Gemcitabine 1000 mg/M^2 given intravenously over 100 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day. Erlotinib 100 mg daily by mouth on days 1-42.
~Surgical removal of the pancreas and duodenum."
11583216|NCT00766636|Experimental|Gemcitabine + Erlotinib With Radiation|Gemcitabine + Erlotinib with radiation - Arm B: Gemcitabine 400 mg/M^2 given intravenously over 40 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day. Erlotinib 100 mg daily by mouth on days 1-42. Radiation therapy 1 time each day for 5 days in a row for 5 1/2 weeks starting on Day 1 for a total of 50.4 Gy. Surgical removal of the pancreas and duodenum.
11583217|NCT00766623|Experimental|High fat meal|A high fat milkshake containing 95g of fat
11583218|NCT00766623|Experimental|Control meal|Milkshake comparable with a normal breakfast
11583219|NCT00766623|Experimental|High fat meal 2|A high fat milkshake containing 95g of fat
11583220|NCT00766623|Experimental|High fat meal 3|A high fat milkshake containing 95g of fat
11583221|NCT00766623|Experimental|Control meal 2|Milkshake comparable with a normal breakfast
11583222|NCT00766623|Experimental|Control meal 3|Milkshake comparable with a normal breakfast
11583422|NCT00765115|Experimental|2|140 mg LY450139 oral
11583223|NCT00766597|Experimental|Vicriviroc in tablet form (20/30 mg) or liquid form (1 mg/ml)|HIV-1 Infected Antiretroviral Therapy Experienced Participants with CCR5-tropic Virus
11583224|NCT00766584||PROOF cohort|This cohort is the same than the PROOF study (NCT00759304). Subjects were recruited amongst the inhabitants of the city of Saint-Etienne, France, and were eligible if aged 65 at the inclusion date in the PROOF study
11583225|NCT00766558||1 Disclosure|Traumatic writing prompts provided. Participant is assigned a potential stress-producing topic for written disclosure.
11583226|NCT00766558||2 control|Received nontraumatic writing prompts. Participant assigned a non-stressful writing condition
11583227|NCT00766545|Experimental|cilostazol|cilostazol oral tablet 100 mg, twice daily
11583228|NCT00766545|Placebo Comparator|placebo|placebo of cilostazol, twice daily
11583229|NCT00766532|Experimental|aromatase inhibitor therapy|aromatase inhibitor therapy for six weeks
11583230|NCT00766519|Experimental|Optimization|volume optimization: continuous monitoring of the respiratory-induced arterial pulse pressure variation during surgery and systematic minimization to 10% or less by volume loading
11583231|NCT00766519|Active Comparator|control; standard volume administration|standard volume administration
11583232|NCT00766506|Experimental|Fentanyl IONSYS|Participants will receive 40 microgram (mcg) of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
11583233|NCT00766506|Active Comparator|Morphine IV PCA|Morphine sulphate solution will be administered intravenously (directly into the vein, IV) by a patient-controlled analgesia (PCA) pump using set bolus (a large amount) doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
11583234|NCT00766493|Experimental|GORE® Embolic Filter|Subjects treated with the GORE® Embolic Filter and an FDA-approved carotid stent.
11583235|NCT00766480|Experimental|Regimen 1|Patients receive low-dose cisplatin IV on days 1 and 29 and low-dose fluorouracil IV on days 1-4 and 29-32. Patients also undergo concurrent radiotherapy on days 1-4 and 29-32. Patients undergo salvage surgery if needed.
11583236|NCT00766480|Experimental|Regimen 2|Patients receive high-dose cisplatin IV on days 1 and 29 and high-dose fluorouracil IV on days 1-4 and 29-32. Patients also undergo concurrent radiotherapy and salvage surgery as in regimen 1.
11583237|NCT00766467|Experimental|Group 1|Armodafinil
11583238|NCT00766467|Placebo Comparator|Group 2|Placebo
11583239|NCT00766441|Active Comparator|1|Sitagliptin 100mg
11583240|NCT00766441|Active Comparator|2|Sulphonylurea
11583241|NCT00766415|Experimental|AZD1981|
11583242|NCT00766415|Placebo Comparator|Placebo|
11583243|NCT00766402|Experimental|Tramadol/Acetaminophen|Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
11583244|NCT00766402|Active Comparator|Diclofenac|Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
11583245|NCT00766389||1|Defined glaucoma patients
11583246|NCT00766389||2|Glaucoma suspects and normal controls
11583247|NCT00766363|Experimental|EVP-6124 (0.1 mg/day)|
11583248|NCT00766363|Experimental|EVP-6124 (0.3 mg/day)|
11583249|NCT00766363|Experimental|EVP-6124 (1.0 mg/day)|
11583250|NCT00766363|Placebo Comparator|Placebo|
11583251|NCT00766350|Active Comparator|amitriptyline|
11583252|NCT00766350|Experimental|quetiapine|
11583253|NCT00766337|Experimental|Dose Group 1|
11583254|NCT00766337|Experimental|Dose Group 2|
11583255|NCT00766337|Placebo Comparator|Dose Group 3|
11583256|NCT00766324|Experimental|A|
11583257|NCT00766324|Experimental|B|
11583258|NCT00766311|Other|1|This single-arm feasibility trial will evaluate the administration of an aggressive exercise regimen.
11583259|NCT00766298|Experimental|1|Weight Loss
11583260|NCT00766298|Experimental|2|Exercise
11583261|NCT00766298|Experimental|3|Exercise and Weight Loss
11583262|NCT00766285|Active Comparator|TIV|50 subjects to receive 45 mcg of TIV administered on Day 0 and Day 28.
11583263|NCT00766285|Experimental|rHAO|50 subjects to receive 405 mcg of rHAO administered on Day 0 and Day 28.
11583264|NCT00766272|Experimental|Arm 1|Body-weight supported treadmill training
11583265|NCT00766259||1|Hemodialysis
11583266|NCT00766259||2|Intensive care
11583267|NCT00766259||3|vascular patients with open wounds
11583268|NCT00766259||4|nursing home
11583269|NCT00766259||5|skin infections
11583270|NCT00766259||6|control- ambulatory care clinic patients with no infections
11583271|NCT00766246|Experimental|First-line|Carboplatin, docetaxel, bevacizumab Open-label, single arm with treatment period up to 6 cycles. Patients completing a total of 2 to 6 cycles of first-line without disease progression will be eligible for maintenance.
11583272|NCT00766246|Experimental|Maintenance|Bevacizumab Open-label, single arm with treatment period up to 18 cycles.
11583273|NCT00766233|Active Comparator|1|Hyperthermal treatment once per week
11583274|NCT00766233|Active Comparator|2|Hyperthermal treatment 3 times a week
11583275|NCT00766220|Active Comparator|SIR-Spheres + Therapy|SIR-Spheres with Cetuximab + Irinotecan Therapy
11583276|NCT00766220|Active Comparator|Therapy Only|Cetuximab + Irinotecan Therapy
11583277|NCT00766207|Experimental|multi-faceted decision support|Multi-faceted decision support
11583278|NCT00766207|Active Comparator|control|stream-lined clinical alert
11583279|NCT00766181||1: Lifestyle|Observatonal
11583280|NCT00766181||2: Lifestyle|Observational
11583281|NCT00766168|Active Comparator|Control|FluoroPerm 30 RGP lens daily wear
11583282|NCT00766168|Experimental|HDS HI 1.54|New rigid gas permeable contact lens material material
11583283|NCT00766155|Active Comparator|Arm I|Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients may receive additional chemoradiotherapy on days 36-38. Patients then undergo surgery. Beginning 4-8 weeks after surgery, patients receive capecitabine twice daily on day 1-15. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11583284|NCT00766155|Experimental|Arm II|Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients also receive oxaliplatin IV over 1 hour on days 1, 8, 15, 22, and 29 prior to radiotherapy followed by surgery. Patients may receive additional chemoradiotherapy on days 36-38. Beginning 4-8 weeks later, patients receive oxaliplatin IV over 2 hours on day 1, and oral capecitabine twice daily on days 1-15. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11583285|NCT00766129|Experimental|T|Implantation of Taxus stent into saphenous vein graft
11583286|NCT00766129|Experimental|C|Implantation of Luc-Chopin stent into saphenous vein graft
11583287|NCT00766116|Experimental|Phase 1 Dose Level 1|"5-Azacitidine, Gemtuzumab ozogamicin
~75 mg/m^2 5-Aza 2 days then GO at 3 mg/m^2"
11583288|NCT00766116|Experimental|Phase 1 Dose Level 2|"5-Azacitidine, Gemtuzumab ozogamicin
~75mg/m^2 5-Aza for 4 days then GO at 6 mg/m^2"
11583289|NCT00766116|Experimental|Phase I Dose Level 3|"5-Azacitidine, Gemtuzumab ozogamicin
~75 mg/m^2 5-Aza for 6 days then GO at 6 mg/m^2"
11583290|NCT00766116|Experimental|Phase 2 Dose Level 1|"5-Azacitidine, Gemtuzumab ozogamicin
~75 mg/m^2 5-Aza for 6 days then GO at 6 mg/m^2"
11583291|NCT00766103|Other|crossover: hypo- and hypercarbia|
11583292|NCT00766090|Experimental|GW685698X|
11583293|NCT00766064|Experimental|Paliperidone Dosing|Paliperidone Dosing up to 6 weeks, with a maximum dosage of 6mg
11583294|NCT00766051|Experimental|Intervention Group|The infants in the intervention group were problem eaters with various diagnosis
11583295|NCT00766051|No Intervention|Matched Historical Comparison Group|The matched historical comparison group were also problem eaters and these infants did not receive the neurophysiologically based occupational therapy Intervention.
11583296|NCT00766038|Experimental|1|The GH treatment arm will receive a starting dose of 400 microgramsg/day, with increases (or decreases) in dose by 100-200 micrograms/day each month, monitoring for side effects, until goal IGF-1 (in the upper quartile of the range for age and body weight) is reached up to maximum dose of 1,000 microgramsg/day. Dose adjustments may be modified by the investigators for participants receiving oral estrogens or other circumstances know to influence GH dosing or atypical responses to treatment.
11583297|NCT00766038|Placebo Comparator|2|Doses for participants receiving placebo will also be adjusted monthly to maintain the blinding.
11583298|NCT00766025|Experimental|Rosuvastatin Calcium|
11583299|NCT00766012|Experimental|1|4 dose panels receiving a specified volume of AZD2066 oral solution once daily for 11 days
11583300|NCT00766012|Placebo Comparator|2|Included in each dose panel
11583301|NCT00765999|Experimental|Linaclotide|Linaclotide 290 μg/day capsules, administered orally once daily for up to 78 weeks in participants with either CC or IBS-C. Dose reduction to 145 μg/day was permitted at the discretion of the Investigator if a participant experienced AEs intolerable enough to prompt consideration of study withdrawal. After a temporary suspension of dosing, participants may have received either 145 μg/day or 290 μg/day of linaclotide, at the discretion of the Investigator. Subsequent dose adjustments (increases or decreases between 290 μg/day and 145 μg/day) were permitted also at the Investigator's discretion.
11583302|NCT00765986||1|Patients with inoperable NSCLC undergoing RT or Chemo-RT
11583303|NCT00765973|Experimental|A|Arm A: TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
11583304|NCT00765973|Experimental|B|Arm B: TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
11583305|NCT00765947|Experimental|Aliskiren-based regimen|All pts starting on aliskiren 150 mg (uptitrated to aliskiren 300 mg), followed by the addition of HCTZ 12.5 mg (uptitrated to 25 mg) and amlodipine 5 mg (uptitrated to 10 mg), as necessary to achieve the Blood Pressure goal.
11583306|NCT00765934|Other|Rapydan|Internal control. Blood from both arms will be drawn. Only one arm of the subject is treated with Rapydan.
11583307|NCT00765921|Experimental|1.0 mg ranibizumab|1.0 mg intravitreal injection given bi-monthly for 22 months
11583308|NCT00765921|Experimental|0.5 mg ranibizumab|0.5 mg intravitreal injection given bi-monthly for 22 months
11583309|NCT00765908|Experimental|A|Patients undergoing elective PCI will be randomised to 90 second balloon inflations rather than the standard less than 30 second inflations in order to induce peri-ischaemic conditioning.
11583310|NCT00765908|Active Comparator|B|Control group. These patients will have a standard procedure with balloon inflations of 30 seconds or less as per standard.
11583311|NCT00765895|Active Comparator|Nortriptyline|Nortriptyline Hydrochloride dose escalation from 10 mg to 75 mg
11583312|NCT00765895|Placebo Comparator|Placebo (for nortriptyline)|No treatment
11583313|NCT00765882|Experimental|1|Linaclotide 290 micrograms
11583314|NCT00765882|Experimental|2|Linaclotide 145 micrograms
11583315|NCT00765882|Placebo Comparator|3|Matching placebo
11583316|NCT00765869|Experimental|1|Bowel cancer screening decision aid, DVD and Question Prompt List (QPL)
11583317|NCT00765869|Experimental|2|Bowel cancer screening decision with DVD only
11583318|NCT00765869|Active Comparator|3|Australian Government Bowel Cancer Screening consumer information booklet
11583319|NCT00765856|Experimental|Opana® ER|Oxymorphone IR - Opioid
11583320|NCT00765843|Active Comparator|custom foot orthoses|Subjects will receive custom fabricated orthoses created from casts of the feet and according to individualized prescriptions. These orthoses are to be used in the standardized shoes provided to all subjects in the study.
11583321|NCT00765843|Active Comparator|pre-fabricated orthoses|Subjects will be provided pre-fabricated (non-customized) orthoses. These orthoses are to be used in the standardized shoes provided to all subjects in the study. for use in their shoes.
11583322|NCT00765843|Sham Comparator|sham insoles|Subjects will receive sham orthoses that are soft and pliable, but not designed to relieve pain. These orthoses are to be used in the standardized shoes provided to all subjects in the study.
11583323|NCT00765830|Experimental|1|50mg qd vildagliptin
11583324|NCT00765830|Placebo Comparator|2|Placebo
11583325|NCT00765817|Placebo Comparator|1|
11583326|NCT00765817|Experimental|2|
11583327|NCT00765804|Active Comparator|Low Dose: DP 7.5 mA-min at 2.5 mA|Ocular Iontophoresis with EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) 7.5 mA-min at 2.5 mA
11583423|NCT00765115|Experimental|3|280 mg LY450139 oral
11583424|NCT00765115|Experimental|4|Placebo
11583328|NCT00765804|Active Comparator|High Dose: DP 10.5 mA-min at 3.5 mA|Ocular Iontophoresis with EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) 10.5 mA-min at 3.5 mA
11583329|NCT00765804|Placebo Comparator|Placebo: 10.5 mA-min at 3.5 mA|Ocular Iontophoresis with Placebo (sodium citrate buffer solution 100 mM at 10.5 mA-min at 3.5 mA)
11583330|NCT00765791|Active Comparator|1|Level IIB is dissected
11583331|NCT00765791|Active Comparator|2|Level IIB is not dissected
11583332|NCT00765765|Experimental|Ixabepilone and hydroxychloroquine|
11583333|NCT00765752||1 Primary Insomnia|Individuals with insomnia not related to another identified cause.
11583334|NCT00765752||3 Healthy comparison subjects|Healthy subjects with no history of insomnia
11583335|NCT00765739|Experimental|1|The group who will get neuromuscular electrical stimulation (NMES)
11583336|NCT00765739|Active Comparator|2|The group who will do the voluntary muscle contraction
11583337|NCT00765726|Other|Moroctocog alfa(AF-CC)|
11583338|NCT00765713|Experimental|CPAP|Continuous positive airway pressure
11583339|NCT00765713|No Intervention|Conventional|Hygienic-dietetic recommendations
11583340|NCT00765700|Active Comparator|Ketoprofen 10% Cream|"Topical Ketoprofen 10% Cream
~1gram three times daily for 7 days"
11583341|NCT00765700|Placebo Comparator|Placebo|"Topical placebo cream
~1gram three times daily for 7 days"
11583342|NCT00765687|No Intervention|Observation|
11583343|NCT00765674|Experimental|Aliskiren / amlodipine|Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
11583344|NCT00765674|Experimental|Aliskiren / hydrochlorothiazide|Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
11583345|NCT00765674|Experimental|Amlodipine / hydrochlorothiazide|Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
11583346|NCT00765674|Experimental|Aliskiren / amlodipine / hydrochlorothiazide|Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
11583347|NCT00765661|Experimental|LCP-Tacro|The initial dose starting at 0.14 mg/kg (the starting daily dose for African-American patients was 0.17 mg/kg), will be administered orally in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.
11583348|NCT00765661|Active Comparator|Prograf (tacrolimus)|"Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.
~Other name: tacrolimus"
11583349|NCT00765648|Active Comparator|1|nicardipine intravenous
11583350|NCT00765648|Active Comparator|2|Labetalol
11583351|NCT00765635|Experimental|2|Taponoto ® (potassium carbonate 20 mg/1 ml, ethyl alcohol, glycerol 480, thymol 0.4; Teofarma Iberica S.A., Barcelona, Spain),
11583352|NCT00765635|Placebo Comparator|3|sterile saline solution (NaCl 0.9%, Braun Medical SA, Barcelona, Spain).
11583353|NCT00765635|Experimental|1: Chlorobutanol|ceruminolytic product, Otocerum® (Chlorobutanol 50 mg/1 ml, phenol 10 mg/1 ml, turpentine essence 0.15 ml/1 ml, ethyl alcohol; Reig Jofre laboratories, Barcelona, Spain),
11583354|NCT00765622||G2|G2 = control group (no incontinence)
11583355|NCT00765622||G1|G1 = urinary incontinence
11583356|NCT00765609||1|Using the information distributed with over-the-counter medication (The Patient Information Leaflet or PIL)
11583357|NCT00765609||2|Paediatric Analgesia Slide (the new device)
11583358|NCT00765596||1 RYGB|Subjects undergoing RYGB with gastric tube placement
11583359|NCT00765596||2 Matched controls|Subjects matched by BMI, age, gender to RYGB group
11583360|NCT00765583|Experimental|restylane|Restylane arm with different re-treatment schedules
11583361|NCT00765570|Active Comparator|Treatment Group 1|Treatment Group 1-one treatment of Grid therapy followed by 15 treatments with standard radiation
11583362|NCT00765570|Active Comparator|Treatment Group-2|Treatment Group 2-15 treatments with standard radiation
11583363|NCT00765557|Placebo Comparator|Randomization|The Investigational Drug Pharmacist will be blinded to all patient data, and physicians and nurses evaluating patients will be blinded to randomization of these patients to laxative versus
11583364|NCT00765557|Active Comparator|Miralax|The Investigational Drug Pharmacist will be blinded to all patient data, and physicians and nurses evaluating patients will be blinded to randomization of these patients to laxative versus
11583365|NCT00765544|Experimental|Arm 1|Anklebot
11583366|NCT00765544|Experimental|Arm 2|Body-weight supported treadmill training
11583367|NCT00765544|Experimental|Arm 3|Combination therapy (Anklebot and BWSTT)
11583368|NCT00765518|Experimental|Ixmyelocel-T|The treatment arm of the study will receive injections of the study cellular product.
11583369|NCT00765518|Other|Standard of Care|Standard of care therapy only.
11583370|NCT00765505|Experimental|1|Exercise Group
11583371|NCT00765505|Experimental|Health Education Group|
11583372|NCT00765492|Experimental|1|
11583373|NCT00765492|Placebo Comparator|2|
11583374|NCT00765479|Experimental|Arm I|Patients receive an oral soy protein isolate beverage once daily.
11583375|NCT00765479|Placebo Comparator|Arm II|Patients receive an oral casein placebo beverage once daily.
11583376|NCT00765453|Experimental|Intracoronary|Patients will be randomised in a 1:1 ratio to receive intracoronary injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
11583377|NCT00765453|Placebo Comparator|Placebo|Placebo infusion
11583378|NCT00765440|Placebo Comparator|Arm I|Patients receive standard oral or enteral nutrition (IMPACT® placebo) over 7 days prior to surgery and over 7 days after surgery.
11583379|NCT00765440|Experimental|Arm II|Patients receive oral or enteral neoadjuvant IMPACT® nutrition over 7 days prior to surgery and enteral adjuvant standard nutrition (IMPACT® placebo) over 7 days after surgery.
11583380|NCT00765440|Experimental|Arm III|Patients receive oral or enteral IMPACT® nutrition over 7 days prior to surgery and enteral adjuvant IMPACT® nutrition over 7 days after surgery.
11583381|NCT00765414|Experimental|1|
11583382|NCT00765401||Group A|The subject with positive breath Test for H.pylori and/or positive stool antigen test
11583383|NCT00765401||Group B|The subject with negative breath Test for H.pylori and negative stool antigen test
11583384|NCT00765388|Experimental|SenSura Uro|The test product is a CE-marked non-sterile one-piece urostomy multi-chamber bag with the SenSura adhesive.
11583385|NCT00765388|Active Comparator|hollister Uro|The comparator product is CE-marked and non-sterile and produced for urostomy operated. It is a flat one-piece urostomy product, Hollister Moderma Flex Urostomy beige, Cut-to-Fit Bag, flat adhesive
11583386|NCT00765375|Experimental|Botox and Placebo on each side of face|Botulinum Neurotoxin Type A (Botox, 1.5-3 units/lesion); Bacteriostatic saline solution (0.11 cc/lesion)
11583387|NCT00765362|Experimental|1|Subjects who are candidates for a total knee replacement and meet the inclusion/exclusion criteria of the study.
11583388|NCT00765349||All patients undergoing major surgery|
11583389|NCT00765336|Active Comparator|Minocycline Extended-Release Tablets|
11583390|NCT00765336|Placebo Comparator|Placebo|
11583391|NCT00765323|Active Comparator|1|84 mg octreotide implant for 6 months
11583392|NCT00765323|Active Comparator|2|Injections of Sandostatin LAR Depot(20, 30, 40 mg) every 4 weeks
11583393|NCT00765310|Active Comparator|Lipoic Acid|600 mg R-alpha lipoic acid in morning on empty stomach (two 300 mg capsules)
11583394|NCT00765310|Placebo Comparator|Placebo|Placebo two caps every morning on empty stomach
11583395|NCT00765297|Experimental|1|Healthy young 18-40years
11583396|NCT00765297|Experimental|2|Healthy elderly
11583397|NCT00765284||Treatment|Ten subjects will be low HDL-C male volunteers who will receive aspirin and Niaspan
11583398|NCT00765284||Placebo|Five subjects will be low HDL-C male volunteers who will receive only aspirin.
11583399|NCT00765271|Active Comparator|Group 2|Abacavir 600 mg (2 x 300mg tablet) once daily throughout the study (days 1- 30) Raltegravir 400 mg (2 x 200mg tablets) twice daily from days 2 to 15 Darunavir/ritonavir 900 (3 x 300mg tablets)/100 (1 x 100mg capsule) mg once daily from day 16 to day 29)
11583400|NCT00765271|Active Comparator|Group 1|Abacavir 600 mg (2 x 300mg tablet) once daily throughout the study (days 1- 30) Darunavir/ritonavir 900 (3 x 300mg tablets)/100 (1 x 100mg capsule) mg once daily from day 2 to day 15) Raltegravir 400 mg (2 x 200mg tablets) twice daily from day 16 to 29
11583401|NCT00765245|Experimental|Arm I: Lenalidomide|
11583402|NCT00765245|Experimental|Arm II: Lenalidomide and Rituximab IV|Patients receive lenalidomide as in arm I and rituximab IV on day 8 of courses 1, 3, 5, 7, 9, and 11 in the absence of disease progression or unacceptable toxicity.
11583403|NCT00765232|Experimental|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
11583404|NCT00765232|Placebo Comparator|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
11583405|NCT00765219|Experimental|1|CBT with ACS
11583406|NCT00765219|Experimental|2|CBT with Counselor
11583407|NCT00765219|Active Comparator|3|Usual Care
11583408|NCT00765206|Experimental|Zegerid|Omeprazole 20 mg /sodium bicarbonate 1100 mg over-the-counter (OTC) Capsule
11583409|NCT00765206|Active Comparator|Prilosec|Omeprazole magnesium 20 mg OTC tablet
11583410|NCT00765193|Other|Skin cancer screening|
11583411|NCT00765180|Active Comparator|2|The investigators evaluate beneficial effect of colonoscopy using narrow band imaging (NBI) for colorectal adenoma detection.
11583412|NCT00765180|Experimental|1|The investigators evaluate the beneficial effect of colonoscopy with a transparent retractable extension (TRE) device on colorectal adenoma detection rate.
11583413|NCT00765167|Placebo Comparator|A|
11583414|NCT00765167|Active Comparator|B|
11583415|NCT00765167|Active Comparator|C|
11583416|NCT00765154|Active Comparator|Group 1|Immediate switch from NNRTI/PI to DRV/r
11583417|NCT00765154|Active Comparator|Group 2|Switch after 10 weeks from NNRTI/PI to DRV/r
11583418|NCT00765141||No treatment|
11583419|NCT00765128|Experimental|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
11583420|NCT00765128|Placebo Comparator|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
11583421|NCT00765115|Experimental|1|100 mg LY 450139 oral
11583425|NCT00765102|Experimental|Romidepsin + Bortezomib|"Romidepsin was given as an infusion on Days 1, 8 and 15 of each 28-day cycle. Bortezomib was administered twice a week for two consecutive weeks (Days 1, 4, 8 and 11) followed by a 17-day rest period.
~Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles."
11583426|NCT00765089|Experimental|Pulmonary Vein isolation|Patients in this arm will receive pulmonary vein isolation during surgery
11583427|NCT00765089|No Intervention|Standard of care|Subjects in this arm will receive standard of care and no pulmonary vein isolation
11583428|NCT00765076|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0
11583429|NCT00765076|Active Comparator|Fluarix elderly Group|Subjects aged >= 65 years receiving 1 dose of Fluarix vaccine at Day 0
11583430|NCT00765076|Active Comparator|Fluarix young Group|Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0
11583431|NCT00765063|Experimental|Active|Active study treatment
11583432|NCT00765050|Experimental|CD133+ cells|CD133+ cells, obtained from peripheral blood in the treatment of diabetic patients with critic ischemia in lower limbs.
11583433|NCT00765037||Encore RSP|Subjects who need treatment for rotator cuff deficiency or glenohumeral arthritis, received the Encore Reverse Shoulder Prosthesis and are willing to participate in the study.
11583434|NCT00765024|Active Comparator|Albendazole|Albendazole for 7 days
11583435|NCT00765024|Experimental|ivermectin|ivermectin 200 mcg/kg single dose
11583436|NCT00765024|Experimental|ivermectin 2 doses|ivermectin 200 mcg/kg two doses in 2 weeks
11583437|NCT00765011|Experimental|Group A|TPF plus concomitant treatment with cetuximab and conventional radiotherapy
11583438|NCT00765011|Other|Grupo B|Surgery
11583439|NCT00764998|Active Comparator|Fluviral|
11583440|NCT00764998|Placebo Comparator|placebo|
11583441|NCT00764985||Syncope|
11583442|NCT00764972|Experimental|Sorafenib and Vinorelbine|
11583443|NCT00764959||Linear Hip|Encore Linear Hip System
11583444|NCT00764946|Experimental|1|raltegravir
11583445|NCT00764933|Experimental|1|Structured information
11583446|NCT00764933|Sham Comparator|2|Unspecific conversation
11583447|NCT00764920||Skin Imaging|non-invasive imaging modalities for assessment of skin
11583448|NCT00764907|Experimental|Arm I|During reinduction, patients receive 1 course of protocol II.
11583449|NCT00764907|Experimental|Arm II|During reinduction, patients receive 2-3 course of protocol III and interim maintenance therapy.
11583450|NCT00764907|Experimental|Arm III|During reinduction, patients are receive 2 courses of protocol II and interim maintenance therapy OR 3-block consolidation regimen and 1 course of protocol II.
11583451|NCT00764894||Foundation Knee|Retrospective data collection on 510(k) approved device
11583452|NCT00764881|Experimental|EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)|Daily oral administration of one capsule BAY86-5027 [estradiol valerate (EV) / dienogest (DNG)] for 28 days per cycle in the sequential 4-phasic regimen for 6 treatment cycles.
11583453|NCT00764881|Active Comparator|EE/LNG (Microgynon) + Placebo|Daily oral administration of one capsule ethinylestradiol (EE) / levonorgestrel (LNG) for 21 days, followed by 1 capsule placebo for 7 days (28 days total per cycle) for 6 treatment cycles.
11583454|NCT00764868|Experimental|LDX|Lisdexamfetamine Dimesylate (LDX)
11583455|NCT00764855||1|Patients undergoing a surgery with general anesthesia
11583456|NCT00764842||CLP Hip|
11583457|NCT00764816|Active Comparator|1 grain (soy) protein diet:|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
11583458|NCT00764816|Active Comparator|2 casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
11583459|NCT00764803||2|Subjects who meet the indications for use and are implanted with the Encore MJS™ Knee System.
11583460|NCT00764803||1|Subjects who meet the indications for and are implanted with the Encore 3DKnee™ system.
11583461|NCT00764790|Experimental|Fluarix Dose A Group|"Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).
~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
11583462|NCT00764790|Experimental|Fluarix Dose B Group|"Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).
~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
11583463|NCT00764790|Active Comparator|Fluzone Group|"Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).
~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
11583464|NCT00764777|Experimental|Stenting|
11583465|NCT00764764|Active Comparator|I|Group I - Shoulder treatment only
11583466|NCT00764764|Experimental|II|Cervical and shoulder treatment
11583467|NCT00764751|Experimental|1|
11583468|NCT00764751|Active Comparator|2|
11583469|NCT00764751|Placebo Comparator|3|
11583470|NCT00764738|Active Comparator|Monthly|Ranibizumab injections every month for 12 months.
11583471|NCT00764738|Active Comparator|As Needed|Ranibizumab injections monthly for 4 months then as needed thereafter.
11583472|NCT00764725|Active Comparator|A|MTX+SSZ+Plaquenil
11583473|NCT00764725|Active Comparator|B|MTX+Infliximab
11583474|NCT00764712|Active Comparator|Matias protocol|A protocol based on the absolute glucose value - Matias protocol (Matias)
11583475|NCT00764712|Active Comparator|Bath protocol|A protocol based on the relative glucose change - Bath protocol (Bath)
11583476|NCT00764712|Active Comparator|eMPC|a computer-based model predictive control algorithm with variable sampling rate (eMPC)
11583477|NCT00764699|Experimental|rhIGF|Treatment with rhIGF (Increlex)
11583478|NCT00764686|Experimental|1|Low disease severity group
11583595|NCT00763932|Experimental|1|
11583479|NCT00764686|Experimental|2|Higher disease severity group
11583480|NCT00764673|Other|Primary|Post market study
11583481|NCT00764660|Experimental|SCH 900435|Participants received SCH 900435 12 mg (as three SCH 900435 4 mg tablets) by mouth twice daily for 12 weeks.
11583482|NCT00764660|Placebo Comparator|Placebo|Participants received matching placebo tablets by mouth twice daily for 12 weeks.
11583483|NCT00764647|Experimental|Single arm|Education program for family caregivers of frail elders.
11583484|NCT00764634|Placebo Comparator|1 Placebo|
11583485|NCT00764634|Active Comparator|2 rBV A/B Vaccine|
11583486|NCT00764634|Placebo Comparator|3 Placebo|
11583487|NCT00764634|Active Comparator|4 rBV A/B Vaccine|
11583488|NCT00764621|Experimental|Arm 1|
11583489|NCT00764621|Active Comparator|Arm 2|
11583490|NCT00764621|Active Comparator|Arm 3|
11583491|NCT00764608||No Treatment|
11583492|NCT00764595|Experimental|imatinib mesylate|All patients start imatinib mesylate as oral dose of 400 mg/d once daily after meal within 28 days after enrollment, and continue the treatment until 3 years after enrollment of the last patient.
11583493|NCT00764582|Experimental|1|
11583494|NCT00764582|Active Comparator|2|
11583495|NCT00764569||Oral Tissue measurement|Fluorescence/Elastic Scattering Spectroscopy Oral tissue measurement
11583496|NCT00764556|Experimental|Tight glycaemic control|Intravenous or subcutaneous insulin to control blood glucose to 4.4-6.5mM
11583497|NCT00764530|Experimental|Investigational|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell.
11583498|NCT00764530|Active Comparator|Control Device|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head.
11583499|NCT00764517|Experimental|Previously untreated|"Patients enrolled with untreated, newly diagnosed mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) [Group I].
~Patients receive vorinostat PO on days 1-14, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 3 (weekly for the first course). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
11583500|NCT00764517|Experimental|Relapsed|"Patients with relapsed disease including indolent Non-Hodgkins Lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL) [Group II].
~Patients receive vorinostat PO on days 1-14, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 3 (weekly for the first course). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
11583501|NCT00764504|Experimental|Primary|Primary shoulder
11583502|NCT00764504|Experimental|Revision|Revision shoulder
11583503|NCT00764504|Experimental|Continued Access|Primary shoulder subjects enrolled at a later date in order to collect more data.
11583504|NCT00764478|Experimental|Asenapine 5 mg BID|Participants were administered one 5 mg asenapine tablet, sublingually BID for 21 days
11583505|NCT00764478|Experimental|Asenapine 10 mg BID|Participants were administered one 10 mg asenapine tablet, sublingually BID for 21 days
11583506|NCT00764478|Placebo Comparator|Placebo BID|Participants were administered one asenapine-matched placebo tablet sublingually BID for 21 days
11583507|NCT00764465|Active Comparator|Group A|Period 1-Maraviroc 300mg BID Period 2- Fosamprenavir 1400mg BID Period 3- Fosamprenavir 1400mg BID + Maraviroc 300mg BID
11583508|NCT00764465|Active Comparator|Group B|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg BID + Maraviroc 300mg BID Period 3-Fosamprenavir 1400mg BID
11583509|NCT00764465|Active Comparator|Group C|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Maraviroc 300mg BID
11583510|NCT00764465|Active Comparator|Group D|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Maraviroc 300mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID
11583511|NCT00764465|Active Comparator|Group E|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3- Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Maraviroc 300mg BID
11583512|NCT00764465|Active Comparator|Group F|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Maraviroc 300mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
11583513|NCT00764439|Active Comparator|1|Standard NRT user direction
11583514|NCT00764439|Experimental|2|Novel NRT user direction
11583515|NCT00764426|Active Comparator|non-alcoholic beverages|dealcoholised red wine, de-alcoholised beer, water
11583516|NCT00764426|Active Comparator|alcoholic beverages|red wine, beer, ethanol
11583517|NCT00764413|Active Comparator|1|Both study arms receive both active treatment = methylprednisolone and an inactive treatment = Sodium chlorid (dummy)
11583518|NCT00764413|Active Comparator|2|Both arms receives both active treatment and inactive treatment = dummy. Active treatment is methylprednisolone, inactive treatment is sodium chlorid.
11583519|NCT00764400|Experimental|Errorless Naming Treatment|
11583520|NCT00764400|Experimental|Verbal+Gestural Facilitation|
11583521|NCT00764387|Experimental|Arm 1|
11583522|NCT00764387|Active Comparator|Arm 2|
11583523|NCT00764374|Experimental|1|
11583524|NCT00764361|Experimental|NanoDOX™ Hydrogel|1.0% doxycycline gel
11583525|NCT00764361|Placebo Comparator|Placebo|placebo gel
11583526|NCT00764348||no treatment|
11583527|NCT00764335||unilateral normal|total hip arthroplasty one side, normal offset of medial femoral head
11583528|NCT00764335||bilateral normal|total hip arthroplasty both sides, normal offset of medial femoral head
11583529|NCT00764335||bilateral abnormal offset|total hip arthroplasty both sides, abnormal offset of medial femoral head
11583530|NCT00764335||controls|Healthy, age-matched control group
11583531|NCT00764322|Experimental|Tamoxifen 20|One arm, containing the ultra-rapid and extensive metabolizer genotypes, continues treatment with tamoxifen at 20mg.
11583532|NCT00764322|Active Comparator|Tamoxifen 40|This arm, containing the intermediate and poor metabolizer genotypes, receives escalated treatment with tamoxifen at 40mg.
11583533|NCT00764309|Experimental|A1|
11583534|NCT00764296||no treatment|The information obtained by the evaluation of both acute and chronic wounds is pivotal to truly understanding the intercellular tactics used by wound biofilms which work to disrupt host tissue and to evade the host's immune system.
11583535|NCT00764283|Experimental|1|Tegaderm dressing
11583536|NCT00764283|Active Comparator|2|Epi-Fix dressing
11583537|NCT00764283|Active Comparator|3|Lockit-Plus dressing
11583538|NCT00764270|Active Comparator|Lipoic acid treatment|Participants take lipoic acid with a washout period before or after placebo.
11583539|NCT00764270|Placebo Comparator|Placebo treatment|Participants take placebo with a washout period before or after lipoic acid treatment
11583540|NCT00764257|Experimental|PREVELLE Shape|
11583541|NCT00764257|Active Comparator|Restylane|
11583542|NCT00764244|Active Comparator|1|Vitrectomy
11583543|NCT00764244|Active Comparator|2|Intravitreal triamcinolone injections
11583544|NCT00764244|Active Comparator|3|Laser photocoagulation
11583545|NCT00764231|Experimental|Exercise|This group will undergo a 12-week home-based exercise intervention with follow-up fitness assessments.
11583546|NCT00764231|Other|Wait list control|This group will go on a 12-week wait list, during which time they will be asked not to change their exercise habits. After 12 weeks, this group will participate in the exercise intervention.
11583547|NCT00764218|Experimental|SAS+HTA+|Obstructive sleep apnea syndrome and hypertension
11583548|NCT00764218|Experimental|SAS+HTA-|non hypertensive patients with obstructive sleep apnea syndrome
11583549|NCT00764218|Experimental|SAS-HTA+|hypertensive patients without obstructive sleep apnea syndrome
11583550|NCT00764218|Experimental|SAS-HTA-|non hypertensive patients without obstructive sleep apnea syndrome
11583551|NCT00764205||Study Group|Troponin measured prior to hospital arrival
11583552|NCT00764205||Control Group|Patients transported to hospital without troponin measurements enroute
11583553|NCT00764192|Experimental|1|14 HD patients are studied before and after a single HD using a polysulphone dialyser.
11583554|NCT00764179|Experimental|1|hyperproteinic milk
11583555|NCT00764179|Active Comparator|2|Normoproteinic milk
11583556|NCT00764166|Experimental|1|
11583557|NCT00764166|Active Comparator|2|
11583558|NCT00764153|Other|Internal fixation|Closed reduction and internal fixation with two parallel screws (Olmed)
11583559|NCT00764153|Other|Bipolar hemiarthroplasty|Hemiarthroplasty with Charnley/ Hastings prosthesis
11583560|NCT00764140||2|Specific tumor growth factors (IGFs, its binding proteins,receptors; transforming growth factor alpha and beta 1 and epidermal growth factor) in the urine and serum will be measured in patients with hepatocellular carcinoma and healthy controls
11583561|NCT00764140||1|Patients with hepatocellular carcinoma and Healthy controls
11583562|NCT00764127||Obese Control|
11583563|NCT00764127||Normal Control|
11583564|NCT00764127||OVERWEIGHT ADOLESCENT PATIENTS UNDERGOING BARIATRIC SURGERY|
11583565|NCT00764114|Active Comparator|1|- group A : during 6 weeks after the inclusion
11583566|NCT00764114|Active Comparator|2|-group B : during 12 weeks after the inclusion
11583567|NCT00764101|Experimental|1|9 sessions of attentional bias modification (computerized training program)
11583568|NCT00764101|Placebo Comparator|2|Attentional control condition (placebo training program)
11583569|NCT00764088||Anaysis of Full Thickness wounds|To demonstrate the effectiveness or ineffectiveness of novel treating agents or agents used for compassionate rescue, subjects and their wounds will be analyzed retrospectively and their non-identifiable information will be compiled in the form of case studies. Subjects who demonstrated characteristics of interest (e.g. healing) as determined by the PI will be chosen for case studies.
11583570|NCT00764075|Experimental|1|guided implantation of the left ventricular lead
11583571|NCT00764075|Placebo Comparator|2|standard implantation of the left ventricular lead
11583572|NCT00764075|Experimental|Pilot Group|feasibility of guided placement of CRT-leads in 20 Patients
11583573|NCT00764062|Experimental|1|7-day amoxicillin treatment (1g per os twice daily)
11583574|NCT00764062|Active Comparator|2|3-day amoxicillin (1g per os twice daily) + 4-day placebo treatment (1g per os twice daily)
11583575|NCT00764049|Experimental|1: Single pass albumin dialysis|Patients entered in the pilot study.
11583576|NCT00764036|Experimental|experimental arm only|add-on therapy with 100, 150 or 200 mg oral artesunate once daily
11583577|NCT00764023||No treatment|
11583578|NCT00764023||human samples|
11583579|NCT00764010|No Intervention|1|No dietary counseling, placebo capsules for omega-3
11583580|NCT00764010|Active Comparator|2|Dietary counseling, placebo capsules for omega-3
11583581|NCT00764010|Active Comparator|3|No dietary counseling, omega-3 capsules
11583582|NCT00764010|Active Comparator|4|Dietary counseling and omega-3 capsules
11583583|NCT00763997|Experimental|1|Dipyrone
11583584|NCT00763997|Active Comparator|2|Ibuprofen
11583585|NCT00763997|Active Comparator|3|Acetaminophen
11583586|NCT00763997|Placebo Comparator|4|Parecoxib/Valdecoxib
11583587|NCT00763984|Active Comparator|1 Usual Care|This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT
11583588|NCT00763984|Experimental|2 Bladder Health Class|Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
11583589|NCT00763971|Experimental|Lisdexamfetamine Dimesylate (LDX)|Overencapsulated LDX 30, 50, or 70mg
11583590|NCT00763971|Active Comparator|Methylphenidate Hydrochloride|Overencapsulated Concerta 18, 36, or 54mg
11583591|NCT00763971|Placebo Comparator|Placebo|Overencapsulated Placebo
11583592|NCT00763958|Experimental|Buprenorphine|Active sublingual buprenorphine provided to participants; dose as clinically indicated up to 32 mg daily for up to 3 months
11583593|NCT00763958|Placebo Comparator|Placebo|Placebo sublingual medication provided to individuals randomized to control up to 3 months
11583594|NCT00763945||1|Patients representing to the hospital with acute coronary syndrome
11583596|NCT00763919|Experimental|Customized Adherence Enhancement (CAE)|"Participants, all of whom have a history of medication nonadherence, will be assigned to one or more treatment modules based on their individual profiles.
~Treatment Modules:
~Psychoeducation module Substance abuse module Improved communication/rapport with provider module Medication routines management module"
11583597|NCT00763906|Placebo Comparator|1|Patients were assigned to norepinephrine infused at the clinician's discretion.
11583598|NCT00763906|Active Comparator|2|Patients were assigned to norepinephrine infused under computerized fuzzy logic control.
11583599|NCT00763893|Placebo Comparator|A: Placebo|placebo
11583600|NCT00763893|Active Comparator|B: Losartan|Losartan
11583601|NCT00763880|Experimental|Lidocaine|Subjects randomly assigned to this arm will receive 2% lidocaine by injection into their fracture site in the form of a hematoma block.
11583602|NCT00763880|Placebo Comparator|Normal Saline|Subjects randomly assigned to this arm will receive normal saline by injection into their fracture site
11583603|NCT00763867|Placebo Comparator|Placebo|Placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks
11583604|NCT00763867|Experimental|Sildenafil|Sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks
11583605|NCT00763841|Experimental|1|Stimulation will be given daily at a particular site for three days a week
11583606|NCT00763841|Sham Comparator|2|
11583607|NCT00763828|Experimental|ThermoSuit-Induced Patient Cooling|The Life Recovery Systems ThermoSuit System will be used to cool STEMI patients under conditions of conscious sedation.
11583608|NCT00763815|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
11583609|NCT00763815|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
11583610|NCT00763802||MNPDR|Type 2 diabetic patients with Mild non-prolipherative retinopathy.
11583611|NCT00763789|Experimental|1|Local anaesthesia and remifentanil sedation
11583612|NCT00763789|Other|2|Total intravenous anaesthesia
11583613|NCT00763776|Other|1|Liver transection by clamp crushing technique
11583614|NCT00763776|Other|2|Liver transection by the ultrasonic dissector
11583615|NCT00763763|Experimental|1|imatinib in combination with chemotherapy by vincristin and dexamethasone
11583616|NCT00763750|Experimental|PPX +TMZ+XRT|XRT 60Gy at 2 GY/fractions x 30 fractions TMZ 75mg/m2/day PPX 40mg/m2/week x 6 weeks Days 1,8,15,22,22,29,36
11583617|NCT00763737|Experimental|1|prenatal FETO at 30-31+6 weeks and removal at 34-34+6 wks, followed by standardized postnatal care
11583618|NCT00763737|No Intervention|2|expectant management during pregnancy followed by standardized neonatal care
11583619|NCT00763724||1|Duloxetine
11583620|NCT00763724||2|Venlafaxine
11583621|NCT00763724||3|SSRI
11583622|NCT00763724||4|TCA
11583623|NCT00763724||5|Multiple Antidepressants
11583624|NCT00763724||6|Depressed (not antidepressant treated)
11583625|NCT00763724||7|General population
11583626|NCT00763711|Experimental|Injection with Needle Guide|
11583627|NCT00763698|Experimental|QuickFlex micro 1258T left heart lead|
11583628|NCT00763685|Active Comparator|etoricoxib 120 mg|active control
11583629|NCT00763685|Placebo Comparator|2|Placebo
11583630|NCT00763685|Active Comparator|3|Paracetamol 1 g and etoricoxib 120 mg
11583631|NCT00763672|Other|A|sFlt-1 status known
11583632|NCT00763672|Other|B|sFlt-1 status unknown
11583633|NCT00763659|Active Comparator|1|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
11583634|NCT00763659|Active Comparator|2|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
11583635|NCT00763659|Placebo Comparator|3|Placebo
11583636|NCT00763633|Active Comparator|highB6|high vitamin B6
11583637|NCT00763633|Active Comparator|lowB6|low vitamin B6
11583638|NCT00763620|Experimental|1|Catheter for mini bronchoalveolar lavage
11583639|NCT00763607||1|Radically resected Non small cell lung cancer patients in stage I-III
11583640|NCT00763594|Active Comparator|IPT|Interpersonal Psychotherapy for Major Depressive Disorder
11583641|NCT00763594|Experimental|BRT|Brief Relational Therapy adapted for treatment of Major Depressive Disorder
11583642|NCT00763568|Experimental|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
11583643|NCT00763555|Experimental|1|CD 2027, 3 ug/g Oily Spray, twice a day for 8 weeks
11583644|NCT00763555|Placebo Comparator|2|
11583645|NCT00763542|Experimental|I|Combined treatment: CBT for SUD plus structured writing therapy for PTSD
11583646|NCT00763542|Active Comparator|II|CBT for SUD only
11583647|NCT00763529|Experimental|Arm 1|
11583648|NCT00763529|Active Comparator|Arm 2|
11583649|NCT00763516|Experimental|Proton radiation and chemotherapy|"Proton radiation
~Capecitabine chemotherapy on radiation days
~Surgery
~Gemcitabine chemotherapy"
11583650|NCT00763503|Experimental|CD 2027|
11583651|NCT00763490|Experimental|Double cord blood transplant|'full intensity, double umbilical cord, stem cell transplant' with 'Flu/Bu4 conditioning regimen'
11583652|NCT00763477|Placebo Comparator|saline injections|
11583653|NCT00763451|Experimental|Lixisenatide (Two-Step Titration)|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
11583654|NCT00763451|Experimental|Lixisenatide (One-Step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to the end of treatment.
11583655|NCT00763451|Placebo Comparator|Placebo (Two-Step Titration)|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
11583656|NCT00763451|Placebo Comparator|Placebo (One-Step Titration)|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, then 20 mcg QD up to the end of treatment.
11583657|NCT00763438|Experimental|Sertindole|
11583658|NCT00763425|Experimental|1|
11583660|NCT00763412|Placebo Comparator|1 Placebo|1 pill before each meal 3-4 times a day for 2 years. All subjects had abnormal glucose tolerance. Subjects were randomized to placebo or drug.
11583661|NCT00763412|Experimental|2. repaglinide|repaglinide 0.5 mg before each meal 3-4 times a day for 2 years. All subjects had abnormal glucose tolerance.Subjects were randomized to placebo or drug.
11583662|NCT00763399|Experimental|97-0549B|
11583663|NCT00763386|Active Comparator|1|Study arm will consist of patients that are treated with the NexGen LPS-Flex Fixed Bearing Knee.
11583664|NCT00763386|Active Comparator|2|Study arm will consist of patients that are treated with the NexGen Legacy Posterior Stabilized Knee.
11583665|NCT00763373||1|Observation group
11583666|NCT00763373||2|Intervention group
11583667|NCT00763360|Experimental|DisCoVisc®|DisCoVisc® Ophthalmic Viscosurgical Device
11583668|NCT00763360|Active Comparator|Healon|Healon
11583669|NCT00763360|Active Comparator|Amvisc Plus|Amvisc Plus
11583670|NCT00763347|Experimental|SYR-619 12.5 mg QD|
11583671|NCT00763347|Experimental|SYR-619 50 mg QD|
11583672|NCT00763347|Experimental|SYR-619 100 mg QD|
11583673|NCT00763347|Experimental|SYR-619 200 mg QD|
11583674|NCT00763347|Placebo Comparator|Placebo QD|
11583675|NCT00763347|Active Comparator|Alogliptin 25 mg QD|
11583676|NCT00763321|Experimental|Open-label ABT-712|2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks (open-label period).
11583677|NCT00763321|Experimental|Double-blind ABT-712|2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period).
11583678|NCT00763321|Placebo Comparator|Double-blind Placebo|2 placebo tablets, twice daily, for 4 weeks (double-blind period).
11583679|NCT00763308|Experimental|1|Participants will use the Web-based Heart Healthy program.
11583680|NCT00763308|No Intervention|2|Participants will receive treatment as usual.
11583681|NCT00763295||HIV infection|
11583682|NCT00763282|Experimental|SM+MI|Self Management (SM) + Motivational Interviewing (MI). Self Management and Motivational Interviewing (SM+MI) participants were assigned to both a self-management and motivational interview group. Motivational Interviewing (MI) is an evidence-based form of counseling to help individuals to engage in behavior change. Self Management (SM) consists of: 1) on-site decisional support to promote provider adherence to ulcer management guidelines, 2) enhanced, interactive PrU education, 3) chronic disease self-management skill building via telephone based groups, 4) proactive care management using MI to support ongoing self-management activities, and 5) distance technology.
11583683|NCT00763282|Active Comparator|ED|Education (ED). An education control intervention (ED) designed to be a credible intervention that is comparable to the SM will control for potential effects of natural history/time, treatment dosing, measurement processes, attention, the non-specific effects of therapeutic alliance, social support, and of receiving a manualized treatment with specific therapist procedures. The ED intervention will differ only in that subjects will not be instructed in any specific problem solving, self-monitoring, or SM techniques, with the exception of encouraging them to become informed consumers of SCI care.
11583684|NCT00763269|Experimental|A|sensitive toothpaste
11583685|NCT00763269|Active Comparator|B|Triclosan control toothpaste
11583686|NCT00763256|Active Comparator|A|
11583687|NCT00763256|Placebo Comparator|B|
11583688|NCT00763243|Experimental|Cogmed Working Memory Training|Cogmed Working Memory Training Program
11583689|NCT00763230|Experimental|active|Full active tDCS treatment
11583690|NCT00763230|Sham Comparator|sham|Placebo tDCS will be give
11583691|NCT00763217||stroke patient cohort|Patients with an hemispheric ischemic or hemorrhage stroke hospitalized during the 48h following the beginning of stroke
11583692|NCT00763204|Experimental|1|AN2728 Cream, 2%
11583693|NCT00763204|Experimental|2|AN2728 Cream, 1%
11583694|NCT00763204|Experimental|3|AN2728 Cream, 0.3%
11583695|NCT00763204|Placebo Comparator|4|AN2728 Cream Vehicle
11583696|NCT00763204|Active Comparator|5|Betnesol®-V Creme (betamethasone 0.1 %)
11583697|NCT00763178|Experimental|PTSD|Duloxetine
11583698|NCT00763165|Active Comparator|A|
11583699|NCT00763165|Placebo Comparator|B|
11583700|NCT00763152||stability of Beacons in prostatic bed|Patients implanted with the Calypso transponders following radical prostatectomy for prostate cancer will be followed for observation of transponder stability.
11583701|NCT00763139|Experimental|Placebo First|Placebo for first 8 weeks, then washout period for 4 weeks, and finally pioglitazone for 8 weeks.
11583702|NCT00763139|Experimental|Pioglitazone First|Pioglitazone for first 8 weeks, then washout period for 4 weeks, and finally placebo for 8 weeks.
11583703|NCT00763126|Active Comparator|Spouse present,|
11583704|NCT00763126|Active Comparator|spouse absent|
11583705|NCT00763113|Experimental|1|Vanguard PS Knee
11583706|NCT00763113|Active Comparator|2|Vanguard CR Knee
11583707|NCT00763100||Breast cancer|Patients in treatment or post-treatment for breast cancer
11583708|NCT00763087|Active Comparator|nonweightbearing exercise|
11583709|NCT00763087|Placebo Comparator|nonexercising control|
11583710|NCT00763087|Experimental|weightbearing exercise|
11583711|NCT00763074|Placebo Comparator|Control|Conventional education of life style intervention for type 2 diabetes
11583712|NCT00763074|Active Comparator|Diet|Dietary calorie restriction
11583713|NCT00763074|Active Comparator|Exercise|Encourage to increase exercise amount: more than 60min's of exercise with moderate activity level two times per day
11583714|NCT00763074|Active Comparator|Diet and exercise|Intervention for both of exercise and diet
11583715|NCT00763061|Experimental|Travoprost 0.004%|Travoprost 0.004%
11583716|NCT00763061|Active Comparator|Timolol 0.5%|Timolol 0.5%
11583717|NCT00763048|Placebo Comparator|A -Control|Fluoride toothpaste (Colgate Great Regular Flavor) is the control for this study. All study toothpastes contain fluoride. The study is evaluating the additional ingredients in the other toothpastes.
11583718|NCT00763048|Active Comparator|B|fluoride/triclosan/copolymer toothpaste (Colgate Total Toothpaste)
11583719|NCT00763035|Active Comparator|A|Arm A will get Dobutamine Stress test with cardiac MR (CMR). Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.
11583720|NCT00763035|Active Comparator|B|Arm B will get Regadenoson stress test with CMR. Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.
11583721|NCT00763022|Experimental|TAK-559 16 mg QD|
11583722|NCT00763022|Experimental|TAK-559 32mg QD|
11583723|NCT00763022|Placebo Comparator|Placebo QD|
11583724|NCT00763009|Other|All subjects receive dipyridamole|Compare to baseline
11583725|NCT00762996|Active Comparator|etafilcon A/etafilcon A|Period 1: etafilcon A, Period 2: etafilcon A
11583726|NCT00762996|Active Comparator|etafilcon A/omafilcon A|Period 1: etafilcon A, Period 2: omafilcon A
11583727|NCT00762996|Active Comparator|omafilcon A/etafilcon A|Period 1: omafilcon A, Period 2: etafilcon A
11583728|NCT00762996|Active Comparator|omafilcon A/omafilcon A|Period 1: omafilcon A, Period 2: omafilcon A
11583729|NCT00762983||Group 1|Pediatric patients who are treated with Claritin for any of the following reasons: allergic rhinitis, urticaria, itching due to skin disease (eczema, dermatitis, or pruritus cutaneous)
11583730|NCT00762970|Experimental|Test Lens 1|Investigational soft contact lenses worn daily.
11583731|NCT00762970|Experimental|Test Lens 2|Investigational soft contact lenses worn daily.
11583732|NCT00762970|Active Comparator|Control lens|Spectacle lenses worn daily.
11583733|NCT00762957|Experimental|TAK-559 16 mg QD + Metformin QD|
11583734|NCT00762957|Experimental|TAK-559 32 mg QD + Metformin QD|
11583735|NCT00762957|Active Comparator|Metformin QD|
11583736|NCT00762931|Experimental|Resolve Stimulator and Proximity Lead|An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation, all subjects will receive active treatment
11583737|NCT00762905|Active Comparator|1|LiquiBand Laparoscopic
11583738|NCT00762905|Active Comparator|2|Dermabond
11583739|NCT00762892|Active Comparator|Raltegravir|Raltegravir in combination with truvada (tenofovir and emtricitabine)
11583740|NCT00762892|Active Comparator|Atazanavir|Atazanavir, low dose ritonavir, and truvada (tenofovir and emtricitabine)
11583741|NCT00762879||No treatment|
11583742|NCT00762866||MDD|Unipolar Major Depressive Disorder, any subtype
11583743|NCT00762866||Bipolar|Bipolar I or II Disorder or Bipolar Disorder NOS
11583744|NCT00762866||Psychosis|Psychotic Disorder including Schizophrenia, Schizoaffective, Schizophreniform, Brief Psychotic Disorder, and Psychotic Disorder NOS
11583745|NCT00762853|Placebo Comparator|A|fluoride toothpaste from Thailand
11583746|NCT00762853|Active Comparator|B|fluoride/triclosan/copolymer toothpaste
11583747|NCT00762840|Experimental|Apexum|the tooth is treated by a standard root canal treatment, supplemented by Apexum Ablator protocol, in which the periapical lesion tissue is minced and removed through the root canal, in a minimally invasive fashion.
11583748|NCT00762840|Active Comparator|Control|the tooth is subject to conventional endodontic procedure alone, (standard root canal treatment)
11583749|NCT00762814|Experimental|Parkinson subjects with freezing|"Each subject will have been diagnosed with Parkinson disease and will serve as his/her own control. Inclusion criteria: history of consistent freezing with ambulation in a straight line and/or when turning, normal central and peripheral neurological function, at least grade 4 strength and normal joint ranges of motion in both legs, normal somatosensory function in the feet (joint position sense), except for their neurological diagnosis and use of levodopa, each must have had clear benefit from levodopa for at least some of his/her PD symptoms, and all subjects with PD must be able to walk independently for 10 feet.
~Exclusion criteria include: serious medical problem that would impair the ability to undergo testing, use of neuroleptic or other dopamine-blocking drug, use of drugs that might affect balance, history or evidence of other neurological deficit that could interfere, such as previous stroke or muscle disease, or participants who are unable to provide informed consent."
11583750|NCT00762788|Active Comparator|senofilcon A contact lens|ACUVUE OASYS
11583751|NCT00762788|Active Comparator|lotrafilcon A contact lens|NIGHT&DAY
11583752|NCT00762788|Active Comparator|lotrafilcon B contact lens|O2Optix
11583753|NCT00762788|Active Comparator|balafilcon A contact lens|PureVision
11583754|NCT00762788|Active Comparator|comfilcon A contact lens|Biofinity
11583755|NCT00762788|Active Comparator|etafilcon A contact lens|ACUVUE 2
11583756|NCT00762775|Experimental|1|Calcium supplementation and placebo
11583757|NCT00762775|Experimental|2|Vitamin D supplementation and placebo
11583758|NCT00762775|Experimental|3|Calcium and Vitamin D supplementation
11583759|NCT00762775|Placebo Comparator|4|Placebos only
11583760|NCT00762762|Active Comparator|A|
11583761|NCT00762762|Placebo Comparator|B|
11583762|NCT00762749|Experimental|diphenhydramine HCl|diphenhydramine HCl / Children's Benadryl Allergy Liquid
11583763|NCT00762736|Experimental|Pioglitazone 15 mg QD + Azilsartan 5 mg QD|
11583764|NCT00762736|Experimental|Pioglitazone 15 mg QD + Azilsartan 40 mg QD|
11583765|NCT00762736|Active Comparator|Pioglitazone 15 mg QD|
11583766|NCT00762736|Experimental|Pioglitazone 45 mg QD + Azilsartan 5 mg QD|
11583767|NCT00762736|Experimental|Pioglitazone 45 mg QD + Azilsartan 40 mg QD|
11583768|NCT00762736|Active Comparator|Pioglitazone 45 mg QD|
11583769|NCT00762723|Experimental|Group 1|Trinica Anterior Lumbar Plate System with fixed screws only
11583770|NCT00762723|Experimental|Group 2|Trinica Anterior Lumbar Plate System with variable screws only
11583771|NCT00762723|Experimental|Group 3|Trinica Anterior Lumbar Plate with hybrid screw configuration (2 fixed-angle screws with 2 variable-angle screws).
11583772|NCT00762710|Experimental|1 - Prazosin Medication|Following randomization, participants in this arm will receive a 2-week titration of Prazosin followed by 10 weeks of stable dosing of Prazosin. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.
11583773|NCT00762710|Placebo Comparator|2 - Placebo Medication|Following randomization, participants in this arm will receive a 2-week titration of placebo followed by 10 weeks of stable dosing of placebo. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.
11583774|NCT00762684|Experimental|TAK-559 32 mg QD|
11583775|NCT00762684|Placebo Comparator|Placebo QD|
11583776|NCT00762671|Placebo Comparator|2|Placebo
11583777|NCT00762671|Active Comparator|1|Ebselen
11583778|NCT00762658|Experimental|1|AN2728 Ointment, 5%
11583779|NCT00762658|Experimental|2|AN2728 Ointment, 2%
11583780|NCT00762658|Experimental|3|AN2728 Ointment, 0.5%
11583781|NCT00762658|Placebo Comparator|4|AN2728 Ointment Vehicle
11583782|NCT00762658|Active Comparator|5|Betnesol®-V Creme (betamethasone 0.1 %)
11583783|NCT00762658|Active Comparator|6|Protopic® Ointment (tacrolimus 0.1 %)
11583784|NCT00762645|Experimental|Travoprost 0.004% (Travatan)|One drop in each eye, once daily at 9 AM
11583785|NCT00762645|Active Comparator|Pilocarpine 1%|One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
11583786|NCT00762619|Placebo Comparator|A -|fluoride toothpaste (Ultrabrite)
11583787|NCT00762619|Active Comparator|B - Postive control|fluoride/triclosan/copolymer toothpaste
11583788|NCT00762606|Active Comparator|Phaco|Cataract extraction surgery utilizing Phacoemulsification
11583789|NCT00762606|Active Comparator|SICS|Small incision cataract surgery (SICS)
11583790|NCT00762593|Experimental|1|transvaginal electrical stimulation with a home use programmable device used 30 minutes every day during 8 weeks
11583791|NCT00762593|Placebo Comparator|2|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
11583792|NCT00762580||Prospective|Patients with full thickness rotator cuff tears being treated with physical therapy
11583793|NCT00762567|Experimental|1|phenylephrine
11583794|NCT00762554|Active Comparator|1|Epidural Depodur after epidural lidocaine
11583795|NCT00762554|Active Comparator|2|Epidural Depodur after spinal bupivacaine
11583796|NCT00762554|Active Comparator|3|Epidural fentanyl infusion after epidural lidocaine or spinal bupivacaine
11583797|NCT00762528|Active Comparator|Total Toothpaste|Triclosan/Copolymer/fluoride toothpaste
11583798|NCT00762528|Placebo Comparator|Fluoride toothpaste|sodium monofluorophosphate toothpaste
11583799|NCT00762515|Placebo Comparator|A|commercially available Fluoride only toothpaste
11583800|NCT00762515|Active Comparator|B|Commercially available triclosan/copolymer/fluoride toothpaste
11583801|NCT00762502|Active Comparator|senofilcon A toric bilaterally|senofilcon A lenses worn daily bilaterally (in both eyes) for 3 months, replaced weekly.
11583802|NCT00762502|Active Comparator|balafilcon A toric bilaterally|balafilcon A lenses worn daily bilaterally (in both eyes) for 3 months, replaced weekly.
11583803|NCT00762502|Active Comparator|senofilcon A/balafilcon A contralaterally|senofilcon A lens worn in one eye and balafilcon A lens worn in the other eye (contralaterally), daily for 3 months, replaced weekly.
11583804|NCT00762489|Other|TAT vs. RT|This arm is comparing the Temporal Artery Thermometer (TAT) temperature to the Rectal Temperature (RT).
11583805|NCT00762489|Other|TAT vs. AT|This arm is comparing the Temporal Artery Thermometer (TAT) temperature to the Axillary Temperature (AT).
11583806|NCT00762476|Placebo Comparator|Placebo|
11583807|NCT00762476|Experimental|3804-250A|
11583808|NCT00762463|Experimental|Celecoxib 200 mg QD|
11583809|NCT00762463|Active Comparator|Diclofenac SR 75 mg QD|
11583810|NCT00762450|Active Comparator|A- Positive Control|fluoride/triclosan/copolymer toothpaste
11583811|NCT00762450|Placebo Comparator|B - Silica control|fluoride only toothpaste
11583812|NCT00762450|Experimental|C- Experimental product|fluoride/triclosan/amino acid toothpaste
11583813|NCT00762437|Experimental|1|
11583814|NCT00762424|Active Comparator|Tamsulosin|
11583815|NCT00762424|Placebo Comparator|Placebo|
11583816|NCT00762411|Experimental|LY450139|Participants received 60 milligrams (mg) LY450139 orally once daily for 2 weeks followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.
11583817|NCT00762411|Placebo Comparator|Placebo|Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, participants in the placebo arm received LY450139 titrated up to 140 mg orally once daily until Week 88.
11583818|NCT00762398||Adult patient undergoing a surgery|Adult patient undergoing a surgery in the supine position and require an arterial line for anesthesia/surgery purposes
11583819|NCT00762385|Active Comparator|galyfilcon A/comfilcon A|galyfilcon A first, comfilcon A second
11583820|NCT00762385|Active Comparator|comfilcon A/galyfilcon A|comfilcon A first, galyfilcon A second
11583821|NCT00762372|Experimental|desflurane|
11583822|NCT00762372|Experimental|desflurane/N2O|
11583823|NCT00762372|Active Comparator|sevoflurane/N2O|
11583824|NCT00762359|Experimental|Lansoprazole 15 mg QD|
11583825|NCT00762359|Active Comparator|Gefarnate 50 mg BID|
11583826|NCT00762346|Experimental|1|
11583827|NCT00762333||Myocardial Infarction|
11583828|NCT00762320|Experimental|Low dose Kaletra tablets|Patients will serve as their own controls as they are switched from the baseline treatment with liquid Kaletra to the study intervention treatment with Low Dose Tablet Kaletra (100mg/25mg)
11583829|NCT00762307|Experimental|1|
11583830|NCT00762294||644-001|Women treated for breast cancer who will be starting Arimidex or Femara
11583831|NCT00762281|Other|Treatment of Hyperopic LASIK|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
11583832|NCT00762268|Experimental|SAMe|"SAMe: SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period."
11583833|NCT00762268|Placebo Comparator|placebo|"Placebo: Placebo SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral pills for only 3 days per week, followed by a 4 day rest-period, before the round. The apparent dosage will be progressively increased each week to mimic a maximum of 1600 mg per day over a 4-week period."
11583834|NCT00762255|Experimental|A - Phase I Dose Escalation|Dose Escalation - Irinotecan and bevacizumab are given IV on days 1 and 15 of each cycle. Vorinostat is given orally on days 1-7 and 15-21 of each cycle.
11583835|NCT00762255|Experimental|B - Treatment at Maximum Tolerated Dose (MTD)|MTD - Treatment at maximum tolerated dose
11583836|NCT00762242||1|Blood sampling and brachial artery ultrasound
11583837|NCT00762229|Active Comparator|Ezetimibe 10 mg|A whole ezetimibe 10 mg tablet
11583838|NCT00762229|Experimental|Ezetimibe 5 mg|"Ezetimibe 5 mg, formulated by splitting a 10 mg ezetimibe tablet in half"
11583839|NCT00762216|Other|Toric|Implantation with the AcrySof® Toric intraocular lens
11583840|NCT00762190|Experimental|TAK-559 32 mg QD + Insulin|
11583841|NCT00762190|Active Comparator|Insulin|
11583842|NCT00762177|Placebo Comparator|A -Control|fluoride toothpaste
11583843|NCT00762177|Experimental|B Experimental toothpaste|Stannous fluoride toothpaste
11583844|NCT00762177|Active Comparator|C- positive control|fluoride/triclosan/copolymer toothpaste
11583845|NCT00762164|Active Comparator|1Vytorin 10/80 divided into 4|Vytorin 10/80 divided into 4
11583846|NCT00762164|Active Comparator|Simvastatin|Simvastatin 20 milligrams
11583847|NCT00762151|Placebo Comparator|Negative Control|Regular Toothpaste
11583848|NCT00762151|Active Comparator|Positive Control|Standard anti-plaque and anti-bacterial toothpaste.
11583849|NCT00762151|Active Comparator|Prototype|AN0128 Toothpaste
11583850|NCT00762138|Other|Autologel System|Autologel System produces platelet rich plasma gel
11583851|NCT00762125|Experimental|Cognitive restructuring and coping skills training (CR+ST)|
11583852|NCT00762125|Experimental|Exposure therapy (ET)|
11583853|NCT00762125|Experimental|Combination (COMB) treatment|
11583854|NCT00762125|Active Comparator|Attention control (AC) treatment|
11583855|NCT00762112|Experimental|TAK-559 32 mg QD|
11583856|NCT00762099|Active Comparator|1|Pregabalin Group
11583857|NCT00762099|Placebo Comparator|2|Placebo group
11583858|NCT00762086|Active Comparator|Treatment Group|AngioPress Intermittent pneumatic compression (IPC) Device
11583859|NCT00762086|Other|Control Group|Aspirin/Clopidegrol and Standard walking exercises
11583860|NCT00762073|Placebo Comparator|1|
11583861|NCT00762073|Experimental|2|Low Dose Group
11583862|NCT00762073|Experimental|3|Medium Dose Group
11583863|NCT00762073|Experimental|4|High Dose Group
11583864|NCT00762060||Active|Surgical site continuous local anesthetic infusion with ONQ silver Soaker System
11583865|NCT00762060||Control|Hospital standard of care for pain management (Patient controlled analgesia or epidural)
11583866|NCT00762047|Experimental|Durasphere|
11583867|NCT00762047|Sham Comparator|Sham|
11583868|NCT00762034|Experimental|Pem/Carbo/Bev|Pemetrexed (Pem), carboplatin (Carbo) and bevacizumab (Bev) followed by pemetrexed and bevacizumab
11583869|NCT00762034|Active Comparator|Pac/Carbo/Bev|Paclitaxel (Pac), carboplatin (Carbo) and bevacizumab (Bev) followed by bevacizumab
11583870|NCT00762021|Experimental|SN60AT|Implantation with the AcrySof Intraocular Lens Model SN60AT
11583871|NCT00762021|Active Comparator|SN60WF|Implantation with the AcrySof Intraocular Lens Model SN60WF
11583872|NCT00762008||Heart Failure|
11583873|NCT00761995|Active Comparator|Azopt|topical eye drop dosed 1 drop 3 times daily
11583874|NCT00761995|Active Comparator|Cosopt|topical eye drop
11583875|NCT00761982|Other|bone marrow stem cells|Procedure: Infusion of autologous CD34+ stem cells into middle cerebral artery.
11583876|NCT00761969||PAB|Subjects with stable peripheral arterial disease; ankle-brachial pressure index on at least one leg =< 0.90.
11583877|NCT00761969||Control|Subjects without peripheral arterial disease (palpable pedal pulses and a normal ankle-brachial pressure index of 0.91-1.30), age- and sex-matched to the stuy group with PAD
11583878|NCT00761956|Active Comparator|1|Study arm will consist of patients that are treated with the NexGen CR-Flex Fixed Bearing Knee.
11583879|NCT00761956|Active Comparator|2|Study arm will consist of patients that are treated with the NexGen CR Knee.
11583880|NCT00761930|Placebo Comparator|A|commercially available Fluoride toothpaste
11583881|NCT00761930|Active Comparator|B|fluoride/triclosan/copolymer toothpaste
11583882|NCT00761930|Experimental|C|fluoride/herbal toothpaste
11583883|NCT00761917||1: Normal|Subjects without dry eye symptoms based on questionnaire.
11583884|NCT00761917||2: Dry Eye|Subjects with dry eye symptoms based on questionnaire.
11583885|NCT00761904|Experimental|receipt of free generic samples|
11583886|NCT00761904|No Intervention|usual prescribing|
11583887|NCT00761891|Experimental|Chewable aspirin|81 mg daily for 2 weeks
11583888|NCT00761878|Active Comparator|Skin treatment|
11583889|NCT00761865|Active Comparator|Air Cast Stirrup Brace|50 patients will be randomly assigned to receive the Air Cast Stirrup Brace.
11583890|NCT00761865|Active Comparator|High Tide Fracture Boot|50 patients will be randomly assigned to the High Tide Fracture Boot.
11583891|NCT00761852|Active Comparator|1|Ruboxistaurin
11583892|NCT00761852|Placebo Comparator|2|Placebo
11583893|NCT00761839|Experimental|Arm 1|These patients receive the experimental intervention--the after-care summary.
11583894|NCT00761839|Active Comparator|Arm 2|These patients are the control group and receive usual care.
11583895|NCT00761813|Experimental|Single Sliding Hip Screw|
11583896|NCT00761813|Experimental|Multiple Cancellous Screws|
11583897|NCT00761787||1|Heart transplanted subjects.
11583898|NCT00761774|Experimental|Brivaracetam|Brivaracetam at flexible dosing up to 200mg /day
11583899|NCT00761761|Experimental|1- Sensoril (Ashwagandha)|Sensoril (Ashwagandha) will be administered using random assignment at a dose of 250 mg/day, increasing to a dose of 500 mg/day by the second week.
11583900|NCT00761761|Placebo Comparator|2 - Placebo|Placebo will be administered using random assignment at a dose of 250 mg/day, increasing to a dose of 500 mg/day by the second week.
11583901|NCT00761748|Experimental|SenSura|SenSura Uro 2-piece. Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.
11583902|NCT00761748|Active Comparator|Convatec|Convatec Uro 2-piece Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.
11583903|NCT00761735|Other|PEG-IFN + RBV: LTFU|Pediatric participants who completed treatment with peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) in P02538 Part 1 of this study (NCT00104052) were enrolled in a 5-year Long Term Follow-Up (LTFU) during P02538 Part 2 (NCT00761735). No study treatment was administered in Part 2.
11583904|NCT00761722|Experimental|Arm 1|"subcutaneous and oral azacitidine
~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.
~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle."
11583905|NCT00761722|Experimental|Arm 2|"Oral Azacitidine
~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle."
11583906|NCT00761709|Experimental|AL-39256|AL-39256 Ophthalmic Suspension, 1%, 1 drop in the study eye(s) at 8 AM from the morning bottle and 1 drop in the study eye(s) at 8 PM from the evening bottle for 4 weeks.
11583907|NCT00761709|Active Comparator|XALATAN|Latanoprost Ophthalmic Solution, 0.005%, 1 drop in the study eye(s) at 8 PM from the evening bottle (morning bottle contained vehicle and was dosed 1 drop in the study eye(s) at 8 AM) for 4 weeks.
11583908|NCT00761709|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in the study eye(s) at 8 AM from the morning bottle and 1 drop in the study eye(s) at 8 PM from the evening bottle for 4 weeks.
11583909|NCT00761696|Experimental|IPI-926|Oral daily dosing
11583910|NCT00761683||1|Patients diagnosed with endometriosis
11583911|NCT00761670|Active Comparator|1|
11583912|NCT00761670|Active Comparator|2|
11583913|NCT00761657|Experimental|A|FG-4592 1.0 mg/kg
11583914|NCT00761657|Experimental|B|FG-4592 1.5 mg/kg
11583915|NCT00761657|Experimental|C|FG-4592 2.0 mg/kg
11583916|NCT00761657|Experimental|D|FG-4592 2.5 mg/kg
11583917|NCT00761657|Experimental|E|FG-4592 3.0 mg/kg
11583918|NCT00761657|Placebo Comparator|F|Placebo
11583919|NCT00761657|Experimental|G|FG-4592 0.7 mg/kg
11583920|NCT00761644|Experimental|Doxil, Bevacizumab + Temsirolimus|"Doxil day 1 of each 21 day cycle, beginning dose level 10 mg/m^2 by vein over 3 hours.
~Bevacizumab day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.
~Temsirolimus days 1, 8 & 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes."
11583921|NCT00761631|Experimental|Single|Open label
11583922|NCT00761618|Experimental|Arm 1 - Daily|Intrapleural Catheters (IPC) drained every day
11583923|NCT00761618|Experimental|Arm 2 - 3 Times a Week|IPC drained 3 times a week
11583924|NCT00761605|Experimental|Paliperidone|Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
11583925|NCT00761592|Active Comparator|1|
11583926|NCT00761592|Active Comparator|2|
11583927|NCT00761579|Experimental|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
11583928|NCT00761566|Experimental|1|
11583929|NCT00761566|Experimental|2|
11583930|NCT00761553|Experimental|1|Solid dietary supplements with exercise
11583931|NCT00761553|Experimental|2|Solid dietary supplements without exercise
11583932|NCT00761553|Experimental|3|Liquid dietary supplements with exercise
11583933|NCT00761553|Experimental|4|Liquid supplements without exercise
11583934|NCT00761540|Experimental|A1|
11583935|NCT00761540|Placebo Comparator|A2|
11583936|NCT00761540|Experimental|B1|
11583937|NCT00761540|Placebo Comparator|B2|
11583938|NCT00761540|Experimental|C1|
11583939|NCT00761540|Placebo Comparator|C2|
11583940|NCT00761527||Participants with allergic rhinitis or idiopathic urticaria|Outpatient pediatric participants (ages 6 months-11 years) in the Philippines with a diagnosis of allergic rhinitis or chronic idiopathic urticaria.
11583941|NCT00761514|Experimental|1|All subjects will receive Adalimumab
11583942|NCT00761501|Experimental|1|
11583943|NCT00761501|Active Comparator|2|
11583944|NCT00761501|Active Comparator|3|
11583945|NCT00761488|Experimental|1|AcrySof® Toric IOL
11583946|NCT00761475|Placebo Comparator|1|primary closure of the midline
11583947|NCT00761475|Active Comparator|2|onlay mesh supported closure
11583948|NCT00761475|Active Comparator|3|sublay mesh supported closure
11583949|NCT00761462|Experimental|Ciprofloxacin|Subjects receiving Ciprofloxacin (group followed-up for 5 years)
11583950|NCT00761462|Active Comparator|Non-quinolone antibiotic|Subjects receiving non-quinolone antibiotic (group followed-up for 2 years)
11583951|NCT00761449|Experimental|1|1. lenalidomide
11583952|NCT00761436|Experimental|Arm 1|
11583953|NCT00761423|Experimental|1|Combination of eccentric exercises and injection of PRP
11583954|NCT00761423|Placebo Comparator|2|Combination of eccentric exercises and physiological saline injection
11583955|NCT00761410|Other|P.F.C. Sigma RP-F Total Knee Replacement|An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
11583956|NCT00761397||Study Program Group|
11583957|NCT00761397||Usual Care Group|
11583958|NCT00761384|Experimental|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
11583959|NCT00761371|Experimental|Imiquimod|Imiquimod 5% cream
11583960|NCT00761358|Experimental|Z-338|
11583961|NCT00761358|Placebo Comparator|placebo|
11583962|NCT00761345|Experimental|radiotherapy and chemotherapy|gemcitabine will be administered at 1000mg/m2 IV on days 1 and 8 of each 21 day cycle. erlotinib at either 100mg (cohort 1-3) or 150mg (cohort 4) PO daily. Low dose fractionated radiotherapy (LDRT) will be given BID on days 1 and 2 and 8 and 9 of each 21 day cycle
11583963|NCT00761332||Teriparatide|Patients treated with teriparatide
11583964|NCT00761332||Antiresorptive|Patients treated with antiresorptive therapy
11583965|NCT00761319|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily for 90 days
11583966|NCT00761319|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily for 90 days
11583967|NCT00761306|Experimental|Vortioxetine|
11583968|NCT00761280|Experimental|trabedersen 10 µM|10 µM trabedersen (AP 12009), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
11583969|NCT00761280|Active Comparator|Chemotherapy|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle, up to 26 cycles; carmustine: i.v. administration, up to 200 mg/sqm/day, 1 day per cycle, up to 8 cycles; lomustine: capsules, 110 mg/sqm/day, 1 day per cycle, up to 8 cycles. Only 1 of these 3 drugs/interventions is administered per patient in the comparator arm.
11583970|NCT00761267|Experimental|Anidulafungin IV|All subjects meeting screening criteria will receive IV anidulafungin.
11583971|NCT00761228|Active Comparator|Apomorphine|Patients will receive an ascending dosing schedule to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
11583972|NCT00761228|Placebo Comparator|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
11583973|NCT00761215|Experimental|TR-701 200 mg|
11583974|NCT00761215|Experimental|TR-701 300 mg|
11583975|NCT00761215|Experimental|TR-701 400 mg|
11583976|NCT00761202|Active Comparator|1|Optive Eyedrops
11583977|NCT00761202|Active Comparator|2|Hylocomod Eyedrops
11583978|NCT00761189|Experimental|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
11583979|NCT00761176|No Intervention|Standard of Care|Standard of Care will be utilized without the device.
11583980|NCT00761176|Other|The Provant Therapy System|Thirty minutes, twice daily treatment
11583981|NCT00761163|Experimental|1|
11583982|NCT00761163|Experimental|2|
11583983|NCT00761163|Experimental|3|
11583984|NCT00761150|Experimental|Open-label ABT-712|2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks (open-label period).
11583985|NCT00761150|Experimental|Double-blind ABT-712|2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period).
11583986|NCT00761150|Placebo Comparator|Double-blind Placebo|2 placebo tablets, twice daily, for 4 weeks (double-blind period).
11583987|NCT00761137|Experimental|Tropicamide placebo|subject received (blinded) each of the 4 drug doses at different visits - 0 mg tropicamide, 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide
11583988|NCT00761137|Experimental|Tropicamide 0.3 mg|subject received (blinded) each of the 4 drug doses at different visits - 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide, 0 mg tropicamide
11583989|NCT00761137|Experimental|Tropicamide 1 mg|subject received (blinded) each of the 4 drug doses at different visits - 1 mg tropicamide, 3 mg tropicamide, 0 mg tropicamide, 0.3 mg tropicamide
11583990|NCT00761137|Experimental|Tropicamide 3 mg|subject received (blinded) each of the 4 drug doses at different visits - 3 mg tropicamide, 0 mg tropicamide, 0.3 mg tropicamide, 1 mg tropicamide
11583991|NCT00761124|Experimental|1|Educational small group session regarding prostate cancer
11583992|NCT00761124|Other|2|Printed material regarding general prostate cancer information provided.
11583993|NCT00761098|Active Comparator|1|Standard Care (albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
11583994|NCT00761098|Experimental|2|Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
11583995|NCT00761085|Active Comparator|Methadone-Children|Methadone comparison to standard of care for pain management
11583996|NCT00761085|Active Comparator|Morphine-Children|Morphine standard of Care pain management
11583997|NCT00761085|Active Comparator|Methadone-Adults|Methadone comparison to standard of care for pain management
11583998|NCT00761085|Active Comparator|Morphine-Adults|Morphine standard of Care pain management
11583999|NCT00761072||1|The source of data will be from spinal surgery procedures performed at CHOP from 4/1/07 to 3/31/08 using a TIVA anesthetic technique of propofol/remifentanil infusions
11584000|NCT00761059|Active Comparator|Glucose 20%|
11584001|NCT00761059|Placebo Comparator|placebo|
11584002|NCT00761033|Experimental|music|children will listen to music during procedure
11584003|NCT00761033|Other|Standard care|Standard care
11584004|NCT00761020|Experimental|Mefloquine|Mefloquine 250 mg orally daily x 3 days beginning 2 days prior to challenge and then weekly for 4 weeks post challenge.
11584005|NCT00761020|Sham Comparator|Control|
11584006|NCT00761007|Experimental|Ibodutant 10 mg|
11584007|NCT00761007|Experimental|Ibodutant 30 mg|
11584008|NCT00761007|Experimental|Ibodutant 60 mg|
11584009|NCT00761007|Placebo Comparator|Placebo|
11584010|NCT00760994|Experimental|1 - Experiential Accepatance|Experiential acceptance
11584011|NCT00760994|Active Comparator|2 - Cognitive Restructuring|Cognitive restructuring
11584012|NCT00760994|Placebo Comparator|3 - Control|No-intervention control: Nutrition information
11584013|NCT00760981|Experimental|Imatinib|200 mg orally daily and 400 mg orally daily for 4 weeks.
11584014|NCT00760968|Experimental|TAK-783 100 mg QD + Methotrexate|
11584015|NCT00760968|Active Comparator|Methotrexate|
11584016|NCT00760955|Experimental|TAK-583 5 mg QD|
11584017|NCT00760955|Experimental|TAK-583 50 mg QD|
11584018|NCT00760955|Experimental|TAK-583 100 mg QD|
11584019|NCT00760955|Placebo Comparator|Placebo QD|
11584020|NCT00760942|Active Comparator|1|Liquid human milk fortifier
11584021|NCT00760942|Active Comparator|2|Powdered human milk fortifier
11584022|NCT00760929|Placebo Comparator|Placebo for R1507 (16mg/kg iv)|
11584023|NCT00760929|Placebo Comparator|Placebo for R1507 (9mg/kg iv)|
11584024|NCT00760929|Experimental|R1507 (16mg/kg iv)|
11584025|NCT00760929|Experimental|R1507 (9mg/kg iv)|
11584026|NCT00760916|Placebo Comparator|Placebo|placebo
11584027|NCT00760916|Active Comparator|UT-15C 0.25 mg|UT-15C 0.25 mg
11584028|NCT00760916|Active Comparator|UT-15C 1 mg|UT-15C 1 mg
11584029|NCT00760916|Active Comparator|UT-15C 5 mg|UT-15C 5 mg
11584030|NCT00760903||> 18 years moderate head trauma|Group I: (Pilot group): 5-10 patients > 18 years old, gender and race indifferent with moderate head trauma.
11584031|NCT00760903||> 18, gender and race indifferent|Group II: 30 patients > 18 years old, gender, and race indifferent with moderate head trauma
11584032|NCT00760903||Pediatric|Group III: 30 patients < 18 years old, gender and race indifferent with moderate head trauma (pediatric patient group)
11584033|NCT00760903||Pre-evaluated|Group IV: 10-20 patients age, gender and race indifferent with moderate head trauma that have been examined with conventional MRI of the brain, MRS and DTI as clinically requested. The images of these patients will be evaluated retrospectively for data- point collection.
11584034|NCT00760903||Control Group|Group V (control group): 20 volunteers without prior history of traumatic brain injury or neurological problems.
11584035|NCT00760890|Experimental|A|Medicinal Iron
11584036|NCT00760890|Experimental|B|Iron fortified wet pack cereal
11584037|NCT00760890|No Intervention|C|Control
11584038|NCT00760877|Experimental|Nilotinib|Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.
11584039|NCT00760877|Active Comparator|Imatinib|Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.
11584040|NCT00760864|Experimental|TAK-715 25 mg BID|
11584041|NCT00760864|Experimental|TAK-715 50 mg BID|
11584042|NCT00760864|Experimental|TAK-715 100 mg BID|
11584043|NCT00760864|Active Comparator|Methotrexate|
11584044|NCT00760851|Experimental|1|Bb-12 supplemented strawberry yogurt drink
11584045|NCT00760851|Placebo Comparator|2|Regular strawberry yogurt drink with no Bb-12 added
11584046|NCT00760838|Experimental|Azithromycin|"Azithromycin 250 mg
~1x/day during 5 days 3x/week afterwards"
11584047|NCT00760838|Placebo Comparator|placebo|"Placebo
~1x/day during 5 days 3x/week afterwards"
11584048|NCT00760825|Experimental|Vaccine|killed bivalent (O1 and O139)whole cell oral cholera vaccine(Shanchol™)
11584049|NCT00760812|Experimental|1|This group will first receive the Early Social Interaction Project parent-implemented intervention (PII) for 9 months, followed by the Early Social Interaction Project information, education, and support (IES) intervention for 9 months.
11584050|NCT00760812|Experimental|2|The group will first receive IES for 9 months, followed by PII for 9 months.
11584051|NCT00760799|Active Comparator|1|Standard discectomy without anular repair
11584052|NCT00760799|Experimental|2|Standard Discectomy with anular repair
11584053|NCT00760786|Active Comparator|1|Intensive lipid lowering plus Omega3-fatty acid
11584054|NCT00760786|Active Comparator|2|Moderate lipid lowering plus Omega3-fatty acid
11584055|NCT00760786|Active Comparator|3|Intensive lipid lowering plus placebo
11584056|NCT00760786|Active Comparator|4|Moderate lipid lowering plus placebo
11584057|NCT00760773|Experimental|1|
11584058|NCT00760773|Experimental|2|
11584059|NCT00760773|Placebo Comparator|3|
11584060|NCT00760760|Experimental|n-3 PUFA|
11584061|NCT00760760|Placebo Comparator|Control|
11584062|NCT00760747|Experimental|Slow Switching Group|Slow Switching Group (switch from full stimulant dose to atomoxetine, 1.2 mg/kg/day, orally (PO), during 10 weeks then continue treatment up to 1.8 mg/kg/day, PO to 14 weeks
11584063|NCT00760747|Experimental|Fast Switching Group|Fast Switching Group (switch from full stimulant dose to atomoxetine 1.2 mg/kg/day, PO, during 2 weeks then continue treatment up to 1.8 mg/kg/day, PO to 14 weeks
11584064|NCT00760734|Experimental|Hyperbaric oxygen therapy-TBI/PCS|Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT
11584065|NCT00760734|Experimental|Hyperbaric Oxygen Therapy-PCS/PTSD|Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT
11584066|NCT00760721|Experimental|1|Educational small group session with HBV screening resources provided
11584067|NCT00760721|Sham Comparator|2|Educational small group discussion, diet/physical activity resources provided
11584068|NCT00760708||undergoing persantine stress test|
11584069|NCT00760695|Active Comparator|A|the patients in this arm are receiving 2,5 mg dronabinol twice daily
11584070|NCT00760695|Placebo Comparator|B|the patients in this arm are receiving 2,5 mg placebo twice daily
11584071|NCT00760682|Experimental|1|30 preoperative HBO sessions, sequestrectomy and 10 postoperative HBO sessions. The duration of each session is 90 minutes. 100 % oxygen is inhaled during decompression to 2.4 ATA.
11584072|NCT00760682|No Intervention|2|Sequestrectomy without HBO treatment
11584073|NCT00760669||Participants Receiving Infiximab|Participants with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PA) receiving infliximab injection will be observed.
11584074|NCT00760656||Research Participants|Participants with a diagnosis of childhood malignancy treated or followed at SJCRH
11584075|NCT00760656||Control Participants|Siblings, parents, relatives or friends of St. Jude patients or former patients or SJCRH employees who are not SJLIFE study team members or supervised by a SJLIFE study team members
11584076|NCT00760630|Experimental|CDP LFC|all patients will have this calculation based upon diagnostic parameters with IVUS and FFR and/or CFR
11584077|NCT00760617|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A
11584078|NCT00760617|Active Comparator|Fluarix elderly Group|Subjects aged ≥65 years received 1 dose of Fluarix vaccine
11584079|NCT00760617|Active Comparator|Fluarix young Group|Subjects aged 18-40 years received 1 dose of Fluarix vaccine
11584080|NCT00760604|Active Comparator|A|En bloc esophagectomy is performed through a transthoracic approach by removing the tumor-bearing esophagus, the pericardium anteriorly, both pleural surfaces laterally, as well as the thoracic duct and all other lymphoareolar tissue wedged posteriorly between the esophagus and the spine, and en-bloc resection of all nodal groups in the middle and lower mediastinum as well as the upper abdomen.
11584151|NCT00760162||2. Nephrology Associates,|Scarborough, ON CANADA, LI H IC5
11584152|NCT00760162||3.New York Harbor VA Medical Center|NYU School of Medicine New York, NY.10010
11584081|NCT00760604|Active Comparator|B|Transhiatal esophagectomy is performed through an abdominal incision and a neck incision. The stomach is mobilized, and the left gastric vessels are transected at its origin. Celiac lymph nodes are dissected, and the intrathoracic esophagus is dissected bluntly through the hiatus and through the neck. The cervical esophagus is divided at the level of the neck. After the esophagogastrectomy is performed, a gastric tube is created. An esophagogastrostomy is then performed in the neck. If a transthoracic approach is used, dissection will be as described for the transhiatal approach.
11584082|NCT00760578|Placebo Comparator|Placebo|Microcrystaline cellulose once daily
11584083|NCT00760578|Active Comparator|Pioglitazone|Pioglitazone 45 mg once daily
11584084|NCT00760578|Experimental|MSDC-0160 90 mg|MSDC-0160 90 mg once daily
11584085|NCT00760578|Experimental|MSDC-0160 220 mg|MSDC-0160 220 mg once daily
11584086|NCT00760565|Experimental|1|
11584087|NCT00760565|Placebo Comparator|10|
11584088|NCT00760565|Experimental|11|
11584089|NCT00760565|Placebo Comparator|12|
11584090|NCT00760565|Placebo Comparator|2|
11584091|NCT00760565|Experimental|3|
11584092|NCT00760565|Placebo Comparator|4|
11584093|NCT00760565|Experimental|5|
11584094|NCT00760565|Placebo Comparator|6|
11584095|NCT00760565|Experimental|7|
11584096|NCT00760565|Placebo Comparator|8|
11584097|NCT00760565|Experimental|9|
11584098|NCT00760552|Active Comparator|Arm 1|VA patients with uncontrolled HTN.
11584099|NCT00760552|Active Comparator|Arm 2|VA patients with uncontrolled HTN.
11584100|NCT00760539|Experimental|Travoprost/Timolol BAC-free|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
11584101|NCT00760539|Active Comparator|Travoprost/Timolol|Travoprost 0.004%/Timolol 0.5% ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
11584102|NCT00760526|Active Comparator|1|continuous glucose monitoring
11584103|NCT00760526|Active Comparator|2|Standard glucose monitoring with a home glucose meter
11584104|NCT00760513|Active Comparator|Omega 3 fatty acid (fish oil)|OMACOR (alternative name: Lovaza) 4 grammes daily, oral capsule
11584105|NCT00760513|Placebo Comparator|dummy pill|4 grammes daily, oral capsule (olive oil)
11584106|NCT00760500||1|
11584107|NCT00760487|Experimental|AcrySof Toric IOL|AcrySof Toric Intraocular Lens (IOL)
11584108|NCT00760474|Experimental|Pregabalin, then placebo|
11584109|NCT00760474|Experimental|Placebo, then pregabalin|
11584110|NCT00760461|Other|Domperidone|
11584111|NCT00760435|Experimental|1|Infliximab plus Intravenous immunoglobulin (IVIG)
11584112|NCT00760435|Placebo Comparator|2|Placebo plus IVIG
11584113|NCT00760422||With fever|
11584114|NCT00760422||Without fever|
11584115|NCT00760409||Radiation Injury|Radiation Injury Recurrent symptoms after radiation therapy of a brain tumor are not always the result of tumor recurrence but may represent radiation necrosis of the brain.
11584116|NCT00760409||Tumor Recurrence|Symptoms are the result of actual tumor recurrence
11584117|NCT00760396|Experimental|Group 1|40mg QD dose group
11584118|NCT00760396|Experimental|Group 2|100mg QD dose group
11584119|NCT00760396|Experimental|Group 3|200mg QD dose group
11584120|NCT00760396|Experimental|Group 4|200mg BID dose group
11584121|NCT00760383|Experimental|EAA+PT|20 g EAA daily for 7 days prior to TKA surgery and for 14 days after surgery.
11584122|NCT00760383|Placebo Comparator|ALA+PT|20 g NEAA daily for 7 days prior to TKA surgery and for 14 days after surgery.
11584123|NCT00760357||Retrospective Anaylsis|Once the patients are identified that have a full thickness wound on a limb clearly identified as having critical limb ischemia, these patients will be evaluated
11584124|NCT00760344|Experimental|SYR-472 3.125 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
11584125|NCT00760344|Experimental|SYR-472 12.5 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
11584126|NCT00760344|Experimental|SYR-472 50 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
11584127|NCT00760344|Experimental|SYR-472 100 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
11584128|NCT00760344|Placebo Comparator|Placebo QD|(with lifestyle modification and/or metformin stable dose therapy)
11584129|NCT00760344|Active Comparator|Sitagliptin 100 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
11584130|NCT00760305|Experimental|1|Patients who received the Pro-Self psychoeducational intervention
11584131|NCT00760305|No Intervention|2|Patients who received standard care
11584132|NCT00760292||1|Type 2 Diabetic Patients
11584133|NCT00760292||2|Non-diabetic individuals
11584134|NCT00760266|Experimental|Aliskiren/HCTZ 300/25 mg|
11584135|NCT00760266|Active Comparator|HCTZ 25 mg|
11584136|NCT00760253||1|pure propofol by TCI pump with titration.
11584137|NCT00760253||2|10ug/kg alfentanyl bolus and propofol TCI pump infusion with titration
11584138|NCT00760253||3|20ug/kg alfentanyl bolus and propofol TCI pump infusion with titration
11584139|NCT00760240||Glaucoma patients|This is a group of patients with restricted visual fields or ETDRS visual acuity of 20/60 or worse
11584140|NCT00760240||Retina patients|A group of patients with retinal pathology(ARMD, CME, diabetic retinopathy) contributing to their decreased vision.
11584141|NCT00760227|Other|1: HPI-C|Child Intervention Only Group
11584142|NCT00760227|Other|2: HPI-CP|Parent and Child Intervention Group
11584143|NCT00760227|No Intervention|3: SC|Standard Care Control Group- No Intervention
11584144|NCT00760214|Experimental|Azilsartan Medoxomil 40 mg QD|
11584145|NCT00760214|Experimental|Azilsartan Medoxomil 80 mg QD|
11584146|NCT00760214|Active Comparator|Ramipril 10 mg QD|
11584147|NCT00760201||1|Hospital executives, physician administrators and hospital legal counsel
11584148|NCT00760175|Active Comparator|intradermal|
11584149|NCT00760175|Active Comparator|intramuscular|
11584150|NCT00760162||HSCB, Brooklyn, NY|State University of New York Brooklyn, NY 11203
11584153|NCT00760162||4.Hospital Juarez De Mexico|Madero, Mexico, D.FC.P. 07760
11584154|NCT00760162||5. Hospital Italiano de Buenos Aires|Buenos Aires, Argentina.
11584155|NCT00760162||6. National Hospital|Abuja, Nigeria
11584156|NCT00760149|Placebo Comparator|1|50 patients, treated with the standard anti-TB regimen, including rifampicin (600 mg), isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 2 placebo tablets resembling rifampicin 300 mg.
11584157|NCT00760149|Active Comparator|2|50 patients, treated with rifampicin (900 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 1 placebo tablet resembling rifampicin 300 mg.
11584158|NCT00760149|Active Comparator|3|50 patients, treated with rifampicin (1200 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment.
11584159|NCT00760123|Experimental|1|Early Physical Therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors, etc.
11584160|NCT00760123|Other|2|Educational Strategy: instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors, etc.
11584161|NCT00760110||1 Morning hypertension and normotension|Based on HBP, subjects were divided into MH and MN patients
11584162|NCT00760110||2 Clinic hypertension and normotension|Based on CBP, subjects were divided into CH and CN patients
11584163|NCT00760097|Experimental|AtCDS|Transcranial direct stimulation
11584164|NCT00760084|Experimental|A|Decitabine will be administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks.
11584165|NCT00760071||1CF-patients<6|Patients with diagnoses of cystic fibrosis from birth to the age of 6 years
11584166|NCT00760071||2 controls|age matched controls
11584167|NCT00760058|Experimental|1|AcrySof® IQ intraocular lens
11584168|NCT00760058|Active Comparator|2|Tecnis® Aspheric intraocular lens
11584169|NCT00760058|Active Comparator|3|Akreos® MI60 intraocular lens
11584170|NCT00760045|Experimental|1|AL-43546 0.15%
11584171|NCT00760045|Experimental|2|AL-43546 0.25%
11584172|NCT00760045|Active Comparator|3|AL-43546 0%(Vehicle)
11584173|NCT00760045|Active Comparator|4|0.1% sodium hyaluronate ophthalmic solutio
11584174|NCT00760032|Experimental|Active|Ciprofloxacin
11584175|NCT00760032|Placebo Comparator|Placebo|Placebo
11584176|NCT00760019|Active Comparator|Salsalate first, then Placebo|In this crossover study, this group was randomly allocated therapy with salsalate first, a 4 week washout, then 4 weeks of placebo therapy in a double-blinded fashion.
11584177|NCT00760019|Placebo Comparator|Placebo first, then Salsalate|In this crossover study, this group was randomly allocated therapy with placebo first, a 4 week washout, then 4 weeks of salsalate therapy in a double-blinded fashion.
11584178|NCT00760006|Active Comparator|Unasyn Antibiotic Arm|Unasyn® is a parenteral antibiotic that combines ampicillin with sulbactam, a beta-lactamase inhibitor. All subjects enrolled in the study will receive a single dose of antibiotic or saline solution (placebo control) intravenously, as the IV will already be in place as standard of care for surgery. The study aims to assess the efficacy of the prophylactic antibiotic in cleft surgery to: decrease the incidence of surgical site infections, speed the progression of postoperative healing, improve the final quality of wound healing achieved, and decrease the rate of palatal fistula formation.
11584179|NCT00760006|Placebo Comparator|Saline Placebo Arm|Saline Placebo. All subjects enrolled in the study will receive a single dose of antibiotic or saline solution (placebo control) intravenously, as the IV will already be in place as standard of care for surgery. This will act as the placebo control.
11584180|NCT00759993|Experimental|A,1|chromium piccolinate 1000mg
11584181|NCT00759993|Placebo Comparator|A,2|matching placebo
11584182|NCT00759980||Platelet Number|Infants randomized to this group will be transfused based on a specific set of transfusion guidelines pertaining to the total number of platelets
11584183|NCT00759980||Platelet Mass|Infants randomized to this group will be transfused based on a specific set of transfusion guidelines pertaining to a combination of platelet number and platelet size (mass)
11584184|NCT00759967|Active Comparator|Short daily hemodialysis|After a 3 month run-in period patients who are randomized to this arm will receive 3 months of short daily hemodialysis(2 hours/day,6 days/week)B/P will be monitored according to the Canadian hypertension guidelines both pre and post each dialysis session. Antihypertensive medication will be adjusted accordingly to maintain BP within the guidelines.At the end of this 3 month period extracellular fluid volume (bioimpedance) will be measured using bioimpedance as well as sympathetic nerve activity using microneurography. Additionally Catecholamines as well as markers of oxidative stress will be collected.
11584185|NCT00759967|Active Comparator|Conventional hemodialysis|After a 3 month run-in period patients who are randomized to this arm will receive 3 months of conventional hemodialysis 3 days/week 3.5-4 hours/ treatment. BP will be monitored according to the Canadian hypertension guidelines both pre and post each dialysis session. Antihypertensive medication will be adjusted accordingly to maintain BP within the guidelines.At the end of this 3 moth period extracellular fluid volume (bioimpedance) will be measured using bioimpedance as well as sympathetic nerve activity using microneurography. Additionally Catecholamines as well as markers of oxidative stress will be collected.
11584186|NCT00759954|Other|1|Treatment A (test product) followed by Treatment B (reference product)
11584187|NCT00759954|Other|2|Treatment B (reference product) followed by Treatment A (test product)
11584188|NCT00759941|Experimental|Xalatan + Azopt|Xalatan dosed once a day at 10 pm, with Azopt dosed three times a day at 8 AM, 2 PM, and 10:05 PM as an adjunctive therapy for 3 months.
11584189|NCT00759941|Active Comparator|Xalatan + Placebo|Xalatan dosed once a day at 10 pm, with placebo dosed three times a day at 8 AM, 2 PM, and 10:05 PM concomitantly for 3 months.
11584190|NCT00759928|Experimental|Erlotinib/Sorafenib|Patients will receive erlotinib 150 mg once daily by mouth and sorafenib 400 mg twice daily by mouth. The study will begin with a 2-week run-in period (which will begin on Day 14 of the study, and continue through Day 1 of the study), in which erlotinib will be dosed alone at 150 mg once daily. Patients will continue taking erlotinib as a single agent at 150 mg once daily through Day 1. After the 2-week run-in period, patients will receive continuous dosing of both agents (erlotinib 150 mg once daily and sorafenib 400 mg twice daily) in cycles of 28 days each. Toxicity will be assessed every cycle (every 4 weeks) for all patients. Because this is not an efficacy study, restaging tumor measurements will be at the discretion of the physician every 8 weeks during treatment. Patients with objective response or stable disease will continue therapy; patients with disease progression or unacceptable toxicity will be discontinued from the study.
11584191|NCT00759915|Other|1|Treatment A (test product) followed by Treatment B (reference product)
11584192|NCT00759915|Other|2|Treatment B (reference product) followed by Treatment A (test product)
11584193|NCT00759902|Other|1|Treatment A (test product) followed by Treatment B (reference product)
11584194|NCT00759902|Other|2|Treatment B (reference product) followed by Treatment A (test product)
11584195|NCT00759889||wound biopsy|diabetic foot,venous leg ulcer, decubitus ulcer
11584196|NCT00759876|Experimental|Ataluren|Participants will receive ataluren 3 times per day with meals at doses of 20 milligrams per kilogram (mg/kg) (breakfast), 20 mg/kg (lunch), and 40 mg/kg (dinner) for up to 89 weeks.
11584197|NCT00759863|Experimental|Lifezig|Subjects watch personalized reminiscence video channels developed by program staff with the help of family members/caregivers (using the LifeZig system)
11584198|NCT00759863|No Intervention|Usual Care|Subjects follow routine activities applied by nurses or caregivers, such as traditional reminiscence, crafts, singing, recreational activities, and other activities.
11584199|NCT00759850|Active Comparator|A|Patient with ST elevation myocardial infarction randomly assigned to receive a Bare Metal Stent n=90)
11584200|NCT00759850|Experimental|B|Patient with ST elevation myocardial infarction randomly assigned to receive a Paclitaxel Eluting Stent (n=90)
11584201|NCT00759850|Experimental|C|Patient with ST elevation myocardial infarction randomly assigned to receive a Sirolimus Eluting Stent (n=90)
11584202|NCT00759837|Experimental|1|
11584203|NCT00759824|Experimental|1|Chemotherapy regimen (adriamycin, cyclophosphamide, vindesine) plus valproic acid
11584204|NCT00759811|Experimental|Methotrexate|Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.
11584205|NCT00759811|Placebo Comparator|Placebo|Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.
11584206|NCT00759798|Experimental|Fludarabine, Cyclophosphamide, Rituximab|"Fludarabine 25 mg/m^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond. Cyclophosphamide 250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond. Rituximab 375 mg/m2 given intravenously on Day 1 of Course 1
~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
11584207|NCT00759785|Experimental|ER-positive Luminal B|Single dose of dalotuzumab 20 mg/kg infused intravenously over 60-120 minutes.
11584208|NCT00759785|Experimental|Triple Negative|Single dose of dalotuzumab 20 mg/kg infused intravenously over 60-120 minutes.
11584209|NCT00759772|Active Comparator|Teriparatide|
11584210|NCT00759772|Placebo Comparator|Placebo|
11584211|NCT00759759|Other|1|Treatment A (test product) followed by Treatment B (reference product)
11584212|NCT00759759|Other|2|Treatment B (reference product) followed by Treatment A (test product)
11584213|NCT00759746|Active Comparator|Weight Maintenance Education|Participants assigned to this group will receive the Weight Maintenance Education intervention. They will meet every other week during the maintenance phase of the study for a total of 16 sessions over 8 months. During the visit, participants will participate in a series of interactive workshops within child and parent groups to learn general information about healthy eating and physical activity.
11584214|NCT00759746|Experimental|SFM+ Low Dose|Participants assigned to this group will receive the SFM+ Low Dose.
11584215|NCT00759746|Experimental|SFM+ High Dose|Participants assigned to this group will receive the SFM+ High Dose.
11584216|NCT00759733||1|Pregnant women with a history of cardiac disease (study group)
11584217|NCT00759733||2|Pregnant women with no history of heart disease (control group)
11584218|NCT00759720|Experimental|TAK-559 16 mg QD + Glyburide QD|
11584219|NCT00759720|Experimental|TAK-559 32 mg QD + Glyburide QD|
11584220|NCT00759720|Active Comparator|Glyburide QD|
11584221|NCT00759707|Experimental|1|ultrasound imaging of saphenous vein bypass graft following an ischemic stimulus, administration of sublingual nitroglycerin and intravenous administration of L-NMMA.
11584222|NCT00759681|Active Comparator|Control|Gelfoam and Thrombin
11584223|NCT00759681|Experimental|Investigational Device|ArterX Surgical Sealant
11584224|NCT00759668|Experimental|SN60D3|AcrySof Natural ReSTOR Intraocular Lens (IOL) Model SN60D3
11584225|NCT00759668|Active Comparator|SN60AT|AcrySof Natural Monofocal Intraocular Lens (IOL) Model SN60AT
11584226|NCT00759655|Other|open label|
11584227|NCT00759642|Experimental|Lapatinib|lapatinib
11584228|NCT00759629|Experimental|A|Interventional treatment group - Patients assigned to PCI will receive the loading dose of clopidogrel, aspirin plus a bolus of heparin and be transferred immediately for interventional treatment. They will receive abciximab as a bolus followed by a continuous infusion of for 12 hours.
11584229|NCT00759629|Active Comparator|B|Conservative treatment group - Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards.
11584230|NCT00759616|Experimental|1|
11584231|NCT00759603|Experimental|Lenalidomide + Rituximab|Oral Lenalidomide 10 mg/day started on Day 9 of cycle 1; Rituximab 375 mg/m^2 intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2. Treatment duration twelve cycles.
11584232|NCT00759590||1|ALI/ARDS patients
11584233|NCT00759577|Other|Home titration|Patients were given drug to self titrate
11584234|NCT00759564|Experimental|IV CP-70,429 and cross over to PF-03709270|
11584235|NCT00759551|Experimental|Azilsartan 2.5 mg QD|
11584236|NCT00759551|Experimental|Azilsartan 5 mg QD|
11584237|NCT00759551|Experimental|Azilsartan 10 mg QD|
11584238|NCT00759551|Experimental|Azilsartan 20 mg QD|
11584239|NCT00759551|Experimental|Azilsartan 40 mg QD|
11584240|NCT00759551|Placebo Comparator|Placebo QD|
11584241|NCT00759551|Active Comparator|Olmesartan 20 mg QD|
11584242|NCT00759538||1|lung transplant patients performing a three week lasting rehabilitation program
11584243|NCT00759525|Active Comparator|1|Glycyrrhetic Acid
11584244|NCT00759525|Placebo Comparator|2|Placebo
11584245|NCT00759512|Active Comparator|Arm 1|This arm received the Kreiger/Kunz method of Therapeutic Touch in addition to Standard of Care
11584246|NCT00759512|No Intervention|Arm 2|Standard of Care
11584247|NCT00759499||Debridement|The intent of this protocol is to salvage wound material that is normally destined for destruction, so it can be used in wound-related scientific studies. This clinical wound material can be studied in order to better understand the molecular, cellular, or ecological components of the wound system. These studies may be able to provide important insights into the keys of wound healing, wound persistence, or wound deterioration.
11584248|NCT00759473|Placebo Comparator|Placebo/Placebo/Placebo/Placebo|Participants were assigned to receive placebo for each of 3 cue exposure sessions and at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
11584249|NCT00759473|Experimental|DCS/DCS/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) for each of 3 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
11584250|NCT00759473|Other|DCS/Placebo/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) at the first and third cue exposure sessions and a placebo at the second cue exposure and the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
11584251|NCT00759473|Experimental|DCS/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) for each of 2 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities. Cue exposure sessions were accompanied by instructions on coping with craving.
11584252|NCT00759473|Active Comparator|Placebo/Placebo/Placebo|Participants were assigned to placebo for each of 2 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities. Cue exposure sessions were accompanied by instructions on coping with craving.
11584253|NCT00759460|Experimental|1|
11584254|NCT00759460|Active Comparator|2|
11584255|NCT00759447||3D investigational imaging|Patients enrolled will be imaged with a 3D mammogram in one of 3 speeds of acquisition
11584256|NCT00759447||3D Imaging with commercial Mammography Device|
11584257|NCT00759434|Active Comparator|Surgery|
11584258|NCT00759434|Experimental|EVLT|
11584259|NCT00759421|Experimental|1|
11584260|NCT00759421|Active Comparator|2|
11584261|NCT00759408|Experimental|1|BQ-123
11584262|NCT00759395|Experimental|AZD2327|AZD2327 3mg BID
11584263|NCT00759395|Placebo Comparator|Placebo|Placebo BID
11584264|NCT00759382||I|Patients with non-small cell lung carcinoma treated with curative intent
11584265|NCT00759369|Experimental|1|Water prescription
11584266|NCT00759356|Other|1|Treatment A (test product) followed by Treatment B (reference product)
11584267|NCT00759356|Other|2|Treatment B (reference product) followed by Treatment A (test product)
11584268|NCT00759343||Control Group|"The control subjects of this study will be asked to undergo renal ultrasound examination, if available, or will be asked to complete a disease history form to determine the presence or lack of a kidney stone. Urine and serum will then be taken for storage until further analysis.
~Controls will be asked to undergo a screening renal ultrasound to ensure they are stone free, this will take approximately 45 minutes. If the controls are asked to complete the history form, this will not take more than 20 minutes. They will also give a blood and urine sample during this time to bring the total extra time up to at most 60 minutes for controls."
11584269|NCT00759343||Stone Group|"The stone group will undergo standard diagnostic procedures for their condition and recovery process. Serum and urine for storage and analysis will be taken prior to stone treatment and 6 weeks following stone treatment. This will allow for the determination of differences in a stone patient's protein profile while they have their stone and after they are stone free. All patients will be required to have a stone patient metabolic evaluation which includes serum and urine testing. The analysis will focus on the serum and urine sample that they provide.
~The stone patient will be asked to undergo one extra tube of blood during their preoperative assessment which should only add a few seconds to their visit."
11584270|NCT00759330|Placebo Comparator|Placebo Tape (Arm 1)|Placebo tape remained on for 12 hours of continuous treatment per day.
11584271|NCT00759330|Experimental|Flurbiprofen Tape (Arm 2)|Flurbiprofen tape remained on for 12 hours of continuous treatment per day.
11584272|NCT00759330|Placebo Comparator|Placebo Tape (Arm 3)|Placebo tape remained on for 24 hours of continuous treatment per day.
11584273|NCT00759330|Experimental|Flurbiprofen Tape (Arm 4)|Flurbiprofen tape remained on for 24 hours of continuous treatment per day.
11584274|NCT00759317|Active Comparator|1|venlafaxine
11584275|NCT00759317|Placebo Comparator|2|
11584276|NCT00759304||PROOF cohort|Healthy inhabitants of the city of Saint-Etienne, France, and aged 65 years at the inclusion date.
11584277|NCT00759291|Active Comparator|Acipimox|Acipimox treatment QID for 7 days
11584278|NCT00759291|Placebo Comparator|Placebo|Placebo treatment QID for 7 days
11584279|NCT00759278||1|Group of 30 women who are pregnant as subjects that take antihypertensive medication
11584280|NCT00759278||2|Group of 30 women who are pregnant and do not take antihypertensive medications as a control group
11584281|NCT00759265|Experimental|resistance training|"During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).
~During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home."
11584282|NCT00759265|No Intervention|control|No intervention was prescribed
11584283|NCT00759239|Experimental|1|One drop of Travoprost 0.004% / Timolol maleate 0.5% in each eye at 9 am and 1 drop of Timolol vehicle as placebo in each eye at 9 pm for 12 weeks.
11584284|NCT00759239|Experimental|2|One drop of Timolol vehicle as placebo in each eye at 9 am and one drop of Travoprost 0.004% / Timolol maleate 0.5% in each eye at 9 pm for 12 weeks.
11584285|NCT00759213||1|Any infant with a length of stay in the NICU of at least 7 days.
11584286|NCT00759200|Experimental|alb-interferon arm 1|
11584287|NCT00759200|Experimental|alb-interferon arm 2|
11584288|NCT00759200|Experimental|alb-interferon arm 3|
11584289|NCT00759200|Experimental|alb-interferon arm 4|
11584290|NCT00759200|Active Comparator|peg-interferon|
11584291|NCT00759187|Placebo Comparator|A|
11584292|NCT00759187|Active Comparator|B|
11584293|NCT00759187|Active Comparator|C|
11584294|NCT00759174||Case Group|
11584295|NCT00759161|Active Comparator|1|AN2728 Ointment, 5%
11584296|NCT00759161|Placebo Comparator|2|AN2728 Ointment Vehicle
11584297|NCT00759148|Experimental|Moxifloxacin AF|Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%, 1 drop in each eye twice daily for 3 days
11584298|NCT00759148|Placebo Comparator|Vehicle|Moxifloxacin AF vehicle, 1 drop in each eye twice daily for 3 days
11584299|NCT00759135|Experimental|1|Single therapeutic dose of 2.5 mg NX-1207
11584300|NCT00759135|Experimental|2|Single low dose of 0.125 mg NX-1207 for dose-response evaluation
11584301|NCT00759135|Active Comparator|3|5.0 mg finasteride q.d.
11584302|NCT00759122|Active Comparator|1|VENLAFAXINE
11584303|NCT00759122|Placebo Comparator|2|
11584304|NCT00759109|Experimental|Arm A - PegIntron|Participants randomized to Arm A received peginterferon α-2b (PegIntron), 50 μg, weekly, subcutaneously (SC), for a period of 3 years.
11584305|NCT00759109|Other|Arm B - Control|Participants randomized to Arm B were under observation and received no treatment.
11584306|NCT00759096|Experimental|Acrysof ReSTOR IOL|AcrySof ReSTOR Intraocular lens (IOL) implanted
11584307|NCT00759083|Experimental|1|Patients with HIT/HITTS who require anticoagulation for PCI
11584308|NCT00759070|Active Comparator|1|Tenofovir (TDF) + emtricitabine (FTC) + efavirenz (EFV)
11584309|NCT00759070|Active Comparator|2|Tenofovir (TDF) + emtricitabine (FTC) + lopinavir/ritonavir (LPV/RTV)
11584310|NCT00759057|Experimental|1 - Investigational|Dynesys Non-Fusion Spinal System
11584311|NCT00759057|Active Comparator|2 - Control|Silhouette Posterior Pedicle Screw System as an adjunct to Posterior Lateral Fusion with Autograft.
11584312|NCT00759044||AMD|Patients diagnosed with AMD
11584313|NCT00759044||DME|Patients diagnosed with DME
11584314|NCT00759031|Placebo Comparator|A - Marketed fluoride toothpaste|
11584315|NCT00759031|Active Comparator|B -Triclosan/NaF/CoPolymer toothpaste|
11584316|NCT00759005|Experimental|A, 4|
11584317|NCT00758992||Immunodeficient mice|Please see the Study Description for complete information.
11584318|NCT00758966|Experimental|NF (Naltrexone+Fluoxetine)|Naltrexone SR 32 mg and fluoxetine 60 mg
11584319|NCT00758966|Active Comparator|Fluoxetine|Fluoxetine 60 mg
11584320|NCT00758966|Active Comparator|Naltrexone|Naltrexone SR 32 mg
11584321|NCT00758953|Experimental|1|
11584322|NCT00758953|Experimental|2|
11584323|NCT00758953|Placebo Comparator|3|
11584324|NCT00758953|Placebo Comparator|4|
11584325|NCT00758940|Experimental|1|Acrysof ReSTOR multifocal IOL
11584326|NCT00758927|Placebo Comparator|2|Placebo administration for 10 weeks with exercise and diet therapy
11584327|NCT00758927|Experimental|1|Omacor 4 gram per day with exercise and diet therapy for 10 weeks
11584328|NCT00758901||1 ROCC Knee prosthesis|Consecutive series of patients with ROCC Knee prosthesis.
11584329|NCT00758888|Experimental|Treatment|Place the blocks under the pelvis for 2 minutes
11584330|NCT00758888|Active Comparator|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
11584331|NCT00758888|Sham Comparator|Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
11584332|NCT00758862|Experimental|1|
11584333|NCT00758849|Placebo Comparator|1|
11584334|NCT00758849|Active Comparator|2|
11584335|NCT00758836|Placebo Comparator|Placebo|Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine
11584336|NCT00758836|Experimental|Telcagepant 280 mg +Ibuprofen 400 mg|Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine
11584337|NCT00758836|Experimental|Telcagepant 280 mg +APAP 1000 mg|Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine
11584338|NCT00758836|Placebo Comparator|Telcagepant 280 mg|Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine
11584339|NCT00758810||1|Patients without cardiac rehabilitation
11584340|NCT00758810||2|Patients with cardiac rehabilitation
11584341|NCT00758797|Experimental|1|DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
11584342|NCT00758784|Experimental|bromfenac ophthalmic solution 0.06%|bromfenac ophthalmic solution 0.06% bilaterally twice a day
11584343|NCT00758771||Cystic Fibrosis|People who have been diagnosed with cystic fibrosis
11584344|NCT00758771||Healthy|People who do not have cystic fibrosis and who do not have any other lung conditions
11584345|NCT00758758|Experimental|Experimental Arm 1|Hedrocel 1 level - No plate
11584346|NCT00758758|Experimental|Experimental Arm 2|Hedrocel 1 level with plate
11584347|NCT00758758|Experimental|Experimental Arm 3|Hedrocel 2 levels with plate
11584348|NCT00758758|Active Comparator|Control Arm 1|Autograft alone - Illiac crest
11584349|NCT00758758|Active Comparator|Control Arm 2|Autograft 1 level with plate
11584350|NCT00758758|Active Comparator|Control Arm 3|Allograft 1 level with plate
11584351|NCT00758758|Active Comparator|Control Arm 4|Autograft 2 levels with plate
11584352|NCT00758758|Active Comparator|Control Arm 5|Allograft 2 levels with plate
11584353|NCT00758745|Active Comparator|Model SN60WF|Implantation with the AcrySof Model SN60WF Intraocular Lens (IOL)
11584354|NCT00758745|Active Comparator|Model MA60AC|Implantation with the AcrySof Model MA60AC Intraocular Lens (IOL)
11584355|NCT00758732|Experimental|1|Docetaxel/carboplatin
11584356|NCT00758732|Experimental|2|Docetaxel/Caelyx
11584357|NCT00758706|Experimental|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
11584358|NCT00758706|Placebo Comparator|Placebo|Dosing to match AZD1236
11584359|NCT00758693|Experimental|1|Bendamustine + Rituximab
11584360|NCT00758680|Experimental|MK-1006 20 mg Once Daily (Panel A)|After a 2-week run-in/wash-off period, participants received single daily doses (q.d.) of 20 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the Clinical Research Unit (CRU).
11584361|NCT00758680|Experimental|MK-1006 40 mg Once Daily (Panel B)|After a 2-week run-in/wash-off period, participants received single daily doses of 40 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
11584362|NCT00758680|Experimental|MK-1006 80 mg Once Daily (Panel C)|After a 2-week run-in/wash-off period, participants received single daily doses of 80 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
11584363|NCT00758680|Experimental|MK-1006 120 mg Once Daily (Panel D)|After a 2-week run-in/wash-off period, participants received single daily doses of 120 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
11584364|NCT00758680|Experimental|MK-1006 20 mg Twice Daily (Panel E)|After a 2-week run-in/wash-off period, participants received twice-daily doses (b.i.d.) of 120 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
11584365|NCT00758680|Experimental|MK-1006 30 mg Twice Daily (Panel F)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 30 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
11584366|NCT00758680|Experimental|MK-1006 50 mg Twice Daily (Panel G)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 50 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
11584367|NCT00758680|Experimental|MK-1006 120 mg Once Daily Outpatient (Panel H)|After a 2-week run-in/wash-off period, participants received single daily doses of 120 mg MK-1006 over a 7-day multiple-dosing period while remaining domiciled in the CRU. Participants were then discharged from the CRU and continued daily dosing of MK-1006 for an additional 21 days as outpatients.
11584368|NCT00758680|Experimental|MK-1006 50 mg Twice Daily Outpatient (Panel I)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 50 mg MK-1006 over a 7-day multiple-dosing period while remaining domiciled in the CRU. Participants were then discharged from the CRU and continued daily dosing of MK-1006 for an additional 21 days as outpatients.
11584369|NCT00758680|Placebo Comparator|Placebo|After a 2-week run-in/wash-off period, participants received dose-matched placebo to MK-1006 over a multiple-dosing period while remaining domiciled in the CRU.
11584370|NCT00758667|No Intervention|Standard treatment|Standard treatment
11584371|NCT00758667|Experimental|Use of Mesna|Standard surgical procedure with Mesna
11584372|NCT00758654||1|Patients with suspected or known stable coronary artery disease
11584373|NCT00758654||2|Healthy subjects as a control group
11584374|NCT00758641|Experimental|L-PRP Injection|L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
11584375|NCT00758641|Active Comparator|Steroid Injection|Corticosteroid injections
11584376|NCT00758628|Active Comparator|1|Bromfenac
11584377|NCT00758628|Placebo Comparator|2|Blink
11584378|NCT00758615|Experimental|I|Walking School Bus Intervention
11584379|NCT00758615|No Intervention|C|Usual school procedures for student transportation to school
11584380|NCT00758602|Active Comparator|MMF, Standard Dose Tacrolimus|Participants received mycophenolate mofetil (MMF) 0.75 to (-) 1 gram (g), orally (PO), twice daily (BID) from Day 0 through Month 12. Participants also received tacrolimus 0.1-0.15 milligrams per kilogram (mg/kg), PO, BID to reach a target trough dose of 8-10 nanograms per milliliter (ng/mL) from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12. Participants also received corticosteroids per center practice.
11584381|NCT00758602|Experimental|MMF, Low Dose Tacrolimus|Participants received MMF 0.75-1 g, PO, BID from Day 0 through Month 12. Participants also received tacrolimus 0.1-0.15 mg/kg, PO, BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to 0.05-0.08 mg/kg, PO, BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12. Participants also received corticosteroids per center practice.
11584382|NCT00758589|Experimental|AZD1981 50 mg|AZD1981 50 mg Twice Daily (Bid)
11584383|NCT00758589|Placebo Comparator|Placebo|Placebo
11584384|NCT00758589|Experimental|AZD1981 400 mg|AZD1981 400 mg Twice Daily (Bid)
11584385|NCT00758589|Experimental|AZD1981 1000 mg|AZD1981 1000 mg Twice Daily (Bid)
11584386|NCT00758576|Experimental|SN6AD1|AcrySof ReSTOR Model SN6AD1 Intraocular Lens
11584387|NCT00758563|Placebo Comparator|A|
11584388|NCT00758563|Active Comparator|B|
11584389|NCT00758550|Experimental|AcrySof Toric IOL|AcrySof Toric Intraocular Lens (IOL)
11584390|NCT00758550|Active Comparator|AcrySof Natural IOL|AcrySof Natural Intraocular Lens (IOL)
11584391|NCT00758537||Patients with chronic kidney disease stage 3|
11584392|NCT00758537||patients with chronic kidney disease stage 4|
11584393|NCT00758537||patients with chronic kidney disease stage 5 (ESRD)|
11584394|NCT00758537||Controls (no kidney disease)|
11584395|NCT00758524|Placebo Comparator|Placebo|
11584396|NCT00758524|Active Comparator|Eplerenone|
11584397|NCT00758524|Experimental|LCI699 1|
11584398|NCT00758524|Experimental|LCI699 2|
11584399|NCT00758524|Experimental|LCI699 3|
11584400|NCT00758524|Experimental|LCI699 4|
11584401|NCT00758511|Active Comparator|1|Orally administrated 25%sucrose before,during and after heel stick across 5 heel sticks during the first 14 days of postnatal life
11584402|NCT00758511|Active Comparator|2|facilitated tucking before, during and after heel stick across 5 heel stick during the first 14 days of postnatal life
11584403|NCT00758511|Active Comparator|3|orally administrated 25% sucrose AND facilitated tucking before, during and after heel stick across 5 heel sticks during the first 14 days of postnatal life
11584404|NCT00758498|Experimental|1|armodafinil - dosage of 50 mg/day
11584405|NCT00758498|Experimental|2|armodafinil - dosage of 150 mg/day
11584406|NCT00758498|Placebo Comparator|3|matching placebo
11584407|NCT00758485|Experimental|sugammadex|Participants receiving 4.0 mg.kg-1 Sugammadex at a target depth of NMB of 1-2 PTC after the last dose of rocuronium
11584408|NCT00758485|Placebo Comparator|Placebo|Participants receiving Placebo (0.9% NaCl) at a target depth of NMB of 1-2 PTC after the last dose of rocuronium
11584409|NCT00758472||Hip Resurfacing|
11584410|NCT00758459|Experimental|1|
11584411|NCT00758459|Placebo Comparator|2|
11584412|NCT00758446|Experimental|A|BLX-028914 50 mg
11584413|NCT00758446|Experimental|B|BLX-028914 15 mg
11584414|NCT00758446|Placebo Comparator|C|Placebo
11584415|NCT00758433|Active Comparator|1|Civamide patch 0.0075%
11584416|NCT00758433|Active Comparator|2|Civamide patch 0.0150%
11584417|NCT00758433|Placebo Comparator|3|Placebo patch
11584418|NCT00758420|Active Comparator|1|Varisolve (polidocanol endovenous mircofoam)
11584419|NCT00758420|Placebo Comparator|2|Agitated saline
11584420|NCT00758407|Active Comparator|1|
11584421|NCT00758407|Placebo Comparator|2|
11584422|NCT00758394|Placebo Comparator|Fluoride - A|Fluoride only toothpaste
11584423|NCT00758394|Active Comparator|Total + Whitening toothpaste - B|Triclosan/fluoride toothpaste
11584424|NCT00758394|Experimental|Triclosan/fluoride/Amino Acid - C|toothpaste containing amino acid #1
11584425|NCT00758394|Experimental|Triclosan/fluoride/Cavistat -D|toothpaste containing amino acid/bicarbonate
11584426|NCT00758381|Experimental|A|"Sorafenib 400 mg po bid, continuously
~Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days."
11584427|NCT00758381|Active Comparator|B|Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days
11584428|NCT00758368|Experimental|Ambulatory Pump|Participants will receive apomorphine via a pump. Participants in the Continuous Delivery Arm will self-administer apomorphine continuously (12-14 hours a day) using a portable pump.
11584429|NCT00758368|Active Comparator|Subcutaneous Injections|Participants will receive apomorphine via an injection pen. Participants in the Intermittent Delivery Arm will self-administer apomorphine at intervals, via a injection, using pen injector.
11584430|NCT00758355||M2A magnum|Consecutive series of patients received Total Hip Resurfacing with ReCap/Magnum
11584431|NCT00758355||Recap Magnum|Consecutive series of patients received Total Hip Replacement with ReCap/Magnum
11584432|NCT00758342|Experimental|Travoprost 0.004% + Brinzolamide 1.0%|Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
11584433|NCT00758342|Active Comparator|Travoprost 0.004% + Tears Natural|Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
11584434|NCT00758329||1|
11584435|NCT00758316|Active Comparator|1|Thoracoscopy with pleurodesis Patients will then undergo standard medical thoracoscopy in the endoscopy center including the use of moderate sedation, prophylactic antibiotics for 1 week and 20F chest tube insertion at the end of the procedure.
11584436|NCT00758316|Experimental|2|Combined thoracoscopy with pleurodesis and pleurx catheter. In the combined procedure group, a PleurxTM tunnelled catheter will be inserted under ultrasound guidance. As this procedure will be done concurrently with thoracoscopy, there is no estimated increase in endoscopy time.
11584437|NCT00758303|Active Comparator|1|Low Dose TRIA-662
11584438|NCT00758303|Active Comparator|2|High Dose TRIA-662
11584439|NCT00758303|Placebo Comparator|3|Matching Placebo for TRIA-662
11584440|NCT00758290|Active Comparator|A|
11584441|NCT00758290|Experimental|B|
11584442|NCT00758277|Active Comparator|Levetiracetam|
11584443|NCT00758277|Placebo Comparator|Placebo|
11584444|NCT00758264|Experimental|Group A|Meningococcal vaccine GSK134612 co-administered with pneumococcal vaccine GSK1024850A.
11584445|NCT00758264|Active Comparator|Group B|Pneumococcal vaccine GSK1024850A followed one month later by meningococcal vaccine GSK134612.
11584446|NCT00758264|Active Comparator|Group C|Meningococcal vaccine GSK134612 followed one month later by pneumococcal vaccine GSK1024850A.
11584447|NCT00758251||1|Adult schizophrenia patients already on Seroquel XR therapy
11584448|NCT00758238|Experimental|myBP intervention|participants will receive access to hypertension self-management tools and support via a personal patient electronic health record
11584449|NCT00758238|No Intervention|usual care|participants allocated to usual care may still opt to use the personal patient electronic health record, but will not have access to the hypertension self-management tools until after the intervention period. The usual care group will be given a web-link for patient hypertension management resources
11584450|NCT00758225|Experimental|only one arm|
11584451|NCT00758212|Experimental|A|The experimental group will consist of HIV/AIDS patients(approx.50) who volunteer to receive a reduced dose Influenza vaccine using mesotherapy as a mode of injecting the vaccine intradermally.
11584452|NCT00758199|Active Comparator|2|Moxifloxacin
11584453|NCT00758199|Placebo Comparator|3|Prednisolone Acetate
11584454|NCT00758199|Active Comparator|1|Bromfenac
11584516|NCT00757653|Active Comparator|1|Stem with plasma sprayed porous Titanium 6Al4V alloy + Plasma sprayed HA
11584517|NCT00757653|Experimental|2|
11584455|NCT00758186|Experimental|Colonic-stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction.
11584456|NCT00758186|Active Comparator|Emergency surgery|Emergency surgery: Patients underwent emergency surgery for acute left-sided malignant colonic obstruction.
11584457|NCT00758160|Experimental|OROS methylphenidate|Participants willl receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
11584458|NCT00758134|Experimental|A|Trastuzumab 6 mg/Kg
11584459|NCT00758121||Observation|Heart failure patients with an implanted CRT-D
11584460|NCT00758082|Active Comparator|1|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support
11584461|NCT00758082|Experimental|2|PDA-phone + phone consultations + standard visit at 3 months
11584462|NCT00758069|Placebo Comparator|1|Placebo
11584463|NCT00758069|Experimental|2|Sitagliptin 100 mg
11584464|NCT00758069|Experimental|3|Sitagliptin 50 mg
11584465|NCT00758043|Experimental|T12PR24 (eRVR+)|Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 12 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
11584466|NCT00758043|Experimental|T12PR48 (eRVR+)|Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
11584467|NCT00758043|Experimental|T12PR48 (eRVR-)|Assigned Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects did not achieve an extended rapid viral response and were assigned to this group
11584468|NCT00758043|Experimental|Other|Other Group: Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20, were not randomized or assigned to a treatment regimen.
11584469|NCT00758017|Experimental|Acupuncture 1|
11584470|NCT00758017|Active Comparator|Acupuncture 2|
11584471|NCT00758004|Other|Reference|Commercial 80 mg atorvastatin tablet
11584472|NCT00758004|Other|Test|Pediatric appropriate atorvastatin 40mg formulation
11584473|NCT00757978|Placebo Comparator|1|Clozapine plus placebo
11584474|NCT00757978|Active Comparator|2|Clozapine plus memantine
11584475|NCT00757939|Experimental|AD Participants|Participants with a diagnosis of mild-to-moderate AD
11584476|NCT00757939|Experimental|Cognitively Normal Elderly Participants|Elderly participants with no cognitive impairment
11584477|NCT00757926|Experimental|1|
11584478|NCT00757926|Placebo Comparator|2|
11584479|NCT00757913|Experimental|1|n-3 enriched nutrition
11584480|NCT00757913|Placebo Comparator|2|isocaloric nutrition without n-3 supplement
11584481|NCT00757900|Active Comparator|1|To receive a sub-unit influenza vaccine
11584482|NCT00757900|No Intervention|2|
11584483|NCT00757887|Experimental|EHMI8|Previously protected volunteers, N=10
11584484|NCT00757887|Active Comparator|control|5 malaria-naive volunteers
11584485|NCT00757874|Experimental|Tacrolimus cream|
11584486|NCT00757874|Active Comparator|Clobetasol cream|
11584487|NCT00757848|Experimental|AZD9668|
11584488|NCT00757848|Placebo Comparator|Placebo|
11584489|NCT00757835|Active Comparator|Travoprost/timolol therapy|treatment with travoprost/timolol fixed combination drops once in the evening for 3 months. 24-hour pressure monitoring.
11584490|NCT00757835|Active Comparator|Latanoprost/timolol therapy|Treatment with latanoprost/timolol fixed combination for 3 months. 24-hour pressure monitoring.
11584491|NCT00757822|Experimental|Arm 1|dronabinol
11584492|NCT00757822|Active Comparator|Arm 2|ondansetron
11584493|NCT00757809|Experimental|QD|Once daily
11584494|NCT00757809|Experimental|BID|Twice daily
11584495|NCT00757783|Experimental|darunavir|darunavir 800 mg tablet once daily for 48 weeks,emtricitabine [FTC]/tenofovir [TDF] 200/300 mg tablet once daily for 48 weeks,ritonavir 100 mg capsule or tablet once daily for 48 weeks
11584496|NCT00757783|Experimental|atazanavir|atazanavir 300 mg capsule once daily for 48 weeks,emtricitabine [FTC]/tenofovir [TDF] 200/300 mg once daily for 48 weeks,ritonavir 100 mg capsule or tablet once daily for 48 weeks
11584497|NCT00757770|Experimental|Group HRV Lot A|
11584498|NCT00757770|Experimental|Group HRV Lot B|
11584499|NCT00757770|Experimental|Group HRV Lot C|
11584500|NCT00757770|Active Comparator|Group Placebo|
11584501|NCT00757757|Experimental|MCS110|
11584502|NCT00757744|Experimental|A|Methadone maintenance treatment with Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
11584503|NCT00757744|Active Comparator|B|Methadone maintenance treatment with standard drug counseling
11584504|NCT00757731|Experimental|Minalcipran 100 mg|
11584505|NCT00757731|Experimental|Minalcipran 150 mg|
11584506|NCT00757731|Experimental|Minalcipran 200 mg|
11584507|NCT00757718|Active Comparator|CPAP treatment|Subjects will have repeat polysomnography on the second night, while wearing a continuous positive airway pressure (CPAP) device. Morning bloodwork will be drawn for inflammatory mediators.
11584508|NCT00757718|Experimental|Oral appliance|Subjects will have repeat polysomnography on the second night, while wearing an oral appliance, as well as a Breathe-Right nasal strip. Morning bloodwork will be drawn for inflammatory mediators.
11584509|NCT00757705|Experimental|Paliperidone Extended-Release (ER)|
11584510|NCT00757692|Experimental|A|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
11584511|NCT00757692|Active Comparator|B|Bicalutamide at 50 mg will be administered orally, daily and continuously.
11584512|NCT00757679|Experimental|Milnacipran|
11584513|NCT00757679|Placebo Comparator|Placebo|
11584514|NCT00757666|Active Comparator|Accelerometer|Patients implanted with a Boston Scientific ALTRUA 60 pacemaker with accelerometer (motion-based) sensor.
11584515|NCT00757666|Active Comparator|Minute Ventilation|Patients implanted with a Boston Scientific ALTRUA 60 pacemaker with minute ventilation sensor.
11584518|NCT00757653|Active Comparator|3|
11584519|NCT00757640|No Intervention|B|no cholecystectomy
11584520|NCT00757640|Experimental|A|cholecystectomy
11584521|NCT00757627|Experimental|1|Etoricoxib
11584522|NCT00757601|Experimental|15 mg MK1006/Placebo/45 mg MK1006/60 mg MK1006/Placebo (Fed)|Participants received 15 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by placebo to MK1006 taken with food (Fed state) in Period 5.
11584523|NCT00757601|Experimental|Placebo/30mg MK1006/45mg MK1006/60mg MK1006/30mg MK1006 (Fed)|Participants received placebo to MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
11584524|NCT00757601|Experimental|15mg MK1006/30mg MK1006/Placebo/60mg MK1006/30mg MK1006 (Fed)|Participants received 15 mg MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
11584525|NCT00757601|Experimental|15mg MK1006/30mg MK1006/45mg MK1006/Placebo/30mg MK1006 (Fed)|Participants received 15 mg MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
11584526|NCT00757601|Experimental|60mg MK1006 / Placebo / 100mg MK1006 / 120mg MK1006 / Placebo|Participants received 60 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by placebo to MK1006 in Period 5.
11584527|NCT00757601|Experimental|Placebo/ 80mg MK1006/ 100mg MK1006/ 120mg MK1006/ 140mg MK1006|Participants received placebo to MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by 140 mg MK1006 in Period 5
11584528|NCT00757601|Experimental|60mg MK1006/ 80mg MK1006/ Placebo/ 120mg MK1006/ 140mg MK1006|Participants received 60 mg MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.
11584529|NCT00757601|Experimental|60mg MK1006/ 80mg MK1006/ 100mg MK1006/ Placebo/ 140mg MK1006|Participants received 60 mg MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.
11584530|NCT00757601|Experimental|140mg MK1006 / Placebo / 200mg MK1006 / 230mg MK1006 / Placebo|Participants received 140 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by placebo to MK1006 in Period 5.
11584531|NCT00757601|Experimental|Placebo/170mg MK1006/ 200mg MK1006/ 230mg MK1006/ 260mg MK1006|Participants received placebo to MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.
11584532|NCT00757601|Experimental|140mg MK1006/170mg MK1006/ Placebo/ 230mg MK1006/ 260mg MK1006|Participants received 140 mg MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by 260 mg MK1006 in Period 5
11584533|NCT00757601|Experimental|140mg MK1006/170mg MK1006/ 200mg MK1006/ Placebo/ 260mg MK1006|Participants received 140 mg MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.
11584534|NCT00757588|Experimental|Saxagliptin, 5 mg + insulin|Saxagliptin, 5 mg, plus insulin, administered to participants with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
11584535|NCT00757588|Placebo Comparator|Placebo + insulin|Placebo administered to participants with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
11584536|NCT00757575||1|
11584537|NCT00757562|Experimental|DL|Desloratadine syrup once daily
11584538|NCT00757562|Placebo Comparator|Placebo|placebo syrup once daily
11584539|NCT00757536|Active Comparator|Group 1|
11584540|NCT00757536|Active Comparator|Group 2|
11584541|NCT00757523|Active Comparator|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation).
11584542|NCT00757523|Experimental|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation).
11584543|NCT00757510||Congenital heart disease|All subjects will have known or suspected congenital heart disease
11584544|NCT00757471|Active Comparator|Group 1|Brillant Blue
11584545|NCT00757471|Active Comparator|Group 2|Indocyanine Green
11584546|NCT00757458|Active Comparator|1|TCI with EDTA
11584547|NCT00757458|Active Comparator|2|Re-filling of propofol syringe (Diprivan®-Astra Zeneca) with propofol containing EDTA
11584548|NCT00757458|Active Comparator|3|Re-filling of propofol syringe (Diprivan®-Astra Zeneca) with propofol without EDTA
11584549|NCT00757458|Active Comparator|4|Target controlled infusion of propofol without EDTA
11584550|NCT00757419|Experimental|1|
11584551|NCT00757419|Placebo Comparator|2|
11584552|NCT00757406||1|Test group - Lymphedema sufferers
11584553|NCT00757406||2|Control group - healthy volunteers
11584554|NCT00757393|Active Comparator|1|
11584555|NCT00757393|Experimental|2|
11584556|NCT00757380|Active Comparator|Group 1|Trypan Blue
11584557|NCT00757380|Active Comparator|Group 2|Brillant Blue
11584558|NCT00757367|Experimental|TI Inhalation Powder|TI Inhalation Powder, single dose, 60 units
11584559|NCT00757354|Experimental|Metal on Metal cementless hip|Metal on Metal cementless hip arthroplasty
11584560|NCT00757341|Experimental|SKI-606|
11584561|NCT00757328||1|Ambulatory bipolar I and II patients, clinically stabilized for at least the two months prior to recruitment and who had at least one acute episode (depressive, manic, hypomanic or mixed) within the year prior to recruitment.
11584562|NCT00757315|Experimental|1|
11584563|NCT00757315|Active Comparator|2|
11584564|NCT00757302|Experimental|I|For the first 10 patients, only a pre-operative procedure will be performed.
11584565|NCT00757302|Experimental|II|The last 100 patients will receive the complete procedure.
11584566|NCT00757289|Experimental|1|PRP injection
11584567|NCT00757289|Active Comparator|2|Corticosteroid Injection
11584568|NCT00757276||1|"All patients > 18 years who are tested for the diagnosis of DI because of a history of polyuria (> 40 ml/kg per 24 hours) in the presence of polydipsia Patients with known DI will be contacted whether they agree to participate in the study and to undergo again a water deprivation test to measure copeptin to confirm the diagnosis.
~The investigators hypothesize that basal copeptin levels can reliably differentiate between the 5 groups(central, nephrogenic, psychogenic and partial forms) with a sensitivity and specificity >80%."
11584569|NCT00757250|Experimental|1|Dose Cohort 1: 50 mcg/kg/day of TXA127
11584570|NCT00757250|Experimental|2|Drug Cohort 2: 100 mcg/kg/day TXA127
11584571|NCT00757250|Experimental|3|Drug Cohort 3: 200 mcg/kg/day TXA127
11584572|NCT00757250|Experimental|4|Drug Cohort 4: 300 mcg/kg/day TXA127
11584573|NCT00757250|Experimental|5|Extended dosing cohort at 300mcg/kg TXA127 for 2 x 28-day treatment cycles, with an extended follow-up period to week 34.
11584574|NCT00757237|Experimental|AZLI 75 mg 3 times a day (TID)|
11584575|NCT00757237|Active Comparator|TIS 300 mg 2 times a day (BID)|
11584576|NCT00757224|No Intervention|non-smoking|
11584577|NCT00757224|No Intervention|smoking parents A|
11584578|NCT00757224|Experimental|smoking parents B|Parents will be educated on the hazards of passive smoke exposure and ways to reduce it
11584579|NCT00757198|Experimental|1|remifentanil o.1 mcg/kg/min
11584580|NCT00757198|Active Comparator|2|remifentanil 0.3 mcg/kg/min
11584581|NCT00757185|Experimental|1|GNRH antagonist alone
11584582|NCT00757185|Experimental|2|GnRH with Testosterone
11584583|NCT00757172|Other|Docetaxel + Cisplatin + Panitumumab + RT|Patients received docetaxel (40 mg/m^2), cisplatin (40 mg/m^2) and panitumumab (6 mg/kg) on weeks 1, 3, 5, 7, and 9 with radiotherapy (RT) (5040 cGy, 180 cGy/day x 28 days) beginning week 5. Resection was planned after completing chemotherapy (CRT).
11584584|NCT00757159|Experimental|1|
11584585|NCT00757159|Active Comparator|2|
11584586|NCT00757133|Experimental|1|Conventional laparotomy closure
11584587|NCT00757133|Active Comparator|2|Laparotomy closure with mesh augmentation
11584588|NCT00757120||1|This group will include current and former smokers who have emphysema.
11584589|NCT00757120||2|This group will include current and former smokers who do not have emphysema.
11584590|NCT00757107|Experimental|Taperloc Microplasty|Patients with primary osteoarthritis with Taperloc microplasty non inferiority
11584591|NCT00757107|Active Comparator|Taperloc Standard|Patients with primary osteoarthritis Taperloc standard
11584592|NCT00757094||I|Patients planning to observe fasting while receiving chemotherapy during the month of Ramadan
11584593|NCT00757081|Experimental|1|
11584594|NCT00757068|Active Comparator|SBT|Women assigned to SBT (blue) will receive a six month program that offers to help them stay quit after having a baby.
11584595|NCT00757068|Experimental|CBT|Women assigned to CBT (pink) will receive a six month treatment designed to provide support and address the concerns of women who have just had a baby and do not want to resume smoking.
11584596|NCT00757055|Active Comparator|1|Patients on ivabradine titrated to heart rate
11584597|NCT00757055|Placebo Comparator|2|No therapy given
11584598|NCT00757042|Active Comparator|AMG 157|Six subjects in each cohort (cohort 1 to 8) will receive AMG 157 in Part A 18 subjects in cohorts 9 and 10 (Part B) will receive AMG 157
11584599|NCT00757042|Placebo Comparator|placebo|2 subjects of each cohort (cohort 1 to 8) will receive placebo in Part A 6 subjects in cohorts 9 and 10 (Part B) will receive placebo
11584600|NCT00757029|Other|open label|
11584601|NCT00757016|Placebo Comparator|B|0.99 ml saline solution 9mg/ml and 0.01 ml fat emulsion will be given once to the sacrospinous ligament insertion.
11584602|NCT00757016|Active Comparator|A|1 ml triamcinolone 20mg/ml (Lederspan), Meda AB, Solna, Sweden) and 1 ml lidocaine hydrochloride 10mg/ml (Xylocain), Astra Zeneca, Södertälje, Sweden)
11584603|NCT00757003|Experimental|Treatment Arm - Placement of TAG device|A TAG device will be used to repair the pathology in the thoracic aorta
11584604|NCT00756990|Experimental|Single group|Depot Naltrexone
11584605|NCT00756977|Experimental|1|multi-dose preparation for oral administration prior to colonoscopy
11584606|NCT00756977|Active Comparator|2|multi-dose preparation for oral administration prior to colonoscopy
11584607|NCT00756964|Active Comparator|Rasburicase|patients receiving rasburicase to lower serum uric acid
11584608|NCT00756964|Placebo Comparator|Placebo|patients will receive a placebo
11584609|NCT00756951|Placebo Comparator|1|Placebo
11584610|NCT00756951|Active Comparator|2|SCV-07 at a dose of 0.02 mg/kg
11584611|NCT00756951|Active Comparator|3|SCV-07 at a dose of 0.10 mg/kg
11584612|NCT00756938|Experimental|Losartan potassium 0.1 to 1.4 mg/kg|Open-label losartan at starting dose of 0.1 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
11584613|NCT00756938|Experimental|Losartan potassium 0.3 to 1.4 mg/kg|Open-label losartan at starting dose of 0.3 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
11584614|NCT00756938|Experimental|Losartan potassium 0.7 to 1.4 mg/kg|Open-label losartan at starting dose of 0.7 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
11584615|NCT00756925||1|Cocaine dependent females
11584616|NCT00756925||2|Cocaine dependent males
11584617|NCT00756912|Experimental|1|
11584618|NCT00756899||Obese|Chilren with BMI of >95th percentile
11584619|NCT00756899||Non-obese|Children with BMI of <85th percentile
11584620|NCT00756886|Active Comparator|Atorvastatin|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
11584621|NCT00756886|Placebo Comparator|Placebo|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
11584622|NCT00756873|Placebo Comparator|1|
11584623|NCT00756873|Experimental|2|Etoricoxib 90 mg qd.
11584624|NCT00756873|Experimental|3|Etoricoxib 120 mg qd. (day 0-7) Etoricoxib 90 mg qd. (day 8-14)
11584625|NCT00756860|Active Comparator|2|30 subjects will be randomized on Day -1
11584626|NCT00756860|Experimental|1|30 subjects will be randomized on Day -1
11584627|NCT00756847|Experimental|1|
11584628|NCT00756834||Mammography Image Collection|Acquired images
11584629|NCT00756834||CAD Radiologist Reader|Retrospective reader study
11584630|NCT00756821||SMA cohort|Subjects between the ages of 2-12 years diagnosed with SMA Type I, II, or III.
11584631|NCT00756821||Control cohort|Healthy children between the ages of 2-12 years. These children may be either genetically-related siblings of SMA children (genetically confirmed non-carriers of SMA),or unrelated children.
11584632|NCT00756795|Experimental|Attention Control|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.
~Patient will be taught how to keep the Activity diary to record walking and physical activities.
~Structured Interview will be conducted at baseline and post-intervention. All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis"
11584633|NCT00756782|Experimental|A|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days
11584634|NCT00756782|Placebo Comparator|B|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
11584635|NCT00756769||1|Patients with SLE
11584636|NCT00756769||2|Related unaffected controls
11584637|NCT00756769||3|Unrelated unaffected controls
11584638|NCT00756756|Experimental|1|post MI post PCI and G-CSF infusion
11584639|NCT00756756|Placebo Comparator|2|post MI and post PCI only placebo infused
11584640|NCT00756743|Experimental|PF-04802540|
11584641|NCT00756743|Placebo Comparator|Placebo|
11584642|NCT00756730|Other|Switch to DRV/r (800mg/100mg) QD|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this arm the sbject switched to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
11584643|NCT00756730|Other|Switch to ATV/r (300mg/100mg QD)|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this are the subject switched to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study
11584644|NCT00756717|Experimental|MK-0752|Oral gamma-secretase inhibitor drug MK-0752, 350 mg for three days, four days off, then three days on, over a period of 10 days
11584645|NCT00756704|No Intervention|Baseline Period|
11584646|NCT00756704|Experimental|Intervention Period|
11584647|NCT00756691||1|First 5 consecutive 18F-FAZA avid subjects that undergo up to 5 PET scans, 13 blood and 2 urine samples over 4.5 hours
11584648|NCT00756691||2|Next 5 consecutive 18F-FAZA avid subjects that undergo up to 4 PET scans, 8 blood and 2 urine samples over 5.5 hours
11584649|NCT00756678|Active Comparator|1|Carboxymethylcellulose and Glycerin
11584650|NCT00756678|Active Comparator|2|Polyethylene glycol 400
11584651|NCT00756652||MemoryGel Breast Implant Participants|MemoryGel Breast Implant Participants received Mentor Silicone Gel-Filled Breast Implants (MemoryGel) during their Breast Augmentation, Breast Reconstruction, or Revision surgery
11584652|NCT00756652||Saline Breast Implant Control Participants|Saline Breast Implant Control Participants received Saline Filled Breast Implants during their Breast Augmentation, Breast Reconstruction, or Revision surgery
11584653|NCT00756639|Experimental|Radiation|Prophylactic cranial irradiation (PCI) treatments to be started within 4 months after the end of chemotherapy or surgery to a total dose of 30 Gy, given at 2 Gy per fraction, 5 days per week for 3 weeks. On the first day of each week of therapy, a brain X-ray will done to see if the radiation is being given to the best area.
11584654|NCT00756626|Experimental|1|Intervention group receives bottle weaning intervention from WIC nutritionist
11584655|NCT00756626|No Intervention|2|Control standard of care
11584656|NCT00756613||465 VADT participants|The participants had previously participated in the VADT CSP #465 study
11584657|NCT00756600|Active Comparator|1|Regional Anesthesia
11584658|NCT00756600|Active Comparator|2|General Anesthesia
11584659|NCT00756587|Active Comparator|I|Group one received feeding by bottle as the standard method of feeding in the NICU
11584660|NCT00756587|Experimental|II|Group 2 received all feeding by cup
11584661|NCT00756574|Active Comparator|1. Surgical|surgical mask
11584662|NCT00756574|Active Comparator|2. N95 Respirator|N95 respirator
11584663|NCT00756548|Experimental|1|multi-dose preparation for oral administration prior to colonoscopy
11584664|NCT00756548|Active Comparator|2|multi-dose preparation for oral administration prior to colonoscopy
11584665|NCT00756535|Experimental|1|Group-based exercise training during hospitalization
11584666|NCT00756535|Active Comparator|2|Usual treatment and rehabilitation during hospitalization
11584667|NCT00756509|Experimental|nilotinib|nilotinib
11584668|NCT00756483||M, 1|Male patients that have undergone total knee replacement
11584669|NCT00756483||F, 1|Female patients that have undergone total knee replacement
11584670|NCT00756483||M, 2|Male patients that have undergone total hip replacement
11584671|NCT00756483||F, 2|Female patients that have undergone total hip replacement
11584672|NCT00756470|Experimental|Neoadjuvant Lapatinib plus Chemotherapy|"Four cycles of Lapatinib and Paclitaxel followed by 4 cycles of Lapatinib plus 5-Fluorouracil, Cyclophosphamide, Epirubicin (FEC75). Cycle is 21 days.
~Lapatinib alone at 1,000 mg orally once daily for a 2-week run-in period, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each.
~Week 3 Paclitaxel 80 mg/m^2 weekly for 4 cycles (12 weeks) administered on Day 1, Day 8, and Day 15) of each cycle combined with Lapatinib 750 mg orally once daily.
~Week 15, second combination treatment consisting of Lapatinib (1,000 mg orally once daily) combined with FEC75 (5-FU 500 mg/m^2, Epirubicin 75 mg/m^2, and Cyclophosphamide 500 mg/m^2 every 3 weeks for 4 cycles)."
11584673|NCT00756457|Active Comparator|Active Treatment Group|Participants in Group A will undergo bracing and perform stretching exercises.
11584722|NCT00756145|Experimental|2|Injection of LMWH 5 minutes after the start of the hemodiafiltration session, at the inlet bloodline
11584674|NCT00756457|Experimental|Passive Treatment Group|Participants in Group B will undergo bracing and perform stretching and strengthening exercises.
11584675|NCT00756444|Active Comparator|Panitumumab plus Chemotherapy|Subjects receiving cisplatin and 5/FU and receiving Panitumumab who have with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
11584676|NCT00756444|Active Comparator|Chemotherapy Alone|Subjects receiving cisplatin and 5/FU and not receiving Panitumumab who have with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
11584677|NCT00756431|Active Comparator|Screw without HA Coating (Hiploc)|
11584678|NCT00756431|Experimental|Screw with HA Coating (Hiploc)|
11584679|NCT00756418|Experimental|1|
11584680|NCT00756418|Active Comparator|2|
11584681|NCT00756405|Active Comparator|Diet Group|Increased antioxidant diet and placebo pill.
11584682|NCT00756405|Active Comparator|Supplement Group|Usual diet and antioxidant supplement.
11584683|NCT00756405|Placebo Comparator|Placebo|Usual diet and placebo pill.
11584684|NCT00756392|Other|1|
11584685|NCT00756379|Experimental|Intensive lifestyle modification|P.E.T. guided comprehensive therapy program. The study intervention is Comprehensive therapy program for risk factor modification. The Comprehensive program of atherosclerotic risk factor modification involves treatment to target lipid levels, blood pressure and diabetes control, smoking cessation, very low fat diet and aerobic exercise program. This is in addition to standard current medical therapy as provided by primary physician. No experimental medications or procedures will be used.
11584686|NCT00756379|No Intervention|Current standard of care|Current standard of care medical management as provided by primary physician.
11584687|NCT00756366|Active Comparator|1|Heart Failure-OSA Group, randomized to early CPAP
11584688|NCT00756366|Active Comparator|2|Heart Failure-OSA Group, randomized to late CPAP
11584689|NCT00756366|Other|3|Heart Failure- no OSA, no CPAP therapy, observational group
11584690|NCT00756353||Wave 1|
11584691|NCT00756353||Wave 2|
11584692|NCT00756340|Experimental|1|"Dose Level 0, Bevacizumab IV every 2 weeks 8 mg/kg, Everolimus 4 mg/m^2
~Dose Level 1 (starting dose), Bevacizumab IV every 2 weeks 10 mg/kg, Everolimus 4 mg/m^2
~Dose Level 2, Bevacizumab IV every 2 weeks 10 mg/kg, Everolimus 5 mg/m^2"
11584693|NCT00756314|Experimental|Personalized contraceptive counseling|All 123 allocated women for the intervention group received personalized counseling (face-to-face) and the contraceptive method chosen for free by a specialized trained doctor in family planning.
11584694|NCT00756314|No Intervention|Control|All 123 women allocated to control group received a standard care available at IMIP.Standard care is comprised of educational group counseling by specialized nursing staff in family planning discussing about contraceptive methods and side effects
11584695|NCT00756301|Active Comparator|Traditional Technique|Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
11584696|NCT00756301|Experimental|Alternative Technique|Local anesthetic (Lidocaine) injected using an alternative technique (inserting the numbing needle into the deeper tissues first and injecting numbing medication from there up to the skin).
11584697|NCT00756301|No Intervention|No Anesthetic|No local anesthetic is used.
11584698|NCT00756288|Experimental|1|Topical retinoid and Light therapy with photosensitizing agent
11584699|NCT00756288|Active Comparator|2|Light therapy with photosensitizing agent
11584700|NCT00756275|Active Comparator|Nicotine Replacement + PLA pill|Nicotine replacement treatment patch plus matched placebo pill
11584701|NCT00756275|Active Comparator|Varenicline + PLA patch|Varenicline plus matched placebo patches containing no nicotine
11584702|NCT00756262|Active Comparator|1|Lactobacillus rhamnosus LGG
11584703|NCT00756262|Placebo Comparator|2|Microcrystalline cellulose capsules
11584704|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.005 mcg/kg|
11584705|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.05 mcg/kg|
11584706|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.5 mcg/kg|
11584707|NCT00756249|Experimental|Lu AA24493 (CEPO): 5.0 mcg/kg|
11584708|NCT00756249|Experimental|Lu AA24493 (CEPO): 50.0 mcg/kg|
11584709|NCT00756249|Placebo Comparator|Placebo|
11584710|NCT00756236|Experimental|M-Group|Patients were randomly assigned to Metoprolol Group. The drug was dispensed in 60ml & 5ml syringes of 0.9% NaCl and 1mg/ml Metoprolol. Investigators and patients were blinded to the group assignment.
11584711|NCT00756236|Experimental|E-Group|Patients were randomly assigned to Esmolol Group. The drug was dispensed in 60ml & 5ml syringes of 0.9% NaCl and 10mg/ml Esmolol. Investigators and patients were blinded to the group assignment.
11584712|NCT00756236|Placebo Comparator|P-Group|Patients were randomly assigned to this group. Patients received 0.9% NaCl only. To maintain the blind, 0.9% NaCl was also dispensed in 60ml & 5ml syringes.
11584713|NCT00756223|Experimental|Arm A|BI 831266 24h infusion on day 1 and day 15 every 4 weeks
11584714|NCT00756223|Experimental|Arm B|BI 831266 24h infusion on day 1 every 3 weeks
11584715|NCT00756197|Experimental|Cryo Spray Ablation Group 1|4 cycles of 10 seconds each
11584716|NCT00756197|Experimental|Cryo Spray Ablation Group 2|2 cycles of 20 seconds each
11584717|NCT00756184|Active Comparator|A|Intervention will consist of intensive teaching on the nature of glaucoma, value of IOP control, need to adhere to medical therapy and counseling on the proper use of travoprost eye drops.
11584718|NCT00756184|Placebo Comparator|B|"Intervention with travoprost therapy and TDA monitoring. Patients of this arm will also be prescribed travoprost and will be followed up in a standard clinical fashion. This group will receive a comparable amount of personal physician attention, but will not be given adherence, or glaucoma education and will not be told that their adherence will be monitored. Their attention placebo intervention will discuss the importance and techniques of good eye health (sunglasses, vitamins, cataract development, etc but no details, or discussion of either glaucoma or adherence) will insure that the study results are not a result of a change in physician attention to a patient, per se, rather than adherence training."
11584719|NCT00756171|Experimental|1|Verum; colesevelam
11584720|NCT00756171|Placebo Comparator|2|placebo
11584721|NCT00756145|Experimental|1|Injection of LMWH at the start of the hemodiafiltration session, at the inlet bloodline
11584872|NCT00755170|Experimental|1|Vinorelbine metronomic + bevacizumab
11584723|NCT00756145|Experimental|3|Injection of LMWH at the start of the hemodiafiltration session, at the outline bloodline
11584724|NCT00756132||Bloods Only (B)|Women aged 18-65 years with a newly diagnosed locally advanced or high risk operable breast cancer
11584725|NCT00756132||A-Cog|Women aged 18-65 years newly diagnosed with LABC/high risk who are willing and able to complete cognitive testing.
11584726|NCT00756132||Control (C)|Healthy women aged 18-65 years who are willing and able to complete cognitive testing.
11584727|NCT00756132||A1-Cog|Women newly diagnosed locally advanced or high risk breast cancer that qualify for cognitive testing but have a condition related to elevated serum levels of cytokines or other inflammatory markers.
11584728|NCT00756106|Experimental|Temozolomide and Radiation Therapy|
11584729|NCT00756093|Experimental|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each one time
11584730|NCT00756093|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
11584731|NCT00756093|Active Comparator|Blink Tears|Blink Tears 1 drop each eye one time
11584732|NCT00756093|Active Comparator|GenTeal Moderate Lubricant Eye Drops|GenTeal Moderate Lubricant Eye Drops 1 drop each eye one time
11584733|NCT00756080|Experimental|1|After receiving a 7-day oral supplementation with citrulline, each subject will be admitted to the Clinical Investigation Unit for a half day, after an overnight fast,and will receive a 5-h intravenous infusion of L-[1-13C]leucine (i.e.; leucine labeled with 13C, a stable isotope of carbon) from 8 am to 1 pm. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, the keto acid of leucine, using gas chromatography-mas spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. The subject will then leave the hospital, take no treatment for13 days (wash-out period). The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with placebo, as a cross-over study design will be used.
11584734|NCT00756080|Placebo Comparator|2|After receiving a 7-day oral supplementation with placebo, each subject will be admitted to the Clinical Investigation Unit for a half day, after an overnight fast,and will receive a 5-h intravenous infusion of L-[1-13C]leucine (i.e.; leucine labeled with 13C, a stable isotope of carbon) from 8 am to 1 pm. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, the keto acid of leucine, using gas chromatography-mas spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. The subject will then leave the hospital, take no treatment for13 days (wash-out period). The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with citrulline, as a cross-over study design will be used.
11584735|NCT00756067|Experimental|Formulation 1|
11584736|NCT00756067|Experimental|Formulation 2|
11584737|NCT00756067|Experimental|Formulation 3|
11584738|NCT00756067|Experimental|Formulation 4|
11584739|NCT00756067|Experimental|Formulation 5|
11584740|NCT00756067|Experimental|Formulation 6|
11584741|NCT00756067|Active Comparator|23 valent pneumococcal vaccine|
11584742|NCT00756041|Experimental|TAK-128 100 mg QD|
11584743|NCT00756028|Experimental|1|Patients receiving short protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-antagonist (Orgalutran®: Ganirelix)
11584744|NCT00756028|Active Comparator|2|Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®: Nafarelin)
11584745|NCT00756015|Active Comparator|Early Motion|Other: Early range of motion post-operative therapy protocol.Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
11584746|NCT00756015|Other|Immobilization|Immobilization following rotator cuff repair.
11584747|NCT00756002|Experimental|Ramelteon 4 mg QD|
11584748|NCT00756002|Placebo Comparator|Placebo QD|
11584749|NCT00755989|Placebo Comparator|1|group to receive topical gel without morphine
11584750|NCT00755989|Experimental|2|Morphine gel
11584751|NCT00755976|Experimental|Epirubicin hydrochloride (75mg/m2 i.v.) Sulindac: 600mg|
11584752|NCT00755963|Experimental|1|
11584753|NCT00755963|Experimental|2|
11584754|NCT00755963|Placebo Comparator|3|Placebo
11584755|NCT00755950|Experimental|1|280 mg of Silymarin administered three times daily for 4 weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
11584756|NCT00755950|Placebo Comparator|3|Placebo: Lactose monohydrate; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
11584757|NCT00755950|Experimental|2.|420 mg silymarin three times daily for four weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
11584758|NCT00755937||Subjects receiving Remicade|Crohn's disease subjects receiving Remicade® per Product Monograph.
11584759|NCT00755911|Experimental|Tissue Repair Cells (TRC)|Subjects will receive Tissue Repair Cell (TRC) therapy plus Gelfoam carrier
11584760|NCT00755911|Sham Comparator|Control|Subjects will receive the control treatment, consisting of Gelfoam carrier without Tissue Repair Cell (TRC) therapy.
11584761|NCT00755898|Active Comparator|1|Patients with a medical diagnosis of cancer appearing at outpatient clinics for treatment and/or monitoring of their disease status
11584762|NCT00755898|Active Comparator|2|Healthy adult volunteers
11584763|NCT00755872|Experimental|1|Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
11584764|NCT00755872|Experimental|2|Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
11584870|NCT00755183|Experimental|testosterone ophthalmic solution|testosterone ophthalmic solution 0.03%
11584765|NCT00755872|Experimental|3|Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
11584766|NCT00755872|Experimental|4|Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
11584767|NCT00755859|Experimental|1|Six month steroid course plus azathioprine
11584768|NCT00755859|Active Comparator|2|six month steroid course
11584769|NCT00755846|Experimental|Alogliptin 6.25 mg QD|
11584770|NCT00755846|Experimental|Alogliptin 12.5 mg QD|
11584771|NCT00755846|Experimental|Alogliptin 25 mg QD|
11584772|NCT00755846|Experimental|Alogliptin 50 mg QD|
11584773|NCT00755846|Experimental|Alogliptin 100 mg QD|
11584774|NCT00755846|Placebo Comparator|Placebo QD|
11584775|NCT00755833||A|
11584776|NCT00755820||EXP-DCS/Exposure-D-cycloserine|Exposure Therapy + D-Cycloserine
11584777|NCT00755820||EXP-PBO|Exposure Therapy + Placebo
11584778|NCT00755820||SP|Supportive psychotherapy
11584779|NCT00755807|Placebo Comparator|Placebo|
11584780|NCT00755807|Experimental|Duloxetine|
11584781|NCT00755794|Experimental|1|Montelukast
11584782|NCT00755781|Active Comparator|CIS|CIS in addition to standard immunosuppressive regimen.
11584783|NCT00755781|No Intervention|SOC|Standard of care (SOC) therapy for lung transplant recipients
11584784|NCT00755755|Experimental|A (PGL4001 5mg)|PGL4001 5 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
11584785|NCT00755755|Experimental|B (PGL4001 10mg)|PGL4001 10 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
11584786|NCT00755755|Placebo Comparator|C (placebo)|PGL4001 matching placebo (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
11584787|NCT00755742|Experimental|Group 1 - Viremic / Non-cirrhotic|13 obese and insulin resistant, non-cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with chronic hepatitis C (HCV RNA positive) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who are naive to antiviral therapy, relapsed or not responded to antiviral therapy.
11584788|NCT00755742|Active Comparator|Group 2 - Non-viremic / Non-cirrhotic|13 obese and insulin resistant, non-cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with cured chronic hepatitis C (HCV RNA negative) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who have cleared hepatitis C virus with previous antiviral therapy.
11584789|NCT00755742|Experimental|Group 3 - Viremic / Cirrhotic|13 obese and insulin resistant, cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with chronic hepatitis C (HCV RNA positive) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who are naive to antiviral therapy, relapsed or not responded to antiviral therapy.
11584790|NCT00755742|Active Comparator|Group 4 - Non-viremic / Cirrhotic|13 obese and insulin resistant, cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with cured chronic hepatitis C (HCV RNA negative) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who have cleared hepatitis C virus with previous antiviral therapy
11584791|NCT00755729|Experimental|OCH|fast from midnight the night before surgery, and consume 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
11584792|NCT00755729|No Intervention|FSD|fast from midnight the night before surgery, and no preoperative oral carbohydrate loading
11584793|NCT00755716|Placebo Comparator|Placebo (sugar pill)|Person receives an inactive placebo
11584794|NCT00755716|Active Comparator|Topiramate|Subjects receive 10 weeks of topiramate with a dosage starting at 25 mg per day. At week two (quit date) subjects increase to 50 mg/day and gradually increase to 200 mg/day for a total time of 10 weeks.
11584795|NCT00755716|Active Comparator|Topiramate and Nicotine patch|Subjects receive 10 weeks of topiramate with a dosage starting at 25 mg per day. At week two (quit date) subjects increase to 50 mg/day and gradually increase to 200 mg/day and one week taper for a total time of 10 weeks. On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
11584796|NCT00755703|Experimental|Group 1|There will be 12 subjects in Group 1 that will receive 10e8 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
11584797|NCT00755703|Experimental|Group 2|There will be 12 subjects in Group 2 that will receive 10e9 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
11584798|NCT00755703|Experimental|Group 3|There will be 12 subjects in Group 3 that will receive 10e10 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
11584799|NCT00755703|Placebo Comparator|Experimental: Group 4|There will be 12 subjects in Group 4 that will receive a placebo consisting of buffer administered via intranasal spray on day 0 and day 28 (+/- 4d).
11584800|NCT00755690|Active Comparator|1|"High/ Low Phosphate diet I. A five-day low phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder / A five-day high phosphate diet.
~II. A five-day low phosphate diet / A five-day high phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder III. A five-day high phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder / A five-day low phosphate diet.
~IV. A five-day high phosphate diet / A five-day low phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder.
~V. A five-day low phosphate diet with the addition of a phosphate binder / A five-day low phosphate diet / A five-day high phosphate diet.
~VI. A five-day low phosphate diet with the addition of a phosphate binder / A five-day high phosphate diet / A five-day low phosphate diet."
11584801|NCT00755690|Active Comparator|2|High/ Low Phosphate diet
11584802|NCT00755690|Active Comparator|3|High/ Low Phosphate diet
11584871|NCT00755183|Placebo Comparator|vehicle|vehicle of testosterone ophthalmic solution
11584803|NCT00755677|Other|pulses|Interventional. Participants are registered sequentially to undergo daily consumption of pulses for eight weeks
11584804|NCT00755664|Active Comparator|Low-dose complex B-vitamins|Intervention group receives Low-dose complex B-vitamins every day. Low-dose complex B-vitamins contain 400µg of folic acid, 2mg of vitamin B6, 10µg of vitamin B12 and 50mg vitamin C. Daily supplementation lasts for 12 months
11584805|NCT00755664|Placebo Comparator|Vitamin C|Control group receives Vitamin C (50mg)every day. Daily supplementation lasts for 12 months.
11584806|NCT00755651|Experimental|H Pipelle|Endometrial sample obtained using the H Pipelle
11584807|NCT00755651|Active Comparator|Pipelle|Endometrial sample obtained with standard Pipelle
11584808|NCT00755638|Experimental|single|8 subjects (6 active and 2 placebo)
11584809|NCT00755599|Active Comparator|1|Vaginal speculum examinations done without stirrups.
11584810|NCT00755599|Active Comparator|2|Speculum examination with feet in stirrups.
11584811|NCT00755586|Experimental|A|
11584812|NCT00755586|Experimental|B|
11584813|NCT00755586|No Intervention|C|
11584814|NCT00755573|Active Comparator|Pregabalin|Pregabalin 300 mg - 600 mg BID
11584815|NCT00755573|Placebo Comparator|Placebo|Placebo arm
11584816|NCT00755560|Active Comparator|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
11584817|NCT00755560|Placebo Comparator|Placebo|Placebo BID for 15 days
11584818|NCT00755547|Experimental|High Intensity|70-85% of peak oxygen uptake for 30 min 3-5 days/week.
11584819|NCT00755547|Experimental|Low Intensity|40-55% of peak oxygen uptake for 60 min 3-5 days/week
11584820|NCT00755547|No Intervention|Sedentary Control|Regular activities of daily living for 6 months
11584821|NCT00755534|Experimental|1|Irinotecan+Erbitux -> XELOX+Erbitux
11584822|NCT00755534|Experimental|2|XELOX+Erbitux ->Irinotecan+Erbitux
11584823|NCT00755521|No Intervention|B|
11584824|NCT00755521|Experimental|A|adding Etoricoxib to the basic therapeutic regimen
11584825|NCT00755508|Experimental|Ramelteon 4 mg QD and Gabapentin 400 mg QD|
11584826|NCT00755508|Experimental|Ramelteon 8 mg QD and Gabapentin 800 mg QD|
11584827|NCT00755508|Experimental|Ramelteon 8 mg QD and Gabapentin Placebo QD|
11584828|NCT00755508|Active Comparator|Gabapentin 800 mg QD|
11584829|NCT00755508|Placebo Comparator|Placebo|
11584830|NCT00755495|Experimental|Ramelteon 8 mg QD and Doxepin 3 mg QD|
11584831|NCT00755495|Experimental|Ramelteon 8 mg QD and Doxepin Placebo QD|
11584832|NCT00755495|Active Comparator|Ramelteon Placebo QD and Doxepin 3 mg QD|
11584833|NCT00755495|Placebo Comparator|Placebo|
11584834|NCT00755482|Active Comparator|1|Subjects were given Aquamin F
11584835|NCT00755482|Placebo Comparator|2|Subjects were given a maltodextran placebo
11584836|NCT00755469|Experimental|1|
11584837|NCT00755456|Active Comparator|Glucose solution|
11584838|NCT00755456|Experimental|Glucose and L-carnitine solution|
11584839|NCT00755443|Experimental|2|
11584840|NCT00755443|Placebo Comparator|1|Bare metal stent
11584841|NCT00755417|Experimental|G-ER 1200 mg|Gabapentin extended-release (G-ER) 1200 mg
11584842|NCT00755417|Experimental|G-ER 1800 mg|Gabapentin extended-release (G-ER) 1800 mg
11584843|NCT00755417|Placebo Comparator|Sugar Pill|Placebo 1200 mg or 1800 mg
11584844|NCT00755404|Active Comparator|A|
11584845|NCT00755404|Experimental|B|
11584846|NCT00755391|Placebo Comparator|supportive psychotherapy|supportive psychotherapy: 14 sessions
11584847|NCT00755391|Active Comparator|cognitive behavior therapy|cognitive behavior therapy: 14 sessions
11584848|NCT00755378|Experimental|1|
11584849|NCT00755378|Placebo Comparator|2|
11584850|NCT00755352|Experimental|1|pravastatin tablets and Welchol tablets
11584851|NCT00755352|Placebo Comparator|2|pravastatin tablets and Welchol placebo tablets
11584852|NCT00755326|Active Comparator|Huo-Luo-Xiao-Ling|Active herb Huo-Luo-Xiao-Ling (HLXL) The subjects in the HLXL group received the medium dose of HLXL (10 capsules/day or 4,000mg/day) in the first 2 weeks to evaluate safety. If no adverse effects were observed, the dose was increased to 14 capsules per day (5,600 mg/day) for the subsequent 6 weeks.
11584853|NCT00755326|Placebo Comparator|Placebo|Placebo Huo-Luo-Xiao-Ling (HLXL): Subjects in the placebo group received an equal number of placebo capsule.
11584854|NCT00755300||1|Standard Total Knee Replacement
11584855|NCT00755300||2|Computer Guided Knee Replacement
11584856|NCT00755287|Active Comparator|insulin glargine|insulin glargine starting dose 10 IU daily in addition to continued prestudy metformin treatment
11584857|NCT00755287|Experimental|taspoglutide 10 mg|taspoglutide 10 mg once weekly in addition to continued prestudy metformin treatment
11584858|NCT00755287|Experimental|taspoglutide 10 mg/20 mg|taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued prestudy metformin treatment
11584859|NCT00755274|Experimental|Group 1: Primed|Have received 2 or more lifetime Flu Vaccinations Prior to Visit 1
11584860|NCT00755274|Experimental|Group 2: Naive/Inadequately Primed|Never Received or Received Only 1 Lifetime Flu Vaccination Prior to Visit 1
11584861|NCT00755261|Experimental|Avastin and Doxorubicin|Patients will be treated with Avastin 15 mg/kg IV infusion plus doxorubicin 60 mg/M2 (body surface area) IV 6-hour infusion on Day 1 of each 21-day treatment cycle. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
11584862|NCT00755248||1|Pts undergoing CABG or OPCAB
11584863|NCT00755235|Experimental|1|Participants will receive depression care management by secure messaging.
11584864|NCT00755235|No Intervention|2|Participants will receive their usual care, with no additional education or care management services.
11584865|NCT00755222|Experimental|AA4500|Clostridial collagenase for injection
11584866|NCT00755222|Placebo Comparator|Placebo|
11584867|NCT00755209|Placebo Comparator|Transamin|"Drug: tranexamic acid
~Loading 1 gram (~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours"
11584868|NCT00755196|Active Comparator|1|AN2728 Ointment, 5%
11584869|NCT00755196|Placebo Comparator|2|AN2728 Ointment vehicle
11584873|NCT00755157|Experimental|1|Docetaxel(metronomic)/Bevacizumab
11584874|NCT00755144|Experimental|1|ROCC
11584875|NCT00755144|Active Comparator|2|LCS
11584876|NCT00755131|Experimental|Training Group|Postinfarction patients undergo 6-month exercise-based Cardiac Rehabilitation Program
11584877|NCT00755131|No Intervention|Control Group|Postinfarction patients NOT undergoing 6-months exercise-based Cardiac Rehabilitation program
11584878|NCT00755118|Experimental|1|LoHP/AIO/Avastin->CPT-11/AIO/Erbitux
11584879|NCT00755092|Active Comparator|1|Doula for Nulliparous women
11584880|NCT00755092|Active Comparator|2|Doula for Multiparous women
11584881|NCT00755079|Placebo Comparator|Arm 1|group of persons with spinal cord injury will receive blinded placebo capsule
11584882|NCT00755079|Experimental|Arm 2|group of persons with spinal cord injury will receive blinded beta-2 adrenergic agonist capsule
11584883|NCT00755066|Experimental|F|Fluticasone propionate 200 µg intranasal
11584884|NCT00755066|Placebo Comparator|P|Placebo intranasal spray
11584885|NCT00755053|Active Comparator|Clotrimazole tablet (Canesten, BAY-B5097)|Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
11584886|NCT00755053|Experimental|Clotrimazole ovule (Canesten, BAY-B5097)|Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
11584887|NCT00755040|Experimental|Ocular Cyclosporine (Restasis)|Patients receive cyclosporine ophthalmic emulsion (Restasis®) drops in each eye twice daily for up to 1 year after transplant.
11584888|NCT00755040|Placebo Comparator|Placebo|Patients receive placebo ophthalmic drops in each eye twice daily for up to 1 year after transplant.
11584889|NCT00755014|Experimental|2|Forty subjects are randomized to a group (n=20) that consumed red wine (100 ml) or a group (n=20) that consumed beer (250 ml) daily for 3 weeks
11584890|NCT00755001||with Plasma HA|BiHapro Hip stem with PPS Ti + Plasma HA
11584891|NCT00755001||with BoneMaster HA|BiHapro Hip stem with PPS Ti + BoneMaster HA
11584892|NCT00754988|Placebo Comparator|Placebo|Once daily oral administration of placebo (matching sitagliptin). Once weekly sc injection of placebo (matching taspoglutide). Continued treatment with metformin at prescribed doses.
11584893|NCT00754988|Active Comparator|Sitagliptin|Once daily oral administration of 100 mg of sitagliptin. Once weekly sc injection of placebo (matching taspoglutide). Continued treatment with metformin at prescribed doses.
11584894|NCT00754988|Experimental|Taspoglutide 10 mg|Once weekly subcutaneous (sc) injection of 10 mg of taspoglutide. Once daily oral administration of placebo (matching sitagliptin). Continued treatment with metformin at prescribed doses.
11584895|NCT00754988|Experimental|Taspoglutide up-titrated to 20 mg|Once weekly sc injection of 10 mg of taspoglutide for the first 4 weeks, then up-titrated to once weekly sc injection of 20 mg of taspoglutide from week 5 onwards. Once daily oral administration of placebo (matching sitagliptin). Continued treatment with metformin at prescribed doses.
11584896|NCT00754975|Experimental|I|JACTAX LD DES
11584897|NCT00754975|Active Comparator|II|TAXUS™ Libertè™ DES
11584898|NCT00754949|Experimental|1|
11584899|NCT00754949|Active Comparator|2|
11584900|NCT00754949|Active Comparator|3|
11584901|NCT00754936|Experimental|Escitalopram|12 week open label with 2 week placebo period (14 weeks total)
11584902|NCT00754923|Experimental|Treatment: Sorafenib|Sorafenib will be administered at a dose of 400 mg taken twice daily, continuously on a 28 day cycle.
11584903|NCT00754910||Group 1|Patients receive porfimer sodium IV over 3-5 minutes and undergo irradiation with red light 48 hours later. Patients receive 2 more treatments at 2-day intervals.
11584904|NCT00754897||1|"We will do a database search to identify children less than 1 year of age that have undergone inguinal hernia surgery during the years of 1999-2007, and children who have had inguinal hernia surgery between the ages of 1 and 3 years during the years 1999-2007.
~We will then do a telephone interview of the parents of these children to determine if there are siblings that are within three years of age and have not have any exposure to anesthetics agents or sedatives before their 3rd birthday."
11584905|NCT00754884|Experimental|A|200 U.I. of intranasal salmon calcitonin
11584906|NCT00754884|Placebo Comparator|B|intranasal saline solution and glycerol
11584907|NCT00754871|Experimental|Arm 1|
11584908|NCT00754871|Experimental|Arm 2|
11584909|NCT00754871|Experimental|Arm 3|
11584910|NCT00754871|Experimental|Arm 4|
11584911|NCT00754858|Experimental|belotecan and Cisplatin|belotecan 0.5 mg/m2 and Cisplatin 60mg/m2
11584912|NCT00754845|Experimental|Letrozole|Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
11584913|NCT00754845|Placebo Comparator|Placebo|Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
11584914|NCT00754832|Experimental|1|Period 1 with Ginseng therapy intervention; Washout Period with no drug; Period 2 with placebo
11584915|NCT00754832|Experimental|2|Period 1 with placebo; Washout period with no drug; Period 2 with ginseng therapy intervention
11584916|NCT00754819|Active Comparator|1|Colchicine 1mg daily oral
11584917|NCT00754819|Placebo Comparator|2|Placebo 1 capsule daily oral
11584918|NCT00754793|Active Comparator|1|escitalopram 10mg - 30mg daily
11584919|NCT00754793|Placebo Comparator|2|
11584920|NCT00754767|Experimental|Arm I|Patients receive oral L-carnitine L-tartrate twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.
11584921|NCT00754767|Placebo Comparator|Arm II|Patients receive oral placebo twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.
11584922|NCT00754754|Experimental|Brain Retraction Monitoring Sensor|
11584923|NCT00754741|No Intervention|Usual care|All Physicians are given limited training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software when they see patients assigned to this arm
11584924|NCT00754741|Active Comparator|Adherence|
11584925|NCT00754741|Active Comparator|Adherence Plus|
11584926|NCT00754728|Experimental|I|
11584927|NCT00754715|Experimental|AZD2516|
11584928|NCT00754715|Placebo Comparator|Placebo|
11584929|NCT00754702|Experimental|1|Vinorelbine metronomic/Lapatinib
11584930|NCT00754689|Active Comparator|Arm 1|Metformin 500mg twice daily (bid) + placebo
11584931|NCT00754689|Active Comparator|Arm 2|Metformin 1000mg bid + placebo
11584932|NCT00754689|Active Comparator|Arm 3|Rimonabant 20mg once daily (od) + placebo
11584933|NCT00754689|Experimental|Arm 4|Rimonabant 10mg bid (from week 2) in combination with metformin 500mg bid
11584934|NCT00754689|Experimental|Arm 5|Rimonabant 10mg bid (from week 2) in combination with metformin 1000mg bid
11584935|NCT00754663|Active Comparator|1|exercise training
11584936|NCT00754663|Placebo Comparator|2|control arm: normal behavior, no additional exercise will be advised
11584937|NCT00754650|Experimental|Bevacizumab 15 mg/kg|Participants received bevacizumab 15 mg/kg intravenously on Day 1 of each 3-week cycle for 8 cycles.
11584938|NCT00754637||510(k) Inclusion Criteria|Any person meeting the inclusion criteria for the device may be included in this study. These patients tend to be those seeking relief from painful or debilitating knee joint disease.
11584939|NCT00754624|Experimental|TI Inhalation Powder|Technosphere® Insulin Inhalation Powder
11584940|NCT00754585||I|"All participants will perform the five Chair Support tasks: (1) quiet standing, sitting, (2) upper back unsupported, (3) sitting, upper back unsupported with Logic Back in place, (4) sitting in a standard ergonomic chair, and (5) sitting in a standard ergonomic chair with Logic Back in place. Aside from the Quiet Standing trials which will be performed first, the order of Chair Support will be randomized. Participants will perform the Chair Support task for 30 minutes while quietly watching a movie DVD of their choice. The DVDs provided will the light in content without a lot of suspense or emotion. Data will be collected for the final two minutes of each 30-minute trial."
11584941|NCT00754572|Experimental|1|
11584942|NCT00754559|Experimental|Tocilizumab|
11584943|NCT00754546|Active Comparator|Arformoterol tartrate|Bronchodilator therapy with arformoterol solution 15 mcg
11584944|NCT00754546|Placebo Comparator|Normal saline|Placebo using normal saline
11584945|NCT00754533|Other|1|Continuous training
11584946|NCT00754533|Other|2|Interval training
11584947|NCT00754520|Experimental|Ceramic On Metal|This arm utilizes the ceramic on metal articulation using the M2a-38™ mm cup.
11584948|NCT00754520|Active Comparator|Metal on Metal|This arm utilizes the metal on metal articulation using M2a-38™ mm cup.
11584949|NCT00754507|Experimental|1|colesevelam tablets and atorvastatin tablets
11584950|NCT00754507|Placebo Comparator|2|colesevelam HCl placebo tablets and atorvastatin tablets
11584951|NCT00754494|Experimental|Erlotinib Hydrochloride (25 mg)|Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
11584952|NCT00754494|Experimental|Erlotinib Hydrochloride (50 mg)|Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
11584953|NCT00754494|Experimental|Erlotinib Hydrochloride (100 mg)|Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
11584954|NCT00754481|Active Comparator|1|
11584955|NCT00754481|Experimental|2|
11584956|NCT00754468|Experimental|Group 1: Cryo Spray Ablation|cryo spray ablation applied to healthy tissue 4 cycles x 10 seconds
11584957|NCT00754468|Experimental|Group 2: Cryo Spray Ablation|cryo spray ablation applied to healthy tissue 2 cycles x20 seconds
11584958|NCT00754455|Experimental|Low dose|
11584959|NCT00754455|Experimental|Mid dose|
11584960|NCT00754455|Experimental|High dose|
11584961|NCT00754455|Placebo Comparator|Placebo|
11584962|NCT00754442|Active Comparator|teriparatide control|control subject
11584963|NCT00754442|Experimental|Teriparatide Patient|Patient with secondary hyperparathyroidism
11584964|NCT00754429|Experimental|A|Losartan 50mg qd for 30 weeks, if blood pressure > 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.
11584965|NCT00754429|Active Comparator|B|Amlodipine 5 mg q.d for 30 weeks, if blood pressure > 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.
11584966|NCT00754416||S.E.S prosthesis|Consecutive series of patients with a S.E.S prosthesis.
11584967|NCT00754403|Experimental|Pioglitazone 30 mg QD + Metformin 1000 mg QD|
11584968|NCT00754403|Active Comparator|Metformin 1000 mg QD|
11584969|NCT00754390|Experimental|Overall Study|Participants consumed 4 experimental diets for 4 weeks each in randomized order
11584970|NCT00754377||PBLI Curriculum group|To evaluate preliminary data on a PBLI curriculum grounded on QI system projects.
11584971|NCT00754377||Comparison group|Received a different curriculum.
11584972|NCT00754364|Experimental|Pemetrexed/Carboplatin|Pemetrexed (500 mg/m2 infusion) plus Carboplatin (AUC5 infusion)
11584973|NCT00754364|Active Comparator|Gemcitabine|Gemcitabine 1250 mg/mq
11584974|NCT00754351|Experimental|1|Bevacizumab->Docetaxel->Gemcitabine
11584975|NCT00754338|Active Comparator|Phase1 - Arm 1|
11584976|NCT00754338|Active Comparator|Phase1 - Arm 2|
11584977|NCT00754338|Active Comparator|Phase 2 - Arm 1|
11584978|NCT00754338|Active Comparator|Phase 2 - Arm 2|
11584979|NCT00754325|Active Comparator|Arm 1 (Dasatinib +Fulvestrant)|
11584980|NCT00754325|Active Comparator|Arm 2 (Fulvestrant)|
11584981|NCT00754312|Experimental|1|ER positive
11584982|NCT00754312|Experimental|2|ER negative and/or PR negative histology
11584983|NCT00754312|Experimental|3|triple negative histology (for ER, PR, HER-2)
11584984|NCT00754286|Experimental|Aromatherapy|Participants will be given aromatherapy wand at the onset of their chemotherapy treatment.
11584985|NCT00754286|Placebo Comparator|Placebo|Participants will be given the placebo wand at the onset of their chemotherapy treatment. Placebo wands will look identical to the scented wands but will not contain a scent.
11584986|NCT00754273||1|PAL samples collected for pneumonia evaluation
11584987|NCT00754260|Experimental|Caffiene reduction group|Caffeine reduction group Intervention is to counseling to reduce caffeine intake
11584988|NCT00754260|No Intervention|No caffeine reduction group|No Caffeine reduction group Intervention is to not counsel regarding caffeine intake
11584989|NCT00754247|Experimental|Regimen A|0.5% hydrocortisone, silicone, vitamin E lotion
11584990|NCT00754247|Experimental|Regimen B|Onion extract gel
11584991|NCT00754247|Placebo Comparator|Regimen C|Cetearyl alcohol lotion
11584992|NCT00754234|Experimental|MyPyramid Menu Days 1-7|Iron absorption measured from one of the 7 different USDA MyPyramid menus for 1 day each, in randomized order for each subject, separated by 2 weeks
11584993|NCT00754221|Experimental|1|
11584994|NCT00754208|Other|methylpehnidate|open-label treatment with methylphenidate
11584995|NCT00754195|Active Comparator|1|Insertion distance of thoracic epidural catheter: 3 cm
11584996|NCT00754195|Active Comparator|2|Insertion distance of thoracic epidural catheter: 5 cm
11584997|NCT00754195|Active Comparator|3|Insertion distance of thoracic epidural catheter: 7 cm
11584998|NCT00754182|Experimental|A|Patients underwent thyroidectomy, emithyroidectomy, parathyroidectomy sutured with synthetic glue
11584999|NCT00754182|Active Comparator|B|Patients underwent thyroidectomy, emithyroidectomy, parathyroidectomy sutured with subcuticular suture
11585000|NCT00754156|Active Comparator|1 ABRA plus KCI ABThera or KCI VAC|ABRA Abdominal Wound Closure System in combination with KCI ABThera or KCI VAC
11585001|NCT00754156|Active Comparator|KCI V.A.C. Therapy or ABThera Alone|KCI V.A.C. Therapy ABThera Alone
11585002|NCT00754143|Placebo Comparator|A|Placebo
11585003|NCT00754143|Experimental|B|FG-3019 5 mg/kg
11585004|NCT00754143|Experimental|C|FG-3019 10 mg/kg
11585005|NCT00754130|Experimental|Placebo/MK-0941 20mg|Participants received Placebo during Period 1 and MK-0941 20 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
11585006|NCT00754130|Experimental|MK-0941 5mg/Placebo|Participants received MK-0941 5 mg during Period 1 and Placebo during Period 2. There was a washout period of at least 8 days between the two treatment periods.
11585007|NCT00754130|Experimental|MK-0941 5mg/MK-0941 20mg|Participants received MK-0941 5 mg during Period 1 and MK-0941 20 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
11585008|NCT00754130|Experimental|Placebo/MK-0941 40mg|Participants received Placebo during Period 1 and MK-0941 40 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
11585009|NCT00754130|Experimental|MK-0941 10mg/Placebo|Participants received MK-0941 10 mg during Period 1 and Placebo during Period 2. There was a washout period of at least 8 days between the two treatment periods.
11585010|NCT00754130|Experimental|MK-0941 10mg/MK-0941 40mg|Participants received MK-0941 10 mg during Period 1 and MK-0941 40 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
11585011|NCT00754117||All patients|All patients
11585012|NCT00754104|Experimental|A|
11585013|NCT00754091|Experimental|1|
11585014|NCT00754078|Other|1|anal cancer patients treated with tomotherapy and chemotherapy
11585015|NCT00754065|Experimental|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one capsule BAY86-5027 [estradiol valerate (EV) / dienogest (DNG)] for 26 days, followed by one capsule placebo for 2 days (28 days total per cycle) for 13 treatment cycles (treatment encapsulated)
11585016|NCT00754065|Active Comparator|Ortho Tri-Cyclen Lo|Daily oral administration of one capsule Ortho Tri-Cyclen Lo [Ethinylestradiol (EE)/ Norgestimate (NGM)] for 21 days, followed by one capsule placebo for 7 days (28 days total per cycle) for 13 treatment cycles (treatment encapsulated)
11585017|NCT00754052|Active Comparator|1|
11585018|NCT00754052|Active Comparator|2|
11585019|NCT00754052|Placebo Comparator|3|
11585020|NCT00754039|Experimental|1|Welchol + TriCor
11585021|NCT00754039|Placebo Comparator|2|Welchol + placebo
11585022|NCT00754026|Active Comparator|1|
11585023|NCT00754026|Active Comparator|2|
11585024|NCT00754013|Active Comparator|Donepezil|
11585025|NCT00754013|Placebo Comparator|Placebo|
11585026|NCT00754000||Cohort 1|All patients in study
11585027|NCT00753987|Experimental|1|
11585028|NCT00753974||biological specimen|Biological specimen is taken from cardiovascular procedures that would have been discarded
11585029|NCT00753961|Active Comparator|1|fermented dairy product
11585030|NCT00753961|Placebo Comparator|2|non fermented acidified dairy product.
11585031|NCT00753948|Experimental|Chronic Tetraplegia|Individuals with chronic tetraplegia
11585032|NCT00753948|Active Comparator|Mild Asthma|Individuals with diagnosed mild asthma
11585033|NCT00753948|Placebo Comparator|Healthy Control|Neurologically intact, otherwise healthy, age-matched control
11585034|NCT00753935|Experimental|Enteric-coated aspirin|patients received enteric-coated aspirin 81 mg qd for 2 weeks
11585035|NCT00753935|Active Comparator|Chewable aspirin|Patients received chewable aspirin 81 mg qd for 2 weeks
11585036|NCT00753922|Other|Primary Augmentation|The Augmentation cohort will include patients who have post-lactational mammary involution or wish general breast enlargement.
11585037|NCT00753922|Other|Primary Reconstruction|"The Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity.
~Congenital deformities will include deformities of the breast itself as well as skeletal abnormalities reflected in breast deformity or asymmetry."
11585038|NCT00753922|Other|Revison Augmentation|Patients in this cohort will have had previous breast augmentation with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast augmentation surgery.
11585039|NCT00753922|Other|Revision Reconstruction|Patients in this cohort will have had previous breast reconstruction with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast reconstruction surgery.
11585040|NCT00753909|Experimental|1|Paclitaxel/Carboplatin/Bevacizumab
11585041|NCT00753896|Experimental|1|
11585042|NCT00753883|Active Comparator|1|simvastatin 20 mg/qd for 8 weeks, and then add on ezetrol 10mg (if ldl-c . 160mg/dl) for another 8 weeks.
11585043|NCT00753883|Active Comparator|2|ezetrol 10 mg/qd for 8 weeks, and then add on simvastatin 20 mg qd (if ldl-c . 160mg/dl) for another 8 weeks
11585044|NCT00753870|Experimental|A|Otherwise healthy smokers
11585045|NCT00753857|Experimental|1|Participants received 2 ads for drugs to reduce cardiovascular risk with drug facts boxes second pages.
11585163|NCT00752960||B|patients receiving risperidone
11585046|NCT00753857|Active Comparator|2|Participants receive the same 2 advertisements for drugs to reduce cardiovascular risk with the standard second page (i.e., brief summary)
11585047|NCT00753831|Experimental|1|Aurosling
11585048|NCT00753818|Experimental|1|
11585049|NCT00753818|Experimental|2|
11585050|NCT00753818|Experimental|3|
11585051|NCT00753818|Other|4|Control
11585052|NCT00753792|Active Comparator|1|methylprednisolone 1.000 mg/day intravenous administration during three days + placebo of methylprednisolone orally administered
11585053|NCT00753792|Experimental|2|methylprednisolone 1.250 mg/day orally administered during three days + placebo of methylprednisolone intravenous administered
11585054|NCT00753779|Experimental|1|colesevelam HCl Tablets and simvastatin tablets
11585055|NCT00753779|Placebo Comparator|2|simvastatin and Welchol placebo
11585056|NCT00753766|Experimental|Multifactorial Intervention|Mulitfactorial intervention - addressing glucose, blood pressure, lipids, smoking, nutrition and exercise.
11585057|NCT00753766|No Intervention|Usual care|Control group
11585058|NCT00753740|Experimental|12mg/m2/dose|12mg per meter squared per dose
11585059|NCT00753740|Experimental|15mg/m2/dose|15mg per meter squared per dose
11585060|NCT00753740|Placebo Comparator|Placebo|5% dextrose infusion (placebo)
11585061|NCT00753714|Experimental|A|Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.
11585062|NCT00753714|Placebo Comparator|B|Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.
11585063|NCT00753688|Placebo Comparator|PLACEBO|matching placebo 800 mg once daily orally
11585064|NCT00753688|Experimental|PAZOPANIB|800 mg once daily orally
11585065|NCT00753675|Experimental|A|Vandetanib 300 mg as a once daily oral dose, from Day 1
11585066|NCT00753675|Experimental|B|Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy)
11585067|NCT00753675|Placebo Comparator|C|Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy).
11585068|NCT00753662|Active Comparator|1|15 patients in group 1 will be treated with 1Hz frequency
11585069|NCT00753662|Active Comparator|2|15 patients in group 2 will be treated with 1Hz frequency 10Hz
11585070|NCT00753662|Sham Comparator|3|15 patients in group 3 will be treated with SHAM (1Hz/10Hz)
11585071|NCT00753649|Experimental|Aboriginal infants group|
11585072|NCT00753649|Active Comparator|Other Non-Aboriginal infants|
11585073|NCT00753636|Experimental|Dynacirc CR (Isradipine)|Dynacirc CR (Isradipine) will start at 5mg dose and increased in increments of 5mg every 2 weeks
11585074|NCT00753623|Active Comparator|Ramelteon first, placebo second|"In a crossover design, a subject will be first assigned to the ramelteon arm and then switched over to the placebo arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night.The ramelteon and placebo will be blinded by the central pharmacy.
~The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long."
11585075|NCT00753623|Placebo Comparator|Placebo first, ramelteon second|"In a crossover design, a subject will be first assigned to the placebo arm and then switched over to the ramelteon arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night. The ramelteon and placebo will be blinded by the central pharmacy.
~The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long."
11585076|NCT00753597|Experimental|1|Receiving active treatment
11585077|NCT00753571|Active Comparator|1|1,CTG,po
11585078|NCT00753571|Placebo Comparator|2|
11585079|NCT00753558|Placebo Comparator|2|Oral solution of 0.45% saline and oral solution of H2O & saccharine. Oral gel composed of mineral oil, gelatine powder, pectin, sodium carboxymethylcellulose, polyethylene
11585080|NCT00753558|Active Comparator|1|Oral solution and buccal gel of gentamicin and polymyxin E
11585081|NCT00753545|Experimental|1|AZD2281
11585082|NCT00753545|Placebo Comparator|2|matching placebo
11585083|NCT00753532|Placebo Comparator|MRI(+ve),|121 volunteers in MRI(+ve) cohort were randomized into two groups to receive either 200mg palm vitamin E (tocotrienols) softgel capsules or a identical looking placebo twice daily. 62 volunteers received 200mg palm vitamin E (tocotrienols) and the remaining 59 received placebo. They were followed up every 3 months for a period of 2 years for their blood biochemistry profile and MRI of the brain was conducted at baseline, 12 months and 24 months..
11585084|NCT00753532|Placebo Comparator|MRI(-ve)|120 volunteers in MRI(-ve) cohort were randomized into two groups to receive either 200mg palm vitamin E (tocotrienols) softgel capsules or a identical looking placebo twice daily. 63 volunteers received 200mg palm vitamin E (tocotrienols) and the remaining 57 received placebo. They were followed up every 3 months for a period of 1 year for their blood biochemistry profile and MRI of the brain was conducted at baseline and 12 months.
11585085|NCT00753519|Experimental|Real iTBS|iTBS is a novel form of excitatory rTMS that may induce larger and longer lasting changes that standard rTMS. iTBS consists of bursts of 3 pulses at 50 Hz repeated at 200 msec intervals. The 2 sec trains were repeated 20 times every 10 sec. iTBS was applied to the primary motor and the dorsolateral prefrontal cortex bilaterally.
11585086|NCT00753519|Sham Comparator|Sham iTBS|The sham coil was placed in the same areas, and made a similar sound as the rTMS but was without a magnetic pulse.
11585087|NCT00753506|Active Comparator|Artemisinin|100 mg artemisinin capsule
11585088|NCT00753506|Placebo Comparator|Placebo|Identical looking placebo capsule
11585089|NCT00753493|Experimental|1|This is a one arm pharmacokinetic and safety study.
11585090|NCT00753467|Experimental|1|IFN-γ 1b monotherapy: 200 micro-grams daily for 30 days
11585091|NCT00753467|Experimental|2|IFN-γ 1b 200 micro-grams daily) combination therapy with Adefovir dipivoxil (10 mg daily) for 30 days
11585092|NCT00753467|Active Comparator|3|Adefovir dipivoxil monotherapy (10 mg QD) 30 days
11585093|NCT00753454|Experimental|CDP870|Patients having completed the week 34 assessment in C87077 (NCT00580840) or patients having been randomized at Week 18 and having met the pre-defined criteria for flare, will be given the option to enroll in C87084 and receive: 400 mg CZP at Entry, Week 2, and Week 4 followed by 200 mg every two weeks in combination with MTX until the drug is commercially available for the indication of RA in the patient's country or region (or until further notice from UCB).
11585094|NCT00753441|Experimental|A|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
11585095|NCT00753441|Active Comparator|B|Endoscopic biliary stenting using metal stent (completed by duodenal stent, if necessary)
11585096|NCT00753428||Baseline evaluation|Prior to the implementation of the pilot project of giving routine HAART as a method of PMTCT, a minimum of 387 households with children under the age of two will be sampled within each community, for a total of 1,548 households for the first round.
11585097|NCT00753428||Following implementation|Two years after full implementation of the pilot project of giving routine HAART for PMTCT across all sites, a minimum of 387 households with children under the age of two will be sampled within each community, for a total of 1,548 households. [Note: At time of implementation, we used the same sampling frame for each community. Because of the population increased observed in parts of Kafue, the final number of households significantly exceeded the minimum threshold.]
11585098|NCT00753415|Experimental|Part A: V935 LD|Two intramuscular (IM) injections of V935 low dose (LD), 1 given every other week over a 3-week period.
11585099|NCT00753415|Experimental|Part A: V934 LD(3)+V935 LD|Three electroporation (EP) injections of V934 (LD) , 1 given every other week over a 5-week period. Following a 4-week observation period, 2 IM injections of V935 (LD) will be administered, 1 given every other week over a 3-week period.
11585100|NCT00753415|Experimental|Part A: V935 HD|Two IM injections of V935 high dose (HD), 1 given very other week over a 3-week period.
11585101|NCT00753415|Experimental|Part A: V934 HD(3)+V935 HD|Three EP injections of V934 (HD), 1 given every other week over a 5-week period. Following a 4-week observation period, 2 IM injections of V935 (HD) will be administered, 1 given every other week over a 3-week period.
11585102|NCT00753415|Experimental|Part A: V934 HD(5)+V935 HD|Five EP injections of V934 (HD), 1 given every other week over a 9-week period. Following a 4-week observation period, 2 IM injections of V935 (HD) will be administered, 1 given every other week over a 3-week period.
11585103|NCT00753415|Experimental|Part B: V935 LD/V934 Booster|Participants who completed Part A could enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster were administered, 1 given every 2 weeks.
11585104|NCT00753415|Experimental|Part B: V934 LD(3)+V935 LD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
11585105|NCT00753415|Experimental|Part B: V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
11585106|NCT00753415|Experimental|Part B: V934 HD(3)+V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
11585107|NCT00753415|Experimental|Part B: V934 HD(5)+V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
11585108|NCT00753402|Placebo Comparator|A|IV Endotoxin plus saline vehicle (placebo)
11585109|NCT00753402|Active Comparator|B|IV Endotoxin plus IV epinephrine
11585110|NCT00753389||1|
11585111|NCT00753363|Experimental|Arm 1|6 months of aerobic exercise training
11585112|NCT00753363|Experimental|Arm 2|6 months of weight loss
11585113|NCT00753350|Experimental|1|Sensate™ anti-Obesity device
11585114|NCT00753337|Experimental|Assurant Cobalt Iliac Stent|Assurant® Cobalt Iliac Stent System
11585115|NCT00753324|Experimental|Routine three-drug antiretroviral prophyalxis|Cohort of 160 HIV-infected women, approached at > 28 weeks gestation and initiated on routine HAART for the purposes of PMTCT.
11585116|NCT00753324|No Intervention|Control arm|A cohort of 160 women will be enrolled from the control clinics, from 28 weeks gestation onward. At these sites, the antenatal zidovudine will be offered, with provision of single-dose nevirapine for self-administration in labor. This practice is in accordance with the current standard of care recommended by the Zambian National Guidelines for PMTCT.
11585117|NCT00753311|Active Comparator|Rizatriptan|Patients with migraine with and without aura will be enrolled and randomly provided with study drug (rizatriptan 10 mg MLT or placebo, ratio 1:1). Patients were encouraged to take migraine medication as soon as their migraine headache became moderate or severe. If the moderate or severe migraine headache persisted 2 h after dosing, or recurred within 24 h, patients had the option of taking their own rescue medication but triptans and ergot derivatives were prohibited for 24 h after study medication intake.
11585164|NCT00752960||C|Patients receiving quetiapine
11585165|NCT00752960||D|Patients receiving aripiprazole
11585166|NCT00752960||E|patients receiving ziprasidone
11585167|NCT00752947|Experimental|A|
11585168|NCT00752947|Active Comparator|B|
11585169|NCT00752934|Experimental|group a|Baclofen followed by Placebo
11585118|NCT00753311|Placebo Comparator|placebo|Patients who met all the study entry criteria were enrolled and randomly allocated to receive either rizatriptan 10 mg wafer or placebo (ratio 1:1).Patients were encouraged to take migraine medication as soon as their migraine headache became moderate or severe. If the moderate or severe migraine headache persisted 2 h after dosing, or recurred within 24 h, patients had the option of taking their own rescue medication but triptans and ergot derivatives were prohibited for 24 h after study medication intake.
11585119|NCT00753298|Experimental|LoFric Primo (POBE) single-use urinary catheter|
11585120|NCT00753298|Active Comparator|LoFric Primo (PVC) single-use urinary catheter|
11585121|NCT00753285|Experimental|Renal Denervation|
11585122|NCT00753272|Experimental|FluNG Group|subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
11585123|NCT00753272|Active Comparator|Fluarix Group|subjects received 2 doses (1 dose per season) of Fluarix™ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
11585124|NCT00753259|Experimental|AF Clinic|
11585125|NCT00753259|Active Comparator|Care as Usual|
11585126|NCT00753246|Placebo Comparator|Arm B|adults with TMZ, RT
11585127|NCT00753246|Experimental|Arm A|adults with TMZ, RT, nimotuzumab
11585128|NCT00753220|Experimental|VDC2008|Cryoablation of prostate followed by dendritic cell injection (dose of 2.5 x 10^7, 7.5 x 10^7, or 1.0 x 10^8 cells depending on assigned cohort) into prostate and low dose cyclophosphamide therapy (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles [1 cycle = 4 weeks] starting Week 2 after cryoablation and going to Week 26)
11585129|NCT00753207|Experimental|Lapatinib and Epirubicin|Fixed dose of lapatinib in combination with escalating dose of epirubicin.
11585130|NCT00753194||1|"Newborns that show a Pass On the newborn hearing screening program before hospital discharge"
11585131|NCT00753194||2|"Newborns that show a fail and will be retested in 15 days."
11585132|NCT00753181|Experimental|A1|Diabetes Meal Plan with Experimental Diabetes-Specific nutritional shake
11585133|NCT00753181|Active Comparator|A2|Usual diet
11585134|NCT00753181|Experimental|A3|Diabetes Meal Plan with Experimental Diabetes-Specific Nutritional Shake, diabetes specific Cereal, and diabetes specific snack bars.
11585135|NCT00753168|Experimental|1|OT-730 ophthalmic solution
11585136|NCT00753168|Active Comparator|2|timolol maleate ophthalmic solution
11585137|NCT00753168|Placebo Comparator|3|placebo eye drops
11585138|NCT00753142|Active Comparator|Participants with ketosis-prone diabetes|Obese African Americans with type 2 diabetes with history of diabetic ketoacidosis (DKA) receiving Intralipid 20% and a glucose infusion.
11585139|NCT00753142|Active Comparator|Participants with ketosis-resistant diabetes|Obese African American with type 2 diabetes with hyperglycemia without ketosis receiving Intralipid 20% and a glucose infusion.
11585140|NCT00753142|Active Comparator|Non-diabetic control group|Obese African Americans without diabetes receiving a glucose infusion.
11585141|NCT00753129|Active Comparator|1|Start with turning to prone position without head elevation, after 2 hours 30° head elevation, after 2 hours back to PP without head elevation.
11585142|NCT00753129|Active Comparator|2|Start with turning to prone position with 30° head elevation, after 2 hours PP without head elevation, after 2 hours back to 0° PP.
11585143|NCT00753103|Experimental|1|Patients with active vasculitis who receive infliximab in addition to standard immunosuppressive therapy
11585144|NCT00753103|Active Comparator|2|Patients with active ANCA associated vasculitis who receive standard immunosuppression but no infliximab
11585145|NCT00753090|Experimental|VG DDRP|This arm utilizes the Vanguard™ Deep Dish Rotating Platform Knee.
11585146|NCT00753090|Active Comparator|VG CR|This arm utilizes the Vanguard™ Cruciate Retaining Knee.
11585147|NCT00753064|Active Comparator|AScVS|a clinical scoring system for dose requirement for AScVS is evolved based on sweating, pulse rate, respiratory rate, blood pressure, CNS effects and presence of priapism. Computed doses were given according to clinical grading as intravenous bolus slowly.
11585148|NCT00753064|Active Comparator|Prazosin.|Prazosin therapy Prazosin (30 micrograms/Kg/dose): 500 micrograms for pediatric patient, and 1mg for adult patients) will be given every 3 hourly orally till complete recovery.
11585149|NCT00753064|Active Comparator|AScVS + Prazosin|Combination AScVS and Prazosin therapy In this group, AScVS therapy will be given as mentioned in AScVS therapy group and in addition, prazosin (500 micrograms for pediatric patient and 1mg for adult patients,30 micrograms/Kg/dose) every 3 hourly will be given.
11585150|NCT00753051|Active Comparator|1.|clozapine as the main agent and it will be adjuncted by haloperidol
11585151|NCT00753051|Active Comparator|2.|clozapine as the main agent and it will be adjuncted by electroconvulsive therapy
11585152|NCT00753025|Experimental|CD133|
11585153|NCT00753025|Experimental|TNC|
11585154|NCT00753025|Placebo Comparator|Placebo|
11585155|NCT00753012|Experimental|Lisdexamfetamine|"Adults who meet DSM-IV-TR criteria for ADHD.
~Group 1 is normotensive adults; Group 1 does not have high blood pressure. Group 2 is primary hypertensive adults; Group 2 does have high blood pressure and is being treated with stable doses of hypertensive medications achieving a blood pressure of <135/85."
11585156|NCT00752999|Experimental|A|150 mg tablet, oral, twice-a-day
11585157|NCT00752999|Placebo Comparator|B|Placebo tablet, oral, twice-a-day
11585158|NCT00752986|Experimental|Vandetanib at the dose of 100 mg|vandetanib at the dose of 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)
11585159|NCT00752986|Experimental|Vandetanib at the dose of 300 mg|vandetanib at the dose of 300 mg orally once-daily plus placebo to match vandetanib 100 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)
11585160|NCT00752986|Placebo Comparator|Placebo to match vandetanib 100 mg and 300 mg|placebo to match vandetanib 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3).
11585161|NCT00752973|Experimental|Treatment arm|MALG treatment
11585162|NCT00752960||A|Patients receiving olanzapine
11585170|NCT00752934|Experimental|group b|Placebo followed by Baclofen
11585171|NCT00752921|Active Comparator|A|Healthy Patients, age 18-65, who typically suffer from a Headache while fasting
11585172|NCT00752921|Placebo Comparator|B|Healthy Patients, age 18-65, who typically suffer from a Headache while fasting
11585173|NCT00752908||Obese patients|Obese patients
11585174|NCT00752908||Normal weight patients and volunteers|Normal weight patients and volunteers
11585175|NCT00752895|Experimental|Arm I - Ginseng|Patients receive oral American ginseng extract twice daily.
11585176|NCT00752895|Placebo Comparator|Arm II - Placebo|Patients receive oral placebo twice daily.
11585177|NCT00752869|Placebo Comparator|B|This group will meet the same inclusion and exclusion criteria as the group receiving the study drug
11585178|NCT00752869|Active Comparator|A|This arm will receive the active medication dutasteride
11585179|NCT00752856|Experimental|1 - Kaletra + Isentress taken twice daily|Kaletra (lopinavir/ritonavir 400/100 mg) + Isentress (Raltegravir 400 mg) twice-daily
11585180|NCT00752856|Active Comparator|2 - Atripla taken once daily|Sustiva (EFV 600 mg), Viread (TDF 300 mg) and Emtriva (FTC 200 mg) taken as Atripla® once-daily
11585181|NCT00752843|Experimental|1|
11585182|NCT00752830|Experimental|1|AZD0328 administration during fasting condition
11585183|NCT00752830|Experimental|2|AZD0328 administration after food intake
11585184|NCT00752817|Experimental|SC|Subjects (surgical trainees) randomised to train under a proficiency-based progression virtual reality simulation curriculum
11585185|NCT00752817|Active Comparator|CC|Subjects (surgical trainees) randomised to the current surgical training curriculum
11585186|NCT00752804|Experimental|1|Dialysis during 4 hours
11585187|NCT00752804|Active Comparator|2|Dialysis during 6 hours
11585188|NCT00752804|Active Comparator|3|Dialysis during 8 hours
11585189|NCT00752791|Experimental|Peginesatide|
11585190|NCT00752739|Placebo Comparator|Arm I|Patients receive oral placebo once daily for 48 months in the absence of disease progression or unacceptable toxicity.
11585191|NCT00752739|Experimental|Arm II|Patients receive low-dose oral selenium once daily for 48 months in the absence of disease progression or unacceptable toxicity.
11585192|NCT00752739|Experimental|Arm III|Patients receive high-dose oral selenium once daily for 48 months in the absence of disease progression or unacceptable toxicity.
11585193|NCT00752726|Active Comparator|Orlistat|Orlistat 60 milligram (mg) capsules to be consumed orally with each meal 3 times per day
11585194|NCT00752726|Placebo Comparator|Placebo|Placebo to match Orlistat 60 mg capsules to be consumed orally with each meal 3 times per day.
11585195|NCT00752713||1|Patients presenting to hospital with AMI
11585196|NCT00752713||2|healthy volunteers as control group
11585197|NCT00752700|No Intervention|1|Control group
11585198|NCT00752700|Active Comparator|2|Conventional resistance training program (CRT)
11585199|NCT00752700|Experimental|3|Whole body vibration resistance training (WBV) on the FITVIBE-platform
11585200|NCT00752687|Other|1|Single dose of ABT-072, dose escalation ranging from 10 mg to 320 mg or placebo in healthy volunteers
11585201|NCT00752687|Other|2|HCV positive subjects administered 160mg ABT-072 or placebo, multi-dose, QD
11585202|NCT00752674|Experimental|1|Neuromuscular balance
11585203|NCT00752622|Experimental|Shortened interval|Infliximab 5 mg/kg, then Infliximab 5 mg/kg every 6 weeks
11585204|NCT00752622|Experimental|Increased dose|Infliximab 5 mg/kg, then Infliximab 7 mg/kg every 8 weeks
11585205|NCT00752609|Experimental|Peginesatide|
11585206|NCT00752596|Experimental|1|1 tablet of 125 mg/day of azimilide 2HCl, oral
11585207|NCT00752583|Experimental|1|Peritoneal dialysis
11585208|NCT00752583|Active Comparator|2|Haemodialysis
11585209|NCT00752570|Placebo Comparator|2|AMG 386 placebo QW, FOLFIRI Q2W
11585210|NCT00752570|Active Comparator|1|Arm 1 : AMG 386 10 mg/kg QW, FOLFIRI Q2W
11585211|NCT00752557|Experimental|1|rhBMP-2/CPM , 1.0 mg/mL
11585212|NCT00752557|Experimental|2|rhBMP-2/CPM , 2.0 mg/mL
11585213|NCT00752557|Active Comparator|3|Oral bisphosphonate therapy (standard of care)
11585214|NCT00752531|Experimental|HAT|
11585215|NCT00752531|No Intervention|Control|
11585216|NCT00752505|Experimental|A|
11585217|NCT00752505|Experimental|B|
11585218|NCT00752492|Active Comparator|Study intervention|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. Ventilation will be assisted to maintain tidal volume of 8-10 mL/kg and respiratory rate of 20-25 breaths per minute to achieve minute ventilation of 15-20 L/min. Isocapnia manifold will maintain end-tidal PCO2 in range of 40-50 mm Hg.
11585219|NCT00752479|Experimental|1|
11585220|NCT00752479|Active Comparator|2|
11585221|NCT00752453|Experimental|1|Dialysis during 4 hours
11585222|NCT00752453|Experimental|2|Dialysis during 6 hours
11585223|NCT00752453|Experimental|3|Dialysis during 8 hours
11585224|NCT00752414|Experimental|1|MP-376 Inhalation Solution
11585225|NCT00752414|Placebo Comparator|2|Placebo
11585226|NCT00752401|Active Comparator|1|6800 IU/day of Cholecalciferol (Vitamin D3) orally for one year
11585227|NCT00752401|Placebo Comparator|2|Oral placebo solution daily for one year
11585228|NCT00752375|Active Comparator|A|Eligible children will be randomized to antibiotic prophylaxis. Children under 3 months will receive amoxicillin 10mg/kg once per day. Children >3months will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component). Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day.
11585229|NCT00752375|Placebo Comparator|B|Eligible children will then be randomized to placebo.
11585230|NCT00752362|Active Comparator|1|Percutaneous coronary intervention with bare metal stent
11585231|NCT00752362|Experimental|2|Percutaneous coronary intervention with paclitaxel-eluting stent
11585232|NCT00752362|Experimental|3|Percutaneous coronary intervention with sirolimus-eluting stent
11585233|NCT00752323|Experimental|Arm I: Newly diagnosed GBM 10mg/kg|Arm I: Newly diagnosed GBM patients receive oral aminolevulinic acid(10mg/kg)at 6 hours before the midpoint of surgery.
11585325|NCT00751673||TESS prosthesis|Consecutive series of patients with a TESS prosthesis.
11585234|NCT00752323|Experimental|Arm II: Newly diagnosed GBM 20mg/kg|Arm II: Newly diagnosed GBM patients receive oral aminolevulinic acid (20mg/kg)at 6 hours before the midpoint of surgery.
11585235|NCT00752323|Experimental|Arm III: Recurrent GBM 10mg/kg|Arm III: Recurrent GBM patients receive oral aminolevulinic acid (10mg/kg)at 6 hours before the midpoint of surgery.
11585236|NCT00752323|Experimental|Arm IV: Recurrent GBM 20mg/kg|Arm IV: Recurrent GBM patients receive oral aminolevulinic acid (20mg/kg)at 6 hours before the midpoint of surgery.
11585237|NCT00752297|Active Comparator|1|Mentor Purified Toxin Botulinum Toxin Type A
11585238|NCT00752297|Placebo Comparator|2|Preservative-free Saline
11585239|NCT00752284|Experimental|A|Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure
11585240|NCT00752284|Active Comparator|B|"Control Group:
~total excision of lower wisdom tooth"
11585241|NCT00752271||1|24 adults with meniscal damage for which arthroscopy is clinically indicated
11585242|NCT00752271||2|8 adults who have already undergone meniscal resection to serve as positive controls
11585243|NCT00752258|Experimental|1|Mentor Purified Toxin Botulinum Toxin Type A
11585244|NCT00752245|Experimental|1|Dialysis during 4 hours
11585245|NCT00752245|Active Comparator|2|Dialysis during 6 hours
11585246|NCT00752245|Active Comparator|3|Dialysis during 8 hours
11585247|NCT00752232|Experimental|ACC-001+QS-21|Active vaccine + adjuvant, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
11585248|NCT00752232|Experimental|ACC-001|Active vaccine, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
11585249|NCT00752232|Placebo Comparator|QS-21|Adjuvant, IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
11585250|NCT00752232|Placebo Comparator|PBS|Placebo, IM injection, Day 1, month 3, 6, 9, 12
11585251|NCT00752219|Experimental|NXL104/CAZ/MTZ|NXL104/ceftazidime + metronidazole
11585252|NCT00752219|Active Comparator|Meropenem|
11585253|NCT00752206|Active Comparator|Saracatinib|Saracatinib will be administered as a once daily, oral dose of 175 mg, for a 28-day cycle, with no breaks between cycles. The duration of treatment with saracatinib will be 13 cycles.
11585254|NCT00752206|Placebo Comparator|Placebo|Placebo will be administered as a once daily, oral dose of 175 mg, for a 28-day cycle, with no breaks between cycles. The duration of treatment with placebo will be 13 cycles.
11585255|NCT00752193|Experimental|1|Probiotic lactobacilli
11585256|NCT00752193|Placebo Comparator|2|Placebo
11585257|NCT00752180|Experimental|Wosulin R|Wosulin R,Regular insulin for injection(Recombinant Human Insulin)(600 nmol/ml, 100IU/ml)in vials 10.0 ml given subcutaneously.
11585258|NCT00752180|Active Comparator|Actrapid|Actrapid, Regular insulin for injection (Recombinant Human Insulin) (600nmol/ml,100IU/ml)in vials 10.0 ml given subcutaneously.
11585259|NCT00752167||Case|all Division I athletes, male and female, at the University of Arizona that are currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff
11585260|NCT00752167||Control|control athletes (ie, not currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff and/or not currently using asthma medications) from the same sport
11585261|NCT00752141|Experimental|1|oral oxybutynin
11585262|NCT00752141|Experimental|2|oxybutynin topical gel
11585263|NCT00752141|Placebo Comparator|3|placebo tablets plus placebo gel
11585264|NCT00752115|Active Comparator|A|Sildenafil plus carboplatin and weekly paclitaxel
11585265|NCT00752115|Placebo Comparator|P|carboplatin and weekly paclitaxel
11585266|NCT00752102|Active Comparator|Calcitriol|"Calcitriol is a synthetic vitamin D analog which is active in the regulation of the absorption of calcium from the gastrointestinal tract and its utilization in the body. Calcitriol is available as capsules containing 0.25 mcg or 0.5 mcg calcitriol and as an oral solution containing 1 mcg/ml of calcitriol. All dosage forms contain butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) as antioxidants.
~Subjects taking calcitriol started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels."
11585267|NCT00752102|Active Comparator|Paricalcitol|"Paricalcitol, USP, the active ingredient in Zemplar® Capsules, is a synthetically manufactured analog of calcitriol, the metabolically active form of vitamin D indicated for the prevention and treatment of secondary hyperparathyroidism in chronic kidney disease. Zemplar is available as soft gelatin capsules for oral administration containing 1 mcg, 2 mcg or 4 mcg of paricalcitol. Each capsule also contains medium chain triglycerides, alcohol, and butylated hydroxytoluene.
~Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels."
11585268|NCT00752089|Experimental|Sodium fluoride/potassium nitrate/Isopentane dentifrice|Participants to brush their teeth for one timed minute twice daily with a gel to foam dentifrice containing active ingredients: 1450 ppm F as sodium fluoride (NaF) and 5% potassium nitrate (KNO3) and isopentane as an excipient ingredient.
11585269|NCT00752089|Experimental|NaF/KNO3 Dentifrice|Participants to brush their teeth for one timed minute twice daily with a gel to foam dentifrice, containing as active ingredients: 1450 ppm NaF and 5% KNO3 but no isopentane.
11585270|NCT00752089|Active Comparator|NaF Dentifrice|Participants to brush their teeth for one timed minute twice daily with a dentifrice containing 1450 ppm F as NaF.
11585271|NCT00752089|Placebo Comparator|Placebo Dentifrice|Participants to brush their teeth for one timed minute twice daily with a fluoride free dentifrice (0 ppm F).
11585272|NCT00752076|Experimental|1|We collected malignant pleural effusion for NSCLC cell lines with different EGFR mutations development and then we can compare the difference responses and signal pathways in these cell lines. We can also explore the detailed mechanism of TKI responsive cancer cell and try to develop other agent to enhance the pathways.
11585273|NCT00752063|Experimental|A|All subjects will receive Sorafenib with Capecitabine and Oxaliplatin
11585274|NCT00752050|Active Comparator|1|Mentor Purified Toxin Botulinum Toxin Type A - Part II ONLY. (Part I is Single Group and all participants receive active drug and are not randomized)
11585275|NCT00752050|Placebo Comparator|2|Preservative-free Saline - Part II ONLY. (Part I is Single Group and all participants receive active drug and are not randomized)
11585276|NCT00752037|Other|1|open label single arm
11585326|NCT00751647|Other|A1|Population receiving the CF specific outpatient PT services.
11585277|NCT00752024|Experimental|1|To position haematoma's location, drills several millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
11585278|NCT00752024|Active Comparator|2|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
11585279|NCT00752011|Experimental|Carboplatin + TAS-106|Carboplatin starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle. TAS-106 starting dose 2.0 mg/m^2 by vein over 24 hours, Day 1 of 3 Week Cycle.
11585280|NCT00751998|Experimental|Arm 1|Test of SpyGlass device
11585281|NCT00751985|Experimental|1|Personalized normative feedback (PFI). The PFI was a single-session intervention; it was displayed in a single screenshot and addressed the participant by name. It consisted of a summary of the participant's weekly consumption, a comparison with maximum drinking limits and a graphical comparison of the participant's consumption to the average level in the municipality (gender-specific), followed by information about health and social risks of heavy drinking as well as links for further self-help material and a local alcohol treatment facility.
11585282|NCT00751985|Experimental|2|Self-help material (SHM). The SHM was a single-session intervention and was displayed in a single screenshot. It consisted of information about maximum drinking limits, followed by information about health and social risks of heavy drinking as well as links for further standardized self-help material and a local alcohol treatment facility.
11585283|NCT00751985|Placebo Comparator|3|Control
11585284|NCT00751972|Experimental|HeartWare® VAS|Ventricular Assist Device (HeartWare® VAS)
11585285|NCT00751959|Active Comparator|2|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
11585286|NCT00751959|Experimental|1|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
11585287|NCT00751946|Active Comparator|1|12 weekly sessions of one-to-one TARGET (psychotherapy)
11585288|NCT00751946|Active Comparator|2|12 weekly sessions of one-to-one ETAU (psychotherapy)
11585289|NCT00751933|Experimental|2|Vaccination with Vivotif and Dukoral
11585290|NCT00751933|Experimental|3|Dietary supplement with oats
11585291|NCT00751933|Placebo Comparator|4|Placebo instead of vaccines No dietary supplement
11585292|NCT00751933|Experimental|1|Vaccination with Vivotif and Dukoral + dietary supplement with oats.
11585293|NCT00751920|Experimental|1|
11585294|NCT00751907|Experimental|Atorvastatin|40mg Atorvastatin nightly for 4 months
11585295|NCT00751907|Placebo Comparator|Placebo|matching placebo nightly for 4 months
11585296|NCT00751881|Experimental|Teriflunomide 7 mg / 14 mg|Core treatment period: Teriflunomide 7 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
11585297|NCT00751881|Experimental|Teriflunomide 14 mg / 14 mg|Core treatment period: Teriflunomide 14 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
11585298|NCT00751881|Placebo Comparator|Placebo / Teriflunomide 14 mg|Core treatment period: Placebo (for teriflunomide) once daily. Extension treatment period: Teriflunomide 14 mg once daily.
11585299|NCT00751868|Experimental|ARM 1|FEC e Ixabepilone. A goal of 48 patients will be enrolled in this study by 16 Italian centres of the GIM (Gruppo Italiano Mammella) Group. Subjects must meet all of the inclusion criteria and none of the exclusion criteria to be enrolled in the study
11585300|NCT00751855|Active Comparator|1|Prolonged Exposure therapy with Hydrocortisone
11585301|NCT00751855|Placebo Comparator|2|Prolonged Exposure therapy with placebo
11585302|NCT00751842|Active Comparator|A|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on days 90 and 270.
11585303|NCT00751842|Active Comparator|B|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on days 90 and 270.
11585304|NCT00751842|Placebo Comparator|C|This arm will receive 4 injections of placebo, 1 each on days 1, 30, 90 and 270.
11585305|NCT00751829|Experimental|1|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to controll BP
11585306|NCT00751829|Active Comparator|2|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
11585307|NCT00751816||Supportive Care|head and neck cancer survivors who are undergoing chemotherapy and radiation therapy
11585308|NCT00751803|Experimental|BI 44370 TA Low Dose|
11585309|NCT00751803|Experimental|BI 44370 TA Medium Dose|
11585310|NCT00751803|Experimental|BI 44370 TA High Dose|
11585311|NCT00751803|Placebo Comparator|Placebo|
11585312|NCT00751803|Active Comparator|Eletriptan|
11585313|NCT00751790|Experimental|Triptorelin|
11585314|NCT00751777|Experimental|Group 1: 37.5 µg LT patch|80 subjects will receive a two vaccination regimen with a LT patch.
11585315|NCT00751777|Placebo Comparator|Group 2: 0 µg LT patch (placebo)|40 subjects will receive a two vaccination regimen with a placebo patch.
11585316|NCT00751764|Experimental|1|
11585317|NCT00751751|Experimental|1|oral olmesartan medoxomil tablets 20 or 40 mg taken once daily for 52 weeks + hydrochlorothiazide tablets 12.5 or 25 mg , if needed to control BP after 12 weeks
11585318|NCT00751751|Active Comparator|2|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tables, after 12 weeks, if needed to control BP.
11585319|NCT00751738|Experimental|1|125 mg azimilide
11585320|NCT00751712||Back of skull cerebral oximeter sensor|All patients enrolled will receive non-invasive oxygen perfusion monitoring on the back of the skull during their standard of care congenital heart surgery
11585321|NCT00751699|Experimental|1|Asacol 6x400 mg Q24h at 7 am for 7 days
11585322|NCT00751699|Experimental|2|Asacol 2x400 mg Q8h at 7 am, 3 pm, and 11 pm for 7 days
11585323|NCT00751699|Experimental|3|Lialda 2x1.2g Q24h at 7 am for 7 days
11585324|NCT00751686||RV GE Group|
11585327|NCT00751634|Experimental|A|Application of the Gaymar Rapr-Round device per approved use
11585328|NCT00751621|Experimental|IgPro20|Subcutaneous (SC) administration by the subject/parent/guardian with the planned weekly dose of IgPro20 to be the same as the subject's last dose recommended by the investigator in study ZLB06_001CR (NCT00542997).
11585329|NCT00751608|Experimental|1|
11585330|NCT00751608|Active Comparator|2|
11585331|NCT00751608|Placebo Comparator|3|
11585332|NCT00751595|Experimental|ARM A (Tat Protein 7.5 or 30 microg 5X)|Group I: Subjects receiving 5 intradermal immunization with Tat (7.5 microg); Group II: Subjects receiving 5 intradermal immunization with Tat (30 microg).
11585333|NCT00751595|Experimental|ARM B (Tat Protein 7.5 or 30 microg, 3X)|Group I: Subjects receiving 3 intradermal immunization with Tat (7.5 microg); Group II: Subjects receiving 3 intradermal immunization with Tat (30 microg)
11585334|NCT00751582|Experimental|2|Food supplementation and nutrition education
11585335|NCT00751582|Experimental|1|Nutrition Education only
11585336|NCT00751569||A1|A group of 3 to 5 pregnant women as donors for umbilical cord blood
11585337|NCT00751556|Experimental|Arm 1|
11585338|NCT00751556|Active Comparator|Arm 2|
11585339|NCT00751530||Protease Inhibitor Group|Subjects who required a protease inhibitor in their new ART regimen
11585340|NCT00751530||Non-protease Inhibitor|Subjects who did not take a protease inhibitor in their regimen
11585341|NCT00751517|Active Comparator|A|Cyclophosphamide
11585342|NCT00751517|Experimental|B|Methotrexate
11585343|NCT00751491|Active Comparator|III|
11585344|NCT00751491|Active Comparator|A|
11585345|NCT00751491|Placebo Comparator|placebo|
11585346|NCT00751478|Experimental|A|2 Placebo capsules (whole) + ALO-01 2 x 60 mg capsules (crushed) in apple juice + apple juice (MSIR placebo)
11585347|NCT00751478|Experimental|B|2 x 60 mg ALO-01 (whole) + 2 x placebo capsules (crushed) in apple juice + apple juice (MSIR placebo)
11585348|NCT00751478|Active Comparator|C|2 x placebo capsules (whole) + 2 X placebo capsules (crushed) in apple juice + 120 mg MSIR in apple juice
11585349|NCT00751478|Placebo Comparator|D|2 x placebo capsules (whole) + 2 X placebo capsules (crushed) in apple juice + apple juice (MSIR placebo)
11585350|NCT00751465|Active Comparator|Task Concentration Training|Task Concentration Training TCT following Bögels et al. (1997)
11585351|NCT00751465|Active Comparator|Standard CBT|standard Cognitive Behavior Therapy, standard CBT following the model of Clark and Wells (1995).
11585352|NCT00751465|No Intervention|Wait list control|Wait list control group
11585353|NCT00751452||1|
11585354|NCT00751452||2|
11585355|NCT00751413|Experimental|1|MK0633
11585356|NCT00751400|Experimental|Naproxen Sodium ER (BAYH6689)|subjects take one tablet Naproxen Sodium ER (extended release) every 24 hours while symptoms last for no more than 10 consecutive days for pain and no more than 3 consecutive days for fever
11585357|NCT00751387||1|
11585358|NCT00751374|Other|group A|Topical gentamicin cream
11585359|NCT00751374|Active Comparator|Group B|topical gentamicin cream alternates with mupirocin cream at monthly basis
11585360|NCT00751361|Active Comparator|1|Treatment group: Patients receive 10 Rheopheresis treatments within 17 weeks
11585361|NCT00751361|No Intervention|2|No treatment control group
11585362|NCT00751348|Experimental|PRIORIX-TETRA GROUP|Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix-Tetra® vaccine at Day 0, administered subcutaneously in the deltoid region of the left upper arm.
11585363|NCT00751348|Active Comparator|PRIORIX + VARILRIX GROUP|Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix™ vaccine together with one dose of Varilrix™ vaccine at Day 0, administered subcutaneously in the deltoid regions of the left or right upper arm, respectively.
11585364|NCT00751335|Experimental|CPAP with ThermoSmart, then CPAP without ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.
~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
11585365|NCT00751335|Experimental|CPAP without ThermoSmart, then CPAP with ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.
~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
11585366|NCT00751322|Active Comparator|1|RBC transfusion of 5 days or less storage age
11585367|NCT00751322|Active Comparator|2|RBC transfusion of conventional storage age
11585368|NCT00751309||1|Lung and heart-lung transplanted subjects.
11585369|NCT00751296|Experimental|Lenalidiomide|Lenalidomide target dose of 10 mg PO OD X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28-day cycle.
11585370|NCT00751283|Experimental|1|GRST Peripheral Catheter System
11585371|NCT00751270|Experimental|A|Arm A for unresectable malignant glioma was closed due to poor accrual.
11585372|NCT00751270|Experimental|B|Arm B for resectable malignant glioma completed the Phase I accrual and long term follow up continues. A follow on study at dose level 3 was opened as a Phase 2a study (see BrTK02).
11585373|NCT00751257|Experimental|1|2400mg N-acetylcysteine (1200mg b.i.d.) for 4 consecutive weeks
11585374|NCT00751257|Placebo Comparator|2|"Identically appearing placebo pills, packaged in an N-acetylcysteine slurry so that placebo will retain smell similar to active NAC capsules"
11585375|NCT00751244|Active Comparator|1|12 weekly sessions of one-to-one TARGET (psychotherapy)
11585376|NCT00751244|Active Comparator|2|12 weekly sessions of one-to-one PCT (psychotherapy)
11585377|NCT00751244|Other|3|90-day wait-list group
11585378|NCT00751231|Active Comparator|Arm 1|300mg or 600mg loading dose of Clopidogrel followed by once daily dosing of 75 mg Clopidogrel for up to 120 days.
11585379|NCT00751231|Experimental|Arm 2|IV bolus of PRT060128 prior to PCI and twice daily administration of 50 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
11585380|NCT00751231|Experimental|Arm 3|IV bolus of PRT060128 prior to PCI and twice daily administration of 100 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
11585638|NCT00749489|No Intervention|No Intervention|No intervention
11585639|NCT00749476|Experimental|1|
11585381|NCT00751231|Experimental|Arm 4|IV bolus of PRT060128 prior to PCI and twice daily administration of 150 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
11585382|NCT00751218|Active Comparator|Arm 1|desloratadine
11585383|NCT00751218|Placebo Comparator|Arm 2|Placebo
11585384|NCT00751218|Active Comparator|Arm 3|cetirizine
11585385|NCT00751205|Experimental|Arm 1|
11585386|NCT00751205|Placebo Comparator|Arm 2|
11585387|NCT00751192|Experimental|A|
11585388|NCT00751192|Active Comparator|B|
11585389|NCT00751179|Active Comparator|Rocuronium - Sugammadex|Rocuronium - Sugammadex 4.0 mg/kg
11585390|NCT00751179|Active Comparator|Succinylcholine|Succinylcholine 1.0 mg/kg
11585391|NCT00751166|Experimental|1|Desloratadine
11585392|NCT00751166|Active Comparator|2|Cetirizine
11585393|NCT00751166|Placebo Comparator|3|placebo
11585394|NCT00751140|Experimental|Lymph Node Dissection at Time of Nephroureterectomy|A prospective single-arm two-stage phase II study to allow for analysis of the treatment-specific outcomes and disease-specific survival of patients treated with open or laparoscopic nephroureterectomy and bladder cuff excision along with a lymph node dissection (modified template retroperitoneal lymph node dissection).
11585395|NCT00751127|Active Comparator|Timolol|
11585396|NCT00751127|Experimental|PhXA41|
11585397|NCT00751114|Experimental|Insulin Glargine|Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL<FPG≤100mg/dL (3.9mmol/L<FPG≤5.5mmol/L).
11585398|NCT00751114|Active Comparator|Sitagliptin|Dose of 100 mg once a day administered with or without food.
11585399|NCT00751101|Experimental|Arm A: Prior to initiation of capecitabine|Patients apply a transdermal nicotine patch once every 24 hours beginning 1 day prior to initiation of capecitabine and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.
11585400|NCT00751101|Experimental|Arm B: After hand-foot syndrome symptoms appear|Patients apply a transdermal nicotine patch once every 24 hours beginning with the course of chemotherapy initiated after hand-foot syndrome symptoms appear and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.
11585401|NCT00751088|Active Comparator|1|Patients treated with Ajust positioning
11585402|NCT00751088|Active Comparator|2|Patients treated with MiniArc positioning
11585403|NCT00751088|Active Comparator|3|Patients treated with TVT secur system
11585404|NCT00751088|Active Comparator|4|Patients treated with tension free vaginal tape
11585405|NCT00751075|Active Comparator|1|MFNS once daily
11585406|NCT00751075|Experimental|2|MFNS twice daily
11585407|NCT00751075|Active Comparator|3|Amoxicillin
11585408|NCT00751075|Placebo Comparator|4|Placebo
11585409|NCT00751062|Active Comparator|Timolol|
11585410|NCT00751062|Experimental|PhXA41|
11585411|NCT00751049|Experimental|PhXA41|
11585412|NCT00751049|Active Comparator|timolol|
11585413|NCT00751036|Experimental|Nilotinib|Patients who were assigned to this treatment group received 400 mg. nilotinib bid.
11585414|NCT00751036|Active Comparator|Imatinib|Patients who were assigned to this treatment group received 400 mg. imatinib bid.
11585415|NCT00751023|Experimental|1|Modafinil 400 mg daily
11585416|NCT00751023|Placebo Comparator|2|Placebo
11585417|NCT00751010||1|In a mailed survey (Part 1 of this study), 127 women with a documented diagnosis of IC agreed to be contacted for an in-office examination.
11585418|NCT00750997||Hypertonic saline|Hypertonic resuscitation
11585419|NCT00750997||Control: normal saline|Normal saline resuscitation
11585420|NCT00750984|Experimental|1|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
11585421|NCT00750984|Active Comparator|2|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
11585422|NCT00750971|Experimental|1|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation
11585423|NCT00750971|Active Comparator|2|Best currently available immunosuppressive/immunomodulatory therapy
11585424|NCT00750958|No Intervention|1|ED patients that are not monitored with conventional therapy.
11585425|NCT00750945|Experimental|A|Treadmill with Music cueing group
11585426|NCT00750945|Active Comparator|B|Treadmill group
11585427|NCT00750945|Placebo Comparator|C|Home walking group
11585428|NCT00750932||T|Control
11585429|NCT00750932||M|Minor with cystic fibrosis
11585430|NCT00750932||A|Adult with cystic fibrosis
11585431|NCT00750919|Experimental|Esmirtazapine|Participants receive esmirtazapine 4.5 mg tablet, orally, once daily (QD) for up to 6 months.
11585432|NCT00750893||Rotarix Group|Subjects who received 2 oral doses of Rotarix. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.
11585433|NCT00750880|Experimental|1|
11585434|NCT00750867|Experimental|1|Interventions included monthly infusions of intravenous immunoglobulin.
11585435|NCT00750854|Experimental|NEM Treatment 1|NEM Formulation X (#0802), 500 mg, once daily, orally
11585436|NCT00750854|Experimental|NEM Treatment 2|NEM Formulation Y (#0505), 500 mg, once daily, orally
11585437|NCT00750841|Experimental|1|Cediranib alone, followed by cediranib plus rifampicin, followed by cediranib alone.
11585438|NCT00750815|Experimental|A. Phase I - Dose Escalation|"Dose of Cyclophosphamide to depend on how many patients we treated:
~Dose Level 1: Cyclophosphamide 250 mg /m^2 IV Day 1; VELCADE, 1.0 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12
~Dose Level 2: Cyclophosphamide 500 mg /m^2 IV Day 1; VELCADE, 1.0 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12
~Dose Level 3: Cyclophosphamide 750 mg /m^2 IV Day 1; VELCADE, 1.0 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12
~Dose Level 4: Cyclophosphamide 750 mg /m^2 IV Day 1; VELCADE, 1.3 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12"
11585439|NCT00750815|Experimental|B. Phase II - Maximum Planned Dose (MPD)|Participants received Cyclophosphamide and VELCADE at Level 4 (the MPD) at the same schedule of the Phase I study. Pegylated doxorubicin and Dexamethasone were given at the same doses and schedule as the Phase I part of study.
11585440|NCT00750802|Experimental|1|
11585441|NCT00750802|Experimental|2|
11585442|NCT00750802|Active Comparator|3|
11585443|NCT00750802|Placebo Comparator|4|
11585444|NCT00750763|Active Comparator|1|PEG (Colonlytely) - 4 litres
11585445|NCT00750763|Active Comparator|2|Picosulphate (Picolax/Picoprep) - 2 sachets
11585446|NCT00750763|Active Comparator|3|Sodium Phosphate (Fleet) - 2 bottles
11585447|NCT00750750|Active Comparator|1|MFNS once daily
11585448|NCT00750750|Experimental|2|MFNS twice daily
11585449|NCT00750750|Active Comparator|3|Amoxicillin
11585450|NCT00750750|Placebo Comparator|4|Placebo
11585451|NCT00750737|Experimental|Posaconazole|Posaconazole 200 mg three times daily by mouth up to 6 weeks (Days 1-42)
11585452|NCT00750737|Experimental|Amphotericin B Lipid Complex (ABLC)|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
11585453|NCT00750724|Placebo Comparator|B|2 ml of Normal saline intraarticular injection to the knee joint weekly for 5 weeks
11585454|NCT00750724|Experimental|A|2 ml of 25 mg sodium hyaluronate intraarticular injection to the knee joint weekly for 5 weeks
11585455|NCT00750711|Experimental|KT,2|There are two arms in this study: KT2 arm and KT4 arm. Patients in KT2 arm will be ablated with the 2 mm irrigated catheter and patients in KT4 mm will be ablated with the 4 mm irrigated catheter.
11585456|NCT00750698|Experimental|1|"Erlotinib-responsive patients are those who progressed following either a complete or partial response to erlotinib or a period of stable disease lasting at least 3 months."
11585457|NCT00750698|Experimental|2|"Erlotinib-nonresponsive patients are those who either progressed immediately during treatment with erlotinib (i.e. after at least 1 full cycle of erlotinib treatment) or had an objective response or period of stable disease lasting less than 3 months."
11585458|NCT00750685|Other|Reconstruction|"The study population will consist of women aged 18 or over who are undergoing primary breast reconstruction.
~The Reconstruction cohort will include subjects with loss of breast tissue due to mastectomy, contralateral breast for post-reconstruction symmetry or subjects with deformities secondary to disease, malignancy, trauma, and congenital deformity. Subjects in this cohort cannot have been implanted with breast implants, but may have tissue expanders. A Becker implant is considered a tissue expander until the port and fill tube have been removed. Women who undergo surgery primarily for a mastopexy will not be part of the reconstruction cohort."
11585459|NCT00750659|Experimental|1|Nilotinib treatment
11585460|NCT00750646||A|Subject's adherence to prescribed therapy will be monitored with an electronic compliance device.
11585461|NCT00750633|Experimental|Moxidex|Moxidex otic solution
11585462|NCT00750633|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
11585463|NCT00750633|Active Comparator|Dexamethasone|Dexamethasone phosphate otic solution
11585464|NCT00750620|Experimental|1. Severe renal impairment|severe renal impairment
11585465|NCT00750620|Experimental|2. Moderate renal impairment|moderate renal impairment
11585466|NCT00750620|Experimental|3. Mild renal impairment|mild renal impairment
11585467|NCT00750620|Experimental|4. Normal renal function|normal renal function
11585468|NCT00750594||1|
11585469|NCT00750594||2|
11585470|NCT00750581|Placebo Comparator|Standard dose group|The infants randomized to the standard dose group will receive indomethacin (0.1 mg/kg) at 24 hr intervals for 5 days. These infants will also receive 5 extra doses of normal saline infusion of similar volume at 12 hrly intervals between the indomethacin schedules to match the Escalating dose Indomethacin Schedule
11585471|NCT00750581|Active Comparator|Escalating dose group|The infants randomized to the Escalating dose group will receive indomethacin started at 0.2 mg/kg/dose every 12 hours for 2 doses with stepwise increment in indomethacin dose by 0.1 mg/kg/dose every 24 hours upto maximum dose of 0.6 mg/kg/dose
11585472|NCT00750568||Group 1|"In-patient in the Pediatric Intensive Care Unit
~Diagnosis of Status asthmaticus
~Receiving a continuous infusion of terbutaline as part of their standard of care
~Ages 2 years to 6 years"
11585473|NCT00750568||Group 2|"In-patient in the Pediatric Intensive Care Unit
~Diagnosis of Status asthmaticus
~Receiving a continuous infusion of terbutaline as part of their standard of care
~Ages greater than 6 years to 12 years"
11585474|NCT00750568||Group 3|"In-patient in the Pediatric Intensive Care Unit
~Diagnosis of Status asthmaticus
~Receiving a continuous infusion of terbutaline as part of their standard of care
~Ages greater than 12 years to 18 years"
11585475|NCT00750555|Other|1|
11585476|NCT00750529|Experimental|Galantamine|
11585477|NCT00750516||Lacid|Hypotensive, non pregnant by history, non comfort care Emergency Department patients.
11585478|NCT00750477|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 8 weeks
11585479|NCT00750477|Placebo Comparator|Placebo|Placebo, 500 mg, once daily, orally for 8 weeks
11585480|NCT00750451|Experimental|LMWH|Women in the LMWH arm are administered 1 mg/kg/day subcutaneously low molecular weight heparin after oocyte collection in addition to routine luteal phase support with vaginal progesterone
11585481|NCT00750451|Active Comparator|Control|Women in the control arm are administered routine luteal phase support without the addition of LMWH
11585482|NCT00750438|Experimental|Propionate ester|
11585483|NCT00750438|Placebo Comparator|Fermentable control|
11585484|NCT00750438|Placebo Comparator|Non fermentable control|
11585485|NCT00750425|Experimental|1|Cediranib alone, followed by cediranib plus ketoconazole, followed by cediranib alone
11585486|NCT00750412|Experimental|TeenScreen|
11585487|NCT00750412|No Intervention|Treatment As Usual|
11585488|NCT00750399|Experimental|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab on a monthly basis depending on response to treatment
11585489|NCT00750386|Experimental|1|Paclitaxel/Carboplatin
11585490|NCT00750373|No Intervention|Conventional|Conventional Treatment based on current guidelines
11585491|NCT00750373|Active Comparator|Surgery|Early surgery within 48 hours of randomization
11585777|NCT00748345|Experimental|1|Caspofungin (drug)
11585492|NCT00750360|Experimental|Unprimed, > 6 to < 72 Months|Subjects aged > 6 months to < 72 months who were previously not vaccinated against influenza (unprimed).
11585493|NCT00750360|Experimental|Unprimed, ≥ 72 to < 108 Months|Subjects aged ≥ 72 months to < 108 months who were previously not vaccinated against influenza (unprimed).
11585494|NCT00750360|Experimental|Primed, > 6 to < 72 Months|Subjects aged > 6 months to < 72 months who previously received a vaccination against influenza (primed).
11585495|NCT00750360|Experimental|Primed, ≥ 72 to < 108 Months|Subjects aged ≥ 72 months to < 108 months who previously received a vaccination against influenza (primed).
11585496|NCT00750360|Experimental|Primed, ≥ 108 to < 216 Months|Subjects aged ≥ 108 months to < 216 months who previously received a vaccination against influenza (primed).
11585497|NCT00750360|Experimental|Primed, ≥ 216 Months|Subjects aged ≥ 216 months who previously received a vaccination against influenza (primed).
11585498|NCT00750334|Experimental|Part A|clofarabine Dose Escalation
11585499|NCT00750334|Experimental|Part B|Part B is an open-label, replicated cross-over study in which 12 additional patients will be enrolled and treated at the MTD determined in part A to evaluate the effect of food on the PK disposition of oral clofarabine.
11585500|NCT00750308|Active Comparator|tadalafil, ramapril, combo, placebo|placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, ramipril + tadalafil, washout, placebo+placebo for three weeks
11585501|NCT00750308|Active Comparator|ramipril, tadalafil, placebo, combo|placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks
11585502|NCT00750308|Active Comparator|combo, placebo, tadalafil, ramipril|ramipril+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks
11585503|NCT00750308|Active Comparator|placebo, combo, ramipril, tadalafil|placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks, washout placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks
11585504|NCT00750308|Active Comparator|tadalafil, placebo, ramipril, combo|placebo+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+ramipril for three weeks, washout, ramipril+tadalafil for three weeks
11585505|NCT00750308|Active Comparator|ramipril, combo, tadalfil, placebo|placebo+ramipril for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo for three weeks
11585506|NCT00750308|Active Comparator|combo, ramipril, placebo, tadalafil|ramipril+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks
11585507|NCT00750308|Active Comparator|placebo, tadalafil, combo, ramipril|placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+ramipril for three weeks
11585508|NCT00750308|Active Comparator|tadalafil, combo, placebo, ramipril|placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+ramipril for three weeks
11585509|NCT00750308|Active Comparator|ramipril, placebo, combo, tadalafil|placebo+ramipril for three weeks, washout, placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks
11585510|NCT00750308|Active Comparator|combo, tadalafil, ramipril, placebo|ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+placebo for three weeks
11585511|NCT00750308|Active Comparator|placebo, ramipril, tadalafil, combo|placebo+placebo for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks
11585512|NCT00750295|Experimental|1|
11585513|NCT00750295|Experimental|2|
11585514|NCT00750295|Experimental|3|
11585515|NCT00750295|Experimental|4|
11585516|NCT00750295|Experimental|5|
11585517|NCT00750295|Experimental|6|
11585518|NCT00750295|Experimental|7|
11585519|NCT00750282|Experimental|Florbetaben (BAY94-9172)|
11585520|NCT00750269|Experimental|Level 1: 8.0 Gy/FX|SBRT 40.0 Gy
11585521|NCT00750269|Experimental|Level 2: 8.5 Gy/FX|SBRT 42.5 Gy
11585522|NCT00750269|Experimental|Level 3: 9.0 Gy/FX|SBRT 45.0 Gy
11585523|NCT00750269|Experimental|Level 4: 9.5 Gy/FX|SBRT 47.5 Gy
11585524|NCT00750269|Experimental|Level 5: 10.0 Gy/FX|SBRT 50.0 Gy
11585525|NCT00750269|Experimental|Level 6: 10.5 Gy/FX|SBRT 52.5 Gy
11585526|NCT00750269|Experimental|Level 7: 11.0 Gy/FX|SBRT 55.0 Gy
11585527|NCT00750269|Experimental|Level 8: 11.5 Gy/FX|SBRT 57.5 Gy
11585528|NCT00750269|Experimental|Level 9: 12.0 Gy/FX|SBRT 60.0 Gy
11585529|NCT00750256|Experimental|Cohorts|This study will be a single-blind, randomized, placebo-controlled, dose-rising, single dose, parallel group study with 6 proposed Cohorts from 2mg to 450mg.
11585530|NCT00750243|Experimental|A|
11585531|NCT00750243|Active Comparator|B|
11585532|NCT00750230|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 30 days.
11585533|NCT00750204|Experimental|APRV|Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.
11585534|NCT00750204|Active Comparator|Conventional MV|Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.
11585535|NCT00750191|Active Comparator|Intradiscal Biacuplasty|"On the day of the procedure, patients were given midazolam for relaxation and, if needed, fentanyl IV during the procedure. For treatment subjects, two TransDiscal probes were positioned under fluoroscopic guidance in the posterior annulus of the intervertebral disc. The probes were attached to the Radiofrequency generator and Radiofrequency energy was delivered. Placement of the probes within the disc annulus was confirmed using oblique, lateral, and anterior-posterior fluoroscopic images.
~Following completion of procedure the patient was transferred to recovery and monitored for 45 minutes then discharged home with instructions. It was expected that the patient limit their activities during the first week after the procedure."
11585774|NCT00748371|Experimental|2|ASA 1300mg daily for 8 weeks followed by 3 weeks of observation
11585536|NCT00750191|Placebo Comparator|Sham|"Sham procedures mimicked active treatment procedures, except that the probes were positioned just outside of the disc and no radiofrequency energy was delivered through the electrodes. Thus, sham patients were provided similar tactile, auditory and visual experiences as treatment patients, without receiving the active RF treatment.
~Following completion of procedure the patient was transferred to recovery and monitored for 45 minutes then discharged home with instructions. It was expected that the patient limit their activities during the first week after the procedure.
~The study will be unblinded at 6 months. If the patients in the IDB group show significant improvement compared to placebo they will be offered IDB."
11585537|NCT00750178|Experimental|A|MK0683
11585538|NCT00750165|Experimental|Titration Night|Treatment with the Fisher & Paykel Sleep Style 200 Auto CPAP device
11585539|NCT00750152|Placebo Comparator|2|placebo
11585540|NCT00750152|Experimental|1|NAFT-500
11585541|NCT00750139|Experimental|1|Naftin 2% cream applied daily for 2 weeks
11585542|NCT00750139|Placebo Comparator|2|Placebo cream applied daily for two weeks
11585543|NCT00750139|Active Comparator|3|Active comparator applied daily for 4 weeks
11585544|NCT00750139|Placebo Comparator|4|placebo cream applied daily for 4 weeks
11585545|NCT00750113|Experimental|Arm 1|
11585546|NCT00750113|Experimental|Arm 2|
11585547|NCT00750113|Experimental|Arm 3|
11585548|NCT00750100|Active Comparator|A|Patients undergo a standard antagonist protocol for in-vitro fertilisation, and are stimulated with recombinant gonadotropins.
11585549|NCT00750100|Experimental|B|Patients are undergo an antagonist protocol for in-vitro fertilisation and are stimulated with recombinant gonadotropins. When the patient has an estradiol value of 600 ng/L or more and when the patient has at least 6 follicles of 12 mm, the administration of gonadotropins is stopped and replaced by low dose human chorionic gonadotropins.
11585550|NCT00750087||1|Schizophrenia patients stabilized on Seroquel XR
11585551|NCT00750074||1|"During volume assist-control ventilation, a 0.4 second end-inspiratory pause will be set and the following pressures measured: peak pressure; plateau pressure; and PEEP. The following ventilator settings will be recorded: inspiratory flow; expired tidal volume; and rate. The presence or absence of autoPEEP will be noted.
~During pressure-control ventilation, the flow versus time waveform will be printed from the ventilator using a conventional computer printer for later analysis. The following ventilator settings will be recorded: inspiratory pressure; PEEP; and expired tidal volume."
11585552|NCT00750061|Placebo Comparator|Placebo|Placebo tablet
11585553|NCT00750061|Experimental|Lithium carbonate|Lithium Carbonate tablet, 250mg
11585554|NCT00750035|Experimental|1|total abdominal hysterectomy and
11585555|NCT00750035|Experimental|2|Subtotal hysterectomy
11585556|NCT00750022|Experimental|E1|
11585557|NCT00750022|Active Comparator|A1|
11585558|NCT00750009|Experimental|Arm I (PRE-ACT)|Patients receive tailored feedback and video content to address clinical trial barriers following baseline assessment.
11585559|NCT00750009|Active Comparator|Arm II (control)|Patients receive generic clinical trials educational feedback taken from NCI publications following baseline assessment.
11585560|NCT00749996|Experimental|Investigational group|Single level herniectomy followed by placement of the DIAM™ Spinal Stabilization System
11585561|NCT00749996|Active Comparator|Control group|Single level herniectomy
11585562|NCT00749983|Experimental|1|creatine intake
11585563|NCT00749983|Placebo Comparator|2|placebo (dextrose) intake
11585564|NCT00749957|Experimental|1|Subjects at least 6 y/o treated with a lower dose of the vector by subretinal injection
11585565|NCT00749957|Experimental|2|Subjects at least 6 y/o treated with a higher dose of the vector by subretinal injection
11585566|NCT00749944|Experimental|varenicline|
11585567|NCT00749944|Placebo Comparator|placebo|
11585568|NCT00749931|Active Comparator|SOC|Standard of Care arm - standard of care lumpectomy procedure
11585569|NCT00749931|Experimental|Device + SOC|Use of the device in addition to the standard of care lumpectomy procedure.
11585570|NCT00749918|Experimental|1|Each subject was evaluated and data was collected before and after the intervention
11585571|NCT00749905|Experimental|1|Low fiber diet for 5 days prior to procedure
11585572|NCT00749905|Active Comparator|2|regular diet
11585573|NCT00749892|Experimental|Treatment (erlotinib hydrochloride)|Participants receive erlotinib hydrochloride PO QD for 3-5 weeks in the absence of disease progression or unacceptable toxicity. Within 24 hours of the last dose, participants undergo cystectomy.
11585574|NCT00749879|Experimental|25 mg AMCC fed|"25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose
~Fed State"
11585575|NCT00749879|Experimental|25 mg AMCC fasting|"25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose
~Fasting State"
11585576|NCT00749879|Experimental|50 mg AMCC fed|"2, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose
~Fed State"
11585577|NCT00749879|Experimental|50 mg AMCC fasting|"2, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose
~Fasting State"
11585578|NCT00749879|Experimental|50 mg SMCC fasting|"2, 25 mg Proellex capsules formulated with SMCC microcrystalline cellulose
~Fasting State"
11585579|NCT00749866|Active Comparator|1|Nebulised Gentamicin
11585580|NCT00749866|Placebo Comparator|2|Nebulised 0.9% Saline
11585581|NCT00749853|Experimental|1|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
11585582|NCT00749853|Active Comparator|2|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
11585583|NCT00749840||HIV Care Questionnaire|Patients with a new diagnosis of HIV infection.
11585584|NCT00749827|Active Comparator|1|Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours
11585585|NCT00749827|Active Comparator|2|Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
11585586|NCT00749814|Experimental|A|Study group will receive melatonin.
11585587|NCT00749814|Placebo Comparator|B|Placebo
11585588|NCT00749814|No Intervention|C|No intervention control group.
11585589|NCT00749801|Active Comparator|A|nattokinase-mono formula (3500FU)
11585590|NCT00749801|Experimental|B|Nattokinase compound-multiple formulae
11585591|NCT00749801|Placebo Comparator|C|Placebo
11585592|NCT00749788|Experimental|1|JTT-302, 200 mg
11585593|NCT00749788|Experimental|2|JTT-302, 400 mg
11585594|NCT00749788|Placebo Comparator|3|Matching placebo tablets
11585595|NCT00749775||Eplerenone|Subjects who are treated with Eplerenone tablet for hypertension disease
11585596|NCT00749749|Experimental|Bupivacaine collagen sponge|Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.
11585597|NCT00749749|Active Comparator|ON-ON-Q PainBuster Post-op Pain relief SystemQ system|Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.
11585598|NCT00749736|Active Comparator|1|4000 IU of cholecalciferol per day
11585599|NCT00749736|Active Comparator|2|1 mcg of doxercalciferol per day.
11585600|NCT00749736|Placebo Comparator|3|placebo for six months
11585601|NCT00749723|Experimental|1: P-HIT-REZ 2005|"intravenous chemotherapy with carboplatin/etoposide,followed by
~high dose chemotherapy with thiotepa, carboplatin, etoposide and autologous stem cell transplantation if patient have achieved a complete remission or
~maintenance therapy with oral trofosfamide, etoposide"
11585602|NCT00749723|Experimental|2: P-HIT-REZ 2005|"oral chemotherapy with temozolomide, followed by
~high dose chemotherapy with temozolomide, thiotepa and autologous stem cell transplantation if patient have achieved a complete remission
~maintenance therapy with oral temozolomide or in case of progression with oral trofosfamide, etoposide"
11585603|NCT00749723|Experimental|3: E-HIT-REZ 2005|Phase II: oral chemotherapy with temozolomide after progression oral trofosfamide, etoposide
11585604|NCT00749723|Experimental|Intraventricular Etoposide|Phase II, intraventricular chemotherapy with etoposide
11585605|NCT00749710|Active Comparator|1|immediate operation - ORIF - of hip fracture in patient treated with clopidogrel
11585606|NCT00749710|Active Comparator|2|ORIF - surgical treatment patients not on antiaggregant therapy
11585607|NCT00749684||Adults with malignant melanoma at high risk of relapse|"Adults with malignant melanoma of the following stages:
~II and III (>/= 1.5 mm Breslow thickness without distant metastases
~melanoma with lymph node metastases"
11585608|NCT00749671|Active Comparator|ICD testing BIS|Bispectral Index Monitoring will be used to assess adequacy of moderate sedation during DFT.
11585609|NCT00749671|Active Comparator|ICD testing Ramsey|Ramsey Sedation Scale will be used to assess adequacy of moderate sedation during DFT
11585610|NCT00749658|Active Comparator|Bupropion + Placebo Varenicline|Bupropion + Placebo Varenicline \Varenicline + Placebo Bupropion; Varenicline + Placebo Bupropion \Bupropion + Placebo Varenicline
11585611|NCT00749658|Active Comparator|upropion + Varenicline|Bupropion + Varenicline \Varenicline + Placebo Bupropion; Varenicline + Placebo Bupropion \Bupropion + Varenicline
11585612|NCT00749645|Active Comparator|1 - FANG(30)|1 - Active comparator, consisted of 30 adult patients with active Rheumatoid Arthritis, randomly assigned, taking the active product, in addition to base medication (Mtx + Pdn)
11585613|NCT00749645|Placebo Comparator|2 - Placebo|2 - Placebo comparator, consisted of 30 adult patients with active Rheumatoid Arthritis, randomly assigned, taking the placebo formulation, in addition to base medication (Mtx + Pdn)
11585614|NCT00749632|Active Comparator|1|
11585615|NCT00749632|Active Comparator|2|
11585616|NCT00749632|Active Comparator|3|
11585617|NCT00749619|Experimental|A|
11585618|NCT00749619|Experimental|B|
11585619|NCT00749619|No Intervention|C|
11585620|NCT00749606|Experimental|Individual Telephone Intervention|Individually administered weight loss intervention, based on the Diabetes Prevention Program, delivered by telephone in primary care practices.
11585621|NCT00749606|Active Comparator|Group Telephone Intervention|Group education conference calls to deliver the weight loss intervention, based upon the Diabetes Prevention Program, in primary care practices.
11585622|NCT00749593||CaHASE 1|Adults with CAH
11585623|NCT00749580|Experimental|1: Boosted PI+RAL|Group 1 Raltegravir 400 mg PO b.i.d. + their current boosted PI regimen Subjects in this study are HIV-Infected Patients who are on a stable boosted PI regimen; in this group are assigned to switched from their NRTIs as a Backbone to Raltegravir
11585624|NCT00749580|No Intervention|2: Boosted PI+NRTIs|Group 2 Continue the same regimen without change
11585625|NCT00749567|Experimental|1|Erlotinib/Bevacizumab
11585626|NCT00749554|Active Comparator|Disc biacuplasty|
11585627|NCT00749554|Placebo Comparator|Sham treatment.|
11585628|NCT00749541||1normal catheter.|
11585629|NCT00749541||abnormal catheter.|
11585630|NCT00749528||1|Children vith recurrent wheezing
11585631|NCT00749528||2|Healthy children
11585632|NCT00749515|Experimental|Single Arm|All patients received the same interventions of deferoxamine challenge, deferasirox dose with pharmacokinetic monitoring and HIDA scan. Then we compared responses between patients who were known to be slow responders to deferasirox and those who were known to be rapid responders (chelated well).
11585633|NCT00749502|Experimental|Part A-Dose escalation and confirmation|
11585634|NCT00749502|Experimental|Part B - Prostate/Ovarian Cancer Cohort|
11585635|NCT00749502|Experimental|Part C - T-PLL/CLL cohort|
11585636|NCT00749502|Experimental|Part D - CRC, endometrial, breast, and ovarian cancer cohort|
11585637|NCT00749489|Experimental|Femoral Nerve Block|Intervention patients will have a continuous fascia iliaca blocks placed by a regional anesthesiologist 24 hours after the initial single injection femoral nerve block or at the time of surgery.
11585640|NCT00749463|Experimental|Gum 2|Nicotine Gum 2 mg for subjects smoking less than 20 cigarettes per day; 2 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
11585641|NCT00749463|Experimental|Gum 4|Nicotine Gum 4 mg for subjects smoking 20 or more cigarettes per day; 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
11585642|NCT00749463|Experimental|Patch|Nicotine Patch; Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
11585643|NCT00749450|Experimental|Arm I|Patients receive OxMdG or XELOX combination chemotherapy for a total of 12 courses for treatment lasting a total of 24 weeks.
11585644|NCT00749450|Experimental|Arm II|Patients receive OxMdG or XELOX combination chemotherapy for a total of 6 courses for treatment lasting a total of 12 weeks.
11585645|NCT00749424|Experimental|1|crushing technique
11585646|NCT00749424|Active Comparator|2|provisional T stenting technique
11585647|NCT00749411|Experimental|Arm 1|
11585648|NCT00749411|Placebo Comparator|Arm 2|
11585649|NCT00749398||Infliximab|Subjects with moderate-to-severe psoriasis who are treated with infliximab in daily clinics according to local country regulations and reimbursements.
11585650|NCT00749385|Experimental|1|PN 400
11585651|NCT00749385|Active Comparator|2|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule(20mg)
11585652|NCT00749385|Active Comparator|3|Enteric-coated naproxen tablet (500mg)
11585653|NCT00749385|Active Comparator|4|EC esomeprazole capsule (20mg)
11585654|NCT00749372|Other|1|Patients who meet eligibility will be sent for radiographic imaging to include T2* cardiac and liver MRI to ascertain quantification of organ-specific iron concentrations as well as cardiac left ventricular ejection fraction.
11585655|NCT00749359|Experimental|open label treatment|On each treatment period, subjects will receive controlled release paroxetine 37.5 milligram (mg) on Day 1.
11585656|NCT00749346|Experimental|A|Treatment with concomitant Alimta and NovoTTF-100L
11585657|NCT00749333|Experimental|1|
11585658|NCT00749333|Placebo Comparator|2|
11585659|NCT00749320|Other|ASL MRI|ASL MRI performed at different time intervals on participants receiving sunitnib or pazopanib for treating RCC
11585660|NCT00749307|Experimental|1|
11585661|NCT00749307|Placebo Comparator|2|
11585662|NCT00749294||Observation|
11585663|NCT00749281||1|Patients with angiographically confirmed significant CAD
11585664|NCT00749281||2|Patients without significant CAD
11585665|NCT00749268|Active Comparator|A|
11585666|NCT00749268|Active Comparator|B|
11585667|NCT00749255||FFDM|a sum of at least 200 cancer cases, mammographically visible, on at least one image view (including masses and calcifications)
11585668|NCT00749242|Other|1|conventional orthopedic brace with antalgic treatment
11585669|NCT00749242|Other|2|balloon kyphoplasty introduction of balloon into the vertebral body, inflation of the balloon which creates a cavity, then balloon is deflated and removed , then introduction of the cement into the cavity.
11585670|NCT00749229|Other|1|Balloon kyphoplasty
11585671|NCT00749216|Experimental|QW|IV infusion of 400mg once each week for 2 months
11585672|NCT00749216|Experimental|Q4W|IV infusion of 400mg once every four weeks for 2 months
11585673|NCT00749216|Experimental|Q8W|IV infusion of 400mg once every eight weeks for 2 months
11585674|NCT00749203|Experimental|Ketamine|Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
11585675|NCT00749203|Active Comparator|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
11585676|NCT00749177|Active Comparator|2|Traditional Healing arm Provides Traditional Healing options only
11585677|NCT00749177|Active Comparator|3|Traditional Healing and usual standard of care arm Subjects will access both treatment options
11585678|NCT00749177|Active Comparator|1|Treatment as usual
11585679|NCT00749151|No Intervention|Literature|
11585680|NCT00749151|Experimental|Lit + Counseling|
11585681|NCT00749138|Experimental|tamoxifen|open label giving of tamoxifen
11585682|NCT00749125|Experimental|1 Lexapro|The depressed participants in this arm will be given Lexapro.
11585683|NCT00749125|No Intervention|2 Control|The nondepressed participants in this arm will not be given any intervention for depression.
11585684|NCT00749112|Experimental|A|
11585685|NCT00749099|Placebo Comparator|Phase I|All subject participate in Phase I
11585686|NCT00749099|Active Comparator|Phase II|All subject participate in Phase II
11585687|NCT00749086|Experimental|2|balloon kyphoplasty
11585688|NCT00749086|Active Comparator|1|vertebroplasty
11585689|NCT00749073|Other|Percutaneous Lumbar Decompression procedure|mild percutaneous lumbar decompression procedure
11585690|NCT00749060|Other|1|conventional treatment
11585691|NCT00749060|Other|2|kyphoplasty by balloons
11585692|NCT00749060|Other|3|vertebroplasty
11585693|NCT00749047|Experimental|1|Open label arm
11585694|NCT00749034|Experimental|1|VPM1002 in three dosages
11585695|NCT00749034|Active Comparator|2|BCG
11585696|NCT00749021|Active Comparator|Regimen 1|Intravitreal injection of Ranibizumab monthly for 12 months.
11585697|NCT00749021|Active Comparator|Regimen 2|Intravitreal injection of ranibizumab for 4 months (at Day 0, Month 1, Month 2, and Month 3) followed by by treatments on predefined re-treatment criteria.
11585698|NCT00749021|Active Comparator|Regimen 3|Intravitreal injection of Ranibizumab 2.0mg monthly for 12 months
11585699|NCT00749021|Active Comparator|Regimen 4|Intravitreal injection 2.0mg ranibizumab for 4 months (at Day 0, Month 1 and Month 2, and Month 3) followed by PRN treatments on pre-defined re-treatment criteria
11585700|NCT00749008||Term Infants|High risk infants with history of respiratory insufficiency requiring NICU care.
11585701|NCT00749008||Preterm Infants|Infants less than 37 weeks gestational age.
11585775|NCT00748371|Placebo Comparator|3|Placebo: one Avicel (cellulose) capsule by mouth twice daily
11585702|NCT00748995||Neurocognition Deployment Health Study (NDHS) participants|Surviving NDHS participants who returned from their initial deployment to Iraq or Afghanistan.
11585703|NCT00748982|Experimental|1|
11585704|NCT00748982|Placebo Comparator|2|
11585705|NCT00748969|Experimental|Growth hormone treatmen|Growth hormone treatment arm. Somatropin (DNA origin)
11585706|NCT00748969|No Intervention|No growth hormone treatment in year 1|No growth hormone treatment in year 1; option for treatment in year 2 open-label period.
11585707|NCT00748956|Experimental|Low dose NPY|Low dose, Receive 50 nmol dose of NPY
11585708|NCT00748956|Experimental|High dose NPY|High Dose, Receive 100 nmol dose of NPY
11585709|NCT00748956|Placebo Comparator|Placebo|Placebo comparator
11585710|NCT00748930||Cohort 1|Subjects previously enrolled in the ATTRACT trial from three Canadian sites.
11585711|NCT00748904|Experimental|A|35 patients receiving rifaximin
11585712|NCT00748904|Experimental|B|35 patients receiving lactulose
11585713|NCT00748891|Experimental|1|Open label 30mg Cediranib administered once daily during scanning phase and if tolerated by patient, until disease progression
11585714|NCT00748865|Experimental|Systane Ultra|Systane Ultra 1 drop each eye one time
11585715|NCT00748865|Active Comparator|Systane|Systane 1 drop each eye one time
11585716|NCT00748852|Experimental|1|JTT-302, 400 mg
11585717|NCT00748826||Infliximab -Rheumatoid Arthritis Participants|
11585718|NCT00748813|Other|1|
11585719|NCT00748800|Experimental|1|
11585720|NCT00748800|Active Comparator|2|
11585721|NCT00748787|Experimental|1|
11585722|NCT00748787|Placebo Comparator|2|
11585723|NCT00748774||MDASI-BT|MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) questionnaire given to patients with a primary brain tumor and their caregivers.
11585724|NCT00748761|Experimental|OCD Active CBT|Children with obsessive-compulsive disorder (OCD) will be treated with cognitive behavioral therapy (CBT) from the time of enrollment.
11585725|NCT00748761|Active Comparator|OCD Waitlist|Children with OCD will receive waitlist treatment at enrollment. Nonresponders will cross over to CBT.
11585726|NCT00748761|No Intervention|Healthy Controls|Healthy control children will be given no intervention.
11585727|NCT00748748|Experimental|1|Lactobacillus rhamnosus GG capsule three times per day while taking their antibiotic(s) and for 7 days following completion of the antibiotic.
11585728|NCT00748735||A1|heart failure patients undergoing CRT implantation
11585729|NCT00748722||1|Female patients, age 18-60 years, suitable for breast reconstruction using the lower abdominal tissue.
11585730|NCT00748709|Experimental|BIBW 2992 (Afatinib)|BIBW 2992 (Afatinib) for patients FISH positive for/or harboring EGFR or HER2 Mutation
11585731|NCT00748696|No Intervention|1|No intervention
11585732|NCT00748696|Experimental|2|patient receiving oral nutrition supplement
11585733|NCT00748696|Experimental|3|resistance training
11585734|NCT00748696|Experimental|4|patients receiving resistance training and oral nutritional supplement
11585735|NCT00748670|Experimental|A|
11585736|NCT00748657|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11585737|NCT00748644|Experimental|1|Experimental drug = rituximab for maintenance
11585738|NCT00748644|Active Comparator|2|Comparator drug = azathioprine for maintenance
11585739|NCT00748631|Experimental|1|balloon Kyphoplasty
11585740|NCT00748618|Other|1|Standard vitamin treatment
11585741|NCT00748618|Active Comparator|2|50,000 I.U. of vitamin D3
11585742|NCT00748605|Placebo Comparator|Placebo|S-2367 placebo + LCD (Low Calorie Diet) +RCD (Reduced Calorie Diet)
11585743|NCT00748605|Experimental|S-2367 1600 mg q.d. 54 weeks|S-2367 placebo + LCD for 6 weeks and 1600 mg S-2367 + RCD for 54 weeks
11585744|NCT00748605|Experimental|S-2367 1600 mg q.d. 60 weeks|S-23671600 mg q.d. + LCD for 6 weeks and S-2367 1600 mg q.d + RCD for 54 weeks
11585745|NCT00748592|Placebo Comparator|Placebo|
11585746|NCT00748592|Experimental|PD 0200390, 5 mg|
11585747|NCT00748592|Experimental|PD 0200390, 15 mg|
11585748|NCT00748592|Experimental|PD 0200390, 30 mg|
11585749|NCT00748579|Experimental|Cohort 1|0.5 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452
11585750|NCT00748579|Experimental|Cohort 2|≤ 1.0 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452
11585751|NCT00748566|Experimental|Active treatment (switch to oral Ziprasidone)|
11585752|NCT00748553|Experimental|All patients|All participants enrolled.
11585753|NCT00748540|Experimental|Implanted|Implanted with Vibrant Soundbridge
11585754|NCT00748527|Active Comparator|Arm I|Patients receive carboplatin IV over 30-60 minutes on day 1.
11585755|NCT00748527|Experimental|Arm II|Patients receive decitabine IV over 6 hours on day 1 and carboplatin IV over 30-60 minutes on day 8.
11585756|NCT00748501|Active Comparator|Cohort 1|SB-509 drug administration via IM injection of neck, arms, and legs
11585757|NCT00748501|Active Comparator|Cohort 2|SB-509 drug administration via IM injection of legs
11585758|NCT00748488|Experimental|A|Physical Therapy aimed to promote the level of physical activity
11585759|NCT00748488|Active Comparator|B|Physical Therapy aimed to move safely
11585760|NCT00748475|Experimental|Neurofeedback|
11585761|NCT00748462|Experimental|1|Fractional CO2 laser resurfacing
11585762|NCT00748449|Active Comparator|1|CT Colonography
11585763|NCT00748449|Active Comparator|2|Colonoscopy
11585764|NCT00748436|Placebo Comparator|A|Matching placebo twice a day
11585765|NCT00748436|Experimental|B|Betahistine 24 mg twice a day (48 mg/day total)
11585766|NCT00748436|Experimental|C|Betahistine 48 mg twice a day (96 mg/day total)
11585767|NCT00748423|Experimental|1|Nitric Oxide in nitrogen
11585768|NCT00748423|Placebo Comparator|2|Nitrogen
11585769|NCT00748410|Experimental|7 Days Repeat Dose|
11585770|NCT00748397|Experimental|A|
11585771|NCT00748384||1|Self trained subjects
11585772|NCT00748384||2|supervised trained subjects
11585773|NCT00748371|Experimental|1|ASA 40mg daily for 8 weeks followed by 3 weeks of observation
11585778|NCT00748332|Active Comparator|1|Standard oral nutritional supplement
11585779|NCT00748332|Experimental|2|Omega-3-enriched oral nutritional supplement
11585780|NCT00748319|Other|1|Detection of KIR receptor
11585781|NCT00748306|Experimental|GSK2190915|Intervention
11585782|NCT00748306|Placebo Comparator|Placebo|
11585783|NCT00748293|No Intervention|A|PEG-ELS 2000 ml ingestion in the morning of colonoscopy
11585784|NCT00748293|Other|B|Low-reside diet on previous day (breakfast, lunch and dinner), PEG-ELS 1500 mL in the morning of colonoscopy
11585785|NCT00748280|Experimental|1|ORCT
11585786|NCT00748280|Experimental|2|PCEM/PMTA
11585787|NCT00748254||Rheumatoid Arthritis|Patients who have active disease affecting the joints in the hand will have Laser Based Photoacoustic Tomography (PAT), MRI, Ultrasound
11585788|NCT00748254||Normal controls|Healthy volunteers who do not have arthritis will also have Laser Based Photoacoustic Tomography (PAT), MRI, Ultrasound on the joints of their hand
11585789|NCT00748241|Experimental|Astra Tech Fixture ST|
11585790|NCT00748228|Experimental|A|10 mEq/day dietary sodium
11585791|NCT00748228|Experimental|B|150 mEq/day dietary sodium
11585792|NCT00748228|Experimental|C|300 mEq/day dietary sodium
11585793|NCT00748215|Experimental|Arm I: CASAD|Oral calcium aluminosilicate anti-diarrheal (CASAD) 4 times daily for 6 weeks in the absence of disease progression or unacceptable toxicity. Participants who develop grade 3 or 4 diarrhea may receive CASAD for an additional 6 weeks.
11585794|NCT00748215|Placebo Comparator|Arm II: Placebo|Oral placebo 4 times daily for 6 weeks in the absence of disease progression or unacceptable toxicity. Participants who develop grade 3 or 4 diarrhea may then receive CASAD for 6 weeks.
11585795|NCT00748202|Active Comparator|1|intravenous administration of C1-Inhibitor, after the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far
11585796|NCT00748202|Active Comparator|2|subcutaneous administration of C1-Inhibitor. After the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far.
11585797|NCT00748189|Experimental|ofatumumab + chlorambucil|ofatumumab dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days; chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
11585798|NCT00748189|Active Comparator|chlorambucil|chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
11585799|NCT00748176||A|
11585800|NCT00748163|Experimental|Stage IV Non-Small Cell Lung Cancer Patients|Patients with stage IV non-small cell lung cancer treated with paclitaxel albumin-stabilized nanoparticle formulation and sunitinib malate as first-line therapy.
11585801|NCT00748150|Experimental|1|
11585802|NCT00748137|Active Comparator|Fixed dose|Fixed meal size and fixed aspart insulin dose except for minor changes based on measured blood glucose. Detemir basal insulin.
11585803|NCT00748137|Experimental|ezy-BICC dose calculation card|variable meal size with variable aspart insulin dose determined with use of individualised dose calculation card. Detemir basal insulin.
11585804|NCT00748124|Experimental|PleuraSeal Sealant Device|
11585805|NCT00748124|Other|Control|
11585806|NCT00748111|Experimental|1|Sudden cardiac death hospitalized
11585807|NCT00748111|Experimental|2|Acute myocardial infarction
11585808|NCT00748111|Experimental|3|Angioplasty procedures programmed
11585809|NCT00748111|Experimental|4|Sudden cardiac death hospitalized without coronary syndrome
11585810|NCT00748098|Other|GSK1838262:placebo|GSK1838262 extended release tablets for Treatment Period 1 followed by Placebo for Treatment Period 2
11585811|NCT00748098|Other|Placebo:GSK1838262|Placebo for Treatment Period 1 followed by GSK1838262 for Treatment Period 2
11585812|NCT00748085|Experimental|Cryospray Ablation|Cryospray Ablation 4, 5-second spray cycles
11585813|NCT00748072|Placebo Comparator|Saline solution|patients treated with 1 ml of s.c. saline solution
11585814|NCT00748072|Experimental|DDAVP|treated with DDAVP (0.3 mcg/Kg s.c.) 1 hour before renal biopsy
11585815|NCT00748059|Experimental|A|Patients with Orthostatic Hypotension
11585816|NCT00748046|Experimental|Radium-223 chloride (Xofigo, BAY88-8223)|The patients will receive Radium-223 chloride as an escalating dose of either 50, 100 or 200 kBq/kg b.w. (0.0014, 0.0027 or 0.0054 mCi/kg).
11585817|NCT00748020|Active Comparator|group 1|Erythematogenic irradiation scheme
11585818|NCT00748020|Active Comparator|group 2|Suberythematogenic irradiation scheme
11585819|NCT00748007|Experimental|A|
11585820|NCT00748007|Placebo Comparator|Placebo|Placebo
11585821|NCT00747994||1|
11585822|NCT00747981|Experimental|A|Thoracic CT Scan
11585823|NCT00747968|Active Comparator|glp-1-analogue|During hyperglycemic clamp and GLP-1-analogue versus placebo infusion 15 patients will be heart OR CNS-PET scanned
11585824|NCT00747968|Placebo Comparator|placebo|During hyperglycemic clamp and GLP-1-analogue versus placebo infusion 15 patients will be CNS OR heart-PET scanned.
11585825|NCT00747942|No Intervention|A|exercise referral to lifestyle activities at the level of moderate intensity without support
11585826|NCT00747942|Active Comparator|B|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
11585827|NCT00747929|Placebo Comparator|S-2367 Placebo|Placebo + reduced calorie diet
11585828|NCT00747929|Experimental|S-2367 800 mg|S-2367 800 mg q.d. + reduced calorie diet
11585829|NCT00747929|Experimental|S-2367 1600 mg|S-2367 1600 mg q.d. + reduced calorie diet
11585830|NCT00747916|Experimental|CryoSpray Ablation (TM) System|subjects will receive cryotherapy using the CryoSpray Ablation (TM) System DOSE: up to 3 cycles of 10-40 second sprays
11585831|NCT00747890|Active Comparator|I|
11585832|NCT00747890|Other|II|
11585833|NCT00747877|Experimental|Arm I|Patients receive high-dose melphalan IV on day -1 followed by autologous stem cell transplantation (ASCT) on day 0.
11585834|NCT00747877|Experimental|Arm II|Patients receive low-dose cyclophosphamide IV or orally once a week for 12-20 weeks for a total of 12 courses.
11585930|NCT00747019|Active Comparator|PE|
11585835|NCT00747812|Experimental|1|Stimulation on from activation to 12 weeks post-activation. Stimulation off from 12 weeks post-activation to 16 weeks post-activation. Stimulation on from 16 weeks post-activation to end of study.
11585836|NCT00747812|Sham Comparator|2|Sham Stimulation from activation of device to 12 weeks post-activation. Stimulation on from 12 weeks post-activation on.
11585837|NCT00747799|Experimental|1|Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)
11585838|NCT00747760||1|Extended family members
11585839|NCT00747760||2|Control- subjects from the same town without known thyroid diseases
11585840|NCT00747747|No Intervention|Control|No coadiuvant treatment. The subject is treated with the antibiotic only and forbidden to take any coadiuvant medicine as a remedy for the symptoms during the period of the study.
11585841|NCT00747747|Active Comparator|Saline solution|Saline solution sprayed according to the product indication. Only one brand/specific product has been selected.
11585842|NCT00747747|Experimental|Sinuclean treatment|Sinuclean DM Spray.
11585843|NCT00747721|Experimental|1|Dexmedetomidine
11585844|NCT00747708|Experimental|Peripheral|Patients are randomised in a 1:1 ratio to receive granulocyte-colony stimulating factor (G-CSF) or placebo injection
11585845|NCT00747708|Experimental|Percutaneous intracoronary injection|All patients will receive granulocyte-colony stimulating factor injections followed by a bone marrow aspiration. Patients will be randomised in a 1:1 ratio to receive intracoronary injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
11585846|NCT00747708|Experimental|Percutaneous intramyocardial injection|All patients will receive granulocyte-colony stimulating factor injections followed by a bone marrow aspiration. Patients will be randomised in a 1:1 ratio to receive intramyocardial injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
11585847|NCT00747656||1|3 lead ECG subjects with chest pain and suspected ischemia transported to the nearest receiving ED and not eligible for bypass based on transport time
11585848|NCT00747656||2|3 lead ECG subjects with chest pain and suspected ischemia transported to the nearest receiving ED and eligible for bypass based on transport time, if 12 lead PHECG was possible
11585849|NCT00747656||3|12 lead ECG subjects with prehospital notification transported to nearest receiving ED adn not eligible for bypass to PCI center based on transport time
11585850|NCT00747656||4|12 lead PHECG subjects with prehospital notification bypassed past the nearest receiving ED to the PCI center.
11585851|NCT00747643|Active Comparator|Varenicline|For participants in the varenicline group, the medication doses followed the recommended dose schedule for the first 15 days of treatment: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day on days 8-15.
11585852|NCT00747643|Placebo Comparator|Placebo|Participants in this group received a placebo instead of medication. The placebo was taken once a day on days 1-3, twice a day on days 4-15.
11585853|NCT00747630|Experimental|Intervention|The group selected to watch the video.
11585854|NCT00747617|Active Comparator|PCOS group|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of recombinant human chorionic gonadotropin administered iv on 5 separate occasions.
11585855|NCT00747617|Active Comparator|Control group|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of recombinant human chorionic gonadotropin administered iv on 5 separate occasions.
11585856|NCT00747604||Increlex patients|Eligible patients will be patients beginning therapy with Increlex® or those previously treated with Increlex.
11585857|NCT00747578||1|"AS patients who fit the modified New York criteria (1984)
~Exclusion criteria :
~Patients who have cognitive impairment.
~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).
~Patients who are less than 18 years old or older than 65 years old.
~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
11585858|NCT00747578||2|"RA patients who fit the American College of Rheumatology (ACR) criteria (1987)
~Exclusion criteria :
~Patients who have cognitive impairment.
~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).
~Patients who are less than 18 years old or older than 65 years old.
~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
11585859|NCT00747578||3|"SLE patients who fit the ACR revised criteria for the classification of SLE (1997)
~Exclusion criteria :
~Patients who have cognitive impairment.
~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).
~Patients who are less than 18 years old or older than 65 years old.
~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
11585860|NCT00747565|Experimental|Tecnis Multifocal IOL group|Subjects implanted bilaterally with the Tecnis Multifocal IOL. Participants were enrolled in this arm in the original study and also in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.
11585861|NCT00747565|Active Comparator|CeeOn 911A monofocal control IOL group|Subjects implanted bilaterally with the CeeOn 911A monofocal IOL. Participants enrolled in this arm only in the original study; no control subjects were enrolled in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.
11585862|NCT00747539||1|This group will be composed of 165 HCV-infected people who are not also HIV infected.
11585863|NCT00747539||2|This group will be composed of 165 HCV-infected people who are also HIV infected.
11585864|NCT00747526|Experimental|Rabeprazole sodium 5 mg|
11585865|NCT00747526|Experimental|Rabeprazole sodium 10 mg|
11585866|NCT00747513|Experimental|I|intervention group
11585867|NCT00747487|Experimental|1|Idebenone
11585868|NCT00747487|Placebo Comparator|2|Placebo
11585869|NCT00747474|Experimental|Lipotecan|Intravenous Lipotecan (TLC388 HCl for Injection)
11585870|NCT00747461|Experimental|Cryospray Ablation|Experimental CSA (Cryospray Ablation)
11585980|NCT00746694||Caelyx|Participants with metastatic breast or ovarian cancer treated with Caelyx as part of standard treatment and according to data sheet approved indications.
11585982|NCT00746681|Active Comparator|B|Tolterodine SR 4 mg once daily
11585871|NCT00747435|Experimental|Original Audiological Criteria|"Inclusion Criteria:
~Pure-tone air-conduction threshold levels shall fall at or within the levels listed in the following chart.
~Frequency (Hz): 250 500 750 1000 1500 2000 4000 8000 Lower Limit: 10 10 10 60 60 70 70 70 Upper Limit: 65 65 75 *110+ *110+*110+ *110+ *90+
~Minimal benefit from optimally fit hearing aid/s, preferably bilateral, with monosyllabic word scores in quiet of ≤50% in the best-aided condition."
11585872|NCT00747435|Experimental|Expanded Audiological Criteria|"Pure-tone air-conduction threshold levels shall fall at or within the levels listed in the following chart.
~Frequency (Hz): 250 500 750 1000 1500 2000 4000 8000 Lower Limit: 10 10 10 60 60 70 70 70 Upper Limit: 65 65 75 *110+ *110+*110+ *110+ *90+
~Minimal benefit from optimally fit hearing aid/s, preferably bilateral, with monosyllabic word scores in quiet of ≤50% in the best-aided condition.
~Study Arm 2 candidates are those who meet the inclusion criteria listed above with the exception that:
~In the ear to be implanted, the pure-tone air conduction threshold(s) at 250, 500, and/or 750 Hz will be greater than or equal to 0 dB HL and less than 10 dB HL, and/or In the ear to be implanted, the pure-tone air conduction threshold(s) at 1000 and/or 1500 Hz will be greater than or equal to 0 dB HL and less than 60 dB HL and/or In their best-aided condition, they score 51-60% on monosyllabic word scores."
11585873|NCT00747422|Experimental|I|
11585874|NCT00747409|Active Comparator|Hum|use of human regular insulin and NPH insulin
11585875|NCT00747409|Active Comparator|Ana|use of insulin aspart and insulin detemir
11585876|NCT00747396|Experimental|Foster Care Placement Group|Children randomized to this group were placed in high quality foster care developed for the study.
11585877|NCT00747396|No Intervention|Care As Usual Group|Children randomized to this group remained in institutional care.
11585878|NCT00747383|Active Comparator|1|
11585879|NCT00747383|Active Comparator|2|
11585880|NCT00747370|Other|1|16 healthy volunteers with no complaints of urinary symptoms and without urogenital prolapse of more than first degree.
11585881|NCT00747370|Other|2|Forty two stress urinary incontinence patients without prior urogenital prolapse or incontinence operation and without genital prolapse more than first degree
11585882|NCT00747370|Other|3|16 genital prolapse women without prior prolapse operations or any symptoms of incontinence
11585883|NCT00747357|Experimental|1|Balloon first
11585884|NCT00747357|Experimental|2|Stent First
11585885|NCT00747344|Placebo Comparator|Placebo - Controlled Period (CP)|
11585886|NCT00747344|Experimental|Ustekinumab 45 mg - CP|
11585887|NCT00747344|Experimental|Placebo to ustekinumab 45 mg - after CP|
11585888|NCT00747344|Experimental|Ustekinumab 45 mg - after CP|
11585889|NCT00747331|Experimental|A|
11585890|NCT00747331|Placebo Comparator|B|
11585891|NCT00747318|Experimental|1|
11585892|NCT00747305|Experimental|Sunitinib|Sunitinib will be administered for 8 weeks prior to sugery
11585893|NCT00747292|Active Comparator|Epidural|Epidural
11585894|NCT00747292|Active Comparator|2|Spinal
11585895|NCT00747292|Active Comparator|3|Patients in this limb receive a PCA
11585896|NCT00747279|Experimental|1|Carbohydrate restrictive strategy
11585897|NCT00747279|Active Comparator|2|Intensive insulin therapy
11585898|NCT00747253|Experimental|Single Active Arm|Only Arm. Patients treated using AutoLITT System.
11585899|NCT00747227|Experimental|ZV9003|modified light transmission intraocular lens
11585900|NCT00747227|Active Comparator|ZA9003|monofocal acrylic intraocular lens
11585901|NCT00747214|Experimental|CRx-102 plus DMARD therapy|
11585902|NCT00747214|Placebo Comparator|Placebo plus DMARD therapy|
11585903|NCT00747201|Active Comparator|2 Packaged intervention only|Patients will be seen by providers who receive the intervention package only.
11585904|NCT00747201|Experimental|1 Packaged intervention, training, and technical assistance|Patients will be seen by providers who receive the packaged intervention, along with provider training and ongoing technical assistance.
11585905|NCT00747188|Experimental|2|
11585906|NCT00747188|No Intervention|A, 2, III|
11585907|NCT00747175|Experimental|1|3 (alt.4) gradually increasing repeated oral doses of AZD1656 given to 3 (alt.4) groups (6 on active and 2 on placebo in each group)
11585908|NCT00747175|Experimental|2|Oral dose of AZD1656 titrated during 3 days to a tolerable dose (15 on active and 5 on placebo)
11585909|NCT00747162|Experimental|1|We will use The INVOS cerebral oximeter to determine oxygen content in the healthy muscle. In addition, we will use a the DermaSpectrometer to determine if there are differences in our readings according to skin color.
11585910|NCT00747149|Experimental|Rosuvastatin 1|titrated
11585911|NCT00747149|Experimental|Rosuvastatin 2|Non-titrated
11585912|NCT00747123|Placebo Comparator|Placebo|Subcutaneous injection on days 1, 29, 57 and 85.
11585913|NCT00747123|Experimental|ACE-011 0.1 mg/kg|Subcutaneous injection of ACE-011 0.1 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
11585914|NCT00747123|Experimental|ACE-011 0.3 mg/kg|Subcutaneous injection of ACE-011 0.3 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
11585915|NCT00747123|Experimental|ACE-011 0.5 mg/kg|Subcutaneous injection of ACE-011 0.5 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
11585916|NCT00747110|Experimental|A|9mg budesonide OD
11585917|NCT00747110|Active Comparator|B|3g mesalazine OD
11585918|NCT00747097|Experimental|1|gemcitabine+cetuximab
11585919|NCT00747084|Experimental|Arm 1: Study Treatment|Study Treatment: warm water loading of the sigmoid colon and warm water irrigation for dealing with colonic spasms.
11585920|NCT00747084|No Intervention|Arm 2: Control Treatment|Control Treatment: no water loading and waiting for spasms to subside.
11585921|NCT00747071|Experimental|1|Hospitalized patients with Clostridium difficile associated diarrhea.
11585922|NCT00747071|Experimental|2|Close hospital contacts of each index case
11585923|NCT00747058|Experimental|healthy volunteers|
11585924|NCT00747058|Placebo Comparator|Placebo|
11585925|NCT00747045|Experimental|Low tidal volume|Tidal volume of 6 mL/Kg ideal body weight
11585926|NCT00747045|Active Comparator|Usual care|Tidal volume of 10 mL/Kg ideal body weight
11585927|NCT00747032|Active Comparator|1|NYC 0462 Ointment
11585928|NCT00747032|Placebo Comparator|2|Placebo
11585929|NCT00747019|Experimental|PBPA|
11585931|NCT00747006|Experimental|TI Inhalation Powder (original protocol)|Under the original protocol, subjects with Type 1 and Type 2 diabetes will have TI Inhalation Powder administered prandially during dose optimization visits and meal challenge visits (with meals of varying carbohydrate contents). Subjects with Type 2 diabetes will also use TI Inhalation Powder daily at each meal between visits.
11585932|NCT00747006|Other|TI Inhalation Powder and Humalog (Amendment 1)|Under Amendment 1, TI Inhalation Powder will be administered prandially to a new subset of subjects with Type 2 diabetes during TI dose optimization visits and TI meal challenge visits (with meals of varying carbohydrate contents). Subjects will be crossed over to administration of Humalog 15 minutes before meals during Humalog dose optimization visits and Humalog meal challenge visits (with meals of varying carbohydrate contents). Subjects will also use TI Inhalation Powder daily at each meal between visits.
11585933|NCT00746993|Experimental|1|Structured contraceptive counseling and routine care.
11585934|NCT00746993|No Intervention|2|Routine care.
11585935|NCT00746980|Experimental|Treatment|Subjects receiving drug
11585936|NCT00746967|Other|Arm 1|
11585937|NCT00746954|Other|Arm 1 BUS to PLA to ACET|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=3
11585938|NCT00746954|Other|ARM 2 ACET to BUS to PLA|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=3
11585939|NCT00746954|Other|ARM 3 PLA to ACET to BUS|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=2
11585940|NCT00746941|No Intervention|Local standard of care|"All participants received local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.
~Participants in this treatment arm had the option of adding 250 mg mefloquine by mouth at Week 4 (Day 28) or Week 8 (Day 56) daily for 3 days, and then weekly through Week 24."
11585941|NCT00746941|Experimental|Local standard of care plus mefloquine 250 mg|"All participants received local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.
~Participants received 250 mg mefloquine by mouth on Days 0, 1, and 2 and then weekly through Week 24."
11585942|NCT00746902|Active Comparator|1|Arm 1: Active CPAP, a nasal continuous positive airway pressure
11585943|NCT00746902|Sham Comparator|2|Arm 2 : Sham CPAP :Placebo/CPAP
11585944|NCT00746889|Active Comparator|Corticosteroid Injection|40 mg of intraarticular triamcinolone acetonide
11585945|NCT00746889|Placebo Comparator|Placebo Injection|Intraarticular injection of 0.9% saline
11585946|NCT00746876|Active Comparator|Unipolar|15 patients randomized for treatment with a unipolar hip hemiarthroplasty
11585947|NCT00746876|Active Comparator|Bipolar|15 patients randomized for treatment with a bipolar hip hemiarthroplasty
11585948|NCT00746863|Experimental|1|Patients randomized to this arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
11585949|NCT00746863|No Intervention|2|Patients assigned to this arm will have the mid-urethral sling placed via the suprapubic approach in the standard fashion with no injection of Marcaine into the retropubic space.
11585950|NCT00746850|Experimental|H|early LC within 72 hours after the diagnosis with H (Harmonic)
11585951|NCT00746850|Active Comparator|MD|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)
11585952|NCT00746837|Experimental|1|Single ascending IV dose, 3 treatment periods separated by a minimum 14 day washout between doses
11585953|NCT00746837|Experimental|2|2 cohorts single IV dose + multiple oral dose period separated by a minimum of 14 days washout between IV and oral dose
11585954|NCT00746824|Experimental|1|"AM dose: 0.85 mg
~PM dose: placebo"
11585955|NCT00746824|Experimental|2|"AM dose: 0.85 mg
~PM dose: 0.85 mg"
11585956|NCT00746824|Experimental|3|"AM dose: 2.55 mg
~PM dose: placebo"
11585957|NCT00746824|Experimental|4|"AM dose: placebo
~PM dose: 2.55 mg"
11585958|NCT00746824|Experimental|5|"AM dose: 2.55 mg
~PM dose: 2.55 mg"
11585959|NCT00746824|Experimental|6|"AM dose: placebo
~PM dose: placebo"
11585960|NCT00746811|Other|1|P-OM3 for the first six weeks of treatment. Placebo for the second six weeks of treatment.
11585961|NCT00746811|Other|2|Placebo for the first six weeks of treatment. P-OM3 for the second six weeks of treatment.
11585962|NCT00746798|Experimental|ChimeriVax WN02 vaccine, low dose|Participants randomized to receive ChimeriVax WN02 vaccine, low dose
11585963|NCT00746798|Experimental|ChimeriVax-WN02 vaccine, medium dose|Participants randomized to receive ChimeriVax-WN02 vaccine, medium dose
11585964|NCT00746798|Experimental|ChimeriVax-WN02 vaccine, high dose|Participants randomized to receive ChimeriVax-WN02 vaccine, high dose
11585965|NCT00746798|Placebo Comparator|Placebo|Participants randomized to receive Placebo (Saline)
11585966|NCT00746785|Experimental|2.5 mg Olanzapine|"2.5 mg Olanzapine
~1x per day for 12 weeks."
11585967|NCT00746785|Active Comparator|5mg Olanzapine|"5 mg Olanzapine
~1x per day for 12 weeks."
11585968|NCT00746785|Placebo Comparator|Placebo|"Placebo
~1x per day for 12 weeks."
11585969|NCT00746772|Active Comparator|1|Patients with oral lichen planus
11585970|NCT00746772|Placebo Comparator|2|Patients with oral lichen planus
11585971|NCT00746759||Standard of Care|
11585972|NCT00746733|Experimental|Vyvanse (LDX)|
11585973|NCT00746733|Experimental|Adderall XR (AXR)|
11585974|NCT00746720|Experimental|A, 1|Study part 1 (n = 8)
11585975|NCT00746720|Placebo Comparator|A, 2|Study part 1 (n = 4)
11585976|NCT00746720|Experimental|B, 1|Study part 2 (n = 20)
11585977|NCT00746720|Placebo Comparator|B, 2|Study part 2 (n = 20)
11585978|NCT00746707|Experimental|1|use of octyl-2-cyanoacrylate adhesive glue for perineal tear grade 1 in 80 women
11585979|NCT00746707|Active Comparator|3|use of traditional suturing for perineal tear grade 1 in 50 women
11585981|NCT00746681|Experimental|A|Tolterodine SR 2 mg once daily combined with pregabalin 75 mg twice daily
11585983|NCT00746681|Placebo Comparator|C|Placebo
11585984|NCT00746681|Experimental|D|Tolterodine SR 4 mg once daily combined with pregabalin 150 mg twice daily
11585985|NCT00746681|Experimental|E|Pregabalin 150 mg twice daily
11585986|NCT00746668|Experimental|Control Group|Subjects randomly assigned to this group had their training delayed for 18 weeks. These subjects underwent four assessments: baseline and at three 6-week intervals' but, they were not given any training during this time. After this data collection period, these control subjects were given training on the three modules. However, their performance after each period of training was not assessed.
11585987|NCT00746668|Experimental|Group 1|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.
~Subjects in this group were trained according to the following counterbalanced module order:
~Training Session 1: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 2: Module 2 (Control of Reading Eye Movements) Training Session 3: Module 3 (Reading Practice with RSVP)"
11585988|NCT00746668|Experimental|Group 2|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.
~Subjects in this group were trained according to the following counterbalanced module order:
~Training Session 1: Module 2 (Control of Reading Eye Movements) Training Session 2: Module 3 (Reading Practice with RSVP) Training Session 3: Module 1 (Visual Awareness and Eccentric Viewing)"
11585989|NCT00746668|Experimental|Group 3|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.
~Subjects in this group were trained according to the following counterbalanced module order:
~Training Session 1: Module 3 (Reading Practice with RSVP) Training Session 2: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 3: Module 2 (Control of Reading Eye Movements)"
11585990|NCT00746668|Experimental|Group 4|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.
~Subjects in this group were trained according to the following counterbalanced module order:
~Training Session 1: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 2: Module 3 (Reading Practice with RSVP) Training Session 3: Module 2 (Control of Reading Eye Movements)"
11585991|NCT00746668|Experimental|Group 5|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.
~Subjects in this group were trained according to the following counterbalanced module order:
~Training Session 1: Module 2 (Control of Reading Eye Movements) Training Session 2: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 3: Module 3 (Reading Practice with RSVP)"
11585992|NCT00746668|Experimental|Group 6|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.
~Subjects in this group were trained according to the following counterbalanced module order:
~Training Session 1: Module 3 (Reading Practice with RSVP) Training Session 2: Module 2 (Control of Reading Eye Movements) Training Session 3: Module 1 (Visual Awareness and Eccentric Viewing)"
11585993|NCT00746655|Other|SBRT / TACE|
11585994|NCT00746642|Experimental|A|"Glucose measurements using Mellitor device."
11585995|NCT00746642|Active Comparator|B|"Glucose measurements conducted by using gold standard, Yellow Springs glucose analyzer"
11585996|NCT00746629|Active Comparator|Prescribed Skills|Behavioral skills are all prescribed and considered necessary tools expected to be used consistently, completely, and uniformly by all participants throughout treatment
11585997|NCT00746629|Experimental|Self-Directed Skills|Behavioral skills are considered a tool box from which families are encouraged to select skills that best apply to that family's situation in attempts to help their child make eating and activity change.
11585998|NCT00746616|Experimental|1|Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
11585999|NCT00746603|Experimental|1|Escalating dose of simvastatin
11586000|NCT00746590|Experimental|1|
11586001|NCT00746564|Experimental|Open Label|SJM Confirm Device
11586002|NCT00746551|Active Comparator|Ferrous fumarate, Ferri-6®, Oral tablet|In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
11586003|NCT00746551|Experimental|iron sucrose, Venofer®, intravenous drug|Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
11586004|NCT00746538|Experimental|1|metallic stent group
11586005|NCT00746538|Active Comparator|2|plastic stent group
11586006|NCT00746525|Experimental|Brain Computer Interface Training Stroke Experimental Group|Individuals in the stroke experimental group received treatment with BCI, FES, and motor learning targeted at their upper extremity motor deficits following stroke.
11586007|NCT00746512|Experimental|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days
11586008|NCT00746512|Placebo Comparator|Placebo 15 mg|Prednisone 15 mg placebo tablets once daily for 15 days
11586082|NCT00746070||A, primary aldosteronism|patients approved to be aldosteronism
11586305|NCT00744263|Placebo Comparator|Placebo|
11586009|NCT00746512|Experimental|Prednisone 7.5 mg|"Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days
~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis."
11586010|NCT00746512|Placebo Comparator|Placebo 7.5 mg|"Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days
~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis."
11586011|NCT00746499|Experimental|1|No control group, only one active arm with subjects taking Raltegravir.
11586012|NCT00746486|Experimental|A|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d
11586013|NCT00746486|Active Comparator|B|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d
11586014|NCT00746473||1|15 HIV-1 infected individuals, with or without AIDS, who had never received ARV. These patients had not yet been indicated for ARV, or had had HIV-1 infection diagnosed a few days before inclusion in this study.
11586015|NCT00746473||2|"27 HIV-1 infected individuals, sick or not, on ARV treatment, five with two nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) and one nonnucleoside reverse transcriptase inhibitor (NNRTI), and 22 on HAART with two NRTI, or one NRTI and one NNRTI, and one protease inhibitor (PI), and VL equal to or greater than 50 copies of plasma RNA/mL.
~Treatment duration in this group varied between three and 145 months (mean 53.62 months; median 42 months)."
11586016|NCT00746473||3|31 HIV-1 infected individuals on ARV treatment, 16 on HAART with two NRTI, or one NRTI and one NNRTI, and one PI, and 15 with two NRTI and one NNRTI. All G3 patients had undetectable VL for at least the past 6 months. Treatment in this group varied between five to 108 months (mean 48.13 months; median 42 months).
11586017|NCT00746473||4|20 blood donors without clinical complaints and negative for anti-HIV-1/2 antibodies. None of them showed any sign of disease.
11586018|NCT00746460|Experimental|A|Behavioral
11586019|NCT00746447|Experimental|3.0g OD|
11586020|NCT00746447|Experimental|1.5g OD|
11586021|NCT00746447|Active Comparator|0.5g TID|
11586022|NCT00746434|Active Comparator|1|Roflumilast cream 0.5%
11586023|NCT00746434|Placebo Comparator|2|Placebo cream
11586024|NCT00746421|Experimental|1|Quetiapine XR 200-400 mg/day
11586025|NCT00746421|Placebo Comparator|2|Placebo one pill per day matching 200, 300, or 400 mg
11586026|NCT00746408||Main 1|Insurants of the health insurance company BARMER using the prototype to receive expert system guided tailored internet information about the type of headache they suffer from.
11586027|NCT00746408||Main 2|Insurants of the health insurance company BARMER using search engines and portals to gather internet information about the type of headache they suffer from.
11586028|NCT00746408||Online 1|Internet users using the prototype to receive expert system guided tailored internet information about the type of headache they suffer from.
11586029|NCT00746408||Online 2|Internet users using search engines and portals to gather internet information about the type of headache they suffer from.
11586030|NCT00746395|Active Comparator|lubiprostone 24mcg single dose|lubiprostone 24mcg single dose po prior to capsule endoscopy
11586031|NCT00746395|Placebo Comparator|Sugar pill|Placebo (sugar pill) - matched single dose po prior to capsule endoscopy
11586032|NCT00746382|Active Comparator|1|Roflumilast cream 0.5%
11586033|NCT00746382|Placebo Comparator|2|Placebo cream
11586034|NCT00746369|No Intervention|2|
11586035|NCT00746369|Experimental|Intervention|IMARA HIV Prevention Intervention. Three individual sessions for incarcerated female teens.
11586036|NCT00746356|Experimental|Promote RF CRT-D|Patients with CRT-D device will have the autocapture features of the device tested.
11586037|NCT00746356|Experimental|Current RF ICD|Patients with ICD device will have the autocapture features of the device tested.
11586038|NCT00746343|Experimental|IRRI|"The integrated risk reduction intervention (IRRI) consists of three components:
~psychiatric treatment by a study psychiatrist
~assessment, referral, monitoring, and coordination by a certified registered nurse practitioner (CRNP) of medical treatment provided by the subject's own primary care physician
~a healthy lifestyle behaviors program delivered by a lifestyle coach. The treating psychiatrist will work in collaboration with a CRNP and a lifestyle coach. The CRNP will assess and monitor the subject's medical needs and refer the subject to their primary care physician for care and will follow-up on adherence to the medical treatment recommendations. The CRNP will be responsible for coordinating the psychopharmacological care provided by the psychiatrist, the healthy lifestyle behaviors program that will be delivered by the lifestyle coach, and the medical care provided by the subject's PCP."
11586039|NCT00746343|Experimental|PCCM|"Psychiatric Care with Medical Monitoring (PCMM)
~The psychiatric care with medical monitoring condition (PCMM) consists of two components:
~psychiatric treatment by a study psychiatrist
~assessment and referral by a psychiatric research nurse for medical treatment provided by the subject's own primary care physician.
~The treating psychiatrist will be assisted by a psychiatric nurse clinician who will assess and monitor the subject's medical needs and refer the subject to their primary care physician for care."
11586040|NCT00746330|Experimental|F12M - PL - F12D - MFF|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 4: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
11586083|NCT00746070||B, essential hypertension|patients approved to be essential hypertension
11586084|NCT00746057|Other|1|Patients aged 18 to 65 years old receiving a first cadaveric renal graft.
11586085|NCT00746044||1|Healthy volunteers >18y, 20 male, 20 female
11586086|NCT00746031|Active Comparator|1|GnRH analogue-Zoladex
11586087|NCT00746031|Active Comparator|2|GnRH antagonist plus GnRH analogue
11586088|NCT00746031|No Intervention|3|
11586190|NCT00745147|Active Comparator|B|Duphalac + Placebo of Chinese herbal formula
11586041|NCT00746330|Experimental|F12D - F12M - MFF - PL|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 2: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
11586042|NCT00746330|Experimental|MFF - F12D - PL - F12M|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 4: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
11586043|NCT00746330|Experimental|PL - MFF - F12M - F12D|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 2: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
11586044|NCT00746317|Experimental|1|
11586045|NCT00746304||1|infantile esotropia
11586046|NCT00746304||2|acquired esotropia
11586047|NCT00746291|Experimental|A|Traumatic brain injury
11586048|NCT00746291|Experimental|B|Cerebral palsy
11586049|NCT00746291|Experimental|C|Controls
11586050|NCT00746278|Experimental|1|Laparoscopic ovarian cystectomy using bipolar
11586051|NCT00746278|Experimental|2|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
11586052|NCT00746278|Active Comparator|3|Laparoscopic ovarian cystectomy using suture
11586053|NCT00746265|Active Comparator|SBT|Standard behavioral treatment based on the LEARN manual.
11586054|NCT00746265|Active Comparator|ABT|Acceptance-based group that is based on the behavioral interventions contained in LEARN manual
11586055|NCT00746252|Experimental|1|risperidone
11586056|NCT00746252|Experimental|2|aripiprazole
11586057|NCT00746239|Active Comparator|1|Subjects will be randomly assigned to receive either Ramelteon and Escitalopram OR Placebo and Escitalopram.
11586058|NCT00746239|Placebo Comparator|2|Subjects will be randomly assigned to receive either Ramelteon and Escitalopram OR Placebo and Escitalopram.
11586059|NCT00746226|Active Comparator|A|Numbers 509-513, 700-709 and 900-909 Probiotic combination of L. acidophilus and B. lactis
11586060|NCT00746226|Placebo Comparator|B|"Numbers 612-624 and 800-811
~Microcrystalline cellulose"
11586061|NCT00746200|Experimental|A|
11586062|NCT00746200|Sham Comparator|S|
11586063|NCT00746187|Experimental|ASTRA TECH Implant System; Fixture ST|Ø 4.5 cm in lengths 9-13 mm
11586064|NCT00746187|Experimental|Biomet 3i; Osseotite® Implants|Ø 4.0 cm in lengths 8.5-13 mm
11586065|NCT00746174|Active Comparator|Rosiglitazone|Subjects in this arm will be randomly assigned to treatment with Rosiglitazone 4mg daily. After 4 weeks, we will assess changes in glucose levels and liver enzymes. The dose will then be increased to Rosiglitazone 8mg daily (if indicated). The patients will be reevaluated every 4 weeks, and at the end of 16 weeks, the participants will all be admitted to the research center at UTSW to measure changes in the following: 1) insulin sensitivity; 2) lipid content of heart, liver, & skeletal muscle; and 3) lipid oxidation using respiratory gas exchange. The patients will then switch to the alternative therapy for 16 additional weeks before the studies are repeated.
11586066|NCT00746174|Placebo Comparator|Placebo|Subjects in this arm will be randomly assigned to treatment with placebo. After 4 weeks, we will assess changes in glucose levels and liver enzymes. The patients will be reevaluated every 4 weeks, and at the end of 16 weeks, the participants will all be admitted to the research center at UTSW to measure changes in the following: 1) insulin sensitivity; 2) lipid content of heart, liver, & skeletal muscle; and 3) lipid oxidation using respiratory gas exchange. The patients will then switch to the alternative therapy for 16 additional weeks before the studies are repeated.
11586067|NCT00746161|Active Comparator|1|Roux-en-Y
11586068|NCT00746161|Experimental|2|double tract reconstruction
11586069|NCT00746148|Experimental|1|Reflexology
11586070|NCT00746148|No Intervention|2|No intervention
11586071|NCT00746135|Active Comparator|A|Conventional Biventricular Stimulation: RV Apex and LV Lead Tip
11586072|NCT00746135|Active Comparator|B|"Anodal-Cathodal Biventricular Stimulation: cathodal LV Stimulation und anodal RVHis Stimulation = Anodal-cathodal Bi-V."
11586073|NCT00746135|Active Comparator|C|Anodal-Cathodal Tri-V Stimulation: RV-apex and LV and RV-His
11586074|NCT00746122|Other|Open repair|Immediate Open Surgery
11586075|NCT00746122|Experimental|Endovascular strategy|Endovascular strategy involves immediate computed tomography (CT) and emergency Endovascular aneurysm repair (EVAR), with open repair for patients anatomically unsuitable for EVAR
11586076|NCT00746109|Placebo Comparator|NOPACKING|The comparison group will undergo a routine incision and drainage procedure but will not have packing placed inside the abscess cavity.
11586077|NCT00746109|Experimental|PACKING|This group will receive wound packing as per usual protocol
11586078|NCT00746096|Experimental|IKH-01|ethinyl estradiol 0.035mg and norethisterone 1mg
11586079|NCT00746096|Placebo Comparator|Placebo|Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
11586080|NCT00746083|Experimental|Intervention group|
11586081|NCT00746083|No Intervention|Control group|
11586186|NCT00745186|Experimental|2|Mayne Glucagon
11586089|NCT00746018|Experimental|1|The patients will already be undergoing a total hysterectomy with removal of the tubes and ovaries for a specific indication diagnosed or defined by their surgeon. If the patient is suitable to proceed by the surgeon, then he/she will perform a right salpingooophorectomy with the LigaSure devices.
11586090|NCT00746005|Experimental|1|3 g EPA-DHA
11586091|NCT00746005|Placebo Comparator|2|Placebo: sunflower oil
11586092|NCT00745992||Fungal infections|"Patients with invasive fungal infections; and
~Patients who receive PO or IV voriconazole for more than 3 days"
11586093|NCT00745953|Active Comparator|Valsartan|This arm will determine if blockade of the renin-angiotensin system reduces myocardial fat levels and improves insulin sensitivity. It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month). Visits 1 & 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, & 24 hr ambulatory blood pressure monitoring. During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits. Visits 2 & 3 are needed for the adjustment of medication to the final dose level. During visits 4 & 5, Dr. Price will check subject's status as they continue the medication. In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.
11586094|NCT00745953|Active Comparator|Hydrochlorothiazide|This arm will determine if thiazide diuretics elevate myocardial triglyceride levels. It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month). Visits 1 & 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, & 24 hr ambulatory blood pressure monitoring. During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits. Visits 2 & 3 are needed for the adjustment of medication to the final dose level. During visits 4 & 5, Dr. Price will check subject's status as they continue the medication. In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.
11586095|NCT00745940|Experimental|MBCT Intervention Group|The curriculum of our mindfulness intervention draws upon elements from the mindfulness-based stress reduction program, and Segal and colleagues manual for mindfulness-based cognitive therapy. It was modified by one of the investigators to address issues associated with traumatic brain injury (e.g., problems with attention, concentration, memory, fatigue). The intervention was increased to ten weeks with one and a half hour weekly sessions, along with a 20-30 minute daily meditation home practice. Further adaptations included simplified language, the use of repetition to reinforce concepts, and visual aids. More attention was paid to fostering learning conditions to encourage an environment of trust and non-judgement. Connections between learning activities was also made more explicit.
11586096|NCT00745940|No Intervention|MBCT Control Group|Control group waited.
11586097|NCT00745927|No Intervention|Room air insufflations|Room air will be used for insufflations during colonoscopy
11586098|NCT00745927|Active Comparator|CO2 insufflations|CO2 will be used for insufflations during colonoscopy
11586099|NCT00745914|Experimental|1|Pioglitazone drug 15mg daily for 3 months then 30mg for 9 months (Peroxisome Proliferator-Activated Receptor-gamma agonist)
11586100|NCT00745914|Placebo Comparator|2|placebo comparator drug 15mg daily for 3months, then 30mg for 9 months
11586101|NCT00745888||1|age > 18 y/o Patients admitted to surgical ICU
11586102|NCT00745875|Experimental|1|ZD4054 + Pemetrexed
11586103|NCT00745875|Placebo Comparator|2|ZD4054 matched placebo + pemetrexed
11586104|NCT00745862||1|female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment
11586105|NCT00745849|Experimental|1|esomeprazole 40mg po bid
11586106|NCT00745849|Placebo Comparator|2|
11586107|NCT00745836|Experimental|atorvastatin 10 mg, 80 mg|
11586108|NCT00745823|Active Comparator|Raltegravir 400 mg b.i.d.|
11586109|NCT00745823|Experimental|Raltegravir 800 mg q.d.|
11586110|NCT00745810||1|sequential changes before and after cardiopulmonary bypass including ROS, antioxidant status, leukocyte elastase, complements, inflammatory cytokines
11586111|NCT00745797|Experimental|Prophylactic WBRT|Take the whole brain radiotherapy radiotherapy
11586112|NCT00745797|No Intervention|Observer Group|The first 14 days after randomization and patient follow-up after 1 month to complete the FACT-L questionnaire and the MMSE scale.
11586113|NCT00745784||1|Young spouses/domestic partners (20-49 years old) of cancer patients who have died from cancer.
11586114|NCT00745771|Active Comparator|1|200 mg Ketoprofen
11586115|NCT00745771|Active Comparator|2|100 mg Ketoprofen
11586116|NCT00745745|Active Comparator|1|Apical ICD lead placement
11586117|NCT00745745|Experimental|2|Mid-Septal ICD lead placement
11586118|NCT00745732|Experimental|Radiation Therapy + ZD6474|"Radiation Therapy - Phase I: 45 Gy at 3 Gy per fractions once a day.
~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day.
~ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth."
11586119|NCT00745719|Experimental|1|surgical total parathyroidectomy with forearm autografting
11586120|NCT00745706|Other|A|Implantable Loop Recorder (ILR) implant
11586121|NCT00745693|Experimental|1|1 hour exposure to filtered air, followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin-1 (5pmol/min)
11586122|NCT00745693|Experimental|2|1 hour exposure to filtered air, followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin receptor antagonists BQ-123 and BQ-788
11586123|NCT00745693|Experimental|3|1 hour exposure to dilute diesel exhaust (300mcg/m3), followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin-1 (5pmol/min)
11586124|NCT00745693|Experimental|4|1 hour exposure to dilute diesel exhaust (300mcg/m3), followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin receptor antagonists BQ-123 and BQ-788
11586125|NCT00745680||A|A: AMI patient
11586126|NCT00745667|Active Comparator|1|laparoscopic
11586127|NCT00745667|Active Comparator|2|open correction
11586128|NCT00745641||1|Sixty patients with abdominal illness and scheduled abdominal X-ray computed tomography examination will be included.
11586187|NCT00745173|Other|1|
11586188|NCT00745160||1|Never-smokers with lung cancer
11586189|NCT00745147|Experimental|A|Chinese herbal formula + Placebo of duphalac
11586304|NCT00744276|Placebo Comparator|6|
11586129|NCT00745615|Experimental|Double-Blind: Laquinimod 0.3 mg|Participants who will be receiving laquinimod 0.3 milligram (mg) tablet once daily orally in double-blind core study, will continue to receive laquinimod 0.3 mg tablet once daily orally in double-blind extension period of this study for up to Week 36.
11586130|NCT00745615|Experimental|Double-Blind: Laquinimod 0.6 mg|Participants who will be receiving laquinimod 0.6 mg (2 tablets of 0.3 mg each) once daily orally in double-blind core study, will continue to receive laquinimod 0.6 mg once daily orally in double-blind extension period of this study for up to Week 36.
11586131|NCT00745615|Experimental|Double-Blind: Placebo/Laquinimod 0.3 mg|Participants who will be receiving placebo matching to laquinimod 0.3 mg tablet once daily orally in double-blind core study, will receive laquinimod 0.3 mg tablet once daily orally in double-blind extension period of this study for up to Week 36.
11586132|NCT00745615|Experimental|Double-Blind: Placebo/Laquinimod 0.6 mg|Participants who will be receiving placebo matching to laquinimod 0.6 mg (2 tablets of placebo) once daily orally in double-blind core study, will receive laquinimod 0.6 mg once daily orally in double-blind extension period of this study for up to Week 36.
11586133|NCT00745615|Experimental|Open-Label: Laquinimod 0.3 mg/Laquinimod 0.6 mg|Participants who will be receiving laquinimod 0.3 mg tablet once daily orally either in double-blind core study or double-blind extension period, will receive laquinimod 0.6 mg capsule once daily orally in open-label extension period of this study until termination (as long as the Sponsor will continue the development of laquinimod 0.6 mg for RRMS) or early discontinuation (up to approximately 10.5 years).
11586134|NCT00745615|Experimental|Open Label: Laquinimod 0.6 mg|Participants who will be receiving laquinimod 0.6 mg (2 tablets of 0.3 mg each) once daily orally either in double-blind core study or double-blind extension period, will receive laquinimod 0.6 mg capsule once daily orally in open-label extension period of this study until termination (as long as the Sponsor will continue the development of laquinimod 0.6 mg for RRMS) or early discontinuation (up to approximately 10.5 years).
11586135|NCT00745602|Experimental|1|Patients referred for elective direct current cardioversion (DCCV) of atrial fibrillation.
11586136|NCT00745589|Active Comparator|higher dose sevelamer|first-line higher dose sevelamer hydrochloride
11586137|NCT00745589|Active Comparator|low dose sevelamer|second-line fixed low-dose sevelamer hydrochloride added to calcium carbonate
11586138|NCT00745576|Experimental|1|
11586139|NCT00745563|Experimental|A|
11586140|NCT00745537|Experimental|Adolescent Mother|aged less than 17 years old and recently gave birth
11586141|NCT00745511|Active Comparator|1|
11586142|NCT00745511|Active Comparator|2|
11586143|NCT00745511|Placebo Comparator|3|
11586144|NCT00745498|Experimental|Preop IVB|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 1 to 14 days before vitrectomy
11586145|NCT00745498|Experimental|Intraop IVB|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
11586146|NCT00745498|No Intervention|No IVB|Patients will not receive bevacizumab before nor during vitrectomy
11586147|NCT00745485|Experimental|Zoldronic|
11586148|NCT00745472||1|
11586149|NCT00745472||2|
11586150|NCT00745459|Experimental|N|20 mL NPO-11
11586151|NCT00745446|Experimental|1|1 hour exposure to filtered air
11586152|NCT00745446|Experimental|2|1 hour exposure to diesel exhaust (300mcg/m3)
11586153|NCT00745446|Experimental|3|1 hour exposure to filtered diesel exhaust
11586154|NCT00745433||A|Repaglinide add-on to metformin.
11586155|NCT00745420|Experimental|Hematopoietic Stem Cell Transplantation|Bone Marrow Transplant with GVHD Prophylaxis Regimen
11586156|NCT00745407|Experimental|fenofibrate 160 mg, placebo|
11586157|NCT00745381||1|This registry will be open to all patients with GEPNET or NET of unknown primary.
11586158|NCT00745368|Experimental|Raltegravir|Raltegravir 400 mg tablets twice daily
11586159|NCT00745355||1|new patients with bladder cancer and/or are scheduled for radical cystectomy and urinary diversion
11586160|NCT00745342|Experimental|Teamwork Group|Families randomized to the Teamwork Group received the behavioral family teamwork intervention.
11586161|NCT00745342|No Intervention|Standard Care|Families in the Standard Care group received standard diabetes care and equal attention from study staff between visits to schedule appointments and encourage regular diabetes follow-up care.
11586162|NCT00745329||2|"patients
~healthy volunteers"
11586163|NCT00745316|Experimental|1|oral Dose 1
11586164|NCT00745316|Experimental|2|oral Dose 2
11586165|NCT00745316|Experimental|3|oral Dose 3
11586166|NCT00745316|Experimental|4|oral Dose 4
11586167|NCT00745316|Experimental|5|oral Dose 5
11586168|NCT00745316|Placebo Comparator|6|Placebo - 2 capsules bid
11586169|NCT00745303||1|Subjects in this group received TCC training for 3 months
11586170|NCT00745303||2|Subjects in this group received no TCC training within 3 months
11586171|NCT00745290|Active Comparator|Bupivacaine HCl|Single dose of 200 mg bupivacaine HCl administered intraoperatively via local infiltration
11586172|NCT00745290|Other|SKY0402|Single dose of 600 mg SKY0402 (study drug) administered intraoperatively via local infiltration
11586173|NCT00745264|Experimental|2|400 mg Ketoprofen from Diractin to 4 joints
11586174|NCT00745264|Experimental|3|100 and 400 mg Ketoprofen used concomittant with heat
11586175|NCT00745264|Experimental|4|100 and 400 mg Ketoprofen concomittant with moderate exercise
11586176|NCT00745264|Experimental|1|100 mg ketoprofen to 2 joints
11586177|NCT00745251|Experimental|VI-0521|15 mg Phentermine and 92 mg Topiramate
11586178|NCT00745251|Placebo Comparator|Placebo|
11586179|NCT00745238|Experimental|Myotonic Dystrophy 1|
11586180|NCT00745225|Experimental|Active intervention arm|Peroxisome proliferator activator receptor gamma treatment, Pioglitazone
11586181|NCT00745225|Placebo Comparator|placebo pill|placebo comparator
11586182|NCT00745199|Experimental|1|Patients on hemodialysis with pruritus, receiving cromolyn sodium
11586183|NCT00745199|Experimental|2|patients on hemodialysis with pruritus, receiving placebo
11586184|NCT00745199|No Intervention|3|Patients on hemodialysis but without pruritus who do not receive any treatment.
11586185|NCT00745186|Active Comparator|1|Glucagen
11586191|NCT00745134|Experimental|Arm I (curcumin)|Patients undergo radiation therapy 5 days a week for a total of 28 fractions. Patients also receive capecitabine PO BID on the days of radiation therapy and curcumin PO BID in weeks 1-11.5.
11586192|NCT00745134|Active Comparator|Arm II (placebo)|Patients undergo radiation therapy and receive capecitabine as in Arm I. Patients also receive placebo PO BID in weeks 1-11.5.
11586193|NCT00745121|Experimental|Group-A, Osteoporosis/osteopenia|Patients with osteoporosis/osteopenia.
11586194|NCT00745121|Experimental|Group-B, Control|Control (non-osteoporotic/-osteopenic patients).
11586195|NCT00745108|Experimental|Tibolone 1.25 mg|
11586196|NCT00745108|Experimental|Tibolone 2.5 mg|
11586197|NCT00745108|Active Comparator|CE/MPA|
11586198|NCT00745095|No Intervention|SCI MoviPrep® (without NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)<=50ml/min and SCI, GFR>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid [MoviPrep®] (without neostigmine plus glycopyrrolate [NG])
11586199|NCT00745095|No Intervention|SCI PIEE (without NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)>=50ml/min) pulsed irrigation enhanced evacuation [PIEE] (without neostigmine plus glycopyrrolate [NG])
11586200|NCT00745095|No Intervention|Control MoviPrep® only|(Control, glomerular filtration rate (GFR)>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid (MoviPrep®) only (no NG)
11586201|NCT00745095|No Intervention|Control PIEE only|(Control, glomerular filtration rate (GFR)>=50ml/min), pulsed irrigation enhanced evacuation (PIEE) only (no NG)
11586202|NCT00745095|Experimental|SCI MoviPrep® (with NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)<=50ml/min and SCI GFR>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid [MoviPrep®] (with neostigmine plus glycopyrrolate [NG])
11586203|NCT00745095|Experimental|SCI PIEE (with NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)>=50ml/min) pulsed irrigation enhanced evacuation (PIEE) (with neostigmine plus glycopyrrolate [NG])
11586204|NCT00745043|Placebo Comparator|R302|Daily placebo capsules
11586205|NCT00745043|Active Comparator|R303|Daily metoprolol 95mg capsules
11586206|NCT00745043|Active Comparator|R304|Daily propranolol 80mg capsules
11586207|NCT00745043|Active Comparator|Open Label|Daily Metoprolol 190mg capsules
11586208|NCT00745030|Experimental|1|Ramelteon (TAK-375) 8mg tablets
11586209|NCT00745030|Placebo Comparator|2|Placebo 8 mg tablets
11586210|NCT00745017|Experimental|1|
11586211|NCT00745017|Experimental|2|
11586212|NCT00745017|Experimental|3|
11586213|NCT00745004|Experimental|1|Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days.
11586214|NCT00745004|Placebo Comparator|2|Placebo 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days.
11586215|NCT00744991|Experimental|Enzastaurin|Open Label
11586216|NCT00744978|Experimental|Varenicline|
11586217|NCT00744978|Placebo Comparator|Placebo|
11586218|NCT00744965|Active Comparator|Glyburide|Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
11586219|NCT00744965|Placebo Comparator|Placebo|Women with mild gestational diabetes will be started ADA diet and placebo.
11586220|NCT00744939||Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Participants received Magnevist in accordance with its labeling
11586221|NCT00744926|Placebo Comparator|placebo|
11586222|NCT00744926|Experimental|taspoglutide 10mg sc|
11586223|NCT00744926|Experimental|taspoglutide 10mg/20mg sc|
11586224|NCT00744913|Experimental|1|
11586225|NCT00744913|Active Comparator|2|
11586226|NCT00744900|Experimental|A|
11586227|NCT00744874|Experimental|Ablated Patients|Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
11586228|NCT00744861|Active Comparator|Low Intensity Pulsed Ultrasound|Low Intensity Pulsed Ultrasound
11586229|NCT00744861|Sham Comparator|Sham|Sham (inactive) low intensity pulsed ultrasound device
11586230|NCT00744848|Active Comparator|Bupivacaine HCl|"100 mg Bupivacaine HCl (e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402.
~A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration."
11586231|NCT00744848|Other|SKY0402|"300 mg SKY0402 in a 40-mL injection volume.
~A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration."
11586232|NCT00744835|Experimental|1|Ablation Management
11586233|NCT00744796|Other|D|Not a comparative group. Assessing single group
11586234|NCT00744757|Experimental|Decitabine|Decitabine 20 milligram per square meter (mg per m^2) will be administered intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
11586235|NCT00744744||Survey|
11586236|NCT00744731|Experimental|001|placebo placebo for 1 week
11586237|NCT00744731|Experimental|002|carisbamate 400 mg/day to 1,200 mg per day
11586238|NCT00744705||1|Normal subjects who received routine health check-up in a comprehensive medical testing center
11586239|NCT00744692|Experimental|RIC Cord Blood Transplant|Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
11586240|NCT00744679|Experimental|Natalizumab 300 mg|Natalizumab infused at 300 mg every 28 days during the screening and assessment periods of the study which continues the therapy of the previous 12 months and maintains steady-state pharmacokinetics.
11586241|NCT00744666|Experimental|1|Patients receive Prednisolone 1% 1gtt qid x 4 weeks. If the intraocular pressure (IOP) after the 4 weeks is > or equal to 21 mmHg, then IVTA will be withheld. If the IOP < 21mmHg, then patients will receive an injection of IVTA.
11586242|NCT00744666|No Intervention|2|Patients will receive an injection of IVTA (no trial of Prednisolone gtts is given).
11586243|NCT00744653|Other|1|Patients with local-regional recurrence of breast cancer, lesion over 3 cm.
11586244|NCT00744640|Experimental|single|single arm study with triple combination chemotherapy
11586245|NCT00744627|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
11586246|NCT00744627|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
11586247|NCT00744614||1|Medical Intensive care unit patients with asthma, COPD, ILD or coronary disease who are at risk of intubation
11586248|NCT00744601||1|Patients with Cocaine Addiction
11586249|NCT00744601||2|Healthy Control Volunteers
11586250|NCT00744588||alcohol dependence|Alcohol-dependent subjects currently being treated in an inpatient treatment facility.
11586251|NCT00744575||1|Chronic Back Pain
11586252|NCT00744575||2|Healthy Sex & Age Matched Controls
11586253|NCT00744562|Experimental|Open-label OMP-21M18|
11586254|NCT00744549|Experimental|A|This group of men will be on active treatment (antioxidants) for one year and placebo for the second year.
11586255|NCT00744549|Experimental|B|This group of men will be on placebo for one year and active treatment (antioxidants) for the second year.
11586256|NCT00744536|Experimental|Lenalidomide and Melphalan|Lenalidomide + Melphalan both given metronomically
11586257|NCT00744523|Experimental|Mo.ma cerebral protection device|Mo.Ma cerebral protection device
11586258|NCT00744510|Experimental|1|Reflexology
11586259|NCT00744510|No Intervention|2|
11586260|NCT00744497|Placebo Comparator|Placebo|Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
11586261|NCT00744497|Active Comparator|Dasatinib|Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
11586262|NCT00744484|Experimental|B1|B1 - training in water
11586263|NCT00744484|Experimental|S1|S1 - training on land
11586264|NCT00744471|Experimental|Tanezumab 10 mg|Tanezumab 10 mg IV every 8 weeks
11586265|NCT00744471|Experimental|Tanezumab 5 mg|Tanezumab 5mg IV every 8 weeks
11586266|NCT00744471|Experimental|Tanezumab 2.5 mg|Tanezumab 2.5 mg IV every 8 weeks.
11586267|NCT00744471|Experimental|Placebo|Placebo
11586268|NCT00744458|Active Comparator|1|
11586269|NCT00744458|Active Comparator|2|
11586270|NCT00744458|Active Comparator|3|
11586271|NCT00744445|Active Comparator|0800|r-HuEPO administered at 0800 hrs
11586272|NCT00744445|Active Comparator|1500|r-HuEPO administered at 1500 hrs
11586273|NCT00744445|Active Comparator|2200|r-HuEPO administered at 2200 hrs
11586274|NCT00744419|Experimental|3 age groups|Assigned to the arm based on age.
11586275|NCT00744406|Experimental|1|
11586276|NCT00744406|Experimental|2|
11586277|NCT00744406|Experimental|3|
11586278|NCT00744393|Active Comparator|A|Active drug
11586279|NCT00744393|Placebo Comparator|P|Placebo drug
11586280|NCT00744380|Active Comparator|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4) as other sedatives are down titrated. Daily awakenings are used.
11586281|NCT00744380|Experimental|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)as other sedatives are down titrated. Daily awakenings are used.
11586282|NCT00744367|Placebo Comparator|Placebo|Placebo in addition to continued stable metformin plus pioglitazone treatment. After the first 24 weeks patients on placebo will be switched to taspoglutide 10mg once weekly or taspoglutide 20mg once weekly (after 4 weeks of taspoglutide 10mg once weekly.
11586283|NCT00744367|Experimental|Taspoglutide 10mg|Taspoglutide 10mg once weekly in addition to continued stable metformin plus pioglitazone treatment
11586284|NCT00744367|Experimental|Taspoglutide 10mg/20mg|Taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued stable metformin plus pioglitazone treatment.
11586285|NCT00744354|Experimental|Non-Randomized Open Label Single Arm|Phase 1 dose escalation trial of vorinostat in combination with bortezomib and pegylated liposomal doxorubicin hydrochloride.
11586286|NCT00744341|Experimental|1|
11586287|NCT00744341|Experimental|2|
11586288|NCT00744341|Experimental|3|
11586289|NCT00744341|Experimental|4|
11586290|NCT00744341|Placebo Comparator|5|
11586291|NCT00744328|Experimental|Transdermal Estradiol|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The capsules for women in this arm do not contain any active ingredients. The skin patch contains transdermal estradiol ranging in dose from 50 to 200 mcg/day
11586292|NCT00744328|Active Comparator|Sertraline|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The skin patch contains no active ingredients, though packaging is designed to match active patches. The capsules contain sertraline ranging in dose from 25 to 200mg/day
11586293|NCT00744328|Placebo Comparator|Placebo|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The capsules for women in this arm do not contain any active ingredients. The skin patch contains no active ingredients, though packaging is designed to match active patches.
11586294|NCT00744315|Other|1|Controlled
11586295|NCT00744302|Experimental|PCD|Physiological calcium (1.25 mmol/L) dialysate therapy All subjects in the study phase will continue to take calcium carbonate and/or active vitamin D agents.
11586296|NCT00744302|Active Comparator|NCD|Normal calcium (1.5 mmol/L) dialysate therapy All subjects in the study phase will continue to take calcium carbonate and/or active vitamin D agents.
11586297|NCT00744289|No Intervention|Arm 1|Participants in Arm 1 will not receive any financial incentive after the second and third dose of hepatitis B vaccine have been administered.
11586298|NCT00744289|Other|Arm 2|Participants in Arm 2 will receive a small financial incentive after the second and third dose of the hepatitis B vaccine
11586299|NCT00744276|Active Comparator|1|
11586300|NCT00744276|Active Comparator|2|
11586301|NCT00744276|Active Comparator|3|
11586302|NCT00744276|Placebo Comparator|4|
11586303|NCT00744276|Placebo Comparator|5|
11586306|NCT00744263|Experimental|13-valent pneumococcal conjugate vaccine|
11586307|NCT00744250|Other|1|"Pre-treatment vs. post-treatment-
~In the first phase, before administration of the capsules and liquid diet, baseline gastric and duodenal secretions will be aspirated via the oro-enteric tube. Subjects will get 5 placebo capsules at Time=0 given orally with the liquid Lundh diet. Pancreato-biliary and duodenal secretions in the duodenal region will be aspirated continuously over the first 20 min. Gastric and duodenal fluids will be aspirated from 20-180 min at specified time points. Following a rest of 1 hour, the same process will be repeated with the drug capsules. At the end of the study the catheter will be removed and patient will be offered a meal."
11586308|NCT00744237|Experimental|1|"Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration
~Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration
~Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration
~Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration
~Open-label amlodipine may be given"
11586309|NCT00744237|Active Comparator|2|"Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration
~Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration
~Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration
~Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration
~Open-label amlodipine may be given"
11586310|NCT00744237|Active Comparator|3|"HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration
~HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration
~Open-label amlodipine may be given"
11586311|NCT00744224|Placebo Comparator|1|
11586312|NCT00744224|Active Comparator|2|
11586313|NCT00744224|Active Comparator|3|
11586314|NCT00744211|Placebo Comparator|Vehicle|Vehicle Group
11586315|NCT00744211|Experimental|ET-ARA 1mg/kg|ET-ARA 1 mg/kg
11586316|NCT00744211|Experimental|ET-ARA 2mg/kg|ET-ARA 2 mg/kg
11586317|NCT00744198|Active Comparator|1|Autologous sling
11586318|NCT00744198|Active Comparator|2|Synthetic sling
11586319|NCT00744198|Active Comparator|3|Biological sling
11586320|NCT00744185|Placebo Comparator|2|30-days placebo treatment
11586321|NCT00744185|Experimental|1|30-days propranolol treatment
11586322|NCT00744172|Active Comparator|I|laparoscopy
11586323|NCT00744172|Active Comparator|2|vaginal
11586324|NCT00744172|Active Comparator|3|abdominal
11586325|NCT00744159||OC|Open colorectal resection
11586326|NCT00744159||LC|Laparoscopic colorectal resection
11586327|NCT00744146|Experimental|1|"Six volunteers total.
~Randomized such that four volunteers will receive Protexia as a single 50 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.
~Volunteers to be followed for approximately 71 days total."
11586328|NCT00744146|Experimental|2|"Six volunteers total.
~Randomized such that four volunteers will receive Protexia as a single 100 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.
~Volunteers to be followed for approximately 71 days total."
11586329|NCT00744146|Experimental|3|"Eight volunteers total.
~Randomized such that six volunteers will receive Protexia as a single 250 mg dose and two volunteers will receive saline placebo of the same volume on Study Days 1 and 72.
~Volunteers to be followed for approximately 142 days total."
11586330|NCT00744146|Experimental|4|"Six volunteers total.
~Randomized such that four volunteers will receive Protexia as a single 500 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.
~Volunteers to be followed for approximately 71 days total."
11586331|NCT00744146|Experimental|5|"Six volunteers total.
~Randomized such that four volunteers will receive Protexia as a single 750 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.
~Volunteers to be followed for approximately 71 days total."
11586332|NCT00744133|Experimental|Group 1: 1, 3, or 5 bites|Part A: 18 subjects receive 1, 3, or 5 bites of Anopheles stephensi mosquitoes infected with the NF54 strain of Plasmodium falciparum.
11586333|NCT00744133|Experimental|Group 2: N bites|Part B: 20 subjects receive N bites of Anopheles stephensi mosquitoes infected with the NF54 strain of Plasmodium falciparum.
11586334|NCT00744094|Placebo Comparator|1|placebo drink
11586335|NCT00744094|Experimental|2|protein drink
11586336|NCT00744068|Experimental|1|Structured Directive Telephone Support Calls
11586337|NCT00744068|Experimental|2|Structured Non-Directive Telephone Continuing Care Support
11586338|NCT00744068|Experimental|3|Unstructured Directive Telephone Support
11586339|NCT00744068|Experimental|4|Unstructured Non-Directive Telephone Support
11586340|NCT00744068|No Intervention|5|
11586341|NCT00744055|Experimental|Prazosin|prazosin (16mg/day)
11586342|NCT00744055|Placebo Comparator|Placebo|Placebo in identical looking capsule blister packs
11586343|NCT00744042|Other|asfotase alfa|asfotase alfa
11586344|NCT00744029|Active Comparator|Intervention group|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
11586345|NCT00744029|No Intervention|Control group|No intervention was performed
11586346|NCT00744016|Placebo Comparator|2|Placebo
11586347|NCT00744016|Active Comparator|1|Granulated mesalamine
11586348|NCT00743990|Active Comparator|A|
11586349|NCT00743990|Placebo Comparator|B|
11586350|NCT00743990|No Intervention|3|no intervention
11586351|NCT00743977|Active Comparator|A|
11586352|NCT00743977|Experimental|B|
11586353|NCT00743964|Experimental|ECX|Epirubicin, cisplatin and capecitabine combination chemotherapy will be administered.
11586354|NCT00743964|Active Comparator|CX|Cisplatin and capecitabine combination chemotherapy will be administered.
11586355|NCT00743951|Experimental|1 Patient decision aid|Patient decision aid about treatment options for osteoarthritis
11586356|NCT00743951|Active Comparator|2 Usual care|Usual patient educational materials
11586357|NCT00743938|Experimental|A1|
11586358|NCT00743938|Active Comparator|B2|
11586359|NCT00743925|Active Comparator|1|A-002 (500 mg QD) plus Atorvastatin (80 mg QD)
11586360|NCT00743925|Placebo Comparator|2|Matching Placebo tablets plus Atorvastatin (80 mg QD)
11586361|NCT00743912|Experimental|1|open-label rifaximin 550 mg TID
11586362|NCT00743899|Experimental|1|The aggressive group
11586363|NCT00743899|Experimental|2|The conservative group
11586364|NCT00743886|Placebo Comparator|2|saline
11586365|NCT00743886|Experimental|1|Plasma Rich in Growth Factors (PRGF)
11586366|NCT00743873|Placebo Comparator|2|saline
11586367|NCT00743873|Experimental|1|Plasma Rich in Growth Factors (PRGF)
11586368|NCT00743860|Experimental|Single dose|single oral dose
11586369|NCT00743860|Experimental|Repeat Dose|28 day repeat dose
11586370|NCT00743847|Placebo Comparator|placebo|
11586371|NCT00743847|Active Comparator|varenicline 0.5 mg BID|
11586372|NCT00743847|Active Comparator|varenicline 1mg BID|
11586373|NCT00743834|Other|A|Effectiveness of Luvox CR plus Web-based CBT for OCD
11586374|NCT00743821||TBI Patients|Individuals who have suffered a mild traumatic brain injury and have persistent post-concussive symptoms (PCS)
11586375|NCT00743821||Normals|Individuals of comparable age and education who have not suffered a traumatic brain injury
11586376|NCT00743795|Placebo Comparator|1|Peginterferon and ribavirin + placebo BID for 48 weeks + 24 weeks treatment-free follow-up (n = 50)
11586377|NCT00743795|Experimental|2|Peginterferon and ribavirin + GS 9190 40 mg BID for 48 weeks + 24 weeks treatment-free follow-up (n = 100)
11586378|NCT00743795|Experimental|3|Peginterferon and ribavirin + GS 9190 40 mg BID for 48 weeks + 24 weeks treatment-free follow-up. However, subjects who achieve RVR (HCV RNA undetectable at Week 4) and maintain that response through Week 24 will stop all study drugs at Week 24 and be followed for an additional 48 weeks (n = 50).
11586379|NCT00743769|Active Comparator|2|"Thymosin Beta 4
~A single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD (once a day)"
11586380|NCT00743769|Placebo Comparator|1|Placebo A single bolus injection of 0.0 mg QD of thymosin beta 4
11586381|NCT00743756|Experimental|1|A total of 20 African-American patients with type 2 diabetes will be randomized to receive home-delivered meals for twelve consecutive months. In addition, the subjects received diabetes education at every visit (8 clinic visits and 8 phone calls)
11586382|NCT00743756|Experimental|2|A total of 20 African-American patients with type 2 diabetes will be randomized to receive home-delivered meals for six consecutive months. In addition, the subjects received diabetes education for up to twelve months(8 clinic visits and 8 phone calls)
11586383|NCT00743756|Other|3|20 subjects received 12 months of diabetes education (8 clinic visits and 8 phone calls)
11586384|NCT00743743|Experimental|1|receive 1 Longevinex brand capsule daily containing 215 mg of resveratrol active ingredient
11586385|NCT00743743|Placebo Comparator|2|Receive 1 capsule daily for 52 weeks containing placebo for comparison to experimental arm
11586386|NCT00743730|Active Comparator|I|Parent and Nurse Controlled Analgesics with basal
11586387|NCT00743730|Active Comparator|II|Parent and Nurse Controlled Analgesics without basal
11586388|NCT00743730|Active Comparator|III|"Intermittent opioid administered IV on an as needed basis"
11586389|NCT00743717|Experimental|1|
11586390|NCT00743717|Active Comparator|2|
11586391|NCT00743691|No Intervention|Arm1|Make a diagnosis of Neonatal infections and refer patients according to IMNCI guideline
11586392|NCT00743691|Active Comparator|2|Health extension Workers will Make a diagnosis of Neonatal infections and treat with antibiotics when referal is not possible
11586393|NCT00743678|Experimental|NEO|NEO : Neoadjuvant therapy with FOLFOX6 plus cetuximab
11586394|NCT00743652|Experimental|Group1|Subjects 6 weeks to <10 months of age with 0 prior dose of Prevnar.
11586395|NCT00743652|Experimental|Group 2|Subjects <12 months of age with 1 prior dose of Prevnar.
11586396|NCT00743652|Experimental|Group 3|Subjects <12 months of age with 2 prior doses of Prevnar.
11586397|NCT00743652|Experimental|Group 4|Subjects ≥12 months to <2 years of age.
11586398|NCT00743652|Experimental|Group 5|Subjects ≥2 years to <5 years of age
11586399|NCT00743639|Other|1|Interventional
11586400|NCT00743626|Other|1|Healthy patients screened for cervical cancer
11586401|NCT00743600|Experimental|1|Patients with shoulder pain who were clinically referred to Ultrasound for evaluation
11586402|NCT00743600|Active Comparator|2|healthy volunteers who do not have shoulder pain
11586403|NCT00743587|Placebo Comparator|A|
11586404|NCT00743587|Active Comparator|B|
11586405|NCT00743587|Active Comparator|C|
11586406|NCT00743587|Active Comparator|D|
11586407|NCT00743574|Experimental|Vitamin D plus Calcium (Ca) supplementation|
11586408|NCT00743561|Other|1|
11586409|NCT00743548|Active Comparator|1|Interdental brush (IB), the intervention is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.
11586410|NCT00743548|Placebo Comparator|2|Dental floss (DF), the positive control, is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.
11586411|NCT00743535|Experimental|1|Transobturatory correction of anterior defect plus TOT
11586412|NCT00743535|Active Comparator|2|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.
~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
11586413|NCT00743522||Control|PROVE Trial settings
11586414|NCT00743522||Experimental|Pre-selected settings
11586415|NCT00743509|Experimental|Oral Cyclophosphamide and Sirolimus (OCR)|Sarcoma patients were given oral Cyclophosphamide and Sirolimus (OCR) in 28 day cycles.
11586416|NCT00743496|Experimental|Group 1|Participants who consent to the study will receive Anti-GD2 antibody.
11586417|NCT00743483|Experimental|rhBSSL|170 mg rhBSSL three times daily for 5 to 6 consecutive days
11586418|NCT00743470|Experimental|A, B|Group 1 receives regimen A and B. A: Healthy volunteers, receiving one 150 mg rifabutin QD alone. B: Healthy volunteers, receiving 150 mg rifabutin QD+ two lopinavir/ritonavir 200/50 mg tablets BID.
11586419|NCT00743470|Experimental|C|Group 2 receives regimen C. C: 150 mg rifabutin QD+ two lopinavir/ritonavir 200/50 mg tablets BID.
11586420|NCT00743457||VPS Patients|Children 6 months-18 years with VPS and symptoms of possible shunt failure
11586421|NCT00743444|Experimental|1|AZD3355
11586422|NCT00743444|Placebo Comparator|2|
11586423|NCT00743431||1|Women with advanced ovarian cancer
11586424|NCT00743418|Other|1|Healthy controls Mini Mental State evaluation score >28/30
11586425|NCT00743418|Other|2|Mild Cognitive Impairment: Mini Mental State Evaluation Score (MMSE)=26-28/30
11586426|NCT00743418|Other|3|Mild Dementia: Mini Mental State Evaluation Score (MMSE)=21-25/30
11586427|NCT00743405|Other|Cohort 1|Subjects will be receive GSK1034702 0.5 milligram (mg) following the dose escalation plan
11586428|NCT00743405|Other|Cohort 2|Subjects will be receive GSK1034702 5 mg following the dose escalation plan
11586429|NCT00743379|Experimental|A|TH-302 in combination with Gemcitabine. 1,000 mg/m2 of Gemcitabine is administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
11586430|NCT00743379|Experimental|B|TH-302 in combination with Docetaxel. 75 mg/m2 of Docetaxel is administered IV over 60 minutes on Day 1 of a 21-day cycle.
11586431|NCT00743379|Experimental|C|TH-302 in combination with Pemetrexed. 500 mg/m2 of Pemetrexed is administered IV over 10 minutes on Day 1 of a 21-day cycle.
11586432|NCT00743366|Experimental|Quetiapine (200mg/day), Marijuana (6.2%, 0.0%)|"Quetiapine (200mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (200 mg) were administered 2 times per day ((1100 and 2300 hours).
~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
11586433|NCT00743366|Placebo Comparator|Placebo, Marijuana (6.2%, 0.0%)|Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.
11586434|NCT00743353|Experimental|A|16 subjects to be enrolled; Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
11586435|NCT00743340|Experimental|Emtricitabine|Participants will receive emtricitabine for as long as they continue to meet specific virologic criteria and until either: (1) the participant chooses to discontinue treatment of emtricitabine and withdraw from the rollover protocol; (2) the participant experiences a toxicity that necessitates the permanent discontinuation of emtricitabine, or (3) emtricitabine is approved for market distribution in the participant's country of residence.
11586436|NCT00743327||1|Participants receiving ADT and pioglitazone
11586437|NCT00743327||2|Participants receiving ADT only
11586438|NCT00743327||3|Participants not receiving ADT and in remission from prostate cancer
11586439|NCT00743301|Active Comparator|Olive oil|
11586440|NCT00743301|Experimental|Palm olein|
11586441|NCT00743301|Active Comparator|Lard|
11586442|NCT00743288|Experimental|Melphalan and Panobinostat|"Schedule A: 10mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 of a 28-day cycle and melphalan PO at 0.05 mg/kg on days 1-5 of week 1.
~Toxicity led to the following changes in dose and schedule Schedule B1: 10mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.
~Schedule B2: 20mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 and 0.05 mg/kg melphalan POon days 1, 3 and 5 of week 1.
~Schedule C: 20mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1 and 2 and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1 Schedule D1: 15 mg/daily LBH589 PO and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.
~Schedule D2: 15 mg/daily LBH589 PO and 0.10 mg/kg melphalan PO on days 1, 3 and 5 of week 1.
~Schedule D3: 20 mg/daily LBH589 PO and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1."
11586443|NCT00743275|Experimental|Study Group|Participants received one dose of Fluzone® vaccine on Day 0.
11586444|NCT00743249|Experimental|Canalicular stent, 10 mm|MINI MONOKA canalicular stent (tube), 10 mm, inserted in the lower lacrimal canaliculus (tear duct) of one eye for up to 3 months
11586445|NCT00743249|Experimental|Canalicular stent, 20 mm|MINI MONOKA canalicular stent (tube), 20 mm, inserted in the lower lacrimal canaliculus (tear duct) of one eye for up to 3 months
11586446|NCT00743236|Experimental|Arm I|Patients undergo warm ischemia followed by partial nephrectomy.
11586447|NCT00743236|Experimental|Arm II|Patients undergo cold ischemia followed by partial nephrectomy.
11586448|NCT00743223||1|Study-group: The volunteers were selected on a randomized form among the individuals who went to the clinic of orofacial pain and temporomandibular disorders of São Paulo Hospital.
11586449|NCT00743223||2|Control-group: The volunteers were selected on a randomized form among the individuals who went to the dental offices of the researchers.
11586450|NCT00743210|Experimental|1|Oral L-citrulline, 3 grams once per day for 3 weeks.
11586451|NCT00743210|Placebo Comparator|2|Placebo, 3 grams once per day for 3 weeks.
11586452|NCT00743197|No Intervention|Usual Care Group|USUAL CARE GROUP-therapy in this group will be no dictated medical therapy, but usual care, as dictated by their referring physician.
11586453|NCT00743197|Active Comparator|Medical Treatment Group|TREATMENT GROUP-therapy in this group will be conventional treatment for CAD but targeting endothelial function, which will include aspirin, ACE-inhibitor and statin therapy, and therapeutic lifestyle changes.
11586454|NCT00743184|Placebo Comparator|1|Placebo + Placebo
11586455|NCT00743184|Experimental|2|15 mg Ozarelix + 15 mg Ozarelix
11586456|NCT00743184|Experimental|3|30 mg Ozarelix + 15 mg Ozarelix
11586457|NCT00743171||1|Good adherent patient: patient performed ≥ 80% of predicted HS within 24 months
11586458|NCT00743171||2|Moderate adherent patient: patient performed ≥ 50% of predicted HS within 24 months
11586459|NCT00743171||3|Non-adherent patient: patient performed < 50% of predicted HS within 24 months.
11586460|NCT00743145|Placebo Comparator|Placebo naltrexone + Inactive marijuana|Placebo naltrexone capsules (0mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.
11586461|NCT00743145|Placebo Comparator|Placebo naltrexone + Active marijuana (5.5% THC)|Placebo naltrexone capsules (0mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.
11586541|NCT00742716|Experimental|CTA018 Injection low to mid dose|low to mid dose IV 3 times a week for 4 weeks
11586607|NCT00742248|Placebo Comparator|C|Placebo pMDI DPI
11586462|NCT00743145|Placebo Comparator|Placebo naltrexone + Active marijuana (6.2% THC)|Placebo naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.
11586463|NCT00743145|Experimental|Naltrexone + Active marijuana (5.5% THC)|Naltrexone capsules (12mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.
11586464|NCT00743145|Experimental|Naltrexone + Active marijuana (6.2% THC)|Naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.
11586465|NCT00743145|Placebo Comparator|Naltrexone + Inactive marijuana|Naltrexone capsules (12mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.
11586466|NCT00743132||1|Postoperative no renal dysfunction
11586467|NCT00743132||2|Postoperative renal dysfunction
11586468|NCT00743119|Placebo Comparator|Placebo + inactive marijuana (0% THC)|Participants received placebo capsules and smoked inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
11586469|NCT00743119|Experimental|Dronabinol 10 mg + Marijuana (0% THC)|Participants received low dose Dronabinol + inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
11586470|NCT00743119|Experimental|Dronabinol 20 mg + Marijuana (0% THC)|Participants received High dose Dronabinol + inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
11586471|NCT00743119|Experimental|Placebo + Marijuana (1.98% THC)|Participants received placebo + low THC marijuana (1.98% THC) on 1 of 5 outpatient sessions in randomized order.
11586472|NCT00743119|Experimental|Placebo + Marijuana (3.56% THC)|Participants received placebo + smoked high THC marijuana (3.56 % THC) on 1 of 5 outpatient sessions in randomized order.
11586473|NCT00743106|Placebo Comparator|Placebo Comparator|Placebo (0.9% Nacl)infusion beginning during surgery and lasting for up to 24 hours
11586474|NCT00743106|Active Comparator|Fenoldopam Comparator|Fenoldopam (0.1 ~g/kg/min)infusion will commence after placing the patient in a lateral/flex position during the operation. The infusion will continue for a total of 24 hours.
11586475|NCT00743093|Experimental|acetaminophen|acetaminophen, 4 grams/day (1 gram every 4 hours for 4 doses)
11586476|NCT00743093|Placebo Comparator|placebo|placebo for acetaminophen 4 grams/day (2 caplets every 4 hours for 4 doses)
11586477|NCT00743080|Experimental|1|Laparoscopic myomectomy and supracervical hysterectomy using GYNECARE MORCELLEX
11586478|NCT00743080|Active Comparator|2|Laparoscopic myomectomy and supracervical hysterectomy using ROTOCUT G1
11586479|NCT00743067|Experimental|Cohort 1|Cohort 1 will include 60 milligram (mg) of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
11586480|NCT00743067|Experimental|Cohort 2|Cohort 2 will include 120 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
11586481|NCT00743067|Experimental|Cohort 3|Cohort 3 will include 240 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
11586482|NCT00743067|Experimental|Cohort 4|Cohort 4 will include 480 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
11586483|NCT00743067|Experimental|Cohort 5|Cohort 5 will include 960 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
11586484|NCT00743041|Experimental|1|Standard of Care plus EFT (Emotional Freedom Techniques)
11586485|NCT00743041|No Intervention|2|Standard of Care (SOC)
11586486|NCT00743028|Experimental|1|
11586487|NCT00743028|Experimental|2|
11586488|NCT00743028|Experimental|3|
11586489|NCT00743028|Experimental|4|
11586490|NCT00743028|Experimental|5|
11586491|NCT00743028|Experimental|6|
11586492|NCT00743002|Experimental|TT223 with Metformin and/or TZD|TT223 as a treatment for Type 2 diabetes is administered by injection once daily at 1 mg, 2 mg and 3 mg patients currently treated with Metformin and/or Thiazolidinedione (TZD).
11586493|NCT00743002|Placebo Comparator|Placebo with Metformin and/or TZD|Placebo as a comparator is administered by injection once daily at 1 mg, 2 mg and 3 mg patients currently treated with Metformin and/or Thiazolidinedione (TZD).
11586494|NCT00742989|Experimental|A|OLT administration
11586495|NCT00742989|Sham Comparator|B|placebo-OLT
11586496|NCT00742976|Active Comparator|1|8 weeks of insulin Detemir, then cross over to 8 Weeks of Insulatard, then cross over to 1 week of Detemir
11586497|NCT00742976|Active Comparator|2|8 weeks of Insulin Insulatard, then cross over to 8 weeks of insulin Detemir, then crossover to 1 week of Insulin Insulatard
11586498|NCT00742963|Experimental|1|75 mg/m2 of Doxorubicin administered by bolus injection starting on Day 1 of a 21-day cycle.
11586499|NCT00742950|Active Comparator|I|Nasal 2.8-mm corneal incision
11586500|NCT00742950|Active Comparator|II|Temporal 2.8-mm corneal incision
11586501|NCT00742950|Active Comparator|III|Superior 2.8-mm corneal incision
11586502|NCT00742937|Placebo Comparator|A|After birth the women will receive one capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E and eight days after delivery the second capsule of vitamin E will be administer.
11586503|NCT00742937|Experimental|B|After birth the women will receive one capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E and eight days after delivery the second capsule of 200,000 UI of retinol palmitate (vitamin A)plus vitamin E will be administer.
11586542|NCT00742716|Experimental|CTA018 Injection mid to high dose|mid to high dose IV 3 times a week for 4 weeks
11586543|NCT00742716|Experimental|CTA018 Injection high dose|high dose IV 3 times a week for 4 weeks
11586544|NCT00742703|Experimental|1|
11586545|NCT00742703|Active Comparator|2|
11586546|NCT00742690|Active Comparator|1|35 patients with cirrhosis and type 1 HRS
11586547|NCT00742690|Experimental|2|35 patients with cirrhosis and type 1 HRS
11587104|NCT00738764|Experimental|Cohort 6|PDL192 Dose Level 6
11586504|NCT00742924|Experimental|Arm 1- Chemotherapy and 1.2 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery .
~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.
~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.
~See Detailed Description."
11586505|NCT00742924|Experimental|Arm 2 - Chemotherapy and 2.3 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.
~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.
~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.
~See Detailed Description."
11586506|NCT00742924|Experimental|Arm 3 - Chemotherapy and 3.5 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.
~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.
~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.
~See Detailed Description."
11586507|NCT00742924|Experimental|Chemotherapy and 2.3 mg/m2 Zoledronic Acid after MTD|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.
~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.
~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.
~See Detailed Description."
11586508|NCT00742911|Experimental|1|
11586509|NCT00742898|Experimental|1|Non-targeted opt-out rapid HIV screening fully integrated into an urban, inner-city ED.
11586510|NCT00742898|Active Comparator|2|Diagnostic rapid HIV testing fully integrated into an urban, inner-city ED.
11586511|NCT00742885|Experimental|Influenza A (H5N1) 20-40 Years Group|Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.
11586512|NCT00742885|Experimental|Influenza A (H5N1) 41-64 Years Group|Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.
11586513|NCT00742872|Experimental|1|Mosapride
11586514|NCT00742872|Placebo Comparator|2|Placebo
11586515|NCT00742859|Experimental|Arm 1: Betrixaban|Betrixaban, 40 mg, orally, once daily for at least 3 months.
11586516|NCT00742859|Experimental|Arm 2: Betrixaban|Betrixaban, 60 mg, orally, once daily for at least 3 months
11586517|NCT00742859|Experimental|Arm 3: Betrixaban|Betrixaban, 80 mg, orally, once daily for at least 3 months
11586518|NCT00742859|Active Comparator|Arm 4: Warfarin|Warfarin will be prescribed by investigators according to the standard of care.
11586519|NCT00742846|Active Comparator|Group 1|The patient receives intra-articular steroid and local anesthetic injection under fluoroscopy.
11586520|NCT00742846|Active Comparator|Group 2|The patient receives subacromial steroid and local anesthetic injection under fluoroscopy.
11586521|NCT00742846|Active Comparator|Group 3|The patient receives intra-articular local anesthetic injection under fluoroscopy.
11586522|NCT00742846|Active Comparator|Group 4|The patient receives subacromial local anesthetic injection under fluoroscopy.
11586523|NCT00742833|Experimental|3|
11586524|NCT00742833|Placebo Comparator|1|
11586525|NCT00742820|Experimental|1|Calcium Acetate Oral Solution 667 mg per 5 mL
11586526|NCT00742820|Active Comparator|2|Calcium Acetate 667 mg Gelcaps
11586527|NCT00742820|Other|3|Calcium Citrate 950 mg Caplets
11586528|NCT00742807|Experimental|1|Administration of low dose of alfentanil hydrochloride before paracervical block
11586529|NCT00742807|Active Comparator|2|Administration of alfentanil hydrochloride dose after paracervical block
11586530|NCT00742794||1|Hymenoptera sting allergic patients under immunotherapy
11586531|NCT00742781|Experimental|Dietary supplement|Dietary supplement of vitamin D
11586532|NCT00742768|Active Comparator|1|softgel capsules
11586533|NCT00742768|Active Comparator|2|Gelpell capsules
11586534|NCT00742755|Experimental|Prospective Intervention|Peer navigator intervention
11586535|NCT00742742|Experimental|A|Nutrition advice (accroding to AHA recommendation) + 30 grams/day supplement of walnuts,walnuts were incorpatated into bread that provided to the participants
11586536|NCT00742742|Sham Comparator|B|Registed dietians give the advice for health lyfestyle
11586537|NCT00742729|Experimental|Arm 1|Educational small group session with free FOBT kit
11586538|NCT00742729|Experimental|Arm 2|Educational small group session with no FOBT kit
11586539|NCT00742729|Sham Comparator|Arm 3|Control
11586540|NCT00742716|Experimental|CTA018 Injection low dose|Low dose IV 3 times a week for 4 weeks
11586606|NCT00742248|Active Comparator|B|Formoterol dry powder
11586548|NCT00742677|Experimental|Group 1 (early feeding)|Patients are offered a liquid diet on day 1 for 24 hours following surgery. Beginning on day 2, patients who tolerate a liquid diet are offered a light regular diet until hospital discharge.
11586549|NCT00742677|Active Comparator|Group 2 (traditional feeding)|Patients are offered nothing by mouth on days 1 and 2 following surgery. Beginning on day 3, patients are offered a liquid diet for 24 hours. Beginning on day 4, patients who tolerate a liquid diet (absence of nausea and vomiting) are offered a semi-solid diet for 24 hours. Beginning on day 5, patients who tolerate a semi-solid diet are offered a light regular diet until hospital discharge.
11586550|NCT00742664|Experimental|1|Will receive 12 sessions of twice weekly psychotherapy targeting obsessive-compulsive symptoms.
11586551|NCT00742664|Placebo Comparator|2|
11586552|NCT00742638|Experimental|The arm 1|Quetiapine fumarate tablet:25mg and 200mg
11586553|NCT00742638|Active Comparator|The arm 2|Sodium valproate tablet 200mg
11586554|NCT00742625|Experimental|Treatment (daunorubicin hydrochloride and bortezomib)|See Detailed Description
11586555|NCT00742612|Active Comparator|1|ARC1779 Injection
11586556|NCT00742612|Placebo Comparator|2|Placebo (normal saline)
11586557|NCT00742599|Active Comparator|N|
11586558|NCT00742599|Placebo Comparator|P|
11586559|NCT00742573|Active Comparator|1 Texas Medication Algorithm|Participants will receive medication treatment according to the Texas Medication Algorithm (TMA) for depression
11586560|NCT00742573|Experimental|2 Patient Choice|Participants will be offered brief interpersonal psychotherapy (IPT-B) alone or combined with the TMA for depression
11586561|NCT00742560|Experimental|Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 5 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
11586562|NCT00742560|Experimental|Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
11586563|NCT00742560|Experimental|Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
11586564|NCT00742560|Experimental|Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)|Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
11586565|NCT00742560|Experimental|Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)|Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
11586566|NCT00742547|No Intervention|Control group|No telephone counseling + usual care
11586567|NCT00742547|Experimental|Telephone Counseling|Telephone counseling + usual care
11586568|NCT00742521|Active Comparator|1|Euglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
11586569|NCT00742521|Active Comparator|2|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
11586570|NCT00742521|Active Comparator|3|Euglycemic glucose clamp procedure x 2 with cortisol infusion of 2ug/kg on Day 1 and hypoglycemic glucose clamp procedure on Day 2.
11586571|NCT00742521|Active Comparator|4|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
11586572|NCT00742508|Experimental|SK&F-105517-D group|SK&F-105517-D 10-80 mg/day
11586573|NCT00742508|Other|Carvedilol-IR group|Carvedilol-IR 5-20 mg/day
11586574|NCT00742469|Active Comparator|1|Rifaximin
11586575|NCT00742469|Placebo Comparator|2|Placebo
11586576|NCT00742456|Experimental|I|Glucose
11586577|NCT00742456|Placebo Comparator|II|Placebo
11586578|NCT00742443|Other|1|Active versus Placebo within patient
11586579|NCT00742443|Other|2|Active vs. Placebo within patient
11586580|NCT00742443|Other|3|Active vs. Active within patient
11586581|NCT00742430||Resistant|patients who are resistant to standard antithrombotic drugs
11586582|NCT00742430||Nonresistant|patients who are not resistant to standard dual antithrombotic drugs
11586583|NCT00742417|Experimental|Albutein 5%|Patients allocated to this arm underwent plasma exchange with Albutein 5%.
11586584|NCT00742417|Sham Comparator|Control|
11586585|NCT00742391|Active Comparator|1|PEP005 (ingenol mebutate) Gel
11586586|NCT00742391|Placebo Comparator|2|Vehicle gel
11586587|NCT00742378||C|Normal controls
11586588|NCT00742378||G|Glaucoma
11586589|NCT00742365||A|Participants will be given a 1-hour lab test of bright light treatment, then the bright light treatment for 6 weeks.
11586590|NCT00742365||B|Participants will be given a 1-hour treatment of the red light placebo, then the bright light treatment for 6 weeks.
11586591|NCT00742352||Breast cancer patients|
11586592|NCT00742352||Lung cancer patients|
11586593|NCT00742339|Active Comparator|1|Fifty patients with cirrhosis and HRS will be randomly assigned to arm 1.
11586594|NCT00742339|Experimental|2|Fifty patients with cirrhosis and HRS will be randomly assigned to arm 2.
11586595|NCT00742326|Experimental|Pioglitazone|pioglitazone 45 mg daily for 48 weeks
11586596|NCT00742326|Placebo Comparator|Placebo|one capsule daily for 48 weeks
11586597|NCT00742313|Experimental|Arm A|Arm A has FloSeal Matrix applied to EVH wound bed.
11586598|NCT00742313|No Intervention|Arm B|Arm B does not have FloSeal Matrix applied to EVH wound bed.
11586599|NCT00742300|Experimental|A|Treatment Group
11586600|NCT00742287|Placebo Comparator|1|placebo
11586601|NCT00742287|Active Comparator|2|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)
11586602|NCT00742274|Experimental|1|TAG+BMT
11586603|NCT00742274|Active Comparator|2|BMT alone
11586604|NCT00742261|Experimental|GSK1363089|Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
11586605|NCT00742248|Active Comparator|A|Formoterol pMDI
11586608|NCT00742235|Experimental|1|Vitamin D insufficient (treated with ergocalciferol 50,000 IU every other day x 5 doses)
11586609|NCT00742235|No Intervention|Vitamin D sufficient|Subjects who did not receive ergocalciferol and had a 25-OH vitamin D level >32 ng/ml
11586610|NCT00742222|Other|single arm, treatment with FDA cleared technology|Patients who have early stage breast cancer, and are candidate for intracavitary accelerated partial breast irradiation may be considered for this study.
11586611|NCT00742209|Placebo Comparator|Placebo|PBO
11586612|NCT00742209|Active Comparator|GSK 1838262 1200 mg/day|600 or 1200 mg/day
11586613|NCT00742209|Active Comparator|GSK 1838262 1800 mg/day|600 or 1200 or 1800 mg/day
11586614|NCT00742209|Active Comparator|GSK 1838262 2400 mg/day|600 or 1200 or 1800 or 2400 mg/day
11586615|NCT00742209|Active Comparator|GSK 1838262 3000 mg/day|600 or 1200 or 1800 or 2400 or 3000 mg/day
11586616|NCT00742196||1|No parapapillary atrophy
11586617|NCT00742196||2|Parapapillary atrophy
11586618|NCT00742183|Experimental|Mepilex® Ag|"Mepilex® Ag consists of a Safetac® soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film. Mepilex® Ag is an antimicrobial soft silicone foam dressing that absorbs exudate and maintains a moist wound environment.
~Mepilex® Ag contains silver sulphate that releases silver ions to inactivate a wide range of wound related pathogens (bacteria and fungi), shown in vitro. By reducing the number of microorganisms, Mepilex® Ag may also reduce odour."
11586619|NCT00742183|Active Comparator|Silvadene® Cream 1%|Silvadene® Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second-and third-degree burns.
11586620|NCT00742170|Active Comparator|Active electroacupuncture|In the active electroacupuncture condition, the current is set at 2 times threshold (approximately 6-10 mA), which typically produces muscle twitching.
11586621|NCT00742170|Sham Comparator|Sham electroacupuncture|In the sham electroacupuncture condition, the current is set at 1 mA, the lowest intensity possible before the HANS device shuts off; this is undetectable stimulation.
11586622|NCT00742157|No Intervention|UNMC Group|Compare the low and high dose effects of Growth Hormone from previously pooled patients (high dose) and UNMC patients (low dose).
11586623|NCT00742144|Experimental|ofatumumab|Japanese patients with CD20 positive follicular lymphoma or chronic lymphocytic leukemia
11586624|NCT00742131|Experimental|Subjects receiving GSK1363089|Eligible subjects will receive GSK1363089 administered orally as a cinnamon-flavored liquid or as solid capsules with the starting dose for cohort 1 as 0.1 milligram/kilogram. Subjects in cohorts 1, 2, and 3A will receive GSK1363089 in the liquid formulation, while Cohorts 3B, 4, 5, 6, 7, and 8 will receive GSK1363089 in the solid capsule formulation.
11586625|NCT00742118|Experimental|2|patient with chronic inflammatory intestinal disease
11586626|NCT00742118|Other|3|patient having no symptoms
11586627|NCT00742118|Experimental|1|patient with irritable bowel syndrome
11586628|NCT00742105|Experimental|BGT226|
11586629|NCT00742092|Experimental|1|miglustat
11586630|NCT00742092|Placebo Comparator|2|placebo
11586631|NCT00742079|Experimental|1 D-cycloserine, placebo|Participants will receive D-cycloserine 1 hour before a cognitive behavioral therapy (CBT) session on Week 1, and they will receive placebo 1 hour before a CBT session on Week 2.
11586632|NCT00742079|Experimental|2 Placebo, D-cycloserine|Participants will receive placebo 1 hour before a CBT session on Week 1, and they will receive D-cycloserine 1 hour before a CBT session on Week 2.
11586633|NCT00742066|Experimental|I|Irbesartan
11586634|NCT00742066|Active Comparator|II|Felodipine
11586635|NCT00742066|Placebo Comparator|III|Placebo
11586636|NCT00742053|Experimental|1|Male or female inpatients, age ≥ 18 and ≤ 80 years, who are in normal sinus rhythm and do not have a pacemaker or other indwelling intracardiac device and require PICC insertion for their routine care will be studied. Intervention: ECG-guided Power PICC placement.
11586637|NCT00742040|Experimental|1|
11586638|NCT00742040|Active Comparator|2|
11586639|NCT00742027|Experimental|Panobinostat|
11586640|NCT00742014|Experimental|1|
11586641|NCT00742001|Experimental|Mirasol Illumination Dose #1|Whole blood units treated with Mirasol at Illumination dose #1 (A1) of 22 Joules per milliliter of red blood cells (J/mL RBCs)
11586642|NCT00742001|Experimental|Mirasol Illumination Dose #2|Whole Blood units treated with Mirasol at Illumination dose #2 (A2) of 33 J/mL RBCs
11586643|NCT00742001|Experimental|Mirasol Illumination Dose #3|Whole Blood units treated with Mirasol at Illumination dose #3 (A3) of 44 J/mL RBCs
11586644|NCT00741988|Experimental|Cohort A|ixabepilone 30 mg/m2 and carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
11586645|NCT00741988|Experimental|Cohort B|ixabepilone 30 mg/m2, carboplatin AUC = 6 intravenously (IV), and bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
11586646|NCT00741975|Experimental|1|Affect Management
11586647|NCT00741975|Active Comparator|2|General Health Promotion
11586648|NCT00741962|Experimental|1|
11586649|NCT00741962|Placebo Comparator|2|
11586650|NCT00741949|Experimental|1|
11586651|NCT00741949|Placebo Comparator|2|
11586652|NCT00741936|Experimental|MaZiRenWan (MZRW)|MZRW granule, 7.5g/sachet
11586653|NCT00741936|Placebo Comparator|Placebo|Placebo granule, 7.5g/sachet
11586654|NCT00741923|Experimental|Bean group|A group consuming 5 cups/week of navy beans for a month
11586655|NCT00741910|Experimental|1|Semapimod 60 mg IV q 6 - 10 weeks
11586656|NCT00741897|Experimental|1|Fexofenadine
11586657|NCT00741884|Experimental|Arm 1|
11586658|NCT00741884|Experimental|Arm 2|
11586659|NCT00741884|Experimental|Arm 3|
11586660|NCT00741884|Active Comparator|Arm 4|
11586661|NCT00741884|Placebo Comparator|Arm 5|
11586662|NCT00741858|Experimental|DuraGen (sutureless)|Duragen duraplasty - the Duragen patch is applied over the dural defect during Chiari decompression surgery. The Duragen represents sutureless technique of posterior fossa duraplasty. Rest of the treatment is as usual.
11586777|NCT00741182|Experimental|Humerus PTH(1-34)|24 participants with collum chirurgicum fracture will be assigned to Forsteo (PTH(1-34)) treatment
11586663|NCT00741858|Active Comparator|DuraGuard (suturable)|Duraguard duraplasty - the Duraguard patch is applied over the dural defect during Chiari decompression surgery and sutured to the dural edge. This represents suturable technique that theoretically provides better (water-tight) dural closure.
11586664|NCT00741845|Active Comparator|1|intravaginal metronidazole 750mg + 200mg miconazole
11586665|NCT00741845|Active Comparator|2|intravaginal metronidazole 750mg
11586666|NCT00741845|Active Comparator|3|intravaginal metronidazole 37.5mg
11586667|NCT00741832|Experimental|I|Patients breath while a conical positive expiratory pressure device during exercises
11586668|NCT00741832|Active Comparator|C|Patients (normal) breath during exercise
11586669|NCT00741819|Experimental|Inhaled treprostinil|Solution for oral inhalation treprostinil (0.6 mg/mL). Inhaled via an ultrasonic nebulizer which provides a dose of 6mcg of treprostinil per breath. Doses are titrated up to 12 breaths four times daily.
11586670|NCT00741806|Experimental|GHB04L1|Single dose, dose escalation
11586671|NCT00741806|Placebo Comparator|SPGN buffer|
11586672|NCT00741780||G-CSF plus plerixafor|Participants in AMD3100-3102 (NCT00103662) who underwent mobilization with granulocyte colony-stimulating factor (G-CSF) and received plerixafor prior to undergoing apheresis.
11586673|NCT00741780||G-CSF plus placebo|Participants in AMD3100-3102 (NCT00103662) who underwent mobilization with granulocyte colony-stimulating factor (G-CSF) and received placebo prior to undergoing apheresis.
11586674|NCT00741767|Other|Salmeterol-fluticasone|Patients randomized to receive salmeterol-fluticasone 250/50 twice daily for 4 weeks. Patients will cross-over and receive placebo medication for 4 weeks later in the study.
11586675|NCT00741767|Other|Placebo|Patients randomized to receive placebo medication twice daily for 4 weeks. Patients will cross-over and receive study medication later in the study.
11586676|NCT00741754|Experimental|I, II|compare the amount of salivary flow of the same patient at different times.
11586677|NCT00741728||general population|Observational study of 10000 adult men and women from the general population who benefited from a free extensive health check up in Paris, France
11586678|NCT00741715|Placebo Comparator|1|
11586679|NCT00741715|Experimental|2|AVE5530 25mg
11586680|NCT00741715|Experimental|3|AVE5530 50mg
11586681|NCT00741715|Active Comparator|4|atorvastatin 10mg
11586682|NCT00741715|Experimental|5|atorvastatin 10mg + AVE5530 25mg
11586683|NCT00741715|Experimental|6|atorvastatin 10mg + AVE5530 50mg
11586684|NCT00741715|Active Comparator|7|atorvastatin 20mg
11586685|NCT00741715|Experimental|8|atorvastatin 20mg + AVE5530 25mg
11586686|NCT00741715|Experimental|9|atorvastatin 20mg + AVE5530 50mg
11586687|NCT00741715|Active Comparator|10|atorvastatin 40mg
11586688|NCT00741715|Experimental|11|atorvastatin 40mg + AVE5530 25mg
11586689|NCT00741715|Experimental|12|atorvastatin 40mg + AVE5530 50mg
11586690|NCT00741715|Active Comparator|13|atorvastatin 80mg
11586691|NCT00741715|Experimental|14|atorvastatin 80mg + AVE5530 25mg
11586692|NCT00741715|Experimental|15|atorvastatin 80mg + AVE5530 50mg
11586693|NCT00741702|Experimental|Intervention group|A home care nurse followed a predefined treatment algorithm of pharmacologic antihypertensive therapy.
11586694|NCT00741702|No Intervention|Control group|Treatment decisions were made by each subject's primary care physician. Participants in this group received usual care.
11586695|NCT00741689|Experimental|1|AZD1656 in 6 increasing oral single doses given to 6 groups (5 on active and 1 on placebo in each group)
11586696|NCT00741676|Active Comparator|2|
11586697|NCT00741676|Experimental|1|
11586698|NCT00741663|Active Comparator|A|
11586699|NCT00741663|Experimental|B|
11586700|NCT00741650|Experimental|1|Information and peer advisor
11586701|NCT00741650|Experimental|2|Information, peer advisor and referral to further treatment
11586702|NCT00741650|No Intervention|3|Treatment as usual
11586703|NCT00741637|Experimental|Vaccine|Live attenuated oral CholeraGarde® (5x107 to 1x109 CFU) vaccine
11586704|NCT00741637|Placebo Comparator|Placebo|A buffer solution containing 2.5 g sodium bicarbonate, and 1.65 g ascorbic acid.
11586705|NCT00741624|Experimental|1|bilateral post refractive surgery subject
11586706|NCT00741611|Experimental|Mesh|Ablation with HD Mesh Ablation System
11586707|NCT00741611|Active Comparator|Drug|Treatment with anti-arrhythmic drugs
11586708|NCT00741598|Experimental|Galantamine-ER|Participants will receive treatment with extended release galantamine
11586709|NCT00741598|Placebo Comparator|Galantamine placebo|Participants will receive treatment with placebo.
11586710|NCT00741585|Active Comparator|1|Treatment with all prescribed hypertension medications on awakening
11586711|NCT00741585|Active Comparator|2|Treatment with at least one prescribed hypertension medication at bedtime
11586712|NCT00741572||1|
11586713|NCT00741572||2|
11586714|NCT00741559|Experimental|1|
11586715|NCT00741546||A|Patients referred for cardiac surgery intervention
11586716|NCT00741520|Placebo Comparator|1|Control group
11586717|NCT00741520|Active Comparator|2|CPAP
11586718|NCT00741507|Active Comparator|1|No alcohol drinking
11586719|NCT00741507|Active Comparator|2|Mild alcohol drinking
11586720|NCT00741507|Active Comparator|3|Moderate alcohol drinking
11586721|NCT00741507|Active Comparator|4|Severe over alcohol drinking
11586722|NCT00741507|Active Comparator|5|Alcohol-dependent
11586723|NCT00741494|No Intervention|1|HBA score over 65% control
11586724|NCT00741494|No Intervention|2|HBA score over 65%, non-participant (to even out the participation between patients with low HBA scores and those with high HBA scores)
11586725|NCT00741494|Active Comparator|3|HBA score over 65%. PICSI dish is used to select the sperm for ICSI.
11586726|NCT00741494|Experimental|4|HBA score less than 65%. PICSI dish used to select sperm for ICSI.
11586727|NCT00741494|No Intervention|5|HBA Score less than 65%. Control
11586728|NCT00741481||1|all study population
11586729|NCT00741468|Experimental|All subjects|Proellex 50 mg CYP1A2 probe CYP2C9 probe CYP2C19 probe CYP2D6 probe CYP3A4 probe
11587284|NCT00737412|Placebo Comparator|2|Placebo
11586730|NCT00741455|Experimental|Study Treatment|Chemotherapy, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate
11586731|NCT00741442|Experimental|1|RDEA806 400 mg qd
11586732|NCT00741442|Experimental|3|RDEA806 400 mg bid
11586733|NCT00741442|Placebo Comparator|2|Placebo QD
11586734|NCT00741442|Placebo Comparator|4|Placebo BID
11586735|NCT00741429||Ex-TI|Ex-Technosphere® Insulin Inhalation Powder (subjects previously received TI Inhalation Powder)
11586736|NCT00741429||Non Ex-TI|Non Ex-Technosphere® Insulin Inhalation Powder (subjects previously received another anti-diabetic medication)
11586737|NCT00741416||Case|Those with a diagnosis of Coronary Artery Disease
11586738|NCT00741416||Control|Those who do not have Coronary Artery Disease (are healthy) but are matched to a Case participant by age, gender, and ethnicity.
11586739|NCT00741403|Experimental|A|IV Infusion of CPI-613 on Days 1,4,8,11,15,18 of 28 day cycle in patients with advanced malignancies
11586740|NCT00741390|Other|Arm A|In Visit 1 subjects tested BD/33G, OTM/33G, and OTM/28G devices. In Visit 2 subjects tested BD/33G and OTM/28G. See purpose for additional information.
11586741|NCT00741390|Other|Arm B|In Visit 1 subjects tested BD/33G, OTM/33G and OTU/28G devices. In Visit 2 subjects tested BD/33G and OTU/28G. See purpose for additional information.
11586742|NCT00741390|Other|Arm C|In Visit 1 subjects tested BD/33G, OTM/33G and ACC/28G devices. In Visit 2 subjects tested BD/33G and ACC/28G. See purpose for additional information.
11586743|NCT00741390|Other|Arm D|In Visit 1 subjects tested BD/33G, OTM/33G and OTM/28G devices. In Visit 2 subjects tested OTM/33G and OTM/28G. See purpose for additional information.
11586744|NCT00741377|Experimental|BHQ880 + zoledronic acid|BHQ880 3-40 mg/kg in combination with zoledronic acid 4 mg on day 1 of a 28-day cycle.
11586745|NCT00741364|Active Comparator|1|vitamin D3 (400 IU/d)
11586746|NCT00741364|Active Comparator|2|vitamin D3 (10,000 IU/d)
11586747|NCT00741364|Active Comparator|3|vitamin D3 (40,000 IU/d)
11586748|NCT00741351|Experimental|IF|Sevoflurane (Inhalation)+Fentanyl
11586749|NCT00741351|Experimental|IR|Sevoflurane (Inhalation)+Remifentanyl
11586750|NCT00741351|Experimental|ER|Propofol (Endovenous)+ Remifentanyl
11586751|NCT00741338|Experimental|Cohort 1|Tolerance Induction Period (TIP): Cyclosporine A (CsA) starting at 5 milligram per kilogram (mg/kg) orally three times daily until the target trough concentration of at least 350 nanogram per milliliter (ng/mL) (preferably 400 ng/mL) achieved along with azathioprine (Aza) 2.5 mg/kg/day orally. Once target CsA trough level achieved and maintained for at least 1 week, participants received laronidase 0.058 mg/kg (low-dose) once weekly intravenous (IV) infusion (starting from Day 1) up to Week 12. CsA and Aza were gradually discontinued. Immune Challenge Period (ICP): following TIP, laronidase dose increased to 0.12 mg/kg once weekly IV infusion for 1 week followed by 0.25 mg/kg once weekly IV infusion for 1 week and then 0.58 mg/kg (full-dose) once weekly IV infusion up to Week 39.
11586752|NCT00741338|Experimental|Cohort 2|TIP: CsA starting at 6.7 mg/kg orally three times daily until the target trough concentration of at least 350 ng/mL (preferably 400 ng/mL) achieved along with Aza 5 mg/kg orally every other day. Once target CsA trough level achieved and maintained for at least 1 week, participants received laronidase 0.058 mg/kg (low-dose) once weekly IV infusion (starting from Day 1) up to Week 18. CsA and Aza were gradually discontinued. ICP: following TIP, laronidase dose increased to 0.12 mg/kg once weekly IV infusion for 1 week followed by 0.25 mg/kg once weekly IV infusion for 1 week and then 0.58 mg/kg (full-dose) once weekly IV infusion up to Week 45.
11586753|NCT00741325||G-CSF plus plerixafor|Participants in Study AMD3100-3101 (NCT00103610)underwent mobilization with granulocyte colony-stimulating factor (G-CSF)and received plerixafor, prior to undergoing apheresis.
11586754|NCT00741325||G-CSF plus placebo|Participants in Study AMD3100-3101 (NCT00103610)underwent mobilization with granulocyte colony-stimulating factor (G-CSF)and received placebo, prior to undergoing apheresis.
11586755|NCT00741312|Experimental|I|
11586756|NCT00741312|Active Comparator|II|
11586757|NCT00741286|Placebo Comparator|Asprin (100mg) plus placebo|Asprin (100mg) plus placebo
11586758|NCT00741286|Active Comparator|Asprin (100mg) plus cilostazol (200mg)|Asprin (100mg) plus cilostazol (200mg)
11586759|NCT00741273|Experimental|Proellex 25 mg healthy|Proellex 25 mg in healthy females
11586760|NCT00741273|Experimental|Proellex 25 mg Impaired|Proellex 50 mg in hepatically impaired females
11586761|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Level 1)|Neratinib 160 mg and Capecitabine 1500 mg/m^2
11586762|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 2)|Neratinib 240 mg and Capecitabine 1500 mg/m^2
11586763|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 3)|Neratinib 240 mg and Capecitabine 2000 mg/m^2
11586764|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 4)|Neratinib 200 mg and Capecitabine 2000 mg/m^2
11586765|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 5)|Neratinib 160 mg and Capecitabine 2000 mg/m^2
11586766|NCT00741260|Experimental|Neratinib and Capecitabine MTD (Dose Group 6)|Neratinib and Capecitabine Maximum Tolerated Dose without prior lapatinib
11586767|NCT00741260|Experimental|Neratinib and Capecitabine MTD (Dose Group 7)|Neratinib and Capecitabine Maximum Tolerated Dose with prior lapatinib
11586768|NCT00741234|Experimental|A|Advanced solid tumors
11586769|NCT00741234|Experimental|B|Advanced hematologic malignancies
11586770|NCT00741234|Experimental|C|Myelodysplastic Syndrome
11586771|NCT00741221|Experimental|1|Pemetrexed/Bevacizumab
11586772|NCT00741208|Other|1|Patients randomized to receive soy isoflavone twice daily for 2 weeks. Patients will cross-over and receive placebo medication for 2 weeks later in the study
11586773|NCT00741208|Other|2|Patients randomized to receive placebo medication twice daily for 2 weeks. Patients will cross-over and receive soy isoflavone for 2 weeks later in the study
11586774|NCT00741195|Experimental|1|Docetaxel/Bevacizumab
11586775|NCT00741182|Experimental|Femur PTH(1-34)|24 participants with trochanteric fractures will be assigned to Forsteo (PTH(1-34)) treatment
11586776|NCT00741182|No Intervention|Femur Control|"24 participants with trochanteric fractures will be assigned to no treatment"
11587700|NCT00734344|Active Comparator|Arm 2|Efavirenz plus Truvada
11586778|NCT00741182|No Intervention|Humerus Control|"24 participants with collum chirurgicum fracture will be assigned to no treatment."
11586779|NCT00741169|Experimental|Treatment Sequence ABC|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence will consist of Treatment A (TMC435350 200 mg once daily for 7 days), Treatment B (rifampin 600 mg once daily for 7 days), and Treatment C (TMC435350 200 mg once daily+rifampin 600 mg once daily for 7 days). Participants will receive 1 treatment (A, B, or C) during each treatment session. There will be 3 treatment sessions, each treatment session will be separated by 10 days.
11586780|NCT00741169|Experimental|Treatment Sequence BCA|
11586781|NCT00741169|Experimental|Treatment Sequence CAB|
11586782|NCT00741169|Experimental|Treatment sequence CBA|
11586783|NCT00741169|Experimental|Treatment Sequence BAC|
11586784|NCT00741169|Experimental|Treatment Sequence ACB|
11586785|NCT00741156|Experimental|Enalaprilat|enalaprilat 0.005-0.01 mg/kg intravenous x 1 dose
11586786|NCT00741143|Experimental|1|Group that receives NaFeEDTA fortified wheat flour
11586787|NCT00741143|Placebo Comparator|2|Unfortified wheat flour
11586788|NCT00741130||C|normal volunteers
11586789|NCT00741130||G|glaucoma patients
11586790|NCT00741117|Active Comparator|Low Bilirubin Group|Low Bilirubin Group: subjects with a bilirubin level less than or equal to 10 mg/dl
11586791|NCT00741117|Active Comparator|Medium Bilirubin Group|Medium Bilirubin Group: subjects with a bilirubin level from 11mg/dl to 30 mg/dl
11586792|NCT00741117|Active Comparator|High Bilirubin Group|High Bilirubin Group: subjects with a bilirubin level greater than or equal to 30 mg/dl
11586793|NCT00741104||RA patients|Patients on maintenance therapy for RA with infliximab for >= the past 12 months.
11586794|NCT00741091|Experimental|Registry|Registry to gather data on early clinical outcomes for the Carotid WALLSTENT Endoprosthesis and FilterWire EZ System in routine clinical practice.
11586795|NCT00741078|Experimental|atorvastatin, amlodipine|
11586796|NCT00741052|Experimental|1|Ciprofloxacin
11586797|NCT00741052|Active Comparator|2|Azithromycin
11586798|NCT00741039|Experimental|1,|Patients > or = to 65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23 valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly).
11586799|NCT00741039|Experimental|2|MSKCC employee volunteer controls > or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly).
11586800|NCT00741026|Placebo Comparator|Placebo|Placebo
11586801|NCT00741026|Experimental|Olanzapine|Olanzapine 10mg po daily x 3 days
11586802|NCT00741013|Placebo Comparator|Placebo pill and placebo IV|
11586803|NCT00741013|Experimental|Lovastatin pill and placebo IV|
11586804|NCT00741013|Experimental|Placebo pill and rhAPC IV|
11586805|NCT00741000|Experimental|Experimental|Cervical low force mobilization procedure.
11586806|NCT00740987|No Intervention|1|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
11586807|NCT00740987|Experimental|2|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
11586808|NCT00740961||Patients with cancer|Patients ≥ 65 years with new stage I-III breast or colon cancer seeking care. Patients will be matched on baseline scores, age and sex. Patients will be age and sex matched due to the known relation between inflammatory markers and demographic characteristics39,40, and will be matched on baseline VES scores to ensure similar baseline VES-13 scores between groups and which will then allow us to then assess effect of cancer treatment on outcomes.
11586809|NCT00740961||Patients without cancer|non-cancer patients, seeking care at out-patient clinics
11586810|NCT00740948|Experimental|1|Rituximab
11586811|NCT00740948|Placebo Comparator|2|Placebo
11586812|NCT00740935|Other|1|Cohort of vaccinated infants against rotavirus
11586813|NCT00740922||1|
11586814|NCT00740909|No Intervention|MAC|Minimal Attention Control
11586815|NCT00740909|Experimental|CBT|Cognitive Behavioral Therapy
11586816|NCT00740896|Active Comparator|1|Participants smoke 8 cigarettes in 4 hours.
11586817|NCT00740896|Sham Comparator|2|Participants are not allowed to smoke for 4 hours.
11586818|NCT00740883|Active Comparator|1|18 months of active warfarin therapy
11586819|NCT00740883|Placebo Comparator|2|18 months of placebo of warfarin
11586820|NCT00740870|Experimental|Melody TPV Implant|Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.
11586821|NCT00740857|Placebo Comparator|1|
11586822|NCT00740857|Active Comparator|2|
11586823|NCT00740857|Active Comparator|3|
11586824|NCT00740844|No Intervention|1|No intermittent pneumatic compression of the lower limbs during patient hospitalisation in réanimation unit
11586825|NCT00740844|Experimental|2|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
11586826|NCT00740831|Experimental|A (PGL4001 5 mg)|Drug: PGL4001 5mg (oral tablets) and leuproreline matching placebo (intramuscular injection)
11586827|NCT00740831|Experimental|B (PGL4001 10mg)|Drug: PGL4001 10 mg (oral tablets) and leuproreline matching placebo (intramuscular injection)
11586828|NCT00740831|Active Comparator|C (GnRH-agonist)|PGL4001 matching placebo (oral tablets) and leuprorelin 3.75 mg (intramuscular injection)
11586829|NCT00740818|No Intervention|A|The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.
11586830|NCT00740818|Sham Comparator|B|A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.
11586831|NCT00740818|Experimental|C|Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
11586981|NCT00739661|Placebo Comparator|Placebo to vismodegib|Patients received placebo to vismodegib orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
11587148|NCT00738426|Active Comparator|Erchonia ML Scanner (MLS)|Red diode low level laser light energy
11586832|NCT00740805|Experimental|Treatment (veliparib, cyclophosphamide, doxorubicin)|"GROUP I: Patients receive veliparib PO every 12 hours on days 1-4 and cyclophosphamide IV over 60 minutes on day 3.
~GROUP II: Patients receive veliparib PO every 12 hours on days 1-4, cyclophosphamide IV over 60 minutes on day 3, and doxorubicin hydrochloride IV over 15 minutes on day 3.
~GROUP III: Patients receive veliparib PO every 12 hours on days 1-7, cyclophosphamide IV over 60 minutes on day 1, and doxorubicin hydrochloride IV over 15 minutes on day 1.
~GROUP IV: Patients receive veliparib PO every 12 hours on days 1-14, cyclophosphamide IV over 60 minutes on day 1, and doxorubicin hydrochloride over 15 minutes on day 1.
~In all groups, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
11586833|NCT00740792|Experimental|azelastine HCl/fluticasone propionate|nasal spray
11586834|NCT00740792|Active Comparator|azelastine HCL|nasal spray
11586835|NCT00740792|Active Comparator|fluticasone propionate|nasal spray
11586836|NCT00740792|Placebo Comparator|placebo|nasal spray
11586837|NCT00740779|Experimental|Silodosin 4 mg|4 mg daily
11586838|NCT00740779|Experimental|Silodosin 8 mg|Silodosin 8 mg daily
11586839|NCT00740779|Placebo Comparator|Placebo|1 placebo capsule daily
11586840|NCT00740766|Experimental|Monitored|
11586841|NCT00740766|No Intervention|Unmonitored|
11586842|NCT00740753|Other|Treatment|yttrium 90 (TheraSphere) administration
11586843|NCT00740740||1|Patients scheduled for elective conventional aneurysm repair
11586844|NCT00740740||2|Patients scheduled for emergent conventional aneurysm repair
11586845|NCT00740740||3|Patients scheduled for aortic bypass surgery
11586846|NCT00740727|Experimental|EASI|Subjects will undergo placement of EASI catheters. All subjects in whom EASI catheters are placed, will receive Human Recombinant Hyaluronidase (HRH) as part of the EASI placement. (No subject will receive HRH, other than as part of EASI catheter placement.)
11586847|NCT00740714|Experimental|A|Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)
11586848|NCT00740714|Experimental|B|Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)
11586849|NCT00740714|Placebo Comparator|C|Placebo (with vitamin E 1200 IU/day)
11586850|NCT00740701|Sham Comparator|Sham TMS|A Sham TMS coil, designed to elicit sham cerebellar transcranial magnetic stimulation, is used to administer sham TMS pulses after letters are presented.
11586851|NCT00740701|Experimental|TMS|A genuine TMS coil is used to administer cerebellar transcranial magnetic stimulation pulses after letter presentation.
11586852|NCT00740688|Experimental|Experimental Group|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
11586853|NCT00740688|Sham Comparator|Sham Group|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
11586854|NCT00740675|Experimental|1|"At post-discharge follow-up visit with PCP, PCP views:
~Discharge medication reconciliation screen.
~Prompts to perform post-discharge reconciliation at the first post-discharge visit."
11586855|NCT00740675|No Intervention|Uusual care|PCPs manage the patient's medications after hospital discharge as they normally would.
11586856|NCT00740662||1|Distal gastric bypass
11586857|NCT00740649|Experimental|1|HSD-016
11586858|NCT00740649|Other|2|placebo
11586859|NCT00740636|Experimental|75 mg/m2/day Temozolomide|75 mg/m2/day Temozolomide for 21 days (7 days off treatment). 28 day cycles.
11586860|NCT00740636|Experimental|200 mg/m2/day Temozolomide|200 mg/m2/day Temozolomide for 5 days (23 days off treatment). 28 day cycles.
11586861|NCT00740623|Experimental|001|Carisbamate 800 mg/day for 14 weeks
11586862|NCT00740623|Experimental|002|Carisbamate 1,200 mg/day for 14 weeks
11586863|NCT00740623|Placebo Comparator|003|placebo for 14 weeks
11586864|NCT00740610|Experimental|Cohort 1|22 subjects to receive 1 mg GS-9450 for 4 weeks
11586865|NCT00740610|Experimental|Cohort 2|22 subjects to receive 5 mg GS-9450 for 4 weeks
11586866|NCT00740610|Experimental|Cohort 3|22 subjects to receive 10 mg GS-9450 for 4 weeks
11586867|NCT00740610|Experimental|Cohort 4|22 subjects to receive 40 mg GS-9450 for 4 weeks
11586868|NCT00740610|Placebo Comparator|Cohort 5|22 subjects to receive placebo to match GS-9450 for 4 weeks
11586869|NCT00740597|Experimental|Arm 1|pre-operative radiation + surgery PTV will receive a total dose of 50 Gy in 25 fractions, 2 Gy per fraction, 5 fractions per week, over approximately 5 weeks. Concurrently, the GTV2, if present, will receive 54 Gy in 25 fraction. Dose will be prescribed to the isodose volume that encompasses the PTV. All patients will be treated by 6 MV photon beam.
11586870|NCT00740584|Experimental|Open Label, only arm|3%w/w SPL7013 vaginal gel (VivaGel)
11586871|NCT00740571|Active Comparator|1|Strategy in which patient starts with amitriptyline
11586872|NCT00740571|Active Comparator|2|Strategy in which patient starts with pregabalin
11586873|NCT00740558|Active Comparator|1|Two groups received a traditional chiropractic adjustment of the lumbar 5 and the other group received a manually assisted mechanical force adjustment of the lumbar 5.
11586874|NCT00740558|Sham Comparator|2|The investigators had two groups, one for each chiropractic technique used in the research project and we had a control group
11586875|NCT00740545|Placebo Comparator|2|
11586876|NCT00740545|Experimental|1|
11586877|NCT00740532||Observation|Breast cancer patients treated with Herceptin-based therapy
11586878|NCT00740519||A|
11586879|NCT00740493|Active Comparator|1|18 months of active warfarin therapy
11586880|NCT00740493|Placebo Comparator|2|18 months of placebo of warfarin
11586881|NCT00740480||Surgical|Adult population (ages 18-65) with clinically significant nasal septum deviation.
11586882|NCT00740454||A|Pregnant or post-partum women with a clinically suspected DVT and a negative distal and proximal leg veins compression ultrasonography
11586883|NCT00740441|Experimental|A|AS1411 treatment
11586884|NCT00740428|Experimental|G1|pregnants for the first time who will receive the physical therapy guide
11586982|NCT00739648|Placebo Comparator|Placebo|Placebo inhaled twice daily via the PARI eFlow nebulizer for 5 consecutive days within a 28-day treatment cycle for up to 12 cycles
11587048|NCT00739154||2|glaucoma patients who also suffer from epileptic disorder receiving anti-convulsant treatment other then Phenytoin
11586885|NCT00740415|Experimental|ARM RiBVD|"RiBVD 6 cycles every 28 days day 1 :
~Rituximab /Mabthera®, 375 mg/m2 en IV
~Bendamustine, 90 mg/m2 en IVD
~Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 2 : - Bendamustine, 90 mg/m2 en IVD
~Dexamethasone, 40 mg IV day 4 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 8 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 11 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD"
11586886|NCT00740376|Experimental|Uniglide Mobile Bearing|Uniglide Mobile Bearing Unicondylar Knee System (MBK)
11586887|NCT00740376|Active Comparator|Uniglide Fixed Bearing|Uniglide Fixed Bearing Unicondylar Knee System (FBK)
11586888|NCT00740363|Experimental|A|Patients will receive 4 weeks of treatment with sitagliptin once daily
11586889|NCT00740363|Placebo Comparator|B|No treatment for 4 weeks
11586890|NCT00740350|Experimental|Experimental|Logan Basic chiropractic adjustments during pregnancy.
11586891|NCT00740337||COPD|Participants in this group will be people who have COPD and plan to undergo lung resection surgery at Barnes-Jewish Hospital (BJH).
11586892|NCT00740337||Control|Participants in this group will be people who do not have COPD and plan to undergo lung resection surgery at BJH.
11586893|NCT00740324|Active Comparator|N|
11586894|NCT00740324|Active Comparator|B|
11586895|NCT00740324|Active Comparator|G|
11586896|NCT00740311|Experimental|Filling|alveoli filling with an injectable calcium phosphate after extraction of mandibular molar or pre molar
11586897|NCT00740311|No Intervention|Without filling|
11586898|NCT00740298|Active Comparator|1|Sweet Taste
11586899|NCT00740298|Active Comparator|2|warmth
11586900|NCT00740285|Experimental|1|
11586901|NCT00740285|Placebo Comparator|2|
11586902|NCT00740272|Experimental|1|AF ablation + pacemaker
11586903|NCT00740272|Active Comparator|2|Pacemaker
11586904|NCT00740220||A|Each subject will be their own control. Each subject will perform three 6MWTs. Intra-subject reproducibility is being tested.
11586905|NCT00740207|Active Comparator|Isovue 250|
11586906|NCT00740207|Active Comparator|VISIPAQUE 270|
11586907|NCT00740194|Experimental|1|Aromatase inhibition
11586908|NCT00740194|Active Comparator|2|Estradiol
11586909|NCT00740181|Experimental|Chemotherapy|Decitabine 20 mg/m2 IV over 1 hr days 1-5 Cytarabine 20 mg/m2 subcut days 1-5 G-CSF 5mcg/kg subcut days 1-5
11586910|NCT00740168||TG|Bevacizumab treatment group with metastasized cancer
11586911|NCT00740155|Experimental|Group 1|
11586912|NCT00740155|Experimental|Group 2|
11586913|NCT00740155|Experimental|Group 3|
11586914|NCT00740155|Experimental|Group 4|
11586915|NCT00740155|Active Comparator|Group 5|
11586916|NCT00740142|Active Comparator|1|Interventional arm: oral L-ornithine-L-aspartate and oral lactulose
11586917|NCT00740142|Placebo Comparator|2|Oral lactulose
11586918|NCT00740129|Other|1|Open label, single arm treatment study
11586919|NCT00740116|Active Comparator|1|Tranexamic acid
11586920|NCT00740116|Placebo Comparator|2|0.9% NaCl solution
11586921|NCT00740103|Experimental|1|Semapimod 60 mg IV x 3 days q 6 - 8 weeks
11586922|NCT00740051|Experimental|Linagliptin|52 week treatment
11586923|NCT00740051|Placebo Comparator|Placebo|First 18 weeks of treatment
11586924|NCT00740051|Active Comparator|Glimepiride|Placebo patients switch to glimepiride week19-52
11586925|NCT00740038|Active Comparator|1|Active Control: Usual Care
11586926|NCT00740038|Experimental|2|Stress Management Intervention
11586927|NCT00740038|Experimental|3|Exercise Intervention
11586928|NCT00740038|Experimental|4|Combined Stress Management and Exercise Intervention
11586929|NCT00740025||QD|Women who received their meds as QD administration
11586930|NCT00740025||BID|Women who received their gonadotropins as a BID dose
11586931|NCT00740012|Active Comparator|Even, low numbers|They start with a alarm- clock night. No venous blood drawing.
11586932|NCT00740012|Active Comparator|Even, high numbers|They start with a nurse performing blood glucose determination. No venous blood drawing.
11586933|NCT00740012|Active Comparator|Uneven, low numbers|They start with an alarm- clock night and have venous blood drawing.
11586934|NCT00740012|Active Comparator|Uneven, high numbers|They start with a nurse performing blood glucose determination and have venous blood drawing.
11586935|NCT00739999|Other|1|6-10 years will be administered with atorvastatin tablet formulation with initial doses based on age cohort.
11586936|NCT00739999|Other|2|10-17 years will be administered 10-mg daily dose of atorvastatin tablet formulation.
11586937|NCT00739986|Experimental|1|Semapimod 60 mg IV x 1 day, placebo IV x 2 days
11586938|NCT00739986|Experimental|2|Semapimod 60 mg IV x 3 days
11586939|NCT00739986|Placebo Comparator|3|Placebo comparator IV x 3 days
11586940|NCT00739973|Placebo Comparator|Placebo|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 5 of the 5 pills taken were placebos.
11586941|NCT00739973|Experimental|Aliskiren 150 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
11586942|NCT00739973|Experimental|Aliskiren 300 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
11586983|NCT00739648|Experimental|MP-376 240 mg Twice Daily (BID)|MP-376 240 mg BID inhaled via the PARI eFlow nebulizer for 5 consecutive days within a 28-day treatment cycle for up to 12 cycles
11586984|NCT00739635|Experimental|1|
11586985|NCT00739635|Placebo Comparator|2|
11586986|NCT00739609|Experimental|1|
11587281|NCT00737425|Active Comparator|1|
11586943|NCT00739973|Experimental|Amlodipine 5 mg capsule|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
11586944|NCT00739973|Experimental|Amlodipine 10 mg capsule|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg
11586945|NCT00739973|Experimental|Aliskiren/amlodipine 150/5 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
11586946|NCT00739973|Experimental|Aliskiren/amlodipine 150/10 mg tablet|150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
11586947|NCT00739973|Experimental|Aliskiren/amlodipine 300/5 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
11586948|NCT00739973|Experimental|Aliskiren/amlodipine 300/10 mg tablet|300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
11586949|NCT00739960|Other|Abatacept|
11586950|NCT00739947||1|Standard of Care
11586951|NCT00739934|Experimental|Children aged 2 to <12 years|Immunocompromised children aged 2 to <12 years who are at high risk for systemic fungal infection.
11586952|NCT00739921|Experimental|1|"Patients with sinusitis compared to patients without.
~To find out if any specific type of fungus or mold is correlated with chronic sinus disease. The study will add new information about the different types of fungus and mold found in the human nose."
11586953|NCT00739908|Experimental|CX157 (TriRima)|
11586954|NCT00739908|Placebo Comparator|Placebo|
11586955|NCT00739895||Athletes|high performing athletes
11586956|NCT00739882|Active Comparator|Efalizumab|
11586957|NCT00739882|Placebo Comparator|Placebo|
11586958|NCT00739869||1|Participants will include women who participated in the Women's Health Initiative Memory Study.
11586959|NCT00739830|Experimental|1|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
11586960|NCT00739830|Active Comparator|2|Investigator's choice of: oral medroxyprogesterone acetate tablets 200 mg daily or oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily) OR Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
11586961|NCT00739765|Experimental|1 Interpersonal Psychotherapy (IPT)|Participants will receive interpersonal psychotherapy.
11586962|NCT00739765|Active Comparator|2 Prolonged Exposure (PE)|Participants will receive prolonged exposure therapy.
11586963|NCT00739765|Active Comparator|3 Relaxation therapy|Participants will receive relaxation therapy.
11586964|NCT00739752|Experimental|Non-Framed-Offered|Non-Framed, Information Only Condition. Vaccine Offered.
11586965|NCT00739752|Experimental|Non-Framed-Recommended|Non-Framed, Information Only Condition. Vaccine Recommended.
11586966|NCT00739752|Experimental|Gain-Framed-Offered|Gain-Framed Intervention emphasizes the benefits associated with receiving HBV vaccine. Vaccine Offered.
11586967|NCT00739752|Experimental|Gain-Framed-Recommended|Gain-Framed Intervention emphasizes the benefits associated with receiving HBV vaccine. Vaccine Recommended.
11586968|NCT00739752|Experimental|Loss-Framed-Offered|Loss-Framed Intervention emphasizes the risks associated with not receiving HBV vaccine. Vaccine Offered.
11586969|NCT00739752|Experimental|Loss-Framed-Recommended|Loss-Framed Intervention emphasizes the risks associated with not receiving HBV vaccine. Vaccine Recommended.
11586970|NCT00739739|Experimental|PD 0299685 15mg|
11586971|NCT00739739|Experimental|PD 0299685 30mg|
11586972|NCT00739739|Placebo Comparator|Placebo|
11586973|NCT00739713|Experimental|SB|Sea buckthorn oil group
11586974|NCT00739713|Placebo Comparator|PL|Placebo group
11586975|NCT00739700||A|There is only one cohort of subjects, the critically ill. The NIBP will be correlated with the IABP in each subject.
11586976|NCT00739687|Experimental|ALT-711|Alagebrium 200 mg BID
11586977|NCT00739687|Experimental|Placebo|Placebo
11586978|NCT00739674|Active Comparator|Losartan-Based Regimen Alone (L Group)|Losartan-based regimen, with sequential titration including HCTZ and CCB as needed to achieve target blood pressure.
11586979|NCT00739674|Experimental|Diet Management and Losartan-Based Regimen (DML Group)|Losartan with sequential titration including HCTZ and CCB as needed to achieve target blood pressure combined with low-salt intake diet.
11586980|NCT00739661|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
11586987|NCT00739596|Experimental|Aliskiren Hydrochlorothiazide (HCTZ)|
11586988|NCT00739596|Active Comparator|Amlodipine|
11586989|NCT00739583|Active Comparator|1|Skin preparation for hip replacement with a Chlorhexidine based skin preparation solution, Chloraprep® (CHG 2% w/v and IPA 70% v/v; Enturia Inc., Leawood, KS, USA)
11586990|NCT00739583|Active Comparator|2|Skin preparation for hip replacement with an Iodine based skin preparation solution, Duraprep® (Iodophor 0.7% and IPA 74% w/w; 3M Healthcare, St. Paul, MN, USA.
11586991|NCT00739570|No Intervention|1|
11586992|NCT00739570|Active Comparator|2|Activator chiropractic technique basic scan protocol
11586993|NCT00739544|Other|1|Quantitative sensory testing (QST) of healthy women to create reference values for QST evaluation of women treated for breast cancer
11586994|NCT00739531||Asthmatics|Subjects with asthma
11586995|NCT00739518|Experimental|MRI scan - new technology|The patient's clinical MRI scan will also utilize some new technology, such as a change in software or additional MRI sequences
11586996|NCT00739505|Experimental|Cohort 1|3 HPP patients are to be enrolled in Cohort 1 and receive a single IV dose and three weekly SC doses of Asfotase Alfa . End of Study for patients in Cohort 1 is at 8 weeks.
11586997|NCT00739505|Experimental|Cohort 2|Cohort 2 will begin when the safety and PK data for Cohort 1 weeks 1-4 has been reviewed by the DSMB. Cohort 2 will enroll 3 HPP patients and will receive a higher dose level than Cohort 1. Cohort 2 patients will have a single IV dose and three weekly SC doses of Asfotase Alfa . End of Study for patients in Cohort 2 is at 8 weeks.
11586998|NCT00739492|Active Comparator|1|deposit based incentive
11586999|NCT00739492|Active Comparator|2|"deposit based incentive framed with maintenance period"
11587000|NCT00739492|No Intervention|3|Control arm, no financial incentive
11587001|NCT00739479|Active Comparator|1|Patients will be randomized to receive PHWP. Since sex and baseline weight can influence the response, randomization will be stratified according to these variables.
11587002|NCT00739479|Placebo Comparator|2|Patients will be randomized to receive PHG. Since sex and baseline weight can influence the response, randomization will be stratified according to these variables.
11587003|NCT00739466|Experimental|low dose|Liposomal Alendronate dose of 0.001 mg
11587004|NCT00739466|Experimental|high dose|Liposomal Alendronate dose of 0.01 mg
11587005|NCT00739466|Placebo Comparator|placebo|IV saline infusion
11587006|NCT00739453|Experimental|Schedule 1|OSI-906 is administered on Days 1-3 every 7 days. Erlotinib will be administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
11587007|NCT00739453|Experimental|Schedule 2|OSI-906 is administered daily starting on Day 1 and erlotinib is administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
11587008|NCT00739453|Experimental|Schedule 3|OSI-906 is administered continuously twice daily starting on Day 1 and erlotinib is administered daily starting on Day 2. The NSCLC expansion cohort will follow Schedule 3 with the exception that erlotinib is administered daily starting on Day 8.
11587009|NCT00739440|Experimental|I|Patients 15 to 60 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex
11587010|NCT00739440|Experimental|II|Patients 15 to 60 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)
11587011|NCT00739414|Experimental|LBH589 (Panobinostat)|
11587012|NCT00739401|Experimental|1|Test subjects requiring endovascular treatment of abdominal aortic or aorto-iliac aneurysms including a proximal cuff extension.
11587013|NCT00739388|Experimental|Arm: 5-azacytidine|5-azacytidine 100 mg/m2/day s.c. on days 1-5 of a 28-day cycle.
11587014|NCT00739362|Experimental|Active|active tDCS stimulation
11587015|NCT00739362|Sham Comparator|Sham|Sham/no-stimulation
11587016|NCT00739349|Experimental|1|Cyclosporine 0.05%
11587017|NCT00739349|Experimental|2|Cyclosporine 0.1%
11587018|NCT00739349|Placebo Comparator|3|vehicle/placebo
11587019|NCT00739336|Experimental|A, 1|Intervention: Immediate 3 month program
11587020|NCT00739336|No Intervention|A, 2|Wait-List Control
11587021|NCT00739310|Experimental|Vest Treatment (HFCWO)|Patients will receive Vest treatments for airway clearance therapy 2 x daily for 12 months. These data will be compared to 12 months of data prior to Vest initiation.
11587022|NCT00739297|Placebo Comparator|1|montelukast Placebo
11587023|NCT00739297|Experimental|2|montelukast
11587024|NCT00739297|Experimental|3|montelukast
11587025|NCT00739297|Experimental|4|montelukast
11587026|NCT00739271|Active Comparator|Study arm|Early enteral feed 48 hours after abdominal surgery
11587027|NCT00739271|Active Comparator|Control arm|Traditional treatment where patient is kept on a nasogastric drainage for a few days after abdominal surgery, wait for bowel sounds to appear and then start enteral feeds.
11587028|NCT00739258||HIDU|intravenous drug user (IDU) with HIV infected
11587029|NCT00739258||IDU|intravenous drug user (IDU) without HIV
11587030|NCT00739258||MH|persons receiving methadone maintenance treatment
11587031|NCT00739232|Active Comparator|Active|Active
11587032|NCT00739232|Placebo Comparator|Placebo|Placebo
11587033|NCT00739219|Active Comparator|eNO group|eNO measurement is used to inform asthma management decisions
11587034|NCT00739219|No Intervention|control group|Asthma is managed according to existing standard of care
11587035|NCT00739206|Experimental|Cohort 1|Adult patients with uncomplicated malaria
11587036|NCT00739206|Experimental|Cohort 2|Pediatric patients with uncomplicated malaria
11587037|NCT00739206|Experimental|Cohort 3|Pediatric patients with severe malaria
11587038|NCT00739193|Placebo Comparator|Placebo|Placebo Control
11587039|NCT00739193|Experimental|PM101|PM101
11587040|NCT00739193|Active Comparator|Amiodarone IV|Amiodarone IV
11587041|NCT00739180|Other|Control|Standard care control
11587042|NCT00739180|Active Comparator|Aerobic Exercise|
11587043|NCT00739180|Active Comparator|Resistance Exercise|
11587044|NCT00739167||Y90 Group|Patients receiving treatment with radioembolization.
11587045|NCT00739167||TACE Group|Patients receiving treatment with transcatheter arterial embolization
11587046|NCT00739167||RFA Group|Patients receiving treatment with radiofrequency ablation.
11587047|NCT00739154||1|glaucoma patients who also suffer from epileptic disorder and receiving chronic oral Phenytoin treatment
11587049|NCT00739154||3|glaucoma patients with no epileptic disorder and not receiving anti-convulsant treatment
11587050|NCT00739141|Experimental|1|There are three chemotherapy drugs involved. They are called fludarabine (5 doses), cyclophosphamide (1 dose), and thiotepa (2 doses). Also two days of radiation therapy. This is called Total Body Irradiation or TBI. The TBI if given for two days before, the transplant. On transplant day, the cord blood cells will be given through a catheter. The immune suppressing drugs given are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through the catheter. Later they can be given as tablets.
11587051|NCT00739128|Active Comparator|1|celiac patients who did not respond to initial hepatitis B vaccine series , will receive repeat hep B vaccine via intramuscular route
11587052|NCT00739128|Active Comparator|2|celiac patients who did not respond to initial hepatitis B vaccine series , will receive repeat hep B vaccine via intradermal route
11587053|NCT00739115|Experimental|1|Heliox gas added to nasal CPAP for the first 72 hours of life
11587054|NCT00739115|No Intervention|2|Conventional nasal CPAP for the first 72 hours of life
11587055|NCT00739102|Experimental|1|S.M.A.R.T.® Nitinol Self-Expandable Stent System
11587056|NCT00739076|Experimental|1|Virtual Reality Hypnosis
11587057|NCT00739076|Experimental|2|Virtual Reality Distraction
11587058|NCT00739076|Experimental|3|Standard treatment.
11587059|NCT00739063|Experimental|Tarceva daily|Tarceva oral 150 mg daily.
11587060|NCT00739050|Experimental|1|Arm 1: Drug
11587061|NCT00739050|Placebo Comparator|2|Arm 2: Placebo
11587062|NCT00739037|Placebo Comparator|A|
11587063|NCT00739037|Experimental|B|
11587064|NCT00739024|Active Comparator|Active Treatment|Ramelteon once daily (double-blind assignment)
11587065|NCT00739024|Placebo Comparator|Placebo|Placebo tablet, once daily (double-blind assignment)
11587066|NCT00739011|Experimental|1|
11587067|NCT00738998|Experimental|Questionnaire and Telephone Assessments|Breast cancer patients assigned to one or two groups: Group 1) enrolled at beginning of anastrozole treatment; or Group 2) if beginning third year of anastrozole treatment.
11587068|NCT00738985|Placebo Comparator|ezetimibe/simvastatin 10/20 mg + placebo|The intervention consisted of an isocaloric diet, an exercise program (30 min/day of aerobic activity) and ezetimibe (+) simvastatin 10/20 mg + placebo for 12 weeks. Safety and efficacy parameters are measured at baseline and 12 weeks later
11587069|NCT00738985|Active Comparator|ezetimibe/simvastatin 10/20 mg + MK0524A|The intervention consisted of an isocaloric diet, an exercise program (30 min/day of aerobic activity) and ezetimibe/simvastatin 10/20 mg + MK0524A 1 gr for 6 weeks, if efficacy achieved will continue with ezetimibe (+) simvastatin 10/20 mg + MK0524A 1 gr + placebo; if not achieved, will receive ezetimibe (+) simvastatin 10/20 mg + MK0524A 2 gr for 6 weeks.
11587070|NCT00738972|Active Comparator|Valsartan 80 mg + Paravastin 40 mg|Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)
11587071|NCT00738972|Active Comparator|Valsartan 80 mg + Simvastatin 40 mg|Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)
11587072|NCT00738972|Experimental|Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg|Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)
11587073|NCT00738972|Active Comparator|Valsartan 80 mg|Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)
11587074|NCT00738959|Experimental|1|
11587075|NCT00738946|Experimental|2|Amodiaquine+pyrimethamine versus placebo
11587076|NCT00738933|Active Comparator|A|A group of patients consuming 2 grams plant stanols 4-8 weeks before the operation
11587077|NCT00738933|Active Comparator|E|A group of patients consuming daily 2 grams plant sterols 4-8 weeks before the operation.
11587078|NCT00738933|Placebo Comparator|C|
11587079|NCT00738920|Active Comparator|MC-CBT|Self Administered Cognitive Behavior Therapy
11587080|NCT00738920|Active Comparator|Standard-CBT|Therapist Administered Cognitive Behavior Therapy
11587081|NCT00738920|Active Comparator|Education/Support|Behavioral Patient Education/Counseling
11587082|NCT00738894|Active Comparator|Medical Management|Antiplatelet medical therapy alone
11587083|NCT00738894|Experimental|Device Closure|PFO closure with study septal occluder device plus antiplatelet medical therapy
11587084|NCT00738881|Experimental|Arm I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11587085|NCT00738881|Experimental|Arm II (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11587086|NCT00738855|Active Comparator|1|Gastrografin group
11587087|NCT00738855|Placebo Comparator|2|Control group
11587088|NCT00738842|Experimental|1|
11587089|NCT00738842|Placebo Comparator|2|
11587090|NCT00738829|Experimental|Treatment Arm|Lenalidomide Dose Escalation combined with Fludarabine/Rituximab followed by maximum tolerated lenalidomide dose/Rituximab maintenance therapy
11587091|NCT00738816|Other|Intervention|Systematic medication review
11587092|NCT00738803|Experimental|1|Leg Length and offset measurement arm
11587093|NCT00738790|Experimental|1|Preoperative radiotherapy with five fractions of 5 Gy during one week and boost 4 Gy after 1 week interval, total dose 29 Gy; after 6 weeks full-thickness local excision
11587094|NCT00738790|Active Comparator|2|"Radiochemotherapy with 28 fractions of 1,8 Gy plus boost 5,4 Gy in 3 fractions
~+ simultaneous bolus 5-Fluorouracil and leucovorin; after 6 weeks full-thickness local excision"
11587095|NCT00738777|Active Comparator|1|Anastrozole
11587096|NCT00738777|Experimental|2|Anastrozole + Fulvestrant
11587097|NCT00738777|Active Comparator|3|Tamoxifen
11587098|NCT00738777|Other|4|Tamoxifen (pre-menopausal and male patients)
11587099|NCT00738764|Experimental|Cohort 1|PDL192 Dose Level 1
11587100|NCT00738764|Experimental|Cohort 2|PDL192 Dose Level 2
11587101|NCT00738764|Experimental|Cohort 3|PDL192 Dose Level 3
11587102|NCT00738764|Experimental|Cohort 4|PDL192 Dose Level 4
11587103|NCT00738764|Experimental|Cohort 5|PDL192 Dose Level 5
11587105|NCT00738751|Experimental|Dose Escalation Followed by Expansion|Eligible participants were enrolled in a 3+3 dose-escalation design to determine the maximum tolerated dose (MTD) of twice weekly panobinostat plus daily erlotinib at 4 planned dose levels (DLs).
11587106|NCT00738725||1|Survey only
11587107|NCT00738725||2|Imaging group
11587108|NCT00738725||3|Non-imaging group
11587109|NCT00738712|Experimental|New MRI techniques|New hardware or software technologies designed to improve MRI (Magnetic Resonance Imaging) exams.
11587110|NCT00738699|Active Comparator|1|MORAb-003 (Farletuzumab) Plus Paclitaxel
11587111|NCT00738699|Placebo Comparator|2|Placebo Plus Paclitaxel
11587112|NCT00738686|Experimental|1|Single-arm study, no placebo or control group
11587113|NCT00738673|Experimental|Degarelix|"Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0.
~Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections."
11587114|NCT00738660|Experimental|A|single experimental arm cross over of patients, addition of Ramipril onto Telmisartan.
11587115|NCT00738647|Active Comparator|Ceram X|Fillings made with a traditional composite material (Ceram X)
11587116|NCT00738647|Experimental|Filtek Silorane|Fillings made with a new composite material (Filtek silorane)
11587117|NCT00738634|Experimental|Physical activity mediated|"Self-motivated physical activity intervention
~Materials mailed to participants"
11587118|NCT00738634|Active Comparator|Nutrition control|"Nutrition attention-control arm.
~Delivered by researcher."
11587119|NCT00738634|Experimental|Physical activity researcher contact|"Self-motivated physical activity intervention
~Delivered by researcher."
11587120|NCT00738621|Active Comparator|1|Oral aprepitant 40 mg - given within 3 hours prior to induction dexamethasone (4mg intravenous) administered immediately after induction ondansetron (4mg (2ml) intravenous) administered at cessation of anesthesia
11587121|NCT00738621|Placebo Comparator|A,2|Oral aprepitant 40 mg- given within 3 hours prior to induction dexamethasone (4mg intravenous) administered immediately after induction Placebo ( intravenous saline 2ml) administered at cessation of anesthesia
11587122|NCT00738608||1|33 pat. with verum
11587123|NCT00738608||2|33 Pat. with placebo
11587124|NCT00738595|Experimental|1|EVT 302, 5 mg once Daily
11587125|NCT00738595|Placebo Comparator|2|Placebo once daily
11587126|NCT00738595|Experimental|3|EVT 302 plus open label Nicotine replacement
11587127|NCT00738595|Active Comparator|4|Placebo plus nicotine replacement therapy
11587128|NCT00738582|Experimental|Open Label|Pemetrexed, Cisplatin and MORAb-009 (Amatuximab)
11587129|NCT00738569|Experimental|Raltegravir|
11587130|NCT00738556|Active Comparator|1|Full cover stenting of coronary lesions
11587131|NCT00738556|Active Comparator|2|Spot-stenting of significantly stenotic parts of a coronary lesion
11587132|NCT00738543|Experimental|Whole group of 48 volunteers|The arm is composed of 48 human volunteers to test 10% povidone-iodine (Isodine Solucion ®, Boehringer-Ingelheim Promeco, Mexico City), Hypochlorite 10% of electrochemical production (Exsept 10% ®, Pisa, Guadalajara, Mexico), and control.
11587133|NCT00738530|Experimental|Bevacizumab + IFN-Alfa-2A|Bevacizumab infusions will be administered every 2 weeks at a dose of 10 milligram per kilogram (mg/kg) for 52 weeks or until disease progression or unacceptable toxicity. Interferon alfa-2a (IFN-Alfa-2A) will be administered 3 times per week as a subcutaneous injection at a dose of 9 million international units (MIU) for 52 weeks or until disease progression or major toxicity.
11587134|NCT00738530|Placebo Comparator|Placebo + IFN-Alfa-2A|Placebo matched with Bevacizumab infusions will be administered every 2 weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A will be administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
11587135|NCT00738517|Active Comparator|1|Immunoadsorption with subsequent immunoglobulin substitution
11587136|NCT00738517|No Intervention|2|
11587137|NCT00738504||1|
11587138|NCT00738504||2|
11587139|NCT00738504||Group 1|Group 1 (Carbohydrate Restrictive Strategy). Patients received intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16,7% proteins and 50% lipids (Glucerna, Abbott Laboratories). These patients received regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and, in stable patients, ideally below 150 mg/dl.
11587140|NCT00738504||Group 2|Group 2 (Intensive Insulin Therapy). Continuous intravenous insulin infusion was adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 to 120 mg/dl. Patients were submitted to capillary glycemic measurements every 2 hours. The insulin dose was adjusted according to an algorithm run by nurses and overseen by physicians. These patients received glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids (Diason, Nutricia Clinical Care Ltd).
11587141|NCT00738491||1|Patients with stable angina pectoris and documented coronary heart disease recruited in Edinburgh
11587142|NCT00738491||2|Patients with stable angina pectoris and documented coronary heart disease recruited in London
11587143|NCT00738478|Experimental|A|Arm A: with nasogastric tube
11587144|NCT00738478|Active Comparator|B|Arm B: without nasogastric tube
11587145|NCT00738452|Experimental|Treatment (chemo, monoclonal antibody therapy, radiation)|CHEMORADIOTHERAPY: Patients undergo external beam radiation therapy 5 days a week for 45 days. Beginning within 24 hours of the start of radiation therapy, patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36 OR cisplatin IV over 60 minutes on days 1, 8, 29, and 36 and etoposide IV over 60 minutes on days 1-5 and 29-33. CONSOLIDATION RADIOIMMUNOTHERAPY: Beginning 6-10 weeks after completion of chemoradiotherapy, patients with stable disease, partial response, or complete response receive a therapeutic dose of yttrium Y 90 anti-CEA monoclonal antibody cT84.66 IV. Treatment continues in the absence of disease progression or unacceptable toxicity.
11587146|NCT00738439||Operative|Diagnosis of adult degenerative or idiopathic scoliosis with a curvature of the spine measuring greater than or equal to 20 degrees requiring surgery.
11587147|NCT00738439||Nonoperative|Diagnosis of adult degenerative or idiopathic scoliosis with a curvature of the spine measuring greater than or equal to 20 degrees not requiring surgery.
11587282|NCT00737425|Sham Comparator|2|
11587149|NCT00738426|Sham Comparator|Sham device|non-therapeutic sham light output
11587150|NCT00738413|Active Comparator|Arm 1|Subjects will be treated for 6 days with deferoxamine.
11587151|NCT00738413|Active Comparator|Arm 2|Subjects will be treated for 6 days with deferasirox.
11587152|NCT00738413|Experimental|Arm 3|Subjects will be treated for 6 days with a combination of deferoxamine and deferasirox.
11587153|NCT00738400|Experimental|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg tablets PRN (pro re nata) for 4 weeks, Vardenafil 5 mg/10 mg/20 mg tablets PRN for consecutive 4 weeks
11587154|NCT00738400|Placebo Comparator|Placebo|Matching placebo tablets PRN (pro re nata) for 4 weeks, placebo tablets PRN for consecutive 4 weeks
11587155|NCT00738387|Experimental|ASA404 + docetaxel|"1800 mg/m2 of ASA404 intravenous (IV) on day 1 of each 21 day cycle
~75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days"
11587156|NCT00738387|Placebo Comparator|Placebo + docetaxel|"Placebo i.v. on day 1 of each 21 day cycle
~75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days"
11587157|NCT00738374|Experimental|1|
11587158|NCT00738361|Experimental|nab-paclitaxel|Administered via intravenous bolus at a dose of 150 mg/m2 weekly for 3 of 4 weeks every 28 days.
11587159|NCT00738348|Active Comparator|2|250mL of 5% glucose plus 300mg of sivelstat was infected through the vein at 10mL per an hour
11587160|NCT00738348|Placebo Comparator|1|250mL of 5% glucose was injected though the vein at 10mL per an hour
11587161|NCT00738322|Experimental|1|
11587162|NCT00738322|Placebo Comparator|2|
11587163|NCT00738309||Operative|Diagnosis of classical Scheuermann's Kyphosis (3 successive vertebrae wedged 5 degrees or more, +/- end plate deformities) or idiopathic structural Kyphosis (rigid structural kyphosis without classic Scheuermann's Kyphosis findings) for which surgical treatment is recommended to prevent progression of the curvature or to correct trunk deformity (unacceptable cosmesis).
11587164|NCT00738309||Non-operative|Diagnosis of classical Scheuermann's Kyphosis (3 successive vertebrae wedged 5 degrees or more, +/- end plate deformities) or idiopathic structural Kyphosis (rigid structural kyphosis without classic Scheuermann's Kyphosis findings) for which surgical treatment was not undertaken.
11587165|NCT00738296|Active Comparator|A|Group A: Comparator
11587166|NCT00738296|Active Comparator|B|Group B: Comparator
11587167|NCT00738296|Experimental|C|Group C: Drug
11587168|NCT00738257|Experimental|Parmidronate|
11587169|NCT00738244||1|Normal hearing listeners
11587170|NCT00738244||2|Listeners with mild-to-moderate sensorineural hearing loss
11587171|NCT00738231|Active Comparator|I|"Group I's training material consisted of a brochure with the information we wanted the public to know about heart disease. The brochure had such titles as Cardiovascular Diseases, let us protect our hearts, the importance of cholesterol in preventing heart diseases, watch out for blood pressure, quit smoking for your health, weight watching, nutrition, food to avoid in cardiovascular disease, an easy method: exercise and exercise control, and an appropriate body weight vs. height chart for adults"
11587172|NCT00738231|Active Comparator|II|The Group II training material document was a letter in the form of a prescription in which the individual was addressed by name, the risk factors established at the first stage were explained, and the suggested measures for protection from such risk factors were indicated.
11587173|NCT00738218|Other|MDCT|Single Arm study. All patients underwent MDCT.
11587174|NCT00738205||1|
11587175|NCT00738205||2|
11587176|NCT00738192|Active Comparator|1|Fentanyl delivered for controlling awaking pain
11587177|NCT00738192|Active Comparator|2|Sufentanil delivered for controlling awaking pain
11587178|NCT00738192|Active Comparator|3|Butorphanol delivered for controlling awaking pain
11587179|NCT00738179|Experimental|1|CPAP plus standard care of cardiovascular risk factors
11587180|NCT00738179|Active Comparator|2|Standard care alone
11587181|NCT00738166|Experimental|II|organic animal manure
11587182|NCT00738166|Active Comparator|III|conventional
11587183|NCT00738166|Experimental|I|organic green manure
11587184|NCT00738153||A|
11587185|NCT00738140|Experimental|A|Intensive lifestyle intervention based on the Diabetes Prevention Program
11587186|NCT00738140|No Intervention|B|Will follow the guidelines for healthy living established by the Food Guide Pyramid and the National Cholesterol Education Program
11587187|NCT00738127|Experimental|1|Group I (treatment with our technique) Eighteen patients (18 wrists) were available for long-term follow-up at an average of 47.8 months after surgery. There were 11 men and seven women. Their mean age at the time of surgery was 35.4 years (range, 22 to 56 years). The dominant hand was involved in 12 patients and the nondominant hand, in six.
11587188|NCT00738127|Experimental|2|Group II (treatment with Inoue et al.'s technique) Fifteen patients (15 wrists) were evaluated at an average of 51 months. Nine patients were men and 6 were women. The mean age of the group at the time of surgery was 37.5 years (range, 24 to 58 years). The dominant hand was involved in 10 and nondominant hand, in seven.
11587189|NCT00738114||1|group without hyperglycemia (fasting blood glucose below 126mg/dl) approximately 1000 patients
11587190|NCT00738114||2|group with hyperglycemia (fasting blood glucose above 125 mg/dl) or history of diabetes approximately 500 patients
11587191|NCT00738101|Experimental|Fish Oil Emulsion Arm|"In infants who meet the eligibility criteria for Fish Oil Emulsion arm will receive Fish Oil Emulsion after enrollment under the study.
~Therapy with Fish Oil Emulsion (Omegaven) will be provided at a dose of 1 gm/kg/day (by continuous infusion) and will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If previously on Intralipid, it will be stopped prior to initiation of Fish Oil Emulsion.Fish oil emulsion will be provided as a continuous intravenous emulsion over 24 hours."
11587192|NCT00738088|Experimental|1|Withdrawal of sulphonylurea for 6 weeks, then re-introduction for 6 weeks, assessed by fasting glucose and HbA1c
11587193|NCT00738075||PD+FOG|Patients with Parkinson's disease prone to freezing
11587194|NCT00738062|Active Comparator|Droxidopa|Study medication
11587195|NCT00738062|Placebo Comparator|Placebo|Placebo
11587196|NCT00738049|Active Comparator|Group 1|Group 1 will receive oral darusentan 100mg for 2 weeks during Phase 1 then placebo for 2 weeks during Phase 2.
11587283|NCT00737412|Active Comparator|1|The probiotic Bio-K+ CL1285 RX®
11587197|NCT00738049|Active Comparator|Group 2|Group 2 will receive placebo for 2 weeks during Phase 1 then oral darusentan 100 mg for two weeks during Phase 2
11587198|NCT00738036||Group P|Exposed to an acute painful phenomenon requiring an analgesic management
11587199|NCT00738036||Group C|Control, not exposed to acute pain
11587200|NCT00738023|Active Comparator|Diabetics|Obese, normotensive African-Americans with diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours, then normal saline 0.9% at 40 ml/hr intravenously for 48 hours, and then randomized to rosiglitazone for six weeks followed by Intralipid 20% at 40ml/hr intravenously for 48 hours
11587201|NCT00738023|Active Comparator|Non-Diabetic|Obese, normotensive African-Americans without diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours
11587202|NCT00738010|Experimental|KH|Kneehab is a garment integrated NMES device with multipath technology.
11587203|NCT00738010|Active Comparator|PS|Poli-Stim, a standard NMES device, used for 3 times per day, five days per week for 12 weeks.
11587204|NCT00738010|Active Comparator|CO|Control group performed voluntary muscle contractions for 20 minutes 3 times per day, 5 days per week for 12 weeks.
11587205|NCT00737997|Placebo Comparator|1|
11587206|NCT00737997|Experimental|2|
11587207|NCT00737984|No Intervention|1|Group 1 patients will receive standard superovulation-IUI treatment without endometrial sampling
11587208|NCT00737984|Active Comparator|2|Group 2 patients will receive standard superovulation-IUI treatment with endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
11587209|NCT00737971|Active Comparator|A|Avastin intravitreal injection D0, Week 4, Week 8
11587210|NCT00737971|Active Comparator|B|Triamcinolone intravitreal injection
11587211|NCT00737971|Active Comparator|C|Avastin + Triamcinolone intravitreal injection simultaneously
11587212|NCT00737958||1|Patients with documented stable coronary artery disease, symptoms of stable angina pectoris, and a positive standard BRUCE exercise stress test at 3 - 13 minutes.
11587213|NCT00737945||2|
11587214|NCT00737932|Experimental|Laquinimod|Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day (sequential cohorts)
11587215|NCT00737932|Placebo Comparator|Placebo|Matching placebo
11587216|NCT00737919|Active Comparator|1|A group of subjects consuming daily 2 grams of plant stanols 4-6 weeks before the operation
11587217|NCT00737919|Active Comparator|2|A group of patients consuming daily 2 grams of plant sterols 4-6 weeks before the operation
11587218|NCT00737906|Experimental|I|Surgical turbinate reduction procedure
11587219|NCT00737893|Experimental|Erythropoietin (EPO)|20,000 units of EPO given on the day before surgery, the day of surgery, and the day after surgery.
11587220|NCT00737893|Placebo Comparator|Placebo|Placebo doses given the day before surgery, the day of surgery, and the day after surgery.
11587221|NCT00737880|Active Comparator|1|In situ organ perfusion using HTK solution during pancreas procurement
11587222|NCT00737880|Active Comparator|2|In situ perfusion using UW solution during pancreas procurement
11587223|NCT00737867|Experimental|A|"Day 1: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Gemcitabine infusion 1000 mg/m2 Day 8: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Gemcitabine infusion 1000 mg/m2
~All patients will receive a maximum of 3 courses with an interval of 3 weeks"
11587224|NCT00737867|Active Comparator|B|"Day 1: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Carboplatin infusion AUC = 5 (Calvert's formula) Day 8: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2
~All patients will receive a maximum of 3 courses with an interval of 3 weeks"
11587225|NCT00737854|Experimental|1 ARM|Otherwise healthy patients with oral lichen planus (precancerous/erosive OLP)
11587226|NCT00737841|Experimental|A|Bifidobacterium breve
11587227|NCT00737841|Placebo Comparator|B|Placebo
11587228|NCT00737828|Active Comparator|A|Control - Standard Perioperative Pathway, clinician decides post-operative care environment (usual care)
11587229|NCT00737828|Experimental|B|Intervention - Perioperative care pathway guided by CPX Results i.e.anaerobic threshold & ventilatory equivalents
11587230|NCT00737815|Active Comparator|A|Magnesium citrate: a total of 500 mg of elemental magnesium
11587231|NCT00737815|Placebo Comparator|B|Placebo pills
11587232|NCT00737802||Normal Control|Normal control subjects are the participants with no history of GERD, no signs and symptoms of GERD
11587233|NCT00737802||GERD Patients|GERD patients are those with history of GERD, signs and symptoms of GERD and selected signs and symptoms of GERD in the questionnaire.
11587234|NCT00737802||Barrett's patients|Barrett's patients are those participants who in addition to all the qualities of GERD patients have long standing history of GERD and mucosal changes in the esophagus.
11587235|NCT00737789|Experimental|Mesalazine once/day|Participants received 4g oral Mesalazine once a day (2 sachets of prolonged release granules) for 8 weeks during the induction period. In addition, participants received a liquid enema of 1g Mesalazine once a day at bedtime for the first 4 weeks. Participants who were in remission at Week 8 received oral mesalazine 2g once daily (1 sachet/day) for an additional 4 weeks (maintenance period).
11587236|NCT00737789|Active Comparator|Mesalazine twice/day|Participants received oral mesalazine 4 g per day in two divided doses (1 sachet prolonged release granules twice a day) for 8 weeks during the induction period. In addition, participants received a liquid enema of 1g Mesalazine once a day at bedtime for the first 4 weeks. Participants who were in remission at Week 8 received oral Mesalazine 2g (one sachet) once a day for an additional 4 weeks (maintenance period).
11587237|NCT00737776||A|
11587238|NCT00737763|Experimental|A|This group will receive weekly efalizumab injections for 6 months
11587239|NCT00737763|Placebo Comparator|B|This group will receive placebo injections for 6 months
11587240|NCT00737750|Experimental|KH|Kneehab is a garment integrated NMES device with multipath technology.
11587241|NCT00737750|Active Comparator|PS|Poli-Stim, a standard NMES device, used for 3 times per day, five days per week for 12 weeks.
11587242|NCT00737750|Active Comparator|CO|Control group performed voluntary muscle contractions for 20 minutes 3 times per day, 5 days per week for 12 weeks.
11587243|NCT00737737|Experimental|Opioid|Participants will receive MS Contin over a 4 week period starting at 15 mg bid. Doses will titrated upwards as tolerated by increments of 15-30 mg to a highest attained dose or a maximum dose of 90 mg
11587244|NCT00737737|Experimental|Placebo|Participants will receive a similar number of placebo tablets which match the study drug with regards to appearance over a period of 4 weeks
11587245|NCT00737724|Experimental|Group 1|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
11587246|NCT00737724|Experimental|Group 2|Receives only antituberculosis therapy, and 2 months afterwards antiretroviral therapy
11587247|NCT00737711|Experimental|Mircera|
11587248|NCT00737698|Experimental|Exercise|Exercise
11587249|NCT00737698|Experimental|Repetitive magnetic stimulation|Repetitive magnetic stimulation of femoral nerve
11587250|NCT00737698|No Intervention|Control|No active treatment
11587251|NCT00737685|Experimental|Fludarabine|
11587252|NCT00737672|Experimental|VIABAHN Treatment Group|Use of GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Comparator Arm
11587253|NCT00737672|Active Comparator|PTA Treatment Group|Percutaneous Transluminal Angioplasty (PTA) in arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Experimental Arm
11587254|NCT00737659|Experimental|1|Concentration Controlled (CC)group will receive an individually adjusted MMF dosing regimen based on the plasma concentrations of mycophenolic acid (MPA,the active metabolite of mycophenolate mofetil).
11587255|NCT00737659|Active Comparator|2|Fixed dose (FD) group will receive an a priori set dose of 2mg\day MMF, the recommended dose, with a possible secondary adaptation by the clinician based on criteria of clinical efficacy, toxicity or interactions with other medications.
11587256|NCT00737646|Other|1|Usual care
11587257|NCT00737646|Experimental|2|Clinic-focused intervention: The clinicians and clinical staff in each of the clinics will be scheduled for training sessions. The provider trainings will be designed for clinicians and clinical staff and will be conducted in at least two separate sessions of approximately 3 hours total duration. The sessions will be scheduled to accommodate the clinic schedule, but will be held with no more than 1 month between them. Participants in clinic training sessions will receive continuing education credit.
11587258|NCT00737646|Experimental|3|"Clinic-focused and patient focused intervention: The clinic focused-intervention as described in Arm 2 will be combined with a patient-focused intervention.
~Patient focused intervention: CRC education packets, based upon previously developed CDC CRC patient education materials, have been adapted for each study site. These CRC educational packets will be mailed to average-risk patients aged 50-80 years who are due for CRC screening (based on electronic records) and who schedule a non-acute ambulatory care visit in clinics assigned to the patient-focused intervention. A cover letter signed by the patient's physician will be included with each packet. The packets will be mailed approximately 1 week before the medical appointment."
11587259|NCT00737633|Experimental|16-Week population|Placebo subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)
11587260|NCT00737633|Experimental|72-Week population|Active treatment subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)
11587261|NCT00737620|Active Comparator|propaten graft|
11587262|NCT00737620|Active Comparator|Standard graft|
11587263|NCT00737594|Placebo Comparator|Placebo TID|Participants receive matching placebo capsules three times daily (TID)
11587264|NCT00737594|Experimental|12 mcg TID|Participants receive 12 mcg Cobiprostone TID
11587265|NCT00737594|Experimental|18 mcg TID|Participants receive 18 mcg Cobiprostone TID
11587266|NCT00737568|Experimental|Tenofovir DF|TDF plus placebo to match FTC/TDF
11587267|NCT00737568|Experimental|FTC/TDF|FTC/TDF plus placebo to match TDF
11587268|NCT00737555|Experimental|1|Once daily oral administration of CHR-2797 ( escalating dose groups) in solid tumour patients receiving paclitaxel infusion every three weeks
11587269|NCT00737542|Placebo Comparator|A|
11587270|NCT00737542|Experimental|B|
11587271|NCT00737529|Experimental|Lenalidomide|"Single agent Lenalidomide
~Lenalidomide: 10mg or 25 mg oral capsules on days 1 to 21 of each 28 day cycle and dependent on renal function; Participants with normal renal function (defined as Creatinine Clearance(CrCl)) of ≥ 60 mL/min in this study) received 25 mg of lenalidomide daily, and those with moderate renal insufficiency (CrCl) ≥ 30 mL/min but < 60 mL/min) were started at a 10-mg dose. Participants could continue to receive treatment until disease progression, development of unacceptable AEs, or voluntary withdrawal."
11587272|NCT00737516|Experimental|single arm|HPC, Cord Blood
11587273|NCT00737503|Experimental|1|All eligible children in the experimental arm will be vaccinated with the Rotavirus vaccine
11587274|NCT00737503|No Intervention|2|Children will not be vaccinated with rotavirus vaccine.
11587275|NCT00737490|Active Comparator|1|"Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm"
11587276|NCT00737490|Active Comparator|2|"Simultaneous BiV pacing. Simultaneous Arm"
11587277|NCT00737477|Experimental|Mircera in Renal Anemia|Participants will receive SC methoxy polyethylene glycol-epoetin beta (Mircera) every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 micrograms (mcg) will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
11587278|NCT00737464|Experimental|Mircera|Participant with chronic renal anemia will receive methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.
11587279|NCT00737451||skin itching|
11587280|NCT00737438|Experimental|1|"Initial chemo for ALL pts (ECX + BEV): Epirubicin 50 mg/m2 d1 every 21 days Cisplatin 60 mg/m2 d1 every 21 days, Capecitabine 625 mg/m2 po bid days 2-21 (held for 48 hours prior to FDG-PET/CT in week 3) Bev 15 mg/kg d1 every 21 days (cycle 1 & cycle 2 only) Salvage chemotherapy for metabolic non-responders (DI + BEV): Docetaxel 30 mg/m2 d1, d8 every 21 days, CPT-11 50 mg/m2 d1, d8 every 21 days, Bev 15 mg/kg d1, cycle 2 only 2 cycles are planned prior to resection.
~Pts who aren't Cisplatin candidates (i.e. Creatinine clearance 40-60/cc, older age, marginal PS,etc.) may get oxaliplatin instead of cisplatin after discus with the PI. Oxaliplatin will be admin at 130 mg/m2 on day 1 every 21 days. Pts who aren't able to get Capecitabine (i.e. insurance restriction, unable to swallow, etc.) may get infusional fluorouracil instead of capecitabine after discus with the PI. Fluorouracil will be admin at 200 mg/m2/d x 21 days (held for 48 hours prior to FDGPET/ CT scan in week 3 of cycle 1)."
11587285|NCT00737399|Experimental|1|Lifestyle Counseling with Emotional Freedom Techniques (EFT)
11587286|NCT00737373|Experimental|1|FLOT
11587287|NCT00737373|Active Comparator|2|FLO
11587288|NCT00737360|Experimental|1|
11587289|NCT00737347|No Intervention|1|usual care. Subjects had one 90 minute visit with registered dietitian
11587290|NCT00737347|Active Comparator|2.|Standard care. Subjects had 4 sessions with registered dietitian
11587291|NCT00737347|Active Comparator|3|Intensive care. subjects had 10 visits with registered dietitian
11587292|NCT00737334|Active Comparator|1|All patients will have continuous EEGo, BIS and FORE-SIGHT monitoring, which will be correlated with arterial to jugular venous lactate differences.
11587293|NCT00737321||2- Diabetics without wound (s)|These group of subject will be control arm, included who have good glycemic control diabetic with HbA1c 8.4 or lower and also without any open wounds. Samples will be collected.
11587294|NCT00737321||1-Subjects with diabetes with wound|This group of subjects will have wound and come for couple of follow up visits for saliva collection, biopsy collection and blood draw.
11587295|NCT00737308|Experimental|A|crown for clasp
11587296|NCT00737295|Experimental|US|There will be no experimental or control group, rather each individual will act as his/her own control.
11587297|NCT00737282|Active Comparator|25 mg Proellex|Proellex 25 mg once daily
11587298|NCT00737282|Active Comparator|Proellex 50 mg|Proellex 50 mg once daily
11587299|NCT00737256|Experimental|1|
11587300|NCT00737256|Active Comparator|2|
11587301|NCT00737243|Experimental|Paclitaxel, Carboplatin, Bevacizumab and Erlotinib|Paclitaxel, Carboplatin, Bevacizumab and Erlotinib
11587302|NCT00737243|Other|Treatment determined by physician|Other treatment determined by physician based on molecular profiling assay
11587303|NCT00737217||Parkinson's disease|
11587304|NCT00737217||Normal Controls|
11587305|NCT00737204|Experimental|Armodafinil|Participants will take armodafinil for 4 weeks. The dose will be titrated up from 50mg to 250mg per day as clinically indicated, using 50mg tablets. If responsive, participants will be offered 12 additional weeks of armodafinil.
11587306|NCT00737204|Placebo Comparator|Placebo|Participants will receive placebo pills for 4 weeks. Placebo tablets that match the 50mg active medication tablets will given following the same dosing strategy as Arm 1. The dose will be titrated from 1 placebo tablet daily to 5 tablets daily as clinically indicated. Non-responders to placebo will then be offered 16 weeks of active medication.
11587307|NCT00737191|Active Comparator|Arm I|Patients receive oral opioid and oral placebo once daily for 4 weeks.
11587308|NCT00737191|Experimental|Arm II|Patients receive oral opioid and 2.5 mg oral olanzapine once daily for 4 weeks.
11587309|NCT00737191|Experimental|Arm III|Patients receive oral opioid and 5 mg oral olanzapine once daily for 4 weeks.
11587310|NCT00737178|Active Comparator|Immediate IUD insertion|Insertion of CuT380A at the routine medication abortion follow-up visit one week after initiation of a medication abortion
11587311|NCT00737178|Active Comparator|Delayed IUD insertion|Insertion of CuT380A four to six weeks after initiation of a medication abortion
11587312|NCT00737165|Experimental|Multimodal community intervention|Multimodal suicide prevention program
11587313|NCT00737165|Active Comparator|Community intervention as usual|Suicide prevention program as usual
11587314|NCT00737152|Experimental|1|All subjects will take RAS 130 administered orally in tablet form at a starting dose of 4 mg once a day or 2 mg tablets twice a day.
11587315|NCT00737139|Active Comparator|1|Intra-articular Injection of Marcaine/Epinephrine
11587316|NCT00737139|Active Comparator|2|Intra-articular Injection of Marcaine alone
11587317|NCT00737126|Placebo Comparator|1|Administration of an oral placebo pill
11587318|NCT00737126|Experimental|2|Administration of oral folic acid
11587319|NCT00737100|Experimental|Tiotropium Respimat 2.5 mcg|patient to receive low dose tiotropium once daily
11587320|NCT00737100|Experimental|Tiotropium Respimat 5 mcg|patient to receive high dose tiotropium once daily
11587321|NCT00737100|Placebo Comparator|Placebo Respimat|patient to receive placebo once daily
11587322|NCT00737087|Other|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
11587323|NCT00737061|Experimental|Adiana Transcervical Sterilization System|Single arm treatment
11587324|NCT00737048|Experimental|Tramadol plus Acetaminophen and Placebo|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively, along with two oral capsules of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed greater than or equal to (>=) 50.0 millimeter (mm) on the Visual Analog Scale (VAS), score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
11587325|NCT00737048|Experimental|Tramadol and Placebo|Tramadol hydrochloride will be administered as single oral dosing of two capsules once at a dose of 75 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed >= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
11587326|NCT00737048|Experimental|Acetaminophen and Placebo|Acetaminophen will be administered as single oral dosing of two capsules once at a dose of 650 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed >= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
11587327|NCT00737035|Experimental|1-Intervention|For 16 weeks, participants will have access to an interactive healthcare communication application (IHCA).
11587328|NCT00737035|Active Comparator|2- Control|For 16 weeks, participants will have access to generally available Internet-based information about parenting, trauma, and child development.
11587329|NCT00736996|Experimental|Pioglitazone|"Pioglitazone
~30 - 45mg tablet daily for 6 months"
11587330|NCT00736996|Active Comparator|Endurance Exercise Training|Endurance Exercise Training (EET) Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
11587331|NCT00736996|Placebo Comparator|Placebo|Placebo matching tablet sugar pill daily for 6 months
11587332|NCT00736983|Active Comparator|1|Adalimumab
11587333|NCT00736983|Placebo Comparator|2|ciprofloxacin
11587701|NCT00734331||IBD|Inflammatory bowel disease patients
11587334|NCT00736970|Experimental|1|10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus
11587335|NCT00736957|Experimental|Tramadol HCL plus Acetaminophen|
11587336|NCT00736944|Experimental|1|"Induction chemotherapy followed by Radiation therapy plus Cisplatin
~Induction chemotherapy:
~Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3.
~Post-Induction:
~Radiation - Monday-Friday weeks 1-7 with concurrent Cisplatin 100 mg/m2 IVPB on radiation day 1, 22, and 42."
11587337|NCT00736944|Experimental|2|"Induction chemotherapy followed by Radiation therapy plus Cetuximab
~Induction chemotherapy:
~Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3.
~Post-Induction:
~Radiation - Monday-Friday weeks 1-7 with concurrent Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB"
11587338|NCT00736931|Experimental|1|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
11587339|NCT00736931|Active Comparator|2|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
11587340|NCT00736931|Active Comparator|3|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
11587341|NCT00736931|Placebo Comparator|4|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
11587342|NCT00736918|Experimental|Case management|Case management
11587343|NCT00736918|Active Comparator|Enhanced usual care|Enhanced usual care
11587344|NCT00736892||A|All patients meeting the American European Consensus definition of acute lung injury will be included, regardless of etiology of respiratory failure. Specifically, all patients with rapid onset of acute lung injury not of cardiac origin (no indication of heart failure or a pulmonary capillary wedge pressure of greater than 18 mmHg, with pulmonary infiltrates in all four quadrants and a PaO2/FIO2 of > 200 to <300 mmHg or ≤ 200 mmHg.
11587345|NCT00736879|Experimental|Dapagliflozin 1 mg|Dapagliflozin: 1 mg
11587346|NCT00736879|Experimental|Dapagliflozin 2.5 mg|Dapagliflozin: 2.5 mg
11587347|NCT00736879|Experimental|Dapagliflozin 5 mg|Dapagliflozin: 5 mg
11587348|NCT00736879|Placebo Comparator|Placebo|Placebo: 0 mg
11587349|NCT00736866|Experimental|Acetylcysteine|
11587350|NCT00736866|Placebo Comparator|Control|
11587351|NCT00736853|Experimental|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|
11587352|NCT00736853|Experimental|Tramadol Hydrochloride Plus Acetaminophen (Double Blind)|
11587353|NCT00736853|Placebo Comparator|Placebo (Double-Blind)|
11587354|NCT00736840|Other|CLD (chronic liver disease)|Chronic liver disease subjects with recent biopsy will be tested with a breath tests using a 13C enriched substrate metabolized by their liver
11587355|NCT00736827||Patients with non-septic shock|Postoperative/posttraumatic surgical critically ill patients with non-septic shock with threatening acute renal failure
11587356|NCT00736827||Patients with septic shock|Postoperative/posttraumatic surgical critically ill patients with septic shock with threatening acute renal failure
11587357|NCT00736814|Active Comparator|Arm I|Patients receive standard chemotherapy of docetaxel and carboplatin.
11587358|NCT00736814|Experimental|Arm II, Genotype A1|Patients receive docetaxel and vinorelbine ditartrate.
11587359|NCT00736814|Experimental|Arm II, Genotype A2|Patients receive gemcitabine hydrochloride and vinorelbine ditartrate.
11587360|NCT00736814|Experimental|Arm II, Genotype B1|Patients receive docetaxel and carboplatin.
11587361|NCT00736814|Experimental|Arm II, Genotype B2|Patients receive gemcitabine hydrochloride and carboplatin.
11587362|NCT00736801|Experimental|A|Treatment with Salmeterol for 2 weeks, followed by a treatment with Salmeterol and Fluticasone for 2 weeks.
11587363|NCT00736788|Experimental|1|Four different oral dose levels of a suspension containing AZD1704
11587364|NCT00736788|Placebo Comparator|2|oral suspension
11587365|NCT00736762|Experimental|GPR|Global postural re-education intervention
11587366|NCT00736749||Observational (long-term follow-up)|Within 3 months of enrollment of ALTE05N1, patients receive a mailed packet introducing the LTFC. Patients are asked to complete a patient response form, verify information provided in packet, and update contact and health status information. The Health Status Update Form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. Patients may respond by use of postage prepaid envelopes, email, or 24-hour toll-free telephone number.
11587367|NCT00736736|Active Comparator|Leg Press|Leg Press exercise for 3 times/week and sustain for 8 weeks.
11587368|NCT00736736|Experimental|Hip Exercise|Additional hip abductor and hip external rotator strength training to leg press exercise for people in this group. All participants received exercise for 3 times per week for 8 weeks.
11587369|NCT00736736|No Intervention|Control|Education was given during 8 weeks of study period. After 8 weeks of study, exercise was given as compensation.
11587370|NCT00736723||Patients non-septic shock|Postoperative/posttraumatic critically ill patients with non-septic shock
11587371|NCT00736723||Patients septic shock|Postoperative/posttraumatic critically ill patients with septic shock
11587372|NCT00736710|Experimental|1|
11587373|NCT00736710|Sham Comparator|2|
11587374|NCT00736697|Experimental|1|
11587375|NCT00736684|Active Comparator|1|Proximal Femoral Nail AntirotationTM (PFNA)
11587376|NCT00736684|Other|2|Gamma Nail 3TM (Gamma3)
11587377|NCT00736671||Observational Parkinson's Disease|Observational study of subjects with Parkinson disease
11587378|NCT00736671||Observational Normal Control aubjects|Observational study of normal control subjects
11587379|NCT00736658|Experimental|AZD1386|4 groups receiving a specified volume of the active component AZD1386 at different points of time.
11587380|NCT00736658|Placebo Comparator|Placebo|Included in each dose group
11587381|NCT00736645|Experimental|Arm I|Patients receive oral selenomethionine and oral finasteride once daily for 4-5 weeks.
11587382|NCT00736645|Experimental|Arm II|Patients receive oral placebo and oral finasteride once daily for 4-5 weeks.
11587383|NCT00736645|Experimental|Arm III|Patients receive oral selenomethionine and oral placebo once daily for 4-5 weeks.
11587384|NCT00736645|Placebo Comparator|Arm IV|Patients receive two oral placebos once daily for 4-5 weeks.
11587385|NCT00736632|Placebo Comparator|Placebo|Patients in the control group will receive placebo pills (instead of vitamin D) and calcium carbonate 500 mg twice daily.
11587386|NCT00736632|Active Comparator|Vitamin D|Patients in the vitamin D group will receive cholecalciferol 4000 units daily and calcium carbonate 500 mg twice daily.
11587387|NCT00736619|Experimental|1|"Cetuximab loading dose, 400 mg/m2 intravenously (IV) IMRT, 1 fraction/day, up to total of approximately 70 Gy, over approximately 33 treatment days
~Cetuximab 250 mg/m2 weekly IV X 7 weeks
~Albumin-bound paclitaxel (Abraxane®) weekly IV X 7 weeks, according to dose escalation scheme"
11587388|NCT00736606|Experimental|Period 1|simvastatin
11587389|NCT00736606|Experimental|Period 2|simvastatin + AZD9056
11587390|NCT00736593|Experimental|1|
11587391|NCT00736580|Active Comparator|Blunt Needles|Cesarean Delivery Performed with Blunt-tipped surgical Needles
11587392|NCT00736580|Placebo Comparator|Sharp Needles|Cesarean delivery performed with sharp surgical needles.
11587393|NCT00736541|Experimental|2|
11587394|NCT00736528|Experimental|PF-04447943 05 mg dose|
11587395|NCT00736528|Experimental|PF-04447943 15 mg dose|
11587396|NCT00736528|Experimental|PF-04447943 45 mg dose|
11587397|NCT00736528|Placebo Comparator|Placebo|
11587398|NCT00736515|Experimental|Combination therapy|The subjects allocated into this arm will receive the combination therapy of oral administration of 60~120mg Gliclazide MR (Diamicron MR) and subcutaneous injection of basal insulin (Insulin Glargine Injection, Lantus) once daily for 3 months
11587399|NCT00736515|Active Comparator|monotherapy|The patients allocated into this arm will receive the monotherapy of subcutaneous injection of premixed insulin (Biosynthetic Human Insulin Injection, Novolin 30R) twice daily for 3 months.
11587400|NCT00736502||Patients HIV-1 positive|
11587401|NCT00736489|Experimental|crossover dose 1|AZD3199 120 microgram
11587402|NCT00736489|Experimental|crossover dose 2|AZD3199 480 microgram
11587403|NCT00736489|Experimental|crossover dose 3|AZD3199 1920 microgram
11587404|NCT00736489|Placebo Comparator|crossover dose 4|Placebo
11587405|NCT00736489|Active Comparator|crossover dose 5|Formoterol 9 microgram
11587406|NCT00736489|Active Comparator|crossover dose 6|Formoterol 36 microgram
11587407|NCT00736476|Experimental|1|
11587408|NCT00736476|Placebo Comparator|2|
11587409|NCT00736463|Active Comparator|1|Aimvastatin 80 mg
11587410|NCT00736463|Active Comparator|2|Atorvastatin 80 mg
11587411|NCT00736450|Experimental|Arm I|See Detailed Description
11587412|NCT00736437|Experimental|1|ME-609
11587413|NCT00736437|Placebo Comparator|2|Vehicle
11587414|NCT00736424||1|Have received bilateral AN stimulation of the anterior nucleus (AN) of the thalamus for epilepsy or are receiving it at the time of enrollment
11587415|NCT00736411|Active Comparator|1|IVF
11587416|NCT00736411|Other|II|treatment
11587417|NCT00736398||Observation|Spinal fusion
11587418|NCT00736385|Active Comparator|Metformin|Metformin XR (extended-release) 2000 mg daily
11587419|NCT00736385|Placebo Comparator|Placebo|Placebo capsule
11587420|NCT00736372|Experimental|Investigational Drug|Dose Escalation
11587421|NCT00736346|Active Comparator|1|
11587422|NCT00736346|Active Comparator|2|
11587423|NCT00736346|Active Comparator|3|
11587424|NCT00736346|No Intervention|4|
11587425|NCT00736333||Pegylated Liposomal Doxorubicin|Subjects with metastatic breast cancer
11587426|NCT00736320|Active Comparator|A|2 cycles ABVD followed by 20 Gy IF-RT irrespective of FDG-PET results after chemotherapy
11587427|NCT00736320|Experimental|B|2 cycles ABVD followed by 20 Gy IF-RT if FDG-PET is positive after chemotherapy; 2 cycles ABVD and treatment stop if FDG-PET is negative after chemotherapy
11587428|NCT00736307|Experimental|1|Cultured limbal stem cells Transplantation
11587429|NCT00736294|Experimental|Ramipril|Inhibition Conversion Enzyme
11587430|NCT00736294|Placebo Comparator|Placebo|Placebo
11587431|NCT00736281|No Intervention|Placebo Food Drops|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
11587432|NCT00736281|Active Comparator|Food Drops|Group 2 (intervention group) will receive sublingual immunotherapy (escalation followed by maintenance) with vials containing glycerin and the previously diagnosed food allergens (peptides).
11587433|NCT00736268|Experimental|CST|Telephone-based Enhanced Coping Skills Training (CST)
11587434|NCT00736268|Other|UMC|Usual Medical Care and COPD education and symptom monitoring (UMC)
11587435|NCT00736255|Experimental|Vyvanse and transdermal nicotine patch|The first group will receive LDX/SPD489 titrated up to 70 mg qd for 4 weeks after the identified quit date. Subjects will continue to receive NRT 21 mg at week 1 post quit date, then 14mg at week 2 post quit date and 7 at weeks 3 and 4 post quit date.
11587436|NCT00736255|Placebo Comparator|Placebo and transdermal nicotine patch|The second group will receive matching placebo and NRT after the quit date.
11587437|NCT00736242||PEG-IFN alfa-2b + RBV|Participants received a combination of PEG-IFN alfa-2b plus RBV according to routine clinical practice and locally-approved product recommendations for a minimum of 12 weeks. No investigational medicinal product was provided by the sponsor.
11587438|NCT00736229|Experimental|Exenatide|0.05 µg/min liquid bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
11587439|NCT00736203||A|non-smokers
11587440|NCT00736190|Experimental|TDF|300-mg tablet (marketed formulation) taken orally once daily
11587441|NCT00736177|Active Comparator|Control|Patients in the control group will undergo conventional IVF cycles with fresh blastocyst transfer.
11587442|NCT00736177|Experimental|Test group|Patients in the Test group will have their embryos cryopreserved for transfer in a second cycle.
11587443|NCT00736164|Experimental|Arm I|Patients receive oral selenomethionine once daily for 8-9 weeks.
11587444|NCT00736164|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 8-9 weeks.
11587445|NCT00736151|Experimental|1|Ralfinamide administered orally at rising doses of 80 - 320 mg/day
11587446|NCT00736151|Active Comparator|2|Placebo controlled with randomization of 2:1
11587447|NCT00736138|Active Comparator|1|training and pellots
11587448|NCT00736138|No Intervention|2|control
11587449|NCT00736125|Active Comparator|1|
11587450|NCT00736125|Active Comparator|2|
11587451|NCT00736112|Experimental|BMT and food allergy|trial subjects will receive food allergy testing and management in conjunction with BMT (Bilateral Myringotomy with Tympanostomy Tubes). Food allergy management involves parental education on how to avoid the specific offending foods.
11587452|NCT00736112|Experimental|BMT and adenoidectomy|"involves BMT (Bilateral Myringotomy with Tympanostomy Tubes), adenoidectomy, and food allergy testing and management.
~Food allergy management involves parental education on how to avoid the specific offending foods."
11587453|NCT00736112|Active Comparator|BMT alone|The standard protocol for children presenting with initial Chronic OME is to perform a BMT (Bilateral Myringotomy with Tympanostomy Tubes).
11587454|NCT00736099|Experimental|linagliptin 5 mg|open label
11587455|NCT00736099|Experimental|linagliptin 5 mg and pioglitazone 30 mg|open label
11587456|NCT00736086||1|Subjects who are ambulated early post-percutaneous, cardiac or peripheral vascular, diagnostic catheterization procedures with the use of StarClose® Vascular Closure System in the femoral artery after diagnostic catheterization procedure.
11587457|NCT00736073|Active Comparator|1|aprepitant
11587458|NCT00736073|Placebo Comparator|2|Placebo
11587459|NCT00736060||1|Sickle cell anemia
11587460|NCT00736060||2|Sickle cell thalassemia
11587461|NCT00736047|Active Comparator|1|
11587462|NCT00736047|Placebo Comparator|2|
11587463|NCT00736021|Experimental|A|Single arm (open label study): Provide twelve weeks of treatment with high does (40 mg daily) of escitalopram to trauma survivors with chronic PTSD.
11587464|NCT00736008||A|Patients with thromboembolic events
11587465|NCT00735995|Experimental|A|Individual CBT
11587466|NCT00735995|Experimental|B|Group CBT
11587467|NCT00735995|No Intervention|C|Waiting-list control
11587468|NCT00735930|Experimental|Treatment (alvocidib, lenalidomide)|Patients receive alvocidib IV over 4.5 hours on days 1, 8, and 15 in course 1 followed by a week of rest. Beginning in course 2 and all subsequent courses, patients receive lenalidomide PO QD on days 1-21 and alvocidib IV over 4.5 hours on days 3, 10, and 17. Treatment repeats every 35 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
11587469|NCT00735917|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO QD on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11587470|NCT00735904|Experimental|AG-013736/Cisplatin/Gemcitabine|
11587471|NCT00735878|Experimental|ABT-751 100 mg and Carboplatin|100 mg BID ABT-751 orally for 7 days. Carboplatin AUC 4.5 once every 21 days.
11587472|NCT00735878|Experimental|ABT-751 125 mg and Carboplatin|125 mg BID ABT-751orally for 7 days. Carboplatin AUC 4.5 or 6 once every 21 days.
11587473|NCT00735878|Experimental|ABT-751 150 mg and Carboplatin|150 mg BID ABT-751orally for 7 days. Carboplatin AUC 6 once every 21 days.
11587474|NCT00735865|Active Comparator|1|
11587475|NCT00735865|Active Comparator|2|
11587476|NCT00735865|Active Comparator|3|
11587477|NCT00735865|Active Comparator|4|
11587478|NCT00735839|Experimental|V710|V710 vaccination (60 mcg) single dose on Day 1
11587479|NCT00735839|Placebo Comparator|Placebo|Placebo single dose on Day 1
11587480|NCT00735826|Experimental|Vorinostat 400 mg|Vorinostat will be administered orally once daily in an open-labeled unblinded manner to all subjects enrolled in the study. Subjects will received 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection.
11587481|NCT00735813|Experimental|A|Tunneled central venous catheters locked with Taurolock
11587482|NCT00735813|Active Comparator|B|Tunneled central venous catheter locked with heparin
11587483|NCT00735800|Active Comparator|Supportive Counseling|
11587484|NCT00735800|Experimental|Problem-Solving|
11587485|NCT00735787|Placebo Comparator|Placebo/Adalimumab|"Loading dose of 2 placebo injections at Week 0 and placebo injections every other week (eow) from Week 1 through Week 15.
~In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27."
11587486|NCT00735787|Active Comparator|Adalimumab|80 mg adalimumab loading dose at Week 0 and 40 mg adalimumab eow from Weeks 1 through 15. For subjects who continued in the second period of the study, subjects received 2 placebo injections at Week 16 to maintain the blind. Open-label 40 mg adalimumab eow was administered from Week 17 through Week 27.
11587487|NCT00735774|Experimental|11C-ORM-13070|
11587488|NCT00735761|Experimental|1|ME-609 (5% acyclovir and 1% hydrocortisone)
11587489|NCT00735761|Active Comparator|2|Acyclovir in ME-609 vehicle (5% acyclovir)
11587490|NCT00735748|Experimental|1|Tramadol per os (Tradonal Odis® orodispersible tablets)
11587491|NCT00735748|Active Comparator|2|Tramadol IV (Tradonal® IV)
11587492|NCT00735722|Active Comparator|Concomitant HIFU ablation|HIFU AF Ablation
11587493|NCT00735722|No Intervention|Best medical treatment|Best medical treatment
11587494|NCT00735709|Experimental|Vortioxetine 1 mg|Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks.
11587495|NCT00735709|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks.
11587496|NCT00735709|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up 8 weeks.
11587497|NCT00735709|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
11587498|NCT00735696|Experimental|ramucirumab + paclitaxel + carboplatin|"Participants will receive ramucirumab in combination with paclitaxel and carboplatin until disease progression, the development of an unacceptable toxicity, or other withdrawal criteria, for up to six cycles (3 weeks per cycle).
~In the absence of any withdrawal criteria, participants will continue to receive ramucirumab monotherapy every 3 weeks, provided there is ongoing evidence of benefit upon review every 6 weeks."
11587499|NCT00735683|Placebo Comparator|1|
11587500|NCT00735683|Experimental|2|
11587501|NCT00735683|Experimental|3|
11587502|NCT00735683|Experimental|4|
11587503|NCT00735683|Experimental|5|
11587504|NCT00735683|Experimental|6|
11587505|NCT00735670|Experimental|Venlafaxine|Venlafaxine HCl is classified as a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) and has been approved by the FDA for the treatment of major depressive disorder. The treatment group will receive a sub-therapeutic dose over a two week period, with a two week titration, starting at 37.5 mg up to a maximum dose of 150 mg per day. At the end of the treatment period, dosage was tapered down in a step-wise fashion over a period of three weeks; 75 mg. for two weeks and 37.5 mg. for one week. While this was the standard protocol, study drug tapering was individualized based on side effects and the clinical judgment of the prescriber.
11587506|NCT00735670|Placebo Comparator|Placebo|Placebo capsules were compounded by filling a matching gelatin capsule with lactose. Titration up and down followed the same schedule as the treatment group.
11587507|NCT00735657|Active Comparator|Group 1|Control
11587508|NCT00735657|Active Comparator|Group 2|Block with short needle
11587509|NCT00735644|Experimental|JE-CV GPO MBP (Lot 1)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 1.
11587510|NCT00735644|Experimental|JE-CV GPO MBP (Lot 2)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 2.
11587511|NCT00735644|Experimental|JE-CV GPO MBP (Lot 3)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 3.
11587512|NCT00735644|Active Comparator|JE-CV WRAIR (Group 4)|Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)
11587513|NCT00735644|Sham Comparator|Hepatitis A (Group 5)|Participants 12 to 18 months of age randomized to receive Hepatitis A vaccine
11587514|NCT00735631|Experimental|1|The single-input-single-output (SISO) model-based predictive closed-loop system will be used to guide patient-individualized ICU sedation with propofol
11587515|NCT00735618|Experimental|Guided Relaxation|Heart rate variability (HRV) high frequency (HF) spectral analysis, before and after a 15 minute, one-time, guided relaxation program
11587516|NCT00735605|Active Comparator|1:BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
11587517|NCT00735605|Active Comparator|2 BTX A|Injected with BTX-A in the left lateral position; anesthesia was not required
11587518|NCT00735605|Active Comparator|3: PDPR|Inner half of puborectalis sling was divided on each side by using a scalpel NO
11587519|NCT00735592||A|Children discharged with the recommendation of performing a follow up X rays after lobar pneumonia
11587520|NCT00735579||Study group|Patients undergoing major abdominal surgery
11587521|NCT00735553|Active Comparator|25 mg Proellex|25 mg oral daily dose of Proellex
11587522|NCT00735553|Active Comparator|50 mg Proellex|50 mg oral daily dose of Proellex
11587523|NCT00735553|Placebo Comparator|placebo|oral daily dose of placebo
11587524|NCT00735540||A|Acute organic diseases
11587525|NCT00735540||B|Patients with chronic diseases
11587526|NCT00735540||C|Patients with psychiatric diagnosis
11587527|NCT00735527|Experimental|1|Intra-nasal lorazepam 0.1 mg/kg (max 4 mg)
11587528|NCT00735527|Active Comparator|2|Intra-venous lorazepam 0.1 mg/kg (max 4 mg)
11587529|NCT00735501||A|
11587530|NCT00735488||A|Thalassemia Minor carriers
11587531|NCT00735488||B|Sickle cell carriers
11587532|NCT00735475|Experimental|Afluria®|
11587533|NCT00735475|Active Comparator|Fluzone®|
11587534|NCT00735462|Experimental|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks
11587535|NCT00735462|Experimental|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
11587536|NCT00735462|Placebo Comparator|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks.
11587537|NCT00735449|Active Comparator|Combigan ®|Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%) adjunctive to Xalatan® (latanoprost 0.005%)
11587538|NCT00735449|Active Comparator|Timolol Maleate 0.5%|Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)
11587539|NCT00735436|Other|Gliadel/Avastin/CPT-11|Gliadel/Avastin/CPT-11
11587540|NCT00735423||No groups|IDE used for outcome measurement not intervention
11587541|NCT00735410|Experimental|1|
11587542|NCT00735397|Experimental|Perampanel|Participants previously receiving perampanel/placebo in the double blind-study, were titrated to receive perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years.
11587543|NCT00735384||Patients with critical illness myopathy|Patients with,e.g., sepsis, with secondary myopathy
11587544|NCT00735384||Patients with Primary Myopathies|Patients with primary myopathy, e.g., Duchenne Muscular Dystrophy, Myotonia
11587545|NCT00735371|Active Comparator|Lisdexamfetamine Dimesylate (LDX) 30 mg|
11587546|NCT00735371|Active Comparator|LDX 50 mg|
11587547|NCT00735371|Active Comparator|LDX 70 mg|
11587548|NCT00735371|Placebo Comparator|Placebo|
11587549|NCT00735358|Active Comparator|A|Single dose cyanoacrylate in one shot
11587550|NCT00735358|Experimental|B|Double doses cyanoacrylate in one shot
11587551|NCT00735345|Experimental|Treatment Arm|Chemo induction therapy followed by chemoradiotherapy and surgical resection or definitive radiotherapy
11587552|NCT00735332|Experimental|Single-Arm|
11588137|NCT00731393|Active Comparator|Group D|Subjects aged 3 to 6 years.
11587553|NCT00735319|No Intervention|A|In the 7 control Capital Health community health centers, babies will be followed up according to the current policy. Bilirubin determinations will be performed at the discretion of the visiting nurse if the infant is inappropriately jaundiced or at the request of the physician if risk factors are present. Transcutaneous Bilirubinometers will not be available in each of these 7 centers for all the duration of the study.
11587554|NCT00735319|Experimental|B|For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained.Depending on the level of bilirubin obtained and whether risk factors (gestational age < 38 weeks, blood group incompatibility with DAT positive) are present or not, a different management plan will apply. The algorithm is based on curves established by Bhutani et al to predict the risk of significant hyperbilirubinemia based on predischarge bilirubin measurements.
11587555|NCT00735306|Experimental|1|Avastin, Tarceva and Radiation Therapy
11587556|NCT00735293|Other|Treatment|There is only one arm to this study. All patients will receive treatment with the VASER for their axillary hyperhidrosis/bromidrosis
11587557|NCT00735280|Experimental|Reduced dose of unfractionated heparin|
11587558|NCT00735254|Active Comparator|Pulsed dye laser|PDL Patient will be have scar treated with pulsed dye laser.
11587559|NCT00735254|Active Comparator|Affirm laser|Patient will be have scar treated with Affirm Laser
11587560|NCT00735254|Active Comparator|combined PDL and Affirm Lasers|Patient will be have scar treated with combined Affirm + PDL
11587561|NCT00735254|Placebo Comparator|Placebo|Patient will be have scar treated with Placebo
11587562|NCT00735228|Active Comparator|1|Perioperative blood glucose was controlled within the normal levels (80-110 mg/dL) by artificial pancreas.
11587563|NCT00735228|Active Comparator|2|Perioperative blood glucose concentration was controlled within the range from 140 to 160 mg/dL by artificial pancreas.
11587564|NCT00735189|Experimental|1|Patient continues to receive anticoagulation care from the Anticoagulation Management Service
11587565|NCT00735189|Active Comparator|2|Patient receives anticoagulation care from their usual primary care physician
11587566|NCT00735176|Experimental|Artificial Cervical Disc|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
11587567|NCT00735176|Active Comparator|ACDF|Anterior cervical discectomy and fusion (ACDF)
11587568|NCT00735163|Experimental|A|improved model predictive control algorithm (eMPC) for glycaemic control in ICU patients
11587569|NCT00735150||1|25 female and 5 male BRCA carriers
11587570|NCT00735137|No Intervention|A|Expectant management in twin pregnancy
11587571|NCT00735137|Experimental|B|Vaginal pessary treatment in twin pregnancy
11587572|NCT00735137|No Intervention|C|Expectant management in singleton pregnancy with short cervix
11587573|NCT00735137|Experimental|D|Vaginal pessary treatment in singleton pregnancy with short cervix
11587574|NCT00735124|Active Comparator|Single pre-op dose of Gabapentine|Active treatment with the study drug
11587575|NCT00735124|Placebo Comparator|Placebo|Placebo arm for blinding the medication
11587576|NCT00735111|Experimental|Karnofsky Performance Status Score|
11587577|NCT00735098|Experimental|1|KBA exercise protocol
11587578|NCT00735098|Experimental|2|strength training exercise protocol
11587579|NCT00735098|Experimental|3|KBA and strength training protocol
11587580|NCT00735098|Sham Comparator|4|
11587581|NCT00735085|Experimental|SLV334|
11587582|NCT00735085|Placebo Comparator|Placebo|
11587583|NCT00735072|Experimental|Maraviroc|Maraviroc (dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).
11587584|NCT00735072|Placebo Comparator|Placebo|Placebo (dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).
11587585|NCT00735059|Experimental|1|treatment with dialyzer ELISIO 170H
11587586|NCT00735059|Active Comparator|2|treatment with dialyzer PES-170DS
11587587|NCT00735046||1|Intervention
11587588|NCT00735046||2|control
11587589|NCT00735020|Experimental|1|
11587590|NCT00735020|Active Comparator|2|
11587591|NCT00735007|Experimental|1|
11587592|NCT00734994|Experimental|Hyperthermia system, Mitomycin C|Pilot study single arm study to test the safety, tolerability and clinical benefit of regional hyperthermia and mitomycin-C intravesical chemotherapy to treat non-invasive Transitional Cell carcinoma (TCC) of the bladder that has recurred after standard resection and adjuvant therapy.
11587593|NCT00734968|Experimental|Treatment|Patients randomly assigned to be treated with nitrofurantoin 100mg PO BID x 3 days post-operatively
11587594|NCT00734968|Placebo Comparator|Placebo|Arm randomly assigned to receive placebo 1 tablet PO BID x 3 days post-operatively.The incidence of UTI in this group will be compared with group one (1)
11587595|NCT00734955|Experimental|Reduction Mammoplasty|Patients undergoing reduction mammoplasty
11587596|NCT00734955|Experimental|Mastectomy|Patients undergoing mastectomy
11587597|NCT00734955|Experimental|Lumpectomy|Patients undergoing a lumpectomy
11587598|NCT00734942|Experimental|1|intervention group
11587599|NCT00734942|No Intervention|2|waiting group
11587600|NCT00734929|Experimental|1|Aprepitant 40 mg preoperatively + dexamethasone 10 mg after induction of anesthesia
11587601|NCT00734929|Active Comparator|2|Ondansetron 4 mg within 30 min of the end of surgery + Dexamethasone 10 mg after induction of anesthesia
11587602|NCT00734916|Active Comparator|1|Omegaven 10%
11587603|NCT00734916|Active Comparator|2|Intralipid 10%
11587604|NCT00734916|Placebo Comparator|3|Placebo
11587605|NCT00734903|Experimental|A Woman's Path to Recovery (WPR)|A gender-focused approach to addiction recovery
11587606|NCT00734903|Active Comparator|12-Step Facilitation (TSF)|An evidence-based, non-gender-focused approach to addiction recovery
11587702|NCT00734331||Control|Average risk patients undergoing screening colonoscopy
11588233|NCT00730743|No Intervention|2|No clamp group
11587607|NCT00734877|Active Comparator|ARM A|The standard TT3 Regimen (S-TT3) will consist of 2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
11587608|NCT00734877|Experimental|ARM B|The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD- PACE
11587609|NCT00734864|Other|1|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs).
11587610|NCT00734864|Other|2|Subjects NOT taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs).
11587611|NCT00734851|Experimental|Multimodality|4 cycles of 70 mg/m2 Docetaxel + 37.5 mg daily Sunitinib for 14 days followed by a 7 day break for 3 cycles + external beam radiotherapy to 66 Gray over 6-7 weeks
11587612|NCT00734838|Experimental|Core needle biopsy|Patients needing a needle biopsy of a breast mass
11587613|NCT00734838|Placebo Comparator|Reduction mammoplasty|Any patients scheduled for a reduction mammoplasty who would like to participate in a study to better understand breast cancer
11587614|NCT00734825|Active Comparator|1|IV contrast
11587615|NCT00734825|Active Comparator|2|IV contrast and oral contrast
11587616|NCT00734812|Active Comparator|1|Laparoscopic supracervical hysterectomy (LSH)
11587617|NCT00734812|Active Comparator|2|Total Laparoscopic Hysterectomy (TLH)
11587618|NCT00734799|No Intervention|2|Usual Care/Wait-List Control
11587619|NCT00734799|Experimental|1|Sleep Intervention for PTSD (SIP)
11587620|NCT00734786|Placebo Comparator|2|Volunteers will be their own control by randomly receiving the active on one face side and the placebo on the opposite one.
11587621|NCT00734760|Experimental|A|a tailored, face-to-face education and counseling intervention with a nurse lasting approximately 45 minutes, followed by a telephonic reinforcement in 30 days
11587622|NCT00734760|No Intervention|B|care-as-usual with data collection at the same time points as the experimental group
11587623|NCT00734747|Experimental|Medigus SRS Endoscopic Stapling System|Endoluminal fundoplication for the treatment of GERD
11587624|NCT00734734|Experimental|1|
11587625|NCT00734721|Active Comparator|A|Presentation of factual information video
11587626|NCT00734721|Active Comparator|B|Presentation of injection syringe/needle
11587627|NCT00734721|Active Comparator|C|Presentation of emotional information video
11587628|NCT00734721|Active Comparator|D|Stress relaxation music
11587629|NCT00734708|Experimental|A|positive drug (0.3% Trafermin contained)
11587630|NCT00734708|Placebo Comparator|P|control
11587631|NCT00734695|Experimental|1|Baruch Pade Medical Center
11587632|NCT00734695|Active Comparator|2|Rambam Medical Center
11587633|NCT00734695|Active Comparator|3|Soroka Medical Center
11587634|NCT00734682|Experimental|Nanoliposomal CPT-11|All patients are treated with nanoliposomal CPT-11
11587635|NCT00734669||1|Type 2 diabetic patients on glibenclamide at individual dosage up to 7 mg/day for more than one year prone to hypoglycemic events
11587636|NCT00734656|Placebo Comparator|Placebo medication + placebo alcohol|
11587637|NCT00734656|Experimental|Placebo Medication + 0.8 gr/kg Ethanol|
11587638|NCT00734656|Experimental|4 mg Dutasteride + Placebo Alcohol|
11587639|NCT00734656|Experimental|4 mg Dutasteride + 0.8 gr/kg Ethanol|
11587640|NCT00734630|Active Comparator|Nebivolol|Nebivolol 5 mg, 5 mg nontrade tablets, oral administration Nebivolol 10 mg, 10 mg nontrade tablets, oral administration Nebivolol 20 mg, 20 mg nontrade tablets, oral administration Nebivolol 40 mg (two 20 mg nontrade tablets), oral administration
11587641|NCT00734630|Placebo Comparator|Placebo|Matching placebo tablets, oral administration
11587642|NCT00734617|Experimental|Less Dependent Smokers|
11587643|NCT00734617|Experimental|More Dependent Smokers|
11587644|NCT00734604|Experimental|T(OaD)/S(PRN)/T(PRN)|Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks
11587645|NCT00734604|Experimental|T(OaD)/T(PRN)/S(PRN)|Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks
11587646|NCT00734604|Experimental|S(PRN)/T(OaD)/T(PRN)|Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks
11587647|NCT00734604|Experimental|S(PRN)/T(PRN)/T(OaD)|Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks
11587648|NCT00734604|Experimental|T(PRN)/T(OaD)/S(PRN)|Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks
11587649|NCT00734604|Experimental|T(PRN)/S(PRN)/T(OaD)|Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks
11587650|NCT00734591||Previously treated with Exubera|
11587651|NCT00734591||Previously treated with comparator|Subjects who had been treated with a comparator (other diabetes treatment such as injected insulin) in a prior Exubera controlled trial.
11587652|NCT00734578|Experimental|SPD503-AM|SPD503 (Guanfacine Extended Release)
11587653|NCT00734578|Experimental|SPD503-PM|SPD503 (Guanfacine Extended Release)
11587654|NCT00734578|Placebo Comparator|Placebo|
11587655|NCT00734565|Experimental|1|
11587656|NCT00734552|Active Comparator|1|α-Keto Acid plus low protein diet
11587657|NCT00734552|Other|2|Normal protein diet
11587658|NCT00734539|Experimental|1|fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
11587659|NCT00734539|Placebo Comparator|2|Placebo IV or PO twice weekly for 6 weeks
11587703|NCT00734318|Experimental|Flutiform 250/10 micrograms|Flutiform 250/10 micrograms (2 puffs bd)
11587704|NCT00734318|Experimental|Flutiform 50/5 micrograms|Flutiform 50/5 micrograms (2 puffs bd)
11587705|NCT00734318|Active Comparator|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|Flixotide pMDI 250 mcg (2 puffs bd) + foradil pMDI 24 50/5 mcg (bd)
11587660|NCT00734526|Experimental|Dose Level 1|"Temozolomide + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle
~Temozolomide 75mg/m^2 daily during radiation therapy, and 150mg/m^2 in the first cycle of adjuvant therapy. Dose Level 1 will receive sorafenib in the adjuvant phase (following radiation therapy) at the dose of 400mg BID in combination with standard dose temozolomide 150-200 mg/m^2 two days out of 28 day cycle. Radiotherapy 2.0 Grey (Gy)/day given daily 5 days per week for total of 60.0 Gy over 6 weeks."
11587661|NCT00734526|Experimental|2|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle + Higher Dose Sorafenib
11587662|NCT00734526|Experimental|3|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Lower Dose Sorafenib
11587663|NCT00734526|Experimental|4|Temozolomide + Higher Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Higher Dose Sorafenib
11587664|NCT00734513|Experimental|1|Partner-assisted Emotional Disclosure
11587665|NCT00734513|Active Comparator|2|Cancer Education
11587666|NCT00734500|Experimental|Treatment|Treatment
11587667|NCT00734487||1. AREDS2 subjects|Subjects enrolled in the AREDS2 clinical trial with a diagnosis of age-related macular degeneration.
11587668|NCT00734487||2. Controls|Age-matched subjects without retinal pathology
11587669|NCT00734474|Experimental|3.0 mg LY2189265|"LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks
~Placebo: tablet, administered orally, once daily for up to 104 weeks
~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
11587670|NCT00734474|Experimental|2.0 mg LY2189265|"LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks
~Placebo: tablet, administered orally, once daily for up to 104 weeks
~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
11587671|NCT00734474|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks
~Placebo: tablet, administered orally, once daily for up to 104 weeks
~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
11587672|NCT00734474|Experimental|1.0 mg LY2189265|"LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks
~Placebo: tablet, administered orally, once daily for up to 104 weeks
~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
11587673|NCT00734474|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks
~Placebo: tablet, administered orally, once daily for up to 104 weeks
~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
11587674|NCT00734474|Experimental|0.5 mg LY2189265|"LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks
~Placebo: tablet, administered orally, once daily for up to 104 weeks
~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
11587675|NCT00734474|Experimental|0.25 mg LY2189265|"LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks
~Placebo: tablet, administered orally, once daily for up to 104 weeks
~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
11587676|NCT00734474|Active Comparator|Sitagliptin|"Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks
~Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
~Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks"
11587677|NCT00734474|Placebo Comparator|Placebo/Sitagliptin (Baseline Through 104 Weeks)|"Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks
~Placebo: tablet, administered orally, once daily for 26 weeks
~Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks
~Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks"
11587678|NCT00734461|Placebo Comparator|Placebo|Placebo, single dose
11587679|NCT00734461|Active Comparator|Oxycodone 20 mg|Oxycodone 20 mg single dose tablet
11587680|NCT00734461|Active Comparator|Oxycodone 40 mg|Oxycodone 40 mg single dose tablet
11587681|NCT00734461|Experimental|PTI-801 20/.001 mg|Oxycodone 20 mg / Naltrexone 0.001 mg
11587682|NCT00734461|Experimental|PTI-801 40/.001 mg|Oxycodone 40 mg / Naltrexone 0.001 mg
11587683|NCT00734461|Experimental|PTI-801 20/.0001 mg|Oxycodone 40 mg / Naltrexone 0.0001 mg
11587684|NCT00734461|Experimental|PTI-801 40/.0001 mg|Oxycodone 40 mg / Naltrexone 0.0001 mg
11587685|NCT00734448|Experimental|A,1|Gestational diabetes patients who take myo-inositol
11587686|NCT00734435|Active Comparator|1|Zonisamide SR 360 mg and olanzapine 10-20 mg daily
11587687|NCT00734435|Placebo Comparator|2|Placebo and olanzapine 10-20 mg daily
11587688|NCT00734422|Experimental|VRET with yohimbine|Virtual Reality Exposure Therapy will be combined with the administration of yohimbine hydrochloride
11587689|NCT00734422|Placebo Comparator|VRET with placebo|Virtual Reality Exposure Therapy will be combined with an inactive placebo pill (Albochin).
11587690|NCT00734409|Experimental|RASS plus (BIS)|Participants in this arm will receive sedation assessment with the RASS scale augmented with Bispectral Index (BIS) Monitor
11587691|NCT00734409|No Intervention|RASS only|Participants will receive sedation assessment only using the RASS scale which is the standard of care at our institution
11587692|NCT00734383|Experimental|1|Propofol Cardioprotection
11587693|NCT00734383|Experimental|2|Volatile Anesthesia Preconditioning
11587694|NCT00734370|Experimental|VRET|Virtual Reality Exposure Therapy for agoraphobic participants
11587695|NCT00734370|Active Comparator|Exposure in vivo|Standard exposure in vivo for panic disorder
11587696|NCT00734370|No Intervention|Wait-list control|Wait-list control group. Participants from this arm are randomized to the two active conditions after 10 weeks of waiting.
11587697|NCT00734357|Experimental|Isovue Arm|Subjects with a clinically scheduled CT examination will be given the contrast Isovue. The investigators of this study will determine which contrast medication subjects will receive using randomization.
11587698|NCT00734357|Experimental|Omnipaque Arm|Subjects with a clinically scheduled CT examination will be given the contrast Omnipaque. The investigators of this study will determine which contrast medication subjects will receive using randomization
11587699|NCT00734344|Active Comparator|Arm 1|Raltegravir plus Truvada
11587706|NCT00734318|Active Comparator|Flixotide pMDI 250 micrograms|Flixatide pMDI 250 micrograms (2 puffs bd)
11587707|NCT00734305|Experimental|Dose Escalation|Cohorts of escalating doses of MM-121 administered IV QW to determine MTD or RP2D + expansion cohort at MTD/RP2D
11587708|NCT00734292|Placebo Comparator|I|"Period 1 Treatment Regimen A: FlutiForm 250/10 ug
~Period 2 Treatment Regimen B: FlutiForm 100/10 ug
~Period 3 Treatment Regimen C: placebo"
11587709|NCT00734292|Placebo Comparator|II|"Period 1 Treatment Regimen B: FlutiForm 100/10 ug
~Period 2 Treatment Regimen C: placebo
~Period 3 Treatment Regimen A: FlutiForm 250/10 ug"
11587710|NCT00734292|Placebo Comparator|III|"Period 1 Treatment Regimen C: placebo
~Period 2 Treatment Regimen A: FlutiForm 250/10 ug
~Period 3 Treatment Regimen B: FlutiForm 100/10 ug"
11587711|NCT00734279|Experimental|1|Girls with Early Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
11587712|NCT00734279|Experimental|2|Girls with Delayed Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
11587713|NCT00734279|Experimental|3|Boys with Early Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
11587714|NCT00734279|Experimental|4|Boys with Delayed Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
11587715|NCT00734266||1 Control|Patients with and without chronic obstructive pulmonary disease diagnosed before scheduling for cardiac surgery.
11587716|NCT00734266||2 COPD|Patients with and without chronic obstructive pulmonary disease diagnosed before scheduling for cardiac surgery.
11587717|NCT00734253|Experimental|1|Pyridorin 150 mg bid
11587718|NCT00734253|Experimental|2|Pyridorin 300 mg bid
11587719|NCT00734253|Placebo Comparator|3|Placebo bid
11587720|NCT00734240|Experimental|A|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 355312 or placebo
11587721|NCT00734240|Experimental|B|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
11587722|NCT00734240|Experimental|C|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
11587723|NCT00734240|Experimental|AA|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving 353512 or placebo
11587724|NCT00734240|Experimental|BB|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
11587725|NCT00734240|Experimental|CC|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
11587726|NCT00734240|Experimental|G|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
11587727|NCT00734240|Experimental|H|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
11587728|NCT00734240|Experimental|I|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
11587729|NCT00734240|Experimental|GG|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
11587730|NCT00734240|Experimental|HH|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
11587731|NCT00734240|Experimental|II|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
11587732|NCT00734240|Experimental|F (100 mg)|single-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
11587733|NCT00734240|Experimental|Dose-Titration 1|multiple-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
11587734|NCT00734240|Experimental|F (200 mg)|single-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
11587735|NCT00734240|Experimental|Dose-Titration 7|multiple-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
11587736|NCT00734227|Active Comparator|A|"Randomization: By the blind card method to TIPS or emergency portacaval shunt. Diagnostic Workup: Completed within 6hr. Rapidity of Therapy: Within 24 hr. Failure of Therapy: Bleeding requiring >6u PRBC in first 7 days, or 8 units PRBC during 12 months.
~Rescue Crossover Therapy: When primary therapy has failed. Followup: Lifelong data collection on line, analysis by biostatistician Florin Vaida, PhD. External Advisory, Data Monitoring and Safety Committee by 3 senior academicians.
~Procedure: Emergency portacaval shunt."
11587737|NCT00734227|Active Comparator|B|Procedure: Emergency TIPS.
11587738|NCT00734214|Experimental|0.9% NaCl|
11587739|NCT00734214|Active Comparator|0.45% NaCl|
11587740|NCT00734201|Experimental|1|Randomised to a parallel group comparison of either one of four doses of study drug (1mg, 2mg, 5mg, 25mg) or placebo. Dosed once daily for 28 days
11587741|NCT00734175|Experimental|1|Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
11587742|NCT00734162|Experimental|Tenofovir disoproxil fumarate (TDF)|
11587743|NCT00734162|Placebo Comparator|Placebo|
11587744|NCT00734149|Experimental|Bortezomib+Melphalan+Prednisone|Bortezomib 1.3 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 4, 8, and 11 of a 28 day cycle. Six cycles are planned. On days when both melphalan and bortezomib are given, melphalan is given at least one hour prior to bortezomib. Melphalan 6 mg/m2 is administered orally on an empty stomach daily on days 1-7 of each cycle. Prednisone 60 mg/m2 is administered orally daily on days 1-7 of each cycle.
11587745|NCT00734136|Other|1|50 surgical subjects undergoing either liver transplantation or hepatic resection
11587746|NCT00734136|Other|2|50 Subjects with Liver disease who are are not surgical candidates
11587747|NCT00734123|Experimental|1|Participants assigned to the intensive arm (1) will be targeted to specified therapeutic aims (concerning lipids, blood pressure and antiplatelets)according to the results of carotid ultrasound and ankle-brachial index.
11587748|NCT00734123|Active Comparator|2|Participants assigned to control group (2) will be followed according to the clinical standard of care.
11587749|NCT00734110|Experimental|P.F.C. Sigma Total Knee Replacement System|Primary total knee arthroplasty using the fixed bearing P.F.C. Sigma Total Knee Replacement System.
11587750|NCT00734097|Experimental|Nexium 40 mgs|
11587751|NCT00734084|Other|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
11587752|NCT00734071|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
11588640|NCT00728065|Experimental|6|Rice Milk (control)
11587753|NCT00734071|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
11587754|NCT00734058|Experimental|Persistent AF|Treatment arm to be compared with historical control.
11587755|NCT00734045||1|Subjects with diagnosed congestive heart failure
11587756|NCT00734045||2|Subjects not diagnosed with congestive heart failure
11587757|NCT00734032|Placebo Comparator|Placebo Group|Matched Placebo
11587758|NCT00734032|Experimental|SB480848 40mg Group|SB480848 40mg/day
11587759|NCT00734032|Experimental|SB480848 80mg Group|SB480848 80mg/day
11587760|NCT00734032|Experimental|SB480848 160mg Group|SB480848 160mg/day
11587761|NCT00734019||P.F.C. Sigma Knee System|Orthopaedic implant for primary total knee replacement with a cobalt-chrome tibial tray and a moderately cross-linked polyethylene tibial insert
11587762|NCT00733993|Experimental|1 Caffeine 150 mg|Caffeine 150 mg
11587763|NCT00733993|Placebo Comparator|2 Placebo|Placebo
11587764|NCT00733993|Experimental|3 Amphetamine|Amphetamine
11587765|NCT00733993|Experimental|4 Caffeine 300 mg|Caffeine 300 mg
11587766|NCT00733980|Experimental|GSK561679 arm|Double blind GSK561679
11587767|NCT00733980|Placebo Comparator|placebo arm|Double blind placebo
11587768|NCT00733967|Placebo Comparator|Placebo|Matching oral placebo capsules as control.
11587769|NCT00733967|Active Comparator|Varenicline|See assigned interventions.
11587770|NCT00733954|Active Comparator|clobetasol propionate spray|clobetasol propionate spray 0.05%
11587771|NCT00733954|Active Comparator|clobetasol propionate ointment|clobetasol propionate ointment 0.05%
11587772|NCT00733941|Experimental|High frequency training|24 interval exercises performed 8 times per week
11587773|NCT00733941|Experimental|Normal frequency training|24 interval exercises performed 3 times per week
11587774|NCT00733928|Other|1 - All Polyethylene Tibia|Total knee replacement with an all polyethylene tibial tray
11587775|NCT00733928|Active Comparator|2 - Poly & Metal Tibia|Total knee replacement with a metal-backed tibial component
11587776|NCT00733915|Experimental|Single arm|Cohort of total knee replacements with LCS Complete knee implants
11587777|NCT00733902|Experimental|Tanezumab 10 mg|
11587778|NCT00733902|Experimental|Tanezumab 5 mg|
11587779|NCT00733902|Experimental|Tanezumab 2.5 mg|
11587780|NCT00733902|Placebo Comparator|Placebo|
11587781|NCT00733889|Experimental|1|
11587782|NCT00733876|Experimental|A|
11587783|NCT00733863|Experimental|1|
11587784|NCT00733863|Placebo Comparator|2|
11587785|NCT00733850|Experimental|1|Kanglaite Injection plus Gemcitabine
11587786|NCT00733850|Active Comparator|2|Gemcitabine
11587787|NCT00733837|Experimental|A|This is a repeated measures study. All participants experience the same conditions.
11587788|NCT00733824|Experimental|Cohort 1|"240 µg/kg SC AMD3100 Day -5
~10 µg/kg SC G-CSF Day -4 thru Day -1
~160 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1
~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
11587789|NCT00733824|Experimental|Cohort 2|"240 µg/kg SC AMD3100 Day -5
~10 µg/kg SC G-CSF Day -4 thru Day -1
~240 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1
~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
11587790|NCT00733824|Experimental|Cohort 3|"240 µg/kg SC AMD3100 Day -5
~10 µg/kg SC G-CSF Day -4 thru Day -1
~320 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1
~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
11587791|NCT00733824|Experimental|Cohort 4|"240 µg/kg SC AMD3100 Day -5
~10 µg/kg SC G-CSF Day -4 thru Day -1
~400 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1
~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
11587792|NCT00733824|Experimental|Phase II|"240 µg/kg SC AMD3100 Day -5
~10 µg/kg SC G-CSF Day -4 thru Day -1
~MTD as determined in Phase I IV AMD3100 and 10 µg/kg SC G-CSF Day 1
~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
11587793|NCT00733811|Experimental|1|Sequential treatment including DFP at 75 mg/kg, divided into three oral daily doses, for four days per week and DFO by subcutaneous infusions (8-12h) at 50 mg/kg/day for the remaining three days per week
11587794|NCT00733811|Active Comparator|2|Deferiprone alone at 75 mg/kg divided into three oral daily doses
11587795|NCT00733798|Experimental|1|
11587796|NCT00733785|Experimental|2mg tablet|2 mg tablet fasted
11587797|NCT00733785|Experimental|4 mg tablet|4 mg tablet fasted
11587798|NCT00733785|Experimental|8mg tablet|8 mg tablet fasted
11587799|NCT00733785|Experimental|2 x 4 mg tablets|2 x 4mg tablets fasting
11587800|NCT00733785|Experimental|2 x 2mg tablets|2 x 2mg tablets fasting
11587801|NCT00733785|Experimental|8 mg tablet fed|8 mg tablet fed
11587802|NCT00733785|Experimental|Repeat dose|8 mg once a day for 6 days
11587803|NCT00733772|Experimental|A|healthy lifestyle counseling + 30 grams/day supplement of Flaxseed
11587804|NCT00733772|Sham Comparator|B|TLC diet
11587805|NCT00733746|Experimental|Neoadjuvant therapy + Surgery + Adjuvant therapy|As part of neoadjuvant therapy, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 29, 36, and 43 and oral erlotinib hydrochloride once daily on days 1-43 in the absence of disease progression or unacceptable toxicity. Within 3-6 weeks after completion of neoadjuvant therapy, patients undergo pancreaticoduodenectomy and patients receive gemcitabine hydrochloride and erlotinib hydrochloride as in neoadjuvant therapy within 5-10 weeks post surgery.
11587806|NCT00733733|Active Comparator|ATG|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
11587807|NCT00733733|No Intervention|Control|Standard immunosuppressive treatment for renal transplantation including tacrolimus/MMF/prednisolone without ATG treatment.
11587808|NCT00733720|Active Comparator|1|Each subject will receive all 3 doses of suboxone and placebo
11587809|NCT00733707|Experimental|1|Text messaging reminders
11587810|NCT00733707|No Intervention|2|No text messaging reminder
11587811|NCT00733694|Other|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
11587812|NCT00733681|Experimental|PFC Sigma RP TC3 Revision Knee System|Revision knee surgery with the PFC Sigma RP TC3 Revision Knee System (mobile bearing).
11587813|NCT00733642|Experimental|PF-04360365 1 mg/kg|
11587814|NCT00733642|Experimental|PF-04360365 3 mg/kg|
11587815|NCT00733642|Experimental|PF-04360365 5 mg/kg|
11587816|NCT00733642|Experimental|PF-04360365 10 mg/kg|
11587817|NCT00733616|Experimental|1|
11587818|NCT00733603|Sham Comparator|Global Therapeutic Massage (GTM)|Non-specific somatic treatment with full-body Western massage.
11587819|NCT00733603|Active Comparator|Myofascial Tissue Manipulation (MTM)|Targeted internal and external Connective Tissue Manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen.
11587820|NCT00733577|Experimental|Cohort 1|15 mg SB756050 or placebo
11587821|NCT00733577|Experimental|Cohort 2|Planned dose for Cohorts 2 50mg SB756050 or placebo
11587822|NCT00733577|Experimental|Cohort 3|Planned dose for Cohort 3 150mg SB756050 or placebo
11587823|NCT00733577|Experimental|Cohort 4|Planned dose for Cohort 4 600mg SB756050 or placebo
11587824|NCT00733564|Active Comparator|1|Paracervical block will be performed
11587825|NCT00733564|Experimental|2|Propofol anesthesia will be performed
11587826|NCT00733564|Experimental|3|Sevoflurane anesthesia will be performed
11587827|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 1|Eligible subjects will receive repeat oral doses of GSK962040 given as 10 milligrams once daily tablet for 14 days.
11587828|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 2|Eligible subjects will receive repeat oral doses of GSK962040 given as 30 milligrams once daily tablet for 14 days.
11587829|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 3|Eligible subjects will receive repeat oral doses of GSK962040 given as 100 milligrams once daily tablet for 14 days.
11587830|NCT00733551|Placebo Comparator|Subjects receiving placebo in cohort 1, 2 and 3|Eligible subjects will receive repeat oral doses of placebo tablets given once daily for 14 days in cohort 1, 2 and 3.
11587831|NCT00733538|Active Comparator|1|patients receiving zometa treatment
11587832|NCT00733538|No Intervention|2|No treatment, just follow-up
11587833|NCT00733525|Experimental|Stepped Care|Participants will receive guided self-help with nine clinician checkups, followed by fluoxetine if nonresponsive, followed by cognitive behavioral therapy if still nonresponsive.
11587834|NCT00733525|Active Comparator|Cognitive Behavioral Therapy|Participants will receive 20 sessions of cognitive behavioral therapy with the addition of fluoxetine at interim points.
11587835|NCT00733512||ReSTOR|AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL)
11587836|NCT00733499|Other|LCS Complete Duofix|102 patients
11587837|NCT00733499|Active Comparator|LCS Complete Porocoat|104 patients
11587838|NCT00733486|Other|L.C.S. APG Knee Anterior Posterior Glide knee|Orthopaedic implant for primary knee replacement
11587839|NCT00733473|Active Comparator|1 Budesonide|This arm consist 50 children with recurrent wheezing who are hospitalized for wheezing epizode. They received 1 mg nebulized budesonide 2 times a day upto 5 days
11587840|NCT00733473|Placebo Comparator|2 Placebo saline|This arm consist 50 children with recurrent wheezing who are hospitalized for wheezing epizode. They received 2ml of nebulized saline 2 times a day upto 5 days
11587841|NCT00733460|Experimental|BF-PET|
11587842|NCT00733434|Experimental|1|Patients receiving PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
11587843|NCT00733434|Placebo Comparator|2|Patients receiving 500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
11587844|NCT00733421|Experimental|1|"Active study drug:
~Etoricoxib 90 mg once daily"
11587845|NCT00733421|Active Comparator|2|Tramadol 100 mg slow release twice daily
11587846|NCT00733408|Experimental|Tx (chemo, MoAb, and enzyme inhibitor)|"INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients achieving complete response, partial response, or stable disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity."
11587847|NCT00733395|Experimental|1|Tart cherry juice
11587848|NCT00733395|Placebo Comparator|2|Fruit juice
11587849|NCT00733382|Experimental|1|
11587850|NCT00733382|Active Comparator|2|
11587851|NCT00733369|Other|PFC Sigma RP-F|125 patients to be allocated to this arm according to blinding envelopes
11587852|NCT00733369|Active Comparator|PFC Sigma RP|125 patients to be allocated to this arm according to blinding envelopes
11587853|NCT00733356|Experimental|Vyvanse Treatment|All subjects were tested at baseline before medication and then titrated to best dose and retested on Vyvanse Medication.
11587854|NCT00733343|Active Comparator|Treatment Group|treatment with Adaptive Servoventilation (Europe: AutoSet CS (USA: VPAP (Variable Positive Airway Pressure) Adapt SV)) + standard medical therapy according to applicable guidelines (ESC, ACC/AHA)
11587855|NCT00733343|No Intervention|Control Group|standard medical therapy according to applicable guidelines (ESC, ACC/AHA)
11587856|NCT00733330|Other|Conventional TKR arm|Patients to receive treatment with either a P.F.C. Sigma or L.C.S. knee using the conventional manual surgical technique
11587857|NCT00733330|Active Comparator|MiTKR CAS arm|Patients to receive treatment with either a P.F.C. or L.C.S. knees in chronological order into the CAS group which will use minimally invasive surgery and computer navigation
11587858|NCT00733317|Active Comparator|1-Budesonide nebulized suspension|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times and will not give after 3 doses
11587859|NCT00733317|Placebo Comparator|2- 0.9% saline|Children will receive 2 ml of saline every 20 minutes for 3 times and will not give after 3 doses
11587860|NCT00733304|Experimental|5 mg/ml TID|eligible participants received 5 mg/ml Pazopanib eye drops three times daily (TID)
11587861|NCT00733304|Experimental|2 mg/ml TID|eligible participants received 2 mg/ml Pazopanib eye drops three times daily
11587862|NCT00733304|Experimental|5 mg/ml QD|eligible participants received 5 mg/ml Pazopanib eye drops once daily (QD)
11587863|NCT00733291|Active Comparator|Nelfilcon A soak / Nelfilcon A no-soak|Nelfilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution, followed by nelfilcon A contact lenses inserted directly from the blister package. Each pair of lenses worn for 2 hours.
11587864|NCT00733291|Active Comparator|Nelfilcon A no soak / nelfilcon A soak|Nelfilcon A contact lenses inserted directly from the blister package, followed by nelfilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution. Each pair of lenses worn for 2 hours.
11587865|NCT00733291|Active Comparator|Etafilcon A soak / etafilcon A no soak|Etafilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution, followed by etafilcon A contact lenses inserted directly from the blister package. Each pair of lenses worn for 2 hours.
11587866|NCT00733291|Active Comparator|Etafilcon A no soak / etafilcon A soak|Etafilcon A contact lenses inserted directly from the blister package, followed by etafilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution. Each pair of lenses worn for 2 hours.
11587867|NCT00733278|Experimental|Copper IUD|Copper IUD
11587868|NCT00733265|Experimental|AZD6140|
11587869|NCT00733239|Experimental|1|Receives 2-4 of the drugs listed under Intervention
11587870|NCT00733226|Active Comparator|1 Broncho-Vaxom|The children received one capsule per oral, OM-85 BV (3.5 mg) per day for the first 10 consecutive days of each month for 3 consecutive months.
11587871|NCT00733226|Placebo Comparator|2 (Placebo OM-85 BV)|The children received one capsule per oral, placebo per day for the first 10 consecutive days of each month for 3 consecutive months.
11587872|NCT00733200|No Intervention|Control group|
11587873|NCT00733187|Experimental|1|
11587874|NCT00733174|Experimental|1|Rosiglitazone
11587875|NCT00733174|Placebo Comparator|2|Placebo
11587876|NCT00733161|Active Comparator|1|Passive leg cycle exercise with stretching and resistance training
11587877|NCT00733161|Active Comparator|2|Stretching and resistance training
11587878|NCT00733148||1|Routine Care
11587879|NCT00733148||2|Insulin infusion based on model predictive algorithm (MPC)
11587880|NCT00733135|Other|Atherectomy with embolic protection|All subjects were treated with atherectomy (with SilverHawk or TurboHawk device) in conjunction with embolic protection (SpiderFX device).
11587881|NCT00733122|Experimental|A|GARDASIL, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
11587882|NCT00733109|Active Comparator|excision of the lesion|
11587883|NCT00733109|No Intervention|espontaneous regression|
11587884|NCT00733096|Experimental|1|Epidural etanercept 4 mg, two doses 2 weeks apart
11587885|NCT00733096|Active Comparator|2|Epidural methylprednisolone 60 mg, two doses 2 weeks apart
11587886|NCT00733096|Placebo Comparator|3|Epidural saline, two doses 2 weeks apart
11587887|NCT00733083|Active Comparator|1|0,1 mg/kg of oxycodone
11587888|NCT00733083|Active Comparator|2|0,1 mg/kg of morphine
11587889|NCT00733083|Active Comparator|3|0,5 mg/kg dexamethasone (max 24 mg
11587890|NCT00733083|Placebo Comparator|4|NaCl 0,9%
11587891|NCT00733057|Experimental|1|Minocycline treatment
11587892|NCT00733057|Placebo Comparator|2|Placebo
11587893|NCT00733044|Experimental|Specialized Care|Stepped-care cognitive behavioural approach with elements from tinnitus retraining therapy
11587894|NCT00733044|Active Comparator|Usual Care|Audiological diagnostics and intervention and, if necessary, one or more consultations with a social worker with a maximum of ten one hour session
11587895|NCT00733031|Experimental|gemcitabine|gemcitabine administered in combination with AZD6918
11587896|NCT00733031|Experimental|pemetrexed|pemetrexed administered in combination with AZD6918
11587897|NCT00733031|Experimental|AZD6918|AZD6918 administered alone
11587898|NCT00733018|Active Comparator|A|Diet A - Western diet
11587899|NCT00733018|Active Comparator|B|Diet B - Balanced diet
11587900|NCT00733005|Experimental|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
11587901|NCT00733005|Placebo Comparator|Arm 2|Matching placebo nasal spray
11587902|NCT00732992|Experimental|CDD|
11587903|NCT00732992|Experimental|2/1|
11587904|NCT00732979|Experimental|A|Infrahepatic inferior vena cava clamping The inferior vena cava is circumferentially dissected below the liver and clamped with a vascular clamp. Patients in this study group will receive intravenous volume for maintenance of fluid hemostasis according to local standards.
11587905|NCT00732979|Active Comparator|B|Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below < 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
11587906|NCT00732966|Experimental|1|Hypertensive patients will be treated with losartan for one months
11587907|NCT00732966|Experimental|2|Hypertensive patients will be treated with valsartan
11587908|NCT00732953|Active Comparator|1|Genous stent implantation with paclitaxel-eluting balloon therapy
11587909|NCT00732953|Active Comparator|2|Genous stent implantation
11587910|NCT00732940|Experimental|Belimumab Q2WKS|Every other week: 100 mg of belimumab (1 injection) subcutaneous (under the skin) on days 0, 7, and 14, then every other week until final evaluation at Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.
11587911|NCT00732940|Experimental|Belimumab 3X/WK|Three times weekly: 200 mg of belimumab (2 injections of 100 mg each) subcutaneous (under the skin) on days 0, 2, and 4 then 100 mg three times a week until final evaluation at Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.
11587912|NCT00732927|Experimental|1|parnaparin, low molecular weight heparin
11587913|NCT00732927|Active Comparator|2|aspirin
11587914|NCT00732914|Active Comparator|1|Sunitinib (first-line) followed by Sorafenib (second-line)
11587915|NCT00732914|Experimental|2|Sorafenib (first-line) followed by Sunitinib (second-line)
11587916|NCT00732901|Experimental|A (escitalopram)|Escitalopram
11587917|NCT00732901|Experimental|B (placebo)|Placebo
11588136|NCT00731393|Active Comparator|Group C|Subjects aged between 6 months and 3 years.
11587918|NCT00732888|Other|1|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 15; and Tasigna® once daily on days 1 and 15 (i.e., Tasigna® alone on day 1, and combination of Tasigna® and calcium supplement on day 15).
11587919|NCT00732888|Other|2|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 1; and Tasigna® once daily on days 1 and 15 (i.e., combination of Tasigna® and calcium supplement on day 1, Tasigna® alone on day 15).
11587920|NCT00732875|Experimental|Open Label Infliximab + Methotrexate|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
11587921|NCT00732862|Experimental|1|Baseline clamp study before treatment phase.
11587922|NCT00732862|Active Comparator|2|Final clamp experiment after 6 months intensive therapy.
11587923|NCT00732849|No Intervention|1|Standard Enteral Nutrition - Peptisorb, Nutricia Ltd.
11587924|NCT00732849|No Intervention|2|Standard Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes
11587925|NCT00732849|Experimental|3|Immunomodulating Enteral Nutrition: Reconvan, Fresenius Kabi Poland
11587926|NCT00732849|Experimental|4|Immunomodulating Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes + Omegaven (Fresenius Kabi), Dipepitven (Fresenius Kabi)
11587927|NCT00732836|Experimental|HAI Abraxane MTD|Dose escalation beginning Day 1, Cycle 2 dose level 180 mg/m^2 for maximum tolerated dose (MTD) of Hepatic Arterial Infusion of Abraxane (HAI Abraxane) following same dose intravenous Abraxane in Cycle 1 of 21 day cycle.
11587928|NCT00732836|Experimental|HAI Abraxane Expansion|HAI Abraxane dose expansion at MTD or dose level 3 (260 mg/m^2) if MTD not defined.
11587929|NCT00732823|Placebo Comparator|Profile A|No device worn
11587930|NCT00732823|Active Comparator|Profile B|Foot 40 mmHg, ankle 40 mmHg, mid-calf 35 mmHg, upper calf 30 mmHg
11587931|NCT00732823|Active Comparator|Profile C|Foot 50 mmHg, ankle 50 mmHg, mid-calf 45 mmHg, upper calf 40 mmHg
11587932|NCT00732823|Active Comparator|Profile D|Foot 60 mmHg, ankle 60 mmHg, mid-calf 55 mmHg, upper calf 50 mmHg
11587933|NCT00732810|Experimental|Breast cancer randomized to SCH 727965|
11587934|NCT00732810|Active Comparator|Breast cancer randomized to capecitabine|
11587935|NCT00732810|Experimental|SCH 727965 in breast cancer after progression on capecitabine|
11587936|NCT00732810|Experimental|NSCLC randomized to SCH 727965|Note: Enrollment of participants with NSCLC was completed per protocol as of 26 JAN 2010
11587937|NCT00732810|Active Comparator|NSCLC randomized to erlotinib|Note: Enrollment of participants with NSCLC was completed per protocol as of 26 JAN 2010
11587938|NCT00732810|Experimental|SCH 727965 in NSCLC after progression on erlotinib|Note: Crossover to SCH 727965 after progression on erlotinib was completed per protocol as of 26 JAN 2010
11587939|NCT00732797|No Intervention|Routine Care|Participants will receive routine care.
11587940|NCT00732797|Active Comparator|Booklet|Participants will receive self-treatment booklets, but no expert telephone support.
11587941|NCT00732797|Active Comparator|Booklet &Therapist Support|Participants will receive self-treatment booklets, and up to an hour's expert telephone support.
11587942|NCT00732784|Other|1|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 15; and Gleevec® once daily on days 1 and 15 (i.e., Gleevec® alone on day 1, and combination of Gleevec® and calcium supplement on day 15).
11587943|NCT00732784|Other|2|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 1; and Gleevec® once daily on days 1 and 15 (i.e., combination of Gleevec® and calcium supplement on day 1, Gleevec® alone on day 15).
11587944|NCT00732771|Experimental|LCI696 1mg bid|
11587945|NCT00732758|Experimental|Vitamin D3|Vitamin D3 1000 IU Tablet
11587946|NCT00732758|Placebo Comparator|Placebo|Placebo Tablet
11587947|NCT00732745|Experimental|Phase II arm I|Patients receive docetaxel IV over 1 hour on days 1 and 8, oxaliplatin IV over 2 hours on day 1, and oral vandetanib (at the maximum tolerated dose determined in phase I) once daily on days 1-21. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue to receive vandetanib beyond 8 courses in the absence of disease progression or unacceptable toxicity.
11587948|NCT00732745|Active Comparator|Phase II arm II|Patients receive docetaxel and oxaliplatin as in arm I. Patients also receive an oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue to receive vandetanib beyond 8 courses in the absence of disease progression or unacceptable toxicity.
11587949|NCT00732732|Experimental|Green banana|Subjects receiving green banana powder.
11587950|NCT00732732|Placebo Comparator|Placebo|Microcrystalline cellulose given as placebo
11587951|NCT00732719|Placebo Comparator|Profile A|Device worn; no pressure given (placebo)
11587952|NCT00732719|Active Comparator|Profile B|Foot at 30mm Hg, Gaiter at 40 mm Hg, mid-calf at 30 mm Hg and upper cuff at 20mm Hg
11587953|NCT00732719|Active Comparator|Profile C|Foot at 20mm Hg, Gaiter at 30 mm Hg, mid-calf at 20 mm Hg and upper cuff at 10mm Hg
11587954|NCT00732719|Active Comparator|Profile D|Foot at 10mm Hg, Gaiter at 20 mm Hg, mid-calf at 10 mm Hg and upper cuff at 0mm Hg
11587955|NCT00732719|Active Comparator|Profile E|Foot at 30mm Hg, Gaiter at 40 mm Hg, mid-calf at 40 mm Hg and upper cuff at 40mm Hg
11587956|NCT00732719|Active Comparator|Profile F|Foot at 20mm Hg, Gaiter at 30 mm Hg, mid-calf at 30 mm Hg and upper cuff at 30mm Hg
11587957|NCT00732719|Active Comparator|Profile G|Foot at 10mm Hg, Gaiter at 20 mm Hg, mid-calf at 20 mm Hg and upper cuff at 20mm Hg
11587958|NCT00732706|Other|Sartorius Twitch|Femoral Nerve detection using Sartorius Twitch
11587959|NCT00732706|Other|Quadriceps Twitch|Femoral Nerve detection using Quadriceps Twitch
11587960|NCT00732693|Experimental|1|Treatment with standard sex steroid replacement regimen
11587961|NCT00732693|Experimental|2|Treatment with physiologic sex steroid regimen
11587962|NCT00732680|Experimental|Botulinum Toxin Type A|Treatment will be in the form of 10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
11588002|NCT00732420|Experimental|Treatment Arm B|Daily oral pazopanib in combination with oral topotecan given for 5 consecutive days every 21 days. Initially rising dose to determine the maximum tolerated dose; finally an additional cohort of patients treated at the maximum tolerated dose.
11587963|NCT00732654|Experimental|Sublingual Immunotherapy (SLIT)|"These subjects will have a dose escalation of the milk protein extract given sublingually. After dose escalation, they will continue on the sublingual daily maintenance dose for approximately one year.
~Milk Protein Extract Immunotherapy : Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years."
11587964|NCT00732654|Experimental|SLIT/ Oral Immunotherpay (OIT) B|"These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 1000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.
~Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years."
11587965|NCT00732654|Experimental|SLIT/ OIT A|"These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 2000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.
~Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
~Milk Protein Extract Immunotherapy : Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks."
11587966|NCT00732641|Experimental|Peginterferon α-2b|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
11587967|NCT00732641|No Intervention|No Treatment|Participants will be observed and will receive no treatment.
11587968|NCT00732628||Boomerang percutaneous closure unit|patients having a Boomerang percutaneous closure device after a Neurointerventional study
11587969|NCT00732615|Placebo Comparator|Placebo|Sterile water for injection
11587970|NCT00732615|Experimental|50, 75, 100 mcg NPSP558|Initial dose of 50mcg, to be titrated up to 75mcg and then 100mcg dependent upon response
11587971|NCT00732602|Active Comparator|B|GLP-2 infusion
11587972|NCT00732602|Placebo Comparator|C|Sodium-chloride infusion
11587973|NCT00732602|Active Comparator|A|GIP-infusion
11587974|NCT00732589|Experimental|A|Suprascapular nerve block
11587975|NCT00732589|Experimental|B|therapeutic ultrasound
11587976|NCT00732576|Active Comparator|1|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA)
11587977|NCT00732576|Active Comparator|2|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (10 µg)
11587978|NCT00732576|Active Comparator|3|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 2 capsules of menaquinone-7 per day (20 µg per day)
11587979|NCT00732576|Active Comparator|4|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (45 µg per day)
11587980|NCT00732576|Active Comparator|5|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA)
11587981|NCT00732576|Active Comparator|6|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (10 µg)
11587982|NCT00732576|Active Comparator|7|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 2 capsules of menaquinone-7 per day (20 µg per day)
11587983|NCT00732576|Active Comparator|8|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (45 µg per day)
11587984|NCT00732550|Experimental|Single trocar|Patients will undergo cholecystectomy by the single trocar approach
11587985|NCT00732550|Active Comparator|Standard lap cholecystectomy|Standard lap choly
11587986|NCT00732537|Experimental|Inhaled Nitric Oxide|iNO started at 20 ppm for 1 hour. The gas was then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off).
11587987|NCT00732537|Placebo Comparator|Placebo|The Oxygen at high concentration (>90%), which was standard therapy for PPHN, was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda).
11587988|NCT00732524|Active Comparator|Glipizide arm|Glipizide XL is an insulin secretagogue and is an extended release tablet designed to provide a controlled rate of delivery. Glipizide XL was chosen because it is the most frequently used discharge oral medication in our ED. It has a quick onset of action within a few hours after oral ingestion, lasts for 24 hours and has a powerful glucose lowering effect. In addition, there are very few contraindications to Glipizide XL and there is published literature regarding their use in subjects with severe hyperglycemia
11587989|NCT00732524|Active Comparator|Glipizide + Glargine|Insulin Glargine is a recombinant human basal insulin analog. It was chosen since it is a non-peaking insulin with cover for 24 hours. It can be injected subcutaneously only once a day and has a low incidence of hypoglycemia
11587990|NCT00732511|Experimental|1|Coreg Cr will be up-titrated as needed to achieve blood pressure <130/80
11587991|NCT00732511|Active Comparator|2|Toprol XL will be up-titrated at weekly intervals to achieve a blood pressure <130/80 mm Hg
11587992|NCT00732498|Experimental|ESHAP followed by Zevalin and Rituximab|Etoposide, Methylprednisolone, Cytarabine, Cisplatin (ESHAP) infusion X 2 Cycles followed by Rituximab and In-Zevalin or Y-Zevalin.
11587993|NCT00732485|Active Comparator|Fenofibrate|
11587994|NCT00732485|Placebo Comparator|Placebo|
11587995|NCT00732472|Experimental|7 day repeat dose|7 day repeat dose
11587996|NCT00732459||1|electro-acupuncture preconditioning group
11587997|NCT00732459||2|control group
11587998|NCT00732446|Active Comparator|2|antibiotic /steroid combination compared with individual administration of steroid and antibiotic
11587999|NCT00732446|Experimental|1|combination antibiotic steroid compared with individual administration of steroid and antibiotic - new therapeutic indication
11588000|NCT00732433|Experimental|digital mammogram|"Digital mammography is a non-invasive imaging technique to obtain an x-ray image of the breast.
~Two-view digital mammogram of the breast with a lesion that has been recommended for biopsy during the subject's regular clinical care. The digital mammogram is then analyzed by a computer program."
11588001|NCT00732420|Experimental|Treatment Arm A|Daily oral pazopanib in combination with weekly oral topotecan. Initially rising dose to determine the maximum tolerated dose: finally an expanded cohort treated at the maximum tolerated dose.
11588003|NCT00732407|Experimental|1|Patients with diabetes melittus treated with an ACE inhibitor will be treated with aliskiren
11588004|NCT00732407|Experimental|2|Patients with diabetes melittus treated with an ACE inhibitor will be given losartan
11588005|NCT00732381|Experimental|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
11588006|NCT00732381|Placebo Comparator|Arm 2|Matching placebo nasal spray
11588007|NCT00732368|Experimental|Mometasone Nasal Spray|Open-label. Two sprays per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
11588008|NCT00732355||I|known syphilis infected patients
11588009|NCT00732355||U|presumed uninfected patients
11588010|NCT00732342|No Intervention|1|Standard Treatment
11588011|NCT00732342|Experimental|2|Standard Treatment with Contingency Management for 12 weeks with a 0.5 probability of winning prizes for each negative sample submitted
11588012|NCT00732342|Experimental|3|Standard Treatment with Contingency Management for 24 weeks with a 0.34 probability of winning prizes for each negative sample submitted
11588013|NCT00732342|Experimental|4|Standard Treatment with Contingency Management for 24 weeks with a 0.5 probability of winning prizes for each negative sample submitted
11588014|NCT00732329|Experimental|A|"optimized home based occupational therapy including:
~diagnostic assessment
~patient-centered definition of targets involving the care giver
~occupational therapy"
11588015|NCT00732329|No Intervention|B|treatment according to guidelines of German Society for Psychiatry, Psychotherapy and Nervous Diseases (DGPPN) and German Society of Neurology (DGN) without optimized occupational therapy
11588016|NCT00732303|Experimental|1|"Pemetrexed (Alimta) 500mg/m^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles
~Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.
~The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks."
11588017|NCT00732290|Active Comparator|1|Clopidogrel then fluoxetine+clopidogrel
11588018|NCT00732290|Active Comparator|2|Fluoxetine+clopidogrel then clopidogrel
11588019|NCT00732277|Experimental|Treatment|Patients in this arm will be given the following IMP intraveneously at 6 hour intervals - hydrocortisone (100mg/m2/24 hours)
11588020|NCT00732277|No Intervention|Control|in each phase of study 15 patients will receive no IMP as control arm
11588021|NCT00732251|Experimental|Allopurinol|Using an open label, naturalistic design, subjects will continue with their current psychiatric medications during the study. Allopurinol will be given at a fixed dose of 300 mg/day for the first week and then 600mg/d for the remainder of the study. Subjects who cannot tolerate the 600mg dose will be given a dose of 300mg/d. Subjects will participate in monthly follow up visits for 24 months. Subjects who develop a substance abuse or substance dependence disorder during the study will be terminated from the study. Also, subjects who develop a medical condition which can affect their mood stability will be terminated from the study.
11588022|NCT00732238|Experimental|Arm 1|Removal of Bladder Catheter. Urine Culture Post Catheter Removal. Shorter Duration of Antibiotic Therapy.
11588023|NCT00732238|Active Comparator|Arm 2|Urinary Catheter Is Not Exchanged. Antibiotic Therapy Is Based On Culture Obtained From Existing Catheter. Longer Duration of Antibiotic Therapy.
11588024|NCT00732225|Active Comparator|DisCoVisc|Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)
11588025|NCT00732225|Active Comparator|DuoVisc|Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)
11588026|NCT00732225|Active Comparator|BioVisc|Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)
11588027|NCT00732225|Active Comparator|Healon5|AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)
11588028|NCT00732225|Active Comparator|Amvisc Plus|Bausch & Lomb Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)
11588029|NCT00732212|Experimental|Doppler endoscopic probe hemostasis|In addition to stigmata of hemorrhage and visual cues, Doppler endoscopic probe will be used for detection of blood flow before and after standard endoscopic hemostasis. If residual blood flow in the lesion is found after standard treatment, further endoscopic treatment will be applied as deemed safe by the investigator-endoscopist.
11588030|NCT00732212|Active Comparator|Standard Endoscopic Hemostasis|Standard, visually guided endoscopic hemostasis based on visual cues of stigmata of hemorrhage and endoscopic control of bleeding or treatment of the stigmata according to current guidelines
11588031|NCT00732199|Other|Arm 1|Determine the apneic threshold and carbon- dioxide reserve using noninvasive positive pressure ventilation during NREM sleep and determine the effect effect of episodic hypoxia on ventilatory long-term facilitation during NREM sleep in Young adults.
11588032|NCT00732199|Experimental|Arm 2|Determine the apneic threshold and carbon- dioxide reserve using noninvasive positive pressure ventilation during NREM sleep and determine the effect of episodic hypoxia on ventilatory long-term facilitation during NREM sleep in Older adults.
11588033|NCT00732186|Experimental|Group 1 and Group 2|
11588034|NCT00732173|Experimental|Arm I|"Patients receive a lifestyle intervention, Survivors of Uterine Cancer Empowered by Exercise and Healthy Diet (SUCCEED), on a group and individual basis consisting of nutrition, exercise, and behavioral modification counseling from a physician, psychologist, registered dietitian, and physical therapist. Sixteen group sessions will be conducted (10 weekly, 6 bi-weekly) for 6 months. Weight and body mass index, satisfaction with study treatment, and exercise/activity logs are assessed weekly and biweekly. Patients receive additional feedback and support during the weeks not met in a group, including newsletters and telephone and e-mail contact."
11588035|NCT00732173|Active Comparator|Arm II|Patients receive usual care informational brochures but no lifestyle counseling related to weight loss, physical activity, and nutrition.
11588036|NCT00732160|Experimental|HS-V/A; LS-V/A|High Sodium diet- Vehicle infusion then Aldosterone infusion Low Sodium diet- Vehicle infusion then Aldosterone infusion
11588037|NCT00732160|Experimental|HS-A/V; LS-A/V|High Sodium diet- Aldosterone infusion then Vehicle infusion Low Sodium diet- Aldosterone infusion then Vehicle infusion
11588038|NCT00732160|Experimental|LS-V/A; HS-V/A|Low Sodium diet- Vehicle infusion then Aldosterone infusion High Sodium diet- Vehicle infusion then Aldosterone infusion
11588039|NCT00732160|Experimental|LS-A/V; HS-A/V|Low Sodium diet- Aldosterone infusion then Vehicle infusion High Sodium diet- Aldosterone infusion then Vehicle infusion
11588040|NCT00732147|Placebo Comparator|2|Type 2 diabetes patients will receive placebo with 3 meals in experimental period.
11588041|NCT00732147|Experimental|1|Type 2 Diabetes patient will receive Pramlintide with 3 meals in experimental period.
11588042|NCT00732121|Active Comparator|1|Sitagliptin
11588043|NCT00732121|Placebo Comparator|2|Placebo arm
11588044|NCT00732108|Experimental|topiramate|topiramate 50mg orally for 2 weeks, then 100mg orally for 6 weeks
11588045|NCT00732108|Placebo Comparator|2|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
11588046|NCT00732095|Experimental|Experimental|Immediate Ad
11588047|NCT00732082|Active Comparator|Dose Level 0|Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.
11588048|NCT00732082|Experimental|Dose Level 1|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.
~IMP321 3 mg SQ anterior surface of either the right or left thigh on Day 2.
~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.
~Each single injection will be separated by a 13-day administration free period."
11588049|NCT00732082|Experimental|Dose Level 2|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.
~IMP321 6.5 mg SQ anterior surface of either the right or left thigh on Day 2.
~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.
~Each single injection will be separated by a 13-day administration free perio"
11588050|NCT00732082|Experimental|Dose Level 3|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.
~IMP321 13 mg SQ anterior surface of either the right or left thigh on Day 2.
~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.
~Each single injection will be separated by a 13-day administration free perio"
11588051|NCT00732082|Experimental|Dose Level 4|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.
~IMP321 26 mg SQ anterior surface of either the right or left thigh on Day 2.
~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.
~Each single injection will be separated by a 13-day administration free perio"
11588052|NCT00732069|Active Comparator|Placebo, then ramipril, then valsartan|placebo, ramipril, valsartan: Subjects were treated sequentially with placebo, ramipril (5mg/day by mouth), then valsartan (160mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
11588053|NCT00732069|Active Comparator|Placebo, then valsartan, then ramipril|placebo, ramipril, valsartan: Subjects were treated sequentially with placebo, valsartan (160mg/day by mouth), then ramipril (5mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
11588054|NCT00732069|Active Comparator|Ramipril, then placebo, then valsartan|placebo, ramipril, valsartan: Subjects were treated sequentially with ramipril (5mg/day by mouth), then placebo (once a day by mouth), then valsartan (160mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
11588055|NCT00732069|Active Comparator|Valsartan, then placebo, then ramipril|placebo, ramipril, valsartan: Subjects were treated sequentially with valsartan (160mg/day by mouth), then placebo (once a day by mouth), then ramipril (5mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
11588056|NCT00732069|Active Comparator|Ramipril, then valsartan, then placebo|placebo, ramipril, valsartan: Subjects were treated sequentially with ramipril (5mg/day by mouth), then valsartan (160mg/day by mouth), then placebo (once a day by mouth). Each drug was given for 7 days after a 3-week washout.
11588057|NCT00732069|Active Comparator|Valsartan, then ramipril, then placebo|placebo, ramipril, valsartan: Subjects were treated sequentially with then valsartan (160mg/day by mouth), then ramipril (5mg/day by mouth), then placebo (once a day by mouth). Each drug was given for 7 days after a 3-week washout.
11588058|NCT00732056|Experimental|1|3+3 cohort dose escalation
11588059|NCT00732043|Experimental|1|
11588060|NCT00732043|Experimental|2|
11588061|NCT00732043|Placebo Comparator|3|
11588062|NCT00732030|Experimental|AcrySof Toric T3|Each enrolled eye receives AcrySof Toric Model SN60T3 Intraocular Lens (IOL)
11588063|NCT00732017|Experimental|HVPC-|This group received standard physical therapy treatment and HVPC with negative polarity.
11588064|NCT00732017|Active Comparator|CG|The control group received only standard physical therapy treatment.
11588065|NCT00732017|Experimental|HVPC+|This group received standard physical therapy treatment and HVPC using active electrodes with positive polarity.
11588066|NCT00732004|Experimental|1|Group 1
11588067|NCT00732004|Experimental|2|Group 2
11588068|NCT00732004|Experimental|3|Group 3
11588069|NCT00731991|Active Comparator|ART|ART to the levator scapulae.
11588070|NCT00731991|Active Comparator|PNF|PNF to the levator scapulae.
11588071|NCT00731991|Placebo Comparator|Control|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
11588072|NCT00731978|No Intervention|Standard|Standard intraoperative fluid management
11588073|NCT00731978|Experimental|Restricted|Restricted intraoperative fluid management
11588074|NCT00731965|Experimental|1|Measles, mumps, rubella booster vaccination within 3 months after randomisation
11588075|NCT00731965|No Intervention|2|Booster vaccination performed by regular health authorities at age 9; at least 1 year after randomisation
11588076|NCT00731952|Experimental|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
11588077|NCT00731939|Other|Titan® OTR IPP|Subjects implanted with Titan® One Touch Release (OTR) Inflatable Penile Prosthesis (IPP)
11588078|NCT00731926|Experimental|1|
11588079|NCT00731926|Active Comparator|2|
11588080|NCT00731926|Placebo Comparator|3|
11588081|NCT00731913||1|Subjects with skin lesions requiring surgical excision and repair. One half of the each wound received Monocryl suture and the other half received Monosyn suture.
11588082|NCT00731913||2|Subjects with skin lesions requiring surgical excision and repair. One half of the each wound received Monocryl suture and the other half received Monosyn suture.
11588135|NCT00731393|Experimental|Group B|Subjects aged 3 to 6 years.
11588083|NCT00731874|Active Comparator|Arm 1 (6 to 8 ng/mL)|Target tacrolimus trough concentration of 6 to 8 ng/mL
11588084|NCT00731874|Active Comparator|Arm 2 (3 to 5 ng.mL)|Target tacrolimus trough concentration of 3 to 5 ng/mL
11588085|NCT00731861|Experimental|1|Paclitaxel plus PTK787
11588086|NCT00731848|Experimental|1|Intervention 1
11588087|NCT00731835|No Intervention|Group I|1. Wound Care (group 1)--Best standard wound care with aggressive debridement
11588088|NCT00731835|Active Comparator|Group 2|"2. Endovascular Intervention + Wound Care (group 2)--Best standard wound care in combination with endovascular revascularization
~Endovascular revascularization is the intervention"
11588089|NCT00731809|Other|1|PET CT
11588090|NCT00731796||1|Stroke victims with a visual field deficit that undergo vision restoration therapy
11588091|NCT00731796||2|Stroke victims with a visual field deficit who do not undergo any rehabilitation intervention
11588092|NCT00731796||3|Stroke victims that do not have a visual field deficit
11588093|NCT00731796||4|Normal individuals who have not had a stroke and do not have a visual field deficit
11588094|NCT00731783|Active Comparator|Index patient only|Only the child recently treated for a skin or soft tissue infection will undergo the decolonization regimen.
11588095|NCT00731783|Active Comparator|Household|All members of the household (over the age of 6 months) will be asked to follow the study protocol.
11588096|NCT00731770|Placebo Comparator|Placebo, then Advair 250- matched|1 puff bid Placebo for two weeks followed by a 4 week washout period with placebo. After the washout period, they then received Advair 250- matched 1 puff bid for two weeks.
11588097|NCT00731770|Active Comparator|Advair 250, then Placebo- matched|1 puff bid Advair 250 for two weeks followed by a 4 week washout period with placebo. After the washout period, they then received Placebo- matched 1 puff bid for two weeks.
11588098|NCT00731757|Experimental|1|Patients being treated with Humira.
11588099|NCT00731731|Experimental|Treatment (radiation therapy, vorinostat, temozolomide)|Patients undergo radiotherapy and receive vorinostat PO QD on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Patients also receive temozolomide PO QD on days 1-42. Beginning 4-6 weeks later, patients receive vorinostat PO QD on days 1-7 and 15-21 and temozolomide PO QD on days 1-5. Treatment with vorinostat and temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11588100|NCT00731705||1|Patients with hematological malignancies who are undergoing evaluation for autologous or allogeneic stem cell transplants OR First-degree relatives of patients evaluated for stem cell transplantation
11588101|NCT00731692|Experimental|FTY720D 0.5 mg|Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment
11588102|NCT00731692|Placebo Comparator|Placebo|Cohort 1 and 2: Patients randomized to placebo continued on placebo after re-randomization
11588103|NCT00731692|Experimental|FTY720D 1.25 mg switch to 0.5 mg|Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment on Nov 2009
11588104|NCT00731679|Placebo Comparator|Placebo|Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
11588105|NCT00731679|Experimental|Rifaximin|Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
11588106|NCT00731666|Other|Titan® IPP|Subjects implanted with Titan® IPP
11588107|NCT00731653|Experimental|1|BCI-024 and BCI-049
11588108|NCT00731640|Active Comparator|Monofocal|Patients unilaterally implanted with ReSTOR lens in one eye and previously implanted with monofocal Intraocular lens (IOL) (unspecified) in other eye
11588109|NCT00731640|Active Comparator|Phakic|Patients unilaterally implanted with ReSTOR lens in one eye and phakic in the other eye with no necessary cataract removal impending
11588110|NCT00731627|Placebo Comparator|1|placebo
11588111|NCT00731627|Active Comparator|11|simvastatin
11588112|NCT00731614|Experimental|Arm 1|Cognitive Behavior Therapy + mirror retraining
11588113|NCT00731614|Active Comparator|Arm 2|Supportive psychotherapy
11588114|NCT00731601|Experimental|1|pantoprazole 40mg/q6h IV infusion for three days
11588115|NCT00731601|Active Comparator|2|pantoprazole 8mg/h for three days
11588116|NCT00731588|Experimental|PPG1A - Adults|Phase I completed: Healthy male and post-menopausal female volunteers between the ages of 18 and 65. Volunteers must not have donated blood in the previous 8 weeks.
11588117|NCT00731588|Experimental|PPG1B - Infants|Phase II in progress: Newborns >= 24 weeks gestation who are patients in the Neonatal Intensive Care Unit at the University of Iowa Hospitals and Clinics that are being treated with the expectation of survival.
11588118|NCT00731562|Experimental|Varenicline Controlled Release, Fasted|
11588119|NCT00731562|Experimental|Varenicline Controlled Release, Fed|
11588120|NCT00731549|Experimental|1|Active Treatment of aripiprazole IM depot (300mg or 400mg)
11588121|NCT00731536||Patients with Hepatosplenic T-cell Lymphoma (HSTCL)|
11588122|NCT00731523|Experimental|1|
11588123|NCT00731510|Experimental|1|Carbohydrate supplements (drinks and gels)
11588124|NCT00731510|Placebo Comparator|2|Primarily Aspartame plus natural flavourings. Powder dissolved in water to provide non-distinguishable placebo drink.
11588125|NCT00731497|Active Comparator|1|children in households/villages using Solar Water Disinfection (SODIS) method of disinfecting household drinking water
11588126|NCT00731497|No Intervention|2|children in households/villages where Solar Water Disinfection (SODIS) has not been implemented
11588127|NCT00731484||Volunteer Patients/Subjects|These subjects should present the general population.
11588128|NCT00731471|Experimental|1|12 Healthy adults infected with HIV
11588129|NCT00731471|Experimental|2|12 HIV+ adults on antiretroviral therapy
11588130|NCT00731432|Experimental|A|Transmucosal Herbal Periodontal Patch (THPP)
11588131|NCT00731432|Placebo Comparator|B|Placebo Patch
11588132|NCT00731419|Active Comparator|SEMS|Self expanding metal stent compared to plastic stent. Both recognised forms of treatment for condition
11588133|NCT00731419|Active Comparator|Plastic stent|
11588134|NCT00731393|Experimental|Group A|Subjects aged between 6 months and 3 years.
11588138|NCT00731380|Experimental|ABI-007 escalation; then radiation + AUC|Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-FU 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
11588139|NCT00731367|Active Comparator|Gelled|Aquacel Ag gelled.
11588140|NCT00731367|Active Comparator|Adherent|Aquacel Ag adherent
11588141|NCT00731354|Active Comparator|SAL|Each patient will have Suction Assisted Lipoplasty procedure on one side of the body (this will be considered the control side)
11588142|NCT00731354|Active Comparator|VAL|Each patient will have VASER- assisted lipoplasty on the opposite side of the body. This will be the comparison side.
11588143|NCT00731341|Experimental|Hysteroscopic cryoablation|Women undergoing hysteroscopic ultrasound guided cryoablation for the treatment of uterine fibroids.
11588144|NCT00731315|Experimental|Treatment Group 1 - uncomplicated UTI|Would receive computer-assisted treatment for a uncomplicated UTI.
11588145|NCT00731315|Active Comparator|Control Group 1|Qualified for expedited treatment for uncomplicated cystitis but would receive usual care in the Emergency Department of Community Health Center.
11588146|NCT00731315|Experimental|Treatment Group 2 - Complicated Cystitis|Would receive expedited treatment for complicated cystitis with longer antibiotic course than the simple UTI patients.
11588147|NCT00731315|Active Comparator|Control Group 2|Qualified for expedited treatment for complicated cystitis treatment but would receive usual care in the clinic or emergency department.
11588148|NCT00731302|Experimental|Aspirin and Meloxicam|Arm: Aspirin and Meloxicam Each participant will receive 81 mg aspirin per day for 7 days, followed by meloxicam 7.5 mg daily plus aspirin 81 mg daily for 5 days
11588149|NCT00731289|Experimental|1|single intraarticular injection of hyaluronan 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
11588150|NCT00731289|Active Comparator|2|single intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)
11588151|NCT00731276|Other|Four Regimens|"The study has four type of regimens, and dosing of irinotecan depends on genotype of patient.
~Four Regimens are:
~Weekly Irinotecan (Irinotecan given at day 1, 8 and 15) every four weekly
~Weekly Xeliri ( Irinotecan given at day 1, 8 and 15)+ (Xeloda tabs 2000mg/m2 consumed over 14 days) every three weekly
~Three-weekly Xeliri (Irinotecan given at day 1 only) + (Xeloda tabs 2000mg/m2 consumed over 14 days) every three weekly
~Two-weekly FOLFIRI (Irinotecan given at day 1 only) + (CI Fluorouracil 600mg/m2 over 22hrs, IV Folinic Acid 200mg/m2 over 2hrs and IVP Fluorouracil 400mg/m2) every two weekly"
11588152|NCT00731263|Experimental|1|The study will start with AZD8055 formulated in a liquid solution prior to the tablet formulation becoming available. The tablet formulation will be introduced in Part A at the beginning of a new cohort at an appropriate dose, no higher than the dose of the liquid formulation in the last completed evaluated cohort. Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
11588153|NCT00731250|Placebo Comparator|PART 1-Visit 1-Placebo|Eligible subjects will receive matching placebo tablets
11588154|NCT00731250|Experimental|PART 1-Visit 1-Capsaicin|Eligible subjects will receive incremental capsaicin doses
11588155|NCT00731250|Placebo Comparator|PART 1-Visit 2-Placebo|Eligible subjects will receive matching placebo tablets
11588156|NCT00731250|Experimental|PART 1-Visit 2-Capsaicin|Eligible subjects will receive maximum capsaicin dose
11588157|NCT00731250|Placebo Comparator|PART 1-Visit 3-Placebo|Eligible subjects will receive matching placebo tablets
11588158|NCT00731250|Experimental|PART 1-Visit 3-Capsaicin|Eligible subjects will receive matching placebo tablets incremental capsaicin doses
11588159|NCT00731250|Placebo Comparator|PART 2-Visit 1-Placebo|Eligible subjects will receive matching placebo tablets
11588160|NCT00731250|Experimental|PART 2-Visit 1-SB-705498|Eligible subjects will receive SB-705498 tablets
11588161|NCT00731250|Experimental|PART 2-Visit 2-Capsaicin|Eligible subjects will receive matching placebo tablets incremental capsaicin doses
11588162|NCT00731237||1|The procedures undergone by this group will be evaluated for: Acute performance, deliverability and resource utilization during the procedure in the catheterization lab during commercial use by various physicians with a range of coronary stenting experience.
11588163|NCT00731224|Experimental|1|
11588164|NCT00731211|Experimental|Pazopanib|800 mg of pazopanib orally each day continuously
11588165|NCT00731198|Experimental|1|Drotaverine hydrochloride
11588166|NCT00731198|Active Comparator|2|Hyoscine-N-butylbromide
11588167|NCT00731185|Experimental|Mometasone Furoate Nasal Spray (MFNS)|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning
11588168|NCT00731185|Placebo Comparator|Placebo|Placebo nasal spray (2 sprays of 50 mcg in each nostril) once daily in the morning
11588169|NCT00731172|Experimental|1|20 mg copaxone(glatiramer acetate)subcutaneous injection(daily through week 12)
11588170|NCT00731172|Placebo Comparator|2|placebo subcutaneous injection(daily through week 12)
11588171|NCT00731159||A|"Sperm capacitation:
~Sperm capacitation is measured in a sample of the same ejaculated sperm unit given for fertilizing human oocytes in an IVF treatment cycle"
11588172|NCT00731146|Active Comparator|1 - Ultrasound|Participants will receive an ultrasound guided interscalene brachial plexus block
11588173|NCT00731146|Active Comparator|2 - Nerve Stimulator|Participants will receive a nerve stimulator guided interscalene brachial plexus block
11588174|NCT00731133|Other|Disulfiram|Disulfiram at 250 mg daily
11588175|NCT00731120|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
11588176|NCT00731120|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg encapsulated tablets, orally, once daily for up to 8 weeks.
11588177|NCT00731120|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg encapsulated tablets, orally, once daily for up to 8 weeks.
11588178|NCT00731107|Active Comparator|1|Veress Needle laparoscopic entry
11588179|NCT00731107|Active Comparator|2|XCEL bladeless trocar laparoscopic entry
11588231|NCT00730756|Placebo Comparator|Arm B|Matching placebo nasal spray intranasally once daily
11588232|NCT00730743|Experimental|1|Intermittent clamp group
11588180|NCT00731094|Experimental|Physical Activity Intervention|Expert system-based physical activity counseling: Individualized baseline counseling and guided goal setting to increase physical activity gradually to at least 150 minutes/week of moderate intensity, with a 12-month follow-up via postal mail of 14 additional counseling contacts generated by responses to a physical activity questionnaire and individually tailored computer-generated expert system feedback messages for physical activity based on stages of the motivational readiness for change model
11588181|NCT00731094|No Intervention|Attention Control|Generalized baseline healthy lifestyle education and suggestion to increase physical activity, with a 12-month follow-up via postal mail of 14 wellness newsletters focused on health issues other than physical activity
11588182|NCT00731068|Experimental|1|PRGF
11588183|NCT00731068|Placebo Comparator|2|
11588184|NCT00731055|Experimental|Intervention 1|"Each participant participates in 4 consecutive interventions in random order.
~Placebo, 1 capsule before the session
~0.5 mg varenicline, 1 capsule before the session 3.1 mg varenicline, 1 capsule before the session
~4. 2 mg varenicline, 1 capsule before the session"
11588185|NCT00731055|Experimental|Intervention 2|Each participant participates in 4 consecutive interventions in random order. 1.0.5 mg varenicline, 1 capsule before the session 2. 1 mg varenicline, 1 capsule before the session 3.2 mg varenicline, 1 capsule before the session 4. Placebo, 1 capsule before the session
11588186|NCT00731055|Experimental|Intervention 3|Each participant participates in 4 consecutive interventions in random order. 1.1 mg varenicline, 1 capsule before the session 2. 2 mg varenicline, 1 capsule before the session 3.Placebo, 1 capsule before the session 4. 0.5 mg varenicline, 1 capsule before the session
11588187|NCT00731055|Experimental|Intervention 4|Each participant participates in 4 consecutive interventions in random order. 1.2 mg varenicline, 1 capsule before the session 2. Placebo, 1 capsule before the session 3. 0.5 mg varenicline, 1 capsule before the session 4. 1 mg varenicline, 1 capsule before the session
11588188|NCT00731042|Experimental|Avagard|3M Avagard Surgical and healthcare Personnel Hand Antiseptic with Moisturizers
11588189|NCT00731042|Active Comparator|Purell|Purell Surgical Scrub with Moisturizers
11588190|NCT00731029|Experimental|Group A|The subjects in this group will be 18-60 years.
11588191|NCT00731029|Experimental|Group B|The subjects in this group will be > 60 years.
11588192|NCT00731029|Active Comparator|Group C|The subjects in this group will be 18-60 years.
11588193|NCT00731029|Active Comparator|Group D|The subjects in this group will be > 60 years.
11588194|NCT00731016|Other|1|Zoledronic acid, pravastatin
11588195|NCT00731003|Experimental|I|ATD procedure
11588196|NCT00731003|Experimental|II|Oxitriptan
11588197|NCT00731003|Placebo Comparator|III|Amino acid mixture with tryptophan
11588198|NCT00731003|Placebo Comparator|IV|Placebo capsule
11588199|NCT00730990|Experimental|Cohort 1|This arm will have no active treatment.
11588200|NCT00730990|Experimental|Cohort 2|
11588201|NCT00730977|Experimental|single|single arm, open label, 4 doses tested.
11588202|NCT00730964|Other|Phase 4|Open Label
11588203|NCT00730951|Experimental|1|0.5g Korean Red Ginseng (1 capsule) 5.5g Corn Starch (11 capsules)
11588204|NCT00730951|Experimental|2|1g Korean Red Ginseng (2 capsules) 5g Corn Starch (10 capsules)
11588205|NCT00730951|Experimental|3|3g Korean Red Ginseng (6 capsules) 3g Corn Starch (6 capsules)
11588206|NCT00730951|Experimental|4|6g Korean Red Ginseng (12 capsules)
11588207|NCT00730951|Experimental|5|6g Corn Starch Control (12 capsules)
11588208|NCT00730938|Active Comparator|1|
11588209|NCT00730938|Placebo Comparator|2|Saline placebo
11588210|NCT00730925|Experimental|BIBW 2992|patient to receive tablets of BIBW 2992 once a day, starting at high dose until progression of the disease
11588211|NCT00730925|Experimental|BIBW 2992 + paclitaxel|patient whose disease progressed on treatment with BIBW 2992 monotherapy to receive tablet of BIBW 2992 once a day in combination with i.v. paclitaxel 3 weekly
11588212|NCT00730912|Experimental|Pediatrics 3 to 6 years|Pediatrics 3 to 6 years
11588213|NCT00730912|Experimental|Pediatrics 7 to 15 years|Pediatrics 7 to 15 years
11588214|NCT00730912|Experimental|Adults 16 to 64 years|Adults 16 to 64 years
11588215|NCT00730886|Experimental|1|Non-invasive procedure for fertility enhancement (i.e., ExAblate treatment)
11588216|NCT00730886|Active Comparator|2|Invasive surgical procedure for fertility enhancement (i.e., myomectomy)
11588217|NCT00730873|Experimental|A|continuous positive airway pressure
11588218|NCT00730860|Experimental|RFA+TACE|treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
11588219|NCT00730860|Active Comparator|RFA only|treatment of hepatocellular carcinoma by radiofrequency ablation only
11588220|NCT00730847|Experimental|Cervarix Group|Healthy female subjects who received three doses of the Cervarix vaccine, administered intramuscularly in the deltoid region according to a 0, 1 and 6-month schedule.
11588221|NCT00730821|Experimental|1|
11588222|NCT00730808|Experimental|Test|Oral nutritional supplement: assignment according to consecutive random numbers.
11588223|NCT00730808|Placebo Comparator|Control|Assignment according to consecutive random numbers.
11588224|NCT00730795|Experimental|Group A|Subjects receiving the low-dose antigen candidate TB vaccine
11588225|NCT00730795|Experimental|Group B|Subjects receiving the high-dose antigen candidate TB vaccine
11588226|NCT00730782|Active Comparator|1|The experimental vaccine PfAMA1 formulated in Alhydrogel
11588227|NCT00730782|Active Comparator|2|The experimental vaccine PfAMA1 formulated in Montanide ISA720
11588228|NCT00730782|Active Comparator|3|The experimental vaccine PfAMA1 formulated in ASO2A
11588229|NCT00730769|Experimental|Single arm|Patients received a short induction of IV ganciclovir (Cymevene®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir (Valcyte®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 900 mg bid (after meals) for 16 days up to complete 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockcroft-Gault equation)
11588230|NCT00730756|Active Comparator|Arm A|Fluticasone Furoate Nasal Spray 110mcg intranasally once daily
11588234|NCT00730730|Experimental|Complete SE Iliac Stent|Complete SE Iliac Stent
11588235|NCT00730717|Experimental|1|Patients who are not concurrently receiving methotrexate treatment for pyoderma gangrenosum
11588236|NCT00730717|Experimental|2|Patients who are receiving concurrent methotrexate for pyoderma gangrenosum
11588237|NCT00730691|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
11588238|NCT00730691|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
11588239|NCT00730691|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
11588240|NCT00730691|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
11588241|NCT00730691|Active Comparator|Duloxetine 60 mg|Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week.
11588242|NCT00730678||All Participants|All participants enrolled on this study will have blood drawn for genetic testing.
11588243|NCT00730665|Experimental|100ug|
11588244|NCT00730665|Experimental|300ug|
11588245|NCT00730665|Experimental|1mg|
11588246|NCT00730665|Experimental|3mg|
11588247|NCT00730665|Placebo Comparator|Placebo|
11588248|NCT00730652|Experimental|MDX1411|An accelerated titration design (ATD) will be utilized and subjects will be assigned to a dose level in the order they enter the study.
11588249|NCT00730639|Experimental|Melanoma - BMS-936558 (MDX-1106)|
11588250|NCT00730639|Experimental|RCC - BMS-936558 (MDX-1106)|
11588251|NCT00730639|Experimental|mCRPC - BMS-936558 (MDX-1106)|
11588252|NCT00730639|Experimental|NSCLC - BMS-936558 (MDX-1106)|
11588253|NCT00730639|Experimental|CRC - BMS-936558 (MDX-1106)|
11588254|NCT00730626|Experimental|1|L.acidophilus and B.lactis (1x10E9 of each probiotics) with 40 mg of green the extract
11588255|NCT00730626|Experimental|2|L.acidophilus and B.lactis (1x 10E10 of each probiotics) with 40 mg of green tea extract
11588256|NCT00730626|Placebo Comparator|3|Placebo
11588257|NCT00730613|Experimental|Treatment (therapeutic autologous lymphocytes)|Patients receive an infusion of autologous antigen-specific CD8+ cytotoxic T-lymphocyte clones over 5-10 minutes on days 1, 3, and 5 of weeks 1 and 2. Treatment repeats every 3 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity.
11588258|NCT00730600|Experimental|1|1= THAI traditional massage
11588259|NCT00730587||1|Full-term healthy infants ages 5 months to 3 years.
11588260|NCT00730574|No Intervention|B|The control group, marked B, gets only B12 vitamin 1mg/day treatment to comply with ethics regulations seeing as they do suffer from B12 deficiency .
11588261|NCT00730574|Experimental|A|The trial group which receives daily treatment of 1mg Vitamin B12 (sublingual tablets) combined with 5 mg Folic acid (tablets)
11588262|NCT00730561|No Intervention|1|
11588263|NCT00730561|Experimental|2|Hematopoietic stem cell transplantation
11588264|NCT00730548|Experimental|1|Remote Arm (OptiVol plus Connexus Telemetry plus CareLink plus Intervention Algorithm), Clinical Management Alerts ON
11588265|NCT00730548|No Intervention|2|No Care Alerts available, standard treatment of the patient
11588266|NCT00730535|Experimental|Tolterodine 1|
11588267|NCT00730535|Experimental|Toterodine 3|
11588268|NCT00730535|Experimental|Tolterodine 6|
11588269|NCT00730522|Active Comparator|1|CPP-109 vigabatrin tablets
11588270|NCT00730522|Placebo Comparator|2|Matching Placebo Tablets
11588271|NCT00730496|Experimental|1|the study group, 45 women
11588272|NCT00730496|No Intervention|2|the control group, 45 women
11588273|NCT00730483|Experimental|DEB-TACE|PVA microporous hydrospheres loaded with doxorubicin hydrochloride used for the treatment of unresectable liver metastases from neuroendocrine tumors.
11588274|NCT00730470|Experimental|1|
11588275|NCT00730457|Experimental|A|Intramuscular (i.m.) vaccination of a single dose of 0.1 µg, 0.3 µg, 1 µg, 2 µg, 3 µg, 5 µg and 8 µg of STF2.HA1 (SI) (VAX125).
11588276|NCT00730431|Experimental|IDX184 5 mg|Healthy participants will be administered a single 5 mg dose of IDX184.
11588277|NCT00730431|Experimental|IDX184 10 mg|Healthy participants will be administered a single 10 mg dose of IDX184.
11588278|NCT00730431|Experimental|IDX184 25 mg|Healthy participants will be administered a single 25 mg dose of IDX184.
11588279|NCT00730431|Experimental|IDX184 50 mg|Healthy participants will be administered a single 50 mg dose of IDX184.
11588280|NCT00730431|Experimental|IDX184 75 mg|Healthy participants will be administered a single 75 mg dose of IDX184.
11588281|NCT00730431|Experimental|IDX184 100 mg|Healthy participants will be administered a single 100 mg dose of IDX184.
11588282|NCT00730431|Placebo Comparator|Placebo|Healthy participants will be administered placebo matching IDX184.
11588283|NCT00730418|Experimental|doxazosin 4mg|doxazosin 4mg group
11588284|NCT00730418|Experimental|doxazosin 8mg|doxazosin 8mg group
11588285|NCT00730405|Active Comparator|Albaconazole 100mg|Albaconazole for 36 weeks
11588286|NCT00730405|Active Comparator|Albaconazole 200mg|Albaconazole for 36 weeks
11588287|NCT00730405|Active Comparator|Albaconazole 400mg|Albaconazole for 36 weeks
11588288|NCT00730405|Active Comparator|Albaconazole 400mg 24 weeks, Placebo 12 weeks|Albaconazole for 24 weeks, Placebo for 12 weeks
11588289|NCT00730405|Placebo Comparator|Placebo 400 mg|Placebo for 36 weeks
11588290|NCT00730392|Experimental|1 drug, 2 placebo|"Etanercept
~Placebo"
11588291|NCT00730379|Experimental|1|ridaforolimus (MK8669) + dalotuzumab (MK0646)
11588292|NCT00730366|Experimental|1|Experimental: IPTp-SP + promotion: Active Comparator
11588293|NCT00730366|Experimental|2|IPTp-SP alone (without promotion)
11588294|NCT00730366|Active Comparator|3|Weekly CQ prophylaxis
11588348|NCT00730002|Active Comparator|2 - patients with SLE, no neuropsych|Systemic Lupus Erythematosus(SLE) patients without neuropsychiatric symptoms - receive MRA
11588641|NCT00728065|Experimental|7|Rice Milk (control)
11588295|NCT00730353|Experimental|1|"Treatment will be administered on an outpatient basis. Chemotherapy will be administered in a 28-day treatment cycle. The 28 days of treatment with paclitaxel and sunitinib malate (plus the time required to recover if toxicity is encountered) is defined as a cycle.
~Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
~Sunitinib malate 37.5 mg orally, daily. After 4 cycles, paclitaxel will be discontinued and patients will continue on sunitinib malate until disease progression, unacceptable toxicity, or physician discretion."
11588296|NCT00730340|Active Comparator|1|Patients will receive closure of the tonsillar fossae following tonsillectomy.
11588297|NCT00730340|Active Comparator|2|Patients will not receive closure to one or both tonsillar fossa following a tonsillectomy
11588298|NCT00730327|Experimental|BIB®|Receives BioEnterics® Intragastric Balloon Intervention as well as diet and exercise counseling with the Behavioral Modification Intervention.
11588299|NCT00730327|Other|Control|Control arm receives the Behavioral modification intervention only.
11588300|NCT00730314|Experimental|1|Unrelated donor
11588301|NCT00730314|Experimental|2|Cord Blood
11588302|NCT00730288|Experimental|1|Received monovalent Vero dengue vaccine in Study DIV12
11588303|NCT00730288|Experimental|2|Received Yellow fever vaccine in Study DIV12
11588304|NCT00730288|Experimental|3|Flavivirus-naive subjects
11588305|NCT00730275|Experimental|Sitagliptin 50 mg|Participants were randomized to sitagliptin 50 mg
11588306|NCT00730275|Experimental|Sitagliptin 100 mg|Participants were randomized to sitagliptin 100 mg
11588307|NCT00730275|Experimental|Sitagliptin 200 mg|Participants were randomized to a single dose of sitagliptin 200 mg
11588308|NCT00730275|Placebo Comparator|Placebo to sitagliptin|Participants were randomized to matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg
11588309|NCT00730262|Experimental|Single-Arm|
11588310|NCT00730249|Active Comparator|1|
11588311|NCT00730249|Placebo Comparator|2|
11588312|NCT00730236|Experimental|AEGR-733|
11588313|NCT00730210|Active Comparator|a: PTH (1-84) 100 ug s.c.inj. once a day|PTH (1-84) 100 ug subcutaneous injections once a day
11588314|NCT00730210|Placebo Comparator|b: placebo 100 ug s.c. inj. once a day|placebo 100 ug sub cutaneous injection once a day
11588315|NCT00730197|Experimental|1|NISOLDIPINE EXTENDED-RELEASE TABLETS, 40 MG
11588316|NCT00730197|Active Comparator|2|Sular® Extended Release 40 mg tablets
11588317|NCT00730184|Active Comparator|1|Participants receive potassium bicarbonate in dosage of 90 mmol/d. This compound has no other name.
11588318|NCT00730184|Placebo Comparator|2|Participants receive placebo as microcrystalline cellulose. This compound has no other name.
11588319|NCT00730171|Experimental|Linaclotide|Linaclotide 290 μg/day capsules, administered orally once daily for up to 78 weeks. Dose reduction to 145 μg/day was permitted at the discretion of the Investigator.
11588320|NCT00730158|Experimental|Arm A|irinotecan+ KD018
11588321|NCT00730158|Experimental|Arm B|irinotecan + placebo
11588322|NCT00730145|Experimental|PD-0332334|
11588323|NCT00730132||New Statin|Group 1 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) whose lipid-lowering therapy was modified by transition to a new statin treatment
11588324|NCT00730132||Statin Dose Titration|Group 2 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) whose lipid-lowering therapy was modified by increasing the dose of ongoing statin treatment
11588325|NCT00730132||Ezetimibe added to existing statin|Group 3 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) and whose lipid-lowering therapy was modified by the addition of ezetimibe to ongoing statin treatment
11588326|NCT00730119||Neonates|Subjects ages birth to 30 days
11588327|NCT00730119||Infants|Subjects aged >30 days to 2 years
11588328|NCT00730119||Adults|Subjects aged 18 years of age or older
11588329|NCT00730106||1|Patients with pre-defined alarm symptoms
11588330|NCT00730106||2|Patients without pre-defined alarm symptoms
11588331|NCT00730093|Other|A|
11588332|NCT00730080||Sapropterin (Kuvan)|Individuals with phenylketonuria (PKU) who are beginning treatment with sapropterin.
11588333|NCT00730080||Control|Healthy individuals without phenylketonuria (PKU).
11588334|NCT00730067|Experimental|1|Sildenafil treatment
11588335|NCT00730067|Placebo Comparator|2|placebo
11588336|NCT00730054|Active Comparator|1|Clonidine
11588337|NCT00730054|Active Comparator|2|Remifentanil
11588338|NCT00730054|Experimental|4|Remifentanil+clonidine
11588339|NCT00730054|Placebo Comparator|3|Placebo
11588340|NCT00730041|Active Comparator|Palatal Implants|Pillar(R) Palatal Implants in combination with continuous positive airway pressure (CPAP) in subjects diagnosed with obstructive sleep apnea (OSA)
11588341|NCT00730041|Sham Comparator|Sham procedure|Sham (procedure but no implants inserted) in combination with continuous positive airway pressure (CPAP) in subjects diagnosed with obstructive sleep apnea (OSA)
11588342|NCT00730028|Experimental|Limited Abscess|Limited abscess with or without cellulitis less than or equal to 5 cm in diameter will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA 300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children; or c) placebo two capsules three times daily.
11588343|NCT00730028|Experimental|Cellulitis or Larger Abscess|Subjects with cellulitis only or abscess > 5 cm in diameter, or with 2 or more sites of skin infection will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children.
11588344|NCT00730015|Experimental|145 μg linaclotide|
11588345|NCT00730015|Experimental|290 μg linaclotide|
11588346|NCT00730015|Placebo Comparator|Matching Placebo|
11588347|NCT00730002|Active Comparator|1- Healthy Subjects|Healthy Subjects- receive MRA
11588349|NCT00730002|Active Comparator|3 - patients with SLE with neuropsych|20 symptomatic neuropsychiatric systemic lupus erythematosus(NPSLE) patients.
11588350|NCT00730002|Active Comparator|4- healthy patients from other cohort|10 Healthy Controls (HC) from an existing cohort as part of another sponsored study.
11588351|NCT00729989|No Intervention|1|
11588352|NCT00729989|Experimental|2|
11588353|NCT00729976|Experimental|1|Ibuprofen Suppository
11588354|NCT00729976|Active Comparator|2|Ibuprofen suspension
11588355|NCT00729963|Experimental|1|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (< 1.8 kg) over the first month of treatment.
11588356|NCT00729963|Active Comparator|2|A standard reference group, which was paired according to age and BMI, received CPAP as a treatment for OSA.
11588357|NCT00729937|Experimental|TMP/SMX vs. Placebo|Subjects with an acute uncomplicated cutaneous abscess will be randomized to receive either Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day) or 4 placebo pills (twice per day).
11588358|NCT00729937|Experimental|TMP/SMX vs. Clindamycin|Subjects with an acute uncomplicated wound infection will be randomized to receive Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day, with alternating 1 identical placebo pill, twice per day) or clindamycin (300 mg, four times per day, with 3 placebo pills on alternating doses).
11588359|NCT00729937|Experimental|Cephalexin and TMP/SMX vs. Cephalexin|Subjects with acute uncomplicated cellulitis will be randomized to receive cephalexin (500 mg, four times per day) and Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day) or cephalexin (500 mg, four times per day) and placebo (4 pills, twice per day).
11588360|NCT00729924|Experimental|Open label oral raltegravir|Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days.
11588361|NCT00729911|Active Comparator|AF ablation|"Subjects assigned to the catheter ablation strategy will undergo catheter based AF ablation. The goal of the procedure is to achieve isolation of all 4 pulmonary veins.
~Subjects assigned to receive Amiodarone will have the oral medication initiated in an clinic setting."
11588362|NCT00729911|Active Comparator|Amiodarone|Amiodarone is taken orally on a daily basis.
11588363|NCT00729898||A|
11588364|NCT00729885|Experimental|1 Goggle I|Optimized Goggle
11588365|NCT00729885|Sham Comparator|2 Google II|Goggle with 20 Degree error
11588366|NCT00729872|Experimental|1|AG011: low dose
11588367|NCT00729872|Placebo Comparator|2|Placebo: low dose
11588368|NCT00729872|Experimental|3|AG011: mid dose
11588369|NCT00729872|Placebo Comparator|4|Placebo: mid dose
11588370|NCT00729872|Experimental|5|AG011: high dose
11588371|NCT00729872|Placebo Comparator|6|Placebo: high dose
11588372|NCT00729859|Experimental|Group 1|Acyline 300 µg/kg injections every two weeks (2 doses) + placebo (no active ingredients) gel daily for 28 days + oral placebo pill daily for 28 days
11588373|NCT00729859|Experimental|Group 2|Acyline 300 µg/kg injections every two weeks (2 doses) + Testosterone gel 100 mg daily for 28 days + oral placebo pill daily for 28 days
11588374|NCT00729859|Experimental|Group 3|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
11588375|NCT00729846|Experimental|A|Patients will receive combination verteporfin with photodynamic therapy at reduced fluence [300mw/cm2] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
11588376|NCT00729846|Experimental|B|Patients will receive combination verteporfin with photodynamic therapy at standard fluence [600mw/cm2] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
11588377|NCT00729833|Experimental|CP-751,871 + Sunitinib|Escalating cohorts of CP-751,871 + Sunitinib
11588378|NCT00729807|Experimental|Pentamidine|
11588379|NCT00729794|Experimental|Study Group|Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.
11588380|NCT00729794|Placebo Comparator|Control Group|Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.
11588381|NCT00729781|Experimental|Polyester Implants|There is one arm for this study. All subjects in this study will receive the investigational nasal implants. See the detailed description for procedure information.
11588382|NCT00729768|Experimental|1|
11588383|NCT00729768|Active Comparator|2|
11588384|NCT00729755|Experimental|Creatine|The subjects with major depressive disorder, treated with creatine in addition to escitalopram
11588385|NCT00729755|Placebo Comparator|Placebo|The subjects with major depressive disorder, treated with placebo in addition to escitalopram
11588386|NCT00729742|Experimental|Part 1|erlotinib
11588387|NCT00729742|Experimental|Part 2|erlotinib + dalotuzumab
11588388|NCT00729729|Placebo Comparator|1|Placebo
11588389|NCT00729729|Experimental|2|Slow release PCA derivative
11588390|NCT00729729|Experimental|3|Slow release PCA derivative higher dose
11588391|NCT00729716|Experimental|A|BioCart™II treatment
11588392|NCT00729716|Active Comparator|B|Microfracture procedure
11588393|NCT00729703|Experimental|1|Dual-chamber detection and activated treatment (at least ATP) in the slow VT-zone plus activated AAIsafeR pacing (basic rate 60 bpm).
11588394|NCT00729703|Experimental|2|Single-chamber ICD following clinical practice but with a monitoring zone active to allow the documentation of all occurring ventricular arrhythmias
11588395|NCT00729690|Experimental|1 Multi-Dose Pregabalin|Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.
11588396|NCT00729690|Experimental|2 single-dose pregabalin|Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
11588397|NCT00729690|Placebo Comparator|3 Placebo|Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
11588688|NCT00727753||Bevacizumab|
11588398|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 1)|BMS-936559 (MDX-1105)
11588399|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 2)|BMS-936559 (MDX-1105)
11588400|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 3)|BMS-936559 (MDX-1105)
11588401|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 4)|BMS-936559 (MDX-1105)
11588402|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 5)|BMS-936559 (MDX-1105)
11588403|NCT00729651|Experimental|1|Alendronate sodium/Cholecalciferol
11588404|NCT00729651|Active Comparator|2|Alendronate sodium
11588405|NCT00729638|Experimental|Single arm|Single arm phase I study
11588406|NCT00729612|Experimental|Treatment (nab-paclitaxel, carboplatin)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and carboplatin IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11588407|NCT00729599|Experimental|1|Cetylpyridinium chloride during 21 consecutive days.
11588408|NCT00729586|Experimental|Arm I (temsirolimus)|Patients receive temsirolimus IV over 30 minutes once weekly for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11588409|NCT00729586|Experimental|Arm II (temsirolimus, megestrol acetate, tamoxifen citrate)|Patients receive temsirolimus as in Arm I and megestrol acetate PO BID for 3 weeks alternating with tamoxifen citrate PO BID for 3 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11588410|NCT00729573||1|Participants in MTN-003. Participants will remain a part of their assigned MTN-003 study groups.
11588411|NCT00729560|Experimental|1|Flutamide
11588412|NCT00729560|Placebo Comparator|2|control to arm 1
11588413|NCT00729547|Placebo Comparator|2|Psychotherapy placebo session
11588414|NCT00729547|Experimental|1|Neurofeedback training which enhance left frontal alpha wave.
11588415|NCT00729521|No Intervention|Control|a control group receiving no special resources or guidance related to fall injury prevention or the community health improvement process;
11588416|NCT00729521|Active Comparator|Standard Program|"a Standard Program group receiving modest funding to implement an evidence-based fall prevention program in their local community;"
11588417|NCT00729521|Experimental|Facilitative System|"a Facilitative System group receiving facilitative system support in addition to the resources provided the Standard Program group"
11588418|NCT00729508|Experimental|1|
11588419|NCT00729508|Experimental|2|
11588420|NCT00729508|Experimental|3|
11588421|NCT00729508|Experimental|4|
11588422|NCT00729508|Placebo Comparator|5|
11588423|NCT00729495|Active Comparator|1|marketed celecoxib
11588424|NCT00729495|Experimental|2|overencapsulated celecoxib
11588425|NCT00729482|Experimental|1|Treatment Arm (RAD001)
11588426|NCT00729469|Experimental|Ospemifene 60 mg/day and K-Y® lubricant|Subjects will receive a single, oral dose (1 tablet) of ospemifene 60 mg each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.
11588427|NCT00729469|Placebo Comparator|Placebo and K-Y® lubricant|Subjects will receive a single, oral dose (1 tablet) of Placebo each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.
11588428|NCT00729456|No Intervention|1|
11588429|NCT00729456|Other|2|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
11588430|NCT00729443|Experimental|1|
11588431|NCT00729443|Placebo Comparator|2|
11588432|NCT00729430|Experimental|Omega-3 Fatty Acids|Participants will receive a highly purified form of omega-3 fatty acids for 6 months.
11588433|NCT00729430|Placebo Comparator|Placebo|Participants will receive placebo for 6 months.
11588434|NCT00729404|Experimental|Arm 1|
11588435|NCT00729404|Experimental|Arm 2|
11588436|NCT00729391|Experimental|1|Women's CoOp
11588437|NCT00729391|Active Comparator|2|Nutrition (Attention-Control)
11588438|NCT00729391|Active Comparator|3|Voluntary Counseling and Testing
11588439|NCT00729378|Experimental|Exercise Intervention|Implementation of intervention program designed to provide skeletal loading through high impact activities. All activities performed by subjects in exercise intervention arm will be assessed by physical activity questionnaire and use of pedometer. Have baseline anthropometric measurements, total body DXA scans and peripheral quantitative computed tomography (pQCT) scans of the tibia and femur.
11588440|NCT00729378|No Intervention|Control|Participants in this arm will not take part in exercise intervention. All activities performed by subjects in control arm will be assessed by physical activity questionnaire and use of pedometer. Have baseline anthropometric measurements, total body DXA scans and peripheral quantitative computed tomography (pQCT) scans of the tibia and femur.
11588441|NCT00729365|Placebo Comparator|Dippers - Placebo Treated|Subjects with normal nighttime blood pressure profile that decreases at night (Dippers). This group are all given placebo.
11588442|NCT00729365|Placebo Comparator|NonDippers - Placebo Treated|Subjects with nighttime blood pressure that does not drop during the night (non-dippers). This group will be given placebo.
11588443|NCT00729365|Active Comparator|NonDippers - Ramipril Treated|Subjects with nighttime blood pressure that does not drop during the night (non-dippers). This group will be given ACE inhibitor (study medication).
11588444|NCT00729352||Control group|18-35 yr old healthy subjects with wild type genotype for NQO1.
11588445|NCT00729352||Case group|18-35 yr old healthy subjects who are homozygotic for minor allele of NQO1 Pro187Ser polymorphism
11588446|NCT00729339|Active Comparator|1|lansoprazole plus mosapride for the first month, and followed by lansoprazole plus placebo for the second month
11588447|NCT00729339|Active Comparator|2|lansoprazole plus placebo for the first month, and lansoprazole plus mosapride for the second month
11588448|NCT00729326|Experimental|Sequence A|
11588449|NCT00729326|Experimental|Sequence B|
11588450|NCT00729313|Experimental|1|"Drug: Lanreotide 30 mg microparticle formulation
~One intra-muscular injection.
~A (maximum) 60 day treatment period (6 intra-muscular injections of lanreotide 30 mg microparticle formulation every 10 days): according to the patient's treatment response at 72h
~For non-responders patients lanreotide will be stopped."
11588689|NCT00727753||Dry AMD|
11588451|NCT00729313|Placebo Comparator|2|"One intra-muscular injection.
~A (maximum) 60 day treatment period (6 intra-muscular injections of placebo every 10 days): according to the patient's treatment response at 72h.
~Non-responder patients having received placebo on the first injection should receive an open-labelled lanreotide treatment."
11588452|NCT00729300|Placebo Comparator|1|Placebo
11588453|NCT00729300|Experimental|2|disulfiram
11588454|NCT00729287|Placebo Comparator|Arm I|Patients receive oral placebo daily in addition to standard care.
11588455|NCT00729287|Experimental|Arm II|Patients receive oral selenium daily in addition to standard care.
11588456|NCT00729274|Active Comparator|hypertonic saline solution|Hypertonic Saline 3% solution alone.
11588457|NCT00729274|Placebo Comparator|nebulized normal saline solution|2 nebulisation with 30 minute interval (max 4ml)
11588458|NCT00729261|Experimental|armA I|Patients remain intubated until the patients Glasgow coma score improves to greater than 8.
11588459|NCT00729261|Experimental|arm 2|Patients that meet standard airway and ventilatory criteria for extubation but have a Glasgow coma score of less than or equal to 8 are immediately extubated.
11588460|NCT00729235|Experimental|1|"Slow VT zone programmed as a Monitoring zone (Monitoring arm)"
11588461|NCT00729235|Experimental|2|Slow VT zone programmed with ATP therapies (therapy arm).
11588462|NCT00729222|Placebo Comparator|1|Placebo
11588463|NCT00729222|Experimental|2|rolofylline
11588464|NCT00729209|Experimental|ARRY-371797 (Schedule 1)|
11588465|NCT00729209|Experimental|ARRY-371797 (Schedule 2)|
11588466|NCT00729209|Placebo Comparator|Placebo|
11588467|NCT00729196|Experimental|1|Low-Glycemic Load Diet
11588468|NCT00729196|Active Comparator|2|Low-Fat Diet
11588469|NCT00729183|Experimental|Odanacatib 50 mg|Participants receive 50 mg odanacatib and open-label 5600 IU vitamin D3 tablets once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
11588470|NCT00729183|Placebo Comparator|Placebo|Participants receive matching placebo to odanacatib and open-label 5600 IU vitamin D3 once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
11588471|NCT00729157|Experimental|Treatment (ziv-aflibercept and fludeoxyglucose F 18)|Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients experiencing clear clinical benefit with aflibercept may continue treatment beyond 12 months, at the discretion of the study sponsor. Patients undergo FDG-PET scans at baseline and after 8 weeks of study therapy to evaluate changes in FDG avidity on FDG-PET scan. Blood samples are obtained at baseline and periodically during study for laboratory correlative studies. Samples are examined for pretreatment serum VEGF concentration, thyroglobulin levels (when elevated), serum pharmacokinetics of aflibercept by ELISA, and anti-aflibercept antibodies.
11588472|NCT00729131||A|Control group: subjects are homozygotic for major allele for TNF-308 promoter polymorphism.
11588473|NCT00729131||B|Case Group: subjects are homozygotic or heterozygotic for minor allele of TNF-308 promoter polymorphism.
11588474|NCT00729118|Experimental|Lenalidomide + Vorinostat|Maintenance post autologous transplant
11588475|NCT00729079|Active Comparator|1|Subject will be randomly assigned to work with providers at Clinton Medical Associates
11588476|NCT00729079|Active Comparator|2|Subjects will be randomly assigned to work with providers at 1655 Elmwood AVe, Suite 125
11588477|NCT00729053|Active Comparator|Previous treatment, 0.16mg/kg|Patients will have clear cell renal carcinoma with previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.16mg/kg
11588478|NCT00729053|Active Comparator|Previous treatment, 0.64mg/kg|Patients will have clear cell renal carcinoma with previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.64mg/kg
11588479|NCT00729053|Active Comparator|Treatment Naive, 0.16mg/kg|Patients will have clear cell renal carcinoma without previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.16mg/kg
11588480|NCT00729053|Active Comparator|Treatment Naive, 0.64mg/kg|Patients will have clear cell renal carcinoma without previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.64mg/kg
11588481|NCT00729040|Active Comparator|1|Stepping Up to Health only
11588482|NCT00729040|Experimental|2|Stepping up to Health PLUS online message boards to talk with other participants
11588483|NCT00729027|Experimental|25 mg/day AVE5530|
11588484|NCT00729027|Experimental|50 mg/day AVE5530|
11588485|NCT00729027|Placebo Comparator|Placebo|
11588486|NCT00729001|Experimental|Group A|Human Rotavirus Vaccine - Formulation 1
11588487|NCT00729001|Experimental|Group B|Human Rotavirus Vaccine - Formulation 2
11588488|NCT00729001|Placebo Comparator|Group C|
11588489|NCT00728988|Experimental|Atorvastatin Group|
11588490|NCT00728988|Other|Usual Care Group|
11588491|NCT00728975||1|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Vancouver Centre,
11588492|NCT00728975||2|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Centre for Southern Interior
11588493|NCT00728975||3|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Fraser Valley Centre
11588494|NCT00728975||4|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Vancouver Island Centre
11588495|NCT00728975||5|Vancouver Coastal Cottage Hospice inpatients
11588496|NCT00728975||6|Vancouver Coastal Richmond Palliative Care Program patients
11588497|NCT00728975||7|Vancouver Coastal Lions Gate Palliative Care Unit inpatients
11588498|NCT00728975||8|Providence Health St Paul's Hospital Palliative Care Unit inpatients
11588499|NCT00728975||9|Providence Health Marion Hospice inpatients
11588500|NCT00728975||10|Vancouver Island Health Authority Victoria Hospice inpatients
11588501|NCT00728975||11|Fraser Health Burnaby Hospital Tertiary Palliative Care Unit inpatients
11588502|NCT00728975||12|Fraser Health Mission Hospice inpatients
11588503|NCT00728975||13|Fraser Health Langley Hospice inpatients
11588631|NCT00728091|Experimental|Satavaptan Dose 2|Fixed High dose up to day 4, followed by optional titration up to day 30
11588504|NCT00728949|Active Comparator|IMC-A12 (cixutumumab) + antiestrogen therapy|Participants will receive intravenous IMC-A12 10 mg/kg over 1 hour every 2 weeks, as well as the same dose and schedule of the last antiestrogen therapy to which their disease became refractory.
11588505|NCT00728949|Experimental|IMC-A12 (cixutumumab)|Participants will receive only IMC-A12 (10 mg/kg over 1 hour every 2 weeks).
11588506|NCT00728936|Experimental|IMO-2125 0.04 mg/kg q week|IMO-2125 given weekly at 0.04 mg/kg
11588507|NCT00728936|Experimental|IMO-2125 0.08 mg/kg q week|IMO-2125 given weekly at 0.08 mg/kg
11588508|NCT00728936|Experimental|IMO-2125 0.16 mg/kg q week|IMO-2125 given weekly at 0.16 mg/kg
11588509|NCT00728936|Experimental|IMO-2125 0.32 mg/kg q week|IMO-2125 given weekly at 0.32 mg/kg
11588510|NCT00728936|Experimental|IMO-2125 0.48 mg/kg q week|IMO-2125 given weekly at 0.48 mg/kg
11588511|NCT00728936|Placebo Comparator|Placebo|Weekly saline placebo
11588512|NCT00728936|Experimental|IMO-2125 0.16 mg/kg twice a week|IMO-2125 given twice a week at 0.16 mg/kg
11588513|NCT00728923|Experimental|1|Minocycline (NPL-2003)
11588514|NCT00728910|Active Comparator|Atorvastatin|atorvastatin 10 mg/day by mouth for a total duration of 4 weeks
11588515|NCT00728910|Active Comparator|ABT335|ABT335 135 mg/day by mouth added to atorvastatin for a total duration of at least 8
11588516|NCT00728910|Active Comparator|ER niacin|ER niacin titrated up to 2 g/day with aspirin 325 mg/day by mouth added to atorvastatin and ABT335 for 10 weeks
11588517|NCT00728897|Experimental|Subjects receiving treatment sequence ABC|Eligible subjects will receive treatment sequence ABC; A= 4x25 milligrams GSK598809 capsule given in fasted state, B= 100 milligrams GSK598809 capsule in given fasted state and C= 100 milligrams GSK598809 capsule given in fed state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
11588518|NCT00728897|Experimental|Subjects receiving treatment sequence ACB|Eligible subjects will receive treatment sequence ACB; A= 4x25 milligrams GSK598809 capsule given in fasted state, C= 100 milligrams GSK598809 capsule given in fed state and B= 100 milligrams GSK598809 capsule in given fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
11588519|NCT00728897|Experimental|Subjects receiving treatment sequence BAC|Eligible subjects will receive treatment sequence BAC; B= 100 milligrams GSK598809 capsule in given fasted state, A= 4x25 milligrams GSK598809 capsule given in fasted state and C= 100 milligrams GSK598809 capsule given in fed state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
11588520|NCT00728897|Experimental|Subjects receiving treatment sequence BCA|Eligible subjects will receive treatment sequence BCA; B= 100 milligrams GSK598809 capsule in given fasted state, C= 100 milligrams GSK598809 capsule given in fed state and A= 4x25 milligrams GSK598809 capsule given in fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
11588521|NCT00728897|Experimental|Subjects receiving treatment sequence CAB|Eligible subjects will receive treatment sequence CAB; C= 100 milligrams GSK598809 capsule given in fed state, A= 4x25 milligrams GSK598809 capsule given in fasted state and B= 100 milligrams GSK598809 capsule in given fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
11588522|NCT00728897|Experimental|Subjects receiving treatment sequence CBA|Eligible subjects will receive treatment sequence CBA; C= 100 milligrams GSK598809 capsule given in fed state, B= 100 milligrams GSK598809 capsule in given fasted state and A= 4x25 milligrams GSK598809 capsule given in fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
11588523|NCT00728845|Experimental|Hydroxychloroquine, Carboplatin, Paclitaxel, Bevacizumab|Cohort 1: Bevacizumab Eligible Patients All on Day 1 Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Bevacizumab 15 mg/kg IV over 90 min for PLUS Hydroxychloroquine 200 mg PO BID Cycles every 3 weeks for 4-6 Cycles
11588524|NCT00728845|Experimental|Hydroxychloroquine, Carboplatin, Paclitaxel|Cohort 2: Bevacizumab Ineligible Patients All on Day 1 Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min PLUS Hydroxychloroquine 200 mg PO BID Cycles every 3 weeks for 4-6 Cycles
11588525|NCT00728832|Active Comparator|1|No test dose + DepoDur + flush with 1 mL normal saline
11588526|NCT00728832|Experimental|2|Test dose + flush with 1 mL normal saline + 3-minute wait + DepoDur + flush with 1 mL normal saline
11588527|NCT00728832|Experimental|3|Test dose + flush with 1 mL normal saline + 10-minute wait + DepoDur + flush with 1 mL normal saline
11588528|NCT00728832|Experimental|4|Test dose + flush with 1 mL normal saline + 15-minute wait + DepoDur + flush with 1 mL normal saline
11588529|NCT00728832|Experimental|5|Test dose + No flush + 3-minute wait + DepoDur + flush with 1 mL normal saline
11588530|NCT00728819|Active Comparator|1|Tapered PICC
11588531|NCT00728819|Active Comparator|2|Non-tapered PICC
11588532|NCT00728780|Experimental|A|ABT-143 15/135mg
11588533|NCT00728780|Active Comparator|B|ABT-335 135mg and rosuvastatin 15mg
11588534|NCT00728767|Experimental|1|
11588535|NCT00728767|Placebo Comparator|2|
11588536|NCT00728754|Experimental|Dental implant Osseotite Prevail|Dental implant with lateralized design
11588537|NCT00728754|Active Comparator|Dental implant Osseotite|Dental implant without the lateralized design
11588538|NCT00728728|Active Comparator|Arm 1: Pregnenolone|Pregnenolone
11588539|NCT00728728|Placebo Comparator|Arm 2: Placebo|Placebo
11588540|NCT00728715|Experimental|A|Medium Dose of budesonide-formoterol
11588541|NCT00728715|Active Comparator|B|High dose of inhaled budesonide (1600 mcg/day)
11588542|NCT00728689|Active Comparator|Group ST-246 Form I (followed by Form V)|Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.
11588632|NCT00728091|Placebo Comparator|Placebo|
11588633|NCT00728078|Experimental|1|low-dose thalidomide adjuvant therapy after RFA for HCC
11588634|NCT00728078|No Intervention|2|control group
11588635|NCT00728065|Experimental|1|White Bread (control)
11588636|NCT00728065|Experimental|2|White Bread (control)
11588543|NCT00728689|Active Comparator|Group ST-246 Form V (followed by Form I)|Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.
11588544|NCT00728663|Experimental|Arm: Cetuximab and Docetaxel|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8 and Docetaxel: 75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle
~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
11588545|NCT00728650||Observation|Patients with primary or metastatic hepatic malignancies
11588546|NCT00728637|Experimental|1|Participants took part in the Family Passport to Heart Health Program.
11588547|NCT00728637|Active Comparator|2|Participants took part in a control group.
11588548|NCT00728611|Experimental|1|
11588549|NCT00728611|Active Comparator|2|
11588550|NCT00728611|Placebo Comparator|3|
11588551|NCT00728598||1|Proliferative diabetic retinopathy, active.
11588552|NCT00728598||2|Proliferative diabetic retinopathy, quiescent.
11588553|NCT00728598||3|Control group. Patients with macular hole or idiopathic epiretinal membrane receiving vitrectomy for their disease.
11588554|NCT00728585|Experimental|Arm I (palifermin)|Patients receive palifermin IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity. Patients then receive palifermin IV on days 0, 1, and 2 after autologous or allogeneic hematopoietic stem cell transplantation.
11588555|NCT00728585|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity. Patients then receive placebo IV on days 0, 1, and 2 after autologous or allogeneic hematopoietic stem cell transplantation.
11588556|NCT00728572|Experimental|Experimental|Participant will receive a brief exam, a Basic Technique apex contact adjustment and Surface EMG.
11588557|NCT00728572|Sham Comparator|Sham|Participants will receive a sham Basic Technique adjustment (an adjacent contact not indicated by examination)and surface EMG.
11588558|NCT00728559|Experimental|1|preemptive trocar site analgesia
11588559|NCT00728559|Experimental|2|trocar site pre skin closure analgesia
11588560|NCT00728559|No Intervention|3|control
11588561|NCT00728546|Experimental|INA dose adjustment, NAT2|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
11588562|NCT00728533|Experimental|1|"Starting dose of 240 mg (40 mg/mL) will be given on Day 0.
~Maintenance doses of 360 mg (60 mg/mL) will be given after 1, 4, 7, and 10 months"
11588563|NCT00728533|Experimental|2|"Starting dose of 240 mg (40 mg/mL) will be given on Day 0.
~Maintenance doses of 480 mg (60 mg/mL) will be given after 1, 4, 7, and 10 months."
11588564|NCT00728507|Experimental|1|Two months of isoniazid, rifapentine, pyrazinamide and moxifloxacin (HPZM) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
11588565|NCT00728507|Active Comparator|2|Two months of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
11588566|NCT00728494||Treatment and Patient Assistance Program|Patient assistance program was provided to the participants treated with PegIntron/Rebetol. The support program consisted of training by physicians or specialized nurses on the significance of treatment compliance, methods for managing adverse events, and correct drug administration, as well as informational materials and assistance in the management of adverse events.
11588567|NCT00728494||Treatment Alone|PegIntron/Rebetol treatment only.
11588568|NCT00728481|Active Comparator|Esomeprazole|Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks for subjects with positive 24 hour pH study (GERD)
11588569|NCT00728481|Active Comparator|Budesonide|Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose [Splenda-registered trademark]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
11588570|NCT00728468|Experimental|Treatment arm|
11588571|NCT00728455|Experimental|A|
11588572|NCT00728455|Experimental|B|
11588573|NCT00728455|Experimental|C|
11588574|NCT00728455|Experimental|D|
11588575|NCT00728455|Experimental|E|
11588576|NCT00728442|Experimental|1|medical decision based on computerized guideline-based decision support system
11588577|NCT00728442|No Intervention|2|
11588578|NCT00728429|No Intervention|standard of care|normal anthracycline therapy
11588579|NCT00728429|Experimental|exercise program|
11588580|NCT00728416|Experimental|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
11588581|NCT00728416|Placebo Comparator|Arm 2|Matching placebo nasal spray
11588582|NCT00728403|Experimental|1|American Ginseng and American Red Ginseng Capsules
11588583|NCT00728403|Experimental|2|American Ginseng Capsules
11588584|NCT00728403|Placebo Comparator|3|Placebo Capsules
11588585|NCT00728390|Experimental|1|
11588586|NCT00728377|Active Comparator|Heath & Wellness|
11588587|NCT00728377|Experimental|Exercise|
11588588|NCT00728351|Experimental|vildagliptin + metformin|
11588589|NCT00728351|Active Comparator|metformin|
11588590|NCT00728338|Experimental|1|Martek Biosciences Corporation Neuromins Capsules 7.5 g DHA oil/day
11588591|NCT00728338|Placebo Comparator|2|7.5 g/ day olive oil
11588592|NCT00728325|Active Comparator|1|Standard Vocational Rehabilitation (VRP)
11588593|NCT00728325|Experimental|2|Supported Employment (SE)
11588594|NCT00728312|Active Comparator|1|Aripiprazole (Abilify), flexible dosing 5-15 mg per day
11588595|NCT00728312|Placebo Comparator|2|Placebo look-alike, flexible dosing 5-15 mg per day
11588596|NCT00728299|Experimental|1|
11588597|NCT00728299|Placebo Comparator|2|
11588637|NCT00728065|Experimental|3|White bread with 7.32 grams Salba hispanica
11588638|NCT00728065|Experimental|4|White bread with 15.58 grams Salba hispanica
11588639|NCT00728065|Experimental|5|White bread with 24 grams Salba hispanica
11588598|NCT00728286||Type 2 diabetes mellitus|We aim to determine the effects of dual antiplatelet therapy with aspirin 75mg once a day and clopidogrel 75mg once a day on platelet dependent thrombogenicity in patients with type 2 diabetes mellitus and acute coronary syndrome. Eighty patients (40 with type 2 diabetes and 40 without) have been studied one week after Non ST-elevation acute coronary syndrome. All patients were on secondary prevention therapy as recommended by international guidelines.
11588599|NCT00728273|Experimental|MMF|multi-micronutrient-fortified biscuit plus placebo deworming-treatment
11588600|NCT00728273|Experimental|Alb|placebo biscuit plus deworming treatment with Albendazole
11588601|NCT00728273|Experimental|MMF + Alb|multiple micronutrient-fortified biscuits with deworming treatment with Albendazole
11588602|NCT00728273|Placebo Comparator|placebo|placebo biscuit (non-fortified) and placebo deworming treatment
11588603|NCT00728260||Menactra Vaccine Recipients|"Children 2 years through 10 years of age who received Menactra vaccine within Kaiser Permanente during the study period. They served as their own controls for evaluation of acute (Days 0-30) events. Rates of events occurring during Days 0-30 following vaccination were compared to rates of events occurring during Days 31-60 following vaccination.
~Six-month surveillance: For each individual receiving Menactra vaccine, the rate of an event in the 30-day follow-up period was compared with the rate of the same event in the 31-180-day follow-up period using age, sex, and seasonality as covariates in Cox regression analyses.
~Menactra vaccine was administered according to routine clinical practice."
11588604|NCT00728234||1|all infants born below 30 weeks gestational age at the medical university vienna within the study period (01/2000 - 12/2002)
11588605|NCT00728221|Placebo Comparator|1|Placebo capsules (3g)
11588606|NCT00728221|Experimental|2|Whole Korean Red Ginseng root (3g)
11588607|NCT00728221|Experimental|3|Ginsenoside fraction of Korean Red Ginseng B (0.22g); bioequivalent to the original whole KRG root
11588608|NCT00728221|Experimental|4|Polysaccharide fraction of KRG root (0.21g); bioequivalent to the original whole KRG root
11588609|NCT00728208|Experimental|GSK372475|Drug
11588610|NCT00728195|Placebo Comparator|Placebo First, Then Olanzapine|Participants will receive 2 matching placebo capsules orally twice daily for 6 consecutive weeks, then 2 matching placebo capsules orally in the morning and olanzapine 10 milligram (mg) capsule along with matching placebo capsule orally in the evening for next 1 week, then 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with olanzapine 5 mg capsule orally in the evening for next 5 weeks.
11588611|NCT00728195|Experimental|JNJ-37822681 10 mg|Participants will receive 1 matching placebo capsule along with JNJ-37822681 10 mg capsule orally twice a day for 12 consecutive weeks.
11588612|NCT00728195|Experimental|JNJ-37822681 20 mg|Participants will receive 1 matching placebo capsule along with JNJ-37822681 20 mg capsule orally twice a day for 12 consecutive weeks.
11588613|NCT00728195|Experimental|JNJ-37822681 30 mg|Participants will receive JNJ-37822681 30 mg (one 10 mg capsule along with JNJ-37822681 20 mg capsule) orally twice a day for 12 consecutive weeks.
11588614|NCT00728195|Active Comparator|Olanzapine|Participants will receive 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with matching placebo capsule orally in the evening for 1 week, then 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with olanzapine 5 mg capsule orally in the evening for next 11 consecutive weeks.
11588615|NCT00728182|Experimental|NA-1|20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
11588616|NCT00728182|Placebo Comparator|Placebo|
11588617|NCT00728156|Active Comparator|C|Patients assigned to clopidogrel in addition to their standard care.(all patients will be on aspirin)We aim to study the effect of clopidogrel as dual antiplatelet therapy in patients with established coronary artery disease and type 2 diabetes. Ninety patients with type 2 diabetes and stable coronary artery disease has been randomly treated with clopidogrel or placebo (45 each) for one week in addition to their standard care (including aspirin,75 mg once daily).
11588618|NCT00728156|Placebo Comparator|P|Patients assigned to placebo in addition to their standard care.(all patients will be on aspirin).This is a single-centre randomised double-blind placebo-controlled parallel design study, comparing efficacy of clopidogrel versus placebo in patients with T2DM and coronary artery disease. Ninety patients have completed the study. All patients were on their routine medications as per standard practice. After informed consent, participants were randomised to receive either clopidogrel 75mg daily or placebo for 7 days.
11588619|NCT00728143|Active Comparator|1|Healthy subjects
11588620|NCT00728143|Experimental|2|Diabetic subjects
11588621|NCT00728130|Experimental|A|A neck dissection of at least the ipsilateral sub-level 1B will be performed in all patients
11588622|NCT00728117|Experimental|ibuprofen-feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen and 24 hours after the last dose of ibuprofen.
11588623|NCT00728117|Experimental|ibuprofen-fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen and 24 hours after the last dose of ibuprofen.
11588624|NCT00728117|Experimental|indomethacin-feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of indomethacin and 24 hours after the last dose of indomethacin.
11588625|NCT00728117|Experimental|indomethacin-fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of indomethacin and 24 hours after the last dose of indomethacin.
11588626|NCT00728104||1|The General Questionnaire: help to understand which characteristics of CVS patients are associated with both beneficial and harmful effects of these treatments
11588627|NCT00728104||2|The Co-Enzyme Q10 Questionnaire: to be completed by individuals who ever taken co-enzyme Q10
11588628|NCT00728104||3|The L-Carnitine Questionnaire: to be completed by individuals who have ever taken L-carnitine
11588629|NCT00728104||4|The Amitriptyline Questionnaire: to be completed by individuals who have ever taken amitriptyline
11588630|NCT00728091|Experimental|Satavaptan Dose 1|Fixed Low dose up to day 4, followed by optional titration up to day 30
11588642|NCT00728065|Experimental|8|Rice Milk with 7.32 grams Salba hispanica
11588643|NCT00728065|Experimental|9|Rice Milk with 15.58 grams Salba hispanica
11588644|NCT00728065|Experimental|10|Rice Milk with 24 grams Salba hispanica
11588645|NCT00728052|Experimental|Subjects receiving treatment sequence ABCD|Subjects will receive treatment sequence ABCD; A= placebo, B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, and D = GSK598809 dose 3.
11588646|NCT00728052|Experimental|Subjects receiving treatment sequence BACD|Subjects will receive treatment sequence BACD; B= GSK598809 dose 1 (75 milligrams), A= placebo, C = GSK598809 dose 2 and D = GSK598809 dose 3
11588647|NCT00728052|Experimental|Subjects receiving treatment sequence BCAD|Subjects will receive treatment sequence BCAD; B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, A= placebo and D = GSK598809 dose 3.
11588648|NCT00728052|Experimental|Subjects receiving treatment sequence BCDA|Subjects will receive treatment sequence BCDA; B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, D = GSK598809 dose 3 and A= placebo.
11588649|NCT00728026||1|Cyclic Vomiting Syndrome
11588650|NCT00728026||2|Irritable Bowel Syndrome
11588651|NCT00728026||3|Postural Orthostatic Tachycardia Syndrome
11588652|NCT00728026||4|Functional Abdominal Pain
11588653|NCT00728026||5|Chronic Nausea
11588654|NCT00728013|Experimental|A|intensive statin group
11588655|NCT00728013|Experimental|B|moderate statin group
11588656|NCT00728000|Experimental|chemotherapy regimen|Gemcitabine and oxaliplatin are given intravenously (into the vein) every 2 weeks. Erlotinib is a pill that is taken by mouth daily.
11588657|NCT00727987|Experimental|CNTO 148 50 mg + methotrexate|
11588658|NCT00727987|Experimental|CNTO 148 100 mg + methotrexate|
11588659|NCT00727987|Placebo Comparator|Placebo + methotrexate|
11588660|NCT00727974||1|"Diagnostic Criteria for CVS:
~3 or more different episodes of vomiting, normal health between episodes, no abnormal test results to account for vomiting [such as endoscopic biopsies (looking at a body part with a lighted tube), hydronephrosis (water block kidney drainage), cholelithiasis (gallstones), pancreatitis (swelling of the pancreas), and hypoglycemia (too little sugar in the blood)];"
11588661|NCT00727974||2|"Diagnostic Criteria for Migraine:
~5 or more different headaches, complete return to health in between headaches, headaches last 2-48 hours and get in the way everyday activity, headache affects one side of head, with pounding moderate-to-severe pain, one of the following: nausea, vomiting, photophobia (fear of light), phonophobia (fear of sound)."
11588662|NCT00727961|Experimental|Arm 1|Caelyx Intravenous, 50 mg/m^2, given for 6 cycles
11588663|NCT00727948|Experimental|receive aspirin|
11588664|NCT00727922|Experimental|1|
11588665|NCT00727909|Experimental|Hearing Aid Treatments|"Hearing aid treatments:
~TC (Traditional Custom), RITA (Receiver-in-the Aid), and RITE (Receiver-in the-Ear)"
11588666|NCT00727896|Experimental|1 is experimental with SMS|Arm 1 is experimental with SMS intervention
11588667|NCT00727896|Active Comparator|2 is (active comparator) standard care|Arm 2 is the usual care arm (standard care)
11588668|NCT00727883||1|Post menopausal women treated with adjuvant TAM for breast cancer
11588669|NCT00727870|Other|1|After the two biopsies, one site will be covered with the antibiotic ointment and the band-aid type bandage (physician's current standard of care) and the other site will be covered the Shapes by PolyMem dressing.
11588670|NCT00727870|Other|2|Arm 2: after the two biopsies, one site will be covered with the antibiotic ointment and the band-aid type bandage (physician's current standard of care) and the other site will be covered the Shapes by PolyMem Silver dressing.
11588671|NCT00727870|Other|3|Arm 3: after the two biopsies, one site will be covered with Shapes by PolyMem dressing and the other site will be covered the Shapes by PolyMem Silver dressing.
11588672|NCT00727857|Experimental|Pioglitazone 15 mg /Metformin 850 mg BID|
11588673|NCT00727857|Active Comparator|Pioglitazone 15 mg BID|
11588674|NCT00727857|Active Comparator|Metformin 850 mg BID|
11588675|NCT00727844|Experimental|Delayed Start Linezolid|Subjects continued their existing regimen for 2 months after which LZD (600 mg once daily) was added. After 2 consecutive AFB negative sputum smears (not to exceed 4 months of LZD therapy), subjects were randomized to continue on 600 mg LZD once daily or to de-escalate to 300 mg once daily. Regardless of the dosage, subjects remained on LZD treatment for 18 months after sputum culture conversion or until they could no longer tolerate therapy.
11588676|NCT00727844|Experimental|Immediate Start Linezolid|Upon completion of entry criteria, subjects had LZD (600 mg once daily) added to their regimen. After 2 consecutive AFB negative sputum smears (or at 4 months) subjects were randomized to continue on 600 mg LZD once daily or to de-escalate to 300 mg once daily. Regardless of the dosage, subjects remained on LZD treatment for 18 months after sputum culture conversion or until they could no longer tolerate therapy.
11588677|NCT00727792|Experimental|Group 2 - Research MRI|Subjects will have additional sequences and/or modification to MRI sequences.
11588678|NCT00727792|Active Comparator|Group 1 - Clinical MRI|Clinically ordered MRI scan. Subjects will not have any additional sequences or modifications to their clinically ordered MRI
11588679|NCT00727779|Experimental|metabolic syndrome|intervention is to undergo eight weeks of progressive strength training; metabolic syndrome subjects will have baseline and post-intervention assessments including muscle biopsies and insulin clamps
11588680|NCT00727779|Active Comparator|control subjects|intervention is to undergo eight weeks of progressive strength training; non-obese sedentary subjects will have the same assessments as the metabolic syndrome subjects and exercise training simultaneously.
11588681|NCT00727766|Experimental|Cohort 1|Clofarabine 1 mg for 14 days followed by 14 days of rest. Each cycle is 28 days long.
11588682|NCT00727766|Experimental|Cohort 2|Clofarabine 2 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
11588683|NCT00727766|Experimental|Cohort 3|Clofarabine 3 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
11588684|NCT00727766|Experimental|Cohort 4|Clofarabine 4 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
11588685|NCT00727766|Experimental|Cohort 5|Clofarabine 5 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
11588686|NCT00727766|Experimental|Cohort 6|Clofarabine 6 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
11588687|NCT00727753||Ranibizumab|
11588690|NCT00727740|Experimental|1|Indomethacin liquid suspension 100 mg (25 mg/5ml) which is 20 cc of suspension instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
11588691|NCT00727740|Placebo Comparator|2|Placebo suspension in the same volume (20 cc) which is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. The placebo suspension is also flushed with 5 cc of normal saline.
11588692|NCT00727727||Parkinsonian patients|
11588693|NCT00727701|Experimental|1|Will receive usual wound prevention care, aftercare summaries, and regular surveillance.
11588694|NCT00727701|No Intervention|2|Will receive usual wound prevention and surveillance only.
11588695|NCT00727701|No Intervention|3|Will receive usual wound prevention only.
11588696|NCT00727675|Other|1|Integrated Cognitive Behavioral Therapy for pain reduction and opioid dependence.
11588697|NCT00727662|Experimental|1|Yoga
11588698|NCT00727662|Active Comparator|2|A Wellness Seminar series
11588699|NCT00727649|Active Comparator|Arm 1|Fiber (psyllium) powder
11588700|NCT00727649|Active Comparator|Arm 2|Loperamide
11588701|NCT00727636|Experimental|Gardasil vaccine - Prospective Study|Prospective study participants received the Gardasil vaccine during the study
11588702|NCT00727636|No Intervention|Retrospective Study|Retrospective study participants had blood drawn in the study after they had received the Gardasil vaccine from their primary medical provider
11588703|NCT00727597|Experimental|Arm A : Boosted Lexiva plus Epzicom|Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg).
11588704|NCT00727597|Experimental|Arm B: Efavirenz plus Epzicom|QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)
11588705|NCT00727584|Active Comparator|Arm I (multi-fraction radiotherapy)|Patients undergo 5 fractions of 20 Gy external-beam radiotherapy.
11588706|NCT00727584|Experimental|Arm II (single-fraction radiotherapy)|Patients undergo 1 fraction of 8 Gy external beam radiotherapy.
11588707|NCT00727571||No CKD or Anemia|Chronic kidney disease (CKD) is based on estimated Glomerular Filtration Rate (GFR), calculated by the Modification of Diet in Renal Disease (MDRD) method, of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per World Health Organization (WHO) criteria. Participants completed the study after Week 1; data contributed to prevalence estimates.
11588708|NCT00727571||No CKD, but Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants completed the study at Week 2 and completed an anemia work-up; data contributed to prevalence estimates.
11588709|NCT00727571||CKD with Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants were observed for 26 weeks and completed an anemia work-up, and mobility and physical performance assessments.
11588710|NCT00727571||CKD with no Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants were observed for 26 weeks and completed mobility and physical performance assessments.
11588711|NCT00727558|Active Comparator|narafilcon A|spherical soft contact lens worn as a daily disposable modality for one week
11588712|NCT00727558|Active Comparator|nelfilcon A|spherical soft contact lens worn as a daily disposable modality for one week
11588713|NCT00727545|Experimental|1|
11588714|NCT00727532|Experimental|Sorafenib|Eligible patients undergo pre-treatment DW-MRI of the abdomen and pelvis. Patient then receive Sorafenib 400mg orally twice daily on days 1-28. Following completion of 28 days of sorafenib, patients obtain a second DW-MRI.
11588715|NCT00727519|Experimental|PG|
11588716|NCT00727519|Experimental|PL|
11588717|NCT00727506|Experimental|BIBW 2992|BIBW 2992 once daily
11588718|NCT00727506|Active Comparator|TMZ|TMZ 21/28 days
11588719|NCT00727506|Experimental|BIBW 2992 plus TMZ|BIBW 2992 once daily plus TMZ 21/28 days
11588720|NCT00727493|Active Comparator|1|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily, dental implant
11588721|NCT00727493|Placebo Comparator|2|placebo once weekly, calcium 1000mg and Vitamin D 800 IU daily; dental implant
11588722|NCT00727493|No Intervention|3|dental implant, calcium 1000mg and Vitamin D 800 IU daily
11588723|NCT00727480|Experimental|A|Ultrasound Imaging of fingertips
11588724|NCT00727467|Experimental|A|"On Days 1-8 of the trial, participants in Group A will be given the iPod with some music on the device to allow all participants to become familiar with the device i.e. turning device on and off, increasing and decreasing the volume. They will be instructed to use the device only when sitting at home, and that the device should not be turned on when walking or performing any mobility related or daily tasks.
~On Days 8-15, participants in Group A will be allocated to the 'intervention' phase. Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks. On Days 15-23, participants in Group A will be allocated to the 'control' phase. During this time period, participants will be provided with the iPod shuffle containing no music or metronome beat."
11588725|NCT00727467|Active Comparator|B|"On Days 1-8 of the trial, participants in Group B will be given the iPod with some music on the device to allow all participants to become familiar with the device. They will be instructed to use the device only when sitting at home, and that the device should not be turned on when walking or performing any mobility related or daily tasks.
~On Days 8-15, participants in Group B will be allocated to the 'control' phase. During this time period, participants will be provided with the iPod shuffle containing no music or metronome beat. On Days 15-23, participants in Group B will be allocated to the 'intervention phase'. Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks."
11588726|NCT00727454|Placebo Comparator|1 Control|No treatment
11589029|NCT00724932|Experimental|Sugammadex|4.0 mg.kg-1 sugammadex at 1-2 PTC
11588727|NCT00727454|Experimental|2 CPAP|Continuous Positive Airway Pressure (CPAP) - REMStar Pro with C-Flex; Respironics, Inc., Murrysville, PA
11588728|NCT00727441|Experimental|Arm A|Patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 1 of Cycle 1 and undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive an additional dose of the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1. Treatment with the vaccine repeats every 28 days for 4 additional cycles.
11588729|NCT00727441|Experimental|Arm B|Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 additional cycles..
11588730|NCT00727441|Experimental|Arm C|Patients receive GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1 and low-dose oral cyclophosphamide twice daily on days 1-7. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21 (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Treatment with the vaccine and cyclophosphamide repeats every 28 days for 4 additional cycles.
11588731|NCT00727428|Experimental|Group A|
11588732|NCT00727402||Observational|healthy patients fit into lotrafilcon A contact lenses for continuous wear
11588733|NCT00727389|Other|groups of women|To evaluate the capacity of muscular function and articular amplitude in the aged women
11588734|NCT00727376||Observation|Esophageal cancer patients
11588735|NCT00727363|Placebo Comparator|1|5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital. Patients fed through NG tube will be administered 5 drops of placebo through the NG tube followed by a 0.5 cc of a normal saline flush. Patients taking PO feeds will be administered 5 drops of placebo in posterior oropharynx after secretions have been suctioned.
11588736|NCT00727363|Experimental|2|5 drops of Lactobacillus reuteri DSM 17938 from an oil based suspension will be administered once a day until death or discharge home. Patients with NG feeds will be administered the probiotic in the amount of 5 drops through the NG tube followed by 0.5 cc of a normal saline flush. Patients with PO feeds will be administered 5 drops of the probiotics in the posterior oropharynx after secretions have been suctioned. If feeds are temporarily suspended because of feeding intolerance or NEC, the probiotic may be re-started once feeds are re-started.
11588737|NCT00727350|Experimental|1|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
11588738|NCT00727337|Experimental|LACE-DVD|Participants will complete the LACE training, however, not in an interactive computer mode but through a static DVD mode
11588739|NCT00727337|Experimental|LACE-COMPUTER|Participants will complete a computer-based auditory training program (i.e., LACE)
11588740|NCT00727337|Active Comparator|PLACEBO-DIRECTED LISTENING|Participants will complete a directed listening to books on CD treatment
11588741|NCT00727337|Active Comparator|CONTROL|Participants will be provided with hearing aids
11588742|NCT00727324|Experimental|1|BIAP
11588743|NCT00727311||PegIntron + Rebetol|Participants with chronic hepatitis C, who are either treatment-naïve or previously relapsed after receiving interferon monotherapy
11588744|NCT00727298||Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
11588745|NCT00727285||A|CF patients followed by the Adult CF Program at National Jewish Health meeting criteria for an acute pulmonary exacerbation.
11588746|NCT00727272|Experimental|Quinine Sulfate Caps 324 mg - Fasting|A single dose of quinine sulfate 324 mg administered with 240 mL of room temperature water after an overnight fast of at least 10 hours.
11588747|NCT00727272|Experimental|Quinine Sulphate Tabs 300 mg - Fasting|A single dose of quinine sulphate 300 mg administered with 240 mL of room temperature water after an overnight fast of at least 10 hours.
11588748|NCT00727272|Experimental|Quinine Sulfate Caps 324 mg - Fed|A single dose of quinine sulfate 324 mg administered with 240 mL of room temperature water thirty minutes after the initiation of a standardized, high-fat breakfast.
11588749|NCT00727259||Patients with chronic hepatitis C|Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol.
11588750|NCT00727246|Experimental|CDP-Choline|Treatment with CDP-Choline
11588751|NCT00727246|Placebo Comparator|Placebo|Treatment with Placebo
11588752|NCT00727220||Insulin Pump Therapy|Children starting insulin pump therapy
11588753|NCT00727220||Insulin Injections|Children remaining on insulin injections.
11588754|NCT00727194|Experimental|1|eculizumab
11588755|NCT00727194|Placebo Comparator|2|Placebo
11588756|NCT00727181|Other|Trifecta Valve|The Trifecta valve is a tri-leaflet stented pericardial valve designed for supra-annular placement in the aortic position.
11588757|NCT00727155|Experimental|1|Treatment
11588758|NCT00727155|No Intervention|2|Waitlist
11588759|NCT00727142|Active Comparator|open shunt|functioning shunt
11588760|NCT00727142|Active Comparator|closed shunt|NON FUNCTIONING SHUNT
11588761|NCT00727116|Experimental|State-wide|All parents of newborns in Pennsylvania hospitals will receive the parent education materials
11589030|NCT00724932|Experimental|Neostigmine|50 µg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2
11588762|NCT00727116|Experimental|Central PA|All of Central PA new parents will receive the state-wide hospital-based intervention. In half of the 31 central PA counties, all primary care providers having offices in those counties provide an office-based booster intervention to new parents. The other half of central PA counties will receive the state-wide, hospital-based intervention, but not the office-based booster intervention.
11588763|NCT00727103|Active Comparator|1 Varenicline|Varenicline will be dispensed in 0.5 mg (blue capsules containing a 0.5 mg varenicline tablet) and 1 mg (red capsules containing a 1 mg varenicline tablet) capsules taken orally. During the first 3 days of medication, participants will take one blue capsule (0.5 mg tablet) of varenicline daily. If the medication is well-tolerated, the dose will be increased to one blue capsule (0.5 mg) po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 red capsule (1 mg) po twice daily. At the end of the 8th week, varenicline will be discontinued.
11588764|NCT00727103|Placebo Comparator|2 Placebo|Placebo will be dispensed in blue and red color coded capsules. During the first 3 days, participants will take one blue capsule po daily. If the medication is well-tolerated, the dose will be increased to one blue capsule po twice daily for 4 days. On day 8, the patients will take 1 red capsule po twice daily. At the end of the 8th week, placebo will be discontinued.
11588765|NCT00727090|Experimental|1|Conivaptan in addition to usual care at the discretion of the attending medical staff
11588766|NCT00727090|No Intervention|2|Usual care by the attending physician staff
11588767|NCT00727077||IntronA/Rebetol|Children age 3 to 17, with chronic hepatitis C, treated in clinical practice at 10 German sites
11588768|NCT00727064|Active Comparator|DVS/VEN|
11588769|NCT00727064|Active Comparator|VEN/DVS|
11588770|NCT00727051||1|Liver and lung transplant candidates referred for coronary angiography will be invited to participate in the study.
11588771|NCT00727038|Experimental|1|Lucentis (ranibizumab) with conventional treatment
11588772|NCT00727038|No Intervention|2|Conventional treatment
11588773|NCT00727012|Other|SJM® Rigid Saddle Ring|The SJM® Rigid Saddle Ring is an annuloplasty ring comprised of a titanium core surrounded by a double-velour, polyester fabric sewing cuff.
11588774|NCT00726999|Active Comparator|1|Gabapentin
11588775|NCT00726999|Placebo Comparator|2|Placebo Comparator -- pill matched in appearance to gabapentin
11588776|NCT00726986|Experimental|Sorafenib, Cisplatin, and Etoposide|
11588777|NCT00726973|Experimental|1|Reduced fluence (3300mW/cm2-50% standard fluence) PDT + ranibizumab
11588778|NCT00726973|Active Comparator|2|Ranibizumab monotherapy
11588779|NCT00726960|Experimental|1|Aprepitant
11588780|NCT00726960|Placebo Comparator|2|Placebo
11588781|NCT00726947|Experimental|1|Ultrasound imaging of Acute DVT (deep vein thrombosis)
11588782|NCT00726947|Experimental|2|Ultrasound imaging of Chronic DVT (deep vein thrombosis)
11588783|NCT00726934|Active Comparator|Neutropenic Diet|Participants will be instructed to follow a Neutropenic Diet. This group will receive the same information as the Food Safety Arm with some additional recommendations for avoiding high bacteria foods during length of time on study.
11588784|NCT00726934|Active Comparator|FDA Food Safety Guidelines|Participants will be instructed to follow the FDA Food Safety Guidelines
11588785|NCT00726895|Experimental|Quinine Sulfate Capsules 1 x 324 mg Dose|Quinine Sulfate 1 x 324 mg capsule dose.
11588786|NCT00726895|Experimental|Quinine Sulfate Capsules 2 x 324 mg Dose|Quinine Sulfate 2 x 324 mg capsules dose.
11588787|NCT00726882|Other|HCV-infected Participants|"Hepatitis C virus (HCV)-infected participants who received ABT-333 at any dose level or matching placebo in a prior clinical study involving ABT-333.
~Participants received no treatment in this follow-up study."
11588788|NCT00726869|Experimental|Cohort 1|2.5 mg/kg
11588789|NCT00726869|Experimental|Cohort 2|5.0 mg/kg
11588790|NCT00726869|Experimental|Cohort 3|10.0 mg/kg
11588791|NCT00726869|Experimental|Cohort 4|20.0 mg/kg
11588792|NCT00726856||Patients|patients with dyslipidemia
11588793|NCT00726843|Active Comparator|1|8 weeks of Yoga, followed by 8 weeks of follow-up
11588794|NCT00726843|Active Comparator|2|8 weeks of follow-up, followed by 8 weeks of yoga
11588795|NCT00726830|Experimental|Arm I: Opioid rotation to oral methadone|Participants are switched from their current opioid medication (oxycodone or morphine) to methadone. Participants receive oral methadone 2-3 times daily for 4 weeks.
11588796|NCT00726830|Experimental|Arm II: Opioid rotation to another long-acting strong opioid|Participants currently receiving oxycodone are switched to sustained-release (SR) morphine. Participants currently receiving morphine are switched to SR oxycodone. Participants receive either oral SR morphine or oxycodone 2-3 times daily for 4 weeks.
11588797|NCT00726817|Placebo Comparator|1|enemas, once daily, containing saline
11588798|NCT00726817|Experimental|2|enemas, once daily, containing 50mM butyrate
11588799|NCT00726817|Experimental|3|enemas, once daily, containing 100mM butyrate
11588800|NCT00726804|Other|2|
11588801|NCT00726791|Experimental|1|high frequency rTMS applied to the motor cortex
11588802|NCT00726778||A, Observational|Healthy European American, African American, and Hispanic American children aged 7-12
11588803|NCT00726765||Referral Strategy 1|"Patient meets at least one of the following three criteria:
~Inflammatory back pain
~Human leukocyte antigen B27 (HLA-B27)
~Sacroiliitis demonstrated by imaging (X-ray, magnetic resonance imagining [MRI], bone scan [if previously available])"
11588804|NCT00726765||Referral Strategy 2|"Patient meets at least two of the following six criteria:
~Inflammatory back pain
~HLA-B27
~Sacroiliitis (on imaging)
~Family history of AS
~Good response of back pain to nonsteroidal anti-inflammatory drugs (NSAIDs)
~Known Extra Articular Manifestations (Uveitis, Iridocyclitis, Psoriasis, Inflammatory Bowel Disease)"
11588805|NCT00726752|Experimental|Axitinib|
11588806|NCT00726739|Experimental|Arm I - LMI + aldesleukin|Patients receive allogeneic large multivalent immunogen vaccine (LMI) LP2307 intradermally on day 1 and aldesleukin subcutaneously (SC) on days 7 and 8. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
11588807|NCT00726739|Active Comparator|Arm II (control) - aldesleukin|Patients receive aldesleukin SC on days 1 and 2. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over and receive treatment on arm I.
11588808|NCT00726739|Experimental|Arm III - Crossover Patients|"Patients who have progressive disease on Arm II were be offered crossover to Arm I provided they continued to meet all study criteria.
~Patients receive allogeneic large multivalent immunogen vaccine (LMI) LP2307 intradermally on day 1 and aldesleukin subcutaneously (SC) on days 7 and 8. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity"
11588809|NCT00726726|Other|A|
11588810|NCT00726726|Experimental|B|
11588811|NCT00726726|Experimental|C|+ Other
11588812|NCT00726713|Experimental|1|Metanx
11588813|NCT00726713|Placebo Comparator|2|Placebo
11588814|NCT00726700|Active Comparator|Arm I (without rituximab)|Patients receive pegfilgrastim subcutaneously (SC) on day 2 or 4 and CHOP comprising cyclophosphamide IV, doxorubicin IV, vincristine IV on day 1, and oral prednisone on days 1-5. Treatment repeats every 2 weeks for up to 6-8 courses in the absence of disease progression or unacceptable toxicity.
11588815|NCT00726700|Experimental|Arm II (with rituximab)|Patients receive pegfilgrastim and CHOP for up to 6-8 courses as in arm I. They also receive rituximab (administered 2 hours before beginning CHOP) on day 1. Treatment with rituximab repeats every 2 weeks for up to 8 courses.
11588816|NCT00726687|Experimental|single|Single arm designed to elicit Maximum Tolerated Dose
11588817|NCT00726661||Chemotherapy Cohort|Eligible participants with HER2-negative disease who received their first cytotoxic chemotherapy and/or targeted therapy were observed until death, withdrawal of consent, loss to follow-up, or until study closure, whichever was sooner (approximately 4.5 years).
11588818|NCT00726661||Hormonal Therapy Cohort|Eligible participants with hormone receptor positive disease who received their first hormonal therapy for advanced disease were observed until death, withdrawal of consent, loss to follow-up, or until study closure, whichever was sooner (approximately 4.5 years).
11588819|NCT00726648|Experimental|1|
11588820|NCT00726648|Experimental|2|
11588821|NCT00726648|Experimental|3|
11588822|NCT00726648|Experimental|4|
11588823|NCT00726648|Placebo Comparator|5|
11588824|NCT00726635|Active Comparator|1|Women in this arm will not receive a psychological intervention but rather will have a conversation with a nurse for one hour (attention control).
11588825|NCT00726635|Experimental|2|Cognitive intervention: Women in this arm will receive a cognitive psychological intervention(cognitive technique:self-talk)
11588826|NCT00726635|Experimental|3|Psycho-physiological intervention: Women in this arm will receive a psycho-physiological intervention (relaxation and guided imagery)
11588827|NCT00726622|Active Comparator|Arm 1: Open laparotomy and rectal resection|Patients undergo open laparotomy and rectal resection. The standard form of surgery is open laparotomy rectal resection. During open laparotomy, the surgeon makes a large incision or cut in the abdomen, and goes in through that cut to remove the tumor and lymph nodes from the rectum.
11588828|NCT00726622|Experimental|Arm 2: Laparoscopic-assisted rectal resection|Patients undergo laparoscopic-assisted rectal resection. Laparoscopic-assisted rectal resection is performed using small instruments on long handles introduced into the abdomen through small ports called trocars in 3 - 6 positions on the abdomen through incisions measuring 5 -10 mm, under the guidance of a video camera. The abdominal wall is held up with carbon dioxide under pressure. The piece of bowel or intestine is removed through another incision (about 8 centimeters), and the ends of the intestine are reconnected to provide normal bowel function.
11588829|NCT00726609||Posaconazole (assigned by physician in normal practice)|"Treatment of invasive fungal infection.
~Prophylaxis of invasive fungal infection."
11588830|NCT00726596|Experimental|Hydroxychloroquine|Hydroxychloroquine - 400 mg (cohort A) Hydroxychloroquine - 600 mg (cohort B)
11588831|NCT00726583|Experimental|Investigational Drug|Dose Escalation
11588832|NCT00726570|Experimental|SCD + LMWH|This group will receive sequential compression device therapy to the lower limbs from their ICU admission until the morning after surgery.
11588833|NCT00726570|Active Comparator|LMWH only|Patients in this group will receive only standard LMWH therapy during their ICU stay.
11588834|NCT00726557||PegIntron + Rebetol|There will be a distinction between the patients depending on the type of substitution drug used (secondary parameters).
11588835|NCT00726544|Placebo Comparator|Placebo|
11588836|NCT00726544|Active Comparator|Low Dose|
11588837|NCT00726544|Active Comparator|Medium Dose|
11588838|NCT00726544|Active Comparator|High Dose|
11588839|NCT00726531|Experimental|OEP|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
11588840|NCT00726531|Experimental|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
11588841|NCT00726531|No Intervention|TAU|Treatment as usual
11588842|NCT00726505|Active Comparator|Group 1|Subjects with T2DM - Dapagliflozin 5 mg
11588843|NCT00726505|Active Comparator|Group 2|Subjects with T2DM - Dapagliflozin 20 mg
11588844|NCT00726505|Active Comparator|Group 3|Healthy Subjects - Dapagliflozin 20 mg
11588845|NCT00726492|Experimental|CSWD + Hydro|Continuous short wave diathermy and hydrotherapy
11588846|NCT00726492|Experimental|Hydro alone|Hydrotherapy alone
11588847|NCT00726492|Experimental|CSWD alone|Continuous short wave diathermy alone
11588848|NCT00726492|No Intervention|Control|No treatment
11588849|NCT00726466|Experimental|I|This is an open-label, study of 0.5 mg intravitreal dose of Ranibizumab in combination with 1 mg/kg/wk subcutaneous dose of Efalizumab in in subjects with AMD.
11588850|NCT00726453|Experimental|Resolute Zotarolimus-Eluting Coronary Stent|Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
11589031|NCT00724919||1|
11589032|NCT00724906|Experimental|Parkinsonian Syndromes|Subjects with Parkinsonian Syndromes
11588851|NCT00726440|Active Comparator|Group1-patient|The patient will be encouraged to use the Navigator® all the time and to modify his treatment according to the continous blood glucose measurements. The patients will follow an educational process in order to adapt insulin doses according to each sensor data.
11588852|NCT00726440|Active Comparator|Group2-diabetologist|"The patient will follow the same educational process as group 1 concerning insulin dose adaptation. They will use the continous glucose monitoring device according to the diabetologist's prescription and they will receive precise instructions to make considering results. The duration of the use of the Navigator® will be increased if one of the following criteria is observed at the consultation each 3 months:
~HbA1c>=7.5%
~1 severe hypoglycaemia or more
~More than 4 benign hypoglycaemia per week
~According to these criteria, every 3 months, the duration of the use of the monitoring system will be increased as following:
~step 1: 3 sensors per month
~step 2: 4 sensors per month
~step 3: 5 sensors per month
~step 4: continuous use"
11588853|NCT00726440|Placebo Comparator|Group3-Control|Usual follow up with self-monitoring blood glucose.
11588854|NCT00726427|Experimental|1|8 increasing oral single doses given to 8 groups (3 on active and 1 on placebo in each group)
11588855|NCT00726427|Experimental|2|2 oral doses of AZD1656 given to 2 groups together with food
11588856|NCT00726414|Experimental|Quinine Sulfate Capsules 2 x 324 mg Capsules - Fasting|A single dose of Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
11588857|NCT00726414|Experimental|Quinine Sulfate Capsules 2 x 324 mg Capsules - Fed|A single dose of Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
11588858|NCT00726401|Active Comparator|1|
11588859|NCT00726401|Placebo Comparator|2|
11588860|NCT00726388|Experimental|A|IV administration of multiple doses of DIC075V (intravenous diclofenac sodium) over multiple days
11588861|NCT00726375|Experimental|Etanercept|a maximum of 8 SQ doses of 'Etanercept (Enbrel) at 0.4mg/kg per dose up to a maximum of 25 mg per dose
11588862|NCT00726362||1|patients with hyperlipidemia newly initiating a statin; or switched from current therapy to a statin, or require dosage adjustment for statin
11588863|NCT00726349||Observation|Patients undergoing isolated elective total hip or knee arthroplasty (primary or revision surgery for a non-malignant condition), aged 60 years or older and able to walk prior to surgery.
11588864|NCT00726323|Experimental|5/9 dosing|240 mg of foretinib on a 5 day on / 9 day off regimen every 14 days.
11588865|NCT00726323|Experimental|daily dosing|80 mg foretinib on a daily dosing regimen
11588866|NCT00726310||SpineLink® , SpineLink® II Group|Spinal fusion surgery with SpineLink®
11588867|NCT00726271|Experimental|active|"Subjects will complete the Zung Depression and Anxiety Scales. At the first visit the subject's medication list, weight, height, and waist measurement will be obtained. The goal is to recruit a minimum of 20 patients.
~Subjects will receive light olive oil, and capsules of fish oil and flaxseed oil, to take daily at home with weight based dosing, based on the doses recommended in Dr. Roberts' work. Doses are within the recommended dietary ranges to improve intermediate outcomes for coronary artery disease subjects.
~They will return weekly for measurement of weight, waist measurements, discussion of any problems with the oils, and dose adjustment of the oils."
11588868|NCT00726258|Placebo Comparator|1|Drip of physiological serum
11588869|NCT00726258|Active Comparator|2|Drip of ketamine
11588870|NCT00726245|Experimental|1|PRGF
11588871|NCT00726245|Placebo Comparator|2|physiological saline
11588872|NCT00726232|Experimental|Ruxolitinib 10 mg BID|Participants received 10 mg Ruxolitinib orally twice a day (BID) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
11588873|NCT00726232|Experimental|Ruxolitinib 25 mg BID|Participants received 25 mg Ruxolitinib orally twice a day (BID) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
11588874|NCT00726232|Experimental|Ruxolitinib 50 mg QD|Participants received 50 mg Ruxolitinib orally once a day (QD) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
11588875|NCT00726219|Other|1|Insertion distance of femoral catheter: 3cm
11588876|NCT00726219|Other|2|Insertion distance of femoral catheter: 7cm
11588877|NCT00726206|Other|1|Recording of the movements Recording of the electroencephalogram
11588878|NCT00726193||1 - standard films|Tibia reconstruction surgery with OsteoGen™ with standard radiographs
11588879|NCT00726193||2 - Standard films plus CT|Tibia reconstruction surgery with OsteoGen™ with standard radiographs and additional CT scan at 10 and 18 weeks.
11588880|NCT00726180|Experimental|Treatment arm|
11588881|NCT00726154|Other|IPSRT|Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.
11588935|NCT00725751||PegIFN-2b/ribavirin with substitution therapy|Participants in this cohort received antiviral treatment and substitution therapy (opioid medicines with long-lasting effects [methadone + buprenorphine] or morphine)
11588936|NCT00725751||PegIFN-2b/ribavirin without substitution therapy|Participants in this cohort received antiviral treatment but did not receive substitution therapy (opioid medicines with long-lasting effects [methadone + buprenorphine] or morphine)
11589117|NCT00724256|Experimental|1|
11588882|NCT00726154|Other|Collaborative care|The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
11588883|NCT00726128||VueLock™ Anterior Cervical Plate Group|VueLock™ Anterior Cervical Plate, Implanted in subjects having an ACDF (Anterior cervical discectomy and fusion)
11588884|NCT00726115|Placebo Comparator|1|arm placebo
11588885|NCT00726115|Experimental|2|arm drug
11588886|NCT00726102|Active Comparator|Meat|Provide locally available meat daily to infants from 6 to 18 mos of age
11588887|NCT00726102|Active Comparator|Control|Daily provision of cereal to infants from 6-18 mos
11588888|NCT00726102|Active Comparator|Fortified rice cereal|Provide equi-caloric serving of fortified rice cereal on daily basis from 6-18 months of age
11588889|NCT00726076|Experimental|Treatment|The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment.
11588890|NCT00726076|Experimental|Control|Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
11588891|NCT00726063|Experimental|Nanotite implant|Nanotite dental implant
11588892|NCT00726063|Active Comparator|Osseotite implant|Osseotite dental implant
11588893|NCT00726037|Experimental|1|Three doses of Ontak 9 mcg/Kg IV over 30 minutes every other day for 1 week
11588894|NCT00726011|Experimental|Tetrodotoxin|There is only one arm; active treatment with TTX
11588895|NCT00725998||1|"The ECAP characteristics have been analyzed in 13 children implanted younger than three years old.
~Series Study Results:
~During the first year of CI use there was a significant statistical growth for the amplitude of N1 peak, in basal electrodes, between the second and third returns. There were not any significant differences obtained for N1 peak, latency, slope, neither for p-NRT nor recovery time, among the returns."
11588896|NCT00725985|Experimental|Cladribine 5.25 mg/kg|
11588897|NCT00725985|Experimental|Cladribine 3.5 mg/kg|
11588898|NCT00725985|Placebo Comparator|Placebo|
11588899|NCT00725972|Experimental|Augmented Oxygen Delivery Group|"Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.
~Intervention: Augment O2 Delivery by hemodynamic protocol. (7/30/17: deleted original text which apparently was pasted from an entirely unrelated study having to do with age of transfused blood, presumably by the creator of this record, Cynthia Hatfield, in 2010. SLW)"
11588900|NCT00725972|Sham Comparator|Control|Patients having the same types of surgery but receiving usual anesthetic care. Intervention: High Risk Surgery. (7/30/17: deleted original text which apparently was pasted from an entirely unrelated study having to do with age of transfused blood, presumably by the creator of this record, Cynthia Hatfield, in 2010. SLW)
11588901|NCT00725959|Experimental|Facebook Arm|Participants in this arm will have exposure to innovative, dynamic and regularly updated HIV Prevention messages on Facebook
11588902|NCT00725959|Active Comparator|Control arm|Participants in this arm will have exposure to static information on HIV prevention currently available online
11588903|NCT00725946|Experimental|Iodine-124 PET-CT scan|
11588904|NCT00725920|Experimental|Topiramate|patients receiving the active drug: topiramate
11588905|NCT00725920|Placebo Comparator|Placebo Control group|patients received pills content placebo, that were identical to the pills content active drug
11588906|NCT00725907|Experimental|1|PGRF
11588907|NCT00725907|Placebo Comparator|2|saline
11588908|NCT00725894||1|The Pediatric Locking Nail was designed to provide stable sub-rigid fixation of femoral fractures in children
11588909|NCT00725881|Experimental|1|.25 mg/kg TSC
11588910|NCT00725881|Experimental|2|.5 mg/kg TSC
11588911|NCT00725881|Experimental|3|.75 mg/kg TSC
11588912|NCT00725881|Experimental|4|1.0 mg/kg TSC
11588913|NCT00725881|Experimental|5|1.25 mg/kg TSC
11588914|NCT00725881|Experimental|6|1.5 mg/kg TSC
11588915|NCT00725881|Experimental|7|1.75 mg/kg TSC
11588916|NCT00725881|Experimental|8|2.0 mg/kg TSC
11588917|NCT00725881|Placebo Comparator|9|5.0 mL 0.9% normal saline
11588918|NCT00725868|Other|1|Data private hospitals, angioplasty, sampling of blood
11588919|NCT00725855|Experimental|1|1 mg dose
11588920|NCT00725855|Experimental|2|5 mg dose
11588921|NCT00725855|Experimental|3|15 mg dose
11588922|NCT00725855|Experimental|4|50 mg dose
11588923|NCT00725855|Placebo Comparator|5|Placebo dose
11588924|NCT00725842||Peg-IFN alfa-2b + ribavirin|Participants with chronic hepatitis C (CHC) treated with Peg-IFN alfa-2b + ribavirin as first treatment, in common clinical practice, who had negative hepatitis-C virus (HCV)-ribonucleic acid (RNA) by the end of treatment (24 or 48 weeks per product labeling).
11588925|NCT00725829|Experimental|1|simvastatin 40g + ezetimibe 10g once a day
11588926|NCT00725829|Placebo Comparator|2|simvastatin 40g + placebo once a day
11588927|NCT00725803|Experimental|Cohort 1|Subjects randomized 3:1 (active:placebo) to receive GS-9450 10 mg/day or placebo.
11588928|NCT00725803|Experimental|Cohort 2|Subjects randomized 3:1 (active:placebo) to receive GS-9450 40 mg/day or placebo.
11588929|NCT00725803|Experimental|Cohort 3|Subjects randomized 3:1 (active:placebo) to receive GS-9450 80 mg/day or placebo.
11588930|NCT00725803|Experimental|Cohort 4|Subjects randomized 3:1 (active:placebo) to receive GS-9450 5 mg/day or placebo. Cohort may or may not be conducted pending blinded review of previous cohorts.
11588931|NCT00725790|Experimental|A|Vardenafil treatment group
11588932|NCT00725790|Placebo Comparator|B|Placebo treatment group
11588933|NCT00725777|Experimental|A|
11588934|NCT00725764|Experimental|Single Arm|Participants who qualified for study entry received 240 mg of GSK1363089 (foretinib) on a 5-day on 9-day off schedule every 2 weeks.
11589118|NCT00724256|Active Comparator|2|
11588937|NCT00725738|Experimental|A|"Stem Cell Transplantation Group: Between the fifth and seventh day post-primary angioplasty (PTCA) we extract the stem cell from iliac crest and during the same day the patient undergoes to a new cardiac catheterization in which we perform the intracoronary injection (about 1-2 million of CD34 cells) through the infarct related artery by a PTCA over-the-wire catheter."
11588938|NCT00725725|Experimental|4 mg Org 25935|Participants took a total of 3 doses of 4 mg Org 25935 prior to therapy sessions over a 2-week period.
11588939|NCT00725725|Experimental|12 mg Org 25935|Participants took a total of 3 doses of 12 mg Org 25935 prior to therapy sessions over a 2-week period.
11588940|NCT00725725|Placebo Comparator|Placebo|Participants took a total of 3 doses of placebo matched to Org 25935 prior to therapy sessions over a 2-week period.
11588941|NCT00725712|Experimental|5-days on/9-days off|Dosing for first 5 days in every 14-day period.
11588942|NCT00725712|Experimental|daily dosing|dosed every day
11588943|NCT00725673||1|GOLD II COPD patients with osteoporosis
11588944|NCT00725673||2|GOLD II COPD patients with a normal bone mineral density
11588945|NCT00725660||1|Pregnant women in second trimester that took the routine triple test, and are having an early routine detailed ultrasound examination.
11588946|NCT00725647||Treated PDA|Infants who had a PDA which the attending physicians treated medically or surgically.
11588947|NCT00725634|Experimental|AV-299 Dose Escalation Arm|AV-299 Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma
11588948|NCT00725634|Experimental|AV-299 in combination with erlotinib|AV-299 Administered by IV Infusion in Combination with Erlotinib (150 mg daily) in Advanced Solid Tumors
11588949|NCT00725621||Remicade|Patients with severe RA (indication according to Austrian labeling) will receive Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions. Remicade induction and maintenance therapy doses and intervals will be at the discretion of the physicians.
11588950|NCT00725608||Patients|Opioid dependent patients currently in maintenance treatment with another medication who are switched to Suboxone (buprenorphine plus naloxone)
11588951|NCT00725595||E, 2, III|To treat CSR with ASV and Bilevel ventilators
11588952|NCT00725582|Experimental|A|
11588953|NCT00725582|Placebo Comparator|B|
11588954|NCT00725569|Active Comparator|A|Bellis perennis and Staphysagria (C6)
11588955|NCT00725569|Active Comparator|B|Bellis perennis and Staphysagria (C30)
11588956|NCT00725569|Placebo Comparator|C|Placebo Remedy
11588957|NCT00725556|Other|1|Speech therapy
11588958|NCT00725543||Remicade|Subjects with AS with severe axial symptoms and elevated serological markers of inflammatory activity will receive Remicade induction therapy consisting of 3 Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians. Whole observation period cannot exceed 102 weeks per subject if the maximal therapy interval of 16 weeks as defined in Summary of Product Characteristics (SPC) is taken into consideration.
11588959|NCT00725530|Active Comparator|balafilcon A / etafilcon A|Balafilcon A worn first, with etafilcon A worn second. Each product worn bilaterally in an extended wear (overnight) basis for 7 days.
11588960|NCT00725530|Active Comparator|etafilcon A / balafilcon A|Etafilcon A worn first, with balafilcon A worn second. Each product worn bilaterally in an extended wear (overnight) basis for 7 days.
11588961|NCT00725517|Experimental|1|Icodextrin group
11588962|NCT00725517|No Intervention|2|Glucose group
11588963|NCT00725504|Experimental|Lidocaine infusion|Each participant will receive an intravenous infusion of lidocaine. Plasma concentrations will be increased gradually from 0-5 µg/ml.
11588964|NCT00725491|Experimental|1|ganirelix
11588965|NCT00725491|Active Comparator|2|triptorelin
11588966|NCT00725465||LAP surgery with CO2 colonoscopy|30 surgical patients, male and female undergoing laparoscopic surgical treatment for colorectal conditions such as neoplasm or rectal prolapse managed with intra-operative carbon dioxide (co2)colonoscopy for standard care of their medical condition.
11588967|NCT00725452||Infliximab|Subjects with plaque psoriasis will receive Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.
11588968|NCT00725439|Experimental|A|Talarozole
11588969|NCT00725426|Experimental|1|Bosutinib
11588970|NCT00725413|Experimental|Arm 1|Healthy premenopausal women requiring a long-term method of contraception
11588971|NCT00725400|Active Comparator|1|Patients will receive a Cetuximab and Radiation Therapy.
11588972|NCT00725400|Active Comparator|2|Patients will undergo Surgery before or after Radiation Therapy.
11588973|NCT00725374|Active Comparator|Arm 1|Postmenopausal women of any age, requiring surgery for early invasive primary breast cancer, with estrogen receptor-positive tumor(s). Treated with tibolone
11588974|NCT00725374|Placebo Comparator|Arm 2|Postmenopausal women of any age, requiring surgery for early invasive primary breast cancer, with estrogen receptor-positive tumor(s). Treated with placebo
11588975|NCT00725361|Experimental|Active|Ambrisentan
11588976|NCT00725348|Experimental|A|R115866
11588977|NCT00725335|Experimental|group A,non-pringle group|Intervention of curative resection of HCC Without pringle manoeuvre in this arm
11588978|NCT00725335|Active Comparator|pringle group(B)|when the curative resection of HCC performed, the pringle manoeuvre will be routinely applied.
11588979|NCT00725322|Experimental|Placebo then Botox|
11588980|NCT00725322|Experimental|Botox then Placebo|
11588981|NCT00725296||Remicade (Infliximab)|Participants with active and progressive PsA who have responded inadequately to disease-modifying anti-rheumatic drugs will receive induction infusions of Remicade at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians. Whole observation period cannot exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in the Summary of Product Characteristics (SPC) is taken into consideration.
11589028|NCT00724945|Active Comparator|balafilcon A/senofilcon A|balafilcon A multifocal lenses worn first, senofilcon A multifocal lenses worn second
11588982|NCT00725283|Experimental|GSK2130579A Group|Patients with cytologically proven AML, as defined by the World Health Organization classification, who were administered a standard dose of GSK2130579A treatment. Patients received 24 doses of the study treatment over a period of approximately 4 years.
11588983|NCT00725270|Placebo Comparator|Placebo|Patients will be randomized to placebo
11588984|NCT00725270|Experimental|Mifepristone|Patients will be randomized to mifepristone
11588985|NCT00725257|Active Comparator|1|Low-carbohydrate, energy-restricted, Mediterranean-type diet
11588986|NCT00725257|Active Comparator|2|Low-fat diet
11588987|NCT00725244|Active Comparator|1|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
11588988|NCT00725244|Active Comparator|2|"Argon Plasma Coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
11588989|NCT00725231|Active Comparator|Arm A|Chemotherapy with dose dense CHOP-14, 6 cycles
11588990|NCT00725231|Experimental|Arm B|Chemotherapy with dose dense CHOP-14, 6-cycles, together with 30mg Alemtuzumab s.c. for the first 4 cycles
11588991|NCT00725218|Placebo Comparator|1|Saline 5 ml injection 10 min prior to propofol administration.
11588992|NCT00725218|Experimental|2|Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
11588993|NCT00725205||Chronic hepatitis C participants|Untreated chronic hepatitis C (CHC) participants starting Peginterferon alfa-2b (injection pen) and Ribavirin combination therapy as their usual medical treatment according to the approved dosage/regimen were selected for this study.
11588994|NCT00725192|Active Comparator|1|Cognitive Processing Therapy
11588995|NCT00725192|Experimental|2|Hypnosis plus Cognitive Processing Therapy.
11588996|NCT00725179||1|Patients receiving oral NAC treatment
11588997|NCT00725179||2|Patients receiving IV NAC treatment
11588998|NCT00725166||Young|Young men 19-25 years old
11588999|NCT00725166||Old|old men 70-76 years old, who participate in the PROOF study (NCT 00759304)
11589000|NCT00725153|Other|PureVision/Acuvue 2|PureVision contact lenses worn first, with Acuvue 2 contact lenses worn second. Both products worn for 10 hours each.
11589001|NCT00725153|Other|Acuvue 2/PureVision|Acuvue 2 contact lenses worn first, with PureVision contact lenses worn second. Both products worn for 10 hours each.
11589002|NCT00725140||Single|
11589003|NCT00725127|Active Comparator|1|100 mg/day ASA upon awakening.
11589004|NCT00725127|Active Comparator|2|100 mg/day ASA at bedtime
11589005|NCT00725114|Active Comparator|Tetrodotoxin|
11589006|NCT00725114|Placebo Comparator|Sugar injection|
11589007|NCT00725101||Fibromyalgia (FM) Participants|FM participants starting any new pharmacologic FM agent.
11589008|NCT00725088|Experimental|1|exercise training group
11589009|NCT00725088|No Intervention|2|control group
11589010|NCT00725075|Experimental|MK-8435 (Org 25935) 8-16 mg per day|Participants will be maintained on a stable dose of Second Generation Antipsychotic (SGA) and receive 4-8 mg MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days. The dose of MK-8435 (Org 25935) can be titrated upward or downward within the specified dose range, as needed, up to Day 42 of the study. The dose must remain stable after Day 42 for the remainder of the study.
11589011|NCT00725075|Experimental|MK-8435 (Org 25935) 24-32 mg per day|Participants will be maintained on a stable dose of SGA and receive 12-16 mg MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days. The dose of MK-8435 (Org 25935) can be titrated upward or downward within the specified dose range, as needed, up to Day 42 of the study. The dose must remain stable after Day 42 for the remainder of the study.
11589012|NCT00725075|Placebo Comparator|Placebo|Participants will be maintained on a stable dose of SGA and receive matching placebo for MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days.
11589013|NCT00725062|Experimental|Patients Receiving CD4+/CD25+ cells|CD4+/CD25+ cells given intravenously over 15-60 minutes on Day -2 (prior to peripheral blood progenitor cell transplant)
11589014|NCT00725049|Active Comparator|Dental implant (Nanotite)|Dental implants of short length placed without sinus lifts
11589015|NCT00725049|No Intervention|Control group|Dental implants of standard length placed simultaneously with sinus augmentation
11589016|NCT00725023|Experimental|1|Treatment: TDP© Lamp used Duration of each treatment 30min Course of treatment 3 times a week for 3-4 weeks
11589017|NCT00725023|Other|2|Treatment: Dummy TDP© Lamp used Duration of each treatment 30min Course of treatment 3 times a week for 3-4 weeks
11589018|NCT00725010||Patients|Participants with newly diagnosed Glioblastoma multiforme who were prescribed temozolomide and radiotherapy as standard care.
11589019|NCT00724997|Other|cohort I|dose level I: 6.4 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
11589020|NCT00724997|Other|cohort II|dose level II: 6.7 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
11589021|NCT00724997|Other|cohort III|dose level III: 7.0 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
11589022|NCT00724997|Other|cohort IV|dose level IV: 7.4 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
11589023|NCT00724997|Other|cohort V|dose level V: 7.7 log10 TCID50/volunteer, 16 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
11589024|NCT00724984|Experimental|1|
11589025|NCT00724971|Experimental|Inotuzumab Ozogamicin + Rituximab|
11589026|NCT00724958||Remicade|Subjects with active luminal and/or fistulizing CD in the hospital or non-hospital setting.
11589027|NCT00724945|Active Comparator|senofilcon A / balafilcon A|senofilcon A multifocal lenses worn first, balafilcon A multifocal lenses worn second
11589033|NCT00724906|Experimental|Non-Parkinsonian Syndromes|Subjects with Non-Parkinsonian Syndromes
11589034|NCT00724893||Stage 1 Participants|Participants with CHC receiving PegIFN-2b using Redipen™ formulation (1.5 mcg/kg) once weekly and ribavirin capsules (800-1400 mg) daily according to routine medical practice at participating study sites.
11589035|NCT00724893||Stage 2 Participants|Participants with CHC Genotype 1 receiving PegIFN-2b using Redipen™ formulation (1.5 mcg/kg) once weekly and ribavirin capsules (800-1400 mg) daily according to routine medical practice at participating study sites.
11589036|NCT00724880|Experimental|1|Clopidogrel is stopped 5 days prior to surgery
11589037|NCT00724880|Experimental|2|Clopidogrel is stopped 3 days prior to surgery
11589038|NCT00724880|Experimental|3|Clopidogrel is stopped 0 days prior to surgery
11589039|NCT00724867|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV every 28 days
11589040|NCT00724867|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV every 28 days
11589041|NCT00724854||Mono-infected with HCV|Participants infected with Hepatitis C Virus (HCV).
11589042|NCT00724854||Co-infected with HCV and HIV|Participants co-infected with HCV and Human Immunodeficiency Virus (HIV).
11589043|NCT00724841|Experimental|1|40 mg/m2 GMX1777 with Temozolomide
11589044|NCT00724841|Experimental|2|50 mg/m2 GMX1777 with Temozolomide
11589045|NCT00724841|Experimental|3|62 mg/m2 GMX1777 with Temozolomide
11589046|NCT00724841|Experimental|4|80 mg/m2 GMX1777 with Temozolomide
11589047|NCT00724841|Experimental|5|100 mg/m2 GMX1777 with Temozolomide
11589048|NCT00724841|Experimental|6|125 mg/m2 GMX1777 with Temozolomide
11589049|NCT00724828||1|
11589050|NCT00724815|Experimental|Sumatriptan|NP101 - sumatriptan iontophoretic transdermal patch
11589051|NCT00724815|Placebo Comparator|Placebo|Placebo iontophoretic transdermal patch
11589052|NCT00724789||Observational Cohort|Subjects with an ongoing pregnancy after controlled ovarian stimulations with recombinant follicle stimulating hormone/ganirelix followed by in vitro fertilization or intra cytoplasmatic sperm injection.
11589053|NCT00724789||Historical Controls|Subjects with an ongoing pregnancy after controlled ovarian stimulations with recombinant follicle stimulating hormone in a long protocol with a gonadotropin releasing hormone agonist followed by IVF or ICSI
11589054|NCT00724776|Experimental|1|Open-label treatment with albinterferon alfa 2b escalating single dose
11589055|NCT00724763|Experimental|1|Treatment group.
11589056|NCT00724763|Sham Comparator|2|control group
11589057|NCT00724750|Experimental|G-SUC|Gauze suction (G-SUC) Negative Pressure Wound Therapy, continuous wall suction at 75 to 80 mm Hg was applied and dressings were changed daily.
11589058|NCT00724750|Active Comparator|Vacuum Assisted Closure|Vacuum Assisted Closure Device (VAC) Negative Pressure Wound Therapy, continuous suction at 75 to 125 mm Hg and the dressing was changed every 48 hours.
11589059|NCT00724737|Active Comparator|fMRI of the brain, no surgery|Healthy volunteers will undergo an fMRI (functional MRI of the brain).
11589060|NCT00724737|Experimental|fMRI of the brain, presurgical|Patients scheduled to have brain surgery will undergo an fMRI (functional MRI of the brain).
11589061|NCT00724724|Experimental|1|Butylphthalide Soft Capsules + Aspirin
11589062|NCT00724724|Active Comparator|2|Aspirin
11589063|NCT00724711|Experimental|FTC/TDF (Truvada [TVD]) + PI/r|Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.
11589064|NCT00724711|Active Comparator|ABC/3TC + PI/r|Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.
11589065|NCT00724698||Group|Patients diagnosed with Allergic Rhinitis or Chronic Idiopathic Urticaria
11589066|NCT00724685|Placebo Comparator|Placebo|
11589067|NCT00724685|Experimental|Active|
11589068|NCT00724672||ETA|RA patients who were scheduled to receive etanercept 50 mg subcutaneously once weekly
11589069|NCT00724672||IFX|RA patients who were scheduled to receive infliximab 3 mg/kg IV at Weeks 0, 2, and 6
11589070|NCT00724672||ADA|RA patients who were scheduled to receive adalimumab 40 mg subcutaneously biweekly
11589071|NCT00724672||non-diseased controls|Healthy individuals who contributed their RNA/cDNA samples prior to the study and for whom ethical approval has already been obtained.
11589072|NCT00724659|Experimental|Ultrasound Pre-Arthrogram|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
11589073|NCT00724659|Experimental|Ultrasound Post-Arthrogram|Ultrasound of the joint(s) after the clinically scheduled arthrogram of the same joint(s), performed while the body still has a contrast agent in it from the arthrogram. The contrast agent varies with different joint areas, but is usually iodine based (like Ultravist.)
11589074|NCT00724646||1|Habilitation assistants
11589075|NCT00724646||2|Parents/ legal guardians
11589076|NCT00724633|Other|1|standard dialysate Na 140 mEq/L
11589077|NCT00724633|Active Comparator|2|dialysate sodium equal to patient's predialysis serum Na
11589078|NCT00724633|Active Comparator|3|dialysate sodium lower than patient's predialysis plasma sodium
11589079|NCT00724620|Experimental|Early Responders (ER)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have responded to therapy at Treatment Week 12 (ie, who are Early Responders defined by HCV-RNA[-] at Treatment Week 12) will continue the combined treatment for a total of 48 weeks and will complete 24 weeks of follow up to determine the Sustained Viral Response (SVR).
11589080|NCT00724620|Experimental|Slow Responders (SR): Decrease in viral load >=2 log|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have a slow response to therapy at Treatment Week 12 (ie, Slow Responders who are not HCV-RNA[-] at Treatment Week 12 but decrease >=2 log) will continue the combined treatment for a total of 72 weeks and will complete 24 weeks of follow up to determine the Sustained Viral Response (SVR).
11589163|NCT00723944|Active Comparator|Osseotite Certain Prevail|Dental implant with lateralized design
11589081|NCT00724620|Experimental|Nonresponders (NR): Decrease in viral load <2 log|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have not responded to therapy at Treatment Week 12 (ie, Nonresponders who are not HCV-RNA[-] at Week 12 of Treatment and/or have a decrease in viral load <2 log) will stop treatment at Treatment Week 12.
11589082|NCT00724607||TBI (Case) Group|Members of the TBI group have sustained a TBI in accordance with inclusion/exclusion criteria. However, the investigative staff administering, scoring, analyzing and interpreting the data will be blinded to the group status of the participant.
11589083|NCT00724607||Non-TBI (Control) Group|Members of the Non-TBI group have not sustained a TBI and are in accordance with other provisions of the inclusion/exclusion criteria. However, the investigative staff administering, scoring, analyzing and interpreting the data will be blinded to the group status of the participant. This longitudinal study will utilize a control group to account for normal aging and other control factors.
11589084|NCT00724607||Non-TBI Non-deployed (Control) Group|Members of the Non-TBI Non-Deployed group have neither sustained a TBI nor have been deployed but are in accordance with other provisions of the inclusion/exclusion criteria. However, the investigative staff administering, scoring, analyzing and interpreting the data will be blinded to the group status of the participant. This longitudinal study will utilize this Non-deployed control group to account for deployment-specific factors.
11589085|NCT00724594|Experimental|N-acetylcysteine|Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.
11589086|NCT00724594|Active Comparator|Control|Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.
11589087|NCT00724581|Experimental|A|
11589088|NCT00724568|Experimental|Combination Drug Therapy|Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11, Doxil at indicated doses on day 4, Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels, and Revlimid at indicated doses on days 1-14 in 3-week cycles for 4-8 cycles. To determine the MTD of the combination of Revlimid, Velcade, dexamethasone, and Doxil, four dose levels are planned.
11589089|NCT00724555||1|Adults living in DC neighborhoods with high proportions of underserved adults. The age of the cohort members will reflect the age of DC residents who suffer most from stroke.
11589090|NCT00724542|No Intervention|Control|Placebo with lifestyle intervention
11589091|NCT00724542|Experimental|Drug|Voglibose tablets with lifestyle intervention
11589092|NCT00724529||Serious Active Crohns Disease|Patients with severe active Crohns Disease who do not show any response to treatment with corticosteroids or immunosuppressive agents, and have no drug tolerance or contraindications to such treatments.
11589093|NCT00724529||Fistula-Type Active Crohns Disease|Patients with fistula-type Crohns Disease who do not show any response to general treatments such as antibiotics, drainage, or immunosuppressant.
11589094|NCT00724529||Ankylosing Spondylitis|Patients with Ankylosing Spondylitis who do not show adequate response to general treatments and with increased serological indices related to severe axial symptoms and inflammation.
11589095|NCT00724516|Experimental|Novel Breast Compression Paddle|Women scheduled to undergo a breast mammography wire localization procedure will have a new breast compression paddle will be used Instead of using the regular wire localization mammography compression paddle.
11589096|NCT00724503|Experimental|mFOLFOX6 + SIRT|A single injection of SIR-Spheres microspheres into the liver plus systemic chemotherapy consisting of Oxaliplatin + Leucovorin + 5-Fluorouracil (FOLFOX)
11589097|NCT00724503|Active Comparator|mFOLFOX6|Systemic chemotherapy consisting of Oxaliplatin + Leucovorin + 5- Fluorouracil (FOLFOX).
11589098|NCT00724477||Subjects treated with INEGY|Subjects suffering from primary hypercholesterolemia that are not controlled by statins as a monotherapy, and are treated with INEGY
11589099|NCT00724464||Participants with Chronic Hepatitis C|Treatment-naïve participants with chronic hepatitis C, undergoing treatment with a standard treatment regimen of PegIntron and Rebetol in clinical practice at approximately 28 sites in Greece
11589100|NCT00724451||Participants with Chronic Hepatitis C (CHC)|Peginterferon-naïve participants with CHC seen in general clinical practice in Italy and treated with either pegylated interferon alfa-2a or alfa-2b + ribavirin.
11589101|NCT00724438||1|Obese women: women with a body mass index (BMI) >30
11589102|NCT00724438||2|Normal weight women: women with a BMI <25
11589103|NCT00724412|Active Comparator|Systane|Systane
11589104|NCT00724412|Active Comparator|Optive|Optive
11589105|NCT00724399||Observations|Women attending screening mammography and gynecology visit
11589106|NCT00724399||A|Women attending their annual screening mammography and gynecology clinic visits.
11589107|NCT00724373||Participants with genotype 1 Hepatitis C Virus infection.|Participants with genotype 1 Hepatitis C Virus (HCV) infection who have been treated with pegylated interferon alfa-2b and ribavirin in the preceding 48 months
11589108|NCT00724347|Experimental|Arm 1|Hearing impaired listeners with hearing aids underwent two months of consonant identification training in their homes.
11589109|NCT00724334|Experimental|1|
11589110|NCT00724321|Other|Iloprost and placebo|Each participant will undergo testing at sea level and altitude after inhalation of iloprost and placebo, sequence is randomly assigned.
11589111|NCT00724308|Experimental|Arm 1|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
11589112|NCT00724308|Experimental|Arm 2|"The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state smoking cessation Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status."
11589113|NCT00724295||Arm 1|Overall study population
11589114|NCT00724282|Other|Eszopiclone or Placebo|Subjects receive either eszopiclone or placebo for 9 days, followed by 3 week washout, then crossover to opposite treatment. Treatment is double-blinded.
11589115|NCT00724269|Active Comparator|Opti Free RepliniSH|Opti Free RepliniSH
11589116|NCT00724269|Active Comparator|ReNu Multi-Plus|ReNu Multi-Plus
11589119|NCT00724243||Rheumatoid Arthritis Patients in Slovakia|Rheumatoid arthritis patients in Slovakia who are starting treatment with infliximab for the first time, in accordance with normal clinical practice.
11589120|NCT00724230||Arm 1|Overall study population.
11589121|NCT00724217|Experimental|Normal weight|BMI < 26
11589122|NCT00724217|Experimental|Overweight|BMI >= 26
11589123|NCT00724204|Placebo Comparator|A|Children that consumed a follow on formula without Lactobacillus salivarius CECT5713
11589124|NCT00724204|Active Comparator|B|Children that consumed a follow on formula with Lactobacillus salivarius CECT5713
11589125|NCT00724191||A|Evaluation of new MRI methods that measure information related to the chemical makeup of the brain in patients undergoing therapy for brain tumors.
11589126|NCT00724178|Experimental|A|Oral cholecalciferol (100,000 IU) administered orally every 60 days plus calcium carbonate (1 gram)given daily
11589127|NCT00724178|Placebo Comparator|B|Double placebo
11589128|NCT00724165|Experimental|1|
11589129|NCT00724165|Active Comparator|2|
11589130|NCT00724152|Experimental|Arm 1/Cognitive Behavioral Therapy|Participants randomly assigned to this experimental group received six weeks of tinnitus education plus cognitive behavioral therapy. Cognitive behavioral therapy for tinnitus participants addressed cognitive and behavioral skills targeting the management of tinnitus and the negative impacts of tinnitus. Long-term self-efficacy and self-sufficiency were emphasized. The major components of CBT for tinnitus included identification of individual responses and beliefs about tinnitus and hearing loss, re-conceptualization of the tinnitus experience as one in which the patient has personal control, presentation of skills to modify cognitions and change behaviors, and reinforcement of skills via goals setting, homework and activities. Skills related to attention control, sleep hygiene, relaxation training are provided. Tinnitus education also included causes, treatments, current research, etc.
11589131|NCT00724152|Active Comparator|Arm 2/Tinnitus Education|Participants randomly assigned to this group received six weeks of tinnitus education. Tinnitus education and skills related to attention control, sleep hygiene and relaxation training such as imagery techniques were provided. Tinnitus education included causes, treatments, current research, epidemiological information, basic anatomy of the ear and brain, and support resources.
11589132|NCT00724152|No Intervention|Arm 3/Standard Care|Participants randomly assigned to this control group received only standard care. Standard care involves audiological measurement and brief education during the standard care appointment.
11589133|NCT00724139|Experimental|1|patients (aged 50-75) with Symptomatic knee OA for at least 6 months, fulfilled American College of Rheumatology clinical criteria for OA of the knee and radiographically assessed osteoarthritis of the knee graded 1-2 according to the Kellgren & Lawrence scale.
11589134|NCT00724126|Placebo Comparator|Placebo|Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
11589135|NCT00724126|Experimental|Rifaximin|Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
11589136|NCT00724113|Active Comparator|1|infiltration intra articular
11589137|NCT00724113|Experimental|2|ARTHRO distension plus intensive mobilisation
11589138|NCT00724087|Experimental|5.5-hour bedtime|
11589139|NCT00724087|Experimental|8.5-hour bedtime|
11589140|NCT00724074|Experimental|S|Patients receive the On-Q local continuous wound infusion system intra-operatively and use it for up to three days post-operatively.
11589141|NCT00724074|Active Comparator|C|Usual care - post operative pain medications as per the knee arthroplasty care map.
11589142|NCT00724061|Experimental|PEG-IFN-α-2b + UV therapy|Pegylated interferon α-2b in combination with UV therapy (either PUVA or NB-UVB).
11589143|NCT00724048|Experimental|ACR16 10 mg|"Participants receive one ACR16 10mg twice daily:
~First four weeks - ACR16 10mg qd - one active 10mg capsule daily. After four weeks - ACR16 10mg bid - two active 10mg capsules taken as two separate doses (20mg ACR16 per day)."
11589144|NCT00724048|Experimental|ACR16 22.5 mg|"Participants receive one ACR16 22.5mg capsule twice daily:
~First four weeks - ACR16 22.5mg qd - one active 22.5mg capsule daily. After four weeks - ACR16 22.5mg bid - two active 22.5mg capsules taken as two separate doses (45mg ACR16 per day)."
11589145|NCT00724048|Experimental|ACR16 45 mg|"Participants receive one ACR16 45mg capsule twice daily:
~First four weeks - ACR16 45mg qd - one active 45mg capsule daily. After four weeks - ACR16 45mg bid - two active 45mg capsule taken as two separate doses (90mg ACR16 per day)."
11589146|NCT00724048|Placebo Comparator|Placebo|"Weeks 1-4, Participants receive a one placebo capsule once daily for four weeks.
~Weeks 5-26, Participants receive a one placebo capsule taken twice daily as two separate doses."
11589147|NCT00724035|Experimental|Infraclavicular|This group will receive an ultrasound-guided infraclavicular brachial plexus block.
11589148|NCT00724035|Active Comparator|Axillary|This group will receive an ultrasound-guided axillary brachial plexus block.
11589149|NCT00724022|Other|A|Standard: Advagraf, CellCept, Decortin H + 2x Simulect Day 0 + 4
11589150|NCT00724022|Experimental|B|Steroidfree: Advagraf, Cellcept, Decortin H until Day 8, 2x Simulect Day 0 + 4
11589151|NCT00724022|Experimental|C|Steroidfree: Advagraf, Cellcept, Decortin H until Day 8, 3 x Thymoglobulin
11589152|NCT00724009|Experimental|Clofarabine|Clofarabine 30 mg/m2/day IV infusion over one hour for 5 consecutive days
11589153|NCT00723996||Group 1|Women receiving a CRC-related questionnaire and a CRC educational video.
11589154|NCT00723996||Group 2|Women who receive only a CRC-related questionnaire.
11589155|NCT00723996||Group 3|Women who receive neither questionnaire nor educational video.
11589156|NCT00723983|Active Comparator|Period 1|Subject dosed with oral sumatriptan succinate during an acute migraine attack.
11589157|NCT00723983|Active Comparator|Period 2|Subject dosed with oral sumatriptan during a non-migraine period.
11589158|NCT00723983|Experimental|Period 3 and Period 6|Subject dosed with NP101 during an acute migraine attack.
11589159|NCT00723983|Experimental|Period 4 and Period 5|Subject dosed with NP101 study patch during a non-migraine period.
11589160|NCT00723970|Experimental|A|Use of quetiapine, flexible dose (150-300 mg/day) for 8 weeks, following a 2-week placebo lead-in phase
11589161|NCT00723957|Experimental|Ixabepilone, 32 mg/m^2 + Carboplatin (AUC 6)|
11589162|NCT00723957|Active Comparator|Paclitaxel, 200 mg/m^2 + Carboplatin (AUC 6)|
11589164|NCT00723944|Placebo Comparator|Osseotite Certain|Dental implant without the lateralized design
11589165|NCT00723931||Participants with Chronic Hepatitis C|Surveillance will be conducted at digestive departments of internal medicine in university or general hospitals where participants with Chronic Hepatitis C are generally treated.
11589166|NCT00723918|Active Comparator|1|methadone plus SAB placebo
11589167|NCT00723918|Experimental|2|methadone plus active SAB
11589168|NCT00723918|Placebo Comparator|3|methadone placebo plus SAB placebo
11589169|NCT00723892||PegIntron/Rebetol and psychotherapy support program|Participants receiving a psychotherapy support program during PegIntron/Rebetol therapy for hepatitis C.
11589170|NCT00723892||PegIntron/Rebetol alone (no psychotherapy)|Participants receiving no psychotherapy support program during PegIntron/Rebetol therapy for hepatitis C.
11589171|NCT00723879||Patients with hepatitis C|Patients receiving a patient assistance program during therapy for hepatitis C will be enrolled into this study. All patients will receive PegIntron plus Rebetol (according to the label) and the patient assistance program.
11589172|NCT00723866|Experimental|1|BtxA+mCIMT (combination group)
11589173|NCT00723866|Placebo Comparator|2|BtxA+ conventional rehabilitation (control group)
11589174|NCT00723853|Experimental|Group 1|Reach-Out Program, Nutritional and Exercise Intervention
11589175|NCT00723853|Active Comparator|Group 2|Reach-In Program, Standard of Care
11589176|NCT00723840||Crohn's Disease Participants|"Participants with Crohn's Disease for at least 6 months, who have a Crohn's Disease Activity Index (CDAI) score >= 150. The CDAI score evaluates Crohn's disease symptoms - a score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
~These participants have active disease despite drug therapy."
11589177|NCT00723827||All Participants|Participants with newly diagnosed glioblastoma multiforme (treat with temozolomide & radiotherapy) or participants with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy (treat with temozolomide).
11589178|NCT00723801|Active Comparator|Subjects Randomized to Losartan|Losartan: 100 mg PO QD
11589179|NCT00723801|Active Comparator|Subjects Randomized to Atenolol|Atenolol: 50 mg PO QD
11589180|NCT00723788|Experimental|Only one arm|All patients enrolled will receive an MRI of the abdomen with detailed views of the appendix
11589181|NCT00723775|Other|Part 1|GSK706769 new vs. current formulation; GSK706769 alone vs. GSK706769 plus Kaletra
11589182|NCT00723775|Other|Part 2|GSK706769 alone for 10 days; GSK706769 + Kaletra for 14 days
11589183|NCT00723762||1|Resident of Hattie Larlham long-term care facility receiving VPA
11589184|NCT00723762||2|Control AED patients will be recruited based on similar AED regimens excluding VPA, length of time on AED (number of months to >1 year), age, and gender; one control patient per VPA patient.
11589185|NCT00723762||3|Control non-AED patients will be recruited based on age and gender; one control patient per VPA patient.
11589186|NCT00723749||Suboxone|Patients for whom a drug dependence therapy with SUBOXONE® is planned and indicated, and who have already been pre-treated with SUBUTEX®, or another maintenance drug for at least 6 months.
11589187|NCT00723736||Pediatric Patients|Those with allergic rhinitis or chronic idiopathic urticaria.
11589188|NCT00723723||Patients with coronary heart disease|Patients being treated with a statin for secondary prevention of coronary heart disease
11589189|NCT00723710||Intron A|Patients with malignant melanoma who are free of disease post-surgery but at high risk for systemic recurrence.
11589190|NCT00723697||Patients|Patients addicted to opiates and requiring replacement treatment. Patients in this non-interventional study were prescribed treatment as per usual clinical practice.
11589191|NCT00723684|Placebo Comparator|Placebo group|This group will receive no real EEG-Neurofeedback.
11589192|NCT00723684|Experimental|NF group|This group will receive real EEG-Neurofeedback
11589193|NCT00723671|Experimental|metabolic peaks|
11589194|NCT00723658|No Intervention|Observation|Non-symptomatic patients are monitored monthly for 3 months, then every 3 months thereafter.
11589195|NCT00723658|Experimental|Treatment|"Symptomatic pts: 2 cycles VTDPACE+R:
~dex 40 mg PO D1-4 thalid 200 mg PO D1-4 cisplatin 10 mg/m2 IV D1-4 dox 10 mg/m2 IV D1-4 cyclophos 400 mg/m2 IV D1-4 etoposide 40 mg/m2 IV D1-4 bortezomib 1.0 mg/m2 IV D1,4,8,11 ritux 375 mg/m2 IV D1,8,15 lovenox 40 mg/d SQ D1-platelets >50,000/mcl GCSF 10 mcg/kg/d IV D9-WBC <2,000/mcl apheresis >/= 20x10^6 when WBC and CD34 within normal range, up to 4 cycles
~st Trans: mel 200 mg/m2 IV D-1 bortezomib 1.3 mg/m2 IV D-4, -1 PBSC >/=3.0x10^6/kg CD34 cells IV D0 GCSF 5 mcg/kg/d SQ D6-WBC recovery D5NS 500 ml IV D-1 dex 40 mg/d PO D-4 to -1 ondansetron 24 mg OR granisetron 2 mg PO D-1
~nd Trans: BCNU 300 mg/m2 IV D-5 etoposide 200 mg/m2 IV D-5 to -2 AraC 400 mg/m2 IV D-5 to -2 mel 140 mg/m2 IV D-1 PBSC infusion >/=3.0x10^6/kg CD34 cells IV D0 GCSF 5 mcg/kg/d SQ D6-WBC recovery D5NS 150 ml/hr IV D-5 to -1 dex 40 mg/d PO D-4 to -1 ondansetron 24 mg OR granisetron 2 mg PO D-1"
11589196|NCT00723645||PEG IFN alfa-2b + RBV|Adult participants with chronic hepatitis C who were treated for the first time with pegylated interferon alfa-2b plus ribavirin and achieved end-of-treatment response prior to the study. Participants received no treatment during this study.
11589197|NCT00723632||Peginterferon alfa-2b and ribavirin|All participants included in the study
11589198|NCT00723619||1|Children and adolescent from German schools in the region Wesel, Hannover and Düsseldorf, selected via special school lists
11589199|NCT00723606|Experimental|Intramuscular ziprasidone|
11589200|NCT00723606|Active Comparator|Intramuscular haloperidol|
11589201|NCT00723580|Experimental|Sleep and Activity by Treatment Condition|Actigraphic measurements were obtained by attaching an actigraphic watch device to the child's non-dominant wrist. The measurements will include three separate three week periods beginning with a baseline period and the period in which the child's pharmacological treatment was initiated. Two additional three week actigraphic measurement periods will occur at 22 months post-baseline period and at 23 months post-baseline period. The resulting five treatment conditions were: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.). Sleep and activity will be evaluated by treatment conditions.
11589202|NCT00723567||Affected Group|Family members of northern European descent in which members have different erythrocyte morphology ranging from atypical HPP to HE to normal and a novel Sp mutation.
11589203|NCT00723554|Experimental|Iloprost|"The study enrolled patients who were already using iloprost with PD-6 without any safety or tolerability concerns, thereby facilitating a direct comparison of the PD-15 to the PD-6.
~The single-arm design allowed each patient to serve as his/her own control"
11589204|NCT00723541|Experimental|A|Develop a computer-aided diagnostic system that will aid in the screening and detection of breast abnormalities/cancer
11589205|NCT00723528|Placebo Comparator|Placebo (CP)|Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
11589206|NCT00723528|Active Comparator|Ustekinumab 45 mg (CP)|Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
11589207|NCT00723528|Active Comparator|Ustekinumab 90 mg (CP)|Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
11589208|NCT00723528|Placebo Comparator|Placebo A (After CP)|After the controlled period (that is [i.e.], during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
11589209|NCT00723528|Placebo Comparator|Placebo B (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
11589210|NCT00723528|Active Comparator|Ustekinumab 45 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
11589211|NCT00723528|Active Comparator|Ustekinumab 90 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
11589212|NCT00723515|Active Comparator|G1|NaF (sodium fluoride varnish) with 2.26% of fluoride
11589213|NCT00723515|Experimental|G2|NaF (sodium fluoride)2.71% of fluoride plus CaF2 (calcium fluoride)
11589214|NCT00723502|Experimental|1|
11589215|NCT00723502|Experimental|2|
11589216|NCT00723489|Experimental|YFV-17D (Right Deltoid)|Participants will be randomized within each atopic dermatitis (AD) severity subgroup or as non-atopic controls to either subcutaneous (SC) or transcutaneous (TC) vaccine administration. In this arm, participants will receive a standard vaccine dose (5.5x10^4 Plaque Forming Units) of YFV-17D administered subcutaneously in the right deltoid and placebo vaccination transcutaneously (then covered with a semi-occlusive dressing) in the left deltoid. The site pharmacist will maintain the blind and an unblinded (i.e., masked) site coordinator will administer assigned treatment: investigators, participants and assessors remain blinded to treatment assignments throughout the duration of the trial.
11589217|NCT00723489|Experimental|YFV-17D (Left Deltoid)|Participants will be randomized within each atopic dermatitis (AD) severity subgroup or as non-atopic controls to either subcutaneous (SC) or transcutaneous (TC) vaccination. In this arm, participants will receive YFV-17D vaccination (1x10^3 Plaque Forming Units) by transcutaneous administration (then covered with a semi-occlusive dressing to optimize YFV-17D absorption) in the left deltoid and placebo by subcutaneous administration in the right deltoid. The site pharmacist will maintain the blind and an unblinded (i.e., masked) site coordinator will administered treatment: investigators, participants and assessors remain blinded to treatment assignments throughout the duration of the trial.
11589218|NCT00723476|Active Comparator|A|Participants will receive three 60- to 90-minute health education control sessions.
11589219|NCT00723476|Experimental|B|Participants will receive three 60- to 90-minute Family Centered Advanced Care Planning sessions.
11589220|NCT00723463|Experimental|A|To determine if apparent diffusion coefficient values can differentiate tumors from normal tissues using a 3T MRI scan.
11589221|NCT00723450|Placebo Comparator|placebo|Placebo Controlled
11589222|NCT00723450|Experimental|lamictal|Flexible Dosing
11589223|NCT00723424|Experimental|1|AZD5672 + Digoxin (single dose on day 12)
11589224|NCT00723424|Experimental|2|AZD5672 (increasing dose up to 150mg) + digoxin (single dose on day 12)
11589225|NCT00723411|Active Comparator|A|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on Days 90 and 270.
11589226|NCT00723411|Active Comparator|B|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on Days 90 and 270.
11589227|NCT00723411|Placebo Comparator|C|This arm will receive 4 injections of placebo, 1 each on Days 1, 30, 90, and 270.
11589228|NCT00723398|No Intervention|Group 1: Control|Control, no intervention
11589229|NCT00723398|Experimental|Group 2: Raloxifene 60 Mg Oral Tablet|Raloxifene 60 mg Orally Daily
11589230|NCT00723398|Experimental|Group 3: Raloxifene 30 Mg Oral Tablet|Raloxifene 30 mg Orally Daily
11589231|NCT00723398|Experimental|Group 4: Lovaza 4 gm oral|Lovaza 4 gm/day Orally with Meals
11589232|NCT00723398|Experimental|Group 5: Lovaza 4gm & Raloxifene 30mg|Lovaza 4 gm/day oral capsule with meals plus Raloxifene 30 mg oral tablet daily
11589233|NCT00723385|Placebo Comparator|Placebo|Placebo administration for 12 weeks with repeated 25-OH D determinations over 12 weeks, dietary, sunshine questionnaire recording
11589234|NCT00723385|Experimental|Vitamin D|Vitamin D (1000 or 2000 IU/day)
11589235|NCT00723359|Experimental|BT062|BT062 single agent dose escalation
11589236|NCT00723346|Experimental|1|
11589237|NCT00723346|Experimental|2|
11589238|NCT00723346|Experimental|3|
11589239|NCT00723346|Active Comparator|4|
11589240|NCT00723333||Affected Group|Patients > 60 years of age with Primary Myelofibrosis that have undergone an allogeneic transplant
11589241|NCT00723320|No Intervention|P+N|placebo without lifestyle intervention
11589242|NCT00723320|Experimental|D+N|Atorvastatin 10mg/d
11589243|NCT00723320|Experimental|P+A|lifestyle intervention without Atorvastatin
11589244|NCT00723320|Experimental|D+A|lifestyle intervention and Atorvastatin 10mg/d
11589246|NCT00723307|Placebo Comparator|Placebo|
11589247|NCT00723294|Experimental|Treatment (cryoablation)|A cryoprobe is inserted percutaneously under ultrasound guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively. Patients undergo surgical resection and sentinel lymph node biopsy and/or axillary dissection within 28 days after completion of cryoablation. Patients complete the Brief Pain Inventory before and after cryoablation and after surgery.
11589248|NCT00723268|Active Comparator|Prednisolone|
11589249|NCT00723268|Active Comparator|Colchicine|
11589250|NCT00723255|Experimental|Treatment (bevacizumab, temsirolimus)|Patients receive bevacizumab IV on days 1 and 15 and temsirolimus IV on days 1, 8, 15, and 22.
11589251|NCT00723229|Active Comparator|1|
11589252|NCT00723229|No Intervention|2|
11589253|NCT00723216|Active Comparator|1|Enoxaparin
11589254|NCT00723216|Other|2|Intermittent Pneumatic Compression (IPC)
11589255|NCT00723203|Experimental|Treatment (panobinostat)|"Patients receive oral panobinostat once on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~panobinostat: 40 mg Monday, Wednesday and Friday of every week in a 28 day cycle"
11589256|NCT00723190|Experimental|Arm A|CLONICEL (Clonidine HCl sustained release)
11589257|NCT00723177|Placebo Comparator|Placebo|This group will receive placebo drug
11589258|NCT00723177|Experimental|Low-dose AV411|This group will receive a low dose of AV411
11589259|NCT00723177|Experimental|High-dose AV411|This group will receive a high dose of AV411
11589260|NCT00723164|Active Comparator|FM|Premedication consisting of fentanyl 0.6 ug/kg and midazolam 9 ug/kg (FM), five minutes before tidal volume sevoflurane 8% induction with 6 L/min O2.
11589261|NCT00723164|Placebo Comparator|NaCl|A 2.5 ml NaCL placebo (NaCl) IV, five minutes before tidal volume sevoflurane 8% induction with 6 L/min O2.
11589262|NCT00723151|Experimental|Low Intensity|One hour of intervention per week
11589263|NCT00723151|Experimental|High Intensity|Five hours of intervention per week, one hour per day for five days per week
11589264|NCT00723125|Experimental|Cohort 1|"Avastin 10 mg/kg IV over 90 minutes day -14
~Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10
~Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles
~Definitive surgery
~Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks"
11589265|NCT00723125|Experimental|Cohort 2|"Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7
~Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7
~Definitive surgery
~Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks"
11589266|NCT00723112||Affected Group|Adult subjects with the diagnosis of MDS based on the French-American-British classification system.
11589267|NCT00723112||Healthy Controls|Control subjects will be selected using frequency matching on gender and age by decade. That is for each MDS patient a healthy volunteer of the same gender and decade (50-59, 60-69, 70-79, etc) will be selected
11589268|NCT00723099|Experimental|Treatment (chemotherapy, transplant)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1-2 hours on day -6. Patients undergo a lower dose of TBI on day -1.
~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo donor umbilical cord blood infusion on day 0.
~IMMUNOSUPRESSIVE THERAPIES: Patients receive cyclosporine IV over 1 hour every 8-12 hours on days 0 to +180 and mycophenolate mofetil IV or PO every 8 hours on days -3 to +96."
11589269|NCT00723073||Caspofungin arm|All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an Absolute Neutrophil Count (ANC) < 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.
11589270|NCT00723073||Micafungin arm|All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an Absolute Neutrophil Count (ANC) < 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent
11589271|NCT00723060|Active Comparator|1|escitalopram high dose group
11589272|NCT00723060|Active Comparator|2|escitalopram conventional group
11589273|NCT00723047|Experimental|1|
11589274|NCT00723021|Experimental|PF-04191834 30mg|
11589275|NCT00723021|Experimental|PF-04191834 100mg|
11589276|NCT00723021|Experimental|PF-04191834 2000mg|
11589277|NCT00723021|Active Comparator|zileuton|
11589278|NCT00723021|Placebo Comparator|placebo|
11589279|NCT00723008|Experimental|A|Upon randomization, a double blinded Alpha Stim 100 device preset to the lowest effective setting (1/6) will be applied to the earlobes of the subject for one hour per day for 5 days per week for 4 weeks; after the blinded period is completed the patient will wear a different Alpha Stim device that has not been blinded for one hour per day for 5 days per week for 4 weeks, with settings at the patient's preference (1 to 6/6). Report of pain, anxiety will be assessed before and after each daily session during the 8 week period.
11589280|NCT00723008|Experimental|B|Upon randomization, a double blinded Alpha Stim 100 device preset to no stimulation (0/6)will be applied to the earlobes of the subject for one hour per day for 5 days per week for 4 weeks; after the blinded period is completed the patient will wear a different Alpha Stim device that has not been blinded for one hour per day for 5 days per week for 4 weeks, with settings at the patient's preference (1 to 6/6). Report of pain, anxiety will be assessed before and after each daily session during the 8 week period.
11589281|NCT00722995|Active Comparator|1|Sleeve gastrectomy
11589282|NCT00722995|Active Comparator|2|Gastric Bypass
11589283|NCT00722982||1|
11589284|NCT00722982||2|
11589285|NCT00722969|Experimental|A|
11589286|NCT00722956|Experimental|1|AZD5672 + atorvastatin
11589287|NCT00722943|Active Comparator|DMT group|These infants will receive tactile stimulation and developmental massage by a licensed therapist. This intervention will be done behind a screen in order to blind the therapy to NICU staff and parents.
11589354|NCT00722384|Experimental|1|0.1 mg bevasiranib in the study eye
11589355|NCT00722384|Experimental|2|0.33 mg bevasiranib in the study eye,
11589288|NCT00722943|Placebo Comparator|SHAM control|These infants will have no tactile stimulation or developmental massage done. The therapist will stand behind a screen but will not touch the infant. The screen will blind the NICU staff and parents to the study arm.
11589289|NCT00722930|Experimental|1. Consolidation with Y90 Ibritumomab Tiuxetan|1. Consolidation with Y90 Ibritumomab Tiuxetan
11589290|NCT00722917|Experimental|TAK-379 25 mg QD|
11589291|NCT00722917|Experimental|TAK-379 100 mg QD|
11589292|NCT00722917|Experimental|TAK-379 200 mg QD|
11589293|NCT00722917|Active Comparator|Pioglitazone 30 mg QD|
11589294|NCT00722917|Placebo Comparator|Placebo|
11589295|NCT00722904||1|patients undergoing routine post-intervention surveillance of aortic coarctation
11589296|NCT00722904||2|Healthy volunteers
11589297|NCT00722891|Active Comparator|Purevision Lens with ReNu|Purevision Lenses with ReNu Multiplus Solution
11589298|NCT00722891|Active Comparator|Purevision Lenses with RepleniSH|Purevision Lenses with Optifree RepleniSH Solution
11589299|NCT00722865|Other|Avastin (Bevacizumab)|single-arm, open-label
11589300|NCT00722852|Experimental|1|
11589301|NCT00722852|Placebo Comparator|2|
11589302|NCT00722839|Experimental|Group A|Participants receive either PADRE-CMV fusion peptide vaccine or tetanus-CMV fusion peptide vaccine subcutaneously (SC) on days 1, 21, 42, and 63 in the absence of unacceptable toxicity.
11589303|NCT00722839|Experimental|Group B|Participants receive either PADRE-CMV fusion peptide vaccine in CpG 7909 adjuvant SC or tetanus-CMV fusion peptide vaccine in CpG 7909 adjuvant SC on days 1, 21, 42, and 63 in the absence of unacceptable toxicity.
11589304|NCT00722800|Experimental|A|drospirenone and ethinyl estradiol
11589305|NCT00722800|Placebo Comparator|B|Placebo
11589306|NCT00722774|Experimental|1|Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
11589307|NCT00722761|Active Comparator|Drosperinone and Ethinyl estradiol|Drospirenone and Ethinyl estradiol (3mg/0.02mg)(YAZ)tablet once a day
11589308|NCT00722761|Placebo Comparator|Placebo tablet|Placebo tablet once a day
11589309|NCT00722748||Genebank|By creating a genebank from patient's blood donations we will ultimately be able to define genes for various cardiovascular conditions.
11589310|NCT00722735|Experimental|1|Group I: Finafloxacin tablets + Ciprofloxacin placebo capsule
11589311|NCT00722735|Active Comparator|2|Group II: Ciprofloxacin capsule + Finafloxacin placebo tablets
11589312|NCT00722722|Active Comparator|4 dose group|4 doses of bortezomib (1.3mg/m^2 of body surface area)
11589313|NCT00722722|Active Comparator|16 dose group|16 doses of bortezomib (1.3mg/m^2 of body surface area)
11589314|NCT00722722|Active Comparator|32 dose group|32 doses of bortezomib (1.3mg/m^2 of body surface area)
11589315|NCT00722709|Experimental|LA|Use of Ropivacaine
11589316|NCT00722709|Placebo Comparator|Placebo|Use of 0.9% saline
11589317|NCT00722683|Experimental|Ultrasound Imaging|Ultrasound Imaging with Contrast
11589318|NCT00722670|Experimental|Woman-focused (WF)|Woman-focused intervention (Women's CoOp)
11589319|NCT00722670|Active Comparator|Treatment as Usual (TAU)|TAU (substance abuse treatment only)
11589320|NCT00722631|Experimental|1|up to 30 mg pioglitazone, tablet, orally, once daily
11589321|NCT00722631|Active Comparator|2|up to 4 mg/day glimepiride, tablet, orally, once daily
11589322|NCT00722618|Active Comparator|Intervention|Written materials, telephone based education
11589323|NCT00722618|Other|Comparison|Written materials
11589324|NCT00722605|Experimental|1|cone-beam CT based
11589325|NCT00722592|Experimental|Vintafolide + PLD|Participants receive vintafolide 2.5 mg intravenous (IV) bolus on Days 1, 3, 5, 15, 17, and 19 and Pegylated Liposomal Doxorubicin (PLD) weight-based dose, IV on Day 1 of each 4-week cycle.
11589326|NCT00722592|Active Comparator|PLD Alone|Participants receive PLD on Day 1 of each 4-week cycle.
11589327|NCT00722579|Experimental|A|The PRESILLION TM Coronary Stent is an L-605 cobalt chromium (CoCr) stent.
11589328|NCT00722566|Experimental|1|VELCADE administered by subcutaneous injection
11589329|NCT00722566|Active Comparator|2|VELCADE administered by intravenous infusion
11589330|NCT00722553|Other|Dietary Supplement Vitamin B12 & Folic Acid (Vitamin B9)|"Vitamin B12 : 1 mg intramuscular injection Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.
~Folic Acid: 1-1.25 mg orally Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate."
11589331|NCT00722540|Experimental|A|
11589332|NCT00722540|Experimental|B|
11589333|NCT00722540|Experimental|C|
11589334|NCT00722540|Experimental|D|
11589335|NCT00722540|Experimental|E|
11589336|NCT00722527||Affected Population|Subjects with an elevated hemoglobin concentration or an elevated platelet count
11589337|NCT00722514|Experimental|IG|Patient education
11589338|NCT00722514|Other|CG|without patient education
11589339|NCT00722501|Active Comparator|ERB-257|7 IV single doses of ERB-257 will be given to 6 healthy subjects per group - 1,4, 15, 45, 90, 180, and 300 mg
11589340|NCT00722501|Placebo Comparator|placebo|2 placebo subjects per group
11589341|NCT00722488|Experimental|1|MLN4924
11589342|NCT00722475|Experimental|IvIg|Repeated infusions of intravenous immunoglobulin in early pregnancy
11589343|NCT00722475|Placebo Comparator|placebo|infusion of human albumin CSL Behring 5%
11589344|NCT00722462|Experimental|1|Active acupuncture
11589345|NCT00722462|Sham Comparator|2|Sham Acupuncture- acupuncture at neutral points
11589346|NCT00722462|No Intervention|3|Embryo transfer with no acupuncture
11589347|NCT00722436|Experimental|Tranexamic acid|Tranexamic acid (100 mg/kg load, 10 mg/kg/hr) intravenous
11589348|NCT00722436|Placebo Comparator|Placebo|Saline was administered intravenously
11589349|NCT00722423|Experimental|Integrated Care Model|Integrated Care
11589350|NCT00722423|Experimental|Usual Care Model|Usual Care
11589351|NCT00722410|No Intervention|A|
11589352|NCT00722410|Experimental|B|VSL#3 for 4 weeks
11589353|NCT00722410|Experimental|C|Mechanical bowel cleansing followed by VSL#3 for 4 weeks.
11589356|NCT00722384|Experimental|3|1.0 mg bevasiranib in the study eye
11589357|NCT00722384|Experimental|4|1.5 mg bevasiranib in the study eye
11589358|NCT00722384|Experimental|5|3.0 mg bevasiranib in the study eye.
11589359|NCT00722371|Experimental|Sitagliptin 100 mg|
11589360|NCT00722371|Experimental|Pioglitazone 15 mg|
11589361|NCT00722371|Experimental|Pioglitazone 30 mg|
11589362|NCT00722371|Experimental|Pioglitazone 45 mg|
11589363|NCT00722371|Experimental|Sitagliptin 100 mg/ Pioglitazone 15 mg|
11589364|NCT00722371|Experimental|Sitagliptin 100 mg/ Pioglitazone 30 mg|
11589365|NCT00722371|Experimental|Sitagliptin 100 mg/ Pioglitazone 45 mg|
11589366|NCT00722358|Active Comparator|BMS-650032|
11589367|NCT00722358|Placebo Comparator|Placebo|
11589368|NCT00722345|Placebo Comparator|1|
11589369|NCT00722345|Experimental|2|
11589370|NCT00722332|Experimental|1|HBV-related liver transplant patients
11589371|NCT00722319||A|Patients on long-term oral anticoagulation who are submitted to PCI-S because of acute coronary syndrome or stable angina. No further groups nor interventions are anticipated since the study is observational
11589372|NCT00722306|Experimental|A425|A425 Treated
11589373|NCT00722293|Experimental|Arm A|once daily oral administration of pazopanib for Days 1-21 days in combination with epirubicin given as a bolus intravenous administration on Day 3
11589374|NCT00722293|Experimental|Arm B|once daily oral administration of pazopanib for Days 1-8 of a 3-week cycle in combination with epirubicin (bolus intravenous administration) on Day 3
11589375|NCT00722293|Experimental|Arm C|epirubicin (bolus intravenous administration) on Day 1 with once-daily oral administration of pazopanib for Days 14-21 of a 3-week cycle
11589376|NCT00722293|Experimental|Arm D|once-daily oral administration of pazopanib (according to schedule selected from either Arm A, B, or C) (3 week cycle) in combination with doxorubicin (bolus intravenous administration) on Day 1 or 3, depending on the schedule selected from either Arm A, B, or C
11589377|NCT00722280|Experimental|Hand Transplantation|Described above
11589378|NCT00722254||PPH|Subjects diagnosed with primary pulmonary hypertension (PPH)
11589379|NCT00722254||Myelofibrosis|Subjects diagnosed with Primary or Secondary Myelofibrosis
11589380|NCT00722241||A|Adult subjects (at least 18 years of age) with a diagnosis of type 1 diabetes (~80%) or insulin-treated type 2 diabetes (~20%); method of insulin delivery may be multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII)
11589381|NCT00722228|Experimental|Autologous or Allogeneic tumor cells|Intervention: 5 vaccine doses, 3 weeks apart, injected subcutaneously.
11589382|NCT00722215|Placebo Comparator|1|Placebo control arm of study
11589383|NCT00722215|Experimental|2|BQ-123 arm of study
11589384|NCT00722215|Active Comparator|3|Nifedipine arm of study
11589385|NCT00722202|Active Comparator|ERB-257|7 IV single doses of ERB-257 will be given to 6 healthy subjects per group - 1, 4, 15, 45, 90, 180, and 300 mg
11589386|NCT00722202|Placebo Comparator|placebo|2 placebo subjects per group
11589387|NCT00722189||A|All patients treated
11589388|NCT00722176|Experimental|1|BL-1020 10 mg
11589389|NCT00722176|Experimental|2|BL-1020 10-30 mg
11589390|NCT00722176|Active Comparator|3|risperidone
11589391|NCT00722163|Experimental|1|behavioural
11589392|NCT00722163|Active Comparator|2|befriending
11589393|NCT00722163|No Intervention|3|TAU
11589394|NCT00722150|Active Comparator|Arm 1|"Oral Artesunate (standard dose)"
11589395|NCT00722150|Active Comparator|Arm 2|"Oral Artesunate (ARC1 dose)"
11589396|NCT00722150|Experimental|Arm 3|"Oral Artesunate (experimental high dose)"
11589397|NCT00722137|Active Comparator|R-CHOP|Rituximab 375 mg/m^2, Cyclophosphamide 750 mg/m^2, Doxorubicin 50 mg/m^2, Vincristine 1.4 mg/m^2, and Prednisone 100 mg/m^2
11589398|NCT00722137|Experimental|VcR-CAP|Rituximab 375 mg/m^2, Cyclophosphamide 750 mg/m^2, Doxorubicin 50 mg/m^2, VELCADE 1.3 mg/m^2, and Prednisone 100 mg/m^2
11589399|NCT00722124|Active Comparator|SAMe 800|Each subject randomized to this arm will take a 400 mg pill of SAMe and one matching placebo pill in the AM and again in the PM
11589400|NCT00722124|Active Comparator|SAMe 1600|Each person randomized to this arm will take 2 400 mg pills of SAMe in the AM and again in the PM
11589401|NCT00722124|Placebo Comparator|Placebo|Each subject randomized to this arm will take 2 placebo pills in the AM and again in the PM
11589402|NCT00722111|Experimental|Arm 1|lingual press (high-intensity, oral, non-swallowing)
11589403|NCT00722111|Experimental|Arm 2|effortful swallowing (high-intensity swallowing)
11589404|NCT00722111|Experimental|Arm 3|natural swallowing (high frequency, low intensity swallowing)
11589405|NCT00722111|Sham Comparator|Arm 4|non-oral sham (control) exercise
11589406|NCT00722098|Experimental|DC Vaccine & Cyclophosphamide|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.
~Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
11589407|NCT00722098|Placebo Comparator|DC Vaccine & Placebo|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.
~Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
11589408|NCT00722085||Observational|
11589459|NCT00721695|Active Comparator|2|OMS302-PE HCl Irrigation Solution
11589460|NCT00721695|Placebo Comparator|3|Standard topical mydriatics and BSS Irrigation Solution
11589848|NCT00718887|Experimental|Entecavir, 0.5 mg QD|
11589409|NCT00722072|Experimental|Fulvestrant/ Sorafenib|"Fulvestrant: A loading dose will be administered intramuscularly to all subjects during cycle 1 of treatment as follows:
~500 mg IM on Day 1
~250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of Fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or unacceptable toxicity occurs requiring discontinuation.
~Sorafenib: Subjects will take Sorafenib 800 mg/day administered as 400 mg bid (twice daily)each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until unacceptable toxicity occurs."
11589410|NCT00722059|Experimental|1|Subjects will undergo a 3D breast Tomosynthesis imaging scan. This is a one time breast imaging scan will last approximately 15 minutes.
11589411|NCT00722046|Experimental|PF-04360365 0.1 mg/kg|
11589412|NCT00722046|Experimental|PF-04360365 0.5 mg/kg|
11589413|NCT00722046|Experimental|PF-04360365 1 mg/kg|
11589414|NCT00722046|Placebo Comparator|Placebo|
11589415|NCT00722046|Experimental|PF-04360365 3 mg/kg|
11589416|NCT00722046|Experimental|PF-04360365 8.5 mg/kg|
11589417|NCT00722033|Other|A|< 30 weeks of gestation
11589418|NCT00722020|Experimental|Vest Arm|HFCWO treatments 2-3 times daily 15 minutes per treatment via the VEST
11589419|NCT00722020|No Intervention|Control|Historical control for PICU asthma patients
11589420|NCT00722007|Experimental|Cormet Hip Resurfacing Post-PMA Group|hip resurfacing
11589421|NCT00721994||1|IDE subjects who received the Cormet Hip Resurfacing device
11589422|NCT00721981||1|Regular treatment for non-small cell lung cancer (NSCLC)
11589423|NCT00721968|Active Comparator|1|Treatment Group (Group 1): Glaukos Trabecular Micro-Bypass Stent Model GTS400; implantation in conjunction with cataract surgery
11589424|NCT00721968|Placebo Comparator|2|Control Group (Group 2): Cataract surgery only
11589425|NCT00721955|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo, may repeat after 2 hours x 2
11589426|NCT00721955|Experimental|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, may repeat after 2 hours x 2
11589427|NCT00721955|Experimental|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, may repeat after 2 hours x 2
11589428|NCT00721929|Experimental|adrenal mass group|
11589429|NCT00721916|Experimental|1|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)
11589430|NCT00721916|Active Comparator|2|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)
11589431|NCT00721903|Active Comparator|Healthy Subjects|Ultrasound scan
11589432|NCT00721903|Active Comparator|Cancer|120 women diagnosed by biopsy to have breast cancer will have an ultrasound scan
11589433|NCT00721890|Experimental|1|
11589434|NCT00721877|Experimental|Arm I|Participants receive oral resveratrol once daily for 4 weeks.
11589435|NCT00721864||Affected Population|Subjects suspected of having Paroxysmal Nocturnal Hemoglobinuria (PNH)
11589436|NCT00721838||1|Surgery group
11589437|NCT00721838||2|Control - Lifestyle modification program
11589438|NCT00721825|Active Comparator|1|Neuroaid
11589439|NCT00721825|Placebo Comparator|2|Neuroaid matched placebo
11589440|NCT00721812|Other|Part A|Single dose escalation
11589441|NCT00721812|Other|Part B|14 day repeat dose escalation
11589442|NCT00721812|Other|Part C|Fixed dose food effect
11589443|NCT00721799|Experimental|FLT PET scan|"Subjects receive 2 18F-Fluorothymidine PET scans
~Scan 1 at baseline (within 30 days prior to the start of chemotherapy and radiation therapy)
~Scan 2 between fraction 5 and 6 of radiation therapy (after 10 Gray of radiation)"
11589444|NCT00721786|Experimental|San Francisco Internet Stop Smoking Site|"UCSF/SFGH Internet Stop Smoking Study site
~Internet Stop Smoking site (TC4) with several intervention elements from which the participants may choose as many as they wish
~The links (URLs) to register for the study are:
~English: www.stopsmoking.ucsf.edu Spanish: www.dejardefumar.ucsf.edu"
11589445|NCT00721773|Experimental|ACE inhibitor, benazepril|Benazepril will be started at 10 mg/day and will be up-titrated to 20 mg/day according to BP control and tolerability.
11589446|NCT00721773|Experimental|Angiotensin receptor blocker, valsartan|Valsartan will be started at 80 mg/day and will be up-titrated to 160 mg/day according to BP control and tolerability.
11589447|NCT00721773|Experimental|RAS inhibitors, benazepril+valsartan|Benazepril will be started at 10 mg/day and will be up-titrated to 20 mg/day, and valsartan will be started at 80 mg/day and will be up-titrated to 160 mg/day according to BP control and tolerability.
11589448|NCT00721773|Active Comparator|non-RAS inhibitors, control|Drug: antihypertensive agents, except ACE inhibitors and ARBs. Administration of antihypertensive agents will select as follows: CCB→β-blocker→α-blocker.
11589449|NCT00721760|Experimental|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery
~Placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind"
11589450|NCT00721760|Active Comparator|Enoxaparin|"Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium
~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
11589451|NCT00721747|Experimental|Unique arm|4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
11589452|NCT00721734|Experimental|Carfilzomib|"Carfilzomib, 15 mg/m², was administered intravenously (IV) on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles for a maximum of 12 cycles.
~If the 15 mg/m² dose was tolerated the dose could be increased to 20 mg/m² starting at Cycle 2. If 20 mg/m² was tolerated, an additional dose escalation to 27 mg/m² was allowed at Cycle 3 or at subsequent cycles."
11589453|NCT00721721|Experimental|1|Participants will follow a low sodium diet for Days 1 through 7, a high sodium diet for Days 7 through 14, and a high sodium diet plus potassium supplement regimen for Days 14 through 21.
11589454|NCT00721708|Experimental|1|Carnosine(450 mg)
11589455|NCT00721708|Experimental|2|Beef (150g)
11589456|NCT00721708|Experimental|3|chicken (150g)
11589457|NCT00721708|Experimental|4|Chicken broth (obtained from 150 g of chicken breast)
11589458|NCT00721695|Experimental|1|OMS302 Irrigation Solution
11589461|NCT00721682||Case|The CASE group will be composed of children for whom the medical team will have chosen to carry out a sign of alert of ill-treatment during his hospitalization and with no plausible cause of traumatism
11589462|NCT00721682||control|The Control group will be composed of children, consulting with the emergency care for traumatism, not having a sign of alarm and having a plausible cause of traumatism.
11589463|NCT00721656|Placebo Comparator|Placebo|
11589464|NCT00721656|Experimental|KLS-0611|
11589465|NCT00721643|Experimental|1|Healthy control, 5g dry power of angel's plant (Angelica keiskei)
11589466|NCT00721643|Experimental|2|Metabolic syndrome, 5g dry powder of angel's plant (Angelica keiskei)
11589467|NCT00721630|Experimental|1|The regimen consists of capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily.
11589468|NCT00721617|Active Comparator|Obese subjects|Obese normotensive subjects will receive 24 hour challenges on 3 separate occasions, in a random order, with IV Normal Saline at 20ml/hour, IV Intralipid (20% solution at 20 ml/hour and an oral fat load (96g/24 hours)
11589469|NCT00721617|Active Comparator|Lean subjects|Lean normotensive subjects will receive 24 hour challenges on 3 separate occasions, in a random order, with IV Normal Saline at 20ml/hour, IV Intralipid (20% solution at 20 ml/hour and an oral fat load (96g/24 hours)
11589470|NCT00721604||1|patients with mean arterial pressure lower than 65 mmHg
11589471|NCT00721591||A|Subjects opting for treatment with unfractionated heparin
11589472|NCT00721591||B|Subjects opting for treatment with low molecular weight heparin
11589473|NCT00721578||1|
11589474|NCT00721565|Experimental|1|behavior change intervention
11589475|NCT00721565|No Intervention|2|written materials
11589476|NCT00721552|Experimental|I|prednisolone + sitagliptin
11589477|NCT00721552|Experimental|II|prednisolone + sitagliptin-placebo
11589478|NCT00721552|Experimental|III|prednisolone-placebo + sitagliptin
11589479|NCT00721552|Placebo Comparator|IV|prednisolone-placebo + sitagliptin-placebo
11589480|NCT00721552|No Intervention|Healthy controls|12 healthy men will be included to assess postprandial microvascular function.
11589481|NCT00721552|No Intervention|Type 2 diabetic subjects|12 men with type 2 diabetes will be included in order to assess postprandial microvascular function.
11589482|NCT00721539|Other|Transoral Robotic Surgery|Pilot study; single arm - use of da Vinci Surgical Robot Platform to access neoplastic disease of the upper aerodigestive tract.
11589483|NCT00721526|Experimental|Disulfiram plus lorazepam|Disulfiram plus lorazepam
11589484|NCT00721513|Experimental|TPFChemotherapy + Concomitant Cetuximab & RT|Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab & Radiation Therapy
11589485|NCT00721500|Experimental|narafilcon A / etafilcon A - etafilcon A - narafilcon A|First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A contact lenses worn in both eyes.
11589486|NCT00721500|Experimental|narafilcon A / etafilcon A - narafilcon A - etafilcon A|First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, narafilcon A contact lenses worn in both eyes. Third, etafilcon A contact lenses worn in both eyes.
11589487|NCT00721500|Experimental|narafilcon A - etafilcon A - narafilcon A / etafilcon A|First, narafilcon A contact lenses worn in both eyes. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.
11589488|NCT00721500|Experimental|etafilcon A - narafilcon A - narafilcon A / etafilcon A|First, etafilcon A contact lenses worn in both eyes. Second, narafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.
11589489|NCT00721487||Fluconazole|30 evaluable patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy.
11589490|NCT00721474|Experimental|1|Bosutinib fasting
11589491|NCT00721474|Experimental|2|Bosutinib fed
11589492|NCT00721461|Experimental|1|V930
11589493|NCT00721435|Experimental|3D Tomosynthesis & 3D Ultrasound for breast masses|Evaluate breast screening diagnostic device, 3D tomosynthesis. Assess utility of adding 3D ultrasound.
11589494|NCT00721435|Experimental|3D Tomosynthesis/ 3D Ultrasound for healthy subjects|Evaluate breast screening diagnostic device, 3D tomosynthesis. Assess utility of adding 3D ultrasound.
11589495|NCT00721422|Experimental|Group 1-Normal|
11589496|NCT00721422|Experimental|Group 2-Mild|
11589497|NCT00721422|Experimental|Group 3-Moderate|
11589498|NCT00721422|Experimental|Group 4-Severe|
11589499|NCT00721409|Experimental|Arm A|letrozole + PD 0332991
11589500|NCT00721409|Active Comparator|Arm B|letrozole
11589501|NCT00721396|Experimental|B+R246|Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations.
11589502|NCT00721396|Experimental|B246_R357|Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age.
11589503|NCT00721396|Experimental|B+R234|Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations.
11589504|NCT00721396|Active Comparator|R234|Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.
11589505|NCT00721383|Experimental|Treatment|Physical activity and caregiver skill-building
11589506|NCT00721383|Active Comparator|Control|caregiver skill-building
11589507|NCT00721370|Experimental|1|Patients imaged using ICG:HSA and NIR imaging system
11589508|NCT00721357||Stroke|Stroke subjects
11589509|NCT00721357||Control|neurologically healthy subjects
11589510|NCT00721344|Experimental|1|
11589511|NCT00721344|Experimental|2|
11589512|NCT00721344|Experimental|3|
11589513|NCT00721344|Experimental|4|
11589514|NCT00721331|Experimental|CRx-197 high dose (0.1% nortriptyline HCl + 0.3% loratadine)|
11589515|NCT00721331|Experimental|CRx-197 low dose (0.1% nortriptyline HCl + 0.1% loratadine)|
11589516|NCT00721331|Experimental|0.1% nortriptyline HCl|
11589517|NCT00721331|Active Comparator|0.1% mometasone furoate|
11589518|NCT00721331|Placebo Comparator|Active ingredient free vehicle cream of CRx-197|
11589519|NCT00721318||1|Patients diagnosed with rheumatoid arthritis
11589520|NCT00721318||2|Population controls to the subjects of group 1
11589521|NCT00721305|Experimental|1|In this arm, subjects will receive 40 mg of Lovastatin (2 tablets of 20 mg each, p.o.), in a daily doses, during twelve months
11589522|NCT00721305|Placebo Comparator|2|In this arm, subjects will receive placebo (2 tablets which will look externally identical to lovastatin: wrapped in the same way, with the same size, shape and color)
11589523|NCT00721266|Experimental|1|
11589524|NCT00721253|Active Comparator|ReSTOR Aspheric +4|ACRYSOF ReSTOR Aspheric +4 Model SN6AD3
11589525|NCT00721253|Active Comparator|Tecnis MF|Abbott Medical Optics Tecnis Multifocal Intraocular Lens (IOL) Model ZM900
11589526|NCT00721253|Active Comparator|Acri.LISA|Meditec Acri.LISA Intraocular Lens (IOL) Model 366D
11589527|NCT00721240|Experimental|single-arm|This investigation is a single-center, two-phase, single-arm study. In order to detect a potential placebo effect, the treatment phase will be preceded by a single-blinded two-week placebo run-in phase, followed by a 12 week open-label treatment phase.
11589528|NCT00721227|Active Comparator|Anterior Curve|Reduction Gastroplasty by Gastric Plication on Anterior Curve
11589529|NCT00721227|Active Comparator|Greater Curve|Reduction Gastroplasty by Gastric Plication on Greater Curve
11589530|NCT00721214|Experimental|Arm A: 5-azacytidine|5-azacytidine as pre-transplant cytoreduction prior to allogeneic stem cell transplantation for High Risk Myelodysplatic Syndromes.
11589531|NCT00721188|Experimental|Pharmacokinetic Population|All subjects who received study drug and completed Pharmacokinetic testing through 24 hours post-dose.
11589532|NCT00721175|Experimental|SEMS|self-expandable metal stent group
11589533|NCT00721175|Active Comparator|PS|plastic stent group
11589534|NCT00721162|Experimental|Ramucirumab|
11589535|NCT00721149|Experimental|NaviStar ThermoCool|
11589536|NCT00721136|Experimental|1|Moderate risk patients (afib, mechanical aortic valve) randomized to continue coumadin at their usual dose through the procedure.
11589537|NCT00721136|Active Comparator|2|Moderate risk patients randomized to hold their coumadin for 4-5 days prior to the procedure (to allow the INR to normalize).
11589538|NCT00721136|Experimental|3|High risk patients (mechanical mitral valve, prior stroke, current deep vein thrombosis, hypercoagulable syndrome) randomized to continue coumadin at the usual dose through the procedure.
11589539|NCT00721136|Active Comparator|4|"High risk patients randomized to holding coumadin for 4-5 days and using bridging anticoagulation with heparin while the coumadin is held."
11589540|NCT00721123|Experimental|Tocilizumab 8 mg/kg|All participants received tocilizumab 8 mg/kg to a maximum of 800 mg, administered by intravenous (IV) infusion over one hour, every 4 weeks. Concomitant therapies were limited to dosage and administration constraints detailed in the protocol.
11589541|NCT00721110|Active Comparator|Lidocaine|Intravenous Lidocaine Group - Lidocaine is administered intravenously throughout surgery and during the 24 hours following surgery
11589542|NCT00721110|Placebo Comparator|Placebo|A lidocaine placebo is administered intravenously throughout surgery and during the 24 hours after surgery.
11589543|NCT00721110|Active Comparator|Ketamine|Intravenous Ketamine Group - Ketamine is administered intravenously throughout surgery and during the 24 hours following surgery
11589544|NCT00721110|Active Comparator|ketamine + Lidocaine|both ketamine and Lidocaine are administered intravenously throughout surgery and during the 24 hours after surgery.
11589545|NCT00721084||Reduced sleep|Habitual sleep duration of less than 6 hours per night on most days of the week and total sleep of less than 43 hours per week.
11589546|NCT00721084||Reference sleep|Habitual sleep duration between 7 and 8.5 hours per night on most days of the week and total sleep of at least 53 hours per week.
11589547|NCT00721071|Experimental|1|
11589548|NCT00721058|Other|1|
11589549|NCT00721045|Active Comparator|A1|15 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection and mapping.
11589550|NCT00721045|Sham Comparator|A2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
11589551|NCT00721045|Active Comparator|B1|15 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection and mapping.
11589552|NCT00721045|Sham Comparator|B2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
11589553|NCT00721045|Active Comparator|C1|15 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection and mapping.
11589554|NCT00721045|Sham Comparator|C2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
11589555|NCT00721032|Experimental|1|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia.
11589556|NCT00721032|Active Comparator|2|Anti-arrhythmic group.
11589557|NCT00721019|Experimental|5-hour bedtime|
11589558|NCT00721019|Experimental|8.5-hour bedtime|
11589559|NCT00721006|Experimental|MESENDO|All subjects will receive active treatment in a blinded fashion in the left or right lower limb. The opposite lower limb will receive placebo.
11589560|NCT00721006|Placebo Comparator|placebo|All subjects will receive placebo injections in a blinded fashion in the left or right lower limb. The opposite lower limb will receive active stem cell infusion
11589561|NCT00720993||1|Control group - patients scheduled for routine colonoscopy procedures with no self or family history or other GI conditions.
11589562|NCT00720993||2|Case group - patients with confirmed colorectal carcinoma scheduled for surgery or observed during routine colonoscopy screening.
11589563|NCT00720967|Active Comparator|1|Control Group (Open heart surgery alone)
11589564|NCT00720967|Experimental|2|Intraoperative Modified Ultrafiltration (MUF) Group (Open heart surgery with intraoperative MUF)
11589565|NCT00720967|Experimental|3|Preoperative Hemodialysis Group (Open Heart Surgery after preoperative hemodialysis)
11589566|NCT00720954|Other|A|CT guided pleural needle biopsy
11589567|NCT00720954|Other|B|Thoracoscopy
11589568|NCT00720941|Active Comparator|Sunitinib|Control arm
11589569|NCT00720941|Experimental|Pazopanib|Experimental arm
11589610|NCT00720590|Experimental|1|Participants will receive treatment with atazanavir and placebo lopinavir/ritonavir.
11589570|NCT00720928|Other|single group|"Posterior uveitis patients having complete or incomplete type of Behcet's disease; typical ocular lesion and at least, one of the main symptoms or two of the additional symptoms.
~Selection of study eye : For patients with unilateral uveitis, the study eye will be the affected eye; for patients with bilateral uveitis, the study eye will be the more severely affected eye (i.e., the eye having suffered more recurrences in the previous year, or if equal, the eye having received more therapy in the previous year, or if equal, the eye having the worse VA, or if equal, the eye clinically judged to be the more severely affected eye)."
11589571|NCT00720915|Other|No Anticoagulant Therapy|No Anticoagulant Therapy
11589572|NCT00720915|Other|Anticoagulant Therapy|Continue on anticoagulant therapy
11589573|NCT00720902|Active Comparator|A|Patients who have undergone transsphenoidal surgery for a pituitary adenoma and have normal growth hormone secretion.
11589574|NCT00720902|Active Comparator|B|Patients who have undergone transsphenoidal surgery for pituitary adenoma who are growth hormone deficient.
11589575|NCT00720889||Reduced sleep|Habitual sleep duration of less than 6 hours per night on most days of the week and total sleep of less than 43 hours per week.
11589576|NCT00720889||Reference sleep|Habitual sleep duration between 7 and 8.5 hours per night on most days of the week and total sleep of at least 53 hours per week.
11589577|NCT00720876|Experimental|Vorinostat and Rituximab|Vorinostat by mouth two times (2X) per day for two weeks followed by one week of rest. Rituximab intravenously once every three weeks .
11589578|NCT00720850|Experimental|lenalidomide|lenalidomide therapy p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT
11589579|NCT00720837|Experimental|Laser Interstitial Thermal Therapy|Laser Interstitial Thermal Therapy (LITT) - An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
11589580|NCT00720824|Active Comparator|1|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions
11589581|NCT00720824|Placebo Comparator|2|Office routine
11589582|NCT00720811|Experimental|ACT, antibiotic, paracetamol|CHWs will test children with acute febrile illness for malaria using RDTs, and for pneumonia by counting their respiratory rate with RRTs. Treatment will then be provided on the basis of the test results, in line with national guidelines. Children with a positive RDT will receive artemether-lumefantrine in Burkina Faso and Uganda, and artesunate-amodiaquine in Ghana. Children with a cough and a high respiratory rate will receive amoxicillin in Ghana and Uganda, and cotrimoxazole in Burkina Faso. Additionally, paracetamol (PCT) will be provided to all children with an axillary temperature > 38.5°C.
11589583|NCT00720811|No Intervention|Presumptive fever management|Presumptive treatment of malaria with ACTs. No antibiotic treatment available
11589584|NCT00720798|Experimental|Tocilizumab|Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.
11589585|NCT00720785|Experimental|1|NK Cell Infusion (cell /kg pt wt)
11589586|NCT00720785|Experimental|2|1.3 mg/m2/dose administered as a 3 to 5 second bolusintravenous injection
11589587|NCT00720772|Experimental|A|
11589588|NCT00720772|No Intervention|B|
11589589|NCT00720759|Experimental|Arm 1|D-cycloserine + distributed treatment
11589590|NCT00720759|Sham Comparator|Arm 2|D-cycloserine + condensed treatment
11589591|NCT00720759|Placebo Comparator|Arm 3|Placebo + distributed treatment
11589592|NCT00720759|Placebo Comparator|Arm 4|Placebo + condensed treatment
11589593|NCT00720733|Experimental|1|Skills Building Group
11589594|NCT00720733|Active Comparator|2|Personal Interview Group
11589595|NCT00720720|Active Comparator|1|plant sterol enriched margarine
11589596|NCT00720720|Placebo Comparator|2|placebo margarine
11589597|NCT00720707|Experimental|(CAF+ADM+EMD)|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
11589598|NCT00720707|Active Comparator|(CAF + ADM)|root coverage procedure by using a coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM)
11589599|NCT00720694|Active Comparator|Verum|"Device: Duolith SD1 (Storz Medical AG) - Focused Extracorporeal shock wave therapy.
~The total energy flux density was increased continuously from 0.01 to 0.25 mJ/mm 2 within 500 introductory impulses. Thereafter, 2000 treatment impulses with 0.25 mJ/mm 2 (four impulses per second) were administered per session,and the interventionwas repeated up to a total of three sessions in weekly intervals."
11589600|NCT00720694|Sham Comparator|Placebo / Sham|Sham Duolith SD1 (Storz Medical AG). The placebo group received identical sham intervention with an air- filled standoff that prevented the transmission of shock waves. The placebo handpiece was identical in design, shape, and weight to ensure that there was no way for the participants to identify the placebo handpiece.
11589601|NCT00720668||1|patient with hepatocellular carcinoma after radiofrequency ablation
11589602|NCT00720655|Experimental|Fatty fish|
11589603|NCT00720655|Experimental|Lean Fish|
11589604|NCT00720655|Placebo Comparator|Control diet|
11589605|NCT00720642||PSAP|This is the population of patients in whom surgical intervention could possibly be avoided. These patients will be those in whom all imaging evidence (mammographic or sonographic) was removed during the Intact BLES procedure, and in whom a definitive diagnosis of ADH could be made using the pathology assessment criteria outlined in the protocol.
11589606|NCT00720642||NPSAP|Patients with a pathology diagnosis of ADH in whom all imaging evidence (mammographic or sonographic) of the target lesion was NOT removed OR in whom a definitive diagnosis of ADH COULD NOT be made by implementing the pathology criteria for evaluation outlined in the protocol AND patients with a diagnosis of DCIS will undergo open surgical excision and will be analyzed separately from the PSAP group.
11589607|NCT00720629|Experimental|First Study Stage: Study Treatment|Visilizumab, Tacrolimus and Methotrexate.
11589608|NCT00720629|Active Comparator|Second Study Stage: Standard Treatment|Second Stage: Antithymocyte-globulin (ATG), Tacrolimus and Methotrexate. The study was closed during first stage and did not proceed to the second stage comparison to ATG in combination with tacrolimus/methotrexate as originally planned.
11589609|NCT00720616|Experimental|1|Growth hormone or Placebo 0.1 mg/day self-administrated once a day.
11589849|NCT00718887|Other|Adefovir, 10 mg QD/Entecavir, 0.5 mg QD|Control
11589611|NCT00720590|Experimental|2|Participants will receive treatment with lopinavir/ritonavir and placebo atazanavir.
11589612|NCT00720590|Placebo Comparator|3|Participants will receive treatment with placebos for both drugs.
11589613|NCT00720577|Active Comparator|1|
11589614|NCT00720577|Active Comparator|2|
11589615|NCT00720577|Active Comparator|3|
11589616|NCT00720538|Experimental|1|Thalidomide
11589617|NCT00720538|Placebo Comparator|2|Placebo
11589618|NCT00720525||1|Patients with diastolic heart failure
11589619|NCT00720525||2|Patients without diastolic heart failure
11589620|NCT00720512|Active Comparator|Arm I|Patients receive either irinotecan hydrochloride over 1 hour or oxaliplatin over 1 hour on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil IV over 46 hours continuously beginning on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11589621|NCT00720512|Experimental|Arm II|Patients receive combination chemotherapy as in arm I and bevacizumab IV on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11589622|NCT00720499|Experimental|BI 1744 CL low dose+tiotropium bromide|BI 1744 CL low dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
11589623|NCT00720499|Experimental|BI 1744 CL medium dose+tiotropium bromide|BI 1744 CL medium dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
11589624|NCT00720486|Experimental|1|Participants will receive Juvenile Justice Anger Management for Girls plus treatment as usual.
11589625|NCT00720486|Active Comparator|2|Participants will receive treatment as usual.
11589626|NCT00720473|Other|A: Other|Open Label Study
11589627|NCT00720473|No Intervention|B: Healthy Controls|
11589628|NCT00720460||Experimental|Healthy Volunteers
11589629|NCT00720434|Experimental|A|500 mg BID
11589630|NCT00720434|Experimental|B|300 mg BID
11589631|NCT00720434|Experimental|C|200 mg BID
11589632|NCT00720434|Placebo Comparator|D|Placebo
11589633|NCT00720421|Other|1|AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 1 mg/Lorazepam Placebo combination therapy
11589634|NCT00720421|Other|2|AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 1mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy
11589635|NCT00720421|Other|3|AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 1 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy
11589636|NCT00720421|Other|4|AZD7325 1 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy
11589637|NCT00720408|Experimental|Prograf-XL + MMF|
11589638|NCT00720408|Active Comparator|Prograf + MMF|
11589639|NCT00720395||1|Women with bipolar disorder who are preconception or pregnant. Primary focus on predictors of postpartum bipolar disorder relapse and burden of illness through first six months postpartum
11589640|NCT00720382|Experimental|1|0.15% azelastine hydrochloride 1644 mcg
11589641|NCT00720382|Experimental|2|Mometasone furoate 200 mcg
11589642|NCT00720369|Experimental|CoEnzyme Q10|Open Label Study
11589643|NCT00720369|No Intervention|Healthy Controls|Healthy controls completed all study procedures completed by the CoQ10 group but did not receive any study medication.
11589644|NCT00720356|Experimental|Treatment|erlotinib and bevacizumab
11589645|NCT00720343|Experimental|Choline|Oral choline
11589646|NCT00720343|Placebo Comparator|Placebo|Gelatin Capsule
11589647|NCT00720330|Active Comparator|Ropivacaine|Paravertebral Group - A local anesthetic (ropivacaine) will be injected near the spine before surgery. Participants will also receive midazolam and fentanyl intravenously (through your vein) for sedation
11589648|NCT00720330|Active Comparator|Lidocaine/ketamine|Participant will receive general anesthesia through the vein before surgery. Lidocaine and ketamine will be administered intravenously throughout surgery and for 60 minutes after surgery.
11589649|NCT00720330|Placebo Comparator|Placebo|General anesthesia plus placebo. Placebo will be administered intravenously until 60 minutes after surgery
11589650|NCT00720304|Experimental|oral erlotinib hydrochloride|
11589651|NCT00720291|Active Comparator|Metronidazole|Subjects who are randomly assigned to receive metronidazole 500 mg po for a period of 7 days following diagnosis of asymptomatic BV.
11589652|NCT00720291|Placebo Comparator|Placebo|Subjects who are randomly assigned to receive a placebo for a period of 7 days following the diagnosis of asymptomatic BV.
11589653|NCT00720278|Placebo Comparator|Placebo Nasal Spray|Placebo nasal spray
11589654|NCT00720278|Experimental|Astepro 0.1%|0.1% azelastine hydrochloride nasal spray
11589655|NCT00720278|Experimental|Astepro 0.15%|0.15% azelastine hydrochloride nasal spray
11589656|NCT00720265|Active Comparator|1|
11589657|NCT00720265|Experimental|2|
11589658|NCT00720252|Experimental|A|
11589659|NCT00720239|No Intervention|0|
11589660|NCT00720239|Experimental|1|Experimental Group 1 (n = 10) will receive TalidermR to the wound once during the treatment phase.
11589661|NCT00720239|Experimental|2|Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.
11589662|NCT00720239|Experimental|3|Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase.
11589663|NCT00720226|Experimental|Losartan|Losartan 100 mg daily
11589664|NCT00720226|Placebo Comparator|Placebo|Placebo 1 pill daily
11589665|NCT00720213|Active Comparator|Respironics BiPAP autoSV2, Then Respironics BiPAP autoSV3|Participants will be randomized to receive Respironics BiPAP autoSV2 first and Respironics BiPAP autoSV3 second.
11589706|NCT00719862|Placebo Comparator|Placebo Nasal Spray|0mg Placebo Nasal Spray
11589666|NCT00720213|Experimental|Respironics BiPAP autoSV3, then Respironics BiPAP autoSV2|Participants will be randomized to receive Respironics BiPAP autoSV3 first and Respironics BiPAP autoSV2.
11589667|NCT00720200|Experimental|1|
11589668|NCT00720200|Active Comparator|2|
11589669|NCT00720174|Experimental|Treatment (cixutumumab and doxorubicin hydrochloride)|Patients receive cixutumumab IV over 1 hour on days 1, 8, and 15 and doxorubicin hydrochloride IV continuously over 44-52 hours beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive cixutumumab in the absence of disease progression or unacceptable toxicity.
11589670|NCT00720161|Active Comparator|A|Metformin during 12 months and then 6 months Placebo
11589671|NCT00720161|Placebo Comparator|B|Placebo during 6 months, afterwards 12 months metformin
11589672|NCT00720135|Experimental|Arm I|Patients receive DI-Leu16-IL2 immunocytokine IV over 4 hours on 4 consecutive Wednesdays. Patients with detectable CD20-positive B-cells pretreatment also receive rituximab IV on 4 consecutive Tuesdays. Treatment repeats every 6-8 weeks for up to a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.
11589673|NCT00720122|Experimental|Anorexia Nervosa Females|
11589674|NCT00720109|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|See Detailed Description
11589675|NCT00720096|Experimental|Liposomal Doxorubicin|Liposomal Doxorubicin - Chemotherapy single agent systemic.
11589676|NCT00720096|Experimental|Topotecan|Topotecan - Chemotherapy single agent systemic.
11589677|NCT00720083|Active Comparator|RT + Cisplatin|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
11589678|NCT00720083|Experimental|RT + Cisplatin + Vandetanib|Patients undergo radiotherapy as in arm I and receive cisplatin IV over 1 hour once a week beginning on day 1 of radiotherapy. Patients also receive oral vandetanib once daily beginning 14 days prior to the start of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
11589679|NCT00720070|Experimental|Arm I|Patients receive standard concurrent chemoradiotherapy (CRT). Patients undergo PET/CT scan at 9-13 weeks after completion of CRT. Patients with complete response of primary site undergo neck dissection within 4 weeks.
11589680|NCT00720070|Active Comparator|Arm II|Patients undergo neck dissection and receive standard concurrent CRT. Patients undergo PET/CT scan at 9-13 weeks after completion of CRT.
11589681|NCT00720057|Experimental|Naproxen sodium ER (BAYH6689)|single dose (1 tablet) ER Naproxen sodium 660 mg with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
11589682|NCT00720057|Placebo Comparator|Placebo|Single dose (1 tablet) of placebo with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
11589683|NCT00720018|Experimental|Period 1|NP101 Patch
11589684|NCT00720018|Experimental|Period 2|NP101 Patch
11589685|NCT00720018|Experimental|Period 3|NP101 Patch
11589686|NCT00720018|Experimental|Period 4|NP101 Patch
11589687|NCT00720018|Experimental|Period 5|NP101 Patch
11589688|NCT00720005||Aspheric Acrysof ResTOR Lens|Implantation of Aspheric Acrysof ResTOR
11589689|NCT00719992|Experimental|1|positive ETT, High HS-CRP
11589690|NCT00719992|Active Comparator|2|positive ETT, Low HS-CRP
11589691|NCT00719979|Experimental|iCBT and TeleCoaching|Participants received the technology-assisted behavioral intervention (iCBT + TeleCoaching).
11589692|NCT00719979|Experimental|iCBT(MoodManager)|Participants received Internet-based cognitive behavioral therapy only.
11589693|NCT00719979|Active Comparator|Treatment as usual / Wait-list control|Participants received treatment as usual . For wait-list control, participants were not provided any intervention for 6 weeks, after which they were allowed to choose coached or self-directed moodManager.
11589694|NCT00719966||Group 1 (hormone receptor-positive)|Patients receive aromatase inhibition therapy for up to 6 months in the absence of unacceptable toxicity.
11589695|NCT00719966||Group 2 (hormone receptor-negative)|Patients do not receive adjuvant treatment.
11589696|NCT00719940|Experimental|1|Cognitive behavioral therapy
11589697|NCT00719940|Placebo Comparator|2|Waiting group
11589698|NCT00719927|Experimental|1|Comadre Treatment
11589699|NCT00719927|Active Comparator|2|Non Support Partner Treatment
11589700|NCT00719914|Active Comparator|1|Intracoronary injection of eptifibatide
11589701|NCT00719914|Placebo Comparator|2|Intra-coronary injection of normal saline.
11589702|NCT00719901|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive obatoclax mesylate IV over 3 hours and bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11589703|NCT00719888|Experimental|Treatment (myeloablative UCBT)|"Patients receive myeloablative conditioning comprising fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 and -6, and undergo high-dose TBI BID on days -4 to -1. Patients then undergo single- or double-unit UCBT on day 0.
~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred > day 30) after engraftment if there continues to be no evidence of acute GVHD."
11589704|NCT00719888|Experimental|Arm II (myeloablative UCBT)|"Patients receive myeloablative conditioning comprising fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 2-4 hours on days -5 and -4, and middle-intensity TBI QD on days -2 and -1. Patients then undergo single- or double-unit UCBT on day 0.
~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred > day 30) after engraftment if there continues to be no evidence of acute GVHD."
11589705|NCT00719875|Experimental|1|
11589707|NCT00719862|Active Comparator|0.15% azelastine hydrochloride nasal spray|0.15% azelastine hydrochloride
11589708|NCT00719849|Experimental|Cyclophosphamide/Fludarabine/TBI|"Subjects with hematological malignancies with prior autologous transplant, >2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months.
~Refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy."
11589709|NCT00719849|Experimental|Cyclophosphamide/Fludarabine/TBI/ATG|Subjects with hematological malignancies with prior autologous transplant >12 mos or <1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months
11589710|NCT00719823|Other|1|
11589711|NCT00719810|Experimental|1|
11589712|NCT00719810|Experimental|2|
11589713|NCT00719810|Active Comparator|3|
11589714|NCT00719797|Experimental|Arm I (FOLFOXIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
11589715|NCT00719797|Experimental|Arm II (FOLFIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
11589716|NCT00719784|Experimental|1|All patients recruited will have VRI recordings done. There is no comparative arm.
11589717|NCT00719771|Other|Global® AP™ Shoulder|Global® AP™ Shoulder
11589718|NCT00719758|Experimental|1|Cross-over study
11589719|NCT00719745|Active Comparator|1|
11589720|NCT00719745|Experimental|2|
11589721|NCT00719732|Experimental|ReSTOR Aspheric +3|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
11589722|NCT00719719||Drug Anaphylaxis|Drug Anaphylaxis
11589723|NCT00719719||Food Anaphylaxis|Food Anaphylaxis
11589724|NCT00719719||Idiopathic Anaphylaxis|Idiopathic Anaphylaxis
11589725|NCT00719719||Venom Anaphylaxis|Venom Anaphylaxis
11589726|NCT00719706|Active Comparator|1|1000-3000mg/day of acetyl-l-carnitine PLUS 600-1800mg/day of alpha-lipoic acid
11589727|NCT00719706|Placebo Comparator|2|
11589728|NCT00719693|Experimental|A|ABT-143 under low-fat meal condition
11589729|NCT00719693|Experimental|B|ABT-143 under fasting meal condition
11589730|NCT00719680|Experimental|IgPro20|The IgPro20 dose will be the same as in the previous pivotal study ZLB04_009CR (NCT00419341) infused subcutaneously weekly or twice a week (in the latter case, half of a weekly dose will be used)
11589731|NCT00719654||EOS-Preeclampsia|Women with symptoms of early-onset preeclampsia
11589732|NCT00719654||Normal|Women who do not have symptoms of early-onset preeclampsia
11589733|NCT00719641||Phase 1: Single Colonoscopy|Feasibility testing using the segmental stiffening wire
11589734|NCT00719641||Phase 2; Not randomized|Phase 2 participants who did not have looping during first colonoscopy
11589735|NCT00719641||Phase 2: Randomized to SSW during first colonoscopy|Phase 2 participants in whom looping occurred on first biopsy, randomized to subsequent use of segmental stiffening wire, then colonoscopy with no segmental stiffening wire upon repeat colonoscopy the next day.
11589736|NCT00719641||Phase 2: Randomized to SSW during second colonoscopy|Phase 2 participants in whom looping occurred on first biopsy, randomized to no subsequent use of the segmental stiffening wire that day, then colonoscopy with segmental stiffening wire upon repeat colonoscopy the next day.
11589737|NCT00719615||Thyroid Cancer in Remission Group|Thyroid Cancer-Remission Group & use of Vitamin D
11589738|NCT00719615||Thyroid Cancer with Active Disease Group|Thyroid Cancer-Active Group & use of Vitamin D
11589739|NCT00719615||Thyroid nodule group (no cancer) & Vit D|Thyroid nodule group without cancer and use of Vitamin D
11589740|NCT00719602|Active Comparator|1|Previously received single-dose nevirapine (SD NVP); assigned to receive either an NNRTI- or PI-based regimen as a part of the study IMPAACT P1060
11589741|NCT00719602|Active Comparator|2|Have not previously received SD NVP; assigned to receive either an NNRTI- or PI-based regimen as a part of the study IMPAACT P1060
11589742|NCT00719589||1|Patient who have had implantation of an interstim.
11589743|NCT00719576|Experimental|MACI|autologous cultured chondrocytes on porcine collagen membrane
11589744|NCT00719576|Active Comparator|Microfracture|Microfracture
11589745|NCT00719563|Experimental|Arm I|Patients receive oral American ginseng twice daily for 14 days. Treatment repeats every 2 weeks for 4 courses.
11589746|NCT00719563|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 14 days. Treatment repeats every 2 weeks for 4 courses.
11589747|NCT00719550|Placebo Comparator|Phase 2 Arm C|AMG 102 placebo plus ECX
11589748|NCT00719550|Other|Phase 1b|Phase 1b dose study with open-labe AMG 102 at 15mg/kg de-escalating to 7.5mg/kg and 5mg/kg if needed.
11589749|NCT00719550|Active Comparator|Phase 2 Arm B|AMG 102 at 7.5mg/kg plus ECX
11589750|NCT00719550|Active Comparator|Phase 2 Arm A|AMG 102 at 15mg/kg plus ECX
11589751|NCT00719537|Placebo Comparator|Aspirin plus Placebo Oral Tablet|Drug: Aspirin 81 mg, given orally once per day Drug: Placebo tablet given orally, once a day
11589752|NCT00719537|Active Comparator|Aspirin plus Progesterone|Drug: Aspirin 81mg, given orally once per day Drug: Progesterone 200mg given orally, once a day
11589753|NCT00719524|Experimental|1|
11589754|NCT00719511|Experimental|1|Patch allergen dose 1
11589755|NCT00719511|Experimental|2|Patch allergen dose 2
11589756|NCT00719511|Experimental|3|Patch allergen dose 3
11589757|NCT00719511|Experimental|4|Placebo
11589758|NCT00719485|Experimental|1|Educational program
11589759|NCT00719485|No Intervention|2|Standard care
11589760|NCT00719472|Experimental|Rituximab 375 mg/m^2|Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m^2 administered by intravenous (IV) infusion on Day 1 of each cycle.
11589761|NCT00719459|Experimental|1|Hospira Iron Sucrose
11589762|NCT00719459|Active Comparator|2|Venofer
11589763|NCT00719433|Experimental|1|
11589764|NCT00719433|Active Comparator|2|
11589765|NCT00719420|Experimental|1|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid for 14 days (with or without omeprazole 20 mg bid)
11589766|NCT00719420|Active Comparator|2|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
11589767|NCT00719407|Experimental|A|All enrolled patients will be in this single arm, who will receive experimental drug treatment.
11589768|NCT00719394|Experimental|GSI 136|
11589769|NCT00719394|Placebo Comparator|placebo|
11589770|NCT00719381|Active Comparator|1|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
11589771|NCT00719381|No Intervention|2|Patients in this arm will receive no intervention
11589772|NCT00719368||pain-free control|Pain-free controls from previous prospective study (KF 01294867), operated >2 years previously
11589773|NCT00719368||Pain Patients|Patients with persistent postherniotomy pain lasting >1 year and pain related impaired daily function
11589774|NCT00719355|Experimental|Walking with Poles|Patients were assigned to a 24 week walking with poles program of rehabilitation. The intervention was the additional of poles to the walking program.
11589775|NCT00719355|Active Comparator|Traditional walking program|Patients were assigned to a 24 week traditional walking program.
11589776|NCT00719329|Experimental|A|Chlorhexidine cleansing of the cord for seven days
11589777|NCT00719329|Experimental|B|Chlorhexidine cleansing of the cord for 1 day
11589778|NCT00719329|Placebo Comparator|C|Dry cord care, as recommended by WHO
11589779|NCT00719316|Experimental|Group 1|Patients receive Aliskiren 300mg for 6 weeks
11589780|NCT00719316|No Intervention|Group 2|4 weeks no antihypertensive medication
11589781|NCT00719303|Experimental|Group I (lifestyle intervention)|Participants receive a dietary intervention designed to promote increased levels of plasma carotenoids, control weight, and to ensure adequacy of micronutrient intake. Participants also undergo a physical activity intervention comprising a moderately low aerobic regimen to raise the usual activity level. Participants also undergo face-to-face counseling, receive educational materials and counseling focused on how to read food labels to estimate grams of fat per serving and serving size, and undergo telephone counseling by a lifestyle intervention counselor twice a week for 4 weeks, then weekly for 2 weeks, twice a month for 5 months, monthly for the subsequent 6 months, and then once every other month for 12 months. Participants complete daily fat gram and step diaries at least three times per week.
11589782|NCT00719303|Active Comparator|Group II (observation)|Participants receive a study notebook containing general study-related information. Participants are not asked to record diet or physical activity but are provided a single sample diary in their study notebook. Participants receive telephone contact on a sliding scale similar to the intervention group, but at less frequent intervals (22 versus 33 calls over the course of the intervention).
11589783|NCT00719290|Active Comparator|1|Phacoemulsification with intraocular lens implant alone
11589784|NCT00719290|Active Comparator|2|Phacoemulsification with intraocular lens implant and goniosynechialysis
11589785|NCT00719264|Experimental|bevacizumab, RAD001 (everolimus)|Participants received oral everolimus 10 mg qd plus intravenous bevacizumab 10mg/kg every 2 weeks
11589786|NCT00719264|Active Comparator|bevacizumab, interferon alfa-2a (IFN)|Participants received subcutaneous IFN dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3 of treatment and subsequently (if tolerated), 3 times per week plus intravenous bevacizumab 10 mg/kg every 2 weeks
11589787|NCT00719251|Experimental|HVG|The patients received standard nursing care and HVPC
11589788|NCT00719251|Experimental|LG|These patients received standard nursing care and LLLT
11589789|NCT00719251|Active Comparator|CG|The control group only was treated with standard nursing care
11589790|NCT00719238|Experimental|1|
11589791|NCT00719238|Active Comparator|2|
11589792|NCT00719212|Experimental|AMG 479|AMG 479 administered on day 1 of each 21-day cycle up to disease progression, unacceptable toxicity, withdrawal of consent or sponsor decision to stop the study.
11589793|NCT00719199|Experimental|1|IMO 2055 is a novel phosphorothioate oligodeoxynucleotide that is an agonist of Toll-like Receptor 9 (TLR9).
11589794|NCT00719186|Active Comparator|A|Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
11589795|NCT00719186|Active Comparator|B|Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
11589796|NCT00719173|Experimental|Arm I|Patients receive aprepitant 125 mg orally once daily on day 1 and 80 mg orally once daily on days 2 and 3. Beginning 1 hour after receiving aprepitant, patients receive an infusion of cyclophosphamide on day 1. During course 2, patients crossover and receive treatment as in arm II.
11589797|NCT00719173|Experimental|Arm II|Patients receive a placebo 125 mg orally once daily on day 1 and 80 mg orally once daily on days 2 and 3. Beginning 1 hour after receiving the placebo, patients will receive an infusion of cyclophosphamide infusion on day 1. During course 2, patients crossover and receive treatment as in arm I.
11589798|NCT00719160|Placebo Comparator|Esomeprazole|
11589799|NCT00719160|Active Comparator|Placebo|
11589800|NCT00719147||1|
11589801|NCT00719134|Experimental|1|Maxalt administration at onset of migraine
11589802|NCT00719134|Placebo Comparator|2|
11589803|NCT00719134|Experimental|3|
11589804|NCT00719134|Placebo Comparator|4|
11589805|NCT00719134|Experimental|5|
11589806|NCT00719134|Experimental|6|
11589807|NCT00719121|No Intervention|A|No Treatment
11589808|NCT00719121|Active Comparator|B|R115866 (0.35% gel)
11589809|NCT00719121|Active Comparator|C|R115866 Vehicle gel
11589810|NCT00719121|Active Comparator|D|Differin™, 0.1% adapalene gel
11589811|NCT00719108|Experimental|Wosulin R|Wosulin R, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml
11589812|NCT00719108|Active Comparator|Actrapid|Actrapid, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml
11589813|NCT00719095|Experimental|1-week buprenorphine taper|1-week buprenorphine taper + behavioral therapy + urine toxicology
11589814|NCT00719095|Experimental|2-week buprenorphine taper|2-week buprenorphine taper + behavioral therapy + urine toxicology
11589846|NCT00718926||control|normal patients
11589847|NCT00718913|Experimental|1|TCX ->RT -> TCX
11589815|NCT00719095|Experimental|4-week buprenorphine taper|4-week buprenorphine taper + behavioral therapy + urine toxicology
11589816|NCT00719082||AARP Community|Members of AARP Geriatric Community
11589817|NCT00719056|Experimental|1|Surgical chemoprophylaxis of one dose of teicoplanin upon introduction of anesthesia for total hip or knee arthroplasty.
11589818|NCT00719056|Active Comparator|2|Surgical chemoprophylaxis with multiple dose of other antimicrobials for up to six consecutive days for total hip or knee arthroplasty.
11589819|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F1-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 1 at Day 0 followed by one booster dose of A/turkey H5N1 vaccine formulation 1 at Day 182 and one dose of placebo (phosphate buffered saline, PBS) at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and Placebo vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, A/turkey H5N1 vaccine was administered intramuscularly in the deltoid region of the dominant arm.
11589820|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F2-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 2 at Day 0 followed by one booster dose of A/turkey H5N1 vaccine formulation 2 at Day 182 and one dose of placebo (phosphate buffered saline, PBS) at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and Placebo vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, A/turkey H5N1 vaccine was administered intramuscularly in the deltoid region of the dominant arm.
11589821|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F3-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 3 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 3 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
11589822|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F1-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) vaccine formulation 1 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 1 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
11589823|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F4-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 4 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 4 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
11589824|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F2-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 2 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 2 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
11589825|NCT00719043|Placebo Comparator|Naïve Placebo-A/turkey Influenza (H5N1)-F3-Group|Healthy subjects aged 18 years of age or older at the time of vaccination received one dose of placebo (phosphate buffered saline, PBS) at Day 0 followed by two doses of A/turkey H5N1 vaccine formulation 3, one dose administered at Day 182 and the other at Day 549. Placebo vaccine and one dose of A/turkey H5N1 vaccine (Day 549) was administered intramuscularly in the deltoid region of the non-dominant arm while the other dose of A/turkey H5N1 vaccine (Day 182) was administered intramuscularly in the deltoid region of the dominant arm.
11589826|NCT00719030|Experimental|1|Pomegranate pill
11589827|NCT00719030|Placebo Comparator|2|
11589828|NCT00719017|Experimental|Vaginectomy group|Upper vaginectomy
11589829|NCT00719017|Experimental|Brachytherapy group|Post-operative brachytherapy
11589830|NCT00719017|Active Comparator|Control group|Standard treatment
11589831|NCT00719004|Experimental|Normals|Normal volunteers having Ultrasound scan of foot.
11589832|NCT00718991|Experimental|1|CLI patients receiving excimer laser recanalisation for the treatment of long infrapopliteal lesions
11589833|NCT00718978|Other|B|the investigators grafted sheets based on the HYAFF11p80® scaffold (the one with the lowest degree of esterification)
11589834|NCT00718978|Other|A|the investigators grafted sheets based on the HYAFF11® scaffold (the one with the highest degree of esterification).
11589835|NCT00718978|Other|A-B|the investigators grafted sheets based on the HYAFF11® scaffold and sheets based on the HYAFF11p80 ® scaffold
11589836|NCT00718965|Experimental|25 mg/day AVE5530|
11589837|NCT00718965|Experimental|50 mg/day AVE5530|
11589838|NCT00718965|Placebo Comparator|Placebo|
11589839|NCT00718952|Experimental|A|Patients in group A will receive vardenafil in double-blinded treatment period.
11589840|NCT00718952|Placebo Comparator|B|Patients in group A will receive placebo in double-blinded treatment period.
11589841|NCT00718939|Other|Rheos ON|Study participants in this arm will have the device turn on for six months and remains on.
11589842|NCT00718939|Other|Rheos OFF|Study participants in this arm will have the device turned off for 6 months and then turned on.
11589843|NCT00718926||Sjogren|Sjogren syndrome with dry eye
11589844|NCT00718926||non-Sjogren|dry eye without Sjogren syndrome
11589845|NCT00718926||Short-BUT|Dry eye by shortened tear break up time
11589850|NCT00718874|Experimental|A, 1|low-carbohydrate (42%)
11589851|NCT00718874|Experimental|A,2|standard carbohydrate (55%) based on ADA recommendations
11589852|NCT00718861|Placebo Comparator|Placebo|Matching placebo administered intravenously.
11589853|NCT00718861|Experimental|Zoledronic acid|
11589854|NCT00718848||1|These are patients treated with conventional hemodialysis (4 hours/session, 3 sessions/week) who convert to incentre nocturnal hemodialysis (8 hours/session, 3 sessions/week).
11589855|NCT00718848||2|These are patients treated with conventional hemodialysis (4 hours/session, 3 session/week) who elect to remain on this dialysis schedule and agree to the study-related investigations at baseline and one year thereafter.
11589856|NCT00718835|Active Comparator|Contingent Voucher condition|Subjects in this condition will receive a brief education intervention plus voucher-based incentives contingent on demonstrating objective evidence of recent smoking abstinence.
11589857|NCT00718835|Placebo Comparator|Noncontingent control condition|Subjects assigned to this control condition will receive the brief education and vouchers delivered independent of smoking status and yoked to the schedule of voucher earnings in the Contingent Voucher condition.
11589858|NCT00718822|Experimental|I|5% oxygen concentration in the culture atmosphere
11589859|NCT00718822|Experimental|II|20% oxygen concentration in the culture atmosphere
11589860|NCT00718809|Experimental|Arm I|Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11589861|NCT00718796|Experimental|1|Individualized naturopathic treatment consisting of dietary and lifestyle advice and individualized supplementation
11589862|NCT00718796|Active Comparator|2|Current care control provided by participants' medical doctor
11589863|NCT00718783||Retinoblastoma|
11589864|NCT00718770|Experimental|Bexarotene|Open label - all patients receive intervention
11589865|NCT00718757|Experimental|1|
11589866|NCT00718744|Experimental|A|In each individual patient, 10 mg/ml histamine dihydrochloride solution and a phenolated saline solution will be applied as positive and negative control respectively.
11589867|NCT00718731|Experimental|1|Subject on active drug
11589868|NCT00718731|Placebo Comparator|2|Subject on placebo
11589869|NCT00718718|Experimental|Part A, Group 1|Participants will receive placebo (Week 0 to Week 10) and later CNTO 136 100 mg (Week 12 to Week 22) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
11589870|NCT00718718|Experimental|Part A, Group 2|Participants will receive CNTO 136 100 mg (Week 0 to Week 10) and later placebo (Week 12 to Week 22) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
11589871|NCT00718718|Experimental|Part B, Group 1|Participants will receive placebo (Week 0 to Week 10) and later CNTO 136 100 mg (Week 12 to Week 24) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
11589872|NCT00718718|Experimental|Part B, Group 2|Participants will receive CNTO 136 100 mg (Week 0 to Week 24) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
11589873|NCT00718718|Experimental|Part B, Group 3|Participants will receive CNTO 136 100 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6, 10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
11589874|NCT00718718|Experimental|Part B, Group 4|Participants will receive CNTO 136 50 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6,10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
11589875|NCT00718718|Experimental|Part B, Group 5|Participants will receive CNTO 136 25 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6,10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
11589876|NCT00718705|Experimental|1|josamycin
11589877|NCT00718705|Placebo Comparator|2|Placebo
11589878|NCT00718692|Experimental|1|Patients treated with Sym001
11589879|NCT00718679|Experimental|1|Study drug
11589880|NCT00718679|Placebo Comparator|2|Placebo
11589881|NCT00718666|Experimental|Group A|Subjects who were previously vaccinated with one dose of GSK134612 at 12 months of age.
11589882|NCT00718666|Experimental|Group B|Subjects who were previously vaccinated with two doses of GSK134612, one each at 9 and 12 months of age.
11589883|NCT00718666|Experimental|Group C|Subjects aged 5-6 years not previously administered meningococcal vaccine.
11589884|NCT00718653|Experimental|1|lutein
11589885|NCT00718653|Experimental|2|Lutein plus green tea extract
11589886|NCT00718640|Experimental|Bortezomib and Dexamethasone|Bortezomib 1.3 milligram (mg) per meter^2 (m^2) bolus (a large amount) intravenous (into the vein) injection will be administered once daily on Days 1, 4, 8 and 11 of each 21-day cycle with addition of Dexamethasone 20 mg per day administered orally, once daily on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-day cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
11589887|NCT00718627|Experimental|HHLivC Therapy Group|
11589888|NCT00718614|Other|1|Patients with long standing IDDM (>10 years) and no diabetic retinopathy
11589889|NCT00718614|Other|2|Patients with long standing IDDM (>10 years) and mild non-proliferative diabetic retinopathy
11589890|NCT00718614|Other|3|Patients with long standing IDDM (>10 years) and moderate to severe non-proliferative diabetic retinopathy
11589891|NCT00718614|Other|4|healthy volunteers, matched for age and sex
11589892|NCT00718601|Experimental|1|3+3 cohort dose escalation
11589893|NCT00718575|Experimental|1|Deceased liver donors that are randomized to this arm will receive the Glucose/Ischemic Preconditioning pre-treatment intra-operatively prior to starting cold preservation of the organ
11589894|NCT00718575|No Intervention|2|Neither donors nor recipients receive any intervention. All procedures will be performed according to our institution's standard of care.
11589895|NCT00718562|Experimental|Nilotinib|
11589945|NCT00718224|Active Comparator|Enoxaparin|"Enoxaparin sodium 30 mg twice daily (20 mg once daily if Severe Renal Impairment [SRI]) for 7-10 days with an initial dose given 12 hours after surgery
~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
11589946|NCT00718198||1|Group admitted 1 (one) month before CPOE protocol changes were made
11589896|NCT00718549|Experimental|Induction: Rituximab, Cladribine, Cyclophosphamide|Participants will receive rituximab at a dose of 375 milligrams per meter squared (mg/m^2) as intravenous (IV) infusion on Day 1, cladribine at a dose of 0.12 milligrams per kilogram per day (mg/kg/day) as IV infusion on Days 2-4, and cyclophosphamide at a dose of 250 mg/m^2/day as IV infusion over 15-30 minutes on Days 2-4 in Cycle 1. Then, rituximab at a dose of 500 mg/m^2 as IV infusion on Day 1, cladribine at a dose of 0.12 mg/kg/day as IV infusion on Days 2-4, and cyclophosphamide at a dose of 250 mg/m^2/day as IV infusion over 15-30 minutes on Days 2-4 will be administered in Cycles 2-6. Each cycle will be of 28 days in duration.
11589897|NCT00718549|Experimental|Maintenance Arm: Rituximab|Participants with PR or CR after induction phase who will be randomized to maintenance arm will receive rituximab treatment for 8 cycles. Twelve weeks after the last induction cycle, participants will receive rituximab at a dose of 375 mg/m^2 as IV infusion on Day 1 of each 12-week cycle until disease progression (up to approximately 96 weeks).
11589898|NCT00718549|No Intervention|Observation Arm: No Intervention|Participants with PR or CR after induction phase who will be randomized to observation arm will not receive any intervention. Participants will be assessed every 4-weeks for the first 12 weeks and every 12-weeks afterwards up to 96 weeks.
11589899|NCT00718536|Experimental|1|Addition of raltegravir 800 mg QD to HAART
11589900|NCT00718523|Placebo Comparator|A|Placebo plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of placebo administered on Day 1 of each 21-day cycle.
11589901|NCT00718523|Experimental|B|AMG 479 plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of AMG 479 single agent administered on Day 1 of each 21-day cycle.
11589902|NCT00718510|Active Comparator|L-arginine first/placebo second|Patients with diagnosis of schizophrenia will be randomised to receive L-arginine first/placebo second 3 grams bid (cross-over design) in addition to treatment as usual. The active treatment period will be 3 weeks, with a wash-out period of 5 days and re-commencing on the alternative arm of the randomization
11589903|NCT00718510|Placebo Comparator|Placebo first/L-arginine second|Patients with diagnosis of schizophrenia will be randomised to receive placebo first/L-arginine second 3 grams bid (cross-over design) in addition to treatment as usual. The active treatment period will be 3 weeks, with a wash-out period of 5 days and re-commencing on the alternative arm of the randomization
11589904|NCT00718497||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
11589905|NCT00718484|Experimental|A|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
11589906|NCT00718484|Active Comparator|B|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
11589907|NCT00718471|Experimental|1|Enoxaparin
11589908|NCT00718471|Active Comparator|2|UFH
11589909|NCT00718458||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
11589910|NCT00718458||Non-ALS|Subjects not having either definite or probable ALS by El Escorial Criteria.
11589911|NCT00718445||MND|"Patients seen in the MDA/ALS Center of Hope at Drexel University College of Medicine
~Patients seen in the Department of Neurology at Drexel University College of Medicine"
11589912|NCT00718432|Active Comparator|UC group|Usual care with education
11589913|NCT00718432|Experimental|ENIC group (IC group in 2009 study)|Exercise and nutritional integrated care
11589914|NCT00718432|Experimental|PSTIC group (IC group in 2009 study)|Problem solving therapy integrated care
11589915|NCT00718419|Experimental|A: Enzastaurin|
11589916|NCT00718406|Active Comparator|A|A=metoprolol
11589917|NCT00718406|Active Comparator|B|B=metoprolol plus morphine
11589918|NCT00718393||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
11589919|NCT00718380|Experimental|Group 1|Dose escalation from Open label 0.05 to 0.25 mg/kg once a day dosing for 21 days
11589920|NCT00718380|Experimental|Group 2|Open label 0.10 mg/kg once a day dosing after safety evolution of Group 1
11589921|NCT00718380|Experimental|Group 3|Open label 0.20 mg/kg once a day dosing after safety evolution of Group 2
11589922|NCT00718380|Experimental|Group 4|Open label 0.25 mg/kg once a day dosing after safety evolution of Group 3
11589923|NCT00718354|Active Comparator|B|Standard Chemotherapy (upto 6 cycles)
11589924|NCT00718354|Experimental|A|Enoxaparin: 1 mg/kg once daily in addition to standard chemotherapy up to 6 months
11589925|NCT00718341|Active Comparator|1|
11589926|NCT00718341|Placebo Comparator|2|
11589927|NCT00718328|Experimental|I|Simvastatin Group
11589928|NCT00718328|Placebo Comparator|II|Placebo Group
11589929|NCT00718315|Experimental|1|
11589930|NCT00718315|Experimental|2|
11589931|NCT00718315|Experimental|3|
11589932|NCT00718302|Experimental|Randomized treatment; antiglide plate|Randomized treatment; antiglide plate
11589933|NCT00718302|Experimental|Randomized treatment; lateral plate|Randomized treatment; lateral plate
11589934|NCT00718289|Experimental|Citrate|Citrate dialysate for haemodialysis
11589935|NCT00718289|Active Comparator|Acetate|Acetate dialysate
11589936|NCT00718276|Active Comparator|1|25(OH)D
11589937|NCT00718276|Active Comparator|2|vitamin D3
11589938|NCT00718250|Experimental|cohort 1|AML Cell Vaccine alone
11589939|NCT00718250|Experimental|cohort 2|Donor leukocytes alone
11589940|NCT00718250|Experimental|cohort 3|AML cell vaccine and Donor Leukocyte Infusion (1x107/kg)
11589941|NCT00718250|Experimental|cohort 4|AML cell vaccine and Donor Leukocyte Infusion (1x108/kg)
11589942|NCT00718237|Experimental|1|RotaTeq™
11589943|NCT00718237|Placebo Comparator|2|Placebo
11589944|NCT00718224|Experimental|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery
~To maintain the blind, placebo for Enoxaparin sodium:
~12 and 24 hours after surgery, then once daily if no SRI
~12 hours after surgery only if SRI"
11589947|NCT00718198||2|Group admitted 1 (one) year after CPOE protocol changes were made
11589948|NCT00718185||A|Patients receiving sildenafil as standard of care
11589950|NCT00718146|Experimental|Group 1|Age 16 to 60 years
11589951|NCT00718146|Experimental|Group 2|Age over 60 years
11589952|NCT00718133|Experimental|1|Children at school age from Haifa bay region
11589953|NCT00718120|Experimental|Fluviral Adult Group|Subjects aged between 18 and 60 years received a single dose of Fluviral® vaccine.
11589954|NCT00718120|Experimental|Fluviral Elderly Group|Subjects aged more than 60 years received a single dose of Fluviral® vaccine.
11589955|NCT00718107||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
11589956|NCT00718094|Experimental|Polyphenon E treatment|Polyphenon E® therapy was given for 56 days.
11589957|NCT00718094|Placebo Comparator|Placebo|Oral Placebo
11589958|NCT00718081|Experimental|1|Oral Sufentanil
11589959|NCT00718081|Experimental|2|Oral sufentanil
11589960|NCT00718081|Placebo Comparator|3|Oral dosage of placebo
11589961|NCT00718068|Experimental|Continuous|This group will receive potassium chloride by continuous infusion on a sliding-scale system based on serum potassium level.
11589962|NCT00718068|Active Comparator|Intermittent|This arm will form the control group and receive potassium chloride by intermittent infusion as per conventional management
11589963|NCT00718042|Experimental|1|All subjects will have their blood tested by the investigational Chagas screening assay.
11589964|NCT00718042|Experimental|2|Testing of blood donor samples with the investigational Chagas screening assay. Samples that test positive will be also tested with the Chagas confirmatory assay.
11589965|NCT00718016||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
11589966|NCT00718003||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
11589967|NCT00717990|Experimental|1|XELIRI/Avastin
11589968|NCT00717951|Experimental|A|"Arm A is docetaxol+capecitabine chemotherapy"
11589969|NCT00717951|Experimental|B|"Arm B is docetaxol+cisplatin chemotherapy"
11589970|NCT00717938|Other|A|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants.Used drugs=cisplatinum or carboplatin and e.g.etoposide.
11589971|NCT00717938|Experimental|B|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
11589972|NCT00717925|Experimental|1|
11589973|NCT00717912|Experimental|Arm 1|Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup
11589974|NCT00717912|Experimental|Arm 2|Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Experimental sweetener syrup
11589975|NCT00717912|Experimental|Arm 3|Experimental sweetener syrup / Classical sugar syrup / Experimental sweetener syrup / Classical sweetener syrup / Classical sugar syrup / Classical sugar syrup / Experimental sweetener syrup
11589976|NCT00717912|Experimental|Arm 4|Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup / Classical sugar syrup / Classical sweetener syrup
11589977|NCT00717912|Experimental|Arm 5|Classical sugar syrup / Experimental sweetener syrup / Classical sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup
11589978|NCT00717912|Experimental|Arm 6|Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Classical sugar syrup
11589979|NCT00717899|Active Comparator|1|School children from Haifa bay region, Israel.
11589980|NCT00717886|Experimental|1|Patients with documented axillary metastases (Stage II breast cancer) will undergo subdermal injection of technetium sulfur colloid (TSC) into the ipsilateral upper extremity approximately 3 hours before surgery.
11589981|NCT00717873|Experimental|HFCWO Arm|Airway clearance provided by the Vest Airway Clearance System
11589982|NCT00717873|No Intervention|CPT Arm|Airway clearance provided by manual CPT
11589983|NCT00717860|Experimental|Caspofungin|caspofungin acetate (MK0991)
11589984|NCT00717860|Active Comparator|Micafungin|Micafungin sodium
11589985|NCT00717847||1|Any patient with NSCLC receiving erlotinib or gefitinib
11589986|NCT00717847||2|Patients with unexpected and/or severe treatment related toxicity whilst receiving EGFR TKI.
11589987|NCT00717834|Experimental|Cohort 1, Treatment Arm 1|Randomization of a total of approx. 200 subjects to one of four treatment arms at 1:1:1:1 ratio to receive 1.25 µg of the RRV Vaccine with/without adjuvant (Al(OH)3), or 2.5 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Cohort 1 is subdivided into Cohort 1a (n = 60, i.e. 15 subjects per dose/adjuvantation combination) to receive the first vaccination on Day 0, with Day 7 safety data being reviewed by a Data Monitoring Committee and, following DMC recommendation, to receive the second vaccination at Day 21; Cohort 1b (n=140, i.e. 35 subjects per dose/adjuvantation combination) is to be vaccinated twice 21 days apart upon availability of DMC recommendation. Booster vaccination to follow 180 days after first vaccination.
11589988|NCT00717834|Experimental|Cohort 1, Treatment Arm 2|Same as Cohort 1, Treatment Arm 1
11589989|NCT00717834|Experimental|Cohort 1, Treatment Arm 3|Same as Cohort 1, Treatment Arm 1
11589990|NCT00717834|Experimental|Cohort 1, Treatment Arm 4|Same as Cohort 1, Treatment Arm 1
11589991|NCT00717834|Experimental|Cohort 2, Treatment Arm 1|Randomization of a total of approx. 100 subjects to one of two treatment arms at 1:1 ratio to receive 5 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Vaccinations take place upon review of Cohort 1a Day 7 safety data by DMC and recommendation to proceed. Booster vaccination to follow 180 days after first vaccination.
11589992|NCT00717834|Experimental|Cohort 2, Treatment Arm 2|Same as Cohort 2, Treatment Arm 1
11589993|NCT00717834|Experimental|Cohort 3, Treatment Arm 1|Randomization of a total of approx. 100 subjects to one of two treatment arms at 1:1 ratio to receive 10 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Vaccinations take place upon review of Cohort 1b and Cohort 2 Day 7 safety data by DMC and recommendation to proceed. Booster vaccination to follow 180 days after first vaccination.
11589994|NCT00717834|Experimental|Cohort 3, Treatment Arm 2|Same as Cohort 3, Treatment Arm 1
11589995|NCT00717821|Experimental|1|
11589996|NCT00717821|Active Comparator|2|
11589997|NCT00717808|Active Comparator|1|During the study the patient will either receive tranilast (300mg twice a day) or a placebo drug for a period of seven days. The patient will then have a seven day break followed by another period of seven days in which the patient will receive the other medication.
11589998|NCT00717808|Placebo Comparator|2|The patient will receive the placebo twice a day for 7 days whilst taking their weekly methotrexate dose
11589999|NCT00717795||1|Arm 1 - Physical Activity intervention
11590000|NCT00717795||2|Arm 2 - Wait-list control
11590001|NCT00717782|Experimental|1|"Patients were injected with 0·6 ml of a solution containing 30 units botulinum toxin A (Botox; Allergan, Ireland).
~A 27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter."
11590002|NCT00717782|Placebo Comparator|2|"Patients in the placebo group received a 0·6-ml injection of saline.
~A27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter."
11590003|NCT00717769|Experimental|1|
11590004|NCT00717769|Placebo Comparator|2|
11590005|NCT00717756|Experimental|Lenalidomide|
11590006|NCT00717743||1|Patients diagnosed with RCC.
11590007|NCT00717730|Placebo Comparator|A|Placebo dietary supplement
11590008|NCT00717730|Experimental|B|Folic acid
11590009|NCT00717730|Experimental|C|Vitamin B12
11590010|NCT00717730|Experimental|D|Folic acid and Vitamin B12
11590011|NCT00717717|No Intervention|Control|No intervention except repeated measurements of physical capacity
11590012|NCT00717717|Experimental|Intervention|Intervention: One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
11590013|NCT00717704|Experimental|1|All participants will receive ixabepilone by vein once every three weeks as well as dasatinib by mouth once daily. All participants will receive the study drugs at a baseline dose. If the side effects are minimal and tolerable, the next cycle of study drugs will be given at same dosage. If side effects are intolerable, then the dose will be lowered.
11590014|NCT00717691|Experimental|1|Immediate fitting with dynamic splinting following diagnosis of hallux limitus.
11590015|NCT00717691|No Intervention|2|Control arm; patients only treated with standard of care following diagnosis of hallux limitus.
11590016|NCT00717678|Experimental|Prograf-XL + MMF|
11590017|NCT00717678|Active Comparator|Prograf + MMF|
11590018|NCT00717665|Experimental|A, 1, I|
11590019|NCT00717665|Active Comparator|A, 2, I|
11590020|NCT00717652|Experimental|1|arbutin, tretinoin, triamcinolone
11590021|NCT00717652|Active Comparator|2|Triluma
11590022|NCT00717639|Experimental|1|single arm study, all patients will undergo Vasovist-enhanced MRA
11590023|NCT00717626|Experimental|Daily administration of low dose FVIII|Low dose daily prophylaxis using FVIII products (e.g.Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS)
11590024|NCT00717613||1|Observational cohort study
11590025|NCT00717600|Experimental|1|Oral probiotics
11590026|NCT00717574|Active Comparator|Sevoflurane group|Sevoflurane based general anesthesia
11590027|NCT00717574|Active Comparator|Propofol group|Propofol based general anesthesia
11590028|NCT00717561|Experimental|Arm 1|
11590029|NCT00717561|Active Comparator|Arm 2|
11590030|NCT00717548|Experimental|A|
11590031|NCT00717522|Experimental|Pomalidomide|7 mg pomalidomide taken orally once daily (QD) on days 1 through 21 of each 28-day cycle
11590032|NCT00717509||clozapine group|"chronic schizophrenia
~have been taking clozapine at leaset one year
~without diabetes, pulmonary tuberculosis"
11590033|NCT00717496|Experimental|A|The intervention will consist of outreach telephone calls daily by bilingual trained nursing staff for the first 2 weeks postpartum using the scripted protocols developed for this program. This group will receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream. The intervention nurse will ask the mothers on their initial intake call for the best time to call each day to minimize time needed to reach the mother.
11590034|NCT00717496|No Intervention|B|Mothers assigned to the control group will receive usual care. This group will also receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream.
11590035|NCT00717483||Type 1 diabetes|children with type 1 diabetes
11590036|NCT00717470|Active Comparator|Prograf + MMF + Steroids|oral
11590037|NCT00717470|Active Comparator|Advagraf (dose 1) + MMF + steroids|oral
11590038|NCT00717470|Active Comparator|Advagraf (dose 2) + MMF + steroids|oral
11590039|NCT00717470|Active Comparator|Advagraf + MMF + Basilixmab + steroids|oral
11590040|NCT00717457|Active Comparator|exenatide|
11590041|NCT00717457|Experimental|taspoglutide 10mg|
11590042|NCT00717457|Experimental|taspoglutide 10mg/20mg|
11590043|NCT00717444|Experimental|1|contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities
11590044|NCT00717444|Experimental|2|contingency management for abstinence plus 12-step facilitation therapy
11590045|NCT00717431|Experimental|Hippocampal Stimulation|Hippocampal Stimulation (Stimulator is turned ON) Surgical Intervention
11590046|NCT00717431|Sham Comparator|Hippocampal Implantation|Hippocampal Implantation (Stimulator is turned OFF)Surgical Intervention
11590047|NCT00717418||1|"cyclosporine ophthalmic emulsion 0.05%
~artificial tears"
11590048|NCT00717405|Experimental|1|
11590049|NCT00717392||Hippotherapy_ADHD|10 children with ADHD who receive hippotherapy
11590050|NCT00717392||Hippotherapy_ASD|10 children with ASD who receive hippotherapy
11590051|NCT00717392||Control_ADHD|10 children with ADHD who DO NOT receive hippotherapy
11590052|NCT00717392||Control_ASD|10 children with ASD who DO NOT receive hippotherapy
11590053|NCT00717379|Active Comparator|1|steroid regimen 1
11590054|NCT00717379|Experimental|2|steroid regimen 2
11590055|NCT00717366|Experimental|MIRCERA Group 1: Intermediate-Conversion-Factor Group|Participants will receive methoxy polyethylene glycol-epoetin beta (MIRCERA) IV injection at a starting dose based on an intermediate conversion factor from their previous Erythropoiesis-stimulating Agent (ESA) dose (4 * previous weekly epoetin dose [international units {IU}]/250 or 4 * previous weekly darbepoetin alfa dose [micrograms {mcg}]/1.1) once every 4 weeks for 20 weeks. Participants who will complete the 20 weeks of treatment with hemoglobin (Hb) level within ± 1 grams per deciliter (g/dL) of their baseline Hb level and within the target range of 10-12 g/dL will enter an optional 52-weeks safety extension period. During this period, the participants will continue to receive MIRCERA IV injection once every 4 weeks.
11590056|NCT00717366|Experimental|MIRCERA Group 2: High-Conversion-Factor Group|Participants will receive MIRCERA IV injection based on a high conversion factor from their previous ESA dose (4 * previous weekly epoetin dose [IU]/125 or 4 * previous weekly darbepoetin alfa dose [mcg]/0.55) once every 4 weeks for 20 weeks. Participants who will complete the 20 weeks of treatment with Hb within ± 1 g/dL of their baseline Hb and within the target range of 10-12 g/dL will enter an optional 52-weeks safety extension period. During this period, the participants will continue to receive MIRCERA IV injection once every 4 weeks.
11590057|NCT00717353||1|Lung cancer
11590058|NCT00717340|Experimental|tivozanib (AV-951) + paclitaxel|
11590059|NCT00717314|Experimental|MMF, 50% CNI Reduction|Participants received mycophenolate mofetil (MMF), 1.5 to 2.0 grams (g) daily, orally (PO), twice per day (BID) from baseline (BL) to Week 52. Participants also received a 50 percent (%) reduced dose of calcineurin inhibitor (CNI) from BL to Week 52.
11590060|NCT00717314|Experimental|MMF, ≥75% CNI Reduction|Participants received MMF, 1.5 to 2.0 g daily, PO, BID from BL to Week 52. Participants also received a 75% reduced dose of CNI from BL to Week 52.
11590061|NCT00717301||Head Trauma|Patients presenting to any of the AHCC/ERNES Emergency Departments with head trauma.
11590062|NCT00717301||Control subjects|Patients presenting to the Univ of Rochester Medical Center/Strong Memorial Hospital Outpatient Laboratory for routine blood draw.
11590063|NCT00717288|Active Comparator|1|Detemir insulin dosed at 50% of calculated basal insulin infusion requirement injected once daily
11590064|NCT00717288|Active Comparator|2|Detemir insulin dosed at 65% of calculated basal insulin infusion requirement injected once daily
11590065|NCT00717288|Active Comparator|3|Detemir insulin dosed at 80% of calculated basal insulin infusion requirement injected once daily
11590066|NCT00717275|Experimental|Temozolomide|
11590067|NCT00717262|Experimental|1|HQK-1001
11590068|NCT00717262|Placebo Comparator|2|
11590069|NCT00717249|Experimental|Test Lens|galyfilcon A contact lens with a silver additive
11590070|NCT00717249|Active Comparator|Control Lens|galyfilcon A control contact lens
11590071|NCT00717236|Experimental|Certolizumab pegol (CZP)|
11590072|NCT00717236|Placebo Comparator|Placebo|
11590073|NCT00717223||Parents with children with diabetes|parents who have children 18 or younger with diabetes
11590074|NCT00717210|Active Comparator|A|Conventional Radiotherapy
11590075|NCT00717210|Experimental|B1/2|1:1 randomization between temozolomide and procarbazine/lomustine/vincristine (PCV)
11590076|NCT00717197|Experimental|Capecitabine|Capecitabine (1,000-1,250 mg/m2) taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
11590077|NCT00717171|Placebo Comparator|1|
11590078|NCT00717171|Experimental|2|
11590079|NCT00717158|No Intervention|I|Usual medical care. They received written healthy lifestyle information
11590080|NCT00717158|Active Comparator|2|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
11590081|NCT00717145|Experimental|1|One risedronate 20 mg DR tablet taken following an overnight fast, followed by a 4-hour fast.
11590082|NCT00717145|Experimental|2|One risedronate 20 mg DR tablet taken following an overnight fast, within 5 minutes after ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
11590083|NCT00717145|Experimental|3|One risedronate 35 mg DR tablet taken following an overnight fast, within 5 minutes after ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
11590084|NCT00717145|Experimental|4|One risedronate 35 mg IR tablet taken following an overnight fast, 30 minutes before ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
11590085|NCT00717132|Experimental|Individual Behavioral Modification|Individual behavioral weight control treatment; parent and child are treated separately for 15 total sessions.
11590086|NCT00717132|Active Comparator|Family-based Behavioral Modification|Family-based behavioral weight control treatment; parent and child are treated together for 15 total sessions.
11590087|NCT00717119||1|Patients with sprain of ankle treated with NSAID
11590088|NCT00717093|Experimental|Active|
11590089|NCT00717093|Placebo Comparator|Placebo|
11590090|NCT00717080|Experimental|Arm 1|IOL surgery with Capsular Tension Ring
11590091|NCT00717080|Placebo Comparator|Arm 2|IOL surgery without Capsular Tension Ring
11590092|NCT00717067|Experimental|Healthy Subjects|Subjects with Normal Renal Function (Creatinine Clearance > 80mL/min) (I) Maraviroc single dose, followed by (II) Maraviroc + Saquinavir/Ritonavir
11590093|NCT00717067|Experimental|Mild Renal Impairment|Subjects with Mild Renal Impairment (Creatinine Clearance >50 and ≤80 mL/min)
11590094|NCT00717067|Experimental|Moderate Renal Impairment|Subjects with Moderate Renal Impairment (Creatinine Clearance ≥30 and ≤50 mL/min)
11590095|NCT00717067|Experimental|Severe Renal Impairment|Subjects with Severe Renal Impairment (Creatinine Clearance <30 mL/min)
11590096|NCT00717067|Experimental|ESRD on Hemodialysis|Subjects with End Stage Renal Impairment receiving Hemodialysis(Creatinine Clearance <30 mL/min) (I) Maraviroc single dose one hour following completion of hemodialysis, followed by (II) Maraviroc single dose three hours prior to start of hemodialysis
11590133|NCT00716807|Placebo Comparator|BMS 2|
11590175|NCT00716430|Active Comparator|QI|Quality Improvement Centres
11590176|NCT00716430|No Intervention|Non-QI|No Quality Improvement Programme
11590270|NCT00715741|Active Comparator|1|Group 1 will receive 30% oxygen plus PEEP + 3 to 5 cm Water duration of anesthesia and surgery
11590097|NCT00717054|Active Comparator|Aprepitant and Scopolamine group|Patients receive aprepitant and scopolamine for prevention of postoperative nausea and vomiting then were followed through the post operative period looking for nausea, vomiting, composite, and rescue medication utilization. This was compared to patients receiving aprepitant and scopolamine placebo looking for a difference in incidence of events.
11590098|NCT00717054|Placebo Comparator|Aprepitant and Scopolamine Placebo Group|Patients receiving aprepitant and placebo scopolamine for prevention of postoperative nausea and vomiting then followed through the post operative period looking for signs of nausea, vomiting, composite, and rescue medication utilization. This was compared to patients receiving aprepitant and scopolamine looking for a difference in incidence of events.
11590099|NCT00717041||Presenting to the ED|Patients who present to the ED
11590100|NCT00717002||1|Patients from Group 1 will undergo thoracoscopy as part of their routine clinical management to drain off excess pleural fluid. Even though taking a sample of the tumour tissue present on the pleural/ lining of the lung may not routinely form part of a routine thoracoscopy, it will be obtained for the study and sent to the laboratory for testing.
11590101|NCT00717002||2|Patients from Group 2 should have tumour samples obtained previously for diagnosis, and these will be obtained from the Department of Pathology. If they are undergoing thoracoscopy as part of their routine clinical management, a sample of the tumour tissue present on the pleural/ lining of the lung will also be obtained during the procedure and sent to the laboratory for testing.
11590102|NCT00716976|Experimental|STS Arm (sodium thiosulfate treatment)|Patients receive sodium thiosulfate IV (dosage 16 g/m2 or 533 mg per kg for patients whose therapeutic protocol administers cisplatin on a per kg basis due to young age or small body) over 15 minutes beginning 6 hours after the completion of each cisplatin infusion. Treatment with sodium thiosulfate continues until the completion of cisplatin therapy.
11590103|NCT00716976|Experimental|Observation Arm (No sodium thiosulfate treatment)|Patients do not receive sodium thiosulfate.
11590104|NCT00716963|Active Comparator|1|Fluticasone propionate (Flovent Diskus) 250 mcg
11590105|NCT00716963|Active Comparator|2|budesonide 400mcg
11590106|NCT00716963|Placebo Comparator|3|placebo
11590107|NCT00716950|Experimental|1|valsartan/amlodipine
11590108|NCT00716950|Active Comparator|2|losartan/amlodpine
11590109|NCT00716937|Experimental|1|Excision of the cyst and Karydakis flap
11590110|NCT00716937|Experimental|2|Excision of the cyst and laying open
11590111|NCT00716924|Experimental|1|300-mg loading dose of clopidogrel given ≥ 6 and ≤ 24 hours before PCI
11590112|NCT00716924|Experimental|2|600-mg loading dose of clopidogrel given ≥ 6 hours and ≤ 24 before PCI.
11590113|NCT00716924|Experimental|3|600-mg loading dose of clopidogrel given immediately (≤ 45 minutes) before PCI.
11590114|NCT00716898||1|"A. Patients with pathologically or cytologically confirmed diagnosis of advanced solid malignancy.
~B. Venous thromboembolism: Deep vein thrombosis (DVT) confirmed by Doppler ultrasound, or pulmonary embolism confirmed by lung ventilation perfusion scan, or computerized tomography.
~C. Treatment with therapeutic dose of low molecular weight heparin. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. Serum creatinine level < 1.5 mg/dl. G. Informed consent"
11590115|NCT00716898||2|"A. Patients with unstable angina pectoris/ atypical chest pain, with no evidence of acute myocardial infarction.
~B. Treatment with therapeutic dose of low molecular weight heparin. C. No evidence of VTE. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. No history of malignancy. G. Serum creatinine level < 1.5 mg/dl. H. Informed consent"
11590116|NCT00716885||CHF|"Informed consented participants are recruited among all patients admitted to the OLVG hospital.
~Inclusion criteria:
~Chronic congestive heart failure patients of all ages selected for biventricular pacemaker implantation for resynchronization therapy
~Dyspnoe NYHA class III and IV
~Optimal and constant heart failure treatment according to the ESC guidelines
~Exclusion criteria:
~Renal failure (creatinine >1.70 mg/dl)
~Signs of infection or inflammation"
11590117|NCT00716885||Control|The control group consists of ten age-matched volunteers with a normal left ventricular ejection fraction and without signs or symptoms of heart failure.
11590118|NCT00716872|Experimental|ImmedSHUTi/ImmedHyp|In the first part of the trial, participants are assigned to the Immediate SHUTi group; that is, they receive access to the SHUTi program right away. In the second part of the trial (3 months later), participants are assigned to the Immediate Hypnosis group; that is, they receive access to the Hypnosis recordings right away.
11590119|NCT00716872|Experimental|ImmedSHUTi/DelayHyp|In the first part of the trial, participants are assigned to the Immediate SHUTi group; that is, they receive access to the SHUTi program right away. In the second part of the trial (3 months later), participants are assigned to the Delayed Hypnosis group; that is, they receive access to the Hypnosis recordings at the end of the study.
11590120|NCT00716872|Experimental|DelaySHUTi/ImmedHyp|In the first part of the trial, participants are assigned to the Delayed SHUTi group; that is, they receive access to the SHUTi program at the end of the study. In the second part of the trial (3 months later), participants are assigned to the Immediate Hypnosis group; that is, they receive access to the Hypnosis recordings right away.
11590121|NCT00716872|No Intervention|DelaySHUTi/DelayHyp|In the first part of the trial, participants are assigned to the Delayed SHUTi group; that is, they receive access to the SHUTi program at the end of the study. In the second part of the trial (3 months later), participants are assigned to the Delayed Hypnosis group; that is, they receive access to the Hypnosis recordings at the end of the study.
11590122|NCT00716859|Active Comparator|Timolol|
11590123|NCT00716859|Experimental|latanoprost|
11590124|NCT00716846|Active Comparator|statin-1|simvastatin
11590125|NCT00716846|Active Comparator|statin-2|atorvastatin
11590126|NCT00716846|Active Comparator|statin-3|pitavastatin
11590127|NCT00716833|Active Comparator|Preemptive|Preemptive group patients get Etoricoxibe twice (before and after surgery) or just a single preoperative dose
11590128|NCT00716833|Placebo Comparator|Postoperative|Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery.
11590129|NCT00716820||SUNITINIB MALATE|Patients taking Sutent.
11590130|NCT00716807|Experimental|TMD 1|
11590131|NCT00716807|Placebo Comparator|TMD 2|
11590132|NCT00716807|Experimental|BMS 1|
11590134|NCT00716781||1 (first year)|Asymptomatic infants born to GBS-positive mothers or to mothers with risk factors and incomplete prophylaxis were managed according to the CDC protocol. Blood cultures and CBC were performed and the infant was observed for 48 hours. Participating hospital were free to perform any additional test, such as CRP, MiniESR, etc
11590135|NCT00716781||2 (second year)|Asymptomatic infants born to GBS-positive mothers or to mothers with risk factors and incomplete prophylaxis were managed with clinical observation only. Clinical surveillance was based on 3 signs: 1. Skin appearance (pink, pale, mottled, cyanotic); 2. Respiratory rate (>50 or <50 breaths per minute); 3. Dyspnea (Yes / No)
11590136|NCT00716768|Active Comparator|Laparoscopic Inguinal Hernia Repair|
11590137|NCT00716768|Active Comparator|Open Inguinal Hernia Repair|
11590138|NCT00716755|Experimental|Dose Reduction|See Intervention
11590139|NCT00716742||1|bimatoprost 0.03% latanoprost 0.005% travoprost 0.004%
11590140|NCT00716729||Pateints with longstanding hip and/groin pain|
11590141|NCT00716716|Experimental|rFIXFc|Six intravenous (IV) dose levels, 1, 5, 12.5, 25, 50, and 100 IU/kg
11590142|NCT00716703|Experimental|1|cohort = pediatric patients in the ED (3-18 yo) with abdominal pain suspicious for appendicitis that are to undergo CT scan
11590143|NCT00716690|Experimental|treatment|
11590144|NCT00716677||1|
11590145|NCT00716677||2|
11590146|NCT00716664|Experimental|1|The experimental group receives the intervention in addition to normal optimal care
11590147|NCT00716664|Active Comparator|2|The active comparator, or control group, receives normal optimal care only
11590148|NCT00716638|Experimental|Treatment group 1|Trauma-focused Cognitive Behavior Therapy (TF-CBT)
11590149|NCT00716638|Experimental|Treatment group 2|Eye Movement Desensitization and Reprocessing (EMDR)
11590150|NCT00716625||sunitinib malate|Patients taking sunitinib malate
11590151|NCT00716612|Placebo Comparator|2|PO Placebo QD
11590152|NCT00716612|Experimental|1|PO Coenzyme Q 10 QD
11590153|NCT00716599|No Intervention|Control|Health centers continue with standard-of-care empiric case management
11590154|NCT00716599|Experimental|RDT training|Health centers randomly selected to receive training and RDTs, for use in routine patient case management
11590155|NCT00716586|Experimental|1|Patients over the age of 18 years with cystoid macular edema and retinal degeneration will be treated with Trusopt.
11590156|NCT00716573|Experimental|1|Introduction of everolimus associated with CNI (ciclosporin or tacrolimus) reduction (50%) to the current immunosuppression schedule
11590157|NCT00716573|No Intervention|2|Maintain of their current immunosuppressive therapy
11590158|NCT00716560||A|Metastatic melanoma treatment with Dartmouth regimen
11590159|NCT00716547|Experimental|1|
11590160|NCT00716547|Experimental|2|
11590161|NCT00716547|Active Comparator|3|
11590162|NCT00716547|Placebo Comparator|4|
11590163|NCT00716534|Experimental|A|12.5 mg ABT-869 + Carboplatin/Paclitaxel
11590164|NCT00716534|Experimental|B|7.5 mg ABT-869 + Carboplatin/Paclitaxel
11590165|NCT00716534|Placebo Comparator|C|Placebo (7.5 mg or 12.5 mg) + Carboplatin/Paclitaxel
11590166|NCT00716521|Placebo Comparator|Placebo|groups of 3-4 subjects for overnight polysomnography assessments
11590167|NCT00716521|Experimental|Low dose Zolpidem|
11590168|NCT00716521|Experimental|High dose zolpidem|
11590169|NCT00716508|Active Comparator|A|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
11590170|NCT00716508|Active Comparator|B|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
11590171|NCT00716469|Experimental|LS11 Administration|"Treatment will be given with a standard 3+3 light dose escalation. The Treatment Period will be 28 days. The LS11 dose will be 30mg/m2. The initial light dose will be 50 J/cm. If criteria for dose escalation are met, then the light dose will be escalated to 100J/cm, 150J/cm and 200J/cm. Once the maximum light dose is determined, up to 6 additional patients will be treated at that level to gain further experience with this modality prior to phase II testing. In particular, at least 3 subjects <12 years of age will be enrolled at the maximum tolerable dose (MTD) to allow for further evaluation of safety in younger children. If grade 3 or 4 toxicities are noted at light dose level #1, the LS11 dose will be decreased to 20mg/m2 (2/3 of the standard dose)."
11590172|NCT00716456|Experimental|1|In the phase I portion, patients will be enrolled in cohorts of 3-6 patients;receiving daily erlotinib 100 mg along with cetuximab given every 2 weeks beginning at 250mg/m2 IV. Following the initial dose, for dose levels 1 and 2 (250 mg/m2 and 375 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 60 minutes. For dose level 3 (500 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 120 minutes. The infusion rate of cetuximab should never exceed 10 mg/minute (5 mL/min). The dose may subsequently be reduced for individual patients, depending on a patient's toxicity.
11590173|NCT00716443|Active Comparator|Pliaglis® Cream|tetracaine 4% / lidocaine 7% cream; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.
11590174|NCT00716443|Active Comparator|benzocaine 20% / lidocaine 6% / tetracaine 4% ointment|apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.
11590226|NCT00716053|Experimental|BLVR|
11590177|NCT00716417|Experimental|A. BIBW 2992-cisplatin-paclitaxel|daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-paclitaxel
11590178|NCT00716417|Experimental|B. BIBW 2992-cisplatin-5FU|daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-5FU
11590179|NCT00716404||1|All (consecutive) patients in whom one or more components of the Benephit Infusion System are planned to be used are eligible for enrollment in the study and should be offered informed consent.
11590180|NCT00716391|Active Comparator|Group A|TPF plus concomitant treatment with cisplatin and conventional radiotherapy.
11590181|NCT00716391|Experimental|Group B|TPF plus concomitant treatment with cetuximab and conventional radiotherapy
11590182|NCT00716365|Experimental|HemCon|"The purpose of this trial is to test HemCon pad after diagnostic percutaneous coronary angiography as an adjunct to manual compression to better control vascular access site bleeding and reduce time-to-hemostasis.
~The HemCon bandage (containing a carbohydrate called chitosan, found in the shells of shrimp, lobster and beetles) will be used to shorten the time needed to achieve hemostasis, time to patient's ambulation, and patient's."
11590183|NCT00716339|Active Comparator|1|motivated
11590184|NCT00716339|No Intervention|2|control
11590185|NCT00716326|Active Comparator|1|Subjects in this study arm will receive active treatment with Cefar TENS device which delivers therapeutic electrical currents 2-3x over sensory threshold in the area of pain.
11590186|NCT00716326|Placebo Comparator|2|Subjects in this study arm will receive placebo treatment with manipulated Cefar TENS device which delivers electrical currents just below sensory threshold in the area of pain.
11590187|NCT00716300||1|obese and insulin resistant subjects
11590188|NCT00716300||2|lean and normolipidaemic subjects
11590189|NCT00716287||1|Anti-angiogenic targeted therapies are used in a wide range of solid tumors including NSCLC, breast cancer, GISTs, CRC, renal cell carcinoma and hepatocellular carcinoma.
11590190|NCT00716274|Experimental|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks (study period II). Participants who complete the study period II will be re-randomized in the study period III of 16-week duration to assess maintenance of benefit following discontinuation of treatment with atomoxetine. Participants assigned to atomoxetine during the study period II will be re-randomized to either atomoxetine or placebo whereas participants previously assigned to placebo will receive atomoxetine.
11590191|NCT00716274|Placebo Comparator|Placebo|Placebo will be packaged in the same way as active comparator to enforce double-blind study design
11590192|NCT00716248|Experimental|1|
11590193|NCT00716248|Active Comparator|2|
11590194|NCT00716235||DCD|Children with a diagnosis of DCD
11590195|NCT00716235||Autism|Children with a diagnosis of Autism disorder
11590196|NCT00716235||ADHD|Children with a diagnosis of ADHD
11590197|NCT00716235||Control|Control group - children with no neurological or psychiatric problems
11590198|NCT00716222||1|Obese adolescent and young adult with sleep disorder
11590199|NCT00716222||2|Obese adolescent and young adult without sleep disorder
11590200|NCT00716222||3|Lean adolescent and young adult with sleep disorder
11590201|NCT00716209||1|Patients with cancers of the gastrointestinal tract (eg. colorectal, gastric, pancreatic, esophageal)
11590202|NCT00716183|Experimental|Probiotic 1|Women receiving Lactobacillus salivarius HN6
11590203|NCT00716183|Experimental|Probiotic 2|Women receiving Lactobacillus reuteri CR20
11590204|NCT00716183|Experimental|Probiotic 3|Women receiving Lactobacillus fermentum LC40
11590205|NCT00716183|Active Comparator|beta-lactam|The evolution of the women ascribed to the other three arms will be compared with that of 100 women suffering lactational mastitis that will follow a conventional antibiotic treatment as prescribed by the pediatrician/gynecologist
11590206|NCT00716170||A:|Patients with type 2 diabetes mellitus
11590207|NCT00716157||Observation|Adult patients receiving both radiation therapy and chemotherapy
11590208|NCT00716144|Active Comparator|A|Talarozole 0.5 mg
11590209|NCT00716144|Active Comparator|B|Talarozole 1.0 mg
11590210|NCT00716144|Active Comparator|C|Talarozole 2.0 mg
11590211|NCT00716144|Placebo Comparator|D|Talarozole matching Placebo
11590212|NCT00716131||ALS|Diagnosed with ALS or other motor system disorder including PLS, Bulbar Palsy or Motor neuropathy
11590213|NCT00716131||Neuro|Diagnosed with other chronic neurologic illnesses (Alzheimers, multiple sclerosis, migraines, etc)
11590214|NCT00716131||Healthy|Normal Controls
11590215|NCT00716131||Autopsy|
11590216|NCT00716118||1|IVF patients.
11590217|NCT00716105|Placebo Comparator|Control|Standard Infant Formula
11590218|NCT00716105|Experimental|Test Product|Infant formula with different level of proteins
11590219|NCT00716105|No Intervention|Breast Milk|Breastfeeding reference group
11590220|NCT00716092|Placebo Comparator|Placebo|Patients received placebo matching 5mg linagliptin and placebo matching 100mg sitagliptin.
11590221|NCT00716092|Experimental|Linagliptin|Patients received 5mg linagliptin, and placebo matching 100mg sitagliptin.
11590222|NCT00716092|Active Comparator|Sitagliptin|Patients received 100mg sitagliptin, and placebo matching 5mg linagliptin.
11590223|NCT00716079|Other|Intensive BP lowering|Management policy to lower the systolic Blood pressure (BP) to a target of 140mmHg within 1 hour of randomization and sustained for 24 hours. Sites were provided with protocols for different intravenous agents and used whichever routinely available drugs were in their hospital.
11590224|NCT00716079|Other|Guideline recommended BP lowering|Patients received management of BP based on the standard guidelines at the time, as published by the American Heart Association (AHA) in 2007 and 2010. The attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, intravenous treatment may be started until the target systolic BP of 180 mmHg is achieved.
11590225|NCT00716066|Experimental|Treatment (immunosuppressive therapy followed by transplant)|Patients receive carmustine IV on day -6, etoposide IV and cytarabine IV BID on days -5 to -2, melphalan IV on day -1 and antithymocyte globulin IV on days -2 and -1. Patients then undergo autologous or syngeneic peripheral blood stem cell transplant on day 0. Patients also receive prednisone PO QD on days 7-21, followed by 2 week taper.
11590228|NCT00716040|Experimental|Intervention|The intervention group will be submitted to four social-psychological individual sessions with a pre-trained health professional.
11590229|NCT00716040|Other|Control|The control group will be submitted to the usual care of the health service.
11590230|NCT00716027|Active Comparator|1|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
11590231|NCT00716027|Experimental|2|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
11590232|NCT00716014|Active Comparator|Foot 1|An active drug injection of TD101 is injected into a callus on the bottom of one foot.
11590233|NCT00716014|Placebo Comparator|Foot 2|An injection of placebo (normal saline) is injected into a callus on the bottom of one foot.
11590234|NCT00716001|Active Comparator|NAC|
11590235|NCT00716001|Placebo Comparator|nonNAC|
11590236|NCT00715988|Experimental|Scheme 1|Patients who are feeding or not feeding and mechanically ventilated, >/=3 d of age and 29 0/7wks-48 6/7 wks PMA, treated with i.v. bolus doses or infusion of fentanyl, morphine or methadone for clinical indications, with arterial/venous line in place & expected treatment for at least 1-2 more days. Pk sampling = 0.5 ml blood samples x6/infant. ECG monitoring. Three patients will be enrolled in 5 PMA groups. Should apnea or hypotension occur, dosages for Treatment Scheme 2 will be reduced (50%); more patients will be studied in Treatment Scheme 1 to insure that the lower dose is well tolerated & effective.
11590237|NCT00715988|Experimental|Scheme 2|Patients defined in Scheme 1, tolerating feeds for >/= 3 days will be studied twice, after i.v. methadone and after enteral methadone after the end of sampling after the first dose. 4-5 samples will be obtained after dose 1 and after dose 2 depending on PMA and weight. Patients will be divided into groups based on PMA..
11590238|NCT00715975|Experimental|1|The patients will be treated with halobetasol once a day for 15 days.
11590239|NCT00715975|Experimental|2|The patients will be treated with clobetasol once a day for 15 days.
11590240|NCT00715962|Active Comparator|Mobility Group|The Walking Intervention includes assistance to walk twice daily with or without a rolling walker. In addition, a behavioral intervention that included goal setting and discussion of how to overcome mobility barriers was used to encourage the mobility group to be more active throughout hospital stay. Participants will keep a diary of out of bed activity and will be encouraged to set goals for additional out of bed activity daily.
11590241|NCT00715962|Placebo Comparator|Control Group|The control group will receive twice daily friendly visits to counter the attention being paid to the intervention group. They will complete a diary but of visitors to their room.
11590242|NCT00715949||Mild Traumatic Brain Injury (MTBI) admits|admitted pediatric patients with mild traumatic brain injury (concussion)
11590243|NCT00715936|Active Comparator|Control|Routine services for infants and young children delivered by the Lady Health Workers of the National Programme for Family Planning and Primary Healthcare (Basic Health and Nutrition Education and Services)
11590244|NCT00715936|Experimental|ECD Group|Stimulation and care for development (plus basic health and nutrition education and services)
11590245|NCT00715936|Experimental|Enhanced Nutrition|Care for Nutrition: Enhanced education messages and Sprinkles for children aged 6-24 months (plus basic health and nutrition education and services)
11590246|NCT00715936|Experimental|ECD and Enhanced Nutrition|Stimulation and care for development and care for nutrition (plus basic health and nutrition education and services)
11590247|NCT00715923|Experimental|1|Modified consent form
11590248|NCT00715923|Active Comparator|2|Standard consent form
11590249|NCT00715910|Experimental|Nimenrix 1 Group|Subjects 11-25 years of age who were previously vaccinated with 1 dose of Nimenrix vaccine at the time of vaccination
11590250|NCT00715910|Active Comparator|Menactra Group|Subjects 11-25 years of age who were previously vaccinated with 1 dose of Menactra vaccine at the time of vaccination
11590251|NCT00715910|Experimental|Nimenrix 2 Group|Subjects 10<11 years of age who were previously vaccinated with 1 dose of Nimenrix vaccine at the time of vaccination
11590252|NCT00715910|Experimental|Nimenrix Naive Group|Subjects 15 to <31 years of age at the time of primary vaccination with 1 dose of Nimenrix vaccine at year 5 of the current study
11590253|NCT00715910|Experimental|Nimenrix Pooled Group|Pooled group of subjects 10-25 years of age from Nimenrix 1 and Nimenrix 2 groups in the primary study (NCT00454909) who had received 1 dose of Nimenrix vaccine in that study and will receive a booster dose in this current study.
11590254|NCT00715910|Active Comparator|Menactra Booster Group|Subjects 11-25 years of age who had received 1 dose of Menactra vaccine in primary study (NCT00454909) and will receive 1 dose of Nimenrix vaccine in this current study.
11590255|NCT00715897|Experimental|Treatment- HBOT|HBOT treatment: 8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
11590256|NCT00715897|No Intervention|control-HBOT|Cross group: Patients in the cross group were evaluated three times-baseline, after 2 months control period of no treatment and after a consequent 2 month of HBOT
11590257|NCT00715884|Experimental|1|CYPHER® ELITE™ Sirolimus-Eluting Stent System.
11590258|NCT00715884|Active Comparator|2|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System
11590259|NCT00715871|Experimental|Active Smokers|Active smokers who used the Smoke-Break nicotine delivery device in an attempt to quit smoking cigarettes.
11590260|NCT00715858|Active Comparator|1 AD doxycycline + rifampin|Participants with AD allocated to doxycycline 100 mg bid od and rifampin 300 mg od for 12 months
11590261|NCT00715858|Active Comparator|2 AD doxycycline|
11590262|NCT00715858|Active Comparator|3 AD rifampin|Participants with AD allocated to rifampin 300 mg od od and placebo matched to doxycycline bid for 12 months
11590263|NCT00715858|Placebo Comparator|4 AD placebo|Participants with AD allocated to placebo matched to doxycycline and placebo matched to rifampin for 12 months
11590264|NCT00715858|No Intervention|5 Control|Age-matched cognitively healthy participants (untreated)
11590265|NCT00715845|Experimental|2|
11590266|NCT00715806|Experimental|1|
11590267|NCT00715806|Active Comparator|2|
11590271|NCT00715741|Active Comparator|2|Group 2 will receive 30% oxygen without PEEP for the duration of anesthesia and surgery
11590272|NCT00715741|Active Comparator|3|Group 3 will receive > 90% oxygen plus PEEP + 3 to 5 cm of water for the duration of anesthesia and surgery
11590273|NCT00715741|Active Comparator|4|Group 4 will receive > 90% oxygen and no PEEP for the duration of anesthesia and surgery
11590274|NCT00715728||1: Bair Hugger|Intraoperative warming with Bair Hugger forced air system
11590275|NCT00715728||2: Hot Dog|Intraoperative warming with Hot Dog resistive heating system
11590276|NCT00715715|No Intervention|1|"Patients that meet the requirements listed above will be selected sequentially. Blood tests, including liver function tests and hepatitis profiles will be taken. A liver biopsy will be done before the treatment to evaluate the severity of hepatitis.
~For randomly selected patients not treated with steroids: The patients will receive 6 weeks of sugar pills (placebo) before taking Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.
~All patients will get another liver biopsy at week 48 to evaluate the improvement of liver inflammation after their treatment. Blood tests will be drawn in accordance with the standard treatment. Generally speaking, hospitalization is not required for this study."
11590277|NCT00715715|Experimental|2|"Patients that meet the requirements listed above will be selected sequentially. Blood tests, including liver function tests and hepatitis profiles will be taken. A liver biopsy will be done before the treatment to evaluate the severity of hepatitis.
~For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.
~All patients will get another liver biopsy at week 48 to evaluate the improvement of liver inflammation after their treatment. Blood tests will be drawn in accordance with the standard treatment. Generally speaking, hospitalization is not required for this study."
11590278|NCT00715702|Experimental|1|Patients with Moderate renal impairment and matched volunteers
11590279|NCT00715702|Experimental|2|Patients with Mild or Severe renal impairment and matched volunteers. Type of patient group determined after safety review of 1st group data
11590280|NCT00715689|Experimental|A|
11590281|NCT00715689|Experimental|B|
11590282|NCT00715689|Experimental|C|
11590283|NCT00715689|Experimental|D|
11590284|NCT00715676|Placebo Comparator|Group 1|
11590285|NCT00715676|Experimental|Group 2|220 ng
11590286|NCT00715676|Experimental|Group 3|440 ng
11590287|NCT00715663||A|
11590288|NCT00715650|Experimental|Arm 1|This counseling consists of four sessions each approximately 60 minutes each. The four sessions are organized as follows: a) Orientation to Benefits Counseling: Your Benefits and Your Goals b) Work and Claims c) Financial Review: Implications of Your Work Plan and d) Your Plans After the Benefits Notice. The first session focuses on the disability application process as a non-confrontational way to explore attitudes towards work. The second session more directly addresses the claimant's attitudes about work and beliefs about whether work will prevent receipt of disability benefits. The third session addresses the same issue as the second, ambivalence about work and disability, from a financial perspective. The fourth session occurs after the disability determination has been made, and it is possible the veteran may feel differently about a benefit that has been awarded.
11590289|NCT00715650|Active Comparator|Arm 2|This will consist of four-session orientation with the sessions organized as follows: a) overview of VHA services, b) Primary Care c) Pharmacy and laboratory services and d) specialty services. After the description of each service, participants will be invited to discuss which services they plan to utilize. The counselor will provide telephone numbers and directions to the sites at which these services are provided.
11590290|NCT00715637|Experimental|Arm A|Amonafide in Combination with Cytarabine
11590291|NCT00715637|Active Comparator|Arm B|Daunorubicin in Combination with Cytarabine
11590292|NCT00715624|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
11590293|NCT00715624|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
11590294|NCT00715611|Experimental|1|This is a multicenter phase II toxicity study of pleurectomy/decortication (P/D) followed by adjuvant chemotherapy and Intensity Modulated Radiation Therapy (IMRT) to the pleura in patients with malignant pleural mesothelioma. Alternatively, chemotherapy may be administered in the neoadjuvant setting prior to P/D, followed by IMRT. Patients deemed resectable at the time of enrollment will undergo P/D with the goal of a macroscopic complete resection (MCR). Those with disease progression or severe toxicity will stop chemotherapy and undergo a PET scan.
11590295|NCT00715598||Neuropathic Pain|Subjects in this group experience chronic neuropathic pain.
11590296|NCT00715598||Musculoskeletal Pain|Subjects in this group experience chronic musculoskeletal pain.
11590297|NCT00715585|Active Comparator|Active Control|patients receive 3 individualized visits with a health educator for education on general diabetes and health promotion
11590298|NCT00715585|Experimental|Intervention 1|patients receive 3 individualized visits with an rd-cde for education focused on modified plate method
11590299|NCT00715585|Experimental|intervention 2|patients receive 3 individualized visits with an rd-cde for education focused on carb counting
11590300|NCT00715572|Active Comparator|A|
11590301|NCT00715572|Active Comparator|B|
11590302|NCT00715559|Experimental|cysteamine bitartrate|Participants received cysteamine bitartrate by mouth up to 300 mg three times daily.
11590303|NCT00715520|Experimental|Aim 1|Healthy adult female and male subjects will receive study drugs and TMS training to measure M1 excitability.
11590304|NCT00715520|Experimental|Aim 2|Healthy adult female and male subjects will receive repetitive TMS (rTMS) at different times or frequencies with respect to the training movement or sham stimulation.
11590305|NCT00715520|Experimental|Aim 3|Female and male subjects who have experienced a cerebral ischemic infarction, will receive study drugs and TMS to measure M1 excitability.
11590306|NCT00715507||1|For the phase of the study in which the utility of the graphical medication monitor is assessed, the monitor will not be shown to anesthesiologists placed in the control condition.
11590307|NCT00715507||2|In the experimental condition, anesthesiologists will be shown the medication monitor to aid their expertise and decision-making.
11590308|NCT00715494|No Intervention|Group 1 - Control|Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
11590309|NCT00715494|Experimental|Group 2 - Intervention|Participants in the experimental group will receive a focused set of interdisciplinary home-based interventions over a 12 week period.
11590310|NCT00715455|Active Comparator|Unfractionated Heparin|Unfractionated Heparin
11590311|NCT00715455|Experimental|REG1 Partial Rev.|REG1 with partial reversal
11590312|NCT00715455|Experimental|REG1 Total Rev.|REG1 with total reversal
11590313|NCT00715442|Experimental|Sunitinib + Nephrectomy|Sunitinib 50 mg by mouth daily for 28 consecutive days. Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
11590314|NCT00715429|Experimental|vitamin D 50,000 U/d x 10d, + vitamin D 50,000 U weekly 7 wks|Vitamin D arm
11590315|NCT00715429|Placebo Comparator|placebo x 10d, + placebo weekly 7 wks|placebo
11590316|NCT00715416|Experimental|1|primary nitinol stent placement of superficial femoral artery lesions
11590317|NCT00715416|Active Comparator|2|balloon angioplasty of superficial artery lesions with secondary stent placement in case of >30% residual stenosis after the procedure
11590318|NCT00715390||1-Children receiving anesthesia|The sample of patients screened will be the entire electronic anesthesia record database from 1998 until 2004 looking for subjects that have dysrhythmias.
11590319|NCT00715377|Experimental|1|
11590320|NCT00715364|Experimental|1|
11590321|NCT00715364|Placebo Comparator|2|
11590322|NCT00715351||A|
11590323|NCT00715351||B|
11590324|NCT00715325|Experimental|A|
11590325|NCT00715312|Experimental|A|
11590326|NCT00715299|Other|Locomotor Training Group|persons who have sustained a stroke within greater than 6 months ago and less than 5 years.
11590327|NCT00715286|Active Comparator|A|Conventional arm: primary surgery followed by chemotherapy
11590328|NCT00715286|Experimental|B|Neoadjuvant chemotherapy followed by interval debulking
11590329|NCT00715273|Active Comparator|1 - single therapy group|Participants will receive atorvastatin, placebo niacin, and placebo colesevelam. The treatment target for LDL-C will be ≤80 mg/dl for the single therapy group.
11590330|NCT00715273|Experimental|2 - double therapy group|Participants will receive atorvastatin, niacin, and placebo colesevelam. The treatment target for LDL-C will be ≤80 mg/dl for the double therapy group.
11590331|NCT00715273|Experimental|3 - triple therapy group|Participants will receive atorvastatin, niacin, and colesevelam. The treatment target for LDL-C will be ≤60 mg/dl for the triple therapy group
11590332|NCT00715260||UP Patients on HD|Uremic Pruritus (UP) patients maintained on hemodialysis (HD)
11590333|NCT00715247||Affected Population|Patients suspected to have one of the following blood disorders: polycythemia vera, myelofibrosis or essential thrombocythemia.
11590334|NCT00715247||Healthy Female Controls|Healthy females who do not have the blood disorders; Polycythemia Vera, Essential Thrombocythemia and/or Myelofibrosis.
11590335|NCT00715234|Experimental|Reminder/recall notices for vaccines|This group will receive up to 4 recall messages (both letters and computer-generated phone messages) reminding them to get their vaccines. There are 4 separate study groups: 1) private pediatric patients 2) public pediatric patients 3) school-based health center patients and 4) family medicine patients.
11590336|NCT00715234|No Intervention|Usual Care|This group will receive usual care. There are 4 separate study groups: 1) private pediatric patients 2) public pediatric patients 3) school-based health center patients and 4) family medicine patients.
11590337|NCT00715221||1|Normal Weight
11590338|NCT00715221||2|Obese without diabetes
11590339|NCT00715221||3|Obese with diabetes
11590340|NCT00715208|Experimental|VELCADE R-CAP|VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 Intravenous on Day 1, cyclophosphamide 750 mg/m2 intravenous on Day 1, doxorubicin 50 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.
11590341|NCT00715208|Experimental|VELCADE R-CP|VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 intravenous on Day 1, cyclophosphamide 1000 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.
11590342|NCT00715195|Experimental|1|Cognitive-behavioral therapy : 50 patients planned
11590343|NCT00715195|No Intervention|2|50 patients planned
11590344|NCT00715182|Experimental|TKI258|
11590345|NCT00715169|Active Comparator|1|
11590346|NCT00715169|Placebo Comparator|2|
11590347|NCT00715156||A|Subjects with mild (S1) reaction to peach fruit
11590348|NCT00715156||B|Subjects with severe reaction to peach fruit
11590349|NCT00715143|Other|N|This treatment arm includes ceramic-on-ceramic hip device
11590350|NCT00715117|Placebo Comparator|Sugar pill|Subjects will receive placebo for for the first 8 weeks administered orally one time daily. After 8 weeks placebo treated subjects are then crossed over to active drug naltrexone 0.1 mg/kg not to exceed 4.5 mg PO once daily for an additional 8 weeks.
11590351|NCT00715117|Experimental|Naltrexone|Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally either in capsules or liquid blinded for 8 weeks followed by open-labeled naltrexone for an additional 8 weeks. Safety and toxicity will be compared to placebo. Also change in Crohn's activity index scores of naltrexone to placebo are compared.
11590352|NCT00715104|Experimental|Sipuleucel-T with Booster|Subjects were to receive 3 infusions of sipuleucel-T 12 weeks prior to RP, and then an additional booster infusion 13 weeks following RP.
11590353|NCT00715104|Experimental|Sipuleucel-T without Booster|Subjects were to receive 3 infusions of sipuleucel-T 12 weeks prior to RP, with no further sipuleucel-T treatment.
11590354|NCT00715091|Experimental|1|continuous (daily) treatment with diclofenac cholestyramine 150 mg (Voltaren Resinate), divided into 75mg Voltaren twice daily
11590355|NCT00715091|Active Comparator|2|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg (Voltaren Resinate). The treatment strategy of the control intervention (on-demand) reflects current clinical practice in AS.
11590410|NCT00714688|Experimental|001|prolonged release (PR) OROS methylphenidate 54 mg 18+36mg once daily for 13 weeks
11590462|NCT00714311|Active Comparator|TFP|Transference-Focused Psychotherapy
11590356|NCT00715078|Active Comparator|Cohort A|Sipuleucel-T with the concentration of 10 μg/mL PA2024 in a cell suspension of 1 x 10^7 peripheral blood mononuclear cells (PBMCs) per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
11590357|NCT00715078|Active Comparator|Cohort B|Sipuleucel-T with the concentration of 5 μg/mL PA2024 in a cell suspension of 1 x 10^7 PBMCs per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
11590358|NCT00715078|Active Comparator|Cohort C|Sipuleucel-T with the concentration of 2 μg/mL PA2024 in a cell suspension of 1 x 10^7 PBMCs per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
11590359|NCT00715065||2|Healthy control subjects (who do not faint at the sight of blood)
11590360|NCT00715065||1|People who faint at sight of blood
11590361|NCT00715052|Experimental|1|40 consecutive one hour treatments at 1.5 ATA with 100% O2
11590362|NCT00715052|No Intervention|2|
11590363|NCT00715039|Active Comparator|lorazepam|
11590364|NCT00715039|Placebo Comparator|placebo|
11590365|NCT00715039|Active Comparator|paroxetine|
11590366|NCT00715026|Other|Trilogy AB Acetabular Hip Implant System|Post Approval Study of Device.
11590367|NCT00715000|Experimental|1|SRO
11590368|NCT00715000|Active Comparator|2|classical hydration via intravenous infusion
11590369|NCT00714987||1: High level PEEP|
11590370|NCT00714987||2: Low level PEEP|
11590371|NCT00714974|No Intervention|1|Standard of care
11590372|NCT00714974|Experimental|2|Sedation based on BIS value, oer treating physician discretion.
11590373|NCT00714961|Experimental|1|
11590374|NCT00714961|Placebo Comparator|2|
11590375|NCT00714948|Experimental|1|This is a phase II trial of gemcitabine and Split-dose cisplatin plus sorafenib.
11590376|NCT00714935|Experimental|3|Decision Counseling Program(DCP) combined with Coronary Artery Disease Decision Aid (CAD-DA) described in Arm 2
11590377|NCT00714935|No Intervention|1|
11590378|NCT00714935|Experimental|2|"Behavioral: Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke
~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
11590379|NCT00714922|Active Comparator|1|PRK
11590380|NCT00714922|Active Comparator|2|SBK
11590381|NCT00714909||1|
11590382|NCT00714896|Other|1|Assessment only + referral list to State quitline and smoking cessation education classes at Kaiser
11590383|NCT00714896|Experimental|2|Participants will receive self-help information handouts, expert system intervention that includes a stage-based manual and individualized written feedback reports plus in-person brief stage-appropriate counseling at baseline and 3-month assessment. Current smokers who indicate desire to quit smoking or former smokers who indicate high cravings for cigarettes will be offered nicotine replacement medications. Participants will receive three telephone counseling sessions delivered between baseline and 3 month at weeks 2, 4 and 8. As-needed telephone check-calls will be provided to participants on and 2 days after quit date, or to participants who have quit smoking and anticipate high risk situations.
11590384|NCT00714870|Other|1|intervention: this group will attend the nutrition and exercise program control group: this group will not attend the nutrition and exercise program
11590385|NCT00714857|Experimental|1|Patients receiving dexmedetomidine sedation
11590386|NCT00714831|Active Comparator|CG|Control Group
11590387|NCT00714831|Experimental|IG|Intervention Group
11590388|NCT00714818|Experimental|GC|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
11590389|NCT00714818|Active Comparator|EB|Educational Booklet: One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants
11590390|NCT00714818|No Intervention|WT|Waitlist
11590391|NCT00714805||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
11590392|NCT00714805||Healthy Control|Subjects having no known ailment.
11590393|NCT00714792||1|Subjects with urge incontinence due to overactive bladder
11590394|NCT00714792||2|women with no urge symptoms
11590395|NCT00714779|Active Comparator|1|Fluoxetine
11590396|NCT00714779|Active Comparator|2|Short-term psychodynamic psychotherapy
11590397|NCT00714766|Experimental|A|
11590398|NCT00714753|Experimental|Intervention Group|Protocol treatment consists of either two high dose-rate (HDR) brachytherapy implantation sessions or one HDR brachytherapy session followed by external beam radiotherapy (EBRT). Each HDR session consists of two 9.5Gy fractions. After the first HDR session of two fractions, patients express a preference for: (1) a second HDR brachytherapy implantation session, or (2) EBRT. The second HDR session or EBRT will begin 2-4 weeks after the first HDR brachytherapy session.
11590399|NCT00714727|Other|1|
11590400|NCT00714714|Experimental|Tretinoin and Adapalene gels|Adapalene facial gel and tretinoin facial gel applied daily for two weeks on opposite sides of the face (in a split-face model)
11590401|NCT00714701||High Risk Group 1|familial Peutz-Jeghers syndrome
11590402|NCT00714701||High Risk Group 2|familial pancreatic cancer relatives
11590403|NCT00714701||High Risk Group 3|germline mutation carriers BRCA1, BRCA2, PRSS, PALB2, p16
11590404|NCT00714701||High Risk Group 4|young-onset pancreatic cancer relative
11590405|NCT00714701||High Risk Group 5|both parents affected
11590406|NCT00714701||Control 1|negative controls
11590407|NCT00714701||Control 2|chronic pancreatitis
11590408|NCT00714701||Control 3|pancreatic cancer
11590409|NCT00714701||Control 4|intraductal papillary mucinous neoplasm (IPMN)
11590411|NCT00714688|Experimental|002|prolonged release (PR) OROS methylphenidate 72 mg 2x36mg once daily for 13 weeks
11590412|NCT00714688|Placebo Comparator|003|Placebo 2xplacebo once daily for 13 weeks
11590413|NCT00714675|Experimental|1|Citrulline
11590414|NCT00714675|Active Comparator|2|Amino acids
11590415|NCT00714649|Other|I-1|"This is a phase I/II trial. PhaseI: The delay between the last administration of cetuximab and surgery will be progressively reduced. Five delay schedules are pre-defined before final administration of 3 preoperative doses of cetuximab with a 24-hour delay between the last dose of cetuximab and surgery. The cohort size is 3 patients per delay schedule, extended to 6 patients if one limiting toxicity is observed.
~Phase II: will proceed if delay schedule V is safe. The patients included in delay schedule V of the Phase I part of the study will be involved in the phase II analysis. Recruitment of a total of 12 patients (3-6 of delay schedule V in phase I plus an additional 3-9 patients)."
11590416|NCT00714636||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
11590417|NCT00714636||Non-ALS|Subjects not having either definite or probable ALS by El Escorial Criteria.
11590418|NCT00714610||1|Unilateral or bilateral large head metal on metal primary total hip arthroplasty
11590419|NCT00714597|Experimental|Semuloparin|Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 10-14 days
11590420|NCT00714597|Active Comparator|Enoxaparin|Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 10-14 days
11590421|NCT00714571|Active Comparator|MST healthy older adults Stage 1|Mnemonic strategy training
11590422|NCT00714571|Active Comparator|MST MCI Stage 1|Exposure training
11590423|NCT00714571|Active Comparator|XP healthy older adults Stage 1|XP healthy older adults Stage 1
11590424|NCT00714571|Active Comparator|XP MCI Stage 1|XP MCI Stage 1
11590425|NCT00714571|Active Comparator|MST healthy older adults Stage 2|MST healthy older adults Stage 2
11590426|NCT00714571|Active Comparator|SCT healthy older adults Stage 2|SCT healthy older adults Stage 2
11590427|NCT00714545|No Intervention|prospective study|This study is a prospective study of patients treated at Scripps Clinic with intracoronary brachytherapy for recurrent restenosis within drug-eluting stents. Beta irradiation with a 40-mm strontium/yttrium-90 source. No placebo will be used in this trial.
11590428|NCT00714532|Active Comparator|1|Expert system only, which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months.
11590429|NCT00714532|Experimental|2|"The intervention consists of 3 components:
~Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months
~scheduled smoking intervention, which includes a tailored-made 3-week smoking reduction schedule and a stage-matched tip guide to explain why and how to use the smoking reduction intervention
~telephone check-in calls to provide brief counseling and technical support to motivate participants to use the intervention materials
~a 2-week supply of nicotine gum or lozenge per participants' choice to use during smoking reduction"
11590430|NCT00714519|Experimental|1|
11590431|NCT00714519|Placebo Comparator|2|
11590432|NCT00714506|Experimental|Intervention|lifestyle weight reduction - low fat eating, low calorie and physical activity
11590433|NCT00714506|Active Comparator|Control|physical activity plus successful aging health education
11590434|NCT00714493|Other|001|Infliximab3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
11590435|NCT00714480|Other|Group I|Administration of anti-thymocyte globulin post-operative days -6,-4,-2, and 0
11590436|NCT00714480|Other|Group II|Administration of anti-thymoglobulin post-operative days -2, 0, 2 and 4
11590437|NCT00714480|Other|Group III|Administration of anti-thymocyte globulin post-operative days 0, 2, 4 and 6
11590438|NCT00714467|Active Comparator|1|Expert system (stage-based manual and 3 individualized tailored feedback reports) only for smokers, paired-supporters (family or friend participant) do not receive any study intervention
11590439|NCT00714467|Experimental|2|Expert system (stage-based manual and 3 individualized tailored feedback report) to all the smoker participants; a family assisted intervention in a form of a self-help booklet that discusses specific strategies to work with smokers at each stage of change to the paired-supporters
11590440|NCT00714454|Active Comparator|APS|
11590441|NCT00714454|Placebo Comparator|Vehicle|
11590442|NCT00714441|Active Comparator|2|Computer Automated Self-Management (CASM). Please see description below for CASM.
11590443|NCT00714441|Active Comparator|3|Computer Automated Self-Management and Problem Solving Therapy (CAPS). Please see descriptions below for CAPS (also refer to CASM with is included in the CAPS program).
11590444|NCT00714441|Active Comparator|1|Lifestyle and Activities Education Program (LEAP-AHEAD). Please see description below for LEAP-AHEAD.
11590445|NCT00714428||Group 1: Item Development|Individuals with TBI to provide input to relevant questions for quality of life measure in TBI
11590446|NCT00714428||Group 2: Item Development|Clinicians who treat those with deployment related TBI to obtain their feedback on relevant questions pertaining to quality of life measures in TBI.
11590447|NCT00714428||Group 3: Instrument Development|Individuals with deployment TBI who will complete the Beta version of the TBI QOL measure.
11590448|NCT00714415||A|Patients with Hemophilia B
11590449|NCT00714402||a|children with proven of probable invasive bacterial infections
11590450|NCT00714376|Experimental|Docetaxel|Docetaxel (Taxotere) 75 mg/m² IV every 3 weeks for 8 cycles.
11590451|NCT00714363|Active Comparator|1|LASIK
11590452|NCT00714363|Active Comparator|2|SBK
11590453|NCT00714350||Simulator Group - With Display|ICU nurses who viewed the new ICU display visualization
11590454|NCT00714350||Simulator Group - Without Display|"ICU nurses who did not view the new ICU display visualization, but instead viewed a traditional spreadsheet style presentation of ICU trends of data"
11590455|NCT00714337|Experimental|1|fasting state
11590456|NCT00714337|Experimental|2|fasting state
11590457|NCT00714337|Experimental|3|non-fasting state
11590458|NCT00714337|Experimental|4|fasting state
11590459|NCT00714337|Experimental|5|non-fasting state
11590460|NCT00714324||1|Paper screening
11590461|NCT00714324||2|Electronic screening
11591073|NCT00710281|Other|2D/3D Phase contrast MR|
11590463|NCT00714311|Active Comparator|ECP|treatment by experienced community psychotherapists
11590464|NCT00714298|Other|1|Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. Treating physicians, biologist physician will be blinded to the results of the markers.
11590465|NCT00714285|Experimental|Quadrivalent influenza vaccine GSK 2115160A Group 1|Subjects in this group received 1 full dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
11590466|NCT00714285|Experimental|Quadrivalent influenza vaccine GSK 2115160A Group 2|Subjects in this group received 1 low dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
11590467|NCT00714285|Active Comparator|Trivalent influenza vaccine GSK 2115160A Group 1|Subjects in this group received 1 low dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
11590468|NCT00714285|Active Comparator|Trivalent influenza vaccine GSK 2115160A Group 2|Subjects in this group received 1 full dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
11590469|NCT00714272|Experimental|A|Granulocytapheresis treatment
11590470|NCT00714272|Placebo Comparator|B|Sham device treatment
11590471|NCT00714259|Other|Non Myeloablative Treatment|"Non-myeloablative Transplant Conditioning Chemotherapy :
~Fludarabine - 30 mg/m2/day x 3 days Total Body Irradiation - 200cGy x1 dose Infusion of Stem Cells - On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight."
11590472|NCT00714246|Experimental|Phase I - Dose Level 1|Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
11590473|NCT00714246|Experimental|Phase I - Dose Level 2A|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
11590474|NCT00714246|Experimental|Phase I - Dose Level 2B|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
11590475|NCT00714246|Experimental|Phase I - Dose Level 3|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
11590476|NCT00714246|Experimental|Phase I - Dose Level 4|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
11590477|NCT00714246|Experimental|Phase I - Dose Level 5|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.3 mg/m2 (Day 1,4,8,11)
11590478|NCT00714246|Experimental|Phase II|Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
11590479|NCT00714233|Experimental|1|Metformin
11590480|NCT00714233|Experimental|2|Oral Contraceptive Pills
11590481|NCT00714233|Active Comparator|3|lifestyle modification program
11590482|NCT00714233|Placebo Comparator|4|placebo to active metformin arm
11590483|NCT00714220||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
11590484|NCT00714220||Neurological Control|Subjects having been diagnosed with a non-ALS neurological condition
11590485|NCT00714220||Healthy Control|Subjects in good health without any neurological conditions
11590486|NCT00714207|Experimental|NOT Intervention|Students in this arm of the study were randomized to receive the reformatted NOT program
11590487|NCT00714207|Active Comparator|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets on smoking cessation
11590488|NCT00714207|Experimental|KB intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
11590489|NCT00714207|Active Comparator|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets on smoking cessation
11590490|NCT00714194|Other|1|Patients in the control group will receive continuous sedative infusions without daily interruption of sedatives based on the standard clinical practice of the TICU.
11590491|NCT00714194|Experimental|2|Patients in the intervention group will receive daily interruption of sedative.
11590492|NCT00714168|Active Comparator|1|Participants will take part in a standard behavioral weight loss program.
11590493|NCT00714168|Experimental|2|Participants will take part in a stepped-care weight loss program.
11590494|NCT00714155||1|Physical examination, questionnaires, retrospective chart review
11590495|NCT00714155||2|Questionnaires, retrospective chart review
11590496|NCT00714155||3|Retrospective chart review
11590497|NCT00714142|Active Comparator|1|Normal volunteers
11590498|NCT00714142|Active Comparator|2|Renal failure patients on dialysis
11590499|NCT00714142|Active Comparator|3|Renal artery stenosis patients
11590500|NCT00714129|Experimental|1|Weight loss diet - normal diet
11590501|NCT00714129|Experimental|2|Weight loss diet - low in simple sugars (specifically fructose)
11590502|NCT00714116|Experimental|SBI-087|
11590503|NCT00714103|Experimental|8-Chloro-Adenosine|Starting dose for first cohort of patients 45 mg/m2 intravenous over 1 hr daily for 5 days every 4 weeks (± 3 days).
11590504|NCT00714090|Active Comparator|A|Double active comparator : venlafaxine (150 mg/day) and rTMS (5 times/week)
11590505|NCT00714090|Experimental|B|active rTMS (5 times/week) and sham venlafaxine (150 mg/day)
11590506|NCT00714090|Sham Comparator|C|sham rTMS (5 times/week) and active venlafaxine (150 mg/day)
11590507|NCT00714077||adjuvant capecitabine|To compare different adjuvant concurrent chemoradiotherapy regimen (Oxaliplatin with capecitabine vs capecitabine) for patients with II/III rectal cancer
11590508|NCT00714077||adjuvant oxaliplatin and capecitabine|To compare different adjuvant concurrent chemoradiotherapy regimen (Oxaliplatin with capecitabine vs capecitabine) for patients with II/III rectal cancer
11590509|NCT00714064|Active Comparator|23vPPV in Pregnancy|
11590510|NCT00714064|Active Comparator|23vPPV at Birth|
11590511|NCT00714064|Other|Control|Control
11590599|NCT00713518|Experimental|Arm 4 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 3 mg of PF-04523655 given by intravitreal injection every 4 weeks from Week 4 to Week 12
11590512|NCT00714051|Experimental|Fall Prevention Training|The falls prevention training group participated in four weekly training sessions on a custom-built treadmill that produced trip-simulating perturbations (movements). While harnessed overhead to prevent actual falls, the treadmill stopped or moved suddenly. The goal for the participant was to try and prevent a fall. Each week, the level of difficulty of the task was increased.
11590513|NCT00714051|Active Comparator|Attention Control|The attention control group participated in four weekly treadmill walking sessions at a self-selected speed.
11590514|NCT00714038||1|Patients with asthma in primary care
11590515|NCT00714025|Experimental|I|40 patients with metastatic or locally advanced transitional bladder cancer with failed platinum-based chemotherapy receiving RAD001 10mg daily PO.
11590516|NCT00714012||1 Visualization users|End users of the domain specific visualizations.
11590517|NCT00713999|Experimental|STI/PZQ 1|Baseline and post-treatment follow-up (anti-STI and praziquantel Rx)
11590518|NCT00713986|Sham Comparator|Noanalgesia|Patients in this group wil receive 2 mL of water PO 2 minutes prior to vaccination, then they will rest in crib during cleansing of the right tigh, during injection of the right tigh for hepatitis B vaccination and 2 minutes after the injection. Infants will not receive any handling during the whole procedure outside the prespecified above.
11590519|NCT00713986|Experimental|Skin-to-skin|Patients in this group wil receive 2mL of water 2 minutes prior vaccination and will be put on skin-to-skin contact with their mothers at the same time. After this time cleansing of the right tigh will be done followed by intra-muscular injection for hepatitis B vaccination. Patients will stay on skin-to-skin contact with their mothers for the following 2 minutes after injection. Infants will not receive any additional sensorial stimulation during the whole procedure outside the prespecified above.
11590520|NCT00713986|Experimental|Glucose|Patients in this group wil receive 2mL of glucose 25% 2 minutes prior vaccination, then they will rest in crib during cleansing of the right tigh, during injection of the right tigh for hepatitis B vaccination and 2 minutes after the injection. Infants will not receive any handling during the whole procedure outside the prespecified above.
11590521|NCT00713986|Experimental|Skin&Glucose|Patients in this group wil receive 2mL of glucose 25% PO 2 minutes prior vaccination and will be put on skin-to-skin contact with their mothers at the same time. After this time cleansing of the right tigh will be done followed by intra-muscular injection for hepatitis B vaccination. Patients will stay on skin-to-skin contact with their mothers for the following 2 minutes after injection. Infants will not receive any additional sensorial stimulation during the whole procedure outside the prespecified above.
11590522|NCT00713973||1|Submitted to the American protocol for prophylaxis of deep vein thrombosis
11590523|NCT00713973||2|Submitted to the Brazilian protocol for prophylaxis of deep vein thrombosis
11590524|NCT00713973||3|Submitted to the SBCP modified protocol for prophylaxis of deep vein thrombosis
11590525|NCT00713960||1|Patients in secondary prevention of cardiovascular disease in primary care
11590526|NCT00713947|Active Comparator|A|Amoxicillin, Clarythromycin or metronidazole,Pantoprazole,Placebo
11590527|NCT00713947|Experimental|B|Pantoprazole
11590528|NCT00713947|Placebo Comparator|C|Placebo
11590529|NCT00713934|Experimental|1|
11590530|NCT00713934|Experimental|2|
11590531|NCT00713895|Active Comparator|Standard Self-Help|receive a standard self-help manual in Chinese and English of the participants' choice at baseline
11590532|NCT00713895|Experimental|Expert System|receive an expert system intervention that included the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
11590533|NCT00713882||Observational|
11590534|NCT00713869||1|Patients between the ages of 21 and 35 undergoing in-vitro fertilization will be included in this study.
11590535|NCT00713869||2|Recipients using only frozen donor eggs
11590536|NCT00713856|Active Comparator|1|
11590537|NCT00713856|Active Comparator|2|
11590538|NCT00713843|Experimental|1 Manual Therapy Utrecht|"Manual Therapy Utrecht (MTU) During the first consultation the manual therapist enquires about the complaints of the patient. The manual therapist conducts a number of measurements according to protocol. During treatment preferred movements are executed by the manual therapist in the patient's joints. The treatment techniques used by the manual therapist are very gentle mobilizations, without high velocity thrust techniques and are in general painless. In Manual Therapy Utrecht (MTU) it is common to give advices and recommend exercises.
~A treatment session lasts between 30 and 60 minutes (repeated after one or two weeks). The maximum number of sessions is six.
~The manual therapist has a minimum of five years of working experience."
11590539|NCT00713843|Active Comparator|2 Physical Therapy - Exercise Therapy|"The physical therapist conducts a complaint related function examination. Treatment consist of active exercises, manual traction or stretching and massage. The aims of active exercises are improvement of strength, mobility and movement coordination. Specific mobilization techniques are not a part of physiotherapeutic treatment. Treatment sessions take place no more than twice a week with a maximum of nine sessions (approximately 30 minutes) with a minimum of twenty minutes on active exercise therapy combined with instruction.
~To prevent overlap with MTU (experimental arm), physical therapists are selected who are not (also) trained as manual therapists or have started this education.
~The physical therapist has at least five years of working experience."
11590540|NCT00713830|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
11590541|NCT00713830|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
11590542|NCT00713817|Experimental|Sativex|
11590543|NCT00713817|Placebo Comparator|Placebo|
11590544|NCT00713804|Experimental|GC|Genetic counseling (GC): One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
11590779|NCT00712283|Active Comparator|A|healthy volunteers
11591074|NCT00710268|Experimental|1|Dose Escalation Study 50, 100, 200, 400 mg
11590545|NCT00713804|Active Comparator|EB|Educational Booklet (EB): One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
11590546|NCT00713804|No Intervention|WT|Waitlist (WT)
11590547|NCT00713791|Experimental|1|There are 5 variations of the ZD4054 (Zibotentan) 10mg tablet - A, B, C, D, and E. A minimum washout period of 1 week will occur between each treatment period.
11590548|NCT00713778|Experimental|1|Laparoscopic ovarian cystectomy using bipolar
11590549|NCT00713778|Experimental|2|Laparoscopic ovarian cystectomy using ultrasonic scalpel
11590550|NCT00713778|Active Comparator|3|Laparotomic ovarian cystectomy using suture
11590551|NCT00713765|Experimental|A|AZD3480 + Donepezil
11590552|NCT00713739|Experimental|1|Alfuzosin 10mg daily
11590553|NCT00713739|Active Comparator|2|Nifedipine XL 30mg daily
11590554|NCT00713739|Active Comparator|3|Doxazosin 4 mg daily
11590555|NCT00713739|Active Comparator|4|Prazosin 1 mg BID
11590556|NCT00713726|Active Comparator|F|Patients that received continued infusion of fentanyl at a steady dose for the first 48 hours and, then, doses were gradually decreases until stop
11590557|NCT00713726|Experimental|T|Patients that received continued infusion of tramadol at a steady dose for the first 48 hours and, then, doses were gradually decreases until stop
11590558|NCT00713713|Experimental|1|Two different tidal volumes (6 and 12 ml.kg-1 of ideal weight) are alternatively delivered to patients 30 minutes each one. The order of the two tidal volumes is randomized. Between the two study tidal volumes, patient returns for 30 minutes to the tidal volume used before the study recruitment.
11590559|NCT00713700|Experimental|Device|
11590560|NCT00713687|Experimental|1|Treatment by combination of photodynamic therapy and chemotherapy
11590561|NCT00713674|No Intervention|1|No Treatment
11590562|NCT00713674|Experimental|2|Theraworx intranasal
11590563|NCT00713674|Active Comparator|3|mupirocin antibiotic ointment intranasal
11590564|NCT00713661|Experimental|TachoSil®|
11590565|NCT00713648|Experimental|rFXIII|
11590566|NCT00713635||1|Fetuses and neonates with congenital heart disease consisting of hypoplastic left heart syndrome (HLHS)
11590567|NCT00713635||2|Fetuses and neonates with congenital heart disease consisting of transposition of the great arteries (TGA)
11590568|NCT00713635||3|Fetuses and neonates with congenital heart disease consisting of tetralogy of fallot
11590569|NCT00713635||4|Fetuses and neonates with lung masses but without congenital heart disease will serve as a control group
11590570|NCT00713622|Active Comparator|1|
11590571|NCT00713622|Active Comparator|2|
11590572|NCT00713609|Experimental|1|Benzoyl peroxide/clindamycin gel + tazarotene cream
11590573|NCT00713609|Active Comparator|2|Benzoyl peroxide/clindamycin gel + vehicle cream
11590574|NCT00713609|Active Comparator|3|Benzoyl peroxide gel + tazarotene cream
11590575|NCT00713609|Active Comparator|4|Clindamycin gel + tazarotene cream
11590576|NCT00713609|Active Comparator|5|Vehicle gel+ tazarotene cream
11590577|NCT00713609|Placebo Comparator|6|Vehicle gel + vehicle cream
11590578|NCT00713596|Sham Comparator|Control group|Septorhinoplasty with postoperative application of nasal taping and an external nasal cast. The tape and cast will be left in place for one week. No tissue glue will be used during the operation, although the nurse and surgical assistant will simulate the preparation and insertion of tissue glue using a syringe containing saline.
11590579|NCT00713596|Experimental|Fibrinogen, tape, and cast|Septorhinoplasty will be performed. At the termination of the procedure, prior to closure, fibrin sealant will be applied by the surgical assistant to the surgical site. Approximately 0.5 cc to 2 cc of tissue sealant will be applied. After closure, tape and cast will be applied and left in place for one week.
11590580|NCT00713596|Experimental|Fibrinogen and tape|Septorhinoplasty will be performed. At the termination of the procedure, prior to closure, 0.5 cc to 2 cc of tissue sealant will be applied. Nasal tape will be applied after closure.
11590581|NCT00713583|Experimental|Levodopa pharmacotherapy|Levodopa pharmacotherapy (800mg levodopa and 200mg carbidopa per day), cognitive behavioral therapy (CBT), and contingency management (CM).
11590582|NCT00713583|Placebo Comparator|Placebo|Placebo, cognitive behavioral therapy (CBT), and contingency management (CM).
11590583|NCT00713570||A,1,II|
11590584|NCT00713557||1|patients with acute ST-elevation myocardial infarction and receiving primary percutaneous coronary intervention Subgroup: Patient Transferring vs. Physician Transferring strategy
11590585|NCT00713557||2|patients with acute ST-elevation myocardial infarction treated by thrombolysis or facilitated PCI Subgroup: upstream use of Tirofiban + primary PCI vs. downstream use of tirofiban + primary PCI
11590586|NCT00713557||3|patients with non-ST-elevation ACS treated by immediate PCI
11590587|NCT00713557||4|patients with non ST-elevation ACS treated by elective PCI
11590588|NCT00713557||5|STEMI patient with multivessel disease, complete revascularization is planned to achieve during the index hospitalization.i.e.P-PCI for culprit lesion,combined with staged PCI for remaining diseased vessel.
11590589|NCT00713557||6|STEMI patient with multivessel disease, complete revascularization is planned to achieve at 6 weeks after STEMI onset.i.e.P-PCI for culprit lesion during index hospitalization,combined with staged PCI for remaining diseased vessel at 6-week's follow-up(secondary hospitalization).
11590590|NCT00713544|Active Comparator|1|
11590591|NCT00713544|Experimental|2|20mg
11590592|NCT00713544|Experimental|3|50mg
11590593|NCT00713544|Experimental|4|100mg
11590594|NCT00713544|Experimental|5|150mg
11590595|NCT00713544|Placebo Comparator|6|
11590596|NCT00713518|Active Comparator|Arm 1 ranibizumab|0.5 mg ranibizumab intravitreal injection given every 4 weeks from baseline to Week 12
11590597|NCT00713518|Experimental|Arm 2 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 3 mg PF-04523655 given by intravitreal injection every 2 weeks from Week 4 to Week 12
11590598|NCT00713518|Experimental|Arm 3 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 1 mg PF-04523655 given by intravitreal injection evey 4 weeks to Week 12
11591257|NCT00708825||1|surgical outcome, observation
11590600|NCT00713518|Experimental|Arm 5 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 1 mg of PF-04523655 (30 minutes later) given in combination every 4 weeks from baseline to Week 12
11590601|NCT00713505|Experimental|Arm I (parent intervention program and usual care)|Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care). Parents also receive 8 weekly face-to-face training sessions (75-90 minutes each) with a therapist over approximately 2-3 months. Phone support/assistance is provided by the therapist within 2-3 days following each training session and then every 2 weeks for up to 6 months after completion of the training sessions.
11590602|NCT00713505|Active Comparator|Arm II (wait-list/usual care control [UCC])|Child participants and their families undergo usual care as in arm I and are placed on a wait-list.
11590603|NCT00713492|Experimental|1|Alcohol
11590604|NCT00713479|Placebo Comparator|Sugar pill|Sugar pill (placebo) drug dosing will begin at 0.5 mg once daily for the first 3 days of condition and will be increased to 0.5 mg twice daily for days 5-6 of this condition, and increased to 1 mg twice daily on days 7-10 of this condition.
11590605|NCT00713479|Active Comparator|Varenicline|Varenicline dosing will begin at 0.5 mg once daily for the first 3 days of condition and will be increased to 0.5 mg twice daily for days 5-6 of this condition, and increased to 1 mg twice daily on days 7-10 of this condition.
11590606|NCT00713466||1|all third year medical students entering their pediatric clerkship at the Medical College of Wisconsin
11590607|NCT00713440|Experimental|1|10 healthy Caucasian subjects without family history of diabetes
11590608|NCT00713427|Other|WallFlex Stent|All patients meeting eligibility criteria recieve the WallFlex™ Biliary Partially-Covered Stent, which has regulatory clearance in the areas in which the study is being conducted.
11590609|NCT00713401|Experimental|Cohort A|Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol low dose infusion
11590610|NCT00713401|Experimental|Cohort B|Period 1: 150 mcg, i.v. bolus. Period 2: 150 mcg, i.v. bolus + esmolol low dose infusion
11590611|NCT00713401|Experimental|Cohort C|Period 1: 300 mcg, i.v. bolus. Period 2: 300 mcg, i.v. bolus + esmolol low dose infusion
11590612|NCT00713401|Experimental|Cohort D|Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol high dose infusion
11590613|NCT00713401|Experimental|Cohort E|Period 1: 150 or 300 mcg, i.v. bolus. Period 2: 150 or 300 mcg, i.v. bolus + esmolol high dose infusion
11590614|NCT00713362|Active Comparator|1|Surgery: Video-assisted thoracoscopic surgery
11590615|NCT00713362|Active Comparator|2|Chest tube drainage
11590616|NCT00713349|Other|1|Xenaderm Vehicle
11590617|NCT00713349|Placebo Comparator|2|Placebo Comparator
11590618|NCT00713336|Experimental|1|ZD4054 + Moxifloxacin placebo
11590619|NCT00713336|Active Comparator|2|ZD4054 placebo + Moxifloxacin
11590620|NCT00713336|Experimental|3|ZD4054 + ZD4054 placebo + Moxifloxacin placebo
11590621|NCT00713336|Placebo Comparator|4|ZD4054 Placebo + Moxifloxacin placebo
11590622|NCT00713323|Experimental|Sativex|Active treatment
11590623|NCT00713310|Experimental|Low-Dose|1.2 - 2.4 g/day Asacol dependent on body weight
11590624|NCT00713310|Experimental|High-Dose|2.0 - 4.8 g/day Asacol dependent on body weight
11590625|NCT00713297||Observation|Those who will use the new CPOE system
11590626|NCT00713284|Other|Study|All subjects who enroll in this study will be converted from their calcineurin inhibitor to sirolimus. There is no comparotor arm
11590627|NCT00713271|Experimental|1|Low dose
11590628|NCT00713271|Experimental|2|intermediate dose
11590629|NCT00713271|Experimental|3|high dose
11590630|NCT00713271|Placebo Comparator|4|
11590631|NCT00713258|Active Comparator|PTH (1-84)|PTH (1-84) + placebo alendronate
11590632|NCT00713258|Active Comparator|Alendronate|PTH (1-84) placebo + alendronate
11590633|NCT00713232||test construction|university student living in Taiwan for more than 5 years No known neurological, psychiatric or speech language disorders
11590634|NCT00713232||normative data|normal subjects 20-80 y/o Living in Taiwan for at least 5 years No know neurological, psychiatric and speech-language disorders
11590635|NCT00713219|Experimental|1|CHEMORADIATION
11590636|NCT00713206|Active Comparator|Dental implant (Osseotite)|Dental implants placed simultaneously with graft augmentation material.
11590637|NCT00713206|No Intervention|Control group|Dental implants placed into graft augmentation material that has four months to heal.
11590638|NCT00713193|Experimental|1|Patients in this arm will receive cyclosporine (Neoral) at a dose of 2-3 mg/kg orally as an adjunct to plasma exchange.
11590639|NCT00713193|Active Comparator|2|Patients in this arm will receive prednisone at a dose of 1 mg/kg as an adjunct to plasma exchange.
11590640|NCT00713180|No Intervention|1|Pterygium free participants
11590641|NCT00713180|Experimental|2|Pterygium participants
11590642|NCT00713167|Experimental|Grape Seed Extract|Enrolled patients who are randomly assigned to receive Grape Seed Extract capsules
11590643|NCT00713167|Placebo Comparator|Placebo|Placebo enrolled patients who are randomly assigned to receive placebo of Grape Seed Extract
11590644|NCT00713154|Placebo Comparator|1|Placebo group
11590645|NCT00713154|Active Comparator|2|Control Group
11590646|NCT00713141||1|Early breast cancer
11590647|NCT00713102||1|The group includes 10189 patients with on board medical or surgical emergencies.
11590648|NCT00713089||1|75 subjects randomised into the placebo arm of an ongoing randomised double-blind placebo controlled clinical trial at National University Hospital, Singapore
11590649|NCT00713089||2|The expecting mothers visiting at the well mother clinics at Gadjah Mada University Hospital were invited to participate in the study
11590650|NCT00713076|Experimental|1|Polyquaternium-preserved Multi-purpose solution
11590651|NCT00713063|Experimental|1|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
11590652|NCT00713063|Active Comparator|2|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
11590653|NCT00713050|Experimental|Experimental|Computer-based Aphasia therapy
11590654|NCT00713050|Active Comparator|Control|Control Arm - Healthy subjects.
11590655|NCT00713037|Experimental|(18F)-FMISO/CT|The study utilizes PET/CT scanning with (18F)-FMISO/CT in addition to standard used CT and MRI. Patients enrolled in this trial completed 2 PET/CT investigations, the first before proton radiation therapy and the second at a dose of approximately 30 Gy (24-36 Gy).
11590656|NCT00713024||1|Healthy control subjects
11590657|NCT00713024||2|Patients having neuropathic pain
11590658|NCT00713011|Experimental|Arm 1|
11590659|NCT00713011|Active Comparator|Arm 2|
11590660|NCT00712998||1|Twenty subjects receiving health check program without X-ray computed tomography examination will be included as the control group.
11590661|NCT00712998||2|Twenty subjects receiving health check program including X-ray computed tomography examination of lung will be included as the treatment group-1.
11590662|NCT00712998||3|Twenty subjects receiving health check program including X-ray computed tomography examination of heart will be included as the treatment group-2.
11590663|NCT00712985|Experimental|Zometa (Zoledronic Acid) X 1 dose|Zometa (Zoledronic Acid) 5 mg IV X 1 dose
11590664|NCT00712972||1|"Patients enrolled in this study are those whom present to our institution for elective knee arthroscopy. All patients scheduled to receive a knee arthroscopy scheduled through the office of Dr. Harold Battenfield will be asked to participate in the study on the day of their procedure as long as they do not fall into one of the exclusion criteria categories.
~Patients will not be allowed to participate in this study if they have an allergy to iodine or shell fish, if they have a knee effusion diagnosed clinically on the day of surgery, if the knee or surrounding tissues display cellulitis or other signs of infection, or if the patient has had a traumatic accident to their knee which significantly changes its anatomical relationships"
11590665|NCT00712959|Experimental|Group 1: Previous Tdap or Tdap-IPV Recipients|Participants received Tdap or Tdap-Inactivated Poliomyelitis Vaccine (IPV) in a previous study (TD9707 or TD9805)
11590666|NCT00712959|Active Comparator|Group 2: Tdap vaccine-naïve|Participants are age-balanced Tdap vaccine-naïve and will receive Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.
11590667|NCT00712959|No Intervention|Group 3|Past participants in Study TD9707 and TD9805 did not qualify for Tdap re-administration in this study or were unwilling to receive a second dose of Tdap. They were not included in the analysis for the study
11590668|NCT00712946||1|Arteriosclerosis obliterans patients undergoing elective vascular surgery
11590669|NCT00712946||2|Healthy age-matched volunteers
11590670|NCT00712933|Experimental|1|1 mg/kg dose of belimumab given IV every 28 days.
11590671|NCT00712933|Experimental|2.|10 mg/kg dose of belimumab given IV every 28 days.
11590672|NCT00712920|Placebo Comparator|1|Placebo
11590673|NCT00712920|Experimental|2|0.15% azelastine hydrochloride 1644 mcg/2 sprays per nostril 2 times a day for 4 weeks
11590674|NCT00712920|Experimental|3|0.1% azelastine hydrochloride 1096 mcg/2 sprays per nostril 2 times a day for 4 weeks
11590675|NCT00712907|Active Comparator|1|vitamin C (Mayrhofer)
11590676|NCT00712907|Placebo Comparator|2|Placebo
11590677|NCT00712894|Experimental|D|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of diltiazem via an infusion microcatheter distal to the angioplasty site was performed.
11590678|NCT00712894|Active Comparator|V|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of verapamil via an infusion microcatheter distal to the angioplasty site was performed.
11590679|NCT00712894|Active Comparator|N|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of nitroglycerin via an infusion microcatheter distal to the angioplasty site was performed.
11590680|NCT00712881|Experimental|(1) Investigational Product|
11590681|NCT00712881|Active Comparator|(2) Comparison Therapy|
11590682|NCT00712868|Experimental|1|Lactic Acid once a day during 21 days
11590683|NCT00712855|Experimental|A|mapatumumab and sorafenib
11590684|NCT00712842||1|Patients with non or mild non-proliferative diabetic retinopathy
11590685|NCT00712842||2|Healthy control subjects
11590686|NCT00712829|Experimental|1|123-I-MIP-1072 administration followed by 123-I-MIP-1095 administration two weeks later.
11590687|NCT00712829|Experimental|2|123-I-MIP-1095 administration followed by 123-I-MIP-1072 administration two weeks later.
11590688|NCT00712816|Experimental|A|
11590689|NCT00712816|Active Comparator|B|
11590690|NCT00712803|Experimental|1|One subcutaneous vaccination (10^3 dose of vaccine) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm.
11590691|NCT00712803|Experimental|2|One subcutaneous vaccination (10^5 dose of vaccine or placebo) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm OR one subcutaneous vaccination (10^1 dose of vaccine or placebo) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm.
11590692|NCT00712790|Experimental|Sequential Radioembolization-Sorafenib|Sorafenib (400 mg twice-daily) was initiated 14 days post-radioembolization with yttrium-90 (Y) resin microspheres given as a single procedure.
11590693|NCT00712777|Active Comparator|1|homozygote mutant: Insertion/Insertion (40 patients)
11590694|NCT00712777|Active Comparator|2|homozygote mutant: Deletion/Deletion (40 patients)
11590695|NCT00712764|Active Comparator|1|
11590696|NCT00712764|Placebo Comparator|2|
11590697|NCT00712751||1|usual care (UC) which is the standard care that patients receive
11590698|NCT00712751||2|Cancer Survivorship Intervention-Sexual Health (CSI-SH)plus Usual Care (US)
11590699|NCT00712725|Experimental|1|MK3207- 2.5 mg
11590700|NCT00712725|Experimental|2|MK3207- 5 mg
11590701|NCT00712725|Experimental|3|MK3207- 10 mg
11590702|NCT00712725|Experimental|4|MK3207- 20 mg
11590703|NCT00712725|Experimental|5|MK3207- 50 mg
11590704|NCT00712725|Experimental|6|MK3207- 100 mg
11590705|NCT00712725|Placebo Comparator|7|Placebo
11590780|NCT00712270|No Intervention|Standard of Care|Screening and Baseline Procedures followed by Referral to Community Care. Baseline Procedures may be repeated at a later time if appropriate.
11590781|NCT00712270|Active Comparator|Drug: Aripiprazole|Screening and Baseline Procedures followed by 16 weeks of treatment with aripiprazole, followed by repeat of baseline procedures and referral to community care.
11591075|NCT00710255||Asthmatics|Asthmatics with exercise induced bronchospasm
11590706|NCT00712699|Experimental|Sequence 1: XR-MAS then placebo|Depending on whether 1) child has had previous medication trial or 2) is on psychotropic medication at time of screening, children will either enter the washout period of 3 days before extended release mixed amphetamine salts (XR-MAS) or placebo (PBO) is initiated or proceed directly to the active treatment sequence they were randomized to. Participants randomized to Sequence 1 first receive treatment with XR-MAR for 3 weeks and then placebo for 3 weeks. Flexible, forced dosing will start at 5 mg/day for the first week, increase to 10 mg/day for the second week and continue to 15 mg/day on the third week. No washout period otherwise occurs (XR-MAS is not clinically suspected to have lingering effects beyond initial dosing/day of administration), including the crossover week to PBO.
11590707|NCT00712699|Experimental|Sequence 2 Placebo then XR-MAS|Depending on whether 1) child has had previous medication trial or 2) is on psychotropic medication at time of screening, children will either enter the washout period of 3 days before extended release mixed amphetamine salts (XR-MAS) or placebo (PBO) is initiated or proceed directly to the active treatment sequence they were randomized to. Participants randomized to Sequence 2 will first receive treatment with PBO for 3 weeks and then XR-MAS for 3 weeks. Flexible, forced dosing will start at 5 mg/day for the first week, increase to 10 mg/day for the second week and continue to 15 mg/day on the third week. No washout period (stimulants are not clinically suspected to have lingering effects beyond initial dosing/day of administration)otherwise occurs, including the crossover week to XR-MAS.
11590708|NCT00712686|Active Comparator|A1|
11590709|NCT00712686|Active Comparator|B1|
11590710|NCT00712673|Experimental|Lixisenatide (Morning Injection)|2-step initiation morning regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
11590711|NCT00712673|Experimental|Lixisenatide (Evening Injection)|2-step initiation evening regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
11590712|NCT00712673|Placebo Comparator|Placebo (Morning Injection)|2-step initiation morning regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
11590713|NCT00712673|Placebo Comparator|Placebo (Evening Injection)|2-step initiation evening regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
11590714|NCT00712660|Experimental|A|In the active-ITAREPS group, the e-mail ALERT message feedback to the investigator will be activated. The core study intervention was 20% antipsychotic dose increase within 24 hours in response to a Pharmacological Intervention Requiring Event (PIRE) defined as either: A) the receipt of any INITIAL ALERT (IA) e-mail. A dose increase was obligatory in such cases regardless of the current clinical status of the patient; or B) the receipt of an ALERT EMERGENCY (AE) e-mail after which the investigator confirmed clinical worsening via phone contact with the patient. AE is defined as further worsening in EWSQ scores during 3 week period after announcement of IA.
11590715|NCT00712660|Placebo Comparator|TAU|In the treatment-as-usual study arm (control, non-active ITAREPS), the e-mail ALERT message feedback will not be activated. In this group, even in the presence of early warning sings, the investigators will be kept blinded to the EWSQ scores, will receive no ALERT message and thus no early pharmacologic intervention based on the ITAREPS program will be prompted. Treatment in the control group will consist of routine clinical and medication management with the frequency of visits common in the outpatient clinical settings. There will be no intevention based on ITAREPS.
11590716|NCT00712647|Active Comparator|1|Asbestos-exposed participants and heavy smokers
11590717|NCT00712647|Placebo Comparator|2|Asbestos-exposed participants and heavy smokers
11590718|NCT00712634|Experimental|CMV-seropositive participants|Participants are randomized to receive 1 of 4 escalating doses of CMVpp65-A*0201 peptide vaccine containing either helper T-lymphocyte (HTL) PADRE peptide or HTL tetanus toxoid peptide. Within each vaccine dose group, two participants are randomized to receive a placebo. Participants receive the vaccine or a placebo subcutaneously (SC) on days 0 and 28 in the absence of unacceptable toxicity.
11590719|NCT00712634|Experimental|CMV-seronegative participants|Participants are randomized to receive 1 of 4 established doses (established in CMV-seropositive participants) of CMVpp65-A*0201 peptide vaccine containing either HTL PADRE peptide or HTL tetanus toxoid peptide. Participants receive the vaccine on days 0, 28, and 56 in the absence of unacceptable toxicity. Participants with a partial or low-level immune response receive one additional booster vaccine on day 90.
11590720|NCT00712621|Other|I|"OUTLINE: This is a randomized, multicenter study. Patients are selected according to age ( 25 to 49 vs 50 to 85), time since initial completion of therapy (3 to 18 months), and are separated in two groups.
~Arm I: Quality of life is assessed at baseline and at 3 and 6 months."
11590721|NCT00712621|Other|II|"OUTLINE: This is a randomized, multicenter study. Patients are selected according to age ( 25 to 49 vs 50 to 85), time since initial completion of therapy (3 to 18 months), and are separated in two groups.
~Arm II: Quality of life is assessed at baseline and at 3 and 6 months."
11590722|NCT00712608|Active Comparator|1|Marketed cow's milk-based formula
11590723|NCT00712608|Experimental|2|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
11590724|NCT00712608|Experimental|3|Cow's milk based formula with prebiotic, different level of fatty acids and fat and a different calcium source
11590725|NCT00712595|Experimental|1|Mifepristone 10 mg daily for three months
11590726|NCT00712595|Experimental|2|Mifepristone 5 mg daily for three months
11590727|NCT00712582|Experimental|Consolidation A|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.
~Patients whose disease is FDG-PET negative or patients whose FDG-PET scan is positive but repeat biopsy is negative and whose initial Ki-67 expression is < 80% will receive 3 cycles of standard dose ICE Chemotherapy."
11590728|NCT00712582|Experimental|Consolidation B|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.
~Patients whose disease is FDG-PET negative or patients whose FDG-PET scan is positive but repeat biopsy is negative and whose initial Ki-67 expression is ≥80% will receive 2 cycles of augmented RICE Chemotherapy (as per MSKCC protocol 03-075)."
11590782|NCT00712270|Active Comparator|Risperidone|Screening and Baseline Procedures followed by 16 weeks of treatment with Risperidone,followed by repeat of baseline procedures and referral to community care.
11591076|NCT00710242|Experimental|1|DF01
11590729|NCT00712582|Experimental|Consolidation C|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.
~Consolidation C: Patients with biopsy proven disease after induction therapy. Patients whose bone marrow remain positive at interim restaging will have the option of getting an allogeneic[m3] stem cell transplant, in lieu of an ASCT, if they have an acceptable HLA match donor. The allogeneic[m4] stem cell transplant regimen will be decided by the MSK Bone Marrow Transplant Service."
11590730|NCT00712569||1|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information.
11590731|NCT00712569||2|Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information.
11590732|NCT00712569||3|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it.
11590733|NCT00712556||Flourine 18-fluorodeoxyglucose PET|PET using fluorine 18-fluorodeoxyglucose to image cancer tumors
11590734|NCT00712543|Experimental|1|Kristalose®, as prescribed, for 7 days.
11590735|NCT00712543|Experimental|2|Liquid lactulose, as prescribed, for 7 days.
11590736|NCT00712530|Experimental|1|"Single low-dose DermaVir immunization
~0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir
~Administered topically with DermaPrep under two skin patches (0.4 mL/patch)"
11590737|NCT00712530|Experimental|2|"Single medium-dose DermaVir immunization
~0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir
~Administered topically with DermaPrep under four skin patches (0.8 mL/patch)"
11590738|NCT00712530|Experimental|3|"Single high-dose DermaVir immunization
~0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir
~Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)"
11590739|NCT00712517|Active Comparator|1|Patients will receive propofol anesthesia during varicose vein stripping surgery.
11590740|NCT00712517|Active Comparator|2|Patients will receive sevoflurane anesthesia during varicose vein stripping surgery.
11590741|NCT00712504|Experimental|1|SU011248 in combination with docetaxel
11590742|NCT00712491|Experimental|1|
11590743|NCT00712491|Experimental|2|
11590744|NCT00712478||A|
11590745|NCT00712465|Experimental|1|AZD1305 tablet
11590746|NCT00712465|Experimental|2|AZD1305 tablet + digoxin
11590747|NCT00712465|Active Comparator|3|Digoxin
11590748|NCT00712452|Other|1|systemic lupus erythematosus
11590749|NCT00712452|Other|2|breast cancer
11590750|NCT00712452|Other|3|Hodgkin disease
11590751|NCT00712439|Experimental|1|
11590752|NCT00712439|Placebo Comparator|2|
11590753|NCT00712426|Active Comparator|A|Randomized to receive creatine monohydrate (up to 40 grams daily)
11590754|NCT00712426|Placebo Comparator|B|Randomized to receive placebo (up to 40 grams daily)
11590755|NCT00712400|Active Comparator|1|Latanoprost 0.005%, Xalatan®
11590756|NCT00712400|Placebo Comparator|2|Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug)
11590757|NCT00712387|No Intervention|A|General surgical trainees who will receive the 'traditional' training programme; i.e. will receive whatever clinical training on a patient their supervising consultant deems appropriate. This is the way junior surgeons are currently trained. They will also receive the standard didactic teaching on the School for Surgeons e-learning resource.
11590758|NCT00712387|Active Comparator|B|Surgical trainees who are assigned to the 'proficiency-based progression' training programme. These trainees will be required to train on the virtual reality simulator (Lap Sim™) for a laparoscopic cholecystectomy. Trainees will have objectively set goals to reach on the simulator and will have to demonstrate proficiency before they are permitted to progress to the next, more challenging level. Group B will also receive the standard School for Surgeons instruction but, unlike Group A, they will have to demonstrate proficiency on the didactic module before they progress to the operating theatre
11590759|NCT00712374|Experimental|Intervention|Children 3 months to 10 years old will receive a treatment dose of SP+AQ on three occasions during the malaria transmission season, delivered by the local health post
11590760|NCT00712361|Experimental|Group A|The group A incorporates three subgroups of individuals at various ages. A.1 Age: 16 - 30 A.2 Age: 31 - 60 A.3 Age > 60 All subgroups will be randomly distributed according to the following factors: BMI, gender, race and hematocrit.
11590761|NCT00712348|Experimental|Taliglucerase alfa|Open label taliglucerase alfa treatment
11590762|NCT00712335|Experimental|1|"Asthmatic smokers treated with combination therapy:
~Fluticasone propionate dosage - DPI 250 mcg BID for 3 months Salmeterol dosage - DPI 50 mcg BID for 3 months"
11590763|NCT00712335|Experimental|2|"Asthmatic smoker treated with Montelukast only:
~Montelukast dosage: PO 10 mg QHS for 3 months"
11590764|NCT00712335|Active Comparator|3|"Non-smoking asthmatics treated with combination therapy:
~Fluticasone propionate dosage - DPI 250 mcg BID for 3 months Salmeterol dosage - DPI 50 mcg BID for 3 months"
11590765|NCT00712335|Active Comparator|4|"Non-smoking asthmatic treated with Montelukast only:
~Montelukast dosage: PO 10 mg QHS for 3 months"
11590766|NCT00712335|No Intervention|5|Normal controls
11590767|NCT00712322|Experimental|Cohort 1|Estimated pediatric study doses of darifenacin liquid oral suspension: (0.030 mg/kg/day).
11590768|NCT00712322|Experimental|Cohort 2|Estimated pediatric study doses of darifenacin liquid oral suspension: (0.0625 mg/kg/day).
11590769|NCT00712322|Experimental|Cohort 3|Estimated pediatric study doses of darifenacin liquid oral suspension: (0.125 mg/kg/day).
11590770|NCT00712322|Experimental|Cohort 4|Estimated pediatric study doses of darifenacin liquid oral suspension: (0.250 mg/kg/day).
11590771|NCT00712309|Active Comparator|1|Percutaneous transluminal angioplasty (PTA)
11590772|NCT00712309|Active Comparator|2|Primary stenting
11590773|NCT00712296|Experimental|ASHMI 4|ASHMI 4 capsules twice a day
11590774|NCT00712296|Experimental|ASHMI 12|ASHMI 12 capsules twice a day
11590775|NCT00712296|Placebo Comparator|Placebo|Placebo 6 capsules twice a day
11590776|NCT00712283|Placebo Comparator|D|healthy volunteers
11590777|NCT00712283|Active Comparator|C|healthy volunteers
11590778|NCT00712283|Active Comparator|B|healthy volunteers
11590783|NCT00712257|Other|Spectranetics Laser plus Gore Viabahn Endoprosthesis|Spectranetics Laser for optimal debulking followed by adjunctive PTA plus GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface placement
11590784|NCT00712244|Active Comparator|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device during cataract surgery.
11590785|NCT00712244|Active Comparator|DuoVisc|Use of DuoVisc Viscoelastic System (Viscoat, Provisc) during cataract surgery.
11590786|NCT00712244|Active Comparator|Healon5|Use of Healon5 ophthalmic viscosurgical device (OVD) during cataract surgery.
11590787|NCT00712244|Active Comparator|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device during cataract surgery.
11590788|NCT00712231||phakic eyes|the cases did not accept any intraocular surgery
11590789|NCT00712231||pseudophakic eyes|tht cases did not accept any intraocular surgery expect for cataract surgery
11590790|NCT00712218|Active Comparator|A|
11590791|NCT00712218|Experimental|B|
11590792|NCT00712205|Placebo Comparator|A|20 Patients with asthma in a crossover design
11590793|NCT00712205|Active Comparator|B|20 Patients with asthma in a crossover design
11590794|NCT00712179||Stroke Survivors|Subjects walked with or with therapists' assistance at different speeds and different amounts of body weight support across conditions.
11590795|NCT00712166|Placebo Comparator|Placebo three times daily (TID)|
11590796|NCT00712166|Experimental|AZLI 75 mg three times daily (TID)|
11590797|NCT00712140|Active Comparator|Arm I|Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity. All patients also receive standard chemotherapy regimens as per local institutional protocols either concurrently with or sequentially to trastuzumab.
11590798|NCT00712140|Experimental|Arm II|Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. All patients also receive standard chemotherapy regimens as per local institutional protocols either concurrently with or sequentially to trastuzumab.
11590799|NCT00712127|Experimental|Diet and Exercise|Diet and Exercise for Class II and Class III Obesity
11590800|NCT00712127|Experimental|Diet and Exercise-Delayed|Diet and Exercise-Delayed for 6 months for Class II and Class III Obesity
11590801|NCT00712127|No Intervention|Control|Normal weight, overweight and Class I obesity
11590802|NCT00712114|Experimental|Cohort 1|10 mg HE3286 (1 x 5 mg HE3286, BID)
11590803|NCT00712114|Experimental|Cohort 2|20 mg HE3286 (2 x 5 mg HE3286 BID)
11590804|NCT00712114|Experimental|Cohort 3|40 mg HE3286 (4 x 5 mg HE3286 BID)
11590805|NCT00712101|Experimental|1|Abciximab bolus administration intracoronary
11590806|NCT00712101|Active Comparator|2|Abciximab bolus intravenously
11590807|NCT00712088|Experimental|1: Group Intervention|Group level intervention
11590808|NCT00712088|Active Comparator|2: HCT|Offer of HIV counseling and testing
11590809|NCT00712075|Experimental|CBSST+PDA|PDA-Assisted Cognitive-Behavioral Social Skills Training (CBSST+PDA): The CBSST rehabilitation intervention will be combined with the use of a PDA to facilitate homework completion and progress towards recovery goal attainment in consumers.
11590810|NCT00712075|Active Comparator|CBSST|Cognitive Behavioral Social Skills Training (CBSST): CBSST is a psychosocial rehabilitation intervention that combines skills from cognitive behavioral therapy and social skills training to assist consumers in improving functioning and recovery goal attainment.
11590811|NCT00712075|Active Comparator|PDA-Only|PDA-only: To control of device contact, the PDA-only arm will not receive CBSST and will only carry a PDA with access to the basic features of the device.
11590812|NCT00712062|Experimental|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
11590813|NCT00712049|Active Comparator|1|Nicotinic acid + Simvastatin
11590814|NCT00712049|Active Comparator|2|Simvastatin
11590815|NCT00712036|Active Comparator|Interim|Methadone maintenance for up to 4 months with emergency counseling only for individuals on program waiting lists.
11590816|NCT00712036|Active Comparator|Comprehensive|Methadone Treatment provided with counseling as usual.
11590817|NCT00712036|Active Comparator|Restored|Methadone Treatment with counseling provided by a clinician with a lower caseload than counseling as usual.
11590818|NCT00712023|Active Comparator|1|warming by circulating-water mattress
11590819|NCT00712023|No Intervention|2|Forced-air warming mattress
11590820|NCT00712010|Experimental|Whey protein native|Whey protein native versus the 6 other arms
11590821|NCT00712010|Experimental|Whey protein microgels|Whey protein microgels versus the 6 other arms
11590822|NCT00712010|Experimental|Hydrolyzed whey protein|Hydrolyzed whey protein versus the 6 other arms
11590823|NCT00712010|Experimental|Casein native|Casein native versus the 6 other arms
11590824|NCT00712010|Experimental|Hydrolyzed casein|Hydrolyzed casein versus the 6 other arms
11590825|NCT00712010|Experimental|Total milk protein native|Total milk protein native versus the 6 other arms
11590826|NCT00712010|Experimental|Hydrolyzed milk protein|Hydrolyzed milk protein versus the 6 other arms
11590827|NCT00711997|Experimental|BC-819|Intratumoral administration of BC-819
11590828|NCT00711984|Active Comparator|1|Renal artery stenting and Best medical treatment
11590829|NCT00711984|Active Comparator|2|Best medical treatment alone
11590830|NCT00711971|Active Comparator|EPA-rich fish oil supplement|EPA-rich fish oil supplement
11590831|NCT00711971|Active Comparator|DHA-rich fish oil supplement|DHA-rich fish oil supplement
11590832|NCT00711971|Placebo Comparator|Soy Oil placebo|Soy oil
11590833|NCT00711958|Experimental|HX575 epoetin alfa Hexal AG|HX575 (erythropoietin alfa of the Sponsor Hexal AG). Eligible patients to be randomized in ratio 2:1 and to be subcutaneously treated (solution for injection (s.c.)) for 12 weeks with HX575 in pre-filled syringes. The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range. Application of the drug required at least once per week and allowed maximum three times per week.
11590921|NCT00711295|Experimental|Cohort 3, Treatment Arm 1|300 chronically ill patients 18 years or older will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.
11590834|NCT00711958|Active Comparator|ERYPO® Janssen-Cilag|ERYPO® Janssen-Cilag, Germany. Eligible patients were treated subcutaneously (solution for injection (s.c.)) with ERYPO® (Janssen-Cilag, Germany) in pre-filled syringes for 12 weeks.The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range. Application of the drug required at least once per week and allowed maximum three times per week.
11590835|NCT00711919|Active Comparator|1|Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months. After administration, serum LDL-cholesterol should be kept between 100 and 80 mg/dL by controlling the dose of Pitavastatin or adding other anti-hyperlipidemia agents other than statins.
11590836|NCT00711919|Active Comparator|2|Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months. After administration, serum LDL-cholesterol should be kept under 80 mg/dL by controlling the dose of Pitavastatin or adding other anti-hyperlipidemia agents other than statins.
11590837|NCT00711906|Experimental|1|HIV-negative women taking CTX as chemoprophylaxis
11590838|NCT00711906|Active Comparator|2|HIV-negative women taking SP as IPT
11590839|NCT00711906|Experimental|3|HIV-positive women (CD4> 200) taking CTX as chemoprophylaxis
11590840|NCT00711906|Active Comparator|4|HIV-positive women (CD4 > 200) taking SP as IPT
11590841|NCT00711893||ICD and CRT-D|Patients indicated for an implantable defibrillator or cardiac resynchronization defibrillator
11590842|NCT00711880|Experimental|Sativex|
11590843|NCT00711880|Placebo Comparator|Placebo|
11590844|NCT00711867|Experimental|VH2|Dynatherm vitalHeat2 (VH2) temperature management system.
11590845|NCT00711867|Active Comparator|Bair Hugger|Arizant Bair Hugger temperature management system.
11590846|NCT00711854|Experimental|1|trimethoprim-sulfamethoxazole (TMP-SMX) plus rifampicin
11590847|NCT00711854|Active Comparator|2|Linezolid
11590848|NCT00711841|Placebo Comparator|saline solution|Placebo (saline solution), 2 mL, intravenous, every 12 hours, for 48 hours
11590849|NCT00711841|Active Comparator|Dexamethasone|Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
11590850|NCT00711828|Experimental|Treatment (R-CYBOR-D)|Patients receive rituximab IV on day 1and cyclophosphamide PO, bortezomib IV, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11590851|NCT00711815||UA|HPV positive
11590852|NCT00711802|Experimental|Daptomycin|"Administered intravenously (IV) every 24 hours for up to 14 days at the following age-dependent dosages.
~Participants ages 7 to 17 years: daptomycin was dissolved in a volume of 50 milliliters (mL) 0.9% sodium chloride for injection over 30 minutes (min) with an infusion rate of 1.67 mL/min.
~Participants 1 to 6 years-old: daptomycin was dissolved in a volume of 25 mL 0.9% sodium chloride for injection over 60 min with an infusion rate was 0.42 mL/min.
~Age Group 1 (for ages 12 to 17 years): 5 milligrams/kilogram (mg/kg)
~Age Group 2 (for ages 7 to 11 years): 7 mg/kg
~Age Group 3 (for ages 2 to 6 years): 9 mg/kg
~Age Group 4 (for ages 1 to <2 years): 10 mg/kg"
11590853|NCT00711802|Active Comparator|Standard of Care (SOC)|The comparator agent for this study was the SOC treatment and dosage deemed appropriate by the Investigator. The recommended SOC agents were IV vancomycin, IV clindamycin, and IV semisynthetic penicillins every 24 hours for up to 14 days.
11590854|NCT00711789|Active Comparator|Angiotensin II|
11590855|NCT00711789|Placebo Comparator|Placebo|
11590856|NCT00711776|Experimental|Subjects receiving new formulation in blank test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
11590857|NCT00711776|Active Comparator|Subjects receiving current formulation in blank test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
11590858|NCT00711776|Experimental|Subjects receiving new formulation in pre-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
11590859|NCT00711776|Active Comparator|Subjects receiving current formulation in pre-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
11590860|NCT00711776|Experimental|Subjects receiving new formulation in main-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
11590861|NCT00711776|Active Comparator|Subjects receiving current formulation in main-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
11590862|NCT00711724||MGH 1|Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
11590863|NCT00711711|Experimental|Manual lymphatic drainage|this arm will receive 5 manual lymphatic drainage treatments from day 2 to day 7 post surgery
11590864|NCT00711711|Placebo Comparator|Relaxation|This arm will receive 5 relaxation treatments from day 2 to day 7 post surgery
11590865|NCT00711698|Active Comparator|1|In this arm patients will be randomized to receive a bolus of narcotic followed by PCA.
11590866|NCT00711698|Active Comparator|2|In this arm patients will be randomized to the current standard of care of bolus narcotic treatment.
11590867|NCT00711672||1|Medical Oncologists treating patients with metastatic colorectal cancer
11590868|NCT00711672||2|Patients with metastatic colorectal cancer receiving re-staging CT scans
11590869|NCT00711659||1|all third year medical students starting their pediatric clerkship rotation
11590870|NCT00711646|Experimental|Sativex|
11590871|NCT00711646|Placebo Comparator|Placebo|
11590872|NCT00711633|Experimental|1|the fermented preterm formula (FPF)
11590873|NCT00711633|Placebo Comparator|2|formula adapted for preterm infants (PF)
11590874|NCT00711620|Experimental|Thymosin alpha 1+Standard Therapy|Patients receive treatment based on SSC guideline with additional thymosin alpha1
11590875|NCT00711620|Placebo Comparator|normal saline+standard therapy|Patients receive treatment based on SSC guideline with additional normal saline.
11590876|NCT00711607|Experimental|1|Group 1: NOMAC-E2 (days 1-24 and day 35)
11590877|NCT00711607|Placebo Comparator|2|Group 2: NOMAC-E2 (days 1-24) followed by Placebo (day 35)
11590878|NCT00711594|Experimental|BIBW 2992 MA2|Phase I step: Find maximum tolerated dose of the non-marketed substance:BIBW 2992 given orally. Escalating doses of BIBW 2992 starting at 20mg daily.
11590981|NCT00710996||AcrySof Natural Intraocular Lens|"AcrySof Natural Intraocular Lens (IOL) - Patients with previous bilateral implant of any Alcon lens model starting with the letters SN"
11591077|NCT00710242|Placebo Comparator|2|
11590879|NCT00711594|Experimental|BIBW 2992 QD|Phase II step: Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop. Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs.
11590880|NCT00711581|Experimental|A|Subjects will undergo a laparoscopic cholecystectomy. The gallbladder will be retracted using the Endograb retractor.
11590881|NCT00711568|Experimental|Arm 1|Left dorsolateral frontal 20 Hz TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
11590882|NCT00711568|Experimental|Arm 2|Right dorsolateral frontal 20 Hz TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
11590883|NCT00711568|Sham Comparator|Arm 3|Left or right dorsolateral frontal 20 Hz sham TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
11590884|NCT00711542|Active Comparator|1|Intracoronary infusion of autologous bone marrow-derived progenitor cells after NSTEMI
11590885|NCT00711542|Placebo Comparator|2|Intracoronary infusion of Placebo after NSTEMI
11590886|NCT00711529|Experimental|Hypnotherapy|"Patients randomized to the experimental arm were scheduled for three one-hour inductions by a single hypnotherapist, each one week apart. Standardized outlines were used for each induction. The second and third sessions also began with a standardized induction, followed by the establishment of an anchor, or physical reference point (forefinger to thumb), used to invoke images of coolness, which were individualized according to patient preference.
~Patients were also instructed by the same hypnotherapist in self-hypnosis and guided imagery techniques to be used at home with the assistance of standardized audio compact disks. Participation lasted eight weeks."
11590887|NCT00711529|Active Comparator|Gabapentin|Patients randomized to the gabapentin arm were prescribed 900mg of the drug daily (300 mg by mouth three times daily).
11590888|NCT00711516|Experimental|1|Armodafinil treatment (200 mg/day) - Study drug was supplied as 50 mg tablets and the dose was titrated from a starting dose of 50 mg taken once daily in the morning (before 0800), increasing to 100 mg/day on Day 2, 150 mg/day on day 5, and then 200 mg/day beginning Day 8 and continuing through the end of the two week double-blind treatment period.
11590889|NCT00711516|Placebo Comparator|2|Placebo comparator - Placebo tablets matching the armodafinil 50 mg tablets drug were supplied and the dose was titrated from a starting dose of one tablet taken once daily in the morning (before 0800), increasing to two tablets/day on Day 2, three tablets/day on day 5, and then four tablets/day beginning Day 8 and continuing through the end of the two week double-blind treatment period.
11590890|NCT00711503|Placebo Comparator|2|The patients are instructed to administer placebo by subcutaneous injection
11590891|NCT00711503|Experimental|1|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection
11590892|NCT00711490|Experimental|Sirolimus|The study eye was treated with sirolimus.
11590893|NCT00711477|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/day
11590894|NCT00711477|Placebo Comparator|Placebo|Placebo tablets
11590895|NCT00711464|Experimental|100 mg|modafinil 100 milligrams oral dose
11590896|NCT00711464|Experimental|200 mg|modafinil 200 mg oral dose
11590897|NCT00711464|Experimental|400 mg|modafinil 400 mg oral dose
11590898|NCT00711464|Placebo Comparator|Placebo|Single oral placebo capsule
11590899|NCT00711451|Active Comparator|manual|Manual removal of placenta
11590900|NCT00711451|Active Comparator|expressed|expressed placental removal
11590901|NCT00711438|Experimental|FT|Breathlessness Intervention Service (BIS)
11590902|NCT00711438|Active Comparator|WL|Best supportive care
11590903|NCT00711425|Experimental|A|
11590904|NCT00711412|Experimental|Induction, Combination and surgery|"Weeks 1-6:
~Capecitabine 1000mg/m2 twice daily Oxaliplatin 70mg/m2 on days 1 and 8
~Weeks 7-12:
~Capecitabine 825 mg/m2 twice daily Oxaliplatin 50mg/m2 weekly Radiation 1.8 Gy Monday-Friday
~Evaluation for response and resection surgery"
11590905|NCT00711399||group A|Study group
11590906|NCT00711386|Experimental|Cohort A|50mg dose once daily for 7 days.
11590907|NCT00711386|Experimental|Cohort B|100mg dose once daily for 8 days.
11590908|NCT00711386|Experimental|Cohort C|200mg dose once daily for 8 days.
11590909|NCT00711386|Experimental|Cohort D|400mg dose once daily for 7 days.
11590910|NCT00711373|Experimental|Unilateral and Bilateral Amputees|
11590911|NCT00711347|Active Comparator|DisCoVisc|Alcon's DisCoVisc Ophthalmic Viscosurgical Device (OVD) used at time of cataract surgery
11590912|NCT00711347|Active Comparator|Healon5|Abbott Medical Optic's (AMO) Healon5 Ophthalmic Viscosurgical Device (OVD) used at time of cataract surgery
11590913|NCT00711321||2|AFFITOPE AD02 with adjuvant
11590914|NCT00711321||1|AFFITOPE AD02 without adjuvant
11590915|NCT00711308|Experimental|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
11590916|NCT00711308|Active Comparator|acenocoumarol|tinzaparin followed by acenocoumarol for 6 months
11590917|NCT00711295|Experimental|Cohort 1, Treatment Arm 1|"Stratum A (18-59 ys)/B(>=60 ys): 120 healthy volunteers per stratum will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.
~Among Stratum A volunteers, 60 will participate in antibody kinetics evaluation and 30 in cellular immunity evaluation.
~Randomization to Treatment Arms 1 and 2 at 2:1 ratio. Subjects in Treatment Arm 1 will be included in the immunologic determination of lot-to-lot consistency."
11590918|NCT00711295|Experimental|Cohort 1, Treatment Arm 2|"Stratum A (18-59 ys)/B(>=60 ys): 60 healthy volunteers per stratum will receive 2 vaccinations with 3.75 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.
~Randomization to Treatment Arms 1 and 2 at 2:1 ratio."
11590919|NCT00711295|Experimental|Cohort 1, Treatment Arm 3|"Stratum A (18-59 ys): 2060 healthy volunteers will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in safety evaluation only.
~Randomization within Treatment Arms 3 and 4 at 1:1:1 ratio per study site to receive one of three different lots of the H5N1 influenza vaccine."
11590920|NCT00711295|Experimental|Cohort 2, Treatment Arm 1|"300 immune compromised individuals 18 years or older will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21.
~100 will participate in immunogenicity evaluation and 30 in cellular immunity evaluation."
11590922|NCT00711295|Experimental|Cohort 1, Treatment Arm 4|"Stratum A (18-59): 540 healthy volunteers will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity assessment.
~Randomization within Treatment Arms 3 and 4 at 1:1:1 ratio per study site to receive one of three different lots of the H5N1 influenza vaccine.
~Subjects in Treatment Arm 4 will be included in the immunologic determination of lot-to-lot consistency."
11590923|NCT00711282|Experimental|A|
11590924|NCT00711282|Experimental|B|
11590925|NCT00711269|Experimental|SM-13496 (lurasidone HCl) 40mg|SM-13496 40 mg was administered orally once daily.
11590926|NCT00711269|Experimental|SM-13496 (lurasidone HCl) 80mg|SM-13496 80mg was administered orally once daily.
11590927|NCT00711269|Placebo Comparator|Placebo|Placebo was administered orally twice daily.
11590928|NCT00711269|Active Comparator|Risperidone|Risperidone was administered orally twice daily.
11590929|NCT00711256|Active Comparator|1|No sunscreen applied
11590930|NCT00711256|Active Comparator|2|Sunscreen applied 0.5 mg/cm2
11590931|NCT00711256|Active Comparator|3|Sunscreen applied 1mg/cm2
11590932|NCT00711256|Active Comparator|4|Sunscreen applied 2mg/cm2
11590933|NCT00711243|Experimental|Cohort 1a|Docetaxel 25 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
11590934|NCT00711243|Experimental|Cohort 2a|Docetaxel 30 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
11590935|NCT00711243|Experimental|Cohort 3a|Docetaxel 40 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
11590936|NCT00711243|Experimental|Cohort 4a|Docetaxel 50 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
11590937|NCT00711243|Experimental|Cohort 5a|Docetaxel 60 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
11590938|NCT00711230|Experimental|1: Low dose DermaVir|"Dosage: 0.2 mg DNA
~Dosage form: 1.6 mL DNA/PEIm nanomedicine
~Administration with 2 DermaPrep patches
~Frequency: every six weeks
~Duration: 18 weeks (4 DermaVir treatments)"
11590939|NCT00711230|Experimental|2: Low dose Placebo|"Dosage form: 1.6 mL Placebo
~Administration with 2 DermaPrep patches
~Frequency: every six weeks
~Duration: 18 weeks (4 Placebo treatments)"
11590940|NCT00711230|Experimental|3: Medium dose DermaVir|"Dosage: 0.4 mg DNA
~Dosage form: 3.2 mL DNA/PEIm nanomedicine
~Administration with 4 DermaPrep patches
~Frequency: every six weeks
~Duration: 18 weeks (4 DermaVir treatments)"
11590941|NCT00711230|Experimental|4: Medium dose Placebo|"Dosage form: 1.6 mL Placebo
~Administration with 4 DermaPrep patches
~Frequency: every six weeks
~Duration: 18 weeks (4 Placebo treatments)"
11590942|NCT00711230|Experimental|5: High dose DermaVir|"Dosage: 0.8 mg DNA
~Dosage form: 6.4 mL DNA/PEIm nanomedicine
~Administration with 8 DermaPrep patches
~Frequency: every six weeks
~Duration: 18 weeks (4 DermaVir treatments)"
11590943|NCT00711230|Experimental|6: High dose Placebo|"Dosage form: 6.4 mL Placebo
~Administration with 8 DermaPrep patches
~Frequency: every six weeks
~Duration: 18 weeks (4 Placebo treatments)"
11590944|NCT00711217|Experimental|#1 Medical food|
11590945|NCT00711217|Placebo Comparator|#2 Control|
11590946|NCT00711204|Placebo Comparator|1|
11590947|NCT00711204|Active Comparator|2|
11590948|NCT00711191|Experimental|single arm|
11590949|NCT00711178|Active Comparator|A|2 hours sunlight
11590950|NCT00711178|Active Comparator|B|3 hours of sunlight
11590951|NCT00711165|Placebo Comparator|Placebo|Placebo, 2 puffs, bid
11590952|NCT00711165|Experimental|Memetasone|Mometasone
11590953|NCT00711152|Experimental|JADE with CHW|Patients will be enrolled into JADE program and will undergo annual comprehensive assessment (CA) with personalized JADE report with additional support by the CHW.
11590954|NCT00711152|Active Comparator|JADE only|Patients will be enrolled into JADE program and undergo annual comprehensive assessment (CA) with personalized JADE report without additional support by the CHW.
11590955|NCT00711139||1|AFFITOPE AD01
11590956|NCT00711139||2|AFFITOPE AD01 + Adjuvant
11590957|NCT00711126|Experimental|Arm 1|HVTs
11590958|NCT00711126|Experimental|Arm 2|HVTs
11590959|NCT00711126|Experimental|Arm 3|HVTs
11590960|NCT00711126|Experimental|Arm 4|HVTs
11590961|NCT00711126|Experimental|Arm 5|HVTs
11590962|NCT00711126|Experimental|Arm 6|HVTs
11590963|NCT00711113|Experimental|A|
11590964|NCT00711100|Experimental|Camel Snus|Camel Snus (oral smokeless tobacco product). Dosage: 1.74-1.97 mg nicotine per portion.
11590965|NCT00711100|Experimental|Marlboro Snus|Marlboro Snus (oral smokeless tobacco product). Dosage: 0.14 - 0.38 mg nicotine per portion.
11590966|NCT00711100|Experimental|Stonewall|Stonewall (oral dissolvable tobacco product). Dosage: 0.28-0.57 mg nicotine per portion.
11590967|NCT00711100|Experimental|Ariva|Ariva (oral dissolvable tobacco product). Dosage: 0.24-0.25 mg nicotine per portion.
11590968|NCT00711100|Experimental|General Snus|General Snus (oral smokeless tobacco product); Dosage: 3.37 mg nicotine.
11590969|NCT00711087|Placebo Comparator|ARM 2|Subjects randomized to receive placebo (saline) sham saline injections on Days 0 and 90.
11590970|NCT00711087|Active Comparator|ARM 1|Subjects randomized to receive 100 units BOTOX-A injections on Days 0 and 90.
11590971|NCT00711074|Experimental|1|
11590972|NCT00711061||1|18-25 year old males, growth hormone deficient, who completed growth hormone treatment 3-5 years prior to enrollment in study
11590973|NCT00711061||2|18-25 year old males, healthy, never treated with growth hormones.
11590974|NCT00711048|Experimental|1|30 mg, oral, single dose
11590975|NCT00711048|Experimental|2|95 mg, oral, single dose
11590976|NCT00711048|Placebo Comparator|3|Oral solution, single dose
11590977|NCT00711035|Experimental|Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection|If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line.
11590978|NCT00711022|Experimental|OsseoSpeed|
11590979|NCT00711009|Active Comparator|LPV/r + FTC/TDF|lopinavir/ritonavir 400/100 milligram (mg) tablet twice-daily + co-formulated emtricitabine/tenofovir disoproxil fumarate 200/300 mg once-daily
11590980|NCT00711009|Experimental|LPV/r + RAL|lopinavir/ritonavir 400/100 mg tablet twice-daily + raltegravir 400 mg twice-daily
11591070|NCT00710333|Placebo Comparator|1|500ng dose
11590982|NCT00710996||AcrySof clear intraocular lens|"AcrySof clear intraocular lens (IOL) - Patients with previous bilateral implant of any Alcon lens model starting with the letters SA"
11590983|NCT00710996||Phakic patients|Phakic patients - Age matched patients who have not had cataract surgery
11590984|NCT00710983|Active Comparator|A|Oral polio vaccine
11590985|NCT00710983|No Intervention|B|No oral polio vaccine
11590986|NCT00710970|Experimental|Single Arm Receiving 25mg Tamoxifen|
11590987|NCT00710957||CHS All Stars|CHS All Stars is an ancillary study of the Cardiovascular Health Study (CHS), a longitudinal, observational, population-based study of the onset, progression, and course of heart disease and stroke in the elderly which began in 1988. The All Stars study reexamined the survivors of CHS to determine the likelihood of maintaining function later in life. A focus was to determine whether age-related biological factors are long-term predicators of functional aging which was assessed through a follow-up exam (Yr 18 visit conducted in 2005-06, n=1674 older adults, mean age =84 years) and 3 yrs of subsequent 6 month interval phone contacts. Vitamin D status (serum 25(OH)D and PTH) is being assessed in all CHS All Stars participants who provided a blood sample at the Yr 18 visit (n~1100).
11590988|NCT00710944|Experimental|Extraction Sockets|Immediate loading in extraction sockets.
11590989|NCT00710944|Experimental|Healed Ridges|Immediate loading in healed ridges.
11590990|NCT00710944|Experimental|Grafted Sites|Immediate loading of implants placed in grafted sites (four months healing after grafting).
11590991|NCT00710931|Experimental|ReSTOR +3 Multifocal Lens|Bilateral implantation of the AcrySof ReSTOR +3 Intraocular Lens (IOL)
11590992|NCT00710905|Experimental|ReSTOR|Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, Acrysof ReSTOR +4 IOL in the other eye.
11590993|NCT00710892|Experimental|Dose Level 1-3|Administration of suicide gene-modified allodepleted T cells.
11590994|NCT00710879|Experimental|Multipurpose Solution|Multi-purpose solution administered to adapted FDA group I soft contact lens wearers and FDA group IV soft contact lens wearers.
11590995|NCT00710866|Experimental|1|2 doses 0.5mL VAXIGRIP® at months 0, 1
11590996|NCT00710866|Active Comparator|2|2 doses 0.25mL VAXIGRIP® at months 0, 1
11590997|NCT00710853|Experimental|1|YiRen Qi gong weekly class for 8 weeks
11590998|NCT00710853|Experimental|2|Tai Chi weekly class for 8 weeks
11590999|NCT00710853|Active Comparator|3|Hatha yoga weekly class for 8 weeks
11591000|NCT00710840|Experimental|1|
11591001|NCT00710840|Active Comparator|2|
11591002|NCT00710827|Experimental|Arm 1|
11591003|NCT00710827|Placebo Comparator|Arm 2|
11591004|NCT00710814|Experimental|Leptin - Placebo|Leptin self-administered subcutaneously twice each day for 16 weeks, then Placebo for 16 weeks.
11591005|NCT00710814|Placebo Comparator|Placebo - Leptin|Placebo self-administered subcutaneously twice each day for 16 weeks, then Leptin for 16 weeks.
11591006|NCT00710788|Experimental|1|sevelamer as Phosphate-binder treatment
11591007|NCT00710788|Active Comparator|2|Calcium carbonate
11591008|NCT00710775|Other|1|Patients undergoing surgical aortic valve replacement on cardiopulmonary bypass.
11591009|NCT00710762|Experimental|BIBF1120|
11591010|NCT00710762|Placebo Comparator|Placebo|
11591011|NCT00710749|Experimental|Disposable device first, then Digital device|
11591012|NCT00710749|Experimental|Digital device first, then Disposable device|
11591013|NCT00710736|Experimental|ARRY-334543 + capecitabine|
11591014|NCT00710723|Experimental|1|vitrification
11591015|NCT00710723|No Intervention|2|Slow freezing
11591016|NCT00710697|Experimental|Single Arm|Picoplatin
11591017|NCT00710684|Experimental|DONEPEZIL + SB-742457 15 MG|SB-742457 - 15mg added to existing donepezil treatment
11591018|NCT00710684|Placebo Comparator|DONEPEZIL + PLACEBO|Placebo added to existing donepezil
11591019|NCT00710684|Experimental|DONEPEZIL + SB-742457 35 MG|SB-742457 - 35mg added to existing donepezil
11591020|NCT00710671||Phase 1|Male, HIV+ participants from ages 16-24 who have had sex with another male in the past year and acquired HIV behaviorally. Participants will be drawn from four participating AMTU sites.
11591021|NCT00710671||Phase 2|Male, HIV+ participants from ages 16-24 who have had sex with another male in the past year and acquired HIV behaviorally. Participants will be drawn from all fifteen AMTU sites.
11591022|NCT00710658|Experimental|1|Patients had access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as to a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.
11591023|NCT00710658|No Intervention|2|The control group receiving usual care
11591024|NCT00710645||Arm I|50 subjects with multiple sclerosis will be tested one time on the Lido Workset. The test will take approximately 25 minutes. The servo-controlled torque motor system will analyze resistance to passive movement of the knee. This testing may be repeated for a group of randomly selected subjects. Each subject will be given the option to participate in the extended testing or to decline. The testing for this subset of subjects will be done as follows: first session, second session one week after the first session, third session three weeks after the first session. The total length of time for participation in this study may be up to three weeks.
11591025|NCT00710645||Arm II|25 normal subjects will be tested on the Lido workset. The testing will be performed one time for each patient and will take approximately 25 minutes. The servo-controlled torque motor system will analyze resistance to passive movement of the knee. This testing may be repeated for a group of randomly selected control subjects. Each subject will be given the option to participate in the extended testing or to decline. The testing for this subset of subjects will be done as follows: first session, second session one week after the first session, third session three weeks after the first session. The total length of time for participation in this study may be up to three weeks.
11591026|NCT00710619||A|
11591027|NCT00710606|Experimental|1- Obese Women /Nuvaring|Obese subjects (BMI 30-39.9)received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
11591071|NCT00710333|Experimental|2|
11591072|NCT00710320||Cover and Uncover|Procedure/Surgery
11591028|NCT00710606|Active Comparator|2- Normal Weight / Nuvaring|Normal weight subjects (BMI 19-24.9) received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
11591029|NCT00710593|Active Comparator|A: HAART naive or no HAART in past 6 months|Participants who are ART naïve or, if ART-exposed, have not received highly active antiretroviral therapy (HAART) for at least the six months prior to study entry. All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
11591030|NCT00710593|Active Comparator|B: HAART atleast 6 months/ 2 viral loads <400 in last 6 months|Participants who have been receiving highly active antiretroviral therapy (HAART) for at least six months at the time of study entry, with two HIV-1 RNA plasma viral loads < 400 copies/ml on two previous clinical visits within the 6 months prior to study entry. All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
11591031|NCT00710580|Experimental|A|
11591032|NCT00710580|Active Comparator|B|
11591033|NCT00710580|Placebo Comparator|C|
11591034|NCT00710567|Other|Historical Data|"DuraHeart Patients will be implanted with a DuraHeart Left Ventricular Assist System (LVAS) as a bridge to transplant until a suitable heart can be found as a replacement. Parameters collected will be compared to a performance goal based on historical data for congestive heart failure patients"
11591035|NCT00710554|Experimental|Sativex|
11591036|NCT00710554|Placebo Comparator|Placebo|
11591037|NCT00710541|Experimental|NPPV group|Subjects in this arm receive standard COPD treatment, LTOT if indicated, and NPPV with ventilators designed for 'non invasive ventilation'(Resmed VPAP III ST-A, Weinmann Ventimotion, Tyco Healthcare Knight Star 330)
11591038|NCT00710541|No Intervention|control gorup|Subjects in this arm receive standard COPD treatment and LTOT if indicated.
11591039|NCT00710528|Experimental|one arm|
11591040|NCT00710515|Experimental|1|with food
11591041|NCT00710515|Experimental|2|without food
11591042|NCT00710502|Experimental|1|Transvaginal NOTES Cholecystectomy (Phase 1)
11591043|NCT00710502|Active Comparator|2|Laparoscopic Cholecystectomy (Phase 2)
11591044|NCT00710502|Experimental|3|Transvaginal NOTES cholecystectomy (Phase 2)
11591045|NCT00710476|Experimental|1|Insemination of the oocytes with a lower concentration of spermatozoa.
11591046|NCT00710476|No Intervention|2|Insemination with a normal concentration of spermatozoa.
11591047|NCT00710463||Control group|patients receive a hospital based comprehensive pulmonary rehabilitation programme, including endurance training, physiotherapy, medical therapy, and long term oxygen treatment when indicated.
11591048|NCT00710463||NIV treatment group|patients receive a hospital based comprehensive pulmonary rehabilitation programme, including endurance training, physiotherapy, medical therapy, and long term oxygen treatment when indicated, plus newly introduced nocturnal non invasive ventilation.
11591049|NCT00710450||1|Allergic Asthma
11591050|NCT00710450||2|Allergic Rhinitis
11591051|NCT00710437||1|Dexmedetomidine - used
11591052|NCT00710437||2|Dexmedetomidine - not used
11591053|NCT00710424|Experimental|Sativex|
11591054|NCT00710424|Placebo Comparator|Placebo|
11591055|NCT00710411||A, 2|Polytraumatized patients with ISS > 18 and healthy controls
11591056|NCT00710398|Experimental|Control|A group consuming twice daily (post-exercise and in morning/afternoon) drinks containing no dairy protein or calcium. Daily protein intake (15% total kcals) should be from non-dairy sources (i.e. meat, egg, fish, chicken, wheat gluten).
11591057|NCT00710398|Experimental|Dairy Protein|A group consuming twice daily drinks (post-exercise and morning) containing 1% chocolate milk (in 1.5 cup servings = 3 cups/d). Daily protein intake is set at 15% total kcals with ~8% coming from dairy sources.
11591058|NCT00710398|Experimental|High Dairy Protein|A group consuming twice daily drinks of 1% artificially sweetened chocolate milk (in 1.5 cup servings = 3 cups/d). Their diet contains 30% protein (as opposed to only 15% in the Con and DairyPro groups) with at least 50% of that coming from dairy sources.
11591059|NCT00710385|Active Comparator|Heroin|Heroin 25 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
11591060|NCT00710385|Active Comparator|Naloxone|Naloxone (NAL) .4 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
11591061|NCT00710385|Experimental|Low Bup Dose|Combined dosing groups of (4 mg and 8mg of Buprenorphine) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
11591062|NCT00710385|Experimental|Low Bup/Nal Dose|Combined dosing groups of (4/1 mg and 8/2mg of Buprenorphine + Naloxone) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
11591063|NCT00710385|Experimental|High Bup Dose|Combined dosing groups of (8mg and 16mg of Bup) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
11591064|NCT00710385|Experimental|High Bup/Nal Dose|Combined dosing groups of (8/2mg and 16/4mg of Buprenorphine + Naloxone) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
11591065|NCT00710385|Placebo Comparator|Placebo|Intravenous placebo (PCB) administration. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
11591066|NCT00710372|Experimental|1|CYT006-AngQb
11591067|NCT00710372|Placebo Comparator|2|
11591068|NCT00710359|Active Comparator|1|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma) given as a single intramuscular injection. The syringe is covered so it is impossible to see whether or not it contains any substance.
11591069|NCT00710359|Sham Comparator|2|"The controls receive an intramuscular injection, however, it is only an introduction of the needle into the muscle, but no injections are given. The syringe is covered so it is impossible to see whether or not it contains any substance."
11591078|NCT00710229|Active Comparator|A|Intravitreal injectin of Ranibizumab (3 monthly injection followed by monthly injectins as long as required
11591079|NCT00710229|Active Comparator|B|Intravitreal injectin of Bevacizumab (3 monthly injection followed by monthly injectins as long as required
11591080|NCT00710216|Active Comparator|A|
11591081|NCT00710216|Experimental|B|
11591082|NCT00710203|Active Comparator|Pulsed dye laser|Four lesions are selected on each subject for study. One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
11591083|NCT00710203|Active Comparator|Curettage|Four lesions are selected on each subject for study. A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
11591084|NCT00710203|Active Comparator|Electrodesiccation|Four lesions are selected on each subject for study. A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
11591085|NCT00710203|Active Comparator|No treatment|Four lesions are selected on each subject for study. A fourth lesion will not be treated and will serve as a control.
11591086|NCT00710190|Experimental|Rheos Implant|
11591087|NCT00710177||PPHN|Infants born at >= 34 weeks who are diagnosed with clinical and/or echocardiographic evidence of PPHN
11591088|NCT00710177||Control|Randomly selected, normal healthy infants born at >= 34 weeks gestational age and do not have PPHN
11591089|NCT00710164|Experimental|A|
11591090|NCT00710164|Placebo Comparator|B|
11591091|NCT00710151||1|Subjects with PCNSL who have survived disease-free for 2 years or more. Treatments will vary depending upon site of enrollment and will include chemotherapy, blood brain barrier disruption (BBBD) with chemotherapy, radiation, and stem cell transplantation.
11591092|NCT00710138|Active Comparator|1|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma) given as a single intramuscular injection. The syringe is covered so it is impossible to see whether or not it contains any substance.
11591093|NCT00710138|Sham Comparator|2|"The controls receive an intramuscular injection, however, it is only an introduction of the needle into the muscle, but no injections are given. The syringe is covered so it is impossible to see whether or not it contains any substance."
11591094|NCT00710125|Experimental|GPX-150 for Injection|GPX-150 is administered IV on Day 1, followed by a 20 day rest period, every 3 weeks.
11591095|NCT00710112||VLBW|infants less than 1500 grams at birth
11591096|NCT00710099|Experimental|1|
11591097|NCT00710099|Active Comparator|2|SNP iontophoresis
11591098|NCT00710086|Active Comparator|1|Intravenous administration of hydromorphone intermittently
11591099|NCT00710086|Experimental|2|Remifentanil intravenous patient-controlled analgesia
11591100|NCT00710073|Experimental|A|Combined sono-electro-magnetic therapy
11591101|NCT00710060|Experimental|1|Participating communities will receive the Community Popular Opinion Leader intervention and HIV/STD educational materials.
11591102|NCT00710060|Active Comparator|2|Participating communities will receive HIV/STD educational materials only.
11591103|NCT00710047|Experimental|1|Fasting state
11591104|NCT00710047|Experimental|2|after high-fat breakfast
11591105|NCT00710034|Active Comparator|Nicotine Gum|Nicotine replacement therapy (4 mg nicotine gum) was provided to the participants for an 12 weeks. Participants were encouraged to completely substitute nicotine gum for cigarettes and asked to use at least 6-8 pieces a day or optimally every 1-2 h and more if necessary. They were advised to reduce consumption by half during weeks 7-9 and three-quarters during weeks 10-12.
11591106|NCT00710034|Experimental|Snus|Oral tobacco (Camel Snus) was provided to the participants for an 12 weeks. Participants were encouraged to completely substitute snus for cigarettes and asked to use at least 6-8 pieces a day or optimally every 1-2 h and more if necessary. They were advised to reduce consumption by half during weeks 7-9 and three-quarters during weeks 10-12.
11591107|NCT00710021|Experimental|vitamin D3 2000 IU|Participants in this arm take a vitamin D3 dose of 2000 international units (IU) daily by mouth for a duration of 12 weeks.
11591108|NCT00710021|Experimental|vitamin D3 4000 IU|Participants in this arm take a vitamin D3 dose of 4000 international units (IU) daily by mouth for a duration of 12 weeks.
11591109|NCT00710021|Placebo Comparator|vitamin D3 placebo|Participants in this arm take a vitamin D3 placebo daily by mouth for a duration of 12 weeks.
11591110|NCT00709995|Experimental|Part 1 Arm A: Enzastaurin + Sunitinib|"(Cohort 1): On cycle 1, day 1 a loading dose 125 milligram (mg) of Enzastaurin was administered by mouth orally, (BID) twice a day, followed by Enzastaurin 125 mg administered, twice a day, Days 2 through 42 of a 6-week cycle.
~(Cohort 2): Cycle 1, Day 1 loading dose 375 mg of Enzastaurin administered po three times a day (TID), followed by 250 mg, po, BID continuously until disease progression, unacceptable toxicity, death, or discontinuation from the study for any other reason.
~Sunitinib 50 mg was administered orally, once daily, Days 1-28, then rest (no drug given) days 29-42.
~Phase 2 (Part 2): Randomized Double-Blind: Dosing was determined by Part 1. Part 2 was not activated per recommendation of safety review committee.
~Enzastaurin: Cycle 1, Day 1 loading dose 375 mg administered orally, (TID) three times a day, followed by Part 1 dose twice a day on Days 2-42 of 6 week cycle.
~Sunitinib: 50 mg administered orally, once daily, on Days 1-28, then rest Days 29-42."
11591111|NCT00709995|Placebo Comparator|Part 2 Arm B: Sunitinib + Placebo|"Part 2 was not activated per recommendation of safety review committee.
~Sunitinib: 50 mg administered orally, once daily, Day 1-28, then rest Days 29-42.
~Placebo: Cycle 1 Day 1 loading dose 3 tablets on Day 1, then 2 tablets daily, days 2-42."
11591112|NCT00709969|Experimental|1|Artemether-lumefantrine
11591113|NCT00709956|Experimental|Active / placebo|Single dose of iloprost (5 µg) on study day 2 followed by single dose of placebo on study day 3
11591114|NCT00709956|Placebo Comparator|Placebo / active|Single dose of placebo on study day 2 followed by single dose of iloprost (5 µg) on study day 3
11591115|NCT00709930|Active Comparator|1,Exposed to ELF-EMF|Device: Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF
11591116|NCT00709930|Placebo Comparator|2,Placebo|Device: Placebo device with no magnetic fields
11591117|NCT00709917||A|
11591118|NCT00709904|Experimental|Semuloparin extension treatment|Extension treatment with Semuloparin sodium 20 mg (10 mg if SRI) for 19-23 days following initial treatment with open-label Semuloparin 20 mg (10 mg if SRI) for 7-10 days.
11591413|NCT00707785|Experimental|3|NEC - vitamin A
11591119|NCT00709904|Placebo Comparator|Placebo extension treatment|Extension treatment with placebo (for Semuloparin sodium) for 19-23 days following initial treatment with open-label Semuloparin 20 mg (10 mg if SRI) for 7-10 days
11591120|NCT00709891|Experimental|cobas® 4800 HPV Test|The cobas 4800 human papillomavirus (HPV) Test combines in a single assay the identification of pooled high-risk oncogenic HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), as well as genotypes 16 and 18 individually.
11591121|NCT00709878||L|Patients treated with lapatinib who developed skin toxicities and have been biopsied for skin rash.
11591122|NCT00709878||C|Patients treated with cetuximab who developed skin toxicities and have been biopsied for skin rash.
11591123|NCT00709878||P|Patients treated with panitumumab who developed skin toxicities and have been biopsied for skin rash.
11591124|NCT00709878||E|Patients treated with erlotinib who developed skin toxicities and have been biopsied for a skin rash.
11591125|NCT00709865|Experimental|1|.03 mg/kg
11591126|NCT00709865|Experimental|2|.15 mg/kg
11591127|NCT00709865|Experimental|3|.3 mg/kg
11591128|NCT00709865|Placebo Comparator|4|Placebo
11591129|NCT00709852|Experimental|Gadobutrol then Gadoteridol|Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) in Period 1 and a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v. in Period 2.
11591130|NCT00709852|Experimental|Gadoteridol then Gadobutrol|Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v. in Period 1 and a single dose of gadobutrol 0.1 mmol/kg bw via i.v. in Period 2.
11591131|NCT00709826|Experimental|apricoxib + gemcitabine + erlotinib|400mg apricoxib + 1000mg/m2 gemcitabine + 100mg erlotinib
11591132|NCT00709826|Placebo Comparator|placebo + gemcitabine + erlotinib|placebo + 1000mg/m2 gemcitabine + 100mg erlotinib
11591133|NCT00709813|No Intervention|1|
11591134|NCT00709813|Experimental|2|
11591135|NCT00709800|Experimental|2|
11591136|NCT00709800|Experimental|3|
11591137|NCT00709800|Experimental|4|
11591138|NCT00709800|Placebo Comparator|5|
11591139|NCT00709800|Experimental|1|
11591140|NCT00709787||Hypertensive Subjects undergoing primary prevention|
11591141|NCT00709761|Experimental|Single Arm|Single arm combination therapy of Lap and NabPaclitaxel combination
11591142|NCT00709748|Active Comparator|1|Subjects in this study arm will receive treatment (fully active) Empi Select TENS devices.
11591143|NCT00709748|Placebo Comparator|2|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
11591144|NCT00709735|Experimental|Reactivation Propranolol (RP)|"0.67 mg/kg short-acting placebo capsules then 1 mg/kg long-acting placebo capsules 90 minutes later on Day 0 (non-reactivation) followed by 0.67 mg/kg short-acting propranolol capsules then 1 mg/kg long-acting propranolol capsules 90 minutes later on Day 2 (reactivation). All participants then underwent a script preparation session in which the investigator elicited five discrete personal memories, including two traumatic combat experiences."
11591145|NCT00709735|Active Comparator|Non-Reactivation Propranolol (NRP)|"0.67 mg/kg short-acting propranolol capsules then 1 mg/kg long-acting propranolol capsules 90 minutes later on Day 0 (non-reactivation) followed by 0.67 mg/kg short-acting placebo capsules then 1 mg/kg long-acting placebo capsules 90 minutes later on Day 2 (reactivation). All participants then underwent a script preparation session in which the investigator elicited five discrete personal memories, including two traumatic combat experiences."
11591146|NCT00709722|Experimental|1|NKT-01
11591147|NCT00709709|Experimental|1|Scan
11591148|NCT00709696|Placebo Comparator|1|Placebo Varenicline
11591149|NCT00709696|Active Comparator|2|Varenicline
11591150|NCT00709683||A|
11591151|NCT00709670|Experimental|whole population who receive both tests|this arm includes the whole study population who will receive both tests: MSCT and stress echocardiography
11591152|NCT00709657|Experimental|1|patients with age-related macular degeneration, which are already scheduled for intravitreal anti-VEGF therapy in one eye are measured before and after treatment.
11591153|NCT00709592|Experimental|ATG 1.7 mg/kg, TBI, transplant|(Rabbit-ATG;Thymoglobulin,Genzyme) ATG 5.1 mg/kg in three divided doses (1.7 mg/kg/d) given over three days (day -9 to -7) followed by 450 cGy TBI and tacrolimus plus MMF GVHD prophylaxis. Patients receive lower dose anti-thymocyte globulin IV on days -9 to -7. Patients undergo total-body radiation (TBI) twice daily (BID) on day -1 and once daily (QD) on day 0. Patients then undergo peripheral blood stem cells or bone marrow transplant on day 0. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: patients receive tacrolimus orally (PO) on days -2 to 90-120 with taper for 2 months, and mycophenolate mofetil (MMF) PO BID on days 0-30.
11591154|NCT00709592|Experimental|ATG 2.5 mg/kg/d, TBI, transplant|(Rabbit-ATG;Thymoglobulin,Genzyme) ATG 7.5 mg/kg in three divided doses (2.5 mg/kg/d) given over three days (day -9 to -7) followed by 450 cGy TBI and tacrolimus plus MMF GVHD prophylaxis. Patients receive higher dose anti-thymocyte globulin intravenously (IV) on days -9 to -7. Patients undergo total-body radiation (TBI) twice daily (BID) on day -1 and once daily (QD) on day 0. Patients then undergo peripheral blood stem cells or bone marrow transplant on day 0. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: patients receive tacrolimus orally (PO) on days -2 to 90-120 with taper for 2 months, and mycophenolate mofetil (MMF) PO BID on days 0-30.
11591155|NCT00709579|Placebo Comparator|placebo|
11591156|NCT00709579|Active Comparator|RV3391A|
11591157|NCT00709566|No Intervention|Control|Waiting List control.
11591158|NCT00709566|Active Comparator|Exercise therapy|
11591159|NCT00709566|Experimental|Combined therapy|Combined Exercise therapy and Manual Therapy
11591160|NCT00709553|Experimental|1|midazolam, one single dose of 705mg
11591161|NCT00709553|Experimental|2|ZD4054(Zibotentan)- 10mg od, 7 days + midazolam (one single dose of 7.5 mg on day 6 )
11591162|NCT00709540|Experimental|single|10 subjects (8 active and 2 placebo)
11591163|NCT00709527|Experimental|1|
11591164|NCT00709514|Experimental|DCB-WH1 ointment|DCB-WH1 ointment 1.25%, topical use, two times daily for 12 weeks or until ulcer closes completely or discontinuation due to treatment failure, whichever comes first.
11591165|NCT00709514|Placebo Comparator|Placebo|Placebo, topical use, two times daily for 12 weeks or until ulcer closes completely or discontinuation due to treatment failure, whichever comes first.
11591203|NCT00709202|Active Comparator|1|Subjects assigned to this arm will receive Betahistine.
11591166|NCT00709501|Experimental|1|"Participants in the intervention condition are encouraged to access the Achieve Together website at least once each week. During each login, the following activities will occur:
~Users will enter their weight and height, how well their plan for a healthy weight has been going, and clarify their goal weight.
~Users will answer questions about each habit they are using to lose weight
~Users will receive automated feedback about each habit and will be encouraged to change or delete habits that are being used but not helpful, more consistently use habits that are helpful but not used being used and to continue to use habits that are helpful and being used consistently.
~Users are encouraged to search for habits that have helped people of similar age and gender to themselves."
11591167|NCT00709501|No Intervention|2|Participants in the control condition will have to wait 12 weeks before accessing the Achieve Together website. These participants will be a given a log where they can document weekly weight measurements (this part did not happen).
11591168|NCT00709488|Experimental|Litx™ BPH Therapy|
11591169|NCT00709475||A|
11591170|NCT00709449|Experimental|1|20 patients with age related macular degeneration
11591171|NCT00709449|Experimental|2|20 patients with primary open angle glaucoma
11591172|NCT00709449|Experimental|3|20 age and sex matched control subjects
11591173|NCT00709436|Experimental|1|PMI-150 (intranasal ketamine) at time 0 and specified time points thereafter.
11591174|NCT00709436|Placebo Comparator|2|Placebo at time 0 and specified time points thereafter.
11591175|NCT00709423|Active Comparator|1|
11591176|NCT00709423|Placebo Comparator|2|
11591177|NCT00709410|Experimental|1|This is a single arm study. All consenting, eligible participants will receive the oral cholera vaccine.
11591178|NCT00709397||Observation|antiretroviral-experienced patients requiring raltegravir to construct an adequately potent antiretroviral regimen.
11591179|NCT00709384|Experimental|Prophylactic intervention|"We performed a prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone). Conduction times between electrodes placed on both sides of the lesions are measured on the second postoperative day. Coronary angiography and electrophysiology study using an electroanatomic mapping system to assess conduction across the line and to try to induce atrial flutter are performed three month after the operation.
~There is only an intervention arm, no control arm"
11591180|NCT00709371|Placebo Comparator|Placebo|Combination tablet containing Zonisamide SR placebo plus bupropion SR placebo SR = Sustained Release
11591181|NCT00709371|Active Comparator|Bupropion 360|Combination tablet containing Zonisamide SR placebo plus bupropion SR 360 mg/day; SR = Sustained Release
11591182|NCT00709371|Active Comparator|Zonisamide 120|Combination tablet containing Zonisamide SR 120 mg/day plus bupropion SR placebo; SR = Sustained Release
11591183|NCT00709371|Active Comparator|Zonisamide 360|Combination tablet containing Zonisamide SR 360 mg/day plus bupropion SR placebo; SR = Sustained Release
11591184|NCT00709371|Experimental|Zonisamide 120/Bupropion 360|Combination tablet containing Zonisamide SR 120 mg/day plus bupropion SR 360 mg/day; SR = Sustained Release
11591185|NCT00709371|Experimental|Zonisamide 360/Bupropion 360|Combination tablet containing Zonisamide SR 360 mg/day plus bupropion SR 360 mg/day; SR = Sustained Release
11591186|NCT00709358|Active Comparator|2|Detection by blood culture
11591187|NCT00709358|Experimental|1|Test LightCycler SeptiFast® (Roche)
11591188|NCT00709345|Experimental|Group Home|Participants will receive cognitive behavioral sessions.
11591189|NCT00709345|Active Comparator|Control|Participants will receive time-matched attention control sessions.
11591190|NCT00709319||Primary|Subjects vitreomacular traction, visual acuity 20/63 to 20/400, retinal thickness >300 microns in the central subfield on OCT, and cataract extraction not being performed in conjunction with vitrectomy.
11591191|NCT00709306|Placebo Comparator|Education|Participants were given a packet of standard skin cancer prevention educational brochures and handouts from major professional organizations to review independently for 10-15 minutes.
11591192|NCT00709306|Active Comparator|Motivational Interviewing|Participants met with a trained counselor who reviewed any personalized feedback of risk derived from the baseline assessments (e.g., history of sunburns, self-reported UV exposure, protective behaviors). Counselors utilized the basic motivational interviewing skills of open-ended questions, reflection of participant statements, affirmations/positive feedback, and summation of major points throughout the discussion. These sessions took about 22 minutes.
11591193|NCT00709306|Active Comparator|UV-detect photos|"Participants were shown a regular black and white photo and a black and white UV-filtered photo of their face. Participants were told that Any dark, spotted, freckled, wrinkled, uneven, or pitted areas indicate existing underlying skin damage that is difficult to reverse. However, protecting the skin from UV radiation can prevent future damage. Participants were asked what they noticed about the photos, what their reactions were, and how this might affect their behavior. These sessions took 12 minutes on average."
11591194|NCT00709306|Experimental|UV-detect photos & MI|Participants met with a trained counselor who reviewed any personalized feedback of risk derived from the baseline assessments (e.g., history of sunburns, self-reported UV exposure, protective behaviors). Counselors utilized the basic motivational interviewing skills of open-ended questions, reflection of participant statements, affirmations/positive feedback, and summation of major points throughout the discussion. In addition to baseline feedback, participants were also interviewed about the black & white and UV-filtered photos of their faces. These sessions took about 25 minutes.
11591195|NCT00709293|Placebo Comparator|1|
11591196|NCT00709293|Active Comparator|2|
11591197|NCT00709280|Experimental|Active treatment group|7% Hypertonic Saline administered via inhalation twice daily for 48 ± 4 weeks
11591198|NCT00709280|Active Comparator|Control group|0.9% Isotonic Saline administered via inhalation twice daily for 48 ± 4 weeks
11591199|NCT00709254|Active Comparator|Treatment Group A|Subjects received an i.v. dose of fentanyl (200 µg)
11591200|NCT00709254|Experimental|Treatment Group B|Subjects received a single dose of 3 mL AeroLEF (500 µg/1 mL)
11591201|NCT00709254|Experimental|Treatment Group C|Subjects received multiple doses of 3 mL AeroLEF (500 µg/1 mL) every 12 hours for a total of five doses over a 3 days
11591202|NCT00709228||PegIntron plus Rebetol|Those with chronic Hepatitis C infected with HCV LVL G1
11591254|NCT00708838||3|
11591255|NCT00708838||4|
11591204|NCT00709202|Placebo Comparator|2|Subjects in this group will received placebo.
11591205|NCT00709176|Experimental|Brief|Dyads randomized to BRIEF arm received the Brief FOCUS Program (two home visits and one phone call by a trained nurse) in addition to standard clinical care.
11591206|NCT00709176|Experimental|Extensive|Dyads randomized to EXTENSIVE arm received the Extensive FOCUS Program (4 home visits and two phone calls by a trained nurse) in addition to standard clinical care.
11591207|NCT00709176|No Intervention|Control|Dyads randomized to CONTROL arm continued with standard clinical care.
11591208|NCT00709163|Active Comparator|1|
11591209|NCT00709163|Placebo Comparator|2|
11591210|NCT00709150|Experimental|1|Patients will receive collaborative depression care management.
11591211|NCT00709150|Active Comparator|2|Patients will receive enhanced usual care.
11591212|NCT00709137|Active Comparator|1|this arm will include patients with resistant hypertension who are on 3 reasonably dosed agents (one being an appropriately dosed diuretic) and spironolactone will be added (dose range 12.5mg-50mg)
11591213|NCT00709137|Active Comparator|2|this arm will include patients with resistant hypertension who are on 3 reasonably dosed agents (one being an appropriately dosed diuretic) and amiloride will be added (dose range 2.5-10mg)
11591214|NCT00709124|Experimental|NMES|60 minute daily NMES sessions every day for the duration of subject's ICU stay.
11591215|NCT00709124|Sham Comparator|Sham|60 minute sham sessions every day for the duration of subjects ICU stay. No voltage will be applied to those receiving sham sessions.
11591216|NCT00709111|Experimental|Maraviroc|Maraviroc (MVC) was taken for 24 weeks, in addition to the subject's current antiretroviral therapy (ART) drug regimen. At week 24, subjects discontinued MVC and were followed for an additional 24 weeks off MVC, but still on current ART drug regimen.
11591217|NCT00709098|Active Comparator|iloprost power 6|iloprost power 15
11591218|NCT00709098|Experimental|iloprost power 15|iloprost power 15
11591219|NCT00709085||1|HCC patients without liver cirrhosis
11591220|NCT00709085||2|HCC patients with liver cirrhosis
11591221|NCT00709072|Experimental|1|SMS reminders
11591222|NCT00709072|No Intervention|2|control group
11591223|NCT00709059||PegIntron Plus Rebetol|Previously untreated patients infected with HCV genotype 1, 4, 5, or 6.
11591224|NCT00709046|Experimental|1|High dose pantoprazole infusion
11591225|NCT00709046|Active Comparator|2|standard dose pantoprazole infusion
11591226|NCT00709033|Experimental|autologous or syngeneic PBTLs and EBV-CTLs|The subject will be assigned a dose of CD19-CD28 chimeric receptor T cells at study entry.
11591227|NCT00709020|Experimental|White Button Mushroom Extract|
11591228|NCT00709007|Experimental|DAART|Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
11591229|NCT00709007|Active Comparator|SAT|Participants take their HIV medications on their own but visit the clinic for opioid agonist substitution therapy.
11591230|NCT00708994|Active Comparator|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.
~Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.
~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
11591231|NCT00708994|Placebo Comparator|Placebo|• Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
11591232|NCT00708981|Active Comparator|Study Group|"Study group will receive multifactorial intervention for advanced diabetic nephropathy:
~Elements of multifactorial intervention:
~BP control of <130/80mmHg and renal protection with reduction of proteinuria to <0.5g/day using therapy with ACE inhibitors and/or ARBs.
~Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.
~Use of hypolipidemic therapy to achieve targets of LDL < 70 mg/dl, HDL > 40/50 mg/dl (M/F)and TG < 200 mg/dl.
~Patient enhanced self-management provided by combined diabetes-renal education curriculum.
~Behavior and social intervention
~Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators."
11591233|NCT00708981|No Intervention|Control Group|Control Group will keep on receiving the usual treatment that they used to receive from their respective clinics and the Diabetes-Renal team would not alter their therapy or interfere in their management.
11591234|NCT00708968|Experimental|FOCUS Intervention|Dyads randomized to this arm received the FOCUS Program, 3 home visits and 2 phone calls by trained nurses.
11591235|NCT00708968|No Intervention|Standard Care|
11591236|NCT00708942|Active Comparator|1|HAL suppository (single administration, HAL 100mg), laser illumination (50J/cm2)
11591237|NCT00708942|Placebo Comparator|2|Placebo suppository (single administration), laser illumination (50J/cm2)
11591238|NCT00708942|No Intervention|3|
11591239|NCT00708942|Active Comparator|4|HAL ointment (5%, 100mg, single administration), LED diode illumination (50J/cm2)
11591240|NCT00708942|Placebo Comparator|5|Placebo ointment (single administration), no illumination
11591241|NCT00708929|Other|1|14 subjects homozygous HH for the Tyr402His single nucleotide polymorphism
11591242|NCT00708929|Other|2|14 subjects homozygous TT for the Tyr402His single nucleotide polymorphism
11591243|NCT00708916|Active Comparator|Apremilast|CC-10004 20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
11591244|NCT00708903|Experimental|1|HKI-272
11591245|NCT00708903|Placebo Comparator|2|Placebo
11591246|NCT00708903|Active Comparator|3|Moxifloxacin
11591247|NCT00708890|Experimental|Intervention group|
11591248|NCT00708890|No Intervention|Control group|Will only get a standard information about TSG group (information about meeting etc.)
11591249|NCT00708877|Experimental|All participants|
11591250|NCT00708851|Active Comparator|NB-UVB Light Device (311-315 nm)|the subject will receive full body NB-UVB light therapy
11591251|NCT00708851|Experimental|LCD Solution with NB-UVB Phototherapy|on half of the body will receive LCD while the full body receives NB-UVB therapy
11591252|NCT00708838||1|
11591253|NCT00708838||2|
11591258|NCT00708812|Active Comparator|The control group|paclitaxel-carboplatin
11591259|NCT00708812|Experimental|The treatment group|paclitaxel-carboplatin plus Endostar
11591260|NCT00708799|Experimental|Arm 1|Standard antibiotic therapy +Azithromycin 500 mg intravenously daily for 5 days
11591261|NCT00708799|No Intervention|Arm 2|Standard antibiotic therapy
11591262|NCT00708773|Experimental|Single Arm|
11591263|NCT00708760||2|web based learning group
11591264|NCT00708760||1|paper based learning group
11591265|NCT00708747|Experimental|B|Patients were randomised to receive a commercially available standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) containing all important transport and inhibitor proteins as well as immunoglobulins
11591266|NCT00708747|Active Comparator|A|Patients were randomised to receive a 5% albumin solution
11591267|NCT00708734|Experimental|Arm 1|functional exercise training
11591268|NCT00708721|Experimental|All patients|All participants enrolled.
11591269|NCT00708708||A|Patients with moderate to severe plaque psoriasis
11591270|NCT00708695||Free Transportation|The 166 families in this treatment condition received free transportation for scheduled prenatal care appointments. This group did not receive any postpartum services or assessments.
11591271|NCT00708695||Transportation, Child Screening/Referral|The 514 families received: 1) free transportation for prenatal care; and 2) child developmental screening and referral services.
11591272|NCT00708695||Prenatal Nurse Home-Visiting|The 230 families received: 1) free transportation for prenatal care; and 2) nurse home-visiting during pregnancy and postpartum (one visit).
11591273|NCT00708695||Nurse Home Visiting through Age 2|The 228 families: 1) free transportation for prenatal care; 2) nurse home-visiting during pregnancy and through child's second birthday; and 3) child developmental screening and referral.
11591274|NCT00708682|Experimental|A|
11591275|NCT00708669|Active Comparator|TAXUS group|
11591276|NCT00708669|Active Comparator|Cypher group|
11591277|NCT00708656|Experimental|1: once daily|Three 800mg tablets of mesalazine (Asacol®) in the morning
11591278|NCT00708656|Active Comparator|2: tds|Mesalazine (Asacol®) 800mg given three times daily
11591279|NCT00708643|Active Comparator|Habitual silicone hydrogel|Habitual contact lens wear.
11591280|NCT00708643|Experimental|narafilcon A|Silicone hydrogel daily disposable contact lens
11591281|NCT00708630|Experimental|1|Provision of extended symptom side effects information
11591282|NCT00708630|No Intervention|2|Standard information on side effects
11591283|NCT00708604|Experimental|1|Islet transplantation
11591284|NCT00708591|Experimental|1|
11591285|NCT00708578|Active Comparator|1|Administration of 4 mg of Glimepiride with Insulin Glargine
11591286|NCT00708578|Active Comparator|2|Administration of 1500 mg of Metformin with Insulin Glargine
11591287|NCT00708578|Experimental|3|Administration of a combination of 4mg Glimepiride plus 1000mg Metformin with Insulin Glargine
11591288|NCT00708552|Experimental|SB-742457 - 15mg|SB-742457 - 15mg
11591289|NCT00708552|Placebo Comparator|Placebo|
11591290|NCT00708552|Experimental|SB-742457 - 35mg|SB-742457 - 35mg
11591291|NCT00708552|Active Comparator|Donepezil|
11591292|NCT00708539|Active Comparator|1|Crinone vaginal gel 8% 90 mg once daily
11591293|NCT00708539|Active Comparator|2|Progesterone mic 400 mg three times daily
11591294|NCT00708526|Experimental|Phase 1 Recovery|Quick Emergence Device is in place for phase 1 anesthesia recovery
11591295|NCT00708526|Other|Standard of care|Tidal volume and respiratory rate are not changed during phase 1 recovery from anesthesia
11591296|NCT00708500|Placebo Comparator|Placebo+PEG2b+RBV, x 44 weeks|Participants in Arm 1 (control) received pegylated interferon alfa 2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by boceprevir placebo + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
11591297|NCT00708500|Experimental|Boceprevir+PEG2b+RBV, Response Guided Therapy|"Participants in Arm 2 (experimental) were assigned either a 36-week or 48-week course of therapy based on their HCV-RNA status at Treatment Week 8.
~PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 32 weeks, then:
~36-week regimen: Participants who have undetectable HCV-RNA at Treatment Week 8 discontinue treatment and enter 36 weeks of post treatment follow-up.
~48-week regimen: Participants who have detectable HCV-RNA at Treatment Week 8 are assigned an additional 12 weeks of therapy, followed by 24 weeks of post treatment follow-up. Placebo replaces boceprevir for the remaining 12 weeks of therapy, and this switch will occur in a blinded fashion."
11591298|NCT00708500|Experimental|Boceprevir+PEG2b+RBV, x 44 weeks|Participants in Arm 3 (experimental) received PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
11591299|NCT00708487|Experimental|1|5% oxygen embryo culture condition
11591300|NCT00708487|Active Comparator|2|21% oxygen embryo culture condition
11591301|NCT00708474|Experimental|OsseoFit™|Treatment of bone graft site with OsseoFit™ Porous Tissue Matrix™.
11591302|NCT00708474|No Intervention|Open|Treatment of bone graft site without OsseoFit™ Porous Tissue Matrix™.
11591303|NCT00708461|Experimental|Worksite Environmental Intervention|Changes to healthy food availability, physical activity opportunities and promotion, body weight scale access, and media enhancements to target weight gain prevention
11591304|NCT00708461|No Intervention|No-contact control|No-treatment control condition. Worksites were offered program materials upon completion of programs at intervention sites.
11591305|NCT00708448|Experimental|All patients|All participants enrolled.
11591306|NCT00708435|Experimental|Beriplex® P/N|
11591307|NCT00708435|Active Comparator|Fresh frozen plasma|
11591308|NCT00708422|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
11591309|NCT00708422|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
11591310|NCT00708409||1|Autograft operations with the subcoronary technique
11591311|NCT00708409||2|Autograft operations with the root replacement technique
11591312|NCT00708396|Experimental|Patients|Patients which diagnosed as OCD and schizophrenia
11591313|NCT00708383|Experimental|1|Embryo culture medium supplemented with 0.5% HSA and 10% SSS
11591314|NCT00708383|Active Comparator|2|Embryo culture medium supplemented with 0.5% HSA only
11591315|NCT00708370|Active Comparator|COACH|
11591316|NCT00708370|Placebo Comparator|Standard Care|
11591317|NCT00708357|Other|1|homozygous mutant: CC allele of the eNOS T-786C gene
11591318|NCT00708357|Other|2|homozygous mutant: TT allele of the eNOS T-786C gene
11591319|NCT00708344|Active Comparator|Group 1|Usual elective titration regimen
11591320|NCT00708344|Active Comparator|Group 2|Active elective titration regimen
11591321|NCT00708331|Experimental|1|
11591322|NCT00708318|Experimental|A, B, C|
11591323|NCT00708305|Experimental|NaF toothpaste (1450 parts per million [ppm] fluoride [F])|Participants brushed for one timed minute with 1.6g of NaF/silica and 0.4 percent carbopol toothpaste containing 1450ppmF as NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
11591324|NCT00708305|Active Comparator|NaF toothpaste (1400ppmF)|Participants brushed for one timed minute with 1.6g of NaF toothpaste containing 1400ppmF as NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
11591325|NCT00708305|Active Comparator|Sodium monofluorophosphate (NaMFP)/ NaF toothpaste (1450ppmF))|Participants brushed for one timed minute with 1.6g of NaMFP/NaF toothpaste containing 1450ppmF from NaMFP and NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
11591326|NCT00708305|Placebo Comparator|Placebo toothpaste (0ppmF)|Participants brushed for one timed minute with 1.6g of fluoride free toothpaste. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
11591327|NCT00708292|Experimental|Single Agent AUY922|
11591328|NCT00708292|Experimental|AUY922 + Bortezomib|
11591329|NCT00708292|Experimental|AUY922 + Bortezomib + Dexamethasone|
11591330|NCT00708279|Experimental|A|After establishing a baseline for the first 4 weeks of trial involvement, thereby providing their own control group, all participants begin the intervention phase of osteopathic manipulation.
11591331|NCT00708266|Placebo Comparator|V2|28 hours continuous saline venous infusion.
11591332|NCT00708266|Experimental|V3|28 hours continuous lipid-heparin venous infusion.
11591333|NCT00708253|Active Comparator|SBE|
11591334|NCT00708253|Active Comparator|DBE|
11591335|NCT00708240|Experimental|Escitalopram|
11591336|NCT00708227||Whites ADRB2:ARG16ARG|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
11591337|NCT00708227||Whites ADRB2:GLY16GLY|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
11591338|NCT00708227||African American ADRB2:ARG16ARG|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
11591339|NCT00708227||African American ADRB2:GLY16GLY|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
11591340|NCT00708214|Experimental|BIBW 2992|To study BIBW 2992 in association with letrozole in hormonoresistant metastatic breast cancer
11591341|NCT00708214|Other|Letrozole|Hormonotherapy for metastatic breast cancer
11591342|NCT00708201|Experimental|Alvimopan|"12 milligrams (mg)
~Alvimopan, 12mg, capsule. Administered orally. One 30 minutes to 5 hours before the scheduled start of surgery on Day 0, and twice daily beginning on Postoperative Day 1 (POD 1) until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment"
11591343|NCT00708201|Placebo Comparator|Placebo|"300 mg polyethylene glycol in a capsule
~Administered orally at least 30 minutes and no later than 5 hours before the scheduled start of surgery on Day 0. On Day 1, a single dose of placebo was given twice a day for a maximum of 7 days in hospital after surgery."
11591344|NCT00708188|Experimental|Multidetector raw CT|
11591345|NCT00708175|Experimental|Pioglitazone|
11591346|NCT00708175|Placebo Comparator|Placebo|
11591347|NCT00708162|Experimental|Elvitegravir|"EVG 85 mg or 150 mg + RAL placebo + background regimen in the Randomized Phase, followed by EVG 85 mg or 150 mg + background regimen in the Open-Label Phase.
~Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their background regimen will receive EVG 85 mg; all other participants will receive EVG 150 mg."
11591348|NCT00708162|Active Comparator|Raltegravir|"RAL 800 mg (400 mg twice daily) + EVG placebo + background regimen in the Randomized Phase, followed by EVG 85 mg or 150 mg + background regimen in the Open-Label Phase.
~Participants receiving LPV/r or ATV/r as part of their background regimen in the Open-Label Phase will receive EVG 85 mg; all other participants will receive EVG 150 mg."
11591349|NCT00708149|Active Comparator|1|lansprazole 30 mg qd from NG route or orally
11591350|NCT00708149|Placebo Comparator|2|control group without any PPI, H2 blockers or other medications for treating peptic ulcers.
11591351|NCT00708123|Active Comparator|Sodium Fluoride (NaF) toothpaste[1350 parts per million(ppm)F]|Participants to brush their natural teeth twice daily with a full ribbon of NaF toothpaste (1350 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
11591352|NCT00708123|Experimental|NaF/Carbopol toothpaste (1400 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaF and 0.5% carbopol toothpaste (1450 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
11591353|NCT00708123|Active Comparator|NaMFP/NaF toothpaste (1450 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaMFPand NaF toothpaste (1450 ppm F - 1000 ppm F as NaMFP and 450 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
11591354|NCT00708123|Active Comparator|NaF toothpaste (250 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaF toothpaste (250 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
11591414|NCT00707785|Placebo Comparator|4|NEC - Placebo
11591355|NCT00708123|Placebo Comparator|Placebo toothpaste (0 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of fluoride free toothpaste (0 ppm F) for one timed minute, after removing their partial denture from their mouth.
11591356|NCT00708110|Experimental|Treatment A|GSK1349572 2 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
11591357|NCT00708110|Experimental|Treatment B|GSK1349572 10 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
11591358|NCT00708110|Experimental|Treatment C|GSK1349572 50 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
11591359|NCT00708097|Experimental|NaF toothpaste(1450 ppmF)|Study toothpaste containing 1450 ppm F as NaF and 0.4% carbopol as excipient.
11591360|NCT00708097|Active Comparator|NaF toothpaste (1400 ppmF)|Study toothpaste containing 1400 ppm F as NaF
11591361|NCT00708097|Active Comparator|NaMFP/NaF toothpaste (1450 ppmF)|Reference toothpaste containing 1000 ppm F as NaMFP and 450 ppm F as NaF
11591362|NCT00708097|Active Comparator|NaF toothpaste (675 ppmF)|Study toothpaste containing 675 ppm F as NaF
11591363|NCT00708097|Placebo Comparator|Placebo toothpaste (0 ppmF)|Fluoride free placebo toothpaste (0 ppm F)
11591364|NCT00708084|Experimental|A|CL184 combined with rabies vaccination
11591365|NCT00708084|Active Comparator|B|HRIG combined with rabies vaccination
11591366|NCT00708071|Experimental|1|One side of the face is treated with FS VH S/D 4; the other side of the face is treated using standard of care.
11591367|NCT00708045|Experimental|All patients|All participants enrolled.
11591368|NCT00708032|Other|spectacles|habitual spectacles worn daily for 12 months
11591369|NCT00708032|Experimental|narafilcon A soft contact lenses|narafilcon A soft contact lenses worn as daily disposable for 12 months
11591370|NCT00708019|Experimental|Low dose|Low dose of the psychoeducational intervention (i.e., 8.0 hours with the intervention nurse over 10 weeks)
11591371|NCT00708019|Experimental|High dose|High dose of the psychoeducational intervention (i.e., 12.3 hours with the intervention nurse over 10 weeks)
11591372|NCT00708006|Experimental|1|HGS1029
11591373|NCT00707993|Experimental|Alogliptin 25 mg QD|
11591374|NCT00707993|Active Comparator|Glipizide 5 mg QD|
11591375|NCT00707980|Experimental|Vortioxetine|Vortioxetine 2.5 mg, 5 mg or 10 mg, encapsulated tablets, orally, once daily for up to 52 weeks. For the first week of treatment all participants received 5 mg/day vortioxetine, thereafter, the dose could be increased to 10 mg/day or decreased to 2.5 mg/day, based on participant's response and tolerability as judged by the investigator.
11591376|NCT00707967|Experimental|Group A|Subjects receiving the candidate vaccine
11591377|NCT00707967|Placebo Comparator|Group B|Subjects receiving the adjuvant
11591378|NCT00707967|Placebo Comparator|Group C|Subjects receiving physiological saline
11591379|NCT00707954|Experimental|TA-7284|
11591380|NCT00707954|Placebo Comparator|Placebo of TA-7284|
11591381|NCT00707941|Experimental|1|Oseltamivir for 5 days for patients with illness duration < 48 hours
11591382|NCT00707941|Placebo Comparator|2|Placebo for 5 days for patients with illness duration < 48 hours
11591383|NCT00707941|Experimental|3|Oseltamivir for 5 days for patients with illness duration ≥ 48 hours
11591384|NCT00707941|Placebo Comparator|4|Placebo for 5 days for patients with illness duration ≥ 48 hours
11591385|NCT00707928|Active Comparator|1|1=nitroglycerine 100 microgram intravenous100-200 microgram of IV.
11591386|NCT00707928|Placebo Comparator|2|2=placebo with the same volume as NTG 100-200 microgram of IV.
11591387|NCT00707915|Experimental|Dose reduction|The benzodiazepine dose will be discontinued in 4 weeks by a weekly 25% reduction. Participants will be observed for 8 weeks.
11591388|NCT00707902|Active Comparator|2|"Drug: Echinacea/sage
~patients received additionally a placebo-spray for the synthetical comparator (chlorhexidine/lidocaine) as the study was double dummy blinded.
~Patients had to apply spray every 2 hours with two puffs to the pharyngeal area up to a maximum of 10 times daily. Treatment duration was until illness was resolved or for a maximum of 5 consecutive days.
~Arms: 1"
11591389|NCT00707902|Active Comparator|1|"Drug: Chlorhexidine/lidocaine
~patients received additionally a placebo-spray for the synthetical comparator (echinacea/sage) as the study was double dummy blinded.
~Patients had to apply spray every 2 hours with two puffs to the pharyngeal area up to a maximum of 10 times daily. Treatment duration was until illness was resolved or for a maximum of 5 consecutive days."
11591390|NCT00707889|Active Comparator|A|Open-label to Bevacizumab plus mFOLFOX6
11591391|NCT00707889|Active Comparator|B|Open-label to High-dose ABT-869 arm plus mFOLFOX6
11591392|NCT00707889|Active Comparator|C|Open-label to low-dose ABT-869 arm plus mFOLFOX6
11591393|NCT00707876|Experimental|1|Dose 1 versus non-contrast MRA
11591394|NCT00707876|Experimental|2|Dose 2 versus non-contrast MRA
11591395|NCT00707876|Experimental|3|Dose 3 versus non-contrast MRA
11591396|NCT00707863|Other|Depressed Subjects Age: 18 - 25 yrs|Subjects receiving Escitalopram (trade name: Lexapro) that are in the age range of 18-25
11591397|NCT00707863|Other|Depressed Subjects Age: 16 - 50 yrs|Subjects receiving Escitalopram (trade name: Lexapro) in the age range of 26-50
11591398|NCT00707850|Experimental|1|Thalassemic Patients with HCV
11591399|NCT00707837|Experimental|Infant Formula|Preterm infant formulas containing lipid soluble compounds
11591400|NCT00707837|Active Comparator|Preterm formulas|Standard preterm infant formula and discharge formulas
11591401|NCT00707824|Placebo Comparator|1|1= placebo
11591402|NCT00707824|Active Comparator|2|2=nalbuphine 5 mg
11591403|NCT00707824|Active Comparator|3|3=nalbuphine 10 mg
11591404|NCT00707798|Experimental|Formulation 1|
11591405|NCT00707798|Experimental|Formulation 2|
11591406|NCT00707798|Experimental|Formulation 3|
11591407|NCT00707798|Experimental|Formulation 4|
11591408|NCT00707798|Experimental|Formulation 5|
11591409|NCT00707798|Experimental|Formulation 6|
11591410|NCT00707798|Active Comparator|23 valent pneumococcal vaccine|
11591411|NCT00707785|Experimental|1|Sepsis - vitamin A
11591412|NCT00707785|Placebo Comparator|2|Sepsis - placebo
11591415|NCT00707772|Active Comparator|1|Genotype 2 or 3 in Hemophilic Patients with HCV
11591416|NCT00707772|Active Comparator|2|Other Genotypes (except 2 or 3) in Hemophilic Patients with HCV
11591417|NCT00707759|Experimental|A: withdrawal steroids|"Arms A: TAC + MMF + withdrawal steroids over a six-days following randomization.
~1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses
~2ºday: Methylprednisolone iv, 2-3 mg/kg/d 3 doses
~3°day: Prednisone 2 mg/kg/d in 2 doses
~4ºday: Prednisone 1 mg/kg/d in 2 doses
~5ºday: Prednisone 0.5 mg/kg/d in 2 doses
~6ºday: Prednisone 0.25 mg/kg/d in 2 doses
~7ºday: Stop Prednisone"
11591418|NCT00707759|Active Comparator|B|"Arms B: TAC + MMF + prednisolone (see schedule)/day
~10°days after Tx: 2 mg/kg/d
~Day 11 - 20: 1 mg/kg/d
~Day 21 - 30: 0.5 mg/kg/d
~Day 31 - 60: 0.3 mg/k/d
~Week 8 - 12: 0.25 mg/k/d
~Week 12 - 16: 0.20 mg/k/d
~Week 16 - 20: 0.15 mg/k/d
~Month 6 - 12: 0.10 - 0.12 mg/k/d"
11591419|NCT00707746|Placebo Comparator|Placebo|1 mL placebo saline, weekly subcutaneous injections for 26 weeks
11591420|NCT00707746|Experimental|Mipomersen|200 mg (1 mL), weekly subcutaneous injections for 26 weeks
11591421|NCT00707720|Experimental|TERIS procedure|TERIS procedure for the treatment of obesity
11591422|NCT00707707|Experimental|1|paclitaxel + AZD2281
11591423|NCT00707694||Probands|Ashkenazi Jews ages 95 and older
11591424|NCT00707694||Offspring|Ashkenazi Jewish offspring of Ashkenazi Jewish parent(s) who lived to at least the age of 95
11591425|NCT00707694||Controls|Ashkenazi Jewish people with no family history of longevity
11591426|NCT00707681|Active Comparator|I|MS-20
11591427|NCT00707681|Placebo Comparator|2|Placebo
11591428|NCT00707668||Control|Chung-ju cohort populations aged over 30 year-old
11591429|NCT00707655|Experimental|Zalutumumab 4 mg/kg|Zalutumumab in combination with radiotherapy for 8 weeks. The treatment period of 8 weeks is followed by a 3 week follow-up period where all adverse events are collected and then additionally a 2 year follow-up period where only serious adverse events are collected.
11591430|NCT00707655|Experimental|Zalutumumab 8 mg/kg|Zalutumumab in combination with radiotherapy for 8 weeks. The treatment period of 8 weeks is followed by a 3 week follow-up period where all adverse events are collected and then additionally a 2 year follow-up period where only serious adverse events are collected.
11591431|NCT00707642|Experimental|1|Low Dose WN-80E API (5 µg) + Alhydrogel (3.5 mg)
11591432|NCT00707642|Experimental|2|Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)
11591433|NCT00707642|Experimental|3|High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)
11591434|NCT00707642|Experimental|4|High Dose WN-80E API (50 µg), no adjuvant
11591435|NCT00707629||Insulin Pump Therapy|Children on insulin pumps for at least three years. Subjects must have type 1 diabetes for at least five years and diagnosed under the age of 5.
11591436|NCT00707616||A|Subjects without type 2 diabetes living in Olmsted County, MN
11591437|NCT00707603||Hepatitis C subjects|Due to start therapy for Hepatitis C
11591438|NCT00707603||Controls|Healthy males
11591439|NCT00707590|Experimental|Part A|"A: BMS-767778, Oral Solution, Oral, 1 mg, once daily, 1 day OR Placebo Comparator, Oral Solution, Oral, 0 mg, once daily, 1 day
~B: BMS-767778, Oral Solution, Oral, 3 mg, once daily, 1 day OR Placebo Comparator, Oral Solution, Oral, 0 mg, once daily, 1 day
~C: BMS-767778, Capsules, Oral, 10 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day
~D: BMS-767778, Capsules, Oral, 30 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day
~E: BMS-767778, Capsules, Oral, 100 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day
~F: BMS-767778, Capsules, Oral, 300 mg, once daily, 2 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 2 days
~G: BMS-767778, Capsules, Oral, 600 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day"
11591440|NCT00707590|Experimental|Part B|"A: BMS-767778, Capsules, Oral, 10 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days
~B: BMS-767778, Capsules, Oral, 30 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days
~C: BMS-767778, Capsules, Oral, 100 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days
~D: BMS-767778, Capsules, Oral, 300 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days
~E: BMS-767778, Capsules, Oral, 600 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days"
11591441|NCT00707590|Experimental|Part C|"A: BMS-767778, Capsules, Oral, Adaptive design (between 10 to 600 mg), 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, 14 days
~B: BMS-767778, Capsules, Oral, Adaptive design (between 10 to 600 mg), 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, 14 days"
11591442|NCT00707577|Experimental|Internet-based maintenance program|9-month Internet based self-monitoring maintenance program to track weight, exercise, and food logs
11591443|NCT00707577|No Intervention|Control|No maintenance program provided
11591444|NCT00707564|Experimental|1|HemCon Dental Dressing
11591445|NCT00707564|Active Comparator|2|Gauze with pressure
11591446|NCT00707551|Experimental|1|Ketoconazole tablet + AZD1305 Extended Release tablet
11591447|NCT00707551|Experimental|2|Verapamil Extended Release tablet + AZD1305 Extended Release tablet
11591448|NCT00707551|Experimental|3|AZD1305 Extended Release tablet
11591449|NCT00707538|Experimental|1|
11591450|NCT00707525|No Intervention|1|Natural cycle oocyte donation
11591451|NCT00707525|Active Comparator|2|"Stimulated cycle oocyte donation.
~Long protocol down-regulation with a GnRH agonist, starting on the midluteal phase of the previous cycle with leuprolide acetate (0.2mg/day).
~Once evidence of downregulation is documented, leuprolide will be halved to 0.1 mg daily.
~COH with be carried on with gonadotropins (150UI/day of rFSH and 75 UI/day of HP-hMG). The dose can be adjusted according to ovarian response as judged by ultrasound and by serum oestradiol (E 2 ) concentrations."
11591452|NCT00707499|Experimental|1|
11591453|NCT00707486|Experimental|Hemcon Dental Dressing|The HemCon® Bandage is an FDA-cleared chitosan-based flat bandage that controls severe arterial bleeding from traumatic injuries. In comparison to traditional bandages, the HemCon® Bandage provides superior control of bleeding, wound site adhesiveness, multiple injury site usage, biocompatibility and provides a barrier to infective agents.
11591492|NCT00707213|Other|1|
11591493|NCT00707200||1|Cases: Severe inpatient malaria, survivors or decedents. Severe malaria consists of any one or combination of severe malarial anemia (SMA), cerebral malaria (CM), lactic acidosis (LA), or a respiratory distress syndrome with hypoxia.
11591454|NCT00707486|Active Comparator|Gauze with pressure and/or Gelfoam|Post operative care for oral surgery subjects consists of the subject biting on sterile cotton gauze to provide pressure to the extraction site. A common alternative practice involves the placement of Gelfoam (with or without antibiotic/steroid medication) into the extraction socket prior to application of the sterile gauze pressure dressing. This treatment was chosen as the study control to compare the HemCon Dental Dressing to the standard of care for oral surgery subjects, including the use of cotton gauze and/or Gelfoam to control post operative bleeding.
11591455|NCT00707473|Experimental|Treatment (docetaxel, cisplatin, and fluorouracil)|"INDUCTION CHEMOTHERAPY: Patients receive docetaxel IV over 1 hour on day 1, cisplatin IV over 30-180 minutes or carboplatin IV on day 1, and fluorouracil IV continuously on days 1-4. Cycles repeat every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
~Patients who achieve CR or PR receive 1 additional course of treatment and undergo chemoradiotherapy over 6-7 weeks. Patients who have SD or PD to induction therapy, or less than a complete response to chemoradiotherapy undergo surgery and radiation therapy."
11591456|NCT00707460|Active Comparator|1|Please, see design section for details.
11591457|NCT00707460|Experimental|2|"Traditional Diet
~Please, see design section for details."
11591458|NCT00707460|Experimental|3|"Healthy Store-bought Diet
~Please, see design section for details."
11591459|NCT00707447|Placebo Comparator|1/Control|Control group received written information about diabetes risks with instructions about healthy eating and increasing physical exercise
11591460|NCT00707447|Experimental|2/PREDIAS|Intervention consists of a group programme (PREDIAS) aiming at modification of lifestyle
11591461|NCT00707434|Experimental|Glucose Monitoring Device|Continuous glucose monitoring in critically ill patients.
11591462|NCT00707421|Placebo Comparator|1|placebo, artificial tears
11591463|NCT00707421|Active Comparator|3|corticosteroid , CS
11591464|NCT00707421|Active Comparator|2|non-steroidal anti-inflammatory drug, NSAID
11591465|NCT00707382|Other|Genotyping for CYP4502D6 and 2C19 polymorphisms|"In this study arm (1) the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment in accordance with the current guidelines from Sct. Hans hospital. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described in the clinical guidelines."
11591466|NCT00707382|Other|(2) Intense clinical monitoring|In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
11591467|NCT00707382|No Intervention|(3) Control|In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
11591468|NCT00707369|Experimental|test|Mechanical debridement plus 500 mg amoxicillin and 400 mg metronidazole three times daily for 7 days. Supportive periodontal therapy in 3-month intervals.
11591469|NCT00707369|Placebo Comparator|control|Mechanical debridement plus two placebo tablets three times daily for 7 days. Supportive periodontal therapy in 3-month intervals.
11591470|NCT00707356|Experimental|WST11(TOOKAD® Soluble)|Treatment with WST11-mediated VTP
11591471|NCT00707343|Experimental|All patients|All participants enrolled.
11591472|NCT00707330|Experimental|1|Subjects randomised to this arm will first be treated with Clarithromycin for a week, then have a 2-week washout, and finally one week of no treatment
11591473|NCT00707330|Active Comparator|2|Subjects randomised to this arm will first receive one week of no treatment, then have a 2-week washout, and finally be treated with Clarithromycin for a week
11591474|NCT00707317||1|HIV infected individuals
11591475|NCT00707317||2|patients with chronic renal failure
11591476|NCT00707317||3|patients after solid organ transplantation (lung, liver, kidney, kidney-pancreas)
11591477|NCT00707317||4|patients with rheumatoid arthritis
11591478|NCT00707317||5|stem cell transplant recipients
11591479|NCT00707317||6|immunocompromised patients with confirmed tuberculosis
11591480|NCT00707317||7|immunocompetent controls with no known risk of exposure or tuberculosis
11591481|NCT00707304|Experimental|1|Talactoferrin alfa (talactoferrin or TLF, also known as recombinant human lactoferrin, rhLF or talactoferrinum alfa) is a recombinant version of the glycoprotein expressed in and purified from Aspergillus niger var. awamori. Talactoferrin is structurally and functionally similar to native human lactoferrin. The structural equivalence of talactoferrin to native human lactoferrin has been demonstrated by a comparison of the 3-dimensional structure, molecular weight, biological activity and other physicochemical properties, and is known to differ only in the nature of glycosylation.
11591482|NCT00707304|Placebo Comparator|2|Placebo contains the same phosphate-based buffer used as the diluent for the talactoferrin solution. In addition, the placebo will contain FD&C/EU grade dyes suitable for oral use to mimic the color of the vialed drug product.
11591483|NCT00707278|Experimental|All patients|All participants enrolled.
11591484|NCT00707265|Experimental|Investigational|Open bilateral posterolateral implantation of the rhBMP-2/CRM/CD HORIZON® Spinal System.
11591485|NCT00707265|Active Comparator|Control|The bilateral posterolateral implantation of the autogenous bone harvested from the iliac crest with the CD HORIZON® Spinal System.
11591486|NCT00707252|Experimental|Phase I/II|Phase I: Polyphenon E + Erlotinib - Polyphenon E 200, 400 and 800 mg/day dose levels evaluated in a step-wise manner with Erlotinib 150 mg/day to establish Maximum Tolerated Dose (MTD) of Polyphenon E. Phase II consists of MTD of Polyphenon E established in Phase I, administered alone for two weeks and thereafter together with Erlotinib 150 mg/day.
11591487|NCT00707239|Experimental|A|
11591488|NCT00707239|Experimental|B|
11591489|NCT00707239|Active Comparator|C|
11591490|NCT00707226||1|15 patients with primary open angle glaucoma
11591491|NCT00707226||2|15 age matched healthy subjects
11591494|NCT00707200||2|Controls: Controls consist of mildly-affected children with P falciparum malaria who are either managed as inpatients or outpatients.
11591495|NCT00707187|Experimental|1|35 doses of study medication, IC 351 (20 mg) -- crossover to placebo
11591496|NCT00707187|Experimental|2|35 placebo pills followed with 35 study medication (20 mg)
11591497|NCT00707174|Active Comparator|1|"Topical imiquimod group:
~treat the LM site two centimeters beyond the perimeter margin with topical imiquimod 5% cream Monday thru Friday of each week for a total of twelve weeks. After three months of topical treatment, a one-month wash out period will be observed to allow for resolution of inflammation that can obscure the pathologist's ability to evaluate the excised tumor/treatment site."
11591498|NCT00707174|Experimental|2|"Topical imiquimod and topical tazarotene 0.1% cream group:
~Patients randomized to this group will undergo an identical treatment protocol as the topical imiquimod group with the addition of topical tazarotene 0.1% cream on Saturday and Sunday of each week."
11591499|NCT00707161|Experimental|All participants|
11591500|NCT00707148|Active Comparator|Group 2: Control|16 pregnant women to receive: antepartum: saline; postpartum; Tdap vaccine.
11591501|NCT00707148|Experimental|Group 1: Intervention|32 pregnant women to receive: antepartum: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) vaccine; postpartum: saline.
11591502|NCT00707148|Active Comparator|Group 3: Control|32 non-pregnant women to receive a single dose of Tdap vaccine.
11591503|NCT00707135|Experimental|1|
11591504|NCT00707122|Other|1, Albumin and Crystalloids|Treatment
11591505|NCT00707122|Other|2, Crystalloids|Control
11591506|NCT00707083|Active Comparator|Standard- or Intermediate-Risk Maintenance Arm I|Patients receive oral mercaptopurine and oral methotrexate on days 1-56, dexamethasone IV on days 1-5 and 29-33, vincristine IV on days 1 and 29, and methotrexate IT on day 50. Treatment repeats every 8 weeks for up to 8 (girls)-11 (boys) courses.
11591507|NCT00707083|Experimental|Standard- or Intermediate-Risk Maintenance Arm II|Patients receive oral mercaptopurine once daily on days 8-28 and 36-56; oral methotrexate once on days 8,15, 22, 36, 43, and 50; dexamethasone IV on days 1-5 and 29-33; and vincristine IV on days 1 and 29. Patients also receive methotrexate IT on day 1, every 8 weeks, for 8 courses.
11591508|NCT00707070|Experimental|1|efalizumab 1 mg/kg/week subcutaneous plus acitretin 0.4 mg/kg/day oral
11591509|NCT00707070|Placebo Comparator|2|efalizumab 1 mg/Kg/week subcutaneous plus oral placebo
11591510|NCT00707057|Experimental|Ibuprofen 600 mg ER group|One-hundred and sixty subjects will be randomly assigned to the Ibuprofen 600 mg ER treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).
11591511|NCT00707057|Placebo Comparator|Placebo group|Eighty subjects will be randomly assigned to the Placebo treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).
11591512|NCT00707044|Experimental|A|Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
11591513|NCT00707044|Active Comparator|B|control group, care as usual, 24 hours intensive care stay
11591514|NCT00707031|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
11591515|NCT00707031|Active Comparator|Exenatide|1-step initiation regimen of exenatide: 5 mcg twice daily (BID) for 4 weeks, followed by 10 mcg BID up to the end of treatment.
11591516|NCT00707018|Experimental|External rotation shoulder sling|External rotation shoulder sling
11591517|NCT00707018|Active Comparator|Internal rotation shoulder sling|Internal rotation shoulder sling
11591518|NCT00706992|Experimental|Arm I - Adj-4 A2 F5 cells|Patients receive anti-MART-1 F5 TCR-transduced peripheral blood lymphocytes (PBLs) intravenously (IV) over 20-30 minutes on day 0. 1 x 10e9 to 5 x 10e10 IV.
11591519|NCT00706992|Experimental|Arm II-Adj-4 A2 F5 cells + MART-1:26-35(27L) Peptide|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I and MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 subcutaneously (SC) on days 0 and 30. 1 x 10e9 to 5 x 10e10 IV + 1.0 mg peptide subcutaneously.
11591520|NCT00706992|Experimental|Arm III-Adj-4 A2 F5 cells + SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I and aldesleukin SC on days 0-4. 1 x 10e9 to 5 x 10e10 IV + IL-2 (based on body weight) 125,000 IU/kg/day subcutaneously.
11591521|NCT00706992|Experimental|Arm IV-Adj-4 A2 F5 cells + MART-1:26-35(27L) Peptide+SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I, MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 as in arm II, and aldesleukin as in arm III. 1 x 10e9 to 5 x 10e10 IV + 1.0 mg peptide subcutaneously + IL-2 (based on body weight) 125,000 IU/kg/day subcutaneously.
11591522|NCT00706992|Experimental|Arm V-Adj-4 A2 F5 cells + ALVAC MART-1:26-35(27L) Vaccine|Patients receive anti-MART-1 F5 TCR-transduced PBLs IV over 20-30 minutes on day 0, and ALVAC-MART-1 vaccine SC on days 0 and 14. 1 x 10e9 to 5 x 10e10 IV + ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL).
11591523|NCT00706992|Experimental|Arm VI-Adj-4 A2 F5 cells + ALVAC MART-1 VAccine + SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs and ALVAC-MART-1 vaccine as in arm V, and low-dose aldesleukin SC on days 0-4. 1 x 10e9 to 5 x 10e10 IV + ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL)+ 125,000 IU/kg/day subcutaneously.
11591524|NCT00706992|Experimental|Arm VII-Adj-4 A2 ALVAC MART-1:26-35(27L) Vaccine|Patients receive ALVAC-MART-1 vaccine SC on days 0 and 14. ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL).
11591525|NCT00706979|Experimental|1|Practice Quit Attempt plus Nicotine Replacement Therapy
11591526|NCT00706979|Active Comparator|2|Practice Quit Attempt only
11591527|NCT00706966|Experimental|Dutasteride|Dutasteride was administered at a dose of 3.5 mg as an oral soft gelatin capsule once daily for 6 months
11591528|NCT00706953|Active Comparator|001|
11591529|NCT00706914|Experimental|Once-daily aclidinium/formoterol|Aclidinium bromide 200 µg/ formoterol fumarate 12 µg fixed-dose combination (FDC) once-daily in the morning, plus placebo once-daily in the evening
11591577|NCT00706654|Experimental|Aripiprazole depot 25 or 50 mg|Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.
11591530|NCT00706914|Experimental|Morning aclidinium/formoterol plus evening formoterol|Aclidinium bromide 200 µg/formoterol fumarate 12 µg FDC once-daily in the morning, plus formoterol fumarate 12µg once-daily in the evening
11591531|NCT00706914|Active Comparator|Formoterol BID|Formoterol fumarate 12 µg twice-daily (BID)
11591532|NCT00706901|Experimental|Arm 1 GMI|Patients randomized to GMI received four structured 75-minute sessions consistent with the central principles and style of motivational interviewing (Miller & Rollnick, 2012). The goal of MI is to develop a sense of discrepancy between personal goals and current behavior and enhance change talk among participants, particularly for taking responsibility of one's substance use and being proactive for remaining in treatment.
11591533|NCT00706901|Experimental|Arm 2 IHMD|Participants randomized to In-Home-Messaging Devices (IHMD) received a 27-day Care Coordination Home Telehealth (CCHT) program targeting their acute recovery from alcohol and other substance use disorder. Participants received their IHMD device through the Charleston VAMC CCHT program, including device accessories and a phone number to reach their CCHT provider. They were provided with specific instructions on how to set up their IHMD in their residence after discharge. The research associate followed-up with the patient one day after receiving the device to ensure that the device was successfully set up and to provide assistance as necessary. Participants received standard VA CCHT services.
11591534|NCT00706901|Active Comparator|Arm 3 TCC|Participants randomized to the Treatment Control Condition (TCC) received a psycho-educational group (e.g., addiction as a chronic disease, relapse prevention, developing a plan to prevent relapse) that was delivered with the aid of sequential standardized PowerPoint presentations. Group members were encouraged to ask questions and make comments. Therapists were encouraged to conduct the sessions using an instructional quality that minimized the use of GMI strategies. TCC consisted of four sessions, lasting 75 minutes, and was conducted on four consecutive days within the course of one week.
11591535|NCT00706888|Active Comparator|1|Female with active product
11591536|NCT00706888|Active Comparator|2|Male with active product
11591537|NCT00706888|Placebo Comparator|3|Female with placebo
11591538|NCT00706888|Placebo Comparator|4|Male with placebo
11591539|NCT00706875||1|30 patients survived GTD post treatment for 0 - 5 years.
11591540|NCT00706875||2|30 patients survived GTD post treatment 6 - 10+ years.
11591541|NCT00706862|Experimental|1|Talactoferrin, Carboplatin, Paclitaxel
11591542|NCT00706862|Placebo Comparator|2|Placebo, Carboplatin, Paclitaxel
11591543|NCT00706849|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
11591544|NCT00706849|Placebo Comparator|Placebo|Participants received a placebo subcutaneous injection once a week for 26 weeks.
11591545|NCT00706836|Active Comparator|Pregabalin 50 mg|Pregabalin oral tablets (50 mg)
11591546|NCT00706836|Active Comparator|Pregabalin 200 mg|Pregabalin oral tablets (200 mg)
11591547|NCT00706836|Placebo Comparator|Placebo|Placebo
11591548|NCT00706823|Experimental|i-gel-SGA|Patients who received i-gel supraglottic device (i-gel airway) for intubation
11591549|NCT00706823|Active Comparator|LMA-Unique|Patients who received the Laryngeal Mask Airway-Unique (uLMA) for intubation
11591550|NCT00706810|Experimental|All participants|
11591551|NCT00706797|Active Comparator|Usual care|Utilized Disease-Modifying Antirheumatic Drugs (DMARDs) from a list of the 6 most commonly prescribed in the participating countries (Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, cyclosporine A and gold).
11591552|NCT00706797|Active Comparator|ETN + MTX|Etanercept (ETN) 50 milligrams (mg) sub-cutaneous (SC) injection once weekly (pre-filled syringe) plus continuation of current dose of Methotrexate (MTX) either oral (PO), SC, or intramuscular (IM).
11591553|NCT00706784|Experimental|A|
11591554|NCT00706771|Active Comparator|Sodium bicarbonate|sodium bicarbonate: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr
11591555|NCT00706771|Active Comparator|Sodium chloride|sodium chloride: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr
11591556|NCT00706758|Active Comparator|1|Structured patients group intervention - IBS school
11591557|NCT00706758|Active Comparator|2|Written information - IBS-guidebook
11591558|NCT00706745|Placebo Comparator|placebo|The control oil is based on the general fat consumption in a Western population and consists of an equal amount (4 gr) of fat. It is a blend of palm (80%) and soybean oil (20%). Two capsules will be taken in the morning and two in the evening.
11591559|NCT00706745|Active Comparator|oil rich in cis9, trans11 CLA|Subjects will receive daily 4 g of CLA oil (2.6 g cis9,trans11-CLA), 2 capsules to be taken in the morning and 2 in the evening.
11591560|NCT00706732|Active Comparator|T1|
11591561|NCT00706732|Active Comparator|T2|
11591562|NCT00706732|Placebo Comparator|C1|
11591563|NCT00706732|Placebo Comparator|C2|
11591564|NCT00706719|Experimental|25 mg Androxal no wash out|1 capsule daily for 6 months of 25 mg of Androxal in men without a 3 month wash out period
11591565|NCT00706719|Active Comparator|Testim 1% (topical testosterone)|Testim 1% Gel applied topically for 6 months
11591566|NCT00706719|Experimental|25 mg Androxal wash out|1 x 25 mg Androxal capsule daily for 6 months in men with a previous 3 month washout period of topical testosterone
11591567|NCT00706706|Experimental|sunitinib|single agent sunitinib, single arm
11591568|NCT00706693|Active Comparator|Glucose|BD glucose tablets (TM) are taken PO in response to a hypoglycemic event by participants randomized to this arm
11591569|NCT00706693|Active Comparator|Fructose|Fruit to Go (TM) is taken PO in response to a hypoglycemic event by participants randomized to this arm
11591570|NCT00706693|Active Comparator|Sucrose|Skittles (TM) are taken PO in response to a hypoglycemic event by participants randomized to this arm
11591571|NCT00706680|Experimental|1|All subjects meeting the entry criteria will be treated with the study immunosuppressive protocol.
11591572|NCT00706667|Placebo Comparator|1|Placebo for EPO and for Ferinject ®
11591573|NCT00706667|Active Comparator|2|Only Ferinject ® , Placebo for EPO
11591574|NCT00706667|Active Comparator|3|Ferinject ® + EPO
11591575|NCT00706654|Experimental|Aripiprazole depot 300 or 400 mg|Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.
11591576|NCT00706654|Active Comparator|Aripiprazole 10-30 mg orally|Patients received aripiprazole 10-30 mg orally daily for 38 weeks.
11591578|NCT00706641|Experimental|Experimental: Neoadjuvant Dasatinib + Radical Cystectomy|Dasatinib 100 mg PO qd x 4 weeks followed by radical cystectomy 8-24 hours post last administered dasatinib dose
11591579|NCT00706602||1|Swiss COPD cohort
11591580|NCT00706602||2|Dutch COPD cohort
11591581|NCT00706589|Experimental|1|Aripiprazole 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)
11591582|NCT00706589|Placebo Comparator|2|Placebo 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)
11591583|NCT00706576|Experimental|Infusion of opioid growth factor|Volunteers will be treated with an intravenous infusion of opioid growth factor(OGF) starting at 100 µg/kg with a 50 µg/kg dose escalation with each succeeding group. The investigational drug, OGF, will be diluted in sterile saline to its appropriate concentration based upon the body weight of the volunteer and administered in a volume of 60 ml over 45 minutes (rate of 2 ml/min)
11591584|NCT00706563|Experimental|Fluarix Adult Group|Subjects who are 18-40 years of age received one dose of Fluarix™.
11591585|NCT00706563|Experimental|Fluarix Elderly Group|Subjects who are ≥ 60 years of age received one dose of Fluarix™.
11591586|NCT00706550|Other|Immediate|"Arm 1 will receive PV (23-valent pneumococcal polysaccharide vaccine) prior to starting antiretroviral treatment and will receive PLACEBO after at least 6 months of starting antiretroviral treatment.
~PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine"
11591587|NCT00706550|Other|Delayed|"Arm 2 will receive PLACEBO prior to starting antiretroviral treatment and will receive PV (23-valent pneumococcal polysaccharide vaccine) after at least 6 months of starting antiretroviral treatment.
~PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine"
11591588|NCT00706537|Experimental|CP-945598 20 mg|
11591589|NCT00706537|Placebo Comparator|Placebo|
11591590|NCT00706511|Experimental|Group with OSA|Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
11591591|NCT00706511|No Intervention|Group without OSA|Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol
11591592|NCT00706485|Experimental|Dural brachytherapy plaque|Patients undergoing spine tumor resection will undergo dural plaque brachytherapy.
11591593|NCT00706459||1|Patients with lumbar back pain scheduled for back surgery.
11591594|NCT00706459||2|Patients with degenerative disease without classic discogenic back pain
11591595|NCT00706459||3|Normal control without back pain.
11591596|NCT00706459||4|Post Surgical discectomy patients
11591597|NCT00706459||5|disc specimens
11591598|NCT00706446|Experimental|1 - Tio/ICS in the Arg/Arg genotype|Tiotropium bromide 18 mcg qd plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Arg genotype
11591599|NCT00706446|Experimental|2 - Tio/ICS in the Arg/Gly genotype|Tiotropium bromide 18 mcg QD plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Gly genotype
11591600|NCT00706446|Experimental|3 - Tio/ICS in the Gly/Gly genotype|Tiotropium bromide 18 mcg QD plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Gly/Gly genotype
11591601|NCT00706446|Active Comparator|4 - LABA/ICS in the Arg/Arg genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Arg genotype
11591602|NCT00706446|Active Comparator|5 - LABA/ICS in the Arg/Gly genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Gly genotype
11591603|NCT00706446|Active Comparator|6 - LABA/ICS in the Gly/Gly genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Gly-Gly genotype
11591604|NCT00706433|Active Comparator|ALA 1000 seconds|Aminolevulinic acid HCL (ALA) applied to the entire facial area 45 minutes prior to BLUE light treatment for 1000 seconds (16 minutes and 40 seconds)
11591605|NCT00706433|Active Comparator|ALA 500 seconds|Aminolevulinic acid HCL (ALA) applied to the entire facial area 45 minutes prior to BLUE light treatment for 500 seconds (8 minutes and 20 seconds)
11591606|NCT00706433|Placebo Comparator|Vehicle 1000 seconds|Vehicle (VEH) applied to the entire facial area 45 minutes prior to BLUE light treatment for 1000 seconds (16 minutes and 40 seconds)
11591607|NCT00706433|Placebo Comparator|Vehicle 500 seconds|Vehicle (VEH) applied to the entire facial area 45 minutes prior to BLUE light treatment for 500 seconds (8 minutes 20 seconds)
11591608|NCT00706420|Experimental|1|Islet cell transplantation alone
11591609|NCT00706407|Experimental|Fully integrated Uro-NIRS:UDS|
11591610|NCT00706394|Experimental|A|Powerlink 34mm cuff stent graft
11591611|NCT00706381|Experimental|1: Carb meal, fat meal, sincalide, placebo, urso|Participants randomized to consume a 100% carbohydrate meal day 1, then a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 2, IV sincalide 0.04mcg/kg + PO placebo day 3, IV placebo + PO placebo day 4, and IV placebo + PO Ursodiol 15mg/kg day 5
11591652|NCT00706030|Experimental|neratinib 160 mg + vinorelbine|neratinib 160 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
11591612|NCT00706381|Experimental|2: Fat meal, carb meal, sincalide, placebo, urso|Participants randomized to consume a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 1, then a 100% carbohydrate meal day 2, IV sincalide 0.04mcg/kg + PO placebo day 3, IV placebo + PO placebo day 4, then IV placebo + PO Ursodiol 15mg/kg day 5
11591613|NCT00706381|Experimental|3: Carb meal, fat meal, placebo, sincalide, urso|Participants randomized to consume a 100% carbohydrate meal day 1, then a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 2, IV placebo + PO placebo day 3, IV sincalide 0.04mcg/kg + PO placebo day 4, then IV placebo + PO Ursodiol 15mg/kg day 5
11591614|NCT00706381|Experimental|4: Fat meal, carb meal, placebo, sincalide, urso|Participants randomized to consume a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 1, then a 100% carbohydrate meal day 2, IV placebo + PO placebo day 3, IV sincalide 0.04mcg/kg + PO placebo day 4, the IV placebo + PO Ursodiol 15mg/kg day 5
11591615|NCT00706368|Experimental|1|Participants in this group will perform self-tests for the first half of the study and will have clinical examinations for the second half of the study
11591616|NCT00706368|Experimental|2|Participants in this group will have clinical examinations for the first half of the study and will perform self-tests for the second half of the study
11591617|NCT00706355|Experimental|1|
11591618|NCT00706342|Experimental|1|
11591619|NCT00706329|Experimental|Deflux|Treatment with Deflux.
11591620|NCT00706316|Experimental|EBV-Specific CTLs and CD45 Mab|A dose escalation schema will be employed. Three to six patients will be treated at each of the following dose levels with EBV-Specific CTLs and CD45 Mab: Dose Level I: 2 x 10^7 cells/m2. Dose Level II: 5 x 10^7 cells/m2. Dose Level III: 1 x 10^8 cells/m2. Dose escalation decisions will be made after review of the data from the current dose level. There will be no intra-patient escalation. An additional 6-10 patients with measurable disease will be treated at the recommended phase II dose to expand the experience at this dose level.
11591621|NCT00706303|Active Comparator|1 Intervention group|Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
11591622|NCT00706303|No Intervention|2|Usual care. The control group will receive usual care, as decided by their GP and or hospital consultant, and the patient themselves (e.g., NHS 24 helpline). They will be asked to complete diary cards and receive telephone follow up calls as an attention control, similar to the intervention group.
11591623|NCT00706290|Experimental|Intervention - CBT|Participants randomized to the intervention group received cognitive behavioral therapy (CBT) for anxiety after completing a baseline assessment consisting of clinician administered psychiatric evaluations and a psychosocial self-report battery. After completing the CBT intervention, consisting of 6-7 sessions over the course of 2-3 months, participants completed a post-intervention assessment identical to the baseline.
11591624|NCT00706290|No Intervention|Routine Care Control|Participants randomized to the control condition completed a baseline assessment consisting of clinician administered psychiatric evaluations and a psychosocial self-report battery. They then received routine medical care. After 2 months and after completing the post clinical assessment identical to the baseline, they were offered the opportunity to receive the CBT intervention for free. This ensured that all participants ultimately received cognitive-behavioral therapy if desired, while permitting an examination of the effect size for the intervention compared to routine care.
11591625|NCT00706277|Active Comparator|TIVA|patients receiving total intravenous anesthesia (TIVA)
11591626|NCT00706277|Active Comparator|balanced|patients receiving balanced anesthesia
11591627|NCT00706264|No Intervention|1|Expectant management
11591628|NCT00706264|Experimental|2|Placement of arabin pessary since 23 weeks until 37 weeks
11591629|NCT00706251||Primary|All the patients in our medical center who underwent nasolacrimal intubation, due to mild epiphora, during the years 2000-2007.
11591630|NCT00706238|Experimental|GSK1203486A Group|"Patients received 4 cycles of MAGE-A3 product as follows:
~Cycle 1: 6 doses, each given at a 2-week interval,
~Cycle 2: 6 doses, each given at a 3-week interval
~Cycle 3: 4 doses, each given at a 6-week interval
~Cycle 4: 4 doses, each given at a 3-month interval followed by 4 doses, each given at a 6-month interval.
~The MAGE-A3 product was administered intramuscularly in the deltoid or lateral regions of the thighs, alternately on the right and left sides."
11591631|NCT00706225|Experimental|1|Bazedoxifene and Conjugated Estrogens (BZA & CE)
11591632|NCT00706199||Group A|donors
11591633|NCT00706173|Experimental|Hydrocortisone|
11591634|NCT00706173|Placebo Comparator|Placebo|
11591635|NCT00706147|Placebo Comparator|1|
11591636|NCT00706147|Active Comparator|2|
11591637|NCT00706134|Placebo Comparator|Placebo|
11591638|NCT00706134|Experimental|Aliskiren 75 mg|
11591639|NCT00706134|Experimental|Aliskiren 150 mg|
11591640|NCT00706134|Experimental|Aliskiren 300 mg|
11591641|NCT00706121|Experimental|Vitamin E + selenium placebo|Vitamin E and selenium placebo daily for 7 - 12 years
11591642|NCT00706121|Experimental|Selenium + vitamin E placebo|Selenium and vitamin E placebo daily for 7 - 12 years
11591643|NCT00706121|Experimental|Vitamin E + selenium|Vitamin E and selenium daily for 7 - 12 years
11591644|NCT00706121|Placebo Comparator|Vitamin E placebo + selenium placebo|Vitamin E placebo and selenium placebo daily for 7 - 12 years
11591645|NCT00706108||1|Simulation of anesthesia induction with critical incidents: Analysis of technical and non-technical performance (15 Teams)
11591646|NCT00706108||2|Analysis of technical and non-technical performance in live anesthesia inductions (40 teams)
11591647|NCT00706108||3|Simulation of anesthesia inductions with advanced simulated critical incidents or events and analysis of technical and non-technical performance (max. 50 teams)
11591648|NCT00706095|Experimental|E7389 1.4 mg/m^2|
11591649|NCT00706095|Experimental|E7389 1.1 mg/m^2|
11591650|NCT00706095|Experimental|E7839 0.7 mg/m^2|
11591651|NCT00706069|Experimental|1|Vinorelbine oral plus Capecitabine
11591653|NCT00706030|Experimental|neratinib 240 mg + vinorelbine|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
11591654|NCT00706030|Experimental|neratinib 240 mg + vinorelbine, No Prior Lapatinib|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
11591655|NCT00706030|Experimental|neratinib 240 mg + vinorelbine, Prior Lapatinib|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
11591656|NCT00706017||A|
11591657|NCT00705978|Experimental|1|
11591658|NCT00705978|Placebo Comparator|2|
11591659|NCT00705965|Experimental|1|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
11591660|NCT00705965|Active Comparator|2|Usual cardiological care including one information session.
11591661|NCT00705952|Experimental|1|
11591662|NCT00705939|Experimental|Naive 30 Units/kg|Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
11591663|NCT00705939|Experimental|Naive 60 Units/kg|Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
11591664|NCT00705939|Experimental|Switchover|Continue taliglucerase alfa treatment from PB-06-002 (NCT00712348)
11591665|NCT00705926|Experimental|A1|Antiretroviral therapy followed by discontinuation at Week 12.
11591666|NCT00705926|Experimental|A2|Antiretroviral therapy followed by discontinuation at Week 32.
11591667|NCT00705926|Placebo Comparator|B|No treatment.
11591668|NCT00705913|Active Comparator|1|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)
11591669|NCT00705913|Active Comparator|2|
11591670|NCT00705900|Experimental|1|LCD Solution: 2 applications / day
11591671|NCT00705900|Active Comparator|2|Calcipotriol cream: 2 applications / day
11591672|NCT00705887|No Intervention|Control|Brochure from the American Academy of Dermatology on protecting your skin from UV rays.
11591673|NCT00705887|Experimental|Intervention|Participation in a brief motivational enhancement session. These participants also received the same American Academy of Dermatology brochure on protecting your skin from UV rays.
11591674|NCT00705874|Experimental|1|CGC-11047 in combination with Gemcitabine
11591675|NCT00705874|Experimental|2|CGC-11047 in combination with Docetaxel
11591676|NCT00705874|Experimental|3|CGC-11047 in combination with Bevacizumab
11591677|NCT00705874|Experimental|4|CGC-11047 in combination with Erlotinib
11591678|NCT00705874|Experimental|5|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
11591679|NCT00705874|Experimental|6|CGC-11047 in combination with 5-Flurouracil / Leucovorin
11591680|NCT00705874|Experimental|7|CGC-11047 in combination with Sunitinib
11591681|NCT00705861|Placebo Comparator|1|
11591682|NCT00705861|Experimental|2|
11591683|NCT00705848||1|10 patients with tracheobronchomalacia
11591684|NCT00705848||2|10 patients with tracheal stenosis
11591685|NCT00705848||3|10 patients with normal airways (no known airway diseases)
11591686|NCT00705835|Experimental|1|This is an ascending, multiple dose study in up to 18 patients. As many as eight patients are planned at each of two dose levels, intrapatient dose escalation is not allowed. Six patients will start on 50μg rsPSMA +0.5 mg Alhydrogel® Weeks 1,2,3 and 7.
11591687|NCT00705835|Experimental|2|This is an ascending, multiple dose study in up to 18 patients. As many as eight patients are planned at each of two dose levels, intrapatient dose escalation is not allowed. Eight patients will start on 250μg rsPSMA + 1.0 mg Alhydrogel Weeks 1,2,3 and 7
11591688|NCT00705822|Experimental|1|Docetaxel + Estramustine + Hydrocortisone
11591689|NCT00705822|Active Comparator|2|Docetaxel + Prednisone
11591690|NCT00705796|Experimental|Group 1|Group 1 will be treated with MPP10, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
11591691|NCT00705796|Active Comparator|Group 2|Group 2 will be treated with AndroGel® 50 mg, once daily in the morning after washing/showering.
11591692|NCT00705783|Experimental|Aripiprazole depot|Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.
11591693|NCT00705783|Placebo Comparator|Placebo depot|Patients received placebo intramuscularly every 28 days for 52 weeks.
11591694|NCT00705770|Placebo Comparator|1|Placebo treatment with vehicle
11591695|NCT00705770|Experimental|2|Low dose of study medication
11591696|NCT00705770|Experimental|3|Middle dose of study medication
11591697|NCT00705770|Experimental|4|High dose of study medication
11591698|NCT00705757|Active Comparator|Lumigan|Patients assigned to Lumigan/bimatoprost one drop before bedtime (qhs) to affected eye(s)
11591699|NCT00705757|Active Comparator|Xalatan|Patients assigned to Xalatan/latanoprost one drop before bedtime (qhs) to affected eye(s)
11591700|NCT00705757|Active Comparator|Travatan|Patients assigned to Travatan/travoprost one drop before bedtime (qhs) to affected eye(s)
11591701|NCT00705744|Experimental|I|
11591702|NCT00705718|Experimental|Endurant Bifurcated arm|The Bifurcated arm includes subjects who have received a bifurcated device. The Endurant Stent Graft System Bifurcated device is administered to treat patients with an Abdominal Aortic Aneurysm.
11591703|NCT00705718|Experimental|Endurant AUI arm|The AUI arm includes subjects who have received an AUI device. The Endurant Stent Graft System AUI device is administered to treat patients with an Abdominal Aortic Aneurysm.
11591704|NCT00705705|Experimental|1|Participating social networks will receive standard HIV risk-reduction counseling and network leadership training on HIV prevention.
11591705|NCT00705705|Active Comparator|2|Participating social networks will receive standard HIV risk-reduction counseling.
11591706|NCT00705692|Experimental|Levamisole|Two 50 mg levamisole tablets daily, six days before and six days after Td vaccination.
11591707|NCT00705692|Placebo Comparator|Placebo|Two placebo tablets daily, six days before and six days after Td vaccination.
11591708|NCT00705679|Experimental|1|TDF 300 mg tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
11591709|NCT00705679|Experimental|2|TDF placebo tablet taken orally once daily and one FTC 200 mg/TDF 300 mg tablet taken orally once daily for 12 to 36 months
11591710|NCT00705679|Experimental|3|TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
11591711|NCT00705679|Experimental|4|Application of tenofovir 1% vaginal gel once daily
11591712|NCT00705679|Experimental|5|Application of tenofovir placebo gel once daily
11591713|NCT00705666||PegIntron as monotherapy or in combination with Ribavirin.|Adult participants with chronic hepatitis C treated with PegIntron as monotherapy or in combination with ribavirin.
11591714|NCT00705653|Experimental|PG-11047|
11591715|NCT00705640|Experimental|Arm 1A|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
11591716|NCT00705640|Experimental|Arm 1B|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
11591717|NCT00705640|Experimental|Arm 1C|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
11591718|NCT00705640|Experimental|Arm 1D|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
11591719|NCT00705640|Experimental|Arm 1E|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (6 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
11591720|NCT00705640|Experimental|Arm 2A|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
11591721|NCT00705640|Experimental|Arm 2B|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
11591722|NCT00705640|Experimental|Arm 2C|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
11591723|NCT00705640|Experimental|Arm 2D|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
11591724|NCT00705640|Experimental|Arm 2E|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
11591725|NCT00705627|Experimental|B|Drug: cisplatin. Patients in the control arm received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
11591726|NCT00705614||Remicade Group|Particpiants with no prior exposure to Remicade, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who start on Remicade will constitute the Remicade Group, regardless of whether they continue with Remicade or switch to another treatment.
11591727|NCT00705614||Standard Therapy Group|Participants who are being treated with standard therapy and are not adequately maintained and will be offered an alternative treatment that does not include Remicade. Standard therapy participants must not have previously received Remicade.
11591728|NCT00705614||Switched to Remicade Group|Participants who started in the Standard Therapy Group but switched over to Remicade sometime during the follow-up period. Participants who switch to Remicade are evaluated in the Standard Therapy group until the time of the switch and are evaluated in the Switched to Remicade group thereafter.
11591729|NCT00705601||1|
11591730|NCT00705588|Experimental|1|Patients treated with epoprostenol (Flolan) will be given tadalafil (Cialis).
11591731|NCT00705588|Experimental|2|Patients receiving iloprost (Ventavis) will receive vardenafil (Levitra)
11591732|NCT00705575|Experimental|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|
11591733|NCT00705575|Active Comparator|Aliskiren (300 mg)|
11591734|NCT00705562|Experimental|1|Experimental milk protein based infant formula with varying carbohydrate and protein source
11591735|NCT00705562|Experimental|2|Experimental milk protein based infant formula with varying carbohydrate and protein source
11591736|NCT00705562|Experimental|3|Experimental milk protein based infant formula with varying carbohydrate and protein source
11591737|NCT00705562|Experimental|4|Experimental milk protein based infant formula with varying carbohydrate and protein source
11591738|NCT00705562|Experimental|5|Experimental milk protein based infant formula with varying carbohydrate and protein source
11591739|NCT00705549|Experimental|1|Gemzar/Cisplatin
11591740|NCT00705549|Experimental|2|Taxotere/Cisplatin
11591741|NCT00705549|Experimental|3|Cisplatin/Navelbine metronomic
11591742|NCT00705549|Experimental|4|Taxotere/Gemzar
11591743|NCT00705549|Experimental|5|Gemzar
11591745|NCT00705549|Experimental|7|Navelbine metronomic
11591746|NCT00705549|Experimental|8|Alimta/Cisplatin
11591747|NCT00705549|Experimental|9|Alimta/Gemzar
11591748|NCT00705549|Experimental|10|Taxotere
11591749|NCT00705549|Experimental|11|Alimta
11591750|NCT00705536|Active Comparator|Humalog first, then Humalog + rHuPH20|"Humalog first, then Humalog + recombinant human hyaluronidase PH20 (rHuPH20)
~A single subcutaneous (SC) injection of 20 units (U) Humalog on Day 1 of the study, followed by a single SC injection of 20 U Humalog + 300 U rHuPH20 after a washout period of at least 6 days"
11591751|NCT00705536|Active Comparator|Humalog + rHuPH20 first, then Humalog|"Humalog + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humalog
~A single subcutaneous (SC) injection of 20 units (U) Humalog + 300 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humalog after a washout period of at least 6 days"
11591752|NCT00705536|Active Comparator|Humulin-R first, then Humulin-R + rHuPH20|"Humulin-R (recombinant human insulin) first, then Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20)
~A single subcutaneous (SC) injection of 20 units (U) Humulin-R on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R + 240 U rHuPH20 after a washout period of at least 6 days"
11591753|NCT00705536|Active Comparator|Humulin-R + rHuPH20 first, then Humulin-R|"Humulin-R (recombinant human insulin) + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humulin-R
~A single subcutaneous (SC) injection of 20 units (U) Humulin-R + 240 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R after a washout period of at least 6 days"
11591754|NCT00705523|Active Comparator|1|
11591755|NCT00705523|Placebo Comparator|2|
11591756|NCT00705510|Active Comparator|A|
11591757|NCT00705510|Placebo Comparator|B|
11591758|NCT00705497|Experimental|1|
11591759|NCT00705484||Remicade Group|Participants with no prior exposure to Remicade or who have been treated with Remicade in the past, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who have been treated in the past with Remicade must have a Remicade-free interval of no less than 90 days from the date of the next expected infusion.
11591760|NCT00705484||Standard Therapy Group|Participants who are scheduled to receive standard therapy (defined as initiation or dose-increase of corticosteroids and/or immunosuppressants) that does not include Remicade. Standard therapy participants must not have previously received Remicade for UC or any other condition.
11591761|NCT00705471||Infliximab|Because of the difficulty of finding subjects with exactly the same disease severity, information will be recorded for the time period for up to three years before and for one year after their initial infliximab infusion for comparison of health care costs and utilization prior to infliximab and post infliximab use.
11591762|NCT00705458|Experimental|CTA|Initial EKG-gated computed tomography angiography of the coronary arteries
11591763|NCT00705458|Active Comparator|MPI|Initial nuclear stress myocardial perfusion imaging
11591764|NCT00705445|Active Comparator|A|This group will not receive any of the intervention supplements. The group will only receive nutritional counselling and education, and treatment provided for any encountered illness according to IMCI guidelines.
11591765|NCT00705445|Experimental|B|"This group will receive micronutrient supplements containing microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid.
~This group will also receive Nutritional Counselling and Education and treatment according to IMCI Guidelines for any serious illness."
11591766|NCT00705445|Experimental|C|"This group will receive Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, Folic Acid, and Zinc.
~This group will also receive nutritional counselling, education and treatment according to IMCI Guidelines in case of any untoward illness."
11591767|NCT00705432|Placebo Comparator|1. Placebo + PEG + RBV|PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks (lead in treatment) followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
11591768|NCT00705432|Experimental|2. Boceprevir + PEG + RBV - 24 Weeks (RGT)|"PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.
~At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable from Treatment Weeks 8 to Treatment Week 24, will proceed to the 44-week follow-up.
~At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up."
11591769|NCT00705432|Experimental|3. Boceprevir + PEG + RBV - 44 Weeks|PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
11591770|NCT00705419||Previous vicriviroc 30 mg QD|Subjects who previously received vicriviroc 30 mg daily in a Phase 2 or 3 clinical trial.
11591771|NCT00705419||Previous vicriviroc 20 mg QD|Subjects who previously received vicriviroc 20 mg daily in a Phase 2 or 3 clinical trial.
11591772|NCT00705419||Control Group|Subjects who previously received active control or placebo in a Phase 2 or 3 clinical trial involving vicriviroc.
11591773|NCT00705406|Experimental|Peramivir 600 mg|600 mg peramivir administered as bilateral 2-mL intramuscular injection.
11591774|NCT00705406|Placebo Comparator|Placebo|Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
11591775|NCT00705380|Experimental|1|Participants will receive cognitive behavioral therapy with panic control treatment.
11591776|NCT00705380|Active Comparator|2|Participants will receive cognitive behavioral therapy with panic control treatment after a 12-week waitlist period.
11591777|NCT00705367|Placebo Comparator|Placebo|
11591778|NCT00705367|Active Comparator|Abatacept, 30 mg/kg|
11591779|NCT00705367|Other|Abatacept, 10 mg/kg|Open-label long-term extension phase
11591780|NCT00705354|Active Comparator|1|Control group undergoing standard ESS will have a saline soaked Nasopore sponge placed during surgery and will receive routine oral antibiotics post-operatively
11591781|NCT00705354|Experimental|2|Treatment group undergoing ESS will have Nasopore sponge soaked with Bacitracin, but will not receive oral antibiotics post-operatively
11591782|NCT00705341|Active Comparator|Low dose fluticasone for phase 2|For people with asthma, fluticasone at 250 mcg per day; phase 2 of study
11591783|NCT00705341|Active Comparator|High dose fluticasone for phase 2|For people with asthma, fluticasone at 1000 mcg per day; phase 2 of study
11591784|NCT00705341|No Intervention|Nonasthmatic controls for phase 1|People without asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study
11591785|NCT00705341|No Intervention|Asthmatic controls for phase 1|People with asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study
11591786|NCT00705328|Experimental|1|
11591787|NCT00705328|Experimental|2|
11591788|NCT00705328|Experimental|3|
11591789|NCT00705315|Experimental|1|Bevacizumab->Epirubicin->Docetaxel
11591790|NCT00705302|Experimental|patient education including self-help|Patients in the arm will participate in a three months patient education and exercise program including a self-help group in 3 months of time.
11591791|NCT00705302|Active Comparator|patient education|Patients in arm 2 will participate in the same patient education and exercise program as arm 1, but without an additional self-help group.
11591792|NCT00705289||RA Subjects/ Infliximab 3 mg/kg|Subjects with rheumatoid arthritis (RA) in whom treatment with infliximab is started for the first time, in line with current clinical practice (and thus consistent with the European Summary of Product Characteristics [SPC] of Remicade®).
11591793|NCT00705276|Experimental|I|
11591794|NCT00705263||Patients with chronic hepatitis C|Patients with chronic hepatitis C who are treated with the PegIntron pen plus Rebetol will answer questions on the patient questionnaire.
11591795|NCT00705250|Experimental|1|bendamustine hcl 120mg/m^2
11591796|NCT00705224||Patients with chronic hepatitis C|Naïve patients with chronic hepatitis C (CHC) of any genotype will be treated with a standard treatment regimen (pegylated interferon and ribavirin) according to routine clinical practice in Russia.
11591797|NCT00705211||Zetia monotherapy|Patients to be treated with Zetia alone (10-mg tablets,) for hypercholesterolemia
11591798|NCT00705211||Zetia combination therapy|Patients to be treated with Zetia (10-mg tablets,) in combination with other lipid-lowering drugs for hypercholesterolemia
11591799|NCT00705198||Newly diagnosed patients|Patients treated with temozolomide for newly diagnosed malignant glioma
11591800|NCT00705198||Relapsed patients|Patients treated with temozolomide for relapsed malignant glioma
11591801|NCT00705198||Newly diagnosed anaplastic astrocytoma patients|Patients treated with temozolomide for newly diagnosed anaplastic astrocytoma
11591802|NCT00705185||1|Adults with Major Depressive Disorder- as defined by the criteria in the DSM-IV
11591803|NCT00705185||2|Healthy Controls- research subjects who have not met criteria for any lifetime Axis-I disorder (DSM-IV)
11591804|NCT00705172||A|
11591805|NCT00705159|Experimental|Loteprednol etabonate and tobramycin|Drug: Zylet (loteprednol etabonate and tobramycin)
11591806|NCT00705159|Active Comparator|Loteprednol etabonate|Drug: Lotemax (loteprednol etabonate)
11591807|NCT00705159|Active Comparator|Tobramycin|Drug: Tobramycin
11591808|NCT00705159|Placebo Comparator|Vehicle|Vehicle of Zylet
11591809|NCT00705146|Active Comparator|Comfort Cool Splint|Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks.
11591810|NCT00705146|Active Comparator|Hybrid Custom-made splint|The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks.
11591811|NCT00705133|Experimental|Treprostinil-treated|Patients with pulmonary fibrosis with an advanced pulmonary hypertension phenotype will be treated with parenteral treprostinil in an open-label fashion
11591812|NCT00705120|Other|1|
11591813|NCT00705120|Other|2|
11591814|NCT00705107||All Treated Patients|All patients participating in the study
11591815|NCT00705094||1|Testicular cancer patients who have received surgery and are scheduled for surveillance
11591816|NCT00705094||2|Testicular cancer patients who have received surgery and are scheduled for chemotherapy
11591817|NCT00705081||Not previously treated|subjects with hypercholesterolemia, who had never been treated with any cholesterol-lowering agent, and received the combination of ezetimibe 10 mg and a statin as initiation therapy
11591818|NCT00705081||Previously treated with statin|subjects with hypercholesterolemia, who were previously treated with a statin, and received ezetimibe 10 mg as add-on therapy
11591819|NCT00705055||1|Normal Males
11591820|NCT00705055||2|Normal Females
11591821|NCT00705055||3|Abnormal Males
11591822|NCT00705055||4|Abnormal Females
11591823|NCT00705042|Experimental|A|25 mg
11591824|NCT00705042|Experimental|B|50 mg
11591825|NCT00705016|Experimental|Cilengitide 2000 mg once weekly+Cetuximab+5-FU+Cisplatin|
11591826|NCT00705016|Experimental|Cilengitide 2000 mg twice weekly+Cetuximab+5-FU+Cisplatin|
11591827|NCT00705016|Active Comparator|Cetuximab+5-FU+Cisplatin|
11591828|NCT00705003|Experimental|Active Drug Combination|BCI-024: over-encapsulated Buspirone tablet 15 mg at bedtime(QD) and BCI-049: over-encapsulated Melatonin tablet 3 mg QD
11591829|NCT00705003|Active Comparator|BCI-024 (Buspirone)|BCI-024: over-encapsulated Buspirone 15 mg QD
11591830|NCT00705003|Placebo Comparator|Matching placebo|Placebo: 1 capsule QD
11591831|NCT00704990|Experimental|A|All study participants take part in the experimental arm
11591832|NCT00704977|Active Comparator|1|Pterygium surgery using alcohol 20% + wound closure by bare sclera technique
11591833|NCT00704977|Active Comparator|2|"Alcohol 20% for pterygium separation + wound closure by sliding flap technique.
~The main steps of surgery are described below.Wound closure technique is as follows.
~Disection of conjunctiva adjascent to the wound, bringing the dissected conjunctiva to the wound area and suturing by vicril 6/0 sutures"
11591834|NCT00704977|Active Comparator|3|"Alcohol 20 % for pterygium separation + using amniotic membrane and biological glue for wound closure.
~The steps of surgery are as described below, wound closure technique is as follows.
~Amniotic membrane is applied with its mesenchimal side to conjunctiva and glued by biological glue (main ingradients: calcium and thrombin)"
11592397|NCT00700999|Other|Arm 1|Intervention-Paroxetine
11591835|NCT00704964||All participants|Each site will be evaluated by a site questionnaire and assigned as either a high or low participant management site. Participants are not randomized to a group. However, treatment completion rates will be evaluated based on the high vs low participant management sites.
11591836|NCT00704951||Patients|Immunosuppressed/Immunocompromised patients at high risk for invasive fungal infections
11591837|NCT00704938|Experimental|anti-p53 TCR PBL + DC + IL-2: Melanoma/RCC|Patients with melanoma and renal cell cancer will receive anti-p53 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + dendritic cells (DC) + interleukin-2 (IL-2)
11591838|NCT00704938|Experimental|anti-p53 TCR PBL + DC + IL-2: Other histology|Patients with other histologies, such as breast cancer, will receive anti-p53 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + dendritic cells (DC) + interleukin-2 (IL-2)
11591839|NCT00704912|Active Comparator|Lifestyle intervention|Orlistat/Meal Replacement/Lifestyle Modification
11591840|NCT00704912|Active Comparator|Oral Contraceptives (OCP)|Loestrin 1/20
11591841|NCT00704912|Active Comparator|Lifestyle/OCP Combined|Combination of treatments
11591842|NCT00704899|Experimental|2|anti-depressants
11591843|NCT00704899|Experimental|1|physiotherapy
11591844|NCT00704886|No Intervention|1|verbal
11591845|NCT00704886|Experimental|2|video
11591846|NCT00704860|Experimental|TR|TR- Subjects defined as having treatment resistant depression, who have failed at least 2 adequate trials of an antidepressant. Subjects will be treated in an open label trial for their depression, with the goal of sustained remission.
11591847|NCT00704847|Active Comparator|1|SMC021 Oral Calcitonin
11591848|NCT00704847|Placebo Comparator|2|SMC021 Placebo
11591849|NCT00704834||1|Normal Controls
11591850|NCT00704834||2|Patients with a clinically isolated syndrome (CIS)
11591851|NCT00704834||3|Patients with relapsing, remitting Multiple Sclerosis (RRMS) who are not on treatment
11591852|NCT00704834||4|Patients with Chronic Progressive Multiple Sclerosis who are not on treatment
11591853|NCT00704821|Experimental|Stage 1|In Stage 1, PTC299 will be given orally twice a day (BID) each day at about the same time each day for the first 28 days of each cycle. Each cycle will constitute a 4-week (28 days) period followed by a ≥2-week (14-day) washout period. Participants will be assigned to 0.3 milligrams (mg)/kilograms (kg)/dose BID, 0.6 mg/kg/dose BID, or 1.2 mg/kg/dose BID sequentially based on safety evaluations by the Sponsor's medical monitor in Cycle 1. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant.
11591854|NCT00704821|Experimental|Stage 2|In Stage 2, PTC299 will be given BID or 3 times a day (TID) orally each day at about the same time each day; therefore, 84 (for BID) or 126 (for TID) doses of PTC299 will be delivered during the 6-week (42-day) period in each cycle. Each participant will be assigned to 100 mg/dose BID, 100 mg/dose TID, 120 mg/dose TID, 160 mg/dose TID, or 200 mg/dose TID sequentially based on safety evaluations by the Sponsor's medical monitor in Cycle 1. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant.
11591855|NCT00704821|Experimental|Stage 3|In Stage 3, PTC299 will be given BID or TID (for total of 42 [for BID] or 63 [for TID] doses) orally about same time per day starting on Day 1 in each 3-week (21-day) cycle. Starting dose will be 1 dose level below maximum tolerated dose (MTD) from Stage 2 or 80 mg/dose BID if 100 mg/dose TID in Stage 2 exceeds MTD. Dose escalation will be based on safety evaluations by Sponsor's medical monitor in Cycle 1. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant. Participants will also receive docetaxel as a 1-hour IV infusion on Day 1 per cycle at starting dose of 75 mg/m^2 with body surface area calculation based on body weight. Dose will be sequentially reduced to 60 and 50 mg/m^2 in participants with a docetaxel-related dose-limiting toxicity (DLT). Participants will be medicated with oral corticosteroids with docetaxel administration. Recommended dose is 8 mg BID dexamethasone for 3 days starting 1 day prior to docetaxel administration.
11591856|NCT00704821|Experimental|Stage 4|In Stage 4, PTC299 will be given orally each day continuously starting on first day of each cycle at about same time per day; so, 42 doses of PTC299 will be delivered for 3 weeks (21-day) in Cycle 1 (BID dosing), and 84 doses will be delivered for 3-weeks (21-day) in Cycle 2 and beyond (TID dosing). For Cycle 1, participants will be assigned to 600, 800, or 1000 mg/dose BID sequentially based on safety evaluations by Sponsor's medical monitor at enrollment. For Cycle 2 and beyond, participants will receive PTC299 160 mg/dose TID. During Cycle 1, Cohort 1 participants will eat a meal containing of ≤15 grams (g) of dietary fat and Cohort 2 participants will eat a meal containing of ≤25 g of dietary fat prior to each dose of PTC299. If ≤2 of 6 participants had experienced DLT during Cycle 1 in either diet plan, then the dose will be escalated to 800 mg BID in Cohort 3 at the optimal diet. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant.
11591857|NCT00704808||Patients|Patients with newly diagnosed and operated glioblastoma multiforme.
11591858|NCT00704795||1|Patients with type 1 diabetes mellitus
11591859|NCT00704795||2|Healthy control subjects matched for body mass index (BMI), age and gender.
11591860|NCT00704782|Experimental|Dimebon|20 mg by mouth 3 times a day
11591861|NCT00704769||1|Children with a history of perennial allergic rhinitis
11591862|NCT00704756||Arm 1|Patients with chronic hepatitis C treated with PegIntron and Rebetol in clinical practice in Belgium.
11591863|NCT00704743|Active Comparator|1|Cylindrical cast
11591864|NCT00704743|Active Comparator|2|Modified sugar tong cast
11591865|NCT00704743|Active Comparator|3|Volar dorsal splint
11591866|NCT00704730|Experimental|1|
11591867|NCT00704730|Placebo Comparator|2|
11591868|NCT00704717||All Treated Patients|All patients participating in the study.
11591869|NCT00704691|Experimental|Lenalidomide|
11591870|NCT00704678|Experimental|1|1g bid
11591871|NCT00704678|Active Comparator|2|0.8 g tid
11591872|NCT00704678|Experimental|3|1.5 g tid
11591873|NCT00704678|Active Comparator|4|1.6 g tid
11591874|NCT00704665|Placebo Comparator|2|Placebo
11591875|NCT00704665|Experimental|A|10ug/kg/day or 25/ug/kg/day
11591876|NCT00704652||A|Diabetic patients suffering from renal insufficiency with stable haemoglobin levels (receiving no EPO supplementation)
11591966|NCT00703937|Active Comparator|Standard Medical Care (SMC) for the treatment of IDA|SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA).
11591877|NCT00704652||B|Diabetic patients with renal insufficiency and in need of recombinant human EPO (darbepoetin alfa) substitution because of inadequate erythropoiesis. In both groups the target haemoglobin level is 10-12 gHb/ml, all treatment is performed according to label.
11591878|NCT00704639|Experimental|Single arm|Chemoradiation (Cetuximab, Carboplatin and Radiotherapy)
11591879|NCT00704626||Cohort 1|Subjects with multiple sclerosis and other autoimmune and inflammatory disease of the nervous system
11591880|NCT00704600|Experimental|nelfinavir|see intervention
11591881|NCT00704574||A|
11591882|NCT00704561|Active Comparator|DES|Zotarolimus drug-eluting stent
11591883|NCT00704561|Active Comparator|BMS|bare metal stent
11591884|NCT00704548|Active Comparator|1|Simvastatin 40 mg
11591885|NCT00704548|Placebo Comparator|2|
11591886|NCT00704535||Subjects with hypercholesterolemia|Subjects with hypercholesterolemia that are using Ezetimibe either alone or in combination with a statin
11591887|NCT00704522||Patients with hepatitis C|Patients receiving a patient assistance program during therapy for hepatitis C at sites in Austria.
11591888|NCT00704509|Experimental|Bifeprunox|
11591889|NCT00704509|Placebo Comparator|Placebo|
11591890|NCT00704509|Active Comparator|Quetiapine|
11591891|NCT00704496|Placebo Comparator|Placebo|Placebo
11591892|NCT00704496|Active Comparator|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
11591893|NCT00704483|Experimental|1|1g tid
11591894|NCT00704483|Active Comparator|2|Sevelamer HCl
11591895|NCT00704483|Experimental|3|SBR759 1.5 g tid
11591896|NCT00704483|Active Comparator|4|Sevelamer HCl
11591897|NCT00704470|Active Comparator|1|Classic one-day simulator training for intensivists.
11591898|NCT00704470|Experimental|2|Crew resource management training
11591899|NCT00704457||A|One arm study. Urine collection.
11591900|NCT00704444||Zetia monotherapy|Patients to be treated with Zetia alone (10-mg tablets,) for hypercholesterolemia
11591901|NCT00704444||Zetia combination therapy|Patients to be treated with Zetia (10-mg tablets,) in combination with other lipid-lowering drugs for hypercholesterolemia
11591902|NCT00704431|Experimental|darapladib|darapladib
11591903|NCT00704418|Experimental|Bromfenac|Bromfenac ophthalmic solution 0.09%, dosed 1 drop daily
11591904|NCT00704418|Placebo Comparator|Placebo|Placebo, dosed 1 drop daily
11591905|NCT00704405|Experimental|24-wk Vaniprevir 600 mg + Peg-IFN/RBV|Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 24 weeks.
11591906|NCT00704405|Experimental|24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV|Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for an additional 24 weeks.
11591907|NCT00704405|Experimental|48-wk Vaniprevir 300 mg + Peg-IFN/RBV|Vaniprevir 300 mg (total daily dose, taken once daily [q.d.]) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
11591908|NCT00704405|Experimental|48-wk Vaniprevir 600 mg + Peg-IFN/RBV|Vaniprevir 600 mg and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
11591909|NCT00704405|Placebo Comparator|48-wk PBO + Peg-IFN/RBV|PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
11591910|NCT00704392|Experimental|1|
11591911|NCT00704379|Placebo Comparator|Placebo|Placebo will be given in a double blind fashion via an equal number of tablets (identical to the sertraline tablets) administered once daily.
11591912|NCT00704379|Experimental|Sertraline|Sertraline will be given in a double blind fashion via tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention.
11591913|NCT00704366|Experimental|1|AZD0530
11591914|NCT00704353|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
11591915|NCT00704353|Active Comparator|Standard Medical Care|Per product label
11591916|NCT00704340|Experimental|1|"DuraSeal Dural Sealant System - FDA Approved Device:
~The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel."
11591917|NCT00704340|Active Comparator|2|"Standard of Care (control):
~Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator."
11591918|NCT00704314|Active Comparator|1|Simvastatin therapy, 80 mg/d for 8 weeks
11591919|NCT00704314|Placebo Comparator|2|Placebo, one pill daily for 8 weeks
11591920|NCT00704301|Experimental|1|Haloperidol: aged 70 years or less: 1 mg haloperidol three times a day i.v. older than 70 years: 0,5 mg haloperidol three times a day i.v. Rivastigmine: two times 1,5 mg a day; The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
11591921|NCT00704301|Placebo Comparator|2|Haloperidol: aged 70 years or less: 1 mg haloperidol three times a day i.v. older than 70 years: 0,5 mg haloperidol three times a day i.v. Placebo: 2 times a day
11591922|NCT00704288|Experimental|1|
11591923|NCT00704275|Experimental|A|0.05% cyclosporin
11591924|NCT00704275|Active Comparator|B|Refresh
11591925|NCT00704262|Experimental|Calcipotriol plus hydrocortisone (LEO 80190)|
11591926|NCT00704249|Experimental|1|Full-dose nevirapine from baseline (200 mg bid).
11591927|NCT00704249|Active Comparator|2|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
11591928|NCT00704236|Experimental|A|
11591929|NCT00704236|Placebo Comparator|B|
11591930|NCT00704223||A|
11592398|NCT00700999|No Intervention|Arm 2|No Intervention
11591931|NCT00704210|Sham Comparator|B|Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
11591932|NCT00704210|Experimental|A|For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.
11591933|NCT00704184|Placebo Comparator|Placebo + Peg-IFN/Ribavirin|Participants took double-blind Placebo + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
11591934|NCT00704184|Experimental|Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 300 mg twice daily (b.i.d.) + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
11591935|NCT00704184|Experimental|Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
11591936|NCT00704184|Experimental|Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
11591937|NCT00704184|Experimental|Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
11591938|NCT00704171|Experimental|PleuraSeal|PleuraSeal Lung Sealant System
11591939|NCT00704171|Active Comparator|Standard of Care|Standard tissue closure techniques (control) - sutures or staples only
11591940|NCT00704145|Experimental|A|Device, paclitaxel drug-eluting stent
11591941|NCT00704132|Experimental|sitagliptin|Participants randomized to this arm will be administered sitagliptin 100mg daily, for six weeks.
11591942|NCT00704132|Placebo Comparator|Placebo|Participants randomized to this arm will be administered matching placebo, daily for six weeks.
11591943|NCT00704106||Group 1|Persistent viremia after 48 weeks or longer.
11591944|NCT00704106||Group 2|<2 log IU/mL drop from initial HBVDNA after 12 weeks of adefovir
11591945|NCT00704106||Group 3|Patients who responded to adefovir and were switched to entecavir.
11591946|NCT00704106||Group 4|Patients with 160 copies/mL (100 IU/mL) or higher at the time of medication switch.
11591947|NCT00704080|Experimental|1|
11591948|NCT00704067|Experimental|1|Supported employment for 12 months plus cognitive training for the first 12 weeks
11591949|NCT00704067|Active Comparator|2|Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks
11591950|NCT00704054|Experimental|1|Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
11591951|NCT00704028|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
11591952|NCT00704028|Active Comparator|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
11591953|NCT00704015|Experimental|A|Smoking cessation
11591954|NCT00704015|No Intervention|B|
11591955|NCT00704002|Experimental|A|antegrade intramedullary splinting
11591956|NCT00704002|Active Comparator|B|conservative treatment
11591957|NCT00703989|Experimental|I|Patients with Type 1 diabetes
11591958|NCT00703989|No Intervention|II|Age-matched male subjects without Type 1 diabetes
11591959|NCT00703976|Active Comparator|Cetuximab, Pemetrexed and Radiation therapy|"Cetuximab, Pemetrexed and Radiation therapy Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
~Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
~Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks"
11591960|NCT00703976|Experimental|Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab|"Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
~Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
~Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks Bevacizumab: Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy."
11591961|NCT00703963|Active Comparator|Usual Care|Subjects will be having their INR tested by their Primary Care Provider as often as their Care Provider dictates. This study phase is twelve weeks long beginning at the day of discharge from our hospital.
11591962|NCT00703963|Active Comparator|Patient Self Testing|Subjects will be testing their INR at home using an FDA approved device (INRatio monitor by Hemosense) reporting their results to Quality Assured Services (QAS) via an 800 phone number; their Primary Care Provider will receive a fax with the INR result. We ask this group of patients to test at minimum one time a week, additional testing as requested by their Primary Care Provider. This phase lasts twelve weeks, beginning on the day of discharge from our hospital.
11591963|NCT00703950|Experimental|A,1|Cup feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
11591964|NCT00703950|Active Comparator|A,2|bottle feeding - conventional method Bottle feeding is the conventional method to feed preterm infant before breastfeeding or to substitute breastfeeding. We are using this method in the control group.
11591965|NCT00703937|Experimental|Ferric Carboxymaltose (FCM)|750 mg of iron as undiluted FCM (15 mg/kg up to a maximum of 750 mg) at 100 mg per minute weekly until the calculated iron deficit dose has been administered (to a maximum cumulative dose of 2,250 mg).
11591967|NCT00703924|Experimental|WR 279,396|WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin
11591968|NCT00703924|Placebo Comparator|Placebo|Topical cream vehicle containing all of the components in WR 279,396 except the active ingredients.
11591969|NCT00703911||activated recombinant human factor VII|Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds
11591970|NCT00703885|Active Comparator|1|"0.25 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan.
~One-time, single dose.
~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
11591971|NCT00703885|Active Comparator|2|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan
~One-time, single dose.
~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
11591972|NCT00703885|Placebo Comparator|Placebo|"Inactive ingredient in liquid matching appearance and volume of the two active alprazolam dose comparators.
~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
11591973|NCT00703872|Experimental|1|Oral HDV-Interferon
11591974|NCT00703872|Experimental|2|Injectable HDV-Interferon + ribavarin
11591975|NCT00703846|Other|KETOCONAZOLE|
11591976|NCT00703833|Experimental|1|Drug
11591977|NCT00703833|Placebo Comparator|2|Placebo
11591978|NCT00703820|Active Comparator|ADE|"Cytarabine + Daunorubicin + Etoposide
~NK cells for infusion are prepared using the CliniMACS System."
11591979|NCT00703820|Active Comparator|Clo/AraC|"Clofarabine + Cytarabine
~NK cells for infusion are prepared using the CliniMACS System."
11591980|NCT00703807|Experimental|1|Daily oral RAD001 for 21 days in combination with oral topotecan on days 1-5 of a 21 day cycle
11591981|NCT00703794||AXIUM Coils|
11591982|NCT00703781|Experimental|Bromfenac|Bromfenac Ophthalmic Solution 0.09%, Dosed 1 Drop Daily
11591983|NCT00703781|Placebo Comparator|Placebo|Placebo, Dosed 1 Drop Daily
11591984|NCT00703768||A|Patients who have been identified as having a doubling in PSA from nadir of greater than one year
11591985|NCT00703768||B|Patients who have been identified as having a doubling in PSA from nadir of less than one year.
11591986|NCT00703755|Experimental|1|
11591987|NCT00703755|Experimental|2|
11591988|NCT00703755|Experimental|3|
11591989|NCT00703755|Experimental|4|
11591990|NCT00703755|Experimental|5|
11591991|NCT00703755|Experimental|6|
11591992|NCT00703755|Placebo Comparator|7|
11591993|NCT00703742|Experimental|A,1|A: Escitalopram, 20 mg/day,8weeks
11591994|NCT00703729|Experimental|Cold Compression (CC)|The Game Ready device provides both active, continuous cold and intermittent, pneumatic compression to the post-op shoulder. The first group will use the Game Ready™ Device (CC) for one week following surgery and will use standard ice bags wrapped to the shoulder (IW) for the remainder of the study period.
11591995|NCT00703729|Active Comparator|Ice Wrap (IW)|The ice bag (IW)is secured to the shoulder using an elastic wrap. The second group will use standard ice bags wrapped to the shoulder (IW) for one week following surgery and will use the Game Ready™ Device (CC) for the remainder of the study period
11591996|NCT00703703|Experimental|1|Darifenacin
11591997|NCT00703703|Active Comparator|2|Tolterodine
11591998|NCT00703703|Placebo Comparator|3|Placebo
11591999|NCT00703690|Experimental|1|MK0767; 2.5 mg/day
11592000|NCT00703690|Experimental|2|MK0767; 5mg/day
11592001|NCT00703690|Experimental|3|MK0767; 10 mg/day
11592002|NCT00703690|Active Comparator|4|fenofibrate 200 mg
11592003|NCT00703690|Placebo Comparator|5|Matching Placebo
11592004|NCT00703677|Other|1|All participants will receive lithium. The dosage will be titrated over a 5-week period. Participants will then be followed prospectively for 6 months. Participants will be evaluated at the screening visit, baseline visit, and weeks 2 and 5 during the titration phase. Clinic study visits will then occur on alternate months through week 28. Telephone visits will occur between clinic study visits.
11592005|NCT00703664|Experimental|Treatment (vorinostat, bortezomib)|"Participants receive vorinostat orally (PO) once daily (QD) on days 1-5 and 8-12. Participants also receive bortezomib intravenously (IV) over 3-5 seconds on days 1, 4, 8, and 11. Vorinostat precedes bortezomib on days of concurrent administration. Courses repeat every 3 weeks in the absence of disease progression - or unacceptable toxicity. After completion of study therapy, participants are followed periodically.
~Treatment arm consists of 3 cohorts, all receiving the same treatment:
~A: Mantle Cell Lymphoma (MCL) - with no prior bortezomib.
~B: Mantle Cell Lymphoma (MCL) - with no prior bortezomib.
~C: Diffuse Large B-Cell Lymphoma (DLBCL) - with no prior bortezomib."
11592006|NCT00703651|Experimental|1|
11592007|NCT00703651|Experimental|2|
11592008|NCT00703651|Active Comparator|3|
11592009|NCT00703638|Experimental|Sorafenib/Pemetrexed/Cisplatin|Patients receiving a dose escalation scheme of daily oral sorafenib (200 mg or 400 mg bid) when given in combination with fixed dose intravenous pemetrexed and cisplatin for the treatment of solid tumors.
11592010|NCT00703625|Experimental|Cohort 1|"Temsirolimus IV 15 mg weekly
~Docetaxel 60 mg/m2 IV once every three weeks."
11592011|NCT00703625|Experimental|Cohort 2|"Temsirolimus IV 25 mg weekly
~Docetaxel IV 60 mg/m2 once every 3 weeks"
11592012|NCT00703625|Experimental|Cohort 1A|"Temsirolimus IV 15 mg weekly
~Docetaxel IV 50 mg/m2 every 3 weeks."
11592013|NCT00703612|Experimental|Treatment Group|This is the only arm and that is the treatment group.
11592014|NCT00703599|Experimental|1|This is the only arm and that is the treatment group.
11592015|NCT00703586|Experimental|1|"ARM A:
~Intensification with maraviroc for 24 weeks at one of the following doses:
~150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor
~600 mg orally BID when coadministered with efavirenz or nevirapine"
11592016|NCT00703586|Active Comparator|2|"ARM B
~Intensification with an additional NRTI for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:
~Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc
~Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofovir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc."
11592078|NCT00703144|Experimental|Pharmacokinetic|
11592017|NCT00703573|Experimental|Group A|S-777469 400 mg BID (two 200 mg tablets of S-777469 and two tablets of placebo BID)
11592018|NCT00703573|Experimental|Group B|S-777469 800 mg BID (four 200 mg tablets of S-777469 BID)
11592019|NCT00703573|Placebo Comparator|Group C|Placebo BID (four tablets of placebo BID)
11592020|NCT00703560||1|HIV and HCV genotype 1 coinfected (any race)
11592021|NCT00703560||2|HCV genotype 1 (any race)
11592022|NCT00703547|Experimental|Subjects receiving treatment in cohort 1|Subjects will receive one of the following sequences; ABDF,BADF, BDAF or BDFA (A=Placebo, B= GSK586529 dose 1 (3 milligrams), D = GSK586529 dose 3, F = GSK586529 dose 5).
11592023|NCT00703547|Experimental|Subjects receiving treatment in cohort 2|Subjects will receive one of the following sequences; ACEG,CAEG, CEAG or CEGA (A = Placebo, C= GSK586529 dose 2, E = GSK586529 dose 4, G = GSK586529 dose 6)
11592024|NCT00703534|Experimental|AZD3355|
11592025|NCT00703534|Placebo Comparator|Placebo|
11592026|NCT00703521|Placebo Comparator|1,2,3,4,5|"Rabies vaccine 1.0 mL IM on day 0, 7, 28,and 1 year
~Rabies vaccine 0.5 mL IM on day 0, 7, 28,and 1 year
~Rabies vaccine 0.1 mL Intradermal on day 0, 7, 28,and 1 year
~Rabies vaccine 0.1 mL Intradermal on day 0, 28,and 1 year
~Japanese encephalitis vaccine 0.25 mL subcutaneous"
11592027|NCT00703508|Experimental|Metformin|Metformin tablet, 500 mg/tablet, 2 tablets every twelve hours, 9 months duration
11592028|NCT00703482|Placebo Comparator|1|
11592029|NCT00703482|Active Comparator|2|
11592030|NCT00703482|Active Comparator|3|
11592031|NCT00703482|Experimental|4|
11592032|NCT00703482|Experimental|5|
11592033|NCT00703482|Experimental|6|
11592034|NCT00703482|Experimental|7|
11592035|NCT00703469|Experimental|1|
11592036|NCT00703469|Placebo Comparator|2|
11592037|NCT00703456|Experimental|1|Balance Training, 3 times a week for 4 weeks
11592038|NCT00703456|No Intervention|2|Education/No intervention
11592039|NCT00703430|Experimental|1|Memantine
11592040|NCT00703417||1|Healthy post-menopausal women
11592041|NCT00703417||2|Diabetic without fracture
11592042|NCT00703417||3|Diabetic with fracture
11592043|NCT00703391|Experimental|1|Active Treatment
11592044|NCT00703391|Placebo Comparator|2|Placebo Treatment
11592045|NCT00703378|Experimental|Group 1|Group 1: normal liver function
11592046|NCT00703378|Experimental|Group 2|Group 2: AST and/or ALT up to 1-5 x upper limit of normal; SAP 1- 5x upper limit of normal, total bilirubin within normal limits
11592047|NCT00703378|Experimental|Group 3|Group 3: Any SAP and AST/ALT >5-10 x upper limit of normal and/or total bilirubin 1-1.5 x upper limit of normal
11592048|NCT00703365|Experimental|1|Sorafenib
11592049|NCT00703352|Active Comparator|1|Eplerenone
11592050|NCT00703352|Placebo Comparator|2|Placebo
11592051|NCT00703326|Experimental|ramucirumab (IMC-1121B) + docetaxel|
11592052|NCT00703326|Placebo Comparator|placebo + docetaxel|
11592053|NCT00703313|Active Comparator|2|described in intervention
11592054|NCT00703313|Active Comparator|3|described in intervention
11592055|NCT00703313|Active Comparator|1|described in intervention
11592056|NCT00703300|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-5 or 1-10 and bortezomib IV on days 5 and 8 or days 5, 8, 12, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Once the maximum tolerated dose is determined, an additional 6 patients are treated at the recommended phase II dose.
11592057|NCT00703287|Sham Comparator|A2|Generic physiotherapy
11592058|NCT00703287|Experimental|A1|Specialized Physiotherapy
11592059|NCT00703274|Experimental|Navigation Group|Participants enrolled in this group will receive education concerning primary and secondary PROTECT DC goals. Primary PROTECT DC goals adhere to the following medication directives: 1) Anti-hypertensive, 2) Lipid Lowering, 3) Anti-Coagulant, and 4) Anti-Diabetic. PROTECT DC secondary goals include the following behaviors 1) Smoking Cessation, 2) Consuming an AHA Diet, 3) Regular Exercise, and 4) Knowledge of Stroke Risk and Warning Signs. Participants will also receive assistance with overcoming resource-related barriers to the PROTECT DC goals.
11592060|NCT00703274|No Intervention|Control Group|Participants enrolled in this group will receive periodic follow up through mailings, phone calls etc to ensure availability for 1 year assessment.
11592061|NCT00703261|Active Comparator|10 mg Atorvastatin|10 mg atorvastatin + placebo
11592062|NCT00703261|Active Comparator|80 mg Atorvastatin|80 mg atorvastatin + placebo
11592063|NCT00703248|Experimental|1|
11592064|NCT00703248|No Intervention|2|
11592065|NCT00703222|Experimental|Dose Level 1|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP
11592066|NCT00703222|Experimental|Dose Level 2|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP
11592067|NCT00703209|Active Comparator|1|Patients who are randomized to receive surgical care, will receive the nerve decompression, along with similar incisions on the opposite leg, but no decompression on that leg. This will serve as the patient's control leg, and also blind them to the treatment leg.
11592068|NCT00703209|No Intervention|2|Subjects who are not randomized to receive the surgical procedure will be followed up with the same clinic visits as the patients who are receiving the surgical procedure.
11592069|NCT00703196|Experimental|Arm I|Patients receive oral folic acid pill once daily for 12 months in the absence of unacceptable toxicity or any other adverse effects.
11592070|NCT00703196|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 12 months in the absence of unacceptable toxicity or any other adverse effects.
11592071|NCT00703183|Experimental|1|ACU-4429
11592072|NCT00703183|Placebo Comparator|2|matching placebo
11592073|NCT00703170|Experimental|Dose Level 1 (original)|"Temsirolimus IV 20 mg weekly
~Pegylated liposomal doxorubicin IV 30 mg/m2 once every 4 weeks"
11592074|NCT00703170|Experimental|Dose Level 1 (revised)|"Temsirolimus IV 20 mg weekly
~Pegylated liposomal doxorubicin IV 25 mg/m2 once every 4 weeks"
11592075|NCT00703170|Experimental|Dose Level 2|"Temsirolimus IV 25 mg weekly
~Pegylated liposomal doxorubicin IV 25 mg/m2 once every 4 weeks"
11592076|NCT00703157|Active Comparator|1|Arm 1: Catheter Ablation
11592077|NCT00703157|Active Comparator|2|Arm 2: Surgical Ablation.
11592080|NCT00703118|Experimental|Group A: T12/PR48|Participants will receive 12 weeks of 750 mg telaprevir eight hourly followed by 4 weeks of Placebo in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
11592081|NCT00703118|Experimental|Group B: T12(DS)/PR48|Participants will receive 4 weeks of Placebo followed by 12 weeks of 750 mg telaprevir eight hourly in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
11592082|NCT00703118|Experimental|Group C: Pbo/PR48|Participants will receive placebo in combination with Peg- IFN-alfa-2a and ribavirin for 16 weeks. Participants will receive Peg- IFN-alfa-2a and ribavirin for next 32 weeks.
11592083|NCT00703105|Experimental|Autologous Dendritic Cell Vaccination|DC vaccination with 1 x 10(6th) tumor lysate or WT1 and MUC1 peptide and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals(6 weeks)
11592084|NCT00703092|Experimental|Fiber-Stat|2 tablespoons daily
11592085|NCT00703079||Group A|>15 patients treated only with SSA (octreotide-LAR or lanreotide depot)
11592086|NCT00703079||Group B|>15 patients treated with surgery after a period of SSA treatment of 6-24 months
11592087|NCT00703079||Group C|>15 patients cured after surgery only
11592088|NCT00703079||Group D|>15 patients treated with surgery first and then with SSA after 6-12 months
11592089|NCT00703066|Experimental|1|three doses of 30µg GMZ2,
11592090|NCT00703066|Experimental|2|3 doses of 100 µg of GMZ2
11592091|NCT00703066|Active Comparator|3|Rabies vaccine
11592092|NCT00703053|Experimental|Group 1|25 subjects: Day 0, A/Vietnam/04 90 mcg; Day 7, A/Vietnam/04 90 mcg.
11592093|NCT00703053|Experimental|Group 9|100 subjects: Day 0, A/Vietnam/04 90 mcg; Day 28, A/Vietnam/04 90 mcg.
11592094|NCT00703053|Experimental|Group 8|100 subjects: Day 0, A/Vietnam/04 90 mcg.
11592095|NCT00703053|Experimental|Group 7|50 subjects: Day 0, A/Indonesia/05 90 mcg; Day 180, A/Indonesia/05 90 mcg.
11592096|NCT00703053|Experimental|Group 6|50 subjects: Day 0, A/Vietnam/04 90 mcg; Day 180, A/Indonesia/05 90 mcg.
11592097|NCT00703053|Experimental|Group 5|50 subjects: Day 0, A/Vietnam/04 45 mcg + A/Indonesia/05 45 mcg; Day 28, A/Vietnam/04 45 mcg + A/Indonesia/05 45 mcg.
11592098|NCT00703053|Experimental|Group 4|50 subjects: Day 0, A/Vietnam/04 90 mcg; Day 28, A/Indonesia/05 90 mcg.
11592099|NCT00703053|Experimental|Group 3|50 subjects: Day 0, A/Indonesia/05 90 mcg; Day 28, A/Indonesia/05 90 mcg.
11592100|NCT00703053|Experimental|Group 2|25 subjects: Day 0, A/Vietnam/04 90 mcg; Day 14, A/Vietnam/04 90 mcg.
11592101|NCT00703040||Component 1|Existing linkage to care protocols will be obtained from the 15 sites. This component does not involve study subjects.
11592102|NCT00703040||Component 2|Person-to-person or telephone interviews with ATN clinical site staff and staff from their community partners will be audio-taped.
11592103|NCT00703040||Component 3|Notes from direct observation of the linkage to medical care process within sites will be taken.
11592104|NCT00703014||Mothers Corifollitropin Alfa 150 µg|Participants from the Base Trial P05787 who received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recombinant Follicle Stimulating Hormone (recFSH); followed by daily SC injections with 200 IU recFSH up to the day of human chorionogonadotropin (hCG); multiple daily SC injections of Ganirelix from Stimulation Day 5 to the day of hCG; a single dose of hCG (5000 or 10,000 IU/USP) was administered when 3 follicles >= 17 mm were observed; and on the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the Base Trial were enrolled in Follow Up Trial P05712, where no study treatments were given, and pregnancy, delivery and neonatal outcome were monitored.
11592105|NCT00703014||Mothers recFSH 200 IU|Participants from the Base Trial P05787 who received a single SC injection of placebo Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 200 IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG; multiple daily SC injections of Ganirelix from Stimulation Day 5 to the day of hCG; a single dose of hCG (5000 or 10,000 IU/USP) was administered when 3 follicles >= 17 mm were observed; and on the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the Base Trial were enrolled in Follow Up Trial P05712, where no study treatments were given, and pregnancy, delivery and neonatal outcome were monitored.
11592106|NCT00703001|Active Comparator|1--Educational Intervention|Students in this arm will receive several in-class educational modules on basic oral health topics.
11592107|NCT00703001|Active Comparator|2--Referral intervention|Parents of student subjects will receive assistance in accessing oral health care for their child
11592108|NCT00702988||Experimental Group 1|all doses of Org 36286 (corifollitropin alfa) (60 μg, 120 μg and 180 μg)
11592109|NCT00702988||Experimental Group 2|150 IU recFSH
11592110|NCT00702962|Experimental|Phase I: Vorinostat 200 mg|"Vorinostat 200 mg PO QD D1-14; Administer with Carbo 6 (AUC) D3; Etoposide 100 mg/m2 D1,2,3 Vorinostat, Carboplatin, Etoposide"
11592111|NCT00702949|Experimental|Pregabalin75|Patients receive 75 mg of oral pregabalin twice daily for 6 weeks.
11592112|NCT00702949|Experimental|Pregabalin150|Patients receive 150 mg of oral pregabalin twice daily for 6 weeks.
11592113|NCT00702949|Placebo Comparator|Placebo|Patients receive oral placebo twice daily for 6 weeks.
11592114|NCT00702936|Active Comparator|R|Twenty-five patients assigned to ramipril 5 mg daily
11592115|NCT00702936|Active Comparator|T|Twenty-five patients assigned to Telmisartan 80 mg daily
11592116|NCT00702923|Experimental|1|Bicalutamide 150mg orally days 1-28 followed by CP-675,206 IV on day 29. Cycle is repeated once at month 3
11592117|NCT00702910|Experimental|GW642444M/lactose|GW642444M/lactose 6.25, 25 and 100 microgram, single inhaled dose for two days treatment in each treatment sequence (crossover design)
11592118|NCT00702910|Experimental|GW642444M/MgSt|GW642444M/MgSt 6.25, 25 and 100 microgram, single inhaled dose for two days treatment in each treatment sequence (crossover design)
11592119|NCT00702910|Placebo Comparator|Placebo|Placebo containing lactose, single inhaled dose for two days treatment in each treatment sequence (crossover design)
11592120|NCT00702884|Experimental|Sunitinib|Sunitinib 37.5 mg daily for a 4 week cycle
11592121|NCT00702871|Active Comparator|1|Arm 1 was given Injection Ranitidine 50mg i.v. 8 hourly for stress ulcer prophylaxis.
11592122|NCT00702871|Active Comparator|2|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
11592123|NCT00702858|Active Comparator|1|Blue Citrus either months 1-3 or 4-6
11592124|NCT00702858|Placebo Comparator|2|Placebo
11592125|NCT00702845|Experimental|corifollitropin alfa 100 µg|Participants received a single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of the menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day by intramuscular [IM] injection), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
11592126|NCT00702845|Active Comparator|recFSH 150 IU|Participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including the day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
11592127|NCT00702832|Experimental|Vestibular rehabilitation|early supported vestibular rehabilitation
11592128|NCT00702832|Active Comparator|standard|standard treatment
11592129|NCT00702806|Experimental|Org 36286 120 μg + Puregon® 150 IU|On Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 120 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
11592130|NCT00702806|Experimental|Org 36286 180 μg + Puregon® 150 IU|Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 180 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
11592131|NCT00702806|Experimental|Org 36286 240 μg + Puregon® 150 IU|Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 240 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
11592132|NCT00702806|Active Comparator|Puregon® 150 IU|On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
11592133|NCT00702793|Experimental|1|Smoking cessation drug - varenicline
11592134|NCT00702780|Experimental|Escitalopram|Escitalopram 20mg tablet by mouth once a day
11592135|NCT00702780|Placebo Comparator|Placebo|Placebo 20mg tablet by mouth once a day
11592136|NCT00702741|Experimental|A|Chondrogen (low dose)
11592137|NCT00702741|Experimental|B|Chondrogen (high dose)
11592138|NCT00702741|Placebo Comparator|C|Hyaluronan
11592139|NCT00702728|Experimental|1|Furosemide and matched saline hydration by RenalGuard system
11592140|NCT00702728|Active Comparator|2|Standard IV saline infusion
11592141|NCT00702715|Experimental|Participants with severe renal impairment|Participants with severe renal impairment will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC. Severe renal impairment was defined as creatinine clearance <30mL/min.
11592142|NCT00702715|Active Comparator|Participants with normal renal function|Participants with normal renal impairment will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC. Normal renal function was defined as creatinine clearance >=80mL/min.
11592143|NCT00702702|Experimental|A 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
11592144|NCT00702702|Experimental|B 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
11592145|NCT00702702|Placebo Comparator|C Placebo|Placebo, 2 capsules daily for 3 months
11592146|NCT00702689|Experimental|Imatinib mesylate in patients with cGVHD|"Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.
~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)"
11592147|NCT00702676|Experimental|1|Quetiapine Fumarate Immediate Release
11592148|NCT00702676|Experimental|2|Quetiapine Fumarate Extended Release
11592149|NCT00702650|Experimental|Testosterone MD-Lotion|"Participants received Testosterone Metered Dose (MD)-Lotion for 120 days. Participants started by receiving 3.0 mL (60 mg) of 2% Testosterone MD-Lotion, and based upon restoration to eugonadal levels, may have had their dose of testosterone adjusted upwards or downwards on Days 45 and 90.
~Doses could be titrated to one of the following:
~1.5 mL (30 mg) of 2% Testosterone MD-Lotion applied daily by 1 dose to the axilla (1.5 mL to one axilla).
~3.0 mL (60 mg) of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to each axilla).
~4.5 mL (90 mg) of 2% Testosterone MD-Lotion applied daily by 3 doses to the axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla).
~6.0 mL (120 mg) of 2% Testosterone MD-Lotion applied daily by 4 doses to the axilla (2 x 1.5 mL to each axilla)."
11592150|NCT00702624||Corifollitropin alfa 100 μg|In follow-up study, no medication or investigational product was administered. In base study P05690 (NCT00702845), participants received single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants in base study P05690 also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day by intramuscular [IM] injection), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
11592151|NCT00702624||recFSH 150 IU|In follow-up study, no medication or investigational product was administered. In base study P05690 (NCT00702845), participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
11592152|NCT00702611|Experimental|1|Seven apheresis treatments over seven consecutive weeks (1/week) in conjunction with a starting dose of 40mg of oral prednisone per day at Week 00 for two weeks which will be tapered down to zero 5 mg/week within nine weeks
11592153|NCT00702611|Active Comparator|2|Treatment with starting dose of 40mg of oral prednisone per day at Week 00 for two weeks and tapered down to zero 5 mg/week within nine weeks
11592154|NCT00702598|Experimental|1|Telephone-based Cognitive Behaviour Therapy
11592155|NCT00702598|Placebo Comparator|2|Telephone reminder calls
11592156|NCT00702585|Experimental|Org 36286 7.5 µg|Org 36286 7.5 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
11592157|NCT00702585|Experimental|Org 36286 15 µg|Org 36286 15 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
11592158|NCT00702585|Experimental|Org 36286 30 µg|Org 36286 30 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
11592159|NCT00702585|Experimental|Org 36286 60 µg|Org 36286 60 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
11592160|NCT00702585|Placebo Comparator|Placebo|Placebo to Org 36286 administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
11592161|NCT00702572|Experimental|1|Phase I dose escalating scheme
11592162|NCT00702572|Experimental|2|Phase 2 will evaluate the toxicities and safety profile of the 4-drug regimen.
11592163|NCT00702546||Corifollitropin alfa 100 μg|In follow-up study, no medication or investigational product was administered. But in base study P05690 (NCT00702845), participants received single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of the menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants in base study P05690 also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
11592164|NCT00702546||recFSH 150 IU|In this follow-up study, no medication or investigational product was administered. However, in base study P05690 (NCT00702845), participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including the day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
11592165|NCT00702533||Healthy Volunteers|Healthy volunteers between the ages of 18 and 60 years of age
11592166|NCT00702533||Patients with gastric acid and secretory disorders|18 years of age who have been diagnosed with Zollinger-Ellison Syndrome or acid hypersecretion.
11592167|NCT00702520||Corifollitropin alpha 100 ug|In the base study (P05788, 38833, NCT00702351), participants were pre-treated with daily subcutaneous (SC) injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase). After suppression of endogenous luteinizing hormone (LH) and follicle stimulating hormone (FSH) was confirmed by estradiol (E2) and progesterone (P) measurements, a single dose of corifollitropin alpha 100 μg was administered in participants weighing <= 60 kg. From stimulation Day 8 onwards, treatment was continued with daily SC of recombinant follicle stimulating hormone (recFSH) injections (maximally 200 IU) up to and including the day of administration of human chorionic gonadotprophin (hCG). No study medications were administered in the present P05783 study (38834, NCT00702520).
11592261|NCT00701896|Active Comparator|HIV Smoking Cessation Arm|Includes up to 365 subjects who are HIV positive and initiate smoking cessation
11592262|NCT00701896|Experimental|Motivational Intervention|Includes up to 100 subjects who are HIV positive, do not wish to quit smoking but are willing to undergo one-on-one Motivational Intervention
11592263|NCT00701883|Placebo Comparator|Placebo/Placebo|
11592264|NCT00701883|Experimental|MBX-8025 50 mg/Placebo|
11592265|NCT00701883|Experimental|MBX-8025 100 mg/Placebo|
11592168|NCT00702520||Corifollitropin alpha 150 ug|In the base study (P05788, 38833, NCT00702351), participants were pre-treated with daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase). After suppression of endogenous LH and FSH was confirmed by E2 and P measurements, a single dose of corifollitropin alpha 150 μg was administered in participants weighing >= 50 kg. From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG. No study medications were administered in the present P05783 study (38834, NCT00702520).
11592169|NCT00702507|Active Comparator|Miconazole Nitrate|
11592170|NCT00702494|Experimental|1|Multiple IV doses of TB-403, an antibody directed against PlGF
11592171|NCT00702481|Experimental|Nimotuzumab/CDDP/RT|Open label treatment arm of Nimotuzumab and cisplatin and radiation
11592172|NCT00702468|Experimental|Sativex|Sativex
11592173|NCT00702468|Placebo Comparator|Placebo|Placebo
11592174|NCT00702455|Active Comparator|Self-Directed|
11592175|NCT00702455|Active Comparator|Guided|
11592176|NCT00702442|Placebo Comparator|A|Placebo Administrated 30min prior to operation
11592177|NCT00702442|Experimental|B|0.625 mg Droperidol administrated i.v 30 min prior surgery
11592178|NCT00702429|Experimental|1|Patients achieve of parodontopathies
11592179|NCT00702429|Placebo Comparator|2|Patients without parodontales diseases
11592180|NCT00702416|Experimental|US Group|In this group, the continuous block will be performed under real-time ultrasound (US) guidance.
11592181|NCT00702416|Active Comparator|ENS Group|In this group, the continuous block will be performed with an electrical nerve stimulation (ENS) technique.
11592182|NCT00702403|Experimental|Treatment (prophylactic inhibition of BCR-ABL tyrosine kinase)|"Beginning after engraftment and blood count recovery (21 to 28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate PO QD until day 80 and then nilotinib PO BID on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO BID beginning after engraftment and blood count recovery until day 445.
~Treatment continues in the absence of disease progression or unacceptable toxicity."
11592183|NCT00702377|Experimental|SYSTANE Ultra|SYSTANE Ultra Lubricant Eye Drops
11592184|NCT00702377|Active Comparator|OPTIVE|OPTIVE Lubricant Eye Drops
11592185|NCT00702364|Experimental|Atomoxetine|40mg atomoxetine twice a day for 2 weeks
11592186|NCT00702364|Placebo Comparator|placebo|Placebo twice a day for two weeks
11592187|NCT00702351|Experimental|Arm 1|150 µg Org 36286 (corifollitropin alfa)
11592188|NCT00702351|Experimental|Arm 2|100 µg Org 36286 (corifollitropin alfa)
11592189|NCT00702338||corifollitropin alfa + recFSH Mothers|Eligible participants in Stage 1a of base study P05693 (NCT00697255) were administered injection(s) with subcutaneous (SC) corifollitropin alfa (15mcg) and daily SC injections with recFSH (50 IU) when the largest follicle reached a size of ≥12 mm. A bolus injection of hCG (5000 IU) was then administered if at least one follicle was ≥18 mm and in total no more than two follicles ≥15 mm were observed. Eligible mothers in this group with an ongoing pregnancy established in the base study (confirmed at ≥10 weeks after hCG bolus injection) were then to be followed for safety and efficacy on the current follow-up (FU) study (P05713) according to standard practice (no treatment administered).
11592190|NCT00702338||corifollitropin alfa + hCG Mothers|Eligible participants in Stage 1b of base study P05693 (NCT00697255) were administered injection(s) with SC corifollitropin alfa (30 mcg) and daily SC injections with hCG (200 IU) when the largest follicle reached a size of ≥12 mm. A bolus injection of hCG (5000 IU) was then administered if at least one follicle was ≥18 mm and in total no more than two follicles ≥15 mm were observed. Eligible mothers in this group with an ongoing pregnancy established in the base study (confirmed at ≥10 weeks after hCG bolus injection) were then followed for safety and efficacy on the current FU study (P05713) according to standard practice (no treatment administered).
11592191|NCT00702325|Experimental|1|
11592192|NCT00702325|Active Comparator|2|
11592193|NCT00702312|Experimental|Study group|Study group that will attend low-salt educational community programme
11592194|NCT00702312|No Intervention|Control group|Subjects in this arm will have routine medical and dietetic treatment for low-salt reduction.
11592195|NCT00702299|Experimental|Receiving Treatment|Dose escalation of day 1 i.p. pemetrexed disodium accrued three patients to each of five dose levels (60-1,000 mg/m2), along with day 2 i.p. cisplatin (75 mg/m2) and day 8 i.p. paclitaxel (60 mg/m2) with a biologic sample preservation procedure
11592196|NCT00702286||1|Two arm, double blinded, comparative, randomized, placebo controlled (active:sham - 2:1) study
11592197|NCT00702286||2|Two arm, double blinded, comparative, randomized, placebo controlled (active:sham - 2:1) study
11592198|NCT00702273||150 µg Corifollitropin Alfa|Participants from the base study P05787 (NCT00696800), received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa (Org 36286) on menstrual cycle Day 2/3 (Day 1); 7 daily SC injections from Days 1 to 7 with placebo-recombinant Follicle Stimulating Hormone (recFSH); followed by daily SC injections with 200 IU recFSH up to the day of human chorionogonadotropin (hCG). Daily SC injections of Ganirelix were given from Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles >= 17 mm. On the day of oocyte pick up (OPU) daily doses of progesterone were started, for up to 6 weeks or menses. Eligible participants from the base study were enrolled in follow up study P05716, where no study treatments were given, and embryos obtained in the base study underwent FTET cycles.
11592199|NCT00702273||200 IU RecFSH|Participants from the base study P05787 (NCT00696800), received a single SC injection of placebo Corifollitropin Alfa on menstrual cycle day 2/3 (Day 1); 7 daily SC injections with 200 IU recFSH from Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Multiple daily SC injections of Ganirelix were given from Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles >= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the base study were enrolled in follow up study P05716, where no study treatments were given, and embryos obtained in the base study underwent FTET cycles.
11592200|NCT00702247|Experimental|1|
11592266|NCT00701883|Active Comparator|Placebo/Atorvastatin 20 mg|
11592267|NCT00701883|Experimental|MBX-8025 50 mg/Atorvastatin 20 mg|
11592268|NCT00701883|Experimental|MBX-8025 100 mg/Atorvastatin 20 mg|
11592399|NCT00700986|Experimental|1|
11592201|NCT00702234||Women/Expectant Mothers - Corifollitropin Alfa 150 µg|In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of Gonadotropin Releasing Hormone (GnRH) antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin ([rec]hCG) (5,000-10,000 IU/250 µg). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh embryo transfer in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered.
11592202|NCT00702221|Experimental|ATV with CoVaccine HT™|Angiotensin Therapeutic Vaccine with CoVaccine HT™ adjuvant (an ingredient that may improve the immune response of the vaccine)
11592203|NCT00702221|Placebo Comparator|CoVaccine HT™ adjuvant alone|CoVaccine HT™ adjuvant alone
11592204|NCT00702208|Other|Single arm study|Paired laboratory results for clinician-collected and Screener collected specimens for cytology (and high-risk human papillomavirus testing for sub-sample)
11592205|NCT00702195||Experimental Group 1|all doses of Org 36286 (corifollitropin alfa) from trial 38805 (7.5 μg, 15 μg, 30 μg and 60 μg)
11592206|NCT00702195||Experimental Group 2|Placebo
11592207|NCT00702195||Experimental Group 3|all doses of Org 36286 (corifollitropin alfa) from trial 38807 (120 μg, 180 μg and 240 μg)
11592208|NCT00702195||Experimental Group 4|150 IU Puregon®
11592209|NCT00702182|Experimental|Conventional Vinorelbine, Erlotinib|Escalating doses of vinorelbine on Day 1 and Day 8 of 21 Day cycle; Erlotinib 100 mg OD
11592210|NCT00702182|Experimental|Metronomic Vinorelbine, Erlotinib|Escalating doses of vinorelbine TIW; erlotinib 100 mg OD
11592211|NCT00702169||1|Premature and term newborn infants (male/female)
11592212|NCT00702156|Experimental|1|Bisoprolol
11592213|NCT00702156|Placebo Comparator|2|Identical appearance matching placebo
11592214|NCT00702143|Experimental|AD subjects|
11592215|NCT00702143|Experimental|MCI Subjects|MCI (mild cognitive impairment)
11592216|NCT00702143|Experimental|Healthy controls|
11592217|NCT00702130|Experimental|A|this arm will receive Pravastatin 40 mg per os daily
11592218|NCT00702130|No Intervention|1|
11592219|NCT00702117|Active Comparator|A|IV flecainide in atrial fibrillation
11592220|NCT00702117|Experimental|B|IV ajmaline in atrial fibrillation
11592221|NCT00702117|Active Comparator|c|iv procainamide in ventricular tachycardia
11592222|NCT00702117|Experimental|d|iv ajmaline in ventricular tachycardia
11592223|NCT00702117|Active Comparator|e|iv flecainide in diagnosis of Brugada Sd
11592224|NCT00702117|Experimental|f|iv ajmaline in diagnosis of Brugada Sd
11592225|NCT00702078|Other|usual care|follow-up according to todays best practice.
11592226|NCT00702078|Experimental|cooperation|Follow-up from the hospital and the primary healthcare in cooperation
11592227|NCT00702065||1|
11592228|NCT00702065||2|
11592229|NCT00702052|Experimental|RAD001|
11592230|NCT00702039||1|Those patients receiving intravitreal injections who will be listening to classical music during injection.
11592231|NCT00702039||2|Those patients receiving intravitreal injections who will not be listening to any music during injection.
11592232|NCT00702026|Experimental|1|
11592233|NCT00702026|Placebo Comparator|2|
11592234|NCT00702013||1|
11592235|NCT00702013||2|
11592236|NCT00702013||3|
11592237|NCT00702013||4|
11592238|NCT00702013||5|
11592239|NCT00702013||6|
11592240|NCT00702013||7|
11592241|NCT00702013||8|
11592242|NCT00702000||1.|Those with ICU-acquired weakness
11592243|NCT00701987|Experimental|1|ALS-357 applied topically twice weekly for four weeks.
11592244|NCT00701987|Experimental|2|ALS-357 applied topically every other day for four weeks.
11592245|NCT00701987|Experimental|3|ALS-357 applied topically once daily for four weeks.
11592246|NCT00701987|Experimental|4|ALS-357 applied topically twice daily for four weeks.
11592247|NCT00701974|Experimental|1|patients treated with collagenase (IRUXOL)
11592248|NCT00701974|Experimental|2|patients treated with collagenase (Kollagenase)
11592249|NCT00701961|Experimental|1|Pregnat women receiving MQ-AS fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, dosed once daily such that mefloquine dose is approximately 8mg/kg/day for 3 days.
11592250|NCT00701961|Active Comparator|2|Non-pregnant women receiving MQ-AS fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, dosed once daily such that mefloquine dose is approximately 8mg/kg/day for 3 days.
11592251|NCT00701948||A-1|Proven nosocomial bacterial infection (NBI)
11592252|NCT00701948||A-2|Possible NBI
11592253|NCT00701948||B-1|Absence of NBI
11592254|NCT00701948||B-2|Probable absence of NBI
11592255|NCT00701935|Placebo Comparator|1|
11592256|NCT00701935|Experimental|2|
11592257|NCT00701909|Experimental|1|During the first wound care procedure, patients will receive either morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline (MS) or morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg (MK) before the WCP according to randomization. During the second wound care procedure, they will receive the drugs and doses that they had not received the first time.
11592258|NCT00701909|Active Comparator|2|During the second wound care procedure, patients will receive either morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline (MS) or morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg (MK), whichever drugs and doses that they had not received the first time.
11592259|NCT00701896|Other|Healthy Control - Non-smoking|Healthy Control arm with 51 subjects who are HIV negative and do not smoke
11592260|NCT00701896|Other|Healthy Control - Smoker|Healthy Control arm, includes 50 subjects who are HIV negative and are smokers.
11592338|NCT00701324|Experimental|Arm B|BI 811283, 24h infusion d1 every 3 weeks
11592269|NCT00701870|Experimental|ezatiostat hydrochloride (Telintra®)|Chemotherapy with docetaxel and carboplatin followed by Telintra until ANC recovery
11592270|NCT00701870|No Intervention|No Intervention|Chemotherapy with docetaxel and carboplatin alone
11592271|NCT00701857|Experimental|Pemetrexed, Cisplatin, Radiation Therapy|Concomitant Pemetrexed and CDDP Plus Radiation Therapy
11592272|NCT00701844|Experimental|Experimental Writing Type 1|
11592273|NCT00701844|Experimental|Experimental Writing type 2|
11592274|NCT00701844|Active Comparator|Control writing type 1|
11592275|NCT00701844|Placebo Comparator|Control writing type 2|
11592276|NCT00701831|Experimental|1|Insulin glargine
11592277|NCT00701805|Experimental|Paricalcitol 2 µg ± 1 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
11592278|NCT00701805|Experimental|Paricalcitol 2 µg ± 2 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
11592279|NCT00701805|Experimental|Paricalcitol 4 µg ± 1 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
11592280|NCT00701805|Experimental|Paricalcitol 4 µg ± 2 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
11592281|NCT00701792|Active Comparator|1|surgery : liver transplantation
11592282|NCT00701792|Active Comparator|2|standard care for liver disease
11592283|NCT00701779|Experimental|Dutasteride|"Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
~Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks."
11592284|NCT00701753||Olanzapine|Subjects treated with olanzapine as part of their routine clinical care
11592285|NCT00701753||Risperidone|Subjects treated with risperidone as part of their routine clinical care
11592286|NCT00701753||Quetiapine|Subjects treated with quetiapine as part of their routine clinical care
11592287|NCT00701740|Active Comparator|A|A - 21 subjects were treated 20mg isotretinoin 3/week plus moisturizer and sunscreen,for three months; 10 randomly selected were submitted to skin biopsies before and after the end of treatment
11592288|NCT00701740|Active Comparator|B|11 subjects received only the same moisturizer/sunscreen
11592289|NCT00701727|Experimental|1|ezetimibe (10mg/day)for 7 weeks
11592290|NCT00701727|Placebo Comparator|2|Placebo control
11592291|NCT00701714|Experimental|1|HX575, EPO HEXAL
11592292|NCT00701714|Active Comparator|2|ERYPO
11592293|NCT00701701|Experimental|Regimen A: Alglucosidase alfa and Cyclophosphamide|Participants exhibiting clinical decline since starting alglucosidase alfa (Myozyme®) therapy and having inhibitory antibodies and/or a sustained high recombinant human acid alpha-glucosidase (rhGAA) antibody titer (defined as at least 2 titers greater than or equal to [>=] 25,600 obtained at least 1 month apart), regardless of their CRIM status, were assigned to Regimen A. In Regimen A, participants received alglucosidase alfa (Myozyme®) Intravenous (IV) infusion of 20 milligram per kilogram (mg/kg) every other week (qow) for a minimum of 18 months or, until the participant reached the age of 2 years (if the participant was less than [<6] months of age at the time of enrollment). In addition, cyclophosphamide 250 milligram per square meter (mg/m^2) IV infusion was administered every 4 weeks (q4w) after Myozyme® infusion for 6 months.
11592294|NCT00701701|Experimental|Regimen B: Alglucosidase alfa, Rituximab and Methotrexate|CRIM-negative participants were assigned to Regimen B if they either(1)exhibited clinical decline since starting alglucosidase alfa (Myozyme®)therapy and did not have inhibitory antibodies and/or a sustained rhGAA antibody titer(defined as at least 2 titers >=25,600 obtained at least 1 month apart),or(2) did not exhibit clinical decline since starting alglucosidase alfa(Myozyme®) therapy, regardless of their anti-rhGAA or inhibitory antibody status. Regimen B participants with CRIM-negative status received alglucosidase alfa(Myozyme®) IV infusion of 20 mg/kg qow for a minimum of 18 months or,until participant reached the age of 2 years (if participant was <6 months of age at time of enrollment). In addition,rituximab 375 mg/m^2 IV was administered weekly beginning the day after Myozyme® infusion for 4 weeks(an optional 2nd cycle could be administered at the discretion of the investigator) and biweekly methotrexate 15 mg/m^2 subcutaneous on the day after Myozyme® infusion for 6 months.
11592295|NCT00701688|Experimental|Dose Level 1|Palifermin 40 mcg/kg/day intravenous
11592296|NCT00701688|Experimental|Dose Level 2|Palifermin 60 mcg/kg/day intravenous
11592297|NCT00701688|Experimental|Dose Level 3|Palifermin 90 mcg/kg/day intravenous
11592298|NCT00701675|Experimental|Sertraline 50mg|sertraline 50 mg daily
11592299|NCT00701675|Experimental|Sertraline 100mg|sertraline 100mg daily
11592300|NCT00701675|Placebo Comparator|Placebo|placebo 50 or 100mg
11592339|NCT00701311|Experimental|Study Drug CC-10004|Study drug CC-10004 20mg taken orally twice a day.
11592396|NCT00701012|Active Comparator|2|high ligation, which the IMA is ligated at its origin from the aorta
11592301|NCT00701662|Experimental|Vivaglobin|Vivaglobin® is a 16% (160 mg/mL) liquid formulation of human normal immunoglobulin for subcutaneous infusion. Subjects will receive weekly infusions of Vivaglobin® at a weekly dosage calculated based on previous intravenous immunoglobulin treatment (between 0.1 to 0.5 g/kg body weight per week).
11592302|NCT00701649|Experimental|1|
11592303|NCT00701649|Placebo Comparator|2|
11592304|NCT00701636|Experimental|Cases|The first 15 subjects enrolled will receive the intervention drug daptomycin as surgical antibiotic prophylaxis.
11592305|NCT00701636|No Intervention|Controls|15 subjects will be enrolled in the standard of care antibiotic group to serve as the controls. Controls will receive no experimental medications or treatments. The purpose of enrolling control patients was to serve as a reference group for intervention patients. Specifically cases and controls will be compared for changes in commonly collected hematologic parameters, creatinine, and CPK. Additionally, parameters collected during anesthesia will be compared. Controls will be matched to the intervention group by age (+/- 10 years), gender, and ethnicity.
11592306|NCT00701623|Experimental|1|patients treated with heparin
11592307|NCT00701623|Experimental|2|Patients treated with heparin
11592308|NCT00701623|Active Comparator|3|patients treated with folder water directly on the injured area
11592309|NCT00701610||1|All infants born in our hospital between August 2007 and August 2009 will participate.
11592310|NCT00701571|Experimental|1|3 cohorts: 18-21 years, 40-60 years, and older than 60 years
11592311|NCT00701558|Experimental|Erlotinib + Gemcitabine|Participants received erlotinib 150 mg/day, orally (po) on a continuous schedule in combination with gemcitabine at 1000 mg/m^2 administered intravenously (iv) on days 1, 8, 15 of each 4 week cycle for 6 cycles as per standard medical care, or until disease progression or participant's withdrawal due to any reason or death.
11592312|NCT00701545||1|Patients with von Willebrand disease treated with Humate P® ivr in Canada
11592313|NCT00701532|Experimental|1|active
11592314|NCT00701532|Placebo Comparator|2|Placebo
11592315|NCT00701506|Experimental|1|"15 Patients (may be expanded) will receive stimulation with the following parameters:
~20-minute session, to each affected knee, 3 times per week for 12 weeks.
~PENS for 20 minutes:
~Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).
~Minimal twitch for 5 minutes.
~Moderate to strong, but well-tolerated twitch contractions for 15 minutes.
~Electrodes placed on quadriceps and hamstrings."
11592316|NCT00701506|Placebo Comparator|2|"5 Patients (may be expanded) will receive stimulation with the following parameters:
~20-minute session, to each affected knee, 3 times per week for 12 weeks.
~Placebo PENS for 20 minutes:
~Electrodes placed on quadriceps and hamstrings."
11592317|NCT00701480|Experimental|1|skin cleanser contained Hibiscus sabdariffa
11592318|NCT00701480|Active Comparator|2|marketed skin cleanser
11592319|NCT00701467||Observation|
11592320|NCT00701454||1|Healthy participants (physically and mentally).
11592321|NCT00701441||Control group: healthy individuals without OSA|healthy individuals without OSA who are matched in weight and age to the participating OSA patients
11592322|NCT00701441||OSA group|Patients in the OSA group receive CPAP for 12 weeks as part of their care. patients with OSA provide measures at baseline and after 12 weeks of CPAP treatment.
11592323|NCT00701428|Active Comparator|1|Hypertensive Men and Women Without OSA on Losartan (n=30)
11592324|NCT00701428|Active Comparator|2|Hypertensive Men and Women With OSA on Losartan (n=30)
11592325|NCT00701428|Experimental|3|Hypertensive Men and Women with OSA on Losartan and CPAP (n=30)
11592326|NCT00701415|Experimental|Fabrazyme 0.5 mg/kg|Fabrazyme 0.5 mg/kg was administered every 2 weeks (up to 131 infusion) up to 260 weeks, the total infusion time was not less than 45 minutes. In case of significant progression of Fabry disease, the dose was increased to 1.0 mg/kg every 2 weeks.
11592327|NCT00701415|Experimental|Fabrazyme 1.0 mg/kg|Fabrazyme 1.0 mg/kg was administered every 4 weeks (up to 66 infusion) up to 260 weeks, the total infusion time was not less than 90 minutes. In case of significant progression of Fabry disease, the dose was increased to 1.0 mg/kg every 2 weeks.
11592328|NCT00701389|Experimental|Sequence 1: A→C→D→B|Participants receive the following: Period 1: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A); Period 2: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C); Period 3: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D); Period 4: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B). Each dosing period is separated by a 5-day washout.
11592329|NCT00701389|Experimental|Sequence 2: B→D→C→A|Participants receive the following: Period 1: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 2: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D): Period 3: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C); Period 4:single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A). Each dosing period is separated by a 5-day washout.
11592330|NCT00701389|Experimental|Sequence 3: C→B→A→D|Participants receive the following: Period 1 :single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C), Period 2: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 3: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A): Period 4: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D). Each dosing period is separated by a 5-day washout.
11592331|NCT00701389|Experimental|Sequence 4: D→A→B→C|Participants receive the following: Period 1: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D), Period 2: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treament A); Period 3: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 4: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C). Each dosing period is separated by a 5-day washout.
11592332|NCT00701376|Other|liver function|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
11592333|NCT00701363|Experimental|Lanreotide Autogel 120 mg|
11592334|NCT00701350||1|Women presenting with preterm gestation and ruptured membranes
11592335|NCT00701337|Experimental|1 Oral|oestradiol by oral administration - Estrofem 2 mg
11592336|NCT00701337|Experimental|2 patch|oestradiol par patch - Estrapatch 60microg/24h
11592337|NCT00701324|Experimental|Arm A|BI 811283, 24h infusion d1 and d15 every 4 weeks
11592340|NCT00701298|Active Comparator|Group 1 (chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients whose disease is not responding after the first course may crossover to group 2.
11592341|NCT00701298|Experimental|Group 2 (chemotherapy and antineoplastic agent)|Patients receive decitabine as in group 1 and pegylated interferon alfa-2b subcutaneously on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11592342|NCT00701285|Active Comparator|1|strong statin
11592343|NCT00701285|Active Comparator|2|mild statin
11592344|NCT00701272||1|Patients undergoing liver transplant for end-stage liver disease due to Hepatitis C
11592345|NCT00701272||2|"Control population:
~Patients undergoing liver transplantation for end-stage liver disease due to alcoholic cirrhosis"
11592346|NCT00701259|Experimental|1|15 mg lansoprazole
11592347|NCT00701259|Experimental|2|30 mg lansoprazole
11592348|NCT00701259|Placebo Comparator|3|placebo
11592349|NCT00701246|Experimental|I|I Treatment: a daily dose (5 times a week) of either 4,2 mg/kg/day of ferrous sulfate + folic acid (50 mcg)
11592350|NCT00701246|Placebo Comparator|II|II Treatment of anemic children with 4,2 mg/kg/day of ferrous sulfate and folic acid placebo.
11592351|NCT00701246|Experimental|III|Prevention of anemia in non-anemic children ( 5 times a week)- 1,4 mg/kg/day of ferrous sulfate and folic acid
11592352|NCT00701246|Placebo Comparator|IV|1,4 mg/kg/day of ferrous sulfate plus folic acid placebo, five days a week.
11592353|NCT00701233|Active Comparator|2|Corticosteroid injection into Carpal Tunnel
11592354|NCT00701233|Active Comparator|1|Botulinum toxin injection into Carpal Tunnel
11592355|NCT00701220|Active Comparator|1|Patients with Ischemic Cardiomyopathy receiving Lipitor.
11592356|NCT00701220|Active Comparator|2|NonIschemic Cardiomyopathy receiving Lipitor treatment
11592357|NCT00701220|No Intervention|3|Healthy subjects with no history of high cholesterol, heart disease, or heart attacks
11592358|NCT00701207|No Intervention|2.|control group-no intervention
11592359|NCT00701207|No Intervention|3|Healthy control group-blood and sputum samples
11592360|NCT00701207|Experimental|1.|nicotine patch; transdermal patch 7mg, 14 mg., 21 mg. 3 months
11592361|NCT00701194|Experimental|1|EIFC/MTFC-P
11592362|NCT00701194|No Intervention|2|Services as usual
11592363|NCT00701194|No Intervention|Community Comparison|Non-maltreated community pre-schoolers from low-income biological families.
11592364|NCT00701181|Active Comparator|Laser|This is a procedure - not a drug intervention.
11592365|NCT00701181|Experimental|PF-04523655 (High)|
11592366|NCT00701181|Experimental|PF-04523655 middle|
11592367|NCT00701181|Experimental|PF-04523655 low|
11592368|NCT00701155||A|
11592369|NCT00701142|Active Comparator|Haemocomplettan® P|Intravenous infusion during aortic surgery
11592370|NCT00701142|Placebo Comparator|Saline solution|
11592371|NCT00701129|Experimental|Alglucosidase Alfa|Alglucosidase alfa (Myozyme®) 20 milligrams per kilogram (mg/kg) intravenous (IV) infusion every other week (qow) (or optionally 20 mg/kg IV infusion every week [qw]) beginning from Day 0 to a minimum of 18 months or if the patient was less than (<) 6 months of age at the time of enrollment, until the patient was 2 years of age, along with methotrexate 0.4 mg/kg subcutaneously for 3 consecutive days qow beginning from Day 0 to Week 6 (9 doses) and rituximab 375 milligrams per square meter (mg/m^2) (or 12.5 mg/kg for patients with body surface area less than or equal to 0.5 m^2) IV infusion qw beginning from Day -1 to Week 4 (4 doses) as per local prescribing information. An additional 4-week cycle of rituximab (up to 4 additional doses) and 6-week cycle of methotrexate (up to 9 additional doses) may have been administered within the first 6 months of the study as per local prescribing information.
11592372|NCT00701103|Experimental|Dalotuzumab 1.25 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 1.25 mg/kg (10 mg/mL) intravenous (IV) infusion 1 time every 1 week (Q1W).
11592373|NCT00701103|Experimental|Dalotuzumab 2.5 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 2.5 mg/kg (10 mg/mL) IV infusion Q1W.
11592374|NCT00701103|Experimental|Dalotuzumab 5 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 5 mg/kg (10 mg/mL) IV infusion Q1W.
11592375|NCT00701103|Experimental|Dalotuzumab 10 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 10 mg/kg (10 mg/mL) IV infusion Q1W.
11592376|NCT00701103|Experimental|Dalotuzumab 10 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 10 mg/kg (20 mg/mL) IV infusion Q1W.
11592377|NCT00701103|Experimental|Dalotuzumab 15 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 15 mg/kg (10 mg/mL) IV infusion Q1W.
11592378|NCT00701103|Experimental|Dalotuzumab 15 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 15 mg/kg (20 mg/ mL) IV infusion Q1W.
11592379|NCT00701103|Experimental|Dalotuzumab 20 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 20 mg/kg (10 mg/mL) IV infusion Q1W.
11592380|NCT00701103|Experimental|Dalotuzumab 20 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 20.0 mg/kg (20 mg/mL) IV infusion Q1W.
11592381|NCT00701103|Experimental|Dalotuzumab 20 mg/kg Q2W (20 mg/mL)|Participants received dalotuzumab 20 mg/kg (20 mg/mL) IV infusion 1 time every 2 weeks (Q2W).
11592382|NCT00701103|Experimental|Dalotuzumab 30 mg/kg Q3W (20 mg/mL)|Participants received dalotuzumab 30 mg/kg (20 mg/mL) IV infusion1 time every 3 weeks (Q3W).
11592383|NCT00701090|Experimental|1|sitagliptin
11592384|NCT00701090|Active Comparator|2|glimepiride
11592385|NCT00701077|Experimental|1|3,4-Di-amino-Pyridine : a single 20 mg dosing
11592386|NCT00701077|Placebo Comparator|2|
11592387|NCT00701064|Experimental|Bright Light Exposure|Bright Light (30 min/day)
11592388|NCT00701064|Placebo Comparator|Negative Ion Generator|Negative Ion Generator (30 min/day)
11592389|NCT00701051|Active Comparator|Arm 1|Older adults, normal glucose tolerance
11592390|NCT00701051|Experimental|Arm 2|Older adults, impaired glucose tolerance
11592391|NCT00701038|Experimental|Device|Provided with an auto adjusting bi-level positive airway pressure device
11592392|NCT00701038|No Intervention|Control|No device
11592393|NCT00701025||1|35 asthmatic participants with EIB
11592394|NCT00701025||2|35 without EIB
11592395|NCT00701012|Experimental|1|low ligation, which the IMA is ligated below the origin of the left colic artery
11592401|NCT00700973|Active Comparator|Arm 1|Substance use disorder usual care
11592402|NCT00700973|Experimental|Arm 2|Interpersonal violence prevention intervention
11592403|NCT00700960||A|
11592404|NCT00700947|Experimental|1|Patients who are asymptomatic with normal left ventricular systolic function and who agree to be treated medically for severe primary mitral regurgitation with Beta-blocker therapy. Patients may entered into the Arm 2 (surgical treatment) later on when they develop symptoms or enlarged left ventricle or left ventricular dysfunction or wishes to have surgical treatment of severe primary mitral regurgitation.
11592405|NCT00700947|No Intervention|2|Patients will be surgically treated for severe primary mitral regurgitation as a routine clinical care if they want to be treated surgically or develop symptoms or significant adverse left ventricular remodeling or left ventricular dysfunction.
11592406|NCT00700947|No Intervention|3|Health Control includes the subjects with no remarkable past medical history and not currently taking any medications. Normal subjects will be used for comparison with patients with severe primary mitral regurgitation in term of clinical, echocardiographic and neuro-hormonal findings.
11592407|NCT00700921|Experimental|Active Drug (Lovastatin)|
11592408|NCT00700921|Placebo Comparator|Placebo (inactive comparator)|
11592409|NCT00700908|Experimental|1|Automated telephone intervention
11592410|NCT00700908|Active Comparator|2|Usual care
11592411|NCT00700895|Experimental|Pharmacogenetics-guided dosing group|For patients randomized to the pharmacogenetics-guided dosing group, this 10mls of blood will be immediately sent for genotyping studies. Genotyping results will be available for pharmacogenetics-guided dosing within 3 working days, (ranging 3 to 5 days). During this period, if patients need to be initiated on anticoagulation, a low molecular weight heparin, Fraxiparine, will be given. Fraxiparine will be overlapped with warfarin for 2 to 3 days until target INR is achieved. Elective cases should have the pharmacogenetics-based warfarin dose available at the time of warfarin therapy.
11592412|NCT00700895|Experimental|Traditional dosing group|For patients randomized to the traditional dosing regime, the blood will be stored and genotyped retrospectively at the end of the study. Overlapping of warfarin with Fraxiparine or heparin till target INR is achieved is allowed for this group as per normal clinical practice. All warfarin dosage adjustments based on INR results will be according to the current protocol used by the NUH Anticoagulant Clinic.
11592413|NCT00700882|Experimental|Dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11592414|NCT00700869|Experimental|1|Tracheal tube withdrawal governs by respiratory behaviour status
11592415|NCT00700856|Experimental|1|metformin 2000 mg + pioglitazone 15-45 mg
11592416|NCT00700856|Active Comparator|2|metformin 2000 mg + glibenclamide 5-15 mg or metformin 2000 mg + gliclazide 30-120 mg or metformin 2000 mg + glimepiride 2-6 mg
11592417|NCT00700830||A|
11592418|NCT00700817|Experimental|Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg|Once-daily subcutaneous dose of liraglutide 1.2 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First week for up-titration of liraglutide from 0.6 mg to 1.2 mg. Subjects continued to receive liraglutide 1.2 mg once daily in extension period 1 (weeks 26-52) and extension period 2 (weeks 52-78).
11592419|NCT00700817|Experimental|Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg|Once-daily subcutaneous dose of liraglutide 1.8 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First 2 weeks for up-titration of liraglutide from 0.6 mg to 1.8 mg. Subjects continued to receive liraglutide 1.8 mg once daily in extension period 1 (weeks 26-52) and extension period 2 (weeks 52-78).
11592420|NCT00700817|Active Comparator|Sita -> Sita|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52).
11592421|NCT00700817|Experimental|Sita -> Sita -> Lira 1.2 mg|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52). In extension period 2 (weeks 52-78), subjects were randomised to liraglutide 1.2 mg + metformin.
11592422|NCT00700817|Experimental|Sita -> Sita -> Lira 1.8 mg|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52). In extension period 2 (weeks 52-78), subjects were randomised to liraglutide 1.8 mg + metformin.
11592423|NCT00700804|Experimental|High Calcium Diet|
11592424|NCT00700804|Experimental|Low Calcium Diet|
11592425|NCT00700791|Placebo Comparator|Group I Single Site Randomization|Patients with 1 surgical scar will be given both oral placebo and topical cream placebo
11592426|NCT00700791|Active Comparator|Group II Single Site Randomization|Single surgical site will be given oral placebo and topical TCT
11592427|NCT00700791|Active Comparator|Group III Single Site Randomization|Patients with 1 surgical scar will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream
11592428|NCT00700791|Active Comparator|Group IV Single Site Randomization|Patients with 1 surgical scar will be given both Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT).
11592429|NCT00700791|Placebo Comparator|Group I: Bilateral Site Randomization|Patients with bilateral surgical scars will be given both oral placebo and topical cream placebo on one surgical site.
11592430|NCT00700791|Active Comparator|Group II: Bilateral Site Randomization|Patients with bilateral surgical scars will be given oral placebo and Natural Vitamin E Tocotrienol Cream (TCT) to one of the surgical sites.
11592431|NCT00700791|Active Comparator|Group III: Bilateral Site Randomization|Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream on one surgical site.
11592432|NCT00700791|Active Comparator|Group IV: Bilateral Site Randomization|Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT) on one surgical site.
11592433|NCT00700791|No Intervention|Normal Skin and Adipost Tissue Group|Normal human skin and adipose tissue will be collected
11592434|NCT00700778|Experimental|Recombinant human chorionic gonadotropin|Patients receive recombinant human chorionic gonadotropin subcutaneously three times weekly. Treatment continues weekly for 90 days in the absence of unacceptable toxicity.
11592435|NCT00700765||A|
11592719|NCT00698906|Active Comparator|Group F|
11592436|NCT00700752|Active Comparator|senofilcon A/balafilcon A|senofilcon A silicone hydrogel contact lens worn during first 4-week period, balafilcon A silicone hydrogel contact lens worn during the second 4-week period. Senofilcon A lenses worn daily on a 2-week replacement schedule; balafilcon A lenses worn daily on a 4-week replacement schedule. Lens replacement conducted in-office in a masked process.
11592437|NCT00700752|Active Comparator|balafilcon A/senofilcon A|balafilcon A silicone hydrogel contact lens worn worn during first 4-week period, senofilcon A silicone hydrogel contact lens worn during the second 4-week period. Senofilcon A lenses worn daily on a 2-week replacement schedule; balafilcon A lenses worn daily on a 4-week replacement schedule. Lens replacement conducted in-office in a masked process.
11592438|NCT00700739|Other|Anterior Cervical Discectomy and Fusion (ACDF)|Anterior Cervical Discectomy and Fusion with Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
11592439|NCT00700739|Active Comparator|Cervical Total Disc Replacement|DISCOVER™ Artificial Cervical Disc
11592440|NCT00700726||A.|participants with atopic and non-atopic asthma
11592441|NCT00700713|Experimental|One-Dose Menactra Group|Participants received one dose of Menactra® in Study MTA26
11592442|NCT00700713|Experimental|Two-Dose Menactra Group|Participants received two doses of Menactra® in Study MTA26
11592443|NCT00700713|Active Comparator|Menactra vaccine-naïve Group|Participants had never received Menactra® vaccine.
11592444|NCT00700700|Active Comparator|CRT-ON/CRT-OFF|Group initially randomized to CRT-ON, then cross-over to CRT-OFF
11592445|NCT00700700|Active Comparator|CRT-OFF/CRT-ON|Group initially randomized to CRT-OFF, then cross-over to CRT-ON
11592446|NCT00700687|Experimental|1|PA32540
11592447|NCT00700687|Experimental|2|PA32540 and celecoxib
11592448|NCT00700687|Active Comparator|3|aspirin and celecoxib
11592449|NCT00700674||1|Entropy group
11592450|NCT00700674||2|Control
11592451|NCT00700661|Experimental|1|Drug
11592452|NCT00700661|Placebo Comparator|2|Pbo
11592453|NCT00700648||A|
11592454|NCT00700635|Experimental|Menactra® Group 1|Participants aged 2 to < 4 years
11592455|NCT00700635|Experimental|Menactra® Group 2|Participants aged 4 to < 6 years
11592456|NCT00700635|Active Comparator|Menactra® Group 3|Participants aged 6 to < 11 years
11592457|NCT00700622|Experimental|TI + Insulin glargine|Technosphere Insulin Inhalation Powder in combination with Lantus (insulin glargine)
11592458|NCT00700622|Experimental|Insulin lispro + Insulin glargine|Humalog (insulin lispro) in combination with Lantus (insulin glargine)
11592459|NCT00700609|Experimental|1|"Attachment Based Family Therapy (ABFT)
~ABFT developed by Dr. Guy Diamond and colleagues is a brief, 12 week, manualized family-based intervention."
11592460|NCT00700609|Active Comparator|2|"Treatment as usual (TAU)
~No attempt is made to standardize TAU. Regular clinical staff will provide mental health services."
11592461|NCT00700596|Active Comparator|1|Salvinorin A (SA)
11592462|NCT00700596|Placebo Comparator|2|Control or Placebo SA
11592463|NCT00700583|Experimental|1|
11592464|NCT00700570|Experimental|1|
11592465|NCT00700557|Active Comparator|Probiotics - Lactobacillus casei and Bifidobacterium breve|"Yakult LB®
~1 sachet (1g) of Lactobacillus casei and Bifidobacterium breve - 6 x 108 UFC/g on a juice three times a day"
11592466|NCT00700557|Placebo Comparator|maize starch|725mg on juice three times a day
11592467|NCT00700544|Active Comparator|B|"Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR
~maintenance therapy every 3 months = 6 courses of reinduction with :
~-idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5 ), subcutaneously
~between the courses, a continuous regimen of methotrexate and 6-mercaptopurine."
11592468|NCT00700544|Experimental|A|"Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR
~maintenance therapy every 3 months = 6 courses of reinduction with :
~idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5, subcutaneously)
~10 to 20 mg (according to body weigh) of norethandrolone daily
~between the courses, a continuous regimen of methotrexate and 6-mercaptopurine."
11592469|NCT00700531|Experimental|1|Participants will receive FLC removal HD undertaken using an extended dialysis schedule on the Gambro HCO 1100 dialysers
11592470|NCT00700531|Active Comparator|2|Patients receive standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
11592471|NCT00700518|Placebo Comparator|1.|placebo cream applied to 2 adjacent fingers on non-dominant hand one time
11592472|NCT00700518|Active Comparator|2|0.6mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand
11592473|NCT00700518|Active Comparator|3|1.2mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
11592474|NCT00700518|Active Comparator|4|1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers on non-dominant hand one time
11592475|NCT00700518|Active Comparator|5|2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
11592476|NCT00700505|Experimental|Heating Garment|FlowPants(R) Garment with Heating
11592477|NCT00700492|No Intervention|control|
11592478|NCT00700492|Experimental|utrogestan|daily use of vaginal progesterone capsules
11592479|NCT00700479|Experimental|A|Aldosterone plus low salt diet
11592480|NCT00700479|Experimental|B|Aldosterone plus high sodium diet
11592481|NCT00700479|Placebo Comparator|C|Placebo plus low sodium diet
11592482|NCT00700479|Placebo Comparator|D|placebo plus high sodium diet
11592483|NCT00700466||1|Patients with hypertension and/or tachycardia prior to induction of anesthesia requiring i.v. beta-blockade for treatment of raised hemodynamic
11592484|NCT00700466||2|Patients with normal hemodynamic values prior to induction of anesthesia not requiring treatment
11592485|NCT00700453|Active Comparator|Control 1 Group|Subjects randomized to the Control 1 group will abstain from playing any video games for the entire study participation.
11592486|NCT00700453|Active Comparator|VG1- Control 2 Group|Subjects randomized to the Control 2 group will play a selected violent video game for 60-120 minutes/day during week 2 of the study and will abstain from any video game play during week 3 of the study.
11592487|NCT00700453|Active Comparator|VG1- VG2 group|Subjects randomized for VG1-VG2 group will play 60-120 minutes/day of a violent video game during weeks 2 & 3 of study participation.
11592488|NCT00700453|Active Comparator|VG1-CT group|Subjects randomized to the VG1-CT group will play 60-120 minutes of a selected violent video game during week 2 of the study and play a selected computerized cognitive training program for 60-120 minutes/day during week 3 of the study.
11592489|NCT00700440|Experimental|Cetuximab|400mg/m^2 intravenous infusion one week before radiotherapy, then 250mg/m^2 intravenous infusion weekly during radiotherapy
11592490|NCT00700427|Experimental|Atomoxetine|Atomoxetine 40-100 milligrams per day (mg/day) orally, once daily or twice daily for 24 weeks, followed by atomoxetine 80-100 mg/day orally, once daily or twice daily for 25 weeks.
11592491|NCT00700427|Placebo Comparator|Placebo|Atomoxetine 40-100 mg/day orally, once daily or twice daily for 24 weeks, followed by placebo orally, once daily for 25 weeks.
11592492|NCT00700414||Participants|Any participant who meets eligibility criteria and consents to participate in the trial.
11592493|NCT00700401||Peginterferon Alfa-2a + Ribavirin|
11592494|NCT00700388|Experimental|1|TPEP added to conventional manually assisted breathing techniques (MABT)
11592495|NCT00700388|Active Comparator|2|Manually assisted breathing techniques (MABT) alone
11592496|NCT00700375|Experimental|Sodium bicarbonate|
11592497|NCT00700375|Experimental|Sodium chloride|
11592498|NCT00700349|No Intervention|1|Individuals who were rejected from receiving a loan from a micro-lending organization were randomized to continue receiving no loan.
11592499|NCT00700349|Experimental|2|"Individuals who were rejected from receiving a loan from a micro-lending organization were randomized to receive a second look, to be reconsidered for a loan by loan officers."
11592500|NCT00700336|Experimental|Arm A|pemetrexed, cisplatin and CBP501
11592501|NCT00700336|Active Comparator|Arm B|pemetrexed and cisplatin
11592502|NCT00700323|Active Comparator|1|Patients receiving active product
11592503|NCT00700323|Placebo Comparator|2|Patients receiving placebo
11592504|NCT00700310|Active Comparator|1|
11592505|NCT00700310|Active Comparator|2|
11592506|NCT00700310|Active Comparator|3|
11592507|NCT00700310|Placebo Comparator|4|
11592508|NCT00700297|Active Comparator|Colchicine|Patients who received Colchicine and went on placebo after 4 months
11592509|NCT00700297|Placebo Comparator|Placebo|Patients who received placebo and went on Colchicine after 4 months
11592510|NCT00700284|Placebo Comparator|A|
11592511|NCT00700284|Experimental|B|
11592512|NCT00700271|Experimental|Morning Intake|After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP >= 140 mmHg and/or msDBP >= 90 mmHg or msSBP >= 130 mmHg and/or msDBP >= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP < 140 mmHg and msDBP < 90 mmHg or msSBP < 130 mmHg and msDBP < 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.
11592513|NCT00700271|Experimental|Evening Intake|After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP >= 140 mmHg and/or msDBP >= 90 mmHg or msSBP >= 130 mmHg and/or msDBP >= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP < 140 mmHg and msDBP < 90 mmHg or msSBP < 130 mmHg and msDBP < 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.
11592514|NCT00700258||1|Patients treated with Temsirolimus for metastatic renal cell carcinoma (mRCC) under usual care settings.
11592515|NCT00700258||2|Patients treated with Temsirolimus for mantle cell lymphoma (MCL) under usual care setting
11592516|NCT00700258||3|Patients treated with Sunitinib for metastatic renal cell carcinoma (mRCC) under usual care setting
11592517|NCT00700258||4|Patients treated with Sunitinib for gastro-intestinal stroma tumor (GIST) under usual care setting
11592518|NCT00700258||5|Patients treated with Axitinib after treatment with Sunitinib or Cytokine for metastatic renal cell carcinoma (mRCC)
11592519|NCT00700245|Active Comparator|EXO|Exercise-only (EXO-12 weeks of regular supervised exercise without diet restriction),
11592520|NCT00700245|Active Comparator|DIO|Diet-only (DIO-8 weeks of very low energy diet (VLED 600 kcal/d) followed by 4 weeks weight maintenance diet)
11592521|NCT00700245|Active Comparator|DEX|Diet+exercise (DEX-8 weeks VLED 800 kcal/d + a four weeks weight maintenance diet combined with regular supervised exercise throughout the 12 weeks).
11592522|NCT00700232||1|Normal multiparous pregnant women without intrahepatic cholestasis of pregnancy (control group)
11592523|NCT00700219||1|Women presenting in preterm labor with intact amniotic membranes
11592524|NCT00700206|Experimental|1|Dose Schedule 1: Two weeks treatment with Telintra 3000 mg per day in two divided doses followed by one week with no treatment per three week cycle.
11592525|NCT00700206|Experimental|2|Dose Schedule 2: Three weeks treatment with Telintra 2000 mg per day in two divided doses followed by one week with no treatment per four week cycle.
11592526|NCT00700193|Other|Group A|Equal to or greater 6 months to less than 3 years old
11592527|NCT00700193|Other|Group B|Equal to or greater 3 years to less than 9 years old
11592528|NCT00700180|Experimental|1|
11592529|NCT00700180|Experimental|2|
11592530|NCT00700167|Experimental|1|"The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months.
~The vaccines will be given during an outpatient visit. If for some reason, you happen to be in the hospital, you can still receive the vaccines. These visits should take no longer than 15-30 minutes."
11592531|NCT00700154|Experimental|Insulin infusion (aspart)|
11592532|NCT00700154|No Intervention|Standard care|Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.
11592533|NCT00700128|Experimental|Group 2|Frovatriptan or placebo given in a certain sequence depending on what group that the woman are randomized to.
11592534|NCT00700128|Experimental|Group1|Group I will receive in a different sequence either frovatriptan 2.5 mg or placebo bid starting the last day of taking OC and continuing during the hormone free interval (HFI) of 4 days.
11592535|NCT00700115|Experimental|Kaletra + Isentress|Kaletra + Isentress
11592536|NCT00700115|Active Comparator|Standard HAART|Pre-study Antiretroviral regimen
11592537|NCT00700102|Active Comparator|Chemotherapy|Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
11592538|NCT00700102|Experimental|Chemotherapy + Bevacizumab|Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal
11592539|NCT00700089|Experimental|A|The concept is to support and guide the person shortly after the in-hospital treatment for self-injury through a recommended follow-up or after treatment based on assertive principles. The intervention is an indicated prevention strategy targeting people with suicide attempts and deliberate self-harm as a high-risk group. They will be offered 8-20 assertive outreach contacts. The outreach contacts will be home visits focusing on providing support and motivating patients to comply with follow-up treatment.
11592540|NCT00700089|Placebo Comparator|B|Standard treatment consists of referral to a range of different treatment modalities depending on the diagnosis and clinical and social condition of the patient. In standard treatment there is no procedure for ensuring that the patient will actually receive the recommended treatment. Patients are often referred to available treatment modalities such as general practitioner, psychological treatment, treatment for alcohol abuse, and most often, the patients are themselves responsible for getting into contact with the treatment to which they are referred.
11592541|NCT00700076|Active Comparator|1|
11592542|NCT00700076|Placebo Comparator|2|
11592543|NCT00700063|Experimental|1|
11592544|NCT00700063|Experimental|2|
11592545|NCT00700063|Experimental|3|
11592546|NCT00700063|Placebo Comparator|4|
11592547|NCT00700063|Experimental|5|
11592548|NCT00700063|Experimental|6|
11592549|NCT00700063|Experimental|7|
11592550|NCT00700063|Placebo Comparator|8|
11592551|NCT00700050|Experimental|1|
11592552|NCT00700050|Active Comparator|2|
11592553|NCT00700050|Active Comparator|3|
11592554|NCT00700050|Active Comparator|4|
11592555|NCT00700037|Experimental|1|Atorvastatin 20mg
11592556|NCT00700037|Active Comparator|2|atorvastatin 5mg
11592557|NCT00700024|Active Comparator|1|testim
11592558|NCT00700024|Experimental|2|placebo
11592559|NCT00700024|Experimental|3|training
11592560|NCT00700011|Active Comparator|10 mg/m2 group|Patients were treated with Clofarabine 10 mg/m2 daily x 5 days per cycle. Cycles were intended on being every 28 days but this was flexible due to the bone marrow neding to recover from each cycle before strting the next one. Neulasta was given on day 5 of each cycle. Patients were treated until disease progression, or intolerable toxicities.
11592561|NCT00700011|Active Comparator|5 mg/m2 group|Patients were treated with Clofarabine 5 mg/m2 daily x 5 days per cycle. Cycles were intended on being every 28 days but this was flexible due to the bone marrow neding to recover from each cycle before strting the next one. Neulasta was given on day 5 of each cycle. Patients were treated until disease progression, or intolerable toxicities.
11592562|NCT00699998|Experimental|Prasugrel|Prasugrel and Low-dose Commercially-available Aspirin
11592563|NCT00699998|Active Comparator|Clopidogrel|Clopidogrel and Low-Dose Commercially-available Aspirin
11592564|NCT00699985||1|Behcet's Disease patients that their diagnosis was based on the new International Criteria for Behcet's Disease (ICBD).
11592565|NCT00699985||2|Non-Behcet's Disease patients were patients mimicking BD.
11592566|NCT00699972|Experimental|1|
11592567|NCT00699972|Experimental|2|
11592568|NCT00699972|Placebo Comparator|3|
11592569|NCT00699959||1|patients with heart failure
11592570|NCT00699959||2|patients without heart failure
11592571|NCT00699946|Active Comparator|1|
11592572|NCT00699946|Placebo Comparator|2|
11592573|NCT00699933||1|Evaluation of one study cohort
11592574|NCT00699920|Experimental|1|Coarsucam double-layer artesunate/amiodaquine tablets
11592575|NCT00699920|Active Comparator|2|Coartem (artemether/lumefantrine) fixed-dose combination tablets
11592576|NCT00699907|Active Comparator|Treatment Arm|Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.
11592577|NCT00699907|No Intervention|High Risk Arm|High risk patients underwent risk-reducing salpingo-oophorectomy.
11592578|NCT00699907|No Intervention|Low Risk Arm|Low risk patients underwent salpingo-oophorectomy for a medical indication.
11592579|NCT00699894|Experimental|1|aprepitant 40 mg + normal saline IV
11592580|NCT00699894|Active Comparator|2|placebo PO + ondansetron 4 mg IV
11592581|NCT00699881|Experimental|A|administer cetuximab in combination with modified FOLFIRI
11592582|NCT00699868|Experimental|1|Infection to CMV
11592583|NCT00699868|Other|2|"Group control CMV"
11592584|NCT00699842|Experimental|Lenalidomide|Lenalidomide will be given orally on day 1-21, followed by a 7day rest (28 day cycle). Cycles will be repeated every 28 days.
11592585|NCT00699829||1|Mohs' micrographic surgery (MMS)
11592586|NCT00699829||2|Conventional surgery
11592587|NCT00699816|Experimental|Immunotherapy Group|Adjuvant adoptive immune therapy using a CIK cell agent(Immuncell-LC) 16 times(4 treatments at a frequency of once per week, followed by 4 treatments every 2 weeks, then 4 treatments every 4 weeks, and finally 4 treatments every 8 weeks.
11592588|NCT00699816|No Intervention|Control Group|Patients who had undergone curative treatment(surgical resection, radiofrequency ablation[RFA], or percutaneous ethanol injection[PEI]) for HCC of pretreatment clinical stage I or II according to the American Joint Committee on Cancer staging system(6th edition) based on radiologic imaging studies were eligible for this study with no adjuvant treatment
11592589|NCT00699803|Active Comparator|T-Pred|Tobramycin prednisolone acetate combination
11592590|NCT00699803|Active Comparator|Pred Forte|Prednisolone acetate
11592591|NCT00699790|Experimental|A1|
11592593|NCT00699777|Experimental|1|One risedronate 150 mg tablet administered orally after an overnight (10 hour) fast, followed by a 4 hour post-dose fast
11592594|NCT00699777|Active Comparator|2|Two risedronate 75 mg tablets administered as a single oral dose after an overnight (10 hour) fast, followed by a 4 hour post-dose fast
11592595|NCT00699764|Experimental|Group A|
11592596|NCT00699764|Placebo Comparator|Group B|
11592597|NCT00699751|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received radium-223 50 kilo Becquerel (kBq)/kg body weight (b.w.) for 6 intravenous (IV) administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).
11592598|NCT00699751|Placebo Comparator|Placebo|Participants received isotonic saline for 6 IV administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).
11592599|NCT00699738|Experimental|1|Healthy women during pregnancy and in the postpartum period, breastfeeding
11592600|NCT00699738|Active Comparator|2|Healthy women during pregnancy and in the postpartum period,bottlefeeding
11592601|NCT00699738|No Intervention|3|Healthy non-pregnant women
11592602|NCT00699725||1|NSAID patients with risk factors treated with gastroprotective drugs
11592603|NCT00699712|Experimental|A|Open-label regimen of doses 1 and 2 of CDNP
11592604|NCT00699712|Experimental|B|Open-label regimen of doses 2 and 3 of CDNP
11592605|NCT00699712|Experimental|C|Open-label regimen of doses 3 and 4 of CDNP
11592606|NCT00699686|Active Comparator|Glargine|During this arm/phase patients take subcutaneous glargine daily for 3 months.
11592607|NCT00699686|Experimental|Detemir|During this arm/phase, patients take insulin Detemir subcutaneously for 3 months.
11592608|NCT00699660|Experimental|CAPS/WHODAS|PTSD assessed using Clinical Assessment of PTSD Symptoms (CAPS) and WHODAS functional impairment structured evidence-based interview
11592609|NCT00699660|Active Comparator|Nonstructured Interview|Usual clinical interview to assess PTSD, without CAPS or WHODAS
11592610|NCT00699621|Active Comparator|1|Platelet transfusion
11592611|NCT00699621|No Intervention|2|No platelet transfusion
11592612|NCT00699608|Experimental|Crossover|All subjects received all three treatments in a randomised order
11592613|NCT00699595||Term pregnant women|Healthy women scheduled for elective Cesarean section.
11592614|NCT00699582|Experimental|1|
11592615|NCT00699582|Experimental|2|
11592616|NCT00699582|Placebo Comparator|3|
11592617|NCT00699569|Experimental|1|Patients receiving active investigational product
11592618|NCT00699569|Placebo Comparator|2|Patients receiving Placebo
11592619|NCT00699556|Experimental|patch+spray|Within subject design. All volunteers complete two laboratory sessions. In one session they receive nicotine patch + nicotine nasal spray.
11592620|NCT00699556|Placebo Comparator|patch+placebo spray|Within subject design. All volunteers complete two laboratory sessions. In one session they receive nicotine patch + placebo nicotine nasal spray.
11592621|NCT00699543|Experimental|C|Coroflex Please stent implantation
11592622|NCT00699543|Active Comparator|T|Taxus stent implantation
11592623|NCT00699530||Hyperprolactinemia|Patients recently diagnosed with hyperprolactinemia
11592624|NCT00699517|Experimental|1|
11592625|NCT00699517|Placebo Comparator|2|
11592626|NCT00699504|Experimental|Lead in Phase|Supratherapeutic dose of cangrelor
11592627|NCT00699504|Experimental|A|therapeutic dose cangrelor treatment
11592628|NCT00699504|Experimental|B|supratherapeutic dose cangrelor treatment
11592629|NCT00699504|Active Comparator|C|active comparator treatment
11592630|NCT00699504|Placebo Comparator|D|placebo treatment
11592631|NCT00699491|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive temsirolimus IV over 30 minutes and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 (cixutumumab is given on days 8, 15, and 22 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11592632|NCT00699478|Experimental|1|post total gastrectomized patients due to gastric cancer who has vitamin B12 deficiency - given oral vitamin B 12 supplementation
11592633|NCT00699465|Active Comparator|1|Early enoxaparin
11592634|NCT00699465|Placebo Comparator|2|Late enoxaparin
11592635|NCT00699452|Active Comparator|1|Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)
11592636|NCT00699452|Placebo Comparator|2|Placebo
11592637|NCT00699439|Active Comparator|A|If a patient is identified as having an asthma exacerbation by the Bayesian Network, the paper-based flow-chart will be printed out to place on the chart.
11592638|NCT00699439|No Intervention|B|If a patient is identified as having an asthma exacerbation by the Bayesian Network, and assigned to the control group, no flow-chart will be printed out.
11592639|NCT00699426|Active Comparator|Nexium + Yoghurt|
11592640|NCT00699426|Placebo Comparator|Nexium + Placebo|
11592641|NCT00699426|Placebo Comparator|Placebo+ Yoghurt|
11592642|NCT00699426|Placebo Comparator|placebo+placebo|
11592643|NCT00699413|Active Comparator|1 - nutrition education plus active supplement|nutrition education plus active supplement
11592644|NCT00699413|Placebo Comparator|2 - nutrition education plus inactive supplement|nutrition education plus inactive supplement
11592645|NCT00699387|Experimental|Benznidazole|Treatment of pediatric Chagas disease with benznidazole
11592646|NCT00699374|Experimental|Arm A|sunitinib arm
11592647|NCT00699374|Active Comparator|Arm B|sorafenib arm
11592648|NCT00699361|Experimental|1|Measurement before Pantoprazole application
11592649|NCT00699361|Experimental|2|Measurements after Pantoprazole application
11592650|NCT00699348|Experimental|C.E.R.A.|
11592651|NCT00699322|Experimental|1|Sitagliptin
11592652|NCT00699322|Active Comparator|2|Glimepiride
11592653|NCT00699309||Taperloc® Microplasty™ Hip System|
11592654|NCT00699296|Experimental|1|
11592655|NCT00699283|Experimental|Brivaracetam (BRV) 1|50 mg daily
11592656|NCT00699283|Experimental|Brivaracetam (BRV) 2|100 mg daily
11592657|NCT00699270||Biomet Humeral Stems|Biomet Humeral Stems: Comprehensive®, BioModular®, and Bi-Angular® Shoulder Systems
11592658|NCT00699257||Oxford® Partial Knee System|
11592659|NCT00699244|Experimental|Peripheral placement of local anesthesia|to receive ultrasound guided peripheral placement of local anesthetic
11592660|NCT00699244|Active Comparator|Central placement of local anesthesia|to receive central placement of local anesthetic
11592661|NCT00699231|Active Comparator|Group A1|Non-responders to vaccination after at least 7 previous injections
11592662|NCT00699231|Experimental|Group A2|Non-responders to vaccination after at least 7 previous injections
11592663|NCT00699231|Active Comparator|Group B1|Vaccine-responders requiring a booster dose
11592664|NCT00699231|Experimental|Group B2|Vaccine-responders requiring a booster dose
11592665|NCT00699231|Active Comparator|Group C1|Volunteers participating in the hospital's vaccination program
11592666|NCT00699231|Experimental|Group C2|Volunteers participating in the hospital's vaccination program
11592667|NCT00699231|Active Comparator|Group D1|Unvaccinated haemodialysis patients
11592668|NCT00699231|Experimental|Group D2|Unvaccinated haemodialysis patients
11592669|NCT00699218|Experimental|rTMS treatment|Active rTMS treatment. Transcranial magnetic stimulation using a device called MagStim
11592670|NCT00699192|Experimental|Amlodipine/Valsartan 5/80 mg|1 capsule amlodipine 5 mg, 1 capsule valsartan 80 mg once daily
11592671|NCT00699192|Active Comparator|Amlodipine/Valsartan 5/40 mg|1 capsule amlodipine 5 mg, 1 capsule valsartan 40 mg once daily
11592672|NCT00699192|Active Comparator|Amlodipine 5 mg|1 capsule amlodipine 5 mg, 1 capsule placebo to match valsartan once daily
11592673|NCT00699179||A|
11592674|NCT00699166|Experimental|1|
11592675|NCT00699166|Experimental|2|
11592676|NCT00699166|Placebo Comparator|3|
11592677|NCT00699153|Experimental|Loteprednol Etabonate|Loteprednol Etabonate 0.5%
11592678|NCT00699153|Placebo Comparator|Vehicle|Vehicle of Ophthalmic Loteprednol Etabonate
11592679|NCT00699140|Experimental|1 treatment group with IGIV3I Grifols|"Open label, non-randomized treatment group with IGIV3I Grifols
~Each patient received a total dose of 2 g/kg IGIV3I Grifols, given intravenously over either 2 days or 5 days in divided doses."
11592680|NCT00699127|Experimental|1|The group that will have lecture of information regarding infants in NICU.
11592681|NCT00699127|No Intervention|2|The group that will not have lecture of information regarding NICU hospitalization
11592682|NCT00699114|Placebo Comparator|Placebo|Single dose placebo capsule
11592683|NCT00699114|Active Comparator|Ibuprofen 400 mg|Single dose ibuprofen 400 mg capsule
11592684|NCT00699114|Active Comparator|Ibuprofen 600 mg|Single dose ibuprofen 600 mg capsule
11592685|NCT00699114|Active Comparator|Ibuprofen 800 mg|Single dose ibuprofen 800 mg capsule
11592686|NCT00699114|Active Comparator|Paracetamol 500 mg|Paracetamol 500 mg (acetaminophen) capsule
11592687|NCT00699114|Active Comparator|Paracetamol 1000 mg|Single dose paracetamol 1000 mg (acetaminophen) capsule
11592688|NCT00699114|Active Comparator|Paracetamol 1000 mg + codeine 60 mg|Single dose paracetamol (acetaminophen) 1000 mg + codeine 60 mg capsule
11592689|NCT00699101|Experimental|A|Conture Multi-Lumen Balloon
11592690|NCT00699088||Balance® Microplasty™ Hip System|
11592691|NCT00699062|Placebo Comparator|Placebo pill|The patients allocated into this placebo comparator arm will receive inhale corticosteroid plus long-acting bronchodilator plus placebo for 6 months.
11592692|NCT00699062|Experimental|Singular pill|The patients in this placebo comparator arm will receive inhale corticosteroid plus long-acting bronchodilator and montelukast for 6 months
11592693|NCT00699049|Placebo Comparator|Alpha blocker and placebo|
11592694|NCT00699049|Experimental|Alpha blocker and solifenacin|
11592695|NCT00699036|Experimental|1|avandia
11592696|NCT00699036|Experimental|2|avandia plus metformin
11592697|NCT00699036|Experimental|3|avandia plus losartan
11592698|NCT00699023|Experimental|1|ezetimibe tablets 10 mg/die + simvastatin tablets 20 mg/die six weeks
11592699|NCT00699023|Placebo Comparator|2|placebo + simvastatin tablets 20 mg/die six weeks
11592700|NCT00699010|Active Comparator|Acurox 5/30mg taken first|oxycodone HCl/Niacin 5/30mg tablets; 8 tablets per dose
11592701|NCT00699010|Active Comparator|Oxycodone 5mg taken first|oxycodone HCl 5mg tablets; 8 tablets per dose
11592702|NCT00698997|Experimental|1 Early Start Denver Model|"Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching & coaching parents to use the ESDM in all natural caretaking routines & play periods with their child. Parents are taught & coached on 1 aspect of the ESDM each week in the clinic session, & then practice it at home daily in natural family routines & play.
~Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines & play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week."
11592703|NCT00698997|Other|2 Standard Care available in the Community|Any intervention that were available and that families accessed in their communities
11592704|NCT00698984|Active Comparator|1|30 mg BONISTEIN(R) 150 ug Vitamin K1 800 IU Vitamin D3 1000 mg PUFA 500 mg Calcium
11592705|NCT00698984|Placebo Comparator|2|500 mg Calcium
11592706|NCT00698958|Active Comparator|1|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
11592707|NCT00698958|Experimental|2|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
11592708|NCT00698945|Active Comparator|2|Alphagan
11592709|NCT00698945|Active Comparator|1|Istalol and Optive
11592710|NCT00698932|Experimental|Saxagliptin 5mg|
11592711|NCT00698932|Placebo Comparator|Placebo|
11592712|NCT00698919||Development cohort|A first group of one hundred patients with SIRS will be included to evaluate the accuracy of this new test.
11592713|NCT00698919||Validation Cohort|Depending on the result of the previous (development) cohort we will more accurately evaluate the need of number of patients with SIRS to include in the second cohort of patients.
11592714|NCT00698906|Experimental|Group A|
11592715|NCT00698906|Experimental|Group B|
11592716|NCT00698906|Experimental|Group C|
11592722|NCT00698880|Active Comparator|HVE|Hepatic vein embolization after portal vein embolization
11592723|NCT00698880|No Intervention|PVE|Only portal vein embolization, historical control group
11592724|NCT00698867||Discovery™ Elbow|Discovery™ Elbow minimally constrained
11592725|NCT00698854||Vanguard™ Complete Knee System|Vanguard Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
11592726|NCT00698854||Vanguard™ Patient-Specific Femur|Vanguard Total Knee System used in combination with Signature technique to provide a patient-specific femur
11592727|NCT00698841|Experimental|Cetuximab|
11592728|NCT00698828|Experimental|Group 1|SUN11031 for injection, low dose, twice daily for 12 weeks
11592729|NCT00698828|Experimental|Group 2|SUN11031 for injection, higher dose, twice daily for 12 weeks
11592730|NCT00698828|Placebo Comparator|Group 3|Placebo injection, twice daily for 12 weeks
11592731|NCT00698815|Experimental|Arm I (pemetrexed)|Patients receive pemetrexed disodium 500 mg/m^2 IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive sunitinib malate as in Arm II as third-line therapy.
11592732|NCT00698815|Experimental|Arm II (sunitinib)|Patients receive sunitinib malate at 37.5 mg PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive pemetrexed disodium as in Arm I as third-line therapy.
11592733|NCT00698815|Experimental|Arm III (pemetrexed and sunitinib)|Patients receive pemetrexed disodium 500 mg/m^2 IV over 10 minutes on day 1 and sunitinib malate at 37.5 mg PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive third-line therapy at the discretion of the treating physician.
11592734|NCT00698802|Experimental|A|
11592735|NCT00698802|Active Comparator|B|
11592736|NCT00698789|Experimental|Treatment A|5 mg of INCB019602 in AM with placebo administration in PM
11592737|NCT00698789|Experimental|Treatment B|20 mg of INCB019602 in AM with placebo administration in PM
11592738|NCT00698789|Experimental|Treatment C|5 mg of INCB019602 in PM with placebo administration in AM
11592739|NCT00698789|Experimental|Treatment D|20 mg of INCB019602 in PM with placebo administration in AM
11592740|NCT00698789|Experimental|Treatment E|7.5 mg of INCB019602 in PM QoD with placebo administration in AM as well as PM on non active dose days
11592741|NCT00698789|Placebo Comparator|Treatment F|Placebo BID
11592742|NCT00698776|Experimental|Active|10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
11592743|NCT00698763|Experimental|A|Levosimendan
11592744|NCT00698763|Placebo Comparator|B|Placebo
11592745|NCT00698750||Copeland™ Humeral Resurfacing Head|Copeland™ Humeral Resurfacing Head
11592746|NCT00698724|Active Comparator|1|Group 1: Xibrom, Optive
11592747|NCT00698724|Active Comparator|2|Group 2: Xibrom, Pred Forte
11592748|NCT00698711|Experimental|1|"Three groups of 5 patients enrolled sequentially comprised from will receive MUC-2-KLH vaccines at the following g amounts of MUC-2-KLH per vaccination.
~10 + 100 μg QS21 30 + 100 μg QS21 3 + 100 μg QS21"
11592749|NCT00698698||Non diabetic|Normal age and sex matched population
11592750|NCT00698698||Grade 1|Diabetic population with no retinopathy or Mild non proliferative diabetic retinopathy
11592751|NCT00698698||Grade 2|Moderate non proliferative diabetic retinopathy
11592752|NCT00698698||Grade 3|Severe non proliferative diabetic retinopathy
11592753|NCT00698698||Grade 4|Proliferative diabetic retinopathy and advanced diabetic eye disease
11592754|NCT00698685|Experimental|Preparative Regimen|"Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)
~Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)
~Followed by Allogeneic hematopoietic stem cell transplantation, related or unrelated donor, on day 0. Patients also receive cyclosporine intravenous (IV) continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper."
11592755|NCT00698672|Active Comparator|2|articulation Spectron EF CoCr/ Reflection All-Poly Eto-sterilized
11592756|NCT00698672|Active Comparator|3|articulation Spectron Ef CoCr/ Reflection All-Poly XLPE
11592757|NCT00698672|Active Comparator|4|articulation Spectron EF Oxinium/ Reflection All-Poly Eto-sterilized
11592758|NCT00698672|Active Comparator|5|articulation Spectron EF Oxinium/ Reflection XLPE
11592759|NCT00698672|Active Comparator|1|articulation Charnley/ Ogee
11592760|NCT00698659||patients on anti-VEGF therapy|"This study aims to assess the pharmacodynamic effects of anti-VEGF therapy. The following groups of patients will be approached:
~Those who are starting on anti-VEGF therapy (such as but not limited to bevacizumab, sunitinib, and sorafenib) as part of routine clinical management or on clinical studies
~All patients must be aged aged ≥ 21 years All patients must have a signed written informed consent prior to study enrollment. A separate consent will be obtained from patients already involved in a clinical study using anti-VEGF treatment.
~Patients with a known allergy to intravenous contrast used in fluorescein and indocyanine green angiography will be exempt from these investigations but will undergo other study assessments."
11592761|NCT00698646|Active Comparator|Valsartan|(patients initiated on valsartan)
11592762|NCT00698646|Active Comparator|HCTZ|(patients initiated on HCTZ)
11592763|NCT00698646|Experimental|Valsartan + HCTZ|(patients initiated on Valsartan+HCTZ)
11592764|NCT00698633||M2a- Taper™ Hip System|M2a- Taper™ Hip System
11592765|NCT00698607|Experimental|E6|Everolimus-eluting stent 6-month clopidogrel therapy
11592766|NCT00698607|Active Comparator|S6|Sirolimus-eluting stent 6-month clopidogrel therapy
11592767|NCT00698607|Experimental|E12|Everolimus-eluting stent 12-month clopidogrel therapy
11592768|NCT00698607|Active Comparator|S12|Sirolimus-eluting stent 12-month clopidogrel therapy
11592769|NCT00698594|Active Comparator|1|Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
11592840|NCT00698243|Experimental|Schedule 3|Once daily
11592770|NCT00698594|Active Comparator|2|Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group
11592771|NCT00698594|Placebo Comparator|3|Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
11592772|NCT00698581|Experimental|Brivaracetam 50 mg|50 mg/day
11592773|NCT00698581|Experimental|Brivaracetam 100 mg|100 mg/day
11592774|NCT00698568|Experimental|Group A|
11592775|NCT00698568|Placebo Comparator|Group B|
11592776|NCT00698555|Experimental|Group A|
11592777|NCT00698555|Experimental|Group B|
11592778|NCT00698555|Experimental|Group C|
11592779|NCT00698555|Experimental|Group D|
11592780|NCT00698555|Experimental|Group E|
11592781|NCT00698555|Active Comparator|Group F|
11592782|NCT00698542||1|Patients in the NCU at VUH
11592783|NCT00698529|No Intervention|No POL Training|Participating NGOs and their staff will receive no specialized training.
11592784|NCT00698529|Experimental|Face-to-Face|Participating NGOs and their staff will receive training through face-to-face seminars held at the NGOs and through post-seminar consultation telephone calls.
11592785|NCT00698529|Experimental|Distance Learning|Participating NGOs and their staff will receive training through Web-based seminars and through post-seminar consultation telephone calls.
11592786|NCT00698516|Experimental|Open label, Single arm|Oral topotecan + IV Bevacizumab
11592787|NCT00698503||M2a- 38™ Hip System|
11592788|NCT00698490|Experimental|Group A|HSV-seronegative subjects
11592789|NCT00698490|Experimental|Group B|HSV-seropositive subjects
11592790|NCT00698490|Experimental|Group C|HSV-seronegative subjects
11592791|NCT00698490|Experimental|Group D|HSV-seronegative subjects
11592792|NCT00698490|Experimental|Group E|HSV-seronegative subjects
11592793|NCT00698464|Experimental|Pasireotide|
11592794|NCT00698451|Experimental|001|doxorubicin HCL liposome; bevacizumab; carboplatin30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
11592795|NCT00698438|Active Comparator|a|Implantation of Ex-PRESS mini glaucoma shunt under a scleral flap
11592796|NCT00698438|Active Comparator|b|Trabecolectomy
11592797|NCT00698425|Experimental|1: 0 mA-min (0 mA for 4 min)|Ocular iontophoresis 0 mA-min (0 mA for 4 minutes)
11592798|NCT00698425|Experimental|2: 4 mA-min (2 mA for 2 min), + polarity|Ocular iontophoresis 4 mA-min (2 mA for 2 minutes), positive polarity
11592799|NCT00698425|Experimental|3: 5 mA-min (2.5 mA for 2 min), +|Ocular iontophoresis 5 mA-min (2.5 mA for 2 minutes), positive polarity
11592800|NCT00698425|Experimental|4: 6 mA-min (3 mA for 2 min), + polarity|Ocular iontophoresis 6 mA-min (3 mA for 2 minutes), positive polarity
11592801|NCT00698425|Experimental|5: 7 mA-min (3.5 mA for 2 min), +|Ocular iontophoresis 7 mA-min (3.5 mA for 2 minutes), positive polarity
11592802|NCT00698425|Experimental|6: 8 mA-min (4 mA for 2 min), + polarity|Ocular iontophoresis 8 mA-min (4 mA for 2 minutes), positive polarity
11592803|NCT00698425|Experimental|7: 7 mA-min (3.5 mA for 2 min), -|7 mA-min (3.5 mA for 2 minutes), negative polarity
11592804|NCT00698425|Experimental|8: 8 mA-min (4 mA for 2 min), - polarity|Ocular iontophoresis 8 mA-min (4 mA for 2 minutes), negative polarity
11592805|NCT00698425|Experimental|9: 20 mA-min (4 mA for 5 min), +|Ocular iontophoresis 20 mA-min (4 mA for 5 minutes), positive polarity
11592806|NCT00698425|Experimental|10: 20 mA-min (2 mA for 10 min), +|Ocular iontophoresis 20 mA-min (2 mA for 10 minutes), positive polarity
11592807|NCT00698425|Experimental|11: 20 mA-min (4 mA for 5 min), -|Ocular iontophoresis 20 mA-min (4 mA for 5 minutes), negative polarity
11592808|NCT00698425|Experimental|12: 20 mA-min (2 mA for 10 min), -|Ocular iontophoresis 20 mA-min (2 mA for 10 minutes), negative polarity
11592809|NCT00698425|Experimental|13: 0 mA-min (0 mA for 10.5 min)|Ocular iontophoresis 0 mA-min (0 mA for 10.5 minutes)
11592810|NCT00698425|Experimental|14: 13.5 mA-min (4.5 mA for 3 min), +|Ocular iontophoresis 13.5 mA-min (4.5 mA for 3 minutes), positive polarity
11592811|NCT00698425|Experimental|15: 15 mA-min (5 mA for 3 min), +|Ocular iontophoresis 15 mA-min (5 mA for 3 minutes), positive polarity
11592812|NCT00698425|Experimental|16: 16.5 mA-min (5.5 mA for 3 min), +|Ocular iontophoresis 16.5 mA-min (5.5 mA for 3 minutes), positive polarity
11592813|NCT00698425|Experimental|17: 18 mA-min (6 mA for 3 min), +|Ocular iontophoresis 18 mA-min (6 mA for 3 minutes), positive polarity
11592814|NCT00698425|Experimental|18: 19.5 mA-min (6.5 mA for 3 min), +|Ocular iontophoresis 19.5 mA-min (6.5 mA for 3 minutes), positive polarity
11592815|NCT00698425|Experimental|19: 20 mA-min (7 mA for 3.84 min), +|Ocular iontophoresis 20 mA-min (7 mA for 3.84 minutes), positive polarity
11592816|NCT00698412|Experimental|1|Cane group
11592817|NCT00698412|No Intervention|2|Control Group
11592818|NCT00698399||1|Live Donor
11592819|NCT00698399||2|Cadaveric Donor
11592820|NCT00698373||1|PET study
11592821|NCT00698360||A|MDRD 10-30
11592822|NCT00698360||B|MDRD 30-60
11592823|NCT00698360||C|MDRD 60-80
11592824|NCT00698360||D|MDRD > 80
11592825|NCT00698347||M2a-Magnum™ Hip System|Patients who received the M2a-Magnum™ Hip System
11592826|NCT00698334|Experimental|HIV infected|HIV infected patients with active TB
11592827|NCT00698334|Active Comparator|HIV negative|HIV negative patients with active TB
11592828|NCT00698321|Experimental|1|Participating schools will deliver HIV/STD prevention modules.
11592829|NCT00698321|Active Comparator|2|Participating schools will deliver general health promotion modules.
11592830|NCT00698282|Experimental|1|
11592831|NCT00698282|Experimental|2|
11592832|NCT00698282|Placebo Comparator|3|
11592833|NCT00698269||A|
11592834|NCT00698269||B|
11592835|NCT00698269||C|
11592836|NCT00698256|Experimental|1|
11592837|NCT00698256|Placebo Comparator|2|
11592838|NCT00698243|Experimental|Schedule 1|Once daily for 3 days every 7 days
11592839|NCT00698243|Experimental|Schedule 2|Once weekly
11592841|NCT00698230|Experimental|Treatment A - INCB013739 & Metformin|INCB013739 5 mg QD and Metformin
11592842|NCT00698230|Experimental|Treatment B - INCB013739 & Metformin|INCB013739 15 mg QD and Metformin
11592843|NCT00698230|Experimental|Treatment C - INCB013739 & Metformin|INCB013739 50 mg QD and Metformin
11592844|NCT00698230|Experimental|Treatment D - INCB013739 & Metformin|INCB013739 100 mg QD and Metformin
11592845|NCT00698230|Experimental|Treatment E - INCB013739 & Metformin|INCB013739 200 mg QD and Metformin
11592846|NCT00698230|Placebo Comparator|Treatment F - Placebo|Matching placebo
11592847|NCT00698204|Experimental|I- Celecoxib|
11592848|NCT00698204|Placebo Comparator|II|
11592849|NCT00698191|Experimental|1|
11592850|NCT00698178||NERD|patients with typical gastro-reflux symptoms but no erosions were discernible on upper gastrointestinal endoscopy
11592851|NCT00698178||EE|Patients with both typical gastroesophageal reflux symptoms and characteristic flam-like erosions as demonstrated on upper gastrointestinal endoscopy
11592852|NCT00698178||FD|Patients report no typical reflux symptoms but fulfill diagnostic criteria of functional dyspepsia, whose upper gastrointestinal endoscopy are negative.
11592853|NCT00698165||Patients|1200 adults with mild to severe Alzheimer's disease
11592854|NCT00698165||Caregivers|1200 informal caregivers
11592855|NCT00698152||ArComXL® polyethylene|ArComXL® polyethylene
11592856|NCT00698139|Active Comparator|Intervention first, then control|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.
~On the first encounter, patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.
~On the second encounter, patients will come to clinic in the morning for baseline measurements.Subsequently, they will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. The rest of the protocol will be as described for the first encounter."
11592857|NCT00698139|Active Comparator|Control first, then intervention|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.
~On the first encounter, patients will come to clinic in the morning for baseline measurements.Subsequently, the control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.
~On the second encounter, patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The rest of the protocol will be as described for the first encounter."
11592858|NCT00698139|Active Comparator|Intervention Only|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.
~Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour."
11592859|NCT00698126||A|
11592860|NCT00698126||B|
11592861|NCT00698113|Active Comparator|1|This group receives the massage intervention for a period of six weeks. Children and parents are asked to journal weekly for the six week period.
11592862|NCT00698113|No Intervention|2|The control group does not receive any massage intervention during the initial six weeks of the study. The children are asked to journal during this six week period.
11592863|NCT00698100|Experimental|1|Patients will get human tyrosinase vaccination.
11592864|NCT00698100|Experimental|2|Patient will get mouse tyrosinase DNA vaccination.
11592865|NCT00698087|Experimental|Group A|
11592866|NCT00698087|Active Comparator|Group B|
11592867|NCT00698087|Experimental|Group C|
11592868|NCT00698074|Experimental|1|Cardiac Resynchronisation Therapy
11592869|NCT00698061|Experimental|Group A|
11592870|NCT00698061|Active Comparator|Group B|
11592871|NCT00698048||1|Controls
11592872|NCT00698048||2|Sepsis
11592873|NCT00698048||3|Septic Shock
11592874|NCT00698035|Active Comparator|Testosterone Cream|Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
11592875|NCT00698035|Active Comparator|Estring|Estring 2mg ring inserted vaginally once every 12 weeks
11592876|NCT00698022|Experimental|Risperidone plus mifepristone|risperidone plus mifepristone daily for 28 days
11592877|NCT00698022|Placebo Comparator|risperidone plus mifepristone-matched placebo|risperidone plus mifepristone-matched placebo daily for 28 days
11592878|NCT00698022|Placebo Comparator|risperidone matched-placebo plus mifepristone|risperidone-matched placebo plus mifepristone daily for 28 days
11592879|NCT00698009|Experimental|Fludarabine + Cyclophosphamide + NK Cell Infusion|Fludarabine 25 mg/m^2 intravenous (IV) Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2. Cyclophosphamide 60 mg/kg IV Daily Over 2 Hours On Days -5 and -4. Natural Killer Cell Infusion on Day 0. Mesna 12 mg/kg By Vein, Over about 15 minutes, 5 Times Per Day on Days -5 and -4. Interleukin-2 subcutaneously three times weekly for 9 total doses following NK Cell Infusion.
11592880|NCT00697983||Fracture cohort|Patients of 50 years and above with a clinical, non-pathological fracture, who attend an osteoporosis outpatient clinic at the Maastricht University Medical Center for standard medical care (including bone densitometry by DXA-scan).
11592881|NCT00697970|Experimental|Group A|
11592882|NCT00697970|Experimental|Group B|
11592883|NCT00697970|Experimental|Group C|
11592884|NCT00697970|Experimental|Group D|
11592885|NCT00697970|Experimental|Group E|
11592886|NCT00697970|Active Comparator|Group F|
11592887|NCT00697957|No Intervention|2|Control group
11592888|NCT00697957|Experimental|1|Exercise
11592889|NCT00697931|Experimental|Group A|
11592890|NCT00697931|Active Comparator|Group B|
11592891|NCT00697918|Experimental|001|RWJ-333369100 mg to 400 mg twice daily
11592892|NCT00697905|Experimental|A|
11592893|NCT00697905|Active Comparator|B|
11592894|NCT00697892|Experimental|Group A4|healthy volunteers assigned to the efavirenz with artemether/lumefantrine intervention
11592895|NCT00697892|Experimental|Group A3|healthy volunteers assigned to the lopinavir/ritonavir with artemether/lumefantrine intervention
11592896|NCT00697879|Experimental|1|Oral, once daily administration of CHR-3996 to determine safety and tolerability
11592897|NCT00697866|Experimental|Group A|HBV-MPL Lot A
11592898|NCT00697866|Experimental|Group B|HBV-MPL Lot B
11592899|NCT00697866|Experimental|Group C|HBV-MPL Lot C
11592900|NCT00697866|Active Comparator|Group D|Engerix™-B
11592901|NCT00697853|Active Comparator|Group A|
11592902|NCT00697853|Experimental|Group B|
11592903|NCT00697853|Experimental|Group C|
11592904|NCT00697853|Experimental|Group D|
11592905|NCT00697853|Experimental|Group E|
11592906|NCT00697840|Experimental|Group A|
11592907|NCT00697840|Active Comparator|Group B|
11592908|NCT00697840|Experimental|Group C|
11592909|NCT00697827|Experimental|1|In-Space
11592910|NCT00697827|Active Comparator|2|X STOP
11592911|NCT00697814|Experimental|Clomiphene|Clomiphene 50 mg/day for 12 weeks
11592912|NCT00697801|Experimental|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
11592913|NCT00697801|Experimental|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
11592914|NCT00697801|Placebo Comparator|Placebo|Placebo delivered by nebulization twice daily for 6 weeks
11592915|NCT00697788|Experimental|Ascending dose study|Ascending doses of dexmedetomidine (as per protocol)
11592916|NCT00697775|Experimental|Group A|HBV-MPL Formulation A at months 0 and 6
11592917|NCT00697775|Experimental|Group B|HBV-MPL Formulation B at months 0 and 6
11592918|NCT00697775|Experimental|Group C|HBV-MPL Formulation A at month 0 and Engerix™-B at month 6
11592919|NCT00697775|Active Comparator|Group D|Engerix™-B at months 0, 1, 6
11592920|NCT00697762|Placebo Comparator|003|Placebo tablet twice daily for 12 weeks
11592921|NCT00697762|Experimental|002|RWJ-333369 200 mg tablet twice daily for 12 weeks
11592922|NCT00697762|Experimental|001|RWJ-333369 100 mg tablet twice daily for 12 weeks
11592923|NCT00697749|Experimental|Group A|
11592924|NCT00697749|Active Comparator|Group B|
11592925|NCT00697710|Experimental|Cohort A|50 mg S-777469 or Placebo, BID
11592926|NCT00697710|Experimental|Cohort B|200 mg S-777469 or Placebo, BID
11592927|NCT00697710|Experimental|Cohort C|800 mg S-777469 or Placebo, BID
11592928|NCT00697697|Experimental|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
11592929|NCT00697697|Experimental|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
11592930|NCT00697684|No Intervention|Cohort 1|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
11592931|NCT00697684|Experimental|Cohort 2|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
11592932|NCT00697684|Experimental|Cohort 3|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
11592933|NCT00697684|Experimental|Cohort 4|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
11592934|NCT00697671|Other|Strata A|Patients with ALL, CML, JMML, MDS, or NHL with bone marrow relapse after stem cell transplant.
11592935|NCT00697671|Other|Strata B|Patients with ALL, CML, JMML , MDS, or NHL with primary induction failure and persistent disease; or participants with relapsed ALL, CML, JMML, MDS, or NHL with persistent disease after re-induction
11592936|NCT00697658||001|
11592937|NCT00697645|Sham Comparator|1|Patients with stroke will be treated with usual stroke care and sham TMS will be applied
11592938|NCT00697645|Experimental|2|Deep TMS applied over the motor strip in patients with stroke in addition to usual stroke care.
11592939|NCT00697632|Experimental|1|
11592940|NCT00697619|Experimental|Test Group|Zometa (zoledronic acid) 4 mg over 15 min IV infusion, every 4 week Anti-neoplastic therapy .Patients can receive concomitant cycles of chemotherapy or radiotherapy.
11592941|NCT00697619|No Intervention|Contorl Group|Anti-neoplastic therapy alone. Patients can receive concomitant cycles of chemotherapy or radiotherapy.
11592942|NCT00697606|Experimental|A|Seprafilm®
11592943|NCT00697606|Sham Comparator|B|Control
11592944|NCT00697593|Experimental|Efalizumab|
11592945|NCT00697580|No Intervention|1|Control (C)
11592946|NCT00697580|Experimental|2|Nutrition (N)
11592947|NCT00697580|Experimental|3|Strength Training & Nutrition (ST + N)
11592948|NCT00697580|Experimental|4|Circuit Training & Nutrition (CT + N)
11592949|NCT00697567|Experimental|Group A|HSV seropositive subjects
11592950|NCT00697567|Experimental|Group B|HSV seronegative subjects
11592951|NCT00697567|Experimental|Group C|HSV seropositive subjects
11592952|NCT00697567|Experimental|Group D|HSV seronegative subjects
11592953|NCT00697554|Experimental|Group A|
11592954|NCT00697554|Active Comparator|Group B|
11592955|NCT00697541|Experimental|A|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after four hours
11592956|NCT00697541|Active Comparator|B|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
11592957|NCT00697528||Group control with healthy subjects|Healthy subjects without thyroid disease, ocular disease and previous surgery in the orbit or eye used in the study.
11592958|NCT00697528||Graves' Ophthalmopathy - fibrotic phase|Patients that are clinically inactive (CAS equal or lower than 2). This group will be subdivided in the miogenic and lipogenic groups.
11592959|NCT00697528||Graves' Ophthalmopathy - active phase|Patients that are clinically active, presenting a CAS of 4 or more points, with or without disthyroid optic neuropathy.
11592960|NCT00697515|Active Comparator|Lisdexamfetamine Dimesylate (LDX, SPD489)|
11592961|NCT00697515|Placebo Comparator|Placebo|
11592962|NCT00697502|Experimental|Group 2: TSER 3R/3R|Cohorts of 3-6 patients in each genotype group will receive escalating doses of capecitabine until MTD is reached. Once MTD is determined, an additional 6-9 patients (for a total of 12 patients) will receive treatment at that dose.
11592963|NCT00697502|Experimental|Group 1: TSER 2R/2R or 2R/3R|Cohorts of 3-6 patients in this genotype group will receive escalating doses of capecitabine until MTD is reached. Once MTD is determined, an additional 6-9 patients (for a total of 12 patients) will receive treatment at that dose.
11592964|NCT00697489|Active Comparator|1|unique surgery
11592965|NCT00697489|Active Comparator|2|Double surgery
11592966|NCT00697476|Experimental|Vorinostat/Topotecan|"Vorinostat/topotecan dose escalation regimen. vorinostat is administered orally once a day for 7 to 14 consecutive days, according to the dose level.Topotecan is administered I.V. for 5 consecutive days every three weeks.
~Vorinostat dose levels go from 300 mg/day for 7 days to 400 mg/day for 14 days. Topotecan dose levels go from 1,2 mg/m2 to 1,5 mg/m2"
11592967|NCT00697463|Experimental|Women with Idiopathic osteoporosis (IOP)|Each subject will receive 20 micrograms of Teriparatide (PTH 1-34) subcutaneously daily for 18 -24 months
11592968|NCT00697450||All participants|
11592969|NCT00697437|Experimental|docetaxel only|
11592970|NCT00697437|Experimental|docetaxel with ketoconazole|
11592971|NCT00697424|Experimental|1|All subjects will be placed on continuous positive airway pressure (CPAP) therapy during a full night sleep study or polysomnography (PSG). The subjects will spend 2 hours on sub-therapeutic CPAP 4 cmH2O of pressure and the remainder on there therapeutic pressure. Values reported on the device will be compared to scored values from manual scoring of the sleep study.
11592972|NCT00697411||Experimental|Individuals with Aicardi syndrome and their first-degree relatives
11592973|NCT00697398|Placebo Comparator|1|Sound placebo
11592974|NCT00697398|Experimental|2|Sound
11592975|NCT00697385|Experimental|TA|on treatment
11592976|NCT00697372|Active Comparator|SES|Patients with coronary bifurcation lesions treated by Sirolimus eluting stent
11592977|NCT00697372|Active Comparator|EES|Patients with coronary bifurcation lesions treated by Everolimus eluting stent
11592978|NCT00697359|Experimental|1|There is only one group in this cohort study.
11592979|NCT00697346|Experimental|Part 1: PIC Dose Escalation|Alisertib 25 or 35 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 21 days followed by a 7-day recovery period in 28-day cycles or alisertib 35, 45, 65 or 90 mg PIC, orally, (QD for 14 days followed by a 14-day recovery period in 28-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 14 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose), followed by their respective dosage assignment.
11592980|NCT00697346|Experimental|Part 1: ECT Dose Escalation|Alisertib 40 mg, Enteric-coated Tablet (ECT) formulation, orally, QD for 14 days followed by a 14-day recovery period in 28-day cycles, or alisertib 30, 40 or 50 mg ECT, orally BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 15 cycles).
11592981|NCT00697346|Experimental|Part 2: PTCL|Participants with peripheral T-cell lymphoma (PTCL) received alisertib 50 mg ECT, orally, BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).
11592982|NCT00697333|No Intervention|A|Irradiation of all tumor manifestations detectable by CT and/or positron emission tomography using fluoro-deoxy-glucose including a part of eventual atelectasis and the whole affected lymph node stations by 60 - 74 Gy/2Gy) irradiation of elective lymph node stations up to 50 Gy/2 Gy
11592983|NCT00697333|Experimental|B|Irradiation of all tumor manifestations detectable by positron emission tomography using fluoro-deoxy-glucose including the whole affected lymph node stations by 60 - 74 Gy/2Gy
11592984|NCT00697320||A|
11592985|NCT00697294|Experimental|Supplement|Subjects will serve as their own control in this single-arm protocol. All subjects will receive 400 IU/day of vitamin D as the intervention. Comparisons will be made between Caucasian and Hispanic infants.
11592986|NCT00697281|Experimental|1|Dose level 1
11592987|NCT00697281|Experimental|2|Dose level 2
11592988|NCT00697281|Experimental|3|Dose level 3
11592989|NCT00697281|Experimental|4|Dose level 4
11592990|NCT00697281|Experimental|5|Dose level 5
11593034|NCT00697021|Active Comparator|1|Patients who suffered acute STEMI and were treated by PPCI and by Aspirin 100mg and Plavix 75mg and showed on treatment platelet over-reactivity observed by TEG system on the 5th day after admission to ICCU
11593035|NCT00697021|Other|2|Patients who suffered acute STEMI and were treated by PPCI and recieved by Aspirin 100mg and Plavix 75mg and showed platelet inhibition observed by TEG system on the 5th day after admission to ICCU
11593036|NCT00697008||GERD patients|Patients with typical GERD symptoms
11593037|NCT00696995||A|
11592991|NCT00697255|Experimental|corifollitropin alfa + recFSH|Eligible participants will receive a subcutaneous (SC) injection of corifollitropin alfa (Stage 1a: 15mcg, Stage Ib/II: 30 mcg) the first, second, or third day after onset of a progestagen-induced withdrawal bleeding. If the follicle growth is insufficient, the participant will receive a second or third dose of corifollitropin alfa (Stage 1a: 15 mcg, Stage Ib/II: 20 mcg). As soon as the largest follicle reaches a size of ≥12 mm, the participant will start daily SC injections with FSH (Stage 1A: 50 IU, Stage II: 75 IU) the same day. A bolus injection of hCG (5000 IU) will be administered if at least one follicle is ≥18 mm and in total no more than two follicles ≥15 mm are observed.
11592992|NCT00697255|Experimental|corifollitropin alfa + hCG|Eligible participants will receive a SC injection of corifollitropin alfa (Stage Ia:15 mcg, Stage Ib/II: 30 mcg) the first, second or third day after onset of a progestagen-induced withdrawal bleeding. If the follicle growth is insufficient the participant will receive a second or third dose of corifollitropin alfa (Stage IA: 15 mcg, stage Ib/II: 20 mcg). As soon as the largest follicle reaches a size of ≥12 mm the participant will start daily SC injections with hCG (Stage Ib/II: 200 IU) the same day. A bolus injection of hCG (5000 IU) will be administered if at least one follicle is ≥18 mm and in total no more than two follicles ≥15 mm are observed.
11592993|NCT00697242|Experimental|Group A|
11592994|NCT00697242|Experimental|Group B|
11592995|NCT00697242|Experimental|Group C|
11592996|NCT00697242|Active Comparator|Group D|
11592997|NCT00697242|Experimental|Group E|
11592998|NCT00697229|Experimental|Group A|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 2 months and will receive a booster dose of HBV-MPL vaccine at 70 months
11592999|NCT00697229|Experimental|Group B|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 2 months and will receive a booster dose of Engerix™-B vaccine at 70 months
11593000|NCT00697229|Experimental|Group C|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 2 months and will receive a booster dose of HBV-MPL vaccine at 70 months
11593001|NCT00697229|Experimental|Group D|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 2 months and will receive a booster dose of Engerix™-B vaccine at 70 months
11593002|NCT00697229|Experimental|Group E|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 6 months and will receive a booster dose of HBV-MPL vaccine at 70 months
11593003|NCT00697229|Experimental|Group F|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 6 months and will receive a booster dose of Engerix™-B vaccine at 70 months
11593004|NCT00697229|Experimental|Group G|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 6 months and will receive a booster dose of HBV-MPL vaccine at 70 months
11593005|NCT00697229|Experimental|Group H|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 6 months and will receive a booster dose of Engerix™-B vaccine at 70 months
11593006|NCT00697216|Experimental|Group A|
11593007|NCT00697216|Active Comparator|Group B|
11593008|NCT00697203|Experimental|Dalcetrapib 300mg|
11593009|NCT00697203|Experimental|Dalcetrapib 600mg|
11593010|NCT00697203|Experimental|Dalcetrapib 900mg|
11593011|NCT00697203|Placebo Comparator|Placebo|
11593012|NCT00697190|Active Comparator|senofilcon A/galyfilcon A|senofilcon A silicone hydrogel toric contact lenses will be worn first. galyfilcon A silicone hydrogel toric contact lenses will be worn second.
11593013|NCT00697190|Active Comparator|galyfilcon A/senofilcon A|galyfilcon A silicone hydrogel toric contact lenses worn first. senofilcon A silicone hydrogel toric contact lenses worn second.
11593014|NCT00697164|Placebo Comparator|1|Patients in group I received intravenous quinine followed by oral ACT for a total period of 6 days.
11593015|NCT00697164|Experimental|2|Patients in group II received antimalarial drug as in group I and in addition 1500U/kg/day of rHUEPO for the initial 3 days.
11593016|NCT00697151|Active Comparator|Warfarin|Warfarin (target International Normalized Ratio: 1.4 to 2.8) plus placebo aspirin
11593017|NCT00697151|Active Comparator|Aspirin|Aspirin 325 mg plus placebo warfarin
11593018|NCT00697138|Experimental|A|
11593019|NCT00697125|Active Comparator|Group A|
11593020|NCT00697125|Experimental|Group B|
11593021|NCT00697125|Experimental|Group C|
11593022|NCT00697112||A|
11593023|NCT00697099|Experimental|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery
~Placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind"
11593024|NCT00697099|Active Comparator|Enoxaparin|"Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium
~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
11593025|NCT00697086|Experimental|1|
11593026|NCT00697086|Placebo Comparator|2|
11593027|NCT00697073|Experimental|1|high dose Idebenone
11593028|NCT00697060|Experimental|Stage 1/2|Imexon plus docetaxel
11593029|NCT00697047|No Intervention|1- Usual Care|Usual Care (UC) includes an annual birthday letter with information on overdue screening tests including CRC screening.
11593030|NCT00697047|Experimental|2 - Automated Mailing|Usual care plus automated mailing. Mailing 1 is a pamphlet about screening choices and number to call for colonoscopy. Mailing 2 is a FIT kit if not requesting colonoscopy. Mailing 3 is a Reminder letter.
11593031|NCT00697047|Experimental|3 - Automated Mailing Plus Assisted|Usual care, automated mailing plus, if screening is still not completed, phone assistance by a medical assistant (MA) who asks about patients screening intent, and provides brief assistance to complete this (e.g. sends another fecal test, assists with provider order for a colonoscopy).
11593032|NCT00697047|Experimental|4 - Auto Plus Assisted Plus Navigation|Usual care, automated mailing, phone assistance by a medical assistant, plus navigation by a registered nurse (RN) if still not screened. Navigators are trained to use motivational interviewing techniques. They assess CRC and procedure risk, facilitate screening choice, address barriers, and provide follow-up until screening is completed.
11593033|NCT00697034|Experimental|1|Study subjects will be patients with chronic plaque-type psoriasis
11593038|NCT00696982|Experimental|A|diabetic patients who are treated with metformin wiyh HBA1C>7% will get sitagliptin
11593039|NCT00696982|Experimental|B|diabetic patients who are treated with metformin with HBA1C>7% will get glibenclamide
11593040|NCT00696969|Active Comparator|1|
11593041|NCT00696969|Experimental|2|
11593042|NCT00696969|Experimental|3|
11593043|NCT00696969|Experimental|4|
11593044|NCT00696956|Placebo Comparator|A|Normal balloon for balloon angioplasty (Submarine, Ampherion Deep by Invatec)
11593045|NCT00696956|Active Comparator|2|Paclitaxel coated balloon (same balloon like in the control group, but coated with 3 µg/mm2 Paclitaxel)
11593046|NCT00696943|Experimental|18F-ML-10,|Pre-treatment baseline and post treatment follow-up 18F ML-10 PET/CT sessions.
11593047|NCT00696917|Active Comparator|Group A|Three doses according to 0, 1, 6-month schedule
11593048|NCT00696917|Experimental|Group B|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
11593049|NCT00696917|Experimental|Group C|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
11593050|NCT00696917|Experimental|Group D|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
11593051|NCT00696904|Other|1|Healthy volunteers, receiving 10-1200 mg ABT-333 or placebo, single dose
11593052|NCT00696904|Other|2|HCV+ treatment-naive subjects receiving 100-300 mg ABT-333 or placebo, multi-dose, QD or BID
11593053|NCT00696904|Other|3|Healthy volunteers, receiving 100 mg ABT-333, multi-dose, food effect
11593054|NCT00696891|Experimental|Group A|
11593055|NCT00696891|Active Comparator|Group B|
11593056|NCT00696878|Experimental|Corifollitropin alfa 150 µg|Up to 3 COS cycles (also called treatment cycles) were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of GnRH antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin ([rec]hCG) (5,000-10,000 IU/250 µg). Administration of (rec)hCG occurred when 3 follicles ≥17 mm were observed on ultrasound scan (USS). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone for luteal phase support was administered starting on the day of oocyte pick-up (34-36 hours after [rec]hCG) and continued for approximately 6 weeks. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur.
11593057|NCT00696865|Experimental|1|
11593058|NCT00696865|Placebo Comparator|2|
11593059|NCT00696852|Active Comparator|Mindfulness Meditation|
11593060|NCT00696852|Active Comparator|Yoga|
11593061|NCT00696852|Active Comparator|Conventional Stress Reduction|
11593062|NCT00696839|No Intervention|1|Usual care (adherence education)
11593063|NCT00696839|Experimental|2|Usual care and Cognitive Behavioral Therapy sessions
11593064|NCT00696813||paliperidone ER|Newly switched to or started on Paliperidone ER, not longer than 2 weeks ago
11593065|NCT00696813||Any other oral antipsychotic|Newly switched to or started on any other oral antipsychotic treatment (either atypical or conventional), not longer than 2 weeks ago
11593066|NCT00696800|Experimental|150 µg Corifollitropin Alfa|Participants received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa (org 36286) on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recFSH; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were administered from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles >= 17 mm. On the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses.
11593067|NCT00696800|Active Comparator|200 IU recFSH|Participants received a single SC injection of placebo Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 200 IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were given from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was administered when 3 follicles >= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses.
11593068|NCT00696787|Placebo Comparator|Placebo|In the first stage, subjects were randomly assigned to receive placebo. Study was stopped after stage 1 by sponsor.
11593069|NCT00696787|Experimental|DVS SR|In the first stage, subjects were randomly assigned to receive DVS SR 200 mg/day. Study was stopped after stage 1 by sponsor.
11593070|NCT00696787|Active Comparator|Pregabalin|In the first stage, subjects were randomly assigned to receive Pregabalin 450 mg/day. Study was stopped after stage 1 by sponsor.
11593071|NCT00696774|Experimental|Duloxetine|Patients who met criteria in Study Period I (screening) were treated with duloxetine 60 milligrams (mg) once daily (QD) in an open-label manner for 4 weeks (Study Period II). Study Period II was considered the acute therapy period. Study Period III was a 4-week interval where patients who did not respond during Study Period II had their duloxetine doses optimized to 120 mg.
11593072|NCT00696761|Active Comparator|group1|Bladder outlet obstruction index(BOOI)≥ 20, Bladder contractility index(BCI)≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.
11593073|NCT00696761|Active Comparator|group2|BOOI≥ 20, BCI<100 Alfuzosin was administered daily (10 mg) for 12 month.
11593074|NCT00696761|Active Comparator|group 3|BOOI<20, BCI≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.
11593075|NCT00696761|Active Comparator|group 4|BOOI<20, BCI<100 Alfuzosin was administered daily (10 mg) for 12 month.
11593076|NCT00696748|Active Comparator|1|Men receiving Nebido
11593077|NCT00696748|Placebo Comparator|2|Men receiving Placebo
11593078|NCT00696735|Active Comparator|1|standard chemotherapy arm, the CHVP (cyclophosphamide, low-dose doxorubicin, teniposide, and prednisone) regimen consisted of cyclophosphamide (600 mg/m2), doxorubicin (25 mg/m2), and teniposide (60 mg/m2), all administered intravenously on day 1, and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.
11593181|NCT00696085|Other|I|Pregnant women are recruited and screened for alcohol use using a validated alcoholism screening questionnaire. Those who screen positive are then entered into the next phase of the study.
11593079|NCT00696735|Experimental|2|VCAP (cyclophosphamide, high-dose doxorubicin, prednisone, and vincristine) regimen as a first-line therapy combining vindesine (3 mg/m2) on day 1, cyclophosphamide (1500 mg/m2) on day 2, doxorubicin (80 mg/m2) on day 2, and prednisolone (50 mg/m2) on days 1 to 5, every 3 weeks.19,31,32 Patients in CR, VGPR, or PR after the second or third VCAP cycle continued on to stem-cell harvesting and received, before transplantation, one course of IMVP16 (ifosfamide, methotrexate, and VP-16), which combined ifosfamide (1.5 g/m2) and VP16 (100 mg/m2) on days 1 through 3, and methotrexate (30 mg/m2) on days 1 and 10. Patients with less than PR after the VCAP cycles received, as salvage therapy, 2 to 3 courses of DHAP (dexamethasone, high-dose cytarabine, and cisplatin) combining cisplatine (100 mg/m2) on day 1, cytarabine (4 g/m2) on day 2, and dexamethasone (40 mg/m2) on days 1 through 4. If at least a PR was obtained after DHAP, stem cells were harvested or patients were considered as failures
11593080|NCT00696722|Experimental|1|Placebo treatment first, atazanavir treatment second
11593081|NCT00696722|Experimental|2|Atazanavir treatment first, placebo treatment second
11593082|NCT00696709|Experimental|Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine|Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine A; 4-dose regimen administered ~30 days apart.
11593083|NCT00696709|Experimental|Part 1: Gamma- Irradiated VZV Vaccine A|Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered ~30 days apart.
11593084|NCT00696709|Placebo Comparator|Part 1: Placebo|Participants received a 4-dose placebo regimen administered ~30 days apart.
11593085|NCT00696709|Experimental|Part 2: Gamma- Irradiated VZV Vaccine B|Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered ~30 days apart.
11593086|NCT00696709|Experimental|Part 2: Gamma- Irradiated VZV Vaccine C|Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine C; 4-dose regimen administered ~30 days apart.
11593087|NCT00696696|Experimental|Combination GES|Combination of Gemcitabine, Erlotinib, and Sorafenib
11593088|NCT00696683||A|Patients from the identified scorpion envenomation cases, who met inclusion/exclusion criteria.
11593089|NCT00696657|Experimental|A|
11593090|NCT00696657|Experimental|B|
11593091|NCT00696657|Experimental|C|
11593092|NCT00696657|Experimental|D|
11593093|NCT00696657|Experimental|E|
11593094|NCT00696657|Experimental|F|
11593095|NCT00696657|Placebo Comparator|G1|
11593096|NCT00696657|Placebo Comparator|G2|
11593097|NCT00696657|Placebo Comparator|G3|
11593098|NCT00696657|Placebo Comparator|G4|
11593099|NCT00696657|Placebo Comparator|G5|
11593100|NCT00696657|Placebo Comparator|G6|
11593101|NCT00696657|Experimental|H|
11593102|NCT00696657|Experimental|I|
11593103|NCT00696644||Patients with severe osteoporosis|Postmenopausal women and men aged > 21 years old affected by severe osteoporosis
11593104|NCT00696631|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
11593105|NCT00696631|Placebo Comparator|Placebo|matching placebo tablets
11593106|NCT00696618|Experimental|A|Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Normosol-R enema (iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home(Stage 2), Followed by Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
11593107|NCT00696618|Experimental|B|Normosol-R enema (iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 2), Followed by Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
11593108|NCT00696618|Experimental|C|Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 2), Followed by Normosol-R enema(iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
11593109|NCT00696579|Active Comparator|A|Group A received BCG instillation 14 days after II look-TURB:6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
11593110|NCT00696579|Experimental|2|14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
11593111|NCT00696566|Experimental|A|All subjects will receive Clopidogrel and Rifampicin.
11593112|NCT00696553|Active Comparator|B1|Nutrition
11593113|NCT00696553|Experimental|B2|Nutrition plus Exercise
11593114|NCT00696540|Experimental|1|Salbutamol is diluted in hypertonic (3%) saline.
11593115|NCT00696540|Active Comparator|2|Salbutamol is diluted in normal (0.9%) saline.
11593116|NCT00696527||1|
11593117|NCT00696514|Placebo Comparator|2|placebo capsule, once per day
11593118|NCT00696514|Experimental|1|Vitamin B12 and folic acid capsule, once a day
11593119|NCT00696488|Experimental|Fluorouracil 0.5%|each subject will receive the study medication: Carac® 0.5% Fluorouracil, a standard treatment for actinic keratoses. Carac® will be dispensed to the subjects in the original tube with MEMS electronic monitoring caps attached. Subjects will be asked to apply the medication daily to AK lesions
11593120|NCT00696475|Experimental|1|Diazoxide equivalent dose
11593121|NCT00696475|Experimental|2|Diazoxide equivalent dose
11593122|NCT00696475|Experimental|3|Diazoxide equivalent dose
11593123|NCT00696475|Placebo Comparator|4|
11593124|NCT00696462|No Intervention|A|Patients in Group A will undergo passive warming with a warmed cotton blanket placed over their upper extremities
11593125|NCT00696462|Active Comparator|B|Patients in Group B will have a forced-air warming device applied to the upper body above the waist at the 43 degree Celsius setting.
11593126|NCT00696449|Experimental|Frequent visits|This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.
11593127|NCT00696449|Experimental|Electronic reminder|This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.
11593128|NCT00696449|Experimental|Parent reminder|In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.
11593129|NCT00696449|Experimental|Standard of care|"This group is considered to be the standard of care arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits."
11593130|NCT00696436|Experimental|Azilsartan Medoxomil 40 mg QD|
11593131|NCT00696436|Experimental|Azilsartan Medoxomil 80 mg QD|
11593132|NCT00696436|Active Comparator|Valsartan 320 mg QD|
11593133|NCT00696436|Active Comparator|Olmesartan 40 mg QD|
11593134|NCT00696436|Placebo Comparator|Placebo QD|
11593135|NCT00696423|Experimental|Infanrix/Hib Single Injection Group|Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.
11593136|NCT00696423|Active Comparator|Infanrix + Hiberix Separate Injection Group|Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.
11593137|NCT00696410|Experimental|CHF patients Given Zinc Acetate|Patients with CHF received zinc acetate 50 mg po TID. This is a pre-post study
11593138|NCT00696410|No Intervention|Healthy controls|Health controls; no zinc acetate administered.
11593139|NCT00696397||A|adult men and women between 18 and 50 years of age with atopic dermatitis
11593140|NCT00696384|Experimental|Azilsartan Medoxomil QD-Open Label Phase (Baseline - Week 26)|
11593141|NCT00696384|Experimental|Azilsartan Medoxomil QD - Double-Blind Phase (Week 26-32)|
11593142|NCT00696384|Placebo Comparator|Placebo QD - Double-Blind Phase (Week 26- 32)|
11593143|NCT00696358|Active Comparator|A|308 nm excimer lamp
11593144|NCT00696358|Active Comparator|B|308 nm excimer laser
11593145|NCT00696345||1|Colorectal cancer patients, Stages I-IV
11593146|NCT00696345||2|Non colorectal cancer patients, verified by colonoscopy
11593147|NCT00696332|Experimental|Talampanel 50mg|50mg Talampanel 3 times per day
11593148|NCT00696332|Experimental|Talampanel 25mg|25mg Talampanel 3 times per day
11593149|NCT00696332|Placebo Comparator|Placebo|placebo 3 times per day
11593150|NCT00696319|Experimental|1|Arm 1 will go through a rehabilitation protocol with perturbation training exercises.
11593151|NCT00696319|Experimental|2|Arm 2 will go through a rehabilitation protocol with traditional exercises for balance and stability training.
11593152|NCT00696293|Experimental|1|"Duloxetine + clinical management
~NOTE -- THIS WORK WAS CONDUCTED AS PART OF A CAREER DEVELOPMENT AWARD. THE CLINICALTRIALS.GOV DESCRIPTION OF THE STUDY WAS UPDATED 1/5/16 TO UPDATE THE OPEN LABEL NATURE OF THIS WORK. THIS IS WHAT IS REPORTED HERE AND HAS BEEN PEER REVIEWED AND PUBLISHED."
11593153|NCT00696280||Group 1|"All patients will be given the Functional Living Index - Emesis (FLIE) standardized questionnaire during their scheduled clinic visit prior to receiving chemotherapy.
~This is a self-administered questionnaire. Patients will complete the questionnaire during the 5 days following carboplatin administration (at 24 hours, 48 hours, 72 hours, and 96 hours) of their first and third cycles of chemotherapy.
~Patients will also be interviewed by a trained CRA or research nurse over the telephone 24-48 hours following carboplatin administration in order to assess the severity of the delayed nausea and vomiting."
11593154|NCT00696241|Experimental|Azilsartan Medoxomil 20 mg QD|
11593155|NCT00696241|Experimental|Azilsartan Medoxomil 40 mg QD|
11593156|NCT00696241|Experimental|Azilsartan Medoxomil 80 mg QD|
11593157|NCT00696241|Active Comparator|Olmesartan 40 mg QD|
11593158|NCT00696241|Placebo Comparator|Placebo QD|
11593159|NCT00696228|Placebo Comparator|AFN A|High Fat Diet Placebo
11593160|NCT00696228|Experimental|AFN B|MUFA
11593161|NCT00696228|Experimental|AFN C|PUFA
11593162|NCT00696228|Experimental|AFN D|SFA
11593163|NCT00696215|Placebo Comparator|1|
11593164|NCT00696215|Active Comparator|2|Rasagiline
11593165|NCT00696202|Experimental|Arm 1|
11593166|NCT00696176|Experimental|A|STAT 3 decoy administration
11593167|NCT00696163||A|
11593168|NCT00696150|Placebo Comparator|loss of resistance|Anterior psoas compartment nerve block inserted using loss of resistance
11593169|NCT00696150|Active Comparator|nerve stimulator|Anterior psoas compartment nerve block inserted using nerve stimulator
11593170|NCT00696150|Active Comparator|ultrasound|Anterior psoas compartment nerve block inserted using ultrasound
11593171|NCT00696137|Experimental|BEMA Fentanyl|BEMA Fentanyl
11593172|NCT00696124|Experimental|Cohort 1|2mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
11593173|NCT00696124|Experimental|Cohort 2|4mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
11593174|NCT00696124|Experimental|Cohort 3|8mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
11593175|NCT00696124|Experimental|Cohort 4|16mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
11593176|NCT00696111|Experimental|1A|Randomized to receive depot Lupron for 6 weeks. Then randomized again to receive estrogen plus placebo for another 6 weeks.
11593177|NCT00696111|Experimental|1B|Randomized to receive depot Lupron for 6 weeks. Then randomized again to receive progesterone plus placebo for another 6 weeks.
11593178|NCT00696111|Experimental|3|Randomized to receive CPAP (continuous positive airway pressure) treatment for 6 weeks.
11593179|NCT00696098|Experimental|1|sodium butyrate
11593180|NCT00696098|Placebo Comparator|2|
11593182|NCT00696072|Active Comparator|A1|
11593184|NCT00696059|Other|1|Open-label, one arm only. All patients receiving active drug according to recommendations (adalimumab (Humira) 40 mg subcutaneously every other week).
11593185|NCT00696033|Experimental|1|Oral Lorazepam
11593186|NCT00696033|Experimental|2|Oral Diazepam
11593187|NCT00696033|Placebo Comparator|3|Oral placebo
11593188|NCT00696020|Experimental|BI 1744 CL low dose/tiotropium bromide|BI 1744 CL low dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
11593189|NCT00696020|Experimental|BI1744CL medium dose/tiotropium bromide|BI 1744 CL medium dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
11593190|NCT00696020|Experimental|BI 1744 CL high dose/tiotropium bromide|BI 1744 CL high dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
11593191|NCT00696020|Experimental|tiotropium bromide|tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
11593192|NCT00696007|Experimental|1|A neoadjuvant chemotherapy (gemcitabine and cisplatin) regimen administered before surgery-nephroureterectomy for upper tract TCC
11593193|NCT00696007|Other|2|A retrospective cohort group (approximately 60 subjects) identified from an institutional cancer registry who have undergone a nephroureterectomy alone over the past five years
11593194|NCT00695994|Experimental|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle.
11593195|NCT00695994|Experimental|Gemcitabine and carboplatin|Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion.
11593196|NCT00695981|Active Comparator|Rotator cuff repair|Surgery following a 3 months period of active non-operative treatment
11593197|NCT00695981|Active Comparator|Conservative treatment|Physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
11593198|NCT00695955|Experimental|Azilsartan Medoxomil|
11593199|NCT00695942||1|pregnancy women
11593200|NCT00695903|Experimental|daptomycin 10 mg/kg|Daptomycin 10 mg/kg IV every 24 hours
11593201|NCT00695903|Experimental|vancomycin high-dose|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
11593202|NCT00695890||1|Healthy volunteers
11593203|NCT00695877|Experimental|1|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^9 virus particles (VP) given at Days 0, 28, and 168
11593204|NCT00695877|Experimental|2|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^10 virus particles (VP) given at Days 0, 28, and 168
11593205|NCT00695877|Experimental|3|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^11 virus particles (VP) given at Days 0, 28, and 168
11593206|NCT00695877|Experimental|4|1 injection of rAd5.ENVA.48 HIV-1 vaccine or placebo at a dose determined by the safety data from Arms 1, 2 and 3 given at Day 0.
11593207|NCT00695864|Placebo Comparator|Placebo - sugar pill|Placebo - sugar pill
11593208|NCT00695864|Experimental|Ondansetron|Ondansetron
11593209|NCT00695851|Experimental|1|15 mg/m2 weekly of PCK3145
11593210|NCT00695851|Experimental|2|7.5 mg/m2 twice per week of PCK3145
11593211|NCT00695838||1|
11593212|NCT00695825|Experimental|A1|Consumption of low GI food product on day 1 Consumption of high GI food product on day 2
11593213|NCT00695825|Experimental|A2|Consumption of high GI food product on day 1 Consumption of low GI food product on day 2
11593214|NCT00695812||1|Siblings of children with Autism
11593215|NCT00695812||2|Siblings of children with typical development
11593216|NCT00695799||1|Anesthesia Providers at UMDNJ
11593217|NCT00695786|Experimental|Schedule A (lenalidomide, rituximab)|Participants receive lenalidomide PO on days 1-21 and rituximab IV over 4-8 hours on day 1 of courses 1-12. Courses repeat every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity
11593218|NCT00695786|Experimental|Schedule B (lenalidomide, rituximab)|Participants receive lenalidomide PO on days 2-22 and rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of course 1 and on day 1 of all subsequent courses. Courses repeat every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11593219|NCT00695747|No Intervention|1|Standard 1 site Procedure using a fornix based incision, performed superiorly
11593220|NCT00695747|Experimental|2|2 Site Combined Procedure
11593221|NCT00695734||Hemodialysis|Patients under chronic hemodialysis for chronic end stage renal failure
11593222|NCT00695708|Experimental|BFT|20 schizophrenic patients
11593223|NCT00695708|Active Comparator|CP|19 schizophrenic patients
11593224|NCT00695708|No Intervention|HCG|20 healthy age and sex matched subjects
11593225|NCT00695669|Experimental|Influenza A (H5N1) 1 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm.
11593226|NCT00695669|Experimental|Influenza A (H5N1) 2 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 14. The vaccine was administered intramuscularly in the deltoid region of the arm.
11593227|NCT00695669|Experimental|Influenza A (H5N1) 3 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 7. The vaccine was administered intramuscularly in the deltoid region of the arm.
11593228|NCT00695669|Experimental|Influenza A (H5N1) 4 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0. The vaccine was administered intramuscularly in the deltoid region of the arm.
11593229|NCT00695656||1|
11593230|NCT00695643|Experimental|A|
11593231|NCT00695643|Placebo Comparator|B|
11593232|NCT00695630|Experimental|1|Flumazenil 2mL
11593233|NCT00695630|Placebo Comparator|2|Saline, 2mL SM
11593234|NCT00695617|Experimental|A|citrate first
11593235|NCT00695617|Experimental|B|no anticoagulation first
11593236|NCT00695604|Placebo Comparator|1|"Placebo Comparator
~All patients assigned to this group will receive:
~Placebo via Metered Dose Inhaler (MDI).
~Albuterol via MDI."
11593237|NCT00695604|Active Comparator|2|"Active Comparator
~All patients assigned to this group will receive:
~Fluticasone via MDI.
~Albuterol via MDI."
11593238|NCT00695591||1SevereRLD,NMD|Patients with FEV1<40%
11593239|NCT00695591||2VerySevereRLD,NMD|FEV1<30%
11593240|NCT00695591||3NINV|FEV1<25%,on non invasive ventilation
11593241|NCT00695591||ModerateRLD,NMD|Patients with FEV1 40-50% of predicted
11593242|NCT00695578|Experimental|Biafin on left arm|Subjects were randomized to apply Biafine® to wounds on the left forearm and polysporin (standard of care) to wounds on the right forearm. Medications were applied three times a day for 4 weeks to the areas that have been treated with liquid nitrogen at the baseline visit.
11593243|NCT00695578|Experimental|Biafin on right arm|Subjects were randomized to apply Biafine to wounds on the right forearm and Polysporin to wounds on the left forearm. Medications were applied three times a day for 4 weeks to the areas that have been treated with liquid nitrogen at the baseline visit.
11593244|NCT00695565|Placebo Comparator|Placebo Gel|Placebo Gel is vehicle without clonidine
11593245|NCT00695565|Active Comparator|Clonidine Topical Gel (ARC-4558)|Clonidine Topical Gel contains 0.1% clonidine hydrochloride
11593246|NCT00695552|Experimental|1|Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
11593247|NCT00695552|Placebo Comparator|2|Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises.
11593248|NCT00695526|Active Comparator|A|
11593249|NCT00695513|Experimental|I|BENEO synergy1
11593250|NCT00695500|Experimental|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
11593251|NCT00695500|Placebo Comparator|Placebo|Placebo tablets, 0 mg per day for 3 weeks
11593252|NCT00695487|Experimental|1|Receives 0.125mg/kg THC before emergence
11593253|NCT00695487|Placebo Comparator|2|Receives NaCl before emergence
11593254|NCT00695474||A|The cohort consists of type 2 diabetics from the outpatient clinic at Silkeborg Hospital.
11593255|NCT00695461|Experimental|1|Receives Lactobacillus plantarum 299v in an oatmeal drink, at a concentration of 10(9) colony-forming-units/ml, 100 ml per day, starting one week before surgery, finishing 5 days after surgery.
11593256|NCT00695461|Placebo Comparator|2|Receives oatmeal drink, 100 ml per day, starting one week before surgery, finishing 5 days after surgery.
11593257|NCT00695448|Experimental|Cohorts|The starting dose is 6mg once daily (QD); dose is to be escalated using a standard 3 + 3 dose escalation scheme.
11593258|NCT00695435|Experimental|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension
11593259|NCT00695435|Active Comparator|TOBREX® Ophthalmic Solution|TOBREX® Ophthalmic Solution
11593260|NCT00695435|Active Comparator|TOBRADEX® Ophthalmic Suspension|TOBRADEX® Ophthalmic Suspension
11593261|NCT00695422||Specimen Collection|Blood collection, anal cytology and biopsy of observed lesions. Additional cervical cytology and biopsy for females.
11593262|NCT00695409|Experimental|Treatment (RIT, ZBEAM, ASCT)|RADIOIMMUNOTHERAPY: Patients receive yttrium Y 90 ibritumomab tiuxetan IV following rituximab IV on day -14. HIGH-DOSE COMBINATION CHEMOTHERAPY: Patients receive carmustine IV on days -7 and -6; etoposide IV over 1 hour twice daily and cytarabine IV over 2 hours twice daily on days -5 to -2; and melphalan IV on day -1. STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplant on day 0. Patients also receive rituximab on day 8*. NOTE: * Some patients may also receive rituximab on day -1. Treatment continues in the absence of disease progression or unacceptable toxicity.
11593263|NCT00695396|Experimental|001|Epoetin alfa 40 000 IU subcutaneously once every week (1 mL dose) for 48 weeks
11593264|NCT00695396|Experimental|002|Epoetin alfa 80 000 IU subcutaneously once every week (2 mL dose) for 48 weeks
11593265|NCT00695396|Placebo Comparator|003|Placebo Matching volume 1 mL for 48 weeks
11593266|NCT00695396|Placebo Comparator|004|Placebo Matching volume 2 mLfor 48 weeks
11593267|NCT00695383|Experimental|1|
11593268|NCT00695383|Active Comparator|2|
11593269|NCT00695344|Experimental|1|Everolimus 2 times per day + cyclosporin low dose +/- steroids
11593270|NCT00695344|Active Comparator|2|Cyclosporin + azathioprine or mofetil mycophenolate +/- steroids (the same treatment that patient had before the study).
11593271|NCT00695331|Experimental|1|Titrated Oral Misoprostol Solution
11593272|NCT00695331|Active Comparator|2|Intravenous Oxytocin
11593273|NCT00695318|Experimental|A, 2, I 0.2 µg/Day + Sham|0.2 µg/Day
11593274|NCT00695318|Experimental|A, 2, II 0.5 µg/Day + Sham|0.5 µg/Day
11593275|NCT00695305|Placebo Comparator|placebo|placebo to match
11593276|NCT00695305|Active Comparator|rilapladib|250 mg/day
11593277|NCT00695292|Experimental|Intervention|"Patients in the study will receive the following for the duration of the study: irinotecan 60 mg/m2 intravenously on Days 1, 8, and 15 and carboplatin AUC=4 on Day 1. The study will consist of 28-day cycles, to a maximum of 6 cycles of therapy with irinotecan and carboplatin. After treatment with irinotecan and carboplatin, sunitinib will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During sunitinib maintenance therapy, patients will receive sunitinib at 25 mg orally daily. Sunitinib maintenance therapy will continue until progressive disease or irreversible toxicity occurs.
~Re-staging will be performed every 2 cycles (every 8 weeks) during the study."
11593278|NCT00695279||Participants|Venipuncture
11593279|NCT00695266||1|
11593280|NCT00695253|Other|1|
11593330|NCT00694902|Experimental|Sequence 2 of Cohort-I|Subjects in Sequence 2 will receive 10 microgram GSK610677 during treatment period 1, Placebo during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
11593331|NCT00694902|Experimental|Sequence 3 of Cohort-I|Subjects in Sequence 3 will receive 10 microgram GSK610677 during treatment period 1, 50 microgram GSK610677 during treatment period 2 and Placebo during treatment period 3.
11593384|NCT00694629|Experimental|2|rifapentine 10 mg/kg, isoniazid, pyrazinamide, ethambutol
11593281|NCT00695240|Experimental|Bupiv analgesia|Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. The catheter was placed in the operating room with a peel-away trocar and attached to the pump. The trocar was inserted through a 5 mm stab incision made near the superior part of the pubic bone between the genitoinguinal fold and the midline of the symphysis. Once through the incision, the trocar is advanced subcutaneously and made to exit the posterior fourchette just beneath the posterior vaginal mucosa where it is advanced by tenting up the skin.
11593282|NCT00695227|Experimental|Screening for Barrett's Esophagus|
11593283|NCT00695214|Other|1|OSA Patients considering surgical treatment
11593284|NCT00695201|Experimental|1|Patients will undergo pump placement and biopsy of diseased liver tissue. Chemotherapy will be initiated as soon as possible following verification of adequate pump placement and perfusion by radiographic pump study. Treatment will continue indefinitely unless a patient experiences a treatment endpoint.
11593285|NCT00695201|Experimental|2|Patients will undergo pump placement and biopsy of diseased liver tissue. Chemotherapy will be initiated as soon as possible following verification of adequate pump placement and perfusion by radiographic pump study. Treatment will continue indefinitely unless a patient experiences a treatment endpoint.
11593286|NCT00695188|Other|Standard dose|Escalating dose
11593287|NCT00695188|Active Comparator|High dose|25 mg
11593288|NCT00695162|Other|1|hearing impaired inpatients
11593289|NCT00695162|Other|2|Non-hearing-impaired inpatients
11593290|NCT00695136|Experimental|Open label single arm|Single group study of Donepezil
11593291|NCT00695123||Only 1 participant group (cohort)|The subject may have a blood disorder, may be a stem cell transplant donor, or may be a healthy volunteer.
11593292|NCT00695110|Experimental|1|Testosterone undecanoate (TU) (300 mg T equivalents) BID for 7 days
11593293|NCT00695110|Experimental|2|TU + testosterone enanthate (TE) (400 mg T equivalents) BID for 7 days
11593294|NCT00695110|Experimental|3|TU (200 mg T equivalents) BID for 8 days
11593295|NCT00695110|Experimental|4|TU + TE (300 mg T equivalents) BID for 7 days
11593296|NCT00695097|Active Comparator|1|Rituximab Group: The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15) and followed up monthly for 1 year. Biopsy was done Baseline and Month 3 and other labs (CBC/Diff, Platelets, HACA, PK, Serum Creatinine, 24-hour protein, HLA antibodies, flow cytometry, and serology testing). Physical exam and vital signs were done.
11593297|NCT00695097|Active Comparator|2|No Rituximab: received standard immunosuppression and was followed up monthly for 1 year. Labs (CBC/Diff, Platelets, HACA, PK, Serum Creatinine, 24-hour protein, HLA antibodies, flow cytometry, and serology testing) vital signs, and physical exam was done.
11593298|NCT00695084|Experimental|1|Treatment with Constraint-Induced Movement Therapy
11593299|NCT00695071|Active Comparator|A|
11593300|NCT00695058|Experimental|1|Women with stress incontinence treated with active TMNS (vibration)
11593301|NCT00695058|Placebo Comparator|2|Women with stress incontinence treated with placebo TMNS (vibration)with an amplitude of 0
11593302|NCT00695058|Experimental|3|Women with overactive bladder syndrome treated with active TMNS (vibration)
11593303|NCT00695058|Placebo Comparator|4|Women with overactive bladder syndrome treated with placebo TMNS (vibration)with an amplitude of 0
11593304|NCT00695058|Experimental|5|males who are still incontinent at a minimum of one year after a radical prostatectomy treated with active TMNS (vibration)
11593305|NCT00695058|Placebo Comparator|6|males who are still incontinent at a minimum of one year after a radical prostatectomy treated with placebo TMNS (vibration)with an amplitude of 0
11593306|NCT00695045|Experimental|1|patients in this group got 100mcg of intrathecal morphine.
11593307|NCT00695045|Experimental|2|patients in this group got 200 mcg intrathecal morphine
11593308|NCT00695045|Experimental|3|patients in this group given 300 mcg intrathecal morphine.
11593309|NCT00695019|Experimental|500 IU qd|500 IU Interferon-alpha lozenge taken once per day plus 2 placebo lozenges per day
11593310|NCT00695019|Experimental|500 IU tid|500 IU interferon-alpha lozenge taken 3 times per day
11593311|NCT00695019|Placebo Comparator|placebo|placebo lozenges taken 3 times per day
11593312|NCT00695006|Sham Comparator|II|Sham Traction
11593313|NCT00695006|Active Comparator|I|Traction
11593314|NCT00694993|Experimental|Subjects receiving GSK1004723 + placebo in cohort I and II|Eligible subjects will receive GSK1004723 nasal spray with single doses of 50 micrograms, 100 micrograms, 200 micrograms, 500 micrograms and 1000 micrograms. Subjects will also receive placebo nasal spray.
11593315|NCT00694993|Experimental|Subjects receiving GSK1004723 200 micrograms in cohort III|Eligible subjects will receive nasal spray of GSK1004723 with escalated repeat doses of 200 micrograms given once daily for 14 days.
11593316|NCT00694993|Experimental|Subjects receiving placebo in cohort III|Eligible subjects will receive nasal spray of placebo given once daily for 14 days.
11593317|NCT00694993|Experimental|Subjects receiving GSK1004723 1000 micrograms in cohort IV|Eligible subjects will receive nasal spray of GSK1004723 with escalated repeat doses of 1000 micrograms given once daily for 14 days.
11593318|NCT00694993|Experimental|Subjects receiving placebo in cohort IV|Eligible subjects will receive nasal spray of placebo given once daily for 14 days.
11593319|NCT00694980|Experimental|1|
11593320|NCT00694967|Active Comparator|1|McDonald cerclage
11593321|NCT00694967|Active Comparator|2|17 hydroxyprogesterone caproate
11593322|NCT00694954|Experimental|1|Wireless capsule endoscopy
11593323|NCT00694954|Active Comparator|2|Standard Care
11593324|NCT00694941|Experimental|E|ONO-2506PO in the presence of Riluzole
11593325|NCT00694928|Experimental|1|clindamycin phosphate/butoconazole nitrate
11593326|NCT00694928|Active Comparator|2|butoconazole nitrate
11593327|NCT00694915|Experimental|Mw|Mycobacterium w
11593328|NCT00694915|Active Comparator|BCG|bacillus Calmette-Guerin (BCG)
11593329|NCT00694902|Experimental|Sequence 1 of Cohort-I|Subjects in Sequence 1 will receive Placebo during treatment period 1, 50 microgram GSK610677 during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
11593441|NCT00694239|Experimental|A|Risk Assessment plus standard care
11593332|NCT00694902|Experimental|Sequence 4 of Cohort-I|Subjects in Sequence 4 will receive 10 microgram GSK610677 during treatment period 1, 50 microgram GSK610677 during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
11593333|NCT00694902|Experimental|Sequence 5 of Cohort-II|Subjects in Sequence 5 will receive Placebo during treatment period 1, 100 microgram GSK610677 during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
11593334|NCT00694902|Experimental|Sequence 6 of Cohort-II|Subjects in Sequence 6 will receive 30 microgram GSK610677 during treatment period 1, Placebo during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
11593335|NCT00694902|Experimental|Sequence 7 of Cohort-II|Subjects in Sequence 7 will receive 30 microgram GSK610677 during treatment period 1, 100 microgram GSK610677 during treatment period 2 and Placebo during treatment period 3.
11593336|NCT00694902|Experimental|Sequence 8 of Cohort-II|Subjects in Sequence 7 will receive 30 microgram GSK610677 during treatment period 1, 100 microgram GSK610677 during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
11593337|NCT00694902|Experimental|Cohort III|Subjects in Cohort III after randomization will either receive 1000 microgram GSK610677 or placebo.
11593338|NCT00694889|Active Comparator|1|Participants will use commercially available computer games.
11593339|NCT00694889|Experimental|2|Participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation.
11593340|NCT00694889|Active Comparator|3|Healthy participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation.
11593341|NCT00694876||1|Adequate Health Literacy (as determined by TOFHLA)
11593342|NCT00694876||2|Inadequate Health Literacy (as determined by TOFHLA)
11593343|NCT00694863|Experimental|1|In this open-label study all patients included are treated in the experimental group.
11593344|NCT00694850|Experimental|Arm 1|
11593345|NCT00694837|Experimental|B|
11593346|NCT00694824||A|
11593347|NCT00694811|Experimental|A|1 week of re-feeding
11593348|NCT00694811|Experimental|B|6 weeks of re-feeding
11593349|NCT00694798|Experimental|Mw|All enrolled patients to receive Mycobacterium w
11593350|NCT00694785|Experimental|Group NT3|Patients will receive a total dose of approximately 1.7 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 3 mcg/mL
11593351|NCT00694785|Experimental|Group T3|Patients will receive a total dose of approximately 1.4 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 3 mcg/mL. The infusion of ARC1779 will be tapered by 50% from 48 hours to 60 hours and again by 50% from 60 hours to 72 hours.
11593352|NCT00694785|Experimental|Group NT6|Patients will receive a total dose of approximately 3.9 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 6 mcg/mL.
11593353|NCT00694785|Experimental|Group T6|Patients will receive a total dose of approximately 3.1 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 6 mcg/mL. The infusion of ARC1779 will be tapered by 50% from 48 hours to 60 hours and again by 50% from 60 hours to 72 hours.
11593354|NCT00694772|Active Comparator|Electrocautery|
11593355|NCT00694772|Experimental|Coblation|
11593356|NCT00694759|Active Comparator|A|Pioglitazone will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
11593357|NCT00694759|Active Comparator|B|Metformin will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
11593358|NCT00694759|Placebo Comparator|C|Placebo will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
11593359|NCT00694746|Experimental|Fish oil|Omega-3-acid ethyl esters in the form of fish oil capsules with ram up from 1g to 4 g/day (capsules 1g)
11593360|NCT00694746|Placebo Comparator|Placebo|Placebo
11593361|NCT00694733|Placebo Comparator|1|Men on placebo injections for 4 months
11593362|NCT00694733|Active Comparator|2|Men who receive Depo Lupron for 4 months, then are replaced with testosterone and aromatase inhibitor for 4 months.
11593363|NCT00694733|Active Comparator|3|Men who receive Depo Lupron for 4 months, then are replaced with testosterone and placebo for 4 months.
11593364|NCT00694733|Placebo Comparator|4|Women on placebo cream
11593365|NCT00694733|Active Comparator|5|Women on estrogen cream
11593366|NCT00694720|Experimental|Dose Level 1|
11593367|NCT00694720|Experimental|Dose Level 2|
11593368|NCT00694720|Experimental|Dose Level 3|
11593369|NCT00694720|Experimental|Dose Level 4|
11593370|NCT00694720|Placebo Comparator|Placebo|12 subjects: 3 subjects per dose level
11593371|NCT00694707|Placebo Comparator|Placebo|Participants received placebo orally once a day for 6 weeks.
11593372|NCT00694707|Experimental|Cariprazine 1.5 mg|Participants received cariprazine 1.5 mg orally once a day for 6 weeks.
11593373|NCT00694707|Experimental|Cariprazine 3.0 mg|Participants received cariprazine 3.0 mg orally once a day for 6 weeks.
11593374|NCT00694707|Experimental|Cariprazine 4.5 mg|Participants received cariprazine 4.5 mg orally once a day for 6 weeks.
11593375|NCT00694707|Active Comparator|Risperidone 4.0 mg|Participants received risperidone 4.0 mg orally once a day for 6 weeks.
11593376|NCT00694694|Experimental|1AZ+AQ|Azithromycin + artesunate
11593377|NCT00694694|Active Comparator|2AL|Artemether-lumefantrine
11593378|NCT00694668|Experimental|1|Cognitive Behavioural Treatment
11593379|NCT00694668|Experimental|2|Mindfulness Based Cognitive Therapy-training
11593380|NCT00694655|Other|vaccine|There are no arms for this study. All participants will receive the YFV vaccine if they meet the screening criteria.
11593381|NCT00694642|Active Comparator|selected CD133+cells|Transendocardial injection of selected CD133+cells
11593382|NCT00694642|No Intervention|no injection|Boths groups were treated with G-CSF, underwent an apheresis and NOGA mapping
11593383|NCT00694629|Active Comparator|1|rifampin, isoniazid, pyrazinamide, ethambutol
11593385|NCT00694629|Experimental|3|rifapentine 15 mg/kg, isoniazid, pyrazinamide, ethambutol
11593386|NCT00694629|Experimental|4|rifapentine 20 mg/kg, isoniazid, pyrazinamide, ethambutol
11593387|NCT00694616|Other|1|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
11593388|NCT00694616|Other|2|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
11593389|NCT00694603|Experimental|Cetuximab|400mg/m2 IV x 1 and then 250mg/m2 IV weekly
11593390|NCT00694590|Experimental|plerixafor|
11593391|NCT00694577|Experimental|Group 1|Study Participants 1-100 Partial Breast Irradiation using 32 Gy / 8 fractions BID in one week
11593392|NCT00694577|Experimental|Group 2|Study Participants 101-200 Partial Breast Irradiation using 36 Gy / 9 fractions BID in one week
11593393|NCT00694577|Experimental|Group 3|Study Participants 201-330 Partial Breast Irradiation using 40 Gy / 10 fractions BID in one week
11593394|NCT00694564|Experimental|Treatment|This an open-labeled study. All participants will be part of the treatment group and receive SAM-e. S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
11593395|NCT00694551|Experimental|A. Level 100 mcg Peptide Vaccine|Peptide vaccine dose level 100 mcg + Poly IC-LC
11593396|NCT00694551|Experimental|B. Level 300 mcg Peptide Vaccine|Peptide vaccine dose level 300 mcg + Poly IC-LC
11593397|NCT00694551|Experimental|C. Level 1 mg Peptide Vaccine|Peptide vaccine dose level 1 mg + Poly IC-LC
11593398|NCT00694538|Active Comparator|1|100 patients are being treated with a single laser beam over pain area.
11593399|NCT00694538|Experimental|2|100 patients are being treated with interferential laser from two independent sources
11593400|NCT00694525||1|Women in this group will have 21-OHD CAH.
11593401|NCT00694525||2|Women in this group will be healthy controls and will not have 21-OHD CAH.
11593402|NCT00694512|Placebo Comparator|1|low fat diet for two weeks.
11593403|NCT00694512|Active Comparator|2|High fat diet for two weeks followed by blood sampling.
11593404|NCT00694512|Active Comparator|3|Medium Chain Triglyceride diet
11593405|NCT00694499||Observation|Patients with blunt liver injury
11593406|NCT00694486||1|Healthy adult volunteers
11593407|NCT00694473|Experimental|Freestyle Navigator|Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
11593408|NCT00694460|Experimental|1|
11593409|NCT00694460|Experimental|2|
11593410|NCT00694460|Experimental|3|
11593411|NCT00694460|Experimental|4|
11593412|NCT00694460|Active Comparator|5|
11593413|NCT00694447|Experimental|Real acupuncture|Real acupuncture
11593414|NCT00694447|Sham Comparator|Sham acupuncture|Sham acupuncture
11593415|NCT00694434||1|Patients with 2 or more frozen blastocyst that scored GES 70 or better in the fresh cycle.
11593416|NCT00694434||2|Patients with 2 or more frozen blastocysts scoring GES <70 in the fresh cycle.
11593417|NCT00694421||1|"adults who participate in study, Social and Psychological Risks for Infectious Disease here at Children's Hospital of Pittsburgh"
11593418|NCT00694421||2|"children 2-6 years who participate in Role of Virus and Genetic Susceptibility study here at Children's Hospital of Pittsburgh"
11593419|NCT00694408|Active Comparator|Steroid immunosuppressive regimen|Freedom from rejection and safety in children undergoing paediatric liver transplant using steroid containing immunosuppression regimen post transplant. This group of patients will receive steroids in conjunction with other prescribed immunosuppressive agents. Intervention is use of methyl prednisolone, hydrocortisone, prednisolone as routine post transplant management
11593420|NCT00694408|Active Comparator|Steroid free immunosuppressive regimen|Freedom from rejection and safety in children undergoing paediatric liver transplant using steroid free immunosuppression regimen post transplant. The patients in this arm will receive immunosuppression but not steroids to compare with those treated with steroids to measure differences in rejection and safety of a steroid free immunosuppressive regimen. Intervention is omission of methyl prednisolone, hydrocortisone, prednisolone as routine post transplant management. No steroids will be used routinely in this arm
11593421|NCT00694382|Experimental|Semuloparin|Semuloparin sodium 20 mg once daily until change in chemotherapy regimen
11593422|NCT00694382|Placebo Comparator|Placebo|Placebo (for semuloparin) once daily until change in chemotherapy regimen
11593423|NCT00694369|Experimental|1|etoricoxib 90 mg
11593424|NCT00694369|Experimental|2|etoricoxib 120 mg
11593425|NCT00694369|Active Comparator|3|ibuprofen 2400 mg
11593426|NCT00694369|Active Comparator|4|acetaminophen 2400 mg/codeine 240 mg
11593427|NCT00694369|Placebo Comparator|5|Matching Placebo
11593428|NCT00694356|Experimental|Dalotuzumab 5 mg/kg|Participants receive dalotuzumab 5 mg/kg by intravenous (IV) infusion once each week for up to 1 year or until participant withdraws consent, experiences an adverse event (AE), progressive disease or major protocol violation, has moved or is lost to follow up.
11593429|NCT00694356|Experimental|Dalotuzumab 10 mg/kg|Participants receive dalotuzumab 10 mg/kg by IV infusion once each week for up to 1 year or until participant withdraws consent, experiences an AE, progressive disease or major protocol violation, has moved or is lost to follow up.
11593430|NCT00694356|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg|Participants receive an initial dose of dalotuzumab 15 mg/kg by IV infusion followed by a maintenance dose of dalotuzumab 7.5 mg/kg by IV infusion once every 2 weeks for up to 1 year or until participant withdraws consent, experiences an AE, progressive disease or major protocol violation, has moved or is lost to follow up.
11593431|NCT00694343|Experimental|Group A|500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
11593432|NCT00694343|Active Comparator|Group B|1000 mL Ringer's Lactate solution
11593433|NCT00694330|Experimental|GM-K562 Vaccination|
11593434|NCT00694304|Experimental|Vortioxetine|
11593435|NCT00694291|Experimental|1|Sorafenib 400 mg orally twice daily
11593436|NCT00694291|Placebo Comparator|2|Placebo
11593437|NCT00694265||1|Surgical treatment
11593438|NCT00694265||2|Conservative treatment
11593439|NCT00694252|Experimental|1|Lapatinib
11593440|NCT00694239|No Intervention|B|Standard Care
11593442|NCT00694226|Experimental|1|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
11593443|NCT00694226|Active Comparator|2|Treatment as usual (TTU): Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol. After completing the assessment individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis
11593444|NCT00694213|Experimental|1|
11593445|NCT00694213|Experimental|2|
11593446|NCT00694213|Experimental|3|
11593447|NCT00694213|Placebo Comparator|4|
11593448|NCT00694200|Experimental|1|Vinorelbine metronomic + bevacizumab
11593449|NCT00694174|Active Comparator|1|2 ml sucrose 25% oral solution one time only dose by mouth
11593450|NCT00694174|Placebo Comparator|2|sterile water 2 ml one time only dose given by mouth prior to heel lance
11593451|NCT00694161|Experimental|Fx-1006A|
11593452|NCT00694135|Active Comparator|EGP-437 1.6 mA-min at 0.4 mA|Ocular iontophoresis with EGP 437 1.6 mA-min at 0.4 mA
11593453|NCT00694135|Active Comparator|EGP-437 4.8 mA-min at 1.2 mA|Ocular iontophoresis with EGP-437 4.8 mA-min at 1.2 mA
11593454|NCT00694135|Active Comparator|EGP-437 10.0 mA-min at 2.5 mA|Ocular iontophoresis with EGP-437 10.0 mA-min at 2.5 mA
11593455|NCT00694135|Active Comparator|EGP-437 14.0 mA-min at 3.5 mA|Ocular iontophoresis with EGP-437 14.0 mA-min at 3.5 mA
11593456|NCT00694122|Active Comparator|Glargine (Lantus) insulin|"Long acting insulin, glargine, that subject currently used as an outpatient. SC injections. Dose given at 22:00 is based on past week blood glucose data during evening overnight hours and AM glucose. 20.2 +/- 11.7 units glargine (mean +/- SD).
~Glargine (Lantus): Sanolfi Aventis
~Hourly blood glucose from 22:00 to 08:00 while receiving glargine (Lantus) insulin will be compared with the NPH insulin arm."
11593457|NCT00694122|Active Comparator|NPH insulin|"Long acting insulin, NPH, that participant was currently while an outpatient. SC injections. Dose (units) given at 22:00 is based on past week blood glucose during evening overnight period and AM glucose. 20.7 +/- 10.0 units NPH (mean +/- SD).
~NPH: Eli Lilly
~Hourly blood glucose from 22:00 to 08:00 while receiving glargine (Lantus) insulin will be compared with the glargine (Lantus) insulin arm."
11593458|NCT00694109|Experimental|Mipomersen|Mipomersen Sodium once a week for up to 4 years (depending on participant's consent). Participants were followed for additional 24 week post-treatment.
11593459|NCT00694096|Experimental|1|
11593460|NCT00694083|Experimental|Ridaforolimus|Ridaforolimus (MK-8669), 20 or 40 mg administered orally on Day 1 followed by a washout of at least 6 days, then QD x5 (five consecutive days) followed by a 2-day holiday through Day 28 (Cycle 1), and QD x5 followed by a 2-day holiday for 21 days (Cycle 2 and subsequent cycles).
11593461|NCT00694070||health care professionals and lay users|h= 8 health care professionals p= 43 lay users
11593462|NCT00694057|Placebo Comparator|Placebo|Placebo capsules BID
11593463|NCT00694057|Experimental|Active|HE3286 10 mg (5 mg BID)
11593464|NCT00694044|Active Comparator|Weekly titration|
11593465|NCT00694044|Active Comparator|Two Week QD|
11593466|NCT00694044|Active Comparator|Two Week BID|
11593467|NCT00694044|Placebo Comparator|Placebo|
11593468|NCT00694031|Active Comparator|A|Hemodialysis
11593469|NCT00694031|Experimental|B|On-line hemodiafiltration
11593470|NCT00694018|Active Comparator|Education and Standard Care|Received standard care and participated in an educational program for individuals with chronic back pain. Also received an uploading pedometer but no feedback or goals about their walking activity.
11593471|NCT00694018|Experimental|Internet Mediated Enhanced Pedometer|In addition to standard care and participating in an educational program, participants received an enhanced pedometer for uploading step information, e-mail messages with weekly step goals and access to a website that provided step goals and feedback, tailored motivational messages and on on-line community for communication asynchronously with staff and other participants.
11593472|NCT00694005|Active Comparator|bifurcation stent techniqe|"cross over stenting without kissing balloon angioplasty leave alone"
11593473|NCT00694005|Experimental|bifurcation stent technique|kissing balloon angioplasty
11593474|NCT00693992|Experimental|Arm I (sunitinib malate)|Patients receive sunitinib malate 37.5 mg PO once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11593475|NCT00693992|Placebo Comparator|Arm II (placebo)|Patients receive placebo 37.5 mg PO once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11593476|NCT00693966|Experimental|Group A|Formulation 1 of the vaccine (MEDI-517 HPV-16/18 VLP AS04 vaccine)
11593477|NCT00693966|Experimental|Group B|Formulation 2 of the vaccine
11593478|NCT00693966|Experimental|Group C|Formulation 3 of the vaccine
11593479|NCT00693966|Experimental|Group D|Formulation 4 of the vaccine [with Al(OH)3]
11593480|NCT00693953||1|Year one
11593481|NCT00693953||2|Year two
11593482|NCT00693940|Experimental|1|Participants will receive treatment with group mediated cognitive behavioral sessions.
11593483|NCT00693940|Active Comparator|2|Participants will receive treatment with health education sessions.
11593484|NCT00693927|Active Comparator|1|Unmanipulated PBSC
11593485|NCT00693927|Experimental|2|CD8-Depleted PBSC
11593486|NCT00693914||1: Brain Tumor Survivors (n=50)|
11593487|NCT00693914||2: Healthy Sibling Controls (n=40)|
11593488|NCT00693914||Solid Tumor Survivors (n=40)|
11593489|NCT00693901|Experimental|1|Parks will be assigned to the community-based participatory research condition.
11593490|NCT00693901|Active Comparator|2|Parks will be assigned to the director-only condition.
11593491|NCT00693901|No Intervention|3|Parks will be assigned to the control condition and will receive no intervention.
11593492|NCT00693888|Experimental|interventional group|individual comprehensive primary advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)
11593493|NCT00693888|No Intervention|Control group|only informative flyer, no further advice in any direction
11593494|NCT00693862|Experimental|Stalevo|
11593495|NCT00693862|Active Comparator|levodopa/carbidopa|
11593496|NCT00693849|Active Comparator|A|Escitalopram
11593497|NCT00693849|Active Comparator|B|Sertraline
11593498|NCT00693849|Active Comparator|C|Venlafaxine-XR
11593499|NCT00693849|No Intervention|D|Healthy matched controls
11593500|NCT00693823|Active Comparator|1|Femoral-popliteal surgical bypass with prosthetic graft
11593501|NCT00693823|Active Comparator|2|Interventional angioplasty and placement of an ePTFE covered stent graft within the femoral-popliteal artery as an endoluminal bypass percutaneously
11593502|NCT00693797||I, observation|patients with aortic stenosis
11593503|NCT00693797||II, observation|patients with aortic stenosis
11593504|NCT00693784|Experimental|Biostat® Disc Augmentation System|Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
11593505|NCT00693771|Experimental|1|
11593506|NCT00693758|No Intervention|1|healthy volunteers without intervention
11593507|NCT00693758|No Intervention|2|patients with suspected coronary artery disease without intervention
11593508|NCT00693758|Experimental|3|Healthy volunteers during adenosine infusion
11593509|NCT00693758|Experimental|4|Healthy volunteers during changes of breathing gases (CO2, O2)
11593510|NCT00693758|Experimental|5|patients with suspected coronary artery disease during adenosine infusion
11593511|NCT00693758|Experimental|6|patients with suspected coronary artery disease during changes of breathing gases
11593512|NCT00693758|Experimental|7|Assessment of reactive hyperemia in arms of healthy volunteers to improve sequences
11593513|NCT00693732|Active Comparator|1, IBS patients|
11593514|NCT00693732|Experimental|2,Healthy controls|
11593515|NCT00693719|Experimental|Etoposide and Irinotecan hydrochloride|Irinotecan 100 mg/m2 IV days 1 and 15. Etoposide 50 mg PO x14 days followed by 2 weeks off.
11593516|NCT00693706|Experimental|GSK 1388442A Group|Subjects aged 18 to 49 years of age at the time of vaccination received 1 dose of GSK 1388442A vaccine at Day 0. The GSK 1388442A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11593517|NCT00693706|Active Comparator|Fluarix Group|Subjects aged 18 to 49 years of age at the time of vaccination received 1 dose of Fluarix® vaccine at Day 0. The Fluarix® vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11593518|NCT00693693|Active Comparator|Cream-|topical hydrocortisone 17-butyrate 0.1% Cream preparation applied twice daily to all lesions of atopic dermatitis
11593519|NCT00693693|Active Comparator|Ointment|topical hydrocortisone 17-butyrate 0.1% Ointment preparation applied twice daily to all lesions of atopic dermatitis
11593520|NCT00693693|Active Comparator|Lipocream|topical hydrocortisone 17-butyrate 0.1% Lipocream preparation applied twice daily to all lesions of atopic dermatitis
11593521|NCT00693680|Active Comparator|1|zinc + imipramine
11593522|NCT00693680|Placebo Comparator|2|placebo + imipramine
11593523|NCT00693667|Placebo Comparator|A|Placebo
11593524|NCT00693667|Active Comparator|B|250 mg active ingredient
11593525|NCT00693667|Active Comparator|C|500 mg active ingredient
11593526|NCT00693667|Active Comparator|D|750 mg active ingredient
11593527|NCT00693654|Experimental|Sarna Lotion|1% pramoxine Sarna lotion
11593528|NCT00693654|Placebo Comparator|Placebo Cetaphil lotion|Placebo Cetaphil lotion
11593529|NCT00693641|Active Comparator|1|"Safe Sea™ jellyfish sting inhibitor (barrier, or repellent) lotion"
11593530|NCT00693641|Placebo Comparator|2|Regular sun lotion
11593531|NCT00693628|Active Comparator|Shrinker|Patients receive 20-30 mmHg compression shrinker, an elastic compression garment that is worn on the residual limb and is used to reduce edema and promote healing.
11593532|NCT00693628|No Intervention|No Shrinker|Control group - participants will not receive an intervention (compression shrinker).
11593533|NCT00693628|Active Comparator|Shrinker 2|Patients receive 30-40 mmHg compression shrinker, an elastic compression garment that is worn on the residual limb and is used to reduce edema and promote healing.
11593534|NCT00693615|Experimental|Group A|Formulation 1 of the vaccine (MEDI-517 HPV-16/18 VLP AS04 vaccine)
11593535|NCT00693615|Experimental|Group B|Formulation 2 of the vaccine [with Al(OH)3]
11593536|NCT00693615|Experimental|Group C|Formulation 3 of the vaccine (without adjuvant)
11593537|NCT00693602|Experimental|1|
11593538|NCT00693589|Active Comparator|R|Rosuvastatin treatment for 6 weeks and after that combined treatment with rosuvastatin and vitamin supplementation for additional 6 weeks
11593539|NCT00693589|Active Comparator|V|Vitamin supplementation with folic acid, vitamin B12 and B6 for 6 weeks and after that combined treatment with vitamin supplementation and rosuvastatin
11593540|NCT00693576|Experimental|A|patients who will take simvastatin 20 mg daily
11593541|NCT00693563|No Intervention|Control Group|The Control Group will receive usual care following discharge from the inpatient rehabilitation unit.
11593542|NCT00693563|Experimental|Treatment Group|Scheduled Telephone Intervention
11593543|NCT00693537|Experimental|A|4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)
11593544|NCT00693537|No Intervention|B|Control
11593545|NCT00693524|Experimental|1|Tacrolimus + Anti-IL2R AB + Mycophenolate mofetil
11593546|NCT00693524|Active Comparator|2|Tacrolimus + Steroid
11593547|NCT00693511|Experimental|Circuit Training|Participants received CT exercise training two times per week for approximately 60-90 min per session for 16 wk
11593598|NCT00693134||Control Patients|Patients with no known cardiomyopathies
11593660|NCT00692705|Other|1|Alzheimer's Disease (AD) patients
11593548|NCT00693511|Experimental|Circuit training + motivational interviewing|Participants in the CT + MI group received the same CT classes but also received four individual MI and four group MI sessions throughout the 16-wk program by two trained research staff
11593549|NCT00693511|No Intervention|Control|No intervention
11593550|NCT00693498|Active Comparator|1|Standard leukoreduced irradiated blood cell transfusion group
11593551|NCT00693498|Experimental|2|Washed leukoreduced irradiated blood cell transfusion group
11593552|NCT00693485|Experimental|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
11593553|NCT00693485|Experimental|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
11593554|NCT00693485|Sham Comparator|Sham (no implant)|Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
11593555|NCT00693472|Experimental|Part 1: Preladenant|Preladenant 25 mg every 12 hours for 13 days
11593556|NCT00693472|Placebo Comparator|Part 1: Placebo|Placebo every 12 hours for 13 days
11593557|NCT00693472|Experimental|Part 2: Preladenant|Preladenant 25 mg every 12 hours for 13 days
11593558|NCT00693472|Active Comparator|Part 2: Standard of Care|Anticholinergic agents or Propranolol as standard-of-care dosing regimen (supplied by the study site)
11593559|NCT00693446|Other|2|"In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation.
~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time."
11593560|NCT00693446|Other|1|Patients receive Tacrolimus from day 0 to the end of the study (Arm Tacrolimus).
11593561|NCT00693433|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive temsirolimus IV over 30 minutes once weekly on days 1, 8, 15, and 22 and oral dexamethasone once on days 1, 2, 8, 9, 15, 16, 22, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11593562|NCT00693420|Experimental|1|Bimatoprost 0.03% solution
11593563|NCT00693420|Placebo Comparator|2|Vehicle solution
11593564|NCT00693407|Experimental|1, FD patients|Eighty male and female FD patients according to Rome III criteria (Drossman, 2006), aged 18 to 70 years, will be recruited from primary and secondary care via advertisements and our referral networks
11593565|NCT00693407|Experimental|2,Healthy controls|Forty male and female healthy volunteers, aged 18 to 70 years without any gastrointestinal pathology or history of significant abdominal pain, bowel disorders, bloating or discomfort during the last 3 months will be recruited.
11593566|NCT00693381|Experimental|1|Tacrolimus/MMF/steroids throughout the study
11593567|NCT00693381|Experimental|2|Tacrolimus/MMF/steroids with MMF reduction from week 7 to 12 and MMF discontinuation at month 3
11593568|NCT00693355|Experimental|1|sodium butyrate
11593569|NCT00693355|Placebo Comparator|2|NaCl
11593570|NCT00693342|Experimental|Arm I|Patients receive polyvalent antigen-KLH conjugate vaccine in combination with OPT-821 subcutaneously (SC) once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.
11593571|NCT00693342|Experimental|Arm II|Patients receive OPT-821 SC once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.
11593572|NCT00693316|Experimental|ORM-12741|
11593573|NCT00693316|Placebo Comparator|Placebo|
11593574|NCT00693303|Experimental|Handwriting Training using My Scrivener|Subjects received 20 minutes of training per week which included writing letters and words with the My Scivener device.
11593575|NCT00693290|Active Comparator|1|Fleet plus low residue diet sheet.
11593576|NCT00693290|No Intervention|2|No intervention, usual care, Fleet plus liquid only diet
11593577|NCT00693264|Experimental|1|Participants will take 1- 750 mg capsule of Hoodia gordonii and have the primary and secondary outcomes measured over an 8 hour visit.
11593578|NCT00693264|Placebo Comparator|2|Participants will take a placebo capsule and have the primary and secondary outcome measures taken over an 8 hour study day.
11593579|NCT00693251|Experimental|bifurcation stent technique|crush technique
11593580|NCT00693251|Active Comparator|bifurcation stent techniqe|provisional T stenting
11593581|NCT00693238|Experimental|Low Risk Proton Radiation|70 Gy/CGE in 28 fractions of 2.5 Gy/CGE/fx
11593582|NCT00693238|Experimental|Intermediate Risk Proton Radiation|72.5 GY/CGE in 29 fractions of 2.5 Gy/CGE/fx
11593583|NCT00693225|Active Comparator|Omeprazole/sodium bicarbonate AM dose|8 weeks of therapy with omeprazole/sodium bicarbonate oral suspension 40 mg, once per day, taken in the morning
11593584|NCT00693225|Experimental|Omeprazole/sodium bicarbonate PM dose|8 weeks of therapy with omeprazole/sodium bicarbonate oral suspension 40 mg, once per day, taken at bedtime
11593585|NCT00693212|Experimental|a|This arm was only open to subjects entering the second, open-label phase. All subjects were given open-label methylphenidate. Dosing was flexible.
11593586|NCT00693212|Experimental|MPH|This is the active treatment arm of the double-blind placebo controlled phase. Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
11593587|NCT00693212|Placebo Comparator|PBO|This 2 week arm is the placebo part of the crossover design. Subjects receive placebo in a manner similar to the MPH arm. It lasts 2 weeks.
11593588|NCT00693199|Experimental|1|
11593589|NCT00693199|Active Comparator|2|
11593590|NCT00693199|Experimental|3|
11593591|NCT00693186|Experimental|1|
11593592|NCT00693186|Experimental|2|
11593593|NCT00693160|Experimental|Intrathecal Ketorolac|In the presence of a remifentanil infusion subject will receive a single intrathecal injection of ketorolac 2 mg Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.
11593594|NCT00693160|Placebo Comparator|Placebo intrathecal injection|In the presence of remifentanil the subject will receive a single intrathecal injection of placebo (preservative-free normal saline) Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.
11593595|NCT00693147|Active Comparator|A|mini Video Assisted Thyroidectomy (miVAT)
11593596|NCT00693147|Active Comparator|B|Classic Total Thyroidectomy
11593597|NCT00693134||Myocarditis Patients|Patients initially diagnosed with myocarditis.
11593599|NCT00693121|Placebo Comparator|Placebo|Identical capsule to amantadine hydrochloride active intervention, administered twice daily x 14 days
11593600|NCT00693121|Active Comparator|Amantadine|Amantadine hydrochloride 100mg capsule administered twice daily x 14 days
11593601|NCT00693108|Experimental|1|Transdermal testosterone treatment during the five days preceding gonadotropin therapy in IVF cycles
11593602|NCT00693108|No Intervention|2|
11593603|NCT00693095|Experimental|1|CMV-ALT + CMV-DCs
11593604|NCT00693095|Experimental|2|CMV-ALT + Saline
11593605|NCT00693082|Experimental|1|
11593606|NCT00693069|Active Comparator|1|Clopidogrel 300 mg the day before PCI
11593607|NCT00693069|Experimental|2|Clopidogrel 600 mg the day before PCI
11593608|NCT00693069|Experimental|3|300 mg followed by 75 mg daily started one week prior to angiography
11593609|NCT00693069|Experimental|4|300 mg followed by 150 mg daily started one week prior to angiography
11593610|NCT00693056|Placebo Comparator|1|
11593611|NCT00693056|Experimental|2|
11593612|NCT00693056|Experimental|3|
11593613|NCT00693056|Experimental|4|
11593614|NCT00693043|No Intervention|Standard anesthesia group|Patients randomized to arm 1 received standard of care anesthesia for pleuroscopy. Duration of the procedure will be recorded. Pain management will be monitored prior to, intraoperatively and at the end of the procedure.
11593615|NCT00693043|Experimental|Lidocaine Group|Patients randomized to arm two will receive a reduced topical dose of lidocaine of 2mg/kg and additional lidocaine 3mg/kg infused into the pleura cavity. Duration of procedure will be monitored from the time initial dose of intradermal lidocaine until the start of surgical wound closing, pain scale will be administered prior to the procedure and at the end of the procedure. Lidocaine serum levels will be monitored at 30, 60, and 120 minutes after initial intradermal administration of lidocaine.
11593616|NCT00693030|Active Comparator|1|Device, Sirolimus drug-eluting stents implanted in overlap
11593617|NCT00693030|Active Comparator|2|Device, paclitaxel polymer drug eluting stent
11593618|NCT00693030|Active Comparator|3|Device, zotarolimus drug eluting stent
11593619|NCT00693030|Active Comparator|4|bare metal coronary stents
11593620|NCT00693017|Active Comparator|Zonisamide|
11593621|NCT00693017|Placebo Comparator|Placebo|
11593622|NCT00693004|Placebo Comparator|Placebo|
11593623|NCT00693004|Experimental|PRX-03140|
11593624|NCT00693004|Active Comparator|donepezil|
11593625|NCT00692991||1|People undergoing percutaneous coronary interventions.
11593626|NCT00692978|Experimental|Asthma|Asthma patients
11593627|NCT00692978|Active Comparator|Healthy volunters|Healthy participants
11593628|NCT00692952|Experimental|1|120 subjects using BenZalkonium Chloride Contraceptive Gel
11593629|NCT00692952|Active Comparator|2|120 subjects using Nonoxynol-9 contraceptive gel
11593630|NCT00692939|Experimental|1|High-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
11593631|NCT00692926|Other|20% primed UCB|20% of UCB is ALDHbr sorted and primed and give on transplant day after conventional graft
11593632|NCT00692926|Other|20% un-primed|20% of UCB is ALDHbr freshly sorted and give on transplant day 4-8 hrs after conventional graft
11593633|NCT00692926|Other|Double- 1 unit primed|patient receives 1 conventional UCB unit and 1 unit that has been ALDHbr sorted and primed
11593634|NCT00692926|Other|Double- 1 unit unprimed|Patient receives 1 UCB unit and a second UCB unit that has been freshly ALDHbr sorted
11593635|NCT00692913|Experimental|FOSAVANCE 5600|alendronate sodium (+) cholecalciferol
11593636|NCT00692913|Other|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.
11593637|NCT00692900|Experimental|1|intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin
11593638|NCT00692900|Experimental|2|intravenous (IV) oxaliplatin and intraperitoneal(IP) docetaxel
11593639|NCT00692887||1|Subjects diagnosed as new CNV or treated CNV
11593640|NCT00692848|Experimental|PCT+|Investigations include CBC, blood culture, urine analysis and culture and procalcitonin. In this arm procalcitonin result is revealed to the attending physician. The decision to treat with antibiotics or to hospitalize was left to him
11593641|NCT00692848|No Intervention|PCT-|Investigations include CBC, blood culture, urine analysis and culture and procalcitonin. In this arm, procalcitonin is not revealed to the attending physician. The decision to treat with antibiotics or to hospitalize was left to him.
11593642|NCT00692835|Active Comparator|A|Patients with mini Video Assisted Thyroidectomy (miVAT)
11593643|NCT00692835|Active Comparator|B|Immediate postoperative course of patients with classic Thyroidectomy (cTT)
11593644|NCT00692809||1|HIV+ve+LTBI (n=100)
11593645|NCT00692809||2|HIV+ve+clinical TB (n=50)
11593646|NCT00692809||3|HIV-ve+clinical TB (n=15)
11593647|NCT00692809||4|Normal control (n=15)
11593648|NCT00692796|Experimental|1|
11593649|NCT00692770|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (BID)
11593650|NCT00692770|Placebo Comparator|Placebo|Participants received 2 tablets of placebo orally twice daily (BID)
11593651|NCT00692757|Experimental|A|Hypochlorous acid
11593652|NCT00692757|Active Comparator|B|Iodopovidone
11593653|NCT00692744||Randomized microsurgical|After randomization, this group was constituted of patients treated by microsurgical clipping.
11593654|NCT00692744||Randomized endovascular|After randomization, this group was constituted of patients treated by endovascular coiling.
11593655|NCT00692744||Prospective observational microsurgical|The randomization was ethically unsuitable because of the aneurysm predisposed to the microsurgical clipping after discussion into the neurovascular interdisciplinary team.
11593656|NCT00692744||Prospective observational endovascular|The randomization was ethically unsuitable because of the aneurysm morphology predisposed to the endovascular coiling after discussion into the neurovascular interdisciplinary team.
11593657|NCT00692744||Prospective observational conservative|This group was constituted of patients whom no curative treatment of the aneurysm sac could not be proposed.
11593658|NCT00692731||Active|Tea catechin sport beverage
11593659|NCT00692731||Control|Control beverage
11593661|NCT00692705|Other|2|Healthy volunteers
11593662|NCT00692692|Experimental|DermaMatrix|experimental group with DermaMatrix acellular dermis over tissue expanders in addition to skin/soft tissue and muscle to allow for more natural appearing breast and prevention of complications
11593663|NCT00692692|Active Comparator|Standard of care|standard of care using skin/soft tissue and muscle coverage of tissue expander for breast reconstruction after mastectomy without acellular dermal matrix
11593664|NCT00692653|Experimental|P4|Participant uses P4 program before meeting with his clinician to discuss treatment options.
11593665|NCT00692653|No Intervention|Usual care+|Usual care plus participant is directed to reputable websites highly rated in research literature to learn more about prostate cancer treatments.
11593666|NCT00692640|Experimental|1|
11593667|NCT00692614|Experimental|1|100 mcg triamcinolone acetonide
11593668|NCT00692614|Experimental|2|500 mcg triamcinolone acetonide
11593669|NCT00692614|Experimental|3|925 mcg triamcinolone acetonide
11593670|NCT00692614|No Intervention|4|sham control - not implanted, no medication
11593671|NCT00692601|Experimental|1|acute oral ingestion of 3 mg capsiate
11593672|NCT00692601|Experimental|2|acute oral ingestion of 10 mg capsiate
11593673|NCT00692601|Placebo Comparator|3|acute oral ingestion of 0 mg capsiate ( same number of capsules as two other trials and identical looking placebo capsules)
11593674|NCT00692588||Placebo|Subjects who received placebo in DARAD Trial
11593675|NCT00692588||Doxycycline|Subjects who received doxycycline in DARAD Trial
11593676|NCT00692588||Rifampicin|Subjects who received rifampicin in DARAD Trial
11593677|NCT00692588||Doxycycline and Rifampicin|Subjects who received doxycycline and rifampicin in DARAD Trial
11593678|NCT00692588||Control|Normal controls
11593679|NCT00692575|Experimental|1: Experimental|Problem-solving, education based telephone counseling.
11593680|NCT00692575|Sham Comparator|2: No intervention|Standard of care control group
11593681|NCT00692562|Experimental|A|
11593682|NCT00692549|Experimental|Ultrasound|use of ultrasound
11593683|NCT00692549|No Intervention|no ultrasound|no ultrasound
11593684|NCT00692536|Active Comparator|1|NNR
11593685|NCT00692536|Active Comparator|2|MPD
11593686|NCT00692523|Active Comparator|1|The control group will receive 8 recreational therapy sessions over a 2-week (14 day) period, to be scheduled in a flexible manner as long as all 8 sessions are completed within the 2 week period, and no more than 2 sessions are completed on any one day.
11593687|NCT00692523|Experimental|2|Patients randomized to Wii technology will receive an intensive program consisting of 8 Wii gaming sessions, 60 minutes each, over a 2-week (14 day) period. These 8 sessions can be scheduled in a flexible manner as long as all 8 sessions are completed within the 2 week period, and no more than 2 sessions are completed on any one day.
11593688|NCT00692510|Experimental|1|AZD3480 + cocktail
11593689|NCT00692510|Placebo Comparator|2|Placebo + cocktail
11593690|NCT00692497|Active Comparator|1|The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
11593691|NCT00692497|No Intervention|2|Patients in the control group are randomised to use the regular patient pathway prior to day case outpatient surgery. All these patients are referred to the surgical outpatient clinic. At the outpatient clinic patients are examined by a surgeon and indications for surgery is decided by the surgeon. If indicated, patients are then referred to outpatient surgery and the surgical procedure is performed several weeks after the examination.
11593692|NCT00692484|Experimental|1|Chlorhexidine gluconate 2%
11593693|NCT00692484|Active Comparator|2|Povidone iodine scrub and paint
11593694|NCT00692471||1|Patients meeting the diagnostic criteria for the Postural Tachycardia Syndrome, a form of Orthostatic Intolerance
11593695|NCT00692471||2|Healthy control subjects who do not meet the criteria for the Postural Tachycardia Syndrome
11593696|NCT00692458|Experimental|1|odanacatib
11593697|NCT00692458|Placebo Comparator|2|placebo
11593698|NCT00692445|Active Comparator|citalopram + TC-5214|
11593699|NCT00692445|Placebo Comparator|citalopram + placebo|
11593700|NCT00692419|Experimental|Symptom management nurse intervention|This arm of the study will have a symptom management nurse facilitate the management of pain, sexual dysfunction and depression. The nurse will work with the patient's renal provider to implement appropriate symptom alleviating treatment. The intervention is patient specific and entirely dependent on the treatment recommendation made by the symptom management nurse.
11593701|NCT00692419|Active Comparator|Feedback intervention|This arm of the study will have pain, sexual dysfunction and depression assessed monthly with feedback given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider. The intervention on symptoms is at the discretion of the renal provider. The interventions implemented were patient specific and consisted of therapies the patient's renal provider decided to implement.
11593702|NCT00692406|Experimental|Smokers not interested in quitting smoking|Smokers were scanned 24 hours after quitting smoking, and scanned after smoking as usual.
11593703|NCT00692393|Active Comparator|1|Surgery : Hartmann intervention
11593704|NCT00692393|Experimental|2|Surgery : primary resection with anastomosis with protective stoma
11593705|NCT00692380|Experimental|A|Fractionated Radiation Therapy followed by Carboplatin and Taxol
11593706|NCT00692367|Other|Exercise|Structured exercise program
11593707|NCT00692341|Experimental|Hepatic Function - Mild Impairment|Subjects with mild hepatic impairment (Child Pugh class A, score 5-6)
11593708|NCT00692341|Experimental|Hepatic Function - Moderate Impairment|Subjects with moderate hepatic impairment(Child Pugh class B,score 7-9)
11593709|NCT00692341|Experimental|Hepatic Function - Normal|"Group 1
~1) subjects with normal hepatic function"
11593710|NCT00692328|Active Comparator|1|The subjects will be told they receive levodopa or acupuncture.
11593711|NCT00692328|Placebo Comparator|2|The subjects will be told they receive placebo/sham levodopa or acupuncture.
11593712|NCT00692328|Experimental|3|The subjects will be told they have 50% chance of receiving real or placebo/sham levodopa or acupuncture.
11593713|NCT00692315|Experimental|Methyl B12|Subcutaneous injection of 75 micrograms/Kg
11593714|NCT00692315|Experimental|Folinic Acid|400 micrograms orally twice a day
11593715|NCT00692302|Experimental|SAFETY I|Phase I participants who will receive SAFETY
11593716|NCT00692302|Experimental|SAFETY II|Phase II participants who will receive SAFETY
11593717|NCT00692302|Active Comparator|Control|Phase II participants who will receive enhanced usual care
11593718|NCT00692276|Experimental|1|Interspinous Process Spacer Device
11593719|NCT00692276|Active Comparator|2|Interspinous Process Spacer Device
11593720|NCT00692263|Experimental|A|Escitalopram - tramadol
11593721|NCT00692263|Experimental|B|Placebo - tramadol
11593722|NCT00692263|Experimental|C|placebo - placebo
11593723|NCT00692237|Active Comparator|1|Sildenafil 100 mg
11593724|NCT00692237|Placebo Comparator|2|Placebo 100 mg
11593725|NCT00692224|Active Comparator|1|study group received zinc gluconate in a dose of 10 mg/day
11593726|NCT00692224|Placebo Comparator|2|placebo group received placebo which was identical in color, taste and appearance and packaged in similar looking bottles.
11593727|NCT00692211|Experimental|Arm 1: Fecal Immunochemical Tests|Mailed fecal immunochemical tests
11593728|NCT00692211|Experimental|Arm 2: Fecal Occult Blood Tests|Mailed fecal occult blood tests
11593729|NCT00692198|Experimental|Supplemental oxygen therapy|Participants will receive treatment with supplemental oxygen therapy.
11593730|NCT00692198|No Intervention|No supplemental oxygen therapy|Participants will receive no supplemental oxygen therapy, unless the participant becomes severely hypoxemic at rest (e.g., meets conventional Medicare criteria for 24-hour supplemental oxygen due to severe hypoxemia at rest).
11593731|NCT00692185|Experimental|1|Participants will take olanzapine.
11593732|NCT00692185|Placebo Comparator|2|Participants will take matched placebo.
11593733|NCT00692172|Experimental|1|
11593734|NCT00692159|Experimental|1|Dose finding single arm
11593735|NCT00692146|Experimental|1|36 subjects receiving a specified volume of the active component AZD1386 in a single dose.
11593736|NCT00692146|Placebo Comparator|2|36 subjects receiving a specified volume of placebo in a single dose.
11593737|NCT00692120|Experimental|1|
11593738|NCT00692120|Experimental|2|
11593739|NCT00692120|Experimental|3|
11593740|NCT00692120|Experimental|4|
11593741|NCT00692107|Active Comparator|1|68 Gy
11593742|NCT00692107|Experimental|2|78 Gy
11593743|NCT00692094|Experimental|1|Subjects will be given 0.5 mg at a time when melatonin should delay the timing of their body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
11593744|NCT00692094|Experimental|2|Subjects will be given 0.5 mg at a time when melatonin should advance the timing of their body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
11593745|NCT00692094|Experimental|3|Subjects will be given a larger dose (up to 10 mg) at a time when the melatonin should advance the timing of the body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
11593746|NCT00692094|Experimental|4|Subjects will be given a larger dose (up to 20 mg) at a time when the melatonin should advance the timing of the body clock. If the subject successfully responds to the treatment, the dose will be reduced gradually until the lowest effective dose is determined (down to 0.025 mg). If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
11593747|NCT00692081|Experimental|A|8 group sessions social competence training (CBT)
11593748|NCT00692081|Active Comparator|B|special vocational training as usual
11593749|NCT00692068||A|with residual renal function
11593750|NCT00692068||B|without residual renal function
11593751|NCT00692055|Experimental|1|PN400
11593752|NCT00692055|Active Comparator|2|naproxen 375 mg
11593753|NCT00692042|Experimental|1|
11593754|NCT00692016|Other|Arm 1|
11593755|NCT00692016|Other|Arm 2|
11593756|NCT00692003|Active Comparator|Zonisamide|
11593757|NCT00692003|Placebo Comparator|Placebo|
11593758|NCT00691990|Active Comparator|A|Classic thyroidectomy with drains
11593759|NCT00691990|Active Comparator|B|Classic thyroidectomy without drains
11593760|NCT00691977|Experimental|A|Radiation Therapy followed by prostatectomy
11593761|NCT00691964|Experimental|A|
11593762|NCT00691964|Active Comparator|B|
11593763|NCT00691964|Placebo Comparator|C|
11593764|NCT00691938|Experimental|Level 1|"LBH589 10 mg/day three times a week on nonconsecutive days in a 28 day cycle.
~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
11593765|NCT00691938|Experimental|Level 2|"LBH589 15 mg/day three times a week on nonconsecutive days in a 28 day cycle.
~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
11593766|NCT00691938|Experimental|Level 3|"LBH589 20 mg/day three times a week on nonconsecutive days in a 28 day cycle.
~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
11593767|NCT00691938|Experimental|Level 4|"LBH589 30 mg/day three times a week on nonconsecutive days in a 28 day cycle.
~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
11593768|NCT00691938|Experimental|Level 5|"LBH589 40 mg/day three times a week on nonconsecutive days in a 28 day cycle.
~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
11593769|NCT00691938|Experimental|Level 5B|"LBH589 40 mg/day three times a week on nonconsecutive days for the first 2 weeks in a 28 day cycle.
~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
11593770|NCT00691938|Experimental|Phase II|"LBH589 will be given in the dose and in the schedule that was found to work in the Phase I portion which was Level 5B.
~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
11593771|NCT00691925||1|bilateral post refractive surgery subject
11593772|NCT00691912|Experimental|Myocet/Paclitaxel|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
11593773|NCT00691899|Experimental|1|
11593774|NCT00691899|Placebo Comparator|2|
11593775|NCT00691886|No Intervention|1|Subjects randomized to arm 1 of the study will recieve standard of care conscious sedation for EBUS; midasolam and or fentanyl.
11593776|NCT00691886|Active Comparator|2|Subjects undergoing EBUS randomized to arm 2 of the study will recieve demedetomadine hydrochloride plus standard of care conscious sedation
11593777|NCT00691873|Placebo Comparator|1|Placebo will be compared to Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
11593778|NCT00691873|Experimental|2|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
11593779|NCT00691860|Experimental|1|Patients receiving conventional sigmoid end colostomy plus a lightweight mesh Ultrapro®
11593780|NCT00691860|Other|2|Patients receiving conventional sigmoid end colostomy, without mesh
11593781|NCT00691847||1|Bilateral post refractive procedure
11593782|NCT00691834|Experimental|1|Intracoronary delivery of unfractionated bone marrow mononuclear cells
11593783|NCT00691834|Placebo Comparator|2|Intracoronary delivery of placebo
11593784|NCT00691821|Active Comparator|1|Standard Dressings
11593785|NCT00691821|Experimental|2|Negative Pressure Wound Therapy
11593786|NCT00691808|Experimental|High Dose|
11593787|NCT00691808|Experimental|Low Dose|
11593788|NCT00691808|Placebo Comparator|Placebo|
11593789|NCT00691795|Experimental|CLONIDINE|Participants randomized to this arm of the study receive 75 micrograms clonidine with the bupivacaine in their epidural when requesting pain relief in advanced labor
11593790|NCT00691795|Experimental|FENTANYL|Participants randomized to this arm of the study receive 75 micrograms fentanyl with the bupivacaine in their epidural when requesting pain relief in advanced labor
11593791|NCT00691782||1|African American females between the ages of 21 and 60
11593792|NCT00691769||I|CCSA subjects will be recruited from patients who have been diagnosed through biopsy with CCSA and treated with standard of care for up to eight months in the Department of Dermatology clinic of Wake Forest University School of Medicine.
11593793|NCT00691769||II|patients with lichen planopilaris (LP) and patients with discoid lupus erythematosus (DLE) will be collected from patients who have been diagnosed through biopsy in the clinic.
11593794|NCT00691769||III|Healthy study subjects will be patients from the Wake Forest University School of Medicine Department of Dermatology population undergoing excisions for cosmetic purposes or excision of free margins around tumors that would have otherwise been discarded.
11593795|NCT00691756|Experimental|1|Cold blood renal perfusion
11593796|NCT00691756|Active Comparator|2|Cold crystalloid renal perfusion
11593797|NCT00691743||1|Primary care
11593798|NCT00691730|Other|Arm I|To analyze proteinuria/hypertension with anti-angiogenic therapies, specifically Bevacizumab, AZD2171, Sunitinib and VEGF Trap. Patients undergo blood and urine sample collection periodically. Urine samples are assessed for PGI2 and TXA2 levels using validated ELISA methods. Urine is also assessed for protein and creatinine levels, microalbumin, osmolality, and electrolytes. Blood samples are assessed for pharmacokinetics and sFlt1, VEGF, and bFGF levels by validated ELISA methods. Blood samples are also assessed for steady state drug concentration, renin, and aldosterone levels. Analyses will be considered purely exploratory and no testing will be performed for difference between treatments.
11593799|NCT00691717|Experimental|24 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 30 mg/mL, single depot administration of 0.8 mL in the study eye
11593800|NCT00691717|Experimental|48 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 60 mg/mL, single depot administration of 0.8 mL in the study eye
11593801|NCT00691717|Experimental|60 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 75 mg/mL, single depot administration of 0.8 mL in the study eye
11593802|NCT00691717|Placebo Comparator|Anecortave Acetate Vehicle|Single depot administration of 0.8 mL in the study eye
11593803|NCT00691704|Experimental|High-risk Multiple Myeloma|Lenalidomide Induction (with Low Dose Dexamethasone) Therapy Followed by Low Dose Melphalan, Prednisone, Lenalidomide and Bortezomib Sequential Maintenance Therapy
11593804|NCT00691691|Experimental|1|Eligible patient will be treated with 48 Gy in 4 fractions encompassing the entire target lesion in 2 weeks with a minimum of 48 hours between each dose.
11593805|NCT00691678|Experimental|chondroitin and glucosamine|Postmenopausal breast cancer patients that have joint symptoms induced by aromatase inhibitors and are receiving chondroitin and glucosamine.
11593806|NCT00691665|Experimental|Olopatadine HCL Nasal Spray, 0.6%|Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
11593807|NCT00691665|Active Comparator|Fluticasone Propionate Nasal Spray, 50 mcg|Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
11593808|NCT00691652|Experimental|Oral Clofarabine + Rituximab in Relapsed B Cell NHL|"Phase I: Oral Clofarabine x 14 days for up to 8 cycles at assigned dose level below (1 cycle equals 14 days on drug, 14 days off).
~Rituximab weekly for 4 weeks than monthly for up to 8 cycles on day 1 of cycle 375 mg/m2 IV
~Dose Level 1: 2 mg Dose Level 2: 4 mg Dose Level 3: 6 mg
~Phase II:
~Oral Clofarabine x 14 days for up to 8 cycles (Dose determined from phase I) AND Rituximab weekly for 4 weeks than monthly for up to 8 cycles on day 1 of cycle 375 mg/m2 IV"
11593809|NCT00691639||1|Patients who are or were participants in any Alcon AL-3789 study.
11593810|NCT00691626|Experimental|Arm 1: CBT for Insomnia plus Imagery Rehearsal|CBT for Insomnia plus Imagery Rehearsal
11593811|NCT00691626|Active Comparator|Arm 2: CBT for Insomnia|CBT for Insomnia
11593812|NCT00691613|Experimental|1|EPO
11593813|NCT00691613|Placebo Comparator|2|NaCl
11593814|NCT00691600|Active Comparator|oral trimethoprim/sulfamethoxazole|subjects with abscesses less than 5cm will be randomized to either study med or placebo
11593815|NCT00691600|Placebo Comparator|placebo|Placebo after incision and drainage of abscess less than 5 cm.
11593816|NCT00691587|Experimental|1|Low-dose KB001, a monoclonal antibody
11593817|NCT00691587|Experimental|2|High-dose KB001, a monoclonal antibody
11593818|NCT00691587|Placebo Comparator|3|Placebo
11593886|NCT00691184|Active Comparator|Group 4|Dose of 250 mg Lamisil® Tablets (Groups 1,2,3) at end of study.
11593819|NCT00691574|Active Comparator|2|Subjects will sit in front of a fluorescent bright light box while completing plasma samples to test for melatonin suppression in blood. This will be completed by both the SMS patient group and the control group of elderly individuals.
11593820|NCT00691574|Experimental|1|Subjects will take up to 3 mg of melatonin daily and will complete frequent (every 2-4 weeks) of saliva and/or plasma sampling to test for a change in the timing of the body clock in response to the melatonin.
11593821|NCT00691561|Experimental|1|Participants receive HIV counseling and testing and 8 intervention sessions to assist them with reducing unsafe sexual behaviors.
11593822|NCT00691561|No Intervention|2|Participants receive HIV counseling and testing only.
11593823|NCT00691548|Experimental|1|
11593824|NCT00691496|Experimental|1|Receives HIV testing and counseling and 5 week intervention
11593825|NCT00691496|No Intervention|2|Receives only HIV Testing and Counseling
11593826|NCT00691483|Placebo Comparator|placebo|
11593827|NCT00691483|Experimental|varenicline|
11593828|NCT00691470|Experimental|1. ATI-5923|Dose adjusted ATI-5923
11593829|NCT00691470|Active Comparator|2. Coumadin|Dose adjusted Coumadin (warfarin)
11593830|NCT00691457|Experimental|1|Opti-Free contact lens solution
11593831|NCT00691457|Active Comparator|2|ReNu Multiplus contact lens solution
11593832|NCT00691457|Active Comparator|3|Clear Care contact lens solution
11593833|NCT00691444|Experimental|1|Subjects will be given up to 0.5 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
11593834|NCT00691444|Experimental|2|Subjects will be given up to 10 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
11593835|NCT00691444|Experimental|3|Subjects will be given up to 20 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
11593836|NCT00691418|Active Comparator|1|600 mg per day of docosahexaenoic acid (DHA)
11593837|NCT00691418|Placebo Comparator|2|Placebo
11593838|NCT00691405|Experimental|A1|Arformoterol 5 mcg BID for 14 days
11593839|NCT00691405|Experimental|A2|Arformoterol 15 mcg BID for 14 days
11593840|NCT00691405|Experimental|A3|Arformoterol 25 mcg BID for 14 days
11593841|NCT00691405|Placebo Comparator|A4|Placebo inhalation solution BID for 14 days
11593842|NCT00691405|Experimental|B1|Arformoterol 15 mcg QD for 14 days
11593843|NCT00691405|Experimental|B2|Arformoterol 25 mcg QD for 14 days
11593844|NCT00691405|Experimental|B3|Arformoterol 50 mcg QD for 14 days
11593845|NCT00691405|Placebo Comparator|B4|Placebo inhalation solution QD for 14 days
11593846|NCT00691392|Experimental|1|Linezolid 600 mg po daily for 16 weeks (112 doses) given in addition to optimized background therapy for MDR TB
11593847|NCT00691392|Placebo Comparator|2|Over-encapsulated microcrystalline methylcellulose (Avicel) - an inert filler
11593848|NCT00691379|Experimental|1|Paclitaxel/Carboplatin/Bevacizumab
11593849|NCT00691340||1|Control 1 (young subjects)
11593850|NCT00691340||2|Control 2 (old subjects)
11593851|NCT00691340||3|Glaucoma patients
11593852|NCT00691340||4|Alzheimer patients
11593853|NCT00691327|Experimental|1|Primary reconstruction
11593854|NCT00691327|Experimental|2|Revision-reconstruction
11593855|NCT00691327|Experimental|3|Revision-augmentation
11593856|NCT00691314|Experimental|1|
11593857|NCT00691314|Active Comparator|2|
11593858|NCT00691301|Experimental|Pemetrexed and cisplatin|Pemtrexed plus cisplatin on day 1 every 21 days
11593859|NCT00691288|Experimental|1|
11593860|NCT00691288|Experimental|2|
11593861|NCT00691275|Placebo Comparator|2|Saline
11593862|NCT00691275|Active Comparator|1|Zofran
11593863|NCT00691262|Experimental|1|
11593864|NCT00691249|Experimental|1|Resistant starch type 4-Raw
11593865|NCT00691249|Experimental|2|Resistant starch type 4-Raw
11593866|NCT00691249|Experimental|3|Resistant starch type 4-Cooked
11593867|NCT00691249|Experimental|4|Resistant starch type 4-Cooked
11593868|NCT00691249|Placebo Comparator|5|Shredded wheat
11593869|NCT00691236|Active Comparator|A|standard chemotherapy which is Adriamycin, Cisplatinum and Ifosfamide
11593870|NCT00691236|Experimental|B|zoledronic acid prior to standard chemotherapy
11593871|NCT00691236|Experimental|C|zoledronic acid alone 4mg IV 3 weekly for 6 doses
11593872|NCT00691223||Experimental|Individuals with Goltz syndrome and their first degree relatives.
11593873|NCT00691210|Experimental|V/N: Level 1|Vorinostat: 400mg Niacinamide: 20 mg/kg rounded to 100mg
11593874|NCT00691210|Experimental|V/N: Level 2|Vorinostat: 400mg Niacinamide: 40 mg/kg rounded to 100mg
11593875|NCT00691210|Experimental|V/N: Level 3|Vorinostat: 400mg Niacinamide: 60 mg/kg rounded to 100mg
11593876|NCT00691210|Experimental|V/N: Level 4|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg
11593877|NCT00691210|Experimental|V/N: Level 5|Vorinostat: 400mg Niacinamide: 100 mg/kg rounded to 100mg
11593878|NCT00691210|Experimental|V/N/E: Level 1|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 25 mg/m2
11593879|NCT00691210|Experimental|V/N/E: Level 2|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 50 mg/m2
11593880|NCT00691210|Experimental|V/N/E: Level 3|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 100 mg/m2
11593881|NCT00691197|Experimental|Carboxymethylcellulose sodium and Glycerin|Carboxymethylcellulose sodium and Glycerin based rewetting drop
11593882|NCT00691197|Active Comparator|Carboxymethylcellulose sodium|Carboxymethylcellulose sodium based rewetting drop
11593883|NCT00691184|Experimental|Group 1|0% Terbinafine HCl Nail Lacquer for 28 days.
11593884|NCT00691184|Experimental|Group 2|10% Terbinafine HCl Nail Lacquer.
11593885|NCT00691184|Active Comparator|Group 3|1% Lamisil® Cream
11593887|NCT00691171||1|GERD: Patients with established diagnoses of GERD based on ICD-9 codes
11593888|NCT00691171||2|Atypical GERD: Patients without an established diagnosis of GERD with atypical symptoms that could be due to GERD (e.g., asthma)
11593889|NCT00691171||3|Chronic NSAID users: Patients using chronic NSAIDs who are at increased risk of GI complications (defined as previous diagnosis of peptic ulcer disease; age 75 or older; or concomitant use of corticosteroids, anticoagulants, or aspirin)
11593890|NCT00691158|Placebo Comparator|1- Normal Saline|4.7 mls normal saline IV bolus
11593891|NCT00691158|Active Comparator|2 Metreleptin|IV Leptin bolus
11593892|NCT00691158|Active Comparator|3 Pramlintide|IV Pramlintide bolus at Timpoint +0 and +30 minutes
11593893|NCT00691158|Active Comparator|4 Leptin plus Pramlintide|leptin and pramlintide IV bolus injection at timpoints 0 and +30 minutes
11593894|NCT00691145|Experimental|1|
11593895|NCT00691132|Experimental|PEITC - Placebo (short-term trial)|Participants are asked to smoke only deuterated NNK cigarettes (provided by the study) and record the exact number of cigarettes smoked and alcoholic drinks consumed each day for 1 month. Participants receive oral phenethyl isothiocyanate (PEITC) four times daily for 5 days in week 2 and oral placebo four times daily for 5 days in week 4. Participants keep a diary of all food and beverages consumed on the days that PEITC or placebo are taken.
11593896|NCT00691132|Experimental|Placebo - PEITC (short-term trial)|Participants receive oral placebo four times daily for 5 days in week 2 and oral PEITC four times daily for 5 days in week 4. Participants are also asked to smoke only deuterated NNK cigarettes, record the number of cigarettes smoked and alcoholic drinks consumed each day, and keep a food and beverage diary as in arm I.
11593897|NCT00691119|Experimental|A|Relaxation and Visualization Therapy group
11593898|NCT00691119|Active Comparator|B|Health education group
11593899|NCT00691119|No Intervention|C|Control group
11593900|NCT00691093||fesoterodine|
11593901|NCT00691080||ASD children|"ASD children as defined by:
~Age greater than or equal to 4 or less than or equal to 9 years
~Diagnosis of Autism Spectrum Disorder; supported by ADOS and the ADI or SCQ (subjects).
~No current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.)
~No current or use within the last 1 month of beta-blockers or melatonin
~No current use of sleep aids
~No presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD)
~(6) No blindness."
11593902|NCT00691080||"Healthy control children"|"Healthy control children as defined by:
~Age greater than or equal to 4 or less than or equal to 9 years
~A SCQ score of less than 10 without parental or physician concern for another neurodevelopmental disorder will be used to define normal children.
~No current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.)
~No current or use within the last 1 month of beta-blockers or melatonin
~No current use of sleep aids;
~No presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD)
~(6) No blindness. (7) No current or past diagnosis of ADHD, depression, anxiety or with any other psychiatric conditions.
~(8) No sibling with a diagnosis of Autism Spectrum Disorder."
11593903|NCT00691067|Experimental|Mifepristone|600mg of Mifepristone
11593904|NCT00691067|Placebo Comparator|Placebos|Placebo
11593905|NCT00691054|Experimental|Abraxane|One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4.
11593906|NCT00691041|Experimental|1|HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
11593907|NCT00691041|No Intervention|2|HIV/STI counseling and testing and a single 15 minute session of resources available in the community
11593908|NCT00691028|Experimental|TA-650 3 mg/kg|
11593909|NCT00691028|Experimental|TA-650 6 mg/kg|
11593910|NCT00691028|Experimental|TA-650 10 mg/kg|
11593911|NCT00691015|Experimental|Chemotherapy or chemotherapy + total body irradiation|"Standard of care (SOC) chemotherapy or ( SOC) chemotherapy + total body irradiation (TBI) of one of the following regimens:
~Regimen I: Patients receive fludarabine phosphate IV and busulfan IV; anti-thymocyte globulin IV.
~Regimen II: Patients undergo total body irradiation (TBI) twice daily for 8 fractions and receive etoposide IV;anti-thymocyte globulin IV.
~Regimen III: Patients undergo TBI once or twice daily for 11 fractions and receive cyclophosphamide IV; anti-thymocyte globulin IV.
~Regimen IV: Patients undergo TBI and receive fludarabine phosphate IV and busulfan IV; anti-thymocyte globulin IV.
~Regimen V: Patients receive carmustine IV, etoposide IV, cytarabine IV, and melphalan IV. Some patients also receive rituximab IV; anti-thymocyte globulin IV.
~Regimen VI: Patients receive fludarabine phosphate IV and melphalan IV. Some patients also undergo TBI; anti-thymocyte globulin IV."
11593912|NCT00691002|Experimental|LEO 80190|
11593913|NCT00691002|Placebo Comparator|LEO 80190 vehicle|
11593914|NCT00691002|Active Comparator|Calcipotriol|
11593915|NCT00691002|Active Comparator|Betametasone|
11593916|NCT00690976|Experimental|1.Group Intervention|A group-based intervention consisting of 4 sessions lasting approximately 90 minutes each. Using a variety of pedagogical and interactive approaches, facilitators will introduce new concepts and skills.
11593917|NCT00690976|Active Comparator|2. HCT|Offer of HIV counseling and testing
11593918|NCT00690937|Experimental|1 ECS|Low dose treatment
11593919|NCT00690937|Experimental|2 ECS|High dose treatment
11593920|NCT00690937|Active Comparator|3 Colesevelam|Active control treatment
11593921|NCT00690937|Placebo Comparator|4 Placebo|Placebo matched to low dose treatment
11593922|NCT00690937|Placebo Comparator|5 Placebo|Placebo matched to high dose treatment
11593923|NCT00690924|Experimental|Calcitriol|
11593924|NCT00690911|Experimental|1|open label adalimumab 40mg
11593925|NCT00690898|Experimental|Lanreotide autogel 120 mg|
11593926|NCT00690885|Experimental|1|lozenges containing 150 IU of natural human interferon-alpha
11593927|NCT00690885|Placebo Comparator|2|matching placebo lozenges
11593928|NCT00690859||1|Ambulatory bipolar I and II patients, clinically stabilized for at least the two months prior to recruitment and who had at least one acute episode (depressive, manic, hypomanic or mixed) within the year prior to recruitment.
11593929|NCT00690846|Experimental|1|40 mg weekly subcutaneous injection of adalimumab
11593930|NCT00690833|Experimental|topical desonide hydrogel 0.05%|Approximately 40 male and female subjects (about 20 age 3 months to <13 years and 20 age 13 and up) with mild to moderate atopic dermatitis will apply desonate gel twice daily to ATD
11593931|NCT00690820|Experimental|A|
11593932|NCT00690820|Placebo Comparator|B|
11593933|NCT00690807|Experimental|1|PH-10 treatment
11593934|NCT00690794|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily for 90 days
11593935|NCT00690794|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily for 90 days
11593936|NCT00690781|Experimental|Casein Pulse|"casein is the main protein consumed, it is given during 6 weeks with a pulse protein feeding pattern : 8% for breakfast, 80% for lunch, 4% around 1600h, and 8% for dinner."
11593937|NCT00690781|Experimental|Casein Spread|"casein is the main protein consumed, it is given during 6 weeks with a spread protein feeding pattern : 25% for breakfast, 25% for lunch, 25% around 1600h, and 25% for dinner."
11593938|NCT00690781|Experimental|MSP Pulse|"Milk soluble proteins (MSP) are the main protein consumed, it is given during 6 weeks with a pulse protein feeding pattern : 8% for breakfast, 80% for lunch, 4% around 1600h, and 8% for dinner."
11593939|NCT00690781|Experimental|MSP Spread|"Milk soluble proteins (MSP) are the main protein consumed, it is given during 6 weeks with a spread protein feeding pattern : 25% for breakfast, 25% for lunch, 25% around 1600h, and 25% for dinner."
11593940|NCT00690768|Experimental|A|Preoperative Intravitreal bevacizumab and pars plana vitrectomy
11593941|NCT00690768|Active Comparator|B|Pars plana vitrectomy only
11593942|NCT00690755||Group 1|type 2 diabetic individuals
11593943|NCT00690755||Group 2|type 1 diabetic individuals or those with diabetes secondary to pancreatic disease
11593944|NCT00690755||Group 3|non-diabetic individuals who are not considered to be overweight
11593945|NCT00690755||Group 4|non-diabetic individuals who are considered to be overweight
11593946|NCT00690755||Group 5|non-diabetic and type 2 diabetic individuals who will be subjected to an exercise study
11593947|NCT00690755||Group 6|individuals who have or are suspected of having glucose intolerance, including patients who have a history of gestational diabetes and patients who have polycystic ovary syndrome
11593948|NCT00690755||Group 7|healthy non-diabetic subjects who will receive one dose of metformin orally 1-2 hours before performing procedures
11593949|NCT00690729|Experimental|1|Bibliotherapy - cognitive behavior therapy focusing on exposure and response prevention directed by the family
11593950|NCT00690729|Active Comparator|2|Cognitive Behavioral Therapy - therapist-directed exposure response prevention over a 12-week period
11593951|NCT00690716|Experimental|1|Nasal CO2
11593952|NCT00690716|Placebo Comparator|2|Inactive Placebo
11593953|NCT00690703|Experimental|1|Treatment
11593954|NCT00690690|Experimental|video|
11593955|NCT00690690|Active Comparator|HCT|Offer of HIV counseling and testing
11593956|NCT00690664||B|Caucasian women
11593957|NCT00690664||A|African American women
11593958|NCT00690651|Active Comparator|2|this group will rest in bed with operated leg well elevated for 48 hour and then mobilize with physiotherapist with aim for discharge home when safe.
11593959|NCT00690651|Experimental|1|mobilize with physiotherapist within 24 hours of surgical fixation of fractured ankle
11593960|NCT00690638|Placebo Comparator|1|Placebo
11593961|NCT00690638|Experimental|2|PHX1149T 200 mg
11593962|NCT00690638|Experimental|3|PHX1149T 400 mg
11593963|NCT00690625|Experimental|A|MyoRx cream
11593964|NCT00690625|Placebo Comparator|B|Placebo cream, same composition as experimental cream, without Omega 3 fatty acid
11593965|NCT00690612|Experimental|1|investigator determines efficacious dose based on child's BP response.
11593966|NCT00690573|Experimental|Adalimumab|
11593967|NCT00690560|Experimental|R-CHOP14 chemotherapy|
11593968|NCT00690547||Test Group|
11593969|NCT00690534|Active Comparator|CMAY|Insulin in young
11593970|NCT00690534|Experimental|IMAY|L-NMMA + insulin in young
11593971|NCT00690534|Experimental|SNPY|SNP in young
11593972|NCT00690534|Active Comparator|CSNP|Insulin in elderly
11593973|NCT00690534|Experimental|ISNP|SNP in elderly
11593974|NCT00690534|Experimental|SNPE|SNP in elderly
11593975|NCT00690534|Active Comparator|CMealO|Meal in elderly
11593976|NCT00690534|Experimental|SMealO|SNP+meal in elderly
11593977|NCT00690534|Active Comparator|MealY|meal in young
11593978|NCT00690534|Experimental|ExIns|insulin+exercise in elderly
11593979|NCT00690534|Experimental|ExMeal|meal+exercise in elderly
11593980|NCT00690521|Active Comparator|1|Patients will be randomized to receive either metolazone or HCTZ in a randomized, double-blind, placebo controlled crossover trial. The patients will receive the alternative medication if The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance. A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day. A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5 If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
11593981|NCT00690521|Active Comparator|2|Patients will be randomized to receive either metolazone or HCTZ in a randomized, double-blind, placebo controlled crossover trial. The patients will receive the alternative medication if The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance. A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day. A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5 If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
11593982|NCT00690495|Experimental|1|Modified propofol (Propofol 0.5%)
11593983|NCT00690495|Active Comparator|2|Propofol 1%
11593984|NCT00690482|Experimental|AZD1981|AZD1981 Oral tablet, twice daily
11593985|NCT00690482|Placebo Comparator|Placebo|Placebo Oral tablet, twice daily
11594034|NCT00690092|Active Comparator|1|Volunteers with a history of pulmonary coccidioidomycosis verified by serology and/or histology or mycology.
11594035|NCT00690092|Active Comparator|2|Volunteers without a history of pulmonary coccidioidomycosis confirmed by serology (naive).
11593986|NCT00690469||Observational (biomarker analysis)|"Participants undergo a structured telephone interview questionnaire. The parental questionnaires collect basic demographic data (including age, race, education, and income), occupational history, medical radiation exposure, diet and supplement use (for the year before pregnancy for father, during pregnancy for mother), tobacco use, and alcohol use. The mothers are also asked about residential pesticides and prior assisted reproductive technology.
~Controls (parents) provide saliva samples. If a patient is also enrolled on COG-ARET0332, then the patient blood and tumor samples should be submitted. Parents of patients on this protocol should also submit a blood sample. Blood samples from the affected child, and blood and/or sputum samples from the parents may be submitted. Tumor specimens should be submitted if available.
~For some patients, a RB1 mutation detection assay on DNA derived from peripheral blood is performed. If the mutation is found, the parents? DNA is also screened."
11593987|NCT00690456|Experimental|Rimonabant|Rimonabant 20 mg once daily on top of metformin
11593988|NCT00690456|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily on top of metformin
11593989|NCT00690443|Active Comparator|2|2.5 mg AEGR 733 plus atorvastatin 20 mg weeks 1-4 followed by 5 mg AEGR 733 plus atorvastatin 20 mg weeks 5-8
11593990|NCT00690443|Active Comparator|1|Following 35-day washout + diet run-in, subjects receive atorvastatin 20 mg for 8 wks.
11593991|NCT00690430|Active Comparator|Pasireotide LAR|Patients assigned to pasireotide LAR will receive a 60 mg dose of pasireotide LAR i.m. depot injection once every 28 days (+/- 3 days) for 6 months at visits 2, 4, 5, 6, 7 and 8. A dose reduction to 40 mg is permitted if tolerability issues arise. In addition, after 24 hours of the first LAR injections the patients were permitted to use pasireotide s.c. formulation for breakthrough symptoms as needed.
11593992|NCT00690430|Active Comparator|Octreotide LAR|Patients assigned to octreotide LAR will receive a 40mg dose of octreotide LAR i.m. depot injection once every 28 days (+/- 3 days) for 6 months at visits 2, 4, 5, 6, 7 and 8. A dose reduction to 30 mg is permitted if tolerability issues arise. Patients requiring a dose reduction are to return to the higher dose once the tolerability issue is resolved, if required for efficacy In addition, after 24 hours of the first LAR injections the patients were permitted to use octreotide s.c. formulation for breakthrough symptoms as needed.
11593993|NCT00690417|Placebo Comparator|1|
11593994|NCT00690417|Active Comparator|2. 2500 IU vitamin D in a food preparation|Daily ingestion of 2500 IU vitamin D in a food preparation.
11593995|NCT00690404|Experimental|1|
11593996|NCT00690391||Surgical observation|patients with cancer in a palliative setting and in need of surgical interventions
11593997|NCT00690378|Experimental|1|NXL/104 ceftazidime
11593998|NCT00690378|Active Comparator|2|comparator 4 x daily
11593999|NCT00690339|Experimental|1|Augmentation
11594000|NCT00690339|Experimental|2|Reconstruction
11594001|NCT00690339|Experimental|3|Revision-augmentation
11594002|NCT00690339|Experimental|4|Revision-reconstruction
11594003|NCT00690326|Experimental|A|"treatment type: behavioral(lifestyle counseling)
~treatment name: behavioral change communication to promote physical activity"
11594004|NCT00690326|Placebo Comparator|B|Arm B given placebo comparator ie pamphlets
11594005|NCT00690313|Active Comparator|Arm 1|Arm 1: receives Vigamox eye drops 3Xday for 3 days prior to intravitreal injection
11594006|NCT00690313|Active Comparator|Arm 2|Arm 2: receives Vigamox eye drops 3Xday for 1 day prior to intravitreal injection
11594007|NCT00690287|Experimental|Part A, arm 1|1) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo together with food
11594008|NCT00690287|Experimental|Part A, arm 2|1) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo without food
11594009|NCT00690287|Experimental|Part B, arm1, 2, and 3|"AZD6370 dose x mg o.d.
~dose x/2 mg b.i.d.
~dose x/4 mg q.i.d."
11594010|NCT00690287|Experimental|Part B, arm 4|4) Placebo
11594011|NCT00690274|Placebo Comparator|Placebo|Volunteers are given Placebo, up to 20mg per day
11594012|NCT00690274|Active Comparator|BF2.649|Volunteers are given BF2.649, up to 20mg per day
11594013|NCT00690261||lung cancer|patients diagnosed of lung cancer with malignant pleural effusions
11594014|NCT00690248||1|Bipolar patients admitted to a psychiatric Unit due to an acute mania episode.
11594015|NCT00690235|Other|Placebo|Patients will be given the Placebo for injection twice daily
11594016|NCT00690235|Other|Pramlintide|volunteers are given 180mg of pramlintide, twice daily
11594017|NCT00690222|No Intervention|TM|Topical mydriasis without pseudoexfoliation
11594018|NCT00690222|Experimental|ICM|Intracameral mydriasis without pseudoexfoliation
11594019|NCT00690222|No Intervention|TM - PXF|Topical mydriasis with pseudoexfoliation
11594020|NCT00690222|Experimental|ICM - PXF|Intracameral Mydriasis with pseudoexfoliation
11594021|NCT00690196|Experimental|1|Tai Chi Chih
11594022|NCT00690196|Active Comparator|2|Cognitive Behavioral Therapy
11594023|NCT00690170|Active Comparator|Ketamine and Nicotine|"0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.
~13.5 µg/kg of nicotine IV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"
11594024|NCT00690170|Placebo Comparator|Placebo Comparator|-Placebo administration: Normal saline (sodium chloride 0.9%)over 95 minutes
11594025|NCT00690170|Active Comparator|Ketamine and Placebo|"Ketamine administration: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes
~Placebo administration: Normal saline (sodium chloride 0.9%)over 94 minutes"
11594026|NCT00690170|Active Comparator|Nicotine and Placebo|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg)IV (in the arm), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
11594027|NCT00690144|Experimental|simulation group|the trainees in the simulation group receive simulation-based training
11594028|NCT00690131|Experimental|1|
11594029|NCT00690131|No Intervention|2|
11594030|NCT00690118|Active Comparator|1|
11594031|NCT00690118|Placebo Comparator|2|
11594032|NCT00690105|Experimental|A|
11594033|NCT00690105|Active Comparator|B|
11594183|NCT00689039|Experimental|A|AZD1305 ER tablet
11594036|NCT00690092|Active Comparator|3|Volunteers with a history of pulmonary histoplasmosis but no history of coccidioidomycosis confirmed by serology.
11594037|NCT00690079|Experimental|AZD1386|7 groups receiving a specified volume of the active component AZD1386 at different points of time.
11594038|NCT00690079|Placebo Comparator|Placebo|7 groups receiving a specified volume of placebo at different points of time
11594039|NCT00690066|Experimental|Prochymal|PROCHYMAL®
11594040|NCT00690066|Placebo Comparator|Placebo|Placebo
11594041|NCT00690053|Experimental|1|
11594042|NCT00690040|Active Comparator|1|Ripening of the unfavorable cervix is done with Single balloon catheter (Foley catheter)
11594043|NCT00690040|Active Comparator|2|Ripening of the unfavorable cervix is done with double balloon catheter (Atad catheter)
11594044|NCT00690027|Active Comparator|A|"Objective: See Brief Summary, page 2. Eligibility: Patients who require > 2 units blood transfusion for bleeding esophageal varices due to cirrhosis.
~Randomization: By the blind card method to emergency portacaval shunt (EPCS) or emergency endoscopic sclerotherapy (EST) followed by long-term repetitive EST.
~Diagnostic Workup: Completed within 6hr. Rapidity of Therapy: Within 8hr. Failure of Therapy: Bleeding requiring >6u PRBC in first 7 days, or 8 units PRBC during 12 months, or rebleeding after varices were obliterated.
~Rescue Crossover Therapy: When primary therapy has failed. Followup: Lifelong. Data Collection on line, analysis by biostatistician Florin Vaida, PhD External Advisory, Data Monitoring and Safety Committee by 3 senior academicians."
11594045|NCT00690027|Active Comparator|B|Emergency endoscopic sclerotherapy
11594046|NCT00690014|Experimental|A|
11594047|NCT00690001||1|HIV-1 infected patients in Taiwan
11594048|NCT00689988|Experimental|SG|Study Group: five children with Down syndrome submitted to speech-language intervention with AAC intervention
11594049|NCT00689962|Experimental|1|Patients with unstable Lisfranc foot fracture-dislocations that receive bioabsorbable screw fixation through surgery.
11594050|NCT00689962|Active Comparator|2|Patients with unstable Lisfranc fracture-dislocations of the foot that receive steel screw fixation through surgery.
11594051|NCT00689949|Other|folic acid|
11594052|NCT00689936|Experimental|Lenalidomide / Dexamethasone until disease progression|Lenalidomide plus low-dose dexamethasone given until disease progression
11594053|NCT00689936|Experimental|Lenalidomide / Dexamethasone for 18 cycles|Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
11594054|NCT00689936|Active Comparator|Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles|Combination of Melphalan, Prednisone and Thalidomide given for 12 six-week cycles
11594055|NCT00689897|Experimental|1|In acupuncture treatment, immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation, the needles are retained for 30 minutes.
11594056|NCT00689897|Active Comparator|2|In acupuncture treatment, immediately after insertion of a needle, it is NOT manually rotated backwards or forwards to induce the DeQi sensation, and retained for 30 minutes.
11594057|NCT00689884|Experimental|Group A|All eligible patients will receive chemotherapy and one dose of Pegfilgrastim
11594058|NCT00689871|Experimental|1|Primary augmentation
11594059|NCT00689871|Experimental|2|Primary reconstruction
11594060|NCT00689871|Experimental|3|Revision-augmentation
11594061|NCT00689871|Experimental|4|Revision-reconstruction
11594062|NCT00689858|Experimental|1|Period 1: Cilostazol, Ginkgo biloba Period 2:Cilostazol, placebo
11594063|NCT00689858|Active Comparator|2|Period 1: Cilostazol, placebo Period 2: Cilostazol, Ginkgo biloba
11594064|NCT00689845|Experimental|Cohort 1|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1. Patients also receive oral prednisolone on days 1-5. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11594065|NCT00689845|Experimental|Cohort 2|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1, oral prednisolone on days 1-5, and filgrastim (G-CSF) subcutaneously (SC) on days 5-12. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
11594066|NCT00689845|Experimental|Cohort 3|Patients receive rituximab IV on days 1, 22, 43, 64, 85, and 106; cyclophosphamide IV and doxorubicin hydrochloride IV on days 1, 15, 29, 43, 57, and 71; methotrexate IV on days 8, 36, and 64; vincristine IV on days 8, 22, 36, 50 ,64, and 78; bleomycin IV on days 22, 50, and 78; and oral prednisolone on days 1-84, followed by a taper.
11594067|NCT00689845|Experimental|Cohort 4|Patients receive rituximab IV on days 1, 22, 43, 64, 85, and 106; cyclophosphamide IV on days 1, 29, and 57; doxorubicin hydrochloride IV on days 1, 15, 29, 43, 57, and 71; etoposide phosphate IV on days 15, 16, 43, 44, 71, and 72; vincristine IV and bleomycin IV on days 8, 22, 36, 50, 64, and 78; and oral prednisolone on days 1-84, followed by a taper.
11594068|NCT00689845|Experimental|Cohort 5|Patients receive rituximab IV, doxorubicin hydrochloride IV, and cyclophosphamide IV on day 1; vindesine IV and bleomycin IV on days 1 and 5; oral prednisone on days 1-5; methotrexate intrathecally on day 2; and G-CSF SC on days 6-13 for 4 courses in the absence of disease progression or unacceptable toxicity. After completion of 4 courses of R-ACVBP, patients receive consolidation therapy comprising high-dose methotrexate IV, rituximab IV, ifosfamide IV, etoposide phosphate IV, and cytarabine SC according to protocol GELA LNH03-2B.
11594069|NCT00689832|Experimental|A|
11594070|NCT00689832|Active Comparator|B|
11594071|NCT00689819|Active Comparator|BP < 140/90 mmHg|This arm will target a blood pressure of < 140/90 mmHg (or < 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
11594072|NCT00689819|Experimental|BP < 120/80 mmHg|This arm will target a more aggressive blood pressure target of < 120/80 mmHg.
11594073|NCT00689806|Placebo Comparator|Placebo|
11594074|NCT00689806|Active Comparator|Lovastin|
11594075|NCT00689793|Active Comparator|1|
11594076|NCT00689793|Placebo Comparator|2|
11594077|NCT00689780|Experimental|1|AZD1940 + Placebo
11594078|NCT00689780|Other|2|
11594079|NCT00689767|Experimental|A|This arm will receive the coated stent
11594080|NCT00689767|Active Comparator|B|This arm will receive a bare metal stent
11594081|NCT00689754|Active Comparator|NGA|Patients will receive the standard of care to proceed with nasogastric tube placement, aspiration and lavage up to 1L of normal saline
11594082|NCT00689754|No Intervention|NO NGA|Patient presenting with Upper GI hemorrhage going straight to endoscopy.
11594083|NCT00689741|Experimental|A|
11594084|NCT00689741|Placebo Comparator|B|
11594085|NCT00689728|Experimental|30 milligram (mg) LY2127399|"Double-blind Treatment: 30 mg LY2127399 administered as a single intravenous (IV) infusion over 30 minutes at 0, 3, and 6 weeks.
~Rescue: At Week 16 primary endpoint, participants without at least 20% improvement in either tender or swollen joint counts based on 28 joints, could receive an additional (unblinded) 30 minute infusion of LY2127399 80 mg or remain on initial randomized treatment up to Week 24.
~Follow-up: Optional visits beyond Week 24, if needed, to assess safety including B cell count recovery."
11594086|NCT00689728|Experimental|80 mg LY2127399|"Double-blind Treatment: 80 mg LY2127399 administered as a single IV infusion over 30 minutes at 0, 3, and 6 weeks.
~Rescue: At Week 16 primary endpoint, participants without at least 20% improvement in either tender or swollen joint counts based on 28 joints, could receive an additional (unblinded) 30 minute infusion of LY2127399 80 mg or remain on initial randomized treatment up to Week 24.
~Follow-up: Optional visits beyond Week 24, if needed, to assess safety including B cell count recovery."
11594087|NCT00689728|Placebo Comparator|Placebo|"Double-blind Treatment: Placebo comparator administered as a single IV infusion over 30 minutes at 0, 3, and 6 weeks.
~Rescue: At Week 16 primary endpoint, participants without at least 20% improvement in either tender or swollen joint counts based on 28 joints could receive an additional (unblinded) 30 minute infusion of LY2127399 80 mg or remain on same initial randomized treatment up to Week 24.
~Follow-Up: Optional visits beyond Week 24, if needed, to assess safety including B cell count recovery."
11594088|NCT00689715|Experimental|EP|Single treatment arm
11594089|NCT00689689|Active Comparator|Fully Coated Prodigy Stem (AML)|Total hip arthroplasty with fully coated prodigy stem (AML)
11594090|NCT00689689|Active Comparator|Cemented Endurance Hip Stem|Total hip arthroplasty with cemented Endurance hip stem component
11594091|NCT00689676||Study Group|20 very low birth weight preterm toddlers
11594092|NCT00689676||Control Group|20 full-term toddlers
11594093|NCT00689663|Active Comparator|1|Dissection staring at the triangle of calots. Dissection with electrocautery.
11594094|NCT00689663|Active Comparator|2|Dissection as fundus first with electrocautery.
11594095|NCT00689663|Active Comparator|3|Dissection as fundus first with ultrasonic dissection.
11594096|NCT00689650|Experimental|A|
11594097|NCT00689650|No Intervention|B|
11594098|NCT00689637|Experimental|1|AZD3480 + warfarin
11594099|NCT00689637|Experimental|2|Placebo+ warfarin
11594100|NCT00689624|Experimental|1|FOLFOXIRI+Erbitux
11594101|NCT00689611|Placebo Comparator|P|Half of patients will receive placebo for 9 weeks.
11594102|NCT00689611|Active Comparator|A|Half of patients will receive bupropion for 9 weeks.
11594103|NCT00689598|Placebo Comparator|III|Placebo
11594104|NCT00689598|Experimental|Experimental|Drug intervention
11594105|NCT00689585|Placebo Comparator|1|
11594106|NCT00689585|Experimental|2|
11594107|NCT00689572|Experimental|Ondansetron|Ondansetron + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
11594108|NCT00689572|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
11594109|NCT00689559|Experimental|1|AZD3480 + Aripiprazole
11594110|NCT00689559|Experimental|2|Placebo + Aripiprazole
11594111|NCT00689546||I/A|All cases of acute viral hepatitis irrespective of type (A, B, E) with underlying Type 2 diabetes mellitus
11594112|NCT00689546||I/B|Age and sex matched non- diabetic patients with acute viral hepatitis (irrespective of type) recruited from all the patients of acute viral hepatitis registered during the time period in which cases were recruited.
11594113|NCT00689546||II/A|All diabetic who have acute icteric viral hepatitis due to HEV infection
11594114|NCT00689546||II/B|Age and sex matched diabetic who have acute icteric viral hepatitis due to hepatiits virus other than HEV.
11594115|NCT00689520|Experimental|tinzaparin|tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months.
11594116|NCT00689520|Active Comparator|acenocoumarol|tinzaparin for 1 weeks followed by acenocoumarol for 6 months
11594117|NCT00689507|Experimental|Dose Escalation Phase(Part A):|1,10, 30, 100 or 300 mg of LY2127399 IV on day 1 of specific 21 day cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of each 21 day cycle
11594118|NCT00689507|Experimental|Dose Confirmation Phase (Part B1):|Dose determined by PK/PD modeling, LY2127399 IV on day 2 of Cycle 1 and on day 1 of specific cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of each cycle
11594119|NCT00689507|Experimental|Dose Confirmation Phase (Part B2):|Dose determined by PK/PD modeling, LY2127399 IV on day 1 of specific cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of specific cycles
11594120|NCT00689481|Experimental|U0267 foam|U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
11594121|NCT00689481|Placebo Comparator|Vehicle foam|Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
11594122|NCT00689468|Placebo Comparator|1|"Osteopathic sham treatment plus placebo Echinacea drops"
11594123|NCT00689468|Active Comparator|2|Active Echinacea drops plus sham osteopathic treatment
11594124|NCT00689468|Active Comparator|3|"Active osteopathic manipulation plus placebo Echinacea drops"
11594125|NCT00689468|Active Comparator|4|Active osteopathic manipulation plus active Echinacea drops.
11594126|NCT00689455||1|Primary care population
11594127|NCT00689442|Experimental|1|JTT-705 600 mg and atorvastatin 20 mg
11594128|NCT00689442|Placebo Comparator|2|Placebo and atorvastatin 20 mg
11594129|NCT00689416|Experimental|1|
11594130|NCT00689416|Placebo Comparator|2|
11594131|NCT00689403|Experimental|Part A: 2x2 crossover|4 different AZD1305 ER formulations
11594132|NCT00689403|Experimental|Part B: 3x3 crossover|2 different AZD1305 ER formulations and a reference formulation
11594181|NCT00689052|Experimental|Pramipexole ER|0.75 mg to 4.5 mg tablets of Pramipexole ER, once daily in the evening
11594182|NCT00689052|Placebo Comparator|Placebo|Placebo tablets, once daily in the evening
11594133|NCT00689390|Other|Participants from Boceprevir Studies|Participants who previously participated in treatment studies in which boceprevir was administered were subsequently enrolled in Part 1 of the current follow-up study P05063 (NCT00689390). Participants may have received boceprevir or control peginterferon plus ribavirin (PR) in the previous treatment study. No treatment was administered in the current follow-up study.
11594134|NCT00689390|Other|Participants from Narlaprevir Studies|Participants who previously participated in treatment studies in which narlaprevir was administered were subsequently enrolled in Part 2 of the current follow-up study P05063 (NCT00689390). Participants may have received narlaprevir or control PR in the previous treatment study. No treatment was administered in the current follow-up study.
11594135|NCT00689377||1|Subjects of either sex, any race, with at least two CVD risk factors, with no overt cardiovascular diseases nor diabetes mellitus
11594136|NCT00689364||CTTCT+CWMT|"CTTCM:taking TCM decoction based on syndrome differentiation daily and each dosage is decocted two times for intervention one year with a Chinese patent medicine at least.
~CWMT :with or without chemotherapy/or radiotherapy after the radical operation (R0) (according to the latest NCCN clinical guideline)."
11594137|NCT00689364||CWMT cohort|CWMT :with or without chemotherapy/or radiotherapy after the radical operation (R0) (according to the latest NCCN clinical guideline).
11594138|NCT00689351|Experimental|1|13vPnC
11594139|NCT00689351|Active Comparator|2|7vPnC
11594140|NCT00689338|Experimental|Treatment Group|Option to treat with oral azole therapy following treatment with anidulafungin
11594141|NCT00689312|Active Comparator|1|
11594142|NCT00689312|Experimental|2|
11594143|NCT00689312|Experimental|3|
11594144|NCT00689299|Placebo Comparator|Dose Group C|Standardized Allergenic Extract, Cat Hair (Felis domesticus) placebo
11594145|NCT00689299|Active Comparator|Dose Group A|Standardized Allergenic Extract, Cat Hair (Felis domesticus) 0.21 Units
11594146|NCT00689299|Active Comparator|Dose Group B|Standardized Allergenic Extract, Cat Hair (Felis domesticus)2.1 units
11594147|NCT00689286|Experimental|"BION twitch stimulation"|"The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation."
11594148|NCT00689286|Experimental|BION tetanic-frequency stimulation|The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions.
11594149|NCT00689286|No Intervention|Standardized program|A third group of experimental subjects will have a standardized program of voluntary exercise.
11594150|NCT00689273|Experimental|PF-04136309|
11594151|NCT00689273|Placebo Comparator|Placebo|
11594152|NCT00689260|Active Comparator|1 - Log Aware|Dose Log Aware (patient is aware that the device records their injection information) Half the subjects in the log aware arm will complete a diary. The other half in the log aware arm will not complete the diary.
11594153|NCT00689260|Active Comparator|2 - Log Unaware|Dose Log Unaware (patient is not aware that the device records their injection information) Half the subjects in the log unaware arm will complete a diary. The other half in the log unaware arm will not complete the diary.
11594154|NCT00689247|Experimental|A|AZD1305 given as oral solution
11594155|NCT00689247|Experimental|B|AZD1305 given as iv infusion
11594156|NCT00689234|Placebo Comparator|A|"At time of inclusion randomised in the no intervention arm (the subjects will be re-evaluated 6 months later and will get intervention at that time (cross-over protocol)"
11594157|NCT00689234|Active Comparator|B|At time of inclusion the subject get the intervention
11594158|NCT00689221|Experimental|Cilengitide + Temozolomide + Radiotherapy|
11594159|NCT00689221|Active Comparator|Temozolomide + Radiotherapy|
11594160|NCT00689195|Experimental|C|Curcumin
11594161|NCT00689195|Experimental|A|Ashwagandha extract
11594162|NCT00689182|Experimental|A|All patients will receive phlebotomy
11594163|NCT00689169|Experimental|Experimental|ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan) ASCT Rituximab
11594164|NCT00689156|Active Comparator|Regimen 1|Epirubicin 90 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times three followed by docetaxel 100 mg/m2 intravenously day 1 every 3 weeks times three
11594165|NCT00689156|Experimental|Regimen 2|Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
11594166|NCT00689117|Experimental|1|CT Gel
11594167|NCT00689117|Active Comparator|2|Clindamycin Gel (clindamycin)
11594168|NCT00689117|Active Comparator|3|Tretinoin Gel (tretinoin)
11594169|NCT00689117|Placebo Comparator|4|Vehicle Gel
11594170|NCT00689104|Placebo Comparator|Placebo|Participants received matching mirabegron placebo tablets and matching tolterodine slow release (SR) placebo capsules orally once a day for 12 weeks.
11594171|NCT00689104|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets and matching tolterodine SR placebo capsules orally once a day for 12 weeks.
11594172|NCT00689104|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 mg tablets and matching tolterodine SR placebo capsules orally once a day for 12 weeks.
11594173|NCT00689104|Active Comparator|Tolterodine SR 4 mg|Participants received tolterodine SR 4 mg capsules and matching mirabegron placebo tablets orally once a day for 12 weeks.
11594174|NCT00689091|Experimental|BIS group|This group will have BIS values visible and will receive alerts when the value is >60.
11594175|NCT00689091|Active Comparator|MAC Alert|This group will receive an alert if total MAC (including intravenous infusions) is <0.5 age-adjusted.
11594176|NCT00689078|Active Comparator|Pred acetate 1%|Prednisolone acetate 1.0% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
11594177|NCT00689078|Active Comparator|Pred acetate .12%|Prednisolone acetate 0.12% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
11594178|NCT00689078|Active Comparator|Lot Etab 0.2%|Loteprednol Etabonate 0.2% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
11594179|NCT00689078|Placebo Comparator|Placebo|Tears Naturale (Artificial Tears) in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
11594180|NCT00689065|Experimental|CALAA-01|
11594184|NCT00689039|Placebo Comparator|B|Placebo tablet
11594185|NCT00689026|Experimental|Experimental|The lubiprostone group will receive an additional two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).
11594186|NCT00689026|Active Comparator|Control|All patients in the study will receive a standard oral dosing of 4L Polyethylene glycol with electrolytes colonoscopy preparation the day prior to their scheduled colonoscopy.
11594187|NCT00689013|No Intervention|1|Patients voluntarily presenting to community pharmacies who request receipt of the herpes zoster vaccine during the first month of observation. These patients have not been exposed to pharmacist-driven interventions utilized in this study. This group serves as the control group.
11594188|NCT00689013|Experimental|2|Patients voluntarily presenting to community pharmacies who request receipt of the herpes zoster vaccine during the second month of observation. These patients may or may not have been exposed to pharmacist-driven interventions utilized in this study. This group serves as the study/intervention group.
11594189|NCT00689000|Experimental|CHR-2797 (tosedostat)|oral, once daily administration of CHR-2797 to determine safety & anti-disease activity.
11594190|NCT00688987|Active Comparator|1|Subjects with AI will be randomized to each of three doses of hydrocortisone for 4 months on each dose.
11594191|NCT00688987|Active Comparator|2|isocaloric diet
11594192|NCT00688974||Roux-en-Y gastric bypass|Patients with class 3 obesity and type 2 diabetes submitted to Roux-en-Y gastric bypass
11594193|NCT00688974||Adjustable gastric banding|Patients with class 3 obesity and type 2 diabetes submitted to adjustable gastric banding
11594194|NCT00688974||Healthy controls|Non-obese, non-diabetic adults
11594195|NCT00688961|No Intervention|1|Baseline
11594196|NCT00688961|Experimental|2|Aspirin (1 day after a single, 625 mg dose)
11594197|NCT00688961|Experimental|3|Omacor
11594198|NCT00688961|Experimental|4|Omacor plus aspirin
11594199|NCT00688935|Experimental|Melatonin|Subjects may opt to enroll in this treatment sub-study involving melatonin treatment (0.1 - 3 mg, daily) for up to 1 year, with a minimum of 6 weeks. Throughout treatment, subjects will continue their saliva, plasma, and/or urine sampling to test for treatment efficacy.
11594200|NCT00688909|Experimental|Letrozole|This study will evaluate whether patients who are intolerant and discontinue anastrozole due to grade 2-3 arthralgia-myalgia have a decrease in rheumatological symptoms while taking letrozole
11594201|NCT00688896|Experimental|1|JTT-705 600 mg and pravastatin 40 mg
11594202|NCT00688896|Experimental|2|JTT-705 300 mg and pravastatin 40 mg
11594203|NCT00688896|Placebo Comparator|3|Placebo and pravastatin 40 mg
11594204|NCT00688883|Experimental|Arm 1|
11594205|NCT00688870|Experimental|1|13vPnC
11594206|NCT00688870|Active Comparator|2|7vPnC
11594207|NCT00688857|Experimental|A|Diazoxide choline controlled-release coated tablets administered orally once daily (Days 1 through 8). Diazoxide choline controlled-release uncoated tablets administered orally once daily (Days 9 through 16).
11594208|NCT00688857|Experimental|B|Diazoxide choline controlled-release uncoated tablets administered orally once daily (Days 1 through 8). Diazoxide choline controlled-release coated tablets administered orally once daily (Days 9 through 16)
11594209|NCT00688844||PKU subjects - baseline|Male and female subjects with PKU at baseline starting KuvanTM therapy.
11594210|NCT00688831|Experimental|A|AZD1305 solution for iv infusion
11594211|NCT00688831|Placebo Comparator|B|NaCl solution for iv infusion
11594212|NCT00688818|Experimental|Quetiapine and existing psychotropics|
11594213|NCT00688818|Placebo Comparator|Placebo and existing psychotropics|
11594214|NCT00688805|Experimental|Arm 1|
11594215|NCT00688805|Placebo Comparator|Arm 2|
11594216|NCT00688779|Experimental|1|
11594217|NCT00688779|Placebo Comparator|2|
11594218|NCT00688766|Experimental|IPI-504|retaspimycin hydrochloride (IPI-504) plus best supportive care
11594219|NCT00688766|Placebo Comparator|Placebo|Placebo plus best supportive care
11594220|NCT00688753|Experimental|RAD001|two 5 mg tablets of everolimus orally, once daily
11594221|NCT00688740|Experimental|TAC (Docetaxel)|docetaxel (75 mg/m^2) in combination with doxorubicin (50 mg/m^2) and cyclophosphamide (500 mg/m^2) on day 1 every 3 weeks for 6 cycles of treatment
11594222|NCT00688740|Active Comparator|FAC (5-fluorouracil)|5-fluorouracil (500 mg/m^2) in combination with doxorubicin (50 mg/m^2) and cyclophosphamide (500 mg/m^2) on day 1 every 3 weeks for 6 cycles of treatment
11594223|NCT00688727|Experimental|1|Cognitive behavioural Therapy
11594224|NCT00688727|Active Comparator|2|Standard Care
11594225|NCT00688714|Experimental|1|
11594226|NCT00688714|Placebo Comparator|2|
11594227|NCT00688701|Placebo Comparator|Placebo (Two-Step Titration)|2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 12.
11594228|NCT00688701|Placebo Comparator|Placebo (One-Step Titration)|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, then 20 mcg QD up to Week 12.
11594229|NCT00688701|Experimental|Lixisenatide (Two-Step Titration)|2-step initiation regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 12.
11594230|NCT00688701|Experimental|Lixisenatide (One-Step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to Week 12.
11594231|NCT00688688|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets and matching tolterodine extended release (ER) placebo capsules orally once a day for 12 months.
11594232|NCT00688688|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 mg tablets and matching tolterodine ER placebo capsules orally once a day for 12 months.
11594233|NCT00688688|Active Comparator|Tolterodine ER 4 mg|Participants received tolterodine ER 4 mg capsules and matching mirabegron placebo tablets orally once a day for 12 months.
11594234|NCT00688675||Treated GERD pts|Previously diagnosed GERD patients on treatment in Switzerland
11594235|NCT00688662|Active Comparator|1.ERCP with sphincterotomy|ERCP with sphincterotomy: cutting the biliary sphincter muscle (sphincterotomy)
11594236|NCT00688662|Placebo Comparator|2.ERCP without sphincterotomy|ERCP without cutting the biliary sphincter muscle (sphincterotomy)
11594237|NCT00688649|Active Comparator|1|Standard ONS
11594238|NCT00688649|Active Comparator|2|High Energy ONS
11594239|NCT00688636|Active Comparator|1|
11594240|NCT00688636|Placebo Comparator|2|
11594241|NCT00688623|Experimental|Everolimus|Everolimus
11594242|NCT00688597|Experimental|Cohort 1|Regimen 1: Low-dose duvoglustat (2.5 grams [g]) once a day (QD) for 3 days, followed by no drug for 4 days, for 11 weeks.
11594243|NCT00688597|Experimental|Cohort 2|Regimen 1: High-dose duvoglustat (5.0 g) QD for 3 days, followed by no drug for 4 days, for 11 weeks.
11594244|NCT00688597|Experimental|Cohort 3|Regimen 2: High-dose duvoglustat (5.0 g) QD for 7 days, followed by no drug for 7 days, for 11 weeks.
11594245|NCT00688584|Experimental|1|
11594246|NCT00688584|Placebo Comparator|2|
11594247|NCT00688584|No Intervention|No intervention control|
11594248|NCT00688571|Experimental|Melody TPV Implant|Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RV-PV conduit.
11594249|NCT00688558|Experimental|1|JTT-705 600 mg and simvastatin 40 mg
11594250|NCT00688558|Placebo Comparator|2|Placebo and simvastatin 40 mg
11594251|NCT00688545||Celecoxib|Patients treated with celecoxib as per treating physician's judgement
11594252|NCT00688545||nsNSAIDs (nonselective nonsteroidal anti-inflammatory drugs)|Patients treated with nsNSAIDs as per treating physician's judgement
11594253|NCT00688532||1|Prostate cancer patients treated with bicalutamide or not
11594254|NCT00688532||2|General population cohort
11594255|NCT00688519|Experimental|U0267 Foam|U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
11594256|NCT00688519|Placebo Comparator|Vehicle foam|Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
11594257|NCT00688506|Experimental|1|Combined sono-electro-magnetic therapy
11594258|NCT00688506|Placebo Comparator|2|placebo therapy
11594259|NCT00688493|Experimental|20 mg single dose of dapagliflozin|20 mg dapagliflozin
11594260|NCT00688493|Experimental|150 mg single dose of dapagliflozin2|150 mg dapagliflozin
11594261|NCT00688493|Active Comparator|400 mg single dose of moxifloxacin|Moxifloxacin
11594262|NCT00688493|Placebo Comparator|Placebo|Placebo
11594263|NCT00688480|Placebo Comparator|I|CKD Stage 3 (estimated GFR 30 - 60 ml/min/1.73m2), Echo LVH
11594264|NCT00688480|Active Comparator|2|
11594265|NCT00688467|Experimental|Navarixin → Placebo|Navarixin 30 mg capsule to be taken once daily in the morning for 10 days in Treatment Period 1, followed by a 2-4 week washout period, followed by matching placebo capsule to be taken once daily in the morning for 10 days in Treatment Period 2
11594266|NCT00688467|Experimental|Placebo → Navarixin|Matching placebo capsule to be taken once daily in the morning for 10 days in Treatment Period 1, followed by a 2-4 week washout period, followed by navarixin 30 mg capsule to be taken once daily in the morning for 10 days in Treatment Period 2
11594267|NCT00688454||Pt with hypercholesteremia|Patients treated with CRESTOR because of hypercholesteremia
11594268|NCT00688441|Experimental|Active|CO2 Gas
11594269|NCT00688441|Placebo Comparator|Placebo|Inactive Placebo Gas
11594270|NCT00688428|Experimental|1|combination capsule of Esomeprazole 40mg + ASA 325mg
11594271|NCT00688428|Experimental|2|Esomeprazole 40 mg capsule and ASA 325 mg tablet
11594272|NCT00688402|Experimental|1|IR Formulation 65 mg
11594273|NCT00688402|Experimental|2|IR Formulation 150 mg
11594274|NCT00688402|Experimental|3|MR formulation, 1h 65 mg
11594275|NCT00688402|Experimental|4|MR Formulation, 1h 150 mg
11594276|NCT00688402|Experimental|5|MR Formulation, 2h 150 mg
11594277|NCT00688389||healthy|
11594278|NCT00688389||DF|
11594279|NCT00688389||DHF|
11594280|NCT00688376|Experimental|1|
11594281|NCT00688376|Placebo Comparator|2|
11594282|NCT00688363|Experimental|1|No blood-glucose self-control, no HbA1c
11594283|NCT00688363|Experimental|2|Blood-glucose self-control, no HbA1c
11594284|NCT00688363|Experimental|3|No blood-glucose self-control, HbA1c
11594285|NCT00688363|Experimental|4|Blood-glucose self-control, HbA1c
11594286|NCT00688350|Experimental|Behavioral feedback|Behavioral feedback intervention to improve adherence to antihypertensive medication
11594287|NCT00688350|No Intervention|Control|Control group
11594288|NCT00688337||1|Patients with newly diagnosed breast cancer. Clinically nodal negative.
11594289|NCT00688324|Experimental|Single Arm|All subjects will have baseline measures, receive acamprosate for 2 weeks, then have measures repeated.
11594290|NCT00688311|Experimental|Synbiotic|Ingestion of synbiotic dietary supplement
11594291|NCT00688311|Placebo Comparator|Placebo|Ingestion of the Placebo
11594292|NCT00688298|Experimental|Arm 1|Female patients Greater than or 18 years of age, diagnosed with Stress Urinary Incontinence (SUI).
11594293|NCT00688285|Active Comparator|1|education and automated clinical alerts
11594294|NCT00688285|Active Comparator|2|education session alone
11594295|NCT00688272|Experimental|Arm 1|Eltrombopag 75 mg QD x 6 days
11594296|NCT00688272|Active Comparator|Arm 2|Ciprofloxicin 500mg BID x 6 days
11594297|NCT00688272|Placebo Comparator|Arm 3|Placebo QD x 6 days
11594298|NCT00688259|Experimental|Cognitive Behavioral Therapy for Psychosis (CBTp)|approximately 6 months of weekly individual manualized cognitive-behavioral psychotherapy for psychosis in which participants set personal goals, identify problematic/ illness-related beliefs and experiences that may interfere with achieving those goals, evaluate the data supporting those beliefs, and then modify the beliefs or behavior as warranted by the data to make progress on those goals.
11594299|NCT00688259|Active Comparator|Supportive Therapy (ST)|approximately 6 months of weekly manualized supportive psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to the participants' lives and concerns
11594300|NCT00688233|Experimental|F-seifi|
11594301|NCT00688220||1|Those wearing garments fabricated with Celliant
11594302|NCT00688220||2|Those not wearing garments fabricated using Celliant (placebo).
11594303|NCT00688207|Experimental|Rosiglitazone|An open-label, single, oral dose of 4mg of rosiglitazone in the morning under fasted conditions
11594304|NCT00688194|Active Comparator|Arm I|Patients receive fulvestrant intramuscularly (IM) on days 0, 14, and 28 of course 1 and on day 1 of all subsequent courses. Patients also receive oral placebo once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11594305|NCT00688194|Active Comparator|Arm II|Patients receive fulvestrant and placebo as in arm I. Patients also receive aromatase inhibitor (AI) therapy (e.g., exemestane, anastrozole, or letrozole) according to standard treatment regulations.
11594306|NCT00688194|Active Comparator|Arm III|Patients receive fulvestrant as in arm I and oral lapatinib tosylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11594307|NCT00688194|Active Comparator|Arm IV|Patients receive fulvestrant as in arm I and lapatinib as in arm III. Patients also receive AI therapy according to standard treatment regulations.
11594308|NCT00688181||Cohort 1|All patients presenting to the institution for treatment of female Urinary Stress Incontinence (SUI), excluding those patients meeting any of the contraindications as noted in the Directions For Use.
11594309|NCT00688168||Symptom Assessments|Patients diagnosed with multiple myeloma (MM) complete questionnaires with Neurocognitive Testing and Neurosensory Testing
11594310|NCT00688155|Experimental|Physical Activity Training|The Physical Activity Training ((PAT) intervention consisted of center-based and home-based sessions comprised of aerobic, strength, flexibility, and balance training with a targeted duration of 150 mins/wk.
11594311|NCT00688155|Experimental|Cognitive Training|The Cognitive Training (CT) intervention was developed to improve consciously-controlled memory processing or recollection of episodic memory information.
11594312|NCT00688155|Experimental|Combined Intervention|"The Combined Intervention (PACT) was designed so that participants received both cognitive and physical activity training on the same day.
~."
11594313|NCT00688155|Active Comparator|Healthy Aging Education|The Healthy Aging Education control intervention consisted of weekly lectures based on health education.
11594314|NCT00688142||1|Individuals with shift work sleep disorder
11594315|NCT00688142||2|Healthy night shift workers without shift work sleep disorder
11594316|NCT00688129|Experimental|KITS Program|The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
11594317|NCT00688129|No Intervention|Services as usual|
11594318|NCT00688116|Experimental|ganetespib|
11594319|NCT00688103|Active Comparator|ETN Alone|etanercept (25mg, twice/week, s.c.)
11594320|NCT00688103|Active Comparator|ETN+MTX|etanercept (25mg, twice/week, s.c.) combined with methotrexate (6-8mg/week)
11594321|NCT00688090|Experimental|Low-Dose Peptide Cohort|
11594322|NCT00688090|Experimental|High-Dose Peptide Cohort|
11594323|NCT00688077|Experimental|1|
11594324|NCT00688077|Placebo Comparator|2|NaCl 0,9% 2 ml, single subcutaneous injection
11594325|NCT00688064|Experimental|1|Adapalene-BPO + Doxycyline
11594326|NCT00688064|Active Comparator|2|Vehicle + Doxycycline
11594327|NCT00688051|Experimental|1|
11594328|NCT00688038|Experimental|Laser Ablation + MRTI|Magnetic resonance thermal imaging = MRTI
11594329|NCT00688025||1|Insomniacs: Individuals reporting difficulty falling asleep or staying asleep within the past month for more than 3 days per week. Individuals much also meet screening criteria based on an overnight polysomnograph of latency to persistent sleep >20 minutes and/or >60 minutes of wake after sleep onset.
11594330|NCT00688025||2|Controls: Individuals reporting no difficulty falling asleep or staying asleep and objective sleep measures based on an overnight polysomnograph of latency to persistent sleep <20 minutes and/or <60 minutes of wake after sleep onset.
11594331|NCT00687999|Other|1|
11594332|NCT00687986|Active Comparator|primary surgery|primary surgical resection
11594333|NCT00687986|Experimental|stereotactic radiotherapy|primary stereotactic radiotherapy
11594334|NCT00687973|Experimental|Valsartan/amlodipine 160/10 mg|Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.
11594335|NCT00687973|Active Comparator|Atenolol/amlodipine 100/10 mg|Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.
11594336|NCT00687960|Experimental|1|Resistant Starch Type 4-Raw
11594337|NCT00687960|Experimental|2|Resistant Starch Type 4-cooked
11594338|NCT00687960|Active Comparator|3|Puffed wheat
11594339|NCT00687960|Placebo Comparator|4|Dextrose
11594340|NCT00687947|Experimental|1|MA-patients
11594341|NCT00687947|Experimental|2|FHM-patients
11594342|NCT00687947|Active Comparator|3|Healthy controls
11594343|NCT00687934|Experimental|Ganetespib|Ganetespib once weekly infusion, dose escalation study, with treatment until progression
11594344|NCT00687921||A|patients over the age of 18 who had knee trauma, intent to or had MRI assessment and are scheduled for arthroscopy.
11594345|NCT00687908|Experimental|1|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel once daily
11594346|NCT00687908|Placebo Comparator|2|Vehicle Gel once daily
11594347|NCT00687895|Experimental|1|training in clinical algorithm plus microscopy
11594348|NCT00687895|Experimental|2|clinical algorithm
11594349|NCT00687895|No Intervention|3|Control
11594350|NCT00687882|Experimental|Intervention: A|Patients with non-occlusive thrombus or resolved thrombosis at 6 weeks.
11594351|NCT00687882|Active Comparator|B|Patients with non-occlusive thrombus or resolved thrombosis at 6 weeks.
11594352|NCT00687882|Other|Parallel Cohort: Persistent Occlusive Thrombosis|Patients with completely occlusive thrombosis at 6 weeks.
11594552|NCT00686452||7|Healthy subjects with symptomatic AHR (asthma) but without treatment
11594353|NCT00687882|Other|Parallel Cohort: Persistent Antiphospholipid Antibody|Patients with persistent Positive Antiphospholipid Antibody at 6 weeks.
11594354|NCT00687869|Experimental|Case management|Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal
11594355|NCT00687869|Active Comparator|usual care|Usual stroke aftercare plus patient-information-notes
11594356|NCT00687856||LVAD Recipients|Participants who have had or are about to have a left ventricular assist device (LVAD) implanted
11594357|NCT00687843|Active Comparator|1|The TS-1 group
11594358|NCT00687843|Experimental|2|The TS-1+PSK Group
11594359|NCT00687830|Active Comparator|Polythylene Glycol (PEG) in the evening|"Bowel preparation with Polyethylene Glycol given in the evening prior to the day of the afternoon colonoscopy.
~'Polyethylene Glycol afternoon'"
11594360|NCT00687830|Experimental|Polythylene Glycol (PEG) in the Morning|"Bowel preparation with Polyethylene Glycol given on the morning of the day of the afternoon colonoscopy.
~'Polyethylene Glycol morning'"
11594361|NCT00687804|Experimental|Ranibizumab 0.5 mg|"Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met:
~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.
~Patients also received sham laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician.
~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.
~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
11594362|NCT00687804|Experimental|Ranibizumab 0.5 mg + laser|"Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met:
~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.
~Patients also received active laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician.
~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.
~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
11594363|NCT00687804|Active Comparator|Laser|"Laser photocoagulation treatment was administered on Day 1 and at intervals of at least 3 months, if deemed necessary by the physician. Patients also received monthly sham intravitreal injection in the study eye for 3 consecutive months. After the third injection, treatment was suspended if either one of the following criteria was met:
~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.
~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.
~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
11594364|NCT00687791|Experimental|1|20 enrolled patients will be chosen according to the enrollment acceptance criteria. The evidence for the determination of enrolled patients shall be recorded, reviewed and approved. 2> Phacotrabeculectomy is performed.3> After completing phacotrabeculectomy, implant/place ologen™ Collagen Matrix on top of the scleral flap under the conjunctiva. For every inspection and observation, the detailed description and/or inspection data shall be recorded. If any unwanted adverse event is observed during inspection and observation, it shall be recorded and be reported to the investigation conductor.
11594365|NCT00687778||1|100 patients with newly diagnosed tumors, which are often non-FDG avid or show only low intensity uptake: Soft tissue sarcomas, well-differentiated thyroid cancer, well-differentiated and bronchoalveolar lung cancer, indolent lymphomas, neuroendocrine tumors, GIST, uterine malignancies, mucin-producing cancer, teratoma, hepatoma, HCC and lobular breast carcinoma.
11594366|NCT00687765|Experimental|1|
11594367|NCT00687752||1|hydramnios
11594368|NCT00687752||2|normal
11594369|NCT00687739|Placebo Comparator|1|GnRH agonist + placebo
11594370|NCT00687739|Active Comparator|2|GnRH agonist + placebo + exercise
11594371|NCT00687739|Experimental|3|GnRH agonist + Estradiol
11594372|NCT00687739|Experimental|4|GnRH agonist + Estradiol + exercise
11594373|NCT00687726|Experimental|G1|Standing balance and mini squat training
11594374|NCT00687726|Active Comparator|G2|Isometric knee extension exercise
11594375|NCT00687713|Active Comparator|Bupropion|Subjects will receive bupropion 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.
11594376|NCT00687713|Placebo Comparator|Placebo|Subjects will receive a matched bupropion placebo 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.
11594377|NCT00687700|Experimental|All subjects|Eligible subjects will receive GSK961081 (400 micrograms or 1200 micrograms), GSK961081 matching placebo, propranolol (80 milligrams) and propranolol matching placebo in five treatment sessions through ten different crossover treatment sequences. There will be a washout period between treatment sessions of 7 to 14 days.
11594378|NCT00687687|Experimental|Pacitaxel/Carboplatin/Iniparib|Participants will be administered pacitaxel, carboplatin and BSI-201 (Iniparib) in 21 day treatment cycles. Treatment will continue until disease progression or adverse effects prohibit further therapy.
11594379|NCT00687674|Experimental|Sorafenib + Lenalidomide + Dexamethasone|
11594380|NCT00687661|Active Comparator|1|Arm #1 will include patients randomized to receive bisphosphonate therapy for 24 months.
11594381|NCT00687661|Placebo Comparator|2|Arm #2 will include patients randomized to receive placebo therapy for 24 months
11594553|NCT00686439|Experimental|adalimumab|
11594382|NCT00687648|Experimental|Arm I|Patients receive aromatase inhibitor (anastrozole, letrozole, or exemestane) as previously prescribed. Patients also receive oral cyclophosphamide once daily on days 1-28 and oral methotrexate twice on days 15, 16, 22, and 23 of course 1. For all subsequent courses, patients receive oral cyclophosphamide once daily and oral prednisolone once daily on days 1-28 and oral methotrexate twice on days 1, 2, 8, 9, 15, 16, 22, and 23. Treatment with cyclophosphamide, methotrexate, and prednisolone repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11594383|NCT00687648|Active Comparator|Arm II|Patients receive cyclophosphamide, methotrexate, and prednisolone as in arm I.
11594384|NCT00687622|Experimental|GSK1120212|Part 1 will identify the maximum tolerated dose using a dose-escalation procedure. Part 2 will explore further the safety, tolerability, and clinical activity of GSK1120212 in subjects with pancreatic, melanoma, non-small cell lung, and KRAS or BRAF mutation-positive colorectal cancer. Part 3 will characterize the range of biologically effective doses by assessing pharmacodynamic markers in tumor tissue
11594385|NCT00687609|Experimental|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
11594386|NCT00687596|Experimental|A|Patients randomized to TAC 101 will receive TAC 101 20 mg (administered as 2 10 mg formulated tablets) PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) for 14 days followed by a 7 day recovery period. This cycle will be repeated every 21 days.
11594387|NCT00687596|Placebo Comparator|B|Patients randomized to placebo will receive 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.
11594388|NCT00687570|Other|B|Nutritional drinks 7 days before surgery instead of traditional Bowel preparation with Laxabon®
11594389|NCT00687570|Other|A|Traditional bowel preparation with Laxabon®
11594390|NCT00687544|Experimental|PEG-IFN + RBV|PEG-IFN + RBV therapy in previously untreated chronic HCV subjects coinfected with HIV
11594391|NCT00687531|Experimental|Mometasone Furoate|Mometasone Furoate 400 mcg once daily in the evening through 12 weeks.
11594392|NCT00687518|Experimental|1|erythropoietin
11594393|NCT00687518|Placebo Comparator|2|Saline serum
11594394|NCT00687505|Experimental|1|Single ascending doses
11594395|NCT00687479||1-NGT|normal glucose tolerance
11594396|NCT00687479||2-GDM|Gestational Diabetes mellitus
11594397|NCT00687479||3.GIGT|Gestational Impaired glucose tolerance
11594398|NCT00687466|Experimental|1|Insulin yes
11594399|NCT00687466|No Intervention|2|Insulin no
11594400|NCT00687453|Experimental|1|Insulin glargine at bedtime
11594401|NCT00687453|Active Comparator|2|NPH twice-daily
11594402|NCT00687440|Experimental|Caelyx, Docetaxel, Trastuzumab|"Stage 1: subjects will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles. At the end of this stage, based on the number of cardiac events, subjects will proceed to a second stage or restart with a lower dose of Caelyx.
~Stage 2: subjects will be treated with the recommended dose of Caelyx (defined in the first stage) in combination with docetaxel and trastuzumab."
11594403|NCT00687427||A|Group A - 25 individuals or more, that start occupational therapy and agree to participate in the research.
11594404|NCT00687427||B|Group B- 25 individuals or more, half a year after hand injury that were treated in occupational therapy at the same institute.
11594405|NCT00687427||C|Group C - 25 individuals or more, a year after hand injury that were treated in occupational therapy at the same institute
11594406|NCT00687414||adults|male and female with MDS and MPD and AML
11594407|NCT00687414||Healthy|Healthy control group
11594408|NCT00687401|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6, and 14.
11594409|NCT00687388|Active Comparator|Alpha-blocker|Alpha-blocker only
11594410|NCT00687388|Active Comparator|NSAID|NSAID only
11594411|NCT00687388|Experimental|alpha-blocker and NSAID|Combination treatment of alpha-blocker and NSAID
11594412|NCT00687375|Other|1|Laparoscopic Inguinal Hernia Repair- Transabdominal preperitoneal (TAPP) approach
11594413|NCT00687375|Other|2|Laparoscopic Inguinal Hernia Repair- Totally extra peritoneal (TEP) Approach
11594414|NCT00687362|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
11594415|NCT00687349|Experimental|Intervention Arm|The training program will assign resident or NP student to a rotation. They will be receiving the educational intervention during 8 half-day sessions.
11594416|NCT00687349|No Intervention|Control Arm|Resident or NP student is assigned to usual education.
11594417|NCT00687336|Active Comparator|1|Empirical eradication treatment
11594418|NCT00687336|Active Comparator|2|Eradication treatment according to a diagnostic test (URT, histological test, breath test or serology).
11594419|NCT00687323|Experimental|Temozolomide|Temozolomide capsules orally, once daily: 1 induction cycle (200 mg/m^2/day for 7 days in 1 28 day cycle), 1 consolidation cycle (200 mg/m^2/day for 7 days in 1 28 day cycle), then 200 mg/m^2/day for 7 days each 28-day cycle or for 5 days each 28-day cycle (12 cycle maximum). Alternatively participants could have received 100 mg/m^2/day for 21 days of each 28-day cycle (12 cycle maximum).
11594420|NCT00687310|Other|1|Educational Intervention At the initial visit (Visit 1), patients in the educational intervention group will complete a short Needs Assessment Questionnaire to help the investigator/nurse determine which section(s) of the tailored patient education booklet to give to, educate, and provide instruction on to the patient. This may, at the discretion of the investigator, include providing their patient with a peak flow meter and instructions on its use.Visit 2 will be scheduled for 1-month after the Visit 1 for the education intervention group. All educational materials provided at Visit 1 will be reviewed with the patient at Visit 2. The investigator/nurse will reassess the patient's use of the Turbuhaler® and asthma treatment plan. Patients will also be asked about any adverse events that may have occurred since Visit 1 and/or are observed at Visit 2. Once Visit 2 is completed with the patient, the investigator/nurse will complete the Educator Satisfaction Questionnaire.
11594508|NCT00686712|Active Comparator|3 - NPH Insulin QHS|NPH insulin injected subcutaneously once daily at bedtime
11594554|NCT00686426|Active Comparator|1|Low Dairy
11594555|NCT00686426|Experimental|2|Adequate Dairy
11594421|NCT00687297|Active Comparator|Vandetanib Maintenance|Docetaxel day 1, carboplatin day 1 + vandetanib induction days 1 through 21 (daily) of a 28-day cycle for 4 cycles. If free of disease progression after 4 cycles, vandetanib maintenance daily until progression.
11594422|NCT00687297|Placebo Comparator|Placebo Maintenance|Docetaxel day 1, carboplatin day 1 + vandetanib induction days 1 through 21 (daily) of a 28-day cycle for 4 cycles. If free of disease progression after 4 cycles, placebo maintenance daily until progression.
11594423|NCT00687284||A|
11594424|NCT00687271|Experimental|MK-6213 160 mg + Atorvastatin 20 mg|1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks
11594425|NCT00687271|Active Comparator|Atorvastatin 20 mg|1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks
11594426|NCT00687271|Experimental|MK-6213 160 mg|1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks
11594427|NCT00687271|Placebo Comparator|Placebo|1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks
11594428|NCT00687258|Experimental|1|VitabranE ViE: Vitamin E-bonded polysulfone dialyzer
11594429|NCT00687258|No Intervention|2|APS-U (Asahi Polysulfone APS): Polysulfone dialyzer
11594430|NCT00687245|Experimental|1|esomeprazole magnesium 5 mg, weight 8 kg to < 20kg
11594431|NCT00687245|Experimental|2|esomeprazole magnesium 10 mg, weight 8 kg to < 20kg
11594432|NCT00687245|Experimental|3|esomeprazole magnesium 10 mg, weight > 20 kg
11594433|NCT00687245|Experimental|4|esomeprazole magnesium 20 mg, weight > 20 kg
11594434|NCT00687232|Experimental|1|AZD4818
11594435|NCT00687232|Placebo Comparator|2|
11594436|NCT00687219|Experimental|Peginterferon alfa-2b + Ribavirin|
11594437|NCT00687206|Experimental|1|
11594438|NCT00687193|Placebo Comparator|Placebo|
11594439|NCT00687193|Experimental|CP-690,550, 10mg|
11594440|NCT00687193|Experimental|CP-690,550, 15mg|
11594441|NCT00687193|Experimental|CP-690,550, 1mg|
11594442|NCT00687193|Experimental|CP-690,550, 3mg|
11594443|NCT00687193|Experimental|CP-690,550, 5mg|
11594444|NCT00687180|Active Comparator|I|MMF
11594445|NCT00687180|Active Comparator|II|
11594446|NCT00687167|Experimental|Zonisamide 100 mg Capsule|A single dose of zonisamide 100 mg administered 30 minutes after initiation of a standardized, high fat breakfast.
11594447|NCT00687167|Experimental|Zonisamide (Zonegran® ) 100 mg Capsule|A single dose of Zonegran® 100 mg administered 30 minutes after initiation of a standardized, high fat breakfast.
11594448|NCT00687154|Active Comparator|1 Sitting|Subjects with (1) OCT central subfield thickness ≤ 299 microns and (2) early proliferative or severe nonproliferative diabetic retinopathy for which investigator intends to perform full scatter photocoagulation in 1 sitting
11594449|NCT00687154|Active Comparator|4 Sittings|Subjects with (1) OCT central subfield thickness ≤ 299 microns and (2) early proliferative or severe nonproliferative diabetic retinopathy for which investigator intends to perform full scatter photocoagulation in 4 sittings.
11594450|NCT00687141|Experimental|1|
11594451|NCT00687141|Placebo Comparator|2|
11594452|NCT00687128|Experimental|1|Low-intensity aerobic exercise
11594453|NCT00687128|Experimental|2|Moderate-intensity aerobic exercise
11594454|NCT00687128|Active Comparator|3|Non-aerobic stretching exercise
11594455|NCT00687115|Other|Overfeeding|an inpatient overfeeding arm in which obesity resistant individuals are prescribed a 150% increase in a weight maintenance calorie diet for 6 weeks which (by random assignment) is either low in protein (6%) content. Overfeeding or Overfeeding Low Pro or with normal (20%) protein content
11594456|NCT00687115|Other|Weight Loss|a weight loss arm in which obese individuals are placed on a 50% decrease from a weight maintenance calorie diet for 6 weeks which (by random assignment) is either a standard 50% decrease in energy intake with all macronutrients held at the same percentage (20% protein, 50% carbohydrate, 30% fat) or a 50% decrease in energy intake with the same absolute protein content (in grams) as the weight maintaining diet while on our clinical research unit then followed as outpatients monthly for 10 months
11594457|NCT00687102|Experimental|Star participants assigned to Tamoxifen|Participants in the parent study, STAR assigned to Tamoxifen who were 65 or older at time of enrollment.
11594458|NCT00687102|Experimental|Star participants assigned to Raloxifene|Participants in the parent study, STAR assigned to Raloxifene who were 65 or older at time of enrollment.
11594459|NCT00687089||Subutex group|People who used opiates and willing to start with subutex treatment
11594460|NCT00687076|Experimental|1|Participants will receive standard of medical care and treatment with intensive lipid modification using a statin plus Ezetimibe and Niaspan.
11594461|NCT00687076|Active Comparator|2|Participants will receive standard of medical care and treatment with standard lipid modifying medications plus placebo Ezetimibe and placebo Niaspan.
11594462|NCT00687063||A|
11594463|NCT00687050|Active Comparator|1|HIV-positive hemodialysis patients (as a high risk group for cachexia) will be given daily drinks of Renilon 7.5 (125 ml, 2 kcal/ml) as peroral supplemental nutrition on top to their recommended high-protein, high-caloric diet.
11594464|NCT00687050|No Intervention|2|Chronic hemodialysis patients randomized to no peroral supplemental nutrition
11594465|NCT00687050|Active Comparator|3|Chronic hemodialysis patients randomized to peroral supplemental nutrition.
11594466|NCT00687037|Experimental|I|Cetylpyridinium chloride during 21 days.
11594467|NCT00687011|Experimental|Palonosetron-dexamethasone|
11594468|NCT00686998|Experimental|AZD2624|AZD2624 40 mg
11594469|NCT00686998|Other|Olanzapine|Olanzapine 15 mg
11594470|NCT00686998|Placebo Comparator|Placebo|Matching Placebo
11594471|NCT00686985|Experimental|A|
11594472|NCT00686972|Experimental|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
11594509|NCT00686699|Experimental|Preladenant 25 mg BID→Placebo BID|Participants received one preladenant 25 mg capsule twice daily (BID) for 14 days during the first treatment period and received one matching placebo capsule BID during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.
11594556|NCT00686413|Experimental|1|
11594557|NCT00686413|Experimental|2|
11594473|NCT00686959|Experimental|Arm A: Pemetrexed + Cisplatin and TRT|"Participants were treated with Pemetrexed plus Cisplatin and concurrent thoracic radiation therapy (TRT) (Concurrent Phase) for three 21-day cycles, followed by a 3-5 week Recovery Period, then treated with consolidation chemotherapy with pemetrexed (Consolidation Phase) for up to four 21-day cycles
~Concurrent Phase:
~Pemetrexed: 500 milligrams per meter squared (mg/m^2), intravenous (IV) on Day 1 of each 21-day cycle for 3 cycles.
~Cisplatin: 75 mg/m^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gray [Gy] per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.
~Consolidation Phase:
~Pemetrexed: 500 mg/m^2, IV on Day 1 of each 21-day cycle up to 4 cycles"
11594474|NCT00686959|Active Comparator|Arm B: Etoposide + Cisplatin and TRT|"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (Concurrent Phase) for two 28-day cycles, followed by a 3-5 week Recovery Period, then received consolidation treatment with cytotoxic chemotherapy of choice (Consolidation Phase) for up to 2 cycles
~Concurrent Phase:
~Etoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m^2, IV on Days1, 8, 29, and 36
~Consolidation Phase options:
~Option 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22"
11594475|NCT00686946||NRAMP|Participants take their antipsychotic medication as prescribed by their clinical treating teams.
11594476|NCT00686933|Experimental|1|
11594477|NCT00686920|Experimental|Rifaximin|Participants from a previous rifaximin HE study and new participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for at least 24 months, until regulatory approval of rifaximin for reduction in risk of overt HE recurrence, or until the sponsor closed the study.
11594478|NCT00686894|Experimental|Infliximab 5 mg/kg|Infliximab infusions: 5 mg/kg at weeks 0, 2, and 6.
11594479|NCT00686881|Experimental|PegIFN-2b|Participants receiving PegIFN-2b at 0.5 ug/kg subcutaneously (SC) once a week for up to 156 weeks.
11594480|NCT00686881|Active Comparator|SNMC|Participants receiving SNMC 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for up to 156 weeks.
11594481|NCT00686868|Experimental|30mg|active
11594482|NCT00686868|Experimental|3mg|active
11594483|NCT00686868|Experimental|0.3mg|active
11594484|NCT00686868|Placebo Comparator|placebo|placebo
11594485|NCT00686868|Experimental|60mg|60mg
11594486|NCT00686868|Experimental|100mg|100mg
11594487|NCT00686855|Experimental|Tacrolimus|Tacrolimus Arm Closed to Accrual as of January 2012
11594488|NCT00686855|Experimental|Dexamethasone|
11594489|NCT00686842|Experimental|VEGF Inhibitor PTC299|Single arm study - all subjects received PTC299
11594490|NCT00686829|Experimental|Vicriviroc 30 mg QD|Vicriviroc 30 mg QD
11594491|NCT00686816|Placebo Comparator|1|
11594492|NCT00686816|Experimental|2|
11594493|NCT00686803|Experimental|PL3994 Dose A|PL3994 Dose A
11594494|NCT00686803|Experimental|PL3994 Dose B|PL3994 Dose B
11594495|NCT00686803|Experimental|PL3994 Dose C|PL3994 Dose C
11594496|NCT00686803|Experimental|PL3994 Dose D|PL3994 Dose D
11594497|NCT00686803|Experimental|PL3994 Dose E|PL3994 Dose E
11594498|NCT00686803|Placebo Comparator|Placebo|Placebo
11594499|NCT00686790|Experimental|PegIntron|All participants received PegIntron (Peginterferon alfa-2b) weekly based on their body weight.
11594500|NCT00686777|Experimental|PEG-IFN + Ribavirin|Pegylated Interferon alfa-2b was administered to participants at 1.5 μg/kg subcutaneously once weekly for 48 weeks. Ribavirin was administered orally every day after morning and evening meals for 48 weeks at 400 mg/day.
11594501|NCT00686764||Group 1|Trans-femoral amputees that meet the eligibility criteria.
11594502|NCT00686751|Experimental|A|"There is only one arm in this study. Each subject will be studied through 3 phases lasting a total of 4 weeks:
~Phase 1: administration of study medication at the end of hemodialysis treatment.
~Phase 2: no administration of study medication. Phase 3: administration of study medication at the beginning of hemodialysis."
11594503|NCT00686738||A|"Study group will be made up of patients hospitalized to National Cancer Center, Korea, aged between 5 and 40 years, and diagnosed with high grade osteosarcoma by histological exam.
~In this group, TGF-b1 measurement, PET/CT and MRS examination at diagnosis, after 1st cycle chemotherapy, and 2nd or 3rd chemotherapy (just before surgery) will be made.
~In addition, evaluation of NF-kB expression status in tumor specimens at diagnostic biopsy and tumor removing surgery will be done.
~The results of above studies will be correlated with the necrosis fractions of the tumor tissues removed by surgery."
11594504|NCT00686725|Active Comparator|Temozolomide + Radiation|"Standard therapy regimen:
~Treatment will start 4 weeks after surgery. Temozolomide will be administered concomitantly with radiotherapy, at 75 mg/m^2/day orally for 42 days. Four weeks after completing concomitant radiotherapy, temozolomide will be administered for an additional six cycles. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m^2/day, and may be increased to 200 mg/m^2/day for Cycle 2 and subsequent cycles depending on nonhematological toxicity observed and neutrophil and platelet count values. Capsules containing 20 mg or 100 mg of temozolomide will be used.
~Radiotherapy will be administered in combination with temozolomide. Radiotherapy will be administered for a total daily dose of 60 Gy in 30 fractions, 5 days a week for 6 weeks."
11594505|NCT00686725|Experimental|Temozolomide alone, then Temozolomide + Radiation|"Early postsurgery temozolomide chemotherapy plus standard regimen:
~Treatment with temozolomide alone will start 2 weeks after surgery at 75 mg/m^2/day orally for 14 days. Then, starting on Day 29 after surgery, temozolomide will be administered according to standard treatment as described for the temozolomide + radiation arm (standard therapy regimen).
~Radiotherapy will be administered in combination with temozolomide. Radiotherapy will be administered for a total daily dose of 60 Gy in 30 fractions, 5 days a week for 6 weeks."
11594506|NCT00686712|Experimental|1 - Insulin glargine QHS|Insulin glargine injected subcutaneously once daily at bedtime
11594507|NCT00686712|Experimental|2 - Insulin glargine QAM|Insulin glargine injected subcutaneously once daily in the morning
11594510|NCT00686699|Placebo Comparator|Placebo BID→Preladenant 25 mg BID|Participants received one matching placebo capsule BID for 14 days during the first treatment period and received one preladenant 25 mg capsule during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.
11594511|NCT00686686|Experimental|Infliximab 5 mg/kg|Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
11594512|NCT00686673|Experimental|A|Providing Videotape-based material & tailored workbook to make informed choice of disclosing terminal illness to patients
11594513|NCT00686673|Other|B|"Attention control arm:
~Providing videotape-based material & non-tailored workbook about pain control"
11594514|NCT00686660|Experimental|1|C-W G: in training period, patients do cycling on cycle ergometry at hospital. in non-training period, patients walk at community.
11594515|NCT00686660|Other|2|C-nonW G: in training period, patients do cycling at cycle ergometry at hospital, in non-training period, patients don't walk at community.
11594516|NCT00686660|Experimental|3|W-W G: in training period, patients do walking along 60 meters place at hospital, in non-training period, patients do walking in community
11594517|NCT00686660|Other|4|W-nonW G: in training period, patients do walking along 60 meter place, in non-training period,patients don't walk at community.
11594518|NCT00686634|Experimental|1|Sitagliptin 100 mg once daily
11594519|NCT00686608|Experimental|Glucose|IV glucose
11594520|NCT00686608|Active Comparator|Fructose|
11594521|NCT00686608|Placebo Comparator|Saline|
11594522|NCT00686595|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg intravenous (IV) infusion administered at Baseline (Week 0), Visit 3 (Week 2), Visit 4 (Week 6), Visit 6 (Week 14), and Visit 8 (Week 22).
11594523|NCT00686582|Experimental|Initially Vaccinia Naive, 2 dose primed, 1 booster dose|"Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)
~1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50"
11594524|NCT00686582|Experimental|Initially Vaccinia Naive, 1 dose primed, 1 booster dose|"Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)
~1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50"
11594525|NCT00686582|Other|Vaccinia Experienced, boosted, blood draw only|"Group 4 Vaccinia Experienced
~1 booster dose of MVA-BN in prior study (POX-MVA-005) Blood draw, Screening Visit only (POX-MVA-023)"
11594526|NCT00686556|Experimental|Cohort -1|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 12 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
11594527|NCT00686556|Experimental|Cohort 1|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 15 Gy on Days -5 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
11594528|NCT00686556|Experimental|Cohort 2|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 18 Gy on Days -6 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
11594529|NCT00686556|Experimental|Cohort 3|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 21 Gy on Days -7 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
11594530|NCT00686556|Experimental|Cohort 4|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 24 Gy on Days -8 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
11594531|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 200 mg TID Days 9-15|POS 200 mg three times a day (TID) on Days 1-8 followed by continued randomized dosing regimen of POS 200 mg TID on Days 9-15, administered with food or oral nutritional supplements.
11594532|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 400 mg BID Days 9-15|POS 200 mg TID on Days 1-8 followed by randomized dosing regimen of POS 400 mg twice a day (BID) on Days 9-15, administered with food or oral nutritional supplements.
11594533|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 400 mg TID Days 9-15|POS 200 mg TID on Days 1-8 followed by randomized dosing regimen of POS 400 mg TID on Days 9-15, administered with food or oral nutritional supplements.
11594534|NCT00686530||1|
11594535|NCT00686517|Experimental|PEG-IFN 24|pegylated interferon alpha-2b 1.5 ug/kg/week for 24 weeks
11594536|NCT00686517|Experimental|PEG-IFN 12|pegylated interferon alpha-2b 1.5 ug/kg/week for 12 weeks
11594537|NCT00686517|Experimental|PEG-IFN + RVB 12|pegylated interferon alpha-2b 1.5 ug/kg/week in combination with ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
11594538|NCT00686491||1|Triathletes
11594539|NCT00686491||2|Cold air athletes
11594540|NCT00686491||3|Swimmers
11594541|NCT00686491||4|Other sports elite athletes
11594542|NCT00686491||5|Control subjects
11594543|NCT00686478|Experimental|interferon alpha 2b (Intron A)|1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
11594544|NCT00686478|Placebo Comparator|Placebo|Placebo administered subcutaneously once a day for 7 days, then three times a week for 23 weeks.
11594545|NCT00686465|Other|PET/CT scan|PET/CT scan
11594546|NCT00686452||1|Swimmers without AHR
11594547|NCT00686452||2|Swimmers with asymptomatic AHR
11594548|NCT00686452||3|Swimmers with symptomatic AHR and use only of beta-2 adrenargic
11594549|NCT00686452||4|Swimmers with asthma and inhaled corticosteroids
11594550|NCT00686452||5|Healthy Subjects
11594551|NCT00686452||6|Healthy subjects with AHR
11594558|NCT00686400||1: FE|FE = first episode schizophrenia
11594559|NCT00686400||2: CO|CO = age and gender-matched control subjects
11594560|NCT00686374|Experimental|Any adalimumab|Adalimumab was administered via subcutaneous injection. Dosage was based on body weight and clinical status, and ranged from 10, 20, or 40 mg every other week to 20 or 40 mg every week.
11594561|NCT00686335|Experimental|Lodotra|After the 4 week run-in period with immediate release prednisone (Cortancyl), patients were switched to the identical dose of modified release prednisone tablets (Lodotra). Study medication for the Lodotra treatment period consisted of Lodotra in 2 dose strengths (5 mg and 1 mg prednisone per tablet). Patients were to take their tablets with or after the evening meal (at 10 pm +/- 30 minutes) for 4 weeks.
11594562|NCT00686335|Active Comparator|Cortancyl|During the 4 week run-in period, patients remained on their respective pre-study dose of prednisone or equivalent. However, patients were standardized to 5 mg and 1 mg tablets of immediate release prednisone (Cortancyl). Patients were to take their tablets with or after the morning meal (at 8am +/- 30 minutes) for 4 weeks.
11594563|NCT00686322|Other|1|Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
11594564|NCT00686296|Active Comparator|Group II|Taliderm™ dressing applied until the next scheduled dressing change (up to eight hours), then replaced by a gauze dressing. Gauze dressing changes will continue per standard of care until the scheduled follow-up visits (first or second visit). At the scheduled follow-up visits, the subject will have a Taliderm™ dressing applied and left in place until the next scheduled dressing change (up to eight hours), then will continue standard of care wet to dry gauze dressing changes until next scheduled follow-up visit.
11594565|NCT00686296|Other|III|standard wet to dry dressing with gauze
11594566|NCT00686296|Active Comparator|group I|Taliderm™ dressing applied until the next scheduled dressing change (up to eight hours), then replaced by a gauze dressing
11594567|NCT00686283|Other|Exercise prescription|Each adolescents with type 1 or type 2 diabetes received individual fitness testing and a personalized exercise program prescription developed by an exercise physiologist. Pretest and posttest measures of glucose control and cardiorespiratory fitness, heart rate variability, metabolic control, lipid profile, body composition, and inflammatory markers, as well as psychological outcomes (i.e., diabetes quality of life) were completed.
11594568|NCT00686270|Experimental|1|apricitabine
11594569|NCT00686257|Experimental|1|Patients receiving NPPV by the 'Total Face Mask'
11594570|NCT00686257|Active Comparator|2|Patients receiving NPPV by 'standard oronasal mask'
11594571|NCT00686244|Experimental|Training Group|"Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).
~Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism"
11594572|NCT00686244|No Intervention|Control Group|No guided training. Exercise optional after detailed consulting and handing over an information dossier for adequate physical activity.
11594573|NCT00686231|Experimental|Dose Test 15mg NTG|Nitroglycerin 15mg (NTG) applied topically to one wrist and placebo to the other wrist at Visit 1
11594574|NCT00686231|Experimental|Dose Test 30mg NTG|Nitroglycerin 30mg applied topically to one wrist and placebo to the other wrist at Visit 1
11594575|NCT00686231|Experimental|Combination Test 20mg Lidocaine|Lidocaine 20mg + Nitroglycerin 30mg applied topically to one wrist, Lidocaine 20mg + placebo applied to the other wrist, at Visit 2
11594576|NCT00686231|Experimental|Combination Test 40mg Lidocaine|Lidocaine 40mg + Nitroglycerin 30mg applied topically to one wrist, Lidocaine 40mg + placebo applied to the other wrist, at Visit 2
11594577|NCT00686218|Experimental|Treatment (panobinostat, imatinib mesylate)|Patients receive oral panobinostat once daily on days 1, 3 and 5; 8, 10, and 12; 15, 17, and 19; and 22, 24, and 26. Patients also receive oral imatinib mesylate once daily on days 1-28. Treatment repeats every 21 or 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11594578|NCT00686205|Experimental|ABBOTT PRISM HIV O Plus assay for Specificity|All subjects will have their blood tested by the investigational HIV test.
11594579|NCT00686205|No Intervention|ABBOTT PRISM HIV O Plus Assay for Sensitivity|Samples collected from specimen vendors or from specimen collection studies were tested by the investigational HIV assay.
11594580|NCT00686179|Experimental|1|Escalating doses of AZD3480 during 6 days
11594581|NCT00686179|Experimental|2|Repeated doses of AZD3480 during 6 days
11594582|NCT00686179|Placebo Comparator|3|Placebo during 6 days
11594583|NCT00686179|Active Comparator|4|Placebo during 5 days, active day 6
11594584|NCT00686166|Experimental|Chemo + Chemo and radiation + Surgery|"Chemotherapy Cycle 1 (1 cycle is 35 days):
~Oxaliplatin, 50 mg/m^2, IV, Days 1,8,15,22,29
~Cetuximab, 400 mg/m^2, IV, Day 1
~Cetuximab, 250 mg/m^2, IV, Days 8,15,22,29
~Capecitabine, 1650 mg/m^2/day, PO, Monday-Friday (Day 1-35)
~Chemotherapy+ Radiation Cycle 2:
~Oxaliplatin, 50 mg/m^2, IV, Days 50,57,71,78
~Cetuximab, 250 mg/m^2, IV, Days 50,57,64,71,78
~Capecitabine, 1650 mg/m^1, PO, Monday-Friday (Day 50-84)
~Radiation therapy: Planning target value 1: 4500 cGy (centigray) in 25 fractions; Planning target value 2 (stage T3 patients): Boost of 540 cGy in 3 fractions; Planning target value 2 (stage T4 patients): Boost of 900 cGy in 5 fractions.
~Therapeutic Surgical procedure: Resection"
11594585|NCT00686140|Experimental|Celecoxib, immune adjustor|Celecoxib
11594586|NCT00686140|Placebo Comparator|Placebo|Placebo looks like the active drug celecoxib, with the same dose
11594587|NCT00686127|Active Comparator|Lidocaine Patch|Drug: lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1 patch was applied topically to the affected site(s) for 12 hours each day.
11594588|NCT00686127|Placebo Comparator|Placebo Patch|Drug: placebo patch, 1 patch was applied topically to the affected site(s) for 12 hours each day.
11594589|NCT00686114|Experimental|A|Enlarged field + Paclitaxel + Cisplatin + Tarceva
11594590|NCT00686114|Experimental|B|Enlarged field + Paclitaxel + Cisplatin
11594591|NCT00686114|Active Comparator|C|Conventional field + Paclitaxel + Cisplatin + Tarceva
11594592|NCT00686114|Active Comparator|D|Conventional field + Paclitaxel + Cisplatin
11594691|NCT00685581|Experimental|C|Arms C: the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed.
11594851|NCT00684437|Experimental|Factual Loss-Framed|Smoking Risk Message - Factual Loss-Framed (FLF)
11594593|NCT00686101||1|Normal control subjects (Males and females between 18-65 years, who smoke cigarettes daily, have an expired CO measurement of > 8 ppm to confirm cigarette smoking, who are not actively trying to quit smoking at the time of the interview, and who must be free from Axis I psychotic disorder.)
11594594|NCT00686101||2|Subjects with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder (Males and females between 18-65 years, who smoke cigarettes daily, have an expired CO measurement of > 8 ppm to confirm cigarette smoking, and who are not actively trying to quit smoking at the time of the interview.)
11594595|NCT00686075|Experimental|MEDI-534, Cohort 1|Participants aged 6 to less than (<) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
11594596|NCT00686075|Placebo Comparator|Placebo, Cohort 1|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
11594597|NCT00686075|Experimental|MEDI-534, Cohort 2|Participants aged 6 to <24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
11594598|NCT00686075|Placebo Comparator|Placebo, Cohort 2|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
11594599|NCT00686075|Experimental|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
11594600|NCT00686075|Placebo Comparator|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
11594601|NCT00686075|Experimental|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
11594602|NCT00686075|Placebo Comparator|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
11594603|NCT00686075|Experimental|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
11594604|NCT00686075|Placebo Comparator|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
11594605|NCT00686062|Experimental|1|Women in this arm view the interactive, computerized, prenatal testing decision tool (PT Tool) we created.
11594606|NCT00686062|Active Comparator|2|Women in this arm view the age-appropriate computerized version of the educational pamphlet on prenatal testing developed and distributed by the State of California
11594607|NCT00686049||Study Group|Participants will complete two audio computer assisted self interviews on laptop computers. This study will also involve the abstraction of participants' viral load and CD4 counts from their medical charts.
11594608|NCT00686036|Experimental|vandetanib|300 mg orally, once daily for up to 18 months
11594609|NCT00686036|Placebo Comparator|Placebo|orally, once daily for up to 18 months
11594610|NCT00686023|Active Comparator|1|DHS fixation
11594611|NCT00686023|Active Comparator|2|IMN fixation
11594612|NCT00686010|Placebo Comparator|1|Placebo
11594613|NCT00686010|Experimental|2|JTT-705 300mg
11594614|NCT00686010|Experimental|3|JTT-705 600mg
11594615|NCT00686010|Experimental|4|JTT-705 900mg
11594616|NCT00685984||1|
11594617|NCT00685984||2|
11594618|NCT00685984||3|
11594619|NCT00685971|Experimental|Vitamin D|vitamin
11594620|NCT00685971|Placebo Comparator|Placebo|
11594621|NCT00685945|Experimental|Control (bradykinin infusion)|Bradykinin (Clinalfa AG, Läufelfingen, Switzerland)
11594622|NCT00685945|Experimental|L-NMMA + bradykinin|N-monomethyl-L-arginine (L-NMMA, NO synthase inhibitor; Bachem, Torrance, CA)
11594623|NCT00685945|Experimental|Isosorbide + L-NMMA + bradykinin|Isosorbide (NO donor)
11594624|NCT00685945|Experimental|Sildenafil + L-NMMA + bradykinin|Sildenafil (phosphodiesterase type 5 (PDE5) inhibitor
11594625|NCT00685932|No Intervention|Control|This arm will be randomly assigned to have conventional retractions (ie Rich retractors and similar) used in the usual fashion during the cesarean procedure.
11594626|NCT00685932|Experimental|Mobius|This arm will be randomized to have the providers who are performing the cesarean section use the Mobius retractor during the cesarean section procedure after the peritoneal cavity is opened.
11594627|NCT00685919|Experimental|1|Carbidopa 200 mg every 6 hours orally
11594628|NCT00685919|Placebo Comparator|2|
11594629|NCT00685906|Experimental|1|
11594630|NCT00685906|Active Comparator|2|
11594631|NCT00685893|No Intervention|Control Arm|6 Community hospital ICUs receiving delayed intervention activities after the completion of the randomized trial
11594632|NCT00685893|Experimental|Intervention Arm|6 community hospital ICUs receiving 5-component intervention.
11594633|NCT00685880|Experimental|Prolotherapy group|Subjects randomized to this arm will receive injection(s) of 10% dextrose solution in the affected thumb joint.
11594634|NCT00685880|Active Comparator|Corticosteroid Group|Subjects randomized to this arm will receive injection(s) of betamethasone solution in the affected thumb joint.
11594635|NCT00685867|Experimental|1|Rapid detection
11594636|NCT00685867|Other|2|Enhanced infection control
11594637|NCT00685841|Experimental|A|Arformoterol 50 mcg QD and placebo MDI
11594638|NCT00685841|Experimental|B|Arformoterol 25 mcg BID and placebo MDI
11594639|NCT00685841|Experimental|C|Arformoterol 15 mcg BID and placebo MDI
11594640|NCT00685841|Active Comparator|D|Salmeterol MDI 42 mcg BID and placebo inhalation solution
11594641|NCT00685841|Placebo Comparator|E|Placebo BID MDI and inhalation solution
11594642|NCT00685828|Active Comparator|Arm I|Patients receive low-dose oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
11594643|NCT00685828|Experimental|Arm II|Patients receive high-dose oral imatinib mesylate twice daily in the absence of disease progression or unacceptable toxicity.
11594644|NCT00685815|Experimental|24 participants|Intravenous Iron (FCM)
11594645|NCT00685815|Placebo Comparator|12 participants|Placebo
11594646|NCT00685802|Experimental|Cilostazol 50 mg Tablets|A single dose of cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours.
11594647|NCT00685802|Experimental|Cilostazol (Pletal® ) 50 mg Tablets|A single dose of Cilostazol (Pletal® tablets, 2 x 50 mg ) administered after an overnight fast of at least 10 hours.
11594648|NCT00685789|Experimental|Acupuncture with Deqi|Needles were inserted and manipulated manually using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation of soreness, numbness, fullness, aching, cool, warmth, heaviness and radiating sensation (Deqi) occurred. The needles were retained for 30 min.
11594649|NCT00685789|Active Comparator|Acupuncture without Deqi|Needles were simply inserted and retained for 30 min, without any other stimulation.
11594650|NCT00685776|Experimental|Anacetrapib|Participants randomly assigned to anacetrapib in base study will continue same treatment if enrolled in study extension.
11594651|NCT00685776|Placebo Comparator|Placebo|Participants randomly assigned to placebo in base study will continue same treatment if enrolled in study extension.
11594652|NCT00685763|Experimental|Proton radiation and chemotherapy|"Chemotherapy and Radiation Combination
~Proton radiation 59.4 cobalt gray equivalent(CGE) in 33 fx at 1.8 CGE per fx over 7 weeks.
~Capecitabine (Xeloda ®) 1,000 mg by mouth approximately every 12 hrs, 5 days/week starting the first day of radiation until the end of radiation, but on radiation days only.
~Consolidation Chemotherapy starting 4 weeks after the completion of radiation
~Gemcitabine (Gemzar ®) Suggested Regimen - 1,000mg/m2 by IV over 30 minutes once a week for 3 weeks (followed by a week of rest) for 12 total doses."
11594653|NCT00685750|Other|ME1|Patients with cutaneous metastatic melanoma receiving dacarbazine or temozolomide as first line treatment
11594654|NCT00685750|Other|ME2|Patients with cutaneous metastatic melanoma receiving first line treatment other than dacarbazine or temozolomide only
11594655|NCT00685750|Other|ME3|Patients with cutaneous metastatic melanoma receiving any second-or higherline chemotherapy treatment
11594656|NCT00685750|Other|ME4|Patients with cutaneous metastatic melanoma receiving local irradiation of cutaneous/subcutaneous tumor lesions
11594657|NCT00685750|Other|ME5|Patients with cutaneous metastatic melanoma receiving local imiquimod
11594658|NCT00685750|Other|NSC|Non-small cell lung cancer patients
11594659|NCT00685750|Other|ME6|Patients with cutaneous metastatic melanoma receiving ipilimumab
11594660|NCT00685737|Active Comparator|1|1-MNA-Low Dose
11594661|NCT00685737|Active Comparator|2|1-MNA-High Dose
11594662|NCT00685737|Placebo Comparator|3|Placebo
11594663|NCT00685724|Experimental|1|Following 2 sessions of MET intervention received by all patients, patients in Condition 1 receive no further intervention.
11594664|NCT00685724|Experimental|2|Patients in Condition 2 will receive 8 sessions of the CBT (Cognitive Behavioral Therapy) intervention.
11594665|NCT00685724|Experimental|3|Patients in Condition 3 will receive 8 sessions of CBT plus aftercare treatment.
11594666|NCT00685711|Placebo Comparator|1|Placebo intradermal n = 2 with each dose level of Cat-PAD.
11594667|NCT00685711|Experimental|2|Intradermal injection of increasing single doses of Cat-PAD (0.03, 0.3, 3, 12 nmol) n = 6 per dose level. Based on review of blinded LPSR, an additional dose of Cat-PAD between 0.03 and 12 nmol may be administered to an additional cohort of 6 subjects.
11594668|NCT00685711|Placebo Comparator|3|Placebo subcutaneous n = 2 with each dose level of Cat-PAD.
11594669|NCT00685711|Experimental|4|Subcutaneous injection of increasing single doses of Cat-PAD (0.03, 0.3, 3, 12, 20 nmol) n = 6 per dose level. Based on review of blinded LPSR, an additional dose of Cat-PAD between 0.03 and 20 nmol may be administered to an additional cohort of 6 subjects.
11594670|NCT00685698|Other|Nemonoxacin|Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
11594671|NCT00685685|Experimental|Lovastatin 40 mg tablet|A single dose of Lovastatin 40 mg administered after an overnight fast of at least 10 hours.
11594672|NCT00685685|Experimental|Lovastatin (Mevacor®) 40 mg Tablet|A single dose of Lovastatin (Mevacor®) 40 mg administered after an overnight fast of at least 10 hours.
11594673|NCT00685672|Experimental|1|adrenalin
11594674|NCT00685672|Placebo Comparator|2|placebo
11594675|NCT00685659|Active Comparator|TAU only|Control condition that consists of treatment as usual, which is Intensive Outpatient Treatment (about 3 months long)
11594676|NCT00685659|Experimental|TMAC only|Adaptive telephone-based counseling
11594677|NCT00685659|Experimental|TMAC plus|Adaptive telephone-based counseling, plus incentives
11594678|NCT00685646|Experimental|Arm I|Patients receive maximum androgen-blockade therapy and zoledronic acid for up to 24 courses.
11594679|NCT00685646|Active Comparator|Arm II|Patients receive maximum androgen-blockade therapy for up to 24 courses.
11594680|NCT00685633|Active Comparator|Arm A|Patients are observed without treatment in weeks 1-12. Patients with a prostate-specific antigen (PSA) rise of > 50% above baseline or nadir (whichever is lowest) and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. In weeks 13-44, patients with a rise PSA ≥ 50% above baseline or nadir, and a PSA rise of at least 5 ng/mL confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue to receive bicalutamide up to 72 weeks.
11594681|NCT00685633|Active Comparator|Arm B|In weeks 1-12, patients receive oral enzastaurin hydrochloride twice daily. Patients with a PSA rise of > 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. In weeks 13-44, patients with a PSA rise of ≥ 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral enzastaurin twice daily and oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue on this combination therapy up to 72 weeks.
11594682|NCT00685620|No Intervention|Group 1|Standard care following detoxification
11594683|NCT00685620|Active Comparator|Group 2|Recovery housing following detoxification
11594684|NCT00685620|Experimental|Group 3|Recovery housing plus counseling
11594685|NCT00685607|Experimental|1|loperamide-simethicone
11594686|NCT00685607|Placebo Comparator|2|matching placebo
11594687|NCT00685594|Experimental|1|Cholecalciferol 20.000 IU per week for 5 years
11594688|NCT00685594|Placebo Comparator|2|
11594689|NCT00685581|Experimental|A|Arms A: the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period
11594690|NCT00685581|Experimental|B|Arms B: the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed.
11594692|NCT00685568|Experimental|Arm I|Patients receive oral celecoxib twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
11594693|NCT00685568|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
11594694|NCT00685542|Experimental|1|Diacerein 50mg bid
11594695|NCT00685542|Placebo Comparator|2|placebo 50mg bid
11594696|NCT00685529|Active Comparator|A|12 µg of racemic formoterol fumarate BID
11594697|NCT00685529|Experimental|B|15 µg of nebulized arformoterol tartrate inhalation solution BID
11594698|NCT00685529|Active Comparator|C|24 µg of racemic formoterol fumarate BID
11594699|NCT00685516|Active Comparator|Arm I - Green Tea|Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.
11594700|NCT00685516|Placebo Comparator|Arm II - Water|Patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.
11594701|NCT00685516|Active Comparator|Arm III - Decaffeinated black tea|Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.
11594702|NCT00685490||Surgical|Retrospective chart review of 70 eyes of 70 consecutive patients who underwent PPV, with and without ILM peeling, for persistent macular edema associated with BRVO
11594703|NCT00685477|Active Comparator|Experimental Sequence ABC|CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg 60 minutes, with at least 2 days between each infusion
11594704|NCT00685477|Active Comparator|Experimental Sequence ACB|CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg 30 minutes, with at least 2 days between each infusion
11594705|NCT00685477|Active Comparator|Experimental Sequence BAC|CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg 60 minutes, with at least 2 days between each infusion
11594706|NCT00685477|Active Comparator|Experimental Sequence BCA|CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg 15 minutes, with at least 2 days between each infusion
11594707|NCT00685477|Active Comparator|Experimental Sequence CAB|CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg 30 minutes, with at least 2 days between each infusion
11594708|NCT00685477|Active Comparator|Experimental Sequence CBA|CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg 15 minutes, with at least 2 days between each infusion
11594709|NCT00685464|Active Comparator|2|Intravenous bolus Abciximab.
11594710|NCT00685464|Active Comparator|Abciximab|Intracoronary bolus abciximab.
11594711|NCT00685425|Experimental|A|Subjects randomized to the levalbuterol arm will complete 1 of 6 possible randomization sequences containing (a) levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
11594712|NCT00685425|Active Comparator|B|Subjects randomized to racemic albuterol will complete 1 of 6 possible randomization sequences containing (a) racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
11594713|NCT00685412|Experimental|0.6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 0.6mg DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
11594714|NCT00685412|Experimental|2mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 2mg of DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
11594715|NCT00685412|Experimental|6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
11594716|NCT00685399|Experimental|Cohort 1|Participants were administered with AIN457 (Sp2/0derived) 10 milligrams per kilogram (mg/kg) intravenous (i.v.) dose on Day 1 and Day 22.
11594717|NCT00685399|Experimental|Cohort 2|Participants were administered with AIN457 (Sp2/0 or Chinese hamster ovary cell (CHO) derived) 10 mg/kg, (CHO derived) 3 mg/kg or (CHO derived) 1 mg/kg i.v. dose on Day 1 and if needed a second dose of AIN457 10 mg/kg i.v. dose either on Day 15 or Day 22. 3 participants from cohort 1 rolled on into this cohort.
11594718|NCT00685399|Experimental|Cohort 3|Participants were administered with AIN457 10 mg/kg i.v. dose on Day 1 and Day 22.
11594719|NCT00685399|Experimental|Cohort 4|Extension period: Participants were administered with AIN457 10 mg/kg, i.v. (with or without a short course of corticosteroids) once a flare had occurred, or periodically at a frequency of not more than once per month at the discretion of the investigator.
11594720|NCT00685399|Experimental|Cohort 5|Participants were administered with AIN457 30 mg/kg single i.v. dose. A second dose was given when all 4 participants completed at least 29 days, and the 30 mg/kg dose was well tolerated by all.
11594721|NCT00685399|Experimental|Cohort 6 Arm 1|Participants were administered with AIN457 300 mg subcutaneously (s.c.) and saline i.v. infusion every two weeks (Days 1, 15, 29, and 43).
11594722|NCT00685399|Experimental|Cohort 6 Arm 2|Participants were administered with AIN457 10 mg/kg i.v. and s.c. saline injections every two weeks (Days 1, 15, 29, and 43).
11594723|NCT00685399|Experimental|Cohort 6 Arm 3|Participants were administered with AIN457 30 mg/kg i.v. and s.c. saline injections every 4 weeks (Days 1 and 29) and saline i.v. infusions and saline s.c. injections on Days 15 and 43 to maintain masking of treatment groups.
11594724|NCT00685386|Experimental|I|
11594725|NCT00685386|Placebo Comparator|II|Room air will be used for insufflation as the placebo comparator arm.
11594726|NCT00685373|Experimental|Canakinumab (ACZ885)|Subcutaneous injection every 8 weeks based on participant's body weight. Body weight >40 kilogram (kg): 150 milligrams (mg) per injection and body weight <= 40 kg: 2 mg/kg per injection. For participants who did not experience sufficient symptomatic relief, an up-titration to the dose and/or more frequent doses were permitted as per protocol.
11594727|NCT00685360|Experimental|1|
11594728|NCT00685360|Experimental|2|
11594729|NCT00685360|Placebo Comparator|3|
11594801|NCT00684801||Usual care (control group)|Patients undergo usual care as determined by core cancer team.
11595005|NCT00683423|Experimental|A|
11594730|NCT00685347|Experimental|A|Subjects randomized to the levalbuterol arm will complete 1 of 6 possible randomization sequences containing (a) levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
11594731|NCT00685347|Active Comparator|B|Subjects randomized to racemic albuterol will complete 1 of 6 possible randomization sequences containing (a) racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
11594732|NCT00685334|Experimental|1|Participants will take olanzapine
11594733|NCT00685334|Active Comparator|2|Participants will take aripiprazole
11594734|NCT00685321|Experimental|1|deep TMS treatment
11594735|NCT00685321|Sham Comparator|2|inactive treatment
11594736|NCT00685295|Experimental|Arm 1 / Fentora|"Intervention Group:
~Subject receives:
~placebo oral/swallowed pill
~Fentanyl (Fentora) 100mcg rapidly dissolving transbuccal tablet"
11594737|NCT00685295|Active Comparator|Arm 2 / Percocet/Prevacid|"Active Comparator Group:
~Subject receives:
~Oxycodone/APAP (Percocet) 5/325 mg oral/swallowed pill
~Lansoprazole 15 mg (Prevacid) comparator rapidly dissolving transbuccal tablet"
11594738|NCT00685282|Other|COGNITIVE BEHAVIORAL INTERVENTIONS|PSYCHOLOGICAL INTERVENTIONS TO INCLUDE, RELAXATION, STRESS REDUCTION, GUIDED IMAGERY, BREATHING EXERCISES
11594739|NCT00685269|Active Comparator|A|eszopiclone 3 mg QD
11594740|NCT00685269|Placebo Comparator|B|placebo tablet
11594741|NCT00685243|Active Comparator|Fraxel|Fraxel laser treatment
11594742|NCT00685243|Active Comparator|PDL|Pulsed dye laser treatment
11594743|NCT00685230|Experimental|1|Alacramyn and midazolam as needed
11594744|NCT00685230|Placebo Comparator|2|placebo and midazolam as needed
11594745|NCT00685217|Experimental|TVT Secur surgical device|Single incision tape device
11594746|NCT00685217|Active Comparator|TVT surgical device|Usual care retropubic tape device
11594747|NCT00685204|Experimental|A|This is a non-random, multicenter, open label, single agent study. Patients with mailgnanat mesothelioma that has reccured or progressed following chemotherapy, and who qualify for this study, will receive oral milataxel.
11594748|NCT00685191|Experimental|1|HIV-1-infected subjects initiating raltegravir-including salvage therapy
11594749|NCT00685178|Experimental|1 topiramate + CR|topiramate and contingency reinforcement for urine sample confirming cocaine abstinence
11594750|NCT00685178|Experimental|2 topiramate + NonCR|Topiramate and random reinforcement irrespective of cocaine use
11594751|NCT00685178|Placebo Comparator|4 Placebo + NonCR|
11594752|NCT00685178|Active Comparator|3 Placebo + CR|Placebo and contingency reinforcement for urine sample confirming cocaine abstinence
11594753|NCT00685165|Experimental|Primidone 50 mg Tablets|A single dose of primidone 50 mg administered after an overnight fast of at least 10 hours.
11594754|NCT00685165|Experimental|Primidone (Mysoline®) 50 mg Tablets|A single dose of Mysoline® 50 mg administered after an overnight fast of at least 10 hours.
11594755|NCT00685152|Experimental|Active rTMS|Repetitive Transcranial Magnetic Stimulation
11594756|NCT00685152|Sham Comparator|2|Device: Sham (placebo)
11594757|NCT00685139|Experimental|Zonisamide 100 mg Capsule|A single dose of zonisamide 100 mg administered after an overnight fast.
11594758|NCT00685139|Experimental|Zonisamide (Zonegran® ) 100 mg Capsule|A single dose of Zonegran® 100 mg administered after an overnight fast.
11594759|NCT00685126|Experimental|A|"Low dose levalbuterol (0.15 mg, 0.31 mg or 0.63 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.
~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
11594760|NCT00685126|Experimental|B|"High dose levalbuterol (0.31 mg, 0.63 mg or 1.25 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.
~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
11594761|NCT00685126|Active Comparator|C|"Racemic albuterol (0.63, 1.25 mg or 2.5 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.
~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
11594762|NCT00685113|Experimental|1|
11594763|NCT00685113|Experimental|2|
11594764|NCT00685113|Placebo Comparator|3|
11594765|NCT00685074|Experimental|Brief computer-delivered intervention for drug use|A single interactive computer intervention based primarily on Motivational Interviewing principles.
11594766|NCT00685074|Placebo Comparator|Time control for drug use|An series of innocuous and therapeutically inactive computer segments.
11594767|NCT00685061|Experimental|A|Thymoglobulin Induction
11594768|NCT00685061|Experimental|B|Campath-1H Induction
11594769|NCT00685061|Experimental|C|Daclizumab Induction
11594770|NCT00685048|Experimental|1|psychoeducation
11594771|NCT00685048|Experimental|2|brief advice
11594772|NCT00685048|Experimental|3|Motivational Enhancement Therapy (MET)/Cognitive-Behavioral Therapy (CBT)
11594802|NCT00684801||DMP (experimental group)|Patients undergo a systematic approach regarding specific domains related to their disease focusing on supportive care and symptom management determined by a multidisciplinary team of providers to help patients and caregivers manage.
11595006|NCT00683423|Placebo Comparator|B|
11595007|NCT00683410||1|
11594773|NCT00685035|Active Comparator|HFCWC with higher pressure/variable frequency settings|Half patients randomly assigned to perform HFCWC therapy first with a higher pressure/variable frequency protocol. This entailed performing a 30 minute session with pressure of 10 and 5 minutes each at frequencies of 8,9, and 10 Hz followed by pressure of 6 and 5 minutes each at frequencies of 18, 19, and 20 Hz. This group subsequently crossed-over to the lower-pressure/mid-frequency HFCWC protocol after a washout period of 2 days. This entailed performing a HFCWC session using a pressure of 5 and frequency of 12 Hz for the entire 30 minute session. The other half of subjects were randomly assigned to perform the lower-pressure/mid-frequency protocol first followed by the higher pressure/mixed-frequency after the 2 day washout period
11594774|NCT00685035|Active Comparator|HFCWC with lower pressure/mid-frequency settings|lower-pressure/mid-frequency protocol first followed by the higher pressure/mixed-frequency
11594775|NCT00685022|Experimental|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses).
~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. All study drug will be administered directly without using a spacer for the entire study."
11594776|NCT00685022|Active Comparator|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. All study drug will be administered directly without using a spacer for the entire study.
11594777|NCT00685009||1|Women from the Women's Health Initiative study taking estrogen hormone therapy
11594778|NCT00685009||2|Women from the WHI study taking estrogen plus progesterone hormone therapy
11594779|NCT00685009||3|Women from the WHI study taking placebo
11594780|NCT00684996|Active Comparator|Phase II Arm I|Patients receive bevacizumab (10mg/kg) IV over 30-90 minutes on days 1 and 15.
11594781|NCT00684996|Active Comparator|Phase II Arm II|Patients receive bevacizumab IV as in arm I at the RPTD determined in phase I, and humanized monoclonal antibody MEDI-522 (8mg/kg) IV over 30 minutes on days 1, 8, 15, and 22.
11594782|NCT00684983|Active Comparator|Arm A (lapatinib ditosylate, capecitabine)|Patients receive capecitabine PO BID on days 1-14 and lapatinib ditosylate PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11594783|NCT00684983|Experimental|Arm B (cixutumumab, lapatinib ditosylate, capecitabine)|Patients receive capecitabine and lapatinib ditosylate as in Arm A. Patients also receive cixutumumab IV over 1 hour on days 1, 8, and 15. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11594784|NCT00684970|Other|Hamsa-1™ TL-118|Once daily Hamsa-1™ TL-118 (single arm)
11594785|NCT00684957|Active Comparator|1|Subject taking growth hormone
11594786|NCT00684957|Active Comparator|2|Subject taking recombinant human IGF-1
11594787|NCT00684944|Active Comparator|1|30mg tid TRx0014
11594788|NCT00684944|Active Comparator|2|60mg tid TRx0014
11594789|NCT00684931|Experimental|1|patients with Attention Deficit Disorder with or without Hyperactivity
11594790|NCT00684931|Sham Comparator|2|healthy volunteer without Attention Deficit Hyperactivity Disorder
11594791|NCT00684918|Experimental|Experimental|In the Pilot Schedule portion of the study 3 hour vs 24 hour infusion schedules of obatoclax.
11594792|NCT00684892|Experimental|1|
11594793|NCT00684866|Experimental|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (8 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (8 cumulative doses).
~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. Treatment will be administered with an AeroChamber Plus ™ spacer for the first cohort (spacer cohort) of subjects and without the AeroChamber Plus ™ spacer (non-spacer cohort) for the second cohort of subjects."
11594794|NCT00684866|Active Comparator|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. Treatment will be administered with an AeroChamber Plus ™ spacer for the first cohort (spacer cohort) of subjects and without the AeroChamber Plus ™ spacer (non-spacer cohort) for the second cohort of subjects.
11594795|NCT00684853|Active Comparator|1|
11594796|NCT00684853|Active Comparator|2|
11594797|NCT00684827|Experimental|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses).
~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. An AeroChamber Plus spacer will be utilized for each dose"
11594798|NCT00684827|Active Comparator|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. An AeroChamber Plus spacer will be utilized for each dose.
11594799|NCT00684814|Experimental|Zolpidem Tartrate 10 mg Tablets|A single dose of zolpidem tartrate 10 mg administered after an overnight fast of at least 10 hours.
11594800|NCT00684814|Experimental|Zolpidem Tartrate (Ambien®) 10 mg Tablets|A single dose of Ambien® 10 mg administered after an overnight fast of at least 10 hours.
11594803|NCT00684788|No Intervention|No Intervention|Participants were offered depot naltrexone injections and were not required to take scheduled injections to work.
11594804|NCT00684788|Experimental|Employment-based reinforcement|Participants were offered depot naltrexone injections and were required to take scheduled injections to work.
11594805|NCT00684775|No Intervention|Work Plus Naltrexone Prescription|Participants could work and earn vouchers but did not to take Vivitrol Injections to work and earn vouchers.
11594806|NCT00684775|Experimental|Work Plus Naltrexone Contingency|Participants could work and earn vouchers and had to take Vivitrol Injections to work and earn vouchers: employment-based reinforcement.
11594807|NCT00684762|Experimental|Cilostazol|A single dose of cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours.
11594808|NCT00684762|Experimental|Pletal® (cilostazol)|A single dose of cilostazol (Pletal® 1 x 100 mg tablet) administered after an overnight fast of at least 10 hours.
11594809|NCT00684723|Experimental|Lovastatin 40 mg Tablet|A single dose of Lovastatin 40 mg administered under fed conditions.
11594810|NCT00684723|Experimental|Lovastatin (Mevacor®) 40 mg Tablet|A single dose of Lovastatin (Mevacor®) 40 mg administered under fed conditions.
11594811|NCT00684710|Experimental|PAZ-417|
11594812|NCT00684710|Placebo Comparator|Placebo|
11594813|NCT00684697|Placebo Comparator|1|low iron dose
11594814|NCT00684697|Active Comparator|2|intermediate iron dose
11594815|NCT00684697|Experimental|3|High Iron dose
11594816|NCT00684684|Experimental|1|
11594817|NCT00684671|Experimental|Twinrix Group|Subjects received a single challenge dose of combined hepatitis A/hepatitis B vaccine (Twinrix).
11594818|NCT00684671|Active Comparator|Engerix + Havrix Group|Subjects received separate administration of a single challenge dose of hepatitis B vaccine (Engerix) and hepatitis A vaccine (Havrix).
11594819|NCT00684671|Active Comparator|HB VAX PRO + Vaqta Group|Subjects received separate administration of a single challenge dose of hepatitis B vaccine (HB VAX PRO) and hepatitis A vaccine (Vaqta).
11594820|NCT00684658|Experimental|1|TeenCope: Internet-based Coping Skills Training
11594821|NCT00684658|Active Comparator|2|Managing Diabetes: Internet-based Diabetes Education
11594822|NCT00684645||Patients treated with SUTENT®|Patients with metastatic or advanced renal cell carcinoma after failure of cytokines therapy.
11594823|NCT00684632|Experimental|1|KW-2246
11594824|NCT00684632|Placebo Comparator|2|Placebo
11594825|NCT00684619|Experimental|Arm A|Nelarabine
11594826|NCT00684606|Experimental|1|Transcervical Foley catheter with IV Oxytocin
11594827|NCT00684606|No Intervention|2|Transcervical Foley catheter only
11594828|NCT00684593|Experimental|Navarixin|Navarixin 30 mg administered orally once daily for 28 days.
11594829|NCT00684593|Placebo Comparator|Placebo|Matching placebo to Navarixin administered orally once daily for 28 days.
11594830|NCT00684580||Observational Group|Data Collection
11594831|NCT00684567|Experimental|Single arm|It is the only arm of the study. Subjects receive a combination of radiotherapy and temozolomide, and then temozolomide monotherapy.
11594832|NCT00684554|Active Comparator|Unobserved-at home|Buprenorphine Unobserved at home induction
11594833|NCT00684554|Active Comparator|Observed|Buprenorphine Observed in office induction
11594834|NCT00684541|Experimental|Interpretation Modification Program|The IMP procedure was identical to the word-sentence association paradigm (WSAP; Beard & Amir, 2009) except participants received feedback about their responses. Participants received positive feedback when they endorsed benign interpretations or rejected threat interpretations of the ambiguous sentences on 100% of trials and negative feedback when they endorsed threat interpretations or rejected benign interpretations on 100% of trials. This feedback manipulation was intended to reinforce a benign interpretation bias and extinguish the threat interpretation bias. Participants completed two blocks of 110 training trials in each session. Participants who completed Set A during the WSAP assessment saw Set B during the IMP and vice versa. Each IMP session lasted approximately 20 min.
11594835|NCT00684541|Placebo Comparator|Interpretation Control Condition|The ICC was identical to the IMP, except that participants received positive feedback when they endorsed threat interpretations on half (50%) of the trials and negative feedback when they endorsed threat interpretations for the remaining half (50%) of trials. This frequency was the same for benign interpretations. Thus, the control group was reinforced equally for making threat and benign interpretations. The ICC was not intended to change interpretation significantly in either direction.
11594836|NCT00684528|Active Comparator|a|This group will receive Metformin and placebo.
11594837|NCT00684528|Experimental|2|The second arm will receive Metformin and Januvia
11594838|NCT00684515|Experimental|Vorapaxar 2.5 mg + Aspirin|Vorapaxar oral tablets; once daily for 60 days + Aspirin.
11594839|NCT00684515|Experimental|Vorapaxar 1 mg + Aspirin|Vorapaxar oral tablets; once daily for 60 days + Aspirin.
11594840|NCT00684515|Placebo Comparator|Placebo + Aspirin|Placebo oral tablets; once daily for 60 days + Aspirin
11594841|NCT00684502|Experimental|1|Oral solution.
11594842|NCT00684502|Placebo Comparator|2|Oral solution
11594843|NCT00684489|Active Comparator|A; B|
11594844|NCT00684489|Active Comparator|2|Arm A is assignment to a clinical hypertension specialist Arm B is assigned renin-guided therapeutics
11594845|NCT00684489|Active Comparator|A is clinical hypertension specialist|Arm A is assigned to a clinical hypertension specialist
11594846|NCT00684489|Active Comparator|Arm B is renin-guided therapeutics|This group will be assigned to renin-guided therapeutics
11594847|NCT00684463|Experimental|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent
11594848|NCT00684450|Active Comparator|1|in vivo protamine titration in cardiac surgery. The titration is done during administration of protamine each 3 minutes to reach 2 consecutive ACT defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds. .The protamine is stopped when this values are obtain. Follow-up is done 15 minutes and 3 hours post-protamine
11594849|NCT00684450|Active Comparator|2|standard protamine administration ACT is done during administration of protamine each 3 minutes the values are recorded but the totality of protamine is given. Follow-up is done 15 minutes and 3 hours post-protamine
11594850|NCT00684437|Experimental|Factual Gain-Framed|Smoking Risk Message - Factual Gain-Framed (FGF)
11594852|NCT00684437|Experimental|Emotional Gain-Framed|Smoking Risk Message - Emotional Gain-Framed (EGF)
11594853|NCT00684437|Experimental|Emotional Loss-Framed|Smoking Risk Message - Emotional Loss-Framed (ELF)
11594854|NCT00684424||Outpatients with epilepsy|
11594855|NCT00684411|Experimental|Imatinib mesylate|The initial starting dose of imatinib mesylate was 400 mg by mouth once daily but intra-patient dose escalation for patients who did not achieve complete response (CR) was built in upon restaging at weeks 8 and 16. At week 8, patients with partial response (PR) or stable disease (SD) were dose escalated to 600 mg. At week 16, if these patients continued in PR or SD, dose escalated to 800 mg and for patients on 400 mg dose escalated to 600 mg. Patients who experienced disease progression could be dose escalated per MD discretion. Patients were treated as long as receiving clinical benefit and no unacceptable toxicity.
11594856|NCT00684346|Experimental|1|
11594857|NCT00684333|Experimental|group 1|volunteers
11594858|NCT00684320|Active Comparator|2 Placebo Condition (PC)|The placebo, group will complete the PC procedure, which is identical to the ADT procedure except that during the presentation of the trials where a disgust or angry face is present, the probe will appear with equal frequency in the position of disgust or angry and neutral face. Thus, disgust, angry nor neutral face will have signal value regarding the position of the probe.
11594859|NCT00684320|Experimental|1 Attention Disengagement Training (ADT)|Those assigned to ADT condition will receive a computer delivered attention retraining protocol designed to enhance attention disengagement from socially threatening stimuli. The ADT protocol includes eight 30-min sessions delivered over a 6-week period (i.e., bi-weekly sessions). During each session, participants will see 320 trials that consist of the various combinations of probe type (E or F) probe position (top or bottom), and emotion type (Neutral, Disgust, Anger). 256 trials will include one neutral face and one disgust face or one angry face: 2 (probe type) X 2 (probe position) X 16 (person) X 4 (repetitions). On trials where participants see one neutral face and one disgust or angry face (i.e., 80% of the trials), the probe will always follow the neutral face.
11594860|NCT00684307|Experimental|1|AZD0837 450 mg
11594861|NCT00684307|Experimental|2|AZD0837 200 mg
11594862|NCT00684307|Experimental|3|AZD0837 300 mg
11594863|NCT00684307|Experimental|4|AZD0837 150 mg
11594864|NCT00684307|Active Comparator|5|Vitamin-K antagonist at INR 2-3
11594865|NCT00684294|Experimental|TAG Vaccine 1 x 10^7 cells/ injection|TAG Vaccine 1 x 10^7 cells/injection
11594866|NCT00684294|Experimental|TAG Vaccine 2.5 X 10^7 cells/injection|TAG Vaccine 2.5 X 10^7 cells/injection
11594867|NCT00684281|Other|1|Subject control
11594868|NCT00684281|Experimental|2|40 patients before hand include in a program
11594869|NCT00684268|Experimental|on treatment nonresponders|naive patients with null response to peginterferon/ribavirin at week 12 or partial response at week 24
11594870|NCT00684268|Experimental|Nonresponders to previous antiviral combination therapy|Nonresponders defined by viral status at weeks 4,12, and 24 of previous peginterferon/ribavirin combination therapy
11594871|NCT00684255|Experimental|Reduced Intensity Regimen for Refractory SLE|RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with medically refractory Systemic Lupus Erythematosus (SLE).
11594872|NCT00684255|Experimental|Reduced Intensity Regimen for SSc|RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with Systemic Sclerosis (SSc).
11594873|NCT00684242|Experimental|Lenalidomide|10 mg by mouth daily
11594874|NCT00684229|Active Comparator|Regional anesthesia and analgesia|Regional anesthesia and analgesia (either epidural or paravertebral anesthesia).
11594875|NCT00684229|Active Comparator|general anesthesia followed by opioid analgesia|Subjects randomized to arm 2 will receive general anesthesia followed by opioid analgesia.
11594876|NCT00684216|Active Comparator|1|capecitabine followed by hormonal treatment
11594877|NCT00684216|Active Comparator|2|hormonal treatment followed by capecitabine
11594878|NCT00684203|Experimental|Vorapaxar 20 mg/1 mg|Vorapaxar 20 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
11594879|NCT00684203|Experimental|Vorapaxar 20 mg/2.5 mg|Vorapaxar 20 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
11594880|NCT00684203|Experimental|Vorapaxar 40 mg/1 mg|Vorapaxar 40 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
11594881|NCT00684203|Experimental|Vorapaxar 40 mg/2.5 mg|Vorapaxar 40 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
11594882|NCT00684203|Placebo Comparator|Placebo|Placebo loading dose + daily placebo maintenance dose + standard of care (Aspirin + Ticlopidine)
11594883|NCT00684190|Experimental|1|AZD3355 150 mg
11594884|NCT00684190|Experimental|2|Esomeprazole 40mg
11594885|NCT00684190|Experimental|3|AZD3355 150mg/Esomeprazole 40mg
11594886|NCT00684177|Experimental|Retapamulin Ointment, 1%|
11594887|NCT00684177|Placebo Comparator|Placebo Ointment|
11594888|NCT00684164|Experimental|1|Subjects in the treatment group will receive standard medical treatment plus Conivaptan administered as a 20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
11594889|NCT00684164|Placebo Comparator|2|Subjects in the placebo control group will receive an equivalent volume loading dose of D5 followed by an infusion of D5 in the same manner as the experimental group.
11594890|NCT00684151||1|Patients with high cardiovascular risk who have been treated with lipid-lowering drugs at least 3 months
11594891|NCT00684138|Experimental|ReSTOR Aspheric +3.0D|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens
11594892|NCT00684138|Active Comparator|ReSTOR Aspheric +4.0D|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens
11594893|NCT00684125|Experimental|1|mediastinal drainage will be accomplished using a 28F or 32F chest tube in the anterior mediastinum and a 19F Blake drain located in the posterior pericardial cavity.
11594894|NCT00684125|Active Comparator|2|mediastinal drainage will be accomplished using two 28F or 32F chest tubes located in the anterior mediastinum.
11594895|NCT00684112|Experimental|Gabapentin|Single dose preoperative gabapentin
11594896|NCT00684112|Placebo Comparator|Placebo Control|Single dose preoperative placebo control
11594897|NCT00684099|Experimental|1|
11595136|NCT00682305|Other|Single-Arm|Single-Arm
11594898|NCT00684073|Experimental|Subutex®/Suboxone®|Subutex® for first two days of study followed by Suboxone® for last 3 days of study
11594899|NCT00684060|Experimental|1|Participants will receive active stem cell infusion 2 to 3 weeks after a percutaneous coronary intervention (PCI).
11594900|NCT00684060|Placebo Comparator|2|Participants will receive placebo infusion (5% human serum albumin [HSA]) 2 to 3 weeks after a PCI.
11594901|NCT00684047|Experimental|FS Grifols Preliminary Part (I)|Open label administration of FS Grifols to all subjects
11594902|NCT00684047|Experimental|FS Grifols Primary Part (II)|Single-blind, randomized (2:1)
11594903|NCT00684047|Active Comparator|Manual Compression Primary Part (II)|Single-blind, randomized (2:1)
11594904|NCT00684034|Other|1|Volunteer healthy
11594905|NCT00684034|Other|2|Patient dialysis patient
11594906|NCT00684034|Other|3|Not dialysed chronic renal insufficient patient
11594907|NCT00684021|Active Comparator|1|Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).
11594908|NCT00684021|Active Comparator|2|Participants will receive active adult stem cell infusion 7 days after PCI.
11594909|NCT00684021|Placebo Comparator|3|Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.
11594910|NCT00684021|Placebo Comparator|4|Participants will receive placebo infusion (5% HSA) 7 days after PCI.
11594911|NCT00684008|Experimental|I|"Single arm dose escalation study. Three successive cohorts of 3 patients each. Doses to be evaluated: 10, 20, and 30 mcg/kg/dose for 3 consecutive doses.
~CYT107 is a recombinant protein belonging to the class of growth factors known as cytokines.
~CYT107 is a heavily glycosylated and sialylated form of recombinant human Interleukin-7.
~CYT107 is supplied as a sterile colorless liquid at a concentration of 4 mg/ml."
11594912|NCT00683995|Experimental|1|KW-2246 (fentanyl citrate)
11594913|NCT00683982|Active Comparator|1|This group will receive oral nitazoxanide preparation
11594914|NCT00683982|Active Comparator|2|This group will receive a mix combination of probiotics
11594915|NCT00683982|Placebo Comparator|3|This is the control group receiving only oral or systemic hydration solutions
11594916|NCT00683969|Experimental|1|
11594917|NCT00683969|Placebo Comparator|2|
11594918|NCT00683930|Experimental|Mycophenolate Mofetil (MMF) 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
11594919|NCT00683930|Experimental|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
11594920|NCT00683930|Placebo Comparator|Placebo|
11594921|NCT00683917|Experimental|Proellex 25 mg|Proellex 25 mg
11594922|NCT00683917|Experimental|Proellex 50 mg|Proellex 50 mg
11594923|NCT00683917|Active Comparator|Lupron|Lupron Depot
11594924|NCT00683904|Active Comparator|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|
11594925|NCT00683904|Active Comparator|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|
11594926|NCT00683878|Experimental|Arm 1|
11594927|NCT00683878|Experimental|Arm 2|
11594928|NCT00683878|Placebo Comparator|Arm 3|
11594929|NCT00683865|Active Comparator|Arm 1|
11594930|NCT00683865|Experimental|Arm 2|
11594931|NCT00683852|Active Comparator|Drug 2mg/Drug 5mg|patients randomly assigned to the drug/drug sequence, the dose of aripiprazole will be 2 mg/day during the first phase of the study, and 5 mg/day in the second phase.
11594932|NCT00683852|Active Comparator|Placebo/Drug 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study.
11594933|NCT00683852|Placebo Comparator|Placebo/Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study.
11594934|NCT00683839|Experimental|2|"Dental practitioners provide the following intervention:
~5As plus nicotine replacement therapy The 5As consist of: Ask, Advise, Assess, Assist and Arrange."
11594935|NCT00683839|No Intervention|1|Usual Care Control: Patients receive treatment as usual.
11594936|NCT00683826|Experimental|L-Leucine 4grams|This will be a triple arm design where subjects will be randomized into three groups. Arm #1 will be 4g of Leucine.
11594937|NCT00683826|Experimental|L-Leucine 8 grams|Arm number two of the study will be a dose of Leucine of 8g.
11594938|NCT00683826|Placebo Comparator|L-Leucine 0 grams|The third arm of the study will be composed of a control drink with no leucine in it.
11594939|NCT00683813|No Intervention|UC|usual care
11594940|NCT00683813|Experimental|vCRP|
11594941|NCT00683800|Experimental|1|desvenlafaxine succinate (DVS) SR
11594942|NCT00683800|Placebo Comparator|2|Placebo
11594943|NCT00683787|Active Comparator|Arm I|Patients receive docetaxel IV once every 3 weeks.
11594944|NCT00683787|Experimental|Arm II|Patients receive docetaxel IV as in arm I and oral vandetanib (100 mg) once daily.
11594945|NCT00683787|Experimental|Arm III|Patients receive docetaxel IV as in arm I and oral vandetanib (300 mg) once daily.
11594946|NCT00683774|Experimental|PCOS subjects|PCOS subjects given diazoxide
11594947|NCT00683774|Active Comparator|Normal subjects|Normal subjects given diazoxide
11594948|NCT00683761|Experimental|1|
11594949|NCT00683748||Kidney transplant|
11594950|NCT00683748||Liver transplant|
11594951|NCT00683735|Active Comparator|Treatment A|sitagliptin and placebo
11594952|NCT00683735|Active Comparator|Treatment B|placebo and metformin
11594953|NCT00683735|Active Comparator|Treatment C|sitagliptin and metformin
11594954|NCT00683735|Placebo Comparator|Treatment D|placebo
11594955|NCT00683722|Experimental|PROCHYMAL™|PROCHYMAL™
11594956|NCT00683722|Placebo Comparator|Placebo|Placebo
11594957|NCT00683709||Counselling as Usual|Discussing Clozapine medication, diet and exercise as per clinical protocol potential weight changes
11594958|NCT00683709||Cognitive Behavoural Therapy|Counselling about Clozapine medication, diet and exercise in a structured fashion using Cognitive Behavioural Therapy about potential weight changes
11594959|NCT00683696|Experimental|CRT=ON|Cardiac Resynchronization Therapy activated.
11594960|NCT00683696|Active Comparator|CRT=OFF|Cardiac Resynchronization Therapy deactivated.
11594961|NCT00683683|Other|Cooling|Cardiac arrest patients will be cooled to 32-34°C within 6 hours of ED arrival
11594962|NCT00683670|Experimental|Dendritic Cell Vaccine (First Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 3 weeks for a total of 6 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 and dose #6 in order to collect PBMC for immune monitoring. Patients with stable disease or better after 6 doses will be eligible to receive additional vaccinations as maintenance therapy every 2 months until progression.
11594963|NCT00683670|Experimental|Dendritic Cell Vaccine (Second Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 3 weeks for a total of 6 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 and dose #6 in order to collect PBMC for immune monitoring. Patients with stable disease or better after 6 doses will be eligible to receive additional vaccinations as maintenance therapy every 2 months until progression.
11594964|NCT00683670|Experimental|Dendritic Cell Vaccine (Third Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 6 weeks for a total of 3 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 in order to collect PBMC for immune monitoring.
11594965|NCT00683657|Experimental|Saxagliptin 5 mg + Metformin|
11594966|NCT00683657|Placebo Comparator|Placebo + Metformin|
11594967|NCT00683644|Experimental|1 - zinc placebo|Zinc sulfate (50 mg elemental zinc) taken once daily for 4 months. Washout 1 month. Placebo oral capsule taken once a day for 4 months.
11594968|NCT00683644|Experimental|2 - placebo zinc|Placebo oral capsule taken once a day for 4 months. Washout 1 month. Zinc sulfate (50 mg elemental zinc) taken once daily for 4 months.
11594969|NCT00683631|Experimental|TheraSphere|TheraSphere
11594970|NCT00683618|Experimental|1|Rosuvastatin 5mg qd
11594971|NCT00683618|Experimental|2|Rosuvastatin 10mg qd
11594972|NCT00683618|Active Comparator|3|Atorvastatin 10mg qd
11594973|NCT00683592|Experimental|1|vilazodone
11594974|NCT00683592|Placebo Comparator|2|
11594975|NCT00683579||1|Participants with CD4+ T cells above 350 cells/mm3 and HIV RNA >1,000 copies/ml who are initiating HAART with possibility of de-intensification (early treatment).
11594976|NCT00683579||2|Participants with CD4+ T cells above 350 cells/mm3 and HIV RNA >1,000 copies/ml who are not initiating treatment.
11594977|NCT00683579||3|Participants with CD4+ T cells < 350 cells/mm3 who are initiating treatment.
11594978|NCT00683579||4|Participants with CD4+ T cells < 350 cells/mm3 who are not initiating treatment.
11594979|NCT00683566|Experimental|1|A session in condition ON DOPAMINE and the other one in condition OFF DOPAMINE.
11594980|NCT00683553|Experimental|I5NP drug|
11594981|NCT00683553|Placebo Comparator|Placebo|
11594982|NCT00683527|Experimental|1|Starting oral iron at day 14 of life (Early Iron group)
11594983|NCT00683527|No Intervention|2|No iron supplementation till 60 days of life (Control group)
11594984|NCT00683514|Other|A|"cycle 1 & 2 (q 28 days) = chemotherapy : oral vinorelbine (50 mg/m2 d1, d8, d15) and cisplatin (20 mg/m2/d from d1 to d4) combined with radiotherapy
~cycle 3 & 4 (q 21 days) = chemotherapy : oral vinorelbine (60 mg/m2 d1, d8 for cycle 1, 80 mg/m2 d1 & d8 for cycle 2) and cisplatin (80 mg/m2 d1) plus Best Supportive Care"
11594985|NCT00683514|Other|B|"cycle 1 & 2 (q 28 days) = chemotherapy : oral vinorelbine (50 mg/m2 d1, d8, d15) and cisplatin (20 mg/m2/d from d1 to d4) combined with radiotherapy
~Best Supportive Care only"
11594986|NCT00683501|Experimental|1|dosage X mg BID
11594987|NCT00683501|Experimental|2|dosage Y mg BID
11594988|NCT00683501|Experimental|3|dosage Z mg BID
11594989|NCT00683501|Experimental|4|dosage 2Z mg BID
11594990|NCT00683501|Placebo Comparator|5|Placebo BID
11594991|NCT00683488|Experimental|1|Focus groups with adolescents with SA (Substance Abuse) will be conducted at each site (one group with 5 to 6 adolescents per site) to provide information on the areas of the intervention in need of adaptation in order to reflect the context of HIV infection.
11594992|NCT00683488|Experimental|2|The first intervention trial will enroll 9 participants (3 participants per site). Exit interviews of participants will assess acceptability, feasibility, and relevance of the intervention. Quantitative assessments pre and post intervention using audio computer-assisted self-interviewing (ACASI) will document immediate changes in substance use, sexual risk, and adherence to medical care. Additional qualitative feedback from interviews with mental health providers and study coordinators will address feasibility, acceptability, and relevance of the intervention and its methods.
11594993|NCT00683488|Experimental|3|The revised intervention will be implemented with 20 participants (6 to 8 at each site). Exit interviews with subjects and feedback from mental health providers and study coordinators will provide the same qualitative information as in the first intervention trial. Quantitative data on participant outcomes such as substance use, sexual risk, and adherence to medical care will be collected pre, post and 3 month post intervention through ACASI.
11594994|NCT00683475|Experimental|IMC-1121B (ramucirumab) + Mitoxantrone + Prednisone|
11594995|NCT00683475|Experimental|IMC-A12 + Mitoxantrone + Prednisone|
11594996|NCT00683462|Placebo Comparator|1|
11594997|NCT00683462|Experimental|2|
11594998|NCT00683462|Experimental|3|
11594999|NCT00683449|Experimental|IV infusion of MN-221|MN-221 total dose of 240 mcg
11595000|NCT00683449|Placebo Comparator|MN-221 PLACEBO|i.v. infusion of MN-221 Placebo for 15 min
11595001|NCT00683436|Experimental|1|adipiplon 6 mg
11595002|NCT00683436|Experimental|2|adipiplon 9 mg
11595003|NCT00683436|Placebo Comparator|3|Placebo
11595004|NCT00683436|Experimental|4|Ambien CR 12.5 mg
11595008|NCT00683397||A|Patients with acute or previous venous thromboembolism >18 years of age
11595009|NCT00683384||1|
11595010|NCT00683371|Active Comparator|1|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery
11595011|NCT00683371|Placebo Comparator|2|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery.
11595012|NCT00683358|Experimental|1|
11595013|NCT00683345|Active Comparator|Anakinra|Anakinra self-administered s.c. in a dose of 100mg daily
11595014|NCT00683345|Placebo Comparator|Placebo|Placebo self-adminsitered s.c in a dose 0.67ml daily
11595015|NCT00683332||A|
11595016|NCT00683293|Active Comparator|1|Randomized group of patients receiving conventional laparoscopic hysterectomy
11595017|NCT00683293|Active Comparator|2|Randomized group of patients receiving robot-assisted laparoscopic hysterectomy
11595018|NCT00683280|Active Comparator|Standard of Care|Medication (varenicline) for 12 weeks (Day 1 through 84) and brief counseling based on public health service guidelines for 5 weeks (Day 1 through 35).
11595019|NCT00683280|Experimental|Standard of Care plus Contingency Management|Medication (varenicline) for 12 weeks (Day 1 through 84), brief counseling based on public health service guidelines for 5 weeks (Day 1 through 35), plus prize-based contingency management for carbon monoxide samples and urinary cotinine samples that meet smoking abstinence criteria.
11595020|NCT00683267|Experimental|1|Study treatment, 4975, is instilled directly into surgical site
11595021|NCT00683267|Placebo Comparator|2|Placebo is instilled directly into surgical site
11595022|NCT00683241|Experimental|1|Subjects with stage II to IV recurrent epithelial ovarian carcinoma or recurrent primary peritoneal cancer, from whom solid tumor, ascites or pleural effusion will be harvested and available and sufficient for lysate preparation; and whose largest tumor nodule is ≤ 2.5 cm. Subjects may have undergone chemotherapy or other therapy following tumor harvesting and prior to enrollment (apheresis).
11595023|NCT00683228|Other|Counseling|some caregivers will be provided counseling related to the hazards of secondhand smoke exposure
11595024|NCT00683202|Active Comparator|1|Acetylsalicylic acid 100 mg daily perorally
11595025|NCT00683202|Placebo Comparator|2|Placebo daily perorally
11595026|NCT00683176|Active Comparator|1|
11595027|NCT00683176|Placebo Comparator|2|
11595028|NCT00683163|Active Comparator|A: 6 months both + 18 months oral only|Group A will receive 6 months of monthly oral ibandronate 150 mg, plus daily PTH 1-84, 1.4 mg; followed by 18 months of ibandronate only. Placebo injections will be given months 13-15. Calcium + Vitamin D supplements, plus multivitamins are provided.
11595029|NCT00683163|Active Comparator|B: (3 months injection + 9 months oral) x 2 years|Group B will receive 3 months of daily PTH 1-84, 1.4 mg; followed by 9 months of monthly oral ibandronate, 150 mg in year 1. In year 2, the group will receive another 3 months of daily PTH 1-84; followed by 9 months of monthly ibandronate. Placebo monthly pills will be given months 1-3 and months 13-15, and placebo injections will be given months 4-6. Calcium + Vitamin D supplements, plus multivitamins are provided.
11595030|NCT00683150||Endothelial Function Test|Patients scheduled to have major abdominal or thoracic surgery.
11595031|NCT00683137|Active Comparator|Arm 1|
11595032|NCT00683137|Active Comparator|Arm 2|
11595033|NCT00683137|Active Comparator|Arm 3|
11595034|NCT00683124|Experimental|Losartan|Losartan administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 100 mg/day for adults and 1,6 mg/kg/die for children minor than 16 years.
11595035|NCT00683124|Experimental|Nebivolol|Nebivolol administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 10 mg/day for adults and 0,16 mg/kg/die for children minor than 16 years.
11595036|NCT00683124|Experimental|Losartan+Nebivolol|"Losartan administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 100 mg/day for adults and 1,6 mg/kg/die for children minor than 16 years.
~Nebivolol administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 10 mg/day for adults and 0,16 mg/kg/die for children minor than 16 years."
11595037|NCT00683111|Active Comparator|1|oral esomeprazole 20 mg daily
11595038|NCT00683111|Active Comparator|2|oral famotidine 40mg daily
11595039|NCT00683098||1|patients, who had a endoscopic total extraperitoneal repair of recurrent inguinal hernia between 1995 and 2008
11595040|NCT00683085|Experimental|Peptide vaccination|VEGFR1-derived HLA-A*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the safety and efficacy of this type of peptide.
11595041|NCT00683072||1|
11595042|NCT00683059|Experimental|Nab-paclitaxel|
11595043|NCT00683046|Experimental|Drug Intervention|
11595044|NCT00683033|Active Comparator|A|Brief counseling based on public health service guidelines.
11595045|NCT00683033|Experimental|B|Brief counseling based on public health service guidelines for quitting smoking plus prize-based contingency management
11595046|NCT00683020|Active Comparator|ATSM Intervention|ATSM Intervention: Automated Telephone Self-Management Support.
11595047|NCT00683020|No Intervention|WAIT LIST Control|WAIT LIST Control: six month Wait List.
11595048|NCT00683007|Active Comparator|1|Crystalloid
11595049|NCT00683007|Active Comparator|2|Hypertonic Saline
11595050|NCT00682994|Other|Decision Making|Questionnaire + Interview
11595051|NCT00682981|Experimental|Phase I A|Obatoclax for 3 hours for 3 days with carboplatin/etoposide.
11595052|NCT00682981|Experimental|Phase I B|Obatoclax for 24 hours for 3 days with carboplatin/etoposide.
11595053|NCT00682981|Experimental|Phase II A|Obatoclax for 3 hours for 3 days with carboplatin/etoposide.
11595054|NCT00682981|Active Comparator|Phase II B|Carboplatin/etoposide without continued study treatment
11595055|NCT00682955|Active Comparator|B|This group has been given Zinc Sulphate in Suspension Form.
11595056|NCT00682955|Active Comparator|A|This group has been given Tablets of Zinc Sulphate.
11595057|NCT00682929|Active Comparator|1) Inhaled Cannabis|Inhaled cannabis is compared to oral placebo.
11595058|NCT00682929|Active Comparator|2) Oral THC|Inhaled placebo is compared to oral THC.
11595059|NCT00682929|Placebo Comparator|3) Placebo|Inhaled placebo is compared to oral placebo.
11595060|NCT00682916|Active Comparator|1|"Subjects will fast prior to the initial visit. Subjects' weight, blood pressure and heart rate will be recorded, waist and hip circumferences measured, and body composition determined. They will receive either the soluble fiber or placebo tablets, in a coded bottle. They will be instructed to take 2 tablets per fat containing meal, 3 times a day within one hour of consuming the meal. They will also be asked to keep records of missed doses and any gastrointestinal symptoms (e.g.: heartburn, indigestion, diarrhea, constipation). During the 4th week, they will be asked to record food intakes for 3 days.
~After taking the supplement for 4 weeks, the participants will return to the clinic after an overnight fast. During this visit, they will turn in their 3-day dietary record. The studies performed during the initial baseline visit will be repeated. At this visit they receive the alternate supplement (placebo or active tablets) in a identical-looking coded bottle."
11595061|NCT00682916|Placebo Comparator|2|"Subjects will fast prior to the initial visit. Subjects' weight, blood pressure and heart rate will be recorded, waist and hip circumferences measured, and body composition determined. They will receive either the soluble fiber or placebo tablets, in a coded bottle. They will be instructed to take 2 tablets per fat containing meal, 3 times a day within one hour of consuming the meal. They will also be asked to keep records of missed doses and any gastrointestinal symptoms (e.g.: heartburn, indigestion, diarrhea, constipation). During the 4th week, they will be asked to record food intakes for 3 days.
~After taking the supplement for 4 weeks, the participants will return to the clinic after an overnight fast. During this visit, they will turn in their 3-day dietary record. The studies performed during the initial baseline visit will be repeated. At this visit they receive the alternate supplement (placebo or active tablets) in a identical-looking coded bottle."
11595062|NCT00682903|Experimental|1|This arm will benefit from the nonstop measure of the subcutaneous glucose during the hospitalization and the week on returning to the place of residence,
11595063|NCT00682890|Placebo Comparator|1|Placebo tablet and birth control pill daily
11595064|NCT00682890|Active Comparator|2|metformin 2000 mg and birth control pill daily
11595065|NCT00682877||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
11595066|NCT00682877||Gastroparesis|Subjects with documented gastroparesis
11595067|NCT00682838|Experimental|Self-Management (SM)|Active Intervention - Self-management: Self-management Educational component focused on sleep apnea and CPAP from a self-management perspective
11595068|NCT00682838|Active Comparator|Telemonitored Care (TC)|Active Comparator - Telemonitored care: Telemonitored care Consists of CPAP therapist actively monitoring care at a distance, and acting on that data per a set protocol
11595069|NCT00682838|Experimental|SM + TC|Self-management and Telemonitored care: Combination of both SM + TC intervention
11595070|NCT00682838|No Intervention|Usual care (UC)|Control Group
11595071|NCT00682825|Experimental|1|Bispectral index-guided protocol
11595072|NCT00682825|Active Comparator|2|End-tidal anesthetic gas-guided protocol
11595073|NCT00682812|Active Comparator|1|125 womens with normal cervix
11595074|NCT00682812|Other|2|105 womens with an intraepithelial lesion
11595075|NCT00682812|Other|3|105 womens with a cancer of the cervix
11595076|NCT00682786|Experimental|Good Risk (Thymidylate Synthase (TYMS)*2/*2, *2/*3, *2/*4)|"Radiation 45 Gy in 25 fractions to the pelvis.
~5FU CIVI 225 mg/m2/day by CIVI during radiation
~Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable."
11595077|NCT00682786|Experimental|Poor Risk (Thymidylate Synthase (TYMS)*3/*3, *3/*4)|"Radiation 45 Gy in 25 fractions to the pelvis.
~5FU CIVI 225 mg/m2/day by CIVI during radiation
~Irinotecan 50 mg/m2 IV weekly for 5 doses.
~Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable."
11595078|NCT00682773|No Intervention|1|Usual care, no educational intervention.
11595079|NCT00682773|Experimental|2|Usual care, nursing home nursing staff receive educational intervention on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
11595080|NCT00682760|Active Comparator|1|Korean botulinum toxin A treatment
11595081|NCT00682760|Placebo Comparator|2|Botox treatment
11595082|NCT00682747|Experimental|HBO|40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen)
11595083|NCT00682747|No Intervention|non HBO|
11595084|NCT00682734|Active Comparator|1|Metoclopramide 10 mg+ diphenhydramine 25 mg. This medication was administered as an intravenous drip over 20 minutes
11595085|NCT00682734|Experimental|2|metoclopramide 20 mg + diphenhydramine 25 mg. Administered as an intravenous drip over 20 minutes.
11595086|NCT00682734|Experimental|3|metoclopramide 40 mg + diphenhdyramine 25mg. Administered as an intravenous drip over 20 minutes.
11595087|NCT00682721|Active Comparator|2|Valacyclovir 1 gm daily x number of days active in the study
11595088|NCT00682721|Placebo Comparator|1|
11595089|NCT00682695||1|"Participants who have had a hemorrhagic stroke at University of Maryland, University of Cincinnati, Massachusetts General Hospital, Duke University, Columbia University and University of Chicago Illinois, age 18 years or greater. Ability of the patient or legal representative to provide informed consent. Racial/ethnic category meets one of the following: African American, Caucasian or Hispanic.
~Healthy volunteers who are matched to the study cases with hemorrhagic stroke within +/- 5 years of age, same gender and same race."
11595090|NCT00682682|Experimental|1|all study participants will have 4 visits: VR alone, VR + opioid, opioid alone, and no VR/opioid
11595091|NCT00682669|Experimental|MBSR|A mindfulness-based stress reduction (MBSR) program consisting of an 8-week, 9-session intervention based on systematic and intensive training in mindfulness meditation and mindful hatha yoga and their application to every day life.
11595092|NCT00682669|Active Comparator|HLC|A Healthy Living Course (HLC) consisting of an 8-week program of lectures and discussion on health-related topics.
11595093|NCT00682656|Active Comparator|A - N- methyl glucamine|Glucantime® , max day of 1,215 mg
11595094|NCT00682656|Experimental|B - Azithromycin|Zithromax ® , one dose 500 mg
11595095|NCT00682643|Placebo Comparator|vehicle placebo nasal spray|
11595096|NCT00682643|Active Comparator|fluticasone furoate nasal spray|
11595135|NCT00682318|Active Comparator|Safflower Oil|Omega-6 polyunsaturated fatty acids (n-6 PUFA)
11595097|NCT00682630|Experimental|Study Group 1|Study Period 1: Treatment A (clinical trial reference tablets) 43 Days wash out Study Period 2: Treatment B (to-be-marketed tablets) 43 Days follow-up
11595098|NCT00682630|Experimental|Study Group 2|Study Period 1: Treatment B (to-be-marketed tablets) 43 Days wash out Study Period 2: Treatment A (clinical trial reference tablets). 43 Days follow-up
11595099|NCT00682617|Experimental|Waitlist Control|Delayed intervention. 3 months on waitlist, crossover to intervention (3 additional months)
11595100|NCT00682617|Experimental|3 Month Exercise Program|3 month exercise program
11595101|NCT00682578|Experimental|Artekin|Dihydroartemisinin+ Paperaquine (DHA+PPQ, Artekin)
11595102|NCT00682578|Active Comparator|Standard treatment|"The standard treatment for uncomplicated falciparum and vivax malaria are as follows:
~Uncomplicated falciparum: artesunate-sulphadoxin/pyrimethamine Vivax malaria: chloroquine"
11595103|NCT00682565|Experimental|Mid Dose CK-1827452 or Placebo|CK-1827452 I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr or placebo, followed by 6 days three times a day oral dose and a final single oral dose
11595104|NCT00682565|Experimental|High Dose CK-1827452 or Placebo|CK-1827452 I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr or placebo, followed by 6 days three times a day oral dose and a final single oral dose
11595105|NCT00682552|Experimental|1|"A cervico-vaginal cervical smear will be realized before every colposcopique examination.
~A new cervical taking for the search(research) and the detection of the HPV 16 and 18 will be realized."
11595106|NCT00682539|Active Comparator|Avastin|15 patients with clinical significant macular edema receive an injection of 2,5 mg Avastin every month. After three initial injections of Avastin re-injection is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns a sham injection is performed.
11595107|NCT00682539|Active Comparator|Triamciolone|30 patients with a clinical significant diabetic macular edema receive an intraocular injection of 8mg triamcinolone at baseline under sterile conditions. 1 and 2 month after the baseline injection, patients receive a sham injection. After three month re-injection of 8mg Triamcinolone is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns patients will receive a sham injection. In between two injection of 8mg Triamcinolone must be an temporal interval of at least 3 months.
11595108|NCT00682539|Active Comparator|Lucentis|15 patients with clinical significant macular edema receive an injection of 0,5 mg Lucentis every month. After three initial injections of Lucentis re-injection is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns a sham injection is performed.
11595109|NCT00682526||Pre-study Period (Group 1 and Group 2).|"The TIME-MC study was conducted from June 2003 to June 2008 at NEMC (Figure 1) and from May 2005 to September 2008 at the six larger medical centers (Figure 2). Two groups were studied. Group 1 included patients at NEMC and Group 2 included patients at the other six medical sites. The study was divided into three periods:
~Pre-study period (Group 1 and Group 2). No PH-ECG transmission system was available."
11595110|NCT00682526||Study Period (Group 1 and Group 2)|Study period (Group 1 and Group 2). PH-ECG transmission to a cardiologist's hand-held device was attempted through pre-assigned EMS ambulances equipped with a wireless ECG transmission device in addition to a STEMI code system. In Group 1, this referred to the pilot study at NEMC from June 2003 to May 2005.
11595111|NCT00682526||Post-study period (Group 1)|Post-study period (Group 1). PH-ECG transmission and a STEMI code system implemented after the pilot study period.
11595112|NCT00682513||ATP1A3 Mutation|Those with RDP, AHC, CP, unaffected carriers of ATP1A3 mutations, and non-carrying family members
11595113|NCT00682500|Experimental|1|Calfactant treatment
11595114|NCT00682500|Placebo Comparator|2|
11595115|NCT00682487||1|patients admitted to the cardiology department with acute Myocardial infarction.
11595116|NCT00682487||2|patients admitted to an internal medicine department due to reasons other than an acute thrombotic event
11595117|NCT00682474|Experimental|CI|Four 30-minute individual student-centered smoking cessation counseling intervention sessions delivered by school nurses to adolescent smokers in grades 9-12
11595118|NCT00682474|Active Comparator|II|Attention-control comparison condition consisting of four individual sessions with the school nurse to check smoking status and deliver a series of standardized pamphlets on smoking and cessation to adolescent smokers in grades 9-12
11595119|NCT00682461|Active Comparator|Marketed formulation|Marketed nicotine replacement therapy product
11595120|NCT00682461|Experimental|prototype|Nicotine prototype
11595121|NCT00682448|Active Comparator|1|Olanzapine plus metformin: olanzapine plus metformin 500 mg titrated up to but no greater than 2,000 mg based upon fasting blood glucose during study visits over six months.
11595122|NCT00682448|Placebo Comparator|2|Olanzapine plus Drug: Placebo. Subjects will remain on olanzapine plus placebo for 6 months.
11595123|NCT00682435|Experimental|Hydromorphone|1 mg IV hydromorphone, + optional 1 mg IV hydromorphone 15 minutes later
11595124|NCT00682422||Parent & Child Dyad|
11595125|NCT00682409|Other|1|Analysis of the value of the imaging of distribution and the late sequence to differentiate the cholesteatoma of the fibrosis in the follow-up operating post at the child
11595126|NCT00682383|Other|ARM 1|"Cisplatin 75 mg/m2 day 1 and 22
~Etoposide 80mg/m2 days 1-3, 22-24
~Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)
~Filgrastim 5µg/kg* SQ injection days 4-13 and days 25-34
~Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles
~Pegfilgrastim 6 mg SQ injection day 2 of each cycle"
11595127|NCT00682370|Experimental|A1|0.3 mg/kg heme arginate
11595128|NCT00682370|Experimental|A2|1 mg/kg heme arginate
11595129|NCT00682370|Experimental|A3|3 mg/kg heme arginate
11595130|NCT00682370|Placebo Comparator|P|Placebo
11595131|NCT00682357|Experimental|1|Methylprednisone 80 mg and Lidocaine 20 mg
11595132|NCT00682357|Experimental|2|Methylprednisolone 16 mg and Lidocaine 20 mg
11595133|NCT00682357|Placebo Comparator|3|Placebo and Lidocaine 20 mg
11595134|NCT00682318|Experimental|Fish oil|Omega-3 polyunsaturated fatty acids (n-3 PUFA)
11595137|NCT00682292|Active Comparator|1, ATG|Thymoglobulin induction during 8 days (1.25 mg/kg per day) associated with tacrolimus, mycophenolate mofetil and steroids
11595138|NCT00682292|Active Comparator|2, Daclizumab|Dacluzamb induction (five infusions, 1 mg/kg per infusion) associated with tacrolimus, mycophenolate mofetil and steroids
11595139|NCT00682279|No Intervention|This is a single-arm, dose escalation|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
11595140|NCT00682266|Experimental|Aerobic interval training|intensity-controlled interval training
11595141|NCT00682266|Experimental|MTG|multidisciplinary approach
11595142|NCT00682240|Active Comparator|group 3|"Group 3: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation.
~Intervention: All patients will receive a multi-session panretinal laser treatment according to the conventional protocol, using a conventional laser system."
11595143|NCT00682240|Active Comparator|group 2|"Group 2: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation randomized into group 2.
~Intervention: This group will receive multi-session panretinal laser treatment. The treatment will be performed using Pascal laser system."
11595144|NCT00682240|Active Comparator|group 1|"Group 1: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation randomized into group1.
~Intervention: One group will receive a single-session panretinal laser treatment, performed using Pascal laser system."
11595145|NCT00682240|Active Comparator|group 4|"Group 4: 20 patients with persistent central or para-central diabetic macular edema receiving focal or grid laser treatment. As the treatment will be performed according to the conventional protocol (single spot), only the Pascal laser system will be used.
~Intervention: focal or grid laser treatment"
11595146|NCT00682227|Experimental|1|
11595147|NCT00682214|Active Comparator|A, Choelcalciferol|Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
11595148|NCT00682214|Placebo Comparator|B, Lactose|
11595149|NCT00682201||1|Healthy pregnant women
11595150|NCT00682188|Experimental|CI|Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)
11595151|NCT00682188|Active Comparator|II|Six individual sessions with the school nurse over 2 months to check weight and behavior changes and provide a series of six pamphlets on weight and weight management
11595152|NCT00682175||Observation|Adult (age > 18 yrs) patients admitted to the Heart Failure Intensive Care Unit with Acute Heart Failure Syndrome requiring placement of a Pulmonary Artery catheter for hemodynamically guided therapy.
11595153|NCT00682162|Sham Comparator|Sham-laser acupuncture|The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
11595154|NCT00682162|Active Comparator|Acupuncture|The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, [22]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
11595155|NCT00682149|Placebo Comparator|Group 1|We planned to compare a study group of 60 subjects with a placebo group of 60 subjects
11595156|NCT00682149|Active Comparator|Group 2|We planned to compare a study group of 60 subjects with a placebo group of 60 subjects
11595157|NCT00682136|Active Comparator|1|Open Laparotomy Arm: All patients enrolled in the study who are undergoing elective open laparotomy surgery.
11595158|NCT00682136|Active Comparator|2|Laparoscopic Arm: All patients enrolled in the study who are undergoing elective laparoscopic abdominal surgery.
11595159|NCT00682097|Experimental|1|
11595160|NCT00682097|Experimental|2|
11595161|NCT00682097|Experimental|3|
11595162|NCT00682097|Experimental|4|
11595163|NCT00682097|Experimental|5|
11595164|NCT00682097|Experimental|6|
11595165|NCT00682097|Experimental|7|
11595166|NCT00682084||1|Patients recently diagnosed with Cushing's syndrome
11595167|NCT00682071||1|transabdominal ultrasound (TAS) guided embryo transfer
11595168|NCT00682071||2|transvaginal ultrasound (TVS) guided embryo transfer
11595169|NCT00682058||LABS patients|Bariatric surgery patients with 35>BMI kg/m2<60 prior to surgery will undergo follow-up post-bariatric surgery.
11595170|NCT00682045||T-SPOT.TB positive|T-SPOT.TB positive patients
11595171|NCT00682032|Experimental|AIM 2: subjects with suspected or definitive NSCLC diagnosis|1 (one) 250mg beta-glucan capsule 3 times a day for 14 days
11595172|NCT00682032|Experimental|AIM 3: subjects with resectable NSCLC|1 (one) 250mg beta-glucan capsule 3 times a day for 10 to 20 days
11595173|NCT00682019|Experimental|Arm 1|
11595174|NCT00682019|Placebo Comparator|Arm 2|
11595175|NCT00682006|Experimental|A|In this arm we recruited 2,400 subjects who received Intervention.
11595176|NCT00682006|Experimental|B|In this Arm, we recruited 2,400 subjects who received intervention.
11595177|NCT00682006|Experimental|C|In this Arm, we recruited 2,400 subjects who received intervention.
11595178|NCT00682006|No Intervention|D|In this Arm, we recruited 2,400 subjects for Observation and comparison. This was the prime control group.
11595179|NCT00681993|Active Comparator|Standard ddAC chemotherapy with concurrent radiation therapy|Standard dose-dense Adriamycin and Cyclophosphamide (ddAC) chemotherapy and concurrent radiation therapy (RT)
11595180|NCT00681993|Active Comparator|Standard AC chemotherapy with concurrent RT|Standard Adriamycin and Cyclophosphamide (AC) chemotherapy and concurrent radiation therapy
11595181|NCT00681993|Active Comparator|Standard TCarbo H chemotherapy with concurrent RT|Standard Taxotere, Carboplatin and Herceptin (TCarbo H) chemotherapy and concurrent radiation therapy
11595182|NCT00681993|Active Comparator|Standard TAC chemotherapy with concurrent RT|Standard Taxotere, Adriamycin and Cyclophosphamide (TAC) chemotherapy with concurrent radiation therapy
11595183|NCT00681993|Active Comparator|Standard TC chemotherapy with concurrent RT|Standard Taxotere and Cyclophosphamide (TC) chemotherapy with concurrent radiation therapy
11595184|NCT00681980|Experimental|A, 2, III|Patients with side effects to corticosteroids
11595185|NCT00681980|Experimental|B|patient with corticosteroids
11595186|NCT00681980|Experimental|3|Valproic acid and corticosteroids
11595187|NCT00681967|Experimental|Cohort 1|post operative combination of gefinib and RT
11595188|NCT00681967|Experimental|Cohort 2|combination of gefitinib with RT and Chemotherapy in non operated patients
11595189|NCT00681954||1, 2, 3|
11595190|NCT00681941|Experimental|1|Sevelamer Carbonate Tablets Dosed Three Times A Day
11595191|NCT00681928||Breast Cancer patients receiving aromatase treatment|
11595192|NCT00681928||Healthy female controls age 60 and older|
11595193|NCT00681915|Experimental|1|
11595194|NCT00681902|Experimental|1|Jet lidocaine
11595195|NCT00681902|Placebo Comparator|2|Jet saline
11595196|NCT00681889|Experimental|Treatment Arm|10 Patients will receive treatment (Ranibizumab)
11595197|NCT00681876|Experimental|1|Irinotecan+Avastin+Erbitux
11595198|NCT00681863|Active Comparator|pramipexole 0.0625 mg BID (twice daily)|all patients to receive one tablet of pramipexole 0.0625 mg BID for first 4 weeks (flexible dosing for all other arms)
11595199|NCT00681863|Active Comparator|pramipexole 0.0625 mg QD (once daily)|patients to receive one tablet of pramipexole 0.0625 mg QD
11595200|NCT00681863|Active Comparator|pramipexole 0.125 mg BID|patients to receive one tablet of pramipexole 0.125 mg BID
11595201|NCT00681863|Active Comparator|pramipexole 0.125 mg TID (three times daily)|patients to receive one tablet of pramipexole 0.125 mg TID
11595202|NCT00681863|Active Comparator|pramipexole 0.25 mg BID|patients to receive one tablet of pramipexole 0.25 mg BID
11595203|NCT00681850||1|Control group
11595204|NCT00681850||2|Benchmarking group
11595205|NCT00681837||1|children from 0 to 17 years old
11595206|NCT00681824|Experimental|FS VH S/D 500 s-apr|Application of FS VH S/D 500 s-apr on top of suture
11595207|NCT00681824|Active Comparator|Standard of Care (Control group)|The treatment of the control group consisted of Standard of Care (SoC) which was defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen based dura substitute.
11595208|NCT00681811|Experimental|HGT-1111 100 U/kg|
11595209|NCT00681811|Experimental|HGT-1111 200 U/kg|
11595210|NCT00681798|Active Comparator|Dose level 1|Vandetanib 100mg/day plus Gemcitabine
11595211|NCT00681798|Active Comparator|Dose level 2|Vandetanib 300mg/day plus Gemcitabine
11595212|NCT00681798|Active Comparator|Dose level 3|Vandetanib 100mg/day plus Gemcitabine plus CapecitabineDose
11595213|NCT00681798|Active Comparator|Dose level 4|Vandetanib 300mg/day plus Gemcitabine plus CapectiabineDose
11595214|NCT00681785|Active Comparator|A|5000IE dalteparine
11595215|NCT00681785|Placebo Comparator|B|NaCL 0.9%
11595216|NCT00681772|Experimental|Arm 1|
11595217|NCT00681759||1|Patients who have been prescribed Low Dose Aspirin (LDA) usage in the past 12 months, or those about to begin LDA, will complete a one-time in-office survey using an electronic personal digital assistant (PDA) device (termed SitePro).
11595218|NCT00681759||2|420 subjects stratified into three groups varying on length of time using Low Dose Aspirin (LDA)
11595219|NCT00681759||3|Up to 20 subjects from the three EMA groups will be interviewed to further debrief their experience with Low Dose Aspirin (LDA) and upper GI symptoms.
11595220|NCT00681746|Experimental|1|
11595221|NCT00681733|Experimental|A|Pioglitazone
11595222|NCT00681733|Active Comparator|B|Pentoxifylline
11595223|NCT00681720|Experimental|1|
11595224|NCT00681707||1|Hypertension patients recovering from stroke
11595225|NCT00681694||MRBT|MRI-assisted brachytherapy, the experimental arm
11595226|NCT00681694||USBT1|Standard ultrasound-guided brachytherapy performed by group 1 (control arm 1)
11595227|NCT00681694||USBT2|Standard ultrasound-guided brachytherapy performed by group 2 (control group 2)
11595228|NCT00681681||1|Men and women with 1 or more cardiovascular risk factors
11595229|NCT00681668|Experimental|Quetiapine Fumarate 150 - 800mg|Quetiapine 150-800mg
11595230|NCT00681655|Experimental|Responses to alcohol|Each subject completed a total of 2 2.8 hr-long clamping sessions.Within each session, procedures differed only by the content of the infusate. In one session, 6% ethanol was infused. In the other session, only vehicle was infused, quantifying the placebo response for every subject. The order of alcohol or placebo sessions was counterbalanced; subjects were blind to which session was which; sessions were scheduled to occur about 2 weeks apart. Measures were collected before, and at beginning and end of infusion, and included subjective perceptions, EMG, EEG, stop-signal performance, eye movements, and auditory responses. Design allowed analysis of effect of alcohol vs placebo, initial effect of alcohol and acute tolerance to alcohol.
11595231|NCT00681642||1|Corneal epithelial tissue with wound cultured in human autoserum
11595232|NCT00681642||2|Corneal epithelial tissue with wound cultured in umbilical cord serum
11595233|NCT00681629|Experimental|Quetiapine XR Alone|Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
11595234|NCT00681629|Experimental|Quetiapine XR With Integrated Care Program (ICP)|Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
11595235|NCT00681616|Placebo Comparator|1|Compartment Monitoring System with Active Fluid Removal
11595236|NCT00681616|Active Comparator|2|Compartment Monitoring System (CMS) without fluid removal
11595237|NCT00681603|Experimental|1|13 cases that accepted subconjunctival injection of bevacizumab
11595238|NCT00681590|Active Comparator|1|vitamin D (cholecalciferol) 400 IU daily orally - low dose
11595239|NCT00681590|Active Comparator|2|vitamin D (cholecalciferol) 2000 IU daily orally - high dose
11595240|NCT00681577|Experimental|A|
11595241|NCT00681564|Experimental|One-Stage Full-Mouth Disinfection|Scaling and root planing, four quadrants in one session Tongue brushing with a 1% chlorhexidine gel (1 minute) Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes) Subgingival chlorhexidine (1%) irrigation in all pockets Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention Basic oral hygiene instructions Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)
11595242|NCT00681564|Active Comparator|Periodontal care|Basic oral hygiene instructions Supragingival plaque removal
11595243|NCT00681551|Active Comparator|Arm 1|
11595244|NCT00681551|Experimental|Arm 2|
11595245|NCT00681538|Experimental|Sativex|"Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.
~Subjects received study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose was 12 actuations (THC 32.4 mg:CBD 30 mg) in 24 hours"
11595246|NCT00681538|Placebo Comparator|Placebo|Contains no active drug but colourants and excipients. Subjects received placebo delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose was 12 actuations in 24 hours.
11595247|NCT00681525|Experimental|A|ABT-335 135 mg
11595248|NCT00681525|Experimental|B|Atorvastatin 80 mg and Ezetimibe 10 mg
11595249|NCT00681525|Experimental|C|ABT-335 135 mg, Atorvastatin 80 mg and Ezetimibe 10 mg
11595250|NCT00681499||malignant|eg. hepatocellular carcinoma, colorectal liver metastases
11595251|NCT00681499||benign|eg. liver cysts, traumatic liver injuries, adenoma etc
11595252|NCT00681486|Active Comparator|A, 1|Ghrelin
11595253|NCT00681486|Active Comparator|A, 2|Ghrelin.
11595254|NCT00681473|Experimental|Proton Radiation Therapy|Proton radiation therapy daily (Monday through Friday) for six weeks. This is a single arm study.
11595255|NCT00681460|Active Comparator|1|gestational diabetes, insulin therapy
11595256|NCT00681460|Experimental|2|gestational diabetes, metformin therapy
11595257|NCT00681447|Other|Group I|Lumbar interlaminar epidural injection with local anesthetic only
11595258|NCT00681447|Other|Group II|Lumbar Interlaminar Epidural Injection with local anesthetic wiht 6 mg of non-particulate Celestone
11595259|NCT00681434|Experimental|1|bilateral training
11595260|NCT00681434|Active Comparator|2|Unilateral training
11595261|NCT00681421|Experimental|A|
11595262|NCT00681408|Active Comparator|Omega 3 recipient arm|
11595263|NCT00681408|Placebo Comparator|Placebo|Placebo fish oil
11595264|NCT00681395|Experimental|1|ABT-143 capsules 20/135 mg
11595265|NCT00681395|Active Comparator|2|ABT-335 135mg and rosuvastatin 20mg
11595266|NCT00681395|Experimental|3|ABT-143 capsules 5/45mg
11595267|NCT00681395|Active Comparator|4|ABT-335 45mg and rosuvastatin 5mg
11595268|NCT00681382||1|Asthma patients using inhaled steroids as maintenance treatment
11595269|NCT00681369||1|Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
11595270|NCT00681356|Experimental|1|4975 - 15 mg
11595271|NCT00681356|Placebo Comparator|2|Placebo
11595272|NCT00681356|Experimental|3|4975 - truncated for Phase 3
11595273|NCT00681343|Experimental|A|Thymoglobulin Induction
11595274|NCT00681343|Experimental|B|Campath-1H Induction
11595275|NCT00681343|Experimental|C|Daclizumab Induction
11595276|NCT00681330|Experimental|A|
11595277|NCT00681317|Experimental|1|
11595278|NCT00681304||1|Only one group of participants will be studies. There are no controls.
11595279|NCT00681291|Active Comparator|1|lightweight polypropylene mesh
11595280|NCT00681291|Active Comparator|2|Strattice
11595281|NCT00681278||1|Hypertension patients with Type II Diabetes mellitus
11595282|NCT00681265|Experimental|glycerin|One eye will randomly receive a single instillation of one drop of a new formulation of an artificial tear containing glycerin 1% as an active with polylysine-graft-polyethylene glycol as an excipient.
11595283|NCT00681265|Active Comparator|polyethylene glycol 400/propylene glycol|The other eye will receive a single instillation of one drop of an artificial tear with propylene glycol (0.3%) and polyethylene glycol (0.4%) as active ingredients with hydroxypropyl-guar as a gelling agent.
11595284|NCT00681252|Experimental|A|
11595285|NCT00681239|Experimental|A|Patients will receive the modified Atkins diet in combination with a 10 oz KetoCal shake for the first month. The second month no shake will be given. Results at 1 month will be compared to 2 months, as well as to historical controls with the modified Atkins diet.
11595286|NCT00681213|Experimental|A|Tacrolimus/Sirolimus
11595287|NCT00681213|Experimental|B|Tacrolimus/MMF
11595288|NCT00681213|Experimental|C|Neoral/Sirolimus
11595289|NCT00681200|Active Comparator|Enhanced health education program|This active treatment group consists of classes in health education and a social support group to enhance participant motivation and positive reinforcement to make healthier lifestyle choices (e.g. wholesome diet, increased exercise, reduced salt intake, and decreased use of alcohol and smoking). Note that is comparison group does not have a stress management component.
11595290|NCT00681200|Experimental|Transcendental Meditation program|Transcendental Meditation program plus health education. Basic AHA recommendations for lifestyle modification to reduce risk of heart disease will be given in a didactic classroom context.
11595291|NCT00681174|Active Comparator|Control|Control intervention will be intraoperative i.v. morphine administration 30 minutes before the end of anesthesia.
11595292|NCT00681174|Experimental|CROxy|The intervention group will receive controlled-release oxycodone 1 h pre-operatively
11595293|NCT00681161|Other|A|
11595294|NCT00681148|Experimental|A|Botox injection
11595295|NCT00681148|Placebo Comparator|B|Saline injection
11595296|NCT00681135|Experimental|1|
11595297|NCT00681135|Experimental|2|
11595298|NCT00681135|Experimental|3|
11595299|NCT00681135|Active Comparator|4|
11595300|NCT00681122||1|Standard therapy
11595301|NCT00681122||2|Standard therapy + educational material
11595302|NCT00681109|Active Comparator|Treatment Arm 1|2.5% IL-1Ra
11595303|NCT00681109|Placebo Comparator|Placebo|Artificial Tear
11595304|NCT00681109|Active Comparator|Treatment Arm 2|5% IL-1Ra
11595305|NCT00681083|Experimental|1|Heated breathing tube
11595306|NCT00681083|Active Comparator|2|Non heated breathing tube
11595307|NCT00681070|Active Comparator|Arm1: Non-absorbable sutures|use of non-absorbable sutures in facial laceration in this arm
11595308|NCT00681070|Active Comparator|Arm 2: Absorbable sutures|use of absorbable sutures in this arm
11595309|NCT00681044|Experimental|SCT with melphalan conditioning|Mobilization with Filgrastim Stem Cell Transplant Melphalan Conditioning Stem Cell infusion
11595310|NCT00681031|Experimental|All Enrolled|Participants received a single dose (0.65 mL) of shingles (herpes zoster) vaccine (live) ZOSTAVAX® by subcutaneous injection at Visit 1 (Day 0)
11595311|NCT00681018|Experimental|1|Liquid human milk fortifier
11595312|NCT00681018|Active Comparator|2|Powder human milk fortifier
11595313|NCT00681005|Active Comparator|Rabeprazole|Rabeprazole 1 # qd
11595314|NCT00681005|Active Comparator|pantoprazole|Pantoprazole 1# qd
11595315|NCT00680992|Experimental|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
11595316|NCT00680966|Experimental|TX1|Functional Family Therapy (FFT) followed by Adolescent Coping With Depression (ACWD)
11595317|NCT00680966|Experimental|TX 2|ACWD (Adolescent Coping With Depression) followed by FFT (Functional Family Therapy)
11595318|NCT00680966|Experimental|TX 3|Combination of an augmented FFT and ACWD - Integrated treatment
11595319|NCT00680953|Experimental|1|Denosumab (subcutaneously - every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).
11595320|NCT00680953|Placebo Comparator|2|Placebo (subcutaneously every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).
11595321|NCT00680953|Active Comparator|3|Alendronate sodium hydrate oral tablets weekly + daily calcium and vitamin D supplements for 24 months (open label reference arm).
11595322|NCT00680940|Active Comparator|Chemotherapy|Paclitaxel + Cisplatin
11595323|NCT00680940|Experimental|Chemoimmunotherapy|Paclitaxel + Cisplatin + Mycobacterium w
11595324|NCT00680914|Experimental|Synflorix Group|Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4.
11595325|NCT00680914|Active Comparator|Prevenar Group|Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4.
11595326|NCT00680901|Experimental|CapeOx plus Lapatinib|CapeOx plus Lapatinib
11595327|NCT00680901|Placebo Comparator|CapeOx plus Placebo|CapeOx plus Placebo
11595328|NCT00680888||1|Children and adolescents with psychosis in outpatients setting on treatment with quetiapine started from january 2003 to june 2006
11595329|NCT00680875|Experimental|Intervention|5th and 6th grade students who attend schools randomly assigned to the intervention condition.
11595330|NCT00680875|No Intervention|Usual Curriculum|5th and 6th grade students attending schools randomly assigned to the usual curriculum control condition.
11595331|NCT00680862||Group 1|VA employees
11595332|NCT00680849||1|Treatment condition from first study. This is a follow-up study.
11595333|NCT00680849||2|Control condition from first study.
11595334|NCT00680836|Active Comparator|Treatment Group|These patients have IBS and are receiving the rifaximin.
11595335|NCT00680836|Placebo Comparator|Placebo group|These patients have IBS and are receiving the placebo.
11595336|NCT00680823|Experimental|Ropivacaine Injections|Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of 0.5% ropivacaine on each side.
11595337|NCT00680823|Placebo Comparator|Normal Saline Injections|Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of normal saline on each side.
11595338|NCT00680823|No Intervention|Observation|Observation for 30 minutes.
11595339|NCT00680797|Experimental|+T +E|+Testosterone, +Estrogen
11595340|NCT00680797|Experimental|+T -E|+Testosterone, -Estrogen
11595341|NCT00680797|Experimental|-T +E|-Testosterone, +Estrogen
11595342|NCT00680797|No Intervention|-T -E|-Testosterone, -Estrogen
11595343|NCT00680784|Experimental|HKT-500 Ketoprofen Topical Patch|Randomized, double-blind, placebo-controlled, multicenter study in men and women 18 years of age or older who have a painful, acute, benign, ankle sprain of the lateral ligament(s) within the previous 48 hours.
11595344|NCT00680784|Placebo Comparator|Placebo Patch|Treatment with placebo patch
11595345|NCT00680771||1|Primary Insomnia
11595346|NCT00680771||2|Good Sleepers
11595347|NCT00680758|Experimental|Therapeutic Intervention|
11595348|NCT00680745|Experimental|1|dapagliflozin 2.5mg + Glimepiride
11595349|NCT00680745|Experimental|2|dapagliflozin 5mg + Glimepiride
11595350|NCT00680745|Experimental|3|dapagliflozin 10mg + Glimepiride
11595351|NCT00680745|Placebo Comparator|4|Placebo + Glimepiride
11595352|NCT00680732|Experimental|A1|Multiple micronutrients supplements (MMS) and weekly chloroquine (CQ)
11595353|NCT00680732|Experimental|A2|Multiple micronutrients supplements (MMS) and intermittent suplphadoxyne-pyrimethamine (SP)
11595354|NCT00680732|Experimental|B1|Iron and folic acid (IFA) and weekly chloroquine (CQ)
11595355|NCT00680732|Experimental|B2|Iron and folic acid (IFA) and intermittent sulphadoxyne-pyrimethamine (SP)
11595356|NCT00680719|Active Comparator|1|Family Therapy plus HIV prevention
11595357|NCT00680719|Active Comparator|2|Family Therapy only.
11595358|NCT00680706|Experimental|Thiamine|Receives thiamine
11595359|NCT00680706|Placebo Comparator|Control|
11595360|NCT00680693|Experimental|1|Mindfulness-based stress management 8-week program
11595361|NCT00680693|Active Comparator|2|Psycho-educational support group for women with IBS
11595362|NCT00680667|Experimental|Trametes Versicolor|Females with Stage I-III infiltrating ductal adenocarcinoma of the breast being treated with Trametes versicolor capsules for 6 weeks after receiving radiation therapy.
11595363|NCT00680654|Experimental|Arm 1|
11595364|NCT00680641|Active Comparator|A|Simvastatin 40mg
11595365|NCT00680641|Placebo Comparator|B|Placebo
11595366|NCT00680628|Placebo Comparator|2|Saline + Enoxaparin
11595367|NCT00680628|Experimental|1|Tenecteplase + Enoxaparin
11595368|NCT00680615|Experimental|Usual Care|
11595369|NCT00680615|Experimental|Enhanced|
11595370|NCT00680602|Experimental|1|Group Cognitive Behavior Therapy
11595371|NCT00680602|Active Comparator|2|Selective Serotonin Reuptake Inhibitor
11595372|NCT00680589|Experimental|1|Injection of mouse TYRP2 DNA in patients with highrisk melanoma.
11595373|NCT00680576|Active Comparator|1|Eight weeks of individual CBT for adolescents who have completed six weeks of group therapy and continue to use drugs.
11595374|NCT00680576|Active Comparator|2|Eight weeks of FFT for adolescents who have received six weeks of group therapy and continue to use drugs.
11595375|NCT00680563|Experimental|1|
11595376|NCT00680537|No Intervention|1|Control group
11595377|NCT00680537|Experimental|2|Exercise group
11595378|NCT00680524|Experimental|Phone Based Outreach Intervention Group|Open pilot trial
11595379|NCT00680511|Active Comparator|1|Family therapy combined with methamphetamine-specific group treatment.
11595380|NCT00680511|Active Comparator|2|Family Therapy.
11595381|NCT00680498|Active Comparator|1|
11595382|NCT00680498|Active Comparator|2|
11595383|NCT00680472|Active Comparator|A,1 HKT-500 Ketoprofen Topical Patch|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Week Study to Assess the Efficacy and Safety of HKT-500 in Subjects with Acute Shoulder Pain
11595384|NCT00680472|Placebo Comparator|A,2 Placebo Patch|Treatment with placebo patch
11595385|NCT00680459|Experimental|1|70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
11595386|NCT00680459|Placebo Comparator|2|heparin flush 10 units/ml lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. heparin flush solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
11595387|NCT00680446|Experimental|1|
11595388|NCT00680433|Experimental|Active|Ketamine
11595389|NCT00680433|Placebo Comparator|Placebo|Saline (placebo)
11595390|NCT00680407|Experimental|silymarin 420 mg|420 mg Legalon (silymarin) three times daily
11595391|NCT00680407|Experimental|silymarin 700 mg|700 mg of Legalon (silymarin) three times daily
11595392|NCT00680407|Placebo Comparator|Placebo|Placebo (lactose pill)
11595393|NCT00680394|Experimental|mifepristone+misoprostol|200 mg mifepristone+ 800 mcg buccal misoprostol
11595394|NCT00680394|Experimental|misoprostol|800 mcg buccal misoprostol+placebo
11595395|NCT00680381|Active Comparator|1|Following 12 weeks of Functional Family Therapy (FFT), semi-weekly therapist phone calls for eight weeks.
11595396|NCT00680381|Active Comparator|2|Following 12 weeks of FFT, weekly one-hour group therapy for eight weeks
11595397|NCT00680381|Active Comparator|3|Following 12 weeks of FFT, an eight-week, customized series of therapist visits with the adolescent, family, teachers, coaches and others who can support the adolescent's reduced level of drug use.
11595398|NCT00680368||Residents and Attending Physicians|This group contains the residents and the attending physicians who consented to participate in the study. They participated in a survey administered by a research assistant. Both physician resident and attending physicians were administered the survey twice within 24-hours and their test-retest responses were compared for reliability. Responses to attending and resident physicians covering the care for the patient and clinical care encounter were compared for accuracy.
11595399|NCT00680355|Other|Golden rice meal with 10g fat|10 g corn oil in the Golden Rice meal
11595400|NCT00680355|Other|Golden Rice with 0g fat|0g corn oil eating with the Golden Rice meal
11595401|NCT00680355|Other|Golden Rice meal with 5 g fat|5 g corn oil in the Golden Rice meal
11595402|NCT00680342|Placebo Comparator|1|Placebo (lactose pill)
11595403|NCT00680342|Experimental|2|700mg of Legalon (silymarin) three times daily
11595404|NCT00680342|Experimental|3|420mg Legalon (silymarin) three times daily
11595405|NCT00680329||Travalert with DuoTrav|One drop in study eye(s) once daily in the evening for four months
11595406|NCT00680316|Experimental|Dornase alfa|
11595407|NCT00680316|Placebo Comparator|Placebo|
11595408|NCT00680303|Experimental|1|The child will receive the Lidcombe Program 2x per week
11595409|NCT00680303|Experimental|2|The child will receive the Lidcombe Program once every 2 weeks (fortnightly visits)
11595410|NCT00680303|Other|3|The child will receive the standard Lidcombe Program once per week (control)
11595411|NCT00680290|Experimental|1|Exercise group
11595412|NCT00680277|Experimental|1|
11595413|NCT00680277|Experimental|2|
11595414|NCT00680264||Operative|Diagnosis of Cerebral Palsy (standard definition of any brain injury before the age of 3) with total body involvement - any functional level Curve >40 degrees on sitting film, A spinal fusion is being undertaken and the patient/family is proceeding with the spinal fusion (with any level of distal fusion).
11595415|NCT00680264||Non-operative|Diagnosis of Cerebral Palsy (standard definition of any brain injury before the age of 3) with total body involvement - any functional level, Curve >40 degrees on sitting film, A spinal fusion is not being undertaken either because the family has refused surgery or because it is not recommended at this point.
11595416|NCT00680238|No Intervention|A|Embryo selection for transfer based on a Day 3 score only.
11595417|NCT00680238|Active Comparator|B|Embryos for transfer by first selecting any embryos that had a positive sHLA-G expression of OD = 190 ±6 and correlating such with the highest GES score available.
11595418|NCT00680225|Experimental|Lucentis Injection|Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
11595419|NCT00680212|Other|1|dietary carotenoids
11595420|NCT00680199||1|Primary Insomnia
11595421|NCT00680199||2|Good Sleepers
11595422|NCT00680186|Experimental|Dabigatran etexilate (150mg bid)|Patients will receive 1 capsule containing 150 mg dabigatran etexilate/matching placebo twice daily
11595423|NCT00680186|Active Comparator|Warfarin (INR 2.0-3.0)|Patients will receive tablets PRN warfarin/matching placebo to maintain a target INR of 2.0-3.0
11595424|NCT00680173|Active Comparator|A|15 patients with HCV genotype 1 infection receiving peginterferon plus ribavirin achieve a sustained virological response
11595425|NCT00680173|Active Comparator|B|15 patients with HCV genotype 1 infection receiving peginterferon plus ribavirin did not achieve a sustained virological response
11595426|NCT00680147|Experimental|Brief HPV vaccine informational intervention|Because we anticipated that knowledge and awareness of the HPV vaccine would be low in our study population, our CASI survey included a brief, informational overview of key facts concerning HPV vaccination prior to assessing vaccine acceptance, perceived barriers to vaccination, and intentions to vaccinate. The overview lasted approximately 3 minutes and consisted of a brief overview of key HPV vaccination facts that were presented visually (on the computer screen) and read aloud using a digital recording. HPV and vaccine knowledge, awareness, and attitudes items were administered prior to participants hearing the informational overview.
11595427|NCT00680134|Experimental|Group/Cohort 1|AN2690 1% Solution (30 subjects)
11595428|NCT00680134|Experimental|Group/Cohort 2|AN2690 5% Solution (30 subjects)
11595429|NCT00680121|Placebo Comparator|Control Group|Placebo
11595430|NCT00680121|Experimental|Benfotiamine|Benfotiamine 600 mg
11595431|NCT00680095|Experimental|A|AN2690 Solution, 2.5%
11595432|NCT00680095|Experimental|B|AN2690 Solution, 7.5%
11595433|NCT00680095|Experimental|C|AN2690 Solution, 5.0%
11595434|NCT00680095|Active Comparator|D|AN2690 Solution, Vehicle
11595435|NCT00680095|Active Comparator|E|Sodium Lauryl Sulfate, 0.5%
11595436|NCT00680082||1|Patients to whom a statin was initiated or switched between 3 and 6 months before consultation
11595437|NCT00680069|Experimental|High Dose Group|Volunteers will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will get 1 dose, clade 1 vaccine-naive subjects receive 2 doses 28 days apart
11595438|NCT00680069|Experimental|Low Dose Group|Volunteers will receive 15 mcg intramuscularly (IM). Subjects who received previous clade 1 vaccine will get 1 dose, clade 1 vaccine-naive subjects receive 2 doses 28 days apart.
11595439|NCT00680056|Active Comparator|1|Formoterol plus Placebo (Tiotropium)
11595440|NCT00680056|Experimental|2|Formoterol plus Tiotropium
11595441|NCT00680043|Experimental|Peginesatide 0.04 mg/kg|
11595442|NCT00680043|Experimental|Peginesatide 0.08 mg/kg|
11595443|NCT00680043|Active Comparator|Epoetin Alfa|
11595444|NCT00680030||1|
11595445|NCT00680017|Experimental|ABT-335 plus rosuvastatin|ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
11595446|NCT00680017|Active Comparator|Rosuvastatin|Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
11595447|NCT00680004||1|Preoperative patients planned for a CT prior to an endograft implantation procedure
11595448|NCT00680004||2|Patients who underwent a complicated endograft implant and/or with increased risk of complications
11595449|NCT00679991|Active Comparator|PRT-201|
11595450|NCT00679991|Placebo Comparator|2|
11595451|NCT00679978||A|A: etidronate
11595452|NCT00679965|Experimental|Group 1|AN2690 Solution, 2.5%
11595453|NCT00679965|Experimental|Group 2|AN2690 Solution: 5%
11595454|NCT00679965|Experimental|Group 3|AN2690 Solution, 7.5%
11595455|NCT00679965|Placebo Comparator|Group 4|AN2690 Solution Vehicle
11595456|NCT00679952|Active Comparator|1|closed suction drainage group (CD group)
11595457|NCT00679952|Active Comparator|2|natural drainage group (ND group)
11595458|NCT00679939|Active Comparator|Arm 1 Treatment A|rosiglitazone up to 8mg/day
11595459|NCT00679939|Active Comparator|Arm 2 Treatment B|metformin up to 2000mg/day
11595460|NCT00679926|Experimental|1|Patients taking lopinavir/ritonavir and tenofovir once daily.
11595461|NCT00679913|Active Comparator|1|standard pancreatoduodenectomy
11595462|NCT00679913|Active Comparator|2|extended pancreatoduodenectomy
11595463|NCT00679900|Experimental|1|
11595464|NCT00679900|Active Comparator|2|
11595465|NCT00679887|Experimental|A|Ischemic compression on trigger points located around the shoulder. Active comparator. Ischemic compression, 5 weeks
11595466|NCT00679874||I|Consecutive patients with first-time diagnosis of metastatic breast cancer undergoing chemotherapy with anthracyclines and/or trastuzumab.
11595467|NCT00679861|Experimental|3|A practitioner delivered counselling and an expert system intervention is implemented in practices allocated to this arm
11595468|NCT00679861|Experimental|1|A practitioner delivered counselling intervention was implemented in practices allocated to this arm
11595469|NCT00679861|Experimental|2|A computer expert system intervention was implemented in practices allocated to this arm
11595470|NCT00679848|Experimental|1|Transoral Suturing
11595471|NCT00679835|Experimental|Group 1|8 mg/kg over a one hour infusion
11595472|NCT00679835|Experimental|Group 2|10mg/kg over a one or two hour infusion
11595473|NCT00679822||Heart Failure|Heart Failure Out Patients at OSU
11595474|NCT00679796||Group A|Subjects with PCR confirmed varicella
11595475|NCT00679796||Group B|Age- and practice-matched control subjects
11595476|NCT00679783|Experimental|1|AZD2281, PARP inhibitor
11595477|NCT00679770|Experimental|Group 1|AN2690 Solution: 2.5%
11595478|NCT00679770|Experimental|Group 2|AN2690 Solution: 5%
11595479|NCT00679770|Experimental|Group 3|AN2690 Solution: 7.5%
11595480|NCT00679770|Placebo Comparator|Group 4|AN2690 Solution Vehicle
11595481|NCT00679744|Active Comparator|4 dose levels|Pyrimethamine at 6.25, 12.5, 25 and 37.5 mg/day will be evaluated sequentially, starting from 6.25 mg/day. Escalation from 6.25 mg/day to 12.5 mg/day, and from 12.5 mg/day to 25 mg/day, will not perform until all patients in the previous dose cohort have been treated for 4 weeks and until results obtained 4 weeks after treatment initiation do not reveal toxicity. Additionally, escalation from 25 mg/day to 37.5 mg/day will not perform until all patients in the 25-mg/day cohort have been treated for 8 weeks, and until results obtained 4 weeks after the 8-week treatment do not reveal toxicity. Dose escalation is considered complete, if 2 patients experience a Grade 3 Adverse Event (AE) or if 1 patient experiences a Grade 4 AE at a particular cohort.
11595482|NCT00679731|Experimental|A|ABT-874
11595483|NCT00679731|Active Comparator|B|Methotrexate
11595484|NCT00679705|Experimental|1|Ritodrine (Pre-Par)
11595485|NCT00679705|Experimental|2|Atosiban (Tractocile)
11595486|NCT00679705|Placebo Comparator|3|Placebo
11595487|NCT00679692||3:|three arms for study
11595488|NCT00679679|Experimental|Metformin|Every patient will be given diet and exercise counseling in both arms. Intervention arm will receive metformin
11595489|NCT00679679|Placebo Comparator|Placebo|Every patient will be given diet and exercise counseling in both arms. Intervention arm will receive metformin
11595490|NCT00679666|Sham Comparator|Sham treatment|Subjects are randomized to control (sham) group or a treatment group with the control group crossed over to the treatment group at the 3 month visit.
11595491|NCT00679666|Active Comparator|Treatment Arm|After randomization, the active arm will have the collagen crosslinking intervention.
11595492|NCT00679653|Active Comparator|1|verapamil/trandolapril
11595493|NCT00679653|Active Comparator|2|metoprolol/HCT
11595494|NCT00679653|Active Comparator|3|felodipine/ramipril
11595495|NCT00679640||1|Outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure
11595496|NCT00679627|Experimental|Galantamine|Galantamine 8mg/ day oral capsule increased to 16mg/day then to 24 mg per day
11595497|NCT00679627|Placebo Comparator|Placebo|Matching placeco
11595498|NCT00679614|Experimental|1|Group A oral tramacet 2 tablets preoperatively, 2 tablets every 6 hours for 5 days then 1-2 tablets of tramacet prn to a maximum of 8 tablets per day. Naloxone infusion starting preop at 0.25ug/kg/hr and continuing during hospital stay (an equivalent of 400ug over 24 hours in a 70 kg man). The infusion will be discontinued 1 hour before patient discharge.
11595499|NCT00679614|Active Comparator|2|Group B will receive oral tramacet 2 tablets preoperatively and then 2 tablets every 6 hours for five days. ( or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). This group will also receive saline infusion at 4-6mls / hour for the duration of the hospital stay.
11595500|NCT00679614|Active Comparator|3|Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay.
11595501|NCT00679588|Experimental|Semuloparin|Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery (placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind)
11595502|NCT00679588|Active Comparator|Enoxaparin|Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium (placebo for Semuloparin sodium 8 hours after surgery to maintain the blind)
11595503|NCT00679575||1|Cases : Patients with a first myocardial infarction
11595504|NCT00679575||2|Referents : Patients recruited by a GP during a routine consultation
11595505|NCT00679562|Experimental|1|
11595506|NCT00679562|Placebo Comparator|2|
11595507|NCT00679549|Experimental|DEVICE|Provided CPAP as an inpatient
11595508|NCT00679549|No Intervention|Control|No device provided
11595509|NCT00679536|Experimental|A|All patients on this trial will receive a conditioning regimen of Busulfan, Fludarabine, Anti-Thymocyte Globulin and Total Body Irradiation (400 cGy)
11595510|NCT00679523|Experimental|Group 1|AN2690 Solution, 5.0%
11595511|NCT00679523|Experimental|Group 2|AN2690 Solution, 7.5%
11595512|NCT00679510|Active Comparator|rosuvastatin|Rosuvastatin Patients were randomly allocated rosuvastatin (crestor) 10 mgs. The drugs (rosuvastatin and placebo) were provided by Astra Zeneca Ltd.
11595513|NCT00679510|Placebo Comparator|Placebo|Placebo. Patients were randomly allocated placebo. The drugs (rosuvastatin and placebo) were provided by Astra Zeneca Ltd.
11595514|NCT00679497|Experimental|1|MVA HIV-B
11595515|NCT00679497|Placebo Comparator|2|Placebo
11595516|NCT00679484|Experimental|1|
11595517|NCT00679484|Experimental|2|
11595518|NCT00679471||Pre-Term|Infants born pre-term with birthweight less than 1KG
11595519|NCT00679471||Full-Term Infants|Well infants who are born full-term
11595520|NCT00679458|Experimental|1.|Study drug: buprenorphine and ultra-low-dose naloxone
11595521|NCT00679458|Active Comparator|2.|Study drug: buprenorphine
11595522|NCT00679445|Experimental|A|Device: NeoVista Ophthalmic System A single procedure using the NeoVista Ophthalmic System plus an injection of Lucentis.
11595523|NCT00679432|Experimental|1: budesonide-MMX® 6 mg|One budesonide-MMX® 6 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
11595524|NCT00679432|Experimental|2: budesonide-MMX® 9 mg|One budesonide-MMX® 9 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
11595525|NCT00679432|Placebo Comparator|3: Placebo|Two placebo Asacol® overencapsulated tablets plus one placebo Budesonide MMX® tablet daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
11595580|NCT00679120|Active Comparator|3|Cementless tibial bearing tray and femur (porous coated and HA coated)
11595581|NCT00679107|Experimental|1|autogenous bone graft with the addition of OP-1 Putty
11595526|NCT00679432|Active Comparator|4: Asacol® 400 mg|Two Asacol® 400 mg overencapsulated tablets plus one placebo budesonide MMX® tablet daily in the morning after breakfast and two Asacol® 400 mg overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
11595527|NCT00679419||Group 0 (Controllgroup)|eGFR >= 90 ml/min/1.73m^2 and no proteinuria
11595528|NCT00679419||Group 1|eGFR >= 90 ml/min/1.73m^2 and proteinuria
11595529|NCT00679419||Group 2|eGFR 60 - 89 ml/min/1.73m^2
11595530|NCT00679419||Group 3|eGFR 30 - 59 ml/min/1.73m^2
11595531|NCT00679419||Group 4|eGFR 15 - 29 ml/min/1.73m^2
11595532|NCT00679419||Group 5|eGFR < 15 ml/min/1.73m^2 or requiring dialysis
11595533|NCT00679406|Experimental|1|Brief Behavioral Treatment for Insomnia
11595534|NCT00679393|Other|Fix|Open reduction internal fixation of severely comminuted calcaneal fracture (Sanders IV)
11595535|NCT00679393|Other|Fuse|Primary subtalar fusion of severely comminuted calcaneal fractures (Sanders IV).
11595536|NCT00679380|Experimental|1: budesonide-MMX® 6 mg|One budesonide-MMX® 6 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.
11595537|NCT00679380|Experimental|2: budesonide-MMX® 9 mg|One budesonide-MMX® 9 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.
11595538|NCT00679380|Active Comparator|3: Entocort EC® 3 mg|Three Entocort EC® 3 mg overencapsulated capsules plus one placebo budesonide MMX® tablet daily in the morning after breakfast.
11595539|NCT00679380|Placebo Comparator|4: Placebo|Three placebo Entocort EC® overencapsulated capsules plus one placebo Budesonide MMX® tablet daily in the morning after breakfast.
11595540|NCT00679367|Experimental|Melphalan Revlimid and Dexamethasone|Melphalan Lenalidomide Dexamethasone
11595541|NCT00679354|Experimental|Treatment (cilengitide)|Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11595542|NCT00679341|Experimental|Trastuzumab emtansine|Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) administered over 30-90 minutes every 3 weeks on Day 1 of each 21-day cycle.
11595543|NCT00679341|Active Comparator|Trastuzumab + docetaxel|Patients received a loading dose of trastuzumab 8 mg/kg IV + docetaxel 75 or 100 mg/m^2 IV on Day 1 of Cycle 1 followed by trastuzumab 6 mg/kg IV + docetaxel 75 or 100 mg/m^2 IV on Day 1 of all subsequent 21-day cycles.
11595544|NCT00679328|Experimental|1|Surgical implantation of OP-1
11595545|NCT00679328|Active Comparator|2|Surgical implantation of bone graft material
11595546|NCT00679315|Experimental|Alpha blocker|alfuzosin hydrochloride XL 10mg
11595547|NCT00679315|Placebo Comparator|Placebo|Placebo
11595548|NCT00679302|Placebo Comparator|placebo group|Maalox and bitter mixture
11595549|NCT00679302|Active Comparator|antibiotic group|Trimethoprim-sulfamethoxazole suspension
11595550|NCT00679289|Experimental|Cohort 1|"KW2871: 5 mg/m^2 IV every 2 weeks until disease progression
~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
11595551|NCT00679289|Experimental|Cohort 2|"KW2871: 10 mg/m^2 IV every 2 weeks until disease progression
~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
11595552|NCT00679289|Experimental|Cohort 3|"KW2871: 20 mg/m^2 IV every 2 weeks until disease progression
~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
11595553|NCT00679276||1|Patients having surgical repair of a vaginal prolapse .
11595554|NCT00679263|Experimental|MN-221|
11595555|NCT00679263|Placebo Comparator|PLACEBO|Placebo intravenous infusion with dosing volume equivalent to active treatment.
11595556|NCT00679250|Experimental|Levocetirizine|Active drug
11595557|NCT00679250|Placebo Comparator|placebo|placebo to levocetirizine
11595558|NCT00679237|Active Comparator|Multifactorial intervention|Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin
11595559|NCT00679237|No Intervention|Control|no intervention
11595560|NCT00679224||ambrisentan prescribed subjects|ambrisentan prescribed subjects
11595561|NCT00679211|Experimental|Trastuzumab emtansine|Trastuzumab emtansine (T-DM1) was administered to participants at a dose of 3.6 mg/kg by intravenous (IV) infusion every 3 weeks until documented disease progression, unmanageable toxicity, or study termination.
11595562|NCT00679198|Experimental|1|We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers
11595563|NCT00679198|No Intervention|2|Standard care
11595564|NCT00679185|Experimental|Experimental-EW|four emotion focused writing assignments
11595565|NCT00679185|Active Comparator|control group|non-emotional writing control
11595566|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 1|Dose of 5.0 x 10^9 colony forming units (CFU) S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
11595567|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 2|Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
11595568|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 3|Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
11595569|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 4|Dose of of 1.7 x 10^10 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
11595570|NCT00679159|Experimental|1|24 children (5 x 10^7pfu)
11595571|NCT00679159|Experimental|2|36 infants (2.5 x 10^7pfu)
11595572|NCT00679159|Experimental|3|36 infants (5 x 10^7 pfu)
11595573|NCT00679159|Experimental|4|36 infants (1 x 10^8pfu)
11595574|NCT00679159|Placebo Comparator|5|36 infants (Prevenar vaccine)
11595575|NCT00679146|Active Comparator|1|1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
11595576|NCT00679146|Active Comparator|2|2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
11595577|NCT00679133|Experimental|1|
11595578|NCT00679120|Active Comparator|1|Cemented single pegged femur with standard tibial bearing tray
11595579|NCT00679120|Active Comparator|2|Cemented twin pegged femur with standard tibial bearing tray
11595582|NCT00679107|Active Comparator|2|autogenous bone graft alone
11595583|NCT00679094|Experimental|Arm I|Participants receive a single dose of oral BBIC or placebo, as an orange juice suspension, immediately followed by consumption of a defined low-fat breakfast. Participants continue to consume a low-fat diet for the next 48 hours and then resume their normal diet.
11595584|NCT00679081|Experimental|CelTx|CelTx
11595585|NCT00679081|Active Comparator|Autologous CTG|Autologous sub-epithelial connective tissue graft
11595586|NCT00679068|Experimental|1|treatment with Bosentan
11595587|NCT00679055|Experimental|MK-0736|Participants will be orally administered 7 mg of MK-0736 once daily for 12 weeks
11595588|NCT00679055|Placebo Comparator|Placebo|Participants will be orally administered placebo once daily for 12 weeks.
11595589|NCT00679042|Experimental|A|All subjects will receive up to 3 transplantations of allogeneic human islets of Langerhans.
11595590|NCT00679029|Experimental|Chemotherapy with Bevacizumab|"AC = Doxorubicin 60 mg /M2 followed by cyclophosphamide 600 mg/M2 will be given every 2 weeks for cycles 1-4.
~TG = Paclitaxel 175 mg/M2 followed by gemcitabine 1500 mg/M2 will be given every 2 weeks for cycles 5-8.
~Beginning cycle 5, B1= Avastin 10 mg/kg will be given as a single IV dose following each TG treatment every 2 weeks for cycles 5-7."
11595591|NCT00679003|Experimental|1|Social learning and cognitive behavioral therapy (SLCBT)
11595592|NCT00679003|Active Comparator|2|Education and support (ES)
11595593|NCT00678990|Experimental|Open, single arm|Transplantation of islets with heparin coating.
11595594|NCT00678977|Experimental|Arm A|"Dose Escalation - Patients will be entered into dose cohorts of three patients. Each cohort will be assigned to a dose level for the duration of the study. There will be no intra-patient dose-escalation. The starting dose will be 400 mg daily of pazopanib, and 1000 mg/m2 gemcitabine. Intermediate dose levels may also be explored. Intravenous gemcitabine will be given on Day 1 and 8 of Cycle 1 and each subsequent cycle.
~Cohort expansion phase - patients will receive gemcitabine alone, at the OTR dose starting on Day 1 of Cycle 1. Pazopanib will be administered at the OTR beginning on Day 2 Cycle 1 after the last blood sample for gemcitabine analysis is collected, and pazopanib administration will continue for the duration of the study. Patients will return to the clinic on Day 8 of Cycle 1 for simultaneous administration of gemcitabine and pazopanib. On Day 1 of Cycle 2 patients will receive the simultaneous administration of gemcitabine and pazopanib"
11595595|NCT00678977|Experimental|Arm B|"Dose Escalation - Patients will be entered into dose cohorts of three patients. Each cohort will be assigned to a dose level for the duration of the study. There will be no intra-patient dose-escalation. The starting dose will be 400 mg daily of pazopanib, 1000 mg/m2 gemcitabine and 60 mg/m2 cisplatin. Doses of gemcitabine may range from 600 to 1250 mg/m2. Doses of cisplatin may range from 60 to 80 mg/m2. Intermediate dose levels may also be explored. Pazopanib administered starting on Day 1 of Cycle 1, gemcitabine co-administration on Day 1 and 8, and cisplatin on Day 1 in each 21-day cycle.
~Cohort expansion - patients will receive gemcitabine and cisplatin alone, at the OTR doses, starting on Day 1 of Cycle 1. Pazopanib will be administered at the OTR dose beginning on Day 2 of Cycle 1, and pazopanib administration will continue for the duration of the study. Patients will return to the clinic on Day 8 of Cycle 1 for simultaneous administration of gemcitabine and pazopanib"
11595596|NCT00678964|Experimental|A|
11595597|NCT00678964|Active Comparator|B|
11595598|NCT00678938|Experimental|1|
11595599|NCT00678938|Experimental|2|
11595600|NCT00678938|No Intervention|3|
11595601|NCT00678925|Active Comparator|1|Choline supplement given from 18-weeks pregnancy through 90 days postpartum
11595602|NCT00678925|Placebo Comparator|2|Placebo capsules given from 18 weeks pregnancy through 90 days postpartum
11595603|NCT00678912|Experimental|1|Children are mechanically ventilated with Smartcare/PS
11595604|NCT00678912|No Intervention|2|Children are mechanically ventilated with usual care
11595605|NCT00678899|Experimental|Surgery|Implantation with the Nucleus Hybrid L24 Cochlear Implant
11595606|NCT00678886|Experimental|otelixizumab|otelixizumab
11595607|NCT00678886|Placebo Comparator|placebo|Placebo
11595608|NCT00678873|Experimental|Surgical group|Patients with ultrasound proven symptomatic cholelithiasis (gallstones).
11595609|NCT00678847|Placebo Comparator|B|
11595610|NCT00678847|Active Comparator|A|
11595611|NCT00678834|Active Comparator|Arm 1|To surgery patients, Tocotrienol capsules. 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
11595612|NCT00678834|Active Comparator|Arm 2|To surgery patients, Tocopherol capsules. 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
11595613|NCT00678834|Active Comparator|Arm 3|Tocotrienol to healthy subjects - 200 mg to take orally two times a day (400 mg a day).
11595614|NCT00678821|Experimental|1|Patients with PH will be randomized to either aerobicexercise training plus education (AET) or education only (Ed-only) treatments
11595615|NCT00678821|Active Comparator|2|A comparison group of patients with ILD who do not have secondary PH (ILD- only) will also undergo the AET arm
11595616|NCT00678795|Experimental|Sativex|Each 100 ul actuation contains 27 mg delta-9-tetrahydrocannabinol (THC) and 25 mg cannabidiol (CBD). A maximum of 48 actuations (130 mg of THC and 120 mg of CBD) was permitted in any 24 hour period.
11595617|NCT00678795|Placebo Comparator|Placebo|Each 100 ul actuation contains the colorants plus excipients. A maximum of 48 actuations was permitted in any 24 hour period.
11595618|NCT00678769|Experimental|Group A (temsirolimus on days 15 and 22 course 1)|Patients receive temsirolimus IV over 30 minutes on days 15 and 22 for course 1 and on days 1, 8, 15, and 22 for all subsequent courses. Patients also receive cixutumumab IV over 60 minutes on days 1, 8, 15, and 22.
11595619|NCT00678769|Experimental|Group B (cixutumumab on days 15 and 22 of course 1)|Patients receive cixutumumab IV over 60 minutes on days 15 and 22 for course 1 and on days 1, 8, 15, and 22 for all subsequent courses. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
11595620|NCT00678769|Experimental|Group C (temsirolimus on days 1, 8, 15, and 22)|Patients receive temsirolimus IV over 30 minutes and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22.
11595678|NCT00678392|Active Comparator|Sorafenib|
11595679|NCT00678379|Placebo Comparator|Normal Saline|1.5 ml injection of Normal Saline into each tonsillar fossa pre-tonsillectomy
11595680|NCT00678379|Active Comparator|Lidocaine (1%) + Bupivacaine 0.5%|Submucosal injection of 1.5 mL Lidocaine (1%) + Bupivacaine 0.5% into the tonsillar fossa, pre-tonsillectomy
11595621|NCT00678730|Active Comparator|1|"Very low dose (0.005 mg/kg = 0.35 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/10th of a marijuana cigarette, or joint.
~Low dose (0.025 mg/kg = 1.75 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/2 of a marijuana cigarette, or joint.
~Medium dose (0.05 mg/kg = 3.5 mg in a 70 kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1 marijuana cigarette, or joint."
11595622|NCT00678730|Placebo Comparator|2|small amount of ethanol, (quarter teaspoon), with no THC
11595623|NCT00678717|Active Comparator|Healthy|Healthy volunteers
11595624|NCT00678717|Experimental|Chronic Visceral Pain|Chronic Visceral Pain patients. Participants will be tested before and after implantation of a Spinal Cord Stimulator (implantation of the Spinal Cord Stimulator is done as usual care and is not a study procedure)
11595625|NCT00678704|Placebo Comparator|Arm 3|
11595626|NCT00678704|Experimental|Arm 1|
11595627|NCT00678704|Experimental|Arm 2|
11595628|NCT00678691|Experimental|A,1|armodafinil
11595629|NCT00678691|Placebo Comparator|A,2|placebo
11595630|NCT00678678|Active Comparator|I - Spirometer|
11595631|NCT00678678|Active Comparator|II - Kit Epap®|Device with Spring load by mask,produced by Brazil (critical med)
11595632|NCT00678652|Experimental|10 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 10 μg with Adjuvant
11595633|NCT00678652|Experimental|25 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 25 μg with Adjuvant
11595634|NCT00678652|Experimental|50 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 50 μg with Adjuvant
11595635|NCT00678652|Experimental|75 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 75 μg with Adjuvant
11595636|NCT00678639|Experimental|Emergency Department (ED) Observation unit|Emergency Department observation unit- Cardiac Magnetic Resonance Imaging (MRI) Protocol. Patients will be transferred to the observation unit and undergo a stress cardiac MRI evaluation.
11595637|NCT00678639|No Intervention|Usual care|This is the comparison arm. Patients are admitted to the hospital and undergo usual care.
11595638|NCT00678626|Experimental|Arm A|combination of CP-751,871 + docetaxel administered
11595639|NCT00678626|Active Comparator|Arm B|chemotherapy
11595640|NCT00678613|Placebo Comparator|1, Primary prophylaxis|"Patients with liver cirrhosis with ascites having ascitic fluid protein <1 gm/dl will be included in this arm.
~They will be randomized between probiotics and placebo."
11595641|NCT00678613|Active Comparator|2, secondary prophylaxis|"Patients with liver cirrhosis with ascites having history of prior SBP will be included in this arm.
~They will be randomized between probiotics and norfloxacin."
11595642|NCT00678600|Active Comparator|Standard (static) Computer Alerts|Participants in this arm will be assigned to standard care. Participants will be monitored for new laboratory toxicity, suboptimal follow up, and virologic failure. Provider computer alerts will be posted on the participant's electronic health record summary page.
11595643|NCT00678600|Experimental|Enhanced Computer Alerts|Participants in this arm will be assigned to the enhanced alert arm. Participants will be monitored for new laboratory toxicity, suboptimal follow up, and virologic failure. Providers will receive population and asynchronous computer alerts with improved functionality.
11595644|NCT00678587|Placebo Comparator|Placebo|placebo, once daily, oral
11595645|NCT00678587|Active Comparator|Active|75 mg, once daily, oral
11595646|NCT00678574|Experimental|Premenstrual Dysphoric Disorder (PMDD) group|PMDD group received fluoxetine 20 mg daily by mouth for 2-3 months
11595647|NCT00678574|No Intervention|Healthy controls|
11595648|NCT00678561|Experimental|2% CP-690,550 QD|
11595649|NCT00678561|Experimental|0.2% CP-690,550 QD|
11595650|NCT00678561|Experimental|0.02% CP-690,550 QD|
11595651|NCT00678561|Experimental|2% CP-690,550 BID|
11595652|NCT00678561|Experimental|0.2% CP-690,550 BID|
11595653|NCT00678561|Experimental|0.02% CP-690,550 BID|
11595654|NCT00678561|Placebo Comparator|Placebo Vehicle QD|
11595655|NCT00678561|Placebo Comparator|Placebo Vehicle BID|
11595656|NCT00678548|Experimental|guided imagery|CD
11595657|NCT00678548|Active Comparator|pain diary|Pain diary
11595658|NCT00678535|Experimental|Cetuximab plus Capecitabine plus Cisplatin|
11595659|NCT00678535|Active Comparator|Capecitabine plus Cisplatin|
11595660|NCT00678509|Experimental|A|
11595661|NCT00678496|Experimental|1|CBT software delivered in a primary care facility (n=6)
11595662|NCT00678496|Experimental|2|CBT delivered at home (n=6)
11595663|NCT00678496|Other|3|Treatment as usual (n=12)
11595664|NCT00678483|Experimental|1|10 mg
11595665|NCT00678483|Experimental|2|20 mg
11595666|NCT00678470|Experimental|Single Arm|Investigational intervention without random assignment
11595667|NCT00678457|Experimental|ondansetron/olanzapine|"ondansetron (4 μg/kg b.i.d.)
~olanzapine (9 μg/kg)"
11595668|NCT00678457|Placebo Comparator|placebo|placebo
11595669|NCT00678444|No Intervention|Arm 1: Non-educational video self-cath|Randomized to not watching educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
11595670|NCT00678444|Experimental|Arm 2: Educational Video Self-cath|Randomized to watch educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
11595671|NCT00678431|Placebo Comparator|Arm 1|Liquid placebo
11595672|NCT00678431|Experimental|Arm 2|Liquid Resveratrol with Glucose, and Malate
11595673|NCT00678418|Experimental|VIVITROL® 380 mg|
11595674|NCT00678418|Placebo Comparator|Placebo|
11595675|NCT00678405|Active Comparator|WLm / WLnm|Best supportive care
11595676|NCT00678405|Experimental|FTm / FTnm|Breathlessness Intervention Service
11595677|NCT00678392|Experimental|Axitinib|
11595681|NCT00678379|Experimental|Lidocaine + Bupivacaine + Clondine|Submucosal injection of 1.5 mL Lidocaine 1% + Bupivacaine 0.5% + Clondine 25mcg into the tonsillar fossa, pre-tonsillectomy
11595682|NCT00678366|Experimental|1|addition of 4% oxygen to the carbon dioxide pneumoperitoneum
11595683|NCT00678366|Active Comparator|2|pure carbon dioxide pneumoperitoneum
11595684|NCT00678353||1|Follow-up to S01-01US, conducted to expand information
11595685|NCT00678340|Active Comparator|1|WACA and PVI
11595686|NCT00678340|Active Comparator|2|PVAC
11595687|NCT00678327|Active Comparator|Arm I|Patients receive ABVD chemotherapy comprising doxorubicin hydrochloride IV, bleomycin IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11595688|NCT00678327|Active Comparator|Arm II|Patients receive AVD chemotherapy comprising doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11595689|NCT00678327|Experimental|BEACOPP-14 chemotherapy|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine hydrochloride and oral prednisolone on days 1-7; and bleomycin IV and vincristine IV on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 8-13 OR pegfilgrastim SC once on day 8. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11595690|NCT00678327|Experimental|BEACOPP-escalated chemotherapy|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine hydrochloride on days 1-7; oral prednisolone on days 1-14; and bleomycin IV and vincristine IV on day 8. Patients also receive G-CSF SC beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11595691|NCT00678314|Active Comparator|Group A|
11595692|NCT00678314|Active Comparator|Group B|
11595693|NCT00678314|Placebo Comparator|Group C|
11595694|NCT00678301|Experimental|SYNFLORIX™ + ZILBRIX™ HIB + POLIO SABIN™|Subjects in this group received 3 doses of Synflorix™ vaccine, according to a 3-dose schedule at 6-10-14 weeks of age co-administered with 3 doses of Expanded Program on Immunization (EPI) vaccines Zilbrix™ Hib and Polio Sabin™ according to the same schedule. The Synflorix™ and Zilbrix™ Hib vaccines were administered by intramuscular injection, in the right and left thigh respectively. The Polio Sabin™ vaccine was administered orally.
11595695|NCT00678301|Experimental|ZILBRIX™ HIB + POLIO SABIN™|Subjects in this group received 3 doses of Expanded Program on Immunization (EPI) vaccines Zilbrix™ Hib and Polio Sabin™ according to a 3-dose schedule at 6-10-14 weeks of age. The Zilbrix™ Hib vaccine was administered by intramuscular injection, in the left thigh. The Polio Sabin™ vaccine was administered orally.
11595696|NCT00678288|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) twice daily (bid) per os (po), continuously.
11595697|NCT00678288|Experimental|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) twice daily (bid) per os (po), continuously plus Interferon (IFN) alpha-2a 3 millions of international unit (MIU) five times a week (FIW) subcutaneous (s.c.), from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
11595698|NCT00678275|Other|A|Hematopoeitic Stem Cell Transplantation from HLA-identical sibling, RECEIVING ATG in conditioning regimen
11595699|NCT00678275|Other|B|Hematopoeitic Stem Cell Transplantation from HLA-identical sibling, NOT RECEIVING ATG in conditioning regimen
11595700|NCT00678249|Experimental|FLAIR|Primary PTA followed by placement of the FLAIR Endovascular Stent Graft
11595701|NCT00678249|Active Comparator|PTA Only|Percutaneous Transluminal Angioplasty
11595702|NCT00678249|Experimental|FLAIR Roll-in Participants|Primary Patency followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
11595703|NCT00678236|Active Comparator|1|Refobacin Bone Cement R
11595704|NCT00678236|Active Comparator|2|Refobacin Plus Bone Cement
11595705|NCT00678210|Experimental|1|
11595706|NCT00678210|Experimental|2|
11595707|NCT00678210|Experimental|3|
11595708|NCT00678210|Placebo Comparator|4|
11595709|NCT00678197|Experimental|A|
11595710|NCT00678197|Experimental|B|
11595711|NCT00678197|No Intervention|C|
11595712|NCT00678171|Experimental|OP-1 Putty|Patients randomized to the OP-1 Putty Spinal System arm will receive OP-1 Putty with AVS™TL PEEK Spacer System and XIA® Spinal System.
11595713|NCT00678171|Active Comparator|Autograft|Patients randomized to the Autograft Spinal System arm will receive iliac crest autograft with AVS™TL PEEK Spacer System and XIA® Spinal System.
11595714|NCT00678158|Experimental|1|Patients with metastatic disease to soft tissue.
11595715|NCT00678158|Experimental|2|Patients with metastatic disease to lymph nodes.
11595716|NCT00678158|Experimental|3|Patients with metastatic disease to the bone.
11595717|NCT00678145|Experimental|Healthy|Healthy individuals will receive drug (naloxone, morphine sulfate, epinephrine) and placebo comparator.
11595718|NCT00678145|Experimental|Type 1 Diabetes|T1D individuals will receive drug (naloxone, morphine sulfate, epinephrine) and placebo comparator.
11595719|NCT00678119|Experimental|1: AGS-003+sunitinib|Single arm study AGS-003 plus sunitinib
11595720|NCT00678106|Experimental|1|
11595721|NCT00678093|Experimental|SNAG|SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
11595722|NCT00678080|Experimental|Metformin|Metformin therapy as prescribed by their health care provider
11595723|NCT00678080|Active Comparator|Insulin|Insulin as prescribed by their health care provider
11595724|NCT00678067|Placebo Comparator|Placebo|12 hypercholesterolemic children 3-13 years of age
11595725|NCT00678067|Experimental|DHA+EPA group|12 hypercholesterolemic children 3-13 years of age
11595726|NCT00678067|Experimental|DHA Group|12 hypercholesterolemic children 3-13 years of age
11595727|NCT00678054|Experimental|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|
11595972|NCT00676338|Active Comparator|Pioglitazone|
11595728|NCT00678041|Experimental|Arm 1: Nitrofurantoin Group|extended release nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
11595729|NCT00678041|Placebo Comparator|Arm 2: Placebo Group|identical appearing placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
11595730|NCT00678015|Experimental|1|
11595731|NCT00678002||QOL###|All child subjects in this cohort will be listed for or already have received a solid organ transplant (kidney, heart, or liver).
11595732|NCT00677989||LA|LA group: patients with perforated appendicitis treated by laparoscopic operation intentionally
11595733|NCT00677989||OA|OA group:patients with perforated appendicitis treated by open approach
11595734|NCT00677976||IBS|Children between the ages of 10 and 18 who meet Rome III criteria for IBS as determined by a pediatric gastroenterologist.
11595735|NCT00677976||Control|Healthy children between the ages of 10 and 18.
11595736|NCT00677963|Other|1|Patients with symptomatic 70-99% carotid stenosis who are operated on.
11595737|NCT00677950|Experimental|1|OP-1 Putty
11595738|NCT00677950|Active Comparator|2|Autograft
11595739|NCT00677937|Experimental|1|Intervention to include education and ongoing support
11595740|NCT00677937|No Intervention|2|Control to receive standard care
11595741|NCT00677924|Experimental|Zalutumumab 8 mg/kg|Zalutumumab in combination with Irinotecan
11595742|NCT00677924|Experimental|Zalutumumab 16 mg/kg|Zalutumumab in combination with Irinotecan
11595743|NCT00677898|Experimental|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
11595744|NCT00677898|Active Comparator|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
11595745|NCT00677872|Experimental|1|
11595746|NCT00677859|Experimental|Single dose Arm|There will be six cohorts of three patients each. Three escalating doses of MultiStem will be evaluated.
11595747|NCT00677859|Experimental|Repeat Dose Arm|There will be six cohorts of three patients each. Four dosing regimens will be evaluated,varying doses at three times weekly or five times weekly.
11595748|NCT00677846||3|Patients with symptoms of deep venous thrombosis less than for 2 weeks, with thrombus occluding without any reperfusion in color mode in the common femoral vein (CFV), the femoral vein (FV) or the popliteal vein (PV)
11595749|NCT00677833|Experimental|1|
11595750|NCT00677833|Experimental|2|
11595751|NCT00677820|Experimental|Trivalent influenza virus vaccine|Frozen trivalent vaccine containing new strains
11595752|NCT00677820|Placebo Comparator|Placebo|treatment with placebo
11595753|NCT00677807|Experimental|Indacaterol 150 µg|"Indacaterol 150 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).
~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
11595754|NCT00677807|Experimental|Indacaterol 300 µg|"Indacaterol 300 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).
~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
11595755|NCT00677807|Placebo Comparator|Placebo|"Placebo once-daily (o.d.) via SDDPI.
~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
11595756|NCT00677794|Active Comparator|1|Clear fluids only after lunch.
11595757|NCT00677794|Active Comparator|2|Two sachets of picosalax the evening prior to Video Capsule Endoscopy (VCE).
11595758|NCT00677794|Active Comparator|3|Polyethylene glycol, 2 liters the evening prior to Video Capsule Endoscopy (VCE).
11595759|NCT00677781||F64|We investigate a cohort of 20 consecutive patients undergoing hepatic or pancreatic surgery (Pilot study)
11595760|NCT00677768||Early ALS|
11595761|NCT00677768||Suspected ALS|
11595762|NCT00677768||Disease Mimics of ALS|
11595763|NCT00677768||Healthy Controls|
11595764|NCT00677755|Experimental|Mf+Ms|The women in mifepristone combined misoprostol group (Mf+Ms) received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
11595765|NCT00677755|Experimental|Ms-alone|The control group (Ms-alone) patients were only administered 0.8 mg of misoprostol orally on day 3.
11595766|NCT00677742|Experimental|1|enhanced initial supply of oral contraception
11595767|NCT00677742|Active Comparator|2|conventional initial supply of oral contraception
11595768|NCT00677729|Active Comparator|1|4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline (NaCl)
11595769|NCT00677729|Placebo Comparator|2|4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl)
11595770|NCT00677716|Experimental|131I-chTNT-1/B MAb (Cotara)|
11595771|NCT00677703|No Intervention|Standard Care|Participants will receive standard care without daily reminders.
11595772|NCT00677703|Experimental|Text Messages|Participants will receive a daily text message reminder for 6 months
11595773|NCT00677690|Active Comparator|NM+PR|Patients undergone to combination of neuromuscular stimulation and pulmonary rehabilitation (NM+PR)
11595774|NCT00677690|Placebo Comparator|SS+PR|Patients undergone to pulmonary rehabilitation
11595775|NCT00677664|Active Comparator|A|Group which received Copaxone
11595776|NCT00677664|Placebo Comparator|B|Group which received Mannitol
11595777|NCT00677651||1|Five caucasian women
11595778|NCT00677651||2|Five caucasian men
11595779|NCT00677638|Experimental|1|Embracer implantation
11595780|NCT00677625||Liver Disease (LD)|These child subjects have some form of liver disease (including those who need a liver transplant) or have already had a liver transplant.
11595781|NCT00677612|Experimental|A|
11595782|NCT00677599|Active Comparator|Intervention A|Experimental arm enriched with flavonoids
11595783|NCT00677599|Placebo Comparator|Intervention B|
11595784|NCT00677586|Experimental|1|simultaneous resection of liver metastasis and the colorectal primary tumor
11595785|NCT00677586|Active Comparator|2|staged resection of the liver metastasis and the colorectal primary tumor
11595786|NCT00677573|Active Comparator|UrFSH|
11595787|NCT00677560||1|Asthma
11595788|NCT00677560||2|COPD
11595789|NCT00677560||3|Normal subjects
11595790|NCT00677547||1|Kidney transplant recipients
11595791|NCT00677547||2|Healthy volunteers
11595792|NCT00677534|Experimental|1|Cholecalciferol (Vitamin D)
11595793|NCT00677521|Experimental|1|
11595794|NCT00677508||C FR|Children with constipation and fecal incontinence.
11595795|NCT00677508||C|Children with constipation but without fecal incontinence.
11595796|NCT00677508||P-C FR|Parents of children with constipation and/or fecal incontinence.
11595797|NCT00677495|Experimental|Gluten-free diet|Gluten-free diet
11595798|NCT00677482||1|Solid organ transplant recipients with both asymptomatic CMV viremia, and symptomatic CMV disease are eligible for inclusion in the study. THis includes liver, kidney, heart, pancreas, lung, intestinal and combined transplant recipients.
11595799|NCT00677469|Experimental|I|Cholestyramine 2g BID, Methimazole 10mg TID, and Propranolol 20mg BID
11595800|NCT00677469|Experimental|II|Cholestyramine 1g BID, Methimazole 10mg TID, and Propranolol 20mg BID
11595801|NCT00677469|Placebo Comparator|III|Placebo powder 1g BID, Methimazole 10mg TID, and Propranolol 20mg BID
11595802|NCT00677456|Active Comparator|1|Patients will receive R-Y reconstruction after total gastrectomy as intervention
11595803|NCT00677456|Active Comparator|2|Patients will receive P-Y reconstruction after total gastrectomy as intervention
11595804|NCT00677456|Active Comparator|3|Patients will receive Pouch reconstruction after total gastrectomy as intervention.
11595805|NCT00677456|Active Comparator|4|Patients will receive P-I reconstruction after total gastrectomy as intervention.
11595806|NCT00677443|Experimental|S-1 and Oxaliplatin|"S-1 and Oxaliplatin
~S-1 : 80 mg/m2/day D1-14 Oxaliplatin : 130 mg/m2/day D1 Repeated every 3 weeks"
11595807|NCT00677443|Active Comparator|Capecitabine and Oxaliplatin|Capecitabine and Oxaliplatin
11595808|NCT00677430||Questionnaire + Digital Imaging|A brief questionnaire packet will be completed. Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
11595809|NCT00677404|Experimental|stem cell recipient|the patients with peripheral vascular disease who receive bone marrow derived mono nuclear cells
11595810|NCT00677391|Active Comparator|1|
11595811|NCT00677391|Placebo Comparator|2|
11595812|NCT00677378||EXPERIMENTAL|Children undergoing an endoscopy for retrosternal chest pain, epigastric pain, regurgitation, heart burn or dyspepsia.
11595813|NCT00677378||CONTROL|Children undergoing an endoscopy for reasons not stated in the experimental group condition (i.e. celiac disease, rectal bleeding, polyps, weight loss, malabsorption).
11595814|NCT00677365|Placebo Comparator|Placebo|Placebo inhaled either once or twice daily via the PARI eFlow nebulizer for 28 days
11595815|NCT00677365|Experimental|MP-376 120 mg QD|MP-376 120 mg inhaled Once Daily (QD) via the PARI eFlow nebulizer for 28 days
11595816|NCT00677365|Experimental|MP-376 240 mg QD|MP-376 240 mg inhaled QD bia the PARI eFlow nebulizer for 28 days
11595817|NCT00677365|Experimental|MP-376 240 mg BID|MP-376 240 mg inhaled twice daily (BID) via the PARI eFlow nebulizer for 28 days
11595818|NCT00677352|Experimental|1|
11595819|NCT00677352|Active Comparator|2|
11595820|NCT00677339|Active Comparator|1|Active L-arginine plus active vitamin D
11595821|NCT00677339|Active Comparator|2|Placebo L-arginine plus active Vitamin D
11595822|NCT00677339|Active Comparator|3|Active L-arginine plus placebo vitamin D
11595823|NCT00677339|Placebo Comparator|4|placebo L-arginine plus placebo vitamin D
11595824|NCT00677326|Experimental|A|Peptide administered
11595825|NCT00677313|Experimental|1|
11595826|NCT00677300|Experimental|Group A|Will receive Raltegravir (400mg twice daily) + Ritonavir-boosted (100mg once daily) Darunavir (800mg once daily)
11595827|NCT00677300|Active Comparator|Group B|Will receive Tenofovir (300mg once daily) + Emtricitabine (200mg once daily) + Ritonavir-boosted (100mg once daily) Darunavir (800mg once daily)
11595828|NCT00677287|Experimental|A|
11595829|NCT00677274|Active Comparator|1|Epidural analgesia initiated at the cervix 0cm
11595830|NCT00677274|Active Comparator|2|Epidural analgesia initiated at the cervix 0.5cm
11595831|NCT00677274|Active Comparator|3|Epidural analgesia initiated at the cervix 1.0cm
11595832|NCT00677274|Active Comparator|4|Epidural analgesia initiated at the cervix 1.5cm
11595833|NCT00677274|Active Comparator|5|Epidural analgesia initiated at the cervix 2.0cm
11595834|NCT00677274|Active Comparator|6|Epidural analgesia initiated at the cervix 3.0cm
11595835|NCT00677274|Active Comparator|7|Epidural analgesia initiated at the cervix 4.0cm
11595836|NCT00677274|Active Comparator|8|Epidural analgesia initiated at the cervix 5.0cm
11595837|NCT00677261|Experimental|1|
11595838|NCT00677261|Experimental|2|
11595839|NCT00677261|Sham Comparator|3|
11595840|NCT00677248|Placebo Comparator|1|Ezetimibe and placebo
11595841|NCT00677248|Experimental|2|Eprotirome dose 1 and ezetimibe
11595842|NCT00677248|Experimental|3|Eprotirome dose 2 and ezetimibe
11595843|NCT00677248|Experimental|4|Eprotirome dose 3 and ezetimibe
11595844|NCT00677235|Experimental|FLAIR|FLAIR Endovascular Stent Graft
11595845|NCT00677235|Active Comparator|PTA Only|Percutaneous Transluminal Angioplasty
11595846|NCT00677222|Experimental|1|Treatment arm
11595847|NCT00677222|No Intervention|2|Registry Arm -standard of care
11595848|NCT00677209|Active Comparator|A|house dust mite allergics will undergo autovaccine immunization
11595849|NCT00677196|Active Comparator|1|The LMA StoneBreakerTM
11595850|NCT00677196|Active Comparator|2|Pneumatic Lithotripsy
11595851|NCT00677183||SN###.#1|All children in this cohort will have biopsy-proven NASH.
11595852|NCT00677183||SN###.#2|This cohort will be parents (mother and father when possible) of child subjects with biopsy-proven NASH.
11595853|NCT00677170|Experimental|1|MLN4924
11596320|NCT00673829|Experimental|Phase Ib: Control|
11595854|NCT00677157||screening|participants evaluated for possible inclusion in a natural history or intervention protocol
11595855|NCT00677144|Experimental|OS (oxalipaltin+S-1)|OS (oxaliplatin + S-1): Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
11595856|NCT00677144|Active Comparator|XELOX (oxalipaltin+capecitabine)|XELOX (oxalipaltin+capecitabine): Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
11595857|NCT00677131|Active Comparator|1|To read the package insert of the drug
11595858|NCT00677131|Active Comparator|2|To read the education information provided by the Pharmacy of NTUH
11595859|NCT00677131|Active Comparator|3|Oral education provided by the pharmacist
11595860|NCT00677118|Experimental|Concurrent and adjuvant|Concurrent chemoradiotherapy plus adjuvant chemotherapy
11595861|NCT00677118|Active Comparator|Concurrent|Concurrent chemoradiotherapy
11595862|NCT00677092|Experimental|Imatinib Mesylate (IM) Treatment|Imatinib mesylate 400 milligrams (mg) orally once daily for 4 months. Dosage was reduced to 200 mg if the participant developed gastrointestinal intolerance or alopecia.
11595863|NCT00677079|Experimental|Iniparib|Iniparib, twice weekly on Days 1 and 4 of each week during 8-week cycles
11595864|NCT00677066|Experimental|1|Children discharged home with oxygen
11595865|NCT00677066|No Intervention|2|Children remain in hospital for oxygen therapy
11595866|NCT00677053|Experimental|TAK-442 10 mg BID|Added with standard care for recurrent ischemic events.
11595867|NCT00677053|Experimental|TAK-442 20 mg BID|Added with standard care for recurrent ischemic events
11595868|NCT00677053|Experimental|TAK-442 40 mg QD|Added with standard care for recurrent ischemic events
11595869|NCT00677053|Experimental|TAK-442 40 mg BID|Added with standard care for recurrent ischemic events
11595870|NCT00677053|Experimental|TAK-442 80 mg QD|Added with standard care for recurrent ischemic events
11595871|NCT00677053|Experimental|TAK-442 80 mg BID|Added with standard care for recurrent ischemic events
11595872|NCT00677053|Experimental|TAK-442 160 mg QD|Added with standard care for recurrent ischemic events
11595873|NCT00677053|Experimental|TAK-442 120 mg BID|Added with standard care for recurrent ischemic events
11595874|NCT00677053|Placebo Comparator|Placebo|Added with standard care for recurrent ischemic events
11595875|NCT00677027|Experimental|1|
11595876|NCT00677027|Placebo Comparator|2|
11595877|NCT00677014|Active Comparator|Echo optimized AV delay|Echo optimized AV delay
11595878|NCT00677014|Active Comparator|Algorithm optimized AV delay|Algorithm optimized AV delay
11595879|NCT00677014|Active Comparator|Fixed AV Delay|Fixed AV Delay
11595880|NCT00676988||Observation|Subjects with Luminal Crohn's Disease receiving infliximab
11595881|NCT00676975|Active Comparator|Traditional Chinese Medicine|Traditional Chinese Medicine 17g herbal extract
11595882|NCT00676975|Placebo Comparator|Traditional Chinese Medicine Placebo|Placebo
11595883|NCT00676962|Experimental|Facilitation|Therapists receive assistance with adopting CBT
11595884|NCT00676949|Experimental|1|cyclophosphamide dose escalation, level 1:150mg/m2,level 2: 300mg/m2, level 3: 300mg/m2x2, with 5 kinds o tumor specific antigen peptides followed by low dose IL-2, 6 patients will be enrolled for each level.
11595885|NCT00676936|Experimental|Methylprednisolone|Methylprednisolone 16 mg twice daily
11595886|NCT00676936|Placebo Comparator|Placebo|Placebo capsules twice daily
11595887|NCT00676897|Experimental|1|Simvastatin 40 mg PO or NGT
11595888|NCT00676897|Placebo Comparator|2|Placebo
11595889|NCT00676884|Experimental|1|Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)
11595890|NCT00676884|Placebo Comparator|2|placebo control
11595891|NCT00676871|Experimental|1|MEDI-538
11595892|NCT00676871|Experimental|2|MEDI-538
11595893|NCT00676871|Experimental|3|MEDI-538
11595894|NCT00676871|Experimental|4|MEDI-538
11595895|NCT00676871|Experimental|5|MEDI-538
11595896|NCT00676871|Experimental|6|MEDI-538
11595897|NCT00676871|Experimental|7|MEDI-538
11595898|NCT00676845|Placebo Comparator|1|A 3-week placebo run-in period.
11595899|NCT00676845|Experimental|2|Olmesartan medoxomil oral tablets, at lowest study dosage for 52-week double-blind treatment period
11595900|NCT00676845|Experimental|3|Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 48 weeks.
11595901|NCT00676845|Experimental|4|Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 4 weeks followed by the highest study dose for 44 weeks.
11595902|NCT00676832|Placebo Comparator|Group 1|
11595903|NCT00676832|Experimental|Group 2|
11595904|NCT00676832|Experimental|Group 3|
11595905|NCT00676832|Experimental|Group 4|
11595906|NCT00676832|Experimental|Group 5|
11595907|NCT00676806|Experimental|Myeloablative conditioning|Umbilical cord blood for hematopoietic rescue following myeloablative conditioning
11595908|NCT00676806|Experimental|Reduced intensity conditioning|Umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
11595909|NCT00676793|Experimental|Polyphenon E|This is a single arm study comparing changes within patients before and after receiving the experimental drug Polyphenon E for the duration of the study, between recruitment and surgery for breast cancer.
11595910|NCT00676780|Experimental|ECGC Extract|Single arm for a phase II study
11595911|NCT00676767|Experimental|1|
11595912|NCT00676767|Active Comparator|2|
11595913|NCT00676767|Placebo Comparator|3|
11595914|NCT00676741||A|
11595915|NCT00676741||B|
11595916|NCT00676741||C|
11595917|NCT00676728|Experimental|JNJ-26481585|
11595918|NCT00676715|Placebo Comparator|Placebo|Participants received two intravenous (IV) infusions of matching placebo separated by 14 days in Cycle 1, followed by two infusions of ocrelizumab 300 mg separated by 14 days in cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4. Each cycle was of 168 days.
11596128|NCT00675298||2|Women with painful bladder syndrome/interstitial cystitis
11595919|NCT00676715|Experimental|Ocrelizumab 600 mg|Participants two IV infusions of ocrelizumab 300 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 600 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
11595920|NCT00676715|Experimental|Ocrelizumab 1000 mg|Participants received two IV infusions of ocrelizumab 1000 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 1000 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 1000 mg was administered on Day 1 of Cycle 3 and a single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycle 4. Each cycle was of 168 days.
11595921|NCT00676715|Active Comparator|Avonex|Participants received weekly intramuscular injections of Avonex 30 microgram (mcg) in Cycle 1, followed by two infusions of OCR 300 mg separated by 14 days in Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
11595922|NCT00676702|Experimental|001|Pancrelipase in combination with Ensure Plus 3 pancrelipase MT 21 capsules containing a total of 63 000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
11595923|NCT00676702|Active Comparator|002|Ensure Plus A high-fat liquid meal of 500 ml of Ensure Plus
11595924|NCT00676689|Experimental|SAPIEN THV|
11595925|NCT00676676|Active Comparator|Testosterone|Testosterone patch delivering 300mcg daily for 8-weeks.
11595926|NCT00676663|Experimental|Exemestane 25 mg + Entinostat 5 mg|Exemestane (Aromasin®) 25 mg tablets orally once daily plus an entinostat 5 mg tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor, whichever occurred first.
11595927|NCT00676663|Placebo Comparator|Exemestane 25 mg + Placebo|Exemestane (Aromasin®) 25 mg tablets orally once daily plus a placebo-matching entinostat tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor, whichever occurred first.
11595928|NCT00676650|Experimental|A|Treatment Arm A - sunitinib + prednisone
11595929|NCT00676650|Placebo Comparator|B|Treatment Arm B - placebo + prednisone
11595930|NCT00676637||Travalert with DuoTrav|One drop in study eye(s) once daily in the evening for four months
11595931|NCT00676624||Uveitis|Patients suffering from uveitis, who have vitrectomy performed for diagnostic purpose
11595932|NCT00676624||Control group|"Patients suffering from either Epiretinal fibrosis og Macula hole who have vitrectomy performed for curative reasons"
11595933|NCT00676585|Placebo Comparator|2|Normal Saline
11595934|NCT00676585|Experimental|1|Hydrocortisone 100mg every 8 hours.
11595935|NCT00676572||Severe asthma|
11595936|NCT00676572||Non-severe asthma|
11595937|NCT00676559|Experimental|Group 1|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
11595938|NCT00676559|Experimental|Group 2|Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
11595939|NCT00676559|Experimental|Group 3|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks in combination with ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
11595940|NCT00676533|Experimental|Arm 1|
11595941|NCT00676520||1|Single-arm study
11595942|NCT00676507|Experimental|Treatment|Treatment Arm: This course of therapy is Best Support Care (BSC) plus monthly intradermal (ID) injections of Lucanix™ (belagenpumatucel-L) consisting of 25,000,000 cells in a volume of 0.40 mL.
11595943|NCT00676507|Placebo Comparator|Control Arm|Control Arm: This course of therapy is Best Support Care (BSC) plus a placebo injection that consists of 0.15% Intralipid® in solution composed of the cryopreservation formulation minus the gene modified cells and dimethyl sulfoxide (DMSO) in a volume of 0.40 mL.
11595944|NCT00676481|Active Comparator|1|Phase III participants who are educated about risk of HIV infection before receiving a rapid HIV test
11595945|NCT00676481|No Intervention|2|Phase III participants who are not educated about risk of HIV infection before receiving a rapid HIV test
11595946|NCT00676468|Other|1|Active Montelukast + Fish Oil Placebo
11595947|NCT00676468|Other|2|Active Fish Oil + Montelukast Placebo
11595948|NCT00676468|Other|3|Active Montelukast + Active Fish Oil
11595949|NCT00676442|Other|1|PN400 administered after meal
11595950|NCT00676442|Other|2|PN400 administered prior to meal
11595951|NCT00676442|Other|3|PN400 administered prior to meal
11595952|NCT00676442|Other|4|PN400 followed by fast
11595953|NCT00676429|Experimental|1|Ziprasidone Hydrochloride oral solution with individual titration from 5 mg to 40 mg per day
11595954|NCT00676429|Placebo Comparator|2|Placebo oral solution
11595955|NCT00676416||1|Propofol general anesthesia for asthmatic patients
11595956|NCT00676416||2|Propofol general anesthesia for non-asthmatic patients
11595957|NCT00676403|Placebo Comparator|1|Placebo
11595958|NCT00676403|Experimental|2|investigational treatment
11595959|NCT00676403|Experimental|3|investigational treatment
11595960|NCT00676403|Experimental|4|investigational treatment
11595961|NCT00676403|Experimental|5|investigational treatment
11595962|NCT00676403|Experimental|6|investigational treatment
11595963|NCT00676390|Other|1|Congestive Heart failure patients
11595964|NCT00676377|Experimental|1|Neostigmine
11595965|NCT00676377|Placebo Comparator|2|Placebo
11595966|NCT00676364|Active Comparator|4% lidocaine topical anesthetic cream|This group received topical 4% lidocaine anesthetic cream under occlusive dressing for 15 minutes prior to needle stick.
11595967|NCT00676364|Placebo Comparator|Placebo|This group received matching placebo cream under occlusive dressing for 15 minutes prior to needle stick.
11595968|NCT00676351|Other|A|body plethysmography Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
11595969|NCT00676338|Experimental|Exenatide Once Weekly|
11595970|NCT00676338|Active Comparator|Metformin|
11595971|NCT00676338|Active Comparator|Sitagliptin|
11595973|NCT00676325|Active Comparator|1|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction were eligible for participation.traditional colporrhaphy in this group.
11595974|NCT00676325|Active Comparator|2|The NAZCA TC™ POP REPAIR SYSTEM (polypropylene mesh repair),promedon™ , cordoba, argentina, is used to repair anterior vaginal prolapse by a transobturator and pre pubic approach . Helical needles are used to anchor graft to the pelvic sidewall at two points transobturator, the other two arms pre pubic needles is used. We designed this randomized control trial to compare the anatomic success rates, effect on quality of life and sexual symptom scores, and rates of adverse events of the procedure with polypropylene mesh with that of anterior colporrhaphy, with planned follow-up of 1 years.
11595975|NCT00676312|Experimental|1|Cross-over treatment with increasing doses of PTH134, placebo and active comparator.
11595976|NCT00676273|Active Comparator|1|TVTO
11595977|NCT00676273|Active Comparator|2|TVTS
11595978|NCT00676260|Experimental|Pioglitazone QD|
11595979|NCT00676260|Placebo Comparator|Placebo QD|
11595980|NCT00676247||preterm|Very-low-birth-weight preterm infants with brain lesion
11595981|NCT00676247||full-term|Healthy fullterm infants
11595982|NCT00676234|No Intervention|1|
11595983|NCT00676234|Experimental|2|Administration of intravenous rhu Epo on Day 0
11595984|NCT00676208|Experimental|Shared Medical Appointments|Medical students participated in shared medical appointments for patients with diabetes for one month.
11595985|NCT00676208|No Intervention|No shared medical appointments|Medical students in this arm did not participate in shared medical appointments.
11595986|NCT00676195|Experimental|N-Acetyl Cysteine|"Dosage of orally administered N-Acetyl Cysteine is as follows:
~Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day"
11595987|NCT00676182||Arm 1: Telerehabilitation|telerehabilitation
11595988|NCT00676169||Observational|Pa negative or concurrently enrolled in the EPIC Clinical Trial
11595989|NCT00676156|Active Comparator|A|This arm involves a 1-day pharmacokinetics study of three different formulations of oral lipoic acid.
11595990|NCT00676156|Active Comparator|B|This arm will examine the pharmacokinetics of LA with and without fish oil supplement in a cross over design.
11595991|NCT00676156|Active Comparator|C|This arm will include the study of a single dose of R enantiomer lipoic acid.
11595992|NCT00676143|Experimental|Bapineuzumab 0.5 mg/kg|
11595993|NCT00676143|Placebo Comparator|Placebo|
11595994|NCT00676130|Active Comparator|Standard therapy|cephalexin plus placebo
11595995|NCT00676130|Experimental|Standard plus anti-CA-MRSA|cephalexin plus trimethoprim-sulfamethoxazole
11595996|NCT00676117|Experimental|1|
11595997|NCT00676117|Active Comparator|2|
11595998|NCT00676104|Experimental|Treatment|
11595999|NCT00676104|Sham Comparator|Control|
11596000|NCT00676091|Experimental|13vPnC|13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).
11596001|NCT00676091|Active Comparator|7vPnC|7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).
11596002|NCT00676065||1|Women who take oral contraceptives containing drospirenone
11596003|NCT00676065||2|Women who take oral contraceptives containing levonorgestrel
11596004|NCT00676065||3|Women who take oral contraceptives containing other progestogens
11596005|NCT00676052|Experimental|Arm 1|GSK233705 12.5mcg
11596006|NCT00676052|Experimental|Arm 2|GSK233705 25mcg
11596007|NCT00676052|Experimental|Arm 3|GSK233705 50mcg
11596008|NCT00676052|Experimental|Arm 4|GSK233705 100mcg
11596009|NCT00676052|Experimental|Arm 5|GSK233705 200mcg
11596010|NCT00676052|Placebo Comparator|Arm 6|Placebo
11596011|NCT00676039|Active Comparator|1|"Crossover Effexor / NOVO-Venlafaxine
~Examination of the bioequivalence of Effexor (Wyeth Pharmaceuticals) and NOVO-Venlafaxine (NOVOPHARM).
~Both drugs will be given at the dose of 75 mg/day (one capsule per day) for 4 consecutive days. A washout period (corresponding to 10 half-life of the active metabolite desmethylvenlafaxine) will be respected after receiving each medication."
11596012|NCT00676039|Active Comparator|2|"Crossover Celexa/Gen-citalopram
~Examination of the bioequivalence of Celexa (Lundbeck, Brand Name) and Gen-Citalopram (Genpharm, Generic). Both drugs will be given at the dose of 40 mg/day (one tablet per day) for 8 consecutive days. A washout period (corresponding to 10 half-life of citalopram) will be respected after receiving each medication."
11596013|NCT00676026|Experimental|Zolpidem 1|Zolpidem will be administered twice to each participant; once in the follicular and luteal phases of the menstrual cycle.
11596014|NCT00676026|Experimental|Progesterone 2|Progesterone will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.
11596015|NCT00676026|Experimental|Fluoxetine 3|Fluoxetine will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.
11596016|NCT00676013|Experimental|Alloderm, Integra, Homograft, Autograft|Burn debridement and grafting using interventions of 1) AlloDerm, 2) Integra, 3) Homograft and 4) Autograft on four separate sites on each patient
11596017|NCT00676000|Active Comparator|1|Interrupted vaginal closure
11596018|NCT00676000|Active Comparator|2|Continuous vaginal closure
11596019|NCT00675987|Active Comparator|Losartan|Losartan 100 mg 1 tab po QD
11596020|NCT00675987|Placebo Comparator|Placebo|Placebo 1 tab po QD
11596021|NCT00675974|Experimental|1|Pressure garment therapy
11596022|NCT00675974|No Intervention|2|No pressure garment therapy
11596023|NCT00675961|Experimental|1|Behavioral Counseling Intervention (BCI) plus treatment as usual (TAU) (i.e. standard referral to and management by an addictions specialist)
11596024|NCT00675961|Experimental|2|Naltrexone/ Brief Behavioral Compliance Enhancement Treatment (BBCET) plus TAU
11596025|NCT00675961|Experimental|3|BCI + Naltrexone/BBCET plus TAU
11596026|NCT00675961|Active Comparator|4|Treatment as Usual (TAU)
11596027|NCT00675948|Experimental|Sativex|Active treatment
11596028|NCT00675948|Experimental|GW-2000-02|Active treatment
11596543|NCT00672360|Placebo Comparator|2|
11596029|NCT00675935|Experimental|1|One high-risk medical unit at each hospital will be randomly assigned to receive the fall prevention toolkit
11596030|NCT00675935|No Intervention|2|One high-risk medical unit at each hospital will be randomly assigned to receive usual care as it relates to fall prevention; i.e., receives no intervention.
11596031|NCT00675922|Experimental|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon 5% Solution and Silver Nitrate soaked dressings to two different burned area. Sites were then monitored for infections during hospitalization.
11596032|NCT00675909|Active Comparator|Oral Midazolam|Oral midazolam 0.5mg/kg
11596033|NCT00675909|Experimental|Aerosolized intranasal midazolam|Intranasal midazolam 0.3mg/kg
11596034|NCT00675909|Experimental|Aerosolized buccal midazolam|Buccal midazolam 0.3mg/kg
11596035|NCT00675896|Experimental|1|Quetiapine Fumarate Sustained Release(Seroquel SR)50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator, using patient tolerance and response as guidelines over the duration of the trial.
11596036|NCT00675896|Placebo Comparator|2|Placebo
11596037|NCT00675883||Prospective|500 patients who will be enrolled in the MS Alliance program will be consented to participate in this study.
11596038|NCT00675883||Retrospective|500 patient chart reviews will be completed for patients who were enrolled in the MS Alliance program between two (2) to three (3) years ago.
11596039|NCT00675870|Experimental|1|
11596040|NCT00675857|Placebo Comparator|A|
11596041|NCT00675857|Active Comparator|B|
11596042|NCT00675844|Experimental|elvucitabine|Subjects currently receiving elvucitabine will continue elvucitabine as part of their ART regimen for an additional 48 months.
11596043|NCT00675831|Experimental|CD25+ Treg depleted DLI dose schema|"Patients will receive a defined dose of CD25+ Treg depleted DLI. 5 patients will be enrolled, initially at dose level B, and subsequent cohorts will be dose adjusted per the CD3+ dose escalation/de-escalation schema:
~Dose level -C: 3x10^7 (CD3+Dose (#cells/kg*))
~Dose level -B: 1x10^7 (CD3+Dose (#cells/kg*))
~Dose level -A: 1x10^6 (CD3+Dose (#cells/kg*)) *Recipient's body weight in Kg"
11596044|NCT00675818|Experimental|1|CVVH: Patients in this arm will receive CVVH at a replacement fluid rate of 35 mL/kg/h.
11596045|NCT00675818|Active Comparator|2|CVVHD: Patients in this arm will receive CVVHD at a dialysate flow rate of 35 mL/kg/h.
11596046|NCT00675805|Active Comparator|Group I|IVIG infusion with filter
11596047|NCT00675805|Placebo Comparator|Group II|IVIG infusion without filter
11596048|NCT00675792|Experimental|Sugammadex|4 mg/kg sugammadex
11596049|NCT00675792|Active Comparator|Neostigmine|50 µg/kg neostigmine
11596050|NCT00675779|Experimental|2|oral contraceptive + atorvastatin
11596051|NCT00675779|Active Comparator|1|oral contraceptive
11596052|NCT00675766||Group 1|HIV-positive adults 50 and older/ HIV-positive adults 18-40 years old
11596053|NCT00675766||Group 2|HIV-negative controls 50 and older / HIV-negative controls 18-40 years old
11596054|NCT00675766||Group 3|HIV-negative controls 50 and older / HIV-negative controls 18-40 years old
11596055|NCT00675766||Group 4|HIV-negative controls 18-40 years old
11596056|NCT00675753||Preterm group|Preterm (36 6/7 weeks gestation or earlier) mothers and their newborns.
11596057|NCT00675753||Term group|Term (> 37 weeks gestation) mothers and their newborns.
11596058|NCT00675740|Experimental|1|
11596059|NCT00675740|Active Comparator|2|physical exercise
11596060|NCT00675740|No Intervention|3|control
11596061|NCT00675714|Experimental|1|Humatrope subcutaneous(SQ) 0.05-0.2 mg/kg/day for up to 2 years post burn
11596062|NCT00675714|Experimental|2|Ketoconazole by mouth (PO) given twice a day throughout hospitalization for up to 2 years post burn
11596063|NCT00675714|Experimental|3|Oxandrolone PO given daily throughout hospitalization for up to 2 years post burn
11596064|NCT00675714|Experimental|4|Propranolol PO given daily throughout hospitalization for up to 2 years post burn
11596065|NCT00675714|Experimental|5|Oxandrolone and propranolol PO to be given daily for up to 2 years post burn
11596066|NCT00675714|Experimental|6|Humatrope SQ and Propranolol PO to be given daily for up to 2 years post burn
11596067|NCT00675714|Placebo Comparator|7|Placebo PO to be given for up to 2 years post burn
11596068|NCT00675714|Experimental|8|Exercise--hospital supervised intensive exercise program
11596069|NCT00675714|Experimental|9|Exercise--home or community based exercise program
11596070|NCT00675701|Placebo Comparator|A|Placebo by mouth
11596071|NCT00675701|Experimental|B|lixivaptan
11596072|NCT00675701|Active Comparator|C|moxifloxacin
11596073|NCT00675688|Experimental|A|
11596074|NCT00675688|Active Comparator|B|
11596075|NCT00675688|Placebo Comparator|C|
11596076|NCT00675675|Active Comparator|Comprehensive Behavioral Intervention for Tics (CBIT)|Habit Reversal Training (HRT) plus functional assessment/intervention designed to identify and ameliorate environmental triggers for and consequences to tics that might serve to maintain and/or generalize these symptoms
11596077|NCT00675675|Other|Minimal Contact Waitlist|Bimonthly phone check-in to assess illness severity and maximize subject retention
11596078|NCT00675662|Experimental|1|Stratification by angiotensin converting enzyme (ACE) genotype
11596079|NCT00675662|Placebo Comparator|2|Waiting list controls
11596080|NCT00675649|Experimental|001|
11596081|NCT00675649|Placebo Comparator|002|
11596082|NCT00675623|Experimental|A|Dimebon, 5 mg orally three times daily
11596083|NCT00675623|Experimental|B|Dimebon 20 mg orally three times daily
11596084|NCT00675623|Placebo Comparator|C|Placebo orally three times daily for six months
11596085|NCT00675610|No Intervention|usual care|providers are not trained and patients are not coached
11596086|NCT00675610|Experimental|intervention arm|providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
11596087|NCT00675597|Experimental|1|Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients with Resected Stage I-III Non-small Cell Lung Cancer
11596129|NCT00675298||3|Children with overactive bladder
11597487|NCT00665574|Active Comparator|4|Corticosteroid
11596088|NCT00675584|Active Comparator|Placebo Budesonide|Participants will receive 0.5 mg of ICS (budesonide as Pulmicort Respules®) once a day at night, except during respiratory tract illnesses. During respiratory tract illnesses, participants will receive placebo each morning and 0.5 mg of budesonide each night for 7 days.
11596089|NCT00675584|Experimental|Budesonide|Participants will receive 1 mg of ICS (budesonide as Pulmicort Respules®) twice a day for 7 days at the onset of a respiratory tract illness; they will receive placebo ICS once a day at all other times during the study.
11596090|NCT00675558||Non-Obese (NO)|Patients with a BMI < 29.9 scheduled for clinically indicated laparoscopic abdominal surgery.
11596091|NCT00675558||Morbidly Obese (MO)|Patients with a BMI > 40.0 scheduled for clinically indicated laparoscopic abdominal surgery.
11596092|NCT00675558||Super-morbidly Obese (SMO)|"Patients with a BMI > 50.0 scheduled for clinically indicated laparoscopic abdominal surgery.
~10 subjects of the original 30 subjects enrolled into this group received a second bariatric procedure. The remaining 20 subjects of the original 30 subjects did not continue on to the second phase (second bariatric surgery) of the study."
11596093|NCT00675545|Experimental|docetaxel and prednisolone|"Patients in study will receive both chemotherapeutic agents on day 1 and day 8 of every 21-day cycle as described below:
~Docetaxel 30 mg/m2 over 1 hour IV infusion, followed by
~Carboplatin (AUC 2) over 1 hour IV infusion
~Additonal medication required: IV Dexamethasone 10 mg followed by PO dexamethasone 4 mg 8 hourly x 4 doses, starting 12 hours after starting iv docetaxel."
11596094|NCT00675532|Experimental|1|Primary Care Counseling
11596095|NCT00675532|Experimental|2|Cognitive-behavioral psychotherapy (CBT)
11596096|NCT00675519|Experimental|BI|
11596097|NCT00675506|Experimental|1|Participants will receive treatment with growth hormone releasing hormone 1-44 (TH9507).
11596098|NCT00675506|Placebo Comparator|2|Participants will receive treatment with placebo medication.
11596099|NCT00675493||A|
11596100|NCT00675480|Experimental|T|Patients treated with thrombectomy: T
11596101|NCT00675480|Active Comparator|P|Patients treated with standard PCI with stent implantation
11596102|NCT00675467||Group 1|Early cancer group-children ages 10-13 years
11596103|NCT00675467||Group 2|Early cancer group-children ages 14 to 18 years
11596104|NCT00675467||Group 3|Early cancer group-parents of patients ages 10-18 years
11596105|NCT00675467||Group 4|Advanced cancer group-children ages 10-13 years
11596106|NCT00675467||Group 5|Advanced cancer group-children ages 14-18 years
11596107|NCT00675467||Group 6|Advanced cancer group-parents of children ages 10-18 years
11596108|NCT00675467||Group 7|End of life group - parents of children ages birth to 18 years of age at time of death
11596109|NCT00675441|Experimental|Lenalidomide|Lenalidomide 10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
11596110|NCT00675428|Experimental|Natalizumab 300 mg|Intravenous (IV) infusions of natalizumab 300 mg once every 28 days for 6 months.
11596111|NCT00675428|Experimental|Natalizumab 450 mg|Intravenous (IV) infusions of natalizumab 450 mg once every 28 days for 6 months.
11596112|NCT00675415|Active Comparator|Capnography|"Capnography: Subjects randomized to capnography-titration arm: The endoscopy team would be made aware of the capnographic abnormalities as they arise.
~In this arm, the endoscopy team will have the graphic representation of respiratory activity (capnography) as well as end-epxiratory levels of carbon dioxide in addition to the normal physiologic monitoring portfolio of pulse oximetry, blood pressure and electrocradiography.
~This observation phase would take place for a baseline prior to sedation, during the administration of sedation as well as throughout the procedure. Monitoring for the study would stop upon completion of the endoscopic procedure."
11596113|NCT00675415|No Intervention|Standard Monitoring|Subjects randomized to capnography-blinded arm: In this arm, the endoscopy team will not have the graphic representation of respiratory activity (capnography) as well as end-expiratory levels of carbon dioxide available. Only a standard of care physiologic monitoring portfolio of pulse oximetry, blood pressure and electrocradiography at the disposal of the endoscopy team to titrate the sedative medications.
11596114|NCT00675402||1|Patients referred to the vascularsurgeon with complaints of claudication for their first time, will be asked to participate with the study, with respect toward the in- and exclusion criteria.
11596115|NCT00675389|Experimental|A|Peer Health Workers Intervention
11596116|NCT00675389|Experimental|B|Peer Health Workers and Mobile Phone Intervention
11596117|NCT00675389|No Intervention|C|Control
11596118|NCT00675363|Active Comparator|PS|Nurse-directed protocols for administering sedation and/or analgesia by continuous infusion.
11596119|NCT00675363|Active Comparator|PS + DI|Nurse-directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
11596120|NCT00675350|Experimental|Homoharringtonine|
11596121|NCT00675337|Active Comparator|perineum|infants maintained at the level of the perineum until umbilical cord clamping
11596122|NCT00675337|Experimental|abdomen|infants placed on the maternal abdomen prior to cord clamping
11596123|NCT00675324|Active Comparator|A|Traditional bowel preparation with Laxabon
11596124|NCT00675324|Active Comparator|B|Bowel preparation with nutritional drinks
11596125|NCT00675311|Active Comparator|DM-Standard|The conventional disease management group will receive management under the site's usual program offering, which includes, but is not limited to, compliance with the prescribed treatment regimens, dietary management, exercise programs, and other measures recommended by the American Diabetes Association (ADA) and the Association of American Endocrinologists (AACE).
11596126|NCT00675311|Active Comparator|DM-Plus|Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology that includes mobile phone client software with web-based companion software, Bluetooth glucose meter cradle, and web-based clinical management software for the clinical management team. The core of the system is the patient's cell phone which is used as an input device and which enables patients to maintain an electronic diary of information such as meal times, blood glucose, insulin use, weight, blood pressure, and exercise. The device is customizable to collect only the information relevant to the patient with diabetes and their healthcare provider. The patient with diabetes enters diary information on his or her mobile phone. No immediate or real-time information is provided to patients as part of this study.
11596127|NCT00675298||1|Men with chronic prostatitis/chronic pelvic pain syndrome
11596130|NCT00675298||4|Bulgarian cohort with chronic prostatitis/chronic pelvic pain syndrome, painful bladder syndrome/interstitial cystitis and children with overactive bladder
11596131|NCT00675298||5|Asymptomatic healthy controls
11596132|NCT00675285|Active Comparator|1|
11596133|NCT00675285|Placebo Comparator|2|
11596134|NCT00675272|Active Comparator|1|hydrocortisone treatment 50mg iv x4
11596135|NCT00675272|Placebo Comparator|2|Placebo iv every 6 hours
11596136|NCT00675259|Experimental|Neoadjuvant, Surgery, Adjuvant|Neoadjuvant chemotherapy : Nab-paclitaxel and carboplatin on days 1, 8, and 15 in combination with bevacizumab on days 1 and 15 administered every 28 days for 5 cycles followed by 1 cycle with Nab-paclitaxel and carboplatin on days 1, 8, and 15. Definitive surgery with either lumpectomy or mastectomy along with axillary lymph node dissection for all pre neo adjuvant chemotherapy node-positive patients approximately 4-5 weeks after the completion of NCT. Use of additional adjuvant chemotherapy and/or radiation therapy depends upon the treating physicians' judgment. Radiation therapy should begin no sooner than 6 weeks after breast cancer surgery. All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
11596137|NCT00675246|Experimental|A|Antenatal corticoid therapy
11596138|NCT00675233|Experimental|Treatment PDT|Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light to the tumor on day 2. At least 6 weeks later, patients achieving partial response, no response, or a geographical miss may undergo a second course of treatment.
11596139|NCT00675220||A|
11596140|NCT00675207|Active Comparator|1|Brimonidine purite 0.15%
11596141|NCT00675207|Active Comparator|2|Dorzolamide 2%
11596142|NCT00675207|Active Comparator|3|Brinzolamide 1%
11596143|NCT00675181|Active Comparator|A, 1|A, 1 = Melatonin
11596144|NCT00675181|Placebo Comparator|A, 2|A,2 = Placebo
11596145|NCT00675155|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
11596146|NCT00675142|Experimental|1|IUI 36 hours after ovulation induction
11596147|NCT00675142|Experimental|2|IUI 42 hours after ovulation induction
11596148|NCT00675142|Experimental|3|IUI 48 hours after ovulation induction
11596149|NCT00675129|Experimental|1|Dialectical behavioral therapy
11596150|NCT00675129|Active Comparator|2|Enhanced Usual Care (standard care plus monitoring and patient safety protocol implemented)
11596151|NCT00675103|Experimental|pegloticase|
11596152|NCT00675090|Experimental|GSK239512|GSK239512 oral tablets
11596153|NCT00675090|Placebo Comparator|Placebo|Placebo to match tablets
11596154|NCT00675077|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
11596155|NCT00675064|Experimental|Anti-malarial experimental drug|After randomization subjects will receive either 5, 25, 100, 250, 500, 1000, 2000 and 3000 mg of GSK3697969 orally . GSK3697969 will be available as 5, 25 and 250 mg capsules.
11596156|NCT00675064|Active Comparator|Matching placebo|After randomization subjects will receive matching placebo of GSK3697969.
11596157|NCT00675038||1|Study participants will be patients who are cared for by the St. Jude Hematology Division and have developed iron overload and require liver biopsy.
11596158|NCT00675025|Experimental|1|
11596159|NCT00675012|Experimental|A|
11596160|NCT00674999|Experimental|1|Amnion with processing procedures involving the use of trypsin-Edetic Acid(EDTA)
11596161|NCT00674999|Experimental|2|Amnion with processing procedures involving the use of Dispase II
11596162|NCT00674999|Active Comparator|3|Prepared Antibiotic ointment Polysporin, Bacitracin and Mycostatin
11596163|NCT00674986|Other|Active Control Group (ACG)|Participants in the Active Control Group received enhanced standard of care (more frequent clinic visits, free blood glucose meters and strips and point-of-care Hemoglobin A1c (HbA1c) test) for management of their Type 2 diabetes.
11596164|NCT00674986|Experimental|Structured Testing Group (STG)|Participants in the Structured Testing Group in addition to enhanced standard of care for the treatment of their Type 2 diabetes used the ACCU-CHEK® 360° View blood glucose analysis system (Tool) to monitor glucose levels at least quarterly.
11596165|NCT00674973|Experimental|Erlotinib|Participants with advanced pancreatic carcinoma with Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received erlotinib 150 mg orally once daily until disease progression, unacceptable toxicity, withdrawal, or death.
11596166|NCT00674973|Placebo Comparator|Placebo|Participants with advanced pancreatic carcinoma with ECOG PS score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received placebo matching to erlotinib 150 mg tablet orally once daily until disease progression, unacceptable toxicity, withdrawal, or death.
11596167|NCT00674960|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
11596168|NCT00674934|Experimental|1|Radiation
11596169|NCT00674921|Placebo Comparator|1|It will comprise patients randomized to receive the placebo (stop cotrimoxazole prophylaxis) at CD4 counts of 200 or more but less than 350 cells/ul as they continue with HAART. Patients will be followed until they achieve a CD4 count of 350 cells/ul.
11596170|NCT00674921|Active Comparator|2|It will comprise patients randomized to continue with cotrimoxazole prophylaxis and HAART at CD4 counts of 200 or more but less than 350 cells/ul. These patients will be followed until they achieve a CD4 count of 350 cells/ul and above, at which point they will be considered for the second randomization.
11596171|NCT00674921|Placebo Comparator|A|This arm will comprise patients who have achieved a CD4 count of 350 or more cells/ul either at the beginning of the study or once they have reached this threshold at the end of follow up in arms 1 and 2. They (including those previously in Arm 1) will receive the placebo (stop cotrimoxazole prophylaxis) after the second randomization but continue with HAART.
11596172|NCT00674921|Active Comparator|B|It will comprise patients randomized to continue or start with cotrimoxazole prophylaxis and HAART at CD4 of 350 or more cells/ul after second randomization. Some of them will have used cotrimoxazole prophylaxis whilst they were in arm 2 and others in arm 1 will restart cotrimoxazole prophylaxis at this stage.
11596173|NCT00674908|Experimental|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
11596174|NCT00674908|Active Comparator|Easy 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
11596175|NCT00674895|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
11596176|NCT00674882||Participants|Data Collection
11596177|NCT00674869|Experimental|1|pit and fissure sealant on one randomized tooth by pair of permanent molar
11596178|NCT00674869|No Intervention|2|No intervention
11596179|NCT00674856|Experimental|naproxcinod|naproxcinod 750mg(375mg caps x2), administered twice a day.
11596180|NCT00674843|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
11596181|NCT00674830|Experimental|1|professionally administered cognitive-behavioral therapy
11596182|NCT00674830|Experimental|2|self-administered form of cognitive behavioral therapy
11596183|NCT00674830|Placebo Comparator|3|usual care
11596184|NCT00674817|Experimental|400 microgrammes GSK961081 and salbutamol|400 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3x 200 microgrammes at 20 min intervals, administered via spacer) of salbutamol at 1h, 12h and 24h of dosing.
11596185|NCT00674817|Experimental|1200 microgrammes GSK961081 and salbutamol|1200 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (3x 200 microgrammes at 20 min intervals, administered via spacer) of salbutamol at 1h, 12h and 24h of dosing.
11596186|NCT00674817|Experimental|400 microgrammes GSK961081 and ipratropium bromide|400 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (20 microgrammes, 20 microgrammes and 40 microgrammes at 20 min intervals, administered via spacer) of ipratropium bromide at 1h, 12h and 24h of dosing.
11596187|NCT00674817|Experimental|1200 microgrammes of GSK961081 and ipratropium bromide|1200 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (20 microgrammes, 20 microgrammes and 40 microgrammes at 20 min intervals, administered via spacer) of ipratropium bromide at 1h, 12h and 24h of dosing.
11596188|NCT00674817|Placebo Comparator|400 microgrammes of GSK961081 and placebo|400 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3 doses at 20 min intervals, administered via spacer) of placebo at 1h, 12h and 24h of dosing.
11596189|NCT00674817|Placebo Comparator|1200 microgrammes of GSK961081 and placebo|1200 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3 doses at 20 min intervals, administered via spacer) of placebo at 1h, 12h and 24h of dosing.
11596190|NCT00674778|Experimental|1|Radial approach
11596191|NCT00674778|Active Comparator|2|Femoral approach
11596192|NCT00674765|Experimental|1|Seroquel
11596193|NCT00674765|Placebo Comparator|2|Placebo
11596194|NCT00674752|Experimental|A|
11596195|NCT00674752|Experimental|B|
11596196|NCT00674752|Placebo Comparator|C|
11596197|NCT00674739|Experimental|imiquimod cream|2.5% imiquimod cream applied daily to wart area for up to 8 weeks
11596198|NCT00674739|Experimental|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
11596199|NCT00674739|Placebo Comparator|placebo cream|placebo cream applied daily to wart areas for up to 8 weeks
11596200|NCT00674726||Group I|Patients with acute appendicitis
11596201|NCT00674726||Group II|Patients with acute gastroenteritis
11596202|NCT00674713|Experimental|A|Patients receiving acupuncture at P6 point plus physiological saline solution
11596203|NCT00674713|Active Comparator|B|Patients receiving ondansetron plus sham acupuncture
11596204|NCT00674713|Other|C|Patients receiving ondansetron plus acupuncture at P6 point
11596205|NCT00674713|Placebo Comparator|D|Patients receiving physiological saline solution plus sham acupuncture
11596206|NCT00674700|Active Comparator|300 IR|300 IR house dust mites allergen extract tablet
11596207|NCT00674700|Active Comparator|500 IR|500 IR house dust mites allergen extract tablet
11596208|NCT00674700|Placebo Comparator|Placebo|Placebo tablet
11596209|NCT00674687|Placebo Comparator|Sequence 1|
11596210|NCT00674687|Experimental|Sequence 2|
11596211|NCT00674661|Active Comparator|Corneal Collagen Cross-linking (CXL) Treatment Group|riboflavin ophthalmic solution and UVA irradiation
11596212|NCT00674661|Sham Comparator|Control Group|riboflavin opthalmic solution without UVA irradiation
11596213|NCT00674648|Experimental|1|This is a non-randomized single institution phase I dose escalation trial, designed to evaluate the toxicity and anti-viral activity of CMV-pp65 peptide-specific T cell lines, generated in vitro from CMV seropositive normal HSCT and 3rd party donors, when adoptively transferred to treat recipients of these transplants who have a CMV infection or persistent CMV antigenemia and are therefore at high risk of a life-threatening CMV infection.
11596214|NCT00674635|Placebo Comparator|Placebo|matching placebo
11596215|NCT00674635|Active Comparator|GSK315234A|Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose
11596216|NCT00674622|Experimental|Group 1-Prolotherapy|Deep injection with 15% dextrose in lidocaine
11596217|NCT00674622|Placebo Comparator|Group 2-Deep Saline/Lidocaine|Deep injection with saline/lidocaine
11596218|NCT00674622|Placebo Comparator|Group 3-Superficial Saline/lidocaine|Superficial injection with saline/lidocaine
11596219|NCT00674609|Placebo Comparator|Placebo|Placebo control
11596220|NCT00674609|Experimental|Sativex|Active treatment
11596221|NCT00674609|Experimental|THC Alone|Active treatment
11596222|NCT00674583|Experimental|Nimenrix Group|Healthy male or female subjects between, and including 2 and 10 years of age, intramuscularly received 1 dose of Nimenrix™ vaccine into the non-dominant deltoid region, at Day 0.
11596223|NCT00674583|Active Comparator|Menjugate Group|Healthy male or female subjects between, and including 2 and 10 years of age, intramuscularly received 1 dose of Menjugate® vaccine into the non-dominant thigh region, at Day 0.
11596224|NCT00674570|Experimental|Arm 1: Hydrocortisone|Hydrocortisone
11596225|NCT00674570|Experimental|Arm 2: D-Cycloserine|D-Cycloserine
11596226|NCT00674570|Placebo Comparator|Arm 3: Placebo|Placebo
11596227|NCT00674544|No Intervention|Control group|No intervention, regular kindergarten program
11596262|NCT00674245|Active Comparator|Pantoprazole|40 mg once daily for four weeks improves sleep quality in patients with GERD
11596228|NCT00674544|Experimental|Intervention group|Kindergarten and homebased increases in physical activity, healthy nutrition, sleep duration and decrease in media use: Involvement of parents and siblings
11596229|NCT00674531|Other|1|Enterovirus RNA analysis
11596230|NCT00674518|Experimental|Counseling|One-on-one sessions conducted by a professional motivational counselor to explore ways to help motivate participants to exercise, eat healthier, and lose weight.
11596231|NCT00674518|Experimental|Group|A nutrition and exercise specialist will lead and teach a group of 4 to 5 subjects in healthy nutrition, exercise and weight loss habits
11596232|NCT00674518|Active Comparator|MD Advice|A physician will provide exercise and nutrition advice to participants immediately following testing
11596233|NCT00674505|Other|Treatment, Open label, Single Group Assignment|
11596234|NCT00674492||Hepatitis C patients|patients who initiated antiviral treatment for hepatitis C
11596235|NCT00674479|Experimental|INCB018424|The starting dose of INCB018424 will be 25 mg by mouth twice daily.
11596236|NCT00674466|Experimental|1|Twice-a-week dose of 1.5 mg CJC-1134-PC
11596237|NCT00674466|Experimental|2|Twice-a-week dose of 1.5 mg CJC-1134-PC for 4 weeks, then once-a-week dose of 2.0 mg CJC-1134-PC plus mid-week dosing of placebo
11596238|NCT00674466|Placebo Comparator|3|Twice-a-week placebo for CJC-1134-PC
11596239|NCT00674453|Experimental|Lasofoxifene 0.25 mg/d|
11596240|NCT00674453|Placebo Comparator|Placebo|
11596241|NCT00674440|Experimental|1|Children diagnosed with hyperinsulinism who have failed other non-surgical interventions and will be scheduled for surgery. Eligible children in this arm will PET imaging with F-DOPA prior to surgery.
11596242|NCT00674440|Experimental|3|Children diagnosed with hyperinsulinism who have had partial pancreas removal but still display signs of hyperinsulinism. Eligible children in this arm may have PET imaging with F-DOPA.
11596243|NCT00674440|Experimental|2|Children diagnosed with hyperinsulinism who are successfully managed with diazoxide, octreotide, other medications,and/or tube feedings. Eligible children in this arm will PET imaging with F-DOPA.
11596244|NCT00674427|Experimental|CR|Subjects who are in CR ater 6-12 weeks after aDLI
11596245|NCT00674427|Experimental|Not in CR|Subjects not in CR after 6-12 weeks after aDLI
11596246|NCT00674414|Active Comparator|Arm I|Patients receive trastuzumab (Herceptin®) IV once weekly for 6 weeks. Patients then undergo surgery.
11596247|NCT00674414|Experimental|Arm II|Patients receive trastuzumab as in arm I and oral everolimus once daily for 6 weeks. Within 24 hours after completing everolimus, patients undergo surgery.
11596248|NCT00674401|Active Comparator|1|"In patients with paroxysmal atrial fibrillation: Empirical pulmonary vein antrum circumferential isolation.
~In patients with persistent atrial fibrillation: Empirical circumferential PV antrum isolation w/out roof line."
11596249|NCT00674401|Active Comparator|2|"In patients with paroxysmal atrial fibrillation: High frequency sites ablation in the LA.
~In patients with persistent atrial fibrillation: A combined approach involving pulmonary vein antrum isolation w/out roof line and high frequency sites ablation"
11596250|NCT00674375|Experimental|1|Primary care clinicians (physicians, nurse practitioners, and physician assistants) randomized to the intervention arm will receive electronic alerts within the electronic medical record system during office visits with patients complaining of chest pain.
11596251|NCT00674375|No Intervention|2|Primary care clinicians randomized to the 'no intervention' arm will evaluate and treat patients complaining of chest pain without the aid of electronic risk alerts.
11596252|NCT00674362|Experimental|Certolizumab pegol 200 mg (CDP870)|Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
11596253|NCT00674362|Placebo Comparator|Placebo|Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
11596254|NCT00674336|Experimental|Shellfish with Norovirus|We dosed shellfish with Norovirus and challenged human volunteers with Shellfish that had norovirus
11596255|NCT00674323|Experimental|Verteporfin and Ranibizumab|Photodynamic therapy with verteporfin in combination with ranibizumab injection. Patients received one treatment at baseline with verteporfin photodynamic therapy (PDT) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
11596256|NCT00674323|Active Comparator|Verteporfin monotherapy|Patients received one treatment at baseline with verteporfin photodynamic therapy in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab placebo (sham intravitreal injection) on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
11596257|NCT00674323|Active Comparator|Ranibizumab monotherapy|Patients received one treatment at baseline with verteporfin placebo (with sham photodynamic therapy) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
11596258|NCT00674297|Experimental|Fluvastatin|All patients will take Fluvastatin 40 mg daily for 3 months.
11596259|NCT00674271||Diabetics|100 patients with newly diagnosed (<5 years since diagnosis) type 2 diabetes referred from general practitioners to Medical Department M, Aarhus University Hospital, Denmark.
11596260|NCT00674271||Controls|100 healthy (no diabetes or prediabetes in oral glucose tolerance test) control subjects matched for age and gender
11596261|NCT00674258|Experimental|B|
11596319|NCT00673829|Experimental|Phase Ia|
11596263|NCT00674245|Placebo Comparator|placebo|To determine if treatment with pantoprazole 40 mg once daily vs placebo improves sleep outcome in patients with GERD.
11596264|NCT00674232|Experimental|Misoprostol|Group 1 randomized to take single dose of 600 mcg oral misoprostol
11596265|NCT00674232|Other|Surgical treatment|Group 2 randomized to receive standard surgical treatment as per local protocol (D&C or MVA)
11596266|NCT00674219|Active Comparator|OCD group|OCD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication.
11596267|NCT00674219|Active Comparator|GAD group|GAD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication.
11596268|NCT00674206|Experimental|Gemcitabine and Oxaliplatin|All patients enrolled on clinical trial will receive Gemcitabine 1000mg/m^2 on Day 1 and Oxaliplatin 100 mg/m^2 intravenously over 2 hours on Day 2.
11596269|NCT00674193||Observational (pharmacological study)|Patients undergo blood and urine collection prior to, periodically during, and after treatment with dactinomycin and vincristine for pharmacokinetic, pharmacodynamic, and pharmacogenetic analysis. Samples are analyzed using a liquid chromatography-tandem mass spectrometry assay. Genomic DNA extracted from peripheral blood mononuclear cells is isolated and analyzed by polymerase chain reaction and genotyping assays for genetic variation in genes relevant to the pharmacology of dactinomycin and vincristine.
11596270|NCT00674180||1|a workbook alone
11596271|NCT00674180||2|a workbook alone and the addition of computerized tailoring using onsite computer kiosks with touch screen monitors
11596272|NCT00674180||3|a workbook, the addition of computerized tailoring using onsite computer kiosks with touch screen monitors, and staff consultations.
11596273|NCT00674167|Experimental|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel and cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
11596274|NCT00674167|Experimental|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
11596275|NCT00674167|Experimental|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycles.
11596276|NCT00674154|Experimental|Vitamin D group|Cholecalciferol 1400 IU, 2 tablets once daily in 52 weeks
11596277|NCT00674154|Placebo Comparator|Placebo group|Placebo, two tablets daily in 52 weeks.
11596278|NCT00674141|Other|1|only one experimental treated group
11596279|NCT00674128|Experimental|Adhesive|Cyanoacrylate tissue adhesive.
11596280|NCT00674128|Active Comparator|Suture|Polyglactin 910 suture.
11596281|NCT00674115|Experimental|Single Dose Zegerid for 1 or 7 days|Omeprazole 20 mg/Sodium Bicarbonate 1680 mg Powder for Oral Suspension
11596282|NCT00674115|Active Comparator|Single Dose Prilosec 1 or 7 days|Omeprazole magnesium 20 mg over-the-counter (OTC) Tablet
11596283|NCT00674115|Active Comparator|Sodium Bicarbonate|Sodium Bicarbonate 1680 mg Oral Suspension
11596284|NCT00674102|Experimental|ASA404|
11596285|NCT00674089|Active Comparator|1|Routine Post-partum Care and Vitamin A supplementation (50,000 IU) to the Newborn
11596286|NCT00674089|Placebo Comparator|2|Routine Post-partum Care with Placebo to the Newborn
11596287|NCT00674076||sleep apnea|a patient has been diagnosed as having obstructive sleep apnea
11596288|NCT00674076||control|a case who has a negative polysomography or noraml score of Pittsburg sleep questionaire
11596289|NCT00674063|Experimental|1|Dose regimen 1
11596290|NCT00674063|Experimental|2|Dose regimen 2
11596291|NCT00674050|Experimental|1|
11596292|NCT00674037|Experimental|inclusion with financial motivation|75 euros for each patient included
11596293|NCT00674037|No Intervention|no incentive|no incentive
11596294|NCT00673985|Active Comparator|1|"PTA Only: Active Comparator
~Percutaneous transluminal angioplasty (PTA) alone"
11596295|NCT00673985|Experimental|2|"Test Arm: Experimental
~The main objective of this study is to assess the safety and effectiveness of the Edwards Lifesciences LifeStent nitinol self expandable stent device and its delivery system in the treatment of occlusive superficial femoral artery (SFA) disease."
11596296|NCT00673972|Active Comparator|EPS|Patients with functional dyspepsia will be classified into EPS or PDS two subgroups according to Rome III diagnostic criteria.
11596297|NCT00673972|Active Comparator|PDS|Patients with functional dyspepsia will be classified into EPS or PDS two subgroups according to Rome III diagnostic criteria.
11596298|NCT00673959|Experimental|Lubricant Eye Drop FID 111421|Lubricant Eye Drop FID 111421 1 drop each eye one time
11596299|NCT00673959|Active Comparator|Optive Lubricant Eye Drop|Optive Lubricant Eye Drop 1 drop each eye one time
11596300|NCT00673946|Active Comparator|1|In this arm, patients are monitored with oximeters displaying true saturation values
11596301|NCT00673946|Experimental|2|In this arm, patients are monitored with oximeters with displayed saturations 3 percentage points above true values
11596302|NCT00673933|Experimental|1|PDT using MAL crem
11596303|NCT00673933|Placebo Comparator|2|PDT using Placebo cream
11596304|NCT00673920|Experimental|1|
11596305|NCT00673920|Experimental|2|
11596306|NCT00673920|Placebo Comparator|3|
11596307|NCT00673907|Sham Comparator|1|Clean air
11596308|NCT00673907|Experimental|2|Wood smoke particle concentration of 200 ug/m3
11596309|NCT00673907|Experimental|3|Wood smoke particle concentration of 400 ug/m3
11596310|NCT00673894|Experimental|Glutamine+Sitagliptin|Glutamine 30 g/d (15 g with breakfast and dinner) + Sitagliptin
11596311|NCT00673894|Placebo Comparator|Glutamine+Placebo|Glutamine 30 g/d (15 g with breakfast and dinner) + placebo
11596312|NCT00673881|Experimental|Abt-335|ABT-335 (choline fenofibrate)
11596313|NCT00673868|Experimental|1|
11596314|NCT00673868|No Intervention|2|
11596315|NCT00673855|Experimental|Lubricant Eye Drops FID 112903|Lubricant Eye Drops FID 112903 1 drop each eye one time
11596316|NCT00673855|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye 1 time
11596317|NCT00673842|Experimental|Implantable Cardioverter Defibrillator + Usual Care|Medtronic ICD
11596318|NCT00673842|Active Comparator|Usual Care|Usual post-MI care
11596321|NCT00673816|Experimental|Sunitinib Malate|Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
11596322|NCT00673803|Other|A|cataract surgery, implantation of a Polylens Y10
11596323|NCT00673803|Other|B|cataract surgery, implantation of a Polylens Y30
11596324|NCT00673790|Active Comparator|Nebivolol|Nebivolol with concomitant losartan or lisinopril
11596325|NCT00673790|Active Comparator|Hydrochlorothiazide (HCTZ)|HCTZ with concomitant losartan or lisinopril
11596326|NCT00673790|Placebo Comparator|Placebo|Placebo with concomitant losartan or lisinopril
11596327|NCT00673777|Experimental|A|
11596328|NCT00673764|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
11596329|NCT00673764|Active Comparator|Optive|Optive Lubricant Eye Drops
11596330|NCT00673751|Placebo Comparator|2|subcutaneous isotonic saline
11596331|NCT00673751|Active Comparator|1|subcutaneous GLP-2
11596332|NCT00673738|Experimental|Cetuximab Plus Radiotherapy|Concurrent Cetuximab plus Conformal Thoracic Radiotherapy (CTRT). Patients were treated with definitive radiotherapy (70 Gy in 35 fractions, per our currently-existing institutional standard) with concurrent cetuximab followed by 3 cycles of consolidation docetaxel plus cetuximab.
11596333|NCT00673725|Experimental|1|
11596334|NCT00673712|Experimental|Continuous Sternal Block|Continuous Sternal block with infusion of local anesthetic via ON-Q Painbuster Silver Soaker system
11596335|NCT00673712|Active Comparator|Opioid based analgesia|Opioid based analgesia including Patient controlled analgesia plus IM, Oral narcotics and other analgesics
11596336|NCT00673699||A|Seventy dyspeptic consecutive patients that going upper gastrointestinal endoscopy
11596337|NCT00673686|Active Comparator|Arm 2|
11596338|NCT00673686|Experimental|Arm 1|
11596339|NCT00673673|Experimental|1|FOLFOX in combination with bevacizumab
11596340|NCT00673660||Statins|Patients with dyslipidemia who are taking or planning to take a statin treatment (Atorvastatin, Fluvastatin, Prevastatin, Rosuvastatin, Simvastatin or generics).
11596341|NCT00673647|Experimental|1|Individual psychotherapy including cognitive behavioral components, motivational interviewing techniques and case management
11596342|NCT00673647|No Intervention|2|Delayed treatment control group
11596343|NCT00673634|Active Comparator|1|Standard preoxygenation
11596344|NCT00673634|Active Comparator|2|BiPAP assisted preoxygenation
11596345|NCT00673621|Experimental|1|
11596346|NCT00673608|Experimental|Deferasirox|
11596347|NCT00673595|Active Comparator|Varenicline|Participants on this arm will receive varenicline tablets for 15 days.
11596348|NCT00673595|Placebo Comparator|Placebo|Participants on this arm will receive placebo tablets for 15 days.
11596349|NCT00673582|Experimental|1|10 mg/day rosuvastatin for 96 weeks
11596350|NCT00673582|Placebo Comparator|2|Placebo
11596351|NCT00673556|Experimental|Course A1|
11596352|NCT00673556|Placebo Comparator|Course A2|
11596353|NCT00673556|Experimental|Course B|Open label extension
11596354|NCT00673543||1|Pregnant women with insulin requiring diabetes
11596355|NCT00673543||2|Pregnant women without insulin requiring diabetes
11596356|NCT00673530|Experimental|1|evidence based clinical nutrition concept
11596357|NCT00673530|Other|2|care as usual
11596358|NCT00673517||1|Patients randomized to high frequency oscillation
11596359|NCT00673517||2|Patients randomized to conventional lung protective ventilation
11596360|NCT00673504|Experimental|A|Gemcitabine + Sunitinib
11596361|NCT00673504|Other|B|Gemcitabine
11596362|NCT00673491|Experimental|1|Patients treated according to clinical pathways
11596363|NCT00673491|No Intervention|2|Patients treated according to usual care
11596364|NCT00673465|Experimental|Treatment sequence 1: SCH 497079 → Placebo → Metformin|Participants received SCH 497079 daily for 4 weeks followed by placebo daily for 4 weeks followed by metformin daily for 4 weeks.
11596365|NCT00673465|Experimental|Treatment sequence 2: Placebo → Metformin → SCH 497079|Participants received placebo daily for 4 weeks followed by metformin daily for 4 weeks followed by SCH 497079 daily for 4 weeks.
11596366|NCT00673465|Experimental|Treatment sequence 3: Metformin → SCH 497079 → Placebo|Participants received metformin daily for 4 weeks followed by SCH 497079 daily for 4 weeks followed by placebo daily for 4 weeks.
11596367|NCT00673465|Experimental|Treatment sequence 4: SCH 497079 → Metformin → Placebo|Participants received SCH 497079 daily for 4 weeks followed by metformin daily for 4 weeks followed by placebo daily for 4 weeks.
11596368|NCT00673465|Experimental|Treatment sequence 5: Placebo → SCH 49709 → Metformin|Participants received placebo daily for 4 weeks followed by SCH 497079 daily for 4 weeks followed by metformin daily for 4 weeks.
11596369|NCT00673465|Experimental|Treatment sequence 6: Metformin → Placebo → SCH 497079|Participants received metformin daily for 4 weeks followed by placebo daily for 4 weeks followed by SCH 497079 daily for 4 weeks.
11596370|NCT00673452|Experimental|Duloxetine|60-120 mg, oral, every day, 12 weeks
11596371|NCT00673452|Placebo Comparator|Placebo|oral, daily, 12 weeks
11596372|NCT00673439|Experimental|Fondaparinux|daily subcutaneous injection of fondaparinux (7.5-10 mg)
11596373|NCT00673426|Experimental|A|
11596374|NCT00673400|Other|Stapled transanal rectum resection|patients operated with stapled transanal rectum resection
11596375|NCT00673387|Placebo Comparator|Placebo-P + Placebo-M|Placebo matched to pramlintide BID plus placebo matched to metreleptin BID
11596376|NCT00673387|Experimental|Pramlintide 360 mcg + Placebo-M|360 mcg pramlintide given twice per day (BID) plus Placebo matched to Metreleptin given BID
11596377|NCT00673387|Experimental|Placebo-P + Metreleptin 5.0 mg|Placebo matched to pramlintide BID plus metreleptin 5.0 mg BID
11596378|NCT00673387|Experimental|Pramlintide 180 mcg + Metreleptin 2.5 mg|Pramlintide 180 mcg BID plus Metreleptin 2.5 mg BID
11596379|NCT00673387|Experimental|Pramlintide 180 mcg + Metreleptin 5.0 mg|Pramlintide 180 mcg BID plus Metreleptin 5.0 mg BID
11596380|NCT00673387|Experimental|Pramlintide 360 mcg + Metreleptin 1.25 mg|Pramlintide 360 mcg BID plus Metreleptin 1.25 mg BID
11597488|NCT00665561||Maraviroc exposed|
11596381|NCT00673387|Experimental|Pramlintide 360 mcg + Metreleptin 2.5 mg|Pramlintide 360 mcg BID plus Metreleptin 2.5 mg BID
11596382|NCT00673387|Experimental|Pramlintide 360 mcg + Metreleptin 5.0 mg|Pramlintide 360 mcg BID plus Metreleptin 5.0 mg BID
11596383|NCT00673374||1|All consecutive emergency department patients undergoing abdominal CT for non-traumatic abdominal pain and tenderness will be prospectively enrolled, except for those meeting pre-specified exclusion criteria.
11596384|NCT00673361|Experimental|"Chemo-Switch Regimen"|
11596385|NCT00673348||1|Patients suspected of invasive fungal infection (proven or probable cases) with immunocompromised state (for example, during neutropenia, receiving HSCT) in Catholic Hematopoietic Stem Cell Transplantation [HSCT] Center in Seoul, Korea.
11596386|NCT00673335|Experimental|Treatment arm|Letrozole, 1 tablet
11596387|NCT00673335|Placebo Comparator|Placebo|Comparator, 1 tablet
11596388|NCT00673322|Experimental|Gene Modified T Cells|Modified T cells
11596389|NCT00673309|Experimental|Growth Hormone|Growth Hormone administered daily until 95% wound healing. Stable Isotope Infusion Study with collection of blood and tissue
11596390|NCT00673309|Experimental|Insulin High Dose|Insulin IV administered continuously to 95% healing. Stable Isotope Infusion Study with collection of blood and tissue
11596391|NCT00673309|Experimental|Oxandrolone|Oxandrolone administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
11596392|NCT00673309|Experimental|Propranolol|Propranolol administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
11596393|NCT00673309|Experimental|IGF-1/IGFBP-3|IGF-1/IGFBP-3 will be administered until 95% wound healing
11596394|NCT00673309|Experimental|Insulin Low Dose|Insulin Low Dose will be administered until 95% wound healing.
11596395|NCT00673309|Experimental|Itraconazole|Itraconazole will be administered until 95% wound healing.
11596396|NCT00673309|Experimental|Growth Hormone and Propranolol|Growth Hormone and Propranolol will be administered until 95% wound healing.
11596397|NCT00673309|Experimental|Oxandrolone and Propranolol|Oxandrolone and Propranolol will be administered until 95% wound healing
11596398|NCT00673309|Placebo Comparator|Control/Placebo|Placebo or Control will be administered until 95% wound healing
11596399|NCT00673296|Other|A|Patients receive intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
11596400|NCT00673283|Experimental|A|
11596401|NCT00673270|Experimental|1|Fludrocortisone and Hydrocortisone
11596402|NCT00673270|Experimental|2|Fludrocortisone and placebo of Hydrocortisone
11596403|NCT00673270|Experimental|3|Placebo of Fludrocortisone and Hydrocortisone
11596404|NCT00673270|Placebo Comparator|4|Placebo of Fludrocortisone and placebo of Hydrocortisone
11596405|NCT00673257|Experimental|Pharmacokinetics of Daunorubicin chemotherapy patients|Patients receiving a chemotherapy regimen including daunorubicin hydrochloride administered as an infusion of any duration < 24 hours on a 1 or a 2 day schedule. Pre-study evaluations no greater than 14 days prior to daunomycin administration. If patients have had significant intercurrent illness or treatment that might affect organ function, laboratory work should be performed at an appropriately closer interval to daunomycin administration. A complete history and physical examination including height, weight and body surface area. Patients should be weighed with only light clothing; shoes must be removed before weight is measured. Patients height should be measured using a stadiometer after removing shoes. Laboratory evaluation: a) CBC with differential and platelet count. b) ALT, AST, bilirubin, creatinine, total protein, albumin, alkaline phosphatase, GGT.
11596406|NCT00673244|Experimental|1|
11596407|NCT00673231|Experimental|1|2.5mg
11596408|NCT00673231|Experimental|2|5mg
11596409|NCT00673231|Experimental|3|10mg
11596410|NCT00673231|Placebo Comparator|4|
11596411|NCT00673218|Placebo Comparator|1|Saline injection to match active
11596412|NCT00673218|Experimental|Treatment|Active treatment with Xolair 150 to 375 mg is administered SC every 2 or 4 weeks
11596413|NCT00673205|Placebo Comparator|A|
11596414|NCT00673205|Active Comparator|B|
11596415|NCT00673179|Experimental|Outpatient Chemotherapy|Pre-Surgery, Regimen 1: Doxorubicin intravenous (IV) 90 mg daily, Cisplatin 60 mg/m^2/day for 2 days, Methotrexate 12 gm/m^2, Leucovorin Rescue 10 mg IV, with 10 mg orally every 6 hours; Surgery; Post-Surgery, Regimen 1: Methotrexate 12 gm/m^2, Doxorubicin IV 90 mg, Cisplatin 60 mg/ m^2 twice daily, Leucovorin Rescue.
11596416|NCT00673179|Experimental|Additional Risk-Adapted Outpatient Chemotherapy|Pre-Surgery, Regimen 2: Dexrazoxane 900 mg/m^2 intravenous (IV) then Doxorubicin IV 90 mg daily, Cisplatin 120 mg/m^2 (intra-arterial); Surgery; Post-Surgery, Regimen 2: Methotrexate 12 gm/m^2, Leucovorin Rescue 10 mg IV, with 10 mg orally every 6 hours; Ifosfamide 2.8 grams m^2/day and Mesna 2.8 gm/m^2/day continuous IV over 6 days; Lung-Directed Chemotherapy, Regimen 2: Gemcitabine, Sargramostim Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg).
11596417|NCT00673153|Experimental|Arm I|"REMISSION INDUCTION THERAPY: Patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 15-22 days for up to 3 courses. .
~CONSOLIDATION THERAPY: Beginning within 60 days after the completion of remission induction therapy, patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8.
~MAINTENANCE THERAPY: Patients receive oral vorinostat once daily on days 1-14. Treatment repeats every 28 days for 4 courses."
11596418|NCT00673140|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
11596419|NCT00673127|Experimental|KHAD|Ketoconazole, Hydrocortisone and Dutasteride Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Dutasteride: 0.5 mg once a day
11596420|NCT00673114|Other|Transplant Recipients|
11596421|NCT00673075|Active Comparator|1|Encapsulated Nebivolol
11596422|NCT00673075|Active Comparator|2|Encapsulated Carvedilol
11596423|NCT00673062|Experimental|SCH 900538|
11596424|NCT00673062|Active Comparator|Encapsulated pseudoephedrine|Encapsulated pseudoephedrine (2X30 mg immediate release tablets)
11596425|NCT00673062|Placebo Comparator|Placebo Capsules|
11596426|NCT00673049|Experimental|Arm A|"The CP 751,871 treatment in combination with erlotinib will be given in three week cycles.
~CP 751,871 (20 mg/kg) + erlotinib (150 mg/day) CP 751,871 will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter."
11596427|NCT00673049|Active Comparator|Arm B|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food)
11596428|NCT00673036||1|Adults (female and male) with a acute coronary syndrome
11596429|NCT00673023|Experimental|1|
11596430|NCT00673023|Experimental|2|
11596431|NCT00673023|Experimental|3|
11596432|NCT00673010|Experimental|1|131 I-iodine (131-I), 124 I-iodine (124-I)
11596433|NCT00672997|Experimental|Travoprost/Timolol BAC-free|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
11596434|NCT00672997|Active Comparator|Travoprost/Timolol|Travoprost 0.004%/Timolol 0.5% ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
11596435|NCT00672984|Experimental|Immediate-release Guanfacine HCl|
11596436|NCT00672984|Active Comparator|Moxifloxacin HCl|
11596437|NCT00672984|Placebo Comparator|Placebo|
11596438|NCT00672971|Experimental|1|4% dimethicone foam
11596439|NCT00672971|Active Comparator|2|1% permethrin
11596440|NCT00672958|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.
11596441|NCT00672958|Experimental|Vortioxetine|Vortioxetine 5 mg, encapsulated tablet, orally, once daily for up to 6 weeks.
11596442|NCT00672945|Experimental|PRX-03140|
11596443|NCT00672945|Placebo Comparator|Placebo|
11596444|NCT00672932|Experimental|raltegravir group|The raltegravir dosing will be 400mg twice daily by mouth. Subjects will continue all of their regular medications throughout the protocol.
11596445|NCT00672932|No Intervention|No augmented treatment|Subjects randomized not to receive augmented treatment will continue in the study with their regular antiretroviral regimen.
11596446|NCT00672919|Experimental|Pioglitazone QD|(and stable statin therapy)
11596447|NCT00672906|Experimental|1|Group Parent Training/Adolescent Skills Training
11596448|NCT00672906|Active Comparator|Active Comparator|Family Therapy according to the Maudsley Model
11596449|NCT00672893||Observation|Patients who present to the clinic with airway obstruction and who are designated to undergo intervention
11596450|NCT00672880|Experimental|1|Psychotherapy
11596451|NCT00672880|Active Comparator|2|Spine Education
11596452|NCT00672880|Placebo Comparator|3|Standard Care
11596453|NCT00672867|Experimental|1|Clevudine
11596454|NCT00672867|Active Comparator|2|Adefovir
11596455|NCT00672854|Active Comparator|Intralipid 20% Intravenous Emulsion|Subjects who require Total Parenteral Nutrition TPN receiving Intralipid 20% (soybean-based)
11596456|NCT00672854|Experimental|ClinOleic 20% Intravenous Emulsion|Subjects who require Total Parenteral Nutrition TPN receiving ClinOleic 20% (olive oil based)
11596457|NCT00672841|Active Comparator|2|Standard care/empiric therapy group
11596458|NCT00672841|Experimental|1|Active surveillance/ preemptive therapy group
11596459|NCT00672828|Active Comparator|Non-tailored CRC screening brochure|Participants undergo a baseline interview via telephone and receive a non-tailored CRC screening brochure in the clinic prior to visit with healthcare provider. Participants then undergo telephone interviews at 1 week, 6 months, and 15 months.
11596460|NCT00672828|Experimental|Interactive computer intervention|Participants undergo a baseline interview via telephone and complete an interactive computer intervention in the clinic prior to visit with healthcare provider. Participants then undergo telephone interviews at 1 week, 6 months, and 15 months.
11596461|NCT00672802|Experimental|Ramelteon 16 mg QD and Placebo QD|
11596462|NCT00672789|Experimental|1|Blood Smear Education
11596463|NCT00672789|Active Comparator|2|Standard education
11596464|NCT00672776|Experimental|1|paroxetine
11596465|NCT00672776|Placebo Comparator|2|placebo
11596466|NCT00672763|Active Comparator|A|Standard corticosteroid treatment PLUS Vitamin D3 (Colecalciferol).
11596467|NCT00672763|Placebo Comparator|B|Standard corticosteroid treatment PLUS placebo (Migliol Oil)
11596468|NCT00672750||I|Patients of Dr C Miller who have undergone laparoscopic myomectomy from 1999- to present
11596469|NCT00672737||Males at risk for OSA|"Males at risk for obstructive sleep apnea were invited to have a sleep study either at home or at Stanford Sleep Center.
~A week after their sleep study (Polysomnography), all volunteers underwent quantitative sensory testing in the laboratory, during which their pain thresholds and tolerances to heat (Heat pain threshold and tolerance) and cold (Cold pain threshold and tolerance) stimuli were assessed, under two different concentrations (1 and 2 mcg/mL, in randomized order) of remifentanil, a short-acting opioid, given as a computer-controlled infusion."
11596470|NCT00672724|Experimental|Ramelteon 8 mg QD|
11596471|NCT00672724|Placebo Comparator|Placebo|
11596472|NCT00672711||C|APS
11596473|NCT00672711||B|HPS
11596474|NCT00672711||A|LPS
11596475|NCT00672698||I|VASCULAR SURGERY
11596476|NCT00672698||II|DIGESTIVE SURGERY
11596477|NCT00672698||III|BILIARY TRACT SURGERY
11596478|NCT00672685|Experimental|1|Omega-3 group without any intervention
11596479|NCT00672685|Experimental|2|Omega-3 combined group (Omega-3 + multi-domain intervention)
11596480|NCT00672685|Experimental|3|Placebo combined group (Placebo + multi-domain intervention)
11596481|NCT00672685|Placebo Comparator|4|Placebo group without any intervention
11596482|NCT00672672|Experimental|II|Patients who do not receive platlet gel.
11596483|NCT00672659|Active Comparator|1|Citalopram, 40 mg daily in combination with Pipamperone, 5 mg twice daily (bd)
11596484|NCT00672659|Placebo Comparator|2|Citalopram, 40 mg daily in combination with Placebo, dummy twice daily (bd)
11596485|NCT00672646|Experimental|AZD1386|
11596486|NCT00672646|Active Comparator|Naproxen|
11596487|NCT00672646|Placebo Comparator|Placebo|Placebo matching AZD1386
11596488|NCT00672633|Experimental|A , Experimental|Lovaza, 4 grams/day orally for 6 months
11596489|NCT00672633|Placebo Comparator|Corn Oil Pill|Corn Oil Pill, 4 pills/day orally for 6 months
11596490|NCT00672620|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
11596491|NCT00672620|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
11596492|NCT00672620|Active Comparator|Duloxetine 60 mg|Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsules, orally, once daily for 1 week after the treatment period.
11596493|NCT00672620|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
11596494|NCT00672607|Experimental|1|
11596495|NCT00672607|Placebo Comparator|2|
11596496|NCT00672594|Experimental|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
11596497|NCT00672581|Experimental|1|Control (healthy volunteers)
11596498|NCT00672581|Experimental|2|Mild Hepatic Impairment
11596499|NCT00672581|Experimental|3|Moderate Hepatic Impairment
11596500|NCT00672581|Experimental|4|Severe Hepatic Impairment
11596501|NCT00672568|Experimental|1|4975
11596502|NCT00672568|Experimental|2|4975
11596503|NCT00672568|Experimental|3|4975
11596504|NCT00672568|Placebo Comparator|4|Placebo
11596505|NCT00672555|Experimental|Pilonidal Sinus T. With Limberg F.|All patients treated by excision and covering of the defect by a Limberg-flap, who gave their informed consent to participate in the study, as there is only one study group.
11596506|NCT00672542|Experimental|A|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from untreated monocytes
11596507|NCT00672542|Experimental|B|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from monocytes transfected with control siRNA
11596508|NCT00672542|Experimental|C|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from monocytes transfected with siRNA targeting the three inducible immunoproteasome subunits
11596509|NCT00672529|Active Comparator|Intervention Group|
11596510|NCT00672529|Placebo Comparator|Placebo Group|
11596511|NCT00672503||1|Patients who acquired a CA-UTI in the PICU between 2004-2007.
11596512|NCT00672503||2|Patients who did not acquire a CA-UTI while hospitalized in the PICU but had an indwelling urinary catheter between 2004-2007.
11596513|NCT00672503||A|Nurses currently employed in the PICU at Children's Mercy Hospital.
11596514|NCT00672503||a|Root Cause Analysis on all patients who acquired a CA-UTI during 2009.
11596515|NCT00672490|Experimental|1|Quetiapine Fumarate - tablets
11596516|NCT00672490|Experimental|2|Quetiapine Fumarate - tablets and Lithium
11596517|NCT00672477|Experimental|Methylnaltrexone|Methylnaltrexone subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; or 0.4 mL (8 mg) every other day if weight between 38 and <62 kg. Subjects with impaired kidney function received reduced doses according to instructions in the Relistor prescribing information.
11596518|NCT00672477|Placebo Comparator|Placebo|Placebo subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL every other day if weight ≥ 62kg; or 0.4 mL every other day if weight between 38 and < 62 kg. Subjects with impaired kidney function received reduced volumes of placebo solution to match the volumes used in the experimental group.
11596519|NCT00672464|Active Comparator|Olanzapine only|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine
11596520|NCT00672464|Experimental|Added Metformin|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Metformin
11596521|NCT00672464|Experimental|Added Simvastatin|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Simvastatin
11596522|NCT00672464|Experimental|Added Metf. + Simv.|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Metformin and Simvastatin
11596523|NCT00672464|No Intervention|Matched Controls|Matched Control Subjects by age, race, and gender
11596524|NCT00672451|Experimental|rhubarb extract|will receive rhubarb extract
11596525|NCT00672451|Placebo Comparator|placebo|receive placebo
11596526|NCT00672438|Placebo Comparator|Saline placebo infusion|Subjects will receive an intravenous infusion of normal saline.
11596527|NCT00672438|Experimental|Alfentanil infusion|Subjects will receive an intravenous infusion of alfentanil.
11596528|NCT00672412|Experimental|1|Participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive liquid ZDV, 3TC, and NVP for the following 14 days of the study.
11596529|NCT00672412|Experimental|2|Participants receive liquid ZDV, 3TC, and NVP for the first 14 days of the study. On Day 15, participants receive GPO-VIR Z30 tablets containing ZDV, 3TC, and NVP for the following 14 days of the study.
11596530|NCT00672399|Experimental|Sequence 1|Period 1 = placebo exenatide/placebo moxifloxacin; Period II = exenatide/placebo moxifloxacin; Period III = placebo exenatide/moxifloxacin
11596531|NCT00672399|Experimental|Sequence 2|Period I = exenatide/placebo moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = placebo exenatide/placebo moxifloxacin
11596532|NCT00672399|Experimental|Sequence 3|Period 1 = placebo exenatide/moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = exenatide/placebo moxifloxacin
11596533|NCT00672399|Experimental|Sequence 4|Period I = placebo exenatide/moxifloxacin; Period II = exenatide/placebo moxifloxacin; Period III = placebo exenatide/placebo moxifloxacin
11596534|NCT00672399|Experimental|Sequence 5|Period I = placebo exenatide/placebo moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = exenatide/moxifloxacin
11596535|NCT00672399|Experimental|Sequence 6|Period I = exenatide/placebo moxifloxacin; Period II = placebo exenatide/placebo moxifloxacin; Period III = placebo exenatide/moxifloxacin
11596536|NCT00672386|Experimental|001|JNJ16269110 5 mg twice daily for 12 weeks
11596537|NCT00672386|Experimental|002|JNJ16269110 10 mg twice daily for 12 weeks
11596538|NCT00672386|Experimental|003|JNJ16269110 15 mg twice daily for 12 weeks
11596539|NCT00672386|Placebo Comparator|004|Placebo twice daily for 12 weeks
11596540|NCT00672373|Experimental|A|Active treatment with EGb-761 capsules (80mg each capsule), 3 capsules each day for 12 weeks
11596541|NCT00672373|Placebo Comparator|B|Matching placebo treatment
11596542|NCT00672360|Experimental|1|
11596544|NCT00672347|Active Comparator|B|compare caudal anesthesia with bupivacaine alone or in addition to morphine, clonidine or both
11596545|NCT00672347|Active Comparator|C|compare caudal anesthesia with bupivacaine plus clonidine with caudal anesthesia with bupivacaine alone or in addition to morphine or morphine plus clonidine
11596546|NCT00672347|Active Comparator|M|compare caudal anesthesia with bupivacaine plus morphine with caudal anesthesia with bupivacaine alone or in addition to clonidine or morphine plus clonidine
11596547|NCT00672347|Active Comparator|CM|compares caudal anesthesia with bupivacaine, morphine and clonidine with caudal anesthesia with bupivacaine alone or in addition to morphine or clonidine
11596548|NCT00672334|Placebo Comparator|2|sodium chloride at 0.5 mmol/kg loading pre-induction and then at 0.2 mmol/kg/hr over 24 hours after induction until the next day
11596549|NCT00672334|Experimental|1|The active intervention is loading (05. mmol/kg) pre-surgery and continuous infusion of bicarbonate at 0.2 mmol/kg/hr for 24 hours after induction
11596550|NCT00672308|Experimental|1|Benefiber (25 g/L)
11596551|NCT00672308|Experimental|2|Benefiber (50 g/L)
11596552|NCT00672308|Experimental|3|the reduced-osmolarity WHO-ORS without Benefiber.
11596553|NCT00672295|Experimental|Dasatinib, paclitaxel,and carboplatin|Combination of dasatinib, paclitaxel,and carboplatin
11596554|NCT00672282|Placebo Comparator|A|
11596555|NCT00672282|Active Comparator|B|
11596556|NCT00672269||1|Families with carcinoid in multiple family members
11596557|NCT00672256|Experimental|Smokers not interested in quitting smoking|Smokers were scanned 24 hours after quitting smoking, and scanned after smoking as usual.
11596558|NCT00672243|Experimental|Erlotinib + Sirolimus|Erlotinib & sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of erlotinib and 5mg of sirolimus for patients not on concurrent Cytochrome P450, family 3 (CY3PA)-inducing anti-epileptics (EIAEDS) and 400 mg of erlotinib and 10 mg of sirolimus for patients on concurrent EIAEDS.
11596559|NCT00672230|Experimental|Lut Supp|
11596560|NCT00672217|Placebo Comparator|Behavioral Placebo Therapy|Behavioral Placebo Treatment
11596561|NCT00672217|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia (CBTI)
11596562|NCT00672204|Experimental|1|Allogeneic islets of Langerhans
11596563|NCT00672191|Experimental|1|
11596564|NCT00672165|Experimental|1|This is a phase I, dose-escalation trial. The starting dose level will be 0.5 μCi/kg of 225Ac-HuM195. Three to six patients will be treated at each dose level, and dose escalation will proceed if less than 33% of patients in a cohort experience dose limiting toxicity. Six patients will be treated at the maximum tolerated dose
11596565|NCT00672152|Experimental|A-WT1 derived peptides|"Wilms' tumor gene 1 (WT1) derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg Granulocyte-macrophage colony-stimulating factor (GM-CSF) in a total volume of 2ml:
~WT peptide #1: (human leukocyte antigen) HLA-A2 restricted: RMFPNAPYL
~WT peptide #2: HLA-A24 restricted: CMTWNQMNL
~WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL
~WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT
~Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs."
11596566|NCT00672139|Experimental|Methylnaltrexone bromide|"Methylnaltrexone subcutaneously as needed no more than 1 dose in a 24-hour period for a maximum of 10 weeks in this study.
~Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; or 0.4 mL (8 mg) every other day if weight between 38 and <62 kg. Subjects with impaired kidney function received reduced doses according to instructions in the Relistor prescribing information."
11596567|NCT00672113|Experimental|Arm 1|
11596568|NCT00672113|Active Comparator|Arm 2|
11596569|NCT00672100|Active Comparator|A|Initial Bolus 5 ml Ropivacaine
11596570|NCT00672100|Active Comparator|B|Initial Bolus 10 ml Ropivacaine
11596571|NCT00672100|Active Comparator|C|Initial Bolus 20 ml Ropivacaine
11596572|NCT00672087||A|Chronic prostatitis/chronic pelvic pain syndrome patients
11596573|NCT00672087||B|Painful bladder syndrome/interstitial cystitis patients
11596574|NCT00672087||C|Asymptomatic controls
11596575|NCT00672074|Active Comparator|1 Ipamorelin|
11596576|NCT00672074|Placebo Comparator|2 Placebo|
11596577|NCT00672061|Experimental|Ramelteon 16 mg QD or Placebo QD|
11596578|NCT00672048|Other|1|
11596579|NCT00672048|Other|2|Control group to receive annual continuing education
11596580|NCT00672035|Experimental|1|7.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
11596581|NCT00672035|Experimental|2|7.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
11596582|NCT00672035|Experimental|3|22.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
11596583|NCT00672035|Experimental|4|22.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
11596584|NCT00672035|Experimental|5|37.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
11596585|NCT00672035|Experimental|6|37.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
11596586|NCT00672035|Experimental|7|50µg LT Dose placed at the Deltoid on Day 0 and Day 21
11596587|NCT00672035|Experimental|8|50µg LT Dose placed at the Lower Back on Day 0 and Day 21
11596588|NCT00672035|Placebo Comparator|9|Placebo (0µg LT) placed at the Deltoid on Day 0 and Day 21
11596589|NCT00672035|Placebo Comparator|10|Placebo (0µg LT) placed at the Lower Back on Day 0 and Day 21
11596590|NCT00672009|Experimental|One|
11596591|NCT00671996|Active Comparator|A|Mangafodipir treatment
11596592|NCT00671996|Placebo Comparator|B|
11596593|NCT00671970|Experimental|Bevacizumab + Erlotinib|Bevacizumab + Erlotinib
11596594|NCT00671957||Patients undergoing gastric bypass|"Patients undergoing gastric bypass surgery and who are participants in Longitudinal Assessment of Bariatric Surgery (LABS-2).
~Inclusion Criteria:
~No acute illnesses
~Weight less than 227 kg (limit of Bod Pod and Treadmill)
~Able to walk at 2.4 mph for 15 minutes (needed for the energy expenditure testing)
~No tobacco use
~Ability to stop alcohol consumption during test phases
~For female subjects; no plans for pregnancy in 24 months and menstrual cycles of 21-35 days
~No history of eating disorder
~No history of current substance abuse
~No history of chest pain or shortness of breath at rest or on exertion.
~Negative pregnancy in women."
11596595|NCT00671944|Experimental|1|Low protein diet
11597489|NCT00665561||Maraviroc unexposed|
11596596|NCT00671931|Active Comparator|I|Dexmedetomidine low infusion, Propofol low infusion
11596597|NCT00671931|Active Comparator|II|Dexmedetomidine high infusion, Propofol low infusion
11596598|NCT00671931|Active Comparator|IV|Dexmedetomidine high infusion, Propofol high infusion
11596599|NCT00671931|Active Comparator|V|Dexmedetomidine intermediate infusion, Propofol intermediate infusion
11596600|NCT00671931|Active Comparator|III|Dexmedetomidine low infusion, Propofol high infusion
11596601|NCT00671918|Experimental|Lymphoseek, Lymphatic mapping, Injection|
11596602|NCT00671905|Active Comparator|1|Circumferential PV isolation
11596603|NCT00671905|Active Comparator|2|HF stimulation-guided and anatomic ablation of the main right and left atrial GP.
11596604|NCT00671905|Active Comparator|3|HF stimulation-guided and anatomic ablation of the main right and left atrial GP followed by circumferential PV isolation
11596605|NCT00671892|Experimental|Challenge|"Experimental Challenge Challenge 1 saline 5000EU 10,000EU 20,000EU
~Challenge 2 Saline 40,000EU 80,000EU"
11596606|NCT00671879|Experimental|Carisprodol SR 700 mg|Carisoprodol 700 mg twice daily
11596607|NCT00671879|Experimental|Carisoprodol SR 500mg|Carisoprodol SR 500 mg twice daily
11596608|NCT00671879|Placebo Comparator|Placebo|Placebo
11596609|NCT00671866||1|Agricultural Workers
11596610|NCT00671866||2|Non - Agricultural Workers
11596611|NCT00671866||3|Kibbitz Residents working else where
11596612|NCT00671853|Experimental|1|Quetiapine XR
11596613|NCT00671853|Placebo Comparator|2|Placebo for quetiapine XR
11596614|NCT00671827||Robotic Gynecologic Surgery|Patients who have undergone or will undergo a robotic-assisted gynecologic procedure.
11596615|NCT00671814|Experimental|1|Single oral dose of TR-701 given once at 200mg, 400mg, 600mg, 800mg, and 1200mg. Multiple oral doses of TR-701 given once daily for 21 days at 200mg, 300mg and 400mg.
11596616|NCT00671814|Placebo Comparator|2|Single oral dose of placebo given in cohorts 1-5. Multiple oral doses of placebo given once daily for 21 days in cohorts 6-8 and twice daily for 21 days in cohort 10.
11596617|NCT00671814|Active Comparator|3|Oral doses of 600mg linezolid given twice daily for 21 days.
11596618|NCT00671801|Experimental|Irinotecan + Lenalidomide|Irinotecan 200 mg/m^2 intravenous once every 2 weeks on days 1 and 15; Lenalidomide orally 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
11596619|NCT00671788|Experimental|Treatment (dasatinib)|Patients receive oral dasatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11596620|NCT00671775||Bariatric surgery patients|
11596621|NCT00671775||Weight loss programs|
11596622|NCT00671749|Experimental|Study Treatment|"adapalene gel, 0.3%
~Other Names:
~Differin® Gel, 0.3% Applied once daily at bedtime
~clindamycin/benzoyl peroxide gel
~Other Names:
~Duac® Gel Applied once daily in the morning"
11596623|NCT00671736|Experimental|1|daily inhalation
11596624|NCT00671736|Experimental|2|inhalation every other day
11596625|NCT00671736|Experimental|3|inhalation twice a week
11596626|NCT00671736|Placebo Comparator|4|daily inhalation
11596627|NCT00671723|Placebo Comparator|Normal saline|Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
11596628|NCT00671723|Active Comparator|Hypertonic saline|Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
11596629|NCT00671723|Active Comparator|Dornase alpha|2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
11596630|NCT00671697|Experimental|Dose Level 1 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.1 mg/kg/day IV x 5 days followed by weekly doses of 0.1 mg/kg IV for 15 additional weeks.
~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
11596631|NCT00671697|Experimental|Dose Level 2 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.2 mg/kg/day IV x 5 days followed by weekly doses of 0.2 mg/kg IV for 15 additional weeks.
~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
11596632|NCT00671697|Experimental|Dose Level 3 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.3 mg/kg/day IV x 5 days followed by weekly doses of 0.3 mg/kg IV for 15 additional weeks.
~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
11596633|NCT00671671|Experimental|Cohort B|
11596634|NCT00671671|Experimental|Cohort A|Dose study drug in subjects who have previously failed to respond to interferon based therapies
11596635|NCT00671658|Experimental|HYPER-CVAD|Rituximab 375 mg/m2 by vein. Cyclophosphamide (CTX) 300 mg/m2 by vein. Doxorubicin 50 mg/m2 by vein. Vincristine 2 mg by vein. Dexamethasone 40 mg by vein or by mouth (P.O.). Methotrexate (MTX) 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7 - 200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8. Cytarabine 100 mg intrathecal for Courses 1,3,5,7 - 3 gm/m2 by vein for Courses 2,4,6,8. G-CSF 10 ug/kg subcutaneous injection. Mesna 600 mg/m2 a day by vein. Pegylated asparaginase 2000 International units/m2 by vein. Pegfilgrastim 6 mg (flat dose) within 72 hrs after completion of chemotherapy. Solumedrol 40 mg by vein for Courses 2,4,6,8.
11596636|NCT00671645|Experimental|1|
11596637|NCT00671632|Experimental|Ramelteon, triazolam, and placebo (56 poss. combinations)|Ramelteon, triazolam, and placebo (56 possible combinations total)
11596638|NCT00671606|Experimental|Intraoperative Lymphatic Mapping|Intraoperative sentinel lymph node identification (lymphatic mapping)
11596639|NCT00671593|Experimental|Experimental inhaled dust mite|All subjects receive the same experimental inhaled challenge interventions
11596640|NCT00671580|Experimental|A|PZ-601
11596641|NCT00671580|Experimental|B|PZ-601
11596642|NCT00671580|Active Comparator|C|Standard of Care
11596643|NCT00671567|Experimental|Ramelteon 8 mg QD|
11596644|NCT00671567|Experimental|Ramelteon 16 mg QD|
11596645|NCT00671567|Placebo Comparator|Placebo|
11596646|NCT00671554|Experimental|Melaxin and BCG|Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million Colony Forming Units (CFU) of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration
11596647|NCT00671541|Active Comparator|Merogel stent vs. Nasopore Stent|This study has two arms consiting of 50 subjects each (100 total) Arm 1 will recieve the standard stent (merogel)in their right sinus and a nasopore stent in their left sinus.
11596648|NCT00671541|Experimental|bacitracin vs. gentamicin treated stent|The second arm will consist of 50 new subjects. These 50 subjects will have a nasopore stent placed in the left sinus. The first 25 subjects will have nasopore stent placed postoperatively with a bacitracin soaked nasopore in right sinus the second 25 will have a gentamycin soaked nasopore stent in right sinus.
11596649|NCT00671528|Experimental|QUADRIDERME® cream|QUADRIDERME® cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)
11596650|NCT00671528|Active Comparator|Betamethasone and Gentamicin|Combination of betamethasone diproprionate cream and gentamicin sulfate cream
11596651|NCT00671528|Active Comparator|Betamethasone|Betamethasone diproprionate cream
11596652|NCT00671515|Experimental|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
11596653|NCT00671502|Experimental|Carisoprodol 700mg|tablet sustained release (SR)
11596654|NCT00671502|Experimental|Carisoprodol 500mg|sustained release(SR) tablet
11596655|NCT00671502|Placebo Comparator|Placebo|tablet
11596656|NCT00671463|Experimental|1|Pre-operative pancreatic duct stenting
11596657|NCT00671463|No Intervention|2|Control group, no endoscopy and no stent pre-operatively
11596658|NCT00671450||Group 1|Participants will be patients diagnosed with PTSD but with no history of TBI. Participants must be between the ages of 19 and 39. Participants must be compentent to sign a consent form and be willing ot participate in a vision screening.
11596659|NCT00671437|Experimental|Arm 1|"Whole body FDG-PET/CT scan and CT scan of neck and chest (within 28 days of Day 1)
~Cetuximab 400 mg/m2 intravenously (IV) over 2 hours on day 1 and 250 mg/m2 IV over 1 hour on days 8, 15, 22, 29, 36, 43, and 50.
~Whole Body FDG-PET/CT scan and CT scan of neck and chest on Day 57 (prior to cetuximab infusion)
~Cetuximab 250 mg/m2 IV over 1 hour on Day 57
~Cetuximab 250 mg/m2 IV over 1 hour weekly until progressive disease"
11596660|NCT00671411|Experimental|1|Patients entering into this protocol will also have a preoperative renal contrast enhanced US for this research study. Renal mass US contrast enhancement results will be compared with surgical pathological findings to determine if contrast enhancement patterns of the renal masses correlate with benign and malignant histopathology, and/or malignant histologic subtype.
11596661|NCT00671398|Experimental|Ramelteon 8 mg QD|
11596662|NCT00671398|Experimental|Ramelteon 16 mg QD|
11596663|NCT00671398|Placebo Comparator|Placebo|
11596664|NCT00671385||Women 21-50 years old|Women without a diagnosis of cancer or a history of cancer.
11596665|NCT00671372|Experimental|Cohorts 1-5|
11596666|NCT00671372|Experimental|Cohorts 6, 6A, 7, 7A|
11596667|NCT00671359|Experimental|after fast|Administration of a single oral dose of 600mg TR-701 to subjects in the fasted state.
11596668|NCT00671359|Experimental|After high fat food|Administration of a single oral dose of 600mg TR-701 to subjects in the fed state.
11596669|NCT00671346||1|Participants in NORVIT and WENBIT allocated to daily oral treatment with folic acid 0.8 mg and vitamin B12 0.4 mg
11596670|NCT00671346||2|Participants in NORVIT and WENBIT allocated to daily oral treatment with folic acid 0.8 mg, vitamin B12 0.4 mg and B6 40 mg.
11596671|NCT00671346||3|Participants in NORVIT and WENBIT allocated to daily oral treatment with vitamin B6 40 mg.
11596672|NCT00671346||4|Participants in NORVIT and WENBIT allocated to daily oral treatment with placebo
11596673|NCT00671333|Active Comparator|1|(LRTI) Ligament reconstruction and tendon interposition
11596674|NCT00671333|Active Comparator|2|Ascension PyroDisk
11596675|NCT00671320|Active Comparator|Arm 1|
11596676|NCT00671320|Active Comparator|Arm 2|
11596677|NCT00671307|Placebo Comparator|Placebo|Placebo
11596678|NCT00671307|Experimental|Low dose|3 mg/kg of rhu-pGelsolin given as an IV infusion over 1 hour
11596679|NCT00671307|Experimental|Mid-dose|6 mg/kg of rhu-pGelsolin given as an IV infusion over 1 hour
11596680|NCT00671307|Experimental|High dose|6 mg/kg of rhu-pGelsolin given a an IV infusion over 1 hour once a day for 3 days
11596681|NCT00671294|Experimental|Ramelteon and Placebo QD (9 possible combinations total)|
11596682|NCT00671281|Experimental|B|This group will be the experimental group which will receive tranexamic acid in oral form three days before and six days after surgery.
11596683|NCT00671281|Placebo Comparator|A|This will be the control group which will take the placebo medication for 3 days before and six days after their functional endoscopic sinus surgery (FESS).
11596684|NCT00671268|Experimental|1|strict subcutaneous
11596685|NCT00671268|Placebo Comparator|2|strict subcutaneous
11596686|NCT00671255|Experimental|Ramelteon 4 mg QD|
11596687|NCT00671255|Experimental|Ramelteon 8 mg QD|
11596688|NCT00671255|Placebo Comparator|Placebo|
11596689|NCT00671242||I|L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer
11596690|NCT00671242||Nuclear|
11596691|NCT00671229||1|African American
11596692|NCT00671229||2|Caucasian
11596693|NCT00671216|Experimental|Period 1|Subjects will receive first placebo, then GSK233705, GW642444 and combination of GSK233705 and GW642444
11596694|NCT00671216|Experimental|Period 2|Subjects will receive first combination of GSK233705 and GW642444, then placebo, GSK233705 and GW642444
11596695|NCT00671216|Experimental|Period 3|Subjects will receive first GSK233705, then GW642444, combination of GSK233705 and GW642444 and later placebo
11596696|NCT00671216|Experimental|Period 4|Subjects will receive first GW642444, then combination of GSK233705 and GW642444, placebo, and later GSK233705
11596697|NCT00671190|Experimental|Ramelteon 1 mg QD|
11596698|NCT00671190|Experimental|Ramelteon 2 mg QD|
11596699|NCT00671190|Experimental|Ramelteon 4 mg QD|
11596700|NCT00671190|Experimental|Ramelteon 8 mg QD|
11596701|NCT00671190|Placebo Comparator|Placebo QD|
11596702|NCT00671177|Experimental|Water Immersion Colonoscopy|Water Immersion Colonoscopy
11597709|NCT00663936|Experimental|1|T-817MA once daily
11596703|NCT00671177|Active Comparator|Standard Air Colonoscopy|Standard Air Colonoscopy
11596704|NCT00671151|Active Comparator|1|Low-dose theophylline on top of standard therapy for COPD exacerbation
11596705|NCT00671151|No Intervention|2|Standard therapy for COPD exacerbation
11596706|NCT00671138|Active Comparator|I|Arm I will be inoculated with the human hookworm necator americanus at weeks 0 and 12.
11596707|NCT00671138|Placebo Comparator|II|Arm II participants will receive and identical sham-inoculums comprising a diluted amount of 0.2ml McIlhenny & Co Tabasco Pepper Sauce®
11596708|NCT00671125|Experimental|Ramelteon 8 mg QD|
11596709|NCT00671125|Experimental|Ramelteon 16 mg QD|
11596710|NCT00671125|Placebo Comparator|Placebo|
11596711|NCT00671112|Experimental|Everolimus and Bortezomib|Patients will receive a combination of Everolimus by mouth and Bortezomib intravenously for a 21 day cycle.
11596712|NCT00671099|Experimental|1|Dietary Supplement: Omega-3 Polyunsaturated Fatty Acid
11596713|NCT00671099|Placebo Comparator|2|Placebo
11596714|NCT00671086|Experimental|Ramelteon 8 mg QD|
11596715|NCT00671086|Experimental|Ramelteon 16 mg QD|
11596716|NCT00671073|Active Comparator|1|Oglemilast low dose, oral administration once daily for 12 weeks
11596717|NCT00671073|Active Comparator|2|Oglemilast middle dose, oral administration, once daily for 12 weeks
11596718|NCT00671073|Active Comparator|3|Oglemilast high dose, oral administration, once daily for 12 weeks.
11596719|NCT00671073|Placebo Comparator|4|Placebo
11596720|NCT00671060|Active Comparator|2|Women in Group 1 will be administered two tablets (2 100 mcg misoprostol tablets), which she will be instructed to hold in her cheeks for 200 minutes, after which she will swallow any medication that remains. In cases where cervical dilation is not complete after six hours, women will be given a second dose of study drug. Study drug will continue to be administered at 6-hourly intervals through hour 42 after the study dose.
11596721|NCT00671060|Placebo Comparator|1|Women in Group 1 will be administered two tablets (a 100 mcg misoprostol tablet and a placebo tablet made to resemble a 100 mcg misoprostol tablet), which she will be instructed to hold in her cheeks for 200 minutes, after which she will swallow any medication that remains. In cases where cervical dilation is not complete after six hours, women will be given a second dose of study drug. Study drug will continue to be administered at 6-hourly intervals through hour 42 after the study dose.
11596722|NCT00671047||1|SLE subjects with flares in the last 12 months in specific organ systems.
11596723|NCT00671034|Experimental|Arm I (calaspargase pegol 2100)|Patients receive calaspargase pegol 2100 together with combination chemotherapy. Patients receive chemotherapy PO, IV, SC, and IT. Some patients also undergo radiation therapy to the head. Treatment may continue for up to 3 1/2 years.
11596724|NCT00671034|Experimental|Arm II (calaspargase pegol 2500)|Patients receive calaspargase pegol 2500 together with combination chemotherapy. Patients receive chemotherapy PO, IV, SC, and IT. Some patients also undergo radiation therapy to the head. Treatment may continue for up to 3 1/2 years.
11596725|NCT00671034|Active Comparator|Arm III (pegaspargase 2500)|Patients receive pegaspargase 2500 together with combination chemotherapy. Patients receive chemotherapy PO, IV, SC, and IT. Some patients also undergo RT to the head. Treatment may continue for up to 3 1/2 years.
11596726|NCT00671021||1|Patients suffering from stable CAD, on chronic ASA therapy
11596727|NCT00671008||A|
11596728|NCT00671008||B|
11596729|NCT00670982|Experimental|First line treatment|Patients with no prior therapy for metastatic breast cancer will receive bevacizumab intravenously every 2 weeks and vinorelbine intravenously once per week, and trastuzumab intravenously once per week
11596730|NCT00670982|Experimental|Second line treatment|Patients with 1 prior line for metastatic breast cancer will receive bevacizumab intravenously every two weeks, vinorelbine intravenously once per week, and trastuzumab intravenously once per week.
11596731|NCT00670969||A|People who will have the portable measurement taken first and handheld measurement taken second
11596732|NCT00670969||B|People who will have the handheld measurement taken first and portable measurement taken second
11596733|NCT00670956|Active Comparator|Active Study Group|STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart
11596734|NCT00670956|Placebo Comparator|Placebo Group|PLACEBO: IM x 2 doses 24 hours apart
11596735|NCT00670943||A|Patients with stable CAD with scheduled discontinuation of clopidogrel
11596736|NCT00670943||B|Patients with stable CAD not taking clopidogrel
11596737|NCT00670930|Active Comparator|omalizumab|Omalizumab was supplied as lyophilized, sterile powder in a single use, 5 ml vial that was designed to deliver 150 mg of omalizumab for subcutaneous (SQ) administration upon reconstitution with 1.4 ml sterile water for injection. The dose administered was individualized for each patient based on the patient's body weight and total serum Immunoglobulin E (IgE) level at Visit 1 and the number of injections and injection volume was determined using protocol-specified dosing tables. Omalizumab 75 to 375 mg was administered SQ every 2 or 4 weeks depending on the dose for the 78 weeks duration of double-blinded treatment.
11596738|NCT00670930|Placebo Comparator|Placebo|Omalizumab matching placebo was supplied as lyophilized, sterile powder in a single-use, 5 ml vial that was designed to deliver omalizumab matching placebo for subcutaneous (SQ) administration upon reconstitution with 1.4 ml sterile water for injection. The number of injections and injection volume was individualized for each patient based on the patient's body weight and total serum Immunoglobulin E (IgE) level at Visit 1 and was determined using protocol-specified dosing tables. Placebo was administered SQ every 2 or 4 weeks for the 78 weeks duration of double-blinded treatment.
11596739|NCT00670917|Active Comparator|L14 acupoint|
11596740|NCT00670917|Sham Comparator|Sham Point|
11596741|NCT00670904|Active Comparator|1|Pharmacist-delivered group program for smoking cession.
11596742|NCT00670904|Placebo Comparator|2|Brief standard care session for tobacco smoking cessation delivered over the telephone.
11596743|NCT00670891|Experimental|HBOT|HBOT
11596744|NCT00670878|Experimental|A|
11596745|NCT00670878|Active Comparator|B|
11596746|NCT00670865|Experimental|eDischarge|The eDischarge arm will consist of two teams on the General Internal Medicine ward at St. Michael's Hospital who have been randomly assigned to use the electronic discharge summary program.
11596788|NCT00670540||1|patients with suspected Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)
11596747|NCT00670865|No Intervention|Traditional|"The traditional arm will consist of two teams on the General Internal Medicine ward at St. Michael's Hospital who have been randomly assigned to use traditional, dictated discharge summaries."
11596748|NCT00670852||I|Patients who received a total shoulder replacement with an anchor peg glenoid and autologous bone grafting from the investigator of this study will be recruited for this study.
11596749|NCT00670839|Active Comparator|A|GenHevac-B 20 microgram intramuscular use at M0, M1 and M6
11596750|NCT00670839|Experimental|B|GenHevac-B 40 microgram intramuscular use at M0, M1 and M6
11596751|NCT00670826|Experimental|1|Use of the Dynatherm Medical vitalHEAT vH2 Temperature Management System to warm patients undergoing orthopedic surgical procedures with an expected duration 2-3 hours and requiring general anesthesia.
11596752|NCT00670826|Active Comparator|2|Use of the Arizant Healthcare Bair Hugger Temperature Management System & Bair Hugger Upper Body Blanket to warm patients undergoing orthopedic surgical procedures with an expected duration 2-3 hours and requiring general anesthesia.
11596753|NCT00670813|Experimental|Modafinil (Vigil)|"Modafinil Arm: during the 40 h sleep deprivation period (morning until evening next day) the depressed patient receives 200 mg of Modafinil each at 12:00, 24:00 and again at 12:00 o' clock"
11596754|NCT00670813|Placebo Comparator|Placebo|"Placebo Arm: during the 40 h sleep deprivation period (morning until evening next day) the depressed patient receives Placebo at 12:00, 24:00 and again at 12:00 o' clock"
11596755|NCT00670800|No Intervention|Normal Controls|Control subjects will have 5 visits (screening, oral glucose tolerance test (OGTT), neuropsychological testing, functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) as they will receive no treatment and will not have repeat studies. The baseline values obtained from the control subjects will be compared to the baseline values acquired from the PCOS affected subjects.
11596756|NCT00670800|Experimental|PCOS Affected Women-Metformin Treatment|Subjects with Polycystic Ovary Syndrome (PCOS) will be scheduled for 9 visits total: following the screening visit they will go through OGTT, neuro-psychological testing, fMRI and PET scan before and after 4 months of metformin use: 500mg tablets once daily with breakfast for 1 week, then increased to one tablet twice daily with breakfast & lunch for 1 week, then increased to one tablet three times daily with breakfast, lunch & dinner.
11596757|NCT00670787|Active Comparator|Combination pill|Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
11596758|NCT00670787|No Intervention|Control group|combination therapy of angiotensin receptor antagonists (losartan potassium 50mg, candesartan 8mg, valsartan 80mg, telmisartan 40mg or olmesartan 20mg) and thiazide or thiazide-like diuretics (hydrochlorothiazide 6.25-12.5mg, trichlormethiazide 0.5-1.0mg, indapamide 0.5-1.0mg or chlorthalidone 6.25-12.5mg)
11596759|NCT00670774|Experimental|Eculizumab|Patients received eculizumab intravenously according to details provided in the intervention description.
11596760|NCT00670761|Active Comparator|1|treatment with 600mcg oral misoprostol
11596761|NCT00670761|Active Comparator|2|treatment with 400mcg sublingual misoprostol
11596762|NCT00670761|Active Comparator|3|treatment with Manual Vacuum Aspiration (MVA)
11596763|NCT00670748|Experimental|#1 Anti-NY-ESO-1 TCR PBL+HD IL-2 Mel/RCC|Patients with melanoma or renal cell cancer (RCC) will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin.
11596764|NCT00670748|Experimental|#2 Anti-NY-ESO-1 TCR PBL+HD IL-2 OtherCa|Patients with cancers other than melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by anti-NY ESO-1 TCR PBL and high dose (HD) aldesleukin
11596765|NCT00670748|Experimental|#3ESO1 TCR PBL+ALVAC ESO1+HD IL2 Mel/RCC|Patients with melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by replication-defective recombinant canarypox virus (ALVAC) NY-ESO-1 vaccine, anti-NY ESO-1 TCR PBL and high dose aldesleukin
11596766|NCT00670748|Experimental|#4ESO1 TCR PBL+ALVAC ESO1+HD IL2 OtherCa|Patients with cancers other than melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by ALVAC NY-ESO-1 vaccine, anti-NY ESO-1 TCR PBL and high dose aldesleukin
11596767|NCT00670722||A|
11596768|NCT00670722||B|
11596769|NCT00670722||C|
11596770|NCT00670722||D|
11596771|NCT00670709||1|Subjects with mild or moderate Huntington's Disease
11596772|NCT00670709||2|Normal Controls
11596773|NCT00670696|Experimental|A|Rapydan medicated plaster administered 30 minutes prior to cannulation on Visit 1 and tetracaine gel administered 45 minutes prior to cannulation on Visit 2.
11596774|NCT00670696|Active Comparator|B|Tetracaine gel administered 45 prior to cannulation on Visit 1 and then Rapydan administered 30 minutes prior to cannulation on Visit 1
11596775|NCT00670683||A|
11596776|NCT00670670|Experimental|1|CPP-ACP (GC Tooth Mousse)
11596777|NCT00670670|Experimental|2|CPP-ACP (GC MI Paste Plus)
11596778|NCT00670670|No Intervention|3|Control group
11596779|NCT00670657|Experimental|1|AmBisome® 2 mg/kg/day in a unique daily IV administration
11596780|NCT00670631|Experimental|Tandem autologous stem cell transplant|"Induction: DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.
~After collection, participants will receive dexamethasone x 4 days every 14 days.
~Transplant 1: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.
~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.
~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide) Transplant 2: 8 weeks to 6 months after the first transplant, participants will have the second transplant Maintenance: Year 1- VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
11596781|NCT00670618|Experimental|1|CPP-ACP (GC Tooth Mousse)
11596782|NCT00670618|Experimental|2|GCC-ACP (GC MI Paste Plus)
11596783|NCT00670618|Experimental|3|Fluoride (Elmex Medical Gel)
11596784|NCT00670618|No Intervention|4|Control group
11596785|NCT00670592|Other|HCD122|
11596786|NCT00670566|Experimental|1|
11596787|NCT00670553|Experimental|LBH589|
11596958|NCT00669344|Experimental|I|Rivastigmine
11596789|NCT00670514|Active Comparator|1 Nix Individual|High Treatment Intensity
11596790|NCT00670514|Placebo Comparator|2 Fimpa dig fri|Low Treatment Intensity
11596791|NCT00670501|Experimental|1|LY333334 40 micrograms/day plus calcium and vitamin D
11596792|NCT00670501|Experimental|2|LY333334 20 micrograms/day plus calcium and vitamin D
11596793|NCT00670501|Placebo Comparator|3|Placebo plus calcium and vitamin D
11596794|NCT00670488|Experimental|MK-2206 30 mg QOD|Participants receive 30 mg oral MK-2206 every other day (QOD) in repeating 4-week treatment cycles.
11596795|NCT00670488|Experimental|MK-2206 60 mg QOD|Participants receive 60 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
11596796|NCT00670488|Experimental|MK-2206 75 mg QOD|Participants receive 75 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
11596797|NCT00670488|Experimental|MK-2206 90 mg QOD|Participants receive 90 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
11596798|NCT00670488|Experimental|MK-2206 90 mg QW|Participants receive 90 mg oral MK-2206 every week (QW) in repeating 4-week treatment cycles.
11596799|NCT00670488|Experimental|MK-2206 135 mg QW|Participants receive 135 mg oral MK-2206 QW in repeating 4-week treatment cycles.
11596800|NCT00670488|Experimental|MK-2206 200 mg QW|Participants receive 200 mg oral MK-2206 QW in repeating 4-week treatment cycles.
11596801|NCT00670488|Experimental|MK-2206 300 mg QW|Participants receive 300 mg oral MK-2206 QW in repeating 4-week treatment cycles.
11596802|NCT00670488|Experimental|MK-2206 250 mg QW|Participants receive 250 mg oral MK-2206 QW in repeating 4-week treatment cycles.
11596803|NCT00670488|Experimental|MK-2206 150 mg QW|Participants receive 150 mg oral MK-2206 QW in repeating 4-week treatment cycles.
11596804|NCT00670475|Active Comparator|P (Pircoxicam Group)|in this arm 100 patients with osteoarthritis of knee will receive piroxicam gel in blinded 60 grams tubes,they will be instructed to use 1 gram of piroxicam gel (with inserted dispensing device) three times in a day on the affected knee.
11596805|NCT00670475|Experimental|O (olive oil group)|in this arm 100 patients with osteoarthritis of knee will receive virgin olive oil in blinded 60 grams tubes,they will be instructed to use 1 gram of olive oil (with inserted dispensing device) three times in a day on the affected knee.
11596806|NCT00670462|Active Comparator|Standard Behavioral Treatment (SBT)|"Standard Behavioral Treatment (SBT) for weight loss intervention introduces a core set of instructions on diet and exercise at the beginning of the intervention and then embellishes these instructions with suggested refinements of behavioral choices over time (e.g., different menus and amounts or types of physical activity)."
11596807|NCT00670462|Experimental|Maintenance-Tailored Treatment (MTT)|"Maintenance-Tailored Treatment (MTT) for weight loss intervention treats diet and exercise strategy embellishments as separate interventions with discrete and independent status. MTT differs from SBT in its emphasis on skills for long-term weight control, namely, the strategy of initiating varied weight-control strategies as a response to the demands of changing environmental challenges and to sustain effective cues and reinforcements needed to motivate weight-loss behaviors."
11596808|NCT00670449|Experimental|Fingolimod 0.5 mg|Patients who received fingolimod 0.5 orally once daily in the core study continued on the same dose in this extension study.
11596809|NCT00670449|Experimental|Fingolimod 1.25 mg|Patients who received fingolimod 1.25 mg orally once daily in the core study continued on the same dose in this extension study.
11596810|NCT00670449|Experimental|Placebo-fingolimod|Patients who were randomized to placebo in the core study were re-randomized to either fingolimod 0.5 or 1.25 mg (1:1) orally once daily in this extension study.
11596811|NCT00670436|Active Comparator|A 1|paclitaxel eluting PTCA balloon (SeQuent please) after bare-metal stenting of a chronic total occlusion in a native coronary artery
11596812|NCT00670436|Active Comparator|A2|historical population of patients with a chronic total occlusion in a native coronary artery treated with the paclitaxel eluting Taxus stent (Boston Scientific)
11596813|NCT00670410|Experimental|Arm A - Related Donor|Related donor transplant: Patients with a related donor (5/6 or 6/6 HLA matched) will receive immunotherapy with a non-myeloablative preparative regimen of Busulfan and Fludarabine followed by allogeneic stem cell transplant (AlloSCT).
11596814|NCT00670410|Experimental|Arm B - Cord Blood Donor|Unrelated cord blood transplant: Patients without a related donor will receive immunotherapy with a non-myeloablative preparative regimen of busulfan and fludarabine followed by allogeneic stem cell transplant (AlloSCT) with either an unrelated umbilical cord blood donor (4/6, 5/6, or 6/6 HLA matched), or a related umbilical cord blood donor (3/6, 4/6, 5/6, or 6/6 HLA matched). Patients will receive Thymoglobulin ((rabbit) Anti-Thymocyte Globulin (ATG)) during the preparative regimen. GVHD prophylaxis will be Tacrolimus and mycophenolate mofetil (MMF).
11596815|NCT00670397|Experimental|Treatment (PDT)|Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light treatment to the tumor bed on day 2. Treatment may repeat every 8 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11596816|NCT00670384|Active Comparator|Dose Group A|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)
11596817|NCT00670384|Active Comparator|Dose Group B|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)
11596818|NCT00670384|Placebo Comparator|Placebo|
11596819|NCT00670371||1|Patients having the following diagnoses are eligible for inclusion into the study: schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, delusional disorder, affective psychosis with mood incongruent delusions, psychotic disorder not otherwise specified or patients being actively psychotic.
11596820|NCT00670371||2|Closest relative(s) /informal caregiver(s)
11596821|NCT00670345|Experimental|1|Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
11596822|NCT00670345|Placebo Comparator|2|Patients belonging to the control group will receive the same volume of saline infusions.
11596823|NCT00670319|Experimental|1|Raloxifene HCL 60 mg orally once a day
11596824|NCT00670319|Experimental|2|Raloxifene HCL 120 mg orally once a day
11596825|NCT00670319|Placebo Comparator|3|
11596826|NCT00670306|Experimental|Cetrorelix 78 mg|Drug: Cetrorelix 52 mg week 0, and 26 mg week 2, intra muscular-2 doses in 2 weeks and follow up to week 26.
11596959|NCT00669331|Experimental|Mannitol|Inhaled mannitol 400mg
11596827|NCT00670293||Subjects with anorexia nervosa|Underweight participants with anorexia nervosa who will restore normal weight levels after inpatient treatment will undergo Positron Emission Tomography (PET) using [11C]raclopride as well as MRI
11596828|NCT00670293||Healthy weight controls|Participants who are healthy controls will undergo Positron Emission Tomography (PET) using [11C]raclopride as well as MRI
11596829|NCT00670280|Experimental|Intervention Group|Those randomized to the Intervention group will meet twice over a two-week period with a trained counselor while visiting the neonatal intensive care unit.
11596830|NCT00670280|Active Comparator|UC Group|Those randomized to the Usual Care group will receive written information on secondary smoke and infant health and will be assessed at 1 month, 3 months, and 6 months post-intervention.
11596831|NCT00670280|Active Comparator|UC-RM Group|Those randomized to the Usual Care - Reduced Measurement group will receive the same information as the Usual Care group but will be measured less often (only at 6 months post-intervention).
11596832|NCT00670267|Experimental|Open Label treatment with oral Nadolol|Dose escalation through 1.25mgs, 2.5mgs, 5.0mgs, 10mgs, 20mgs, and 40mgs of nadolol at 2 week intervals as tolerated.
11596833|NCT00670254|Experimental|Hydrocortisone|
11596834|NCT00670254|Placebo Comparator|Placebo|
11596835|NCT00670241|Active Comparator|1|
11596836|NCT00670241|Active Comparator|2|
11596837|NCT00670241|Placebo Comparator|3|
11596838|NCT00670228|Active Comparator|Intensive Insulin Therapy (IIT)|In IIT arm, subjects received intravenous (IV) insulin glulisine and subcutaneous (sc) insulin glargine to maintain a Blood Glucose (BG) concentration between 90-130 mg/dL.
11596839|NCT00670228|Active Comparator|Standard Glycemic Care (SGC)|"In SGC arm subjects assigned to standard of care received subcutaneous regular insulin per sliding scale."
11596840|NCT00670215|Experimental|Arm 1|
11596841|NCT00670215|Experimental|Arm 2|
11596842|NCT00670202|Experimental|Drug: Fasudil hydrochloride|Fasudil hydrochloride 40 mg three times a day X 14 days
11596843|NCT00670202|Placebo Comparator|Drug: Placebo oral tablet|Placebo 1 tablet three times daily x 14 days
11596844|NCT00670189|Experimental|BMS-833923|
11596845|NCT00670176|Experimental|I|
11596846|NCT00670163|Experimental|1|Participating community will provide Comunidades Positivas plus enhanced partner therapy.
11596847|NCT00670163|Experimental|2|Participating community will provide enhanced partner therapy alone.
11596848|NCT00670163|Experimental|3|Participating community will provide Comunidades Positivas alone.
11596849|NCT00670163|Active Comparator|4|Participating community will provide standard of care.
11596850|NCT00670124|No Intervention|1|Standard medical treatment
11596851|NCT00670124|Active Comparator|2|Standard medical treatment plus hypothermia (33°C) maintained for 72 hours
11596852|NCT00670111|Experimental|RAP On then Off at 1 month visit|"Rate Adaptive Pacing (RAP) On for first cardiopulmonary exercise test (CPX) at one month.
~Rate Adaptive Pacing (RAP) Off for second cardiopulmonary exercise test (CPX) at one month."
11596853|NCT00670111|Experimental|RAP Off then On at 1 month visit|"Rate Adaptive Pacing (RAP) Off for first cardiopulmonary exercise test (CPX) at one month.
~Rate Adaptive Pacing (RAP) On for second cardiopulmonary exercise test (CPX) at one month."
11596854|NCT00670098|Experimental|1|
11596855|NCT00670098|Experimental|2|
11596856|NCT00670059|Active Comparator|A|group: single embryo transfer without aneuploidy screening
11596857|NCT00670059|Experimental|B|group: single embryo transfer with aneuploidy screening
11596858|NCT00670046|Other|Arm I (standard of care)|Patients undergo observation according to the standard of care. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.
11596859|NCT00670046|Experimental|Arm II (valproic acid)|Patients receive oral valproic acid twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.
11596860|NCT00670033|Experimental|Travoprost new formulation|Travoprost ophthalmic solution (new formulation), 1 of 3 dose levels, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
11596861|NCT00670033|Active Comparator|TRAVATAN|Travoprost ophthalmic solution 0.004%, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
11596862|NCT00670033|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
11596863|NCT00670020|Experimental|1|supplemental perioperative oxygen
11596864|NCT00670020|No Intervention|2|Normal
11596865|NCT00670007|Experimental|Zemaira®|
11596866|NCT00669994|Experimental|Arm 1|
11596867|NCT00669981|Experimental|1|Participants will receive immediate cognitive behavioral couples therapy for PTSD.
11596868|NCT00669981|Active Comparator|2|Participants will receive delayed cognitive behavioral couples therapy for PTSD after a 3-month waitlist period.
11596869|NCT00669955|Active Comparator|OAC 7 days|Triple therapy, given for 7 days at a dose of omeprazole 20 mg twice daily, amoxicillin 500 mg 2 capsules twice daily, and clarithromycin 500 mg 1 tablet twice daily
11596870|NCT00669955|Experimental|OBMT 10 days|OBMT (Pylera), consisting of a 3 in 1 capsule, made of bismuth subcitrate potassium 120 mg, metronidazole 125 mg, and tetracycline 125 mg, administered as 3 capsules 4 times daily. Omeprazole 20 mg is administered twice daily.
11596871|NCT00669942|Experimental|Part 1 - AIN457A 0.3 mg/kg|AIN457A 0.3 mg/kg was administered intravenously as a single dose.
11596872|NCT00669942|Experimental|Part 1 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as a single dose.
11596873|NCT00669942|Experimental|Part 1 - AIN457A 3.0 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as a single dose.
11596874|NCT00669942|Experimental|Part 1 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as a single dose.
11596875|NCT00669942|Placebo Comparator|Part 1 - Placebo|Placebo to AIN457A was administered intravenously as a single dose.
11596876|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
11596877|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 3.0 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
11596878|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
11596879|NCT00669942|Placebo Comparator|Parts 2 and 3 - Placebo|Placebo to AIN457A was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
11596880|NCT00669942|Experimental|Part 1 - Healthy Volunteers - AIN457A 3 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as a single dose.
11596881|NCT00669942|Experimental|Part 1 - Healthy Volunteers - AIN457A 10 mg/kg|AIN457A 10 mg/kg was administered intravenously as a single dose.
11596882|NCT00669942|Placebo Comparator|Part 1 - Healthy Volunteers - Placebo|Placebo to AIN457A was administered intravenously as a single dose.
11596883|NCT00669929||1|patients visited to Severance hospital
11596884|NCT00669929||2|patients visited to Youngdong Severance hospital
11596885|NCT00669929||3|patients visited to Wonju Christian hospital
11596886|NCT00669916|Experimental|AIN457|AIN457A 3mg/kg was administered intravenously as a single dose.
11596887|NCT00669916|Placebo Comparator|Placebo|Placebo was administered intravenously as a single dose.
11596888|NCT00669903|Experimental|1|AZD0328 low dose
11596889|NCT00669903|Experimental|2|AZD0328 Optimal dose
11596890|NCT00669903|Experimental|3|AZD0328 High dose
11596891|NCT00669903|Placebo Comparator|4|Placebo Comparator
11596892|NCT00669890|Experimental|study 515|
11596893|NCT00669877|Experimental|Hyper-CVAD|Hyper-CVAD (odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses. Rituximab 375 mg/m2 days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses. Cyclophosphamide 300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3. Doxorubicin 50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses). Vincristine 2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses). Dexamethasone 40 mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses). G-CSF 10 mg/kg/day (rounded) until neutrophil recovery 1 x 10^9/L or higher can be substituted or can be added to pegfilgrastim if neutrophils have not recovered to 1 x 10^9/L by day 21.
11596894|NCT00669864|Experimental|BIAsp 30-30|Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 1000-2000mg, up to three times daily
11596895|NCT00669838||PL|Patients who receive local anesthesia with 2% lidocaine without epinephrine
11596896|NCT00669838||LE|Patients who receive local anesthesia with 2% lidocaine with 1:100.000 epinephrine
11596897|NCT00669825|Placebo Comparator|A|Placebo
11596898|NCT00669825|Active Comparator|B|ALV003 (Active Study Drug)
11596899|NCT00669799|Experimental|1|clyndamyacin
11596900|NCT00669799|Experimental|2|gentamicin
11596901|NCT00669786|Active Comparator|HMG|Human Menopausal Gonadotropin (HMG)
11596902|NCT00669786|Active Comparator|r-FSH|Recombinant Follicle Stimulating Hormone
11596903|NCT00669773|Experimental|Adriamycin|Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly
11596904|NCT00669773|Experimental|Docetaxel|
11596905|NCT00669760||Observation|CF-patients with persistent culture of Staphylococcus aureus in their respiratory specimens
11596906|NCT00669747|Experimental|A|Carboplatin infused into DCIS-involved duct on Days 1 & 15
11596907|NCT00669747|Experimental|B|Carboplatin infused into DCIS-involved duct Day 1 and Normal Saline infused into DCIS-involved duct on Day 15
11596908|NCT00669747|Placebo Comparator|C|Normal Saline infused into DCIS-involved duct Days 1 & 15
11596909|NCT00669734|Experimental|Treatment (vaccine therapy, sargramostim)|Patients receive falimarev vaccine intratumorally using endoscopic ultrasound guidance on day 1. Patients also receive inalimarev vaccine SC on day 1 and sargramostim SC on days 1-4. Patients then receive falimarev vaccine SC on days 15 and 29 and sargramostim SC on days 15-18 and 29-32 in the absence of unacceptable toxicity. Beginning on day 43, patients with stable or improving pancreatic cancer receive falimarev vaccine SC and sargramostim SC (given on the day of and for 3 days after each falimarev vaccination) monthly in the absence of disease progression or unacceptable toxicity. Beginning on day 71, patients with no irreversible or dose limiting toxicity, receive falimarev vaccine SC and sargramostim SC (given on the day of and for 3 days after each falimarev vaccination) monthly in the absence of disease progression or unacceptable toxicity.
11596910|NCT00669721|Experimental|A|This patients start a run in period with LMWH schedule as hemodialysis circuit anticoagulation. Then they'll undergo hemodialysis with LMWH for a second period of two weeks: in this checking phase samples will be collected during the midweek hemodialysis sessions. After the checking phase the patients will be crossed to UFH schedule. A wash out period of two weeks with UFH will be done. At the end of this period two weeks of checking phase will starts.
11596911|NCT00669721|Active Comparator|B|The patients randomized to receive UFH will start a run in period with this heparin schedule. Then they'll undergo hemodialysis with UFH for a second period of two weeks: in this checking phase samples will be collected during the midweek hemodialysis sessions. After the checking phase the patients will be crossed to LMWH. A wash out period of two weeks with UFH will be done. At the end of this period two weeks of checking phase will starts.
11596912|NCT00669708|Active Comparator|1|ph5 Eucerin Lotion with cooling compound
11596913|NCT00669708|Placebo Comparator|2|ph5 Eucerin Lotion
11596914|NCT00669695|Placebo Comparator|Stat/CPAP|Atorvastatin and CPAP treatments
11596915|NCT00669695|Placebo Comparator|Stat/sham CPAP|Atorvastatin and sham CPAP treatments
11596916|NCT00669695|Sham Comparator|Placebo/CPAP|Placebo and CPAP treatments
11596917|NCT00669695|Active Comparator|Placebo/sham CPAP|Placebo and sham CPAP treatments
11596918|NCT00669682||Group A|The study group will include Class III to IV heart failure patients followed in the device clinic that have a chronically implanted (more than 90 days) Medtronic biventricular defibrillator with the ability to monitor intrathoracic impedance.
11596919|NCT00669669|Experimental|Treatment (chemotherapy, autologous stem cell transplant)|See Detailed Description
11596920|NCT00669656|Experimental|Prostate Health Cocktail|
11596960|NCT00669331|Placebo Comparator|Control|Matched control - inhaled mannitol 50mg
11596921|NCT00669643|Active Comparator|R-MDT PB|R-MDT PB group: standard/regular treatment recommended by WHO - All patients presenting fewer than 6 skin lesions will receive the standard treatment regimen for paucibacillary patients as the intervention; Intervention - PB 6 doses of rifampicin and dapsone
11596922|NCT00669643|Experimental|U-MDT PB|U-MDT PB group: a unified treatment for all patients - All patients presenting fewer than 6 lesions (WHO PB) will receive 6 doses of rifampicin, clofazimine and dapsone as the intervention; Intervention - PB 6 doses of rifampicin, clofazimine and dapsone
11596923|NCT00669643|Experimental|R-MDT MB|R-MDT MB group: standard/regular treatment recommended by WHO - All patients presenting 6 skin or more lesions will receive the standard treatment regimen for multibacillary patients as the intervention; Intervention - MB 12 doses of rifampicin, clofazimine and dapsone
11596924|NCT00669643|Experimental|U-MDT MB|U-MDT MB group: a unified treatment for all patients - All patients presenting 6 lesions or more (WHO MB) will receive 6 doses of rifampicin, clofazimine and dapsone as the intervention; Intervention - MB 6 doses of rifampicin, clofazimine and dapsone
11596925|NCT00669617|Experimental|Ind 150μg, Salm/flut, Ind 300μg, Placebo, Salbut|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Indacaterol 150 μg (Ind 150μg), Salmeterol/fluticasone 50/500 μg (Salm/flut), Indacaterol 300 μg (Ind 300μg), Placebo, Salbutamol 200 μg (Salbut). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11596926|NCT00669617|Experimental|Ind 300μg, Ind 150μg, Salbut, Salm/flut, Placebo|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Indacaterol 300 μg (Ind 300μg), Indacaterol 150 μg (Ind 150μg), Salbutamol 200 μg (Salbut), Salmeterol/fluticasone 50/500 μg (Salm/flut), Placebo. At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11596927|NCT00669617|Experimental|Salm/flut, Placebo, Ind 150μg, Salbut, Ind 300μg|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Salmeterol/fluticasone 50/500 μg (Salm/flut), Placebo, Indacaterol 150 μg (Ind 150μg), Salbutamol 200 μg (Salbut), Indacaterol 300 μg (Ind 300μg). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11596928|NCT00669617|Experimental|Salbut, Ind 300μg, Placebo, Ind 150μg, Salm/flut|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Salbutamol 200 μg (Salbut), Indacaterol 300 μg (Ind 300μg), Placebo, Indacaterol 150 μg (Ind 150μg), Salmeterol/fluticasone 50/500 μg (Salm/flut). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11596929|NCT00669617|Experimental|Placebo, Salbut, Salm/flut , Ind 300μg, Ind 150μg|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Placebo, Salbutamol 200 μg (Salbut), Salmeterol/fluticasone 50/500 μg (Salm/flut), Indacaterol 300 μg (Ind 300μg), Indacaterol 150 μg (Ind 150μg). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11596930|NCT00669591|Experimental|1|Patients will receive up to six (6) 28-day cycles of docetaxel plus weekly bavituximab during the treatment phase. During the follow-up phase, patients will continue to receive weekly bavituximab until disease progression
11596931|NCT00669578|Experimental|CC-4047|
11596932|NCT00669552||Medtronic defibrillator|Patients undergoing a percutaneous coronary intervention (PCI) with an implanted Medtronic defibrillator with the capability of telemetry of the intracardiac signal.
11596933|NCT00669539||Combined-Mechanism Amblyopia|
11596934|NCT00669539||Strabismus-Only Amblyopia|
11596935|NCT00669526|Active Comparator|SMHC referral|Referral to local Specialty Mental Health Care Services
11596936|NCT00669526|Experimental|BCBT|Brief Cognitive Behavioral Therapy
11596937|NCT00669513|No Intervention|1|
11596938|NCT00669513|Experimental|2|Partial sleep deprivation
11596939|NCT00669487|Experimental|1. GPO-VIR S 1 pill orally every 12 hours|
11596940|NCT00669487|Experimental|2 GPO-VIR Z 1 pill orally every 12 hours|
11596941|NCT00669487|Experimental|3 Truvada 1 pill oral q 24 hr and NVP 1 pill oral q 12 hr|
11596942|NCT00669474|Other|1|Suction curettage
11596943|NCT00669474|Active Comparator|2|Treatment with Botox
11596944|NCT00669461|Experimental|Patients|
11596945|NCT00669435|Active Comparator|1|Amlodipine and Simvastatin
11596946|NCT00669435|Experimental|2|Losartan and Simvastatin
11596947|NCT00669409|Experimental|10 mcg/kg|
11596948|NCT00669409|Experimental|100 mcg/kg|
11596949|NCT00669409|Experimental|200 mcg/kg|
11596950|NCT00669409|Experimental|25 mcg/kg|
11596951|NCT00669409|Experimental|50 mcg/kg|
11596952|NCT00669409|Placebo Comparator|Placebo|
11596953|NCT00669396|Experimental|1|IUD
11596954|NCT00669396|Active Comparator|2|Oral levonorgestrel
11596955|NCT00669383|Active Comparator|A|Betamethasone (Celestone) 12 mg intramuscular q 24 hours x 2 doses
11596956|NCT00669383|Placebo Comparator|B|Placebo dose intramuscular q 24 hours x 2 doses
11596957|NCT00669344|Placebo Comparator|II|Placebo
11596961|NCT00669318|Experimental|Treatment (Pentostatin, Alemtuzumab, Rituximab)|"Course 1: Patients receive:
~2 mg/m^2 pentostatin IV on days 8 and 22;
~3 mg alemtuzumab subcutaneously (SC) on day 3;
~10 mg alemtuzumab SC on day 4;
~30 mg alemtuzumab SC on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33;
~20 mg/m^2 rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33;
~6 mg Sargramostim (GM-CSF) SC on days 10-14. Patients then proceed to course 2.
~Courses 2 and 3: Patients receive:
~2 mg/m^2 pentostatin IV on days 1 and 15;
~30 mg alemtuzumab SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26;
~20 mg/m^2 rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26;
~6 mg GM-CSF SC on days 3-7. After completion of course 2, patients with a complete response proceed to observation. Patients with a partial response or stable disease receive another course of therapy (course 3)."
11596962|NCT00669305||Cohort 1|Human participants affected with sickle cell disease or thalassemia will donate bone marrow for use in experimental models
11596963|NCT00669279|Experimental|Carvedilol CR|
11596964|NCT00669279|Experimental|Atenolol|
11596965|NCT00669266||Tumor|Tumor material and corresponding biosamples from patients with adrenal tumors
11596966|NCT00669266||control group|Biomaterial from patients without adrenal tumor
11596967|NCT00669253|Experimental|1|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
11596968|NCT00669253|Active Comparator|2|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods (ultrasonic and manual means)
11596969|NCT00669253|Active Comparator|3|Surgery at baseline for all deep pockets using conventional methods (ultrasonic and manual means)
11596970|NCT00669240||1. Non-interventional|Patients prescribed varenicline in a non interventional manner.
11596971|NCT00669227|Active Comparator|1|autologous stem cells, Ficoll preparation, intracoronary administration at the same day of bone marrow cell aspiration
11596972|NCT00669227|Placebo Comparator|2|placebo is visually indistinguishable from verum due to integration of autologous erythrocytes, intracoronary administration the same day of bone marrow aspiration
11596973|NCT00669214|Experimental|Efalizumab|
11596974|NCT00669214|Placebo Comparator|Placebo|
11596975|NCT00669201||1|healthy young volunteers Inclusion: age 18-40, Exclusion: wrist trauma/surgery
11596976|NCT00669201||2|"patients with know osteoarthritis wrist changes according to pre-existing x-rays No age limits
~exclusion: previous wrist surgery"
11596977|NCT00669201||3|Mixed group of 50 patients that perform routine MRI of the wrist for various indications
11596978|NCT00669188|Experimental|Information Type 1|genetic risk information
11596979|NCT00669188|Sham Comparator|Information Type 2|information absent
11596980|NCT00669162|Experimental|RT, Docetaxel, Hormonal Therapy|Radiation Therapy (RT) to 66 Gy in 33 treatment fractions at 2.0 Gy/fx Concurrent Docetaxel (with RT) at 20 mg/m2 weekly x 7 Casodex (50 mg po daily)x 6 months Zoladex (10.8 mg sc q 3 mos x 2) or Lupron (22.5 mg im q 3 mos x 2)
11596981|NCT00669149|Experimental|1|group without anticoagulant therapy
11596982|NCT00669149|Active Comparator|2|group with heparin
11596983|NCT00669149|Active Comparator|3|group with enoxaparin
11596984|NCT00669149|Active Comparator|4|group with bivalirudin
11596985|NCT00669136|Other|1|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
11596986|NCT00669123|Placebo Comparator|2|
11596987|NCT00669123|Experimental|1|Chondroitin sulphate
11596988|NCT00669110|Experimental|A|
11596989|NCT00669097|Experimental|TKI258|
11596990|NCT00669071|Active Comparator|IPL / Tri-Luma® Cream|
11596991|NCT00669071|Active Comparator|IPL/Cetaphil® Moisturizing Cream as Inactive Control|
11596992|NCT00669032|Experimental|hyaluronic acid|Cycles of 5 injections of hyaluronic acid at specified intervals
11596993|NCT00669032|Placebo Comparator|Placebo|Cycles of 5 injections of saline at specified intervals
11596994|NCT00669019|Experimental|Saracatinib|Patients receive saracatinib 175 mg oral once daily in the absence of disease progression or unacceptable toxicity.
11596995|NCT00669006||1|New patients with a diagnosis of Neuropathic Pain
11596996|NCT00668993|Experimental|A, B|A is treatment group B is waitlist group
11596997|NCT00668980||Study group|20 infants with Down syndrome
11596998|NCT00668980||Control Group|15 typically developing children
11596999|NCT00668967|Other|Reference|marketed extended release verapamil tablet
11597000|NCT00668967|Other|Test|reformulated extended release verapamil tablet
11597001|NCT00668954|Active Comparator|Pomegranate Juice|
11597002|NCT00668954|Placebo Comparator|Placebo Juice (non-Pomegranate)|
11597003|NCT00668941|Experimental|1|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will receive a continuous regimen of daily teriparatide (20 mcg subcutaneously) for 48 months, in addition to alendronate. Biopsies will be performed at Week 7 or Month 7.5. The participants will then have the option to be followed while taking alendronate alone for 24-48 months.
11597004|NCT00668941|Experimental|2|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will receive a cyclical regimen of teriparatide, in addition to alendronate. Teriparatide will be administered subcutaneously in 20-mcg doses daily for 3 months. They will receive no teriparatide for the following 3 months, and then teriparatide treatment will continue for the 3 months after that. This schedule will continue for 24 months with an aption to all participants to continue cyclic teriparatide for another 24 months. Biopsies will be performed at Week 7 or Month 7.5.
11597005|NCT00668941|Active Comparator|3|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will continue taking alendronate alone. Biopsies will be performed at Week 7 and then participants in this group will be offered teriparatide as part of Group 2 or 3.
11597006|NCT00668941|Experimental|4|Participants in this group will receive a continuous regimen of teriparatide (20 mcg delivered subcutaneously) daily for 48 months. Biopsies will be performed at Week 7 or Month 7.5. At 24 months the participants will then have the option of taking alendronate and remaining in the study for another 24 months.
11597059|NCT00668447|Experimental|1|Soy protein and isoflavone tablets
11597060|NCT00668447|Active Comparator|2|Soy protein and placebo tablets
11597007|NCT00668941|Experimental|5|Participants in this group will receive a cyclical regimen of teriparatide. Teriparatide will be administered subcutaneously in 20-mcg doses daily for 3 months. They will receive no teriparatide for the following 3 months, and then teriparatide treatment will continue for the 3 months after that. This schedule will continue for 24 months with an option to all participants to continue cyclic teriparatide for another 24 months. Biopsies will be performed at Week 7 or Month 7.5.
11597008|NCT00668941|Active Comparator|6|Participants in this group will take only calcium and vitamin D supplements. Biopsies will be performed at Week 7. Participants will then be offered the standard care for osteoporosis or they may enter the study in Group 4 or 5.
11597009|NCT00668915||A|Primary arthroplasty
11597010|NCT00668902|Experimental|EM of CYP2C19|CYP2C19 enzyme activity in extensive metabolizers of CYP2C19 (CYP2C19*1/*1 genotype, or wild type) was measured by 13C)Pantoprazole breath test.
11597011|NCT00668902|Experimental|IM of CYP2C19|CYP2C19 activity in heterozygous for deficient CYP2C19 alleles (*2 and *3, IM of CYP2C19) was measured by (13C)Pantoprazole breath test.
11597012|NCT00668902|Experimental|PM of CYP2C19|Homozygous for CYP2C19 null alleles (*2/*2, *2/*3 or *3/*3, Poor metabolizers) was measured by (13C)Pantoprazole breath test.
11597013|NCT00668876|Active Comparator|1|Group A: perioperative immunonutrition
11597014|NCT00668876|Active Comparator|2|Group B: postoperative immunonutrition
11597015|NCT00668876|Active Comparator|3|Group C: control
11597016|NCT00668863|Experimental|1|
11597017|NCT00668850|Experimental|1|Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
11597018|NCT00668850|Active Comparator|2|Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
11597019|NCT00668811|Experimental|Treatment Arm - Sutent|Sutent 37.5 mg/day will be given orally.
11597020|NCT00668798||A|mother CMV positive
11597021|NCT00668798||B|mother CMV negative
11597022|NCT00668785|Experimental|Ranibizumab|Ranibizumab is being used off-label to test the safety and efficacy of its use in Diabetic Macular Edema post panretinal photocoagulation. Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
11597023|NCT00668772|Experimental|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
11597024|NCT00668772|Active Comparator|Tiotropium QD|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
11597025|NCT00668772|Active Comparator|Salmeterol BID|Salmeterol Inhalation Powder, hard PE capsule
11597026|NCT00668772|Active Comparator|Tiotropium/Salmeterol QD + Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
11597027|NCT00668772|Placebo Comparator|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
11597028|NCT00668759|Experimental|1|"Vernakalant Injection:
~In one infusion line, subjects will receive a 10-minute infusion of vernakalant followed by a 15-minute observation period, followed by an additional 10-minute infusion of vernakalant if required (if the subject is still in AF). To maintain blinding, a 60-minute infusion of placebo (D5W) will be administered in a second infusion line, followed by a maintenance infusion of placebo for a minimum of an additional 60 minutes."
11597029|NCT00668759|Active Comparator|2|"Amiodarone Injection:
~In one infusion line subjects will receive a 60-minute infusion of amiodarone followed by a maintenance infusion of amiodarone over an additional 60 minutes. To maintain blinding, a 10-minute infusion of placebo (normal saline) will be administered in a second infusion line, followed by a 15 minute observation period, followed by a 10 minute infusion of placebo if the subject is still in AF."
11597030|NCT00668746|Experimental|Minocycline HCl microspheres|Minocycline HCl microspheres
11597031|NCT00668746|No Intervention|No drug intervention|No drug intervention
11597032|NCT00668720|Experimental|1|
11597033|NCT00668720|Sham Comparator|2|
11597034|NCT00668707|Experimental|1|To receive 20 mg of melatonin nightly for 1 year
11597035|NCT00668707|Placebo Comparator|2|To receive matched supplement to the experimental arm in same schedule
11597036|NCT00668694|No Intervention|1|Anemia without stimulation.
11597037|NCT00668694|Experimental|2|Anemia with stimulation
11597038|NCT00668694|No Intervention|3|Non-anemic group: Hb >80-109 g/L ferritin levels >12 μg/L and TfR <6 will be enrolled without stimulation
11597039|NCT00668694|No Intervention|4|Non-anemic group: Hb >80-109 g/L ferritin levels >12 μg/L and TfR <6 will be enrolled with stimulation
11597040|NCT00668681|Active Comparator|Endorefix|Evaluation of EndoRefix Endovascular Delivery System and Staple
11597041|NCT00668655||1|Female Subjects aged 20 to 75 inclusive, with a diagnosis of moderate (Global Severity Score of 3) Rosacea
11597042|NCT00668642|Experimental|A: Dutasteride During First Off-Cycle|Arm A patients received dutasteride (0.5 mg/day) during the first off-cycle and received placebo during the second off-cycle
11597043|NCT00668642|Placebo Comparator|B: Placebo During First Off-Cycle|Arm B patients received placebo during the first off-cycle and received dutasteride (0.5 mg/day) during the second off-cycle
11597044|NCT00668616|Active Comparator|1|
11597045|NCT00668616|Experimental|2|
11597046|NCT00668603|Experimental|2|Postmenopausal women with severe vasomotor symptoms
11597047|NCT00668603|Experimental|1|Postmenopausal women without vasomotor symptoms
11597048|NCT00668590|Experimental|1|
11597049|NCT00668590|Active Comparator|2|
11597050|NCT00668564|Experimental|Intent-to-Treat|All patients treated with study regimen.
11597051|NCT00668551||1|Telemedicine care
11597052|NCT00668551||2|Standard of care
11597053|NCT00668525|Active Comparator|2|Escitalopram low dose
11597054|NCT00668525|Experimental|3|Escitalopram high dose
11597055|NCT00668525|Placebo Comparator|1|Placebo
11597056|NCT00668512|Experimental|Antimelanoma injection-GSL alpha-Gal|Intervention consists of injection of a single melanoma metastasis with two injections of GSL alpha-Gal separated by four weeks. Both injections done with the same dose of GSL alpha-GAL each time. Phase 1 dose escalating scheme: 0.1mg, 1 mg, 10mg
11597057|NCT00668473||1|Subjects with diffuse scleroderma
11597058|NCT00668473||2|Healthy controls
11597061|NCT00668447|Active Comparator|3|control protein and Isoflavone tablets
11597062|NCT00668447|Placebo Comparator|4|control protein and placebo tablets
11597063|NCT00668434|Experimental|Prednisone|Participants will receive a 15-day tapering course of prednisone capsules.
11597064|NCT00668434|Placebo Comparator|Placebo|Participants will receive a 15-day course of placebo capsules.
11597065|NCT00668421|Experimental|CEP-701 (Lestaurtinib)|Subject is to receives Lestaurtinib, in Phase 1: standard cohort dose escalation; Phase 2: single stage design to estimate the percentage of subjects with a 15% or greater reduction in JAK2 V617F allele frequency in peripheral blood granulocytes in 6 months of treatment
11597066|NCT00668408|Other|LTOT group|Study group: optimal medical therapy plus LTOT = or > 15 hours pro die
11597067|NCT00668408|Other|Non LTOT group|control group: optimal medical therapy without LTOT
11597068|NCT00668395|Other|CYP2B6*1/*1 genotype|Efavirenz clearance in this genotype was compared with the other genotypes
11597069|NCT00668395|Other|CYP2B6*1/*6|Efavirenz clearance in this genotype was compared with the other genotypes
11597070|NCT00668395|Other|CYP2B6*6/*6|Efavirenz clearance in this genotype was compared with the other genotypes
11597071|NCT00668382|Experimental|Alpha-Gal Glycosphingolipid injection|Intervention: Intratumoral injection of a single dose of Alpha-Gal Glycosphingolipid (0.1 mg,1mg, 10mg)
11597072|NCT00668369|Experimental|1|Liver transplant recipients with HCV infection fulfilling inclusion criteria.
11597073|NCT00668356|Experimental|1|
11597074|NCT00668356|Active Comparator|2|
11597075|NCT00668343|Active Comparator|1|
11597076|NCT00668343|Placebo Comparator|2|
11597077|NCT00668330|Active Comparator|Ibandronate+alfacalcidol+calcium|Bonviva
11597078|NCT00668330|Active Comparator|Placebo ibandronate+alfacalcidol+calcium|
11597079|NCT00668317|Other|omeprazole and ranitidine|20 mg oralomeprazole oral tablet twice daily and ranitidine 300 mg oral tablet once daily nocte
11597080|NCT00668304|Experimental|Arm 1|
11597081|NCT00668291||CNC|Primary pigmented nodular adrenocortical disease (PPNAD) and the Carney complex (CNC)
11597082|NCT00668291||MC-L|cardiac myxoma or isolated lentiginosis
11597083|NCT00668278|Active Comparator|A|Laryngeal Mask Airway insertion
11597084|NCT00668278|Active Comparator|B|I-gel insertion
11597085|NCT00668265|Experimental|Seroquel|
11597086|NCT00668252||1|Non menopausal women
11597087|NCT00668252||2|age matched men
11597088|NCT00668252||3|Menopausal women
11597089|NCT00668252||4|age matched men
11597090|NCT00668239|Active Comparator|1|Laser treatment: laser was applied to the macular region according to the modified grid technique in inverted C, preserving 500 μ of the foveolus and avascular zone, with 100μ diameter shots, energy varying from 0.2 to 0.5 joules, with a time of exposure between 0.2 and 0.4 seconds. One hundred and fifty to 200 shots were applied according to the size of the retinal area². ND YAG laser (Crystal Focus (EMERED®) was used
11597091|NCT00668239|Experimental|2|triamcinolone as previously described
11597092|NCT00668200|Other|zoledronic acid|5 mg of Reclast (ZOL446, zoledronic acid) injection in 100 mL ready to infuse solution administered intravenously via a vented line. The infusion time was to be not less than 15 minutes given over a constant infusion rate.
11597093|NCT00668187||Gangliosidosis Diseases Study Population|This study observes one cohort: 42 infantile or juvenile Tay-Sachs disease, Sandhoff disease, or GM1 gangliosidosis affected subjects; and 10 late-onset gangliosidosis disease affected subjects.
11597094|NCT00668174|Experimental|1|Exercise
11597095|NCT00668174|No Intervention|2|Control
11597096|NCT00668161|Experimental|1|Exercise
11597097|NCT00668161|No Intervention|2|Control
11597098|NCT00668148|Experimental|IMC-A12 (cixutumumab)|
11597099|NCT00668135|Experimental|Arm 1|
11597100|NCT00668135|Placebo Comparator|Arm 2|
11597101|NCT00668122|Experimental|Arm 1|
11597102|NCT00668122|Experimental|Arm 2|
11597103|NCT00668109|Experimental|Arm 1|
11597104|NCT00668109|Active Comparator|Arm 2|
11597105|NCT00668096|Placebo Comparator|Arm 2|
11597106|NCT00668096|Experimental|Arm 1|
11597107|NCT00668070|Experimental|ASP9831 Low Dose|
11597108|NCT00668070|Experimental|ASP9831 Higher Dose|
11597109|NCT00668070|Placebo Comparator|Placebo|
11597110|NCT00668057|Experimental|Arm 1|
11597111|NCT00668057|Experimental|Arm 2|
11597112|NCT00668057|Experimental|Arm 3|
11597113|NCT00668057|Placebo Comparator|Arm 4|
11597114|NCT00668057|Placebo Comparator|Arm 5|
11597115|NCT00668057|Placebo Comparator|Arm 6|
11597116|NCT00668044|Experimental|Arm 1|
11597117|NCT00668044|Experimental|Arm 2|
11597118|NCT00668031|Experimental|Arm 1|
11597119|NCT00668031|Placebo Comparator|Arm 2|
11597120|NCT00668018|Experimental|Arm 1|
11597121|NCT00668005|Experimental|Arm 1|
11597122|NCT00668005|Placebo Comparator|Arm 2|
11597123|NCT00667992|Active Comparator|Budesonide Hydrofluoroalkane (HFA) 100|Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks
11597124|NCT00667992|Active Comparator|Budesonide HFA 400|Budesonide HFA 400 mcg twice daily for 2 weeks
11597125|NCT00667992|Active Comparator|Budesonide Chlorofluorocarbon (CFC) 100|Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks
11597126|NCT00667992|Active Comparator|Budesonide CFC 400|Budesonide CFC 400 mcg twice daily for 2 weeks
11597127|NCT00667979|Experimental|Arm 1|
11597128|NCT00667979|Placebo Comparator|Arm 2|
11597129|NCT00667966|Experimental|Vardenafil + Placebo|Subjects received single dose of 10 mg vardenafil followed by 20 mg vardenafil and then crossed over to 10 mg placebo followed by 20 mg placebo.
11597130|NCT00667966|Experimental|Placebo + Vardenafil|Subjects received single dose of 10 mg placebo followed by 20 mg placebo and then crossed over to 10 mg vardenafil followed by 20 mg vardenafil.
11597131|NCT00667953|Experimental|Arm A:|
11597228|NCT00667225|Experimental|II|Subjects in this group will have topical application of cantharidin at each visit.
11597229|NCT00667212|Active Comparator|2|Supportive Psychotherapy
11597132|NCT00667940|Experimental|Workshop|Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
11597133|NCT00667940|No Intervention|Delayed workshop|No specific intervention until after follow-up assessment, then receives same workshop.
11597134|NCT00667927|Other|1|
11597135|NCT00667914|Experimental|Orthogeriatric unit|Geriatric work-up on hip-fracture patients
11597136|NCT00667914|Active Comparator|Orthopedic care as usual|Traditional care in the orthopedic unit
11597137|NCT00667888|Active Comparator|Intensity Modulated Radiotherapy (IMRT)|A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
11597138|NCT00667888|Experimental|Hypofractionated Intensity Modulated Radiotherapy (HIMRT)|A total dose of 72 Gy will be delivered in 30 fractions to the PTV.
11597139|NCT00667875|Placebo Comparator|1|
11597140|NCT00667875|Active Comparator|2|Naltrexone
11597141|NCT00667875|Active Comparator|3|Naltrexone + Aripiprazole
11597142|NCT00667862|Experimental|Panobinostat|
11597143|NCT00667849|Active Comparator|Exogen 4000+|Single arm, Exogen 4000+
11597144|NCT00667849|Sham Comparator|Sham|Single arm, sham (identical device with the exception of administration of ultrasound).
11597145|NCT00667823|Experimental|ACT-064992|ACT-064992
11597146|NCT00667810|Experimental|Bapineuzumab 0.5 mg/kg|
11597147|NCT00667810|Experimental|Bapineuzumab 1.0 mg/kg|
11597148|NCT00667810|Placebo Comparator|Placebo|
11597149|NCT00667797|Experimental|1|levalbuterol 1.25 mg
11597150|NCT00667797|Active Comparator|2|Racemic albuterol 2.5 mg
11597151|NCT00667784||Anxiety Assessment|Minor Donors + Sibling Non-Donors + Parents or Legal Guardians
11597152|NCT00667758|Experimental|1|Cetrorelix
11597153|NCT00667758|Placebo Comparator|2|NaCl solution
11597154|NCT00667745|Experimental|1|Participants received lithium plus optimized medication treatment, as needed.
11597155|NCT00667745|Active Comparator|2|Participants only received optimized medication treatment, as needed; lithium was not be used.
11597156|NCT00667732|Active Comparator|1|Participants will receive exenatide as part of their diabetes treatment
11597157|NCT00667732|Placebo Comparator|2|Participants will receive placebo rather than exenatide as part of their diabetes treatment
11597158|NCT00667719|Experimental|A|aliskiren 300/mg + amlodipine 10 mg + hydrochlorothiazide
11597159|NCT00667706|Active Comparator|1|Patients who will undergo Laparoscopic Sleeve Gastrectomy
11597160|NCT00667706|Active Comparator|2|Patients who will undergo Laparoscopic Roux-en-Y Gastric Bypass
11597161|NCT00667693|Active Comparator|Macintosh laryngoscope|Intubation with a Macintosh laryngoscope
11597162|NCT00667693|Active Comparator|Pentax AWS|Intubation with a Pentax AWS
11597163|NCT00667680|Active Comparator|1|anodal tDCS
11597164|NCT00667680|Sham Comparator|2|Sham tDCS
11597165|NCT00667667|Active Comparator|1|vertical vibration device (using Vibrafit whole body vibration platforms)
11597166|NCT00667667|Active Comparator|2|side-alternating vibration device (using Board 3000 whole body vibration platforms)
11597167|NCT00667667|Sham Comparator|3|wellness-control group
11597168|NCT00667654|Experimental|100-200 µg CNTX-4975|single dose
11597169|NCT00667654|Experimental|300-425 µg CNTX-4975|Total dose delivered as two separate lower doses
11597170|NCT00667654|Experimental|600-700 µg CNTX-4975|Total dose delivered as two separate lower doses
11597171|NCT00667654|Experimental|800 µg CNTX-4975|Total dose delivered as two separate lower doses
11597172|NCT00667654|Experimental|900-1000 µg CNTX-4975|Total dose delivered as two separate lower doses
11597173|NCT00667628|Experimental|A|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days
11597174|NCT00667628|Placebo Comparator|B|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
11597175|NCT00667615|Experimental|1|vorinostat in combination with cyclophosphamide, etoposide,prednisone and rituximab,peg-filgrastim or filgrastim
11597176|NCT00667602|Experimental|MenACWY-CRM197 (2 doses) + Concomitant Vaccines|Infants received two doses of MenACWY-CRM197 at 6 to 8 and 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months.
11597177|NCT00667602|Experimental|MenACWY-CRM197 (1 dose) + Concomitant Vaccines|Infants received one dose of MenACWY-CRM197 at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.
11597178|NCT00667602|Active Comparator|MenC (1 dose) + Concomitant Vaccines|Infants received one dose of MenC vaccine at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.
11597179|NCT00667589|Experimental|urea 40% cream|
11597180|NCT00667589|Experimental|fluocinonide 0.05% cream|
11597181|NCT00667589|Experimental|tazarotene 0.1% cream|
11597182|NCT00667589|Experimental|bland emollient cream|
11597183|NCT00667576|Experimental|Paricalcitol 2 µg ± 1 µg|Paricalcitol initial dosage 2 micrograms (µg) with incremental adjustment of 1 µg
11597184|NCT00667576|Experimental|Paricalcitol 2 µg ± 2 µg|Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg
11597185|NCT00667576|Experimental|Paricalcitol 4 µg ± 1 µg|Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg
11597186|NCT00667576|Experimental|Paricalcitol 4 µg ± 2 µg|Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg
11597187|NCT00667576|Other|Maxacalcitol 5 or 10 µg ± 2.5 µg|Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg
11597188|NCT00667563|Experimental|Gardasil Vaccination|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
11597189|NCT00667537|Experimental|Radium-223 chloride|IV administrations of 100 kBq/kg b.w (=110 kBq/kg based on the 2015 National Institute of Standards and Technology standardization). Two administrations took place with an interval of 6 weeks
11597190|NCT00667524||I|
11597191|NCT00667511|Active Comparator|Home Short Daily Hemodialysis|Intervention: Patients perform short daily hemodialysis (2 to 4 hour treatments) in the home setting using the NxStage System One.
11597192|NCT00667511|Experimental|Home Nocturnal Hemodialysis|Intervention: Patients perform nocturnal hemodialysis (6 to 10 hour treatments) in the home setting using the NxStage System One.
11597193|NCT00667498|Experimental|1|
11597194|NCT00667498|Placebo Comparator|2|
11597195|NCT00667485|Experimental|Weekly Rapamcyin|Rapamycin (liquid) taken weekly and Bevacizumab (IV infusion ) once every 3 weeks
11597196|NCT00667485|Experimental|Daily Rapamycin|Daily oral rapamycin (tablets) and Bevacizumab (IV infusion)once every 3 weeks
11597197|NCT00667472|Experimental|Ranibizumab|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
11597198|NCT00667472|Experimental|Pulsed Dye Laser|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
11597199|NCT00667459|Experimental|Investigational|PRESTIGE® LP Cervical Disc
11597200|NCT00667459|Active Comparator|Control|Control patients who received a ACDF fusion treatment from a previous IDE trial (NCT00642876)
11597201|NCT00667446|Experimental|Leuprolide Acetate 3M Depot 11.25 mg|Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months (3M) apart.
11597202|NCT00667446|Experimental|Leuprolide Acetate 3M Depot 30 mg|Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.
11597203|NCT00667433|Other|Single Arm|Single arm where subjects will receive Raltegravir 400 mg BID along with Truvada once a day for 104 weeks
11597204|NCT00667420|Experimental|EOXP chemotherapy|open-label, single-arm EOXP Epirubicin 50mg/m2 by IV on day 1 of each 21 day cycle, Oxaliplatin 100 mg/m2 by IV on day 1 of each 21 day cycle, Capecitabine 400 mg/m2 twice daily by mouth on days 1-21 of the 21 day cycle Panitumumab - 9mg/kg by IV on day 1 of each 21 day cycle
11597205|NCT00667407|Experimental|1|Levalbuterol 1.25 mg
11597206|NCT00667407|Active Comparator|2|Racemic Albuterol 2.5 mg
11597207|NCT00667394|Experimental|Tandutinib & Bevacizumab in GBM Patients|GBM (glioblastoma multiforme) Tandutinib 500 mg by mouth daily dose twice a day. Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
11597208|NCT00667394|Experimental|Tandutinib & Bevacizumab in AG Patients|AG (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, and malignant astrocytoma NOS (not otherwise specified)) Tandutinib 500 mg by mouth daily dose twice a day. Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
11597209|NCT00667381|No Intervention|Control|The combination of anatomic landmarks and fluoroscopic localization of the femoral head will be used to guide femoral arterial access.
11597210|NCT00667381|Experimental|Ultrasound|Patients randomized to Ultrasound will have anatomic landmarks checked and real-time ultrasound guidance to aid femoral arterial access.
11597211|NCT00667368|No Intervention|Control|Bi-monthly testing for BV without treatment.
11597212|NCT00667368|Experimental|Intervention|Metronidazole 500mg twice daily for 7 days for Bacterial Vaginosis (BV) detection
11597213|NCT00667355|Experimental|Adalimumab|Adalimumab 40 mg or 80 mg subcutaneously (SC) administered every other week (eow) until approval of adalimumab for Ankylosing Spondylitis (AS) in Japan. All subjects received 40 mg of adalimumab SC eow at Baseline. The subjects who completed 16 weeks of therapy and who failed to achieve Assessments in Ankylosing Spondylitis 20 (ASAS 20) response on or after Week 16, could increase the dose of adalimumab to 80 mg eow. When the dose was increased, the higher dose was to be continued during the rest of the study.
11597214|NCT00667342|Experimental|Localized Resectable Disease (Stratum A)|Participants with localized resectable disease receive Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin, and doxorubicin, or methotrexate. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, or methotrexate.
11597215|NCT00667342|Experimental|Metastatic Disease (Stratum B)|Participants with metastatic disease (Stratum B) receive Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin and doxorubicin, methotrexate or ifosfamide, and etoposide. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, methotrexate, or ifosfamide, and etoposide. Radiotherapy will be given post-operatively.
11597216|NCT00667342|Experimental|Unresectable Disease (Stratum C)|Participants with unresectable disease (Stratum C) receive treatment identical to Stratum B: Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin and doxorubicin, methotrexate or ifosfamide, and etoposide. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, methotrexate, or ifosfamide, and etoposide. Radiotherapy will be given post-operatively.
11597217|NCT00667329|Experimental|2CdA + Cyclophosphamide + Rituximab|2CdA 1.5 mg/m^2 subcutaneous injection three times daily x 7 days. Cyclophosphamide 40 mg/m^2 PO twice daily x 7 days. Rituximab 375 mg/m^2 IV once weekly x 4 weeks.
11597218|NCT00667316||A|Workers from companies and workers' health care organizations who go for their periodic medical checkup.
11597219|NCT00667303||1|
11597220|NCT00667290|Experimental|1|
11597221|NCT00667290|No Intervention|2|
11597222|NCT00667277|Experimental|bevacizumab (Avastin)|Use of bevacizumab (Avastin) in the treatment of myelofibrosis.
11597223|NCT00667264|Active Comparator|Active|3-7 days of perineural local anesthetic infusion
11597224|NCT00667264|Placebo Comparator|Placebo|3-7 days of perineural normal saline infusion
11597225|NCT00667251|Active Comparator|Lapatinib|Plus taxane based chemotherapy
11597226|NCT00667251|Active Comparator|Trastuzumab|Plus taxane based chemotherapy.
11597227|NCT00667225|Placebo Comparator|I|Subjects in this group will have topical application of cantharidin's vehicle at each visit.
11597230|NCT00667212|Active Comparator|1|Cognitive Behavioral Therapy (Cognitive Restructuring, Relaxation, and Coping Skills Training: CRCST)
11597231|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-5kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (5kBq/kg) and individual body weight.
~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
11597232|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-25 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (25kBq/kg) and individual body weight.
~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
11597233|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-50 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (50kBq/kg) and individual body weight.
~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
11597234|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-100 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (100kBq/kg) and individual body weight.
~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
11597235|NCT00667186|Active Comparator|Targeted Screening|"Targeted Screening
~Participants approached at ED for voluntary HIV counseling and testing based on risk for HIV"
11597236|NCT00667186|Active Comparator|Routine Screening|"Routine Screening
~Participants approached at ED for voluntary HIV counseling and testing regardless of established risk according to age criteria"
11597237|NCT00667173|Experimental|1|
11597238|NCT00667173|Placebo Comparator|2|
11597239|NCT00667173|Placebo Comparator|3|
11597240|NCT00667160|Experimental|1|
11597241|NCT00667160|Active Comparator|2|
11597242|NCT00667147|Experimental|A|
11597243|NCT00667147|Experimental|B|
11597244|NCT00667134||1|Subjects with diffuse scleroderma
11597245|NCT00667134||2|Subjects with limited scleroderma
11597246|NCT00667134||3|Subjects without a fibrosing or autoimmune disease.
11597247|NCT00667108|Experimental|Gabapentin 250 mg|
11597248|NCT00667108|Experimental|Gabapentin 500 mg|
11597249|NCT00667108|Placebo Comparator|Placebo|
11597250|NCT00667095|Experimental|Botox and DMSO instillation|Botulinum-A Toxin (Botox) 300 units in 50 cubic centimeters of Dimethyl Sulfoxide (DMSO) 50% w/w aqueous solution
11597251|NCT00667095|Placebo Comparator|DMSO instillation|Dimethyl Sulfoxide (DMSO) 50% w/w aqueous solution, 50 cubic centimeters
11597252|NCT00667082|Experimental|NPI-0052 + Vorinostat Dose-Escalation|4 dose-escalation cohorts
11597253|NCT00667056|Experimental|1|
11597254|NCT00667056|Placebo Comparator|2|
11597255|NCT00667043|Active Comparator|Study group 1|Midazolam and fentanyl; continuous intravenous infusions
11597256|NCT00667043|Active Comparator|Study group 2|Propofol and remifentanil; continuous intravenous infusion
11597257|NCT00667030|Experimental|Lifestyle Modification|Combined hypocaloric diet and aerobic exercise training
11597258|NCT00667017|Experimental|IMTOX25 at 2mg/m²/dose|Patients will receive IMTOX25 at 2mg/m²/dose, by IV administration, every other day for a total of 3 doses. A total of 6 cycles of treatment will be allowed. A cycle is equal to 6 weeks, with IMTOX25 infusion on Day 1, 3 and 5, followed by a 5 week rest period.
11597259|NCT00667004|Experimental|1|ecabet ophthalmic solution
11597260|NCT00667004|Placebo Comparator|2|Placebo comparator
11597261|NCT00666991|Experimental|Nanotax, 50 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 50 mg/m2 once every 28 days until progression or unacceptable toxicity
11597262|NCT00666991|Experimental|Nanotax, 82.5 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 82.5 mg/m2 once every 28 days until progression or unacceptable toxicity
11597263|NCT00666991|Experimental|Nanotax, 125 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 125 mg/m2 once every 28 days until progression or unacceptable toxicity
11597264|NCT00666991|Experimental|Nanotax, 175 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 175 mg/m2 once every 28 days until progression or unacceptable toxicity
11597265|NCT00666991|Experimental|Nanotax, 225 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 225 mg/m2 once every 28 days until progression or unacceptable toxicity
11597266|NCT00666991|Experimental|Nanotax 275 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 275 mg/m2 once every 28 days until progression or unacceptable toxicity
11597267|NCT00666978|Experimental|Bupropion Arm|Subjects undergo smoking cessation intervention and take bupropion.
11597268|NCT00666978|Placebo Comparator|Health Education Arm|Subjects receive counseling intervention and take placebo.
11597269|NCT00666965|Placebo Comparator|1|inactive placebo
11597270|NCT00666965|Experimental|2|2.25 mg first week: 2.25 mg 1 sheet plus placebo 1 sheet 2nd to 6th week :2.25mg 1 sheet plus placebo 2 sheets
11597271|NCT00666965|Experimental|3|4.5 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 2 sheets pus placebo 1 sheet
11597272|NCT00666965|Experimental|4|6.75 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 3sheets
11597273|NCT00666952|Experimental|1|
11597274|NCT00666952|Active Comparator|2|
11597275|NCT00666939|Experimental|A|
11597276|NCT00666939|Experimental|B|
11597277|NCT00666939|Placebo Comparator|C|
11597278|NCT00666926|Experimental|1|
11597279|NCT00666926|Experimental|2|
11597280|NCT00666926|Experimental|3|
11597281|NCT00666926|Experimental|4|
11597282|NCT00666900|Experimental|1|
11597283|NCT00666900|Experimental|2|
11597284|NCT00666900|Placebo Comparator|3|
11597285|NCT00666887|Active Comparator|Minocycline|Minocycline 100 mg oral for up to 24 months
11597286|NCT00666887|Placebo Comparator|Placebo|Lactose Monohydrate NF (Spray-dried) 235 mg/cap Magnesium Stearate NF 1 mg/cap Croscarmellose Sodium NF 4 mg/cap Stearic Acid 10 mg/cap Placebo CAP Lt orange OP-Purple OP (APO 100)
11597287|NCT00666874|Experimental|1|Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
11597288|NCT00666874|Active Comparator|2|General information about healthy food choices and exercise
11597289|NCT00666848|Placebo Comparator|2 (enalapril 5mg)|Subjects received Enalapril 5mg on study day and a placebo pill for 5 days prior or subjects received enalapril 5mg on study day and sitagliptin 100mg/day for 5 days prior .
11597290|NCT00666848|Placebo Comparator|1 (placebo)|Subjects received a placebo pill on study day and received a placebo pill for 5 days prior or subjects received a Placebo pill on study day and sitagliptin 100mg for 5 days prior.
11597291|NCT00666848|Placebo Comparator|3 (enalapril 10mg)|Subjects received Enalapril 10mg on study day and a placebo pill for 5 days prior, or subjects received Enalapril 10mg on study day and sitagliptin 100mg for 5 days prior.
11597292|NCT00666835|Experimental|HX575 epoetin alfa Hexal AG|Eligible patients were switched from the comparator ERYPO®, to epoetin alfa HX575 Hexal AG in ratio 2:1 to be intravenously treated with HX575 in pre-filled syringes for 24 weeks (solution for injection i.v.). The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.
11597293|NCT00666835|Active Comparator|ERYPO®, Janssen-Cilag|Eligible patients were randomized and continued to be treated with ERYPO® Janssen-Cilag in pre-filled syringes intravenously (solution for injection i.v.) for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.
11597294|NCT00666809|Active Comparator|Arm 1|
11597295|NCT00666809|Placebo Comparator|Arm 2|
11597296|NCT00666796|Placebo Comparator|A|
11597297|NCT00666796|Experimental|B|
11597298|NCT00666796|Experimental|C|
11597299|NCT00666796|Experimental|D|
11597300|NCT00666783|Experimental|PAL|receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2)
11597301|NCT00666783|Active Comparator|GRA|receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2)
11597302|NCT00666770|Experimental|Gabapentin 250 mg|
11597303|NCT00666770|Experimental|Gabapentin 500 mg|
11597304|NCT00666770|Placebo Comparator|Placebo|
11597305|NCT00666757|Experimental|duloxetine|study drug
11597306|NCT00666757|Active Comparator|citalopram|
11597307|NCT00666757|Active Comparator|fluoxetine|
11597308|NCT00666757|Active Comparator|paroxetine|
11597309|NCT00666757|Active Comparator|sertraline|
11597310|NCT00666744|Experimental|1|Exercise Intervention - additional lower limb exercises will be completed by the person with stroke with the assistance of his/her family for 35 minutes daily for a period of 8 weeks.
11597311|NCT00666744|No Intervention|2|Participants in this group will receive routine exercise therapy following stroke
11597312|NCT00666718|Active Comparator|Glargine|Glargine plus Insulin Lispro (2-3 injections)
11597313|NCT00666718|Experimental|ILPS|Insulin Lispro Protamine Suspension (ILPS) plus Insulin Lispro (2-3 injections)
11597314|NCT00666705|Experimental|Maraviroc alone|
11597315|NCT00666705|Experimental|Maraviroc + Raltegravir|
11597316|NCT00666705|Experimental|Raltegravir alone|
11597317|NCT00666692|Experimental|1|Escalating doses of volociximab at 10, 20, and 30 mg/kg with carboplatin, paclitaxel, and bevacizumab
11597318|NCT00666679|Active Comparator|1|mometasone
11597319|NCT00666679|Placebo Comparator|2|montelukast followed by placebo; or placebo followed by montelukast.
11597320|NCT00666666|Experimental|AT101 (R-(-)-gossypol acetic acid)|Patients will receive Hormone therapy with at least one LHRH agent (Leuprolide Acetate or Goserelin) for 6 weeks and include bicalutamide. Patients will begin AT101 daily at 6 weeks for 3 weeks of every 4 weeks (4 weeks - 1 cycle) and continue for 8 cycles of combined therapy (combined AT101, and LHRH agonist). After 8 cycles patients will continue hormonal therapy.
11597321|NCT00666640||1|50 subjects who have suffered a hip fracture
11597322|NCT00666640||2|50 age matched controls
11597323|NCT00666627|Active Comparator|1|Ibandronate
11597324|NCT00666627|Active Comparator|2|Risedronate
11597325|NCT00666627|Active Comparator|3|Alendronate 70mg once weekly
11597326|NCT00666627|No Intervention|4|Young women control group
11597327|NCT00666614|Other|Intervention|Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.
11597328|NCT00666614|Other|Standard Care|Normal Hospital Environment
11597329|NCT00666601|Experimental|Pilot study|3 subjects, open lable, microdialysis single dose.
11597330|NCT00666601|Experimental|Main Study|12 subjects, open label, single dose of 600 mg.
11597331|NCT00666588|Experimental|Bortezomib 1.3mg/m2-assess efficacy-low anthracycline exposure|Bortezomib 1.3mg/m2 to assess efficacy in low prior anthracycline exposure. Patients receive idarubicin IV (12 mg/m2/day) over 15 minutes on days 1-3, low-dose cytarabine IV (100 mg/m2/day) continuously over days 1-7, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity (closed as of 08/01/10). Dosage modification based on age < 3 years old.
11597332|NCT00666588|Experimental|Bortezomib 1.0mg/m2-assess feasibility high anthracycline exp|Bortezomib 1.0 mg/m2 to assess feasibility in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.0 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11597379|NCT00666315||Conventional|Group operated with Electrocauery and Clip/Suture
11597380|NCT00666302|Experimental|1|
11597381|NCT00666302|Active Comparator|2|
11597382|NCT00666276||linezolid (Zyvox)|Patients taking Linezolid.
11597333|NCT00666588|Experimental|Bortezomib 1.3 mg/m2-assess feasibility high anthracycline exp|Bortezomib 1.3 mg/m2 to assess feasibility in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity (dose-finding phase closed as of 10/10).
11597334|NCT00666588|Experimental|Bortezomib 1.3 mg/m2-assess efficacy high anthracycline exp|Bortezomib 1.3 mg/m2 to assess efficacy in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity
11597335|NCT00666575|Experimental|Gabapentin|
11597336|NCT00666575|Placebo Comparator|Placebo|
11597337|NCT00666562|Placebo Comparator|Arm I (placebo)|Patients receive six oral placebo capsules once daily for 14-28 days.
11597338|NCT00666562|Experimental|Arm II (polyphenon E, placebo)|Patients receive four oral polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.
11597339|NCT00666562|Experimental|Arm III (polyphenon E, trans-urethral resection or cystectomy)|Patients receive six oral polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
11597340|NCT00666536|Active Comparator|Aggressive treatment regimen (5/320 mg to 10/320 mg)|Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)
11597341|NCT00666536|Active Comparator|Moderate treatment regimen (5/160 mg)|Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)
11597342|NCT00666523|Experimental|1|
11597343|NCT00666523|Placebo Comparator|2|
11597344|NCT00666510||Bronchospasm|Patients who presented bronchospasm during anesthesia induction
11597345|NCT00666510||Asthma|Patients who presented bronchospasm during anesthesia induction and were identified as asthmatics
11597346|NCT00666510||Control|Patients who were submitted to anesthesia induction and showed no complications
11597347|NCT00666497|Experimental|A|Azacitidine
11597348|NCT00666497|Experimental|B|MGCD0103
11597349|NCT00666497|Experimental|C|Azacitidine + MGCD0103
11597350|NCT00666484|Experimental|Treatment Group 1: stages 1A, 1B, 2A: OEPA x 2|"OEPA (28day cycle):
~Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15"
11597351|NCT00666484|Experimental|Treatment Group 2: stages 2AE, 2B, 3A: OEPA x 2 + COPP x 2|"OEPA (28 day cycle) Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15
~COPP (28 day cycle) Cyclophosphamide 500mg/m^2 iv d1 and 8 Vincristine 1.5mg/m^2 iv d1,8 (capped 2mg/dose) Procarbazine 100mg/m^2 po d1-15* Prednisolone 40mg/m^2 po d1-15"
11597352|NCT00666484|Experimental|Treatment Group 3: stages 2BE, 3AE, 3B, 4: OEPAx2 + COPPx4|"OEPA (28 day cycle) Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15
~COPP (28 day cycle) Cyclophosphamide 500mg/m^2 iv d1 and 8 Vincristine 1.5mg/m^2 iv d1,8 (capped 2mg/dose) Procarbazine 100mg/m^2 po d1-15* Prednisolone 40mg/m^2 po d1-15"
11597353|NCT00666471|Experimental|1|MICE
11597354|NCT00666471|Active Comparator|2|SPA ligation
11597355|NCT00666458|Experimental|1|saxagliptin add-on to metformin
11597356|NCT00666458|Active Comparator|2|sitagliptin add-on to metformin
11597357|NCT00666445||1|Patients diagnosed with Alzheimer's Disease
11597358|NCT00666445||2|Aged-matched normal controls
11597359|NCT00666432||1|Controls
11597360|NCT00666432||2|Patient Family
11597361|NCT00666432||3|Patients
11597362|NCT00666406|Experimental|1|Advate rAHF-PFM
11597363|NCT00666406|Active Comparator|2|Recombinate rAHF
11597364|NCT00666393|Experimental|001|
11597365|NCT00666380|Experimental|10 ug of FMP010 antigen in 0.5 mL AS01B adjuvant|
11597366|NCT00666380|Experimental|50 ug of FMP010 antigen in 0.5 mL AS01B adjuvant|
11597367|NCT00666367|Active Comparator|1|Vitamin D (D-cure) will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
11597368|NCT00666367|Placebo Comparator|2|Placebo will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
11597369|NCT00666354|Active Comparator|1|
11597370|NCT00666354|Active Comparator|2|
11597371|NCT00666354|Active Comparator|3|
11597372|NCT00666341|Placebo Comparator|Placebo|Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
11597373|NCT00666341|Experimental|20 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
11597374|NCT00666341|Experimental|40 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
11597375|NCT00666341|Experimental|80 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
11597376|NCT00666341|Experimental|120 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
11597377|NCT00666328|Experimental|clevidipine|This will be a single-arm study with no reference therapy.
11597378|NCT00666315||Harmonic|Group operated with Harmonic device
11597383|NCT00666263|Experimental|IGIV, 10% Then Placebo|"STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: IGIV, 10% (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human)(Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3).
~Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg body weight (BW) per infusion cycle)."
11597384|NCT00666263|Experimental|Placebo Then IGIV, 10%|"STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human) (Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: IGIV, 10% (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3).
~Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg BW per infusion cycle)"
11597385|NCT00666250|No Intervention|Baseline|Baseline values off chocolate supplement
11597386|NCT00666250|Experimental|Low Dose|Low dose of dietary supplement 30 ml tid (Activ Xocai Drink)
11597387|NCT00666250|Experimental|High-dose|High dose of dietary supplement 90 ml tid (Xocai Activ drink)
11597388|NCT00666237|Active Comparator|1|
11597389|NCT00666237|Active Comparator|2|
11597390|NCT00666224|Experimental|Glatiramer acetate|Glatiramer acetate 20 mg once daily by subcutaneous injection is administered in both the double-blind and open label periods.
11597391|NCT00666224|Placebo Comparator|Placebo (DB) to GA (OL)|Placebo matching glatiramer acetate once daily by subcutaneous injection during the double-blind period (DB). Glatiramer acetate (GA) 20 mg once daily by subcutaneous injection during the open-label period (OL).
11597392|NCT00666211|Active Comparator|Standard of Care|Standard pain control drugs.
11597393|NCT00666211|Experimental|Opioid Titration|Pain will be Monitored and Medication Titrated
11597394|NCT00666198||SILDENAFIL|Patients taking SILDENAFIL.
11597395|NCT00666185|Experimental|1|
11597396|NCT00666185|Active Comparator|2|
11597397|NCT00666159|Experimental|1|
11597398|NCT00666159|Active Comparator|2|
11597399|NCT00666146||1|Case Families ( Family with a schizophrenia proband)
11597400|NCT00666146||2|Control Families
11597401|NCT00666146||3|Control subjects
11597402|NCT00666133|No Intervention|2|Women in Group II (standard of care) will receive an 8 mL loading dose containing 4g magnesium sulfate administered manually per standard hospital protocol. The solution will be diluted with normal saline according to standard hospital practice, and given IV over 20 minutes. For women in Group II, the IV loading dose will be followed immediately with 20 mL treatment by IM injection, given as 10 mL (5 g magnesium sulfate) into each buttock. This dose will be followed by 10 mL treatments (5g magnesium sulfate) every four hours, injected into alternate buttock. Treatment will be discontinued when clinically indicated.
11597403|NCT00666133|Experimental|1|Women in Group I (Springfusor® arm) will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4will be administered using the Springfusor® pump. For women in Group I, the administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours for upto 24 hours postpartum.
11597404|NCT00666120|Active Comparator|1|Cow's milk based infant formula
11597405|NCT00666120|Active Comparator|2|Partially hydrolyzed cow's milk based infant formula
11597406|NCT00666094|Active Comparator|endurance training|supervised endurance training
11597407|NCT00666094|Experimental|strength training|Supervised strength training
11597408|NCT00666081|Experimental|Cohort 1|GSK690693 for injection. This is a dose escalation study.
11597409|NCT00666068|Experimental|1|"Patients with hypopituitarism
~Cross over design: see interventions 1-2"
11597410|NCT00666068|Placebo Comparator|2|"Parallel design:
~Healthy controls to be compared with placebo condition in patients with hypopituitarism"
11597411|NCT00666055||Group 1|30 post-menopausal HIV-infected women
11597412|NCT00666055||Group 2|12 pre-menopausal HIV-infected women
11597413|NCT00666042|Experimental|A|Vigamox delivered as spray
11597414|NCT00666042|Active Comparator|B|Patients will receive the commercially available Vigamox drops
11597415|NCT00666029|Active Comparator|Atorvastatin|Active arm atorvastatin 40 mg. o.d.
11597416|NCT00666029|Placebo Comparator|Placebo|Placebo arm dummy pill
11597417|NCT00666016|Experimental|1|TRO19622 500 mg
11597418|NCT00665990|Other|Treatment|All participants will receive bevacizumab, sorafenib, and cyclophosphamide until maximum tolerated dose is reached.
11597419|NCT00665977|Sham Comparator|A|"To enter into the single-blind placebo phase, subjects will be setup with a Fisher & Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily."
11597482|NCT00665587||A = MAZE|Patients indicated to a cardiac surgery (bypass, valve repair or combinated surgery)with documented atrial fibrillation in 6 preoperative months undergo the operation together with MAZE procedure
11597483|NCT00665587||B = non-MAZE|Patients indicated to a cardiac surgery (bypass, valve repair or combinated surgery)with documented atrial fibrillation in 6 preoperative months undergo the operation (without MAZE procedure).
11597484|NCT00665574|Experimental|1|ActaVisc
11597420|NCT00665977|Active Comparator|Double Blind Treatment Group 2|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher & Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
11597421|NCT00665977|Active Comparator|Double Blind Treatment Goup 1|a Fisher & Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
11597422|NCT00665964|Experimental|X-3|X-3 polyethylene which is a new highly cross-linked poly that is theorized to be more durable in vivo
11597423|NCT00665964|Active Comparator|N2Vac polethylene|conventional polyethylene
11597424|NCT00665951|Active Comparator|A|Kaletra tablets
11597425|NCT00665951|Experimental|B|Lopimune granules
11597426|NCT00665951|Experimental|C|Lopimune tablets
11597427|NCT00665938|Active Comparator|1|
11597428|NCT00665938|Experimental|2|
11597429|NCT00665938|Experimental|3|
11597430|NCT00665925|Experimental|1|R788, 100 mg tablet, orally, twice-a-day
11597431|NCT00665925|Experimental|2|R788, 150 mg tablet, orally, once a day
11597432|NCT00665925|Placebo Comparator|3|Placebo, orally, either once a day, or twice a day
11597433|NCT00665912|Other|1|Standard post-lobectomy wound care plus use of PRP and PPPc in the thoracic cavity.
11597434|NCT00665912|Active Comparator|2|Standard post-lobectomy wound care in the thoracic cavity
11597435|NCT00665899|Experimental|Cancer-Focused Relationship Enhancement|Cancer-Focused Relationship Enhancement
11597436|NCT00665899|Experimental|Couple's Cancer Education|Couple's Cancer Education
11597437|NCT00665899|No Intervention|Usual Care|Cancer-Related Community and Internet Resources
11597438|NCT00665886|Experimental|1|"Experimental Group (Closed System):
~Nexiva® Safety IV Catheter from BD (Becton Dickinson). The catheter has wings, a passive safety feature, an integrated Y extension tubing integrated and needle-less access using a split septum BD QSyte®. In order to completely close the Y connector a second Q-Syte® is added from the moment of catheter insertion"
11597439|NCT00665886|Active Comparator|2|"Control group (Open System):
~A 'mounted' system consisting of the Vasocan® Safety catheter of B. Braun Medical, SA. To the control catheters a three-way tap ('stopcock') with extension tubing 10 cm long (Connecta® Extra 3, from BD) is added. This comes as one unit (tap and tubing are integrated). When not in use the three-way tap ('stopcock') remains closed using a red cork Luer/Luer-Lock Sollner®, made by Amebil, SA."
11597440|NCT00665873|Active Comparator|A|Antibiotics
11597441|NCT00665873|Active Comparator|B|No Antibiotics
11597442|NCT00665860|Placebo Comparator|1|Placebo
11597443|NCT00665860|Active Comparator|2|
11597444|NCT00665860|Active Comparator|3|
11597445|NCT00665847|Experimental|Etravirine (TMC125)|
11597446|NCT00665834|Placebo Comparator|1|Rosuvastatin 20 mg versus placebo 20 mg
11597447|NCT00665834|Active Comparator|2|rosuvastatin 20 mg versus atorvastatin 80 mg
11597448|NCT00665808||A|
11597449|NCT00665808||B|
11597450|NCT00665795||1Patients with Graves´orbitophathy.|Patients with Graves´orbitophathy.
11597451|NCT00665795||2 Patients with detected DON|Patients with Graves´orbitophaty and detected dysthyroid optic neuropathy (DON)
11597452|NCT00665769|Placebo Comparator|Hypercapnia|Hypercapnic ventilation. The goal will be to maintain transcutaneous CO2 55 mm Hg (50-60 mm Hg) during the first week of life, or until extubation. A written, laminated hypercapnic ventilator algorithm will be placed at the bedside.
11597453|NCT00665769|Active Comparator|Normocapnia|Normocapnic ventilation. The goal will be to maintain transcutaenous CO2 40 mm Hg (35-45 mm Hg) during the first week of life, or until extubation. A written, laminated normocapnic ventilator algorithm will be placed at the bedside.
11597454|NCT00665756|Active Comparator|1|second trabeculectomy
11597455|NCT00665756|Active Comparator|2|Ahmed silicone drainage device implantation
11597456|NCT00665743|Experimental|A|PN400 (naproxen/esomeprazole)
11597457|NCT00665743|Active Comparator|B|naproxen 500 mg
11597458|NCT00665743|Active Comparator|C|naproxen 500 mg
11597459|NCT00665730|Experimental|Sepraspray|Sepraspray Powder applied on the viscera directly under the midline incision followed by incision closure. Sepraspray dose applied was between 2 g and 4 g per patient.
11597460|NCT00665730|No Intervention|Control|No anti-adhesion treatment used.
11597461|NCT00665717|Active Comparator|A|Pravastatin 40 mg QD for 4 days
11597462|NCT00665717|Active Comparator|B|Raltegravir 400mg BD for 4 days
11597463|NCT00665717|Experimental|C|Interaction between pravastatin and raltegravir
11597464|NCT00665704|Experimental|Tobacco Tactics Website|Nine veteran smokers who will pilot test the Tobacco Tactics website
11597465|NCT00665691||1|
11597466|NCT00665678|Experimental|1|paroxetine
11597467|NCT00665678|Placebo Comparator|2|placebo
11597468|NCT00665665|Experimental|A|
11597469|NCT00665665|Experimental|B|
11597470|NCT00665665|Experimental|C|
11597471|NCT00665665|Experimental|D|
11597472|NCT00665652|Experimental|Lenalidomide|
11597473|NCT00665639|Experimental|1|Daily dose
11597474|NCT00665639|Active Comparator|2|
11597475|NCT00665639|Experimental|3|Every other day dose, alternating with placebo
11597476|NCT00665626|Experimental|Arm 1|Fostamatinib disodium (R935788) 100 mg tablet, orally, twice-a-day
11597477|NCT00665626|Placebo Comparator|Arm 2|Placebo, orally, twice-a-day
11597478|NCT00665600|Experimental|1|Levalbuterol 0.63 mg TID
11597479|NCT00665600|Experimental|2|Levalbuterol 1.25 mg TID
11597480|NCT00665600|Active Comparator|3|Racemic Albuterol 2.5 mg TID
11597481|NCT00665600|Placebo Comparator|4|Placebo TID
11597485|NCT00665574|Experimental|2|ActaVisc Mx Intra-articular Injection
11597486|NCT00665574|Placebo Comparator|3|Saline
11597490|NCT00665548||Normal Subjects|Female subjects scoring Kellgren & Lawrence grade 0.
11597491|NCT00665548||OA Subjects|Female subjects with Kellgren & Lawrence score of 2 or 3.
11597492|NCT00665535|Other|2. High Risk|High risk for pressure ulcers according to the Braden Scale for Predicting Pressure Sore Risk (Score 10-12)
11597493|NCT00665535|Other|1. Moderate Risk|Moderate risk for pressure ulcers according to the Braden Scale for Predicting Pressure Sore Risk (Score 13 and 14)
11597494|NCT00665522||001|fentanyl iontophoretic transdermal system (40mcg) No Placebo 40 mcg per dose maximum of 6 doses/hourtotal maximum 80 doses/24 hours
11597495|NCT00665522||002|IV PCA with standard of care opioid analgesia per 24 hour period
11597496|NCT00665509|Experimental|1|
11597497|NCT00665496|Experimental|Arm 1|
11597498|NCT00665496|Placebo Comparator|Arm 2|
11597499|NCT00665483|Experimental|1|Skin Prick Test
11597500|NCT00665470|Experimental|Cohort I - high dose Aldesleukin|Patients receive high-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).
11597501|NCT00665470|Experimental|Cohort II - low dose Aldesleukin|Beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion, patients receive low-dose aldesleukin subcutaneous (SC) once daily 5 days a week for up to 6 weeks.
11597502|NCT00665457|Experimental|Celecoxib|"•Neoadjuvant chemotherapy: Patients receive docetaxel IV over 1 hour on days 1, 8, and 15, oral capecitabine twice daily on days 1-14, and oral celecoxib twice daily on days 1-21. Courses repeat every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
~Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV once daily on day 1, oral celecoxib twice daily on days 1-14, and filgrastim subcutaneously once daily on days 3-10. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Celecoxib is stopped one week prior to surgery.
~•Surgery: Patients undergo definitive surgery (either modified radical mastectomy or lumpectomy combined with axillary node dissection). Patients may also undergo adjuvant radiotherapy and hormonal therapy at the discretion of multidisciplinary breast team."
11597503|NCT00665444|Experimental|A|Aripiprazole
11597504|NCT00665431|Experimental|Arm 1 PN 400 (VIMOVO)|PN400: 500 mg naproxen/20 mg esomeprazole bid
11597505|NCT00665431|Active Comparator|Arm 2 (Celebrex)|Celecoxib 200 mg
11597506|NCT00665431|Placebo Comparator|Arm 3 (Placebo)|sugar pill
11597507|NCT00665418|Experimental|1|
11597508|NCT00665405||PN|Control - Induced or natural labor under anesthesia
11597509|NCT00665405||PC|Case - Cesarean section under anesthesia
11597510|NCT00665392|Experimental|cetuximab|
11597511|NCT00665379|Active Comparator|1|Regular compression therapy with non elastic trico bandaging
11597512|NCT00665379|Active Comparator|2|New two layer compression bandage coban 2
11597513|NCT00665366|Placebo Comparator|Placebo + valproate or lithium|Participants randomly received placebo (1:1 to study drug) as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks.
11597514|NCT00665366|Active Comparator|Aripiprazole + valproate or lithium|Participants randomly received aripiprazole as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks. Aripiprazole was provided in 5-, 10-, or 15-mg oral tablets and administered at a starting dose of 5 mg per day for Week 1. For Weeks 2 through 3, the dose was titrated up to 10 mg per day, and for Weeks 4 through 6, the dose increased to 15 mg per day. Flexible doses of either 15 or 30 mg per day were administered for Weeks 7 through 12. If participants were unable to tolerate the dose of 15 mg per day of study drug, the dose was decreased to 10 mg per day for Weeks 7 through 12.
11597515|NCT00665353|Experimental|PIO (step 1) then PIO+PEG-INF+RBV (step 2)|All participants in this study will receive pioglitazone therapy for 24 to 28 weeks. Participants will continue pioglitazone and add peginterferon and ribavirin to their treatment regimen for up to 48 additional weeks.
11597516|NCT00665340|Placebo Comparator|Arm 1|
11597517|NCT00665340|Experimental|Arm 2|
11597518|NCT00665327|Experimental|Arm 1|
11597519|NCT00665327|Active Comparator|Arm 2|
11597520|NCT00665314|Experimental|AMD3100 added to a G-CSF Mobilisation regimen|AMD3100 added to a G-CSF Mobilisation regimen
11597521|NCT00665314|Active Comparator|G-CSF plus placebo|G-CSF plus placebo
11597522|NCT00665262|Experimental|1|comibined use of tramacet and naloxone infusion perioperatively
11597523|NCT00665249|Active Comparator|Full Motivational Interviewing|"This condition consisted of all the standard elements of MI, both the non-directive and directive strategies (Miller & Rollnick, 2002). Rogerian elements, such as warmth, egalitarianism, genuineness, and a client-centered approach to the therapeutic relationship, are commonly referred to as MI Spirit (Moyers, Martin, Manual, Hendricksen, & Miller, 2005). MI is comprised of MI spirit and includes specific directive strategies geared to focus the client toward targeted behavior change, such as confidence and importance rulers, visualization of behavior change, or a decisional balance. The directive elements of MI are those that selectively reinforce positive change talk or enhance discrepancy between a client's wish to change and stay with the status quo."
11597524|NCT00665249|Active Comparator|No Intervention: Self Change|Participants in this condition were not assigned to treatment, but were asked to attempt to change on their own during the 8-week follow-up period. SC participants were told that research had shown that some individuals could reduce their drinking without professional help; that participating in the IVR might facilitate their efforts; and that they would be offered professional treatment at the end of the 8-week period. As noted in the Introduction, SC was selected rather than a traditional wait-list control because the aim of the study was to decompose MI into its 3 hypothesized components that include self-change.
11597525|NCT00665249|Active Comparator|Spirit-Only Motivational Interviewing|While this condition retained the Rogerian elements to MI, directive elements were excluded. For example, SOMI consisted of the non-directive elements including therapist stance (warmth, genuineness, egalitarianism), emphasis on client responsibility to change, extensive use of reflective listening skills (e.g., open-ended questions, simple reflections), and avoidance of MI-inconsistent behaviors (advise, confront, take expert role, interpretation). Reflective listening was focused on the whole experience of the client and the client's affect, and targeting a particular behavior or eliciting change talk about drinking was proscribed. Furthermore, tools utilized frequently in MI to develop discrepancy, such as amplified or double-sided reflections, were proscribed.
11597526|NCT00665236|Experimental|1|Craniosacral therapy administered once a week for an hour by a trained craniosacral therapist.
11597527|NCT00665236|Active Comparator|2|Low-strength static magnets placed around the body for periods of up to an hour once a week.
11597528|NCT00665223|Experimental|ACR16 - once daily dose|Participant received ACR16 45 mg once daily for four weeks. Weeks 5-26, ACR16 45 mg capsule and one placebo capsule were taken as two separate doses.
11597529|NCT00665223|Experimental|ACR16 - twice daily dose|Participant received ACR16 45 mg once daily for four weeks. Weeks 5-26, an ACR16 45 mg capsule was taken twice daily as two separate doses (total dose: 90 mg).
11597530|NCT00665223|Placebo Comparator|Placebo|Participant received a placebo capsule once daily for four weeks. Weeks 5-26, a placebo capsule was taken twice daily as two separate doses.
11597531|NCT00665197|Active Comparator|Protracted Course Radiotherapy|"High Dose Rate brachytherapy 8.0 Gy x 2
~External beam radiotherapy 30 Gy in 10 fractions of 3.0 Gy"
11597532|NCT00665197|Experimental|Short Course Radiotherapy|"High Dose Rate brachytherapy 8.0 Gy x 2
~External beam radiotherapy 20 Gy in 5 fractions of 4.0 Gy"
11597533|NCT00665184|Experimental|High force LE resistance training|High force lower extremity resistance training + Standard exercise care. The high force lower extremity resistance training group will participate in a 3 day per week progressive eccentric ergometry program that will be gradually increased over 3 weeks from 5-20 minutes per day and remain at that duration for the next 9 weeks. In addition, they will engage in exercises including moderate intensity aerobic training, concentric upper extremity resistance training and stretching (axial mobility exercises).
11597534|NCT00665184|Active Comparator|Standard Care Control Group|"Standard care exercise group: The standard care control group is an active control group, i.e., individuals who will engage in our standard of care (an evidence based exercise program). These exercises include moderate intensity aerobic training (15 minutes), concentric upper extremity resistance training (5-10 minutes), balance training (5 minutes), and stretching (axial mobility exercises-5-10 minutes)."
11597535|NCT00665158|Active Comparator|UC|Usual Care Group
11597536|NCT00665158|Active Comparator|BI|Behavioural Intervention Group
11597537|NCT00665145|Experimental|1|Cohort 1
11597538|NCT00665145|Experimental|2|Cohort 2
11597539|NCT00665145|Placebo Comparator|3|Cohort 3
11597540|NCT00665145|Experimental|4|Cohort 4
11597541|NCT00665132|Experimental|StimRouter (SR) for CTS|Percutaneous implantation of StimRouter System
11597542|NCT00665119|Experimental|treatment|Any patient alternatively receive both remifentanil and isotonic saline (placebo)infusion. The order of infusion is randomized. An interval of 30 minutes is planned between the two infusions.
11597543|NCT00665106|Experimental|cohort 1|5 up to 6 patients per arm. Emulsion at 0.8% of drug product.
11597544|NCT00665106|Experimental|cohort 2|5 up to 6 patients per arm. Emulsion at 0.8% of drug product.
11597545|NCT00665106|Experimental|cohort 3|5 up to 6 patients per arm. Emulsion at 3.2% of drug product.
11597546|NCT00665106|Experimental|cohort 4|5 up to 6 patients per arm. Oily solution at 3.4% of drug product.
11597547|NCT00665093||A|
11597548|NCT00665093||B|
11597549|NCT00665054|Experimental|Arm 1|
11597550|NCT00665054|Placebo Comparator|Arm 2|
11597551|NCT00665041|Experimental|PR1|
11597552|NCT00665041|Placebo Comparator|PL1|
11597553|NCT00665028||1|Postoperative myocardial ischemia
11597554|NCT00665002|Experimental|WT-1 Analog Peptide Vaccine|Participants received 6 bi-weekly vaccinations over 10 weeks. WT-1 vaccine was given with Montanide. Participants also received an injection of Sargramostim (GM-CSF) two days before each vaccination and again on the day of the WT-1 injection at the same spot.
11597555|NCT00664976|Experimental|1|Electroconvulsive therapy
11597556|NCT00664976|Active Comparator|2|Treatment as usual
11597557|NCT00664963|Experimental|1|YUKON Sirolimus-eluting Stent
11597558|NCT00664963|Active Comparator|2|YUKON Stent (uncoated)
11597559|NCT00664950|Active Comparator|SHS|sliding hip screw
11597560|NCT00664950|Active Comparator|InterTAn IM Nail|interTAN IM nail
11597561|NCT00664937|Placebo Comparator|I|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
11597562|NCT00664937|Placebo Comparator|II|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
11597563|NCT00664937|Placebo Comparator|III|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
11597564|NCT00664911|Other|Chemotherapy|chemotherapy regimen
11597565|NCT00664898|Experimental|1|
11597566|NCT00664885|Experimental|CSCT|
11597567|NCT00664872|Experimental|case management|
11597568|NCT00664859|Experimental|Single|Open-label LCP-AtorFen
11597569|NCT00664846|Experimental|1|
11597570|NCT00664846|Active Comparator|2|
11597571|NCT00664833|Experimental|Arm 2|
11597572|NCT00664833|Other|Arm 4|
11597573|NCT00664833|Experimental|Arm 3|
11597574|NCT00664833|Experimental|Arm 1|
11597575|NCT00664820|Experimental|Treatment group|Will receive two Urex-CAP-5 (probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14) capsules daily for 3 months.
11597576|NCT00664794|Active Comparator|without acromioplasty|
11597577|NCT00664794|Active Comparator|with acromioplasty|
11597578|NCT00664768|Experimental|New Neocate|new Neocate
11597579|NCT00664768|Active Comparator|Neocate Infant|Neocate Infant formula
11597580|NCT00664755|Experimental|Varenicline|Participant randomized to receive active varenicline and placebo transdermal nicotine patch.
11597581|NCT00664755|Active Comparator|Transdermal Nicotine Patch|Participant randomized to receive active transdermal nicotine patch and placebo varenicline.
11597582|NCT00664742|Experimental|Fluvastatin XL® Treatment|80 mg once daily, at bedtime.
11597583|NCT00664729|Active Comparator|1|Caloric Restriction
11597584|NCT00664729|Experimental|2|Caloric restriction + Moderate-intensity aerobic exercise
11597585|NCT00664729|Experimental|3|Caloric restriction + Vigorous-intensity aerobic exercise
11597586|NCT00664716|Placebo Comparator|Placebo|subcutaneous administration of placebo given for 12 weeks
11597587|NCT00664716|Experimental|One Dose|BG9924 - dosage level administered as per Biogen Idec protocol
11597588|NCT00664716|Experimental|Second Dose|BG9924 - dosage level administered as per Biogen Idec protocol
11597589|NCT00664716|Experimental|Third Dose|BG9924 - dosage level administered as per Biogen Idec protocol
11597590|NCT00664716|Experimental|Fourth Dose|BG9924 - dosage level administered as per Biogen Idec protocol
11597591|NCT00664716|Experimental|Fifth Dose|BG9924 - dosage level administered as per Biogen Idec protocol
11597592|NCT00664703|Experimental|Lobeline 7.5 mg|Sublingual tablet
11597593|NCT00664703|Experimental|Lobeline 15 mg|Sublingual tablet
11597594|NCT00664703|Experimental|Lobeline 30 mg|Sublingual tablet
11597595|NCT00664703|Active Comparator|Methylphenidate HCl 15 mg|Capsule
11597596|NCT00664703|Active Comparator|Methylphenidate HCl 30 mg|Capsule
11597597|NCT00664703|Placebo Comparator|Lobeline 0 mg (placebo)|Sublingual tablet
11597598|NCT00664703|Placebo Comparator|Methylphenidate HCl 0 mg (placebo)|Capsule
11597599|NCT00664690|Experimental|1|celebrex
11597600|NCT00664690|Placebo Comparator|2|placebo
11597601|NCT00664677|Experimental|Terameprocol (EM-1421)|Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off).
11597602|NCT00664664|Experimental|1|APD125 20 mg
11597603|NCT00664664|Experimental|2|APD125 40 mg
11597604|NCT00664664|Placebo Comparator|3|Matching Placebo
11597605|NCT00664625|Experimental|1|"BMS-791325 (100 mg)
~or
~placebo match for (100 mg)"
11597606|NCT00664625|Experimental|2|"BMS-791325 (300 mg)
~or
~placebo match for (300 mg)"
11597607|NCT00664625|Experimental|3|"BMS-791325 (900 mg)
~or
~placebo match for (900 mg)"
11597608|NCT00664625|Experimental|4|"BMS-791325 (potential dose between 10-800 mg)
~or
~placebo match for (10-800 mg)"
11597609|NCT00664612|Experimental|1|Air Traq then Macintosh
11597610|NCT00664612|Experimental|2|Macintosh then AirTraq
11597611|NCT00664599|Experimental|1|Rituximab
11597612|NCT00664599|Active Comparator|2|Cytotoxics combination
11597613|NCT00664586|Experimental|Terameprocol (EM-1421)|Terameprocol (EM-1421) will be administered as an intravenous infusion over 24 hours, weekly. Dose will commence in the first cohort with 100 mg per hour (2400 mg in a 24 hour period)with escalation in the 5 cohorts of 3 to 6 patients with increments of 25 mg per hour to a maximum of 200 mg/hr (4800 mg/24 hour period) or until MTD is defined. When the MTD has been declared, then 11 additional subjects will be enrolled at the MTD dose level (to total 14 subjects treated in dosage cohort).
11597614|NCT00664573|Experimental|Group 2|Drug: BG9924 - dose administered as per Biogen-Idec protocol
11597615|NCT00664573|Experimental|Group 1|Drug: BG9924 - dose administered as per Biogen-Idec protocol
11597616|NCT00664573|Experimental|Group 3|Drug: BG9924 - dose administered as per Biogen-Idec protocol
11597617|NCT00664573|Experimental|Group 4|Drug: BG9924 - dose administered as per Biogen-Idec protocol
11597618|NCT00664560|Experimental|ARM 1 PN 400 (VIMOVO)|PN400: 500 mg naproxen/20 mg esomeprazole
11597619|NCT00664560|Active Comparator|Arm 2 (celebrex)|Celecoxib 200 mg
11597620|NCT00664560|Placebo Comparator|Arm 3 (placebo)|sugar pill
11597621|NCT00664547|No Intervention|C|
11597622|NCT00664547|Active Comparator|DWL|Diet Weight Loss
11597623|NCT00664547|Active Comparator|EWL|Exercise Weight Loss
11597624|NCT00664547|Active Comparator|EWS|Exercise without weight loss
11597625|NCT00664534|Active Comparator|Glargine|Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)
11597626|NCT00664534|Experimental|Premixed Insulin Lispro|Premixed Insulin Lispro (mid-mixture or low-mixture) 1,2 or 3 injections plus OAMs
11597627|NCT00664521|Experimental|Rituximab Plus Atacicept|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by atacicept 150 mg subcutaneously once a week from Week 7 to 32.
11597628|NCT00664521|Placebo Comparator|Rituximab Plus Placebo|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by placebo matched to atacicept subcutaneously once a week from Week 7 to 32.
11597629|NCT00664508|Active Comparator|Lateral approach|Lateral approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
11597630|NCT00664508|Active Comparator|Anterior approach|Anterior approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
11597631|NCT00664508|Active Comparator|Posterior approach|Posterior approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
11597632|NCT00664495|No Intervention|C|Control
11597633|NCT00664495|Active Comparator|DWL|Diet Weight Loss
11597634|NCT00664495|Active Comparator|EWL|Exercise Weight Loss
11597635|NCT00664495|Active Comparator|EWS|Exercise Without Weight Loss
11597636|NCT00664482|Experimental|1|AGS-006
11597637|NCT00664469|Experimental|EZE+statin|ezetimibe 10 mg per day is added to actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
11597638|NCT00664469|Active Comparator|Stat2|patients on statins has their dose doubled for 6 weeks followed by another 6 weeks in which ezetimibe is added or the statin dose is doubled again.
11597639|NCT00664456|Active Comparator|AHT group|Randomized patients undergo 3-month neoadjuvant therapy (NHT)within 14 days and receive 9-month adjuvant therapy (AHT) following after Iodine I-125 implantation (TPPB).
11597707|NCT00663949|Active Comparator|A,1,II|patients in this arm takes 25 mg captopril q8h
11597708|NCT00663949|Active Comparator|A,2,II|
11597640|NCT00664456|Active Comparator|Non-AHT group|Rondomized patients undergo 3-month neoadjuvant therapy (NHT) within 14 days and receive Iodine I-125 implantation therapy (TPPB). 40 weeks observation is followed under no further treatment.
11597641|NCT00664443||Dispatch-assisted CPR|Emergency ambulance dispatcher interaction to provide dispatch-assisted CPR instructions in order to determine bystander CPR rates and the impact of instructions on survival to hospital discharge
11597642|NCT00664430|Other|Calcitriol challenge followed by paricalcitol|Participants began a controlled calcitriol therapy period (calcitriol challenge) to confirm calcitriol resistance. After this period, those who failed to reduce PTH (according to parameters in protocol) initiated paricalcitol therapy.
11597643|NCT00664417|Experimental|1|
11597644|NCT00664417|Experimental|2|
11597645|NCT00664417|Experimental|3|
11597646|NCT00664417|Experimental|4|
11597647|NCT00664417|Experimental|5|
11597648|NCT00664417|Experimental|6|
11597649|NCT00664417|Active Comparator|7|
11597650|NCT00664417|Active Comparator|8|
11597651|NCT00664417|Placebo Comparator|9|
11597652|NCT00664404|Other|fMRI|Functional Magnetic Resonance Imaging (fMRI)
11597653|NCT00664391|Experimental|1|
11597654|NCT00664378|Experimental|I|CYT997
11597655|NCT00664365|Experimental|Subjects receiving GSK958108 + placebo in cohort 1|Eligible subjects will receive GSK958108 with a starting dose of 1 milligram. The dose escalation will be continued up to 4 ascending doses. Subjects will also receive placebo. Each treatment period will be separated by at least 7 days washout period.
11597656|NCT00664365|Experimental|Subjects receiving GSK958108 + placebo in cohort 2|Eligible subjects will start dosing once the cohort 1 has completed the treatment phase and the initial dose will be the same as top dose in Cohort1.The dose escalation will be continued up to 4 ascending doses. Subjects will also receive placebo. Each treatment period will be separated by at least 7 days washout period.
11597657|NCT00664352|Experimental|1|
11597658|NCT00664352|Experimental|2|
11597659|NCT00664352|Experimental|3|
11597660|NCT00664352|Experimental|4|
11597661|NCT00664352|Other|5|
11597662|NCT00664339|Active Comparator|Vaccine|Flu Vaccine
11597663|NCT00664339|Other|Control|Conventional treatment therapy for heart failure
11597664|NCT00664326|Experimental|Regorafenib (Stivarga, BAY73-4506)|Participants received Regorafenib 160 mg per os (po) every day (qd) for 3 weeks on 1 week off of every 4 week cycle
11597665|NCT00664313|Experimental|1|Linezolid 600 mg po QD
11597666|NCT00664313|Placebo Comparator|2|Placebo
11597667|NCT00664300||2|One group with Gilles de la Tourette's Syndrome One group with healthy paired volunteers
11597668|NCT00664287|Experimental|Group 1|Patients will remain on existing lipid-modifying therapy throughout the study. Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
11597669|NCT00664287|Placebo Comparator|Group 2|Patients will remain on existing lipid-modifying therapy throughout the study. Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
11597670|NCT00664274|Other|CRT Group|
11597671|NCT00664248|Experimental|1|
11597672|NCT00664248|Active Comparator|2|
11597673|NCT00664248|Active Comparator|3|
11597674|NCT00664248|Placebo Comparator|4|
11597675|NCT00664209|Other|Active-placebo|These subject receive treatment with active triple therapy followed by treatment with placebo therapy.
11597676|NCT00664209|Other|Placebo-active|These subject receive treatment with placebo therapy followed by treatment with active triple therapy.
11597677|NCT00664196|Experimental|1|
11597678|NCT00664183|Experimental|1|
11597679|NCT00664183|Experimental|2|
11597680|NCT00664170|Experimental|1|ANX-514
11597681|NCT00664170|Active Comparator|2|Taxotere
11597682|NCT00664157|Other|2|40 patients with an idiopathic Parkinson's disease and 40 healthy paired volunteers (control group)
11597683|NCT00664131||1|
11597684|NCT00664118|Active Comparator|1|Doula combined epidural analgesia in the latent phase of first stage of labor
11597685|NCT00664118|Sham Comparator|2|Epidural analgesia in the latent phase of the first stage of labor without doula accompany
11597686|NCT00664105|Experimental|Therapeutic Intervention|
11597687|NCT00664092|No Intervention|1|Usual Aftercare Condition
11597688|NCT00664092|Experimental|2|Oxford House Condition
11597689|NCT00664092|Experimental|3|Therapeutic Community Condition
11597690|NCT00664079||1|Patients who are receiving vasoactive medications and/or are mechanically ventilated.
11597691|NCT00664053|Experimental|1|DHEA and Yoga
11597692|NCT00664053|Active Comparator|2|DHEA and exercise
11597693|NCT00664053|Active Comparator|3|Placebo and Yoga
11597694|NCT00664053|Placebo Comparator|4|Placebo and exercise
11597695|NCT00664027|Experimental|25 mg|25 mg RTA 402 (Bardoxolone methyl)/Stratum 1
11597696|NCT00664027|Experimental|75 mg|75 mg RTA 402 (Bardoxolone methyl)/Stratum 1
11597697|NCT00664027|Experimental|150 mg|150 mg RTA 402 (Bardoxolone methyl)/Stratum 1
11597698|NCT00664027|Experimental|25/75 mg|25 mg -> 75 mg RTA 402 (Bardoxolone methyl)/Stratum 2
11597699|NCT00664014|Experimental|Tolvaptan|
11597700|NCT00664014|Placebo Comparator|Placebo|
11597701|NCT00664001|Placebo Comparator|Control|Placebo tablet
11597702|NCT00664001|Active Comparator|Intervention|Anti-oxidant supplementation
11597703|NCT00663988|Experimental|III|The effect of human partial facial allotransplantation
11597704|NCT00663975|Experimental|1|DCI-1020 Capsules contain an enteric-coated buffered microspheres of pancrelipase, encapsulated in clear capsules. Capsules are equivalent to 4,000 USP units of lipase
11597705|NCT00663962|Experimental|Perioperative pregabalin|Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-operatively (n=3) or Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-operatively (n=4).
11597706|NCT00663962|Placebo Comparator|Placebo control|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op. (N=8)
11597710|NCT00663936|Placebo Comparator|2|Placebo once daily
11597711|NCT00663923|Experimental|cross-cylinder|In this technique the laser is programmed with the axis and amount of cylinder,so that the steepest meridian is flattened with central cylindrical ablation and the flattest meridian steepens with paracentral ablation
11597712|NCT00663923|Active Comparator|single|In this technique ,cylinder is treated only on one meridian by performing an elliptical ablation to to flatten the steeper meridian to match the flatter meridian.
11597713|NCT00663897|Experimental|1|Treatment with lansoprazole (30 mg) once daily for 14 days
11597714|NCT00663897|Active Comparator|2|Treatment with mosapride (5 mg) thrice daily for 14 days
11597715|NCT00663884|Experimental|M|Mitiglinide
11597716|NCT00663884|Active Comparator|V|Voglibose
11597717|NCT00663871|Active Comparator|1|Participants will take fish oil supplements daily for 4 months.
11597718|NCT00663871|Placebo Comparator|2|Participants will take soybean oil (placebo) supplements daily for 4 months.
11597719|NCT00663858|Experimental|Cetrorelix 78+78|
11597720|NCT00663858|Experimental|Cetrorelix 78 + Placebo|
11597721|NCT00663858|Placebo Comparator|Placebo|
11597722|NCT00663845|Experimental|Arm 1|
11597723|NCT00663845|Placebo Comparator|Arm 2|
11597724|NCT00663832|Experimental|LBH589|
11597725|NCT00663819|Active Comparator|Device|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular staplers
11597726|NCT00663819|Other|Procedure/Surgery|Procedure/Surgery: colorectal, coloanal, and ileoanal anastomotic staple line without reinforcement
11597727|NCT00663806|Experimental|Arm 1|
11597728|NCT00663806|Experimental|Arm 2|
11597729|NCT00663793|Experimental|Oral testosterone|"(Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by immediate release T 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
11597730|NCT00663793|Experimental|Finasteride plus Oral Testosterone|"(Day -2 to Day 12) 1 mg Finasteride PO once daily for 14 days total. (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by immediate release T 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
11597731|NCT00663767|Placebo Comparator|Placebo|
11597732|NCT00663767|Experimental|Placebo, ARRY-371797|
11597733|NCT00663767|Experimental|ARRY-371797, Placebo|
11597734|NCT00663767|Experimental|ARRY-371797|
11597735|NCT00663767|Active Comparator|Celecoxib, Placebo|
11597736|NCT00663767|Experimental|Celecoxib, ARRY-371797|
11597737|NCT00663754|Active Comparator|1|Participants will receive a mailed brochure about body image only.
11597738|NCT00663754|Active Comparator|2|Participants will receive the 4-hour dissonance-based eating disorder prevention program.
11597739|NCT00663754|Experimental|3|Participants will receive the 8-hour dissonance-based eating disorder prevention program.
11597740|NCT00663741|Experimental|Arm 1|
11597741|NCT00663741|Experimental|Arm 2|
11597742|NCT00663741|Experimental|Arm 3|
11597743|NCT00663728|Experimental|Arm 1|
11597744|NCT00663728|Placebo Comparator|Arm 2|
11597745|NCT00663715||1|Pediatric Patients of ages 11-17
11597746|NCT00663702|Experimental|1|
11597747|NCT00663689|Experimental|1|non-randomized open-label uncontrolled phase II trial erlotinib 150mg qd until disease progression or unacceptable toxicity
11597748|NCT00663663|Experimental|1|Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
11597749|NCT00663663|Experimental|2|Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
11597750|NCT00663650|Active Comparator|1|Permanent Section Control
11597751|NCT00663650|Active Comparator|2|Frozen Section Control
11597752|NCT00663624|Experimental|Experimental|Subcutaneous aspart insulin every 2 hours
11597753|NCT00663624|Placebo Comparator|Active Comparator|Usual care as prescribed by the ED physicians
11597754|NCT00663611|Experimental|Study I and IB|Each involve six subjects &amp; are designed to test the hypothesis that pulsatile subcutaneous infusion of GH via a subcutaneous infusion pump will yield a reasonable pulsatile GH pattern. The dose of GH used in Study IB will be three-fold higher than that in Study I. Study I and IB will be done first before proceeding to Study II
11597755|NCT00663611|Experimental|Study II|Is a randomized, double-blinded, placebo-controlled 12 week study involving 26 subjects divided into 2 groups: Group A and Group B. Group A will involve 13 subjects receiving pulsatile GH or placebo infusion for 4 weeks with 8 week washout after intervention. Group B will involve 13 subjects receiving conventional once a day subcutaneous infusion of GH or placebo for 4 weeks with 8 week washout after intervention.
11597756|NCT00663598|Experimental|Arm 1|
11597757|NCT00663585|Experimental|1|Structured Intervention Group
11597758|NCT00663585|Active Comparator|2.Comparison group|Unstructured comparison group
11597759|NCT00663559|Other|1|This study has only one arm with Sunitinib
11597760|NCT00663533|No Intervention|Device study only.|
11597761|NCT00663520||1|"Women with chest pain and Clean heart vessels"
11597762|NCT00663520||2|Healthy volunteers
11597763|NCT00663481|Experimental|1|CoFactor
11597764|NCT00663481|Experimental|2|CoFactor
11597765|NCT00663481|Active Comparator|3|Leucovorin
11597766|NCT00663468||A|
11597767|NCT00663455|Other|A|Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
11597768|NCT00663455|No Intervention|B|Standard CSA-dosing without reduction. Therapy control by C2-monitoring.
11597769|NCT00663442|Experimental|1|OROS methylphenidate 18, 36, 54m placebo in randomized order (except never starting with highest dose)
11597770|NCT00663416|Experimental|1|
11597771|NCT00663416|Placebo Comparator|2|
11597772|NCT00663390|Experimental|I|
11597773|NCT00663364|Active Comparator|I|Physiogel AI Lotion
11597774|NCT00663364|Active Comparator|II|Physiogel Lotion twice daily
11597775|NCT00663351|Active Comparator|1|Investigational: Reflection Ceramic-Ceramic Hip System. Ceramic femoral head component and the ceramic acetabular cup insert are composed of Biolox forte aluminum oxide material.
11597776|NCT00663351|Active Comparator|2|Control: Reflection FSO V (5 hole). Acetabular shell with a ultra high molecular weight polyethylene insert and an alumina ceramic femoral head with a Synergy or Spectron EF femoral stem. The Synergy femoral stem are composed of implant grade titanium while the Spectron EF stem is composed of implant grade cobalt chrome.
11597777|NCT00663338|Experimental|A|All patients receive placebo or rotigotine at some stage in the trial but the exact point is randomized.
11597778|NCT00663325|Experimental|1|Lactic acid in small quantity during 21 days
11597779|NCT00663299|Other|Trufill Detachable Coil System|There is only one treatment arm in the registry and it is all patients receiving treatment with Trufill Detachable Coil System. The use of bare platinum coils for the endovascular occlusion of cerebral aneurysms.
11597780|NCT00663286|Experimental|1|
11597781|NCT00663286|Active Comparator|2|
11597782|NCT00663286|Active Comparator|3|
11597783|NCT00663286|Placebo Comparator|4|
11597784|NCT00663273|Experimental|1|Lactic acid in small quantity during 21 days.
11597785|NCT00663260|Active Comparator|Dapagliflozin (10 mg)|
11597786|NCT00663260|Active Comparator|Dapagliflozin (5 mg)|
11597787|NCT00663260|Placebo Comparator|Placebo|
11597788|NCT00663247|Placebo Comparator|B|placebo used as control for comparison with active drug
11597789|NCT00663247|Active Comparator|A|
11597790|NCT00663234|Experimental|Age 10 to 14|Participants ages 10 to 14 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
11597791|NCT00663234|Experimental|Age 15 to 23|Participants ages 15 to 23 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
11597792|NCT00663221|Placebo Comparator|1|
11597793|NCT00663221|Experimental|2|
11597794|NCT00663208|Active Comparator|Group 1|"Daclatasvir (1 mg), once daily
~or
~Matching Placebo, once daily"
11597795|NCT00663208|Active Comparator|Group 2|"Daclatasvir (10 mg), once daily
~or
~Matching Placebo, once daily"
11597796|NCT00663208|Active Comparator|Group 3|"Daclatasvir (1-100 mg), once or twice daily
~or
~Matching Placebo, once or twice daily"
11597797|NCT00663208|Active Comparator|Group 4|"Daclatasvir (1-100 mg), once or twice daily
~or
~Matching Placebo, once or twice daily"
11597798|NCT00663208|Active Comparator|Group 5|"Group 5: Active Comparator
~Daclatasvir (1-100 mg), once or twice daily
~or
~Matching Placebo, once or twice daily"
11597799|NCT00663208|Active Comparator|Group 6|"Group 6: Active Comparator
~Daclatasvir (1-100 mg), once or twice daily
~or
~Matching Placebo, once or twice daily"
11597800|NCT00663182|Experimental|A|Patients with decompensated HBV-related cirrhosis
11597801|NCT00663182|No Intervention|B|Untreated
11597802|NCT00663169|Experimental|Canakinumab|Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.
11597803|NCT00663169|Active Comparator|Dexamethasone|Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.
11597804|NCT00663156|Experimental|subject|10 subjects receiving breast augmentation with fat grafting
11597805|NCT00663156|Other|control|10 control will have breast augmentation using breast implants
11597806|NCT00663143||Stromal Cell Sample|
11597807|NCT00663130|Experimental|Arm 1|
11597808|NCT00663130|Active Comparator|Arm 2|
11597809|NCT00663117|Placebo Comparator|Placebo, Sugar pill|placebo for 3 months blinded then followed by an open-labelled study and all are treated with naltrexone 4.5 mg for 3 additional months
11597810|NCT00663117|Active Comparator|Naltrexone-HCl|Subjects are treated in a blinded fashion for 3 months with naltrexone 4.5 mg po for active Crohn's disease followed an open-labelled study where naltrexone is given an additional 3 months at 4.5 mg po; hence the total treatment interval in this arm is 6 months. The response to the intervention administered is measured in the activity index and mucosal healing by colonoscopy.
11597811|NCT00663104|Active Comparator|1|exercise (3 sessions/week)
11597812|NCT00663104|Active Comparator|2|"exercise and phytoestrogen (cimicifuga racemosa)"
11597813|NCT00663104|Placebo Comparator|3|wellness control, placebo
11597814|NCT00663091|Experimental|Bacteriophages|
11597815|NCT00663078|Experimental|A|Group A: Women from GP practices and area of Knowle West, Bristol
11597816|NCT00663078|Experimental|B|Group B: Women from Wellspring, GP practice or geographical area of Barton Hill Bristol.
11597817|NCT00663065|Experimental|arm 1|
11597818|NCT00663052|Experimental|Group A|A
11597819|NCT00663052|Experimental|Group B|B
11597820|NCT00663039|Experimental|Oxytocin, then Placebo|Participants first received 24IU of Oxytocin administered intranasally with 6 total sprays (three in each nostril) on the morning and at midday of one study visit. Then, after at least month the participants returned for a second study day and received placebo.
11597869|NCT00662753|Active Comparator|home monitoring|home blood pressure monitor
11597870|NCT00662753|Experimental|monitor & phone call|home blood pressure monitor + phone calls
11597821|NCT00663039|Experimental|Placebo, then Oxytocin|Participants first received a placebo (saline nasal spray) administered intranasally with 6 total sprays (three in each nostril) on the morning and at midday of one study visit. Then, after at least month the participants returned for a second study day and received Oxytocin.
11597822|NCT00663026|Experimental|A|5 mg/week
11597823|NCT00663026|Experimental|B|10 mg/week
11597824|NCT00663026|Experimental|C|Placebo
11597825|NCT00663013|Active Comparator|1|The first treatment session will involve 5-7 minutes of burn wound care while distracted by VR, and 5-7 minutes of burn wound care without the distraction of VR. The second session of burn wound care (performed within the next 3 days) will involve 5-7 minutes of burn wound care without the distraction of VR, and 5-7 minutes of burn wound care with the distraction of VR. The treatment order will be randomized.
11597826|NCT00663013|Active Comparator|2|The first treatment session will involve 5-7 minutes of burn wound care while distracted by VR, and 5-7 minutes of burn wound care without the distraction of VR. The second session of burn wound care (performed within the next 3 days) will involve 5-7 minutes of burn wound care without the distraction of VR, and 5-7 minutes of burn wound care with the distraction of VR. The treatment order will be randomized.
11597827|NCT00663000||acromegalics|"Acromegaly in adult subjects either controlled or uncontrolled (Diagnosis should be based on OGTT where Acromegaly is defined as a lack of suppression of GH nadir to < 0.5 ng/dL, after oral administration of 75 g of glucose, OGTT and IGF-I levels at least 10 % above the normal value ± 2 SD).
~Written informed consent"
11597828|NCT00662987|Placebo Comparator|Group B|Received 3 days of amoxicillin followed by 4 days of placebo
11597829|NCT00662987|Active Comparator|Group A|Received 7 days of amoxicillin
11597830|NCT00662974|Experimental|A|parturients during the second stage of labor massaged by Wheat Germ Oil
11597831|NCT00662974|Experimental|B|parturients during the second stage of labor massaged by almond oil
11597832|NCT00662961|Experimental|1|Periosteum
11597833|NCT00662961|Experimental|2|Bone
11597834|NCT00662948|Experimental|A|Consolidation with one dose of 90Y Ibritumomab tiuxetan (Zevalin®) 0,4 mCi/Kg
11597835|NCT00662948|Active Comparator|B|Maintenance with 375 mg/m2 of Rituximab every 8 weeks during 24 months
11597836|NCT00662935|Experimental|2|the sequence of stimulation begins by OFF
11597837|NCT00662935|Experimental|1|the sequence of stimulation begins by ON
11597838|NCT00662922||1|patients with hypoglycemia during intensive care
11597839|NCT00662922||2|patients without hypoglycemia during intensive care
11597840|NCT00662909|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once a day for 12 weeks
11597841|NCT00662909|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks
11597842|NCT00662909|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 m tablets, orally once a day for 12 weeks
11597843|NCT00662896|Experimental|naproxcinod 375 mg bid|
11597844|NCT00662896|Active Comparator|naproxen 250 mg bid|
11597845|NCT00662896|Active Comparator|ibuprofen 600 mg tid|
11597846|NCT00662896|Experimental|naproxcinod 750 mg bid|
11597847|NCT00662896|Active Comparator|naproxen 500 mg bid|
11597848|NCT00662883|Experimental|A|"PMI-150 (intranasal ketamine HCl), day 1
~mometasone furoate, days 2-15
~PMI-150 (intranasal ketamine HCl), day 15"
11597849|NCT00662870|Experimental|DAPTACEL Lot 1|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 1
11597850|NCT00662870|Experimental|DAPTACEL Lot 2|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 2
11597851|NCT00662870|Experimental|DAPTACEL Lot 3|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 3
11597852|NCT00662870|Active Comparator|Pentacel|Participants receiving Pentacel vaccine
11597853|NCT00662857|Experimental|1: TI Inhalation Powder A|Technosphere® Insulin Inhalation Powder, two 15 U cartridges
11597854|NCT00662857|Experimental|2: TI Inhalation Powder B|Technosphere® Insulin Inhalation Powder, one 30 U cartridge
11597855|NCT00662857|Experimental|3: RAA Population|Rapid Acting Analogue subjects received 10 IU sc Insulin Lispro
11597856|NCT00662844|Placebo Comparator|A1 vitamin D3 400IU|Orally for one year
11597857|NCT00662844|Placebo Comparator|A2 vitamin D3 800IU|Orally for one year
11597858|NCT00662844|Placebo Comparator|A3 vitamin D3 1600IU|Orally for one year
11597859|NCT00662844|Placebo Comparator|A4 Vitamin D3 2400 IU|Orally for one year
11597860|NCT00662844|Placebo Comparator|Placebo|Placebo for one year
11597861|NCT00662831|Experimental|Active|Active study treatment
11597862|NCT00662831|Placebo Comparator|Placebo|Placebo
11597863|NCT00662818|Experimental|Telcagepant 300 mg→Acetaminophen/Paracetamol 1000 mg|Participants receive up to 12 doses of telcagepant (280 mg tablet/capsule 300 mg), orally, and placebo to acetaminophen/paracetamol (APAP) (2- 500 mg dry filled capsules), orally, for up to 12 migraine attacks in Period 1 (6 weeks). Participants receive APAP and placebo to telcagepant for up to 12 doses, for up to 12 migraine attacks in Period 2 (6 weeks). The participant may take a blinded optional second dose of study medication or their own rescue medication if 2 hours after initial treatment, the participant still has a moderate or severe migraine headache or if the headache has returned.
11597864|NCT00662818|Experimental|Placebo and APAP 1000 mg→Telcagepant 300 mg|Participants receive 1 dose of placebo to APAP and placebo to telcagepant for the first migraine attack and then up to 11 doses of APAP and placebo to telcagepant for up to 11 migraine attacks in Period 1 (6 weeks). Participants receive up to 12 doses of telcagepant and placebo to APAP for up to 12 migraine attacks in Period 2 (6 weeks). The participant may take a blinded optional second dose of study medication or their own rescue medication if 2 hours after initial treatment, the participant still has a moderate or severe migraine headache or if the headache has returned.
11597865|NCT00662805||Salmeterol/Fluticasone propionate (50/500 μg)|Open label, 6 visits, single arm study
11597866|NCT00662779|Experimental|1|15 mcg arformoterol nebulizer + 1 inhalation of placebo inhalation powder
11597867|NCT00662779|Active Comparator|2|1 inhalation of formoterol fumarate inhalation powder (12 mcg/inhalation) + 2 ml of normal saline nebulizer
11597868|NCT00662779|Placebo Comparator|3|1 inhalation of placebo inhalation powder + 2 ml of normal saline nebulizer
11597871|NCT00662740|Experimental|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
11597872|NCT00662740|Active Comparator|Tiotropium QD|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
11597873|NCT00662740|Active Comparator|Salmeterol BID|Salmeterol Inhalation Powder, hard PE capsule
11597874|NCT00662740|Active Comparator|Tiotropium/Salmeterol QD+ Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
11597875|NCT00662740|Placebo Comparator|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
11597876|NCT00662727|Active Comparator|A|A - Treatment group. Patients in this group receive actual shockwave therapy.
11597877|NCT00662727|Placebo Comparator|B|Placebo group. This group of patients undergo the same procedure as the treatment group, however shockwaves are not delivered to the heart.
11597878|NCT00662714|Experimental|1|Repaglinide; oral
11597879|NCT00662714|Active Comparator|2|short-acting Insulin (Actrapid)
11597880|NCT00662701|Active Comparator|1|Catheter RF ablation with complete circumferential ablation around the right and PVs, and additional lines between the lower and upper PVs, and towards the mitral valve ring.
11597881|NCT00662701|Active Comparator|2|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
11597882|NCT00662688|Active Comparator|chemotherapy|chemotherapy at investigator's discretion
11597883|NCT00662688|Experimental|dalteparin|dalteparin: 5000 UI sub-cutaneous injection, from Day 1 to Day 28.
11597884|NCT00662675|Experimental|001|Pancrease MT 10.5 or MT 21 Pancrease MT capsules for maximum dose of 10 000 lipase units / Kg / day
11597885|NCT00662675|Experimental|002|Placebo for Pancrease MT 10.5 or MT 21 Capsules with Pancrease MT excipients without the active enzymes
11597886|NCT00662662||Oropharyngeal Cancer|
11597887|NCT00662662||Non-Oropharyngeal Cancer|
11597888|NCT00662649|Experimental|Fingolimod 1.25 mg|Patients continued the same dose to which they had been randomized in the Core study (CFTY720D2301/NCT00289978), fingolimod 1.25 mg/day, in this Extension study.
11597889|NCT00662649|Experimental|Fingolimod 0.5 mg|Patients continued the same dose to which they had been randomized in the Core study, fingolimod 0.5 mg/day, in this Extension study.
11597890|NCT00662649|Experimental|Placebo-fingolimod|Patients randomized to placebo in the Core study were re randomized to fingolimod (either 0.5 or 1.25 mg/day) in this Extension study.
11597891|NCT00662649|Experimental|Placebo-fingolimod 1.25 mg|Patients randomized to placebo in the Core study were re randomized to fingolimod 1.25 mg/day in this Extension study.
11597892|NCT00662649|Experimental|Placebo-fingolimod 0.5 mg|Patients randomized to placebo in the Core study were re randomized to fingolimod 0.5 mg/day in this Extension study.
11597893|NCT00662636|Experimental|Arm I|Patients receive oral dasatinib and lapatinib ditosylate once daily on days 1-28.
11597894|NCT00662623|Experimental|1|
11597895|NCT00662623|Active Comparator|2|Usual Care (Standard Care)
11597896|NCT00662610|Experimental|naproxcinod 375 mg - 750 mg -1125 mg bid|dose escalating
11597897|NCT00662610|Active Comparator|naproxen 250 mg -500 mg -750 mg bid|dose escalating
11597898|NCT00662597|Experimental|ASA404|
11597899|NCT00662597|Placebo Comparator|ASA40 Placebo|
11597900|NCT00662584|Experimental|1|This was an open-label study - all subjects received the intervention (rTMS treatment)
11597901|NCT00662571||A|"Our hypothesis is that effective acamprosate response in alcohol dependent subjects may be influenced by genetically controlled variation in the functionality of the N-methyl-D-aspartate receptor (NMDA) and/or the type 5 metabotropic glutamate receptor (mGluR5). Hypothesis confirmation could lead to development of effective individualized treatment recommendations for alcohol dependent patients based on pharmacogenomically relevant genetic variations.
~There will be no placebo drug given. Just measurement of genetic response."
11597902|NCT00662558|Experimental|celecoxib|
11597903|NCT00662558|Active Comparator|tramadol|
11597904|NCT00662545|Experimental|A|Entecavir 1 mg for 24 weeks in addition to continued standard of care antiretroviral therapy containing tenofovir in addition to emtricitabine or lamivudine
11597905|NCT00662545|Active Comparator|B|continued standard of care antiretroviral therapy which will include tenofovir in addition to emtricitabine or lamivudine
11597906|NCT00662532|Experimental|Minocycline HCl|1 mg microspheres of minocycline hydrochloride
11597907|NCT00662532|No Intervention|No Intervention|Control group receiving no drug intervention
11597908|NCT00662519|Experimental|Neulasta|Subjects will receive Neulasta subcutaneously every 2 weeks for 12 weeks (6 doses). In addition, the following test will be done: Mixed Meal Tolerance Test (MMTT), Hemoglobin A1C (HbA1c) blood test, and Human Leukocyte Antigen (HLA) DNA Test.
11597909|NCT00662519|Placebo Comparator|Placebo|Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. In addition, the following test will be done: Mixed Meal Tolerance Test (MMTT), Hemoglobin A1C (HbA1c) blood test, and Human Leukocyte Antigen (HLA) DNA Test.
11597910|NCT00662506|Experimental|Treatment (enzyme inhibitor therapy, chemotherapy, IMRT)|See Detailed Description
11597911|NCT00662493|Experimental|1|Motor control retraining program
11597912|NCT00662480|Experimental|1|Invited to screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm
11597913|NCT00662480|No Intervention|2|Participants which are not offered vascular screening
11597914|NCT00662467|Active Comparator|1|aspirin and clopidogrel
11597915|NCT00662467|Experimental|2|aspirin, clopidogrel, and warfarin
11597916|NCT00662454|Active Comparator|I|10 normal weight women (BMI < 25 kg/m2)
11597917|NCT00662454|Active Comparator|II|10 obese women (BMI >30 kg/m2)
11597918|NCT00662441|Experimental|Arm 1|
11597919|NCT00662428|Experimental|Intervention|
11597920|NCT00662428|Active Comparator|Control|
11597921|NCT00662415|Other|1|12 non-amputee control subjects will be scanned at 0, 2 and 4 weeks but will not recieve mirror therapy.
11597922|NCT00662415|Experimental|2|24 unilateral lower extremity amputee subjects will recieve daily mirror therapy for phantom limb pain and will be scanned at 0, 2, and 4 weeks.
11597923|NCT00662402|Experimental|1-Extensive Consultations|Intervention- Receives extensive consulting services
11597924|NCT00662402|No Intervention|2-Regular levels of service|Control - Receives regular levels of service; one hour free services from each of the 4 units, with option to pay for more.
11597925|NCT00662389|Experimental|A|
11597926|NCT00662376|Experimental|Test|oral nutritional supplement (assignment: according to consecutive random numbers)
11597927|NCT00662376|Placebo Comparator|Control|placebo (assignment: according to consecutive random numbers)
11597928|NCT00662363|Experimental|Lubiprostone and placebo Senna|Lubiprostone (Amitiza) 24 µg po BID given with meals for 6 days with two tabs placebo Senna at noon
11597929|NCT00662363|Active Comparator|Senna active plus Lubiprostone Placebo|Senna 2 tabs daily for 6 days at noon and placebo Lubiprostone 1 Cap BID
11597930|NCT00662350||Symptomatic Benign Protate Hypertrophy|Symptom Score (IPSS) greater than 15, requiring invasive treatment, Prostate size greater than 25 g, Prostatic urethra length between 2.0 cm and 5.5 cm
11597931|NCT00662337|Experimental|1|Diphenydramine HCl
11597932|NCT00662324||1|Trial experienced cancer patients and their primary caregivers.
11597933|NCT00662324||2|Trial naive cancer patients and their caregivers.
11597934|NCT00662324||3|Health care professionals who are involved in running Phase I, II or III clinical trials.
11597935|NCT00662311|Experimental|Treatment (vorinostat with paclitaxel and radiotherapy)|Patients receive vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.
11597936|NCT00662298|Experimental|Severe Asthma|
11597937|NCT00662285|Other|A: Niferex|100 mg Fe++
11597938|NCT00662272|Experimental|1|Arm includes treatment with Fluzone® vaccine mixed with study product JVRS-100 adjuvant
11597939|NCT00662272|Active Comparator|2|Arm includes treatment with half adult dose of Fluzone® vaccine
11597940|NCT00662272|Active Comparator|3|Arm includes treatment with full adult dose Fluzone® vaccine
11597941|NCT00662259|Experimental|alprazolam|Alprazolam, an FDA-approved drug, will be administered to 24 patients with generalized anxiety disorder.
11597942|NCT00662259|Placebo Comparator|placebo|A placebo comparator will be administered to 12 patients with generalized anxiety disorder
11597943|NCT00662246|Experimental|1|"Primary objectives :
~to determine the recommended dose (i.e., the safest and most effective dose) by evaluating frequency of patients developing unacceptable (grade 3 or higher) acute toxicities attributable to proton beam radiotherapy for HCC."
11597944|NCT00662220|Active Comparator|Standard dose|Standard-dose ribavirin (12-15 mg/kg/day) in combination with peginterferon 180µg QW
11597945|NCT00662220|Experimental|High dose|High-dose ribavirin (25-29 mg/kg/day) in combination with peginterferon 180µg QW
11597946|NCT00662207|Experimental|Arm 1|Use a vibrator on the patient's bottom to determine if it will induce a bladder contraction; Use an anal dilator to determine if urethral relaxation will occur
11597947|NCT00662194||1|HIV-HBV co-infected and receiving anti-retroviral therapy (ART) and CD4 count > 500cells/mm3
11597948|NCT00662194||2|HIV-HBV co-infected and receiving ART and CD4 count 200-500 cells/mm3
11597949|NCT00662194||3|HIV-HBV co-infected and receiving ART and CD4 count <200cells/mm3
11597950|NCT00662194||4|HIV-HBV co-infected and not receiving ART
11597951|NCT00662194||5|HIV-HCV co-infected & receiving anti-retroviral therapy (ART) and CD4 count > 500cells/mm3
11597952|NCT00662194||6|HIV-HCV co-infected and receiving ART and CD4 count 200-500 cells/mm3
11597953|NCT00662194||7|HIV-HCV co-infected and receiving ART and CD4 count <200cells/mm3
11597954|NCT00662194||8|HIV-HCV co-infected and not receiving ART
11597955|NCT00662181||H, NH|HIV positive patients with and without lipodystrophy
11597956|NCT00662168||observation|Individuals with a diagnosis of carcinoid carcinoma
11597957|NCT00662155|Experimental|Continuous 1 (QHS-10)|continued nightly use with 10mg zolpidem
11597958|NCT00662155|Experimental|Partial Reinforcement (PRS-10)|partial reinforcement with 10mg zolpidem (PRS-10 [nightly pill use with 50% active meds and 50% placebos])
11597959|NCT00662155|Experimental|Intermittent (IDS-10)|intermittent dosing with 10mg zolpidem
11597960|NCT00662155|Experimental|Continuous 2 (QHS-5)|continued nightly use with 5mg zolpidem
11597961|NCT00662142|Experimental|1|DHA 400 mg/day (200mg twice daily), vs DHA 1200 mg/day (400 mg three times daily), vs placebo; 1:1:1 ratio
11597962|NCT00662129|Experimental|paclitaxel + gemcitabine + bevacizumab|"Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Quality of life is assessed at baseline and after every other course, and then after completion of treatment.
~After completion of study treatment, patients are followed periodically for 5 years."
11597963|NCT00662116|Experimental|1|
11597964|NCT00662116|Placebo Comparator|2|
11597965|NCT00662103|Active Comparator|progressive, aerobic exercise program|Patients undergo aerobic exercise training over approximately 45 minutes (not including warm-up or cool-down exercises) 3 days a week for 18 months.
11597966|NCT00662103|Active Comparator|progressive, resistance exercise program|Patients undergo resistance exercise training 3 days a week for 18 months.
11597967|NCT00662103|Active Comparator|flexibility and relaxation training [control]|Patients perform a series of whole body flexibility (stretching) and relaxation (guided imagery, progressive neuromuscular relaxation, focused breathing) exercises 3 days a week for 18 months.
11597968|NCT00662077|Experimental|1|Ibandronate + Lifestyle modifications
11597969|NCT00662077|Other|2|Lifestyle modifications
11597970|NCT00662064||1|Patients with lower urinary tract dysfunction
11597971|NCT00662064||2|Controls with normal lower urinary tract function
11597972|NCT00662051||OCP Users|
11597973|NCT00662051||Non-users of OCPs|
11597974|NCT00662038|Experimental|Treatment|pirfenidone
11597975|NCT00662025|Experimental|1|
11597976|NCT00662012|Experimental|Sodium Stibogluconate (SSG) 20 mg/kg|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with 20 mg/kg once daily intravenously with SSG.
11598093|NCT00661219|Placebo Comparator|Arm 2|
11597977|NCT00661999|Experimental|Arm I|Patients receive darbepoetin alfa subcutaneously and sodium ferric gluconate complex IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
11597978|NCT00661999|Experimental|Arm II|Patients receive darbepoetin alfa as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
11597979|NCT00661999|Experimental|Arm III|Patients receive darbepoetin alfa as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
11597980|NCT00661986|Experimental|1|dark chocolate 6 g/day
11597981|NCT00661986|Active Comparator|2|dark chocolate 25 g/day
11597982|NCT00661973|Experimental|overall|
11597983|NCT00661960|No Intervention|1|HIV Negative volunteers
11597984|NCT00661960|Active Comparator|2|HIV-Positive volunteers taking raltegravir in combination with two other nucleoside reverse transcriptase inhibitors (NRTI) medications
11597985|NCT00661960|Active Comparator|3|HIV-Positive volunteers taking efavirenz or any other non-nucleoside reverse transcriptase inhibitors (NNRTI) in combination with two other nucleoside reverse transcriptase inhibitor (NRTI) medications
11597986|NCT00661947||Public|General public. Those who are not currently taking any medication besides birth control pills.
11597987|NCT00661934||1|Dialysis Group
11597988|NCT00661934||2|Cardiac Malfunction Group
11597989|NCT00661921|Active Comparator|40 mg AMG 108 Q2W|
11597990|NCT00661921|Active Comparator|150 mg AMG 108 Q2W|
11597991|NCT00661921|Active Comparator|75 mg AMG 108 Q2W|
11597992|NCT00661921|Placebo Comparator|Placebo Q2W|
11597993|NCT00661908||1|insulin-treated diabetic subjects of North-western part of Switzerland
11597994|NCT00661895|Experimental|Intervention|Intervention group subjects will receive education and assistance from a Community Health Center or Cardiac Center nurse practitioner or physician, health educator, dietitian, social worker, and Cardiac Center-trained community members called Community Health Advocates (CHAs).
11597995|NCT00661895|Active Comparator|Control|No intervention
11597996|NCT00661869|Active Comparator|Wellness Group|
11597997|NCT00661856|Active Comparator|1|Soy Protein group 25g of Soy protein with no Isoflavones
11597998|NCT00661856|Experimental|2|Soy Isoflavone group 25g of Soy Protein with 90mg of Isoflavones
11597999|NCT00661856|Placebo Comparator|3|25g of Milk protein
11598000|NCT00661843|Experimental|1|Intervention group: Intervention constitutes of 2 supervised yoga classes per week incorporating gentle Yoga postures, relaxation and meditation sequences In addition: daily home based sessions of yogic relaxation and meditation using a pre-recorded audio CD
11598001|NCT00661843|No Intervention|2|Control in waiting to be crossed over after control phase completed. Participants of this group studied using same objective and subjective outcome measures.
11598002|NCT00661830|Experimental|1|Gemcitabine + Sorafenib
11598003|NCT00661830|Placebo Comparator|2|Gemcitabine + Placebo
11598004|NCT00661817|Active Comparator|1|Participants in this group will receive usual medical care and reading materials on weight loss.
11598005|NCT00661817|Experimental|2|Participants in this group will take part in the lifestyle modification program.
11598006|NCT00661804||Thalassemia cohort|"Thalassemia as documented by clinical diagnosis, including:
~thalassemia (intermedia or major); HbH disease; HbH with non-deletional mutations, e.g., HbH Constant Spring E beta-thalassemia; Homozygous alpha-thalassemia (i.e., 4-gene alpha deletion or equivalent null alpha mutation); Other thalassemic conditions not explicitly excluded; Thalassemia intermedia due to heterozygous beta mutation with alpha-gene excess."
11598007|NCT00661804||Successful SCT cohort|Individuals who have received a successful hematopoietic SCT, defined as engraftment of all three cell lines and transfusion independence by 100 days post-transplant, for any of the disorders listed above;Monitored for end-organ injury related to thalassemia prior to their successful SCT;Participants who were enrolled in TCRN Registry or had a successful SCT after 01 Jan 2002.
11598008|NCT00661791|No Intervention|A|Control Group receives routine care.
11598009|NCT00661791|Experimental|B.|massage group, receives massage only.
11598010|NCT00661791|Experimental|C.|Massage and Exercise group, receives both massage and exercise.
11598011|NCT00661778|Experimental|Bevacizumab + cisplatin + docetaxel|Participants received bevacizumab 15 mg/kg intravenously (IV) followed by docetaxel 75 mg/kg IV in combination with cisplatin 75 mg/m^2 IV on Day 1 of each 3-week cycle for a maximum of 6 cycles. After completing the 6 cycles of combined chemotherapy, participants received bevacizumab 15 mg/kg IV until disease progression, unacceptable toxicity, or withdrawal of consent.
11598012|NCT00661765|Active Comparator|Chantix immediate release tablet formulation|
11598013|NCT00661765|Experimental|Varenicline transdermal delivery system|
11598014|NCT00661752||FBP studies|standard filtered backprojection image processing/reconstruction of full-time acquisition data
11598015|NCT00661752||half-time WBR|wide-beam reconstruction of simulated half-time acquisitions from standard full-time acquisitions
11598016|NCT00661752||Quarter-time stress|4 seconds per stop post-stress SPECT acquisitions reconstructed by the wide-beam reconstruction method
11598017|NCT00661752||Quarter-time rest|6 seconds per stop rest SPECT acquisitions reconstructed by the wide-beam reconstruction method
11598018|NCT00661739|Experimental|Singular Arm|Bendamustine treatment
11598019|NCT00661726|Experimental|1|Participants will receive injected decitabine for 12 weeks.
11598020|NCT00661713|Experimental|rMenB06|Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and two injections of placebo (at month 1, month 2). A second injection of rMenB+OMV NZ vaccine was given later (month 6).
11598021|NCT00661713|Experimental|rMenB0|Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and three injections of placebo (month 1, month 2 and month 6).
11598022|NCT00661713|Experimental|rMenB016|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).
11598023|NCT00661713|Experimental|rMenB01|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and two injection of placebo (at month 2 and month 6).
11598094|NCT00661206|Active Comparator|Clopidogrel|
11598024|NCT00661713|Experimental|rMenB026|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).
11598025|NCT00661713|Experimental|rMenB02|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and two injections of placebo (at month 1 and month 6).
11598026|NCT00661713|Experimental|rMenB012|Subjects received three injections of rMenB+OMV NZ vaccine (at month 0, month 1 and month 2) and one injection of placebo later (at month 6).
11598027|NCT00661713|Experimental|rMenB6|Subjects received three injections of placebo(at month 0, month 1 and month 2) and one injection of rMenB+OMV NZ vaccine(at month 6).
11598028|NCT00661700|Placebo Comparator|Arm 2|
11598029|NCT00661700|Experimental|Arm 1|
11598030|NCT00661687|Active Comparator|Purevision Contact Lens #1|PureVision Soft Contact Lens Design (currently marketed)
11598031|NCT00661687|Experimental|PureVision Contact Lens #2|Redesign of the currently marketed PureVision soft contact lens.
11598032|NCT00661674|Experimental|Sequence 1: Placebo, Combo, Palonosetron|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.
~Week 1: Placebo
~Week 2: Palonosetron + Hydroxyzine Combo
~Week 3: Palonosetron"
11598033|NCT00661674|Experimental|Sequence 2: Palonosetron, Combo, Placebo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.
~Week 1: Palonosetron
~Week 2: Palonosetron + Hydroxyzine Combo
~Week 3: Placebo"
11598034|NCT00661674|Experimental|Sequence 3: Combo, Placebo, Palonosetron|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.
~Week 1: Palonosetron + Hydroxyzine Combo
~Week 2: Placebo
~Week 3: Palonosetron"
11598035|NCT00661674|Experimental|Sequence 4: Placebo, Palonosetron, Combo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.
~Week 1: Placebo
~Week 2: Palonosetron only
~Week 3: Palonosetron + Hydroxyzine Combo"
11598036|NCT00661674|Experimental|Sequence 5: Combo, Palonosetron, Placebo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.
~Week 1: Palonosetron + Hydroxyzine Combo
~Week 2: Palonosetron only
~Week 3: Placebo"
11598037|NCT00661674|Experimental|Sequence 6: Palonosetron, Placebo, Combo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.
~Week 1: Palonosetron only
~Week 2: Placebo
~Week 3:Palonosetron + Hydroxyzine Combo"
11598038|NCT00661661|Experimental|CP-690,550|
11598039|NCT00661648|No Intervention|1|glucose levels were controlled using sliding scale
11598040|NCT00661648|Experimental|2|received programmed infusions of insulin determined by the control algorithm of the artificial pancreas
11598041|NCT00661635|Active Comparator|Arm 1|
11598042|NCT00661635|Active Comparator|Arm 2|
11598043|NCT00661635|Placebo Comparator|Arm 3|
11598044|NCT00661622|Experimental|Immunoembolization|Liver embolization treatment with injection of GM-CSF.
11598045|NCT00661622|Active Comparator|Plain embolization|Liver embolization with normal saline injected in place of GM-CSF
11598046|NCT00661609|Experimental|AZD4877|Single agent AZD4877
11598047|NCT00661596|Experimental|Arm 1|
11598048|NCT00661596|Placebo Comparator|Arm 2|
11598049|NCT00661583|Experimental|Ranibizumab alone|Treatment with ranibizumab 0.5 mg intravitreally injected (n=10)
11598050|NCT00661583|Experimental|Ranibizumab and MMC|Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10)
11598051|NCT00661583|Active Comparator|MMC alone|MMC therapy alone (n=10)
11598052|NCT00661570|Experimental|Early feasability arm|
11598095|NCT00661206|Placebo Comparator|Placebo|
11598053|NCT00661557|Experimental|Mencevax Primed Group|Subjects who were previously vaccinated with meningococcal vaccine Mencevax ACWY in study NCT00227422 received in the current study a single dose of meningococcal conjugate vaccine Nimenrix, administered intramuscularly in the deltoid muscle of the non-dominant arm.
11598054|NCT00661557|Active Comparator|Mencevax Naive Group|Subjects who did not receive (or had not received in the preceding 10 years) any meningococcal vaccination received in the current study a single dose of meningococcal conjugate vaccine Nimenrix, administered intramuscularly in the deltoid muscle of the non-dominant arm.
11598055|NCT00661544|Experimental|Arsenic Trioxide + Vitamin C + Melphalan|Arsenic Trioxide + Ascorbic Acid + Melphalan as a preparative regimen for autologous stem cell transplantation (delivered on Day 0)
11598056|NCT00661531|Experimental|Estrace & Anastrozole|Estrace 10 mg three times a day for 3 months. After 3 months of estrace, the estrace will be stopped and anastrazole 1 mg daily will be administered
11598057|NCT00661518||1|Patients scheduled for conventional aneurysm repair
11598058|NCT00661518||2|Patients scheduled for endovascular aneurysm repair
11598059|NCT00661505|Experimental|C.E.R.A. 120, 200, or 360 mcg|Eligible participants were administered Continuous Erythropoietin Receptor Activator (C.E.R.A.) at a dose of 120, 200, or 360 microgram (mcg), intravenously (IV), every 4 weeks i.e. Weeks 4, 8, 12, 16 and 20 but not on Weeks 24 and 28. The initial dose of C.E.R.A.was based on the last dose of the previous Erythropoiesis Stimulating Agent (ESA). The ESA therapy was administered from enrollment to the 4 weeks stability verification period (SVP), weekly, either as epoetin (<8000 IU, 8000-16000 IU, or >16000 IU) or darbepoetin alpha (<40 mcg, 40-80 mcg, or >80 mcg). A telephone follow-up visit took place 4 weeks after the end of C.E.R.A. treatment (Week 28).
11598060|NCT00661492|Experimental|Arm 1|Erbitux (cetuximab) and Novantrone (mitoxantrone)
11598061|NCT00661492|Experimental|Arm 2|Novantrone (mitoxantrone)
11598062|NCT00661479|Experimental|400 µg Brimonidine Tartrate Implant Group B|400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
11598063|NCT00661479|Experimental|200 µg Brimonidine Tartrate Implant Group B|200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
11598064|NCT00661479|Experimental|100 µg Brimonidine Tartrate Implant Group B|100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
11598065|NCT00661479|Experimental|100 µg Brimonidine Tartrate Implant Group A|100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
11598066|NCT00661466|Experimental|1|Either three or four 5x5-cm bupivacaine sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
11598067|NCT00661466|Placebo Comparator|2|Either three or four 5x5-cm placebo sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
11598068|NCT00661453|Experimental|1|All patients will receive VPA and carnitine.
11598069|NCT00661440|Other|1|
11598070|NCT00661440|Other|2|
11598071|NCT00661427|Active Comparator|Cetuximab 500 mg/m^2|Cetuximab 500 mg/m^2 IV over 2 hours every other week
11598072|NCT00661427|Active Comparator|Cetuximab 750 mg/m^2|Cetuximab 750 mg/m^2 IV over 3 hours every other week
11598073|NCT00661388|Experimental|Continuous erythropoietin receptor activator (C.E.R.A.)|Eligible participants will be administered C.E.R.A subcutaneously, every 4 weeks for 44 weeks. The initial dose of C.E.R.A. will be 1.2 micrograms/kilogram. Subsequent doses will be adjusted to maintain the individual participant's hemoglobin within the target range of 10.0 and 12.0 grams/deciliter.
11598074|NCT00661375|Experimental|Arm 1|
11598075|NCT00661362|Experimental|1|Metformin + Saxagliptin
11598076|NCT00661362|Placebo Comparator|2|Metformin + Placebo
11598077|NCT00661349|Active Comparator|1|Nevirapine
11598078|NCT00661349|Experimental|2|Lopinavir/ritonavir
11598079|NCT00661323||1|Healthy volunteers will be recruited through the use of an approved study recruitment flyer.
11598080|NCT00661323||2|Chemotherapy patients will be approached at the time of their nuclear scan to rule out cardiac disease prior to chemotherapy. These patients will be referred to the study by their doctor for the assessment of heart function.
11598081|NCT00661310|Experimental|I|Intervention by team consisting of Doctor, pharmacist and nurse
11598082|NCT00661310|No Intervention|C|
11598083|NCT00661297|Experimental|Arm 1|
11598084|NCT00661297|Placebo Comparator|Arm 2|
11598085|NCT00661284||Ⅰ|Subject who have participated in previous studies and achieved DAS28 of < 3.2 at the last observation and at least one time point among the two previous assessment time points in a previous studies.
11598086|NCT00661271|Experimental|Mindfulness-Based Stress Reduction|8-week mindfulness-based stress reduction program with one retreat session
11598087|NCT00661271|Active Comparator|Healthy Topics|8-week health education program with one retreat session - based on a health curriculum developed by McGraw/Hill
11598088|NCT00661258|Experimental|Intervention|The intervention group patients were given their electronic drug monitoring feedback data at each monthly visit. The study coordinator would quickly calculate whether the patient's adherence was below 95% in the previous month. If so, that patient was flagged for enhanced counseling with a clinic doctor and this counseling was based on a printout containing the electronic drug monitoring data.
11598089|NCT00661258|No Intervention|Comparison|"The comparison group patients were not given the data from the electronic data monitoring feedback data. Instead, they filled out a self report form that all patients fill out. If they indicated in this report that their adherence in the previous was less than 95%, then they were flagged for enhanced counseling with a doctor. This counseling was based on the patient's self report. Thus both groups received enhanced counseling if they indicated poor adherence, but only the intervention group were given their electronic data output."
11598090|NCT00661245|Experimental|TOGA|The TOGA procedure is an incision-free treatment using a set of flexible staplers introduced into the mouth and esophagus to create a sleeve in the stomach (transoral formation of a gastric sleeve). The TOGA sleeve limits the amount of food that can be eaten and gives the patient a feeling of fullness after a small meal.
11598091|NCT00661245|Sham Comparator|Control|A gastric sleeve is not formed.
11598092|NCT00661219|Active Comparator|Arm 1|
11598096|NCT00661193|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11598097|NCT00661193|Active Comparator|Arm II|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for 4 courses. Beginning in course 5 and for all subsequent courses, patients receive oral erlotinib hydrochloride alone on days 1-21. Courses with erlotinib hydrochloride repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11598098|NCT00661180|Experimental|Arm 1|
11598099|NCT00661167|Experimental|1|ABI-007
11598100|NCT00661141|Experimental|Cohort 1: Antizol 1.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 1.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.
11598101|NCT00661141|Experimental|Cohort 2: Antizol 3.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 3.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.
11598102|NCT00661141|Experimental|Cohort 3: Antizol 5.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 5.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.
11598103|NCT00661141|Experimental|Cohort 4: Antizol 1.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 7.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.
11598104|NCT00661128||1|European American people who have experienced SCA.
11598105|NCT00661128||2|European American people who have not experienced SCA.
11598106|NCT00661128||3|African American people who have experienced SCA.
11598107|NCT00661128||4|African American people who have not experienced SCA.
11598108|NCT00661115|Experimental|Arm 1|
11598109|NCT00661115|Placebo Comparator|Arm 2|
11598110|NCT00661102|Experimental|1|
11598111|NCT00661102|Active Comparator|2|
11598112|NCT00661102|Placebo Comparator|3|
11598113|NCT00661089|Experimental|Intramuscular OnabotulinumtoxinA|Injection of Botulinum Toxin type A - onabotulinumtoxinA into specified shoulder muscles at second visit
11598114|NCT00661089|Active Comparator|Intramuscular Placebo (Saline)|Injection of saline into specified shoulder muscles at Visit 2. Blind broken and subjects were offered study drug if initially in the placebo group, at week 12
11598115|NCT00661076|Experimental|1|
11598116|NCT00661076|Experimental|2|
11598117|NCT00661076|Active Comparator|3|
11598118|NCT00661063|Experimental|K|drug - ketamine 1% gel
11598119|NCT00661063|Placebo Comparator|P|vehicle gel
11598120|NCT00661063|Experimental|M|association of ketamine and clonidine gel
11598121|NCT00661063|Experimental|C|clonidine gel
11598122|NCT00661037||1|Patients having VF induction with shock termination at implant
11598123|NCT00661037||2|Patients not having VF induction at implant or during follow-up
11598124|NCT00661024|Placebo Comparator|1|RLN visualization alone
11598125|NCT00661024|Experimental|2|IONM of the RLN
11598126|NCT00661011|Experimental|A|Lobectomy followed by mediastinal concomitant chemoradiotherapy
11598127|NCT00660998|Experimental|Arm 1|
11598128|NCT00660998|Placebo Comparator|Arm 2|
11598129|NCT00660985|Experimental|Differin® Gel, 0.3%|Gel, 0.3%, 2g, once daily for 30 days
11598130|NCT00660985|Active Comparator|Differin® Gel, 0.1%|Gel, 0.1%, 2g, once daily for 30 days
11598131|NCT00660972|Experimental|1|Oral RAL and FTC/TDF for 72 weeks
11598132|NCT00660959|Experimental|Active Comparator|lixivaptan
11598133|NCT00660959|Placebo Comparator|Placebo|placebo
11598134|NCT00660946||37 dialysis patients|37 chronic hemodialysis patients on warfarin requiring Laboratory INR monitoring for anticoagulation management.
11598135|NCT00660933|Active Comparator|Group A|Group A: Administration of intravenous iron sucrose.
11598136|NCT00660933|Placebo Comparator|Group B|Group B: Administration of intravenous NaCl 0,9%.
11598137|NCT00660920|Experimental|ponatnib|Comparison of different dosages of ponatinib given orally once per day.
11598138|NCT00660907|Experimental|1|dapagliflozin plus metformin
11598139|NCT00660907|Active Comparator|2|glipizide plus metformin
11598140|NCT00660894|Experimental|tegafur-gimeracil-oteracil potassium|Patients receive tegafur-gimeracil-oteracil potassium(S-1) orally twice daily for 28 days with a subsequent pause of 14 days. This repeats 4 times every 6 weeks.
11598141|NCT00660894|Active Comparator|tegafur-uracil and folinate calcium|Patients receive tegafur-uracil(UFT) plus folinate calcium(leucovorin) orally every 8 hours for 21 days with a subsequent pause of 7 days. This repeats 5 times every 5 weeks.
11598142|NCT00660881|Experimental|EMAB|1200 mg epratuzumab given in 2 doses every other week in 12 week treatment cycles.
11598143|NCT00660868||1|Patients with posttraumatic, idiopathic, and postinflammatory cause of smell loss; patients age between 18 and 50 years. Odor threshold better than 1.
11598144|NCT00660855|Other|Arm 1|
11598145|NCT00660842|Experimental|A|weekly chemotherapy
11598146|NCT00660842|Active Comparator|B|every 3 weeks chemotherapy
11598147|NCT00660829|Placebo Comparator|1|Placebo
11598148|NCT00660829|Active Comparator|2|0.15% Azelastine Hydrochloride
11598149|NCT00660816|Active Comparator|Arm I|Patients receive pemetrexed disodium IV over 10 minutes OR docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive standard chemotherapy with or without erlotinib hydrochloride in the absence of disease progression or unacceptable toxicity.
11598150|NCT00660816|Experimental|Arm II|Patients receive pemetrexed disodium IV over 10 minutes OR docetaxel IV over 60 minutes on day 1 and erlotinib hydrochloride PO once daily on days 2-19. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive standard chemotherapy with or without erlotinib hydrochloride in the absence of disease progression or unacceptable toxicity.
11598229|NCT00660179|Experimental|1|Macitentan (ACT-064992) tablet, 3 mg, once daily
11598151|NCT00660803||1|Postmenopausal women with hormone-receptor positive, advanced breast cancer who have failed at least one previous endocrine therapy and who have been treated at any one of the participating centres with fulvestrant.
11598152|NCT00660790||Patients with Type 2 Diabetes|diabetic subjects, above targets
11598153|NCT00660777|Sham Comparator|1|Control Group
11598154|NCT00660777|Active Comparator|2|Therapy Group
11598155|NCT00660764||1|Patients eligible for the study were patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C ≥ 3.2 mmol/l. Patients were aged ≥ 18 years and ≤ 70 years (men) and ≤ 75 years (women), according to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention. The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation. Patient approved to place anonymous results at the disposal of AstraZeneca
11598156|NCT00660751|Active Comparator|1|
11598157|NCT00660751|Placebo Comparator|2|
11598158|NCT00660738||01|Patients with clinical and spirometric diagnosis of COPD, with FEV1<80%
11598159|NCT00660725|Other|Vandetanib/GEMOX|All subjects receive the same combination study drug and follow the same study schedule. As a phase 1 study, only the doses will vary between subjects.
11598160|NCT00660712||1|Patients with bipolar disorder
11598161|NCT00660699|Experimental|Arm 1 (gemcitabine, docetaxel, 5FU, radiation)|"Gemcitabine 1000 mg/m2 IV on Day 1 and Day 8 of a 21 day cycle for 2 cycles
~Docetaxel 35 mg/m2 IV on Day 1 and Day 8 of a 21 day cycle for 2 cycles
~5FU CIVI 225 mg/m2 per day throughout radiation (starts 3 weeks after start of cycle 2)
~Radiation 5040 cGy or 5400 cGy for positive margins (starts 3 weeks after start of cycle 2). Daily dose of 1.8 Gy five days per week.
~Gemcitabine 1000 mg/m2 IV on Days 1 and 8 of 21 day cycle for 2 cycles (this starts 4 weeks after radiation)
~Docetaxel 35 mg/m2 IV on Days 1 and 8 of 21 day cycle for 2 cycles (this starts 4 weeks after radiation)"
11598162|NCT00660686|Experimental|1|Progressive resistance training program 3 times a week for 12 months
11598163|NCT00660686|Active Comparator|2|Seated flexibility training 3 times a week for 12 months
11598164|NCT00660673|Experimental|1|Levodopa-carbidopa intestinal gel
11598165|NCT00660660|Experimental|Nexium 20mg|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
11598166|NCT00660660|Placebo Comparator|Placebo|
11598167|NCT00660647|Experimental|methotrexate + adalimumab|Methotrexate and intraarticular triamcinolone hexacetonide plus adalimumab.
11598168|NCT00660647|Placebo Comparator|methotrexate + placebo|Methotrexate and intraarticular triamcinolone hexacetonide and placebo
11598169|NCT00660634|No Intervention|B|
11598170|NCT00660634|Experimental|A|Endovascular angioplasty/stenting
11598171|NCT00660595|Experimental|1|Oral
11598172|NCT00660595|Active Comparator|2|Oral
11598173|NCT00660569||1|Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion, previously treated with Pulmicort chlorofluorocarbons (CFC) who have changed their treatment to Pulmicort HFA
11598174|NCT00660543|Experimental|Ferumoxytol|Patients receive ferumoxytol non-stoichiometric magnetite IV on day 2 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose). Ferumoxytol non-stoichiometric magnetite administration continues in the absence of unacceptable toxicity.
11598175|NCT00660543|Active Comparator|Gadoteridol|Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).
11598176|NCT00660543|Active Comparator|Gadoteridol Leakage Corrected|Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).
11598177|NCT00660530|Active Comparator|1|One week before the administration of crushed or chewed lanthanum, the subjects were instructed to discontinue their P-binding agents, if prescribed previously. At the end of the 1-week washout period, subjects whose serum P exceeded 5.5 mg/dL were randomized to receive, in a crossover fashion, lanthanum 1000 mg (Fosrenol, Shire US Inc., Wayne, PA, USA) 3 times daily to be chewed with meals (chewed LAN) or lanthanum 1000 mg crushed into a ﬁne powder and taken with meals 3 times daily (crushed LAN), for 4 weeks each. The lanthanum tablets were crushed into a ﬁne powder using a mortar and pestle by the investigators, individually wrapped in powder packets and dispensed to the subjects on a weekly basis. The subjects were instructed to empty the powder into a small plastic cup provided, mix with 2 tablespoonfuls of applesauce and take it with meals. After each treatment (chewed or crushed LAN), there was a 1-week washout period.
11598178|NCT00660530|Experimental|2|After the one-week washout period, the subject received the other lanthanum treatment (chewed or crushed) that they did not receive in the initial treatment period.
11598179|NCT00660517|Experimental|MP29-02|azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray
11598180|NCT00660517|Active Comparator|azelastine Hcl 548 mcg|azelastine Hcl 548 mcg nasal spray
11598181|NCT00660517|Active Comparator|fluticasone propionate 200 mcg|fluticasone propionate 200 mcg nasal spray
11598182|NCT00660517|Placebo Comparator|placebo|placebo nasal spray
11598183|NCT00660504|Experimental|1|Amrubicin Hydrochloride-Cisplatin combined chemotherapy
11598184|NCT00660504|Active Comparator|2|Etoposide-Cisplatin combined chemotherapy
11598185|NCT00660491|No Intervention|1|Control
11598186|NCT00660491|No Intervention|2|moderate exercise training group
11598187|NCT00660491|Experimental|3|high intensity exercise group
11598188|NCT00660478|Active Comparator|1|Zotarolimus eluting stent
11598189|NCT00660478|Active Comparator|2|Sirolimus stent
11598190|NCT00660465||A18|
11598191|NCT00660452|Active Comparator|1|360 active patients with house dust mites related asthma with or without allergic rhinitis
11598192|NCT00660452|Placebo Comparator|2|180 patients in the placebo group with house -dust mites related asthma with or without allergic rhinitis.
11598193|NCT00660439|Experimental|A|Treatment group, receives Narrative Exposure Therapy immediately after first assessment. Patients are assessed 1 and 6 months after treatment.
11598194|NCT00660439|No Intervention|B|Waiting list control group, receives no intervention for 3 months after first assessment. A second assessment is then administered and patients receives Narrative Exposure Therapy. Patients are assessed 1 and 6 months after treatment.
11598195|NCT00660426|Experimental|Dose Level 1 (starting level)|"Oxaliplatin 85 mg/m2 IV on days 1 and 15.
~Gemcitabine 800 mg/m2 IV on days 1 and 15.
~Capecitabine 600 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.
~Each cycle is 28 days."
11598196|NCT00660426|Experimental|Dose Level 2|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.
~Gemcitabine 800 mg/m2 IV on days 1 and 15.
~Capecitabine 600 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.
~Each cycle is 28 days."
11598197|NCT00660426|Experimental|Dose Level 3|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.
~Gemcitabine 800 mg/m2 IV on days 1 and 15.
~Capecitabine 800 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.
~Each cycle is 28 days."
11598198|NCT00660426|Experimental|Dose Level 4|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.
~Gemcitabine 1000 mg/m2 IV on days 1 and 15.
~Capecitabine 800 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.
~Each cycle is 28 days."
11598199|NCT00660413|Experimental|AMG|Acceleromygraphy monitoring
11598200|NCT00660413|Active Comparator|MMG|Mechanomyography monitoring
11598201|NCT00660400|Experimental|Combined Therapy|5-azacitidine therapy followed Allogeneic Hematopoietic Cell Transplantation (HCT).
11598202|NCT00660387|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG) + Placebo Capsules|Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
11598203|NCT00660387|Active Comparator|Placebo Gel + Levodopa-Carbidopa Capsules|Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.
11598204|NCT00660374|Active Comparator|A|
11598205|NCT00660374|Experimental|B|
11598206|NCT00660361||A|individuals co-infected with HIV-HBV and receiving tenofovir as aprt of their HAART regimen
11598207|NCT00660348|Active Comparator|morphine|morphine given traditionally (IV, pill, patch). This is standard of care dosing.
11598208|NCT00660348|Active Comparator|Intrathecal pump|Pump internal used to deliver morphine. This is a newer method for delivery of morphine. Morphine is FDA approved for intrathecal use. The intrathecal pump will be titrated gradually to effect by the interventional pain medicine team. These are the maximum doses and concentrations in keeping with the Polyanalgesic Consensus Conference guidelines: Dose (mg/day):15 ; Conc (mg/cc): 20
11598209|NCT00660335|Experimental|1|
11598210|NCT00660322|No Intervention|Control|Families assigned to the control arm will receive usual asthma care from the child's primary care provider.
11598211|NCT00660322|Experimental|Intervention|The Telephone Asthma Program and usual care.
11598212|NCT00660309|Experimental|Aliskiren|On Day 1 participants received a single oral dose of 25 mg captopril. Starting on Day 2 participants received aliskiren 300 mg tablets orally once a day for 14 days.
11598213|NCT00660309|Active Comparator|Irbesartan|On Day 1 participants received a single oral dose of 25 mg captopril. Starting on Day 2 participants received irbesartan 300 mg tablets orally once a day for 14 days.
11598214|NCT00660296|Other|2|Air insufflation in colonoscopy
11598215|NCT00660296|Other|1|CO2 insufflation in colonoscopy
11598216|NCT00660270|Experimental|Arm 1|"Surgery (pancreaticoduodenectomy, either standard or pylorus-preserving, with either standard or extended lymph node dissection, with or without portal vein resection) should occur at 8 weeks (plus or minus 2, not to exceed 10)
~Radiation therapy will occur 8 weeks (plus or minus 2, not to exceed 10) postoperatively. Daily dose of 1.8 Gy five days per week. The first 45 Gy will be given to planning target volume 1. After 45 Gy, portals will be reduced to encompass planning target volume 2. The boost dose will be 5.4 Gy.
~Cisplatin IV 25 mg/m2 on days 1, 8, 15, 22, 29, and 36 during radiation.
~5-FU CIVI at 175 mg/m2/d on days 1-38 without interruption during radiation.
~Alpha-interferon SQ 3,000,000 units on Mondays, Wednesdays, and Fridays during radiation therapy.
~Gemcitabine IV 1000 mg/m2 4 weeks after conclusion of radiation (on a 3 weeks on/1 week off schedule) on days 71, 78, 85, 99, 106, and 113."
11598217|NCT00660257|Experimental|No.1: 1.25 ug|
11598218|NCT00660257|Experimental|No.2: 2.5 ug|
11598219|NCT00660257|Experimental|No.3: 5.0 ug|
11598220|NCT00660257|Experimental|No. 4: 10 ug|
11598221|NCT00660244||1|
11598222|NCT00660231|Experimental|GemBex|Gemcitabine days 1 and 8 of a 3 week cycle (4 cycles total - 12 weeks) Bexarotene daily: in combination with Gemcitabine during first 12 weeks, then Bexarotene maintenance until disease progression.
11598223|NCT00660218|Experimental|Radiation therapy, cetuximab, paclitaxel poliglumex|Radiation therapy to 69.96 Gy, 2.12 Gy per day for 33 treatments, starting week 2. Cetuximab loading dose of 400 mg/m² week 1, 250 mg/m² weekly for 7 weeks. Paclitaxel poliglumex starting week 2 40 mg/m².
11598224|NCT00660205||operation|Patients with upper gastro intestinal cancer who underwent surgery
11598225|NCT00660205||palliation|Patients with upper gastro intestinal cancer who did not underwent surgery
11598226|NCT00660205||control|Persons with no cancer who accepted to be control with blood samples and flow doppler ultrasound examination of both legs.
11598227|NCT00660192|Placebo Comparator|Placebo|Subjects are randomized to receive Placebo which is inactive saline (sterile salt water solution). The Subjects are injected with a comparable amount of placebo solution (2cc-3cc) as received by those randomized to receive active study drug. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.
11598228|NCT00660192|Active Comparator|Botox|Subjects are randomized to receive Active study drug Botox (onobotulinumtoxinA). The Botox is prepare by diluting 100units of toxin /1cc Saline. The Subjects are injected with 200-300units of units of Botox which is 2cc-3cc of solution. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.
11598230|NCT00660179|Experimental|2|Macitentan (ACT-064992) tablet, 10 mg, once daily
11598231|NCT00660179|Placebo Comparator|3|Matching placebo, once daily
11598232|NCT00660166|Experimental|1|
11598233|NCT00660153|Experimental|single arm; multiple cohort|Single arm; multiple cohort
11598234|NCT00660140|Experimental|Gemcitabine + Carboplatin|"Gemcitabine 1000 mg/m2 IV for 30 minutes on days 1 and 8 of 21 day cycle. Maximum of 9 cycles.
~Carboplatin AUC 5 IV for 1 hour on day 1 of 21 day cycle. Maximum of 9 cycles."
11598235|NCT00660101|Experimental|1|5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
11598236|NCT00660101|Experimental|2|2.5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
11598237|NCT00660101|Experimental|3|0.5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
11598238|NCT00660088||1|10 gram x 7 days, then 20 gram x 7 days active ingredient of original formulation
11598239|NCT00660088||2|20 grams x 14 days active ingredient of original formulation
11598240|NCT00660088||3|10 grams x 7 days; then 20 grams x 7 days of low protein formulation
11598241|NCT00660088||4|20 grams x 14 days of low protein formulation
11598242|NCT00660088||5|10 grams x 7 days; then 20 grams x 7 days of high protein formulation
11598243|NCT00660088||6|20 grams x 14 days of high protein formulation
11598244|NCT00660075|Experimental|1|Sitagliptin 100 mg/d for 6 weeks
11598245|NCT00660075|Placebo Comparator|2|Placebo for 6 weeks
11598246|NCT00660062|Experimental|Escitalopram 10 mg daily|Escitalopram 10 mg daily
11598247|NCT00660062|Experimental|Escitalopram 20 mg daily|Escitalopram 20 mg daily
11598248|NCT00660062|Experimental|escitalopram 30 mg daily|escitalopram 30 mg daily
11598249|NCT00660062|Active Comparator|Nortriptylin 100 mg daily|Nortriptylin 100 mg daily
11598250|NCT00660049|Experimental|SNaP application|"This is an open label pilot study of SNaP Advanced Wound Care System"
11598251|NCT00660036|Experimental|Gemtuzumab ozogamicin/Mitoxantrone/Etoposide|
11598252|NCT00660023|Experimental|Mircera in Renal Anemia|Participants with chronic renal anemia previously treated with ESA therapy will receive intravenous Mircera, also known as continuous erythropoietin receptor activator (CERA), every 4 weeks for a total of 52 weeks in this single-arm study. The first dose will be determined by the dose of ESA received prior to administration of study treatment, and subsequent doses will be adjusted to achieve target Hb concentrations.
11598253|NCT00660010|Experimental|1|
11598254|NCT00659997|Active Comparator|1|1 Individuals treated with Albendazole
11598255|NCT00659997|Active Comparator|2|Individuals treated with Levamisole
11598256|NCT00659984|Experimental|Ultratrace™ Iobenguane I 131|"Eligible patients received a diagnostic imaging dose of Ultratrace™ Iobenguane I 131 (1-5 mCi) within 7 days of study enrollment, followed by three dosimetry scans over 3-6 days. If the imaging dose demonstrated normal biodistribution and tumor uptake, then the patient received a therapeutic dose within 7-28 days of the diagnostic imaging dose, followed by a single imaging scan on Day 7 post therapy. As per protocol, therapeutic dosing was to begin at 12.0 mCi/kg and escalate to 15.0, 18.0, and 21.0 mCi/kg until the MTD was established or the 21.0 mCi/kg dose level was reached. Actual doses administered ranged from 8.8 to 18.6 mCi/kg. Based on actual doses administered, patients were grouped into 3 mean dose groups: 11.2, 15.5, and 18.2 mCi/kg.
~The dosimetry dose was administered over a period of 1-3 minutes by injection; the therapeutic dose was diluted in up to 25 mL normal saline and infused intravenously over 30 to 60 minutes."
11598257|NCT00659971|Experimental|1|PAC113 0,15% mouthrinse
11598258|NCT00659971|Experimental|2|PAC113 0,075% mouthrinse
11598259|NCT00659971|Experimental|3|PAC113 0,0375% mouthrinse
11598260|NCT00659971|Active Comparator|4|Nystatin suspension
11598261|NCT00659958|Experimental|1|
11598262|NCT00659945|Active Comparator|1|Pre-op Aprepitant plus Ondansetron for PONV prophylaxis in patients undergoing outpatient plastic surgery
11598263|NCT00659945|Placebo Comparator|2|Pre-op Placebo plus Ondansetron for PONV prophylaxis in patients undergoing outpatient plastic surgery
11598264|NCT00659932|Experimental|1|
11598265|NCT00659932|Active Comparator|2|
11598266|NCT00659919|Placebo Comparator|Placebo|The patients in this arm received placebo
11598267|NCT00659919|Active Comparator|Trazodone|The patients on this arm received Trazodone for 3 consecutive days
11598268|NCT00659906|Experimental|1|Progressive resistance training program 3 times a week for 12 months
11598269|NCT00659906|Active Comparator|2|Flexibility training 3 times a week for 12 months
11598270|NCT00659893|Experimental|1|Cohort 1 One 25 cm2 treatment area; on one arm
11598271|NCT00659893|Experimental|2|Cohort 2 One 50cm2 contiguous treatment area; on one arm
11598272|NCT00659893|Experimental|3|Cohort 3 Two 25cm2 treatment areas; one on each arm
11598273|NCT00659893|Experimental|4|Cohort 4 One 25cm2 treatment area; and one 50cm2 contiguous treatment area; one on each arm
11598274|NCT00659893|Experimental|5|Cohort 5 One 75cm2 contiguous treatment area; on one arm
11598275|NCT00659893|Experimental|6|Cohort 6 Two 50cm2 contiguous treatment area; one on each arm
11598276|NCT00659893|Experimental|7|Cohort 7 One 25cm2 treatment area; and one 75cm2 contiguous treatment area; one on each arm
11598277|NCT00659893|Experimental|8|Cohort 8 One 100cm2 contiguous treatment area; on one arm
11598278|NCT00659867|Experimental|A|Chromoscopy-guided endomicroscopy with targeted biopsies
11598279|NCT00659867|Active Comparator|B|Standard endoscopy with random and targeted biopsies
11598280|NCT00659854|Placebo Comparator|Non milk or soy based formula|25 infants , non milk or soy based formula .
11598281|NCT00659854|Active Comparator|2|Intervention with milk based formula will be given to 25 infants.
11598282|NCT00659841|Active Comparator|1|Ciclesonide 200µg
11598283|NCT00659841|Placebo Comparator|2|Placebo
11598284|NCT00659828|Experimental|Recombinant Methionyl Human Leptin|Recombinant methionyl human leptin: Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss).
11598285|NCT00659815|Active Comparator|ReNu in Currently Marketed Bottle|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.
11598286|NCT00659815|Experimental|ReNu in Clear Resin Bottle|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.
11598287|NCT00659802|Placebo Comparator|placebo|Matching dose of placebo will be given orally in capsules three times per day for 56 days.
11598288|NCT00659802|Experimental|HMPL-004 low dose|A total of 1200 mg of HMPL-004 per day in three divided doses will be given orally in capsules, 200 mg each, for 56 days.
11598289|NCT00659802|Experimental|HMPL-004 high dose|A total of 1800 mg of HMPL-004 per day in three divided doses will be given orally in capsules, 200 mg each, for 56 days.
11598290|NCT00659789|Experimental|Vacc-4x|Vacc-4x reconstituted in sterile water (0.1 mL) at a dose of 1.2mg per intradermal administration. Participants are given a total of 6 immunizations over 18 weeks (weeks 1, 2, 3, 4, 16, 18). Recombinant human granulocyte macrophage colony stimulating factor (rhuGM-CSF) Leukine (0.06mg in 0.1 mL) administered intradermally is used as a local adjuvant.
11598291|NCT00659789|Placebo Comparator|Placebo|Placebo injections consisting of sterile water (0.1 mL) in place of Vacc-4x. Placebo injections consisting of sterile water (0.1 mL) in place of Leukine.
11598292|NCT00659776|Active Comparator|1|Subjects with MS or any other inflammatory process
11598293|NCT00659776|Active Comparator|2|Subjects with stroke
11598294|NCT00659776|Active Comparator|3|Subjects receive ferumoxytol before cardiac surgery or CNS vascular surgery
11598295|NCT00659776|Active Comparator|4|Subjects receive ferumoxytol after cardiac surgery or CNS vascular surgery
11598296|NCT00659763||A|Patients suspected of irritable bowel syndrome referred from GP´s, who fulfill the ROM III criteria for IBS
11598297|NCT00659763||B|Patients suspected of irritable bowel syndrome referred from GP´s, who fulfill he ROME III criteria for IBS
11598298|NCT00659750|Active Comparator|1|Ciclesonide 200µg
11598299|NCT00659750|Placebo Comparator|2|Placebo
11598300|NCT00659737|Placebo Comparator|Aprepitant|"Oral Aprepitant pill and placebo transdermal patch at least 1 hour prior to surgical procedure.
~Emend (Aprepitant) + Placebo"
11598301|NCT00659737|Active Comparator|Scopolamine|Oral Aprepitant pill and Scopolamine transdermal patch at least 1 hour prior to surgical procedure.
11598302|NCT00659711|Active Comparator|Januvia 100mg|The first group will be started on 100 mg sitagliptin daily for 12 weeks
11598303|NCT00659711|Placebo Comparator|placebo|will be placed on a placebo for 12 weeks.
11598304|NCT00659698|Experimental|1|received programmed infusions of insulin determined by the control algorithm of the artificial pancreas
11598305|NCT00659698|No Intervention|2|glucose levels were controlled using a manual injection of insulin according to the commonly used sliding scale
11598306|NCT00659685|Experimental|A|Subjects received Kali formulated products under fasting conditions
11598307|NCT00659685|Active Comparator|B|Subjects received GlaxoSmithKline formulated products under fasting conditions
11598308|NCT00659659|Experimental|1|MEDI-563
11598309|NCT00659659|Experimental|2|MEDI-563
11598310|NCT00659659|Placebo Comparator|4|Placebo
11598311|NCT00659659|Placebo Comparator|5|Placebo
11598312|NCT00659646|Experimental|A|Gentamicin sponge applied into wound plus levofloxacin, 750 mg by mouth (po) or intravenous (IV) every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing
11598313|NCT00659646|Active Comparator|B|Levofloxacin, 750 mg po or IV every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing
11598314|NCT00659633|Experimental|Lidocaine|Intravenous lidocaine for neuropathic pain
11598315|NCT00659620|Experimental|1|transplantation of mesenchymal stem cell
11598316|NCT00659594|Active Comparator|1|Ciclesonide 200µg
11598317|NCT00659594|Placebo Comparator|2|Placebo
11598318|NCT00659581||Patients with hypertension|
11598319|NCT00659555|Experimental|Treatment A receivers|Subjects received pazopanib, single dose as 2 x 40 microliter drops of 5 mg/mL solution in Period 1
11598320|NCT00659555|Experimental|Treatment B receivers|Subjects received ketoconazole, daily 400 mg oral dose on Days 1 to 8; pazopanib, single dose as 2 x 40 microliter drops of 5 mg/mL solution on Day 5 in Period 2
11598321|NCT00659542|No Intervention|1|mesh fixation by absorbable sutures
11598322|NCT00659542|Experimental|2|mesh fixation by cyanoacrylate glue
11598323|NCT00659529|Experimental|1|All subjects will receive oral sildenafil three times per day during the study. Study endpoints will be measured before the treatment period and at the end of the treatment period.
11598324|NCT00659516||1|intubated patients
11598325|NCT00659516||2|non intubated patients
11598326|NCT00659503|Active Comparator|1|Ciclesonide 200µg
11598327|NCT00659503|Placebo Comparator|2|Placebo
11598328|NCT00659490|Experimental|AZD1940|AZD1940 800ug given predose
11598329|NCT00659490|Active Comparator|Naproxen|Naproxen 500mg given pre-surgery
11598330|NCT00659490|Placebo Comparator|Placebo|Placebo given pre-surgery
11598331|NCT00659477|Experimental|single arm|
11598332|NCT00659464||1|Children who present to the heart center exercise stress lab for investigation of syncope
11598333|NCT00659451|Experimental|2|Losartan
11598334|NCT00659451|Active Comparator|1|Amlodipine
11598335|NCT00659438|Experimental|1|Bicalutamide 150mg + ZD6474 300mg
11598336|NCT00659438|Placebo Comparator|2|Bicalutamide 150mg + placebo
11598337|NCT00659425|Experimental|5 microgram per kilogram (mcg/kg)|Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
11598338|NCT00659425|Experimental|10 microgram per kilogram (mcg/kg)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
11598339|NCT00659425|Experimental|20 microgram per kilogram (mcg/kg): Schema A|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
11598340|NCT00659425|Experimental|20 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
11598341|NCT00659425|Experimental|30 microgram per kilogram (mcg/kg): Schema A|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
11598342|NCT00659425|Experimental|30 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
11598343|NCT00659425|Experimental|40 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
11598344|NCT00659425|Experimental|32 microgram per kilogram (mcg/kg): Schema C|Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
11598345|NCT00659425|Experimental|50 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
11598346|NCT00659425|Experimental|50 microgram per kilogram (mcg/kg): Schema C|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
11598347|NCT00659412|Experimental|Course A1|
11598348|NCT00659412|Placebo Comparator|Course A2|
11598349|NCT00659412|Experimental|Course B|Open-label extension
11598350|NCT00659386|Experimental|A|Patients with chronic idiopathic cardiomyopathy and EMB proven high PVB19 virus load.
11598351|NCT00659373|Active Comparator|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
11598352|NCT00659373|Experimental|T+OFS|Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
11598353|NCT00659373|Experimental|E+OFS|Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
11598354|NCT00659360|Experimental|Arm I|Patients receive oral AZD0530 (saracatinib ) at a dose of 175 mg, once daily, in the absence of disease progression or unacceptable toxicity.
11598355|NCT00659347|Active Comparator|1|
11598356|NCT00659347|Placebo Comparator|2|
11598357|NCT00659334|Active Comparator|1|Adults with brain tumor to receive Combidex infusion only
11598358|NCT00659334|Active Comparator|2|Adults with brain tumors to receive Combidex infusion and neurosurgery
11598359|NCT00659334|Other|3|Adults with brain tumors to receive neurosurgery only (NO Combidex)
11598360|NCT00659334|Active Comparator|4|Children with brain tumors to receive Combidex only
11598361|NCT00659334|Active Comparator|5|Children with brain tumors to receive Combidex and neurosurgery
11598362|NCT00659334|Other|6|Children with brain tumors to receive neurosurgery only, NO Combidex
11598363|NCT00659334|Active Comparator|7|Adults with Inflammatory lesions (stroke or MS) to receive Combidex only
11598364|NCT00659321|Active Comparator|1|16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
11598365|NCT00659321|Placebo Comparator|2|16 weeks treatment with placebo
11598366|NCT00659295||Type 1 diabetes|Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.
11598367|NCT00659295||Type 2 diabetes|Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.
11598368|NCT00659282||A|biphasic insulin aspart
11598369|NCT00659269|Active Comparator|Multivitamin (MV)|1 multivitamin pill will be taken orally, daily starting on the first day of chemotherapy and continuing for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts)
11598370|NCT00659269|Experimental|Multivitamin + Vitamin B12 + Vitamin B6|"1 multivitamin pill will be taken orally, daily starting on the first day of chemotherapy and continuing for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts).
~The patient will also take the following, starting on the first day of chemotherapy:
~pyridoxine 50 mg three times per day, orally and continue for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts)
~Vitamin B12 one mg injected intramuscularly, every 3 or 4 weeks, depending on the timing of the chemotherapy for 4 doses."
11598371|NCT00659243|Experimental|rhBSSL|
11598372|NCT00659243|Placebo Comparator|Placebo|
11598373|NCT00659230|Placebo Comparator|Placebo|Arm 1
11598374|NCT00659230|Active Comparator|Nepicastat|Arm 2
11598375|NCT00659217|Experimental|2|mesenchymal stem cell Autologous MSC transplantation
11598376|NCT00659204|Experimental|nano-silver gel|
11598377|NCT00659204|Active Comparator|alcohol-based gel|
11598378|NCT00659178|Experimental|SB-485232 plus pegylated liposomal doxorubicin|Subjects will receive one dose of pegylated liposomal doxorubicin on Day 1 plus two doses of SB-485232 on Day 3 and Day 9 in each cycle.
11598379|NCT00659165|Experimental|Insulin Detemir|Insulin Detemir
11598380|NCT00659165|Experimental|Insulin Glargine|Insulin Glargine
11598381|NCT00659152||1: ALI/ARDS|
11598382|NCT00659126|Experimental|Diagnostic (Gd, ferumoxytol, 3T or 7T MRI)|Patients receive gadolinium IV on day 1 and ferumoxytol non-stoichiometric magnetite IV on day 2. Patients undergo anatomical MRI sequences with 3T or 7T at baseline and on days 1-3. Patients also undergo DSC MRI and DCE MRI on days 1-2. Day 1 and day 2 imaging sessions may be separated by up to 7 days.
11598383|NCT00659100|Experimental|A|
11598384|NCT00659087|Experimental|Femoral Block|Those receiving femoral block in addition to usual pain management
11598385|NCT00659087|Active Comparator|Usual Care|Those receiving only usual pain management without a femoral block
11598386|NCT00659074|Experimental|A|Ondansetron ODT
11598387|NCT00659074|Active Comparator|B|Zofran ODT
11598388|NCT00659061|Active Comparator|Intervention|Multiple micronutrient fortificant (Sprinkles) and nutrition education given by LHWs.
11598389|NCT00659061|No Intervention|Control|Routine public health massages by Lady Health Workers (LHWs) during their community visits.
11598390|NCT00659048|Active Comparator|1|Ciclesonide 200µg
11598391|NCT00659048|Placebo Comparator|2|Placebo
11598392|NCT00659035||IT|Subjects receiving 1-10 mg/day of morphine or its equivalent doses of opioid medications through intrathecal route. Intrathecal medications are administered through a catheter in spinal cord
11598393|NCT00659035||Oral|Subjects receiving oral opioids (morphine, oxycodone, hydrocodone, methadone), but not also receiving anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK
11598394|NCT00659035||Oral + Anticonvulsant|Subjects receiving oral opioids (morphine, oxycodone, hydrocodone, methadone) and anticonvulsants (gabapentin, pregabalin, topiramate), but not also receiving muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK
11598395|NCT00659035||Control -Pain|Subject not receiving opioid medications, anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK.
11598396|NCT00659035||Control -No Pain|Age-matched volunteers (NO PAIN) not receiving opioid medications, anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK.
11598397|NCT00659022|Active Comparator|A|immediate surgery of the primary colorectal tumor, no neoadjuvant therapy
11598398|NCT00659022|Experimental|B|neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary
11598399|NCT00659022|Experimental|C|neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
11598400|NCT00659022|Experimental|D|neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
11598401|NCT00659009|Active Comparator|1|Barometric pressure equivalent to sea level (760 mm Hg).
11598402|NCT00659009|Experimental|2|Barometric pressure equivalent to 6000 feet (609 mm Hg)
11598403|NCT00659009|Experimental|3|Barometric pressure equivalent to 8000 feet (565 mm Hg).
11598404|NCT00658996|Experimental|SofLens DD Toric|Bausch & Lomb SofLens Daily Disposable Toric Contact Lens
11598405|NCT00658996|Active Comparator|Ciba Vision Toric Lens|Ciba Vision Focus Dailies Toric Contact Lens
11598406|NCT00658983|Experimental|1|Autologous Platelet Enriched Gel
11598407|NCT00658983|Active Comparator|2|Metalloproteinase Inhibitor (Promogran)
11598408|NCT00658957|Experimental|A|Daily standard wound care and topical application of the gentamicin-collagen sponge twice weekly
11598409|NCT00658957|Placebo Comparator|B|Daily standard wound care and topical application of the placebo sponge twice weekly
11598410|NCT00658944||A|Patients suffering from stress or mixed urinary incontinence
11598411|NCT00658931|Experimental|Treatment|
11598412|NCT00658918|Active Comparator|1|Ciclesonide 200µg
11598413|NCT00658918|Active Comparator|2|Ciclesonide 100µg
11598414|NCT00658918|Active Comparator|3|Ciclesonide 25µg
11598415|NCT00658918|Placebo Comparator|4|Placebo
11598416|NCT00658905|Active Comparator|rhBSSL|
11598417|NCT00658905|Placebo Comparator|Placebo|
11598418|NCT00658879||Somavert (Pegvisomant)|Patients taking Somavert (Pegvisomant).
11598419|NCT00658853|Active Comparator|1|High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a 5% graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.
11598420|NCT00658853|Active Comparator|2|4 times 4 minutes interval training in hyperoxia - 100% oxygen
11598421|NCT00658853|Active Comparator|3|One leg at a time training 4 times 4 minutes interval training using cycling ergometer
11598422|NCT00658840|Experimental|1|"Primary objectives :
~To evaluate the tumor response rate, local control rate and compliance (acute and late toxicity, esp. gastrointestinal tract toxicity) of concurrent chemo-radiotherapy with oral capecitabine in patients with unresectable locally advanced pancreatic carcinoma
~Secondary objectives :
~To evaluate the impact of concurrent chemo-radiotherapy with oral capecitabine in patients with unresectable locally advanced pancreatic carcinoma by analyzing the progression-free survival rate and overall survival rate."
11598423|NCT00658827||Group 1a: Remicade Cohort|Female patients who were exposed to Remicade at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
11598424|NCT00658827||Group 1b: Remicade Cohort|Infants born to Group 1a patients.
11598425|NCT00658827||Group 2a: Other Anti-TNF agents Cohort|Female patients who were exposed to anti-TNFs other than Remicade at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
11598426|NCT00658827||Group 2b: Other Anti-TNF agents Cohort|Infants born to Group 2a patients.
11598427|NCT00658827||Group 3a: Non-biologic Systemic Therapy Control Cohort|Female patients who were exposed to systemic therapy other than biologic agents at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
11598428|NCT00658827||Group 3b: Non-biologic Systemic Therapy Control Cohort|Infants born to Group 3a patients.
11598429|NCT00658827||Group 4a: Population Control Cohort|Female patients with no record of the diseases of interest and no exposure to biologic or non-biologic systemic therapy at any time during pregnancy (and up to 3 months prior to LMP, if the information is available).
11598430|NCT00658827||Group 4b: Population Control Cohort|Infants born to Group 4a patients.
11598431|NCT00658814|Experimental|Treatment (azacitidine, gemtuzumab)|See Detailed Description
11598432|NCT00658788|Active Comparator|Study Treatment|"clobetasol propionate spray 0.05%
~Other Names:
~Clobex® Spray 0.05% clobetasol propionate spray, 0.05%, applied topically twice daily
~calcitriol ointment
~Other Names:
~Calcitriol Ointment calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily"
11598433|NCT00658775|Experimental|1|
11598434|NCT00658775|Active Comparator|2|
11598435|NCT00658762|Experimental|PD 0332334 225 mg BID|
11598436|NCT00658762|Experimental|PD 0332334 300 mg BID|
11598437|NCT00658762|Active Comparator|Paroxetine 20 mg q am|
11598438|NCT00658762|Placebo Comparator|Placebo BID|
11598439|NCT00658749|Experimental|1|AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor) solution (diluent: physiologic saline solution)
11598440|NCT00658749|Placebo Comparator|2|Physiologic saline solution
11598441|NCT00658736|Experimental|1|EUS guided celiac block with bupivicaine and triamcinolone. Patient will undergo endoscopic ultrasound and celiac plexus blockade using an EUS needle inserted into the celiac plexus. 20 cc of injectate will be administered.
11598442|NCT00658736|Placebo Comparator|2|EUS guided celiac block with bupivicaine only. Patient will undergo endoscopic ultrasound and celiac plexus blockade using an EUS needle inserted into the celiac plexus. 20 cc of injectate will be administered.
11598443|NCT00658723|Experimental|1|
11598444|NCT00658723|Active Comparator|2|SURGICEL™ Absorbable Hemostat
11598445|NCT00658710|Active Comparator|1|patients who continue physical therapy sessions during two months.
11598446|NCT00658710|No Intervention|2|patients who stop physical therapy sessions during two months
11598447|NCT00658697|Experimental|Docetaxel, Bevacizumab, and ADT|"Docetaxel:
~Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
~Bevacizumab:
~Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
~ADT or Luteinizing hormone-releasing hormone agonist (LHRH):
~Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
~Bicalutamide:
~Oral Bicalutamide on day 84 once daily (after completing docetaxel, at 3 month) at dose of 50 mg for a total 15 months (4-18 months)"
11598448|NCT00658684|Experimental|Fesoterodine fumarate|
11598449|NCT00658671|Experimental|1|Dose-escalation
11598450|NCT00658671|Experimental|2|Advanced cancer, excluding patients with colorectal or ovarian cancers
11598451|NCT00658671|Experimental|3|Recurrent or resistant epithelial ovarian cancer
11598452|NCT00658671|Experimental|4|Colorectal cancer patients who have progressed and/or failed on irinotecan- and oxaliplatin-based regimens
11598453|NCT00658658|Experimental|Panitumumab|Participants received panitumumab at planned doses ranging from 2.5 mg/kg weekly (QW) to 9.0 mg/kg every 3 weeks (Q3W) until the patient experienced disease progression, was unable to tolerate study drug, withdrew consent, or other reasons that warranted removal from the study.
11598454|NCT00658645|Experimental|Bifeprunox|
11598455|NCT00658645|Placebo Comparator|Placebo|
11598456|NCT00658645|Active Comparator|Quetiapine|
11598457|NCT00658632|Experimental|1|
11598458|NCT00658632|Active Comparator|2|
11598459|NCT00658619|Other|400 µg Brimonidine Tartrate Implant Stage 1|Stage 1: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
11598460|NCT00658619|Other|200 µg Brimonidine Tartrate Implant Stage 1|Stage 1: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
11598461|NCT00658619|Other|400 µg Brimonidine Tartrate Implant Stage 2|Stage 2: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
11598462|NCT00658619|Other|200 µg Brimonidine Tartrate Implant Stage 2|Stage 2: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
11598463|NCT00658619|Sham Comparator|Sham (no implant) Stage 2|Stage 2: sham in both eyes on Day 1 and Month 6.
11598464|NCT00658606|Active Comparator|Alefacept alone|15 mg alefacept intramuscularly (IM) once weekly for 12 weeks
11598465|NCT00658606|Experimental|Alefacept + nbUVB|15 mg alefacept intramuscularly once weekly and narrow band Ultraviolet B (nbUVB) phototherapy 3 times per week for 12 weeks
11598466|NCT00658593|Active Comparator|GEMCAP|Gemcitabine 1000mg/m2 IV days 1 and 8 ever 21 days; Capecitabine 650mg/m2 PO BID days 1-14 every 21 days.
11598467|NCT00658593|Active Comparator|Gemcitabine Alone|Gemcitabine 1000mg/m2 IV days 1, 8 and 15 every 28 days
11598468|NCT00658580|Active Comparator|A|Every 3 weeks intravenous cisplatin plus etoposide
11598469|NCT00658580|Experimental|B|Every 3 weeks intravenous epirubicin plus ifosfamide plus etoposide
11598470|NCT00658567|Experimental|2|pimavanserin tartrate (ACP-103) 20 mg, tablet, once daily by mouth, 6 weeks
11598471|NCT00658567|Placebo Comparator|Placebo|Placebo tablet, once daily by mouth, 6 weeks
11598472|NCT00658567|Experimental|1|pimavanserin tartrate (ACP-103) 10 mg, tablet, once daily by mouth, 6 weeks
11598473|NCT00658541|Experimental|Zolpidem Tartrate 10 mg Tablets|A single dose of zolpidem tartrate 10 mg administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
11598474|NCT00658541|Active Comparator|Zolpidem Tartrate (Ambien®) 10 mg Tablets|A single dose of Ambien® 10 mg administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
11598475|NCT00658528|Experimental|1|
11598476|NCT00658528|Active Comparator|2|
11598477|NCT00658515|Experimental|Dalcetrapib (RO4607381)|
11598478|NCT00658515|Placebo Comparator|Placebo|
11598479|NCT00658502||1|
11598480|NCT00658502||2|
11598481|NCT00658489|Active Comparator|1|Residents randomized to the promotion of oral health group will receive training consisting of 7 modules (3 on the Bright Futures curriculum and 4 on oral health promotion). They will then enroll 3 patient-child dyads from their practice who present for a well child care visit. Outcomes will be obtained by completing pre- and post-study surveys. Residents will be observed by a faculty preceptor during 3 different patient encounters, and will receive feedback at the end of the 6 month study period.
11598482|NCT00658489|Active Comparator|2|Residents randomized to the prevention of iron deficiency group will complete one web-based module.
11598483|NCT00658476|Experimental|Omega-3 Fatty Acids|Adolescents receive cognitive behavior therapy in combination with Omega-3 fatty acid supplements.
11598484|NCT00658476|Placebo Comparator|Placebo|Adolescents receive cognitive behavior therapy in combination with placebo.
11598485|NCT00658463|Experimental|1|The study is designed with a one-month steady state period with placebo then on a cross-over design with two 6-week periods of placebo or rosuvastatin (20 mg). An in vivo kinetic study will be performed at the end of each 6-week period.
11598486|NCT00658463|Placebo Comparator|2|The study is designed with a one-month steady state period with placebo then on a cross-over design with two 6-week periods of placebo or rosuvastatin (20 mg). An in vivo kinetic study will be performed at the end of each 6-week period.
11598585|NCT00657774|Active Comparator|3|Oral Prednisone 10 mg
11598487|NCT00658450|Experimental|Cognitive rehabilitation training|Children in this arm will the receive the intervention comprising of 16 cognitive rehabilitation training (CRT) exercises for 8 weeks. These exercises will train different cognitive skills including attention, visual spatial processing, logical skills and memory.
11598488|NCT00658450|No Intervention|Treatment as usual|Children in this group will not receive any intervention, they will undergo the usual post discharge treatment for brain injured children at Mulago Hospital (the study site). This is the treatment as usual (TAU) group.
11598489|NCT00658411|Experimental|All patients|Deferoxamine for >=2 weeks prior to stem cells
11598490|NCT00658398|Experimental|ICP to prevent alcohol misuse.|Interactive Computer Program (ICP) to prevent alcohol misuse.
11598491|NCT00658398|Sham Comparator|ICP to enhance balanced diet|2. Interactive Computer Program to enhance balanced diet (sham intervention)
11598492|NCT00658385|Experimental|1|GCSF (human recombinant granulocyte colony stimulating factor)Neupogen(Amgen), Filgrastim, Central venous line placement, Stem cell Collection (leukapheresis)
11598493|NCT00658372|Experimental|PD 0332334 225 mg BID|
11598494|NCT00658372|Experimental|PD 0332334 300 mg BID|
11598495|NCT00658372|Active Comparator|Paroxetine 20 mg QD|
11598496|NCT00658372|Placebo Comparator|Placebo BID|
11598497|NCT00658359|Active Comparator|Treatment Arm 1|Treatment Arm 1 will also receive standard of care medications
11598498|NCT00658359|Experimental|Treatment Arm 2|Treatment Arm 2 will also receive standard of care medications
11598499|NCT00658359|Experimental|Treatment Arm 3|Treatment Arm 3 will also receive standard of care medications
11598500|NCT00658346||1|HIV-1 group O infected patients
11598501|NCT00658346||2|HIV-1 group M infected patients
11598502|NCT00658333|Experimental|Enteric-coated Mycophenolate Acid|Equimolar dose of enteric-coated mycophenolate acid with mycophenolate mofetil placebo. 1000 mg mycophenolate mofetil = 720 mg enteric-coated mycophenolate acid (MPA equivalent dose). The active and placebo study medications were dispensed in separate bottles identified as Bottle A and Bottle B.
11598503|NCT00658333|Active Comparator|Mycophenolate Mofetil|Mycophenolate mofetil therapy with placebo enteric-coated mycophenolate acid. The active and placebo study medications were dispensed in separate bottles identified as Bottle A and Bottle B.
11598504|NCT00658320|Experimental|Everolimus + Reduced dose of cyclosporine|An initial everolimus dose of 0.75 mg orally twice daily (1.5 mg/day) was administered 24-36 hours from reperfusion after transplantation and dose adjustments based on everolimus trough level (target trough level 3-8 ng/mL). Reduced dose of cyclosporine was initiated either pre-transplantation or within 24 hours after transplantation following the local regimen. Patients were treated with antibody induction therapy using 20 mg basiliximab two hours prior to transplant and 20 mg basiliximab 4 days post transplant or according to local practice. Corticosteroids were administered according to local practice. Patients were treated for 12 months in the core study and 12 months in the extension study. Everolimus was available after 24 months for compassionate use.
11598505|NCT00658320|Active Comparator|Mycophenolate mofetil (MMF) + Standard dose of cyclosporine|Patients were treated with 1 gram twice a day (2 grams/day) of Mycophenolate mofetil (MMF) and standard dose of cyclosporine for 12 months post renal transplant. Patients were treated with antibody induction therapy using 20 mg basiliximab two hours prior to transplant and 20 mg basiliximab 4 days post transplant or according to local practice. Corticosteroids were administered according to local practice. Patients were treated for 12 months in the core study and 12 months in the extension study.
11598506|NCT00658307|Experimental|1|
11598507|NCT00658307|Experimental|2|
11598508|NCT00658307|Sham Comparator|3|
11598509|NCT00658281||OBI KV System + CBCT Scanning|Breast cancer patient radiation treatment set up using OBI KV system and CBCT scanning or CT-on-rail system to verify standard EPID for positioning.
11598510|NCT00658268|Experimental|1|
11598511|NCT00658268|Placebo Comparator|2|
11598512|NCT00658255|Experimental|1|
11598513|NCT00658255|Active Comparator|2|
11598514|NCT00658242||I|Subjects having Craniofacial surgery
11598515|NCT00658229|Experimental|Strength training group|A four months strength training program during androgen deprivation therapy for prostate cancer patietns.
11598516|NCT00658229|No Intervention|Control group|Patients in the control group are not discouraged from performing normal activities. They are however asked not to start a strength training program or increase their activity level in the same period as the experimental group is performing their strength training program. We will offer the control group a modified strength training program after the post-intervention assessment.
11598517|NCT00658216||Longitudinal|Prospective study : cohort of consecutive patients recruited over 2 years
11598518|NCT00658203|Active Comparator|1|PEA optimized CRT
11598519|NCT00658203|Other|2|Standard optimized CRT
11598520|NCT00658190||1|Women obtaining routine Pap tests for cervical cancer screening
11598521|NCT00658177|Experimental|Arm 1|
11598522|NCT00658177|Placebo Comparator|Arm 2|
11598523|NCT00658164|Experimental|1|
11598524|NCT00658138|Experimental|Adhesive A|
11598525|NCT00658138|Active Comparator|Adhesive B|
11598526|NCT00658125|Experimental|Experimental|
11598527|NCT00658112|Experimental|Benzoyl Peroxide 5%|Subjects will be given standard instructions in the use of topical benzoyl peroxide gel and will be provided with a supply of medication fitted with a Medication Event Monitoring System (MEMS) cap. This cap records dates and times the assembly is opened which can be downloaded at the final visit and tabulated with associated software. When the tubes are weighed, data from the MEMS Caps will be collected. Study coordinators will record adherence, while assessors are blinded to adherence rates. All subjects will be assigned to treatment with topical benzoyl peroxide to the entire face.
11598528|NCT00658099||A|
11598529|NCT00658099||B|
11598530|NCT00658086|Active Comparator|1|ALN-RSV01
11598531|NCT00658086|Placebo Comparator|2|Normal saline
11598532|NCT00658073|Active Comparator|A|Patients in Group A will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive standard regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF.
11598533|NCT00658073|Active Comparator|B|Patients in Group B will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive 80% less of calcineurin inhibitor than in Group A. Other immunosuppressive agents such as glucocorticoid and MMF remained the same doses as in Group A.
11598534|NCT00658073|Active Comparator|C|Patients in Group C will receive anti-interleukin 2 receptor antibody (Basiliximab)for induction therapy. Patients will receive the same doses of regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF as in Group A.
11598535|NCT00658060||1|"1.Fulfilling the Tel Hashomer criteria for the diagnosis of FMF [5].
~2.Suffering from episodes of exertional leg pain and or exertional ankle edema
~3.18-45 years old
~4.On a stable (≥ 2 weeks) dose of oral colchicine therapy
~5.Non-smokers"
11598536|NCT00658060||2|"Control group
~1.Healthy subjects
~2.18-45 years old
~3.Non-smokers"
11598537|NCT00658047|Experimental|0.25 mg CH-1504|0.25 mg CH-1504
11598538|NCT00658047|Experimental|0.5 mg CH-1504|0.5 mg CH-1504
11598539|NCT00658047|Experimental|1.0 mg CH-1504|1.0 mg CH-1504
11598540|NCT00658047|Active Comparator|Methotrexate|Methotrexate (MTX) 10 mg/week for 2 weeks, 15 mg/week for 2 weeks, 20 mg/week for 8 weeks
11598541|NCT00658034|Active Comparator|1|Acupuncture
11598542|NCT00658034|Sham Comparator|2|Placebo Acupuncture
11598543|NCT00658021|Placebo Comparator|Placebo|Subcutaneous injection, twice a day
11598544|NCT00658021|Experimental|Exenatide 5 µg|Subcutaneous injection, twice a day
11598545|NCT00658021|Experimental|Exenatide 10 µg|Subcutaneous injection, twice a day
11598546|NCT00658008|Experimental|PD 0332334 175 mg BID|
11598547|NCT00658008|Experimental|PD 0332334 225 mg BID|
11598548|NCT00658008|Experimental|PD 0332334 75 mg BID|
11598549|NCT00658008|Active Comparator|Paroxetine 20 mg QD|
11598550|NCT00658008|Placebo Comparator|Placebo BID|
11598551|NCT00657995|Experimental|2|Thirty patients who underwent pancreatic resection for pancreatic neoplasm were prospectively randomized. Perioperative blood glucose levels were continuously monitored using an artificial endocrine pancreas (STG-22). Glucose levels were controlled using either the sliding scale method or the artificial pancreas.
11598552|NCT00657982|Experimental|1|RAD001 10 BID 6 weeks before definite treatment for localized prostate cancer
11598553|NCT00657969||1|CAD-group (Cervical Artery Dissection - group): consecutive patients with cervical artery dissection, with or without associated cerebral ischemia, hospitalized in one of the participating neurological centers; standardized inclusion and exclusion criteria apply
11598554|NCT00657969||2|IS-group (Ischemic Stroke - Group): patients selected among consecutive patients hospitalized for an ischemic stroke without CAD, in the same centers as patients from group1, frequency-matched on age and gender with group1; standardized inclusion and exclusion criteria apply
11598555|NCT00657969||3|HC-group (Healthy Control - Group): DNA of healthy individuals from existing DNA-databases will be used as controls for the Belgian, French, German and Swiss centers; the other centers are recruiting their own age- and sex-matched healthy controls; individuals from the 3 groups (CAD, IS and HC) are strictly matched on geographical origin in order to avoid stratification bias
11598556|NCT00657943|Experimental|1M|Metformin + Levemir x1
11598557|NCT00657943|Placebo Comparator|1P|Placebo + Levemir x1
11598558|NCT00657943|Experimental|2M|metformin + NovoMix
11598559|NCT00657943|Placebo Comparator|2P|Placebo + NovoMix
11598560|NCT00657943|Experimental|3M|Metformin + 4x therapy
11598561|NCT00657943|Placebo Comparator|3P|Placebo + 4x therapy
11598562|NCT00657930||A|
11598563|NCT00657917|Experimental|Paromomycin +Gentamicin topical cream|WR279,396 topically twice a day for 20 days
11598564|NCT00657904|Experimental|1|
11598565|NCT00657904|Placebo Comparator|2|
11598566|NCT00657891|Placebo Comparator|1|Placebo Injection
11598567|NCT00657891|Experimental|2|Xolair at 0.016 mg/kg/IgE(iu/ml)/4 wks
11598568|NCT00657878|Experimental|non platinum based chemotherapy|a non platinum based therapy (corresponding to stealth liposomal doxorubicin, or topotecan, or gemcitabine,or any other drug approved in clinical practice for the treatment of patients with ovarian cancer after previous platinum-based chemotherapy) followed by a platinum based chemotherapy at disease progression
11598569|NCT00657878|Active Comparator|platinum based chemotherapy|platinum based chemotherapy (corresponding to the combination of carboplatin + paclitaxel, or carboplatin + gemcitabine for patients with significant but lower than grade 3 neuropathy at baseline) followed by a non platinum based chemotherapy at disease progression
11598570|NCT00657865|Active Comparator|1|Ramipril
11598571|NCT00657865|Placebo Comparator|2|Placebo
11598572|NCT00657852|Experimental|Pamidronate|Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
11598573|NCT00657852|Placebo Comparator|Placebo|500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
11598574|NCT00657839|Experimental|Arm 1|
11598575|NCT00657839|Placebo Comparator|Arm 2|
11598576|NCT00657826|Experimental|19mm arotic valve implant|Single arm study for patients who require a smaller valve size of the ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm.
11598577|NCT00657813|Experimental|Access [123I]MNI-330 and SPECT Imaging|
11598578|NCT00657800|Experimental|Group 1|Behavioral - Intensified coordinated inpatient diabetes education program (IDEP)
11598579|NCT00657800|No Intervention|Group 2|Diabetes education as is typically provided by clinical staff
11598580|NCT00657787||PTSD|Combat-exposed men and women with PTSD deployed to OIF/OEF.
11598581|NCT00657787||High Utilizers|A comparison group of combat veterans who are high utilizers of VA medical care, but who have not received a diagnosis of PTSD
11598582|NCT00657787||Not OIF/OEF|A second comparison group will consist of veterans with similar service record and demographic backgrounds, who were not deployed to the OIF/OEF war zones
11598583|NCT00657774|Experimental|1|FlutiForm 250/10 ug
11598584|NCT00657774|Experimental|2|FlutiForm 100/10 ug
11598586|NCT00657774|Placebo Comparator|4|Placebo inhaler and/or placebo tablets
11598587|NCT00657761|Placebo Comparator|Placebo|Saline solution 0.9% sc/12h for 7 days
11598588|NCT00657761|Experimental|Enfuvirtide|Enfuvirtide 90 mg/12h sc for 7 days
11598589|NCT00657748|Experimental|1|
11598590|NCT00657735|Experimental|1|Deep TMS treatment
11598591|NCT00657735|Sham Comparator|2|inactive stimulation
11598592|NCT00657722|Experimental|1|Angiography and Computed Tomography
11598593|NCT00657709|Experimental|rMenB Lot1|Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
11598594|NCT00657709|Experimental|rMenB Lot2|Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
11598595|NCT00657709|Experimental|rMenB Lot3|Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
11598596|NCT00657709|Active Comparator|Routine|Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.
11598597|NCT00657709|Active Comparator|MenC + Routine|Subjects received the routinely administered infant vaccines and Men C vaccine at 2, 4 and 6 months of age.
11598598|NCT00657696||Group 1|Physicians and staff in VA non-contract primary care outpatient clinics and patients seen in last 12 months in the same clinics
11598599|NCT00657696||Group 2|Patients seen in last 12 months in Group 1 clinics
11598600|NCT00657683|Experimental|1|
11598601|NCT00657683|Placebo Comparator|2|
11598602|NCT00657670|Experimental|1|Ready-made spectacles
11598603|NCT00657670|Active Comparator|2|Spectacles
11598604|NCT00657657|Experimental|Group 1|Neonates from mother HBsAg (+) and HBeAg (+) had received HBV vaccine at Month 0, 1, 2, 12, 60 (5 doses)
11598605|NCT00657657|Experimental|Group 2|Neonates from mother HBsAg (+) and HBeAg (+) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
11598606|NCT00657657|Experimental|Group 4|Neonates from mother HBsAg (+) and HBeAg (-) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
11598607|NCT00657657|Experimental|Group 6|Neonates from mother HBsAg (-) and HBeAg (-) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
11598608|NCT00657644|Experimental|Arm 1|
11598609|NCT00657631|Experimental|A|Acceptance and Commitment Therapy will be administered to all subjects.
11598610|NCT00657618|Experimental|Treatment only|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with Sodium Stibogluconate (SSG).
11598611|NCT00657605|Experimental|Recombinant methionyl human leptin|Participants with congenital leptin deficiency will receive the Recombinant methionyl human leptin intervention subcutaneously, once a day with a dose of 0.02 to 0.04 mg/kg (adjusted according to weight loss).
11598612|NCT00657579|Experimental|1|
11598613|NCT00657579|Experimental|2|
11598614|NCT00657579|Experimental|3|
11598615|NCT00657579|Placebo Comparator|4|
11598616|NCT00657566|Active Comparator|1|antibiotics received for up to two days following normalization of white blood cell count, temperature, and gastrointestinal function
11598617|NCT00657566|Experimental|2|4 +/- 1 days of antibiotics
11598618|NCT00657553|Active Comparator|Bortezomib/Treatment Arm|Bortezomib Maintenance Year 1 - bortezomib days 1, 4, 8, 11 every 28 days Year 2 - bortezomib days 1, 4, 8, 11 every 2 months Year 3 - bortezomib days 1, 4, 8, 11 every 3 months
11598619|NCT00657553|No Intervention|Observation Arm (watchful waiting)|monitor myeloma parameters every 3-6 months
11598620|NCT00657540|Experimental|Analatro|Antivenin Latrodectus (Black Widow) Equine Immune F(ab)2
11598621|NCT00657540|Placebo Comparator|Normal Saline Placebo|Normal Saline
11598622|NCT00657527|Experimental|1|Rosuvastatin
11598623|NCT00657527|No Intervention|2|Diet
11598624|NCT00657514|Active Comparator|A|Drug arm - 500mg tablet po bid up to 1000mg (2 500mg tablets) po bid
11598625|NCT00657514|Placebo Comparator|P|Placebo arm - 1 tablet po bid up to 2 tablets po bid if tolerated
11598626|NCT00657501|Experimental|testosterone gel|1% testosterone transdermal gel
11598627|NCT00657501|Placebo Comparator|Placebo gel|placebo transdermal gel
11598628|NCT00657488|Experimental|A|Thalidomide 100mg/day. Dexamethasone is administered at a dose of 40 mg/d, on 4 consecutive days (D1 - D4), with one course every four week in case of stable disease after 12 weeks of treatment or in case of Disease Progression
11598629|NCT00657488|Active Comparator|B|Thalidomide 400mg/day. Dexamethasone is administered at a dose of 40 mg/d, on 4 consecutive days (D1 - D4), with one course every four week in case of stable disease after 12 weeks of treatment or in case of Disease Progression
11598630|NCT00657475|Experimental|2|Cardiac surgery with Mini Extra Corporeal Circulation (MECC). Heparin low dose (150 UI/Kg).
11598631|NCT00657475|Active Comparator|1|Cardiac surgery with Mini Extra Corporeal Circulation (MECC). Heparin Full Dose (300 UI/Kg)
11598632|NCT00657462|Experimental|A|Receives the intervention (reminders displayed at the startup of the application) for both periods (period 1 and period 2) of the study.
11598633|NCT00657462|Active Comparator|B|Receives the intervention (reminders displayed at the application startup) only during the second period (period 2) of the study.
11598634|NCT00657449|Active Comparator|Arm 1|
11598635|NCT00657449|Active Comparator|Arm 2|
11598636|NCT00657423|Experimental|1|
11598637|NCT00657423|Active Comparator|2|
11598638|NCT00657410|Experimental|ARM A - PDN|PDN is administered orally at the daily dose of 1 mg/Kg for 4 consecutive weeks (from day 0 to day 28), then, therapy is tapered within 14 days. The patients considered NOT RESPONDER at day 42 or WHO HAVE LOST THE RESPONSE within the evaluation of final response (see paragraph 8.1), will be crossed to ARM B.
11598639|NCT00657410|Experimental|ARM B - DXM|"DXM is administered orally at single fixed daily doses of 40 mg for 4 consecutive days, every 14 days, for 3 consecutive courses. If platelet count is £ 20x109/L or bleeding symptoms related to thrombocytopenia are present, lowdose DXM (0.035 mg/Kg/day) between courses is given. The patients (either from ARM A+B or from ARM B) considered NOT RESPONDER at day 46 or who HAVE LOST THE RESPONSE within the evaluation of final response (see paragraph 8.1), will be considered OFF TREATMENT.
~For these patients a second line therapy will be considered, according to the medical practice of the Centre (splenectomy or other)."
11598640|NCT00657397|Experimental|A|Methadone inducted by a primary care physician
11598641|NCT00657397|Active Comparator|B|Methadone inducted (in CSAPA)
11598642|NCT00657384|Experimental|acid tranexamic|acid tranexamic
11598643|NCT00657384|Placebo Comparator|2|Nacl 0.9%
11598644|NCT00657371|Experimental|Third Eye Retroscope|Colonoscopy exam using the Third Eye Retroscope device
11598645|NCT00657358|Experimental|Lidocaine|Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
11598646|NCT00657345||1|This is a tissue acquisition and collection protocol that will analyze potential cellular changes that occur after treatment with trastuzumab.
11598647|NCT00657319||A|
11598648|NCT00657306|Experimental|1|Hydrocortisone, 50 mg/6 h per day
11598649|NCT00657306|Placebo Comparator|2|dextrose solution 5%
11598650|NCT00657293|Sham Comparator|C|In an attempt to make the groups comparable in terms of attention, the control group will receive a sham.
11598651|NCT00657293|Active Comparator|ATP|Patients will undergo a specific arm training program (ATP).
11598652|NCT00657280|Experimental|All subjects recieve Sitagliptin|All subjects are aware of what they are taking. Nobody is blinded in this study. study
11598653|NCT00657267|Experimental|Single-Arm Study|
11598654|NCT00657254|Experimental|Arm 1|
11598655|NCT00657241|Active Comparator|A|Valsartan 160 mg (one week); valsartan 320 mg (3 weeks)
11598656|NCT00657241|Active Comparator|B|Coreg CR 20 mg (one week) and Coreg CR 40 mg (3 weeks).
11598657|NCT00657228|Placebo Comparator|2|Standard treatment (epinephrine, corticosteroids, diphenhydramine, and H2 blockers) plus an equal volume bolus of normal saline after the first doses are administered.
11598658|NCT00657228|Experimental|1|Standard therapy plus a one-time bolus of heparin at 80 U/kg (maximum dose of 10,000 Units) given immediately after the first doses of standard treatment.
11598659|NCT00657202|Experimental|Ranibizumab|
11598660|NCT00657189|Experimental|1|MEDI-545
11598661|NCT00657189|Experimental|2|MEDI-545
11598662|NCT00657189|Experimental|3|MEDI-545
11598663|NCT00657189|Experimental|4|MEDI-545
11598664|NCT00657189|Placebo Comparator|5|Placebo
11598665|NCT00657163|Experimental|1|fluoxetine
11598666|NCT00657163|Placebo Comparator|2|Placebo
11598667|NCT00657150|Experimental|Dabigatran etexilate|220 mg once daily
11598668|NCT00657150|Active Comparator|Enoxaparin|40 mg once daily
11598669|NCT00657137|Experimental|A|apricoxib + lapatinib + capecitabine
11598670|NCT00657137|Placebo Comparator|B|placebo + lapatinib + capecitabine
11598671|NCT00657124|Experimental|1|receive a preoperative supplementation with carbohydrate and branched-chain amino acids-enriched nutrient
11598672|NCT00657124|Placebo Comparator|2|receive a preoperative supplementation without carbohydrate and branched-chain amino acids-enriched nutrient
11598673|NCT00657111|Experimental|A1|Subjects 01-08; 5 mg CS-8958
11598674|NCT00657111|Placebo Comparator|A2|Subjects 01-08; placebo
11598675|NCT00657111|Experimental|B1|Subjects 09-16; 10 mg CS-8958
11598676|NCT00657111|Placebo Comparator|B2|Subjects 09-16; placebo
11598677|NCT00657111|Experimental|C1|Subjects 17-24; 20 mg CS-8958
11598678|NCT00657111|Placebo Comparator|C2|Subjects 17-24; placebo
11598679|NCT00657111|Experimental|D1|Subjects 25-32; 40mg CS-8958
11598680|NCT00657111|Placebo Comparator|D2|Subjects 25-32; placebo
11598681|NCT00657098||Observation|
11598682|NCT00657059|Active Comparator|Pred group|Pred Group: Prednisone treatment Patients will give methylprednisolone intravenously at a dose of 0.5 g/day for 3 days at the start of months 1, 3, and 5; then take oral prednisone (0.5 mg/kg/d) on alternate days. Prednison will be tapered 5 mg per month from the seventh month to the 12th month.
11598683|NCT00657059|Active Comparator|MMF Group|MMF Group: MMF treatment Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt < 50kg) for the first 6-month of drug treatment phase, then 0.5 bid for the remaining 6-month.
11598684|NCT00657059|Active Comparator|Pred plus MMF Group|"Pred plus MMF Group: Prednisone plus MMF treatment. Patients will give methylprednisolone intravenously at a dose of 0.5 g/day for 3 days at the start of months 1, 3, and 5; then take oral prednisone (0.5 mg/kg/d) on alternate days. Prednison will be tapered 5 mg per month from the seventh month to the 12th month.
~Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt < 50kg) for the first 6-month of drug treatment phase, then 0.5 bid for the remaining 6-month."
11598685|NCT00657046|Active Comparator|1|Droxidopa at 400 mg (2 capsules each containing 200 mg droxidopa plus one capsule with Placebo)
11598686|NCT00657046|Active Comparator|2|Droxidopa at 600 mg (3 capsules each containing 200 mg droxidopa)
11598687|NCT00657046|Placebo Comparator|3|Placebo (3 capsules with mannitol substituted for droxidopa)
11598688|NCT00657033|Experimental|Arm 1|
11598689|NCT00657033|Experimental|Arm 2|
11598690|NCT00657020|Experimental|Nicotine lozenge|Nicotine lozenge containing 4 mg of nicotine to be placed in mouth and suck to dissolution.
11598691|NCT00657020|Placebo Comparator|Placebo lozenge|Placebo lozenge to be placed in mouth and suck to dissolution.
11598692|NCT00657007|Placebo Comparator|Placebo|IV infusion over 2 hours
11598693|NCT00657007|Experimental|Belimumab 1 mg/kg|1 mg/kg IV infused over 2 hours
11598694|NCT00657007|Experimental|Belimumab 4 mg/kg|4 mg/kg IV infused over 2 hours
11598695|NCT00657007|Experimental|Beimumab 10 mg/kg|10 mg/kg IV infused over 2 hours
11598696|NCT00657007|Experimental|Belimumab 20 mg/kg|20 mg/kg IV infused over 2 hours
11598697|NCT00656994|Experimental|Ramelteon 16 mg QD|
11598698|NCT00656994|Placebo Comparator|Placebo|
11598699|NCT00656981|Experimental|Arm 1|
11598700|NCT00656981|Placebo Comparator|Arm 2|
11598701|NCT00656968|Active Comparator|10-day concomitant therapy|esomeprazole and amoxicillin and clarithromycin and metronidazole for 10 days
11598702|NCT00656968|Experimental|10-day sequential therapy|esomeprazole and amoxicillin for 5 days, followed by esoprazole and clarithromycin and metronidazole for 5 more days
11598703|NCT00656955||Renal cancer patients|Renal cancer patients
11598762|NCT00656500|Experimental|2|Brief intervention to promote quitline utilization
11598704|NCT00656942||Healthy|"subjects with no pain and no opioid treatment for at least six months
~subjects receive quantitative sensory testing (QST)"
11598705|NCT00656942||Pain, no opioid|"subjects have chronic pain but have not taken any opioid medication for at least 3 months
~subjects receive QST"
11598706|NCT00656942||Pain, opioid|"subjects have chronic pain and have been taking opioid medication for at least 3 months
~subjects receive QST"
11598707|NCT00656929|Active Comparator|1|Vitamin D3 50 mcg (2000 IU) daily
11598708|NCT00656929|Placebo Comparator|2|Placebo tablets
11598709|NCT00656916|Experimental|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
11598710|NCT00656916|No Intervention|Observational Group|Comparator group, no intervention.
11598711|NCT00656890|Placebo Comparator|2|sterile saline for injection
11598712|NCT00656890|Experimental|1|MDX-1100 for injection
11598713|NCT00656864|Active Comparator|1|Pioglitazone arm
11598714|NCT00656864|Placebo Comparator|2|Placebo arm
11598715|NCT00656851|Active Comparator|Pioglitazone|Pioglitazone (Actos, 30mg/day for 16 weeks)
11598716|NCT00656851|Active Comparator|Exercise Training|Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks
11598717|NCT00656838|Active Comparator|1|Patient has had PCP contact (letter, phone call, office visit, educational materials).
11598718|NCT00656838|No Intervention|2|Usual Care
11598719|NCT00656825|Active Comparator|Panel I|The first 12 subjects will be selected and ranodmized in order to receive the first treatment dose of 100 μg/mL or placebo in a 8:4 ratio
11598720|NCT00656825|Active Comparator|Panel II|The second 12 subjects will be selected and randomized in order to receive the second treatment dose of 200 μg/mL or placebo in a 8:4 ratio
11598721|NCT00656825|Active Comparator|Panel III|The third 12 subjects will be selected and randomized in order to receive the third treatment dose of 300 μg/mL or placebo in a 8:4 ratio
11598722|NCT00656825|Placebo Comparator|Placebo|Patients from each panel will be given placebo in a 4:8 ratio.
11598723|NCT00656812|Experimental|Treatment Arm|Combination therapy Rituximab plus 2CdA
11598724|NCT00656799|Experimental|Sugammadex|IV single bolus dose of 4.0 mg/kg sugammadex
11598725|NCT00656786|Experimental|Group 1|Subjects will be treated if, after starting treatment with an EGFRi, acute signs and symptoms of rash on the face/neck and/or upper chest emerge, that are suspected of being related to the EGFRi treatment.
11598726|NCT00656786|Experimental|Group 2|Subjects will receive pre-emergent rash treatment starting 1 day prior to beginning EGFRi therapy
11598727|NCT00656773|Experimental|1|
11598728|NCT00656773|Active Comparator|2|
11598729|NCT00656760|Experimental|A|All patients have PET/CT and biopsies with the surgeon blinded to the result of PET/CT. Additional biopsies are performed (or not) after the surgeon has the PET/CT results revealed.
11598730|NCT00656747|Active Comparator|Arm 2|
11598731|NCT00656747|Experimental|Arm 1|
11598732|NCT00656734|Experimental|MDX 1411|Dose Escalation Cohorts
11598733|NCT00656721|Experimental|Flutter Valve|This a crossover study, so all subjects performed both, control and experimental interventions. In Flutter Valve intervention the subjects remained comfortably seated, breathing through the device for 15 minutes, starting off from the total pulmonary capacity, and being free to cough. Thereafter, a 5-min session of cough ensued. In the control intervention the subjects followed the same sequence of the Flutter Valve intervention, but the metallic sphere and the cover of the device were removed. Since the patients were not acquainted with the valve, they did not know its proper assembly. As in the Flutter Valve intervention, during 15 minutes the patients could expectorate spontaneously and return to the device. A 5-min coughing session took place.
11598734|NCT00656708|Experimental|PB|All patients admitted to the burn unit during the prospective portion (interventional portion) of the study who have open wounds will have Kerlix AMD applied to their wounds; only those patients consenting to the study will have data abstracted.
11598735|NCT00656695|Experimental|1|taking Iminoral
11598736|NCT00656695|Active Comparator|2|taking Neoral
11598737|NCT00656682|Active Comparator|Dietitian Counseling Alone|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian. Registered Dietitian Counseling Alone
11598738|NCT00656682|Experimental|Dietitian Plus Community Group Lifestyle|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based diabetes prevention lifestyle intervention offered by the community. Dietitian Counseling Plus Community Group Lifestyle Intervention.
11598739|NCT00656669|Experimental|1|The study will be conducted in 3 sequential treatment segments.
11598740|NCT00656656|Other|Immunoadsorption/Dexamethasone/Rituximab|
11598741|NCT00656643|Experimental|1|
11598742|NCT00656643|Experimental|2|
11598743|NCT00656643|Experimental|3|
11598744|NCT00656643|Placebo Comparator|4|
11598745|NCT00656630|Active Comparator|1|Acamprosate
11598746|NCT00656630|Active Comparator|2|Naltrexone
11598747|NCT00656630|Placebo Comparator|3|
11598748|NCT00656617|Experimental|Idarubicin + Ara-C + Vorinostat|Idarubicin 12 mg/m^2 by vein (IV) over 1 hour daily for 3 days (days 4 to 6). Ara-C (Cytarabine) 1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7). Vorinostat initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
11598749|NCT00656604|Experimental|Women with breast cancer|Patients undergo DCE-MRI and MRS prior to their breast cancer surgery.
11598750|NCT00656604|No Intervention|Healthy volunteers|Women without breast cancer undergo DCE-MRI and MRS.
11598751|NCT00656578|Experimental|1|4975
11598752|NCT00656578|Placebo Comparator|2|Drug, Single dose, solution
11598753|NCT00656565||1|subjects with bronchiectasis
11598754|NCT00656539|Experimental|1|AzaSite®
11598755|NCT00656539|No Intervention|2|
11598756|NCT00656526|Placebo Comparator|A01L|
11598757|NCT00656526|No Intervention|B01C|
11598758|NCT00656513|Active Comparator|Pilocarpine: Phase III|
11598759|NCT00656513|Experimental|ALTENS: Phase III|
11598760|NCT00656513|Experimental|ALTENS: Phase II|
11598761|NCT00656500|Active Comparator|1|Brief assistance with smoking abstinence
11598803|NCT00656188|Placebo Comparator|Arm 2|
11598763|NCT00656487|Experimental|Cannabis-dependent rimonabant|Cannabis dependent young adults administered rimonabant 90 mg at Day 0 and followed for 28 days post.
11598764|NCT00656487|Placebo Comparator|Cannabis-dependent placebo|Cannabis dependent young adults administered matched placebo at Day 0 and followed for 28 days post.
11598765|NCT00656487|No Intervention|Non-cannabis using control|Non-cannabis using demographically similar young adults followed for 28 days.
11598766|NCT00656474|Experimental|1|GLYC-101 Active Retro-auricular Site (1 per participant)
11598767|NCT00656474|Placebo Comparator|2 Comparator|"Placebo Retro-auricular Site (1 per participant)
~This arm undergoes laser ablation with subsequent Placebo gel administration"
11598768|NCT00656461|Experimental|1|
11598769|NCT00656448|Experimental|Procrit Arm|Participants receive Procrit along with blood transfusions. Procrit 40,000 units subcutaneously every week starting within two weeks (before or after) from the start of induction chemotherapy.
11598770|NCT00656448|No Intervention|No Procrit: Standard Arm|Participants do not receive Procrit before receiving blood transfusions.
11598771|NCT00656435|Experimental|A|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
11598772|NCT00656435|No Intervention|B|Patients will not receive bevacizumab pretreatment
11598773|NCT00656422|Experimental|insulin Levemir|
11598774|NCT00656422|Experimental|insulin Lantus|
11598775|NCT00656396|Active Comparator|Control|Standard care
11598776|NCT00656396|Experimental|Intervention|Point of care monitoring used
11598777|NCT00656383|Active Comparator|1|Client is randomized to receive leg ulcer treatment in the home
11598778|NCT00656383|Active Comparator|2|Client randomized to receive leg ulcer care in the clinic
11598779|NCT00656370|Experimental|NS Infusion Group|Normal Saline (NS) and Hylenex
11598780|NCT00656370|Experimental|LR Infusion Group|Lactated Ringer's (LR) and Hylenex
11598781|NCT00656357|Placebo Comparator|A|SYN117 placebo and Ascending doses of cocaine (10, 20, 40 mg) and placebo
11598782|NCT00656357|Experimental|B|Ascending doses of SYN117 (placebo, 80 mg, 160 mg) and ascending doses of cocaine (10 mg, 20 mg, 40 mg) and placebo
11598783|NCT00656331|Active Comparator|1|Amlodipine
11598784|NCT00656331|Active Comparator|2|HCTZ
11598785|NCT00656318||Group 1 (Zovia)|Subjects will be randomized to receive either the oral contraceptive pill (OCP) Zovia or Necon for 2 months. Prior to beginning the OCP, women will undergo 1 imaging scan. Upon completion of the scan they will receive their first dose of their OCP. Three hours later they will undergo a 2nd imaging scan. Each scan last approximately 1 hour and 15 minutes. This test day is typically scheduled on a Saturday, and lasts approximately 7 hours. Upon completion of the Saturday test day, subjects will remain on their OCP for the remainder of that month and continue taking the pill for a 2nd month. At the end of the 2 months on the pill, subjects will have the option of discontinuing the pill or receiving 1 additional month at no charge before being discharged from the study.
11598786|NCT00656318||Group 2 (Necon)|Subjects will be randomized to receive either the oral contraceptive pill (OCP) Zovia or Necon for 2 months. Prior to beginning the OCP, women will undergo 1 imaging scan. Upon completion of the scan they will receive their first dose of their OCP. Three hours later they will undergo a 2nd imaging scan. Each scan last approximately 1 hour and 15 minutes. This test day is typically scheduled on a Saturday, and lasts approximately 7 hours. Upon completion of the Saturday test day, subjects will remain on their OCP for the remainder of that month and continue taking the pill for a 2nd month. At the end of the 2 months on the pill, subjects will have the option of discontinuing the pill or receiving 1 additional month at no charge before being discharged from the study.
11598787|NCT00656305|Experimental|ExAblate Treatment Arm|
11598788|NCT00656305|Sham Comparator|ExAblate Sham Arm|
11598789|NCT00656292|Placebo Comparator|Simvastatin|Subjects randomized to this arm will receive statin therapy (simvastatin 40 mg) two days before surgery -- allowing three doses of simvastatin before incision -- and these will be continued until patients are either discharged from the hospital or have completed a 3-day postoperative course (6 days of simvastatin therapy), whichever occurs earlier. If patients are unable to take oral medications, the enteral route via nasogastric tube (at our institution, nasogastric tubes are routinely placed for both lumbar and thoracic instrumentation) will be used to deliver either placebo or the statin, as no parenteral form of this drug is currently available.
11598790|NCT00656292|Experimental|Placebo|Subjects randomized to this arm will receive placebo two days before surgery -- allowing three doses of placebo before incision -- and these will be continued until patients are either discharged from the hospital or have completed a 3-day postoperative course (6 days of placebo), whichever occurs earlier. If patients are unable to take oral medications, the enteral route via nasogastric tube (at our institution, nasogastric tubes are routinely placed for both lumbar and thoracic instrumentation) will be used to deliver either placebo or the statin, as no parenteral form of this drug is currently available.
11598791|NCT00656279|Experimental|1|Intensive dietary phosphorus education
11598792|NCT00656279|No Intervention|2|Standard dietary education consists of the dietitian assessing laboratory values and dietary intake and providing dietary education for abnormal values using handouts developed for specific nutrients.
11598793|NCT00656266|Placebo Comparator|tacrolimus & corticosteroids|Standard post-transplant immunosuppression medications: tacrolimus and corticosteroids
11598794|NCT00656266|Experimental|low-dose tacrolimus + steroids + MMF|Comparison arm: low-dose tacrolimus + steroids + MMF
11598795|NCT00656253|Experimental|A|
11598796|NCT00656253|Placebo Comparator|B|
11598797|NCT00656240|Experimental|1|
11598798|NCT00656240|Experimental|2|
11598799|NCT00656214|Active Comparator|A|Patients with symptomatic oral lichen planus
11598800|NCT00656214|Placebo Comparator|B|Patients with symptomatic oral lichen planus
11598801|NCT00656201|Active Comparator|Crinone 8% Vaginal Gel|Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
11598802|NCT00656201|Active Comparator|Intramuscular Progesterone|"Progesterone-50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.
~."
11598805|NCT00656175|Active Comparator|Immediate|Immediate switch of PI or NNRTI to Raltegravir
11598806|NCT00656175|Active Comparator|Delayed|Continue current therapy unchanged for 24 weeks, then switch PI or NNRTI to Raltegravir
11598807|NCT00656149|Active Comparator|Telerehabilitation of hand function|Intervention: for one hour per day participants perform exercise therapy on a home-based tele-rehabilitation workstation, the Rehabilitation Joystick for Computerized Exercise (ReJoyce) with which participants play computer games associated with activities of daily life. A remote therapist coaches each one-hour session over the Internet, with the use of the ReJoyce tele-rehabilitation system. Hand grasp-release is assisted with functional electrical stimulation (FES) triggered voluntarily by the participant with the use of a wireless earpiece with a sensor that detects toothclicks.
11598808|NCT00656149|Active Comparator|Conventional exercise therapy|Intervention: for one hour per day participants perform conventional range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 with the use of the ReJoyce tele-rehabilitation min). A remote therapist coaches each one-hour session A remote therapist coaches each one-hour session over the Internet, with the use of the ReJoyce tele-rehabilitation system.
11598809|NCT00656136|Placebo Comparator|Placebo|Patients receive placebo once daily
11598810|NCT00656136|Experimental|BIBW 2992|Patients receive BIBW 2992 tablets once daily
11598811|NCT00656123|Experimental|CY and colon GVAX|
11598812|NCT00656110|Experimental|1-T|Treatment Group
11598813|NCT00656110|Placebo Comparator|2-P|Placebo comparator
11598814|NCT00656097|Experimental|A|CL184 combined with rabies vaccination
11598815|NCT00656097|Active Comparator|B|HRIG combined with rabies vaccination
11598816|NCT00656097|Placebo Comparator|C|Placebo combined with rabies vaccination
11598817|NCT00656084|Experimental|Experimental arm|Patients will be treated a maximum of 8 cycles or until the patient has evidence of a response, progressive disease, or until intolerable toxicity develops. Patients with a complete response will receive an additional 2 cycles of treatment (not to exceed 8 cycles). Drug order is gemcitabine, mitoxantrone, and rituximab.
11598818|NCT00656071||1|Control -- postoperative mechanical ventilation patients without ARDS
11598819|NCT00656071||2|Cases -- postoperative mechanical ventilation patients with ARDS
11598820|NCT00656058|Experimental|Montelukast to Treat Bronchiolitis Obliterans|Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.
11598821|NCT00656045|Experimental|A|Arm A focuses on increasing the participant's physical activity level.
11598822|NCT00656045|Experimental|B|Arm B focuses on decreasing the amount of time the participant spends watching Television.
11598823|NCT00656032|Active Comparator|1|SOC medication for treatment of renal osteodystrophy
11598824|NCT00656032|Active Comparator|2|alternate SOC medication for treatment of renal osteodystrophy
11598825|NCT00656019|No Intervention|Normal Vitamin D Levels|No additional Vitamin D administered
11598826|NCT00656019|Experimental|Low-normal Vitamin D Levels|2000 IU dose of Vitamin D per day administered orally
11598827|NCT00656019|Experimental|Low Vitamin D Levels|4000 IU dose of Vitamin D per day administered orally
11598828|NCT00656019|Experimental|Very-low Vitamin D Levels|6000 IU dose of Vitamin D per day administered orally
11598829|NCT00655993|Placebo Comparator|1|placebo drug
11598830|NCT00655993|Active Comparator|2|simvastatin
11598831|NCT00655980|Experimental|Treatment|Vitamin B12 and folic acid
11598832|NCT00655980|Placebo Comparator|Comparator|Nitrous oxide and placebo
11598833|NCT00655980|Other|Standard of care|standard of care
11598834|NCT00655967|Experimental|1|Acamprosate(Campral)
11598835|NCT00655954||Healthy volunteers non smoker|18 volunteers
11598836|NCT00655954||Healthy volunteers smoker|15 volunteers
11598837|NCT00655954||Chronic Obstructive Pulmonary Disease COPD|39 volunteers
11598838|NCT00655941|Experimental|1|Dietary instruction (low-energy diet. This is given by instructions in groups of 8
11598839|NCT00655941|Active Comparator|2|Exercise
11598840|NCT00655941|No Intervention|3|Control
11598841|NCT00655928|Experimental|N-acetylcysteine|Participant received N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively
11598842|NCT00655928|Placebo Comparator|Placebo|Participant received 0.9% saline 1 litre intravenous over 12 hours pre-operatively
11598843|NCT00655915||Injection Patients|Those patients who receive corticosteroid injections for carpal tunnel syndrome
11598844|NCT00655902|Experimental|1|
11598845|NCT00655902|Placebo Comparator|2|
11598846|NCT00655889|Experimental|Active|
11598847|NCT00655876|Experimental|Chemoradiation + Cetuximab|External beam radiation therapy (RT) with concurrent weekly paclitaxel, cisplatin, and cetuximab
11598848|NCT00655876|Active Comparator|Chemoradiation|External beam radiation therapy with concurrent weekly paclitaxel, and cisplatin
11598849|NCT00655863|Placebo Comparator|Placebo QD|
11598850|NCT00655863|Experimental|Alogliptin 25 mg QD|
11598851|NCT00655863|Experimental|Alogliptin 25 mg QD + Pioglitazone 30 mg QD|
11598852|NCT00655850|Experimental|Paclitaxel and Gemcitabine + Avastin|Patients will be treated with metronomic chemotherapy with paclitaxel and gemcitabine weekly for 3 out of 4 weeks which constitutes one cycle (4 weeks). Avastin will be administered every 2 weeks. Treatment with metronomic chemotherapy and Avastin will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with Avastin will continue until disease progression, intolerable toxicity, or withdrawal of consent.
11598853|NCT00655837|Experimental|1|
11598854|NCT00655824|Experimental|Ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
11598855|NCT00655811|Active Comparator|Capsaicin|Capsaicin 0.1% cream application to the volar side of forearm.
11598856|NCT00655811|Placebo Comparator|Placebo moisturizing cream|Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.) to the opposite forearm.
11598857|NCT00655798|Placebo Comparator|1|
11598858|NCT00655798|Active Comparator|2|
11598859|NCT00655798|Active Comparator|3|
11598860|NCT00655798|Active Comparator|4|
11598861|NCT00655785|Experimental|Phase 1/2 study|
11598862|NCT00655746|Experimental|1|
11598863|NCT00655733|Experimental|HMPL-004|Subjects who fulfilled all entry criteria and randomized HMPL-004 arm will receive HMPL-004 400 mg 3 times daily 3 times daily for 56 days (8 weeks) with a 28-day (4-week) follow-up.
11598864|NCT00655733|Placebo Comparator|Placebo|Subjects who fulfilled all entry criteria and randomized Placebo arm will receive matching placebo 400 mg 3 times daily 3 times daily for 56 days (8 weeks) with a 28-day (4-week) follow-up.
11598865|NCT00655720|Active Comparator|1|
11598866|NCT00655720|Experimental|2|
11598867|NCT00655720|Experimental|3|
11598868|NCT00655707|Experimental|Autologous CD34+ cells|Autologous Cluster Designation 34+(CD34+) cells
11598869|NCT00655681|Experimental|A|Receives pamidronate 1mg/kg
11598870|NCT00655681|Placebo Comparator|B|receives saline injection
11598871|NCT00655668|Experimental|Lenalidomide|Open-label, oral lenalidomide monotherapy
11598872|NCT00655655|Experimental|Arm I|See Detailed Description
11598873|NCT00655642|Active Comparator|Ondansetron|Ondansetron 4 mg intravenous administration
11598874|NCT00655642|Active Comparator|Metoclopramide|Metoclopramide 10 mg intravenous administration
11598875|NCT00655642|Active Comparator|Promethazine|Promethazine 10 mg intravenous administration
11598876|NCT00655642|Placebo Comparator|Saline Placebo|Volume-matched saline placebo
11598877|NCT00655629|Experimental|Vardenafil ODT (STAXYN, BAY38-9456)|Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
11598878|NCT00655629|Placebo Comparator|Placebo|Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
11598879|NCT00655616|Active Comparator|1|The active comparator arm consists of Flixotide® (fluticasone propionate) via accuhaler (Diskus) dry powder inhaler device as per current inhaled steroid dose plus oral montelukast
11598880|NCT00655616|Placebo Comparator|2|The placebo comparator arm consists of Seretide® (salmeterol plus equivalent dose of fluticasone) via accuhaler dry powder inhaler device as per current inhaled steroid dose plus placebo for montelukast
11598881|NCT00655603|Experimental|1|10 patients with Type 2 Diabetes Mellitus
11598882|NCT00655603|Experimental|2|10 healthy, matched control participants
11598883|NCT00655590|Experimental|Arm 1|
11598884|NCT00655590|Active Comparator|Arm 2|
11598885|NCT00655590|Placebo Comparator|Arm 3|
11598886|NCT00655577|No Intervention|2|Control group
11598887|NCT00655577|Experimental|1|Exercise group
11598888|NCT00655564|Experimental|Alefacept|Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.
11598889|NCT00655551|Experimental|Lacosamide 200 mg cohort|Single loading dose of intravenous (iv) lacosamide 200 mg followed by 6.5 days of oral lacosamide 100 mg twice daily
11598890|NCT00655551|Experimental|Lacosamide 300 mg combined cohorts|Single loading dose of intravenous (iv) lacosamide 300 mg dose followed by 6.5 days of oral lacosamide 150 mg twice daily
11598891|NCT00655551|Experimental|Lacosamide 400 mg cohort|Single loading dose of intravenous (iv) lacosamide 400 mg followed by 6.5 days of oral lacosamide 200 mg twice daily
11598892|NCT00655538|Experimental|Dalcetrapib|
11598893|NCT00655538|Placebo Comparator|Placebo|
11598894|NCT00655525|Active Comparator|1|
11598895|NCT00655525|Placebo Comparator|2|
11598896|NCT00655512|Active Comparator|1|
11598897|NCT00655512|Active Comparator|2|
11598898|NCT00655512|Active Comparator|3|
11598899|NCT00655512|Active Comparator|4|
11598900|NCT00655512|Placebo Comparator|5|
11598901|NCT00655486|Experimental|Lacosamide|Lacosamide 100 to 800 mg/day, flexible dosing, administered twice daily throughout the duration of the study (up to 2 years)
11598902|NCT00655473|Experimental|Dalcetrapib (RO4607381)|
11598903|NCT00655473|Placebo Comparator|Placebo|
11598904|NCT00655460|Experimental|eProtocol|
11598905|NCT00655447||1|all women having a hysterectomy with oophorectomy
11598906|NCT00655447||2|all women having a hysterectomy without removal of ovaries
11598907|NCT00655434||SAA|Sexually Active Adults- Intercourse in the last twelve months with at least one sexual partner. Subjects must be ≥ 18 years old. No more than 60% of one gender.
11598908|NCT00655421|Experimental|Unaided|Unaided Visual Inspection of the Oral Cavity
11598909|NCT00655421|Experimental|VelScope|VelScope assisted examination of the oral cavity
11598910|NCT00655421|Experimental|Toluidine|Examination of oral cavity after the local application of Toluidine Blue dye
11598911|NCT00655408|Active Comparator|A|"For infants with ages between six and 24 months, iron supplementation is the main treatment for iron deficiency.This study was carried out using two intervention groups. All children received 12 weekly doses of 25 mg of elemental iron.
~Group 1 administered in the government healthcare clinic. Group 2 administered children's home.
~The study showed treatment compliance in both groups."
11598912|NCT00655395|Experimental|1|"Laromustine 300 mg/m2 (cohort 1) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.
~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
11598913|NCT00655395|Experimental|2|"Laromustine 400 mg/m2 (cohort 2) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.
~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
11598914|NCT00655395|Experimental|3|"Laromustine 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.
~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
11598981|NCT00654966|Active Comparator|2|Healthy subjects
11598982|NCT00654953|Placebo Comparator|1|Placebo capsules
11598983|NCT00654953|Experimental|2|sertraline (200 mg/day)
11598915|NCT00655395|Experimental|5|"Laromustine will be administered at the recommended phase II dose on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.
~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
11598916|NCT00655395|Experimental|4|"Laromustine 600 mg/m2 (cohort 4) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.
~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
11598917|NCT00655369|Experimental|15 mg|
11598918|NCT00655369|Experimental|25 mg|
11598919|NCT00655369|Experimental|35 mg|
11598920|NCT00655369|Experimental|5 mg|
11598921|NCT00655369|Experimental|50 mg|
11598922|NCT00655369|Placebo Comparator|Placebo|
11598923|NCT00655356|Experimental|Active|
11598924|NCT00655356|Placebo Comparator|Placebo|
11598925|NCT00655343|Experimental|ATG-F|"ATG-Fresenius S (20 mg/kg body weight at days -3 to -1 (total dose: 60 mg/kg)
~cyclosporine A (target trough level > 200ng/ml (day -1 until day +100)
~methotrexate: 15mg/m2 at day +1, 10mg/m2 at days +3, +6, and +11"
11598926|NCT00655343|No Intervention|non-ATG-F|"cyclosporine A (target trough level > 200ng/ml (day -1 until day +100)
~methotrexate: 15mg/m2 at day +1, 10mg/m2 at days +3, +6, and +11"
11598927|NCT00655330|Active Comparator|1|Valsartan (160mg/day)is given in combination with Placebo
11598928|NCT00655330|Experimental|2|Valsartan (160mg/day) + Probucol (750mg/day)
11598929|NCT00655317|Active Comparator|1|Treatment Acupuncture Group (Therapeutic Acupuncture Treatment): treatment with actual acupuncture needles
11598930|NCT00655317|Sham Comparator|2|SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
11598931|NCT00655304|Active Comparator|1|Treatment with 6-8 hours of Prometheus (R) liver support dialysis
11598932|NCT00655304|Active Comparator|2|Treatment with 6-8 hours of CVVHDF
11598933|NCT00655291|Placebo Comparator|A|
11598934|NCT00655291|Experimental|B|
11598935|NCT00655278|Experimental|1|T2000 at 600-1000 mg daily
11598936|NCT00655265|Experimental|Colesevelam hydrochloride film-coated tablets|
11598937|NCT00655265|Placebo Comparator|Placebo|
11598938|NCT00655239|Active Comparator|Control|Participants will use commercially available computer games.
11598939|NCT00655239|Experimental|Active|Participants will receive targeted neuroadaptive cognitive training with neuroplasticity-based software created by Posit Science Corporation.
11598940|NCT00655239|Active Comparator|Healthy Control|Healthy participants will receive targeted neuroadaptive cognitive training with neuroplasticity-based software created by Posit Science Corporation.
11598941|NCT00655226|Experimental|CBT skills based group sessions|Cognitive Behavioral Therapy skills based group sessions
11598942|NCT00655226|Active Comparator|Hepatitis C educational support groups|Hepatitis C educational support groups
11598943|NCT00655213|Active Comparator|1|AAISafeR mode programming
11598944|NCT00655213|Active Comparator|2|DDD with long AV Delay programming
11598945|NCT00655213|Active Comparator|3|DDDAMC mode programming
11598946|NCT00655213|Other|4|AAISafer mode programming in non randomized patients
11598947|NCT00655200||A|
11598948|NCT00655187||Group A|Cases
11598949|NCT00655187||Group B|Controls
11598950|NCT00655174|Placebo Comparator|1|
11598951|NCT00655174|Experimental|2|
11598952|NCT00655174|Experimental|3|
11598953|NCT00655148|Experimental|A|DTaP-IPV vero vaccination at 2, 3½, 5 and 16 months of age
11598954|NCT00655148|Active Comparator|B|DTaP-IPV mkc vaccination at 2, 3½, 5 and 16 months of age
11598955|NCT00655135|Placebo Comparator|1|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received placebo administered intravenously to patients on Day 1 and Day 29.
11598956|NCT00655135|Experimental|2|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received 0.5 mg/kg of LDP-02 administered intravenously to patients on Day 1 and Day 29.
11598957|NCT00655135|Experimental|3|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received 2 mg/kg of LDP-02 administered intravenously to patients on Day 1 and Day 29.
11598958|NCT00655122|Active Comparator|Dalteparin sodium|
11598959|NCT00655122|Placebo Comparator|Placebo|
11598960|NCT00655109|Active Comparator|1|Olopatadine
11598961|NCT00655109|Active Comparator|2|Fluticasone
11598962|NCT00655109|Placebo Comparator|3|Placebo nasal spray
11598963|NCT00655109|Placebo Comparator|4|Placebo Eyedrops
11598964|NCT00655096||Affected participants|Adults and children with either diagnosed or undiagnosed ocular conditions.
11598965|NCT00655096||Disease free control|Adults and children without any ocular disorders.
11598966|NCT00655096||Unaffected relative|Unaffected first degree relative of a genetic ocular disease participant.
11598967|NCT00655083|Experimental|1|Nepadutant 0.1 mg/kg
11598968|NCT00655083|Experimental|2|Nepadutant 0.5 mg/kg
11598969|NCT00655057|Active Comparator|1|Healthy participants will undergo TRODAT-1 SPECT imaging.
11598970|NCT00655057|Experimental|2|Participants with depression will undergo TRODAT-1 SPECT imaging and treatment with s-citalopram.
11598971|NCT00655057|Active Comparator|3|Participants with depression will undergo TRODAT-1 SPECT imaging and treatment with cognitive behavioral therapy.
11598972|NCT00655044||Type 1 and type 2 diabetes patients|
11598973|NCT00655031|Experimental|1|Pomegranate concentrate (POMx)
11598974|NCT00655031|Placebo Comparator|2|Fruit flavored juice low in antioxidants
11598975|NCT00655018|Experimental|Vitamin group|alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
11598976|NCT00655018|Placebo Comparator|2|placebo and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
11598977|NCT00654992|Active Comparator|EPO group|
11598978|NCT00654992|Placebo Comparator|Placebo group|
11598979|NCT00654979|Experimental|Single arm|SafeFlo IVC Filter
11598980|NCT00654966|Experimental|1|Heart failure patients
11598984|NCT00654953|Experimental|3|sertraline (200 mg/day) plus gabapentin (1,200 mg/day)
11598985|NCT00654940|Active Comparator|A|
11598986|NCT00654940|Placebo Comparator|B|
11598987|NCT00654914|Experimental|Arm 1|
11598988|NCT00654901|Experimental|DTaP-IPV-Hep B-PRP~T Batch 1|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651); and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
11598989|NCT00654901|Experimental|DTaP-IPV-Hep B-PRP~T Batch 2|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651) and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
11598990|NCT00654901|Experimental|DTaP-IPV-Hep B-PRP~T Batch 3|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651) and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
11598991|NCT00654901|Active Comparator|Infanrix Hexa™|Participants had received 3 primary doses of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), (Infanrix Hexa™) plus Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed in Study A3L11 (NCT00404651) and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
11598992|NCT00654888|Active Comparator|1|Group one submitted to automated lamellar keratectomy(ALK) with mitomycin (0,02% in 30 seconds after keratectomy).
11598993|NCT00654888|Active Comparator|2|automated lamellar keratectomy without mitomycin
11598994|NCT00654875|Experimental|Aliskiren 300 mg (Once a Day)|Participants received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening for a total of 10 weeks.
11598995|NCT00654875|Experimental|Aliskiren 150 mg (Twice a Day)|Participants received Aliskiren 150 mg tablet + Placebo to Aliskiren matching 300 mg tablet daily in the morning and Aliskiren 150 mg tablet daily in the evening for the first 6 weeks then for the next 4 weeks received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening.
11598996|NCT00654862|Experimental|1|Subjects with stage 1 hypertension
11598997|NCT00654862|Experimental|2|Subjects with optimal blood pressure
11598998|NCT00654849|Experimental|1|compare security and effectiveness of use Electrosurgical Bipolar Plasmakinetic Vessel Sealing
11598999|NCT00654849|Active Comparator|2|traditional abdominal hysterectomy technique with the use of sutures
11599000|NCT00654836|Experimental|Carboplatin, ABI-007 and Bevacizumab|Participants will receive combination carboplatin, nanoparticle albumin-bound paclitaxel (ABI-007-Abraxane), and bevacizumab (Avastin)
11599001|NCT00654810|Experimental|1|Low intensity group (40% of maximal exercise capacity)
11599002|NCT00654810|Experimental|2|High intensity group (80% of maximal exercise capacity)
11599003|NCT00654797|Experimental|eProtocol|
11599004|NCT00654784|Experimental|1|
11599005|NCT00654784|Placebo Comparator|2|
11599006|NCT00654771||1|women undergoing evaluation for pre-eclampsia
11599007|NCT00654758|Experimental|1|Escalating doses of volociximab at 10, 20, and 30 (or 15) mg/kg with carboplatin and paclitaxel.
11599008|NCT00654745|Experimental|aml + olm + hctz|amlodipine; and olmesartan medoxomil, if required; and hydrochlorothiazide, if required.
11599009|NCT00654732|Experimental|Arm A (rituximab, combination chemotherapy)|Participants receive rituximab intravenously IV over 7 hours on days 1, 8, 15, and 22 of course 1 and on days 1 and 8 of course 2. Participants also receive doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine IV over 1 hour on days 1 and 15. Treatment with ABVD repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11599010|NCT00654732|Active Comparator|Arm B (combination chemotherapy)|Participants receive doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine as in Arm A.
11599011|NCT00654719|Active Comparator|NutriDrink|Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
11599012|NCT00654719|Placebo Comparator|Placebo|
11599013|NCT00654706|Experimental|Sertindole|
11599014|NCT00654706|Active Comparator|Quetiapine|
11599015|NCT00654693||monitored|patients hospitalized for longer than 24 hours and are located on the 4th, 5th, and 6th floors of the Vanderbilt University Medical Center Round Wing
11599016|NCT00654680|Experimental|Arm 1|
11599017|NCT00654680|Placebo Comparator|Arm 2|
11599018|NCT00654667|Placebo Comparator|2|Placebo
11599019|NCT00654667|Experimental|Experimental 1|Resveratrol
11599020|NCT00654654|Experimental|Active|
11599021|NCT00654641|Experimental|Negative pressure wound closure|Negative Pressure wound closure
11599022|NCT00654641|Active Comparator|Standard wound closure|Standard Wound Closure
11599023|NCT00654628|Experimental|1|Patients with intermediate or high risk dyslipidemia will be enrolled to receive treatment with Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks
11599024|NCT00654615|Active Comparator|1|"Intramedullary Radius Fixation (Micronail) - Group 1
~A new device was developed to provide intramedullary distal radius fracture fixation. This new device allows the placement of the orthopaedic hardware inside the medullary canal of the radius."
11599025|NCT00654615|Active Comparator|2|"Volar Plate Fixation - Group 2
~Volar locking plates provide rigid external fixation and are placed on the outside of the radius. Volar plates are placed directly on the distal radius using a metal plate contoured to the shape of the distal radius."
11599026|NCT00654589|Experimental|deferasirox|
11599027|NCT00654576|Active Comparator|1|the comparator arm will only receive one of the seven antipsychotic
11599028|NCT00654576|Experimental|2|the experimental group will receive one of the seven study drugs combination with psychosocial intervention
11599030|NCT00654537|Experimental|1|Rosuvastatin
11599031|NCT00654537|Active Comparator|2|Atorvastatin
11599032|NCT00654537|Active Comparator|3|Pravastatin
11599033|NCT00654537|Active Comparator|4|Simvastatin
11599034|NCT00654524|Experimental|1|Patients in this arm will be treated with goserelin depot-3.6mg plus add-back therapy.
11599035|NCT00654524|No Intervention|2|The patient with advanced endometriosis（stage III-IV）confirmed histologically after conservative laparoscopic surgery will be suggested to prepare for spontaneous pregnancy rather than any medical administration.
11599036|NCT00654511|Active Comparator|Fentanyl 1|Fentanyl 1 micrograms (mcg)/kilogram (kg)
11599037|NCT00654511|Active Comparator|Fentanyl 2|Fentanyl 2 micrograms (mcg)/kilogram (kg)
11599038|NCT00654511|Experimental|Dex 3|Dexmedetomidine 2 micrograms (mcg)/kilogram (kg)
11599039|NCT00654511|Experimental|Dex 4|Dexmedetomidine 4 micrograms (mcg)/kilogram (kg)
11599040|NCT00654498|Other|Pramipexole|4 weeks of individual dose titration starting with Pramipexole 0.125 mg, next dose steps 0.25 mg, 0.5 mg and 0.75 mg, fixed dose for 2 weeks, once daily
11599041|NCT00654498|Other|Placebo|4 weeks of individual dose titration as for the investigational product, once daily
11599042|NCT00654485|Experimental|1|Rosuvastatin
11599043|NCT00654485|Active Comparator|2|Atorvastatin
11599044|NCT00654472||A|Mitral valve area above 1.5 cm2
11599045|NCT00654472||B|Mitral valve area 1.5 cm2 and below 1.5 cm2
11599046|NCT00654459||A|
11599047|NCT00654459||B|
11599048|NCT00654446|Experimental|1|Rosuvastatin
11599049|NCT00654446|Active Comparator|2|Simvastatin
11599050|NCT00654433|Experimental|I|
11599051|NCT00654420|Experimental|Ph I: Dalotuzumab 5 mg/kg + Erlotinib|During the Phase I part of the study, participants receive dalotuzumab intravenously (IV) at 5 mg/kg weekly plus open-label erlotinib at 150 mg daily for 4 weeks. After 4 weeks of therapy, participants in Phase I who do not have disease progression and are satisfactorily tolerating study drug can continue to receive study drug.
11599052|NCT00654420|Experimental|Ph I: Dalotuzumab 10 mg/kg + Erlotinib|During the Phase I part of the study, participants receive dalotuzumab intravenously (IV) at 10 mg/kg weekly plus open-label erlotinib at 150 mg daily for 4 weeks. After 4 weeks of therapy, participants in Phase I who do not have disease progression and are satisfactorily tolerating study drug can continue to receive study drug.
11599053|NCT00654420|Experimental|Ph II: Dalotuzumab 10 mg/kg + Erlotinib|During the Phase II part of the study, participants are randomized to receive dalotuzumab intravenously (IV) at 10 mg/kg weekly plus open-label erlotinib at 150 mg daily until disease progression or occurrence of unacceptable toxic effects.
11599054|NCT00654420|Active Comparator|Ph II: Erlotinib|During the Phase II part of the study, participants are randomized to receive open-label erlotinib at 150 mg daily until disease progression or occurrence of unacceptable toxic effects.
11599055|NCT00654407|Experimental|1|Rosuvastatin
11599056|NCT00654407|Active Comparator|2|Atorvastatin
11599057|NCT00654407|Active Comparator|3|Simvastatin
11599058|NCT00654394|Experimental|1|
11599059|NCT00654381|Active Comparator|voglibose 0.2 mg three times a day (TID)|patient to receive a tablet containing 0.2 mg voglibose TID plus 2 placebo tablets matching BI 1356
11599060|NCT00654381|Experimental|BI 1356 low dose|patient to receive a tablet containing BI 1356 and matching placebo plus 3 placebo tablets matching voglibose
11599061|NCT00654381|Experimental|BI 1356 high dose|patient to receive 2 tablets containing BI 1356 plus 3 placebo tablets matching voglibose
11599062|NCT00654381|Placebo Comparator|placebo|patient to receive 2 placebo tablets matching BI 1356 plus 3 placebo tablets matching voglibose
11599063|NCT00654368|Active Comparator|Etanercept + Methotrexate|After six months of treatment with 50 mg/week subcutaneous etanercept added to existing methotrexate therapy of at least 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses) participants were randomized to continue both etanercept plus methotrexate for an additional 18 months.
11599064|NCT00654368|Experimental|Etanercept Only|After six months of treatment with 50 mg/week subcutaneous etanercept added to existing methotrexate therapy of at least 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses) participants were randomized to discontinue methotrexate (tapered over 6 weeks) and continue etanercept alone for an additional 18 months.
11599065|NCT00654355|Experimental|Active Drug|tacrolimus ointment
11599066|NCT00654342|Other|1|In vivo injection group
11599067|NCT00654342|Other|2|Ex vivo injection group
11599068|NCT00654329|Experimental|Dexmedetomidine 1microgram/kilogram|Dexmedetomidine 1microgram/kilogram intranasal
11599069|NCT00654329|Experimental|Dexmedetomidine 2 micrograms/kilogram|Dexmedetomidine 2 micrograms/kilogram intranasal
11599070|NCT00654329|Active Comparator|Fentanyl 2 micrograms/kilogram|Fentanyl 2 micrograms/kilogram intranasal
11599071|NCT00654329|Placebo Comparator|Normal saline placebo|Normal saline placebo intranasal
11599072|NCT00654316|Experimental|1|BCG delivered intradermally into the deltoid region in volunteers who have received BCG 10 - 20 years previously.
11599073|NCT00654303|Experimental|1|Rosuvastatin
11599074|NCT00654290|Experimental|P|Propranolol from 7 days pre-operation to 5 days post CABG
11599075|NCT00654290|Active Comparator|A|Amiodarone treated 7 days pre-operation to 5 days post CABG
11599076|NCT00654290|Active Comparator|AP|Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
11599077|NCT00654277|Experimental|A|Subjects received Kali formulated products under fasting conditions
11599078|NCT00654277|Active Comparator|B|Subjects received GlaxoSmithKine product under fasting conditions
11599079|NCT00654264|Other|1|Patients will have water immersion on first day and sitting in a tub without water on the second day.
11599080|NCT00654264|Other|2|Patients will sit in a tub without water on the first day and have water immersion on the second day.
11599081|NCT00654238|Experimental|1|This is a single arm study.
11599082|NCT00654225|Experimental|1|Rosuvastatin
11599083|NCT00654225|Active Comparator|2|Atorvastatin
11599084|NCT00654212|Active Comparator|1|endoluminal stenting followed by laparoscopic resection (endo-laparoscopic limb, the study group)
11599085|NCT00654212|Other|2|emergency open surgery (open limb, the control group)
11599087|NCT00654173|Experimental|1|Rosuvastatin
11599088|NCT00654173|Active Comparator|2|Simvastatin
11599089|NCT00654173|Active Comparator|3|Atorvastatin
11599090|NCT00654147|Active Comparator|Raltegravir & Lopinavir/ritonavir|Raltegravir 400 mg tablet and Lopinavir/ritonavir capsule by mouth, every 12 hours for 48 weeks
11599091|NCT00654147|Active Comparator|Raltegravir & emtricitabine/tenofovir|Raltegravir 400 mg tablet bu mouth, every 12 hours for 48 weeks and tenofovir/embritcitabine 200 mg/100 mg table by mouth, once daily for 48 weeks
11599092|NCT00654121|Active Comparator|1|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
11599093|NCT00654121|No Intervention|2|
11599094|NCT00654108|Experimental|Cohort 1: vaccine dosage level 1 or placebo|Vaccine dose level 1: 1 X 10^7 colony forming unit (CFU) or placebo, treated with Cipro on days 7-11.
11599095|NCT00654108|Experimental|Cohort 4: vaccine dosage level 4 or placebo|Vaccine dose level 4: 1 X 10^10 CFU or placebo, treated with Cipro on days 7-11.
11599096|NCT00654108|Experimental|Cohort 2: vaccine dosage level 2 or placebo|Vaccine dose level 2: 1 X 10^8 CFU or placebo, treated with Cipro on days 7-11.
11599097|NCT00654108|Experimental|Cohort 3: vaccine dosage level 3 or placebo|Vaccine dose level 3: 1 X 10^9 CFU or placebo, treated with Cipro on days 7-11.
11599098|NCT00654095|Experimental|Ezetimibe + Atorvastatin|Ezetimibe 10 mg + Atorvastatin 20 mg
11599099|NCT00654082|Active Comparator|Arm 1|
11599100|NCT00654082|Placebo Comparator|Arm 2|
11599101|NCT00654069|Placebo Comparator|Placebo|Tablet
11599102|NCT00654069|Active Comparator|Acurox 5/30mg|Oxycodone HCl 5mg/Niacin 30mg tablet
11599103|NCT00654069|Placebo Comparator|Acurox 7.5/30|Oxycodone HCl 7.5mg/Niacin 30mg tablet
11599104|NCT00654056|Experimental|L1|Actrapid infusion, 0.5 mU/kg/min.
11599105|NCT00654056|Experimental|L2|Actrapid infusion 1.5 mU/kg/min
11599106|NCT00654056|Experimental|H1|Actrapid infusion 3.0 mU/kg/min
11599107|NCT00654056|Experimental|H2|Actrapid infusion 5.0 mU/kg/min
11599108|NCT00654043|Experimental|A|Subjects received Par formulated products under fed conditions
11599109|NCT00654043|Active Comparator|B|Subjects received Roche formulated products
11599110|NCT00654030|Experimental|1650-G Vaccine|Patients receive 2 injections of 1650-G Vaccine given 4 weeks apart, for a total of 52 weeks on study.
11599111|NCT00654017|Placebo Comparator|placebo|
11599112|NCT00654017|Active Comparator|sildenafil|
11599113|NCT00654004||Subjects|Subjects are patients with a long-chain fatty acid oxidation disorder including CPT2, VLCAD, TFP or LCHAD deficiency.
11599114|NCT00654004||Controls|Subjects do not have a fatty acid oxidation disorder.
11599115|NCT00653991|Experimental|SOLVE-IT|Participants will receive the intervention SOLVE-IT. The SOLVE-IT intervention is a videogame designed to optimize self-regulation, reduce shame, and reduce risky choices for young men who have sex with men (YMSM).
11599116|NCT00653991|Active Comparator|Waitlist Control|Participants will receive the intervention, SOLVE-IT, a video game designed to optimize self-regulation reduce shame, and reduce risky sexual choices for YMSM, after a 6-month waitlist period.
11599117|NCT00653978|Experimental|1|patients receiving one stent
11599118|NCT00653978|Active Comparator|2|patients receiving two stents
11599119|NCT00653965|Experimental|1|Rosuvastatin
11599120|NCT00653965|Active Comparator|2|Atorvastatin
11599121|NCT00653952|Experimental|001|
11599122|NCT00653952|Active Comparator|002|
11599123|NCT00653939|Active Comparator|Arm 1: Chemotherapy+Bevacizumab|Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg)administered intravenously on Day 1 of a 21-day cycle for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab (15 mg/kg) alone on Day 1 every 3 weeks until progression or until 12 months from randomization.
11599124|NCT00653939|Experimental|Arm 2: Active Comparator+Fosbretabulin|Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg), administered intravenously Day 1 of a 21-day cycle and fosbretabulin (60 mg/m2) on Days 7, 14, and 21 for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab (15 mg/kg) on Day 1 and fosbretabulin on Days 1, 7 and 14 every 3 weeks until progression or until 12 months from randomization.
11599125|NCT00653926|Active Comparator|A|Group A (Active) receives a multimodal injection intra- and postoperatively
11599126|NCT00653926|Placebo Comparator|P|Group P (Placebo) receives no injection intraoperatively and a saline injection postoperatively
11599127|NCT00653913|Active Comparator|Group A|SCH 58235 (Period 1) Pitavastatin (Period 2) Coadministration (Period 3)
11599128|NCT00653913|Active Comparator|Group B|SCH 58235 (Period 1) Coadministration (Period 2) Pitavastatin (Period 3)
11599129|NCT00653913|Active Comparator|Group C|Pitavastatin (Period 1) SCH 58235 (Period 2) Coadministration (Period 3)
11599130|NCT00653913|Active Comparator|Group D|Pitavastatin (Period 1) Coadministration (Period 2) SCH 58235 (Period 3)
11599131|NCT00653913|Active Comparator|Group E|Coadministration (Period 1) SCH 58235 (Period 2) Pitavastatin (Period 3)
11599132|NCT00653913|Active Comparator|Group F|Coadministration (Period 1) Pitavastatin (Period 2) SCH 58235 (Period 3)
11599133|NCT00653900||1|All patients undergoing elective, invasive cardiac procedure on plavix prior to admission
11599134|NCT00653887|Active Comparator|A|biofeedback (active group)
11599135|NCT00653887|Placebo Comparator|B|discussion about digestive tract (placebo group)
11599136|NCT00653874|Experimental|1: TcB|transcutaneous bilirubinometry (TcB) was used for deciding the need for blood sampling to measure serum total bilirubin (STB)
11599137|NCT00653874|Active Comparator|2: CaB|clinical assessment of jaundice (CaB) was used for deciding the need for blood sampling to measure serum total bilirubin (STB)
11599138|NCT00653861|Experimental|Juvederm with Lidocaine|Subjects receive Juvederm with Lidocaine (either Ultra or Ultra Plus at investigator's discretion) in one nasolabial fold.
11599139|NCT00653861|Active Comparator|Juvederm|Subjects receive Juvederm without Lidocaine (either Ultra or Ultra Plus at investigator's discretion) in the other nasolabial fold.
11599140|NCT00653848|Experimental|Docetaxel arm|six of docetaxel every third week + hormonal treatment
11599141|NCT00653848|No Intervention|Control|hormonal treatment only
11599142|NCT00653835|Experimental|Ezetimibe + Simvastatin|
11599143|NCT00653835|Active Comparator|Simvastatin|
11599144|NCT00653822|Experimental|1a|IV
11599145|NCT00653822|Placebo Comparator|1b|IV
11599146|NCT00653822|Experimental|2a|Lower SC dose
11599147|NCT00653822|Placebo Comparator|2b|SC to match lower dose
11599148|NCT00653822|Experimental|3a|Higher SC dose
11599149|NCT00653822|Placebo Comparator|3b|SC to match higher dose
11599150|NCT00653809||A, 1, I|Caucasian women without preeclampsia or PIH, delivering their first child
11599151|NCT00653809||A, 1, II|Caucasian women with preeclampsia or PIH, delivering their first child
11599152|NCT00653809||A, 2, I|African-american women without preeclampsia or PIH, delivering their first child
11599153|NCT00653809||A, 2, II|African-American women with preeclampsia or PIH, delivering their first child
11599154|NCT00653809||B, 1, I|Caucasian women without preeclampsia or PIH, delivering at least their second child
11599155|NCT00653809||B, 1, II|Caucasian women with preeclampsia or PIH, delivering at least their second child
11599156|NCT00653809||B, 2, I|African-american women without preeclampsia or PIH, delivering at least their second child
11599157|NCT00653809||B, 2, II|African-american women with preeclampsia or PIH, delivering at least their second child
11599158|NCT00653796|Experimental|Ezetimibe + Atorvastatin|
11599159|NCT00653796|Active Comparator|Atorvastatin|
11599160|NCT00653770|Experimental|1|FP85A at day 0
11599161|NCT00653770|Experimental|2|MVA85A at day 0 and FP85A at day 28
11599162|NCT00653770|Experimental|3|FP85A at day 0 and MVA85A at day 28
11599163|NCT00653744|Experimental|1|Rosuvastatin
11599164|NCT00653744|Active Comparator|2|Atorvastatin
11599165|NCT00653731|Experimental|Snoezelen ©|
11599166|NCT00653731|Experimental|Reminiscence|
11599167|NCT00653731|Experimental|10 min activation|
11599168|NCT00653731|Active Comparator|Talk|
11599169|NCT00653705|Active Comparator|Probiotic|Children given probiotic BB12 enriched yogurt drink.
11599170|NCT00653705|Placebo Comparator|Control|Children given dairy drink.
11599171|NCT00653692||Observational|Poly drug dependent women
11599172|NCT00653653||Group A|Recruited patients will be prospectively observed as one cohort with genotyping/medication interaction analysis after 3 months, followed up by a further 3 month observational period.
11599173|NCT00653640|Experimental|1|body weight supported treadmill training
11599174|NCT00653640|Placebo Comparator|2|traditional physical therapy
11599175|NCT00653627|Experimental|A|Study of BCG quantification and immunogenicity 2 weeks after BCG vaccination
11599176|NCT00653627|Experimental|B|Study of BCG quantification and immunogenicity 4 weeks after BCG vaccination
11599177|NCT00653614|Experimental|Arm 1|E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for 24 days and DRSP (ZK 30595) dose 1 (SHT04984F) for one day and placebo for three days in a 28 day cycle
11599178|NCT00653614|Experimental|Arm 2|E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for 24 days and DRSP (ZK 30595) dose 1 (SHT04984F) for two days and placebo for two days in a 28 day cycle
11599179|NCT00653614|Experimental|Arm 3|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for days 9-16, E2/DRSP (BAY 86-4891) dose 3 (80458755) for days 17-24, and placebo for days 25-28 in a 28 day cycle
11599180|NCT00653614|Experimental|Arm 4|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for days 9-16, E2/DRSP (BAY 86-4891) dose 3 (80458755) for days 17-24, placebo for 3 days, and DRSP (ZK 30595) dose 1 (SHT04984F) for one day in a 28 day cycle
11599181|NCT00653614|Experimental|Arm 5|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 4 (80458720) for days 9-16, E2/DRSP (BAY 86-4891) dose 5 (80458712) for days 17-24, and placebo for 4 days in a 28 day cycle
11599182|NCT00653614|Experimental|Arm 6|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 4 (80458720) for days 9-16, E2/DRSP (BAY 86-4891)dose 5 (80458712) for days 17-24, placebo for 3 days, and DRSP (ZK 30595) dose 2 (80458690) for one day in a 28 day cycle
11599183|NCT00653601||1|Patients who receive bridge therapy with tirofiban who were previously on plavix for drug eluting or bare metal stent prior to scheduled invasive procedures
11599184|NCT00653601||2|"Patients who do NOT receive bridge therapy previously on plavix for drug eluting or bare metal stent prior to scheduled invasive procedures. This will entail of a matching case-control for the following characteristics.
~# of RF for stent thrombosis
~types of stents
~time frame when the stents were placed
~procedure type"
11599185|NCT00653588|Experimental|1|rosuvastatin (40 mg)
11599186|NCT00653588|Active Comparator|2|atorvastatin (80 mg)
11599187|NCT00653575||1|Women who report a history of childhood sexual abuse
11599188|NCT00653575||2|Women who do not report a history of childhood sexual abuse
11599189|NCT00653562|Experimental|1|Patients will receive placebo in one part and zolpidem in the other part
11599190|NCT00653549|Experimental|A|Subjects received Par formulated product under fasting conditions
11599191|NCT00653549|Active Comparator|B|Subjects received Roche formulated product under fasting conditions
11599192|NCT00653523|Experimental|Ezetimibe + Simvastatin|Ezetimibe 10 mg + Simvastatin 20 mg
11599193|NCT00653510|Experimental|Euglycemic|The patients will be examined with a blood glucose at around 5-7 mmol/L.
11599194|NCT00653510|Experimental|Hyperglycemic|The patients will be examined with a blood glucose at around 18-20 mmol/L
11599195|NCT00653497|Experimental|1|Community-based aquatic exercise program (Arthritis Foundation Aquatics Program). Two classes per week, 45-60 minutes in duration.
11599196|NCT00653497|No Intervention|2|Usual care; abstention from initiation of new exercise programs. Invited to participate in Arthritis Foundation Aquatics Program after study completion.
11599197|NCT00653484|Experimental|Physical Activity Only|Physical Activity
11599198|NCT00653484|Experimental|Dietary Energy Restriction|Energy restriction
11599199|NCT00653484|Experimental|Physical Activity+Dietary Energy Restriction|Physical Activity ad Energy Restriction
11599200|NCT00653471|Active Comparator|Lean|Lean patients
11599201|NCT00653471|Active Comparator|Obese no OSA|Obese patients without osa
11599202|NCT00653471|Active Comparator|Obese osa|Obese patients with osa
11599203|NCT00653458|Experimental|A|Subjects received Kali formulated products under fed conditions
11599204|NCT00653458|Active Comparator|B|Subjects received GlaxoSmithKline's formulated products under fed conditions
11599205|NCT00653445|Experimental|1|Rosuvastatin 40mg/Ezetimibe 10mg combination therapy
11599206|NCT00653445|Experimental|2|Rosuvastatin 40 mg
11599207|NCT00653432|Experimental|Monovisc®|Injectable Hyaluronic Acid Gel
11599208|NCT00653432|Placebo Comparator|Saline|0.9% Sterile Saline
11599209|NCT00653419|Experimental|A|Subjects received the Par formulated product (Buspirone HCl) under fasting conditions
11599210|NCT00653419|Active Comparator|B|Subjects received the Bristol-Myers Squibb formulated product (Buspar) under fasting conditions
11599211|NCT00653393|Experimental|A|Subjects received Kali product under fasting conditions
11599212|NCT00653393|Active Comparator|B|Subjects received Parnate product under fasting conditions
11599213|NCT00653380|Experimental|A|Subjects received the Par product (Doxycycline Monohydrate) under fasting conditions.
11599214|NCT00653380|Active Comparator|B|Subjects received Oclassen's product (Monodox) under fasting conditions.
11599215|NCT00653367|Experimental|NS|Nerve section of intercostal nerve during surgery
11599216|NCT00653367|No Intervention|Control|Control
11599217|NCT00653354|Active Comparator|Arm 1|
11599218|NCT00653354|Active Comparator|Arm 2|
11599219|NCT00653354|Placebo Comparator|Arm 3|
11599220|NCT00653328|Experimental|Therapeutic Intervention|
11599221|NCT00653315|Experimental|A|Subjects received kali product under fasting conditions
11599222|NCT00653315|Active Comparator|B|Subjects received Ortho-Mcneil product under fasting conditions
11599223|NCT00653302|Experimental|1|Lantus once a day plus Glucophage 1000mg, twice a day per os
11599224|NCT00653276|Active Comparator|Treatment A|Treatment A: subjects will be given a single oral dose of cyclosporine 100 mg capsules on Day 1.
11599225|NCT00653276|Active Comparator|Treatment B|Treatment B: subjects will receive single oral daily doses of ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through 6, followed by coadministration of a single oral dose of ezetimibe 20 mg (2 x 10 mg tablets) and cyclosporine 100 mg capsule on Day 7.
11599226|NCT00653263||Methamphetamine dependent|Methamphetamine dependent participants admitted to Recovery Centers of Arkansas
11599227|NCT00653250|Experimental|Therapeutic Intervention|Correlative
11599228|NCT00653237|Other|1|crossover trial. insertion of both devices consecutively, computer randomized order
11599229|NCT00653224|Placebo Comparator|Placebo|Matched placebo tablets
11599230|NCT00653224|Experimental|LCTZ|5 mg tablet
11599231|NCT00653198||A|Cases
11599232|NCT00653198||B|Controls
11599233|NCT00653185|Experimental|SYR-472 25 mg QD|(with lifestyle modification and/or metformin therapy)
11599234|NCT00653185|Experimental|SYR-472 50 mg QD|(with lifestyle modification and/or metformin therapy)
11599235|NCT00653185|Experimental|SYR-472 100 mg QD|(with lifestyle modification and/or metformin therapy)
11599236|NCT00653185|Experimental|SYR-472 200 mg QD|(with lifestyle modification and/or metformin therapy)
11599237|NCT00653185|Placebo Comparator|Placebo QD|(with lifestyle modification and/or metformin therapy)
11599238|NCT00653172|Experimental|1|NXL103
11599239|NCT00653172|Active Comparator|3|
11599240|NCT00653172|Experimental|2|NXL103
11599241|NCT00653159|Active Comparator|Mirena IUD [LNG-IUS]|Participants in this arm had a Levonorgestrel-releasing intrauterine device (LNG-IUS), also known as the Mirena IUD, inserted within the first 5 days of the adolescent's menstrual cycle, at least 7 weeks after a vaginal or cesarean delivery or second-trimester abortion or at least 3 weeks after a first-trimester abortion. For participants who had used depot-medroxyprogesterone acetate, insertions occurred at least 6 months after the participant's last injection. Participants were blinded to the device type; however, investigators and research assistants were not.
11599242|NCT00653159|Active Comparator|Paragard IUD [Copper T380A]|Participants in this arm had a Copper T380A intrauterine device (CuT380A), also known as the Paragard IUD, inserted within the first 5 days of the adolescent's menstrual cycle, at least 7 weeks after a vaginal or cesarean delivery or second-trimester abortion or at least 3 weeks after a first-trimester abortion. For participants who had used depot-medroxyprogesterone acetate, insertions occurred at least 6 months after the participant's last injection. Participants were blinded to the device type; however, investigators and research assistants were not.
11599243|NCT00653146|Experimental|Mindfulness-based stress reduction|The MBSR program includes meditation techniques, body scan, awareness of breathing, mindful yoga, eating meditation, and walking meditation, and meets for 2 hours, once weekly for 8 weeks.
11599244|NCT00653146|Placebo Comparator|Healthy Lifestyles Program|The Healthy Lifestyles Program includes information on nutrition and physical activity, and meets for 2 hours, once weekly for 8 weeks.
11599245|NCT00653133|Active Comparator|USPNB|Ultrasound imaging guided peripheral nerve block
11599246|NCT00653133|Active Comparator|NSPNB|Peripheral nerve stimulator guided peripheral nerve block catheter placement for continuous infusion of local anesthetic
11599247|NCT00653120|Experimental|A|Subjects received Par Products under fasting conditions
11599248|NCT00653120|Active Comparator|B|Subjects received Wyeth Pharmaceuticals product under fasting conditions
11599249|NCT00653107|Experimental|A|Stent followed by 3 brachytherapy fractions
11599250|NCT00653107|Active Comparator|B|3 fractions of brachytherapy
11599251|NCT00653094|Other|A|
11599252|NCT00653081|Active Comparator|A|Supervised Exercises performed at ulleval Hospital for patients with shoulder pain. Dosage: 45 minutes each time, max 2-3 times a week in max 12 weeks
11599253|NCT00653081|Active Comparator|B|Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
11599282|NCT00652834|Other|kidney recipients with GI symptoms|This was a four-week study designed to investigate GI mucosal lesions by SBCE in kidney transplant recipients who were using MMF, and to examine the changes in clinical symptoms and intestinal mucosa lesions 30 days after switching over from MMF to EC-MPS. The patient was switched from MMF to EC-MPS (Myfortic) on the equimola basis.
11599283|NCT00652821|Experimental|A|Subjects received Kali product under fed condition
11599254|NCT00653068|Experimental|Arm I (chemotherapy, autologous PBSC, 3D-CRT)|"Patients receive vincristine IV on days 1, 8, and 15; high-dose methotrexate IV on day 1; leucovorin calcium orally or IV; etoposide IV on days 4, 5, and 6; cyclophosphamide IV on days 4 and 5; cisplatin IV on day 6, and G-CSF IV or SC on day 7 until ANC recovers.
~Within 2-6 weeks after induction therapy or radiation therapy, patients receive high-dose carboplatin IV and high-dose thiotepa IV on days 1 and 2 and undergo autologous PBSC rescue on approximately day 4. Patients also receive G-CSF IV or SC once daily until ANC recovers. Treatment with consolidation therapy followed by stem cell rescue repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. After consolidation therapy, patients undergo 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks."
11599255|NCT00653068|Experimental|Arm II (chemotherapy, 3D-CRT, autologous PBSC)|"Patients receive vincristine IV on days 1, 8, and 15; high-dose methotrexate IV on day 1; leucovorin calcium orally or IV; etoposide IV on days 4, 5, and 6; cyclophosphamide IV on days 4 and 5; cisplatin IV on day 6, and G-CSF IV or SC on day 7 until ANC recovers.
~Patients undergo 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks. Within 2-6 weeks after completion of radiation therapy, patients receive high-dose carboplatin IV and high-dose thiotepa IV on days 1 and 2 and undergo autologous PBSC rescue on approximately day 4. Patients also receive G-CSF IV or SC once daily until ANC recovers. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
11599256|NCT00653055|Experimental|A|Subjects received the test product, Cabergoline 0.5 mg tablets under fasting conditions
11599257|NCT00653055|Active Comparator|B|Subjects received the reference product, Dostinex under fasting conditions
11599258|NCT00653003|Experimental|A|Subjects received Kali formulated product under fed conditions
11599259|NCT00653003|Active Comparator|B|Subjects received Aventis formulated products under fed conditions
11599260|NCT00652977|Active Comparator|I|The delivery of the fetal head should be managed by Ritgens maneuver, i.e. lifting the fetal chin anteriorly, using the fingers of one hand placed between the anus and the coccyx, and thereby extending the fetal neck, whereas the other hand should be placed on the fetal occiput to control the pace of the expulsion of the fetal head.
11599261|NCT00652977|Other|II|Standard care at delivery: Manual support of the perineum
11599262|NCT00652964||Observation|a family of congenital central hypoventilation syndrome
11599263|NCT00652951|Active Comparator|Synflorix + Infanrix hexa Group|Subjects received 3 doses of SynflorixTM vaccine co-administered with Infanrix hexaTM at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (SynflorixTM) or left (Infanrix hexaTM) thigh or deltoid.
11599264|NCT00652951|Experimental|Synflorix + Pediacel Group|Subjects received 3 doses of SynflorixTM vaccine co-administered with PediacelTM at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (SynflorixTM) or left (PediacelTM) thigh or deltoid.thigh or deltoid.
11599265|NCT00652951|Active Comparator|Prevenar + Pediacel Group|Subjects received 3 doses of PrevenarTM co-administered with PediacelTM vaccine at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (PrevenarTM) or left (PediacelTM) thigh or deltoid.
11599266|NCT00652938|Active Comparator|Cervarix & Engerix Group|Subjects received 3 doses of Cervarix™ (Human Papillomavirus [HPV] vaccine) co-administered with Engerix™ (Hepatitis B [HBV] vaccine) according to a 0, 1, 6-month schedule.
11599267|NCT00652938|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ (Human Papillomavirus [HPV] vaccine) according to a 0, 1, 6-month schedule.
11599268|NCT00652938|Active Comparator|Engerix Group|Subjects received 3 doses of Engerix™ (Hepatitis B [HBV] vaccine) according to a 0, 1, 6-month schedule.
11599269|NCT00652925|Experimental|High Dose|
11599270|NCT00652925|Experimental|Low Dose|
11599271|NCT00652925|Active Comparator|Naproxen|Control comparator, 15 mg/kg/dy target dose
11599272|NCT00652912|Experimental|A|Subjects received the Kali formulated products under fasting conditions
11599273|NCT00652912|Active Comparator|B|Subjects received the Roche's product under fasting conditions
11599274|NCT00652899|Experimental|Total Body Irradiation|"This group includes patients that received all chemotherapy, infusion of natural killer (NK) cells and total body irradiation per protocol.
~1. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m^2 on Days 6 through 2 preceding NK cell infusion. 4. Radiation: total-body irradiation 200 cGy Day 1 preceding NK cell infusion. 5. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 * 10^7/kg. 6. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0."
11599275|NCT00652899|Experimental|No Total Body Irradiation|"This group includes patients that received chemotherapy and infusion of natural killer cells, but did not receive total body irradiation.
~1. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m^2 on Days 6 through 2 preceding NK cell infusion. 4. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 * 10^7/kg. 5. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0."
11599276|NCT00652886|Experimental|A|Subjects received Kali's products under fasting conditions
11599277|NCT00652886|Active Comparator|B|Subjects received BTG products under fasting conditions
11599278|NCT00652873|Experimental|A|Subjects received the test product, Cabergoline 0.5 mg tablets under fed conditions
11599279|NCT00652873|Active Comparator|B|Subjects received the reference product, Dostinex under fed conditions
11599280|NCT00652847|Experimental|group 1|group 1: ezetimibe 10 mg per day is added to actual statin regimen for 6 weeks followed by an observational phase of 6 months.
11599281|NCT00652847|Active Comparator|Group 2|Group 2: patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase.
11599284|NCT00652821|Active Comparator|B|Subjects received Ortho-Mcneil product under fed conditions
11599285|NCT00652808|Active Comparator|Arm 1|
11599286|NCT00652808|Active Comparator|Arm 2|
11599287|NCT00652795|Experimental|A|Subjects received the Par product (Doxycycline Monohydrate) under fasting conditions.
11599288|NCT00652795|Active Comparator|B|Subjects received the Oclassen's product (Monodox) Capsules under fasting conditions.
11599289|NCT00652782|Experimental|1|rolofyline 2.5 mg IV QD
11599290|NCT00652782|Experimental|2|rolofyline 15 mg IV QD
11599291|NCT00652782|Experimental|3|rolofyline 30 mg IV QD
11599292|NCT00652782|Experimental|4|rolofyline 60 mg IV QD
11599293|NCT00652782|Placebo Comparator|5|placebo for rolofyline IV QD
11599294|NCT00652769|Active Comparator|B|Control arm: Current practice for diagnosing and staging lung cancer. Most patients with intra-thoracic disease suspected of lung cancer will undergo bronchoscopy (or CT guided biopsy), PET scan and possibly mediastinoscopy.
11599295|NCT00652769|Experimental|A|Active arm: A new pathway for the diagnosis and staging of lung cancer with endobronchial (EBUS) or endoscopic ultrasound (EUS) as a first test. If EBUS or EUS is negative the patient will have PET scan +/- mediastinoscopy.
11599296|NCT00652756|Experimental|1|Patient is placed on a transport ventilator.
11599297|NCT00652756|Other|2|Patient is ventilated using the current standard at this institution.
11599298|NCT00652743|Experimental|GSK1562902A M6 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) and boosted 6 months (M6) after primary vaccination with one dose of Pandemic influenza candidate vaccine (GSK1562902A) in study 109630 (NCT00449670), administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
11599299|NCT00652743|Experimental|GSK1562902A M12 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) in study 109630 (NCT00449670) receiving one dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, at 12 Months (M12) after the primary vaccination, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
11599300|NCT00652743|Experimental|GSK1562902A M36 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) in study 109630 (NCT00449670) receiving one dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, at 36 Months (M36) after the primary vaccination, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
11599301|NCT00652730|Experimental|A|Subjects received the Par formulated product under fasting conditions
11599302|NCT00652730|Experimental|B|Subjects received the Par formulated product under fed conditions
11599303|NCT00652730|Active Comparator|C|Subjects received the Bristol-Myers Squibb formulated product under fed conditions
11599304|NCT00652717|Experimental|1|arm 1 - Ezetimibe 10 mg daily that was added on Statin Therapy (prescribed clinically suitable dose by the physician).
11599305|NCT00652717|Active Comparator|2|arm 2- simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
11599306|NCT00652704|Experimental|A|Subjects received the test product, Doxycycline Monohydrate Capsules (Par) under fed conditions
11599307|NCT00652704|Active Comparator|B|Subjects received the reference product, Monodox (Oclassen) under fed conditions
11599308|NCT00652704|Experimental|C|Subjects received the test product, Doxycycline Monohydrate Capsules (Par) under fasting conditions
11599309|NCT00652665|Experimental|A|Subjects received kali product under fasting conditions
11599310|NCT00652665|Active Comparator|B|Subjects received Aventis product under fasting conditions
11599311|NCT00652639|Experimental|A|Subjects received the kali formulated products under fasting conditions
11599312|NCT00652639|Active Comparator|B|Subjects received the Roche formulated products under fasting conditions
11599313|NCT00652626|Experimental|Azacitidine 25 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 25 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
11599314|NCT00652626|Experimental|Azacitidine 50 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 50 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
11599315|NCT00652626|Experimental|Azacitidine 75 mg/m^2|Participants with normal renal function received subcutaneous doses of azacitidine 75 mg/m^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
11599316|NCT00652626|Experimental|Azacitidine 100 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 100 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
11599317|NCT00652626|Experimental|Severe RI: azacitidine 75 mg/m^2|Participants with severe renal impairment (RI; defined as creatinine clearance < 30 mL/min/1.73 m^2) received subcutaneous doses of azacitidine 75 mg/m^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
11599318|NCT00652613|Active Comparator|1|3 dimensional conformal radiotherapy
11599319|NCT00652613|Experimental|2|Intensity Modulated Radiation Therapy (IMRT)
11599320|NCT00652600|Experimental|A|Subjects received Par formulated product under fed conditions
11599321|NCT00652600|Active Comparator|B|Subjects received Wyeth Pharmaceuticals formulated product under fed conditions
11599322|NCT00652587|Experimental|A, LRTACE|hepatectomy with adjuvant transcatheter arterial chemoembolization
11599323|NCT00652587|Active Comparator|B, LR|hepatectomy alone
11599324|NCT00652574|Experimental|Dasatinib|Dasatinib = BMS-354825, Sprycel
11599325|NCT00652561|Experimental|1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks.
11599326|NCT00652522|Active Comparator|A|Best Medical Treatment, ICD/CRT implant
11599327|NCT00652522|Experimental|B|AF Ablation, ICD/CRT implant
11599328|NCT00652509|Experimental|1|IDEA
11599329|NCT00652509|Active Comparator|2|IE
11599330|NCT00652509|No Intervention|3|UC: Patients receive no research intervention.
11599331|NCT00652496|Experimental|1|Bimatoprost 0.01% ophthalmic solution
11599332|NCT00652496|Experimental|2|Bimatoprost 0.015% formulation 1 ophthalmic solution
11599333|NCT00652496|Experimental|3|Bimatoprost 0.015% formulation 2 ophthalmic solution
11599334|NCT00652496|Experimental|4|Bimatoprost 0.02% ophthalmic solution
11599335|NCT00652496|Active Comparator|5|Bimatoprost 0.03% ophthalmic solution
11599336|NCT00652483|Experimental|1|Brimonidine ophthalmic solution 0.1%
11599337|NCT00652483|Active Comparator|2|Brimonidine ophthalmic solution 0.2%
11599338|NCT00652470|Active Comparator|ETV|
11599339|NCT00652470|Active Comparator|CSF Shunt|
11599340|NCT00652457|Experimental|Memantine|Memantine 10 mg BID for three months
11599341|NCT00652457|Placebo Comparator|Placebo|Placebo 10 mg BID for three months
11599342|NCT00652444|Experimental|1|Coadministration arm: simvastatin 20mg and ezetimibe 10mg
11599343|NCT00652444|Experimental|2|Monotherapy arm: simvastatin 20mg and ezetimibe placebo
11599344|NCT00652431|Experimental|Vytorin + Niaspan|NIASPAN 1000 mg (1 x 1000 mg tablet) once-daily in the morning on Days 1 to 2, followed by NIASPAN 2000 mg (2 x 1000 mg tablets) once-daily in the morning on Days 3 to 7 + VYTORIN 10/20 mg (1 x 10/20 mg tablet containing ezetimibe 10 mg and simvastatin 20 mg) once-daily in the morning for 7 days
11599345|NCT00652431|Active Comparator|Vytorin|VYTORIN 10/20 mg (1 x 10/20 mg tablet containing ezetimibe 10 mg and simvastatin 20 mg) once-daily in the morning for 7 days
11599346|NCT00652431|Active Comparator|Niaspan|NIASPAN 1000 mg (1 x 1000 mg tablet) once-daily in the morning on Days 1 to 2, followed by NIASPAN 2000 mg (2 x 1000 mg tablets) once-daily in the morning on Days 3 to 7 for a total of 7 days of treatment
11599347|NCT00652418|Active Comparator|Arm 1|
11599348|NCT00652418|Experimental|Arm 2|
11599349|NCT00652405|Experimental|treatment A|four weeks of white wine consumption (25g alcohol/day; ~2.5 standard drinks)
11599350|NCT00652405|Placebo Comparator|Treatment B|Four weeks of water
11599351|NCT00652392|Experimental|1|
11599352|NCT00652392|Placebo Comparator|2|
11599353|NCT00652379|Experimental|1|Co-treatment with Pegvisomant (15-30 mg twice a week) and a 50 percent reduced somatostatin-analog dose
11599354|NCT00652379|Active Comparator|2|Somatostatin analog, unaltered dosage
11599355|NCT00652366|Active Comparator|Gemcitabine, Erlotinib Standard Dose|Participants received erlotinib, 100 milligrams (mg), orally (PO), once daily until disease progression or unacceptable toxicity. Participants also received gemcitabine, 1000 mg per (/) square meter (m^2), intravenously (IV), on Days 1, 8, and 15 of consecutive 4 week cycles until disease progression or unacceptable toxicity.
11599356|NCT00652366|Experimental|Gemcitabine, Erlotinib Escalating Dose|Participants received erlotinib, beginning at 150 mg/day, PO, once daily, and increasing in increments of 50 mg every 2 weeks up to a maximum of 250 mg/day, until development of a grade 2 rash, or occurrence of other, non-rash, dose-limiting toxicity; treatment was continued until disease progression, unacceptable toxicity, death or withdrawal. Participants also received gemcitabine, 1000 mg/m^2, IV, on Days 1, 8, and 15 of consecutive 4 week cycles until disease progression or unacceptable toxicity.
11599357|NCT00652353|Experimental|Intervention|Participants will be given a standardized information sheet providing a mnemonics to help remember the Ottawa Ankle and foot Rules.
11599358|NCT00652353|Placebo Comparator|0|control group
11599359|NCT00652340|Experimental|A|
11599360|NCT00652340|Placebo Comparator|B|
11599361|NCT00652327|Experimental|Ezetimibe + Statin|
11599362|NCT00652327|Active Comparator|Double Statin|
11599363|NCT00652314|Experimental|1 - Thrombi-gel treatment|Thrombi-gel treatment
11599364|NCT00652314|Active Comparator|2 - Gelatin Sponge (Gelfoam)|Gelatin Sponge (Gelfoam) plus thrombin
11599365|NCT00652301|Experimental|1|ezetimibe 10 mg tablet plus simvastatin 20 mg tablet
11599366|NCT00652301|Active Comparator|2|ezetimibe 10 mg tablet
11599367|NCT00652301|Active Comparator|3|simvastatin 20 mg tablet
11599368|NCT00652301|Placebo Comparator|4|matching placebo
11599369|NCT00652288|Active Comparator|Catheter day 4|Adolescents with type 1 diabetes with catheters day #4
11599370|NCT00652288|Active Comparator|Catheter day 1|Adolescents with type 1 diabetes with catheter day #1
11599371|NCT00652288|Active Comparator|Aspart and Detemir|Adolescents with type 1 diabetes
11599372|NCT00652288|Active Comparator|Lispro and Glargine|Adolescents with type 1 diabetes
11599373|NCT00652275|Experimental|A|"Biological/Vaccine: 189 volunteers will receive the Malaria vaccine MSP3 Long Synthetic Peptide (LSP)
~Arms: MSP3 LSP vaccine Biological/Vaccine:MSP3 LSP 30 micrograms of MSP3 LSP
~Arms: I, MSP3 LSP vaccine"
11599374|NCT00652275|Active Comparator|B|189 volunteers will receive standard vaccine against rabies on the similar schedule on days 0, 28, and 56
11599375|NCT00652262|Experimental|Arm 1|
11599376|NCT00652249||Extraventricular Drainage/Pressure|Includes pediatric hydrocephalus patients that are in recovery from shunt explanation.
11599377|NCT00652236||FCT|Patients passing a function- centred rehabilitation
11599378|NCT00652236||PCT|Patients passing a pain-centred rehabilitation
11599379|NCT00652223|Experimental|1|
11599380|NCT00652210|Experimental|MPM|Subject tissue was reviewed using multiphoton microscopy
11599381|NCT00652197||Extraventricular Drainage|Includes pediatric hydrocephalus patients that are in recovery from shunt explanation.
11599382|NCT00652184|Placebo Comparator|1|Placebo cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10
11599383|NCT00652184|Active Comparator|2|Placebo cream BID for 10 days and active valaciclovir caplets TID from days 1-10
11599384|NCT00652184|Experimental|3|Active cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10
11599385|NCT00652184|Other|4|Active cream BID for 10 days and active valaciclovir caplets TID from days 1-10
11599386|NCT00652171|Active Comparator|1|17 Patients - Mean age of 26 years old, 14 female and 3 male - with major depressive disorder in single or recurrent episodes, with moderate to severe intensity. Besides, They also had a history of treatment-resistant depression stage II or above according to the criteria of by Thase and Rush: failure to respond to treatment with at least 2 antidepressants of different classes, at the maximum tolerated dose for at least 6 weeks and absence of psychotic symptoms.
11599387|NCT00652171|Placebo Comparator|2|17 Patients - 11 females and 6 males mean age of 29 years old - with major depressive disorder in single or recurrent episodes, with moderate to severe intensity. Besides, They also had a history of treatment-resistant depression stage II or above according to the criteria of by Thase and Rush: failure to respond to treatment with at least 2 antidepressants of different classes, at the maximum tolerated dose for at least 6 weeks and absence of psychotic symptoms.
11599388|NCT00652158|Experimental|A|
11599389|NCT00652145|Experimental|Increase mesalamine dose by 2.4g/day|Increase dose of mesalamine by 2.4 gm per day
11599390|NCT00652145|No Intervention|Maintain mesalmine dose|Maintain current mesalamine dose at 2.4 g/day
11599391|NCT00652132|Active Comparator|Arm I (cisplatin)|Neoadjuvant and adjuvant cisplatin: patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
11599392|NCT00652132|Experimental|Arm II (cisplatin + STS)|Neoadjuvant and adjuvant cisplatin and sodium thiosulphate (STS): patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (beginning 6 hours after completion of cisplatin) on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (as in neoadjuvant therapy) on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
11599393|NCT00652119|Experimental|Paclitaxel + Carboplatin + Avastin|"Paclitaxel Cycle 1 = 60 mg/m^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m^2 IP weekly over 1 hour x 3 weeks of each cycle.
~Carboplatin Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.
~Avastin Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle."
11599394|NCT00652106|Experimental|1|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution
11599395|NCT00652106|Active Comparator|2|Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution
11599396|NCT00652106|Active Comparator|3|0.2% brimonidine ophthalmic solution
11599397|NCT00652093|Experimental|Opana then darvocet then placebo|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
11599398|NCT00652093|Experimental|Opana then placebo then darvocet|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
11599399|NCT00652093|Experimental|Placebo then opana then darvocet|Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
11599400|NCT00652093|Experimental|Placebo then darvocet then opana|Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
11599401|NCT00652093|Experimental|Darvocet then opana then placebo|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
11599402|NCT00652093|Experimental|Darvocet then placebo then opana|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
11599403|NCT00652080|Experimental|1|Active Cream 3%; AM & PM
11599404|NCT00652067||1|Only one patient is being treated under a single patient IND.
11599405|NCT00652054|Experimental|1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks.
11599406|NCT00652041|Experimental|1|Induction: 6 alternating cycles Bortezomib-Melfalan-Prednisone or Bortezomib- Adriamycine-Melfalan-Prednisone and Thalidomide-Cyclophosphamide-Dexamethasone, followed by other 6 maintenance cycles
11599407|NCT00652028|Other|Group 1|Dose level 1
11599408|NCT00652028|Other|Group 2|Dose level 2
11599409|NCT00652028|Other|Group 3|Dose level 3
11599410|NCT00652028|Other|Group 4|Dose level 4
11599411|NCT00652015||1|Patients having developed an in-stent-thrombosis (40 SAT, 40 LT)
11599412|NCT00652015||2|Patients having not developed an in-stent-thrombosis after stent implantation using PTCA
11599413|NCT00652002|Experimental|1|
11599414|NCT00652002|Active Comparator|2|budesonide
11599415|NCT00652002|Active Comparator|3|formoterol
11599416|NCT00651989||A|healthy individuals
11599417|NCT00651976|Experimental|treatment|
11599418|NCT00651950||Operator Dependence|
11599419|NCT00651937|Active Comparator|Standard Dose|Melphalan + Stem Cell Infusion (Standard Dose): Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10^6 cluster of differentiation 34 (CD34)/kg on Day 0. Melphalan 100 mg/m^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion. Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days. Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
11599463|NCT00651664|Experimental|Alisertib 100 mg BID 7D|Alisertib 100 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 21 cycles).
11599633|NCT00650442|Placebo Comparator|2|Estradiol Transdermal System Placebo - Current Adhesive
11599634|NCT00650429|Experimental|Arm A|
11599420|NCT00651937|Active Comparator|High Dose|Melphalan + Stem Cell Infusion (High Dose): High Dose (Arm 2) = Stem cell dose of between 10-15 x 10^6 CD34/kg On Day 0. Melphalan 100 mg/m^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion. Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days. Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
11599421|NCT00651924|No Intervention|Phase 1|Review the materials and provide feedback regarding how understandable, engaging, and informative the materials are
11599422|NCT00651924|Experimental|Phase 2|Piloting the 'IVR-based Cognitive-behavior therapy' using the new materials
11599423|NCT00651898||A|This group will receive the circulating water garment
11599424|NCT00651898||B|This group will receive the circulating water mattress and be covered by a forced air warming device for both the upper body and lower body connected to two warmers.
11599425|NCT00651885|Placebo Comparator|2 arm|
11599426|NCT00651885|Experimental|1 arm|treprostinil dienthalomine
11599427|NCT00651872||Marx|
11599428|NCT00651859|Experimental|1|Bimatoprost 0.01% Ophthalmic Solution
11599429|NCT00651859|Experimental|2|Bimatoprost 0.03% Ophthalmic Solution
11599430|NCT00651859|Placebo Comparator|3|Bimatoprost Vehicle Ophthalmic Solution
11599431|NCT00651846|Experimental|Arm 1|
11599432|NCT00651846|Active Comparator|Arm 2|
11599433|NCT00651833|Experimental|1|All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. Patient will also receive cisplatin, 75 mg/m2 as a 1- to 3-hour infusion on Day 1 of each cycle.
11599434|NCT00651820|Experimental|Collagenase Santyl Rate of Wound Closure|Dermatome-induced skin wounds treated with drug active (collagenase).
11599435|NCT00651820|Placebo Comparator|Vehicle Rate of Wound Closure|Dermatome-induced skin wounds treated with Vehicle alone.
11599436|NCT00651807|Active Comparator|Arm 1|etonogestrel
11599437|NCT00651807|Placebo Comparator|Arm 2|Placebo
11599438|NCT00651794|Active Comparator|Control (NRP Curriculum with LFT and no team training)|Standard Neonatal Resuscitation Program (NRP) curriculum with no team training; simulated resuscitation using low-fidelity simulators for low-fidelity training (LFT)
11599439|NCT00651794|Experimental|NRP with LFT and team training|Standard Neonatal Resuscitation Program (NRP) curriculum + team training; simulated resuscitation using low-fidelity simulators for low-fidelity training (LFT)
11599440|NCT00651794|Experimental|NRP with HFT and team training|Standard Neonatal Resuscitation Program (NRP) curriculum + team training; simulated resuscitations using high-fidelity simulators for high-fidelity training (HFT)
11599441|NCT00651781|Experimental|1|"Phase I:3 dose levels Cytarabine (200 mg/m2- 500 mg/m2-1000 mg/m2) with scheme Flag-Ida in combination with Velcade until determinate the appropriate dose.
~Phase II:
~Fludarabine, Cytarabine and Idarubicin in combination with 2 times per week of Velcade administration. Each 28-day treatment, patients will be evaluated, and in absence of disease progression or unacceptable toxicity, patients will start second cycle with Bortezomib in monotherapy two times per week followed by a 10 days rest period. That is, patients who response with acceptable toxicity will receive the combined sequential scheme twice (as induction and consolidation)."
11599442|NCT00651768|Experimental|1|
11599443|NCT00651768|Sham Comparator|2|
11599444|NCT00651755|Experimental|Aprepitant + CHOP/R-CHOP|Aprepitant 125 mg oral (PO) Day 1 of Cycle 1 followed by 80 mg PO Daily Days 2-3 with CHOP (steroid in CHOP) or R-CHOP plus Rituximab 375 mg/m^2 intravenous Day 1. CHOP or R-CHOP chemotherapy: (1) bolus or 48-hour infusion CHOP [cyclophosphamide 750 mg/m^2 IV Day 1, doxorubicin 25 mg/m^2/day IV given bolus or over 48 hours continuous infusion Days 1-2, vincristine 2 mg IV Day 1, prednisone PO 100 mg * 5 days]; or (2) Bolus or 48-hour infusion R-CHOP [Rituximab 375 mg/m^2 on Day 1 + CHOP as above]. [For patients receiving R-CHOP, CHOP may be administered starting on Day 2 at the discretion of the treating physician]
11599445|NCT00651755|Experimental|Standard of Care (Control) + CHOP/R-CHOP|Anti-emetics, Ondansetron 8 mg daily for 2 days, plus steroids in CHOP or R-CHOP regimen.
11599446|NCT00651742|Experimental|1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks.
11599447|NCT00651729|Experimental|1|Botulinum Toxin Type A
11599448|NCT00651716||Allogeneic Stem Cell Transplant Patients|Patients undergoing allogeneic stem cell transplant (SCT). Potential study candidates will be identified by participating physicians.
11599449|NCT00651703|Experimental|1|
11599450|NCT00651703|Experimental|2|
11599451|NCT00651703|Experimental|3|
11599452|NCT00651703|Experimental|4|
11599453|NCT00651690|Experimental|1|Botulinum Toxin Type A
11599454|NCT00651690|Placebo Comparator|2|Saline
11599455|NCT00651677|Active Comparator|HAL Proctectomy|Hand-assisted laparoscopic proctectomy
11599456|NCT00651677|Active Comparator|SL Proctectomy|"straight laparoscopic proctectomy"
11599457|NCT00651664|Experimental|Alisertib 5 mg QD 7D|Alisertib 5 mg, capsules, orally, once daily (QD) for 7 days (D) followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 3 cycles).
11599458|NCT00651664|Experimental|Alisertib 80 mg QD 7D|Alisertib 80 mg, capsules, orally, QD for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 4 cycles).
11599459|NCT00651664|Experimental|Alisertib 150 mg QD 7D|Alisertib 150 mg, capsules, orally, QD for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles).
11599460|NCT00651664|Experimental|Alisertib 50 mg BID 7D|Alisertib 50 mg, capsules, orally, twice daily (BID) for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 29 cycles).
11599461|NCT00651664|Experimental|Alisertib 60 mg BID 7D|Alisertib 60 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles).
11599462|NCT00651664|Experimental|Alisertib 75 mg BID 7D|Alisertib 75 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 8 cycles).
11599464|NCT00651664|Experimental|Alisertib 50 mg QD 14D|Alisertib 50 mg, capsules, orally, QD for 14 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 25 cycles).
11599465|NCT00651664|Experimental|Alisertib 50 mg QD 21D|Alisertib 50 mg, capsules, orally, QD for 21 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 10 cycles).
11599466|NCT00651664|Experimental|Alisertib 70 mg QD 21D|Alisertib 70 mg, capsules, orally, QD for 21 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).
11599467|NCT00651651|Experimental|1|Symbicort
11599468|NCT00651651|Active Comparator|2|budesonide
11599469|NCT00651651|Active Comparator|3|formoterol
11599470|NCT00651625|Experimental|1|The intervention is the use of the reciprocating procedure device (RPD) (AVANCA Re No. 1091001) (intervention) (Arm 1) with and without ultrasound guidance (intervention) in a syringe and needle procedure in comparison to a conventional syringe (BD Ref 309604) (control, Arm 2).
11599471|NCT00651625|Active Comparator|2|The conventional syringe (BD Ref 309604) is used to performed the syringe and needle procedure and outcome (effect of procedure (pain scores at 2 weeks and 6 months compared to preprocedural pain scores), and procedural pain (pain scores during procedure) are determined) and compared to Arm 1.
11599472|NCT00651612|Experimental|1|Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
11599473|NCT00651612|Active Comparator|2|Concurrent Brimonidine 0.2% and 0.5% Timolol
11599474|NCT00651599|Placebo Comparator|Arm 2|
11599475|NCT00651599|Experimental|Arm 1|
11599476|NCT00651586|Experimental|1|Gatifloxacin 0.3% ophthalmic solution
11599477|NCT00651586|Active Comparator|2|Ciprofloxacin 0.3% ophthalmic solution
11599478|NCT00651573|Active Comparator|Blood transfusion triggers of 24% hematocrit value|Red blood cell transfusion will be given when hematocrit values fall below the assigned group 1 value which is 24%. When the hematocrit value falls to less 24%, a 1 unit RBC transfusion will be administered. Following administration of the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to transfusion and is greater than or equal to 24%, no further transfusions will be administered.
11599479|NCT00651573|Active Comparator|Blood transfusion triggers of 28% hematocrit value|Red blood cell transfusion will be given when hematocrit values fall below the assigned group 1 value which is 28%. When the hematocrit value falls to less 28%, a 1 unit RBC transfusion will be administered. Following administration of the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to transfusion and is greater than or equal to 28%, no further transfusions will be administered.
11599480|NCT00651547|Experimental|1|
11599481|NCT00651547|Active Comparator|2|
11599482|NCT00651547|Active Comparator|3|
11599483|NCT00651521||1|CKD stage 1 patients
11599484|NCT00651521||2|CKD stage 2 patients
11599485|NCT00651521||3|CKD stage 3a patients
11599486|NCT00651521||4|CKD stage 3b patients
11599487|NCT00651521||5|CKD stage 4 patients
11599488|NCT00651521||6|CKD stage 5 patients
11599489|NCT00651508|Experimental|Single Arm 25mg/m2|KOS-1584 25mg/m2
11599490|NCT00651495|Experimental|1|Participants receive a $50 financial incentive if they view at least 3 of 5 patient decision aids in a group screening.
11599491|NCT00651495|Active Comparator|2|No financial incentive for watching patient decision aids in group screenings
11599492|NCT00651482|Experimental|Bevacizumab + RAD001 (everolimus)|"Study treatment, consisting of bevacizumab + everolimus, was administered as 28-day cycles
~Bevacizumab 10 mg/kg administered by IV infusion every 14 days (dose suspension permitted, dose reduction not permitted)
~Everolimus 10 mg daily was administered orally (dose reduction to 5 mg daily and then 5 mg every other day, was permitted as needed for toxicity or tolerability)"
11599493|NCT00651469|Experimental|Arm 1|
11599494|NCT00651469|Placebo Comparator|Arm 2|
11599495|NCT00651456|Active Comparator|1|Standard Chemotherapy
11599496|NCT00651456|Experimental|2|Standard Chemotherapy + bevacizumab (Avastin)
11599497|NCT00651443|Experimental|1|
11599498|NCT00651430||A|
11599499|NCT00651417|Active Comparator|1|Organic Germanium tablets 5 times a day
11599500|NCT00651417|Placebo Comparator|2|Placebo tablets 3 -5 times per day
11599501|NCT00651404|Experimental|Ezetimibe|
11599502|NCT00651404|Placebo Comparator|Placebo|
11599503|NCT00651391|Experimental|Ezetimibe + Simvastatin|
11599504|NCT00651391|Active Comparator|Simvastatin|
11599505|NCT00651391|Placebo Comparator|Placebo|
11599506|NCT00651378|Experimental|Rosuvastatin|
11599507|NCT00651378|Active Comparator|Ezetimibe + Atorvastatin|
11599508|NCT00651378|Active Comparator|Double Atorvastatin|
11599509|NCT00651365|Experimental|001|
11599510|NCT00651352|Experimental|2 mg nicotine prototype|2 mg nicotine prototype
11599511|NCT00651352|Active Comparator|2 mg nicotine lozenge|marketed formulation
11599512|NCT00651352|Experimental|4 mg nicotine prototype|4 mg
11599513|NCT00651352|Active Comparator|4 mg nicotine lozenge|4 mg
11599514|NCT00651339||A|
11599515|NCT00651326|Active Comparator|Antiandrogen; LHRH; Docetaxel, Radiation Therapy|Antiandrogen (Flutamide or Bicalutamide) LHRH agonist (Eligard) Docetaxel
11599516|NCT00651326|Active Comparator|Antiandrogen; LHRH; Radiation Therapy|Antiandrogen (Flutamide or Bicalutamide) LHRH agonist (Eligard)
11599517|NCT00651313|Active Comparator|Active|Lidocaine 10% (150mg) vaginal gel
11599518|NCT00651313|Placebo Comparator|Placebo|Placebo vaginal gel
11599519|NCT00651300|Experimental|Group 1|
11599520|NCT00651300|Placebo Comparator|Group 2|
11599521|NCT00651287|Active Comparator|quinapril 20 mg|
11599522|NCT00651287|Active Comparator|quinapril 20 mg+hydrochlorothiazide 12.5 mg|
11599523|NCT00651287|Active Comparator|quinapril 40 mg|
11599524|NCT00651274|Experimental|Ezetimibe|
11599525|NCT00651274|Placebo Comparator|Placebo|
11599628|NCT00650468|Experimental|2|long-term maintenance steroids
11599629|NCT00650455|Active Comparator|Arm 2|
11599630|NCT00650455|Placebo Comparator|Arm 3|
11599526|NCT00651261|Experimental|Induction and consolidation chemotherapy plus midostaurin|Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and the experimental drug midostaurin. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with the experimental drug midostaurin. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with midostaurin for twelve (12) months.
11599527|NCT00651261|Active Comparator|Induction and consolidation chemotherapy plus placebo|Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and placebo. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with placebo. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with placebo for twelve (12) months.
11599528|NCT00651235|Experimental|B|In combination therapy,the maximal dose of Losartan is 100 mg/day for adult and 50 mg/day for children. 50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children
11599529|NCT00651235|Active Comparator|A|The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
11599530|NCT00651222||1|All deceased patients who underwent brachytherapy at Chicago Prostate Center between 10/14/1997 and 6/15/2007
11599531|NCT00651209|Experimental|1|Sub-group 1- continue telbivudine if HBV DNA non-detectable at week 24 Sub-group 2- tenofovir added to telbivudine in patients if HBV DNA detectable at week 24
11599532|NCT00651196||1|Type 1 diabetics
11599533|NCT00651196||Healthy controls|Healthy age and sex matched controls
11599534|NCT00651157|Experimental|Treatment (viral therapy)|Patients receive wild-type reovirus (Reolysin®) IV administered at a dose of 3 x 10^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11599535|NCT00651144|Experimental|Ezetimibe + Rosuvastatin|
11599536|NCT00651144|Active Comparator|Ezetimibe|
11599537|NCT00651144|Active Comparator|Rosuvastatin|
11599538|NCT00651144|Placebo Comparator|Placebo|
11599539|NCT00651118|Active Comparator|fluticasone propionate|
11599540|NCT00651118|Experimental|azelastineHcl/fluticasone propionate|
11599541|NCT00651118|Placebo Comparator|Placebo|
11599542|NCT00651118|Active Comparator|azelastine Hcl|
11599543|NCT00651105|Experimental|1|
11599544|NCT00651105|Placebo Comparator|2|
11599545|NCT00651092|Active Comparator|A1|since the two methods of turbinectomy are in used on a regular basis there is no way to perform double blind study- both the surgeon and the patients are well aware of the operation they are about to go. we just compare several parameters in patients who are anyway about to undergo an operation in a specific method that is used by their surgeon
11599546|NCT00651092|Active Comparator|A2|the resection of the inferior turbinates will be performed endonasally with an endoscopical instruments
11599547|NCT00651066|Experimental|1|RBT (150 mg TPW during 3 weeks switch to 150mg OD for the following 3 weeks) associated with LPV/r based ART
11599548|NCT00651066|Experimental|2|RBT (150 mg OD during 3 weeks switch to 150mg TPW for the following 3 weeks) associated with LPV/r based ART
11599549|NCT00651040|Active Comparator|Prednison|"Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms.
~ARM 1 has only Prednisone"
11599550|NCT00651040|Active Comparator|Prednison + methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
11599551|NCT00651027|Experimental|A|
11599552|NCT00651027|Experimental|B|
11599553|NCT00651027|Experimental|C|200 mg
11599554|NCT00651014|Experimental|Ezetimibe|
11599555|NCT00651014|Placebo Comparator|Placebo|
11599556|NCT00650988|Experimental|Barrett's Esophagus with intramucosal carcinoma (IMCA)|
11599557|NCT00650988|Experimental|Barrett's Esophagus with High Grade Dysplasia (HGD)|
11599558|NCT00650975|Active Comparator|ELCA|Laser Thromboablation
11599559|NCT00650975|Active Comparator|PTCA|PTCA (Direct Stenting)
11599560|NCT00650962|Active Comparator|CPR first|Compression First (CF)
11599561|NCT00650962|Active Comparator|Analysis First|Rhythm analysis first
11599562|NCT00650949|Experimental|CYT997|
11599563|NCT00650936|Other|AMPLATZER Septal Occluder|Subjects were enrolled if the implant of the AMPLATZER Septal Occluder device was completed or was attempted (delivery system entered the subject's body).
11599564|NCT00650923|Experimental|Arm 1|See Detailed Description
11599565|NCT00650910|Experimental|lapatinib + digoxin|All subjects received 0.5mg digoxin on Days 1 and 9 with daily dosing of 1500mg oral lapatinib starting on Day 2 and continuing through Day 9. Subjects could continue past Day 9 on daily oral lapatinib until Week 10 when they could transfer into a rollover study (EGF19060 or EGF111767).
11599566|NCT00650897|Experimental|A|Patients with Diabetes Mellitus and Major Depression
11599567|NCT00650884|No Intervention|1|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). CONTROL PATIENTS will only be treated with Standard of Care during this 12 week trial, but will also be treated with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch after completion of this study.
11599631|NCT00650455|Active Comparator|Arm 1|
11599632|NCT00650442|Experimental|1|Estradiol Transdermal System Placebo - Alternate Adhesive
11599635|NCT00650416|Experimental|1|Carvedilol Tablets 12.5 mg
11599568|NCT00650884|Experimental|2|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). EXPERIMENTAL PATIENTS will also be treated with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch while sleeping.
11599569|NCT00650884|Other|3|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). CROSS-OVER patients will be initially treated only with Standard of Care, and after six weeks, they will be Crossed-Over and fit with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch while sleeping.
11599570|NCT00650858|Active Comparator|0.3 mg rt-PA|In stage 1 of the protocol, dose finding, subjects were randomized to either this 0.3 mg dose arm or the 1.0 mg dose arm. Subjects in this arm (0.3 mg) received up to 8 doses of 0.3 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.
11599571|NCT00650858|Active Comparator|1.0 mg rt-PA|In stage 1 of the protocol, dose finding, subjects were randomized to either this 1.0 mg dose arm or the 0.3 mg dose arm. Subjects in this arm (1.0 mg) received up to 8 doses of 1.0 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.
11599572|NCT00650858|Experimental|1.0 mg Rt-PA q8h|In stage 2 of the protocol, dose frequency, subjects received up to 8 doses of 1.0 mg of rt-PA (Cathflo) every 8 hours through the intraventricular catheter to treat intraventricular hemorrhage.
11599573|NCT00650845|Experimental|Dotarem®-enhanced MRI|Patients undergoing Dotarem®-enhanced MRI for diagnostic purposes
11599574|NCT00650845|Other|Non-enhanced MRI|Patients undergoing non-enhanced MRI for diagnostic purposes
11599575|NCT00650819|Experimental|Ezetimibe + Simvastatin|
11599576|NCT00650819|Active Comparator|Simvastatin|
11599577|NCT00650819|Active Comparator|Ezetimibe|
11599578|NCT00650806|Experimental|Canagliflozin 50 mg|Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
11599579|NCT00650806|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
11599580|NCT00650806|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
11599581|NCT00650806|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 12 weeks.
11599582|NCT00650780||1|All of the subjects will have measurements of Gc concentration and phenotype
11599583|NCT00650767|Experimental|ARRY-438162 (Schedule 1)|
11599584|NCT00650767|Experimental|ARRY-438162 (Schedule 2)|
11599585|NCT00650767|Experimental|ARRY-438162 (Schedule 3)|
11599586|NCT00650767|Placebo Comparator|Placebo|
11599587|NCT00650754|Experimental|DHEA|Dehydroepiandrosterone (DHEA) administered at a dose of 25 mg tid po. DHEA is a weak androgen produced naturally by the adrenal in men and women. DHEA production is diminished with increasing age. Peak levels of DHEA occur in the late teenage years.
11599588|NCT00650754|Placebo Comparator|Placebo|Blinded placebo
11599589|NCT00650741||1|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), no repetition of test
11599590|NCT00650741||2|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), Repetition with Nitroglycerin
11599591|NCT00650741||3|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), repetition of test with the Endotect
11599592|NCT00650715|Active Comparator|VG|Vibration Group (VG) underwent a protocol with whole-body vibration exercise twice a week for a total of six weeks. The group continued with their usual pharmacological treatment.
11599593|NCT00650715|Placebo Comparator|CG|The Control Group (CG) underwent the same protocol of exercises than VG but without vibratory stimulus. The CG continued with their usual pharmacological treatment.
11599594|NCT00650702|Experimental|1|Low Latanoprost-PPDS
11599595|NCT00650702|Experimental|2|Medium Latanoprost-PPDS
11599596|NCT00650702|Experimental|3|High Latanoprost-PPDS
11599597|NCT00650689|Experimental|Ezetimibe + Atorvastatin|
11599598|NCT00650689|Active Comparator|Atorvastatin|
11599599|NCT00650676||A|
11599600|NCT00650663|Experimental|Ezetimibe + Simvastatin|
11599601|NCT00650663|Active Comparator|Simvastatin|
11599602|NCT00650637|Experimental|1|
11599603|NCT00650637|Experimental|2|
11599604|NCT00650624|Active Comparator|Arm 1|
11599605|NCT00650624|Active Comparator|Arm 2|
11599606|NCT00650624|Active Comparator|Arm 3|
11599607|NCT00650624|Placebo Comparator|Arm 4|
11599608|NCT00650611|Active Comparator|Low-Dose Ziprasidone|
11599609|NCT00650611|Active Comparator|High-Dose Ziprasidone|
11599610|NCT00650598|Active Comparator|Arm 1|
11599611|NCT00650598|Active Comparator|Arm 2|
11599612|NCT00650585|No Intervention|Control group|Did not receive Project ALERT
11599613|NCT00650585|Experimental|Treatment group|Received Project ALERT
11599614|NCT00650572|Experimental|ARRY-380|
11599615|NCT00650559|Experimental|1|Experimental surgical intervention.
11599616|NCT00650546|Experimental|A pre treatment NAS score|liver biopsy score pre treatment with exenatide 5 micrograms SQ (sub-cutaneous) twice a day titrated to 10 mcg SQ twice a day as tolerated
11599617|NCT00650533|Experimental|1|Glimepiride Tablets 1 mg
11599618|NCT00650533|Active Comparator|2|Amaryl® Tablets 1 mg
11599619|NCT00650520|Experimental|1|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL)and BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
11599620|NCT00650520|Active Comparator|2|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL) and Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
11599621|NCT00650507|Experimental|1|
11599622|NCT00650507|Active Comparator|2|
11599623|NCT00650494|Experimental|1|Valacyclovir Hydrochloride Tablets 1000mg
11599624|NCT00650494|Active Comparator|2|Valtrex® Tablets 1000 mg
11599625|NCT00650481|Experimental|1|Oxybutynin Chloride Extended-release Tablets 5 mg
11599626|NCT00650481|Active Comparator|2|Ditropan XL® Tablets 5 mg
11599627|NCT00650468|Experimental|1|early steroid cessation
11599636|NCT00650416|Active Comparator|2|Coreg® Tablets 12.5 mg
11599637|NCT00650403|Experimental|1|Paroxetine hydrochloride 40 mg tablet
11599638|NCT00650403|Active Comparator|2|Paxil® 40 mg Tablet
11599639|NCT00650377|Experimental|1|Finasteride Tablets 5 mg
11599640|NCT00650377|Active Comparator|2|Proscar® Tablets 5 mg
11599641|NCT00650364|Experimental|1|Midodrine HCl Tablets 5 mg
11599642|NCT00650364|Active Comparator|2|ProAmatine® Tablets 5 mg
11599643|NCT00650351|Experimental|1|Ciprofloxacin Extended-Release Tablets 1000 mg
11599644|NCT00650351|Active Comparator|2|Cipro® XR Tablets 1000 mg
11599645|NCT00650338|Experimental|1|<described in intervention>
11599646|NCT00650338|Experimental|2|<described in intervention>
11599647|NCT00650338|Experimental|3|<described in intervention>
11599648|NCT00650338|Placebo Comparator|4|<described in intervention>
11599649|NCT00650338|Active Comparator|5|<described intervention>
11599650|NCT00650325|Experimental|1|Sertraline Hydrochloride Tablets 100 mg
11599651|NCT00650325|Active Comparator|2|Zoloft® Tablets 100 mg
11599652|NCT00650312|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
11599653|NCT00650312|Active Comparator|2|Glucophage® XR Tablets 500 mg
11599654|NCT00650299|Experimental|1|Alprazolam Extended-release Tablets 3 mg
11599655|NCT00650299|Active Comparator|2|Xanax XR® Tablets 3 mg
11599656|NCT00650286|Experimental|1|Modafinil Tablets 200 mg
11599657|NCT00650286|Active Comparator|2|Provigil® Tablets 200 mg
11599658|NCT00650273|Experimental|1|Azithromycin Tablets 600 mg
11599659|NCT00650273|Active Comparator|2|Zithromax® Tablets 600 mg
11599660|NCT00650260|Experimental|vH2 System Group|The vital heat vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical. The vital heat vH2 System will be used for patient warming during these surgical procedures. Monitoring of core temperature via esophageal probe will be done for the purpose of data collection.
11599661|NCT00650260|Active Comparator|Control Group|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket. The Bair Hugger System is the site's current approach to patient warming during these surgical procedures. Monitoring of core temperature via esophageal probe will be done for the purpose of data collection.
11599662|NCT00650247|Experimental|1|Sumatriptan Succinate Tablets 100 mg
11599663|NCT00650247|Active Comparator|2|Imitrex® Tablets 100 mg
11599664|NCT00650234|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
11599665|NCT00650234|Active Comparator|2|Glucophage® XR Tablets 500 mg
11599666|NCT00650221|Experimental|1|
11599667|NCT00650221|Active Comparator|2|
11599668|NCT00650208|Experimental|1|Lamotrigine Tablets 25 mg
11599669|NCT00650208|Active Comparator|2|Lamictal® Tablets 25 mg
11599670|NCT00650195|Experimental|1|Metolazone Tablets 10 mg
11599671|NCT00650195|Active Comparator|2|Zaroloxyn® Tablets 10 mg
11599672|NCT00650169|Experimental|1|Clopidogrel Bisulfate Tablets 75 mg
11599673|NCT00650169|Active Comparator|2|Plavix® Tablets 75 mg
11599674|NCT00650156|Experimental|40 mg adalimumab|
11599675|NCT00650156|Experimental|80 mg Adalimumab|
11599676|NCT00650143|Active Comparator|1|"Application G-CSF (10µg/kg/d divided in two doses subcutaneously) over a period of 5 days and Sitagliptin 100 mg each day for 28 days.
~n=74"
11599677|NCT00650143|Placebo Comparator|2|"NaCl 0.9% applied twice daily over a period of 5 days and oral Placebo given once a day for 28 days.
~n=74"
11599678|NCT00650130||1|drivers of motorised vehicles suspected of being under the influence of psychoactive drugs
11599679|NCT00650117|Experimental|1|Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)
11599680|NCT00650117|Experimental|2|Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
11599681|NCT00650117|Experimental|3|Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)
11599682|NCT00650117|Experimental|4|Duragesic 25 mcg/h + Scotch Duct Tape (3M)
11599683|NCT00650117|Experimental|5|Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
11599684|NCT00650117|Experimental|6|Duragesic 25 mcg/h + Microfoam Tape (3M)
11599685|NCT00650104|Active Comparator|Active|Open label medication - Ropinirole CR
11599686|NCT00650091|Active Comparator|1|Participants will receive N-acetylcysteine (NAC) for 60 weeks.
11599687|NCT00650091|Placebo Comparator|2|Participants will receive placebo for 60 weeks.
11599688|NCT00650078|Experimental|NP01|Modified Release (MR) prednisone 5 mg
11599689|NCT00650078|Placebo Comparator|Placebo|
11599690|NCT00650065|Experimental|1|Cetirizine HCl Tablets 10 mg
11599691|NCT00650065|Active Comparator|2|Zyrtec® Tablets 10 mg
11599692|NCT00650052|Experimental|1|Zonisamide Capsules 100 mg
11599693|NCT00650052|Active Comparator|2|Zonegran® Capsules 100 mg
11599694|NCT00650039|Active Comparator|Arm 1|
11599695|NCT00650039|Active Comparator|Arm 2|
11599696|NCT00650039|Placebo Comparator|Arm 3|
11599697|NCT00650013|Experimental|1|Midodrine HCl Tablets 5 mg
11599698|NCT00650013|Active Comparator|2|ProAmatine® Tablets 5 mg
11599699|NCT00650000|Experimental|1|Modafinil Tablets 200 mg
11599700|NCT00650000|Active Comparator|2|Provigil® Tablets 200 mg
11599701|NCT00649987|Experimental|1|Albuterol Sulfate Extended-Release Tablets 8 mg
11599702|NCT00649987|Active Comparator|2|VoSpire® ER Tablets 8 mg
11599703|NCT00649974|Experimental|1|Valacyclovir Hydrochloride Tablets 1000 mg
11599704|NCT00649974|Active Comparator|2|Valtrex® Tablets 1000 mg
11599705|NCT00649961|Experimental|Melatonin Open Label Single Arm|Infants born less than 31 weeks gestation who are less than 7 days old
11599706|NCT00649948|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
11599707|NCT00649948|Active Comparator|2|Glucophage XR 500 mg
11599708|NCT00649935|Experimental|1|Azithromycin Tablets 600 mg
11599709|NCT00649935|Active Comparator|2|Zithromax® Tablets 600 mg
11599710|NCT00649922|Placebo Comparator|Double Blind|
11599711|NCT00649922|Experimental|Open Label|
11599712|NCT00649909||Observation|Type 2 diabetic patients with reduced laboratory response to aspirin.(Aspirin Resistance)and with HbA1c >8%.
11599713|NCT00649896|Experimental|1|Mylan Estradiol Transdermal System 0.025 mg/day
11599714|NCT00649896|Active Comparator|2|Climara® Transdermal System 0.025 mg/day
11599715|NCT00649883|Experimental|1|
11599716|NCT00649883|Active Comparator|2|
11599717|NCT00649870|Experimental|1|Valacyclovir Hydrochloride Tablets 1000 mg
11599718|NCT00649870|Active Comparator|2|Valtrex® Tablets 1000 mg
11599719|NCT00649857|Experimental|1|Cetirizine HCl Tablets 10 mg
11599720|NCT00649857|Active Comparator|2|Zyrtec® 10 mg
11599721|NCT00649844|Active Comparator|A|
11599722|NCT00649844|Experimental|B|
11599723|NCT00649831|Active Comparator|Group 2|
11599724|NCT00649831|Active Comparator|Group 1|
11599725|NCT00649818|Experimental|1|Lorazepam Tablets 2 mg
11599726|NCT00649818|Active Comparator|2|Ativan Tablets 2 mg
11599727|NCT00649805|Experimental|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
11599728|NCT00649805|Active Comparator|2|Verelan® PM extended-release capsules controlled-onset 300 mg
11599729|NCT00649779|Experimental|1|albuterol sulfate extended-release 8 mg tablets
11599730|NCT00649779|Active Comparator|2|VoSpire™ ER 8 mg tablets
11599731|NCT00649766|Active Comparator|1|tailored print messages to encourage eye examination behavior
11599732|NCT00649766|Active Comparator|2|targeted print messages to encourage eye examination behavior
11599733|NCT00649753|No Intervention|A|
11599734|NCT00649753|Experimental|B|
11599735|NCT00649753|Experimental|C|
11599736|NCT00649753|Experimental|D|
11599737|NCT00649740|Experimental|1|Topiramate Sprinkle Capsules 25 mg
11599738|NCT00649740|Active Comparator|2|Topamax® Sprinkle Capsule 25 mg
11599739|NCT00649727|Experimental|1|Oxybutynin Chloride ER Tablets 10 mg
11599740|NCT00649727|Active Comparator|2|Ditropan XL® Tablets 10 mg
11599741|NCT00649714|Experimental|1|Zonisamide Capsules 100 mg
11599742|NCT00649714|Active Comparator|2|Zonegran® Capsules 100 mg
11599743|NCT00649701|No Intervention|1|
11599744|NCT00649701|Experimental|2|Text-based webpage
11599745|NCT00649701|Experimental|3|Talking about HIV video
11599746|NCT00649701|Experimental|4|The Morning After video
11599747|NCT00649701|Experimental|5|Both videos
11599748|NCT00649688|Experimental|1|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
11599749|NCT00649688|Active Comparator|2|Lopressor HCT® Tablets 100/50 mg
11599750|NCT00649675|Experimental|1|Meloxicam Tablets 15 mg
11599751|NCT00649675|Active Comparator|2|Mobic® Tablets 15 mg
11599752|NCT00649662|Experimental|1|Ciprofloxacin Extended-Release Tablets 1000 mg
11599753|NCT00649662|Active Comparator|2|Cipro® XR Tablets 1000 mg
11599754|NCT00649649|Experimental|1|Quinapril Hydrochloride Tablets 40 mg
11599755|NCT00649649|Active Comparator|2|Accupril® Tablets 40 mg
11599756|NCT00649636|Experimental|1|Fluoxetine Capsules 40 mg
11599757|NCT00649636|Active Comparator|2|Prozac Pulvules 40 mg
11599758|NCT00649623|Experimental|1|Olmesartan Medoxomil Tablets 40 mg
11599759|NCT00649623|Active Comparator|2|Benicar® Tablets 40 mg
11599760|NCT00649610|Active Comparator|Arm 1|
11599761|NCT00649610|Active Comparator|Arm 2|
11599762|NCT00649597|Experimental|1|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
11599763|NCT00649597|Active Comparator|2|Lotensin HCT® Tablets 20 mg/25 mg
11599764|NCT00649584|Experimental|1|SGN-35 alone or in combination with gemcitabine
11599765|NCT00649571|Experimental|1|Doxycycline Monohydrate Tablets 100 mg
11599766|NCT00649571|Active Comparator|2|Adoxa Tablets 100 mg
11599767|NCT00649558|Experimental|1|Pioglitazone HCl Tablets 45 mg
11599768|NCT00649558|Active Comparator|2|Actos® Tablets 45 mg
11599769|NCT00649532|Experimental|1|Ondansetron Tablets 24 mg
11599770|NCT00649532|Active Comparator|2|Zofran® Tablets 24 mg
11599771|NCT00649519|Experimental|1|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
11599772|NCT00649519|Active Comparator|2|Lotrel® Capsules 10 mg/20 mg
11599773|NCT00649506|Experimental|1|Nitrofurantoin Macrocrystals 100 mg Capsules
11599774|NCT00649506|Active Comparator|2|Macrodantin® 100 mg Capsules
11599775|NCT00649493|Experimental|1|Rabeprazole Sodium Tablets 20 mg
11599776|NCT00649493|Active Comparator|2|Aciphex® Tablets 20 mg
11599777|NCT00649480|Experimental|1|BALSALAZIDE DISODIUM CAPSULES, 750 MG
11599778|NCT00649480|Active Comparator|2|COLAZAL® Capsules 750 mg
11599779|NCT00649467|Experimental|1|Topiramate Sprinkle Capsules 25 mg
11599780|NCT00649467|Active Comparator|2|Topamax® Sprinkle Capsules 25 mg
11599781|NCT00649454|Experimental|1|Glipizide and Metformin HCl Tablets 5 mg/500 mg
11599782|NCT00649454|Active Comparator|2|Metaglip® Tablets 5 mg/500 mg
11599783|NCT00649441|Experimental|1|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
11599784|NCT00649441|Active Comparator|2|Accuretic™ Tablets 20 mg/25 mg
11599785|NCT00649428|Experimental|Active|
11599786|NCT00649428|Placebo Comparator|Control|
11599787|NCT00649415|Active Comparator|Arm 1|
11599788|NCT00649415|Active Comparator|Arm 2|
11599789|NCT00649402|Experimental|1|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
11599790|NCT00649402|Active Comparator|2|Lotrel® Capsules 10 mg/20 mg
11599791|NCT00649389|Experimental|OM40/AML10|olmesartan medoxomil 40mg and amlodipine 10mg
11599792|NCT00649389|Active Comparator|OM40/HCTZ25|olmesartan medoxomil 40mg and hydrochlorothiazide 25mg
11599793|NCT00649389|Active Comparator|AML10/HCTZ25|amlodipine 10mg and hydrochlorothiazide 25mg
11599794|NCT00649389|Active Comparator|OM40/AML10/HCTZ25|olmesartan medoxomil 40mg, amlodipine 10mg, and hydrochlorothiazide 25mg
11599795|NCT00649376|Experimental|1|Fexofenadine Tablets 180 mg
11599796|NCT00649376|Active Comparator|2|Allegra® Tablets 180 mg
11599797|NCT00649363|Experimental|1|Ondansetron Orally Disintegrating Tablets 8 mg
11599798|NCT00649363|Active Comparator|2|Zofran ODT® Tablets 8 mg
11599799|NCT00649350|Experimental|1|Metformin Hydrochloride ER Tablets 750 mg
11599800|NCT00649350|Active Comparator|2|Glucophage XR 750 mg
11599801|NCT00649337|Experimental|1|Adjunct screening with sonocine
11599802|NCT00649324|Experimental|1|Hydrochlorothiazide Tablets 50 mg
11599803|NCT00649324|Active Comparator|2|Hydrochlorothiazide Tablets 50 mg
11599804|NCT00649311|Experimental|Eplerenone group|
11599805|NCT00649311|Active Comparator|Losartan group|
11599806|NCT00649298|Experimental|extended hours|24 or more hours per week of hemodialysis
11599807|NCT00649298|Active Comparator|standard hours|18 or less hours per week of hemodialysis
11599808|NCT00649285|Experimental|1|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
11599809|NCT00649285|Active Comparator|2|Macrobid® Capsules 100 mg
11599810|NCT00649272|Experimental|1|Oxybutynin Chloride Extended-Release Tablets, 15 mg
11599811|NCT00649272|Active Comparator|2|Ditropan XL® Extended-release tablets, 15 mg
11599812|NCT00649259|Experimental|1|Oxybutynin Chloride ER Tablets 10 mg
11599813|NCT00649259|Active Comparator|2|Ditropan XL® Tablets 10 mg
11599814|NCT00649246||1|"controls:
~healthy individuals with no family history of type 1 diabetes"
11599815|NCT00649246||2|"high-risk:
~Subjects with islet autoantibodies or high-risk diabetes genes"
11599816|NCT00649246||3|"type 1 diabetes:
~subjects with type 1 diabetes"
11599817|NCT00649233|Experimental|1|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
11599818|NCT00649233|Active Comparator|2|Lopressor HCT® Tablets 100/50 mg
11599819|NCT00649220|Experimental|Memantine|
11599820|NCT00649207|Experimental|1|"This is an open label study; therefore, there are no numbered/labeled study arms.
~This is a dose escalation study, ABT-888 dose will be escalated in conjunction with two schedules of whole brain radiation therapy (WBRT). Subjects may be treated WBRT for 3 weeks (15 days) or 2 weeks (10 days)."
11599821|NCT00649194|Experimental|1|Rabeprazole Sodium Delayed-Release Tablets 20 mg
11599822|NCT00649194|Active Comparator|2|Aciphex® Tablets 20 mg
11599823|NCT00649181|Experimental|1|Metolazone Tablets 5 mg
11599824|NCT00649181|Active Comparator|2|Zaroloxyn® Tablets 5 mg
11599825|NCT00649168|Experimental|1|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL)and BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
11599826|NCT00649168|Active Comparator|2|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL) and Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
11599827|NCT00649155|Experimental|1|Ciprofloxacin Extended-Release Tablets 500 mg
11599828|NCT00649155|Active Comparator|2|Cipro® XR Tablets 500 mg
11599829|NCT00649142|Active Comparator|A|Open sutured mesh repair
11599830|NCT00649142|Active Comparator|B|Laparoscopic mesh glue fixation
11599831|NCT00649129|Experimental|1|Oxybutynin Chloride ER Tablets 10 mg
11599832|NCT00649129|Active Comparator|2|Ditropan XL® Tablets 10 mg
11599833|NCT00649116|Experimental|1|Metoprolol Tartrate Tablets 100 mg
11599834|NCT00649116|Active Comparator|2|Lopressor® Tablets 100 mg
11599835|NCT00649103|Experimental|1|Quinapril Hydrochloride Tablets 40 mg
11599836|NCT00649103|Active Comparator|2|Accupril® Tablets 40 mg
11599837|NCT00649090|Active Comparator|Exemestane group|
11599838|NCT00649077|Experimental|1|Meloxicam Tablets 15 mg
11599839|NCT00649077|Active Comparator|2|Mobic® Tablets 15 mg
11599840|NCT00649064|Experimental|Ziprasidone|
11599841|NCT00649051|Experimental|1|Metolazone Tablets 2.5 mg
11599842|NCT00649051|Active Comparator|2|Zaroloxyn® Tablets 2.5 mg
11599843|NCT00649038|Experimental|1|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
11599844|NCT00649038|Active Comparator|2|Lotensin HCT® Tablets 20 mg/25 mg
11599845|NCT00649025|Experimental|1|FlutiForm 250/10ug
11599846|NCT00649025|Active Comparator|2|SKP Fluticasone 250ug
11599847|NCT00649025|Active Comparator|3|Flovent Fluticasone HFA
11599848|NCT00649012|Experimental|1|Pioglitazone HCl Tablets 45 mg
11599849|NCT00649012|Active Comparator|2|Actos® Tablets 45 mg
11599850|NCT00648999|Active Comparator|1|
11599851|NCT00648999|Active Comparator|2|
11599852|NCT00648986|Experimental|1|Uncontrolled, Open-Label Pilot Study
11599853|NCT00648973|Experimental|1|Diphenhydramine 50 mg
11599854|NCT00648973|Experimental|2|Diphenhydramine 25 mg
11599855|NCT00648973|Active Comparator|3|Pseudoephedrine 120 mg
11599856|NCT00648960|Experimental|1|
11599857|NCT00648960|Active Comparator|2|
11599858|NCT00648947|Experimental|1|Clopidogrel Bisulfate Tablets 75 mg
11599859|NCT00648947|Active Comparator|2|Plavix® Tablets 75 mg
11599860|NCT00648934|Experimental|1|Topiramate Sprinkle Capsules 25 mg
11599861|NCT00648934|Active Comparator|2|Topamax® Sprinkle Capsules 25 mg
11599862|NCT00648921|Experimental|1|Olanzapine Tablets 5 mg
11599863|NCT00648921|Active Comparator|2|Zyprexa® Tablets 5 mg
11599864|NCT00648895|Active Comparator|1|Nebivolol
11599865|NCT00648895|Active Comparator|2|Metoprolol ER (TM)
11599866|NCT00648882|Experimental|1|LEVOTHYROXINE SODIUM TABLETS,USP 300 mcg;
11599867|NCT00648882|Active Comparator|2|SYNTHROID® 300 mcg Tablets
11599868|NCT00648856|Experimental|1|Sertraline Hydrochloride Tablets 100 mg
11599869|NCT00648856|Active Comparator|2|Zoloft® Tablets 100 mg
11599870|NCT00648843|Experimental|1|Oxybutynin Chloride Extended-release Tablets 5 mg
11599871|NCT00648843|Active Comparator|2|Ditropan XL® Tablets 5 mg
11599872|NCT00648830|Experimental|1|Clarithromycin 250 mg immediate-release oral tablet
11599873|NCT00648830|Active Comparator|2|Biaxin® (Clarithromycin) 250 mg tablet
11599874|NCT00648817|Placebo Comparator|Group 1|"Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil) for the first 14 days of the study.
~Tenofovir DF placebo tablet QD for the last 14 days of the study."
11599875|NCT00648817|Active Comparator|Group 2|"Tenofovir DF placebo tablet QD for the first 14 days of the study.
~Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil) for the last 14 days of the study."
11599876|NCT00648804|Experimental|1|Ondansetron Orally Disintegrating Tablets 8 mg
11599877|NCT00648804|Active Comparator|2|Zofran ODT® Tablets 8 mg
11599878|NCT00648791|Experimental|1|Finasteride Tablets 5 mg
11599879|NCT00648791|Active Comparator|2|Proscar Tablets 5 mg
11599880|NCT00648778|Experimental|1|Loxapine Succinate Capsules 25 mg
11599881|NCT00648778|Active Comparator|2|Loxitane® Capsules 25 mg
11599882|NCT00648765|Experimental|1|Anagrelide Hydrochloride Capsules 1 mg
11599883|NCT00648765|Active Comparator|2|Agrylin® Capsules 1 mg
11599884|NCT00648739|Experimental|Samalizumab|All doses of samalizumab were individualized based on the participant's body surface area in mg/m^2 based on screening height and weight. Participants were assigned to a dose cohort, ranging from 50 to 600 mg/m^2, and received a single IV dose of samalizumab. Participants who tolerated the drug and demonstrated at least stable disease received up to 3 additional cycles of samalizumab at the same dose originally received at a minimum of 28-day intervals and beginning no sooner than 6 weeks after the initial dose. If no participants enrolled into a cohort experienced a DLT, escalation to the next dose level occurred with a new cohort. If any 1 of the initial 3 participants in the cohort experienced a DLT, the cohort was expanded to at least 6 participants. Then, if less than one third of participants within the cohort experienced a DLT, escalation to the next dose level occurred with a new cohort. Dose cohorts were enrolled sequentially.
11599885|NCT00648726|Active Comparator|Arm 1|
11599886|NCT00648726|Active Comparator|Arm 2|
11599887|NCT00648726|Active Comparator|Arm 3|
11599888|NCT00648713|Experimental|1|Terbinafine Hydrochloride Tablets 250 mg
11599889|NCT00648713|Active Comparator|2|Lamisil® Tablets 250 mg
11599890|NCT00648700|Experimental|1|Levothyroxine Sodium Tablets 300 μg
11599891|NCT00648700|Active Comparator|2|Levothroid® Tablets 300 μg
11599892|NCT00648687|Experimental|I|this group will receive oral water and glucose prior to eye exam
11599893|NCT00648687|No Intervention|II|this group is the control group.
11599894|NCT00648674|Experimental|1|Apligraf
11599895|NCT00648661|Experimental|1|Escitalopram Oxalate Tablets 20 mg
11599896|NCT00648661|Active Comparator|2|Lexapro® Tablets 20 mg
11599897|NCT00648648|Experimental|MK-1775 325 mg Single Dose|Participants received MK-1775 325 mg, orally, on Day 1.
11599898|NCT00648648|Experimental|MK-1775 650 mg Single Dose|Participants received MK-1775 650 mg, orally, on Day 1.
11599899|NCT00648648|Experimental|MK-1775 1300 mg Single Dose|Participants received MK-1775 1300 mg, orally, on Day 1.
11599900|NCT00648648|Experimental|MK-1775 100 mg Single Dose + Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m^2 as an intravenous (IV) infusion on Days 1, 8, and 15 in each 4-week cycle plus MK-1775 100 mg single dose, orally, on Day 2 of each cycle.
11599901|NCT00648648|Experimental|MK-1775 200 mg Single Dose + Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 in each 4-week cycle plus MK-1775 200 mg single dose, orally, on Day 2 of each cycle.
11599902|NCT00648648|Experimental|MK-1775 100 mg Single Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 100 mg single dose orally, on Day 2 of each cycle.
11599903|NCT00648648|Experimental|MK-1775 200 mg Single Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 200 mg single dose orally, on Day 2 of each cycle.
11599904|NCT00648648|Experimental|MK-1775 100 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin at an area under the time curve concentration of 5 mg/min/ml (AUC5) as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 100 mg single dose orally, on Day 2 of each cycle.
11599905|NCT00648648|Experimental|MK-1775 200 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin AUC5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 200 mg single dose orally, on Day 2 of each cycle.
11599906|NCT00648648|Experimental|MK-1775 325 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin AUC5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 325 mg single dose orally, on Day 2 of each cycle.
11599907|NCT00648648|Experimental|MK-1775 25 mg BID x2.5 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4-week cycle plus MK-1775 25 mg orally twice daily (BID) for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 additional doses of MK-1775 25 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each cycle.
11599908|NCT00648648|Experimental|MK-1775 50/25 mg BID x2.5 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 50 mg orally BID for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 doses of MK-1775 25 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each 4 week cycle.
11599909|NCT00648648|Experimental|MK-1775 50 mg BID x2.5 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion given once weekly for 3 consecutive weeks of a 4 week cycle plus MK-1775 50 mg orally BID for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 additional doses of MK-1775 50 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each 4 week cycle.
11599950|NCT00648466|Experimental|1|Sumatriptan Succinate Tablets 100 mg
11599951|NCT00648466|Active Comparator|2|Imitrex® Tablets 100 mg
11599952|NCT00648440|Experimental|1|Midodrine HCl Tablets 5 mg
11599910|NCT00648648|Experimental|MK-1775 100 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 100 mg orally once daily (QD) on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
11599911|NCT00648648|Experimental|MK-1775 125 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 125 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
11599912|NCT00648648|Experimental|MK-1775 150 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 150 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
11599913|NCT00648648|Experimental|MK-1775 175 mg QD x2 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion given on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
11599914|NCT00648648|Experimental|MK-1775 200 mg QD x2 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 200 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
11599915|NCT00648648|Experimental|MK-1775 50 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 50 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
11599916|NCT00648648|Experimental|MK-1775 100 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 100 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
11599917|NCT00648648|Experimental|MK-1775 125 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 125 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
11599918|NCT00648648|Experimental|MK-1775 150 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 150 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
11599919|NCT00648648|Experimental|MK-1775 200 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 200 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
11599920|NCT00648648|Experimental|MK-1775 250 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 250 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
11599921|NCT00648648|Experimental|MK-1775 75 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 75 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
11599922|NCT00648648|Experimental|MK-1775 150 mg BID x 2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 150 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
11599923|NCT00648648|Experimental|MK-1775 225 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 225 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
11599924|NCT00648648|Experimental|MK-1775 325 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 325 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
11599925|NCT00648635||PET + QOL|Survey of how recurrent rectal cancer treatment affects well being + QOL
11599926|NCT00648622|Experimental|1|Carvedilol Tablets 12.5 mg
11599927|NCT00648622|Active Comparator|2|Coreg® Tablets 12.5 mg
11599928|NCT00648609||Home-based palliative care services|Patients who are 60 or more years of age and have a diagnosis of COPD.Patients who have received two or more unscheduled acute care visits during the 12 months prior to the start of the study.
11599929|NCT00648609||Standard of care|Patients who are 60 or more years of age and have a diagnosis of COPD.Patients who have received two or more unscheduled acute care visits during the 12 months prior to the start of the study.
11599930|NCT00648596|Placebo Comparator|Arm 2|
11599931|NCT00648596|Active Comparator|Arm 1|
11599932|NCT00648583|Experimental|1|Ondansetron Tablets 24 mg
11599933|NCT00648583|Active Comparator|2|Zofran® Tablets 24 mg
11599934|NCT00648570|Experimental|1|Escitalopram Oxalate Tablets 20 mg
11599935|NCT00648570|Active Comparator|2|Lexapro® Tablets 20 mg
11599936|NCT00648557|Experimental|1|Levothyroxine Sodium Tablets 200 mg
11599937|NCT00648557|Active Comparator|2|Synthroid Tablets 200 mg
11599938|NCT00648544|Experimental|1|
11599939|NCT00648544|Active Comparator|2|
11599940|NCT00648531|Experimental|1|Balsalazide Disodium Capsules 750 mg
11599941|NCT00648531|Active Comparator|2|Colazal® Capsules 750 mg
11599942|NCT00648518|Experimental|1|Metformin Hydrochloride ER Tablets 750 mg
11599943|NCT00648518|Active Comparator|2|Glucophage® XR Tablets 750 mg
11599944|NCT00648505|Experimental|1|Glipizide and Metformin HCl Tablets 5 mg/500 mg
11599945|NCT00648505|Active Comparator|2|Metaglip® Tablets 5 mg/500 mg
11599946|NCT00648492|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
11599947|NCT00648492|Active Comparator|2|Glucophage® XR 500 mg
11599948|NCT00648479|Experimental|1|
11599949|NCT00648479|Active Comparator|2|
11599953|NCT00648440|Active Comparator|2|ProAmatine® Tablets 5 mg
11599954|NCT00648427|Experimental|1|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg
11599955|NCT00648427|Active Comparator|2|Paxil CR™ Tablets 25 mg
11599956|NCT00648414|Experimental|1|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1 - blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
11599957|NCT00648414|Experimental|2|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2 - tourniquet applied just below patch application site and above blood draw site
11599958|NCT00648414|Experimental|3|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3 - tourniquet applied just above patch application site
11599959|NCT00648414|Experimental|4|Duragesic 25 mcg/h + Clinical Procedure 1 - blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
11599960|NCT00648414|Experimental|5|Duragesic 25 mcg/h + Clinical Procedure 2 - tourniquet applied just below patch application site and above blood draw site
11599961|NCT00648414|Experimental|6|Duragesic 25 mcg/h + Clinical Procedure 3 - tourniquet applied just above patch application site
11599962|NCT00648401|Experimental|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
11599963|NCT00648401|Active Comparator|2|Verelan® PM Extended-Release Capsules, 300 mg
11599964|NCT00648388|Experimental|1|Cilostazol Tablets 100 mg
11599965|NCT00648388|Active Comparator|2|Pletal® Tablets 100 mg
11599966|NCT00648375|Experimental|Propranolol|Participants will take propranolol for 14 weeks. Medication will be self-administered times they experience acute onset of hyperarousal symptoms, not more than twice per day.
11599967|NCT00648375|Placebo Comparator|Placebo|Participants will take placebo for 14 weeks. Medication will be self-administered times they experience acute onset of hyperarousal symptoms, not more than twice per day.
11599968|NCT00648362|Experimental|1|Glimepiride Tablets 1 mg
11599969|NCT00648362|Active Comparator|2|Amaryl® Tablets 1 mg
11599970|NCT00648349|Experimental|1|Rabeprazole Sodium Delayed-Release Tablets 20 mg
11599971|NCT00648349|Active Comparator|2|Aciphex® Delayed-Release Tablets 20 mg
11599972|NCT00648336|Experimental|1|Mercaptopurine 50 mg
11599973|NCT00648336|Active Comparator|2|Purinethol® Tablets 50 mg
11599974|NCT00648323|Experimental|A|
11599975|NCT00648310|Active Comparator|1|arm 1: Tolterodine 4 mg once daily for 12 weeks
11599976|NCT00648310|Experimental|2|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks
11599977|NCT00648297|Experimental|1|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
11599978|NCT00648297|Active Comparator|2|Corzide® Tablets 80 mg/5 mg
11599979|NCT00648271|Experimental|1|Metoprolol Tartrate Tablets 25 mg
11599980|NCT00648271|Active Comparator|2|Lopressor® Tablets 50 mg
11599981|NCT00648258|Active Comparator|Arm 1|
11599982|NCT00648258|Active Comparator|Arm 2|
11599983|NCT00648245|Experimental|1|
11599984|NCT00648245|Experimental|2|
11599985|NCT00648245|Experimental|3|
11599986|NCT00648245|Placebo Comparator|4|
11599987|NCT00648245|Experimental|5|
11599988|NCT00648232|Experimental|A|Participants will receive voluntary brief HIV counseling and testing plus enhanced linkage to care.
11599989|NCT00648232|Experimental|B|Participants will receive voluntary brief HIV counseling and testing plus routine referral to care.
11599990|NCT00648232|Experimental|C|Participants will receive voluntary longer, more detailed HIV counseling and testing plus enhanced linkage to care.
11599991|NCT00648232|Experimental|D|Participants will receive voluntary longer, more detailed HIV counseling and testing plus routine referral to care.
11599992|NCT00648232|Active Comparator|E|Participants who are found to be healthy will receive voluntary brief HIV counseling and testing only.
11599993|NCT00648232|Active Comparator|F|Participants who are found to be healthy will receive voluntary longer, more detailed HIV counseling and testing only.
11599994|NCT00648219|Experimental|1|Olmesartan Medoxomil Tablets 40 mg
11599995|NCT00648219|Active Comparator|2|Benicar® Tablets 40 mg
11599996|NCT00648206||1|drivers of motorised vehicles suspected of driving under the influence of psychoactive drugs or alcohol
11599997|NCT00648206||2|drivers stopped in police traffic controls and breathalysed positive for alcohol
11599998|NCT00648193|Experimental|1|Paroxetine hydrochloride 40 mg tablet
11599999|NCT00648193|Active Comparator|2|Paxil® 40 mg Table
11600000|NCT00648180|Experimental|1|Doxycycline Monohydrate Tablets 100 mg
11600001|NCT00648180|Active Comparator|2|Adoxa Tablets 100 mg
11600002|NCT00648167|Experimental|KRX-0502 (ferric citrate)|All patients will be switched from their current phosphate binder to Zerenex, and titrated to the maximum tolerated dose (up to about 12g/day) based on their serum phosphorus levels.
11600003|NCT00648154|Experimental|1|Letrozole Tablets 2.5 mg
11600004|NCT00648154|Active Comparator|2|Femara® Tablets 2.5 mg
11600005|NCT00648141|Experimental|A|
11600006|NCT00648141|Experimental|B|
11600007|NCT00648141|Active Comparator|C|
11600008|NCT00648128|Active Comparator|2|
11600009|NCT00648128|Experimental|1|
11600010|NCT00648115|Other|Basic Vocational Services|Veteran receives basic vocational services
11600011|NCT00648115|Active Comparator|Self-Study|Veteran participates in self-study vocational program
11600012|NCT00648115|Active Comparator|Group program|Group based vocational program
11600013|NCT00648089|Experimental|1|
11600014|NCT00648089|No Intervention|2|
11600015|NCT00648076|Experimental|1|Divalproex Sodium Extended-Release Tablets 500 mg
11600016|NCT00648076|Active Comparator|2|Depakote ER® Tablets 500 mg
11600017|NCT00648063|Experimental|1|Letrozole Tablets 2.5 mg
11600018|NCT00648063|Active Comparator|2|Femara® Tablets 2.5 mg
11600019|NCT00648050|Experimental|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
11600020|NCT00648050|Active Comparator|2|Verelan® PM Extended-Release Capsules, 300 mg
11600085|NCT00647608|Experimental|1|Propranolol Hydrochloride Extended-Release Capsules 160 mg
11600021|NCT00648037|Experimental|Rituximab|Patients following a T cell depleted HLA-mis-matched related or unrelated hematopoietic stem cell transplant (HSCT) will be treated with monthly Rituximab.
11600022|NCT00648024|Experimental|1|Anagrelide Hydrochloride Capsules 1 mg
11600023|NCT00648024|Active Comparator|2|Agrylin® Capsules 1 mg
11600024|NCT00648011|Experimental|1|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
11600025|NCT00648011|Active Comparator|2|Accuretic™ Tablets 20 mg/25 mg
11600026|NCT00647998|Experimental|Darbepoetin|Patients received 1mg/kg IV Darbepoetin immediately prior to surgery
11600027|NCT00647998|Placebo Comparator|Standard care|No Darbepoetin
11600028|NCT00647985|Experimental|1|Fexofenadine Tablets 180 mg
11600029|NCT00647985|Active Comparator|2|Allegra® Tablets 180 mg
11600030|NCT00647972|Experimental|1|Olanzapine Tablets 20 mg
11600031|NCT00647972|Active Comparator|2|Zyprexa® Tablets 20 mg
11600032|NCT00647959|Experimental|1|Doxycycline Tablets, 150mg
11600033|NCT00647959|Active Comparator|2|Adoxa Tablets 150 mg
11600034|NCT00647946|Experimental|A|Stop zidovudine (ZDV) or stavudine (d4T) and start tenofovir DF 300mg once daily along with the other antiviral drugs that are used as part of their HAART regimen
11600035|NCT00647946|Active Comparator|B|Stop zidovudine (ZDV) or stavudine (d4T) and start abacavir 300mg twice daily along with the other antiviral drugs that are used as part of their HAART regimen
11600036|NCT00647933|Experimental|Org 36286 15 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 15 μg.
11600037|NCT00647933|Experimental|Org 36286 30 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 30 μg.
11600038|NCT00647933|Experimental|Org 36286 60 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 60 μg.
11600039|NCT00647933|Experimental|Org 36286 120 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 120 μg.
11600040|NCT00647920|Experimental|40 mg|
11600041|NCT00647920|Placebo Comparator|Placebo|
11600042|NCT00647907|Experimental|A|
11600043|NCT00647894|Experimental|1|Alprazolam Extended-Release Tablets 1 mg
11600044|NCT00647894|Active Comparator|2|Xanax XR Tablets 1 mg
11600045|NCT00647881|Experimental|1|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg
11600046|NCT00647881|Active Comparator|2|Paxil CR™ Tablets 25 mg
11600047|NCT00647868|Experimental|Groups 1 and 2|Twice daily (7:00 am and 12:00 am or 7:00 am and 10:00 pm) dosing with intranasal testosterone for 14 days
11600048|NCT00647868|Experimental|Groups 3a and b|Single daily administration of testosterone (at 7:00 am or 10:00 pm) for 14 days
11600049|NCT00647868|No Intervention|Group 4|24-h blood sampling in healthy eugonadal controls
11600050|NCT00647855|Experimental|1|Levothyroxine Sodium Tablets 300 μg
11600051|NCT00647855|Active Comparator|2|Synthroid® Tablets 300 μg
11600052|NCT00647842|Experimental|1|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay
11600053|NCT00647842|Active Comparator|2|Fentanyl Transdermal System 25 mcg/h
11600054|NCT00647829|Active Comparator|Arm 1|
11600055|NCT00647829|Active Comparator|Arm 2|
11600056|NCT00647829|Placebo Comparator|Arm 3|
11600057|NCT00647816|Experimental|1|Propranolol Hydrochloride Extended-Release Capsules 160 mg
11600058|NCT00647816|Active Comparator|2|Inderal® LA Capsules 160 mg
11600059|NCT00647790||1|Patients with a confirmed diagnosis of invasive breast cancer who are undergoing surgery.
11600060|NCT00647777|Experimental|1|Olanzapine Tablets 5 mg
11600061|NCT00647777|Active Comparator|2|Zyprexa® Tablets 5 mg
11600062|NCT00647764|Experimental|Single Arm|
11600063|NCT00647751|Experimental|1|Lamotrigine Tablets 25 mg
11600064|NCT00647751|Active Comparator|2|Lamictal® Tablets 25 mg
11600065|NCT00647738|Experimental|1|
11600066|NCT00647738|Active Comparator|2|
11600067|NCT00647725|Active Comparator|I|Active phrase analgesia
11600068|NCT00647725|Active Comparator|II|Latent phrase analgesia
11600069|NCT00647712|Experimental|1|Divalproex Sodium Extended-Release Tablets 500 mg
11600070|NCT00647712|Active Comparator|2|Depakote ER® Tablets 500 mg
11600071|NCT00647699|Active Comparator|Corneal Collagen Cross-linking (CXL) Treatment Group|riboflavin ophthalmic solution and UVA irradiation
11600072|NCT00647699|Sham Comparator|Control Group|riboflavin ophthalmic solution without UVA irradiation.
11600073|NCT00647686|Experimental|1|Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay
11600074|NCT00647686|Active Comparator|2|Fentanyl Transdermal System 25 mcg/h
11600075|NCT00647673|Experimental|1|Verapamil HCL Extended-Release Capsules 300 mg
11600076|NCT00647673|Active Comparator|2|Verelan® PM Extended-release Capsules 300 mg
11600077|NCT00647660|Experimental|1|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
11600078|NCT00647660|Active Comparator|2|Corzide® Tablets 80 mg/5 mg
11600079|NCT00647647|Experimental|1|Terbinafine Hydrochloride Tablets 250 mg
11600080|NCT00647647|Active Comparator|2|Lamisil® Tablets 250 mg
11600081|NCT00647634|Experimental|1|Alprazolam Extended-Release Tablets 3 mg;
11600082|NCT00647634|Active Comparator|2|Xanax XR® Tablets 3 mg
11600083|NCT00647621|Experimental|1|Extended Phenytoin Sodium Capsules 100 mg
11600084|NCT00647621|Active Comparator|2|Dilantin® Kapseals® 100 mg
11600086|NCT00647608|Active Comparator|2|Inderal® LA Capsules 160 mg
11600087|NCT00647595|Experimental|A|Women in this group will exercise 3x per week at a moderate/vigorous level for 45 min per session through their 36 week of pregnancy.
11600088|NCT00647595|No Intervention|B|Women in this group will continue their usual activities throughout their pregnancy.
11600089|NCT00647569|Experimental|A|No previous major abdominal surgery
11600090|NCT00647569|Experimental|B|Previous major abdominal surgery
11600091|NCT00647556|Active Comparator|adapalene|adapalene
11600092|NCT00647556|Active Comparator|tretinoin|Tretinoin
11600093|NCT00647543|Experimental|High Risk|
11600094|NCT00647543|Experimental|Low Risk|
11600095|NCT00647543|Experimental|Medium Risk|
11600096|NCT00647530|Experimental|Pre&Post Op Chemo|12 weeks of OxFP neuoadjuvantly followed by surgery and 18 weeks of OxFP
11600097|NCT00647530|Experimental|Pre&Post Op Chemo with P-mab|12 weeks of OxFP and panitumumab neuoadjuvantly followed by surgery and 18 weeks of OxFP alone.
11600098|NCT00647530|Active Comparator|Post Op Chemo|surgery followed by 24 weeks of OxFP.
11600099|NCT00647517|Experimental|ultracet|
11600100|NCT00647517|Placebo Comparator|placebo|
11600101|NCT00647504||1|Restenosis in Bare metal stent
11600102|NCT00647504||2|Restenosis in Drug eluting stent
11600103|NCT00647504||3|Stent thrombosis
11600104|NCT00647504||4|Control group
11600105|NCT00647491|Experimental|20 mg|20 mg adalimumab eow
11600106|NCT00647491|Experimental|40 mg|40 mg adalimumab eow
11600107|NCT00647491|Experimental|80 mg|80 mg adalimumab eow
11600108|NCT00647491|Placebo Comparator|Placebo|Placebo eow
11600109|NCT00647478||1|AD
11600110|NCT00647478||2|Control elderly subjects with normal cognitive function
11600111|NCT00647478||3|MCI
11600112|NCT00647465|Active Comparator|1|IFNalpha 2b
11600113|NCT00647465|Placebo Comparator|2|Placebo
11600114|NCT00647452|Experimental|1|Healthy male volunteers
11600115|NCT00647452|Experimental|2|Healthy female volunteers
11600116|NCT00647426|Experimental|Sorafenib + Docetaxel/Carboplatin|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
11600117|NCT00647413|No Intervention|1|
11600118|NCT00647413|Experimental|2|expert system intervention on smoking behaviour + feedback of a biomarker
11600119|NCT00647400|Experimental|Adalimumab 40 mg every other week|
11600120|NCT00647400|Experimental|Adalimumab 80 mg every other week|
11600121|NCT00647387|Experimental|1|Implantation with the device
11600122|NCT00647374||1|
11600123|NCT00647361|Experimental|NAVA|
11600124|NCT00647348|Active Comparator|1|Simvastatin 80mg OD
11600125|NCT00647348|Placebo Comparator|2|Placebo
11600126|NCT00647335||1|Women with diagnosis of PCOS
11600127|NCT00647322|Experimental|1|Reduction in anti-epileptic medications
11600128|NCT00647322|Active Comparator|2|No change in medication. Unchanged treatment
11600129|NCT00647309||1|
11600130|NCT00647309||2|
11600131|NCT00647296|Placebo Comparator|matched placebo|
11600132|NCT00647296|Experimental|low-dose KNS-760704|
11600133|NCT00647296|Experimental|mid-dose KNS-760704|
11600134|NCT00647296|Experimental|high-dose KNS-760704|
11600135|NCT00647283|Experimental|1|Stable liver transplant recipients fulfilling inclusion criteria.
11600136|NCT00647270|Placebo Comparator|Placebo|Placebo 12 weeks, 40mg adalimumab remaining 12 weeks
11600137|NCT00647270|Active Comparator|40 mg|40 mg every other week
11600138|NCT00647270|Active Comparator|80 mg|80 mg monthly
11600139|NCT00647257|Active Comparator|A|
11600140|NCT00647257|Placebo Comparator|B|
11600141|NCT00647244|Active Comparator|1|Tenofovir
11600142|NCT00647244|Active Comparator|2|Abacavir
11600143|NCT00647231|Experimental|A, 2, II, HKT-500 Topical Patch|A Randomized, Multicenter, Double-Blind, Single Dose Study of the Analgesic Properties of HKT-500 and Placebo in Subjects With Pain Caused by Mild to Moderate Osteoarthritis of the Knee
11600144|NCT00647231|Placebo Comparator|Placebo Patch|Treatment with placebo patch
11600145|NCT00647218|Experimental|Experimental|
11600146|NCT00647205|Sham Comparator|1|HIV infected antiretroviral naïve patients originated from low TB prevalence countries without any active TB with CD4 cell count > 350/mm3
11600147|NCT00647205|Sham Comparator|2|HIV infected antiretroviral naïve patients originated from low TB prevalence countries without any active T with CD4 < 350/mm3)
11600148|NCT00647205|Sham Comparator|3|HIV infected antiretroviral naïve patients originated from high TB prevalence countries without any active TB with CD4 < 350/mm3)
11600149|NCT00647205|Sham Comparator|4|HIV infected antiretroviral naïve patients originated from high TB prevalence countries without any active TB with CD4 > 350/mm3)
11600150|NCT00647205|Sham Comparator|5|HIV infected patients with active TB
11600151|NCT00647205|Sham Comparator|6|HIV negative patients with active TB
11600152|NCT00647192|Active Comparator|1|Eplerenone treatment
11600153|NCT00647192|Placebo Comparator|2|
11600154|NCT00647179||1|Patients recently diagnosed with acromegaly
11600155|NCT00647166|Experimental|1|Drug: corticosteroid and azathioprine
11600156|NCT00647166|Placebo Comparator|2|Drug: corticosteroid and placebo
11600157|NCT00647153|Experimental|Radiation: iodine I 123 anti-CEA recombinant diabody T84.66|
11600158|NCT00647140|Experimental|1|18F-L6DOPA PET
11600159|NCT00647127|Active Comparator|Buprenorphine|
11600160|NCT00647127|Active Comparator|Fentanyl|
11600161|NCT00647127|Placebo Comparator|Placebo|
11600162|NCT00647114|Experimental|1|V930
11600163|NCT00647114|Experimental|2|V932
11600164|NCT00647101|Experimental|Latanoprost group|
11600165|NCT00647088||aortic stenosis|various age and disease severity
11600166|NCT00647088||Controls|Controls free of valvular disease
11600167|NCT00647075|Experimental|1|Yunzhi extract 3.5 g/day
11600168|NCT00647075|Placebo Comparator|2|Placebo
11600169|NCT00647049|Experimental|A|first diagnosis of PCNSL: combined chemotherapy with methotrexate
11600170|NCT00647049|Experimental|B|Patients with relapse or progressive disease of PCNSL after methotrexate containing chemotherapy
11600171|NCT00647036|Active Comparator|1|Dipeptiven (L-glutamine- Lalanine)
11600172|NCT00647036|Placebo Comparator|2|Isonitrogenous Vaminolact
11600173|NCT00647023|Experimental|A|
11600174|NCT00646997||1|Patients with postoperative atrial fibrillation
11600175|NCT00646997||2|Patients without postoperative atrial fibrillation.
11600176|NCT00646984|Active Comparator|1|Standard continuous antiretroviral therapy
11600177|NCT00646984|Experimental|2|CD-4 guided interruption arm
11600178|NCT00646984|Experimental|3|Viral load driven treatment interruption
11600179|NCT00646971|Experimental|1|CPAP
11600180|NCT00646971|Sham Comparator|2|sham CPAP
11600181|NCT00646958|Experimental|1|Radezolid 450 mg PO QD
11600182|NCT00646958|Experimental|2|Radezolid 450 mg PO BID
11600183|NCT00646958|Active Comparator|3|Linezolid 600 mg PO BID
11600184|NCT00646945|Experimental|A|50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)
11600185|NCT00646945|Placebo Comparator|B|50% oxygen/50% Nitrogen premix
11600186|NCT00646932|Experimental|1|
11600187|NCT00646932|Experimental|2|
11600188|NCT00646932|Experimental|3|
11600189|NCT00646932|Experimental|4|
11600190|NCT00646919||1|All pre-operative pediatric patients in our outpatient clinic
11600191|NCT00646906|Experimental|Phase 1a: Acetaminophen 1000mg / aspirin|"All subjects in this arm (smokers (n=8) and non-smokers (n=8) will receive 81 mg aspirin at approximately 8 am followed by 1000 mg acetaminophen at approximately 10 am during one crossover period (see Crossover period: Aspirin first intervention). During the other crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 1000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see Crossover Period: Aspirin last intervention). The occurrence of the two crossover periods will be randomized by order. Smokers and non-smokers will be matched for age and gender."
11600192|NCT00646906|Experimental|Phase 1a: Acetaminophen 2000mg / aspirin|"All subjects in this arm (smokers (n=8) and non-smoking volunteers (n=8)) will receive 81 mg aspirin at approximately 8 am followed by 2000 mg acetaminophen at approximately 10 am during one crossover period (see Crossover Period: Aspirin first intervention). During the other crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 2000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see Crossover Period: Aspirin last intervention). The occurrence of the two crossover periods will be randomized by order. Smokers and non-smokers will be matched for age and gender."
11600193|NCT00646906|Experimental|Phase 1b: Acetaminophen 1000 mg alone|"Eight male and non-pregnant female subjects who are healthy and non-smoking will be recruited. They will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM (see Acetaminophen 1000 mg/d intervention). Study assessments will be performed on day 1 and on day 6. This is not a crossover design. Just one treatment period."
11600194|NCT00646906|Experimental|Phase 2: Acetaminophen vs. Ibuprofen|"Eight male and non-pregnant female subjects who are healthy and non-smoking will be recruited. In one period of this crossover study acetaminophen (1000 mg p.o.) will be administered orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days (see Crossover Period: Acetaminophen 4000 mg/d intervention). The last dose will be administered on day four at 8 AM In the other crossover period, after a washout period of at least 14 days, the subjects will receive ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days (see Crossover Period: Ibuprofen 800 mg/d intervention). The last dose will be administered on day four at 8 AM Study assessments will be performed on day 1 and day 4 of each crossover period. The occurrence of the two crossover periods will be randomized by order."
11600195|NCT00646893|No Intervention|1|Control: assisted hatching, without Preimplantation Genetic Diagnosis
11600196|NCT00646893|Experimental|2|Test: embryo biopsy with Preimplantation Genetic Diagnosis
11600197|NCT00646880|Active Comparator|Propiverine/tolterodine group|
11600198|NCT00646880|Active Comparator|Tolerodine/propiverine group|
11600199|NCT00646867|Experimental|1|Experimental
11600200|NCT00646867|Placebo Comparator|2|Placebo
11600201|NCT00646854|Active Comparator|Arm A|
11600202|NCT00646854|Experimental|Arm B|
11600203|NCT00646841|Experimental|A|
11600204|NCT00646828||without PHA1|patients without mineralocorticoid receptor mutation
11600205|NCT00646828||PHA 1|patients with a rare disease, pseudohypoaldosteronism type 1, due to heterozygous inactivating mutations of the mineralocorticoid receptor
11600206|NCT00646815|Experimental|a|the aim of the present study is to characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic-intramyocellular lipids in 12 adult patients, recently diagnosed with growth hormone deficiency
11600207|NCT00646815|No Intervention|Control|Intramyocellular, intrahepatic and intraabdominal lipid content, lean body mass and body fat percentage, are assessed in ten healthy controls matched on age, gender and BMI.
11600208|NCT00646802|Active Comparator|A|Progesterone 200 mg
11600209|NCT00646802|Placebo Comparator|B|Placebo
11600210|NCT00646789|Experimental|1|MK0633
11600211|NCT00646776|Active Comparator|A|
11600212|NCT00646776|Active Comparator|B|
11600213|NCT00646763|Active Comparator|Abdomen|These subjects will have their cytokine injections administered only to their abdomen.
11600214|NCT00646763|Active Comparator|Extremities|The extremity arm will have their injections administered to their upper and/or lower extremities.
11600215|NCT00646750|Experimental|1|BEAM preceded by Ybritumomab Tiuxetan (Zevalin)
11600216|NCT00646737|Experimental|1|Mycophenolate sodium
11600217|NCT00646724|Experimental|1|cotransplantation of islet and mesenchymal stem cell
11600218|NCT00646711|Experimental|Sequence Group I|Depakote Delayed Release/Depakote Sprinkle
11600219|NCT00646711|Experimental|Sequence Group II|Depakote ER
11600220|NCT00646698||1|Premenopausal Upper Body Obese (UBO) women with waist-hip ratio > 0.85 and BMI > 28
11600221|NCT00646698||2|Premenopausal Lower Body Obese (LBO) women with waist hip ratio < 0.8 and BMI > 28
11600222|NCT00646698||3|Premenopausal lean women with BMI < 25
11600223|NCT00646685|Other|1|
11600225|NCT00646646|Active Comparator|propofol|active drug
11600226|NCT00646646|Active Comparator|dexmedetomidine|sedative
11600227|NCT00646646|Active Comparator|midazolam|Sedative
11600228|NCT00646646|Placebo Comparator|placebo|placebo control
11600229|NCT00646633|Active Comparator|Acupuncture & educ|Patients will receive a total of 8 acupuncture treatments. In each of the first four sessions, they will also receive patient education.
11600230|NCT00646633|No Intervention|2. Standard care|Patients in the control arm will continue to receive standard care from their physician.
11600231|NCT00646620|Experimental|1|budesonide/formoterol
11600232|NCT00646620|Active Comparator|2|fluticasone/salmeterol
11600233|NCT00646620|Active Comparator|3|albuterol
11600234|NCT00646607|Experimental|A|FOLFOX-4 (infusional 5-Fluouracil, leucovorin and oxaliplatin) for 3 months or XELOX (capecitabine and oxaliplatin) for 12 weeks.
11600235|NCT00646607|Active Comparator|B|FOLFOX-4 (infusional 5-Fluouracil, leucovorin and oxaliplatin) for 6 months or XELOX (capecitabine and oxaliplatin) for 24 weeks.
11600236|NCT00646594|Experimental|1|budesonide/formoterol
11600237|NCT00646594|Active Comparator|2|fluticasone/salmeterol
11600238|NCT00646581|Placebo Comparator|Placebo (1)|Subjects are given a one-time, single dose of placebo intranasal spray
11600239|NCT00646581|Experimental|Single-Dose Intranasal Insulin|Subjects are given a one-time, single dose of intranasal insulin
11600240|NCT00646542|Experimental|1|
11600241|NCT00646542|Placebo Comparator|2|
11600242|NCT00646529|Experimental|1|budesonide/formoterol
11600243|NCT00646529|Active Comparator|2|budesonide
11600244|NCT00646516|Experimental|1|
11600245|NCT00646503|Experimental|1|600 mg/day, oral telbivudine for 52 weeks
11600246|NCT00646490||A|patients with parapneumonic pleural effusion due to community acquired pneumonia
11600247|NCT00646490||B|patients with pleural effusion of other etiologies
11600248|NCT00646477|Experimental|A|Phase 1 : manual Phase 2 : automatic Descent rate pressure : slow
11600249|NCT00646477|Experimental|B|Phase 1 : manual Phase 2 : automatic Descent Rate Pressure : fast
11600250|NCT00646477|Experimental|C|Phase 1 : automatic Phase 2 : manual Descent rate pressure : slow
11600251|NCT00646477|Experimental|D|Phase 1 : automatic Phase 2 : manual Descent Rate Pressure : fast
11600252|NCT00646464||2|Children 6-12 years old diagnosed as not suffering from ADHD
11600253|NCT00646464||1|children 6-12 diagnosed as ADHD
11600254|NCT00646451|Experimental|1|Pregabalin 75 mg bid to a maximum dose of 300 mg bid
11600255|NCT00646451|Placebo Comparator|2|Placebo to 4 capsules bid
11600256|NCT00646438|Active Comparator|1|strict glucose control (study arm)
11600257|NCT00646438|No Intervention|2|standard insulin treatment (control arm)
11600258|NCT00646425|Experimental|1|Basiliximab
11600259|NCT00646425|Placebo Comparator|2|
11600260|NCT00646412|Experimental|A|A-Part® Gel
11600261|NCT00646412|No Intervention|B|untreated control group
11600262|NCT00646399|Placebo Comparator|Placebo|Phosphate Buffered Saline
11600263|NCT00646399|Experimental|Pagibaximab 50 mg/mL|Pagibaximab at 100 mg/kg intravenously at Days 0, 1, 2, 9, 16 and 23.
11600264|NCT00646386|Active Comparator|A|
11600265|NCT00646386|Placebo Comparator|B|
11600266|NCT00646360|Experimental|1|Docosahexonic acid (400 mg/day)
11600267|NCT00646360|Placebo Comparator|2|
11600268|NCT00646347|Experimental|A|Conventional stroke upper limb rehabilitation is given
11600269|NCT00646347|Active Comparator|B|Neuro Hand Orthosis Program is given
11600270|NCT00646334|Experimental|A|Optilene® Mesh Elastic
11600271|NCT00646334|Active Comparator|B|Ultrapro® Mesh
11600272|NCT00646321|Experimental|1|budesonide/formoterol
11600273|NCT00646321|Active Comparator|2|budesonide
11600274|NCT00646308||I|Adult patients with GH deficiency due to a nonsecreting pituitary tumor
11600275|NCT00646308||2|Adult patients with a nonsecreting pituitary tumor but without GH deficiency
11600276|NCT00646295|Experimental|A|To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes
11600277|NCT00646282|Experimental|Doxercalciferol|Stable kidney transplant recipients will receive Doxercalciferol
11600278|NCT00646282|No Intervention|Control|Stable kidney transplant recipients will not receive any drug
11600279|NCT00646269|Active Comparator|1|
11600280|NCT00646269|Experimental|2|
11600281|NCT00646269|Experimental|3|
11600282|NCT00646269|Experimental|4|
11600283|NCT00646256|No Intervention|no training|
11600284|NCT00646256|Experimental|COGPACK training|
11600285|NCT00646243||1 Heart Failure|216 consecutive consenting patients with refractory heart failure candidate to cardiac resynchronization therapy by clinical and electrocardiographic criteria
11600286|NCT00646243||2 Healthy subjects|120 healthy subject includes defined as absence of history and symptoms of any cardiovascular disease, normal physical examination and ECG.
11600287|NCT00646230|Experimental|Single arm of CIV infusion of emulsion 4-HPR|Single arm study of continuous intravenous infusion (CIV) of emulsion 4-HPR
11600288|NCT00646217|Experimental|1|SELF CARE Talk
11600289|NCT00646217|No Intervention|2|Comparison Group
11600290|NCT00646204|Experimental|1|memantine 10 mg bid
11600291|NCT00646204|Placebo Comparator|2|2 tabs bid
11600292|NCT00646191|Active Comparator|A|
11600293|NCT00646191|Active Comparator|B|
11600294|NCT00646191|Active Comparator|C|
11600295|NCT00646178|Active Comparator|A|
11600296|NCT00646178|Placebo Comparator|B|
11600297|NCT00646126|Active Comparator|1|1:Active comparator sulfadoxine-pyrimethamine plus artesunate
11600298|NCT00646126|Placebo Comparator|2|2:placebo comparator
11600299|NCT00646113|Experimental|OsseoSpeed™ TX 3.0S (Dental implant)|OsseoSpeed™ TX 3.0S, Dental implants, 3.0 mm diameter, in lengths of 11, 13 and 15 mm
11600300|NCT00646100|Active Comparator|TACE|chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization
11600301|NCT00646100|No Intervention|control|best support care
11600302|NCT00646087|Experimental|Ketamine (6K)|6K: 6 ketamine injections (0.5 mg/kg of ketamine) every other day for 12 days
11600303|NCT00646087|Active Comparator|Ketamine/Placebo (2K4P)|2K4P = two active ketamine injections(2K) and four placebo (saline) injections over 12 days.
11600304|NCT00646074|Experimental|1|Self-Care TALK
11600305|NCT00646074|No Intervention|2|
11600306|NCT00646061|Experimental|1|morphine, ketorolac, and buscopan
11600307|NCT00646061|No Intervention|2|morphine and ketorolac
11600308|NCT00646048|Experimental|Arm 1|This arm is for patient that receive the TriVascular Stent-Graft System.
11600309|NCT00646035|Placebo Comparator|A|
11600310|NCT00646035|Placebo Comparator|B|
11600311|NCT00646022||Family Members|Family members in which two members are diagnosed with carcinoid tumor, or currently diagnosed with multiple primary tumors
11600312|NCT00646022||Unaffected partners|Unaffected partners of patients with a carcinoid tumor who have biological children with the patient
11600313|NCT00646009|Experimental|1|budesonide/formoterol
11600314|NCT00646009|Active Comparator|2|fluticasone/salmeterol
11600315|NCT00646009|Active Comparator|3|albuterol
11600316|NCT00645996|Experimental|1|
11600317|NCT00645996|Placebo Comparator|2|Cornflour
11600318|NCT00645983|Experimental|1|Chamomile Extract
11600319|NCT00645983|Placebo Comparator|2|Anxiolytic Therapy
11600320|NCT00645970||Group 1|
11600321|NCT00645957|Active Comparator|2|This group will have a red rubber drain(s) placed during surgery. This drain(s) will be irrigated intra and post-operatively
11600322|NCT00645957|Active Comparator|1|This group will have a penrose drain(s) placed during surgery to facilitate drainage post-operatively. This drain (s) will not be irrigated.
11600323|NCT00645944|Experimental|Eszopiclone Group|Participants assigned to this arm will receive Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
11600324|NCT00645944|Placebo Comparator|Placebo Group|"Participants assigned to this arm will receive placebo (an inactive substance or a sugar pill) to be taken each night for all weeks of the study."
11600325|NCT00645918|Active Comparator|A|"Tailored clopidogrel regimen - an additional clopidogrel 600-mg loading dose (eight 75-mg tablets taken orally; daily 150 mg clopidogrel dose plus additional 450 mg clopidogrel) on the day of randomization and then 150-mg clopidogrel every day thereafter for 6 months."
11600326|NCT00645918|Placebo Comparator|B|"Standard clopidogrel regimen - a placebo loading dose (six placebo tablets taken orally plus daily dose of one placebo tablet plus 75 mg clopidogrel) on the day of randomization followed by one placebo tablet plus 75 mg clopidogrel every day thereafter for 6 months."
11600327|NCT00645918|Placebo Comparator|C|Responders: A random sample of clopidogrel responders treated with a placebo loading dose (six placebo tablets taken orally plus daily dose of one placebo tablet plus 75 mg clopidogrel) on the day of randomization followed by one placebo tablet plus 75 mg clopidogrel every day thereafter for 6 months.
11600328|NCT00645905|Active Comparator|A|
11600329|NCT00645905|Placebo Comparator|B|
11600330|NCT00645892|Active Comparator|A|
11600331|NCT00645892|Placebo Comparator|B|
11600332|NCT00645879|Experimental|OKG, Glutamine, and Disodium Citrate|Ornithine Alpha Ketoglutarate for 4 weeks, followed by 2 week washout period. 4 weeks Glutamine, followed by 2 week washout period. 4 weeks Disodium Citrate, followed by 2 to 12 week washout period. Then continue an additional 30 weeks on Disodium Citrate (drug producing the best increment in plasma glutamine levels).
11600333|NCT00645853|Experimental|1|
11600334|NCT00645853|Active Comparator|2|
11600335|NCT00645840|Experimental|Anakinra|After study enrollment, all subjects started anakinra (Kineret™; Amgen, Thousand Oaks, CA, USA) as a subcutaneous daily injection. Subjects weighing >25 kg at the time of enrollment received 100 mg daily, whereas those weighing <25 kg received 50 mg daily. Anakinra was continued for 28 d with no dose adjustment.
11600336|NCT00645827|Experimental|Insulin infusion conversion equation|Insulin infusion conversion equation is used to determine subcutaneous insulin dosing for first 24 hours after cessation of an IV insulin infusion.
11600337|NCT00645827|Active Comparator|Control|Judgment of patient's healthcare provider is used to determine subcutaneous insulin dosing for first 24 hours after cessation of IV insulin infusion.
11600338|NCT00645814|Placebo Comparator|A|
11600339|NCT00645814|Active Comparator|B|
11600340|NCT00645814|Active Comparator|C|
11600341|NCT00645801|Active Comparator|1|Patients will receive both Amitiza and GoLYTELY
11600342|NCT00645801|Placebo Comparator|2|Patients will receive Amitiza Placebo plus GoLYTELY
11600343|NCT00645788|Experimental|32.50 mg Ciprofloxacin DPI (BAYQ3939)|32.50 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days
11600344|NCT00645788|Experimental|48.75 mg Ciprofloxacin DPI (BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days
11600345|NCT00645788|Placebo Comparator|Matching Placebo for 32.50 mg|Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days
11600346|NCT00645788|Placebo Comparator|Matching Placebo for 48.75 mg|Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days
11600347|NCT00645775|Placebo Comparator|1|Compare active to placebo
11600348|NCT00645762|Active Comparator|Balloon Dilation|Balloon dilation with FinESS device
11600349|NCT00645749|Experimental|Helminth ova|Subjects serving as their own controls (baseline - end-of-treatment) will receive a dose of 2,500 ova, in liquid form, every 2 weeks
11600350|NCT00645736||1|Single cohort
11600351|NCT00645723|Experimental|A|Intravenous colistin and nebulized colistin
11600352|NCT00645723|Placebo Comparator|B|intravenous colistin and saline solution nebulized
11600353|NCT00645710|Experimental|Arm I|"Patients receive floxuridine as a continuous hepatic arterial infusion on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 9 and 11. Patients also receive yttrium Y 90 anti-CEA monoclonal antibody cT84.66 IV over 25 minutes on day 9. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
~Patients may receive an additional course of floxuridine in combination with systemic therapy at the discretion of the treating physician."
11600354|NCT00645684|Experimental|A|one layer running suture technique
11600355|NCT00645684|Experimental|B|two-layer suture technique
11600356|NCT00645671|Experimental|Loteprednol Etabonate|Loteprednol etabonate 0.5% ophthalmic ointment
11600357|NCT00645671|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate ointment
11600358|NCT00645645||holoprosencephaly (HPE)|individuals with overt or subtle clinical findings consistent with the HPE spectrum are eligible to participate
11600359|NCT00645619||1|Patients with pure viral pneumonia
11600360|NCT00645619||2|Patients with viral pneumonia along with secondary bacterial pneumonia
11600361|NCT00645619||3|Patients with significant bacterial pneumonia
11600362|NCT00645619||4|Patients with congenital heart disease undergoing cardiopulmonary bypass who have no pneumonia
11600363|NCT00645606|No Intervention|Observation|Observation every 8 weeks during 2 years
11600364|NCT00645606|Experimental|rituximab arm|rituximab :500 mg/m² every 8 weeks during 2 years
11600365|NCT00645593|Active Comparator|Arm 1, Gemcitabine and Cisplatin|Gemcitabine and Cisplatin, as described in the intervention
11600366|NCT00645593|Experimental|Arm 2, Cetuximab, Gemcitabine and Cisplatin|Gemcitabine and Cisplatin with Cetuximab, as described in the intervention
11600367|NCT00645580|Experimental|A|
11600368|NCT00645567||Unassisted manual transfer|this group will use no additional aid in transfer.
11600369|NCT00645567||Standard sliding board transfer|The standard transfer board is a flat surface board designed to bridge the gap that exists with transfers from wheelchair to vehicle and/or other horizontally displaced seating surfaces.
11600370|NCT00645567||Glide n' Go Lift|The Glide n' Go lift is a flip down power list seat that enables the person to enter and exit the vehicle by lifting them from their wheelchair up tot eh vehicle seat that they can make an easy transfer into the vehicle. Trunk stability may be required to successfully use the device.
11600371|NCT00645567||Easy Reach lift|The Easy Reach lift seat allows the vehicles original seat to swivel out of the vehicle and lower to wheelchair height. the chair extends far from the vehicle to provide access for a safe, easy transfer.
11600372|NCT00645567||Ryno lift|The Ryno lift is an under-vehicle list (UVL) system. Using this lift, the wheelchair user is raised into the vehicle cab using independent controls and can then maneuver into a convenient position in the cab. The wheelchair is locked down and the lift stored beneath the vehicle chassis. This technology eliminated the need to store and retrieve a wheelchair during transit.
11600373|NCT00645541|Experimental|Axillary Reverse Mapping (ARM)|
11600374|NCT00645528|Experimental|Insulin Education Class Participants|Participation in an insulin educational class at week 0 and again at week 2
11600375|NCT00645515|Experimental|Arm A|
11600376|NCT00645515|Active Comparator|Arm B|
11600377|NCT00645489|Other|1|Control condition is wait-list control.
11600378|NCT00645489|Experimental|2|Active treatment condition: psychoeducational intervention for patients with HF
11600379|NCT00645463|Experimental|Group A|
11600380|NCT00645463|Experimental|Group B|
11600381|NCT00645450|Experimental|Propranolol|Weekly doses of short and long acting propranolol following recollection of traumatic memory
11600382|NCT00645450|Placebo Comparator|Placebo|Weekly doses of placebo following recollection of traumatic memory
11600383|NCT00645424|Experimental|Arm A|
11600384|NCT00645424|Experimental|Arm B|
11600385|NCT00645424|Experimental|Arm C|
11600386|NCT00645411|Experimental|Cohorts 1 + Cohort 2 (9-17 Yrs) cTIV|All subjects received one 0.5 mL IM injection, of cell culture-derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like, and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
11600387|NCT00645411|Active Comparator|Cohorts 1 + Cohort 2 (9-17 Yrs) eTIV|All subjects received one 0.5 mL injection, of egg -derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere.
11600388|NCT00645411|Experimental|Cohort 3 (3-8 Yrs) cTIV|All subjects received two 0.5 mL injections, administered four weeks apart, of cell culture-derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
11600389|NCT00645411|Active Comparator|Cohort 3 (3-8 Yrs) eTIV|All subjects received two 0.5 mL injections, administered four weeks apart of egg -derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
11600390|NCT00645398|Experimental|A|
11600391|NCT00645398|Experimental|B|
11600392|NCT00645398|Experimental|C|
11600393|NCT00645398|Placebo Comparator|D|
11600394|NCT00645385||MRS of the neural system|MRS to study epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism.
11600395|NCT00645372|Active Comparator|A|
11600396|NCT00645372|Experimental|B|
11600397|NCT00645359||Diffusion MRI|Patients will undergo a Diffusion MRI (dMRI) at baseline and 7 days.
11600398|NCT00645346|Experimental|1|Subjects will receive either 5, 10 or 20 mcg of the vaccine
11600399|NCT00645346|Placebo Comparator|2|Subjects will receive placebo control
11600400|NCT00645333|Experimental|MK-0752, Docetaxel, Pegfilgrastim|MK-0752, Docetaxel, Pegfilgrastim in combination with escalating doses of MK-0752
11600401|NCT00645320|Experimental|A|
11600402|NCT00645294|Other|Treatment Group A|ADV (0.14 mg/kg) oral suspension formulation on Day 1 followed by ADV (0.3 mg/kg) oral suspension formulation on Day 8 in 2-6 and 7-11 year old age group
11600403|NCT00645294|Other|Treatment Group B|ADV (0.3 mg/kg) oral suspension formulation on Day 1 followed by ADV (0.14 mg/kg) oral suspension formulation on Day 8 in 2-6 and 7-11 year old age group
11600404|NCT00645294|Other|Treatment Group C|ADV 10 mg single dose on Day 1 in 12-17 year old age group
11600405|NCT00645281|Experimental|tolterodine ER group|
11600406|NCT00645268|Active Comparator|Arm 1|
11600407|NCT00645268|Placebo Comparator|Arm 2|
11600409|NCT00645255|Other|1|Single-blind Placebo Run-in with behavioral intervention called Health Management Resources Maintenance Program which provided weekly classes for 12 months with meal replacement
11600410|NCT00645255|Placebo Comparator|2|Double-blind Treatment with behavioral intervention called Health Management Resources Maintenance Program which provided weekly classes for 12 months with meal replacement
11600411|NCT00645242|Experimental|Arm A|
11600412|NCT00645229|Experimental|Arm A|
11600413|NCT00645216|Experimental|CP-945,598 with Grapefruit Juice|CP-945,598 with Grapefruit Juice
11600414|NCT00645216|Experimental|CP-945,598 alone|CP-945,598 alone
11600415|NCT00645203|Other|1|
11600416|NCT00645177|Active Comparator|A|"In study, this arm is a randomized (blinded) to ABT-869 arm plus paclitaxel.
~Note: Prior to randomization, approximately 6-12 subjects will be enrolled in open-label lead-in to assess the tolerability of the combination. The initial open-label, lead-in cohort of six subjects will be monitored for 2 cycles (8 weeks) to assess the PK interactions and the safety of the combination of 0.20 mg/kg QD ABT-869 and paclitaxel (90 mg/m2). Enrollment into the randomized portion will begin after a cohort has completed two cycles (8 weeks) of therapy and no toxicities prohibit the cohort from continuing on to Cycle 3.
~Alternative doses may be explored based on the tolerability of the combination"
11600417|NCT00645177|Placebo Comparator|B|"In study, this arm is a randomized (blinded) to placebo for ABT-869 plus paclitaxel arm.
~Note: Prior to randomization, approximately 6-12 subjects will be enrolled in open-label lead-in to assess the tolerability of the combination. The initial open-label, lead-in cohort of six subjects will be monitored for 2 cycles (8 weeks) to assess the PK interactions and the safety of the combination of 0.20 mg/kg QD ABT-869 and paclitaxel (90 mg/m2). Enrollment into the randomized portion will begin after a cohort has completed two cycles (8 weeks) of therapy and no toxicities prohibit the cohort from continuing on to Cycle 3.
~Alternative doses may be explored based on the tolerability of the combination"
11600418|NCT00645164|Experimental|Xenaderm|Subject serves as own control
11600419|NCT00645151|Experimental|High Risk|
11600420|NCT00645151|Experimental|Low Risk|
11600421|NCT00645151|Experimental|Medium Risk|
11600422|NCT00645138|Active Comparator|Paravertebral Block|Patients receiving Paravertebral Block.
11600423|NCT00645138|Active Comparator|General Anesthesia|Patients receiving General Anesthesia.
11600424|NCT00645125|Active Comparator|1|
11600425|NCT00645125|Active Comparator|2|
11600426|NCT00645112|Active Comparator|1|
11600427|NCT00645112|Active Comparator|2|
11600428|NCT00645099|Experimental|001|paliperidone ER 6-mg or 9-mg tablet once daily flexible dosing for 6 months
11600429|NCT00645099|Active Comparator|002|olanzapine 10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
11600430|NCT00645086|Active Comparator|A|
11600431|NCT00645086|Active Comparator|B|
11600432|NCT00645073|Active Comparator|A|
11600433|NCT00645073|Active Comparator|B|
11600434|NCT00645060|Experimental|Y-90-DOTA-M5A anti-CEA antibody|
11600435|NCT00645047|Experimental|Telemedicine CBT|Cognitive behaviour therapy (CBT) delivered using videoconference telemedicine.
11600436|NCT00645047|Active Comparator|In-Person CBT|Cognitive behaviour therapy (CBT) delivered using in-person consultation.
11600437|NCT00645034|Active Comparator|Arm 1|
11600438|NCT00645034|Placebo Comparator|Arm 2|
11600439|NCT00645021|Experimental|Mild hepatic function|
11600440|NCT00645021|Experimental|Moderate hepatic function|
11600441|NCT00645021|Experimental|Normal hepatic function|
11600442|NCT00644995|Active Comparator|Usual Care Control|Participants will receive usual care which includes advice to stop smoking and referral to standard care treatment available through participants' health insurance and health plan.
11600443|NCT00644995|Experimental|Step Up Intervention|Participants will receive the Step Up Wellness Program. The intervention is detailed below.
11600444|NCT00644982|Experimental|Sertaline group|
11600445|NCT00644982|Active Comparator|Venlafaxine group|
11600446|NCT00644969|Placebo Comparator|Placebo Arm|Randomization 2:1 treatment to placebo
11600447|NCT00644969|Active Comparator|Treatment Arm|
11600448|NCT00644956|Active Comparator|Arm 1|
11600449|NCT00644956|Active Comparator|Arm 2|
11600450|NCT00644943|Active Comparator|1|
11600451|NCT00644943|Active Comparator|2|
11600452|NCT00644930|Experimental|1|ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated.
11600453|NCT00644930|Active Comparator|2|Patients in the standard therapy group without indications for urgent intubation were only given standard medical therapy (such as oxygen, antibiotics, and bronchodilators), and IMV through an endotracheal tube was applied when intubation criteria were met.
11600454|NCT00644917|Experimental|A|Drug
11600455|NCT00644917|Placebo Comparator|B|Placebo comparator
11600456|NCT00644917|No Intervention|C|Subjects serve as own controls.
11600457|NCT00644904|Experimental|Treatment|Starting dose of 4,000 IU per day of Vitamin D3 titrating up to a dose of 40,000 IU per day of Vitamin D3 by month six. In the second six-month part of the trial, patients titrate back down to 4,000 IU per day of Vitamin D3 and then discontinue it completely at the end of the 12 month trial period.
11600458|NCT00644904|Other|Control|Patients are allowed to supplement with up to 4,000 IU per day of Vitamin D3 if desired.
11600459|NCT00644891|Active Comparator|1|
11600460|NCT00644891|Active Comparator|2|
11600461|NCT00644878|Experimental|Nilotinib|
11600462|NCT00644852||001|
11600463|NCT00644839|Experimental|CP-945,598|
11600464|NCT00644826|Experimental|1|
11600465|NCT00644826|No Intervention|2|
11600466|NCT00644813||Scapular with glenoid neck fractures|Collect outcome and radiological data on patients with scapular fractures involving the glenoid neck (bone joining the shoulder joint and the scapular body) for a period of 1 year.
11600467|NCT00644800|Experimental|Arm A|
11600531|NCT00644280|Active Comparator|Ranibizumab|Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at 3 time points: 9 days before Ahmed tube insertion for open-angle glaucoma, 1 month post-surgery, and 2 months post-surgery
11600468|NCT00644787|Experimental|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14. Participants who met the predefined criteria at the end of Titration Phase enter the Double Blind Phase.
11600469|NCT00644787|Experimental|Fentanyl 1-day transdermal patch (Double Blind Phase)|Participants who meet the predefined criteria at the end of Titration Phase and enter the Double Blind Phase receive fentanyl 1-day application transdermal patch and placebo matched to fentanyl 3-day application (JNS005) transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
11600470|NCT00644787|Active Comparator|Fentanyl 3-day transdermal patch (Double Blind Phase)|Participants who meet the predefined criteria at the end of Titration Phase and enter the Double Blind Phase receive fentanyl 3-day application transdermal patch and placebo matched to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
11600471|NCT00644774|Active Comparator|1|
11600472|NCT00644774|Active Comparator|2|
11600473|NCT00644761|Other|Treatment Arm 1|Adefovir dipivoxil 10 mg once daily with tacrolimus or cyclosporine for 14 days
11600474|NCT00644748|Experimental|Gabapentin group|
11600475|NCT00644735|Experimental|1|Nexium
11600476|NCT00644735|Active Comparator|2|Prevacid
11600477|NCT00644722|Active Comparator|1|Single use metallic blades
11600478|NCT00644722|Active Comparator|2|Classic reusable metallic blades
11600479|NCT00644709|Experimental|Arm A|
11600480|NCT00644696|Experimental|Irinotecan and Bortezomib|Irinotecan and Bortezomib will both be administered
11600481|NCT00644670|Experimental|Previous Treatment with a Usual Maintenance Dose of a Statin|
11600482|NCT00644670|Experimental|Statin-Naive|
11600483|NCT00644644||1|monitored
11600484|NCT00644644||2|control
11600485|NCT00644631|Active Comparator|Arm 1|
11600486|NCT00644631|Placebo Comparator|Arm 2|
11600487|NCT00644618|Active Comparator|A|
11600488|NCT00644618|Experimental|B|
11600489|NCT00644605|Active Comparator|Arm 1|
11600490|NCT00644605|Active Comparator|Arm 2|
11600491|NCT00644605|Active Comparator|Arm 3|
11600492|NCT00644605|Placebo Comparator|Arm 4|
11600493|NCT00644592|Active Comparator|1-Fenofibrate then Placebo|4 weeks of drug at 160 mg orally per day, 4 week washout, then 4 weeks of placebo
11600494|NCT00644592|Active Comparator|2 Placebo then Fenofibrate|4 weeks of placebo then 4 week washout then 4 weeks of Fenofibrate at 160 mg/day orally.
11600495|NCT00644579|Active Comparator|1|bLAC high dose
11600496|NCT00644579|Active Comparator|2|bLAC low dose
11600497|NCT00644579|Placebo Comparator|3|
11600498|NCT00644566|No Intervention|TAU|Treatment as usual. These subjects and their providers were told to pursue treatment services as they normally would do.
11600499|NCT00644566|Experimental|shared care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
11600500|NCT00644553|Active Comparator|A|
11600501|NCT00644553|Active Comparator|B|
11600502|NCT00644540|Experimental|1|
11600503|NCT00644540|Active Comparator|2|
11600504|NCT00644527|Experimental|1|Listening to one of two different specific music programs (Group A), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
11600505|NCT00644527|Experimental|2|Listening to one of two different specific music programs (Group B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
11600506|NCT00644527|Sham Comparator|3|Control I (Group C) : Listening 30 min in the morning and 30 min in the evening to unspecific music (Mozart) over 5 weeks.
11600507|NCT00644527|No Intervention|4|Control II (Group D): Waiting list. - Each 50% of the subjects will be assigned randomly to either Group A (arm 1) and B (arm 2) after 5 weeks of waiting time.
11600508|NCT00644514|Experimental|LPS endotoxin inh f/u bronchoscopy|Participants receive inhalation of LPS endotoxin, followed by bronchoscopy in this study.
11600509|NCT00644501|Experimental|1|
11600510|NCT00644488|Experimental|A1|Active
11600511|NCT00644475|Experimental|2|Imidapril
11600512|NCT00644475|Active Comparator|1|Candesartan
11600513|NCT00644462||1|Asthmatic subjects
11600514|NCT00644462||2|Healthy subjects
11600515|NCT00644449|Experimental|1|
11600516|NCT00644449|Experimental|2|
11600517|NCT00644436|Experimental|1|Single topical application
11600518|NCT00644436|Active Comparator|2|Single topical application
11600519|NCT00644423|Active Comparator|1|Omega-3 Fatty Acid
11600520|NCT00644423|Placebo Comparator|2|Placebo
11600521|NCT00644410|Active Comparator|1|The number of mesenchymal stromal cells reached after two culture expansion passages.
11600522|NCT00644410|Placebo Comparator|2|Saline
11600523|NCT00644397||Blade Plate Group|95-degree Angled Blade Plate
11600524|NCT00644397||Locking Plate Group|4.5mm Condylar Locking Plate
11600525|NCT00644371|Experimental|1|
11600526|NCT00644358|Experimental|Vilazodone|Vilazodone titrated up to 40 mg/day for 1 year.
11600527|NCT00644306|Placebo Comparator|A|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
11600528|NCT00644306|Active Comparator|B|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
11600529|NCT00644293|Experimental|1|
11600530|NCT00644293|Experimental|2|
11600532|NCT00644280|No Intervention|Usual care|Standard of care Ahmed tube insertion for open-angle glaucoma without injections of Ranibizumab
11600533|NCT00644267|Active Comparator|1|Subjects will use a telemedicine system for blood pressure control
11600534|NCT00644267|No Intervention|2|Patients with hypertension receiving usual care by a primary care physician
11600535|NCT00644254||Resected DPAC|145 consecutive resections for primary ductal pancreatic adenocarcinoma (DPAC)performed between 1998 and 2005.
11600536|NCT00644241|Experimental|stem cell|
11600537|NCT00644228|Active Comparator|Arm I (dexamethasone and lenalidomide)|Patients receive dexamethasone PO QD on days 1, 8, 15, and 22 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11600538|NCT00644228|Experimental|Arm II (dexamethasone, lenalidomide, bortezomib)|Patients receive dexamethasone PO QD on days 1, 2, 4, 5, 8, 9, 11, and 12; lenalidomide PO QD on days 1-14; and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
11600539|NCT00644215|Experimental|1|5-FU injection has been done
11600540|NCT00644215|Experimental|2|Mitomycin drop has been administrated
11600541|NCT00644202|Experimental|Group 1|Intervention Group
11600542|NCT00644202|No Intervention|Group 2|Usual Care Group
11600543|NCT00644189|Other|Clofarabine|Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
11600544|NCT00644176|Experimental|1|
11600545|NCT00644176|Experimental|2|
11600546|NCT00644163|Experimental|1|Participants will receive Eban HIV/STD Risk Reduction Intervention.
11600547|NCT00644163|Active Comparator|2|Participants will receive Eban Health Promotion Intervention.
11600548|NCT00644150|Experimental|1|Physicians of county level will receive Ai Shi Zi training provided by experts in the fields of HIV/STIs, behavioral counseling, and stigma reduction.
11600549|NCT00644150|Experimental|2|Physicians of township level will receive Ai Shi Zhi training provided by the county level physicians.
11600550|NCT00644150|Experimental|3|HIV/STI patients will receive standard of care and specialized care from physician participants trained in Ai Shi Zi.
11600551|NCT00644150|No Intervention|4|Physicians of county level who will not participate in Ai Shi Zi training
11600552|NCT00644150|No Intervention|5|Physicians of township level who will not participate in Ai Shi Zi training
11600553|NCT00644150|Sham Comparator|6|HIV/STI patients who will receive standard care only
11600554|NCT00644137|Experimental|A|pregabalin 300mg/day given in conjunction with smoking cigarettes.
11600555|NCT00644137|Experimental|2|cigarettes given in conjunction with pregabalin
11600556|NCT00644124|Experimental|Aflibercept RCHOP 14|Aflibercept (25 mg/ml by IV over an hour) in combination with fixed dose of rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) administered every 2 weeks. A dose of 2.0 mg/kg administered as Dose Level 1, 4.0 mg/kg as Dose Level 2, and 6.0 mg/kg dose as Dose level 3.
11600557|NCT00644124|Experimental|Aflibercept RCHOP 21|Aflibercept (25 mg/ml by IV over an hour) in combination with fixed dose of rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) administered every 3 weeks. A dose of 3.0 mg/kg administered as Dose Level 1, 6.0 mg/kg as Dose Level 2, and 8.0 mg/kg dose as Dose level 3.
11600558|NCT00644111|Placebo Comparator|1|Control group receiving saline placebo through an epidural catheter
11600559|NCT00644111|Active Comparator|2|Experimental group receiving active medication through the epidural catheter
11600560|NCT00644098|Placebo Comparator|Placebo|cellulose and soybean oil
11600561|NCT00644098|Experimental|Intervention|soluble fibre complex and medium chain triglycerides
11600562|NCT00644085|Experimental|1|oral administration of aspirin 100 mg
11600563|NCT00644085|Placebo Comparator|2|oral administration of placebo
11600564|NCT00644059|Experimental|TIV-adj|Adjuvanted trivalent inactivated subunit influenza vaccine
11600565|NCT00644059|Active Comparator|Flu-control|Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine
11600566|NCT00644059|Sham Comparator|Non-flu Control|Novartis meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
11600567|NCT00644046|No Intervention|1|Chronic kidney disease patient with standardized nephrology care
11600568|NCT00644046|Active Comparator|2|chronic kidney disease patient with multidisciplinary predialysis care
11600569|NCT00644033|Active Comparator|1|
11600570|NCT00644033|Active Comparator|2|
11600571|NCT00644033|Placebo Comparator|3|
11600572|NCT00644020||Group 1|the Tyroserleutide for injection at the dosage of 3mg/d
11600573|NCT00644020||Group 2|the Tyroserleutide for injection at the dosage of 6mg/d
11600574|NCT00644020||Group 3|the Tyroserleutide for injection at the dosage of 12mg/d
11600575|NCT00644020||Group 4|the placebo group
11600576|NCT00644007|Placebo Comparator|Group 1|
11600577|NCT00644007|Experimental|Group 2|
11600578|NCT00643994|Experimental|CyberKnife Stereotactic Radiosurgery|
11600579|NCT00643968|Active Comparator|1|TDF+EFV
11600580|NCT00643968|Experimental|2|TDF+3TC+EFV
11600581|NCT00643955||DS|Individual with Down Syndrome
11600582|NCT00643942||1|
11600583|NCT00643929||Observational|Subjects who have participated in a prior eltrombopag study, receiving either placebo or eltrombopag
11600584|NCT00643916|Experimental|Vaccinated at Age 9 and 12 Months|Participants received Menactra® vaccine at 9 and 12 Months of age
11600585|NCT00643916|Experimental|Vaccinated at Age 9 and 15 Months|Participants received Menactra® vaccine at 9 and 15 Months of age
11600586|NCT00643916|Experimental|Vaccinated at Age 12 and 15 Months|Participants received Menactra® vaccine at Age 12 and 12 Months of age
11600587|NCT00643916|Experimental|Vaccinated at Age 15 Months|Participants received Menactra® vaccine at 15 Months of age
11600588|NCT00643916|Experimental|Vaccinated at Age 18 Months|Participants received Menactra® vaccine at 18 Months of age
11600589|NCT00643916|Active Comparator|Vaccinated at Age 3 Years to <6 Years|Participants received Menomune® vaccine at Age 3 years to <6 years of age
11600767|NCT00642837||006|
11600768|NCT00642837||007|
11600590|NCT00643903|Experimental|1|Participants will receive five individual sessions of coping effectiveness training.
11600591|NCT00643903|Active Comparator|2|Participants will receive standard care and one delayed group workshop of coping effectiveness training.
11600592|NCT00643877|Experimental|B|PHRAC was performed 7 days before surgery. Adjuvant chemotherapy using FOLFOX7 was done for 8 cycle with 28 days after surgery.
11600593|NCT00643877|No Intervention|A|Adjuvant chemotherapy using FOLFOX7 was done for 8 cycle with 28 days after surgery.
11600594|NCT00643864|Other|Mirror training|"Training will be performed one-on-one by an investigator in a quiet room, one hour a day, five days a week, for four weeks. The mirror-box apparatus consists of an 18 x 24 vertical mirror secured in the center of a wooden platform. During training, the mirror-box will be placed on a table in front of the subject so that the mirror is perpendicular to the chest, slightly lateral of midline. Subjects will be asked to attend to the mirror reflection of their unaffected hand performing a series of tasks, while keeping their affected limb still. At the end of the four week training period, posttests will be administered by the same therapist who performed the pretests."
11600595|NCT00643851|Experimental|Arm 1|Dapagliflozin (5 mg) + Metformin XR (up to 2000 mg)
11600596|NCT00643851|Experimental|Arm 2|Dapagliflozin (5 mg)
11600597|NCT00643851|Active Comparator|Arm 3|Metformin XR (500 mg up to 2000 mg)
11600598|NCT00643838|Experimental|A|Misture of 50% nitrous oxide and 50% oxygen
11600599|NCT00643825|Active Comparator|A: prolonged adj TMZ|
11600600|NCT00643825|Other|B : Stop and Go|Rechallenging patients with TMZ at relapse
11600601|NCT00643812|Experimental|1|"The Early intervention arm received a gun locker at baseline"
11600602|NCT00643812|Active Comparator|2|Households in this arm received a gun locker at 12 months following the baseline survey
11600603|NCT00643799|Experimental|A|
11600604|NCT00643799|Active Comparator|B|
11600605|NCT00643799|Placebo Comparator|C|
11600606|NCT00643786|Experimental|A|Oxygène
11600607|NCT00643786|Placebo Comparator|B|Air Médical
11600608|NCT00643773|Experimental|A|Leucine supplement
11600609|NCT00643773|Placebo Comparator|B|Wheat flour
11600610|NCT00643760|Placebo Comparator|Placebo|Placebo
11600611|NCT00643760|Other|Pregabalin|Pregabalin 300mg/day (positive control), maintenance treatment 14 weeks
11600612|NCT00643760|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks
11600613|NCT00643760|Experimental|GEn 2400mg/day|gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks
11600614|NCT00643760|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, maintanance treatment 14 weeks
11600615|NCT00643747|Experimental|A|Injection of vector
11600616|NCT00643734|Experimental|1|
11600617|NCT00643734|Experimental|2|
11600618|NCT00643721||D,FR|Young healthy athletes
11600619|NCT00643708||A|14 cases
11600620|NCT00643708||B|14 cases
11600621|NCT00643708||C|14 cases
11600622|NCT00643708||D|14 Cases
11600623|NCT00643695|Experimental|1|Home-based walking program
11600624|NCT00643695|Other|2|educational intervention
11600625|NCT00643682|Experimental|A|Patients in this arm will be given an educational card in addition to the standard pre-endoscopy instructions.
11600626|NCT00643682|No Intervention|B|Patients in this arm will be given the standard pre-endoscopy instructions.
11600627|NCT00643669|Experimental|AL-3789|AL-3789 Sterile Suspension, single depot administration of 0.8 mL in the study eye
11600628|NCT00643669|No Intervention|No treatment|Fellow eye, as randomized
11600629|NCT00643656|Experimental|A|Mixture of 50% nitrous oxide and 50% oxygen
11600630|NCT00643656|Placebo Comparator|B|Mixture of 50% oxygen and 50% nitrogen
11600631|NCT00643643|Experimental|A|
11600632|NCT00643643|Experimental|B|
11600633|NCT00643643|Experimental|C|
11600634|NCT00643643|Experimental|D|
11600635|NCT00643643|Placebo Comparator|E|
11600636|NCT00643630|Experimental|1|Twice daily topical application
11600637|NCT00643630|Placebo Comparator|2|Twice daily topical application
11600638|NCT00643617|Other|Heterogeneous dose|38 Gy delivered in 4 fractions of 9.5 Gy per fraction with CyberKnife Stereotactic Radiosurgery
11600639|NCT00643604|Experimental|treprostinil sodium|all subjects had switched from IV epoprostenol to IV treprostinil sodium
11600640|NCT00643591||Observational|Patients with a primary glioblastoma
11600641|NCT00643578|Active Comparator|2|a single dose of 24 mcg of formoterol
11600642|NCT00643578|Active Comparator|1|a single dose of 12 mcg of formoterol
11600643|NCT00643565|Experimental|Bevacizumab + Chemotherapy|Participants received continuous IV infusion of bevacizumab (7.5 mg/kg every 3 weeks) on Day 1 of 3-week cycles followed by induction chemotherapy (4 cycles of IVADo-containing chemotherapy followed by 5 cycles of IVA-containing chemotherapy) as per institutional practice for a total of 9 cycles during induction treatment phase. As per the investigator decision, local therapy (radiotherapy and /or surgery) was expected to start after 4 weeks of the last bevacizumab administration in the induction phase and resumed to bevacizumab in the maintenance phase at least 4 weeks after the last dose of local therapy. During maintenance treatment phase, participants received IV infusion of bevacizumab (5 mg/kg every 2 weeks) followed by vinorelbine- and cyclophosphamide-containing chemotherapy (as per institutional practice) on Days 1 and 15 of 4-week cycles for a total of 12 cycles.
11600644|NCT00643565|Active Comparator|Chemotherapy|Participants received 9 cycles of induction chemotherapy (4 cycles of IVADo-containing chemotherapy followed by 5 cycles of IVA-containing chemotherapy administered every 3 weeks as per institutional practice. As per the investigator evaluation, participants had option to undergo local therapy (radiotherapy and /or surgery) during last 3 cycles of IVA (i.e. from Cycle 6 to Cycle 9). During maintenance treatment phase, participants received vinorelbine- and cyclophosphamide-containing chemotherapy (as per institutional practice) on Day 1 and 15 of 4-week cycles for a total of 12 cycles.
11600645|NCT00643539|Experimental|1|
11600646|NCT00643539|Experimental|2|
11600647|NCT00643526|Experimental|Injection Site: First Thigh Then Abdomen|Participants will self inject subcutaneously placebo using auto injector at thigh followed by self injection of placebo subcutaneously at abdomen on Day 1.
11600648|NCT00643526|Experimental|Injection Site: First Abdomen then Thigh|Participants will self inject subcutaneously placebo using auto injector at abdomen followed by self injection of placebo subcutaneously at thigh on Day 1.
11600649|NCT00643487||1|observation of the behavior of the infrapatellar plica
11600650|NCT00643474|Experimental|A|
11600651|NCT00643474|Experimental|B|
11600652|NCT00643461||Adhesive A|
11600653|NCT00643461||Adhesive B|
11600654|NCT00643461||Adhesive C|
11600655|NCT00643448|Experimental|AZD1305 loading dose 250 mg + 125 mg|Tablets
11600656|NCT00643448|Experimental|AZD1305 loading dose 500 mg + placebo|Tablets
11600657|NCT00643448|Placebo Comparator|Placebo corresponding to AZD1305 loading dose|Tablets
11600658|NCT00643435|Experimental|1|These residents receive training provided by standardized patient instructors, in use of self-efficacy enhancing interviewing techniques to support patient health behavior change,
11600659|NCT00643435|Active Comparator|2|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
11600660|NCT00643422||Observation|
11600661|NCT00643409|Experimental|1|
11600662|NCT00643409|Experimental|2|
11600663|NCT00643383|Active Comparator|1|
11600664|NCT00643383|Placebo Comparator|2|
11600665|NCT00643370||1|single arm study
11600666|NCT00643357|Experimental|A|50% Oxygen/50% Nitrous oxide premix (Kalinox® 170 bar)
11600667|NCT00643357|Placebo Comparator|B|50%Oxygen/50% Nitrogen premix
11600668|NCT00643344|Experimental|CALMM+|Participants receiving CALMM intervention, ie program that combines stress reduction, mindful eating practices with diet and exercise
11600669|NCT00643344|Active Comparator|TLC|Participants receiving diet and exercise classes only
11600670|NCT00643331|Experimental|1|Exercise performed at the gym and at home
11600671|NCT00643331|No Intervention|2|Usual care no additional exercise
11600672|NCT00643318|Experimental|CyberKnife Stereotactic Radiosurgery|
11600673|NCT00643305|Experimental|1|Skills Building with Motivational Interviewing (SB-MI)- combines education and general skills-building participants can use to reduce their at-risk behavior for HIV with increasing motivation to change HIV risk behaviors
11600674|NCT00643305|Active Comparator|2|Skills Building (SB) - provides education and general skills-building for reduction of HIV risk behaviors.
11600675|NCT00643292|Experimental|1|
11600676|NCT00643292|Experimental|2|
11600677|NCT00643279|Experimental|CHRONICLE|Subjects randomized to the CHRONICLE group were managed using data from an implantable hemodynamic monitoring (IHM) device, including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The Chronicle IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.
11600678|NCT00643279|Placebo Comparator|CONTROL|Subjects randomized to the CONTROL group implanted with the Chronicle implantable hemodynamic monitoring (IHM) device, but the intracardiac diagnostic information was blinded to both the patient and the physician during the randomized period of the study. Subjects were managed conventionally with standard of care. Physicians and patients have access to the intracardiac data after the randomized period of the study is over, at 6 months.
11600679|NCT00643266|Experimental|1|Recollection training via graduated increases in task difficulty, carried out over 36 sessions over 9 training days
11600680|NCT00643266|Active Comparator|2|Computer-delivered information sessions about memory and aging with Jeopardy-like games to engage participants
11600681|NCT00643253|Experimental|1|Receipt of behavioral interventions to encourage breastfeeding.
11600682|NCT00643253|No Intervention|2|Standard of Care
11600683|NCT00643240|Experimental|111 In-BU-12|111In-BU-12 is the 111Indium-labeled murine monoclonal antibody used for imaging and dosimetry.
11600684|NCT00643227|Experimental|1|
11600685|NCT00643227|Experimental|2|
11600686|NCT00643214|Experimental|1|Twice daily topical application
11600687|NCT00643214|Placebo Comparator|2|Twice daily topical application
11600688|NCT00643201|Active Comparator|Apixaban|apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.
11600689|NCT00643201|Experimental|Enoxaparin + Warfarin|Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until international normalized ratio (INR) ≥2.
11600690|NCT00643188|Experimental|1|"Radiofrequency ablation of atrial fibrillation:
~Subjects assigned to the catheter AF ablation strategy will undergo ablation within 48 hours after baseline evaluation. The aim of the procedure is to achieve isolation of all Pulmonary Veins (PVs) and to restore sinus rhythm. Only radiofrequency catheter based AF ablation is permitted; other methods, like cryoablation, ultrasound and laser, are not permitted in this study.
~Before ablation, a transesophageal echocardiogram must be performed in order to rule out presence of atrial thrombi.
~Anticoagulation should be initiated, or continued, for at least six months post ablation. Six months after successful ablation and in absence of any recurrence of AF, antiarrhythmic drugs should be discontinued."
11600691|NCT00643188|Active Comparator|2|"Conventional treatment:
~Subjects assigned to the conventional treatment strategy will be treated according to current guidelines for the management of patients with chronic heart failure and/or atrial fibrillation. Efforts to maintain sinus rhythm in this study arm are recommended.
~Anticoagulation will be initiated, if not already started, and maintained throughout the study according to current guidelines."
11600692|NCT00643175||1|Osteoporosis in patients with fragility hip fractures.
11600693|NCT00643162|Experimental|Swedish Massage|Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.
11600694|NCT00643162|Sham Comparator|Light-Touch|Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.
11600695|NCT00643149|Experimental|1|
11600696|NCT00643149|Experimental|2|
11600697|NCT00643136|Experimental|Pregabalin|
11600698|NCT00643136|Placebo Comparator|Placebo|
11600769|NCT00642837||008|
11600770|NCT00642837||009|
11600771|NCT00642824|Experimental|1|
11600772|NCT00642811|Experimental|1|Aspirin + Ticagrelor
11600699|NCT00643123|Experimental|Allopurinol|Subjects will be randomized to allopurinol at a fixed dose of 300 mg/day for the first week and then 600mg/day while continuing their current medications during the 7-week study. A battery of assessments will be administered at baseline and weeks 1, 2, 4, 6 after baseline. At each assessment, subjects will also be asked about side effects including potential side effects of allopurinol. Side effects will be assessed by the Treatment Emergent Side Effects Scale. Serum levels of lithium, valproic acid, carbamazepine, atypical antipsychotics or atypical antipsychotic metabolite, uric acid blood levels will be drawn at screen and at week 6 after baseline. Subjects taking only lithium, valproic acid, and/or carbamazepine will also have their serum levels drawn at week 2.
11600700|NCT00643123|Placebo Comparator|Placebo|Subjects will be randomized to placebo and will follow the same protocol as the allopurinol group.
11600701|NCT00643097|Experimental|Arm I (ACTIVATE)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)-specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, every 2 weeks starting 4 weeks after the completion of radiation. Subsequent vaccinations were given once a month until clinical or radiographic evidence of progression or death.
11600702|NCT00643097|Experimental|Arm II (ACT II STD)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)- specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, biweekly starting within 6 weeks of completing radiation. Additional vaccinations were given until clinical or radiographic evidence of progression or death. Patients subsequently receive temozolomide at a targeted dose of 200 mg/m2 for the first 5 days of a 28 day cycle.
11600703|NCT00643097|Experimental|Arm III (ACT II DI)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)- specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, biweekly starting within 6 weeks of completing radiation. Additional vaccinations were given until clinical or radiographic evidence of progression or death. Patients subsequently receive temozolomide at a targeted dose of 100 mg/m2 for the first 21 days of a 28 day cycle.
11600704|NCT00643084|Experimental|1|patients will consume a low residue diet prior to surgery and have no routine bowel preparation
11600705|NCT00643084|Other|2|standard bowel preparation
11600706|NCT00643071|Experimental|1|
11600707|NCT00643058|Experimental|1|Sterile Saline, LPS endotoxin
11600708|NCT00643045|Experimental|1|Low dose (50-100mg/day)
11600709|NCT00643045|Experimental|2|High dose (150-200 mg/day)
11600710|NCT00643045|Placebo Comparator|3|
11600711|NCT00643032|Active Comparator|I|
11600712|NCT00643032|Active Comparator|II|
11600713|NCT00643019|Experimental|SAFE Intervention|Behavioral Intervention
11600714|NCT00643019|Other|Control|Sexually Transmitted Infection Risk Reduction Counseling
11600715|NCT00643006|Experimental|A. High intensive exercise|High intensive exercise
11600716|NCT00643006|Active Comparator|B. Low-intensive exercise|Low-to-moderate intensive supervised walks
11600717|NCT00642993|Experimental|SCH 497079|SCH 497079, administered orally, once daily
11600718|NCT00642993|Placebo Comparator|Placebo|Placebo capsules, administered orally, once daily
11600719|NCT00642980|Active Comparator|Clindamycin Cure 1|Arm 1
11600720|NCT00642980|Active Comparator|Clindamycin Cure 2|Arm 2
11600721|NCT00642980|Placebo Comparator|Placebo|Arm placebo
11600722|NCT00642967|Experimental|1|
11600723|NCT00642954|Experimental|Level 1: Vorinostat 300 mg + lenalidomide 10 mg|Participants will receive vorinostat 300 mg orally once-daily (QD) on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
11600724|NCT00642954|Experimental|Level 2: Vorinostat 400 mg + lenalidomide 10 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
11600725|NCT00642954|Experimental|Level 3: Vorinostat 400 mg + lenalidomide 15 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 15 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
11600726|NCT00642954|Experimental|Level 4: Vorinostat 400 mg + lenalidomide 20 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 20 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
11600727|NCT00642954|Experimental|Level 5: Vorinostat 400 mg + lenalidomide 25 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 25 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
11600728|NCT00642941|Experimental|Cohort 1: Ewing's Sarcoma Primary Cohort|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.
11600773|NCT00642811|Active Comparator|2|Aspirin + Clopidogrel
11600774|NCT00642785||1|Patients with active oral or genital HSV skin lesions
11600775|NCT00642785||2|Patients with a history of recurrent oral or genital HSV but without an active lesion at the time of treatment
11600776|NCT00642785||3|Patients with active shingles/zoster
11600729|NCT00642941|Experimental|Cohort 2: Ewing's Sarcoma Secondary Cohort|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.
11600730|NCT00642941|Experimental|Cohort 3: Ewing's Sarcoma Expanded Cohort|Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.
11600731|NCT00642941|Experimental|Cohort 4: Osteosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.
11600732|NCT00642941|Experimental|Cohort 5: Synovial Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.
11600733|NCT00642941|Experimental|Cohort 6: Rhabdomyosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.
11600734|NCT00642941|Experimental|Cohort 7a: Alveolar Soft Part Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a includes individuals with alveolar soft part sarcoma.
11600735|NCT00642941|Experimental|Cohort 7b: Desmoplastic Small Round Cell Tumors.|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.
11600736|NCT00642941|Experimental|Cohort 7c: Extraskeletal Myxoid Chondrosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.
11600737|NCT00642941|Experimental|Cohort 7d: Clear Cell Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.
11600738|NCT00642941|Experimental|Cohort 7e: Myxoid Liposarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.
11600739|NCT00642941|Experimental|Cohort 8: Diagnosis Not Specified|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.
11600740|NCT00642928|Placebo Comparator|Placebo|
11600741|NCT00642928|Experimental|BF 2.649-5 mg|
11600742|NCT00642928|Experimental|BF 2.649 10 mg|
11600743|NCT00642928|Experimental|BF 2.649 20 mg|
11600744|NCT00642928|Experimental|BF 2.649 40 mg|
11600745|NCT00642902|Experimental|Atacicept 25 mg|
11600746|NCT00642902|Experimental|Atacicept 75 mg|
11600747|NCT00642902|Experimental|Atacicept 150 mg|
11600748|NCT00642902|Placebo Comparator|Placebo|
11600749|NCT00642889|Experimental|High Dose|150-200mg/day
11600750|NCT00642889|Experimental|Low dose|50-100mg/day
11600751|NCT00642889|Placebo Comparator|Placebo|
11600752|NCT00642876|Active Comparator|Control|The Control cohort are patients that receive the fusion treatment.
11600753|NCT00642876|Experimental|Investigational|The Investigational cohort are the study patients that received the PRESTIGE® Cervical Disc.
11600754|NCT00642863|Experimental|Low birth iron|Infants with low birth iron who receive vitamins A and D + iron
11600755|NCT00642863|Experimental|Marginal birth iron 1|Infants with marginal birth iron randomized to receive vitamins A and D + iron
11600756|NCT00642863|Active Comparator|Marginal birth iron 2|Infants with marginal birth iron randomized to receive vitamins A and D without iron
11600757|NCT00642863|Active Comparator|Normal birth iron|Infants with normal birth iron who receive vitamins A and D without iron
11600758|NCT00642863|Experimental|Combined ID|Marginal-birth-iron vitamins only-treated infants who have IDA at 9 mo.
11600759|NCT00642863|Experimental|Early postnatal IDA|Infants with IDA at 9 months whose cord blood was collected at birth but who were not assessed and assigned to vitamins with or without iron at 6 weeks
11600760|NCT00642863|Experimental|Late postnatal IDA|Infants with IDA at 18 months whose cord blood was collected at birth but who were not assessed and assigned to vitamins with or without iron at 6 weeks. These infants were also not anemic when screened at 9 months.
11600761|NCT00642850|Experimental|1|
11600762|NCT00642837||001|
11600763|NCT00642837||002|
11600764|NCT00642837||003|
11600765|NCT00642837||004|
11600766|NCT00642837||005|
11600777|NCT00642785||4|Patients with post herpetic neuralgia
11600778|NCT00642772|Experimental|Group Physical Therapy|12-week group-based program of physical therapy. Participants will meet approximately every other week for a total of 6 visits. The group sessions will include education about appropriate self-care for knee osteoarthritis and instructions and participation in group exercises. Participants will also be instructed in a home exercise program.
11600779|NCT00642759|Experimental|Chemotherapy|Carboplatin, nab-paclitaxel, and bevacizumab
11600780|NCT00642746|Experimental|FOLFOX with Erlotinib|Subjects received FOLFOX (Leucovorin, Fluorouracil, and Oxaliplatin) and Erlotinib. Treatment consisted of a 28 day cycle. Subjects received FOLFOX on days 1, 2, and 3, and 15-16, followed by Erlotinib on days 3-8, and 17-22.
11600781|NCT00642746|Experimental|FOLFIRI with Erlotinib|Subjects received FOLFIRI (Leucovorin, Fluorouracil, and Irinotecan) and Erlotinib. Treatment consisted of a 28 day cycle. Subjects received FOLFIRI on days 1, 2, and 3, and 15-16, followed by Erlotinib on days 3-8, and 17-22.
11600782|NCT00642733|Experimental|1|
11600783|NCT00642720|Other|pegvisomant-placebo|patients in this arm received(as addition)for the first 8 weeks Pegvisomant and the later for 8 weeks Placebo. This was divided by a 4 weeks wash-out period.
11600784|NCT00642720|Other|placebo-pegvisomant|Patient received for the first 8 weeks Pegvisomant and after a wash out period of 4 weeks the received 8 of placebo treatment
11600785|NCT00642707|Active Comparator|Arm 1|PRO 140 for three single SC doses: Days 1, 8, and 15
11600786|NCT00642707|Active Comparator|Arm 2|PRO 140 for three single SC doses: Days 1, 8 and 15
11600787|NCT00642707|Active Comparator|Arm 3|PRO 140 for two single SC doses: Days 1 and 15 plus one SC dose of PBO at Day 8
11600788|NCT00642707|Placebo Comparator|Arm 4|PBO for three single SC doses: Days 1, 8 and 15
11600789|NCT00642694|Experimental|1|Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Ramelteon (One 8 mg capsule at night)
11600790|NCT00642694|Placebo Comparator|2|Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Matching Placebo (One capsule at night)
11600791|NCT00642681||1: TI Inhalation Powder|Technosphere® Insulin (TI) Inhalation Powder
11600792|NCT00642668|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants received methoxy polyethylene glycol-epoetin beta treatment monthly for 36 weeks with an efficacy evaluation period (EEP) during weeks 29-36 and followed by a 4 week follow-up period.
11600793|NCT00642642|Experimental|Double blinded active|Subject will receive autologous fibroblast treatment on either their left or right side of their face
11600794|NCT00642642|Placebo Comparator|Double blinded placebo|Subject will receive placebo treatment on the opposite side of the face from active treatment
11600795|NCT00642629|Active Comparator|1|STA-5326 mesylate
11600796|NCT00642629|Placebo Comparator|2|Placebo
11600797|NCT00642616|Experimental|Technosphere® Insulin (Asthma)|Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Asthma
11600798|NCT00642616|Active Comparator|Usual Care (Asthma)|Usual anti diabetic care in Diabetic participants with Asthma
11600799|NCT00642616|Experimental|Technosphere® Insulin (COPD)|Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
11600800|NCT00642616|Active Comparator|Usual Care (COPD)|Usual anti diabetic care in Diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
11600801|NCT00642603|Experimental|XELOX + bevacizumab (Q2W)|
11600802|NCT00642603|Experimental|XELIRI + bevacizumab (Q2W)|
11600803|NCT00642590||1|Healthy couples who are planning their first pregnancy.
11600804|NCT00642577|Experimental|1|
11600805|NCT00642577|Active Comparator|2|
11600806|NCT00642564||001|
11600807|NCT00642551|Active Comparator|MK-7|1 capsule per day existing of 180 µg menaquinone-7
11600808|NCT00642551|Placebo Comparator|Placebo|1 placebo capsule per day for three years
11600809|NCT00642538|Experimental|1|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
11600810|NCT00642538|Experimental|2|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
11600811|NCT00642538|Experimental|3|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
11600812|NCT00642538|Placebo Comparator|4|TIP (placebo comparison)
11600813|NCT00642538|Active Comparator|5|10 ug subcutaneous control
11600814|NCT00642525|Experimental|A|A prospective, blinded, intraindividual controlled study is conducted with patients with transthoracic esophagectomy due to esophageal cancer. A radiographic contrast study is performed prior to endoscopy at the 5th to 7th postoperative day.
11600815|NCT00642512|Experimental|1|
11600816|NCT00642512|Active Comparator|2|
11600817|NCT00642512|Other|3|
11600818|NCT00642512|Placebo Comparator|4|
11600819|NCT00642499|Experimental|1|
11600820|NCT00642499|Placebo Comparator|2|
11600821|NCT00642486|Active Comparator|1|laboratory-based testing
11600822|NCT00642486|Active Comparator|2|home-based testing
11600823|NCT00642473|Experimental|Prevention (Erlotinib + Metronidazole Actavis)|Participants will receive erlotinib orally daily. Metronidazole actavis treatment will be initiated at the same day as the start of erlotinib. Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks. Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
11600824|NCT00642473|Experimental|Treatment (Erlotinib + Metronidazole Actavis)|Participants will receive erlotinib orally daily. Metronidazole actavis treatment will be initiated when participants develop rash. Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks. Left side of the face and chest was treated according to local standard procedures (ie, with non-active moisturizing cream).
11600825|NCT00642460|Experimental|1|
11600826|NCT00642460|Placebo Comparator|2|
11600827|NCT00642447|Experimental|1|
11600828|NCT00642434|Active Comparator|1|study drug
11600829|NCT00642434|Active Comparator|2|study drug
11600830|NCT00642421|Experimental|Population A|Based on the dose of their previous Sandostatin-LAR treatment, Population A will receive 10 or 20 mg of C2L-OCT-01 PR at 5-week intervals.
11600883|NCT00642109|Other|TVT-O|Transobturator Tape inside-out (TVT-O)
11600884|NCT00642096|Experimental|1|Metoprolol Succinate + Hydrochlorothiazide
11600831|NCT00642421|Experimental|Population B|Population B, naive patients and patients who have stopped their treatment with prolonged release octreotide for at least 12 weeks, will receive 20 mg C2L-OCT-01 PR at 5-week intervals.
11600832|NCT00642408|Experimental|MMN|multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
11600833|NCT00642408|Active Comparator|IFA|iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
11600834|NCT00642395|Experimental|1|bortézomib
11600835|NCT00642382|Active Comparator|Active|Agilus (Hyaluronic Acid)
11600836|NCT00642382|Placebo Comparator|Control|Normal Saline
11600837|NCT00642369|Experimental|quetiapine fumarate|quetiapine fumarate was administered 25mg on the 1st day,738±41mg/day on the 14th day, and 738±48mg/day on the 28th day.
11600838|NCT00642369|Active Comparator|haloperidol|haloperidol was administered 2mg on the 1st day,16±7mg/day on the 14th day, and 18±6mg/day on the 28th day.
11600839|NCT00642356|Experimental|Carbidopa/levodopa/entacapone|
11600840|NCT00642356|Active Comparator|Immediate release carbidopa/levodopa|
11600841|NCT00642343|Placebo Comparator|1|Children with severe to profound deafness that have not received any intervention.
11600842|NCT00642343|Active Comparator|2|Children with an unilateral cochlear implant.
11600843|NCT00642343|Active Comparator|3|Children with bilateral cochlear implants.
11600844|NCT00642343|Active Comparator|4|Children who receive their second implant during the duration of the study.
11600845|NCT00642330|Active Comparator|I|
11600846|NCT00642330|Active Comparator|O|
11600847|NCT00642317||Asian Youth and Tobacco Control|Smoking Questionnaire for self-identified Chinese or Vietnamese participants.
11600848|NCT00642304|Experimental|methoxy polyethylene glycol-epoetin beta|
11600849|NCT00642291|Experimental|1|Treatment naive pediatric patients (Group 1: ages 3 to 24 months)were to receive emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if <30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if >=7 to <15kg; 10/2.5 mg/kg BID if >=15 to <=40 kg)
11600850|NCT00642291|Experimental|2|Treatment naive or experienced pediatric patients (Group 2: ages 7 to 12 years; Group 3: ages 13-17 years) received emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
11600851|NCT00642278|Experimental|Canagliflozin 50 mg daily|Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
11600852|NCT00642278|Experimental|Canagliflozin 100 mg daily|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
11600853|NCT00642278|Experimental|Canagliflozin 200 mg daily|Each patient will receive 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
11600854|NCT00642278|Experimental|Canagliflozin 300 mg daily|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo capsule once daily (in the evening).
11600855|NCT00642278|Experimental|Canagliflozin 300 mg twice daily|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.
11600856|NCT00642278|Active Comparator|Sitagliptin 100 mg daily|Each patient will receive 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
11600857|NCT00642278|Placebo Comparator|Placebo|Each patient will receive matching placebo twice daily for 12 weeks.
11600858|NCT00642265|Experimental|1|operative treatment
11600859|NCT00642265|Active Comparator|2|conservative treatment
11600860|NCT00642252|Experimental|B|226 ppm fluoride + 30 ppm calcium 'prototype/new' mouthrinse
11600861|NCT00642252|Active Comparator|A|ADA-accepted over-the-counter 226 ppm fluoride mouthrinse (i.e. ACT, 226 ppm fluoride mouthrinse distributed by Chattem, Inc.)
11600862|NCT00642239|Placebo Comparator|2|Concurrent radiochemotherapy and placebo
11600863|NCT00642239|Experimental|1|concurrent radiochemotherapy and Sodium Glycididazole
11600864|NCT00642226|Active Comparator|1|Grid Laser
11600865|NCT00642226|Experimental|2|Vitrectomy in combination with 20 mg triamcinolone
11600866|NCT00642213||ischemic stroke sample with DNA|We prospectively collected 450(1999), 502(2005), and 512(2010) ischemic stroke patients who agreed to participate and also most provided a sample for DNA. The cohort data consists of a baseline interview, medical record abstraction and various timeframes of followup interviews from 3m to 3yrs. See website (www.gcnkss.com for data forms)
11600867|NCT00642213||stroke data from medical record review|The second part of the study is a retrospective medical record review of all potential ischemic strokes, TIAs, and Hemorrhagic strokes in our 5 county region that occurred in all study years.
11600868|NCT00642200|Active Comparator|1|Patients receive Lichtenstein hernioplasty as a treatment for recurrent inguinal hernia.
11600869|NCT00642200|Active Comparator|2|Patients receive laparoscopic TEP as a treatment for recurrent inguinal hernia.
11600870|NCT00642187|Experimental|1|Pulmicort
11600871|NCT00642187|Placebo Comparator|2|Placebo
11600872|NCT00642174|Experimental|Prasugrel|Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.
11600873|NCT00642174|Active Comparator|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.
11600874|NCT00642148|Active Comparator|Seretide|
11600875|NCT00642148|Placebo Comparator|Placebo|Placebo tablet
11600876|NCT00642148|Experimental|GW856553|
11600877|NCT00642135|Active Comparator|1|Premature newborns and neonates treated using Phenylephrine and tropicamide eyedrops
11600878|NCT00642135|Active Comparator|2|Premature newborns and neonates treated using insert Mydriasert®
11600879|NCT00642122|Experimental|1|Pulmicort RESPULES
11600880|NCT00642122|Experimental|2|Pulmicort TURBUHALER
11600881|NCT00642109|Other|TVT|Tension-free Vaginal Tape (TVT)
11600882|NCT00642109|Other|TOT|Transobturator Tape outside-in (TOT Monarc)
11600885|NCT00642096|Active Comparator|2|Metoprolol Succinate
11600886|NCT00642096|Active Comparator|3|Hydrochlorothiazide
11600887|NCT00642083|Experimental|1|viabahn stent-graft
11600888|NCT00642070||Host|Women with current symptoms of a urinary tract infection
11600889|NCT00642044|Experimental|A|The eye with the worst visual acuity receives the treatment. (the other eye serve as control).
11600890|NCT00642044|No Intervention|B|The eye with the best visual acuity do not receive the treatment.
11600891|NCT00642031|Experimental|Triciribine|Triciribine 15 mg/m^2 intravenous (IV) Weekly Over 1 Hour On Days 1, 8, and 15.
11600892|NCT00642018|Active Comparator|A: Docetaxel|Standard of care (SOC) docetaxel 75 mg/m² intravenously every 3 weeks and prednisone 5 mg orally twice daily continuously while receiving docetaxel therapy
11600893|NCT00642018|Experimental|B: LY2181308 + Docetaxel|LY2181308 administered with docetaxel 75 mg/m² intravenously every 3 weeks and prednisone 5 mg orally twice daily continuously while receiving docetaxel
11600894|NCT00642005|Experimental|1|Humidified and warmed carbon dioxide laparoscopic insufflation.
11600895|NCT00642005|Placebo Comparator|2|Cold and dry carbon dioxide laparoscopic insufflation.
11600896|NCT00641992||1|Response to medical treatment
11600897|NCT00641992||2|Failure to medical treatment (surgery or percutaneous resolution)
11600898|NCT00641979|Experimental|1|Rhinocort
11600899|NCT00641979|Placebo Comparator|2|
11600900|NCT00641953|Experimental|A|IMX-150 (0.3%) 0.5 g topically BID each foot
11600901|NCT00641953|Experimental|B|IMX-150(0.6%) 0.5 g topically BID to each foot
11600902|NCT00641953|Placebo Comparator|C|Placebo 0.5 g topically BID to each foot for 4 weeks
11600903|NCT00641940|Experimental|1|Girls in Transition (GT) program
11600904|NCT00641940|Other|2|Waitlist control
11600905|NCT00641927|Experimental|1|Antidepressant
11600906|NCT00641927|Active Comparator|2|Drug
11600907|NCT00641914|Experimental|1|
11600908|NCT00641914|Placebo Comparator|2|
11600909|NCT00641901||Observation|Pregnant women with gingivitis
11600910|NCT00641888||1|10 patients starting on non-nucleoside reverse transcriptase inhibitor based regimen. 5 women and 5 men.
11600911|NCT00641888||2|10 patients starting a protease inhibitor based regimen. 5 women and 5 men.
11600912|NCT00641862|Active Comparator|Vitamin B12|Vitamin B12
11600913|NCT00641862|Placebo Comparator|Placebo|Placebo
11600914|NCT00641849|Active Comparator|Group A|Minimum Intervention Group A will fill out data forms at zero (0), two (2), four (4), and six (6) months.
11600915|NCT00641849|Active Comparator|Group B|Maximum Intervention Group B will fill out data forms at zero (0), one (1), two (2), three (3), four (4), five (5), and six (6) months.
11600916|NCT00641823||1|
11600917|NCT00641823||2|
11600918|NCT00641823||3|
11600919|NCT00641810|Experimental|A|After one week at usual levels of caffeine use, patients are asked to reduce their caffeine consumption to no more than 2 cups of coffee (or equivalent) for one week and then to zero for two weeks.
11600920|NCT00641797|Active Comparator|Arm 1, Conventional Therapy|Patients will receive standard conventional medication therapy (i.e., meclizine, diphenhydramine, lorazepam, ondansetron).
11600921|NCT00641797|Experimental|Arm 2, Epley Maneuver|Patients will receive vestibular rehabilitation (the Epley Maneuver).
11600922|NCT00641784|Experimental|1|Oral Nifedine
11600923|NCT00641784|Active Comparator|2|Intravenous Magnesium
11600924|NCT00641771|Experimental|1|MK0217A
11600925|NCT00641771|Placebo Comparator|2|Placebo
11600926|NCT00641758|Placebo Comparator|Placebo|
11600927|NCT00641758|Active Comparator|Pycnogenol|
11600928|NCT00641745|Experimental|1|Lurasidone
11600929|NCT00641745|Active Comparator|2|Risperidone
11600930|NCT00641732|Experimental|TAK-442 40 mg QD|
11600931|NCT00641732|Experimental|TAK-442 80 mg QD|
11600932|NCT00641732|Experimental|TAK-442 10 mg BID|
11600933|NCT00641732|Experimental|TAK-442 20 mg BID|
11600934|NCT00641732|Experimental|TAK-442 40 mg BID|
11600935|NCT00641732|Experimental|TAK-442 80 mg BID|
11600936|NCT00641732|Active Comparator|Enoxaparin 30 mg BID|
11600937|NCT00641719|Experimental|Duloxetine 40 mg|Duloxetine 40 milligrams (mg) once daily (QD), orally (PO), 1 year
11600938|NCT00641719|Experimental|Duloxetine 60 mg|Duloxetine 60 mg QD, PO, 1 year
11600939|NCT00641706|Experimental|Stratum 1 (not undergoing surgery)|Patients receive oral vorinostat (SAHA) once daily on days 1-14 and bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11600940|NCT00641706|Experimental|Stratum 2 (undergoing surgery)|Patients receive oral SAHA once daily for 2 days prior to surgery and then on the day of surgery. Patients also receive bortezomib IV on the day of surgery. After receiving the 3rd dose of SAHA, patients undergo surgery to remove the tumor. Beginning at least 7 days after surgery, patients receive SAHA and bortezomib as in stratum 1.
11600941|NCT00641693|Experimental|1|Nasal Spray
11600942|NCT00641693|Placebo Comparator|2|
11600943|NCT00641680|Experimental|1|Budesonide
11600944|NCT00641680|Active Comparator|2|Fluticasone propionate
11600945|NCT00641680|Placebo Comparator|3|
11600946|NCT00641667|Experimental|Fentanyl|
11600947|NCT00641654|Active Comparator|A|Patients having previously received 24 weeks of therapy with pegylated interferon and ribavirin will be treated with pegylated interferon alfa-2a kD (PEGASYS) plus ribavirin, (Copegus) for a treatment period of 48 weeks, with a follow-up period of 24 weeks irrespective of the level of HCV-RNA measured in plasma on treatment day 27.
11600948|NCT00641654|Active Comparator|B|Patients having previously received less than 24 weeks but at least 12 weeks of therapy with pegylated interferon and Ribavirin and having detectable HCV-RNA in a plasma sample obtained on treatment day 27 (i.e. the day before the 5th dose of pegylated interferon in this study) as analyzed by means of COBAS TaqMan 48TM will be treated with pegylated interferon alfa-2a KD (PEGASYS®) plus ribavirin, (Copegus®) for a treatment period of 48 weeks, with a follow-up period of 24 weeks.
11601058|NCT00640835|Experimental|Sublingual administration|Buprenorphine/naloxone film strip administered sublingually
11600949|NCT00641654|Active Comparator|C|Patients having previously received less than 24 weeks but at least 12 weeks of therapy with pegylated interferon and Ribavirin and having undetectable HCV-RNA in a plasma sample obtained on treatment day 27 (i.e. the day before the 5th dose of pegylated interferon in this study) as analyzed by means of COBAS TaqMan 48TM will be treated with pegylated interferon alfa-2a KD (PEGASYS®) plus ribavirin, (Copegus®) for a treatment period of 24 weeks, with a follow-up period of 24 weeks.
11600950|NCT00641641|Experimental|antiretroviral therapy|tenofovir (TDF) + emtricitabine (FTC) as a fixed dose combination administered orally once per day and raltegravir (RAL) administered orally twice per day.
11600951|NCT00641628||1|
11600952|NCT00641615|Experimental|Phase 1|
11600953|NCT00641602|Experimental|1|Nexium
11600954|NCT00641602|Active Comparator|2|Prevacid
11600955|NCT00641563|Active Comparator|Dex/Remi followed by Mida/Remi|Sedation with dexmedetomidine and remifentanil followed by sedation with midazolam and remifentanil separated by one week
11600956|NCT00641563|Active Comparator|Mida/Remi followed by Dexa/Remi|Sedation with midazolam and remifentanil followed by sedation with dexmedetomidine and remifentanil separated by one week
11600957|NCT00641550|Experimental|2|Pregnant women starting to practice physical exercise at 13 weeks(Walking moderate activity)
11600958|NCT00641550|Experimental|3|Pregnant women starting exercise at 20 weeks
11600959|NCT00641550|No Intervention|1|Pregnant women without exercise practice.
11600960|NCT00641537|Placebo Comparator|Cladribine Low/Placebo (LLPP)|
11600961|NCT00641537|Placebo Comparator|Cladribine High Dose/Placebo (HLPP)|
11600962|NCT00641537|Experimental|Cladribine Low/Low Dose (LLLL)|
11600963|NCT00641537|Experimental|Cladribine High/Low Dose (HLLL)|
11600964|NCT00641537|Experimental|Placebo/Cladribine Low Dose (PPLL)|
11600965|NCT00641524|Other|treatment|Iron depletion via phlebotomy
11600966|NCT00641511|Experimental|1 (Medication arm - SYN117 aka Nepicastat)|"Veterans will be receiving the study medication Nepicastat initiated with a 3-day loading phase of 40 mg on day 1, 80 mg on day 2 and 120 mg on day 3 (orally) and be continued at 120 mg once daily; During the 8 weeks (weeks: 7-14) extension phase, those from both treatment groups of the RCT phase will start open-label, active Nepicastat (i.e. no chance of placebo) treatment and be followed for an additional 8 weeks. Those who have a prior defined positive clinical response to the study medication, Nepicastat, will be continued on open label Nepicastat at 120mg once daily, in order to assess further improvement and safety; those who do not have a positive clinical response during the 6 weeks RCT will be offered the addition of the standard first-line PTSD pharmacotherapy, Paroxetine. Paroxetine is an allowed concomitant medication (i.e. rescue medication) and is not considered a research medication or subject of a research question during the 8 weeks extension phase."
11600967|NCT00641511|Placebo Comparator|2 (Placebo arm)|During the 6 weeks ( weeks: 1-6) double- blind, randomized clinical trial (RCT) phase, the veterans who have been randomized to the placebo treatment group will be receiving placebo pills. During the 8 weeks (weeks: 7-14) extension phase, all veterans from both treatment groups of the RCT phase will start open-label, active Nepicastat (i.e. no chance of placebo) treatment and be followed by the study team for an additional 8 weeks. The veterans on the placebo during the RCT will receive the study medication at end of the study week 6, the medication will be initiated with a 3-day loading phase of 40 mg on day 1, 80 mg on day 2 and 120 mg on day 3 (orally) and be continued at 120 mg once daily for 8 weeks until the end of the study.
11600968|NCT00641498|No Intervention|Control|Usual therapy
11600969|NCT00641498|Experimental|Active group|Individual supportive psychotherapy initiated in the Emergency department
11600970|NCT00641472|Experimental|1|Budesonide inhalation suspension
11600971|NCT00641472|Active Comparator|2|Montelukast sodium
11600972|NCT00641459||001|
11600973|NCT00641446|Experimental|1|Pulmicort
11600974|NCT00641446|Active Comparator|2|Varivax
11600975|NCT00641433|Experimental|experimental|Subjects will daily dress their nail bed with oxidized regenerated cellulose collagen-silver, until healing occurs.
11600976|NCT00641433|Active Comparator|Control|Topical silver sulfadiazine cream will be applied daily to the wound bed until healing has occured.
11600977|NCT00641420|Experimental|1|Patients receive fractional laser resurfacing to 17% of the face five times one month apart at 10mJ.
11600978|NCT00641420|Experimental|2|Patients receive fractional laser resurfacing to 17% of the face five times one month apart at 40mJ.
11600979|NCT00641407|Experimental|1|
11600980|NCT00641407|Active Comparator|2|
11600981|NCT00641394|Experimental|1|Psychotherapy: Emotional Freedom Techniques (EFT), a psychotherapy intervention with a somatic component
11600982|NCT00641394|Active Comparator|2|Psychotherapy: Cognitive Behavioral Therapy (CBT), a psychotherapy intervention
11600983|NCT00641394|No Intervention|3|
11600984|NCT00641381|Experimental|Treatment (high-dose chemotherapy, anti-HIV therapy)|Patients undergo leukapheresis to obtain PBSCs for transplantation. At least 5 days later, patients with an adequate number of collected cells proceed to high-dose chemotherapy. Patients receive carmustine IV over 4 hours on days -7 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. Patients receive an autologous PBSC infusion on day 0.
11600985|NCT00641368|Experimental|1|R4Power Program
11600986|NCT00641368|Other|2|Waitlist Control
11600987|NCT00641342|Active Comparator|onlay mesh|
11600988|NCT00641342|Active Comparator|sublay mesh|
11600989|NCT00641342|No Intervention|no mesh|
11600990|NCT00641329|Experimental|1|
11600991|NCT00641329|Placebo Comparator|2|
11600992|NCT00641316|Experimental|1|Teeth extraction followed by natural healing
11600993|NCT00641316|Experimental|2- FDBA/TCP|
11600994|NCT00641316|Experimental|3 FDBA/TCP+PRP|
11600995|NCT00641316|Experimental|4 FDBA/TCP + PDGF|
11600996|NCT00641303|Sham Comparator|Arm I (control)|Patients receive 8 weekly sessions of sham acupuncture treatment comprising 20 minutes of a non-penetrating device consisting of a retractable needle and an adhesive tube on the skin using the Park Sham Device (PSD) in 14 non-acupuncture points. Patients may receive 4 free acupuncture sessions (not sham) after the 12 or 24-week follow-up visit.
11601059|NCT00640835|Experimental|Buccal administration|Buprenorphine/naloxone film strip administered buccally
11601499|NCT00637624|Active Comparator|1|N-Acetylcysteine
11600997|NCT00641303|Experimental|Arm II (treatment)|Patients receive 8 weekly sessions of acupuncture treatment comprising 20 minutes of needle insertion in 15 acupuncture points including CV 4, CV 6, CV12 and bilateral LI 4, MH 6, GB 34, ST 36, KI 3, BL 65.
11600998|NCT00641251|Active Comparator|1|intensive medical management
11600999|NCT00641251|Active Comparator|2|Roux-en-Y gastric bypass with intensive medical management
11601000|NCT00641238||Early stage NSCLC|Early stage non-small cell lung cancer
11601001|NCT00641225|Experimental|1|SBI-087
11601002|NCT00641212|Experimental|1|Budesonide
11601003|NCT00641212|Placebo Comparator|2|
11601004|NCT00641199|Active Comparator|1|Jarrow-Dophilus EPS
11601005|NCT00641199|Placebo Comparator|2|Placebo
11601006|NCT00641186|Experimental|A|sodium oxybate 4.5 to 9.0 gms per night
11601007|NCT00641173|Experimental|1|paroxetine v placebo
11601008|NCT00641173|Placebo Comparator|2|placebo
11601009|NCT00641160|Experimental|Cohort 1|
11601010|NCT00641160|Experimental|Cohort 2|
11601011|NCT00641160|Experimental|Cohort 3|
11601012|NCT00641147|Experimental|Arm I (curcumin)|Patients receive curcumin PO BID for 12 months. Laboratory Biomarker Analysis
11601013|NCT00641147|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 12 months. Laboratory Biomarker Analysis
11601014|NCT00641134|Other|A|A:Home-Based exercise program,-at discharge from in-Hospital CR program-, with one reinforcement session each month for the first 6 months.
11601015|NCT00641134|No Intervention|B|Usual care, after CR, consisting of recommendation on usefulness of physical exercise and standard follow-up visits and functional assessment at 6 and 12 months.
11601016|NCT00641108|Experimental|ADAM SPECT|Participants with depression will undergo ADAM SPECT scans and cognitive behavioral therapy.
11601017|NCT00641108|Active Comparator|Control|Healthy subjects without depression will undergo ADAM SPECT scans.
11601018|NCT00641095|Experimental|Fludarabine/Cyclophosphamide/Rituximab|"Fludarabine 40mgs/m2 oral days 1-3 Cyclophosphamide 250mgs/m2 oral days 1-3 Rituximab 375mgs/m2 day 1 iv infusion
~Every 28 days"
11601019|NCT00641095|Active Comparator|Fludarabine/Cyclophosphamide|"Fludarabine 40mgs/m2 oral days 1-3 Cyclophosphamide 250mgs/m2 oral days 1-3
~Every 28 days"
11601020|NCT00641082|Experimental|1|Clevudine
11601021|NCT00641082|Active Comparator|2|Adefovir
11601022|NCT00641056|Experimental|1|
11601023|NCT00641056|Active Comparator|2|
11601024|NCT00641043|Experimental|BI 1356 (5 mg)|BI 1356 5mg in initial combination therapy with pioglitazone 30 mg
11601025|NCT00641043|Placebo Comparator|Placebo matching BI 1356 5 mg|Placebo in initial combination therapy with pioglitazone 30 mg
11601026|NCT00641017|Experimental|1 and 2 - Adults|One immunization of 1x10^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
11601027|NCT00641017|Experimental|3A - Seropositive Children|One immunization of 1x10^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
11601028|NCT00641017|Placebo Comparator|3B - Seropositive Children|One dose of 1x10^6 TCID50 rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
11601029|NCT00641017|Experimental|4A - Seronegative Infants and Children|One immunization of 1x10^5 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
11601030|NCT00641017|Placebo Comparator|4B - Seronegative Infants and Children|One dose of 1x10^5 TCID50 rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
11601031|NCT00641017|Experimental|5A - Seronegative Infants and Children|One immunization of 1x10^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
11601032|NCT00641017|Placebo Comparator|5B - Seronegative Infants and Children|One dose of rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
11601033|NCT00641004|Experimental|1|Rebamipide 100mg TID for 12 weeks
11601034|NCT00641004|Active Comparator|2|Esomeprazole 40mg OD + Esomeprazole-matching placebo BID for 12 weeks
11601035|NCT00640991|No Intervention|Control|Patients assigned to the control arm will receive usual care for AMI, according to local practice of each participating centre.
11601036|NCT00640991|Experimental|Intervention|The experimental arm will have an IV infusion of glulisine insulin started directly after randomization for at least 24 hours and for as long as CCU-level care is required, and the insulin infusion will be adjusted to achieve and maintain a target glucose range of 5.0-6.6 mmol/L (90-118 mg/dL). Once transferred to the ward, patients in the experimental arm will switch to glargine insulin and will continue this treatment for the remainder of their hospitalization and after hospital discharge, for a total duration of 30 days post randomization.
11601037|NCT00640978|Experimental|Erlotinib + RAD001|Erlotinib 150 mg orally daily for 28 Days + RAD001 (Everolimus) 30 mg orally weekly for 4 Weeks
11601038|NCT00640965|Experimental|A|DP-VPA
11601039|NCT00640965|Placebo Comparator|B|
11601040|NCT00640939|Active Comparator|A|Topical diclofenac sodium patch
11601041|NCT00640939|Placebo Comparator|B|Topical patch identical in appearance to active comparator
11601042|NCT00640926|Experimental|1|Radezolid 300 mg
11601043|NCT00640926|Experimental|2|Radezolid 450 mg
11601044|NCT00640926|Experimental|3|Radezolid 450 mg BID
11601045|NCT00640913||I|Twenty consecutive patients operated on with low anterior resection of the rectum for cancer with a defunctioning stoma who accept participation.
11601046|NCT00640900|Experimental|Commercial program at center|
11601047|NCT00640900|Experimental|Commercial program over the telephone|
11601048|NCT00640900|Other|Usual care|Weight loss counseling
11601049|NCT00640887|Experimental|1|RBT associated with EFV based ART
11601050|NCT00640887|Experimental|2|RBT associated with NVP based ART
11601051|NCT00640887|Experimental|3|RBT associated with LPV/r based ART
11601052|NCT00640874||PIPET C|Contact group members of people with diagnosed influenza who are recommended to receive NA inhibitor prophylaxis for short periods of time will be enrolled following provision of informed consent.
11601053|NCT00640848|Experimental|1|
11601054|NCT00640848|Experimental|2|
11601055|NCT00640848|Experimental|3|
11601056|NCT00640848|Experimental|4|
11601057|NCT00640848|Experimental|5|
11601060|NCT00640822|Experimental|Calcipotriol plus Hydrocortisone ointment|Calcipotriol plus Hydrocortisone ointment once daily for up to 8 weeks
11601061|NCT00640822|Active Comparator|Tacalcitol|Tacalcitol once daily for up to 8 weeks
11601062|NCT00640822|Placebo Comparator|Calcipotriol plus Hydrocortisone ointment vehicle|Calcipotriol plus Hydrocortisone ointment vehicle once daily for up to 8 weeks
11601063|NCT00640809|Experimental|A|
11601064|NCT00640809|Placebo Comparator|B|
11601065|NCT00640809|Active Comparator|C|
11601066|NCT00640796|Experimental|Treatment|Participants undergo haploidentical donor derived natural killer cell infusion (cells obtained from donors and selected using CliniMACS cell selection system) and chemotherapy (cyclophosphamide, fludarabine, interleukin-2, mesna).
11601067|NCT00640783|Experimental|1|Mediterranean diet
11601068|NCT00640783|Active Comparator|2|Control diet
11601069|NCT00640770|Active Comparator|balloon angioplasty|balloon angioplasty
11601070|NCT00640770|Experimental|Drug eluting stent|CYPHER SELECT+ Coronary or Infrapopliteal Stent
11601071|NCT00640757|Active Comparator|Low Methionine 1|Methionine deficient diet
11601072|NCT00640757|Placebo Comparator|Placebo 2|Placebo comparator methionine complete diet
11601073|NCT00640744|Other|A|An untreated carotid plaque will be obtained at the first endarterectomy. Atorvastatin 80mg will be administered for 3 months. The contralateral (treated) plaque will be obtained at the second endarterectomy. Hence, each patient will be his/her own control
11601074|NCT00640705|Active Comparator|A|Topical diclofenac sodium patch
11601075|NCT00640705|Placebo Comparator|B|Topical patch identical in appearance to active comparator, except without diclofenac sodium
11601076|NCT00640692||1|
11601077|NCT00640692||2|
11601078|NCT00640679|Active Comparator|Clopidogrel Tapering|
11601079|NCT00640679|Active Comparator|Abrupt Clopidogrel Interruption|
11601080|NCT00640666|Experimental|Physical activity intervention|Behavior change intervention
11601081|NCT00640666|No Intervention|Standard of care with written materials|Written materials
11601082|NCT00640653|Experimental|Abstinence-only|Participants will receive the abstinence-only HIV/STD risk-reduction intervention.
11601083|NCT00640653|Experimental|Safer-sex only|Participants will receive the safer-sex-only HIV/STD risk-reduction intervention.
11601084|NCT00640653|Experimental|Comprehensive-long|Participants will receive the 12-h long comprehensive HIV/STD risk-reduction intervention.
11601085|NCT00640653|Experimental|Comprehensive-short|Participants will receive the 8-h short comprehensive HIV/STD risk-reduction intervention.
11601086|NCT00640653|Active Comparator|Health-promotion control|Participants will receive the health promotion control intervention.
11601087|NCT00640640|Experimental|A|All study patients will be evaluated in a similar way
11601088|NCT00640627|Experimental|A|
11601089|NCT00640627|Placebo Comparator|B|
11601090|NCT00640614|Experimental|Sensitives|Subjects with a clinical history and positive patch test (current or previous) to any of the seven allergens. Subjects must otherwise be healthy and fulfill entry criteria.
11601091|NCT00640614|Experimental|Consecutives|Subjects who are being seen for standard allergy patch testing, that are asked to participate in the study.
11601092|NCT00640588|Experimental|1|Telbivudine
11601093|NCT00640588|Active Comparator|2|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
11601094|NCT00640575|Experimental|A|Local
11601095|NCT00640575|Active Comparator|B|Systemic
11601096|NCT00640562|Experimental|Quetiapine Extended Release|
11601097|NCT00640562|Active Comparator|Risperidone|
11601098|NCT00640549|Placebo Comparator|2|
11601099|NCT00640549|Active Comparator|1|
11601100|NCT00640536||1|Newly diagnosed obstructive sleep apnea patients without systemic and pulmonary arterial hypertension
11601101|NCT00640536||2|Age, sex and and body mass index-matched matched healthy subjects
11601102|NCT00640510|Experimental|IM olanzapine 10mg|Patients will receive at least one injection of Intramuscular (IM) olanzapine 10mg. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
11601103|NCT00640510|Placebo Comparator|IM placebo|Patients will receive at least one injection of Intramuscular placebo. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
11601104|NCT00640497|Experimental|1|Treatment arm
11601105|NCT00640484|Experimental|A|CHF 4226 (carmoterol) 2 μg once a day, in the morning
11601106|NCT00640484|Experimental|B|CHF 4226 (carmoterol) 4 μg once a day, in the morning
11601107|NCT00640484|Placebo Comparator|C|placebo once a day, in the morning
11601108|NCT00640484|Active Comparator|D|salmeterol 50 μg twice daily, in the morning and in the evening
11601109|NCT00640471|Active Comparator|Brivanib|
11601110|NCT00640471|Active Comparator|Placebo|
11601111|NCT00640458|Placebo Comparator|Placebo|Study Period 1 or 2
11601112|NCT00640458|Experimental|Experimental|Study Period 1 or 2
11601113|NCT00640445|Experimental|Expressive Writing|Participants assigned to the Expressive Writing (EW) condition will write about their deepest thoughts and feelings associated with their experience transitioning from being a soldier to being a civilian for 20 minutes a day for 4 days within a week.
11601114|NCT00640445|Active Comparator|Control Writing|Those assigned to control writing condition will write factually about the information needs of veterans transitioning from active duty to civilian status for 20 minutes on 4 days within one week.
11601115|NCT00640445|No Intervention|No Writing Control|Treatment As Usual
11601116|NCT00640432|Active Comparator|A|
11601117|NCT00640432|Experimental|B|
11601118|NCT00640419|Experimental|1|
11601119|NCT00640419|Experimental|2|
11601120|NCT00640419|Placebo Comparator|3|
11601121|NCT00640406|Experimental|STN|Device: Dynamic Renal Stent plus Best Medical Treatment
11601122|NCT00640406|Active Comparator|BMT|Drug: Best Medical Treatment
11601123|NCT00640393|Active Comparator|Part 1 - Etanercept|All participants received etanercept 50 mg twice a week for 12 weeks.
11601124|NCT00640393|Active Comparator|Part 2 - Etanercept and nbUVB|Participants who did not reach a 90 percent reduction in psoriasis area and severity index (PASI-90) after 12 weeks and were randomized to the narrow band ultra violet B (nbUVB) group. They received nbUVB treatments three times a week and 50 mg Etanercept once per week.
11601125|NCT00640393|Active Comparator|Part 2 - Etanercept|Participants who did not reach PASI-90 after 12 weeks and were randomized to the Etanercept group. They received 50 mg Etanercept once per a week.
11601126|NCT00640380|Experimental|1|CPVB with NS
11601127|NCT00640380|Active Comparator|2|CPVB with LOR
11601128|NCT00640367|Experimental|IA thrombolysis|IA recombinant tissue plasminogen activator and/or mechanical thrombolysis
11601129|NCT00640367|Active Comparator|IV rtPA|IV recombinant tissue plasminogen activator
11601130|NCT00640354|Experimental|1|Pediatric residents randomized to having an automated external defibrillator
11601131|NCT00640354|Active Comparator|2|Pediatric residents randomized to having a manual defibrillator
11601132|NCT00640341|Experimental|PureVision|PureVision Contact Lens
11601133|NCT00640341|Active Comparator|Acuvue Oasys|Acuvue Oasys Contact Lens
11601134|NCT00640341|Active Comparator|O2Optix|O2Optix Contact Lens
11601135|NCT00640328|Experimental|Cohort 1.1|100mg ofatumumab then placebo
11601136|NCT00640328|Experimental|Cohort 1.2|placebo then 100mg ofatumumab
11601137|NCT00640328|Experimental|Cohort 2.1|300mg ofatumumab then placebo
11601138|NCT00640328|Experimental|Cohort 2.2|placebo then 300mg ofatumumab
11601139|NCT00640328|Experimental|Cohort 3.1|700mg ofatumumab then placebo
11601140|NCT00640328|Experimental|Cohort 3.2|placebo then 700mg ofatumumab
11601141|NCT00640315|Experimental|Riociguat (Adempas, BAY63-2521) 1.0 mg|Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.
11601142|NCT00640315|Experimental|Riociguat (Adempas, BAY63-2521) 2.5 mg|Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.
11601143|NCT00640302||PIPET A|Patients presenting at study sites with the recognised clinical case definition for pandemic influenza (to be distributed by State and Commonwealth Departments of Health when first clinical case occurs) will be eligible to be enrolled on the study. Informed consent to participate in the study will be sought including parental/guardian consent for minors and presumed consent for adults who are incapacitated (consistent with NHMRC requirements).
11601144|NCT00640289|Experimental|A|Treatment
11601145|NCT00640276|Active Comparator|T|Lifestyle modification + active drug(Pitavastatin)
11601146|NCT00640276|Other|C|Lifestyle Modification
11601147|NCT00640263|Experimental|1|infant peri-exposure prophylaxis with lopinavir/ritonavir
11601148|NCT00640263|Active Comparator|2|infant peri-exposure prophylaxis with lamivudine
11601149|NCT00640250|Experimental|Sensitives|Subjects with a clinical history and positive patch test (current or previous) to either Disperse Blue 106 or Bronopol. Subjects must otherwise be healthy and fulfill entry criteria.
11601150|NCT00640237|Experimental|1|Arm 1 - the patients will receive two large doses of vitamin D.
11601151|NCT00640237|No Intervention|2|Arm 2 - the patients vitamin D status will be checked during the hospitalization and they will receive the recommendation to treat the vitamin D deficiency in the out-patient department.
11601152|NCT00640224|Active Comparator|Rosiglitazone|Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
11601153|NCT00640224|Active Comparator|Drospirenone/ethinyl estradiol|Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
11601154|NCT00640224|No Intervention|Overweight/Obese without PCOS|Overweight adolescent females without PCOS to use as comparison of normal developmental changes. *No participants were enrolled in this Arm.
11601155|NCT00640224|No Intervention|Lean without PCOS|Lean healthy girls without PCOS to serve as controls for the cardiovascular markers. *No participants were enrolled in this Arm.
11601156|NCT00640211||PIPET B|Participants in this study will be health care and other essential workers receiving long term neuraminidase inhibitor prophylaxis.
11601157|NCT00640198|Active Comparator|Group 1 Memantine|Patients included in this group will receive memantine alone followed by memantine combined with intensive speech-language therapy.
11601158|NCT00640198|Placebo Comparator|Group 2|Patients included in this group will receive placebo alone followed by memantine combined with intensive speech-language therapy.
11601159|NCT00640185|Placebo Comparator|1|
11601160|NCT00640185|Experimental|2|
11601161|NCT00640185|Experimental|3|
11601162|NCT00640172||Anemic Elderly|
11601163|NCT00640172||Non-anemic adults (non-elderly, without bone marrow biopsy)|
11601164|NCT00640172||Non-anemic adults (non-elderly, with bone marrow biopsy)|
11601165|NCT00640172||Non-anemic Elderly (control without bone marrow biopsy)|
11601166|NCT00640172||Non-anemic Elderly (control, with bone marrow biopsy)|
11601167|NCT00640159|Experimental|A|Open label switch from current oral selegiline dose to orally disintegrating selegiline (Zelapar) titrated to a dose of 2.5 mg QD.
11601168|NCT00640146|Experimental|MNTX|Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) subcutaneously (SC) once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.
11601169|NCT00640146|Placebo Comparator|Placebo|Participants will receive placebo matching to MNTX SC once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.
11601170|NCT00640133|Active Comparator|Active DBS|Participants will receive deep brain stimulation.
11601171|NCT00640133|Sham Comparator|Sham DBS|Participants will receive sham deep brain stimulation for several months and then active deep brain stimulation thereafter.
11601172|NCT00640120||1|Asthmatic subjects
11601173|NCT00640120||2|Healthy subjects
11601174|NCT00640094|Experimental|A: Melatonin|Melatonin: intravenous infusion and intracoronary bolus
11601175|NCT00640094|Placebo Comparator|B: Placebo of melatonin|Placebo: intravenosus infusion and intracoronary bolus
11601176|NCT00640081|Active Comparator|D|Intermittent chemotherapy plus intermittent cetuximab treatment comprising 12 weeks of chemotherapy plus cetuximab followed by a period off all therapy, with reintroduction of the same chemotherapy and cetuximab regimen for a further 12 weeks after initial progression off treatment
11601177|NCT00640081|Experimental|E|Intermittent chemotherapy plus continuous cetuximab treatment comprising 12 weeks of chemotherapy plus cetuximab followed by a period of withdrawal of the chemotherapy, but continued weekly cetuximab monotherapy (maintenance cetuximab), with reintroduction of the same chemotherapy regimen to the cetuximab for a further 12 weeks after initial progression off chemotherapy treatment
11601178|NCT00640068||1|All patients in whom a clinical CCTA was ordered by their physician at a participating site. Patient must have a prescription for CCTA ordered by their physician.
11601179|NCT00640055|Active Comparator|1|Coordinator (non-physician)
11601180|NCT00640055|Placebo Comparator|2|Physician
11601181|NCT00640042|Experimental|1|
11601182|NCT00640029|Experimental|1|Cervical - Arthroplasty
11601183|NCT00640029|Active Comparator|2|Cervical - Arthrodesis
11601184|NCT00640029|Experimental|3|Lumbar - Over 50 years - Arthroplasty
11601185|NCT00640029|Active Comparator|4|Lumbar - Over 50 years - Arthrodesis
11601186|NCT00640029|Experimental|5|Lumbar - Under 50 years - Arthroplasty
11601187|NCT00640016|Placebo Comparator|Placebo|Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
11601188|NCT00640016|Experimental|CAT-354 1 mg/kg|CAT-354 1 milligram per kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
11601189|NCT00640016|Experimental|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
11601190|NCT00640016|Experimental|CAT-354 10 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56
11601191|NCT00640003|Experimental|1|
11601192|NCT00640003|Experimental|2|
11601193|NCT00639990|Active Comparator|Control|Patients without lung injury and brain injury
11601194|NCT00639990|Experimental|Brain No ALI 1|Patients with brain injury and no lung injury within 72 hours from ICU entry
11601195|NCT00639990|Experimental|Brain No ALI 2|Patients with brain injury and no ALI after 72 hours from ICU entry
11601196|NCT00639990|Experimental|Brain ALI|Patients with brain injury and Acute Lung Injury (ALI)
11601197|NCT00639977|Sham Comparator|2|20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
11601198|NCT00639977|Active Comparator|1|20-minute session of acupuncture with needles inserted in specific points (Tong Zi Liao, Yang Bai and Jing Ming)
11601199|NCT00639977|No Intervention|3|
11601200|NCT00639964|Other|type 1 diabetic pregnant women|type 1 diabetic pregnant women
11601201|NCT00639964|Other|type 2 diabetic pregnant women|type 2 diabetic pregnant women
11601202|NCT00639964|Other|healthy pregnant women|healthy pregnant women with normal glucose tolerance
11601203|NCT00639951|Active Comparator|A Normal dose Group|20 vials up front in a Single Dose of Antivipmyn in 500 ml of solution IV, administered in 60 minutes. After 12 hours, it has to be perfomed a clinical evaluation of the patient. Each patient is going to have clinical studies of coagulation time and also the fibrinogen measures, this at 2, 4, 6, 8, 10, 12, 48, 72, 96 hours.All patients who have received at least one dose of medication study will be contacted by telephone to investigate the presence of symptoms suggestive of continuing with effect snake venom, or the presence of an adverse event, or any signs or symptoms indicating the presence of a hypersensitivity response to Antivipmyn® including serum sickness. If symptoms suggestive of an adverse event were discovered, the patient will referred for appropriate treatment.
11601204|NCT00639951|Placebo Comparator|B Placebo Group|20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®. The treatment schedule for each subject is a dose of 5 vials Antivipmyn® every 2 hours to complete 20 vials, the total duration is 6 hours of the treatment. Each dose IV shall apply in physiological solution 250ml, and finish its application in 15 minutes. For pediatric patients the volume administered should not exceed the recommended fluid volume according to your body weight. After the assessment at 12 hours, it can be administered at the discretion of more antivenom attending by the physician.
11601205|NCT00639938|Active Comparator|1|"Mother dosing regimen: Single dose of 200 mg NVP taken orally at onset of labor
~Infant dosing regimen: Single dose of 2 mg/kg NVP taken orally within the first week after delivery"
11601206|NCT00639938|Experimental|2|"Mother dosing regimen: Single dose of 200 mg NVP taken orally at onset of labor
~Infant dosing regimen: 2 mg/kg NVP taken orally within the first week after delivery and 5 mg NVP taken orally daily from Day 8 through Week 6"
11601207|NCT00639938|Experimental|3|"Mother dosing regimen: Single 12 gm intravenous dose of HIVIGLOB at 36 - 37 weeks gestation and 200 mg NVP taken orally at onset of labor
~Infant dosing regimen: Single 1.2 gm intravenous dose HIVIGLOB within 18 hours of birth and 2 mg/kg NVP taken orally within the first week after delivery"
11601208|NCT00639925|Experimental|Phase I study|
11601209|NCT00639912|Active Comparator|A: low volume saline|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 1 ml/kg/hour for 12 hours after the procedure, starting in the Cath Lab.
11601210|NCT00639912|Active Comparator|B: high volume saline|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath lab.
11601211|NCT00639912|Active Comparator|C: low volume sodium bicarbonate|Solution of 154 mEq/L of sodium bicarbonate. Rate of infusion: 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath Lab.
11601212|NCT00639912|Active Comparator|D: high volume sodium bicarbonate|Solution of 154 mEq/L of sodium bicarbonate. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath Lab.
11601213|NCT00639873|Experimental|AS 2mg/kg|Artesunate monotherapy 2mg/kg/day for 7 days
11601214|NCT00639873|Experimental|AS 4mg/kg|Artesunate monotherapy 4mg/kg/day for 7 days
11601215|NCT00639873|Active Comparator|QD Control|Quinine-doxycycline for 7 days
11601216|NCT00639860|Experimental|Placing OSSIX-Plus in Extraction Site|Placement of OSSIX-Plus, a resorbable collagen membrane, and the promotion of bone healing following exodontia.
11601267|NCT00639418||Participants 6 to 23 months|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 6 to 23 months of age
11601217|NCT00639847|No Intervention|group 1|this is the standard of care control group. The control group will be instructed to return to their regular physicians for routine follow up at a time to be specified by the physician.
11601218|NCT00639847|Active Comparator|Group 2|Group 2 will receive routine home visits from nurses provided by a home health care agency.
11601219|NCT00639847|Active Comparator|Group 3|In-home asthma management program (AMP) provided by respiratory therapists. The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
11601220|NCT00639834|Experimental|1|Active MDX-1342 given in combination with Methotrexate
11601221|NCT00639821||inflammatory bowel disease|Patients with refractory inflammatory bowel disease (ulcerative colitis and Crohn's disease) before and after treatment with infliximab.
11601222|NCT00639808|Placebo Comparator|1|
11601223|NCT00639808|Experimental|2|TZP-101
11601224|NCT00639795|Active Comparator|A|Patients randomized to receive thoracic paravertebral nerve blockade in addition to general endotracheal anesthesia during video assisted thoracoscopy procedure
11601225|NCT00639795|Sham Comparator|B|Patients randomized to receive sham single-injection thoracic peripheral nerve blockade (no injection) in addition to general endotracheal anesthesia
11601226|NCT00639782|Active Comparator|ONX|On-X heart Valve Replacement
11601227|NCT00639782|Active Comparator|SJM|SJM heart valve replacement
11601228|NCT00639769|Experimental|Therapeutic Intervention|
11601229|NCT00639756|Other|1|Placebo
11601230|NCT00639756|Active Comparator|2|Allopurinol given for 2 weeks with diet
11601231|NCT00639743|Experimental|group A|tenecteplase (group A)
11601232|NCT00639743|Placebo Comparator|group B|placebo ( group B)
11601233|NCT00639730|Experimental|A|This is open-label - all patients are placed on the diet. There is no control or placebo arm.
11601234|NCT00639717|Experimental|Etanercept and ECP|"Etanercept and ECP (Extracorporeal Photopheresis) in addition to standard GVHD prevention:
~Etanercept will be given twice weekly by subcutaneous injection starting on the day of HSCT (Hematopoietic stem cell transplantation) conditioning until 8 weeks post transplant. ECP treatments will begin at once weekly starting at 4 weeks post transplant and continue at less frequent intervals until 6 months post transplant.
~GVHD prophylaxis will consist of a standard two drug regimen: mycophenolate for 4 weeks and tacrolimus (titrated to a therapeutic level) for 8 weeks, then weaned over 4 months with discontinuation by 6 months post-transplant."
11601235|NCT00639691|Experimental|1|
11601236|NCT00639678|Experimental|1|
11601237|NCT00639678|Experimental|2|
11601238|NCT00639678|Placebo Comparator|3|
11601239|NCT00639678|Placebo Comparator|4|
11601240|NCT00639652||1. 3D-histology|Nodular, micronodular, or sclerosing BCCs
11601241|NCT00639652||2. Shave excision|Superficial BCCs
11601242|NCT00639639|Experimental|Arm I (first randomization)|Patients receive CMV-ALT IV over 45-90 minutes (course 1 only) and CMV pp65-LAMP mRNA-loaded DC (CMV-DC) vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
11601243|NCT00639639|Experimental|Arm II (first randomization)|Patients receive CMV-DC vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
11601244|NCT00639639|Experimental|Arm I (second randomization)|Within 6 to 24 hours prior to vaccination, patients undergo skin site preparation with unpulsed DCs at the vaccination site in one inguinal region. Patients then receive indium In 111-labeled CMV-DC.
11601245|NCT00639639|Experimental|Arm II (second randomization)|Within 6 to 24 hours prior to vaccination, patients undergo vaccination skin site preparation in the opposite inguinal region with tetanus toxoid. Patients then receive 111 In-labeled CMV-DC.
11601246|NCT00639626|Experimental|Levemir|
11601247|NCT00639613||1|Patients with type 2 diabetes
11601248|NCT00639613||2|Healthy subjects
11601249|NCT00639561|Experimental|A|diet composed of 10g of fibre per day
11601250|NCT00639561|Experimental|B|diet composed of 40g of fibre per day
11601251|NCT00639522|Experimental|A|
11601252|NCT00639509|Experimental|Treatment (monoclonal antibody therapy)|Patients receive anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
11601253|NCT00639496|Experimental|1|patients taking NAC 600 mg t.i.d.
11601254|NCT00639496|Placebo Comparator|2|
11601255|NCT00639483|Experimental|A|
11601256|NCT00639483|Placebo Comparator|B|
11601257|NCT00639457|Experimental|Pioglitazone|Pioglitazone (Actos; 30mg/day) for 16 weeks.
11601258|NCT00639457|Active Comparator|Pioglitazone + Exercise training|Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.
11601259|NCT00639444|Active Comparator|Gluten free diet|the intervention in this group is keeping a gluten-free diet from 0 to 12 months
11601260|NCT00639444|No Intervention|Gluten containing diet|infants in this group are started on gluten-containing cereals at 6 months (control group)
11601261|NCT00639431|Experimental|1|Direct observation of a sequence of right foot movements performed by the experimenter while visualizing moving the amputated or phantom right foot.
11601262|NCT00639431|Experimental|2|Direct observation of a sequence of left foot movements performed by the experimenter while visualizing moving the amputated or phantom left foot.
11601263|NCT00639431|Experimental|3|Direct observation of a sequence of left and right foot movements performed by the experimenter while visualizing moving the amputated or phantom left and right feet.
11601264|NCT00639431|Experimental|4|Mental visualization with closed eyes of a sequence movements performed with the right amputated or phantom foot.
11601265|NCT00639431|Experimental|5|Mental visualization with closed eyes of a sequence movements performed with the left amputated or phantom foot.
11601266|NCT00639431|Experimental|6|Mental visualization with closed eyes of a sequence movements performed with the left and right amputated or phantom feet.
11601268|NCT00639418||Participants 24 to 59 months|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 24 to 59 months of age
11601269|NCT00639418||Participants 5 to 8 years|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 5 to 8 years of age
11601270|NCT00639418||Participants 9 to 17 years|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 9 to 17 years of age
11601271|NCT00639405||1|subjects who are diagnosed with parathyroid adenomas. There will be 6 subjects who have not had surgery and 25 subjects who have had surgery.
11601272|NCT00639392|Placebo Comparator|2|Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive placebo are 1 out of 3.
11601273|NCT00639392|Experimental|1|Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive Zolendronic Acid are 2 out of 3.
11601274|NCT00639379|Experimental|senofilcon A|senofilcon A toric daily wear contact lenses
11601275|NCT00639379|Active Comparator|alphafilcon A|alphafilcon A toric daily wear contact lenses
11601276|NCT00639353|Active Comparator|spherical contact lens|Subjects will wear and evaluate a spherical soft contact lens daily for 2 weeks
11601277|NCT00639353|Experimental|toric contact lens|Subjects will wear and evaluate a toric soft contact lens daily for 2 weeks
11601278|NCT00639327|Experimental|A|CPT-11+ S-1
11601279|NCT00639327|Active Comparator|B|CPT-11
11601280|NCT00639314|Experimental|1|In PpPD, the proximal duodenum was divided 3-4cm distal to the pylorus ring
11601281|NCT00639314|Active Comparator|2|In PrPD, the stomach is divided just above the pylorus ring. the nearly total stomach more than 95% was preserved.
11601282|NCT00639301||1|Long term survivors of retinoblastoma
11601283|NCT00639288|Experimental|1|modified CPT-C
11601284|NCT00639262|Experimental|Cohort 1 - Brain Metastasis|Sorafenib and Radiotherapy
11601285|NCT00639262|Experimental|Cohort 2 - Gliomas|Sorafenib and Radiotherapy, plus Temozolomide
11601286|NCT00639249|Placebo Comparator|P|Placebo
11601287|NCT00639249|Experimental|A1|SA4503
11601288|NCT00639249|Experimental|A2|SA4503
11601289|NCT00639223|Active Comparator|Pravastatin|
11601290|NCT00639223|Experimental|Red yeast Rice|
11601291|NCT00639210|Other|A|Supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.
11601292|NCT00639210|No Intervention|B|
11601293|NCT00639197|Active Comparator|1|To Tunnel
11601294|NCT00639197|Active Comparator|2|Not to tunnel
11601295|NCT00639184|Experimental|1|Home intervention program
11601296|NCT00639184|Active Comparator|2|health education counseling
11601297|NCT00639171||1|Subjects with suspicious breast lesions that warrant further evaluation will be followed to determination and confirmation of diagnosis.
11601298|NCT00639171||2|Normal subjects used to evaluate software and to develop and optimize MR sequences will be examined.
11601299|NCT00639158|Active Comparator|ABT-335 + atorvastatin + ezetimibe|
11601300|NCT00639158|Placebo Comparator|Placebo + atorvastatin + ezetimibe|
11601301|NCT00639106|Experimental|A|Expander Placement WITH Alloderm
11601302|NCT00639106|Active Comparator|B|Expander Placement WITHOUT Alloderm
11601303|NCT00639093|Experimental|1|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).
~During the immersions in VR, 45 of the participants will use a virtual reality arm to catch and crush virtual cigarettes (on a computer)."
11601304|NCT00639093|Active Comparator|2|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).
~During the immersions in VR, the 45 participants in the control condition will use a virtual reality arm to catch and crush virtual fruits (on a computer)."
11601305|NCT00639080||Entire study population|All study subjects.
11601306|NCT00639067||1|"Asymptomatic High Risk Subjects. Smokers aged >=18 undergoing chest CT.
~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
11601307|NCT00639067||2|"Symptomatic High Risk Subjects Without a Tissue Diagnosis. This group will comprise patients who are undergoing medical evaluation for a pulmonary symptom such as chronic unexplained cough or hemoptysis.
~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
11601308|NCT00639067||3|"Symptomatic High Risk Subjects With a Tissue Diagnosis. This group will be found to include a. lung cancer, and b. diseases other than lung cancer e.g. sarcoidosis, COPD or pulmonary infection.
~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
11601309|NCT00639067||4|"Apparently healthy individuals having no signs and symptoms of lung carcinoma.
~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
11601310|NCT00639054||Newly diagnosed patients|Newly diagnosed high-dose therapy candidates. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) and blood samples (24 ml of peripheral blood) for biochemical and genetic analyses regarding multiple myeloma, and granting access to clinical data relating to multiple myeloma.
11601311|NCT00639054||Relapse patients|Formerly high-dose treated patients with progressive disease. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) and blood samples (24 ml of peripheral blood) for biochemical and genetic analyses regarding multiple myeloma, and granting access to clinical data relating to multiple myeloma.
11601312|NCT00639054||Healthy controls|Healthy blood and bone marrow donors. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) for genetic analyses serving to compare normal bone marrow with bone marrow from multiple myeloma patients.
11601313|NCT00639041|Placebo Comparator|placebo|
11601314|NCT00639041|Active Comparator|n-3 LC-PUFA|
11601315|NCT00639028|Other|1|Ankle echography
11601316|NCT00639028|Other|2|echography + stress radiography
11601317|NCT00639028|Other|3|stress radiography
11601318|NCT00639015|Experimental|1|Phenylephrine
11601319|NCT00639015|Active Comparator|2|Norepinephrine
11601500|NCT00637624|Placebo Comparator|2|Placebo
11601552|NCT00637247|Experimental|imexon + gemcitabine|imexon + gemcitabine
11601320|NCT00639002|Experimental|Ruxolitinib then Ruxolitinib + Dexamethasone|Patients received ruxolitinib 25 mg orally twice daily (bid) in each treatment cycle of 28 days. For those patients who had disease progression at any time or stable disease for 3 cycles and did not meet a withdrawal criterion, or withdrew consent, then 40 mg of dexamethasone was added to ruxolitinib on Days 1 to 4, 9 to 12, and 17 to 20 of four 28-day cycles. After the 4th cycle, 40 mg of dexamethasone was administered only on Days 1 to 4 of each subsequent cycle. Patients could continue to receive monotherapy or combination therapy indefinitely as long as no withdrawal criterion was met, did not have progressive disease and were receiving some clinical benefit.
11601321|NCT00638989|Experimental|CAT-354 150 mg (intravenous)|A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
11601322|NCT00638989|Experimental|CAT-354 150 mg (subcutaneous)|A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
11601323|NCT00638989|Experimental|CAT-354 300 mg (subcutaneous)|A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
11601324|NCT00638976|Other|1.Integrilin, GSK|Pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide (Integrilin, GSK) vs matched placebo.
11601325|NCT00638976|Placebo Comparator|2|Pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide (Integrilin, GSK) vs matched placebo.
11601326|NCT00638963|Experimental|Temozolomide|
11601327|NCT00638963|No Intervention|Observational|
11601328|NCT00638950|Placebo Comparator|Placebo|
11601329|NCT00638950|Active Comparator|n-3 LC-PUFA|
11601330|NCT00638937|Experimental|Treatment (saracatinib)|Patients receive saracatinib PO, at a dose of 175 mg QD on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression
11601331|NCT00638924||Exercise Capacity|Individuals from the female gender; age range of 20 to 30 years old; considered healthy (i.e. with no diagnosed health condition; considered sedentary (i.e. performing less than 150 minutes of moderate intensity physical activity per week); will be asked to volunteer in the research and perform a exercise capacity test.
11601332|NCT00638911||Patients with hypertention|
11601333|NCT00638898|Experimental|Arm I|See Detailed Description
11601334|NCT00638885||Group 1|
11601335|NCT00638872|Experimental|1|PDRN
11601336|NCT00638872|Placebo Comparator|placebo|placebo
11601337|NCT00638846|Experimental|senofilcon A toric|senofilcon A, daily wear, toric contact lens worn for two weeks
11601338|NCT00638846|Active Comparator|balafilcon A toric|balafilcon A, daily wear, toric contact lens worn for two weeks
11601339|NCT00638833|Active Comparator|A|Memantine 30 mg/day
11601340|NCT00638833|Placebo Comparator|B|Placebo
11601341|NCT00638820|Experimental|Intent-To-Treat|Patients enrolled and received study treatment.
11601342|NCT00638807|Experimental|A|
11601343|NCT00638807|Placebo Comparator|B|
11601344|NCT00638794||Surgical|Patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications.
11601345|NCT00638794||Observational|Consecutive patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications
11601346|NCT00638781|Active Comparator|1|Desmoteplase 62.5 µg/kg BW i.v. bolus
11601347|NCT00638781|Active Comparator|2|Desmoteplase 90 µg/kg BW i.v. bolus
11601348|NCT00638781|Active Comparator|3|Desmoteplase 125 µg/kg BW i.v. bolus
11601349|NCT00638781|Placebo Comparator|4|Placebo i.v. bolus
11601350|NCT00638768|Active Comparator|Physiotherapy|Including 10 individual visits with a physiotherapist and home exercises
11601351|NCT00638768|No Intervention|2|Usual care
11601352|NCT00638755|Experimental|1|The following treatment sequence: A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide), D (placebo)
11601353|NCT00638755|Experimental|2|The following treatment sequence: B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide), D (placebo), A (Nasal Carbon Dioxide)
11601354|NCT00638755|Experimental|3|The following treatment sequence: C (Nasal Carbon Dioxide), D (placebo), A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide)
11601355|NCT00638755|Experimental|4|The following treatment sequence: D (placebo), A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide)
11601356|NCT00638742|Experimental|1|
11601357|NCT00638729|Active Comparator|Midazolam|Pre-anesthetic medication with midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
11601358|NCT00638729|Active Comparator|Clonidine|pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
11601359|NCT00638729|Placebo Comparator|Placebo|Pre-anesthetic medication with an inert tablet, p.o., 60-90 min prior to estimated induction time
11601360|NCT00638716|Experimental|1|12 weekly doses of 1.5 mg CJC-1134-PC
11601361|NCT00638716|Experimental|2|4 weekly doses of 1.5 mg CJC-1134-PC followed by 8 weekly doses of 2.0 mg CJC-1134-PC
11601362|NCT00638716|Placebo Comparator|3|12 weekly doses of placebo
11601363|NCT00638703|Experimental|I|Size 2 enteric coated capsule containg lyophilized Oxalobacter formigenes
11601364|NCT00638703|Placebo Comparator|II|Size 2 enteric coated capsule containg placebo
11601365|NCT00638690|Experimental|Abiraterone acetate plus prednisone/prednisolone|
11601366|NCT00638690|Placebo Comparator|Placebo plus prednisone/prednisolone|
11601367|NCT00638677|Placebo Comparator|1|Sorbitol tablet
11601368|NCT00638677|Placebo Comparator|2|Xylitol tablet
11601369|NCT00638677|Active Comparator|3|Xylitol + BB12 tablet
11601370|NCT00638651|Active Comparator|1|The tattoo will be treated with laser and imiquimod 5% cream
11601371|NCT00638651|Placebo Comparator|2|The tattoo will be treated with laser and placebo topical cream
11601372|NCT00638638|Experimental|1|"Early Abciximab bolus during prehospital transportation in ambulance 0.25 mg/Kg iv with Heparin 40 UI/kg bolus.
~Abciximab placebo bolus and Abciximab infusion 10 µg/Kg/min after coronary angiography and before angioplasty."
11601373|NCT00638638|Experimental|2|"Abciximab placebo bolus during prehospital transportation in ambulance with Heparin 40 UI/kg bolus.
~Abciximab 0.25 mg/Kg bolus after coronary angiography and before angioplasty followed by Abciximab infusion 10 µg/Kg/min."
11601498|NCT00637650|Other|A|Control group: Patients in whom all fragments resulting from laser lithotripsy of ureteral stones were actively retrieved
11601374|NCT00638612|Experimental|A resectable|Arm A is for resectable tumors. The first AdV-tk course is given prior to surgery by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery again followed by 14 days of valacyclovir.
11601375|NCT00638612|Experimental|B locally advanced|"Arm B is for locally advanced tumors for which chemoradiation is the planned standard of care treatment. AdV-tk is delivered by CT or EUS guided injection into the tumor. The first AdV-tk injection is given prior to starting chemoradiation and the second in week 3 of chemoradiation. Both injections are followed by 14 days of valacyclovir.
~Enrollment has been completed for Arm B."
11601376|NCT00638599|Experimental|1|LMA® is placed after anesthesia induction till the end of operation
11601377|NCT00638599|Active Comparator|2|Standard tracheal tube is inserted after anesthesia induction till the end of operation
11601378|NCT00638586||1|Femoral access
11601379|NCT00638586||2|Radial access
11601380|NCT00638560|Experimental|1|"Antioxidant treatment arm:
~Vitamin E, 400 IU po, once daily Vitamin C, 1g po, twice daily"
11601381|NCT00638560|Placebo Comparator|2|Control
11601382|NCT00638547|Experimental|Intent-to-Treat|All patients who have received at least one dose of Laronidase.
11601383|NCT00638508|Active Comparator|Ketorolac|Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
11601384|NCT00638508|Experimental|Ketorolac with Ropivacaine|Patients will receive Ketorolac 5 mg and Ropivacaine 0.5% (Group 2) via an infusion catheter at the incision site
11601385|NCT00638495|Experimental|1|
11601386|NCT00638495|Placebo Comparator|2|
11601387|NCT00638482|Experimental|1|Hydrochlorothiazide
11601388|NCT00638469|Other|left/right|left or right body side
11601389|NCT00638456|Active Comparator|1|oral viscous budesonide plus Prevacid
11601390|NCT00638456|Placebo Comparator|2|placebo plus Prevacid
11601391|NCT00638443|Other|Pregabalin then Diphenhydramine|Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days; no drug for 7 days; diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
11601392|NCT00638443|Other|Diphenhydramine then Pregabalin|diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days; no drug for 7 days; pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
11601393|NCT00638430||1|low myopic group
11601394|NCT00638430||2|moderate myopic group
11601395|NCT00638417|Experimental|maximal strength training|maximal dynamic strength training
11601396|NCT00638417|Other|conventional rehabilitation|rehabilitation as usual
11601397|NCT00638404||1|Elective Cesarean Sections-this portion completed
11601398|NCT00638404||3|Any in-patient gynecologic procedure- this portion completed
11601399|NCT00638391||1|all patients treated with Anastrozole
11601400|NCT00638378|Experimental|Ruxolitinib|Participants received ruxolitinib 25 mg orally twice daily in 12-hour intervals for 21-day cycles for as long as the study medication was tolerated and provided clinical benefit.
11601401|NCT00638365|Experimental|1|KB001, a monoclonal antibody
11601402|NCT00638365|Placebo Comparator|2|Placebo
11601403|NCT00638339||1|critically ill patients undergoing invasive mechanical ventilation in medical ICU and CCU
11601404|NCT00638339||2|critically ill patients undergoing noninvasive mechanical ventilation in medical ICU and CCU
11601405|NCT00638326|No Intervention|1|Patients who show adequate response to 600 mg loading dose of clopidogrel and receive standard 1x75 mg clopidogrel
11601406|NCT00638326|Experimental|2|Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x150 mg clopidogrel for 28 days
11601407|NCT00638326|Active Comparator|3|Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x75 mg clopidogrel
11601408|NCT00638313|Placebo Comparator|Placebo|
11601409|NCT00638313|Experimental|PF-04603629|
11601410|NCT00638300|Experimental|1|large pore dialyzers (FX80, Fresenius, Germany)
11601411|NCT00638300|Experimental|2|small pore dialyzers ( F8HPS, Fresenius, Germany)
11601412|NCT00638300|Experimental|A|dialysate bicarbonate concentration of 33 mEq/l
11601413|NCT00638300|Experimental|B|dialysate bicarbonate concentration of 40 mEq/l
11601414|NCT00638300|Experimental|I|dialysate calcium concentration of 3 mEq/L
11601415|NCT00638300|Experimental|II|dialysate calcium concentration of 2.5 mEq/L
11601416|NCT00638274|Active Comparator|Air|Air 3 ml used to identify epidural space
11601417|NCT00638274|Active Comparator|Saline|Saline 3 ml used to identify epidural space
11601418|NCT00638261|Other|left/right|left or right body side
11601419|NCT00638248|Active Comparator|1|Desmoteplase 90µg/kg BW
11601420|NCT00638248|Active Comparator|2|Desmoteplase 125 µg/kg BW
11601421|NCT00638248|Placebo Comparator|3|Placebo
11601422|NCT00638235||Phase I (IntePro, US only)|AMS Apogee™ with IntePro(Began May 2006 - Closed)
11601423|NCT00638235||Phase I (InteXen LP, US only)|AMS Apogee™ with InteXen LP (Began May 2006 - Closed)
11601424|NCT00638235||Phase II (France only)|AMS Perigee™ with IntePro (Began February 2007 - Closed)
11601425|NCT00638235||Phase III/IV (Perigee IntePro Lite, US only)|AMS Perigee™ with IntePro Lite (Began April 2007 - Closed)
11601426|NCT00638235||Phase III/IV (Apogee IntePro Lite, US only)|AMS Apogee™ with IntePro Lite (Began April 2007 - Closed)
11601427|NCT00638235||Phase V (Elevate Posterior IntePro Lite, US & EU)|AMS Elevate™ Apical & Posteiror with IntePro Lite (Began April 2008 - Closed)
11601428|NCT00638235||Phase V (Elevate Posterior InteXen, US only)|AMS Elevate™ Apical & Posteiror with IntXen LP (Began April 2008 - Closed)
11601429|NCT00638235||Phase VI (Elevate Anterior Gen 1, For Study Use Only, EU only)|AMS Elevate™ Anterior & Apical with IntePro Lite (Generation 1, For Study Use Only, Began October 2008 - Closed)
11601430|NCT00638235||Phase VII (Elevate Anterior Gen 2, US & EU)|AMS Elevate™ Anterior & Apical with IntePro Lite (Generation 2, Began April 2009 - Closed)
11601548|NCT00637273|Active Comparator|2|
11601431|NCT00638222|Active Comparator|All Study Participants|All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
11601432|NCT00638209|Active Comparator|I|
11601433|NCT00638209|Placebo Comparator|P|
11601434|NCT00638196|Experimental|1|placebo/active crossover
11601435|NCT00638170|Active Comparator|A|Cranberry juice
11601436|NCT00638170|Placebo Comparator|B|Placebo juice
11601437|NCT00638157|Active Comparator|Daptomycin Alone|daptomycin 6 mg/kg q24h for treatment of right-sided infective endocarditis
11601438|NCT00638157|Experimental|Daptomycin plus gentamicin|daptomycin 6 mg/kg q24h with concomitant initial gentamicin dosed for the first 2 days of therapy for the treatment of right-sided infective endocarditis
11601439|NCT00638144||1|patients with resolved infection
11601440|NCT00638144||2|chronically infected patients
11601441|NCT00638131|Experimental|1|Bosentan 62.5mg bid x4 weeks; up-titrated to 125mg bid x12 weeks;
11601442|NCT00638131|Placebo Comparator|2|placebo given bid same as experimental arm;
11601443|NCT00638092|Experimental|Iodine|This is the hypothetical active arm
11601444|NCT00638092|Placebo Comparator|Placebo|this is the hypothetical placebo
11601445|NCT00638079|Experimental|A|Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) with a high fat meal
11601446|NCT00638079|Active Comparator|B|Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) following an overnight fast
11601447|NCT00638066|Experimental|1|
11601448|NCT00638066|Active Comparator|2|
11601449|NCT00638053|Experimental|1|
11601450|NCT00638040||1|The purpose of this study is to analyze the gene expression patterns associated with various microenvironmental stresses in tumors to understand their roles in tumor progression and treatment responses. To achieve this goal, we will perform gene expression analysis of the tumor samples collected from an IRB-approved study (IRB #: 4516-05-2R2) International Phase III Study of Chemoradiotherapy versus Chemoradiotherapy Plus Hyperthermia for Locally Advanced Cervical Cancer directed by Dr. Mark Dewhirst. We will correlate the gene expression signatures of different microenvironmental stresses with the measured physiological parameters to understand their role in tumor progression, treatment response and clinical outcomes.
11601451|NCT00638027|Experimental|1|Memantine 10 mg bid
11601452|NCT00638027|Placebo Comparator|2|Placebo
11601453|NCT00638014|Active Comparator|1|Conventional wires only
11601454|NCT00638014|Experimental|2|Rapid Sternal Closure System supplemented with wires
11601455|NCT00637988|Experimental|1|Nexium 40mg
11601456|NCT00637988|Experimental|2|Nexium 40mg + aspirin
11601457|NCT00637988|Experimental|3|Nexium 40mg + Rofecoxib 25 mg
11601458|NCT00637988|Active Comparator|4|Rofecoxib 25mg
11601459|NCT00637975|Experimental|A|oxycodone 20 mg/day plus pregabalin at increasing dose starting from 50 mg/day for 15 days or until unacceptable toxicity develops
11601460|NCT00637975|Active Comparator|B|pregabalin 50 mg/day plus oxycodone at increasing dose starting from 20 mg/day. For 15 days or until unacceptable toxicity develops
11601461|NCT00637962|Experimental|Active product|CN54gp140 + gel
11601462|NCT00637962|Placebo Comparator|Gel alone|Gel alone
11601463|NCT00637949|Experimental|1|
11601464|NCT00637949|Active Comparator|2|
11601465|NCT00637936|Active Comparator|1|Group 1 is given 30% oxygen during and 2 hours after surgery
11601466|NCT00637936|Active Comparator|2|Group 2 is given 80% during and 2 hours after surgery.
11601467|NCT00637923|Experimental|1|One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
11601468|NCT00637923|Placebo Comparator|2|One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
11601469|NCT00637910|Experimental|Erlotinib Arm|
11601470|NCT00637910|Active Comparator|Docetaxel Arm|
11601471|NCT00637897|Experimental|Paricalcitol (Zemplar)|Paricalcitol (Zemplar)
11601472|NCT00637871|Experimental|1|
11601473|NCT00637871|Active Comparator|2|
11601474|NCT00637858|Placebo Comparator|1|
11601475|NCT00637858|Active Comparator|2|Lyc-o-Mato 5mg
11601476|NCT00637858|Active Comparator|3|Lyc-o-Mato 15mg
11601477|NCT00637858|Active Comparator|4|Lyc-o-Mato 30mg
11601478|NCT00637858|Active Comparator|5|Lycopene capsules (non Lyc-o-mato) 15 mg
11601479|NCT00637845|Experimental|1|40mg once daily
11601480|NCT00637845|Active Comparator|2|30mg twice daily
11601481|NCT00637806|Active Comparator|1|Megestrol acetate concentrated suspension 110 mg/mL
11601482|NCT00637806|Active Comparator|2|Megestrol acetate concentrated suspension 60 mg/mL
11601483|NCT00637806|Placebo Comparator|3|
11601484|NCT00637793|Placebo Comparator|1|Placebo capsules
11601485|NCT00637793|Experimental|2|2 capsules in the am of each treatment period
11601486|NCT00637793|Experimental|3|2 capsules in the am of each treatment period
11601487|NCT00637793|Experimental|4|2 capsules in am of each treatment period
11601488|NCT00637780|Experimental|1|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 6 days
11601489|NCT00637741|Experimental|Everflex 200|study group treated with at least one 200 mm Everflex stent
11601490|NCT00637728|Active Comparator|1|Megestrol acetate concentrated suspension 110 mg/mL
11601491|NCT00637728|Placebo Comparator|2|Placebo suspension
11601492|NCT00637702|Experimental|ARRY-334543|
11601493|NCT00637676|Active Comparator|1|Implantation of PleurX-Pleural catheter plus talc pleurodesis
11601494|NCT00637676|Active Comparator|2|talc pleurodesis, no implantation of PleurX-Pleural catheter
11601495|NCT00637663|Experimental|A|entecavir 0.5 mg QD
11601496|NCT00637663|Active Comparator|B|lamivudine 100 mg QD
11601497|NCT00637650|Experimental|B|"Experimental group: patients in whom stone dust was left for spontaneous elimination"
11601501|NCT00637598|Experimental|Tomosynthesis scans|This is a case-only study with only one group/cohort. All women receive both mammography and tomosynthesis imaging.
11601502|NCT00637572|Experimental|Megestrol acetate oral suspension nanocrystal dispersion|Megestrol acetate oral suspension nanocrystal dispersion formulation 115 mg/mL
11601503|NCT00637572|Active Comparator|Megestrol acetate oral suspension micronized formulation|Megestrol acetate oral suspension micronized formulation 60 mg/mL
11601504|NCT00637559|Experimental|1|40mg twice daily
11601505|NCT00637559|Experimental|2|40mg three times daily
11601506|NCT00637559|Experimental|3|20mg three times daily
11601507|NCT00637546|Experimental|A,1|Physiotherapy
11601508|NCT00637533|Placebo Comparator|Placebo|Saline injection
11601509|NCT00637533|Experimental|Botulinum Toxin Type A|Sympathetic Blockade containing Botulinum Toxin Type A
11601510|NCT00637520||1|Subjects with NAFLD
11601511|NCT00637520||2|Subjects without liver disease
11601512|NCT00637520||3|Subjects with non-steatotic hepatitis
11601513|NCT00637507|No Intervention|2|Patients treated solely with a pressure- and volume-limited ventilatory strategy (target plateau pressure of 30 cm H2O) aimed at minimizing lung stress and strain, and thus, ventilator-induced lung injury.
11601514|NCT00637507|Experimental|1|Intermittent application of High-frequency Oscillation (HFO) and Tracheal Gas Insufflation (TGI) according to pre-specified criteria described in the Detailed Description. HFO-TGI sessions are interspersed with lung protective conventional mechanical ventilation until the PaO2/FiO2 ratio stabilizes at >150 mm Hg.
11601515|NCT00637494|Active Comparator|1|Mifepristone followed by an antidepressant
11601516|NCT00637494|Placebo Comparator|2|Placebo followed by an antidepressant
11601517|NCT00637481|Experimental|Arm I (lower dose atorvastatin calcium)|Participants receive oral atorvastatin once daily for 3 months.
11601518|NCT00637481|Experimental|Arm II (atorvastatin calcium)|Participants receive oral atorvastatin (at a higher dose than in arm I) once daily for 3 months.
11601519|NCT00637481|Experimental|Arm III (higher dose atorvastatin calcium)|Participants receive oral atorvastatin (at a higher dose than in arm II) once daily for 3 months.
11601520|NCT00637481|Other|Arm IV (no intervention)|Participants do not receive treatment. Participants undergo blood sample collection and fine needle aspiration of breast tissue at baseline and at 3 months for correlative biomarker studies.
11601521|NCT00637468|Experimental|1|Local intra-arterial fibrinolysis (LIF)
11601522|NCT00637468|Active Comparator|2|Conservative standard therapy
11601523|NCT00637442|Experimental|CASL-MRI|Drug monitoring with CASL-MRI for new diagnosed patients with mild to moderate Alzheimer's Disease treated with Reminyl
11601524|NCT00637429||General Co-infection|Individuals with HIV infection and hepatitis B surface antigen positive results who are currently receiving or planning to commence HAART.
11601525|NCT00637416|Active Comparator|Lansoprazole and dietary control|Lansoprazole and dietary control
11601526|NCT00637416|Placebo Comparator|Placebo and dietary control|Dietary control and placebo
11601527|NCT00637403|Active Comparator|I|Megestrol acetate concentrated suspension in subjects with normal renal function
11601528|NCT00637403|Experimental|II|Megestrol acetate concentrated suspension in subjects with mild renal impairment
11601529|NCT00637403|Experimental|III|Megestrol acetate concentrated suspension in subjects with moderate renal impairment
11601530|NCT00637403|Experimental|IV|Megestrol acetate concentrated suspension in subjects with severe renal impairment
11601531|NCT00637403|Experimental|V|Megestrol acetate concentrated suspension in subjects with end stage renal disease
11601532|NCT00637390|Experimental|one|
11601533|NCT00637377|Active Comparator|Ranibizumab 0.5mg Q4|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
11601534|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
11601535|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
11601536|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
11601537|NCT00637351||Group A|Subjects with diagnosed pneumonia & positive culture of streptococcus pneumoniae
11601538|NCT00637351||Group B|Subjects with diagnosed pneumonia & positive culture of non-typable haemophilus influenzae
11601539|NCT00637338|Experimental|PF-04603629|The dose range initially planned is 3 mg up to 70 mg, although the specific doses administered may be modified based on emerging study data.
11601540|NCT00637338|Placebo Comparator|Placebo|
11601541|NCT00637325|Experimental|A|"In the maintenance study:
~ARM A: maintenance of trastuzumab
~In the 2nd line study:
~ARM A: trastuzumab plus chemotherapy treatment"
11601542|NCT00637325|No Intervention|B|"In the maintenance study:
~ARM B: interruption of trastuzumab treatment
~In the 2nd line study:
~ARM B: chemotherapy alone"
11601543|NCT00637312|Experimental|Advent™ Cervical Disc|Cervical artificial disc replacement: Advent™ Cervical Disc
11601544|NCT00637312|Active Comparator|Standard care - Control|Anterior cervical discectomy and fusion (ACDF) with Hallmark™ Anterior Cervical Plate System
11601545|NCT00637299|Active Comparator|Active osteopathic treatment (OMT+PR)|The examination was performed by osteopathic practitioners with emphasis on the neuromusculoskeletal system including palpatory diagnosis for somatic dysfunction and viscerosomatic change, in the context of total patient care. The examination was concerned with range of motion of all parts of the body, performed with the patient in multiple positions to provide static and dynamic evaluation.
11601546|NCT00637299|Sham Comparator|SOT + PR|Sham osteopathic treatment (manipulation)
11601547|NCT00637273|Experimental|1|
11601553|NCT00637247|Active Comparator|Placebo + gemcitabine|Placebo in combination with gemcitabine
11601554|NCT00637234|Experimental|1|
11601555|NCT00637234|Placebo Comparator|2|
11601556|NCT00637208|Experimental|1|
11601557|NCT00637208|No Intervention|2|Watch-full follow-up
11601558|NCT00637195|Experimental|Cervarix™ & Engerix™ Group|Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™) (Months 0, 1 & 6) and 4 doses of Hepatitis B (Engerix™) vaccine (Months 0, 1, 2 & 12).
11601559|NCT00637195|Active Comparator|Engerix™ Group|Subjects received 4 doses of Hepatitis B (HBV) vaccine (Months 0, 1, 2 & 12).
11601560|NCT00637169|Experimental|1|Supplemental oxygen to maintain functional arterial oxygen saturations in the range of 85-89%. Dose of oxygen is determined by the individual infant's need to achieve the target oxygen saturations.
11601561|NCT00637169|Active Comparator|2|Supplemental oxygen to maintain functional arterial oxygen saturations in the range of 91-95%. Dose of oxygen is determined by the individual infant's need to achieve the target oxygen saturations.
11601562|NCT00637156|Experimental|PRESTIGE LP Device|
11601563|NCT00637156|Other|ATLANTIS Cervical Plate System|
11601564|NCT00637143|Experimental|1|Oral
11601565|NCT00637143|Active Comparator|2|Oral
11601566|NCT00637130|Experimental|Travoprost 0.0008%|Travoprost ophthalmic solution, 0.0008%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
11601567|NCT00637130|Experimental|Travoprost 0.001%|Travoprost ophthalmic solution, 0.001%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
11601568|NCT00637130|Experimental|Travoprost 0.0012%|Travoprost ophthalmic solution, 0.0012%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
11601569|NCT00637130|Active Comparator|TRAVATAN + Vehicle|TRAVATAN, one drop in study eye(s) once daily (8 PM), and Vehicle, one drop in study eye(s) once daily (8 AM), for two weeks
11601570|NCT00637130|Placebo Comparator|Vehicle|Vehicle, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
11601571|NCT00637104|Experimental|A - Mar-tyn|It includes the implant of the Mar-tyn TiN coated stent
11601572|NCT00637104|Active Comparator|B - Vision|Includes all the patients treated with the Vision stent
11601573|NCT00637091|Experimental|EGFR expression|Patients' accrual will be adjusted by EGFR expression (positive vs. negative)
11601574|NCT00637078|Active Comparator|1|Drug: Fix dose combination therapy
11601575|NCT00637078|No Intervention|2|Guidelines based management
11601576|NCT00637065|Active Comparator|1|Bosentan tablets (62.5mg bd for first 4 weeks, then 125mg bd as tolerated)
11601577|NCT00637065|Placebo Comparator|2|Placebo tablets
11601578|NCT00637052|Experimental|ARRY-520|
11601579|NCT00637013|Active Comparator|Acromioplasty|Acromioplasty + physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
11601580|NCT00637013|Active Comparator|Physiotherapy|Physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
11601581|NCT00637000|Experimental|Buprenorphine soluble film|"Day 1: Buprenorphine soluble film administered at a dose of 4 mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.
~Days 2-5: Buprenorphine soluble film administered at a dose of 16 mg to 24 mg once per day, plus placebo. Dosing occurred at 0900 hours."
11601582|NCT00637000|Experimental|Buprenorphine/naloxone soluble film|"Day 1: Buprenorphine/naloxone soluble film administered at a dose of 4mg/1mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.
~Days 2 to 5: Buprenorphine/naloxone soluble film administered at a dose of 16mg/4 mg to 24 mg/6 mg once per day, plus placebo. Dosing occurred at 0900 hours."
11601583|NCT00636987|Other|Implanted with Biocor or Biocor Supra Valves|
11601584|NCT00636961|Experimental|Sequence 1: Indacaterol 300μg followed by Placebo|In period I, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. In period II, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. For each treatment period and for each patient, the doses were to be administered between 7am and 12am. A period of at least 4 days but no more than 21 days separated each treatment period. Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
11601585|NCT00636961|Experimental|Sequence 2 : Placebo followed by Indacaterol 300μg|In period I, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. In period II, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. For each treatment period and for each patient, the doses were to be administered between 7am and 12am. A period of at least 4 days but no more than 21 days separated each treatment period. Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
11601586|NCT00636935|Experimental|1|Antibiotic only therapy in patients with PCP and a pO2 of > 70mmHg.
11601587|NCT00636935|Experimental|2|Antibiotics and Corticosteroid therapy in patients with PCP and pO2 >70 mmHg.
11601588|NCT00636935|Active Comparator|3|Standard of care therapy for patients with PCP and pO2 < 70mmHg.
11601589|NCT00636922|Experimental|Everolimus with 5-azacitidine|Everolimus increasing oral doses days 5-21 each cycle 5-azacitidine 75mg sub cutaneously 7 doses in 21 days
11601590|NCT00636909|Experimental|1|Study treatment arm with G-CSF
11601591|NCT00636896|Experimental|1|Olanzapine 10 mg plus modafinil 200 mg
11601592|NCT00636896|Placebo Comparator|2|Olanzapine plus Placebo
11601593|NCT00636857|Experimental|I|Perioperative fluid management based on body weight
11601594|NCT00636857|Active Comparator|II|Perioperative fluid management based on Lean Body Mass (LBM)
11601595|NCT00636844||Group A|Patients receiving chemotherapy (anthracycline and/or adjuvant trastuzumab) for the first time
11601596|NCT00636831|Placebo Comparator|cont|
11601597|NCT00636831|Active Comparator|intervention|
11601598|NCT00636818|Experimental|Atomoxetine|
11601599|NCT00636805|Experimental|1|Patient receives IV Aloxi
11601600|NCT00636792|Experimental|1|This is a phase 2, single-arm, open label, multicenter study evaluating the efficacy and safety of the combination of VELCADE, bendamustine, and rituximab in subjects with relapsed or refractory follicular lymphoma, who have received 4 or more doses of rituximab. Subjects may be sensitive or refractory to prior therapies, including rituximab.
11601601|NCT00636779||1|Up to five hundred eligible patients seen at each of the nine participating Integrative Medicine Centers will be approached (by mail, phone, at the time of their visit, etc.) and invited to consent to the paper and pencil study.
11601602|NCT00636766|Experimental|1|
11601603|NCT00636753||1|schizophrenic patients
11601604|NCT00636753||2|controls
11601605|NCT00636740|Experimental|B|MER-101 20mg Tablets Regimen 1
11601606|NCT00636740|Experimental|C|MER-101 20mg Tablets Regimen 2
11601607|NCT00636740|Active Comparator|A|Zometa Injection
11601608|NCT00636727|Active Comparator|1|arthrocentesis
11601609|NCT00636727|Active Comparator|2|arthroscopy
11601610|NCT00636727|Active Comparator|3|arthroplasty
11601611|NCT00636714|Experimental|Nurse-directed|Using nursing judgement to control blood glucose
11601612|NCT00636714|Active Comparator|Nomogram-directed|Blood glucose control directed by pre-approved paper nomogram
11601613|NCT00636701|Experimental|Primed rTMS|Receive 10 min. of 6-Hz rTMS Repetitive Transcranial Magnetic Stimulation at 90% RMT (3,600 pulses). Followed by 30 min. of 1-Hz rTMS at 95% RMT (1,880 pulses)
11601614|NCT00636701|Placebo Comparator|Unprimed rTMS)|Receive 10 min. of sham rTMS Repetitive Transcranial Magnetic Stimulation. Followed by 30 min. of 1-Hz rTMS at 95% RMT (1,880 pulses)
11601615|NCT00636688|Experimental|1|Behavioral (Lifestyle Counseling)
11601616|NCT00636688|Active Comparator|2|Control group
11601617|NCT00636675|Experimental|Fall QI|Falls QI includes quality improvement training about falls to be implement by indigenous nursing home staff with support of study personnel.
11601618|NCT00636675|Experimental|Connect & Falls QI|Connect is delivered, followed by Falls. Behavioral intervention to improve staff interaction for better care planning and execution. Connect will be delivered, followed by the Falls quality improvement intervention.
11601619|NCT00636662||all|any patient exhibiting symptoms of influenza
11601620|NCT00636649|Experimental|A|Escitalopram
11601621|NCT00636649|Placebo Comparator|B|Placebo
11601622|NCT00636636|Experimental|G-ER|Gabapentin - Extended Release
11601623|NCT00636636|Placebo Comparator|Placebo|Sugar pill
11601624|NCT00636623|Other|2|Pilates exercises
11601625|NCT00636623|Other|1|Connective tissue massage
11601626|NCT00636610|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily starting on Day 3 of each 2-week treatment cycle. In addition, patients received either Modified FOLFOX (FOL=leucovorin calcium [folinic acid], F=fluorouracil, OX=oxaliplatin) + bevacizumab or FOLFIRI (FOL=leucovorin calcium [folinic acid] F=fluorouracil, IRI=irinotecan hydrochloride) + bevacizumab on Days 1-3 of each 2-week treatment cycle. The decision of which regimen (FOLFOX or FOLFIRI) to use was made by the treating physician and patient.
11601627|NCT00636610|Placebo Comparator|Placebo to vismodegib|Patients received placebo to vismodegib orally once daily starting on Day 3 of each 2-week treatment. In addition, patients received either Modified FOLFOX (FOL=leucovorin calcium [folinic acid], F=fluorouracil, OX=oxaliplatin) + bevacizumab or FOLFIRI (FOL=leucovorin calcium [folinic acid] F=fluorouracil, IRI=irinotecan hydrochloride) + bevacizumab on Days 1-3 of each 2-week treatment cycle. The decision of which regimen (FOLFOX or FOLFIRI) to use was made by the treating physician and patient.
11601628|NCT00636597||1|
11601629|NCT00636584|Experimental|1|arm1: sodium nitroprusside group
11601630|NCT00636584|Placebo Comparator|2|arm2: control group,saline infused instead of sodium nitroprusside
11601631|NCT00636558|Experimental|CVA21|IV administration of CVA21 in a dose escalation manner
11601632|NCT00636545|Experimental|Part 1|Cohort 1- Genasense will be administered as a 2-hour intravenous infusion once weekly for 3 weeks at a dose of 300 mg to the first subject enrolled and, in the absence of dose-limiting toxicity, in increasing increments of 100 mg to each successive subject enrolled to a maximum dose of 1000 mg.
11601633|NCT00636545|Experimental|Part 2|Genasense will be administered as a 2-hour intravenous infusion twice weekly for 3 weeks at a dose established based on Part 1 of the study.
11601634|NCT00636545|Experimental|Cohort 2|Also in Part 1 of the study, Genasense will be administered as a 2-hour intravenous infusion once weekly for 3 weeks at a starting dose of 1100 mg and increasing in increments of 100 mg to the MTD. Patients will be pretreated with a corticosteroid.
11601635|NCT00636519|Experimental|Stage A|Botulism Antitoxin Bivalent (Equine) Types A and B Vs. Placebo
11601636|NCT00636519|Experimental|Stage B|Botulism Antitoxin Heptavalent (Equine) Types A-G Vs. Placebo
11601637|NCT00636506|Experimental|AMS 700 IPP 2005 Implant Group|Male subjects 21 years of age and older who are implanted with an AMS 700 IPP with MS (Momentary Squeeze) pump for erectile dysfunction.
11601638|NCT00636493|Experimental|Vein Occlusion Eye|Eye with retinal vein occlusion receiving fluocinolone acetonide sustained drug delivery device
11601639|NCT00636480|Experimental|CHG 2%-26 ml|Chlorhexidine gluconate in an aqueous base, 26 ml applicator
11601640|NCT00636480|Active Comparator|ChloraPrep 26 ml|ChloraPrep One-Step 26 ml Active drug contains chlorhexidine gluconate and alcohol
11601641|NCT00636480|Placebo Comparator|Sterile Saline|Sterile salt water administered topically.
11601642|NCT00636467|Experimental|No label|Injection of Nanocis® or Nanocoll® (Tc-colloid) on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)
11601643|NCT00636454|Active Comparator|1|This group will serve as the control group and will receive only the care usually given to OA patients.
11601644|NCT00636454|Experimental|2|This group will take part in the 10-session treatment program that will teach patients cognitive and behavioral skills to cope with pain.
11601645|NCT00636441|Active Comparator|Guided Arm|"Genomically-guided treatment allocation.
~This arm has the following cohorts:
~AC sensitive patients [>60% probability of response to AC]
~TC sensitive patients [>60% probability of response to TC]
~Patients sensitive to neither AC nor TC; randomized to AC or TC"
11601646|NCT00636441|Active Comparator|Non-Guided Arm|"Non-genomically-guided treatment allocation.
~This arm has the following cohorts:
~In patients randomly assigned to AC:
~Patients sensitive to AC
~Patients sensitive to TC
~Patients sensitive to neither AC nor TC
~In patients randomly assigned to TC:
~Patients sensitive to AC
~Patients sensitive to TC
~Patients sensitive to neither AC nor TC"
11601647|NCT00636428|Active Comparator|1|Oral midazolam
11601648|NCT00636428|Active Comparator|2|IV Midazolam
11601649|NCT00636415|Experimental|A|G1 patients received morphine intra-articular route G2 patients received bupivacaine without epinephrine.
11601650|NCT00636402|Experimental|1|Vessel Sealing System Tonsillectomy (VSST)
11601651|NCT00636402|Active Comparator|2|Cold Knife Tonsillectomy (CKT)
11601652|NCT00636389|Other|HD-C4 First, then 210H|Subjects will be randomly assigned to begin the first week of three consecutive treatments with the Polyflux HD-C4 dialyzer. Following the third treatment, the subjects will be switched to the Polyflux 210H dialyzer for a second week of three consecutive treatments. Therefore each subject will have a total of six consecutive dialysis treatments.
11601653|NCT00636389|Other|210H First, then HD-C4|Subjects will be randomly assigned to begin the first week of three consecutive treatments with the Polyflux 210H dialyzer. Following the third treatment, the subjects will be switched to the Polyflux HD-C4 dialyzer for a second week of three consecutive treatments. Therefore each subject will have a total of six consecutive dialysis treatments.
11601654|NCT00636376|Experimental|1|Single arm--no randomization. All subjects enrolled will have vitals collected and three ultrasounds at different levels of head of the bed elevations.
11601655|NCT00636363|Experimental|Multipurpose Solution - Rub Care|Bausch & Lomb Multipurpose Solution for use with contact lens care
11601656|NCT00636363|Experimental|Multipurpose Solution - No Rub Care|Bausch & Lomb Multipurpose Solution for use with contact lens care
11601657|NCT00636363|Active Comparator|Ciba Vision Aquify Multipurpose Solution|Ciba Vision Aquify Multipurpose Solution for use with contact lens care
11601658|NCT00636337|Experimental|1|Participants meeting inclusion criteria will be provided with a laptop computer outfitted with a wireless card for the duration of the intervention and will be trained in the use of RoboMemo in the clinic by study personnel. Although many participants may have ready access to home computers, we decided that all participants will be required to use laptops provided by the study for two reasons: 1) to ensure that coaches and participants are blind to treatment condition (as described above), and 2) to ensure that participants will always have access to the intervention program (i.e., they will not compete with other family members for computer time). Once trained, children will complete the intervention at home. The intervention will consist of four 30- to 45-minute sessions per week for 8 weeks (total = 32 sessions). This intervention schedule is similar to the schedule employed by Klingberg and colleagues in their home-based CT trials with ADHD children.
11601659|NCT00636337|Placebo Comparator|2|The design will be a double-blind, placebo-controlled trial in which half of the participants will be randomized to the intervention condition and half will receive a comparison computer program. Specifically, participants assigned to the comparison (placebo) condition will complete a modified version of the CT at home. The treatment and comparison CT programs begin identically, at the lowest difficulty level. Those in the treatment condition will complete activities of increasing difficulty over the intervention period. Those in the placebo condition, in contrast, will complete the same basic tasks during each session of the intervention, regardless of performance. In this way, a true estimate can be obtained of the efficacy of the treatment program.
11601660|NCT00636324|Experimental|1|Nasal CPAP, level of 7 to 9 cmH2O
11601661|NCT00636324|Active Comparator|2|Nasal CPAP, level 4 to 6 cmH2O
11601662|NCT00636311|Active Comparator|1|IGEV regimen (Ifosfamide, Gemcitabine, Vinorelbine)
11601663|NCT00636311|Experimental|2|B-IGEV (Bortezomib + IGEV)
11601664|NCT00636298|Experimental|A|Single arm treatment with combination of cetuximab and bevacizumab
11601665|NCT00636285|Placebo Comparator|1|Placebo
11601666|NCT00636285|Experimental|2|BSYX-A110, Dosed intravenously, 3mg/kg
11601667|NCT00636285|Experimental|3|BSYX-A110, Dosed intravenously, 10mg/kg
11601668|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-satellite150/4|
11601669|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-satellite150/6|
11601670|NCT00636246|Active Comparator|sertraline-satellite|
11601671|NCT00636246|Active Comparator|sertraline-main|
11601672|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-satellite150/2|
11601673|NCT00636246|Placebo Comparator|Placebo|
11601674|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-main|
11601675|NCT00636246|Active Comparator|[S,S]-reboxetine-main|
11601676|NCT00636233||Anencephaly|Fetuses with anencephaly, parents and siblings
11601677|NCT00636220||A, Observational|
11601678|NCT00636207|Experimental|Montelukast 0.1 mg|"Participants receive Montelukast inhalation powder, 0.1 mg.
~Part I: Administered as a single dose followed by at least a 3-day washout period."
11601679|NCT00636207|Experimental|Montelukast 0.3 mg|"Participants receive Montelukast inhalation powder, 0.3 mg.
~Part I: Administered as a single dose followed by at least a 3-day washout period."
11601680|NCT00636207|Experimental|Montelukast 1 mg|"Participants receive Montelukast inhalation powder, 1 mg.
~Part I: Administered as a single dose followed by at least a 3-day washout period.
~Part II: Administered once daily (QD) for 5 days followed by at least a 3-day washout period."
11601681|NCT00636207|Experimental|Montelukast 3 mg|"Participants receive Montelukast inhalation powder, 3 mg.
~Part I: Administered as a single dose followed by at least a 3-day washout period.
~Part II: Administered QD for 5 days followed by at least a 3-day washout period.
~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
11601682|NCT00636207|Experimental|Montelukast 10 mg|"Participants receive Montelukast inhalation powder, 10 mg.
~Part I: Administered as a single dose followed by at least a 3-day washout period.
~Part II: Administered QD for 5 days followed by at least a 3-day washout period.
~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
11601683|NCT00636207|Placebo Comparator|Placebo|"Participants receive Placebo to Montelukast inhalation powder.
~Part I: Administered as a single dose followed by at least a 3-day washout period.
~Part II: Administered QD for 5 days followed by at least a 3-day washout period.
~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
11601684|NCT00636194|Experimental|B&L Multipurpose solution|Bausch & Lomb Multipurpose Contact Lens Solution
11601685|NCT00636194|Active Comparator|Alcon Multipurpose Solution|Alcon OptiFree Replenish Multipurpose Contact Lens Solution
11601686|NCT00636181|Active Comparator|Auto Aflex|auto adjusting positive pressure therapy with AFLEX
11601687|NCT00636181|Active Comparator|Auto CPAP|auto adjusting positive pressure therapy
11601688|NCT00636181|Active Comparator|CPAP|continuous positive airway pressure
11601689|NCT00636168|Active Comparator|A|
11601690|NCT00636168|Placebo Comparator|B|
11601691|NCT00636155|Experimental|all patients|EL625 combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide)
11601692|NCT00636142|Active Comparator|1|Infliximab
11601693|NCT00636142|Placebo Comparator|2|Placebo
11601694|NCT00636129||1|Relaxation Response + Stress Management Curriculum
11601695|NCT00636116|Experimental|Group 1|Anavip with Anavip Maintenance Therapy
11601696|NCT00636116|Experimental|Group 2|Anavip with Placebo Maintenance Therapy
11601697|NCT00636116|Active Comparator|Group 3|CroFab with CroFab Maintenance Therapy
11601698|NCT00636103|Experimental|CUF2|
11601699|NCT00636103|Placebo Comparator|Placebo|
11601700|NCT00636077|Other|HD-C4 Big|3 consecutive treatments with the HD-C4 Big dialyzer.
11601701|NCT00636077|Other|HD-C4 Small|3 consecutive treatments with the HD-C4 Small dialyzer.
11601702|NCT00636077|Other|F160NR|3 consecutive treatments with the F160NR dialyzer.
11601703|NCT00636077|Other|F200NR|3 consecutive treatments with the F200NR dialyzer.
11601704|NCT00636064|Placebo Comparator|A|
11601705|NCT00636064|Experimental|B|
11601706|NCT00636064|Experimental|C|
11601707|NCT00636051||1|staff Registered Nurses receiving EBP peer mentoring
11601708|NCT00636051||2|staff Registered Nurses not receiving EBP peer mentoring
11601709|NCT00636025||Observational|
11601710|NCT00636012|Experimental|1|verum acupuncture
11601711|NCT00636012|Sham Comparator|2|sham acupuncture
11601712|NCT00635999|Experimental|Purely Behavioral therapy|Participants will receive treatment with progressive and applied relaxation and self-control desensitization.
11601713|NCT00635999|Experimental|Cognitive-Behavioral Therapy|Participants will receive treatment with cognitive therapy, progressive and applied relaxation, and self-control desensitization
11601714|NCT00635999|Experimental|Cognitive Therapy (CT)|Participants will receive purely cognitive therapy including identification of maladaptive thought processes and training in cognitive restructuring.
11601715|NCT00635986|Experimental|A|group 1 (n = 14) patients received 5 mL of a 100 mcg Fentanyl solution in saline without preservative by the epidural route and 2 mL saline intravenously. Group 2 (n = 15) patients received 5 mL saline by the epidural route and 2 mL (100 mcg) Fentanyl intravenously
11601716|NCT00635960|Experimental|1|Patients randomly assigned to treatment
11601717|NCT00635960|Placebo Comparator|2|Patients randomly assigned to placebo
11601718|NCT00635947|Active Comparator|1|isotonic solution - 1.5L
11601719|NCT00635947|Active Comparator|2|water- 1.5L
11601720|NCT00635947|Placebo Comparator|3|water-200mL
11601721|NCT00635934|Experimental|A-MAV™disc|
11601722|NCT00635921|Active Comparator|I ziprasidone|
11601723|NCT00635921|Placebo Comparator|II placebo|
11601724|NCT00635895|Active Comparator|1|Manual Lymph Drainage Therapy is a manual therapy method
11601725|NCT00635895|Active Comparator|2|Connective Tissue Massage
11601726|NCT00635882|Experimental|MF/F MDI 100/10 mcg|
11601727|NCT00635882|Experimental|MF/F MDI 200/10 mcg|
11601728|NCT00635882|Experimental|MF/F MDI 400/10 mcg|
11601729|NCT00635882|Experimental|MF DPI 200 mcg|
11601730|NCT00635882|Experimental|MF MDI 200 mcg|
11601731|NCT00635882|Experimental|Placebo|
11601732|NCT00635869||ARCC standard|RNs on unit receiving basic ARCC information with staff nurse champion
11601733|NCT00635869||ARCC enhanced|RNs on unit receiving ARCC standard content plus with an EBP mentor
11601734|NCT00635869||C|RNs on the unit receiving the placebo intervention
11601735|NCT00635843|Experimental|MAVERICK™ Disc|
11601736|NCT00635843|Active Comparator|Fusion|
11601737|NCT00635830|Experimental|1|Open Label
11601738|NCT00635817|Experimental|Leuprolide acetate 11.25 mg|There are 2 arms that received leuprolide acetate 11.25 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm A and subjects who have previously been treated with leuprolide acetate are designated to be in Arm B.
11601739|NCT00635817|Experimental|Leuprolide acetate 30 mg|There are 2 arms that received leuprolide acetate 30 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm C and subjects who have previously been treated with leuprolide acetate are designated to be in Arm D.
11601740|NCT00635804|Experimental|Pt 1: MK-3281 100 mg BID (Panel A)|Healthy male participants in this Part I serial panel receive 100 mg MK-3281 orally twice daily (BID) for 10 consecutive days for a total daily dose administered of 200 mg. The evening (PM) dose of MK-3281 was not administered on Day 10.
11601741|NCT00635804|Experimental|Pt 1: MK-3281 200 mg BID (Panel B)|Healthy male participants in this Part I serial panel receive 200 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 400 mg. The PM dose of MK-3281 was not administered on Day 10.
11601742|NCT00635804|Experimental|Pt 1: MK-3281 400 mg BID (Panel C)|Healthy male participants in this Part I serial panel receive 400 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 800 mg. The PM dose of MK-3281 was not administered on Day 10.
11601743|NCT00635804|Experimental|Pt 1: MK-3281 800 mg BID (Panel D)|Healthy male participants in this Part I serial panel receive 800 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 10.
11601744|NCT00635804|Experimental|Pt 2: MK-3281 800 mg BID (Panel E)|Genotype (GT)1 HCV-infected male participants in this Part II serial panel receive 800 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 7.
11601745|NCT00635804|Experimental|Pt 2: MK-3281 800 mg BID (Panel F)|GT1a/GT1-nontypeable/GT3/GT1b HCV-infected male participants in this Part II serial panel receive 800 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 7.
11601837|NCT00635193|Other|Group B|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg q2wk (or other dose and schedule)
11601746|NCT00635804|Experimental|Pt 2: MK-3281 1200 mg BID (Panel G)|GT1a (and/or GT1 nontypeable) and GT1b HCV-infected male participants in this Part II serial panel receive 1200 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 2400 mg. The PM dose of MK-3281 was not administered on Day 7.
11601747|NCT00635804|Placebo Comparator|Placebo|Participants receive dose-matched placebo to MK-3281 orally BID for 7 or 10 consecutive days depending on randomization. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
11601748|NCT00635791|Experimental|Sorafenib tosylate and vorinostat|Patients receive sorafenib tosylate by mouth twice a day on days 1-21 and vorinostat by mouth every day on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11601749|NCT00635778|Experimental|dalotuzumab 2.5/2.5 mg/kg|Participants received a loading dose of dalotuzumab 2.5 mg/kg administered by intravenous (IV) infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 2.5 mg/kg administered by IV infusion every two weeks for up to 18 months.
11601750|NCT00635778|Experimental|dalotuzumab 5.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 5.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
11601751|NCT00635778|Experimental|dalotuzumab 10.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 10.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
11601752|NCT00635778|Experimental|dalotuzumab 15.0/5.0mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
11601753|NCT00635778|Experimental|dalotuzumab 20.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 20.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
11601754|NCT00635778|Experimental|dalotuzumab 15.0/10.0 mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 10.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
11601755|NCT00635778|Experimental|dalotuzumab 15.0/15.0 mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 15.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
11601756|NCT00635752|Experimental|1|Participants will receive trauma-focused cognitive behavioral therapy (TF-CBT)
11601757|NCT00635752|Active Comparator|2|Participants will receive sessions of treatment as usual (TAU)
11601758|NCT00635739|Active Comparator|A, 1|
11601759|NCT00635739|Placebo Comparator|A, 2|
11601760|NCT00635726|Experimental|1|MVAC -> GEM+CDDP
11601761|NCT00635713|Experimental|1|Faslodex 125mg and Arimidex 1 mg
11601762|NCT00635713|Experimental|2|Faslodex 250mg and Arimidex 1mg
11601763|NCT00635700|Experimental|1|
11601764|NCT00635700|Placebo Comparator|2|
11601765|NCT00635687|Experimental|Fibroscan|
11601766|NCT00635674|Experimental|Group I - compliant|CPAP use for more than 4 hr/night
11601767|NCT00635674|Active Comparator|Group 2-noncompliant|CPAP for less than 4 hr/night
11601768|NCT00635648|Experimental|Caspofungin 50 mg Intravenous (IV)|
11601769|NCT00635635|Active Comparator|1|Guided Imagery Audio
11601770|NCT00635635|Active Comparator|2|Music Audio
11601771|NCT00635622|Experimental|1|Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10^9 cfu/dose. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
11601772|NCT00635622|Placebo Comparator|2|Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
11601773|NCT00635609|Experimental|Doxycycline hyclate (Doryx)|
11601774|NCT00635609|Active Comparator|Doxycycline hyclate|
11601775|NCT00635596|Experimental|I|
11601776|NCT00635583|Experimental|Increased Dairy Consumption|Increased Dairy Consumption - Each subject in this arm will receive three additional servings of dairy to consume each day for 18 months.
11601777|NCT00635583|No Intervention|Control|This group will not receive the intervention but will continue their normal diet; they will act as the control.
11601778|NCT00635570|Active Comparator|Contraceptive vaginal ring|Contraceptive vaginal ring (NuvaRing)
11601779|NCT00635570|Active Comparator|Oral contraceptive pill|Oral contraceptive pill (Ortho Tri-cyclen Lo)
11601780|NCT00635544|Experimental|1|dietary treatment with a high-glycemic index low-fibre diet (HGI-LF)
11601781|NCT00635544|Active Comparator|2|dietary treatment with a low-glycemic index high-fibre diet (LGI-HF)
11601782|NCT00635531|Placebo Comparator|Placebo group|
11601783|NCT00635531|Active Comparator|Alprazolam XR group|
11601784|NCT00635518|Other|I, Intervention|
11601785|NCT00635505|Experimental|T|albuterol HFA 180 mcg QID
11601786|NCT00635505|Active Comparator|R|180 mcg QID 12 weeks
11601787|NCT00635505|Placebo Comparator|P|2 actuations QID 12 weeks or until use of rescue drug
11601788|NCT00635492||1|exenatide
11601789|NCT00635492||2|insulin
11601790|NCT00635479|Experimental|VAC Device placement|will have the VAC device used for post-operative management of acetabular fractures and pelvic fractures.
11601791|NCT00635479|Active Comparator|Gauze dressing|will receive current traditional surgical wound management with daily dressing changes in post operative management of acetabular fractures and pelvic fractures.
11601792|NCT00635466|Experimental|Lap, 1|Patients undergoing laparoscopic surgery for rectal carcinoma
11601838|NCT00635193|Other|Group C|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk (or other dose and schedule)
11601793|NCT00635453|Experimental|I, Intervention|"Physicians, nurses and administrative staff of all intervention health centers participated in a training of Dietary Advice in January 2008 based on the Ten Steps for Healthy Feeding for Brazilian Children from Birth to Two Years of Age guideline.13 An experienced nutritionist conducted a standardized session for the health care team to outline the Ten Steps recommendations and strategies and to provide suggestions how best to incorporate these into the consultations. Printed materials were provided to the Health Care Centers for use by these professionals and for access to the Brazilian Ministry of Healthy Nutrition Department´s website. Health staff members received a pocket guide for use during the appointments and waiting room sessions."
11601794|NCT00635453|No Intervention|II, Control|Healthcare centers randomized to the non-intervention group continued their routine medical assistance without any involvement of the research team. No materials were provided to these clinics.
11601795|NCT00635440|Active Comparator|A|
11601796|NCT00635440|Sham Comparator|B|
11601797|NCT00635427|Experimental|VPRIV 60 U/kg(VPRIV Parent Study 45 or 60 U/kg- TKT032,GCB039)|"This arm is the Overall velaglucerase alfa (VPRIV) 60 U/kg and includes patients from the following groups:
~VPRIV 45 U/kg or 60 U/kg, IV, EOW for 51 weeks in parent study TKT032 (NCT00430625) and switched to 60 U/kg in HGT-GCB-044 to maintain blindness or 60 U/kg, IV, EOW for 39 weeks in parent study HGT-GCB-039 (NCT00553631)"
11601798|NCT00635427|Experimental|VPRIV 60 U/kg (Parent study-imiglucerase(60 U/kg) HGT-GCB-039)|imiglucerase 60 U/kg, IV, EOW for 39 weeks in parent study HGT-GCB-039 (NCT00553631)and switched 60 U/kg VPRIV in HGT-GCB-044
11601799|NCT00635427|Experimental|VPRIV 15-60 U/kg (Parent study VPRIV (15-60 U/kg) TKT034)|VPRIV 15- 60 U/kg, IV, EOW for 51 weeks in parent study TKT034 (NCT00478647) and continued in HGT-GCB-044 at the same dose as prescribed in TKT034
11601800|NCT00635414|Experimental|1|40mg administered orally
11601801|NCT00635414|Experimental|2|15 minute intravenous infusion
11601802|NCT00635401|Experimental|0.5 mg BID|
11601803|NCT00635388|Sham Comparator|1|
11601804|NCT00635388|Experimental|2|
11601805|NCT00635388|Experimental|3|
11601806|NCT00635375|Experimental|1|LED fiberoptic blanket phototherapy
11601807|NCT00635375|Experimental|2|metal halide phototherapy
11601808|NCT00635375|Active Comparator|3|LED bank phototherapy
11601809|NCT00635375|Experimental|4|Combination metal halide phototherapy plus LED fiberoptic blanket phototherapy
11601810|NCT00635362|Experimental|postplacental insertion after cesarean|"Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta
~Device of intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)"
11601811|NCT00635362|Active Comparator|delayed insertion group|"Insertion of the LNG-IUS 4-8 weeks after cesarean delivery
~Device of intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)"
11601812|NCT00635349|Active Comparator|Non-steroidal Anti-inflammatory Drug (NSAIDs)|Participants will receive fixed dose combination of tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg, 1 to 3 tablets per day along with meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 1 to Day 28. Participants who will have the numeric rating scale score 4 or less on Day 29 will be randomly assigned to the treatment of NSAIDs to receive either meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 29 to Day 85.
11601813|NCT00635349|Experimental|Tramadol Hydrochloride Plus Acetaminophen|Participants will receive fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 1 to Day 28. Participants who will have the numerical rating scale score 4 or less on Day 29 will be randomly assigned to the treatment of fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
11601814|NCT00635323|Experimental|A|
11601815|NCT00635310|Active Comparator|HD patients with CHC or CHB|Chronic hepatitis C (CHC) or chronic hepatitis B (CHB) patients with hemodialysis (HD), pretreated with DDAVP 0.3 ug/kg body weight infusion 30-60 minutes before percutaneous liver biopsies (PLBs)
11601816|NCT00635310|Active Comparator|Ordinary patients with CHC or CHB|Chronic hepatitis C (CHC) or chronic hepatitis B (CHB) patients with normal renal function (NRF) receiving percutaneous liver biopsies (PLBs)
11601817|NCT00635297|Active Comparator|1|50 osteoporotic patients with a vertebral insufficiency fracture will receive treatment of the vertebrae with standard vertebroplasty
11601818|NCT00635297|Experimental|2|50 osteoporotic patients with a vertebral insufficiency fracture will receive treatment of the vertebrae with standard vertebroplasty. The adjacent vertebrae will be treated with 3-5 ml of PMMA
11601819|NCT00635284|Experimental|ABI-009|
11601820|NCT00635258||GnRH-ant|Patients were treated with a GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
11601821|NCT00635258||GnRH-a|GnRH long protocol using 0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state. Furthermore, the triptorelin administration was maintained until the day of donor's hCG administration.
11601822|NCT00635232|Active Comparator|Irbesartan 300mg|Irbesartan 300 mg once daily
11601823|NCT00635232|Placebo Comparator|Placebo|Blinded Placebo Treatment
11601824|NCT00635232|Experimental|PS433540 200mg|PS433540 200mg once daily
11601825|NCT00635232|Experimental|PS433540 400mg|PS433540 400mg once daily
11601826|NCT00635232|Experimental|PS433540 800mg|PS433540 800mg once daily
11601827|NCT00635219|Placebo Comparator|Placebo|
11601828|NCT00635219|Experimental|Vortioxetine: 2.5 mg|
11601829|NCT00635219|Experimental|Vortioxetine: 5 mg|
11601830|NCT00635219|Experimental|Vortioxetine: 10 mg|
11601831|NCT00635219|Other|Duloxetine: 60 mg|Active reference
11601832|NCT00635206|Active Comparator|1|Auto M series device set to Bi Flex
11601833|NCT00635206|Active Comparator|2|Set to standard CPAP
11601834|NCT00635193|Other|Cohort 1|Three subjects will be treated with liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab, 7.5 mg/kg qwk
11601835|NCT00635193|Other|Cohort 2|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk
11601836|NCT00635193|Other|Group A|liposomal doxorubicin, 40 mg/m2 q4wk
11601839|NCT00635180|Experimental|1|1: Healthy subjects
11601840|NCT00635167|Experimental|Contrast Enhanced Transrectal Ultrasound (TRUS)|
11601841|NCT00635154|Experimental|Anakinra with/without Dexamethasone|"Anakinra was given alone for 6 months at which time response was assessed.
~If participants achieved a minor response or better they continued on Anakinra alone until disease progression.
~If participants achieved stable disease, they added low dose Dexamethasone to Anakinra until progression.
~If at any time a participant progresses, they were administered high dose Dexamethasone with Anakinra."
11601842|NCT00635141|Experimental|1|
11601843|NCT00635141|Experimental|2|
11601844|NCT00635128|Experimental|BOOSTRIX-POLIO GROUP|Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™-Polio vaccine in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
11601845|NCT00635128|Experimental|BOOSTRIX + IPV MÉRIEUX GROUP|Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™ and IPV Mérieux® vaccines in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
11601846|NCT00635115|Experimental|1|
11601847|NCT00635115|Active Comparator|2|
11601848|NCT00635102|Active Comparator|Alcohol dependent|Alcohol dependent patients will receive 4 interventions
11601849|NCT00635102|Active Comparator|Healthy subjects|Healthy subjects will receive 4 interventions
11601850|NCT00635089|Other|Open-Label Reslizumab|Open-label reslizumab intravenous (IV) infusion at an initial dose of 1 mg/kg monthly
11601851|NCT00635076|Placebo Comparator|Placebo group|
11601852|NCT00635076|Active Comparator|Alprazolam XR group|
11601853|NCT00635063|Experimental|AD 923|
11601854|NCT00635063|Active Comparator|MSIR|
11601855|NCT00635050|Experimental|Doxil, Paclitaxel, Cyclophosphamide + Avastin|Two stage phase II single arm trial to evaluate the pathologic complete response rate to sequential dose dense chemotherapy using Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, in patients with locally advanced invasive breast cancer.
11601856|NCT00635037|Experimental|A|"G1 (n=15)received trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.
~G2(n=15) was submitted to classical and trigger point acupuncture twice a week."
11601857|NCT00635024|Experimental|Anti-thymocyte Globulin/Melphalan|Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m^2)
11601858|NCT00634998|Placebo Comparator|2|1000mg Placebo capsules orally twice daily for 90 days
11601859|NCT00634998|Experimental|1|1000mg Vitamin C capsules orally twice daily for 90 days
11601860|NCT00634985|Experimental|A|
11601861|NCT00634972|Experimental|1|
11601862|NCT00634972|Placebo Comparator|2|
11601863|NCT00634959|Experimental|1|
11601864|NCT00634959|Experimental|2|
11601865|NCT00634959|Experimental|3|
11601866|NCT00634959|Experimental|4|
11601867|NCT00634959|Placebo Comparator|5|
11601868|NCT00634946|Experimental|I|
11601869|NCT00634946|Experimental|II|
11601870|NCT00634946|Experimental|III|
11601871|NCT00634946|Placebo Comparator|IV|
11601872|NCT00634933|Experimental|Arm 1|Consists of Arms 1a and 1b
11601873|NCT00634933|Experimental|Arm 2|Consists of Arms 2a and 2b
11601874|NCT00634933|Placebo Comparator|Arm 3|Consists of Arms 3a and 3b.
11601875|NCT00634920|Experimental|Everolimus (CNI-free)|Patients in this group were converted to everolimus immunosuppressive therapy. The patients in the everolimus group were treated with everolimus, off-label (CNI-free) use, and EC-MPS and corticosteroids in accordance with local practice and approved label. Conversion to everolimus was as follows: Day 1: begin everolimus 3 mg in the evening. Usual morning dose of CsA and 50% reduced evening dose of CsA Day 2: everolimus 2 mg in the morning and 2 mg in the evening, complete discontinuation of CsA Day 3 or 4, and onwards: everolimus according to trough level 6-10 ng/mL.The given total daily dose of the immunosuppressive drugs (everolimus) was divided into two (equal) doses, applied 12 hours apart.
11601876|NCT00634920|Active Comparator|Control (CsA)|Patients in the control group continued on an immunosuppressive regimen. The patients in this Control group were treated with CsA, EC-MPS and corticosteroids in accordance with local practice and approved label. The given total daily dose of the immunosuppressive drugs (CsA and EC-MPS) was divided into two (equal) doses, applied 12 hours apart.
11601877|NCT00634907|Experimental|Pharmacogenetic-based warfarin dosing|"Pharmacogenetic-based warfarin dosing: Warfarin dosing based on formula that incorporates genetic testing results.
~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm, as noted above."
11601878|NCT00634907|Active Comparator|Standard of care (control)|"Control or usual care warfarin dosing
~NOTE: Standard of care (usual care) for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm, as noted above."
11601879|NCT00634894|Experimental|Femara|
11601880|NCT00634894|Placebo Comparator|Placebo|
11601881|NCT00634881|Experimental|Cohort A: Alemtuzumab i.v.|Intravenous administration of alemtuzumab according to the 3 + 3 dose escalation design.
11601882|NCT00634881|Experimental|Cohort B: Alemtuzumab s.c.|After i.v. MTD (maximum tolerable dosage) has been determined, subcutaneous dose escalation is performed according to the same escalation rules as for cohort A, starting with the recommended dose level of i.v. application.
11601883|NCT00634868|Sham Comparator|1|The device is emitting a sham light
11601884|NCT00634868|Experimental|2|The device is emitting curative light
11601885|NCT00634855||Complicated|Women with pregnancies complicated by intrauterine growth restriction or preeclampsia
11601886|NCT00634855||Normal|Women with normal pregnancies
11601887|NCT00634842|Experimental|FPG 70-90 mg/dL|Aggressive FPG (fasting plasma glucose) titration target range group
11601888|NCT00634842|Experimental|FPG 80-110 mg/dL|Conventional FPG (fasting plasma glucose) titration target range group
11601889|NCT00634829|Experimental|T|Armstrong Albuterol HFA Inhalation Aerosol
11601890|NCT00634829|Active Comparator|R|2 inhalations Proventil-HFA Albuterol Sulfate, 108 mcg, prior to exercise
11601891|NCT00634829|Placebo Comparator|P|Placebo-HFA
11601892|NCT00634816||Chemotherapy recipients|Subjects who have undergone chemotherapy will receive DXA scan
11601893|NCT00634803|Experimental|CBT for POD|Integrated cognitive behavioral therapy for chronic pain and opioid dependence
11601894|NCT00634803|Active Comparator|Educational Counseling for POD|Educational Counseling is a didactic, lecture-discussion format to supplement the information and advice provided by physicians in physician management (PM)
11601895|NCT00634803|Active Comparator|Physician Management|PM is a relatively brief intervention that approximates the medically focused advice and brief counseling about medical issues that is typically provided by physicians to patients with chronic pain or other chronic medical conditions, such as diabetes or asthma.
11601896|NCT00634790|Active Comparator|alprazolam group|
11601897|NCT00634764||Pregnant|Pregnant women who present to MUSC's Cannon Place or Prenatal Wellness Center
11601898|NCT00634751|Experimental|Phase I: 200mg Sorafenib+2DOC|"Cohort 1: 200mg Sorafenib+2DOC
~Oxaliplatin + Oral Capecitabine + Sorafenib"
11601899|NCT00634751|Experimental|Phase I: 400mg Sorafenib BID+2DOC|"Cohort 2: 400mg Sorafenib+2DOC
~Oxaliplatin + Oral Capecitabine + Sorafenib"
11601900|NCT00634751|Experimental|Phase II: Pancreatic Cancer|Oxaliplatin + Oral Capecitabine + Sorafeni
11601901|NCT00634751|Experimental|Phase II: Biliary Tract Cancer|Oxaliplatin + Oral Capecitabine + Sorafeni
11601902|NCT00634738|Experimental|one|
11601903|NCT00634725|Active Comparator|Arm 1 (A1) - Gemcitabine|Gemcitabine 2 months, then stop until progression
11601904|NCT00634725|Experimental|Arm 2 (B1) Gemcitabine + Erlotinib|B1 Gemcitabine + Erlotinib (100mg/d) 2 months, then erlotinib maintenance (150 mg/d)until progression
11601905|NCT00634725|Experimental|Arm 3 (A2) CRT|A2 CRT then stop until progression
11601906|NCT00634725|Experimental|Arm 4 (B2) CRT then erlotinib|B2 CRT then erlotinib maintenance (150mg/d) until progression
11601907|NCT00634712|Active Comparator|1|
11601908|NCT00634712|Placebo Comparator|2|
11601909|NCT00634699|Experimental|One|Ischemic Compression on Triggers Points on Muscles along the Median Nerve. Active Comparator
11601910|NCT00634686|Experimental|1|
11601911|NCT00634686|Placebo Comparator|2|
11601912|NCT00634673|Other|TT|patients homozygous for Thr54 (TT)
11601913|NCT00634673|Other|AA|patients homozygous for Ala54 (AA)
11601914|NCT00634660|Active Comparator|0.001 mg/kg|One subcutaneous injection of 0.001 mg/kg of rAvPAL-PEG.
11601915|NCT00634660|Active Comparator|0.003 mg/kg|One subcutaneous injection of 0.003 mg/kg of rAvPAL-PEG.
11601916|NCT00634660|Active Comparator|0.01 mg/kg|One subcutaneous injection of 0.01 mg/kg of rAvPAL-PEG.
11601917|NCT00634660|Active Comparator|0.03 mg/kg|One subcutaneous injection of 0.03 mg/kg of rAvPAL-PEG.
11601918|NCT00634660|Active Comparator|0.1 mg/kg|One subcutaneous injection of 0.1 mg/kg of rAvPAL-PEG.
11601919|NCT00634660|Active Comparator|0.3 mg/kg|One subcutaneous injection of 0.3 mg/kg of rAvPAL-PEG.
11601920|NCT00634660|Active Comparator|1.0 mg/kg|One subcutaneous injection of 1.0 mg/kg of rAvPAL-PEG.
11601921|NCT00634647|Experimental|Satraplatin|satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days
11601922|NCT00634634|Experimental|Sorafenib and Letrozole|
11601923|NCT00634608|No Intervention|Survey|Control group participants are sent a survey within one week of clinic visit
11601924|NCT00634608|Experimental|Health Information Prescription|Health Information Prescription is emailed to participants within 24 hours of clinic visit.
11601925|NCT00634595|Experimental|A|E10A combined with Cisplatin and Paclitaxel
11601926|NCT00634595|Active Comparator|B|Cisplatin and Paclitaxel
11601927|NCT00634569|Experimental|Flebogamma 5% DIF|
11601928|NCT00634556|Experimental|levodopa solution 2mg/ml for i.v. use|"levodopa solution in saline, given intravenously, dosed as per final protocol in Black et al 2003."
11601929|NCT00634556|Placebo Comparator|Placebo|normal saline i.v.
11601930|NCT00634543|Experimental|Tramadol hydrochloride (HCl)/ Acetaminophen|Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3, 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
11601931|NCT00634543|Active Comparator|Gabapentin|Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
11601932|NCT00634530|Other|I, Intervention|
11601933|NCT00634517|Experimental|T|Armstrong Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
11601934|NCT00634517|Active Comparator|R|Proventil-HFA, Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
11601935|NCT00634504|Experimental|A|High-dose methotrexate, leucovorin, and Voraxaze
11601936|NCT00634504|Active Comparator|B|High-dose methotrexate and leucovorin without Voraxaze (glucarpidase)
11601937|NCT00634491|Active Comparator|1|150 meq/l NaHco3 3cc/kg/hr one Hour before and 1cc/kg/hr 6 hour after angiography
11601938|NCT00634491|Active Comparator|2|Acetazolamide 250 mg + 1cc/kg/hr normal salin 6 hour before and after angiography
11601939|NCT00634491|Active Comparator|3|normal salin 1cc/kg/hr before and after angiography
11601940|NCT00634478|Experimental|1|preleminiscal radiation deep brain stimulation
11601941|NCT00634478|Active Comparator|2|VIM deep brain stimulation
11601942|NCT00634465||1|
11601943|NCT00634452|Experimental|MDX-1401|MDX-1401 iv at various doses
11601944|NCT00634439||A|All patients 18 years or older who received a first dispensing of atomoxetine during the time period of the study (January 1, 2003 through December 31, 2006) and had at least 6 months of continuous enrollment prior to first dispensing are included in the study cohort. Patients are excluded for presence of pre-existing arrhythmia and heart failure during the baseline period. The study entry date for this cohort is the date of first atomoxetine dispensing.
11601945|NCT00634439||B|All patients 18 years or older who received a first dispensing of a stimulant medication (methylphenidate or mixed salts of amphetamine) during the time period of the study with no dispensing of the same drug in the prior 6 months and had at least 6 months of continuous enrollment prior to the first dispensing are identified. Patients are excluded for presence of pre-existing arrhythmia and heart failure during the baseline period. Patients who are matched to atomoxetine initiators using this propensity score method are retained and followed as one comparator cohort. The study entry date is the date of the first dispensing of a comparator ADHD medication.
11601946|NCT00634439||C|Patients with at least 6 months of continuous enrollment in the database, and without a history of arrhythmia or heart failure during the baseline period are sampled and frequency matched on age and gender to the atomoxetine cohort in a 2:1 ratio. Study entry dates are assigned so as to be similar to the distribution of study entry dates in the atomoxetine cohort. Patients identified and matched as initiators of atomoxetine or stimulant ADHD medications are not eligible for inclusion in this cohort
11601947|NCT00634426||1|De novo surgical cohort
11601948|NCT00634426||2|Nonoperative treatment cohort
11601949|NCT00634426||3|Secondary surgical treatment cohort
11601950|NCT00634413|Experimental|1|
11601951|NCT00634413|Placebo Comparator|2|
11601952|NCT00634400|Active Comparator|1|
11601953|NCT00634400|Placebo Comparator|2|
11601954|NCT00634387|Active Comparator|A|Anthocyans
11601955|NCT00634387|Placebo Comparator|B|no effective agent
11601956|NCT00634374|No Intervention|1|Oral Syringe
11601957|NCT00634374|Active Comparator|2|Rx medibottle
11601958|NCT00634361|Experimental|A|
11601959|NCT00634348|Active Comparator|Aripiprazole|
11601960|NCT00634348|Active Comparator|Ziprasidone|
11601961|NCT00634335||sk|professional Israeli bicyclists
11601962|NCT00634322|Experimental|A|HDMTX-LV with glucarpidase
11601963|NCT00634322|Active Comparator|B|HDMTX-LV with placebo
11601964|NCT00634322|Experimental|C|compassionate use group to treat or prevent life threatening toxicity in the event of delayed elimination of MTX and/or renal impairment
11601965|NCT00634309|Active Comparator|1|
11601966|NCT00634309|Placebo Comparator|2|
11601967|NCT00634296|Active Comparator|G2|Inspiratory muscle training added by aerobic training to aerobic training alone
11601968|NCT00634283|Experimental|antidepressant-experienced|Subjects who had previously been exposed to active antidepressant medication (venlafaxine)
11601969|NCT00634283|Placebo Comparator|antidepressant-naive|Subjects who had previously been exposed to placebo only (and never to active antidepressant medication)
11601970|NCT00634270|Experimental|Sirolimus|"Design
~Sirolimus oral solution will be administered orally BID on a continuous dosing schedule (28 days = 1 treatment course) with pharmacokinetically-guided dosing.
~Disease status will be evaluated using volumetric MRI analysis at regular intervals.
~The plasma pharmacokinetics and pharmacodynamics of sirolimus will be evaluated, as will pharmacogenetic polymorphisms and their influence on the metabolism of sirolimus in this patient population.
~Pain reduction and quality of life outcomes will also be assessed.
~Toxicity of chronic sirolimus administered will be evaluated using physical and laboratory evaluations."
11601971|NCT00634257||Patients|Patients with advanced cancer receiving palliative care.
11601972|NCT00634257||Caregivers|Primary caregivers of Patients with advanced cancer receiving palliative care.
11601973|NCT00634244|Experimental|Arm A (carboplatin and topotecan hydrochloride)|Patients receive carboplatin and topotecan hydrochloride IV continuously over 24 hours on days 1-5.
11601974|NCT00634244|Experimental|Arm B (alvocidib, mitoxantrone, cytarabine)|Patients receive alvocidib IV over 4.5 hours QD on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9.
11601975|NCT00634244|Experimental|Arm C (sirolimus, mitoxantrone, etoposide, cytarabine)|Patients receive sirolimus PO QD on days 2-9, mitoxantrone hydrochloride IV over 15 minutes QD, etoposide IV over 1 hour QD, and cytarabine IV over 3 hours QD on days 4-8 or 5-9. (Closed to accrual)
11601976|NCT00634231|Experimental|AdV-tk|AdV-tk + valacyclovir in combination with standard of care radiation
11601977|NCT00634218|Active Comparator|1|Mail-based Self Help (MSH) treatment. Participants will receive the self-help manual developed specifically for LGBT smokers.
11601978|NCT00634218|Active Comparator|2|Mail-based Self Help plus an Internet-based Smoking Treatment (IST). In the IST condition, participants will receive the manual plus access to an Internet-based intervention that includes social support.
11601979|NCT00634218|Active Comparator|3|Mail-based Self-Help plus Telephone Counseling (TC). In the TC condition, participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions.
11601980|NCT00634218|Active Comparator|4|Mail-based Self-Help plus an Internet-based Intervention plus Telephone Counseling. Participants will receive a self-help manual, have access to an internet-based smoking treatment and participante in 6 telephone counseling sessions.
11601981|NCT00634205|Experimental|A|Continuous oral administration of valproate plus every 3 weeks, intravenous administration of doxorubicin
11601982|NCT00634192|Experimental|1|
11601983|NCT00634192|Experimental|2|
11601984|NCT00634179|Experimental|Treatment (VR-CHOP regimen)|"INDUCTION: Patients receive bortezomib IV on days 1 and 8; rituximab IV, doxorubicin hydrochloride IV over 3-5 minutes, cyclophosphamide IV over 60 minutes, and vincristine sulfate IV over 10 minutes on day 1; and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression.
~MAINTENANCE: Patients achieving complete response (CR) receive rituximab IV once every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or partial response (PR) receive rituximab IV and bortezomib once weekly for 4 weeks every 6 months for up to 2 years in the absence of disease progression or unacceptable toxicity."
11602370|NCT00631098|Experimental|1|Cannulation of external jugular vein and cannulation of cubital vein
11601985|NCT00634166|Other|Historical Control|Treated within the last 5 years (if possible) with topical prophylactic therapies that did not include mafenide acetate or mafenide salt forms.
11601986|NCT00634166|Experimental|Prospective Patients/Active Drug|Prospective subjects with thermal injuries of 20-60% TBSA on the chest, abdomen, or proximal upper and lower extremities requiring meshed autografts on these areas will receive SS5% as the initial topical moist dressing over the meshed autograft(s) placed at the initial graft procedure (Day 1).
11601987|NCT00634140|Experimental|1|ezetimibe
11601988|NCT00634140|Placebo Comparator|2|placebo for 4-6 weeks
11601989|NCT00634114|Experimental|1|Esomeprazole and Omeprazole
11601990|NCT00634114|Experimental|2|Esomeprazole
11601991|NCT00634101|Active Comparator|nefilcon A|Subjects randomized to this arm received the nelfilcon A lens throughout the entire duration of the study.
11601992|NCT00634101|Experimental|narafilcon A|Subjects randomized to this arm received the narafilcon A lens throughout the entire duration of the study.
11601993|NCT00634088|Experimental|Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|Dose Level 1
11601994|NCT00634088|Experimental|Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|Dose Level 2
11601995|NCT00634088|Experimental|Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|Dose Level 3
11601996|NCT00634088|Experimental|Ixabepilone + Lapatinib + Capecitabine|Triplet Combination
11601997|NCT00634075|Experimental|1|
11601998|NCT00634075|Placebo Comparator|2|
11601999|NCT00634062|Active Comparator|1|
11602000|NCT00634062|Placebo Comparator|2|
11602001|NCT00634049|Experimental|Isavuconazole|Administration of isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days followed by daily administration of isavuconazole (IV) or oral
11602002|NCT00634036|Active Comparator|1|
11602003|NCT00634036|Placebo Comparator|2|
11602004|NCT00634010|Active Comparator|Morphine Capsule|Morphine 15 mg slow release orally every 12 hours + additional doses as needed
11602005|NCT00634010|Active Comparator|Methadone Capsule|Methadone 5 mg orally every 12 hours + additional as needed doses up to 40-50 mg/day
11602006|NCT00633997|Experimental|1|Healthy volunteers
11602007|NCT00633997|Experimental|2|Type II diabetics
11602008|NCT00633984|Active Comparator|Cognitive Behavioral Group Therapy + D-Cycloserine|Participants received Cognitive Behavioral Group Therapy and 50mg D-Cycloserine.
11602009|NCT00633984|Placebo Comparator|Cognitive Behavioral Group Therapy + Placebo|Participants received Cognitive Behavioral Group Therapy and 50mg Placebo.
11602010|NCT00633971|Experimental|A|Complex lymphedema therapy (which includes compression stocking use)
11602011|NCT00633971|Other|B|Standard of care (compression stocking use at 30-40 mm Hg)
11602012|NCT00633958|Experimental|18F-FLT|All subjects will receive 18F-FLT prior to PET imaging.
11602013|NCT00633945|Experimental|Lenalidomide|Open label lenalidomide received.
11602014|NCT00633945|Experimental|Lenalidomide 2|Open label lenalidomide received.
11602015|NCT00633932|Experimental|1|Esomeprazole 20mg
11602016|NCT00633932|Experimental|2|Esomeprazole 40mg
11602017|NCT00633932|Active Comparator|3|Omeprazole 20mg
11602018|NCT00633919|Active Comparator|Active|SLITone Dermatophagoides Mix
11602019|NCT00633919|Placebo Comparator|Placebo|SLITone Placebo
11602020|NCT00633906|Experimental|1|HORIZONS HIV Intervention. Two-session, group-based interactive intervention.
11602021|NCT00633906|Active Comparator|2|Enhanced standard-of-care session. One hour, video-based and brief discussion.
11602022|NCT00633893|Experimental|1|2.5 mg
11602023|NCT00633893|Experimental|2|5.0 mg
11602024|NCT00633893|Active Comparator|3|0 mg
11602025|NCT00633880|Experimental|Droxidopa|Double-blind
11602026|NCT00633880|Placebo Comparator|Placebo|Double-blind
11602027|NCT00633867|Active Comparator|Intubation c McGrath videolaryngoscope|Tracheal Intubation using McGrath video-laryngoscope
11602028|NCT00633867|Active Comparator|Intubation using Macintosh Laryngoscope|Tracheal intubation using Macintosh Laryngoscope
11602029|NCT00633854||1|30 volunteer subjects who are age 60 and older
11602030|NCT00633841|Active Comparator|1|AFFITOPE AD02 without adjuvant
11602031|NCT00633841|Active Comparator|2|AFFITOPE AD02 with adjuvant
11602032|NCT00633828|Experimental|A Intervention group|Increased physical education in primary school (daily)
11602033|NCT00633828|No Intervention|B Control group|Normal physical education in primary school (typically once per week)
11602034|NCT00633815||Fontan patients|Subjects will undergo exercise testing in both the supine and upright positions
11602035|NCT00633815||Healthy controls|Subjects will undergo exercise testing in both the supine and upright positions
11602036|NCT00633802|Placebo Comparator|2|
11602037|NCT00633802|Experimental|1|
11602038|NCT00633789|Experimental|1|
11602039|NCT00633789|Placebo Comparator|2|
11602040|NCT00633776|Experimental|1|Formoterol fumarate 20 mcg (Perforomist) nebulized via Pari C nebulizer at Test Visit 1; Formoterol 12 mcg (Foradil) via aerosolizer dry powder inhaler at Test Visit 2
11602041|NCT00633776|Active Comparator|2|Formoterol fumarate 12 mcg (Foradil) via aerosolizer dry powder inhaler at Test Visit 1; Formoterol fumarate 20 mcg (Perforomist) nebulized via Pari C nebulizer at Test Visit 2
11602042|NCT00633763||1|Healthy individuals with normal C-peptide levels following i.v. glucagon challenge. These individuals will be administered 18F-fallypride and then subjected to PET-CT scanning of the pancreas and brain. The subject will be positioned in the PET/CT scanner and a low-dose CT (15-20 secs) of the abdomen carried out (with subjects breathing normally). A 30-min PET acquisition will then be started (three 10 min static frames or one 30 min static frame). The subject will then be repositioned for a low-dose CT scan of the head (15-20 secs) following which a 20-min PET acquisition will then be started (two 10 min static frames or one 20 min static frame).
11602107|NCT00633230|Active Comparator|1|standardized herbal formula, Sho-saiko-to (SST): 3 capsules containing 700 mg of the SST herbal extract/capsule and 28 mg of the excipients, magnesium stearate and silicon dioxide/capsule 2 x day
11602108|NCT00633230|Placebo Comparator|2|placebo capsules that look and smell identical to the active Sho-saiko-to (SST) capsules
11602109|NCT00633217|Active Comparator|arm 1|
11602043|NCT00633763||2|Patients with longstanding T1DM and <20% C-peptide levels following i.v. glucagon challenge will be consented. 18F-Fallypride injected intravenously and subjects allowed to wait for approx 1 hr for the uptake.(b) Subject positioned in the PET/CT scanner and a low-dose CT (15-20 secs) of the abdomen (pancreas) carried out (with subjects breathing normally).(c) A 30-min PET acquisition will then be started (three 10 min static frames or one 30 min static frame).(d) Subject repositioned for a low-dose CT scan of the head (15-20 secs).(e) A 20-min PET acquisition will then be started (two 10 min static frames or one 20 min static frame).(f) End of PET/CT scanning procedures. Subject taken out of the scanner.
11602044|NCT00633750|Experimental|Tarceva|
11602045|NCT00633737|Experimental|1|Stress reduction intervention
11602046|NCT00633737|No Intervention|2|Standard care
11602047|NCT00633724|Experimental|1|
11602048|NCT00633711|Active Comparator|fixed CPAP|
11602049|NCT00633711|Experimental|Auto-CPAP|"Auto-CPAP Weinmann Somnosmart2"
11602050|NCT00633698|Active Comparator|1|Nicotinic acid (niacin)
11602051|NCT00633698|Placebo Comparator|2|Placebo
11602052|NCT00633685|Experimental|Fluoxetine|Receives Fluoxetine at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
11602053|NCT00633685|Placebo Comparator|Placebo|
11602054|NCT00633672|Experimental|1|20mg Oral tablet daily
11602055|NCT00633672|Experimental|2|40mg oral tablet daily
11602056|NCT00633672|Active Comparator|3|150mg oral twice daily
11602057|NCT00633659|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
11602058|NCT00633659|Experimental|Control|Voluven (HES 130/0.4)
11602059|NCT00633646|Active Comparator|1|low protein diet
11602060|NCT00633646|Active Comparator|2|low protein diet with keto acids
11602061|NCT00633646|Active Comparator|3|high protein diet
11602062|NCT00633633|Other|Group 1|Usual Care
11602063|NCT00633633|Experimental|Group 2|Exercise Training + Dietary Counseling
11602064|NCT00633620|Experimental|colonoscopy|Non-NBI HDTV colonoscopy
11602065|NCT00633594|Experimental|rituximab/bortezomib/lenalidomide|"Patients in Phase I & II to receive treatment with rituximab, bortezomib and lenalidomide in 21-day cycles up to 6 cycles.
~Phase I: Cohorts of 3 patients will be enrolled at escalating dose levels to determine the maximum tolerated dose (MTD). Doses may be de-escalated if necessary.
~Phase II: patients will be treated with the MTD determined in Phase I."
11602066|NCT00633581|Experimental|1|Intravenous injections of 10 grams(20ml as a solution) of vitamin C with 100ml of normal saline over 30 minutes.
11602067|NCT00633581|Placebo Comparator|2|Intravenous injections of 120ml of normal saline over 30 minutes.
11602068|NCT00633568|Active Comparator|A|One course of chemotherapy with cisplatin and docetaxel followed by induction chemoradiotherapy followed by two courses of consolidation chemotherapy
11602069|NCT00633568|Experimental|B|Three courses of induction chemotherapy followed by consolidation chemoradiotherapy
11602070|NCT00633542|Experimental|TD|thalidomide-dexamethasone
11602071|NCT00633542|Active Comparator|ID|Interferon-dexamethasone
11602072|NCT00633529|Experimental|I|Single arm: triple combination
11602073|NCT00633516||Medical tool|Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
11602074|NCT00633503||A-Observation|All patients undergoing pedicle and free tissue transfer.
11602075|NCT00633490|Experimental|A|
11602076|NCT00633477|Experimental|Resatorvid 2.4 mg/kg/day|
11602077|NCT00633477|Placebo Comparator|Placebo|
11602078|NCT00633464|Experimental|Arm A (ixabepilone 40 mg^2)|ixabepilone 40 mg/m^2 every 3 weeks
11602079|NCT00633464|Experimental|Arm B (cetuximab 250 mg/m^2 + ixabepilone 40 mg/m^2)|cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks
11602080|NCT00633451|Experimental|1|Manual Therapy + Exercise
11602081|NCT00633451|Active Comparator|2|Exercise Only
11602082|NCT00633438|Placebo Comparator|B|
11602083|NCT00633438|Experimental|A|
11602084|NCT00633412|Experimental|1|20mg Oral tablet daily
11602085|NCT00633412|Experimental|2|40mg Oral tablet daily
11602086|NCT00633412|Active Comparator|3|150mg oral twice daily
11602087|NCT00633399|Experimental|1|Patients in group 1 will receive Ziprasidone for the full 8 weeks of Phase 2. If they are in remission following phase two, and decide to enter phase three, they will continue on Ziprasidone for 12 months.
11602088|NCT00633399|Placebo Comparator|2|Patients in group 2 will receive Placebo for the full 8 weeks of Phase 2. If they are in remission following phase two, and decide to enter phase three, they will continue on Placebo for 12 months.
11602089|NCT00633386|Experimental|A|
11602090|NCT00633386|Placebo Comparator|B|
11602091|NCT00633360|Experimental|Drospirenone and ethinyl estradiol|
11602092|NCT00633360|Placebo Comparator|Placebo|
11602093|NCT00633347|Active Comparator|A|A: Antagonist
11602094|NCT00633347|Active Comparator|B|Agonist GnRH
11602095|NCT00633321|Experimental|1|TA-NIC 100 μg
11602096|NCT00633321|Experimental|2|TA-NIC 250 μg
11602097|NCT00633321|Placebo Comparator|3|
11602098|NCT00633308|Experimental|A|Long hemodialysis
11602099|NCT00633295|Experimental|nilotinib|
11602100|NCT00633282|Experimental|Lifestyle intervention|Life style intervention including aerobic exercise and reducing energy intake(-500kcal) without drug
11602101|NCT00633282|Experimental|Life style intervention, pioglitazone|Life style intervention with pioglitazone 15mg qd for 16 weeks
11602102|NCT00633282|Experimental|Life style intervention, berberine|Life style intervention with berberine 0.5g tid for 16 weeks
11602103|NCT00633256|Experimental|Cycloserine|50 mg cycloserine
11602104|NCT00633256|Sham Comparator|Placebo|Matched placebo
11602105|NCT00633243|Experimental|Modified Directly Observed Therapy (mDOT)|Hepatitis C Virus (HCV) Treatment in Modified Directly Observed Therapy (mDOT) in Methadone Maintenance Treatment (MMT)
11602106|NCT00633243|Active Comparator|Self-Administered Therapy at Liver Specialty Clinic (SAT)|Hepatitis C virus (HCV) at a liver specialty clinic as self-administered therapy
11602110|NCT00633217|Experimental|arm 2|
11602111|NCT00633191|Experimental|Anti-pseudomonas IgY gargle|Intervention: Gargles with anti-pseudomonas IgY every night
11602112|NCT00633178|Experimental|Group Interpersonal Therapy (IPT)|Participants will receive group interpersonal therapy.
11602113|NCT00633178|Active Comparator|Treatment as Usual (ETAU)|Participants will receive psychiatric treatment as usual.
11602114|NCT00633178|No Intervention|No Treatment|Participants are healthy and will receive no treatment.
11602115|NCT00633152|Experimental|Ceftaroline|Intramuscular every 12 hours
11602116|NCT00633152|Active Comparator|linezolid plus optional aztreonam|Intravenous every 12 hours
11602117|NCT00633139|Experimental|Cohort 1|Cohort 1: 50 U/kg Recombinant human Arylsulfatase A (rhASA)
11602118|NCT00633139|Experimental|Cohort 2|Cohort 2: 100 U/kg Recombinant human Arylsulfatase A (rhASA)
11602119|NCT00633139|Experimental|Cohort 3|Cohort 3: 200 U/kg Recombinant human Arylsulfatase A (rhASA)
11602120|NCT00633126|Experimental|A|ceftaroline
11602121|NCT00633113|Active Comparator|1|- Medial Parapatellar Arthrotomy (MPPA) technique
11602122|NCT00633113|Active Comparator|2|- Subvastus (SV) technique
11602123|NCT00633087|Experimental|2-deoxyglucose|
11602124|NCT00633074|Experimental|Thiomersal-free FluAS25 adjuvanted vaccine group|Subjects received 1 dose of thiomersal-free FluAS25 adjuvanted vaccine
11602125|NCT00633074|Experimental|Thiomersal reduced FluAS25 adjuvanted vaccine group|Subjects received 1 dose of thiomersal reduced FluAS25 adjuvanted vaccine
11602126|NCT00633061|Experimental|A-randomized to treatment|Patients diagnosed with asymptomatic catheter-related DVT who are randomized to treatment with enoxaparin for 6 weeks
11602127|NCT00633061|No Intervention|B-randomized to close|Patients diagnosed with asymptomatic catheter-related DVT who are randomized to close observation for 6 weeks
11602128|NCT00633048|Experimental|NSA-789|active drug
11602129|NCT00633048|Placebo Comparator|placebo|placebo
11602130|NCT00633035|Active Comparator|1|oral esomeprazole tablet dissolved in water given through NG tube
11602131|NCT00633035|Active Comparator|2|intravenous famotidine injection
11602132|NCT00633022|Experimental|LOSMAPIMOD 7.5 MG TWICE DAILY|Participants received 1 tablet of 7.5 mg Losmapimod orally twice daily, each morning and evening for a period of 12 weeks
11602133|NCT00633022|Placebo Comparator|Placebo|Participants received 1 tablet of placebo matching Losmapimod orally twice daily, each morning and evening for a period of 12 weeks.
11602134|NCT00633022|Experimental|LOSMAPIMOD 7.5 MG ONCE DAILY|Participants received 1 tablet of 7.5 mg Losmapimod each morning once daily and placebo tablet each evening once daily orally for a period of 12 weeks.
11602135|NCT00633009|Active Comparator|LtSTA 15 ug|Naive volunteers tested with 15 ug injection of LtSTA. Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin tests were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
11602136|NCT00633009|Active Comparator|LtSTA 30 ug|Naive volunteers tested with 30 ug injection of LtSTA.Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin testes were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
11602137|NCT00633009|Active Comparator|LtSTA 50 ug|Naive volunteers tested with 50 ug injection of LtSTA.Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin testes were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
11602138|NCT00632996|Experimental|1|
11602139|NCT00632970|Experimental|Raltegravir plus Truvada|Raltegravir (400mg), 1 tablet, administered twice daily (BID) and Truvada (Emtricitabine/Tenofovir disoproxil fumarate) (200mg/300mg), 1 tablet administered once daily (QD)
11602140|NCT00632970|Active Comparator|Lopinavir/Ritonavir plus Truvada|Lopinavir/Ritonavir (400mg/100mg) (Kaletra), 2 tablets administered twice daily (BID) and Truvada (Emtricitabine/Tenofovir disoproxil fumarate) (200mg/300mg), 1 tablet administered once daily (QD)
11602141|NCT00632957|Active Comparator|Fish oil|
11602142|NCT00632957|Placebo Comparator|Placebo|
11602143|NCT00632931|Experimental|A|Arm A: Drug/Placebo
11602144|NCT00632931|Experimental|B|Arm B: Placebo/Drug
11602145|NCT00632905||1|Normal - BMD with T-score at or above -1.0
11602146|NCT00632905||2|Osteopenic - BMD with T-score between -1.1 and -2.4
11602147|NCT00632905||3|Osteoporotic - BMD with T-score at or below -2.5
11602148|NCT00632866|Experimental|1|Active treatment : Hydroxychloroquine
11602149|NCT00632866|Placebo Comparator|2|Placebo
11602150|NCT00632853|Active Comparator|Arm A - Standard Radiotherapy + Chemotherapy|"Radiotherapy (every day, Monday-Friday, for a total of 3 weeks) XRT: 45 Gy BID (1.5 Gy/fx) starting on day 1 of Cycle 1 or 2, every day, for 3 weeks
~Chemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):
~Cisplatin 80 mg/m2 IV on day 1 OR Carboplatin AUC 5 IV day 1, every 21 days
~Etoposide 100 mg/m2 IV Register/ on days 1, 2, and 3, every 21 days"
11602151|NCT00632853|Experimental|Arm B - High Dose Radiotherapy + Chemotherapy|"Radiotherapy (every day, Monday-Friday, for a total of 7 weeks) XRT: 70 Gy QD (2.0 Gy/fx), starting on day 1 of Cycle 1 or 2, every day, for 7 weeks
~Chemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):
~Cisplatin 80 mg/m2 IV on day 1 OR Carboplatin AUC 5 IV day 1, every 21 days
~Etoposide 100 mg/m2 IV on days 1, 2, and 3, every 21 days"
11602152|NCT00632840|Placebo Comparator|P|placebo group
11602153|NCT00632840|Active Comparator|Feno|Fenofibrate
11602154|NCT00632840|Active Comparator|ATV|Atorvastatin
11602204|NCT00632476|Active Comparator|B|Participants will receive a vitamin C capsule throughout pregnancy.
11602205|NCT00632476|No Intervention|C|A group of non-smoking pregnant women will not receive placebo or vitamin C.
11602206|NCT00632463|Experimental|1|Dose regimen 1
11602207|NCT00632463|Experimental|2|Dose regimen 2
11602208|NCT00632463|Placebo Comparator|3|Placebo
11602209|NCT00632450||1|
11602210|NCT00632437||Speckle-Contrast Imaging|
11602211|NCT00632424|Experimental|1|
11602212|NCT00632411|Experimental|Proactive group|Research study staff will contact participant to initiate the program. Half of participants will be randomized to the proactive condition and the other half to the reactive conditions.
11602371|NCT00631085|Other|1|
11602155|NCT00632827|Experimental|Treatment Plan|(1) Induction Chemo A; Two 21-day cycles of Gemcitabine 1000 mg/m2 days (D) 1, 8, Navelbine 20 mg/m2 D1, D8; Doxil 15 mg/m2 Days 1 and 8, G-CSF Days 4-6 and 10-15 (2) Induction Chemo B: Two 21-day cycles of Cyclophosphamide 2000 mg/m2 day 1; Doxorubicin 50 mg/m2 day 1; Vincristine 1.4 mg/m2 day 1; Prednisone 100 mg/m2 days 1-5; Methotrexate 3000 mg/m2 IV over 4h day 15; Leucovorin rescue (3) Disease Evaluation (4) High-dose Consolidation Chemo, high dose Ara-C, Denileukin diftitox (Ontak) and Stem Cell Collection (5) Consolidation Cytarabine 2000 mg/m2 IV over 2 h q 12h days 1-4, Etoposide 40 mg/m2 continuous intravenous infusion (CIVI), days 1-4, Denileukin Diftitox (Ontak) 9 mcg/kg/day days 6-10, G-CSF 10 mcg/kg/day day 14+, Stem cell collection day 22 (6) Autologous Stem Cell Transplant Carmustine 550 mg/m2 day -6, Etoposide 60 mg/kg IV over 4h day -4, Cyclophosphamide 100 mg/kg day -2, Stem cell infusion D0 (7) Post-transplant: Denileukin Diftitox (Ontak) 18 mcg/kg/day days 1- 5
11602156|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg qw|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection once per week [qw] (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
11602157|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), biw (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection twice per week [biw] (30 IU/kg [day 1] + 40 IU/kg [day 4]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
11602158|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), tiw (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 75 IU/kg, dosing by injection three times per week [tiw] (3 x 25 IU/kg [day 1, 3, 5]) for 9 months. No escalation opportunity for participants in this group
11602159|NCT00632801|Other|A|Chewing gum or not
11602160|NCT00632788||intervention group|patients presented with acute ST-elevation myocardial infarction and received emergency cardiac catheterization between March 1, 2007 and Oct. 31, 2007
11602161|NCT00632788||control group|patients presented with acute ST-elevation myocardial infarction and received emergency cardiac catheterization between April 1, 2006 and Feb. 28, 2007
11602162|NCT00632775|Active Comparator|1|Subjects in this arm will receive hypotonic (0.45% NaCl/5% dextrose) intravenous (IV) maintenance fluids.
11602163|NCT00632775|Active Comparator|2|Subjects in this arm will receive isotonic (0.9% NaCl/5% dextrose) intravenous (IV) maintenance fluids.
11602164|NCT00632762|Active Comparator|1|Amantadine MANTADIX
11602165|NCT00632762|Placebo Comparator|2|placebo
11602166|NCT00632749|Experimental|Schedule A|BI 811283 on days 1 and 15 in combination with Cytarabine 20 mg twice daily on Days 1-10
11602167|NCT00632749|Experimental|Schedule B|BI 811283 on Day 1 in combination with Cytarabine 20 mg twice daily on Days 1-10
11602168|NCT00632736|Active Comparator|Ropinirole XL (formerly CR)|Ropinirole XL (formerly CR)
11602169|NCT00632710|Experimental|b|laser
11602170|NCT00632710|Placebo Comparator|a|laser placebo
11602171|NCT00632697|Active Comparator|1|
11602172|NCT00632697|Placebo Comparator|2|
11602173|NCT00632684|Active Comparator|1|Participants in Phase 1 will undergo four interviews, including a single treatment planning session.
11602174|NCT00632684|Experimental|2|Participants in Phase 2 will receive the adaptive treatment model.
11602175|NCT00632671||Obese persons cohorte|constitution of a prospective data collection (biological, clinical, paraclinical and questionnaires) in morbidly obese persons.
11602176|NCT00632658||Patients with cGVHD|Pediatric Patients with cGVHD will be asked to participate in an interview with their Physician. The interview will ask the pediatric patients questions about their cGVHD. The interview will be audio-recorded.
11602177|NCT00632645|Experimental|1|Olanzapine Mylan
11602178|NCT00632645|Active Comparator|2|Xenazine
11602179|NCT00632645|Active Comparator|3|Tiapridal
11602180|NCT00632632|Experimental|D-Cycloserine (DCS)|
11602181|NCT00632632|Placebo Comparator|Placebo|
11602182|NCT00632619|Active Comparator|1|Participants will receive stimulant medication therapy and referrals to community-based psychosocial treatments.
11602183|NCT00632619|Experimental|2|Participants will receive stimulant medication therapy and group-based behavior therapy.
11602184|NCT00632606|Active Comparator|Arm 1|magnesium sulfate 2 grams intravenously w/ acetaminophen 1 gram orally
11602185|NCT00632606|Active Comparator|Arm 2|metoclopramide 10 mg intravenously w/ 1 gram acetominophen orally
11602186|NCT00632593|Active Comparator|Circular Stapled|Patients operated performing the gastric pouch of the gastric bypass with a circular staple device
11602187|NCT00632593|Active Comparator|Handsewn anastomosis|Patients operated performing the gastric pouch of the gastric bypass in a handsewn manner
11602188|NCT00632580|Active Comparator|1|intraarticular injection with local anesthetic
11602189|NCT00632580|Experimental|2|intracapsular injection with local anesthetic
11602190|NCT00632567|Experimental|1|caesarean section
11602191|NCT00632567|Active Comparator|2|vaginal delivery
11602192|NCT00632554|Experimental|1|prednisolone therapy for three months
11602193|NCT00632554|Active Comparator|2|prednisolone therapy for six months
11602194|NCT00632541|Experimental|Single Arm A|Sorafenib 200mg po daily, Bevacizumab 5mg/kg every other week, 1 Cycle = 4 weeks. Imaging every third cycle
11602195|NCT00632528|Experimental|1|Administration of MEOPA gaz during postoperative physical therapy
11602196|NCT00632528|Placebo Comparator|2|Administration of medical air during postoperative physical therapy
11602197|NCT00632515||Questionnaire|Patients with Colorectal Cancer and their First Degree Relatives (FDRs).
11602198|NCT00632502|Experimental|Navarixin|Navarixin (MK-7123, SCH 527123) 30 mg capsule, to be taken by mouth once daily in the morning for 4 weeks
11602199|NCT00632502|Placebo Comparator|Placebo|Placebo capsule to match navarixin, to be taken by mouth once daily in the morning for 4 weeks
11602200|NCT00632489|Experimental|LBH589 with Capecitabine|MTD, LBH589 with Capecitabine
11602201|NCT00632489|Experimental|LBH589 and Lapatinib|LBH589 and Lapatinib
11602202|NCT00632489|Experimental|LBH589, Capecitabine and Lapatinib|LBH589, Capecitabine and Lapatinib (Breast Cancer Patients)
11602203|NCT00632476|Placebo Comparator|A|Participants will receive a placebo capsule throughout pregnancy.
11602213|NCT00632411|Experimental|Reactive group|Participant will contact the research study staff to initiate the program.
11602214|NCT00632398|Active Comparator|Attention control (reading)|Caregivers read to patients from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks.
11602215|NCT00632398|Experimental|Touch, Caring and Cancer DVD program|Caregivers apply the instruction of the Touch, Caring and Cancer DVD program for patients for recommended 20 minutes at least 3 times per week for 4 weeks.
11602216|NCT00632385|Experimental|A|
11602217|NCT00632372||HeartPOD™ System with Cardiac Resynchronization Therapy|All patients will receive both a HeartPod device and a CRT-D device.
11602218|NCT00632359|Experimental|Lenalidomide|Lenalidomide 10 mg daily given for 12 months.
11602219|NCT00632346||1 group|200 patients presenting to the Adolescent Medicine Clinic at Brooke Army Medical Center between the ages of 18 and 23 years-old.
11602220|NCT00632333|Experimental|1|
11602221|NCT00632320||S, 1, A|group (success or failure), case number, measurement method
11602222|NCT00632307||1|COPD
11602223|NCT00632307||2|lung cancer
11602224|NCT00632307||3|airway infection
11602225|NCT00632307||4|interstitial lung disease
11602226|NCT00632307||5|sleep apnea
11602227|NCT00632307||6|pulmonary disorders with pleural infusions
11602228|NCT00632307||7|sarcoidosis
11602229|NCT00632307||8|healthy persons
11602230|NCT00632294||Retrieved Allograft|Patients that require the retrieval of a bone allograft (transplant).
11602231|NCT00632268|Experimental|A|Drug:RAD001 Drug:Cisplatin Drug:5-FU
11602232|NCT00632255||1|Patients with CML who have been treated with Imatinib (Glivec) within 6 months of diagnosis as first line therapy. Initial therapy with Hydroxyurea is permitted
11602233|NCT00632242|Experimental|TTP Remission Cohort 1|Patients will receive a total dose of 0.47 mg/kg of ARC1779 over 4 hours to achieve a target plasma concentration of 6 mcg/mL
11602234|NCT00632242|Experimental|TTP Remission Cohort 2|Patients will receive a total dose of 1.67 mg/kg of ARC1779 over 24 hours to achieve a target plasma concentration of 6 mcg/mL
11602235|NCT00632242|Experimental|TTP Remission Cohort 3|Patients will receive a total dose of 3.34 mg/kg of ARC1779 over 24 hours to achieve a target plasma concentration of 12 mcg/mL
11602236|NCT00632242|Experimental|Acute TTP Cohort 4|Patients will receive up to a total dose of 40.78 mg/kg of ARC1779 for ≤ 14 days to achieve a target plasma concentration of 12 mcg/mL
11602237|NCT00632242|Experimental|vWD-Type2b Cohort 5|Subjects will receive either ARC1779, desmopressin or a combination of ARC1779 and desmopressin in a 3-period crossover design. The maximum dose of ARC1779 will be 0.47 mg/kg to achieve a target plasma concentration of 6 mcg/mL.
11602238|NCT00632229|Experimental|Paliperidone|Recieves study medication called paliperidone
11602239|NCT00632229|Placebo Comparator|Pill placebo|Placebo comparator
11602240|NCT00632203|Experimental|Temozolomide treatment|Subjects will receive temozolomide at a dose of 75 mg/m^2 orally (PO) daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
11602241|NCT00632203|No Intervention|Observation|Observation
11602242|NCT00632164||1|Cervical adjustments
11602243|NCT00632164||2|Thoracic adjustments
11602244|NCT00632125|Experimental|HX575 epoetin alfa i.v.|This post-authorization safety study was designed as a multi-center, multinational, prospective, single-arm clinical study with a 6-month HX575 (recombinant human) erythropoietin alfa treatment period. It was planned to include approximately 1,500 patients.
11602245|NCT00632099|Placebo Comparator|Placebo|matched placebo
11602246|NCT00632099|Experimental|Oral micronized progesterone|Oral micronized progesterone (up to 400 mg/day)
11602247|NCT00632086|Experimental|1|Single oral dose of 325 mg aspirin administered as PA32540
11602248|NCT00632086|Experimental|2|aspirin core
11602249|NCT00632086|Active Comparator|3|active
11602250|NCT00632073|Experimental|VCV + Failing HAART|Vicriviroc plus failing highly-active antiretroviral therapy
11602251|NCT00632060|No Intervention|1|Standard Care Control Group - Participants randomized to the standard care group will continue their use of non-prescription or prescription medication and reduced duty loads, as prescribed by the credentialed medical provider.
11602252|NCT00632060|Experimental|2|Manual / Manipulative Therapy Group: Participants randomized to the M/MT group will receive a course of M/MT along with standard care. The patient will see the chiropractor twice a week for the entire course of the study, regardless of manipulation or not.
11602253|NCT00632034|Experimental|1|
11602254|NCT00632021|No Intervention|1|Patients will receive usual care at hospital discharge, which generally includes physician reconciliation of medications and a nurse-provided explanation of how to take medications at the time of discharge.
11602255|NCT00632021|Experimental|2|Participants will receive pharmacist-led medication reconciliation, pharmacist counseling prior to discharge, a follow-up telephone call 1-4 days after discharge, and additional telephone support as needed.
11602256|NCT00632008|Experimental|1|SBG
11602257|NCT00632008|Placebo Comparator|2|
11602258|NCT00631995|Experimental|Group 1|
11602259|NCT00631995|Experimental|Group 2|
11602260|NCT00631995|Experimental|Group 3|
11602261|NCT00631995|Experimental|Group 4|
11602262|NCT00631995|Experimental|Group 5|
11602263|NCT00631995|Active Comparator|Group 6|
11602264|NCT00631982|Experimental|Group I|patients with PCO undergoing in vitro maturation and subsequently IVF and embryo transfer
11602265|NCT00631969|Experimental|Vardenafil ODT (STAXYN, BAY38-9456)|Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
11602266|NCT00631969|Placebo Comparator|Placebo|Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
11602267|NCT00631943|Experimental|1|
11602268|NCT00631917|Experimental|Aliskiren|For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration.
11602365|NCT00631124|Experimental|Arm 2|
11602269|NCT00631917|Active Comparator|Ramipril|For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study.
11602270|NCT00631904||Single Observation|Patients with permanent pacemakers undergoing medically indicated MRI scanning.
11602271|NCT00631878|Placebo Comparator|Placebo|
11602272|NCT00631878|Experimental|10 mg/kg|10 mg/kg was given on Days 0, 14
11602273|NCT00631878|Experimental|30 mg/kg|30 mg/kg was given on Days 0, 14
11602274|NCT00631878|Experimental|60 mg/kg|60 mg/kg was given on Days 0, 14
11602275|NCT00631878|Experimental|90 mg/kg|90 mg/kg was given on Days 0, 14
11602276|NCT00631865|Experimental|cell transplantation group|Epidermal Cell transplantation in patients with vitiligo
11602277|NCT00631852|Experimental|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
11602278|NCT00631839||1|There is only one group in this study. The patients of this group will go through procedures as follow: basic pre-treatment information collected,treatment include platinum-based chemotherapy and 3-D conformal radiotherapy, blood test during RT 6am every Monday and follow-up visits with treatment-induced injury assessed.
11602279|NCT00631813|Active Comparator|1|Prucalopride 0.5 mg
11602280|NCT00631813|Active Comparator|2|Prucalopride 1 mg
11602281|NCT00631813|Active Comparator|3|Prucalopride 2 mg
11602282|NCT00631813|Placebo Comparator|4|
11602283|NCT00631800|Placebo Comparator|Placebo|Placebo
11602284|NCT00631800|Experimental|60 mg/kg|60 mg/kg was given on Days 0, 7, 14
11602285|NCT00631800|Experimental|90 mg/kg|90 mg/kg was given on Days 0, 7, 14
11602286|NCT00631774|Active Comparator|1|a meal replacement program with Glucerna SR on top of the exchange-diet plan
11602287|NCT00631774|Active Comparator|2|an caloric-matched exchange-diet plan only.
11602288|NCT00631761|Experimental|1|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas of the human bladder.
11602289|NCT00631761|Placebo Comparator|2|The control group will be instructed to read a urethrocystoscopy textbook chapter at home
11602290|NCT00631748|Experimental|Study Drug|Subjects randomized to the experimental arm of the study will be initially administered 50mg/day quetiapine fumarate (Seroquel XR) to be titrated up to 400mg/day by the end of the second week. Subjects will be stabilized at a dose of 400mg/day or alternatively 300, 200, 100, or 50mg/day or quetiapine fumarate as tolerated. During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
11602291|NCT00631748|Placebo Comparator|Placebo|Subjects randomized to the placebo arm of the study will follow the same titration and dosing procedure as the experimental arm but will receive matched placebo tablets. During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
11602292|NCT00631722|Experimental|A|
11602293|NCT00631722|Active Comparator|B|
11602294|NCT00631709|Experimental|1|Pacemaker Patients
11602295|NCT00631696|Experimental|1|
11602296|NCT00631696|Placebo Comparator|2|
11602297|NCT00631683||MICU-1|Mechanically ventilated patients who are about to start a weaning trial at the medical intensive care unit of Memorial Hermann Hospital.
11602298|NCT00631670|Experimental|Single Treatment Group|15 Gy dose in one stereotactic body radiation treatment
11602299|NCT00631670|Experimental|25 Treatments Group|25 treatments, given once a day, Monday through Friday for about five weeks; Dose: 70 Gy at 2.8 Gy/treatment
11602300|NCT00631657|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine 4.5 mg tablets, administered once a day for 6 months
11602301|NCT00631657|Placebo Comparator|Placebo|Participants receive placebo tablets, administered once a day for 6 months
11602302|NCT00631631||Mifamurtide (L-MTP-PE)|Mifamurtide (L-MTP-PE), intravenous, at a dose of 2 mg/m^2 twice weekly (at least 3 days apart) for 12 weeks, and then weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.
11602303|NCT00631618|Experimental|Suntinib|Suntinib
11602304|NCT00631605||1|
11602305|NCT00631605||2|
11602306|NCT00631592|Other|GSK1349572|GSK1349572
11602307|NCT00631566|Experimental|1|
11602308|NCT00631566|Placebo Comparator|2|
11602309|NCT00631566|No Intervention|No MRSA colonization|
11602310|NCT00631540|Experimental|1|renal artery stenting
11602311|NCT00631527|Experimental|Sunitinib Malate, Hormone Ablation + RT|Sunitinib Malate + Hormone Ablation (Leuprolide or Goserelin + Bicalutamide) + Radiation Therapy (RT)
11602312|NCT00631514|No Intervention|1|Hypertensive persons taking either lisinopril/hydrochlorothiazide fixed combination or amlodipine all the time.
11602313|NCT00631514|Experimental|2|Intervention: NSAID. Hypertensives with osteoarthritis taking already amlodipine (5-10 mg o.d. per os) were randomized to the following drug interventions: to take either acetaminophen (1000 mg t.i.d. per os), piroxicam (10-20 mg o.d. per os) or ibuprofen (400-600 mg t.i.d. per os) for 1 month
11602314|NCT00631514|Experimental|3|Hypertensives with osteoarthritis taking already lisinopril/hydrochlorothiazide (20/12.5 mg o.d. per os), were sequentially randomized to the following drug interventions: acetaminophen (1000 mg t.i.d.), ibuprofen (400-600 mg t.i.d.) or piroxicam (10-20 mg o.d.), for 1 month each
11602315|NCT00631501|Placebo Comparator|2|
11602316|NCT00631501|Experimental|Doxycycline|100 mg twice daily
11602317|NCT00631488|Experimental|MK-0893 + Sitagliptin|
11602318|NCT00631488|Experimental|MK-0893 + Metformin|
11602319|NCT00631488|Active Comparator|Sitagliptin + Metformin|
11602320|NCT00631475|Experimental|1|"For patients who were administered bosentan during BUILD 3 (NCT00391443):
~Same dose will continue
~For patients who were administered placebo during BUILD 3 (NCT00391443):
~Initial dose: 62.5 mg for 4 weeks Maintenance dose: 125 mg"
11602321|NCT00631462|Experimental|1|
11602322|NCT00631449|Active Comparator|Raltegravir|For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
11602323|NCT00631449|Placebo Comparator|Placebo|For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
11602324|NCT00631436||1|If the individuals who meet the blast exposure criteria have a PCL score above 50 and meet the Hoge et al PCL criteria, thus indicating likely PTSD, they will be invited to participate as members of the Blast Exposed + PTSD group.
11602325|NCT00631436||2|Other individuals meeting the blast exposure criteria will be invited to participate in the as members of the Blast Exposed + No PTSD group if they have PCL scores below 30.
11602326|NCT00631436||3|Individuals reporting that they were not exposed to explosive blast will be recruited to participate. Those not exposed to blast but with PCL scores over 50 and meeting the Hoge et al PCL criteria will be invited to participate as members of the No Blast + PTSD group.
11602327|NCT00631436||4|Individuals not exposed to blast with PCL scores below 30 will be invited to participate as members of the No Blast + No PTSD group.
11602328|NCT00631423||1|Patients with vena cava inferior thrombosis
11602329|NCT00631423||2|Patients with isolated lower-extremity DVT matched for gender and age
11602330|NCT00631410|Experimental|A|
11602331|NCT00631410|Experimental|B|
11602332|NCT00631397||Premature Infants|Premature Infants weighing less than 1500 gms
11602333|NCT00631384|Experimental|1|Women to be asked to bring husbands for couple VCT
11602334|NCT00631384|Active Comparator|2|Women to receive individual VCT
11602335|NCT00631371|Experimental|1|Bevacizumab 10 mg/kg intravenous (IV) q8wks + Temsirolimus 25 mg IV weekly
11602336|NCT00631371|Active Comparator|2|Bevacizumab 10 mg/kg intravenous (IV) q8wks + Interferon-Alfa 9MU SC TIW
11602337|NCT00631358|Experimental|Maxidex|Maxidex
11602338|NCT00631358|Sham Comparator|No treatment|Healthy normal control group receiving no treatment
11602339|NCT00631345|Experimental|Lifestyle|This Group-Based Lifestyle Intervention (Phases 1 and 2) will be led by lay health counselors (LHCs). The 6-month Phase 1 includes weekly meetings on nutrition and physical activity, psychosocial factors related to health behaviors, and question and answer periods. The 18-month Phase 2 will consist of monthly group meetings and individual telephone contacts. Intervention participants who choose to participate in the study continuation (Phase 3) will be further randomized to receive either extended group or self-directed maintenance. Those who are randomized to receive Extended Group Maintenance (Phase 3) will continue attending monthly meetings; those who receive Self-Directed Maintenance (Phase 3) will no longer attend groups.
11602340|NCT00631345|Other|Comparison|The comparison condition exceeds the usual care provided to similar community members and is an individual education program that builds on an increased awareness of existing community resources. In the initial trial, these subjects will receive two individual sessions with the RD and a monthly newsletter. In the study continuation, comparison participants will receive biannual nutrition counseling and a monthly newsletter.
11602341|NCT00631319|Experimental|OROS Hydromorphone|OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg
11602342|NCT00631319|Placebo Comparator|Placebo|Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).
11602343|NCT00631306||Bottle number 615|Patients are randomized to either Bottle number 615 or Bottle number 429 (actual product vs. placebo). This is a blinded study.
11602344|NCT00631306||Bottle number 429|Patients are randomized to either Bottle number 615 or Bottle number 429 (actual product vs. placebo). This is a blinded study.
11602345|NCT00631293|Experimental|1|administration of lactisole
11602346|NCT00631293|Placebo Comparator|2|administration of placebo
11602347|NCT00631280|Experimental|Choice|
11602348|NCT00631280|Active Comparator|Recommendation|
11602349|NCT00631267|Placebo Comparator|1|Manual Manipulation
11602350|NCT00631267|Active Comparator|2|Finger Trap Traction
11602351|NCT00631254|Active Comparator|1|"Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.
~Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.
~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
11602352|NCT00631254|Active Comparator|2|"Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.
~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
11602353|NCT00631241|Experimental|Intraoperative Lymphatic Mapping|Single Photon Emission Computed Tomography - First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients. Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
11602354|NCT00631228||1|The group will be monitored to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
11602355|NCT00631215|Experimental|1|Healthy Adults
11602356|NCT00631202|Experimental|I|Treatment arm
11602357|NCT00631189|Active Comparator|1|Rosuvastatin and Pravastatin
11602358|NCT00631189|Active Comparator|2|Rosuvastatin and Atorvastatin
11602359|NCT00631176|No Intervention|1|
11602360|NCT00631176|Experimental|2|
11602361|NCT00631163|Experimental|Deferasirox|"The recommended initial daily dose of Deferasirox is 20 mg/kg body weight for most patients.
~An initial daily dose of 30 mg/kg or 10mg/kg should be considered for patients requiring more intensive or less intensive chelation, respectively"
11602362|NCT00631137|Placebo Comparator|Arm 1: Control Group|whey protein powder
11602363|NCT00631137|Active Comparator|ARM 2 : Treatment Group|Testosterone Gel (10g pouch/day) applied to skin
11602364|NCT00631124|Experimental|Arm 1|
11602372|NCT00631072|Other|GM-CSF +INKT|"INKT will be administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.
~GM-CSF will be given subcutaneously once daily for 10 days beginning the second day of the second and third infusion"
11602373|NCT00631046|Experimental|Fish Oil|containing n-3 LCPUFA
11602374|NCT00631046|Placebo Comparator|Sunflower oil|containing n-6 PUFA
11602375|NCT00631033|Placebo Comparator|1|Placebo
11602376|NCT00631033|Experimental|2|Diazoxide
11602377|NCT00631033|Experimental|3|Metformin + Diazoxide
11602378|NCT00631020|Experimental|CBME +/- NRT|6 weeks CBME with optional 4 weeks NRT
11602379|NCT00631007|Experimental|INT131 besylate 0.5 mg|INT131 besylate 0.5 mg once-daily administration and matching placebo to pioglitazone HCl.
11602380|NCT00631007|Experimental|INT131 besylate 1 mg|INT131 besylate 1 mg once-daily administration and matching placebo to pioglitazone HCl
11602381|NCT00631007|Experimental|INT131 besylate 2 mg|INT131 besylate 2 mg administered once-daily and matching placebo to pioglitazone HCl
11602382|NCT00631007|Experimental|INT131 besylate 3 mg|INT131 besylate 3 mg administered once-daily and matching placebo to pioglitazone HCl
11602383|NCT00631007|Active Comparator|pioglitazone HCl 45 mg|pioglitazone HCl 45 mg administered once-daily and matching placebo to INT131 besylate
11602384|NCT00631007|Placebo Comparator|placebo|placebo administered once-daily, matching placebo to INT131 besylate and matching placebo to pioglitazone HCl
11602385|NCT00630981||Intervention group|"Combined psychotherapy and pharmacological treatment
~Open single arm 'pilot' clinical trial in patients with dissociative disorders, admitted to the psychiatric emergency unit of Geneva and in the Hogan Psychotherapeutic Center in Montreux.
~Patients will be interviewed according to the Dissociative Experiences Scale (DES) and, if their score is 30 or higher, the Structured Clinical Interview for DSM-IV Dissociative Disorders (SCID) will be administered."
11602386|NCT00630955|Experimental|1|20 mg memantine
11602387|NCT00630955|Experimental|2|40 mg memantine
11602388|NCT00630955|Placebo Comparator|3|
11602389|NCT00630942|Experimental|Single Arm, active treatment|
11602390|NCT00630929|Active Comparator|A|
11602391|NCT00630929|Placebo Comparator|C|
11602392|NCT00630929|Experimental|B|
11602393|NCT00630916|No Intervention|A|
11602394|NCT00630903|Active Comparator|A|8-MOP + UVA x 24 weeks
11602395|NCT00630903|Active Comparator|B|IFN alone, 2 weeks, 8-MOP + UVA irradiation + IFN, 22 weeks
11602396|NCT00630890|Experimental|1|External beam radiation with Cyberknife radiosurgery boost and concurrent capecitabine
11602397|NCT00630877|Experimental|NER/ASA|
11602398|NCT00630877|Experimental|NER/ASA Placebo|
11602399|NCT00630877|Experimental|NER Placebo/ASA Placebo|
11602400|NCT00630864|Experimental|1|Fx-1006A 20mg soft gelatin capsules once daily for 12 months
11602401|NCT00630851|Experimental|1|
11602402|NCT00630851|Placebo Comparator|2|
11602403|NCT00630838|Experimental|1|VSL#3 probiotic
11602404|NCT00630838|Placebo Comparator|2|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
11602405|NCT00630825|Experimental|1.0/2.0 milligram (mg) LY2189265|LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks
11602406|NCT00630825|Experimental|1.0/1.0 milligram (mg) LY2189265|LY2189265: 1.0 mg, subcutaneous (SC) injection, once weekly (QW) for 16 weeks
11602407|NCT00630825|Experimental|0.5/1.0 milligram (mg) LY2189265|LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks
11602408|NCT00630825|Placebo Comparator|Placebo|Placebo: subcutaneous (SC) injection, once weekly (QW) for 16 weeks
11602409|NCT00630812|Experimental|A|active treatment
11602410|NCT00630812|Placebo Comparator|B|
11602411|NCT00630799|Experimental|1|leuprolide acetate administered by i.m. injection as two doses of 17 mg each during a period of 6 months (one dose every 3 months)
11602412|NCT00630786|Experimental|Panitumumab plus conatumumab|Participants received 10 mg/kg conatumumab and 6 mg/kg panitumumab administered on the same day by sequential intravenous (IV) infusions once every 2 weeks until progressive disease, intolerability, withdrawal, or death.
11602413|NCT00630760|Experimental|1|NRX 194204 capsules in escalating doses, starting at 3mg/m2.
11602414|NCT00630747|Experimental|Idursulfase|
11602415|NCT00630734|Experimental|SLCO1B1 Group 1|Participants with the SLCO1B1 *1A/*1A diplotype; Interventions: pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
11602416|NCT00630734|Experimental|SLCO1B1 Group 2|Participants with the SLCO1B1 *1A/*1B or *1B/*1B diplotype; Interventions: Pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
11602417|NCT00630734|Experimental|SLCO1B1 Group 3|Participants who carry at least one SLCO1B1 *5, *15, or *17 diplotype; Interventions: Pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
11602418|NCT00630721|Other|IFNbeta-1b|no drug was given under study. patients already taking IFNbeta-1b were enrolled for blood draw only.
11602419|NCT00630708|Active Comparator|1|Benazepril group
11602420|NCT00630708|Active Comparator|2|Losartan group
11602421|NCT00630708|Active Comparator|3|Benazepril+Losartan group
11602422|NCT00630695|Experimental|1|Lanreotide LP 90
11602423|NCT00630695|Placebo Comparator|2|
11602424|NCT00630682|Active Comparator|Dextroamphetamine|Active drug
11602425|NCT00630682|Placebo Comparator|Placebo|Placebo of drug
11602426|NCT00630669|Active Comparator|1|Rubber band ligation
11602427|NCT00630669|Active Comparator|2|Bipolar coagulation
11602428|NCT00630656|Experimental|1|Talactoferrin alfa
11602429|NCT00630656|Placebo Comparator|2|Placebo
11602434|NCT00630591|Experimental|Standardized Materials Group|
11602435|NCT00630591|Experimental|Independent Tailored Intervention|
11602436|NCT00630591|Experimental|Partner-Assisted Tailored Intervention|
11602437|NCT00630578|Active Comparator|1|Cognitive Processing Therapy
11602438|NCT00630578|No Intervention|2|Arm 2 participants will monitor their symptoms for a period of 10 weeks, prior to being crossed over into active treatment. This will allow investigators to account for the passage of time without intervention when tracking symptoms.
11602439|NCT00630565|Experimental|Bone Marrow Transplant (2-70 Years old)|Patients over the age of two will receive a cytoreductive regimen of total-body irradiation and cyclophosphamide (TBI/CY) as well as sargramostim, dexamethasone, etoposide, transplantation (bone marrow transplantation/hematopoietic stem cell transplantation/peripheral blood stem cell transplantation).
11602440|NCT00630565|Experimental|Bone Marrow Transplant (less and 2 years old)|Patients under the age of two, and patients who cannot receive total body irradiation (TBI), will receive a cytoreductive regimen of Busulfan and cyclophosphamide (BU/CY) as per the Johns Hopkins University Hospital regimen as well as sargramostim, dexamethasone, etoposide, transplantation (bone marrow transplantation/hematopoietic stem cell transplantation/peripheral blood stem cell transplantation).
11602441|NCT00630552|Placebo Comparator|Placebo + Gemcitabine|
11602442|NCT00630552|Experimental|AMG 655 + Gemcitabine|
11602443|NCT00630552|Experimental|AMG 479 + Gemcitabine|
11602444|NCT00630539|Placebo Comparator|Subjects on placebo|Subjects will self-administer 1 placebo tablet daily (in the morning with food) for 12 weeks
11602445|NCT00630539|Experimental|Subjects on ospemifene 5 mg/day|Subjects will self-administer 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks
11602446|NCT00630539|Experimental|Subjects on ospemifene 15 mg/day|Subjects will self-administer 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks
11602447|NCT00630539|Experimental|Subjects on ospemifene 30 mg/day|Subjects will self-administer 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks
11602448|NCT00630513|Experimental|E|3 days regimen with Ertapenem
11602449|NCT00630513|Active Comparator|AS|3 days treatment with Ampicillin-Sulbactam
11602450|NCT00630500|Active Comparator|Memantine|Active treatment with memantine
11602451|NCT00630500|Placebo Comparator|Placebo|Placebo matching active study drug
11602452|NCT00630487|Placebo Comparator|Placebo|
11602453|NCT00630487|Active Comparator|Verum|
11602454|NCT00630474|Active Comparator|1|nasal application of xylometazoline
11602455|NCT00630474|Placebo Comparator|2|nasal application of placebo
11602456|NCT00630448||Group 1|Control Group. Normal (healthy) individuals without Von Willebrand Disease.
11602457|NCT00630448||Group 2|Case Group. Individuals with known Von Willebrand Disease.
11602458|NCT00630435|Experimental|1|
11602459|NCT00630435|Experimental|2|
11602460|NCT00630435|Experimental|3|
11602461|NCT00630435|Active Comparator|4|
11602462|NCT00630422||64|All Patients
11602463|NCT00630409|Experimental|Treatment|Patients will receive 3 cycles of therapy as an outpatient. Each 21-day cycle of therapy will comprise: Gemcitabine: IV on days 1 and 8. Doxil: on day 1. Patients with either responding or stable disease will continue to receive additional 3 cycles of therapy with gemcitabine and Doxil until there is radiological evidence of disease progression or they are unable or unwilling to continue treatment.
11602464|NCT00630383|Experimental|1|Patients will receive 25 live hookworm larvae.
11602465|NCT00630383|Placebo Comparator|2|Patients will receive 0.01 % histamine solution.
11602466|NCT00630370|Placebo Comparator|1|2 Placebo tablets, TID, orally, 58 days
11602467|NCT00630370|Experimental|2|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
11602468|NCT00630370|Experimental|3|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
11602469|NCT00630370|Experimental|4|2 ATI 40mg tablets, TID, orally, 58 days
11602470|NCT00630344|Experimental|RAD001 + Bicalutamide|"RAD001: once daily dose of 10 mg (5 mg tablets)
~Bicalutamide: once daily dose of 50 mg (50 mg tablets)
~1 cycle=28 days
~Both agents are administered continuously until progression of disease or unacceptable toxicity."
11602471|NCT00630331|Experimental|CCI|Subjects received one dose of cell culture-derived influenza vaccine.
11602472|NCT00630331|Experimental|IVV|Subjects received one dose of the trivalent egg-derived influenza vaccine.
11602473|NCT00630331|Placebo Comparator|Placebo|Subjects received one dose of phosphate buffered solution (PBS).
11602474|NCT00630305|Other|Session A|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session A only contains senofilcon A toric and alphafilcon A toric lenses.
11602475|NCT00630305|Other|Session B|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session B only contains senofilcon A toric and alphafilcon A toric lenses.
11602476|NCT00630305|Other|Session C|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session C only contains senofilcon A toric and lotrafilcon B toric lenses.
11602477|NCT00630305|Other|Session D|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session D only contains senofilcon A toric and lotrafilcon B toric lenses.
11602478|NCT00630292|Experimental|1|
11602479|NCT00630279|Placebo Comparator|1|
11602480|NCT00630279|Experimental|2|
11602481|NCT00630279|Experimental|3|
11602482|NCT00630279|Experimental|4|
11602483|NCT00630253|Experimental|Cyclophosphamide/Fludarabine/ATG|Patients with Fanconi Anemia receiving cyclophosphamide, fludarabine phosphate, antithymocyte globulin followed by matched sibling donor hematopoietic stem cell transplantation (HSCT). Patients also receive Mycophenolate Mofetil, methylprednisolone, cyclosporine and filgrastim.
11602484|NCT00630240||1|only one arm for study
11602485|NCT00630227|Experimental|Single|all patients are treated with the experimental therapy
11602486|NCT00630214|No Intervention|C|No supplements after total thyroidectomy and central neck dissection
11602487|NCT00630214|No Intervention|D|No central neck dissection group (total thyroidectomy alone)
11602488|NCT00630214|Active Comparator|A|Oral calcium plus vitamin D supplements after total thyroidectomy and central neck dissection
11602489|NCT00630214|Active Comparator|B|Oral calcium alone supplement after total thyroidectomy and central neck dissection
11602490|NCT00630201|Experimental|Probuphine|buprenorphine implant
11602491|NCT00630188|Experimental|1|"For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with physician
~For Physicians: a one-time educational session on prostate cancer and the value of shared decision making"
11602492|NCT00630188|Active Comparator|2|Highway Safety video
11602493|NCT00630149|Experimental|1|
11602494|NCT00630136||A|Adult parent or legally authorized representative (LAR) of child who has consented to undergo an out-patient endoscopy at Children's Mercy Hospital as a diagnostic procedure
11602495|NCT00630123||1|Electroconvulsive Therapy (ECT): blood sample taken from this group at start and after therapy; subjects not randomized to therapy option.
11602496|NCT00630123||2|Transcranial Magnetic Stimulation (TMS): blood sample taken from this group at start and after therapy; subjects not randomized to therapy option.
11602497|NCT00630110|Active Comparator|docetaxel|docetaxel (75 mg/m2)
11602498|NCT00630110|Experimental|NPI-2358 + docetaxel|NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
11602499|NCT00630084|Active Comparator|A|40 naïve CHC patients concomitant with malignancy other than hepatocellular carcinoma
11602500|NCT00630084|Active Comparator|B|80 naïve CHC patients without malignancy
11602501|NCT00630058|Experimental|Group A (MP-424 High)|
11602502|NCT00630058|Experimental|Group B (MP-424 Low)|
11602503|NCT00630045|Experimental|1|2~3 cycles of neoadjuvant chemotherapy before resection of liver metastasis
11602504|NCT00630045|Active Comparator|2|no neoadjuvant chemotherapy, resect the liver metastasis directly
11602505|NCT00630032|Active Comparator|Arm A|3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of D (100 mg/m² every 3 weeks)
11602506|NCT00630032|Experimental|Arm B|3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of Ixabepilone (40 mg/m² every 3 weeks);
11602507|NCT00630019|Experimental|1|
11602508|NCT00630019|Active Comparator|2|
11602509|NCT00629993|Experimental|Multi-component Academic Detailing|"Multi-component, academic detailing regarding ACS guidelines on cervical cancer screening approaches.
~Includes an interactive, digitized CD-ROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients."
11602510|NCT00629980|Experimental|1|
11602511|NCT00629980|No Intervention|2|
11602512|NCT00629967|Active Comparator|A|Eligible patients will be randomized into two groups with a ratio of 1:1 (Arm A & B)
11602513|NCT00629967|Active Comparator|B|Eligible patients will be randomized into two groups with a ratio of 1:1 (Arm A & B)
11602514|NCT00629954||I|
11602515|NCT00629941|Experimental|1|
11602516|NCT00629928|Experimental|1|20mg capsule once daily
11602517|NCT00629928|Experimental|2|40mg capsule daily
11602518|NCT00629928|Placebo Comparator|3|
11602519|NCT00629902||A1|Patients with prosthesis-patient mismatch after mitral valve replacement
11602520|NCT00629902||A2|Patients without prosthesis mismatch after mitral valve replacement
11602521|NCT00629889|Active Comparator|Levetiracetam|Patients assigned to Levetiracetam are treated with the initial dose of 2 x 250mg per day up to one year
11602522|NCT00629889|Active Comparator|Pregabalin|Patients assigned to Pregabalin are treated with the initial dose of 2 x 75mg per day up to one year
11602523|NCT00629876|Experimental|Peginesatide|
11602524|NCT00629850|Experimental|Powerlung Performer|The arm will receive the lung trainer device to use for 10 weeks
11602525|NCT00629850|No Intervention|Control|Control. This arm will not receive any device
11602526|NCT00629837|Experimental|Arm 1|
11602527|NCT00629837|Experimental|Arm 2|
11602528|NCT00629837|Active Comparator|Arm 3|
11602529|NCT00629837|Active Comparator|Arm 4|
11602530|NCT00629824|Active Comparator|A|110 naïve CHC patients who are 65 to 80 years of age
11602531|NCT00629824|Active Comparator|B|140 naïve CHC patients who are 50 to 64 years of age
11602532|NCT00629824|Active Comparator|C|40 HCV-1 infected patients with an RVR who are 65-80 years of age will receive 24 weeks of treatment
11602533|NCT00629798|Experimental|1|This is a single arm phase II trial to assess the efficacy (decrease the transplant related mortality) and safety of peri-transplant Palifermin in combination with a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with advanced MDS and AML evolved from MDS. The addition of Palifermin is to decrease the toxicity and the infection rate associated with this regimen and transplant type and to foster earlier immune reconstitution.
11602534|NCT00629772|Placebo Comparator|Placebo then infliximab|Placebo at weeks 0, 2, 6 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.
11602535|NCT00629772|Active Comparator|Infliximab|Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
11602536|NCT00629759|Experimental|1|1e8 pfu (plaque forming units)total dose each treatment day
11602537|NCT00629759|Experimental|2|3e8 pfu (plaque forming units) total dose each treatment day
11602538|NCT00629759|Experimental|3|1e9 pfu (plaque forming units) total dose each treatment day
11602539|NCT00629759|Experimental|4|3e9 pfu (plaque forming units) total dose each treatment day
11602540|NCT00629746|Experimental|NIM (Nerve Integrity Monitor)|
11602541|NCT00629733|Experimental|Ro-14|
11602542|NCT00629707|Active Comparator|1|Slower infusion rate: Patients in this arm will receive an initial intravenous fluid bolus of 10cc/Kg followed by rehydration calculated to replace a deficit of 7.5% of body weight over 48 hours.
11602655|NCT00628836|Active Comparator|SE group|surface stimulation
11602656|NCT00628836|Experimental|BE group|BION stimulation
11602543|NCT00629707|Active Comparator|2|More rapid infusion: Patients in this arm will receive an initial bolus of 20 cc/Kg of intravenous fluids followed by replacement of an estimated deficit of 10% of body weight over 36 hours plus replacement of 1/2 of urine output volume.
11602544|NCT00629694|Active Comparator|A-T|
11602545|NCT00629694|Experimental|A-M|
11602546|NCT00629681|Experimental|1|
11602547|NCT00629655||1|healthy people, male
11602548|NCT00629655||2|male patients with cerebral infarction, chronic stage
11602549|NCT00629642|Experimental|I.Solifenacin succinate 10mg (2x5mg 1/day)|Oral
11602550|NCT00629642|Experimental|II.Solifenacin succinate 5mg (5mg 1/day)|Oral
11602551|NCT00629642|Active Comparator|III.Oxybutynin hydrochloride 15mg (5mg 3/day)|Oral
11602552|NCT00629642|Placebo Comparator|IV. Placebo|Oral
11602553|NCT00629629|Other|I, Intervention|
11602554|NCT00629616|Experimental|Arm A|Anastrozole
11602555|NCT00629616|Experimental|Arm B|Fulvestrant
11602556|NCT00629603|Experimental|cytokine polymorphisms, HCV infection|Relate the fibrosis cytokine gene polymorphisms with disease severity of HCV-related chronic liver disease
11602557|NCT00629590|Experimental|1|
11602558|NCT00629590|No Intervention|2|
11602559|NCT00629564|Active Comparator|1|20mg oral
11602560|NCT00629564|Active Comparator|2|15 minute intravenous infusion
11602561|NCT00629551|Experimental|Saredutant 100mg and Paroxetine 20 mg|combined saredutant 100mg and paroxetine 20mg once daily for a maximum of 8 weeks
11602562|NCT00629551|Experimental|Saredutant 30mg and Paroxetine 20mg|combined saredutant 30mg and paroxetine 20mg once daily for a maximum of 8 weeks
11602563|NCT00629551|Active Comparator|Paroxetine 20 mg and saredutant placebo|paroxetine 20mg and saredutant placebo once daily for a maximum of 8 weeks
11602564|NCT00629551|Placebo Comparator|Placebo|Saredutant placebo and paroxetine placebo once daily for one week during screening period and maximum of 8 weeks for the active phase
11602565|NCT00629525|Experimental|RAD001|RAD001 at a dose of 10 mg PO daily
11602566|NCT00629512|Experimental|1|20mg oral daily
11602567|NCT00629512|Experimental|2|40mg oral daily
11602568|NCT00629512|Placebo Comparator|3|
11602569|NCT00629499|Experimental|Intervention|100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle) in combination with 600 mg/m2 of IV cyclophosphamide once every 3 weeks for 4 cycles (i.e., a total treatment period of 12 weeks [84 days]). Patients with fluorescence in situ hybridization (FISH) HER2+ or IHC3+ breast cancer will also receive treatment with trastuzumab in addition to the nab paclitaxel / cyclophosphamide combination therapy. Maintenance therapy with trastuzumab will continue (for the HER2+ patients who are receiving trastuzumab) after the 12-week treatment period with combination nab paclitaxel/cyclophosphamide/trastuzumab. The total treatment time for trastuzumab will be 52 weeks rather than only 12 weeks.
11602570|NCT00629486|Experimental|cytokines were determined|prevalence of genetic polymorphisms of interleukin 1B was measured in HBV-related hepatocellular carcinoma
11602571|NCT00629473|Experimental|Arm AM: advanced malignancies|Dose Escalation - 9 dose cohorts NPI-0052 on Days 1, 8, 15 every 28 days NPI-0052 doses ranging from 0.1 to 0.9 mg/m2
11602572|NCT00629473|Experimental|Arm MM: multiple myeloma|Dose Escalation - 8 dose cohorts NPI-0052 on Days 1, 4, 8, 11 every 21 days NPI-0052 doses ranging from 0.075 to 0.6 mg/m2 Dexamethasone 20 mg oral or IV day before and day after NPI-0052 dosing.
11602573|NCT00629460||1|there is only one group/cohort. This is a non-therapeutic study.
11602574|NCT00629447|Experimental|1|The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
11602575|NCT00629434|Experimental|1|This arm will receive diabetes education via telemedicine
11602576|NCT00629434|Active Comparator|2|diabetes education in-person
11602577|NCT00629395|Experimental|1|Participate in 12 week computer program.
11602578|NCT00629382|Experimental|1|
11602579|NCT00629382|Other|2|
11602580|NCT00629369|Experimental|A|subjects with Occlusion Support Device with active pushing in the second stage of labor
11602581|NCT00629369|No Intervention|2|Subjects without Occlusal Support Device with active pushing in the second stage of labor
11602582|NCT00629343|Experimental|Treatment|
11602583|NCT00629330|Experimental|Multi-component Academic Detailing|Includes an interactive, digitized CDROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients.
11602584|NCT00629317|Active Comparator|A|
11602585|NCT00629317|Placebo Comparator|B|
11602586|NCT00629304|Placebo Comparator|1|standard visit at 3 and 6 months
11602587|NCT00629304|Active Comparator|2|PDA-FIT system + standard visit at 3 and 6 months
11602588|NCT00629304|Active Comparator|3|PDA-FIT system + 12 telephone visits + standard visit at 6 months
11602589|NCT00629291||1|Sickle cell anemia patients
11602590|NCT00629291||2|Sickle cell β thalassemia
11602591|NCT00629265|Active Comparator|Active NMES + Swallowing Exercise|Active Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES) therapy will be paired concomitantly with repeated effortful sallowing exercises, for 60 swallows, 2 times per day, 6 days per week, for 12 weeks.
11602592|NCT00629265|Sham Comparator|Sham NMES + Swallowing Exercise|Sham (inactive) Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES) therapy will be paired concomitantly with repeated effortful sallowing exercises, for 60 swallows, 2 times per day, 6 days per week, for 12 weeks.
11602593|NCT00629252|Experimental|1|Schizophrenic patients treated with sertindole
11602594|NCT00629252|Active Comparator|2|Schizophrenic patients treated with risperidone
11602595|NCT00629252|No Intervention|3|Healthy controls without any treatment.
11602596|NCT00629239|Experimental|1|AZD4818
11602597|NCT00629239|Placebo Comparator|2|Placebo
11602598|NCT00629226|Experimental|Group I|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8, 11, 22, 25, 29, 32, 43, 46, 50, and 53. Beginning on day 8 or 9, patients undergo standard intensity-modulated radiotherapy (IMRT) once daily, 5 days a week, for up to 8 weeks.
11602657|NCT00628823|No Intervention|A1|Gluten-containing diet
11602658|NCT00628823|Active Comparator|A2|Gluten-free diet
11602599|NCT00629226|Experimental|Group II|Patients receive cetuximab, bortezomib (beginning at one dose level below the MTD determined in group I), and IMRT as in group I. Patients also receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, and 57.
11602600|NCT00629213|Active Comparator|1|
11602601|NCT00629213|Placebo Comparator|2|
11602602|NCT00629200|Experimental|SSG + Intron A|Sodium Stibogluconate (SSG) 400 mg/m^2 intravenous (IV) daily on days 1-5 + Interferon Alfa-2b (Intron A) 3x10^6 units subcutaneously three times weekly
11602603|NCT00629187|Experimental|1|
11602604|NCT00629174|Experimental|1|Exercise
11602605|NCT00629174|Experimental|2|Mental training (computer lessons)
11602606|NCT00629174|No Intervention|3|
11602607|NCT00629161|Experimental|A|
11602608|NCT00629161|Placebo Comparator|B|
11602609|NCT00629148|Active Comparator|combination chemotherapy|Simultaneous use of Vinorelbine and Capecitabine
11602610|NCT00629148|Experimental|sequential chemotherapy|Sequential use of Vinorelbine and Capecitabine
11602611|NCT00629135|Experimental|1|For adult patients with intra-abdominal abscesses matching the criteria to be included will and enrolled in the study arm 1: Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily.
11602612|NCT00629135|Active Comparator|2|For adult patients with intra-abdominal abscesses matching the criteria to be included will and enrolled in the study arm 2: Piperacillin / Tazobactam 4,5 g administered intravenously three times daily
11602613|NCT00629122|Experimental|A: Tacrolimus and Nystatin Suspension|"Administer sublingual tacrolimus 2 mg every 12 hours (subject weight < 90 kg) or 3 mg every 12 hours (subject weight > 90kg) (study day 1 - 3). Tacrolimus capsules will be opened and the contents placed under the participants tongue. Oral tacrolimus at same dose every 12 hours (study day 6 - 8). Tacrolimus capsules will be administered by mouth.
~Nystatin suspension 5 mL every 12 hours (study days 1 - 3 and 6 - 8)."
11602614|NCT00629122|Experimental|B: Tacrolimus and Clotrimazole Troche|"Administer sublingual tacrolimus 1 mg every 12 hours (subject weight < 90 kg) or 2 mg every 12 hours (subject weight > 90 kg) (study day 1 - 3). Tacrolimus capsules will be opened and the contents placed under the participants tongue. Oral tacrolimus at same dose every 12 hours (study day 6 - 8). Tacrolimus capsules will be administered by mouth.
~Clotrimazole troche 10 mg every 12 hours (study day 1 - 3 and 6 - 8)."
11602615|NCT00629096|Experimental|1|All included patients are assigned to arm 1, in which they are treated by the intervention
11602616|NCT00629083|Experimental|1|Bulkamid Hydrogel injection
11602617|NCT00629083|Active Comparator|2|Contigen injection
11602618|NCT00629070|Experimental|ST|Traditional strength training
11602619|NCT00629070|Experimental|VT|Velocity-enhanced training
11602620|NCT00629057|Experimental|1|Lowest dose level
11602621|NCT00629057|Experimental|2|Middle level dose
11602622|NCT00629057|Experimental|3|Highest dose level
11602623|NCT00629044|Active Comparator|G|
11602624|NCT00629044|Active Comparator|AMD|
11602625|NCT00629044|Active Comparator|Healthy subjects|
11602626|NCT00629031|Active Comparator|2|Paromomycin for 21 days @ 11mg/kg
11602627|NCT00629031|Experimental|1|Paromomycin for 14 days @ 11mg/kg
11602628|NCT00629018|Experimental|SC Group|"SC therapy,'Bone Marrow Stimulation','CD34+ autologous stem cell transplantation':
~In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect"
11602629|NCT00629018|No Intervention|Controls|Patients receiving no cell therapy.
11602630|NCT00629005|Experimental|Arm 1|Constraint-Induced Movement Therapy (wear a mitt on non-paretic hand for 90% of waking hours + functional task practice for 3 hours) plus 1 hour of strength training for the arms and hands 3x/week
11602631|NCT00629005|Active Comparator|Arm 2|Constraint-Induced Movement Therapy (wear a mitt on non-paretic hand for 90% of waking hours + functional task practice for 3 hours) plus non-resisted arm and hand movements for 1 hour 3x/week
11602632|NCT00628992|Other|1|
11602633|NCT00628992|Active Comparator|2|
11602634|NCT00628992|Active Comparator|3|
11602635|NCT00628992|Active Comparator|4|
11602636|NCT00628979|Other|1|CBT
11602637|NCT00628953|Experimental|1|
11602638|NCT00628953|Placebo Comparator|2|
11602639|NCT00628940|Experimental|1|18F-fluoromethylcholine
11602640|NCT00628927||METH and/or cocaine dependent group|The METH and/or cocaine dependent group were also enrolled in CTN0031 (NCT00573183) and seeking treatment. This group will be analyzed based on whether or not they completed treatment as defined by the study.
11602641|NCT00628927||Non METH and/or cocaine dependent group|The Non METH and/or cocaine dependent group participants are normal controls recruited from the community.
11602642|NCT00628914|Experimental|1|Open label escitalopram plus eszopiclone for 8 weeks
11602643|NCT00628914|Other|2|Escitalopram and eszopiclone for initial 4 weeks, then switch to escitalopram and placebo for final 4 weeks.
11602644|NCT00628914|Placebo Comparator|3|Escitalopram plus placebo for 8 weeks
11602645|NCT00628901|Experimental|Arm 1|
11602646|NCT00628901|Active Comparator|Arm 2|
11602647|NCT00628888|Experimental|Unified Protocol for Adolescents (UP-A)|Participants receive the UP-A intervention for 8-21 weeks immediately following randomization.
11602648|NCT00628888|Experimental|Delayed Treatment/Waitlist|Participants receive an 8-week waitlist condition with some attentional-control via monitoring for clinical deterioration. After a post-waitlist assessment, participants in this condition are offered the UP-A treatment for 8-21 weeks.
11602649|NCT00628862|Experimental|F 4.5 bid|Formoterol 4.5 ug twice daily (bid)
11602650|NCT00628862|Experimental|F 9.0 bid|Formoterol 9.0 ug bid
11602651|NCT00628862|Placebo Comparator|PBO|Placebo
11602652|NCT00628849||1|This group will have 2 mm plates and screws placed according to Champy principles
11602653|NCT00628849||2|This group will have 2 mm plates placed according to modified Champy principles
11602654|NCT00628849||3|This group will have larger (2.3 mm or greater) plates and screws placed according to the AO technique
11602659|NCT00628810|Experimental|FOLFIRI fort plus bevacizumab|Bevacizumab 5 mg/kg D1, irinotecan 260 mg/m2 D1, LV 400 mg/m2 D1, 5FU 400 mg/m2 IV bolus D1, and 5FU 2,400 mg/m2 46-hour infusion D1-2 every 2 weeks. Treatment was started within 2 weeks after inclusion in the study.
11602660|NCT00628797|Other|A UVA1 B no UVA1|half body irradiation with random allocation right and left; after three months of treatment treatment of both sides
11602661|NCT00628797|Experimental|A UVA1|
11602662|NCT00628784|Experimental|Group 1|Specialized intestinal metaplasia (Barrett's esophagus) documented via endoscopic esophageal biopsy, with standard surveillance biopsies (four-quadrant biopsies obtained every 2-cm the entire length of the specialized intestinal metaplasia in the esophagus) performed within the past two years prior to study enrollment. Biopsies show either low grade dysplasia, indeterminate for dysplasia, or no dysplasia.
11602663|NCT00628784|Experimental|Group 2|Diagnosis of Barrett's esophagus and high grade dysplasia or intramucosal carcinoma. Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney, or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement). Endoscopic ultrasound* (EUS) demonstrating no evidence of metastatic lymph node involvement or extension of carcinoma beyond the mucosa (T1).
11602664|NCT00628784|Experimental|Group 3|Diagnosis of esophageal carcinoma (T1smN0 or T2N0 via EUS). Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney, or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement).
11602665|NCT00628784|Experimental|Group 4|Diagnosis of severe dysplasia within esophageal squamous mucosa on pathology review. Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement). EUS with no evidence of metastatic lymph node involvement or extension of carcinoma beyond the mucosa.
11602666|NCT00628771|Active Comparator|Usual Care|Participants will receive usual care for their prenatal visits.
11602667|NCT00628771|Experimental|CenteringPregnancy Plus|Participants will receive the CenteringPregnancy Plus treatment program, which includes an HIV/STD prevention component.
11602668|NCT00628758|Experimental|Symbicort|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
11602669|NCT00628758|Experimental|Conventional BP|Conventional Best Practice for Treatment of Asthma
11602670|NCT00628745||Observational|
11602671|NCT00628732|Experimental|1|
11602672|NCT00628719|Experimental|1|a single dose of 10 mg/kg of liposomal amphotericin B
11602673|NCT00628719|Active Comparator|2|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
11602674|NCT00628706|Experimental|A|Inhalation of THC, using a Volcano vaporizer
11602675|NCT00628706|Placebo Comparator|B|Inhalation of vehicle, using a Volcano vaporizer
11602676|NCT00628680|Experimental|AAT-023 (Zuragen Arm)|Active experimental consisting of AAT-023 (Zuragen)solution
11602677|NCT00628680|Active Comparator|Heparin|5000 units diluted with normal saline to the exact catheter lumen volume
11602678|NCT00628667|Experimental|1|
11602679|NCT00628667|Placebo Comparator|2|
11602680|NCT00628654||Volunteers|Serum samples will be obtained from volunteers, but no tissue specimens. Volunteers will complete a questionnaire.
11602681|NCT00628654||Patients with cancer|Ascites from patients with ovarian, peritoneal, and fallopian tube cancers for basic science studies
11602682|NCT00628628|Experimental|Group A|As Needed Rasburicase .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
11602683|NCT00628628|Experimental|Group B|Fixed Dose Rasburicase .15 mg/kg IV Over 30 Minutes Daily
11602684|NCT00628615||2|male patients with lower urinary tract symptoms
11602685|NCT00628615||1|Female patients with overactive bladder syndrome
11602686|NCT00628602|Experimental|Rx Group|BION Therapy Group
11602687|NCT00628602|Placebo Comparator|Control Group|control group
11602688|NCT00628589|Experimental|Inhaled Loxapine 5 mg|Inhaled Loxapine 5 mg, may repeat x 1 or 2 after 2 hours
11602689|NCT00628589|Experimental|Inhaled Loxapine 10 mg|Inhaled Loxapine 10 mg, may repeat x 1 or 2 after 2 hours
11602690|NCT00628589|Placebo Comparator|Inhaled placebo|Inhaled Loxapine placebo, may repeat x 1 or 2 after 2 hours
11602691|NCT00628576|Active Comparator|1|UFH: patients treated with unfractionated heparin
11602692|NCT00628576|Experimental|2|FH: patients treated with low-molecular-weight (fractionated) heparin
11602693|NCT00628563||1|Asthma patients
11602694|NCT00628550|Experimental|1|Pediatric patients that experience in-hospital CPA who remain in cardiac arrest despite CPR and an initial, standard dose of epinephrine (0.01 mg/kg), will be randomly assigned to receive vasopressin (0.8 units/kg) rescue as the second vasopressor medication.
11602695|NCT00628550|Active Comparator|2|Pediatric patients that experience in-hospital CPA who remain in cardiac arrest despite CPR and an initial, standard dose of epinephrine (0.01 mg/kg), will be randomly assigned to receive standard dose epinephrine (0.01 mg/kg)rescue as the second vasopressor medication.
11602696|NCT00628537|Experimental|1|BION™ Experimental Group
11602697|NCT00628537|Active Comparator|2|Surface Stimulation Group
11602698|NCT00628537|Active Comparator|3|Control Group with conservative therapy (Range of motion exercises)
11602699|NCT00628524||1|> 500 consecutive patients with coronary artery disease fulfilling eligibility criteria.
11602700|NCT00628511||observation|
11602701|NCT00628498|Experimental|Defibrotide|Defibrotide 25 mg/kg day given in 4 divided doses approximately every 6 hours
11602702|NCT00628485|Experimental|Low Stimulation|"The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation."
11602703|NCT00628485|Experimental|High Stimulation|"The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions."
11602704|NCT00628485|Placebo Comparator|Control Group|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises.
11602705|NCT00628459|Active Comparator|1|
11602708|NCT00628433|Placebo Comparator|1|Placebo
11602709|NCT00628433|Experimental|2|HE3286 5 mg daily
11602710|NCT00628433|Experimental|3|HE3286 10 mg daily
11602711|NCT00628433|Experimental|4|HE3286 20 mg daily
11602712|NCT00628433|Experimental|5|HE3286 4 mg daily
11602713|NCT00628420|Other|1|Patients recieved single low dose of ACP-104
11602714|NCT00628420|Other|2|Patients recieved a high dose of ACP-104
11602715|NCT00628420|Other|3|Patients recieved a placebo
11602716|NCT00628394|Other|Atomox/CR|Patients are given the drug Atomoxetine and Cognitive Remediation training.
11602717|NCT00628394|Other|Atomox/Control|Patients are given the drug Atomoxetine and Remediation Control training.
11602718|NCT00628394|Other|Placebo/CR|Patients are given a Placebo and Cognitive Remediation training.
11602719|NCT00628394|Other|Placebo/Control|Patients are given Placebo and Remediation Control training.
11602720|NCT00628381|Experimental|AA|24 ICU patients with severe sepsis will get a L-citrulline 8 h enteral supplementation.
11602721|NCT00628381|Active Comparator|AB|24 ICU patients with severe sepsis will get an alternative isocaloric amino acid supplementation (L-alanine) during 8 hours
11602722|NCT00628355|Experimental|lidocaine injection|"Lidocaine injection. Women randomized for this treatment was submitted to 2 milliliters of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point.
~Patients received lidocaine injections once a week for 4 weeks"
11602723|NCT00628355|Experimental|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation (TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
11602724|NCT00628342|Experimental|1|
11602725|NCT00628342|Experimental|2|
11602726|NCT00628342|Placebo Comparator|3|
11602727|NCT00628329||1|
11602728|NCT00628329||2|
11602729|NCT00628303|Experimental|1|Motavizumab
11602730|NCT00628303|Placebo Comparator|2|Placebo
11602731|NCT00628290|Experimental|1|
11602732|NCT00628290|Active Comparator|2|
11602733|NCT00628277|Experimental|1|Arm 1: high caloric expenditure exercise plus dietary counseling
11602734|NCT00628277|Active Comparator|2|Arm 2: low caloric expenditure exercise plus dietary counseling
11602735|NCT00628264|Experimental|AP214|
11602736|NCT00628264|Placebo Comparator|Placebo|
11602737|NCT00628251|Experimental|1|AZD2281 Oral 200 mg BID
11602738|NCT00628251|Active Comparator|2|Liposomal Doxorubicin
11602739|NCT00628251|Experimental|3|AZD2281 Oral 400 mg BID
11602740|NCT00628238|Active Comparator|A|Subjects younger than 65 years old.
11602741|NCT00628238|Active Comparator|B|Subjects aged 65 years and older
11602742|NCT00628225|No Intervention|1|Usual Care
11602743|NCT00628225|Experimental|2|Multifacetted smoking cessation intervention (aimed at professional (training and education) and at patients (counseling + nicotine replacement)
11602744|NCT00628225|Experimental|3|Multifacetted smoking cessation intervention (aimed at professional (training and education) and at patients (counseling + nicotine replacement + bupropion-SR)
11602745|NCT00628212|Experimental|Teneligliptin 10 mg|Teneligliptin 10 mg, orally, once daily
11602746|NCT00628212|Experimental|Teneligliptin 20 mg|Teneligliptin 20 mg, orally, once daily
11602747|NCT00628212|Experimental|Teneligliptin 40 mg|Teneligliptin 40 mg, orally, once daily
11602748|NCT00628212|Placebo Comparator|Placebo|Teneligliptin placebo-matching tablets, orally, once daily
11602749|NCT00628186|Experimental|1|Pancreaticojejunostomy has a risk factor of pancreatic fistula. Type of stent tube (external stent vs. short stent)across pancreaticojejunostomy was randomized for the patients with pancreaticoduodenectomy.
11602750|NCT00628173|Experimental|1|patients with refractory glaucoma who were candidate for AGV implantation allocated in superior site
11602751|NCT00628173|Experimental|2|patients with refractory glaucoma who were candidate for AGV implantation allocated in inferior site
11602752|NCT00628160|Experimental|Terlipressin group|Terlipressin in continuous infusion plus alpha adrenergic drugs (noradrenaline and/or dopamine in continuous infusion)
11602753|NCT00628160|Active Comparator|Control group|Alpha adrenergic drugs (noradrenaline and/or dopamine in continuous infusion)
11602754|NCT00628147|Experimental|Narrow band imaging colonoscope|narrow band imaging colonoscope
11602755|NCT00628147|No Intervention|White Light|Conventional White Light Examination
11602756|NCT00628134|Experimental|1|Subjects inhaled calfactant then isotonic saline
11602757|NCT00628134|Experimental|2|Subjects inhaled isotonic saline then calfactant
11602758|NCT00628121|Experimental|Cetrorelix 1 mg|
11602759|NCT00628121|Experimental|Cetrorelix 2 mg|
11602760|NCT00628121|Experimental|Cetrorelix 3 mg|
11602761|NCT00628108|Placebo Comparator|Placebo|
11602762|NCT00628108|Experimental|Levocetirizine|
11602763|NCT00628095|Experimental|Active|
11602764|NCT00628095|Placebo Comparator|Placebo|
11602765|NCT00628082||HfpEF|Patients with Heart Failure with preserved ejection fraction
11602766|NCT00628082||Control|Healthy Volunteers
11602767|NCT00628069||Group 1|performers who will participate in the training sessions.
11602768|NCT00628069||Assistants|Assisants-paired with the performers and will be allowed to assists only, without the opportunity to practice the technical skills related to the task.
11602769|NCT00628056|Active Comparator|1|
11602770|NCT00628056|Placebo Comparator|2|
11602771|NCT00628043|Experimental|EPOCH|
11602772|NCT00628043|Placebo Comparator|placebo|
11602813|NCT00627744|Placebo Comparator|BE 1|Patients in this arm are randomly assigned to treatment with placebo
11602919|NCT00627068||4|Low cardiovascular risk age over 25 under 61.
11602773|NCT00628030|Experimental|NOURISH|The first 2 waves and second 2 waves of participants will receive a 12 and 6 week face-to-face intervention (NOURISH), respectively. The interventions differ only in duration. They cover the same concepts which are grounded in Social Cognitive Theory (SCT). Throughout the interventions the influence of social learning on behavioral outcomes (e.g., parent's modeling of healthy behavior) will be emphasized. Weekly topics provide information about implementing healthy lifestyle behaviors, authoritarian parenting approaches, and strategies for overcoming barriers to change. Parents will receive pedometers for themselves and 1 of their children. A one-hour booster session will be available for all intervention participants 2 months after completion of the interventions.
11602774|NCT00628030|Placebo Comparator|Wellness Group|The placebo control group will attend a group session moderated by an independent interventionist. This interventionist will be blinded to the Specific Aims and hypotheses of this study. The session will address the role of diet and exercise in pediatric overweight. In addition, control parents will receive pedometers (and instructions on their use) for themselves and 1 of their children. Finally, control participants will be mailed publicly available brochures on pediatric overweight on 2 occasions during the study. Control participants will also be sent home one additional packet of information (essentially a review of previous mail outs) 2 months after post-testing.
11602775|NCT00628017|Experimental|1|omega-3 PUFAs(180mg eicosapentaenoic acid[EPA] + 120mg docosahexaenoic acid[DHA]/capsule), 3 capsules twice daily, total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA
11602776|NCT00628017|Placebo Comparator|2|three identical placebo capsules twice daily which contained olive oil esters.
11602777|NCT00628004|Experimental|1|
11602778|NCT00628004|Active Comparator|2|
11602779|NCT00628004|No Intervention|No treatment|No treatment as wound was healed
11602780|NCT00627978|Experimental|Ixabepilone|Participants are treated with Ixabepilone.
11602781|NCT00627978|No Intervention|Control|
11602782|NCT00627965|Experimental|1|Sildenafil citrate
11602783|NCT00627965|Placebo Comparator|2|Placebo
11602784|NCT00627952|Active Comparator|amlodipine 10 mg|
11602785|NCT00627952|Active Comparator|manidipine 20 mg|
11602786|NCT00627926|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
11602787|NCT00627926|Experimental|Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week|Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.
11602788|NCT00627926|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.
11602789|NCT00627913|Active Comparator|1|Healon 5
11602790|NCT00627913|Experimental|2|Retrobulbar Anesthetic Injection
11602791|NCT00627900|Other|BMS|Implantation of a bare metal stent
11602792|NCT00627900|Other|SES|Implantation of a sirolimus-eluting stent
11602793|NCT00627887|Experimental|ECT+pharmacotherapy|Unilateral brief pulse ECT weekly for 6 weeks thereafter every 2 weeks; Venlafaxine target dose 300mg/day; Lithium target dose 0,5-0,8 mmol/L.
11602794|NCT00627887|Active Comparator|pharmacotherapy|Venlafaxine target dose 300mg/day; Lithium 0,5-0,8 mmol/L.
11602795|NCT00627874|Experimental|1|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
11602796|NCT00627874|No Intervention|2|
11602797|NCT00627861|Experimental|Aliskiren and metoprolol succinate|
11602798|NCT00627835|Experimental|Treatment Group 1: Cohort 1|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
11602799|NCT00627835|Experimental|Treatment Group 1: sorafenib and radiation: Cohort 2|Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
11602800|NCT00627835|Experimental|Treatment Group 2: Cohort 3|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
11602801|NCT00627835|Experimental|Treatment Group 2: Cohort 4|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
11602802|NCT00627835|Experimental|Treatment Group 2:Cohort 5|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
11602803|NCT00627822||Ward|Patients in the hospital ward
11602804|NCT00627822||Emergency room|Patients in the emergency waiting room
11602805|NCT00627822||Intensive care unit|Family members of patients admitted to the intensive care unit
11602806|NCT00627809|Experimental|1|Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given
11602807|NCT00627809|Active Comparator|2|Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed
11602808|NCT00627796|Experimental|A|Newly diagnosed patients with acromegaly
11602809|NCT00627783|Experimental|Intervention|Patients are referred to a cardiologist for a systematic detection of silent ischemia by a bicycle exercise test performed according to the French Society of Cardiology protocol after washout of cardiovascular medications likely to interfere with the test. Dipyridamole Single Photon Emission Computed Tomography (SPECT) is used in patients unable to perform the exercise test, with a sub-maximal negative exercise test result or with electrocardiographic abnormalities impairing the interpretation of the exercise test. Subsequent investigations (such as coronary angiography) and treatments (such as revascularization procedures) are left at the cardiologist's decision.
11602810|NCT00627783|No Intervention|Control|Patients are treated according current guidelines but are not referred to a cardiologist
11602811|NCT00627757||Food challenge test|"Patients
~51 patients included"
11602812|NCT00627757||C|Controls 93 healthy controls are included
11602814|NCT00627744|Active Comparator|BE 2|Patients in this arm are randomly assigned to treatment with Sitagliptin
11602815|NCT00627731|Active Comparator|1|mPSL 240 mg per day for 5 days
11602816|NCT00627731|Experimental|2|PSL 40mg per day for 10 days
11602817|NCT00627718|Other|A|All patients with possible neovascular ARMD are assessed with HRT to determined the positive predictive value of the test
11602818|NCT00627705|Active Comparator|N-Acetyl Cysteine|active compound N-Acetyl Cysteine
11602819|NCT00627705|Placebo Comparator|Sugar pill|Placebo or sugar pill
11602820|NCT00627692|Active Comparator|1|Prucalopride
11602821|NCT00627692|Active Comparator|2|Prucalopride
11602822|NCT00627692|Active Comparator|3|Prucalopride
11602823|NCT00627692|Placebo Comparator|5|Placebo
11602824|NCT00627692|Active Comparator|4|Prucalopride
11602825|NCT00627679|Experimental|Treatment sequence: A, B, D, C|Treatment visits were separated by a 48-72 hour washout period. Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 2; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 3; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 4; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 5
11602826|NCT00627679|Experimental|Treatment sequence: B, C, A, D|Treatment visits were separated by a 48-72 hour washout period. Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 2; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 3; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 4; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 5
11602827|NCT00627679|Experimental|Treatment sequence: C, D, B, A|Treatment visits were separated by a 48-72 hour washout period. Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 2; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 3; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 4; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 5
11602828|NCT00627679|Experimental|Treatment sequence: D, A, C, B|Treatment visits were separated by a 48-72 hour washout period. Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 2; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 3; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 4; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 5
11602829|NCT00627653|Experimental|1|
11602830|NCT00627640|Experimental|1|1 active (50 - 100 mg/day)
11602831|NCT00627640|Placebo Comparator|2|
11602832|NCT00627627|Experimental|1|IPI-504
11602833|NCT00627614|Experimental|breast imaging study|
11602834|NCT00627588|Experimental|Dose Evaluation|To assess the safety and efficacy of up to three dose levels of ProSavin
11602835|NCT00627588|Sham Comparator|Sham element|The potential use of sham comparator to confirm efficacy
11602836|NCT00627575|Active Comparator|Lamotrigine|Subjects will receive 40 milligram (mg) of Atrovastatin from Days 1-7, from Days 8-56 subjects will receive Lamotrigine and Subjects will receive 300 mg/day of Lamotrigine and 40 mg/day of atorvastatin each morning on Days 57-77.
11602837|NCT00627575|Active Comparator|phenytoin|Subjects will receive 40 mg of Atrovastatin from Days 1-7, from Days 8-28, subjects will receive 4mg/kg/day of phenytoin in the morning and will continue to take 40 mg/day of atorvastatin each morning. Subjects will receive taper dose of phenytoin from Days 29-30.
11602838|NCT00627562|Experimental|1|robot assisted endoscopic head and neck surgery
11602839|NCT00627549|Active Comparator|1|
11602840|NCT00627549|Active Comparator|2|
11602841|NCT00627536|Experimental|1|Avotermin 5ng/100μL/linear cm wound margin
11602842|NCT00627536|Placebo Comparator|2|Placebo
11602843|NCT00627536|Experimental|3|Avotermin 50ng/100μL/linear cm wound margin
11602844|NCT00627536|Placebo Comparator|4|Placebo matched to avotermin 50ng/100μL/linear cm
11602845|NCT00627536|Experimental|5|Avotermin 200ng/100μL/linear cm
11602846|NCT00627536|Placebo Comparator|6|Placebo matched to avotermin 200ng/100μL/linear cm
11602847|NCT00627536|Experimental|7|Avotermin 500ng/100μL/linear cm wound margin
11602848|NCT00627536|Placebo Comparator|8|Placebo matched to avotermin 500ng/100μL/linear cm
11602849|NCT00627523|Experimental|Active|The active treatment arm
11602850|NCT00627523|Experimental|Control|Control
11602851|NCT00627510||A|all patients consecutively admitted to psychiatric inpatient treatment (naturalistic sample from routine psychiatric hospital intake)
11602852|NCT00627497|Experimental|DIAM Group1|
11602853|NCT00627497|Active Comparator|Single-Level Posterior Decompression|
11602854|NCT00627497|Experimental|DIAM Group2|
11602855|NCT00627497|Active Comparator|Posterolateral Interbody Fusion|
11602856|NCT00627484||Group 1: GBP non-diabetic|Non-diabetic subjects scheduled to receive gastric bypass
11602857|NCT00627484||Group 2: BND non-diabetic|Non-diabetic subjects scheduled to receive gastric banding
11602858|NCT00627484||Group 3: GBP diabetic|Diabetic subjects scheduled to receive gastric bypass
11602859|NCT00627484||Group 4: VLCD diabetic|Diabetic subjects scheduled to receive very low calorie diet
11602860|NCT00627484||Group 5: SG diabetic|Diabetic subjects scheduled to receive sleeve gastrectomy
11602861|NCT00627471|Active Comparator|A|This group must follow a defined algorithm. Only the physicians assigned to this group will know the algorithm.
11602862|NCT00627471|Active Comparator|B|This is the control group, following the physician's standard practice.
11602863|NCT00627458|Experimental|INFANRIX HEXA PF GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-free (PF) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
11602916|NCT00627068||1|High cardiovascular risk age over 61 years.
11602917|NCT00627068||2|Low Cardiovascular risk age over 61.
11602918|NCT00627068||3|High cardiovascular risk age over 25 but under 61.
11602864|NCT00627458|Experimental|INFANRIX HEXA PC GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-containing (PC) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
11602865|NCT00627458|Active Comparator|CONTROL GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the licensed formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
11602866|NCT00627445|Experimental|BIAsp 50-50-30|Biphasic insulin aspart 50 administered before breakfast and lunch + biphasic insulin aspart 30 at dinner combined with metformin
11602867|NCT00627445|Active Comparator|BIAsp 30-30|Biphasic insulin aspart 30 administered before breakfast and dinner combined with metformin
11602868|NCT00627419|Experimental|1|IPI-504
11602869|NCT00627406|Experimental|A|More than 14 follicles with a diameter of > 11mm: triggering of ovulation with 0.5 mg GnRHa (Buserelin) (s.c.) + 1500 IU hCG (Pregnyl)
11602870|NCT00627406|Active Comparator|B|More than 14 follicles with a diameter of > 11mm: triggering of ovulation with hCG (Pregnyl) 5.000 IU (s.c.)
11602871|NCT00627406|Experimental|C|14 or less follicles with a diameter of > 11mm: triggering of ovulation with 0.5 mg GnRHa (Buserelin) (s.c.) + 1500 IU hCG (Pregnyl) (s.c.) at 35 hours and 1500 IU hCG (Pregnyl) (s.c.) 7 days after triggering of ovulation (OPU + 5)
11602872|NCT00627406|Active Comparator|D|14 or less follicles with a diameter of > 11mm: triggering of ovulation with 5000 IU hCG (Pregnyl) (s.c.)
11602873|NCT00627393|Experimental|1|Participants will receive granulocyte transfusions in addition to standard antimicrobial therapy
11602874|NCT00627393|Active Comparator|2|Participants will receive standard antimicrobial therapy alone
11602875|NCT00627393|Other|3|Participants will donate granulocytes after receiving a combination of two drugs, G-CSF and dexamethasone
11602876|NCT00627380|Placebo Comparator|STOC|Standard of care arm continues to receive standard of care treatment for HIV, but does not receive any new treatment/intervention or change in anti-HIV medications. Runs parallel to experimental group. At the end of this 16-wk control period, participants are invited to crossover into the experimental group
11602877|NCT00627380|Experimental|YOGA|Yoga lifestyle intervention administered by certified yoga instructor.
11602878|NCT00627367|Experimental|Protocolized|"1mg IV hydromorphone followed by an additional 1mg at 15 minutes if the patient answer yes to the question, Do you want more pain medication?"
11602879|NCT00627367|Active Comparator|Nonprotocolized|An IV opioid the type and dose of which will be determined by the treating clincian
11602880|NCT00627341|Experimental|Exposure and Response Prevention|Participants will receive Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa for 6 months.
11602881|NCT00627341|Active Comparator|Cognitive Behavior Therapy|Participants will receive cognitive behavioral therapy for anorexia nervosa for 6 months.
11602882|NCT00627328||1|pacemaker patients with previously diagnosed AT.
11602883|NCT00627328||2|pacemaker patients without previously diagnosed AT.
11602884|NCT00627315||Surgery|Obese adult men and women who are undergoing bariatric surgery (gastric bypass or gastric banding).
11602885|NCT00627302|Active Comparator|2|Systane
11602886|NCT00627302|Active Comparator|1|PEG-400
11602887|NCT00627289||1|patients with chronic postherniotomy pain (>1 year), affecting everyday activities severely
11602888|NCT00627276|Experimental|Arm I|Patients receive oral omega-3 fatty acid capsules 3 times daily for up to 8 weeks.
11602889|NCT00627276|Placebo Comparator|Arm II|Patients receive oral placebo olive oil capsules 3 times daily for up to 8 weeks.
11602890|NCT00627263|No Intervention|1|Participants will receive the usual cardiologic care for ICD patients provided by their medical team.
11602891|NCT00627263|Experimental|2|In addition to the usual cardiologic care for ICD patients provided by the participants medical team, those randomized to Intervention will receive the stress reduction treatment (SRT) program (see below).
11602892|NCT00627250|Experimental|A|Amantadine 100 mg every morning and 12 noon
11602893|NCT00627250|Placebo Comparator|B|Placebo tablet every morning and 12 noon
11602894|NCT00627237|Experimental|Immediate start|Starts the 12 week intervention immediately after enrollment
11602895|NCT00627237|Experimental|Waitlist group|Starts the 12 week intervention 12 weeks after initial enrollment
11602896|NCT00627211|No Intervention|Room air insufflation|Air used for insufflation during gastroscopy to expand the lumen for inspection of the mucosal lining. This is current standard procedure, i.e. no experimental intervention.
11602897|NCT00627211|Experimental|CO2 insufflation|CO2 used for insufflation during gastroscopy to expand the lumen for inspection of the mucosal lining. This is not standard procedure and therefore experimental intervention.
11602898|NCT00627185|Experimental|1|Intervention group (dental practices) that received the interactive motivational website for patient tobacco cessation
11602899|NCT00627185|Placebo Comparator|2|Control group (dental practices) that did not receive any materials or resources on tobacco cessation. This is a wait-list control.
11602900|NCT00627159|Other|1|high risk
11602901|NCT00627159|Other|2|low to moderate risk
11602902|NCT00627146|Placebo Comparator|B|
11602903|NCT00627146|Active Comparator|A|ChAgly CD3
11602904|NCT00627133|Experimental|1|
11602905|NCT00627120|Experimental|1|1mg dose group
11602906|NCT00627120|Experimental|2|10mg dose group
11602907|NCT00627120|Experimental|3|100mg dose group
11602908|NCT00627120|Experimental|4|200mg dose group
11602909|NCT00627120|Experimental|5|400mg dose group
11602910|NCT00627120|Experimental|6|800mg dose group
11602911|NCT00627107|Experimental|A|A group of paraplegics.
11602912|NCT00627094|Experimental|Biatain Ibu|Biatain Ibu
11602913|NCT00627094|Active Comparator|Biatain|Biatain
11602914|NCT00627081|Placebo Comparator|1|general anesthesia and thoracic epidural administration of saline
11602915|NCT00627081|Active Comparator|2|general anesthesia and thoracic epidural administration of chirocaine
11602920|NCT00627055|Experimental|1|LPV/r monotherapy
11602921|NCT00627055|Active Comparator|2|LPV/r + 2NRTIs (TDF/FTC or TDF/3TC)
11602922|NCT00627042|Experimental|Ramucirumab (IMC-1121B)|
11602923|NCT00627029|Experimental|Intervention|Care coordination, consisting variously (depending on the demonstration site)--nurse telephonic counseling, nurse in-person home visits, home telemonitoring equipment, and physician education and feedback.
11602924|NCT00627029|No Intervention|Control|Usual care in Medicare fee-for-service from beneficiaries' physicians and other health care providers
11602925|NCT00627016|Experimental|Dexlansoprazole 30 mg QD|
11602926|NCT00627016|Placebo Comparator|Placebo|
11602927|NCT00627003|Experimental|1|
11602928|NCT00627003|Experimental|2|
11602929|NCT00626990|Active Comparator|RT alone|radiation therapy alone
11602930|NCT00626990|Active Comparator|RT & Concurrent CT|Radiotherapy and concurrent temozolomide chemotherapy
11602931|NCT00626990|Active Comparator|RT + Adjuvant CT|Radiotherapy plus adjuvant temozolomide chemotherapy
11602932|NCT00626990|Active Comparator|RT & Concurrent CT + adjuvant CT|Radiotherapy and concurrent chemotherapy plus adjuvant temozolomide chemotherapy
11602933|NCT00626977||R|R group:15 mL of 0.125% ropivacaine (18.75 mg)
11602934|NCT00626977||RC|RC group:0.0625% ropivacaine (9.375 mg) plus 75 ug clonidine
11602935|NCT00626964||Lifestyle or bariatric surgery|Morbid Obesity with BMI >= 40 kg/m2 or BMI >= 35 with Comorbidity
11602936|NCT00626951|Experimental|1|LMA Supreme
11602937|NCT00626951|Experimental|2|LMA ProSeal
11602938|NCT00626938||sarcoidosis|sarcoidosis patients
11602939|NCT00626938||controls|healthy volunteers and other interstitial lung disease (ILD) patients
11602940|NCT00626925|Active Comparator|Total Topiramate Group|topiramate capsules beginning at 25 mg/day with gradual increase to a maximum of 200 mg orally)
11602941|NCT00626925|Placebo Comparator|Total Placebo Group|inactive placebo matched in appearance with topiramate capsules
11602942|NCT00626912|Active Comparator|1|platinum coils
11602943|NCT00626912|Active Comparator|2|hydrogel coils
11602944|NCT00626886|Experimental|1|Two, 5x5cm bupivacaine collagen sponges implanted during surgery
11602945|NCT00626886|Placebo Comparator|2|Placebo collagen sponge implanted during surgery
11602946|NCT00626873|Experimental|Definity|Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.
11602947|NCT00626847||1|Primary Open Angle Glaucoma (POAG)
11602948|NCT00626847||2|Controls (Normals, patients without glaucoma)
11602949|NCT00626834|Experimental|Vigabatrin Dose 1|
11602950|NCT00626834|Experimental|Vigabatrin Dose 2|
11602951|NCT00626834|Experimental|Vigabatrin Dose 3|
11602952|NCT00626834|Placebo Comparator|Matching placebo|
11602953|NCT00626821|Experimental|1|
11602954|NCT00626808||1|Children less than 24 months of age
11602955|NCT00626808||2|Children 24 to 59 months of age with a claim associated with a diagnosis of asthma
11602956|NCT00626808||3|Children 24 to 59 months of age without a claim associated with a diagnosis of asthma, but with dispensed medication for wheezing
11602957|NCT00626808||4|Children 24-59 months of age with immunosuppression
11602958|NCT00626795|Experimental|1|
11602959|NCT00626795|Experimental|2|
11602960|NCT00626795|Active Comparator|3|
11602961|NCT00626782|Experimental|A: Ranibizumab 0.5mg (0.05mL) injection|Ranibizumab 0.5mg (0.05mL) injection at end of trabeculectomy surgery. This intra-operative adjunct therapy was administered sub-conjunctivally 8-10mm posteriorly to the limbus as an antifibrotic agent.
11602962|NCT00626782|Active Comparator|B: Mitomycin C 0.4 mg/ml sponge|Mitomycin C 0.4 mg/ml soaked sponge applied to sclera (for up to 2 min) after flap is made during trabeculectomy surgery. This is the typical method used as an antifibrotic agent.
11602963|NCT00626769||1|Postmenopausal women with established osteopenia receiving aglycone genistein 54 mg/day for 3 years
11602964|NCT00626769||2|Postmenopausal women with established osteopenia receiving placebo (Calcium and vitD) for 3 years
11602965|NCT00626756|Experimental|LI|arm controled by LIDCO technology
11602966|NCT00626756|No Intervention|CA|standard approach
11602967|NCT00626743|Experimental|SK3530|Active Drug
11602968|NCT00626743|Placebo Comparator|Placebo|Tablet which has the same appearance and taste but doesn't contain active ingredient
11602969|NCT00626717|Experimental|1|
11602970|NCT00626717|Sham Comparator|2|
11602971|NCT00626704|Experimental|Arm 1|AMG 655 + Doxorubicin
11602972|NCT00626704|Placebo Comparator|Arm 2|Placebo + Doxorubicin
11602973|NCT00626678|Experimental|1|Oral administration of prednisone and azathioprine throughout study
11602974|NCT00626678|Placebo Comparator|2|Oral administration of prednisone and placebo throughout study
11602975|NCT00626665|Placebo Comparator|Placebo|One placebo tablet every alternate day for 6 weeks
11602976|NCT00626652|Experimental|1|
11602977|NCT00626639|Placebo Comparator|Placebo|Three days before the start of radiotherapy (Day -3), participants received a single intravenous (IV) bolus injection of matching placebo. During radiotherapy (beginning on Day 1), participants received a weekly single IV bolus injection of matching placebo after the last radiation fraction of that week (usually on Fridays) until grade ≥3 oral mucositis occurred, or for a maximum 8 doses (completion of radiotherapy). Participants also received cisplatin 100 mg/m^2 on days 1, 22 and 43.
11602978|NCT00626639|Experimental|Palifermin|Three days before the start of radiotherapy (Day -3), participants received a single intravenous (IV) bolus injection of palifermin at 120 μg/kg. During radiotherapy (beginning on Day 1), participants received a weekly single IV bolus injection of palifermin at 120 μg/kg after the last radiation fraction of that week (usually on Fridays) until grade ≥3 oral mucositis occurred, or for a maximum 8 doses (completion of radiotherapy). Participants also received cisplatin 100 mg/m^2 on days 1, 22 and 43.
11603023|NCT00626327|Experimental|MenACWY-CRM|
11603024|NCT00626314|Experimental|1|myoblast
11603025|NCT00626314|Sham Comparator|2|sham injection procedure
11602979|NCT00626626|Experimental|"Clofar, Cyclophos, Alemtuzumab"|"Phase 1: 1-3 patients will be treated in order to establish Cyclophosphamide and Clofarabine dose and to confirm reasonable safety and engraftment efficacy.
~Drug - Clofarabine,Cyclophosphamide & Alemtuzumab - Clofar (30mg/m2) D -8 to -4; Cyclo (500mg/m2) D -8 & -7 & Alem (20mg over 2hrs)"
11602980|NCT00626626|Experimental|"Clofar, Cyclophos,Alemtuzumab(Ph II)"|"Phase II patients 4-9 will treat at the selected dose level of Clofarabine and Cyclophosphamide.
~Drug - Clofarabine, Cyclophosphamide & Alemtuzumab Clofar (30mg/m2) D -8 to -4; Cyclo (1000mg/m2) D -8 & -7 & Alem (20mg)-pts."
11602981|NCT00626587|Placebo Comparator|A|Conventional diagnostic procedures (transbronchial biopsy and bronchial washing) for peripheral pulmonary lesions
11602982|NCT00626574|Active Comparator|A|Group A will receive Procrit® intravenous injections (40,000U) once daily for 3 days (Study Days 1, 2, and 3). The first dose of Procrit® will be given within 36 hours of the initial SAH event / symptoms and immediately before the vascular clipping procedure.
11602983|NCT00626574|Placebo Comparator|B|Group B will receive Saline intravenous injections once daily for 3 days (Study Days 1, 2, and 3).
11602984|NCT00626561|Experimental|Bevacizumab + Paclitaxel|Bevacizumab 10 mg/kg intravenous (IV) twice weekly and Paclitaxel 60 mg/m^2 IV weekly.
11602985|NCT00626548|Placebo Comparator|Placebo|Matching Placebo
11602986|NCT00626548|Experimental|ZD4054|ZD4054 (Zibotentan)
11602987|NCT00626535|Experimental|1|20mg once daily
11602988|NCT00626535|Placebo Comparator|2|Oral once daily
11602989|NCT00626522|Experimental|1|
11602990|NCT00626522|Experimental|2|
11602991|NCT00626522|Experimental|3|
11602992|NCT00626522|Placebo Comparator|4|
11602993|NCT00626522|Placebo Comparator|5|
11602994|NCT00626522|Placebo Comparator|6|
11602995|NCT00626483|Experimental|CMV pp65-LAMP mRNA-loaded DC vaccination|Basiliximab will be safe in combination with CMV pp65-LAMP mRNA-loaded DC vaccination and GM-CSF
11602996|NCT00626470|Active Comparator|-TSP|Patients operated without TSP
11602997|NCT00626470|Active Comparator|+TSP|Patients operated with TSP
11602998|NCT00626457|Experimental|Maintenance First|
11602999|NCT00626457|Active Comparator|Weight Loss First|
11603000|NCT00626444|Experimental|1|Intravenous vitamin C
11603001|NCT00626431|Experimental|Leuprolide acetate - Formulation A|Leuprolide acetate 45 mg, 6-month depot
11603002|NCT00626431|Experimental|Leuprolide acetate - Formulation B|Leuprolide acetate, 45 mg, 6-month depot
11603003|NCT00626418|Placebo Comparator|1|This will be a crossover study. Ascending doses of active drug will be administered on study nights 3-5 with an option of 3 additional nights in an attempt to identify a tolerable efficacious dose. Night 1 will be an adaptation night and night two will be a placebo night.
11603004|NCT00626418|Active Comparator|2|This will be a crossover study. Ascending doses of active drug will be administered on study nights 3-5 with an option of 3 additional nights in an attempt to identify a tolerable efficacious dose. Night 1 will be an adaptation night and night two will be a placebo night.
11603005|NCT00626405|Experimental|Arm I|Patients receive oral temozolomide on days 1-5 and bevacizumab IV over 30-90 minutes on days 1 and 15.
11603006|NCT00626405|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1.
11603007|NCT00626392|Experimental|NER 500; ASA run-in, ASA coadmin|Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
11603008|NCT00626392|Experimental|NER 500; ASA Pbo run-in, ASA coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
11603009|NCT00626392|Experimental|NER 500; ASA Pbo run-in, ASA Pbo coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
11603010|NCT00626392|Experimental|NER 1000; ASA run-in, ASA coadmin|Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
11603011|NCT00626392|Experimental|NER 1000; ASA Pbo run-in, ASA coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
11603012|NCT00626392|Experimental|NER 1000; ASA Pbo run-in, ASA Pbo coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
11603013|NCT00626366|Experimental|Nasal spray|This arm of the study will contain subjects who will spray 2-4 sprays of a nasal contrast solution in their nares. Following administration of the spray, the subjects will then have a Xoran mini-CAT scan of their sinuses.
11603014|NCT00626366|Experimental|Nasal drop|This arm will contain subjects who will place two drops of a nasal contrast solution in each nose. Following administration of the nasal contrast, the subjects will then have a Xoran miniCAT scan of their sinuses.
11603015|NCT00626353|Experimental|Intervention|Patients treated by an interdisciplinary, intersectoral and interventional team responsible for providing home-based rehabilitation.
11603016|NCT00626353|Active Comparator|Control|Control patients treated following standard care procedures in our department with no interference from the interventional team.
11603017|NCT00626340|Active Comparator|MDD diagnosis and Estrogen treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen alone.
11603018|NCT00626340|Active Comparator|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
11603019|NCT00626340|Active Comparator|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
11603020|NCT00626340|Active Comparator|No depression and estrogen treatment|Non-depressed menopausal women between the ages of 40-70 receiving treatment with estrogen alone.
11603021|NCT00626327|Experimental|MenACWY-CRM+ MMRV|
11603022|NCT00626327|Active Comparator|MMRV|
11603026|NCT00626301|Experimental|1|Children who have completed HIV-NAT 017. Children treated with other double boosted PIs such as indinavir plus lopinavir/ ritonavir are also included.
11603027|NCT00626288|Experimental|A|Mesalazine cpr 800 mg t.i.d. for 12 weeks
11603028|NCT00626288|Placebo Comparator|B|Placebo cpr t.i.d. for 12 weeks
11603029|NCT00626275|Experimental|ADL5859 -- 200 mg (Part A)|ADL5859: 200 milligrams (mg), capsules, administered orally as a single dose during 1 of 3 Treatment Periods in Part A of the study
11603030|NCT00626275|Active Comparator|Naproxen -- 500 mg (Part A)|Naproxen: 500 mg, capsules, administered orally as a single dose during 1 of 3 Treatment Periods in Part A of the study
11603031|NCT00626275|Placebo Comparator|Placebo (Part A)|Matching placebo, capsules, administered orally, as a single dose during 1 of 3 Treatment Periods in Part A of the study
11603032|NCT00626275|Experimental|ADL5859 - 100 mg (Part B)|ADL5859: 100 mg, capsules, administered orally, twice daily (BID) for 2 weeks during Part B of the study
11603033|NCT00626275|Placebo Comparator|Placebo (Part B)|Matching placebo, capsules, administered orally, BID for 2 weeks during Part B of the study
11603034|NCT00626262|Experimental|1|20mg oral
11603035|NCT00626262|Experimental|2|20mg IV
11603036|NCT00626249|Experimental|T Inhalation powder in diabetic subjs w/ normal renal func|T inhalation powder in diabetic subjects with normal renal function, Single dose, 30 units
11603037|NCT00626249|Experimental|T Inhalation powder diabetic subj w/mild or moderate nephrop|T Inhalation powder in diabetic subjects w/mild or moderate nephropathy - Single dose, 30 units
11603038|NCT00626236|Experimental|Treatment 1|
11603039|NCT00626236|Experimental|Treatment 2|
11603040|NCT00626236|Experimental|Treatment 3|
11603041|NCT00626236|Experimental|Treatment 4|
11603042|NCT00626223|Experimental|A|patients treated with intravenous 5-MTHF (Prefolic®, Knoll, Milan, Italy) 50 mg at the end of each hemodialysis session; The group will receive supplementation with vitamin B6 300 mg (Benadon®, Roche, Milan, Italy) and vitamin B12 1000 mcg (Dobetin®, A.C.R.A.F, Rome, Italy) administered by intravenous injection at the end of the hemodialysis session three times per week
11603043|NCT00626223|Active Comparator|B|"treated with 5 mg per day of oral folic acid (Folina® Schwarz Pharma, Milan, Italy).
~The group will receive supplementation with vitamin B6 300 mg (Benadon®, Roche, Milan, Italy) and vitamin B12 1000 mcg (Dobetin®, A.C.R.A.F, Rome, Italy) administered by intravenous injection at the end of the hemodialysis session three times per week"
11603044|NCT00626210|Experimental|Modafinil|
11603045|NCT00626197|Experimental|1|
11603046|NCT00626197|Placebo Comparator|2|
11603047|NCT00626184|Placebo Comparator|A|Placebo
11603048|NCT00626184|Active Comparator|B|Active study Drug: ALV003
11603049|NCT00626171|Other|1|Allergen challenge
11603050|NCT00626158|Experimental|Gem/Cape|
11603051|NCT00626145|Placebo Comparator|1|Patients receive intracoronary injections of saline 7 days after PCI.
11603052|NCT00626145|Experimental|2|Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
11603053|NCT00626132|Experimental|Eucommia|Eucommia capsules two orally three times a day for 2 weeks
11603054|NCT00626132|Placebo Comparator|1|
11603055|NCT00626119||Control|
11603056|NCT00626119||diseased|
11603057|NCT00626106|Placebo Comparator|Placebo|
11603058|NCT00626106|Active Comparator|Investigational Product|
11603059|NCT00626106|Other|Roll-over|
11603060|NCT00626093|Other|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)|Patients in the study who received a Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for it. It's a single arm study in which patients underwent defibrillation threshold (DFT) testing at implant and 6 months.
11603061|NCT00626067|Active Comparator|1 Fully functional monitoring device|Fully functional monitoring device
11603062|NCT00626067|Active Comparator|2 Partially functional monitoring device|Partially functional monitoring device
11603063|NCT00626067|Sham Comparator|3 Non-functional monitoring device|Non-functional monitoring device
11603064|NCT00626054|Active Comparator|1|Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
11603065|NCT00626054|Active Comparator|2|Group 2 will receive half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test.
11603066|NCT00626041|Other|1|referral to primary care network for management of blood pressure, lipids and diabetes.
11603067|NCT00626028|Experimental|Nitric Oxide First, Oxygen Last|10 minute dose of Nitric Oxide (NO) at 80 ppm, then 10 minute dose of NO plus Oxygen, then 10 minute washout, then 10 minute dose of 100% Oxygen on Day 1.
11603068|NCT00626028|Experimental|Oxygen First, Nitric Oxide Last|10 minute dose of 100% Oxygen, then 10 minute dose of NO plus Oxygen, then 10 minute washout, then 10 minute dose of NO at 80 ppm on Day 1.
11603069|NCT00626015|Experimental|Arm I|Temozolomide, PEP-3-KLH conjugate vaccine, and daclizumab
11603070|NCT00626015|Experimental|Arm II|Temozolomide, PEP-3-KLH conjugate vaccine, and normal saline
11603071|NCT00626015|Experimental|Basiliximab|Patients will receive basiliximab 20 mg IV with vaccine # 1 only and continue with PEP-3-KLH, temozolomide.
11603072|NCT00626002|Experimental|1|
11603073|NCT00625989|Placebo Comparator|Diluent|Inhalation challenge preformed with diluent.
11603074|NCT00625989|Active Comparator|Allergen|Inhalation challenge preformed with allergen.
11603075|NCT00625976|Experimental|1|
11603076|NCT00625976|Experimental|2|
11603077|NCT00625963||I,A|I=Pulmonary Hypertension Patients A=ILD patients with Pulmonary Hypertension Patients
11603078|NCT00625924||1|autogenous tissue breast reconstruction
11603079|NCT00625924||2|tissue expander/implant breast reconstruction
11603080|NCT00625924||3|mastectomy alone
11603081|NCT00625911|Active Comparator|morphine only|standard analgesia protocol
11603082|NCT00625911|Experimental|morphine ketamine|alterantive regimen for intravenous patient controlled analgesia
11603083|NCT00625898|Active Comparator|1A: TCH-H|Docetaxel (T), Carboplatin (C), and Trastuzumab (H) followed by Trastuzumab (H)
11603302|NCT00624403|Active Comparator|1|LMA ProSeal
11603303|NCT00624403|Experimental|2|I-Gel
11603084|NCT00625898|Experimental|1B: TCHB-HB|Docetaxel (T), Carboplatin (C), Trastuzumab (H), Bevacizumab (B) followed by Trastuzumab (T) and Bevacizumab (B)
11603085|NCT00625898|Active Comparator|2A: TH-FEC-H|Docetaxel (T) and Trastuzumab (H) followed by 5-fluorouracil (F), Epirubicin (E), and Cyclophosphamide (C) followed by Trastuzumab (H)
11603086|NCT00625898|Experimental|2B: THB-FEC-HB|Docetaxel (T), Trastuzumab (H), and Bevacizumab (B) followed by 5-Fluorouracil (F), Epirubicin (E), and Cyclophosphamide (C) followed by Trastuzumab (H) and Bevacizumab (B)
11603087|NCT00625872|Active Comparator|Treatment Group|Somatropin for 12 months
11603088|NCT00625872|Other|Control Group|In the first 6 months no intervention, afterwards Somatropin for 12 months
11603089|NCT00625859|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive treatment A in period 1, treatment B in period 2 and treatment C in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
11603090|NCT00625859|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive treatment B in period 1, treatment C in period 2 and treatment A in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
11603091|NCT00625859|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive treatment C in period 1, treatment A in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
11603092|NCT00625859|Experimental|Subjects receiving treatment sequence 4|Eligible subjects will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
11603093|NCT00625859|Experimental|Subjects receiving treatment sequence 5|Eligible subjects will receive treatment B in period 1, treatment A in period 2 and treatment C in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
11603094|NCT00625859|Experimental|Subjects receiving treatment sequence 6|Eligible subjects will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
11603095|NCT00625846|Experimental|Cohort 1 (DTC)|Patients with differentiated thyroid cancer (DTC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11603096|NCT00625846|Experimental|Cohort 2 (MTC)|Patients with medullary thyroid cancer (MTC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11603097|NCT00625846|Experimental|Cohort 3 (ATC)|Patients with anaplastic thyroid cancer (ATC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11603098|NCT00625846|Experimental|Expansion Cohort (DTC)|Patients with confirmed, differentiated thyroid cancer (DTC) who are thyroglobulin antibody negative receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11603099|NCT00625833|Placebo Comparator|Placebo|
11603100|NCT00625833|Experimental|2|
11603101|NCT00625820|Experimental|6R BH4|Subjects will receive 6R-BH4 400mg bid for 6 weeks, sequentially followed by 6R-BH4 plus Vitamin C 500mg bid for another 6 weeks. Patients will have scheduled visits at Weeks 0,3,6,9 and 12, with an exit-visit at week 16. Albuminuria will be assessed in 24-hour urine collections as well as early morning spot urine samples for albumin:creatinine ratio. Blood and urine will be tested for routine clinical laboratory tests, blood nitric oxide (NO), and also archived for later assays for special biomarkers. The primary outcome will be level of albuminuria as measured in a 24-hour urine collection at 6 and 12 weeks of therapy. Secondary outcomes will include urine albumin/creatinine ratio, estimated glomerular filtration rate (eGFR), and blood pressure .
11603102|NCT00625807|Active Comparator|Program A - Relaxation Response (RR)|One of the 2 stress reduction courses
11603103|NCT00625807|Active Comparator|Program B - Mindfullness-based stress reduction (MBSR)|One of the 2 stress reduction courses
11603104|NCT00625794|Experimental|1|8 weeks or counseling plus 6 weeks of nicotine nasal spray
11603105|NCT00625794|Active Comparator|2|8 weeks or counseling only.
11603106|NCT00625781|Experimental|B2|IGT randomized to treatment
11603107|NCT00625781|No Intervention|B1|"IGT randomized to no treatment"
11603108|NCT00625742|Experimental|Multimodal Treatment Strategy|Exercise Program + Pharmacologic Intervention (Melatonin + Atenolol + Ibuprofen) + Nutritional Supplementation (Juven) - Resistance training sessions twice weekly using Thera-bands. Walking or running for 3-4 minutes at 70-80% of maximum predicted heart rate. Melatonin 20 mg by mouth (PO) Daily. 90 calories of Juven, twice a day.
11603109|NCT00625729|Experimental|Treated Patients|Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with donor natural killer cells infusion, rituximab, aldesleukin and chemotherapy.
11603110|NCT00625703|Experimental|A|
11603111|NCT00625677|Experimental|1|"Pediacel - 2,3,4 months Prevenar - 2,4 months Menjugate - 3 months Hib/ pneumo conjugate/ Men C conjugate - 12 months
~Blood collected - 4,5,12,13 months"
11603112|NCT00625677|Experimental|2|"Pediacel - 2,3,4 months Prevenar - 2,4 months Neis-vacC - 3 months Hib/ pneumo conjugate/ Men C conjugate - 12 months
~Blood collected - 4,5,12,13 months"
11603113|NCT00625664|Experimental|1|
11603114|NCT00625664|Active Comparator|2|
11603115|NCT00625651|Experimental|AMG 655 Low Dose|AMG 655 (low dose) + mFOLFOX6 + Bevacizumab
11603116|NCT00625651|Placebo Comparator|Placebo|Placebo + mFOLFOX6 + Bevacizumab
11603117|NCT00625651|Experimental|AMG 655 High Dose|AMG 655 (high dose) + mFOLFOX6 + Bevacizumab
11603118|NCT00625638|Experimental|Standard Care Only|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
11603119|NCT00625638|Experimental|Standard Care + IVR System|Standard Care + Interactive Voice Response (IVR) System Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes. Phone calls made once daily, each taking about 3-5 minutes to complete.
11603120|NCT00625612|Placebo Comparator|2|
11603121|NCT00625612|Experimental|1|Denufosol Tetrasodium (INS37217) Inhalation Solution
11603358|NCT00624065|Experimental|carvedilol CR + lisinopril|
11603122|NCT00625599||1|Salvadorian students at the Evangelical University in non-health track studies over the age of 18. The students must accept the invitation to participate along with signing the informed consent to be eligible.
11603123|NCT00625599||2|Patients over the age of 45 presenting to Hospital Zacamil with an acute fracture. Patients must accept the invitation to the study and sign the informed consent to be eligible.
11603124|NCT00625586|Experimental|RAV12 plus gemcitabine|
11603125|NCT00625560|Experimental|A|entecavir 1.0 mg QD
11603126|NCT00625560|Active Comparator|B|lamivudine 100 mg QD
11603127|NCT00625547|Experimental|1|
11603128|NCT00625547|Experimental|2|
11603129|NCT00625534|Experimental|1|Laparoscopic repair
11603130|NCT00625534|Active Comparator|2|Open tension free inguinal hernia mesh repair
11603131|NCT00625521|Experimental|1|Drug: ASF 1096 0.5 % cream applied twice daily
11603132|NCT00625521|Placebo Comparator|2|Cream vehicle for ASF 1096 cream applied twice daily
11603133|NCT00625495|Experimental|1|IV Nexium
11603134|NCT00625495|Experimental|2|Oral Nexium
11603135|NCT00625482|Active Comparator|Boys 1|OPV as usual
11603136|NCT00625482|Experimental|Boys 2|OPV plus BCG
11603137|NCT00625482|Active Comparator|Girls 1|OPV as usual
11603138|NCT00625482|Experimental|Girls 2|OPV plus BCG
11603139|NCT00625469|Experimental|treatment with bosentan|patients with resting or exercise induced PAH receive bosentan in a randomized open label fashion
11603140|NCT00625469|No Intervention|PAH group with no therapy|patients with resting or exercise PAH get randomized to receive no specific therapy
11603141|NCT00625469|No Intervention|No PAH and no therapy|patients with no evidence of either resting or exercise PAH receive no intervention but are followed until lung transplantation
11603142|NCT00625456|Experimental|Single Arm, dose escalation|dose escalation starting dose 1e5 pfu/kg bw to 3e7 pfu/kg bw; Recombinant Vaccinia GM-CSF (JX-594)
11603143|NCT00625443|Experimental|Placebo (double-blind)|
11603144|NCT00625443|Experimental|Avatrombopag tablets (open-label)|
11603145|NCT00625443|Experimental|Avatrombopag tablets (double-blind)|
11603146|NCT00625430|Experimental|1|Six Cohorts with escalating vector dose
11603147|NCT00625417|Experimental|Optical spectroscopy on tumor margins|Optical spectroscopy is performed on breast tumor margins obtained from patients undergoing surgery
11603148|NCT00625404|Experimental|Truvada Arm|Daily single oral tablet of Truvada (TDF/FTC), a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
11603149|NCT00625404|Placebo Comparator|Placebo Arm|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
11603150|NCT00625391|Placebo Comparator|Placebo pill|24 weeks of placebo.
11603151|NCT00625391|Active Comparator|Green Tea Polyphenols (GTP)|24 weeks of green tea polyphenols
11603152|NCT00625391|Active Comparator|Placebo+Tai Chi (TC)|24 weeks of placebo plus Tai Chi exercise.
11603153|NCT00625391|Active Comparator|GTP+TC|24 weeks of green tea polyphenols plus Tai Chi exercise.
11603154|NCT00625378|Experimental|Sorafenib (Nexavar, BAY43-9006)|All patients are treated with sorafenib according to the dosage scheme of their previous trial
11603155|NCT00625365|Other|DEFINITY® (Perflutren Lipid Microsphere)|Patients who had undergone unenhanced echocardiography yielding suboptimal images and who were determined by the Principal Investigator to require DEFINITY-enhanced echocardiography
11603156|NCT00625339|Experimental|A|entecavir 0.5 mg QD
11603157|NCT00625339|Active Comparator|B|lamivudine 100 mg QD
11603158|NCT00625326|Experimental|75 µg/g COL-121 Ointment|75 µg/g COL-121 Ointment
11603159|NCT00625326|Experimental|150 µg/g COL-121 Ointment|150 µg/g COL-121 Ointment
11603160|NCT00625326|Experimental|300 µg/g COL-121 Ointment|300 µg/g COL-121 Ointment
11603161|NCT00625326|Active Comparator|50 µg/g Calcipotriene Ointment|50 µg/g Calcipotriene Ointment (active control)
11603162|NCT00625326|Placebo Comparator|Placebo Ointment|Placebo Ointment
11603163|NCT00625313|Experimental|HMY Model YA-60BB IOL|Patients receiving a Hoya HMY Acrylic Foldable Intraocular Lens.
11603164|NCT00625300|Active Comparator|1|Active treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
11603165|NCT00625300|Sham Comparator|Placebo|Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (sham) over the motor cortex and the prefrontal cortex.
11603166|NCT00625274|Experimental|1|Oral
11603167|NCT00625274|Experimental|2|Oral
11603168|NCT00625274|Experimental|3|Oral
11603169|NCT00625261|Experimental|1|The mothers of the two-years old children in the intervention group took part at the Heidelberg Parent-based Language Intervention HPLI
11603170|NCT00625261|No Intervention|2|Waiting group, no intervention until children were three years of age
11603171|NCT00625248||no anthithrombotic|procedures where there were no antithrombotics
11603172|NCT00625248||Antithrombotic - continued|patients who are on antithrombotics
11603173|NCT00625248||Discontinued Antithrombotic|Patients who were on antithrombotics but have been discontinued
11603174|NCT00625235|Other|1|High Carbohydrate diet
11603175|NCT00625235|Other|2|High Protein diet
11603176|NCT00625222|Experimental|1|
11603177|NCT00625209|Placebo Comparator|1|placebo of hydrocortisone, placebo of fludrocortisone and placebo of activated protein C
11603178|NCT00625209|Active Comparator|2|Hydrocortisone plus fludrocortisone and a placebo of activated protein C
11603179|NCT00625209|Active Comparator|3|placebo of hydrocortisone, placebo of fludrocortisone and activated protein C
11603180|NCT00625209|Active Comparator|4|hydrocortisone plus fludrocortisone plus activated protein C
11603304|NCT00624390|Experimental|Sepraspray|Sepraspray applied directly to both sides of the uterus, Fallopian tubes, and ovaries (or opposing sites if not possible to apply directly). Sepraspray was applied via a sterile cannula at a tissue concentration of approximately 5 mg/cm^2.
11603181|NCT00625196|Experimental|Subjects receiving fluticasone foroate/ vilanterol|Eligible subjects will receive single dose of fluticasone foroate/ vilanterol combination treatment 800 micrograms/ 50 micrograms administered using a novel powder inhaler. There will be a washout period of 7 to 10 days between treatments.
11603182|NCT00625196|Active Comparator|Subjects receiving fluticasone foroate|Eligible subjects will receive single dose of fluticasone foroate 800 micrograms administered using a novel powder inhaler.
11603183|NCT00625196|Active Comparator|Subjects receiving vilanterol|Eligible subjects will receive single dose of vilanterol 50 micrograms administered using a novel powder inhaler.
11603184|NCT00625196|Placebo Comparator|Subjects receiving placebo|Eligible subjects will receive single dose of placebo administered using a novel powder inhaler.
11603185|NCT00625183|Experimental|Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy|Oxaliplatin: 50 mg/m2 weekly x 5 Capecitabine 725 mg/m2BID on days of RT Selenomethionine: 4000mcg/m2 PO BID X 7 days prior to RT, then 4000mcg/m2 PO QD from first to last day of RT, including weekends
11603186|NCT00625170|Active Comparator|1|Healthy men
11603187|NCT00625170|Active Comparator|2|Healthy men with a positive family anamneses of schizophrenia
11603188|NCT00625157|Experimental|1|
11603189|NCT00625157|Placebo Comparator|2|
11603190|NCT00625131|Active Comparator|Active Nicotine Patch Group|Transdermal nicotine patch
11603191|NCT00625131|Placebo Comparator|Placebo Patch Group|Transdermal placebo patch
11603192|NCT00625118||1|Children in receipt of a Hib containing vaccine at pre-school booster (3.5-6 years old).
11603193|NCT00625105|Active Comparator|Biofeedback|HRV coherence biofeedback procedure
11603194|NCT00625105|Sham Comparator|Sham intervention|Passive monitor viewing
11603195|NCT00625092|Experimental|Hyperthermic Treatment|Patients receiving combination of hyperthermic intraperitoneal chemotherapy (HIPC) with oxaliplatin plus intraperitoneal 5-Fu and intraperitoneal leucovorin with peritoneal metastases.
11603196|NCT00625079|Placebo Comparator|Pre-transplant placebo|There are two placebo comparators.... one for the group of patients with resting PAH and another for the group of patients with exercise PAH
11603197|NCT00625079|Experimental|Pre-transplant sildenafil|There are two active comparators, one group with resting PAH and another with exercise PAH, both receiving drug.
11603198|NCT00625079|No Intervention|Pre-transplant no PAH-specific therapy|this group of patients has no evidence for either resting or exercise PAH but will be followed without specific drug intervention
11603199|NCT00625053|Experimental|1|Laparoscopic repair
11603200|NCT00625053|Active Comparator|2|Open repair
11603201|NCT00625040||A|Obese patients without diabetes with a Body Mass Index > 37 kg/m2
11603202|NCT00625027||Group 1|Children presenting to the Emergency Department under the care of a parent or guardian, between 0600 and 2400 during the study period.
11603203|NCT00625014|Experimental|1|Healthy men
11603204|NCT00625001||1|Women with Turner syndrome
11603205|NCT00625001||2|Healthy control women
11603206|NCT00624988|Experimental|Vibration Therapy|Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
11603207|NCT00624975|Experimental|Vaccine|
11603208|NCT00624975|Placebo Comparator|Placebo|
11603209|NCT00624962|Other|Correlative/Supportive Care|
11603210|NCT00624949||1|women with Turner syndrome
11603211|NCT00624949||2.|Control women
11603212|NCT00624936|Experimental|Vidaza and Velcade|Vidaza 75mg/m2 IV over 30 min daily on days 1-7 This dose is the same for all dose levels. Velcade will be given immediately after Vidaza is completed at one of the following dose levels: 1, 2, 3, 4
11603213|NCT00624923|Experimental|1- Active Pharmacologic|Salsalate
11603214|NCT00624923|Placebo Comparator|2- Placebo|Placebo
11603215|NCT00624910|Experimental|1|A total of three 5 × 5-cm bupivacaine sponges implanted at specified layers in the wound prior to wound closure
11603216|NCT00624910|Placebo Comparator|2|A total of three 5 × 5-cm collagen sponges implanted at specified layers in the wound prior to wound closure
11603217|NCT00624910|No Intervention|3|The patient will recieve the standard of care, but no implant during surgery
11603218|NCT00624884||A|Patients with moderate-to-severe aortic regurgitation having normal left ventricular ejection fraction
11603219|NCT00624884||B|Age, sex and bodymass index matched healthy subjects
11603220|NCT00624871|Active Comparator|A|Infants will receive intravenous ascorbic acid and oral ibuprofen for 3 days
11603221|NCT00624871|Placebo Comparator|B|Infants will receive equivalent amount of placebo
11603222|NCT00624858|Experimental|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg/ day
11603223|NCT00624845|Experimental|Drug|
11603224|NCT00624845|Placebo Comparator|Vehicle|
11603225|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 30-300 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.
11603226|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 700-2000 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 700- 2000 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.
11603227|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 301-699 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 301- 699 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.
11603228|NCT00624832|Placebo Comparator|Placebo|By subcutaneous injection of a solution with a concentration of 125 mg/mL placebo in a supine position: Patients in Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL) group received doses of 150 mg to 375 mg of placebo every 2 or 4 weeks for 12 or 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL) group received doses of 450 mg, 525 mg, or 600 mg of placebo every 2 weeks for 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 301- 699 IU/mL) group received doses of 225 mg to 375 mg of placebo every 2 weeks for 6 weeks.
11603305|NCT00624390|No Intervention|Control|No anti-adhesion treatment was used.
11603306|NCT00624377||COPD patients|
11603307|NCT00624351|Placebo Comparator|Placebo|Phosphate-buffered Saline (PBS) infusions at study weeks 0, 1, 2, and 3.
11603229|NCT00624819|Experimental|Synflorix + Infanrix + Havrix and/or Varilrix Group|This group consisted of subjects primed with Synflorix vaccine in the 10PN-PD-DIT-001 (1105553) and 007 (107046) studies. In 105553 study, subjects had been primed with 3 doses of Synflorix vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In 107046 study, subjects had received a booster dose of Synflorix vaccine at 12-18 months of age co-administered with Infanrix hexa vaccine. In this study, in the Year 4 (111347 study), subjects received at Month 48 (4 years post Dose 1 in study 105553) one additional dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix) and/or against varicella (a single dose of Varilrix).
11603230|NCT00624819|Active Comparator|Prevenar + Infanrix + Havrix and/or Varilrix Group|This group consisted of subjects vaccinated with Prevenar vaccine in the 10PN-PD-DIT-001 (105553) and 007 (107046) studies. In 105553 study, subjects had been primed with 3 doses of Prevenar vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In 107046 study, subjects had received a booster dose at 12-18 months of age of Prevenar vaccine co-administered with Infanrix hexa vaccine. In this study, in the Year 4 111347 study, subjects had received at Month 48 (4 years post Dose 1 in study 105553) one dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix and/or against varicella (a single dose of Varilrix).
11603231|NCT00624819|Experimental|Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix|This group consisted of subjects vaccinated with Prevenar and Synflorix vaccines in the 10PN-PD-DIT-001 (105553) and 10PN-PD-DIT-007 (107046) studies. In 105553 study, subjects had been primed with 3 doses Prevenar vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In the 107046 study, subjects had received at 12-18 months of age a booster dose of Synflorix vaccine co-administered with Infanrix hexa vaccine. In this study, in the Year 4 (111347 study), subjects had received at Month 48 (4 years post Dose 1 in study 105553) one additional dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix and/or against varicella (a single dose of Varilrix).
11603232|NCT00624819|Experimental|Unprimed Group|"This group consisted of subjects between, and including, 64-68 months of age at the time of additional vaccination (primed subjects) or dose 1 (unprimed subjects), and for whom the investigator believed that their parents/guardians could and would comply with the requirements of the protocol. Subjects were not previously vaccinated with any pneumococcal vaccine and received 2 doses of Synflorix vaccine at 64-68 and 66-70 months of age (at Day 0 and Month 2).
~The Unprimed Group was added only in Year 4 of the study."
11603233|NCT00624806|Experimental|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers
11603234|NCT00624806|Active Comparator|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
11603235|NCT00624793|Experimental|I. Standard|Standard - Formula Acup Protocol
11603236|NCT00624793|Experimental|2. Individualized|Individualized Acup protocol based on TCM diagnosis
11603237|NCT00624793|Sham Comparator|3|(Control Group) Sham acupuncture
11603238|NCT00624780|Experimental|1|
11603239|NCT00624780|Active Comparator|2|
11603240|NCT00624780|Experimental|3|
11603241|NCT00624780|Placebo Comparator|4|
11603242|NCT00624767|Experimental|1|Insulin Nasal Spray
11603243|NCT00624767|Active Comparator|2|NovoLog
11603244|NCT00624754|Experimental|1|Patients with OAD will receive Symbicort® at the dose of two puffs morning and evening, each delivering 400/12 µg of budesonide/formoterol. Symbicort® will be administered by inhalation using the Turbuhaler (TH) system
11603245|NCT00624754|Placebo Comparator|2|Patients with OAD will receive lactose as a placebo, administered by inhalation using the Turbuhaler (TH) system
11603246|NCT00624728|Experimental|A|
11603247|NCT00624715|Active Comparator|THC|"High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking a full joint
~Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual)IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint
~Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol.Equivalent to smoking 1/10 of a joint"
11603248|NCT00624715|Placebo Comparator|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
11603249|NCT00624702|Active Comparator|1|Active Comparator 1 different salt formulation of Indacaterol.
11603250|NCT00624702|Active Comparator|2|Active Comparator 2 different salt formulation of Indacaterol.
11603251|NCT00624702|Active Comparator|3|Active Comparator 3 different salt formulation of Indacaterol.
11603252|NCT00624702|Placebo Comparator|4|
11603253|NCT00624689|Experimental|1|Modified formula
11603254|NCT00624689|No Intervention|2|Standard formula
11603255|NCT00624689|No Intervention|3|Breastfed
11603256|NCT00624676|Experimental|A|LHA formulation
11603257|NCT00624676|Active Comparator|B|5% benzoyl peroxide
11603258|NCT00624663|Active Comparator|1|(1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule) X 2 per day, total of 5 intakes
11603259|NCT00624663|Active Comparator|2|(2 x 1.5 mg Exelon® Capsules) X 2 per day, total of 5 intakes
11603260|NCT00624663|Placebo Comparator|3|(2 x Placebo Capsules) X 2 per days, total of 5 intakes
11603261|NCT00624650|Active Comparator|Modified FACTT (control)|The investigators control arm consists of a simplified algorithm for conservative management of fluids in patients with ALI, as to be published by the ARDSnet group, based on the protocol used in the FACTT trial. The protocol calls for strict adherence to ARDSnet ventilation, our weaning protocol and use of only select vasoactive, beta-adrenergic drugs as it is felt that variation in these treatments could seriously confound our results. Albuterol administration will not be permitted in the either arm except for life threatening bronchospasm not responsive to ipratropium. Ipratropium may be administered at the treating physician's discretion for bronchospasm. PiCCO's will be placed in each control patient and data recorded twice daily. The treating physician's will be blinded to this data.
11603300|NCT00624442|Experimental|Cohort 5|2 treatment periods with a 72 hour infusion. The 2 treatment periods are randomly assigned and consist of 1 dose level of CK-1827452 (with dose de-escalation possible depending on tolerability) and 1 placebo treatment. Treatment period 2 occurs at least 7 days after the conclusion of period 1.
11603301|NCT00624416|Other|Prednisolone and Isoproteronol Together|Beta-adrenergic agonists and corticosteroid
11603262|NCT00624650|Experimental|EVLW|"When EVLW exceeds 9 ml/kg PBW the algorithmic treatment is begun and continued until EVLW ≤9 ml/kg PBW or extubation whichever comes first as tolerated (see figure 6). Furosemide and volume contraction are initiated when sufficient volumetric preload (GEDI) is available to enact volume contraction as a means to decrease measured EVLW without causing concomitant hypoperfusion. Fluid administration is also guided by changes in EVLW. An increase in EVLW > 2ml/kg PBW as a result of fluid administration curtails any further fluid administration until the next scheduled measurement.
~Our ultimate treatment goal is to maximally lower EVLW towards the normal range - thus improving lung mechanics and gas exchange - without causing concomitant hemodynamic compromise and end-organ injury. By doing so we feel this algorithmic, goal directed, therapeutic approach should improve outcome."
11603263|NCT00624637|Other|A|infants after craniofacial surgery receive one massage with aromatherapy three hours postoperatively
11603264|NCT00624637|Other|B|infants after craniofacial surgery receive one massage with carrier oil three hours postoperatively
11603265|NCT00624637|No Intervention|C|no intervention, standard postoperative care
11603266|NCT00624624||1|"Eugonadal men with Lapband"
11603267|NCT00624624||2|"Hypogonadal men with Lapband"
11603268|NCT00624624||3|Eugonadal men with gastric bypass procedure
11603269|NCT00624624||4|Hypogonadal men with gastric bypass procedure
11603270|NCT00624611|Active Comparator|1|Residual pump blood management post aortic cannula removal
11603271|NCT00624611|Experimental|2|Residual pump blood management post aortic cannula removal
11603272|NCT00624598|Experimental|SMART Group|The experimental group will have a nutrition program based solely on measured resting metabolic rate. The nutrition plan will be a specific calorie level that will promote a 1-2.5 lb per week weight reduction. No experimental participants' nutrition plan will be below 1200 Kcal/day for women or 1600 Kcal/day for men. Second, the experimental group will receive a downloadable copy of a computerized nutrition software program (BalanceLog: Microlife USA, Inc. Golden, CO) that functions s on a Windows 2000-XP or Palm operating system.
11603273|NCT00624598|Active Comparator|Usual Care|Standard 1200 kcal/day diet (women) 1600 kcal/day diet (men) using a sample 3-day menu program. The diet will be follow current government based recommendations for carbohydrates (i.e. 55%), fat (30%), and protein (15%). Study participants will receive a standard paper-based food and exercise journal
11603274|NCT00624585|Experimental|Dasatinib Dose Escalation|Patients will be started on dasatinib at a continuous oral daily dose of 100 mg per day. At 8 weeks, if the initial dose is well tolerated and patient has not achieved a partial response, the dose may be increased to 150 mg per day. All patients will be followed per protocol for a total core period of 16 weeks from the first dose. Responding patients will continue dasatinib treatment for up to 48 weeks in the absence of treatment failure, disease progression, limiting toxicity or death. Patients continuing after 48 weeks will be enrolled in a separate extension study for future follow up.
11603275|NCT00624559|Experimental|Celebrex; Low sodium|Subject completes a normal sodium diet (3 days), a low salt diet (7 days), followed by a high salt diet (7 days) while taking a celebrex pill (100 mg twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
11603276|NCT00624559|Experimental|Celebrex, High Sodium|Subject completes a normal sodium diet (3 days), a high salt diet (7 days), followed by a low salt diet (7 days) while taking a celebrex pill (100 mg twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
11603277|NCT00624559|Placebo Comparator|Placebo, Low Sodium|Subject completes a normal sodium diet (3 days), a low salt diet (7 days), followed by a high salt diet (7 days) while taking a placebo pill (twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
11603278|NCT00624559|Placebo Comparator|Placebo, High Sodium|Subject completes a normal sodium diet (3 days), a high salt diet (7 days), followed by a low salt diet (7 days) while taking a placebo pill (twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
11603279|NCT00624546||1|gerd patients
11603280|NCT00624546||2|non gerd controls
11603281|NCT00624533|Active Comparator|A|Primary Health Care Conventional Physiotherapy Treatment (based in electrotherapy)
11603282|NCT00624533|Experimental|B|Group B was treated with the GDS Method (muscular and articular chains physiotherapy method)
11603283|NCT00624520|Active Comparator|Cognitive Behavioral Stress Management|10 week program of Cognitive Behavioral Stress Management (CBSM) group sessions
11603284|NCT00624520|Active Comparator|Patient Education|10 week program of once weekly Patient Education group sessions
11603285|NCT00624494|Active Comparator|Conventional monitoring|hemodynamic monitoring - conventional monitoring
11603286|NCT00624494|Active Comparator|Advanced monitoring|hemodynamic monitoring - advanced monitoring
11603287|NCT00624481|Active Comparator|1|
11603288|NCT00624481|Experimental|2|
11603289|NCT00624481|Experimental|3|
11603290|NCT00624481|Experimental|4|
11603291|NCT00624481|Experimental|5|
11603292|NCT00624468|Experimental|Atacicept|
11603293|NCT00624468|Placebo Comparator|Placebo|
11603294|NCT00624455|Active Comparator|1|One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.
11603295|NCT00624455|Placebo Comparator|2|Placebo
11603296|NCT00624442|Experimental|Cohort 1|4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
11603297|NCT00624442|Experimental|Cohort 2|4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
11603298|NCT00624442|Experimental|Cohort 3|4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
11603299|NCT00624442|Experimental|Cohort 4|4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
11603308|NCT00624351|Experimental|EMAB 600mg|600 mg Epratuzumab infusions at study weeks 0, 1, 2, and 3.
11603309|NCT00624351|Experimental|EMAB 100mg|100 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
11603310|NCT00624351|Experimental|EMAB 400mg|400 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
11603311|NCT00624351|Experimental|EMAB 1200mg|1200 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
11603312|NCT00624351|Experimental|EMAB 1800mg|1800 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
11603313|NCT00624338|Experimental|Atacicept 75 mg|
11603314|NCT00624338|Experimental|Atacicept 150 mg|
11603315|NCT00624338|Placebo Comparator|Placebo|
11603316|NCT00624325|Experimental|1|12 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
11603317|NCT00624325|Experimental|2|9 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
11603318|NCT00624325|Experimental|3|6 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
11603319|NCT00624312|Active Comparator|1|Pre-operatively randomized to Procrit
11603320|NCT00624312|Placebo Comparator|2|Pre-operatively randomized to placebo
11603321|NCT00624299|Experimental|Botox|Botox
11603322|NCT00624299|Placebo Comparator|Placebo|Saline injection
11603323|NCT00624286|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11603324|NCT00624286|Placebo Comparator|Placebo to indacaterol|Patients inhaled placebo to indacaterol once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11603325|NCT00624273|Other|1, active ulcers|sildenafil treatment
11603326|NCT00624260|Active Comparator|2|Usual follow up : Pet-TDM for current indication (high isolated markers or before a metastasis curative resection)
11603327|NCT00624260|Experimental|1|Semi-annual systematic PET-TDM (M6, M12, M18, M24, M30 and M36 after initial surgery)
11603328|NCT00624247|Other|Immediate|Individuals assigned to be approached for routine HIV testing immediately upon admission to the jail.
11603329|NCT00624247|Other|Following Day|Individuals assigned to be approached for routine HIV testing the day following admission to the jail.
11603330|NCT00624247|Other|Delayed|Individuals assigned to be approached for routine HIV testing several days following admission to the jail.
11603331|NCT00624234|Experimental|NF-Tutoring Program 1|Tutoring Program I
11603332|NCT00624234|Experimental|NF-Tutoring Program 2|Tutoring Program II
11603333|NCT00624234|No Intervention|Typically Developing Readers|Control group
11603334|NCT00624234|Experimental|IRD-Tutoring Program 1|Tutoring Program I
11603335|NCT00624234|Experimental|IRD-Tutoring Program 2|Tutoring Program II
11603336|NCT00624234|No Intervention|Waitlist Control|Intervention Control Group (RD)
11603337|NCT00624221|Active Comparator|1|An Eye bank pre-cut the donor grafts used for the corneal transplant procedures.
11603338|NCT00624221|Active Comparator|2|The surgeon dissected the donor grafts used for the transplant procedures.
11603339|NCT00624208|Active Comparator|1|Intravenous injection of droperidol 20 mcg.kg-1 and saline (group 1)
11603340|NCT00624208|Active Comparator|2|Intravenous injection of ondansetron 0.1 mg.kg-1 and saline (group 2
11603341|NCT00624208|Active Comparator|3|Intravenous injection of droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1 (group 3)
11603342|NCT00624208|Placebo Comparator|4|Intravenous injection of saline and saline (group 4)
11603343|NCT00624195|Experimental|CNS-targeted|"CNS-T will comprise two components: 1) initial selection of agents to optimize CNS penetration of the overall regimen; and 2) modification of the regimen if an interim pharmacokinetic (PK) assessment determines that plasma ARV exposure is not appropriate (overdosing, under dosing).
~Possible regimens include combinations of these FDA approved antiretroviral agents: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
11603344|NCT00624195|Active Comparator|non-CNS-targeted|"Subjects in the non-CNS-T (Comparison) arm will be randomized to receive a regimen (see list of FDA approved antiretrovirals listed below) designed to suppress plasma Viral Load, but not expected to have targeted CNS penetration.
~Combinations of FDA approved antiretroviral agents: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
11603345|NCT00624182|Experimental|Phase I study|
11603346|NCT00624156||1|emotional disclosure writing intervention
11603347|NCT00624156||2|control writing
11603348|NCT00624143|Active Comparator|1|Oral Voriconazole
11603349|NCT00624143|Active Comparator|2|IV Amphotericin B
11603350|NCT00624130|Experimental|Arm 1|
11603351|NCT00624130|Active Comparator|Arm 2|
11603352|NCT00624117|Experimental|A|
11603353|NCT00624104||1|Lean male
11603354|NCT00624104||2|Males with type 2 diabetes
11603355|NCT00624091|Experimental|1|Early-surgery, within 48 hours from randomization
11603356|NCT00624091|Active Comparator|2|State-to-the-art group. Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
11603357|NCT00624078|Experimental|1|Patients who arrive to emergency room with scorpion sting envenomation will be evaluated according to inclusion/exclusion criteria. After informed consent has been signed they will be assigned to unique treatment arm with Anascorp.
11603359|NCT00624065|Active Comparator|lisinopril + placebo|
11603360|NCT00624039|Other|1|ultrasound biomicrocopic examinations and pilocarpine instillation
11603361|NCT00624026|Experimental|1|
11603362|NCT00624013|Placebo Comparator|Placebo|Placebo 50 mg up to 100 mg daily for 6 months
11603363|NCT00624013|Active Comparator|Sertraline (Zoloft)|Sertraline (Zoloft) 50 mg up to 100 mg daily for 6 months
11603364|NCT00624000|Experimental|1|IA administration of Alteplace vs. IV administration of Alteplace
11603365|NCT00624000|Active Comparator|2|IA administration of Alteplase vs.IV administration of Alteplase
11603366|NCT00623987|Active Comparator|A|warfarin treatment
11603367|NCT00623987|No Intervention|B|withholding warfarin therapy
11603368|NCT00623974|Experimental|Calcium + Calcitriol|1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
11603369|NCT00623974|Experimental|Teriparatide 20 mcg|Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
11603370|NCT00623974|Experimental|Teriparatide 40 mcg|Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
11603371|NCT00623974|Experimental|Teriparatide 60 mcg|Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
11603372|NCT00623948|Other|Arm 1|
11603373|NCT00623935|Experimental|Fludarabine plus Busulfan (CR)|Patients in CR will receive a reduced intensity transplant regimen consisting of Fludarabine plus Busulfan (FluBu2).
11603374|NCT00623935|Experimental|Fludarabine plus Busulfan (PR)|Patients in PR will receive a full intensity transplant regimen consisting of Fludarabine plus Busulfan (FluBu4).
11603375|NCT00623922|Experimental|1|Patient education
11603376|NCT00623922|No Intervention|2|Usual care
11603377|NCT00623909|Experimental|1|To demonstrate the safety of the AvicennaTM class IV laser for application over the skin of human subjects. This study was terminated prior to subject enrollment and closed.
11603378|NCT00623883|Experimental|1|All identified ACF eliminated by cold or hot colonoscopic biopsy forceps
11603379|NCT00623883|Sham Comparator|2|ACF quantified and observed, re-evaluated after one year
11603380|NCT00623870|Experimental|1|
11603381|NCT00623857|Active Comparator|1|Zinc
11603382|NCT00623857|Active Comparator|2|Vitamins and minerals other than zinc
11603383|NCT00623857|Active Comparator|3|Vitamins plus zinc and other minerals
11603384|NCT00623857|Placebo Comparator|4|Placebo for all vitamins and minerals
11603385|NCT00623844|Experimental|Intervention|Physical activity intervention: structured daily 30-min activity classes at preschool, activity homeworks, parent and teacher education
11603386|NCT00623844|No Intervention|Control|Keep usual activities in kindergarten
11603387|NCT00623831|Experimental|Cohort 1|Subjects received MBV at a starting dose of 250 EU (dose level 1) twice weekly, with intrasubject dose escalations for each subsequent administration in the absence of a DLT until the desired pyrogenic effect was observed. The maximum possible dose to be investigated was 547,000 EU (dose level 8).
11603388|NCT00623831|Experimental|Cohort 2|Subjects received MBV twice weekly at the fixed dose (60,800 EU [dose level 6]) that was determined to be the pyrogenic dose level in Cohort 1.
11603389|NCT00623805|Active Comparator|Bevacizumab+capecitabine+oxaliplatin|Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.
11603390|NCT00623805|Experimental|Bevacizumab(B)+capecitabine(C)+oxaliplatin followed by B+C|Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle for 6 cycles followed by bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.
11603391|NCT00623792|No Intervention|1|Usual preoperative care
11603392|NCT00623792|Experimental|2|Preoperative Lifestyle Intervention
11603393|NCT00623766|Experimental|Ipilimumab, 10 mg/kg, IV in corticosteroid-free patients|Participants who had not received corticosteroid therapy for at least 10 days before starting study drug received ipilimumab,10 mg/kg, as a 90-minute intravenous (IV) infusion every 3 weeks (Weeks 1, 4, 7, and 10) during the Induction Phase. Those eligible (patients who did not discontinue due to toxicity, did not show progression at 24 weeks, and who remained clinically stable) for the Maintenance Phase continued to receive ipilimumab, 10 mg/kg IV, every 12 weeks, beginning at Week 24.
11603394|NCT00623766|Experimental|Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients|Participants who were dependent on corticosteroid therapy received ipilimumab, 10 mg/kg, as a 90-minute intravenous (IV) infusion every 3 weeks (Weeks 1, 4, 7, and 10) during the Induction Phase. Those eligible (patients who did not discontinue due to toxicity, did not show progression at 24 weeks, and who remained clinically stable) for the Maintenance Phase continued to receive ipilimumab, 10 mg/kg IV, every 12 weeks, beginning at Week 24.
11603395|NCT00623753|Experimental|A|
11603396|NCT00623740|Experimental|1: hydrocortisone|1: active arm treated with low doses of HC during the first 10 days of life
11603397|NCT00623740|Placebo Comparator|2: Placebo|2:placebo arm treated with placebo at the same conditions than active arm
11603398|NCT00623727|Experimental|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight of BAY79-4980 1x/week plus 2 dummy injections/week (dummy = rFVIII (recombinant factor VIII)-FS (formulated with sucrose) excipient reconstituted in WFI (sterile water for injection))
11603399|NCT00623727|Active Comparator|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight of rFVIII-FS 3x/week (employing 1 percent POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)-alone liposome (rFVIII-FS-POPC) as blinding agent used for first weekly injection and rFVIII-FS in WFI for 2nd and 3rd injection)
11603400|NCT00623714|Experimental|Arm 1|study medication + Pbo
11603401|NCT00623714|Experimental|Arm 2|Pbo + study medication
11603402|NCT00623701|Placebo Comparator|1|sublingual placebo preparation
11603403|NCT00623701|Experimental|2|Sublingual preparation, 40 micro grams Phl p 5 maintenance dose
11603404|NCT00623688|Experimental|1|Subjects receive active medication (albuterol) delivered by a Proair metered dose inhaler used with an Opti-chamber and placebo (normal saline solution) by nebulizer aerosol.
11603405|NCT00623688|Active Comparator|2|Subjects receive active medication (albuterol) delivered by nebulizer and placebo (no medicine) delivered by a demonstrator Placebo metered dose inhaler demonstrator.
11603406|NCT00623675|Experimental|A|
11603407|NCT00623662|Active Comparator|1|Glucose infusion.
11603408|NCT00623662|Placebo Comparator|2|Normal saline infusion.
11603409|NCT00623649|Experimental|Cohort 1|VCH-916 100 mg three times a day (t.i.d.)
11603410|NCT00623649|Experimental|Cohort 2|VCH-916 200 mg (t.i.d.)
11603411|NCT00623649|Experimental|Cohort 3|VCH-916 300 mg twice daily for three days
11603412|NCT00623649|Experimental|cohort 4|VCH-916 400 mg twice daily for three days
11603413|NCT00623636|Experimental|MAP0004|MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks.
11603414|NCT00623636|Other|Placebo|Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks.
11603415|NCT00623623|Experimental|Tenecteplase|Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention
11603416|NCT00623623|Other|primary PCI|Standard primary PCI
11603417|NCT00623597|Experimental|1|
11603418|NCT00623584|Experimental|1|Patients in this arm randomly receive a corneal graft cultured in a serum free culture medium
11603419|NCT00623584|Active Comparator|2|Patients in this arm randomly receive a corneal graft cultured in a serum supplemented culture medium
11603420|NCT00623571|Experimental|1|Patients treated by hospital-at-home service (GHHS)
11603421|NCT00623571|Active Comparator|2|Patients treated in a general medical ward (GMW)
11603422|NCT00623558|Active Comparator|1|Docetaxel+CDDP
11603423|NCT00623558|Experimental|2|Docetaxel+CDDP+Cetuximab
11603424|NCT00623545|Experimental|Exenatide|Exenatide. Dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks Each subject serves as their own control for outcome measures taken before and during drug treatment.
11603425|NCT00623532|Experimental|CA|"Cognition and action are an inseparable whole while functioning, a new intervention based approach using familiarity based movements and non judgmental approach was labeled cognition-action."
11603426|NCT00623532|Active Comparator|AT|Adapted Tai Chi is based on Tai Chi like movements
11603427|NCT00623532|No Intervention|C|Control
11603428|NCT00623519||1|Women with hormone receptor positive breast cancer under adjuvant treatment with Anastrozole
11603429|NCT00623506|Active Comparator|1|Pregnenolone
11603430|NCT00623506|Placebo Comparator|2|Placebo
11603431|NCT00623480|Experimental|Recombinant Factor VIII prophylaxis treatment|Participants received 25 IU/kg of Recombinant Factor VIII (Kogenate FS, BAY14-2222) intravenously (IV), 3 times per week. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) for patients exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
11603432|NCT00623480|Experimental|Recombinant Factor VIII on-demand treatment|Participants received Recombinant Factor VIII (Kogenate FS, BAY14-2222) IV for bleeds in accordance with package insert instructions and study physician recommendations.
11603433|NCT00623467|Experimental|Gadobutrol (Gadavist, BAY86-4875)|Participants were administered a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) bolus administration using a power injector via a peripheral vein (an antecubital vein was preferred). Gadobutrol was injected at a rate of 2 mL/second followed by a 20-mL 0.9% saline flush at the same rate.
11603434|NCT00623428|Experimental|PEG-IFN alfa-2a + Ribavirin for 24 weeks|After 24 weeks of treatment with pegylated interferon alfa-2a (PEG-IFN alfa-2a) 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, at which time treatment was stopped. Participants were followed for an additional 48 weeks during the treatment-free follow-up period.
11603435|NCT00623428|Active Comparator|PEG-IFN alfa-2a + Ribavirin for 48 weeks|After 24 weeks of treatment with PEG-IFN alfa-2a 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, and continued treatment for another 24 weeks (for a total of 48 weeks of treatment). Participants were followed for an additional 24 weeks during the treatment-free follow-up period.
11603436|NCT00623415|Active Comparator|Verum|flupirtine + interferon beta 1b
11603437|NCT00623415|Placebo Comparator|Placebo|placebo + interferon beta 1b
11603438|NCT00623402|Experimental|A|
11603439|NCT00623389|Experimental|A|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.
11603440|NCT00623376|Active Comparator|1|first on treatment then on Placebo
11603441|NCT00623376|Placebo Comparator|2|first on placebo then on treatment
11603442|NCT00623363|Active Comparator|piclozotan|
11603443|NCT00623363|Placebo Comparator|0.9 % sodium chloride (normal saline)|
11603444|NCT00623350|Active Comparator|1|Acute Stroke Telephone consult for the decision of tPA within 3 hours of symptoms onset.
11603445|NCT00623350|Active Comparator|2|Acute Stroke consult via audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
11603446|NCT00623337|Experimental|Newhints|Home visits
11603447|NCT00623337|No Intervention|Control|Community based surveillance volunteers will continue with current duties eg urging attendance at immunisation clinics and child health weeks
11603448|NCT00623324|Active Comparator|1|Aplindore titrated to safe and tolerable dose
11603449|NCT00623324|Placebo Comparator|2|
11603450|NCT00623298|Experimental|1|NET
11603451|NCT00623298|No Intervention|3|6-months baseline
11603452|NCT00623298|Experimental|2|group IPT
11603453|NCT00623285|Experimental|Group 1|
11603454|NCT00623285|Placebo Comparator|Group 2|
11603455|NCT00623259|Experimental|1|
11603456|NCT00623246|Active Comparator|1|Participants will receive motivational enhancement therapy (MET) for 12 weeks.
11603457|NCT00623246|Active Comparator|2|Participants will receive educational therapy (ED) for 12 weeks.
11603458|NCT00623246|No Intervention|3|Participants will receive standard clinical care.
11603459|NCT00623233|Experimental|Gemcitabine + Bevacizumab|"Gemcitabine 2500 milligrams per square meter (mg/m^2) intravenous (IV) over 30 minutes given on Day 1 every 14 days (q 14 days) until disease progression (PD) or unacceptable toxicity.
~Bevacizumab 10 milligrams per kilogram (mg/kg) initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity."
11603460|NCT00623220|Experimental|A|O2 and N2O
11603461|NCT00623220|Active Comparator|B|O2 only
11603462|NCT00623207|Placebo Comparator|1|Pateints who achieve target haert rate or conclusive test will not be given Atropine
11603463|NCT00623207|Active Comparator|2|Patients who won't achieve tarhet heart rate or conclusive results will be given Atropine
11603464|NCT00623194|Experimental|insulin detemir|Insulin detemir up to twice daily plus insulin aspart at larger meals, doses are adjusted individually (treatment up to 104 weeks)
11603465|NCT00623181|Experimental|Fluzone Intradermal First, Then Fluzone Intramuscular|
11603466|NCT00623181|Experimental|Fluzone Intramuscular First, Then Fluzone Intradermal|
11603467|NCT00623168|Experimental|Treatment Only|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with Ribavirin.
11603468|NCT00623155|No Intervention|1|Control group
11603469|NCT00623155|Experimental|2|Test group
11603470|NCT00623142|No Intervention|A|Patients in this arm were not treated with HBO prior to CABG
11603471|NCT00623142|Experimental|B|Patients in this arm were treated with HBO prior to CABG
11603472|NCT00623103|Experimental|Rivastigmine capsule|Rivastigmine capsules starting at a total dose of 3 mg/day (1.5 mg twice daily orally) titrated up in 3 mg/day increments every 4 weeks to a final dose of 12 mg/day (6 mg twice daily orally). The 12 mg/day dose or the highest dose tolerated was maintained until week 76.
11603473|NCT00623103|Experimental|Rivastigmine patch|Rivastigmine patch once a day in the morning, worn for 24 hours, starting at 5 cm^2 (delivering 4.6 mg rivastigmine over a 24 hour period) for 4 weeks then titrated up to 10 cm^2 daily (delivering 9.5 mg rivastigmine over a 24 hour period). The 10 cm^2 patch or the highest well tolerated dose was maintained until week 76.
11603474|NCT00623090|Experimental|1 Website|Participants receive the Login information for the Internet we developed on prostate cancer screening.
11603475|NCT00623090|Active Comparator|2 Booklet|Participants receive the education booklet we developed on prostate cancer screening.
11603476|NCT00623090|Placebo Comparator|3 Usual Care|Usual care: participants receive no intervention.
11603477|NCT00623077|Experimental|Total Marrow Irradiation (MTI) with Tomotherapy|TMI given prior to alkylator intensive conditioning regimen (Busulfan 9.6 mg/kg intravenously (IV) (>4 yrs of age) or 13.2 mg/kg IV (< 4 years of age), Melphalan 100 mg/m^2, Thiotepa 500 mg/m^2 for high risk solid tumor patients, Whole lung radiation 1500cGy in 10 fractions by Day 60, stem cell transplantation on day 0. Ifosfamide, etoposide, and mesna are given Days 0-4 followed by filgrastim for 3 doses. Cohorts of patients (n=3) will be treated with increasing doses of TMI (600, 1000, 1200 cGy) directed toward the bones.
11603478|NCT00623051|Experimental|1|Male circumcision by experimented doctor or nurse
11603479|NCT00623025|Experimental|1|
11603480|NCT00623025|Placebo Comparator|2|
11603481|NCT00623012|Experimental|1|
11603482|NCT00622999||All|All patients
11603483|NCT00622986|Experimental|A1|perimenopausal women
11603484|NCT00622986|Placebo Comparator|A2|perimenopausal women
11603485|NCT00622986|Experimental|B1|early staged postmenopausal women
11603486|NCT00622986|Placebo Comparator|B2|early staged postmenopausal women
11603487|NCT00622973|Other|A|Diffusion-weighted MRI
11603488|NCT00622973|Other|B|Sinerem (USPIO)- enhanced MRI
11603489|NCT00622960|Experimental|High MUFA diet|Those subjects assigned to a high monounsaturated fat diet
11603490|NCT00622960|Active Comparator|High CHO diet|Those subjects assigned to a high carbohydrate diet
11603491|NCT00622947|Active Comparator|repetitive transcranial magnetic stimulation|Low frequency ( 1 HZ) rTMS of the right prefrontal cortex. On each of 15 consecutive week days (apart from weekends), the patients received two 60-second1-Hz trains delivered at an intensity of 110% of motor thresholdand with a 180 seconds' intertrain interval.
11603492|NCT00622947|Sham Comparator|Placebo stimulation|Sham- rTMS of the right prefrontal cortex. On each of 15 consecutive week days (apart from weekends), the patients received two 60-second1-Hz trains delivered at an intensity of 110% of motor thresholdand with a 180 seconds' intertrain interval.
11603493|NCT00622934|Active Comparator|1|
11603494|NCT00622934|Placebo Comparator|2|
11603495|NCT00622921|Other|1|Couples-based behavioral psychotherapy
11603496|NCT00622908|Experimental|ISV-403|ISV-403 0.6%
11603497|NCT00622908|Placebo Comparator|Vehicle|Vehicle of ISV-403
11603498|NCT00622895|Experimental|Treatment: allogeneic UCB after reduced intensity conditioning|Patients receive fludarabine phosphate IV on days -4, -3 and -2, cyclophosphamide IV over 1-2 hours on days -6, -5, 3, and 4, and undergo low-dose TBI on day -1. Patients receive hematopoietic cell transplantation on day 0.
11603499|NCT00622882|Active Comparator|ID|Patients receiving an early Infectious disease consultation ( within first 48 hours of a positive blood culture)
11603500|NCT00622882|No Intervention|NO ID|Includes those patients who do not receive an Infectious disease consultation in the first 48 hours
11603501|NCT00622869|Experimental|Everolimus + reduced tacrolimus|Low dose tacrolimus (tacrolimus reduced) + everolimus + corticosteroids.
11603502|NCT00622869|Experimental|Tacrolimus elimination|Low-dose tacrolimus (until Month 4, then tacrolimus eliminated) + everolimus + corticosteroids.
11603503|NCT00622869|Active Comparator|Tacrolimus control|Control dose tacrolimus + corticosteroids.
11603504|NCT00622856|Experimental|1|Psychological intervention for strengthening parental authority
11603505|NCT00622856|Active Comparator|2|Diabetes education- 5 sessions with diabetes nurse, taking place once a week
11603506|NCT00622856|No Intervention|3|Control group- regular treatment without any intervention
11603507|NCT00622843|Experimental|Group 1|PCV, 210 patients
11603508|NCT00622843|Active Comparator|Group 2|PPV, 110 patients
11603509|NCT00622843|Active Comparator|Group 3|PPV, HIV-negative, 25 patients
11603510|NCT00622817|Active Comparator|1|Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
11603511|NCT00622817|Experimental|2|Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
11603512|NCT00622804|Other|1|Billroth-II (B-II)reconstruction
11603513|NCT00622804|Other|2|Roux en Y gastrojejunostomy (RY-GJ)
11603514|NCT00622804|Other|3|uncut Roux en Y gastrojejunostomy (uncut RY-GJ)
11603515|NCT00622791||CABG group|Patients undergoing coronary artery bypass graft with cardiopulmonary bypass
11603516|NCT00622791||OPCAB group|Patients undergoing off-pump coronary artery bypass graft
11603517|NCT00622778||1|Patients from daily practice
11603518|NCT00622765|Experimental|001|R256918 5 mg capsule twice daily
11603519|NCT00622765|Experimental|002|R256918 10 mg capsule twice daily
11603520|NCT00622765|Experimental|003|R256918 15 mg capsule twice daily
11603521|NCT00622765|Placebo Comparator|004|placebo Placebo capsule twice daily
11603522|NCT00622752|Experimental|1|EVT 302, 10 mg
11603523|NCT00622752|Experimental|2|EVT 302, 10 mg + NRT patch, 21 mg
11603524|NCT00622752|Experimental|3|NRT patch, 21 mg
11603525|NCT00622752|Placebo Comparator|4|Placebo to match EVT 302 and placebo patch to match NRT patch
11603526|NCT00622739|Active Comparator|ziprasidone rapid dose|Rapid Dose Titration Group
11603527|NCT00622739|Active Comparator|ziprasidone slow dose|Slow Dose Titration Group
11603528|NCT00622726|Experimental|Bevacizumab for ROP|Intravitreal Bevacizumab Therapy is the Experimental Arm of this Study
11603529|NCT00622726|Active Comparator|Conventional Laser for ROP|Conventional Laser to the Peripheral Retina is the Control Arm of this Study
11603530|NCT00622700|Placebo Comparator|Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg|"Core treatment period: Placebo matched to teriflunomide tablet once daily orally.
~Extension treatment period: Re-randomized in 1:1 ratio to either teriflunomide 7 mg or 14 mg once daily orally."
11603531|NCT00622700|Experimental|Teriflunomide 7 mg/7 mg|"Core treatment period: Teriflunomide 7 mg tablet once daily orally.
~Extension treatment period: Teriflunomide 7 mg tablet once daily orally."
11603532|NCT00622700|Experimental|Teriflunomide 14 mg/14 mg|"Core treatment period: Teriflunomide 14 mg tablet once daily orally.
~Extension treatment period: Teriflunomide 14 mg tablet once daily orally."
11603533|NCT00622687|Active Comparator|A|low dose iloprost therapy 0.5 ng/kg x min
11603534|NCT00622687|Active Comparator|B|high-dose therapy
11603535|NCT00622674|Experimental|Bortezomib and Cetuximab|The starting dose of bortezomib will be 1.3 mg/m2 with a 0.1 increment increase with each successive dose level to a maximum of 2.0 mg/m2. A loading dose of cetuximab will be given on day 1 (400 mg/m2) followed by a weekly dose of 250 mg/m2.
11603536|NCT00622661|Other|1|Normal weight
11603537|NCT00622661|Other|2|Overweight
11603538|NCT00622648|Experimental|A|Enoxaparin: 40 mg once daily for 6 to 14 days (10 ± 4 days)
11603539|NCT00622648|Placebo Comparator|B|Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
11603540|NCT00622635|Experimental|Indacaterol 300 μg - placebo to indacaterol - salmeterol 50 μg|In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11603541|NCT00622635|Experimental|Placebo to indacaterol - salmeterol 50 μg - indacaterol 300 μg|In treatment period 1, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); and in treatment period 3, patients received indacaterol 300 μg once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11603542|NCT00622635|Experimental|Salmeterol 50 μg - indacaterol 300 μg - placebo to indacaterol|In treatment period 1, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); in treatment period 2, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); and in treatment period 3, patients received placebo to indacaterol once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11603543|NCT00622635|Experimental|Placebo to indacaterol - indacaterol 300 μg - salmeterol 50 μg|In treatment period 1, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received indacaterol 300 μg once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11603584|NCT00622284|Active Comparator|Glimepiride|patient to receive 1mg or 2mg or 3mg (not in US) or 4mg Glimepiride capsule plus one inactive placebo tablet matching BI 1356 (plus one inactive placebo capsule in US)
11603585|NCT00622271|Other|Wait List Control|Patients and their families will be enrolled into either a treatment group or a wait list control (WLC) group to receive the group therapy intervention.
11603586|NCT00622258|Experimental|Everolimus|
11603544|NCT00622635|Experimental|Indacaterol 300 μg - salmeterol 50 μg - placebo to indacaterol|In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); and in treatment period 3, patients received placebo to indacaterol once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11603545|NCT00622635|Experimental|Salmeterol 50 μg - placebo to indacaterol - indacaterol 300 μg|In treatment period 1, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); and in treatment period 3, patients received indacaterol 300 μg once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11603546|NCT00622622|Experimental|Phase I study|
11603547|NCT00622609|Experimental|Subjects receiving GSK249320A|Eligible subjects will receive escalating doses of GSK249320A in cohort 1 to 6 with a starting dose of 0.04 milligrams/kilograms up to the maximum dose of 25 milligrams/kilograms, administered as a slow intravenous infusion over 1 hour on Day 1.
11603548|NCT00622609|Placebo Comparator|Subjects receiving placebo|Eligible subjects will receive single dose of sodium chloride in cohort 1 to 6, administered as a slow intravenous infusion over 1 hour on Day 1.
11603549|NCT00622596|Experimental|Mobile Access to Buprenorphine|High risk populations accessing a mobile health care system can obtain Buprenorphine for treatment.
11603550|NCT00622583||Observation Group|Subjects who meet the inclusion/exclusion criteria who have had a hernia repair.
11603551|NCT00622570|Experimental|1|Pentobarbital
11603552|NCT00622570|Active Comparator|2|thiopental
11603553|NCT00622557||Surgical|
11603554|NCT00622531||BNP Open|Subjects treated based on clinical assessment and knowledge of BNP values
11603555|NCT00622531||Control|Subjects treated based on clinical assessment alone
11603556|NCT00622518|Active Comparator|1|homeopathic ear drops in addition to standard care for otitis media
11603557|NCT00622518|No Intervention|2|No ear drops, standard care for otitis
11603558|NCT00622505|Experimental|zoldronic acid|
11603559|NCT00622492||VV-ECMO|newborn infants with reversible causes of PPHN eligible for ECMO treatment
11603560|NCT00622492||VA-ECMO|newborn infants with reversible causes of PPHN eligible for ECMO treatment
11603561|NCT00622479|Experimental|Arm 1|
11603562|NCT00622466|Experimental|Sorfenib + Paclitaxel|Oral sorafenib tosylate twice daily on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15
11603563|NCT00622453||Registry of Arrhythmias|Screening of individuals with myotonic muscular dystrophy to evaluate the utility of non-invasive electrocardiographic screening methods and history in predicting serious arrhythmic events.
11603564|NCT00622440|Active Comparator|1|
11603565|NCT00622440|Placebo Comparator|2|
11603566|NCT00622427|Experimental|Ramelteon then placebo|8 mg tablets every night for 2 weeks, then a 2 week washout,then crossover to placebo tablets for 2 weeks.
11603567|NCT00622427|Experimental|Placebo then Ramelteon|placebo tablets for every night for 2 weeks, then a 2 week washout, followed by 8 mg tablets every night for 2 weeks.
11603568|NCT00622414|Experimental|Treatment (ziv-aflibercept)|"PART 1: Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days for 2 years in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive aflibercept until the maximum tolerated dose (MTD) is determined.
~PART 2: Patients receive aflibercept as in part 1 at 150% of the MTD determined in part 1. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity."
11603569|NCT00622401|Experimental|Group 1|Dendritic Cell/Tumor Fusion Vaccine Only
11603570|NCT00622401|Experimental|Group 2|Dendritic Cell/tumor fusion vaccine and low dose IL-12
11603571|NCT00622401|Experimental|Group 3|Dendritic Cell/tumor fusion vaccine and higher dose IL-12
11603572|NCT00622388|Experimental|Ofatumumab|8 weekly intra-venous (I.V.) infusions, 1 x 300mg and 7 x 1000mg
11603573|NCT00622375|Experimental|1|
11603574|NCT00622362|Active Comparator|A|Subcutaneous administration
11603575|NCT00622362|Experimental|B|Sublingual administration
11603576|NCT00622362|Placebo Comparator|C|Sublingual administration
11603577|NCT00622349|Experimental|A|
11603578|NCT00622349|Active Comparator|B|
11603579|NCT00622349|Experimental|C|
11603580|NCT00622336|Experimental|Lenalidomide 25mg (CC-5013)|Oral 25mg daily on Days 1-21 every 28 days
11603581|NCT00622310|Experimental|1 Exercise|Subjects in the EX group will perform supervised exercise 5 d/wk. Exercise will consist primarily of walking on an inclined motor-driven treadmill, but alternate activities will be permitted for 20% of the total exercise sessions (1 of 5 days). Exercise sessions will be preceded by a 5 min warm-up performed at a HR corresponding to 40% of VO2max. The initial exercise duration and intensity at baseline will be 20 minutes at an intensity that elicits a heart rate (HR) corresponding to 60% of VO2max. The target EE will be achieved by a gradual progression of exercise duration and intensity over the first 8 weeks of the exercise program. The target exercise intensity will be the workload corresponding to 75% of VO2max.
11603582|NCT00622310|Experimental|2 Walk|Subjects in the WALK group will also perform exercise 5 d/wk. Exercise will consist exclusively of walking on level grades, and will be prescribed in two equal duration bouts each day. Subjects in the WALK group will be individually prescribed a walking program based on the EE during moderate intensity walking. The target exercise intensity will be walking speeds corresponding 45% of VO2max.
11603583|NCT00622284|Experimental|BI 1356 5mg, once daily|patient to receive a tablet containing 5mg BI 1356 plus one (two in US) inactive placebo capsule matching Glimepiride
11603587|NCT00622245|Experimental|Lu AA34893: 4 mg|
11603588|NCT00622245|Experimental|Lu AA34893: 12 mg|
11603589|NCT00622245|Experimental|Lu AA34893: 18 mg|
11603590|NCT00622245|Other|Quetiapine fumarate|Active reference 300 mg
11603591|NCT00622245|Placebo Comparator|Placebo|
11603592|NCT00622219|Experimental|Drug Testing|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
11603593|NCT00622219|No Intervention|Control|Adolescents randomized to the control condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated) but will not be called for drug tests.
11603594|NCT00622206|Active Comparator|1|Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
11603595|NCT00622193|Experimental|1 Active 50 mg|
11603596|NCT00622193|Experimental|2 Active 100 mg|
11603597|NCT00622193|Placebo Comparator|3 Placebo|
11603598|NCT00622180|Active Comparator|Daavlin Right vs. Excilite Left|Right hand treated with narrow-band UVB light and left hand treated with focal 308nm light.
11603599|NCT00622180|Active Comparator|Excilite Right vs. Daavlin Left|Right hand treated with focal 308-nm light and left hand treated with narrow-band UVB light
11603600|NCT00622167|Other|1|All patients will receive integrated backscatter IVUS and dual source CT.
11603601|NCT00622141|Active Comparator|A|Day 1: receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg 7-day washout period will follow. Day 8: take generic GPO squinavir/Norvir
11603602|NCT00622141|Active Comparator|B|Day 1: take generic GPO squinavir/Norvir 7-day washout period will follow. Day 8: receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg
11603603|NCT00622128|Experimental|1|Pilot study. Developing intervention
11603604|NCT00622115|Experimental|A|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 4 hours following the last injection of enoxaparin
11603605|NCT00622115|Experimental|B|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 6 hours following the last injection of enoxaparin
11603606|NCT00622115|Experimental|C|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 10 hours following the last injection of enoxaparin
11603607|NCT00622102|Experimental|1|50% of the consenting subjects will take part in the lottery and use the Med-eMonitor as a device to monitor adherence
11603608|NCT00622102|Other|2|50% of the consenting subjects will use only the Med-eMonitor as a device to monitor adherence
11603609|NCT00622089|Experimental|1|150mg DIO-902 + 10mg Atorvastatin
11603610|NCT00622089|Experimental|2.|300mg DIO-902 + 10mg Atorvastatin
11603611|NCT00622089|Experimental|3|450mg DIO-902 + 10mg Atorvastatin
11603612|NCT00622076|Active Comparator|1|postoperative catheterization after anterior colporrhaphy during five days.
11603613|NCT00622076|Active Comparator|2.|postoperative catheterization after anterior colporrhaphy during two days
11603614|NCT00622050|Experimental|1|This arm will be experiencing the same protocol as the control group, only their TV viewing time will be reduced. The TV viewing time reduction is the experimental intervention.
11603615|NCT00622050|Active Comparator|Control|The control group will be experiencing the exact protocol; only their TV viewing time will not be reduced.
11603616|NCT00622037|Active Comparator|1|PEG-400 based artificial tear
11603617|NCT00622037|Active Comparator|2|Systane
11603618|NCT00622011|Experimental|1|zotepine , start from 50mg/day then titrate according to individual case
11603619|NCT00622011|Active Comparator|2|Risperidone, start from 1mg/day
11603620|NCT00621998|Experimental|1|Flexible dose of olanzapine
11603621|NCT00621998|Active Comparator|2|Flexible dose of risperidone
11603622|NCT00621985|Experimental|Experimental|Experimental therapy with nocturnal dexamethasone.
11603623|NCT00621972||Observation|Chronic kidney disease patients presenting for fisulta evaluation with documented GFR<30ml/min by abbreviated MDRD calculation.
11603624|NCT00621959|Placebo Comparator|Placebo|Matched placebo tablets once daily
11603625|NCT00621959|Experimental|LCTZ|5 mg levocetirizine dihydrochloride tablet
11603626|NCT00621946|Placebo Comparator|Placebo|Placebo Matching Escitalopram given orally daily (for a 12-week duration).
11603627|NCT00621946|Active Comparator|Escitalopram|Once daily oral administration (for a 12-week duration) of 10 mg escitalopram tablets with an increase to 20 mg in those with a less than 30% decrease in HAM-D scores at week 4.
11603628|NCT00621933||All Patients Receiving Cataract Surgery|All Patients Receiving Cataract Surgery
11603629|NCT00621907|Experimental|1|patient who received levobupivacaïne
11603630|NCT00621907|Placebo Comparator|2|patient who received placebo
11603631|NCT00621894|Experimental|LGD4665|LGD-4665: Experimental Thrombopoietin mimetic
11603632|NCT00621894|Placebo Comparator|Placebo|Placebo
11603633|NCT00621881|Experimental|1|750 mg naproxcinod
11603634|NCT00621868|Experimental|1|Lowest dose
11603635|NCT00621868|Experimental|2|Low-middle dose
11603636|NCT00621868|Experimental|3|High-middle dose
11603637|NCT00621868|Experimental|4|Highest dose
11603638|NCT00621868|Placebo Comparator|5|placebo
11603639|NCT00621855|Experimental|Dabigatran etexilate 50mg|twice daily dosing,
11603640|NCT00621855|Experimental|Dabigatran etexilate 75mg|twice daily dosing, patients with moderate renal impairment allocated 50mg bid
11603641|NCT00621855|Experimental|Dabigatran etexilate 110mg|twice daily dosing, patients with moderate renal impairment allocated 75mg bid
11603642|NCT00621855|Experimental|dabigatran etexilate 150mg|twice daily dosing, patients with moderate renal impairment allocated 110mg bid
11603643|NCT00621855|Placebo Comparator|placebo|matched placebo
11603644|NCT00621842|Experimental|Open-Label Lamotrigine Treatment|
11603773|NCT00620919|Experimental|1|Drug + MDCT
11603645|NCT00621829|Active Comparator|1|"High susceptibility ALOX5 gene polymorphisms. Patients will be classified as having high susceptibility ALOX5 gene polymorphisms based on the number of repeats of the SP1 promoter."
11603646|NCT00621829|Active Comparator|2|"Low susceptibility ALOX5 gene polymorphisms. Low susceptibility ALOX5 gene polymorphisms. Patients will be classified as having high susceptibility ALOX5 gene polymorphisms based on the number of repeats of the SP1 promoter."
11603647|NCT00621816|Active Comparator|1|Blinded nitroprusside infusion
11603648|NCT00621816|Placebo Comparator|2|Blinded placebo infusion
11603649|NCT00621790|Experimental|Fenoldopam|Fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min) for up to 4 days
11603650|NCT00621790|Placebo Comparator|Placebo|Placebo (normosaline), continuous perfusion
11603651|NCT00621777|Active Comparator|Randomized Phase: Varenicline|Varenicline is a partial agonist at alpha4beta2 nicotinic acetylcholine receptors (nAChRs) and a full agonist at alpha 7 nAChRs that has been shown to be effective for smoking cessation compared with placebo and bupropion, with effects on abstinence rates for up to one year. Varenicline has demonstrated safety when dosed at 1 mg twice per day for up to one year. Because varenicline, at a dose of 1 mg twice per day, may be a more effective treatment for sustained abstinence than bupropion, it was chosen as the medication intervention for this study.
11603652|NCT00621777|Placebo Comparator|Randomized Phase: Placebo|
11603653|NCT00621764|Experimental|JE-CV/Hepatitis A (Group 1)|Participants aged 2 to 5 years at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
11603654|NCT00621764|Experimental|Hepatitis A/JE-CV (Group 2)|Participants aged 2 to 5 years at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)
11603655|NCT00621764|Experimental|JE-CV/Hepatitis A (Group 3)|Participants aged 12 to 24 months at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
11603656|NCT00621764|Experimental|Hepatitis A/JE-CV (Group 4)|Participants aged 12 to 24 months at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)
11603657|NCT00621751|Experimental|A|Carbamazepine 800 mg daily
11603658|NCT00621751|Placebo Comparator|B|Placebo
11603659|NCT00621725|Experimental|1|
11603660|NCT00621712|Active Comparator|A|Patients in group A will be provided with a commercially available and CE certified standard double lumen catheter without surface coating (GamCath® catheter, No. CE 76891).
11603661|NCT00621712|Experimental|B|Patients in group B will be treated with a CE certified double lumen catheter with a new antibacterial bismuth-containing surface coating (GamCath Dolphin® Protect, No. CE 90671).
11603662|NCT00621699|Experimental|C|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg tacrolimus)
11603663|NCT00621699|Active Comparator|A|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe)
11603664|NCT00621699|Active Comparator|B|administration of 1 capsule Prograf(R) (5 mg tacrolimus)
11603665|NCT00621686|Experimental|Sorafenib + Bevacizumab/Group A|"Patients receive oral sorafenib 400 mg (200 mg twice daily) days 1-5 and 8-12 and 5 mg/kg bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days.
~Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies.
~Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment.
~After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years."
11603666|NCT00621686|Experimental|Sorafenib + Bevacizumab /Group B|"Patients receive oral sorafenib 200 mg once daily on days 1-14 and 5 mg/kg bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days.
~Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies.
~Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment.
~After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years."
11603667|NCT00621673|Other|Arm 1|
11603668|NCT00621660|Experimental|Acupuncture|
11603669|NCT00621660|Placebo Comparator|Sham|
11603670|NCT00621647|Experimental|1|1st fixed dose
11603671|NCT00621647|Experimental|2|2nd fixed dose
11603672|NCT00621647|Sham Comparator|3|Placebo
11603673|NCT00621634|Experimental|1|Active treatment with omega-3 fish oil capsules (1 g each capsule, 50% DHA), 6 capsules each day for 12 weeks
11603674|NCT00621634|Placebo Comparator|2|Matching placebo treatment
11603675|NCT00621621|Experimental|Freezor Catheter for AVNRT|Subjects with Atrio Ventricular Reentrant Tachycardia (AVNRT)will be treated with cryo (freezing) energy to ablate the slow pathway causing the arrythmia.
11603676|NCT00621621|Other|External Data Supporting the Study|This arm was taken from pier reviewed published reports that include adult subjects ablated with the Freezor catheter for AVNRT.
11603677|NCT00621608|Experimental|1|Hyperbaric Oxygen Therapy
11603678|NCT00621608|Sham Comparator|2|Placebo Hyperbaric Oxygen Chamber
11603679|NCT00621595|Active Comparator|1|Fasting
11603680|NCT00621569|Active Comparator|1|Group intervention with no dietary focus
11603681|NCT00621569|Experimental|2|DASH diet intervention
11603682|NCT00621556|Experimental|1|Drug + MR with MRCP
11603683|NCT00621543|Experimental|Observation- All subjects|Women choosing intra-uterine contraception after medical abortion.
11603684|NCT00621530|Experimental|Ketorolac|ketorolac 2 mg ketorolac tromethamine opthalmic solution
11603685|NCT00621530|Placebo Comparator|Placebo|placebo will be added to the patient's routine spinal anesthetic for surgery
11603686|NCT00621517|Experimental|1|Participants will receive 150MG Bupropion nightly.
11603687|NCT00621517|Placebo Comparator|2|Participants will receive matching placebo capsule nightly.
11603774|NCT00620906|Other|A|Manipulation
11603688|NCT00621504|Experimental|Ceftaroline fosamil for Injection|"Ceftaroline fosamil was administered in two consecutive 300-mg IV infusions over 30 minutes, every 12 hours (q12h).
~In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism."
11603689|NCT00621504|Active Comparator|IV Ceftriaxone|"Ceftriaxone was administered as a 1-g IV infusion over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h).
~In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism."
11603690|NCT00621491|Placebo Comparator|1|Single daily dose of Placebo during six months
11603691|NCT00621478|Active Comparator|Cohort 1|"Cohort 1 (preconsented) patients will involve obtaining informed consent from the legally authorized representative of a potential study subject before they present to the ED in SE. Patient assent will be obtained for patients as per local IRB rules. The consent document (enclosed in this application) will inform parents that if their child comes to the ED and qualifies for the study based on study inclusion/exclusion criteria, they will be enrolled.
~Patients who cannot be contacted to confirm consent will be enrolled in Cohort 2 (EFIC) as detailed below.
~Patients in Cohort 1 will be randomized in a blinded fashion to either lorazepam 0.1 mg/kg or diazepam 0.2 mg/kg"
11603692|NCT00621478|Active Comparator|Cohort 2|"Cohort 2 (EFIC) will include patients who appear in the ED with SE and qualify for the study but have not given prior consent. These patients will be enrolled under the EFIC regulations. The parent/guardian will be given the opportunity to object to participation or ask additional questions.
~The child will be enrolled (dosed) with study medication under an EFIC. Once the child is stabilized, a research staff member will approach the parent or LAR to obtain informed consent to continue the child's participation in the study. If a parent or LAR refuses continued participation, then no further study procedures will be performed. Safety and data will be collected in accordance with federal regulations.
~Cohort 2 will be randomized, like Cohort 1, to either lorazepam 0.1 mg/kg or diazepam 0.2 mg/kg"
11603693|NCT00621465|Active Comparator|1|Participants will receive standard aftercare and community care services.
11603694|NCT00621465|Experimental|2|Participants will receive usual care and the Critical Time Intervention.
11603695|NCT00621452|Experimental|Treatment (autologous CD20 specific T-cells)|"CHEMOTHERAPY: Patients receive cyclophosphamide IV over 60 minutes.
~IMMUNOTHERAPY: Beginning 2 days after completion of cyclophosphamide, patients receive autologous CD20-specific T-cells IV over 30 minutes. Treatment repeats every 2-5 days for 3 courses.
~MAINTENANCE THERAPY: Beginning 2 hours after the last T-cell infusion, patients receive low-dose aldesleukin subcutaneously twice daily for 14 days.
~Subjects who have achieved at least a partial remission lasting a minimum of 6 months may, on a case-by-case basis, receive additional stored T cells following relapse."
11603696|NCT00621439|Experimental|I|Receives 1 dose of Pegylated Interferon
11603697|NCT00621439|Placebo Comparator|II|Receives placebo
11603698|NCT00621426||Observation|Patients with end-stage renal disease (ESRD) treated with hemodialysis three (3) times per week for at least 3 continuous months
11603699|NCT00621387|Experimental|1|ofloxacin and roxithromycin
11603700|NCT00621387|Placebo Comparator|2|placebo
11603701|NCT00621374|Experimental|Random Order 1|Randomization Order 1= 1)CONT, 2)CBT, 3)HYP, 4) CBT-HYP
11603702|NCT00621374|Experimental|Random Order 2|Randomization order 2= 1)CONT, 2)HYP, 3)CBT, 4) CBT-HYP
11603703|NCT00621361|Experimental|1|
11603704|NCT00621361|Active Comparator|2|Etoposide + Cisplatin
11603705|NCT00621348|Active Comparator|Isotonic fluid group|Normal saline in 5% dextrose at standard maintenance rate
11603706|NCT00621348|Active Comparator|Fluid restriction group|Reduced volume (2/3 maintenance rate) of N/5 saline in 5% dextrose
11603707|NCT00621348|Active Comparator|Hypotonic fluid group|N/5 saline in 5% dextrose at standard maintenance rate
11603708|NCT00621322|Placebo Comparator|Control Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the control GSK Biologicals' AS01B adjuvanted system, at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
11603709|NCT00621322|Active Comparator|GSK692342_F1 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the non-adjuvanted GSK692342 vaccine formulation 1 (F1), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
11603710|NCT00621322|Experimental|GSK692342_F2 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 2 (F2), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
11603711|NCT00621322|Experimental|GSK692342_F3 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 3, at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
11603712|NCT00621322|Experimental|GSK692342_F4D1 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 4 dosage 1 (F4D1), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
11603713|NCT00621322|Experimental|GSK692342_F4D2 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 4 dosage 2 (F4D2), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
11603714|NCT00621309|Active Comparator|1|Subjects are given 300 mg / 7 days of rifampicin to induce CYP3A4. Midazolam clearance is measured on the 8th day.
11603715|NCT00621309|Active Comparator|2|Sulforaphane (SFN), a natural product derived from broccoli sprouts, is utilized as a putative inhibitor of ligand (Rifampin) activation of the Pregnane X-receptor. In this arm, both SFN (putative inhibitor of ligand binding to PXR) and Rifampin (strong activating ligand of PXR) are given together.
11603775|NCT00620893|Active Comparator|1|1. PEG-400 based artificial tear
11603776|NCT00620893|Active Comparator|2|2. Systane
11603777|NCT00620867|Experimental|Ibuprofen|
11603778|NCT00620867|Experimental|Celecoxib|
11603716|NCT00621309|Active Comparator|3|This arm involves the administration of Sulforaphane (SFN) alone, in the absence of the PXR ligand, rifampicin. The hypothesis is that SFN will have no effect on the expression of PXR-regulated genes. Alternatively, it is possible that SFN could inhibit as yet unidentified endogenous ligands to the PXR receptor, thereby causing down-regulations of genes regulated wholely or in part by PXR. SFN is administered as a broccoli sprout extract at a dose rate of 75 mg (~420 umoles) per day for 7 days.
11603717|NCT00621296|Experimental|MP-424|
11603718|NCT00621283|Experimental|1|Drug + MR with MRCP
11603719|NCT00621270|Experimental|1|BCI-540 80 mg once a day (q.d.)
11603720|NCT00621270|Experimental|2|BCI-540 80 mg three times a day (t.i.d.)
11603721|NCT00621270|Placebo Comparator|3|Placebo
11603722|NCT00621257|Active Comparator|Treatment A|2,000 IU/day of ergocalciferol orally for 6 weeks (control arm)
11603723|NCT00621257|Experimental|Treatment B|2,000 IU/day of cholecalciferol orally for 6 weeks
11603724|NCT00621257|Experimental|Treatment C|50,000 IU of ergocalciferol once a week orally for 6 weeks
11603725|NCT00621257|Active Comparator|Maintenance A|400 IU/day of ergocalciferol orally over 2 years (control arm)
11603726|NCT00621257|Experimental|Maintenance B|2,000 IU/day of ergocalciferol orally from November 1 to April 30, and 1,000 IU/day of ergocalciferol orally for the remainder of the year over 2 years
11603727|NCT00621244|Experimental|Arm 1, Group X|
11603728|NCT00621244|Experimental|Arm 1, Group Y|
11603729|NCT00621244|Experimental|Arm 2, Group X|
11603730|NCT00621244|Experimental|Arm 2, Group Y|Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week, as part of a 28-day treatment cycle. Group Y is a sub-arm, based on disease indication.
11603731|NCT00621231|Placebo Comparator|1|
11603732|NCT00621231|Experimental|2|
11603733|NCT00621218|Active Comparator|1|
11603734|NCT00621218|Placebo Comparator|2|
11603735|NCT00621192|Experimental|Meropenem|"These
~Participants were subdivided into the following four groups based on Gestational Age (GA) and Postnatal Age (PNA):
~Group 1: GA at birth below 32 weeks - PNA <2 weeks; Group 2: GA at birth below 32 weeks - PNA ≥2 weeks and <91 days; Group 3: GA at birth 32 weeks or older - PNA <2 weeks; Group 4: GA at birth 32 weeks or older - PNA ≥2 weeks and <91 days."
11603736|NCT00621179|Active Comparator|Group 1|Positive endometrial alpha v, beta 3 vitronectin expression. Standard controlled ovarian stimulation protocol followed by in vitro fertilization Intervention: No intervention
11603737|NCT00621179|Experimental|Group 2|Intervention: Positive endometrial alpha v beta 3 vitronectin expression, 3 months of leuprolide acetate in depot suspension administration prior to initiation of controlled ovarian stimulation followed by in vitro fertilization
11603738|NCT00621179|Experimental|Group 3|Negative endometrial alpha v, beta 3 vitronectin and administration of leuprolide acetate in depot suspension for 3 months prior to initiation of controlled ovarian stimulation
11603739|NCT00621179|Active Comparator|Group 4|Negative endometrial alpha v, beta 3 vitronectin expression and standard controlled ovarian stimulation protocol followed by in vitro fertilization. Intervention: No intervention
11603740|NCT00621166|Other|1|generic lopinavir/ritonavir
11603741|NCT00621153|Active Comparator|1|Candesartan cilexetil 16mg monotherapy
11603742|NCT00621153|Experimental|2|Candesartan cilexetil 16mg/HCT combination therapy
11603743|NCT00621153|Active Comparator|3|candesartan cilexetil 32mg monotherapy
11603744|NCT00621153|Experimental|4|Candesartan Cilexetil 32 mg/HCT combination therapy
11603745|NCT00621140|Experimental|linagliptin 5 mg|linagliptin 5 mg once daily
11603746|NCT00621140|Placebo Comparator|placebo|placebo matching linagliptin 5 mg tablets
11603747|NCT00621114|Active Comparator|1|Patients in group 1 will be provided with a commercially available and CE certified standard double lumen catheter without surface coating (GamCath® catheter, No. CE 76891).
11603748|NCT00621114|Experimental|2|Patients in group 2 will be treated with a CE certified double lumen catheter with a new antibacterial bismuth-containing surface coating (GamCath Dolphin® Protect, No. CE 90671).
11603749|NCT00621101|Active Comparator|A|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe)
11603750|NCT00621101|Active Comparator|B|administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus)
11603751|NCT00621101|Experimental|C|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus)
11603752|NCT00621088|Active Comparator|Intertan|
11603753|NCT00621075||1|Pulmonary Arterial Hypertension
11603754|NCT00621062|Active Comparator|High Ligation of the GSV|
11603755|NCT00621062|Active Comparator|Endovenous Laser Ablation|
11603756|NCT00621062|Active Comparator|Radiofrequency ablation|
11603757|NCT00621062|Active Comparator|Foam Sclerotherapy|
11603758|NCT00621049|Experimental|Docetaxel/Carboplatin/Bevacizumab/Erlotinib|
11603759|NCT00621049|Active Comparator|Docetaxel and Carboplatin|
11603760|NCT00621036|Experimental|methotrexate IV once every 2 weeks|
11603761|NCT00621023|Experimental|1|Drug: Decitabine, Arsenic Trioxide and Ascorbic Acid for MDS
11603762|NCT00621010|Experimental|Cohort|
11603763|NCT00620997|Experimental|1|"patients randomized to 0.05% Proparacaine drops on a PRN basis for up to 7 days
~Acetaminophen with Codeine for breakthrough pain
~topical Gatifloxacin drops"
11603764|NCT00620997|Placebo Comparator|2|"placebo drops on a PRN basis for up to 7 days post injury
~Acetaminophen with Codeine for breakthrough pain
~Gatifloxacin drops"
11603765|NCT00620971|Experimental|1|NC/Avastin->DG/Avastin
11603766|NCT00620971|Experimental|2|DG/Avastin
11603767|NCT00620958|Experimental|1|Participants will receive individual cognitive behavioral therapy with parent reinforcement training.
11603768|NCT00620958|Experimental|2|Participants will receive individual cognitive behavioral therapy with parent relationship training.
11603769|NCT00620958|Active Comparator|3|Participants will receive individual cognitive behavioral therapy alone.
11603770|NCT00620945|Experimental|1|Treatment Group
11603771|NCT00620932|No Intervention|Control Group|These patients will continue with whatever routine exercise they already engage in.
11603772|NCT00620932|Experimental|Exercise Arm|These patients will participate in a controlled, supervised exercise program.
11603779|NCT00620867|Placebo Comparator|placebo|
11603780|NCT00620854|Experimental|rsCTA|Oral Tablet
11603781|NCT00620854|Experimental|rsCTB|Oral Tablet
11603782|NCT00620854|Active Comparator|Fortical|Nasal Spray
11603783|NCT00620841||A|Patients treated with tacrolimus and experiencing a drug interaction
11603784|NCT00620828|Placebo Comparator|Block Negative|Subjects receive intra-op saline injection per protocol
11603785|NCT00620828|Experimental|Block Positive|Subjects receive intra-op Ropivicaine 0.5% injection per protocol
11603786|NCT00620815|Experimental|T/P-A|One dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Aflunov (A) on day 22
11603787|NCT00620815|Experimental|A/P-T|One dose of the Aflunov (A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Tetravalent influenza vaccine (T) on day 22.
11603788|NCT00620815|Active Comparator|A/S-A|One dose of Aflunov (A) and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed Aflunov (A) on day 22.
11603789|NCT00620815|Experimental|T/P-A (V2 blood draw)|One dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by a blood draw at visit 2 (V2) prior to Aflunov (A) vaccination on day 22.
11603790|NCT00620815|Experimental|A/P-T (V2 blood draw)|One dose of the Aflunov(A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by additional blood draw at visit 2 (V2) prior to the Tetravalent influenza vaccination (T) on day 22.
11603791|NCT00620815|Active Comparator|A/S-A (V2 blood draw)|One dose of Aflunov (A)and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed by an additional blood draw at visit 2 (V2) prior to Aflunov (A) vaccination on day 22.
11603792|NCT00620802|Experimental|A|CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg)
11603793|NCT00620802|Active Comparator|B|Plavix (clopidogrel 75 mg)
11603794|NCT00620789|Active Comparator|1|Cognitive-Behavior Therapy for insomnia (CBT-I) + Antidepressant medication
11603795|NCT00620789|Placebo Comparator|2|Cognitive Behavior Therapy for Insomnia (CBT-I) + placebo medication
11603796|NCT00620789|Sham Comparator|3|Antidepressant medication + Sleep Hygiene Control (SH)
11603797|NCT00620776|Experimental|Combined Treatment|Patients who receive combined cognitive behavioral therapy (CBT) plus medication (venlafaxine XR, flexibly dosed between 75-225 mg/day) treatment for GAD. CBT was once/week sessions for 12 weeks. Medication continued for the full 6 months.
11603798|NCT00620776|Active Comparator|Venlafaxine XR 75-225 mg alone|These patients receive only medication treatment for GAD. Patients take venlafaxine (flexibly dosed from 75-225 mg/day) as part of NCT00183274 and are assessed over a 6 month period. Medication continued for the full 6 months.
11603799|NCT00620763|Experimental|A|Dietary Intervention: High meat and high acid load diet followed by low meat and low acid load diet
11603800|NCT00620763|Experimental|B|Dietary Intervention: Low meat and low acid load diet followed by high meat and high acid load diet
11603801|NCT00620750|Experimental|Extended release injectable naltrexone|
11603802|NCT00620737|Experimental|Active Arm|Active Treatment
11603803|NCT00620737|Placebo Comparator|Control Arm|Placebo treatment
11603804|NCT00620724|Placebo Comparator|A|Placebo three times daily
11603805|NCT00620724|Experimental|B|20 mg of slow-release Nifedipine three times daily
11603806|NCT00620711|Experimental|1|Babies that meet criteria will be offered participation in feasibility trial, there are no other arms.
11603807|NCT00620698||ALS patients|Patients with clinically established amyotrophic lateral sclerosis
11603808|NCT00620685|Placebo Comparator|1|
11603809|NCT00620685|Experimental|2|
11603810|NCT00620685|Experimental|3|
11603811|NCT00620672|Other|1|The dietary supplement is 400 mg/day of the omega 3 fatty acid docosahexaenoic acid . The docosahexaenoic acid is provided in triglycerides from Martek Biosciences, Maryland. The supplement is a blend of soybean and canola oil, blended to resemble the usual fat composition of the diet. Both the supplement and placebo provide a total of about 10 calories per day to the diet.
11603812|NCT00620672|Other|2|Dietary supplement is vegetable oil, the placebo.
11603813|NCT00620659|Experimental|1|Arm 1: Treatment period 1: MK0249; Treatment period 2: Placebo; Treatment period 3: modafinil
11603814|NCT00620659|Experimental|2|Arm 2: Treatment period 1: Placebo; Treatment period 2: modafinil; Treatment period 3: MK0249
11603815|NCT00620659|Experimental|3|Arm 3: Treatment period 1: modafinil; Treatment period 2: MK0249; Treatment period 3: Placebo
11603816|NCT00620659|Experimental|4|Arm 4: Treatment period 1: MK0249; Treatment period 2: modafinil; Treatment period 3: Placebo
11603817|NCT00620659|Experimental|5|Arm 5: Treatment period 1: Placebo; Treatment period 2: MK0249; Treatment period 3: modafinil
11603818|NCT00620659|Experimental|6|Arm 6: Treatment period 1: modafinil; Treatment period 2: Placebo; Treatment period 3: MK0249
11603819|NCT00620646|Experimental|A|Aspirin plus increasing clopidogrel group
11603820|NCT00620646|Experimental|B|Aspirin, clopidogrel plus cilostazol group
11603821|NCT00620633|Experimental|1|Patients with leukemia or myelodysplastic syndrome (MDS) who, following an HLA-matched allogeneic hematopoietic cell transplant, have relapsed with leukemia as demonstrated morphologically on peripheral blood smear or bone marrow aspirate
11603822|NCT00620620|Placebo Comparator|Inhaled Placebo|Staccato Placebo
11603823|NCT00620620|Experimental|Inhaled Zaleplon 0.5 mg|Staccato Zaleplon 0.5 mg
11603824|NCT00620620|Experimental|Inhaled Zaleplon 1 mg|Staccato Zaleplon 1 mg
11603825|NCT00620620|Experimental|Inhaled Zaleplon 2 mg|Staccato Zaleplon 2 mg
11603826|NCT00620620|Experimental|Inhaled Zaleplon 4 mg|Staccato Zaleplon 4 mg
11603827|NCT00620594|Experimental|BEZ235 Alone, Dose Escalation|
11603828|NCT00620594|Experimental|BEZ235 + trastuzumab, Dose Escalation|
11603829|NCT00620594|Experimental|BEZ235 Alone, MTD Expansion|
11603830|NCT00620594|Experimental|BEZ235 + Trastuzumab, MTD Expansion|
11603831|NCT00620581|Placebo Comparator|Paroxetine 10mg;paroxetine 20mg; Placebo|
11603832|NCT00620568|Experimental|1|
11603833|NCT00620568|Experimental|2|
11603834|NCT00620568|Experimental|3|
11603835|NCT00620568|Experimental|4|
11603837|NCT00620542|Experimental|Rosuvastatin 20 mg|Rosuvastatin 20 mg distributed in 2-week run-in period
11603838|NCT00620542|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg distributed in 2-week run-in period
11603839|NCT00620542|Experimental|Rosuvastatin 40 mg|Rosuvastatin 40 mg distributed in core 2-year study
11603840|NCT00620542|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg distributed in core 2-year study
11603841|NCT00620529|Experimental|1|20/50 fish oil, 1000mg capsules, Ocean Nutrition 2050,4g/day.
11603842|NCT00620529|Placebo Comparator|2|olive oil capsules
11603843|NCT00620503|Experimental|Formulation A Fed|Single dose of Proellex 25 mg formulation A, fed
11603844|NCT00620503|Experimental|Formulation B Fed|Single dose of Proellex 25 mg formulation B, fed
11603845|NCT00620503|Experimental|Formulation B Fasted|Single dose of Proellex 25 mg formulation B, fasted
11603846|NCT00620490|Experimental|1|Ropivacaine 0.5% 0.1 ml/kg per hour
11603847|NCT00620490|Placebo Comparator|2|
11603848|NCT00620477|Experimental|1|injection in the knee joint with 20 ml of chirocaine 0.125%
11603849|NCT00620477|Placebo Comparator|2|injection in the knee joint with 20 ml of physiological fluid
11603850|NCT00620464|Active Comparator|Radiopaque Implanon (ro imp)|The radiopaque rod (Radiopaque Implanon) is similar to the Implanon rod except for the addition of barium sulfate.
11603851|NCT00620464|Active Comparator|Implanon (imp)|"Implanon® (Org 32222) is a single rod contraceptive implant of 4 cm length and
~2 mm in diameter. Implanon® contains approximately 68 mg etonogestrel (ENG) (Org 3236, 3-ketodesogestrel) dispersed in a matrix of ethylene vinyl acetate (EVA)copolymer, surrounded by an EVA membrane.
~The ENG dose released by Implanon® amounts to about 60-70 μg/day shortly after
~insertion and decreases to about 40 μg/day at the start of the second year, and to about 25-30 μg/day at the end of the third year."
11603852|NCT00620451|Experimental|Larazotide acetate 4 mg|larazotide acetate capsules 4 mg TID
11603853|NCT00620451|Experimental|Larazotide acetate 8 mg|Larazotide acetate capsules 8 mg TID
11603854|NCT00620451|Placebo Comparator|Placebo|Placebo capsules
11603855|NCT00620438|Experimental|1|nevirapine arm
11603856|NCT00620438|Experimental|2|efavirenz arm
11603857|NCT00620438|Experimental|3|Rifampicin arm
11603858|NCT00620412|Active Comparator|treatment|
11603859|NCT00620412|Placebo Comparator|placebo|
11603860|NCT00620399|Experimental|1|brace
11603861|NCT00620399|Placebo Comparator|2|no brace
11603862|NCT00620386|Experimental|1|Intubation with Bonfils intubating fiberscope
11603863|NCT00620386|Active Comparator|2|Intubation with Macintosh laryngoscopy
11603864|NCT00620373|Experimental|Mammography and Molecular Breast Imaging|Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (20-mCi) Technetium (99mTc) sestamibi injection.
11603865|NCT00620360|Experimental|fructose|acute fructose administration
11603866|NCT00620347|Experimental|Single arm|Single arm (sunitinib arm) until PD, unacceptable toxicity, patients refused
11603867|NCT00620334||1|"ASTHMA:
~PREVOUSLY DIAGNOSED MILD ASTHMA PATIENTS"
11603868|NCT00620334||2|"CONTROL:
~PATIENTS WHO HAVE NEVER BEEN DIAGNOSED WITH ASTHMA"
11603869|NCT00620321|Experimental|LY2181308 sodium, idarubicin, cytarabine|
11603870|NCT00620308|Experimental|CD-NP low-dose study drug|
11603871|NCT00620308|Experimental|CD-NP high-dose study drug|
11603872|NCT00620308|Placebo Comparator|Placebo|
11603873|NCT00620295|Experimental|Gemcitabine / Bortezomib|"Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose on day 1 and day 8 of a 21 day cycle.
~Bortezomib will be given 1 hour after gemcitabine by IVP over 3 to 5 seconds followed by a standard saline on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles."
11603874|NCT00620282|Experimental|Lira 1.8|Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)
11603875|NCT00620282|Placebo Comparator|Placebo|Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)
11603876|NCT00620282|Active Comparator|Glimepiride|Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12
11603877|NCT00620269|Experimental|study arm 1|Induction (with Erlotinib X 3 cycles) -> CCRT with Erlotinib (X 2 cycles) -> continue Erlotinib (X 6 cycles)
11603878|NCT00620269|Experimental|study arm 3|Induction (IP X 3 cycles) -> CCRT with IP (X 2 cycles)
11603879|NCT00620269|Active Comparator|control arm|CCRT with IP (X 2 cycles) -> consolidation IP (X 3 cycles)
11603880|NCT00620269|Experimental|study arm 2|Induction (Erlotinib X 3 cycles) -> CCRT with IP (X 2 cycles) -> recurrence -> Erlotinib (until PD)
11603881|NCT00620256|Experimental|AL-37807|AL-37807 ophthalmic suspension, 0.1%, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
11603882|NCT00620256|Active Comparator|Timolol|Timolol gel forming solution, 0.5%, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
11603883|NCT00620256|Placebo Comparator|AL-37807 vehicle|AL-37807 ophthalmic solution vehicle, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
11603884|NCT00620243|Experimental|1|The study will evaluate the potential of PET imaging to identify early responders to chemotherapy. Patients entered into this study will undergo FDG PET within 2 weeks prior to chemotherapy and prior to initiation of the second course of chemotherapy. All images will be carried out in the same manner with respect to equipment, acquisition parameters, and time post injection, to ensure that changes in standard uptake value(SUV) correlate with metabolic changes. This will be correlated with response determined by changes in serum CA 125 levels.
11603885|NCT00620230|Experimental|1|
11603886|NCT00620230|Placebo Comparator|2|
11603887|NCT00620217|Experimental|1|intramyocardial injection of bicistronic VEGF-A165/bFGF plasmid
11603888|NCT00620217|Placebo Comparator|2|intramyocardial injection of placebo plasmid
11603889|NCT00620204|Experimental|A|Atorvastatin group
11603890|NCT00620204|No Intervention|B|Control group
11603891|NCT00620191|Placebo Comparator|Matching Placebo|Placebo identical to metformin
11603892|NCT00620191|Experimental|Metformin|Metformin 1000 mg twice a day
11603893|NCT00620178||1|Candesartan
11603894|NCT00620178||2|Losartan
11603895|NCT00620165|Experimental|1|
11603896|NCT00620165|Placebo Comparator|2|
11603897|NCT00620152|Experimental|1|Low glycemic load diet
11603898|NCT00620152|Active Comparator|2|Low fat diet
11603899|NCT00620139||A|Some patients presenting with suspicious lesions of the oropharynx or oral cavity will need to undergo transoral biopsy in the clinic to confirm the diagnosis of carcinoma. Of those patients who choose to participate in the study, an extra piece of tumor will be harvested for investigational purposes related to this trial.
11603900|NCT00620126|Experimental|Intervention|UC Home Automated Telemanagement
11603901|NCT00620126|Active Comparator|Control|Best Available Care
11603902|NCT00620113|Placebo Comparator|Placebo|After an observation period of ~5 weeks, participants receive dose-matched placebo to odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 International Units (IU) vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
11603903|NCT00620113|Experimental|Odanacatib 10 mg|After an observation period of ~5 weeks, participants receive 10 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
11603904|NCT00620113|Experimental|Odanacatib 25 mg|After an observation period of ~5 weeks, participants receive 25 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
11603905|NCT00620113|Placebo Comparator|Odanacatib 50 mg|After an observation period of ~5 weeks, participants receive 50 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
11603906|NCT00620087|Other|Diagnostic Arm|Women with core-biopsy proven atypia, LCIS, or radial scar who have not yet undergone surgical excision were enrolled in the diagnostic arm. A molecular breast imaging study will be obtained.
11603907|NCT00620087|Other|Surveillance arm|Women with a diagnosis of ADH, ALH, or LCIS within the past 5 years were enrolled in the surveillance arm. A molecular breast imaging study was done at enrollment (Year 0) and repeated at Yer 2 and Year 4. Patients continued with routine screening mammography during this time period.
11603908|NCT00620074|Experimental|combination 2|anidulafungin plus voriconazole
11603909|NCT00620074|Experimental|combination 1|anidulafungin plus voriconazole
11603910|NCT00620061|Experimental|All Participants|Lubiprostone: 24 mcg capsule twice daily (BID) for 36 weeks
11603911|NCT00620048|Experimental|Low dose of autologous CD34-positive cells (stem cells)|
11603912|NCT00620048|Experimental|High dose of autologous CD34-positive cells (stem cells)|
11603913|NCT00620035|Experimental|Radiopaque Etonogestrel Implant|"Radiopaque Etonogestrel Implant (drug) inserted with the Next Generation Applicator (NGA)
~The Radiopaque Implant is a single rod contraceptive implant of 4 cm length and
~2 mm in diameter which is placed at the inner side of the non-dominant upper-arm
~about 8-10 cm above the medial epicondyle. The Radiopaque Implant contains
~approximately 68 mg etonogestrel (ENG) dispersed in a matrix of ethylene vinyl acetate (EVA) copolymer and barium sulfate, surrounded by an EVA membrane. The barium-sulfate provides radio-opacity and allows detection by X-ray.
~The ENG dose released from the implant amounts to about 60-70 mcg/day shortly after insertion and decreases to about 40 mcg/day at the start of the second year, and to about 25-30 mcg/day at the end of the third year."
11603914|NCT00620022|Experimental|Indacaterol 300 μg followed by placebo|Patients first received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning for 3 weeks. After a 3-week washout period, patients received placebo delivered od via a SDDPI in the morning for 3 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11603915|NCT00620022|Experimental|Placebo followed by indacaterol 300 μg|Patients first received placebo delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning for 3 weeks. After a 3-week washout period, patients received indacaterol 300 μg delivered od via a SDDPI in the morning for 3 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11603916|NCT00620009|No Intervention|Control|Therapists and patients record their estimates of the patient's Global Assessment of Functioning, but do not discuss these estimates in therapy sessions.
11603917|NCT00620009|Experimental|Empathy Feedback|Therapists and patients record their ratings of the patient's Global Assessment of Functioning and discuss these ratings.
11603918|NCT00619996|Experimental|1|
11603919|NCT00619983|Active Comparator|Donepezil|Donepezil 5 mg once per day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
11603920|NCT00619983|Active Comparator|Duloxetine|Group 2: Will receive duloxetine 30 mg twice a day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
11603921|NCT00619983|Active Comparator|Donepezil + Duloxetine|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
11603922|NCT00619983|Placebo Comparator|Placebo|Group 4:Will receive placebo pills. Gabapentin will be titrated in all groups beginning at week 8.
11603923|NCT00619970|Active Comparator|Healthy Control|Healthy controls
11603924|NCT00619970|Active Comparator|Children receiving Rifaximin|2/3 Patients with CAP
11603925|NCT00619970|Placebo Comparator|Children receiving Placebo|1/3 patients with CAP
11603926|NCT00619957|Placebo Comparator|1|Placebo tablet once a week for 2 years followed by once a week Risedronate for 2 years
11603927|NCT00619957|Experimental|Risedronate|35 mg risedronate tablet once a week for 2 years followed by open label 35 mg risedronate once a week for 2 years
11603928|NCT00619944|Experimental|1|Lumefantrine lopinavir drug interaction arm
11603929|NCT00619944|Active Comparator|2|lumefantrine only arm
11603930|NCT00619931||1|APD791 or placebo
11603931|NCT00619931||2|APD791 or placebo
11603932|NCT00619931||3|APD791 or placebo
11603933|NCT00619931||4|APD791 or placebo
11603934|NCT00619931||5|APD791 or placebo
11603935|NCT00619918|Experimental|1|3% saline
11603936|NCT00619918|Placebo Comparator|2|Normal saline
11603937|NCT00619905|Experimental|1|
11603938|NCT00619905|Placebo Comparator|2|
11603939|NCT00619892|Active Comparator|Quetiapine XR|Our target daily dose for quetiapine XR was 200 mg/day. The detailed quetiapine XR dosing guidelines were as follows: 50 mg 1 tab po at HS × 3 days, then, if 50 mg tolerated, increase to 50 mg 2 tabs at HS × 4 days; at the beginning of week 2, if the last dose was tolerated increase to 50 mg 3 tabs at HS × 3 days, then, if 150 mg tolerated, increase to 4 tabs at HS; at the beginning of week 3, if no efficacy & the 200 mg dose was well tolerated, increase to one 300 mg tab at HS-otherwise remain at 200 mg one tab at HS; at week 4 if still no improvement, & 300 mg was tolerable, increase to 200 mg tablet 2 at HS. From the beginning of week 5 to the end of the trial, quetiapine XR doses were held. We used quetiapine XR tablets provided by Astra Zeneca (50, 200, and 300 mg designations).
11603940|NCT00619892|Placebo Comparator|Placebo|Subjects received identical-appearing placebo tablets provided by Astra Zeneca (50, 200, and 300 mg designations).
11603941|NCT00619866|Placebo Comparator|Placebo|Participants received placebo tablets once a day for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) QD for 12 weeks.
11603942|NCT00619866|Experimental|Elagolix 150 mg|Participants received elagolix 150 mg tablets once a day for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg QD for an additional 12 weeks.
11603943|NCT00619866|Experimental|Elagolix 250 mg|Participants received elagolix 250 mg tablets once a day for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.
11603944|NCT00619840|Active Comparator|1|
11603945|NCT00619840|Placebo Comparator|2|
11603946|NCT00619827|Experimental|300 IR|300 IR grass pollen allergen extract tablet
11603947|NCT00619827|Placebo Comparator|Placebo|Placebo tablet
11603948|NCT00619814|Other|Cohort group|Cohort group of asymptomatic patients 50-80 years old with a positive fecal occult blood test done for colorectal cancer screening.
11603949|NCT00619801|Placebo Comparator|Placebo|
11603950|NCT00619801|Experimental|Levocetirizine|
11603951|NCT00619788|Experimental|1|Patients receiving 4.0-5.0mm AngioSculpt Scoring Balloon Catheter (AngioScore, Inc.) for femoropopliteal use
11603952|NCT00619749|Experimental|1|
11603953|NCT00619749|Placebo Comparator|2|
11603954|NCT00619736|Experimental|NSA-789|
11603955|NCT00619736|Placebo Comparator|Placebo|
11603956|NCT00619723|Active Comparator|Citicoline|Participants will receive active medication throughout the study. Citicoline will be given beginning at two capsules (500 mg/day) with an increase to four capsules (1000 mg/day) at week 2, six capsules (1500 mg/day) at week 4, and eight capsules (2000 mg/day) at week 6. Doses will be decreased, based on clinician judgment, due to side effects.
11603957|NCT00619723|Placebo Comparator|Placebo|Participants will receive placebo identical in appearance to Citicoline throughout the study. Placebo will be given beginning at two capsules (500 mg/day) with an increase to four capsules (1000 mg/day) at week 2, six capsules (1500 mg/day) at week 4, and eight capsules (2000 mg/day) at week 6. Doses will be decreased, based on clinician judgment, due to side effects.
11603958|NCT00619710|Experimental|1|Meropenem
11603959|NCT00619710|Active Comparator|2|Imipenem-cilastatin
11603960|NCT00619684|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity.
11603961|NCT00619658|Experimental|1|All women undergoing medical abortion will have telephone follow-up approximately one week after using mifepristone and misoprostol.
11603962|NCT00619645|Other|RIST for Heme malignancies|Busulfan 3.3 mg/kg over 3 hours on day -6 and day -5 Fludarabine 30 mg/m2 IV over 30 minutes on day -6 to day -2 followed by Transplant followed by Immunosuppressive/GVHD therapy
11603963|NCT00619632|Experimental|1|LC- Primary-care based lactation consultant meeting women pre- and post-natally.
11603964|NCT00619632|Experimental|2|Provider Prompt
11603965|NCT00619632|Experimental|3|LC+Provider Prompt
11603966|NCT00619632|No Intervention|Control|
11603967|NCT00619619|Experimental|A|
11603968|NCT00619593|Active Comparator|2|Standard follow-up in patients without appropriate ICD therapy
11603969|NCT00619593|Experimental|1|Following 1st appropriate ICD therapy, the patients have to be called to the clinic for intensified clinical diagnostics and, if necessary or useful, intensified therapy.
11603970|NCT00619580||positive E coli|positive E coli at UPMC
11603971|NCT00619567|Experimental|Cognitive Stimulation|Subjects will be given Internet access to the Smartbrain cognitive stimulation program. They will complete exercises for ~30 minutes, at least three times per week, for a period of 24 weeks.
11603972|NCT00619567|No Intervention|Control|"These individuals will receive usual care during the 24 week follow-up period."
11603973|NCT00619541|Experimental|A|"5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days
~Sorafenib 400 mg bid orally continuously
~5-FU will be administered for a maximum of 12 cycles.
~Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease."
11603974|NCT00619528|Experimental|1|No separate arms: All Enrolled Receive Same Treatment
11603975|NCT00619515|Experimental|CyberKnife® stereotactic radiosurgery|
11603976|NCT00619502|Experimental|DTaP-IPV-Hep B-PRP~T Vaccine Group|Participants received a primary series of 3 vaccinations with DTaP-IPV-Hep B-PRP~T, with 1 dose each at 2, 3, and 4 months of age, in Study A3L10; they will receive a booster dose of DTaP-IPV-HepB-PRP~T at 15 to 18 months of age in the present study
11603977|NCT00619502|Active Comparator|Pentaxim™ + Engerix B™ Vaccines Group|Participants received a primary series of 3 vaccinations with Pentaxim™ and Engerix B™ vaccines, with 1 dose each at 2, 3, and 4 months of age, in Study A3L10; they will receive a booster dose of DTaP-IPV-Hep B-PRP~T at 15 to 18 months of age in the present study.
11603978|NCT00619489|Experimental|Vedolizumab 2 mg/kg|Participants received vedolizumab, 2 mg/kg, intravenously (IV), on Days 1, 15 and 43, and thereafter once every 8 weeks for up to 78 weeks.
11603979|NCT00619489|Experimental|Vedolizumab 6 mg/kg|Participants received vedolizumab, 6 mg/kg, IV, on Days 1, 15 and 43, and thereafter once every 8 weeks for up to 78 weeks.
11603980|NCT00619476|Placebo Comparator|Placebo|placebo
11603981|NCT00619476|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks
11603982|NCT00619476|Experimental|GEn 2400mg/day|gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks
11603983|NCT00619476|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, maintenance treatment 14 weeks
11603984|NCT00619463|Experimental|exercise then monitor|8 weeks of aerobic exercise followed by 16 weeks of monitoring
11603985|NCT00619463|Experimental|monitor than exercise|8 weeks of monitoring followed by 16 weeks of aerobic exercise
11603986|NCT00619424|Experimental|pazopanib + erlotinib|Pazopanib and erlotinib are to be combined at different specified dose levels until an optimally tolerated dose level is identified. Pazopanib, a multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, and -3, PDGFR-alpha and beta, and c-kit and erlotinib, an epidermal growth factor (EGFR) inhibitor, are to be combined in an effort to simultaneously block two tightly woven cell signaling pathways.
11603987|NCT00619424|Experimental|pazopanib + pemetrexed|Pazopanib and pemetrexed are to be combined at different specified dose levels until an optimally tolerated dose regimen is identified. Combination of an anti-VEGF therapy (such as bevacizumab) with systemic chemotherapy has demonstrated increased clinical efficacy in comparison with systemic chemotherapy alone in several malignancies. Hence, pazopanib, a multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, and -3, PDGFR-alpha and beta, and c-kit, was chosen to be combined with pemetrexed, a chemotherapeutic agent that inhibits the enzyme thymidylate synthase, in an effort to determine if an anti-angiogenesis inhibitor would enhance the activity of the approved chemotherapeutic agent pemetrexed.
11603988|NCT00619411|Experimental|I|
11603989|NCT00619398|Active Comparator|1|
11603990|NCT00619398|Experimental|2|
11603991|NCT00619385|Experimental|Proellex 100 mg|Proellex 100 mg daily for 7 days
11603992|NCT00619385|Experimental|Proellex 150 mg|Proellex 150 mg daily for 7 days
11603993|NCT00619385|Experimental|Proellex 200 mg|Proellex 200 mg daily for 7 days
11603994|NCT00619372|Experimental|B|Low dose OKT3 with GC
11603995|NCT00619372|Experimental|C|Mid dose OKT3
11603996|NCT00619372|Experimental|D|Mid OKT3 dose with GC
11603997|NCT00619372|Experimental|E|High dose OKT3
11603998|NCT00619372|Experimental|F|GC only
11603999|NCT00619372|Experimental|A|Low dose OKT3
11604000|NCT00619359|Experimental|1|Arm 1: study medication
11604001|NCT00619359|Active Comparator|2|Arm 2: Active comparator
11604002|NCT00619346|Placebo Comparator|1|Placebo tablets resembling 100 mg tablet of active drug BID X 14 days
11604003|NCT00619346|Active Comparator|2|Pafuramidine maleate, 100 mg tablet, BID X 14 days
11604004|NCT00619333|Other|1|
11604005|NCT00619320|Experimental|Safer Sex Skill Building (SSB)|Safer Sex Skill Building Intervention (SSB) A five session behavioral intervention focused on HIV/STD prevention and safer sex negotiation skills
11604006|NCT00619320|Active Comparator|2|one group session focused on standard HIV/STD education
11604007|NCT00619307|Active Comparator|Transition with prophylactic ibuprofen|
11604008|NCT00619307|Active Comparator|Transition with PRN ibuprofen|
11604009|NCT00619281||Oberservation|600 consecutive patients undergoing cardiac surgery
11604010|NCT00619268|Experimental|A|
11604011|NCT00619268|Active Comparator|B|
11604012|NCT00619268|Active Comparator|C|
11604013|NCT00619255|Experimental|Intervention|Adolescent Trauma Support Program
11604014|NCT00619255|No Intervention|Control|Usual Care Control Condition
11604015|NCT00619242|Experimental|sorafenib|sorafenib 2 tablets by mouth
11604016|NCT00619229|Experimental|Alprostadil|Alprostadil
11604017|NCT00619229|Placebo Comparator|Placebo|Placebo
11604018|NCT00619203|Active Comparator|A|Two active ingredients
11604019|NCT00619203|Active Comparator|B|One active ingredient
11604020|NCT00619203|Active Comparator|C|One (other) active ingredient
11604021|NCT00619203|Placebo Comparator|D|
11604022|NCT00619190|Experimental|open aripipraprazole|Openly provided, flexibly dosed aripiprazole in doses from 1mg to 30mg
11604023|NCT00619190|No Intervention|no medication control|group of children whose parents do not want them to take medications for autism over the year following enrollment in the trial.
11604024|NCT00619164|Experimental|1|
11604025|NCT00619164|Experimental|2|
11604026|NCT00619164|Experimental|3|
11604027|NCT00619164|Placebo Comparator|4|
11604028|NCT00619151|Active Comparator|1|CarboMedics Supra-annular Top Hat Valve
11604029|NCT00619151|Active Comparator|2|St. Jude Medical Regent Valve
11604030|NCT00619138|Active Comparator|1|
11604031|NCT00619138|Active Comparator|2|
11604032|NCT00619125||A|20 patients with IBS C
11604033|NCT00619125||D|20 Subjects without IBS
11604034|NCT00619125||B|20 patients with IBS D
11604035|NCT00619125||C|20 patients with IBS M
11604036|NCT00619112|Experimental|Temozolomide|single arm trial; Patients treated with temozolomide at a dose of 150mg/m2 daily for seven consecutive days of every other week. One 28-day cycle will include treatment with temozolomide on days 1-7 and days 15-21 with no treatment on days 8-14
11604037|NCT00619099|Experimental|1|
11604038|NCT00619099|Experimental|2|
11604039|NCT00619086|Placebo Comparator|A, 1|Placebo 45 minutes prior to surgery
11604040|NCT00619086|Active Comparator|A, 2|8 mg Dexamethasone 45 minutes prior to surgery
11604041|NCT00619073|Active Comparator|Clopidogrel + aspirin|The subjects will be randomized to clopidogrel 75 mg plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., clopidogrel) will then be discontinued and aspirin continued for another 43 days.
11604096|NCT00618709|Experimental|Cohort 2|ATX-101 (2 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid
11604042|NCT00619073|Placebo Comparator|Placebo + aspirin|The subjects will be randomized to placebo plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., placebo) will then be discontinued and aspirin continued for another 43 days.
11604043|NCT00619060|Experimental|Myristyl (right), Placebo (Left)|Participants apply topical myristyl nicotinate to the right forearm and topical placebo to the left forearm once daily for 4 weeks; Myristyl (Right), Placebo (Left) Topical Myristyl Nicotinate Cream and Placebo
11604044|NCT00619060|Experimental|Myristyl (Left), Placebo (Right)|Participants apply topical myristyl nicotinate to the left forearm and topical placebo to the right forearm once daily for 4 weeks; Myristyl (Left), Placebo (Right)Topical Myristyl Nicotinate Cream and Placebo
11604045|NCT00619047||Observation|
11604046|NCT00619034|Experimental|latanoprost|Medical intervention cross-over
11604047|NCT00619034|Active Comparator|diclofenac|medical intervention
11604048|NCT00619034|Experimental|dorzolamide|dorzolamide eyedrops twice daily in one week
11604049|NCT00619021|Experimental|Cohort 1|Patient receives gemcitabine 600 mg/m^2.
11604050|NCT00619021|Experimental|Cohort 2|Patient receives gemcitabine 800 mg/m^2.
11604051|NCT00619021|Experimental|Cohort 3|Patient receives gemcitabine 1000 mg/m^2.
11604052|NCT00619021|Experimental|Cohort 4|Patient receives gemcitabine 1200 mg/m^2.
11604053|NCT00619008|Experimental|1|Ad libitum low carbohydrate diet
11604054|NCT00619008|Experimental|2|Ad libitum high complex carbohydrate diet
11604055|NCT00619008|Experimental|3|Energy-restricted high complex carbohydrate diet
11604056|NCT00618995|Experimental|A|Arm A: ER niacin/laropiprant + Placebo to laropiprant
11604057|NCT00618995|Experimental|B|Arm B: ER niacin + Placebo to laropiprant
11604058|NCT00618995|Experimental|C|Arm C: laropiprant + Placebo to ER Niacin/laropiprant
11604059|NCT00618995|Placebo Comparator|D|Arm D: Placebo
11604060|NCT00618982|Experimental|Sorafenib (Nexavar, BAY43-9006)|Intrapatient dose escalation of sorafenib from 400 mg orally twice daily (bid) for the first cycle, 600 mg bid for the second cycle and 800 mg bid until disease progression, unacceptable toxicity or withdrawal of consent. Dose reductions due to toxicities were allowed.
11604061|NCT00618969|Experimental|Haploidentical allogeneic PBSC transp|Non-myeloablative preparative regimen (reduced-intensity) of busulfan, melphalan and alemtuzumab followed by a haploidentical-related peripheral blood stem cell transplant.
11604062|NCT00618956|Experimental|1|
11604063|NCT00618956|Placebo Comparator|2|
11604064|NCT00618930|Experimental|1|
11604065|NCT00618930|Active Comparator|2|Use of Fleet
11604066|NCT00618917|Experimental|MnSOD|
11604067|NCT00618904|Experimental|1|Probiotic containing Lactobacillus and Bifidobacterium
11604068|NCT00618904|Placebo Comparator|2|Placebo
11604069|NCT00618878|Active Comparator|1|Electroacupuncture
11604070|NCT00618878|Active Comparator|2|Laser Therapy
11604071|NCT00618865|Experimental|1|omega-3 fatty acid with 2.2 g of eicosapentanoic acid (EPA) and 1.2 g of docosahexanoic acid (DHA)
11604072|NCT00618865|Placebo Comparator|2|Placebo (olive oil ethyl esters)
11604073|NCT00618852|Experimental|1|Furosemide
11604074|NCT00618852|Placebo Comparator|2|
11604075|NCT00618839|Experimental|StrataGraft : cadaver allograft|All patients enrolled received StrataGraft skin tissue and an intrapatient control area treated with cadaver allograft in a split-wound design
11604076|NCT00618826|Experimental|Treatment Period|Treatment will be administered once every 2 weeks. One cycle of therapy will consist of 14 days. Paclitaxel is administered first after appropriate premedications. Gemcitabine is administered second and Avastin is administered after chemotherapy, all given on day 1 of each cycle.
11604077|NCT00618813|Experimental|Treatment (combination chemotherapy)|See Detailed Description
11604078|NCT00618800|Experimental|Pharmacist Care|Pharmacist Intervention
11604079|NCT00618800|Active Comparator|Control|Written information only group
11604080|NCT00618787|Active Comparator|Arm 1|
11604081|NCT00618787|Active Comparator|Arm 2|
11604082|NCT00618761|Experimental|1|kidney-pancreas recipients
11604083|NCT00618761|Active Comparator|2|kidney recipients
11604084|NCT00618761|Active Comparator|3|healthy controls
11604085|NCT00618761|Active Comparator|4|beta-cell recipients
11604086|NCT00618748|Experimental|Pre-Olanzapine|Participants who received olanzapine 5-20 mg/day in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
11604087|NCT00618748|Experimental|Pre-Placebo|Participants who received placebo in acute phase of Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
11604088|NCT00618748|Experimental|New Olanzapine|Participants who did not participate in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 48 weeks.
11604089|NCT00618735|Experimental|1|Subjects in Schedule A will take BIIB021 in the morning at approximately 0800 with at least 6 ounces of water following an overnight fast (Beginning at midnight).
11604090|NCT00618735|Experimental|2|Subjects in Schedule B will take BIIB021 in the morning at approximately 0800 with at least 6 ounces of water following an overnight fast (beginning at midnight). The second dose will be taken, following at least a 2-hour fast, 12 hours (+/- 2 hours) after the first dose, except on Day 1 of Cycle 1 and Day 1 of Cycle 2.
11604091|NCT00618722|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received 0.5% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (1 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
11604092|NCT00618722|Experimental|Deoxycholic acid Injection 2 mg/cm²|Participants received 1.0% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (2 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
11604093|NCT00618722|Experimental|Deoxycholic acid Injection 4 mg/cm²|Participants received 2.0% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (4 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
11604094|NCT00618722|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
11604095|NCT00618709|Experimental|Cohort 1|ATX-101 (1 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid
11604097|NCT00618709|Experimental|Cohort 3|3 subgroups in Cohort 3: 3a: ATX-101 (4 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid 3b: ATX-101 (2 mg/cm2) at a volume of 0.2 ml on a 0.7 cm grid 3c: ATX-101 (2 mg/cm2) at a volume of 0.4 ml on a 1.0 cm grid
11604098|NCT00618709|Experimental|Cohort 4|3 subgroups in Cohort 4: 4a: ATX-101 (8 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid 4b: ATX-101 (4 mg/cm2) at a volume of 0.2 ml on a 0.7 cm grid 4c: ATX-101 (4 mg/cm2) at a volume of 0.4 ml on a 1.0 cm grid
11604099|NCT00618696|Experimental|AHN-12|2.0, 5.0, 7.5, 10.0 or 12.5 mCi/m^2 of ^90Y-AHN-12 at Day 7/8
11604100|NCT00618683|Other|Study Arm|Mapping and Ablation
11604101|NCT00618670|Experimental|1|Home-based program with progressive increases in exercise duration and intensity (i.e., cadence); walking duration will be longer for the home-based group because the intensity of walking will be lower than the graded treadmill walking performed by the supervised group
11604102|NCT00618670|Experimental|2|Supervised program consisting of graded treadmill walking, with progressive increments in exercise duration from 15 to 40 minutes, and progressive increments in exercise intensity from 50 to 70% of exercise capacity
11604103|NCT00618670|Active Comparator|3|Light resistance training without any walking exercise
11604104|NCT00618657|Experimental|Arm I (HER-2 positive)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes, carboplatin IV over 60 minutes, and trastuzumab IV over 90 minutes , then weekly over 30-60 minutes. Treatment repeats every week for 12 weeks in the absence of disease progression or unacceptable toxicity. In both arms, beginning 21-40 days later, patients undergo surgery.
11604105|NCT00618657|Experimental|Arm II (HER-2 negative)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as in Arm I. Patients also receive bevacizumab IV over 90 or 60 or 30 minutes once every two weeks for 5 doses in the absence of disease progression or unacceptable toxicity. In both arms, beginning 21-40 days later, patients undergo surgery.
11604106|NCT00618644|Experimental|1|Ranibizumab injection
11604107|NCT00618618|Experimental|Deoxycholic Acid Injection 0.2 mL/0.7 cm|Participants received deoxycholic acid administered in 0.2 mL injections, 0.7 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
11604108|NCT00618618|Placebo Comparator|Placebo 0.2 mL/0.7 cm|Participants received placebo administered in 0.2 mL injections, 0.7 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
11604109|NCT00618618|Experimental|Deoxycholic Acid Injection 0.2 mL/1.0 cm|Participants received deoxycholic acid administered in 0.2 mL injections, 1.0 cm apart, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
11604110|NCT00618618|Placebo Comparator|Placebo 0.2 mL/1.0 cm|Participants received placebo administered in 0.2 mL injections, 1.0 cm apart, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
11604111|NCT00618618|Experimental|Deoxycholic Acid Injection 0.4 mL/1.0 cm|Participants received deoxycholic acid administered in 0.4 mL injections, 1.0 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
11604112|NCT00618618|Placebo Comparator|Placebo 0.4 mL/1.0 cm|Participants received placebo administered in 0.4 mL injections, 1.0 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
11604113|NCT00618605|Experimental|1|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^9 virus particles (VP) given at Days 0, 28, and 168
11604114|NCT00618605|Experimental|2|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^10 VP given at Days 0, 28, and 168
11604115|NCT00618605|Experimental|3|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^11 VP given at Days 0, 28, and 168
11604116|NCT00618605|Experimental|4|2 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at a dose to be determined by the safety data from Arms 1, 2 and 3 given at Days 0 and 168
11604117|NCT00618592|Experimental|CHO|
11604118|NCT00618592|No Intervention|FAST|
11604119|NCT00618579|Experimental|LMWH arm - active LMWH|
11604120|NCT00618579|Placebo Comparator|LMWH arm - placebo|
11604121|NCT00618579|Experimental|Warfarin arm - active warfarin|
11604122|NCT00618579|Other|Warfarin arm - control|
11604123|NCT00618566|Experimental|Oregon|
11604124|NCT00618553|Experimental|Pulmonary Rehabilitation|Pulmonary Rehabilitation - Rehabilitation treatment given over about 3-4 weeks. Questionnaire regarding quality-of-life that lasts about 30 minutes.
11604125|NCT00618540|Experimental|Alemtuzumab|Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
11604126|NCT00618527|Experimental|1|Rebif with Cellcept
11604127|NCT00618527|Placebo Comparator|2|Rebif alone
11604128|NCT00618514|Active Comparator|1|Bright Tip Laser Fiber - FDA-cleared study device
11604129|NCT00618514|Active Comparator|2|Standard bare tip Laser Fiber - Any commercially available laser device (the control)
11604130|NCT00618488|Experimental|1|Bifidobacterium lactis
11604131|NCT00618488|Placebo Comparator|2|Placebo
11604132|NCT00618475|Experimental|Treatment|Individual cognitive behavioral therapy (CBT)
11604133|NCT00618475|Other|Wait-list control|Individual cognitive behavioral therapy (CBT) after 3 month wait-list period
11604134|NCT00618462|Experimental|1|Participants will receive psychoeducation therapy plus case management and a referral to Gamblers Anonymous.
11604135|NCT00618462|Experimental|2|Participants will receive cognitive behavioral therapy plus contingency management and a referral to Gamblers Anonymous.
11604136|NCT00618462|Experimental|3|Participants will receive cognitive behavioral therapy and a referral to Gamblers Anonymous.
11604137|NCT00618449|Experimental|Arm 2|Subjects residing in villages assigned to treatment arm 2 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0), as well as receive an initial treatment with 1 gm oral dose of Azithromycin; receive a second 1 gm oral dose of Azithromycin at Day 30; be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60 and Day 360.
11604179|NCT00617994|Experimental|Group B|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 1.
11604138|NCT00618449|Active Comparator|Arm 1|Subjects residing in villages assigned to treatment arm 1 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0); be treated at Day 30 with the WHO standard of care for trachoma - 1 gm oral dose of Azithromycin; be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60 and Day 360.
11604139|NCT00618436|Active Comparator|Levetiracetam|Group 1 - The levetiracetam (Keppra®) group will receive a loading dose of 20 mg/kg IV over 15 minutes (rounded to the nearest 250mg) up to a maximum of 2000 mg, then started on maintenance dose (1000 mg, IV BID)as prophylaxis for 7 days.
11604140|NCT00618436|Active Comparator|Phenytoin|Group 2-The phenytoin group will receive a loading dose of 20 mg/kg IV to a maximum of 2000mg, then started on maintenance dose at 5 mg/kg/day (rounded to nearest 100mg dose, IV, divided into three doses a day) as prophylaxis for 7 days. Phenytoin levels are to be checked daily and dose adjusted as needed to maintain therapeutic levels of 10-20 µg/dL.
11604141|NCT00618423|Placebo Comparator|Physiologic saline|
11604142|NCT00618423|Active Comparator|Ketamine|
11604143|NCT00618410|Active Comparator|Carbon dioxide|nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge
11604144|NCT00618410|Placebo Comparator|Placebo|nasal placebo administered 30 minutes prior to nasal challenge
11604145|NCT00618397|Experimental|Arm 1|Ketamine will be administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to in PICU patients that meet eligibility criteria.
11604146|NCT00618384|Active Comparator|1|Patients with TACE therapy will be treated with Sorafenib (2 x 400 mg/day) until progressive disease
11604147|NCT00618371|Experimental|Raltegravir intensification|Patients will be administered raltegravir 400 mg orally twice daily in addition to antiretroviral therapy
11604148|NCT00618358|Experimental|Vascular Sealant)|
11604149|NCT00618358|Active Comparator|Gelfoam/Thrombin|
11604150|NCT00618332|Active Comparator|1|2 weeks of treatment
11604151|NCT00618332|Placebo Comparator|2|2 weeks of treatment
11604152|NCT00618319|Experimental|1|BIIB021
11604153|NCT00618293|Active Comparator|1|intravenous infusion of Haemate (dosage dependent on body weight)
11604154|NCT00618293|Placebo Comparator|2|intravenous infusion of 0.9% NaCl solution
11604155|NCT00618280|Active Comparator|1|schizophrenic and non schizophrenic patient stratified by smoking and non smoking will get nicotine and placebo on first day on the second day placebo and nicotine
11604156|NCT00618280|Placebo Comparator|2|schizophrenic and non schizophrenic patient stratified by smoking and non smoking will get nicotine and placebo on first day on the second day placebo and nicotine
11604157|NCT00618241|Experimental|A|"Group A: day 1-5 Raltegravir 400 mg oral BD (twice daily). Lamotrigine one oral dose 100 mg on day 4. Wash-out 6-31. Followed by one oral dose Lamotrigine 100 mg on day 34.
~5 days Raltegravir 400 mg oral BD. Lamotrigine one oral dose 100mg on day 34."
11604158|NCT00618241|Active Comparator|B|"Group B: day 4 Lamotrigine one oral dose on day 4. Wash-out day 6-28 followed by Raltegravir 400 mg oral BD day 29-33. One dose Lamotrigine 100 mg oral on day 32.
~One dose Lamotrigine 100 mg oral."
11604159|NCT00618215|Experimental|I|"ROE Group
~Interventions:behaviorial"
11604160|NCT00618215|Experimental|2|"MIM Group
~Interventions:behaviorial"
11604161|NCT00618176|Experimental|B|
11604162|NCT00618176|Experimental|A|
11604163|NCT00618176|Experimental|C|
11604164|NCT00618150|Experimental|A|
11604165|NCT00618124|Experimental|A|
11604166|NCT00618098|Experimental|Octaplex (human prothrombin complex concentrate)|Participants to receive1 or more Octaplex infusions intravenously until their International Normalized Ratio (INR) was < 1.5.
11604167|NCT00618098|Active Comparator|Fresh frozen plasma|Participants to receive1 or more fresh frozen plasma infusions intravenously until their International Normalized Ratio (INR) was < 1.5.
11604168|NCT00618085|Experimental|1|"All patients will receive the occupational therapy and physiotherapy normally given in their setting.
~In addition; the experimental group will receive 2 instruction DVD's introducing them to motor imagery practice, taking 35 minutes in total. The research therapist will also attend the first session with the physiotherapist and with the occupational therapist to help incorporate motor imagery within the therapy. Thereafter the therapist will help the patient use motor imagery as part of their normal treatment. The total amount spent on motor imagery during therapy sessions will be 6.5 hours in 6 weeks."
11604169|NCT00618085|Active Comparator|2|"All patients will receive the occupational therapy and physiotherapy normally given in their setting.
~In addition; the control group will receive 2 DVDs for 35 minutes in total. These will show background information on their condition, explaining the importance of practice of activities, and on the principles of motor learning and phased movement which underlie most therapy.The research therapist will also attend the first session with the physiotherapist and with the occupational therapist to control for attention. The total amount the physiotherapist and occupational therapist spend with the patients should be the same in both groups."
11604170|NCT00618072|Placebo Comparator|A: Study diet|EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of placebo metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of placebo rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day.
11604171|NCT00618072|Active Comparator|B: Study diet plus Metformin|"Metformin and Rosiglitazone Placebo
~EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of placebo rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day."
11604172|NCT00618072|Active Comparator|C: Study diet plus metformin and avandia|"Metformin and Rosiglitazone
~EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day."
11604173|NCT00618033|Active Comparator|1|
11604174|NCT00618033|Active Comparator|2|
11604175|NCT00618007|Experimental|30 mg QD|
11604176|NCT00618007|Experimental|20 mg QD|
11604177|NCT00618007|Placebo Comparator|Placebo|
11604178|NCT00617994|Experimental|Group A|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a small percent BSA.
11604180|NCT00617994|Experimental|Group C|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 2.
11604181|NCT00617981|Experimental|1|ThermoDox 50 mg/m2 start infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
11604182|NCT00617981|Sham Comparator|2|Sham infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
11604183|NCT00617955||Surgical|Cardiac surgery patients that received Aprotinin or Amicar
11604184|NCT00617942|Experimental|Neo-adjuvant cohort 1|
11604185|NCT00617942|Experimental|Neo-adjuvant cohort 2|
11604186|NCT00617942|Experimental|Adjuvant cohort 1|
11604187|NCT00617942|Experimental|Adjuvant cohort 2|
11604188|NCT00617929|Experimental|Conditioning for Graft Failure|Primary or secondary graft failure after hematopoietic stem cell transplantation defined as a > 50% loss of previously best donor chimerism or less than 25% donor chimerism beyond day +42 with pancytopenia and no evidence of relapse. Patients with any diagnosis, type of donor, hematopoietic cell graft or conditioning regimen should be considered for this study. Patients receive anti-thymocyte globulin, rituximab, and clofarabine.
11604189|NCT00617903|Experimental|Azelaic acid foam, 15% (BAY39-6251)|Participants received azelaic acid foam, 15% topically twice daily for 12 weeks
11604190|NCT00617903|Placebo Comparator|Vehicle foam|Participants received vehicle foam topically twice daily for 12 weeks
11604191|NCT00617890|Experimental|Group 1: 0.3 mg/kg|Participants received robatumumab 0.3 mg/kg intravenously (IV) as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 0.3 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
11604192|NCT00617890|Experimental|Group 1: 10 mg/kg|Participants who received robatumumab 10 mg/kg IV as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 10 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
11604193|NCT00617890|Experimental|Group 2: 10 mg/kg|Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with relapsed and unresectable osteosarcoma refractory to prior chemotherapy with a platinum- and doxorubicin-containing regimen.
11604194|NCT00617890|Experimental|Group 3: 10 mg/kg|Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, or vincristine.
11604195|NCT00617877|Experimental|1|Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day in case of BP more than 140/90 mm Hg. HCTZ 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
11604196|NCT00617864|Experimental|1|Group will receive infusion of human albumin
11604197|NCT00617864|Placebo Comparator|2|Group will receive infusion of saline
11604198|NCT00617851|Experimental|Influenza virus vaccine (lot A)|Lot A of the investigational influenza virus vaccine
11604199|NCT00617851|Experimental|Influenza virus vaccine (lot B)|Lot B of the investigational influenza virus vaccine
11604200|NCT00617851|Experimental|Influenza virus vaccine (lot C)|Lot C of the investigational influenza virus vaccine
11604201|NCT00617851|Experimental|Influenza virus vaccine (pooled)|Pooled data of all three lots (Lot A, B and C) of the investigational influenza virus vaccine
11604202|NCT00617851|Active Comparator|Comparator influenza vaccine|A US licensed influenza virus vaccine
11604203|NCT00617838|Active Comparator|1|Optimization of gluten introduction by nutritional councelling
11604204|NCT00617838|No Intervention|2|No specific nutritional councelling. Follow-up of gluten introduction
11604205|NCT00617812|Experimental|Shan5|
11604206|NCT00617773|Experimental|hu3S193|
11604207|NCT00617760|Experimental|1|Concomitant administration of MenC-TT vaccine and PCV7, 170 subjects
11604208|NCT00617760|Active Comparator|2|PCV7 administration only, 85 subjects
11604209|NCT00617760|Active Comparator|3|MenC-TT vaccine only, 85 subjects
11604210|NCT00617747|Experimental|1|
11604211|NCT00617747|Placebo Comparator|2|
11604212|NCT00617734|Experimental|IMC-A12 (cixutumumab)|
11604213|NCT00617734|Experimental|IMC-A12 (cixutumumab) + cetuximab|
11604214|NCT00617721||1|patients with unexplained bleeding disorder
11604215|NCT00617721||2|healthy volunteers
11604216|NCT00617708|Experimental|Arm I (erlotinib, gemcitabine, cixutumumab)|Patients receive erlotinib hydrochloride PO once daily on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11604217|NCT00617708|Active Comparator|Arm II (erlotinib, gemcitabine)|Patients receive erlotinib hydrochloride and gemcitabine hydrochloride as in arm I. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11604218|NCT00617695|Experimental|1|
11604219|NCT00617695|Placebo Comparator|2|
11604220|NCT00617682|Active Comparator|Group 1|Group 1 (experimental)
11604221|NCT00617682|Placebo Comparator|Group 2|Group 2 (placebo comparator)
11604222|NCT00617669|Active Comparator|Placebo + Docetaxel|placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks
11604223|NCT00617669|Experimental|ZD4054 + Docetaxel|ZD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks
11604224|NCT00617656|Active Comparator|A|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
11604225|NCT00617656|Experimental|B1|Low RAP expression and any levels of BRCA1 expression: Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
11604226|NCT00617656|Experimental|B2|Intermediate or high RAP expression and low or intermediate BRCA1 expression: Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
11604227|NCT00617656|Experimental|B3|Intermediate or high RAP expression and high BRCA1 expression: Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
11604228|NCT00617643|Active Comparator|2|Triomune® 30 one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
11604229|NCT00617643|Experimental|1|Triomune® 30 one tablet twice daily for two weeks
11604230|NCT00617617|Experimental|A|Dietary Supplement: Prevastein HC®
11604231|NCT00617617|Placebo Comparator|B|Placebo
11604232|NCT00617604|Placebo Comparator|Placebo|Participants received placebo administered intra-operatively as an intravenous (IV) bolus on Day 0, another IV bolus on Day 3 and weekly subcutaneous injections thereafter for 12 weeks. Participants also received tacrolimus, mycophenolate mofetil (MMF) and steroid treatment.
11604233|NCT00617604|Experimental|Alefacept|Participants received 7.5 mg alefacept administered intra-operatively as an IV bolus on Day 0, another 7.5 mg IV bolus on Day 3, and weekly subcutaneous injections of 15 mg alefacept thereafter for 12 weeks. Participants also received tacrolimus, MMF and steroid treatment.
11604234|NCT00617591|Experimental|Induction and Maintenance Therapy|"Induction Phase Followed by Maintenance Therapy.
~Patients received lenalidomide 25 mg orally on days 1-21, dexamethasone 40 mg orally on days on 1-4, and Pegylated Liposomal Doxorubicin (PLD) 40 mg/m^2 intravenously on day 1 (reduced to 30 mg/m^2 after the initial 29 patients were treated). Cycles were repeated every 28 days.
~At the best response (4-8 cycles of induction), patients could proceed with either high-dose therapy or maintenance with lenalidomide and dexamethasone at the tolerated doses on the same schedule until disease progression.
~Dd-R: Lenalidomide (Revlimid®) combined with Pegylated Liposomal Doxorubicin (Doxil®) and Dexamethasone (Decadron®) as outlined in the Detailed Description."
11604235|NCT00617578|Experimental|1|programming of VF therapy: ATP (antitachycardia pacing) One Shot ON
11604236|NCT00617578|Active Comparator|2|programming of VF therapy: ATP (antitachycardia pacing) One Shot OFF
11604237|NCT00617552|Placebo Comparator|1|
11604238|NCT00617552|Experimental|2|
11604239|NCT00617552|Experimental|3|
11604240|NCT00617552|Experimental|4|
11604241|NCT00617552|Experimental|5|
11604242|NCT00617552|Experimental|6|
11604243|NCT00617552|Experimental|7|
11604244|NCT00617552|Experimental|8|
11604245|NCT00617539|Experimental|irinotecan and temozolomide|
11604246|NCT00617526|Experimental|RDEA806 400 mg|Placebo or RDEA806 400 mg twice daily (BID) for 7 days and a single morning dose on Day 8.
11604247|NCT00617526|Experimental|RDEA806 600 mg|Placebo or RDEA806 600 mg once daily (QD) for 7 days with an additional dose on the morning of Day 8.
11604248|NCT00617526|Experimental|RDEA806 800 mg|Placebo or RDEA806 800 mg QD using enteric coated tablets for 7 days with an additional morning dose on Day 8.
11604249|NCT00617526|Experimental|RDEA806 1000 mg|Placebo or RDEA806 1000 mg QD using enteric coated tablets for 7 days with an additional dose on the morning of Day 8.
11604250|NCT00617513|Active Comparator|1|
11604251|NCT00617513|Active Comparator|2|
11604252|NCT00617513|Active Comparator|3|
11604253|NCT00617513|Placebo Comparator|4|
11604254|NCT00617500|Active Comparator|Hormone|
11604255|NCT00617500|Experimental|flower therapy|
11604256|NCT00617500|Experimental|therapeutic touch|
11604257|NCT00617500|Experimental|auriculotherapy|
11604258|NCT00617474|Experimental|1|Group of patient with anemia, that treated by erythropoietin
11604259|NCT00617474|Placebo Comparator|2|Patients group with anemia that treated by placebo
11604260|NCT00617461|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, 4 weeks treatment in either the first or second treatment period
11604261|NCT00617461|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, 4 weeks treatment in either the first or second treatment period
11604262|NCT00617448|Active Comparator|I|conventional diathermy haemorrhoidectomy under spinal anaesthesia
11604263|NCT00617448|Active Comparator|II|conventional diathermy haemorrhoidectomy with local anaesthesia combined with intravenous sedation (group II)
11604264|NCT00617448|Active Comparator|III|Ligasure haemorrhoidectomy under spinal anesthesia
11604265|NCT00617448|Active Comparator|IV|Ligasure haemorrhoidectomy under local anesthesia
11604266|NCT00617435|Experimental|V|
11604267|NCT00617435|Experimental|N|
11604268|NCT00617435|Experimental|J|
11604269|NCT00617409|Active Comparator|Standard of Care|Arm A - Active Comparator: Observation (Standard of Care) + Second Line Chemotherapy
11604270|NCT00617409|Experimental|Ad.p53-DC Vaccines|Arm B - Experimental: Ad.p53-DC vaccines + Second Line Chemotherapy
11604271|NCT00617409|Experimental|Ad.p53-DC Vaccines + ATRA|Arm C - Experimental: Ad.p53-DC vaccines + All -trans Retinoic Acid (ATRA) + Second Line Chemotherapy
11604272|NCT00617396|Experimental|Quetiapine treatment group|All subjects will receive seroquel treatment for 8 weeks. Seroquel is the intervention.
11604273|NCT00617370|Experimental|1|The regimen consists of EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 with pegfilgrastim subcutaneously (SQ) on day # 2, followed by paclitaxel (175 mg/m2) q 14 days x 6 with pegfilgrastim SQ on day # 2.
11604274|NCT00617357|Experimental|1|Strattice Reconstructive Tissue Matrix
11604275|NCT00617344|Experimental|CYD Dengue Vaccine 5555 Formulation|Participants received 3 doses of CYD dengue vaccine (5555 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
11604276|NCT00617344|Experimental|CYD Dengue Vaccine 5553 Formulation|Participants received 3 doses of CYD dengue vaccine (5553 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
11604277|NCT00617344|Experimental|CYD Dengue Vaccine 4444 Formulation|Participants received 3 doses of CYD dengue vaccine (4444 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
11604278|NCT00617331|Experimental|Dose 7.5 mcg|7.5 micrograms of vaccine administered on Day 0 and Day 28.
11604279|NCT00617331|Experimental|Dose 30 mcg|30 micrograms of vaccine administered on Day 0 and Day 28.
11604280|NCT00617318|Experimental|A|
11604281|NCT00617318|Placebo Comparator|B|
11604282|NCT00617305|Experimental|Ambrisentan|Patients were assigned ambrisentan at open-label enrollment or randomization, and received at least one dose of ambrisentan plus an approved phosphodiesterase type-5 (PDE-5) inhibitor (PDE-5i; sildenafil or tadalafil).
11604283|NCT00617305|Active Comparator|Placebo|Patients were assigned placebo at randomization and received at least one dose of placebo plus an approved PDE-5i (sildenafil or tadalafil).
11604284|NCT00617292||Category 1, Group 1|Children who have 21OHD and received prenatal dexamethasone treatment
11604285|NCT00617292||Category 1, Group 2|Children who have 21OHD and did not receive prenatal dexamethasone treatment (control)
11604286|NCT00617292||Category 2|Mothers of children who received prenatal dexamethasone treatment
11604287|NCT00617279|Active Comparator|GORE PROPATEN Vascular Graft:|
11604288|NCT00617279|Active Comparator|Disadvantaged Autologous Vein Graft|
11604289|NCT00617266|Active Comparator|Arm 1 Control Group|Distribution of pamphlets containing information on the hazards of tobacco
11604290|NCT00617266|Experimental|Arm 2|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
11604291|NCT00617266|Experimental|Arm 3|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
11604292|NCT00617266|Experimental|Arm 4|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
11604293|NCT00617253|Experimental|A|
11604294|NCT00617253|Experimental|B|
11604295|NCT00617253|Experimental|C|
11604296|NCT00617253|Experimental|D|
11604297|NCT00617240|Experimental|1|metformin in doses from 250mg to 2000mg/day for 26 weeks
11604298|NCT00617240|Placebo Comparator|2|Matched placebo to metformin, doses between 250/0mg and 2000/0mg per day
11604299|NCT00617214||All|Schizophrenic outpatients who are treated with Seroquel IR and who are additionally intended to start with an integrated care program
11604300|NCT00617201|Experimental|1|Atomoxetine
11604301|NCT00617201|Placebo Comparator|2|Matched Placebo
11604302|NCT00617188|Experimental|Fulvestrant|Fulvestrant 500 milligrams (mg) Day 1; 250 mg Day 1, 29 and every 28 days thereafter.
11604303|NCT00617175|Experimental|Long NID|Programming a number of 30 out of 40 intervals to detect (NID)ventricular arrhythmia
11604304|NCT00617175|Active Comparator|Short NID|Programming a number of 18 out of 24 intervals to detect (NID)ventricular arrhythmia
11604305|NCT00617136|Experimental|III|Prewarming by HotDog
11604306|NCT00617136|Active Comparator|I|Intraoperative warming by Bair Hugger
11604307|NCT00617136|Active Comparator|II|Intraoperative warming by HotDog
11604308|NCT00617123|Experimental|Vorapaxar|Participants receive a vorapaxar 2.5 mg tablet administered orally once daily for 1 year
11604309|NCT00617123|Placebo Comparator|Placebo|Participants receive a matching placebo tablet to vorapaxar administered orally once daily for 1 year
11604310|NCT00617110|Sham Comparator|allergic clean air|subjects with allergic rhinitis will be exposed to clean air followed by LAIV
11604311|NCT00617110|Active Comparator|Allergic diesel|subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
11604312|NCT00617110|Sham Comparator|control clean air|Healthy control subjects will be exposed to clean air followed by LAIV
11604313|NCT00617110|Sham Comparator|Control diesel|Healthy control will be exposed to diesel followed by LAIV
11604314|NCT00617097|Active Comparator|paracervical block with lidocaine|Subjects who receive pain control using paracervical block with lidocaine during first trimester surgical abortion
11604315|NCT00617097|Experimental|paracervical block with ketorolac and lidocaine|Subjects who receive pain control using paracervical block with ketorolac and lidocaine during first trimester surgical abortion
11604316|NCT00617084|Active Comparator|1. Resolute|Medtronic Endeavor Resolute
11604317|NCT00617084|Active Comparator|2. XIENCE V|Abbott Xience V
11604318|NCT00617058|Experimental|1|metformin, 250mg-2000 mg/day, in BID to TID doses for 26 weeks. Open, flexibly adjusted.
11604319|NCT00617058|Experimental|2|Healthy lifestyle intervention. Additional meeting at each psychiatric visit to review weight changes, level of physical activity and healthy eating behaviors
11604320|NCT00617058|No Intervention|3|Self-selected patients will be followed at major timepoints to assess weight and related measures.
11604321|NCT00617045|Experimental|Duloxetine|type of experimental agent
11604322|NCT00617032|Active Comparator|1|1x10^10 DRP/mL tgAAC94
11604323|NCT00617032|Active Comparator|2|1x10^11 DRP/mL tgAAC94
11604324|NCT00617032|Placebo Comparator|3|Single dose tgAAC94 placebo
11604325|NCT00617019||Parkinson's patients|Observational study to compare rates of impulse control disorders in patients taking different medications for Parkinson's Disease
11604326|NCT00617006||Before (Control)|Study group representative of standard practice
11604327|NCT00617006||After(Treatment)|After treatment group with the personal hand hygiene device ie. Device Group.
11604328|NCT00616993|Placebo Comparator|2|Vehicle
11604329|NCT00616993|Experimental|1|Difluprednate
11604330|NCT00616980|Active Comparator|Low Dose|
11604331|NCT00616980|Active Comparator|High Dose|
11604332|NCT00616980|Placebo Comparator|Saline|
11604333|NCT00616967|Active Comparator|Arm I|Patients receive carboplatin IV and paclitaxel albumin-stabilized nanoparticle formulation IV on day 1 and an oral placebo on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
11604334|NCT00616967|Experimental|Arm II|Patients receive carboplatin and paclitaxel albumin-stabilized nanoparticle formulation as in arm I and oral vorinostat on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
11604335|NCT00616954|Experimental|1|with ATG-F
11604336|NCT00616954|No Intervention|2|control
11604337|NCT00616941|Experimental|Cohort 1|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) once every 3 weeks for a total of 5 vaccinations.
11604338|NCT00616941|Experimental|Cohort 2|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) in combination with Montanide ISA-51 vegetable grade (VG) once every 3 weeks for a total of 5 vaccinations.
11604528|NCT00615316|Placebo Comparator|B|
11604339|NCT00616941|Experimental|Cohort 3|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) in combination with Montanide ISA-51 VG and poly-ICLC once every 3 weeks for a total of 5 vaccinations.
11604340|NCT00616928|Experimental|Influenza A (H5N1) 18-64Y Group|Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
11604341|NCT00616928|Placebo Comparator|Placebo 18-64Y Group|Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
11604342|NCT00616928|Experimental|Influenza A (H5N1) >64Y Group|Subjects aged > 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
11604343|NCT00616928|Placebo Comparator|Placebo >64Y Group|Subjects aged > 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
11604344|NCT00616928|Experimental|Influenza A (H5N1) Group|Pooled group of subjects aged >18 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
11604345|NCT00616928|Placebo Comparator|Placebo Group|Pooled group of subjects aged >18 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
11604346|NCT00616928|Experimental|Influenza A (H5N1) 18-60Y Group|Subjects aged 18-60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
11604347|NCT00616928|Placebo Comparator|Placebo 18-60Y Group|Subjects aged 18-60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
11604348|NCT00616928|Experimental|Influenza A (H5N1) >60Y Group|Subjects aged >60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
11604349|NCT00616928|Placebo Comparator|Placebo >60Y Group|Subjects aged > 60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
11604350|NCT00616915|Other|1|Wellbutrin SR switched to Wellbutrin XL
11604351|NCT00616902|Active Comparator|Paricalcitol Injection 4 mcg/mL|Paricalcitol Injection 4 mcg/mL given intravenously 3 times per week during dialysis
11604352|NCT00616902|Placebo Comparator|Placebo Injection 4 mcg/mL|Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
11604353|NCT00616889||1|Seroquel added to medication regime and sleep quality measured
11604354|NCT00616876|Experimental|1|Study group will receive 1% lactulose in all their feeds (human milk or preterm formula)
11604355|NCT00616876|Placebo Comparator|2|Control group will receive 1% dextrose placebo in all their feeds (human milk or preterm formula).
11604356|NCT00616850|Active Comparator|Group A|Group A subjects will receive a continuous femoral block catheter and a Patient Controlled Analgesia (PCA).
11604357|NCT00616850|Experimental|Group B|Group B subjects will receive a low dose lidocaine (1.33 mg/kg/hr) infusion and a Patient Controlled Analgesia.
11604358|NCT00616850|Placebo Comparator|Group C|Group C subjects will receive placebo (preservative free normal saline) infusion and a Patient Controlled Analgesia.
11604359|NCT00616837|Active Comparator|Standard consultation|Standard care in orthopaedic outpatient clinic
11604360|NCT00616837|Experimental|Telemedicine consultation|Orthopaedic care in outpatient clinic by use of telemedicine.
11604361|NCT00616824|Active Comparator|Traditional Method|Arm which uses the Serratus Anterior muscle mobilization for lateral coverage of the tissue expander
11604362|NCT00616824|Experimental|Dermamatrix Arm|Arm which uses Dermamatrix as the lateral expander coverage
11604363|NCT00616811|Experimental|Vildagliptin|
11604364|NCT00616811|Active Comparator|Sitagliptin|
11604365|NCT00616798|Experimental|3|
11604366|NCT00616798|Placebo Comparator|4|
11604367|NCT00616798|Experimental|1|
11604368|NCT00616798|Experimental|2|
11604369|NCT00616772|Experimental|ABT-335 + Atorvastatin|ABT-335 (135 mg) and atorvastatin (up to 40 mg) once daily for 2 years.
11604370|NCT00616772|Placebo Comparator|Placebo + Atorvastatin|Placebo and atorvastatin (up to 40 mg) once daily for 2 years.
11604371|NCT00616759|Active Comparator|1|ECT as usual
11604372|NCT00616759|Experimental|2|ECT-induced seizures terminated with propofol
11604373|NCT00616746|Experimental|1|Three test days, within-subject design.
11604374|NCT00616733|Experimental|1|
11604375|NCT00616733|Experimental|2|
11604376|NCT00616733|Experimental|3|
11604377|NCT00616655|Active Comparator|1|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
11604378|NCT00616655|Active Comparator|2|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
11604379|NCT00616655|Placebo Comparator|3|Placebo total daily dose 0.9 mg
11604380|NCT00616642|Experimental|Group 1 (ACTH-secreting adenomas)|Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 6 months in the absence of disease progression or unacceptable toxicity.
11604431|NCT00616161|Experimental|3|Istaroxime dose of 1.5 microgram/kg body weight/minute of iv infusion for six ours
11604381|NCT00616642|Experimental|Group 2 (non-secreting macroadenomas)|Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 12 months in the absence of disease progression or unacceptable toxicity.
11604382|NCT00616616|Experimental|1|all subjects
11604383|NCT00616603|Other|Group A|This is the control arm and subjects in Group A will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 2ml IV of normal saline.
11604384|NCT00616603|Experimental|Group B|Subjects in Group B will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 8mg Dexamethasone + 2ml IV of normal saline.
11604385|NCT00616603|Active Comparator|Group C|Subjects in Group C will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 2ml IV (8mg)of Dexamethasone.
11604386|NCT00616577|Experimental|Group CB|Subjects in this arm will receive caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine after induction of general anesthesia prior to surgical incision.
11604387|NCT00616577|Active Comparator|Group CA|Group CA (Caudal After-control group) will receive caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine after completion of surgery but before emergence from anesthesia.
11604388|NCT00616577|Active Comparator|Group LIA|Group LIA (Local Infiltration After-control group) will receive local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site at the conclusion of surgery but before emergence from anesthesia.
11604389|NCT00616551|Experimental|A|
11604390|NCT00616551|Active Comparator|B|
11604391|NCT00616538|Active Comparator|Cutivate(r)|Topical mid-strength steroid
11604392|NCT00616538|Experimental|EpiCeram(r)|EpiCeram(r) topical barrier repair cream.
11604393|NCT00616512|Experimental|1|GF Strong Water Protocol/ water allowed between meals after oral care for selected clients/ Fraser Water Protocol
11604394|NCT00616486|Experimental|1|
11604395|NCT00616486|Placebo Comparator|2|
11604396|NCT00616473||1 Nursing Home Staff|Direct care staff
11604397|NCT00616473||2 Family Members|Family members/Significant other of nursing home resident.
11604398|NCT00616460|Experimental|Bivalirudin|
11604399|NCT00616447|Experimental|1|
11604400|NCT00616447|Sham Comparator|2|
11604401|NCT00616434|Experimental|Interferon beta-1a|Interferon beta-1a 30 µg intramuscular (IM) injection twice weekly for 12 weeks
11604402|NCT00616434|Placebo Comparator|Placebo|Placebo IM injection twice weekly for 12 weeks
11604403|NCT00616421|Experimental|MenACWY-CRM (1 dose)|1 injection of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study day 1.
11604404|NCT00616421|Active Comparator|Licensed polysaccharide vaccine|1 injection of a licensed meningococcal MenACWY polysaccharide-protein conjugate vaccine administered by intramuscular (IM) injection on study day 1
11604405|NCT00616421|Experimental|MenACWY-CRM (2 doses)|2 injections of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study days 1 and 61.
11604406|NCT00616408||A|Newly diagnosed active acromegaly out of the 297 patients coming to our Department for acromegaly who received first-line treatment with LAR
11604407|NCT00616395||no grouping|IDE used for outcome measurement not for an intervention.
11604408|NCT00616382|Experimental|Stepwise Indo|Stepwise escalating doses of indomethacin, until ductal closure or maximum of 1 mg/kg/dose.
11604409|NCT00616382|Experimental|PTX|Combined administration of indomethacin and pentoxifylline, an inhibitor of TNF alpha
11604410|NCT00616369||1|"I:
~For those patients who have had blood samples drawn as a result of participating in current protocol, Identification of Genetic Markers for Primary Pulmonary Hypertension study (X980515002), we would like to use their previously obtained blood and continue to draw samples (12mL; less than 3 tablespoons) ONLY if they change disease therapies.
~For those patients who participated in Pulmonary Arterial Hypertension (PAH) Database study (X030403017), these participants will also sign a consent form to participant in this new trial. We would like to use the previously obtained data from the X030403017 in part with this study.
~As for the X980515002 expired patients, we would like to use the previously obtained data ONLY in part for this study that was collected as a result of the X980515002 study."
11604411|NCT00616369||2|"II:
~Group 2: After signing a consent form, these participants will have a 12mL (less than 3 teaspoons) blood sample drawn at baseline, at 3-4 month, at 6-8 month, at 12 month, and at 24 month visits. With each disease therapy change, the blood draws (12mL samples) will begin again at baseline and continue through the 3-4, 6-8, 12, and 24 month visits."
11604412|NCT00616343|Active Comparator|Zonisamide|
11604413|NCT00616330|Experimental|1|clindamycin phosphate/butoconazole nitrate
11604414|NCT00616330|Active Comparator|2|clindamycin phosphate
11604415|NCT00616330|Active Comparator|3|butoconazole nitrate
11604416|NCT00616304|Active Comparator|A|L-arginine infusion
11604417|NCT00616304|Placebo Comparator|S|Normal saline infusion
11604418|NCT00616291|Experimental|Group I|MHC Class I binding peptide at 1000 mcg
11604419|NCT00616291|Experimental|Group II|MHC Class II binding peptide at 1000 mcg
11604420|NCT00616291|Experimental|Group III|Combination MHC Class I and II binding peptide at 1000 mcg each
11604421|NCT00616265|No Intervention|B|Group B. Only Usual Control
11604422|NCT00616265|Experimental|A|Group A: Cpap treatment plus Usual control
11604423|NCT00616239|Active Comparator|A|Subjects randomized to have the right side of the face peeled with salicylic acid every 2 weeks for a total of 4 peels (first 2 at 20% and last 2 at 30%). Subjects will apply 4% hydroquinone cream to affected areas on entire face for 14 weeks.
11604424|NCT00616239|Active Comparator|B|Subjects randomized to have the left side of the face peeled with salicylic acid every 2 weeks for a total of 4 peels (first 2 at 20% and last 2 at 30%). Subjects will apply 4% hydroquinone cream to affected areas on entire face for 14 weeks.
11604425|NCT00616200|Experimental|A|
11604426|NCT00616187|Active Comparator|interferon|
11604427|NCT00616187|Sham Comparator|untreated|
11604428|NCT00616174|Other|1|Active warming with Bair Hugger blanket
11604429|NCT00616161|Experimental|1|Istaroxime dose of 0.5 microgram/kg body weight/minute of iv infusion for six ours
11604430|NCT00616161|Experimental|2|Istaroxime dose of 1.0 microgram/kg body weight/minute of iv infusion for six ours
11604432|NCT00616161|Placebo Comparator|4|Placebo iv infusion for six ours
11604433|NCT00616148|Placebo Comparator|Placebo|
11604434|NCT00616148|Experimental|YKP3089|
11604435|NCT00616122|Experimental|Sunitinib, Cyclophosphamide, and Methotrexate|
11604436|NCT00616109|Experimental|Maintenance Sunitinib|"Main interventional arm of study. Subjects who received maintenance sunitinib experimentally on this study were from a population of (consenting) patients with histologically or cytologically documented Extensive-State Small Cell Lung Cancer (ES-SCLC) who did not progress (were classified as Complete Response or CR, Partial Response or PR, or Stable Disease or SD) after an induction chemotherapy (Cisplatin and etoposide)"
11604437|NCT00616096|Experimental|1|
11604438|NCT00616083||1|Healthy breast fed infants
11604439|NCT00616070|Experimental|1|Difluprednate
11604440|NCT00616070|Placebo Comparator|2|Vehicle
11604441|NCT00616057|Placebo Comparator|B|Maltodextrin, non digestible carbohydrate
11604442|NCT00616057|Experimental|A|fructans, non digestible carbohydrates fermented in the caeco-colon
11604443|NCT00616044|Experimental|CSA|For CSA, an 22-G catheter (Spinocath, B.Braun Melsungen, Germany) over a 27-G Quincke needle was used. After identification of the epidural space with a Crawford needle, the catheter with the spinal needle inside was advanced through the epidural space until the dural puncture was felt and CSF was seen in the catheter. The catheter was then fed over the needle into the intrathecal space. The spinal needle and the modified Tuohy needle were removed and a luer connector and a filter previously filled with the anesthetic solution were attached to the catheter.
11604444|NCT00616044|Experimental|CSE|"CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany). The block consists of performing a spinal block via a 27-G spinal needle (Spinocan 125mm) introduced through an 18-G Tuohy needle (Perican 88mm) which was placed cranially directed in the epidural space. We did rotate the Tuohy needle between the spinal block and the insertion of the epidural catheter."
11604445|NCT00616018|Experimental|A|all subjects receive 4 g/day of acetaminophen for 10 consecutive days in this open-label study
11604446|NCT00616005|Other|1|Pts taking EIAEDs
11604447|NCT00616005|Other|2|Pts not taking EIAEDs
11604448|NCT00615979||Miniature echo machine|Diagnostic capabilities Wireless transfer
11604449|NCT00615966|Experimental|1|
11604450|NCT00615966|Experimental|2|
11604451|NCT00615966|Placebo Comparator|3|
11604452|NCT00615940|Experimental|1|Capecitabine, 1000 mg/m2, twice daily by mouth, on Days 1 to 14, followed by a 7 day rest in each 21 day cycle given in combination with WX-671 once daily by mouth, Days 1-21 inclusive.
11604453|NCT00615940|Experimental|2|Capecitabine, 1000 mg/m2, twice daily by mouth, on Days 1 to 14, followed by a 7 day rest in each 21 day cycle given in combination with placebo once daily by mouth, Days 1-21 inclusive.
11604454|NCT00615927|Experimental|Astrocytoma|Grade II Astrocytoma
11604455|NCT00615927|Experimental|Oligodendroglioma|Grade II Oligodendroglioma or oligoastrocytomas
11604456|NCT00615901|Experimental|1|This is a pilot study using 8 cycles of CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2), at 14 day intervals supported by PEG-filgrastim for a cohort of 38 patients. A safety analysis will then be performed.
11604457|NCT00615888|Active Comparator|A|Traditional management including preoperative bowel washout, patient controlled analgesia (PCA), delayed start of enteral feeding
11604458|NCT00615888|Experimental|B|Fast track management including no bowel washout, patient controlled epidural anesthesia, early enteral feeding
11604459|NCT00615875|Active Comparator|A|
11604460|NCT00615875|Placebo Comparator|P|
11604461|NCT00615862||AUD+ and AUD-|AUD stands for alcohol use disorders. Patients with alcohol use disorders are assigned the label AUD+. Patients without alcohol use disorders are assigned the label AUD-.
11604462|NCT00615836|Experimental|Desmopressin Melt 10 μg|Participants received desmopressin melt 10 μg once a day, placed under the tongue one hour before bedtime until they were re-randomized to one of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).
11604463|NCT00615836|Experimental|Desmopressin Melt 25 μg|Participants received desmopressin melt 25 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
11604464|NCT00615836|Experimental|Desmopressin Melt 50 μg|Participants received desmopressin melt 50 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
11604465|NCT00615836|Experimental|Desmopressin Melt 100 μg|Participants received desmopressin melt 100 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
11604466|NCT00615823|Active Comparator|1|Atorvastatin group: receive atorvastatin 10 mg daily in addition to supportive care
11604467|NCT00615823|Placebo Comparator|2|Placebo group: receive matching placebo in addition to supportive care.
11604468|NCT00615810|Active Comparator|2|Open label Kivexa (abacavir (as sulfate) 600 mg/lamivudine 300 mg) once daily for oral administration plus Sustiva (efavirenz 600 mg) once daily for oral administration
11604469|NCT00615810|Experimental|1|Open label Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir DF 300 mg) once daily for oral administration to be taken on an empty stomach
11604470|NCT00615797|Experimental|1|Group randomized to receive intravenous immunoglobulins in addition to standard therapy for sydenham's chorea
11604471|NCT00615797|Placebo Comparator|2|Group randomized to receive standard intervention for sydenham's chorea alone
11604472|NCT00615784|Experimental|A|
11604473|NCT00615771|Experimental|Day 2 embryo transfer|Embryos are transferred 2 days after fertilization.
11604474|NCT00615771|Active Comparator|Day 3 embryo transfer|Standard of care for women undergoing IVF with a limited number of embryos is to transfer all embryos on Day 3 after fertilization
11604475|NCT00615758|Experimental|1|Tarceva
11604476|NCT00615745|Experimental|Single Arm|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
11604477|NCT00615732|Experimental|1|qigong
11604478|NCT00615732|Active Comparator|2|exercise therapy
11604479|NCT00615732|No Intervention|3|
11604480|NCT00615719||ED patients undergoing coronary CTA|Emergency Department patients suspected of having acute coronary syndrome undergoing Coronary Computed Tomographic angiography.
11604481|NCT00615706||1|Asthmatics
11604482|NCT00615706||2|Healthy volunteers (without asthma)
11604483|NCT00615693|Experimental|1|
11604484|NCT00615667|Experimental|tacrolimus(fk506) treatment|tacrolimus(fk506) treatment
11604485|NCT00615654|Other|2|
11604486|NCT00615641||1|3 year old children
11604487|NCT00615641||2|4 year old children
11604488|NCT00615641||3|5 year old children
11604489|NCT00615628||family members|family members of the proband and father identified
11604490|NCT00615615|Experimental|Levetiracetam (LEV)|LEV dose was titrated to a level of 60 mg/kg/day. The initial dose level was 20 mg/kg/day for the first two weeks, followed by a dose level of 40 mg/kg/day for two weeks. If lower doses were well tolerated, the LEV dose was increased to a dose level of 60 mg/kg/day for the remaining 10 weeks. The dose level could be reduced to 40 mg/kg/day if the patient did not tolerate LEV at a dose level of 60 mg/kg/day.
11604491|NCT00615615|Placebo Comparator|Placebo|Subjects received Placebo matching to LEV treatment.
11604492|NCT00615602|Experimental|1|FEC -> TXT+H 12m
11604493|NCT00615602|Experimental|2|FEC -> TXT+H 6m
11604494|NCT00615589|Experimental|Flu-Bu4|Fludarabine Busulfan chemotherapy regimen(Flu-Bu4), followed by allogeneic stem cell transplant from best available, matched donor.
11604495|NCT00615576|Experimental|Subjects receiving SB-656933|Eligible subjects will be randomized to receive once daily doses of 100 milligrams of SB- 656933 for 14 days.
11604496|NCT00615576|Placebo Comparator|Subjects receiving placebo|Eligible subjects will be randomized to receive placebo for 14 days.
11604497|NCT00615563||genotype test|
11604498|NCT00615563||combined phenotype/genotype test|
11604499|NCT00615550|Placebo Comparator|Placebo|placebo vaginal gel
11604500|NCT00615550|Active Comparator|Prochieve|Progesterone 8% Vaginal Gel
11604501|NCT00615511|Placebo Comparator|placebo|Approximately one third of subjects
11604502|NCT00615511|Experimental|Pregnenolone|
11604503|NCT00615498||Surgical cases|Subjects who are undergoing bariatric surgery
11604504|NCT00615498||Controls|Subjects who qualify for bariatric surgery but do not undergo the procedure
11604505|NCT00615472|Experimental|Group 1|Inhaled Anesthesia - isoflurane
11604506|NCT00615472|Experimental|Group 2|Intravenous Anesthesia - propofol, remifentanil
11604507|NCT00615459|Experimental|Sequence 1: Placebo,Tiotropium, Indacaterol 150 μg|In period I, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. In period II, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via single dose dry powder inhaler (SDDPI). In period III, indacaterol 150 μg once daily delivered via SDDPI and placebo to tiotropium was delivered once daily via the tiotropium inhalation device. Daily inhaled corticosteroid (ICS) monotherapy (where applicable) was provided to remain stable throughout study. The Short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
11604508|NCT00615459|Experimental|Sequence 2: Indacaterol 300 μg, Indacaterol 150 μg, Tiotropium|In period I,indacaterol 300 μg once daily delivered via single dose dry powder inhaler (SDDPI)and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period II, indacaterol 150 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period III, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via SDDPI. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
11604509|NCT00615459|Experimental|Sequence 3: Indacaterol 150 μg, Indacaterol 300 μg, Placebo|In period I, indacaterol 150 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period II, indacaterol 300 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period III, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
11604510|NCT00615459|Experimental|Sequence 4: Tiotropium, Placebo, Indacaterol 300 μg|In period I, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via SDDPI. In period II, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. In period III, indacaterol 300 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
11604511|NCT00615446|Experimental|A|
11604512|NCT00615433|Experimental|Lurasdione 40mg tablets|
11604513|NCT00615433|Experimental|120mg|
11604514|NCT00615433|Active Comparator|15mg Olz|
11604515|NCT00615433|Placebo Comparator|Sugar pill|
11604516|NCT00615420|Experimental|Manuka Honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed
11604517|NCT00615420|Placebo Comparator|Placebo|Sugar-free placebo gel 5ml 4 times a day, swished and held in mouth for 30 secs then swallowed
11604518|NCT00615407||Alcohol Drinkers|Asthmatics who consume 3 or more alcoholic beverages per day (on average)
11604519|NCT00615407||Non Drinkers|Asthmatics who do not drink alcohol or consume less than or equal to 2 alcoholic beverages per month
11604520|NCT00615381|Active Comparator|Normal insulin|Maintenance of intraoperative euglycemia (blood glucose 80--110 mg/dL) using normal intensive insulin infusion rates (0-10 U/hr).
11604521|NCT00615381|Experimental|Supraphysiologic insulin|Maintenance of intraoperative euglycemia (blood glucose 80--110 mg/dL) using supraphysiologic insulin infusion doses (0.3 U/kg/hr) and exogenous dextrose to provide stable blood glucose levels .
11604522|NCT00615368|Placebo Comparator|Placebo|Isotonic NaCl, intravenously injection
11604523|NCT00615368|Experimental|Active|Epoetin alfa, injected
11604524|NCT00615355|Other|Body location|Different body locations receive specific treatments
11604525|NCT00615355|Active Comparator|Control|Treatment with narrow-band UVB
11604526|NCT00615329||Soft tissue tumor|Any patient with soft tissue tumor will be asked to give a sample for this study
11604527|NCT00615316|Experimental|A|
11604538|NCT00615238|Experimental|Diet plus short bouts|diet-plus-short bouts of vigorous aerobic exercise accumulated throughout the day
11604539|NCT00615238|Experimental|Diet plus moderate lifestyle activity|diet-plus-moderate intensity lifestyle activity accumulated throughout the day
11604540|NCT00615225||Brain dead patients|All patients meeting criteria for brain death
11604541|NCT00615225||Healthy control|Any healthy volunteers accepting to give some blood
11604542|NCT00615225||Volunteers having hip surgery|Patients undergoing hip surgery for degenerative non-inflammatory hip disease
11604543|NCT00615212|Active Comparator|Subjects receiving midazolam|Eligible subjects will receive midazolam oral syrup with a dose of 5 milligrams on Day 1.
11604544|NCT00615212|Active Comparator|Subjects receiving rosiglitazone|Eligible subjects will receive rosiglitazone oral tablet with a dose of 4 milligrams on Day 2.
11604545|NCT00615212|Active Comparator|Subjects receiving flurbiprofen|Eligible subjects will receive flurbiprofen oral tablet with a dose of 50 milligrams on Day
11604546|NCT00615212|Experimental|Subjects receiving GSK376501|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams from Day 4 to Day 10.
11604547|NCT00615212|Experimental|Subjects receiving GSK376501+ midazolam|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with midazolam oral tablet of 5 milligrams on Day 11.
11604548|NCT00615212|Experimental|Subjects receiving GSK376501 + rosiglitazone|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with rosiglitazone oarl tablet of 4 milligrams on Day 12.
11604549|NCT00615212|Experimental|Subjects receiving GSK376501 + flurbiprofen|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with flurbiprofen oral tablet of 50 milligrams on Day 13.
11604550|NCT00615199|Experimental|1mg BD|
11604551|NCT00615199|Experimental|5mg BD|
11604552|NCT00615199|Experimental|15mg BD|
11604553|NCT00615199|Placebo Comparator|Placebo BID|
11604554|NCT00615186|Experimental|A|"Prior Surgery
~Rickham Catheter placement 99mTc-DTPA Flow Study
~Neuradiab Dosimetry Study
~Neuradiab Therapeutic Dose Administration
~Radiation Therapy (XRT) + Temozolomide:
~XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.
~Post-Radiation Temozolomide Therapy:
~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
11604555|NCT00615186|Active Comparator|B|"Prior Surgery: Gross total resection (< 1 cm. enhancing rim)
~Radiation Therapy (XRT) + Temozolomide:
~XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks
~Post-Radiation Temozolomide Therapy:
~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
11604556|NCT00615173|Experimental|1|tacrolimus(fk506) treatment in induction and maintenance phase
11604557|NCT00615173|Active Comparator|2|intravenous cyclophosphamide pulses treatment in induction phase; and Aza in the maintenance phase
11604558|NCT00615160|Experimental|A|PTK787/ZK 222584 (PTK-ZK) taken orally with a daily flat dose of 1250 mg on days 1 to 28 (= 1 cycle)
11604559|NCT00615160|Experimental|B|combined treatment with DTIC 850 mg/m² on day 1 + PTK-ZK 1250 mg flat dose on days 1 to 28
11604560|NCT00615147||1|Patients to have a CT pulmonary angiogram for suspected pulmonary embolism will have a d-dimer drawn as is routinely done.
11604561|NCT00615134|Experimental|1|
11604562|NCT00615134|Active Comparator|2|
11604563|NCT00615121||arteries from PAD patients|peripheral arteries from patients undergoing amputation for end stage peripheral arterial occlusive disease
11604564|NCT00615121||arteries from Free Fib transfers|peripheral arteries from patients without evidence of peripheral arterial occlusive disease
11604565|NCT00615095||1|Cases will be patients 18 years or older with a histologically confirmed, second or multiple primary melanoma.
11604566|NCT00615095||2|Controls will be patients 18 years or older with a histologically confirmed first primary melanoma diagnosed no earlier than 12 months prior to the study start date.
11604567|NCT00615095||3|Healthy controls will be subjects 18 years or older recruited from the general population through random digit dialing. These subjects will have no history of melanoma. They will also be frequency matched to cases on the basis of sex and 10-year age group.
11604568|NCT00615082|Experimental|Mindfulness-Based Stress Reduction|
11604569|NCT00615082|Active Comparator|Caregiver Education & Social Support|
11604570|NCT00615069|Experimental|31 mm GORE EXCLUDER® Test Subjects|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
11604571|NCT00615056|Active Comparator|B|Bevacizumab (avastin)
11604572|NCT00615056|Experimental|C|AG-013736 (axitinib)
11604573|NCT00615056|Experimental|A|AG-013736 (axitinib)
11604574|NCT00615056|Active Comparator|D|bevacizumab (avastin)
11604575|NCT00615043||TURBT group|Subjects undergoing transurethral resection of bladder tumor or other transurethral biopsy procedure who agree to provide bladder tissue specimens
11604576|NCT00615030|Experimental|Indacaterol Morning,Indacaterol Evening, Salmeterol|In period I, indacaterol 300 μg once a day in the morning delivered via single dose dry powder inhaler (SDDPI) with a placebo to salmeterol delivered via dry powder inhaler (DPI). Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, Salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and second dose in the evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
11604620|NCT00614796|Experimental|1|5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
11604866|NCT00612846|Experimental|B|
11604577|NCT00615030|Experimental|Indacaterol Evening,Indacaterol Morning, Placebo|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
11604578|NCT00615030|Experimental|Salmeterol, Placebo, Indacaterol Morning|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose was in the evening along with placebo matching indacaterol delivered by SDDPI. In period II, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
11604579|NCT00615030|Experimental|Placebo, Salmeterol, Indacaterol Evening|In period I, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, salmeterol 50 μg twice daily delivered via dry powder inhaler (DPI). One of the two daily doses of salmeterol was administered in the morning and the second dose was in the evening along with placebo matching indacaterol delivered by SDDPI. In period III, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via dry DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
11604580|NCT00615030|Experimental|Indacaterol Morning, Placebo, Indacaterol Evening|In period I, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, During morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, Patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
11604581|NCT00615030|Experimental|Indacaterol Evening,Salmeterol, Indacaterol Morning|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period II, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
11604582|NCT00615030|Experimental|Salmeterol, Indacaterol Evening, Placebo|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
11604583|NCT00615030|Experimental|Placebo, Indacaterol Morning, Salmeterol|In period I, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via dry powder inhaler DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
11604584|NCT00615030|Experimental|Indacaterol Morning, Salmeterol, Placebo|In period I, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
11604621|NCT00614796|No Intervention|2|daily physical activity is assessed at baseline, 3 months, 9 months and 15 months. No counseling.
11604622|NCT00614770|Experimental|1|Standard White Light Colonoscopy
11604623|NCT00614770|Experimental|2|High Definition White Light Colonoscopy
11604585|NCT00615030|Experimental|Indacaterol Evening, Placebo, Salmeterol|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via dry powder inhaler DPI. In period II, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
11604586|NCT00615030|Experimental|Salmeterol, Indacaterol Morning, Indacaterol Evening|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
11604587|NCT00615030|Experimental|Placebo, Indacaterol Evening, Indacaterol Morning|In period, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
11604588|NCT00615017|Experimental|AZD9773 cohort 1 (50 units/kg)|AZD9773: single infusion of 50 units/kg
11604589|NCT00615017|Experimental|AZD9773 cohort 2 (250 units/kg)|AZD9773: single infusion of 250 units/kg
11604590|NCT00615017|Experimental|AZD9773 cohort 3 (250/50 units/kg)|AZD9773: loading infusion of 250 units/kg then 9 maintenance doses of 50 units/kg q12hrs
11604591|NCT00615017|Experimental|AZD9773 cohort 4 (500/100 units/kg)|AZD9773: loading infusion of 500 units/kg then 9 maintenance doses of 100 units/kg q12hrs
11604592|NCT00615017|Experimental|AZD9773 cohort 5 (750/250 units/kg)|AZD9773: loading infusion of 750 units/kg then 9 maintenance doses of 250 units/kg q12hrs
11604593|NCT00615017|Placebo Comparator|Placebo|Placebo
11604594|NCT00615004||1-SSA|All patients receiving first-line depot SSA treatment, with either octreotide-LAR or lanreotide, achieving control of the disease, and with available follow-up after 12 months of treatment.
11604595|NCT00615004||2-Surgery|All patients treated with first-line surgery via trans-sphenoidal route by microscopic and/or endoscopic approach, who did not require any additional therapy for acromegaly and with available follow-up after 12 months of treatment
11604596|NCT00614991|Active Comparator|Group A|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg BID Period 3-Fosamprenavir 1400mg BID + Raltegravir 400mg BID
11604597|NCT00614991|Active Comparator|Group B|Period 1-Raltegravir 400mg BID Period2-Fosamprenavir 1400mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg BID
11604598|NCT00614991|Active Comparator|Group C|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID
11604599|NCT00614991|Active Comparator|Group D|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 700mg BID + Raltegravir 100mg BID
11604600|NCT00614991|Active Comparator|Group E|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID
11604601|NCT00614991|Active Comparator|Group F|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
11604602|NCT00614978|Experimental|I|Lapatinib plus temozolomide
11604603|NCT00614965|Experimental|1|IC
11604604|NCT00614965|Experimental|2|PC
11604605|NCT00614952|Experimental|PR|
11604606|NCT00614952|Active Comparator|PSG|
11604607|NCT00614939|Experimental|Saxa|Saxagliptin
11604608|NCT00614939|No Intervention|Placebo|Placebo to match
11604609|NCT00614926|Experimental|Modafinil|Eligible patients will be treated at baseline through Week 4. Those who choose to continue will have additional in-person visits at Weeks 8 and 12 visits (and Week 16 for those starting modafinil at Week 4).
11604610|NCT00614926|Placebo Comparator|Placebo|Sugar pill equivalent to the active comparator. Dosing schedule will be the same as the dosing schedule for Modafinil.
11604611|NCT00614887||2|Patients scheduled for elective cerebral aneurysmal surgery
11604612|NCT00614887||1|Patients with subarachnoid hemorrhage
11604613|NCT00614874|Experimental|1|Subjects took rosiglitazone 2 mg for 4 weeks, then 4mg for 4 weeks, then 8 mg for 4 weeks
11604614|NCT00614861||001|
11604615|NCT00614848|Experimental|1|Endeavor Drug Eluting Coronary Stent
11604616|NCT00614848|Active Comparator|2|Driver bare-metal coronary stent
11604617|NCT00614835|Experimental|1 patients with completely resected uterine leiomyosarcoma|Docetaxel plus Gemcitabine
11604618|NCT00614822|Other|one arm for study|Carboplatin, Pemetrexed and Bevacizumab are given day 1 every 3 weeks for 6 cycles and will be continued if patient tolerates treatments and has stable disease. The Bevacizumab will be continued every 3 weeks for 1 year if the patient tolerates treatment and has stable disease.
11604619|NCT00614809|Experimental|1|non-randomized open-label uncontrolled phase II trial
11604624|NCT00614770|Experimental|3|Narrow Band Imaging Colonoscopy
11604625|NCT00614757|No Intervention|2|One half of the patients will take not medication for 30 days and then have labs redrawn
11604626|NCT00614757|Experimental|1|one half of the patients with insulin resistance will take 4ml of 20% N-acetylcysteine BID for 30 days
11604627|NCT00614744|Experimental|Whole-body Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
11604628|NCT00614744|Active Comparator|Normothermia|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
11604629|NCT00614731|Experimental|ID immunizations (100 mcg)|Participants will receive a total of two 100 mcg intradermal (ID) KLH carrier-protein immunizations with 1 mg/ml KLH per immunization. Immunizations will be given 21 days apart at Visits 5 and 6.
11604630|NCT00614731|Experimental|Scarification by 3 jabs|Participants will receive two scarification immunizations by 3 jabs containing 20 mg/ml of KLH carrier-protein. The immunizations will occur 21 days apart at Visits 5 and 6.
11604631|NCT00614731|Experimental|ID immunizations (250 mcg)|Enrollment will begin after the safety data for Groups 1A and 2A have been reviewed. Participants in this group will receive two 250 mcg ID KLH vaccinations containing 10 mg/ml of KLH carrier-protein. Immunizations will occur 21 days apart at Visits 5 and 6.
11604632|NCT00614731|Experimental|Scarification by 15 jabs|Enrollment will begin after the safety data from groups 1A and 2A has been examined. Participants in this group will receive a total of two scarification immunizations by 5 needles used to administer 15 jabs, each containing, 20 mg/ml of KLH carrier-protein. Immunizations will occur 21 days apart at Visits 5 and 6.
11604633|NCT00614718||1|Total number of patients receiving an ICD between 1993 and 2004 and not having re interventions due to malfunctioning leads.
11604634|NCT00614718||2|Patients with ICD lead failure receiving a new ICD lead
11604635|NCT00614718||3|Patients with ICD lead failure but intact shock-coil of the ICD lead receiving only an additional pace/sense lead.
11604636|NCT00614705|Experimental|1|
11604637|NCT00614705|Placebo Comparator|2|
11604638|NCT00614679|Experimental|1|single arm trial of experimental catheter lock solution
11604639|NCT00614666|Experimental|A|nikkomycin Z 50 mg BID versus placebo BID x 14 days
11604640|NCT00614666|Experimental|B|nikkomycin Z 250 mg BID versus placebo BID x 14 days
11604641|NCT00614666|Experimental|C|nikkomycin Z 500 mg BID versus placebo BID x 14 days
11604642|NCT00614666|Experimental|D|nikkomycin Z 750 mg TID versus placebo TID x 14 days
11604643|NCT00614653|Experimental|Bevacizumab, Erlotinib + Capecitabine|Bevacizumab intravenous (IV) every 2 weeks at 5 mg/kg, Erlotinib 100 mg orally (PO) daily + Capecitabine 400 mg/m2 PO twice daily (BID) only on days of radiation. Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy.
11604644|NCT00614640|Experimental|1|One 0.8 ml vaccine-containing patch and 1 placebo patch placed on upper back or upper thigh for 24 hours on Days 0, 42, and 84
11604645|NCT00614640|Experimental|2|Four 0.8 ml vaccine-containing patches placed on upper back or upper thigh for 24 hours on Days 0, 42, and 84
11604646|NCT00614640|Experimental|3|Four 0.8 ml vaccine-containing patches placed on upper back or upper thigh for 24 hours on Days 0, 7, 42, 49, 84, and 91
11604647|NCT00614614|Experimental|Menhibrix 1 Group|Subjects received 3 doses of Menhibrix vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age during the Primary Vaccination Phase. For the Booster Vaccination Phase, subjects were re-randomized and received either 1 dose of Nimenrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) [Nimenrix 1 Group] or a fourth dose of Menhibrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) [Menhibrix 2 Group], or 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine (at 15-18 months of age) [Nimenrix 2 Group].
11604648|NCT00614614|Active Comparator|ActHIB- Infanrix Group|Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age and 1 booster dose of Infanrix vaccine at 15-18 months of age.
11604649|NCT00614601|Experimental|1|Vaccine + chemo + chemoradiation therapy
11604650|NCT00614601|Experimental|2|Vaccine Only
11604651|NCT00614588||observation group|Patients undergoing laparoscopic surgery requiring general anesthesia and a bladder catheter.
11604652|NCT00614575||BI-Sifrol® Tablets (Pramipexole)|BI-Sifrol® Tablets, pramipexole dose: 0.125 mg, 0.5 mg, No reference therapy
11604653|NCT00614562|Experimental|NAVA|
11604654|NCT00614549||Levetiracetam|Patients treated with Levetiracetam
11604655|NCT00614536||001|
11604656|NCT00614523|Experimental|Romiplostim|Weekly subcutaneous dosing based on platelet count for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period. Starting dose is at 750 μg, up to a maximum dose of 1000 μg, or reduced to a minimum of 250 μg.
11604657|NCT00614523|Placebo Comparator|Placebo|Weekly subcutaneous dosing with blinded matching placebo dose level for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period.
11604658|NCT00614484|Experimental|Proton therapy with chemotherapy|"Induction Chemotherapy - Two cycles Taxol 200mg/m2 and Carboplatin AUC6 on day 1 and day 22. Weekly chemotherapy concurrent with radiotherapy Taxol 50mg/m2 and Carboplatin AUC 2 weekly for 5 weeks.
~Proton therapy - 76 Gy in 5 weeks to lung tumor."
11604659|NCT00614471|Active Comparator|1|
11604660|NCT00614471|Experimental|2|
11604661|NCT00614471|Experimental|3|
11604662|NCT00614458|Experimental|Raltegravir and VPA to ART|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
11604663|NCT00614445|Experimental|Diclectin®|Diclectin® (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) delayed release tablet
11604664|NCT00614445|Placebo Comparator|Placebo|Placebo tablets identical in size, shape, taste, and color to the experimental treatment (Diclectin®)
11604665|NCT00614432||1|Women who are anticoagulated.
11604666|NCT00614432||2|Matched case controls.
11604667|NCT00614419|Active Comparator|1|The Lichtenstein tension-free hernioplasty with polypropylene mesh
11604715|NCT00614042|Experimental|1|Dose escalation and expansion cohorts
11604716|NCT00614029|Experimental|A|IMITREX -abd. to Intraject-abd. to IMITREX -thigh to Intraject-thigh
11604717|NCT00614029|Experimental|B|Intraject-abd. to IMITREX -abd. to Intraject-thigh to IMITREX -thigh
11604718|NCT00614029|Experimental|C|Intraject-abd to IMITREX -abd to Intraject-arm. to IMITREX -arm.
11604668|NCT00614419|Experimental|2|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
11604669|NCT00614406|Experimental|1|
11604670|NCT00614406|Placebo Comparator|2|
11604671|NCT00614393|Experimental|Dalotuzumab 10 mg/kg Q1W (DB)|In double-blind (DB) Week 1, participants receive cetuximab 400 mg/m^2 intravenously (IV) loading dose and irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV one time each week (Q1W) maintenance dose, irinotecan IV Q1W and DB dalotuzumab 10 mg/kg IV Q1W for up to 32 months of treatment.
11604672|NCT00614393|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (OL)|In the open-label (OL) portion of the study, ≥6 participants receive cetuximab 400 mg/m^2 Q1W + irinotecan Q1W at their pre-study dosage + OL dalotuzumab (loading dose of 15 mg/kg IV followed by a maintenance dose of 7.5 mg/kg 2 weeks later) to verify the safety of the regimen. In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV. In DB Week 2, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV + DB dalotuzumab 15 mg/kg IV. In DB Week 3, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV. Starting with DB Week 4, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 7.5 mg/kg IV Q2W for up to 32 months of treatment.
11604673|NCT00614393|Experimental|Dalotuzumab 10 mg/kg Q1W (OL)|In the OL portion of the study, ≥6 participants receive cetuximab 400 mg/m^2 Q1W+ irinotecan Q1W at their pre-study dosage + OL dalotuzumab 10 mg/kg IV Q1W to verify the safety of the regimen. In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 10 mg/kg IV Q1W for up to 32 months of treatment.
11604674|NCT00614393|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (DB)|In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. In DB Week 2, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV + DB dalotuzumab 15 mg/kg IV. In DB Week 3, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV. Starting with DB Week 4, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 7.5 mg/kg IV Q2W for up to 32 months of treatment.
11604675|NCT00614393|Active Comparator|Placebo + Cetuximab + Irinotecan (DB)|In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB normal saline (placebo) IV Q1W for up to 32 months of treatment.
11604676|NCT00614354|Experimental|1|
11604677|NCT00614341|Active Comparator|1, 2|"Pulse MedRelief SE 55
~Continuous MedRelief SE 55"
11604678|NCT00614328|Active Comparator|1|Naltrexone (50 mg once a day) + placebo baclofen + behavioral therapy (n=10)
11604679|NCT00614328|Active Comparator|2|Placebo naltrexone + baclofen (10 mg t.i.d) + behavior therapy (n=10)
11604680|NCT00614328|Active Comparator|3|Baclofen (10 mg t.i.d) + naltrexone (50 mg once per day) + behavior therapy (n=10)
11604681|NCT00614328|Placebo Comparator|4|Placebo baclofen + placebo naltrexone + behavior therapy
11604682|NCT00614315|Experimental|FLAIR Endovascular Stent Graft and Delivery System|
11604683|NCT00614276||Phase I - Focus Groups|
11604684|NCT00614276||Phase II TENDRILS|Phase II - TENDRILS Program only.
11604685|NCT00614276||Phase II TENDRILS + Counseling|Phase II - TENDRILS + Sexual Counseling Sessions.
11604686|NCT00614263||Blinded Group|SEDline output is unknown to anesthesiologist.
11604687|NCT00614263||Unblinded Group|SEDline output is known to anesthesiologist.
11604688|NCT00614250|Experimental|Dose Level 1|
11604689|NCT00614250|Experimental|Dose Level 2|
11604690|NCT00614250|Experimental|Dose Level 3|
11604691|NCT00614250|Experimental|Dose Level 4|
11604692|NCT00614250|Placebo Comparator|Placebo|12 subjects: 3 subjects per dose level
11604693|NCT00614224|Experimental|A|Treadmill training group (TAEX)
11604694|NCT00614224|Active Comparator|B|Attention control group (CON)
11604695|NCT00614211|Active Comparator|1|Total Abdominal Radical Hysterectomy
11604696|NCT00614211|Experimental|2|Total Laparoscopic or Robotic Radical Hysterectomy
11604697|NCT00614198|Experimental|Gluten- and casein-free diet|Stage 1: Gluten- and casein-free dietary intervention for first 8 or 12 months. 8 or 12 months: Interim analysis based on surpassing statistical thresholds. If showed group significant improvements then progressed to stage 2 (continued on a gluten- and casein-free diet for a further 12 months).
11604698|NCT00614198|No Intervention|No dietary intervention|Stage 1: No special dietary intervention for first 8 or 12 months. 8 or 12 months: Interim analysis based on surpassing statistical thresholds. If gluten- and casein-free dietary group showed group significant improvements then progressed to stage 2 (introduction of a gluten- and casein-free diet for 12 months).
11604699|NCT00614172|Experimental|Proton Radiotherapy|Two week course of proton radiotherapy to the breast.
11604700|NCT00614159||GI Endoscopy|
11604701|NCT00614146|Experimental|1|
11604702|NCT00614146|Active Comparator|2|
11604703|NCT00614133|Experimental|1|Preoperative nutrition.
11604704|NCT00614133|Active Comparator|2|Preoperative fasting.
11604705|NCT00614120|Experimental|Lira 0.6 + Met|Liraglutide 0.6 mg + metformin + glimepiride placebo
11604706|NCT00614120|Experimental|Lira 1.2 + Met|Liraglutide 1.2 mg + metformin + glimepiride placebo
11604707|NCT00614120|Experimental|Lira 1.8 + Met|Liraglutide + metformin + glimepiride placebo
11604708|NCT00614120|Experimental|Glim + Met|Glimepiride 4.0 mg + metformin + liraglutide placebo
11604709|NCT00614081|Experimental|1|Renal transplant recipients
11604710|NCT00614068|Experimental|A|Participants will receive 12 sessions of trauma-focused cognitive behavioral therapy over 3 months.
11604711|NCT00614068|Active Comparator|B|Participants will receive 12 sessions of treatment as usual over 3 months.
11604712|NCT00614055|Active Comparator|Insulin glargine|
11604713|NCT00614055|Experimental|SIAC 30 (B)|
11604714|NCT00614055|Experimental|SIAC 45 (B)|
11604719|NCT00614029|Experimental|D|IMITREX-abd to Intraject-abd to IMITREX-arm. to Intraject-arm.
11604720|NCT00614029|Experimental|E|IMITREX-arm to Intraject-arm to IMITREX-thigh to Intraject-thigh
11604721|NCT00614029|Experimental|F|Intraject-thigh to IMITREX-thigh to Intraject-arm to IMITREX-arm
11604722|NCT00614016|Experimental|single|8 subjects total (6 active and 2 placebo)
11604723|NCT00614003|Experimental|1|decision support
11604724|NCT00613964|Placebo Comparator|Standard Therapy|Standard heart failure therapy excluding carperitide administration
11604725|NCT00613964|Active Comparator|Carperitide Therapy|Addition of carperitide administration to standard heart failure therapy
11604726|NCT00613951|Experimental|SIAC 30 (B)|
11604727|NCT00613951|Experimental|SIAC 45 (B)|
11604728|NCT00613951|Active Comparator|BIAsp 30|
11604729|NCT00613938|Placebo Comparator|004|placebo 1 capsule q4-6 hrs for 3 days
11604730|NCT00613938|Active Comparator|003|oxycodone 10mg capsule q4-6 hrs for 3 days
11604731|NCT00613938|Experimental|001|Tapentadol (CG5503) 50mg capsule q4-6 hrs for 3 days
11604732|NCT00613938|Experimental|002|Tapentadol (CG5503) 75mg capsule q4-6 hrs for 3 days
11604733|NCT00613925|Active Comparator|Pipelle Group|Women were randomized to have an endometrial biopsy collected using Pipelle de Cornier instrument.
11604734|NCT00613925|Active Comparator|Explora group|Women were randomized to have an endometrial biopsy collected using Explora curette instrument.
11604735|NCT00613912||A|Ambulant patients with major depression
11604736|NCT00613899|Other|Telesurveillance|"At time of discharge from hospital, 40 ALS patients willbe enrolled in a telesurveillance program (TP) for the management of cought at home.
~Two hours of an in-hospital educational training will be provided to patients and caregivers on the use of:
~air stacking with Ambu balloon
~manual manoeuvres and
~in-Exoflator device indications and use"
11604737|NCT00613886|Experimental|1|Subjective comparisons made for patients - before and after external lumbar drain, before and after shunt surgery
11604738|NCT00613873||1|Women participating in a community based mammography or cervical screening program will also participate in colonoscopy screening. Participation will be measured by stating an interest in colorectal cancer screening and then following through with colonoscopy screening. Furthermore we will assess whether those complying with colonoscopy will also recommend colonoscopy screening for their spouses or household members.
11604739|NCT00613847|Active Comparator|1|Patients with invasive solid tumors
11604740|NCT00613847|Active Comparator|2|Patients with advanced solid tumors that express HER2 with tumors that are HER2 1+ by IHC or FISH.
11604741|NCT00613834|Experimental|Lidocaine group|Participants receive transcervical instillation of 5 ml 4% lidocaine solution 3 minutes prior to transcervical tubal sterilization
11604742|NCT00613834|Placebo Comparator|Control group|Participants receive transcervical instillation of 5 ml saline 3 minutes prior to transcervical tubal sterilization
11604743|NCT00613821|Experimental|Lidocaine infusion|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
11604744|NCT00613821|Active Comparator|Paracervical block only|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
11604745|NCT00613808|No Intervention|A - Standard of Care (control)|Standard of care - dressings and sustained compression only for the two week screening period and then for 20 weeks thereafter
11604746|NCT00613808|Active Comparator|B Same treatment for 6 weeks, 200ppm NO gas|Subjects were treated by topical application of 200ppm Nitric Oxide gas delivered to the wound area for 8 hours per day for 6 weeks
11604747|NCT00613795|Active Comparator|1|Lactobacillus
11604748|NCT00613795|Placebo Comparator|2|placebo
11604749|NCT00613782|Active Comparator|1|Reandron 100 treatment
11604750|NCT00613782|Placebo Comparator|2|Placebo
11604751|NCT00613769|Active Comparator|ordinary per operative prophylaxis|cefuroxime(1500mg) i.v.+ metronidazole (1500mg)i.v.given at the time point of induction of anesthesia
11604752|NCT00613769|Experimental|Per oral alternative|Trimethoprim-sulfamethoxazole(160mg/800mg)p.o.+metronidazole (1200mg)p.o.given 06.00 am on the day of operation
11604753|NCT00613743|Placebo Comparator|1|D1-D3 receive placebo
11604754|NCT00613743|Active Comparator|2|receive D1 D3 morphine
11604755|NCT00613730|Experimental|Gemcitabine + panitumumab|Panitumumab 6 mg/kg was administered intravenously (IV) before gemcitabine on Day 1 of Weeks 1, 3, 5, and 7, and then every 2 weeks (day 1 and 15) of each subsequent 4-week chemotherapy cycle. Gemcitabine 1000 mg/m^2 was administered IV once weekly (on Day 1) for 7 weeks, followed by a 1-week rest period. In subsequent cycles, gemcitabine was given once weekly (on Day 1) for 3 consecutive weeks followed by 1 week of rest. Panitumumab and gemcitabine treatment continued until disease progression, unacceptable adverse events, death, or study withdrawal occurred.
11604756|NCT00613717|Experimental|a|pre- and early postnatal iron
11604757|NCT00613717|Experimental|b|iron prenatal only
11604758|NCT00613717|Experimental|c|iron early postnatal only
11604759|NCT00613717|Active Comparator|d|no iron pre- or postnatal
11604760|NCT00613691|Experimental|SPI-1620|SPI-1620 an endothelin B agonist
11604761|NCT00613678|Active Comparator|1|Exercise + Education: Eight group sessions (8-15 people) during which participants engage in muscular strength and flexibility exercises. In addition, weekly educational lectures on topics germane to osteoarthritis management are included.
11604762|NCT00613678|Experimental|2|Exercise + Activity Strategy Training: 7/8 sessions will be in a group format in which participants engage in muscular strength & flexibility exercises and listen to education lessons on management strategies for osteoarthritis. The remaining session includes a home assessment by an occupational therapist to facilitate adequate participation in daily living and leisure activities.
11604763|NCT00613665|Experimental|1|
11604764|NCT00613665|Experimental|2|
11604765|NCT00613665|Experimental|3|
11604766|NCT00613665|Experimental|4|
11604767|NCT00613665|Placebo Comparator|5|
11604768|NCT00613665|Experimental|6|
11604769|NCT00613665|Experimental|7|
11604858|NCT00612950|Experimental|GIP|
11604859|NCT00612950|Placebo Comparator|saline|
11604860|NCT00612924|Experimental|Anaconda|
11604861|NCT00612911||Major group|Patients with Idiopathic dilated cardiomyopathy
11604770|NCT00613626|Placebo Comparator|Arm A: ZD6474 Matched Placebo|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 matched placebo oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
11604771|NCT00613626|Active Comparator|Arm B: ZD6474|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
11604772|NCT00613626|Experimental|Safety Lead-In|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator. The safety lead-in will be conducted to determine the safety of the combination of ZD6474 and cisplation + etopiside. If this combination is found to be unsafe, no patients will be randomized in the Phase II portion of the trial. If the combination is deemed safe according to the protocol, participants from the safety lead-in cohort will not be included in the efficacy analysis.
11604773|NCT00613613||1|High drug metabolism genotype All receive fenofibrate
11604774|NCT00613613||2|Low drug metabolism genotype All receive fenofibrate
11604775|NCT00613600|Experimental|1|Two 665 mg capsules of glucomannan three times a day for eight weeks
11604776|NCT00613600|Placebo Comparator|2|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
11604777|NCT00613548|Active Comparator|1|CABG Alone
11604778|NCT00613548|Active Comparator|2|CABG + Mitral repair
11604779|NCT00613535|Active Comparator|Lavage debridement to remove loose fragments|Articular cartilage defect left untreated by surgical tool during partial meniscectomy
11604780|NCT00613535|Active Comparator|Mechanical Debridement|Remove large chondral flaps and loose fragments
11604781|NCT00613535|Active Comparator|RF based Debridement|Debridement to remove loose fragments followed by use of Paragon T-2 RF wand to smooth the base of the shoulder of the tear
11604782|NCT00613522||case|Fist ischaemic hemispheric stroke or TIA
11604783|NCT00613522||control|No ischaemic hemispheric stroke or TIA
11604784|NCT00613509|Experimental|Study Group 1: ALVAC melanoma vaccine|Participants will receive a multi-antigen of modified canarypox virus (ALVAC[2]) melanoma vaccine and granulocyte macrophage colony stimulating factor (GM-CSF) every 3 weeks, followed by 4 weeks of high-dose interferon alpha-2b 5 times per week.
11604785|NCT00613509|Active Comparator|Study Group 2: Interferon alpha-2b|Participants on 4 weeks of high-dose interferon alpha-2b 5 times per week. Participants who showed disease progression after Cycle 1 will be permitted to cross over to Group 1 treatment.
11604786|NCT00613496|Placebo Comparator|2|Placebo treatment in each patient during the study (9 weeks) using an intraindividual cross-over design
11604787|NCT00613496|Active Comparator|1|Irbesartan treatment in each patient during the study (9 weeks) using an intraindividual cross-over design
11604788|NCT00613470|Experimental|Citalopram and escitalopram|"Citalopram tablet or solution starting at 20 mg, increase to 40 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5.
~Escitalopram tablets starting at 10 mg, increase to 20 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5."
11604789|NCT00613457|Experimental|I|o Arm I (closed to accrual as of 6/30/2006): Patients receive prednisone (PRED) on days 8-28.
11604790|NCT00613457|Experimental|II|o Arm II (closed to accrual as of 6/30/2006): Patients receive dexamethasone (DEXA) on days 8-28.
11604791|NCT00613457|Experimental|Reintensification Arm I|o Arm I (standard reinduction therapy, protocol II [closed to accrual as of 6/30/2006]): SR and IR patients receive DEXA on days 1-22; VCR and doxorubicin hydrochloride (DOX) in weeks 2-5; ASP on days 8, 11, 15, and 18; CPM on day 36; ARA-C and thioguanine (TG) on days 36-49; and MTX IT on days 38 and 45. Patients then proceed to maintenance therapy.
11604792|NCT00613457|Experimental|Reintensification Arm II|• Arm II (reduced-intensity reinduction therapy, protocol III [closed to accrual as of 6/30/2006]): SR patients receive DEXA on days 1-15; VCR and DOX on days 1 and 8; ASP on days 1, 4, 8, and 11; CPM on day 15; ARA-C and TG on days 15-28; and MTX IT on days 16 and 23. Patients then proceed to maintenance therapy.
11604793|NCT00613457|Experimental|Reintensification Arm III|• Arm III (reduced-intensity reinduction/second delayed reinduction therapy [double reintensification therapy] [closed to accrual as of 6/30/2006]): IR patients receive reduced-intensity reintensification therapy as in arm II. After a 10-week interim maintenance phase, treatment repeats once for a second delayed course of reintensification therapy. Patients then proceed to maintenance therapy.
11604794|NCT00613457|Experimental|Reintensification Arm IV|"• Arm IV (standard reintensification therapy [closed to accrual as of 6/30/2006]): HR patients receive one sequence of the following HR therapy elements, in this order: 1, 2, 3, following standard reinduction therapy protocol II repeated twice after a four weeks Interim Maintenance phase. Patients then proceed to maintenance therapy.
~Element HR-1: Patients receive DEXA on days 1-5; VCR on days 1 and 6; ARA-C twice on day 5; MTX and CPM every 12 hours on days 2-4 (5 doses); ASP on day 6 ; and MTX/ARA-C/PRED IT on day 1.
~Element HR-2: Patients receive DEXA on days 1-5; vindesine on days 1 and 6; DNR on day 5; MTX and ifosfamide every 12 hours on days 2-4 (5 doses); ASP on day 6; and MTX/ARA-C/PRED IT on day 1.
~Element HR-3: Patients receive DEXA on days 1-5; ARA-C every 12 hours on days 1-2 (4 doses); etoposide five times daily on days 3-5; ASP on day 5; and MTX/ARA-C/PRED IT on day 1."
11604795|NCT00613457|Experimental|Reintensification Arm V|"• Arm V (extended reintensification therapy [triple protocol III] [closed to accrual as of 6/30/2006]): HR patients receive HR therapy elements 3, 2, and 1 following reintensification therapy repeated the therapy element three times with 4-week interim maintenance phases in between. Patients then proceed to maintenance therapy.
~Interim maintenance/maintenance therapy: Patients receive MTX once weekly and MP daily until week 104 plus IT MTX every eight weeks.
~Radiotherapy: HR patients or patients with T-cell acute lymphoblastic leukemia or CNS disease undergo CNS radiotherapy."
11604862|NCT00612898|Experimental|1|800mg BID apricitabine plus optimised background
11604863|NCT00612898|Active Comparator|2|150mg BID lamivudine plus optimised background
11604864|NCT00612872|Experimental|Assess [123-I]CLINDE and brain imaging|Subjects will be injected with up to 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) of 123-I CLINDE followed by serial SPECT imaging.
11604865|NCT00612846|Experimental|A|
11604796|NCT00613444|Experimental|LumaCare LC-122M non-coherent light source|"Split Face Comparison. One half of subject's face will receive topical photosensitizer applications followed by LumaCare LC-122M non-coherent light source illumination. Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.
~The other half of the face will not receive any treatment and will serve as internal control."
11604797|NCT00613431|Experimental|1|6 dose groups, 9 subjects on active, 3 subjects on placebo in each group
11604798|NCT00613431|Placebo Comparator|2|3 subjects on placebo in each group
11604799|NCT00613418|Other|single|Historical control
11604800|NCT00613405|Experimental|Stress + cue exposure|Individuals were exposed to the Trier Social Stress Test (TSST) as well as neutral cues and marijana cues.
11604801|NCT00613405|Experimental|No stress + cue exposure|Individuals were not exposed to a stress test, but were exposed to neutral cues and marijuana cues.
11604802|NCT00613392|Experimental|1|
11604803|NCT00613392|Placebo Comparator|2|
11604804|NCT00613379|Experimental|Arm 1|10 mg/kg PRO 140, one IV dose (N=10)
11604805|NCT00613379|Experimental|Arm 2|5 mg/kg PRO 140, one IV dose (N=10)
11604806|NCT00613379|Placebo Comparator|Arm 3|Placebo, one IV dose (N=10)
11604807|NCT00613366|Experimental|Misoprostol|Cervical preparation with misoprostol prior to intrauterine device insertion
11604808|NCT00613366|Placebo Comparator|Placebo|Cervical preparation with placebo prior to intrauterine device insertion
11604809|NCT00613353||I|Caucasian and African American females between the ages of 18 and 65.
11604810|NCT00613340|Experimental|1|Cervical medial branch blocks with 0.25 ml of injectate
11604811|NCT00613340|Experimental|2|Cervical medial branch blocks with 0.5 ml of local anesthetic and contrast
11604812|NCT00613327|Experimental|Oxybutynin Chloride OROS|
11604813|NCT00613288|Experimental|A|
11604814|NCT00613249|Experimental|A|
11604815|NCT00613249|Experimental|B|
11604816|NCT00613249|Placebo Comparator|C|
11604817|NCT00613223|Experimental|Vandetanib and Etoposide|Patients will be stratified based on whether they are receiving an enzyme-inducing anti-epileptic drug (EIAED). The dose level of vandetanib will be increased in successive cohorts of subjects. Etoposide will be given daily at a dose of 50 mg/ day for 21 days followed by 7 days with no etoposide.
11604818|NCT00613210||1|women without contraction at 24-34 weeks of gestation
11604819|NCT00613210||2|women without contractions between 24-34 weeks of gestation with a history of preterm labor
11604820|NCT00613210||3|women with preterm contractions 24-34 weeks of gestation
11604821|NCT00613197|Experimental|1 Epanova|
11604822|NCT00613197|Placebo Comparator|2 Placebo|
11604823|NCT00613184|Experimental|1|Nylon Flocked swab Left Nasal Wash right
11604824|NCT00613184|Experimental|2|Nylon Flocked swab R Nasal Wash L
11604825|NCT00613184|Experimental|3|Nasal Wash Left Nylon Flocked swab Right
11604826|NCT00613184|Experimental|4|Nasal Wash R Nylon flocked swab L
11604827|NCT00613171|Experimental|1|
11604828|NCT00613158||1|Participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with significant subclinical atherosclerosis (SA) and a low Framingham risk score
11604829|NCT00613158||2|Participants from MESA with no SA and a low Framingham risk score
11604830|NCT00613158||3|Healthy participants from Northwestern University
11604831|NCT00613145|Active Comparator|A|Treatment with Capecitabine and Sorafenib
11604832|NCT00613145|Active Comparator|B|Treatment with Capecitabine and Sorafenib
11604833|NCT00613132|Experimental|1|Pts receiving EIACDs
11604834|NCT00613132|Experimental|2|Pts not receiving EIACDs
11604835|NCT00613106|Experimental|HZT-501|HZT-501: ibuprofen 800mg/famotidine 26.6mg
11604836|NCT00613106|Active Comparator|Ibuprofen|Ibuprofen 800mg
11604837|NCT00613093|Active Comparator|Patients with glioblastoma multiforme|
11604838|NCT00613093|Active Comparator|Patients with Anaplastic Glioma|
11604839|NCT00613080|Other|IMRT + Chemotherapy , Resection, Postoperative Chemotherapy|Radiation therapy (intensity modulated radiation therapy [IMRT] + three dimensional conformal radiation therapy [3D-CRT]) + neoadjuvant chemotherapy (capecitabine and oxaliplatin) followed by resection and postoperative chemotherapy (FOLFOX)
11604840|NCT00613067|Experimental|GAD|35 patients with Generalized Anxiety disorder
11604841|NCT00613054|Experimental|Zactima + Gleevec + Hydrea|
11604842|NCT00613041||1|Patients with one or more pulmonary nodules 5-15 mm in diameter.
11604843|NCT00613028|Experimental|Temo + Avastin|Patients treated with bevacizumab + temozolomide
11604844|NCT00613028|Experimental|VP-16 + Avastin|Patients treated with bevacizumab and VP-16 (etoposide)
11604845|NCT00613015|Experimental|Modafinil/Stress|Participants received placebo for 2 days. modafinil on the third day and participated in the TRIER social stress task on the third day.
11604846|NCT00613015|Experimental|Modafinil/no stress|Participants received placebo for 2 days. modafinil on the third day and did not participate in the TRIER social stress task on the third day.
11604847|NCT00613015|Experimental|Guanfacine/stress|Participants received guanfacine for 3 days and participated in the TRIER social stress task on the third day.
11604848|NCT00613015|Experimental|Guanfacine/no stress|Participants received guanfacine for 3 days and did not participate in the TRIER social stress task on the third day.
11604849|NCT00613015|Placebo Comparator|Placebo/Stress|Participants received placebo for 3 days and participated in the TRIER social stress task on the third day.
11604850|NCT00613015|Placebo Comparator|Placebo/no stress|Participants received placebo for 3 days and did not participate in the TRIER social stress task on the third day.
11604851|NCT00613002|Experimental|testosterone gel|1% testosterone transdermal gel
11604852|NCT00613002|Placebo Comparator|placebo gel|placebo transdermal gel
11604853|NCT00612989|Experimental|1|Schedule 1
11604854|NCT00612989|Experimental|2|Schedule 2
11604855|NCT00612989|Experimental|3|Schedule 2, Neulasta-supported
11604856|NCT00612976||1|Patients with COPD treated with budesonide/formoterol
11604857|NCT00612950|Experimental|GLP-1|
11604867|NCT00612833|Active Comparator|cautery excision with fascial interposition|Contraception using cautery and excision with fascial interposition
11604868|NCT00612833|Active Comparator|B|Cautery and excision without fascial interposition
11604869|NCT00612833|Active Comparator|C|Ligation and excision with fascial interposition
11604870|NCT00612807|Active Comparator|Control|Medication management with a study doctor every other week.
11604871|NCT00612807|Experimental|Combination|Medication management with a study doctor every other week plus weekly marital therapy.
11604872|NCT00612794|Experimental|1|exenatide once weekly, 0.8mg
11604873|NCT00612794|Experimental|2|exenatide once weekly, 2.0mg
11604874|NCT00612794|Placebo Comparator|3|volume equivalent to 0.8mg of exenatide once weekly
11604875|NCT00612794|Placebo Comparator|4|volume equivalent to 2.0mg of exenatide once weekly
11604876|NCT00612781|Other|A|
11604877|NCT00612781|Other|B|
11604878|NCT00612768|Experimental|T.R.U.E. Test allergens Fragrance Mix and Thimerosol|"Concordance (agreement) between positive patch reactions to
~fragrance mix (0.43 mg/cm2) in polyvinylpyrrolidone (PVP) vs fragrance mix (0.43 mg/cm2) in hydroxypropylcellulose (HPC)
~thimerosol (0.008 mg/cm2) in polyvinylpyrrolidone (PVP) vs thimerosol (0.008 mg/cm2) in hydroxypropylcellulose (HPC)
~fragrance mix T.R.U.E. Test allergen vs fragrance mix reference allergen (petrolatum)
~thimerosol T.R.U.E. Test allergen vs thimerosol reference allergen (petrolatum)
~will be measured"
11604879|NCT00612755|Experimental|1|Peginterferon alfa-2a 180 mcg/week + 1000-1200 mg/day ribavirin during 24 weeks
11604880|NCT00612755|No Intervention|2|
11604881|NCT00612742|Experimental|testosterone gel|1% testosterone transdermal gel
11604882|NCT00612742|Placebo Comparator|placebo gel|placebo transdermal gel
11604883|NCT00612716|Experimental|Allogeneic Transplantation|Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.
11604884|NCT00612690|Experimental|Links to Learning|Participants received the community mental health consultation model program.
11604885|NCT00612690|Active Comparator|Services as Usual|Participants received treatment as usual and referrals.
11604886|NCT00612677|Experimental|Premetrexed and Oxaliplatin|Patients will be treated with oxaliplatin 120 mg/m^2 i.v. over 2 hours and pemetrexed 500 mg/m^2 i.v. over 10 minutes on Day 1 of a 21day cycle. Cycles of treatment will be repeated every 3 weeks. Folic acid and B12 supplementation is obligatory.
11604887|NCT00612664|Active Comparator|Arm 1|0.1 mg/kg every 3 weeks
11604888|NCT00612664|Active Comparator|Arm 2|1 mg/kg every 3 weeks
11604889|NCT00612664|Active Comparator|Arm 3|1 mg/kg every 6 weeks
11604890|NCT00612664|Active Comparator|Arm 4|5 mg/kg every 3 weeks
11604891|NCT00612651|Other|enzyme-inducing anti-epileptic drugs (EIAEDs)|Patients receiving enzyme-inducing anti-epileptic drugs (EIAEDs)such as carbamazepine, phenobarbitol, phenytoin, phosphenytoin, oxcarbamazepine, primadone)
11604892|NCT00612651|Other|no enyzme-inducing anti-epileptic drugs|Patients on non CYP3A4-inducing anti-convulsants or patients not on any anti-convulsants.
11604893|NCT00612638|Experimental|1|Pts receiving Dilantin, Tegretol or Phenobarbital
11604894|NCT00612638|Experimental|2|Pts on anti-convulsants other than Dilantin, Tegretol / Phenobarbital / pts not on any anti-convulsants
11604895|NCT00612625|Experimental|GLP-1|A graded glucose infusion with an infusion of GLP-1 (1½ pmol/kg/min)
11604896|NCT00612625|Experimental|Saline|A graded glucose infusion together with a continuous infusion of saline
11604897|NCT00612612|Experimental|Treatment (obatoclax mesylate, fludarabine, rituximab)|"Patients receive obatoclax mesylate IV over 3 hours on days 1 and 3, fludarabine IV over 20-30 minutes on days 1-5, and rituximab IV over 4 hours on day 1 (days 1 and 3 of course 1 only). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~Patients undergo peripheral blood collection for correlative studies. Samples are analyzed for expression of pro- and anti-apoptotic Bcl-2 family members by western blot; apoptosis induction by measurement of lymphocyte count, Annexin V staining, and Caspase and PARP cleavage; activated Bax by immunoprecipitation; and Bax promoter polymorphism by PCR amplification and direct sequencing."
11604898|NCT00612586|Experimental|Enzastaurin + 5-FU/LV + Bev|5-fluorouracil/leucovorin (5-FU/LV) plus bevacizumab (Bev) in combination with enzastaurin
11604899|NCT00612586|Placebo Comparator|Placebo + 5-FU/LV + Bev|5-fluorouracil/leucovorin (5-FU/LV) plus bevacizumab (Bev) in combination with placebo
11604900|NCT00612573|Experimental|Doxycyline 0.6 mg/kg/day|Doxycycline dosed at 40 mg/day to subjects of appropriate weights
11604901|NCT00612573|Experimental|Doxycycline 1.2 mg/kg/day|Doxycycline dosed at 80 mg/day to subjects of appropriate weights
11604902|NCT00612573|Experimental|Doxycycline 2.4 mg/kg/day|Doxycycline dosed at 160 mg/day to subjects of appropriate weights
11604903|NCT00612573|Placebo Comparator|Placebo|
11604904|NCT00612560|Experimental|2|Flaxseed 25 mg per day and 1 placebo pill per day
11604905|NCT00612560|Experimental|3|25 mg flaxseed per day and 1 mg anastrozole pill per day
11604906|NCT00612560|Placebo Comparator|4|Placebo pill 1 per day
11604907|NCT00612560|Experimental|1|Anastrozole 1 mg pill per day
11604908|NCT00612547||Observation|Children under the age of five years (2 months to 5 years) residing in the zone covered by the community-based service provider throughout the entire follow-up period
11604909|NCT00612534|Experimental|1|
11604910|NCT00612534|Experimental|2|
11604911|NCT00612534|Experimental|3|
11604912|NCT00612534|Placebo Comparator|4|
11604913|NCT00612521|Other|1|Either Placebo or Adenosine mixed with normal saline at a concentration of 6 micrograms per milliliter.
11604914|NCT00612521|Other|2|Either Placebo or Adenosine mixed with normal saline at a concentration of 6 micrograms per milliliter.
11604915|NCT00612508|Active Comparator|Desogen|"Drug: ethinyl estradiol and desogestrel
~1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol; secen inactive pills every 28 days.
~Subjects receive baseline vaginal biopsy, followed by treatment with the OC for six cycles and repeat biopsy at 3 and after 6 cycles"
11604979|NCT00612079|Experimental|1|Healthy volunteers with low sensory gating levels.
11604980|NCT00612066|Experimental|Rosiglitazone|
11604981|NCT00612040|Experimental|SIBA (D)|
11604916|NCT00612508|Active Comparator|NuvaRing|"Intravaginal Contraception
~ethinyl estradiol (0.15 mg/d) and etonogestrel (0.12 mg/d) Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
~Subjects had baseline vaginal biopsy followed by 6 cycles of ring use and repeat biopsy at 3 and after 6 cycles"
11604917|NCT00612482|No Intervention|1|"Participants in the no intervention condition will receive the usual high school science curriculum."
11604918|NCT00612482|Experimental|2|"Participants in the experimental arm will receive the 5-lesson, science-based substance abuse prevention curriculum in their science classes."
11604919|NCT00612469|Placebo Comparator|NaF|Sodium fluoride application
11604920|NCT00612469|Experimental|V3|Topical application of 3% vancomycin
11604921|NCT00612469|Experimental|V10|Topical application of 10% vancomycin
11604922|NCT00612469|Active Comparator|CHX|Topical application of 1% chlorhexidine
11604923|NCT00612456|Experimental|Arm 1|Pazopanib eye drops formulation 5 mg/mL daily for 28 days
11604924|NCT00612456|Experimental|Arm 2|Pazopanib eye drop formulation 5mg/mL TID for 28 days
11604925|NCT00612456|Experimental|Arm 3|Pazopanib eye drop formulation 2mg/mL TID for 28 days
11604926|NCT00612443|Experimental|1|non-contact Healing Touch treatment for 20-30 minutes once a week during the course of radiation therapy
11604927|NCT00612443|Sham Comparator|2|A RN graduate assistant will provide a sham treatment of 20-30 minutes of presence.
11604928|NCT00612430|Experimental|Bevacizumab + Etoposide|Grade III and IV patients will receive: Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If patient tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day.
11604929|NCT00612417|Experimental|1|recombinant FVIII
11604930|NCT00612417|Placebo Comparator|2|Placebo
11604931|NCT00612404||1|patients with gastrointestinal disorders who need an endoscopy.
11604932|NCT00612391|Experimental|Lateral, Minimally Invasive Approach|Lateral, Minimally Invasive Approach in GT fractures treated operatively (plates and screws)
11604933|NCT00612391|Active Comparator|Deltopectoral approach:|Deltopectoral approach for GT fracture treated operatively
11604934|NCT00612378|Experimental|1|
11604935|NCT00612365||1|Participants from the Multi-Ethnic Study of Atherosclerosis (MESA) for abdominal aortic calcium (AAC) who have undergone computed tomography (CT) scans of the abdomen
11604936|NCT00612352|Active Comparator|Family HIstory Positive|Subjects with a positive family history of alcoholism.
11604937|NCT00612352|Active Comparator|Family History Negative|Subjects with a negative family history of alcoholism.
11604938|NCT00612339|Experimental|Avastin and Temozolomide|Avastin administered at 10 mg/kg every 2 weeks beginning a minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide dosed at 200 mg/m2 daily for 5 days in a 28-day cycle.
11604939|NCT00612326||1|Patients with newly diagnosed locally or regionally advanced transitional cell carcinoma of the bladder.
11604940|NCT00612313|Active Comparator|Continued medication alone|Participants will receive antidepressant treatment with fluoxetine for 30 weeks
11604941|NCT00612313|Experimental|Continued medication plus CBT|Participants will receive antidepressant treatment with fluoxetine for 30 weeks plus relapse prevention cognitive behavioral therapy for the last 24 weeks of treatment
11604942|NCT00612300|Experimental|A-B|Gait training by an automatic gait trainer (Lokomat) for 3 weeks followed by 3 weeks of categorized gait training by a physical therapist
11604943|NCT00612300|Experimental|B-A|Categorized gait training by physical therapists for 3 weeks followed by 3 weeks of lokomat training
11604944|NCT00612287|Experimental|A|
11604945|NCT00612274|Experimental|1|sirolimus, tacrolimus and short course methotrexate
11604946|NCT00612261|Experimental|1|The group 1 patients receive AV sheathotomy for macular edema secondary to branch retinal vein occlusion.
11604947|NCT00612261|Active Comparator|2|The group 2 patients receive IVTA.
11604948|NCT00612248|Experimental|SG|Study group
11604949|NCT00612248|No Intervention|CG|Control group
11604950|NCT00612235||Lamotrigine Monotherapy|Lamotrigine Monotherapy
11604951|NCT00612235||Levetiracetam Monotherapy|Levetiracetam Monotherapy
11604952|NCT00612235||Carbamazepine Monotherapy|Carbamazepine Monotherapy
11604953|NCT00612235||Normal control (no epilepsy)|Normal control (no epilepsy)
11604954|NCT00612222|Experimental|ALVAC plus anti-MART-1 F5 TCR PBL + HD IL-2|"ALVAC plus anti-MART-1 F5 T cell receptor (TCR ) peripheral blood lymphocytes (PBL) + high dose (HD) interleukin 2 (IL-2): ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 cell culture infectious dose 50% (CCID50) (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.
~Aldesleukin - 720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days."
11604955|NCT00612209|Experimental|1|
11604956|NCT00612196|Experimental|1|
11604957|NCT00612196|Experimental|2|
11604958|NCT00612196|Experimental|3|
11604959|NCT00612196|Experimental|4|
11604960|NCT00612196|Experimental|5|
11604961|NCT00612196|Experimental|6|
11604962|NCT00612196|Experimental|7|
11604963|NCT00612196|Experimental|8|
11604964|NCT00612196|Experimental|9|
11604965|NCT00612196|Placebo Comparator|10|
11604966|NCT00612170|Experimental|3|
11604967|NCT00612170|Sham Comparator|4|
11604968|NCT00612170|Experimental|1|
11604969|NCT00612170|Experimental|2|
11604970|NCT00612157|Active Comparator|OSA CPAP|
11604971|NCT00612157|Placebo Comparator|Placebo|
11604972|NCT00612144|Experimental|1|Amaryl M group
11604973|NCT00612144|Active Comparator|2|Metformin group
11604974|NCT00612105|Experimental|1|Retigabine
11604975|NCT00612105|Placebo Comparator|2|Placebo
11604976|NCT00612092|Experimental|1|Standard spiral CT protocol
11604977|NCT00612092|Active Comparator|2|Sequential CT protocol
11604978|NCT00612079|Experimental|2|Healthy volunteers with high sensory gating levels.
11604984|NCT00612027||1|patients with gastrointestinal disorders and patients with acid associated gastrointestinal symptoms treated with esomeprazole.
11604985|NCT00612014|Placebo Comparator|1|
11604986|NCT00612014|Experimental|2|40 micrograms/kg
11604987|NCT00612014|Experimental|3|80 micrograms/kg
11604988|NCT00612014|Experimental|4|160 micrograms/kg
11604989|NCT00612014|Experimental|5|320 microgram/kg
11604990|NCT00612014|Experimental|6|600 microgram/kg
11604991|NCT00612001|Experimental|dendritic cell vaccine|
11604992|NCT00611988|Experimental|1|The intervention includes individual therapy, group reinforcement, and follow-up phone contact
11604993|NCT00611988|Active Comparator|2|Attention control group will receive routine follow-up phone calls
11604994|NCT00611975|Experimental|A|Participants will receive treatment with fluoxetine for 2 months
11604995|NCT00611975|Experimental|B|Participants will receive treatment with bupropion for 2 months
11604996|NCT00611949|Active Comparator|1 Geranium Oil|
11604997|NCT00611949|Active Comparator|2 Geramium Oil|
11604998|NCT00611936|Placebo Comparator|2|Second arm is placebo
11604999|NCT00611936|Experimental|1|One arm is atomoxetine 40 mg per day
11605000|NCT00611923|Placebo Comparator|B|Participants will take placebo flutamide
11605001|NCT00611923|Experimental|A|Participants will take flutamide
11605002|NCT00611910|Experimental|DES|drug-eluting stents
11605003|NCT00611910|Active Comparator|BMS|bare metal stents
11605004|NCT00611897|Active Comparator|Arm I|The NAC capsules were administered orally in divided doses: 2000 mg followed by 1000 mg 2 hours later. Each morning, 165 min after NAC administration, subjects received a 1-min bolus of normal saline, followed by a 70-minlong saline infusion during which behavioral, cognitive, and ERP data were collected. Ketamine was administered intravenously as a bolus of .23 mg/kg over 1 min followed by .58 mg/kg for 30 min (SPM and RVP), and then .29 mg/kg for 40 min (P300 and MMN).
11605005|NCT00611897|Placebo Comparator|Arm II|The placebo capsules were administered orally in divided doses: 2000 mg followed by 1000 mg 2 hours later. Each morning, 165 min after placebo administration, subjects received a 1-min bolus of normal saline, followed by a 70-minlong saline infusion during which behavioral, cognitive, and ERP data were collected. Ketamine was administered intravenously as a bolus of .23 mg/kg over 1 min followed by .58 mg/kg for 30 min (SPM and RVP), and then .29 mg/kg for 40 min (P300 and MMN).
11605006|NCT00611884|Experimental|SIBA (D)|
11605007|NCT00611884|Experimental|SIBA (E)|
11605008|NCT00611884|Experimental|SIBA (D) M, W, F|
11605009|NCT00611884|Active Comparator|IGlar|
11605010|NCT00611871|Experimental|1|Propranolol following traumatic memory
11605011|NCT00611871|Active Comparator|2|Propranolol following neutral memory
11605012|NCT00611871|Placebo Comparator|3|Placebo following traumatic memory
11605013|NCT00611858|Experimental|Cetuximab, 5-FU and Radiation|"Cetuximab: Participants first receive cetuximab at the initial dose of 400 mg/m2 intravenously (IV) administered over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes. Cetuximab is given as single agent during the first 3 weeks on study and then in combination with 5-FU and radiation.
~Radiation: Radiation therapy given as standard of care is initiated after the 3rd dose of cetuximab with a total dose of 50.4 Gray (Gy) in 28 fractions over approximately 5.5 weeks.
~5-FU: Participants receive 5-Fluorouracil (5-FU) continuous infusion through central venous access at 225 mg/m2/day given 7 days a week starting day 1 of radiation (no later than 3 days) and lasting the duration of radiation therapy.
~Duration of neoadjuvant therapy is estimated to be 9 weeks. Surgery follows at week 13-17. Sigmoidoscopy is performed for biopsy prior to the 1st dose and after 3rd dose of cetuximab before the initiation of radiation and/or 5-FU."
11605014|NCT00611832|Active Comparator|Standard|"Standard information-only version of the television series that includes only modeling and demonstration of the targeted parenting skills"
11605015|NCT00611832|Experimental|Enhanced|"Enhanced behavior activation version of the television series that includes all of the content of the standard information-only version, but is also designed to actively promote parental behavior change, through additional content elements addressing attributions, self-efficacy and expectancies, social support, and emotional reactivity."
11605016|NCT00611832|No Intervention|Control|Waitlist control
11605017|NCT00611819|Experimental|1|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 24 weeks
11605018|NCT00611819|Active Comparator|2|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
11605019|NCT00611806|Active Comparator|Folate with B12|Participants will take folic acid plus B12 for 18 weeks.
11605020|NCT00611806|Placebo Comparator|Placebo|Participants will take placebo for 18 weeks.
11605021|NCT00611793|Experimental|1|PTK787/ZK222584 and Bevacizumab
11605022|NCT00611780|Experimental|1|Reduced tube voltage of 100kV.
11605023|NCT00611780|Active Comparator|2|Standard tube voltage of 120kV.
11605024|NCT00611767|Active Comparator|Family History Negative for Alcoholism|Family History Negative for Alcoholism subjects will receive 2 interventions
11605025|NCT00611767|Placebo Comparator|Family History Positive for Alcoholism|Family History Positive for Alcoholism subjects will receive 2 interventions
11605026|NCT00611741|Experimental|Drug intervention, longitudinal|Furosemide and Na supplements
11605027|NCT00611715|Experimental|First line/hormone-therapy naive|
11605028|NCT00611715|Experimental|Second-line/prev hormone-therapy tx|
11605029|NCT00611689|Experimental|A|Imatinib and PTK/ZK222584
11605030|NCT00611676|Experimental|A|All subjects receive placebo for the first two weeks and then Venlafaxine for the next 10 weeks, but they are blind to what they are receiving
11605031|NCT00611663|Experimental|1|Vaccination with conjugate vaccine Prevenar® (WYETH-LEDERLE) at week 0 and Poly Saccharidic vaccine Pneumo23® (Sanofi Pasteur MSD) after 6 months (W24)
11605032|NCT00611663|Placebo Comparator|2|Vaccination with placebo at W0 and Poly Saccharidic vaccine Pneumo23® at W24
11605033|NCT00611650|Experimental|Arm I|Patients receive oral Polyphenon E twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
11605034|NCT00611650|Placebo Comparator|Arm II|Patients receive a placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
11605035|NCT00611637|Experimental|1|
11606596|NCT00599664|Experimental|1|Drug
11605036|NCT00611624|Experimental|Five Days of Mammosite Therapy|Five Days of Mammosite Therapy (Radiotherapy)
11605037|NCT00611611||1|SLE
11605038|NCT00611611||2|healthy controls
11605039|NCT00611598||1|second primary lung cancer
11605040|NCT00611598||2|single primary lung cancer
11605041|NCT00611585|Other|Hip Resurfacing|Birmingham Hip Resurfacing
11605042|NCT00611572|Active Comparator|1|Active iomazenil and ketamine
11605043|NCT00611572|Placebo Comparator|2|placebo iomazenil and ketamine
11605044|NCT00611559|Experimental|Infanrix hexa Preservative-Free Formulation Group|Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa
11605045|NCT00611559|Active Comparator|Infanrix hexa Preservative-Containing Formulation Group|Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa
11605046|NCT00611559|Active Comparator|Infanrix penta Preservative-Free Formulation Group|Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta.
11605047|NCT00611546|Placebo Comparator|1|Perenteral nutrition bottle and tubing are not protected from light
11605048|NCT00611546|Active Comparator|2|Perenteral nutrition bottle and tubing are protected from light
11605049|NCT00611533|Active Comparator|Atomoxetine|Subjects were enrolled into a double-blind, placebo-controlled cross over study where they will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks or placebo (PBO) for 6 weeks, followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week. Subjects undergo assessments of cognition, mood, and menopausal symptoms prior to randomization, after 6 weeks in the first treatment condition (ATX or PBO) and then finally after the second 6-week period of the alternate treatment condition. Subjects are monitored every other week to assess medication compliance and side effects. Subjects will be instructed to take one capsule of ATX 40mg/d or placebo per day. If tolerated, the number of pills of ATX will be increased to 2 per day at the end of Week 1 of both Trials A and B. Subjects will remain on two capsules per day for the remaining 5 weeks of Trials A and B.
11605050|NCT00611533|Placebo Comparator|Placebo|Subjects were enrolled into a double-blind, placebo-controlled cross over study where they will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks or placebo (PBO) for 6 weeks, followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week. Subjects undergo assessments of cognition, mood, and menopausal symptoms prior to randomization, after 6 weeks in the first treatment condition (ATX or PBO) and then finally after the second 6-week period of the alternate treatment condition. Subjects are monitored every other week to assess medication compliance and side effects. Subjects will be instructed to take one capsule of ATX 40mg/d or placebo per day. If tolerated, the number of pills of ATX will be increased to 2 per day at the end of Week 1 of both Trials A and B. Subjects will remain on two capsules per day for the remaining 5 weeks of Trials A and B.
11605051|NCT00611520||1|Patients with COPD treated with budesonide/formoterol
11605052|NCT00611494|Active Comparator|A|MMF
11605053|NCT00611494|Active Comparator|B|EC-MPS
11605054|NCT00611481|Experimental|Tai Chi|
11605055|NCT00611481|Active Comparator|B. Strength training|
11605056|NCT00611481|Other|C. Low-Impact|
11605057|NCT00611468|Experimental|Intravenous Topotecan and Oral Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
11605058|NCT00611455|Experimental|ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
11605059|NCT00611455|Placebo Comparator|1000 ml Saline|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
11605060|NCT00611442|Active Comparator|1|split-dose PEG solution without dietary restrictions plus lubiprostone 24mcg gelcap pretreatment
11605061|NCT00611442|Placebo Comparator|2|split-dose PEG solution without dietary restrictions plus placebo pretreatment
11605062|NCT00611429|Experimental|Group A|Participants will receive treatment consisting of at least three individual counseling sessions and one group workshop over 12 months
11605063|NCT00611429|Active Comparator|Group B|Participants will receive treatment consisting of one individual counseling session and one group workshop during the last month of the study
11605064|NCT00611416|Experimental|1|Active treatment A
11605065|NCT00611416|Experimental|2|Active treatment B
11605066|NCT00611416|Experimental|3|Active treatment C
11605067|NCT00611416|Active Comparator|4|Positive control
11605068|NCT00611416|Placebo Comparator|5|Placebo
11605069|NCT00611403|Active Comparator|RESTASIS®|Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)
11605070|NCT00611403|Active Comparator|REFRESH ENDURA®|Artificial Tears (REFRESH ENDURA®)
11605071|NCT00611390|Active Comparator|1|treatment with spray containing aromatic essential oils of some herbal plants.
11605072|NCT00611390|Placebo Comparator|2|spray containing placebo.
11605073|NCT00611377||1|
11605074|NCT00611364|Experimental|Study group|
11605075|NCT00611364|Active Comparator|Control group|
11605076|NCT00611351|Experimental|Unrelated Donor Allogeneic|Matched unrelated donor allogeneic stem cell transplantation with a conditioning regimen of targeted busulfan, cyclophosphamide and thymoglobulin.
11605077|NCT00611338|Active Comparator|Standard of Care, Wait-List Control|Participants received standard medical care, which in most clinics included informational brochures provided by physicians and clinic staff. Participants were given HIV prevention information and materials in English and Spanish and were provided referrals for services. Each individual completed assessments at immediate post intervention, 3-, 6-, and 12- months. At the end of the 12-month assessment, the wait-list control participants participated in the Trauma + HIV group arm.
11605123|NCT00610961||Thymoglobulin Induction|Retrospective (historical or control) group: patients have already received a kidney transplant and were treated with Thymoglobulin®, Myfortic®, and Prograf® with or without steroids. This treatment was Standard of Care at a time of transplant.
11605208|NCT00610428|Placebo Comparator|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
11605078|NCT00611338|Active Comparator|HIV Prevention|Eight, 90 minute group sessions. Three of the sessions focused on health education (e.g., medication adherence, nutrition, exercise) and five focused on HIV prevention skills (e.g., condom skills, communication, social support). Each individual completed assessments at immediate post intervention, 3-, 6-, and 12- months. At the end of the 12-month assessment, the participants in this arm were given the option to receive the 3 trauma-focused sessions from the Trauma + HIV group arm.
11605079|NCT00611338|Active Comparator|HIV Prevention plus Trauma|The same format as the HIV Prevention arm with eight, 90 minute group sessions. The participants received the same five HIV prevention skills sessions along with three sessions that focused on reducing trauma-related stress (e.g., breathing training, relaxation exercises, grounding exercises, coping, trauma-related triggers). Each individual completed assessments at immediate post intervention, 3-, 6-, and 12- months.
11605080|NCT00611325|Experimental|EIAED|Patients taking enzyme-inducing anti-epileptic drugs (EIAEDs). Avastin was administered intravenously at a dose of 15 mg/kg every 3 weeks. Bortezomib was adminstered intravenously at a dose of 2.5 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day cycle.
11605081|NCT00611325|Experimental|Non-EIAED|Patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs). Avastin was administered intravenously at a dose of 15 mg/kg every 3 weeks. Bortezomib was adminstered intravenously at a dose of 1.7 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day cycle.
11605082|NCT00611312|Experimental|1|Cognitive Training
11605083|NCT00611286|Experimental|1|treatment with Aspirin and clopidogrel for 24 months after coronary intervention with stents. This group of patients will be randomized in a 1:1:1:1 ratio to receive bare metal stent, Zotarolimus-eluting stent, paclitaxel-eluting stent or everolimus-eluting stent.
11605084|NCT00611286|Active Comparator|2|Treatment with aspirin and clopidogrel for minimum 1 or 6 month(s) after BMS or DES implantation, respectively. This group of patients will be randomized in a 1:1:1:1 ratio to receive bare metal stent, Zotarolimus-eluting stent, paclitaxel-eluting stent or everolimus-eluting stent
11605085|NCT00611273|Experimental|1|Patients who have presented to the investigator for correction of glabellar furrows, as classified per the Rated Numeric Kinetic Line Scale Score for Facial Wrinkles Secondary to Hyperkinetic Function (Note: Class 1 or Higher)7 (Appendix R) are candidates for this study.
11605086|NCT00611260|Experimental|Meditation Cohort|25 patients will be given instruction in vipassana meditation. Vipassana meditation is thought to reduce the incidence of atrial and ventricular arrhythmias in patients with congestive heart failure, and improve their overall psychological profile.
11605087|NCT00611260|Active Comparator|Standard Care|25 patients will receive current standard of care to manage their congestive heart failure, implanted cardiac devices, and psychological health.
11605088|NCT00611247|Experimental|Methylated AGAT Promoter (Group 1)|Induction: 200 mg/m2/day oral Temozolomide x 7 days
11605089|NCT00611247|Experimental|Un-Methylated AGAT Promoter (Group 2)|Priming: 100 mg/m2/day oral Temozolomide x 14 days, followed by Induction: 200 mg/m2/day oral Temozolomide x 7 days
11605090|NCT00611221|Active Comparator|1|Massage therapy by a regulated massage therapist
11605091|NCT00611221|Active Comparator|2|Massage by anyone else, eg. husband, nurse, doula
11605092|NCT00611208|Experimental|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diptheria toxin)
11605093|NCT00611195|Other|1|Larynx assessment under stimulation
11605094|NCT00611182||1|Patients with Pulmonary Fibrosis
11605095|NCT00611169|Experimental|1|Aspirin, clopidogrel, unfractionated heparin plus tirofiban infusion at high bolus dose
11605096|NCT00611169|No Intervention|2|Aspirin, clopidogrel, unfractionated heparin
11605097|NCT00611156|Experimental|A|Spice
11605098|NCT00611156|Experimental|B|Spice
11605099|NCT00611156|Experimental|C|Spice
11605100|NCT00611156|Experimental|D|Spice
11605101|NCT00611156|Placebo Comparator|E|Placebo
11605102|NCT00611143|Experimental|1|Atorvastatin group
11605103|NCT00611143|No Intervention|2|Control group
11605104|NCT00611130|Experimental|1|3 Vigabatrin Tablets, 500 mg, bid, for 9 weeks
11605105|NCT00611130|Placebo Comparator|2|3 Placebo Tablets, bid, for 9 weeks
11605106|NCT00611117|Experimental|1|High intensity exercise and high fat diet
11605107|NCT00611117|Experimental|2|Low intensity exercise and high fat diet
11605108|NCT00611091|Experimental|I|Intervention Group - (receive intervention) randomized at patient level - includes all health plan members, aged 65+, hospitalized at the study site hospital and discharged to an outpatient health plan clinic provider.
11605109|NCT00611091|No Intervention|C|Control Group - (do not receive intervention) randomized at patient level - includes all health plan members, aged 65+, hospitalized at the study site hospital and discharged to an outpatient health plan clinic provider.
11605110|NCT00611052|Experimental|1|Group cognitive intervention (the Adolescent Coping with Stress)
11605111|NCT00611052|Active Comparator|2|Treatment as usual
11605112|NCT00611052|Active Comparator|3|Healthy controls, receive usual health education in school health care
11605113|NCT00611039|Experimental|1|Darunavir 900mg + ritonavir 100 mg once a day
11605114|NCT00611039|Active Comparator|2|Darunavir 600mg + ritonavir 100mg twice day
11605115|NCT00611026|Active Comparator|1|
11605116|NCT00611026|Placebo Comparator|2|
11605117|NCT00611026|Experimental|3|
11605118|NCT00610987|Active Comparator|Cefazolin|Group I will receive 1-g doses of cefazolin every eight hours for the next 24 hours after surgical repair of the closed limb fracture.
11605119|NCT00610987|Placebo Comparator|Placebo|Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo, after the intraoperative dose(s) of cefazolin
11605120|NCT00610974|Active Comparator|1|One of 2 types of body-weight supported treadmill training (BWSTT) with the Lokomat, which differ only in the level of assistance that the Lokomat provides to leg movements while walking.
11605121|NCT00610974|Experimental|2|One of 2 types of body-weight supported treadmill training (BWSTT) with the Lokomat, which differ only in the level of assistance that the Lokomat provides to leg movements while walking.
11605122|NCT00610961||Basiliximab (Simulect) Induction|Prospective group: patients are scheduled to receive a kidney transplant; and will receive Simulect®, Myfortic® and Prograf® with or without steroids according to routine care (Standard of Care).
11605124|NCT00610948|Experimental|Group 1|Patients receive oral everolimus once daily on days 1-28. Patients also receive leucovorin calcium IV followed by fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11605125|NCT00610948|Experimental|Group 2|Patients receive oral everolimus once daily on days 1-28 and panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11605126|NCT00610948|Experimental|Group 3|Patients receive oral everolimus once daily on days 1-28, leucovorin calcium IV followed by fluorouracil IV continuously over 46 hours beginning on day 1, and oxaliplatin IV over 2-4 hours on day 1. Some patients may also receive panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11605127|NCT00610935|Placebo Comparator|Placebo|Placebo intramuscular injection
11605128|NCT00610935|Experimental|Peramivir|Single intramuscular injection of 300mg peramivir
11605129|NCT00610922|No Intervention|1|
11605130|NCT00610922|Experimental|2|
11605131|NCT00610909|Experimental|1|Those in the active treatment group will receive doses of Paxil CR in increments of 12.5 mg daily for the first week and increased at 12.5 mg increments at visit weeks to a maximum of 50 mg daily, as determined by the investigator. The investigator will adjust dosage based on clinical response. Following the completion of the double-blind phase, patients on placebo and non-responders to the study drug will be tapered off the study drug back to 0 over 2 weeks, and they will be referred to their Primary Care Physician, Internist or Gastroenterologist to be prescribed treatment for Irritable Bowel Syndrome.
11605132|NCT00610909|Placebo Comparator|2|Same shape placebo
11605133|NCT00610896||Observation|30 Patients with dualchamber pacemakers or implantable cardioverter-defibrillators (ICDs)
11605134|NCT00610883|Experimental|1 - LSA4|
11605135|NCT00610870|Experimental|1|Atorvastatin group
11605136|NCT00610870|No Intervention|2|Control group
11605137|NCT00610857|Experimental|Anti-CTLA4 monoclonal antibody and HDI|Specific Aim #1: Test the hypothesis that the combination of IFNa-2b and anti-CTLA-4 monoclonal antibody will improve the response rate in patients with recurrent inoperable AJCC stage III and stage IV melanoma. Our therapeutic target is achieving, with acceptable toxicity, a 20% or better rate of objective response, CR or PR by RECIST criteria, as compared to the 5% to 10% expected in patients eligible for study. Study size is planned in terms of our primary efficacy endpoint, objective response.
11605138|NCT00610844|Experimental|1|pulmonary radiofrequency ablation
11605139|NCT00610831|Experimental|DirectView CR Mammography|Each subject will have routine clinical care imaging obtained and 4 standard mammogram views (RMLO, RCC, LMLO, LCC) using CR mammography. If routine mammograms were obtained on a day previous to enrollment in the study, those images (4 views; 2 views for mastectomy patients) will not be repeated for this study; only the CR images will be obtained.
11605140|NCT00610818||A|Patients receiving palifermin to prevent mucositis from bone marrow transplant.
11605141|NCT00610805|Experimental|1|Participants randomized to this arm (n=15) will be followed by Preventive Cardiology and will have appropriate goal oriented interventions on their risk factor levels for 2 years.
11605142|NCT00610805|Other|2|Participants randomized to this arm (n=15) will receive usual care. The PI will send a letter of all testing results to their primary care physician. No standard care will be withheld.
11605143|NCT00610792|Experimental|1|
11605144|NCT00610779|Active Comparator|1|treatment with spray containing aromatic essential oils of some herbal plants.
11605145|NCT00610779|Placebo Comparator|2|spray containing placebo.
11605146|NCT00610766||1|
11605147|NCT00610753|Experimental|Family Behavioral Therapy|This intervention focuses on counseling the parents (and other family members) on refeeding their child. When weight is being steadily regained the focus of therapy shifts to allow the child more independence.
11605148|NCT00610753|Active Comparator|Systems Family Therapy|This therapy focuses primarily on clarifying psychological processes within the family.
11605149|NCT00610740|Experimental|Patients Treated with CerviPrep™|CerviPrep™, a novel drug delivery device, was developed specifically for applying pharmaceuticals directly on the cervix. It consists of a syringe-like tube attached to a plastic cap that covers the cervix. Drug can be delivered through the tube, directly to the cervix without spillage onto vaginal or vulvar tissues.
11605150|NCT00610727|Experimental|Inhaled prochlorperazine 0.625 mg vs IV|Prochlorperazine 0.5 mg IV over 5 sec crossover Inhaled prochlorperazine 0.625 mg
11605151|NCT00610727|Experimental|Inhaled prochlorperazine 1.25 mg|Inhaled Staccato prochlorperazine 1.25 mg
11605152|NCT00610727|Experimental|Inhaled prochlorperazine 2.5 mg|Inhaled Staccato prochlorperazine 2.5 mg
11605153|NCT00610727|Experimental|Inhaled prochlorperazine 5 mg|Inhaled Staccato prochlorperazine 5 mg
11605154|NCT00610727|Experimental|Inhaled prochlorperazine 10 mg|Inhaled Staccato prochlorperazine 10 mg
11605155|NCT00610727|Placebo Comparator|inhaled Placebo|inhaled Staccato Placebo (0 mg)
11605156|NCT00610714|Active Comparator|Active Comparator|carboplatin plus paclitaxel
11605157|NCT00610714|Experimental|2|AZD0530 in combination with carboplatin plus paclitaxel
11605158|NCT00610701|Experimental|Anterior pin placement|Anterior pin placement
11605159|NCT00610701|Experimental|Lateral pin placement|Lateral pin placement
11605160|NCT00610688|Placebo Comparator|Prenatal Vitamin D3|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3)along with a placebo tablet containing 0IU of Vitamin D
11605161|NCT00610688|Experimental|2|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3)along with a tablet containing 1600IU of Cholecalciferol (Vitamin D3)
11605162|NCT00610688|Experimental|3|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3) along with a tablet containing 3600IU of Cholecalciferol (Vitamin D3).
11605163|NCT00610675|Experimental|Esmirtazapine|One tablet of Esmirtazapine, 4.5 mg orally, daily for up to 52 weeks
11605164|NCT00610649|Experimental|Part 1: Block A MK-8777|Participants receive MK-8777 initiated at 100 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 16 days.
11605165|NCT00610649|Placebo Comparator|Part 1: Block A Placebo|Participants receive placebo BID for a total of 16 days.
11605207|NCT00610428|Experimental|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
11605166|NCT00610649|Experimental|Part 1: Block B MK-8777|Participants receive MK-8777 initiated at 200 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 13 days.
11605167|NCT00610649|Placebo Comparator|Part 1: Block B Placebo|Participants receive placebo BID for a total of 13 days.
11605168|NCT00610649|Experimental|Part 1: Block C MK-8777|Participants receive MK-8777 initiated at 300 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 10 days.
11605169|NCT00610649|Placebo Comparator|Part 1: Block C Placebo|Participants receive placebo BID for a total of 10 days.
11605170|NCT00610649|Experimental|Part 1: Block D MK-8777|Participants receive MK-8777 initiated at 100 mg BID and titrated to a maximum dose determined by the results of Block A. Participants receive MK-8777 for a total of 13 days.
11605171|NCT00610649|Placebo Comparator|Part 1: Block D Placebo|Participants receive placebo BID for a total of 13 days.
11605172|NCT00610649|Experimental|Part 2: MK-8777 200 mg|Participants receive MK-8777 100 mg BID for 27 days followed by one day of 100 mg QD. Participants receive MK-8777 for a total of 28 days.
11605173|NCT00610649|Experimental|Part 2: MK-8777 800 mg|Participants receive MK-8777 200 mg BID for 3 days followed by 400 mg BID for 24 days followed by one day of 400 mg QD. Participants receive MK-8777 for a total of 28 days.
11605174|NCT00610649|Placebo Comparator|Part 2: Placebo|Participants receive placebo BID for 27 days followed by one day of placebo QD. Participants receive placebo for 28 days.
11605175|NCT00610636|Experimental|1|The patients with secondary resectable colorectal hepatic metastasis undergoing surgery
11605176|NCT00610636|Active Comparator|2|The patients with secondary resectable colorectal hepatic metastasis who underwent continuous chemotherapy
11605177|NCT00610623|Experimental|1|azithromycin iv 300 mg/day
11605178|NCT00610623|Placebo Comparator|2|Placebo
11605179|NCT00610610|Experimental|A|Paroxetine - Controlled Release
11605180|NCT00610610|Placebo Comparator|B|Same colour, shape placebo
11605181|NCT00610597||1|alcoholic liver disease
11605182|NCT00610597||2|chronic hepatitis C virus infection
11605183|NCT00610584|Experimental|1|verum acupuncture plus rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
11605184|NCT00610584|Placebo Comparator|2|minimal (sham) acupuncture plus rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
11605185|NCT00610584|Active Comparator|3|rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))alone
11605186|NCT00610571|Experimental|Oral Topotecan and Temodar|Two separate strata to accrue independently. Stratum 1: Patients taking receiving Dilantin, Tegretol, Trileptal or Phenobarbital. Stratum 2: Patients on anti-convulsants other than Dilantin, Tegretol, Trileptal or Phenobarbital or patients not on any anti-convulsants
11605187|NCT00610558|Experimental|Arm 1: Juvenile Myoclonic Epilepsy|Juvenile Myoclonic Epilepsy group of subjects will participate for imaging assessment
11605188|NCT00610558|Experimental|Arm 2: Frontal Lobe Epilepsy|Frontal Lobe Epilepsy group of subjects will participate for imaging assessment
11605189|NCT00610558|Experimental|Arm 3: Normal Controls|Normal Controls, eligible subjects don't have Juvenile Myoclonic Epilepsy or Frontal Lobe Epilepsy will be placed in this group
11605190|NCT00610545|Active Comparator|1|Use Atorvastatin 80mg for 60 days , and the vascular surgery will be made between day-7 and day-60
11605191|NCT00610545|Active Comparator|2|Use Atorvastatin 20 mg for 60 days , and the vascular surgery will be made between day-7 and day-60
11605192|NCT00610532|Experimental|A|intravenous phenytoin alone
11605193|NCT00610532|Experimental|B|intravenous phenytoin plus probenecid
11605194|NCT00610519|Active Comparator|1|treatment with spray containing aromatic essential oils of some herbal plants.
11605195|NCT00610519|Placebo Comparator|2|spray containing placebo.
11605196|NCT00610506|Experimental|A|Lexapro
11605197|NCT00610493|Experimental|Bevacizumab + Temsirolimus|Bevacizumab 5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle. Temsirolimus 5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle. First tumor biopsy during screening visit and Second at the end of Cycle 1. DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1.
11605198|NCT00610480|Active Comparator|Optive, then Systane Artificial Tears|Artificial Tears (Optive, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, artificial tears (Systane, 40 microliters) will be administered using the same procedure protocol.
11605199|NCT00610480|Active Comparator|Systane, then Optive Artificial Tears|Artificial Tears (Systane, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, artificial tears (Optive, 40 microliters) will be administered using the same procedure protocol.
11605200|NCT00610467|Experimental|Disease Group|Patients with suspicious breast diseases
11605201|NCT00610467|Experimental|Control Group|Healthy volunteers for system testing
11605202|NCT00610441|Experimental|MK-8777 FD→PBO|Participants receive a fixed dose (FD) of MK-8777 100 mg twice each day (BID) for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive a fixed dose of placebo (PBO) BID for 3 weeks (Treatment Period 2).
11605203|NCT00610441|Experimental|PBO→MK-8777 FD|Participants receive a fixed dose of placebo BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive a fixed dose of MK-8777 100 mg BID for 3 weeks (Treatment Period 2).
11605204|NCT00610441|Experimental|MK-8777 RD→PBO|Participants receive rising doses (RD) of MK-8777 100-300 mg BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive rising doses of placebo BID for 3 weeks (Treatment Period 2).
11605205|NCT00610441|Placebo Comparator|PBO→MK-8777 RD|Participants receive rising doses of placebo BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive rising doses of MK-8777 100-300 mg BID for 3 weeks (Treatment Period 2).
11605206|NCT00610428|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo
11608865|NCT00581087|Experimental|1|DHEA
11605209|NCT00610402||blood sample tear drop sample|blood sample tear drop sample
11605210|NCT00610389|Experimental|1|
11605211|NCT00610376|Experimental|1A|Preschools randomized to this group received a multicomponent intervention to improve handwashing behavior of the children. Children within the preschool intervention group were individually randomized to a home intervention or a home control intervention program. The children in this arm received the home intervention component.
11605212|NCT00610376|Active Comparator|2|This group did not receive any special treatment during the study, but did receive the intervention at the close of the study
11605213|NCT00610376|Experimental|1B|Preschools randomized to this group received a multicomponent intervention to improve handwashing behavior of the children. Children within the preschool intervention group were individually randomized to a home intervention or a home control intervention program. The children in this arm received the home control component.
11605214|NCT00610363|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 16.
11605215|NCT00610363|Experimental|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 16.
11605216|NCT00610350|Experimental|L|
11605217|NCT00610350|Experimental|P|
11605218|NCT00610337|Placebo Comparator|1|
11605219|NCT00610337|Experimental|2|1mg Cethrin®
11605220|NCT00610337|Experimental|3|3mg Cethrin®
11605221|NCT00610337|Experimental|4|6mg Cethrin®
11605222|NCT00610337|Experimental|5|12mg Cethrin®. Administration of this dose is dependent on data from lower doses.
11605223|NCT00610337|Experimental|6|18mg Cethrin®. Administration of this dose is dependent on data from lower doses.
11605224|NCT00610324|Experimental|1|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
11605225|NCT00610324|Active Comparator|2|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
11605226|NCT00610311|Experimental|ALVAC plus anti-gp100:154-162 TCR PBL + HD IL-2|"ALVAC plus anti-gp100:154-162 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + high dose (HD) interleukin-2 (IL-2): ALVAC vaccine two hours prior to cell infusion patients will receive 0.5 ml containing a target dose of 10^7 cell culture infectious dose 50% (CCID50) (with a range of approximately 10^6.4 to 107.9/mL of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2mL. This will be repeated on day 14.
~Aldesleukin (IL2, Proleukin, Recombinant human interleukin 2)- 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)"
11605227|NCT00610298|Experimental|I|Subjects who receive whole body vibration
11605228|NCT00610298|No Intervention|N|Subjects do not receive whole body vibration intervention
11605229|NCT00610285||non-invasive immobilization system|This is a feasibility study to evaluate the accuracy of an alternative, non-invasive immobilization system in combination with image guided patient setup for SRS treatments. The aim is to determine whether or not the non-invasive system can provide comparable accuracy as the conventional invasive head ring system. If successful, patient discomfort can be significantly reduced for such treatments.
11605230|NCT00610272|Experimental|Single Site Radiation 4Gy Fraction|4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
11605231|NCT00610272|Active Comparator|Single Site Radiation 8Gy Fraction|8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
11605232|NCT00610272|Active Comparator|Multiple Sites Radiation 8Gy Fraction|8 Gy in a single fraction; retreatments > 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
11605233|NCT00610272|Experimental|Multiple Sites Radiation 12Gy Fraction|12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments > 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
11605234|NCT00610259|Experimental|1|brief behavioral therapy for insomnia (bBT-I) in addition to treatment as usual (TAU)
11605235|NCT00610259|Active Comparator|2|Treatment as usual (TAU)
11605236|NCT00610246|Experimental|Sorafenib and Radiation|Eligible patients (not candidates for curative treatment) will have measurable lesions in the anatomic thorax, abdomen or pelvis (any histology) amenable to palliative radiation treatment (30 Gy in 10 fractions). Patients receive sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. If full oral dose (400 mg po bid) is reached in a given cohort (dose level three) then an additional dose level will open where sorafenib treatment (400 mg bid) is extended following radiation for a total of eight weeks.
11605237|NCT00610233|Active Comparator|A|Urodynamic investigation with deep brain stimulation ON
11605238|NCT00610233|Experimental|B|Urodynamics with deep brain stimulation OFF
11605239|NCT00610220|Active Comparator|1|
11605240|NCT00610220|Experimental|2|
11605241|NCT00610207|Experimental|AFP|Anal fistula plug placement performed during surgical procedure
11605242|NCT00610194|Experimental|Arm 1|In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
11605243|NCT00610181||Breast MRI|Magnetic resonance imaging (MRI) of breast for patients with invasive lobular carcinoma of the breast.
11605358|NCT00609310|Experimental|I|Flavonoid treatment
11605359|NCT00609297||Supportive Care|Alive Hospice Patients with Pain
11605244|NCT00610168|Experimental|BOOSTRIX I GROUP|Subjects, who had received Boostrix™ vaccine in the primary study (263855/004), received one additional booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.
11605245|NCT00610168|Experimental|BOOSTRIX II GROUP|Subjects, who had received Wyeth's (formerly Lederle) combined adult diphtheria and tetanus vaccine and GSK Biologicals' acellular pertussis vaccine in the primary study (263855/004), received one booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.
11605246|NCT00610155|Placebo Comparator|1|
11605247|NCT00610155|Experimental|2|
11605248|NCT00610155|Experimental|3|
11605249|NCT00610142|Active Comparator|1|
11605250|NCT00610142|Active Comparator|2|
11605251|NCT00610129|Experimental|1|MK-0646
11605252|NCT00610116|Other|LV lead electronically repositioning|Single arm study
11605253|NCT00610103|Active Comparator|KW-6500|Drug: KW-6500 (apomorphine hydrochloride (USAN))
11605254|NCT00610103|Placebo Comparator|Placebo|Placebo
11605255|NCT00610090|Experimental|Treatment - UniFit AAA Stent Graft|
11605256|NCT00610077|Experimental|1|Letrozole
11605257|NCT00610077|Active Comparator|2|Clomiphene citrate
11605258|NCT00610064|Other|A|Baseline neuroimaging
11605259|NCT00610064|Other|B|Neuroimaging during sacral neuromodulation
11605260|NCT00610051|Placebo Comparator|trial arm|6 months central continuous infusion with Papeilin by infusion pump.
11605261|NCT00610051|Active Comparator|Placebo arm|6 months central infusion with NS by infusion pump with exact infusion rat as trial arm.
11605262|NCT00610038|Experimental|1|Glibenclamide
11605263|NCT00610025|Active Comparator|1|10 patients with no previous abdominal surgeries, pre-insufflation of the abdomen using a veress needle (standard procedure for insufflating the abdomen for laparoscopic surgery)
11605264|NCT00610025|Active Comparator|2|10 patients with history of previous abdominal surgeries, pre-insufflation of the abdomen using veress needle (standard procedure for insufflating the abdomen for laparoscopic surgery)
11605265|NCT00610025|Active Comparator|3|10 patients with no previous history of abdominal surgeries, no veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
11605266|NCT00610025|Active Comparator|4|10 patients with history of previous abdominal surgeries, no veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
11605267|NCT00610025|Active Comparator|5|10 patients, all with no previous mid to upper abdominal surgeries, no Veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
11605268|NCT00610025|Active Comparator|6|10 patients, all with previous mid-to-upper abdominal surgeries, no Veress needle pre-insufflation, endoscopic take-down of intra-abdominal adhesions (if identified)
11605269|NCT00609999|Experimental|Stratum A|Pts not on EIAEDs
11605270|NCT00609999|Experimental|Stratum B|Pts on EIAEDs
11605271|NCT00609986|Experimental|Intensive|The experimental group will receive the intravenous regular insulin infusion protocol for the maintenance of blood sugar levels 70-110 mg/dL while hospitalized up to 7 am post operative day #3 and after hospitalization will receive subcutaneous insulin to maintain blood sugar levels 70-140 mg/dL.
11605272|NCT00609986|Active Comparator|Control|The control group will receive subcutaneous insulin injections (NPH or glargine and aspartame) to maintain a blood sugar level between 70-180 mg/dL while hospitalized and after hospitalization subcutaneous insulin to maintain blood sugar levels 90-180 mg/dL.
11605273|NCT00609973|Active Comparator|A|Ciprofloxacin 500 mg bid
11605274|NCT00609973|Placebo Comparator|B|Placebo bid
11605275|NCT00609960|No Intervention|1|no medication or clowns present during the preopertaive phase
11605276|NCT00609960|Active Comparator|2|midazolam a anxiolytic drug was given in the preoperative phase
11605277|NCT00609960|Active Comparator|3|clowns where present during the preoperative phase
11605278|NCT00609947|Experimental|Endeavor Zotarolimus-Eluting Coronary Stent|Zotarolimus-eluting stent (ZES) implanted using standard percutaneous coronary intervention (PCI) technique via the femoral approach
11605279|NCT00609934|Experimental|Sorafenib and palliative radiotherapy|
11605280|NCT00609921|Active Comparator|1|ARQ197
11605281|NCT00609908|Active Comparator|A1|Acute Burn Wounds: Wound debridement and split skin grafting
11605282|NCT00609908|Experimental|A2|Acute Burn Wounds: excision of the burn wound and primary closure, using a skin stretching device
11605283|NCT00609908|Active Comparator|B1|Scar reconstruction: serial excision
11605284|NCT00609908|Experimental|B2|Scar reconstruction: primary closure, using skin stretching device
11605285|NCT00609882|Active Comparator|HHFNC|Infants randomized to the Humidified High Flow Nasal Cannula (HHFNC) treatment group post extubation
11605286|NCT00609882|Active Comparator|nCPAP|Infants randomized to the nasal Continuous Positive Airway Pressure (nCPAP) treatment group
11605287|NCT00609869|Experimental|Lenalidomide and Rituximab|"28 day cycles of Lenalidomide administered orally and Rituximab administered intravenously.
~Lenalidomide: Escalating doses starting with of 2.5 mg daily on 28-days cycles.
~Rituximab: at 375 mg/m^2 on a weekly basis for the first cycle starting on day 15."
11605288|NCT00609856|Active Comparator|1|Pioglitazone
11605289|NCT00609856|Active Comparator|2|Insulin glargine
11605290|NCT00609843|Experimental|1|
11605291|NCT00609830|Experimental|Tailored Materials|
11605292|NCT00609830|Experimental|Physician Feedback|
11605293|NCT00609830|Active Comparator|Generic Materials|
11605294|NCT00609830|Placebo Comparator|Placebo Comparator|Participants receive no information
11605295|NCT00609817|Experimental|GCS-100|
11605296|NCT00609804|Experimental|Sorafenib+Erlotinib|Sorafenib 400 mg twice daily by mouth Erlotinib 150 mg once daily by mouth
11605297|NCT00609804|Active Comparator|Sorafenib|Sorafenib 400 mg twice daily by mouth.
11605298|NCT00609791|Experimental|nab-paclitaxel|
11605299|NCT00609778|Experimental|1:Mechanical CPR with LUCAS|A Mechanical device that provides chest compressions
11605300|NCT00609778|Active Comparator|2 Manual CPR|Manual chest compressions
11609109|NCT00579085|Placebo Comparator|1|
11605301|NCT00609765|Experimental|Protocol Specified Chemotherapy|"Protocol Specified Chemotherapy Every 28 Days: Avastin, Fluorouracil, Doxorubicin, Streptozocin.
~Premedications: Dexamethasone, Ondansetron"
11605302|NCT00609752|Active Comparator|1|
11605303|NCT00609752|Active Comparator|2|
11605304|NCT00609739|Experimental|Cytarabine + Mitoxantrone|This is a phase I-II study designed to evaluate the efficacy of the administration of high dose cytosine arabinoside and mitoxantrone followed by HCT in patients with JMML who have residual disease or have relapsed after initial HCT.
11605305|NCT00609713|Experimental|1|Comprehensive 12-month family-based obesity treatment with separate adolescents and parents group sessions
11605306|NCT00609713|Active Comparator|2|Individual 12-month nutrition education program
11605307|NCT00609700||1|Historical group: patients treated with Ringer's Lactate solution after severe burn injury
11605308|NCT00609700||2|Actual group: patients treated with Ringer's Acetate solution after severe burn injury
11605309|NCT00609687|Other|A|Patients with suspected sarcoid-related posterior segment inflammation with inconclusive clinical exam findings, ancillary testing, and laboratory results
11605310|NCT00609674|Experimental|fluticasone furoate nasal spray|
11605311|NCT00609674|Placebo Comparator|Placebo|
11605312|NCT00609661||1|Patients presenting to the Ohio State University Emergency Department or directly admitted to the Ohio State University Burn Unit following thermal burn.
11605313|NCT00609661||2|Healthy volunteers
11605314|NCT00609648|Experimental|CARL|CARL computer program
11605315|NCT00609648|Active Comparator|Pamphlet|Reassuring pamphlet about dental injections
11605316|NCT00609622|Experimental|A|Treatment arm A - sunitinib plus mFOLFOX6
11605317|NCT00609622|Active Comparator|B|Treatment arm B - bevacizumab plus mFOLFOX6
11605318|NCT00609609|Experimental|Corticosteroids|Methylprednisolone at a dose of 2 mg/kg/day with a taper to no less than 1 mg/kg/day by day 14, and no less than 0.4 mg/kg/day by day 28.
11605319|NCT00609609|Experimental|ECP + Corticosteroids|Extracorporeal Photopheresis (ECP) 8-9 treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60 + Methylprednisolone at a dose of 2 mg/kg/day with a taper to no less than 1 mg/kg/day by day 14, and no less than 0.4 mg/kg/day by day 28.
11605320|NCT00609596|Other|Arm 1|
11605321|NCT00609570|Experimental|Fruit and vegetables|Fruits and vegetables
11605322|NCT00609570|Active Comparator|Whey protein|Whey protein
11605323|NCT00609570|Active Comparator|Ca|Calcium pills
11605324|NCT00609557|Experimental|A|All subjects receive placebo for the first two weeks and then duloxetine for the next 10 weeks, but they are blind to what they are receiving.
11605325|NCT00609544|Experimental|1|
11605326|NCT00609544|Placebo Comparator|2|
11605327|NCT00609531|Experimental|Active|Individuals with an Autism Spectrum Disorder receiving citalopram
11605328|NCT00609531|Placebo Comparator|Placebo|Individuals with an Autistic Spectrum Disorder receiving placebo
11605329|NCT00609518|Active Comparator|Standard Vitamin and Steroid Schedule + Pemetrexed|Standard vitamin and steroid schedule that is used with pemetrexed consisting of a minimum of 5 daily doses of folic acid before first pemetrexed dose and dexamethasone on day before, day of, and day after treatment.
11605330|NCT00609518|Experimental|Simplified Vitamin and Steroid Schedule + Pemetrexed|Simplified vitamin and steroid schedule to be used with pemetrexed consisting of 2 daily doses of folic acid before first pemetrexed dose and dexamethasone on day of treatment only.
11605331|NCT00609505|Other|TM|Telemedicine genetic counseling group
11605332|NCT00609505|Other|FTF|Face-to-face genetic counseling group
11605333|NCT00609492|Experimental|Preterm I Group|Children born after a gestation period of 27-30 weeks
11605334|NCT00609492|Experimental|Preterm II Group|Children born after a gestation period of 31-36 weeks
11605335|NCT00609492|Active Comparator|Full term Group|Children born after a gestation period of more than 36 weeks
11605336|NCT00609479|Experimental|1|Internal fixation with Micronail. 41 patients.
11605337|NCT00609479|Experimental|2|External fixation with Hoffmann-II-non-bridging. 41 patients.
11605338|NCT00609466|Experimental|1|CG5503 IR 75mg 4 to 6 hourly for 72 hours
11605339|NCT00609466|Active Comparator|2|Morphine IR 30 mg 4 to 6 hourly for 72 hours
11605340|NCT00609466|Placebo Comparator|3|Matching placebo 4 to 6 hourly for 72 hours
11605341|NCT00609453|Experimental|1|Individuals with major depressive disorder receiving therapy
11605342|NCT00609440|Other|A|A single case study, of a patient that was submitted to a physiotherapeutic treatment.
11605343|NCT00609427|Experimental|EA|Training in external memory aids
11605344|NCT00609427|Experimental|MT|Mnemonic training intervention
11605345|NCT00609427|No Intervention|WL|Wait-list control
11605346|NCT00609401|Experimental|1|Sorafenib 400 bid + IL-2 3 MU per 5 day/week for 2 weeks every 4
11605347|NCT00609401|Experimental|2|Sorafenib 400 mg bid
11605348|NCT00609388|Active Comparator|A|Group A receives an intraportal Tacrolimus-infusion, ATG Induction, Tacrolimus and Steroids.
11605349|NCT00609388|Placebo Comparator|B|Group B receives a placebo-Saline solution (0.9%)-Infusion, ATG induction, Tacrolimus and Steroids.
11605350|NCT00609375|Experimental|I|Administration of cefepime in continuous infusion (3 Gr over 24 hours) for at least 7 days and no more than 14 days days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
11605351|NCT00609375|Active Comparator|II|Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for at least 7 days and no more than 14 days days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
11605352|NCT00609362|Active Comparator|Rosiglitazone|25 women age 60 to 75 years receiving rosiglitazone 8 mg/day
11605353|NCT00609362|Placebo Comparator|Placebo|25 women 60 to 75 years of age receiving placebo once a day for 14 weeks
11605354|NCT00609349|Other|connective tissue disease|all patients suffer from a connective tissue disease representing a risk for the development of pulmonary hypertension
11605355|NCT00609336|Experimental|Treatment (chemotherapy, radiation, pancreaticoduodenectomy)|See Detailed Description
11605356|NCT00609323|Experimental|1|
11605357|NCT00609323|Placebo Comparator|2|
11605360|NCT00609284|Experimental|1|Radiotherapy 70Gy, Erbitux, Carboplatin-5FU
11605361|NCT00609284|Active Comparator|2|Radiotherapy 70Gy, Erbitux
11605362|NCT00609271|Experimental|1|low carbohydrate diet
11605363|NCT00609271|Active Comparator|2|low fat diet
11605364|NCT00609245|Experimental|Placebo then Valproic Acid (VPA)|all patients will have placebo on day 1 and VPA infusion on day 2
11605365|NCT00609219|Experimental|EBV specific CTL|autologous EBV specific CTLs
11605366|NCT00609193||1|Study subjects receiving lithium
11605367|NCT00609193||2|Study subjects receiving quetiapine
11605368|NCT00609180|Experimental|1|Participants will receive initial minimal (trophic) enteral feeding and the omega-3 fatty acid and anti-oxidant supplements
11605369|NCT00609180|Experimental|2|Participants will receive initial full-calorie enteral feeding and the omega-3 fatty acid and anti-oxidant supplements
11605370|NCT00609180|Experimental|3|Participants will receive initial minimal (trophic) enteral feeding and the placebo supplement
11605371|NCT00609180|Placebo Comparator|4|Participants will receive initial full-calorie enteral feeding and the placebo supplement
11605372|NCT00609154|Experimental|A|Type 2 diabetes
11605373|NCT00609154|Experimental|B|non diabetic control, matched
11605374|NCT00609141|Experimental|Treatment (monoclonal antibody therapy)|Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for up to 2 years in the absence of unacceptable toxicity or disease progression.
11605375|NCT00609128|Experimental|Olopatadine|one drop in one eye only two times per day at an interval of 6 to 8 hours for 1 week
11605376|NCT00609115|Experimental|T|The Test Group will have 18 half hour AMES (Assisted Movement with Enhanced Sensation) treatments per qualified subject limb with the AMES device. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
11605377|NCT00609115|Sham Comparator|C-1|Eighteen treatment sessions for each qualifying subject limb using the AMES device programed to provide placebo therapy. Each treatment session consisting of 30 minutes of placebo therapy. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
11605378|NCT00609115|Active Comparator|C-2|Crossover treatment of subjects who received placebo treatment during Phase 1 of the study to provide 18 regular (i.e., non-placebo) AMES (Assisted Movement with Enhanced Sensation) treatment sessions. Sessions to be scheduled preferably 2 to 3 times per week with each session one-half hour in length.
11605379|NCT00609102|Placebo Comparator|Placebo|
11605380|NCT00609102|Active Comparator|antioxidant drug|n-acetylcysteine
11605381|NCT00609089|Experimental|I|Community Reinforcement and Family Training for Retention in Treatment and Recovery and Reduction of HIV Risk Behavior (CRAFT-T)
11605382|NCT00609089|Active Comparator|II|Treatment As Usual
11605383|NCT00609063|Experimental|1|Participants will receive atorvastatin for 6 months.
11605384|NCT00609063|Placebo Comparator|2|Participants will receive matching placebo for 6 months.
11605385|NCT00609050|Active Comparator|1|Self-Regulated Exercise with Telephone Reinforcement
11605386|NCT00609050|Active Comparator|2|Attention Control
11605387|NCT00609037||1|Individuals who has had a weight reduction procedure such as gastric bypass and have body contouring surgery to remove the excessive skin due to the weight loss
11605388|NCT00609037||2|Normal controls include individuals who schecule to have an abdominoplasty and are within normal for height and weight
11605389|NCT00608985|Experimental|1|almorexant 200 mg
11605390|NCT00608985|Experimental|2|almorexant 100 mg
11605391|NCT00608985|Placebo Comparator|3|Placebo
11605392|NCT00608985|Active Comparator|4|zolpidem 10 mg
11605393|NCT00608972|Experimental|Doxil, Carboplatin and Bevacizumab|
11605394|NCT00608959|Experimental|omiganan 1% gel|Omiganan has a rapid bactericidal and fungicidal effect which is under development for the prevention of infections arising from short-term central venous catheters, as well as for the prevention of surgical wound infections in contaminated wounds.
11605395|NCT00608959|Active Comparator|chlorhexidine 2%|
11605396|NCT00608946|Experimental|1|efficacy of the intake of 8 mg of copper daily per os for one year under observation of cognitive status unless unacceptable side effects appear
11605397|NCT00608946|Placebo Comparator|2|placebo
11605398|NCT00608933|Active Comparator|Arm I (intervention)|Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
11605399|NCT00608933|Other|Arm II (wait-list)|Health providers are enrolled on a wait-list. After 2 months, the educational materials in arm I (educational intervention) are made available to the wait-list health providers.
11605400|NCT00608920|Experimental|SPECT lymph node mapping|"Diagnostic pelvic CT
~Nuclear tracer injection (Tc-99m) - same time as the ACCULOC seed implantation
~CT simulation (2 hours after prostate markers are placed)
~SPECT lymphoscintigraphy (first set of images 3-6 hours after injection and second set may be obtained 18-24 hours after injection)"
11605401|NCT00608907|Experimental|VELCADE|Control arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle.
11605402|NCT00608907|Experimental|VELCADE + rifampicin|Treatment Arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3.
11605403|NCT00608907|Experimental|VELCADE + dexamethasone|Treatment arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3.
11605404|NCT00608894|Experimental|LCP-Tacro|LCP-Tacro tablets(1,2,and 5mg tacrolimus)+ prednisone tablets(5mg)
11605405|NCT00608894|Active Comparator|Azathioprine|Azathioprine tablets(50mg)+ prednisone tablets(5mg)
11605406|NCT00608881|Active Comparator|A - coenzyme Q10 2400 mg/day|Randomized to active treatment (coenzyme Q10 2400 mg/day)
11605407|NCT00608881|Placebo Comparator|B - Placebo|Randomized to placebo
11605408|NCT00608842|Experimental|Deoxycholic Acid 1%|Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
11605409|NCT00608842|Experimental|Deoxycholic Acid 2%|Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
11605410|NCT00608842|Experimental|Deoxycholic Acid 4%|Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
11605411|NCT00608842|Placebo Comparator|Placebo|Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
11605412|NCT00608829|Experimental|GORE TAG® Thoracic Endoprosthesis|Gore 45mm TAG Thoracic Endograft Implantation
11605413|NCT00608816|Experimental|1|Hyperinsulinemic euglycemic glucose clamp study on day 1 Hyperinsulinemic euglycemic clamp study on day 2 with epinephrine infusion
11605414|NCT00608816|Experimental|2|Hyperinsulinemic hypoglycemic glucose clamp x 2 on day 1 Hyperinsulinemic euglycemic clamp with epinephrine infusion on Day 2
11605415|NCT00608803|Experimental|Single arm|Once the maximum tolerated dose (MTD) is determined, an expanded cohort of 20 subjects with advanced, ifosfamide and doxorubicin naive soft-tissue sarcoma subjects will be dosed at the MTD and evaluated for efficacy.
11605416|NCT00608790|Experimental|1|
11605417|NCT00608764||NHW COPD Participants|Non-Hispanic white participants with COPD
11605418|NCT00608764||NHW Control Group|Non-Hispanic white participants with normal spirometry (do not have COPD)
11605419|NCT00608764||AA COPD Participants|African-American participants with COPD
11605420|NCT00608764||AA Control Group|African-American participants with normal spirometry (do not have COPD)
11605421|NCT00608751|Experimental|IMRT|External beam radiation with 6 MV photons will be delivered in 200 cGy daily fractions, 35 fractions over 7 weeks for a total dose of 7000 cGy.
11605422|NCT00608725|Other|Patients|Patients with orthostatic intolerance
11605423|NCT00608725|Other|Healthy Control Subjects|"Healthy subjects to determine normal response"
11605424|NCT00608673|Experimental|1|Patients in arm one used twice daily pimecrolimus 1% cream on their facial discoid lupus erythematosus lesions for 8 weeks.
11605425|NCT00608673|Active Comparator|2|Twice daily betamethasone valerate 0.1% cream to facial lesions of discoid lupus erythematosus for 8 weeks
11605426|NCT00608660|Experimental|A|staging acupuncture for treating Bell's Palsy
11605427|NCT00608660|Experimental|B|staging acupuncture and moxibustion for treating Bell's Palsy
11605428|NCT00608660|Experimental|C|staging electroacupuncture for treating Bell's Palsy
11605429|NCT00608660|Experimental|D|staging acupuncture along Yangming musculature for treating Bell's Palsy
11605430|NCT00608660|Experimental|E|non-staging acupuncture for treating Bell's Palsy
11605431|NCT00608634|Placebo Comparator|Placebo|Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
11605432|NCT00608634|Experimental|Low Dose POH 0.30%|Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
11605433|NCT00608634|Experimental|High Dose POH 0.76%|Patients apply perillyl alcohol (POH) cream (0.76%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
11605434|NCT00608621||1-physostigmine|"Physostigmine 4 mg in 50 ml NaCl 0.9% per 24 h as syringe pump continuously for 48 hours, plus physostigmine 2mg (in NaCl 0.9% 50 ml)at termination of sedation
~PCA: Patient-controlled analgesia with piritramide 1 mg/ml, on demand: bolus of 2 mg, maximum of 10 mg in 60 min"
11605435|NCT00608621||2-placebo|"NaCl 0.9% 50 ml per 24 h continuously over 48 hours, plus 50 ml NaCl 0.9% at termination of sedation
~PCA: Patient-controlled analgesia with piritramid 1 mg/ml, on demand: bolus of 2 mg, maximum of 10 mg in 60 min"
11605436|NCT00608595|Experimental|Therapeutic Intervention/Celecoxib|Celecoxib
11605437|NCT00608582|Experimental|Real rTMS|These patients receive a series of 10 Real Transcranial Magnetic Stimulation, Repetitive (rTMS), treatments, only. There is pre-testing, and post-testing at 2 months after the last Real rTMS treatment.
11605438|NCT00608582|Sham Comparator|Sham rTMS|Patients receive a series of 10 Sham Transcranial Magnetic Stimulation, Repetitive (rTMS) treatments, followed by a series of 10 Real rTMS treatments. Sham rTMS treatments are identical to the Real rTMS treatments, however, no magnetic pulse is released. There is pre-testing, and post-testing at 2 months after the last Sham rTMS treatment.
11605439|NCT00608569|Experimental|mDOT arm|Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.
11605440|NCT00608569|Active Comparator|non-mDOT arm|Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.
11605441|NCT00608543|Other|Aripiprazole augmentation|This is a single arm trial in which all participants recieved open label aripiprazole augmentation of their current escitalopram, citalopram or sertraline treatment.
11605442|NCT00608530|Experimental|Cognitive Behavioral Therapy-Psychologist-Delivered|10 hours of Cognitive Behavioral Training delivered by a psychologist over 8 weeks by telephone and face-to-face contact
11605443|NCT00608530|Active Comparator|Supportive Psychotherapy-Psychologist-Delivered|10 hours of Rogerian Psychotherapy delivered by a psychologist over 8 weeks by telephone and face-to-face contact
11605444|NCT00608530|Experimental|Cognitive Behavioral Therapy-Nurse-Delivered|10 hours of Cognitive Behavioral Training delivered by a primary care medical nurse over 8 weeks by telephone and face-to-face contact
11605445|NCT00608530|Active Comparator|Supportive Psychotherapy-Nurse-Delivered|10 hours of Rogerian Psychotherapy delivered by a primary care medical nurse over 8 weeks by telephone and face-to-face contact
11605446|NCT00608517|Experimental|Pediatric Myeloablative conditioning|Patients undergo total-body irradiation on days -7 to -4, and receive cyclophosphamide IV over 1 hour on days -3 and -2, methylprednisolone IV twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4 hours on days -3 to -1.
11605687|NCT00606853|No Intervention|4|Standard Treatment
11605447|NCT00608517|Experimental|Adult Myeloablative conditioning|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -4, cyclophosphamide IV over 1 hour on days -5 and -4, and undergo total-body irradiation on days -3 to -1.
11605448|NCT00608517|Experimental|Reduced-intensity conditioning|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on day -6 and undergo total-body irradiation on day -1.
11605449|NCT00608491|Active Comparator|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
11605450|NCT00608491|Experimental|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
11605451|NCT00608465|Active Comparator|Treatment A|Eplerenone (study drug)
11605452|NCT00608465|Active Comparator|Treatment B|Ramipril
11605453|NCT00608452||1|
11605454|NCT00608439|Placebo Comparator|Placebo|Placebo CAST
11605455|NCT00608439|Active Comparator|Centella asiatica selected triterpenes|Active CAST
11605456|NCT00608426|No Intervention|Usual Care|Group who can elect to receive reactive (usual) care for smoking cessation.
11605457|NCT00608426|Experimental|Proactive Care|Group who will be proactively offered smoking cessation care with their choice of smoking cessation services (telephone care or in-person care).
11605458|NCT00608400|Experimental|1|CLA 1.5 g/d
11605459|NCT00608400|Experimental|2|CLA 3.0 g/d
11605460|NCT00608400|Placebo Comparator|3|
11605461|NCT00608387|Experimental|A|Participants will receive usual care from their healthcare providers and have access to a Web-based CVD risk-factor management program.
11605462|NCT00608387|No Intervention|B|Participants will receive usual care from their healthcare providers.
11605463|NCT00608361|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11605464|NCT00608348|Experimental|1|Hyperinsulinemic euglycemic or hypoglycemic clamp with Muscle and skin sympathetic nerve activity recording in arm and/or leg
11605465|NCT00608348|Experimental|2|Exercise with insulin or no insulin infused with muscle and skin sympathetic nerve activity measurements
11605466|NCT00608335|Experimental|1. Micafungin 3.0 mg|IV
11605467|NCT00608335|Experimental|2. Micafungin 4.5 mg|IV
11605468|NCT00608322|Experimental|1|Subjects receive inhaled nitric oxide (40 parts per million) for six hours.
11605469|NCT00608322|Sham Comparator|2|Subjects receive sham inhaled nitric oxide for six hours.
11605470|NCT00608296||1|Study subjects on lithium
11605471|NCT00608296||2|study subjects on quetiapine
11605472|NCT00608283||Live Kidney Donors|People who are going to donate a kidney at one of the three transplant centers from August 2007 until June 2011
11605473|NCT00608244|Experimental|LCP-Tacro|"Prograf was administrated BID, doses per product labeling, with an interval of 12±1 hours between the morning and evening doses. Patients continued on the same dose from Day 0 through Day 7. On Day 8, all patients were converted to LCP Tacro QD for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro was administered orally once daily in the morning, with an interval of 24 ± 1 h between doses. Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL.
~LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
11605474|NCT00608231|Experimental|PD-STN|Parkinson's Disease -- STN target
11605475|NCT00608231|Experimental|PD - GPi|Parkinson's Disease -- GPi target
11605476|NCT00608231|Experimental|ET - VIM|Essential Tremor -- VIM target
11605477|NCT00608231|Experimental|Dystonia - GPi|Dystonia -- GPi target
11605478|NCT00608231|Placebo Comparator|PD - STN Control|Parkinson's Disease -- STN target
11605479|NCT00608231|Placebo Comparator|PD - GPi Control|Parkinson's Disease -- GPi target
11605480|NCT00608231|Placebo Comparator|ET - VIM Control|Essential Tremor -- VIM target
11605481|NCT00608231|Placebo Comparator|Dystonia - GPi Control|Dystonia -- GPi target
11605482|NCT00608218||Artist|
11605483|NCT00608205|Active Comparator|Arm A: Radiation with concurrent Cisplatin|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
11605484|NCT00608205|Experimental|Arm B: Radiation with concurrent 5-FU and Cisplatin|Patients undergo radiotherapy as in arm I and receive fluorouracil IV and cisplatin IV continuously on days 1-4 and 22-25 of radiotherapy.
11605485|NCT00608192|Active Comparator|Testing, Education, & Counseling (TEC)|HIV and hepatitis screening is done on-site, but vaccination and medical care will be provided by off-site referral. HIV and Hepatitis, Testing, Education, & Counseling (TEC) participants will receive standard HIV and hepatitis education & counseling. TEC participants will not receive case management services.
11605486|NCT00608192|Experimental|Hepatitis Care Coordination (HCC)|Participants will receive on-site HIV and viral hepatitis screening. Hepatitis A and B combination vaccination will be provided on-site. Participants will receive on-site theory-based HIV and hepatitis education, counseling, and 6 months of case management to promote adherence to HIV and HCV evaluation.
11605487|NCT00608179|Experimental|1|
11605488|NCT00608179|Experimental|2|
11605489|NCT00608179|Experimental|3|control-euglycemia
11605490|NCT00608179|Experimental|4|control-hypoglycemia
11605491|NCT00608153||1|Patient with essential hypertension under treatment with candesartan or candesartan HCT
11605492|NCT00608140|Experimental|1|Participants will receive optimal medical therapy plus surgical mitral valve repair with complete annular ring placement
11605493|NCT00608140|Active Comparator|2|Participants will receive optimal medical therapy alone
11605494|NCT00608140|Experimental|3|Participants will receive optimal medical therapy plus 18-month delayed surgical mitral valve repair with complete annular ring placement
11605495|NCT00608127|Experimental|1|Single arm open label
11605496|NCT00608101|Experimental|1|Day 1 hyperinsulinemic euglycemic clamps with either 0.2 mg fludrocortisone, 0.75 mg Dexamethasone, or both given orally before each morning and afternoon clamp. Day 2 hyperinsulinemic hypoglycemic glucose clamp.
11605497|NCT00608101|Experimental|2|Fludrocortisone will be administered in doses of 0.05mg, 0.1mg and 0.2 mg form at the start of each clamp period on day 1. Dexamethasone will be administered orally in the doses of 0.18 mg, 0.375mg and 0.75mg doses. The combination of the 0.05mg fludrocortisone and 0.18mg dexamethasone and 0.1mg of fludrocortisone and 0.375 mg doses will be administered at the start of each day 1 clamp period. Day 2 90 minutes of moderate exercise.
11605498|NCT00608088|Active Comparator|1|Usual Care
11605499|NCT00608088|Active Comparator|2|Health Nurse/Peer Councelor Intervention
11605500|NCT00608075|Other|1|Manic Patients
11605501|NCT00608075|Other|2|Depressed Patients
11605502|NCT00608062|Experimental|Pre1|Premenopausal - GnRHant plus estradiol
11605503|NCT00608062|Placebo Comparator|Pre2|Premenopausal - GnRHant plus placebo
11605504|NCT00608062|Experimental|Peri1|Perimenopausal (early) - GnRHant plus estradiol
11605505|NCT00608062|Placebo Comparator|Peri2|Perimenopausal (early) - GnRHant plus placebo
11605506|NCT00608062|Experimental|Peri3|Perimenopausal (late) - GnRHant plus estradiol
11605507|NCT00608062|Placebo Comparator|Peri4|Perimenopausal (late) - GnRHant plus placebo
11605508|NCT00608062|Experimental|Post1|Postmenopausal - GnRHant plus estradiol
11605509|NCT00608062|Placebo Comparator|Post2|Postmenopausal - GnRHant plus placebo
11605510|NCT00608049|Experimental|1|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/high GI, high carbohydrate/low GI, low carbohydrate/high GI, and low carbohydrate/low GI
11605511|NCT00608049|Experimental|2|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/high GI, high carbohydrate/low GI, low carbohydrate/low GI, and low carbohydrate/high GI
11605512|NCT00608049|Experimental|3|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/low GI, high carbohydrate/high GI, low carbohydrate/high GI, and low carbohydrate/low GI
11605513|NCT00608049|Experimental|4|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/low GI, high carbohydrate/high GI, low carbohydrate/low GI, and low carbohydrate/high GI
11605514|NCT00608049|Experimental|5|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/high GI, low carbohydrate/low GI, high carbohydrate/high GI, and high carbohydrate/low GI
11605515|NCT00608049|Experimental|6|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/high GI, low carbohydrate/low GI, high carbohydrate/low GI, and high carbohydrate/high GI
11605516|NCT00608049|Experimental|7|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/low GI, low carbohydrate/high GI, high carbohydrate/high GI, and high carbohydrate/low GI
11605517|NCT00608049|Experimental|8|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/low GI, low carbohydrate/high GI, high carbohydrate/low GI, and high carbohydrate/high GI
11605518|NCT00608023|Experimental|Tesamorelin 12 months (T-T)|Tesamorelin 2 mg/day for 12 months
11605519|NCT00608023|Experimental|Tesamorelin-Placebo (T-P)|Tesamorelin 2 mg/day for 6 months - Placebo for 6 months
11605520|NCT00608023|Experimental|Placebo-Tesamorelin (P-T)|Placebo 6 months - Tesamorelin 2 mg/day for 6 months
11605521|NCT00608010|Experimental|1|Vitrification
11605522|NCT00608010|Active Comparator|2|Slow freezing
11605523|NCT00607997|Experimental|All Study Patients|"Schedule A: 72 mg/m2 vosaroxin Days 1, 8 and 15
~Schedule B: 72 mg/m2 vosaroxin on Days 1 and 8
~Schedule C: 72 mg/m2 on Days 1 and 4, or
~Schedule C: 90 mg/m2 on Days 1 and 4"
11605524|NCT00607984|Experimental|single|
11605525|NCT00607971|Experimental|1|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
11605526|NCT00607958|Experimental|1|dose reduction
11605527|NCT00607945|Placebo Comparator|0 g CLA|Avandia (Rosiglitazone) 4-8mg/day OR other diabetes medication currently prescribed to participant, 0 g CLA, 8 g Placebo oil (based on typical American diet)
11605528|NCT00607945|Experimental|3.2 g CLA|Avandia 4-8mg/day OR other diabetes medication currently prescribed to participant, 3.2 g CLA, 4.8 g placebo oil (based on typical American diet)
11605529|NCT00607945|Experimental|6.4 g CLA|Avandia 4-8mg/day OR other diabetes medication currently prescribed to participant, 6.4 g CLA, 1.6 g placebo oil (based on typical American diet)
11605530|NCT00607932|Experimental|Brassica Vegetables Diet Intervention|
11605531|NCT00607932|Experimental|Pill|
11605532|NCT00607919|Experimental|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 milligram/kilogram/day (mg/kg/day) given orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine
11605533|NCT00607919|Placebo Comparator|Placebo|Placebo will be packaged in the same way as experimental drug to enforce double-blind study design. Placebo will be administered orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine.
11605534|NCT00607906|Experimental|Subjects receiving treatment in cohort A1|Eligible subjects will receive oral immediate release capsules of SB-756050 with doses of 5 milligrams, 15 milligrams, 50 milligrams, or 100 milligrams.
11605535|NCT00607906|Experimental|Subjects receiving treatment in cohort A2|Eligible subjects will receive oral immediate release capsules of SB-756050 with doses of 100 milligrams, 200 milligrams, 300 milligrams, or 400 milligrams.
11605536|NCT00607906|Experimental|Subjects receiving treatment in cohort A3|Eligible subjects will receive oral immediate release capsules of SB-756050 with a dose of 150 milligrams. Subjects will also receive oral modified release capsules of SB-756050 with doses of 150 milligrams, 300 milligrams, or 400 milligrams.
11605537|NCT00607906|Experimental|Subjects receiving treatment in cohort A4|Eligible subjects will receive SB-756050 in this additional cohort.
11605793|NCT00606138|Experimental|Anti-VEGF injection|Intravitreal injection of 0.5-mg dose of ranibizumab
11605538|NCT00607906|Experimental|Subjects receiving treatment in cohort B1|Eligible subjects will receive oral modified release capsules of SB-756050 with doses of 50 milligrams, 150 milligrams or 400 milligrams. Subjects will also receive immediate release oral capsules of SB-756050 with a dose of 150 milligrams.
11605539|NCT00607893|Sham Comparator|Sham CPAP|Participants will receive sham continuous positive airway pressure (CPAP) for a 2 month period. Sham CPAP involves wearing a device that appears similar to a standard CPAP device, but administers a negligible pressure. Adherence will be tracked while the participant wears the device.
11605540|NCT00607893|Active Comparator|Treatment CPAP|Participants will receive continuous positive airway pressure for a 2 month period. The optimal treatment pressure will be identified during a titration study prior to trial enrollment. Adherence will be tracked while the participant wears the device.
11605541|NCT00607880|Active Comparator|Standard Port|Patients undergo insertion of the conventional vascular access port (C. R. Bard, Inc., Murray Hill, NJ). Patients then receive standard chemotherapy.
11605542|NCT00607880|Experimental|Vortex Implantable Access Port|Patients undergo insertion of the Vortex® implantable vascular access port (Horizon Medical Products, Manchester, GA). Patients then receive standard chemotherapy.
11605543|NCT00607867|Active Comparator|Arm 1|A LoBAG30, weight maintenance diet will be given to subjects on metformin. All food will be provided for 5 weeks.
11605544|NCT00607867|Placebo Comparator|Arm 2|A weight maintenance, control diet consisting of 55% carbohydrate, 15% protein, 30% fat will be given to subjects on metformin. All food will be provided for 5 weeks.
11605545|NCT00607854|Experimental|Zevalin|Zevalin associated with a Fludarabine-based reduced-intensity conditioning regimen,all patients will receive Zevalin in the conditioning regimen
11605546|NCT00607841|Experimental|Dose Escalation Cohort 1|Ispinesib given on days 1 and 15 of a 28 day cycle.
11605547|NCT00607841|Experimental|Dose Escalation Cohort 2|Ispinesib given on days 1 and 15 of a 28 day cycle.
11605548|NCT00607841|Experimental|Dose Escalation Cohort 3|Ispinesib given on days 1 and 15 of a 28 day cycle.
11605549|NCT00607815|Active Comparator|Cognitive Processing Therapy|Cognitive Processing Therapy
11605550|NCT00607815|Active Comparator|Present Centered Therapy|Present Centered Therapy
11605551|NCT00607789|Experimental|Duloxetine Group|Start with 30 mg duloxetine hydrochloride capsule/day to be increased up to 120 mg per day.
11605552|NCT00607789|Placebo Comparator|Placebo Group|Sugar pill with matching dosage as Duloxetine
11605553|NCT00607776|Active Comparator|1|Systane
11605554|NCT00607776|Experimental|2|Blink tears
11605555|NCT00607763|Experimental|1. Micafungin|
11605556|NCT00607750|Placebo Comparator|1|
11605557|NCT00607750|Experimental|ATG003|
11605558|NCT00607737|Experimental|1|insulin detemir
11605559|NCT00607737|Placebo Comparator|2|saline
11605560|NCT00607724|Experimental|Stage 1: GDC-0449 (150 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 milligram (mg) on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 150 mg, orally, continuing until disease progression (deterioration of evaluable lesions and/or tumor-related symptoms defined using Response Evaluation Criteria in Solid Tumors Version 1.0 (RECIST v1.0), maximum benefit, or intolerability.
11605561|NCT00607724|Experimental|Stage 1: GDC-0449 (270 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 270 mg, orally, continuing until disease progression, maximum benefit, or intolerability.
11605562|NCT00607724|Experimental|Stage 1: GDC-0449 (540 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 540 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 540 mg, orally, continuing until disease progression, maximum benefit, or intolerability.
11605563|NCT00607724|Experimental|Stage 2: BCC [GDC-0449 (150 mg)]|Participants with basal cell carcinoma (BCC) received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
11605564|NCT00607724|Experimental|Stage 2: BCC [GDC-0449 (270 mg)]|Participants with BCC received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
11605565|NCT00607724|Experimental|Stage 2:Safety Expansion Cohort [GDC-0449 (150 mg)]|Participants received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
11605566|NCT00607724|Experimental|Stage 2: New Formulation [GDC-0449 (150 mg )]|Participants received a daily oral dose of GDC-0449 Phase II drug product hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
11605567|NCT00607711|Experimental|Single arm|
11605568|NCT00607685|Experimental|1|The participants will receive a subconjunctival injection of a mixture of 5FU with hyaluronic acid.
11605569|NCT00607685|Active Comparator|2|Participants will receive a subconjunctival injection of 5 Fluorouracil only.
11605570|NCT00607672|Placebo Comparator|1|Patients are randomized to placebo prior to surgery
11605571|NCT00607672|Active Comparator|2|Patients are randomized to Ramipril prior to surgery
11605572|NCT00607672|Active Comparator|3|Patients are randomized to Candesartan (ARB) prior to surgery
11605573|NCT00607659||Chlamydia Positive|Adolescent females, 11-21 years old, evaluated for pelvic examinations or STI screening will be asked to participate in this study. Participants are being asked to give us permission to collect:additional cervical or vaginal swabs, rectal swabs, blood draws where three tablespoons of blood, a urine pregnancy test, and a comprehensive health history. You may be asked to provide a urine specimen at the initial visit instead of having a cervical swab. The study team will obtain a cervical swab when you come back for your follow-up appointments. If your culture is positive for Chlamydia, you will be asked attend 3 additional follow-up appointments after 3 months, 6 months, 1 year, 2 years, and 3 years .
11605574|NCT00607659||Control/Chlamydia Negative|Some participants with negative cultures will be included in this study as a control group. The same specimens, exams and blood draws will apply for those subjects with visits at 3 months, 6 months, 1 year, 2 years, and 3 years
11605901|NCT00605384|Experimental|2|
11605575|NCT00607646|Experimental|1|Hyperinsulinemic (high dose insulin) hypoglycemic clamp studies with oral administration of DHEA or placebo prior to each clamp x 2 on day 1. Day 2 hyperinsulinemic hypoglycemia. Participant randomized to either DHEA or placebo for baseline trial (arm 1) and 6 weeks treatment.
11605576|NCT00607646|Experimental|2|Following 6 weeks randomized treatment, Day 1 hyperinsulinemic hypoglycemic clamps x 2 with DHEA or placebo dose given prior to each clamp. Day 2 hypoglycemia with prior dose of randomized treatment.
11605577|NCT00607646|Experimental|Arm 3 (optional)|Individuals will be asked to return after at least 2 months and repeat the trial they did not complete (for example, placebo if they were in the DHEA trial before). Again Day 1 would consist of two hyperinsulinemic clamps with placebo or DHEA given orally. Day 2 hyperinsulinemic hypoglycemic clamp with oral administration of placebo or DHEA.
11605578|NCT00607646|Experimental|Arm 4|Following 6 weeks randomized treatment, Day 1 hyperinsulinemic hypoglycemic clamps x 2 with DHEA or placebo dose given prior to each clamp. Day 2 hypoglycemia with prior dose of randomized treatment.
11605579|NCT00607633||1|Patient with essential hypertension and LVH under treatment with candesartan or candesartan HCT
11605580|NCT00607620|Experimental|Intervention|Providers receive training in alcohol screening and brief interventions from study staff in compliance with American College of Surgeons' Alcohol Screening and Brief Intervention Mandate
11605581|NCT00607620|No Intervention|Usual Care|Usual care for alcohol use problems after American College of Surgeons' Alcohol Screening and Brief Intervention Mandate
11605582|NCT00607607|Experimental|A|Ovarian Cancer Patients
11605583|NCT00607607|Experimental|B|Endometrial Cancer Patients
11605584|NCT00607594|Experimental|Treatment (kinase inhibitor therapy)|Patients receive saracatinib PO, at a dose of 175 mg QD in the absence of disease progression or unacceptable toxicity.
11605585|NCT00607581|Experimental|1|"The participants receive up to 9 28-day cycles of
~cyclophosphamide: 500 mg orally on days 1, 8, 15;
~lenalidomide: 15 mg orally on days 1-21;
~dexamethasone: 40 mg orally on days on days 1, 8, 15, 22."
11605586|NCT00607568|Experimental|1|atomoxetine 40mg per day
11605587|NCT00607568|Placebo Comparator|2|second arm is placebo, sugar pill
11605588|NCT00607555||Observation|Premature infants over 23 weeks of gestation and less than 1.25 kilograms at birth, who are tolerating feedings, and are clinically stable
11605589|NCT00607542|Active Comparator|1|starting dose of baclofen 2.5 mg PO TID with dose escalation as tolerated
11605590|NCT00607529||1|Patients having a creatinine drawn
11605591|NCT00607516|Active Comparator|Cemented|Cemented primary bipolar hemiarthroplasty of the hip
11605592|NCT00607516|Active Comparator|Uncemented|Uncemented primary bipolar hemiarthroplasty of the hip
11605593|NCT00607503|Experimental|1|
11605594|NCT00607490|Experimental|Cognitive-behavioral Therapy|10 weekly individual 60-minute sessions
11605595|NCT00607490|Active Comparator|Supportive Psychotherapy|10 weekly individual 60-minute sessions
11605596|NCT00607477|Active Comparator|1|Minoxidil
11605597|NCT00607477|Active Comparator|2|Hydralazine
11605598|NCT00607464|Experimental|1|Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
11605599|NCT00607464|No Intervention|2|Standard care
11605600|NCT00607451|Experimental|1|
11605601|NCT00607451|Experimental|2|
11605602|NCT00607451|Experimental|3|
11605603|NCT00607451|Experimental|4|
11605604|NCT00607425||1|Non-small cell lung cancer patients
11605605|NCT00607425||2|Healthy control subjects
11605606|NCT00607412|Experimental|1|Present focused, integrated psychotherapy for PTSD and substance use disorders
11605607|NCT00607412|Active Comparator|2|Supportive therapy using 12-step model
11605608|NCT00607399|Experimental|Single arm|
11605609|NCT00607386|Other|Idursulfase|Open-label treatment with idursulfase
11605610|NCT00607373|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
11605611|NCT00607373|Placebo Comparator|Placebo|Participants received placebo as a subcutaneous injection once a week for 26 weeks.
11605612|NCT00607360|No Intervention|Standard Drug Court|Participants received standard services from drug court
11605613|NCT00607360|Experimental|Drug Court plus Therapeutic Workplace|Participants receive standard drug court services plus therapeutic workplace intervention
11605614|NCT00607347|Experimental|A|The subjects will be undergoing a oral glucose tolerance test.
11605615|NCT00607334|Experimental|GP|Children with Developmental Language Impairments were enrolled in this group.
11605616|NCT00607334|Experimental|GC|Children with normal language development were enrolled in this group.
11605617|NCT00607321|Experimental|1|Medtronic Bifurcation Stent System
11605618|NCT00607308|Experimental|0.1 mg/kg|
11605619|NCT00607308|Experimental|0.5 mg/kg|
11605620|NCT00607308|Experimental|1 mg/kg|
11605621|NCT00607308|Experimental|5 mg/kg|
11605622|NCT00607308|Placebo Comparator|Placebo|
11605623|NCT00607308|Experimental|10 mg/kg|
11605624|NCT00607295|Experimental|1|Clino-san 2ml vaginal application 3 times per week for 12 weeks
11605625|NCT00607295|Placebo Comparator|2|placebo 2ml vaginal application 3 times per week for 12 weeks
11605626|NCT00607282|Placebo Comparator|Placebo|normal control group
11605627|NCT00607282|Experimental|Udenafil|oral administration of placebo for Udenafil (Dong-A Pharmaceutical co., Ltd, Seoul, Korea)
11605628|NCT00607269|No Intervention|Control|Control condition receiving minimal incentives for service program attendance and participation.
11605629|NCT00607269|Experimental|Contingency Management|Contingency management (Voucher-Based Reinforcement Therapy) intervention providing positive reinforcement for service program participation and attendance, enactment of prosocial/health behavior, and/or clean urine samples (i.e., no illicit drug use) and clean breathalyzer tests (i.e., BA < 0.05).
11605630|NCT00607256|Experimental|Open Label|
11605631|NCT00607243|Experimental|Conventional dose group|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
11605632|NCT00607243|Experimental|Low dose group|Diluted CJ-50300 2.5 x 10000pfu/dose vaccination
11605633|NCT00607230|Experimental|E|BCG vaccination
11605634|NCT00607230|Placebo Comparator|P|Saline vaccination
11605635|NCT00607217|Experimental|CAD-Exp|Enrolled coronary artery disease patients who are randomly assigned to receive influenza vaccine
11605636|NCT00607217|Placebo Comparator|CAD-Control|Enrolled coronary artery disease patients who are randomly assigned to receive placebo of influenza vaccine
11605637|NCT00607217|Experimental|Healthy-Control|Enrolled healthy subjects serve as control for CAD-Exp
11605638|NCT00607178|Experimental|Influenza vaccine|Enrolled patients who are randomly assigned to receive influenza vaccine
11605639|NCT00607178|Placebo Comparator|Placebo|Enrolled patients who are randomly assigned to receive placebo of influenza vaccine
11605640|NCT00607152|Experimental|1|IV infusion at a dose level of 0.20mg/kg per day
11605641|NCT00607152|Active Comparator|2|100mg tablets, administered orally, according to standard medical practice
11605642|NCT00607126|Experimental|1|locomotor training using body weight support on a treadmill, using robotic device to provide locomotor training. Locomotor training will be done using the Lokomat device. the patient is suspended over a treadmill while their legs are in the Lokomat, which moves the legs on the treadmill.
11605643|NCT00607126|Active Comparator|2|resistive training using weights and therabands
11605644|NCT00607113|Experimental|Avastin|Cycle 1 (First 3 weeks of study) - Avastin 15 mg/kg intravenous (IV)
11605645|NCT00607113|Experimental|Avastin + RAD001|Cycle 2: Avastin 15 mg/kg intravenous (IV) every 3 weeks + RAD001 10 mg orally daily for 3 weeks
11605646|NCT00607113|Experimental|RAD001|Cycle 1 (First 3 weeks of study)- RAD001 10 mg orally daily for 21 Days
11605647|NCT00607100||1|Patients with Band atrophy of the optic nerve
11605648|NCT00607100||2|Normal Controls
11605649|NCT00607087|Experimental|sequence 1|sequence 1: insulin glulisine / insulin aspart / insulin lispro.
11605650|NCT00607087|Experimental|Sequence 2|Sequence 2: insulin aspart / insulin lispro / insulin glulisine
11605651|NCT00607087|Experimental|Sequence 3|Sequence 3: insulin lispro / insulin glulisine / insulin aspart
11605652|NCT00607074|Experimental|1|
11605653|NCT00607061|Other|1|Full term newborn babies with gestational age > 37 weeks of amenorrhea and weight of birth > tenth percentile.
11605654|NCT00607061|Other|2|Low birth weight newborn babies (gestational age < 32 weeks of amenorrhea and/or weight of birth < 1500 g and/or weight of birth < third percentile for their gestational age.
11605655|NCT00607061|Other|3|Full term newborn babies (gestational age > 37 weeks of amenorrhea and weight of birth > tenth percentile).
11605656|NCT00607048|Other|Schedule A|Schedule A (CP-870,893 administration schedule)
11605657|NCT00607048|Other|Schedule B|Schedule B (CP-870,893 administration schedule)
11605658|NCT00607035|Experimental|A|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
11605659|NCT00607035|Experimental|H|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
11605660|NCT00607022|Active Comparator|immediate load|immediate load of dental implant based on the bone quality determined by the insertion torque value
11605661|NCT00607022|Active Comparator|Loading at 6 weeks|delayed load (6 weeks post surgery) of dental implants based on bone quality determined by the insertion torque value
11605662|NCT00607022|Active Comparator|Loading at 12 weeks|traditional loading of dental implants (12 weeks post surgery) based on bone quality determined by the insertin torque value.
11605663|NCT00607009|Experimental|Intervention|ALIVE - received emails about chosen behavioral intervention path - physical activity, fruits/vegetables or fats/sugars
11605664|NCT00607009|No Intervention|Control|no intervention
11605665|NCT00606996|Experimental|IPT-G|Group Interpersonal Psychotherapy
11605666|NCT00606996|Active Comparator|PSYCHOED|Psychoeducation
11605667|NCT00606983|No Intervention|1|
11605668|NCT00606983|Experimental|2|oral administration of Tamsulosin
11605669|NCT00606970|Experimental|Intervention group|Seigen Alpha EV Treatment
11605670|NCT00606970|Placebo Comparator|2|Identically packaged placebo packets taken 3x daily for 3 months maximum
11605671|NCT00606944|Experimental|ERP group|fast-track rehabilitation with early ambulation and diet after elective colorectal resection
11605672|NCT00606944|No Intervention|control group|traditional, conventional care group
11605673|NCT00606931|Experimental|one arm|
11605674|NCT00606918||1|Individuals with ALS
11605675|NCT00606918||2|Healthy Adults
11605676|NCT00606905|Active Comparator|1|IVIG, either Gamimune N (Talecris Biotherapeutics, Inc., Clayton, NC) or Gamunex 10% (Talecris Biotherapeutics, Inc., Clayton, NC), both as a 10% solution
11605677|NCT00606905|Placebo Comparator|2|normal saline
11605678|NCT00606892|Experimental|Placebo First, varenicline, + IV Nic|Subjects received a Placebo tablet once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg).After a minimum of a 5 day washout subjects then received varenicline tablet (1mg). once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,0.7 mg per 70kg).
11605679|NCT00606892|Experimental|Varenicline first, placebo, + IV Nic|Subjects received Varenicline tablet (1 mg) per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg). After a washout of a minimum of 5 days subjects then received placebo tablet for per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,, and 0.7mg per 70 kg).
11605680|NCT00606879|Experimental|Single arm|
11605681|NCT00606866|Placebo Comparator|I|placebo pill
11605682|NCT00606866|Active Comparator|II|Sorafenib, 200 mg bid
11605683|NCT00606866|Active Comparator|III|Sorafenib, 400 mg bid
11605684|NCT00606853|Experimental|1|Standard Treatment plus prize contingency management for abstinence with an expected probability of winning about $250 in prizes and twice-weekly breath and urine samples.
11605685|NCT00606853|Experimental|2|Standard Treatment plus prize contingency management for abstinence with an expected probability of winning about $560 in prizes and twice-weekly breath and urine samples.
11605686|NCT00606853|Experimental|3|Standard Treatment plus prize contingency management for attendance with an expected probability of winning about $250 in prizes and twice-weekly breath and urine samples.
11605688|NCT00606840|Experimental|1|One arm is a large changes group in which participants will be asked to make periodic large changes in their eating and activity, aimed at producing initial weight loss, in order to prevent weight gain over time.
11605689|NCT00606840|Experimental|2|The second arm is a small changes group in which participants will be asked to make small changes to their eating and activity and maintain these changes forever in order to prevent weight gain.
11605690|NCT00606827|Experimental|A|Bicarbonate
11605691|NCT00606827|Active Comparator|B|Saline
11605692|NCT00606801|Active Comparator|Galantamine 8 mg/day|Galantamine 8 mg/day
11605693|NCT00606801|Placebo Comparator|Placebo|placebo
11605694|NCT00606788|Active Comparator|AW|Patients received computer-driven protocolized weaning (= Automated Weaning)
11605695|NCT00606788|Active Comparator|CW|Patients received physician-directed non-protocolized weaning (= Conventional Weaning)
11605696|NCT00606775|Experimental|Carvedilol|
11605697|NCT00606775|No Intervention|Control|
11605698|NCT00606762|Active Comparator|LPLC, HPLC|LPLC: Low pressure pneumoperitoneum is defined as intraabdominal pressure kept at8 mm Hg after initial trocar insertion at 12 mm Hg HPLC: High pressure pneumoperitoneum is defined as intra abdominal pressure kept at 12 mm Hg throughout the procedure
11605699|NCT00606736||patients|subjects with right ventricular outflow tract arrhythmia
11605700|NCT00606736||control|subjects ,age match,healthy
11605701|NCT00606723|Experimental|1|"Group I: Relapsed AML-patients with blast cell reduction to <20% before the second course of induction therapy. These patients will receive conventional SCT.
~Group II: Patients with non response to frontline treatment of AML, patients with blast cells <20% before the second course of induction therapy who do not achieve a second remission and relapsed AML-patients with blast cells >=20% before the second course of induction therapy. If these patients have a matched donor (MSD/MD) they will receive SCT with FLAMSA.
~Group III: Patients who are eligible for Group II but have no matched donor. These patients will receive SCT from a haploidentical donor."
11605702|NCT00606697|Active Comparator|Overall study|Male and female subjects, 18-64 years of age (inclusive), with a primary diagnosis of primary insomnia
11605703|NCT00606684|Active Comparator|GW642444|GW642444
11605704|NCT00606684|Placebo Comparator|placebo|
11605705|NCT00606671||1|lean control women without PCOS
11605706|NCT00606671||2|lean women with PCOS
11605707|NCT00606671||3|Obese control women without PCOS
11605708|NCT00606671||4|Obese women with PCOS
11605709|NCT00606671||1xx - 04 LC|lean control women
11605710|NCT00606671||1xx-04 LP|lean women with PCOS
11605711|NCT00606671||1xx-04 OC|obese control women
11605712|NCT00606671||1xx-04 OP|obese women with PCOS
11605713|NCT00606658|Other|Oil dripping therapy|Single Arm
11605714|NCT00606645|Experimental|1|XmAb2513
11605715|NCT00606632|Other|124-Iodine-cG250 (124I-cG250)|Single arm study, comparing 124I cG250 PET/CT and CT. Each patient underwent a PET/CT and CT scan days (+/-2days) after receipt of 124I cG250.
11605716|NCT00606619|No Intervention|1|Conventional feeding : They begin ingesting sips of water on third postoperative day and continued with a liquid diet for the next two days. Patients were given a soft diet on sixth postoperative day.
11605717|NCT00606619|Experimental|2|Early oral feeding : The patients begin ingesting sips of water on the first postoperative day. If they are tolerable, they continued with a clear liquid diet the next day and a soft diet on the third post operative day.
11605718|NCT00606606|Experimental|I - Intervention units|nursing home units, provided HIT CDS intervention
11605719|NCT00606606|No Intervention|C - control units|nursing home units, not provided the HIT CDS intervention
11605720|NCT00606593|Experimental|ABECD|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
11605721|NCT00606593|Experimental|BCADE|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
11605722|NCT00606593|Experimental|CDBEA|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
11605723|NCT00606593|Experimental|DECAB|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
11605724|NCT00606593|Experimental|EADBC|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
11605725|NCT00606593|Experimental|DCEBA|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
11605726|NCT00606593|Experimental|EDACB|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
11605727|NCT00606593|Experimental|AEBDC|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
11605728|NCT00606593|Experimental|BACED|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
11605729|NCT00606593|Experimental|CBDAE|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
11605730|NCT00606580|Experimental|WR 279,396 Topical Treament|WR 279,396 topical cream (15% paromomycin + 0.5% gentamicin topical cream)
11605731|NCT00606580|Experimental|Paromomycin Alone Topical treatment|Paromomycin Alone topical cream (15% paromomycin topical cream)
11605732|NCT00606580|Placebo Comparator|Vehicle Placebo Cream|The cream base without the addition of paromomycin or gentamicin
11605733|NCT00606567|Active Comparator|1-treatment|remote monitoring with carelink every 3 months
11605734|NCT00606567|No Intervention|2- control|device interrogations in clinic every 3 months
11605735|NCT00606554|Experimental|Computer-assisted weaning|Group assigned to the computer-assisted weaning program
11605736|NCT00606554|Active Comparator|Standard of care weaning|Group assigned to receive current, evidence-based, standard of care for discontinuation of mechanical ventilation.
11605737|NCT00606541|Experimental|1|Quetiapine XR 50mg-400mg per day
11605738|NCT00606541|Placebo Comparator|2|Placebo
11605739|NCT00606528||Group A|patients with chronic Hepatitis C Virus infection who have not previously received antiviral therapy
11605740|NCT00606528||Group B|Healthy volunteers willing to donate blood on 2 separate occasions
11605741|NCT00606515|Experimental|A|Liposomal paclitaxel
11605742|NCT00606515|Active Comparator|B|Paclitaxel
11605964|NCT00604890|Placebo Comparator|4|Placebo AM and PM
11605743|NCT00606502|Experimental|Pralatrexate|Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
11605744|NCT00606502|Active Comparator|Erlotinib|"150 mg orally in tablet form
~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
11605745|NCT00606489|Placebo Comparator|1|
11605746|NCT00606489|Experimental|2|
11605747|NCT00606476|Active Comparator|1|0.15 mg/kg active bapineuzumab
11605748|NCT00606476|Active Comparator|2|0.5 mg/kg active bapineuzumab
11605749|NCT00606476|Active Comparator|3|1.0 mg/kg active bapineuzmab
11605750|NCT00606463|Experimental|(Gen2 Cardiac Ablation System)|Ablation of isthmus-dependent atrial flutter
11605751|NCT00606450|Experimental|20 mg Apremilast daily|20 mg of CC-10004 daily
11605752|NCT00606450|Experimental|20mg Apremilast twice daily|CC-10004 twice daily
11605753|NCT00606450|Placebo Comparator|Placebo|Placebo arm
11605754|NCT00606437|Experimental|I|Total Body Irradiation (TBI)/Flu Conditioning followed by combined UCB
11605755|NCT00606411|Active Comparator|Topiramate|Study medication arm, 25-300mg of Topiramate
11605756|NCT00606411|Placebo Comparator|Placebo|Placebo arm of study, 25-300mg of sugar pill
11605757|NCT00606385|Experimental|laparoscopic liver resection|Patients who underwent laparoscopic liver resection for HCC
11605758|NCT00606385|Active Comparator|open liver resection|Patients who underwent open liver resection for HCC
11605759|NCT00606372||1|Patients with ischemic heart disease, with EuroSCORE 6 additive points and more, operated with use of the cardio-pulmonary bypass
11605760|NCT00606372||2|Patients with ischemic heart disease, with EuroSCORE 6 additive points and more, operated without use of the cardio-pulmonary bypass
11605761|NCT00606359|Experimental|Study Group 1|
11605762|NCT00606359|Active Comparator|Study Group 2|
11605763|NCT00606346||Anti TNF therapy including infliximab|Treatments will be prescribed according to investigator judgement.
11605764|NCT00606346||No Biologics|Treatments will be prescribed according to investigator judgement.
11605765|NCT00606333|Experimental|Investigational arm|Subjects randomized to treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
11605766|NCT00606333|Active Comparator|Control Arm|Subjects randomized to treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System.
11605767|NCT00606320|Experimental|Aripiprazole|
11605768|NCT00606307|Experimental|ITF2357|Initial dose of 50 mg b.i.d. that was subsequently escalated to 50 mg t.i.d in case of lack of significant toxicity.
11605769|NCT00606294|Experimental|Cohort 1 (closed to accrual)|Cohort 1 (closed to accrual) Cohort 1 (closed to accrual) There will be no change or intervention in a patient's treatment regime using chemoradiation where both the primary and the neck nodes receive 70Gy. This is currently one accepted standard of care. In a subcohort of patients in Cohort 1 with tumors that are positive for HPV who exhibited no evidence of hypoxia on their baseline 18F-FMISO PET/ CT scan or whose tumors have early resolution of hypoxia on their repeat early response 18F-FMISO PET/CT scan will undergo an alternative treatment where the primary tumor site receives 70Gy while the neck nodes receive 60Gy followed by a planned FDG PET/CT scan and observation.
11605770|NCT00606294|Experimental|Cohort 2 (closed to accrual)|Experimental: Cohort 2 (closed to accrual) Cohort 2 HPV+ tumors that demonstrate no evidence of hypoxia on an 18F-FMISO PET scan will receive 30Gy to the surgical bed and neck lymph nodes concurrent with standard chemotherapy followed by a 3-4 month post-treatment neck dissection. In patients who exhibit a complete response with this method of treatment, no further treatment is necessary. For patients within this select group who still have pathologic nodal disease, further standard chemoradiation will be given. All other patients in this cohort (i.e. those who are not in the select HPV+ tumor group outlined above) will receive standard of care treatment following their surgery.
11605771|NCT00606281|Experimental|1|
11605772|NCT00606281|Placebo Comparator|2|
11605773|NCT00606268|Experimental|1|1.0 mg/kg
11605774|NCT00606268|Experimental|2|1.5 mg/kg
11605775|NCT00606255||A|Active training group: Electronic Pill-Boxes with SMS service 1/week, training material provided
11605776|NCT00606255||B|Passive training group: Electronic Pill-Boxes ,Training material provided
11605777|NCT00606255||C|Usual treatment group: Electronic Pill-Boxes, maintain current treatment method
11605778|NCT00606242|Active Comparator|Low dose steroid|Fluticasone, 100 mcg per day
11605779|NCT00606242|Active Comparator|High dose steroid|Fluticasone, 1000 mcg per day
11605780|NCT00606229|Experimental|1|
11605781|NCT00606216||A|TBI and Chemotherapy Conditioning Regimen. Twenty (20) patients will undergo conditioning treatment with TBI and chemotherapy prior to receiving a myeloablative allogeneic or an autologous HSCT.
11605782|NCT00606216||B|Chemotherapy Alone Conditioning Regimen Twenty (20) patients will undergo conditioning treatment with an all chemotherapy regimen prior to receiving an allogeneic or an autologous HSCT.
11605783|NCT00606216||C|A cohort of twenty (20) healthy controls, frequency matched on age, gender, and education, will be recruited at WCMC to participate in the study.
11605784|NCT00606203|Experimental|A|The aims of this study are to investigate the prophylactic effect of milnacipran in post stroke depression.
11605785|NCT00606203|Placebo Comparator|B|Placebo
11605786|NCT00606190|Active Comparator|Retrograde brain perfusion|Pt may be randomized to retrograde brain perfusion when having a repair of the ascending aortic artery (aorta) including the aortic arch. This is one of the standard methods used while the body and the brain are cooled down to sub-normal levels (hypothermia). This will take place while on the heart-lung machine.
11605787|NCT00606190|Active Comparator|Antegrade brain perfusion|Pt may be randomized to antegrade brain perfusion when having a repair of the ascending aortic artery (aorta) including the aortic arch. This is one of the standard methods used while the body and the brain are cooled down to sub-normal levels (hypothermia). This will take place while on the heart-lung machine.
11605788|NCT00606177|Experimental|1|
11605789|NCT00606177|Placebo Comparator|2|
11605790|NCT00606164|Placebo Comparator|Placebo|
11605791|NCT00606164|Experimental|10 ug/m2 Bryostatin|
11605792|NCT00606164|Experimental|15 ug/m2 Bryostatin|
11605965|NCT00604877|Experimental|1|
11605966|NCT00604877|Active Comparator|2|
11605794|NCT00606138|Active Comparator|PRP Laser|Additional panretinal photocoagulation (up to 500 300-500 um laser spots)
11605795|NCT00606125|Experimental|Arm 1|
11605796|NCT00606112|Placebo Comparator|1|
11605797|NCT00606112|Placebo Comparator|2|
11605798|NCT00606112|Placebo Comparator|3|
11605799|NCT00606112|Placebo Comparator|4|
11605800|NCT00606099|Experimental|1|telbivudine
11605801|NCT00606099|Active Comparator|2|adefovir dipivoxil
11605802|NCT00606086|Experimental|1|GI-5005 monotherapy continuing on to triple therapy
11605803|NCT00606086|Active Comparator|2|Standard of care alone
11605804|NCT00606073|Active Comparator|I|IVF Procedure-IVF Medium
11605805|NCT00606073|Active Comparator|II|IVF Procedure - ISM1 Medium
11605806|NCT00606073|Active Comparator|III|ICSI Procedure - IVF Medium
11605807|NCT00606073|Active Comparator|IV|ICSI Procedure - ISM1 Medium
11605808|NCT00606060|Experimental|Arm 1|
11605809|NCT00606047||Asymptomatic patients|Asymptomatic, healthy patients (without hip pain or prior hip disease) will be recruited. Patients will undergo a magnetic resonance imaging (MRI) of the hip joints to evaluate for the prevalence of femoroacetabular impingement (FAI).
11605810|NCT00606034|Experimental|All subjects active|All subjects will receive the experimental treatment (U-500 insulin via Omnipod) since they have already failed all other previous insulin treatment regimens.
11605811|NCT00606021|Experimental|A: Pemetrexed + Best Supportive Care|"Pemetrexed: 500 milligrams per square meter (mg/m²) , intravenous (IV), Day 1 of each 21-day cycle for 6 cycles
~Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."
11605812|NCT00606021|Active Comparator|B: Best Supportive Care|Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
11605813|NCT00606008|Experimental|Sutent Treatment|Sutent was administered daily for 4 weeks at a dose of 50 mg followed by a 2 week study drug free break.
11605814|NCT00605995|Experimental|Simvastatin|Simvastatin, 20 mg Tablet, given once daily. Dosage increased to 40 mg/day at the end of week 4 until endpoint.
11605815|NCT00605995|Placebo Comparator|Placebo|Placebo pill, similar in its appearance to Simvastatin, taken once daily for the duration of the trial.
11605816|NCT00605982|Experimental|1|Women with core biopsy proven DCIS with or without microinvasion seen for surgical consultation at Memorial Sloan-Kettering Cancer Center and for whom operative intervention is planned.
11605817|NCT00605969|Active Comparator|FAI patients|This group consists of participants diagnosed with femoroacetabular impingement that are undergoing surgical correction.
11605818|NCT00605969|Placebo Comparator|Control|This group consists of healthy control participants with no hip problems.
11605819|NCT00605956|Experimental|1|NatrOVA Creme Rinse - 1% Spinosad
11605820|NCT00605956|Experimental|2|NatrOVA Vehicle - no Spinosad
11605821|NCT00605956|Placebo Comparator|3|Blank Patch
11605822|NCT00605930|Active Comparator|Pyruvate, creatine, niacinamide|Pyruvate, creatine, niacinamide administered
11605823|NCT00605930|Placebo Comparator|Placebo|placebo
11605824|NCT00605917||Sertraline hydrochloride.|The patients of Panic disorder taking Sertraline hydrochloride.
11605825|NCT00605904|Experimental|Acamprosate|Subjects received 3 tablets of 333mg acamprosate orally, three times daily (total dose of 999 mg) for a minimum of 2 weeks.
11605826|NCT00605904|Placebo Comparator|Placebo|Subjects received 3 tablets of placebo orally, three times daily, for a minimum of 2 weeks.
11605827|NCT00605891|Experimental|A|carmoterol (CHF 4226) 1.0 μg once a day, in the morning
11605828|NCT00605891|Experimental|B|carmoterol (CHF 4226) 2.0 μg once a day, in the morning
11605829|NCT00605891|Experimental|C|carmoterol (CHF 4226) 4.0 μg once a day, in the morning
11605830|NCT00605891|Placebo Comparator|D|Placebo once a day, in the morning
11605831|NCT00605891|Active Comparator|E|Salmeterol 50 μg BID, in the morning and in the evening
11605832|NCT00605878||Grouo 3|Healthy (pediatric) controls
11605833|NCT00605878||Group 1|Healthy (adult) volunteers
11605834|NCT00605878||Group 2|AD patients
11605835|NCT00605878||Group 4|Patients diagnosed with the primary immunodeficiency hyperIgE syndrome (HIES)
11605836|NCT00605878||Group 5|Patients diagnosed with the primary immunodeficiency Wiskott-Aldrich Syndrome (WAS)
11605837|NCT00605878||Group 6|Patients diagnosed with the combined immunodeficiency associated with DOCK8 mutation (DOCK8)
11605838|NCT00605865||Sertraline hydrochloride.|Patients taking Sertraline hydrochloride.
11605839|NCT00605852|Experimental|Subjects receiving treatment in cohort I|Eligible subjects will receive three single doses of GSK835726 and one single dose of placebo in cohort I.
11605840|NCT00605852|Experimental|Subjects receiving GSK835726 in cohort II|Eligible subjects will receive repeat doses of GSK835726 once daily for 7 days.
11605841|NCT00605852|Placebo Comparator|Subjects receiving placebo in cohort II|Eligible subjects will receive repeat doses of placebo once daily for 7 days.
11605842|NCT00605852|Experimental|Subjects receiving treatment in cohort III|Eligible subjects will receive two single doses of GSK835726 and one single dose of placebo in cohort III.
11605843|NCT00605839|Experimental|Glucopak Care|Glucopak cell phone and intensive monitoring. This group will be given the experimental device, and placed in close communication with the clinic.
11605844|NCT00605839|Active Comparator|Cell Phone Care|Cell phone only, without the Glucopak. Participants will be given cell phones and encouraged to communicate more closely with the clinic, but will not use the Glucopak.
11605845|NCT00605839|Placebo Comparator|Usual Care|Usual care, without cell phone or glucopak
11605846|NCT00605826|Experimental|Blinded injection of NASHA/Dx gel at randomization.|Blinded injection of NASHA/Dx (Solesta) Gel. For each treatment, a series of 4 equally spaced injections with 1 mL of Solesta into the anal canal. Subjects will be followed for 6 months during the blinded phase. During a subsequent open phase, these subjects will be followed to Month 36 (ie, for an additional 30 months).
11605902|NCT00605371|Experimental|Subjects receiving regimen A|Eligible subjects will receive regimen A containing lamotrigine extended release tablet of 200 milligrams plus 50 milligrams in fasted state
11605963|NCT00604890|Placebo Comparator|3|Placebo cream AM; 1.5% active cream PM
11605847|NCT00605826|Sham Comparator|Blinded sham inject. at randomization|"Blinded sham injection (needle stick with empty syringes). For each treatment, a series of 4 equally spaced Sham injections (needle sticks) into the anal canal. Subjects will be followed for 6 months during the blinded phase.
~Sham-treated subjects have the option to receive open-label injection of NASHA/Dx (Solesta) Gel at the 6-month time point following completion of the blinded phase (ie, blinded sham injection at randomization + NASHA/Dx Gel at 6 months). Following injection of NASHA/Dx gel at the start of the open phase, these subjects will be followed to Month 30 (ie, for an additional 24 months)."
11605848|NCT00605826|Other|Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo.|"Blinded sham injection at randomization. Subjects will be followed for 6 months during the blinded phase.
~Sham-treated subjects have the option to receive open-label injection of NASHA/Dx (Solesta) Gel at the 6-month time point following completion of the blinded phase (ie, blinded sham injection at randomization + NASHA/Dx Gel at 6 months). Following injection of NASHA/Dx gel at the start of the open phase, these subjects will be followed to Month 30 (ie, for an additional 24 months)."
11605849|NCT00605813||Sertraline hydrochloride.|Patients taking Sertraline hydrochloride.
11605850|NCT00605800||1|normal healthy volunteers
11605851|NCT00605800||2|Patients undergoing major liver resections
11605852|NCT00605787|Active Comparator|Single group|Single group all treated similarly, outcome evaluated as changes within individuals during intervention
11605853|NCT00605774|Experimental|1|Hyperinsulinemic euglycemic glucose clamps x 2 on Day 1 Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion on Day 2
11605854|NCT00605774|Experimental|2|Day 1 euglycemic exercise period x 2 Day 2 hyperinsulinemic euglycemic glucose clamp with epinephrine infusion
11605855|NCT00605761|Experimental|Cohort 1|50 mg treatment
11605856|NCT00605761|Experimental|Cohort 2|150 mg treatment
11605857|NCT00605748|Active Comparator|1|Segmental PV-Isolation of the arrhythmogenic vein(s)
11605858|NCT00605748|Active Comparator|2|Segmental PV-Isolation of all veins
11605859|NCT00605735|Experimental|A1|
11605860|NCT00605735|Placebo Comparator|P1|
11605861|NCT00605722|Experimental|bevacizumab + erlotinib|Participants received bevacizumab (Avastin) 5 mg/kg intravenous (iv) on day 1 of each 2 week cycle plus erlotinib (Tarceva) 150 mg orally once a day until disease progression or unmanageable toxicity.
11605862|NCT00605709|Experimental|1|Active Cream 3% ; AM & PM
11605863|NCT00605709|Active Comparator|2|Placebo Cream AM; 3% Active Cream PM
11605864|NCT00605709|Active Comparator|3|Placebo Cream AM; 1.5% Active Cream PM
11605865|NCT00605709|Placebo Comparator|4|Placebo Cream AM & PM
11605866|NCT00605696|Experimental|1|Participants will receive insulin to target glucose 80-110 mg/dl within 6-12 hours after presenting to ED.
11605867|NCT00605696|Active Comparator|2|Participants will receive insulin to target 150-180 mg/dl for 48 hours after ICU admission followed by usual clinical care.
11605868|NCT00605683|Active Comparator|1|50 mg/day Safinamide
11605869|NCT00605683|Active Comparator|2|Safinamide 100mg/day
11605870|NCT00605683|Placebo Comparator|3|Placebo 0mg/Safinamide
11605871|NCT00605670||1|Postoperative Breast Surgery Patients
11605872|NCT00605670||2|Preoperative Breast Surgery Patients
11605873|NCT00605657|Experimental|Valproic acid|Single arm study involving oral administration of valproic acid and monitoring of its efficacy by CT scans done before and after the intervention. Blood samples were also obtained to monitor safety labs and biomarkers.
11605874|NCT00605644|Placebo Comparator|Placebo|Placebo
11605875|NCT00605644|Experimental|150 mg|MOA-728
11605876|NCT00605644|Experimental|300 mg|MOA-728
11605877|NCT00605644|Experimental|450 mg|MOA-728
11605878|NCT00605644|Experimental|600 mg|MOA-728
11605879|NCT00605631|Experimental|1|
11605880|NCT00605631|Active Comparator|2|
11605881|NCT00605631|Other|3|
11605882|NCT00605618|Experimental|Single Arm|
11605883|NCT00605605|Experimental|1|
11605884|NCT00605592|Experimental|1|Islet cell transplant
11605885|NCT00605566|Experimental|I|Patients will receive sorafenib and cyclophosphamide.
11605886|NCT00605553|Experimental|1|Active medication Tozadenant 20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
11605887|NCT00605553|Placebo Comparator|2|Crossover from arm 1 to arm 2 with one week washout. One of the arms is placebo control
11605888|NCT00605540||Study COPD population|Patients with diagnosis of mild to very severe chronic obstructive pulmonary disease
11605889|NCT00605488|Experimental|1|Pet Scan
11605890|NCT00605475|Experimental|Canakinumab|"Eligible participants were assigned to receive canakinumab in one of four cohorts; 1) Single IV infusion of canakinumab 0.3 mg/kg; 2) Singe IV infusion of canakinumab 10 mg/kg; 3) single IV infusion of canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of canakinumab 0.03 mg/kg.
~All participants were required to take a concomitant stable daily dose of metformin during the study."
11605891|NCT00605475|Placebo Comparator|Placebo|"Eligible participants were assigned to receive placebo to canakinumab in one of four cohorts; 1) Single IV infusion of placebo to canakinumab 0.3 mg/kg; 2) Singe IV infusion of placebo to canakinumab 10 mg/kg; 3) single IV infusion of placebo to canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of placebo to canakinumab 0.03 mg/kg.
~All participants were required to take a concomitant stable daily dose of metformin during the study."
11605892|NCT00605436|Experimental|A|Restorative yoga therapy group: one orientation workshop for 3 hours, then twice-weekly group yoga therapy classes for first 5 weeks followed by once-weekly group yoga classes for another 5 weeks. The group will also be asked to practice their yoga postures at home for 30 minutes three times per week.
11605893|NCT00605436|No Intervention|B|The control group is a wait-list control group with no active intervention.
11605894|NCT00605423|Active Comparator|1|Dose 0.2 ug/day Medidur implant
11605895|NCT00605423|Active Comparator|2|Dose 0.5 ug/day Medidur implant
11605896|NCT00605410|Active Comparator|1|
11605897|NCT00605410|Placebo Comparator|2|
11605898|NCT00605397|Experimental|1|breast cancer pt receiving trastuzumab therapy will undergo two complete PET studies.
11605899|NCT00605397|Experimental|2|breast cancer pt receiving trastuzumab therapy will undergo one complete PET studies
11605900|NCT00605384|Experimental|1|
11605903|NCT00605371|Experimental|Subjects receiving regimen B|Eligible subjects will receive regimen B containing lamotrigine extended release caplet of 250 milligrams in fasted state.
11605904|NCT00605371|Experimental|Subjects receiving regimen C|Eligible subjects will receive regimen C containing lamotrigine extended release caplet of 250 milligrams in fed state.
11605905|NCT00605358|Active Comparator|Open Door Intervention|Subjects who receive the Open Door Intervention will work with the study counselor to identify barriers to participation in mental health treatment, set goals, and problem-solve, in addition to receiving a referral.
11605906|NCT00605358|No Intervention|Services Referral|"Subjects who do not receive the Open Door intervention will receive:
~an evaluation
~referral to a local mental health provider
~booklet information on depression and mental health care, and will complete an application for HEAP, a Westchester County service that provides reduced rates from oil companies on heating to seniors."
11605907|NCT00605345|Experimental|CERA Treatment Once Monthly|
11605908|NCT00605345|Active Comparator|Darbepoetin Alfa Once Biweekly|
11605909|NCT00605332|Experimental|1|Investigative Device (Crux Biomedical IVC Filter) will be evaluated for its ability to capture thrombus for the prevention of pulmonary embolism.
11605910|NCT00605319|Other|Toviaz (Fesoterodine)|Toviaz 4mg to 8mg
11605911|NCT00605306|Experimental|indacaterol maleate/mometasone furoate|Participants received 2 inhalations of indacaterol maleate / mometasone furoate 250/400 μg once daily in the evening (full dose 500/800 μg) delivered via the Twisthaler device for 14 days.
11605912|NCT00605306|Placebo Comparator|Placebo|Participants received 2 inhalations of placebo to indacaterol maleate / mometasone furoate once daily in the evening delivered via the Twisthaler device for 14 days.
11605913|NCT00605293|Experimental|C.E.R.A|Participants received starting dose of 120, 200 or 360 mcg of C.E.R.A IV once monthly for 6 months. The starting dose was based on the dose of epoetin alfa administered in Week -1.
11605914|NCT00605293|Active Comparator|Epoetin Alfa|Participants received IV injection of 6000 International Units (IU) of epoetin alfa every 3 weeks (q3wk) during the Stability Verification Period (SVP; Week -4 to -1), and 7443 IU of epoetin alfa q3wk during Dose Titration Period (DTP; Week 0 to 15), 7363 IU of epoetin alfa q3wk during Efficacy Evaluation Period (EEP; Week 16 to 23) up to 23 weeks.
11605915|NCT00605280|Sham Comparator|Sham Control|
11605916|NCT00605280|Experimental|Macugen|
11605917|NCT00605267|Active Comparator|1|Tamoxifen
11605918|NCT00605267|Experimental|2|Anastrazole (Arimidex)
11605919|NCT00605241|Other|GSK598809|Drug
11605920|NCT00605228|Experimental|1|
11605921|NCT00605228|Active Comparator|2|
11605922|NCT00605215|Experimental|Laquinimod|0.6 mg Laquinimod oral once daily
11605923|NCT00605215|Placebo Comparator|Placebo|oral placebo once daily
11605924|NCT00605215|Active Comparator|Interferon|Interferon β-1a (Avonex®) 30 mcg IM once weekly
11605925|NCT00605202|Active Comparator|Licorice|
11605926|NCT00605202|Active Comparator|Licorice and HCTZ|
11605927|NCT00605189|Active Comparator|VAC NPWT|
11605928|NCT00605189|Active Comparator|Gauze-Based NPWT|
11605929|NCT00605189|Active Comparator|Moist Wound Therapy|
11605930|NCT00605176|Active Comparator|3.75% imiquimod cream|
11605931|NCT00605176|Active Comparator|2.5% imiquimod cream|
11605932|NCT00605176|Placebo Comparator|Placebo cream|
11605933|NCT00605150||Patients enrolled|Total number of patients enrolled
11605934|NCT00605124|Experimental|exercise|progressive exercise, home-based exercise program, tree exercise sessions weekly, chec-up visits every third month
11605935|NCT00605124|Active Comparator|Conventional treatment|Normal treatment, single guidance to home exercise
11605936|NCT00605098|Active Comparator|1|
11605937|NCT00605098|Experimental|2|
11605938|NCT00605085|Experimental|1|IC51
11605939|NCT00605085|Placebo Comparator|2|Placebo
11605940|NCT00605072|Experimental|Candesartan|Angiotensin Receptor Blocker
11605941|NCT00605072|Experimental|Lisinopril|Angiotensin-Converting Enzyme (ACE) Inhibitor
11605942|NCT00605072|Active Comparator|HCTZ|Hydrochlorothiazide (diuretic)
11605943|NCT00605059|Experimental|Assess [123I] AV94 and SPECT imaging|
11605944|NCT00605046|Experimental|Asses [123I] AV151 and SPECT imaging|
11605945|NCT00605033|Active Comparator|Suboxone|Double-blind, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) plus matching Subutex placebo during Week 1 followed by open-label, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.
11605946|NCT00605033|Active Comparator|Subutex|Double-blind, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) plus matching Suboxone placebo during Week 1 followed by open-label, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.
11605947|NCT00604994||Malignant|Patients with malignant gynaecological conditions including cancers of the cervix, uterus, ovary, vulva and vagina
11605948|NCT00604994||Benign|Patients without malignant gynaecological cancers
11605949|NCT00604981|Experimental|1|Multisystemic Therapy (MST)
11605950|NCT00604981|Active Comparator|2|Shapedown
11605951|NCT00604968|Experimental|Caelyx|
11605952|NCT00604955|Experimental|A|Paromomycin IM Injection (approved product in India)
11605953|NCT00604942|Experimental|Achalasia|Long vs Short Myotomy repair of Achalasia
11605954|NCT00604942|Experimental|Dysphagia control|Conservative Management
11605955|NCT00604942|Experimental|GORD for surgery|Partial vs Full Fundoplication repair
11605956|NCT00604942|Experimental|GORD not for surgery|esomeprazole 40 mg vs no esomeprazole
11605957|NCT00604929|Experimental|1|
11605958|NCT00604916|Experimental|E|received a 7 day standardized oral care protocol
11605959|NCT00604916|Placebo Comparator|C|received a 7 day mimic protocol
11605960|NCT00604903|Experimental|Patients implanted with Pressure Sensor|Implant of Pressure sensor. These are patients, who were implanted with the Remon CHF Implantable Pressure Sensor utilizing the corresponding delivering system.
11605961|NCT00604890|Experimental|1|Active cream, 3% AM & PM
11605962|NCT00604890|Placebo Comparator|2|Placebo cream AM ; 3% active cream PM
11605967|NCT00604864|Experimental|1|women with a deep endometriosis nodule of at least 1 cm in diameter; and severe pain (at least one severe pain score on Biberoglu Behrman scale)
11605968|NCT00604864|Placebo Comparator|2|women with a deep endometriosis nodule of at least 1 cm in diameter; and severe pain (at least one severe pain score on Biberoglu Behrman scale)
11605969|NCT00604838|Experimental|I|
11605970|NCT00604825|Placebo Comparator|Placebo|Placebo
11605971|NCT00604825|Active Comparator|GSK232802|GSK232802
11605972|NCT00604825|Experimental|PREMARIN|PREMARIN
11605973|NCT00604812|Experimental|Panel A Rizatriptan|"Subjects allocated to Panel A and randomized to receive a single dose of rizatriptan 5 mg orally disintegrating tablet (ODT) on Day 1.
~Subjects weighing 20-39 kg were allocated to Panel A."
11605974|NCT00604812|Placebo Comparator|Panel A Placebo|"Subjects allocated to Panel A and randomized to receive a single dose of rizatriptan 5 mg orally disintegrating tablet (ODT) placebo on Day 1.
~Subjects weighing 20-39 kg were allocated to Panel A."
11605975|NCT00604812|Experimental|Panel B Rizatriptan|"Subjects allocated to Panel B and randomized to receive a single dose of rizatriptan 10 mg orally disintegrating tablet (ODT) on Day 1.
~Subjects weighing 40 kg and above were allocated to Panel B."
11605976|NCT00604812|Placebo Comparator|Panel B Placebo|"Subjects allocated to Panel B and randomized to receive a single dose of rizatriptan 10 mg orally disintegrating tablet (ODT) placebo on Day 1.
~Subjects weighing 40 kg and above were allocated to Panel B."
11605977|NCT00604812|Experimental|Panel C Rizatriptan|"Subjects allocated to Panel C and randomized to receive a single dose of rizatriptan ODT on Day 1. Subjects in Panel C weighing 20-39 kg received a 5 mg dose and subjects weighing 40 kg and above received a 10 mg dose.
~Panel C was added to the study by amendment to increase the number of male subjects in the 12-17 year old age group."
11605978|NCT00604812|Placebo Comparator|Panel C Placebo|"Subjects allocated to Panel C and randomized to receive a single dose of rizatriptan ODT placebo on Day 1. Subjects in Panel C weighing 20-39 kg received a 5 mg placebo dose and subjects weighing 40 kg and above received a 10 mg placebo dose.
~Panel C was added to the study by amendment to increase the number of male subjects in the 12-17 year old age group."
11605979|NCT00604799|Active Comparator|Test (Enrollment Completed)|Patients diagnosed with a TAA of degenerative etiology that are considered candidates for open surgical repair whom are low to moderate risk (0, 1, & 2) per the modified SVS/AAVS criteria who meet inclusion/exclusion criteria. The aneurysm must be at least 20 mm distal to the left common carotid artery & 20 mm proximal to the origin of the celiac artery.
11605980|NCT00604799|Other|Registry (Enrollment Completed)|Surgical candidates of low to moderate risk (SVS 0, 1, 2) that meet the Registry Inclusion/Exclusion criteria.
11605981|NCT00604799|Other|High Risk (Enrollment Completed)|"Patients that meet one or more of the following:
~High Risk (SVS 3)
~Non-surgical candidates not associated with SVS scoring
~Traumatic thoracic injuries"
11605982|NCT00604799|Other|Talent Captivia (Recruiting)|Patients diagnosed with a TAA of degenerative etiology that are considered candidates for open surgical repair who meet inclusion/exclusion criteria.
11605983|NCT00604786|Experimental|Omalizumab subcutaneous|"This active are will receive treatment with omalizumab subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).
~The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks"
11605984|NCT00604786|Placebo Comparator|Placebo Subcutaneous|"This placebo arm will receive identical treatment with placebo injections subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).
~The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks."
11605985|NCT00604773||delirious patients|minimal one positive CAM-ICU score during ICU admission
11605986|NCT00604773||non-delirious patients|without any positive CAM-ICU scores during ICU admission
11605987|NCT00604760|Experimental|A|
11605988|NCT00604760|Experimental|B|
11605989|NCT00604760|Experimental|C|
11605990|NCT00604760|Placebo Comparator|D|
11605991|NCT00604747|Other|1, 2|
11605992|NCT00604734|Other|ReCap|ReCap Total Hip Resurfacing System
11605993|NCT00604721|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive a single dose of selumetinib on day 1 and undergo blood collection for PK sampling pre-dose (within 30 min of dosing), 15 and 30 minutes and 1, 2, 4, 8, 12, 24 and 48 hours post-dose. Beginning 48 hours after the initial dose and continuing until day 21, patients receive oral selumetinib twice daily. Patients also undergo blood collection for PK sampling on day 15 of course 1. In all subsequent courses, patients receive selumetinib on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11605994|NCT00604708|Experimental|IC51|6 mcg (microgram) i.m. (intramuscular) on Day0, 14 and 28
11605995|NCT00604708|Active Comparator|JE-VAX|given s.c. on Day 0, 7 and 28
11605996|NCT00604695|Active Comparator|1|Two (4mg) doses of tenecteplase
11605997|NCT00604695|Placebo Comparator|2|Two (4mL) doses of sterile saline
11605998|NCT00604682|Experimental|Administration of CC10004|
11605999|NCT00604630|Placebo Comparator|placebo|50ml 0.9% NaCL
11606000|NCT00604630|Active Comparator|verum|erythropoietin alfa 40,000 IU iv in 50ml 0.9% NaCl
11606001|NCT00604604|No Intervention|1|Control group (usual postpartum care)
11606002|NCT00604604|Experimental|2|Experimental group (usual postpartum care plus telephone-based support from an experienced mother who has participated in a 4-hour training session)
11606003|NCT00604591|Placebo Comparator|Placebo then Tolcapone|"Participants take placebo during study week 1 and then tolcapone during week 3.
~On Day 1, 100 mg of tolcapone/placebo will be taken at three specific times: once in the morning, once in the afternoon, once at night. Then, from Days 2-6, 200 mg of tolcapone/placebo will be taken three times a day: once in the morning, once in the afternoon, once at night. On Day 7, 200 mg of tolcapone/placebo will be taken only in the morning and afternoon. On Day 8, 200 mg of tolcapone/placebo will be taken only in the morning. After the last dose on Day 8 is taken, the wash-out period begins and lasts through Day 14."
11606004|NCT00604591|Experimental|Tolcapone then Placebo|"Participants take tolcapone during study week 1 and then placebo during week 3.
~On Day 1, 100 mg of tolcapone/placebo will be taken at three specific times: once in the morning, once in the afternoon, once at night. Then, from Days 2-6, 200 mg of tolcapone/placebo will be taken three times a day: once in the morning, once in the afternoon, once at night. On Day 7, 200 mg of tolcapone/placebo will be taken only in the morning and afternoon. On Day 8, 200 mg of tolcapone/placebo will be taken only in the morning. After the last dose on Day 8 is taken, the wash-out period begins and lasts through Day 14."
11606005|NCT00604565|Experimental|SFP dialysate|dialysate with added soluble ferric pyrophosphate (SFP)
11606006|NCT00604565|Placebo Comparator|standard dialysate|standard dialysate without soluble ferric pyrophosphate (SFP)
11606007|NCT00604552|Other|Lifeline Registry|All comers registry for the on-label treatment of AAA with the AneuRx Stent Graft sponsored by the Foundation of Society for the Vascular Surgery (SVS)
11606008|NCT00604552|Other|PS Registry|All comers registry for the on-label treatment of AAA with the AneuRx Stent Graft sponsored by Medtronic
11606009|NCT00604539|Experimental|1|Chondroitin sulphate
11606010|NCT00604539|Placebo Comparator|2|
11606011|NCT00604526|Experimental|1|Questionnaires, Iridium 192 radioactive seeds
11606012|NCT00604513|Experimental|1|
11606013|NCT00604513|Sham Comparator|2|
11606014|NCT00604500|Experimental|MF/F MDI 100/10 mcg BID with dose counter|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MFF MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
11606015|NCT00604487|Active Comparator|1|Insertion of the Atad double balloon ripener device (100 ml NS in each balloon).
11606016|NCT00604487|Active Comparator|2|Insertion of the double balloon instillation device (100 ml NS in each balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
11606017|NCT00604487|Active Comparator|3|Insertion of the folly catheter (40 ml NS in the balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
11606018|NCT00604474|Active Comparator|1|
11606019|NCT00604461|Experimental|Dose Escalation Followed by Maintenance Therapy|"A: Tiered Dose Escalation/Phase II Dose -
~Tier -1: Carboplatin AUC 4 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.
~Tier 1: Carboplatin AUC 5 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.
~Tier 2: Carboplatin AUC 6 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.
~B: Maintenance Therapy -
~Patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first."
11606020|NCT00604448|Experimental|Pulse group|a group receiving a meal with pulses (5 cups/week) for 8 weeks
11606021|NCT00604448|Experimental|Energy-restricted group|a group with a diet restriction of 500 kcal/day for 8 weeks
11606022|NCT00604435|Active Comparator|chemotherapy|neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin
11606023|NCT00604435|Experimental|chemotherapy plus endostatin|neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin plus endostatin
11606024|NCT00604422||A|Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease
11606025|NCT00604409|Experimental|Treatment (SIRT and capecitabine)|Patients receive capecitabine PO twice daily on days 1-14. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients undergo SIRT on day 2 and may undergo a second course of SIRT on day 58.
11606026|NCT00604383|Experimental|Ruboxistaurin|
11606027|NCT00604383|Placebo Comparator|Placebo|
11606028|NCT00604370||1|Acutely ill medical and surgical patients who were hospitalized at BWH, and at-risk for VTE, but were not treated with prophylaxis at hospital discharge.
11606029|NCT00604370||2|Acutely ill medical and surgical patients who were at risk for VTE at time of hospital discharge and prescribed a prophylaxis strategy.
11606030|NCT00604357|Experimental|1|Prior to reperfusion 500 mg Prednisolone will be administered i.v.. After the transplantation, a combination of anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure), and MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake) will be applied. Earliest, on day 10 after LT Sirolimus will be introduced aiming at 24 hours trough-levels for Sirolimus between 4 and 8 ng/mL. Steroids will be started on day 1 after transplantation with 1mg/kg BW and will be tapered every 2 days for 5 mg to a dosage of 20 mg and for 2.5 mg every two days to 7.5 mg. Thereafter the dosage will be reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter. Additionally, every patient with risk constellation will receive cytomegalovirus (CMV) prophylaxis and prophylaxis against Pneumocystis carinii infection during the first 3 months after liver transplantation.
11606031|NCT00604331|Active Comparator|A|Pyruvate
11606032|NCT00604318|Placebo Comparator|placebo|To receive the placebo treatment in connection with the primary RI therapy and the T3 tablets and rh-TSH injections prior to second RI uptake measurement
11606033|NCT00604318|Active Comparator|rh-TSH|To continue with L-T3 and to receive rh-TSH stimulation with 0,9 mg Thyrogen® (Genzyme) x 2 days minus 1 and 2 prior to RI therapy, and following this to have placebo tablets and placebo injections with isotone NaCl prior to the RI uptake measurement 4-6 months later
11606034|NCT00604305|Active Comparator|Acrysof|Routine monofocal IOL
11606035|NCT00604305|Active Comparator|Acuity's AIOL|Accomodaing IOL
11606036|NCT00604292||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases
11606037|NCT00604279|Experimental|Paliperidone palmitate|Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion.
11606038|NCT00604279|Active Comparator|Risperidone long acting injection (LAI)|Risperidone LAI intramuscular at a dose of 25 milligram (mg) on Day 8 and Day 22; flexible dose of either 25 or 37.5 mg on Day 36 with same dose on Day 50; and either 25, 37.5, or 50 mg on Day 64 with same dose on Day 78; along with oral risperidone 2 mg tablet on Day 1, flexible doses (1-6 mg/day) for first 28 days; and 1-2 mg/day during Day 36-57 and Day 64-85 if the dose of risperidone LAI was increased on Day 36 and Day 64.
11606039|NCT00604266||1|10-15 patients with potentially resectable hiilar cholangiocarcinoma
11606040|NCT00604240||1|Parents / caregivers of any infant who has a length of stay of at least 1 week in the NICU at Christiana Hospital or Thomas Jefferson University Hospital.
11606041|NCT00604227|Experimental|1|high altitude exposure
11606042|NCT00604214|Experimental|Drotrecogin alfa (activated)|
11606043|NCT00604214|Placebo Comparator|Placebo|
11606044|NCT00604201|Experimental|Co-infusion of UCB and Haploidentical CD34+ cells|Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)
11606045|NCT00604188|Experimental|Direct Suboxone Induction|Participants received 8 mg of Suboxone and placebo Subutex on Day 1, 16 mg of Suboxone and placebo Subutex on Day 2, and all participants received open label Suboxone from Day 3 to Day 28. Suboxone dosage may be titrated from Day 4 to Day 28 up to 24 mg per day.
11606046|NCT00604188|Active Comparator|Subutex-to-Suboxone Induction|Participants received 8 mg Subutex and placebo Suboxone on Day 1, 16 mg Subutex and placebo Suboxone on Day 2, and all participants received open label Suboxone from Day 3 to Day 28. Suboxone dosage may be titrated from Day 4 to Day 28 up to 24 mg per day.
11606047|NCT00604175|Experimental|Stratum A|Participants with screening CD4 count >350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
11606048|NCT00604175|Experimental|Stratum B|Participants with screening CD4 count >200 to <=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
11606049|NCT00604175|Experimental|Stratum C|Participants with screening CD4 count <=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
11606050|NCT00604162|Experimental|PillCam COLON and Colonoscopy|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases, had capsule endoscopy with PillCam COLON after bowel preparation and before standard colonoscopy.
11606051|NCT00604149||1|case of out-of-hospital cardiac arrest
11606052|NCT00604149||2|cases of MI
11606053|NCT00604149||3|controls without coronary disease
11606054|NCT00604123|Experimental|JNJ-17166864|
11606055|NCT00604123|Placebo Comparator|Placebo|
11606056|NCT00604097|Experimental|1|Attachment-Based Family Therapy
11606057|NCT00604097|Active Comparator|2|Enhanced Usual Care
11606058|NCT00604084|Experimental|Ivermectin|Non-pregnant, non-breastfeeding, taller than 90cm and 5 years or older
11606059|NCT00604084|Experimental|Permethrin|Pregnant, breastfeeding, children under 90cm or under 5 years old
11606060|NCT00604071||1|subjects with AMD related lesions: New onset (up to 60 days) non-treated CNV
11606061|NCT00604058|Experimental|Group A|
11606062|NCT00604058|Active Comparator|Group B|
11606063|NCT00604045|Experimental|1 Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
11606064|NCT00604045|Placebo Comparator|2 Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
11606065|NCT00604032|Placebo Comparator|1|
11606066|NCT00604019|Active Comparator|Dopamine|Patients that get Dopamine as an infusion for hypotension
11606067|NCT00604019|Active Comparator|Norepinephrine|Patients that get norepinephrine as an infusion for hypotension
11606068|NCT00604006|Experimental|Group A|
11606069|NCT00604006|Placebo Comparator|Group B|
11606070|NCT00603993|Experimental|Adalimumab|Adalimumab 40 mg or 80 mg (same dose subject was receiving in preceding Study M03-651 [NCT 00235872]) subcutaneously (sc) administered every other week (eow) until approval of adalimumab in Japan
11606071|NCT00603980|Other|Treatment sequence 1|Sequence 1: Q, 1, 2, 7, 3, 6, 4, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
11606072|NCT00603980|Other|Treatment sequence 2|Sequence Q, 2: 2, 3, 1, 4, 7, 5, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
11606073|NCT00603980|Other|Treatment sequence 3|Sequence 3: Q, 3, 4, 2, 5, 1, 6, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
11606074|NCT00603980|Other|Treatment sequence 4|Sequence 4: Q, 4, 5, 3, 6, 2, 7, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
11606075|NCT00603980|Other|Treatment sequence 5|Sequence 5: Q, 5, 6, 4, 7, 3, 1, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
11606076|NCT00603980|Other|Treatment sequence 6|Sequence 6: Q, 6, 7, 5, 1, 4, 2, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
11606077|NCT00603980|Other|Treatment sequence 7|Sequence 7: Q, 7, 1, 6, 2, 5, 3, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
11606078|NCT00603980|Other|Treatment sequence 8|Sequence 8: Q, 5, 4, 6, 3, 7, 2, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
11609205|NCT00578370|Placebo Comparator|5|
11606079|NCT00603980|Other|Treatment sequence 9|Sequence 9: Q, 6, 5, 7, 4, 1, 3, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
11606080|NCT00603980|Other|Treatment sequence 10|Sequence 10: Q, 7, 6, 1, 5, 2, 4, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
11606081|NCT00603980|Other|Treatment sequence 11|Sequence 11: Q, 1, 7, 2, 6, 3, 5, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
11606082|NCT00603980|Other|Treatment sequence 12|Sequence 12: Q, 2, 1, 3, 7, 4, 6, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
11606083|NCT00603980|Other|Treatment sequence 13|Sequence 13: Q, 3, 2, 4, 1, 5, 7, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
11606084|NCT00603980|Other|Treatment sequence 14|Sequence 14: Q, 4, 3, 5, 2, 6, 1, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
11606085|NCT00603967|Other|Aromatase inhibitor|
11606086|NCT00603954|Active Comparator|1|Conditioning regimen consisting of fludarabine 30 mg/m2 on days -4, -3 and -2 (total dose 90 mg/m2), followed by a singe dose of 2 Gy TBI administered on day 0, at a low dose-rate (≈ 7 cGy/min), before infusion of cells.
11606087|NCT00603954|Active Comparator|2|Conditioning consisting of 8 Gy TLI and ATG. TLI will be administered by linear accelerator at a dose of 80 cGy daily, starting 11 days before transplantation, until a total of 10 doses (800 cGy) has been delivered. The irradiation will consist of a supradiaphragmatic mantle field, a subdiaphragmatic field including an inverted Y and splenic ports, encompassing all major lymphoid organs, including the thymus, spleen, and lymph nodes, as used in the treatment of Hodgkin's disease (Kaplan HS, Cancer Research 26:1268-1276, 1966). The Waldeyer ring is not included. ATG (Thymoglobulin®, Genzyme), at a dose of 1.5 mg/kg/d, will be given intravenously on days -11 through -7.
11606088|NCT00603941|Experimental|Cohort 1; 0.15 mg CS-7017|Participants who received 0.15 mg twice daily (BID) oral CS-7017 and 135 [Dose Level 1a] or 175 [Dose Level 1b] mg/m^2 intravenous (IV) paclitaxel once every 3 weeks.
11606089|NCT00603941|Experimental|Cohort 2; 0.30 mg CS-7017|Participants who received 0.30 mg twice daily (BID) oral CS-7017 and 175 mg/m^2 IV paclitaxel once every 3 weeks.
11606090|NCT00603941|Experimental|Cohort 3; 0.50 mg CS-7017|Participants who received 0.50 mg twice daily (BID) oral CS-7017 and 175 mg/m^2 IV paclitaxel once every 3 weeks.
11606091|NCT00603915|Experimental|GC Plus Erlotinib|Eligible patients are treated with cisplatin/carboplatin and gemcitabine (GC) for 6 cycles of therapy followed by maintenance erlotinib. Those patients achieving SD or PR with chemotherapy will be started on maintenance erlotinib until disease progression. Those patients achieving CR with chemotherapy will be started on erlotinib for 6 cycles of treatment and those achieving CR on erlotinib will be treated with a maximum of 6 further cycles of erlotinib. Those patients with disease progression while on chemotherapy will be offered erlotinib 2 weeks following the last dose of chemotherapy until further disease progression.
11606092|NCT00603902|Experimental|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening
11606093|NCT00603902|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
11606094|NCT00603902|Placebo Comparator|Matching Placebo|Matching placebo tablet each morning and evening
11606095|NCT00603889|Experimental|Na-ASP-2 Hookworm Antigen Skin Test|All participants will have the same number of concentrations of the Na-ASP-2 skin test reagent applied to their arms, using both the prick-puncture and intradermal techniques.
11606096|NCT00603876|Experimental|2|Step 1 dietary counseling plus 100-110 grams of almonds daily
11606097|NCT00603876|No Intervention|1|Step 1 dietary counseling
11606098|NCT00603863|Experimental|multiple dose levels|1 of 3 different dose levels of 90Y-hPAM4 given once weekly for 3 weeks along with 4 weekly doses of gemcitabine.
11606099|NCT00603850||1|Intermediate AMD Patients
11606100|NCT00603837|Experimental|Blanket|This arm includes those Extremely low gestational age newborns (ELGANs) who are to be placed on a sodium acetate warming blanket after delivery.
11606101|NCT00603837|Experimental|Wrap|This arm includes those ELGANs randomized to be wrapped in polyethylene after delivery.
11606102|NCT00603824|Experimental|A|Fondaparinux
11606103|NCT00603824|Active Comparator|B|Direct thrombin inhibitor
11606104|NCT00603811|Experimental|1|VAX102, a recombinant fusion protein that links the influenza A virus M2e antigen to S. typhimurium flagellin, a TLR5 ligand.
11606105|NCT00603811|Placebo Comparator|2|Vaccine buffer
11606106|NCT00603798|Active Comparator|3.75% imiquimod cream|
11606107|NCT00603798|Active Comparator|2.5% imiquimod cream|
11606108|NCT00603798|Placebo Comparator|Placebo cream|
11606109|NCT00603785|Placebo Comparator|A|Subjects to receive placebo treatment for 6 months
11606110|NCT00603785|Experimental|B|Subjects to receive Xolair treatment for 6 months
11606111|NCT00603772|Experimental|1|Safety when exposed to sunlight
11606112|NCT00603759|Active Comparator|1|
11606113|NCT00603759|Placebo Comparator|2|
11606114|NCT00603746|Experimental|GW685698X|GW685698X
11606115|NCT00603733|Experimental|Pentasa® modified extended release|5-ASA (5-Aminosalicylate)
11606116|NCT00603733|Active Comparator|Pentasa®|5-ASA (5-Aminosalicylate)
11606117|NCT00603720|Active Comparator|L-Name in Young|20 individuals age 18-35 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME.
11606177|NCT00603317|Experimental|1|Order 1 : Firstly Amoxicillin-Acid clavulanic, and Secondly Placebo
11606118|NCT00603720|Active Comparator|Phenylephrine|25 individuals age 18-35 will be getting an infusion of phenylephrine (primarily an alpha agonist) during 3 separate PET study days
11606119|NCT00603720|Active Comparator|L-arginine in Young|20 individuals age 18-35 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
11606120|NCT00603720|Active Comparator|L-arginine in Old|20 individuals age 60-75 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
11606121|NCT00603720|Experimental|L-NAME in Old|20 individuals age 60-75 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME
11606122|NCT00603707||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
11606123|NCT00603707||Constipated|Adult subjects with functional constipation as define by Rome II criteria
11606124|NCT00603694||1|(Experimental group): Receiving > 2 Gy SRS to left hippocampus (n=10)
11606125|NCT00603694||2|(Low-dose control group): Receiving < 0.5 Gy SRS to left hippocampus (n=10)
11606126|NCT00603694||3|(High-dose control group): Receiving whole brain PCI (n=10)
11606127|NCT00603681|Experimental|T|Test product
11606128|NCT00603681|Active Comparator|C|Reference product
11606129|NCT00603668|Experimental|milatuzumab|different doses of hLL1
11606130|NCT00603655|Experimental|A|This group will receive a low glycemic load
11606131|NCT00603655|Active Comparator|B|This group will receive a high glycemic load
11606132|NCT00603642|Placebo Comparator|AMG 531|Double blinded placebo-controlled study
11606133|NCT00603642|Placebo Comparator|Placebo|
11606134|NCT00603629||I|People with acute asthma in the Emergency department or inpatient settings
11606135|NCT00603616|Placebo Comparator|1|Placebo pills
11606136|NCT00603616|Active Comparator|2|Rifaximin
11606137|NCT00603603|Experimental|80% inhaled oxygen-non-rebreather|10 liters of oxygen via non re-breather mask during cesarean section and up to two hours post-operatively
11606138|NCT00603603|Active Comparator|30% inhaled oxygen-nasal cannula|2 liters of oxygen via nasal cannula (standard of care) during cesarean section only
11606139|NCT00603590|Experimental|Polypill|Fixed dose combination therapy with Aspirin 81mg, Hydrochlorothiazide 12.5mg, Enalapril 2.5mg and Atorvastatin 20mg
11606140|NCT00603590|Placebo Comparator|Control|Identical placebo
11606141|NCT00603577|Placebo Comparator|Placebo|
11606142|NCT00603577|Experimental|Xaliproden|
11606143|NCT00603564|Active Comparator|1|CPAP delivered by a helmet
11606144|NCT00603564|No Intervention|2|O2 administration via a conventional Venturi mask
11606145|NCT00603551||Chemotherapy|Postmenopausal women who have been diagnosed with a breast or gynecological cancer and who have undergone chemotherapy as a result of that diagnosis
11606146|NCT00603538|Experimental|CP-751,871|
11606147|NCT00603525|Experimental|Ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each treatment cycle consisting of two IV infusion taken 14 days apart. A total of 8 infusion cycles given over a 144 week period
11606148|NCT00603525|Placebo Comparator|1000 ml Saline|1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
11606149|NCT00603512|Placebo Comparator|CP-690,550, 0mg|
11606150|NCT00603512|Experimental|CP-690,550, 10mg|
11606151|NCT00603512|Experimental|CP-690,550, 1mg|
11606152|NCT00603512|Experimental|CP-690,550, 3mg|
11606153|NCT00603512|Experimental|CP-690,550, 5mg|
11606154|NCT00603499|Active Comparator|1|Magnesium chloride
11606155|NCT00603499|Placebo Comparator|2|Placebo
11606156|NCT00603473|Experimental|gabapentin|
11606157|NCT00603460|Active Comparator|A|
11606158|NCT00603460|Active Comparator|B|
11606159|NCT00603447|Experimental|Carfilzomib + Lenalidomide + Dexamethasone|Treatment during Cycles 1 through 12 consisted of carfilzomib (15, 20, or 20/27 mg/m²) on Days 1, 2, 8, 9, 15, and 16; lenalidomide (10, 15, 20, or 25 mg) on Days 1 to 21; and low-dose dexamethasone (40 mg) given 30 minutes to 4 hours before the carfilzomib dose on Days 1, 8, and 15, as well as on Day 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
11606160|NCT00603434|Experimental|1|Osmotic-Release Methylphenidate
11606161|NCT00603434|Experimental|2|Osmotic-Release Methylphenidate
11606162|NCT00603434|Experimental|3|Osmotic-Release Methylphenidate
11606163|NCT00603421|Experimental|1|Patient benefits from treatment as usual plus access to a crisis 24 hour phone line.
11606164|NCT00603421|Active Comparator|2|Patient benefits from treatment as usual
11606165|NCT00603408|Experimental|Cisplatin + Radiation + Recommended Surgery|"Cisplatin 75 mg/m^2 IV Day 1 Week 1, Day 1 Week 2, Day 1 Week 7, Day 1 Week 10
~Radiation = Total dose to breast or chest wall will be 50-60 Gy in 1.8-2.0 Gy daily fractions. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks.
~Surgery (recommended) mastectomy with/without axillary lymph node dissection"
11606166|NCT00603395|Other|ReCap|ReCap Total Hip Resurfacing System
11606167|NCT00603382|Placebo Comparator|Placebo|
11606168|NCT00603382|Experimental|GW685698X|
11606169|NCT00603369|Experimental|1|13 session group intervention including sexual health information, affect management skills, cognitive monitoring, and communication skills training.
11606170|NCT00603369|Active Comparator|2|2 session group intervention including sexual health information training.
11606171|NCT00603356|Experimental|1|Dose Escalation
11606172|NCT00603343|Active Comparator|1|
11606173|NCT00603343|Placebo Comparator|2|
11606174|NCT00603330|Experimental|1|MSC infusion for steroid-refractory grade II-IV acute GVHD. In this arm, 4 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
11606175|NCT00603330|Experimental|2|MSC infusion for poor graft function. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
11606176|NCT00603330|Experimental|3|MSC + DLI for poor donor T-cell chimerism after allogeneic HCT. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
11606178|NCT00603317|Experimental|2|Order 2 : Firstly Placebo, and Secondly Amoxicillin-Acid clavulanic
11606179|NCT00603304|Placebo Comparator|Placebo|Participants will take one 320 mg placebo gelcap daily for 24 weeks one gelcap); followed by 640 mg daily for 24 weeks (two gelcaps) followed by 960 mg daily for 24 weeks (three gelcaps).
11606180|NCT00603304|Active Comparator|Saw Palmetto|Extract of Serenoa Repens 320 mg once daily for 24 weeks (one gelcap); followed by 640 mg daily for 24 weeks (two gelcaps) followed by 960 mg daily for 24 weeks (three gelcaps).
11606181|NCT00603291|Experimental|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening
11606182|NCT00603291|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
11606183|NCT00603291|Placebo Comparator|Matching Placebo|Matching placebo tablet each morning and evening
11606184|NCT00603278|Placebo Comparator|Arm 1|
11606185|NCT00603278|Experimental|Arm 2|
11606186|NCT00603265|Experimental|ADL5859|2 x 50 milligrams (mg) ADL5859 capsules administered orally once in the morning and once in the evening for 28 days
11606187|NCT00603265|Active Comparator|Duloxetine|2 x 30 mg duloxetine capsules administered orally once in the morning and 2 placebo capsules filled with lactose administered orally once in the evening for 28 days
11606188|NCT00603265|Placebo Comparator|Placebo|2 placebo capsules filled with lactose administered orally once in the morning and once in the evening for 28 days
11606189|NCT00603239|Experimental|Exenatide twice daily (BID)|
11606190|NCT00603239|Placebo Comparator|Placebo|
11606191|NCT00603226||1|Patients diagnosed with slow coronary artery flow during coronary angiography
11606192|NCT00603226||2|Patients with normal coronary artery flow observed during coronary angiography
11606193|NCT00603200||Group 1|Patients with cirrhosis, who have refractory ascites requiring large volume paracentesis
11606194|NCT00603174|Experimental|A|Intubated and mechanically ventilated infants with respiratory failure (age < 1 year old). see inclusion-exclusion criteria.
11606195|NCT00603135|Experimental|A|
11606196|NCT00603122|Experimental|1|fast ascent
11606197|NCT00603122|Active Comparator|2|slow ascent
11606198|NCT00603109|Experimental|I|Subjects receive rimonabant 20 mg per day PO
11606199|NCT00603109|Placebo Comparator|II|Subjects take placebo capsule one a day PO
11606200|NCT00603096|Experimental|1|patients will benefit from a complete polysomnography under NIV
11606201|NCT00603096|Active Comparator|2|settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas
11606202|NCT00603083|Active Comparator|A|This group receive local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg 10 and 22 hours after the operation. The medicine solution is given in a catheter, wich is placed in the hip at the end of the operation.
11606203|NCT00603083|Placebo Comparator|B|This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, wich is placed in the hip at the end of the operation.
11606204|NCT00603070||1|All physicians and nurse practitioners at 1 ambulatory care clinics
11606205|NCT00603070||2|All physicians and nurse practitioners at 1 ambulatory care clinics
11606206|NCT00603057||Lung Cancer Imaging Patients|Adult patients (>18 years of age)with histologically confirmed or clinically diagnosed lung cancer who require radiation therapy, with or without surgery and with or without chemotherapy.
11606207|NCT00603044|Active Comparator|Fluticasone furoate|55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy
11606208|NCT00603044|No Intervention|No treatment|
11606209|NCT00603031|Experimental|GLP-1|time -30-90 min: Continuous infusion with GLP-1 (1,2pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
11606210|NCT00603031|Placebo Comparator|NaCl|time -30-90 min: Continuous infusion with NaCl time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
11606211|NCT00603031|Experimental|GIP|time -30-90 min: Continuous infusion with GIP-1 (3,6pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
11606212|NCT00603018|Experimental|Annorexia nervosa|Participants recovered from anorexia nervosa before and after administration of fluoxetine
11606213|NCT00603005|Experimental|1|
11606214|NCT00603005|Experimental|2|
11606215|NCT00603005|Experimental|3|
11606216|NCT00603005|Experimental|4|
11606217|NCT00602979|Other|Macintosh laryngoscope|Macintosh laryngoscope (control group/direct laryngoscopy) - current standard
11606218|NCT00602979|Other|Airtraq Optical Laryngoscope|Airtraq® Optical Laryngoscope (an experimental group/indirect laryngoscopy)
11606219|NCT00602979|Other|Storz DCI Video Laryngoscope|Storz DCI Video Laryngoscope® (an experimental group/indirect laryngoscopy)
11606220|NCT00602979|Other|GlideScope Video Laryngoscope|GlideScope® Video Laryngoscope (an experimental group/indirect laryngoscopy)
11606221|NCT00602979|Other|McGRATH Video Laryngoscope|McGRATH® Video Laryngoscope (an experimental group/indirect laryngoscopy)
11606222|NCT00602966||Slow Freeze|
11606223|NCT00602966||Vitrification|
11606224|NCT00602953||Healthy volunteers|Normal weight and normal glucose tolerance.
11606225|NCT00602953||Pre-diabetes|Impaired fasting glucose of impaired glucose tolerance.
11606226|NCT00602953||Overweight|Overweight or obese volunteers, but with normal fasting and postprandial glucose levels.
11606227|NCT00602953||Type 2 diabetes|Patients with type 2 diabetes.
11606228|NCT00602953||Type 1 diabetes|Patients with type 1 diabetes.
11606229|NCT00602940|Experimental|1|Active acupuncture treatment
11606230|NCT00602940|Sham Comparator|2|Sham acupuncture treatment
11606231|NCT00602927|Placebo Comparator|Placebo|
11606232|NCT00602927|Active Comparator|Varenicline|
11606233|NCT00602914|Experimental|1|10 healthy volunteers will receive 0.1 U/kg. Once administered with a conventional needle (SQ) and then with MicronJet needle (ID) in a randomized order
11606234|NCT00602914|Experimental|2|10 Type II DM subject will receive 0.2 U/kg. Once administered with a conventional needle (SQ) and then with MicronJet needle (ID) in a randomized order
11606235|NCT00602901|Experimental|HVLA-SM|High-velocity low amplitude spinal manipulation (HVLA-SM)
11606236|NCT00602901|Experimental|LVVA-SM|Low-velocity variable amplitude spinal manipulation (LVVA-SM)
11606237|NCT00602901|Active Comparator|Usual Medical Care|Usual medical care - (Celebrex, Aleve, Bextra, Naproxen)
11606238|NCT00602862|Experimental|1|10 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/1mg 111In-Bevacizumab. Patients are then treated with Sorafenib 200 mg 2dd2 po for 4 weeks. In the last week of treatment, the same injection is given to determine tumor accumulation of the radiolabeled mAb after Sorafenib treatment. Whole-body scintigraphic images are recorded 1 week after both injections to calculate tumor uptake. After Sorafenib treatment, patients will undergo surgery.
11606239|NCT00602862|Experimental|2|10 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/10mg 111In-cG250. Patients are then treated with Sorafenib 200 mg 2dd2 po for 4 weeks. In the last week of treatment, the same injection is given to determine tumor accumulation of the radiolabeled mAb after Sorafenib treatment. Whole-body scintigraphic images are recorded 1 week after both injections to calculate tumor uptake. After Sorafenib treatment, patients will undergo surgery.
11606240|NCT00602862|Active Comparator|3|5 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/1mg 111In-Bevacizumab. Whole-body scintigraphic images are recorded 1 week after the injection to calculate tumor uptake. Hereafter, patients will undergo surgery.
11606241|NCT00602836|Experimental|PCR-Lenalidomide|Pentostatin, Cyclophosphamide, Rituximab + Lenalidomide
11606242|NCT00602797|Experimental|Treatment (vinorelbine tartrate, paclitaxel)|Patients receive vinorelbine tartrate IV over 6-10 minutes and paclitaxel IV over 1 hour once weekly for 6 weeks.
11606243|NCT00602784|Experimental|IC41-B-01/02|peptide dose 0.00 mg, polyarginine dose 2.00 mg
11606244|NCT00602784|Experimental|IC41-C-01/02|peptide dose: 5.00 mg, polyarginine dose: 0.00 mg
11606245|NCT00602784|Experimental|IC41-G-01/02|peptide dose: 2.50 mg, polyarginine dose: 1.25 mg
11606246|NCT00602784|Experimental|IC41-H-01/02|peptide dose: 2.50 mg, polyarginine dose: 2.00 mg
11606247|NCT00602784|Experimental|IC41-K-01/02|peptide dose: 5.00 mg, polyarginine dose: 2.00 mg
11606248|NCT00602771|Experimental|Arm I|Patients receive 600 mg of oral tipifarnib twice daily on days 1-14 and 100 mg of oral etoposide once daily on days 1-3 and 8-10.
11606249|NCT00602771|Experimental|Arm II (closed to accrual as of November 2008)|Patients receive 400 mg of oral tipifarnib twice daily on days 1-14 and 200 mg of oral etoposide once daily on days 1-3 and 8-10.
11606250|NCT00602758|Experimental|Enhanced Counseling|Participants meet with a counselor trained in motivational interviewing and cognitive behavioral techniques
11606251|NCT00602758|No Intervention|Standard Care|Participants receive usual clinical care provided by health care providers and they participate only in evaluation components of the study
11606252|NCT00602758|Experimental|Enhanced Counseling/Modified Directly Observed Therapy|Participants receive their ART medications delivered to them by study staff and they receive the enhanced counseling
11606253|NCT00602745|Active Comparator|5-Fluorouracil|
11606254|NCT00602745|Experimental|S-1|
11606255|NCT00602732|Experimental|1|Participants assigned to the ROSE program
11606256|NCT00602732|Active Comparator|2|Participants assigned to enhanced care as usual
11606257|NCT00602693|Experimental|UCB post-transplant Treg Cell Infusion|Includes patients with high risk malignancy receiving allopurinol, fludarabine phosphate, cyclophosphamide, sirolimus, total body irradiation, double umbilical cord blood transplantation and Treg infusion cells after transplant. Patients will receive differing dose levels as they are entered and assigned to determine the maximum tolerated dose.
11606258|NCT00602680|Experimental|1|dose 1
11606259|NCT00602680|Experimental|2|dose 2
11606260|NCT00602680|Experimental|3|dose 3
11606261|NCT00602680|Placebo Comparator|4|
11606262|NCT00602680|Active Comparator|5|
11606263|NCT00602667|Experimental|Low-Risk Patients|"Patients with GTR/M0 medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.
~Note: Accrual to the low-risk medulloblastoma cohort is closed as of 12/2/2015. Accrual to the low-risk high grade glioma remains open."
11606264|NCT00602667|Experimental|High-Risk Patients|Patients with CNS metastatic disease will receive induction chemotherapy and high-risk therapy.
11606265|NCT00602667|Experimental|Intermediate-Risk Therapy|Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.
11606266|NCT00602641|Active Comparator|Arm I (thalidomide)|"INDUCTION THERAPY: Patients receive melphalan PO and prednisone PO QD on days 1-4, and thalidomide PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive thalidomide PO QD and continue in the absence of disease progression."
11606267|NCT00602641|Experimental|Arm II (lenalidomide)|"INDUCTION THERAPY: Patients receive melphalan PO and prednisone PO QD on days 1-4, and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive lenalidomide PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression."
11606268|NCT00602602|Experimental|GemOx and Bev, then chemoradiation, then surgery|"Gemcitabine 1000 mg/m2 over 100 min on day 1 every 2 weeks
~Oxaliplatin 85 mg/m2 over 2 hours on day 2 every 2 weeks
~Bevacizumab 10 mg/kg over 90 minutes on day 1 every 2 weeks. Infusion duration may be shortened in subsequent courses if tolerated.
~One cycle is 2 weeks. Chemoradiation to begin prior to 4 weeks from last dose of Gem. Between 4 and 6 weeks following chemoradiotherapy, patients will undergo re-staging with CT or MRI and CA 19-9. If there is no evidence of disease progression, the patient will be referred to the surgeon for re-evaluation and consideration of surgical intervention"
11606269|NCT00602576|Experimental|Arm A|Patients who were temozolomide naive and had no brain metastases received oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.
11606270|NCT00602576|Experimental|Arm B|Patients who were temozolomide naive and had no brain metastases received sorafenib tosylate as in arm A and oral TMZ once daily on days 1-5 and 29-33.
11606301|NCT00602264||1|Treatment-naïve patients with a recent diagnosis of anorexia nervosa
11606302|NCT00602264||2|The weight recovered subgroup of group 1
11606342|NCT00601848|Experimental|Photodynamic Therapy|PDT
11606271|NCT00602576|Experimental|Arm C|Patient with or without treated brain metastases who were treated with prior temozolomide and progressed were treated with oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.
11606272|NCT00602576|Experimental|Arm D|Patients with treated brain metastases were treated with sorafenib tosylate as in arm B and oral TMZ once daily on days 1-5 and 29-33.
11606273|NCT00602563|Experimental|1 Attention Modification Program (AMP)|The AMP is a computer-delivered attention modification
11606274|NCT00602563|Active Comparator|Applied Relaxation (AR)|Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev & Chambless, 2007)
11606275|NCT00602563|Placebo Comparator|Clinical monitoring control|participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions ; however, they will not be randomized to treatment until after the 3-month follow-up assessment. To control for the effects of psychoeducation, symptom monitoring, contact by project staff, and maturation effects, participants will be asked to complete pre-, mid- and post-assessments, and will be informed that they will receive treatment.
11606276|NCT00602563|Experimental|Combining the AMP and AR|Both AMP and AR
11606277|NCT00602537|Experimental|I|Antidepressant therapy
11606278|NCT00602537|Active Comparator|II|Mood stabilizer therapy
11606279|NCT00602511|Active Comparator|1|Bortezomib - dexamethasone
11606280|NCT00602511|Experimental|2|Thalidomide - dexamethasone
11606281|NCT00602472|Experimental|linagliptin 5 mg|linagliptin 5 mg once daily
11606282|NCT00602472|Placebo Comparator|placebo|placebo matching linagliptin 5 mg tablets
11606283|NCT00602459|Active Comparator|Arm A (rituximab, fludarabine phosphate)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: Patients receive rituximab IV over 1-4 hours on days 1 (50 mg/m^2), 3 (325 mg/m^2), and 5 (375 mg/m^2) of course 1 and on day 1 (375 mg/m^2) of all subsequent courses. Patients also receive fludarabine phosphate 25 mg/m^2/day IV over 30 minutes or PO on days 1-5.
11606284|NCT00602459|Experimental|Arm B (rituximab, fludarabine phosphate, lenalidomide)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: rituximab IV over 1-4 hours on days 1 (50 mg/m^2), 3 (325 mg/m^2), and 5 (375 mg/m^2) of course 1 and on day 1 (375 mg/m^2) of all subsequent courses. Patients also receive fludarabine phosphate 25 mg/m^2/day IV over 30 minutes or PO on days 1-5. Participants without progression receive consolidation therapy lenalidomide 5mg/day cycle 1, 10 mg/day cycles 2-6 PO QD on days 1-21 of 28 day cycle.
11606285|NCT00602459|Experimental|Arm C (rituximab, fludarabine phosphate, cyclophosphamide)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: rituximab IV over 4 hours on days 1 (50mg/m^2) and 3 (325 mg/m^2) of course 1 and on day 1 (500 mg/m^2) of all subsequent courses. Patients then receive fludarabine phosphate (age < 70: 25 mg/m^2/day; age >= 70: 20 mg/m^2/day) IV piggyback over 30 minutes or PO (32 mg/m^2/day) followed by cyclophosphamide (age < 70: 250 mg/m^2/day; age >= 70: 150 mg/m^2/day) IV piggyback over 30 minutes on days 1-3.
11606286|NCT00602459|Experimental|Arm D (rituximab, fludarabine, cyclophosphamide, lenalidomide)|Patients receive the first course of induction therapy as in Arm A or B before being re-assigned to Arm D. Beginning in course 2, patients receive rituximab IV (500 mg/m^2) on day 1 and fludarabine phosphate (age < 70: 25 mg/m^2/day; age >= 70: 20 mg/m^2/day) IV piggyback over 30 minutes or PO (32 mg/m^2/day) and cyclophosphamide IV (age < 70: 250 mg/m^2/day; age >= 70: 150 mg/m^2/day) piggyback over 30 minutes on days 1-3. Participants without progression receive consolidation therapy: lenalidomide 5mg/day cycle 1, 10 mg/day cycles 2-6PO QD on days 1-21 of 28 day cycle.
11606287|NCT00602446|Experimental|Deferasirox Treated|Includes patients that were treated with deferasirox for 6 months.
11606288|NCT00602433||questionnaire and laboratory biomarker analysis|Subjects with advanced non-small cell lung cancer and take erlotinib as part of their anticancer therapy for at least 3 months. Subjects have had some changes in hair growth, acne or menses (periods) that might be a side effect of erlotinib. Subjects will complete a questionnaire and blood collected for biomarker analysis.
11606289|NCT00602420|Experimental|Naproxen|Patients receive oral naproxen twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.
11606290|NCT00602420|Placebo Comparator|Placebo|Patients receive an oral placebo twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.
11606291|NCT00602355|Placebo Comparator|1 (Placebo)|Participants receiving placebo pill with clinical management plus mothercrafting
11606292|NCT00602355|Active Comparator|2 (Sertraline)|Participants receiving active medication sertraline with clinical management plus mothercrafting
11606293|NCT00602355|Active Comparator|3 (IPT)|Participants receiving interpersonal psychotherapy (IPT) alone
11606294|NCT00602329|Experimental|Arm I|Patients receive leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours (FOLFOX) beginning on day 1. Patients also receive bevacizumab at 5 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
11606295|NCT00602329|Experimental|Arm II|Patients receive FOLFOX as in arm I and bevacizumab at 10 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
11606296|NCT00602329|Active Comparator|FOLFOX alone (control)|Patients receive FOLFOX as in arm I.
11606297|NCT00602290|Active Comparator|1 - Citalopram and placebo|Participants will take a combination of citalopram and placebo for 16 weeks
11606298|NCT00602290|Active Comparator|2 - Methylphenidate and placebo|Participants will take a combination of methylphenidate and placebo for 16 weeks
11606299|NCT00602290|Active Comparator|3 - Methylphenidate and Citalopram|Participants will take a combination of methylphenidate and citalopram for 16 weeks
11606300|NCT00602277|Experimental|Treatment (viral therapy)|Patients receive wild-type reovirus IV over 60 minutes on days 1-5 in course 1, followed by insertion of an IP access port. Beginning in course 2, patients receive wild-type reovirus IV over 60 minutes on days 1-5 and wild-type reovirus IP over 10 minutes on days 1 and 2*. Treatment with IV and IP wild-type reovirus repeats every 28 days in the absence of disease progression or unacceptable toxicity. (phase II closed as of 1/7/2011). NOTE: *Patients receive IP wild-type reovirus on days 2 and 3 in course 3.
11606303|NCT00602264||3|Recovered patients with a previous history of anorexia nervosa but normal menstrual cycles and body weight at the present time
11606304|NCT00602264||4|Control group
11606305|NCT00602225|Experimental|Arm I|See Detailed Description
11606306|NCT00602212|Active Comparator|VR + Mobile Phone without Biofeedback|In this experimental condition patients received an eight-session VR-based treatment including relaxation and exposure
11606307|NCT00602212|Experimental|VR + Mobile Phone with biofeedback|The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
11606308|NCT00602186|Experimental|1|taking Tamsulosin
11606309|NCT00602186|Active Comparator|2|taking prasosin
11606310|NCT00602160|Active Comparator|1|2 different dosages
11606311|NCT00602160|Placebo Comparator|2|
11606312|NCT00602147||Retrospective sample|People who have been diagnosed with multiple myeloma and have received high-dose melphalan.
11606313|NCT00602147||Prospective sample|People who have been diagnosed with multiple myeloma and will be receiving high-dose melphalan.
11606314|NCT00602095|Experimental|1|Labour induction with misoprostol
11606315|NCT00602095|Active Comparator|2|Labour induction with dinoprostone
11606316|NCT00602095|Experimental|3|Labour induction with bard
11606317|NCT00602069|Experimental|1|Participants will receive cognitive behavioral therapy through the Helping to Overcome PTSD through Empowerment program
11606318|NCT00602069|Active Comparator|2|Participants will receive standard shelter services
11606319|NCT00602056|Experimental|1|Redesigned immunization card
11606320|NCT00602056|Experimental|2|Center based education to mothers/caregivers
11606321|NCT00602056|Experimental|3|Redesigned immunization card with center based education to mothers/caregivers
11606322|NCT00602056|No Intervention|4|Standard care only
11606323|NCT00602043|Experimental|Diagnostic (FES)|Patients undergo [^18F] FES PET scan. Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan.
11606324|NCT00602030|Experimental|1|Lead in Open Label Phase 1 dose-finding study to identify a safe dose of entinostat in combination with erlotinib for further evaluation
11606325|NCT00602030|Experimental|2|erlotinib (Tarceva) and entinostat
11606326|NCT00602030|Placebo Comparator|3|"erlotinib (Tarceva) and matched Placebo
~patients in this arm who progress will be offered the opportunity to receive SNDX-275 with erlotinib for up to 6 28-day treatment cycles"
11606327|NCT00601978|Active Comparator|1|Immediate-Release Carbidopa/Levodopa
11606328|NCT00601978|Active Comparator|2|Carbidopa/Levodopa/Entacapone
11606329|NCT00601965|Experimental|CBT/Escitalopram|12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.
11606330|NCT00601965|Active Comparator|No CBT/escitalopram|12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks.
11606331|NCT00601965|Placebo Comparator|CBT/placebo|12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.
11606332|NCT00601965|Placebo Comparator|No CBT/placebo|"12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks pill placebo
~12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks."
11606333|NCT00601952|Experimental|1 Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
11606334|NCT00601952|Placebo Comparator|2 Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
11606335|NCT00601939|Experimental|Psychoeducational intervention (PEI)|Culturally competent group empowerment psychoeducational treatment (group intervention that is culturally informed and educational in nature)
11606336|NCT00601939|Active Comparator|Enhanced Treatment as Usual|Enhanced treatment as usual that includes an adherence protocol (regular care at the hospital plus an adherence protocol)
11606337|NCT00601926|Experimental|Bevacizumab|15 mg/kg over 90 minutes
11606338|NCT00601913|Experimental|Erlotinib|Erlotinib
11606339|NCT00601900|Experimental|Arm I (endocrine therapy with monoclonal antibody)|Patients receive endocrine therapy* (tamoxifen citrate* or letrozole) PO QD on days 1-21 and bevacizumab 15 mg/kg IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11606340|NCT00601900|Active Comparator|Arm II (endocrine therapy)|Patients receive endocrine therapy* (tamoxifen citrate* or letrozole) PO QD on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11606341|NCT00601861|Experimental|A|
11610248|NCT00569946|Experimental|AG-013736|
11606343|NCT00601835|Experimental|Canadian Td Vaccine Group|Participants received Canadian manufactured Td vaccine
11606344|NCT00601835|Active Comparator|United States Td Vaccine Group|Participants received US manufactured Td vaccine
11606345|NCT00601822|Experimental|1|Group receiving cognitive behavioral therapy for anorexia nervosa (CBT-AN)
11606346|NCT00601822|Experimental|2|Group receiving cognitive behavioral therapy for anorexia nervosa, plus cognitive remediation therapy (CBT-AN+CRT)
11606347|NCT00601809|Experimental|GG|
11606348|NCT00601809|Other|TT|
11606349|NCT00601796|Experimental|Combination Immunotherapy|Vaccine + Cytoxan + ATRA as outlined in Detailed Description
11606350|NCT00601770|Experimental|IC41|8 injections of 4 x 0.125mL
11606351|NCT00601757|Other|1|Participants assigned to the Postpartum Prevention Program
11606352|NCT00601757|Other|2|Participants assigned to enhanced care as usual
11606353|NCT00601744||Patient|Diagnosis of orbital or head and neck cancer and a history of orbital exenteration.
11606354|NCT00601744||Family Member/Friend|Family member or close friend of a patient with a diagnosis of orbital or head and neck cancer and a history of orbital exenteration.
11606355|NCT00601731|Experimental|Adjuvanted MenACWY vaccine group|Blood test
11606356|NCT00601731|Active Comparator|Non-adjuvanted MenACWY vaccine group|Blood test
11606357|NCT00601718|Experimental|Treatment (enzyme inhibitor, monoclonal antibody, chemotherapy|Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
11606358|NCT00601705|Experimental|Epirubicin, Oxaliplatin and Fluorouracil|
11606359|NCT00601692|Experimental|Regimen 1|Patients receive docetaxel IV over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 8, patients receive docetaxel IV over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 (week 8) and 8 (week 9). Patients also undergo radiotherapy once daily, 5 days a week, in weeks 8-10. Treatment with chemoradiotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
11606360|NCT00601692|Experimental|Regimen 2|Patients receive docetaxel IV and irinotecan hydrochloride as in regimen 1 induction chemotherapy. They also receive cisplatin IV over 20-30 minutes on days 1 and 8. Treatment with irinotecan hydrochloride, docetaxel, and cisplatin repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients receive docetaxel IV, irinotecan hydrochloride IV, and undergo radiotherapy as in regimen 1 chemoradiotherapy. Patients also receive cisplatin IV over 20-30 minutes on days 1 (week 8) and 8 (week 9). Treatment with irinotecan hydrochloride, docetaxel, cisplatin, and radiotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
11606361|NCT00601679|Experimental|NT-proBNP|Surveillance NT-proBNP levels disclosed to physicians. Intervention (e.g. Diuretic management) based on NT-proBNP results.
11606362|NCT00601679|No Intervention|Usual Care|Surveillance NT-proBNP levels blinded. Intervention (e.g. Diuretic management) based on clinical judgments.
11606363|NCT00601653|Active Comparator|1|Cognitive behavioral therapy plus general nutrition counseling
11606364|NCT00601653|Experimental|2|Cognitive behavioral therapy plus low energy density diet counseling
11606365|NCT00601640|Experimental|Eflornithine HCL|Patients apply Eflornithine HCL ointment to their left forearm twice daily on days 1-90.
11606366|NCT00601640|Active Comparator|Diclofenac Na|Patients apply topical Diclofenac Na gel to their left forearm once daily on days 1-90.
11606367|NCT00601640|Experimental|Eflornithine HCL and Diclofenac Na|Eflornithine HCl ointment and Diclofenac Na gel applied twice and once daily, respectively on days 1-90.
11606368|NCT00601627|Experimental|Panitumumab|"Chemotherapy concurrent with radiation: Radiation 5 days per week for 5½ weeks; Panitumumab on days 1, 15, and 29 of radiation therapy 5-fluorouracil (5FU) continuous infusion, starting on day 1 and through last day of radiation.
~4-6 weeks after completion of radiation therapy: Gemcitabine on days 1, 8, and 15 of each cycle, for 3 cycles; Panitumumab on days 1 and 15 of each cycle, for 3 cycles. Maintenance therapy: Panitumumab on days 1 and 15 of each cycle, for 6 cycles."
11606369|NCT00601549|Experimental|1|Patients with low rectal cancer after CCRT undergoing laparoscopic surgery
11606370|NCT00601549|Active Comparator|2|Patients with low rectal cancer after CCRT undergoing traditional open surgery
11606371|NCT00601523|Active Comparator|Pramipexole|Patient to receive Pramipexole ER 0.375-4.5 mg tabl form daily
11606372|NCT00601523|Placebo Comparator|Placebo|Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
11606373|NCT00601510|Experimental|Imatinib mesylate|Imatinib mesylate 300mg/day(maximum dose will be 800 mg) on day -4, -3, -2, -1, 1, 2, 3 through d21 in combination with capecitabine 1250 mg/m2 twice daily (d1-d14) and iv cisplatin 60mg/m2
11606374|NCT00601497|Experimental|1|
11606375|NCT00601497|Placebo Comparator|2|
11606376|NCT00601484|Experimental|1|
11606377|NCT00601484|Placebo Comparator|2|
11606378|NCT00601471|Experimental|1|proximal tibiofibular manipulation
11606379|NCT00601471|Experimental|2|distal tibiofibular manipulation
11606380|NCT00601471|No Intervention|3|no treatment
11606381|NCT00601458|Active Comparator|Arm 1: Pregabalin 300 mg|
11606382|NCT00601458|Active Comparator|Arm 2: naproxen sodium 550 mg|
11606383|NCT00601458|Placebo Comparator|Arm 3: Placebo|
11606384|NCT00601419||Somatropin|Patients administered Somatropin.
11606385|NCT00601393|Active Comparator|1|Participants will receive treatment as usual followed by 8 weeks of Internet-based cognitive behavioral therapy treatment
11606386|NCT00601393|Experimental|2|Participants will receive 8 weeks of Internet-based cognitive behavioral therapy treatment
11606438|NCT00600925|Experimental|1|Insertion of 2 gentamicin-collagen sponges before closure of the laparotomy (each 10 x 10 cm sponge contains 280 mg collagen and 130 mg gentamicin).
11606439|NCT00600925|No Intervention|2|Standard of care, ie, no gentamicin-collagen sponge.
11606440|NCT00600912|Experimental|1-SMOFlipid®|lipid emulsion based on soybean oil, medium-chain triglycerides, olive oil and fish oil SMOFlipid®-Group (n = 21)
11606387|NCT00601367|Experimental|flibanserin flexible dose|"Initial dosage:
~Patients were to take one 50 mg flibanserin tablet in the evening.
~Subsequent dosage titrations:
~Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.
~Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.
~Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site."
11606388|NCT00601354|Experimental|Emotion Regulation Group therapy + alli|Group taking the weight loss medication orlistat (alli), in conjunction with the alli weight loss program, plus 12 weekly sessions of guided self-help group psychotherapy
11606389|NCT00601354|Active Comparator|Orlistat/alli program meds only|Group taking the weight loss medication orlistat (alli), in conjunction with the alli weight loss program alone
11606390|NCT00601341|Experimental|1|lumbosacral joint manipulation
11606391|NCT00601341|Experimental|2|lumbar passive range of motion
11606392|NCT00601341|Other|3|lie on exam table for 3 minutes
11606393|NCT00601276|Experimental|1|
11606394|NCT00601276|Active Comparator|2|
11606395|NCT00601263|Active Comparator|1a|Low dose ASHMI (2 caps bid).
11606396|NCT00601263|Placebo Comparator|1b|Placebo 2 caps bid.
11606397|NCT00601263|Active Comparator|2a|Medium dose ASHMI (4 caps bid).
11606398|NCT00601263|Placebo Comparator|2b|Placebo 4 caps bid.
11606399|NCT00601263|Active Comparator|3a|High dose ASHMI (6 caps bid).
11606400|NCT00601263|Placebo Comparator|3b|Placebo 6 caps bid.
11606401|NCT00601250|Experimental|Linagliptin|Patients receive linagliptin 5 mg tablets once daily
11606402|NCT00601250|Placebo Comparator|Placebo|Patients receive placebo tablets matching linagliptin 5 mg tablets once daily
11606403|NCT00601237|Experimental|A|Participants will receive HIV-related text messages
11606404|NCT00601237|Active Comparator|B|Participants will receive nutrition-related text messages
11606405|NCT00601237|No Intervention|C|Participants will attend a 90-minute focus group to develop messages for the cell-phone program
11606406|NCT00601224|Experimental|1|Participants will receive social cognition and interaction training plus treatment as usual
11606407|NCT00601224|Active Comparator|2|Participants will receive treatment as usual
11606408|NCT00601198|Experimental|Treatment Period|The chemotherapy regimen will be given for 2 consecutive days. On day #1, pt. will be premedicated with drugs to prevent nausea and vomiting in addition to intravenous fluids. Then they will receive amifostine intravenously followed by oxaliplatin, 5FU and leucovorin. This will be followed by an infusion of 5FU given in a pump over 22 hours. If the doctor decides on giving the pt. Avastin, this will be given on day #1. On day #2, they will receive the same treatment except for oxaliplatin.
11606409|NCT00601185||1|Patients undergoing a shave biopsy and confocal microscopy.
11606410|NCT00601172|Placebo Comparator|Control|Placebo + standard antiemetics
11606411|NCT00601172|Experimental|Single Dose IV|Casopitant + standard antiemetics
11606412|NCT00601159|Experimental|gemcitabine and cisplatin|cisplatin and gemcitabine in the management of triple negative metastatic breast cancer
11606413|NCT00601146|Experimental|Low-dose Chest CT screening|Annual low-dose Chest CT screening
11606414|NCT00601133||Patient Postural Instability|Participants having difficulty walking and with balance after cancer treatment that are leaving the M.D. Anderson rehabilitation hospital or after treatment through the rehabilitation mobile team.
11606415|NCT00601107|Experimental|Doxercalciferol 2.5 mcg/day|Doxercalciferol 2.5 microgram (mcg) capsule orally once daily up to Week 24.
11606416|NCT00601107|Experimental|Doxercalciferol 5 mcg/day|Doxercalciferol 5 mcg capsules orally once daily up to Week 24.
11606417|NCT00601107|Experimental|Doxercalciferol 7.5 mcg/day|Doxercalciferol 7.5 mcg capsules orally once daily up to Week 24.
11606418|NCT00601107|Placebo Comparator|Placebo|Placebo matching to doxercalciferol capsules orally once daily up to Week 24.
11606419|NCT00601094|Experimental|experimental arm|
11606420|NCT00601081||1|Very low birth weight and preterm infants who will likely receive fortification of breast milk with HMF
11606421|NCT00601068||Observational|Group of patients with osteochemonecrosis related to oral bisphosphonate use
11606422|NCT00601055|Experimental|Problem Solving-Rx Adherence (PSA)|Participants will receive problem-solving therapy integrated with adherence-enhanced procedures (PSA).
11606423|NCT00601055|Active Comparator|PID-C|Participants will receive adherence-enhanced (PID-C) procedures, a treatment mobilizing patients to participate in their care.
11606424|NCT00601042|Experimental|1|Swedish snus ad libitum as a substitute for cigarettes
11606425|NCT00601042|Placebo Comparator|2|Tobacco-free, nicotine-free placebo snus ad libitum as a substitute for cigarettes
11606426|NCT00601029||1|Winter Phase - Observational
11606427|NCT00601029||2|Summer Phase - Observational
11606428|NCT00601003|Experimental|Nifurtimox|
11606429|NCT00600977|Active Comparator|doxorubicine|VAD
11606430|NCT00600977|Experimental|Doxorubicine pegylated|Doxorubicine pegylated 40 MG/M² J1
11606431|NCT00600964|Experimental|GX15-070MS|GX15-070MS at various doses and schedules
11606432|NCT00600951||1|Patients with moderate chronic kidney disease (stage 3, according to the classification of chronic kidney disease by the National Kidney Foundation, i.e., with eGFR comprised between 30 and 59 mL/min/1.73m2)
11606433|NCT00600951||2|Patients with severe chronic kidney disease or kidney failure (stages 4 and 5, according to the classification of chronic kidney disease by the National Kidney Foundation, i.e., with eGFR stably below 30 mL/min/1.73m2)
11606434|NCT00600938|Experimental|Deferasirox|20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
11606435|NCT00600938|Active Comparator|Deferasirox Placebo|50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
11606436|NCT00600938|Experimental|Extension: deferoxamine to deferasirox|"DFO to ICL (patients who switched from DFO to deferasirox in extension)"
11606437|NCT00600938|Experimental|Extension: deferasirox to deferoxamine|"ICL to DFO (patients who switched from deferasirox to DFO in extension)"
11606441|NCT00600912|Active Comparator|2-ClinOleic 20%®|olive and soybean oil-group (n=21)
11606442|NCT00600899|Experimental|A|Group A patients will receive perisciatic continuous infusion of ropivacaine 2 mg/ml through an elastomeric pump (Baxter, Deerfield, IL, USA)) 8 ml/h (reservoir of 500 ml)as postoperative analgesia.
11606443|NCT00600899|Active Comparator|B|Group B patients will receive standard treatment: continuous perisciatic infusion of 2 mg/ml ropivacaine 5 ml/t (Baxter infusor with 275 ml reservoir)
11606444|NCT00600886|Experimental|Pasireotide LAR|Patients in this arm received Pasireotide LAR 40 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 20 or 60 mg, respectively. Patients who responded to Pasireotide LAR (i.e. the randomized treatment) at the end of the core (Month 12), continued Pasireotide LAR treatment in the extension. Patients who did not respond to Pasireotide LAR at the end of the core (Month 12) were allowed to switch to receive Octreotide LAR in the extension.
11606445|NCT00600886|Active Comparator|Octreotide LAR|Patients in this arm received Octreotide LAR 20 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 10 or 30 mg, respectively. Patients who responded to Octreotide LAR (i.e. the randomized treatment) at the end of the core (Month 12) continued Octreotide LAR treatment in the extension (up to 2 years of treatment). Patients who did not respond to Octreotide LAR at the end of the core (Month 12) were allowed to switch to receive Pasireotide LAR in the extension.
11606446|NCT00600873|Experimental|1|patients with early ALS
11606447|NCT00600860||MDS patients|Patients with MDS according to current WHO criteria and International Prognostic Scoring System (IPSS) classification
11606448|NCT00600847|Active Comparator|1|desloratadine 20 mg
11606449|NCT00600847|Active Comparator|2|desloratadine 5 mg
11606450|NCT00600847|Placebo Comparator|3|
11606451|NCT00600834||1|patients with moderate CKD (stage 3, according to the classification of CKD by the National Kidney Foundation, i.e., with eGFR comprised between 30 and 59 mL/min/1.73m2)
11606452|NCT00600834||2|patients with severe CKD or kidney failure (stages 4 and 5, according to the classification of CKD by the National Kidney Foundation, i.e., with eGFR stably below 30 mL/min/1.73m2).
11606453|NCT00600821|Active Comparator|B|Bevacizumab will be administered in combination with carboplatin and paclitaxel.
11606454|NCT00600821|Experimental|A|AG-013736 will be administered in combination with carboplatin and paclitaxel.
11606455|NCT00600795||A|Patients diagnosed with Normal Pressure Hydrocephalus
11606456|NCT00600782|Experimental|Group A|These subjects were further stratified into 3 groups according to the size of their PPD skin test reactions
11606457|NCT00600769|Other|treatment of MAC and other NTM|Clarithromycin drug given twice daily.
11606458|NCT00600756|Experimental|Quetiapine XR|
11606459|NCT00600756|Active Comparator|Risperidone|
11606460|NCT00600743|Placebo Comparator|1 'Instructions to eat normally'|'Instructions to eat normally' Placebo 1 mg dose
11606461|NCT00600743|Active Comparator|2 'Instructions to eat normally'|'Instructions to eat normally' drug 1 mg dose 'GSKI181771X (CCK-1R agonist)'
11606462|NCT00600743|Placebo Comparator|3 'Instructions to eat normally'|'Instructions to eat normally' 2 mg placebo
11606463|NCT00600743|Active Comparator|4 'Instructions to eat normally'|'Instructions to eat normally' 2 mg drug 'GSKI181771X (CCK-1R agonist)'
11606464|NCT00600743|Placebo Comparator|5 'Instructions to eat normally'|'Instructions to eat normally' 4 mg placebo
11606465|NCT00600743|Active Comparator|6 'Instructions to eat normally'|'Instructions to eat normally' 4 mg drug 'GSKI181771X (CCK-1R agonist)'
11606466|NCT00600743|Placebo Comparator|7 Instructions to binge eat|Instructions to binge eat 4 mg placebo
11606467|NCT00600743|Active Comparator|8 Instructions to binge eat|Instructions to binge eat 4 mg drug 'GSKI181771X (CCK-1R agonist)'
11606468|NCT00600730|Experimental|1|Hyperinsulinemic euglycemic clamp with fMRi
11606469|NCT00600730|Experimental|2|Hyperinsulinemic hypoglycemic clamp with fMRI
11606470|NCT00600717||Pediatric Patients and Healthy Children|Healthy children without dental works. Pediatric patients with epilepsy and migraine (headache).
11606471|NCT00600704|Active Comparator|RESTRICTED FLUIDS|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary Bypass
11606472|NCT00600704|Active Comparator|FREE FLUIDS|Free fluid infusion unless Hb< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
11606473|NCT00600691|Experimental|1|5mg finasteride orally, daily for 2 weeks prior to prostate biopsy and one week following prostate biopsy.
11606474|NCT00600678|Experimental|1|
11606475|NCT00600665|Active Comparator|Usual Care|In Part 1 of the study, participants will access PAINReportIt and computer games. PAINReportIt helps the patient describe the pain experienced. In Part 2 of the study, participants will continue to access PAINReportIt when they are seen in the clinic, emergency department (ED), acute care center (ACCA), and hospital. They will gain access to the PAINUCope computer-based programs, which provides multimedia education tailored to the patient's misconceptions about pain management. They will receive medial usual care at the outpatient clinic, ED, ACC, and hospital.
11606476|NCT00600665|Experimental|PAINUCope/PAINConsultN|In Part 1 of the study, participants will access PAINReportIt and PAINUCope computer-based programs. PAINReportIt helps the patients describe the pain experiences and PAINUCope provides multimedia education tailored to the patient's misconceptions about pain management. In Part 2 of the study, participants will continue to access PAINReportIt and PAINUCope programs when they are seen in the clinic, emergency department (ED), acute care center (ACC), and hospital. Their doctors will have access to PAINConsultN when seen at the ED, ACC, and hospital. PAINConsultN is just-in-time decision support for the physicians with the pain data summarized and suggestions for analgesics that may be useful to help manage the patient's pain.
11606477|NCT00600652||1|glucocorticoid-resistant patients
11606478|NCT00600652||2|glucocorticoid-sensitive patients
11606479|NCT00600652||3|normal controls
11606480|NCT00600639|Experimental|1|non-invasive ventilation with BiPAP Vision or another ICU ventilator with NIV option
11606481|NCT00600639|Active Comparator|2|standard therapy + oxygen
11606482|NCT00600613|Experimental|1|Patients going for treatment of liver metastases with radiation therapy.
11606483|NCT00600600|Experimental|Tigecycline|tigecycline titrated dose according to patient age and clinical status
11606593|NCT00599677|Experimental|group 4|acupoints of the other meridian
11606484|NCT00600587|Experimental|A|Erlotinib targeted NSCLC population based on EGFR gene analysis(EGFR gene status: activating mutation)
11606485|NCT00600587|Active Comparator|B|Non-erlotinib targeted NSCLC population based on EGFR gene analysis
11606486|NCT00600574|Active Comparator|S|physiotherapy in warm pool by means of stretching
11606487|NCT00600574|Experimental|AI|physiotherapy in warm pool by means of Ai Chi
11606488|NCT00600561|Active Comparator|1-Day MBSR|One-day condensed MBSR class
11606489|NCT00600561|Experimental|8-week MBSR|8-week Mindfulness-Based Stress Reduction Intervention
11606490|NCT00600548|Experimental|1.1|Cutaneous leishmaniasis patients in Manaus-Amazonas randomized to receive Miltefosine.
11606491|NCT00600548|Active Comparator|1.2|Cutaneous leishmaniasis patients in Manaus-Amazonas randomized to receive Meglumine antimoniate (standard treatment).
11606492|NCT00600548|Experimental|2.1|Cutaneous leishmaniasis patients in Corte de Pedra-Bahia randomized to receive Miltefosine.
11606493|NCT00600548|Active Comparator|2.2|Cutaneous leishmaniasis patients in Corte de Pedra-Bahia randomized to receive Meglumine antimoniate (standard treatment).
11606494|NCT00600535|Experimental|Abiraterone acetate (non-fasting)|
11606495|NCT00600535|Experimental|Abiraterone acetate (fasting)|
11606496|NCT00600522||1|Patients selected for hepatectomy because carriers of hepatocellular carcinoma or colorectal cancer liver metastases invading the middle hepatic vein at caval confluence (last 4 cm).
11606497|NCT00600496|Experimental|1|AZD6244 + docetaxel
11606498|NCT00600496|Experimental|2|AZD6244 + Dacarbazine
11606499|NCT00600496|Experimental|3|AZD6244 + Erlotinib
11606500|NCT00600496|Experimental|4|AZD6244 + Temsirolimus
11606501|NCT00600483|Experimental|1|Insertion of 2 gentamicin-collagen sponges between the sternal halves before closure of the sternotomy
11606502|NCT00600483|No Intervention|2|Standard of care, ie, insertion of no gentamicin-collagen sponge.
11606503|NCT00600470|Experimental|1|Doctor-office collaborative care management
11606504|NCT00600470|Active Comparator|2|"Treatment as usual: psychoeducation and outside referral to treatment (PORT). In papers, this arm is referred to as Enhanced Usual Care (EUC)."
11606505|NCT00600457||A,1|
11606506|NCT00600444|Active Comparator|A|Venae Sectio technique will be used to insert totally implantable access port (TIAP) by a surgeon
11606507|NCT00600444|Experimental|B|Punction of Vena Subclavia will be used to insert totally implantable access port (TIAP) by a radiologist.
11606508|NCT00600431||1|Study group: 16 children under 18 years undergoing systemic chemotherapy
11606509|NCT00600431||2|Control group: 16 age and sex matched healthy children under 18 years
11606510|NCT00600405|Experimental|I|Subjects randomized to the experimental group receive ibuprofen, oxycodone, and tamsulosin 0.4 mg orally daily for ten days.
11606511|NCT00600405|Other|II|Standard therapy arm: subjects randomized to standard therapy receive ibuprofen and oxycodone alone.
11606512|NCT00600392||1|patients who meet criteria for CRT-D implantation
11606513|NCT00600379|Experimental|A,|Virtual Reality training for an overall of 18 sessions 2/week + usual care.
11606514|NCT00600379|No Intervention|B,|Usual care
11606515|NCT00600353|Experimental|Melphalan, dexamethasone, aprepitant, palonosetron|"Group A: Subjects with Multiple Myeloma
~Conditioning regimen, over a 7 day period, includes:
~Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion
~Group B: Subjects with Lymphoma
~Conditioning regimen, over a 7 day period, includes: (BEAC)
~BCNU 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant"
11606516|NCT00600340|Active Comparator|A Bev+Pac|Bevacizumab plus Paclitaxel
11606517|NCT00600340|Active Comparator|B Bev+Cap|Bevacizumab plus Capecitabine
11606518|NCT00600327|Experimental|1|
11606519|NCT00600314||High risk|Patients who are at high risk of developing acute or chronic GVHD
11606520|NCT00600314||GVHD|Patients who currently have either grade II or greater acute GVHD, or clinically extensive chronic GVHD
11606521|NCT00600288|Experimental|1|
11606522|NCT00600288|Placebo Comparator|2|
11606523|NCT00600275|Experimental|BGT226|
11606524|NCT00600223||1|Patients undergoing laryngectomy and pharyngeal reconstruction
11606525|NCT00600210|Experimental|I|
11606526|NCT00600197|Experimental|Back school|a kind of educational program for low back pain
11606527|NCT00600197|Experimental|back school|
11606528|NCT00600171|Placebo Comparator|Placebo|Placebo Multi dose dry powder inhlaer
11606529|NCT00600171|Experimental|GW642444M|GW642444M
11606530|NCT00600158|Experimental|2|lidocaine intravenously
11606531|NCT00600158|Active Comparator|1|epidural local anesthetic
11606532|NCT00600145|Experimental|1|Mirtazapine
11606533|NCT00600145|Placebo Comparator|2|Placebo
11606534|NCT00600119|Placebo Comparator|A|Placebo
11606535|NCT00600119|Experimental|B|NKTR-118
11606536|NCT00600106|Active Comparator|Hormone replacement therapy|Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
11606537|NCT00600106|Placebo Comparator|Placebo|1mg placebo
11606538|NCT00600093|Experimental|A|
11606539|NCT00600080|Other|etafilcon A first nelfilcon A second|etafilcon A worn daily during week 1, nelfilcon A worn daily for week 2
11606540|NCT00600080|Other|nelfilcon A first, etafilcon A second|nelfilcon A worn daily during week 1, etafilcon A worn daily for week 2
11606541|NCT00600067|Experimental|1|
11606542|NCT00600067|Placebo Comparator|2|
11606543|NCT00600054|Experimental|Single arm|
11606544|NCT00600041|Experimental|A|Pantoprazole IV
11606545|NCT00600041|Placebo Comparator|B|NaCl 0.9% IV
11606546|NCT00600028|Experimental|Experimental: Thalidomide, then placebo|Participants first received Thalidomide tablet for 12 weeks. After a washout period of two weeks, they then received placebo tablet for 12 weeks.
11606594|NCT00599677|Sham Comparator|group 5|non-acupoints
11606595|NCT00599677|Active Comparator|group 6|Itopride
11606547|NCT00600028|Experimental|Experimental: Placebo, then Thalidomide|Participants first received Placebo tablet for 12 weeks. After a washout period of two weeks, they then received Thalidomide tablet for 12 weeks.
11606548|NCT00600015|Experimental|Combination Therapy|Erlotinib + Sorafenib
11606549|NCT00600015|Placebo Comparator|Placebo|Erlotinib + Placebo
11606550|NCT00600002|Experimental|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
11606551|NCT00599989|Experimental|APBI|
11606552|NCT00599963|Experimental|1|paricalcitol 1 mg/day for 12 weeks, followed by a washout period of 4 weeks, then crossed over to no treatment for another 12 weeks
11606553|NCT00599963|Active Comparator|2|no treatment for 12 weeks, followed by a washout period of 4 weeks, then crossed over to paricalcitol for another 12 weeks
11606554|NCT00599950|Experimental|1|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
11606555|NCT00599950|Placebo Comparator|2|Photorefractive keratectomy (PRK)without mitomycin C.
11606556|NCT00599937|No Intervention|ATRA ->Chemo|Patients 65 years of age with a WBC count less than 5,000 were randomized to receive the reference ATRA treatment of our previous trial (APL91 trial), ie, 45 mg/m2/d ATRA followed by CT or ATRA plus CT (ATRA+CT). In the ATRA followed byCT group, patients received 45 mg/m2/d ATRA orally until CR, with a maximum of 90 days. After CR achievement, they received a course of 60 mg/m2/d daunorubicin (DNR) for 3 days and 200 mg/m2/d AraC for 7 days (course I). However, course I was added to ATRA if the WBC count was increased to greater than 6,000, 10,000, or 15,000 by day 5, 10, and 15 of ATRA treatment, respectively, because, from our experience, patients were at risk of ATRA syndrome above those thresholds.
11606557|NCT00599937|Experimental|ATRA+CT|Patients randomized to the ATRA+CT group received the same combination of ATRA and CT, with course I of CT starting on day 3 of ATRA treatment. This 48-hour interval before onset of CT was based on our previous report, because it allowed correction of coagulopathy.
11606558|NCT00599937|No Intervention|High WBC|Patients with a WBC count greater than 5,000 at presentation (irrespective of their age) and patients 66 to 75 years of age with a WBC count 5,000 were not randomized but received ATRA plus CT course I from day 1 (high WBC group) and the same schedule as in the ATRA->CT group (elderly group), respectively.
11606559|NCT00599937|No Intervention|no maintenance|No maintenance
11606560|NCT00599937|Experimental|maintenance ATRA|Intermitent ATRA as maintenance
11606561|NCT00599937|Experimental|maintenance Cxt|continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally) as maintenance
11606562|NCT00599937|Experimental|maintenance both|continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally) AND ATRA as maintenance
11606563|NCT00599924|Experimental|Single arm|"SU011248 [sunitinib] in combination with FOLFOX; FOLFOX is a chemotherapy regimen that combines oxaliplatin and leucovorin with bolus and infusion 5-FU. The modified FOLFOX 6 (mFOLFOX6) regimen is one of several different regimens of FOLFOX used in clinic, according to different dosages of the 4 drugs. mFOLFOX6 was administered every 2 weeks on Days 1 and 2 of each cycle.
~25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in three different dosing regimens: schedule 2/2 (2 weeks on, 2 weeks off), schedule 4/2 (4 weeks on, 2 weeks off), and continuous daily dosing (every day); FOLFOX will be administered every 2 weeks, using the modified FOLFOX 6 (mFOLFOX6) regimen, consisting of: oxaliplatin 85 mg/m2 + leucovorin 400 mg/m2 as a 2-hr IV infusion; 5-FU 400 mg/m2 IV bolus, followed by - 5-FU 2400 mg/m2 as a 46-hr IV infusion"
11606564|NCT00599911|Experimental|Lu AA24530: 5 mg|
11606565|NCT00599911|Experimental|Lu AA24530: 10 mg|
11606566|NCT00599911|Experimental|Lu AA24530: 20 mg|
11606567|NCT00599911|Active Comparator|Duloxetine: 60 mg|
11606568|NCT00599911|Placebo Comparator|Placebo|
11606569|NCT00599898|Experimental|1|
11606570|NCT00599898|Experimental|2|
11606571|NCT00599885|Active Comparator|1|
11606572|NCT00599885|Active Comparator|2|
11606573|NCT00599872|Active Comparator|Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract administered via the sublingual oral route (27.6 to 77.3 Amb a 1 Units)
11606574|NCT00599872|Placebo Comparator|Placebo|Standardized Ragweed Allergenic Extract Placebo via the sublingual oral route
11606575|NCT00599859|Active Comparator|1|Participants in arm 1 are grouped as lactose digesters based on genetic analysis and breath hydrogen results. In discrepant cases the genetic status is accepted. Arm 1 is initially withdrawn from dairy foods(lactose) and then asked to consume lactose 50g in divided doses mixed in water for 2 weeks.
11606576|NCT00599859|Active Comparator|2|Arm 2 are lactose maldigesters: 2 interventions are a. withdrawal from lactose for 2 weeks and b. consumption of 50g lactose in divided doses mixed in water for a 2 week period.
11606577|NCT00599807|Active Comparator|1: 2000 IU D3/day|2000 IU vitamin D3 taken orally each day for 2 years
11606578|NCT00599807|Active Comparator|2: 800 IU D3 / day|800 IU vitamin D3 taken orally each day for 2 years
11606579|NCT00599794||1|Healty volunteers who are euvolemic.
11606580|NCT00599794||2|Critically ill patients who will be having a central venous catheter with a monitor to measure central venous pressure placed as part of their planned care independent of this study.
11606581|NCT00599781|Experimental|PBL/HSC|
11606582|NCT00599755|Experimental|Gem/Cis or Gem/Carbo|
11606583|NCT00599742|Active Comparator|A|Balance training group
11606584|NCT00599742|Active Comparator|B|Motor Training
11606585|NCT00599729||1|patient demonstrating degenerative changes in the knee joint (osteoarthritis)
11606586|NCT00599716|Experimental|1|study drug
11606587|NCT00599716|Placebo Comparator|2|vehicle control
11606588|NCT00599703||1|neurosurgical patients
11606589|NCT00599690|Experimental|A|Epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
11606590|NCT00599677|Experimental|group 1|specific acupoints of Stomach meridians
11606591|NCT00599677|Experimental|group 2|Non-specific acupoints of Stomach meridians
11606592|NCT00599677|Experimental|group 3|alarm and transport points
11606597|NCT00599664|Placebo Comparator|2|Vehicle
11606598|NCT00599651|Experimental|1|Surfactant by LMA
11606599|NCT00599651|Other|2|Standard of care
11606600|NCT00599638|Active Comparator|1|
11606601|NCT00599638|Experimental|2|
11606602|NCT00599638|Placebo Comparator|3|
11606603|NCT00599625|Experimental|1|Patients with active Crohn's Disease
11606604|NCT00599612|Experimental|Healthy male volunteers|Six healthy male volunteers aged between 30-60 years old will be recruited for this study,
11606605|NCT00599599|Experimental|1|Prolonged Exposure Therapy.
11606606|NCT00599599|No Intervention|2|Weekly monitoring/Waitlist Control Group.
11606607|NCT00599586|Experimental|group 1|specific acupoints of Shaoyang meridians
11606608|NCT00599586|Experimental|Group 2|Non-specific acupoints of Shaoyang meridians
11606609|NCT00599586|Experimental|group 3|Acupoints of other meridians
11606610|NCT00599586|Sham Comparator|group 4|Non-acupoints
11606611|NCT00599573|Experimental|1|Ondansetron
11606612|NCT00599560|Experimental|1. Meniere's disease|Patients were eligible for enrollment if they had received a clinical diagnosis of Meniere's disease according to the 1995 AAO-HNS criteria (Committee, 1995). These criteria can be briefly described as follows: 1) Repeated attacks of vertigo: A definitive spell is spontaneous vertigo lasting at least 20 minutes. A mixed type of spontaneous nystagmus is observed during attacks. 2) Fluctuating cochlear symptoms: The hearing test usually reveals a marked fluctuation of the threshold in the low and middle tone range.
11606613|NCT00599560|No Intervention|2. Acoustic neurinoma|Diagnosed by CT and/or MRI
11606614|NCT00599547|Experimental|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
11606615|NCT00599534|Active Comparator|1|4 mg tablet for 16 weeks
11606616|NCT00599534|Placebo Comparator|2|5 mg for 16 weeks
11606617|NCT00599521|Experimental|Adapalene lotion 0.1%|
11606618|NCT00599521|Placebo Comparator|Adapalene Lotion vehicle|
11606619|NCT00599508|Active Comparator|grape juice active intervention|Concord grape juice administered daily for 12 or 16 weeks
11606620|NCT00599508|Placebo Comparator|juice placebo|berry placebo juice administered daily for 12 or 16 weeks
11606621|NCT00599508|Active Comparator|blueberry juice active intervention|wild blueberry juice administered daily for 12 weeks
11606622|NCT00599508|Active Comparator|blueberry powder intervention|whole fruit blueberry powder administered daily for 16 weeks
11606623|NCT00599508|Placebo Comparator|powder placebo|placebo powder administered daily for 16 weeks
11606624|NCT00599482|Other|1|Far Infrared Radiation
11606625|NCT00599469|Other|1|Far Infrared Radiation
11606626|NCT00599456|Experimental|1|Omega 3 vitamin supplements
11606627|NCT00599456|Placebo Comparator|2|Placebo capsule
11606628|NCT00599443|Experimental|1|
11606629|NCT00599443|Placebo Comparator|2|
11606630|NCT00599430|Placebo Comparator|1|Placebo
11606631|NCT00599430|Active Comparator|Active 1|One probiotic strain
11606632|NCT00599430|Active Comparator|Active 2|Blend of two strains
11606633|NCT00599417|Experimental|1|
11606634|NCT00599417|Placebo Comparator|2|
11606635|NCT00599391|Other|1|Far Infrared Radiation
11606636|NCT00599378|Experimental|1|Implementation Intentions-based telephone counseling. Partnership intervention between rural Primary Care Physicians, their patients, and CRC Information Specialists using an implementation intentions based approach.
11606637|NCT00599378|No Intervention|2|Healthy Living information on Physical Activity and Nutrition
11606638|NCT00599365|Experimental|Pharmacy Care arm|"The pharmacist:
~will take all the patient's medication bottles, and give medication boxes filled with medications in the order the patient should take them in.
~will need to obtain a complete list of medications.
~will teach the patient about the medications.
~will provide a medication schedule, and other papers about the medications.
~will count the pills in the medication boxes.
~will review all the medications with the patient and answer any question.
~will check to see if the medication is working for the patient.
~will work with the patient's kidney doctor to adjust medications if needed.
~will give the medication boxes filled with medications to take home."
11606639|NCT00599365|No Intervention|Control|"The pharmacist:
~will obtain a complete list of medications.
~will count the pills in the patients' medication bottles.
~will inform patients to take their medications from these bottles."
11606640|NCT00599352|Experimental|1|Magnesium infusion
11606641|NCT00599339||Neupro|Neupro at study onset
11606642|NCT00599339||Dopamine Agonist|Other Dopamine-Agonist at study onset
11606643|NCT00599339||L-Dopa|L-Dopa
11606644|NCT00599339||Neupro + L-Dopa|Neupro in combination with L-Dopa at study onset
11606645|NCT00599339||Dopamine Agonist + L-Dopa|Other Dopamine Agonist in combination with L-Dopa at study onset
11606646|NCT00599326|Experimental|A|
11606647|NCT00599313|Experimental|Sunitinib Malate|Sunitinib Malate (Sutent) (50 mg/day on Days 1-28 of 42-day cycles)
11606648|NCT00599287|No Intervention|1|No intervention
11606649|NCT00599287|Experimental|2|Methylphenidate
11606650|NCT00599287|Experimental|3|Rivastigmine
11606651|NCT00599287|Experimental|4|Haloperidol
11606652|NCT00599274||A|This group was treated with Avonex once a week
11606653|NCT00599274||B|This group was treated with Rebif three times a week
11606654|NCT00599261|Experimental|1|Removal of the fibrotic pocket surrounding the generator and leads
11606655|NCT00599261|Experimental|2|Tissue is not removed
11606656|NCT00599248|Experimental|1|TissueGene-C single intraarticular injection of 3x10e6 cells/joint
11606657|NCT00599248|Experimental|2|TissueGene-C single intraarticular injection of 1x10e7 cells/joint
11606658|NCT00599248|Experimental|3|TissueGene-C single intraarticular injection of 3x10e7 cells/joint
11606659|NCT00599248|Placebo Comparator|4|Placebo control single intraarticular injection
11606660|NCT00599235|Experimental|1|
11606661|NCT00599235|Active Comparator|2|
11606662|NCT00599222|Active Comparator|TTT|TTT is given every three months
11606663|NCT00599222|Sham Comparator|Sham TTT|Sham TTT is given every three months
11610367|NCT00568776|Active Comparator|4|
11606664|NCT00599209|Experimental|A - coded unit ID|Nursing home units provided the CDS intervention
11606665|NCT00599209|No Intervention|B - coded unit ID|Nursing home units not provided the CDS intervention
11606666|NCT00599196|Experimental|Rotigotine|Rotigotine
11606667|NCT00599183|Other|1|Participants will receive baseline conventional MRI of the cervical spine as part of their clinical care with an additional diffusion tensor imaging (DTI)sequence as part of the research; they will complete an anonymized questionnaire about their condition. Participants will receive an MRI with DTI and tractography as part of the research and will complete an anonymized questionnaire about their condition. The baseline and follow up data will be compared.
11606668|NCT00599170|Experimental|Arm 1|Rituximab 375 mg/m2 iv on day 1 q 15 days just prior to CHOP, beginning with cycle 1.
11606669|NCT00599144|Experimental|1|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
11606670|NCT00599144|Experimental|2|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
11606671|NCT00599144|No Intervention|3|Group3: control group without any local anesthetic use.
11606672|NCT00599131|Experimental|Chemotherapy/Radiation/Surgery|"Patients will undergo induction chemotherapy with (TPF): Docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 on day 1, and 5-FU 750 mg/m2 days 1-4.
~On day 20 patients will receive a single dose of cetuximab (C-225) 400 mg/m2.
~Depending upon disease response, patients will undergo salvage laryngectomy followed by radiation therapy and chemotherapy."
11606673|NCT00599118||atrial fibrillation|Atrial fibrillation
11606674|NCT00599118||Control|Control subjects with no atrial fibrillation
11606675|NCT00599079|Experimental|Azithromycin|Azithromycin combined with 2 other drugs given 3 times weekly for MAc lung disease
11606676|NCT00599066||Study cases|Application of a second M-Entropy probe on the forehead of the patient; at the end the patient will have 2 probes on the forehead, one in the right and one in the left.
11606677|NCT00599053|Experimental|1|Early treatment with azithromycin
11606678|NCT00599053|No Intervention|2|Expectant (usual) management
11606679|NCT00599040|Active Comparator|Weight loss|Weight loss diet focused on the DASH diet
11606680|NCT00599040|Active Comparator|DASH diet|The DASH diet without weight loss
11606681|NCT00599040|Active Comparator|Diary|Dairy Intervention
11606682|NCT00599027|Experimental|Mometasone furoate nasal spray|Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
11606683|NCT00599027|Placebo Comparator|Placebo nasal spray|Placebo nasal spray once daily (two puffs per nostril) in the morning.
11606684|NCT00599001|Experimental|Escalating Dose of SD-101|
11606685|NCT00599001|Placebo Comparator|Placebo|
11606686|NCT00598988|Experimental|A|Traditional Chinese acupuncture in conjunction with standard medical care
11606687|NCT00598988|Active Comparator|B|standard medical care
11606688|NCT00598975|Experimental|NKTR-102 100 mg/m2 + Cetuximab|NKTR-102 100 mg/m2 + Cetuximab
11606689|NCT00598962|Experimental|azithromycin and rifabutin/rifampin|Azithromycin and rifabutin/rifampin administered three times weekly.
11606690|NCT00598936||Cardiac Surgery or Hospitalization|"Patients scheduled for a Cardiac Surgery procedure, two types of cerebral oximetry devices were compared at the same time during the surgical procedure.
~The second group were patients hospitalized (in the Intensive Care Unit or ICU, with any diagnosis, excluding head trauma patients. Those patients were monitored using two types of cerebral oximetry devices at the same time for up to 72 hours."
11606691|NCT00598923|Experimental|1|Phenytoin 20mg/kg load, then Topiramate, 100 mg twice daily, starting at 24 hours post-TBI for 6 days.
11606692|NCT00598923|Experimental|2|topiramate for 3 months after loading dose of phenytoin
11606693|NCT00598923|Placebo Comparator|3|Phenytoin 20 mg/kg as loading dose than 300 mg/day for total of 7 days
11606694|NCT00598910|Experimental|A|
11606695|NCT00598910|Placebo Comparator|B|
11606696|NCT00598897|Experimental|clarithromycin and rifabutin/rifampin|Clarithromycin and rifabutin/rifampin with ethambutol given three times weekly.
11606697|NCT00598884|Experimental|6-week delay start|This group begins treatment 6 weeks after recruitment and baseline.
11606698|NCT00598884|Experimental|No delay start|This group begins treatment after enrollment and assessment with no wait period.
11606699|NCT00598871|Placebo Comparator|2|There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of eyedrops to the affected eye, identical to the active drug but with no thymosin beta 4 (0.00% thymosin beta 4, w/w), 2 drops 4 times a day (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
11606700|NCT00598871|Active Comparator|1|There are 2 groups: active drug and placebo. The patients in the active comparator arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times a day (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
11606701|NCT00598858|Experimental|Treatment (docetaxel and prednisone)|Patients receive docetaxel IV over 60 minutes on days 1 and 2 and prednisone PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11606702|NCT00598845||Consecutive numbers|Patients with endometrial cancer
11606703|NCT00598832|Experimental|Adapalene lotion 0.1%|
11606704|NCT00598832|Placebo Comparator|Adapalene Lotion vehicle|
11606705|NCT00598819|Experimental|Healthy Volunteers|Healthy subjects testing the device.
11606706|NCT00598806|Experimental|Apaziquone|TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
11606707|NCT00598806|Placebo Comparator|Placebo|TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT
11606708|NCT00598780||1|Patients with newly diagnosed persistent allergic rhinitis, within the approved age limits.
11606709|NCT00598741|Experimental|1|
11606710|NCT00598728||1|Hodgkin lymphoma Survivors
11606711|NCT00598715|Experimental|Same drug|sirolimus-eluting stent will be implanted for restenosis after previous the implantation of a sirolimus-eluting stent
11606712|NCT00598715|Active Comparator|Different drug|paclitaxel eluting stent will be implanted for restenosis after previous the implantation of a sirolimus-eluting stent
11606713|NCT00598702|Experimental|IV Acetaminophen|40 to 75 mg/kg/day every 4 to 6 hours
11606714|NCT00598689|Experimental|Lubricant|Patients scheduled to receive LASIK surgery and randomized to receive 0.3% hypromellose ophthalmic solution prior to surgery.
11606715|NCT00598689|No Intervention|No Lubricant|Patients scheduled to receive LASIK surgery and randomized to receive no intervention of 0.3% hypromellose ophthalmic solution prior to surgery
11606716|NCT00598676|Experimental|BPRES|biodegradable polymer rapamycin-eluting stent
11606717|NCT00598676|Active Comparator|PPRES|permanent polymer rapamycin-eluting stent
11606718|NCT00598676|Active Comparator|PPEES|permanent polymer everolimus-eluting stent
11606719|NCT00598663|Experimental|Off/On|"6 month-Period Off: Continuous Subcutaneous Insulin Infusion (CSII) and Self Monitoring Blood Glucose [Device: Paradigm® Real-Time pump with Sensor Off feature]
~4 month wash out period
~6 month-Period On: Continuous Subcutaneous Insulin Infusion (CSII) + personal continuous glucose monitoring (personal CGM) [Device: Paradigm® Real-Time pump with Sensor On feature continuously]"
11606720|NCT00598663|Experimental|On/Off|"6 month-Period On: Continuous Subcutaneous Insulin Infusion (CSII) + personal continuous glucose monitoring (personal CGM) [Device: Paradigm® Real-Time pump with Sensor On feature continuously]
~4 month wash out period
~6 month-Period Off: Continuous Subcutaneous Insulin Infusion (CSII) and Self Monitoring Blood Glucose [Device: Paradigm® Real-Time pump with Sensor Off feature]"
11606721|NCT00598650|Experimental|1|
11606722|NCT00598637|Active Comparator|EES|Everolimus-eluting stent (Xience)
11606723|NCT00598637|Experimental|ZES|Zotarolimus-eluting stent (Endeavor Resolute)
11606724|NCT00598624|Experimental|A|
11606725|NCT00598611|Active Comparator|1|desloratadine 20 mg
11606726|NCT00598611|Active Comparator|2|desloratadine 20 mg
11606727|NCT00598585|Experimental|sidenafil|sidenafil
11606728|NCT00598585|Placebo Comparator|placebo|placebo
11606729|NCT00598572|Experimental|1|All participants will receive various dose-regimens of the study drug (deferoxamine mesylate). Each dose cohort will consist of at least 3 subjects.
11606730|NCT00598559|Experimental|1 g IV Acetaminophen|1 g q6h IV Acetaminophen
11606731|NCT00598559|Experimental|650 mg IV Acetaminophen|650 mg q4h IV Acetaminophen
11606732|NCT00598559|Other|Standard of Care|The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
11606733|NCT00598546||1|
11606734|NCT00598533|Experimental|Dual-DES|Rapamycin + Probucol-eluting stent
11606735|NCT00598533|Active Comparator|ZES|Polymer based Zotarolimus-eluting stent
11606736|NCT00598507|Experimental|Chemotherapy - ZK-EPO|ZK-EPO (ZK 219477) (Sagopilone), 16 mg/m^2, was administered intravenously over 3-hours every 21 days until progression or unacceptable toxicity.
11606737|NCT00598481|Experimental|Gene Therapy|Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan
11606738|NCT00598442|Experimental|Peginesatide 0.025 mg/kg|
11606739|NCT00598442|Experimental|Peginesatide 0.04 mg/kg|
11606740|NCT00598442|Active Comparator|Darbepoetin alfa|
11606741|NCT00598429|Active Comparator|High dose|PGE1 300 ng/kg/min via nebulizer over a 72-hour period
11606742|NCT00598429|Active Comparator|Low dose|PGE1 150 ng/kg/min via nebulizer over a 72-hour period
11606743|NCT00598429|Placebo Comparator|Placebo|Normal saline, the diluent for the drug, via nebulizer over a 72-hour period
11606744|NCT00598416|Experimental|Psychoeducation|
11606745|NCT00598403|Experimental|1|Cefditoren pivoxil
11606746|NCT00598403|Active Comparator|2|Ciprofloxacin
11606747|NCT00598377|Active Comparator|1|Patients with autosomal dominant polycystic kidney disease
11606748|NCT00598377|Active Comparator|2|Healthy subjects
11606749|NCT00598364||Thyroidectomy or neck dissection|Patients with thyroid cancer or benign thyroid disease (nodules or goiter) who underwent thyroidectomy and/or neck dissection as standard of care.
11606750|NCT00598351||Patients|Patients must have the diagnosis of NF2 by established clinical criteria or genetic testing.
11606751|NCT00598338|Active Comparator|1|Prucalopride
11606752|NCT00598338|Placebo Comparator|2|Placebo
11606753|NCT00598325|Experimental|NicVAX|
11606754|NCT00598325|Experimental|NicVAX Lot 2|2nd cohort receives a different lot of vaccine from the 1st cohort
11606755|NCT00598299||A|Healthy adult serum
11606756|NCT00598299||B|cord blood serum
11606757|NCT00598273|Experimental|Peginesatide 0.025 mg/kg|
11606758|NCT00598273|Experimental|Peginesatide 0.04 mg/kg|
11606759|NCT00598273|Active Comparator|Darbepoetin Alfa|
11606760|NCT00598260|Experimental|1- study group|study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
11606761|NCT00598260|No Intervention|2 - control group|control group
11606762|NCT00598247|Experimental|A|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks. A
11606763|NCT00598234|Active Comparator|1|Celecoxib (Celebrex)
11606764|NCT00598234|Placebo Comparator|2|Placebo
11606765|NCT00598208|Experimental|1|60 µg Org 36286 (corifollitropin alfa)
11606766|NCT00598208|Experimental|2|120 µg Org 36286 (corifollitropin alfa)
11606767|NCT00598208|Experimental|3|180 µg Org 36286 (corifollitropin alfa)
11606768|NCT00598208|Active Comparator|4|Follitropin beta injection
11606769|NCT00598195|No Intervention|Ketamine Pharmacokinetics|The pharmacokinetic action of Ketamine used in Children having heart surgery.
11606770|NCT00598169|Experimental|CD20+ Non-Hodgkin Lymphoma|"Part A: Velcade Day 1 and Day 8, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2. Dexamethasone 20 mg IV and etoposide 100 mg/m2 IV Days 8-10, carboplatin dosed to AUC=5 (maximum 750 mg) IV and ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna on Day 9 of a 28-day cycle.
~Part B: Velcade on Days 1 and 8, dexamethasone 20 mg IV Days 1-3 and Day 8; etoposide 100 mg/m2 IV on Days 1-3; carboplatin dosed to AUC=5 (maximum 750 mg) IV on Day 2; ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna and administered as a continuous IV infusion over 24 hours on Day 2, rituximab 375mg/m2 on Day 1 of a 21-day cycle."
11606821|NCT00597805||1|Patients scheduled for a total, anterior or posterior pelvic exenteration
11606822|NCT00597792|Active Comparator|A|Active Plicator Treatment
11606771|NCT00598169|Experimental|CD20- Non-Hodgkin Lymphoma|"Part A: Velcade Day 1 and Day 8, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2. Dexamethasone 20 mg IV and etoposide 100 mg/m2 IV Days 8-10, carboplatin dosed to AUC=5 (maximum 750 mg) IV and ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna on Day 9 of a 28-day cycle.
~Part B: Velcade on Days 1 and 8, dexamethasone 20 mg IV Days 1-3 and Day 8; etoposide 100 mg/m2 IV on Days 1-3; carboplatin dosed to AUC=5 (maximum 750 mg) IV on Day 2; ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna and administered as a continuous IV infusion over 24 hours on Day 2, 21-day cycle."
11606772|NCT00598156|Experimental|1|bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab and erlotinib as maintenance treatment until progression
11606773|NCT00598156|Experimental|2|bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab every third week until progression
11606774|NCT00598143||Group A|Ten healthy smokers will provide a saliva sample used to genotype UGT1A7 and complete a questionnaire to assess understanding of and willingness to participate in molecular risk assessments.
11606775|NCT00598143||Group B|Thirty smokers will receive standard smoking cessation therapy and provide urine specimens for PGE-M analysis at approximate 3-monthly intervals over one year. Self-reported smoking status and expired-air carbon monoxide (CO) will also be recorded at 3-monthly clinic visits.
11606776|NCT00598130|Experimental|I|patients who will be treated in accordance with standard of care
11606777|NCT00598130|Active Comparator|II|patients for which the Fibrin Fleece will be applied directly on the active bleeding site.
11606778|NCT00598117||1|Group 1 (newly diagnosed patients) Initial assessment → first post op visit → 6 and 12 months post surgery
11606779|NCT00598117||2|Group 2 (post-treatment patients) A one-time assessment will be conducted at least 18 months following treatment
11606780|NCT00598104|Experimental|1|
11606781|NCT00598104|Placebo Comparator|2|
11606782|NCT00598091|Active Comparator|A|
11606783|NCT00598091|Active Comparator|B|
11606784|NCT00598078|Experimental|1|
11606785|NCT00598078|Experimental|2|
11606786|NCT00598078|Placebo Comparator|3|
11606787|NCT00598052|Active Comparator|A|Escitalopram + cognitive-behavior treatment
11606788|NCT00598052|Placebo Comparator|B|Placebo + cognitive-behavior therapy
11606789|NCT00598026|Experimental|1|Tele- follow-up: remote transmission to the implantation centre every 3 months
11606790|NCT00598026|Active Comparator|2|Conventional follow-up: visits at the implantation centre every 3 months
11606791|NCT00598013|Experimental|1|
11606792|NCT00598013|No Intervention|2|
11606793|NCT00598000||1|Determine the impact, in terms of quality of life (QOL), of minimally invasive, video-assisted thoracic surgery (VATS)
11606794|NCT00598000||2|Determine the impact, in terms of quality of life (QOL), in traditional thoracotomy and anatomic lung resection in early stage lung cancer.
11606795|NCT00597987||1|RNA samples
11606796|NCT00597974||Patients having angioplasty (case)|Patients undergoing carotid artery angioplasty and/or stent-supported angioplasty for the treatment of carotid artery stenosis will receive neurological and neuropsychological evaluations
11606797|NCT00597974||Patients having angiography (control)|Patients undergoing coronary angiography for the treatment of carotid artery stenosis will receive neurological and neuropsychological evaluations
11606798|NCT00597948|Experimental|1|Workshop Group: Receives Healthy Lifestyles curriculum and subsequent support.
11606799|NCT00597948|No Intervention|2|Comparison Group: Does not receive Healthy Lifestyles curriculum and subsequent support.
11606800|NCT00597935|Experimental|SSLF and PMT|Sacrospinous Ligament Fixation (SSLF) and Pelvic Muscle Training & Exercises (PMT)
11606801|NCT00597935|Experimental|ULS and PMT|Uterosacral Vaginal Vault Ligament Suspension (ULS) and Pelvic Muscle Training & Exercises (PMT)
11606802|NCT00597935|Experimental|SSLF without PMT|Sacrospinous Ligament Fixation (SSLF) without Pelvic Muscle Training & Exercises (PMT)
11606803|NCT00597935|Experimental|ULS without PMT|Uterosacral Vaginal Vault Ligament Suspension (ULS) without Pelvic Muscle Training & Exercises (PMT)
11606804|NCT00597922||1|2,000 women between the ages of 18 and 55 years who are hospitalized with a heart attack
11606805|NCT00597922||2|1,000 men between the ages of 18 and 55 years who are hospitalized with a heart attack
11606806|NCT00597909|Experimental|Arm 1|
11606807|NCT00597909|Experimental|Arm 2|
11606808|NCT00597909|Placebo Comparator|Arm 3|
11606809|NCT00597896|Experimental|Active pramipexole|Day 1: Random assignment to drug or placebo and dosage starting at 0.125 mg BID, which will be increased every week to a target dose of 1.5 mg/day. Targeted maximum dose of 1.5 mg/day is expected to be reached by week 4, however, dosing will be flexible based upon side effects reported. The maximum dose will be 1.5 mg/day.
11606810|NCT00597896|Placebo Comparator|Placebo pramipexole|Day 1: Random assignment to drug or placebo and dosage starting at 0.125 mg BID, which will be increased every week to a target dose of 1.5 mg/day. Targeted maximum dose of 1.5 mg/day is expected to be reached by week 4, however, dosing will be flexible based upon side effects reported. The maximum dose will be 1.5 mg/day.
11606811|NCT00597870|Experimental|Treatment of Thoracic Lesions|Endoluminal treatment of thoracic lesions
11606812|NCT00597857|Placebo Comparator|1|receipt of a placebo pill for 16 days
11606813|NCT00597857|Active Comparator|2|oral pill of hydrocortisone (ranging from 20mg - 2.5mg) taken for 10 days with a taper for 6 days (based on Pitman et al, 2002).
11606814|NCT00597844|Experimental|1|voice evaluation and fMRI prior to surgical rehabilitation of UVCP
11606815|NCT00597844|Other|2|Healthy volunteers-voice evaluation and fMRI
11606816|NCT00597831||A|All patients in the Rijnstate Hospital with an indication for unilateral ECT treatment and a major depression or psychotic depression according to DSM IV-TR criteria.
11606817|NCT00597818|Placebo Comparator|Placebo|Participants receive matching placebo capsules for 20 months
11606818|NCT00597818|Experimental|Cobiprostone QD|Participants receive 18 mcg cobiprostone once daily (QD) for 20 months
11606819|NCT00597818|Experimental|Cobiprostone BID|Participants receive 18 mcg cobiprostone twice daily (BID) for 20 months
11606820|NCT00597818|Experimental|Cobiprostone TID|Participants receive 18 mcg cobiprostone three times daily (TID) for 20 months
11606823|NCT00597779|Active Comparator|EM device|Extramedullary Device (EM)
11606824|NCT00597779|Active Comparator|IM device|Intramedullary Device (IM)
11606825|NCT00597766|Active Comparator|Low Dose|"Drug: Lidocaine (Neer's Test)
~Drug: 20 mg Triamcinolone + Lidocaine"
11606826|NCT00597766|Active Comparator|Standard Dose|"Drug: Lidocaine (Neer's Test)
~Drug: 40 mg Triamcinolone + Lidocaine"
11606827|NCT00597766|Experimental|High Dose|"Drug: Lidocaine (Neer's Test)
~Drug: 60 mg Triamcinolone + Lidocaine"
11606828|NCT00597753|Experimental|Peginesatide|
11606829|NCT00597753|Active Comparator|Epoetin alfa|
11606830|NCT00597727|Active Comparator|Blinded Peanut SLIT|Blinded subjects who received peanut sublingual drops for the initial 12 month blinded phase of the study.
11606831|NCT00597727|Placebo Comparator|Blinded Placebo SLIT|Blinded subjects who received placebo sublingual drops for the initial 12 month blinded phase of the study.
11606832|NCT00597727|Other|Ext. maint. open label peanut SLIT|After completing the blinded phase of the study, subjects receiving Blinded Peanut SLIT continued on extended maintenance open-label peanut SLIT for the duration of the study. Subjects receiving Blinded Placebo SLIT were crossed over and underwent the 12 month buildup protocol on open label peanut SLIT and then continued on extended maintenance treatment for the duration of the study.
11606833|NCT00597727|Other|Early unblinded peanut SLIT|Subjects who were unblinded prematurely during the blinded phase of the study and then re-enrolled as an open label cohort.
11606834|NCT00597727|Other|Pilot peanut SLIT rollover cohort|Subjects from the original phase 1 study of peanut SLIT (NCT00429429) who were rolled over into the current protocol as an open label peanut SLIT cohort.
11606835|NCT00597714|Experimental|Cohort A - Lymphoid Disease|Group A: Patients with a high chance of progressive lymphoid or myelomatous disease undergo Non-myeloablative Stem Cell Transplantation.
11606836|NCT00597714|Experimental|Cohort B - Myeloid Disease|Group B: Patients with a high chance of progressive myeloid diseases, marrow failure syndromes or myeloproliferative disorders undergo Non-myeloablative Stem Cell Transplantation.
11606837|NCT00597714|No Intervention|Donor|Donor priming and apheresis will include filgrastim 8 mcg/kg subcutaneously twice daily for 4 days prior to stem cell collection and continuing until pheresis is completed. Alternative mobilization strategies may be employed at the investigator's discretion.
11606838|NCT00597701|Active Comparator|Baclofen|Standard benzodiazepine therapy plus baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
11606839|NCT00597701|Placebo Comparator|Placebo|Standard benzodiazepine therapy plus placebo every eight hous as inpatients for 72 hours or until discharge if less than 72 hours.
11606840|NCT00597688|Active Comparator|1|Chlorhexidine gel
11606841|NCT00597688|Placebo Comparator|2|Placebo gel
11606842|NCT00597675|Placebo Comparator|Placebo|Oat flour ingested daily as a placebo
11606843|NCT00597675|Active Comparator|Peanut OIT|Peanut flour ingested daily as oral mucosal immunotherapy
11606844|NCT00597662|Experimental|1|
11606845|NCT00597662|Active Comparator|2|
11606846|NCT00597649|Experimental|1|Bicifadine 800 mg/day for a year
11606847|NCT00597649|Experimental|2|Bicifadine 1200 mg/day for a year
11606848|NCT00597636||1|NEVER SMOKERS WITH LUNG CANCER
11606849|NCT00597636||2|NEVER SMOKERS WITHOUT ANY CANCER
11606850|NCT00597623|Experimental|1|2 injections of Adalimumab (Humira®)
11606851|NCT00597623|Placebo Comparator|2|2 injection of Placebo
11606852|NCT00597610|Experimental|1|
11606853|NCT00597597|Experimental|A|Open label; all subjects receive active drug, Erlotinib
11606854|NCT00597584|Experimental|Peginesatide|
11606855|NCT00597584|Active Comparator|Epoetin|
11606856|NCT00597558|Experimental|Egg white protein|Subjects, who are egg allergic, are given egg white protein for desensitization with the hypothesis they will develop tolerance.
11606857|NCT00597545|Active Comparator|Conventional Shunt|"Patients with diabetes mellitus (DM) undergoing carotid endarterectomy will receive a shunt only if it is indicated by EEG, by conventional management."
11606858|NCT00597545|Experimental|Prophylactic Shunt|Patients with diabetes mellitus (DM) undergoing carotid endarterectomy will receive a shunt even when by standard criteria they would not need to receive one.
11606859|NCT00597532|Experimental|1|soy (soy protein supplementation 50 grams/day)
11606860|NCT00597532|Placebo Comparator|2|milk protein supplementation 50 grams/day
11606861|NCT00597519|Experimental|Treatment|Patients with hematopoietic malignancy at high-risk for relapse or with advanced disease will receive myeloablative conditioning with cyclophosphamide (Cy), low dose fludarabine (Flu) and total body irradiation (TBI) with post transplantation cyclosporine (CSA) and mycophenolate mofetil (MMF) for GVHD prophylaxis.
11606862|NCT00597506|Experimental|Bevacizumab and Everolimus|10 mg Everolimus(RAD001) daily by mouth, days 1-28 10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle
11606863|NCT00597493|Experimental|Sorafenib + Temozolomide|"Subjects receive 400mg of Sorafenib twice daily and 50mg/m^2 of Temozolomide once daily
~Subjects continue to receive treatment until any of the following: progressive disease, unacceptable toxicity, non-compliance with study guidelines, withdrawal of patient consent, intercurrent non-cancer-related illness that prevents continuation of therapy or regular follow-up, general or specific changes in a subject's condition which render the patient unacceptable for treatment in the judgement of the investigator, or study closure"
11606864|NCT00597480|Active Comparator|1|the recommended dose in the EU of rhGH (Norditropine SimpleXx®)
11606865|NCT00597480|Active Comparator|2|"the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)"
11606866|NCT00597467|Experimental|Test Contact Lenses|VISA (comfilcon A) Silicone Hydrogel Soft contact lens
11606867|NCT00597467|Active Comparator|Control Contact Lenses|Acuvue 2 Soft Contact Lens
11606868|NCT00597454|Experimental|1|
11606869|NCT00597441|Experimental|I|Thymic tissue from third party donor
11606870|NCT00597428|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
11606871|NCT00597428|Experimental|Lubiprostone|24 mcg capsules twice daily (BID)
11606872|NCT00597415|Placebo Comparator|A 1|A 1=placebo
11606873|NCT00597415|Active Comparator|A 2|A 2=celecoxib
11606874|NCT00597402|Experimental|Avastin, radiation, temozolomide, and irinotecan|
11606875|NCT00597389|Active Comparator|1|oral solution of propranolol (propranolol HCL 20 mg/5 ml solution) or a liquid placebo twice daily for 10 days (and taper for 5 days; based on Pitman et al, 2002). Dose was calculated as determined by Famularo et al. (1988) to be 2.5 mg/kg/d with a maximum dose of 40 mg bid (Green, 2001).
11606876|NCT00597389|Placebo Comparator|2|A 25/5ml solution of placebo (a sugar solution that looks and tastes like the propranolol solution)
11606877|NCT00597376|Experimental|1|On Cerefolin NAC and open-label multivitamin supplement
11606878|NCT00597376|Placebo Comparator|2|On placebo and open label multivitamin supplement
11606879|NCT00597363|Experimental|1|Neptune PAD utilization to accelerate closure of the vascular access site
11606880|NCT00597363|Active Comparator|2|manual compression for closure of the vascular access site
11606881|NCT00597350||1|Group with diabetes mellitus
11606882|NCT00597337|Experimental|1|Receiving FearNot
11606883|NCT00597337|No Intervention|2|Control: Treatment as usual (normal curriculum)
11606884|NCT00597324|Active Comparator|1|Patients with normal Allen's test
11606885|NCT00597324|Experimental|2|Patients with intermediate Allen's test
11606886|NCT00597324|Experimental|3|Patients with abnormal Allen's test
11606887|NCT00597311|Experimental|1|preoperative short term radiation group 5x5 Gy and surgery after 6 weeks
11606888|NCT00597311|Experimental|2|preoperative chemoradiotherapy group 50Gy + 5FU/Lv and surgery after 6 weeks.
11606889|NCT00597298|Active Comparator|1|inspiratory muscle training program using a pressure threshold device
11606890|NCT00597298|Sham Comparator|2|
11606891|NCT00597272|Experimental|1|Vaccine- KLH conjugates with GD2L and GD3L
11606892|NCT00597259|Experimental|A|
11606893|NCT00597259|Active Comparator|B|Entecavir Alone
11606894|NCT00597246|Experimental|1|
11606895|NCT00597220|Experimental|1|Omega 3
11606896|NCT00597220|Placebo Comparator|2|
11606897|NCT00597207|Experimental|1|Mechanical CPR with AutoPulse
11606898|NCT00597207|Other|2|Manual CPR
11606899|NCT00597194|Active Comparator|OH|Inguinal hernia operated using a classic open herniotomy(OH)
11606900|NCT00597194|Active Comparator|LH|Laparoscopic herniorraphy (LH) for inguinal hernia
11606901|NCT00597181|Active Comparator|1|Trabeculectomy with Mitomycin C 0.2 mg/cc for 2 minutes
11606902|NCT00597181|Active Comparator|2|Ex-Press mini shunt; Model R50 with mitomycin C 0.2 mg/cc for 2 minutes
11606903|NCT00597142|Experimental|1|
11606904|NCT00597129|Experimental|Multi Dose levels|different doses of 90YhPAM4 will be given only once.
11606905|NCT00597116|Active Comparator|1|Vinorelbine
11606906|NCT00597116|Experimental|2|Vandetanib
11606907|NCT00597103||1|Prevalent patients who have been receiving more frequent dialysis.
11606908|NCT00597103||2|Incident patients new to more frequent dialysis
11606909|NCT00597103||3|Patients who switch from one more frequent hemodialysis treatment regimen to another more frequent dialysis regimen.
11606910|NCT00597090||1|
11606911|NCT00597077|Active Comparator|Rate control|
11606912|NCT00597077|Active Comparator|Rhythm control|
11606913|NCT00597038|Experimental|Phase I Dose Escalation|Dasatinib and Dacarbazine (DTIC). The first cohort was a dasatinib dose of 50 mg by mouth (PO) twice a day (BID) given days 2-19 with DTIC given at a dose of 800 mg/m2 once every 3 weeks. The dose escalation was continued until MTD and a recommended Phase II dose was established.
11606914|NCT00597038|Experimental|Phase II Dose Treatment|Dasatinib and Dacarbazine (DTIC). The recommended phase II dose was dasatinib 70 mg BID with dacarbazine 800 mgm^2.
11606915|NCT00597025|Active Comparator|Group A|Center Hemodialysis patients
11606916|NCT00597025|Active Comparator|Group B|Center hemodialysis patients
11606917|NCT00597025|No Intervention|Group C|Center Hemodialysis Patients
11606918|NCT00597025|Active Comparator|Group D|Peritoneal dialysis patients
11606919|NCT00597025|No Intervention|Group E|Peritoneal dialysis patients
11606920|NCT00597012|Experimental|Surgical|Participants will undergo arthroscopic partial menisectomy (APM) surgery and offered postoperative rehabilitative physical therapy.
11606921|NCT00597012|Active Comparator|Nonoperative|Participants will undergo standard physical therapy that will include strengthening and stretching sessions one to three times a week for 8 weeks.
11606922|NCT00596999||1|all subjects will be treated with UCB and HPDSC
11606923|NCT00596986|Active Comparator|AD|Antidepressant Duloxetine
11606924|NCT00596986|Active Comparator|PT|Psychotherapy (CBASP) - Cognitive Behavioural Analysis System of Psychotherapy
11606925|NCT00596973|Experimental|Ileal transposition with SG|Procedure: Surgical Treatment
11606926|NCT00596960|Experimental|Motivational Enhancement Therapy|Motivational enhancement therapy
11606927|NCT00596960|Active Comparator|Health Education|health education intervention
11606928|NCT00596947|Experimental|Prednisone Withdrawal|Participants randomized to the prednisone withdrawal group, received 4 medications to prevent rejection. Thymoglobulin (rabbit antithymocyte globulin) was given intravenously in the operating room at the time of transplant. Subsequent intravenous doses were administered to participants an inpatient or outpatient for a total of 3 to 5 doses. Participants also began taking Prograf (tacrolimus) and CellCept (mycophenolate mofetil)orally within 24 hours of transplant and continued indefinitely. The steroids were initially given in the operating room intravenously at time of transplant as Solu-medrol (methylprednisolone)and were then switched to daily oral prednisone doses. The participant's dose of prednisone was rapidly decreased until it was completely eliminated by day 6 post-transplant.
11606929|NCT00596947|Active Comparator|Prednisone Maintenance|Participants randomized to the prednisone maintenance group, received 4 medications to prevent rejection. Thymoglobulin (rabbit antithymocyte globulin) was initiated intravenously in the operating room at the time of transplant. Subsequent intravenous doses were administered an inpatient or outpatient for a total of 3 to 5 doses. Participants began taking Prograf (tacrolimus) and CellCept (mycophenolate mofetil)orally within 24 hours of transplant and continued on them indefinitely. The steroids were initially given intravenously in the operating room at time of transplant as Solu-medrol (methylprednisolone) and were then switched to daily oral prednisone tablets. Participants remained on all drugs according to their doctor's standard of care, and the prednisone was not be eliminated.
11606930|NCT00596934|Experimental|Metreleptin treatment group|Treatment group
11606931|NCT00596908||1|Subjects with Parkinsonian Tremor (PT)
11606932|NCT00596908||2|Subjects with non Parkinsonian Tremor (nPT)
11606933|NCT00596895|Experimental|1|Isoflavone treatment
11606934|NCT00596882|Other|1|Threat only message. Participants hear information about the negative health consequences of smoking
11606935|NCT00596882|Other|2|Genetic threat + threat. Participants will bear infomration about genetic influences of smoking in additon to the negative health consequences of smoking.
11606936|NCT00596856|Active Comparator|1|25 randomly selected pediatric practices that have never participated in IMB will receive the newly developed risk assessment forms and guidelines through the mail with instructions on how to implement them in the practice. (Passive dissemination to non-participating practices)
11606937|NCT00596856|Experimental|2|25 randomly selected pediatric practices currently participating in IMB will receive the newly developed risk assessment forms and guidelines through the mail with instructions on how to implement them in the practice. (Passive dissemination to participating practices)
11606938|NCT00596856|Experimental|3|25 randomly selected pediatric practices currently participating in IMB will receive the newly developed risk assessment forms and guidelines through an intense in-office intervention. (Intense intervention with participating practices)
11606939|NCT00596843|Experimental|1|Motivational intervention
11606940|NCT00596843|Active Comparator|2|Educational intervention
11606941|NCT00596830|Experimental|A|Patients in Arm A will receive CP-751, 871 in combination with paclitaxel and carboplatin intravenously every 21 days for up to six cycles.'
11606942|NCT00596830|Active Comparator|B|Patient in Arm B will receive paclitaxel and carboplatin intravenously every 21 days for up to six cycles.
11606943|NCT00596817|Placebo Comparator|Placebo|
11606944|NCT00596817|Experimental|Vortioxetine: 5 or 10 mg|
11606945|NCT00596791|Other|1 arm|Open-lable study with one arm.
11606946|NCT00596778|Other|C, CP|Thirty-one adults were randomly assigned to control (C) and chest physiotherapy (CP) groups. Chest physiotherapy group received treatment at the post-anesthesia unit care and control group did not.
11606947|NCT00596765|Experimental|1|Neuropsychological cognitive behavioral psychotherapy for patients with acquired brain injury consists of 25 weekly 1-hr sessions of individualized outpatient treatment. The therapeutical intervention is modularised, patients are assigned to specific interventional modules according to the results of cognitive testing and interviews. Modules concern on the one hand the treatment of deficits in attention, memory, and executive functions. On the other hand psychosocial adjustment to chronic illness is addressed through modules that concern the development of a positive self-concept, the adjustment of life-goals and coping with negative affect (e.g. depressive symptoms, irritability, guilt).
11606948|NCT00596765|Other|2|"Waiting list: Patients are randomly assigned to one of two existing groups after completion of the first session of various neuropsychological tests and interviews.
~Patients assigned to the experimental group receive therapy immediately after completing the first session of various neuropsychological tests and interviews. Patients randomized to the waiting list receive the treatment as specified above after waiting for 5 month."
11606949|NCT00596752|Experimental|Alprostadil|Prostavasin® 40 μg will be infused intravenously twice daily over 2 hours in 50 to 150 ml isotonic sodium chloride solution during a Treatment Phase of 4 weeks.
11606950|NCT00596752|Placebo Comparator|Placebo|Placebo will be infused intravenously twice daily over 2 hours in 50 to 150 ml isotonic sodium chloride solution during a Treatment Phase of 4 weeks.
11606951|NCT00596713||1|Both genders aged 20 to 80 years and living in private households in the city of São Paulo. Pregnant or lactating women, people with physical or mental impairment and workers in night shifts are not part of the population of interest.
11606952|NCT00596700|Experimental|Device|"Patient preparation procedure will be done according to chapter 4 in the Given Diagnostic System user manual. In brief: to drink only clear liquids beginning 12:00 noon the day before.at least 8 hours (since 12:00 PM) fast prior to the procedure. Patient will undergo a standard capsule endoscopy. Patients will be allowed to drink clear liquids 2 hours post ingestion, and eat 4 hours post ingestion.
~Eight hours post ingestion, data recorder will be removed and the patient will be dismissed.
~A local experienced reader will review the RAPID video to determine the diagnosis blinded to the results of the standard workup procedures, and to each other results. Results will be recorded in the case report forms. A decoded video will be transferred to the principal investigator for reevaluation"
11606953|NCT00596687|Experimental|1|Glargine once daily plus glulisine given before meals plus supplemental glulisine for BG > 140
11606954|NCT00596687|Active Comparator|2|Sliding scale regular insulin four-times daily achs.
11606955|NCT00596674|Experimental|Lifestyle Counts Intervention|A wellness intervention that includes 8 weeks of behavior change classes focused on acquiring the skills and knowledge to improve health behaviors (e.g., exercise, stress management), followed by 3 months of phone support.
11606956|NCT00596674|Placebo Comparator|Attention Countrol|8 weeks of general health classes followed by phone calls for 3 months
11606957|NCT00596661|Experimental|TRIMAXX|TRIMAXX Coronary Stent
11606958|NCT00596648|Experimental|Phase 1 Arm|Escalating doses of XL184 + erlotinib
11606959|NCT00596648|Experimental|Phase 2 Arm 1|XL184 + erlotinib (dose determined from Phase 1 portion of study)
11606960|NCT00596648|Experimental|Phase 2 Arm 2|XL184 administered as a single agent
11606961|NCT00596635|No Intervention|Control Group|No cranberry capsules administered
11606962|NCT00596635|Active Comparator|One cranberry capsule|1 650mg cranberry capsule daily
11606963|NCT00596635|Active Comparator|Two cranberry capsules|1 650 mg cranberry capsule twice daily (bid)
11606964|NCT00596622|Experimental|Bipolar Manic Subjects Treated|Bipolar mania picture response during fMRI before and after treatment with lithium
11606965|NCT00596622|Experimental|Bipolar Depressed Subjects Treated|Bipolar depression picture response during fMRI before and after treatment with lithium
11606966|NCT00596622|Experimental|Bipolar Euthymic Subjects Treated|Bipolar euthymia picture response before and after treatment with lithium
11606967|NCT00596609||1|Group 1 will be subjects who receive Intrathecal Morphine.
11606968|NCT00596609||2|Group 2 will be subjects who do not receive Intrathecal Morphine.
11606969|NCT00596596|Active Comparator|1|0,5 mg prucalopride
11610368|NCT00568750|Experimental|Dasatinib|
11606970|NCT00596596|Active Comparator|2|1 mg prucalopride
11606971|NCT00596596|Active Comparator|3|2 mg prucalopride
11606972|NCT00596596|Placebo Comparator|5|Placebo arm
11606973|NCT00596596|Active Comparator|4|4 mg prucalopride
11606974|NCT00596583|Active Comparator|High Dose|
11606975|NCT00596583|Active Comparator|Low Dose|
11606976|NCT00596570||1|Patient with atrial fibrillation who underwent PCI
11606977|NCT00596557|Experimental|Everolimus, Immunosupression|everolimus and reduced dose CNI: reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
11606978|NCT00596544||1|FSFI score <= 26
11606979|NCT00596544||2|FSFI score >26
11606980|NCT00596531|Active Comparator|A|"Subjects will take acamprosate (Campral) at a dose of 666 mg. three times daily (morning, lunch time, bed time) for 28 days. Only responders will be included in the subsequent double-blind cross over arms after a minimum washout period of 4 weeks.
~Subjects will randomly be assigned to Group 1 (A/B) or Group 2 (B/A) after completion of Phase I and its subsequent washout period (Figure 1, periods 1 and 2). Group 1 will receive acamprosate (Campral) at a dose of 666 mg. three times daily for 24 weeks followed by a 4-week washout period"
11606981|NCT00596531|Placebo Comparator|B|Group 2 will be assigned to the placebo group and take matched placebos for next 24 weeks followed by a 4-week washout period. After the washout period each group will be assigned to the other intervention (acamprosate or placebo) and complete another trial for 24 weeks.
11606982|NCT00596518|Experimental|PF-00734200|
11606983|NCT00596505||1|Group 1 will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
11606984|NCT00596505||2|Group 2 will not receive bevacizumab pretreatment
11606985|NCT00596492|Active Comparator|High Dose|
11606986|NCT00596492|Active Comparator|Low Dose|
11606987|NCT00596466|Experimental|1|
11606988|NCT00596453|Placebo Comparator|Placebo|
11606989|NCT00596453|Experimental|Ciprofloxacin hydrochloride|
11606990|NCT00596440||1|Relatives of Cancer Patients
11606991|NCT00596440||2|Relatives of Orthopedic Patients
11606992|NCT00596427|Placebo Comparator|Placebo tablet 3 tablets 2x/day|Type-2 diabetes mellitus patients
11606993|NCT00596427|Experimental|Colesevelam HCL 625 mg: 3 tablets 2x/day|Type-2 diabetes mellitus patients
11606994|NCT00596414|Placebo Comparator|1|
11606995|NCT00596414|Experimental|2|midazolam
11606996|NCT00596414|Experimental|3|midazolam + pethidine
11606997|NCT00596401||1|HP eradication group
11606998|NCT00596401||2|No eradication group
11606999|NCT00596401||3|No Hp group
11607000|NCT00596388||1|Subjects diagnosed as intermediate AMD
11607001|NCT00596375|No Intervention|Routine Care Group|The routine care group will help us to quantify the routine amount of distress associated with catheterization.
11607002|NCT00596375|Experimental|Lidocaine Group|A experimental group will include patients who will have 2% Lidocaine instilled into the urethra prior to catheterization. This group of subjects receiving routine care plus Lidocaine, will be evaluated during each of the four phases of the intervention.
11607003|NCT00596375|Experimental|Instillation|This group will undergo catheterization utilizing routine care plus lubricant jelly instilled into the urethra. This placebo group will aid in discerning the effects of instillation into the urethra on pain and associated distress.
11607004|NCT00596362|Experimental|1|AVASTIN
11607005|NCT00596349||A|epithelial ovarian cancer survivors (women disease-free at 5 to 10 years from diagnosis of ovarian cancer)
11607006|NCT00596349||B|women in second- or greater remission (women who have had one or more relapses from ovarian cancer but are considered to be currently clinically disease-free 5 to 10 years from original diagnosis of ovarian cancer).
11607007|NCT00596349||C|women surviving with epithelial ovarian cancer (women alive with disease 5 to 10 years from original diagnosis of ovarian cancer)
11607008|NCT00596336|Active Comparator|Group A CLL patients|Vaccination with current trispecific influenza vaccine Day 1
11607009|NCT00596336|Experimental|Group B CLL patients|Vaccination with current trispecific influenza vaccine Day 1, together with the application of Imiquimod cream to the vaccination site on day 2 to 6.
11607010|NCT00596336|Active Comparator|Group C volunteers|Vaccination with current trispecific influenza vaccine Day 1
11607011|NCT00596310|Experimental|1|Screening CT
11607012|NCT00596297|Experimental|A|Preoperative Intravitreal bevacizumab and pars plana vitrectomy
11607013|NCT00596297|Active Comparator|B|Pars plana vitrectomy only
11607014|NCT00596284|Experimental|CBT-AD|Participants will receive Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)
11607015|NCT00596284|Active Comparator|EUC|EUC will consist of regular ongoing care from healthcare providers and phone assessments at 1-month and 2-month. Following the 6 month assessment, participants in EUC will be offered a half-day Cognitive Behavior Workshop.
11607016|NCT00596271|Active Comparator|IC51 and Placebo|6 mcg i.m. IC51 with 2 injections (day 0 and 28)and placebo 0.5 mL with 1 injection (day 0)
11607017|NCT00596271|Active Comparator|HAVRIX and placebo|HAVRIX with 1 injection (day 0) and placebo 0.5 mL with 2 injections (day 0 and 28)
11607018|NCT00596271|Active Comparator|IC51 and HAVRIX|IC51 6 mcg i.m. with 2 injections (day 0 and 28) and HAVRIX with 1 injection (day 0)
11607019|NCT00596258|Experimental|A-007|Single arm open label
11607020|NCT00596245|Experimental|1|MT 400, naproxen sodium 550mg
11607021|NCT00596232||Asthma|People who have been diagnosed with Asthma
11607022|NCT00596232||Cystic Fibrosis|People who have been diagnosed with Cystic Fibrosis
11607023|NCT00596232||Healthy|People who are non-asthmatic, non smokers with less than 10 pack years and who do not have cystic fibrosis
11607024|NCT00596219|Experimental|1|
11607025|NCT00596206|Experimental|1|100 mg of leflunomide
11607026|NCT00596206|Active Comparator|2|20 mg of leflunomide
11607027|NCT00596193||Group I|patients with normal or irreversible pulpitis teeth with capsaicin administered at increasing volumes.
11607028|NCT00596193||Group II|Patients with normal teeth only with capsaicin added at a specific volume only
11607029|NCT00596180||1|HBOT
11607086|NCT00595647|Active Comparator|1|Percutaneous coronary intervention
11611155|NCT00562484|Other|2|
11607030|NCT00596167|Experimental|Intravenous antibiotics|Intervention: administer intravenous vancomycin, gentamicin and levofloxacin. This study will determine the pharmacokinetics of intravenous vancomycin, gentamicin and levofloxacin in subjects receiving short-daily hemodialysis. There will not be a control arm for this study. The intervention for this arm will be to administer intravenous vancomycin, gentamicin and levofloxacin and draw blood samples at periodic intervals. The blood samples will be tested for these medications and pharmacokinetic analysis will be performed.
11607031|NCT00596154|Experimental|1|Rituximab, methotrexate (MTX), procarbazine and vincristine (R-MPV). The peripheral blood stem cell (PBSC) harvest procedure will be performed at the discretion of the hematology attending (usually after the 1st or 2nd cycle of R-MPV)and high dose chemotherapy Busulfan, Thiotepa, and Cyclophosphamide. Patients will be off study at the time of death. All patients will be followed for survival every 6 months throughout their lifetime. Survival status may be obtained by phone call, clinical visit or medical records (e.g. physician notes/laboratory results of clinic or hospital visit.
11607032|NCT00596141|Experimental|1|Conventional postoperative care and instructions on dental hygiene will be provided along with the TOWE treatment which consists of the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site 3 times daily for a period of 7 days. At three (3) days and seven (7) days postoperatively, photographs will be taken of all vertical releasing incisions (before suture removal).
11607033|NCT00596141|No Intervention|2|Conventional postoperative care and instructions on dental hygiene.
11607034|NCT00596128|No Intervention|1|Blood sugar monitoring and intervention as clinical routine, no SOP defined and implemented
11607035|NCT00596128|Experimental|2|Blood sugar monitoring after implementation of SOP
11607036|NCT00596089||1|Men and women 60 years and older
11607037|NCT00596089||2|Men and women 20-30 years of age
11607038|NCT00596076|Experimental|1|Workers with low back pain
11607039|NCT00596063|Experimental|Wosulin R|Regular insulin for subcutaneous injection (recombinant human insulin), 600nmol, 100 IU
11607040|NCT00596063|Active Comparator|Novolin R|Regular insulin for injection (recombinant human insulin)
11607041|NCT00596050|Active Comparator|ketamine and midazolam|ketamine and midazolam
11607042|NCT00596050|Active Comparator|etomidate and fentanyl and lidocaine|etomidate and fentanyl and lidocaine
11607043|NCT00596037|Experimental|LB03002 throughout|administered LB03002 for preceding 26 weeks
11607044|NCT00596037|Experimental|Switched to LB03002|administered placebo for preceding 26 weeks
11607045|NCT00596024|Experimental|1|Daily Lutein/zeaxanthin supplementation with a meal
11607046|NCT00596024|Placebo Comparator|2|
11607047|NCT00596011|Active Comparator|Polyphenon E Treatment|Polyphenon E, 200 mg epigallocatechin gallate (EGCG) twice a day (BID)
11607048|NCT00596011|Placebo Comparator|Placebo Administration|Matching placebo BID
11607049|NCT00595998||1|newly onset CNV secondary to AMD
11607050|NCT00595998||2|Intermediate AMD
11607051|NCT00595985|Experimental|A|administer sorafenib 400mg bid until disease progression or intolerable toxicity or patients withdrawal of consent
11607052|NCT00595972|Experimental|A|patients will be treated by ECF regimen (epirubicin, cisplatin plus 5-FU) combined with endostar
11607053|NCT00595959|Experimental|Laser Treatment|CLiRpath Photoablation Atherectomy System
11607054|NCT00595946|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
11607055|NCT00595946|Experimental|Lubiprostone|24 mcg capsules twice daily (BID)
11607056|NCT00595933|Experimental|1|Each participant will receive an unidentified product to use for a one week period. This will continue until all 7 dry-mouth products have been evaluated.
11607057|NCT00595920|Experimental|Tovaxin, open-label|Tovaxin; 30-45 million autologous myelin reactive T cells
11607058|NCT00595894||1|CLEAR enrollees include African American patients with early rheumatoid arthritis, as defined using ACR criteria
11607059|NCT00595894||2|VARA enrollees will include male veterans with established RA diagnosed using ACR criteria
11607060|NCT00595881||Ultrasound|One group of patients will undergo emergency bedside ultrasound in addition to the clinical examination.
11607061|NCT00595868|Experimental|Varenicline|
11607062|NCT00595868|Placebo Comparator|Placebo|
11607063|NCT00595855|Active Comparator|TE|trabeculectomy
11607064|NCT00595855|Experimental|DS|deep sclerectomy
11607065|NCT00595842||Group one|Subjects are drawn from a search of all patients treated with MTA between ages 5-40
11607066|NCT00595829|Experimental|1|
11607067|NCT00595816|Experimental|1|Active treatment: physical training and counselling
11607068|NCT00595790|Active Comparator|IC51 2 x 6 mcg|2 x 6 mcg (microgram)
11607069|NCT00595790|Active Comparator|IC51 1 x 12 mcg|1 x 12 mcg (microgram)
11607070|NCT00595790|Active Comparator|IC51 1 x 6 mcg|1 x 6 mcg (microgram)
11607071|NCT00595777|No Intervention|1. Comparison|The centres allocated to the comparison group will continue to provide usual care only.
11607072|NCT00595777|Experimental|2. Experimental|The EPAT package consists of an educational programme, which deals with the common barriers to effective cancer pain control and the bedside pain tool.
11607073|NCT00595764|Active Comparator|1|Physician Management
11607074|NCT00595764|Experimental|2|Physician Management plus Cognitive Behavioral Therapy
11607075|NCT00595738||Heart Failure Patients|Patients admitted with advanced heart failure for tailoring of heart failure therapy via placement of a pulmonary artery (PA) catheter. In our study, the patients will already have a PA catheter placed for clinical/treatment reasons when we approach them for the study.
11607076|NCT00595725|Experimental|1|
11607077|NCT00595712|Active Comparator|A|Using Iliac crest allograft in high tibial osteotomy
11607078|NCT00595712|Active Comparator|B|Using iliac crest autograft in high tibial osteotomy
11607079|NCT00595699|Placebo Comparator|2|Double-blind
11607080|NCT00595699|Experimental|1|escitalopram group
11607081|NCT00595686|Experimental|Single Arm|
11607082|NCT00595660|Active Comparator|1|Needle 21 for FNA
11607083|NCT00595660|Active Comparator|2|22 needle for FNA
11607084|NCT00595660|Active Comparator|3|23 needle for FNA
11607085|NCT00595660|Active Comparator|4|24 needle for FNA
11607087|NCT00595647|Placebo Comparator|2|Percutaneous coronary intervention
11607088|NCT00595621|Active Comparator|MGP-1 ON|Experimental Pacemaker on for 6 weeks
11607089|NCT00595621|Active Comparator|MGP-1 OFF|Experimental Pacemaker on or off for 4 weeks
11607090|NCT00595608|Active Comparator|1|Nasal Sterimar spray
11607091|NCT00595608|Active Comparator|2|Nasal saline spray
11607092|NCT00595582|Other|single arm|Curcumin + Bioperine
11607093|NCT00595569||Type 1 diabetes|
11607094|NCT00595556|Experimental|A|Zonisamide
11607095|NCT00595556|Placebo Comparator|B|placebo
11607096|NCT00595543|Active Comparator|1|
11607097|NCT00595543|Active Comparator|2|
11607098|NCT00595543|Active Comparator|3|
11607099|NCT00595530|Experimental|Ketamine|This group will receive ketamine
11607100|NCT00595517|Experimental|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
11607101|NCT00595504|Experimental|1|Ramelteon 8mg/day
11607102|NCT00595504|Placebo Comparator|2|sugar pill
11607103|NCT00595491|Experimental|allergic asthmatic, allergic nonasthmatic, healthy|Adults who are allergic asthmatics, allergic nonasthmatics, or healthy controls will receive segmental allergen challenge to the lung
11607104|NCT00595478|Experimental|1|Motivational Enhancement Therapy (MET)/CBT+CM/BPT
11607105|NCT00595478|Active Comparator|2|Motivational Enhancement Therapy (MET)/CBT
11607106|NCT00595465|Active Comparator|IC51 Batch A|
11607107|NCT00595465|Active Comparator|IC51 Batch B|
11607108|NCT00595465|Active Comparator|IC51 Batch C|
11607109|NCT00595426|Experimental|1. YM150 Dose X, twice daily|
11607110|NCT00595426|Experimental|2. YM150 Dose Y, once daily|
11607111|NCT00595426|Experimental|3. YM150 Dose Y, twice daily|
11607112|NCT00595426|Experimental|4. YM150 Dose Z, once daily|
11607113|NCT00595426|Active Comparator|5. Warfarin|various doses
11607114|NCT00595413|Experimental|Atacicept 150 mg with loading dose|
11607115|NCT00595413|Experimental|Atacicept 150 mg without loading dose|
11607116|NCT00595413|Active Comparator|Adalimumab|
11607117|NCT00595413|Placebo Comparator|Placebo|
11607118|NCT00595387|Active Comparator|1|Participants receiving supportive psychotherapy
11607119|NCT00595387|Experimental|2|Participants receiving cognitive behavioral therapy
11607120|NCT00595361|Active Comparator|Arg/Arg|Arg/Arg subjects on 2 week salmeterol treatment
11607121|NCT00595361|Active Comparator|Gly/Gly|Gly/Gly subjects on 2 week salmeterol treatment
11607122|NCT00595335|Experimental|Rituximab|Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion.
11607123|NCT00595335|Placebo Comparator|Placebo|Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
11607124|NCT00595322|Experimental|1|bevacizumab and radiation (IMRT)
11607125|NCT00595309|Active Comparator|A|
11607126|NCT00595296||1|All eligible patients.
11607127|NCT00595283|Experimental|1|Participants assigned to Parent-Child Interaction Therapy-Emotional Development
11607128|NCT00595283|Active Comparator|2|Participants assigned to Developmental Education Parenting Intervention
11607129|NCT00595270|Other|IC51|In study IC51-305, subjects who had received IC51 in study IC51-304 were tested for seroconversion 6 months after the first vaccination. Subjects who had protective titers were again tested for persistence of immunity at 12 months after the first immunization,whereas subjects who had titers below the seroconversion threshold by Month 6 received a booster dose of 1x6 mcg IC51 at Month 11. Their immune response was also assessed at Month 12. Thereafter, subjects who had no protective titer by Month 12 received a booster dose of 1x6 mcg IC51 at Month 23, regardless of prior treatment; and neutralizing antibody titers were reassessed at Month 24. Subjects who had protective titers at month 12 did not receive a booster at Month 23, and their neutralizing antibody titer was also assessed at Month 24.
11607130|NCT00595257|Experimental|1|injection of BMAC into ischemic limb
11607131|NCT00595257|Active Comparator|2|Injection and Infusion of BMAC into ischemic lower limb
11607132|NCT00595231|Experimental|SYN111|500 mg 1 week, followed by 1000 mg for 7 weeks
11607133|NCT00595231|Placebo Comparator|Placebo|0 mg tablets
11607134|NCT00595218|No Intervention|1|Patients whose radiation oncologist are blinded to their patient preference survey results
11607135|NCT00595218|Active Comparator|2|Patients whose radiation oncologist are not blinded to their patient preference survey results
11607136|NCT00595205||Group IS|Subjects <1 year of age with definite intussusception cases who had received Rotarix™.
11607137|NCT00595166||B|Speculum Sheath group. Participants all received the speculum sheath.
11607138|NCT00595153|Active Comparator|B|Asthmatics not on inhaled corticosteroids who will be put on an inhaled steroid during the study
11607139|NCT00595153|No Intervention|A|Healthy, non-asthmatics who will not be put on any intervention
11607140|NCT00595153|Active Comparator|C|Asthmatics, who are already on inhaled corticosteroids who will be put on standardized dose of inhaled corticosteroids
11607141|NCT00595140|No Intervention|1|patients with acromegaly on stable pegvisomant therapy
11607142|NCT00595140|Active Comparator|2|Patients with acromegaly on stable pegvisomant therapy and additional application of octreotide 100µg
11607143|NCT00595140|Active Comparator|3|Patients with acromegaly on stable pegvisomant therapy and additional application of cabergoline 0.5mg orally
11607144|NCT00595127|Experimental|1|This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m^2 dose [intended specific activity of ~20 mCi/mg protein] preceded by administration of 50mg/1.73m^2 of unlabeled 8H9.
11607145|NCT00595114||MIA 1|Participants from the MIA trial who are polymerase chain reaction (PCR) negative and have received treatment with placebo
11607146|NCT00595114||MIA 2|Participants from the MIA trial who are PCR negative and have received treatment with the antibiotic clarithromycin
11607147|NCT00595114||MIA 3|Participants from the MIA trial who are PCR positive and have received treatment with placebo
11607148|NCT00595114||MIA 4|Participants from the MIA trial who are PCR positive and have received treatment with the antibiotic clarithromycin
11607341|NCT00593515|Experimental|1|Family CBT
11607149|NCT00595114||LEUKO 1|Participants from the LEUKO trial who have received treatment with placebo
11607150|NCT00595114||LEUKO 2|Participants from the LEUKO trial who have received treatment with zileuton
11607151|NCT00595101|Experimental|PF-03187207 High Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
11607152|NCT00595101|Experimental|Latanoprost 0.005% and PF-03187207 Vehicle|A single drop of each, once daily in study eye for 28 days
11607153|NCT00595101|Experimental|PF-03187207 Medium Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
11607154|NCT00595101|Experimental|PF-03187207 Low Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
11607155|NCT00595088|Experimental|20 mg of BC-819/PEI|Six intravesical instillations of 20 mg of plasmid DNA (BC-819) complexed with PEI into the bladder of patients with intermediate-risk superficial bladder cancer [recurrent stages Ta (low or high grade) and T1 (low grade) TCC] who have failed prior intravesical therapies including BCG and/or chemotherapy.
11607156|NCT00595075|Experimental|1|Ramelteon 8 mg will be given once prior to a 2-hour nap
11607157|NCT00595075|Placebo Comparator|2|Placebo will be given once prior to a 2-hour nap
11607158|NCT00595062|Experimental|1|
11607159|NCT00595049|Experimental|bosentan|
11607160|NCT00595023||1|All eligible subjects
11607161|NCT00595010|Experimental|Managing Child Behavior|Families with a high risk for or a history of child abuse and are enrolled in Comprehensive Home-Based Services and receive services as usual, which includes SafeCare, plus Managing Child Behavior module if they report significant behavior problems with their child between the ages of 2-12.
11607162|NCT00594997|Experimental|A|Students who receive an educational intervention which consists of a 45 minute interactive presentation as well as a 30 minute health education entertainment by a juggler.
11607163|NCT00594997|Active Comparator|B|Students who fill out pre and post surveys and receive the intervention after the post-survey
11607164|NCT00594984|Active Comparator|Arm 1 - Phase 1|"Cetuximab + Irinotecan + Brivanib
~OR
~Cetuximab + Irinotecan + Brivanib Placebo"
11607165|NCT00594984|Placebo Comparator|Arm 2 - Phase 2|"Cetuximab + Irinotecan + Brivanib
~OR
~Cetuximab + Irinotecan + Brivanib Placebo"
11607166|NCT00594971|Other|B|90 terminally ill cancer patients will be referred to a specialist palliative care team at time of discharge.
11607167|NCT00594971|Other|C|90 terminally ill cancer patients will be discharged from hospital with extra effort put into improving the communication between the hospital and the primary sector.
11607168|NCT00594971|No Intervention|A|90 terminally ill cancer patients will be discharged from hospital, receiving usual care.
11607169|NCT00594958|Active Comparator|IC51 Group A|IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
11607170|NCT00594958|Active Comparator|IC51 Group B|IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
11607171|NCT00594958|Active Comparator|IC51 Group C|IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
11607172|NCT00594945|Experimental|Intranasal Clonazepam 2 mg|
11607173|NCT00594945|Experimental|Intranasal Clonazepam 3 mg|
11607174|NCT00594945|Experimental|Intranasal Clonazepam both Dose Groups 2 mg & 3 mg|
11607175|NCT00594932|Active Comparator|Arm I:|Participants randomly assigned to Arm I will receive mycophenolate mofetil in ascending doses during Month 1, and 3 grams/day (or less if there are tolerance issues) for Months 2 through 6. During Month 1 these participants receive the same number of pills as every other month, but with ascending doses of mycophenolate mofetil and descending numbers of placebo pills. Week one for a total of 1.5 gm/day of mycophenolate mofetil, Week two 2.0 gm/day, Week three 2.5 gm/day and Week 4 3 gm/day. Dose can be held or decreased for tolerance issues at any time.
11607176|NCT00594932|Placebo Comparator|Arm 2|Patients Randomly Assigned to Arm 2 will receive a placebo comparator. The placebo treatment will be structured so that they will undergo the same type of dosing in Month 1 that the ascending dose patient from Arm 1 undergo, but will have placebo in both bottles of pills. At the end of three months, after assessment of primary outcome, these patients enter open label treatment for three more months. During the fourth month this group continues to receive the same number of pills as they received before, with ascending doses of mycophenolate mofetil given vs descending placebo pills so that their induction is the same as those in Arm 1 at the first month.
11607177|NCT00594919||AKI group|Acute kidney injury group after cardiac surgery.
11607178|NCT00594919||NKF group|Normal kidney function group after cardiac surgery
11607179|NCT00594906|Active Comparator|Injection|30 participants will receive teriparatide (Forteo) injection pens.
11607180|NCT00594906|Placebo Comparator|Placebo|30 participants will receive placebo injection pens.
11607181|NCT00594893|Active Comparator|1|Mini Incision Approach
11607182|NCT00594893|Active Comparator|2|2 Incision Approach
11607183|NCT00594880|Active Comparator|Pegasys 180 mcg/week|ART replacement treatment with Pegylated Interferon-alpha 2a, 180 mcg/week sc
11607184|NCT00594880|Active Comparator|Pegasys 90 mcg/week|ART replacement treatment with Pegylated Interferon-alpha 2a, 90 mcg/week sc
11607185|NCT00594867|Active Comparator|1|Acetaminophen - 4 grams per day + Placebo
11607186|NCT00594867|Active Comparator|2|Aspirin - 325 mg per day + Placebo
11607187|NCT00594867|Experimental|3|Acetaminophen 4 gram per day + Aspirin 325 mg per day
11607188|NCT00594854|Experimental|PN400|PN 400 (esomeprazole/naproxen) dosed twice daily
11607189|NCT00594854|Active Comparator|Diclofenac/Misoprostol|diclofenac 75mg/misoprostol 200 mcg dosed twice daily
11607190|NCT00594841|Active Comparator|1|Conservative (nonoperative) management of the AC joint dislocation.
11607191|NCT00594841|Experimental|2|Operative fixation (i.e., ORIF) of the dislocation with a hook plate and screws.
11607192|NCT00594828|Experimental|1|6 months of supervised patient self testing using an expert system
11607193|NCT00594828|Active Comparator|2|6 months of routine medical care by the anticoagulation management service
11607194|NCT00594815|Experimental|1|
11607195|NCT00594802||CHART REVIEW ONLY|CHART REVIEW OF PATIENTS WITH SYSTEMIC REACTIONS
11607196|NCT00594789|Experimental|1 (physician-only)|Physician(s) connected with a fracture that meets study inclusion criteria.
11611485|NCT00560183|Experimental|1|
11607197|NCT00594789|Experimental|2 (physician/patient)|Physician(s) and patient connected with a fracture that meets study inclusion criteria.
11607198|NCT00594789|No Intervention|Control|Usual care.
11607199|NCT00594776||1|Patients who have received a structrual allograft or vascularized fibular autograft surgery to reconstruct their tibia, femur, ulna/radius or humerus for treatment of a bone tumor.
11607200|NCT00594763||TS|Women with Turner syndrome
11607201|NCT00594750||Asthma|People who have been diagnosed with Asthma
11607202|NCT00594724|Experimental|1|
11607203|NCT00594711||1|Case-group
11607204|NCT00594711||2|Control-group
11607205|NCT00594685||Isolated HIT|Hospitalized patients with isolated Heparin-Induced Thrombocytopenia (HIT), diagnosed by a fall in platelet count and a positive Platelet Factor 4 (PF4)-heparin Enzyme-Linked ImmunoSorbent Assay (ELISA) test
11607206|NCT00594672||AREDS participants|Participants who were enrolled in the AREDS or AREDS2 protocol and successfully completed the final AREDS or AREDS2 follow-up visit.
11607207|NCT00594659|Active Comparator|1|Therapist delivered cognitive behavioral treatment
11607208|NCT00594659|Experimental|2|Computerized Cognitive Behavioral treatment
11607209|NCT00594659|Active Comparator|3|Motivational enhancement therapy
11607210|NCT00594646|Other|Group 1|TRUVADA + raltegravir
11607211|NCT00594633|Experimental|1|donepezil and questionaires
11607212|NCT00594620|Experimental|1|Subjects receive supplement
11607213|NCT00594620|Placebo Comparator|2|Subjects will receive placebo
11607214|NCT00594607|Active Comparator|1: AN69ST|Hemodialysis sessions with use of the dialysis filter AN69ST.
11607215|NCT00594607|Active Comparator|2:Fx8|Hemodialysis sessions with use of the dialysis filter Fx8
11607216|NCT00594594|Experimental|1|Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
11607217|NCT00594581|Active Comparator|1|Juvista (avotermin) 50ng/100μl/linear cm wound margin
11607218|NCT00594581|Active Comparator|2|Juvista (avotermin) at 200ng/100μl/linear cm
11607219|NCT00594568|Placebo Comparator|Placebo|Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 milligrams (mg) orally once daily until Week 88.
11607220|NCT00594568|Experimental|100 mg LY450139|Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.
11607221|NCT00594568|Experimental|140 mg LY450139|Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.
11607222|NCT00594555|Experimental|Single Arm - treatment period|"Drug Name/Days Administered
~Neupogen/Days 1-6
~CLAG/Days 2-6
~Gleevec/Days 2-15"
11607223|NCT00594542|Experimental|0.5% lidocaine group|Group that receives 0.5% lidocaine with 1:200,000 epinephrine
11607224|NCT00594542|Experimental|1.0% lidocaine group|Group that receives 1.0% lidocaine with 1:100,000 epinephrine
11607225|NCT00594529|Other|1|
11607226|NCT00594516|Experimental|001|tapentadol (CG5503) Immediate Release (IR) Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100 150 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second,tapentadol (CG5503) Immediate Release IR 21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period
11607227|NCT00594516|Experimental|002|tapentadol (CG5503) Extended Release (ER) During 2 double blind periods: Tapentadol ER 100 150 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second
11607228|NCT00594503|Experimental|Hyperbaric oxygen therapy-TBI|Low pressure hyperbaric oxygen therapy
11607229|NCT00594490||Silicone|patients undergoing placement of silicone breast prosthetics
11607230|NCT00594477|Experimental|IMRT|The prescribed dose for all patients will be 5040 cGy in 28 fractions. Patients will receive external beam treatment once a day, five days a week for approximately five and a half weeks.
11607231|NCT00594464|Experimental|1|Rotigotine
11607232|NCT00594451||I|multicenter Veteran Affairs Rheumatoid Arthritis (VARA) registry
11607233|NCT00594451||II|NIH-funded Consortium for the Longitudinal Evaluation of African Americans with Early RA (CLEAR)
11607234|NCT00594438|Experimental|1, A|Femoral reaming with the Synthes Reamer-Irrigator-Aspirator (RIA)
11607235|NCT00594438|Active Comparator|2 B|Femoral reaming with a Zimmer Sentinel Reamer.
11607236|NCT00594425|Experimental|1|PDT using MAL concentration A
11607237|NCT00594425|Experimental|2|PDT using MAL concentration B
11607238|NCT00594425|Placebo Comparator|3|PDT using Placebo cream
11607239|NCT00594399|Experimental|Arm 1 Physical Activity counseling|Physical activity (PA) counseling program with the following components: baseline in-person counseling session; telephone calls, one physician endorsement of PA in a primary care clinic visit, monthly automated telephone calls from the primary care provider encouraging PA; and quarterly mailed materials providing personalized feedback.
11607240|NCT00594399|No Intervention|Arm 2|Usual care from primary, womens or geriatric clinics
11607241|NCT00594386|Experimental|Rotigotine|
11607242|NCT00594373|Experimental|1|Application of 1% tenofovir gel for 14 consecutive days between menses
11607243|NCT00594373|Placebo Comparator|2|Application of 1% tenofovir placebo gel for 14 consecutive days between menses
11607244|NCT00594360|Active Comparator|1|
11607245|NCT00594347|Experimental|Group A|Pneumo 23
11607246|NCT00594347|Active Comparator|Group B|Prevnar
11607247|NCT00594334|Experimental|E, I|
11607248|NCT00594321|Active Comparator|2|Subjects randomized to the control arm of the study will have a standard vertebroplasty with any FDA-approved bone cement done in accordance with the usual method employed by the treating physician.
11607249|NCT00594321|Experimental|1|Subjects randomized to the experimental arm of the study will have a vertebroplasty with the SPACE CpsXL Bone cement (FDA-approved) and SPACE 360 Delivery System (FDA-approved).
11607342|NCT00593515|Active Comparator|2|Child-focused CBT
11607343|NCT00593502|Active Comparator|1|Oseltamivir
11607250|NCT00594282|Experimental|1|Enhanced Mammography (EM) - Women who are randomized to the Enhanced Mammography (EM) condition will receive a mammogram in which a MammoPad radiolucent breast plate cushion is used.
11607251|NCT00594282|No Intervention|2|Routine Mammography (RM) - Women who are randomized to the Routine Mammography (RM) condition will obtain a routine, un-altered mammogram during which typical exam protocol will be followed and no radiolucent cushion is used.
11607252|NCT00594269|Placebo Comparator|A|Discontinuation of antipsychotic or antidepressants
11607253|NCT00594256|Experimental|Sodium oxybate|Active treatment
11607254|NCT00594243|Experimental|Intervention|8-week mindfulness based stress reduction program
11607255|NCT00594243|Active Comparator|Wait-list control|Wait-list received no intervention during the time the treatment group received the 8-week program
11607256|NCT00594230|Experimental|Panobinostat 20 mg|Treatment with LBH589 (Panobinostat) 20 mg
11607257|NCT00594230|Experimental|Panobinostat 30 mg|Treatment with LBH589 (Panobinostat) 30 mg
11607258|NCT00594217|Experimental|Progesterone|oral micronized progesterone suspension, single 100 mg oral dose
11607259|NCT00594217|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
11607260|NCT00594204|Active Comparator|varenicline|
11607261|NCT00594204|Placebo Comparator|placebo|
11607262|NCT00594191|Placebo Comparator|A|Placebo treatment
11607263|NCT00594191|Experimental|B|
11607264|NCT00594178|Experimental|A|Exercise group
11607265|NCT00594165|Experimental|Rotigotine|Rotigotine
11607266|NCT00594152|No Intervention|1Control|Standard treatment of type 1 diabetes mellitus with 3-4 subcutaneous injections of insulin daily
11607267|NCT00594152|Experimental|Treatment|Intervention: three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to standard subcutaneous insulin.
11607268|NCT00594139|Experimental|1|Receipt of autologous neo-bladder construct
11607269|NCT00594126|Other|1|3+3 cohort dose escalation
11607270|NCT00594113|Experimental|1|Multimedia Colorectal Cancer Screening
11607271|NCT00594100|Experimental|GFRS Pivotal Subjects|All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).
11607272|NCT00594087|Active Comparator|1|Lunesta 2 or 3 mg
11607273|NCT00594087|Placebo Comparator|2|Placebo 2mg or 3 mg
11607274|NCT00594074|Experimental|1|This group will receive 3.25 ounces of white wine with lunch and dinner
11607275|NCT00594074|No Intervention|2|This group receives the same amount of calories as the experimental group
11607276|NCT00594061|Experimental|A|There is no arm to this study--(each participant serves ashis or her own control). Blinding or masking procedures are not included in the design, as it is not possible to conceal the presence or absence of a cochlear implant from device recipients and/or clinical investigators.
11607277|NCT00594048|Experimental|1|15 hypertensive patients use the Resperate for 9 weeks and measure their blood pressure before and after using this device
11607278|NCT00594048|Active Comparator|2|15 patients use a discman with freely chosen music for 9 weeks and measure their blood pressure before and after use of this device
11607279|NCT00594035|Experimental|1|Spinal Sealant
11607280|NCT00594035|Active Comparator|2|Standard of care
11607281|NCT00594022|Active Comparator|"Group 1- VirtuSom - Stim"|Normal sleepers (7.5 - 9.0 hours), MSLT (multiple sleep latency test) >=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with active device (electric stimulation of the Vestibular nerve).
11607282|NCT00594022|Placebo Comparator|"Group 2- VirtuSom- Sham"|Normal sleepers (7.5 - 9.0 hours), MSLT >=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with placebo / sham device (NO electric stimulation of the Vestibular nerve).
11607283|NCT00594009|Experimental|Venovenous CO2 Removal (VVCO2R) in COPD|All patients enrolled in the trial will receive VVCO2R which consists of a circuit with a centrifugal pump, tubing, double lumen intravenous catheter and hollow fiber oxygenator
11607284|NCT00593996|Placebo Comparator|1|oral placebo 3 times weekly
11607285|NCT00593983|Experimental|1|
11607286|NCT00593983|Placebo Comparator|2|Control
11607287|NCT00593970||1|All women presenting to our prenatal clinic and postpartum floor during the study period.
11607288|NCT00593957|Experimental|DM1( 0.25 mg/kg /day)|Dextromethorphan 0.25 mg/kg per day
11607289|NCT00593957|Experimental|DM2 (2.5 mg/kg/day)|Dextromethorphan 2.5 mg/kg/day
11607290|NCT00593957|Experimental|DM3 (5mg/kg/day)|Dextromethorphan 5mg/kg/day
11607291|NCT00593944|Experimental|1|Patients will receive active MDX-1342.
11607292|NCT00593931|Experimental|A|Normal Subjects
11607293|NCT00593918||Toll-like Receptor 4 -2026/GG Genotype|Toll-like Receptor 4 (TLR4) -2026/GG Genotype of interest hypothesized to be associated with less inflammation during Respiratory Syncytial virus (RSV) infection
11607294|NCT00593918||Toll-like Receptor 4 -2026/AG and AA Genotypes|Toll-like Receptor 4 (TLR4) -2026/AG and AA control genotypes hypothesized to be associated with more inflammation during respiratory syncytial virus (RSV) infection
11607295|NCT00593905||Group 1|"GROUP 1
~Patients have to be currently enrolled or previously enrolled in STRIDE FPH01, FPH01-XC FPH02, FPH02x, FPH03, FPH04 or FPH06.
~WHO Group 1 Pulmonary arterial Hypertension: Idiopathic, Familial, Associated with (APAH) Collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, Drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan, methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy) Associated with significant venous or capillary involvement, Pulmonary veno-occlusive disease, Pulmonary-capillary hemangiomatosis."
11607344|NCT00593502|Placebo Comparator|2|Placebo
11607345|NCT00593489|Experimental|Basal Insulin Initiation Strategy|
11607346|NCT00593489|No Intervention|Usual Practice|
11607347|NCT00593476|Active Comparator|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
11607348|NCT00593476|Active Comparator|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
11607349|NCT00593463|Experimental|1|Receives 2-4 of the interventions listed
11607296|NCT00593905||Group 2|"Group 2
~Patients currently receiving bosentan or ambrisentan OR who have previously received bosentan or ambrisentan for greater than 4 (four) months.
~WHO Group 1 Pulmonary Arterial Hypertension: Idiopathic, Familial, Associated with (APAH), collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan, methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, or splenectomy), associated with significant venous or capillary involvement, pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis."
11607297|NCT00593892||Observation|All patients who are admitted to UAB for trauma, are 19 years of age and older, and whose Injury Severity Score (ISS) is greater than 9.
11607298|NCT00593879|Placebo Comparator|1|Placebo
11607299|NCT00593879|Experimental|2|
11607300|NCT00593866|Experimental|Radiation Dose Escalation with Gemcitabine|"INTENSITY MODULATED RADIOTHERAPY
~Radiation dose escalation:
~Total dose Dose per fraction BED* Dose equivalent (1.8 Gy/fraction) Level 1 45.0 1.8 53.1 45.0 Level 2 50.0 2.0 60.0 50.4 Level 3 52.5 2.1 63.5 54.0 Level 4 55.0 2.2 67.1 57.0 Level 5 57.5 2.3 70.7 60.0 Level 6 60.0 2.4 74.4 63.0 Level 7 62.5 2.5 78.1 66.2 Level 8 65.0 2.6 81.9 69.4
~BED=Biological Effective Dose; =10 Five fractions weekly, fraction size determined by dose level
~Gemcitabine:
~1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment"
11607301|NCT00593853|Active Comparator|1|
11607302|NCT00593853|Placebo Comparator|2|
11607303|NCT00593840|Experimental|Intensity modulated radiation therapy (IMRT)|-This study provides guidelines for volume to be contoured during IMRT based on tumor site and stage of tumor site. The clinical tumor volume (CTV)1 will be treated to 66 Cy in 33 fractions or 60 Gy in 30 fractions. The CTV2 will be treated to 54 Gy in 33 fractions or 52 Gy in 30 fractions. The CTV3 will be modified based on tumor site and stage of tumor site in order to reduce volume.
11607304|NCT00593827|Active Comparator|Arm 1|ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest
11607305|NCT00593827|Active Comparator|Arm 2|ixabepilone 40 mg/m^2 every 3 weeks
11607306|NCT00593801|Active Comparator|2: late rhEPO|late EPO treatment from the fourth week for 6 weeks
11607307|NCT00593801|No Intervention|3: no EPO|control group, no EPO treatment
11607308|NCT00593801|Active Comparator|1: early rhEPO|early rhEPO treatment from the first week until 9 weeks
11607309|NCT00593788||1|Normal-hearing adults between 18 and 31 years of age.
11607310|NCT00593775|No Intervention|control|control group without intervention
11607311|NCT00593775|Active Comparator|AH group|assisted hatching performed on the embryo
11607312|NCT00593749|Active Comparator|HCS|Intervention group
11607313|NCT00593749|Placebo Comparator|Control|Control
11607314|NCT00593736|Experimental|Ramelteon 1 mg QD|
11607315|NCT00593736|Experimental|Ramelteon 4 mg QD|
11607316|NCT00593736|Experimental|Ramelteon 8 mg QD|
11607317|NCT00593736|Placebo Comparator|Placebo QD|
11607318|NCT00593723|Experimental|IMRT + Concurrent chemotherapy|"180 cGy daily fractions to a total dose of 5400 cGy to PTV1 and 200 cGy daily fractions to a total dose of 6000 cGy to PTV2. Once a day, five days a week, for approximately 6 weeks.
~Planned chemotherapy: cisplatin (75 mg/m2) day 1 and 5-FU (1000 mg/m2) days 1-4 on weeks 1, 5, 10, and 14 of therapy. Please note that drug regimens and doses may vary and will be at the discretion of the medical oncologist."
11607319|NCT00593710|Experimental|1|Losartan
11607320|NCT00593710|Active Comparator|2|Atenolol
11607321|NCT00593697|Active Comparator|A|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) (HT x3 -> FE75C x3)
11607322|NCT00593697|Active Comparator|B|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)
11607323|NCT00593684|Experimental|Algidex patch|Infants in this group received the Algidex patch on top of the line insertion sites of any of the following lines: umbilical arterial line, umbilical venous line, peripheral arterial line, peripheral long line, and central venous line. This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2. Every 7 days, each insertion site was cleansed and then a new patch was placed and covered with a fresh occlusive dressing (Tegaderm, Opsite).
11607324|NCT00593684|No Intervention|Control group|Infants in this group served as the control group and received line-dressing changes every 7 days according to standard hospital protocol specific for the type of line inserted. Insertion sites were covered with only an occlusive dressing (Tegaderm, Opsite).
11607325|NCT00593671|Active Comparator|PGS group|
11607326|NCT00593671|No Intervention|control group|
11607327|NCT00593658|Experimental|single|
11607328|NCT00593645|Experimental|Arm 1: Non-myeloablative conditioning regimen|"Clofarabine 40mg/m2/day IV over two hours daily x 5 days on Days -6 thru -2
~Cytarabine 1gm/m2/day IV over two hours daily x 5 days on Days -6 thru -2 after the START of Clofarabine.
~Thymoglobulin 1.0mg/kg IV over 6 hours X 1 day on Day -4, then 2.5mg/kg/day x 2 days on Days -3 and -2.
~Stem Cell Transplant - On day 0 a minimum of total CD34+ cell dose of 2 x10E6/kg (actual weight of recipient) will be infused."
11607329|NCT00593632|Experimental|High Fiber Intake|Two 3/4 Cup servings of high fiber Uncle Sam cereal daily
11607330|NCT00593619|Active Comparator|Iron Dextran|
11607331|NCT00593619|Active Comparator|Iron Sucrose|
11607332|NCT00593606|Experimental|Rotigotine|Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.
11607333|NCT00593580|Active Comparator|1|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
11607334|NCT00593580|Placebo Comparator|2|
11607335|NCT00593567|Experimental|A|Daily topical gentamicin sponge and standard daily wound care
11607336|NCT00593567|Active Comparator|B|Daily oral levofloxacin 750 mg and standard daily wound care
11607337|NCT00593554|Active Comparator|1|Total body Irradiation; Thiotepa; Fludarabine; Rabbit ATG;
11607338|NCT00593554|Experimental|2|Palifermin; Total Body Irradiation; Thiotepa; Fludarabine; Rabbit ATG
11607339|NCT00593528|Active Comparator|A|Naked Stents
11607340|NCT00593528|Experimental|B|PTFE Covered Stents
11607350|NCT00593450|Active Comparator|1|Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.
11607351|NCT00593450|Experimental|2|Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.
11607352|NCT00593450|Experimental|3|Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.
11607353|NCT00593450|Experimental|4|Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.
11607354|NCT00593437||1|diagnosed with normal bone density by Norland Excel
11607355|NCT00593437||2|diagnosed with osteopenia by Norland Excel densitometer
11607356|NCT00593437||3|diagnosed with osteoporosis by Norland Excel densitometer
11607357|NCT00593424|Active Comparator|1|Low Fat/High Carbohydrate
11607358|NCT00593424|Active Comparator|2|High Monounsaturated Fat/Low Carbohydrate
11607359|NCT00593385|Other|iCAST covered stent|This is a one arm trial. All subjects received the iCAST covered stent.
11607360|NCT00593372|Experimental|I|Drug Plus Behavioral Therapy
11607361|NCT00593372|No Intervention|II|Drug Therapy Only
11607362|NCT00593359||A|Lactated Ringer's replacement for blood loss and placebo eye drops
11607363|NCT00593359||B|Lactated Ringer's replacement for blood loss and brimonidine eye drops
11607364|NCT00593359||C|Albumin replacement for blood loss and placebo eye drops;
11607365|NCT00593359||D|Albumin replacement for blood loss and brimonidine eye drops
11607366|NCT00593346|Experimental|Accelerated partial breast brachytherapy|Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
11607367|NCT00593333|Active Comparator|1, A|Standard femoral intramedullary nail that utilizes a piriformis fossa portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur.
11607368|NCT00593333|Experimental|2, B|Trigen Trochanteric Femoral Nail (Smith & Nephew, Memphis)using a trochanteric insertion portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur
11607369|NCT00593320|Active Comparator|1|Low-dose arm Single-fraction Stereotactic Radiosurgery (SRS) to 14 Gy
11607370|NCT00593320|Active Comparator|2|High-dose arm Single-fraction Stereotactic Radiosurgery (SRS) to 18Gy
11607371|NCT00593307|Experimental|Low GI|low GI breakfast
11607372|NCT00593307|Experimental|Low GI -low carb|Low GI and Low carb breakfast
11607373|NCT00593307|Experimental|High GI|High GI breakfast
11607374|NCT00593307|Experimental|High GI Low Carb|high GI low carb breakfast
11607375|NCT00593294|Experimental|A,1,I|
11607376|NCT00593294|Active Comparator|B, 2, II|
11607377|NCT00593294|Placebo Comparator|C,3,III|
11607378|NCT00593281|No Intervention|1|IV Morphine
11607379|NCT00593281|Experimental|2|SC Morphine with Hylenex
11607380|NCT00593281|Active Comparator|3|SC Morphine with Saline
11607381|NCT00593242|Experimental|infusions|infants who arrive at the study site within the first 14 postnatal days and had a history of moderate to severe hypoxic ischemic encephalopathy, and have cells available for infusion that pass Carolinas Cord Blood Bank Quality checks Outcomes will be measured at 22-26 months fby neurodevelopment assessment
11607382|NCT00593242|Other|historical control|Infants who had moderate to severe hypoxic ischemic encephalopathy in the neonatal period but did not receive autologous cord blood cells.
11607383|NCT00593229||3|Familial atypical HUS
11607384|NCT00593229||4|Thrombotic thrombocytopenic purpura (TTP)
11607385|NCT00593229||1|Severe diarrhea-associated hemolytic uremic syndrome (D+HUS)
11607386|NCT00593229||2|Non-familial atypical HUS
11607387|NCT00593216||Healthy|Healthy volunteers devoid of any ear problems
11607388|NCT00593216||Vertigo|Patients with the symptoms of vertigo
11607389|NCT00593190|Experimental|1|
11607390|NCT00593177|Experimental|Treatment Group 1|0.05% PTH (1-34) Gel
11607391|NCT00593177|Experimental|Treatment Group 2|0.10% PTH (1-34) Gel
11607392|NCT00593177|Placebo Comparator|Treatment Group 3|Placebo (Vehicle) Gel
11607393|NCT00593164|Experimental|1|Comatose post-resuscitation patients cooled with ThermoSuit and treated with intravenous magnesium sulfate (30 mg per kg IV over 15 min).
11607394|NCT00593164|Active Comparator|2|Comatose post-resuscitation patients cooled with ThermoSuit and treated with intravenous normal saline.
11607395|NCT00593151|Experimental|A, C, 320 mcg|Bi-weekly subcutaneous doses of Locteron (controlled-release interferon alpha 2b) with oral ribavirin.
11607396|NCT00593151|Experimental|B, C, 640 mcg|Bi-weekly subcutaneous doses of Locteron (controlled-release interferon alpha 2b) with oral ribavirin.
11607397|NCT00593151|Active Comparator|A, B, C PEG|Weekly subcutaneous injections of 1.5 ug/kg PegIntron (12 kDalton pegylated interferon alpha 2b) with oral ribavirin.
11607398|NCT00593138|Experimental|1|
11607399|NCT00593125|Experimental|1|levetiracetam
11607400|NCT00593112|Experimental|OROS Methylphenidate|
11607401|NCT00593112|Other|Control|Healthy Volunteer Control group
11607402|NCT00593099|Experimental|1|Buproprion
11607403|NCT00593099|Placebo Comparator|2|Placebo
11607404|NCT00593086|Active Comparator|A|Standard of care pain management
11607405|NCT00593086|Experimental|B|SnoWorld Virtual Reality Game
11607406|NCT00593073|Experimental|1|Tailored Reminder Message
11607407|NCT00593073|Experimental|2|General Reminder Message
11607408|NCT00593047|Placebo Comparator|1|Statin + placebo
11607409|NCT00593047|Experimental|2|Statin + KB2115 dose 1
11607410|NCT00593047|Experimental|3|Statin + KB2115 dose 2
11607411|NCT00593047|Experimental|4|Statin + KB2115 dose 3
11607412|NCT00593034||1|"Participants in this study will be 12-21 year old patients who have been referred to the Adolescent Substance Abuse Program for evaluation of drug or alcohol use and are participating in the parent study, Medical Office Intervention for Adolescent Drug Abuse."
11607413|NCT00592995|Placebo Comparator|1|
11607414|NCT00592995|Active Comparator|2|
11607415|NCT00592943|Active Comparator|Armodafinil (100mg)|
11607416|NCT00592943|Active Comparator|Armodafinil (250 mg)|
11607417|NCT00592930|Experimental|1|olanzapine
11607418|NCT00592930|Placebo Comparator|2|matching placebo
11607419|NCT00592917|Active Comparator|Ia|1718 subjects randomised for active calcium and vitamin-D -intervention, data collection with questionnaires at baseline and end of the study, data of falls and fractures in telephone-interviews annually except Ib (every four months)
11607420|NCT00592917|Active Comparator|Ib|random sample of 292 of 1718 (Ia), data collection by questionnaires mentioned in Ia, data of falls an fractures by telephone interviews every four months, bone density measurements, clinical tests, laboratory sample collections at baseline and end of follow-up as described in study design
11607421|NCT00592917|No Intervention|IIa|1714 subjects randomised to no intervention group, data collection with questionnaires at baseline and end of the study, data of falls and fractures in telephone-interviews annually except IIb (every four months)
11607422|NCT00592917|No Intervention|IIb|random sample of 314 of 1714 (IIa), data collection by questionnaires mentioned in IIa, data of falls an fractures by telephone interviews every four months, bone density measurements, clinical tests, laboratory sample collections at baseline and end of follow-up as described in study design
11607423|NCT00592904|Experimental|1|
11607424|NCT00592891|Experimental|Hyperbaric oxygen therapy|Patients undergoing low pressure HBOT for chronic brain injury
11607425|NCT00592852|Experimental|Fluoxetine|
11607426|NCT00592839|Experimental|1|0.3 mg SCE-B Daily
11607427|NCT00592839|Experimental|2|0.625 mg SCE-B Daily
11607428|NCT00592839|Placebo Comparator|3|Placebo
11607429|NCT00592813|Experimental|1|
11607430|NCT00592813|Placebo Comparator|cardiovascular education (attention control)|
11607431|NCT00592800||1|children between 11 and 13 years of age
11607432|NCT00592800||2|children between 14 to 15 years of age
11607433|NCT00592800||3|children between 16 and 18 years of age
11607434|NCT00592774|Placebo Comparator|Placebo Cohort 1|
11607435|NCT00592774|Experimental|Perampanel Cohort 1, 3-week Titration|
11607436|NCT00592774|Experimental|Placebo Cohort 2|
11607437|NCT00592774|Experimental|Perampanel Cohort 2, 1-week Titration|
11607438|NCT00592774|Experimental|Perampanel Cohort 2, 2- Week Titration|
11607439|NCT00592761|Experimental|Within subjects treatment, no-treatment|Within subject, treatment and no-treatment periods. Each participant served as his/her own control in this AABB/BBAA alternating treatment conditions design. Results were also compared across groups (treatment v. no-treatment).
11607440|NCT00592748|Active Comparator|Group 1|40-44 Treatments
11607441|NCT00592748|Active Comparator|Group 2|37-40 Treatments
11607442|NCT00592735||1|
11607443|NCT00592696||Observation|
11607444|NCT00592683|Active Comparator|Aripiprazole plus Fish Oil|Subjects administered aripiprazole and randomized to receive fish oil
11607445|NCT00592683|Placebo Comparator|Aripiprazole plus Placebo|Subjects administered aripiprazole and randomized to receive placebo
11607446|NCT00592670|Experimental|1|Baseline measures followed by a randomized 6 weeks treatment of Prozac.
11607447|NCT00592670|Placebo Comparator|2|Baseline followed by a 6 week randomized treatment of placebo.
11607448|NCT00592657||1|Patients diagnosed with rhabdomyolysis and no history of jimsonweed ingestion
11607449|NCT00592657||2|Patients diagnosed with rhabdomyolysis and history of jimsonweed ingestion
11607450|NCT00592644|Experimental|1|Pulse Dye Laser
11607451|NCT00592644|Active Comparator|2|Traditional surgeries
11607452|NCT00592631|Experimental|CPAP|Subjects will use CPAP of 8-12 during days 2 through 6 of the study.
11607453|NCT00592631|Sham Comparator|SHAM|Subjects will use sham CPAP of 0-2 during days 2 through 6 of the study.
11607454|NCT00592592|Experimental|Proton Beam Radiation|Proton Beam Radiation
11607455|NCT00592579|Experimental|1|Open label, oral administration of 2ME2
11607456|NCT00592566|No Intervention|1|Standard supportive care
11607457|NCT00592566|Experimental|2|Dexamethasone treatment
11607458|NCT00592566|Experimental|3|Desmopressin treatment
11607459|NCT00592553|Experimental|High-Dose Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 20 milligrams/kilogram (mg/kg) at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for 48 weeks.
11607460|NCT00592553|Experimental|Low-Dose Ataluren|Participants will receive ataluren suspension orally TID, 10 mg/kg at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 48 weeks.
11607461|NCT00592553|Placebo Comparator|Placebo|Participants will receive placebo matched to ataluren orally TID at morning, midday, and evening for 48 weeks.
11607462|NCT00592540|Experimental|Unrelated Donor BMT|
11607463|NCT00592501|Experimental|Proton/Photon Radiotherapy, Cisplatin, Fluorouracil|
11607464|NCT00592488|Other|A|Placebo for first 6 hours then Acetyl-L-Carnitine (ALC) for 12 hours
11607465|NCT00592488|Other|B|Acetyl-L-Carnitine (ALC) for first 12 hours then placebo for next 6 hours
11607466|NCT00592475|Experimental|Regimen 1 Conivaptan 12.5 mg|Conivaptan intravenous loading dose (10 mg) + 2.5 mg continuous infusion over 6.5 hours
11607467|NCT00592475|Experimental|Regimen 2 Conivaptan 25 mg|Conivaptan intravenous loading dose (20 mg) + 5 mg continuous infusion over 6.5 hours
11607468|NCT00592475|Placebo Comparator|Regimen 3 Placebo|Placebo continuous intravenous infusion over 6.5 hours
11607469|NCT00592462||Whole Body MRI|
11607470|NCT00592449|No Intervention|1|Participants with knee OA who meet research diagnostic criteria for insomnia will partake in Phase 1
11607471|NCT00592449|No Intervention|2|Participants with knee OA who meet research diagnostic criteria for normal sleep will partake in Phase 1
11607472|NCT00592449|No Intervention|3|Participants without knee OA or a pain syndrome who meet research diagnostic criteria for primary insomnia will partake in Phase 1
11607473|NCT00592449|No Intervention|4|Participants without knee OA or a pain syndrome who meet research diagnostic criteria for normal sleep will enroll in Phase I
11607474|NCT00592449|Experimental|5|Phase 1 participants with knee OA who meet research diagnostic criteria for insomnia will enroll in Phase 2 of the study and are assigned to receive behavioral desensitization treatment for insomnia
11611486|NCT00560183|Placebo Comparator|2|
11607475|NCT00592449|Experimental|6|Phase 1 participants with knee OA who meet research diagnostic criteria for insomnia will enroll in Phase 2 of the study and are assigned to receive cognitive behavior therapy for insomnia
11607476|NCT00592436||1|
11607477|NCT00592423|Other|1|"A convenience sample of children will be utilized for this study, which will include both genders and all ethnicities. There is no known predilection for any racial or gender inequalities with regard to subject recruitment or outcome variables related to this study."
11607478|NCT00592410|Experimental|1|
11607479|NCT00592397|Experimental|1|All participants underwent the same dietary intervention
11607480|NCT00592384|Placebo Comparator|placebo|identically encapsulated placebo pills 37.5 - 300 mg/day for 12 weeks
11607481|NCT00592384|Experimental|venlafaxine XR|venlafaxine XR 37.5 - 300 mg/day for 12 weeks
11607482|NCT00592358|Experimental|1|
11607483|NCT00592332|Experimental|2|Hyperinsulinemic glucose clamp with Xanax given orally at beginning of each 2 hour clamp on day 1.
11607484|NCT00592332|Experimental|1|Hyperinsulinemic glucose clamp in group with no drug.
11607485|NCT00592319|Experimental|PDL+Celebrex|endoscopic treatment with once-time PDL radiation at 6.0-8.0 J on laryngeal papilloma, followed by oral taking of 9-month Celebrex (100mg, BID), in 15 subjects
11607486|NCT00592319|Active Comparator|standard surgery|"once-time and routine surgery, with either of carbon dioxide (CO2) laser radiation at 10.0-20.0 W or cold surgery with microinstruments, in 15 subjects"
11607487|NCT00592306|Active Comparator|thymoglobulin (intraoperative)|we plan to blindly randomize these 25 lung transplant patients to intraoperative dosing of thymoglobulin followed by 3 additional postoperative doses (the first of these 3 postoperative doses will be placebo)
11607488|NCT00592306|Placebo Comparator|thymoglobulin (postoperative dosing)|We plan to blindly randomize these 25 lung transplant patients to 3 postoperative doses of thymoglobulin (the intraoperative dose will be placebo)
11607489|NCT00592293|Experimental|Proton Beam Radiation|Proton Beam Radiation
11607490|NCT00592280|Experimental|1|
11607491|NCT00592267||1|
11607492|NCT00592254||A|
11607493|NCT00592241|No Intervention|A|Subject is diagnosed as a diabetic, or subject is parent/guardian of a diabetic child age under 18 years.
11607494|NCT00592228|Other|1|Fractional flow guided drug-eluting stent implantation arm
11607495|NCT00592228|Other|2|Routine drug-eluting stent implantation
11607496|NCT00592215|Experimental|A|Mifepristone followed by labor induction with misoprostol after 6-8 hours
11607497|NCT00592202|Experimental|1|Adolescents between the ages 14 through 17 with a BMI of 40 or more or with a BMI of 35 or more and with an obesity related comorbidity will undergo placement of an adjustable gastric band
11607498|NCT00592189|Experimental|1|Amnion tissue and blood collection
11607499|NCT00592176|Experimental|Bevacizumab|Bevacizumab injection: 0.1ml, 6 monthly doses plus baseline and 1 week post baseline
11607500|NCT00592163|Experimental|Single Arm|
11607501|NCT00592150|Experimental|1|Fenoldopam infusion
11607502|NCT00592150|Placebo Comparator|2|Placebo infusion
11607503|NCT00592137|Placebo Comparator|C|During one three week session of a controlled diet subjects will receive a smoothie based on soy protein two times per day that does not contain any additional calcium
11607504|NCT00592137|Active Comparator|B|During one three week period half of the participants will receive two smoothies per day based on soy protein that contain 650 mg Ca as calcium carbonate
11607505|NCT00592137|Active Comparator|A|During one three week session subjects will receive two smoothies per day based on dairy protein containing 650 mg calcium
11607506|NCT00592124|Experimental|1|Oral tenofovir disoproxil fumarate (TDF) for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
11607507|NCT00592124|Experimental|2|Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
11607508|NCT00592124|Experimental|3|Oral TDF and vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and vaginal tenofovir gel application for Weeks 15 through 20
11607509|NCT00592124|Experimental|4|Oral TDF and vaginal tenofovir gel application for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF for Weeks 15 through 20
11607510|NCT00592124|Experimental|5|Oral TDF for Weeks 1 through 6, oral TDF and vaginal tenofovir gel application for Weeks 8 through 13, and vaginal tenofovir gel application for Weeks 15 through 20
11607511|NCT00592124|Experimental|6|Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF and vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF for Weeks 15 through 20
11607512|NCT00592111|Experimental|1|
11607513|NCT00592111|Experimental|2|
11607514|NCT00592111|Experimental|3|
11607515|NCT00592098|Experimental|1|2PX
11607516|NCT00592098|Placebo Comparator|2|Placebo
11607517|NCT00592085|Active Comparator|Relapse Prevention Counseling|Motivational Relapse Counseling: 6 counseling calls over two weeks accompanied by questionnaires
11607518|NCT00592085|Active Comparator|Relapse Prevention + Alcohol Counseling|Motivational Relapse Prevention Plus Alcohol Risk Reduction Counseling: 6 counseling calls over two weeks for both smoking cessation and at-risk alcohol use accompanied by questionnaires
11607519|NCT00592072|Experimental|Medium chain fatty acid (Octanoic and Decanoic acid)|
11607520|NCT00592072|Placebo Comparator|Splenda (Placebo Control)|
11607521|NCT00592046|Experimental|Single Arm|
11607522|NCT00592033|No Intervention|2|Rehabilitation, no supplemental oxygen
11607523|NCT00592033|Experimental|1|Rehabilitation plus supplemental oxygen
11607524|NCT00592020|Active Comparator|1|Short Transverse Incision
11607525|NCT00592020|Active Comparator|2|Hockey Stick Incision
11607526|NCT00592007|Experimental|A|Single-arm study
11607527|NCT00591981||Primary|All patients 70 years old and above scheduled for a thoracic oncologic surgery (typically esophageal or lung cancer) will be approached for entry into this study
11607528|NCT00591968|No Intervention|1|The control group will receive traditional ultrasound consults (i.e. travel to nearest tertiary center for intraabdominal sonographic evaluation and return with radiologist's report).
11611805|NCT00557518|Active Comparator|1|
11607529|NCT00591968|Experimental|2|The experimental group will receive the teleultrasound service. Participants are randomly assigned to this group. All patients will receive a traditional clinical work-up. An ultrasound examination will be offered if, based on initial clinical evaluation by an attending physician, the patient is found to have symptoms consistent with any the following abnormalities: ascites, blunt abdominal trauma, cholelithiasis, cholecystitis, cholangitis, pancreatitis, hydronephrosis, abdominal aortic aneurysm, hepatitis, portal hypertension, urolithiasis, abnormal uterine bleeding, ovarian mass or torsion.
11607530|NCT00591942|Active Comparator|VivaGlass dental cement|36 subjects (TOTAL) received two crowns each and another group of 11 subjects received a three-unit fixed dental bridge. Cross over design. One dental crown cemented with VivaGlass Cement/subject. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
11607531|NCT00591942|Active Comparator|MultiLink dental cement|36 subjects (TOTAL) received two crowns each and another group of 11 subjects received a three-unit fixed dental bridge. Cross Over design. One dental crown per subject was cemented with Multilink Dental Cement. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
11607532|NCT00591929|No Intervention|1|No Continuous passive motion following ORIF of fractures around the knee
11607533|NCT00591929|Active Comparator|2|Continuous Passive Motion following ORIF of fractures around the knee
11607534|NCT00591916|Experimental|1|Microbial Nanocellulose (NC), an inert material produced by Acetobacter xylinum is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
11607535|NCT00591916|Experimental|2|fine mesh gauze impregnated with hyaluronan and thrombin (HT) is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
11607536|NCT00591916|Active Comparator|3|Scarlet Red is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
11607537|NCT00591890|Experimental|Single Arm|
11607538|NCT00591877|Active Comparator|AC|"Acupuncture:
~The patients will receive acupuncture by a trained doctor with acupuncture expertise, at 3 points relevant to reflux symptoms. Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation."
11607539|NCT00591877|Sham Comparator|SAC|The patients randomized to this arm will receive acupuncture for a similar duration and number of sessions. The sham acupoints are at least 2 cm away from the actual acupoints to prevent acupressure effects
11607540|NCT00591877|Active Comparator|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
11607541|NCT00591851|No Intervention|1|single arm study
11607542|NCT00591838|Experimental|Phase I Dose Level A: SBRT 9Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 9Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
11607543|NCT00591838|Experimental|Phase I Dose Level B: SBRT 10Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
11607544|NCT00591838|Experimental|Phase I Dose Level C: SBRT 11Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
11607545|NCT00591838|Experimental|Phase I Dose Level D: SBRT 12Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
11607546|NCT00591838|Experimental|Phase II: SBRT 11Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week. The phase II dose was determined during the phase I portion of the study.
11607547|NCT00591825|Placebo Comparator|Non-Phobic Control - Placebo|Participants without phobia will be given one placebo administration.
11607548|NCT00591825|Active Comparator|Non-Phobic Control - DCS|Participants without phobia will be given one D-cycloserine (DCS) administration of 100mg.
11607549|NCT00591825|Placebo Comparator|Spider-phobic Placebo|Participants with phobia will be given one placebo administration.
11607550|NCT00591825|Experimental|Spider-phobic DCS|Participants with phobia will be given one D-cycloserine (DCS) administration of 100mg.
11607551|NCT00591812|Experimental|1 - ComPreSs system|
11607552|NCT00591799|Experimental|Jarvik 2000 Ventricular Assist System|Jarvik 2000 Ventricular Assist System
11607553|NCT00591786|Experimental|Sugammadex 0.5 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the second twitch (T2) response to Train-of-four (TOF) stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
11607554|NCT00591786|Experimental|Sugammadex 1.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
11607555|NCT00591786|Experimental|Sugammadex 2.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
11607596|NCT00591552|Active Comparator|Group A|Electrocautery used for dissection.
11607597|NCT00591552|Active Comparator|Group B|Harmonic Scalpel used for dissection
11607949|NCT00588588|Active Comparator|2|CPIS
11607556|NCT00591786|Experimental|Sugammadex 4.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
11607557|NCT00591786|Experimental|Sugammadex 8.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.8 mg/kg sugammadex was administered IV.
11607558|NCT00591786|Experimental|Sugammadex 0.5 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
11607559|NCT00591786|Experimental|Sugammadex 1.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
11607560|NCT00591786|Experimental|Sugammadex 2.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
11607561|NCT00591786|Experimental|Sugammadex 4.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
11607562|NCT00591786|Experimental|Sugammadex 8.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
11607563|NCT00591773|Experimental|Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD|
11607564|NCT00591773|Experimental|Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD|
11607565|NCT00591773|Active Comparator|Chlorthalidone 25 mg QD|
11607566|NCT00591760|Experimental|GH|Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0.012 mg/kg every second day, added to their background optimized CHF therapy
11607567|NCT00591760|No Intervention|Placebo|PLacebo will be admistred with the same devices of GH, also on top of Optimal CHF treatment
11607568|NCT00591747|Experimental|1|Progressive resistance training program 3 times a week for 12 months
11607569|NCT00591747|Active Comparator|2|Flexibility training 3 times a week for 12 months
11607570|NCT00591734|Experimental|Intervention|All patients received bevacizumab 15 mg/kg, administered by intravenous (IV) infusion on day 1 of each 21 day course. In addition, patients received everolimus 10 mg orally on a daily basis.
11607571|NCT00591721|Experimental|Energy conservation education|Participants received 6-70 minute group teleconference sessions with an occupational therapist facilitator. The intervention provided education, guided discussion, and peer support for learning about and applying energy conservation principles
11607572|NCT00591721|Other|Wait list control|Participants received 6-70 minute group teleconference sessions with an occupational therapist facilitator. The intervention provided education, guided discussion, and peer support for learning about and applying energy conservation principles.
11607573|NCT00591708|Experimental|B|Supplementation of a higher level of calcium (500-1300 mg/d) via calcium fortified beverages (calcium citrate malate) to a basal diet of 600 mg/d for 21 consecutive days. All excreta will be collected.
11607574|NCT00591708|Experimental|A|Supplementation of a lower level of calcium (0-400 mg/d) via calcium fortified beverages (calcium citrate malate) to a basal diet of 600 mg/d for 21 consecutive days. All excreta will be collected.
11607575|NCT00591695|Active Comparator|A|positioning in emergency of a prosthetic metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
11607576|NCT00591695|Active Comparator|B|emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
11607577|NCT00591682|Experimental|1|MSX-122
11607578|NCT00591669|Experimental|1|IBD patients
11607579|NCT00591669|Other|2|Control subjects
11607580|NCT00591643|Experimental|Imaging, Adrenal acans & Radiation|
11607581|NCT00591630|Active Comparator|Zevalin + BEAM + Rituximab +Stem Cell Transplant + Rituximab|Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab
11607582|NCT00591630|Active Comparator|Zevalin + BEAM + Rituximab +Stem Cell Transplant|Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant
11607583|NCT00591630|Active Comparator|BEAM + Rituximab + Stem Cell Transplant + Rituximab|BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab
11607584|NCT00591630|Active Comparator|BEAM + Rituximab + Stem Cell Transplant|BEAM + Rituximab Followed by Stem Cell Transplant
11607585|NCT00591617|Active Comparator|1: MM|Medical Management: group receives medical management from study physician and Suboxone pharmacotherapy
11607586|NCT00591617|Active Comparator|2: CBT|Cognitive Behavioral Therapy (CBT) group receives CBT, medical management and Suboxone pharmacotherapy
11607587|NCT00591617|Active Comparator|3: CM|Contingency Management (CM) group receives CM, medical management, and Suboxone pharmacotherapy
11607588|NCT00591617|Active Comparator|4: CBT + CM|Cognitive Behavioral Therapy (CBT) and Contingency Management (CM) group receives CBT, CM, medical management, and Suboxone pharmacotherapy
11607589|NCT00591604|Experimental|1|Vitamin D administration
11607590|NCT00591591|Experimental|OSA|Persons with suspected obstructive sleep apnea (OSA) undergoning overnight sleep evaluation
11607591|NCT00591591|No Intervention|Controls|Healthy controls
11607592|NCT00591578|Experimental|Azilsartan Medoxomil 40 mg QD|
11607593|NCT00591578|Experimental|Azilsartan Medoxomil 80 mg QD|
11607594|NCT00591578|Active Comparator|Valsartan 320 mg QD|
11607595|NCT00591565|Experimental|1|acamprosate tablets
11607909|NCT00588874||1|men 50 yrs of age or older
11607598|NCT00591539||Carotid Ultrasound|Carotid Ultrasound: Irradiated and non-irradiated sides of the neck in long-term survivors of pediatric cancers who received unilateral radiation therapy involving the carotid artery as part of their treatment
11607599|NCT00591526|No Intervention|A|"Patients aged ≤ 60 years and with initial WBC ≤ 10000/mm3 Induction treatment
~a) ATRA and chemotherapy ATRA 45 mg/m2/d until hematological CR first intensive chemotherapy course : DNR 60 mg/m2/d during 3 days AraC 200 mg/m2/d during 7 days
~2) Consolidation treatment
~First consolidation course (=2nd chemotherapy course) DNR 60 mg/m2/d d1-3 (intravenous bolus injection) AraC 200 mg/m2/d d1-7 (continuous infusion)
~Second consolidation course AraC 1g/m2/12h d1-4 (1 hour infusion) Daunorubicin 45 mg/m2/d d1-3 (intravenous bolus injection) 3) Maintenance treatment
~Consists of the combination of continuous low dose chemotherapy and intermittent ATRA, during 2 years
~Continuous low dose chemotherapy
~Intermittent ATRA"
11607600|NCT00591526|Experimental|B|Patients aged ≤ 60 years and with initial WBC ≤ 10000/mm3 (Group B) Same treatment as Group A but without AraC.
11607601|NCT00591526|No Intervention|C|"First consolidation course (=2nd chemotherapy course) DNR 60 mg/m2/d d1-3 (intravenous bolus injection) AraC 200 mg/m2/d d1-7 (continuous infusion)
~Second consolidation course AraC 1g/m2/12h d1-4 (1 hour infusion) Daunorubicin 45 mg/m2/d d1-3 (intravenous bolus injection)
~CNS prophylaxis : consists of 5 intrathecal (IT) injections of MTX 15mg and AraC 50 mg (12 mg/m2 maximum 15 mg, and 30mg/m2, maximum 50 mg, respectively, in children) + depomedrol IT. I
~3) Maintenance treatment"
11607602|NCT00591526|No Intervention|D|"Patients aged >60 years and initial WBC ≤ 10000/mm3 Induction treatment
~a) ATRA and chemotherapy ATRA 45 mg/m2/d until hematological CR first intensive chemotherapy course : DNR 60 mg/m2/d during 3 days (intravenous bolus injection) NO ARA C DURING THIS FIRST COURSE
~2) Consolidation treatment
~First consolidation course DNR 60 mg/m2/d d1-3 AraC 100 mg/m2/d d1-5 G-CSF
~Second consolidation course DNR45 mg/m2/d d1-3 AraC 100 mg/m2/d d1-5 G-CSF
~3) maintenance treatment: similar to other groups"
11607603|NCT00591500||Control|The control group comprises patients with a first primary melanoma diagnosed in a twelve-month period.
11607604|NCT00591500||Cases|Cases are patients diagnosed with a second or higher order primary in a six-year period.
11607605|NCT00591487|Active Comparator|I|Infiltration with 0.9% saline+1:1,000,000 epinephrine+0.06% Lidocaine
11607606|NCT00591487|Placebo Comparator|II|Infiltration with 0.9% saline+1:1,000,000 epinephrine
11607607|NCT00591474|Experimental|1|VRE positive patients
11607608|NCT00591474|Placebo Comparator|2|VRE positive patients
11607609|NCT00591461||1|Study participants must be older than 18 years of age who are having an endoscopy performed to evaluate symptoms of GERD such as heartburn, acid taste in the mouth, dysphagia, dyspepsia, or those who are having a screening/surveillance exam for BE.
11607610|NCT00591448|Experimental|Virtual Reality|Patients with burns participate in VR during occupational therapy (OT) or physical therapy (PT) sessions ranging from 2 to 9 min in length
11607611|NCT00591435||1|200 laparoscopic cholecystectomies will be included, consultant cases will be compared to resident cases
11607612|NCT00591435||2|200 laparoscopic pelviscopies will be included, consultant cases will be compared to resident cases
11607613|NCT00591435||3|200 transurethral resection of urinary bladder or prostate gland will be included, consultant cases will be compared to resident cases
11607614|NCT00591422|Experimental|Single Arm|
11607615|NCT00591409|Placebo Comparator|Rocuronium + Placebo|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
11607616|NCT00591409|Experimental|Rocuronium + 0.5 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
11607617|NCT00591409|Experimental|Rocuronium + 1.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
11607618|NCT00591409|Experimental|Rocuronium + 2.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
11607619|NCT00591409|Experimental|Rocuronium + 4.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
11607620|NCT00591409|Placebo Comparator|Vecuronium + Placebo|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
11607621|NCT00591409|Experimental|Vecuronium + 0.5 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
11607622|NCT00591409|Experimental|Vecuronium + 1.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
11607623|NCT00591409|Experimental|Vecuronium + 2.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
11607624|NCT00591409|Experimental|Vecuronium + 4.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
11607625|NCT00591396|Experimental|Single Arm|
11607626|NCT00591383|Experimental|Single Arm|Once Maximum Tolerated Dose (MTD) is determined an expanded cohort will be enrolled to evaluate efficacy.
11607627|NCT00591370|Experimental|1 - Temozolomide (TMZ)|
11607628|NCT00591357|Active Comparator|A|Loperamide
11607629|NCT00591357|Placebo Comparator|B|Placebo
11607630|NCT00591344|Active Comparator|Progressive resistance training|Subjects will perform between 60 and 90 minutes of progressive resistance training two times a week for two years at a local gym. These sessions will be supervised by a personal trainer two times a week for the first six months of training and then once a week for the remaining 18 months of training.
11607631|NCT00591344|Active Comparator|Modified Fitness Counts|Subjects will perform between 60 and 90 minutes of modified Fitness Counts two times a week for two years at a local gym. These sessions will be supervised by a personal trainer two times a week for the first six months of training and then once a week for the remaining 18 months of training.
11607632|NCT00591331|Experimental|1|NatrOVA Creme Rinse - 1%
11607633|NCT00591331|Experimental|2|NatrOVA Creme Rinse Vehicle Only
11607634|NCT00591331|Placebo Comparator|3|Blank patch
11607635|NCT00591318|Experimental|A|IV Ceftriaxone 2 grams/day
11607636|NCT00591318|Placebo Comparator|B|IV Placebo (Normal Saline)
11607637|NCT00591305|Experimental|PDL+DIM pill|once-time 585 nm pulsed dye laser (PDL) treatment on the lesions, immediately followed by 3-month oral taking diindolylmethane (DIM, at 1.2-1.75mg/kg/day), in 15 subjects
11607638|NCT00591305|Placebo Comparator|PDL+placebo pill|once-time PDL treatment on the lesions, then followed by 3-month oral taking DIM placebo, in other 15 subjects
11607639|NCT00591292|Experimental|Single Arm|
11607640|NCT00591279||A|Barium enema and colonoscopy at one and three years after entry.
11607641|NCT00591279||B|Barium enema and colonoscopy at three years only after entry.
11607642|NCT00591266|Experimental|Azilsartan Medoxomil 40 mg QD and Amlodipine 5 mg QD|
11607643|NCT00591266|Experimental|Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD|
11607644|NCT00591266|Active Comparator|Amlodipine 5 mg QD|
11607645|NCT00591253|Experimental|Azilsartan Medoxomil 40 mg QD|
11607646|NCT00591253|Experimental|Azilsartan Medoxomil 80 mg QD|
11607647|NCT00591253|Placebo Comparator|Placebo QD|
11607648|NCT00591240||Multiplex pathogen identification.|Urine samples of patients at risk for urinary tract infections were collected. Biosensor based assays were used to detect the most common uropathogens in these samples. Analytical validity of the biosensor assays was examined by comparing biosensor results to those obtained using standard clinical microbiology laboratory methods. No interventions were performed.
11607649|NCT00591240||Antimicrobial susceptibility testing.|Urine samples of patients at risk of urinary tract infections were collected. Biosensor based antimicrobial susceptibility test, in concert with pathogen identification assay was directly performed on these samples. Analytical validity of the biosensor assays was examined by comparing biosensor results to those obtained using standard clinical microbiology laboratory methods. No interventions were performed.
11607650|NCT00591227|Active Comparator|1-aspart detemir|these subjects will be treated with insulin aspart every 2 hours if blood glucose is more than 200 mg/dl during their ER evaluation. If they are admitted to hospital then they will receive a weight-based dose of insulin detemir immediately prior to admission and then every 24 hours thereafter combined with mealtime doses of insulin aspart if they are eating.
11607651|NCT00591227|No Intervention|2 usual care|these subjects will receive no insulin per protocol during their ER stay or during a possible inpatient admission. The care for their diabetes will be solely determined by the physician(s) in the ER and by the physician(s) caring for them in the hospital if they are admitted. They may receive no therapy, oral agents or insulin per primary physician preference.
11607652|NCT00591214|Experimental|MP-424|
11607653|NCT00591201|Experimental|A|Infliximab
11607654|NCT00591201|Placebo Comparator|B|Placebo
11607655|NCT00591188|Experimental|1|All patients will receive capecitabine and interferon-alpha.
11607656|NCT00591175||1|Standard Care
11607657|NCT00591175||2|Standard Care with Hygienist Counseling
11607658|NCT00591175||3|Standard Care with Hygienist Counseling & Personalized Risk Communication
11607659|NCT00591162|Active Comparator|1|Compare bone density of severly burned children to normal non-burned population
11607660|NCT00591149|Experimental|1|"Patients will be treated with oxaliplatin 130 MG/M2 IV over 2 hours on day 1 and docetaxel 60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle. Cycles of treatment will be repeated every 3 weeks for a total of 4 cycles or until disease progression or intolerable toxicity.
~Patients who were treated with 4 cycles of oxaliplatin and docetaxel and had a response or stable disease will be treated with cetuximab at 400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks, or until disease progression or intolerable toxicity."
11607661|NCT00591136|Experimental|Single Arm|
11607662|NCT00591123|Experimental|single arm|
11607663|NCT00591110|Active Comparator|1|Educational intervention communicating practical information about vision, eye conditions and eye care.
11607664|NCT00591110|Sham Comparator|2|
11607665|NCT00591097||pediatric|
11607666|NCT00591084|Experimental|ginsenoside-Rd 10mg|both a ginsenoside-Rd injection (10mg/1ml/each) and a specific dilution (10%, 1ml trimethylene glycol) were respectively diluted by a specific dilution (10%, 9 ml trimethylene glycol) and then mixed.
11607667|NCT00591084|Placebo Comparator|placebo|2 specific dilutions (10%, 1ml trimethylene glycol) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed.
11607668|NCT00591084|Experimental|ginsenoside-Rd 20mg|2 ginsenoside-Rd injections (10mg/1ml/each) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed
11607669|NCT00591071|Active Comparator|B|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
11607670|NCT00591071|Experimental|A|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
11607671|NCT00591058|Experimental|Cohort 1|0.04 mg/kg TM-601 dose per administration
11607672|NCT00591058|Experimental|Cohort 2|0.08 mg/kg TM-601 dose per administration
11607673|NCT00591058|Experimental|Cohort 3|0.16 mg/kg TM-601 dose per administration
11607674|NCT00591058|Experimental|Cohort 4|0.3 mg/kg TM-601 dose per administration
11607675|NCT00591058|Experimental|Cohort 5|0.6 mg/kg TM-601 dose per administration
11607676|NCT00591058|Experimental|Cohort 6|1.2 mg/kg TM-601 dose per administration
11607677|NCT00591045|Experimental|1|The patients will undergo neoadjuvant chemotherapy with mFOLFOX and then an operation and then individualized adjuvant chemotherapy.
11607678|NCT00591045|No Intervention|2|No neoadjuvant chemotherapy and surgery and then adjuvant chemotherapy.
11607679|NCT00591019|Active Comparator|modafinil|
11607680|NCT00591019|Placebo Comparator|Placebo|
11607681|NCT00591006|Experimental|Four Treatments Per Participant|This study has one arm due to a crossover design. All 17 subjects received 4 treatments: placebo then placebo, phenytoin then placebo, placebo then hydrocortisone, and phenytoin then hydrocortisone. Each treatment was randomly assigned and had a unique sequence out of 24 possible sequences.
11607682|NCT00590993||1 - MRSI / MRI|
11607683|NCT00590980||Observation|Patients with intracranial or extracranial vertebrobasilar occlusion or stenosis ≥ 50% presenting with vertebrobasilar distribution TIA or stroke.
11607684|NCT00590967|Experimental|Treatment Group 1|"Pelvic Lymph Nodes Only Positive on FDG PET.
~IMRT External Beam radiation to the para-aortic region (45 Gy)
~Pelvis intracavitary brachytherapy (6 HDR treatments)
~Weekly cisplatin 40 mg/m^2"
11607685|NCT00590967|Experimental|Treatment Group 2|"Para-Aortic Lymph Nodes Positive on FDG PET
~IMRT (50.4 Gy to para-aortic lymph node bed with a 10.8 Gy boost to nodes)
~IMRT external beam pelvic radiation therapy as appropriate for stage
~Intracavitary brachytherapy (6 HDR treatments)
~Weekly cisplatin (40 mg/m^2)"
11607686|NCT00590954|Experimental|Treatment|Following a diagnosis of tumor recurrence or progression, all patients will receive perifosine monotherapy until toxicity, progression, or death.
11607687|NCT00590941|No Intervention|R-CHOP|Patients receiving R-CHOP via standard of care which consists of cyclophosphamide 750 mg/m2 IV day 1 of each 21 day cycle, doxorubicin 50 mg/m2 IV day 1 of each 21 day cycle, vincristine 1.4 mg/m2 IV day 1 of each 21 day cycle, prednisone 100 mg PO days 1-5 of each 21 day cycle, and rituximab 375 mg/m2 IV day 1 of each 21 day cycle.
11607688|NCT00590928|Active Comparator|1|patients with indication for stress ulcer prophylaxis and gastric pH < 4
11607689|NCT00590928|Active Comparator|2|patients with indication for stress ulcer prophylaxis and gastric pH < 4
11607690|NCT00590902|Experimental|1 - OSI-774|
11607691|NCT00590889|Other|St. Jude Medical (SJM) Conventional|St. Jude Medical (SJM) Standard Masters Series Mechanical Heart Valve with Conventional Cuff
11607692|NCT00590889|Other|St. Jude Medical (SJM) Silzone|St. Jude Medical (SJM) Masters Series Mechanical Heart Valve with Silzone Coating
11607693|NCT00590876||1|T1DM patients with a history of severe hypoglycemia and/or hypoglycemia unawareness who have been selected based upon this history to undergo islet cell transplantation at the University of Minnesota.
11607694|NCT00590876||2|T1DM patients (C-peptide negative) who are matched for age, gender, and duration of diabetes, who also have a history of severe hypoglycemia and/or hypoglycemia unawareness meeting the criteria for islet cell transplantation. The hemoglobin A1c for each of these subjects will fall within 1% of the islet transplant recipient to whom they are matched.
11607695|NCT00590876||3|Nondiabetic subjects (fasting plasma glucose < 110 mg/dl) who are matched for age and gender to the islet transplant recipient to whom they are matched.
11607696|NCT00590863|Active Comparator|SSRI + placebo|Participants will take escitalopram plus placebo.
11607697|NCT00590863|Active Comparator|Escitalopram + Bupropion SR|Participants will take escitalopram + bupropion-SR.
11607698|NCT00590863|Active Comparator|Venlafaxine XR + Mirtazapine|Participants will take venlafaxine-XR + mirtazapine.
11607699|NCT00590850|No Intervention|1|Closed Treatment
11607700|NCT00590850|Active Comparator|2|Open Reduction and Internal Fixation (ORIF) with Plate and Screws
11607701|NCT00590850|Active Comparator|3|Pin Fixation
11607702|NCT00590837|Experimental|1|Patients will be treated by adding lomustine to chemotherapy
11607703|NCT00590837|No Intervention|2|Patients will be treated without adding lomustine to chemotherapy
11607704|NCT00590824|Experimental|A|Hu14.18-IL2 -->Resection-->Hu14.18-IL2
11607705|NCT00590824|Experimental|B|Resection -->Hu14.18-IL2-->Hu14.18-IL2
11607706|NCT00590811||adolescents|3rd year high school girls (14-16 years old)
11607707|NCT00590811||young adults|1st year university young females (18 - 20 years old)
11607708|NCT00590798|Experimental|1|Patients are asked to walk within 30 minutes after implantation of the Star- Close vascular closure system.
11607709|NCT00590785|Experimental|1|
11607710|NCT00590785|Experimental|2|
11607711|NCT00590772|Active Comparator|montelukast|montelukast 10 mg daily
11607712|NCT00590772|Placebo Comparator|Placebo|Placebo tablet
11607713|NCT00590759|Other|GORE TAG® Thoracic Endoprosthesis|
11607714|NCT00590720|Experimental|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
11607715|NCT00590720|Placebo Comparator|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
11607716|NCT00590707|Active Comparator|Deeper sedation|"Patients randomly assigned to this arm will receive enough sedative drugs to keep their level of awareness during the hip fracture repair, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), at an OAA/S score of 0. This is the deeper sedation arm."
11607717|NCT00590707|Active Comparator|Moderate sedation|"Patients randomly assigned to this arm will receive enough sedative drugs to keep their level of awareness during the hip fracture repair, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), at an OAA/S score of 4-5. This is the moderate sedation arm."
11607718|NCT00590694|Active Comparator|Group1|Will receive ranibizumab treatments until resolution of macular edema only and as macular edema recurs.
11607719|NCT00590694|Active Comparator|Group 2|Will receive ranibizumab treatments until resolution of both macular edema and PED, and as macular edema or PED recur.
11607720|NCT00590681|Experimental|one|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
11607721|NCT00590655|Active Comparator|2|Treatment B includes a four month weight loss programme (10 weeks on a VLED and 17 weeks behavior modification visits). Treatment lasts 17 weeks and after that there will be one and two year control visits including weighing and questionnaires for eating behavior and quality of life.
11607722|NCT00590655|Experimental|1|Treatment includes a four month weight loss programme (10 weeks on a VLED and 17 weeks behavior modification visits). After that a maintenance programme starts with monthly sessions for one year. Weight loss, quality of life, and eating behavior will be assessed at the end of the maintenance program and one year later.
11607723|NCT00590642||1|
11607724|NCT00590616||1|
11607725|NCT00590603|Experimental|1|Dose escalation study with two cohorts. A standard dose of Arsenic Trioxide will be given with escalating dose of Bortezomib.
11607726|NCT00590590|Placebo Comparator|3 (Placebo)|
11607727|NCT00590590|Experimental|1 (Lidocaine)|
11607728|NCT00590590|Experimental|2 (Lidocaine/Diphenhydramine)|
11607729|NCT00590577|Experimental|001|Paliperidone palmitate 25 mg eq. Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8 36 64
11607730|NCT00590577|Experimental|002|Paliperidone palmitate 100 mg eq. Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8 36 64
11607731|NCT00590577|Experimental|003|Paliperidone palmitate 150 mg eq. Paliperidone palmitate 150 mg eq. i.m. Days 1 8 36 64
11607732|NCT00590577|Placebo Comparator|004|Placebo Placebo i.m. Days 1 8 36 64
11607733|NCT00590564|Experimental|1|All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal.
11607734|NCT00590551|Experimental|1-6|
11607735|NCT00590538|Active Comparator|Phenylbutyrate|"The standard oral adult dose is 20 g/day for 4 days.
~Every participant will receive Genistein during the NPD."
11607736|NCT00590538|Placebo Comparator|Placebo|The placebo is given to match the active comparator for 4 days. Every participant will receive Genistein.
11607737|NCT00590525||1|
11607738|NCT00590512|Active Comparator|High Sodium|High sodium
11607739|NCT00590512|Active Comparator|Low sodium|Low sodium
11607740|NCT00590499||agitation group|The Riker sedation-agitated scale (SAS) levels 5-7.
11607741|NCT00590499||non-agitation group|The Riker sedation-agitated scale (SAS) levels 1-4.
11607742|NCT00590473|Active Comparator|1|Unilateral Placement of Interstim IPG
11607743|NCT00590473|Active Comparator|2|Bilateral Placement of Interstim IPG
11607744|NCT00590460|Experimental|Single Arm Study: Stem Cell Transplant|CAMPATH-1H Anti-CD45 Fludarabine Stem Cell Infusion
11607745|NCT00590447|Experimental|A|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients achieving a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 further courses of single agent rituximab on days 50, 72, 94 and 116.
11607746|NCT00590447|Experimental|B|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients who do not achieve a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 courses of R-CHOP on days 50, 72, 94 and 116.
11607747|NCT00590434||1|Patients older than 80 years presenting for average risk screening or surveillance colonoscopy
11607748|NCT00590434||2|Patients younger than 80 years presenting for average risk screening or surveillance colonoscopy
11607749|NCT00590421||1|145 individuals treated by irradiation in their childhood
11607750|NCT00590421||2|150 matched control subjects with no history of irradiation
11607751|NCT00590408|Active Comparator|1|
11607752|NCT00590408|Placebo Comparator|2|
11607753|NCT00590395|Experimental|FDG-PET/CT to determine Cholecystitis|19 patients with suspected acute cholecystitis and a positive HIDA will be included in the study. This is purposely a highly selective population which most likely will have surgical proof of the findings. Subjects will receive an FDG PET/CT exam to determine the presence of gallbladder inflammation/infection(cholecystitis). Please note that 18FDG is an FDA approved radiopharmaceutical.
11607754|NCT00590369|Active Comparator|1|KCI VAC type negative pressure wound therapy device
11607755|NCT00590369|Experimental|2|Versatile One (EZCare) negative wound therapy device
11607756|NCT00590356|Active Comparator|A2|AngioSeal®
11607757|NCT00590356|Experimental|A1|StarClose®
11607758|NCT00590343|Experimental|1|Intervention=Patients will receive treatment with PTK787/ZK222584 daily. A treatment cycle will be defined as a 28-day period. Subjects will continue on their present treatment regimen of receiving Sandostatin LAR 30mg IM every 4 weeks.
11607759|NCT00590317|Active Comparator|Prochlorperazine|Patients receiving Prochlorperazine 10mg IV
11607760|NCT00590317|Active Comparator|Ondansetron|Patient receiving Ondansetron 4mg IV
11607761|NCT00590304||EU, LV, MA, EL, DU|The population will consist of 120 English-speaking participants ages 4-17 years from four rural schools with physician-diagnosed asthma or symptoms of asthma in the previous 12 months. As of June 2008, an additional rural school has been added to the population criteria, making a total of five rural schools.
11607762|NCT00590291||Cases|premature CAD and MI, AVM
11607763|NCT00590291||Controls|No CAD, MI, AVM
11607764|NCT00590265|Experimental|1|
11607765|NCT00590265|Placebo Comparator|2|
11607766|NCT00590252||Scheduled for an MRI|Clinically Indicated Adults
11607767|NCT00590226|Experimental|detremir + aspart insulin|Detemir insulin once daily + aspart insulin before meals three times a day at an initial total dose of 0.5 units/kg/day, subcutaneously
11607768|NCT00590226|Active Comparator|NPH + regular insulin|NPH insulin once a day + regular insulin before breakfast and dinner at an initial total dose of 0.5 units/kg/day, subcutaneously
11607769|NCT00590187|Experimental|A sapacitabine|200 mg b.i.d. x 7 days every 3-4 weeks
11607770|NCT00590187|Experimental|B sapacitabine|300 mg b.i.d. x 7 days every 3 - 4 weeks
11607771|NCT00590187|Experimental|C sapacitabine|400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
11607772|NCT00590187|Experimental|D sapacitabine|200 mg b.i.d. x 7 consecutive days every 4 weeks
11607773|NCT00590187|Experimental|E sapacitabine|300 mg q.d. x 7 consecutive days every 4 weeks
11607774|NCT00590187|Experimental|F sapacitabine|300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
11607775|NCT00590187|Experimental|G sapacitabine|200 mg b.i.d. x 7 consecutive days every 4 weeks
11607776|NCT00590187|Experimental|H sapacitabine|300 mg q.d. x 7 consecutive days every 4 weeks
11607777|NCT00590187|Experimental|I sapacitabine|100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
11607778|NCT00590174|Experimental|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
11607779|NCT00590174|Active Comparator|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
11607780|NCT00590161|Experimental|1|Pentoxifylline (PTX) 400 mg by mouth (PO) three times daily (TID)
11607781|NCT00590161|Placebo Comparator|2|Placebo three times daily (TID)
11607782|NCT00590135|Experimental|AORTIC STENOSIS PATIENTS|Atorvastatin (Lipitor) 40mg by mouth daily is administered to patients with aortic stenosis
11607783|NCT00590122|Experimental|b|Parcopa at equivalent dosage to subjects surrent stable dose
11607784|NCT00590122|Active Comparator|a|carbidopa-levodopa at subjects current stable dose
11607785|NCT00590109||1|
11607786|NCT00590083|Experimental|Virus Specific Cytoxic T lymphocytes|Virus Specific Cytoxic T lymphocytes
11607787|NCT00590070|Active Comparator|1|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered.
11607788|NCT00590070|Active Comparator|2|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered.
11607789|NCT00590070|Placebo Comparator|3|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered
11607790|NCT00590044|Experimental|Insulin glargine+glulisine|Daily insulin glargine + glulisine before meals
11607791|NCT00590044|Active Comparator|Split-mixed NPH + Regular insulin|Split-mixed NPH + Regular insulin twice daily
11607792|NCT00590031|Experimental|1|External Beam Radiation Therapy, Cisplatin, Irinotecan
11607793|NCT00590018|Experimental|1|Subjects in this arm will receive a 5 day tapering course of hydrocortisone.
11607794|NCT00590018|Placebo Comparator|2|Subjects in this arm will receive 5 days of placebo.
11607795|NCT00590005||Children with severe asthma|This group consists of children with severe asthma as defined per ATS workshop criteria (published in 2000).
11607796|NCT00590005||Children with non-severe asthma|This group includes children with asthma who do not meet the ATS criteria for severe asthma as outlined in the 2000 workshop report.
11607797|NCT00589979|Experimental|Lidoderm (Lidocaine 5% Patch)|Lidoderm (lidocaine 5% patch) 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)
11607798|NCT00589979|Placebo Comparator|Placebo Patch|Placebo Patch 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)
11607799|NCT00589966|Experimental|Coping Skills Training|
11607800|NCT00589966|Active Comparator|Prostate Cancer Education|
11607801|NCT00589953|Placebo Comparator|EPO###|"All subjects will be identified as a such by the study identifier EPO### where EPO designates enrollment in this study and ### is a numeric identifier (e.g. 103)."
11607802|NCT00589953|Experimental|EPO ###|"All subjects will be identified as a such by the study identifier EPO### where EPO designates enrollment in this study and ### is a numeric identifier (e.g. 103)."
11607803|NCT00589927|Experimental|cilostazol|Cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
11607804|NCT00589927|Placebo Comparator|placebo|Control placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
11607805|NCT00589914|Active Comparator|RISPERDAL CONSTA|RISPERDAL CONSTA 25-50 mg eq every 2 weeks
11607806|NCT00589914|Experimental|R092670|Paliperidone Palmitate 50-150 mg eq every 4 wks
11607807|NCT00589901|Experimental|A|phase II trial of capecitabine and cyclophosphamide in the management of metastatic breast cancer
11607808|NCT00589888|Active Comparator|Intralipid 20%@ 20cc/hour|Intralipid 20% IV infusion at 20cc/hour
11607809|NCT00589888|Active Comparator|Intralipid 20% @ 40cc/hour|Intralipid 20% IV infusion at 40cc/hour
11607810|NCT00589888|Placebo Comparator|Normal Saline infusion @ 40cc/hour|Normal Saline continuous IV infusion at 40cc/hour for 8 hours
11607811|NCT00589888|Active Comparator|32-gram oral fat load|32-gram oral fat load once
11607812|NCT00589888|Active Comparator|64-gram oral fat load|64-gram oral fat load once
11607813|NCT00589875|Experimental|Single arm|This study is an extension of evaluation of the surgical resection arm, Arm B, from a phase Ib study in which dose escalation on arm B was completed.
11607814|NCT00589862|Experimental|1|
11607815|NCT00589849||1|
11607816|NCT00589836||Cardiac Pathologies|Patients with cardiomyopathy, ischemic heart disease, will have tissue Doppler echocardiograms performed
11607817|NCT00589823|Active Comparator|1|Immediate Release Morphine sulphate capsules taken at start of relevant BTCP episode. Each episode treated with either this medication OR the experimental comparator.
11607818|NCT00589823|Experimental|2|Nasalfent spray taken at start of relevant BTCP episode. Each episode to be treated with either this medication OR the active comparator (IRMS)
11607819|NCT00589810||Controls|Controls = Patients in Genebank that had BMS placed that did not go on to have ISR within 1 year of BMS placement and have not had prior ISR in any vessel ever. If testing is available, the Control status will be further verified by angiographic documentation of <50% luminal loss with the stent or negative stress test six or more months after stenting.
11607820|NCT00589810||Cases|Cases = Patients in Genebank that had BMS placed that went on to have ISR which is defined as PCI or CABG to the Target Vessel within 1 year of the BMS placement.
11607821|NCT00589797|Experimental|Investigational|Implantation of the Activ-L Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
11607822|NCT00589797|Active Comparator|Control|Implantation of either the ProDisc-L Total Disc Replacement or Charité Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
11607910|NCT00588861|Active Comparator|Answer® hip stem with Simplex Cement|Femoral stem replacement with Answer® hip stem & Simplex Bone Cement
11608049|NCT00587691|Experimental|Dose Level 1|6-9 million MRTC
11607823|NCT00589784|Experimental|Treatment|Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks, followed by a two-week rest period. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Imaging studies will be performed after every other cycle. Patients may continue on study as long as they are tolerating treatment and in the absence of disease progression.
11607824|NCT00589771|Experimental|A|"Capsule Saccharomyces boulardii 250 mg TDS for six weeks.
~Ispahgula husk 1 Tsf daily after dinner for six weeks."
11607825|NCT00589771|Placebo Comparator|B|"Capsule Placebo TDS for six weeks.
~Ispaghula husk 1 Tsf daily after dinner for six weeks"
11607826|NCT00589758||Acute Decompensated Heart Failure|"Admitted to Heart Failure ICU for acute decompensated heart failure. 2D and 3D echocardiography will be obtained at baseline, 24 -48 hours and 1-2 weeks post discharge.
~Blood and urine will be collected for biomarker evaluation at each timepoint"
11607827|NCT00589745|Other|Subjects being evaluated for CF|Subjects will be referred from physicians who are clinically concerned about the possibility of Cystic Fibrosis. Nasal potential difference measurement will be obtained to potentially help aid in diagnosis.
11607828|NCT00589732|Experimental|Valsartan treatment gorup|Valsartan 160mg per day group
11607829|NCT00589732|No Intervention|No Valsartan treatment group|No valsartan treatment
11607830|NCT00589719||2000,3000,4000|Children at risk for asthma were identified using a cross-sectional asthma screening survey.
11607831|NCT00589706|Experimental|A|All patients receive the same treatment of MAb-425 +Iodine 125 in a total of three injections. The purpose of this protocol is to allow you to receive course(s) of 1251-MAB 425 until your brain tumor begins to grow, you develop side effects to the treatment, or your medical condition changes (ie: become affected with human immunodeficiency virus (HIV) or develop another cancer).
11607832|NCT00589693|Experimental|Doripenem|Doripenem from Days 1 to 7 and imipenem-cilastatin placebo from Days 1 to 10
11607833|NCT00589693|Active Comparator|Imipenem-Cilastatin|Imipenem-Cilastatin Days 1 to 10 and doripenem placebo from Days 1 to 7
11607834|NCT00589680||2|Patients treated for DKA under DKA protocol implemented by hospital
11607835|NCT00589680||1|To establish a baseline on how patients are being treating with DKA in general and without a standardized DKA protocol
11607836|NCT00589667|Experimental|Treatment|Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle.
11607837|NCT00589654||1|
11607838|NCT00589641|Experimental|CBT-RP + Enhanced TAU|CBT-RP augmenting relapse prevention intervention, in addition to enhanced treatment as usual, monthly check-ins, and monitoring
11607839|NCT00589641|Active Comparator|Enhanced TAU (Treatment as Usual)|Treatment as usual in the community, monthly monitoring regarding service use and needs, monitoring
11607840|NCT00589628|Active Comparator|1|5mg/kg/dose of infliximab IV every 4 weeks for 9 doses
11607841|NCT00589628|Active Comparator|2|10mg/kg/dose of infliximab IV every 4 weeks for 9 doses.
11607842|NCT00589615|Active Comparator|1|The multidisciplinary osteoporosis prevention study started with a five-day program at a rehabilitation centre and will be followed by one-day group appointments twice.
11607843|NCT00589615|No Intervention|2|The control group will get information about osteoporosis through media and health care system.
11607844|NCT00589602|Experimental|T-Cell Depletion Transplant|"Our protocol is designed to attempt to improve the current results of matched unrelated donor (MUD) allo bone marrow transplant (BMT) and will be a major step towards the introduction and refinement of graft engineering. Our approach will address in a rational fashion all major technical and clinical aspects of MUD allo BMT.
~Peripheral blood lymphocyte therapy; cyclophosphamide, tacrolimus, peripheral blood stem cell transplantation; total-body irradiation; 'allogeneic hematopoietic stem cell transplantation'"
11607845|NCT00589589|Active Comparator|A|
11607846|NCT00589563|Experimental|Fludarabine/Melphalan Conditioning|"Fludarabine/Melphalan Conditioning with
~Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis"
11607847|NCT00589563|Experimental|FTBI/Cytoxan Conditioning|FTBI/Cytoxan Conditioning with Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis
11607848|NCT00589563|Experimental|FTBI/Etoposide Conditioning|"FTBI/Etoposide Conditioning with
~Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis"
11607849|NCT00589550|Experimental|Peginterferon alfa-2b|Peginterferon alfa-2b will be administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
11607850|NCT00589498|Experimental|1|Subjects who are randomized to overfeed will visit with the General Clinical Research Center dieticians as often as necessary to gain 2 kg of fat (about 4 kg overall) over a period of 8 weeks.
11607851|NCT00589498|No Intervention|2|Subjects who are randomized to non-overfeeding will continue with their normal diet and activity levels for a period of 8 weeks.
11607852|NCT00589485||1|
11607853|NCT00589485||2|
11607854|NCT00589472|Experimental|Treatment (Antihormone therapy and enzyme inhibitor therapy)|Patients receive bicalutamide PO QD for 1 month and leuprolide acetate IM or goserelin acetate SC once a month until surgery. Patients also receive vorinostat PO QD beginning on the first day of androgen depletion therapy and continuing for up to 8 weeks or until the day of surgery. Patients then undergo an open or laparoscopic radical prostatectomy. Patients with positive surgical margins undergo immediate adjuvant external beam radiotherapy to the prostatic fossa, based on the judgment of the treating physician.
11607855|NCT00589459||1|non-diabetic women with acute coronary syndrome (ACS)
11607856|NCT00589459||2|non-diabetic men with acute coronary syndrome (ACS)
11607857|NCT00589446|Experimental|1|Embryoscopy will be evaluated in women with at least two previous miscarriages, after confirmation of missed abortion by ultrasound. Embryoscopy will only be performed in patients in whom curettage is clinically indicated, and will only be added to the D&C if there is a possibility of visualizing embryonic tissue, i:e. from approximately 5½ weeks onwards when there is an embryonic pole detected on ultrasound.
11607858|NCT00589433||1|
11607859|NCT00589420|Experimental|Phase II|All patients received sorafenib 200 mg bid daily and docetaxel 75 mg/m2 every 3 weeks
11611806|NCT00557518|Placebo Comparator|2|
11607860|NCT00589394|Other|pneumococcal vaccination (Pneumovax)|"Intervention:
~Patients receive one dose of the Pneumovax vaccine. The 23 pneumococcal serotypes are measured before and after vaccination in order to measure response in a healthy population."
11607861|NCT00589368||1|stroke group
11607862|NCT00589368||2|control group
11607863|NCT00589355||1|postmenopausal women with glucose intolerance (either pre-diabetes or diet-controlled diabetes)
11607864|NCT00589355||2|postmenopausal women with normal glucose tolerance
11607865|NCT00589329|Experimental|A|"roup A will be assigned to receive antibiotics:
~Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.
~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days."
11607866|NCT00589329|Placebo Comparator|B|Group B will not receive antibiotics for pregnancy prolongation, but will receive a matching masked placebo (IV saline and pill) regimen.
11607867|NCT00589316|Experimental|Treatment (chemo, TBI, transplant, immunosuppression)|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 via central line on day -14.
~NONMYELOABLATIVE CONDITIONING: Patients receive FLU IV over 30 minutes on days -6 to -2 and CY IV over 1 hour on days -6 and -5. Patients undergo TBI on day -1.
~TRANSPLANTATION: Patients undergo allogeneic bone marrow transplantation on day 0.
~POST-TRANSPLATATION IMMUNOSUPPRESSION: Patients receive CY IV over 1-2 hours on day 3, MMF IV or PO TID on days 4 to 35, and tacrolimus IV over 1-2 hours or PO on days 4 to 180 with taper on day 84."
11607868|NCT00589303|Active Comparator|Drug Therapy|FDA approved rate and rhythm control drugs
11607869|NCT00589303|Active Comparator|Atrioventricular Node (AVN) Ablation / Pacing|AV Node ablation and device implant
11607870|NCT00589290|Experimental|Belinostat Treatment|1000 mg/m^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
11607871|NCT00589277|Experimental|1|"Yale coaching counseling + Yale print information"
11607872|NCT00589277|Placebo Comparator|2|Standard care counseling + standard care print information
11607873|NCT00589264|Experimental|1|iron + copper + zinc
11607874|NCT00589264|Active Comparator|2|iron + copper only
11607875|NCT00589251|Other|penicillin skin test|Patients will have the skin test placed
11607876|NCT00589238|Other|Arm 1 (Standard Arm)|Arm 1 (Standard Arm) Preoperative (primary/ neoadjuvant) intravenous weekly paclitaxel 80 mg/m2 for 12 weeks followed by doxorubicin 60 mg/m2 in combination with cyclophosphamide 600 mg/m2 every 21 days for 4 cycles.
11607877|NCT00589238|Experimental|Arm 2 (Experimental Arm)|Arm 2 (Experimental Arm) Preoperative intravenous weekly paclitaxel 80 mg/m2 in combination with carboplatin AUC 2 on D1, D8 and D15 every 28 days for 4 cycles followed by doxorubicin 60 mg/m2 in combination with cyclophosphamide 600 mg/m2 every 21 days for 4 cycles.
11607878|NCT00589225||1|Genetic Analysis
11607879|NCT00589212|Experimental|1|Patients with 1-3 brain metastases
11607880|NCT00589199|Experimental|1|Functional Electrical Stimulation for Production of Artificial Cough
11607881|NCT00589173|Experimental|Intervention|Patients referred to the IPHR
11607882|NCT00589173|Active Comparator|Control|"Patients receiving standard preventive care"
11607883|NCT00589147|Active Comparator|1|One study group will consist of patients treated with the modular cemented tibia.
11607884|NCT00589147|Active Comparator|2|Study arm will consist of patients that are treated with non-modular cemented tibia.
11607885|NCT00589147|Active Comparator|3|Study arm will consist of patients that are treated with non-modular uncemented tibia.
11607886|NCT00589134|Experimental|1|type of beverage
11607887|NCT00589121|Experimental|Cohort A - Chemotherapy|Radiation therapy with neoadjuvant or adjuvant or concurrent or interdigitated chemotherapy followed by surgery followed by, for patients with positive margins, radiation therapy boost
11607888|NCT00589121|Experimental|Cohort B - No Chemotherapy|Radiation therapy followed by surgery followed by, for patients with positive margins, radiation therapy boost
11607889|NCT00589108|Active Comparator|Mobile-Bearing Knee|Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
11607890|NCT00589108|Active Comparator|Modular-Metal-Backed Knee|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
11607891|NCT00589108|Active Comparator|All-Polyethylene Knee|Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray
11607892|NCT00589095||1|
11607893|NCT00589082|Active Comparator|1|standard 3+7
11607894|NCT00589082|Experimental|2|DNX 3+7
11607895|NCT00589056|Experimental|Single arm|Nelfinavir
11607896|NCT00588991|Experimental|Treatment (veliparib, topotecan hydrochloride, carboplatin)|Patients receive veliparib orally twice daily on days 1-8, 1-14, or 1-21 and topotecan hydrochloride with or without carboplatin IV continuously over 120 hours on days 3-7. Treatment repeats every 28-63 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11607897|NCT00588978|Active Comparator|1|Diet alone
11607898|NCT00588978|Active Comparator|2|Exercise alone
11607899|NCT00588978|Active Comparator|3|Diet and exercise (combined)
11607900|NCT00588965|Placebo Comparator|1|Subjects are assigned to placebo.
11607901|NCT00588965|Active Comparator|2|Subjects will take propranolol LA 80 mg daily for one week then 160 mg for one week followed by the exercise test.
11607902|NCT00588952|Experimental|Family History Positive|Subjects with a positive family history of alcoholism
11607903|NCT00588952|Experimental|Family History Negative|Subjects with a negative family history of alcoholism
11607904|NCT00588939||I|participants with symptoms of acid reflux disease (heartburn)
11607905|NCT00588926|Experimental|A|The patients get a period of sedation with remifentanil, before, during and after which, the changes in the electrical activity of the Basal Ganglia is recorded.
11607906|NCT00588900|Experimental|irinotecan + cediranib|"Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and oral cediranib once daily on days 1-21. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
~After completion of study therapy, patients are followed up every 3 months for up to 2 years from study entry."
11607907|NCT00588887||1|
11607908|NCT00588887||2|
11607911|NCT00588861|Active Comparator|Answer® hip stem with Palacos Cement|Femoral stem replacement with Answer® hip stem & Palacos Bone Cement
11607912|NCT00588848|Experimental|Autoadjusting CPAP (VPAP auto)|The intervention will be the use of an Autoadjusting CPAP unit that will be applied to the subject during the 8 hours overnight the first night after surgery (study night). During this time, they will undergo a full night attended polysomnogram in their hospital room.
11607913|NCT00588848|Active Comparator|CPAP arm (usual care)|The intervention will be the use of the subject's own CPAP machine and this will be applied to the subject during the 8 hours overnight the first after surgery (study night). During the study night, they will undergo full polysomnography in their hospital room.
11607914|NCT00588835|Experimental|A|Aprepitant 125mg oral on day 1 and 80mg on day 2 and 3 during CE treatment.
11607915|NCT00588835|Active Comparator|B|CE cycle with standard anti-emetic regimen.
11607916|NCT00588822|Experimental|Rituximab|"Subjects will receive rituximab administered at the standard dose and schedule as an initial cycle of therapy, followed by a re-evaluation at 6 months. If the neuropathy is stable or responding at 6 months, the subject will receive Cycle 2 of rituximab, followed by a re-evaluation at 12 months.
~Rituximab will be given as a 375 mg/m^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22)."
11607917|NCT00588809|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
11607918|NCT00588796||Healthy Volunteers|Healthy Volunteers
11607919|NCT00588796||Burn patients|Patients who have sustained burn injury greater than or equal to 20% of total body surface area
11607920|NCT00588796||Trauma patients|Patients who have undergone trauma
11607921|NCT00588783||1|
11607922|NCT00588783||2|
11607923|NCT00588770|Active Comparator|Arm IA (docetaxel, cisplatin)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11607924|NCT00588770|Experimental|Arm IB (docetaxel, cisplatin, bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and docetaxel and cisplatin as in Arm IA.
11607925|NCT00588770|Active Comparator|Arm IIA (docetaxel, carboplatin)|Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11607926|NCT00588770|Experimental|Arm IIB (docetaxel, carboplatin, bevacizumab)|Patients receive bevacizumab as in Arm IB and docetaxel and carboplatin as in Arm IIA.
11607927|NCT00588770|Active Comparator|Arm IIIA (cisplatin, fluorouracil)|Patients receive cisplatin IV over 1-2 hours on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11607928|NCT00588770|Experimental|Arm IIIB (cisplatin, fluorouracil, bevacizumab)|Patients receive bevacizumab as in Arm IB and cisplatin and fluorouracil as in Arm IIIA.
11607929|NCT00588770|Active Comparator|Arm IVA (carboplatin, fluorouracil)|Patients receive carboplatin IV over 30 minutes on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11607930|NCT00588770|Experimental|Arm IVB (carboplatin, fluorouracil, bevacizumab)|Patients receive bevacizumab as in Arm IB and carboplatin and fluorouracil as in Arm IVA.
11607931|NCT00588757|Active Comparator|1|Optease filter
11607932|NCT00588757|Active Comparator|2|Tulip filter
11607933|NCT00588731|Experimental|Cannabidiol|
11607934|NCT00588731|Placebo Comparator|Placebo|
11607935|NCT00588718||Cases|Infants who meet the entry criteria
11607936|NCT00588718||Controls|Banked blood samples from newborns who do not meet inclusion criteria for this study will be held at Stanford University Core Laboratory and will constitute controls. Proteomic and genomic profiles in blood samples of cases will be compared with blood samples of controls.
11607937|NCT00588705||focus group & questionaire|The group will discuss its views about how and when to talk about the risk of getting breast cancer. The focus group will be video recorded and the video recorded material will be later transcribed and carefully analyzed. In addition you will be asked to answer questions about yourself, such as education and marital status.
11607938|NCT00588692|Active Comparator|SphygmoCor Unblinded|The use of the sphygmocor values will determine medication adjustments to optimize HF treatment.
11607939|NCT00588692|Placebo Comparator|SphygmoCor Blinded|Sphygmocor values will be blinded to the investigator.
11607940|NCT00588679|Experimental|1|Patients taking part in this study will have one MRI and one MRSI scan acquired in succession during a single MR examination. For those patients who have undergone prostate biopsy it is recommended that this should be done at least eight weeks after the prostate biopsy and should take one hour to one hour and ten minutes total to complete.
11607941|NCT00588666|Experimental|Bevacizumab, Carboplatin, Gemcitabine|Patients will initially receive bevacizumab 10 mg/kg followed by a 2 week treatment-free interval. Treatment will then begin with combination therapy. Gemcitabine 1000 mg/m2 will be administered intravenously on day 1 and 8 and carboplatin AUC 4.5 on day 1 with treatment recycled every 21 days. Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of each 21-day cycle. Restaging evaluations will be performed after every 3 cycles of treatment (approximately 9 weeks). Patients will receive a total of 6 cycles of chemotherapy unless disease progression or unacceptable toxicity occurs. Patients who achieve stable disease, a partial response, or a complete response after completion of 6 cycles, will be eligible to continue bevacizumab at the same dose and schedule until disease progression for a maximum of 18 additional doses.
11607942|NCT00588653|Active Comparator|1|All patients were to undergo all 4 diagnostic modalities, and each of these was compared to the consensus clinical diagnosis. Readers of each modality were blinded to the results of the other 3.
11607943|NCT00588640|Experimental|Phase I, Group|This is an open label dose-ranging trial. The first cohort of 8 patients will receive 40mg of d-methadone every 12 hours.
11607944|NCT00588640|Experimental|Phase II, Group I|patients receiving around the clock opioid therapy-No patients were accrued to this group
11607945|NCT00588640|Experimental|Phase II, Group II|patients not receiving around the clock opioid therapy.No patients were accrued to this group
11607946|NCT00588627||1|Post Nasal Drip and chronic cough
11607947|NCT00588627||2|Post nasal drip and no cough
11607948|NCT00588588|Active Comparator|1|Bronchoscopy
11607950|NCT00588562||Primary Hyperoxaluria patients|Registry will include data on patients with confirmed diagnosis of Primary Hyperoxaluria.
11607951|NCT00588562||Dent Disease Patients|Registry will include data on patients with confirmed diagnosis of Dent Disease.
11607952|NCT00588562||Cystinuria Patients|Registry will include data on patients with confirmed diagnosis of Cystinuria.
11607953|NCT00588562||APRT deficiency Patients|Registry will include data on patients with confirmed diagnosis of APRT deficiency.
11607954|NCT00588536|Experimental|1|MTX, 6-TG, Leucovorin
11607955|NCT00588523|Experimental|1|temozolomide followed by high dose busulfan and thiotepa
11607956|NCT00588510||Blood draw|Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible.
11607957|NCT00588497||Study Group|Twenty-five subjects for this study will be recruited from patients who have requested a form of permanent sterilization, and who, after considering all the options, choose the trans-cervical hysteroscopic sterilization for this end. Any subject who is deemed suitable for the micro-insert hysteroscopic sterilization system (Essure micro-insert system, Conceptus Incorporated, Mountain View, California) placement will be offered the opportunity to participate in the study.
11607958|NCT00588484||1|Men, age 35 to 65, being seen at the Mayo Clinic Department of Cardiovascular Health clinic, or has an appointment for a carotid duplex ultrasound exam.
11607959|NCT00588484||2|Women, age 35 to 65, being seen at the Mayo Clinic Department of Cardiovascular Health clinic, or has an appointment for a carotid duplex ultrasound exam.
11607960|NCT00588471|Active Comparator|Simvastatin|Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
11607961|NCT00588471|Placebo Comparator|Placebo|Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
11607962|NCT00588458|Experimental|single arm|All patients with PSC in will have CT cholangiography.
11607963|NCT00588445|Experimental|Treatment|
11607964|NCT00588432||1|Hemiparesis as the result of an ischemic hemispheric stroke.
11607965|NCT00588432||2|Immobilization following severe Achilles tendon tear or rupture, ankle injury or plantar fascial pain.
11607966|NCT00588432||3|Myofascial trigger points in trapezius muscle.
11607967|NCT00588432||4|Hyperthyroid Myopathy
11607968|NCT00588419||1|Patients who have undergone mastectomy Patients who have undergone immediate, twostage expander/implant breast reconstruction; Patients who have undergone immediate, autogenous tissue flap reconstruction including: pedicled and/or free TRAM flap or DIEP flap reconstruction
11607969|NCT00588406|Experimental|B|Budesonide, 2mg, 4 doses, plus standard care
11607970|NCT00588406|Placebo Comparator|P|Placebo plus standard care
11607971|NCT00588380|Experimental|GLP-1|All participants recieved GLP-1 intravenously at 0.75 pmol/kg/min for the first hour and then at 1.5 pmol/kg/min for the next hour
11607972|NCT00588367||1|Suspected pancreatic ductal adenocarcinoma.
11607973|NCT00588367||2|Chronic pancreatitis and slated for decompression treatment.
11607974|NCT00588367||3|Autoimmune pancreatitis.
11607975|NCT00588354|Experimental|Clonidine|Transforaminal epidural clonidine injection
11607976|NCT00588354|Active Comparator|Steroid|Transforaminal epidural steroid injection
11607977|NCT00588341|Experimental|Treatment|
11607978|NCT00588328|Experimental|1|
11607979|NCT00588315||skin lesions|The integrated dermoscopic-and-confocal microscopic video-mosaics will be used to compare morphologic patterns and cellular patterns to each other and to the corresponding pathology
11607980|NCT00588315||normal skin|The integrated dermoscopic-and-confocal microscopic video-mosaics will be used to compare morphologic patterns and cellular patterns to each other and to the corresponding pathology
11607981|NCT00588302|Experimental|A, 1|All patients received an open-label moexipril during the study period.
11607982|NCT00588276|Experimental|1|Patients will receive 124IAZGP(124I-Iodo-Azomycin Galacto-Pyranoside).
11607983|NCT00588250|Experimental|A|
11607984|NCT00588250|No Intervention|B|
11607985|NCT00588237|Experimental|1|Paclitaxel, Cisplatin, Bevacizumab
11607986|NCT00588224||1|adults
11607987|NCT00588224||2|adolescents
11607988|NCT00588211||1|We will recruit fifteen New York University College of Dentistry (NYUCD) clinic patients who report current tobacco use.
11607989|NCT00588211||2|Second, we will recruit thirty dental clinic smokers (10 per day for 3 days) from the NYUCD waiting room.
11607990|NCT00588211||3|Third, we will survey 200 student participants from Adelphi University.
11607991|NCT00588211||4|Queens Hospital Center with 800 patients.
11607992|NCT00588198||1|Melanoma patients
11607993|NCT00588185|Experimental|1|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
11607994|NCT00588172|Sham Comparator|1|Individuals with no nsSNPs or mutations known to alter oct1 function
11607995|NCT00588172|Active Comparator|2|Individuals with nsSNPs or mutations known to alter oct1 function
11607996|NCT00588159|Experimental|Gabapentin preoperatively|Preoperative gabapentin 600 mg orally within 2 hours prior to surgery.
11607997|NCT00588159|Placebo Comparator|Active placebo|Diphenhydramine 12.5 mg orally 2 hours preoperatively.
11607998|NCT00588146|Experimental|Pegylated Interferon Alpha2b, then Standard Care|Weekly subcutaneous injection of pegylated interferon alpha2b 1 microgram/kg/week for 6 months, then standard care for 6 months.
11607999|NCT00588146|Experimental|Standard Care, then Pegylated Interferon Alpha2b|Standard care for 6 months, then weekly subcutaneous injection of pegylated interferon alpha2b 1 microgram/kg/week for 6 months.
11608000|NCT00588133|Experimental|1|New drug dosing schedule
11608001|NCT00588133|Active Comparator|2|Standard drug dosing schedule
11608002|NCT00588120|Experimental|C-13 labeled oxalate|Hyperoxaluric patients
11608003|NCT00588107|Experimental|Web site access|Web intervention- and access to pharmacotherapy
11608004|NCT00588107|Active Comparator|print materials|Receives tailored print materials and access to pharmacotherapy (Materials condition)
11608050|NCT00587691|Experimental|Dose Level 2|30-45 million MRTC
11608051|NCT00587691|Experimental|Dose Level 3|60-90 million MRTC
11608005|NCT00588094|Experimental|Treatment|R-ICEesc will be administered with the intent of administering 2 cycles, each 21 days apart admixed with 4 doses of rituximab. G-CSF will be administered at 960 ug or 10 ug/kg if patient is > 100 kg after cycles one and two for PBPC collection for the first 10 patients enrolled. G-CSF will be administered in standard dosing for cycle one and then at 960 ug or 10 ug/kg (if patient is > 100 kg) after cycle two for PBPC collection for the remaining 22 patients. All responding patients who make at least 2 x 106 CD34+ cells/kg will receive high dose therapy and ASCT on other protocols.
11608006|NCT00588081|Other|1|Participants will receive a cover letter, questionnaire and invitation to participate in a post-operative interview.
11608007|NCT00588068||1|Tumor and Marrow Markers
11608008|NCT00588042|Active Comparator|1|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
11608009|NCT00588042|Sham Comparator|2|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
11608010|NCT00588029||1|breast cancer patients
11608011|NCT00588029||2|control subjects without breast cancer
11608012|NCT00588016|Experimental|Itraconazole|Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
11608013|NCT00588003|Experimental|1|This is an exploratory study utilizing micro-array technology and immunohistochemistry to test the hypothesis that changes in gene expression occur as an early event in response to endocrine therapy and that these changes can be correlated with changes in surrogate biological markers.
11608014|NCT00588003|Placebo Comparator|2|no medication before surgery
11608015|NCT00587990|Experimental|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive lower dose mesenchymal stem cell injections for a total of 2 x 10^7 cells
11608016|NCT00587990|Experimental|Higher dose MSC injection|Participants will receive higher dose of mesenchymal stem cell injections for a total of 2 x 10^8 cells
11608017|NCT00587990|Placebo Comparator|(3) Placebo|Participants will receive placebo injections
11608018|NCT00587977||1|Aortic aneurysm repair
11608019|NCT00587977||2|Aortic aneurysm growth
11608020|NCT00587977||3|Aortic aneurysm growth stable.
11608021|NCT00587964|Experimental|Treatment|
11608022|NCT00587951||A|Candidates for epilepsy surgery, undergoing pre-surgical evaluation at Mayo Clinic, and in whom SISCOM was ordered by the treating physician as part of that evaluation
11608023|NCT00587938||A|BNP level from protocol blood tests initiated in the ED, reported to ED physician prior to ED disposition.
11608024|NCT00587938||B|BNP level from protocol blood tests initiated in the ED, NOT reported to ED physician prior to ED disposition.
11608025|NCT00587925|Experimental|1|Bone Mineral Density
11608026|NCT00587899|Other|1|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation.
11608027|NCT00587899|No Intervention|2|The control group of patients will undergo operation for mitral valve disease without the additional Pulmonary Vein Isolation
11608028|NCT00587886||Cases|Cases will be women with newly diagnosed endometrial or ovarian cancer who are residents of six counties in New Jersey.
11608029|NCT00587886||Controls|Controls will be selected from the general population in those counties by use of random digit dialing for those under 65 years of age, from Centers for Medicare and Medicaid Services (CMS) lists for those aged 65 years and over, and from neighborhood sampling.
11608030|NCT00587873|Experimental|1|MTX, 6-TG, and Leucovorin combination
11608031|NCT00587860|Placebo Comparator|Placebo|
11608032|NCT00587860|Active Comparator|St. John's Wort|
11608033|NCT00587847|Other|Campath maintenance treatment|Single arm, open label trial of Campath on a maintenance schedule for patients who have had a response to prior conventional chemotherapy. Treatments consist of dose escalation (3, 10 and 30mg) during week 1 followed by weekly dosing of Campath at 30 mg once weekly for 7 weeks followed by Campath 30 mg every 2 weeks for 16 weeks followed by Campath 30 mg once every 3 weeks for 24 weeks. Total duration of treatment up to 48 weeks.
11608034|NCT00587834|Experimental|1|Within-subject design: one side of the mouth receives Gintuit
11608035|NCT00587834|Active Comparator|2|Within-subject control: one side of mouth receives tissue harvested from the palate
11608036|NCT00587821||1|The first 250 samples will be used as a training set and results of these breast biopsies (benign or malignant) will be used to determine the peptide profile characteristic of a diagnosis of breast cancer on biopsy.
11608037|NCT00587821||2|The predictive capacity of this profile will then be prospectively assessed using the next 250 samples, which will serve as a validation set. Subjects who are candidates for enrollment on cohort B of this study (metastatic disease)
11608038|NCT00587808||HFpEF|Patients with a history of HFpEF
11608039|NCT00587808||control|Patients with a without a history of CHF
11608040|NCT00587795|Active Comparator|StabilAir Wrist Brace|One study group will consist of patients treated with the StabilAir Wrist Brace.
11608041|NCT00587795|Placebo Comparator|Control|Study arm will consist of patients that are treated with placement of sugar tong splint or plaster cast.
11608042|NCT00587769|Experimental|Bupropion SR & Varenicline|All 38 smokers will receive open-label bupropion SR and varenicline. Bupropion SR is an oral medication with recommended dosing of 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day. Varenicline is an oral medication with recommended dosing of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment. Subjects will quit on Day #8 after starting both medications.
11608043|NCT00587756||1|Prospective cohort of consecutive patients who undergo surgery for colorectal cancer liver metastases
11608044|NCT00587730|Active Comparator|Clinical SPECT|GE Hawkeye Attenuation Correction Camera is being compared to the approved clinical use SPECT camera.
11608045|NCT00587717|Active Comparator|1|Two 80 mg pills simvastatin taken 24 hours prior to surgery
11608046|NCT00587717|Placebo Comparator|2|Two 80 mg pills placebo are taken 24 hours prior to surgery
11608047|NCT00587704|Other|Nerve Stimulation|Use of nerve stimulator for placement of PVB nerve block
11608048|NCT00587704|Other|Anatomic landmarks|Use of anatomic landmarks for placement of PVB block
11608052|NCT00587678|Experimental|Randomized|Patients are imaged at baseline and randomized to Simvistatin 40 mg each night or Simvistatin 40mg/Zetia 10mg each night for 2 years
11608053|NCT00587678|Experimental|Ezetemibe|Patients are imaged at baseline and treated with ezetimibe 10mg each night for 2 years.
11608054|NCT00587665|Experimental|1|Low dose ketamine given
11608055|NCT00587665|Placebo Comparator|2|Saline given as control
11608056|NCT00587652||1|Intermediate Segment Barrett's (2-4cm)
11608057|NCT00587652||2|Long segment Barrett's (>4 cm)
11608058|NCT00587639|Experimental|rTMS Treatment|All subjects will have active rTMS treatment (10Hz, L-DLPFC - 3,000 Stimulations/treatment)
11608059|NCT00587626|Active Comparator|1|InterX treatment plus rehabilitation exercises
11608060|NCT00587626|Placebo Comparator|2|Inactive InterX treatment plus rehabilitation exercises
11608061|NCT00587600|Active Comparator|Photodynamic therapy|will have photodynamic therapy
11608062|NCT00587600|Active Comparator|radiofrequency ablation of barretts esophagus|radiofrequency ablation of barretts esophagus
11608063|NCT00587587|Experimental|A|Apligraf (bilayered living cell therapy)
11608064|NCT00587587|Active Comparator|B|Dressing regimen comprised of a primary nonadherent dressing, dry gauze dressing and bolster gauze dressing, if necessary
11608065|NCT00587574||I|Chronic graft-versus-host disease
11608066|NCT00587574||II|No chronic graft-versus-host disease
11608067|NCT00587561|Experimental|1 Social Cognition Interaction Training|Will receive 20-26 sessions of a manualized group treatment called Social Cognition Interaction Training
11608068|NCT00587561|Other|2 Wait List Control|Wait list control; 6 months of treatment as usual followed by Social Cognition Interaction Training group
11608069|NCT00587535||Hemochromatosis|Hemochromatosis
11608070|NCT00587535||Living-related liver donation|Living-related liver donation
11608071|NCT00587522|Experimental|A|NDO Full-thickness Plicator Procedure
11608072|NCT00587496|Experimental|1|placebo, 6 capsules per day for 30 days
11608073|NCT00587496|Experimental|2|500 mg Valtrex one capsule per day plus 5 capsules of placebo per day for 30 days
11608074|NCT00587496|Experimental|3|500 mg Valtrex capsule one per day, Acetylsalicylic acid (aspirin) 325 mg capsules three per day, plus 2 placebo capsules per day for 30 days
11608075|NCT00587483|Active Comparator|Lidocaine 1.5 mg /kg|Lidocaine is a class I (sodium channel block) antiarrhythmic drug.
11608076|NCT00587483|Active Comparator|Amiodarone 300 mg|Amiodarone is used to treat and prevent certain types of serious, life-threatening ventricular arrhythmias (a certain type of abnormal heart rhythm) when other medications did not help or could not be tolerated. Amiodarone is in a class of medications called antiarrhythmics. It works by relaxing overactive heart muscles.
11608077|NCT00587483|Placebo Comparator|placebo (saline)|
11608078|NCT00587470|Experimental|1|Atacand treatment.
11608079|NCT00587470|Placebo Comparator|2|Placebo
11608080|NCT00587457|Experimental|CAT-8015 5 microgram per kilogram (mcg/kg)|Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
11608081|NCT00587457|Experimental|CAT-8015 10 mcg/kg|Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
11608082|NCT00587457|Experimental|CAT-8015 20 mcg/kg|Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
11608083|NCT00587444|Other|1|control standard dose heparin dose
11608084|NCT00587444|Active Comparator|2|high dose heparin dose
11608085|NCT00587444|Active Comparator|3|hepcon guided therapy
11608086|NCT00587431|Experimental|1|
11608087|NCT00587431|Active Comparator|2|
11608088|NCT00587418|Experimental|Arginine|
11608089|NCT00587418|Placebo Comparator|Placebo|
11608090|NCT00587405|Active Comparator|1|Cryotherapy
11608091|NCT00587405|Active Comparator|2|Argon Plasma Coagulation
11608092|NCT00587392||A|Active NDO Endoscopic Full-thickness Plicator Procedure
11608093|NCT00587379|Active Comparator|1|Patients randomized to take 1 40mg Atorvastain pill per day for 6 week study period
11608094|NCT00587379|Placebo Comparator|2|Patients randomized to 1 40mg placebo pill per day for 6 week study
11608095|NCT00587340||1|15 subjects with subjective sleep disturbance based on the Pittsburgh Sleep Quality Index
11608096|NCT00587340||2|mild/moderate subjective sleep disturbance (insomnia) based on the Pittsburgh Sleep Quality Index
11608097|NCT00587340||3|severe subjective sleep disturbance (insomnia)based on the Pittsburgh Sleep Quality Index
11608098|NCT00587327|Experimental|Barusiban|
11608099|NCT00587327|Experimental|Atosiban|
11608100|NCT00587327|Placebo Comparator|Placebo|
11608101|NCT00587314||1|Patients with Barrett's Esophagus or early esophageal adenocarcinoma who will or have had ablation therapy will be enrolled in this long term follow up study
11608102|NCT00587301|Experimental|Lap-Band|Lap-band surgery in treatment of morbidly obese adolescents
11608103|NCT00587288|Experimental|Reslizumab 3 mg/kg|Reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles
11608104|NCT00587288|Placebo Comparator|Placebo|Saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles
11608105|NCT00587275|Experimental|1|AST-120, 2 gram sachets
11608106|NCT00587275|Placebo Comparator|2|Celphere CP-305, stained to match appearance of AST-120 in 2g sachets.
11608107|NCT00587262||1|Two pediatric participants with high frequency hearing loss post cochlear implant with either long or short electrode array.
11608108|NCT00587262||2|Eight participants with high frequency hearing loss post cochlear implant with either short or long electrode array.
11608109|NCT00587262||3|Fifteen participants from the existing Cochlear Implant data base.
11608110|NCT00587249|Experimental|3|50 mcg of ICC-1132 with alhydrogel adjuvant.
11608111|NCT00587249|Experimental|2|20 mcg of ICC-1132 with alhydrogel adjuvant.
11608112|NCT00587249|Experimental|1|10 mcg of ICC-1132 with alhydrogel adjuvant.
11608113|NCT00587236||1|Patients with chronic ulcerative colitis and concurrent primary sclerosing cholangitis.
11608114|NCT00587236||2|Patients with chronic ulcerative colitis and known dysplasia or cancer.
11608115|NCT00587223|Experimental|1|Apligraf (a living bilayered cell therapy product)
11608116|NCT00587223|Active Comparator|2|Dressing regimen comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer.
11608117|NCT00587210||Suspected or known Crohn Disease|Suspected or known Crohn Disease
11608118|NCT00587184||1|patients who were seen clinically indicated endoscopic surveillance and biopsies of BE and confocal microscopy was performed.
11608119|NCT00587171|Active Comparator|Active|2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
11608120|NCT00587171|Sham Comparator|Control|2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
11608121|NCT00587158|Other|Immunosuppression without paricalcitol (control)|Subjects will receive the standard immunosuppressive therapies consisting of induction therapy with Alemtuzumab (Campath®) and Methylprednisolone (Solumedrol®), then maintained with corticosteroid avoidance using Mycophenolate Mofetil (Cellcept®) and Tacrolimus (Prograf®).
11608122|NCT00587158|Active Comparator|Immunosuppression with paricalcitol|Subjects will receive the standard immunosuppressive therapy consisting of induction therapy with Alemtuzumab (Campath®) and Methylprednisolone (Solumedrol®), then maintained with corticosteroid avoidance using Mycophenolate Mofetil (Cellcept®) and Tacrolimus (Prograf®). In addition, subjects will receive the study medication paricalcitol (Zemplar®).
11608123|NCT00587132|Experimental|New Onset Diabetes|"Adults diagnosed diabetes within two years, and at least one of the following: no family history of diabetes, abdominal discomfort, anorexia, weight loss, elevated serum cancer antigen 19-9 (CA 19-9), or those undergoing endoscopic ultrasound (EUS) with or without Fine Needle Aspiration (FNA) for pancreatic cancer screening.
~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
11608124|NCT00587132|Experimental|Familial Pancreatic Cancer|"Adults age 35-99 with familial pancreatic cancer with two or more first degree relatives with pancreatic cancer.
~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
11608125|NCT00587132|Experimental|Peutz-Jeghers Syndrome|"Adults age 35-99 with Peutz-Jeghers syndrome.
~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
11608126|NCT00587132|Experimental|Clinical Symptoms of Pancreatic Cancer, Normal CT|"Adults age 35-99 with suspicious clinical symptoms of pancreatic cancer, but had normal CT of the abdomen with iodinated contrast within 2 weeks.
~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
11608127|NCT00587119|Experimental|1|Single arm, active treatment
11608128|NCT00587106||1|One cohort group of patient with PNDS or suspected PNDS
11608129|NCT00587093|Other|1|CT scan and CA-125
11608130|NCT00587067|Experimental|1|
11608131|NCT00587054|Experimental|Transplant Patients|
11608132|NCT00587041|Placebo Comparator|Placebo|Participants received placebo for 6 weeks: 1 placebo packet daily and 1 placebo capsule twice daily
11608133|NCT00587041|Active Comparator|Oxadrop|Participants received Oxadrop for 6 weeks: Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis)
11608134|NCT00587041|Active Comparator|Agri-King Synbiotic|Participants received AKSB for 6 weeks: AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
11608135|NCT00587028||Oral Omnipaque MCA|Ten participant minimum: for stool tagging two days preceding the CT colonography, if applicable, with oral Omnipaque. This cohort at Scottsdale Mayo Clinic only.
11608136|NCT00587028||IV Iodine MCR|Ten participant minimum: for intravenous iodine contrast dye. This cohort at Rochester Mayo Clinic only.
11608137|NCT00587028||NO oral and no IV MCR|Five participant minimum for no oral or IV contrast.
11608138|NCT00587028||Replacement Group|Five participant minimum for either cohorts 1, 2, or 3 as above should there be poor imaging results. A like prepped participant will replace that who had poor quality imaging to meet 25 imaging data sets.
11608139|NCT00587015|Active Comparator|1|CAT-8015
11608140|NCT00587002|Active Comparator|1|Gender comparison
11608141|NCT00586989||1|Patient with Barrett's Esophagus with a history of High grade dysplasia or early esophageal adenocarcinoma
11608142|NCT00586976|Experimental|1|Ropivicaine infusion into the sternal wound
11608143|NCT00586976|Placebo Comparator|2|Normal saline infusion into the sternal wound
11608144|NCT00586937||1|Lung Cancer Survivors
11608145|NCT00586924|Experimental|5 mcg/kg|Participants received intravenous infusion of 5 microgram per kilogram (mcg/kg) moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
11608146|NCT00586924|Experimental|10 mcg/kg|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
11608147|NCT00586924|Experimental|20 mcg/kg|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
11608148|NCT00586924|Experimental|30 mcg/kg|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
11608149|NCT00586924|Experimental|40 mcg/kg|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
11608150|NCT00586924|Experimental|50 mcg/kg|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
11608151|NCT00586911|Active Comparator|Cystadane|
11608152|NCT00586911|Placebo Comparator|Identical Placebo|
11608153|NCT00586898|Experimental|1|
11608154|NCT00586885|Experimental|1|Single arm, active treatment
11608155|NCT00586872||1|patients with barretts esophagus and/or early esophageal adenocarcinoma who have undergone endoscopic mucosal resection
11608156|NCT00586859|Experimental|A|NDO Full-thickness Plicator Procedure
11608157|NCT00586846|Experimental|1|
11608158|NCT00586833||1|No CHF/HTN Never diagnosed with CHF and undergoing current treatment for HTN
11608159|NCT00586833||2|CHF with HFpEF HFpEF Cases will be recruited from the community. Subjects will be largely drawn from an existing Mayo database examining all incident cases of HF in Olmsted County.
11608160|NCT00586833||3 Healthy normal adults|No identifiable cardiac issues at time of exercise.
11608161|NCT00586820|Experimental|BQ-123|BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
11608162|NCT00586820|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
11608163|NCT00586807|Other|Infliximab|Subjects on infliximab
11608164|NCT00586794|Active Comparator|A|
11608165|NCT00586794|Placebo Comparator|B|from the 26th weeks on open-label, all patients were treated with Sildenafil
11608166|NCT00586781|Experimental|3|The S.T.A.R. ankle system is the study device. The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants. Both ankles of every subject will be treated with the STAR ankle.
11608167|NCT00586755|Experimental|Intensive Induction-BMT|Patients will undergo induction regimen and stem cell mobilization with cyclophosphamide for bone marrow transplant (BMT). This will be immediately followed by high dose therapy with stem cell support.
11608168|NCT00586742|Active Comparator|1|Labral repair with suture anchors
11608169|NCT00586742|Active Comparator|2|Biceps tenodesis with suture anchor
11608170|NCT00586742|Sham Comparator|3|only a diagnostic arthroscopy performed
11608171|NCT00586729|Experimental|Vashe|Vashe Wound Therapy applied to gauze dressing every 6 hours or as necessary to keep dressing moist for a total treatment duration of 5 days.
11608172|NCT00586729|Active Comparator|5% Mafenide Acetate|5% Mafenide Acetate applied to gauze dressing every 6 hours or as necessary to keep dressing moist for a total treatment duration of 5 days.
11608173|NCT00586716|Other|Group 1 intravenous immune globulin|Intravenous immunoglobulin for: patients who do not have a living donor, have a PRA greater than 30% for 3 consecutive months, and have one positive crossmatch with a cadaveric donor while on kidney transplant waiting list
11608174|NCT00586716|Other|Group 2 intravenous immune globulin|Intravenous immune globulin for patients who have living donors with positive crossmatch results.
11608175|NCT00586703|Experimental|NK-CD56|NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors
11608176|NCT00586690|Experimental|NK Cell Infusion|Natural Killer (NK) Cell infusion using CD56 monoclonal antibody
11608177|NCT00586690|Other|Donor Apheresis|Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for >24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
11608178|NCT00586677|Active Comparator|RF|Relationship focused where the primary goals are to strengthen the relationship between the parent and the child and to give the parent additional skills that can be used to manage the behavior of the child.
11608179|NCT00586677|Active Comparator|HS|The physical health and safety are the primary components of this parenting program where the parent is taught about basic healthcare and safety in the home.
11608180|NCT00586664|Experimental|Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5%|
11608181|NCT00586664|Experimental|Bepotastine Besilate Ophthalmic Solution 1.0%|
11608182|NCT00586664|Placebo Comparator|Placebo|
11608183|NCT00586651|Experimental|lestaurtinib|
11608184|NCT00586638|Experimental|1|Video Game play with training strategy
11608185|NCT00586638|Active Comparator|2|Video game play without training strategy
11608186|NCT00586638|No Intervention|3|Minimal contact control
11608187|NCT00586625|Experimental|Bepreve|bepotastine besilate ophthalmic solution 1.5%
11608188|NCT00586625|Placebo Comparator|Placebo|vehicle
11608189|NCT00586612|Experimental|Preterm group|Subjects born after a gestation period of less than or equal to 36 weeks and who received 3 doses (at 2, 4 and 6 months of age) of Menitorix™, Infanrix™ penta and Prevenar™ and a booster dose of Menitorix™, Infanrix™ IPV and Prevenar™ at 16-18 months of age.
11608190|NCT00586612|Active Comparator|Full-term group|Subjects born after a gestation period of more than 36 weeks and who received 3 doses (at 2, 4 and 6 months of age) of Menitorix™, Infanrix™ penta and Prevenar™ and a booster dose of Menitorix™, Infanrix™ IPV and Prevenar™ at 16-18 months of age.
11608191|NCT00586599|Other|Control|Subjects who have no inflammatory disease who will be age/gender matched controls for the 2 other arms.
11608192|NCT00586599|Other|IBD and infliximab|Subjects who have IBD and will be receiving infliximab for the first time.
11608193|NCT00586599|Other|Newly Diagnosed IBD|Subjects who are newly diagnosed with IBD and given corticosteroid therapy.
11608194|NCT00586586|Experimental|Group CBT|The behavioral intervention FRIENDS (cognitive behavior therapy program developed by P. Barratt) delivered in groups of 4 to 8. 10 weekly sessions plus 2 booster sessions.
11608195|NCT00586586|Experimental|Individual CBT|"The behavioral intervention FRIENDS (cognitive behavior therapy program developed by P. Barratt) delivered individually.
~10 weekly sessions plus 2 booster sessions."
11608196|NCT00586586|No Intervention|Wait-list control|Wait-list control condition for 5 weeks after last child has been included.
11608197|NCT00586573|Experimental|Namenda|
11608198|NCT00586560|Experimental|1|Stratum 1 (~ 25 patients) will include patients with known bone marrow metastases or those who have had prior intensive myelosuppression therapy (including autologous or allogeneic stem cell rescue [SCR], total body irradiation [TBI], craniospinal irradiation [CSI], or hemipelvic radiation).
11608199|NCT00586560|Experimental|2|Stratum 2 (~ 25 patients) will include patients without previous intensive myelosuppressive therapy and bone marrow metastases.
11608200|NCT00586547|Experimental|Treatment|After patients have completed preparation to receive cells, they will be treated at one of five dose levels.
11608201|NCT00586534|Active Comparator|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
11608202|NCT00586534|Experimental|I/GDC + VR/CER|Second Arm:NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
11608203|NCT00586521|Experimental|rFVIII-FS (octocog-alfa), (Kogenate FS)|On-demand treatment was to follow the same treatment pattern the subject was using before entering the study. While on prophylactic treatment, all subjects were to be treated at a dose of 20-40 IU/kg, 3 times per week at a stable dose.
11608204|NCT00586508|Experimental|Enzastaurin + Bevacizumab|
11608205|NCT00586495|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 200 mg tablets (400 mg [2 x 200 mg tablets] twice daily [bid] or 400 mg once daily [od] or 400 mg every other day [qod]) administered orally
11608206|NCT00586482|Active Comparator|Nicotine lozenge|"Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.
~Subjects also received an abstinence advisement: a brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times."
11608207|NCT00586482|Placebo Comparator|Placebo lozenge|"Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day.
~Subjects also received an abstinence advisement: a brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times."
11608208|NCT00586469|Experimental|Old Bulk|This group receives a full dose of Fluviral made from aged bulk material
11608209|NCT00586469|Active Comparator|New Bulk|This group receives a full dose of Fluviral made from new material
11608210|NCT00586443|Other|I|This is a Phase I safety study. There is only one arm.
11608211|NCT00586430|Active Comparator|1|single 2 mg dose of lorazepam
11608212|NCT00586430|Placebo Comparator|2|single dose of placebo
11608213|NCT00586417|Experimental|1|This is a basic research study. There are no treatments with drugs or devices. Wound healing is being studied in healthy volunteers.
11608214|NCT00586404||A|Patients with confirmed Barrett's Esophagus
11608215|NCT00586391|Experimental|CD19CAR-28-zeta T cells|"Three dose levels of CTLs will be evaluated. Each patient will receive one injection according to their assigned dose over 1-10 minutes IV.
~*At the discretion of the attending physician, if after a 4 to 6-week evaluation period the patient has had apparent clinical benefit (as determined by symptoms, physical exam or radiological studies); repeat infusions separated by 4 to 6 weeks (up to a maximum of 3 extra doses) of modified T cells at the same dose level or below the patient's original dose can be administered."
11608216|NCT00586365|Experimental|1|Will receive 500 mg Naproxen twice a day for two weeks
11608217|NCT00586365|No Intervention|2|Will not receive naproxen
11608218|NCT00586352|Active Comparator|Normal|Subjects who have normal endoscopic findings
11608219|NCT00586352|Active Comparator|Newly diagnosed Crohn's disease|Subjects who are newly diagnosed with Crohn's disease after endoscopy.
11608220|NCT00586352|Active Comparator|Newly diagnosed Ulcerative Colitis|Subjects diagnosed with Ulcerative Colitis after endoscopy
11608221|NCT00586339|Experimental|HIV+/Cervarix Group|Human immunodeficiency virus positive (HIV+) female subjects who received 3 doses of Cervarix vaccine administrated by intramuscular injection into the deltoid region of the non-dominant arm, according to a 0, 1, 6-month schedule.
11608222|NCT00586339|Active Comparator|HIV+/Aluminium Hydroxide Group|Human immunodeficiency virus positive (HIV+) female subjects who received 3 doses of control Aluminium Hydroxide [Al(OH)3], administrated by intramuscular injection into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
11608223|NCT00586339|Experimental|HIV-/Cervarix Group|Human immunodeficiency virus negative (HIV-) subjects who received 3 doses of Cervarix vaccine administrated by intramuscular injection into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
11608224|NCT00586326|Experimental|Women with DCIS|Women with DCIS
11608225|NCT00586313|Experimental|a1: Tru-Cut biopsy for liver|Tru-Cut Biospy.
11608226|NCT00586300|Active Comparator|1|Physical training program
11608227|NCT00586300|Active Comparator|2|Self-management training program
11608228|NCT00586300|Active Comparator|3|Physical and self-management training programs
11608229|NCT00586287|Experimental|A|Algorithm which uses serum albumin and weight to determine the loading dose of phenprocoumon within the first 5 days
11608230|NCT00586287|Experimental|B|Algorithm which uses serum age and weight to determine the loading dose of phenprocoumon within the first 5 days
11608231|NCT00586287|Active Comparator|C|The physician chooses the loading dose of phenprocoumon according to his/her experience
11608232|NCT00586274|Experimental|CD34 selected haploidentical PBSCT|CD34 selected haploidentical PBSCT
11608233|NCT00586261|Placebo Comparator|Placebo|Placebo 30 mg daily for 6 months, nitroglycerin was given to check the brachial reactivity.
11608234|NCT00586261|Active Comparator|Pioglitazone|Pioglitazone 30 mg daily for 6 months, nitroglycerin was given to check the brachial reactivity.
11608235|NCT00586235||1|patients with indeterminate kidney or liver lesions
11608236|NCT00586222|Placebo Comparator|2|
11608237|NCT00586222|No Intervention|Healthy Comparsions|We will compare the BP group with 32 age-, gender-, and handedness-matched healthy adolescents. Subjects who have a first or second degree relative with a psychiatric history will be excluded from the healthy comparison group. Subjects must be safe to undergo MRI scanning as per Mayo MRI safety screening which is explained in detail elsewhere in this protocol. We will exclude the subjects with cardiac pacemakers, metallic clips, other bodily metallic implants and dental braces because of the MRS procedure. Subjects who cannot complete clinical assessments or the MRI scan and subjects who are not fluent in English will be excluded from the study.
11608238|NCT00586222|Experimental|1|
11608239|NCT00586209|Experimental|L-glutamine|"L-glutamine group will be given at the following dosage:
~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily >66.7 at 15 g 2X daily"
11608240|NCT00586209|Placebo Comparator|Placebo|"Maltodextrin group will be given at the following dosage:
~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily >66.7 at 15 g 2X daily"
11608241|NCT00586196|Active Comparator|1|
11608242|NCT00586196|Placebo Comparator|2|
11608243|NCT00586183|Experimental|1|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
11608244|NCT00586170|Experimental|EBI Bone Healing System + Surgery|Subject will be using the EBI Bone Healing System (active device) in conjunction with ORIF surgery of the nonunion site.
11608245|NCT00586170|Placebo Comparator|Placebo Device + Surgery|Subject will be using a placebo device in conjunction with ORIF surgery of the nonunion site.
11608246|NCT00586157|Active Comparator|Methylphenidate Transdermal System (MTS)|
11608247|NCT00586157|Placebo Comparator|Placebo|
11608248|NCT00586131|Active Comparator|Low normal pH (arterial pH 7.36-7.38)|Ammonium chloride or sodium citrate/citrate acid as needed to achieve the target pH
11608249|NCT00586131|Active Comparator|High Normal pH (arterial pH 7.44-7.46)|High Normal pH (7.44-7.46) with use of increasing doses of sodium bicarbonate up until the desired pH is achieved
11608250|NCT00586118||1-Sevo|Sevoflurane/ACD group (n=60)
11608251|NCT00586118||2-Propofol|Propofol group (n=60)
11608252|NCT00586105|Experimental|Sorafenib (Nexavar, BAY43-9006)|400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
11608253|NCT00586092|Other|1|This trial employs a phase I design with a dose escalation stage (stage I) and an expansion stage (stage 2) to better describe the tolerability of this combination and the effect of this combination on several biomarkers. In this second stage there will be two groups, each with ten patients, to better describe the tolerability of the bevacizumab/ABT-510 combination and the effect of this combination on several biomarkers. The primary objective of this study is to estimate the MTD/recommended phase II dose regimen. All other objectives are exploratory in nature.
11608254|NCT00586079|Experimental|A|Ten patients who have had deep brain stimulation surgery for Parkinson's disease at Mayo Clinic Arizona.
11608255|NCT00586079|Experimental|B|Ten patients who are scheduled to have deep brain stimulation surgery for Parkinson's disease at Mayo Clinic Arizona.
11608256|NCT00586066|Placebo Comparator|Placebo|Placebo-matching memantine 5 mg tablet once per day for 1 week; dose increase if tolerated to placebo-matching memantine 5 mg twice a day, in the morning and the evening in Week 2; dose increase if tolerated to placebo-matching memantine 5 mg in the morning and placebo-matching memantine 10 mg in the evening in Week 3; dose increase if tolerated to placebo-matching memantine 10 mg twice a day, in the morning and the evening Weeks 4 to 12.
11608257|NCT00586066|Experimental|Memantine|Re-purposed Alzheimer's drug to treat cognitive dysfunction associated with bipolar disorder. Memantine 5 mg tablet once per day for 1 week; dose increase if tolerated to memantine 5 mg twice a day, in the morning and the evening in Week 2; dose increase if tolerated to memantine 5 mg in the morning and memantine 10 mg in the evening in Week 3; dose increase if tolerated to memantine 10 mg twice a day, in the morning and the evening Weeks 4 to 12.
11608258|NCT00586053||1|485 patients,who have an average risk (asymptomatic and without colon screening in the last 5 years) or those who have a high risk for colon cancer (strong family history of colon cancer or polyps and/or personal history of colon cancer or polyps).
11608259|NCT00586053||2|160 patients, with a known colorectal lesion at or greater than 1 cm.
11608260|NCT00586053||3|610 patients, who are of average risk for colon cancer (asymptomatic and no colon cancer screening in the last 5 years).
11608261|NCT00586040|Experimental|1|superficial closure with PTB
11608262|NCT00586040|Active Comparator|2|superficial sutures
11608263|NCT00586027||NT-proBNP|150 consecutive patients undergoing cardiac surgery with an intraoperative measured cardiac output <2L/min/m².
11608264|NCT00586014|Experimental|I|High-dose sequential cyclophosphamide and VP-16 followed by myeloablation with high-dose BCNU and melphalan with autologous stem cell transplant
11608265|NCT00586001|Experimental|1|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders The UP is a form of transdiagnostic cognitive-behavioral therapy (CBT) for individuals diagnosed with anxiety disorders, depression and related disorders.
11608266|NCT00586001|No Intervention|2|Wait-list control: Participants were asked to wait 16 weeks before receiving treatment.
11608267|NCT00585988|Other|1|
11608268|NCT00585988|Other|2|
11608269|NCT00585975|Experimental|Bromfenac Ophthalmic Solution 0.18%|
11608270|NCT00585975|Experimental|Xibrom 0.09%|
11608271|NCT00585949||Angiography|Patients undergoing coronary angiography without percutaneous coronary angioplasty
11608272|NCT00585949||Percutaneous Coronary Angioplasty|Patients with stable coronary artery disease undergoing angioplasty
11608273|NCT00585936||1|Normal controls without evidence of diabetes or islet specific autoimmunity
11608274|NCT00585936||2|Individuals within 6 months of diagnosis with type 1 diabetes
11608386|NCT00585117|Experimental|5. Esophagus|PET imaging with CuATSM
11608275|NCT00585936||3|Individuals at high risk for the development of type 1 diabetes
11608276|NCT00585936||4|Individuals with longstanding autoimmune diabetes
11608277|NCT00585923|Active Comparator|Usage of Fixed hole C-Tek™ Plate|Fixed Hole Plate - The fixed hole plate means that the screws do not move, restricting motion and providing additional stability
11608278|NCT00585923|Active Comparator|Usage of Slotted hole C-Tek™ Plate|Slotted Hole Plate - Bone screw translates while plate is stationary, which ultimately promotes grafts settling through load sharing.
11608279|NCT00585910|Experimental|1|Total treatment period is 7 weeks. Atomoxetine treatment will be initiated and maintained for 4 weeks. If the subject is a partial responder to atomoxetine treatment, OROS methylphenidate will then be added to his or her treatment regimen for the final 3 weeks of the study.
11608280|NCT00585897|Experimental|Behavioral counseling|Individual sessions which utilize motivational interviewing to assist participants to discontinue sugar sweetened beverages from their diet.
11608281|NCT00585871|Experimental|Clonidine therapy group|clonidine 0.1 TID
11608282|NCT00585871|Active Comparator|Metoprolol control group|metoprolol 25 TID
11608283|NCT00585858||1|Subjects on mimimal or no immunosuppression and no rejection history
11608284|NCT00585858||2|Subjects who have had rejection on conventional immunosuppression
11608285|NCT00585858||3|Subjects who have not had acute or chronic rejection who are on conventional immunosuppression
11608286|NCT00585845|Experimental|CRS-207|
11608287|NCT00585832|Experimental|A|DASH-4-Teens Intervention
11608288|NCT00585832|Other|B|Routine Care
11608289|NCT00585819|Experimental|2. Free breathing|Freebreathing in Body fix mold
11608290|NCT00585819|Experimental|1. breathing cycle|reproducing breathing cycles
11608291|NCT00585806||1|Subjects with Heart Failure and ejection fraction greater than or equal to 45%
11608292|NCT00585806||2|Healthy Volunteers
11608293|NCT00585793||PEPFAR 1|
11608294|NCT00585780|Active Comparator|High Alcohol Withdrawal on Prazosin|High AW was determined by those scoring at or above the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. High AW were randomized to Prazosin 16 mg/day (tid) administered for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
11608295|NCT00585780|Placebo Comparator|High Alcohol Withdrawal on PLA|High AW was determined by those scoring at or above the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. High AW were randomized to Placebo tablets administered tid for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
11608296|NCT00585780|Active Comparator|Low Alcohol Withdrawal on Prazosin|Low AW was determined by those scoring below the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. Low AW were randomized to Prazosin 16 mg/day (tid) administered for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
11608297|NCT00585780|Placebo Comparator|Low Alcohol Withdrawal on PLA|Low AW was determined by those scoring below the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment.Placebo tablets administered tid for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
11608298|NCT00585767||1|Patients with two kidneys
11608299|NCT00585767||2|Patients with solitary kidney
11608300|NCT00585754|Active Comparator|Guanfacine|
11608301|NCT00585754|Placebo Comparator|PLA|
11608302|NCT00585741|Experimental|2. Head and neck|Imaging with 18F-FLT PET
11608303|NCT00585741|Experimental|3. Lung|Imaging with 18F-FLT PET
11608304|NCT00585741|Experimental|4. prostate|Imaging with 18F-FLT PET
11608305|NCT00585741|Experimental|5. esophagus|Imaging with 18F-FLT PET
11608306|NCT00585741|Experimental|1.CNS|Imaging with 18F-FLT PET
11608307|NCT00585728|Other|1|CT virtual proctoscopy
11608308|NCT00585715|Experimental|Candela DCD with cooling|Laser treatment with Candela DCD cooling which produces a cryogenic fluid that cools the epidermis prior to each laser pulse. Treatment will be conducted on either the left or the right thigh, which will also be randomly determined. The contra-lateral side will not be treated and will serve as a control. The laser system to be used in is Candela GentleYAG, a 1064nm Nd:YAG laser. This arm will receive a coolant during the laser procedure.
11608309|NCT00585715|Active Comparator|Candela DCD without Cooling|Laser treatment without cooling before each laser pulse. Treatment will be conducted on either the left or the right thigh, which will also be randomly determined. The contra-lateral side will not be treated and will serve as a control. The laser system to be used in is Candela GentleYAG, a 1064nm Nd:YAG laser. This arm will not receive a coolant during the laser procedure.
11608310|NCT00585702||1|Pregnant women with bipolar disorder
11608311|NCT00585702||2|Pregnant women without bipolar disorder
11608312|NCT00585689|Experimental|Neoadjuvant ABI-007, Carboplatin, and Gemcitabine|Neoadjuvant ABI-007 (260 mg/m^2) on day 1, Carboplatin (Target AUC [Area under the curve] =5) on day 1, and Gemcitabine (800 mg^m2) on days 1 and 8, every 21 days.
11608313|NCT00585676||Diabetic|Patients with Diabetes
11608314|NCT00585676||Abnormal glucose level|Patients who were screened and had abnormal blood glucose levels
11608315|NCT00585676||Control|Non-diabetic (normal glucose screening)
11608316|NCT00585650|Experimental|Treatment Group|Etanercept (Enbrel) 50mg twice weekly injections for 12 weeks
11608317|NCT00585650|Placebo Comparator|Placebo Group|Placebo Injections twice weekly for 12 weeks
11608318|NCT00585637|Active Comparator|1|No Vitamin D
11608319|NCT00585637|Active Comparator|2|1000 IU of Vitamin D
11608320|NCT00585637|Active Comparator|3|2000 IU of Vitamin D
11608321|NCT00585637|Active Comparator|4|4000 IU of Vitamin D
11608322|NCT00585624|Experimental|1|Supplement: 3 servings/day of Impact Advanced Recovery in addition to regular food or any other supplements recommended or desired by patient or primary care/surgical team.
11608323|NCT00585624|Placebo Comparator|2|Standard Care: Food, beverages, or supplements as recommended or desired by patient or primary care/surgical team.
11608387|NCT00585104|Experimental|1|All randomized patients receive drug.
11608324|NCT00585611|Experimental|Atorvastatin|Heart failure patients assigned to atorvastatin
11608325|NCT00585611|Placebo Comparator|2|
11608326|NCT00585598||1|all patients that are admitted to the trauma bay with a supralaryngeal airway
11608327|NCT00585585|Experimental|Arm 1: Betahistine dihydrochloride|Oral betahistine dihydrochloride; daily dose 50-300 mg
11608328|NCT00585559|Placebo Comparator|1|Placebos for acetaminophen and N-acetylcysteine
11608329|NCT00585559|Active Comparator|2|Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
11608330|NCT00585559|Active Comparator|3|N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
11608331|NCT00585559|Active Comparator|4|Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
11608332|NCT00585559|Active Comparator|5|Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
11608333|NCT00585546|Experimental|LVAD and Clenbuterol|
11608334|NCT00585533|Other|A|
11608335|NCT00585520|Active Comparator|PG|
11608336|NCT00585520|Placebo Comparator|PLA|
11608337|NCT00585507|Experimental|single|fulvestrant 500mg
11608338|NCT00585494||Preoperative orthopedic|Patients undergoing elective total hip, knee and spinal surgery at University of Wisconsin hospital, having their preoperative visit between December 1, 2007 and November 30, 2008.
11608339|NCT00585481||1|All subjects will perform samples collection for RSV analysis. Subject's enrolled in Porto Alegre's site will perform lung function tests.
11608340|NCT00585468|Experimental|Myfortic - Fed State|Mycophenolate sodium taken with a meal.
11608341|NCT00585468|Experimental|Myfortic - Fasting State|Mycophenolate sodium taken separately from food by 2 hours.
11608342|NCT00585455||A|Chronic heart failure patients with concomitant depression
11608343|NCT00585442|Experimental|Calcitriol|
11608344|NCT00585442|Placebo Comparator|Placebo|
11608345|NCT00585429||1|ESLD subjects on active liver transplant waiting list
11608346|NCT00585429||2|Subjects post-liver transplant with good liver function
11608347|NCT00585429||3|Subjects without liver disease undergoing kidney biopsy for diagnostic purposes
11608348|NCT00585416|Experimental|1|CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
11608349|NCT00585403||Children|Early and late pubertal girls and boys
11608350|NCT00585390|Experimental|Essential omega-3 fatty acid replacement|
11608351|NCT00585390|Placebo Comparator|Placebo|
11608352|NCT00585377|Other|1|
11608353|NCT00585364||CF (non-ABPA)|cystic fibrosis and culture positive for A. fumigatus in airway cultures.
11608354|NCT00585364||CF and ABPA|cystic fibrosis and diagnosis of ABPA
11608355|NCT00585364||healthy control|healthy non-CF
11608356|NCT00585351|Experimental|I|Advanced Notification + Ranitidine
11608357|NCT00585351|Active Comparator|II|Advanced Notification + Placebo
11608358|NCT00585351|Active Comparator|III|No advanced notification + Ranitidine
11608359|NCT00585351|Placebo Comparator|IV|No advanced notification + Placebo
11608360|NCT00585338|Experimental|Tandem 532/1064 nm Laser|Treatment of Vascular LesionsWith a Tandem 532/1064 nm Laser
11608361|NCT00585325|Experimental|Instilled 1% Lidocaine|5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
11608362|NCT00585325|Placebo Comparator|Instilled Placebo (0.9% Normal Saline)|receive .9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
11608363|NCT00585312|Experimental|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
11608364|NCT00585312|Placebo Comparator|Placebo|Masked, placebo comparator
11608365|NCT00585299|Experimental|Low-fat diet|20% kcals from fat diet followed for 8 weeks then 8 weeks of maintenance diet with visits to dietitian every other week
11608366|NCT00585299|Active Comparator|Traditional|Traditional low-fat diet given and dietitian follows up in 16 weeks
11608367|NCT00585286|Experimental|Fractional carbon dioxide laser system|Thirty total healthy subjects from two research centers with skin type I-IV of moderate to severe acne scarring received treatment with the 10,600 nm fractional carbon dioxide laser system.
11608368|NCT00585273||1|Incident users of antipsychotics.
11608369|NCT00585273||2|Non-users of antipsychotics
11608370|NCT00585260|Experimental|Exploratory Mannitol|This is an exploratory / ancillary study open to all participants in the BASALT trial [NCT00495157] who consented to undergo mannitol bronchoprovocation procedures during the 36 week treatment period
11608371|NCT00585247|Experimental|Imiquimod|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
11608372|NCT00585247|Placebo Comparator|Placebo|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
11608373|NCT00585234||1|We intend to photograph male and female subjects from age 1 through skeletal maturity. Healthy children will be photographed to determine the normative characteristics of thoracic function using this technique. We will also enroll patients with thoracic pathology to determine how digital imaging can document thoracic dysfunction. There are no specific disease related exclusion criteria. Participation is voluntary.
11608374|NCT00585221|Experimental|All patients|All participants enrolled in the study.
11608375|NCT00585208|Active Comparator|Active drug|Ramelteon - this group receives active drug at a fixed dose of 8mg daily throughout study
11608376|NCT00585208|Placebo Comparator|Placebo (sugar pill)|placebo (sugar pill) - this arm receive the fake pill, also know as placebo or the sugar pill
11608377|NCT00585195|Experimental|1|
11608378|NCT00585182|Experimental|1|
11608379|NCT00585169|Experimental|memantine|10 to 30 mg/day memantine. The study consisted of 10 weeks of open-label memantine. All eligible study subjects were started at 10 mg/day for 2 weeks. The dose was increased to 20 mg/day after 2 weeks and then to 30 mg/day after 4 weeks unless remission of PG symptoms was attained at a lower dose.
11608380|NCT00585156|Experimental|Arm #1|Celebrex treatment group
11608381|NCT00585143|Experimental|1|
11608382|NCT00585117|Experimental|1 CNS|imaging with CuATSM
11608383|NCT00585117|Experimental|2. Head and Neck|Imaging with CuATSM
11608384|NCT00585117|Experimental|3. Lung|imaging with CuATSM
11608385|NCT00585117|Experimental|4. Prostate|PET imaging with CuATSM
11608388|NCT00585091|Other|A|All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
11608389|NCT00585078|Experimental|CAPOX|Participants self-administered capecitabine 1,000 mg/m2 orally twice daily (total daily dose 2,000 mg/m2), days 1-14 in 21-day cycles. Only 500 mg tablets were used, and doses were rounded to the nearest dose that could be administered with 500 mg tablets. Oxaliplatin 130 mg/m2 was administered intravenously on day 1 every 21 (±2) days. Treatment continued until tumor progression or toxicity requiring discontinuation of therapy.
11608390|NCT00585065||1|
11608391|NCT00585052|Experimental|Paclitaxel and lovastatin|Paclitaxel given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly. Lovastatin self-administered at 80mg daily.
11608392|NCT00585039|Experimental|A|levalbuterol nebulization
11608393|NCT00585013|Experimental|Nitric Oxide Delivery Group|Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
11608394|NCT00585013|No Intervention|Placebo|Placebo delivery of oxygen at standard dose.
11608395|NCT00585000|Experimental|1|
11608396|NCT00584987|Placebo Comparator|Placebo FF + Placebo OXY|Placebo Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
11608397|NCT00584987|Active Comparator|FF + Placebo OXY|Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
11608398|NCT00584987|Active Comparator|Placebo FF + OXY|Placebo Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
11608399|NCT00584987|Active Comparator|FF + OXY|Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
11608400|NCT00584974|Experimental|0.5 mg SEP-225289|0.5 mg SEP-225289
11608401|NCT00584974|Experimental|2.0 mg of SEP-225289|2.0 mg of SEP-225289
11608402|NCT00584974|Active Comparator|Venlafaxine|150 mg Venlafaxine
11608403|NCT00584974|Placebo Comparator|Placebo|placebo
11608404|NCT00584961||600 patients|Patients with diagnosis of Bipolar Disorder (DSM-IV TR)
11608405|NCT00584948|Experimental|Memantine|
11608406|NCT00584948|Placebo Comparator|Placebo|
11608407|NCT00584935|Experimental|Rituximab|The Rituximab dose is 1000 mg (1gm) given as an IV infusion every two weeks for 2 doses (Days 1 and 15).
11608408|NCT00584922||AF ablation group|Patients undergoing catheter ablation of atrial fibrillation or left atrial macroreentrant tachycardia.
11608409|NCT00584909|Experimental|Open Label|
11608410|NCT00584883|Experimental|ABT 510|The only arm will receive the ABT 510 following standard therapy with radiation and temozolomide chemotherapy concurrent.
11608411|NCT00584870|Active Comparator|Naproxen|
11608412|NCT00584870|Placebo Comparator|Placebo|
11608413|NCT00584870|Experimental|RN624|
11608414|NCT00584857|Experimental|Chemotherapy|Single
11608415|NCT00584844|Experimental|F tularensis Vaccine (0.0025 mL)|Subjects receive a small amount of F tularensis vaccine (0.0025mL) placed on a cleansed site on the skin on the volar surface of the forearm. A bifurcated needle was used to make 15 superficial punctures at the vaccination site to permit percutaneous penetration of the vaccine.
11608416|NCT00584831|Active Comparator|Group 2 LSBO|contact lenses worn in this order: lotrafilcon B toric, senofilcon A toric, balafilcon A toric, omafilcon A toric
11608417|NCT00584831|Active Comparator|Group 3 LOSB|contact lenses worn in this order: lotrafilcon B toric, omafilcon A toric, senofilcon A toric, balafilcon A toric
11608418|NCT00584831|Active Comparator|Group 4 LBSO|contact lenses worn in this order: lotrafilcon B toric, balafilcon A toric, senofilcon A toric, omafilcon A toric
11608419|NCT00584831|Active Comparator|Group 5 LBOS|contact lenses worn in this order: lotrafilcon B toric, balafilcon A toric, omafilcon A toric, senofilcon A
11608420|NCT00584831|Active Comparator|Group 6 SLOB|contact lenses worn in this order: senofilcon A toric, lotrafilcon B toric, omafilcon A toric, balafilcon A toric
11608421|NCT00584831|Active Comparator|Group 7 SLBO|contact lenses worn in this order: senofilcon A toric, lotrafilcon B toric, balafilcon A toric, omafilcon A toric
11608422|NCT00584831|Active Comparator|Group 8 SOLB|contact lenses worn in this order: senofilcon A toric, omafilcon A toric, lotrafilcon B toric, balafilcon A toric
11608423|NCT00584831|Active Comparator|Group 9 SBLO|contact lenses worn in this order: senofilcon A toric, balafilcon A toric, lotrafilcon B toric, omafilcon A toric
11608424|NCT00584831|Active Comparator|Group 10 SBOL|contact lenses worn in this order: senofilcon A toric, balafilcon A toric, omafilcon A toric, lotrafilcon B toric
11608425|NCT00584831|Active Comparator|Group 11 OSLB|contact lenses worn in this order: omafilcon A toric, senofilcon A toric, lotrafilcon B toric, balafilcon A toric
11608426|NCT00584831|Active Comparator|Group 12 OSBL|contact lenses worn in this order: omafilcon A toric, senofilcon A toric, balafilcon A toric, lotrafilcon B toric
11608427|NCT00584831|Active Comparator|Group 13 OBLS|contact lenses worn in this order: omafilcon A toric, balafilcon A toric, lotrafilcon B toric, senofilcon A toric
11608428|NCT00584831|Active Comparator|Group 14 OBSL|contact lenses worn in this order: omafilcon A toric, balafilcon A toric, senofilcon A toric, lotrafilcon B toric
11608429|NCT00584831|Active Comparator|Group 15 BLSO|contact lenses worn in this order: balafilcon A toric, lotrafilcon B toric, senofilcon A toric, omafilcon A toric
11608430|NCT00584831|Active Comparator|Group 16 BLOS|contact lenses worn in this order: balafilcon A toric, lotrafilcon B toric, omafilcon A toric, senofilcon A toric
11608431|NCT00584831|Active Comparator|Group 17 BSOL|contact lenses worn in this order: balafilcon A toric, senofilcon A toric, omafilcon A toric, lotrafilcon B toric
11608432|NCT00584831|Active Comparator|Group 18 BOLS|contact lenses worn in this order: balafilcon A toric, omafilcon A toric, lotrafilcon B toric, senofilcon A toric
11608433|NCT00584831|Active Comparator|Group 19 BOSL|contact lenses worn in this order: balafilcon A toric, omafilcon A toric, senofilcon A toric, lotrafilcon B toric
11608434|NCT00584831|Active Comparator|Group 1 LSOB|contact lenses worn in this order: lotrafilcon B toric/senofilcon A toric/omafilconA toric/balafilcon A toric
11608435|NCT00584805|Experimental|Vaccination|Inactivated, Dried, TSI-GSD 104, EEE
11608436|NCT00584792||1|Controls (No prostate cancer)
11613248|NCT00546039|Placebo Comparator|2|
11608437|NCT00584792||2|Cases (Prostate Cancer Diagnosed)
11608438|NCT00584779|Experimental|1|
11608439|NCT00584779|Experimental|2|
11608440|NCT00584779|Experimental|3|
11608441|NCT00584779|Experimental|4|
11608442|NCT00584766|Experimental|1|
11608443|NCT00584753|Other|1|Normal volunteers
11608444|NCT00584753|Active Comparator|2|Breast PET/CT scan
11608445|NCT00584753|Active Comparator|3|Whole body and breast PET/CT
11608446|NCT00584740|Experimental|AIN457|AIN457 10 mg/kg was given as an intravenous infusion at day 1 and day 22.
11608447|NCT00584740|Placebo Comparator|Placebo|Matching placebo to AIN457 was given as an infusion at day 1 and day 22.
11608448|NCT00584727|Active Comparator|senofilcon A/alphafilcon A/etafilcon A|First intervention:senofilcon A toric contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: etafilcon A sphere contact lenses
11608449|NCT00584727|Active Comparator|alphafilcon A/etafilcon A/senofilcon A|First intervention: alphafilcon A toric contact lenses Second intervention: etafilcon A sphere contact lenses Third intervention: senofilcon A toric contact lenses
11608450|NCT00584727|Active Comparator|etafilcon A/senofilcon A/alphafilcon A|First intervention: etafilcon A sphere contact lenses Second intervention:senofilcon A toric contact lenses Third intervention: alphafilcon A toric contact lenses
11608451|NCT00584727|Active Comparator|senofilcon A/etafilcon A/alphafilcon A|First intervention: senofilcon A toric contact lenses Second intervention: etafilcon A sphere contact lenses Third intervention: alphafilcon A toric contact lenses
11608452|NCT00584727|Active Comparator|alphafilcon A/senofilcon A/etafilcon A|First intervention: alphafilcon A toric contact lenses Second intervention: senofilcon A toric contact lenses Third intervention: etafilcon A sphere contact lenses
11608453|NCT00584727|Active Comparator|etafilcon A/alphafilcon A/senofilcon A|First intervention: etafilcon A sphere contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: senofilcon A toric contact lenses
11608454|NCT00584701|Experimental|Risperidone|Risperidone was started at 0.5mg at bedtime for 4 days. If that dosage was tolerated and there were continued behavioral symptoms, the dose was increased to 1mg at bedtime for an additional 4 days. If tolerated and indicated, 0.5mg was added in the morning for a daily total of 1.5 mg.
11608455|NCT00584662|Active Comparator|1|Oxymetazoline Hydrochloride
11608456|NCT00584649|Other|Single Group Assignment|electrophysiology study and radiofrequency ablation
11608457|NCT00584636|Experimental|Pulmicort Respules|using pulmicort respules
11608458|NCT00584610|Experimental|1|Levonorgestrel-containing intrauterine device insertion
11608459|NCT00584610|Active Comparator|2|Copper containing intrauterine device
11608460|NCT00584597|Placebo Comparator|1|Saline
11608461|NCT00584597|Experimental|2|Traumeel S 1 mL
11608462|NCT00584597|Experimental|3|Traumeel S 2 mL
11608463|NCT00584597|Experimental|4|Traumeel S 3 mL
11608464|NCT00584584|Experimental|1|
11608465|NCT00584584|Placebo Comparator|2|
11608466|NCT00584571|Active Comparator|Sensory Adaptation training|a large compliant balloon is placed in the rectum attached to a barostat. The balloon is distended in 1 mm increments until patient reports moderate discomfort and then increased in 1 mm increments until maximum tolerable pressure. Gradually over 6 training sessions, administered biweekly, the maximum tolerable pressure is increased over 3 months, if treatment is successful.
11608467|NCT00584571|Experimental|Escitalopram Therapy|Patients randomized to this arm will receive daily 10 mg escitalopram for 3 months. If the medication is effective their bowel symptoms and pain thersholds will improve.
11608468|NCT00584558||1|Patients undergoing catheter ablation.
11608469|NCT00584532|Placebo Comparator|A|A=Placebo ARM of Study
11608470|NCT00584532|Active Comparator|B|B=GCP Capsules. Ten 500 mg capsules per day for a total of 5 grams a day.
11608471|NCT00584519||500 patients|Patients with diagnosis of schizophrenia, schizophreniform or schizoaffective disorder (DSM-IV TR) with BMI (body mass index) more or equal to 25 Kg/m2
11608472|NCT00584480|Active Comparator|1|Active Hyperbaric Oxygen Treatment (HBOT)
11608473|NCT00584454|Experimental|Q Fever Vaccine (NDBR 105)|Volunteers will receive and intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase 1, MNLBR 110) in the volar aspect of the arm. Skin test will be evaluated; if erythema occurs after the skin test, it is medically contraindicated to vaccinate that volunteer. Volunteers with skin test reactions will not be vaccinated and withdrawn from the study.
11608474|NCT00584441||1|Women with pre-menstrual asthma (PMA): As defined by a 20% or more fall in PEFR and / or change by 20% or more of daily symptom score.
11608475|NCT00584441||2|Women without pre-menstrual asthma
11608476|NCT00584441||3|Women on oral contraceptives
11608477|NCT00584428|Experimental|1|
11608478|NCT00584415|Active Comparator|GP + PVI ablation|This study contains only one arm, which is GP ablation + PV antrum isolation. The intervention (GP ablation + PV isolation) was performed using ThermoCool Navistar catheters in all patients
11608479|NCT00584402|Experimental|Contrast sonography|Contrast-enhanced sonography perflutren lipid microspheres
11608480|NCT00584389|Experimental|1|Rimonabant treatment (20mg/d) for 12 weeks
11608481|NCT00584389|Other|2|Dietary intervention
11608482|NCT00584376|Active Comparator|1|Pregabalin
11608483|NCT00584376|Placebo Comparator|2|Placebo
11608484|NCT00584350|Experimental|A: Hydratation according LVEDP + NaHCO3|"Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.
~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours."
11608485|NCT00584350|Active Comparator|B: Standard hydratation|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
11608486|NCT00584350|Experimental|C: Hydratation with sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
11608487|NCT00584337||1|
11608488|NCT00584337||2|
11608489|NCT00584324|Experimental|Bispectral Index (BIS) 40|Target BIS 40
11608490|NCT00584324|Experimental|Bispectral Index (BIS) 60|Target BIS 60
11608491|NCT00584311|Experimental|1|All patients (with no structural damage on the plain x-ray) will receive a MRI and Ultrasound (US) of their most involved joint and an asymptomatic joint.
11608492|NCT00584298|Experimental|1|
11608493|NCT00584298|Placebo Comparator|2|
11608494|NCT00584285||Corneal Topographer Fluorescein Patterns|Use corneal topography to evaluate fluorescein pattern of rgp contact lens. Used corneal topography to develop theoretical fluorescein patters on a virtual eye. Theoretical lens developed by the topographer was ordered to compare to the actual fluorescein pattern on the actual eye.
11608495|NCT00584246|Experimental|1|Pregabalin (Lyrica)
11608496|NCT00584246|Placebo Comparator|2|Placebo
11608497|NCT00584233|Experimental|Breast CT and Breast MRI|Four hundred women who will be having breast biopsy as part of their standard care (BIRADS 4 and 5) will undergo pre- and post- contrast breast computed tomography and pre- and post- contrast magnetic resonance imaging.
11608498|NCT00584220|Other|senofilcon A toric / alphafilcon A toric|senofilcon A toric contact lenses worn daily during the first period, then alphafilcon A toric contact lenses worn daily during the second period
11608499|NCT00584220|Other|alphafilcon A toric / senofilcon A toric|alphafilcon A toric contact lenses worn daily during the first period, then senofilcon A toric contact lenses worn daily during the second period
11608500|NCT00584194|Experimental|TSI-GSD 200 RVF Vaccine|Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine, will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to < 1:40.
11608501|NCT00584181||Lung transplant recipients|Lung transplant recpients enrolled as study subjects will undergo pulmonary function tests (spirometry and lung volume measurements) and initial HRCT of chest. These subjects will receive nebulized ipratropium followed by pulmonary function tests (spirometry and lung volume measurements) and repeat HRCT.
11608502|NCT00584168|Placebo Comparator|2|Patient will receive a placebo.
11608503|NCT00584168|Experimental|1|Patient will receive dexamethasone.
11608504|NCT00584155|Placebo Comparator|1|Each patient will receive a bottle containing normal saline and 0.03% ofloxacin.
11608505|NCT00584155|Experimental|2|Each patient will receive a bottle containing Lactated Ringer's solution and 0.03% ofloxacin.
11608506|NCT00584142|Experimental|1|
11608507|NCT00584142|No Intervention|2|
11608508|NCT00584129|Experimental|1|Patients will receive pre-treatment swallowing exercises.
11608509|NCT00584129|Active Comparator|2|Post-treatment swallowing exercises.
11608510|NCT00584103|Experimental|Beta P Experimental|Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
11608511|NCT00584103|Other|Alpha P Control|Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
11608512|NCT00584090|Experimental|1|
11608513|NCT00584090|Placebo Comparator|2|
11608514|NCT00584077||Stable lung transplant recipients|All enrolled subjects receive the same procedures; bronchoscopy with administration of mechanical and chemical irritants to the airway mucosa
11608515|NCT00584051||1|
11608516|NCT00584051||2|
11608517|NCT00584051||3|
11608518|NCT00584038|No Intervention|1 Standard Care (SC)|Participants receive usual contraceptive care administered by clinic provider.
11608519|NCT00584038|Other|2 Standard Care + Educational (SCE)|Participants receive standard contraceptive care from clinic provider, followed by 45-minute educational intervention.
11608520|NCT00584038|Other|3 Standard Care + Educational + Phone Calls (SCEP)|Participants receive standard contraceptive care from clinic provider, followed by phone calls weekly until onset of menses and monthly thereafter for six consecutive months.
11608521|NCT00584025|Experimental|1|Keppra IV
11608522|NCT00584025|Placebo Comparator|2|Placebo
11608523|NCT00584012|Experimental|Dose Esclation|Determine the maximum tolerated dose (MTD) of escalating doses of lovastatin in combination with docetaxel in patients with any type of solid tumor.
11608524|NCT00583999||A|bariatric surgery
11608525|NCT00583986|Experimental|1|Levalbuterol HFA MDI with top mounted actuation indicator
11608526|NCT00583973||1|Chronic hemodialysis patients
11608527|NCT00583947|Other|ARF/LEV|"Cross-over phase: one day active treatment with arformoterol 7.5 microgram per nebulization followed by a 7 day washout. Then a one day active treatment with levalbuterol 0.63 milligram per nebulization.
~Open-label phase: Following another 7 day washout, one day treatment with arformoterol 15 micrograms per nebulization."
11608528|NCT00583947|Other|LEV/ARF|"Cross-over phase: one day active treatment with levalbuterol 0.63 milligram per nebulization followed by a 7 day washout. Then a one day active treatment with arformoterol 7.5 micrograms per nebulization.
~Open-label phase: Following another 7 day washout, one day treatment with arformoterol 15 micrograms per nebulization."
11608529|NCT00583934||A|Those six months post treatment for head and neck cancer.
11608530|NCT00583908|Active Comparator|Group 1: lotrafilcon B/senofilcon A/balafilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. Period 1: lotrafilcon B /period 2: senofilcon A / period 3: balafilcon A / period 4: omafilcon A
11608531|NCT00583908|Active Comparator|Group 2 lotrafilcon B/omafilcon A/senofilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: lotrafilcon B / period 2: omafilcon A / period 3: senofilcon A / period 4: balafilcon A
11608532|NCT00583908|Active Comparator|Group 3 lotrafilcon B/balafilcon A/senofilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: lotrafilcon B / period 2: balafilcon A / period 3: senofilcon A / period 4: omafilcon A
11608631|NCT00583154|Experimental|2|BLI-801 Dose 2
11608533|NCT00583908|Active Comparator|Group 4 senofilcon A/lotrafilcon B/omafilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: lotrafilcon B / period 3: omafilcon A / period 4: balafilcon A
11608534|NCT00583908|Active Comparator|Group 5 senofilcon A/omafilcon A/balafilcon A/lotrafilcon B|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: omafilcon A / period 3: balafilcon A / period 4: lotrafilcon B
11608535|NCT00583908|Active Comparator|Group 6 senofilcon A/balafilcon A/lotrafilcon B/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: balafilcon A / period 3: lotrafilcon B / period 4: omafilcon A
11608536|NCT00583908|Active Comparator|Group 7 omafilcon B/lotrafilcon B/senofilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: omafilcon A / period 2: lotrafilcon B / period 3: senofilcon A / period 4: balafilcon A
11608537|NCT00583908|Active Comparator|Group 8 balafilcon A/lotrafilcon B/senofilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: lotrafilcon B / period 3: senofilcon A / period 4: omafilcon A
11608538|NCT00583908|Active Comparator|Group 9 balafilcon A/lotrafilcon B/omafilcon A/senofilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: lotrafilcon B / period 3: omafilcon A / period 4: senofilcon A
11608539|NCT00583908|Active Comparator|Group 10 balafilcon A/senofilcon A/lotrafilcon B/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: senofilcon A / period 3: lotrafilcon B / period 4: omafilcon A
11608540|NCT00583908|Active Comparator|Group 11 balafilcon A/senofilcon A/omafilcon A//lotrafilcon B|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: senofilcon A / period 3: omafilcon A / period 4: lotrafilcon B
11608541|NCT00583908|Active Comparator|Group 12 balafilcon A/omafilcon A/lotrafilcon B/senofilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: omafilcon A / period 3: lotrafilcon B / period 4: senofilcon A
11608542|NCT00583895|Active Comparator|1|Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
11608543|NCT00583895|Placebo Comparator|2|Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
11608544|NCT00583882|Other|1|Change every 6 days, rewire every 6 days
11608545|NCT00583882|Other|2|New site every 6 days
11608546|NCT00583882|Other|3|New site every 12 days
11608547|NCT00583869|Placebo Comparator|1|Patient to receive placebo beginning on the day of surgery until discharge.
11608548|NCT00583869|Experimental|2|Patient to receive 75mg PO BID pregabalin beginning on the day of surgery until discharge.
11608549|NCT00583869|Experimental|3|Patient to receive 150mg PO BID pregabalin beginning on the day of surgery until discharge.
11608550|NCT00583843||Ultrasound|The group of women who are being followed by Ultrasound.
11608551|NCT00583830|Active Comparator|A|Paclitaxel and carboplatin
11608552|NCT00583830|Experimental|B|Paclitaxel, carboplatin and Mapatumumab 10 mg/kg
11608553|NCT00583830|Experimental|C|Paclitaxel, carboplatin and Mapatumumab 30 mg/kg
11608554|NCT00583817|Experimental|Ascending Aortic Arm|Investigational endovascular stent-graft implantation to exclude aneurysm or repair dissection of the ascending aorta.
11608555|NCT00583817|Experimental|Arch Branch Arm|Investigational endovascular stent-graft implantation to exclude aneurysm or repair dissection of the aortic arch.
11608556|NCT00583817|Experimental|Thoracoabdominal Aortic Arm|Investigational endovascular stent-graft implantation to exclude thoracoabdominal aortic pathology including aortic aneurysms, renal artery aneurysms, and superior mesenteric artery aneurysms.
11608557|NCT00583804|Experimental|Stimulation ON|Individuals implanted with stimulator/sensor device. Stimulator is turned on and is active.
11608558|NCT00583804|Active Comparator|Stimulation OFF|Function with stimulation turned off.
11608559|NCT00583791|Experimental|Main Cohort|Device closure with the AMPLATZER Muscular VSD Occluder for patients with muscular ventricular septal defects which are hemodynamically significant and are either isolated or present in conjunction with other congenital heart defects.
11608560|NCT00583778|Active Comparator|1|levalbuterol 1.25 mg every 20 minutes for 3 doses plus placebo (saline)
11608561|NCT00583778|Experimental|2|ipratropium 0.5 mg nebulized every 20 minutes for 3 doses added to levalbuterol 1.25 mg every 20 minutes for 3 doses
11608562|NCT00583765||A|Critically ill patients with acute renal failure requiring continuous renal replacement therapy
11608563|NCT00583752|Experimental|Arm B|On Arm B, subjects will be started on androgen deprivation therapy (ADT) 14 days prior to beginning the vaccinations.
11608564|NCT00583752|Experimental|Arm A|On Arm A, subjects can begin the three vaccinations immediately.
11608565|NCT00583739|Active Comparator|1|Yoga intervention
11608566|NCT00583739|No Intervention|2|Control. No Yoga for 8 weeks.
11608567|NCT00583726|Active Comparator|1|The control arm receives written information and pedometers
11608568|NCT00583726|Experimental|2|This arm also receives telephone counseling.
11608569|NCT00583713|Experimental|Renal Group|Patients with moderate renal impairment
11608570|NCT00583713|Active Comparator|Healthy volunteers|Healthy volunteers
11608632|NCT00583154|Experimental|3|BLI-801 Dose 3
11608571|NCT00583713|Experimental|Hepatic Group|Patients with mild/moderate hepatic impairment.
11608572|NCT00583700|No Intervention|1|Control for study - watchful waiting.
11608573|NCT00583700|Experimental|2|Combined treatment with Pentoxifylline and Vitamin E.
11608574|NCT00583674|Experimental|B|
11608575|NCT00583674|Experimental|A|
11608576|NCT00583674|Active Comparator|C|
11608577|NCT00583661|Experimental|EXCOR Pediatric|Implantation of the EXCOR Pediatric Ventricular Assist Device
11608578|NCT00583648|Experimental|1|Recieves urinalysis by nurse per set protocol based off of inclusion criteria
11608579|NCT00583648|No Intervention|2|ordering of test will be up to the treating physician
11608580|NCT00583635||1|Low Risk Pregnancy, Placebo
11608581|NCT00583635||2|Low Risk Pregnancy, Active Food Supplement
11608582|NCT00583635||3|High Risk Pregnancy, Placebo
11608583|NCT00583635||4|High Risk Pregnancy, Active Food Supplement
11608584|NCT00583622|Experimental|Bevacizumab + High-Dose Chemotherapy|Bevacizumab 5 mg/kg by vein (IV) daily over 90 minutes for 2 Days + Carboplatin 333 mg/m^2 by vein over 2 hours for 3 Days + Docetaxel 300 mg/m^2 by vein over 2 hours for 1 Day + Gemcitabine 1,800 mg/m2 by vein over 3 hours for 4 Days + Melphalan 50 mg/m^2 by vein over 15 minutes for 3 Days + Stem Cell Transplant
11608585|NCT00583609|Experimental|1|PEG3350
11608586|NCT00583596|Experimental|implant to close PDA|
11608587|NCT00583570|Experimental|A|
11608588|NCT00583557|Experimental|Belimumab|
11608589|NCT00583544|Placebo Comparator|1|
11608590|NCT00583544|Experimental|2|
11608591|NCT00583531|Experimental|I|Active treatment with AST-120
11608592|NCT00583492|Experimental|Ad5-yCD/mutTKSR39rep-ADP + IMRT|Gene Therapy + IMRT
11608593|NCT00583492|Active Comparator|IMRT Alone|IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
11608594|NCT00583479|Other|A|subjects who get one medication injection into the celiac ganglion during the EUS
11608595|NCT00583479|Other|B|subjects who get divided dose of the medication injected into two locations within the celiac ganglion during the EUS
11608596|NCT00583466|Active Comparator|1 Normal saline arm|Polypectomy with normal saline injected for submucosal cushion creation
11608597|NCT00583466|Active Comparator|2 HPMC arm|Polypectomy after injection of hydroxypropyl methylcellulose (HPMC) to create submucosal cushion
11608598|NCT00583466|Experimental|3 Blood arm|Polypectomy after injection of autologous blood
11608599|NCT00583453|Active Comparator|A|Celecoxib 200 mg tablets
11608600|NCT00583453|Placebo Comparator|B|Placebo with same dosing schedule as the active comparator arm
11608601|NCT00583440|Experimental|1|
11608602|NCT00583440|Active Comparator|2|
11608603|NCT00583427|Experimental|Sulodexide|
11608604|NCT00583414|Experimental|Endovascular Aneurysm Repair|Investigational stent-graft implant to exclude aneurysm
11608605|NCT00583388||A|42 healthy subjects aged 18 to 60 will be be randomly assigned to 6 different treatment sequences.
11608606|NCT00583375|Active Comparator|Group 1|"Standard Rigid Fixation plus autograft
~Standard of Care: Autologous Bone Graft"
11608607|NCT00583375|Experimental|Group 2|Standard Rigid Fixation plus Augment® Bone Graft
11608608|NCT00583362|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV over one hour every 28 days.
11608609|NCT00583349|Experimental|Abraxane administration|Patients will restrict their fluid intakes the morning of treatments and will have emptied their bladders at each of their visits and have up to 100ml of Abraxane solution administered to their bladder via urinary catheter once weekly for six weeks.
11608610|NCT00583336|Experimental|Diagnostic|
11608611|NCT00583323|Experimental|1|Lomotil given
11608612|NCT00583323|Placebo Comparator|2|Normal Saline given
11608613|NCT00583310|No Intervention|Control|Subjects receive standard written educational information at baseline, but do not receive the telephone-based intervention. Subjects may participate in the intervention following completion of the study.
11608614|NCT00583310|Experimental|Intervention|Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
11608615|NCT00583297||ABCD Subjects|The cohort will consist of original subjects of the ABCD trial who consent to participate in the genetic sub-study
11608616|NCT00583271||1|subjects who are getting a celiac block for chronic pancreatitis
11608617|NCT00583271||2|subjects who are getting a celiac block for pancreatic cancer
11608618|NCT00583258|Experimental|A|
11608619|NCT00583258|Placebo Comparator|B|
11608620|NCT00583245|Experimental|1|Gait training
11608621|NCT00583232|Active Comparator|Corticosteroid|Subjects receiving corticosteroid therapy (1-2 mg/kg/day up to 60mg/day) with taper.
11608622|NCT00583232|Active Comparator|infliximab|Subjects receiving infliximab therapy (5 mg/kg at 0, 2 and 6 weeks, followed by every 8 week therapy)
11608623|NCT00583219|Experimental|Botox/DMSO Solution|"Subjects received Botulinum-A toxin and Dimethyl sulfoxide solution. The first 3 subjects in Phase 1 underwent bladder instillation of 50 cc of the solution utilizing 200 units of botulinum-A toxin and 50cc DMSO. The next 6 subjects in the Phase 1 trial received 300 units of botulinum-A toxin and 50cc DMSO.
~All subjects in the Phase 2 trial received 300 units of botulinum-A toxin and 50cc DMSO."
11608624|NCT00583193|Other|1|Open-label Study
11608625|NCT00583180||A|Capsaicin treated patients
11608626|NCT00583180||P|Placebo treated patients
11608627|NCT00583167||A1|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA >20,000 copies/mL. CD4+ T cell count >200 cells/mm3. Group A1 will undergo continuous CSF ( cerebrospinal fluid) sampling via intrathecal catheter.
11608628|NCT00583167||A2|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA >20,000 copies/mL. CD4+ T cell count <200 cells/mm3. Group A2 will undergo continuous CSF sampling via intrathecal catheter.
11608629|NCT00583167||B|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA >20,000 copies/mL. Group B will not undergo continuous CSF sampling, but will undergo sparse CSF sampling by lumbar punctures.
11608630|NCT00583154|Experimental|1|BLI-801 Dose 1
11608633|NCT00583154|Experimental|4|BLI-801 Dose 4
11608634|NCT00583128|Experimental|1|AST-120, 2 gram sachets
11608635|NCT00583128|Placebo Comparator|2|Celphere® CP-305, stained to match appearance of AST-120, in 2g sachets
11608636|NCT00583115|Experimental|Gleevec|Drug taken orally 260mg/M2/day once per day
11608637|NCT00583102|Experimental|Lovastatin followed by Cytarabine|The subject will receive high dose cytarabine as well as lovastatin. The subject will take doses of lovastatin twice a day, about 12 hours apart. On the third day, the subject will begin high-dose cytarabine IV over 3 hours, twice a day, starting 1 hour after the lovastatin dose for 5 days.
11608638|NCT00583089||1|Algorithm Test Set
11608639|NCT00583089||2|Algorithm Development Set
11608640|NCT00583076|Experimental|1|AST-120, 2grams, three times daily
11608641|NCT00583063|Experimental|A|Sunitinib taken by mouth every day. Rapamycin (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.
11608642|NCT00583063|Experimental|B|Rapamycin taken by mouth every day. Sunitinib (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.
11608643|NCT00583050|Experimental|Endovascular Aneurysm Repair|Endovascular Aneurysm Repair of TAAA/AAA with Fenestrated/Branched Stent Grafts
11608644|NCT00583037|Experimental|NAVA|Implementation of NAVA for 24 hours
11608645|NCT00583024|Experimental|Arm A|
11608646|NCT00583011|Experimental|A|Local anesthesia group
11608647|NCT00583011|Placebo Comparator|B|Placebo normal saline group
11608648|NCT00582998|Active Comparator|Standard Wound Dressing|Standard post-operative wound dressing
11608649|NCT00582998|Active Comparator|Vacuum Assisted Closure Device|Vacuum Assisted Closure (VAC) device
11608650|NCT00582972|Experimental|Experimental|Subjects will receive omeprazole 40 mg daily for 30 days
11608651|NCT00582959|Other|1|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
11608652|NCT00582946|Experimental|Magnetic Contact Hearing Aid|Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss. Acute performance and safety assessed at 4 months compared to unaided baseline pre-treatment, followed by longer-term assessment of safety up to 10 months.
11608653|NCT00582933|Experimental|1|25 research participants with HLA Identical Related Donor using PBSC, 6 with BMT
11608654|NCT00582933|Experimental|2|70 research participants with HLA-Matched Unrelated Donor using PBSC, 17 with BMT
11608655|NCT00582933|Experimental|3|25 research participants with HLA-Mismatched Related Donor using PBSC, no BMT
11608656|NCT00582907|Experimental|1|Treatment Arm A: Rilonacept (IL-1 Trap) at a dose of 2.2 mg/kg/wk (max 160 mg)given by subcutaneous injection for 3 months plus colchicine at a stable dose for those subjects already taking colchicine, or without colchicine for those intolerant or non-compliant with colchicine. Since the colchicine dose is stable throughout the study for each subject, at the prestudy dose, colchicine was not considered an intervention
11608657|NCT00582907|Placebo Comparator|2|Treatment Arm B: Placebo given by subcutaneous injection weekly with or without colchicine for 3 months. Since the colchicine dose is stable throughout the study for each subject, at the prestudy dose, colchicine was not considered an intervention.
11608658|NCT00582894|Other|A|Preparative regimen of 1)Busulfex 3.2 mg/kg/day for 2 days, infused over 3 hours, on Day-6 and Day-5 2)Fludarabine 30 mg/m2/day for 5 days on Day-6 to D-2 and 3) Alemtuzumab 10 mg/day IV on days - 5 to -1
11608659|NCT00582868||Hemorrhage|Patients having experienced subarachnoid hemorrhage and have in place a ventriculostomy
11608660|NCT00582855|Experimental|1|
11608661|NCT00582855|Placebo Comparator|2|
11608662|NCT00582842||1|Men with prostate cancer
11608663|NCT00582842||2|Men with prostate cancer
11608664|NCT00582829||1|"Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant."
11608665|NCT00582829||2|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
11608666|NCT00582829||3|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
11608667|NCT00582816|Experimental|1|patients will undergo a standard pre-transplant evaluation, but will also have blood drawn to evaluate their HLA class I killer immunoglobulin-like receptor (KIR) ligand typing. Parents will undergo KIR genotyping and phenotyping, and a donor will be selected based on which parent shows the greatest degree of KIR receptor-ligand mismatching. Once the donor has been selected he/she will undergo a peripheral blood stem cell (PBSC) collection utilizing G-CSF and GM-CSF for stem cell mobilization. The PBSC collection will be performed utilizing standard procedures. The PBSC will then be processed in the UW BMT Laboratory in order to deplete the graft of T cells. This will be accomplished using the CliniMACS cell separation system. T cell depletion is a standard procedure for patients receiving haploidentical stem cell grafts. The resulting stem cell product will be analyzed for T cell, stem cell and NK cell content.
11608668|NCT00582790|Experimental|1|Interleukin-2 subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles in combination with Zoledronic acid IV on day 1 of every 4 week (28 days) cycle.
11608669|NCT00582777|Active Comparator|USUAL|USUAL treatment - The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
11608670|NCT00582777|Experimental|HS Dosing|"HS DOSING - In this period, the patient's antihypertensive regimen at the baseline visit will be standardized for the once/day medications to be given at bedtime.
~For those on monotherapy with a once/day antihypertensive regimen, the time of administration will be changed to bed time.
~For those on multi-drug therapy, the time of administration of all once a day antihypertensive drugs will be changed to bed time."
11608792|NCT00581620|Active Comparator|G1|G1: HIV+
11608793|NCT00581620|Active Comparator|G2|G2: Sicle Cell disease
11608794|NCT00581620|Active Comparator|G3|G3: neprotic symdrome
11615000|NCT00531752|Experimental|Fixed Dose|
11608671|NCT00582777|Experimental|ADD-ON DOSING|ADD-ON DOSING - This regimen will start with the USUAL regimen to which an additional agent will be added at bed time. An additional dose of ramipril, diltiazem, or hydralazine are three possible options for the add on medication. The intent of the ADD ON therapy is to lower nocturnal BP with minimal impact on daytime BP. Thus, agents with < 24 hr duration of action are preferred. The specific choice and dose of add-on therapy (of the three agents) will be up to the site investigator considering the clinical situation of each participant based on the guidelines below.
11608672|NCT00582764||1|Any patient undergoing MRI guided preoperative needle localization or MRI guided biopsy of the breast.
11608673|NCT00582738|Active Comparator|CsA-TAC|Continuation of current immunosuppressive regimen (continuation of Calcineurin Inhibitor [CNI] with or without Enteric-coated mycophenolate sodium (myfortic) or mycophenolate mofetil(Cellcept)[MPA], with or without steroids) / no everolimus introduction.
11608674|NCT00582738|Experimental|everolimus|Initiation of everolimus with discontinuation of CNI/MPA, with or without steroids.
11608675|NCT00582725|Experimental|R-CHOP + GM-CSF|R-CHOP therapy (6-8 cycles) with GM-CSF
11608676|NCT00582712|Experimental|Lithium Capsules|Lithium carbonate
11608677|NCT00582699||1|Patients with pancreatic cancer who meet DSMIV criteria for a current diagnosis of a Major Depressive Episode (N=25).
11608678|NCT00582699||2|Patients with pancreatic cancer who do not meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25)
11608679|NCT00582699||3|Healthy controls who meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25).
11608680|NCT00582699||4|Healthy controls who do not meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25).
11608681|NCT00582686|Active Comparator|ORIF with Bone Grafting|This study will be designed as a randomized, prospective, blinded evaluation of patients who have sustained an intra-articular calcaneous fracture that would require open reduction with internal fixation as the preferred method of treatment. Group A will be made up of patients that undergo ORIF and Tricortical iliac crest bone grafting.
11608682|NCT00582686|Active Comparator|ORIF without Bone Grafting|This study will be designed as a randomized, prospective, blinded evaluation of patients who have sustained an intra-articular calcaneous fracture that would require open reduction with internal fixation as the preferred method of treatment. Group B will consist of patients that undergo open reduction with internal fixation without bone grafting
11608683|NCT00582673|Experimental|1|
11608684|NCT00582673|Placebo Comparator|2|
11608685|NCT00582660|Active Comparator|study drug BID for 7 days before surgery|400 mg Celecoxib the study drug will be given for 7 days before surgery
11608686|NCT00582660|Placebo Comparator|Placebo for 7 days before surgery|Placebo in a one to one randomization prior to surgery
11608687|NCT00582634|Experimental|Docetaxel followed by cisplatin|Docetaxel (75mg/m2) given IV followed by cisplatin (75mg/m2) given IV on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for 4 cycles.
11608688|NCT00582608|Experimental|131I-8H9 and 8H9|This is an open-label single arm study of 131 I-8H9. injected intravenously at 10mCi/1.73m^2 dose [intended specific activity of '20mCi/mg protein] preceded by administration of 50mg/1.73m2 of unlabeled -8H9.
11608689|NCT00582582|Experimental|A|Docetaxel plus doxercalciferol
11608690|NCT00582582|Placebo Comparator|B|Docetaxel plus placebo
11608691|NCT00582556|Active Comparator|1|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
11608692|NCT00582556|Active Comparator|2|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given at mo 6
11608693|NCT00582556|Active Comparator|3|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
11608694|NCT00582543|Experimental|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position.
11608695|NCT00582530||1 men with prostate cancer|Patients who have opted for radical prostatectomy as treatment for prostate cancer.
11608696|NCT00582517|Active Comparator|Group A External Brace|Group A will have a non-invasive range of motion external brace placed following surgery
11608697|NCT00582517|Experimental|Group B Compass Knee Hinge|Group B will have a Compass Knee Hinge placed
11608698|NCT00582504|Experimental|Vaccination|VEE TC-83
11608699|NCT00582491|Experimental|I|Modafinil 400mg orally everyday for 16 days
11608700|NCT00582491|Placebo Comparator|II|Placebo orally everyday for 16 days
11608701|NCT00582478||1|women with breast cancer
11608702|NCT00582465||Observation|Lupus
11608703|NCT00582452||2|Affected patients who are at high risk for metachronous colorectal tumors due to mutation status.
11608704|NCT00582452||1|Unaffected patients who are at high risk for developing colon cancer based on family history and/or mutation status.
11608705|NCT00582439|Other|1|Repair of Orthopaedic Trauma Fractures and Non-Unions
11608706|NCT00582426|Experimental|Octreotide Long Acting Release|Prevention of Chemotherapy Induced Diarrhea (CID)
11608707|NCT00582426|Other|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
11608708|NCT00582413||1|Patients who have been diagnosed with Carcinoma of the oral cavity
11608709|NCT00582400|Experimental|I|
11608710|NCT00582387||nonmuscle invasive bladder cancer|This is a hospital-based cohort study in which subjects with non-muscle invasive bladder cancer diagnosed within the previous 12 months will be evaluated to determine whether candidate genetic variants in patients with superficial bladder cancer can predict the risk of disease recurrence and/or progression, with the goal of modifying surveillance schedules as a function of predicted risk of recurrence or progression. All patients will be treated according to the treatment plan as outlined by their attending physician. The study will not require any deviation from the planned usual treatment.
11608711|NCT00582374||A|Pregnant Women
11608712|NCT00582361|Active Comparator|1, A|Group A patients will have a standard dressing applied following initial treatment of their open fracture.
11608713|NCT00582361|Experimental|2, B|Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture.
11608714|NCT00582309|Active Comparator|Glucommander|Glucommander-Guided Intravenous Insulin Infusion
11608715|NCT00582309|Active Comparator|Standard|Standard Intravenous Insulin Infusion Algorithm consists of four levels (Algorithm 1-3 and a doubling of the insulin rate). Most patients begin in algorithm 1, where the insulin rate varies from 0.2 units per hour for BG in the range 70-109 mg/dl up to 6 units/hr for BG > 360 mg/dl. If algorithm 1 fails to bring the patient's BG into target range in 2 hrs, then the patient is moved up to algorithm 2, where the insulin rate varies from 0.5 to 12 units/hr; and if that fails, the patient moved up to algorithm 3, where insulin rate varies from 1 to 16 units/hr depending on the latest BG. Algorithm failure is a blood glucose outside the target range for 2 hrs, and the blood glucose does not decrease by at least 60 mg/dl within 1 hr. If algorithm 3 fails, the insulin rate is doubled.
11608716|NCT00582309|Active Comparator|Simple|Simple Calculated Intravenous Insulin Infusion consists of an initial insulin infusion rate varying from 0.5 units per hour for BG in the target range 80-120 mg/dl up to 8 units/hour for BG > 400 mg/dl. After the initial insulin rate and if BG is still > 120 mg/dl, then the insulin rate is increased by 1-2 units every 1 hour until BG is in the target range. If BG is still >120 mg/dl in 2 hours, then the insulin rate is doubled.
11608717|NCT00582296||1|multi-organ follow-up
11608718|NCT00582296||2|control follow-up
11608719|NCT00582283|Other|Diagnostic: iodine I-124 NM404 CT/PET scan|Patients undergo iodine I-124 NM404 CT/PET scan at 1-2, 4-6, 24, and 48 hours and at 5-10 days.
11608720|NCT00582270||1|Follicular Lymphoma
11608721|NCT00582270||2|Non-follicular Lymphoma
11608722|NCT00582257||High Genetic Risk:|"Early Onset Gastric Cancer - diagnosis of gastric cancer before the age of 50 without a family history of the disease.
~Familial Gastric Cancer - having a family history of gastric cancer as defined as one first degree relative or 2 second degree relatives.
~Relative - Relatives of participants eligible for the High Genetic Risk Cohort will be eligible for participation. These relatives may also be at high risk of developing gastric cancer. These individuals will fall under the Cancer Cohort. Eligible relatives will be defined as someone having a relative who meets criteria for either the Early Onset Cancer Cohort or the Familial Gastric Cancer Cohort, or having a family history of a genetic mutation known to be associated with gastric cancer."
11608723|NCT00582257||Low Genetic Risk: Closed to Accrual|"Sporadic Gastric Cancer - gastric cancer that appears to have occurred by random or sporadic mutation. Specifically, a patient with gastric cancer not eligible for either High Genetic Risk cohort.
~Control (closed to accrual) - A participant that is not a blood relative of a patient or relative participant, without gastric cancer and without a family history of a CDH1 gene mutation. Select MSK participants with Hereditary Diffuse Gastric Cancer with identified CDH1 germline genetic mutation will be invited by MSKCC only to complete the onetime Pre-implantation Genetic Diagnosis (HDGC PGD) survey. These patients may be verbally consented over the telephone."
11608724|NCT00582244|Experimental|1|CBT and relaxation.
11608725|NCT00582244|Experimental|2|Physical activity
11608726|NCT00582244|Experimental|3|CBT and physical activity
11608727|NCT00582244|No Intervention|4|Control group
11608728|NCT00582231||1|Participants that are starting penile injections therapy.
11608729|NCT00582205|Experimental|Paclitaxel, Cisplatin IP|There is only one arm for this study and it represents the participants receiving the intraperitoneal chemotherapy
11608730|NCT00582192||1|Participants with certain types of cancers that are eligible for studies at Memorial Sloan-Kettering Cancer Center.
11608731|NCT00582179|Active Comparator|1, A|Group A patients will be treated with a pressure dressing and observation.
11608732|NCT00582179|Active Comparator|2, B|Group B patients will be treated with a Vacuum Assisted Closure device (VAC).
11608733|NCT00582166|Experimental|Ibritumomab Tiuxetan (Zevalin) with Rituximab maintenance|
11608734|NCT00582140|Experimental|Cohort Level 1|pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
11608735|NCT00582140|Experimental|Cohort Level 2|pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
11608736|NCT00582140|Experimental|Cohort Level 3|pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
11608737|NCT00582127||1|Mild-moderate Alzheimer's Disease
11608738|NCT00582127||2|Age-matched Controls
11608739|NCT00582114|Active Comparator|1|Atenolol
11608740|NCT00582114|Experimental|2|Lisinopril
11608741|NCT00582101|Experimental|Family-based HIV|
11608742|NCT00582101|Active Comparator|Family-based HP|
11608743|NCT00582088|Experimental|Vaccine|VEE C-84 - Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI-GSD 205
11608744|NCT00582075|Experimental|Radiosurgery 15-24 Gy + Adjuvant Temozolomide|
11608745|NCT00582062||1|Positive controls will include patients who have positive cytology or positive biopsy of peritoneal metastases. Cell lines which over-express these tumor markers will also be used as positive controls. Sensitivity will be defined using serial dilutions of several established gastric and pancreatic tumor cell lines. The mRNA of the tumor markers will be normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA expression.
11608746|NCT00582062||2|Patients who are scheduled to undergo laparoscopy for benign disease (e.g., laparoscopic cholecystectomy, hernia repair, or prophylactic BSO) will be recruited as negative controls. A leukemia cell line which does not express epithelial cell markers will also be used as a negative control for the RT-PCR reactions.
11608747|NCT00582049||1|Cases: retinoblastoma patients
11608748|NCT00582049||2|Controls: first cousins or other blood relatives of the retinoblastoma patients (relative controls) or friends of the retinoblastoma patients or children of friends of the parents (friend controls).
11608749|NCT00582036|Active Comparator|Arm 1|Regular Sliding Scale Insulin administration for hyperglycemia
11608750|NCT00582036|Experimental|Arm 2|MiniMed Paradigm monitoring device for hyperglycemia
11608751|NCT00582010|Experimental|1. Experimental|iNO administration
11608752|NCT00582010|Placebo Comparator|2. Placebo|Placebo (nitrogen)
11608753|NCT00581997|Experimental|1|QAX576
11608754|NCT00581997|Placebo Comparator|2|Placebo
11608755|NCT00581971|Experimental|Celecoxib+Carboplatin/Paclitaxel+Radiation Therapy|
11608795|NCT00581620|Active Comparator|G4|G4: Chronic pulmonary disease
11608796|NCT00581607|Active Comparator|Bosentan for 16 weeks|Active drug
11608797|NCT00581607|Placebo Comparator|Placebo|Placebo for 16 weeks
11616137|NCT00521963|Experimental|E|
11608756|NCT00581958||Patients undergoing HSCT|Research subjects will have blood and/or urine sampled at three time points in the Department of Radiation Oncology. Participating patients will have at least a total two samples collected at each time point. The first sampling will occur before the first TBI treatment is given. The second sampling will occur before the second TBI treatment, usually 3 to 8 hours after the first treatment (in the case of multifraction TBI). If a patient is being treated with single fraction TBI, then the second sampling will occur approximately 3-8 hours after the first TBI treatment. The third and final sampling will occur at the next morning blood draw, prior to the fourth TBI treatment (in the case of multifraction TBI), 24 hours after the first TBI treatment.
11608757|NCT00581945|Experimental|Canakinumab|Participants received an initial dose of 1 mg/kg canakinumab (ACZ885) via intravenous infusion. Four weeks later, participants received a dose of 3 mg/kg canakinumab, and another dose of 3 mg/kg two weeks later. Thereafter, participants received doses of 6 mg/kg every four weeks until completion of the 45-week treatment period.
11608758|NCT00581945|Placebo Comparator|Placebo|Participants received a matching placebo intravenous infusion at weeks 1, 5, 7, and thereafter every four weeks until completion of the 45-week treatment period.
11608759|NCT00581932||A|One group, all subjects with DSM-IV diagnosis of Schizophrenia, age 18-65 who are initiating clozapine therapy.
11608760|NCT00581919|Experimental|Bort, Dex, and Dox with ALCAR|
11608761|NCT00581906||pts undergoing surgery or chemo-radiation treatment|
11608762|NCT00581893|Experimental|1|Phenytoin administration
11608763|NCT00581893|Placebo Comparator|2|Placebo
11608764|NCT00581880||1|Terminally Ill patients
11608765|NCT00581867|Experimental|Intranasal Insulin Aspart|Participants were administered intranasal insulin aspart (40 IU) in a double-blinded fashion approximately 30 minutes prior to functional MRI scanning. After a washout period of 48 hours, participants completed the other arm. The order of saline vs. insulin was counterbalanced.
11608766|NCT00581867|Active Comparator|Intranasal Saline (placebo)|Participants were administered intranasal saline (placebo) in a double-blinded fashion approximately 30 minutes prior to functional MRI scanning. After a washout period of 48 hours, participants completed the other arm. The order of saline vs. insulin was counterbalanced.
11608767|NCT00581841||1|Healthy adult participants with no history of knee injury or osteoarthritis.
11608768|NCT00581828|Experimental|1|Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).
11608769|NCT00581815|Experimental|1|
11608770|NCT00581802||1|Intensively studied participants initiating potentially suppressive drug therapy. Group 1 participants may undergo optional leukapheresis. Group 1 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 1 participants will default to either Group 3 or Group 4.
11608771|NCT00581802||2|Intensively studied, well-suppressed participants on HAART. Participants in Group 2 may undergo optional leukapheresis. Group 2 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 2 participants will default to either Group 3 or Group 4.
11608772|NCT00581802||3|Nonintensively studied participants initiating potentially suppressive drug therapy
11608773|NCT00581802||4|Nonintensively studied well-suppressed participants on HAART
11608774|NCT00581802||5|Intensively studied participants who are currently participating in the Merck Expanded Access Program and receiving raltegravir. Participants in Group 5 may undergo optional leukapheresis. Group 5 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 5 participants will default to either Group 3 or Group 4.
11608775|NCT00581789|Experimental|1|Erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
11608776|NCT00581776|Experimental|VCR-CVAD with rituximab maintenance|Induction chemotherapy with Bortezomib, cyclophosphamide, rituximab, vincristine, doxorubicin, and dexamethasone. Subjects will receive 6 cycles of induction chemotherapy, of 21 days each. After completing induction, subjects will receive rituximab consolidation (4 weeks), and then rituximab maintenance therapy for up to 5 years.
11608777|NCT00581763||Observation|Those with a condition
11608778|NCT00581750||LCIS diagnosis|Patient with LCIS diagnosis
11608779|NCT00581724||1|"First 50 breast cancer survivors and then after demonstrating feasibility of the study design in the first 50 participants, recruitment will be opened to the other services Colorectal, Genitourinary, Head and Neck, and Thoracic.
~Participants will be recruited in allotments of 50 patients from each service."
11608780|NCT00581711|No Intervention|Control|Usual Care
11608781|NCT00581711|Experimental|HIT Intervention without feedback|3-Part Intervention: Training, Otitis Media Episode Grouper, Clinical Decision Support
11608782|NCT00581711|Experimental|HIT Intervention with feedback|4-Part Intervention: Training, Episode Grouper, Clinical Decision Support, and Physician Feedback.
11608783|NCT00581711|Experimental|Feedback only|1 part intervention: Physician Feedback
11608784|NCT00581698||Surgical|Patients with primary melanomas Clark III and Breslow thickness > 1 mm, or Clark IV-V and any Breslow thickness, and clinically negative regional nodes
11608785|NCT00581685|Placebo Comparator|2|Prospective, single center, randomized, double-blinded, placebo controlled study
11608786|NCT00581672||questionnaires|Black men with prostate cancer
11608787|NCT00581659||Lens A, Lens B|The first independent variable is the contact lens. Each subject will wear both PureVision (TM0 aspheric contact lenses and conventional spherical contact lenses on separate visits. The second independent variable is visibility condition. Subjects will complete the study drive both in clear nighttime conditions and at night under glare conditions. In both cases, the driver will experience oncoming traffic; however, in the glare condition, the simulator will be equipped with a point light source sufficient to provide glare similar to that provided by oncoming traffic in the real world.
11608788|NCT00581646||1|gynecologic cancer survivors
11608789|NCT00581646||2|survivors of any type of malignancy with history of BMT/SCT
11608790|NCT00581646||3|non-cancer infertile women awaiting third party reproduction
11608791|NCT00581633|Experimental|1|saline infusion for sodium loading
11608798|NCT00581594|Other|1|Posterior repair with graft augmentation.
11608799|NCT00581594|Other|2|Posterior repair without graft augmentation.
11608800|NCT00581581||1|Randomized to cooling (original randomized clinical trial): All children, now 6-8 years old who were randomized to cooling in the original trial were included in this arm. Cooling was achieved via the CoolCap system (Olympic Medical/Natus Corporation) in these babies.
11608801|NCT00581581||2|Randomized to standard care (original randomized clinical trial): All children, now 6-8 years old, who were treated using the standard of care at the time (normal temperature) were included in this arm. Infants' temperatures were monitored per standard of care. Most infants were cared for on an open wamer that was servo-controlled to normal body temperature (37 C) or in a standard bassinette.
11608802|NCT00581568|Experimental|Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
11608803|NCT00581555|Experimental|etanercept|Participants were administered a 50 mg dose of etanercept subcutaneously once a week after an initial course of ciclosporin.
11608804|NCT00581555|Placebo Comparator|placebo|Participants were administered placebo subcutaneously once a week after an initial course of ciclosporin.
11608805|NCT00581542|Active Comparator|Moxifloxacin Opthalmic solution|
11608806|NCT00581542|Active Comparator|Polymyxin B-trimethoprim opthalmic solution|
11608807|NCT00581529|Experimental|Radiotherapy|IMRT (Intensity-modulated Radiation Therapy), 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
11608808|NCT00581503||diagnostic|oct imaging
11608809|NCT00581490||Idiopathic premature pubarche|Children with premature pubarche without precious puberty, adrenal hyperplasia or androgen secreting tumors
11608810|NCT00581477|Placebo Comparator|2|
11608811|NCT00581477|Experimental|1|
11608812|NCT00581464|Active Comparator|1|
11608813|NCT00581464|Active Comparator|2|
11608814|NCT00581451|Experimental|A|bifeprunox 25 day
11608815|NCT00581451|Experimental|B|bifeprunox 14 day
11608816|NCT00581451|Experimental|C|bifeprunox 14 day
11608817|NCT00581451|Experimental|D|bifeprunox 9 day
11608818|NCT00581438||1|
11608819|NCT00581425|Experimental|Treated|
11608820|NCT00581399|Experimental|NO-NUMO Chest Tube|The NO-NUMO™ High Vacuum Body Cavity Drainage System consist of disposable NO-NUMO™ body cavity drainage tubes, disposable Vario™ fluid management canisters Vario™ portable vacuum pump
11608821|NCT00581399|Active Comparator|Standard Chest Tube|Classic PVC Chest Tube
11608822|NCT00581386|Experimental|LTS-D|All the cases were divided into one of the group LTS-D, PLMA, and ETC
11608823|NCT00581386|Experimental|ProSeal Laryngeal Mask Airway|All patients were divided into either LTS-D, PLMA, or the ETC group.
11608824|NCT00581386|Experimental|Esophageal Tracheal Combitube (ETC)|All patients are divided into one of the group, LTS-D, PLMA, or the ETC.
11608825|NCT00581373|Experimental|1|water 16 oz
11608826|NCT00581360|Other|Bortezomib + Doxorubicin|Patients with incurable adenoid cystic carcinoma of the head and neck who receive doxorubicin and bortezomib
11608827|NCT00581347|Other|Outreach|Receives outreach services
11608828|NCT00581347|No Intervention|Standard of Care|Receives standard medical care provided by primary care practice.
11608829|NCT00581321|Experimental|1|water ingestion
11608830|NCT00581308|Experimental|GORE® HELEX® Septal Occluder|Subjects who received a GORE® HELEX® Septal Occluder
11608831|NCT00581295||trauma|Diffuse optical spectroscopy measurment
11608832|NCT00581282||1|Cocaine abstinent group
11608833|NCT00581282||2|Normal healthy control group
11608834|NCT00581269|Active Comparator|1|low-impact aerobic exercise group
11608835|NCT00581269|Active Comparator|2|dietary restriction group
11608836|NCT00581269|No Intervention|3|control group
11608837|NCT00581256|Experimental|1|Best Delivery-optimized radiotherapy technique (IMRT)
11608838|NCT00581256|Active Comparator|2|Best 3-dimensional standard PWTF technique
11608839|NCT00581243|Experimental|1|2 mg SLV-313 SR (fixed dose)
11608840|NCT00581243|Experimental|2|5 mg SLV-313 SR (fixed dose)
11608841|NCT00581243|Experimental|3|10 mg SLV-313 SR (fixed dose)
11608842|NCT00581243|Experimental|4|xx mg SLV-313 SR (titration)
11608843|NCT00581230|Experimental|Laryngoscopy without RAMP|First, laryngoscopy will be preformed utilizing a traditional Macintosh size 4 blade laryngoscope. The view of the laryngeal aperture will be recorded, and a photo will be taken by the Airway Cam™.
11608844|NCT00581230|Experimental|Laryngoscopy with RAMP|Next, the Rapid Airway Management Positioner (RAMP) will be positioned and inflated underneath the patient so that the patient is placed in the optimal sniffing position. The investigator will again perform laryngoscopy utilizing the same technique and the laryngeal view will be recorded.
11608845|NCT00581217||Single arm study|Burn patients or patients with skin loss requiring split-thickness skin graft
11608846|NCT00581204||Diagnostic Tool|Near-Infrared Diffuse Optical Spectroscopy Imaging
11608847|NCT00581191|Experimental|1|0.5 mg SLV-351 (fasted)
11608848|NCT00581191|Experimental|2|1 mg SLV-351 (fasted)
11608849|NCT00581191|Experimental|3|2.5 mg SLV-351 (fasted)
11608850|NCT00581191|Experimental|4|5 mg SLV-351 (fasted)
11608851|NCT00581191|Experimental|5|10 mg SLV-351 (fasted)
11608852|NCT00581191|Experimental|6|15 mg SLV-351 (fasted)
11608853|NCT00581191|Experimental|7|20 mg SLV-351 (fasted)
11608854|NCT00581191|Experimental|8|30 mg SLV-351 (fasted)
11608855|NCT00581191|Experimental|9|xx mg SLV-351 (fasted and fed)
11608856|NCT00581139|Active Comparator|1|
11608857|NCT00581139|Active Comparator|2|
11608858|NCT00581139|Active Comparator|3|
11608859|NCT00581139|Active Comparator|4|
11608860|NCT00581126|Experimental|1|Patients will receive Benefix IV according to blood amount
11608861|NCT00581113|Active Comparator|1|Standard Whole Brain Radiotherapy
11608862|NCT00581113|Experimental|2|Neural Stem Cell-Preserving Whole Brain Radiotherapy
11608863|NCT00581100|Active Comparator|1|etanercept 50 mg SC injection twice weekly for 12 weeks reducing to etanercept 50 mg once weekly to week 24
11608864|NCT00581100|Active Comparator|2|etanercept 50 mg SC once weekly for the complete 24 week treatment period
11608866|NCT00581087|Placebo Comparator|2|Placebo
11608867|NCT00581074|Active Comparator|G|grapefruit
11608868|NCT00581074|Active Comparator|J|Juice
11608869|NCT00581074|Placebo Comparator|W|placebo
11608870|NCT00581061|Experimental|Vesicare Treatment|
11608871|NCT00581048|Experimental|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
11608872|NCT00581035|Experimental|1|Prevenar and Meningitec
11608873|NCT00581035|Experimental|2|Prevenar
11608874|NCT00581035|Experimental|3|Meningitec
11608875|NCT00581022||1|Patients with Chronic Orthostatic Intolerance
11608876|NCT00581009|Experimental|1|chronobiological augmentation group
11608877|NCT00581009|Experimental|2|medication only group
11608878|NCT00581009|Experimental|MDD Mechanism|
11608879|NCT00580996|Experimental|1|16 oz water in AM
11608880|NCT00580996|Active Comparator|2|water 1 oz in AM
11608881|NCT00580983|Experimental|Chemo-IMRT|"Chemotherapy:
~Chemotherapy will consist of Paclitaxel 30mg/m² IV over 1 hour, followed by Carboplatin (AUC 1) IV over 30 minutes, or Carboplatin 100mg/m² per IV over 30 minutes or Cisplatin 100mg/m² per IV over 1 hour, or Cisplatin (80mg/m²) or Carboplatin (AUC 5) IV on day 1 and 5-Fluorouracil (1000mg/m²) as a 24-hour continuous infusion, daily x 4 days.
~Intensity-modulated Radiation Therapy (IMRT):
~Primary RT: 70 Gy to gross disease and 56-63 Gy to subclinical disease in 35 fractions.
~Post-operative RT: 64 Gy to high-risk targets (postoperative tumor bed, first-echelon nodes) and 57.6 Gy to low-risk targets, in 32 fractions."
11608882|NCT00580970|Experimental|Lovastatin for 1 yr|Lovastatin (20-80 mg/d) was started on day 1 of radiation and continued for 12 months. Patients were followed for an additional 12 months. Lovastatin once per day for 1 year. After the implant, they are asked to return for checkups (study visits 4-13) 4 weeks, 8 weeks, 4 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months and 24 months after the procedure. At 8 weeks, 4 months, 6 months, 9 months and 12 months, will also have a blood test to check their liver.
11608883|NCT00580957|Experimental|Blocked|Active treatment arm. Transient autonomic blockade with Trimethaphan and blood pressure restoration with L-NMMA will be used during insulin clamp
11608884|NCT00580957|Placebo Comparator|Intact|Saline will be used instead of trimethaphan during insulin clamp
11608885|NCT00580944|Experimental|Port Wien Stain Birthmark|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
11608886|NCT00580931|Experimental|1|Subjects will receive experimental drug in a blinded fashion.
11608887|NCT00580931|Placebo Comparator|2|Identical in size, shape and color to experimental drug.
11608888|NCT00580918||1|Mild Traumatic Brain Injury group
11608889|NCT00580918||2|Normal healthy control group
11608890|NCT00580905|Active Comparator|1|To compare the effects of adenosine at a dose of 80 mcg/kg/min for 30 minutes, Sodium nitroprusside will be used at a dose that produce similar systemic effects (5 mcg/kg/.min)
11608891|NCT00580905|Active Comparator|2|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.
~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
11608892|NCT00580892||Airway and Pleural Disorders|Optical Coherence Tomography imaging
11608893|NCT00580866|Experimental|Joint Active Systems Brace (JAS Brace)|Elbow is placed in a brace to apply an extension force
11608894|NCT00580866|No Intervention|PT Only Group|No brace is used
11608895|NCT00580853|Experimental|varenicline|varenicline 2mg/day
11608896|NCT00580853|Experimental|Bupropion|Bupropion 300mg/day
11608897|NCT00580853|Placebo Comparator|Placebo|Placebo Control
11608898|NCT00580840|Active Comparator|Certolizumab pegol 400 mg and placebo|400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
11608899|NCT00580840|Experimental|Certolizumab pegol 200 mg and placebo|200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
11608900|NCT00580840|Placebo Comparator|Placebo|Placebo administered as two injections every 2 weeks
11608901|NCT00580827|Placebo Comparator|placebo disulfiram|placebo disulfiram (0 mg/day)
11608902|NCT00580827|Experimental|disulfiram 62.5|disulfiram at 62.5 mg/day
11608903|NCT00580827|Experimental|disulfiram 125|disulfiram at 125 mg/day
11608904|NCT00580827|Experimental|disulfiram 250|disulfiram at 250 mg/day
11608905|NCT00580801|Experimental|Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin|Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 2 to 50.
11608906|NCT00580801|Experimental|Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin|Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily), from Week 1 to 48.
11608907|NCT00580801|Active Comparator|Placebo+Pegylated-interferon-alfa-2a+Ribavirin|Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks along with pegylated-interferon-alfa 2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily), from Week 1 to 48.
11608908|NCT00580788|Experimental|PTHrP(1-36) 2 pmol/kg/hr|PTHrP(1-36) at 2 picomoles/kg/hr for one week.
11608909|NCT00580788|Experimental|PTHrP (1-36) 4 pmol/kg/hr|PTHrP(1-36) at 4 picomoles/kg/hr for one week.
11608910|NCT00580788|Experimental|PTHrP(1-36) 5 pmol/kg/hr|PTHrP(1-36) at 5 picomoles/kg/hr for one week.
11608911|NCT00580788|Experimental|PTHrP(1-36) 6 pmol/kg/hr|PTHrP(1-36) at 6 picomoles/kg/hr for one week.
11608912|NCT00580775||Placebo|Observing heart rate variability in placebo and active estrogen preparations
11608955|NCT00580489|Active Comparator|D|either fentanyl or morphine
11608913|NCT00580775||Active estogen|Observing heart rate variability in placebo and active estrogen preparations
11608914|NCT00580762|Experimental|ESRD|End-Stage Renal Disease (ESRD) patients on dialysis who meet the NIH guidelines and preoperative requirements for RYGB will undergo laparoscopic RYGB
11608915|NCT00580762|Active Comparator|Non-ESRD|Non-ESRD patients who meet the NIH guidelines and preoperative requirements for RYGB will undergo laparoscopic RYGB
11608916|NCT00580749|Active Comparator|DJ|Naso disal jejunal(DJ) feedings randomized to 50% of subjects meeting criteria.
11608917|NCT00580749|Active Comparator|NG|Placement of naso gastric feeding tube through nare into stomach for enteral feeding.
11608918|NCT00580736|Experimental|Optical Clearing|Optical Clearing
11608919|NCT00580723|Experimental|PRK 124|Topical PRK 124 (Pyratine-6)(0.125%) moisturizing lotion applied twice daily to the face for 48 weeks. Subjects will wash their faces prior to application. The applications will occur in the mornings and one hour before bedtime.
11608920|NCT00580710||conventionally treated|conventionally treated, relatively poorly controlled patients with type 1 diabetes
11608921|NCT00580710||intensively treated|intensively treated, well controlled patients with type 1 diabetes
11608922|NCT00580710||lean healthy|age- and sex- matched non-diabetic, normal weight (BMI > or = 18.5 but < or = 25 kg/m2) control subjects
11608923|NCT00580710||obese subjects|obese individuals defined as BMI > or = 30kg/m2
11608924|NCT00580710||type 2 diabetics|Type 2 diabetics on diet only or diet and Metformin
11608925|NCT00580710||type 1 diabetes unaware|Type 1 diabetics unaware of hypoglycemic symptoms
11608926|NCT00580710||type 1 diabetes aware|Type 1 diabetics aware of hypoglycemic symptoms
11608927|NCT00580684|Active Comparator|G1|G1: prevenar
11608928|NCT00580684|Active Comparator|G2|G2: pneumo 23
11608929|NCT00580671|Experimental|MET/CBT+CM/BPT|Integrated psychosocial counseling. 14 weekly session. Twice weekly urine testing. Abstinence-based incentives based on urine test results. 14 weekly behavioral parenting sessions.
11608930|NCT00580671|Experimental|MET/CBT+CM|Integrated psychosocial counseling. 14 weekly sessions. Twice weekly urine testing. Abstinence-based incentives based on urine test results.
11608931|NCT00580671|Active Comparator|MET/CBT|Integrated psychosocial counseling. 14 weekly sessions.
11608932|NCT00580645|Experimental|varenicline|varenicline 1mg/day or 2mg/day
11608933|NCT00580645|Placebo Comparator|Placebo|Placebo Controlled
11608934|NCT00580619|Experimental|1 (markers of sympathetic activity)|To evaluate if the various indices of sympathetic activity (Autonomic Function Testing) differ between patients with chronic fatigue syndrome and postural tachycardia syndrome (CFS-P), and CFS without POTS.
11608935|NCT00580619|Experimental|2 (saline)|To test the null hypothesis that there is no difference between two saline therapies (pulse saline vs. sham saline) in improving both the fatigue score and postural tachycardia syndrome.Saline infusions
11608936|NCT00580619|Experimental|3 (NO inhibition/ autonomic blockade)|Response to nitric oxide inhibition in the presence and absence of an intact autonomic nervous system will be evaluated. L-NMMA trimethaphan will be used for NO inhibition and autonomic blockade, respectively.
11608937|NCT00580619|Active Comparator|4 (methyldopa)|The effects of chronic autonomic withdrawal on improving symptoms of chronic fatigue and postural tachycardia syndrome will be evaluated
11608938|NCT00580606|Experimental|Low Dose Peanut SLIT (Double Blind to Open Label)|Subjects ingest peanut protein (glycerinated peanut allergenic extract) daily starting with 0.000165 mcg, followed by a build-up phase (escalating peanut doses every 2 weeks, achieving maintenance dose by 36 weeks). Thereafter, subjects are on a maximally tolerated maintenance dose (165 mcg to 1,386 mcg) for >= 8 weeks. After Week 44, subjects are given a 5,000 mg Oral Food Challenge (OFC) using peanut powder. Subjects/study staff are unblinded following this OFC and continue on an open label peanut protein maintenance dose of 1,386 mcg/day or may attempt escalation up to this dose. Subjects who at the Week 116 OFC are unable to consume >= 5,000 mg peanut powder or 10-fold the amount of peanut powder compared to the baseline OFC will discontinue study therapy. SLIT=Sublingual Immunotherapy.
11608939|NCT00580606|Placebo Comparator|Placebo (DB) Crossed Over to High Dose Peanut SLIT (OL)|Subjects ingest placebo (glycerin) daily beginning with a dose of 0.000165 mcg, followed by a build-up phase (escalating placebo doses every 2 weeks, achieving a maintenance dose by 36 weeks). Thereafter, subjects are on a maximally tolerated maintenance dose (165 mcg to 1,386 mcg) for >= 8 weeks. After Week 44, subjects are given a 5,000 mg Oral Food Challenge (OFC) using peanut powder. Subjects/study staff are unblinded following this OFC and subjects no longer receive placebo dosing but are crossed over and receive open label high dose peanut SLIT; the study procedures and schedule are the same as for the Low Dose Peanut SLIT group, the only difference is the maximum maintenance dose is almost 3-fold higher at 3,696 mcg/day. DB=Double Blind, SLIT=Sublingual Immunotherapy, OL=Open Label.
11608940|NCT00580593|Active Comparator|1|
11608941|NCT00580593|Sham Comparator|2|
11608942|NCT00580580|Active Comparator|1|"Administration of Optison (0.1-0.4 mL) intravenously followed by Contrast Pulse Sequencing to image both the coronary and carotid arteries.
~Use will depend on availability of the contrast for the given study Optison will not be used on patients with blood allergies or Jehovah Witnesses"
11608943|NCT00580580|Active Comparator|2|Intravenous injection of Definity (0.05-0.20 mL) followed by Contrast Pulse Sequencing to image both coronary and carotid arteries
11608944|NCT00580580|Active Comparator|3|intravenous Injection of PESDA at a rate of 0.05-0.20 mL followed by image of coronary and carotid arteries PESDA will be used exclusively in patients who are eligible for other IRB studies
11608945|NCT00580567||1|Pathological Gamblers
11608946|NCT00580567||2|Non-Pathological Gamblers
11608947|NCT00580528|Experimental|1|
11608948|NCT00580528|Experimental|2|
11608949|NCT00580528|No Intervention|3|
11608950|NCT00580515|Experimental|1|6 sessions of Family Focused Group Therapy
11608951|NCT00580515|Experimental|2|10 Sessions of Family Focused Group Therapy
11608952|NCT00580515|Active Comparator|3|Standard Care- Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request
11608953|NCT00580502|Experimental|LAGB for low BMI patients|the LAP-BAND® Adjustable Gastric Band (LAGB®) for patients with BMI between 30-40 kg/m2 with co-morbidities
11608954|NCT00580489|Active Comparator|C|either fentanyl or morphine
11616516|NCT00518921|Experimental|Arm 3|
11608956|NCT00580476||1|150 patients will be women with breast cancer (75 early stage and 75 late stage)
11608957|NCT00580476||2|150 will be men with prostate cancer (75 early stage and 75 late stage)
11608958|NCT00580450|No Intervention|2|
11608959|NCT00580450|Experimental|1|
11608960|NCT00580437|Experimental|Arm 1|stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
11608961|NCT00580411||Alcohol Problem First|Alcohol Problem precedes Insomnia
11608962|NCT00580411||Insomnia First|Insomnia Precedes Alcohol Problem
11608963|NCT00580398|No Intervention|Control|Usual care included physician advice to quit smoking.
11608964|NCT00580398|Experimental|Intervention|Intervention participants were provided with a cognitive-behavioral 12-week program consisting of varenicline (1mg bid, with initial titration up over week 1) and smoking cessation counseling targeted to the issues of thoracic cancer patients. We offered 7 counseling sessions but were flexible in offering additional counseling when needed. Counseling was delivered by a certified Tobacco Treatment Counselor using Motivational Interviewing (MI) techniques.
11608965|NCT00580385|Experimental|1|
11608966|NCT00580372|Experimental|Study Treatment|Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.
11608967|NCT00580359|Active Comparator|A|S-1 40mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
11608968|NCT00580359|Active Comparator|B|Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
11608969|NCT00580346|Experimental|2|
11608970|NCT00580333|Experimental|Cisplatin/Avastin|Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide , adjuvant (optional) paclitaxel, adjuvant (optional)
11608971|NCT00580320|Experimental|A|dacarbazine + bortezomib
11608972|NCT00580307|Placebo Comparator|Septoplasty|Septoplasty only
11608973|NCT00580307|Experimental|Septoplasty and correction|Septoplasty and endoscopic contact point correction
11608974|NCT00580294|Experimental|oxymorphone|participants switched to oxymorphone extended release (ER) via both oral and intravenous patient-controlled analgesia (IV-PCA) oxymorphone. After 24 hours, participants were discharged with oral oxymorphone ER and oxymorphone immediate release (IR) as needed
11608975|NCT00580281|Experimental|blood, urine, and dexa scan|This study will involve venipuncture for obtaining blood samples; a spot second void (whenever possible) urine sample will be obtained at the same time. A Dexa scan to evaluate bone density will be obtained at the beginning, middle and end of the study.
11608976|NCT00580268||H|Pregnant women with bipolar disorder
11608977|NCT00580242|Experimental|1|This is a Phase I dose escalation trial with three cohorts of 3-6 patients each plus 10 additional patients (up to a maximum total of 28 patients) treated at the candidate maximum tolerated dose.Cohorts will receive increasing doses of bortezomib at 0.7, 1, and 1.3 mg/m2 on days 1, 4, 8, and 11 in combination with lenalidomide at 10 mg a day for Days 1-21. Each cycle will be 28 days. Patients will receive up to 9 cycles of treatment, with efficacy assessed after 3, 6, and 9 cycles.
11608978|NCT00580229|Experimental|prednisone|Prednisone 40mg by mouth 30-60 minutes prior to rituximab.
11608979|NCT00580216|Experimental|Idrabiotaparinux|"Idrabiotaparinux sodium, 3.0 mg, once-weekly for 7 weeks followed a maintenance dosing adjusted according to the age and to the renal function for a minimum total treatment duration of 6 months.
~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or overdosage)."
11608980|NCT00580216|Active Comparator|Warfarin|Warfarin, INR-adjusted dose, for a minimum total treatment duration of 6 months.
11608981|NCT00580203||1|Patients with head and neck cancers
11608982|NCT00580190|Active Comparator|1|
11608983|NCT00580190|Placebo Comparator|2|
11608984|NCT00580190|Experimental|3|
11608985|NCT00580177|Active Comparator|L|The Lichtenstein procedure for repair of inguinal hernia (Single On-lay patch)
11608986|NCT00580177|Active Comparator|P|The well-konown PerFixPlug technique for inguinal hernia repair.
11608987|NCT00580177|Active Comparator|PHS|The well-known Prolene Hernia System method for inguinal hernia repair.
11608988|NCT00580164||1|Splint
11608989|NCT00580164||2|No Splint
11608990|NCT00580151|Experimental|1|
11608991|NCT00580151|Placebo Comparator|2|
11608992|NCT00580138||Stroke or Head & Neck Cancer|Any subject who has suffered a stroke or has some form of head & neck cancer (non-laryngectomee) may be enrolled.
11608993|NCT00580125|Experimental|A2|
11608994|NCT00580125|Placebo Comparator|A5|
11608995|NCT00580125|Active Comparator|A4|
11608996|NCT00580125|Experimental|A3|
11608997|NCT00580125|Experimental|A1|
11608998|NCT00580112|Experimental|Group A|Participants with triple negative phenotype: estrogen receptor, progesterone receptor and human estrogen receptor-2 (HER-2) negative status for breast cancer (abnormal tissue that grows and spreads in the body until it kills) will receive trabectedin 1.3 milligram per meter square (mg/m^2) intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over 3-hours (hrs) every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 milligram (mg) orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72hrs after the start of study drug infusion from Day 1 to 3.
11609042|NCT00579683||1|This is a protocol to study tissue specimens to identify changes in tumor DNA in NSCLC patients who have previously responded to therapy and who have subsequently experienced disease progression.
11609155|NCT00578760|Placebo Comparator|2|placebo OD during course of chemotherapy
11609156|NCT00578760|Experimental|1|325mg ASA OD during course of chemotherapy
11617231|NCT00512941||3|HBV: isolate anti-HBc
11608999|NCT00580112|Experimental|Group B|Participants with overexpressing HER-2 breast cancer will receive trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 milligram (mg) orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion from Day 1 to 3.
11609000|NCT00580112|Experimental|Group C|Participants with familial breast cancer gene 1 (BRCA1) or breast cancer gene 2 (BRCA2) mutation carriers cancer will receive trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 mg orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion from Day 1 to 3.
11609001|NCT00580099|Experimental|1|4 weeks of assisted exercise using passive range of motion on all major joints
11609002|NCT00580099|Active Comparator|2|cuddle for 20 minutes
11609003|NCT00580086||1|
11609004|NCT00580073|Experimental|1|FOLFOX4 + Cetuximab
11609005|NCT00580047|Active Comparator|1|Zoledronic Acid 4mg intravenously once a year for 2 years
11609006|NCT00580047|Active Comparator|2|Alendronate 70mg orally once a week for 2 years
11609007|NCT00580047|Placebo Comparator|3|Combination drug entity: calcium 1200 mg with vitamin D 800 International Units daily
11609008|NCT00580034|Experimental|Campath Purged Non-myeloablative ASCT|Campath Purged Non-myeloablative Allo Stem Cell Transplant (ASCT) in lymphoma, myeloma, or marrow failure: leukemia or myelodysplasia; and solid tumors
11609009|NCT00580034|Other|Donor Apheresis|"Donor must be a sibling, half sibling, parent, child or first cousin familial relationship and 3-5/6 Human Leukocyte Antigen matched related to subject. They must not have any medical condition which would make apheresis and G-CSF administration more than a minimal risk, and should have the following:
~Adequate cardiac function by history and physical examination
~bilirubin and hepatic transaminases < 2.5 x upper limit of normal
~normal hematologic parameters Females should have a negative serum pregnancy test."
11609010|NCT00580021||1|Patients with breast and pancreas cancer.
11609011|NCT00579995|No Intervention|1, oral N-Acetylcysteine|
11609012|NCT00579995|No Intervention|2, Intravenous Sodium Bicarbonate|
11609013|NCT00579982|Experimental|Arm 1|Lamictal orally disintegrating tablet (ODT)
11609014|NCT00579969|Experimental|1|prostaglandin analogue
11609015|NCT00579969|Experimental|2|prostaglandin analogue
11609016|NCT00579956|Experimental|Meropenem|Meropenem
11609017|NCT00579956|Active Comparator|Ceftazidime|Ceftazidime
11609018|NCT00579943||premature infants|Inpatient very low birth weight infants who are ventilated and have an umbilical arterial catheter in place
11609019|NCT00579917||1 Cognitive-behavioral therapy (CBT)|Cognitive-behavioral therapy (CBT) involves one-on-one counseling
11609020|NCT00579917||2 Usual Care|Usual Care
11609021|NCT00579904|Active Comparator|walnuts|Patients will be randomized to receive walnuts
11609022|NCT00579904|Active Comparator|almonds|Patients will be randomized to receive almonds
11609023|NCT00579878|Active Comparator|1 Leflunomide alone vs combination therapy|Group A: Leflunomide alone
11609024|NCT00579878|Active Comparator|Methotrexate-Sulfasalazine-Hydroxychloroquine|Methotrexate, Sulfasalazine, Hydroxychloroquine.
11609025|NCT00579878|Active Comparator|3|Leflunomide-Sulfasalazine-Hydroxychloroquine
11609026|NCT00579865||Group A|Patients scheduled for percutaneous drainage
11609027|NCT00579865||Group B|Patients scheduled for a surgical bypass or resection of a high bile duct tumor.
11609028|NCT00579852||1|Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day.
11609029|NCT00579839|Experimental|A|Delayed Cord Clamping
11609030|NCT00579839|Active Comparator|B|Immediate cord clamping
11609031|NCT00579826|Experimental|Letrozole|Letrozole, 2.5 mg daily for 6 months
11609032|NCT00579826|Placebo Comparator|Placebo|Placebo, daily for 6 months
11609033|NCT00579813|No Intervention|1|Baseline studies (OGTT, DXA, RMR, FSIGT, and biopsies) on normal control subjects. Oral glucose tolerance tests, body composition assessment, resting metabolic rate, insulin sensitivity measurement with the frequently sampled method and Minimal Model. These studies will establish baseline data in lean subjects on adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition. There is no intervention.
11609034|NCT00579813|Active Comparator|2|Baseline studies (OGTT, DXA, RMR, FSIGT, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment. All of the studies described in arm 1 are repeated after treatment. The subjects in this group have impaired glucose tolerance. After the measurement of adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition, subjects are treated with pioglitazone, working up to 45 mg/day, for 10 weeks. After this time, adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition are repeated.
11609035|NCT00579800|Experimental|women undergoing routine breast MRI|Conventional images will be taken using the standard sequences consisting of T2-weighted imaging and T1-weighted imaging before and after contrast; these will be used for the diagnostic examination. FIESTA will be performed on 50 patients, while Vibrant-DE and IDEAL will be performed on the other 50 patients.
11609036|NCT00579787||1|Women with early stage cervical cancer undergoing radical trachelectomy
11609037|NCT00579787||2|Women with early stage cervical cancer undergoing radical hysterectomy
11609038|NCT00579774|Experimental|1 - Low AGE Diet|Low Age Diet
11609039|NCT00579774|Active Comparator|2 - Regular Diet|Regular Diet
11609040|NCT00579748||1|
11609041|NCT00579709|Experimental|1|Thymus Tissue for Transplantation
11609204|NCT00578370|Active Comparator|4|
11609043|NCT00579657|Placebo Comparator|1|"Intervention: 'control diet, supported by dietary supplement twice daily'
~control diet [carbohydrates 55(50 - 60)% , protein 15(10 - 20)% protein; fat ca. 30% of energy content; dietary fiber < 15 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement daily)]"
11609044|NCT00579657|Experimental|2|"Intervention: 'high cereal fiber diet, supported by dietary supplement twice daily'.
~high cereal fiber diet [carbohydrates 55(50 - 60)% , protein 15(10 - 20)% protein; fat ca. 30% of energy content; dietary fiber > 20 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 15 g cereal fiber daily)]"
11609045|NCT00579657|Experimental|3|"Intervention: 'high protein diet, supported by dietary supplement twice daily'
~high protein diet [carbohydrates 40 - 45% , protein > 25 - 30%; fat ca. 30% of energy content; dietary fiber < 15 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 25 g whey and plant protein daily)]"
11609046|NCT00579657|Experimental|4|"Intervention: diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily.
~high cereal fiber/high protein (MIX) moderately high cereal fiber/high protein diet (carbohydrates 45- 50)% , protein 20 - 25%; fat ca. 30% of energy content; dietary fiber 15 - 20 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 15 g cereal fiber and 2 x 25 g whey and plant protein daily)"
11609047|NCT00579644|Active Comparator|1 Methotrexate* & minocycline|"Methotrexate Dosing:
~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.
~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.
~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg"
11609048|NCT00579644|Active Comparator|2|"Methotrexate Dosing:
~Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.
~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.
~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.
~6, 8 and 10 month evaluations:
~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.
~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month
~12 month evaluation: End of the blinded portion of the study."
11609049|NCT00579631||1|Questionnaire or Interview
11609050|NCT00579605|Experimental|1|1 intervention group 1 attention intervention group Behavioral: Motivational Interviewing Client-centered strategy that may decrease ambivalence in behavior performance
11609051|NCT00579592|Experimental|1|Campath, Rituximab, Myfortic, and 10-20 days of cyclosporine
11609052|NCT00579579||1|Patients Undergoing Surgery for Rectal Cancer
11609053|NCT00579566||1|Sarcoma patients undergoing core biopsy, incisional biopsy or definitive surgical resection for soft tissue masses of extremity, trunk or retroperitoneum
11609054|NCT00579553|Active Comparator|A|Intramuscular Progesterone
11609055|NCT00579553|Experimental|B|Vaginal Progesterone
11609056|NCT00579540|Active Comparator|1|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
11609057|NCT00579540|Active Comparator|2|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
11609058|NCT00579540|Active Comparator|3|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
11609059|NCT00579527|Experimental|Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression|Patients with complete DiGeorge Anomaly (cDGA) undergo cultured thymus tissue implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function.
11609060|NCT00579527|Experimental|CTTI with Parathyroid Transplantation w/immunosuppression|Patients with complete DiGeorge Anomaly (cDGA) undergoes cultured thymus tissue thymus implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function. If the patient has hypoparathyroidism, and is eligible, the patient may also receive a parathyroid transplant.
11609061|NCT00579514|Active Comparator|1|"All incident second primary cancers of colon, breast, bladder, kidney, prostate, ovarian cancer lung cancer and lymphoid cancer diagnosed between 1999 and present will be included in the secondary design to compare second primary cancer cases and first primary controls."
11609062|NCT00579514|Placebo Comparator|2|Controls will be volunteer blood donors from the New York Blood Center as well as normal volunteers from other AMDeC sites.
11609063|NCT00579501|Experimental|Trabectedin|Trabectedin at a dose of 1.5 milligram per meter square (mg/m^2) will be given as an intravenous (iv) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 24-hour every 3 weeks for a minimum of 3 and a maximum of 6 cycles prior to definitive surgery. Dexamethasone 20 mg iv will also be administered within 30 minutes before start of each trabectedin infusion.
11609064|NCT00579475|Placebo Comparator|Placebo|
11609065|NCT00579475|Active Comparator|I|Mifepristone (Mifegyne) 50 mg every other day for 3 months
11609066|NCT00579462||1|Patients with advanced lung cancer.
11609067|NCT00579449|Active Comparator|HF 36|For those randomly assigned to the 3-year HFD group, services begin during the third trimester of pregnancy. These families are assigned a Family Support Worker, who begins to initiate contact with the family at approximately 6 months gestation, when possible, so that the family can be engaged and services begun at seven months gestation. The Family Support Worker will provide home visiting services according the existing HFD model, which combines the empirically supported Parents as Teachers Curriculum (see attached description of the Parents as Teachers curriculum) provided in accordance with Healthy Families America standards of service delivery. The 3-year HFD group will receive services to the child's third birthday.
11609107|NCT00579098|Active Comparator|Atorvastatin|Lipitor (atorvastatin) 80 mg tablet taken once daily by mouth for 90 days
11609108|NCT00579098|Placebo Comparator|Placebo|Placebo (dummy) tablet taken once daily by mouth for 90 days
11609068|NCT00579449|Active Comparator|HF 18|For those randomly assigned to the 18-month HFD group, services begin during the third trimester of pregnancy. These families are assigned a Family Support Worker, who begins to initiate contact with the family at approximately 6 months gestation, so that the family can be engaged and services begun at seven months gestation. The Family Support Worker will provide home visiting services according the existing HFD model, which combines the empirically supported Parents as Teachers Curriculum (see attached description of the Parents as Teachers curriculum) provided in accordance with Healthy Families America standards of service delivery. Services for this group are terminated when the child is 18 months old, with clinically necessary referrals made for ongoing psychosocial and health needs.
11609069|NCT00579449|Active Comparator|YC|For those assigned to the Yearly Checkup group, a clinically-trained member of the HFD team will make yearly home visits to conduct the evaluation assessment. Information about community services and assistance with referrals are provided based on needs identified.
11609070|NCT00579449|No Intervention|MCC|Women placed in the community services as usual (Maternity Care Coordination only) group will receive no additional services or assessments as a part of this study.
11609071|NCT00579436|Active Comparator|Fish oil group|4g Lovaza (omega-3 fatty acid) daily.
11609072|NCT00579436|Placebo Comparator|Control group|placebo (4 non-active capsules daily)
11609073|NCT00579423|Experimental|vaccine|Patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administrated at the standard dose of 100ug.
11609074|NCT00579410||A|Patients with Barrett's Esophagus
11609075|NCT00579410||B|Patients with reflux symptoms but no Barrett's Esophagus
11609076|NCT00579410||C|Patients without reflux symptoms and a normal endoscopy
11609077|NCT00579397||1|"For Objective #1:
~Healthy adult volunteers"
11609078|NCT00579397||2|"For Objectives #2 & #3:
~Recipients undergoing an allogeneic stem cell transplant"
11609079|NCT00579384|Experimental|001|
11609080|NCT00579371|Experimental|1|
11609081|NCT00579345|Experimental|cTIV|Cell culture derived seasonal trivalent influenza vaccine (cTIV)
11609082|NCT00579345|Active Comparator|eTIV_a|Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)
11609083|NCT00579345|Experimental|FLU (cTIV or eTIV_a)|Cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
11609084|NCT00579345|Active Comparator|FLU (cTIV or eTIV_a) + PV|23-valent Pneumococcal vaccine (PV) concomitantly administered with cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
11609085|NCT00579332|Placebo Comparator|1|one a day placebo
11609086|NCT00579332|Experimental|2|Brassica intake
11609087|NCT00579332|Experimental|3|indole-3-carbinol supplement
11609088|NCT00579306||SPS3 patient cohort|All SPS3 patients who participate in Baseline and 1-Year F/U blood draw
11609089|NCT00579280|Active Comparator|Quetiapine SR|Quetiapine SR (Quetiapine Sustained Release)
11609090|NCT00579280|Active Comparator|Divalproex Sodium ER|Divalproex Sodium ER (Divalproex Sodium Extended Release)
11609091|NCT00579280|Placebo Comparator|Placebo|placebo
11609092|NCT00579241|Experimental|1|Transcranial imaging using Doppler ultrasound
11609093|NCT00579228||1|Normal controls both men and women
11609094|NCT00579228||2|Individuals with type 2 Diabetes with good control
11609095|NCT00579228||3|Individuals with type 1 diabetes with good control
11609096|NCT00579215|Experimental|1|Enhance Care (EC) will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits.
11609097|NCT00579215|Other|2|As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
11609098|NCT00579189|Experimental|Moxidex|Moxidex otic solution
11609099|NCT00579189|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
11609100|NCT00579150||Exenatide|Exposure to any form of exenatide during pregnancy for treatment of type 2 diabetes. Patients also taking Insulin may be included, though only as part of a combination treatment.
11609101|NCT00579150||Non-exenatide group|Exposure to non-insulin antidiabetic medication not including exenatide for treatment of pre-existing type 2 diabetes during pregnancy. Patients also taking Insulin may be included, though only as part of a combination treatment.
11609102|NCT00579137|Experimental|Participants With SCID or Primary Immunodeficiency Disorder|all patient will receive an allogeneic transplant with the following conditioning regimen Campath -1H, Fludarabine, Anti-CD45
11609103|NCT00579124|Other|1. CliniMACS CD3+/CD19+ depletion|"6/6 or 8/8 matched (fully matched)
~1 antigen or allele mismatched (mismatch at A or B or DRB1)
~2 antigen or allele mismatched (mismatch ONLY at A and B but NOT at DRB1 plus either A or B).
~Patients will receive grafts that have undergone CD3+ and CD19+ depletion. The CD3(-) fraction will be infused."
11609104|NCT00579124|Other|2. CliniMACS CD3+/CD19+ depletion|"Stratum 2. CliniMACS CD3+/CD19+ depletion:
~Haploidentical match
~2 antigen and/or allele mismatched where one of the mismatches includes DRB1
~For patients in Stratum 2 we will perform CD3+ (T cell) and CD19+ (B cell) depletion. There will be no T cell add back in this stratum."
11609105|NCT00579111|Experimental|HLA-identical sibling transplant|Recipients of HLA identical sibling stem cell transplants
11609106|NCT00579111|Experimental|Unrelated Matched or Single Antigen Mismatched transplant|Recipients of unrelated matched or single antigen mismatched donor stem cell transplant or single antigen mismatched family donor stem cell transplants
11609110|NCT00579085|Experimental|2|"INFUSION PLAN:
~All patients will be infused intravenously with 100 ml of normal saline with or without ketamine for four hours (25 ml/hr) daily for 10 days. The maximum intravenous ketamine infusion dose for this study will be 0.35 mg/kg/hr, not to exceed 25 mg/hr (100 mg of ketamine over a 4 hour period). On the first day, the intravenous ketamine infusion will be set to 50% of the maximum rate. On the second day, the intravenous ketamine infusion will be increased to 75% of the maximum rate. On the third day, the intravenous ketamine infusion will be increased to the maximum rate. The daily ketamine infusion rate is maintained at this level for the duration of the ten day study."
11609111|NCT00579072||Longitudinal Study|Take part in this study because subject has prostate cancer and are over 64 years old. To run this study,need men from two groups. First, we need men who are about to start hormone treatment. Second, we need men who do not plan to use this treatment in the future. We will use this second group as a control group and compare this group to the men who are using this treatment.
11609112|NCT00579072||Group Comparison|Take part in this study because subject has prostate cancer and are over 64 years old. Also, because subject has been on hormone therapy for about two to three years.
11609113|NCT00579059|Other|1|Maxim® Pop-Top® Tibia
11609114|NCT00579059|Other|2|Maxim® Regular Tibia
11609115|NCT00579046|Experimental|1|
11609116|NCT00579033|Sham Comparator|1|
11609117|NCT00579033|Active Comparator|2|
11609118|NCT00579020|Experimental|Moxidex|Moxifloxacin/dexamethasone phosphate ophthalmic solution, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
11609119|NCT00579020|Active Comparator|Moxifloxacin|Moxifloxacin ophthalmic solution 0.5%, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
11609120|NCT00579020|Active Comparator|Dexamethasone|Dexamethasone phosphate solution, 0.1%, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
11609121|NCT00579007||1|Women with a strong family history of breast cancer.
11609122|NCT00578994||Oxford® Meniscal Unicompartmental Knee|Patients with PKA using the Oxford® Meniscal Unicompartmental Knee System
11609123|NCT00578981|Experimental|Arm 1|
11609124|NCT00578981|No Intervention|Arm 2|
11609125|NCT00578968|Experimental|Tiotropium|Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of 18 mcg tiotropium powder.
11609126|NCT00578968|Placebo Comparator|Placebo|Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose.
11609127|NCT00578968|No Intervention|Healthy Controls|Healthy age and gender matched controls were recruited for comparing cardiovascular responses to participants with chronic obstructive pulmonary disease prior to the intervention.
11609128|NCT00578955|Experimental|1|
11609129|NCT00578955|Active Comparator|2|
11609130|NCT00578955|Active Comparator|3|
11609131|NCT00578942|Experimental|Campath Purged Non-myeloablative ASCT|Campath Purged Non-myeloablative Allo Stem Cell Transplant (ASCT) in lymphoma, myeloma, or marrow failure: leukemia or myelodysplasia; and solid tumors
11609132|NCT00578929|Experimental|Olopatadine 0.6% 1 Spray|Olopatadine HCl 0.6% 1 spray per nostril twice daily
11609133|NCT00578929|Placebo Comparator|Vehicle 1 spray|Vehicle 1 spray per nostril twice daily
11609134|NCT00578929|Experimental|Olopatadine 0.6% 2 sprays|Olopatadine HCl 0.6% 2 sprays per nostril twice daily
11609135|NCT00578929|Placebo Comparator|Vehicle 2 sprays|Vehicle 2 sprays per nostril twice daily
11609136|NCT00578916|Experimental|1|
11609137|NCT00578903|Experimental|Patients|"Patients with a diagnosis of severe aplastic anemia who require an allogeneic stem cell transplant but lack an Human Leukocyte Antigen (HLA) identical family member.
~Cytoxan, Campath, TBI-Total Body Irradiation, FK-506, Methotrexate, Stem Cell Infusion"
11609138|NCT00578890|Experimental|1|
11609139|NCT00578877|Active Comparator|Arm 1|Gynol II (2% N-9 gel)
11609140|NCT00578877|Experimental|Arm 2|Buffer Gel
11609141|NCT00578864|Experimental|Protracted Oral Etoposide|"Protracted oral etoposide for cycles 1, 2 and 4 of induction. Etoposide will be given in combination with IV cisplatin (a standard of care agent). If a subject does not respond after cycle 2, cycle 4 will be bolus etoposide in combination with IV cisplatin.
~All patients will receive Adriamycin and cyclophosphamide for cycle 3 and 5 as a standard of care."
11609142|NCT00578864|Active Comparator|IV Bolus Etoposide|"IV bolus etoposide in combination with IV cisplatin will be given for cycles 1,2, and 4 of induction chemotherapy for patients who are not eligible for the experimental arm (e.g.require emergent treatment)
~All patients will receive Adriamycin and cyclophosphamide for cycle 3 and 5 as a standard of care."
11609143|NCT00578851||C2a Taper recipients|Patients who receive a THA with the C2a - Taper™ Acetabular System
11609144|NCT00578838||1|25 patients with metastatic colorectal cancer. Each patient will have 4 MR exams: prior to or within one week of the start of the chemotherapy regimen, one after 6 weeks of chemotherapy, a third after completion of chemotherapy (between 12 and 24 weeks post-initiation of chemotherapy) and a long term followup study at least 4 months after the completion of chemotherapy.
11609145|NCT00578838||2|25 patients with non-metastatic colorectal cancer. Each patient will have 4 MR exams: prior to or within one week of the start of the chemotherapy regimen, one after 6 weeks of chemotherapy, a third after completion of chemotherapy (between 12 and 24 weeks post-initiation of chemotherapy) and a long term followup study at least 4 months after the completion of chemotherapy.
11609146|NCT00578838||3|11 healthy volunteers, who will also undergo two scans 2-3 weeks apart.
11609147|NCT00578812|Experimental|PCM Cervical Disc - Investigational|PCM Cervical Disc replacement at one level from C3 to T1
11609148|NCT00578812|Active Comparator|ACDF - Control Group|Anterior cervical discectomy and fusion (ACDF) at one level from C3 to T1
11609149|NCT00578799|Active Comparator|Kyo-Dophilus|Kyo-Dophilus (5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening)
11609150|NCT00578799|Placebo Comparator|Placebo|placebo capsules (potato starch)
11609151|NCT00578786|Experimental|Ambrisentan|2.5, 5 or 10 mg ambrisentan
11609152|NCT00578773|Experimental|Moxidex|Moxidex otic solution
11609153|NCT00578773|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
11609154|NCT00578773|Other|TT only|Tympanostomy tubes only
11609157|NCT00578734|Experimental|Lucinactant|SURFAXIN® (lucinactant) for intratracheal instillation
11609158|NCT00578734|Sham Comparator|Sham Air|Sham air (placebo) instillation
11609159|NCT00578721|Experimental|325 mg Aspirin|325 mg aspirin po qd with arginine-restricted diet
11609160|NCT00578708|Experimental|1|
11609161|NCT00578695|Experimental|Active|Lixivaptan
11609162|NCT00578695|Placebo Comparator|Placebo|Placebo
11609163|NCT00578682|Experimental|1|Single IV dose of 0.3 mg/kg MEDI-557
11609164|NCT00578682|Experimental|2|Single IV dose of 3 mg/kg MEDI-557
11609165|NCT00578682|Experimental|3|Single IV dose of 15 mg/kg MEDI-557
11609166|NCT00578682|Experimental|4|Single IV dose of 30 mg/kg MEDI-557
11609167|NCT00578669|Active Comparator|1|Sequential antidepressant pharmacotherapy with (20mg) fluoxetine, begun 8 weeks prior to and extended throughout brief (behavioral) standard smoking cessation treatment with transdermal nicotine patch.
11609168|NCT00578669|Placebo Comparator|2|Sequential placebo medication (dextrose), begun 8 weeks prior to and extended throughout brief (behavioral) standard smoking cessation treatment with transdermal nicotine patch.
11609169|NCT00578656|Experimental|1|Baked milk and at least 4 oral food challenges as clinically indicated
11609170|NCT00578643|Experimental|Allogeneic unrelated transplant|Conditioning from Day -9 to Day -1. Stem cells given on Day 0. Busulfan, alemtuzumab, cyclophosphamide, fludarabine, cyclosporine, stem cell infusion.
11609171|NCT00578630||1|All Pediatric Oncology and Bone Marrow Transplantation Service patients with a histologically proven tumor for whom there is an intent to treat with chemotherapy
11609172|NCT00578617|Active Comparator|Pharmacologic Therapy|Pharmacologic Therapy Rate and/or Sinus Rhythm Control: Patients without other heart disease will receive beta or calcium channel blockers as first line rate control therapy. Patients with underlying coronary artery disease will receive beta-blockers, patients with limited ventricular hypertrophy not warranting exclusion would receive either beta- or calcium channel blockers, while patients with heart failure would be expected to receive carvedilol or metoprolol. Patients randomized to drug therapy may be started on a membrane active drug, in an approach consistent with the recommended Guidelines for Management of Subjects with AF. Each patient will be placed on an anti-arrhythmic drug for an appropriate period and the patient cardioverted to sinus rhythm if necessary. Patients will then be followed for a period of up to 3 months, during which dosage adjustment can be made or the drug replaced with a different anti-arrhythmic drug.
11609173|NCT00578617|Active Comparator|Ablation Therapy|Left Atrial Catheter Ablation: The specific choice of ablation catheters will be left to the investigator from the following list: Lifewire TC XLS, Therapy Dual/Thermocouple, NAVI-STAR/NAVI-STAR DS, Celsius Braided Tip, NAVI-STAR Thermo-Cool, Freezor/FreezorMax, Stinger, Blazer II RF/RPM/SteeroCath /XP, Chilli Cooled.
11609174|NCT00578604||Patients with a diabetic wound|Patients with a diabetic wound
11609175|NCT00578604||Control|Patients without a diabetic wound
11609176|NCT00578591|Experimental|Patient|Four Rituximab doses administered to patients who have developed SR-aGVHD following allogeneic hematopoietic transplant (AHT)
11609177|NCT00578578|Active Comparator|1|"Active Arm:
~1000 mg Lemon flavored Capsules. Three capsules every morning."
11609178|NCT00578578|Placebo Comparator|2|"Placebo Arm:
~Cornstarch Capsules provided by Clinical Encapsulation services. Three capsules every morning."
11609179|NCT00578565|Experimental|1|open label, all subjects will receive rituximab
11609180|NCT00578552|Placebo Comparator|Placebo|Non active placebo pill
11609181|NCT00578552|Active Comparator|Gabapentin - 1800 mg/day|Gabapentin - 1800 mg/day
11609182|NCT00578552|Active Comparator|Gabapentin - 2700 mg/day|Gabapentin - 2700 mg/day
11609183|NCT00578539|Experimental|Stem Cell Transplant|All patients will receive Ara C IV every 12 hours for 6 doses starting at 1400 hours on day -8. Cyclophosphamide IV once daily on day -7 and day -6 starting at 1400 hours. MESNA will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide. Campath 1h will be given on day -4, day -3, day -2 and day-1. TBI (Total Body Irradiation) will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1. Stem cell Infusion are infused on day 0.
11609184|NCT00578526|Active Comparator|Arm 1|SU011248 - 4 weeks on followed by 2 weeks rest period every 6 weeks
11609185|NCT00578526|Placebo Comparator|Arm 2|1 50 mg capsule OD PO for 4 weeks with 2 week rest until disease progression. Any patient with disease progression will be unblinded and patients on the placebo arm may then be considered for the open label Sutent treatment.
11609186|NCT00578500|Active Comparator|OCCT|Patients referred to ovarian cryopreservation.
11609187|NCT00578474|Experimental|Moxidex|Moxidex otic solution
11609188|NCT00578474|Active Comparator|FLOXIN|Ofloxacin otic solution
11609189|NCT00578461|Experimental|Stem Cell Transplant|patient's will be recieving a stem cell transplant on study Conditioning includes: Ara C, Cyclophosphamide, MESNA, TBI-Total Body Irradiation
11609190|NCT00578448|Active Comparator|A|"10mg/kg
~6 doses (Day 1, 5, week 2, 4, 8 and 12) for 12 weeks"
11609191|NCT00578448|Active Comparator|B|"5mg/kg
~33 doses (every 4 weeks) for 144 weeks"
11609192|NCT00578422||Arm I: In Vitro IVUS Plaque studies|IVUS of Amputation Specimens
11609193|NCT00578422||Arm 2: Obserational Study|IVUS for patients undergoing standard lower extremity angiography for PAD.
11609194|NCT00578396|Active Comparator|Dose Level 1|1 lb/day fresh red grapes
11609195|NCT00578396|Active Comparator|Dose Level 2|2/3 lb/day fresh red grapes
11609196|NCT00578396|Active Comparator|Dose Level 3|1/3 lb/day fresh red grapes
11609197|NCT00578383|Sham Comparator|Sham (inactive) Treatment BPD|20 minutes of sham treatment with the Low Field Magnetic Stimulation Device (LFMS)in bipolar depressed subjects
11609198|NCT00578383|Active Comparator|Active LFMS treatment in BPD|20 minutes of active treatment with the Low Field Magnetic Stimulation Device (LFMS)in bipolar depressed subjects
11609199|NCT00578383|Sham Comparator|Sham LFMS Comparator: in MD|20 minutes of sham treatment with the Low Field Magnetic Stimulation Device (LFMS) in major depressed subjects
11609200|NCT00578383|Active Comparator|Experimental LFMS: in MD|20 minutes of active treatment with the Low Field Magnetic Stimulation Device (LFMS) in major depressed subjects
11609201|NCT00578370|Experimental|1|
11609202|NCT00578370|Experimental|2|
11609203|NCT00578370|Active Comparator|3|
11609206|NCT00578357|Experimental|1|immediate intervention
11609207|NCT00578357|No Intervention|2|note: participants in this arm will receive the intervention after the 6-month follow-up (serving as control during the trial)
11609208|NCT00578344|Experimental|Allogeneic BMT/SCT Transplant|"Busulfan, Campath 1H, Cyclophosphamide and MESNA:
~Bone marrow infusion with pre-meds as per SOPs to take place on Day 0.
~Bone marrow dose: To ensure the probability for bone marrow engraftment, 4 x 10^8 nucleated cells/kg patient weight will be the target at donor bone marrow harvest."
11609209|NCT00578331|Experimental|Olopatadine 0.6% Nasal Spray|2 sprays each nostril twice daily
11609210|NCT00578331|Placebo Comparator|Placebo Nasal Spray|2 sprays each nostril twice daily
11609211|NCT00578318|Experimental|Motivational Interviewing Active|Patients received a stepped progression of talk based treatment utilizing Motivational Interviewing as the basis.
11609212|NCT00578318|Active Comparator|Delayed Control|Patients received Treatment as usual (TAU) (i.e. no specific intervention and supportive check-ins from the study staff)
11609213|NCT00578305|Experimental|Rituximab 500 mg|Participants received rituximab 500 mg iv on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants received further treatment courses on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
11609214|NCT00578305|Experimental|Rituximab 1000 mg|Participants received rituximab 1000 mg iv on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants received further treatment courses on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
11609215|NCT00578305|Placebo Comparator|Placebo|Participants received placebo intravenously (iv) on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants were switched to receive rituximab 1000 mg iv on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
11609216|NCT00578292|Experimental|Bone Marrow or Stem Cell Infusion|"Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H
~Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.
~Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor."
11609217|NCT00578279|Other|A|subject randomized to 10ml of dehydrated alcohol
11609218|NCT00578279|Experimental|B|subject randomized to 20ml of dehydrated alcohol
11609219|NCT00578266|Other|No Arms|
11609220|NCT00578227|Experimental|Cervarix™ & Twinrix™ Group|Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A & Hepatitis B (HAB) vaccine (Months 0, 1 & 6).
11609221|NCT00578227|Experimental|Cervarix™ Group|Subjects received 3 doses of HPV vaccine (Months 0, 1 & 6).
11609222|NCT00578227|Active Comparator|Twinrix™ Group|Subjects received 3 doses of HAB vaccine (Months 0, 1 & 6).
11609223|NCT00578214|Active Comparator|Randomized Midazolam|Single-dose midazolam
11609224|NCT00578214|Placebo Comparator|Placebo|
11609225|NCT00578214|Experimental|Prospective Midazolam|
11609226|NCT00578201|Experimental|1|radiochemotherapy,combination Cetuximab-FOLFOX
11609227|NCT00578188||RP100-400|Subjects with Chlamydia. The control group will also be identified with these numbers.
11609228|NCT00578175|Experimental|Group A|Subjects received refrigerator-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation A) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
11609229|NCT00578175|Experimental|Group B|Subjects received freezer-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation B) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
11609230|NCT00578175|Active Comparator|Group C|Subjects received ProQuad® co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
11609231|NCT00578162||1|Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory.
11609232|NCT00578136|Active Comparator|1|1) One group will receive the rectus sheath block prior to Umbilical hernia repair.
11609233|NCT00578136|Active Comparator|2|2) The second group will receive local anesthetic infiltration of the surgical site at the end the umbilical hernia repair.
11609234|NCT00578123|Other|1 Questionnaire|Quality of Life Questionnaires
11609235|NCT00578110|Experimental|Group 1|Glaucoma Patients
11609236|NCT00578110|Experimental|Group 2|Glaucoma suspects
11609237|NCT00578110|Active Comparator|Group 3|Controls
11609238|NCT00578097|Experimental|A - 125 units|
11609239|NCT00578097|Experimental|B - 250 units|
11609240|NCT00578097|Experimental|C - 500 units|
11609241|NCT00578097|Placebo Comparator|D|
11609242|NCT00578084||surgery|those subjects who went to surgery to treat their lung cancer
11609243|NCT00578084||no surgery|those subjects who did not go to surgery for their lung cancer
11609244|NCT00578084||NSCLC|subjects with NSCLC
11609245|NCT00578084||Small cell lung cancer|those with small cell lung cancer
11609246|NCT00578071|Experimental|Treatment|panitumumab, oxaliplatin, capecitabine and EBRT
11609247|NCT00578058|Other|1|Counseling plus everyday noise type 1
11609248|NCT00578058|Other|2|Counseling plus static noise type 2
11609249|NCT00578058|Other|3|Counseling plus static noise type 3
11609250|NCT00578058|Other|4|Hearing aid and counseling plus everyday noise type 1
11609251|NCT00578058|Other|5|Hearing aid and counseling plus static noise type 2
11609252|NCT00578058|Other|6|Hearing aid and counseling plus static noise type 3
11609253|NCT00578045|Experimental|1|Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
11609254|NCT00578032||1|Patients with head and neck malignancies that require simultaneous surgical resection and reconstruction of the ablative defect will be eligible to participate.
11609255|NCT00578019|Active Comparator|1, A|
11609256|NCT00578019|Experimental|2, B|Group B patients will have their fracture stabilized with the LISS plates (Synthes [USA], Paoli, PA, USA).
11609257|NCT00578006|Experimental|A|If you are in group A, the investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
11609258|NCT00578006|Experimental|B|If you are in group B, the investigators will provide you with access to the STAR website using a computer in the waiting area, into which you can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy. The investigators may also provide you with a website address so that you can access STAR from home (or any other location) to report your symptoms at any time.
11609259|NCT00577993|Active Comparator|1: FND + Rituximab Followed by Interferon|Fludarabine/Novantrone/Decadron + Rituximab Followed by Interferon
11609260|NCT00577993|Active Comparator|2: FND Followed by Interferon & Rituximab|Fludarabine/Novantrone/Decadron Followed by Interferon & Rituximab
11609261|NCT00577993|Active Comparator|3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon|Cyclophosphamide/Vincristine/Doxorubicin/Bleomycin (1st Sequence) + Rituximab; Etoposide/Cisplatin/Ara-C/Methyl-Prednisol (2nd Sequence); Novantrone/Vincristine/Procarbazine/Prednisone + Rituximab (3rd Sequence) Followed by Interferon
11609262|NCT00577980|Experimental|Testosterone|Testosterone 200 mg administered parenterally by intramuscular (IM) injection every 2 weeks
11609263|NCT00577954||1|Patients in a coma condition after a traumatic brain injury (250), stroke, cerebral anoxia or subarachnoid hemorrhage (150), for at least 7 days.
11609264|NCT00577928||1|
11609265|NCT00577928||2|
11609266|NCT00577915|Experimental|Breast MR Spectroscopy|Conventional images will be taken with standard pulse sequences. These images will be used for the diagnostic examination for which the patient will have been scheduled. Following the diagnostic study, a pulse sequence designed to obtain spectroscopy data will be used.This will be used on the existing magnets 1.5T and 3T. Memorial Sloan-Kettering Cancer Center has 1.5T and 3T magnets. The patient will have only one injection of contrast (gadolinium-DTPA) for the initial diagnostic study. No additional contrast will be administered. The additional sequence should take about 10 minutes, depending on breast size.
11609267|NCT00577902||Observational|This is an observational study
11609268|NCT00577889|Experimental|Arm I (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 154 mg/m2 tanespimycin IV over 1 hour on day 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
11609269|NCT00577889|Experimental|Arm II (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 154 mg/m2 tanespimycin IV over 1 hour on days 2 and 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
11609270|NCT00577889|Experimental|Arm III (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on day 8 and 154 mg/m2 tanespimycin IV over 1 hour on days 1 and 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
11609271|NCT00577876|Experimental|1|Day of Surgery:Patient is admitted through the Preoperative Surgical Center (PSC). If a large APA is identified, then subject will continue on study Dissect APA (without any changes from what is routinely done) with a penile injection of Trimix. Once the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion.
11609272|NCT00577850|Experimental|1|0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks
11609273|NCT00577850|Active Comparator|2|0.45 mg 14C-labeled alendronate, followed 7 days later with oral 70 mg of alendronate once a week for 52 weeks
11609274|NCT00577837|Active Comparator|1|5 mg risedronate, once daily for 6 months
11609275|NCT00577837|Experimental|2|100 mg risedronate, once a month for 6 months
11609276|NCT00577837|Experimental|3|150 mg risedronate, once a month for 6 months
11609277|NCT00577837|Experimental|4|200 mg risedronate, once a month for 6 months
11609278|NCT00577824|Experimental|1|
11609279|NCT00577824|Experimental|2|
11609280|NCT00577824|Placebo Comparator|3|
11609281|NCT00577811||1|Patients from 6 different Special Need Plans
11609282|NCT00577811||2|
11609283|NCT00577798|No Intervention|Observational|Only had observational arm
11609284|NCT00577785||cystectomy group|Subjects undergoing planned cystectomy who agree to provide bladder tissue from removed bladder post cystectomy and/or cystoscopic biopsy tissue prior to cystectomy
11609285|NCT00577772|Active Comparator|Healthy Participants|Healthy Participants will report for simultaneous lactulose hydrogen breath test (H_2BT) and SmartPill study after an overnight fast. They will swallow the SmartPill Capsule at the study site. After 4 hours, they will be allowed to leave the study site and consume their usual diet. They will return for removal of the data recorder 5 days later.
11609409|NCT00576667|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
11609457|NCT00576251|Experimental|Tobramycin 0.3%/Dexamethasone 0.05%|Tobramycin 0.3%/Dexamethasone 0.05% 1 drop 4 times daily in both eyes
11617232|NCT00512941||4|HBV: vaccinated
11609286|NCT00577772|Active Comparator|Symptomatic Participants|"Subjects with symptoms suggestive of small bowel bacterial overgrowth (SBBO) (e.g., diarrhea, bloating, abdominal discomfort) for at least 3 months will be divided into 2 groups based on the results of their previous testing for SBBO (5 SBBO positive patients, 5 SBBO negative patients).
~The symptomatic participants will report for simultaneous lactulose hydrogen breath test (H_2BT) and SmartPill study after an overnight fast. They will swallow the SmartPill Capsule at the study site. After 4 hours, they will be allowed to leave the study site and consume their usual diet. They will return for removal of the data recorder 5 days later.
~After the capsule has been demonstrated to be passed from the subject, the subjects with SBBO present will then enter into an open-label treatment using Rifaximin (400 mg PO TID) for 7 days."
11609287|NCT00577759|Experimental|Active Intervention|Direct referral to community organizations, with support for practices to do so. These include the North Carolina Tobacco Quitline, public health department dietitians, and the YMCA.
11609288|NCT00577759|Experimental|Passive Intervention|Provision of information about community organizations to patients as above.
11609289|NCT00577759|Placebo Comparator|Usual Care|Usual care
11609290|NCT00577746||surgery|Those subjects who went to surgery for treatment for their lung cancer.
11609291|NCT00577746||no surgery|The subjects who did not go to surgery for treatment of their lung cancer.
11609292|NCT00577733||obese|obese
11609293|NCT00577733||healthy volunteers|healthy volunteers
11609294|NCT00577720|Active Comparator|35 mg IRBB|35 mg immediate release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
11609295|NCT00577720|Experimental|35 mg DRFB|35 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
11609296|NCT00577720|Experimental|50 mg DRFB|50 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
11609297|NCT00577720|Experimental|50 mg DRBB|50 mg delayed release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
11609298|NCT00577707|Experimental|Patients With Stage IB-IIIA NSCLC With EGFR Mutations|This is a open label, single center, phase II trial for patients with clinical stage IB-IIIA NSCLC (T1-3N0-2M0) who have resectable tumors that harbor EGFR activating mutations. Patients will receive erlotinib x 3 weeks prior to initiation of concurrent erlotinib and chemotherapy.
11609299|NCT00577694|Other|single arm study|1
11609300|NCT00577681||1|Participants from the SMART study who were randomly assigned to episodic or continuous ART and who have no history of CVD
11609301|NCT00577681||2|Participants from the SMART study who were randomly assigned to episodic or continuous ART and who experienced a major CVD event during the study, analyzed along with 2 matched controls
11609302|NCT00577681||3|Participants from the SMART study who have no previous use of ART or have taken ART but not done so within 6 months prior to study entry; allows for a comparison of immediate ART versus deferred ART
11609303|NCT00577668|Experimental|VDT and Melphalan|To find out if three drugs, bortezomib, thalidomide, and dexamethasone in addition to high doses of melphalan (M-VTD) and autologous transplant can be given safely and effectively to subjects who have failed previous regimens with transplant(s).
11609304|NCT00577655|Experimental|Albuterol|Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days. HFA-MDI refers to a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant.
11609305|NCT00577655|Placebo Comparator|Placebo|"A placebo of a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant. (Hereafter noted as Placebo-HFA-MDI.)"
11609306|NCT00577642|Other|Single arm|Single arm biomarker study after a single dose of zoledronic acid
11609307|NCT00577629|Experimental|Induction + Consolidation + Bexxar|Induction:Cyclophosphamide, Etoposide, and Rituxan (rituximab) followed by Consolidation: Cytarabine and Doxorubicin followed by radioimmunotherapy: Bexxar (tositumomab)
11609308|NCT00577616|Other|1|Endovascular repair
11609309|NCT00577616|Other|2|conventional surgery repair
11609310|NCT00577603|Active Comparator|2|mesh reinforcement at stoma
11609311|NCT00577603|Active Comparator|Arm 1|standard stoma
11609312|NCT00577590|Placebo Comparator|Metformin Alone|Participants assigned to take Metformin alone.
11609313|NCT00577590|Experimental|Metformin and Rosiglitazone|Participants assigned to take Metformin and Rosiglitazone
11609314|NCT00577590|Experimental|Metformin and Lovaza|Participants assigned to take Metformin and Lovaza
11609315|NCT00577538||1|
11609316|NCT00577538||2|
11609317|NCT00577525||1|Case : Patients with steroid sensitive nephrotic syndrome
11609318|NCT00577525||2|Controls (matched for age and sexe with the first group)
11609319|NCT00577512|Experimental|HD DTPACE|DTPACE
11609320|NCT00577499||Only group|adult cystic fibrosis patients who are not at goal body mass index and have started lubiprostone therapy within one month of study enrollment
11609321|NCT00577473|Active Comparator|1|mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
11609322|NCT00577473|Experimental|2|mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
11609323|NCT00577460|Active Comparator|Pramipexole|Patients to receive Pramipexole ER 0.375 - 4.5 mg in tablet form daily
11609324|NCT00577460|Placebo Comparator|Placebo|Patients to receive placebo tablets identical to Pramipexole ER tablets only during transfer phase
11609325|NCT00577447|Active Comparator|1|DHA supplemented group
11609326|NCT00577447|Placebo Comparator|2|Placebo group
11609327|NCT00577421|Experimental|1|5 mg/day risedronate
11609328|NCT00577408|Experimental|Depot Naltrexone|Depot Naltrexone. Vivitrol (380 mg)given monthly
11609329|NCT00577408|Active Comparator|Oral Naltrexone|Oral Naltrexone. For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday).
11609330|NCT00577395|Experimental|2|one 150 mg risedronate once a month, orally
11609331|NCT00577395|Placebo Comparator|1|Placebo tablet once a month, orally
11609410|NCT00576654|Experimental|Dose escalation (irinotecan hydrochloride and veliparib)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and veliparib PO BID on days -1 to 14 (days 3-14 of course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11609332|NCT00577382|Experimental|Sunitinib|"Cohort A participants received 50 mg sunitinib orally daily for 4 weeks followed by a two-week break from treatment. These 6-week cycles would be repeated until progression or unacceptable toxicity up to 1 year.
~Cohort B participants received 37.5 mg sunitinib daily on a continuous basis until progression or unacceptable toxicity up to 1 year."
11609333|NCT00577369|Active Comparator|1|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
11609334|NCT00577330|Experimental|Myalgesin|Subjects receive Myalgesin twice daily
11609335|NCT00577330|Active Comparator|Acetaminophen|Subjects receive acetaminophen 1000 mg three times a day
11609336|NCT00577317|Experimental|Arm 1|Patients receive standard home maintenance therapy and perform self-manual lymphatic drainage once daily for 60 minutes for 24 weeks.
11609337|NCT00577317|Experimental|Arm II|Patients receive Flexitouch® home maintenance therapy once daily for 60 minutes for 24 weeks
11609338|NCT00577304|Other|2|Placebo - Topical AmphiMatrix
11609339|NCT00577304|Active Comparator|1|Topical AmphiMatrix with Nitroglycerin
11609340|NCT00577278|Experimental|Treatment (chemo, monoclonal antibody therapy, transplant)|REDUCED-INTENSITY CONDITIONING: Patients receive rituximab IV followed by indium In-111 ibritumomab tiuxetan IV over 10 minutes on day -21 and rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14. Patients also receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. STEM CELL TRANSPLANTATION: Patients undergo APBSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO and sirolimus PO beginning on day -3 and continuing for up to 6 months with taper.
11609341|NCT00577252||1|Adolescents with CF.
11609342|NCT00577226||1 Shilla Technique|The patients whose data is observed are those who have undergone the shilla surgical technique.
11609343|NCT00577200|No Intervention|Control|Control group subjects are not undergoing any surgical procedures and will not be randomized to any anesthetic drug group.
11609344|NCT00577200|Experimental|Midazolam + Sufentanil + Propofol|"Midazolam 0.03 mg/kg + Sufentanil 0.1 µg/kg + Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.
~For subjects who are chronic pain patients undergoing minor surgical procedures."
11609345|NCT00577200|Experimental|Midazolam and Sufenatnil|"Midazolam 1-5 mg in holding area + Sufentanil 5-10 mcg.
~For subjects who are chronic pain patients undergoing minor surgical procedures."
11609346|NCT00577174||1. Controls|Healthy children ages 8 to 18 years
11609347|NCT00577174||2. Obese childrens|Obese children, ages 8 to 18 years
11609348|NCT00577161|Active Comparator|Comparator|fludarabine and rituximab
11609349|NCT00577161|Experimental|Experimental|fludarabine, rituximab, pixantrone
11609350|NCT00577148|Experimental|Rimonabant|Rimonabant 20 mg once daily.
11609351|NCT00577148|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
11609352|NCT00577135|Experimental|Q12 hour bolus|Furosemide-Q12 hour bolus
11609353|NCT00577135|Experimental|Continuous Infusion|Furosemide-Continuous Infusion
11609354|NCT00577135|Experimental|Low Intensification|Furosemide-Low Intensification
11609355|NCT00577135|Experimental|High Intensification|Furosemide-High Intensification
11609356|NCT00577122|Experimental|Cohort I (MPA)|Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.
11609357|NCT00577122|Experimental|Cohort II (MPA, low-dose chemotherapy)|"Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.
~Cyclophosphamide will be administered orally as a single daily dose. Methotrexate will be administered twice daily on days 1 and 2 of each week."
11609358|NCT00577109|Experimental|1|
11609359|NCT00577096|Experimental|Exercise|Study participants were computer randomized to an individualized exercise program. Participants were stratified within Arm according to whether or not they received thalidomide with heparin, and by age (60 and younger versus older than 60)
11609360|NCT00577096|Active Comparator|usual care|Study participants were asked to remain as active as possible but not prescribed an individualized exercise program. Participants were stratified within Arm according to whether or not they received thalidomide with heparin, and by age (60 and younger versus older than 60)
11609361|NCT00577083|Experimental|Initial cap-fitted|Initial cap-fitted colonoscopy for the first insertion
11609362|NCT00577083|Active Comparator|Initial regular|Initial regular no cap on the end of the colonoscope for the first insertion
11609363|NCT00577070|Active Comparator|H1|"Includs 20 patients.These patients will be given 4 weeks (5 days a week) of deep TMS,20 minutes each session, to the left prefrontal cortex using H1 coil, in frequency of 20 HZ, with intensity of 120 % of motor threshold. H1-coil is an extracorporeal device positioned on the patient's scalp, designed to stimulate deep prefrontal brain regions, preferentially in the left hemisphere. The effective part of the coil, which has contact with the patient's scalp, includes 14 strips of 7-12 cm length. These strips are oriented in an anterior-posterior axis.This coil stimulates neuronal fibers in anterior-posterior orientation.
~During deep TMS exposure patients will listen to a clinical interview in which they describe the different expressions of their depression including their ruminations and depressive schemas."
11609364|NCT00577070|Experimental|H2|Includs 20 patients.These patients will be given 4 weeks (5 days a week) of deep TMS, 20 minutes each session, to the prefrontal cortex bilateraly using H2 coil, in frequency of 0.1 HZ, with intensity of 120 % of motor threshold. H2-coil is designed to stimulate deep prefrontal brain regions bilaterally (without any preferencefor either hemisphere). The effective part of the coil, which has contact with the patient's scalp, includes 10 strips of 14-22 cm length.These strips are oriented in a right-left direction (lateral-medial axis).This coil is destined to stimulate lateral-medial neuronal fibers. During deep TMS exposure patients will listen to a clinical interview in which they describe the different expressions of their depression including their ruminations and depressive schemas.
11609365|NCT00577031|Experimental|1|
11609366|NCT00577018|Active Comparator|1|
11609367|NCT00577018|Active Comparator|2|
11609368|NCT00577018|Placebo Comparator|3|
11609369|NCT00577005|Experimental|1|Levetiracetam tablets
11609370|NCT00577005|Placebo Comparator|2|matching placebo
11609371|NCT00576992||GI observation|Patients presenting for an upper endoscopy procedure with gastrointestinal symptoms or complaints.
11609458|NCT00576251|Active Comparator|TOBRADEX|TOBRADEX 1 drop 4 times daily in both eyes
11609372|NCT00576979|Experimental|Treatment (radiation therapy, chemotherapy, transplant)|PREPARATIVE REGIMEN: Patients undergo IMRT using helical tomotherapy once or twice daily on days -10 to -6 or -10 to -7. Patients also receive etoposide IV on day -6 or -5 and cyclophosphamide IV on day -4 or -3. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell or bone marrow transplantation on day -1 or day 0.
11609373|NCT00576940|Experimental|IMEN: 1|Enteral nutrition with immunostimulating diet (IMEN group: formula supplemented with arginine, glutamine, omega-3 fatty acids)
11609374|NCT00576940|Active Comparator|SEN|postoperative enteral nutrition - standard oligopeptic diet
11609375|NCT00576927|Experimental|Group1|SHI followed by Active Drug Ramelteon
11609376|NCT00576927|Placebo Comparator|Group 2|SHI Followed by Placebo
11609377|NCT00576914|Active Comparator|A|vinorelbine plus cisplatin plus recombinant human endostatin
11609378|NCT00576914|No Intervention|B|vinorelbine plus cisplatin
11609379|NCT00576901|Experimental|1|
11609380|NCT00576888||Vascular Anomaly with Coagulopathy|All patients diagnosed with Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) or with a vascular anomaly with coagulopathy
11609381|NCT00576875||Depressed|Older individuals with major depression
11609382|NCT00576875||Non-depressed|Older individuals without major depression
11609383|NCT00576862|Experimental|1|
11609384|NCT00576849|Experimental|A|Total balanced volume replacement regimen consisting of a balanced HES 130/0.42 plus a balanced crystalloid
11609385|NCT00576849|Active Comparator|B|Conventional volume replacement strategy consisting of 6% HES 130/0.4 prepared in saline solution plus Ringer's lactate
11609386|NCT00576836|Experimental|Cultured Thymus Tissue Implantation w Parathyroid Transplant|"Cultured Thymus Tissue Implantation With Parathyroid Tissue Transplantation. Subjects who were enrolled in this arm underwent cultured thymus tissue implantation with parathyroid transplantation, if eligible.
~No specific dose was assigned. The thymus tissue dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the recipient.
~There was a one time administration of the cultured thymus tissue and parathyroid tissue."
11609387|NCT00576836|Experimental|Cultured Thymus Tissue Implantation|"Cultured Thymus Tissue Implantation. Subjects who were enrolled in this arm underwent cultured thymus tissue implantation (CTTI) only.
~No specific dose was assigned. The thymus tissue dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the recipient.
~There was a one time administration of the cultured thymus tissue.
~."
11609388|NCT00576823|Experimental|Alfuzosin solution - 2-7 years|Alfuzosin solution, daily dose divided in 3 doses given at breakfast, lunch and dinner to children 2-7 years of age.
11609389|NCT00576823|Experimental|Alfuzosin solution - 8-16 years|Alfuzosin solution, daily dose divided in 3 doses given at breakfast, lunch and dinner to children and adolescents 8-16 years of age who were not able to swallow tablets or preferred to take the solution or had a body weight < 30 kg.
11609390|NCT00576823|Experimental|Alfuzosin tablet - 8-16 years|Alfuzosin tablet, daily dose divided in 2 doses given at breakfast and dinner to children and adolescents 8-16 years of age who were able to swallow tablets and had a body weight ≥ 30 kg.
11609391|NCT00576784|Active Comparator|A|pioglitazone/glimepiride
11609392|NCT00576771|Experimental|1|"ALI/ARDS patients
~evaluated the effect of PSV, NAVA and assisted controlled mechanical ventilation by patient through a button"
11609393|NCT00576758|Experimental|Obinutuzumab|Participants received 1000 mg obinutuzumab intravenous (IV) infusion once a week on Days 1, 8, 15, and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression, were eligible to receive a 1000 mg IV infusion every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
11609394|NCT00576758|Active Comparator|Rituximab|Participants received 375 mg/m^2 rituximab IV infusion once a week on Days 1, 8, 15 and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression were eligible to receive a 375 mg/m^2 rituximab IV infusion once every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
11609395|NCT00576745|Active Comparator|1 Vicryl Suture|Patients will have their incision closed with vicryl suture
11609396|NCT00576745|Experimental|2 Steri-Strips|Patients will have their incisions closed with 3M Surgical-Strips
11609397|NCT00576732|Experimental|001|Risperidone low dose Risperidone oral solution 0.125 mg (if <45 kg) or 0.175 mg (if >=45 kg) qd or bid for 6 weeks
11609398|NCT00576732|Experimental|002|Risperidone high dose Risperidone oral solution 1.25 mg (if <45 kg) or 1.75 mg (if >=45 kg) qd or bid for 6 weeks
11609399|NCT00576732|Placebo Comparator|003|Placebo Oral solution qd or bid for 6 weeks
11609400|NCT00576719|Experimental|1|Participants will receive intensive cognitive behavioral therapy treatment without parent involvement
11609401|NCT00576719|Experimental|2|Participants will receive intensive cognitive behavioral therapy treatment with parent involvement
11609402|NCT00576719|Placebo Comparator|3|Waitlist control group
11609403|NCT00576706|Experimental|1|
11609404|NCT00576706|Active Comparator|2|
11609405|NCT00576693|Experimental|intensive medical management plus stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl).
11609406|NCT00576693|Experimental|intensive medical management alone|Intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl)
11609407|NCT00576680|Experimental|Temozolomide with RAD001|
11609408|NCT00576667|Experimental|Rimonabant|Rimonabant 20 mg once daily.
11609411|NCT00576654|Experimental|Expansion portion (irinotecan hydrochloride and veliparib)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and veliparib PO BID on days 1-15 (days 2-15 of course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11609412|NCT00576654|Experimental|Intermittent dose escalation (irinotecan, ABT-888)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 3 and 10 and veliparib PO BID on days 1 to 4 and 8-11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11609413|NCT00576641|Experimental|Vaccine|
11609414|NCT00576628|Experimental|C.E.R.A|Participants received methoxy polyethylene glycol-epoetin beta (Continuous Erythropoietin Receptor Activator [C.E.R.A]) subcutaneously every four weeks for 44 weeks. The participants received initial dose of 1.2 microgram per kilogram (mcg/kg) of C.E.R.A. Once the Hemoglobin (Hb) concentration was attained within the target range of 11.0 and 13.0 gram per deciliter (g/dL), the dose was adjusted to maintain the Hb concentration within the target range.
11609415|NCT00576615||1: placebo|placebo solution
11609416|NCT00576615||2: propofol|propofol
11609417|NCT00576602|Experimental|1|
11609418|NCT00576602|Active Comparator|2|
11609419|NCT00576589|Experimental|CE-326,597|
11609420|NCT00576589|Placebo Comparator|Placebo|
11609421|NCT00576576|Experimental|A|All patients in this arm are given atorvastatin therapy.
11609422|NCT00576563|Other|FDG PET CT|To investigate the evolution of the 18F-deoxyglucose (FDG) uptake and the tumour characteristics determined in the plasma of patients with rectal cancer during and after radiotherapy or combined radiotherapy and chemotherapy.
11609423|NCT00576550|Experimental|1:1|Part 1 of the study (maintenance part)
11609424|NCT00576550|No Intervention|1:2|Part 1 of the study (maintenance part)
11609425|NCT00576550|Experimental|2:1|Part 2 of the study (eczema part)
11609426|NCT00576550|Active Comparator|2:2|Part 2 of the study (eczema part)
11609427|NCT00576537|Experimental|Dendritic Cell Immunotherapy|Patients who consent to participate in the study and receive the Dendritic Cell vaccine manufactured from their own tumor cells.
11609428|NCT00576524|Experimental|Sham Device first, ITD next|Subjects will be randomized to recieve sham device first, ITD next after washout of 7 days.
11609429|NCT00576524|Experimental|ITD first, sham device next|Subjects will be randomized to receive ITD first, sham device next, after washout of 7 days.
11609430|NCT00576511|Active Comparator|1|Prucalopride
11609431|NCT00576511|Placebo Comparator|2|
11609432|NCT00576498|Experimental|1- Narrow Band Imaging|"NBI-AFI imaging - Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.
~Autofluorescence Imaging (AFI)- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm)"
11609433|NCT00576498|Other|2-Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars
11609434|NCT00576485|Experimental|1|Cataract surgery and implantation of a spherical intraocular lens
11609435|NCT00576485|Experimental|2|Cataract surgery and implantation of a spherical intraocular lens
11609436|NCT00576472|Experimental|Treatment|
11609437|NCT00576459|Experimental|Fluocinolone acetonide 0.59 mg|0.59 mg fluocinolone acetonide intravitreal implant
11609438|NCT00576459|Experimental|Fluocinolone acetonide 2.1 mg|2.1 mg fluocinolone acetonide intravitreal implant
11609439|NCT00576459|Active Comparator|Laser photocoagulation|standard of care laser photocoagulation
11609440|NCT00576446|Experimental|1|
11609441|NCT00576433|Experimental|1|
11609442|NCT00576420|Experimental|FS VH S/D 500 s-apr - 60-Seconds|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) will be applied to the study suture line, 60-second polymerization time
11609443|NCT00576420|Experimental|FS VH S/D 500 s-apr - 120-Seconds|FS VH S/D 500 s-apr will be applied to the study suture line, 120-second polymerization time
11609444|NCT00576420|Active Comparator|Control Group- Manual compression with surgical gauze pads|Treatment of the study-suture line will be manual compression with surgical gauze pads.
11609445|NCT00576407|Experimental|Cultured Thymus Tissue Implantation in Complete DiGeorge|"Participants with Complete DiGeorge Syndrome, who were eligible, received cultured thymus tissue implantation (CTTI).
~No specific dose was assigned. There was a one time administration of the cultured thymus tissue."
11609446|NCT00576394|Active Comparator|1Moderate Glycemic Control|Patients will receive an insulin drip to keep blood glucose levels between 120-180mg/dl
11609447|NCT00576394|Active Comparator|2Aggressive Glycemic Control|Patients will receive an insulin drip designed to maintain serum glucose between 80-120mg/dl
11609448|NCT00576381|Experimental|A|Neonates will be administered a single bolus dose of dexmedetomidine followed by a continuous infusion for up to 24 hours post cardiac surgery.
11609449|NCT00576368|Experimental|1|
11609450|NCT00576355|Active Comparator|2|Participants will receive treatment as usual
11609451|NCT00576355|Experimental|1|Participants will receive interpersonal and social rhythm therapy for adolescents
11609452|NCT00576342|Other|AL-3862+timolol, then COSOPT|AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, followed by dorzolamide+timolol ophthalmic solution,1 drop in both eyes, 1 day later.
11609453|NCT00576342|Other|COSOPT, then AL-3862+timolol|Dorzolamide+timolol ophthalmic solution, 1 drop in both eyes, followed by AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, 1 day later.
11609454|NCT00576329|Placebo Comparator|A|
11609455|NCT00576329|Experimental|B|
11609456|NCT00576303|Experimental|RO0503821 (C.E.R.A.), 1x/4weeks|Eligible participants started RO0503821 (Continuous Erythropoietin Receptor Activator [C.E.R.A]) intravenously, at a dose of 120, 200 or 360 microgram (µg) every four weeks. The dose of C.E.R.A was based on the epoetin alfa or beta dose of<8000, 8000-16000, or >16000 international units (IU)/week, administered during the stability verification period (SVP) of 4 weeks. The SVP period was followed by dose titration period (DTP) of 16 weeks, efficacy evaluation period (EEP) of 8 weeks and long term safety period (LTSP) of 28 weeks
11609459|NCT00576238|Experimental|1:1|Part 1 - eczema treatment
11609460|NCT00576238|Active Comparator|1:2|Part 1 - eczema treatment
11609461|NCT00576238|Experimental|2:1|Part 2 - maintenance treatment
11609462|NCT00576238|No Intervention|2:2|Part 2 - maintenance treatment
11609463|NCT00576225|Experimental|Experimental|
11609464|NCT00576225|Active Comparator|Control|
11609465|NCT00576212|Experimental|A|Subjects in the intervention group will receive supportive telephone calls biweekly for 6 months.
11609466|NCT00576212|No Intervention|B|Subjects in the control group will receive no intervention.
11609467|NCT00576199|Experimental|Bevacizumab 5 mg/kg|Participants received bevacizumab 5 mg/kg intravenously every 2 weeks and within 24-48 hours prior to each transarterial chemoembolization (TACE) until disease progression or unmanageable toxicity. TACE was conducted for 4 sessions at 8-10 week intervals.
11609468|NCT00576186||1|Patients being referred for the routine Equilibrium Radionuclide Angiocardiography (ERNA) for assessment of their left ventricular function will be asked to participate in the study. All patients will be asked to sign the consent form. Patients will be given a choice to participate in either or both studies (i.e. ERNA plus ACGBS or ERNA plus ACGBS and 3 DE).
11609469|NCT00576160|No Intervention|A|"Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin.
~Usual Care: Participants assigned to UCC will only receive the pre- and post-assessment session, and any adherence education or encouragement that is regularly provided by their treating physicians."
11609470|NCT00576160|Experimental|B|Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin. After Baseline, there is an initial session telephone session with PST therapist. Subsequent treatment sessions provide a context for the patient to discuss the problems and difficulties they face and that give rise to medication non-adherence.
11609471|NCT00576147|Experimental|CT scan|The standard head CT done to head trauma patients
11609472|NCT00576121||1|Left ventricular ejection fraction (LVEF) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
11609473|NCT00576121||2|End-diastolic volume (LVEDV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
11609474|NCT00576121||3|End-systolic volume (LVESV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
11609475|NCT00576108|Experimental|KD7040 topical gel|
11609476|NCT00576108|Placebo Comparator|Placebo gel|
11609477|NCT00576095||PMD|Patients diagnosed with major depression with psychotic features
11609478|NCT00576095||NPMD|Patients diagnosed with major depression without psychotic features
11609479|NCT00576095||Controls|Participants with no psychiatric or depression history
11609480|NCT00576069||asthma, quality of life, lung function|All Asthmatics will be treated with 1 of 3 long acting beta 2 agonist + corticosteroid using low or medium dose of inhaled (Advair) fluticasone or equivalent corticosteroid 200-500mcg/day plus salmeterol 100 mcg/day or (Symbicort) budesonide 320-640 mcg +formoterol 18 mcg/day or (Dulera) mometasone 400-800mcg + formoterol 20 mcg/day. In addition tiotropium 18ucg/day will be used. Additionally, albuterol 0.083%/ipratropium 0.02% solution or MDI HFA for acute exacerbation.Will measure lung function and asthma quality of life questionaire
11609481|NCT00576056|Experimental|Tace and Sorafenib|Patients with unresectable HCC will be treated with TACE in combination with oral sorafenib administration. TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin. Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment.
11609482|NCT00576043|Active Comparator|1: Training|3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator
11609483|NCT00576043|No Intervention|2: No Training|No simulator training before starting endoscopy training on real patients
11609484|NCT00576030|Other|H|habitual coffee drinkers
11609485|NCT00576030|Other|N|non-habitual coffee drinkers
11609486|NCT00576004|Active Comparator|group A|Pelvic organ prolapse repair plus concomitant Burch Colposuspension
11609487|NCT00576004|Active Comparator|group B|Pelvic organ prolapse without Burch colposuspension
11609488|NCT00575991|Experimental|A|
11609489|NCT00575991|Placebo Comparator|B|
11609490|NCT00575978|Experimental|Hydralazine|"The objective of this study is to determine the MTD for hydrazaline added to standard neoadjuvant chemotherapy for operable breast cancer. Four dose levels of hydrazalline are planned:
~Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID"
11609491|NCT00575965|Experimental|Simvastatin|Simvastatin at 20 mg daily for the first week, then dose escalated weekly by 20 mg a day to a maximum of 80 mg daily by week 4. Patients were maintained on therapy until progression.
11609492|NCT00575952|Experimental|Treatment (doxorubicin hydrochloride, cisplatin, paclitaxel)|"Patients receive doxorubicin hydrochloride IV over 30 minutes followed by cisplatin IV over 1 hour on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
~Patients then receive doxorubicin hydrochloride IV and cisplatin IV or IP on day 1, and paclitaxel IP on days 1 or 8. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
11609493|NCT00575939||HIV positive|HIV infected treatment naive with CD4 cell count of at least 400
11609494|NCT00575939||Healthy controls|Healthy controls
11609495|NCT00575926|Active Comparator|A: Lingzhi extract|Oral 300mg capsules containing Lingzhi extract (4 to 6 capsules per day as dosed by patients' age)
11609496|NCT00575926|Placebo Comparator|B: Placebo|Starch with same appearance and taste as LingZhi
11609497|NCT00575900|Experimental|1|Low carbohydrate and low fat.
11609498|NCT00575900|Experimental|2|Low carbohydrate fat rich diet
11609499|NCT00575900|Active Comparator|3|A balanced low fat diet
11609500|NCT00575887|Experimental|1|
11609501|NCT00575874|Experimental|1|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
11609502|NCT00575874|Experimental|2|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
11609503|NCT00575874|Experimental|3|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
11609504|NCT00575874|Active Comparator|4|30 mg pioglitazone HCl capsules once daily for 12 weeks
11609505|NCT00575874|Placebo Comparator|5|Matching rivoglitazone HCL placebo tablets and/or matching pioglitazone HCL placebo capsules
11609506|NCT00575861|Active Comparator|1|Advair 250/50 (baseline) fluticasone/salmeterol 250/50
11609507|NCT00575848|Active Comparator|1|
11609508|NCT00575848|Placebo Comparator|2|
11609509|NCT00575835|Active Comparator|1|
11609510|NCT00575835|Experimental|2|
11609511|NCT00575822|Active Comparator|1|NDO Endoscopic Full-thickness Plicator procedure
11609512|NCT00575822|Sham Comparator|2|Sham control procedure
11609513|NCT00575809||Obsevational|
11609514|NCT00575796|Experimental|1|"Children will be treated with Vinblastine Sulphate chemotherapy via intravenous administration once a week over a period of 26 weeks. MRI disease evaluation should be performed at weeks 12 and 26 (+/- 1 week). If response on MRI at week 26 > stable (i.e. stable disease, objective or partial or complete response compared to the baseline MRI exam), continue weekly Vinblastine to the total duration of treatment (i.e. 70 weeks).
~All children will be followed until they demonstrate clear signs tumour progression."
11609515|NCT00575783||1A, 1B|"Type 1 diabetic subjects with a history of severe hypoglycemia and hypoglycemia unawareness who:
~1A) meet criteria for islet cell transplantation and are referred by a participating islet cell transplantation center
~1B) meet similar criteria but are not currently planning islet cell transplantation"
11609516|NCT00575783||2|Type 1 diabetics who are not optimally controlled (>8% HbA1c) and rarely experience hypoglycemia
11609517|NCT00575783||3|Healthy non-diabetics
11609518|NCT00575757||Primary|HIV infected with abnormal liver enzymes in the absence of HCV or HBV coinfections.
11609519|NCT00575744|No Intervention|1|
11609520|NCT00575731|Experimental|Fine-Tuning|2-month intervention (8 lifestyle counseling classes)
11609521|NCT00575731|Active Comparator|Record-Keeping|2-month intervention (8 lifestyle counseling classes)
11609522|NCT00575718|Active Comparator|1|Hospital Counseling + Nicotine Replacement Therapy (HC+NRT)
11609523|NCT00575718|Experimental|2|Hospital Counseling + Nicotine Replacement Therapy + Pre-surgical Schedule Reduced Smoking (HC+NRT+PS/SRS)
11609524|NCT00575692||PulmoHypertension|Patients with suspected, latent or manifest pulmonary hypertension
11609525|NCT00575692||Controls|Controls without history of cardiac or pulmonary diseases
11609526|NCT00575679|Experimental|1|Brief motivational interview
11609527|NCT00575679|No Intervention|2|No discussion
11609528|NCT00575666|Experimental|A|Intranasal Insulin Treatment
11609529|NCT00575666|Placebo Comparator|B|Drug: Placebo
11609530|NCT00575653||11-18 (Primary)|Enrolled members of one of the participating health plans who are ages 11-18 at any time during the study period, March 1, 2005 through August 31, 2008.
11609531|NCT00575653||19-21 (Secondary)|Enrolled members of one of the participating health plans who are ages 19-21 at any time during the study period, March 1, 2005 through August 31, 2008.
11609532|NCT00575640|Active Comparator|1|"The objective of this study is to determine the MTD for Hydralazine added to standard neoadjuvant chemotherapy for operable recta cancer. Four dose levels of hydralazine are planned:
~Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID"
11609533|NCT00575627|No Intervention|2|
11609534|NCT00575627|Experimental|1|Drug: peginterferon α-2a (40 kDa) plus ribavirin for 24-48 weeks
11609535|NCT00575614|Active Comparator|1|
11609536|NCT00575614|Placebo Comparator|2|
11609537|NCT00575601|Active Comparator|A|
11609538|NCT00575601|Placebo Comparator|B|
11609539|NCT00575588|Experimental|Saxagliptin|
11609540|NCT00575588|Experimental|Glipizide|
11609541|NCT00575575|Experimental|A,2|
11609542|NCT00575536||Rhizotomy for children with spasticity|Children with spasticity needing Rhizotomy surgery
11609543|NCT00575523|Active Comparator|1: Atropine|Atropine 0,5mg is administered intravenously immediately before starting percutaneous ethanol instillation.
11609544|NCT00575523|Placebo Comparator|2: Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
11609545|NCT00575510|Experimental|Intervention|Culturally targeted behavioral and normative beliefs + knowledge/skills + salience + environmental constraints/barriers counseling
11609546|NCT00575510|Active Comparator|Active Control|nontargeted behavioral and normative beliefs + knowledge/skills + salience + environmental constraints/barriers counseling
11609547|NCT00575510|No Intervention|Standard Care Only|Clinical standard of care at time of study
11609548|NCT00575497|Experimental|A|Six Day per week short daily hemodialysis
11609549|NCT00575497|Experimental|B|Six nights per week nocturnal hemodialysis
11609550|NCT00575497|Experimental|C|Every other day short daily hemodialysis
11609551|NCT00575497|Experimental|D|Every other night hemodialysis
11609552|NCT00575497|Experimental|E|5 days per week short daily hemodialysis
11609553|NCT00575497|Experimental|F|5 nights per week hemodialysis
11609554|NCT00575497|Active Comparator|G|Conventional three time per week short daily hemodialysis
11609555|NCT00575484|Placebo Comparator|1|
11609556|NCT00575484|Active Comparator|2|
11609557|NCT00575471|Experimental|1|rivoglitazone HCl 0.5 mg tablets once daily for 12 weeks
11609558|NCT00575471|Experimental|2|rivoglitazone HCl 1 mg tablets once daily for 12 weeks
11609559|NCT00575471|Experimental|3|rivoglitazone HCl 1.5 mg tablets once daily for 12 weeks
11609560|NCT00575471|Placebo Comparator|4|Matching placebo tablets once daily for 12 weeks
11609561|NCT00575458||1|Static Splint
11609562|NCT00575458||2|Dynamic Splint
11609563|NCT00575445||1|Pediatric patients with previously diagnosed asthma
11609564|NCT00575432||1|
11609565|NCT00575419|Experimental|1, IV NAC|N-acetylcysteine administered intravenously
11609566|NCT00575419|Experimental|2, IA NAC|N-acetylcysteine administered intra-arterial
11609567|NCT00575406|Active Comparator|R-CHOP|Treatment with Rituximab, Cyclophosphamide, Doxorubicin, Vincristin and Prednisolone
11609568|NCT00575406|Experimental|R-COMP|Treatment with Rituximab, Cyclophosphamide, liposomal Doxorubicin, Vincristin and Prednisolone
11609569|NCT00575380|Active Comparator|AzaSite Eye Drops|One drop two times a day for two days and once a day for the next five days
11609570|NCT00575380|Active Comparator|Vigamox Eye Drops|One drop three times a day for seven days
11609571|NCT00575367|Active Comparator|AzaSite|
11609572|NCT00575367|Active Comparator|Vigamox|
11609573|NCT00575354|Active Comparator|1|Sevoflurane: induction 3-6%, maintenance 2-3%
11609574|NCT00575354|Active Comparator|2|Isoflurane: induction 3-6%, maintenance 2-3%
11609575|NCT00575341|Active Comparator|1|substitution of DHEA-hormone, oral, once daily
11609576|NCT00575341|Placebo Comparator|2|substitution of placebo, oral, once daily
11609577|NCT00575328|Experimental|Maca Root|Subjects in this arm will be given 3g/day of Maca Root.
11609578|NCT00575328|Placebo Comparator|Placebo|Subjects in this arm will receive inactive placebo.
11609579|NCT00575302|Active Comparator|300|administration of 300 IU Gonal-f® in a short agonist protocol.
11609580|NCT00575302|Experimental|450|administration of 450 IU Gonal-f® in a short agonist protocol.
11609581|NCT00575276||1|Females with acute cholecystitis
11609582|NCT00575276||2|Females with Chronic Cholecystitis
11609583|NCT00575276||3|Males with acute cholecystitis
11609584|NCT00575276||4|Males with Chronic Cholecystitis
11609585|NCT00575263||Normal Teeth|Normal molar teeth
11609586|NCT00575263||painful teeth|Painful molar teeth
11609587|NCT00575250|Active Comparator|1|Osteoporosis Prevention and Self-Management Course (4 x 2 1/2 hours)
11609588|NCT00575250|Active Comparator|2|"One introductory osteoporosis education session (1 x 2 1/2 hours)"
11609589|NCT00575237|No Intervention|Control|In the control group, CO2 was removed by passive deflation of the abdominal cavity through the holes of the trocar.
11609590|NCT00575237|Experimental|Intervention|
11609591|NCT00575224|Other|A|Pegylated interferon and ribavirin for 24 weeks
11609592|NCT00575224|Other|B|Pegylated interferon and ribavirin for 48 weeks
11609593|NCT00575211||Cardiomyopathy|
11609594|NCT00575198|Experimental|1|No drainage threshold
11609595|NCT00575198|Active Comparator|2|Drainage <2 mL/kg
11609596|NCT00575185|Active Comparator|Valomaciclovir|Valomaciclovir 2 grams orally twice daily for 21 days
11609597|NCT00575185|Placebo Comparator|placebo|placebo 2 tablets twice daily for 21 days
11609598|NCT00575172||U|Intensified insulin therapy with ultrarapid insulin-analogue (Insulin-Aspart)
11609599|NCT00575172||R|Intensified insulin therapy with human regular insulin
11609600|NCT00575159|Experimental|Arm a|GSK189075
11609601|NCT00575159|Placebo Comparator|Arm b|Placebo
11609602|NCT00575146|Experimental|1|ketogenic diet
11609603|NCT00575120|No Intervention|A|Endothelial Function of forearm assessed by FMD, PAT, BOLD-MRI before 15 min. ischemia reperfusion of forearm
11609604|NCT00575120|Active Comparator|B|Endothelial Function of forearm assessed by FMD, PAT, BOLD-MRI after 15 min. ischemia reperfusion
11609605|NCT00575107|Experimental|VSC-VLC|velocity-controlled variable resistance, lengthening contraction
11609606|NCT00575107|Active Comparator|SC|Constant weight shortening contraction
11609607|NCT00575081||Stereotactic Brain Procedures|Patients who have consented to undergo or have undergone a stereotactic brain procedure for any reason including those who need Deep Brain Stimulation, SEEG or other brain neurmodulation device implant.
11609608|NCT00575068|Experimental|1|
11609609|NCT00575055|Experimental|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
11609610|NCT00575055|Placebo Comparator|Placebo Dose|infusion every 13 weeks for a total of 6 infusions.
11609611|NCT00575055|Experimental|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions.
11609612|NCT00575042|Experimental|Patients treated with Fenofibrate|Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) 160 mg table per day for 1 year
11609613|NCT00575029|Experimental|megace treatment|Study subjects will be given 600mg of MA for oral ingestion per day for duration of 8 weeks. They will be monitored every week clinically for the development of adrenal insufficiency by review of symptoms, physical exam, body weight, pulse, and blood pressure. Subjects also will undergo biochemical evaluation of adrenal status every two weeks by measurement of serum electrolytes, serum cortisol, serum adrenocorticotropic hormone(ACTH) levels, and the adrenal response to a low dose ACTH (1µgm) stimulation test(see methods).
11609614|NCT00575016|Experimental|1|botulinum toxin Type A (50U); botulinum toxin Type A (200U)
11609615|NCT00575016|Experimental|2|botulinum toxin Type A (100U); botulinum toxin Type A (200U)
11609616|NCT00575016|Experimental|3|botulinum toxin Type A (200U)
11609617|NCT00575016|Other|4|placebo; botulinum toxin Type A (200U)
11609618|NCT00575003|Experimental|1|
11609619|NCT00575003|Placebo Comparator|2|
11609620|NCT00574990||VA Physicians|VA providers who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
11609621|NCT00574990||VA Nurses|VA nurses who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
11609622|NCT00574990||VA Pharmacists|VA pharmacists who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
11609623|NCT00574977|Experimental|A|Subjects who have been vaccinated with vaccinia virus (small pox)and will receive vvDD-CDSR by intratumoral injection
11609624|NCT00574977|Experimental|B|Subjects will include those who have not been vaccinated with vaccinia virus (small pox)and will receive vvDD-CDSR by intratumoral injection.
11609625|NCT00574977|Experimental|C|Subjects will be those who have been vaccinated with vaccinia virus (small pox)and will be receiving the vvCD-CDSR via intravenous infusion
11609626|NCT00574964|Experimental|1|
11609627|NCT00574951|Experimental|AMG 706|AMG 706 daily
11609628|NCT00574912|Experimental|Placebo then Insulin Glargine|"Placebo: administer single dose of Placebo subcutaneously (SC) with blood glucose monitoring over 24 hours.
~Then Insulin Glargine SQ 8 weeks later, in increasing doses (0.5, 1.0, 1.5, 2.0 u/kg body wt.) with blood glucose monitoring monitoring over a 24 hour period. Each dose is separated by 8 weeks (5 separate study visits)"
11609629|NCT00574899||1|patients scheduled to receive standard of care with a Radical prostatectomy
11609630|NCT00574899||2|patients scheduled to receive standard of care with radiation therapy
11609631|NCT00574886|Experimental|1|
11609632|NCT00574873|Experimental|1|Bosutinib
11609633|NCT00574873|Active Comparator|2|Imatinib
11609634|NCT00574860|Experimental|EN3285 (NAC ProGelz)|The EN3285 arm is the product under development
11609635|NCT00574860|Placebo Comparator|No active ingredients (placebo)|This will be an oral product that contains no active ingredient
11609636|NCT00574860|Other|Standard of Care|This arm will reflect the typical standard of care for the patient
11609637|NCT00574847|Experimental|Escitalopram|Escitalopram treatment
11609638|NCT00574847|Placebo Comparator|Placebo|Placebo
11609639|NCT00574834|Active Comparator|Ramipril|Patients randomized to 6 months treatment of Ramipril.
11609640|NCT00574834|Active Comparator|HCTZ|PAtients randomized to 6 months treatment of HCTZ.
11609641|NCT00574834|Active Comparator|Ramipril+HCTZ|Patients randomized to 6 months treatment of Ramipril+HCTZ.
11609642|NCT00574808|Experimental|intervention|Outreach Facilitation implementing elements of the Chronic Care Model. The facilitators will provide hands on support to practices and help to implement tools and processes designed to incorporate evidence-based practice into the routine delivery of cardiovascular care. Specifically, they will a) assist with practice performance assessment, feedback, and consensus building towards goal setting, b) offer clinical, technical, organizational resources and practical advice, and c) provide encouragement to face and overcome the challenges of implementing system change.
11609643|NCT00574808|No Intervention|control|Baseline data before implementation of the program will serve as the control. Comparisons will be made between baseline and post-intervention within each divisions of primary care practices as well as between divisions (ie. baseline information from one division will serve as the control for another).
11609644|NCT00574769|Experimental|1|
11609645|NCT00574756|Other|1|Active drug for 2 weeks, then washout period for 2 weeks, then placebo for 2 weeks
11609646|NCT00574756|Other|2|Placebo for 2 weeks, then washout for 2 weeks, then ranolazine for 2 weeks
11609647|NCT00574743|No Intervention|2|
11609648|NCT00574743|Active Comparator|1|
11609649|NCT00574730|Experimental|Arm 1|
11609650|NCT00574717|Experimental|A|Infants will receive spectacle under-correction of their hyperopia.
11609651|NCT00574704|Experimental|1|
11609652|NCT00574704|Placebo Comparator|2|
11609653|NCT00574704|Experimental|3|
11609654|NCT00574704|Placebo Comparator|4|
11609655|NCT00574691|Other|1|Vascular Closure Device
11609656|NCT00574678|No Intervention|1|
11609657|NCT00574665|Experimental|1|
11609658|NCT00574652|Other|1|it is a single arm study
11609659|NCT00574639|Experimental|Arm 1|Day 1 study two hyperinsulinemic (high Insulin dose) euglycemic (normal glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
11609660|NCT00574639|Experimental|Arm 2|Day 1 study two hyperinsulinemic (high Insulin dose) euglycemic (normal glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
11609661|NCT00574639|Experimental|Arm 3|Day 1 study two hyperinsulinemic (high Insulin dose) hypoglycemic (low glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
11609662|NCT00574639|Experimental|Arm 4|Day 1 study two hyperinsulinemic (high Insulin dose) hypoglycemic (low glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
11609663|NCT00574626|Experimental|PBSCT|Peripheral Blood Stem Cell Transplant
11609664|NCT00574626|Active Comparator|BMT|Bone Marrow Transplantation
11609665|NCT00574613|Experimental|1|
11609666|NCT00574613|Placebo Comparator|2|
11609667|NCT00574600|Experimental|Vaccine|SAAVI DNA-C2 administered as 1 ml intramuscularly in either deltoid at study entry and Months 1 and 2; SAAVI MVA-C administered as 0.5 ml intramuscularly in either deltoid at Months 4 and 5
11609668|NCT00574600|Placebo Comparator|Placebo|Placebo administered at Months 0, 1, 2, 4 and 5
11609669|NCT00574587|Experimental|Vorinostat Plus Paclitaxel|Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks (and trastuzumab if HER2-positive), followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery
11609670|NCT00574574|Experimental|1|500mg/d of anthocyanin, contained in 4 X 250mg capsules (125mg anthocyanin/ capsule). 2 capsules to be taken with food, twice per day (n=4 in total).
11609671|NCT00574574|Placebo Comparator|2|500mg/d of placebo control containing no anthocyanin, 2 X 250mg capsules to be taken with food, twice per day (n=4, 250mg capsules in total / d).
11609672|NCT00574548|Experimental|Group 1.1|Group 1.1 = 13vPnC then 13vPnC
11609673|NCT00574548|Experimental|Group 1.2|Group 1.2 = 13vPnC then 23vPS
11609674|NCT00574548|Experimental|Group 2|Group 2 = 23vPS then 13vPnC
11609675|NCT00574522|Other|1|Infrared Radiation, wavelength between 5 and 20 microns
11609676|NCT00574509|Experimental|131I-Anti-B1|BEAM + 131Iodine-Anti-B1 radioimmunotherapy and autologous HSCT
11609677|NCT00574496|Experimental|High-Risk or Relapsed Hodgkin Lymphoma|This is a phase 2 intention-to-treat study of salvage chemotherapy followed by allogeneic HSC transplant for the treatment of primary refractory or relapsed HL. Patients who 1) do not progress on salvage chemotherapy, and 2) have both suitable HSC donors and 3) a satisfactory pre-allograft work-up will proceed to allograft. Patients who fail any of these 3 criteria will be off-study and considered treatment failures for the purposes of the intention-to-treat study.
11609678|NCT00574483|Experimental|1|Unblinded treatment arm
11609679|NCT00574470|Experimental|1|Treatment with daclizumab/infliximab
11609680|NCT00574457|Other|All subjects that meet the inclusion criteria invited|
11609731|NCT00574067|Active Comparator|Counseling + CHC|Counseling only in prisons and Buprenorphine upon release at a community health center (CHC)
11609732|NCT00574054|Other|1|
11609681|NCT00574444|Experimental|Procedure|Procedure/Surgery: transvaginal diagnostic peritoneoscopy For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
11609682|NCT00574431|Other|Observation|Observation
11609683|NCT00574431|Active Comparator|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
11609684|NCT00574418|Other|1|
11609685|NCT00574405|Active Comparator|1|MDI = 3-4+ insulin injections/day, using split-mix NPH insulin + regular insulin or Lantus + Novolog® (or Humalog®).
11609686|NCT00574405|Experimental|2|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
11609687|NCT00574392||1|Multiwavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented lesions on skin in vivo
11609688|NCT00574379|Experimental|1|Bilastine 20mg once per day
11609689|NCT00574379|Experimental|2|Bilastine 20mg twice per day
11609690|NCT00574379|Experimental|3|Bilastine 10mg once per day
11609691|NCT00574379|Experimental|4|Bilastine 10mg twice per day
11609692|NCT00574379|Placebo Comparator|5|
11609693|NCT00574366|Experimental|Erlotinib/RAD001 Ph I|"Tarceva (OSI-774; erlotinib) Everolimus (RAD001)
~Study did not progress to Phase II:
~Experimental: Erlotinib/RAD001 Phase II Maximum tolerated dose of erlotinib (Tarceva,OSI-774) and RAD001 (Everolimus)"
11609694|NCT00574353|Experimental|1|FMISO PET study.
11609695|NCT00574340|Active Comparator|Control study then antecedent hypoglycemia study group|Day 1 euglycemia, day 2 hypoglycemia Hyperinsulinemic Hypoglycemic Clamp: hyperinsulinemic glucose clamp separated by 8 weeks then participants proceeded to antecedent hypoglycemia study Day 1 hypoglycemia, Day 2 hypoglycemia
11609696|NCT00574340|Active Comparator|Antecedent Hypoglycemic clamp study|Day 1 hypoglycemia, day 2 hypoglycemia Hyperinsulinemic Hypoglycemic Clamp: hyperinsulinemic glucose clamp separated by 8 weeks then participants proceeded to control study Day 1 euglycemia, Day 2 hypoglycemia
11609697|NCT00574327||A- Barrett's Esophagus subjects|Patients with documented Barrett's Esophagus with or without dysplasia (LGD or HGD) that will undergo surveillance endoscopies dictated by the grade of dysplasia.
11609698|NCT00574327||B- gastroesophageal reflux subjects|Patients undergoing endoscopy for evaluation of GERD symptoms.
11609699|NCT00574327||C-subjects without BE or GERD|The control group would include patients undergoing upper endoscopy for reasons other than stated above, such as evaluation of iron deficiency anemia, weight loss, positive fecal occult blood, etc.
11609700|NCT00574314||Women|Women with varying backgrounds
11609701|NCT00574301|Experimental|1|
11609702|NCT00574288|Experimental|Dose Escalation: Daratumumab|
11609703|NCT00574288|Experimental|Dose Expansion: Daratumumab|
11609704|NCT00574275|Placebo Comparator|Placebo and Gemcitabine|Participants with metastatic pancreatic cancer administered Placebo and 1000 mg/m^2 Gemcitabine.
11609705|NCT00574275|Experimental|Aflibercept and Gemcitabine|Participants with metastatic pancreatic cancer administered 4 mg/kg Aflibercept and 1000 mg/m^2 Gemcitabine.
11609706|NCT00574249|Active Comparator|adalimumab + placebo|adalimumab + placebo (vehicle ointment)
11609707|NCT00574249|Active Comparator|adalimumab + calcipotriol/betamethasone|adalimumab + calcipotriol/betamethasone ointment
11609708|NCT00574236|Experimental|A|
11609709|NCT00574223|Experimental|Arm 1|
11609710|NCT00574223|Placebo Comparator|Arm 2|
11609711|NCT00574210|Experimental|1|Bilastine oral 20 mg once per day (1 x 20 mg bilastine tablet plus 1 placebo tablet)
11609712|NCT00574210|Experimental|2|Bilastine oral 20 mg twice per day (2 x 20 mg bilastine tablets)
11609713|NCT00574210|Experimental|3|Bilastine oral 10 mg once per day (1 x 10 mg bilastine tablet plus 1 placebo tablet)
11609714|NCT00574210|Experimental|4|Bilastine oral 10 mg twice per day (2 x 10 mg bilastine tablets)
11609715|NCT00574210|Placebo Comparator|5|Placebo oral twice per day (2 placebo tablets)
11609716|NCT00574197|Other|Enteric-coated Mycophenolate Sodium (Myfortic)|1440mg/day (720mg by mouth, twice a day) of enteric-coated Mycophenolate Sodium (Myfortic) for 6 months
11609717|NCT00574171|Experimental|1|
11609718|NCT00574145|Experimental|Radiotherapy/Supportive Care (A)|Patients receive radiotherapy and healing touch therapy from a healing touch therapist once a week for the duration of their radiotherapy
11609719|NCT00574145|Sham Comparator|Control ARM (B)|Patients receive radiotherapy and sham healing touch therapy from a sham healing touch therapist once a week for the duration of their therapy
11609720|NCT00574132|Experimental|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
11609721|NCT00574132|Placebo Comparator|Placebo Control|infusion every 13 weeks for a total of 6 infusions.
11609722|NCT00574132|Experimental|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions.
11609723|NCT00574119|Experimental|Results with spironolactone|patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.
11609724|NCT00574106|Other|1|Infrared Radiation
11609725|NCT00574093|Experimental|A|A: This will be a single arm study. Patients will be administered Lucentis™ on Day 1,at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
11609726|NCT00574080|Experimental|Arm A|DPACE Induction, Melphalan/DPACE Transplant 1, BEAM Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases
11609727|NCT00574080|Experimental|Arm B|DPACE Induction, Melphalan/DPACE + VTD Transplant 1, BEAM + VTD Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases
11609728|NCT00574067|Experimental|Buprenorphine+OTP|Buprenorphine and counseling in prison and continued at opioid treatment program (OTP) upon release.
11609729|NCT00574067|Experimental|Buprenorphine+CHC|Buprenorphine and counseling in prison and continued at a community health center (CHC) upon release.
11609730|NCT00574067|Active Comparator|Counseling + OTP|Counseling only in prison and Buprenorphine upon release at a opioid treatment program (OTP)
11609733|NCT00574041|Experimental|1|titrated dose of Avonex
11609734|NCT00574041|Active Comparator|2|full dose Avonex
11609735|NCT00574015|Active Comparator|oral|administration of oral analgesia
11609736|NCT00574015|Experimental|Dental Block|Administration of supraperiosteal nerve block to effected tooth
11609737|NCT00574002||Group A|Patients that have their chest tube removed when drainage is 400mL or less in 24 hours.
11609738|NCT00574002||Group B.|Patients that have their chest tube removed when drainage is 200mL or less in 24 hours.
11609739|NCT00573989|Experimental|Erlotinib|Erlotinib
11609740|NCT00573963|Active Comparator|1|Ropivacaine
11609741|NCT00573963|Placebo Comparator|2|Placebo
11609742|NCT00573950|Experimental|Cilostazol|cilostazol group
11609743|NCT00573950|Placebo Comparator|Placebo|placebo group
11609744|NCT00573937|Active Comparator|Methadone|Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
11609745|NCT00573937|Active Comparator|Morphine|Oral slow-release morphine (15 mg) every 8 hours, and immediate-release morphine (10 mg) every 4 hours as needed for breakthrough pain.
11609746|NCT00573924|Active Comparator|1|Oral PPI
11609747|NCT00573924|Active Comparator|2|Intravenous PPI
11609748|NCT00573885|Experimental|Arm I|Patients receive oral defined green tea catechin extract twice daily for 6 months.
11609749|NCT00573885|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 6 months.
11609750|NCT00573872|Experimental|Spinal Radiosurgery|Patients will be fitted in a custom immobilization device. A CT simulation scan will then be performed to pinpoint intended radiosurgery target producing a computer optimized radiation plan to be confirmed by planning radiation physicist. Patient will then be placed in their immobilization device and aligned with the treatment planning position. Patient then receives radiosurgery. Treatment delivery will be divided into components of 3-5Gy with repeat CT based localization in between each of these components. For all patients, a nominal prescription dose of 24Gy will be entered into the tomotherapy cost function. Once the plan that provides maximal spinal sparing has been generated, the plan will be renormalized to produce no more than 8Gy (prior RT) or 10Gy (no prior RT) to 0.5cc of spinal cord by dividing the single fraction treatment into fractions of 3-5Gy.
11609751|NCT00573859|Experimental|ADHD medication versus placebo|For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication (e.g., Dextroamphetamine; Amphetamine mixed salts; Atomoxetine; O-Methylphenidate; Lisdexamfetamine). For the placebo condition, a placebo pill was administered.
11609752|NCT00573833|Experimental|HDR Brachytherapy|9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days
11609753|NCT00573820|Other|1|
11609754|NCT00573807|Other|1|
11609755|NCT00573794|Experimental|Adalimumab 40 mg EOW/EW|Open-label adalimumab 40 mg every other week (EOW) or every week (EW). Participants who entered from an open-label cohort continued their previous dosing regimen of adalimumab EOW or EW; participants who entered from a double-blind cohort received adalimumab EOW.
11609756|NCT00573781|Experimental|A|Diet with increased intake of rye bread, berries and fish
11609757|NCT00573781|Experimental|B|Increased intake of whole grain and rye bread
11609758|NCT00573781|Active Comparator|C|Control diet with decreased intake of rye bread, berries and fish
11609759|NCT00573768|Active Comparator|1|
11609760|NCT00573768|Placebo Comparator|2|
11609761|NCT00573768|Active Comparator|3|
11609762|NCT00573755|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11609763|NCT00573755|Active Comparator|Arm II|Patients receive oral placebo twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11609764|NCT00573729|Experimental|Pulsed Dye Laser 577 nm|Pulsed Dye Laser Treatment 577 nm treatment of Port Wine Stain Birthmarks
11609765|NCT00573729|Experimental|Pulsed Dye Laser 595 nm|Pulsed Dye Laser Treatment 595 nm treatment of Port Wine Stain Birthmarks
11609766|NCT00573716||1|15 subjects who are taking aripiprazole monotherapy
11609767|NCT00573716||2|15 subjects who are taking Risperidone therapy
11609768|NCT00573716||3|30 healthy volunteers with an ethnicity, sex, and pubertal stage match of subjects taking aripiprazole monotherapy and Risperidone therapy
11609769|NCT00573703|Active Comparator|Group A|
11609770|NCT00573703|Experimental|Group B|
11609771|NCT00573690|Experimental|Group 1|Patients receive cisplatin IV over 1 hour on day 2 of courses 1 and 2 and on day 1 of all subsequent courses; etoposide IV over 30 minutes on days 1-3; and oral sorafenib tosylate once or twice daily on days 1-21. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.
11609772|NCT00573690|Experimental|Group 2|Patients receive carboplatin IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Patients also receive sorafenib tosylate as in group 1. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.
11609773|NCT00573664|Active Comparator|1|Gabapentin
11609774|NCT00573664|Placebo Comparator|2|Placebo
11609775|NCT00573651|Other|Group A pauciarticular JIA|Females age 9-26 with pauciarticular JIA. All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some Blood Draws for serum titres taken to measure antibody and RNA titers.
11609776|NCT00573651|Other|Group B polyarticular JIA|Females age 9-26 with polyarticular JIA. All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some Blood Draws for Serum Titers taken to measure antibody and RNA titers.
11609777|NCT00573651|Other|Group C seronegative arthritis|Females age 9-26 with seronegative arthritis (including ankylosing spondylitis and psoriatic arthritis). All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers.
11609832|NCT00573157|Placebo Comparator|Placebo Plus Mycophenolate mofetil Plus Corticosteroids|
11610435|NCT00568256|Other|Other|Mind/Body Course
11609778|NCT00573612|Placebo Comparator|1|Telephone Call for the Attention Control Group Each AC call will follow the same format as the MI call. During the AC call, study subjects will receive health information on important topics relevant to their illness. Specifically, there will be one topic during each phone call that includes the following: (a) overview of FMS, (b) pain, (c) fatigue (d) sleep, (e) stress, and (f) living well with FMS. The AC calls will be an avenue to transfer relevant health information from the RA to the study subject. The scheduled topics during each contact will give the call face validity (i.e., establish a credible pretense for the contact) while being neutral with respect to encouragement of exercise.
11609779|NCT00573612|Active Comparator|2|Telephone-delivered Motivational Interviewing Participants will receive 6 telephone calls throughout the study. Harland et al reported that the most effective intervention for promoting exercise in the primary care setting was the most intensive treatment arm that included six MI sessions (208). Importantly, in our pilot study, participants who completed 5 to 6 phone calls achieved greater symptomatic benefits than participants who had ≤ 4 phone calls. The phone calls will be scheduled at week 3, 4, 6, 8, 10 and 12 of the study. Telephone sessions may run for 30 minutes on the average
11609780|NCT00573599|Experimental|1|prochlorperazine and benadryl IV, saline subQ
11609781|NCT00573599|Active Comparator|2|imitrex SubQ, saline IV
11609782|NCT00573586|Other|HIFU|"Completely destroy prostate cancer tissue, without causing damage to the intervening tissue, with a drop in PSA levels to <0.5ng/ml.
~Result in negative biopsies for evidence of viable malignant cells after the treatment (12 months if Nadir is not reached or PSA rises from Nadir)
~Safely treat localized prostate cancer patients, with minimal and acceptable adverse effects"
11609783|NCT00573573|Other|1|
11609784|NCT00573534|Experimental|Open Label Vyvanse|Open Label Vyvanse (lisdexamphetamine) in doses of 30-70 mgs over 8 weeks in younger siblings of substance abusing older siblings with a history of treatment for ADHD
11609785|NCT00573508|Active Comparator|Placebo|Matching placebo tablet taken once daily
11609786|NCT00573508|Experimental|Solifenacin Succinate|5mg or 10mg tablet taken once daily
11609787|NCT00573495|Experimental|hTERT/Survivin Multi-Peptide Vaccine|
11609788|NCT00573482|Active Comparator|control group|Control (only exposure to the food labels and the new lower ED foods).
11609789|NCT00573482|Experimental|intervention group|Education in REDE techniques plus exposure to the food labels and the new lower ED foods.
11609790|NCT00573469|Active Comparator|1|D9421-C 9 mg
11609791|NCT00573469|Active Comparator|2|D9421-C 15 mg
11609792|NCT00573469|Placebo Comparator|3|Placebo
11609793|NCT00573456|Other|1|
11609794|NCT00573443|Experimental|DM 30 mg/Q 10 mg|AVP-923-30/10 Capsules (30 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
11609795|NCT00573443|Experimental|DM 20 mg/ Q 10 mg|AVP-923-20/10 Capsules (20 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
11609796|NCT00573443|Placebo Comparator|Placebo|Placebo Capsules once daily for 1 week and then twice daily for an additional 11 weeks
11609797|NCT00573430|Experimental|1|Candesartan Cilexetil
11609798|NCT00573430|Experimental|2|Candesartan Cilexetil
11609799|NCT00573430|Experimental|3|Candesartan Cilexetil
11609800|NCT00573417|Experimental|modafinil|modafinil 100mg, 200mg, or 300mg (dose escalation)
11609801|NCT00573417|Placebo Comparator|placebo|placebo
11609802|NCT00573404|Experimental|Therapeutic Intervention|
11609803|NCT00573391|Experimental|VTD = Velcade, Thal, and Dex|VTD = Velcade, Thalidomide, and Dexamethasone
11609804|NCT00573391|Experimental|VMD = velcade, melphalan, and dex|VMD = velcade, melphalan, and dexamethasone
11609805|NCT00573378|Experimental|1|
11609806|NCT00573365|Experimental|Treatment|LED treatment with Gentlewaves Select™ handheld high energy LED array 5 to 10 minutes before each radiation treatment and again 5-10 minutes after each radiation treatment
11609807|NCT00573365|Other|Control|Radiation only
11609808|NCT00573352|Other|1|Far infrared radiation
11609809|NCT00573339||Normal Controls|
11609810|NCT00573326|Experimental|1|Imatinib 200 mg p.o. once a day for 6 months
11609811|NCT00573313|Experimental|S-adenosylmethionine (SAMe)|Alcoholic liver disease patients receiving S-adenosylmethionine (SAMe)at 400 mg capsule three times daily for 24 weeks
11609812|NCT00573313|Placebo Comparator|Sugar pill|ALD subjects receiving Placebo three times daily for 24 weeks.
11609813|NCT00573300||Schizophrenia|Schizophrenia Patients
11609814|NCT00573300||Healthy Controls|Healthy Controls
11609815|NCT00573287|Experimental|Clozapine|clozapine: clozapine--tablets, 12.5-100 mg, daily for 24 weeks
11609816|NCT00573287|Active Comparator|Risperidone|risperidone: risperidone--tablets, 0.5-5.0mg daily for 24 weeks
11609817|NCT00573274||1|Elective cesarean section patients
11609818|NCT00573261|Experimental|Pregabalin|Pregabalin medication
11609819|NCT00573261|Placebo Comparator|Placebo|Placebo
11609820|NCT00573248|Experimental|4|
11609821|NCT00573209|Other|1|
11609822|NCT00573196|Experimental|1|
11609823|NCT00573183|Experimental|STAGE-12|STAGE-12 received 3 individual and 5 group 12-step facilitation sessions focusing on 12-step principles plus an intensive referral in which counselors linked participants to community-based 12-step volunteers. These sessions took the place of 3 individual and 5 group sessions in the standard intensive outpatient drug treatment program and were integrated into treatment as usual.
11609824|NCT00573183|Active Comparator|Treatment as Usual|Treatment as usual received standard care provided in intensive outpatient drug treatment program without the STAGE-12 components.
11609825|NCT00573170|Other|TPB|TREXIMET® (Attack 1), placebo (Attack 2), BCM (Attack 3)
11609826|NCT00573170|Other|TBP|TREXIMET® (Attack 1), BCM (Attack 2), placebo (Attack 3)
11609827|NCT00573170|Other|BTP|BCM (Attack 1), TREXIMET® (Attack 2), placebo (Attack 3)
11609828|NCT00573170|Other|BPT|BCM (Attack 1), placebo (Attack 2), TREXIMET® (Attack 3)
11609829|NCT00573170|Other|PTB|placebo (Attack 1), TREXIMET® (Attack 2), BCM (Attack 3)
11609830|NCT00573170|Other|PBT|placebo (Attack 1), BCM (Attack 2), TREXIMET® (Attack 3)
11609831|NCT00573157|Experimental|Atacicept Plus Mycophenolate mofetil Plus Corticosteroids|
11617468|NCT00510718|Experimental|1|MDV3100
11609833|NCT00573144|Placebo Comparator|Placebo|Infusion of 72 hours of saline solution (packaged to match active comparator).
11609834|NCT00573144|Active Comparator|Nesiritide|Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
11609835|NCT00573131|Experimental|Group 1|OncoGel, radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.
11609836|NCT00573131|Active Comparator|Group 2|Radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.
11609837|NCT00573118||1|The study group included 49 patients with a previous history of one or more of the following pregnancy complications: preeclampsia (n = 17), severe IUGR (n = 13), IUFD (n = 14) or placental abruption (n = 5).
11609838|NCT00573118||2|The control group included 49 healthy women who delivered during the study period, who did not smoke during pregnancy and in whom pregnancy and delivery were uneventful
11609839|NCT00573105|Experimental|1|Laparoscopic Ventral hernia repair by heavy weight mesh
11609840|NCT00573105|Experimental|2|Laparoscopic Ventral hernia repair by lighter weight mesh
11609841|NCT00573092||1|Data and specimens from three large population-based studies of heart attack, sudden death, and stroke in people treated for high blood pressure with one of the four major classes of high blood pressure drugs
11609842|NCT00573079||Observation|Premature infants in the NICU; 500-1500g birthweight, >=25 weeks gestation
11609843|NCT00573066|Experimental|Dosing level|A predetermined dose of Dexmedetomidine
11609844|NCT00573053|Active Comparator|High|Arterial oxygen saturations in the range of 91-95%
11609845|NCT00573053|Experimental|Low|Arterial oxygen saturations in the range of 85-89%
11609846|NCT00573040||1|"Inclusion criteria
~Histological or cytological proven NSCLC
~UICC stage I-III
~Performance status 0-2
~FeV1 and DLCO at least 30% of age-predicted value
~Exclusion criteria:
~Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)
~Stage IV
~Performance status 3 or more
~FeV 1 or DLCO < 30% of the age-predicted value"
11609847|NCT00573027|Other|Single Arm|"fill out baseline demographic and health/medical history questionnaires, CV risk factors, reasons of diagnosis of ischemia, information of coronary artery, and medication use
~undergo clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory (Appendix);
~undergo noninvasive Peripheral Artery Tonometry (PAT) testing (Appendix);
~undergo clinically indicated Cardiac Magnetic Resonance (CMR) imaging (Appendix) to detect subendocardial ischemia (if indicated and referred by the treating physician). The three tests (heart catheterization with adenosine coronary flow reserve testing, acetylcholine provocative vasomotor testing during heart catheterization, cardiac MRI) are performed for standard care.
~have blood and urine testing.
~fill out health questionnaires
~be followed prospectively 6-week, 6-month, and annually for clinical status"
11609848|NCT00573014||OBTP|Obtunded blunt trauma patients with normal CT C-spine
11609849|NCT00573001|Experimental|1|
11609850|NCT00573001|Experimental|2|
11609851|NCT00573001|Experimental|3|
11609852|NCT00573001|Active Comparator|4|
11609853|NCT00572975|Experimental|1|
11609854|NCT00572962|Experimental|1|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
11609855|NCT00572949||1|Patients with chest pain syndrome
11609856|NCT00572936|Other|Latanoprost/Dorzolamide/Timolol|The participants received latanoprost at night and vehicle in the morning for two weeks, then 6 week washout, then Dorzolamide BID for two weeks, then 6 week washout, then Timolol BID for two weeks. The order in which the participants received the three different drugs was random.
11609857|NCT00572923||1|"Inclusion criteria
~Histological or cytological proven SCLC
~UICC stage I-III, limited disease
~Performance status 0-2
~FeV1 and DLCO at least 30% of age-predicted value
~Exclusion criteria:
~Not SCLC or mixed SCLC and other histologies (e.g. non-small cell carcinoma)
~stage IV
~performance status 3 or more
~FeV 1 or DLCO< 30% of the age-predicted value"
11609858|NCT00572910|Experimental|V710 - Group 1|V710 (60 mcg without MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
11609859|NCT00572910|Experimental|V710 - Group 2|V710 (60 mcg without MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
11609860|NCT00572910|Experimental|V710 - Group 3|V710 (60 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
11609861|NCT00572910|Experimental|V710 - Group 4|V710 (60 mcg with MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
11609862|NCT00572910|Experimental|V710 - Group 5|V710 (90 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
11609863|NCT00572910|Placebo Comparator|Group 6|Placebo on Day 1, 28 and 180.
11609864|NCT00572897|Experimental|Fludarabine, Melphalan +/- ATG|Fludarabine, Melphalan +/- ATG
11609865|NCT00572871||Exercise after fasting|Will complete 2 resistance exercise sessions and 2 plyometric exercise sessions after a 10-hour fast
11609866|NCT00572871||No exercise|Will complete a ten-hour fast but do no exercise
11609867|NCT00572871||Exercise after snack|Will complete 2 resistance exercise sessions and 2 plyometric exercise sessions 2 hours following a 500 calorie nutritional supplement
11609868|NCT00572858||Premenopausal women|Female patients who have undergone coronary angiography and are under the age of 55
11609869|NCT00572845|Experimental|1|Weaning of Spasticity Medication over a three day period while measuring Modified Ashworth Scale and Penn Spasm Frequency Score. Then titration of medication back to previous dose over a three day period.
11609870|NCT00572832|Active Comparator|6 mon. 3rd dose of quadrivalent human papillomavirus vaccine|Receipt of three doses of quadrivalent human papillomavirus vaccine according to the regular schedule of 0,2, and 6 months.
11609871|NCT00572832|Active Comparator|12 mon. 3rd dose of quadrivalent human papillomavirus vaccine|Receipt of three doses of quadrivalent human papillomavirus vaccine on a delayed schedule of 0,2, and 12 months.
11609872|NCT00572819|Active Comparator|Misoprostol|
11609873|NCT00572819|Placebo Comparator|Placebo|
11609874|NCT00572780||CTE with CD|Crohn's disease patients who underwent a CT enteroclysis as part of their clinical evaluation for symptomatic Crohn's disease.
11609875|NCT00572767|Experimental|1|
11609876|NCT00572767|Placebo Comparator|2|
11609877|NCT00572741|Experimental|1|Nutritional supplementation
11609878|NCT00572741|Placebo Comparator|2|Placebo
11609879|NCT00572728|Experimental|Diagnostic (18F-FLT)|Patients undergo 18F-FLT PET /CT at baseline (prior to chemotherapy, FLT-1), early therapy (5-10 days after the initiation of the first course of chemotherapy, FLT-2), and post therapy (within 3 weeks prior to surgery, FLT-3). Patients undergo standard surgical resection of residual tumor following completion of neoadjuvant chemotherapy.
11609880|NCT00572715||Observation|"Inclusion criteria - Families of infants (birthweight >1500g) be asked to participate in the study.
~Exclusion criteria - Infants with prenatal renal ultrasound diagnosis of severe hydronephrosis or other known renal abnormalities will be excluded"
11609881|NCT00572702|Active Comparator|A|Patients with 3 compartment pelvic organ prolapse after hysterectomy, treated with Amreich-Richter procedure; it will be set randomly
11609882|NCT00572702|Active Comparator|B|Patients with 3 compartment pelvic organ prolapse after hysterectomy, treated with total Prolift procedure; it will be set randomly
11609883|NCT00572689|Experimental|A|Subject receives injection of 10 micrograms of Exenatide sub-cutaneously the given mixed meal test and blood samples will be drawn for laboratory testing.
11609884|NCT00572689|No Intervention|B|Patients given mixed meal test and blood samples drawn for laboratory testing
11609885|NCT00572650|Active Comparator|1|
11609886|NCT00572624|Experimental|Diet|Participants who received counseling and instruction about weight loss through diet and exercise
11609887|NCT00572624|Experimental|Gastric bypass surgery|Participants who received gastric bypass surgery
11609888|NCT00572611|Experimental|I|Single oral dose of 20 mg [14C]-bilastine
11609889|NCT00572585|Experimental|AEB071|
11609890|NCT00572585|Placebo Comparator|Placebo|
11609891|NCT00572572|Experimental|Arm A: Aprepitant, Then Placebo|Participants first received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 1, then received matched placebo PO daily on days 3 through 7 during study cycle 2
11609892|NCT00572572|Experimental|Arm B: Placebo, Then Aprepitant|Participants first received matched placebo PO daily on days 3 through 7 during study cycle 1, then received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 2
11609893|NCT00572559|Experimental|1|
11609894|NCT00572559|Experimental|2|
11609895|NCT00572533|Active Comparator|Control|ESA Dose Adjustment per standard Anemia Management Protocol
11609896|NCT00572533|Experimental|Treatment|"ESA Dose Adjustment per Smart Anemia Manager Algorithm"
11609897|NCT00572520|Active Comparator|1|Evidence-based behavioral weight loss treatment with health education counseling
11609898|NCT00572520|Experimental|2|Evidence-based behavioral weight loss treatment with brief behavior therapy for depression
11609899|NCT00572507|Experimental|MonoMax|MonoMax is used for abdominal wall closure
11609900|NCT00572494|Experimental|1|Stenting with AMS
11609901|NCT00572494|Active Comparator|2|PTA alone
11609902|NCT00572481|Other|Sentinel Lymph Node Biopsy Only|Axillary Reverse Mapping
11609903|NCT00572481|Other|Full Axillary Lymph Node Dissection|Axillary Reverse Mapping
11609904|NCT00572468|Active Comparator|Simvastatin|Twenty-two men will be on the Statin arm and take 40 mg of simvastatin.
11609905|NCT00572468|Placebo Comparator|Placebo|Twenty-two men will be on the placebo arm.
11609906|NCT00572455|Experimental|Stage 1: PF-04217329 - Lowest Dose|
11609907|NCT00572455|Experimental|Stage 1: PF-04217329 - Low Dose|
11609908|NCT00572455|Experimental|Stage 1: PF-04217329 - Middle Dose|
11609909|NCT00572455|Experimental|Stage 1: PF-04217329 - High Middle Dose|
11609910|NCT00572455|Experimental|Stage 1: PF-04217329 - High Dose|
11609911|NCT00572455|Experimental|Stage 1: PF-02417329 - Highest Dose|
11609912|NCT00572455|Experimental|Stage 1: PF-04217329 - Vehicle|
11609913|NCT00572455|Experimental|Stage 2: PF-04217329 - Low Dose + Latanoprost Vehicle|
11609914|NCT00572455|Experimental|Stage 2: PF-04217329 - Middle Dose + Latanoprost Vehicle|
11609915|NCT00572455|Experimental|Stage 2: PF-04217329 - High Dose + Latanoprost Vehicle|
11609916|NCT00572455|Experimental|Stage 2: PF-04217329 - Low Dose + Latanoprost 0.005%|
11609917|NCT00572455|Experimental|Stage 2: PF-04217329 - Middle Dose + Latanoprost 0.005%|
11609918|NCT00572455|Experimental|Stage 2: PF-04217329 - High Dose + Latanoprost 0.005%|
11609919|NCT00572455|Experimental|Stage 2: PF-04217329 - Vehicle + Latanoprost 0.005%|
11609920|NCT00572442||1|"Subjects without any cardiovascular risk factors:
~Age ≥ 45 in men; Age ≥ 55 in women.
~Hypertension: BP > 140/90 mmHg or on BP meds.
~Diabetes Mellitus: Known fasting blood sugar >126 mg/dl or on DM meds.
~Dyslipidemia: On lipid lowering medication or LDL ≥ 160 mg/dl in absence of other risk factors; ≥ 130 mg/dl if other non-diabetic risk factors; ≥ 100 mg/dl if diabetic. Known HDL < 40 mg/dl.
~Cigarette smoking (past or present).
~Family history of premature CAD in first degree relatives: Age < 55 in men; Age < 65 in women."
11609921|NCT00572442||2|Subjects with 1 cardiovascular risk factor (listed above)
11609922|NCT00572442||3|Subjects with 2 cardiovascular risk factors (listed above)
11609923|NCT00572442||4|Subjects with more than 2 cardiovascular risk factors (listed above)
11609924|NCT00572429|Placebo Comparator|A|
11609925|NCT00572416|Experimental|1|Four component behavioral sleep intervention comprised of activity-rest, sleep-wake, phychological distress and symptom management. Four components of the Individual Sleep Promotion Plan are: stimulus control, sleep restruction, relaxation, and sleep hygiene.
11609926|NCT00572416|Placebo Comparator|2|Equal time and attention, information about healthy eating and general conversation
11609927|NCT00572390|Placebo Comparator|1|No oestrogen treatment
11609928|NCT00572390|Experimental|2|Oestrogen treatment
11609929|NCT00572377|Active Comparator|FemLife Gel|
11609930|NCT00572377|Placebo Comparator|Placebo|
11609931|NCT00572351|Active Comparator|Red Wine|
11609932|NCT00572351|Active Comparator|White Wine|
11609933|NCT00572338||patients with myeloma/related diseases|
11609934|NCT00572325||1|"Inclusion criteria
~Histological or cytological proven NSCLC
~UICC stage I-III
~Performance status 0-2
~FeV1 and DLCO at least 30% of age-predicted value
~Exclusion criteria:
~Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)
~stage IV
~performance status 3 or more
~FeV 1 or DLCO< 30% of the age-predicted value"
11609935|NCT00572299||glucocorticoids|patients receiving glucocorticoid treatment
11609936|NCT00572299||glucocorticoids and bisphosphonates|patients receiving both glucocorticoids and bisphosphonates
11609937|NCT00572286||1|heart transplant patient ( pre or post)
11609938|NCT00572260|Experimental|A|Daptomycin as a single preoperative dose within 30 minutes prior to surgery Dosage: if creatinine clearance ≥ 30 ml/min: 6 mg/kg IV
11609939|NCT00572247|Experimental|1|Behavioral
11609940|NCT00572247|No Intervention|2|
11609941|NCT00572234|Experimental|Receiving Bupropion SR|receiving bupropion SR 12 week course of bupropion SR 150 mg, BID (twice a day)
11609942|NCT00572234|No Intervention|Treatment as Usual|Not receiving bupropion
11609943|NCT00572221|Other|CQI Program Only|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. (The SAVE+ intervention, the CQI system with facility responsible for identifying or designing care protocols for the identified problem condition.)
11609944|NCT00572221|Other|CQI Program and Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions. (The SAVE+ intervention, a CQI system plus best-practice protocols designed by study team to address identified problem condition.)
11609945|NCT00572208|Active Comparator|1|Gabapentin group
11609946|NCT00572208|No Intervention|2|placebo
11609947|NCT00572195|Experimental|Evaluation Group (stimulation ON)|Group of subjects that have an RNS® System implanted, completed the RNS® System Pivotal or Feasibility study, and elected to continue to receive RNS® System responsive stimulation for the long term.
11609948|NCT00572169|Experimental|VDTPACE|Velcade, Dexamethasone, Thalidomide, Cisplatinin, Adriamycin, Cyclophosphamide and Etoposide
11609949|NCT00572156|Active Comparator|1. rhGH Alone|
11609950|NCT00572156|Experimental|2. Combination Dose|
11609951|NCT00572156|Experimental|3. Combination Dose|
11609952|NCT00572156|Experimental|4. Combination Dose|
11609953|NCT00572143|Active Comparator|1|Postoperative follow-up of ca coli patients at the surgical outpatient dpt
11609954|NCT00572143|Active Comparator|2|Postoperative follow-up of ca coli patients by GP's
11609955|NCT00572130|Experimental|Rexin-G Dose 1|
11609956|NCT00572130|Experimental|Rexin-G Dose 2|
11609957|NCT00572117|Placebo Comparator|Placebo (inert pill) Arm|Half the participants will receive topiramate and half will receive placebo. Neither participants nor study staff will know who is receiving which pills until the end of the study. Subjects will receive placebo pills identical to the active pills (pills that contain the study drug, topiramate) for the 12 treatment weeks of the study and will have the pills discontinued over the next four weeks of the study. All subjects will be re-evaluated at 26 and 52 weeks.
11609958|NCT00572117|Experimental|Topiramate|Half the participants will receive topiramate and half will receive placebo. Neither participants nor study staff will know who is receiving which pills until the end of the study. The pills will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
11609959|NCT00572104|Experimental|resistance exercise|12 month resistance exercise training
11609960|NCT00572104|Experimental|plyometric exercise|12 month plyometric exercise training
11609961|NCT00572091|Experimental|1|Patient is screened for study and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
11609962|NCT00572078|Experimental|Sorafenib, Bevacizumab & Paclitaxel|Paclitaxel is given as i.v infusion over 60 min on days 1, 8, 15 every 28 days. Sorafenib is given orally starting with cycle 1 day 2. Bevacizumab is given as i.v infusion on days 1 and 15 every 28 days.
11609963|NCT00572065|Experimental|All Patients|Arsenic trioxide [TrisenoxTM Injection], will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12.
11609964|NCT00572039|Experimental|PST|Problem Solving Treatment (PST)
11609965|NCT00572039|Placebo Comparator|ST|Supportive Therapy (ST)
11609966|NCT00572026|Experimental|1|Daytrana
11609967|NCT00572026|No Intervention|2|No treatment for ADHD
11609968|NCT00572013|Experimental|Arm I|
11609969|NCT00571987|Other|1|This is a non-randomized one arm study, all subjects receive treatment (radiofrequency ablation).
11609970|NCT00571974|Experimental|Phase 1 light dose escalation|"During Phase I, to determine the maximum tolerated energy density of the Pulse Dye Laser operated at 585 nm with a pulse time of 1.5 ms (PDL-585), when used in combination with 5-aminolevulinic acid (5-ALA) applied topically to the premalignant lesion.
~The maximum tolerated energy density will be called the Maximum Tolerated Dose (MTD). Procedure: Fluorescence Diagnosis Imaging Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 6, 7 and 8 J/cm2."
11609971|NCT00571974|Experimental|Phase 2 - Treatment efficacy of PDT|"Procedure: Fluorescence Diagnosis Imaging
~Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 8 J/cm2."
11609972|NCT00571961|Experimental|1|HIV negative subjects currently enrolled in a long-term buprenorphine maintenance therapy program for at least 3 months who have been on stable dose of buprenorphine for at least 3 weeks will be admitted to the General Clinical Research Center (GCRC) for pharmacokinetic (PK) blood draws at intervals over a 24-hour period. Subjects will then receive Kaletra and buprenorphine coadministered for 14 days. Subjects will be admitted to the GCRC for a second PK sampling day.
11609973|NCT00571948|Active Comparator|Babyfood with usual meat content and corn oil|Infants in the control group received vegetable-potato-meat-meals as part of complementary food containing common amounts of meat and corn oil marketed in Germany.
11609974|NCT00571948|Experimental|more meat and a vegetable oil rich in omega-3 fatty acids|Infants in the intervention group received vegetable-potato-meat-meals as part of complementary food containing higher amounts of meat than the control group and rapeseed oil instead of corn oil.
11609975|NCT00571922|Active Comparator|Acamprosate|
11609976|NCT00571922|Placebo Comparator|Placebo|
11609977|NCT00571909|Experimental|video thoracoscopic splanchnicectomy (VSPL)|
11609978|NCT00571896|Experimental|SennaS|This group of participants will receive SennaS to use after surgery.
11609979|NCT00571896|Placebo Comparator|Placebo|This group of participants will receive placebo pills to use after surgery.
11609980|NCT00571870|Active Comparator|A|Stimulated as conventional protocol
11609981|NCT00571870|Experimental|B|GnRH antagonist stopped one day earlier than conventional protocol
11609982|NCT00571844|Experimental|DASH diet|
11609983|NCT00571844|Experimental|DASH diet plus Weight loss|
11609984|NCT00571844|No Intervention|Usual Care|Usual Care Control Group: Patients in the Usual Care control group will be asked to maintain their usual dietary and exercise habits for 4 months until they are re-evaluated. At biweekly intervals we will ask patients to describe any spontaneous changes in their eating habits or food preferences. To ensure patient safety, BPs will also be monitored biweekly by our staff.
11609985|NCT00571831|No Intervention|letter|a blue-filtering IOL an UV-filtering IOL
11609986|NCT00571818|Active Comparator|EP|
11609987|NCT00571818|Active Comparator|HP|
11609988|NCT00571818|Active Comparator|EK|
11609989|NCT00571818|Active Comparator|HC|
11609990|NCT00571805|Active Comparator|1|Varenicline
11609991|NCT00571805|Placebo Comparator|2|placebo
11609992|NCT00571792||1|Individuals with normal lung function who do not smoke
11609993|NCT00571792||2|Individuals who smoke but who do not demonstrate symptoms of chronic obstructive pulmonary disease
11609994|NCT00571792||3|Individuals who smoke that demonstrate symptoms of COPD
11609995|NCT00571766|Experimental|1|Oral L-Arginine 2 g twice a day for 14 weeks
11609996|NCT00571766|Placebo Comparator|2|Placebo 2 g, twice a day for 14 weeks
11609997|NCT00571753|Experimental|Test|Isoniazid dose adapted according to NAT2 status i.e. appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively
11609998|NCT00571753|Active Comparator|Control|Treatment with standard isoniazid dose (appr. 5 mg/kg b.w.)
11609999|NCT00571740|Active Comparator|Arm I (second-line therapy)|Patients receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 46 hours beginning on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
11610000|NCT00571740|Experimental|Arm II (second-line therapy)|Patients receive bevacizumab and modified FOLFOX7 as in arm I. Patients also receive cetuximab IV over 2 hours on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
11610001|NCT00571727|Experimental|mecasermin, injections BID of rhIGF-1|
11610002|NCT00571714|Active Comparator|1|Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day)in 2 divided daily doses
11610003|NCT00571714|Active Comparator|2|Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day) in 2 divided daily doses plus betaine (20gm/day) in 2 divided doses for 12 weeks followed by Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day) in 2 divided daily doses for 36 weeks
11610004|NCT00571701|Active Comparator|celecoxib first, then placebo|Patients randomized to start celecoxib 6 months after enrollment. Then cross over to placebo after 1 year. Celecoxib dosing will be given orally 400mg once a day for adults, 200 mg once a day for pediatric patients between 12-25kg, 100mg once a day for pediatric patients < 12kg
11610005|NCT00571701|Placebo Comparator|Placebo first, then celecoxib|Patients randomized to start placebo 6 months after enrollment. One placebo capsule will be taken orally once a day. Placebo will match appearance of active celecoxib capsules. Cross over to 12 months of treatment with celecoxib after 1 year.
11610006|NCT00571688|Experimental|Risperdal Consta|Risperdal Consta injection in conjunction with existing treatment
11610007|NCT00571688|Active Comparator|Treatment As Usual|Clinician and patient decide upon treatment, as in a non-research clinical setting. The only treatment exclusion is any form of risperidone.
11610008|NCT00571675|Experimental|1|AT-101, prednisone and docetaxel
11610009|NCT00571675|Placebo Comparator|2|Placebo, prednisone and docetaxel
11610010|NCT00571662|Experimental|Cohort I|Pentostatin to be administered intravenously on days - 10, -9, and -8 at a dose of 4mg/m2/day
11610011|NCT00571649|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 10 mg oral rivaroxaban tablet once daily (OD) for 35 +/- 4 days, plus subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
11610012|NCT00571649|Active Comparator|Enoxaparin|Participants received oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days, plus 40 mg subcutaneous enoxaparin solution OD for 10 +/- 4 days
11610013|NCT00571636|Active Comparator|fentanyl|Patients assigned to this arm will receive continuous infusion of fentanyl + open label boluses of Fentanyl if necessary.
11610014|NCT00571636|Placebo Comparator|placebo|Patients assigned to this arm will receive continuous infusion of placebo+ open label boluses of Fentanyl if necessary.
11610015|NCT00571623||1|All subjects act as their own contral
11610016|NCT00571610|Experimental|1|Patient is screened for study and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
11610017|NCT00571571|Experimental|TFP-A|Specific aspects of TFP-A involve the setting up of a treatment contract/collaboration between patient and therapist to deal with the likely threats both to the treatment and to the patient's well being that may occur in the course of the treatment. After the behavioral symptoms of identity pathology are contained through structure and limit setting, the psychological structure that is believed to be the core of identity pathology are analyzed. In particular, treatment would involve the family in setting up the contract parameters, provide a psychoeducational component to the family and patient, inclusion of school personnel as appropriate to reinforce contract parameters, place an emphasis on the technique of clarification to understand specific emotional states.
11610018|NCT00571571|Active Comparator|Control|The Control Group is treatment as usual in the outpatient clinic. Treatment in this arm will be carried out by therapists in the Outpatient Department. Treatment will be determined by the therapist(s) and carried out according to their particular orientation and their assessment of patient's needs. It is expected based on clinic data that the majority of patients will be seen at least one time per week.
11610019|NCT00571558|Experimental|Treatment (aminolevulinin acid and photodynamic therapy)|Patients receive aminolevulinic acid PO 3-4 hours before undergoing photodynamic therapy using pulsed dye laser on day 1.
11610103|NCT00570960|Active Comparator|2: Standard of Care Human Albumin|antibiotic therapy in addition to human albumin, 1.5 g/kg on day one and 1.0 g/kg on day three
11610020|NCT00571545|Experimental|1|Subjects recruited from the community with a history of traumatic brain injury were enrolled into a 10 week supervised exercise program and encouraged to exercise at home as well.
11610021|NCT00571545|Other|2|Controls were wait-listed for the supervised exercise program but were not treated during the 10 week wait period.
11610022|NCT00571519|Experimental|1|rivoglitazone HCl 0.5mg
11610023|NCT00571519|Experimental|2|rivoglitazone HCl 1.0 mg
11610024|NCT00571519|Experimental|3|rivolglitazone HCl 1.5 mg
11610025|NCT00571519|Placebo Comparator|4|placebo matching rivoglitazone HCl tablets
11610026|NCT00571519|Active Comparator|5|pioglitazone HCl 15 mg
11610027|NCT00571519|Active Comparator|6|pioglitazone HCl 30 mg
11610028|NCT00571519|Active Comparator|7|pioglitazone HCl 45 mg
11610029|NCT00571519|Placebo Comparator|8|matching placebo for pioglitazone
11610030|NCT00571506|Experimental|1|Rosiglitazone 4 mg by mouth daily
11610031|NCT00571506|Active Comparator|2|Pioglitazone 30 mg by mouth daily
11610032|NCT00571493|Experimental|Bortezomib Dose Escalation|"The phase I section of the study will follow a standard 3 + 3 design to determine the maximum tolerated dose (MTD) of bortezomib when added to a standard BEAM (BCNU (carmustine), etoposide, cytarabine, melphalan) conditioning regimen followed by autologous hematopoietic stem cell transplantation (ASCT).
~After the MTD is defined, additional patients will enroll in Phase II to obtain preliminary estimates of survival using the Phase I regimen."
11610033|NCT00571480|Experimental|1 true acupuncture|acupuncture needles are inserted into three preselected ear acupuncture points which are thought to be specific for low back pain
11610034|NCT00571480|Sham Comparator|2|three acupuncture needles are inserted to three ear acupuncture points which are not specific for low back pain during pregnancy
11610035|NCT00571480|Other|3|standard of care
11610036|NCT00571467|Experimental|PRTX-100 (Staphylococcal protein A)|"Cohort 1: 0.075 mcg/kg
~Cohort 2: 0.15 mcg/kg
~Cohort 3: 0.30 mcg/kg"
11610037|NCT00571454|Experimental|1|Telephone depression care management + treatment as usual
11610038|NCT00571454|No Intervention|2|Treatment as usual
11610039|NCT00571441||Primary|All subjects are included in this group, non-randomized observational study.
11610040|NCT00571428|Experimental|15 mcg BID / 30 mcg QD|Arformoterol 15 microgram twice a day (BID) taken each morning and evening for one visit followed by Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for the next visit.
11610041|NCT00571428|Experimental|30 mcg QD / 15 mcg BID|Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for one visit followed by Arformoterol 15 microgram twice a day (BID) in the morning and evening for the next visit.
11610042|NCT00571415||cervix cancer patients|
11610043|NCT00571402|Experimental|FFT|Family-focused therapy (FFT) and pharmacotherapy for adolescents, a 21 session family psychoeducational interventio0n administered with best practice medication treatment
11610044|NCT00571402|Active Comparator|Echanced Care|Enhanced care (EC) and pharmacotherapy for adolescents
11610045|NCT00571376||1|Those exposed to health information technology or health information exchange
11610046|NCT00571376||2|Those not exposed to health information technology or health information exchange
11610047|NCT00571363|Active Comparator|standard surgery|basal cell carcinomas were excised with 4 mm margins
11610048|NCT00571363|Active Comparator|Mohs|Basal cell carcinoma were removed via Mohs Micrographic surgery
11610049|NCT00571350|Active Comparator|A|women with vaginal prolapse who underwent TVT O
11610050|NCT00571324|Experimental|Exendin-(9-39) first, the Vehicle|Exendin-(9-39) will be administered intravenously (IV) after an overnight fast. Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. The following day, after another overnight fast, normal saline (control) vehicle infusion will be administered intravenously (IV) over 6 hours. During both infusions, blood glucose levels will be measured every 20 minutes.
11610051|NCT00571324|Placebo Comparator|Vehicle first, then Exendin-(9-39)|Normal saline vehicle infusion will be administered intravenously (IV) after an overnight fast. The infusion will be given over 6 hours. The following day, after another overnight fast, Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. During both infusions, blood glucose levels will be measured every 20 minutes.
11610052|NCT00571298|Experimental|Extrapleural pneumonectomy (EPP)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
11610053|NCT00571298|Experimental|Pleurectomy/Decortication (P/DC)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
11610054|NCT00571298|Experimental|Tumor Debulking (TD)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
11610055|NCT00571285|Placebo Comparator|Placebo|Placebo capsule once a week and 600 IU vitamin D daily for 26 weeks
11610056|NCT00571285|Experimental|Vitamin D|50K IU vitamin D3 (high dose) weekly plus 600 IU Vitamin D3 capsule daily for 26 weeks
11610057|NCT00571272||1|Infants less than 6 months old with a cholestatic liver disease who were initially enrolled into the Childhood Liver Disease Research and Education Network (ChiLDREN) Prospective Biliary Atresia Epidemiology study (PROBE study; P003)
11620458|NCT00480116|Active Comparator|3|
11610058|NCT00571272||2|Participants with a cholestatic liver disease who are between birth and 25 years old who were NOT initially enrolled into the Childhood Liver Disease Research and Education Network (ChiLDREN) Prospective Biliary Atresia Epidemiology study (PROBE study; P003)
11610059|NCT00571272||3|Post-liver transplant participants with a cholestatic liver disease who are between 1 day and 25 years old. Affected parents of patients enrolled in the study are eligible for enrollment if they are 25 years old or less
11610060|NCT00571272||4|A screening group of participants, birth through 25 years old, suspected of having ALGS, PFIC (or BRIC) or BAD, who do not meet complete enrollment criteria for Group 1, 2, or 3.BRIC)
11610061|NCT00571272||5|Affected siblings (without evidence of liver disease) of Alpha-1 Antitrypsin Deficiency participants who are enrolled in LOGIC.
11610062|NCT00571259|Active Comparator|1|Catheter lock with heparin 1,000 units/mL
11610063|NCT00571259|Active Comparator|2|Catheter lock with gentamicin 320 micrograms/mL in sodium citrate 4%
11610064|NCT00571246|Experimental|Topiramate|Participants will be randomized to topiramate (250mg)
11610065|NCT00571246|Experimental|Lamotrigine|Participants will be randomized to lamotrigine (250mg)
11610066|NCT00571246|Placebo Comparator|Placebo|Participants will be randomized placebo
11610067|NCT00571233||1|Group one consists of children 1 month - 6 years old who have structurally normal hearts, no heart failure, and a patent ductus arteriosus (PDA).
11610068|NCT00571233||2|Group two consists of children 1 month - 6 years old who have single ventricle physiology. Children with and without heart failure may participate.
11610069|NCT00571220||Gastric bypass surgery|Surgical group of obese patients with type 2 diabetes undergoing gastric bypass surgery
11610070|NCT00571220||Diet induced weight loss|Diet group of obese patient with type 2 diabetes, matched with the surgical group for diabetes duration, diabetes control (HbA1C), BMI, age.
11610071|NCT00571207||I|Drivers suspected of driving under the influence of drugs
11610072|NCT00571207||II|Drivers not suspected of driving under the influence of drugs
11610073|NCT00571194|Other|peritoneal dialysis (CCPD)|PK profile of pravastatin
11610074|NCT00571181|Experimental|1|
11610075|NCT00571181|Active Comparator|2|
11610076|NCT00571168|Experimental|A|Aprepitant plus standard therapy (Kevatril + Dexamethason) on day 1-4
11610077|NCT00571168|Placebo Comparator|B|Placebo plus standard therapy (Kevatril + Dexamethason) on day 1-4
11610078|NCT00571155|Other|1|
11610079|NCT00571142|Active Comparator|1|Renal disease
11610080|NCT00571142|Active Comparator|2|Without renal disease
11610081|NCT00571129|Active Comparator|with tubes or mitomycin|After DCR bicanalicular tubes were inserted After re-DCR mitomycin in cottonpads were placed into rhinostoma for 5 minutes
11610082|NCT00571129|Active Comparator|without tubes or mitomycin|After DCR no tubes were inserted After re-DCR no mitomycin was used
11610083|NCT00571116|Experimental|Disulfiram and arsenic trioxide|"Patients receive disulfiram 250 mg PO twice daily and arsenic trioxide IV over 1-2 hours on Monday through Friday, alternating two weeks on treatment followed by two weeks off treatment. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
~The Arsenic trioxide dose will be escalated or reduced until a tolerable dose is reached. Arsenic trioxide will be administered at a starting dose of 0.05 mg/kg. If the initial dose is tolerated, the patient will be dose escalated to 0.10 mg/kg/day. If the first dose escalation is tolerated, then a second dose escalation will be attempted to 0.15 mg/kg/day, the current dose recommended for leukemia. Dosing will be continued for two weeks on alternating with two weeks off as long as tolerated to a maximum of 60 doses."
11610084|NCT00571103|Experimental|1 Open Label|Open Label. At visit 2, all participants were started on Acamprosate, 1,998 mg divided into 3 equal doses.
11610085|NCT00571090||Thyroid nodule|Subjects who present with thyroid nodules will be enrolled into the study. Euthyroid and hypothyroid subjects with a solitary thyroid nodule or multinodular goiter will be enrolled. For subjects with a suppressed TSH, a thyroid scan will be performed. Subjects with a hypoactive nodule in the thyroid scan and a low TSH will be enrolled.
11610086|NCT00571077||A|"This is a a single arm study evaluating the efficacy and accuracy of EIS in detecting malignant thyroid nodules.
~PAtients with thyroid nodules scheduled for surgery will undergo EIS examination."
11610087|NCT00571064|Experimental|1|
11610088|NCT00571051|Experimental|1|MBSR 8 week course
11610089|NCT00571051|No Intervention|2|8 weeks of natural history
11610090|NCT00571038|Experimental|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
11610091|NCT00571038|Active Comparator|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
11610092|NCT00571025|Experimental|1|AD risk assessment based on family history and APOE genotype
11610093|NCT00571025|Active Comparator|2|AD risk assessment based on family history alone
11610094|NCT00571012||Only one group- A|Healthy young subjects aged 18-45.
11610095|NCT00570999|Experimental|Arm A|Palifermin once daily at a dose of 60 mg/kg/day for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
11610096|NCT00570999|Placebo Comparator|Arm B|Placebo at a dose of 1.2 mL (saline 0,9%) once daily for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
11610097|NCT00570986|Placebo Comparator|1|Arm #1 is used for entire study. At week 12, arm is rerandomized.
11610098|NCT00570986|Active Comparator|2|Arm #2 is used for entire study. At week 12, arm is rerandomized.
11610099|NCT00570986|Active Comparator|3|Arm #3 is not used for weeks 0-11. At week 12, arm is rerandomized.
11610100|NCT00570973|Active Comparator|1|Endoscopic Band ligation combined with medical therapy (orally, daily administered propranolol and mononitrate)
11610101|NCT00570973|Active Comparator|2|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent
11610102|NCT00570960|Experimental|1: Dextran 70|antibiotic therapy in addition to dextran 70, 1.0 g/kg on days one, two and three
11610104|NCT00570947|Active Comparator|Class|The control group will be advised to take a traditional CPR class and be offered a list of local classes.
11610105|NCT00570934|Experimental|Placebo|order of interventions placebo,calcium, cholecalciferol, calcium plus cholecalciferol
11610106|NCT00570934|Experimental|Calcium|order of treatment calcium, placebo, calcium plus cholecalciferol, cholecalciferol
11610107|NCT00570934|Experimental|Cholecalciferol|order of treatments cholecalciferol, calcium and Cholecalciferol, placebo, and calcium
11610108|NCT00570934|Experimental|Calcium and cholecalciferol|order of treatment calcium and cholecalciferol, cholecalciferol, calcium, placebo
11610109|NCT00570921|Experimental|Fulvestrant + Everolimus|"Fulvestrant + Everolimus
~Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14, and then 250 mg on day 28 and every 4 weeks ± 3 days thereafter. Everolimus was administered initially at a dose of 5 mg daily in the first 5-patient cohort for the first month of treatment and then increased to 10 mg PO daily after that."
11610110|NCT00570908|Experimental|Study Group|capecitabine administered concurrently with WBRT followed by combination the combination of capecitabine with sunitinib
11610111|NCT00570895|Active Comparator|A|Subjects in Arm A will receive the juice without ascorbic acid in addition to the muffin with ferrous fumarate.
11610112|NCT00570895|Active Comparator|B|Subjects in Arm A will receive the juice with 25mg ascorbic acid in addition to the muffin with ferrous fumarate
11610113|NCT00570882|Active Comparator|Sunitinib 4/2|Sunitinib 50 mg PO 4-week on and 2-week off
11610114|NCT00570882|Experimental|Sunitinib 2/1|Sunitinib 50 mg PO 2-week on 1-week off
11610115|NCT00570869|Active Comparator|CPR Class|mothers who are currently certified in CPR (i.e., have taken the traditional CPR class, or have been recertified in CPR by classroom instruction, within the past two years).
11610116|NCT00570856|Experimental|1|Folic acid supplementation
11610117|NCT00570856|Placebo Comparator|2|
11610118|NCT00570843|Active Comparator|1.|
11610119|NCT00570843|Placebo Comparator|2.|
11610120|NCT00570830|Other|1|single armed case series in which all patients underwent the same treatment.
11610121|NCT00570817|Other|1|"The child will receive prehydration at the methotrexate infusions in the following order:
~At the 1st methotrexate infusion the child will receive 4 hours prehydration. At the 2nd methotrexate infusion the child will receive 12 hours prehydration. At the 3rd methotrexate infusion the child will receive 4 hours prehydration. At the 4th methotrexate infusion the child will receive 12 hours prehydration. At the 5th methotrexate infusion the child will receive 4 hours prehydration. At the 6th methotrexate infusion the child will receive 12 hours prehydration. At the 7th methotrexate infusion the child will receive 4 hours prehydration. At the 8th methotrexate infusion the child will receive 12 hours prehydration."
11610122|NCT00570817|Other|2|"The child will receive prehydration at the methotrexate infusions in the following order:
~At the 1st methotrexate infusion the child will receive 12 hours prehydration. At the 2nd methotrexate infusion the child will receive 4 hours prehydration. At the 3rd methotrexate infusion the child will receive 12 hours prehydration. At the 4th methotrexate infusion the child will receive 4 hours prehydration. At the 5th methotrexate infusion the child will receive 12 hours prehydration. At the 6th methotrexate infusion the child will receive 4 hours prehydration. At the 7th methotrexate infusion the child will receive 12 hours prehydration. At the 8th methotrexate infusion the child will receive 4 hours prehydration."
11610123|NCT00570804|Other|MAPS+|"MAPS+ (Motivation and Problem-Solving Plus):
~Counseling using specific treatment approach that focuses on combined smoking cessation and the reduction of at-risk alcohol use."
11610124|NCT00570804|Other|MAPS|"MAPS (Motivation and Problem-Solving):
~Counseling treatment approach with a focus on smoking cessation."
11610125|NCT00570791||Effect of age on intraocular pressure|Correlation between age and IOP with GAT compared to other tonometers.
11610126|NCT00570791||Effect of CCT and IOP|Correlation between CCT and IOP among all tonometers
11610127|NCT00570778|Experimental|indacaterol/glycopyrrolate 300/50 μg|One indacaterol/glycopyrrolate 300/50 μg capsule + 1 placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.
11610128|NCT00570778|Active Comparator|indacaterol 600 μg|Two indacaterol 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
11610129|NCT00570778|Active Comparator|indacaterol 300 μg|One capsule indacaterol 300 μg + one placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.
11610130|NCT00570778|Placebo Comparator|placebo|Two placebo capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
11610131|NCT00570765|Experimental|10 mg PO QD|
11610132|NCT00570765|Experimental|50 mg PO QD|
11610133|NCT00570765|Placebo Comparator|Placebo PO QD|
11610134|NCT00570752|Active Comparator|Placebo + background low to moderate dose statin|Placebo + background low to moderate dose statin Tablets, Oral, 0 mg, once daily, for 12 weeks
11610135|NCT00570752|Experimental|BMS-582949 + Background low to moderate dose statin|BMS-582949 + Background low to moderate dose statin Tablets, Oral, 100 mg, once daily for 12 weeks
11610136|NCT00570752|Active Comparator|Atorvastatin|Atorvastatin Tablets, oral, 80 mg once daily for 12 weeks
11610137|NCT00570739|Placebo Comparator|Diabetic Participants: Metformin HCl+Placebo for Colesevelam|Participants will receive either 850 mg or 1700 mg of metformin HCl, depending on tolerability + 6 placebo tablets matching colesevelam 625 mg. Study medication is to be administered once daily for 16 weeks.
11610138|NCT00570739|Experimental|Diabetic participants: Metformin HCl + Colesevelam|Participants will receive either 850 mg or 1700 mg of metformin HCl, depending on tolerability + 6 colesevelam tablets, 625 mg. Study medication is to be administered once daily for 16 weeks.
11610139|NCT00570739|Placebo Comparator|Pre-diabetic Participants: Colesevelam Placebo|Participants will receive 6 placebo tablets matching colesevelam 625 mg. Study medication is to be administered once daily for 16 weeks.
11610140|NCT00570739|Experimental|Pre-diabetes Participants: Colesevelam|Participants will receive 6 colesevelam tablets, 625 mg. Study medication is to be administered once daily for 16 weeks.
11610183|NCT00570388|Active Comparator|2|Subjects in the active Prometa group will receive flumazenil, gabapentin, and hydroxyzine per the Prometa Protocol.
11610184|NCT00570388|Placebo Comparator|1|"Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine"
11610141|NCT00570713|Experimental|MORAb-009|MORAb-009 plus gemcitabine ('MORAb-009'): MORAb-009 was administered at 5 mg/kg on Day 1 of Weeks 1 through 7 during the first cycle and on Day 1 of Weeks 1 through 3 of subsequent cycles. Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
11610142|NCT00570713|Active Comparator|Placebo|Placebo plus gemcitabine ('Placebo') Placebo was administered on Day 1 of Weeks 1 through 7 during the first cycle and on Day 1 of Weeks 1 through 3 of subsequent cycles. Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
11610143|NCT00570700|Experimental|Dasatinib|Patients receive oral dasatinib once daily in the absence of disease progression or unacceptable toxicity.
11610144|NCT00570687|Experimental|1|Technosphere Insulin
11610145|NCT00570674|Experimental|Phase I Dose Level 1: ACE-RT|Phase I Dose Level 1 participants received Abraxane 20mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. One dose (400 mg/m2 IV) of Erbitux was given prior to start of radiation, then weekly at 250 mg/m2 IV. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
11610146|NCT00570674|Experimental|Phase I Dose Level -1: AC-RT|Phase I Dose Level -1 participants received Abraxane 20mg/m2 IV then carboplatin AUC 1.5 weekly IV during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
11610147|NCT00570674|Experimental|Phase I Dose Level 2: AC-RT|Phase I Dose Level 2 participants received Abraxane 30mg/m2 IV then carboplatin AUC 1.5 weekly IV during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
11610148|NCT00570674|Experimental|Phase I Dose Level 3: AC-RT|Phase I Dose Level 3 participants received Abraxane 40mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
11610149|NCT00570674|Experimental|Phase I Dose Level 4: AC-RT|Phase I Dose Level 4 participants received Abraxane 50mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
11610150|NCT00570661|Experimental|ITF2357|
11610151|NCT00570648|Experimental|1|1% sodium hyaluronate (Healoon) applied at the end of surgery to the surface of the corneal transplant
11610152|NCT00570648|No Intervention|2|Nothing applied at the end of surgery
11610153|NCT00570635|Experimental|A|
11610154|NCT00570635|Experimental|B|
11610155|NCT00570622|Active Comparator|1|Patients receive 60mg of pioglitazone once a day orally for 9 days
11610156|NCT00570622|Placebo Comparator|2|Patients receive Placebo orally once a day for 9 days
11610157|NCT00570609|Experimental|CPR Anytime|Participants will be asked to complete the program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
11610158|NCT00570583||Depressed|Older individuals with major depression
11610159|NCT00570583||Non-depressed|Older individuals without psychiatric disorder
11610160|NCT00570570|Other|group 1|Muscular Strengthening for paretic knee flexor and extensor
11610161|NCT00570570|Active Comparator|group 2|conventional physiotherapy
11610162|NCT00570557|No Intervention|Group A Nurses|Participants receive neither web-based refresher courses nor periodic feedback by SLP
11610163|NCT00570557|Experimental|Group B Nurses|Participants receive web-based skill refresher courses but no periodic feedback by SLP
11610164|NCT00570544||1|patients with moderate to severe copd with varying extent of emphysema
11610165|NCT00570531|Experimental|Bevacizumab|
11610166|NCT00570518||1|randomly stopped drivers of motorised vehicles and bicycles
11610167|NCT00570518||2|drivers of motorised vehicles and bicycles injured or killed in road traffic accidents
11610168|NCT00570505|Experimental|LapBand|All subjects who receive the LAP-BAND System.
11610169|NCT00570492|Placebo Comparator|Placebo nasal spray|
11610170|NCT00570492|Experimental|Fluticasone furoate nasal spray|
11610171|NCT00570479|Active Comparator|1|50 mgs of anecortave acetate (0.5 ml of a 10% suspension)
11610172|NCT00570479|Active Comparator|2|Patients will receive 30 mgs of anecortave acetate (0.5 ml of a 6% suspension)
11610173|NCT00570479|Active Comparator|3|Patients will receive 24 mgs of anecortave acetate (0.4 ml of a 6% suspension)
11610174|NCT00570479|Active Comparator|4|Patients will receive 12 mgs of anecortave acetate (0.2 ml of a 6% suspension)
11610175|NCT00570466|Experimental|Video games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit, vegetable and water intake, physical activity and decrease TV viewing.
11610176|NCT00570466|Placebo Comparator|Web and DVD knowledge|Parallel web and DVD based knowledge games on fruit, vegetable, water, physical activity and physical inactivity.
11610177|NCT00570440|Experimental|A|
11610178|NCT00570440|Active Comparator|B|
11610179|NCT00570427|Experimental|1.|All participants
11610180|NCT00570414|Active Comparator|1|Laryngeal mask airway (LMA)
11610181|NCT00570414|Active Comparator|2|Endotracheal tube (ETT)
11610182|NCT00570401|Experimental|Dasatinib|"Beginning 1 week after completion of erlotinib hydrochloride or gefitinib therapy, patients receive oral dasatinib twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
~Response is assessed by CT scan at 4 weeks, 8 weeks, and then every 8 weeks thereafter."
11610185|NCT00570375|Experimental|Single Arm|All patients will receive 150 mg of Erlotinib
11610186|NCT00570349|Experimental|Low Dose Cohort|Subjects in the low dose cohort receive 20 part per million (ppm) of nitric oxide via nasal cannula over a 44 hour period.
11610187|NCT00570349|Experimental|High-Dose Cohort|Subjects in the high dose cohort receive 40 ppm of nitric oxide via nasal cannula over a 44 hour period.
11610188|NCT00570349|Placebo Comparator|Nitrogen|100% Nitrogen (placebo) will be administer at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
11610189|NCT00570336|Experimental|2.5 milligram (mg) CTS-1027|2.5 mg CTS-1027
11610190|NCT00570336|Experimental|5 mg CTS-1027|5 mg CTS-1027
11610191|NCT00570336|Experimental|10 mg CTS-1027|10 mg CTS-1027
11610192|NCT00570336|Experimental|30 mg CTS-1027|30 mg CTS-1027
11610193|NCT00570336|Placebo Comparator|Placebo|Placebo
11610194|NCT00570323|Active Comparator|ARM A / Arimidex with Faslodex|Arimidex with Faslodex in postmenopausal women
11610195|NCT00570323|Active Comparator|ARM B Arimidex without Faslodex|Arimidex without Faslodex in postmenopausal women.
11610196|NCT00570310|Active Comparator|A|Patients in Group A will remain on pregabalin (up to 600 mg/day po) treatment for the entire double-blind period.
11610197|NCT00570310|Placebo Comparator|B|Patients in Group B will be treated with placebo.
11610198|NCT00570284|Experimental|LBH589|
11610199|NCT00570271|Experimental|1|
11610200|NCT00570271|Experimental|2|
11610201|NCT00570271|Experimental|3|
11610202|NCT00570271|Experimental|4|
11610203|NCT00570271|No Intervention|5|
11610204|NCT00570271|No Intervention|6|
11610205|NCT00570258|Placebo Comparator|2|"Fulvestrant: 250 mg IM Q 4 weeks
~Placebo: 150 mg PO QD"
11610206|NCT00570258|Active Comparator|1|"Fulvestrant: 250 mg IM Q 4 weeks
~Erlotinib: 150 mg PO QD"
11610207|NCT00570245|No Intervention|A|Neither donors or recipients will receive NO
11610208|NCT00570245|Active Comparator|B|Donor will not receive NO, recipient will receive up to 48 hours of NO
11610209|NCT00570245|Active Comparator|C|The donor will receive NO for 3 hours and the recipient will receive NO for up to 48 hours
11610210|NCT00570232|Other|Tarceva|All patients will be prescribed erlotinib 150mg daily
11610211|NCT00570219|Experimental|B|Gradual benzodiazepine discontinuation and valproate treatment
11610212|NCT00570219|No Intervention|A|Gradual benzodiazepine discontinuation
11610213|NCT00570206|Experimental|1|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
11610214|NCT00570206|No Intervention|2|Probation officers who are interested in Motivational Interviewing, but have not yet been trained to use it while conducting meetings with probationers.
11610215|NCT00570206|No Intervention|3|Treatment as usual. Regular probation officers conduct standard meetings with probationers.
11610216|NCT00570193|Experimental|I|Combined treatment with verteporfin (Visudyne) and ranibizumab (Lucentis)
11610217|NCT00570193|Experimental|II|Treatment with ranibizumab (Lucentis)
11610218|NCT00570180|Experimental|Single Arm|Please see intervention description for Bortezomib (Velcade)
11610219|NCT00570167|Active Comparator|2|Total cementless hip arthroplasty with metal-on-metal bearings
11610220|NCT00570167|Active Comparator|1|Hip resurfacing
11610221|NCT00570141|Active Comparator|OASIS Wound Matrix (Oasis)|This is a single arm study with only the test article Oasis used on all subjects
11610222|NCT00570128|Active Comparator|1|
11610223|NCT00570128|Placebo Comparator|2|
11610224|NCT00570115||A|The subjects for this group are matched for age, gender, body mass index. The presence of obstructive sleep apnea will divide the cohort in 02 subgroups: non-Obstructive Sleep Apnea and Obstructive Sleep Apnea
11610225|NCT00570102|Active Comparator|A highly hydrolyzed casein formula|
11610226|NCT00570102|Placebo Comparator|A conventiona cow's milk based formula|
11610227|NCT00570089|Experimental|Study Drug Ranexa, Then Placebo|"Participants first received study drug Ranexa, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
~After a washout period of 2 weeks, they then received Placebo tablet (matching Ranexa tablet)."
11610228|NCT00570089|Experimental|Placebo, Then Study Drug Ranexa(Ranolazine)|"Participants first received Placebo tablet (matching Ranexa tablet) for two weeks.
~After washout period of 2 weeks, they then received Ranexa 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval."
11610229|NCT00570063|Placebo Comparator|1|PF-02545920 15 mg tablets taken twice a day by mouth for 21 days
11610230|NCT00570063|Placebo Comparator|2|Matching placebo tablets taken twice a day by mouth for 21 days
11610231|NCT00570050|Experimental|Intranasal Insulin nasal spray|
11610232|NCT00570050|Experimental|Placebo nasal spray (i.e., no active treatment)|
11610233|NCT00570037|Active Comparator|Immunization Program|Intervention Hospital - Standing postpartum vaccine orders, influenza vaccine clinic on postpartum ward for household contacts, mailed vaccine reminders
11610234|NCT00570037|No Intervention|No Immunization Program|Comparison Hospital - Receipt of vaccine through routine clinical care
11610235|NCT00570024|Active Comparator|TA|Active TA
11610236|NCT00570024|Other|AA|
11610237|NCT00570024|No Intervention|Waiting Group|
11610238|NCT00570011|Experimental|1|
11610239|NCT00570011|Experimental|2|
11610240|NCT00569985|Experimental|Treatment (autologous HCT)|CONDITIONING: Patients receive carmustine IV over 1-2 hours on days -7 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. TRANSPLANTATION: Patients undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells IV on day 0.
11610241|NCT00569972|Experimental|15 mg PD 0200390|
11610242|NCT00569972|Experimental|30 mg PD 0200390|
11610243|NCT00569972|Experimental|45 mg PD 0200390|
11610244|NCT00569972|Experimental|60 mg PD 0200390|
11610245|NCT00569972|Experimental|Placebo PD 0200390|
11610246|NCT00569959|Other|Fasting|
11610247|NCT00569959|Other|Non-fasting|
11610249|NCT00569933|Other|A/B/C|Patients are randomized to voice/music/ or no CD
11610250|NCT00569920|Placebo Comparator|1|Placebo
11610251|NCT00569920|Active Comparator|2|"dexamethasone low-dose"
11610252|NCT00569920|Active Comparator|3|"Dexamethasone high-dose"
11610253|NCT00569894||2|TIV
11610254|NCT00569894||1|FluMist
11610255|NCT00569894||3|Unvaccinated
11610256|NCT00569881||1|Corneal epithelial wound healing with moxifloxacin
11610257|NCT00569881||2|Corneal epithelial wound healing with gatifloxacin
11610258|NCT00569868|Experimental|Velcade|"Treatment on this study will last 2 cycles. Each cycle consists of 3 weeks, or 21 days. After you have gone off study, you will be followed every three months for approximately 2 years.
~Each cycle will consist of 3 weeks (21 days) according to the schedule below.
~DRUG ROUTE DOSE DAYS Velcade IV 1.3 mg/m2 1,4,8, and 11 This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a two cycles."
11610259|NCT00569855|Experimental|1|Receive phenoxybenzamine in preparation for cardiopulmonary bypass during open-heart surgery
11610260|NCT00569842||observational|
11610261|NCT00569829|Experimental|1|Cognitive behavioral therapy
11610262|NCT00569829|No Intervention|2|Waitlist
11610263|NCT00569816|Active Comparator|Group 1|Propofol as the primary anesthetic
11610264|NCT00569816|Experimental|Group 2|Sevoflurane administered continuously after induction of anesthesia until initiation of cardiopulmonary bypass.
11610265|NCT00569816|Experimental|Group 3|Sevoflurane administered repetitive up to 1 MAC from induction of anesthesia until initiation of cardiopulmonary bypass. Wash in and wash out performed twice.
11610266|NCT00569803|Active Comparator|Belatacept 50 mg Subcutaneous Injection|Belatacept 50 mg subcutaneous (SC) injection
11610267|NCT00569803|Active Comparator|Belatacept 100 mg Subcutaneous Injection|Belatacept 100 mg SC injection
11610268|NCT00569803|Active Comparator|Belatacept 125 mg Subcutaneous Injection|Belatacept 125 mg SC injection
11610269|NCT00569803|Active Comparator|Belatacept 150 mg Subcutaneous Injections|2 SC injections of 75 mg Belatacept
11610270|NCT00569803|Active Comparator|Belatacept 200 mg Subcutaneous Injections|2 SC injections of 100 mg Belatacept
11610271|NCT00569803|Active Comparator|Belatacept 250 mg Subcutaneous Injections|2 SC injections of 125 mg Belatacept
11610272|NCT00569803|Active Comparator|Belatacept 125 mg Intravenous Infusion|125 mg Belatacept intravenous (IV) injection
11610273|NCT00569803|Placebo Comparator|Placebo|SC injection of placebo solution
11610274|NCT00569790|Experimental|1|S-1, Irinotecan, Bevacizumab
11610275|NCT00569777|Experimental|K-lens|etafilcon A contact lens with ketotifen.
11610276|NCT00569777|Placebo Comparator|Placebo|etafilcon A contact lens without ketotifen
11610277|NCT00569764||observational|patients with schizophrenia who want to change an antipsychotics due to metabolic side effect
11610278|NCT00569738||A|patients with neuroendocrine tumors
11610279|NCT00569699|Experimental|1|S-1, Bevacizumab
11610280|NCT00569686|Active Comparator|1|treatment with lovaza
11610281|NCT00569686|Placebo Comparator|2|
11610282|NCT00569660|Experimental|Azacitidine|75 mg/m^2 Subcutaneous Daily for 7 days every 4 weeks
11610283|NCT00569647|Experimental|v|Use of VRH headset
11610284|NCT00569647|Placebo Comparator|c|
11610285|NCT00569634|Other|1|
11610286|NCT00569621|Experimental|1|
11610287|NCT00569621|Placebo Comparator|2|
11610288|NCT00569608|Experimental|EDA|Neonates submitted to the protocol of early discharge.
11610289|NCT00569608|No Intervention|SDP|Discharge following the standard protocol of the neonatal intensive care unit.
11610290|NCT00569595|Experimental|1|Multi-Level, Patient-Directed, Lifestyle Change, Health Promotion Program
11610291|NCT00569595|Sham Comparator|2|"Patient health counseling program by lay health educators Entitled Fighting Cancer with Advice."
11610292|NCT00569582|Experimental|1|
11610293|NCT00569569|Experimental|1|Patients treated with Retaane
11610294|NCT00569556|No Intervention|Usual Care|Patients receive care through primary care provider
11610295|NCT00569556|Experimental|Case Management|Specially trained nurse case managers contact patients by telephone; monitor blood pressure, LDL, and HgbA1C;, and recommend lifestyle and medication changes as needed
11610296|NCT00569530|Active Comparator|Treatment Surfactant (Infasurf) ONY, NY|Patients receive inhaled nitric oxide and scheduled doses of Infasurf on study days 0, 3, 7, 10, and 14, if infant remains ventilated.
11610297|NCT00569530|Placebo Comparator|Sham (no treatment)|Infants receiving inhaled nitric oxide will receive Sham (no treatment) on study days 0, 3, 7, 10, and 14, if infant remains ventilated.
11610298|NCT00569517|Experimental|1|6-CBT-sessions for weight loss
11610299|NCT00569517|Experimental|2|Single educational intervention for weight
11610300|NCT00569504||A, observatoin|inpatients and outpatients in Seoul National Hospital
11610301|NCT00569478|Active Comparator|1|rehabilitation
11610302|NCT00569478|No Intervention|2|controls
11610303|NCT00569465|Placebo Comparator|A|
11610304|NCT00569465|Experimental|B|
11610305|NCT00569452|Experimental|A|
11610306|NCT00569452|Experimental|B|
11610307|NCT00569439|Experimental|D5|5% Dextrose Solution in Normal Saline
11610308|NCT00569439|Experimental|D10|
11610309|NCT00569439|Placebo Comparator|NS|
11610310|NCT00569413||1|Healthy control subjects (n=20) age 21-65 who do not suffer from a psychiatric diagnosis or neurological damage, are under age, or are pregnant women
11610311|NCT00569413||2|20 patients who suffer from sexual disorder (reduced sexual desire or sexual function) from a sexual disorder clinic, age 21-65, without any other psychiatric disorder, neurological damage, are not under age or pregnant women.
11610312|NCT00569387|Experimental|Vaccine group|
11610313|NCT00569361|Other|A|Collection of nasal epithelial cells by brushing
11610314|NCT00569335|Experimental|1|S-1, Irinotecan, Bevacizumab
11610369|NCT00568737|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
11610370|NCT00568737|Placebo Comparator|2|0.9% sodium chloride
11610315|NCT00569309|Experimental|Prevnar|The conjugate vaccine for Streptococcus pneumoniae will be administered during weeks 9, 17, and 25 after autologous HSCT - the study nurse will arrange for the vaccine to be administered at the specified time and the patient will be instructed to notify an investigator or study nurse of any side effects of vaccine administration. At the specified times, patients will fill out the quality-of-life assessment. All patients enrolled on this trial will have samples procured for all proposed laboratory correlative studies.
11610316|NCT00569296|Experimental|T-cells|EGFRBi-armed autologous activated T cells
11610317|NCT00569270|Active Comparator|Tiotropium 18 µg capsule, bronchodilator|tiotropium 18 µg capsule for 1 month versus placebo. To study bronchodilation and effect following metronome paced hyperventilation and induced dynamic hyperinflation of active tiotropium versus placebo
11610318|NCT00569270|Placebo Comparator|2|placebo 18ug tiotropium for 1 month
11610319|NCT00569244|Experimental|Arm 1|
11610320|NCT00569244|Active Comparator|Arm 2|
11610321|NCT00569231|Experimental|Candida Antigen|
11610322|NCT00569192|Experimental|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
11610323|NCT00569192|Placebo Comparator|Placebo|Placebo delivered by nebulization twice daily for 12 weeks
11610324|NCT00569192|Experimental|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
11610325|NCT00569179|Experimental|Alloreactive NK cell infusion|Escalating doses of alloreactive NK cells.
11610326|NCT00569166|Active Comparator|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
11610327|NCT00569166|Active Comparator|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
11610328|NCT00569166|Placebo Comparator|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
11610329|NCT00569153|Experimental|Arm 1 (TAK-700)|
11610330|NCT00569153|Experimental|Arm 2 (TAK-700 at 400 mg & 5 mg prednisone)|
11610331|NCT00569153|Experimental|Arm 3 (TAK-700 at 600 mg & 5 mg prednisone)|
11610332|NCT00569153|Experimental|Arm 4 (TAK-700 at 600 mg)|
11610333|NCT00569140|No Intervention|1|E10030
11610334|NCT00569127|Experimental|Arm I (octreotide acetate and bevacizumab)|Patients receive depot octreotide acetate IM and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11610335|NCT00569127|Experimental|Arm II (octreotide acetate and recombinant interferon alfa-2b)|Patients receive octreotide acetate IM as in arm I on day 1 and recombinant interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11610336|NCT00569114|Other|1|
11610337|NCT00569101|Experimental|single|single arm study (tacrolimus trial group)
11610338|NCT00569088|Experimental|B|A combined treatment would be used in the arm.That means Chinese herb formula would be used with the current Modern Medicine therapy for stroke in this arm.
11610339|NCT00569088|Active Comparator|A|just the current Modern Medicine therapy for stroke would be available in the arm.
11610340|NCT00569075||High Risk|High risk disease prone population
11610341|NCT00569075||Low Risk|Low risk disease population
11610342|NCT00569062|Experimental|Arm 1|GW856553X 7.5mg BID for 6 weeks
11610343|NCT00569062|Placebo Comparator|Placebo|Placebo to match, BID, 6 weeks
11610344|NCT00569036|Experimental|BMS-754807|Single arm, multiple-ascending dose escalation study
11610345|NCT00569023|Experimental|A,1,I|
11610346|NCT00569010|Experimental|Low-Dose Ara-C + AZA-Level 0|"Group 1 = Low-Dose Ara-C + Azacitidine-Level 0
~Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days Azacitidine (AZA): 37.5 mg/m^2 intravenous (IV) Over 20-30 minutes Daily for 7 Days"
11610347|NCT00569010|Experimental|Low-Dose Ara-C + AZA-Level 1|"Group 2 = Low-Dose Ara-C + Azacitidine-Level 1
~Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days AZA: Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days"
11610348|NCT00569010|Experimental|High-Dose Ara-C + AZA-Level 0|Group 3 = High-Dose Ara-C + Azacitidine-Level 0 High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age<65years) or 3 days (age>=65years) AZA: 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days
11610349|NCT00569010|Experimental|High-Dose Ara-C + AZA-Level 1|"Group 4 = High-Dose Ara-C + Azacitidine-Level 1
~High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age<65years) or 3 days (age>=65 years) AZA:Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days"
11610350|NCT00568997||1|Single-group Open Label Registry of patients exposed to Elidel/Pimecrolimus
11610351|NCT00568971|Experimental|weekly chemo|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
11610352|NCT00568958|Experimental|Naltrexone|Active naltrexone (25 mg daily +25 targeted)+ BASICS counseling
11610353|NCT00568958|Placebo Comparator|Placebo Naltrexone|Placebo Naltrexone (targeted + daily) + BASICS Counseling
11610354|NCT00568945|Experimental|Arm 1|
11610355|NCT00568893|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
11610356|NCT00568880|Experimental|Hydroxychloroquine Added to Bortezomib|Dose escalated by cohorts Hydroxychloroquine 200-600 mg pill every other day. Bortezomib 1.0-1.3mg/m2 IV, days 1, 4, 8, and 11 of each 21 day cycle.
11610357|NCT00568854|Active Comparator|Participants with diabetes|Persons with diagnosis of diabetes. Received biological intervention: BCG
11610358|NCT00568854|Active Comparator|Participants without diabetes|Persons with no diagnosis of diabetes and negative diabetes screening labs. Received biological intervention: BCG.
11610359|NCT00568841|Experimental|1|
11610360|NCT00568815|Experimental|Chemo|
11610361|NCT00568802|Experimental|Hydroxyurea|
11610362|NCT00568802|Placebo Comparator|Placebo|
11610363|NCT00568789|Experimental|Ramelteon 8 mg, zolpidem 10 mg and placebo|
11610364|NCT00568776|Placebo Comparator|1|
11610365|NCT00568776|Active Comparator|2|
11610366|NCT00568776|Active Comparator|3|
11610371|NCT00568724||1|Children referred to surgical treatment of congenital hydronephrosis
11610372|NCT00568724||2|15 age- and sex-matched controls
11610373|NCT00568724||Children with healthy pelvic tissue|Children referred to nephrectomy due to nephrotic syndrome
11610374|NCT00568724||Adults with healthy pelvic tissue|Adults referred to nephrectomy due to another cause than hydronephrosis
11610375|NCT00568711|Active Comparator|1|a 5-day course of daily 200-mg doses of doxycycline
11610376|NCT00568711|Active Comparator|2|a 5-day course of daily 600-mg doses of rifampin
11610377|NCT00568698|Experimental|Hydroxyurea|
11610378|NCT00568698|Placebo Comparator|Placebo|
11610379|NCT00568685|Active Comparator|Atomoxetine 0.2 milligram per kilogram per day (mg/kg/day)|
11610380|NCT00568685|Active Comparator|Atomoxetine 0.5 mg/kg/day|
11610381|NCT00568685|Active Comparator|Atomoxetine 1.2 mg/kg/day|
11610382|NCT00568672|Active Comparator|1|Olanzapine 5 mg / day
11610383|NCT00568672|Placebo Comparator|2|Placebo
11610384|NCT00568659|Experimental|1|
11610385|NCT00568646|Experimental|1|
11610386|NCT00568633|Experimental|Allo-HSCT + TLI + ATG|"Participants achieving complete remission after consolidation therapy & who have 5 of 6 HLA-match sibling donor to provide PBSC harvest for transplant. Pre-transplant subjects receive:
~Total lymphoid radiation (TLI) Days -11 to -7, and Days -4 to -1 (2 fractions on day -1)
~Anti-thymocyte globulin (ATG) Days -11 to -7
~Methylprednisolone Days -11 to -7
~Cyclosporine (CSP) Days -4 to +2
~5+ of 6 HLA-matched CD34+ cells on Day 0
~Mycophenolate mofetil (MMF), Day 0 to Day +28"
11610387|NCT00568633|Active Comparator|Best Standard Care|"Regular medical care for participants who achieve complete remission after standard consolidation therapy, but do not have a 5 of 6 HLA-match sibling donor. Treatment may consist of:
~Additional consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)
~Autologous transplantation
~Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning
~Umbilical cord blood transplantation
~Haploidentical transplantation"
11610388|NCT00568620|Experimental|1: Nasogastric feeding tube|
11610389|NCT00568620|Experimental|2: Placement of nasojejunal feeding tube|
11610390|NCT00568607|Experimental|IFO, VP-16, DDP, DXM|
11610391|NCT00568594|Experimental|1|
11610392|NCT00568594|Placebo Comparator|2|
11610393|NCT00568568|Experimental|Growth hormone|
11610394|NCT00568555|Experimental|Low Dose Naltrexone first|LDN first, then placebo.
11610395|NCT00568555|Placebo Comparator|Placebo - sugar pill first|Placebo first, then LDN.
11610396|NCT00568542|Active Comparator|1|35 I.E. erythropoetin beta given by subcutaneous injection once per week for 6 months. The drug is self-administered.
11610397|NCT00568542|Placebo Comparator|2|Placebo to erythropoetin beta.
11610398|NCT00568529|Experimental|Combine Chemotherapy|XELOX(Xeloda and oxaliplatin combination)
11610399|NCT00568516|Experimental|1.Low dose group|
11610400|NCT00568516|Experimental|2.High dose group|
11610401|NCT00568503|Active Comparator|1|QAX028 high dose
11610402|NCT00568503|Placebo Comparator|2|Placebo
11610403|NCT00568503|Active Comparator|3|Tiotropium bromide
11610404|NCT00568503|Active Comparator|4|QAX028 medium dose
11610405|NCT00568503|Active Comparator|5|QAX028 low dose
11610406|NCT00568477|Experimental|Arm 1|Treatment with rituximab
11610407|NCT00568477|No Intervention|Arm 2|Treatment without rituximab
11610408|NCT00568464|Experimental|A|
11610409|NCT00568451|Experimental|PC (previously treated)|Previously chemotherapy treated cohorts: Paclitaxel and Carboplatin (PC)
11610410|NCT00568451|Experimental|PC (chemo naive)|Chemotherapy-naive cohorts: Paclitaxel and Carboplatin (PC)
11610411|NCT00568451|Experimental|TMZ (previously treated)|Previously chemotherapy treated cohorts: Temozolomide (TMZ)
11610412|NCT00568451|Experimental|TMZ (chemo naive)|Chemotherapy-naive cohorts: Temozolomide (TMZ)
11610413|NCT00568412|Active Comparator|1|Zarzenda applied topically twice daily for three weeks
11610414|NCT00568412|Active Comparator|2|Elidel 1% cream, applied topically twice daily for three weeks
11610415|NCT00568399|Experimental|Active Treatment|This is the only arm and involves active treatment with sodium thiosulfate in those subjects with high coronary artery calcium scores.
11610416|NCT00568386|Experimental|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop in each eye one time
11610417|NCT00568386|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each one time
11610418|NCT00568373|Experimental|Treatement|All subjects that meet the requirement for gastric stimulator placement
11610419|NCT00568347||long acting bronchodilator|salmeterol 50mcg bid by DPI, no fluticasone in patients with COPD/emphysema to evaluate effect on bronchodilation and exhaled nitric oxide
11610420|NCT00568347||bronchodilator/ inhaled corticosteroid|fluticasone 250mcg/salmeterol 50 mcg bid X 3momths to evaluate effect on lung function and exhaled nitric oxide
11610421|NCT00568347||C|Fluticasone 100mcg/salmeterol 50mcg
11610422|NCT00568334|Experimental|VARILRIX HSA-FREE GROUP|Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine produced without human serum albumin (HSA-Free), administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).
11610423|NCT00568334|Experimental|VARILRIX GROUP|Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine, administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).
11610424|NCT00568321|Experimental|1|
11610425|NCT00568321|Active Comparator|2|
11610426|NCT00568321|Placebo Comparator|3|
11610427|NCT00568308|Placebo Comparator|1|
11610428|NCT00568308|Experimental|2|
11610429|NCT00568295|Experimental|Acetaminophen|Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP
11610430|NCT00568295|Active Comparator|Refecoxib 12.5 mg|Rofecoxib: Capsules 12.5 mg, oral, C-904-1A
11610431|NCT00568295|Active Comparator|Rofecoxib 12.5 x 2|Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A
11610432|NCT00568269|Active Comparator|Lichtenstein|
11610433|NCT00568269|Experimental|TEP|
11610434|NCT00568256|Experimental|Experimental|Mind/Body Course
11610436|NCT00568243||1|normal adult volunteers and patients with eye movement problems
11610437|NCT00568230|Experimental|1|Patient is screened for study, and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
11610438|NCT00568217|Active Comparator|1 drug|diclofenac 15 mg/kg suppository once
11610439|NCT00568217|Placebo Comparator|2 drug|Placebo suppository once
11610440|NCT00568217|Active Comparator|3 drug|acetaminophen mixture 15 mg/kg up to four times a day
11610441|NCT00568217|Active Comparator|4 drug|ibuprofen mixture 10 mg/kg up to four times a day
11610442|NCT00568217|Placebo Comparator|5 drug|oral placebo mixture up to four times a day
11610443|NCT00568204|Experimental|1|Mexyn-A
11610444|NCT00568191||1|retinal thickness program Stratus OCT software 4.0
11610445|NCT00568191||2|retinal cube 200x200 program of Cirrus OCT
11610446|NCT00568178|Experimental|Losartan Double-Blind Base Study (12-weeks)|"Normotensive participants received losartan.
~Hypertensive participants received either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo)."
11610447|NCT00568178|Active Comparator|Amlodipine Double-Blind Base Study (12-weeks)|Hypertensive participants were randomized to receive either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo) for 12 weeks.
11610448|NCT00568178|Experimental|Losartan Open-Label Extension Phase (Month 36)|Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
11610449|NCT00568178|Active Comparator|Enalapril Open-Label Extension Phase (Month 36)|Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
11610450|NCT00568165|Experimental|1|Mobile Team
11610451|NCT00568165|Active Comparator|2|Standard care
11610452|NCT00568152|Experimental|Low PA apple puree|230grams of low PA apple puree (Golden Delicious) consumed daily for 14 days.
11610453|NCT00568152|Experimental|High PA apple puree|High PA apple puree (Mitchalin) 230grams consumed daily for 14 days
11610454|NCT00568152|Placebo Comparator|Aspirin|75mg dispersable aspirin taken daily for 14 days
11610455|NCT00568139||Mitotane|Patients with adrenocortical carcinoma treated with mitotane
11610456|NCT00568139||Control|Patients with adrenocortical carcinoma not treated with mitotane
11610457|NCT00568126|Experimental|Maca Root|Subjects in this arm will be given 3g/day of maca root for 12 weeks
11610458|NCT00568126|Placebo Comparator|Placebo|Subjects in this arm will receive inactive placebo for 12 weeks.
11610459|NCT00568113|Experimental|NAC group|NAC given plus 17Oh progesterone caproate
11610460|NCT00568113|Active Comparator|Progesterone group|17 OH progesterone caproate
11610461|NCT00568100|Experimental|1|COPD patients
11610462|NCT00568087|Active Comparator|N-acetylcysteine|Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
11610463|NCT00568087|Placebo Comparator|Placebo|Patients will take oral placebo (identical matching placebo) during the study period.
11610464|NCT00568061|Experimental|Inhaled Nitric Oxide|Inhaled Nitric oxide administered at 80 parts per million (ppm)
11610465|NCT00568061|Placebo Comparator|Placebo|Inhaled nitrogen gas (Placebo) administered at 80 ppm
11610466|NCT00568048|Experimental|Combination Therapy Temozolomide & Bevacizumab|"Combination therapy
~Temozolomide 150 mg/m2 p.o., days 1-7, repeated every 14 days
~Bevacizumab 10 mg/kg i.v., day 1, repeated every 14 days"
11610467|NCT00568035|Active Comparator|QR-333|
11610468|NCT00568035|Placebo Comparator|Placebo|
11610469|NCT00568022|Experimental|Ixabepilone + Capecitabine|
11610470|NCT00567996|Experimental|Indacaterol 150 μg|"Indacaterol 150 μg once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening.
~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
11610471|NCT00567996|Placebo Comparator|Placebo|"Placebo to Indacaterol once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening.
~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
11610472|NCT00567996|Active Comparator|Salmeterol 50 μg|"Salmeterol 50 μg twice daily delivered via a proprietary dry powder inhaler in the morning and in the evening. Placebo to Indacaterol daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI).
~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
11610473|NCT00567983|Active Comparator|1.|
11610474|NCT00567983|Placebo Comparator|2.|
11610475|NCT00567957|Placebo Comparator|C|Saline starting before induction till entry to abdominal cavity
11610476|NCT00567957|Active Comparator|R|Remifentanil starting before induction till entry to abdominal cavity
11610477|NCT00567931|Experimental|Treatment (Immunomodulating therapy)|Patients receive oral 1-methyl-d-tryptophan (1-MT) once or twice daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11610478|NCT00567918|Experimental|1|FK506 ophthalmic suspension
11610479|NCT00567905|Experimental|A|Green tea extract
11610480|NCT00567905|Placebo Comparator|B|
11610481|NCT00567892|Experimental|1. rTMS|"Stimulation Settings:
~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
11610482|NCT00567892|Sham Comparator|2. Sham rTMS|Sham rTMS appears identical to and mimics sounds and sensations of active magnet.
11610483|NCT00567879|Experimental|Panobinostat with trastuzumab|Panobinostat intravenously (i.v.) or orally was given in combination with trastuzumab.
11610484|NCT00567866|Experimental|1|placebo -50 mg quetiapine- 100 mg quetiapine
11610485|NCT00567866|Experimental|2|50 mg quetiapine -100 mg quetiapine- placebo
11610486|NCT00567866|Experimental|3|50 mg quetiapine -placebo- 100 mg quetiapine
11610487|NCT00567853|Other|MEMO 3D ring|All patients in the study will be implanted with the MEMO 3D ring
11610488|NCT00567840|Experimental|1|PA-824 200 mg/qd
11610489|NCT00567840|Experimental|2|PA-824 600 mg/qd
11610490|NCT00567840|Experimental|3|PA-824 1000 mg/qd
11610491|NCT00567840|Experimental|4|PA-824 1200 mg/qd
11610492|NCT00567840|Active Comparator|5|Rifafour e-275 mg
11610493|NCT00567814|Active Comparator|1|Lower dose combination of metyrapone with oxazepam
11610494|NCT00567814|Active Comparator|2|Higher dose combination of metyrapone with oxazepam
11610495|NCT00567814|Placebo Comparator|3|
11610496|NCT00567801|Active Comparator|1|conventional embolectomy/thrombectomy
11610497|NCT00567801|Experimental|2|embolectomy/thrombectomy with controlled reperfusion
11610498|NCT00567788|Active Comparator|1|Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
11610499|NCT00567788|Active Comparator|2|Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
11610500|NCT00567762|Experimental|1|FK506 ophthalmic suspension
11610501|NCT00567762|Placebo Comparator|2|Base of eye drops
11610502|NCT00567749||A, Observational|
11610503|NCT00567736|Active Comparator|1|Disci/Rhus toxicodendron comp.®
11610504|NCT00567736|Placebo Comparator|2|placebo solution
11610505|NCT00567736|No Intervention|3|waiting list group
11610506|NCT00567723||1|Test group: Patients who have received a minimum of 12 consecutive weeks of treatment with Fosrenol
11610507|NCT00567723||2|Historical control group: Patients with no lanthanum exposure
11610508|NCT00567723||3|Concomitant therapy group: Patients being treated for hyperphosphatemia with any marketed product
11610509|NCT00567710|Experimental|I|BL - 1020 lowdose
11610510|NCT00567710|Experimental|II|BL 1020 high dose
11610511|NCT00567710|Placebo Comparator|III|
11610512|NCT00567710|Active Comparator|IV|Risperidone
11610513|NCT00567697|Active Comparator|A|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection
11610514|NCT00567697|Sham Comparator|B|
11610515|NCT00567684|Experimental|CTU + IVU|CTU = Computed Tomography Urography + IVU = Intravenous Urography
11610516|NCT00567671|Experimental|Treatment|Corneal collagen cross-linking
11610517|NCT00567671|Sham Comparator|Control|Sham Treatment
11610518|NCT00567658|Placebo Comparator|A 1|Arm I: placebo group receives BID placebo
11610519|NCT00567658|Experimental|A2|subjects receive active drug, esomeprazole 40 mg BID
11610520|NCT00567606|Experimental|1|Subjects in the G1 group receive 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week and strength/weight training exercises for upper and lower extremities and the spine.
11610521|NCT00567606|Experimental|2|Subjects in the G2 group receive the calcium, vitamin D, and risedronate, but do not participate in strength/weight training exercises.
11610522|NCT00567593|Other|Rosiglitazone|Rosiglitazone; 8mg tablet once a day for 14 days
11610523|NCT00567580|Active Comparator|Arm I|(Prostate bed radiotherapy [PBRT] alone): Patients undergo PBRT once daily, 5 days a week, Monday through Friday, for approximately 7-8 weeks (36 to 39 fractions).
11610524|NCT00567580|Experimental|Arm II|(PBRT and short-term androgen deprivation [STAD]): Beginning 2 months before the start of PBRT, patients undergo STAD, using a combination of antiandrogen (AA) and LHRH agonist therapy, for a total of 4-6 months. Patients receive AA therapy comprising either oral flutamide 3 times daily or oral bicalutamide once daily for at least 4 months. Patients receive LHRH agonist injection beginning concurrently with or 2 weeks after the start of AA therapy. LHRH agonist injection consists of analogs approved by the FDA (or by Health Canada for Canadian institutions) (e.g., leuprolide, goserelin, buserelin, or triptorelin) and may be given in any possible combination (may be given as a single 4-month injection and one to two 1-month injection[s], two 3-month injections, or a 6-month injection), such that the total LHRH agonist treatment time is 4-6 months. Approximately 2 months after beginning of STAD, patients undergo PBRT as in arm I.
11610525|NCT00567580|Experimental|Arm III|(Pelvic lymph node radiotherapy [PLNRT], PBRT, and STAD): Beginning 2 months before the start of radiotherapy, patients receive STAD therapy as in arm II. Approximately 2 months after beginning of STAD, patients undergo PBRT and PLNRT once daily, 5 days a week, Monday through Friday, for approximately 5 weeks (25 fractions) followed by PBRT only once daily, 5 days a week for approximately 2-3 weeks (11-14 fractions).
11610526|NCT00567567|Active Comparator|Consolidation Arm A: single myeloablative consolidation|Patients receive melphalan IV over 15-30 minutes on days -7 to -5, etoposide IV over 24 hours and carboplatin IV over 24 hours on days -7 to -4, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Patients undergo autologous PBSCT on day 0.
11610527|NCT00567567|Experimental|Consolidation Arm B: tandem myeloablative consolidation|Patients receive thiotepa IV over 2 hours on days -7 to -5, cyclophosphamide IV over 1 hour on days -5 to -2, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Following clinical recovery from initial myeloablative therapy, patients also receive melphalan, etoposide, and carboplatin as in Arm A. Patients undergo autologous PBSCT on day 0.
11610528|NCT00567554|Experimental|1|EC-T
11610529|NCT00567554|Experimental|2|EC-T +/- B
11610530|NCT00567554|Experimental|3|Pw
11610531|NCT00567554|Experimental|4|Pw + RAD001
11610532|NCT00567554|Experimental|5|EC-T + H
11610533|NCT00567554|Experimental|6|EC-T + L
11610534|NCT00567541|Active Comparator|Active BBPM stimulation|Therapeutic Stimulation is applied via the Battery Powered Microneuromodulator (BBPM) which is programmed to deliver set stimulation parameters with approximate frequency of 30 Hz, current 5mA for 200 microseconds for the first 12 weeks of the study. The BBPM is implanted near the axillary nerve within the quadrilateral space.
11610535|NCT00567541|Placebo Comparator|Sham BBPM stimulation|The Battery Powered Microneuromodulator is implanted near the axillary nerve within the quadrilateral space. The BBPM is programmed for the first 12 weeks of the study to deliver short bursts of extremely low amplitude electrical stimulation at very wide time intervals to give appearance, impression, and sensation of therapeutic treatment. After 24 weeks, the device will be reprogrammed to deliver therapeutic stimulation over a 12 week period.
11610536|NCT00567528|Other|1|Active ibuprofen liposomal transdermal gel with placebo ibuprofen capsule
11610537|NCT00567528|Other|2|Placebo ibuprofen liposomal transdermal gel with active ibuprofen capsules
11610538|NCT00567515|Experimental|LAA Clip|AtriCure LAA Exclusion System
11610539|NCT00567502||1|XAGRID® (anagrelide hydrochloride)
11610540|NCT00567502||2|Xagrid + Other cytoreductive
11610541|NCT00567502||3|Other cytoreductive
11610542|NCT00567489|Active Comparator|Non glucose sparing|Dianeal only
11610543|NCT00567489|Experimental|glucose sparing|PEN solutions: Nutrineal, Extraneal, and Physioneal
11610544|NCT00567476|Active Comparator|Omalizumab + Conventional Therapy|Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 20 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of immunoglobulin E (IgE). Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued using their current formulation of inhaled corticosteroid (ICS) and long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.
11610545|NCT00567476|Active Comparator|Conventional Therapy|Participants continued using their current formulation of inhaled corticosteroid (ICS) and a long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.
11610546|NCT00567463|Placebo Comparator|Placebo|Placebo inhalator will be used by subjects in the placebo group(same course as patients in the treated group)
11610547|NCT00567450|Active Comparator|B|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
11610548|NCT00567450|Experimental|A|30 ml of ropivacaine 0.75%
11610549|NCT00567437|Other|A|10 patients with no aortic stenosis
11610550|NCT00567437|Other|B|100 patients with asymptomatic AS
11610551|NCT00567411|Active Comparator|I|Eyes receiving Apraclonidine 0.5% (Iopidine) prior to SLT
11610552|NCT00567411|Active Comparator|A|Eyes receiving Brimonidine 0.1% (Alphagan) prior to SLT
11610553|NCT00567398|Active Comparator|non glucose sparing|Dianeal only
11610554|NCT00567398|Experimental|Glucose sparing|Physioneal, Extraneal, Nutrineal
11610555|NCT00567359|Experimental|Erlotinib|
11610556|NCT00567346|Active Comparator|grass pollen extract twice weekly|Current standard dose regimen of grass pollen immunotherapy (9,500 BU), given twice weekly. Note: patients in twice weekly dosing regimen will also receive placebo on days no active treatment is given.
11610557|NCT00567346|Active Comparator|Grass pollen extract, daily|Grass pollen immunotherapy, 9,500 BU, given daily
11610558|NCT00567346|Active Comparator|Increased dose of grass pollen extract|Increased dose of grass pollen immunotherapy, 19,000 BU, given daily
11610559|NCT00567346|Placebo Comparator|Placebo control|Patients randomized to placebo will receive placebo daily.
11610560|NCT00567333|Other|1|
11610561|NCT00567333|Other|2|
11610562|NCT00567320|Active Comparator|Varenicline|
11610563|NCT00567320|Active Comparator|Sugar Pill or Placebo|Placebo is compared to active drug varenicline
11610564|NCT00567307|Experimental|The Red Heart Pill 2b (Polypill) (A)|The Polypill is composed of 75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide
11610565|NCT00567307|Active Comparator|Standard Practice Group (B)|Standard Practice
11610566|NCT00567294|Active Comparator|A|Participants will receive mailed education materials on osteoporosis and medication use.
11610567|NCT00567294|Experimental|B|Participants will receive a telephone coaching program.
11610568|NCT00567294|Experimental|C|Participants will receive a telephone coaching program, and doctors of these participants will receive medication adherence alert notifications.
11610569|NCT00567281|Experimental|1|Active bilateral rTMS to left/right Wernicke's area and opposite side middle temporal gyrus
11610570|NCT00567281|Active Comparator|2|Active rTMS to left/right Wernicke's region plus sham rTMS to opposite hemisphere middle temporal cortex
11610571|NCT00567268||Gabapentin|Patients taking Gabapentin
11610572|NCT00567255|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/day with ancillary therapy
11610573|NCT00567255|Placebo Comparator|Placebo|Placebo with ancillary therapy
11610574|NCT00567242|Experimental|Word-finding with intention component|Treats word-finding (picture naming, category member generation) with an intention manipulation (complex left-hand movement to initiate word-finding trials)
11610575|NCT00567242|Active Comparator|Word-finding with no intention component|Word-finding trials similar to intention mediated treatment, but without intention manipulation
11610576|NCT00567229|Experimental|Lenalidomide and Rituximab|This study will employ a Simon optimal two-stage design. Patients will receive lenalidomide 25 mg daily for days 1-21 of each 28 day cycle. Rituximab 375 mg/m2 will be given weekly for 4 weeks beginning 1 week after the start of lenalidomide therapy (weeks 2-5), and then once 8 weeks later (week 13). Patients with stable disease or better after 4 cycles (week 16, in the absence of delays for toxicity) will be able to continue on therapy on the same lenalidomide schedule and with rituximab 375 mg/m2 given once every 8 weeks.
11610577|NCT00567216|No Intervention|G|Endoscopic injection of cyanoacrylate alone
11610578|NCT00567216|Active Comparator|C|Combination of GVO and nadolol
11610579|NCT00567203|Experimental|1|
11610580|NCT00567203|Experimental|2|
11610581|NCT00567203|Placebo Comparator|3|
11620518|NCT00479492|Placebo Comparator|4|
11610582|NCT00567190|Experimental|Pertuzumab + Trastuzumab + Docetaxel|Participants randomized to this arm received pertuzumab 420 milligrams (mg) intravenously (IV) once every 3 weeks (q3w) and trastuzumab 6 milligrams per kilogram (mg/kg) IV q3w, plus docetaxel 75 milligrams per square metre of body surface (mg/m^2) IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.
11610583|NCT00567190|Placebo Comparator|Placebo + Trastuzumab + Docetaxel|Participants randomized to this arm received placebo IV q3w and trastuzumab 6 mg/kg IV q3w, plus docetaxel 75 mg/m^2 IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.
11610584|NCT00567177|Active Comparator|1|
11610585|NCT00567177|Placebo Comparator|2|
11610586|NCT00567164|Experimental|Flexible (extended) regimen no. 1 of EE20/DRSP (BAY86-5300)|Minimum of 3 cycles of treatment, each cycle comprising 120 days (maximum) intended treatment with one tablet daily of BAY86-5300 (SH T00186D) followed by a 4-day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred between days 25 to 120 of the treatment cycle, a 4-day tablet-free interval was advised. The minimum period between 2 tablet-free intervals was 24 days. After each 4-day tablet-free interval, a new 124-day intended treatment cycle was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment
11610587|NCT00567164|Experimental|Flexible (extended) regimen no. 2 of EE20/DRSP (BAY86-5300)|Minimum of 3 cycles of treatment, each cycle comprising 120 days (maximum) uninterrupted treatment with one tablet daily of BAY86-5300 (SH T00186D) and a 4-day tablet-free interval. Subjects were permitted to schedule their withdrawal bleeding (ie, 4-day tablet-free interval) at any time between days 25 to 120 of the cycle. Subjects had the option to follow the bleeding rules of the flexible (extended) regimen no. 1 of BAY86-5300. The minimum period between 2 tablet-free intervals was 24 days. After each 4-day tablet-free interval, a new 124-day intended treatment cycle was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
11610588|NCT00567164|Active Comparator|Conventional regimen of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets of BAY86-5300 (YAZ, SH T00186D) followed by 4 days of tablets without active substance (together resulting in one cycle of 24+4 standard treatment). 13 withdrawal bleeding episodes during one year of treatment were expected.
11610589|NCT00567125||I|Patients with cholelithiasis operated on using standard laparoscopy method
11610590|NCT00567125||II|Patients with cholelithiasis operated on using low-pressure CO2 pneumoperitoneum laparoscopy
11610591|NCT00567112|Experimental|DFC (fasted)|
11610592|NCT00567112|Experimental|OCT (fasted)|
11610593|NCT00567112|Experimental|OCT (after meal)|
11610594|NCT00567112|Active Comparator|OCT (before meal)|
11610595|NCT00567086|Placebo Comparator|A|
11610596|NCT00567086|Experimental|B|
11610597|NCT00567086|Experimental|C|
11610598|NCT00567086|Experimental|D|
11610599|NCT00567073||Pregnant Women Receiving Treatment for Pompe Disease|Pregnant Women with Pompe Disease Enrolled in the Pompe Disease Registry (NCT00231400)That Are Receiving Treatment of alglucosidase alpha (Myozyme)
11610600|NCT00567073||Pregnant Women Receiving No Treatment for Pompe Disease|Pregnant Women with Pompe Disease Enrolled in the Pompe Disease Registry (NCT00231400)That Are Not Receiving Treatment
11610601|NCT00567073||Infants Born to Mothers Receiving Treatment for Pompe|The Infants of Mothers with Pompe Disease Enrolled in the Pompe Disease Registry (NCT00231400)Where the Mothers Are Receiving Treatment of alglucosidase alpha (Myozyme)
11610602|NCT00567073||Infants Born to Mothers Receiving No Treatment for Pompe|The Infants of Mothers with Pompe Disease Enrolled in the Pompe Disease Registry (NCT00231400)Where the Mothers Are Not Receiving Treatment
11610603|NCT00567047|Experimental|1|Vildagliptin
11610604|NCT00567034|Active Comparator|1|taking naltrexone
11610605|NCT00567034|Placebo Comparator|2|taking placebo
11610606|NCT00567021||1|patients with GERD or NSAID-related ulcers
11610607|NCT00567008|Experimental|1|Varenicline (Chantix)
11610608|NCT00567008|Placebo Comparator|2|Placebo
11610609|NCT00566995|Experimental|Vandetanib in Participants with Kidney Cancer|300 mg/day (starting dose) oral dose of vandetanib once a day for 28 days
11610610|NCT00566982|Experimental|Ospemifene 60 mg/day|Ospemifene will be taken orally, once daily, in the morning, with food for 52 weeks.
11610611|NCT00566982|Placebo Comparator|Placebo|Placebo will be taken once daily, in the morning, with food for 52 weeks.
11610612|NCT00566969|Placebo Comparator|Sugar Pill|To be compared to active drug
11610613|NCT00566969|Active Comparator|Carvedilol 25 mg|To be compared to placebo and Carvedilol 50 mg
11610614|NCT00566969|Active Comparator|Carvedilol 50 mg|To be compared to placebo and Carvedilol 25 mg
11610615|NCT00566956|Experimental|1|For those assigned to Group 1, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
11610616|NCT00566956|No Intervention|2|Patients assigned to group 2 will not have the hydrosalpinx aspirated
11610617|NCT00566943|Active Comparator|Control|"Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple lines including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine). intestine or mesentery.
~Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without buttress at the GJ anastomosis. Linear buttress at the stomach/pouch staple line is required."
11610713|NCT00566189|Experimental|1|Roux-en-Y bypass gastroplasty
11610714|NCT00566150|Active Comparator|Levetiracetam|
11610618|NCT00566943|Experimental|PSD Veritas|"Linear Peri-Strips Dry Veritas Group: Patients who have laparoscopic Roux-en-Y gastric by-pass surgery with PSD Veritas used as a staple line buttress at the stomach/pouch.
~In addition to buttress of the stomach/pouch, patients may have PSD Veritas linear buttress at any of the following staple lines: intestine, mesentery, or anastomosis junction (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine).
~Circular Peri-Strips Dry Veritas Group: Patients who have laparoscopic Roux-en-Y gastric by-pass surgery with PSD Veritas circular buttress used as a staple line buttress at the GJ anastomosis. Linear buttress at the stomach/pouch is required."
11610619|NCT00566930|No Intervention|1|
11610620|NCT00566930|Active Comparator|2|spinal manipulation
11610621|NCT00566930|Experimental|3|Spinal manipulation + exercises
11610622|NCT00566917|Active Comparator|1|Anterior colporrhaphy (standardised)
11610623|NCT00566917|Experimental|2|Anterior PROLIFT
11610624|NCT00566904|Experimental|1|Participants will receive one of three different topical treatments on Days 8, 15, or 22.
11610625|NCT00566891|Active Comparator|A|Tirofiban
11610626|NCT00566891|Placebo Comparator|B|Clopidogrel
11610627|NCT00566865|Experimental|2|mitiglinide + gemfibrozil
11610628|NCT00566865|Placebo Comparator|1|mitiglinide + placebo for gemfibrozil
11610629|NCT00566852|Experimental|WBRT+Memantine|Whole brain radiation therapy (WBRT) and memantine
11610630|NCT00566852|Active Comparator|WBRT+Placebo|Whole brain radiation therapy (WBRT) and placebo
11610631|NCT00566839|Experimental|1|
11610632|NCT00566839|Active Comparator|2|
11610633|NCT00566826|Experimental|1|Patient support treatment sessions
11610634|NCT00566826|Active Comparator|2|Treatment as usual
11610635|NCT00566813|Active Comparator|Group 1 (Islet Cell Transplant)|1-3 Islet transplants by the Edmonton Protocol of Steroid Free Immunosuppression using daclizumab 1 mg/kg IV immediately pre-transplant and 2, 4, 6, and 8 weeks after transplant; sirolimus dosed to maintain serum trough levels 12-15 ng/mL for three months post-transplant and 7-10 ng/mL therafter; tacrolimus dosed to maintain serum trough levels 3-6 ng/mL throughout the study.
11610636|NCT00566813|Active Comparator|Group 2 (Islet Cell Transplant plus)|1-3 islet transplants by the Edmonton Protocol of Steroid Free Immunosuppression using daclizumab 1 mg/kg IV immediately pre-transplant and 2, 4, 6, and 8 weeks after transplant; sirolimus dosed to maintain serum trough levels 12-15 ng/mL for 3 months post-transplant and 7-10 mg/mL thereafter; tacrolimus dosed to serum trough levels 3-6 ng/mL throughout the study; etanercept 50 mg IV pre-transplant, 25 mg subcutaneously post-transplant Days 3, 7, 10; exenatide 5-mcg subcutaneously twice daily for I week, then up to 10-mcg twice daily for 6 months after the last islet transplant.
11610637|NCT00566774|Experimental|1|
11610638|NCT00566774|Active Comparator|2|
11610639|NCT00566735|Placebo Comparator|1|
11610640|NCT00566735|Active Comparator|2, Galantamine|
11610641|NCT00566722|Experimental|Open Label|
11610642|NCT00566709|Experimental|RBCT based on rSO2 value|Intervention: In the rSO2 - strategy group, patients will be transfused to attain a post-transfusion rSO2 values higher than 60%.
11610643|NCT00566709|Active Comparator|RBCT based on hemoglobin level value|Intervention: In the hemoglobin - strategy group, patients will be transfused to reach post-transfusion hemoglobin levels between 8.5 g/dL and 10 g/dL.
11610644|NCT00566696|Experimental|High-Risk Hematologic Malignancies|"Participants meeting eligibility criteria undergo haploidentical stem cell transplantation along with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (after January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.
~Grafts from suitable haploidentical donors are processed using the CliniMACS system."
11610645|NCT00566683|Active Comparator|1|Diazemuls-Pethidine
11610646|NCT00566683|Active Comparator|2|Propofol- Alfentanil
11610647|NCT00566670||Observation (all participants)|Stage 5 Chronic Kidney Disease and hemodialysis patients
11610648|NCT00566657|Experimental|Riferminogene pecaplasmid|4 administrations of riferminogene pecaplasmid 4 mg at 2-week intervals
11610649|NCT00566657|Placebo Comparator|Placebo|4 administrations of placebo (for riferminogene pecaplasmid) at 2-week intervals
11610650|NCT00566631|Experimental|Paliperidone Extended Release (ER)|
11610651|NCT00566618|Experimental|Dasatinib + Zoledronic Acid|"Dasatinib Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.
~Zoledronic Acid Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort. Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
11610652|NCT00566605|Active Comparator|Group 1|
11610653|NCT00566605|Active Comparator|Group 2|
11610654|NCT00566592|Experimental|1|Oral ethanol, overnight
11610655|NCT00566592|Experimental|2|IV ethanol, overnight
11610656|NCT00566592|Placebo Comparator|3|Placebo, overnight
11610657|NCT00566592|Placebo Comparator|4|Placebo, daytime
11610658|NCT00566579|Experimental|A|Double-freezing cryotherapy was done within one month after the primary hpv testing was positive. Pap smear and colposcopy were done at 6 months and 12 months. HPV testing was repeated again at 12 months.
11610659|NCT00566579|No Intervention|B|Pap smear and colposcopy were done at 6 months and 12 months. HPV testing was repeated again at 12 months.
11610660|NCT00566566||1|ALL survivors 5 years after completion of treatment, during routine medical follow up
11610661|NCT00566553|Active Comparator|Grape Seed Extract # 1|200 mg [1 pill]
11610662|NCT00566553|Active Comparator|Grape Seed Extract # 2|200 mg [2 pills]
11610663|NCT00566553|Active Comparator|Grape Seed Extract # 3|200 mg [3 pills]
11610664|NCT00566553|Active Comparator|Grape Seed Extract # 4|200 mg [4 pills]
11610715|NCT00566150|Placebo Comparator|Placebo|
11610716|NCT00566124|Active Comparator|1|Insulin detemir
11610717|NCT00566124|Active Comparator|2|Insulin glargine
11610718|NCT00566124|Active Comparator|3|NPH insulin
11610719|NCT00566111|Active Comparator|A|
11610720|NCT00566111|Placebo Comparator|P|
11610768|NCT00565747|Placebo Comparator|Control culture|Culture without GM-CSF
11610665|NCT00566540|Experimental|Treatment (neoadjuvant, adjuvant chemotherapy and radiation)|"PREOPERATIVE:Patients receive cisplatin IV over 2 hours three times weekly in week 1 once daily(QD),5 days a week, in weeks 1-2.
~SURGERY:Patients undergo triple endoscopy and biopsy with submandibular gland transfer in week 3.
~INTRAOPERATIVE: Patients also undergo Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation.
~POSTOPERATIVE: Patients receive paclitaxel IV over 3 hours in weeks 7-10 and cisplatin IV over 1-2 hours three times weekly in weeks 7 and 10. Patients also undergo Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation QD, 5 days a week, in weeks 7-10."
11610666|NCT00566527|Experimental|Arm 1: ProQuad® at 9 and 12 months|Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 at 12 months of age.
11610667|NCT00566527|Experimental|Arm 2: ProQuad® at 11 and 14 months|Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 at 14 months of age.
11610668|NCT00566527|Active Comparator|Arm 3: ProQuad at 12 and 15 months|Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 at 15 months of age.
11610669|NCT00566514|Active Comparator|1|D-ribose 5 grams TID orally
11610670|NCT00566514|Placebo Comparator|2|Dextrose 5 grams TID
11610671|NCT00566501|Experimental|23 mg SR in Study 326|Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.
11610672|NCT00566501|Experimental|10 mg IR in Study 326|Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.
11610673|NCT00566488|Experimental|Thymus and Parathyroid transplantation|Thymus/Parathyroid Transplantation in Complete DiGeorge Syndrome Infants
11610674|NCT00566475|No Intervention|1|usual care
11610675|NCT00566475|Experimental|2|Telemedicine intervention in the school involving school personnel, the child with diabetes and at least 1 parent of the child
11610676|NCT00566462|Experimental|perampanel|
11610677|NCT00566462|Placebo Comparator|1|
11610678|NCT00566449|Experimental|001|JNJ-31001074 10 mg daily for 4 weeks
11610679|NCT00566449|Placebo Comparator|003|Placebo one dose daily for 4 weeks
11610680|NCT00566449|Experimental|002|JNJ-31001074 30 mg daily for 4 weeks
11610681|NCT00566436|Active Comparator|REA|Patients presenting with a long occlusion of the superficial femoral artery enrolled in REA arm will undergo remote endarterectomy of the occluded superficial femoral artery
11610682|NCT00566436|Active Comparator|Bypass|Patients presenting with a long occlusion of the superficial femoral artery enrolled in Bypass arm will undergo suprageniculate femoropopliteal bypass surgery to bypass the occluded superficial femoral artery
11610683|NCT00566423|Experimental|1|Patients with Pulmonary Arterial Hypertension
11610684|NCT00566397|Experimental|1|
11610685|NCT00566397|Experimental|2|
11610686|NCT00566397|Placebo Comparator|3|
11610687|NCT00566384|Active Comparator|Arm 1|
11610688|NCT00566384|Placebo Comparator|Arm 2|
11610689|NCT00566371|Experimental|1|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
11610690|NCT00566371|Placebo Comparator|2|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
11610691|NCT00566358|Experimental|1|Duodenal exclusion
11610692|NCT00566345|Experimental|1|Vero-cell derived influenza vaccine
11610693|NCT00566345|Placebo Comparator|2|Phosphate buffered saline (packaged in syringes identical to those used for the investigational vaccine)
11610694|NCT00566332|Active Comparator|1|Chlorambucil 8mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months
11610695|NCT00566332|Active Comparator|2|Fludarabine
11610696|NCT00566319|Experimental|1|
11610697|NCT00566319|Active Comparator|2|
11610698|NCT00566306|Experimental|A|PHMG will be introduced in three wards for hand hygiene and environmental disinfection in CDAD patients' rooms. The rooms for showers and toilets will be coated with biocide coating (PHMG) as well as bed frames in investigational wards.
11610699|NCT00566306|No Intervention|B|Three wards will be control wards and continue using alcohol based hand disinfectants and routine environmental cleaning and disinfection with quats/chloramines.
11610700|NCT00566280|Other|Molecular Breast Imaging|
11610701|NCT00566267|Experimental|2|Low carb diet plus simvastatin 20 mg/ezetimibe 10 mg
11610702|NCT00566254|Placebo Comparator|Placebo|Participants had a starting dose of 1 mg/kg/day of placebo matching Zonisamide. Dose was titrated upwards with weekly dose increases until a dose of 8 mg/kg/day was reached at the end of the Titration Period (Week 8). Dose during the Maintenance Period remained unchanged from Week 8.
11610703|NCT00566254|Experimental|Zonisamide|Participants had a starting dose of 1 mg/kg/day of Zonisamide. Dose was titrated upwards with weekly dose increases until a dose of 8 mg/kg/day was reached at the end of the Titration Period (Week 8). Dose during the Maintenance Period remained unchanged from Week 8.
11610704|NCT00566241|Experimental|IGF-1|Recombinant human IGF-1
11610705|NCT00566241|Placebo Comparator|Placebo|Placebo
11610706|NCT00566228|Experimental|Immunologic autograft engineering|Patients' stem cells are collected according to modified Amicus settings (i.e., MNC OFFSET = 0.0 and RBC = 7.0). Patients undergo ASCT IV on the day of apheresis (lymphocyte enriched autograft).
11610707|NCT00566228|Active Comparator|Standard autograft collection|Patients' stem cells are collected according to standard Amicus settings (i.e., MNC OFFSET = 1.5 and RBC OFFSET = 5.0). Patients undergo ASCT IV on the day of apheresis.
11610708|NCT00566215|Experimental|1|Duodenal exclusion plus total omentectomy
11610709|NCT00566215|Active Comparator|2|Duodenal exclusion without omentectomy
11610710|NCT00566202|Experimental|JNJ-18038683|
11610711|NCT00566202|Placebo Comparator|Placebo|
11610712|NCT00566202|Active Comparator|Escitalopram|
11610721|NCT00566098|Experimental|ASCT+MILs|Autologous stem cell transplant with a conditioning regimen of melphalan 100 mg/m^2 on each of Days -2 and -1. Infusion of activated marrow infiltrating lymphocytes (MILs) on Day 3. PCV13 vaccine will be given before and/or after Day 0 depending on when participants are enrolled.
11610722|NCT00566085|Other|Molecular Breast Imaging|
11610723|NCT00566072|Experimental|1|instructions and coaching on the use and intake of ganciclovir
11610724|NCT00566072|No Intervention|2|
11610725|NCT00566046|Experimental|Levetiracetam|
11610726|NCT00566046|Placebo Comparator|Placebo|
11610727|NCT00566033|Experimental|1|
11610728|NCT00566033|No Intervention|2|Patients in this arm (arm 2) will undergo to standard care.
11610729|NCT00566020|Experimental|Lamotrigine|study drug
11610730|NCT00566007|Active Comparator|1|Discectomy/micro discectomy
11610731|NCT00566007|Active Comparator|2|Intradiscal ozone infiltration
11610732|NCT00566007|Active Comparator|3|Intradiscal oxygen infiltration (control arm)
11610733|NCT00565994||Hemodialysis patients|Male and female patients undergoing hemodialysis therapy as outpatients
11610734|NCT00565994||Control|Male and female healthy volunteers
11610735|NCT00565994||Pre-dialysis patients|Male and female patients with Stage 3, 4, or 5 chronic kidney disease, but not yet on dialysis
11610736|NCT00565981|Experimental|Overall study|The FLUSALEM protocol combines 4 cycles of oral fludarabine phosphate (40mg/m² d1-3; q 29d) and an intensive dose schedule of alemtuzumab (30mg sc.3 times weekly for 16 weeks) in an outpatient setting
11610737|NCT00565968|Experimental|Sorafenib dose escalation|
11610738|NCT00565955|Active Comparator|A1|Children Between 5-15 Years of Age Receiving Montelukast
11610739|NCT00565955|Placebo Comparator|A2|Children Between 5-15 Years of Age Receiving Placebo
11610740|NCT00565942|Active Comparator|Usual care|Treatment as usual coordinated by general practitioners in primary care.
11610741|NCT00565942|Active Comparator|Integrative care|Selected complementary therapies (Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong) added to usual care.
11610742|NCT00565929|Experimental|Group A: MVA-BN 1 X 10^7 TCID 50|10 participants to receive vaccine dose 1X10^7 TCID 50; 2 participants to receive placebo.
11610743|NCT00565929|Experimental|Group B: MVA-BN 1 X 10^8 TCID 50|10 participants to receive vaccine dose 1X10^8 TCID 50; 2 participants to receive placebo.
11610744|NCT00565916|Experimental|estrogen plus progesterone|Hormone replacement therapy (HRT): estrogen plus progesterone
11610745|NCT00565916|Active Comparator|estrogen plus placebo|Hormone replacement therapy (HRT): estrogen plus placebo
11610746|NCT00565890|No Intervention|2|No replacement therapy
11610747|NCT00565877|Experimental|1 - Neck Ultrasound|post-PICC insertion ultrasound inspection of the ipsilateral neck
11610748|NCT00565877|No Intervention|2 - Control|No post-PICC insertion ultrasound inspection of the ipsilateral neck
11610749|NCT00565864|Experimental|1 (Low-normal TSH target)|Treatment arm 1 targets a thyroid stimulating hormone (TSH) of 0.28 -2.49 milliunits/liter (mU/L) (the theoretical optimal range). The intervention is as follows: Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses.
11610750|NCT00565864|Experimental|2 (High-normal TSH target)|"Treatment arm 2 targeting a TSH of 2.5 - 5.0 mU/L. The intervention is as follows:
~Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses."
11610751|NCT00565864|Experimental|3 (Mildly elevated TSH target)|"Treatment arm 3 is targeting a TSH level o f 5.1-12.0 mU/L. The intervention is as follows:
~Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses."
11610752|NCT00565851|Active Comparator|Arm I (paclitaxel, docetaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours or docetaxel IV over 1 hour and carboplatin over 30 minutes on day 1. Treatment repeats every 21 days.
11610753|NCT00565851|Experimental|Arm II (paclitaxel, docetaxel, carboplatin, bevacizumab)|Patients receive chemotherapy as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days.
11610754|NCT00565851|Experimental|Arm III (gemcitabine hydrochloride, carboplatin)|Patients receive gemcitabine hydrochloride IV over 60 minutes on days 1 and 8 and carboplatin as in Arm I.
11610755|NCT00565851|Experimental|Arm IV (gemcitabine hydrochloride, bevacizumab, carboplatin)|Patients receive gemcitabine hydrochloride IV as in Arm III, bevacizumab IV and carboplatin IV as in Arm II.
11610756|NCT00565838||2|G1 - Autologous Fascial Sling G2 - TVT
11610757|NCT00565812|Active Comparator|200 mg|High dose active comparator
11610758|NCT00565812|Active Comparator|50 mg|Low dose active comparator
11610759|NCT00565812|Placebo Comparator|Placebo|Placebo comparator to be used for control purposes
11610760|NCT00565799|Active Comparator|1. Omentectomy|LAGB & Omentectomy
11610761|NCT00565799|Placebo Comparator|2 No Omentectomy|LAGB Only
11610762|NCT00565786||ArCom® Polyethylene|ArCom® Polyethylene
11610763|NCT00565786||ArComXL® Polyethylene|ArComXL® Polyethylene
11610764|NCT00565773|Experimental|Immunosuppressive medications|"Renal transplant recipients will be given an experimental combination of immunosuppressive drugs. Participants will receive a single dose of alemtuzumab on the day of transplantation and will receive belatacept and sirolimus for 1 year.
~At the time of transplant, all patients will receive a single dose of 500 mg of methylprednisolone IV over 30 minutes, followed within 1 hour by an IV infusion of 30 mg of alemtuzumab over 3 hours."
11610765|NCT00565760|Experimental|1|
11610766|NCT00565760|Placebo Comparator|2|
11610767|NCT00565747|Experimental|Test culture|Culture with GM-CSF
11610769|NCT00565734||Posterior surgical approaches|Posterior surgical approaches for symptomatic cervical spondylotic myelopathy (CSM)
11610770|NCT00565734||Anterior surgical approaches|Anterior surgical approaches for symptomatic cervical spondylotic myelopathy (CSM).
11610771|NCT00565721|Experimental|Fluciclatide Injection - (AH111585 (F18))|Using of the drug product named, AH111585 (F18) Injection. It's generic chemical name is Fluciclatide.
11610772|NCT00565708|Experimental|acetylsalicylic acid|200mg OD for 3 years
11610773|NCT00565708|Placebo Comparator|Placebo|200mg OD for 3 years
11610774|NCT00565682|Experimental|A|Etoricoxib 120 mg
11610775|NCT00565669|Experimental|Blink Tears|
11610776|NCT00565669|Experimental|Systane|
11610777|NCT00565656|Experimental|A|Bevacizumab
11610778|NCT00565643|Experimental|HA-CMC Group|Hyaluronic Acid-Carboxymethylcellulose placed as an adhesion barrier
11610779|NCT00565643|Placebo Comparator|Routine Closure Group|Routine Closure without placement of an adhesion barrier
11610780|NCT00565630|Experimental|1|Vigamox via the experiemntal device
11610781|NCT00565630|Active Comparator|2|Vigamox drops from the commercially available bottles
11610782|NCT00565617|Experimental|Synergy, Epidural cortical stimulation|Epidural cortical stimulation (medial prefrontal cortex) for treatment resistant depression. The primary aim of this pilot study was to assess the feasibility and safety of EpCS in patients with treatment-resistant depression. Ultimately, for EpCS to be found effective, a much larger double blind placebo controlled study would be needed.
11610783|NCT00565604|Experimental|Short Catheter Delviery|Patients with duplex ultrasound documented incompetent perforator veins will be treated using a short catheter delivery system in conjunction with a Bright Tip Laser fiber.
11610784|NCT00565591|Placebo Comparator|Dose escalation|
11610785|NCT00565565|Experimental|BAY60-4552, 1 mg|Subjects were planned to receive 1 mg of BAY60-4552 as solution
11610786|NCT00565565|Experimental|BAY60-4552, 2.5 mg|Subjects were planned to receive 2.5 mg of BAY60-4552 as tablet
11610787|NCT00565565|Experimental|BAY60-4552, 5 mg|Subjects were planned to receive 5.0 mg of BAY60-4552 as tablet
11610788|NCT00565565|Experimental|BAY60-4552, 7.5 mg|Subjects were planned to receive 7.5 mg of BAY60-4552 as tablet
11610789|NCT00565565|Experimental|BAY60-4552, 10 mg|Subjects were planned to receive 10 mg of BAY60-4552 as tablet
11610790|NCT00565552|Active Comparator|1|Each patient uses the silicone gel on one half of the scar, leaving the other one blank as an internal control.
11610791|NCT00565513|Other|A|cord blood and maternal milk tests
11610792|NCT00565500|Experimental|1|
11610793|NCT00565500|Experimental|2|
11610794|NCT00565500|Placebo Comparator|3|
11610795|NCT00565487|Experimental|Single arm|This is a single arm dose escalation study with a cohort expansion.
11610796|NCT00565474|Active Comparator|1|fluvastatin 40mg b.i.d.
11610797|NCT00565474|Placebo Comparator|2|Placebo b.i.d.
11610798|NCT00565461|Experimental|Group 1|40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT patch on the left deltoid by a Clinician on Day 0. Two weeks later will have the same treatment repeated on the right deltoid by the clinician
11610799|NCT00565461|Experimental|Group 2|40 subjects will be pretreated with SPS:Buffer and a patch containing 37.5ug will be applied on the left deltoid by the Clinician. Fourteen days later, the same procedure will occur on the left thigh by the clinician.
11610800|NCT00565461|Experimental|Group 3|40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT on the left deltoid by the clinician. Two weeks later subject will have the same treatment repeated by self-application in the clinic on the left thigh.
11610801|NCT00565461|Experimental|Group 4|40 subjects will have skin prepared using SPS:Buffer and will have 37.5ug LT patch on the left deltoid by a clinician. Two weeks later subjects will have the same treatment repeated by self-application at home on the left thigh.
11610802|NCT00565448|Experimental|Docetaxel/Cisplatin/5-FU (TCF)|"Docetaxel 75 milligrams per square meter (mg/m²) over 1 hour on Day 1 every 3 weeks
~Cisplatin 75 mg/m² Day 1 over 6 hours every 3 weeks
~5-Fluorouracil 750 mg/m²/day continuous infusion Days 1 to 4 every 3 weeks as an induction therapy
~Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks."
11610803|NCT00565448|Active Comparator|Cisplatin/5-FU (CF)|"Cisplatin 80 mg/m² Day 1 over 6 hours every 3 weeks
~5-Fluorouracil 1000 mg/m²/day continuous infusion Day 1 to 4 every 3 weeks as an induction therapy.
~Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks."
11610804|NCT00565422|Experimental|Single Arm|Escitalopram
11610805|NCT00565409|Active Comparator|1|
11610806|NCT00565409|Active Comparator|2|
11610807|NCT00565409|Placebo Comparator|3|
11610808|NCT00565396|Active Comparator|1|Fosinopril 10mg/day(oral)
11610809|NCT00565396|Active Comparator|2|Fosinopril 20mg/day(oral)
11610810|NCT00565396|Active Comparator|3|Losartan 50mg/day(oral)
11610811|NCT00565396|Active Comparator|4|Losartan 100mg/day(oral)
11610812|NCT00565383|Active Comparator|Intravenous fentanyl analgesia|Intravenous fentanyl (50 mcg) analgesia
11610813|NCT00565383|Experimental|Combined spinal-epidural analgesia|Combined spinal-epidural analgesia (intrathecal fentanyl 2.5 mg plus bupivacaine 2.5 mg) single administration
11610814|NCT00565370|Experimental|A|XP+sorafenib
11610815|NCT00565370|Placebo Comparator|B|XP
11610816|NCT00565357|Experimental|E|
11610817|NCT00565357|No Intervention|C|
11610818|NCT00565331|Active Comparator|1|Rituximab
11610819|NCT00565331|Placebo Comparator|2|Placebo
11610820|NCT00565318|Active Comparator|A|
11610821|NCT00565318|Placebo Comparator|B|
11610822|NCT00565305|Experimental|Healing Touch|Healing Touch + Standard Treatment Healing Touch treatments daily following standard Radiation Therapy. Standard radiation therapy is part of their medical care and is not administered as part of this study. Protocol of 4 HT techniques will be used including Pain Drain, Chakra connection, Magnetic Unruffling, and Mind Clearing. Treatments will be approximately 20-30 minutes.
11610823|NCT00565305|Active Comparator|Usual Care|Standard Treatment. These patients receive usual medical care but no additional intervention. Standard treatment is not administered as part of this study but as part of their medical treatment.
11610824|NCT00565279|Experimental|ASF1057|
11610825|NCT00565279|Placebo Comparator|ASF1057 placebo|
11610826|NCT00565279|Placebo Comparator|ASF1057 Vehicle|
11610827|NCT00565266|Experimental|"Tio + 1xICS || LABA + 1xICS || 2xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:
~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)
~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)
~beclomethasone dipropionate 160 mcg twice daily (2xICS)
~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
11610828|NCT00565266|Experimental|"TIO + 1xICS || 2xICS || LABA + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:
~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)
~beclomethasone dipropionate 160 mcg twice daily (2xICS)
~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)
~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
11610829|NCT00565266|Experimental|"LABA + 1xICS || Tio + 1xICS || 2xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:
~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)
~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)
~beclomethasone dipropionate 160 mcg twice daily (2xICS)
~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
11610830|NCT00565266|Experimental|"LABA + 1xICS || 2xICS || Tio + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:
~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)
~beclomethasone dipropionate 160 mcg twice daily (2xICS)
~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)
~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
11610831|NCT00565266|Experimental|"2xICS || Tio + 1xICS| || LABA + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:
~beclomethasone dipropionate 160 mcg twice daily (2xICS)
~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)
~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)
~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
11610832|NCT00565266|Experimental|"2xICS || LABA + 1xICS || Tio + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:
~beclomethasone dipropionate 160 mcg twice daily (2xICS)
~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)
~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)
~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
11610833|NCT00565240|Experimental|Oral Contraceptive|
11610834|NCT00565240|Experimental|Contraceptive Ring|
11610835|NCT00565240|Experimental|Aromatase Inhibitors|
11610836|NCT00565240|No Intervention|Control|
11610837|NCT00565227|Experimental|docetaxel plus vorinostat|
11610838|NCT00565214|Active Comparator|Group 1|On Day 1, Group 1 will initiate in a double-blinded fashion, a once daily vitamin combination of selenomethionine(400 μg), vitamin E(400 IU), and vitamin C (1000 mg) orally for 30 days at home. After 30 days of treatment with Vitamin supplements, the gene expression of the airway epithelium will be compared to that of the Placebo group.
11610839|NCT00565214|Placebo Comparator|Group 2|On Day 1, Group 2 will initiate the placebo in a double-blinded fashion.
11610840|NCT00565201|Experimental|Botox and Rehab|"Patients will receive BOTOX® (100 to 360 U) injected into the any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site).
~Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs."
11610841|NCT00565201|Placebo Comparator|Placebo and Rehab|Patients will placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
11610842|NCT00565188|Experimental|I|
11610843|NCT00565188|No Intervention|C|
11610844|NCT00565175|Experimental|famotidine|
11610845|NCT00565175|Placebo Comparator|Placebo|
11610846|NCT00565149|Experimental|1|Normal Protein (15%) diet
11610847|NCT00565149|Experimental|2|Low Protein (5%) diet
11610848|NCT00565149|Experimental|3|High Protein (25%) diet
11610849|NCT00565136|Experimental|TOPAS|TOPAS AMS Pelvic Floor Repair System
11610850|NCT00565123|Experimental|Group A|Experimental dosage
11610851|NCT00565123|Active Comparator|Group B|Classical dosage
11610923|NCT00564538|Experimental|1|Patients in arm 1 will receive induction with thymoglobulin at time of transplant with delayed initiation of tacrolimus
11610924|NCT00564538|Active Comparator|2|patients in arm 2 will not receive thymo induction at time of transplant and will have immediate initiation of tacrolimus
11610925|NCT00564525|Placebo Comparator|1|
11610926|NCT00564525|Experimental|2|Amitriptyline given
11610852|NCT00565110|No Intervention|Enhanced Usual Care|EUC patients receive medical center standard oncology care and supportive services routinely provided to all patients with cancer. In addition, EUC patients are given a patient focused and a family focused educational pamphlet on depression and cancer and a listing of financial and community resources (in Spanish for Spanish-speaking patients). With patient consent, as described in the informed written consent, the treating oncologist is informed via medical chart note if EUC patients screen positive for major depression. Treating oncology attending physicians, fellows and residents are invited to attend a didactic session led by the study psychiatrist on treating depression in cancer patients.
11610853|NCT00565110|Experimental|ADAPt-C intervention|Intervention patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
11610854|NCT00565097|Placebo Comparator|2|Placebo
11610855|NCT00565097|Experimental|1|Lanreotide
11610856|NCT00565084|Active Comparator|1|Ibuprofen
11610857|NCT00565084|Placebo Comparator|2|Placebo 1
11610858|NCT00565084|Placebo Comparator|3|Placebo 2
11610859|NCT00565071|Other|Field microscopy|Field microscopy is the main method of malaria diagnosis
11610860|NCT00565071|Other|Paracheck Pf® device|Paracheck Pf® device (Rapid Diagnostic Test) is the main method for malaria diagnosis
11610861|NCT00565071|No Intervention|Presumptive diagnostic method|
11610862|NCT00565058|Experimental|Pilot|Pilot PD Study (Delayed GTI-2040) Group: In the Pilot PD Study Group, addition of GTI-2040 is delayed until 24 hours after initiation of HiDAC.
11610863|NCT00565058|Experimental|Phase II arm|Phase II PD Study (Early GTI-2040) Group: In the Phase II PD Study Group, GTI-2040 is given 24 hours prior to addition of HiDAC.
11610864|NCT00565045|Experimental|CCFES|"CCFES - Contralaterally Controlled Functional Electrical Stimulation
~Stimulation to finger and thumb extensors and flexors only in response to and with an intensity proportional to opening and closing of the contralateral unimpaired hand
~A glove instrumented with sensors and worn on the unimpaired hand detects the degree of hand opening and determines stimulation intensity
~Therapy sessions are done with the subject being assisted by the CCFES system."
11610865|NCT00565045|Active Comparator|cNMES|"cNMES - Cyclic NeuroMuscular Electrical Stimulation.
~Preprogrammed cycles of finger and thumb flexor and extensor stimulation repeatedly and automatically close and open the hand without any effort or voluntary intent required by the subject.
~Subject instructed to relax, not attempt to assist the stimulation, and not to move the contralateral arm/hand during stimulation
~Therapy sessions are done without the stimulation system"
11610866|NCT00565019|No Intervention|Control|
11610867|NCT00565019|Experimental|Steroid|
11610868|NCT00564993|Active Comparator|A|"necessary re-intervention (pulmonary valve replacement) after repair of Fallot:
~2 Visits with cardiac imaging under rest and stress (Dobutamin) before and after pulmonary valve replacement"
11610869|NCT00564993|Active Comparator|B|"comparison group: with a good result of repair of tetralogy of fallot and good ventricular function:
~1 Visit with cardiac imaging under rest and stress (Dobutamin)"
11610870|NCT00564980|Active Comparator|1|Wafer Procedure
11610871|NCT00564980|Active Comparator|2|Ulnar shortening osteotomy
11610872|NCT00564967|Experimental|1|CBT via the Internet
11610873|NCT00564967|Experimental|2|15 weeks, CBT group therapy, 1 session/week (2.5 hours).
11610874|NCT00564954|Experimental|Dex-methylphenidate hydrochloride (Focalin XR)|20 mg capsule orally once a day for 7 days
11610875|NCT00564954|Placebo Comparator|Placebo|orally once a day for 7 days
11610876|NCT00564941|Experimental|Deferasirox|
11610877|NCT00564928|Experimental|IPI-504: Group A|No Prior treatment for prostate cancer with cytotoxic chemotherapy (adjuvant or neoadjuvant chemotherapy is acceptable if completed >2 years prior to study)
11610878|NCT00564928|Experimental|IPI-504: Group B|"Must have evidence of radiographic metastatic disease
~Must have been treated with a docetaxel-based chemotherapy regimen for HRPC with a minimum of 2 cycles with either PSA or RECIST defined radiographic progression during or witin 60 days of completeing docetaxel based chemotheraph or be intolerant of docetaxel-based chemotherapy
~No more than three prior chemotherapies regimens for HRPC"
11610879|NCT00564902|Placebo Comparator|Lutein|9 mg of Lutein for 12 months
11610880|NCT00564902|Active Comparator|Zeaxanthin and Lutein|3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
11610881|NCT00564902|Active Comparator|Zeaxanthin|3R 3'R Zeaxanthin 8 mg per day during 12 months
11610882|NCT00564889|Experimental|CRD|"Lenalidomide 15mg daily (days 1-21)
~Cyclophosphamide 300 mg/m^2 (days 1, 8, 15)
~Dexamethasone 40 mg weekly"
11610883|NCT00564876|Experimental|Treatment|Neoadjuvant dasatinib is to be administered as an oral dose of 70 mg PO twice daily on a continuous basis for 3 weeks prior to surgery. Patients will begin adjuvant dasatinib (70 mg PO twice daily) between 4-6 weeks after standard adjuvant therapy is complete or 4-8 weeks after surgery for those patients that do not receive adjuvant chemotherapy. Adjuvant dasatinib will be given on a continuous basis for up to 3 months after adjuvant chemotherapy or after surgery if no adjuvant chemotherapy is given.
11610884|NCT00564863|Other|CS19 expressing ETEC strain|Ascending dose finding study in 5-10 subjects per dose; to identify the dose able to give a diarrheal attack rate greater than or equal to 80%.
11610885|NCT00564850|Experimental|Triptorelin pamoate 11.25mg (Decapeptyl® SR)|
11610886|NCT00564837|Experimental|Home-based|Home-based post-operative rehabilitation program with 4 scheduled physiotherapy sessions over the first 3 post-op months
11610887|NCT00564837|Active Comparator|Physiotherapy supervised|Physiotherapy-supervised rehabilitation program including 17 scheduled physiotherapy sessions in the first 3 post-op months
11610927|NCT00564512|Experimental|FCCAM|Fludarabine-Cyclophosphamide-Campath (FCCam) Oral Fludarabine: 40 mg/m2 per os, D1 to D3 Oral Cyclophosphamide: 250 mg/m2/day as one dose at noon, D1 to D3 Campath®: 30 mg sc, D1 to D3 without dose escalation
11611047|NCT00563472|Active Comparator|4|20 mg E4 and 200 mg progesterone
11625349|NCT00426621|Placebo Comparator|2|
11610888|NCT00564824|Experimental|CAD patients|Patients with prior history of coronary artery disease (CAD) (myocardial infarction, cerebrovascular accident, coronary angioplasty, S/p CABG operation) who will be given on the first day either caffeine of placebo tablet and 1-2 hours thereafter a brachial artery endothelial function testing (BRT) will be assessed for measuring the FMD. After 1 week the patients will come for a second BRT on placebo/caffeine tablets. If the patient received caffeine tablet the first BRT, he will be receiving placebo tablet the second week, however, if the patient received placebo the first BRT, a caffeine tablet will be given prior to the second BRT.
11610889|NCT00564824|Experimental|Placebo|Patients with prior history of coronary artery disease (CAD) (myocardial infarction, cerebrovascular accident, coronary angioplasty, S/p CABG operation) who will be given on the first day either caffeine of placebo tablet and 1-2 hours thereafter a brachial artery endothelial function testing (BRT) will be assessed for measuring the FMD. After 1 week the patients will come for a second BRT on placebo/caffeine tablets. If the patient received caffeine tablet the first BRT, he will be receiving placebo tablet the second week, however, if the patient received placebo the first BRT, a caffeine tablet will be given prior to the second BRT.
11610890|NCT00564811|No Intervention|G1|
11610891|NCT00564811|Experimental|G2|
11610892|NCT00564798||1|Study Group
11610893|NCT00564798||2|Control Group
11610894|NCT00564785|Placebo Comparator|Placebo|
11610895|NCT00564785|Experimental|Synera(TM)|
11610896|NCT00564772|Experimental|single arm|all subjects dosed the same
11610897|NCT00564746|Experimental|6 subjects in a single cohort|Each subject will be administered a single 10 milligrams (50 microcurie) oral dose of [14C]SB-681323.
11610898|NCT00564733|Experimental|Chemotherapy|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients undergo FDG PET/CT (fludeoxyglucose F 18 positron emission tomography/computed tomography) scan between days 18-21. The FDG PET/CT is an imaging biomarker analysis. Patients that are responding to treatment receive paclitaxel IV and carboplatin IV on day 1. Treatment repeats every 3 weeks for up to 3 additional courses in the absence of disease progression or unacceptable toxicity.Patients that are not responding to chemotherapy per FDG PET then receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 3 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Non-responding patients undergo an additional FDG PET/CT scan between days 18-21 of course 2.
11610899|NCT00564720|Experimental|1|GEM/TAR
11610900|NCT00564720|Experimental|2|GEM/OX/TAR
11610901|NCT00564707|Active Comparator|1|Standard biofeedback therapy will be given for painful levator ani syndrome over a course of eight weeks.
11610902|NCT00564707|Active Comparator|2|Botulinum toxin type A will be injected under EMG guidance into spastic and painful levator ani muscles. This may be repeated only twice on separate visits.
11610903|NCT00564681|Active Comparator|botulinum toxin Type A|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
11610904|NCT00564681|Active Comparator|botulinum toxin Type A Formulation 2|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
11610905|NCT00564681|Other|Placebo (Normal Saline) / botulinum toxin Type A|Intramuscular injections of the assigned study medication into the affected muscles (placebo for treatment cycle 1 and botulinum toxin Type A for subsequent treatments). Maximum dose of 360 units. Subjects may receive up to three treatments.
11610906|NCT00564681|Other|Placebo (Normal Saline) / botulinum toxin Type A Formulation 2|Intramuscular injections of the assigned study medication into the affected muscles (placebo for treatment cycle 1 and botulinum toxin Type A Formulation 2 for subsequent treatments). Maximum dose of 360 units. Subjects may receive up to three treatments.
11610907|NCT00564655|Active Comparator|1|Patients in the control group will receive localized infiltration of local anesthesia at the beginning of the procedure as is current standard practice.
11610908|NCT00564655|Experimental|2|Patients in the experimental group will receive a regional anesthetic blockade of the anterior abdominal wall via the transversus abdominis plane.
11610909|NCT00564629|Experimental|IV acetaminophen plus oral placebo.|Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever. Randomization to receive 1 g of acetaminophen in 100 ml of intravenous solution and oral placebo.
11610910|NCT00564629|Active Comparator|Oral acetaminophen plus IV placebo.|Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever. Randomization to receive oral acetaminophen 1 g plus 100 ml of intravenous placebo solution.
11610911|NCT00564616|Placebo Comparator|voice group|"the voice group received voice CPR instruction via a voice-only cell phone"
11610912|NCT00564616|Experimental|video group|"the video group received interactive voice and video instruction via a video cell phone"
11610913|NCT00564603|Placebo Comparator|1|Saline with same volume added to tramadol infusion combined with morphine PCA.
11610914|NCT00564603|Active Comparator|2|Dexamethasone 10mg in 2mL added to tramadol infusion adjunct to morphine PCA.
11610915|NCT00564590|Experimental|A|Melatonin treatment group
11610916|NCT00564590|Active Comparator|B|Omeprazole 20 mg once a day for 3 months
11610917|NCT00564590|Experimental|C|Placebo once a day for 3 months
11610918|NCT00564577|Other|CFA/I and CS17 challenge strain|Colonization factor antigen (CFA/I) and CS17 challenge strainAscending dose finding study in 5-10 subjects per dose; to identify the dose able to give a diarrheal attack rate greater than or equal to 80%.
11610919|NCT00564564|Experimental|Quetiapine augmentation|Quetiapine up to 200mg/day plus SSRI at maximum tolerated or recommended dosage
11610920|NCT00564564|Active Comparator|Clomipramine augmentation|Clomipramine up to 150mg/day plus SSRI at maximum tolerated or recommended dosage
11610921|NCT00564551|Active Comparator|2|High dairy intake and calcium supplement. High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.
11610922|NCT00564551|Placebo Comparator|1|Usual diet of low dairy and calcium intake. Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet.
11610928|NCT00564512|Active Comparator|FCR|"Fludarabine-Cyclophosphamide-Rituximab (FCR)
~First course:
~Rituximab 375 mg/m2 on D1.
~D2 to D4:
~oral Fludarabine: 40 mg/m2/day as a single morning dose oral Cyclophosphamide: 250 mg/m2/day as a single dose at noon
~Subsequent courses (2 to 6)
~Rituximab 500 mg/m2 on D1
~D1 to D3:
~oral Fludarabine: 40 mg/m2/day as a single morning dose oral Cyclophosphamide: 250 mg/m2/day as a single dose at noon"
11610929|NCT00564486|Placebo Comparator|IV Placebo 100 ml|IV Placebo 100 ml dosed every every 6 hours for 24 hours (4 doses total).
11610930|NCT00564486|Placebo Comparator|IV Placebo 65 ml|IV Placebo 65 ml dosed every every 4 hours for 24 hours (6 doses total).
11610931|NCT00564486|Experimental|IV Acetaminophen 1 gm|IV Acetaminophen 1 gm dosed every every 6 hours for 24 hours (4 doses total).
11610932|NCT00564486|Experimental|IV Acetaminophen 650 mg|IV Acetaminophen 650 mg dosed every every 4 hours for 24 hours (6 doses total).
11610933|NCT00564473||A|patients hospitalized in the Department of Internal Medicine of the Shaare Zedek Medical Center, Jerusalem, Israel.
11610934|NCT00564460|Active Comparator|1|Finasteride 5 mg PO once daily for 8 weeks prior to TURP
11610935|NCT00564460|Placebo Comparator|2|Placebo
11610936|NCT00564447|Experimental|Azithromycin-30 minutes Post dose|
11610937|NCT00564447|Experimental|Azithromycin-2 hours post dose|
11610938|NCT00564447|Experimental|Azithromycin-12 hours post dose|
11610939|NCT00564447|Experimental|Azithromycin-24 hours post dose|
11610940|NCT00564447|Experimental|Moxifloxacin-30 minutes post dose|
11610941|NCT00564447|Experimental|Moxifloxacin-2 hours post dose|
11610942|NCT00564447|Experimental|Moxifloxacin-12 hours post dose|
11610943|NCT00564447|Experimental|Moxafloxacin-24 hours post dose|
11610944|NCT00564421|Experimental|Epinastine low concentration:low dose volume|
11610945|NCT00564421|Experimental|Epinastine low concentration:high dose volume|
11610946|NCT00564421|Experimental|Epinastine high concentration:low dose volume|
11610947|NCT00564421|Experimental|Epinastine high concentration:high dose volume|
11610948|NCT00564421|Placebo Comparator|Placebo nasal spray|
11610949|NCT00564408|Experimental|I|
11610950|NCT00564395|Experimental|Insulin Detemir+RAI, then Insulin Detemir and RAI separately|Participants first received, Insulin Detemir mixed with RAI, twice daily as subcutaneous injection for 10 days. Then they received Insulin Detemir and RAI as separate subcutaneous injections, twice daily for the next 10 days.
11610951|NCT00564395|Active Comparator|Insulin Detemir and RAI separately, then Insulin Detemir+RAI|Participants first received Insulin Detemir and RAI as separate subcutaneous injections, twice daily for 10 days. Then they received Insulin Detemir mixed with RAI, twice daily as subcutaneous injection for the next 10 days.
11610952|NCT00564382|Other|1|Patients with ACS in the emergency department and primary tests (ECG, TNT) negative for myocardial ischemia
11610953|NCT00564369|Experimental|1|2006 CDC recommendations
11610954|NCT00564369|Active Comparator|2|Prior CDC recommendations
11610955|NCT00564356|Other|A|patients under coumadin and antiaggregants operated by phacoemulsification
11610956|NCT00564343||ChSt, water training, Observation|Subjects suffer from chronic hemiplegia (a year or more post stroke) that upon questioning was judged to meet the following inclusion criteria: (a) able to stand independently 90 seconds; (b) able to walk 10 meters (with cane if necessary); (c) able to understand verbal instructions. The exclusion criteria will be: (a) Serious visual impairment; (b) Inability to ambulate independently (cane acceptable, walker not). (c) Severely impaired cognitive status (score less then 24 in Mini Mental State Examination). (d) Persons with impaired communication capabilities.
11610957|NCT00564330|Active Comparator|esomeprazole|Esomeprazole 20mg twice daily
11610958|NCT00564330|Placebo Comparator|placebo|Placebo tablet twice daily
11610959|NCT00564317|Experimental|1 KIDNET|Narrative Exposure Therapy for Children
11610960|NCT00564317|Experimental|2 Meditation/Relaxation|mixed Meditation/Relaxation Protocol
11610961|NCT00564317|Experimental|3 KIDNET + Meditation/Relaxation|KIDNET according to protocol, waiting time of 5 months, then Meditation/Relaxation according to protocol
11610962|NCT00564317|Experimental|4 Meditation/Relaxation + KIDNET|Med/Relax according to protocol, 5 months waiting time, KIDNET according to protocol
11610963|NCT00564291||1|Healthy volunteers
11610964|NCT00564291||2|CSME secondary to diabetic retinopathy
11610965|NCT00564291||3|ARMD with CNV before and after therapy
11610966|NCT00564291||4|ARMD atrophic
11610967|NCT00564291||5|Retinal vein occlusion
11610968|NCT00564291||6|retinitis pigmentosa
11610969|NCT00564291||7|vitreoretinal proliferation
11610970|NCT00564278|Active Comparator|Standard antidepressant therapy|Participants will receive standard antidepressant therapy, including selecting among 9 FDA-approved antidepressants from several classes.
11610971|NCT00564278|Experimental|Motivational antidepressant therapy|Participants will receive motivational antidepressant therapy, including selecting among the same list of 9 FDA-approved antidepressants from several classes as in the control arm.
11610972|NCT00564265||GIST|GIST from all gastrointestinal origins: esophagus, stomach, duodenum, jejunum, ileum, colon and rectum
11610973|NCT00564239|Experimental|A|
11610974|NCT00564239|Active Comparator|B|
11610975|NCT00564239|No Intervention|C|
11610976|NCT00564226|Experimental|SSR240600C Dose Level 1|
11610977|NCT00564226|Experimental|SSR240600C Dose Level 2|
11610978|NCT00564226|Experimental|SSR240600C Dose Level 3|dose level 3
11610979|NCT00564226|Active Comparator|Tolterodine|
11610980|NCT00564226|Placebo Comparator|Placebo|
11610981|NCT00564213|Experimental|1|A single intraoperative topical application of mitomycin C 0.02% for 15 seconds
11610982|NCT00564213|Experimental|2|A single intraoperative topical application of mitomycin C 0.02% for 30 seconds
11610983|NCT00564187|Active Comparator|1|"Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:
~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
11611046|NCT00563472|Active Comparator|3|20 mg estetrol and 150 microg desogestrel
11610984|NCT00564187|Active Comparator|2|• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B
11610985|NCT00564174|Experimental|a|
11610986|NCT00564174|Active Comparator|b|Low dose aspirin only
11610987|NCT00564161||1|
11610988|NCT00564161||2|
11610989|NCT00564148|Experimental|A,1, II|
11610990|NCT00564135|Experimental|A B C|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
11610991|NCT00564122||All subjects|
11610992|NCT00564096|Active Comparator|Real TMS|10 patients will be given 20 minutes stimulation with real deep H1-Coil TMS to the Left Temporo-parietal Cortex in frequency of 1 Hz with 120% motor threshold during 20 consecutive working days.
11610993|NCT00564096|Placebo Comparator|Sham & real TMS|10 patients will be given 20 minutes stimulation with sham deep H1-Coil TMS to the Left Temporo-parietal Cortex in frequency of 1 Hz with 120% motor threshold during 10 consecutive working days, and thereafter 20 sessions of real TMS with the same parameters (=Left Tempor-oparietal Cortex in frequency of 1 Hz with 120% motor threshold).
11610994|NCT00564070|Active Comparator|Enhanced treatment as usual|Enhanced treatment as usual plus single-session life-steps treatment
11610995|NCT00564070|Experimental|CBT-AD|Enhanced treatment as usual plus multiple-session CBT treatment (CBT-AD)
11610996|NCT00564057|Experimental|1|candesartan 8-16 mg once daily
11610997|NCT00564057|Active Comparator|2|lercanidipine 10-20 mg once daily
11610998|NCT00564044|Active Comparator|2|
11610999|NCT00564031|Placebo Comparator|1|
11611000|NCT00564031|Experimental|2|
11611001|NCT00564031|Experimental|3|
11611002|NCT00564031|Experimental|4|
11611003|NCT00564018|Experimental|Detemir|24 subjects randomized to therapy with a combination of insulins detemir and aspart at diagnosis of diabetes.
11611004|NCT00564018|Experimental|Glargine|24 subjects randomized to therapy with a combination of insulins glargine and aspart at diagnosis of diabetes.
11611005|NCT00564018|Experimental|NPH|24 subjects randomized to therapy with a combination of insulins NPH and aspart at diagnosis of diabetes.
11611006|NCT00564005|Experimental|1|constraint-induced therapy
11611007|NCT00564005|Experimental|2|bilateral arm training
11611008|NCT00564005|Experimental|3|combined therapy
11611009|NCT00564005|Active Comparator|Control intervention|
11611010|NCT00563992|Experimental|1|Participants will take lithium for 12 months
11611011|NCT00563992|Experimental|2|Participants will take valproate for 12 months
11611012|NCT00563979|Active Comparator|1|VitaluxPlus®
11611013|NCT00563979|Active Comparator|2|Omega 3
11611014|NCT00563953|Experimental|1|Primary chemotherapy regimen consisting of four cycles of pegylated-liposomal doxorubicine at 35 mg/m² IV plus CPM 600 mg/m² on Day 1 every 4 weeks followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
11611015|NCT00563940||1|
11611016|NCT00563940||2|
11611017|NCT00563914|Experimental|1|
11611018|NCT00563914|Active Comparator|2|
11611019|NCT00563901||1|Adults with a high risk for high blood pressure from the ALLHAT study
11611020|NCT00563888|Experimental|A|Narrative Exposure Therapy (NET)
11611021|NCT00563888|No Intervention|B|Waitinglist Control Group
11611022|NCT00563836|Experimental|1|
11611023|NCT00563797|Experimental|Mecamylamine|Mecamylamine is a noncompetitive, high-affinity nAChR antagonist with low selectivity for the alpha-7 receptor. Those receiving mecamylamine started at 2.5mg once daily (second dose was placebo). The dose was increased to 5.0 mg twice daily over 3 weeks.
11611024|NCT00563797|Placebo Comparator|Placebo|Placebo capsules were prepared by the pharmacy and were identical in size and color to the medication capsules.
11611025|NCT00563784|Experimental|Erlotinib + Paclitaxel + Carboplatin|Oral Erlotinib 150 mg daily + Paclitaxel 45 mg/m^2 by vein weekly + Carboplatin 2 AUC by vein weekly and Radiation Therapy 63 GY/35 fractions for 7 weeks cycles
11611026|NCT00563745|Experimental|Telemedicine|Patients were submitted to a Telemedicine program for 1 year
11611027|NCT00563745|No Intervention|Control group|Patients were submitted to usual care (i.e: educational plan and outpatient visits every 3 months)
11611028|NCT00563706|Experimental|1|
11611029|NCT00563706|Active Comparator|2|4mg/day
11611030|NCT00563706|Placebo Comparator|3|matching placebo
11611031|NCT00563693|Experimental|A|The patients use ASV
11611032|NCT00563693|Active Comparator|B|Patients without ASV
11611033|NCT00563680|Experimental|Exploratory Cohort|If a total of two or more responses (partial and complete) in EFTs/DSRCTs are documented in this or the ongoing phase 1 study (20050118), then the study will allow enrollment of up to 10 additional EFT/DSRCT subjects who have been exposed to prior anti-IGF-1R targeting therapy.
11611034|NCT00563680|Experimental|Main Cohort|Subjects with relapsed Ewing's Family Tumors (EFTs) and Desmoplastic Small Round Cell Tumors (DSRCTs) who have not received prior anti-IGF-1R therapy will receive AMG 479 at 12mg/kg.
11611035|NCT00563641|Experimental|1|Early NCPAP plus very early surfactant
11611036|NCT00563641|Active Comparator|2|NCPAP alone
11611037|NCT00563602|Active Comparator|2|Standard Therapy: Endoscopic ligation (LEV) + Nadolol + Isosorbide mononitrate (MNI)(drugs carefully titrated until achieve maximum tolerated dose)
11611038|NCT00563602|Experimental|1|"Hemodynamic guided therapy:
~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
11611039|NCT00563576|Experimental|Depo-Provera/Femring|Subjects will receive an estrogen vaginal ring (100 mcg) during the first 90 days of Depo-Provera use.
11611040|NCT00563576|Other|Depo-Provera Injection Alone|Subjects will receive Depo-Provera intramuscular injection.
11611041|NCT00563563|Experimental|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg daily subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
11611042|NCT00563537|Experimental|1|18F-X PET Scan imaging
11611043|NCT00563524|Placebo Comparator|1|
11611044|NCT00563472|Active Comparator|1|10 mg estetrol
11611045|NCT00563472|Active Comparator|2|20 mg estetrol
11611048|NCT00563459|Experimental|001|carisbamate 400-1200 mg/day for 12 months
11611049|NCT00563459|Active Comparator|002|topiramate 200-400mg/day for 12 months
11611050|NCT00563459|Active Comparator|003|levetiracetam 1000-3000mg/day for 12 months
11611051|NCT00563433|Active Comparator|ofloxacin|an oral antibiotic (ofloxacin 400 mg) twice a day and a placebo vehicle topical cream twice a day for 14 days, extended up to 28 days if clinically warranted
11611052|NCT00563433|Active Comparator|MSI-78|an oral placebo twice a day and MSI-78 1%/2% Topical Cream twice a day for 14 days, extended up to 28 days if clinically warranted.
11611053|NCT00563394|Active Comparator|ofloxacin|an oral antibiotic (ofloxacin 400 mg) twice a day and a placebo vehicle topical cream twice a day for 14 days, extended up to 28 days if clinically warranted
11611054|NCT00563394|Active Comparator|MSI-78|an oral placebo twice a day and MSI-78 1%/2% Topical Cream twice a day for 14 days, extended up to 28 days if clinically warranted.
11611055|NCT00563381|Active Comparator|Tiotropium + Placebo|patients inhale Tiotropium 18mcg once daily via HandiHaler and Placebo MDI twice daily
11611056|NCT00563381|Active Comparator|Salmeterol + Placebo|patients inhale Salmeterol 50mcg twice daily via MDI and Placebo HandiHaler once daily
11611057|NCT00563368|Experimental|VI-0521 Top|VI-0521; high dose phentermine/topiramate
11611058|NCT00563368|Experimental|VI-0521 Mid|VI-0521; mid dose phentermine/topiramate
11611059|NCT00563368|Active Comparator|TPM 46|mid dose topiramate
11611060|NCT00563368|Active Comparator|TPM 92|high dose topiramate
11611061|NCT00563368|Active Comparator|PHEN 7.5|mid dose phentermine
11611062|NCT00563368|Active Comparator|PHEN 15|high dose phentermine
11611063|NCT00563368|Placebo Comparator|Placebo|
11611064|NCT00563316|Experimental|Panitumumab + Irinotecan|Participants received panitumumab 6 mg/kg and irinotecan 180 mg/m² administered by intravenous (IV) infusion every 2 weeks until disease progression or intolerance of panitumumab, irinotecan or both.
11611065|NCT00563303|Experimental|H|Hydrocortisone
11611066|NCT00563303|Placebo Comparator|P|Treatment by NaCl (placebo)
11611067|NCT00563290|Experimental|Arm I (dasatinib 100 mg PO BID)|Patients receive 100 mg dasatinib PO BID on days 1-28
11611068|NCT00563290|Experimental|Arm II (dasatinib 70 mg PO BID)|Patients receive 70 mg dasatinib PO BID on days 1-28
11611069|NCT00563264|Active Comparator|1|Participants receive monthly newsletter (for 10 months) including general health and reading information for child and mother and incentives for completing the baseline and 2 follow-up assessments
11611070|NCT00563264|Experimental|2|Mothers and preschoolers in the intervention group will receive monthly mailed family kits that encourage interactive mother/child exercises for healthy lifestyle change. Mailings are supported by counseling calls and two in-person motivational/informational group sessions. The content of the intervention addresses parenting skills, healthy eating, and physical activity. Families can earn $40 for returning postcards describing their activities in the past month.
11611071|NCT00563238|No Intervention|Control|
11611072|NCT00563238|Active Comparator|Metoprolol|
11611073|NCT00563212|Experimental|A1|
11611074|NCT00563186|Experimental|A|Admission to a novel hospital ward (e.g. abundance of sinks, predominance (80%) of private rooms, absence of shared bathrooms, absence of curtains)
11611075|NCT00563186|No Intervention|B|Hospital admission to a ward with traditional design features (eg. lack of sinks, predominance of 4-bed rooms [80%], shared bathrooms, curtains present)
11611076|NCT00563173|Other|1|Low dose
11611077|NCT00563173|Other|2|Medium dose
11611078|NCT00563173|Other|3|High dose
11611079|NCT00563147|Experimental|A|tivozanib (AV-951) plus temsirolimus
11611080|NCT00563082||1|SLE participants positive for both APA and CHD
11611081|NCT00563082||2|Normal participants with a high titer of APA
11611082|NCT00563056|Experimental|Flutiform|2 puffs 50/5 or 125/5 mcg
11611083|NCT00563056|Active Comparator|Flixotide plus Foradil|Flixotide 2 puffs 50 or 125 mcg; Foradil 1 puff 12 mcg
11611084|NCT00563030||1|Patients undergoing CABG with CPB
11611085|NCT00563030||2|Patients undergoing off-pump CABG
11611086|NCT00563004|Active Comparator|A|Patients receive the herbal medication DBCARE for 3 months
11611087|NCT00563004|Placebo Comparator|B|PATIENTS RECEIVE PLACEBO PILLS
11611088|NCT00562991||FeNO group|asthma patients, exhaled NO is used to monitor asthma
11611089|NCT00562991||Symptom group|asthma patients, exhaled NO is not used to monitor asthma
11611090|NCT00562978|Experimental|Treatment|"Preparation for transplantation: Peripheral blood stem cells (PBSCs) are collected via leukapheresis. Samples are analyzed by cytogenetic studies, immunophenotyping, and gene rearrangement. Patients with an adequate number of collected CD34-positive cells (≥ 3 times 10^6 /kg) proceed to radioimmunotherapy.
~Radioimmunotherapy: Patients receive yttrium Y 90 ibritumomab tiuxetan IV on days -21 and -14. Patients undergo bone marrow biopsy and dose estimation on day -7.
~Chemotherapy: Patients receive etoposide IV on day -4 and cyclophosphamide IV over 2 hours on day -2.
~Transplantation: Patients undergo reinfusion of PBSCs on day 1.
~Growth factor therapy: Patients receive filgrastim (G-CSF) IV beginning on day 1 and continuing until blood counts recover.
~Treatment continues in the absence of disease progression or unacceptable toxicity."
11611091|NCT00562965|Experimental|A|Subjects will receive rituximab intravenously at a dose level of 375 mg/m² on day 1 of each cycle followed by inotuzumab ozogamicin administered intravenously at a dose level of 1.8 mg/m2 on day 2. The sequence will be repeated every 28 days.
11611092|NCT00562965|Active Comparator|B|Subjects will receive the investigator's choice from the following rituximab-containing regimens: R-CVP or R-FND. The investigator's choice of therapy will be administered every 21 days. Dosing for R-CVP will be intravenous rituximab at a dose of 375 mg/m2 on day 1, intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1, intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1, and oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5. Dosing for R-FND will be as follows: rituximab 375 mg/m2 intravenous on day 1, mitoxantrone 10 mg/m2 intravenous on day 2, fludarabine 25 mg/m2 intravenous on days 2 through 4 and oral dexamethasone 20 mg/day on days 1-5.
11611093|NCT00562952|Active Comparator|1|Patient will receive cardiac therapy to decrease NT-proBNP levels. This will be primarily RAAS-Antagonists and Betablocker. Blood pressure will be lowered to target values. A decrease of NT-proBNP is also known form life-style changes. Thus the patient will be educated to be trained
11611094|NCT00562952|Placebo Comparator|2|Patients will be followed 2 years. Care will be given by the responsible unit ( Dept.of Endocrinology) as clinical appropriate. Event rates will be obtained. After one year NT-proBNP will be measured.
11611095|NCT00562939|Experimental|A|1 mg CpG 7909 + pneumococcal vaccines
11611096|NCT00562939|Placebo Comparator|B|Pneumococcal vaccines
11611097|NCT00562913|Experimental|Arm 1|
11611098|NCT00562900|Active Comparator|A, robotic|
11611099|NCT00562900|Active Comparator|B, laparoscopic|
11611100|NCT00562887|Placebo Comparator|1|
11611101|NCT00562887|Experimental|400 mg|
11611102|NCT00562887|Experimental|700mg|
11611103|NCT00562874|Experimental|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months.
11611104|NCT00562874|Active Comparator|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy flour as an ingredient for 5 days each week for 12 months.
11611105|NCT00562874|Sham Comparator|Wheat Biscuit|75 women and one of their children will receive a biscuit containing pm;u wheat flour as a source of protein as an ingredient for 5 days each week for 12 months.
11611106|NCT00562861|Active Comparator|citalopram + mood stabilizer|All patients are on baseline mood stabilizers and are randomized to receive citalopram or placebo. In this arm, they are randomly assigned to citalopram.
11611107|NCT00562861|Placebo Comparator|placebo + mood stabilizer|All patients are on baseline mood stabilizers and are randomized to receive citalopram or placebo. In this arm, they are randomly assigned to placebo
11611108|NCT00562848|Experimental|Subjects enrolled in single dose escalation cohort|Subjects will receive escalated doses of GSK962040 with a starting dose of 1 milligrams along with placebo in fasted state.
11611109|NCT00562848|Experimental|Subjects enrolled in gastric emptying cohort|Subjects will receive escalated doses of GSK962040 with a starting dose of 1 milligrams along with placebo in fasted state.
11611110|NCT00562848|Experimental|Subjects enrolled in gastro-enteral contractility cohort|Eligible subjects will receive GSK962040 and placebo in the fasted state in crossover manner.
11611111|NCT00562835|Active Comparator|1|Methylprednisolone
11611112|NCT00562835|Placebo Comparator|2|
11611113|NCT00562822|Active Comparator|Arthroscopic Surgery|Arthroscopic surgery optimized with physical and medical therapy
11611114|NCT00562822|Active Comparator|Physical and medical therapy|treatment with physical and medical therapy alone
11611115|NCT00562796||1|Participants with abdominal obesity without growth hormone deficiency
11611116|NCT00562796||2|Participants with abdominal obesity with growth hormone deficiency
11611117|NCT00562796||3|Participants who are lean controls
11611118|NCT00562770|Active Comparator|1|Valacyclovir
11611119|NCT00562770|Active Comparator|2|Valganciclovir
11611120|NCT00562757||A|Post myocardial infarction patients who received an ICD, stratified into low versus high WMI groups
11611121|NCT00562744|Experimental|SIM|Participants complete training and assessment of performance in PALS scenarios using high-fidelity simulator
11611122|NCT00562744|No Intervention|MAN|Participants complete training and assessment of performance in PALS scenarios using mannequin
11611123|NCT00562718|Experimental|Surgery and Chemotherapy|Eligible patients had undergone surgery and chemotherapy for high risk breast cancer, defined as either a T3 or T4 primary tumor, or N2 by either clinical or pathological criteria.
11611124|NCT00562705|Experimental|1|Growth hormone and nutritional intervention
11611125|NCT00562705|Active Comparator|2|growth hormone
11611126|NCT00562692|Experimental|A|Nesiritide
11611127|NCT00562692|Placebo Comparator|B|Placebo
11611128|NCT00562679||2 groups|The cohort is grouped according to one group with sleep apnea and one group without sleep apnea
11611129|NCT00562666|Experimental|1|Single hepatic intra arterial administration of 500 millions T gamma delta lymphocytes
11611130|NCT00562666|Experimental|2|Single hepatic intra arterial administration of 1000 millions T gamma delta lymphocytes
11611131|NCT00562666|Experimental|3|Single hepatic intra arterial administration of 2000 millions T gamma delta lymphocytes
11611132|NCT00562666|Experimental|4|Single hepatic intra arterial administration of 4000 millions T gamma delta lymphocytes
11611133|NCT00562653||1|infective endocarditis patients before treatment
11611134|NCT00562653||2|infective endocarditis treatment after treatment
11611135|NCT00562653||3|control
11611136|NCT00562640|Experimental|WT1-Specific T Cells|This is a phase I dose escalating trial designed to identify tolerable, clinically active doses of Wilms' tumor gene (WT1) peptide sensitized T cells when administered alone or with nonmyelosuppressive chemotherapy in patients with recurrent or persistent, evaluable WT1+ ovarian, primary peritoneal, or fallopian tube carcinomas.
11611137|NCT00562627|Experimental|LIA IV|Local infiltration analgesia with ropivacaine and adrenaline and intravenous ketorolac and morphine
11611138|NCT00562627|Experimental|LIA IA|Local infiltration analgesia with ropivacaine, adrenaline and ketorolac and morphine
11611139|NCT00562627|Active Comparator|EDA|standard continuous epidural analgesia
11611140|NCT00562614|Experimental|1|SLx-2101
11611141|NCT00562614|Placebo Comparator|2|Comparative Placebo Dose
11611142|NCT00562575|Experimental|1|SLx-4090
11611143|NCT00562575|Placebo Comparator|2|Matching Placebo Dose
11611144|NCT00562562|Other|MOT|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
11611145|NCT00562549|Experimental|1|SLx-2101
11611146|NCT00562549|Placebo Comparator|2|Matching Placebo Dose
11611147|NCT00562536|Experimental|A 1|Delayed umbilical cord clamping 30-45 seconds.
11611148|NCT00562536|No Intervention|A 2|Immediate umbilibcal cord clamping
11611149|NCT00562523|Experimental|Arm 1|
11611150|NCT00562510|Experimental|Raltegravir|
11611151|NCT00562510|Placebo Comparator|Raltegravir matching placebo|
11611152|NCT00562497|Placebo Comparator|Placebo|Placebo
11611153|NCT00562497|Active Comparator|Prochymal™|Subjects assigned to the active treatment group will receive Prochymal™.
11611154|NCT00562484|Experimental|1|
11611156|NCT00562471|Experimental|1|Adhesion Prevention Gel Arm
11611157|NCT00562471|Other|2|Standard of Care Comparator Arm (standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure)
11611158|NCT00562445||1|Peptic bleeding
11611159|NCT00562445||2|Portal hypertension bleeding
11611160|NCT00562445||3|Severe acute pancreatitis
11611161|NCT00562432|Experimental|Plexisyl-AF|Plexisyl-AF implants
11611162|NCT00562432|Sham Comparator|No Treatment|Surgery without experimental treatment
11611163|NCT00562419|Experimental|1|CT-322
11611164|NCT00562419|Experimental|2|CT-322 and irinotecan hydrochloride
11611165|NCT00562406|Active Comparator|1|laser photocoagulation to the retina at the area of edema
11611166|NCT00562406|Experimental|2|intravitreal injection of ranibizumab
11611167|NCT00562406|Experimental|3|laser photocoagulation to the retina at the area of edema and intravitreal injection of ranibizumab
11611168|NCT00562393|Experimental|Overfeeding|4 weeks of 1250 kcal added daily
11611169|NCT00562354|Experimental|1|Stratum 1: >= 65 years of age
11611170|NCT00562354|Experimental|2|Stratum 2: 50 to 64 years of age
11611171|NCT00562341||bariatric surgery|description of enrollees
11611172|NCT00562328|Experimental|Alemtuzumab + Rituximab + GM-CSF|Alemtuzumab + Rituximab + GM-CSF
11611173|NCT00562315|Other|FACBC PET-CT and ProstaScint CT|Participants diagnosed with localized prostate carcinoma with subsequent definitive therapy or suspicion of recurrent cancer will undergo an FACBC PET-CT scan and the ProstaScinct CT.
11611174|NCT00562302|Experimental|Bio-Seal Group|Bio-Seal Plug Implanted
11611175|NCT00562302|No Intervention|Control Group|Control group with no intervention
11611176|NCT00562289|Active Comparator|aspirin|aspirin use like antiplatelet
11611177|NCT00562289|Experimental|anticoagulant|Antivitamins K or rivaroxaban or dabigatran or apixaban
11611178|NCT00562289|Experimental|Devices for PFO closure|Devices for PFO closure
11611179|NCT00562276|Experimental|1|Immediate IUD insertion following suction aspiration between 5 and 12 weeks gestation
11611180|NCT00562276|No Intervention|2|Delayed IUD insertion 2-6 weeks following suction aspiration between 5 and 12 weeks gestation
11611181|NCT00562263|Experimental|Lifestyle Modification|Parents are randomized to attend 12 educational sessions covering strategies to manage children's health behaviors.
11611182|NCT00562263|No Intervention|Control|Teen participates in lifestyle intervention, but parent does not attend parent education sessions
11611183|NCT00562250|Experimental|Arm 1|
11611184|NCT00562250|Active Comparator|Arm 2|
11611185|NCT00562250|Active Comparator|Arm 3|
11611186|NCT00562237|Placebo Comparator|1|
11611187|NCT00562237|Experimental|2|
11611188|NCT00562237|Experimental|3|
11611189|NCT00562237|Experimental|4|
11611190|NCT00562237|Experimental|5|
11611191|NCT00562237|Experimental|6|
11611192|NCT00562237|Experimental|7|
11611193|NCT00562224|Experimental|Arm 1|All study subjects will receive PCI-24781 (study drug).
11611194|NCT00562211|Experimental|1|
11611195|NCT00562211|Active Comparator|2|
11611196|NCT00562198|Experimental|1|Investigational drug Stalevo 200
11611197|NCT00562172|Experimental|1|
11611198|NCT00562172|Active Comparator|2|
11611199|NCT00562159|Placebo Comparator|Placebo|Matching Placebo
11611200|NCT00562159|Experimental|SCH 697243|
11611201|NCT00562146||1|Successful progression of spiral tube to duodenum within 3 days
11611202|NCT00562146||2|Failure of progression to duodenum within 3 days
11611203|NCT00562133|Experimental|1|One Day Treatment with Insulin Glulisine
11611204|NCT00562133|Active Comparator|2|One day Treatment with Human insulin
11611205|NCT00562120|Placebo Comparator|Placebo|
11611206|NCT00562120|Active Comparator|Allegra|
11611207|NCT00562120|Active Comparator|Allegra-D|
11611208|NCT00562120|Experimental|PF-03654746|
11611209|NCT00562107|Experimental|1|AAIsafeR /SafeR Patient randomized with the SafeR switched ON
11611210|NCT00562107|Experimental|2|DDD(R) mode. Patients randomized with the SafeR mode switched OFF
11611211|NCT00562094||Pantoprazole|
11611212|NCT00562081|Placebo Comparator|1|Patient does not have 24/7 access to a Certified Asthma Educator.
11611213|NCT00562081|Active Comparator|2|Patient has 24/7 access to a Certified Asthma Educator.
11611214|NCT00562055|Experimental|Arm A|
11611215|NCT00562055|Active Comparator|Arm B|
11611216|NCT00562042||1|Patients diagnosed with acute pulmonary embolism were enrolled in this study.
11611217|NCT00562029|Experimental|DJB patient|Patient has undergone a duodeno-jejunal bypass
11611218|NCT00562016|Experimental|IMPELLA LP 2.5|
11611219|NCT00562016|Active Comparator|IABP Intra-aortic balloon pump|
11611220|NCT00561990|Active Comparator|Nimotuzumab|Nimotuzumab
11611221|NCT00561990|Placebo Comparator|Placebo|Placebo
11611222|NCT00561977|Active Comparator|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
11611223|NCT00561977|Active Comparator|Low Saturated Fat|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal per day.
11611224|NCT00561977|Active Comparator|Combination Diet|Combination low saturated fat (≤7% of total calories);high fiber (>30g fiber per day) -500 kcal from RMR, not less than 1200 kcal/day.
11611225|NCT00561964|Experimental|1|
11611226|NCT00561964|Placebo Comparator|2|
11611227|NCT00561951|Experimental|Fesoterodine fumarate 4 mg (Double-Blind)|
11611228|NCT00561951|Placebo Comparator|Placebo (Double-Blind)|
11611229|NCT00561951|Experimental|Fesoterodine fumarate 8 mg (Double-Blind)|
11611230|NCT00561925|Experimental|nevirapine XR|400 mg QD
11611231|NCT00561925|Active Comparator|nevirapine IR|200 mg BID
11611275|NCT00561561|Active Comparator|4|Family members of healthy controls
11611483|NCT00560196||2|Patients with depression without pain
11611232|NCT00561912|Experimental|Decitabine + Interferon Alfa-2b|Decitabine 15 mg/m^2 intravenous (IV) daily over one hour for 5 days + Interferon Alfa-2b 0.5 million Units Subcutaneously Twice Daily Continuously, as of Cycle 3, Day 1.
11611233|NCT00561899|Experimental|1|SP+AQ
11611234|NCT00561899|Experimental|2|Piperaquine plus SP arm
11611235|NCT00561899|Experimental|3|Du-Cotecxin
11611236|NCT00561886|Experimental|1|Patients with COPD receiving once 24 µg formoterol
11611237|NCT00561860|No Intervention|1|This pathway represents our standard clinical protocol when a patient has been diagnosed with sleep apnea and CPAP therapy is initiated. After prescription of CPAP, all patients will be seen by our CPAP coordinator and oriented to the device during a 20 minute session. Patients are also provided the telephone number of the CPAP coordinator who can be contacted if any problems or questions arise.
11611238|NCT00561860|Experimental|2|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
11611239|NCT00561834|Experimental|Ranibizumab|To determine the mean change in best corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study testing system at 6 months in NAION patients treated as needed (PRN) with ranibizumab.
11611240|NCT00561821|Experimental|Esmirtazapine 0.5 mg|one placebo tablet daily for 14 days, followed by one 0.5 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
11611241|NCT00561821|Experimental|Esmirtazapine 1.5 mg|one placebo tablet daily for 14 days, followed by one 1.5 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
11611242|NCT00561821|Experimental|Esmirtazapine 3.0 mg|one placebo tablet daily for 14 days, followed by one 3.0 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
11611243|NCT00561821|Placebo Comparator|Placebo|one placebo tablet daily for 14 days, followed by one placebo tablet daily for 16 days, and then one placebo tablet daily for 7 days
11611244|NCT00561808|Experimental|Observational|
11611245|NCT00561795|Experimental|Arm A|Oral Pazopanib 800 mg once a day+ carboplatin area under the concentration-time curve (AUC) 5 intravenous (IV) over 1 hour every 3 weeks + paclitaxel 175 mg/m^2 IV over three hours day one q 3 weeks for six cycles
11611246|NCT00561795|Experimental|Arm B|Oral Pazopanib 800 mg once a day+ carboplatin AUC 6 IV over 1 hour every 3 weeks + paclitaxel 175 mg/m^2 IV over three hours day one q 3 weeks for six cycles
11611247|NCT00561782||Group 1|Spinal cord injured with chronic central neuropathic pain.
11611248|NCT00561782||Group 2|Spinal cord injured without chronic central neuropathic pain.
11611249|NCT00561782||Group 3|Able-bodied without history of chronic pain of any type
11611250|NCT00561782||Group 4|Traumatically Brain Injured with a history of pain that onset after their TBI
11611251|NCT00561769||A|poor responder
11611252|NCT00561756|Experimental|Vaccine Therapy|This single arm, open-label, phase I clinical trial of xenogeneic CD20 DNA vaccination is designed to evaluate its safety in patients with B cell lymphoma. The study is a dose escalation study at three test doses, 0.5 mg, 2 mg and 4 mg of purified plasmid DNA per injection. There will be an initial cohort of three patients receiving a pre-level 1 dose of 0.1 mg/vaccination before proceeding to the three test doses.
11611253|NCT00561730||Pantoprazole|All patients enrolled
11611254|NCT00561717|Experimental|Arm 1|
11611255|NCT00561717|Active Comparator|Arm 2|
11611256|NCT00561717|Active Comparator|Arm 3|
11611257|NCT00561717|Placebo Comparator|Arm 4|
11611258|NCT00561678|Experimental|Precedex|Precedex (Dexmedetomidine)
11611259|NCT00561678|Placebo Comparator|Placebo|Placebo - normal saline
11611260|NCT00561652|Active Comparator|Education + exercise|Education was provided in four, 1-hour sessions to improve patients' understanding of their back problem, reduce unwarranted concern about serious outcomes, & empower them to maintain normal activities & reduce risk of future back problems. Patients were taught that recovery depends on moving & restoring normal function & fitness. Patients were shown stretching & strengthening exercises to perform daily at home to enhance mobility & increase trunk endurance while minimizing spinal load. At follow-up, therapists reviewed exercise form & adherence. Participants allocated to no chiropractic care also were scheduled for 10 weekly 10-15 minute sessions to equalize provider attention vs. the group also receiving chiropractic care & not to provide education, exercise instruction, or therapy.
11611261|NCT00561652|Experimental|Education + exercise + chiropractic|In addition to education & exercise, all participants in this arm will be assigned chiropractic treatment. A minimum of 4 & up to 12 treatments will be provided over 6 weeks, based on patient response (i.e. treatments stopped if symptoms resolve). Each treatment visit will last 10-20 minutes. After 6 weeks, if the treating chiropractor determined that the patient's LBP was continuing to improve but hadn't reached therapy goals defined at baseline, the patient could receive up to 12 additional treatments over the next 6 weeks. Chiropractic treatment was delivered following standardized protocols. Treatment consisted of manual therapies, including SMT and mobilization techniques, with the assistance of light soft tissue techniques as indicated to facilitate the SMT.
11611262|NCT00561626|Experimental|A|
11611263|NCT00561626|Experimental|B|
11611264|NCT00561613|Placebo Comparator|1|SILCS with K-Y Jelly
11611265|NCT00561613|Active Comparator|2|SILCS with N-9
11611266|NCT00561600|Active Comparator|A|ASR™-XL Modular Acetabular Cup System stem
11611267|NCT00561600|Active Comparator|B|Pinnacle™ acetabular shell, with a 28mm or 36mm ULTAMET® metal liner, and a 28mm or 36mm Articul/eze M head.
11611268|NCT00561587|Active Comparator|1|
11611269|NCT00561587|No Intervention|2|
11611270|NCT00561574|Experimental|Esmirtazapine 1.5 mg|Participants receive esmirtazapine 1.5 mg tablets, one tablet administered orally once daily for up to 52 weeks
11611271|NCT00561574|Experimental|Esmirtazapine 3.0 mg|Participants receive esmirtazapine 3.0 mg tablets, one tablet administered orally once daily for up to 52 weeks
11611272|NCT00561561|Experimental|1|Subjects with schizophrenia
11611273|NCT00561561|Active Comparator|2|Health controls
11611274|NCT00561561|Active Comparator|3|Family members of subjects with schizophrenia
11611276|NCT00561548|Other|A|Patients with active Crohn disease and with azathioprine treatment
11611277|NCT00561548|Other|B|Patient with active crohn disease and without azathioprine disease
11611278|NCT00561535|Experimental|A|Lactobacillus FARCIMINIS
11611279|NCT00561535|Placebo Comparator|B|Placebo
11611280|NCT00561522|Experimental|Intervention treatment|Capecitabine
11611281|NCT00561522|No Intervention|No intervention treatment|No other preventive treatment
11611282|NCT00561509||A|SSRIs
11611283|NCT00561509||B|Dual antidepressants
11611284|NCT00561496|Other|Twice daily|Tenofovir gel intravaginal twice daily for 14 days
11611285|NCT00561496|Other|Once daily|Tenofovir gel intravaginal once daily for 14 days
11611286|NCT00561483||Observation|Patients admitted to the hospital with decompensated heart failure
11611287|NCT00561470|Placebo Comparator|Placebo/FOLFIRI|Participants with Metastatic Colorectal Cancer administered Placebo followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
11611288|NCT00561470|Experimental|Aflibercept/FOLFIRI|Participants with Metastatic Colorectal Cancer administered Aflibercept followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
11611289|NCT00561457|Experimental|Iliac Stenting|Stent placement in the iliac artery
11611290|NCT00561444||Quality of Life Study|Prostate cancer patients
11611291|NCT00561431|Active Comparator|1|Standard dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 20 ml/kg/hr
11611292|NCT00561431|Experimental|2|High dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 35 ml/kg/hr
11611293|NCT00561418|Experimental|Vorinostat (SAHA)|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles with the dose escalations.
11611294|NCT00561405|Experimental|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner.
11611295|NCT00561405|Active Comparator|Body weight supported treadmill training|Body Weight Supported Treadmill Training. Participants walk on a treadmill while partially supported with an overhead harness system. Mass repetition of the normal gait cycle is encouraged through the support of the harness, the movement of the treadmill, and the assistance of one or two trainers to position limbs and trunk.
11611296|NCT00561392|Experimental|Rivastigmine 5 and 10 cm^2 patch|For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm^2 patch, with adjustments as necessary for safety and tolerability.
11611297|NCT00561379|Active Comparator|1|
11611298|NCT00561379|Active Comparator|2|
11611299|NCT00561366|Placebo Comparator|1|
11611300|NCT00561366|Experimental|2|
11611301|NCT00561353|Experimental|TMC435 25 mg (Cohort 1/Panel A and B)|Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with peginterferon alpha-2a (PegIFNα-2a) (P) and ribavirin (R) for 21 days (Panel A) OR TMC435 25 mg once daily coadministered with PR for 28 days (Panel B).
11611302|NCT00561353|Experimental|TMC435 75mg (Cohort 1/Panel A and B)|Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily for 21 days with PegIFNα-2a (P) and ribavirin (R) OR TMC435 75 mg once daily coadministered with PR for 28 days (Panel B).
11611303|NCT00561353|Placebo Comparator|Placebo (Cohort 1/Panel A and B)|Treatment-naïve participants received placebo (identical in appearance to TMC435 25/75 mg) once daily for 7 days followed by placebo once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR and Placebo once daily coadministered with PR for 28 days (Panel B).
11611304|NCT00561353|Experimental|TMC435 200 mg (Cohort 2, Panel A and B)|Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR TMC435 200 mg once daily coadministered with PR for 28 days (Panel B).
11611305|NCT00561353|Placebo Comparator|Placebo (Cohort 2/Panel A and B)|Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed by placebo once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR placebo once daily coadministered with PR for 28 days (Panel B).
11611306|NCT00561353|Experimental|TMC435 75 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
11611307|NCT00561353|Experimental|TMC435 150 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
11611308|NCT00561353|Experimental|TMC435 200 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
11611309|NCT00561353|Placebo Comparator|Placebo (Cohort 4/Panel C)|Treatment-experienced non-responders received placebo once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
11611310|NCT00561353|Experimental|TMC435 200 mg (Cohort 5/Panel D)|Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
11611311|NCT00561340|Experimental|1 Can of Pediasure Supplement Plus Nutritional Counseling|Pediasure and nutritional counseling
11611312|NCT00561340|Active Comparator|Counseling by the Provider on Ways to Encourage Caloric Intake|Behavioral intervention - Nutritional Counseling
11611313|NCT00561327||A|Patients chronically treated with drug losartan
11611314|NCT00561327||B|Patients not chronically treated with losartan
11611315|NCT00561301|No Intervention|1|
11611316|NCT00561288|Experimental|1|2000 mg acetaminophen per day
11611317|NCT00561288|Placebo Comparator|2|2000 mg cornstarch per day
11611318|NCT00561249|Experimental|1|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo.
11611319|NCT00561249|No Intervention|2|No intervention
11611412|NCT00560729|Active Comparator|II|oral nutrition
11611320|NCT00561223|Experimental|1|"This study will examine the hypothesis that iloprost maintains and improves ventilation perfusion matching in patients with COPD as reflected by 1) a constant or reduced alveolar to arterial O2 difference as calculated from the measured arterial blood gases obtained before and after iloprost administration, 2) an improvement in the lung diffusing capacity for carbon monoxide that occurs in the absence of a change in spirometry, 3) an improvement in the ventilatory equivalent for oxygen and CO2 measured by expired gas analysis.
~It is anticipated that a positive result in this pilot study would lead to a larger long-term study examining the effect of iloprost on gas exchange, exercise tolerance and quality of life in patients with COPD."
11611321|NCT00561210|Experimental|I|Total enteral tube feeding
11611322|NCT00561210|Active Comparator|II|Total enteral tube feeding
11611323|NCT00561184|Experimental|1|
11611324|NCT00561184|Experimental|2|
11611325|NCT00561171|Experimental|1|high dose
11611326|NCT00561171|Experimental|2|lower dose
11611327|NCT00561158|Experimental|A|
11611328|NCT00561158|No Intervention|2|
11611329|NCT00561145|Experimental|Young men|Energy restriction period
11611330|NCT00561145|Experimental|Elderly men|Energy restriction period
11611331|NCT00561132|Experimental|1|
11611332|NCT00561132|Placebo Comparator|2|
11611333|NCT00561119|No Intervention|Arm 1|Observation after 6 cycles of gemcitabine plus paclitaxel till progression
11611334|NCT00561119|Experimental|Arm 2|Maintenance chemotherapy with gemcitabine plus paclitaxel after 6 cycles of gemcitabine plus paclitaxel till progression
11611335|NCT00561106|Active Comparator|1|
11611336|NCT00561106|Placebo Comparator|2|
11611337|NCT00561093|Experimental|A|Group A (n=25) Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
11611338|NCT00561093|Experimental|B|Group B (n=25) Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND Placebo to imitate pentoxiphylline while undergoing hemodialysis and the following non-dialysis day (6 days per week)
11611339|NCT00561093|Experimental|C|Group C (n=25) Placebo dietary supplement to imitate Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
11611340|NCT00561093|Placebo Comparator|D|Group D (n=25) Placebo to imitate Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND Placebo to imitate pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
11611341|NCT00561080|Experimental|Single Dose of Zostavax|Zostavax 0.65mL intramuscular injection administered on Day 0
11611342|NCT00561080|Experimental|Zostavax - Day 0 and Month 1|Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 1
11611343|NCT00561080|Experimental|Zostavax - Day 0 and Month 3|Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 3
11611344|NCT00561067|Active Comparator|1|Methylprednisolone
11611345|NCT00561067|Experimental|2|Erythropoietin
11611346|NCT00561054|No Intervention|1|CISPLATIN gENCITABINE cETUXIMAB
11611347|NCT00561041|Experimental|1|Brief phone aftercare intervention composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
11611348|NCT00561041|Experimental|2|Individual aftercare therapy - composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
11611349|NCT00561041|No Intervention|3|No intervention
11611350|NCT00561028||1|ST-elevation acute myocardial infarction.
11611351|NCT00561028||2|high-risk unstable angina or non-ST-elevation myocardial infarction.
11611352|NCT00561028||3|known coronary artery disease, either asymptomatic or with stable angina.
11611353|NCT00561028||4|blood donors without known coronary artery disease.
11611354|NCT00561015|Experimental|TVR then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 2|Participants who are never treated for chronic hepatitis C (inflammation of the liver) genotype 2 will receive telaprevir (TVR) 750 milligram (mg) tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15. Participants will then be treated with standard treatment regimen of pegylated interferon (Peg-IFN)-alfa-2a and ribavirin (RBV) from Day 15 to Week 26 (standard treatment phase). Each dose of pegylated interferon 180 microgram (mcg) will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 26 weeks.
11611355|NCT00561015|Experimental|TVR with Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 2|Participants who are never treated for CHC genotype 2 will receive TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
11611356|NCT00561015|Active Comparator|Pbo with Peg-IFN-alfa-2a + RBV (Pbo/PR24) - Genotype 2|Participants who are never treated for CHC genotype 2 will receive TVR matching placebo (Pbo) tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
11611357|NCT00561015|Experimental|TVR then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 will receive TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15. Participants will then be treated with standard treatment regimen of Peg-IFN-alfa-2a and RBV from Day 15 to Week 26 (standard treatment phase). Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 26 weeks.
11611413|NCT00560729|Experimental|III|oral nutrition
11611414|NCT00560729|Experimental|IV|oral nutrition
11611415|NCT00560703|Active Comparator|COL-101 (doxycycline, USP) capsules|COL-101
11611416|NCT00560703|Placebo Comparator|Placebo|Sugar capsule
11611358|NCT00561015|Experimental|TVR with Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 received TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
11611359|NCT00561015|Active Comparator|Pbo with Peg-IFN-alfa-2a + RBV (Pbo/PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 will receive TVR matching Pbo tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
11611360|NCT00561002|Experimental|Influenza vaccine Naive/Inadequately Primed|Participants had no more than one previous lifetime dose of influenza vaccine and received two doses of Fluzone®, on Days 0 and 14.
11611361|NCT00561002|Experimental|Influenza Vaccine Primed|Participants had previously received 2 injections of Influenza vaccine in the same season and received a single dose of Fluzone® on Day 0.
11611362|NCT00560989||1|CBD cases
11611363|NCT00560989||2|Beryllium-exposed, non-diseased control subjects
11611364|NCT00560989||3|Sarcoidosis cases
11611365|NCT00560989||4|Sarcoidosis control subjects
11611366|NCT00560976|Experimental|Iron Saccharate (Venofer)|IV Iron Saccharate (Venofer)100 mg
11611367|NCT00560963|Experimental|1 RAD001|
11611368|NCT00560950|Experimental|1st Revaccination Group|
11611369|NCT00560950|Experimental|2nd Revaccination Group|
11611370|NCT00560937|Active Comparator|1|Pregnenolone
11611371|NCT00560937|Placebo Comparator|2|Placebo
11611372|NCT00560911|Other|1Self-management|
11611373|NCT00560911|Other|2 Routine control|
11611374|NCT00560898|Experimental|2|contact lenses disinfected in multipurpose solution
11611375|NCT00560898|Experimental|3|contact lenses disinfected in multipurpose solution
11611376|NCT00560898|Experimental|4|contact lenses disinfected in multipurpose solution
11611377|NCT00560898|Experimental|1|contact lenses disinfected in multipurpose solution
11611378|NCT00560885|Experimental|AtriCure Bipolar System|The AtriCure Synergy Bipolar Ablation system is used to create lesions outlined in the Maze IV procedure during a concomitant open cardiac surgical procedure.
11611379|NCT00560872|Other|1|conventional ablation with manual catheter navigation
11611380|NCT00560872|Active Comparator|2|ablation with remote magnetic catheter navigation
11611381|NCT00560859|Active Comparator|Early AT Surgery|There will be removal of tonsils and adenoids that will be performed within 4 weeks of the baseline visit.
11611382|NCT00560859|Other|Watchful Waiting|Children will be closely monitored and re-evaluated for AT by an otolaryngologist after the primary 7 month monitoring period.
11611383|NCT00560846|Experimental|Nutrition|Pre-operative immunonutritrion, pre-operative glucose load, post-operative early immunonutrition
11611384|NCT00560846|No Intervention|Control|No immunonutrition, no glucose load, no early enteral immunonutrition
11611385|NCT00560833|Placebo Comparator|Placebo|Participants receive placebo, encapsulated tablets, orally (PO), once daily (QD) for up to 12 weeks
11611386|NCT00560833|Experimental|Esmirtazapine 2.25 mg|Participants receive esmirtazapine 2.25 mg, encapsulated tablets, PO, QD for up to 12 weeks
11611387|NCT00560833|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine 4.5 mg, encapsulated tablets, PO, QD for up to 12 weeks
11611388|NCT00560833|Experimental|Esmirtazapine 9 mg|Participants receive esmirtazapine 9 mg, encapsulated tablets, PO, QD for up to 12 weeks
11611389|NCT00560833|Experimental|Esmirtazapine 18 mg|Participants receive esmirtazapine 18 mg, encapsulated tablets, PO, QD for up to 12 weeks
11611390|NCT00560820|Experimental|Deferasirox|30 mg/kg/day
11611391|NCT00560807|No Intervention|A|Zero treatment/3 weeks
11611392|NCT00560807|Active Comparator|B|Frequency of Mobilization:1/week Duration of Mobilization Treatment: 3 weeks
11611393|NCT00560807|Active Comparator|C|Frequency of Mobilization: 1/week Duration of Mobilization Treatment: 6 weeks
11611394|NCT00560807|Active Comparator|D|Frequency of Mobilization: 1/week Duration of Mobilization Treatment: 12 weeks
11611395|NCT00560807|Active Comparator|F|Frequency of Mobilization: 2/week Duration of Mobilization Treatment: 3 weeks
11611396|NCT00560807|Active Comparator|G|Frequency of Mobilization: 2/week Duration of Mobilization Treatment:6 weeks
11611397|NCT00560807|Active Comparator|H|Frequency of Mobilization: 2/week Duration of Mobilization Treatment: 12 weeks
11611398|NCT00560807|Active Comparator|J|Frequency of Mobilization: 3/week Duration of Mobilization Treatment: 3 weeks
11611399|NCT00560807|Active Comparator|K|Frequency of Mobilization: 3/week Duration of Mobilization Treatment:6 weeks
11611400|NCT00560807|Active Comparator|L|Frequency of Mobilization: 3/week Duration of Mobilization Treatment:12 weeks
11611401|NCT00560807|No Intervention|E|Zero treatment/6 weeks
11611402|NCT00560807|No Intervention|I|Zero treatment/12 weeks
11611403|NCT00560794|Experimental|Blinatumomab|Participants received blinatumomab as continuous intravenous infusion at constant flow rate over 4 weeks followed by a 2 week treatment-free period (defined as one treatment cycle), for up to a maximum of 10 cycles. The initial dose was 15 μg/m^2/day. A dose increase to 30 μg/m^2/day was permitted with evidence for insufficient response to blinatumomab treatment.
11611404|NCT00560781|Active Comparator|1|Pregnenolone
11611405|NCT00560781|Placebo Comparator|2|Placebo
11611406|NCT00560768|Experimental|1|
11611407|NCT00560755|Experimental|ProQuad®|Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.
11611408|NCT00560742|Active Comparator|Control|
11611409|NCT00560742|Experimental|Intramuscular|
11611410|NCT00560742|Experimental|Intracoronary|
11611411|NCT00560729|No Intervention|I|
11611484|NCT00560196||3|Healthy controls
11611417|NCT00560690|Placebo Comparator|Placebo|standard treatment with pegylated interferon and ribavirin + placebo
11611418|NCT00560690|Experimental|Metformin|standard treatment with pegylated interferon and ribavirin + metformin
11611419|NCT00560664|Experimental|1|Autologous chondrocytes transplantation
11611420|NCT00560664|Active Comparator|2|Mosaicoplasty
11611421|NCT00560651||1|Cross linked eyes
11611422|NCT00560638|Experimental|Loteprednol Etabonate TID|loteprednol etabonate ophthalmic suspension, 0.5%, TID
11611423|NCT00560638|Experimental|Loteprednol Etabonate QID|loteprednol etabonate ophthalmic suspension, 0.5%, QID
11611424|NCT00560638|Placebo Comparator|Vehicle|vehicle of loteprednol etabonate
11611425|NCT00560612|Active Comparator|Paroxetine|Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
11611426|NCT00560612|Placebo Comparator|Placebo|
11611427|NCT00560599|No Intervention|1: Standard of care|Standard of care (no body decolonization regimen) and Standard of care (no environmental decolonization regimen)
11611428|NCT00560599|Experimental|2: Body decolonization regimen|Body decolonization regimen and Standard of care (no environmental decolonization regimen)
11611429|NCT00560599|Experimental|3 Environmental decolonization regimen|Standard of care (no body decolonization regimen) and Environmental decolonization regimen
11611430|NCT00560599|Experimental|4 Body and Environmental decolonization regimens|Body decolonization regimen and Environmental decolonization regimen
11611431|NCT00560586|Experimental|Budesonide|Budesonide for 6 weeks followed by crossover to placebo
11611432|NCT00560586|Placebo Comparator|Placebo|Placebo for 6 weeks followed by crossover to treatment.
11611433|NCT00560573|Experimental|1|
11611434|NCT00560560|Experimental|1|Single arm study
11611435|NCT00560547|Experimental|1|
11611436|NCT00560521|Active Comparator|1|
11611437|NCT00560508|Experimental|Pramipexole Extended Release|patient to receive a tablet containing 0.375 mg Pramipexole ER once a day plus containing 0.125 mg Pramipexole IR placebo twice a day -> a tablet containing 1.5 mg Pramipexole ER three times daily (TID) plus 0.5 mg Pramipexole IR placebo TID
11611438|NCT00560508|Active Comparator|Pramipexole Immediate Release|patient to receive a tablet containing 0.125 mg Pramipexole IR twice a day plus containing 0.375 mg Pramipexole ER placebo once a day -> a tablet containing 0.5 mg Pramipexole IR three times daily (TID) plus 1.5 mg Pramipexole ER placebo TID
11611439|NCT00560482|Active Comparator|A|
11611440|NCT00560482|Placebo Comparator|B|
11611441|NCT00560469||1|Men and Women over age 40 who are obese (BMI>30) and insulin-resistant.
11611442|NCT00560469||2|Men and women over age 40 who are obese (BMI>30) and insulin-sensitive.
11611443|NCT00560456|Experimental|1|snorers
11611444|NCT00560456|Other|2|healthy volonters (control)
11611445|NCT00560456|Experimental|3|young subjects
11611446|NCT00560456|Experimental|4|mature subjects
11611447|NCT00560443|Active Comparator|1|children 4-17 y. old with not compound bone fracture treated with ketorolac
11611448|NCT00560443|Experimental|2|children 4-17 y. old with not compound bone fracture treated with tramadol
11611449|NCT00560430|Active Comparator|T1|Telmisartan 80 mg/d
11611450|NCT00560430|Active Comparator|T2|Telmisartan 160 mg/d
11611451|NCT00560430|Placebo Comparator|P|placebo
11611452|NCT00560417|Active Comparator|ILPS|Insulin Lispro Protamine Suspension (ILPS)
11611453|NCT00560417|Active Comparator|Glargine|Insulin Glargine
11611454|NCT00560404|Experimental|1|
11611455|NCT00560404|Active Comparator|2|
11611456|NCT00560391|Experimental|Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 70 mg QD, lenalidomide, 15 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
11611457|NCT00560391|Experimental|Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 70 mg QD, lenalidomide, 20 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
11611458|NCT00560391|Experimental|Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 100 mg QD, lenalidomide, 20 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
11611459|NCT00560391|Experimental|Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 100 mg QD, lenalidomide, 25 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
11611460|NCT00560391|Experimental|Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, lenalidomide, and dexamethasone in varying doses in 28-day cycles.
11611461|NCT00560378|Experimental|Tacrolimus Ointment 0.1%|
11611462|NCT00560352|Experimental|Dasatinib + Bortezomib + Dexamethasone|Phase I dose escalation study
11611463|NCT00560326|Experimental|1|
11611464|NCT00560313|Experimental|4CMenB|
11611465|NCT00560313|Experimental|MenACWY CRM|
11611466|NCT00560300|Experimental|1|Doxercalciferol + Calcium Carbonate
11611467|NCT00560300|Experimental|2|Doxercalciferol + Sevelamer
11611468|NCT00560300|Experimental|3|Calcitriol + Calcium Carbonate
11611469|NCT00560300|Experimental|4|Calcitriol + Sevelamer
11611470|NCT00560287|Active Comparator|1|Volume assist non-invasive ventilation
11611471|NCT00560287|Active Comparator|2|Pressure Assist mode
11611472|NCT00560274|Experimental|1|
11611473|NCT00560261|Experimental|1:Children with sickle cell disease|"NO-CO inhalation and expiration:
~Children with sickle cell disease"
11611474|NCT00560261|Active Comparator|2: Healthy volunteers|"NO-CO inhalation and expiration:
~Healthy volunteers"
11611475|NCT00560248||I|Patients presenting to the Emergency Department with chest pain suspected to be of cardiac origin.
11611476|NCT00560235|Experimental|1|
11611477|NCT00560222|Active Comparator|A|This group will receive daily lactoferrin supplementation
11611478|NCT00560222|Placebo Comparator|B|placebo
11611479|NCT00560209|Placebo Comparator|P|
11611480|NCT00560209|Experimental|E2|
11611481|NCT00560209|Experimental|E1|
11611482|NCT00560196||1|Patients with panic anxiety disorder without pain
11611487|NCT00560170|Experimental|high dose statin|40mg of Simvastatin (n=20)
11611488|NCT00560170|Active Comparator|combination arm|10mg/10mg of Ezetimibe/Simvastatin (n=20)
11611489|NCT00560157|Active Comparator|I|Sondalis HP
11611490|NCT00560157|Experimental|II|Crucial
11611491|NCT00560144|Experimental|1|
11611492|NCT00560144|Experimental|2|
11611493|NCT00560144|Experimental|3|
11611494|NCT00560105|Active Comparator|Acapella|The Active Comparator is the Acapella, a OPEP device
11611495|NCT00560105|Experimental|Lung Flute|The Active Comparator is the Lung Flute, a new indication of this device
11611496|NCT00560092|Experimental|intrathecal magnesium sulfate|
11611497|NCT00560079|Experimental|1|Lithium 900mg/day plus allopurinol 600mg/day
11611498|NCT00560079|Active Comparator|2|
11611499|NCT00560079|Placebo Comparator|3|
11611500|NCT00560066|Experimental|cTIV|Subjects received one vaccination of cell culture-derived influenza vaccine
11611501|NCT00560066|Active Comparator|TIV|Subjects received one vaccination of egg-derived influenza vaccine
11611502|NCT00560014|Experimental|1|Arginine and Canola oil supplemented group
11611503|NCT00560014|Experimental|2|Arginine and Coromega
11611504|NCT00560014|No Intervention|3|Control
11611505|NCT00560001|Experimental|A|Those subjects that receive an MD.2 Medication Dispenser
11611506|NCT00560001|No Intervention|B|Control subjects that do not receive an MD.2 Medication Dispenser, but continue to take their medications utilizing standard care, such as pill boxes, etc.
11611507|NCT00559988|Experimental|Home Monitoring Guided OAC|Home Monitoring is fully enabled and continuous remote surveillance data is available to investigators. Patients will be treated according to a predefined anticoagulation plan, which uses the total duration of AF/AFL combined with patients' CHADS2 score to determine the start, stop, and restart of OAC.
11611508|NCT00559988|Active Comparator|Physician-Directed OAC|"In Control (Group 2), Home Monitoring is active for Safety Net alerts, but the remote AF/AFL data is not revealed to the patient or treating physician. These patients receive physician-directed OAC consistent with current standards of care.
~Safety Net data include:
~ERI/EOS
~Special Implant Status
~Implant in Backup Mode (ROM)
~VT/ VF Detection Inactive
~Emergency Pacing
~250 Ω > RV Pacing Impedance > 1500 Ω
~Symptomatic VT/VF therapies including both ATP and shock
~VT/VF storm
~HM transmission failure >3 days"
11611509|NCT00559975|Active Comparator|1|
11611510|NCT00559975|Active Comparator|2|
11611511|NCT00559975|Experimental|3|
11611512|NCT00559975|Experimental|4|
11611513|NCT00559975|Experimental|5|
11611514|NCT00559962|Placebo Comparator|1|Placebo
11611515|NCT00559962|Active Comparator|2|2.5 mg AEGR-733
11611516|NCT00559962|Active Comparator|3|5 mg AEGR-733
11611517|NCT00559962|Active Comparator|4|7.5 mg AEGR-733
11611518|NCT00559962|Active Comparator|5|10 mg AEGR-733
11611519|NCT00559962|Active Comparator|6|5 mg AEGR-733 + 20 mg atorvastatin
11611520|NCT00559962|Active Comparator|7|5 mg AEGR-733 + 145 mg fenofibrate
11611521|NCT00559962|Active Comparator|8|5 mg AEGR-733 + 10 mg ezetimibe
11611522|NCT00559949|Experimental|Arm I|Patients receive oral selumetinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression.
11611523|NCT00559936|Experimental|Topical Avastin 1.0%|Each patient will receive topical Avastin in one eye.
11611524|NCT00559910|Experimental|PH-797804|PH-797804 at four dose levels
11611525|NCT00559910|Placebo Comparator|Placebo|Placebo
11611526|NCT00559897|Experimental|3'-deoxy-3'-[18F]FLT PET & zoledronic acid|"Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid
~Single photon emission computed tomography. Patient should receive the dose of zoledronic acid within 48 hrs of the first '3'-deoxy-3'-[18F]FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid."
11611527|NCT00559871|Placebo Comparator|1|One placebo tablet administered tid from Day 1 to 28
11611528|NCT00559871|Active Comparator|2|One 30-mg tablet of Fipamezole tid from Day 1 to 28
11611529|NCT00559871|Active Comparator|3|One 30-mg tablet of Fipamezole tid from Day 1 to 7; and one 60-mg tablet of Fipamezole tid from Day 8 to 28
11611530|NCT00559871|Active Comparator|4|One 30-mg tablet of Fipamezole tid from Day 1 to 7; one 60-mg tablet of Fipamezole tid from Day 8 to 14; and one 90-mg tablet of Fipamezole tid from Day 15 to 28
11611531|NCT00559845|Experimental|Bevacizumab|Participants will receive FEC, followed by paclitaxel, given concomitantly with bevacizumab for approximately 3-12 months.
11611532|NCT00559832|No Intervention|Normoxia|Sleeping in normoxia for 14 nights prior to one night at 4500 m
11611533|NCT00559832|Experimental|Hypoxia|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
11611534|NCT00559819|Active Comparator|Alcohol|Alcohol
11611535|NCT00559819|Placebo Comparator|Placebo|Orange juice
11611536|NCT00559806|Experimental|1|9 healthy elderly males
11611537|NCT00559806|Experimental|2|11 healthy young males
11611538|NCT00559780|Experimental|1|12 weeks of resistance training
11611539|NCT00559780|Experimental|2|12 weeks of neuromuscular electrical stimulation
11611540|NCT00559780|Other|3|12 weeks of standard rehabilitation
11611541|NCT00559754|Experimental|1|
11611542|NCT00559715|Experimental|A|
11611543|NCT00559715|Active Comparator|B|
11611544|NCT00559702|Experimental|1|Natalizumab IV (Participants with secondary progressive multiple sclerosis)
11611545|NCT00559702|Experimental|2|Natalizumab IM (Participants with secondary progressive multiple sclerosis)
11611546|NCT00559702|Experimental|3|Natalizumab SC (Participants with secondary progressive multiple sclerosis)
11611547|NCT00559702|Other|4|Standard of care as determined by the Investigator and Treating Neurologist (Participants with secondary progressive multiple sclerosis)
11611548|NCT00559702|Experimental|5|Natalizumab SC (Participants with relapsing forms of multiple sclerosis)
11611549|NCT00559702|Experimental|6|Natalizumab IV (Participants with relapsing forms of multiple sclerosis)
11611550|NCT00559689||1|receive once-daily administration of inhaled glucocorticosteroids at bedtime
11611551|NCT00559689||2|receive twice-daily administration of inhaled glucocorticosteroids
11611552|NCT00559663|Active Comparator|GT|The green tea group is given initially green tea treatment and then after a washout period of four weeks switched to the dark chocolate treatment.
11611553|NCT00559663|Active Comparator|DC|The dark chocolate group is given initially dark chocolate treatment and then after a washout period of four weeks switched to the green tea treatment.
11611554|NCT00559650|Placebo Comparator|Arm 1|
11611555|NCT00559650|Experimental|Arm 2|
11611556|NCT00559637|Experimental|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month. The starting dose will be 1.2 mcg/kg of body weight. Further dose adjustments will be performed during the study depending on the hemoglobin value. Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
11611557|NCT00559611|Experimental|Endobronchial Ultrasound vs. Mediastinoscopy|"Endobronchial Ultrasound - A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.
~Mediastinoscopy - Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS."
11611558|NCT00559585|Active Comparator|Subcutaneous (SC) Abatacept|Participants received 125 mg weekly SC abatacept injections (with an intravenous [IV] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
11611559|NCT00559585|Active Comparator|Intravenous (IV) Abatacept|Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).
11611560|NCT00559572|Experimental|1|Exercise information group
11611561|NCT00559572|Active Comparator|2|General health information group
11611562|NCT00559559|Other|Control Group|Patient Notifier turned OFF
11611563|NCT00559559|Experimental|Treatment group|Patient Notifier turned ON
11611564|NCT00559546|Active Comparator|1|3 weeks of Montelukast and 3 weeks of placebo treatment
11611565|NCT00559546|Active Comparator|2|3 weeks of placebo and 3 weeks of montelukast treatment
11611566|NCT00559533|Experimental|1|
11611567|NCT00559520|Active Comparator|Impact|"patient receiving 3 drinks Impact a day during 5 days before surgery"
11611568|NCT00559520|Experimental|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
11611569|NCT00559507|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11611570|NCT00559494|Experimental|Minocycline|
11611571|NCT00559494|Placebo Comparator|Placebo|
11611572|NCT00559494|Experimental|SCPP augmentation|
11611573|NCT00559494|Sham Comparator|SCPP control|
11611574|NCT00559468|Experimental|Sugammadex + Sevoflurane|After receiving sevoflurane and the last dose of rocuronium, at the reappearance of first twitch (T1; 3-10% starting amplitude), a dose of 4.0 mg/kg sugammadex was administered.
11611575|NCT00559468|Experimental|Sugammadex + Propofol|After receiving propofol and the last dose of rocuronium, at the reappearance of first twitch (T1; 3-10% starting amplitude), a dose of 4.0 mg/kg sugammadex was administered.
11611576|NCT00559455|Experimental|1|
11611577|NCT00559442|Experimental|1|high altitude exposure without prior acclimatization
11611578|NCT00559429|Active Comparator|C1|
11611579|NCT00559429|Active Comparator|C2|
11611580|NCT00559429|Active Comparator|C3|
11611581|NCT00559429|Active Comparator|C4|
11611582|NCT00559403|Experimental|HIV/STD Sessions|The HIV/STD Risk-Reduction Intervention arm focuses on reducing the risk of STDs, including HIV.
11611583|NCT00559403|Active Comparator|Health Promotion Control Sessions|The Health Promotion Intervention arm focuses on physical activity, diet, and other behaviors linked to risk of heart disease, high blood pressure, stroke, diabetes, and certain cancers, which are all leading causes of morbidity and mortality among South Africans.
11611584|NCT00559390||Pre-PCOS|First degree relatives, either sisters or daughters, of women with Polycystic Ovary Syndrome.
11611585|NCT00559390||Controls|Sisters and daughters of women who do not have PCOS
11611586|NCT00559377|Experimental|Diagnostic FMISO AND FDG PET|Patients receive ^18F FMISO IV over 1 minute followed by PET scanning. Patients undergo a second ^18F FMISO PET scan 4-8 weeks later. Patients who have not had a prior ^18F FDG PET scan as part of their routine clinical management undergo ^18F FDG PET scanning at baseline.
11611587|NCT00559364|Experimental|Viokase® 16|
11611588|NCT00559364|Placebo Comparator|Placebo|
11611589|NCT00559351|Active Comparator|S|esophagectomy
11611590|NCT00559351|Experimental|CHTS|neoadjuvant chemotherapy followed by esophagectomy
11611591|NCT00559351|Experimental|CHRTS|neoadjuvant chemoradiotherapy followed by esophagectomy
11611592|NCT00559338|Active Comparator|1|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
11611593|NCT00559338|Placebo Comparator|2|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
11611594|NCT00559312|Experimental|FSC 250/50|fluticasone 250μg/salmeterol 50μg combination
11611595|NCT00559312|Placebo Comparator|Placebo|matched placebo inhaler
11611596|NCT00559286|Experimental|A|treatment with 80 mg Telmisartan per day for 30 days
11611597|NCT00559286|Active Comparator|B|treatment with 20mg Telmisartan per day for 30 days
11611598|NCT00559273|Experimental|Mircera|Participants will receive Mircera (Methoxy polyethylene glycol-epoetin beta), administered subcutaneously (SC) at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.
11611599|NCT00559273|Active Comparator|Darbepoetin Alfa|Participants will receive darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.
11611600|NCT00559247|Experimental|or Placebo - Dose Panel 1|Oral Suspension, 10 mg
11611601|NCT00559247|Experimental|or Placebo - Dose Panel 2|Oral Suspension 50 mg
11611602|NCT00559247|Experimental|or Placebo - Dose Panel 3|Oral Suspension, 200 mg
11611603|NCT00559247|Experimental|or Placebo - Dose Panel 4|Oral Suspension or Solution, 2.5 to 600 mg
11611604|NCT00559221|No Intervention|1|
11611605|NCT00559208||Children's Aid Societies|Comparing differential response (Wraparound) with usual care
11611606|NCT00559182|Experimental|Parts A and B: MK-8033|Dose Escalation Study
11611607|NCT00559182|Experimental|Part C: MK-8033 +/- omeprazole|Crossover Study
11611608|NCT00559143|Active Comparator|1|DDD(R)-RV pacing
11611609|NCT00559143|Experimental|2|DDD(R)- BIV pacing
11611610|NCT00559117|Experimental|Cohort|
11611611|NCT00559104|Active Comparator|Irradiation in conditioning|total-body irradiation, etoposide, cyclophosphamide, infusion of peripheral blood stem cells, granulocyte-colony stimulating factor (G-CSF), autologous hematologic stem cell transplantation, peripheral blood stem cell transplantation
11611612|NCT00559104|Active Comparator|Carmustine in conditioning|Carmustine, etoposide, cyclophosphamide, infusion of peripheral blood stem cells, granulocyte-colony stimulating factor (G-CSF), autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
11611613|NCT00559091|Experimental|I|Ribavirin
11611614|NCT00559078||CAH|Women diagnosed with CAH (either simple virilizing or salt-losing)
11611615|NCT00559065||Benzene Cohort|Benzene exposed and unexposed workers.
11611616|NCT00559052|No Intervention|1|Baseline measurement. No drug with the liquid meal during perfusion procedure to establish baseline secretion.
11611617|NCT00559052|Experimental|2|The Viokase 16 is to be taken as 3 tablets with the liquid meal during perfusion procedure.
11611618|NCT00559026|Active Comparator|1|
11611619|NCT00559026|Experimental|2|
11611620|NCT00559013|Active Comparator|1|PSD Veritas Collagen Matrix Reinforcement Arm
11611621|NCT00559000|No Intervention|Waitinglist Control|
11611622|NCT00559000|Experimental|KIDNET|
11611623|NCT00558987|Experimental|1|
11611624|NCT00558987|Sham Comparator|2|
11611625|NCT00558961|Experimental|I|Gleevec Chlorambucil
11611626|NCT00558896|Experimental|Relapsed Myeloma (<4 Prior Regimens)|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle
~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
11611627|NCT00558896|Experimental|Lenalidomide Refractory Myeloma|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle
~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
11611628|NCT00558896|Experimental|Bortezomib/Lenalidomide Refractory/Relapsed Myeloma|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle
~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
11611629|NCT00558896|Experimental|Bortezomib/Lenalidomide Relapsed/Refractory Myeloma|"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle
~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
11611630|NCT00558896|Experimental|Relapsed Myeloma (< 4 Prior Regimens)|"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle
~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
11611631|NCT00558896|Experimental|Relapsed/Refractory Myeloma|"Pomalidomide: 4 mg orally once daily, days 1-21 of 28 day cycle
~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
11611632|NCT00558896|Experimental|Relapsed Amyloidosis|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle
~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
11611633|NCT00558883|Active Comparator|1|treatment with Acarbose: 2 weeks 1 x 50mg; 2 weeks 3 x 50mg; 16 weeks 3 x 100mg
11611634|NCT00558883|Placebo Comparator|2|treatment with placebo: 2 weeks 1 x 50mg 2 weeks 3 x 50mg 16 weeks 3 x 100mg
11611635|NCT00558870|Active Comparator|Morphine Only|"Morphine - Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain."
11611636|NCT00558870|Active Comparator|Morphine + Methadone|"Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain.
~1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)"
11611637|NCT00558857|Active Comparator|DSM|Treatment using DSM to guide ablation
11611638|NCT00558844|Active Comparator|A|Arikayce™ at 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
11611639|NCT00558844|Placebo Comparator|B|Matching placebo for 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
11611640|NCT00558844|Active Comparator|C|Arikayce™ at 70 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
11611641|NCT00558844|Active Comparator|D|Arikayce™ at 140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
11611642|NCT00558844|Placebo Comparator|E|Matching placebo for 70 mg/140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
11611643|NCT00558831|Active Comparator|Benzoyl Peroxide|Benzoyl Peroxide (BP) 2.5%
11611644|NCT00558831|Active Comparator|Benzoyl Peroxide plus moisturizing lotion|Benzyol Peroxide 2.5% plus moisturizing lotion
11611645|NCT00558805|Active Comparator|1|Usual Care + Family Intervention for Suicide Prevention (FISP)
11611646|NCT00558805|Other|2|Usual Care
11611647|NCT00558792|Experimental|Isovue 370, 70 mL|iopamidol injection 370, 70 mL
11611648|NCT00558792|Experimental|Isovue 370, 80 mL|iopamidol injection 370, 80 mL
11611649|NCT00558792|Experimental|Isovue 370, 90 mL|iopamidol injection 370, 90 mL
11611650|NCT00558779|Experimental|1|
11611651|NCT00558779|Active Comparator|2|
11611652|NCT00558753|Placebo Comparator|1 Placebo|Half of the patients will receive PO placebo for 14 days
11611653|NCT00558753|Experimental|2 Pregabalin|PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
11611654|NCT00558740||healthy volunteers|
11611655|NCT00558701|Active Comparator|Microcurrent Stimulator + Silverlon|Patients receiving active electrical stimulation (15-50 microamps) during treatment of skin donor sites with Silverlon wound contact dressing. Intervention is active electrical stimulation via microcurrent stimulator.
11611807|NCT00557505|Experimental|PF-03732010|Single Arm study
11611656|NCT00558701|Sham Comparator|Silverlon alone|Patients receiving treatment of skin donor sites with Silverlon wound contact dressing alone (i.e., without active electrical stimulation)
11611657|NCT00558688|Experimental|1|Light Therapy
11611658|NCT00558688|Experimental|2|Light Therapy
11611659|NCT00558675|Experimental|1|Single intravenous infusion of AlloStim
11611660|NCT00558675|Experimental|2|Intravenous AlloStim infusion on day 1 and day 7
11611661|NCT00558675|Experimental|3|Intravenous AlloStim infusion on day 1, day 7 and day 14
11611662|NCT00558675|Experimental|4|Intravenous AlloStim infusion on day 1, day 7, day 14 and day 21
11611663|NCT00558662|Active Comparator|1|Coban 2 Layer Compression System
11611664|NCT00558662|Active Comparator|2|Short-Stretch Bandage
11611665|NCT00558649|Experimental|1|Low dose flu vaccine delivered intradermally using microneedles
11611666|NCT00558649|Experimental|2|Medium dose flu vaccine delivered intradermally using microneedles
11611667|NCT00558649|Active Comparator|3|Standard dose flu vaccine delivered intramuscularly with a regular needle
11611668|NCT00558636|Experimental|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), [400 mg, (2 tablets x 200 mg each) orally, twice daily] on Study Days 2-19 and paclitaxel (175 mg/m^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
11611669|NCT00558636|Placebo Comparator|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
11611670|NCT00558623|Placebo Comparator|1|Placebo
11611671|NCT00558597||1|30 patients with stable graft function
11611672|NCT00558597||2|30 patients with acute rejection after lung transplantation
11611673|NCT00558584|Active Comparator|IA/IgG group|immunoadsorption using IA columns and subsequent IgG substitution
11611674|NCT00558584|Placebo Comparator|control group|pseudo-immunoadsorption followed by an intravenous infusion without IgG
11611675|NCT00558571|Placebo Comparator|Placebo|
11611676|NCT00558571|Experimental|BI 10773 low dose|
11611677|NCT00558571|Experimental|BI 10773 medium dose|
11611678|NCT00558571|Experimental|BI 10773 high dose|
11611679|NCT00558558|Other|Fermented Soy Supplement|4 oz Haelan orally twice daily for 8 weeks
11611680|NCT00558532||Surgical|Those subjects undergoing bariatric surgery or abdominal surgery following a previous bariatric surgery.
11611681|NCT00558532||Control|Volunteers who have dietary habits similar to the subjects.
11611682|NCT00558519|Experimental|Treatment (chemotherapy, radiotherapy)|"Patients are given a series of leukemia treatments that are divided into several sequential courses and different chemotherapy combinations of treatment. Please see the Detailed Description section for more information."
11611683|NCT00558506|Experimental|A|Abatacept
11611684|NCT00558493|Experimental|1|switching treatment from lamivudine to clevudine
11611685|NCT00558480|Active Comparator|1|Vitamin A
11611686|NCT00558480|Placebo Comparator|2|Vitamin A placebo
11611687|NCT00558467|Other|Pramipexole|
11611688|NCT00558467|Placebo Comparator|Placebo|
11611689|NCT00558454|Placebo Comparator|1|Placebo
11611690|NCT00558454|Experimental|2|1 mg/kg/day from age 6 weeks to 6 months
11611691|NCT00558454|Experimental|3|2 mg/kg/day from age 6 weeks to 6 months
11611692|NCT00558441|Experimental|1|
11611693|NCT00558402|Experimental|1|Meditation class, 90min/week for 8 weeks, with home assignments, adapted from MBCT program
11611694|NCT00558402|Active Comparator|2|Education
11611695|NCT00558402|Active Comparator|3|Respite care only, 90 mins per week for 8 weeks
11611696|NCT00558376|Active Comparator|1|Ingestion of 3L polyethylene Glycol
11611697|NCT00558376|Active Comparator|2|Ingestion of 2 doses of sodium phosphate 45 cc
11611698|NCT00558363|Experimental|Avodart|Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months.
11611699|NCT00558363|Placebo Comparator|Placebo Arm|Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months.
11611700|NCT00558350||1|lobectomy / segmentectomy in patients with lung cancer
11611701|NCT00558337|Active Comparator|A|
11611702|NCT00558337|Active Comparator|B|
11611703|NCT00558324|Experimental|I|Corneal flaps were created with mechanical microkeratome (Hansatome 160μm (Chiron Vision Corp, Claremont, Calif)
11611704|NCT00558324|Experimental|II|Corneal flaps were created with mechanical microkeratome K3000 130μm ( BD Ophthalmic Systems, Waltham, Mass) .
11611705|NCT00558324|Experimental|III|Corneal flaps were created with microkeratome femtoseconds laser (Intralase Corp, Irvine, Calif.)
11611706|NCT00558311|Experimental|Clazosentan|A continuous intravenous infusion of clazosentan was started within 56 hours post-aSAH and was scheduled to continue during the hospitalization until Day 14 post-aSAH, or at least until Day 10.
11611707|NCT00558311|Placebo Comparator|Placebo|A continuous intravenous infusion of placebo-matching clazosentan was started within 56 hours post-aSAH and was scheduled to continue during the hospitalization until Day 14 post-aSAH, or at least until Day 10.
11611708|NCT00558285|Experimental|indacaterol/glycopyrrolate 600/100 μg|"Two capsules indacaterol/glycopyrrolate 300/50 μg delivered via a single dose dry powder inhaler in the morning for 14 days.
~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
11611709|NCT00558285|Experimental|indacaterol/glycopyrrolate 300/100 μg|"One capsule indacaterol/glycopyrrolate 300/100 μg and one placebo capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
11611843|NCT00557349|Active Comparator|Omeprazole|40 mg Omeprazole daily
11611844|NCT00557349|Active Comparator|Famotidine|40 mg Famotidine daily
11625735|NCT00422383|Experimental|2|
11611710|NCT00558285|Experimental|indacaterol/glycopyrrolate 150/100 μg|"One capsule indacaterol/glycopyrrolate 150/50 μg and one capsule 50 μg glycopyrrolate delivered via a single dose dry powder inhaler in the morning for 14 days.
~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
11611711|NCT00558285|Active Comparator|indacaterol 300 μg|"One capsule indacaterol 300 μg and one placebo capsule delivered via s single dose dry powder inhaler in the morning for 14 days.
~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
11611712|NCT00558285|Placebo Comparator|placebo|"Two placebo capsules delivered via a single dose dry powder inhaler in the morning for 14 days.
~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
11611713|NCT00558272|Experimental|AZD0530 175 mg|AZD0530 (saracatinib) 175 mg once daily
11611714|NCT00558272|Experimental|Zoledronic Acid 4 mg|Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period
11611715|NCT00558259|Experimental|dabigatran etexilate 150 mg BID|Patient to receive dabigatran etexilatate capsules 150 mg twice daily
11611716|NCT00558259|Placebo Comparator|matching placebo twice daily (BID)|Patient to receive dabigatran extexilate matching placebo capsules twice daily
11611717|NCT00558246|Experimental|I|On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.
11611718|NCT00558246|Active Comparator|II|On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.
11611719|NCT00558233|Experimental|Intervention group|
11611720|NCT00558233|Placebo Comparator|Placebo group|
11611721|NCT00558220|Experimental|A|Intensive induction followed by high-dose consolidation with stem cell support ± radiotherapy
11611722|NCT00558207|Experimental|1|ARQ 197
11611723|NCT00558207|Active Comparator|2|Gemcitabine
11611724|NCT00558194|Experimental|1|Standard behavioral weight loss treatment with cognitive and affective skills training
11611725|NCT00558194|Active Comparator|2|Standard behavioral weight loss treatment
11611726|NCT00558181|Experimental|Rituximab, Methylprednisolone|
11611727|NCT00558155|Experimental|SEN|standard enteral nutrition
11611728|NCT00558155|Experimental|IMEN|immunostimulating enteral nutrition
11611729|NCT00558155|Experimental|SPN|standard parenteral nutrition
11611730|NCT00558155|Experimental|IMPN|immunostimulating parenteral nutrition
11611731|NCT00558142|Active Comparator|1|Healthy volunteers will be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
11611732|NCT00558142|Active Comparator|2|Volunteers with CKD III will be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
11611733|NCT00558142|Active Comparator|3|Healthy volunteers will receive a single IV dose of 100mls Visipaque 320 (iodixanol, equivalent to 320 mg iodine/ml). They will then be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
11611734|NCT00558142|Active Comparator|4|Volunteers with CKD III will receive Visipaque 320 during coronary angiography. They will have been randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
11611735|NCT00558129|Experimental|Investigational|X-STOP® PEEK IPD
11611736|NCT00558129|Active Comparator|Control|Laminectomy
11611737|NCT00558116|Experimental|1|Treatment with Dynasplint device
11611738|NCT00558116|No Intervention|2|Control group; does not receive conservative or surgical treatment.
11611739|NCT00558103|Active Comparator|arm 1|Lapatinib
11611740|NCT00558103|Active Comparator|arm2|Pazopanib monotherapy (open label)
11611741|NCT00558103|Experimental|arm3|Lapatinib+ pazopanib
11611742|NCT00558090|Active Comparator|A|patients receive 2,5 mg morphine iv, before the first intervention on the day after admission in the ICU
11611743|NCT00558077|Experimental|A|Metformin plus clomiphene citrate
11611744|NCT00558077|Active Comparator|B|Laparoscopic ovarian drilling
11611745|NCT00558051|Active Comparator|Intradermal administration|Intradermal administration
11611746|NCT00558051|Active Comparator|Intranodal administration|Intranodal administration
11611747|NCT00558051|Active Comparator|Intralymphatic infusion|Intralymphatic infusion
11611748|NCT00558038|Active Comparator|1|
11611749|NCT00558038|Experimental|2|
11611750|NCT00558025|Experimental|Pramipexole Extended Release (ER)|Pramipexole Extended Release (ER) once daily
11611751|NCT00558025|Experimental|Pramipexole Immediate Release (IR)|Pramipexole Immediate Release (IR) once daily
11611752|NCT00558012|Experimental|Active Medication Group|One-time dose: Intravenous Zoledronic Acid 5.0 mg; Vitamin D (800 IU/daily); Calcium 1200 mg/daily (supplement plus diet)
11611753|NCT00558012|Placebo Comparator|Placebo|One-time dose: intravenous saline; Vitamin D (800 IU/daily); 1200 mg calcium (supplement plus diet)
11611754|NCT00557999|Other|Experimental group|Application of a weaning mechanical ventilation protocol
11611755|NCT00557999|No Intervention|Control group|
11611756|NCT00557986|No Intervention|A|Standard Systemic Therapy only group (no primary surgery)
11611757|NCT00557986|Other|B|Surgery group
11611758|NCT00557973|Experimental|XP19986 SR1 10 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 10 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
11611759|NCT00557973|Experimental|XP19986 SR1 20 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 20 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
11611760|NCT00557973|Experimental|XP19986 SR1 30 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 30 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
11611761|NCT00557947|Experimental|I|Dermabond Protape-Incision segments are randomized & patient is own control
11611762|NCT00557947|Active Comparator|II|Intradermal Suture - Incision segments are randomized & patient is own control. Investigator selected suture on the basis of standard local practice.
11611763|NCT00557934|Experimental|1|
11611764|NCT00557921|Experimental|1|
11611765|NCT00557921|Active Comparator|2|
11611766|NCT00557908||VWF/FVIII product infusions|One to three infusions of factor replacement as needed to control bleeding.
11611767|NCT00557882|Active Comparator|mesh|Vaginal reconstructive surgery with synthetic polypropylene mesh
11611768|NCT00557882|Active Comparator|no mesh|Vaginal reconstructive surgery without mesh
11611769|NCT00557856|Experimental|1|
11611770|NCT00557843|Active Comparator|bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
11611771|NCT00557843|Placebo Comparator|Placebo|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
11611772|NCT00557830|Active Comparator|Group A: Escalated Dose|Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen). Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
11611773|NCT00557830|Active Comparator|Group B: Standard Dose|Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen). Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
11611774|NCT00557817|No Intervention|1|No medication given
11611775|NCT00557817|Active Comparator|2|Aranesp 300 µg/15 days
11611776|NCT00557817|Active Comparator|3|Aranesp 300 µg/15 days. Venofer 200 mg on days 28, 42, and 56 after the transplant.
11611777|NCT00557791|Active Comparator|A|Lucentis® (0.5 mg) every 4 weeks.
11611778|NCT00557791|Experimental|B|Bevasiranib (1.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
11611779|NCT00557791|Experimental|C|Bevasiranib (2.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
11611780|NCT00557791|Experimental|D|Bevasiranib (2.5 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
11611781|NCT00557778||1|Receives treatment with rosuvastatin, according to International and National Guidelines on hypercholesterolemia.
11611782|NCT00557778||Group 2|Receives the same treatment as group 1 and information on health improvement, diet and exercises applied to the disease that is being treated. The positive impact of the information upon treatment will be statistically evaluated.
11611783|NCT00557752|Active Comparator|1|Addition to the standard therapy of non-invasive mechanical ventilation. Continuously for the first 24 hours, then trials to discontinuation every 24 hours. Interface adjusted for the associated injuries.
11611784|NCT00557752|No Intervention|2|Standard therapy for severe post-traumatic hypoxia: pain control with epidural anesthesia and oxygen.
11611785|NCT00557739|Experimental|1|CRx-191 (0.1% mometasone furoate + 0.05% nortriptyline HCl)
11611786|NCT00557739|Experimental|2|CRx-191 (0.1% mometasone furoate + 0.1% nortriptyline HCl)
11611787|NCT00557739|Active Comparator|3|0.1% mometasone furoate
11611788|NCT00557739|Active Comparator|4|0.05% nortriptyline HCl
11611789|NCT00557739|Active Comparator|5|0.1% nortriptyline HCl
11611790|NCT00557739|Placebo Comparator|6|Vehicle (placebo)
11611791|NCT00557726||1|patients with a variety of infectious and inflammatory diseases
11611792|NCT00557713|Experimental|A|"-Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)
~-Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))
~-Surgery (6-8 weeks after last bevacizumab dose)
~-Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)"
11611793|NCT00557700|Placebo Comparator|2|Administration of placebo
11611794|NCT00557700|Experimental|1|Administration of inhaled tiotropium bromide
11611795|NCT00557648|Experimental|1|CBT for children only
11611796|NCT00557648|Experimental|2|CBT for children with parental involvement
11611797|NCT00557648|No Intervention|3|No intervention control group: families free to seek treatment on their own
11611798|NCT00557622|Experimental|paroxetine|Drug 2 (20 mg/day or placebo) will be administered once daily after supper for the first two weeks after the run-in phase. If the investigator/subinvestigator judges that a sufficient response is achieved, Drug 2 will be continued for the remaining period. If a sufficient response is not achieved with Drug 2 but treatment is well tolerated, the dose will be titrated to one step higher level until a sufficient response is achieved [i.e., Drug 3 (30 mg/day or placebo) → Drug 4 (40 mg/day or placebo) → Drug 5 (50 m/day or placebo)] at intervals of at least two weeks by once daily administration after supper. Once a sufficient response is achieved, that dose will be continued.
11611799|NCT00557622|Placebo Comparator|placebo|placebo
11611800|NCT00557557|Experimental|IHP with Oxaliplatin and 5-Fluorouracil (5-FU)|Isolated Hepatic Perfusion with Oxaliplatin and 5-Fluorouracil (5-FU)
11611801|NCT00557544|Experimental|1|metoclopramide 0,15 mg/kg and Ketoprofen 1 mg/Kg per os in single dose
11611802|NCT00557544|Active Comparator|2|metoclopramide 0,15 mg/Kg + placebo per os
11611803|NCT00557544|Active Comparator|3|ketoprofen 1 mg/Kg and placebo in single dose
11611804|NCT00557531|Experimental|BL-1040|
11611808|NCT00557492|Experimental|Single Arm|"Intervention: Drug: Avastin (bevacizumab) 10 mg/kg, days 1, 15, 29 and 43
~Intervention: Drug: Gemzar (Gemcitabine) On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).
~Intervention:Radiation: external beam radiotherapy 3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy"
11611809|NCT00557466|Experimental|indacaterol 62.5 μg|Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
11611810|NCT00557466|Experimental|indacaterol 125 μg|Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
11611811|NCT00557466|Experimental|Indacaterol 250 μg|Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
11611812|NCT00557466|Experimental|indacaterol 500 μg|Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
11611813|NCT00557466|Active Comparator|formoterol|Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
11611814|NCT00557466|Placebo Comparator|placebo|Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
11611815|NCT00557453||A|Antibiotic treatment
11611816|NCT00557453||B|Non antibiotic treatment
11611817|NCT00557440|Experimental|Ind/M - FP/Salm - Pbo|"In Treatment Period 1 (Days 1 & 2) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via multi-dose dry powder inhaler (MDDPI), one inhalation in the evening and one inhalation the following morning.
~In Treatment Period 2 (Days 8 & 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.
~In Treatment Period 3 (Days 15 & 16) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.
~Each treatment period was separated by a 6-day washout period."
11611818|NCT00557440|Experimental|FP/Salm - Pbo - Ind/M|"In Treatment Period 1 (Days 1 & 2) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.
~In Treatment Period 2 (Days 8 & 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.
~In Treatment Period 3 (Days 15 & 16) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.
~Each treatment period was separated by a 6-day washout period."
11611819|NCT00557440|Experimental|Pbo - Ind/M - FP/Salm|"In Treatment Period 1 (Days 1 & 2) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.
~In Treatment Period 2 (Days 8 & 9) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.
~In Treatment Period 3 (Days 15 & 16) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.
~Each treatment period was separated by a 6-day washout period."
11611820|NCT00557427|Experimental|A|hypericum 250mg tablets twice daily for 8 weeks
11611821|NCT00557427|Active Comparator|B|fluoxetine 20mg - 40mg daily for 8 weeks
11611822|NCT00557401|Experimental|XP19986 SR3, 20 mg QD|XP19986, 20 mg QD for approximately 32 days
11611823|NCT00557401|Experimental|XP19986 SR3, 40 mg QD|XP19986, 40 mg QD for approximately 32 days
11611824|NCT00557401|Experimental|XP19986 SR3, 60 mg QD|XP19986, 60 mg QD for approximately 32 days
11611825|NCT00557401|Experimental|XP19986 SR3, 30 mg BID|XP19986, 30 mg BID for approximately 32 days
11611826|NCT00557401|Placebo Comparator|Placebo|Placebo for approximately 32 days
11611827|NCT00557388|Experimental|1|Young men 18-30 years, BMI < 27 kg/m2
11611828|NCT00557388|Experimental|2|Young men 18-30 years, BMI < 27 kg/m2
11611829|NCT00557388|Experimental|3|Old men 70-85 years, BMI < 27 kg/m2
11611830|NCT00557388|Experimental|4|Old men 70-85 years, BMI < 27 kg/m2
11611831|NCT00557388|Experimental|5|Old men 70-85 years, BMI < 27 kg/m2
11611832|NCT00557388|Experimental|6|Old men 70-85 years, BMI < 27 kg/m2
11611833|NCT00557388|Experimental|7|Old men 70-85 years, BMI < 27 kg/m2
11611834|NCT00557388|Experimental|8|Old men 70-85 years, BMI < 27 kg/m2
11611835|NCT00557388|Experimental|9|Old men 70-85 years, BMI < 27 kg/m2
11611836|NCT00557388|Experimental|10|Old men 70-85 years, BMI < 27 kg/m2
11611837|NCT00557375||1|Brain tumor patients
11611838|NCT00557375||2|Caregivers of brain tumor patients
11611839|NCT00557362|Active Comparator|1|Topical voriconazole with corneal de-epithelialization
11611840|NCT00557362|Active Comparator|2|Topical voriconazole without corneal de-epithelialization
11611841|NCT00557362|Active Comparator|3|Topical natamycin with corneal de-epithelialization
11611842|NCT00557362|Active Comparator|4|Topical natamycin without corneal de-epithelialization
11611845|NCT00557323||1|Patients being treated for hyperphosphatemia with any marketed product
11611846|NCT00557310|Experimental|Teriparatide|20 micrograms (mcg) teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
11611847|NCT00557284|Experimental|1|Montelukast
11611848|NCT00557284|Placebo Comparator|2|
11611849|NCT00557245|Active Comparator|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
11611850|NCT00557245|Active Comparator|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
11611851|NCT00557245|Placebo Comparator|Placebo|Placebo TDF + Placebo FTC/TDF orally, once daily.
11611852|NCT00557219|Placebo Comparator|Placebo|Control group receiving placebo
11611853|NCT00557219|Experimental|Ketanserin|patients receiving ketanserin infusion
11611854|NCT00557219|Experimental|Fenoldopam|patients receiving fenoldopam infusion
11611855|NCT00557206|Experimental|1|This is a single arm trial.
11611856|NCT00557193|Experimental|Arm A (standard risk MLL-G)|Population Description: Eligible patients with MLL-G (germline, or non-rearranged)
11611857|NCT00557193|Active Comparator|Arm B (IR/HR MLL-R chemotherapy)|Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age >= 90 days at diagnosis and High Risk (HR) if age < 90 days at diagnosis.
11611858|NCT00557193|Experimental|Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)|Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age >= 90 days at diagnosis and High Risk (HR) if age < 90 days at diagnosis.
11611859|NCT00557180||BASALT|Participants in the ACRN BASALT study
11611860|NCT00557180||TALC|Participants in the ACRN TALC study
11611861|NCT00557154|Experimental|1|Ultrasound used to visualize peripheral venous anatomy. This guides subsequent attempts at venipuncture.
11611862|NCT00557154|Active Comparator|2|Routine venipuncture using standard methods.
11611863|NCT00557141||1|Age > 18 years, Asthma with irregular or regular use of short acting beta-agonists and / or: Asthma treatment with inhaled steroids, Ability to understand the questionnaire
11611864|NCT00557115|No Intervention|Usual Care|Usual Care (UC): usual follow up care post acute COPD exacerbation
11611865|NCT00557115|Experimental|EPR|Early pulmonary rehabilitation (EPR): pulmonary rehabilitation commenced within 1-week of hospital discharge from an acute COPD exacerbation
11611866|NCT00557102|Other|cetuximab, FOLFIRI|
11611867|NCT00557089|Other|1|This arm will receive the active treatment for 28 days, followed by a 28 day washout period and then the placebo treatment for 28 days.
11611868|NCT00557089|Other|2|This arm will receive the placebo treatment for 28 days, followed by a 28 day washout period and then the active treatment for 28 days.
11611869|NCT00557076|Experimental|Familiar Auditory Sensory Training|FAST is a standardized passive auditory stimulation protocol. The patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. The FAST protocol is provided on compact discs (CDs), using portable players and noise cancelling headphones, while patients were awake (ie, eyes open). Speakers were used for one patient not tolerating his headphones. The CDs were identical according to track duration, labeling, and administration procedures.
11611870|NCT00557076|Sham Comparator|Sham Auditory Sensory Training|Placebo protocol is silence. Patients receive sham protocols for 10 minutes 4 times per day, with at least 2 hours in between, for 6 weeks.
11611871|NCT00557037|Experimental|A|Patients with chemotherapy naïve androgen independent disease
11611872|NCT00557037|Experimental|B|Patients with rising PSA after radical prostatectomy or radiotherapy that are androgen dependent
11611873|NCT00557024|Experimental|1|radiotherapy after RFA
11611874|NCT00557024|Active Comparator|2|RFA alone
11611875|NCT00557011|Experimental|1|NRP104
11611876|NCT00557011|Active Comparator|2|Adderall XR
11611877|NCT00557011|Placebo Comparator|3|Placebo
11611878|NCT00556998|Experimental|1|
11611879|NCT00556972|Experimental|Fecal Incontinence management system|Fecal Incontinence Management System is based on the same principle as fecal pouches. A barrier around anus to ensure adhesion and prevent leakage.
11611880|NCT00556959|Experimental|1|CLONICEL High Dose
11611881|NCT00556959|Experimental|2|CLONICEL Low Dose
11611882|NCT00556959|Placebo Comparator|3|Placebo
11611883|NCT00556946|Other|Combined Photodynamic & Pulsed Dye Laser Treatment|Treatment of Port Wine Stains
11611884|NCT00556933|Experimental|Group 1|Kidney transplant recipients given a single large dose of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression.
11611885|NCT00556933|Experimental|Group 2|Kidney transplant recipients given 4 small doses of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression.
11611886|NCT00556933|Experimental|Group 3|Kidney transplant recipients given a single large dose of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression until tacrolimus is replaced with mycophenolate mofetil after about 6 months.
11611887|NCT00556933|Experimental|Group 4|Kidney transplant recipients given 4 small doses of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression until tacrolimus is replaced with mycophenolate mofetil after about 6 months.
11611888|NCT00556907|Other|1|Patients will receive IORT
11611889|NCT00556894|Experimental|CF101 0.1 mg|CF101 0.1 mg was given orally q12h
11611890|NCT00556894|Experimental|CF101 1 mg|CF101 1 mg was given orally q12h
11611891|NCT00556894|Placebo Comparator|Placebo|Matched placebo was given orally q12h
11611892|NCT00556868|Experimental|A|Breakfast on the first day of intervention, fasting (no breakfast) on the second day of intervention
11611893|NCT00556868|Experimental|B|Fasting (no breakfast) on the first day of intervention, breakfast on the second day of intervention
11611894|NCT00556855|Experimental|A|applied on one hand
11611895|NCT00556855|Placebo Comparator|B|applied on the other hand
11611896|NCT00556842|Active Comparator|1|Participants will undergo total hip arthroplasty.
11612011|NCT00555906|Experimental|1|
11611897|NCT00556842|Active Comparator|2|Participants will undergo hemi-arthroplasty.
11611898|NCT00556816|Active Comparator|Conventional outpatient clinic|Conventional outpatient clinic
11611899|NCT00556816|Experimental|On demand outpatient clinic|On demand outpatient clinic
11611900|NCT00556803|Experimental|1|TACE after RFA within one month as an adjuvant therapy
11611901|NCT00556803|Active Comparator|2|RFA alone
11611902|NCT00556790|Other|1|Standard Care
11611903|NCT00556790|Other|2|Fast Track Care
11611904|NCT00556764|Experimental|2 cohorts|"In this observational study 2 cohorts will participate. Cohort 1 will include people with Parkinson disease and Cohort 2 will include healthy volunteers.
~A subset of twelve subjects (8 PD and 4 HC) will be enrolled in the [123I] IBVM and SPECT imaging portion of this study"
11611905|NCT00556738|Experimental|nHFPV|Intrapulmonary Percussive Ventilation
11611906|NCT00556738|Active Comparator|nCPAP|Nasal Continuous Positive Airway Pressure ventilation
11611907|NCT00556712|Experimental|Erlotinib|Participants received erlotinib, 150 milligrams (mg), orally (PO), daily from randomization until progressive disease (PD), death, or unacceptable toxicity.
11611908|NCT00556712|Placebo Comparator|Placebo|Participants received a placebo, PO, daily, from randomization until PD, death, or unacceptable toxicity.
11611909|NCT00556699|Experimental|1|
11611910|NCT00556686||1|Individuals with a history of canker sores.
11611911|NCT00556686||2|Individuals with no history of canker sores.
11611912|NCT00556673|Experimental|Indacaterol/mometasone - Placebo|In Treatment Period 1 (Day 1) participants received 2 inhalations of indacaterol maleate 250 μg / mometasone furoate 200 μg once a day in the morning via the Twisthaler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of placebo via the Twisthaler device once a day in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.
11611913|NCT00556673|Experimental|Placebo - indacaterol/mometasone|In Treatment Period 1 (Day 1) participants received 2 inhalations of placebo in the morning via the Twistheler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of indacaterol maleate 250 μg / mometasone furoate 200 μg via the Twisthaler device in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.
11611914|NCT00556660|Experimental|1|SPECT imaging
11611915|NCT00556647||A|Fast-track diagnosis
11611916|NCT00556634|Active Comparator|B|
11611917|NCT00556634|Experimental|A|
11611918|NCT00556621|Other|gemcitabine, cisplatine, radiotherapy|
11611919|NCT00556608|Experimental|Sinovial|3 intra-articular injections of Sinovial®
11611920|NCT00556608|Active Comparator|Sinvisc|
11611921|NCT00556595|Experimental|1|primary electrophysiological approach
11611922|NCT00556595|Active Comparator|2|primary anatomical approach
11611923|NCT00556569|Experimental|Intervention|2 Intervention schools are cluster randomized to receive CHAM JAM (previously known as the Moving Smart Program) in Year 1
11611924|NCT00556569|No Intervention|Wait-Listed Control|2 Wait-Listed Control Schools will receive CHAM JAM (previously known as the Moving Smart Program) in Year 2 of the study
11611925|NCT00556543|Other|Treatment|
11611926|NCT00556504|Experimental|TCM-700C|an add-on drug (2 tablets/t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
11611927|NCT00556504|Placebo Comparator|Placebo|placebo add on(2 tablets/t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
11611928|NCT00556491|Active Comparator|minocycline|
11611929|NCT00556491|Placebo Comparator|placebo|
11611930|NCT00556478|Active Comparator|Double-Blind Active|Double-blind Phase: Subjects will be randomised to PSD502 respectively if the patient meets all the entry criteria.
11611931|NCT00556478|Placebo Comparator|Double-Blind Placebo|Double-blind Phase: Subjects will be randomised to Placebo respectively if the patient meets all the entry criteria.
11611932|NCT00556478|Active Comparator|Open Label Phase|Subjects will all receive PSD502 if they wish to continue in the trial.
11611933|NCT00556465|Experimental|A, 1,III|in this arm patients took 1200 mg N-acetylcysteine
11611934|NCT00556465|No Intervention|B,2, III|
11611935|NCT00556452|Experimental|Clo/BU4|"Study will start at the 2nd dose level of three Clofarabine levels, in combination with Busulfan. The Clofarabine level that each subsequent patient is treated at is determined by a method using continual reassessment.
~After pre-conditioning, subjects will receive a peripheral blood stem cell transplant."
11611936|NCT00556439|Experimental|A and C|This is a randomized withdrawal design protocol. All participants will receive abatacept and prednisone (a glucocorticoid) for the first 3 months. Abatacept will be given intravenously on selected days. Prednisone will be started at a dose of 40 to 60mg, then tapered to 20mg by Month 3, and finally further tapered until discontinuation is reached. At Month 3, participants who have achieved remission will be randomly assigned under double-blind conditions to receive monthly infusions of either abatacept or placebo. Participants who are assigned to abatacept at this point will be in Group A for giant cell arteritis and Group C for Takayasu arteritis.
11611937|NCT00556439|Placebo Comparator|B and D|This is a randomized withdrawal design protocol. All participants will receive abatacept and prednisone (a glucocorticoid) for the first 3 months. Abatacept will be given intravenously on selected days. Prednisone will be started at a dose of 40 to 60mg, then tapered to 20mg by Month 3, and finally further tapered until discontinuation is reached. At Month 3, participants who have achieved remission will be randomly assigned under double-blind conditions to receive monthly infusions of either abatacept or placebo. Participants who are assigned to placebo at this point will be in Group B for giant cell arteritis and Group D for Takayasu arteritis.
11611938|NCT00556426|Experimental|Filter|All subjects enrolled to the study are in this arm. All subjects receive a filter.
11611939|NCT00556400|Active Comparator|Lo-ovral|1 tablet of lo-ovral is administered twice a day
11611940|NCT00556400|Placebo Comparator|sugar pill|Sugar pill was provided as a placebo
11611941|NCT00556387|Placebo Comparator|1|Placebo Group receiving Saline Infusion.
11611942|NCT00556387|Experimental|2|Case Group receiving Ketamine infusion.
11611943|NCT00556374|Experimental|Denosumab|Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
11611944|NCT00556374|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
11611945|NCT00556374|Experimental|SubStudy: Zoledronic Acid|Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive a single 5 mg intravenous dose of zoledronic acid 8 months after the last open-label dose of denosumab.
11611946|NCT00556374|Other|Substudy: Standard of Care|Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive standard of care 8 months after the last open-label dose of denosumab.
11611947|NCT00556361|Placebo Comparator|1|
11611948|NCT00556361|Experimental|2|
11611949|NCT00556348|Experimental|1|
11611950|NCT00556335|Experimental|manual aspiration|manual aspiration
11611951|NCT00556335|Active Comparator|conventional drainage|conventional drainage
11611952|NCT00556322|Experimental|1|
11611953|NCT00556322|Active Comparator|2|
11611954|NCT00556309||Diagnostic Tool|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
11611955|NCT00556296|Experimental|1|
11611956|NCT00556296|Experimental|2|
11611957|NCT00556296|Experimental|3|
11611958|NCT00556296|Placebo Comparator|4|
11611959|NCT00556283|Experimental|1|STARR
11611960|NCT00556283|Active Comparator|2|Biofeedback
11611961|NCT00556270||Matrix II|
11611962|NCT00556257|Active Comparator|Treatment Arm 1|Treatment Arm 1 will also receive standard of care medications.
11611963|NCT00556257|Experimental|Treatment Arm 2|Treatment Arm 2 will also receive select standard of care medications.
11611964|NCT00556244|Active Comparator|2|
11611965|NCT00556231||1|Children with congenital heart lesions - males/females, ages 6-20, scheduled for a regular stress test
11611966|NCT00556231||2|Children without congenital heart lesions - males/females, ages 6-20, scheduled for a regular stress test
11611967|NCT00556231||3|
11611968|NCT00556231||4|
11611969|NCT00556231||5|
11611970|NCT00556231||6|
11611971|NCT00556218|Other|Tibetan Meditation|
11611972|NCT00556218|Other|No Meditation|
11611973|NCT00556205|Active Comparator|1|Bevacizumab monotherapy 10 mg/kg IV q2 weeks
11611974|NCT00556205|Active Comparator|2|Combination Sunitinib & Bevacizumab Bevacizumab 10 mg/kg IV q2 weeks Sunitinib 50 mg PO QD on 4/2 schedule
11611975|NCT00556192|Active Comparator|1|Rituximab
11611976|NCT00556192|Active Comparator|2|Rituximab + Cyclophosphamide
11611977|NCT00556192|Active Comparator|3|Cyclophosphamide
11611978|NCT00556179|Experimental|1|
11611979|NCT00556166|Experimental|Enterra Therapy|The Enterra Therapy Gastric Stimulator will be used on subjects who have failed all other medical options to treat gastroparesis and all have a gastric stimulator implanted.
11611980|NCT00556153||Phase I|Children, ages 5-15 years with brain tumors
11611981|NCT00556140|Experimental|Major Depression with Psychotic Features|
11611982|NCT00556127|Experimental|1|
11611983|NCT00556114||Optical Coherence Tomography|Optical Coherence Tomography
11611984|NCT00556088|Experimental|Part 1|"Part I Phase I dose escalation trial. LBH589 will be administered orally on Monday and Thursday or Tuesday and Friday each week (twice weekly). Paclitaxel and carboplatin will be administered intravenously every 21 days.
~Part II LBH589, paclitaxel, and carboplatin dosing will be determined in the first phase of this study (Phase I). The drug dosages to be administered will be reduced one level from the determined Maximum Tolerated Dose (MTD). In addition, bevacizumab 15 mg/kg will be added to the second portion of this trial."
11611985|NCT00556075|Placebo Comparator|Placebo|Placebo once daily
11611986|NCT00556075|Experimental|25 mg|Proellex 25 mg once daily
11611987|NCT00556075|Experimental|50 mg|Proellex 50 mg once daily
11611988|NCT00556062|Experimental|1: Lot 1|
11611989|NCT00556062|Experimental|2: Lot 2|
11611990|NCT00556062|Experimental|3: Lot 3|
11611991|NCT00556062|Active Comparator|4: control vaccine|
11611992|NCT00556049|Experimental|1|Sunitinib and gemcitabine
11611993|NCT00556036||1|lean healthy women, age 18-45
11611994|NCT00556036||2|overweight healthy women, age 18-45
11611995|NCT00556036||3|women with hypothalamic amenorrhea (have not had a period in three months), age 18-45
11611996|NCT00556036||4|women with anorexia nervosa, age 18-45
11611997|NCT00556023|Experimental|CP-675,206 and gemcitabine|
11611998|NCT00555997|Active Comparator|1|Patients in group 1 will receive Ziprasidone for the full 12 weeks of the study.
11611999|NCT00555997|Active Comparator|2|Patients in Group 2 will receive placebo for the first 6 weeks of the study, then will receive Ziprasidone for the last 6 weeks.
11612000|NCT00555997|Placebo Comparator|3|Patients in Group 3 will receive placebo for the full 12 weeks of the study.
11612001|NCT00555984|Active Comparator|Total Intravenous anesthetic|Intravenous anesthetics (propofol + remifentanil) for maintenance of General Anesthesia
11612002|NCT00555984|Active Comparator|Volatile Anesthetic|Inhalational anesthetics (sevoflurane+remifentanil) for maintenance of General Anesthesia. Patients receive Sevoflurane as a volatile anesthetic and remifentanil as an IV agent for maintenance of general anesthesia.
11612003|NCT00555971|Placebo Comparator|Placebo Group|Subjects randomized to placebo
11612004|NCT00555971|Active Comparator|Omalizumab Group|Subjects randomized to omalizumab
11612005|NCT00555958|Experimental|A|All study subjects will be implanted with the Maestro System, and all will receive VBLOC therapy.
11612006|NCT00555945|Active Comparator|1|Gamma3 intramedullary nail
11612007|NCT00555945|Active Comparator|2|Sliding hip screw
11612008|NCT00555932|Active Comparator|1|The research head ultrasound (HUS) will be performed at the bedside in the Neonatal Unit. The ultrasound examination will be performed within 10 hours time window of the MR and or CT study.
11612009|NCT00555919|Experimental|Arm 1|
11612010|NCT00555919|Experimental|Arm 2|
11612012|NCT00555893|Experimental|Active Drug|"Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:
~for weight <=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)"
11612013|NCT00555893|Placebo Comparator|Placebo|Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: <=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
11612014|NCT00555880|Experimental|1|
11612015|NCT00555880|Placebo Comparator|2|
11612016|NCT00555867||1|Standard routine care for breast cancer
11612017|NCT00555867||2|Standard + Intervention arm: standard routine care for breast cancer and additional information material via post
11612018|NCT00555841|Experimental|ALC|I g three times daily
11612019|NCT00555841|Placebo Comparator|Placebo|1 g three times daily
11612020|NCT00555828|Experimental|A1|5 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection
11612021|NCT00555828|Other|A2|5 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
11612022|NCT00555828|Experimental|B1|5 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection
11612023|NCT00555828|Other|B2|3 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
11612024|NCT00555828|Experimental|C1|5 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection
11612025|NCT00555828|Other|C2|2 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
11612026|NCT00555815||1|Extended hygiene measures
11612027|NCT00555815||2|Standard hygiene measures
11612028|NCT00555789|Active Comparator|1|mycophenolic and tacrolimus
11612029|NCT00555789|Experimental|2|mycophenolic and tacrolimus
11612030|NCT00555776|Active Comparator|1|Randomly,half of the subjects are given Gabapentin.
11612031|NCT00555776|Placebo Comparator|2|Randomly,half of the subjects receive placebo.
11612032|NCT00555763|Active Comparator|1|
11612033|NCT00555750|Experimental|eszopiclone (3mg)|active medication (eszopiclone 3mg tablet) by mouth nightly 30 min before bed
11612034|NCT00555750|Placebo Comparator|placebo|identical placebo tablet by mouth nightly 30 min before bed
11612035|NCT00555724|Experimental|BIIB022|
11612036|NCT00555711||Modulated Imaging|Modulated Imaging
11612037|NCT00555698|Experimental|DBS|DBS
11612038|NCT00555685|Active Comparator|A|Group of patients that will receive hypertonic saline solution (NaCl 7,5%)
11612039|NCT00555685|Placebo Comparator|B|Group of patients that will receive placebo
11612040|NCT00555672|Experimental|A|
11612041|NCT00555646|Experimental|1|Each subject's study plaque areas will be assigned by the investigator to two PH-10 treatment plaque areas and one control plaque area.
11612042|NCT00555620|Experimental|A|
11612043|NCT00555620|Experimental|B|
11612044|NCT00555607|Active Comparator|steroid|Group receiving oral prednisolone (0.5 mg/kg bodyweight per day) during 14 days.
11612045|NCT00555607|Placebo Comparator|placebo|Group receiving placebo tablets during 14 days, followed by an open prednisolone treatment (0.5 mg/kg bodyweight per day) during a following 14 days.
11612046|NCT00555594|Active Comparator|A|Patients with corneal neovascularization of infectious etiology, steroid reactors, and know glaucoma or glaucoma suspects. They received one dose of 0.1cc of subconjunctival Bevacizumab (Avastin™ Genentech, Inc, USA) in bulbar conjunctiva, 2 mm from the limbus, according to the location of the vessels.
11612047|NCT00555594|Active Comparator|B|Patients with corneal neovascularization of any cause except for infectious disease. Patients of this group received one application of 0.1cc of subconjunctival Bevacizumab™ + 0.1cc of triamcinolone acetonide (ATLC; Grin laboratories, México city) in bulbar conjunctiva, 2 mm from de limbus, according to the location of the vessels.
11612048|NCT00555581|Experimental|400 mg daily of Imatinib Mesylate|All patients were treated with imatinib mesylate at a target dose of 400 mg daily by mouth for 12 months. Dose modifications and interruptions were made for AE and were recorded. After 12 months of treatment, imatinib was stopped for 3 months. Patients were reassessed and offered entrance to an extension phase of the trial.
11612049|NCT00555568|Experimental|Peer-led Groups|Arm 1 is a 3-month recovery-focused mental health education and support group led by peer facilitators
11612050|NCT00555568|Experimental|Clinician-led Groups|Arm 2 is a 3-month recovery-focused mental health education and support group led by a mental health clinician
11612051|NCT00555568|No Intervention|Treatment as Usual|Arm 3 is treatment as usual (no intervention)
11612052|NCT00555555|Experimental|Coagulation FVIII/VWF|Anti-Hemophilic/von Willebrand Factor VIII (Human) Alphanate SD/HT
11612053|NCT00555542|Experimental|1|Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15.
11612054|NCT00555529||1|
11612055|NCT00555529||2|
11612056|NCT00555516|Active Comparator|1|"The chemotherapy regimen of group 1 is restricted to AC or CAF during the first cycle
~Group 1 will receive EW02 for 15 consecutive days during the second cycle
~will receive EW02 at 700mg tid/day for 15 consecutive days during the third cycle."
11612057|NCT00555516|Placebo Comparator|2|"The chemotherapy regimen of group 2 is restricted to AC or CAF during the first cycle
~Group 2 will receive 15 consecutive days of Placebo
~Group 2 will receive EW02 at 700mg tid/day for 15 consecutive days during the third cycle"
11612058|NCT00555503||1|Patients who have risk-reduction mastectomy of any type, per protocol inclusion and exclusion criteria.
11612059|NCT00555490|Experimental|1|
11612060|NCT00555477|Experimental|anastrozole|
11612123|NCT00555074|Experimental|1|Sodium Tungstate
11612124|NCT00555074|Placebo Comparator|2|
11612125|NCT00555061|Experimental|Arm 1|Single Arm Retapamulin 1% Ointment
11612061|NCT00555464|Experimental|1|Vincristine is a drug that has been used to treat cancers in children (including infants). It has been effective in treating a small number of infants with hemangiomas, most of whom failed previous therapies including steroids. Vincristine must be administered into a vein. Given the encouraging response data and documented safety record, Vincristine is a good choice for a clinical trial treating infants with complicated hemangiomas.
11612062|NCT00555464|Active Comparator|2|The standard treatment for hemangioma at most centers is oral steroids (Prednisolone). Prednisolone has been used to stop the growth of infantile hemangiomas that are life threatening, that could harm important functions, or are likely to result in severe disfigurement (scarring) without treatment.
11612063|NCT00555438|Experimental|1|patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery
11612064|NCT00555425|Active Comparator|1|Buprenorphine/naloxone maintenance (Mtn) is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services.
11612065|NCT00555425|Experimental|2|Buprenorphine/naloxone detoxification (Dtx) is identical to Mtn for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Buprenorphine/naloxone.
11612066|NCT00555412|Experimental|A - 10 mg loxapine q 4 h x 3 (30 mg total)|
11612067|NCT00555412|Experimental|B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|
11612068|NCT00555412|Experimental|C - 5 mg loxapine q 4 h x 3 (15 mg total)|
11612069|NCT00555412|Placebo Comparator|D - inhaled placebo q 4 h x 3|
11612070|NCT00555399|Experimental|Ph I: Arm 1|Vorinostat plus isotretinoin
11612071|NCT00555399|Experimental|Ph I: Arm 2|Temozolomide plus isotretinoin
11612072|NCT00555399|Experimental|Ph I: Arm 3|Vorinostat plus isotretinoin plus temozolomide
11612073|NCT00555399|No Intervention|Ph II: Arm 1|Non-Surgical
11612074|NCT00555399|Other|Ph II: Arm 2|Surgical Arm
11612075|NCT00555386|Active Comparator|1|6g of chocolate (supplemented with selenium and isoflavones) per day for the duration of one menstrual cycle (25-35 days)
11612076|NCT00555386|Placebo Comparator|2|6g of chocolate (control) per day for the duration of one menstrual cycle (25-35 days)
11612077|NCT00555373|Other|Sirolimus|Single arm
11612078|NCT00555360|Experimental|Arm 1|Veterans with heart failure that can identify an out-of-home informal caregiver
11612079|NCT00555360|Active Comparator|Arm 2|Veterans with heart failure that can identify an out-of-home informal caregiver
11612080|NCT00555347|Active Comparator|Armnodafinil|Armodafinil
11612081|NCT00555347|Placebo Comparator|Placebo|
11612082|NCT00555334|Experimental|1|nucleoid antiviral therapy after RFA
11612083|NCT00555334|Active Comparator|2|RFA only
11612084|NCT00555321|Experimental|Group 1: Basiliximab+Belatacept (MI) + MMF|
11612085|NCT00555321|Experimental|Group 2: Belatacept (MI) + MMF|
11612086|NCT00555321|Experimental|Group 3: Belatacept Less Intensive (LI) + MMF|
11612087|NCT00555321|Other|Group 4: Tacrolimus + MMF|Other
11612088|NCT00555321|Active Comparator|Group 5: Tacrolimus|
11612089|NCT00555308|Experimental|one|undergo EDTU
11612090|NCT00555282|Experimental|1|coated central venous catheter
11612091|NCT00555282|Active Comparator|2|standard central venous catheter
11612092|NCT00555269||MB|
11612093|NCT00555269||IFCG|
11612094|NCT00555256|Experimental|1|Patients will be instructed to take sunitinib and rapamycin every morning for 4 weeks, then to take 2 weeks off. The sunitinib dose will be 25mg in the first cohort and the rapamycin dose will be 2 mg.
11612095|NCT00555243|Experimental|1|Laparoscopic Simulation Education
11612096|NCT00555243|Placebo Comparator|2|
11612097|NCT00555230|Experimental|1|Rosuvastatin
11612098|NCT00555230|Placebo Comparator|2|Placebo
11612099|NCT00555217|Experimental|Combination of ARB and ACEI|Combination of an angiotensin converting enzyme inhibitor (ACEI) with an angiotensin receptor blocker (ARB)
11612100|NCT00555217|Active Comparator|Monotherapy ARB|Mono therapy arm. Standard treatment with angiotensin receptor blocker (ARB)
11612101|NCT00555204|Experimental|A|
11612102|NCT00555204|Experimental|B|
11612103|NCT00555204|Experimental|C|
11612104|NCT00555204|Experimental|D|
11612105|NCT00555204|Experimental|E|
11612106|NCT00555204|Experimental|F|
11612107|NCT00555204|Placebo Comparator|G|
11612108|NCT00555191|Active Comparator|1|PATIENTS IN THIS ARM IS INSTRUCTED IN FRUCTOSE REDUCED DIET FOR A PERIOD OF 3 MONTHS
11612109|NCT00555191|No Intervention|2|these patients use their usual diet
11612110|NCT00555178||1|Patients with polymorphic light eruption without medical photohardening treatment
11612111|NCT00555178||2|Patients with polymorphic light eruption treated with medical photohardening
11612112|NCT00555178||3|Patients with other disorders (including psoriasis) treated with phototherapy
11612113|NCT00555178||4|Normal healthy subjects
11612114|NCT00555165|Experimental|I|
11612115|NCT00555152|Experimental|Arm I (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO once QD for 2-6 weeks until the time of surgery.
11612116|NCT00555152|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 2-6 weeks until the time of surgery.
11612117|NCT00555139|Experimental|GW876008|The subjects will be randomized to one of the six sequences A/B/D A/D/B B/A/D B/D/A D/A/B D/B/A across three treatment periods where A represents placebo, B represents GW876008 and D represents alprazolam.
11612118|NCT00555139|Experimental|GSK561679|The subjects will be randomized to one of the six sequences A/C/D A/D/C C/A/D C/D/A D/A/C D/C/A across three treatment periods where A represents placebo, C represents GSK561679 and D represents alprazolam.
11612119|NCT00555126|Active Comparator|Warming with Forced Air|Forced Air Warming
11612120|NCT00555126|Experimental|Endovascular Warming|Warming with Endovascular Catheter
11612121|NCT00555113||1|pseudoxanthoma elasticum
11612122|NCT00555087|Experimental|A= Nebido|It is and intervention study with 1 arm
11612126|NCT00555048|Experimental|Alemtuzumab|Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant.
11612127|NCT00555022|Experimental|All subjects|Eligible subjects will receive one of the following treatment in cohort I and cohort II in five different treatment periods; Placebo, GSK1160724 (10 micrograms, 50 micrograms or 125 micrograms) and tiotropium bromide
11612128|NCT00555009|Experimental|Genotropin treatment arm|
11612129|NCT00555009|Placebo Comparator|Placebo|
11612130|NCT00554996|Other|E. coli 83972 coated urinary catheter|E. coli 83972 coated urinary catheter
11612131|NCT00554983|Placebo Comparator|2|
11612132|NCT00554983|Experimental|1|
11612133|NCT00554970|Other|Treatment 1 then Treatment 2|Subjects received Treatment 1 in period 1 followed by a 7 day washout period and then Treatment 2 in period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.
11612134|NCT00554970|Other|Treatment 2 then Treatment 1|Subjects received Treatment 2 in period 1 followed by a 7 day washout period and then Treatment 1 period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.
11612135|NCT00554970|Other|Treatment 3 then Treatment 4|Subjects received Treatment 3 in period 1 followed by a 7 day washout period and then Treatment 4 period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.
11612136|NCT00554970|Other|Treatment 4 then Treatment 3|Subjects received Treatment 4 in period 1 followed by a 7 day washout period and then Treatment 3 in period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.
11612137|NCT00554957||NBC|All dancers with the National Ballet of Canada will be given the opportunity to participate in the study.
11612138|NCT00554957||TDT|All dancers with the Toronto Dance Theatre will be given the opportunity to participate.
11612139|NCT00554957||KDC|All members of the Kibbutz Contemporary Dance company will be given the opportunity to participate.
11612140|NCT00554957||BDC|All dancers with the Batsheva Dance Company or Ensemble will be given the opportunity to participate.
11612141|NCT00554957||RSB|All dancers with the Royal Swedish Ballet will be given the opportunity to participate.
11612142|NCT00554957||RDB|All dancers with the Royal Danish Ballet will be given the opportunity to participate.
11612143|NCT00554905|Experimental|1|TACE first, then RFA within 2 weeks
11612144|NCT00554905|Active Comparator|2|RFA alone
11612145|NCT00554892|Active Comparator|1|Bowel preparation
11612146|NCT00554892|Experimental|2|without bowel preparation
11612147|NCT00554879|Experimental|1|Acupuncture
11612148|NCT00554879|Sham Comparator|2|Sham Acupuncture
11612149|NCT00554866|Experimental|VLBW between 6 and12 hours after birth|"Blood sample and buccal swab sample. One blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.
~Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab."
11612150|NCT00554853|Other|Pioglitazone then placebo|Oral daily pioglitazone 30 mg tablets daily for 2 weeks, followed by 45 mg daily tablets until end of study for 3 months compared to placebo in tablets of equal presentation for 3 months, then crossover after a 2 month washout.
11612151|NCT00554853|Other|placebo then study drug (pioglitazone)|Oral daily placebo for 3 months compared to pioglitazone for 3 months, then crossover after a 2 month washout. Similar doses as mentioned above.
11612152|NCT00554840|Active Comparator|varenicline|
11612153|NCT00554840|Placebo Comparator|placebo|
11612154|NCT00554827|Experimental|Pralatrexate Injection (FOLOTYN,PDX,Pralatrexate(R|"Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
~Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or 4 weeks (depending on cohort), with 1 week of rest."
11612155|NCT00554814|Experimental|3|Blédilait Biofer® milk (1,1mg/100kcal)
11612156|NCT00554814|Experimental|1|Blédilait Biofer® milk (2mg/100kcal)
11612157|NCT00554814|Active Comparator|2|Milk supplemented with ferrous sulphate (2mg/100kcal)
11612158|NCT00554801|Experimental|Blast|The study group includes soldiers who have recently been exposed to a high-explosive blast while stationed in Iraq or Afghanistan. They will be recruited at Walter Reed Army Medical Center, Washington, DC. They will undergo audiological testing.
11612159|NCT00554801|Active Comparator|Control|Control group are subjects matched to the experimental group by age, gender, and hearing loss, but who have not been exposed to a blast. They will undergo the same audiological testing as the experimental group
11612160|NCT00554788|Experimental|Treatment (chemotherapy, radiotherapy, autologous SCI)|"INDUCTION: Patients receive vincristine IV; cisplatin IV; cyclophosphamide IV; and G-CSF SC beginning on day 3 and continuing until blood counts recover.
~CONSOLIDATION (stage 4a or 4b disease only): Patients receive carboplatin IV; thiotepa IV; and etoposide IV.
~AUTOLOGOUS STEM CELL INFUSION (stage 4a or 4b disease only): Patients undergo autologous stem cell infusion on day 0 and receive G-CSF SC beginning on day 1 and continuing until blood counts recover.
~RADIOTHERAPY: Patients with stage 2 or 3 disease (orbital and/or regional involvement) undergo radiotherapy to sites that were initially involved beginning within 42 days after the start of course 4 of induction chemotherapy. Patients with stage 4a or 4b disease undergo radiotherapy to sites initially involved based on response beginning approximately 42 days after autologous stem cell infusion."
11612161|NCT00554775|Experimental|erlotinib hydrochloride|WBRT plus Tarceva (OSI-774, erlotinib) PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
11612162|NCT00554775|Placebo Comparator|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride arm
11612163|NCT00554749|Other|1 Behavioral intervention|Behavioral intervention in all seven subjects Weekly sessions in the home and the kindergarten using defocused communication and stimulus fading interventions
11625736|NCT00422383|Experimental|3|
11612164|NCT00554736|Experimental|1|In the first phase, subjects with a history of grass pollinosis, with positive skin tests to grass, will be studied out of season and will be randomized to active treatment for 4 months.
11612165|NCT00554723|Experimental|A|NeuroAid
11612166|NCT00554723|Placebo Comparator|B|NeuroAid matched Placebo
11612167|NCT00554710|Experimental|1|Patients received three infusions of infliximab 5 milligrams per kilogram (weeks 0, 2 and 6) in combination with azathioprine 2-2.5 milligrams per kilogram per day from day 0 onwards. If the patients responded and tolerated both drugs, azathioprine was continued for the duration of the trial. Patients who were intolerant to azathioprine received methotrexate at an initial dose of 25 milligrams administered subcutaneously each week for 12 weeks with dose reduction to 15 milligrams per week thereafter. Following initial therapy, patients who developed worsening symptoms were retreated with additional infusions of infliximab. If symptoms persisted methylprednisolone was initiated and azathioprine or methotrexate was continued.
11612168|NCT00554710|Active Comparator|2|Induction with methylprednisolone (MP) or budesonide (BUD): MP 32 mg/day for 3 weeks was followed by tapering by 4 mg per week to 0; BUD 9 mg per day for 8 weeks with tapering to 0 by 3 mg per week thereafter.Patients who worsened during the tapering had the dose increased to the initial dose and tapered again. If patients worsened, azathioprine (2-2.5 mg per day) was introduced. Patients who relapsed following withdrawal of steroids received a second course in combination with azathioprine. For patients who failed 4 weeks of steroids, MP dose was given at 64 mg/day for 2 weeks, tapered by 8 mg per week; azathioprine was added. Patients who remained symptomatic despite 16 weeks of azathioprine received infliximab (5 mg/kg IV at weeks 0, 2 and 6). Patients who relapsed despite methotrexate or those intolerant to both azathioprine and methotrexate also received infliximab, without antimetabolite therapy. Infliximab was repeated upon relapse of symptoms in these patients.
11612169|NCT00554697||1|
11612170|NCT00554697||2|
11612171|NCT00554671|Experimental|Pharmacist-led Group Visits|Algorithm driven medication titration, Behavioral: Monitoring, Behavioral: Group support, Behavioral: Self efficacy
11612172|NCT00554671|No Intervention|Usual Care|Patient continues on usual care for diabetes
11612173|NCT00554658|Active Comparator|A|Patients will be taken quetiapine for the treatment of first episode schizophrenia.
11612174|NCT00554645|Experimental|1|Multi-disciplinary group intervention
11612175|NCT00554645|Active Comparator|2|traditional information
11612176|NCT00554632|Active Comparator|1|Use of transdermal hormonal contraceptive
11612177|NCT00554632|Active Comparator|2|Use of oral hormonal contraceptive
11612178|NCT00554619|Experimental|GSK1325760A|
11612179|NCT00554606|Experimental|1|ACZ885
11612180|NCT00554580|Active Comparator|A|Usual care of pulmonary acute oedema
11612181|NCT00554580|Experimental|B|CPAP + usual care of pulmonary acute oedema
11612182|NCT00554567|Experimental|Intervention Arm|Fully Decentralized HIV Testing and Care Services
11612183|NCT00554541||Normal Body-Mass|BMI Index: 18.5-24.9 Ankle Brachial Index Venous physiologic study
11612184|NCT00554541||Obese Body-Mass|BMI Index: 30.0-39.9 Ankle Brachial Index Venous physiologic study
11612185|NCT00554541||Morbidly Obese Body-Mass|BMI Index: ≥ 40 Ankle Brachial Index Venous physiologic study
11612186|NCT00554528|Other|A|patient receiving cervical disc prosthesis with a mobile insert named Mobi-C and product by LDR médical
11612187|NCT00554528|Other|B|patient receiving intersomatic cage
11612188|NCT00554515|Experimental|HD IL2|Participants received high-dose (HD) IL2, 600,000 IU/kg/dose (Prometheus Laboratories Inc.) i.v. every 8 hours for 5 days (maximum of 14 doses) beginning on day 1 and again on day 15. One course generally consisted of 5 days of treatment, 9 days of rest, 5 more days of treatment, and 9 weeks of rest, followed by up to two additional courses of HD IL2 for patients who benefited and tolerated most of the planned IL2 doses. A treatment delay of up to 4 weeks was allowed for resolution of side effects between courses. Patients were eligible to receive a maximum of three courses of treatment.
11612189|NCT00554502|Active Comparator|A|
11612190|NCT00554502|Active Comparator|B|
11612191|NCT00554463|Experimental|Combined Modality Therapy with Growth Factor Support|Concurrent radiation therapy, cisplatin, etoposide, and filgrastim followed by adjuvant cisplatin, etoposide, and pegfilgrastim.
11612192|NCT00554450|Experimental|Arm 1|50 mg single dose
11612193|NCT00554450|Experimental|Arm 2|20 mg up to 7 days
11612194|NCT00554437|Experimental|1|Intermediate-intensity, community-based, multifactorial falls intervention
11612195|NCT00554437|Active Comparator|2|Occupational therapist home safety evaluation
11612196|NCT00554424|Active Comparator|LA|Intravaginal and pre-peritoneal injection of 1% lignocaine into each side of the upper vagina under ultrasound guidance immediately prior to ultrasound guided transvaginal oocyte retrieval
11612197|NCT00554424|Placebo Comparator|P|Intravaginal saline placebo injection into each side of upper vagina under ultrasound guidance immediately prior to transvaginal oocyte retrieval
11612198|NCT00554398|Experimental|A|MK-0518 400mg twice a day
11612199|NCT00554398|No Intervention|B|No intervention
11612200|NCT00554385|Experimental|1|
11612201|NCT00554372|Experimental|Low Dose|1e8 pfu (plaque forming units) total dose of JX-594 (recombinant vaccinia virus) on each of three (3) treatment days (2 weeks apart)
11612202|NCT00554372|Experimental|High Dose|1e9 pfu (plaque-forming units) total dose of JX-594 (recombinant vaccinia virus) on each of three (3) treatment days (2 weeks apart)
11612203|NCT00554359|Experimental|I5NP drug|
11612204|NCT00554359|Placebo Comparator|Placebo|
11612205|NCT00554346|Active Comparator|1|Etoricoxib 90mg
11612206|NCT00554346|Placebo Comparator|2|placebo
11612207|NCT00554333|Experimental|1|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
11612208|NCT00554333|Active Comparator|2|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
11612209|NCT00554320|Active Comparator|A|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most [or predominant] painful side [or the side where the symptoms begin or the left as a default]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
11612404|NCT00552721|Active Comparator|B|Physical therapy without strength training.
11625802|NCT00421824|Experimental|B|
11612210|NCT00554320|Placebo Comparator|C|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
11612211|NCT00554307||Indo|Infants that are treated with indomethacin
11612212|NCT00554307||Neo|Infants treated with neoprofen
11612213|NCT00554307||Control|Infants without PDA
11612214|NCT00554294|No Intervention|Control group|Control schools had school curriculum as usual and did not receive environmental intervention.
11612215|NCT00554294|Experimental|Intervention group|Intervention schools received water dispensers, drinking bottles and lessons as intervention.
11612216|NCT00554281|No Intervention|A|Run in period
11612217|NCT00554281|Experimental|B|
11612218|NCT00554268|Experimental|PBI-05204|PBI-05204 starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle.
11612219|NCT00554229|Experimental|ZD4054|ZD4054 10 mg oral tablet once daily
11612220|NCT00554229|Placebo Comparator|Placebo|Matching Placebo, oral tablets once daily
11612221|NCT00554216|Experimental|VI-0521 Low|VI-0521; low dose phentermine/topiramate (PHEN/TPM 3.75 mg/23 mg)
11612222|NCT00554216|Experimental|VI-0521 Top|Top Dose VI-0521 consisting of 15 mg of Phentermine and 92 mg of Topiramate.
11612223|NCT00554216|Placebo Comparator|Placebo|Placebo to match
11612224|NCT00554190|Experimental|1|AdvaCoat compared to Merogel Injectable Bioresorbable Nasal Dressing
11612225|NCT00554190|Active Comparator|2|Merogel Injectable Bioresorbable Nasal Dressing compared to AdvaCoat
11612226|NCT00554177|Experimental|1|Medicane (mifepristone)
11612227|NCT00554177|Placebo Comparator|2|Placebo
11612228|NCT00554164|Active Comparator|B1|Six cycles of the (R-)CHOP regimen.
11612229|NCT00554164|Experimental|B2|Six blocks of the B-ALL protocol.
11612230|NCT00554164|Active Comparator|A1|Four cycles of the (R-)CHOP regimen.
11612231|NCT00554164|Active Comparator|A2|Four cycles of the (R-)CHOP regimen plus two additional doses rituximab.
11612232|NCT00554138|Placebo Comparator|1|
11612233|NCT00554138|Experimental|2|
11612234|NCT00554125|Active Comparator|2, III ,intervention|
11612235|NCT00554112|Active Comparator|1|Exercise
11612236|NCT00554112|Active Comparator|2|Exercise
11612237|NCT00554112|No Intervention|3|Control
11612238|NCT00554099|Placebo Comparator|Placebo|Days 1 thru Days 10 to 14 (Visit 2): daily antibiotic therapy, dietary advice, and 6 placebo tablets (matching mesalamine) once a day. Visit 2 thru Week 12 : 1 placebo capsule (matching probiotic) and 6 placebo tablets (matching mesalamine) daily.
11612239|NCT00554099|Active Comparator|Mesalamine|Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once a day. Visit 2 thru Week 12: 1 placebo capsule (matching probiotic) and 6 - 400 mg mesalamine tablets daily.
11612240|NCT00554099|Active Comparator|Mesalamine & Probiotic|Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once daily. Visit 2 thru Week 12: 1- Bifidobacterium infantis 35624 capsule and 6 - 400 mg mesalamine tablets daily
11612241|NCT00554047|Experimental|1|Multidisciplinary Memory Clinic
11612242|NCT00554047|Active Comparator|2|General practitioner
11612243|NCT00554021||1|Department of Traumatology and Critical Care Medicine, National Defense Medical College
11612244|NCT00554008|Active Comparator|1|children randomized to open appendectomy
11612245|NCT00554008|Active Comparator|2|children randomized to laparoscopic appendectomy
11612246|NCT00553995|Experimental|Salsalate|Salsalate
11612247|NCT00553995|Placebo Comparator|Placebo|Placebo
11612248|NCT00553982|Experimental|1|Patellar resurfacing
11612249|NCT00553982|Active Comparator|2|Patellar retention
11612250|NCT00553969|Experimental|1|Coreg CR + lisinopril
11612251|NCT00553969|Experimental|2|Coreg CR + placebo
11612252|NCT00553969|Experimental|3|lisinopril + placebo
11612253|NCT00553969|Placebo Comparator|4|placebo + placebo
11612254|NCT00553956|Experimental|1|Intervention group A treatment combination of Narrative Exposure Therapy and Interpersonal Psychotherapy (5 individual sessions NET in addition to 3 individual sessions IPT)
11612255|NCT00553956|No Intervention|2|Waiting list control
11612256|NCT00553943|Experimental|Rituximab + Cytarabine|
11612257|NCT00553930|Experimental|G 2/3|Patients with chronic hepatitis or compensated cirrhosis by hepatitis C virus, genotypes 2 or 3, and HIV-coinfected.
11612258|NCT00553917||1|Pregnant women currently taking Prozac for the treatment of depression
11612259|NCT00553917||2|Pregnant women currently taking Zoloft for the treatment of depression
11612260|NCT00553917||3|Pregnant women not currently using medication for the treatment of depression
11612261|NCT00553917||4|Pregnant women with no history of, symptoms of, or treatment for depression
11612262|NCT00553891|Experimental|Nasonex Nasal Spray|
11612263|NCT00553891|Placebo Comparator|Placebo Nasal Spray|
11612264|NCT00553878|Placebo Comparator|dutasteride|
11612265|NCT00553865|Experimental|Group 1|OJP-2028 1mg/day
11612266|NCT00553865|Experimental|Group 2|OJP-2028 2mg/day
11612267|NCT00553865|Experimental|Group 3|OJP-2028 4mg/day
11612268|NCT00553865|Placebo Comparator|Group 4|Placebo
11612269|NCT00553865|Other|Group 5|Reference drug
11612270|NCT00553852|Experimental|1|The clinical examination will determine anthropometric indexes (weight, height, BMI, waist circumference). The biochemical evaluation will include the measurement of lipid profile, fasting plasma glucose and insulin, liver test function, FT3, FT4, GHRH + Arginine test to detect GHD, plasma IGF-I levels. The instrumental evaluation will include DEXA Total Body and bioimpedance analysis to determine body composition, and liver ultrasounds.
11612271|NCT00553852|Placebo Comparator|2|PHASE II: In the medical treatment protocol very severe obese patients with persistent GHD after LASGB will be inclosed. Starting from 15-day, GHD patients were re-evaluated by GHRH + Arginine test. After evaluation, the patients with persistent GHD will be randomized to be treated with Recombinant GH replacement therapy (Group A: Recombinant GH replacement therapy at the initial dose 0.15-0.30 mg/die; dose adjustment will be made according to IGF-I levels; Group B: no GH treatment).
11612272|NCT00553839|Other|Ketamine|Then a 2 mg/kg IV bolus of Ketamine hydrochloride will be given as part of general anesthesia for procedure
11612273|NCT00553800|Experimental|Bevacizumab & Erlotinib|bevacizumab 15 mg/kg intravenous every three weeks and erlotinib pill 150 mg by mouth every day
11612274|NCT00553787|Experimental|VI-0521 Top|high dose experimental treatment
11612275|NCT00553787|Experimental|VI-0521 Mid|mid dose experimental treatment
11612276|NCT00553787|Placebo Comparator|Placebo|Placebo
11612277|NCT00553774|Experimental|Flavanol|Cocoa Flavanol
11612278|NCT00553774|Placebo Comparator|Placebo|
11612279|NCT00553748|Experimental|I|
11612280|NCT00553735|Active Comparator|Cyclosporine A 0.05%|"If patients pass the screening criteria, both eyes are randomized to therapy. One eye will receive Cyclosporine A 0.05% (Restasis) and the other eye will receive Placebo (Artificial Tear)
~The objective signs will be corneal and conjunctival staining, Schirmer test (with and without anesthesia), and tear break-up time. The subjective endpoints will be the SANDE symptom global score."
11612281|NCT00553735|Placebo Comparator|Artificial Tear|"If patients pass the screening criteria, both eyes are randomized to therapy. One eye will receive Cyclosporine A 0.05% (Restasis) and the other eye will receive Placebo (Artificial Tear)
~The objective signs will be corneal and conjunctival staining, Schirmer test (with and without anesthesia), and tear break-up time. The subjective endpoints will be the SANDE symptom global score."
11612282|NCT00553722|Experimental|Eplerenone|Administer Eplerenone, 25 mg, orally twice daily for 4 weeks.
11612283|NCT00553722|Placebo Comparator|placebo|Administer a placebo tablet orally twice daily for 4 weeks
11612284|NCT00553709|Experimental|Nicotine patch|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
11612285|NCT00553709|Placebo Comparator|Placebo patch|Placebo patch 10 cm2
11612286|NCT00553696|Experimental|A|
11612287|NCT00553683|Experimental|poly ICLC|
11612288|NCT00553670||1|Patients with elective coronary intervention for LAD-diagonal bifurcation lesion with provisional side branch intervention strategy with successful intravascular ultrasound and fractional flow reserve measurement
11612289|NCT00553644|Experimental|Treatment (bortezomib, lenalidomide)|Patients receive induction therapy comprising bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete or partial response as best response after completion of induction therapy receive maintenance therapy comprising bortezomib IV on days 1 and 8 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 6 years in the absence of disease progression or unacceptable toxicity.
11612290|NCT00553631|Experimental|GA-GCB|VPRIV™ ,velaglucerase alfa
11612291|NCT00553631|Active Comparator|imiglucerase|
11612292|NCT00553618|Experimental|Proleukin/DTIC Arm|Adjucant proleukin and DTIC
11612293|NCT00553605|Active Comparator|I|Ketoprofen plus placebo parecoxib
11612294|NCT00553605|Active Comparator|II|Parecoxib plus placebo ketoprofen
11612295|NCT00553592|Experimental|Drug|Bicifadine
11612296|NCT00553592|Experimental|Drug: 2|Bicifadine
11612297|NCT00553592|Placebo Comparator|Control|Placebo of Bicifadine
11612298|NCT00553579||DE|All subjects will have clinically significant dry eye.
11612299|NCT00553553|Active Comparator|1|IV morphine group
11612300|NCT00553553|Experimental|2|Remifentanil-intrathecal morphine group
11612301|NCT00553540|No Intervention|Control Group|Patients in this group will receive physical therapy and posture education for low back pain
11612302|NCT00553540|Active Comparator|Test Group|Patients in this group will receive spinal / back supports in addition to physical therapy and posture education for low back pain
11612303|NCT00553527|Other|1|Patient will receive standard of care humeral stem replacement. Only a data collection study. There will be no changes in standard of care for diagnosis.
11612304|NCT00553514|Experimental|AS900672-Enriched 10 mcg|
11612305|NCT00553514|Experimental|AS900672-Enriched 20 mcg|
11612306|NCT00553514|Experimental|AS900672-Enriched 30 mcg|
11612307|NCT00553514|Experimental|AS900672-Enriched 40 mcg|
11612308|NCT00553514|Active Comparator|Follitropin alfa 75 IU|
11612309|NCT00553501|Experimental|Epratuzumab Plus Rituximab|"Induction Therapy (Month 1): Epratuzumab 360 mg/m^2 by IV days 1, 8, 15 & 22; Rituximab 375 mg/m^2 by IV day 3, 8, 15 & 22
~Extended Induction (Weeks 12, 20, 28 & 36) Epratuzumab 360 mg/m^2 by IV weeks 12, 20, 28 & 36; Rituximab 375 mg/m^2 by IV weeks 12, 20, 28 & 36"
11612310|NCT00553488|Active Comparator|1|Regular insulin SC at -17 mins
11612311|NCT00553488|Active Comparator|2|Regular insulin ID at -17 mins
11612312|NCT00553488|Active Comparator|3|Regular insulin ID at -2 mins
11612313|NCT00553488|Active Comparator|4|Insulin lispro given SC at -2 mins
11612314|NCT00553488|Experimental|5|Insulin lispro given ID at -2 mins
11612315|NCT00553475|Placebo Comparator|Placebo|
11612316|NCT00553475|Experimental|Pregabalin 300 mg/day|
11612317|NCT00553475|Experimental|Pregabalin 600 mg/day|
11612318|NCT00553462|Experimental|paclitaxel + carboplatin + radiation + erlotinib|"Patients receive paclitaxel IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses. Patient with rapid disease progression outside of the chest after induction therapy are removed from study.
~Patients with intrathoracic disease progression within the potential radiation field may continue protocol therapy at the discretion of the Study Chair. Patients with no disease progression outside the planned radiation field (either regional or distant) proceed to concurrent erlotinib hydrochloride and radiotherapy.
~Beginning on day 43 (week 7), patients receive oral erlotinib hydrochloride once daily. Patients also undergo concurrent radiotherapy 5 days a week for up to 7 weeks (33 fractions) in the absence of rapid disease progression outside of the chest or unacceptable toxicity.
~After completion of study therapy, patients are followed every 3 months for 1 year, and then every 6 months for up to 2 years"
11612319|NCT00553436|Experimental|Enrolled Subjects treated with TAS device|All enrolled subjects treated with the Tissue Apposition System (TAS) device
11612320|NCT00553423|Experimental|1|Lactulose 30 ml q6h for 48 hrs
11612321|NCT00553423|Placebo Comparator|2|Placebo 30 ml q6 hrly for 48hrs
11612322|NCT00553410|Active Comparator|Continuous letrozole|Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)
11626778|NCT00411229|No Intervention|2|
11612323|NCT00553410|Experimental|Intermittent letrozole|Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months
11612324|NCT00553397||Live Lung Donors|Participants had a living donor lobectomy at one of the two participating study centers, the University of Southern California and the Washington University Medical Center between 1993 and 2006.
11612325|NCT00553358|Experimental|Arm 1 Lapatinib|1500 mg lapatinib for 6 weeks followed by lapatinib plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib.
11612326|NCT00553358|Active Comparator|Arm 2 Trastuzumab|4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks followed by 2 mg/kg trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
11612327|NCT00553358|Experimental|Arm 3 Lapatinib plus Trastuzumab|1000 mg lapatinib plus 4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks, followed by 750 mg lapatinib plus 2 mg/kg IV weekly trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib (1000 mg) in combination with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
11612328|NCT00553332|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11612329|NCT00553319|Placebo Comparator|Placebo|Placebo
11612330|NCT00553319|Experimental|Adderall-XR 60 mg|Adderall-XR 60 mg
11612331|NCT00553319|Experimental|Adderall-XR 80 mg|Adderall-XR 80 mg
11612332|NCT00553306|Experimental|Arm I|Beginning 48 hours before T-cell infusion, patients receive cyclophosphamide IV. Patients then receive antigen-specific CD8+ T cells IV alone or with CD4+ T helper clones over 1-2 hours on day 0. Patients also receive aldesleukin subcutaneously twice daily on days 0-13. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11612333|NCT00553293|Active Comparator|A,1|rFSH + rLH arm
11612334|NCT00553293|Placebo Comparator|A,2|rFSH alone
11612335|NCT00553280|Experimental|pregabalin|
11612336|NCT00553254|Experimental|1|
11612337|NCT00553241||1|"Dept. of Neurology, Beijing Anzhen Hospital, Capital Medical University Beijing 100029, P.R.China
~Every patient admitted to Beijing anzhen hospital with transient ischemic attack will be enrolled in this study, from 06/2007 to 12/2008. duration of the symptom not larger than 1 hour."
11612338|NCT00553228|Experimental|group I|Tdap
11612339|NCT00553228|Active Comparator|group 2|Td
11612340|NCT00553202|Experimental|Treatment (chemotherapy and allogeneic SCT)|"Patients receive busulfan IV every 6 hours on days -9 to -6, high-dose cyclophosphamide IV over 1 hour on days -5 to -2, anti-thymocyte globulin IV once or twice daily over 4 hours on days -3 to -1, and methylprednisolone IV on days -3 to -1.
~Patients undergo allogeneic hematopoietic stem cell transplantation (SCT) or allogeneic bone marrow transplantation (BMT) on day 0.
~Patients receive cyclosporine or tacrolimus IV or orally beginning on day -2 and continuing until day 50, followed by a taper until week 24. Patients also receive methotrexate IV on days 1, 3, 6, and 11.
~Blood samples will be collected periodically from both patients and donors for studies of natural killer cells in support of the pharmacological study objectives"
11612341|NCT00553176||Patients with Crohn's disease|The Registry is an observational research program featuring clinical, economic, and humanistic measures characterizing the treatment of Crohn's disease
11612342|NCT00553163|Active Comparator|Gut-focussed hypnotherapy (GFH).|Gut-focussed hypnotherapy (GFH).
11612343|NCT00553163|Sham Comparator|Educational sessions|Regular sessions to learn about UC from research nurse
11612344|NCT00553150|Experimental|Everolimus (RAD001), Radiation (RT), Temozolomide (TMZ)|"Patients receive oral everolimus and oral temozolomide and 3D-conformal radiotherapy or IMRT as in phase I. Patients will undergo a 4-6 week rest period in course 2 and then proceed to adjuvant therapy.
~Adjuvant therapy with everolimus and temozolomide (courses 3-8): Patients receive oral everolimus and oral temozolomide as in phase I.
~Adjuvant therapy with everolimus alone (courses 9 and all subsequent courses): Patients receive oral everolimus as in phase I.
~All patients undergo fludeoxyglucose (FDG)- or fluorothymidine-labeled PET/CT scans at baseline and periodically during treatment."
11612345|NCT00553137|Active Comparator|1|single dose fluconazole (750 mg) and placebos 150 mg tablets once daily for 14 days
11612346|NCT00553137|Active Comparator|2|150 mg fluconazole once daily for 14 days and placebos (5 placebos tablets) 750 mg once
11612347|NCT00553111|Experimental|1|pre survey, intervention, post test survey
11612348|NCT00553111|No Intervention|2|pre test survey and post test survey
11612349|NCT00553111|Experimental|3|video intervention and post test survey
11612350|NCT00553111|No Intervention|4|post test survey
11612351|NCT00553098|Experimental|Treatment (chemotherapy, low dose radiation)|"CONDITIONING REGIMEN: *Patients with no life-threatening viral or fungal infections within 1 month before the planned HCT receive alemtuzumab IV over 6 hours on day -10 and fludarabine phosphate IV over 30 minutes on days -4 to -2. They also undergo low-dose TBI on day 0. Patients with HLH, IPEX syndrome, DiGeorge syndrome, or life-threatening viral or fungal infections within 1 month before the planned HCT receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo 2 low doses of TBI on day 0.
~HEMATOPOIETIC CELL TRANSPLANTATION: Patients undergo HCT on day 0.
~IMMUNOSUPPRESSION: Patients receive cyclosporine IV or PO 2-3 times daily beginning on day -3 and continuing until day 100 followed by a taper until day 180. They also receive mycophenolate mofetil IV or PO 3 times daily beginning on day 0 and continuing until day 40 followed by a taper until day 96."
11612352|NCT00553085||Anx group|
11612353|NCT00553085||ADHD group|
11612354|NCT00553085||Nonanx/nonadhd group|
11612355|NCT00553072|Active Comparator|Magnesium sulphate, neurological outcome|Magnesium sulphate 250mg/kg after every 24 hours starting within 6 hours from birth
11612356|NCT00553072|Placebo Comparator|Placebo|Placebo every 24 hours for 3 doses starting from 6 hours after birth
11612357|NCT00553059|Experimental|Arm I: Palonosetron, Dexamethasone + Dronabinol|Palonosetron hydrochloride intravenous (IV) and dexamethasone IV 30 minutes before chemotherapy administration on day 1, and oral dronabinol 3 times a day for 5 days beginning 30 minutes before chemotherapy administration on day 1.
11612358|NCT00553059|Active Comparator|Arm II: Palonosetron + Dexamethasone|Palonosetron hydrochloride and dexamethasone as in arm I, and oral placebo 3 times a day for 5 days beginning 30 minutes before chemotherapy on day 1.
11612359|NCT00553046||family burden|chronich respiratory failure home ventilated patients
11612360|NCT00553033||A|
11612361|NCT00552994|Active Comparator|1|Cypher Select plus stent
11612362|NCT00552994|Active Comparator|2|Xience V stent
11612363|NCT00552981|Active Comparator|1|
11612364|NCT00552981|Sham Comparator|2|
11612365|NCT00552942|Experimental|1|surgery plus omentectomy
11612366|NCT00552942|No Intervention|2|standard gastric bypass
11612367|NCT00552929|Experimental|Sugammadex 0.5 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the second twitch (T2) response to Train-of-four (TOF) stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
11612368|NCT00552929|Experimental|Sugammadex 1.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
11612369|NCT00552929|Experimental|Sugammadex 2.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
11612370|NCT00552929|Experimental|Sugammadex 4.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
11612371|NCT00552929|Experimental|Sugammadex 8.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
11612372|NCT00552929|Experimental|Sugammadex 0.5 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
11612373|NCT00552929|Experimental|Sugammadex 1.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
11612374|NCT00552929|Experimental|Sugammadex 2.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
11612375|NCT00552929|Experimental|Sugammadex 4.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
11612376|NCT00552929|Experimental|Sugammadex 8.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
11612377|NCT00552916|Other|1|Participants will be randomized to either an intervention arm where they will receive 'true' FES and the other control arm where they will receive 'false' FES. The sham group will receive 'false' FES.
11612378|NCT00552916|Other|2|The intervention group will receive 'true' FES
11612379|NCT00552903|Experimental|1|Active intervention - personal health coaching provided
11612380|NCT00552903|No Intervention|2|Control arm - no intervention, data on health outcomes collected at baseline (entry to the study) and during the 12 month follow-up
11612381|NCT00552890|Experimental|ATK|modified Atkins diet
11612382|NCT00552890|Experimental|ADA|subjects assigned to follow ADA recommended diet for 1 year
11612383|NCT00552877|Active Comparator|1|Cypher Select plus stent
11612384|NCT00552877|Active Comparator|2|Xience V stent
11612385|NCT00552864|Active Comparator|R|
11612386|NCT00552864|Active Comparator|L|
11612387|NCT00552851|Other|Pegvisomant|patients with active acromegaly and impaired cardiac function
11612388|NCT00552838|No Intervention|A|Physicians in this arm did not have any intervention with the AUT. Antimicrobial prescriptions were based on hospital guidelines or on the physician's medical knowledge.
11612389|NCT00552825||1|all were in a single group
11612390|NCT00552812|Experimental|Stent therapy of aortic coarctation|Stenting of aortic coarctation
11612391|NCT00552799|Experimental|1|Penicillin VK 250 mg b.d.
11612392|NCT00552799|Placebo Comparator|2|placebo tablet b.d.
11612393|NCT00552786|Experimental|Acetin|
11612394|NCT00552786|Placebo Comparator|Glucose|
11612395|NCT00552773|Experimental|Cyclamen Europaeum|
11612396|NCT00552773|Placebo Comparator|Placebo|
11612397|NCT00552760|Experimental|Ramelteon|8 mg
11612398|NCT00552760|Placebo Comparator|Placebo|
11612399|NCT00552747|Active Comparator|1|fenofibrate 160 mg capsules (QD) Taken once daily with the largest meal of the day
11612400|NCT00552747|Placebo Comparator|2|placebo (capsules identical to those of fenofibrate) taken once daily (QD)with the largest meal of the day
11612401|NCT00552734||Control|The other half of the patients were randomized to the control group who were followed for their routine diabetes care and had to visit the clinic on the same schedule as the experimental group.
11612402|NCT00552734||Experimental|Half of the subjects were randomized to this group using insulin guidance software on a PDA to adjust their insulin dose at home based on the prescription provided by the provider.
11612403|NCT00552721|Experimental|A|Physical therapy with strength training.
11630231|NCT00371904|Active Comparator|2|
11612405|NCT00552695|Active Comparator|1|Lidocaine 70 mg/tetracaine 70 mg skin patch
11612406|NCT00552695|Placebo Comparator|2|
11612407|NCT00552682|Experimental|A|Duloxetine 60 mg, 1 tablet/day
11612408|NCT00552682|No Intervention|B|To continue with the antidepressive treatment if exist
11612409|NCT00552669|Experimental|A--Oral Rapamycin plus BMS|Oral sirolimus plus bare metal stent implantation
11612410|NCT00552669|Active Comparator|B -- Drug Eluting Stent|Drug Eluting Stents
11612411|NCT00552656||1|the group of patients with angiographic results of complex coronary lesions(refer to the definition of protocol)are enrolled and given a clinical follow up and angiographic follow up during the following one year.
11612412|NCT00552643|Experimental|1|Treatment with Polyheal 1
11612413|NCT00552643|Active Comparator|2|Saline
11612414|NCT00552630|Experimental|1|This group will receive d-penicillamine for 6 weeks
11612415|NCT00552630|Placebo Comparator|2|This group will receive placebo for 6 weeks
11612416|NCT00552617|Placebo Comparator|Rocuronium + Placebo|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
11612417|NCT00552617|Experimental|Rocuronium + 0.5 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
11612418|NCT00552617|Experimental|Rocuronium + 1.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
11612419|NCT00552617|Experimental|Rocuronium + 2.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
11612420|NCT00552617|Experimental|Rocuronium + 4.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
11612421|NCT00552617|Placebo Comparator|Vecuronium + Placebo|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
11612422|NCT00552617|Experimental|Vecuronium + 0.5 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
11612423|NCT00552617|Experimental|Vecuronium + 1.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
11612424|NCT00552617|Experimental|Vecuronium + 2.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
11612425|NCT00552617|Experimental|Vecuronium + 4.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
11612426|NCT00552604|Experimental|1|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
11612427|NCT00552604|Placebo Comparator|2|matching placebo capsules, twice daily
11612428|NCT00552591|Experimental|1|Family Heart Health Program
11612429|NCT00552591|No Intervention|2|Usual Care
11612430|NCT00552578|Active Comparator|Tapering doses of buprenorphine|Participants assigned to this arm will receive tapering doses of buprenorphine for detoxification.
11612431|NCT00552578|Experimental|Steady doses of buprenrophine|Participants assigned to this arm will receive a steady dose of buprenorphine for maintenance.
11612432|NCT00552565|Placebo Comparator|1|
11612433|NCT00552565|Experimental|2|
11612434|NCT00552565|Experimental|Rezular 37.5mg|
11612435|NCT00552565|Experimental|Rezular - 75mg|
11612436|NCT00552552|Experimental|1|
11612437|NCT00552552|Other|2|waiting control group
11612438|NCT00552539|Experimental|1|pre test survey, educational video, post test survey
11612439|NCT00552539|No Intervention|2|no intervention
11612440|NCT00552539|Experimental|3|educational video and post test survey
11612441|NCT00552539|No Intervention|4|post test survey
11612442|NCT00552526|Active Comparator|Ketogenic diet|
11612443|NCT00552526|Active Comparator|AED|Most appropriate antiepileptic drug
11612444|NCT00552513|Other|Early Coronary Intervention|Coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) as soon as possible (within 24 hours of randomisation).
11612445|NCT00552513|Other|Delayed Coronary Intervention|Delayed intervention: Coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) any time after 36 hours after randomisation.
11612446|NCT00552500|Active Comparator|Schizophrenics|i) meets DSM-IV criteria for schizophrenia, any type, treated with atypical or high potency typical neuroleptics for at least 3 months; ii) aged 18 to 60 years; iii) able to give informed consent; iv) no antipsychotic medication changes for 3 months, and no other medication changes for 2 weeks prior to Baseline Evaluations.
11612447|NCT00552487|Other|1|healthy people without Hashimoto disease receive a 1µg ACTH stimulation test
11612448|NCT00552487|Other|2|patients with Hashimoto disease with well being receive a 1 µg ACTH stimulation test
11612449|NCT00552487|Other|3|patients with Hashimoto disease an impaired well-being receive a 1 µg ACTH stimulation test
11612920|NCT00548652|Experimental|4|MOVE plus methylphenidate
11612450|NCT00552487|Other|4|patients with Hashimoto disease and negative TPO antibodies receive a 1µg ACTH stimulation test
11612451|NCT00552474|Placebo Comparator|Group B|Implanted but no active stimulation
11612452|NCT00552474|Experimental|Group A|Active Stimulation
11612453|NCT00552461|Experimental|1|
11612454|NCT00552448|Experimental|1|Use of the HFCC device in addition to standard therapy for status asthmaticus. The use of HFCC will not affect the therapy received
11612455|NCT00552448|No Intervention|2|This group will not use the VEST or HFCC. They will just have standard therapy for status asthmaticus. The standard therapy will not be affected if they are in this group.
11612456|NCT00552435|Experimental|1|Micropulse 810nm diode laser
11612457|NCT00552435|Active Comparator|2|Argon laser photocoagulation
11612458|NCT00552422|Experimental|Domperidone Arm|Study subjects will self-administer oral domperidone 10mg four times a day. If symptoms persist for more than 7 days, the investigator may increase the dose to 20mg four times a day. 20mg four times a day will be the maximal dose. Subjects with signiﬁcant renal impairment will received a starting dose of 10mg twice a day. The maximal dose in subjects with signiﬁcant renal impairment will be 20mg twice a day.
11612459|NCT00552409|Experimental|Cholecalciferol|
11612460|NCT00552409|Placebo Comparator|Placebo|
11612461|NCT00552344|Experimental|Certolizumab Pegol|Certolizumab Pegol 200 mg/vial; 400 mg subcutaneously at Week 0, 2 and 4, thereafter 400 mg subcutaneously at every 4 weeks.
11612462|NCT00552331|Active Comparator|LISS|Treatment of distal femur fracture with less invasive stabilization system
11612463|NCT00552331|Active Comparator|Standard Treatment|Treatment of distal femoral fractures using locking condylar plates or dynamic condylar screws
11612464|NCT00552305|Experimental|Lacosamide|50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing
11612465|NCT00552279|Experimental|Cervarix-12 Group|Women received 3 doses of Cervarix TM (human papillomavirus (HPV) vaccine) administered according to a 0, 1, 12-month schedule
11612466|NCT00552279|Active Comparator|Cervarix-6 Group|Women received 3 doses of Cervarix TM (HPV vaccine) administered according to a 0, 1, 6-month schedule.
11612467|NCT00552253|Experimental|1|under eltroxin
11612468|NCT00552240|Active Comparator|NVP 200mg bis indie (BID)|after receiving nevirapine (NVP) 200 mg quaue die (QD) for 2 weeks, pt titrated to NVP 200 mg bis in die (BID) combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks
11612469|NCT00552240|Active Comparator|Atazanavir 300 mg QD/ritonavir 100 mg QD|patients to receive atazanavir 300 mg QD boosted with ritonavir 100 mg QD combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks
11612470|NCT00552227|Experimental|1|
11612471|NCT00552227|Placebo Comparator|2|
11612472|NCT00552188|Experimental|VIA-2291|VIA-2291 100mg
11612473|NCT00552188|Placebo Comparator|Placebo|Matching placebo
11612474|NCT00552175|Experimental|Duloxetine 60|duloxetine 60 milligram (mg) taken orally every day
11612475|NCT00552175|Experimental|Duloxetine 40|Duloxetine 40 mg taken orally every day
11612476|NCT00552175|Placebo Comparator|Placebo|placebo comparator taken orally every day
11612477|NCT00552162|Active Comparator|1|NOTES Transvaginal cholecystectomy The gallbladder will be dissected free and will be removed through an incision in the vagina.
11612478|NCT00552162|Active Comparator|2|NOTES Transvaginal Appendectomy. The appendix will be dissected free and will be removed through an incision in the vagina.
11612479|NCT00552149|Active Comparator|1|GEMOX
11612480|NCT00552149|Experimental|2|GEMOX + CETUXIMAB
11612481|NCT00552110|Experimental|Combination1|Mometasone Furoate nasal spray (MFNS) with oxymetazoline nasal spray (OXY) 1 spray once daily
11612482|NCT00552110|Experimental|Combination3|MFNS with OXY 3 sprays once daily
11612483|NCT00552110|Active Comparator|Mometasone|MFNS once daily
11612484|NCT00552110|Active Comparator|Oxymetazoline|OXY twice daily
11612485|NCT00552110|Placebo Comparator|Placebo|Placebo nasal spray
11612486|NCT00552097|Experimental|EZ/Simva|
11612487|NCT00552097|Placebo Comparator|Placebo/Simva|
11612488|NCT00552084|Experimental|Fish Oil|4 grams fish oil daily for 24 weeks
11612489|NCT00552084|Placebo Comparator|Placebo|corn oil taken daily for 24 weeks
11612490|NCT00552071|Experimental|Ultrasound-guided IM injections of octreotide LAR|Subjects received octreotide LAR 30 mg injection via ultrasound-guided IM gluteal injection every 28 days for 3 months.
11612491|NCT00552071|Active Comparator|Regular IM injections of octreotide LAR|Subjects received octreotide LAR 30 mg injection via regular IM gluteal injections every 28 days for 3 months
11612492|NCT00552058|Experimental|Certolizumab pegol|Certolizumab pegol 400 mg for subcutaneous (sc) injection
11612493|NCT00552058|Placebo Comparator|Placebo|Placebo, saline solution for sc injection
11612494|NCT00552045||subject|individuals with epilepsy
11612495|NCT00552032|Experimental|Mometasone Furoate nasal spray|
11612496|NCT00552032|Placebo Comparator|Placebo|
11612497|NCT00552006|Experimental|NET|
11612498|NCT00552006|Active Comparator|AC|
11612499|NCT00552006|No Intervention|WL|Waiting list
11612500|NCT00551993|Active Comparator|2|Robotic Sacral Colpopexy
11612501|NCT00551993|Active Comparator|1|Laparoscopic Sacral Colpopexy
11612502|NCT00551980|Experimental|Cognitive and physical program|Randomized group of workers of the same institution ( City of Turin, Italy).
11612503|NCT00551980|No Intervention|Control group|Randomized group of workers of the same institution ( City of Turin, Italy).
11612504|NCT00551967|Active Comparator|E1 polyethylene|All patients received an E1 polyethylene liner which is the material being monitored in this study.
11612505|NCT00551954|Experimental|1|20 weeks of treatment with acarbose (100 mg t.i.d.)
11612506|NCT00551954|Placebo Comparator|2|20 weeks of treatment with placebo (one tablet t.i.d.)
11612507|NCT00551941|Active Comparator|2|non-union of diaphysary tibial fractures will be treated with allograft together with DBM
11612508|NCT00551941|Experimental|1|non-union of diaphysary tibial fractures will be treated with BMP-7 in adjunct to fresh frozen allograft
11612509|NCT00551928|Active Comparator|A|Oral therapy with Lenalidomide Melphalan and Prednisone.
11612510|NCT00551928|Active Comparator|B|High dose Melphalan therapy (200mg/sm)with autologous stem cell support, for 2 cycles every 4 months (only 1 cycle if the patient reached almost a VGPR after the 1st MEL200)
11612511|NCT00551915|Experimental|AR51 (12, 10)|Participants were vaccinated with 0.5 ml of AR51 (12,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
11612512|NCT00551915|Experimental|PR51 (3, 10)|Participants were vaccinated with 0.5 ml of PR51 (3,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
11612513|NCT00551915|Experimental|PR51 (6, 10)|Participants were vaccinated with 0.5 ml of PR51 (6,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
11612514|NCT00551915|Active Comparator|PENTACEL™ + RECOMBIVAX HB™|Participants were vaccinated with 0.5 ml each of PENTACEL™ + RECOMBIVAX HB™ via intramuscular injection as a primary series at 2, 4, and 6 months of age, and with 0.5 ml PENTACEL™ as a booster at 12 to 14 months of age.
11612515|NCT00551902|Experimental|1|Trabeculectomy with anterior chamber infusion system
11612516|NCT00551902|Active Comparator|2|Trabeculectomy without anterior chamber infusion system
11612517|NCT00551863|Active Comparator|IVPT|Intervention based on Motivational Interviewing and CBT
11612518|NCT00551850|Experimental|1|
11612519|NCT00551824|Experimental|1|"First dilation session with topical mitomycin applied over esophageal mucosa after dilation.
~Second dilation session (after 14 days): standard dilation without topical mitomycin."
11612520|NCT00551824|Experimental|2|"First dilation session: standard dilation without topical mitomycin.
~Second dilation session (after 14 days) with topical mitomycin applied over esophageal mucosa after dilation."
11612521|NCT00551811|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive single doses of placebo in period 1, SB-656933-AAA with a dose of 50 milligrams in period 2 and 150 milligrams in period 3.
11612522|NCT00551811|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive single doses of SB-656933-AAA with a dose of 50 milligrams in period 1, placebo in period 2 and SB-656933-AAA 150 milligrams in period 3.
11612523|NCT00551811|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive single doses of SB-656933-AAA with a dose of 50 milligrams in period 1, 150 milligrams in period 2 and placebo in period 3.
11612524|NCT00551785||1|Women prescribed Intrinsa and estrogen therapy
11612525|NCT00551785||2|Women prescribed estrogen therapy
11612526|NCT00551759|Experimental|Neoadjuvant therapy, Surgery, adjuvant therapy|"Neoadjuvant chemoradiotherapy and cetuximab: Patients (pts) receive oxaliplatin IV over 2 hours on days 1, 15, and 29, cetuximab IV over 1-2 hours on days 1, 8, 15, 22, and 29, and 5-FU IV over 24 hours on days 1-35. Pts also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33. Pts then proceed to surgery.
~Surgery: Pts undergo surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab. Pts with an R0 or R1 resection proceed to adjuvant therapy. Pts whose tumors have not been completely resected or who have metastatic disease discontinue protocol therapy and receive further therapy at the discretion of the treating physician.
~Adjuvant therapy: Within 4-8 weeks after surgery, pts receive docetaxel IV over 1 hour on days 1, 8, 15, 22, and 29 and cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
11612527|NCT00551746|Active Comparator|1|Grape Juice
11612528|NCT00551746|Placebo Comparator|2|Grape Juice Placebo
11612529|NCT00551733|Experimental|Arm I|Patients receive paclitaxel poliglumex IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11612530|NCT00551733|Active Comparator|Arm II|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11612531|NCT00551720|Experimental|Standard Care|
11612532|NCT00551720|Experimental|Motivational Enhancement|
11612533|NCT00551707|Experimental|CRx-102 (2.7/180)|CRx-102 dose 1 total daily dose during treatment period (days 14-98) 2.7 mg prednisolone plus 180 mg dipyridamole administered as 1.8 mg prednisolone plus 90 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 90 mg dipyridamole at 1 PM titration dose (days 0-13) 2.7 mg prednisolone plus 90 mg dipyridamole administered as 1.8 mg prednisolone plus 45 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 45 mg dipyridamole at 1 PM
11612534|NCT00551707|Experimental|CRx-102 (2.7/360)|CRx-102 Dose 2 total daily dose during treatment period (days 14-98) 2.7 mg prednisolone plus 360 mg dipyridamole administered as 1.8 mg prednisolone plus 180 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 180 mg dipyridamole at 1 PM titration dose 1 (days 0-6) 2.7 mg prednisolone plus 90 mg dipyridamole administered as 1.8 mg prednisolone plus 45 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 45 mg dipyridamole at 1 PM titration dose 2 (days 7-13) 2.7 mg prednisolone plus 180 mg dipyridamole administered as 1.8 mg prednisolone plus 90 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 90 mg dipyridamole at 1 PM
11612535|NCT00551707|Active Comparator|Prednisolone|treatment dose ( days 0-98) total daily dose of 2.7 mg prednisolone administered as 1.8 mg prednisolone at 8 AM and 0.9 mg prednisolone at 1 PM
11612536|NCT00551707|Active Comparator|Dipyridamole|total daily dose during treatment period (days 14-98) 360 mg dipyridamole administered as 180 mg dipyridamole at 8 AM and and 180 mg dipyridamole at 1 PM titration dose 1 (days 0-6) 90 mg dipyridamole administered 45 mg dipyridamole at 8 AM and 45 mg dipyridamole at 1 PM titration dose 2 (days 7-13) 180 mg dipyridamole administered as 90 mg dipyridamole at 8 AM and 90 mg dipyridamole at 1 PM
11612537|NCT00551707|Placebo Comparator|Placebo|placebo administered twice per day at 8 AM and 1 PM
11612538|NCT00551681|Active Comparator|1|Epicardial left ventricular lead placement
11612539|NCT00551681|Active Comparator|2|transvenous left ventricular lead
11612540|NCT00551668|Experimental|1|Operative
11612541|NCT00551668|Experimental|2|Nonoperative
11612542|NCT00551642|Other|Group A|24+0-25+6 days weeks gestational age
11612543|NCT00551642|Other|Group B|26+0 - 28+6 days weeks Gestational Age
11612772|NCT00549900|Experimental|Cervarix Group|Subjects received 3 doses of GSK580299 vaccine (Cervarix™, HPV -16/18 L1 VLP AS04 vaccine) according to a 0, 1, 6-month schedule.
11612544|NCT00551629|Experimental|AR51 (12, 10)|Participants were vaccinated with 0.5 ml of AR51 (12, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
11612545|NCT00551629|Experimental|PR51 (3, 10)|Participants were vaccinated with 0.5 ml of PR51 (3, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
11612546|NCT00551629|Experimental|PR51 (6, 10)|Participants were vaccinated with 0.5 ml of PR51 (6, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
11612547|NCT00551629|Experimental|PR51 (6, 15)|Participants were vaccinated with 0.5 ml of PR51 (6, 15) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
11612548|NCT00551616|Experimental|1|
11612549|NCT00551616|Active Comparator|2|
11612550|NCT00551603|Experimental|1|Group Epo will receive anaemia treatment according to the Romanian Best Practice Guidelines recommendation, with once-weekly SC epoetinum beta during the first phase, then will be switched to receive SC once-fortnightly darbepoetinum. Anaemia treatment schedule will continue according to the Romanian Best Practice Guidelines recommendations, with the same dose. A conversion factor of 1:200 will be used.
11612551|NCT00551603|Active Comparator|2|Subjects in the Darbepo Group will receive anaemia treatment according to the Romanian Best Practice Guidelines recommendation, with once-fortnightly or once-monthly darbepoetin SC administration, continuing their previous schedule and will continue their previous schedule of anaemia treatment during the second phase of the study
11612552|NCT00551590|Placebo Comparator|1|placebo PO (placebo control for sitagliptin) for three days. Saline IV (placebo control for exendin(9-39) on two consecutive study days.
11612553|NCT00551590|Experimental|2|Sitagliptin 100 mg PO for three days. Saline IV (placebo control for exendin(9-39)) on two consecutive study days
11612554|NCT00551590|Experimental|3|Sitagliptin 100 mg PO for three days. Exendin(9-39) IV on two consecutive study days.
11612555|NCT00551590|Placebo Comparator|4|placebo PO (placebo control for sitagliptin) for three days. Exendin(9-39)IV on two consecutive study days.
11612556|NCT00551577|Active Comparator|A1|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
11612557|NCT00551577|Experimental|A2|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
11612558|NCT00551564|Experimental|Subjects in healthy normal and overweight control arm|Subjects in the Healthy Normal or Overweight Control Population will be included in this arm and they will receive Rosiglitazone 4 milligram twice daily.
11612559|NCT00551564|Experimental|Subjects in healthy obese with T2DM arm|Subjects who are in the Healthy Obese or T2DM Population will be included in this arm and they will receive Rosiglitazone 4 milligram twice daily.
11612560|NCT00551551|Experimental|Rééducation|Standardized pelvic floor muscle training program with a physiotherapist in 8 sessions (20-30 minutes each) between 24 and 36 weeks of gestation AND Written instructions about personal (Kegel) pelvic floor exercises
11612561|NCT00551551|Active Comparator|Control|Written instructions about personal (Kegel) pelvic floor exercises
11612562|NCT00551538|Active Comparator|1|Lispro mixture 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
11612563|NCT00551538|Active Comparator|2|Glargine, once-daily, SC injection, given in conjunction with oral antidiabetic medications.
11612564|NCT00551525|Experimental|Radiotherapy + Samarium 153|Samarium 153 infusion followed by radiotherapy 12 weeks later
11612565|NCT00551512|Experimental|CBP501 and Cisplatin|Dose escalation study
11612566|NCT00551499|No Intervention|CRT for patients with CSA|Patients suffering from HF with central Sleep Apnea (CSA) programmed to DDD/45 (CRT) for 12 weeks. Intervention is CRT.
11612567|NCT00551499|Active Comparator|CRT + AOP for patients with CSA|Patients suffering from HF with central Sleep Apnea programmed to DDD/+15 bpm nocturnal rate (CRT + AOP) for 12 weeks. Intervention is the AOP in addition to CRT.
11612568|NCT00551486||1|Patients with thyroid incidentaloma underwent ultrasound-guided fine needle aspiration biopsy
11612569|NCT00551460|Experimental|Treatment|"Induction:
~ATRA 45mg/m2 PO D1-CR Gemtuzumab Ozogamicin 9 mg/m2 IV D1 Arsenic Trioxide 0.15 mg/kg/d IV 5days/wk D10-CR
~Consolidation 1 and 2:
~Arsenic Trioxide 0.15 mg/kg/d IV 5days/wk x 5 weeks, repeat after 2 weeks rest
~Consolidation 2 and 3:
~ATRA 45 mg/m2 PO D1-7 Daunomycin 50 mg/m2/d IV D1-3
~Consolidation 5 and 6:
~GO 9mg/m2 IV D1
~Maintenance:
~ATRA 45 mg/m2/d PO D1-7 every 14 days 6-MP 60 mg/m2/d PO daily for 1 year Methotrexate 20 mg/m2 PO once/wk for 1 year"
11612570|NCT00551434|Experimental|1|
11612571|NCT00551434|Experimental|2|
11612572|NCT00551434|Experimental|3|
11612573|NCT00551434|Placebo Comparator|4|
11612574|NCT00551421|Experimental|Arm I|"Phase I: Patients receive pertuzumab IV over 30-60 minutes on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 2, 8, and 15 of course 1 and on days 1, 8, and 15 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Phase II: Patients receive treatment as in phase I. Pertuzumab is administered at the recommended phase II dose (determined in phase I)."
11612575|NCT00551408||A|20 patients with idiopathic pulmonary arterial hypertension in the WHO functional class II to III, and had a mean pulmonary artery pressure >30 mm Hg on right heart catheterization able to walk >50 m during a standardized 6-min walk test.
11612576|NCT00551395|Experimental|SLT Early Completion (Arm 1)|Intervention: 180 degrees of laser on Day 1, 180 degrees of laser on the other 180 degree on Day 2
11612577|NCT00551395|Active Comparator|SLT Late Completion (Arm 2)|Intervention: 180 degrees of laser on Day 1, 180 degrees of laser on the other 180 degrees at 1 month follow up appointment.
11612578|NCT00551382|Experimental|A|
11612579|NCT00551382|Placebo Comparator|B|
11612580|NCT00551369|Experimental|SBRT|Stereotactic body radiation therapy (SBRT)
11612581|NCT00551356|Active Comparator|2|Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
11612582|NCT00551356|Active Comparator|1|Lispro mix 25 SC twice-daily in conjunction with oral antidiabetic medications.
11612583|NCT00551343|Other|PWS|
11612584|NCT00551343|Other|Controls|
11612585|NCT00551330|Experimental|1|Vicriviroc 30 mg QD
11612586|NCT00551330|Placebo Comparator|2|Placebo
11612587|NCT00551291|Experimental|Mycophenolate Mofetil + Prednisone + Erythropoietin Beta|Mycophenolate mofetil (MMF) 1 gm twice daily orally and prednisone 10 mg/day orally until the end of the study. Recombinant human erythropoietin beta 30,000 IU/week, subcutaneously for 6 weeks was added in case of no significant response at Week 12.
11612588|NCT00551278||1|Patients with previous diagnosis of breast cancer scheduled for sentinel lymph node dissection.
11612589|NCT00551265|Experimental|Arm I|Patients undergo delayed-type hypersensitivity (DTH) skin testing with oregovomab and a standard anergy panel (i.e., mumps, Candida, and tetanus toxoid) on day 0 (at baseline) and at week 14. The skin test response is measured 48 hours later. Patients receive cyclophosphamide IV on day 6 and oregovomab IV over 20 minutes on day 9 or 10. Patients then receive oregovomab alone at weeks 6 and 10 and then every 12 weeks for up to 2 years (10 doses) in the absence of disease progression or unacceptable toxicity.
11612590|NCT00551265|Active Comparator|Arm II|Patients undergo DTH skin testing and receive oregovomab as in arm I.
11612591|NCT00551252|Experimental|I|
11612592|NCT00551239|Active Comparator|Arm I (control)|Patients receive rituximab IV on day 1 and fludarabine phosphate IV on days 2-4. Treatment repeats every 28 days for up to 6 courses.
11612593|NCT00551239|Experimental|Arm II|Patients receive rituximab and fludarabine phosphate as in arm I. Patients also receive pixantrone IV on day 2. Treatment repeats every 28 days for up to 6 courses.
11612594|NCT00551226||1|Patients with tuberculosis
11612595|NCT00551226||2|Healthy controls
11612596|NCT00551213|Experimental|Robatumumab→Robatumumab|Participants receive 1 dose of robatumumab 0.3 mg/kg intravenously (IV) followed by 1 dose of robatumumab 10 mg/kg IV once every 2 weeks (Q2W) until disease progression. A cycle of robatumumab is defined as 2 weeks of treatment (i.e., 1 dose of robatumumab) with no recovery period between cycles.
11612597|NCT00551213|Active Comparator|Chemotherapy→Robatumumab|Participants receive 1 cycle of standard colorectal cancer chemotherapy currently approved and available on the market for use in colorectal cancer (to be selected by the Investigator based on participant's prior treatment) followed by 1 dose of robatumumab 10 mg/kg IV Q2W until disease progression. A cycle of robatumumab is defined as 2 weeks of treatment (i.e., 1 dose of robatumumab) with no recovery period between cycles.
11612598|NCT00551200|Active Comparator|BUPHENYL® to HPN-100 vs. HPN-100|Buphenyl treatment for one week was followed by dose escalation to HPN-100. Dose of Buphenyl was gradually decreased while HPN-100 dose was gradually increased until subject reached dosing of 100% HPN-100. HPN-100 at 100% of the dose was given for 1 week before subject was switched back to original Buphenyl treatment.
11612599|NCT00551187|Experimental|1|V504 + Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
11612600|NCT00551187|Placebo Comparator|2|Placebo + Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
11612601|NCT00551174|Experimental|1|
11612602|NCT00551174|Active Comparator|2|
11612603|NCT00551161|Experimental|single-arm|24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 20 mg per day, in addition to their ongoing stable cholinesterase inhibitor treatment
11612604|NCT00551148|Experimental|15 mg|
11612605|NCT00551148|Experimental|30 mg|
11612606|NCT00551148|Experimental|5 mg|
11612607|NCT00551148|Experimental|60 mg|
11612608|NCT00551148|Placebo Comparator|Placebo|
11612609|NCT00551135|Experimental|3|
11612610|NCT00551135|Placebo Comparator|4|
11612611|NCT00551135|Experimental|2|
11612612|NCT00551135|Experimental|1|
11612613|NCT00551122|Experimental|Paclitaxel, gemcitabine, cisplatin, ifosfamide|"Day 1 Dexamethasone sodium phosphate 25mg I/V ) before Chlorphenamine 10mg I/V 30 - 60 mins ) paclitaxel Ranitidine 50mg I/V ) Paclitaxel - 175 mg m2 I/V in 500ml normal saline over 3 hours Gemcitabine - 1200mg per m2 I/V in 500ml normal saline over 30 mins Days 1-5 Cisplatin 20mg per m2 in 1 litre normal saline over 4 hours 2 litres normal saline over 16 hours, each litre containing 10 mmol MgSO4 and 20mmol KCL.
~If urine output is insufficient (less than 600ml per 6 hours) or if excessive weight gain (greater than 2kg) 100 - 200ml 10% mannitol should be used. Alternatively, low dose frusemide (20mg I/V) can be used.
~Days 2 - 6 Ifosfamide 1G per m2 + MESNA 0.5G m2 in 500 ml normal saline over 1 hour after the cisplatin infusion.
~MESNA 0.5G m2 to be included in first 1 litre post cisplatin hydration bag Pegylated G-CSF will be given on day 7 as an alternative to daily G-CSF."
11612614|NCT00551109|Placebo Comparator|P|Placebo
11612615|NCT00551109|Experimental|A1|SA4503
11612616|NCT00551109|Experimental|A2|SA4503
11612617|NCT00551096|Experimental|Gemcitabine, capecitabine and ZD6474|"Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.
~Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off .
~ZD6474 administered orally at 300 mg/day once daily. One cycle will consist of 28 days."
11612618|NCT00551083|Experimental|CDSS-D|Computer Decision Support System for Depression (CDSS-D) - This arm provided physicians with a computerized treatment algorithm and a decision support system to treat their patients suffering Major Depressive Disorder
11612619|NCT00551083|Active Comparator|UC|Usual Care (UC) - This group of physicians treated their patients suffering from Major Depressive Disorder with their standard treatment as usual, and received no algorithm support with regard to treatment decisions
11612620|NCT00551070|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11612621|NCT00551044|Active Comparator|Bicalutamide|Osteoporotic patients (T score ≤ -2.5) on bicalutamide
11612622|NCT00551031|Experimental|Influenza Virus Vaccine Formulation 1|Influenza Virus Vaccine Formulation 1
11612623|NCT00551031|Experimental|Influenza Virus Vaccine Formulation 2|Influenza Virus Vaccine Formulation 2
11612624|NCT00551031|Active Comparator|Fluzone® Elderly Group|
11612625|NCT00551031|Active Comparator|Fluzone® High-dose Group|Participants enrolled at age ≥ 65 years
11612626|NCT00551031|Active Comparator|Fluzone® Adults Group|Participants enrolled at age 18-49 years.
11612773|NCT00549887||Rapid acting to short acting|Patients on rapid-acting analog insulins who switch to short-acting human insulin
11631021|NCT00362427|Experimental|Group B|
11612627|NCT00551018|Experimental|Vicriviroc + Reyataz + ritonavir|vicriviroc 30 mg tablet QD + Reyataz® (atazanavir sulfate) 300 mg (1x300 mg capsule or 2x150 mg capsules) QD + Norvir® (ritonavir) 100 mg capsule QD
11612628|NCT00551018|Active Comparator|Truvada® + Reyataz + ritonavir|Truvada® 200/300 combination tablet QD + Reyataz® (atazanavir sulfate) 300 mg (1x300 mg capsule or 2x150 mg capsules) QD + Norvir® (ritonavir) 100 mg capsule QD
11612629|NCT00550979||1|Black women with history of pregnancy/ies complicated by gestational diabetes mellitus
11612630|NCT00550979||2|Black women with history of normal, uncomplicated pregnancy/ies
11612631|NCT00550979||3|White women with a history of pregnancy/ies complicated by gestational diabetes.
11612632|NCT00550979||4|White women with a history of normal, uncomplicated pregnancy/ies.
11612633|NCT00550966|Active Comparator|1|"Randomized controlled trial with a 12-month follow-up involving two groups, one of which is the intervention group that includes patients receiving a psychoeducative program and the other is the control group formed by patients treated for FM in the usual way.
~Setting. Three urban PC centers in the province of Barcelona (Spain) Sample. The total sample comprises 218 patients (over 18 years of age) suffering FM, selected from a database (Rheumatology service-Viladecans hospital) of patients with this illness. Only those patients introduced in the database between the years 2005 and 2007 are included in the selection. Selected patients are asked for written informed consent to participate in the study."
11612634|NCT00550914||Control arm|The conventional therapy arm will undergo debridement with either a powered microdebrider or cold instrumentation excision as per the preference of the individual surgeon. Debridement will be deemed complete after removal of gross papilloma to the extent that the individual surgeon feels can be safely accomplished. Standard microsurgical principles of the larynx will guide debridement in that no opposing mucosal surfaces of the true vocal folds, laryngeal ventricle or inter-arytenoid space will be simultaneously debrided
11612635|NCT00550914||Experimental Arm|Patients enrolled into the conventional therapy plus PDL treatment arm will undergo debridement of the supraglottis and subglottis via conventional techniques as per the individual surgeons preferences followed by therapy to anterior commissure, true vocal folds, laryngeal ventricle and inter-arytenoid space with the pulsed dye laser. Standard laser settings will be a 450 microsecond pulse width, 5 J per pulse maximum of 1Hz, 1 mm spot fiber, 1-2 mm spot size and fluences of 38-255 J/cm2.
11612636|NCT00550875|Experimental|1|
11612637|NCT00550875|Experimental|2|10* concentration of arm 1
11612638|NCT00550875|Placebo Comparator|3|
11612639|NCT00550862|Experimental|INT-747 10 mg|INT-747 10 mg once daily in combination with URSO for 12 weeks.
11612640|NCT00550862|Experimental|INT-747 25 mg|INT-747 25 mg once daily in combination with URSO for 12 weeks.
11612641|NCT00550862|Experimental|INT-747 50 mg|INT-747 50 mg once daily in combination with URSO for 12 weeks.
11612642|NCT00550862|Placebo Comparator|Placebo|Placebo once daily in combination with URSO for 12 weeks.
11612643|NCT00550849|Experimental|1|RTA 402
11612644|NCT00550849|Experimental|2|RTA 402
11612645|NCT00550849|Experimental|3|RTA 402
11612646|NCT00550836|Active Comparator|Arm A: GE|Patients receive 1000 mg/m^2 gemcitabine hydrochloride IV on days 1, 8, and 15; and 100 mg oral erlotinib hydrochloride on days 1-28. Treatment repeats every 28 days for 2 courses. Patients achieving a complete response (CR) after 2 courses receive 2 additional courses of treatment; patients achieving a partial response (PR) receive retreatment as above. Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride and erlotinib hydrochloride until second progression.
11612647|NCT00550836|Experimental|Arm B: PGE|Patients receive 1000 mg/m^2 gemcitabine hydrochloride IV on days 1, 8, and 15; 100 mg oral erlotinib hydrochloride on days 1 - 28; and 4.0 mg/kg panitumumab IV on days 1 and 15. Treatment repeats every 28 days for 2 courses. Patients achieving a CR after 2 courses receive 2 additional courses of treatment; patients achieving a PR receive retreatment as above. Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride and panitumumab until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride, erlotinib hydrochloride, and panitumumab until second progression.
11612648|NCT00550823|Experimental|A,1|
11612649|NCT00550797|Experimental|No.1 ASM8 (oligonucleotide)|TPI ASM8 1mg/mL in phosphate buffered saline (PBS) solution; 1 mg will be administered daily (morning) by inhalation
11612650|NCT00550797|Placebo Comparator|Phosphate Buffer solution|Placebo solution (PBS) will be administered daily in the form of 1 mL of PBS (phosphate buffered saline) by inhalation
11612651|NCT00550771|Active Comparator|Doxorubicin Based Regimen|
11612652|NCT00550771|Experimental|Pegylated Liposomal Doxorubicin (PLD) Based Regimen|
11612653|NCT00550745|Experimental|1|Arm 1: vaccine
11612654|NCT00550745|Placebo Comparator|2|Arm 2: Placebo Comparator
11612655|NCT00550732|Experimental|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
11612656|NCT00550706||1Pediatric Dept A|Children's files from this department will be analysed once weekly and medication prescription data will be registered
11612657|NCT00550706||2 Pediatric Dept B|Children's files from this department will be analysed once weekly and medication prescription data will be registered
11612658|NCT00550693|Placebo Comparator|A|The patients in this arm continued with the local catheter care protocol.
11612659|NCT00550680|Experimental|Mircera in Renal Anemia|Participants with chronic renal anemia who have been previously treated with erythropoiesis-stimulating agent (ESA) therapy will receive IV Mircera every 4 weeks for a total of 24 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment. Subsequent doses will be adjusted to maintain Hb concentrations within target of 10.5 and 12.5 grams per deciliter (g/dL).
11612660|NCT00550654|Experimental|Radiation Therapy in Metastatic Cancer|Patients undergo hypofractionated highly conformal radiotherapy with helical tomotherapy once every other day over 5 days for a total of 3 fractions.
11612661|NCT00550641|Active Comparator|1|
11612662|NCT00550641|Experimental|2|
11612774|NCT00549887||Short acting to rapid acting|Patients on short-acting human insulins who switch to rapid-acting analog insulin
11612775|NCT00549874|Experimental|1|
11612663|NCT00550628||resection of a non-sarcomatous primary colon neoplasm|The surgically removed colon will undergo ex-vivo imaging after examination in pathology. A PET scanner will be used to acquire a scan of the whole specimen.
11612664|NCT00550615|Experimental|Dasatinib Dose Escalation|Phase 1 employed a standard 3+3 dose-escalation design to assess safety, MTD and dose-limiting toxicity (DLT). Maximum Tolerated Dose (MTD) was defined as the next lowest dose level below where ≥ 2/3 or ≥ 3/6 patients experience dose limiting toxicities in cycle 1.
11612665|NCT00550615|Experimental|Dasatinib Maximum Tolerated Dose|Once the maximum tolerated dose is determined, an additional patients will be enrolled into the Phase II portion of this trial.
11612666|NCT00550589|Experimental|Cidofovir|1.0% topical cidofovir cream
11612667|NCT00550576|Experimental|digibind|Injection of digibind and psychological tests
11612668|NCT00550563|Experimental|Oral Cholecalciferol|Patients receive oral cholecalciferol 2000 IU once daily for 1 year
11612669|NCT00550550|Placebo Comparator|Placebo|Matching Placebo
11612670|NCT00550550|Experimental|SCH 697243|Grass Sublingual Tablet (Phleum pratense extract)
11612671|NCT00550537|Experimental|Treatment|Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
11612672|NCT00550524|Experimental|A|Knee osteoarthritis
11612673|NCT00550511|Other|Ultrasound|Surgeon-performed ultrasound as intervention, as a complement to clinical investigation and standardized laboratory testing.
11612674|NCT00550511|No Intervention|Control|Control group examined with clinical examination including standardized laboratory tests.
11612675|NCT00550498|Experimental|A|Behcet's Disease with ocular lesions
11612676|NCT00550485|Other|1|Healthy subjects with a single nucleotide polymorphism (SNP) of the ABCB1-gene (Genotype A)
11612677|NCT00550485|Other|2|Healthy subjects with a single nucleotide polymorphism (SNP) of the ABCB1-gene (Genotype B)
11612678|NCT00550472|Experimental|Probiotic|intervention
11612679|NCT00550459|Placebo Comparator|1|Placebo tablet given once a day for 21 days
11612680|NCT00550459|Active Comparator|2|Tolvaptan 15 mg-60 mg tablet given once a day for 21 days.
11612681|NCT00550446|Active Comparator|1|
11612682|NCT00550446|Experimental|2|
11612683|NCT00550446|Experimental|3|
11612684|NCT00550446|Experimental|4|
11612685|NCT00550446|Experimental|5|
11612686|NCT00550446|Experimental|6|
11612687|NCT00550446|Placebo Comparator|7|
11612688|NCT00550420|Experimental|Arm 1|Rosiglitazone XR
11612689|NCT00550407|Placebo Comparator|Placebo|
11612690|NCT00550407|Active Comparator|BW430C(lamotrigine)|
11612691|NCT00550394|Active Comparator|Quetiapine and Placebo|Quetiapine and Placebo
11612692|NCT00550394|Experimental|Quetiapine and Topiramate|Quetiapine and Topiramate
11612693|NCT00550381|Placebo Comparator|1|10mg
11612694|NCT00550381|Placebo Comparator|2|20mg
11612695|NCT00550381|Placebo Comparator|3|40mg
11612696|NCT00550381|Placebo Comparator|4|80mg
11612697|NCT00550381|Placebo Comparator|5|160mg
11612698|NCT00550381|Placebo Comparator|6|240mg
11612699|NCT00550381|Placebo Comparator|7|400mg
11612700|NCT00550381|Placebo Comparator|8|640mg
11612701|NCT00550381|Placebo Comparator|9|960mg
11612702|NCT00550381|Placebo Comparator|10|placebo
11612703|NCT00550368|Experimental|Helicobacter pylori negative|Persons who tested negative for H. pylori by both serology and Urea breath test. All participants will receive the Biological intervention: Enteropathogenic E. coli.
11612704|NCT00550368|Experimental|Helicobacter pylori positive|Persons who tested positive for H. pylori by both serology and Urea breath test. All participants will receive the Biological intervention: Enteropathogenic E. coli.
11612705|NCT00550355|Experimental|1|
11612706|NCT00550355|Experimental|2|
11612707|NCT00550355|Experimental|3|
11612708|NCT00550355|Placebo Comparator|4|
11612709|NCT00550342|Experimental|Rituximab|Rituximab (375 mg/m2) will be administered intravenously as per current package label in a facility capable of handling infusion reactions. Subjects would be pre dosed with diphenhydramine and acetaminophen. Solu-Medrol, 1.5 mg/kg would be dosed 1 hour prior to the first dose of rituximab. Three subsequent doses of rituximab will be given at weekly intervals.
11612710|NCT00550290|Active Comparator|Cefazolin Preoperatively|Participants received Cefazolin 2 grams intravenously within 30 minutes prior to incision
11612711|NCT00550290|Experimental|Cefazolin Postoperatively|Participants received Cefazolin 2 gram intravenous within 30 minutes prior to incision and 1 gram Cefazolin every 8 hours for the first 24 hours post-op
11612712|NCT00550277|Other|Treatment|LBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring, all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles. Patients with objective response or stable disease after re-evaluation at week 8 will continue LBH589 at the same dose until disease progression, unacceptable toxicity and/or at the discretion of the investigator.
11612713|NCT00550264|Experimental|1|
11612714|NCT00550264|No Intervention|2|
11612715|NCT00550251|Active Comparator|Acupressure Bands|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
11612716|NCT00550251|Placebo Comparator|Placebo|Elasticated wrist bands without active bead.
11612717|NCT00550238|Experimental|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
11612718|NCT00550225|Experimental|Sequence 1|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by placebo in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and 1500 micrograms of GSK961081 edisylate in session 4.
11612719|NCT00550225|Experimental|Sequence 2|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by 1500 micrograms of GSK961081 edisylate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and placebo in session 4.
11612776|NCT00549874|Experimental|2|
11612777|NCT00549861|No Intervention|A1|CMR study for the assessment of irreversible tissue damage
11612720|NCT00550225|Experimental|Sequence 3|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by placebo in session 2. The subjects will receive 1500 micrograms of GSK961081edisylate in session 3 and an additional dose of GSK961081 succinate in session 4.
11612721|NCT00550225|Experimental|Sequence 4|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by 1500 micrograms of GSK961081 edisylate in session 2. The subjects will receive placebo in session 3 and an additional dose of GSK961081 succinate in session 4.
11612722|NCT00550225|Experimental|Sequence 5|In session 1, subjects will receive 1500 micrograms of GSK961081 edisylate followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and placebo in session 4.
11612723|NCT00550225|Experimental|Sequence 6|In session 1, subjects will receive placebo followed by 900 micrograms of GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and 1500 micrograms of GSK961081 edisylate in session 4.
11612724|NCT00550225|Experimental|Sequence 7|In session 1, subjects will receive 1500 micrograms of GSK961081 edisylate followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive placebo in session 3 and an additional dose of GSK961081 succinate in session 4.
11612725|NCT00550225|Experimental|Sequence 8|In session 1, subjects will receive placebo followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 edisylate in session 3 and an additional dose of GSK961081 succinate in session 4.
11612726|NCT00550212|Experimental|1|240 mg
11612727|NCT00550199|Experimental|LBH589 and Gemcitabine|Phase I dose escalation study
11612728|NCT00550186|Placebo Comparator|1|No preload
11612729|NCT00550186|Active Comparator|2|Preload with cristalloid infusion
11612730|NCT00550186|Active Comparator|3|Preload with collid infusion
11612731|NCT00550173|Experimental|Pemetrexed + Erlotinib|Pemetrexed 500 milligrams per meter squared (mg/m^2) of body surface area, administered by intravenous (IV) infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
11612732|NCT00550173|Active Comparator|Erlotinib|Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
11612733|NCT00550173|Active Comparator|Pemetrexed|Pemetrexed 500 mg/m^2 of body surface area, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months.
11612734|NCT00550160|Active Comparator|1|The Home Management of Malaria (HMM) is a strategy aimed at improving access to prompt and effective antimalarial treatment of all fevers in children under 5 years. Community Drug Distributors (CDD) have been trained and equipped for this task.
11612735|NCT00550160|Experimental|2|An Intermittent Preventive Treatment (IPTc) schedule for asymptomatic pre-school children during high malaria transmission seasons alongside an ongoing Home Management of Malaria programme
11612736|NCT00550147|Experimental|1|Oros Methylphenidate and Quetiapine
11612737|NCT00550134||1, Non Cancer group|A noncancer control group (N=35), frequency matched on age (< 50 and ≥ 50) and education (less than college or some college and above) will also be recruited and evaluated with the same neuropsychological test battery on a schedule that matches the inter-test interval of the patients.
11612738|NCT00550134||2 Breast Cancer Patients Scheduled for chemotherapy|We will recruit patients with localized breast cancer undergoing adjuvant chemotherapy for the first time and will test the effects of chemotherapy will be given a battery of neuropsychological tests and an MRI evaluation prior to beginning chemotherapy and approximately one month (plus/minus 4 weeks) following completion of treatment.
11612739|NCT00550134||3 Breast Cancer Patients Not Scheduled for Chemotherapy|We will recruit patients with localized breast cancer not undergoing adjuvant chemotherapy.
11612740|NCT00550121|Experimental|1|
11612741|NCT00550121|Placebo Comparator|2|
11612742|NCT00550108|No Intervention|A|Observation of pancreatic cysts
11612743|NCT00550108|Experimental|B|Ethanol lavage of pancreatic cysts
11612744|NCT00550095|Experimental|1|valsartan
11612745|NCT00550056|Experimental|1|NET
11612746|NCT00550056|Experimental|2|TC
11612747|NCT00550056|No Intervention|3|Monitoring Group
11612748|NCT00550043|Experimental|Cohort 1: Treatment Group A|INCB018424 15 mg twice daily (BID) or matching placebo
11612749|NCT00550043|Experimental|Cohort 2: Treatment Group B|INCB018424 5 mg BID or matching placebo
11612750|NCT00550043|Experimental|Cohort 2: Treatment Group C|INCB018424 25 mg BID or matching placebo
11612751|NCT00550043|Experimental|Cohort 2: Treatment Group D|INCB018424 50 mg once daily (QD) or matching placebo
11612752|NCT00550043|Placebo Comparator|Placebo|Matching placebo, oral
11612753|NCT00550030|Experimental|left/right|half-body comparison
11612754|NCT00550017|Experimental|1|
11612755|NCT00550004|Active Comparator|Arm 1|RP101 and Gemcitabine
11612756|NCT00550004|Placebo Comparator|Arm 2|Placebo and Gemcitabine
11612757|NCT00549978|Other|1|Two compartments with cross-over and parallel
11612758|NCT00549978|Other|2|Two compartments with cross-over and parallel
11612759|NCT00549939|Placebo Comparator|Placebo|Matching placebo 0.1 mg/kg/day or 0.2 mg/kg/day
11612760|NCT00549939|Experimental|Alfuzosin 0.1 mg/kg/day|
11612761|NCT00549939|Experimental|Alfuzosin 0.2 mg/kg/day|
11612762|NCT00549926|Active Comparator|1|
11612763|NCT00549926|Active Comparator|2|
11612764|NCT00549926|Active Comparator|3|
11612765|NCT00549926|Active Comparator|4|
11612766|NCT00549913|Experimental|1|10 subjects to receive lowest dose of NeoFuse (MPCs)
11612767|NCT00549913|Active Comparator|2|4 subjects standard posterolateral spinal fusion with instrumentation
11612768|NCT00549913|Experimental|3|10 subjects to receive middle dose of NeoFuse
11612769|NCT00549913|Active Comparator|4|3 subjects standard posterolateral spinal fusion with instrumentation
11612770|NCT00549913|Experimental|5|10 subjects to receive highest dose of NeoFuse
11612771|NCT00549913|Active Comparator|6|3 subjects with standard posterolateral spinal fusion with instrumentation
11612917|NCT00548652|No Intervention|1|standard nutrition counselling
11612778|NCT00549848|Experimental|HD PEG|"Participants randomized to receive higher dose PEG-asparaginase during the continuation phase.
~Interventions:
~Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine
~Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib"
11612779|NCT00549848|Active Comparator|CD PEG|"Participants randomized to receive conventional dose PEG-asparaginase during the continuation phase..
~Interventions:
~Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine
~Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib"
11612780|NCT00549835|Active Comparator|Real Acupuncture|Participants will have acupuncture performed at a rate of 3 times (Mon, Wed, Fri) / week for total of 2 weeks (total of 6 sessions). We will follow Saam Acupuncture methods, which have been the mainstream of acupuncture methodology in most Korean Oriental Medical Colleges and among clinical practitioners >400 years. Standardized acupuncture prescriptions for mucositis will be acupuncture points tonifying Spleen Meridian (R side) and Small Intestine Meridian (L side). In Oriental Medicine, the spleen has functions of promoting water metabolism, transporting nutrients, and controlling blood. Mouth belongs to the spleen system according to Five element theory. Small intestine is related with mucositis symptoms including thirst and tongue ulcers. We will use sterile, disposable, filiform needles, size 0.16 (40Gauge) - 0.30 mm (30Gauge) in diameter and 15-40 mm long. Total number of acupuncture needles will be 8 (4 needles each side) and needles will be retained for 20 minutes.
11612781|NCT00549835|Sham Comparator|Sham Acupuncture|Newly diagnosed leukemia patients will be recruited from the large patient population on the Leukemia Inpatient Services who will be receiving high dose preperative regimens such as Busulfan + Cytarabine for marrow transplantation.
11612782|NCT00549822|Experimental|Intermittent letrozole therapy|Letrozole 2.5 mg administered by mouth daily during each 28 day treatment cycle. Treatment is intermittent with possible breaks between each 28 day treatment cycle based on CA 15-3 or CA 27.29 levels. Letrozole is administered until the participant has disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors), experiences severe side effects, or decides to stop treatment.
11612783|NCT00549809|Active Comparator|IMV, SIMV|
11612784|NCT00549796|Active Comparator|1|PCI performed at a hospital with co-located (on-site) cardiac surgery
11612785|NCT00549796|Other|2|PCI performed at a hospitals without co-located (on-site) cardiac surgery
11612786|NCT00549783|Active Comparator|Botulinum toxin type A 900kD|First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
11612787|NCT00549783|Placebo Comparator|Placebo|First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
11612788|NCT00549770|Experimental|LCZ696 100 mg|Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
11612789|NCT00549770|Experimental|LCZ696 200 mg|Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
11612790|NCT00549770|Experimental|LCZ696 400 mg|Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
11612791|NCT00549770|Active Comparator|Valsartan 80 mg|Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
11612792|NCT00549770|Active Comparator|Valsartan 160 mg|Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsatan and AHU377 (5 tablets and 2 capsules) daily.
11612793|NCT00549770|Active Comparator|Valsartan 320 mg|Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
11612794|NCT00549770|Experimental|AHU377 200 mg|Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.
11612795|NCT00549770|Placebo Comparator|Placebo|Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
11612796|NCT00549757|Experimental|Aliskiren|"In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.
~With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment"
11612797|NCT00549757|Placebo Comparator|Placebo|"In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.
~With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment."
11612798|NCT00549731||Healthy individuals|"No intervention
~Healthy participants ages 14-32 for a neuroimaging study."
11612799|NCT00549731||Individuals with Autism Spectrum Disorder|"No intervention
~ASD participants ages 14-32 for a neuroimaging study."
11612800|NCT00549718|Experimental|Lurasidone 40mg|
11612801|NCT00549718|Experimental|Lurasidone 80mg|
11612802|NCT00549718|Experimental|Lurasidone 120mg|
11612803|NCT00549718|Placebo Comparator|Sugar Pill|
11612804|NCT00549692|Experimental|Omacor|
11612805|NCT00549692|Placebo Comparator|Placebo Omacor|
11612806|NCT00549679|Experimental|25 mcg|25 microgram inhaled once daily
11612807|NCT00549679|Experimental|87.5 mcg|87.5 microgram inhaled once daily
11612808|NCT00549679|Placebo Comparator|Placebo|Placebo inhaled once daily
11612809|NCT00549666|Experimental|Lurasidone 40 mg|
11612810|NCT00549666|Placebo Comparator|Placebo|
11612811|NCT00549666|Active Comparator|Ortho Tri-Cyclen|
11612918|NCT00548652|Experimental|2|MOVE -weight loss intervention
11612919|NCT00548652|Experimental|3|MOVE plus medical crisis counselling
11612812|NCT00549640|Active Comparator|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
11612813|NCT00549640|Placebo Comparator|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
11612814|NCT00549614|Experimental|1|
11612815|NCT00549614|Placebo Comparator|2|
11612816|NCT00549601|Experimental|Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|
11612817|NCT00549601|Experimental|Rivastigmine patch (9.5 mg/day)|
11612818|NCT00549601|Active Comparator|Rivastigmine capsules (6 mg to 12 mg/day)|
11612819|NCT00549575|Experimental|A|Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories). Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venous was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
11612820|NCT00549575|Placebo Comparator|B|After double blind randomization, patients received a placebo. Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venous was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
11612821|NCT00549562|Other|Paliperidone ER|8-Week Open-Label
11612822|NCT00549549|Active Comparator|1|
11612823|NCT00549549|Experimental|2|
11612824|NCT00549549|Experimental|3|
11612825|NCT00549549|Experimental|4|
11612826|NCT00549536|No Intervention|2|
11612827|NCT00549536|Active Comparator|1|Patients on calcium supplementation
11612828|NCT00549523|Placebo Comparator|Placebo|Placebo (capsule filled with inert materials)
11612829|NCT00549523|Experimental|Low Dose|400 mg bid Lessertia Frutescens
11612830|NCT00549523|Experimental|Mid Dose|800 mg bid Lessertia Frutescens
11612831|NCT00549523|Experimental|High Dose|1200 bid Lessertia Frutescens
11612832|NCT00549497|Other|GW870086X|
11612833|NCT00549484||1|10 mL/kg platelet transfusion
11612834|NCT00549484||2|15 mL / kg platelet transfusion
11612835|NCT00549471|Experimental|BG|cooperative quadriplegic CP children ages 8-11 years, gross motor function level 4 with troublesome hypertonia that will respond to treatment. BG children will be given Botulinum Toxin A, as clinically required, in addition to an equivalent program of intensive therapy
11612836|NCT00549471|No Intervention|Control Group|control group: Twenty cooperative quadriplegic CP children ages 8-11 years, gross motor function level 4 with troublesome hypertonia that will respond to treatment.CG children will undergo a program of intensive therapy.
11612837|NCT00549445||Azithromycin-treated|Participants in the COPD Network Macrolide Study who received azithromycin for 1 year.
11612838|NCT00549445||Placebo-treated|Participants in the COPD Network Macrolide Study who received placebo for 1 year.
11612839|NCT00549432|Experimental|1|
11612840|NCT00549419|Experimental|1|In the Treatment group, the traditional vital signs and APCO are made continuously available for fluid and catecholamine optimization and clinical decision making.
11612841|NCT00549419|Active Comparator|2|
11612842|NCT00549406|Experimental|1|computer-based visual-training program UFOV
11612843|NCT00549406|Experimental|2|video-game based visual training
11612844|NCT00549406|Placebo Comparator|3|computerized word puzzles
11612845|NCT00549393|Experimental|1|Daily bathing with 2% chlorhexidine gluconate
11612846|NCT00549393|No Intervention|2|Standard bathing with soap and water basin or disposable cloth
11612847|NCT00549380|Experimental|1|
11612848|NCT00549367|Other|1|Clients in the control arm of the study will receive nutrition assessment only for the first 24 weeks and the be transferred to nutrition counselling group
11612849|NCT00549341|Active Comparator|1|
11612850|NCT00549341|Placebo Comparator|2|
11612851|NCT00549328|Experimental|Pazopanib Open-label|Single-arm, non-randomised, single-stage pazopanib monotherapy.
11612852|NCT00549315|Experimental|1|
11612853|NCT00549302|Active Comparator|20 mg tadalafil|20 milligram (mg) tadalafil taken once a day
11612854|NCT00549302|Active Comparator|40 mg tadalafil|40 mg tadalafil tablet taken once a day
11612855|NCT00549237|Active Comparator|Nutrition|Pre-operative Glucose load and post-operative immediate enteral nutrition
11612856|NCT00549237|No Intervention|Control|No pre-operative glucose load. No early post-operative nutrition
11612857|NCT00549198|Experimental|ABC/3TC + EFV|
11612858|NCT00549198|Active Comparator|TDF/FTC + EFV|
11612859|NCT00549172|Active Comparator|Operative (O)|Partial resection of degenerative tear of medial meniscus
11612860|NCT00549172|Sham Comparator|Conservative (K)|Arthroscopy (diagnostic)
11612861|NCT00549159|Experimental|Cavaterm|
11612862|NCT00549159|Active Comparator|TCRE|Transcervical resection of the endometrium
11612863|NCT00549120|Experimental|Propranolol alone|Propranolol 80 mg (5 doses at 6 hourly intervals)
11612864|NCT00549120|Experimental|Propranolol + salbutamol|Propranolol 80 mg (5 doses at 6 hourly intervals) + salbutamol 600 μg (4 doses at 6 hourly intervals)
11612865|NCT00549120|Experimental|Salbutamol alone|Salbutamol 600 μg (4 doses at 6 hourly) + placebo (5 doses at 6 hourly intervals)
11612866|NCT00549120|Placebo Comparator|Placebo|Placebo (5 doses at 6 hourly)
11612867|NCT00549120|Experimental|Propranolol + ipratropium + salbutamol|Propranolol 80 mg (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose)
11612868|NCT00549120|Experimental|Placebo + ipratropium + salbutamol|Placebo (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose)
11612869|NCT00549107|Experimental|1|
11612870|NCT00549107|Active Comparator|2|
11631077|NCT00361881|Experimental|1|ME-609
11612871|NCT00549081|Experimental|1|IVF patients who had a low ovarian response in a previous hormonal-stimulation treatment, treated with recombinant FSH and LH.
11612872|NCT00549081|No Intervention|2|IVF patient who had a low ovarian response in a previous hormonal-stimulation treatment, treated with recombinant FSH and LH.
11612873|NCT00549055||1|Patients who obtained reimbursement of Macugen.
11612874|NCT00549042|Experimental|OROS hydromorphone|OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg
11612875|NCT00549042|Placebo Comparator|placebo|Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).
11612876|NCT00549029||1,2|Group 1 for the patients with rhabdomyolysis Group 2 for the control without any myopathy
11612877|NCT00549016|Experimental|1|
11612878|NCT00548990|Experimental|1|a 10-month moderate aerobic exercise training program
11612879|NCT00548990|Placebo Comparator|2|flexibility/balance control group
11612880|NCT00548964|Experimental|Ketamine + Lithium|All participants receive the study drug, IV ketamine, open-label
11612881|NCT00548964|Active Comparator|Ketamine + Placebo|All participants receive the study drug, IV ketamine, open-label
11612882|NCT00548951|Active Comparator|1|Subject receives Snoezelen sessions once per week.
11612883|NCT00548951|Active Comparator|2|Subject receives Snoezelen sessions three times per week.
11612884|NCT00548951|Other|3|Subject receives no sessions per week.
11612885|NCT00548925|Experimental|1|
11612886|NCT00548925|Placebo Comparator|2|
11612887|NCT00548899|Other|Sorafenib|Single Arm: All patients receive sorafenib in addition to the established chemotherapy
11612888|NCT00548886|Experimental|Epinephrine|Healthy pediatric subjects will receive epinephrine. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes.The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes. The epinephrine infusion is then discontinued.
11612889|NCT00548860|Experimental|Ferric Carboxymaltose (FCM)|Undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg)
11612890|NCT00548860|Active Comparator|Standard Medical Care (SMC)|Varied as determined by the Investigator
11612891|NCT00548847|Experimental|GM-CSF, Interferon-α-2b|
11612892|NCT00548821|Experimental|2|ARM 2: Weekly cisplatin 40mg/m2, concurrent with radiotherapy.
11612893|NCT00548821|Experimental|1|ARM 1: 5-day 3 weekly cisplatin 20mg/m2 for 5 days, concurrent with radiotherapy
11612894|NCT00548808|Experimental|Insulin lispro low mixture|Insulin lispro low mixture (1, 2 or 3 daily injections)
11612895|NCT00548808|Active Comparator|Insulin glargine|Insulin glargine (alone or with 1, 2 or 3 daily injections of insulin lispro)
11612896|NCT00548782|Active Comparator|A|Subjects will be placed on Paleolithic diet and markers of insulin resistance, lipid profiles and vascular reactivity will be measured. a paleolithic diet excludes dairy, grains, legumes and processed foods.
11612897|NCT00548782|Active Comparator|B|Subjects will be placed on ADA ( American Diabetes Association) recommended diet and markers of insulin resistance, lipid profiles and vascular reactivity will be measured. An ADA diet is lower fat and more whole grains.
11612898|NCT00548769|Experimental|Sequence ADBC|Subjects will be administered formulation A, formulation D, formulation B and formulation C across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
11612899|NCT00548769|Experimental|Sequence BACD|Subjects will be administered formulation B, formulation A, formulation C and formulation D across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
11612900|NCT00548769|Experimental|Sequence CBDA|Subjects will be administered formulation C, formulation B, formulation D and formulation A across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
11612901|NCT00548769|Experimental|Sequence DCAB|Subjects will be administered formulation D, formulation C, formulation A and formulation B across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
11612902|NCT00548756|Experimental|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy
11612903|NCT00548756|Other|Observation|Observation
11612904|NCT00548743|Experimental|1|Intervention arm
11612905|NCT00548743|Placebo Comparator|2|Usual care
11612906|NCT00548730||Observation|Patients with known or suspected malignancies of the lung and with a medical indication for a bronchoscopy
11612907|NCT00548717|Experimental|Siro/MMF|Sirolimus and Mycophenolate Mofetil as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF)
11612908|NCT00548717|Experimental|Siro/MMF/Bort|Sirolimus, Mycophenolate Mofetil, and Bortezomib as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF) Bortezomib (Velcade) *added with study reopening in 2012
11612909|NCT00548691|Experimental|Ferric Carboxymaltose (FCM)|Subjects received an undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg) or subjects received 200 mg of FCM IV push undiluted directly into the venous line of the dialyzer.
11612910|NCT00548691|Active Comparator|Standard Medical Care (SMC)|SMC for IDA (as determined by the Investigator) for treating CKD related anemia.
11612911|NCT00548678|Experimental|A|intravenous diclofenac sodium
11612912|NCT00548678|Active Comparator|B|intravenous ketorolac
11612913|NCT00548678|Active Comparator|C|oral diclofenac (Cataflam)
11612914|NCT00548678|Active Comparator|D|oral aspirin
11612915|NCT00548665|Experimental|1|Carotid plaque screening and brief advice for smoking cessation: Smokers with at least one carotid plaque will receive pictures of their own plaques with a structured explanation on the general significance of plaques.
11612916|NCT00548665|Active Comparator|2|Brief advice for smoking cessation (without carotid ultrasound for plaque screening): to ensure equal contact conditions, smokers not undergoing ultrasound will receive a relevant explanation on the risks associated with tobacco smoking.
11631215|NCT00360256||Control|
11612921|NCT00548652|Experimental|5|MOVE plus methyphenidate plus medical crisis counselling
11612922|NCT00548639|Experimental|Statin Choice|Statin Choice Decision Aid The provider will introduce the patient to the choice of statins using the decision aid. The patient may make a choice then or defer this choice; in all cases, the patient goes home with the Statin Choice decision aid and pamphlet.
11612923|NCT00548639|Sham Comparator|Usual Care|Control Pamphlet the provider meets with the patient to discuss treatment options in the usual fashion.
11612924|NCT00548626|Active Comparator|A|Patients assigned to simple needle group (SN) will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
11612925|NCT00548626|Experimental|B|Patients assigned to multiple needle group (MN) will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
11612926|NCT00548613|Experimental|A|Patients with documented acute myocardial infarction (heart attack) occurring within 4-24 hours after onset of symptoms
11612927|NCT00548613|Experimental|B|Candidates for coronary artery bypass grafting that suffered a myocardial infarction (heart attack) within the past 12 months
11612928|NCT00548600|Experimental|1|Iridium implant plus external beam irradiation
11612929|NCT00548600|Active Comparator|2|Standard external beam irradiation alone
11612930|NCT00548587|Active Comparator|1|Participants will receive one 50 mg E5555 tablet and two 100 mg placebo tablets, once daily for 12 weeks.
11612931|NCT00548587|Active Comparator|2|Participants will receive one 50 mg placebo tablet, one 100 mg E5555 tablet, and one 100 mg placebo tablet, once daily for 12 weeks.
11612932|NCT00548587|Active Comparator|3|Participants will receive one 50 mg placebo tablet and two 100 mg E5555 tablets, once daily for 12 weeks.
11612933|NCT00548587|Placebo Comparator|4|Participants will receive one 50 mg placebo tablet and two 100 mg placebo tablets, once daily for 12 weeks.
11612934|NCT00548548|Experimental|Bevacizumab|Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.
11612935|NCT00548548|Placebo Comparator|Placebo|Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.
11612936|NCT00548522||1|Pregnant (12 - 16 wks gestation) women with Type 1 diabetes
11612937|NCT00548522||2|Pregnant women (34-38 wks gestation) with Type 1 diabetes
11612938|NCT00548522||3|Post partum women with Type 1 diabetes
11612939|NCT00548522||4|Non pregnant women with Type 1 diabetes
11612940|NCT00548496|Experimental|Placebo-Controlled based on the two Intervention Groups below|Placebo-Controlled based on the two Intervention Groups below.
11612941|NCT00548483|Active Comparator|1|dexamethasone 5mg was administered every 6 hour for 1 day
11612942|NCT00548483|Active Comparator|2|dexamethasone 10mg was administered every 6 hour for 1 day
11612943|NCT00548470|Experimental|varenicline|open label varenicline 2mg/day
11612944|NCT00548457||A|
11612945|NCT00548444|Experimental|Group 1|Volunteers will receive a single dose of MVA85A followed by regular blood tests to measure the resulting cellular immune response.
11612946|NCT00548444|Experimental|Group 2|Volunteers will receive a single dose of MVA85A followed by an infusion of labelled (deuterated) glucose and regular blood tests.
11612947|NCT00548444|Experimental|Group 3|Volunteers will receive a single dose of MVA85A followed by an infusion of labelled (deuterated) glucose and regular blood tests.
11612948|NCT00548431|Experimental|6 mercaptopurine arm|All patients received basic daily 6MP (6-mercaptopurine) (25 mg/m^2) and in addition high-dose methotrexate(HDM) every 3rd week (3 times HDM in total) and PEG-asparaginase every 14th day. Patients increased the dose of 6MP 2 weeks after each HDM if if the myelotoxicity had been acceptable. This means 2 increments since the study stopped 2 weeks after the last HDM
11612949|NCT00548418|Experimental|I|"Cisplatin 50 mg/m2 IV day 1 of a 21 day cycle
~Topotecan 0.75 mg/m2 IV Days 1, 2, 3 of a 21 day cycle
~Bevacizumab 15 mg/kg day 1 of a 21 day cycle"
11612950|NCT00548405|Experimental|Alemtuzumab 12 mg|Alemtuzumab (Lemtrada™) 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
11612951|NCT00548405|Experimental|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
11612952|NCT00548405|Active Comparator|Interferon Beta-1a|Interferon Beta-1a (Rebif®) 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
11612953|NCT00548379|Active Comparator|1|Vitamin D
11612954|NCT00548379|Placebo Comparator|2|
11612955|NCT00548366|Experimental|1|4 gram sodium diet
11612956|NCT00548366|Active Comparator|2|2 gram sodium diet
11612957|NCT00548353|Experimental|1|MK3207 Orally administered to patients with water. During each period (with and without acute migraine).
11612958|NCT00548353|Placebo Comparator|2|MK3207 placebo as tablets will be Orally administered to patients with water. During each period (with and without acute migraine).
11612959|NCT00548340|Experimental|VEC-162 20 mg|VEC-162 (tasimelteon) 20 mg capsules PO daily for five weeks
11612960|NCT00548340|Experimental|VEC-162 50 mg|VEC-162 (tasimelteon) 50 mg capsules PO daily for five weeks
11612961|NCT00548340|Placebo Comparator|Placebo|Placebo capsules PO daily five weeks
11613003|NCT00548054|Experimental|Vaccine Group for Vibriocidal and Measles Assay|Killed whole cell cholera vaccine bled at day 14 and 28 for measles immunogenicity testing
11613388|NCT00545129|Experimental|Tanezumab 10 mg IV + opioids|
11612962|NCT00548327|Active Comparator|Atomoxetine|"Atomoxetine 80 mg final dose. Arm lasts 14 days.
~Schedule 25 mg Day 1 (or Day 22), 40 mg Day 2-3 (or Days 23-24), 60 mg Days 4-5 (or Days 25-26), 80 mg Days 6-14 (or Days 27-35).
~After 14 days, subjects undergo functional magnetic resonance imaging (MRI) and neuropsychological testing in addition to psychopathology ratings"
11612963|NCT00548327|Placebo Comparator|Placebo|"Placebo administered for 14 days. Schedule Atomoxetine 25 mg Placebo Day 1 (or Day 22), Atomoxetine 40 mg Placebo Day 2-3 (or Days 23-24), Atomoxetine 60 mg Placebo Days 4-5 (or Days 25-26), Atomoxetine 80 mg Placebo Days 6-14 (or Days 27-35).
~After 14 days, subjects undergo functional magnetic resonance imaging and neuropsychological testing in addition to psychopathology ratings"
11612964|NCT00548314|Experimental|1|After excision and adequate hemostasis, the selected wound will be treated with the dermal substitute Matriderm, a split skin graft (SSG), mesh 1:1.5 and VAC therapy. The VAC system will be set at 125mmHg, continuous mode, for 3-5 days.
11612965|NCT00548314|Experimental|2|After excision and adequate hemostasis, the selected wound will be treated with the dermal substitute Matriderm, a split skin graft (SSG), mesh 1:1.5.
11612966|NCT00548314|Experimental|3|After excision and adequate hemostasis, the selected wound will be treated with a split skin graft (SSG), mesh 1:1.5 and VAC therapy. The VAC system will be set at 125mmHg, continuous mode, for 3-5 days.
11612967|NCT00548314|Active Comparator|4|After excision and adequate hemostasis, the selected wound will be treated with a split skin graft (SSG), mesh 1:1.5.
11612968|NCT00548275|Experimental|1|Enhanced Sexual Risk Management (ESRM): Patients assigned to ESRM will attend 4 individual gender-specific interactive counseling sessions, once weekly over a four-week period. They will attend 2 sessions (20 minutes, weeks 2 and 3) followed by 2 sessions (40 minutes, weeks 4 and 5) that will be gender-specific to the patient and gender-matched with the study physicians (one female and one male) who will be trained in HIV testing and risk counseling. Sessions will include skill-building in condom use, safer sex negotiation, self-control of triggers and coping skills, didactic materials, and distribution of written material and address self-perception of risk, barriers to risk reduction, and negotiation of a risk-reduction plan.
11612969|NCT00548275|Active Comparator|2|Standard Sexual Risk Management (SSRM): In SSRM, patients will attend two 10-minute gender non-specific individual educational sessions about HIV/AIDS provided by one of the study physicians who will be trained in HIV testing and risk counseling. Session 1 will coincide with the physician visit at the time of randomization. The patient will receive pre-test counseling at this time and undergo HIV antibody testing. Session 2 will take place 7 days later when the patient returns to receive their HIV test results and post-test counseling. In addition, subjects will receive didactic prevention messages about HIV relevant to their reported risks and will be asked if they have questions regarding this information.
11612970|NCT00548262|Experimental|1|
11612971|NCT00548249|Placebo Comparator|0 µg iron/dL of dialysate|Placebo 0 micrograms (µg) of iron/ deciliter (dL) of dialysate
11612972|NCT00548249|Experimental|5 µg iron/dL of dialysate|5 micrograms (µg) of iron/ deciliter (dL) of dialysate
11612973|NCT00548249|Experimental|10 µg iron/dL of dialysate|10 micrograms (µg) of iron/ deciliter (dL) of dialysate
11612974|NCT00548249|Experimental|12 µg iron/dL of dialysate|12 micrograms (µg) of iron/ deciliter (dL) of dialysate
11612975|NCT00548249|Experimental|15 µg iron/dL of dialysate|15 micrograms (µg) of iron/ deciliter (dL) of dialysate
11612976|NCT00548236|Experimental|1|Immediate participation in a 16-week exercise program
11612977|NCT00548236|No Intervention|2|Control population; will receive exercise plan after 16-week control period
11612978|NCT00548223|Experimental|Dengzhan Shengmai capsule|Dengzhan Shengmai capsule 0.18g by mouth twice a day for 1year
11612979|NCT00548223|Placebo Comparator|Placebo|Placebo 0.18g by mouth twice a day for 1year
11612980|NCT00548197|Experimental|Intervention group|Intravitreal Bevacizumab will be injected 2.5 mg IVB 3-5 days before operation in diabetic patients who were candidates for vitrectomy before performing pars plana vitrectomy
11612981|NCT00548197|No Intervention|Control group|no injection before performing pars plana vitrectomy in diabetic patients who were candidates for vitrectomy
11612982|NCT00548184|Experimental|Single Group Assignment|Lapatinib Trastuzumab Endocrine
11612983|NCT00548171|Experimental|Boostrix I Group|Subjects who had received the Boostrix™ vaccine in the primary study 263855/002 (NCT01267058), were boosted in the current study with one dose of the same vaccine, intramuscularly in the deltoid region of the non-dominant arm.
11612984|NCT00548171|Active Comparator|Boostrix II Group|Subjects who had received the Td vaccines in the primary study 263855/002 (NCT01267058), were boosted in the current study with one dose of the Boostrix™ vaccine intramuscularly in the deltoid region of the non-dominant arm.
11612985|NCT00548145|Experimental|1|
11612986|NCT00548145|Active Comparator|2|
11612987|NCT00548132|No Intervention|1|Patients in this arm will continue to get routine care
11612988|NCT00548132|Experimental|Chlorhexidine-impregnated foam dressing|Patient's catheters were cleaned with chlorhexidine-alcohol solution at least weekly before application of the Biopatch. These were evaluated daily and if the dressing was bloody, soiled or damaged, the dressing and the Biopatch were replaced prior to the 7-day period.
11612989|NCT00548119|Experimental|NeoCart|
11612990|NCT00548119|Active Comparator|microfracture|
11612991|NCT00548106|Experimental|1|Infants will be fed the new hydrolyzate formula.
11612992|NCT00548106|Placebo Comparator|2|Nan HA infant formula
11612993|NCT00548093|Experimental|1|descriptive: adenocarcinoma histology
11612994|NCT00548093|Experimental|2|descriptive: non-adenocarcinoma histology
11612995|NCT00548067|Active Comparator|1|
11612996|NCT00548067|Active Comparator|2|
11612997|NCT00548067|Active Comparator|3|
11612998|NCT00548067|Experimental|4|
11612999|NCT00548054|Experimental|Vaccine Group for Vibriocidal Assay|Killed whole cell cholera vaccine bled at day 42 for vibriocidal assay
11613000|NCT00548054|Experimental|Vaccine Group for EPI Assay|Killed whole cell cholera vaccine bled at day 56 for EPI immunogenicity testing
11613001|NCT00548054|Placebo Comparator|Placebo Group for Vibriocidal Assay|Placebo bled at day 42 for vibriocidal assay
11613002|NCT00548054|Placebo Comparator|Placebo Group for EPI Assay|Placebo bled at day 56 for EPI immunogenicity testing
11613245|NCT00546065|No Intervention|non ablation|non ablation only surveillance
11613004|NCT00548054|Placebo Comparator|Placebo Group for Vibriocidal and Measles Assay|Placebo bled at day 14 and 28 for measles immunogenicity testing
11613005|NCT00548041|Other|Rapid HIV Tested|Subjects have HIV testing by oral swab performed.
11613006|NCT00548015|Active Comparator|State of the Art strategy|education, reminders, performance feedback,
11613007|NCT00548015|Experimental|extended strategy|state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
11613008|NCT00548002||1 and 2|Patients were randomly assigned to receive either 1) standard treatment or 2) standard treatment combined with a fluoroquinolone (trovafloxacin or levofloxacin).
11613009|NCT00547989|Active Comparator|1|control
11613010|NCT00547989|Experimental|2|PVB with ropivacaine and postoperative pump 5ml/h
11613011|NCT00547989|Experimental|Experimental 1|PVB with ropivacaine, 10 patients included but not analysed
11613012|NCT00547963|Experimental|1|two brief counseling sessions delivered to ED patients who report conjoint alcohol and marijuana use
11613013|NCT00547950|Experimental|1|drug
11613014|NCT00547937|Sham Comparator|Sham-CPAP|The sham CPAP device consisted of a conventional CPAP device, in which the area of the exhalation port was amplified, thereby nearly cancelling nasal pressure; an orifice resistor was connected between the tubing and the CPAP unit that loads the blower with the same airflow resistance as in effective CPAP
11613015|NCT00547937|Active Comparator|CPAP|
11613016|NCT00547911|Experimental|LDOPS + Placebo; LDOPS + CAR; LDOPS + ENT|Each subject received 400 mg of droxidopa (LDOPS) with three separate interventions, i.e., LDOPS with 200 mg placebo, LDOPS with 200 mg carbidopa (CAR), and LDOPS with 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days. This arm received the three interventions in the order of: LDOPS + Placebo, followed by LDOPS + CAR, followed by LDOPS + ENT.
11613017|NCT00547911|Experimental|LDOPS + Placebo; LDOPS + ENT; LDOPS + CAR|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + Placebo, followed by LDOPS + ENT, and lastly LDOPS + CAR.
11613018|NCT00547911|Experimental|LDOPS + CAR; LDOPS + Placebo; LDOPS + ENT|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + CAR, followed by LDOPS + Placebo, and lastly LDOPS + ENT.
11613019|NCT00547911|Experimental|LDOPS + CAR; LDOPS + ENT; LDOPS + Placebo|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + CAR, followed by LDOPS + ENT, and lastly LDOPS + Placebo.
11613020|NCT00547911|Experimental|LDOPS + ENT; LDOPS + Placebo; LDOPS + CAR|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + ENT, followed by LDOPS + Placebo, and lastly LDOPS + CAR.
11613021|NCT00547911|Experimental|LDOPS + ENT; LDOPS + CAR; LDOPS + Placebo|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + ENT, followed by LDOPS + CAR, and lastly LDOPS + Placebo.
11613022|NCT00547898|Experimental|Placebo|
11613023|NCT00547898|Experimental|Crofelemer 125 mg|
11613024|NCT00547898|Experimental|Crofelemer 250 mg|
11613025|NCT00547898|Experimental|Crofelemer 500 mg|
11613026|NCT00547885|Active Comparator|1|Active dihydrocodeine, long acting and Placebo dihydrocodeine short acting
11613027|NCT00547885|Active Comparator|2|Placebo dihydrocodeine, long acting and active dihydrocodeine short acting.
11613028|NCT00547872|Experimental|1|Best medical/behavioral treatment according to guidelines suggestions plus CAD screening by ECG tolerance testing followed by revascularization in case of coronary stenosis.
11613029|NCT00547872|No Intervention|2|Best medical/behavioral treatment according to guidelines suggestions
11613030|NCT00547833||Experimental|Children with language-learning disabilities reading at approximately a 6th grade level
11613031|NCT00547833||Age-Matched|Typical language learners each of whom is pair match to an experimental participant by age and gender.
11613032|NCT00547833||Language-Matched|Typical language learners, each of whom is pair-matched to an experimental participant by reading comprehension skills and gender.
11613033|NCT00547820|Experimental|A|with application of urinary sensor
11613034|NCT00547820|Placebo Comparator|B|without use of urinary sensor
11613035|NCT00547794||CRT-D + AVJ Ablation|
11613036|NCT00547794||Single-Chamber ICD + Pharmacological Therapy|
11613037|NCT00547729|Experimental|HeartPOD™ System|Implantation of HeartPOD™ System
11613038|NCT00547716|Experimental|1.|Omega-3 Fatty Acids 4 grams/day
11613039|NCT00547716|Placebo Comparator|2.|Placebo comparator along with interferon.
11613040|NCT00547703|Active Comparator|Nortriptyline|Patients in this group will receive Nortriptyline 25mg at night for 8 weeks.
11613041|NCT00547703|Placebo Comparator|Sugar pill|Patients in this group will receive an identical placebo capsule at night for 8 weeks.
11613042|NCT00547690|Experimental|1|Acupuncture and strength training
11613043|NCT00547690|Other|2|Strength training
11613044|NCT00547664|Experimental|A|
11613045|NCT00547664|Placebo Comparator|B|
11613046|NCT00547651|Experimental|Amrubicin|Amrubicin
11613047|NCT00547651|Active Comparator|Topotecan|Topotecan
11613048|NCT00547638|Experimental|Dermabond Protape|DERMABOND PROTAPE (Prineo) Topical Skin Adhesive
11613049|NCT00547638|Active Comparator|Dermabond HVD|DERMABOND HVD Topical Skin Adhesive
11613050|NCT00547625|Placebo Comparator|1|Placebo run in followed by 5 mg treatment phase 1 and then 20 mg treatment phase 2 which both include a placebo control.
11613051|NCT00547625|Active Comparator|2|Treatment phase 1 includes 5 mg tadalafil 6 weeks then treatment phase 2 which includes 20 mg tadalafil for 6 weeks.
11613052|NCT00547599|Active Comparator|1|20 mg tadalafil tablet
11613053|NCT00547586|Placebo Comparator|Placebo|
11613054|NCT00547586|Experimental|150 mg|
11613055|NCT00547586|Experimental|300 mg|
11613056|NCT00547586|Experimental|450 mg|
11613057|NCT00547586|Experimental|600 mg|
11613058|NCT00547573|Active Comparator|2|10 mg tadalafil tablet
11613059|NCT00547573|Active Comparator|3|20 mg tadalafil tablet
11613060|NCT00547573|Placebo Comparator|1|placebo tablet
11613061|NCT00547560|Other|GSI+Placebo|
11613062|NCT00547547|Experimental|Treatment (high-selenium therapy and chemotherapy)|
11613063|NCT00547534|Experimental|Lymphoma Subjects receiving protocol therapy|Subjects that met all eligibility criteria and were treated with Bendamustine, Rituxan and Bortezomib.
11613064|NCT00547521|Experimental|Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort|In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants were also administered a stable MTX dose of greater than or equal to 10 mg once weekly for at least 4 weeks prior to first injection of SC abatacept.
11613065|NCT00547521|Experimental|SC Abatacept Monotherapy Cohort|In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants did not receive MTX at screening i.e., MTX naive, or discontinued MTX due to lack of efficacy or tolerability at least 4 weeks prior to first injection of SC abatacept.
11613066|NCT00547508|Placebo Comparator|1|Placebo
11613067|NCT00547508|Placebo Comparator|2|Placebo
11613068|NCT00547508|Active Comparator|3|tadalafil
11613069|NCT00547508|Active Comparator|4|tadalafil
11613070|NCT00547508|Active Comparator|5|tadalafil
11613071|NCT00547508|Active Comparator|6|tadalafil
11613072|NCT00547495|Placebo Comparator|1|Placebo tablet
11613073|NCT00547495|Active Comparator|2|5 mg tadalafil
11613074|NCT00547495|Active Comparator|3|10 mg tadalafil
11613075|NCT00547495|Active Comparator|4|20 mg tadalafil
11613076|NCT00547482|Sham Comparator|Control|They will all be implanted but not activated for the Initial Study Period (24 weeks), followed by all subjects assigned to treatment (Control Group with device activation) in the Study Extension Period (an additional 24 weeks). Subjects will remain in the study (Safety Monitoring Period) with semi-annual evaluations until a determination of safety and efficacy is made by the FDA.
11613077|NCT00547482|Active Comparator|Treatment|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation). They will be followed for the Initial Study Period (24 weeks), followed by the Study Extension Period (an additional 24 weeks). Subjects will remain in the study (Safety Monitoring Period) with semi-annual evaluations until a determination of safety and efficacy is made by the FDA."
11613078|NCT00547456|Other|Decrease in oxygen level when sleeping|Patients are their own controls and tested pre and post the addition of night time supplemental oxygen
11613079|NCT00547443|Active Comparator|Arm I|Patients receive chemoradiotherapy comprising paclitaxel, carboplatin, and high-dose external beam radiotherapy (HDRT) as in phase I. Patients also receive consolidation therapy comprising paclitaxel and carboplatin as in phase I.
11613080|NCT00547443|Experimental|Arm II|Patients receive chemoradiotherapy comprising paclitaxel, carboplatin, and HDRT as in phase I. Patients also receive consolidation therapy comprising paclitaxel, carboplatin, and sorafenib tosylate at the MTD as in phase I, as well as maintenance therapy comprising sorafenib tosylate at the MTD as in phase I.
11613081|NCT00547417|Active Comparator|1|tadalafil
11613082|NCT00547391|No Intervention|1|patients on waiting list for a minimum of 5 months. These patients receive no prophylactic intervention for their recurrent pharyngitis episodes.
11613083|NCT00547391|Active Comparator|2|Tonsillectomy as soon as possible after randomization (within 2-3 weeks).
11613084|NCT00547378|Other|1|InterStim Therapy
11613085|NCT00547378|Active Comparator|2|Standard Medical Therapy
11613086|NCT00547365|Experimental|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
11613087|NCT00547352|Active Comparator|1|sildenafil treatment for at least 10 weeks prior to a 1 week wash out
11613088|NCT00547352|Active Comparator|2|Tadalafil treatment for 8 weeks following the 1 week washout period.
11613089|NCT00547326|Experimental|1|Treatement with osteopatic cranial techniques
11613090|NCT00547326|Placebo Comparator|2|Treatment with placebo
11613091|NCT00547300|Experimental|Nebivolol|Nebivolol 5 mg, 10 mg or 20 mg
11613092|NCT00547300|Active Comparator|Metoprolol ER|Metoprolol ER 50 mg, 100 mg or 200 mg
11613093|NCT00547287|Active Comparator|1|Currently prescribed dosage of sildenafil is continued until wash-out period.
11613094|NCT00547287|Active Comparator|2|20 mg tadalafil given after one week sildenafil wash-out period.
11613095|NCT00547261|Experimental|Arm A|1 hour IV infusion D1
11613096|NCT00547261|Experimental|Arm B|1 hour IV infusion D1, D8, D15
11613246|NCT00546052|Experimental|1|Losartan (MK0954) / Losartan + HCTZ (MK0954A)
11613097|NCT00547248|Experimental|Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group|Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.
11613098|NCT00547248|Active Comparator|Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group|Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.
11613099|NCT00547248|Experimental|Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group|Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.
11613100|NCT00547248|Active Comparator|Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group|Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix and Poliorix™ at 12-18 months of age.
11613101|NCT00547209|Active Comparator|1|ventilation with air and oxygen
11613102|NCT00547209|Experimental|2|ventilation with nitrous oxide and oxygen
11613103|NCT00547196|Experimental|Regimen I (age < 50 years, no contraindication to FTBI)|Patients undergo FTBI 2-3 times a day on days -9 to -6 for a total of 11 fractions. Patients also receive cyclophosphamide IV over 2 hours on days -5 and -4 and fludarabine phosphate IV on days -5 to -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
11613104|NCT00547196|Experimental|Regimen II (age < 50 and unable to tolerate FTBI)|Patients receive a test dose of busulfan on day -10 and then dose adjusted busulfan IV 3-4 times daily on days -9 to -6, melphalan IV on days -5 and -4, and fludarabine phosphate IV on days -5 to -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
11613105|NCT00547196|Experimental|Regimen III (unable to tolerate regimen I or II)|Patients receive fludarabine phosphate IV on days -8 to -4 and cyclophosphamide IV over 2 hours on day -3 and undergo TBI (single dose) on day -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
11613106|NCT00547196|Experimental|Regimen IV (unable to tolerate regimen I or II)|Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
11613107|NCT00547183|Active Comparator|2|2.5 mg tadalafil
11613108|NCT00547183|Active Comparator|3|5 mg tadalafil
11613109|NCT00547183|Placebo Comparator|1|
11613110|NCT00547170|Experimental|1|Half of enrolled women will be randomly assigned to group 1.
11613111|NCT00547170|Active Comparator|2|Half of enrolled women will be randomly assigned to group 2
11613112|NCT00547157|Active Comparator|ARM 1 CRT|Cisplatin plus RT
11613113|NCT00547157|Experimental|ARM 2 PRT|Panitumumab plus RT
11613114|NCT00547144|Experimental|Gemcitabine|
11613115|NCT00547118|Experimental|1|Rimonabant
11613116|NCT00547118|Placebo Comparator|2|Placebo
11613117|NCT00547105|Experimental|erlotinib in combination with SBRT|Patients enrolled on the trial will have been receiving or will begin to receive erlotinib at standard doses (150 mg po per day). SBRT will commence within 4 weeks of the initiation of erlotinib
11613118|NCT00547092|Active Comparator|1|tadalafil given the first 12 weeks and after a 4 week washout sildenafil is given for 12 weeks.
11613119|NCT00547092|Active Comparator|2|sildenafil given the first 12 weeks and after a 4 week washout tadalafil is given for 12 weeks.
11613120|NCT00547066|Experimental|veltuzumab|veltuzumab is a humanized CD20 antibody administered subcutaneously.
11613121|NCT00547040||A|incident renal transplant patients
11613122|NCT00547014|Experimental|Cohort 1 1mg|
11613123|NCT00547014|Experimental|Cohort 2|
11613124|NCT00547014|Experimental|Cohort 3|
11613125|NCT00547014|Experimental|Cohort 4|
11613126|NCT00547014|Experimental|Cohort 5|
11613127|NCT00547001|Active Comparator|1|Group A will be tapered over 4 weeks, starting at baseline (week 0). Subjects in this group will take one tablet of ET daily (effective dose, 0.75 mg) for week 1, then one 0.50 mg tablet daily for week 2, then one 0.25 mg tablet daily for week 3, and finally one 0.125 mg tablet daily for week 4.
11613128|NCT00547001|Placebo Comparator|2|Group B will be administered placebo. These tablets will appear identical to those administered to subjects in Group A, but the tablets will contain no estrogen. Subjects in this group will be instructed to take one pill every day for the 4 weeks. Thus, while patients will, in effect, be stopped abruptly from their therapy, there is still the potential of a placebo effect.
11613129|NCT00547001|No Intervention|3|"Group C will have their therapy discontinued acutely at baseline (week 0); i.e., these subjects will not take any tablets after the 8-week stabilization phase ends. While we recognize that this group will not be blinded to the regimen they are receiving, we feel that group C will be important to include in light of the consistent decrease in vasomotor symptoms experienced by women taking placebo. Because women taking placebo have approximately a 35% decrease in vasomotor symptoms, it will be important to compare our taper regimen to the real life scenario of stopping medication abruptly."
11613130|NCT00546988|No Intervention|Standard risk IFN|Administration of interferon alpha as a maintenance treatment following autologous stem cell transplantation
11613131|NCT00546988|No Intervention|Standard risk PEGIFN|Maintenance treatment with pegylated interferon following autologous stem cell transplantation
11613132|NCT00546988|Experimental|High risk allo|Allogeneic stem cell transplantation from an HLA identical related or unrelated donor
11613133|NCT00546988|No Intervention|High risk auto|Second cycle of high-dose melphalan in subjects without an HLA-identical donor
11613134|NCT00546975|Experimental|1|Resource Support® Novartis
11613135|NCT00546975|Active Comparator|2|Resource Protein®, Novartis
11613136|NCT00546975|Placebo Comparator|3|
11613137|NCT00546949|Active Comparator|decompression|Minimal invasive decompression
11613138|NCT00546949|Experimental|x-stop|X-stop, an interspinous decompression device
11613139|NCT00546936|Experimental|ranibizumab intravitreal injection|0.5 mg intravitreal injection of ranibizumab
11613140|NCT00546936|Active Comparator|Photodynamic Therapy|Photodynamic therapy with Visudyne
11613141|NCT00546910|Experimental|Atomoxetine|0.5 milligram per kilogram (mg/kg) per day lead-in dose for 1 weeks followed by 7 weeks at 1.2 mg/kg per day dose.
11613142|NCT00546910|Placebo Comparator|Placebo|Placebo matched to 1 week lead-in and 7 week standard target dose of atomoxetine
11613143|NCT00546897|Experimental|Cohort 1|"Lenalidomide 50 mg/day oral for 14 days followed by 30 days of rest. Lenalidomide 50 mg/day oral for 21 days (this is Cycle 1 and Cycle 2).
~If no progressive disease (PD) then lenalidomide 10 mg/day oral for 28 days for 12 cycles."
11613144|NCT00546897|Experimental|Cohort 2|"Cycle 1: Oral lenalidomide 50 mg/day x 28 days induction therapy. Treatment will then depend on the response to Cycle 1: if patients obtain a complete remission (CR) they will proceed to low dose lenalidomide therapy, if patients have a non-CR they will receive a second high dose cycle of lenalidomide 50 mg/day x 28 days (Cycle 2) Cycle 2 consists of lenalidomide 50mg/day x 28 days Further treatment will depend on the response to Cycle 2: if patients obtain a CR/partial remission (PR)/stable disease (SD) they will proceed to low dose lenalidomide therapy, if patients have PD they will be removed from the study.
~Low Dose Cycles: low dose lenalidomide therapy consisting of 10 mg daily for a 28 day cycle.be 1) For patients that achieve a CR, 2 cycles of low dose lenalidomide will be administered, and then patients observed off therapy. For patients with PR/SD, low dose lenalidomide will continue for a total of 6 cycles and then patients will be observed off therapy."
11613145|NCT00546884|Placebo Comparator|MI|The MI condition will expose participants to the provision of an advance directive and written instructions, roughly mimicking community standards and the requirements of the federal Patient Self Determination Act.
11613146|NCT00546884|Active Comparator|GI|Subjects randomized to the GI group will be invited to meet individually with a health care professional specializing in EOL care
11613147|NCT00546858||Survey|Patients with interstitial cystitis
11613148|NCT00546832|Placebo Comparator|1|placebo
11613149|NCT00546832|Active Comparator|2|celecoxib 200 mg qd p.o.
11613150|NCT00546832|Experimental|3|TDS-943 40 mg bid topically
11613151|NCT00546819|Experimental|ZOSTAVAX™|Participants administered ZOSTAVAX™ on Day 1.
11613152|NCT00546819|Placebo Comparator|Placebo|Participants administered Placebo on Day 1.
11613153|NCT00546806|Experimental|1|"AVIVA Soft Tissue Injury Care Model"
11613154|NCT00546806|Experimental|2|Pre-approved Framework Guideline for Grade I and II Whiplash Associated Disorders (PAF)
11613155|NCT00546806|Active Comparator|3|Physician-based Education and Activation
11613156|NCT00546793|Experimental|veltuzumab|veltuzumab is a humanized CD20 antibody administered subcutaneously in this study.
11613157|NCT00546780|Active Comparator|Arm A|Tanespimycin + Bortezomib
11613158|NCT00546780|Active Comparator|Arm B|Bortezomib
11613159|NCT00546767|Experimental|Mail and Live Phone|
11613160|NCT00546767|Experimental|IVR|
11613161|NCT00546767|Experimental|Computer Kiosk|
11613162|NCT00546767|Active Comparator|Traditional|
11613163|NCT00546754|Experimental|1|Drug Arm
11613164|NCT00546754|Active Comparator|2|active comparator
11613165|NCT00546741|Experimental|1|
11613166|NCT00546741|Active Comparator|2|
11613167|NCT00546741|Active Comparator|3|
11613168|NCT00546728|Experimental|Exenatide|Subjects were randomlly assigned to treatment arm: Exenatide 10 mcg twice daily vs. Metformin 500 mg twice daily.
11613169|NCT00546728|Active Comparator|Metformin|Subjects were randomlly assigned to treatment arm: Exenatide 10 mcg twice daily vs. Metformin 500 mg twice daily.
11613170|NCT00546715|Active Comparator|Dose Panel A|"Daclatasvir - 1 mg
~Placebo - 0 mg"
11613171|NCT00546715|Active Comparator|Dose Panel B|"Daclatasvir - 10 mg
~Placebo - 0 mg"
11613172|NCT00546715|Active Comparator|Dose Panel C|"Daclatasvir - 100 mg
~Placebo - 0 mg"
11613173|NCT00546715|Active Comparator|Dose Panel D|"Daclatasvir - 0.5 - 200 mg (to be determined)
~Placebo - 0 mg"
11613174|NCT00546689||1 , 2|those with HIV
11613175|NCT00546663|Experimental|Open-label|
11613176|NCT00546650|Experimental|A|NP101 patch applied to the upper arm and left in place for 4 hours. The NP101 patch is designed to deliver ~ 10 mg of sumatriptan utilizing up to 600 mA minutes.
11613177|NCT00546650|Active Comparator|B|Sumatriptan succinate (Imitrex®) tablet: 100 mg orally.
11613178|NCT00546650|Active Comparator|C|Sumatriptan succinate (Imitrex®) injection: 6 mg subcutaneously (SQ).
11613179|NCT00546650|Active Comparator|D|Sumatriptan (Imitrex®) nasal spray: 20 mg (one spray) intranasal (IN) into one nostril.
11613180|NCT00546650|Experimental|E|NP101 patch applied to the upper arm and left in place for 4 hours. The NP101 patch is designed to deliver ~ 10 mg of sumatriptan utilizing up to 600 mA minutes.
11613181|NCT00546637|Experimental|Fesoterodine 4mg or 8mg|
11613182|NCT00546637|Placebo Comparator|Placebo|
11613183|NCT00546611|Active Comparator|1|Three day application of 0.05% PEP005 Topical Gel to one or two common warts located on the hand.
11613184|NCT00546598|Other|Duraloc Option COC Hip|
11613185|NCT00546585|Experimental|90 mcg of Influenza A/H7N7|25 subjects to receive 90 mcg of Influenza A/H7N7.
11613186|NCT00546585|Experimental|15 mcg of Influenza A/H7N7|25 subjects to receive 15 mcg of Influenza A/H7N7.
11613187|NCT00546585|Experimental|7.5 mcg of Influenza A/H7N7|25 subjects to receive 7.5 mcg of Influenza A/H7N7.
11613188|NCT00546585|Experimental|45 mcg of Influenza A/H7N7|25 subjects to receive 45 mcg of Influenza A/H7N7.
11613189|NCT00546585|Placebo Comparator|Saline placebo|25 subjects to receive placebo.
11613190|NCT00546572|Experimental|1|Receives 13vPnC at year 0 and 13vPnC at year 1
11613191|NCT00546572|Active Comparator|2|Receives 23vPS at year 0 and 13vPnC at year 1
11613192|NCT00546546|No Intervention|control = conventional treatment|conventional treatment: use of immunosuppressants only if steroid dependency or chronic active disease
11613193|NCT00546546|Experimental|Immunossuppresive treatment|Switch to different immunosuppresive treatment in case of relapse.
11613194|NCT00546507|Placebo Comparator|A|placebo
11613195|NCT00546507|Active Comparator|B|celecoxib 200 mg qd p.o.
11613196|NCT00546507|Experimental|C|TDS-943 40 mg bid topically
11613197|NCT00546481|Experimental|Correction Phase: CERA|
11613198|NCT00546481|Active Comparator|Correction Phase: Epoetin Beta|
11613199|NCT00546468|Experimental|Laparoscopy assisted distal gastrectomy|Laparoscopy assisted distal gastrectomy with D2 lymph node dissection.Surgery will be done in similar operative extent with control open distal gastrectomy. Omentectomy will be omitted.
11613200|NCT00546468|Active Comparator|Open Distal Gastrectomy|Conventional standard D2 open distal gastrectomy without omentectomy.
11613201|NCT00546455|Experimental|A|Subjects in this cohort will be given Fenretinide
11613202|NCT00546455|Placebo Comparator|B|Subjects in this cohort will be given placebo.
11613203|NCT00546442|Placebo Comparator|2|Placebo of metformine 850-2550 mg/daily for 48 weeks
11613204|NCT00546442|Experimental|1|Metformine 850-2550 mg/daily for 48 weeks
11613205|NCT00546429|Other|A|Monitoring of trochanteric fractures after treatment with the ATN system.
11613206|NCT00546403|Placebo Comparator|Placebo|Adjunctive treatment with placebo
11613207|NCT00546403|Experimental|Modafinil|Treatment with titrated dose of study drug, modafinil.
11613208|NCT00546390|Experimental|Ischemic Preconditioned Group (rIP)|A 15-cm sterile blood pressure cuff was placed around the right thigh and connected to the inflating device, and the patient was draped obscuring the visibility of the cuff. Subsequently, the patient was randomly allocated (by opening of an envelope) to RIPC consisting of four 5-min cycles of lower limb ischemia-reperfusion induced by a tourniquet inflated to 300 mmHg
11613209|NCT00546390|No Intervention|No Cuff|No rIP
11613210|NCT00546377|Experimental|Mitoxantrone|
11613211|NCT00546364|Experimental|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|
11613212|NCT00546364|Experimental|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|
11613213|NCT00546364|Active Comparator|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|
11613214|NCT00546351|Experimental|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.
11613215|NCT00546325|Experimental|1|Rimonabant
11613216|NCT00546325|Placebo Comparator|2|Placebo
11613217|NCT00546286|Experimental|1|dorzolamide HCl/timolol maleate
11613218|NCT00546286|Experimental|2|dorzolamide hydrochloride/timolol maleate + prostaglandin
11613219|NCT00546273|Experimental|RUTI 5 micrograms of FCMtb|RUTI dose: 5 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
11613220|NCT00546273|Experimental|RUTI 25 micrograms of FCMtb|RUTI dose: 25 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
11613221|NCT00546273|Experimental|RUTI 100 micrograms of FCMtb|RUTI dose: 100 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
11613222|NCT00546273|Experimental|RUTI 200 micrograms of FCMtb|RUTI 200 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
11613223|NCT00546273|Placebo Comparator|placebo|placebo of the vaccine RUTI (total n=8, n=2 for each period)
11613224|NCT00546260|Placebo Comparator|1|Placebo for each Dose cohort: 10, 20, 40, and 60 mg
11613225|NCT00546260|Experimental|2|Experimental drug for each Dose cohort: 10, 20, 40, and 60 mg
11613226|NCT00546247|Experimental|1|
11613227|NCT00546234|Active Comparator|1|
11613228|NCT00546234|Active Comparator|2|
11613229|NCT00546221|Experimental|Psychosocial support|Comprising 22 participants engaging in the experimental exercise programme, exercising with psychosocial support.
11613230|NCT00546221|Active Comparator|Prescribed exercise|Comprising 21 participants engaging in a programme of typical prescribed exercise.
11613231|NCT00546208||1|adolescents and young adults who underwent, as newborns, unilateral low loop cutaneous ureterostomy for severe bilateral hydro-ureteronephrosis, and that, afterwards, underwent stomal closure
11613232|NCT00546169||A|
11613233|NCT00546156|Active Comparator|HR+, HER2-|Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.
11613234|NCT00546156|Active Comparator|Triple Negative Breast Cancer Cohort|Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.
11613235|NCT00546143|Experimental|1|Omalizumab 900 mg
11613236|NCT00546143|Experimental|2|Omalizumab 1050 mg
11613237|NCT00546143|Experimental|3|Omalizumab 1200 mg
11613238|NCT00546130|Experimental|1|Irinotecan hydrochloride + Cisplatin + Krestin Therapy
11613239|NCT00546117|Experimental|Lansoprazole (Prevacid)|Prevacid SoluTab (15 or 30 mg tab) once daily for 2 months
11613240|NCT00546117|Placebo Comparator|Placebo|Placebo SoluTab once daily for 2 months
11613241|NCT00546104|Experimental|Dasatinib|50- 100 mg PO BID
11613242|NCT00546078|Experimental|Cervarix™ 4-Dose Group|Subjects who had received 3 doses of Cervarix™ in study 580299/001 (NCT00689741), received a 4th dose of Cervarix™ on Day 0 in the current study.
11613243|NCT00546078|Experimental|Cervarix™ 3-Dose Group|Subjects who had received 3 doses of placebo in study 580299/001 (NCT00689741), received 3 doses of Cervarix™ (Day 0, Month 1 and Month 6) in the current study.
11613244|NCT00546065|Other|ablation of Barretts with concomitant esomeprazole therapy|comparison of recurrence-free survival
11613247|NCT00546039|Active Comparator|1|
11613249|NCT00546026|Active Comparator|Active group|Receive assessment of placental function
11613250|NCT00546013||AAA group, control group|AAA group : with AAA Control group: without AAA
11613251|NCT00546000|Experimental|1|Receive between 22 and 29 days of Cutivate lotion treatment
11613252|NCT00545987|Active Comparator|intramuscular injection|administration of an HIV-1 vaccine by conventional intramuscular injection
11613253|NCT00545987|Experimental|TriGrid Delivery System|electroporation-mediated intramuscular delivery using the TriGridTM device by Ichor Medical Systems, Inc.
11613254|NCT00545974|Experimental|1|Memantine 10mg BID
11613255|NCT00545974|Placebo Comparator|2|Placebo condition
11613256|NCT00545961|Placebo Comparator|1|placebo Ora-Plus (registered trademark) mixture with an strawberry sweetening agent to make the placebo mixture similar in appearance and taste to active drug
11613257|NCT00545961|Active Comparator|2|amoxicillin-clavulanate acid
11613258|NCT00545948|Other|Arm A-Vinorelbine|Resected tumor was used for genomic expression profiling. Patients with a genomic expression pattern suggestive of vinorelbine sensitivity were given cisplatin + vinorelbine.
11613259|NCT00545948|Other|Arm B-Pemetrexed|Resected tumor was used for genomic expression profiling. Patients with a genomic expression pattern suggestive of pemetrexed sensitivity were given cisplatin + pemetrexed.
11613260|NCT00545935|Active Comparator|1-Methylenblue-Amodiaquine|
11613261|NCT00545935|Active Comparator|2-Methylenblue-Artesunate|
11613262|NCT00545935|Active Comparator|3-Artesunate-Amodiaquine|
11613263|NCT00545922|Experimental|A|7 weekly sessions of group cognitive behavioral therapy
11613264|NCT00545922|Active Comparator|B|Minimal Telephone Contact
11613265|NCT00545909|Experimental|1|
11613266|NCT00545909|Active Comparator|2|
11613267|NCT00545870|Experimental|A|Bevacizumab treatment
11613268|NCT00545870|Active Comparator|B|Ranibizumab treatment
11613269|NCT00545857|Experimental|Pioglitazone|
11613270|NCT00545857|Placebo Comparator|Placebo control|
11613271|NCT00545844|Experimental|1|montelukast sodium
11613272|NCT00545831|Experimental|A|Use of taurolidine in prevention of bloodstream infection related to central venous access
11613273|NCT00545831|Placebo Comparator|B|Use of Physiologic Serum to compare to arm A
11613274|NCT00545818|Experimental|Group-1, Implant length 6 mm|Subjects treated with OsseoSpeed™ implant, length: 6 mm
11613275|NCT00545818|Other|Group-2, Implant length 11 mm|Subjects treated with OsseoSpeed™ implant, length: 11 mm
11613276|NCT00545805|Experimental|OM group|
11613277|NCT00545805|Active Comparator|CT group|Control group
11613278|NCT00545792|Experimental|Avastin|Avastin
11613279|NCT00545779|Experimental|Ibandronate|Participants completed Candidate Identification Questionnaire (CIQ) in Part A and received Ibandronate 150 milligram (mg) tablet orally once-monthly up to 6 months in Part B of the study.
11613280|NCT00545766|Experimental|Interventional|
11613281|NCT00545753|Experimental|A - NatrOVA 1% - no nit combing|NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
11613282|NCT00545753|Experimental|B - NatrOVA 1% - nit combing required|NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
11613283|NCT00545753|Active Comparator|C - NIX|NIX Creme Rinse (permethrin 1%) applied to Over the Counter (OTC) Instructions for Use
11613284|NCT00545740|Experimental|SPD476 (1.2 g)|
11613285|NCT00545740|Experimental|SPD476 (2.4 g)|
11613286|NCT00545740|Experimental|SPD476 (4.8 g)|
11613287|NCT00545740|Placebo Comparator|Placebo|
11613288|NCT00545727|Other|HGI|High/standard glycemic index diet
11613289|NCT00545727|Experimental|LGI|Low glycemic index diet
11613290|NCT00545714|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants will receive 6 cycles (cycle length = 28 days) of treatment with rituximab (375 milligrams per square meter [mg/m^2] as intravenous [IV] infusion on Day 0 of Cycle 1 and 500 mg/m^2 as IV infusion on Day 1 of Cycles 2-6); fludarabine (25 mg/m^2 on Days 1-3) and cyclophosphamide (250 mg/m^2 on Days 1-3). Participants with a partial or complete response and appropriate neutrophil conditions will receive maintenance treatment with rituximab (375 mg/m^2 as IV infusion every 2 months) from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
11613291|NCT00545701|Experimental|1|
11613292|NCT00545688|Experimental|1|
11613293|NCT00545688|Experimental|2|
11613294|NCT00545688|Experimental|3|
11613295|NCT00545688|Experimental|4|
11613296|NCT00545675|Experimental|1|Abilify(aripiprazole) + Depakote(divalproate)
11613297|NCT00545675|Placebo Comparator|2|Divalproate + Placebo
11613298|NCT00545662|Experimental|Placebo|Placebo tablets formulated to resemble the citicoline treatment.
11613299|NCT00545662|Experimental|Citicoline|Experimental treatment administered orally or enterally depending upon whether the participant can swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.
11613300|NCT00545649|Experimental|1|Exercise and education
11613301|NCT00545649|Active Comparator|2|Education only
11613302|NCT00545623|Active Comparator|ACU+RR|acupuncture + relaxation response CD
11613303|NCT00545623|Active Comparator|SHAM+RR|sham acupuncture + relaxation response CD
11613304|NCT00545623|Active Comparator|ACU+EDU|acupuncture+control CD
11613305|NCT00545623|Sham Comparator|SHAM+EDU|sham acupuncture+control CD
11613306|NCT00545610||Test 1 (n=50)|1 x 10^5 (+/-10%) CD34+ cells/kg of body weight
11613307|NCT00545610||Test 2 (n=50)|5 x 10^5 (+/-10%) CD34+ cells/kg of body weight
11613308|NCT00545610||Placebo (n=50)|Saline plus 5% autologous plasma
11613309|NCT00545584|Experimental|Sitagliptin with Standard of Care|Subjects received sitagliptin 100 mg once daily for 26 Weeks, and: No specific intervention (standard recommendation) on physical exercise and diet.
11613310|NCT00545584|Experimental|Sitagliptin with Diet Advice|"Subjects received sitagliptin 100 mg once daily for 26 Weeks,
~and:
~Intervention on diet which includes advice on diet with a leaflet and a diary"
11613386|NCT00545168|Active Comparator|C - NIX|Nix Creme Rinse (permethrin 1%) applied according to OTC Instructions for Use
11613387|NCT00545155||Geriatric EMS Patients|Cohort for reliability and concurrent validity testing.
11613311|NCT00545584|Experimental|Sitagliptin with Diet and Physical Activity Advice|"Subjects received sitagliptin 100 mg once daily for 26 Weeks,
~and:
~Intervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week."
11613312|NCT00545571|Experimental|Mircera in Renal Anemia|Participants will receive intravenous Mircera every 4 weeks for a total of 52 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
11613313|NCT00545558|Experimental|1|Participants will receive ART consisting of efavirenz and the co-formulation of emtricitabine and tenofovir disoproxil fumarate. If participants are unable to tolerate the treatment, a different regimen will be prescribed.
11613314|NCT00545545|Experimental|Arm 1, Cohort 1|2.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
11613315|NCT00545545|Experimental|Arm 1, Cohort 2|4.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
11613316|NCT00545545|Experimental|Arm 1, Cohort 3|6.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
11613317|NCT00545545|Experimental|Arm 2, Cohort 1|2.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
11613318|NCT00545545|Experimental|Arm 2, Cohort 2|4.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
11613319|NCT00545545|Experimental|Arm 2, Cohort 3|6.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
11613320|NCT00545532|Experimental|Conventional dose|Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.
11613321|NCT00545532|Experimental|Double dose|Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.
11613322|NCT00545519|Experimental|Dose Level 1|Thymoglobulin 2.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
11613323|NCT00545519|Experimental|Dose Level 2|Thymoglobulin 3.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
11613324|NCT00545519|Experimental|Dose Level 3|Thymoglobulin 4.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
11613325|NCT00545506|Active Comparator|conventional bandage|conventional bandage on sternal wound after skin closure after cardiac surgery. conventional gauze covered with elastic adhesive (Medipore™ Dress-it) The designated bandage will be positioned in the operating room by the surgeons after the skin will be closed. The conventional elastic bandage consists of several layers of gauze covered with a special adhesive bandage
11613326|NCT00545506|Active Comparator|warming bandage|The Warm-Up bandage consists of an adhesive shell and a foam frame that supports a clear window about one cm above the surface of the wound. A battery-powered heating card can then be inserted into the window to provide gentle warming of the wound. The surface temperature of heating card is fixed at 38°C, and heat is usually provided for two hours at a time. That is, the experimental bandage will be continuously applied to the wound and heated to 38°C using a two-hour on/off cycle.
11613327|NCT00545493|Experimental|Group 1|"Tacrolimus capsules (Prograf; dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter)"
11613328|NCT00545493|Experimental|Group 2|"Intravenous immunoglobulins (IVIG) infusions (Octagam; dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months)."
11613329|NCT00545480|Experimental|1|
11613330|NCT00545480|Active Comparator|2|
11613331|NCT00545467|Active Comparator|1|fast tapering of the previous medication within 1 week after initiating aripiprazole for 2 weeks
11613332|NCT00545467|Active Comparator|2|slow tapering of the previous medication within 4 weeks after initiating aripiprazole for 2 weeks
11613333|NCT00545454|Experimental|SSR150106 QD|90 micro grams oral solution once daily (QD)
11613334|NCT00545454|Experimental|SSR150106 OEQD|90 micro grams oral solution once every other day (OEQD)
11613335|NCT00545454|Placebo Comparator|Placebo|oral solution QD or OEQD
11613336|NCT00545441|Experimental|1|Surgisis® AFP
11613337|NCT00545441|Active Comparator|2|Flap
11613338|NCT00545428|Experimental|1|Rhinoplasty
11613339|NCT00545415|Experimental|1|
11613340|NCT00545415|Experimental|2|
11613341|NCT00545415|Experimental|3|
11613342|NCT00545415|Experimental|4|
11613343|NCT00545415|Experimental|5|
11613344|NCT00545415|Experimental|6|
11613345|NCT00545402|Experimental|MMF, Adjusted Dose; Tacrolimus; Corticosteroids|Participants received mycophenolate mofetil (MMF) 3 grams per day (g/d), orally (PO), twice per day (BID) with meals from Day 0 to Day 4; the dose was adjusted based on total exposure (AUC) using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12. Participants also received tacrolimus adjusted to a target trough level of 8 to (-) 12 nanograms per milliliter (ng/mL) from Day 0 to Month 1; the dose was adjusted to reach a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12. Participants also received corticosteroids 10-15 milligrams per kilogram (mg/kg), intravenously (IV), pre-operation on Day 0.
11613346|NCT00545402|Active Comparator|MMF, Standard Dose; Tacrolimus; Corticosteroids|Participants received MMF 2 g/d, PO, BID with meals from Day 0 to Month 12. Participants also received tacrolimus adjusted to a target trough level of 8-12 ng/mL from Day 0 to Month 1; the dose was reduced to reach a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12. Participants also received corticosteroids 10-15 mg/kg, IV, pre-operation on Day 0; followed by 20 mg/d, PO, 4 times per day (QDS) from Day 0 through Month 1; 15 mg/d, PO, 3 times per day (TID) from the end of Month 1 through Month 2; 10 mg/d, PO, BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
11613347|NCT00545376|No Intervention|1|This group will leave after the first visit without additional instruction and will be asked to return in two weeks for a follow up lung assessment.
11613429|NCT00544791|Placebo Comparator|B|
11613348|NCT00545376|Experimental|2|This group, at the first visit, will be taught three home OMT techniques that a family member or friend can administer to them. They will be asked to do these techniques at least 4 times a week, up to every day, for two weeks before returning for a follow up lung assessment.
11613349|NCT00545376|Experimental|3|This arm is the physicians that I will recruit participants through. They will be exposed to education about the use of OMT for asthma.
11613350|NCT00545363|Experimental|Bone Marker Feedback (BMF) Participants|"Postmenopausal women will receive ibandronate 150 milligrams (mg) once monthly (QM) orally for 6 months. Participants, in this arm, will receive BMF at Month 3. BMF will be given in terms of providing serum carboxy-terminal collagen crosslinks (CTX) level at Month 3. A BMF-form will be provided to the physicians to allow offering the bone marker result in an easy way. Participants will be informed if their results are within or outside of the desired range. In addition, participants will also supported by PRP, to be carried out by supplying alarm devices, specifically designed to support the participant's regular drug intake."
11613351|NCT00545363|Active Comparator|No BMF Participants|Postmenopausal women will receive ibandronate 150 milligrams (mg) once monthly (QM) orally for 6 months. Participants will be supported by PRP, to be carried out by supplying alarm devices, specifically designed to support the participant's regular drug intake.
11613352|NCT00545350|No Intervention|1|Usual activity / care
11613353|NCT00545350|Experimental|2|"Physical exercise classes plus home exercises:
~Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home. The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises."
11613354|NCT00545311|Experimental|1|NVA237
11613355|NCT00545311|Experimental|2|NVA237
11613356|NCT00545311|Experimental|3|NVA237
11613357|NCT00545311|Experimental|4|NVA237
11613358|NCT00545311|Placebo Comparator|5|Placebo
11613359|NCT00545298|No Intervention|A - Standard of Care (control)|Standard of care - dressings and sustained compression only
11613360|NCT00545298|Experimental|B Same treatment for 6 weeks|200ppm NO gas 8hrs/day 6 weeks NO gas in nitrogen is delivered constantly to a patch over the wound
11613361|NCT00545298|Experimental|C - modified treatment, 5 wks lower dose|200 ppm No gas 8 hrs/day 1 wk, 20ppm 8hrs/day 5 weeks Gas is NO in nitrogen delivered constantly for 8 hours to a patch over the wound
11613362|NCT00545285|Active Comparator|1|Total hip Arthroplasty E-Poly™ liner in a titanium plasma sprayed RingLoc® shell
11613363|NCT00545285|Active Comparator|2|Total hip Arthroplasty ArcomXL® polyethylene liner in a titanium plasma sprayed RingLoc® shell
11613364|NCT00545285|Active Comparator|3|Total hip Arthroplasty E-Poly™ liner with Regenerex Ringloc +™ shell
11613365|NCT00545285|Active Comparator|4|Total hip Arthroplasty ArcomXL® polyethylene liner with Regenerex Ringloc +™ shell
11613366|NCT00545272|Experimental|indacaterol 62.5 μg|Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
11613367|NCT00545272|Experimental|indacaterol 125 μg|Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
11613368|NCT00545272|Experimental|indacaterol 250 μg|Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
11613369|NCT00545272|Experimental|indacaterol 500 μg|Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
11613370|NCT00545272|Active Comparator|formoterol|Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
11613371|NCT00545272|Placebo Comparator|placebo|Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
11613372|NCT00545259|Experimental|1|AEB071
11613373|NCT00545246|Experimental|aflibercept + docetaxel|
11613374|NCT00545233|Experimental|PEG-INF alpha-2a + ribavirin+ pioglitazone|Participants received pioglitazone in a 16 week run-in period (30 mg per day orally for 8 weeks followed by 45 mg per day orally for 8 weeks). Participants then received piogliatzone 45 mg daily orally plus 18 μg of Peginterferon Alfa-2a (PEG-INF alpha-2a) subcutaneous (sc) once a week plus ribavirin (1000 - 1600 mg/day orally as a split dose in the morning and the evening based on the participant's body weight) for 48 weeks in the anti-HCV treatment phase. Participants received 45 mg of pioglitazone per day orally in the 24 week follow-up period.
11613375|NCT00545233|Active Comparator|PEG-INF alpha-2a + ribavirin|Participants received 18 μg of Peginterferon Alfa-2a (PEG-INF alpha-2a) subcutaneous (sc) once a week plus ribavirin (1000 - 1600 mg/day orally as a split dose in the morning and the evening based on the participant's body weight) for 48 weeks in the anti-HCV treatment phase followed by a treatment free 24 week follow-up period.
11613376|NCT00545220|Experimental|1|PST
11613377|NCT00545220|Sham Comparator|2|Attention Control
11613378|NCT00545207|Experimental|1|
11613379|NCT00545207|Placebo Comparator|2|
11613380|NCT00545194|Active Comparator|A|sustained release preparation of prostaglandin E2
11613381|NCT00545194|Active Comparator|B|short-acting (instant-released) preparation of prostaglandin E2
11613382|NCT00545181|Experimental|Metronidazole plus gel|Receive metronidazole plus vaginal gel
11613383|NCT00545181|Active Comparator|Control- metronidazole alone|Oral Metronidazole antibiotic therapy alone
11613384|NCT00545168|Experimental|A - NatrOVA 1% - no nit combing|NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
11613385|NCT00545168|Experimental|B - NatrOVA 1% - nit combing required|NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
11631216|NCT00360256||Case group|
11613389|NCT00545129|Placebo Comparator|Placebo + opioids|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
11613390|NCT00545116|Experimental|a|Active carrier 1: biscuit providing 250 mg hesperidin per piece(6g)
11613391|NCT00545116|Experimental|b|Active carrier 2: liquid skim milk providing 250 mg hesperidin/serve (200 ml) and containing around 300 mg calcium/serving
11613392|NCT00545116|Placebo Comparator|c|Placebo carrier 1: biscuit with the same nutrient composition and appearance as the active biscuit carrier but minus hesperidin
11613393|NCT00545116|Placebo Comparator|d|Placebo carrier 2: liquid skim milk with the same nutrient composition and appearance as the active milk carrier but minus hesperidin
11613394|NCT00545103|Experimental|SPD476 (1.2 g)|
11613395|NCT00545103|Experimental|SPD476 (2.4 g)|
11613396|NCT00545103|Experimental|SPD476 (4.8 g)|
11613397|NCT00545103|Placebo Comparator|Placebo|
11613398|NCT00545090|Experimental|1|
11613399|NCT00545077|Active Comparator|Arm A: Endocrine Therapy (ET)|Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
11613400|NCT00545077|Experimental|Arm B: ET with Bevacizumab (ET-B)|Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
11613401|NCT00545051|Experimental|Ibandronate|Participants received monthly oral ibandronate (150 milligrams [mg]) for 12 months.
11613402|NCT00545051|Placebo Comparator|Placebo|Participants received monthly oral placebo for 12 months.
11613403|NCT00545025|Experimental|GSK1247446A Group|Subjects aged between 18 and 60 years, having previously received one dose of the AS03-adjuvanted GSK1247446A vaccine in the primary study NCT00374842, received a single dose of GSK1247446A vaccine adjuvanted with a half dose of AS03 adjuvant at Day 0 of the current follow-up study NCT00545025. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Subjects in this group originated from either the GSK1247446A Formulation 1 or GSK1247446A Formulation 2 groups in study NCT00374862.
11613404|NCT00545025|Active Comparator|Fluarix Group|Subjects aged between 18 and 60 years, having previously received one dose of Fluarix™ vaccine during the primary study NCT00374842, received one dose of Fluarix™ vaccine at Day 0 of the current follow-up study NCT00545025. The vaccine was administered intramuscularly, in the deltiod region of the non-dominant arm. Subjects in this group originated from the Fluarix Group in study NCT00374862.
11613405|NCT00544960|Experimental|1|AT-101 and docetaxel
11613406|NCT00544960|Placebo Comparator|2|placebo and docetaxel
11613407|NCT00544947||D, F|"Group D will be patients at Princess Royal Maternity Hospital in Glasgow, where supplementation with intrathecal diamorphine 300mcg is the current anaesthetic technique of choice.
~Group F will be patients at the Queen Mother's Maternity Hospital in Glasgow, where supplementation with intrathecal fentanyl 15mcg plus post-operative morphine PCA is the current anaesthetic technique of choice for elective caesarean section."
11613408|NCT00544934|Experimental|250 mg|
11613409|NCT00544934|Experimental|500 mg|
11613410|NCT00544934|Experimental|750 mg|
11613411|NCT00544934|Placebo Comparator|Placebo|
11613412|NCT00544921|Experimental|50 mg|
11613413|NCT00544921|Experimental|100 mg|
11613414|NCT00544921|Experimental|250 mg|
11613415|NCT00544921|Experimental|500 mg|
11613416|NCT00544921|Experimental|750 mg|
11613417|NCT00544921|Experimental|1000 mg|
11613418|NCT00544921|Placebo Comparator|Placebo|
11613419|NCT00544908|Experimental|Dasatinib|Dasatinib 70 mg po bid (1 cycle=28 days)
11613420|NCT00544882|Experimental|DR-1021|After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).
11613421|NCT00544882|Active Comparator|Mircette|After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).
11613422|NCT00544869|Experimental|1|
11613423|NCT00544856|Experimental|1|cognitive intervention
11613424|NCT00544856|Placebo Comparator|2|
11613425|NCT00544830|Experimental|Treatment (androgen therapy, radiation therapy)|"ADT: Patients not currently on ADT receive goserelin acetate SC or leuprolide acetate via injection once every 4 or 12 weeks and bicalutamide PO QD. Treatment repeats every 12 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients already receiving ADT at the time of enrollment continue treatment until they have received 36 weeks of therapy.
~RADIATION THERAPY: Patients achieving PSA normalization after initiation of androgen deprivation therapy undergo intensity-modulated radiation therapy daily for 2-7 weeks during or after completion of androgen deprivation therapy."
11613426|NCT00544817|Experimental|Combination Therapy|"In the combined modality portion of the study, patients were administered:
~Radiation Therapy - 2 Gy/fraction, Single daily fractions M-F, to 60 Gy total Temozolomide - 75 mg/m2 by mouth once daily
~Patients took a four week break before beginning follow-up systemic therapy:
~Temozolomide - 150 mg /m2 by mouth on days 1-5 every 28 days for 6 cycles Sorafenib - 400 mg by mouth twice a day for 6 months"
11613427|NCT00544804|Experimental|Lapatinib|Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer
11613428|NCT00544791|Experimental|A|melatonin 5 mg, daily dose for 6 months
11613430|NCT00544778|Experimental|Arm 1|High-dose chemotherapy with doxorubicin at 120 mg/m2 and ifosfamide at 2 g/m2 followed by a prolonged schedule of CPT-11 at 20 mg/m2.
11613431|NCT00544765|Experimental|resp: 4xTAC|Patients sufficiently responding (iPR, iCR) will recieve 4 further cycles of TAC
11613432|NCT00544765|Experimental|resp: 6xTAC|Patients sufficiently responding (iPR, iCR) will recieve 6 further cycles of TAC
11613433|NCT00544765|Experimental|nonResp: 4xTAC|Patients non-sufficiently responding (iNC) will recieve 4 further cycles of TAC
11613434|NCT00544765|Experimental|nonResp: 4xNX|Patients non-sufficiently responding (iNC) will recieve 4 further cycles of NX
11613435|NCT00544752|Experimental|16|indoor temperature of 16 degrees celcius
11613436|NCT00544752|Experimental|20|indoor temperature 20 degrees celcius
11613437|NCT00544752|Experimental|24|indoor temperature of 24 degrees celcius
11613438|NCT00544739||1|323 women with established coronary artery disease before 55 year of age
11613439|NCT00544739||2|347 clinically healthy, age matched women selected from the National Health Survey WOBASZ study with negative history of CVD or negative exertional chest pain.
11613440|NCT00544726|Active Comparator|1|Physical training
11613441|NCT00544726|Placebo Comparator|2|No physical training
11613442|NCT00544713|Experimental|Carboxymethylcellulose and Glycerin based artificial tear|Carboxymethylcellulose and Glycerin based artificial tear
11613443|NCT00544713|Active Comparator|Carboxymethylcellulose based artificial tear|Carboxymethylcellulose based artificial tear
11613444|NCT00544700|Active Comparator|Arm A: Bevacizumab monotherapy|Bevacizumab maintenance monotherapy
11613445|NCT00544700|Other|Arm B: No maintenance|No antitumor treatment until progression
11613446|NCT00544687|Experimental|1|CRx-191 (0.1% mometasone furoate + 0.05% nortriptyline HCl)
11613447|NCT00544687|Experimental|2|CRx-191 (0.1% mometasone furoate + 0.1% nortriptyline HCl)
11613448|NCT00544687|Active Comparator|3|0.1% mometasone furoate
11613449|NCT00544687|Active Comparator|4|0.1% nortriptyline HCl
11613450|NCT00544687|Active Comparator|5|Karison® Creme (clobetasol-17-propinate 0.05%)
11613451|NCT00544687|Placebo Comparator|6|Vehicle (placebo)
11613452|NCT00544674|Experimental|PR104|PR104 will be administered once every 21 days by IV
11613453|NCT00544648|Experimental|Treatment|nab-paclitaxel+ carboplatin + radiation
11613454|NCT00544635|Experimental|A|scars will be treated with light
11613455|NCT00544635|Placebo Comparator|B|no intervention
11613456|NCT00544609|Other|Sorafenib|2 weeks:Sorafenib, 6 weeks and a half:Sorafenib with radiotherapy, 4 weeks:Sorafenib
11613457|NCT00544596|Experimental|Treatment (R-(-)-gossypol acetic acid, cisplatin, etoposide)|"Patients receive oral R-(-)-gossypol twice daily on days 1-3, cisplatin IV over 60 minutes on day 1*, and etoposide IV over 30 minutes on days 1*-3. Treatment repeats every 21 days for up to 6 courses during the dose escalation and 4 courses in the expanded extensive stage small cell lung cancer cohort, in the absence of disease progression or unacceptable toxicity.
~Blood samples are collected on day 1 of courses 1 and 2 for pharmacokinetic analysis, biomarker assays, and correlative studies.
~After completion of study treatment, patients are followed for 30 days.
~[Note: *Cisplatin and etoposide will be started on day 2 during course 1; they will be given on day 1 during all subsequent courses.]"
11613458|NCT00544583|Active Comparator|A|Interrupted closure with Vicryl equivalent sutures (USP 2, 45 cm)
11613459|NCT00544583|Experimental|B|Continuous closure with PDS II equivalent sutures (USP 1, 150 cm loops)
11613460|NCT00544557||Patients with Ankylosing Spondylitis|
11613461|NCT00544544|Experimental|Riluzole|Riluzole 50 mg twice daily for 2 weeks, increased to riluzole 50 mg in the morning and 100 mg in the evening for 1 week if tolerated, with a further increase to riluzole 100 mg twice daily if tolerated for 3 weeks.
11613462|NCT00544518|Experimental|2|
11613463|NCT00544518|Active Comparator|1|
11613464|NCT00544492|Experimental|A1|Buttonhole cannulation technique
11613465|NCT00544492|Active Comparator|A2|Rope ladder cannulation technique
11613466|NCT00544492|Experimental|B1|Catheter with bevel point
11613467|NCT00544492|Active Comparator|B2|Catheter with cylindrical point
11613468|NCT00544466|Experimental|Treatment (enzyme inhibitor, radiation therapy, transplant)|PREPARATIVE REGIMEN*: Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. Patients also undergo helical tomotherapy twice daily on days -7 to -4. TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0. NOTE: *Treatment begins 2 days earlier in patients receive tacrolimus and/or sirolimus for GVHD prophylaxis.
11613469|NCT00544440|Experimental|Abiraterone acetate plus prednisone|Patients will be treated orally with abiraterone acetate 1000 mg daily and prednisone 5 mg twice a day until clinical disease progression.
11613470|NCT00544414|Experimental|Treatment|"Patients receive neoadjuvant induction chemotherapy comprising docetaxel IV over 1 hour on day 1 and cisplatin IV, leucovorin IV, and fluorouracil IV over 24 hours on days 1-4. Induction chemotherapy repeats every 28 days for 3 courses.
~Patients with partial response at the primary site may undergo radical or functional resection of the primary tumor within 3 weeks of completion of neoadjuvant therapy.
~Beginning within 4 weeks of completion of neoadjuvant therapy, patients with persistent disease or complete response after chemotherapy at the primary or neck then undergo radiotherapy 5 days a week for 7 weeks and receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 60 minutes on day 1 of each week of radiotherapy."
11613471|NCT00544401|Experimental|1|Hypnopuncture Treatment
11613472|NCT00544401|No Intervention|2|Conventional IVF/ICSI treatment only
11613473|NCT00544375||Neonatal Tissues|Optical measurement neonatal tissues
11613474|NCT00544362|Experimental|Neoadjuvant chemoradiotherapy|Weekly cetuximab (400 mg/m2 one week before start of radiotherapy RT and 250 mg/m2 during radiotherapyRT), and 5 FU (500 mg/m2 per day D1-D4) combined with cisplatin CDDP (40 mg/m2 D1) on week 1 and 5
11613475|NCT00544336||Supportive|
11613476|NCT00544310|Experimental|1|Post surgery adhesion prevention treatment
11613477|NCT00544297|Experimental|PEP005 gel administration|0.05% PEP005 Topical Gel administered for two consecutive days to a 25cm2 contiguous AK treatment area on the top of the hand
11613559|NCT00543439|Experimental|1|On-Demand therapy for 6 months, followed by Routine Prophylaxis treatment for 1 year.
11631794|NCT00353613|Other|1|LBJ Hospital
11613478|NCT00544284|Experimental|Treatment (temozolomide, bortezomib)|GROUP A: Patients receive oral temozolomide once a day on days 1-5 and bortezomib IV on days 2, 5, 9, and 12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. GROUP B: Patients receive temozolomide and bortezomib as in group A. Cohorts of patients in both groups receive escalating doses of both study drugs until the maximum tolerated doses are determined. All patients undergo blood sample collection periodically for pharmacokinetic studies. Samples are analyzed for bortezomib concentration (groups A and B) and trough levels of anticonvulsants (group A only).
11613479|NCT00544258|Experimental|1|Two days consecutive days of application of 0.05% PEP005 Topical Gel to a 100cm2 contiguous AK treatment area of the arm.
11613480|NCT00544232|Experimental|epirubicin, paclitaxel and CMF +/- darbepoetin|"Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×
~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel"
11613481|NCT00544232|Experimental|EC followed by paclitaxel +/- darbepoetin|"Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF
~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF"
11613482|NCT00544219|Other|R-Chop 14|Standard treatment
11613483|NCT00544206|Experimental|#1|Diabetes specific enteral feeding product
11613484|NCT00544206|Active Comparator|#2|Standard enteral feeding product
11613485|NCT00544167|Experimental|Intervention|All patients received doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC) both administered intravenously day 1 every 3 weeks for four cycles, followed by paclitaxel 175 mg/m2 intravenously day 1 every 3 weeks for four cycles or 80 mg/m2 for twelve weeks (physician discretion), combined with sorafenib 400 mg orally twice daily. Sorafenib was held during radiation therapy where indicated and resumed once completed. Sorafenib was continued for a total of 12 months and in combination with adjuvant hormonal therapy where indicated.
11613486|NCT00544128|Active Comparator|Epzicom Arm|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
11613487|NCT00544128|Active Comparator|Truvada Arm|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg
11613488|NCT00544115|Active Comparator|Regimen I|Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.
11613489|NCT00544115|Active Comparator|Regimen II|Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2.
11613490|NCT00544115|Active Comparator|Regimen III|Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3.
11613491|NCT00544115|Active Comparator|Regimen IV|Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2.
11613492|NCT00544115|Active Comparator|Regimen V|Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.
11613493|NCT00544115|Active Comparator|Regimen VI|Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2.
11613494|NCT00544076|Experimental|Sildenafil Citrate/Mo+Aprostadil/day|Patients receive intraurethral alprostadil once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
11613495|NCT00544076|Active Comparator|Sildenafil Citrate Monthly|Patients receive 3 doses of oral sildenafil citrate on 3 separate occasions at least 48 hours apart monthly for 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
11613496|NCT00544076|Experimental|Daily Sildenafil Citrate|Patients receive oral sildenafil citrate once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
11613497|NCT00544037||Group 1|
11613498|NCT00544024||Reference|Lariam was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
11613499|NCT00544024||T1|Mephaquin was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
11613500|NCT00544024||T2|Mefloquine-AC Farma was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
11613501|NCT00543998||Optical Measurement transillumination|Optical Measurement of sinus
11613502|NCT00543985|Experimental|Stress Echocardiography|Echocardiography was performed prior to and within 60 seconds of completing the standard Bruce treadmill protocol.
11613503|NCT00543959|Experimental|Part1 - Arm 1|Part1: Arm 1: drug
11613504|NCT00543959|Placebo Comparator|Part1 - Arm 2|Part1 - Arm 2: Pbo comparator
11613505|NCT00543959|Placebo Comparator|Part 2 - Arm 1|Part 2 - Arm 1: Pbo
11613506|NCT00543959|Experimental|Part 2 - Arm 2|Part 2- Arm 2: drug 5mg
11613507|NCT00543959|Experimental|Part 2 - Arm 3|Part 2 - Arm 3: drug 15mg
11613508|NCT00543959|Experimental|Part 2 - Arm 4|Part 2 - Arm 4: drug 30mg
11613509|NCT00543959|Active Comparator|Part 2 - Arm 5|Part 2 - Arm 5: active comparator
11613510|NCT00543933|Experimental|iNO administered|iNO administered at 40 ppm via a non-rebreather mask
11613560|NCT00543439|Experimental|2|Routine Prophylaxis Crossover
11613561|NCT00543426|Experimental|1|Fuzheng Huayu Tablets
11613511|NCT00543907||Pre programmatic development|Patients who have undergone mastectomy for breast cancer prior to implementation of the deep inferior epigastric perforator flap microsurgical breast reconstruction program
11613512|NCT00543907||Post programmatic development|Patients who have undergone mastectomy for breast cancer after implementation of the deep inferior epigastric perforator flap microsurgical breast reconstruction program
11613513|NCT00543881|Experimental|1|Interventional group
11613514|NCT00543881|Active Comparator|2|Usual care group
11613515|NCT00543855|Experimental|3 mg Donepezil hydrochloride|
11613516|NCT00543855|Experimental|5 mg Donepezil hydrochloride|
11613517|NCT00543855|Experimental|10 mg Donepezil hydrochloride|
11613518|NCT00543855|Placebo Comparator|Placebo|
11613519|NCT00543842|Experimental|Bevacizumab + Erlotinib + Capecitabine + Radiation Therapy|Bevacizumab 5 mg/kg intravenous (IV) every 2 weeks for 3 Doses (Weeks 1, 3, 5). Erlotinib starting dose 50 mg orally daily Weeks 1-3. Capecitabine starting dose 650 mg/m^2 orally twice daily Monday-Friday for 6 Weeks. Radiation Therapy 30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments. At least 8 weeks after radiation therapy, surgical removal of rectal tumor.
11613520|NCT00543829|Experimental|1|4 cycles of doxorubicin and docetaxel with tamoxifen
11613521|NCT00543829|Active Comparator|2|4 cycles of doxorubicin and docetaxel without tamoxifen
11613522|NCT00543790|Experimental|1|
11613523|NCT00543777|Experimental|MRE + 2PD MRI|MRE - Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue. 2PD MRI - Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
11613524|NCT00543764||Pre pathway|Pre pathway
11613525|NCT00543764||Post pathway|Post pathway
11613526|NCT00543725|Active Comparator|002|efavirenz 600 mg tablet once daily for 96 weeks
11613527|NCT00543725|Experimental|001|TMC278 25 mg tablet once daily for 96 weeks
11613528|NCT00543686|Active Comparator|1|Montelukast
11613529|NCT00543686|Active Comparator|2|Fluticasone
11613530|NCT00543673|Experimental|Milk based formula A|Experimental milk based infant formula
11613531|NCT00543673|Active Comparator|Standard formula|standard milk based infant formula
11613532|NCT00543673|Other|Reference|Human milk
11613533|NCT00543673|Experimental|Milk based formula C|Experimental milk based infant formula
11613534|NCT00543660|Experimental|Intervention arm DSEK|Intervention: DSEK
11613535|NCT00543647|Experimental|1|
11613536|NCT00543647|Placebo Comparator|2|
11613537|NCT00543634|Active Comparator|1|
11613538|NCT00543634|Active Comparator|2|
11613539|NCT00543608|Experimental|1|Dose 1 iclaprim
11613540|NCT00543608|Experimental|2|Dose 2 iclaprim
11613541|NCT00543608|Active Comparator|3|vancomycin
11613542|NCT00543582|Experimental|1|
11613543|NCT00543569|Active Comparator|Tacrolimus/MMF/Basiliximab|Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.
11613544|NCT00543569|Experimental|Alefacept QW/Tacrolimus/MMF|Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.
11613545|NCT00543569|Experimental|Alefacept QW/Tacrolimus|Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.
11613546|NCT00543569|Experimental|Alefacept QOW/Tacrolimus/MMF|Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.
11613547|NCT00543543|Experimental|Low-dose V503|V503 (9-Valent Human Papillomavirus [HPV] Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study.
11613548|NCT00543543|Experimental|Mid-dose V503|V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study. A subset of participants (Cohort 1) received a fourth V503 mid-dose vaccination in the extension study.
11613549|NCT00543543|Experimental|High-dose V503|V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study.
11613550|NCT00543543|Active Comparator|Gardasil|Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study. Participants (Cohort 2) were offered the V503 mid-dose 3-dose regimen in the extension study.
11613551|NCT00543504|Experimental|Bevacizumab + Sunitinib|Arm 1: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Sunitinib 12.5 mg orally daily for 4 weeks, then 2 weeks off.
11613552|NCT00543504|Experimental|Bevacizumab + Sorafenib|Arm 2: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Sorafenib 200 mg by mouth daily for 28 Days
11613553|NCT00543504|Experimental|Bevacizumab + Erlotinib + Cetuximab|Arm 3: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Erlotinib 50 mg By Mouth Daily for 28 Days + Cetuximab loading dose 100 mg/m² IV and maintenance 75 mg/m² on Days 1, 8, 15, 22.
11613554|NCT00543504|Experimental|Bevacizumab + Trastuzumab + Lapatinib|Arm 4: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Trastuzumab loading dose 2 mg/kg IV then maintenance dose 1 mg/kg IV on Day 1 + Lapatinib 250 mg By Mouth Daily for 21 Days.
11613555|NCT00543478|Active Comparator|1|Receive active drug Saccharomyces boulardii 250mg twice a day for 8 weeks.
11613556|NCT00543478|Placebo Comparator|2|Placebo will be given twice a day for 10 weeks
11613557|NCT00543452|Active Comparator|oxygen|4 liters of oxygen a minute
11613558|NCT00543452|Placebo Comparator|air|4 liters of room air
11633798|NCT00325364|Active Comparator|2|
11613562|NCT00543426|Sham Comparator|2|sham Fuzheng Huayu Tablets
11613563|NCT00543413|Experimental|1|Arm 1: Drug 250 mg
11613564|NCT00543413|Experimental|2|Arm 2: Drug 500 mg
11613565|NCT00543413|Active Comparator|3|Arm 3: Active Comparator
11613566|NCT00543413|Placebo Comparator|4|Arm 4: Pbo Comparator
11613567|NCT00543400|Active Comparator|70 U/kg of unfractionated heparin given IV|Venous injection (IV) of 70 units per kilogram (U/kg) of unfractionated heparin prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
11613568|NCT00543400|Experimental|50 IU/KG of M118|Venous injection of 50 international units per kilogram (IU/kg) of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
11613569|NCT00543400|Experimental|75 IU/KG of M118|Venous injection of 75 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
11613570|NCT00543400|Experimental|100 IU/KG of M118|Venous injection of 100 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
11613571|NCT00543387|Experimental|MK-5108 200 mg BID (Panel 1)|Participants receive 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
11613572|NCT00543387|Experimental|MK-5108 400 mg BID (Panel 1)|Participants receive 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
11613573|NCT00543387|Experimental|MK-5108 800 mg BID (Panel 1)|Participants receive 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
11613574|NCT00543387|Experimental|MK-5108 1200 mg BID (Panel 1)|Participants receive 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
11613575|NCT00543387|Experimental|MK-5108 1500 mg BID (Panel 1)|Participants receive 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
11613576|NCT00543387|Experimental|MK-5108 1800 mg BID (Panel 1)|Participants receive 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
11613577|NCT00543387|Experimental|MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 100 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.
11613578|NCT00543387|Experimental|MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
11613579|NCT00543387|Experimental|MK-5108 225 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
11613580|NCT00543387|Experimental|MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Crossover)|After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
11613581|NCT00543387|Experimental|MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Crossover)|After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
11613582|NCT00543374|Placebo Comparator|Placebo|Placebo
11613583|NCT00543374|Active Comparator|PROCHYMAL Low dose|Low dose (total of 600 million cells)
11613584|NCT00543374|Active Comparator|PROCHYMAL High dose|High dose (total of 1200 cells)
11613585|NCT00543348|Active Comparator|1|CUTTING BALLOON
11613586|NCT00543348|Placebo Comparator|2|
11613587|NCT00543335|Experimental|Sorafenib + Radiation Therapy|Sorafenib starting dose 200 mg orally daily + 45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
11613588|NCT00543309|Experimental|I- nesiritide|Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
11613589|NCT00543309|Active Comparator|II- Milrinone|Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
11613590|NCT00543309|Placebo Comparator|III- placebo|Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
11613591|NCT00543296|Experimental|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
11613592|NCT00543270|Experimental|A|EVAR (Powerlink System)
11613593|NCT00543270|Active Comparator|B|Open Surgical Control
11613594|NCT00543257||Parents|Parents of children with ADHD will be recruited from the greater Boston community. We are interested in enrollment of parents with a range of educational and technical backgrounds, and specifically will look to enroll parents who may not have much computer experience.
11613595|NCT00543244||1|Patients with chronic hepatitis C who receive pegylated interferon plus ribavirin for 24 weeks (genotype 1 or 2) and for 48 weeks (genotype 1)
11613596|NCT00543218|Active Comparator|A|teriparatide 20 micrograms/day subcutaneous
11613597|NCT00543218|Active Comparator|B|
11613598|NCT00543166|Placebo Comparator|2|180 patients divided to two separate groups (each containing 90 patients). This study has a cross-over, wash-out design, which consists of two 4 month treatment period separated by a one month long wash-out period. During one treatment period the patient gets placebo and during one of the treatment periods the patient gets 50mg of dehydroepiandrosterone (DHEA) in the morning.
11613599|NCT00543153||Patients diagnosed with cancer|
11613600|NCT00543140|Other|REALIZE™ Swedish Adjustable Gastric Band|All subjects have the REALIZE™ Swedish Adjustable Gastric Band. Single arm - no comparator.
11613824|NCT00541177|Experimental|1|use 0.25% atropine once a week
11613601|NCT00543127|Experimental|Fulvestrant + Anastrozole|Fulvestrant loading dose regimen will consist of two 5 ml intramuscular injections on day 0 (500 mg), 250 mg single injection on days 14 and 28, and 250 mg single injection every 28 days thereafter for 3 years plus Anastrozole 1 mg PO once daily for 5 years
11613602|NCT00543127|Active Comparator|Anastrozole|Anastrozole 1 mg will be administered orally as one tablet daily for 5 years.
11613603|NCT00543114|Experimental|Lenalidomide, fludarabine and rituximab|Lenalidomide-Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period fludarabine- Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days Rituximab- Given intravenously on Day 1 of each 28 day cycle
11613604|NCT00543101|Active Comparator|Switch to DRV/r|Switch to DRV/r at a dose of 600/100 BID for 48 weeks
11613605|NCT00543101|Active Comparator|Continue on Current Dual Boosted PI|Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (< 400 copies/ml) for the first 24-weeks of the study and are followed for an additional 24 weeks
11613606|NCT00543062|Other|Treatment Sequence ABCD|Treatment Sequence ABCD where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
11613607|NCT00543062|Other|Treatment Sequence BDAC|Treatment Sequence BDAC where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
11613608|NCT00543062|Other|Treatment Sequence CABD|Treatment Sequence CABD where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
11613609|NCT00543062|Other|Treatment Sequence DCBA|Treatment Sequence DCBA where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
11613610|NCT00543049|Other|1 non-continuous|Subjects will receive open-label sunitinib = SU11248 at a dose of 50.0 mg once daily. After 28 days, treatment will be paused for 14 days and cycle one is completed, followed by resumption of therapy as cycle one for up to one year (therapy can be continued in case of tumor response and benefit for the patient for more than one year).
11613611|NCT00543049|Other|2 continuous|Subjects will receive open-label sunitinib = SU11248 at a dose of 37.5 mg once daily continuously. Treatment period up to one year (therapy can be continued in case of tumor response and benefit for the patient for more than one year).
11613612|NCT00543023|Experimental|A|teriparatide 20 micrograms/day subcutaneous
11613613|NCT00543023|Active Comparator|B|salmon calcitonin 100 IU/day subcutaneous
11613614|NCT00542997|Experimental|IgPro20|
11613615|NCT00542984|Active Comparator|A|teriparatide 20 micrograms/day subcutaneous
11613616|NCT00542984|Active Comparator|B|salmon calcitonin 100 IU/day subcutaneous
11613617|NCT00542971|Experimental|Sorafenib + Idarubicin + Ara-C|Sorafenib starting dose 400 mg orally for 7 days; Idarubicin 12 mg/m^2 intravenous (IV) daily (days 1-3); and Ara-C 1.5 g/m^2 IV over 24 hours daily (days 1-4)
11613618|NCT00542958|Experimental|NK012|"This is a Phase I dose-escalation study of the intravenous administration of NK012 in patients with refractory solid tumors. Patients will receive NK012 as an intravenous infusion over 30 minutes on Day 1 followed by a 20-day observation period for a total of 21 days (3 weeks) per cycle. Two patient populations will be evaluated separately: patients with UGT1A1*28 genotype homozygous wild type (wt/wt) and heterozygous (wt/*28) variants as one group, and patients with UGT1A1*28 homozygous variant (*28/*28) as another group. Dose-escalation in each patient population will proceed according to the predefined dose level.
~For UGT1A1*28 (wt/wt and wt/*28) patients, at least 3 evaluable patients will be treated at each dose level.
~UGT1A1 homozygous (*28/*28) patients will be treated at 50% of the current dose level.
~Patients will receive up to 6 cycles of NK012, unless they experience unacceptable toxicity or disease progression, requiring withdrawal from the study."
11613619|NCT00542945|Experimental|A|Heart Failure nonischemic ethiology
11613620|NCT00542945|Active Comparator|B|
11613621|NCT00542932|No Intervention|I|
11613622|NCT00542932|Active Comparator|II|Exercise
11613623|NCT00542919|Experimental|T-Cell|T-Cell (TCL): Peripheral and cutaneous T-cell lymphoma (PTCL, CTCL). Participants received enzastaurin 1125 milligram (mg) loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
11613624|NCT00542919|Experimental|Indolent B-Cell|Indolent B-Cell (IBCL): Small lymphocytic lymphoma, follicular lymphoma (Grade 1 or 2) and marginal zone lymphoma. Participants received enzastaurin 1125 mg loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
11613625|NCT00542919|Experimental|Aggressive B-Cell|Aggressive B-Cell (ABCL): Primary central nervous system (CNS) lymphoma, follicular lymphoma (Grade 3a and 3b) and aggressive lymphoma with prior clinical history of indolent lymphoma. Participants received enzastaurin 1125 mg loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
11613626|NCT00542906|Other|1|healthy volunteers
11613627|NCT00542893|Experimental|Group 1|Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
11613628|NCT00542893|Experimental|Group 2|Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
11613629|NCT00542880|Experimental|Symbicort Turbuhaler First, then Seretide Diskus|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg First, then Seretide Diskus (salmeterol/fluticasone) 50/500 μg
11613630|NCT00542880|Experimental|Seretide Diskus First, then Symbicort Turbuhaler|Seretide Diskus (salmeterol/fluticasone) 50/500 μg First, then Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg
11613631|NCT00542854||MP3|4 different brands of MP3 players will be tested at 3 distances from pacemakers and ICDs.
11613632|NCT00542841|Experimental|1|
11613633|NCT00542828|Experimental|Thymoglobulin|
11613634|NCT00542815|Experimental|1|
11613635|NCT00542815|Active Comparator|2|
11613636|NCT00542802|Experimental|LEV|Levetiracetam
11613637|NCT00542802|Active Comparator|CAR|Carbamazepina
11613638|NCT00542789|Placebo Comparator|1|Placebo
11613639|NCT00542789|Experimental|2|Esomeprazole 20 mg
11613640|NCT00542776||1|IBD patients on immunosuppressive therapy
11613641|NCT00542776||2|IBD patients on non-immunosuppressive therapy (e.g., aminosalicylates, antibiotics) or on no medications
11613642|NCT00542750|Experimental|N-Acetylcysteine|All participants will receive N-Acetylcysteine 1200 mg twice daily during four weeks of participation. Tolerability, marijuana use, and reactivity to marijuana cues will be investigated.
11613643|NCT00542737|Active Comparator|Early Intervention Group|
11613644|NCT00542737|Active Comparator|Delayed Intervention Group|
11613645|NCT00542724|Experimental|A|VIAject™
11613646|NCT00542724|Active Comparator|B|Regular Human Insulin
11613647|NCT00542698|No Intervention|Control|Control group uses 90 minutes of standard diabetes education/ 7 days using the International Diabetes Center curriculum & update phone call at 4 weeks.
11613648|NCT00542698|Experimental|Intervention|Interventional group received standard diabetes education, CGMS monitor, and extra educational topics including CGMS counceling.
11613649|NCT00542685|Experimental|PD 0332334 300 mg BID|
11613650|NCT00542685|Placebo Comparator|Placebo BID|
11613651|NCT00542685|Experimental|PD 0332334 225 mg BID|
11613652|NCT00542685|Experimental|PD 0332334 175 mg BID|
11613653|NCT00542633|Experimental|A|VIAject™
11613654|NCT00542633|Active Comparator|B|Regular Human Insulin
11613655|NCT00542620|Experimental|Mixed injection|
11613656|NCT00542620|Active Comparator|Separate injection|
11613657|NCT00542581|Experimental|The Acrysof toric SN60T3 IOL|Multifocal Intraocular Lens
11613658|NCT00542568|Experimental|1|Cohort 1 (Low Dose group) 18-25 IU/kg/day
11613659|NCT00542568|Experimental|2|Cohort 2 (Intermediate Dose group): 35-45 IU/kg/day
11613660|NCT00542568|Experimental|3|Cohort 3 (High Dose group): 55-65 IU/kg/day
11613661|NCT00542555|Placebo Comparator|Placebo bid|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
11613662|NCT00542555|Experimental|Naproxcinod 375 mg bid|
11613663|NCT00542555|Active Comparator|Naproxen 500 mg bid|
11613664|NCT00542555|Experimental|Naproxcinod 750 mg bid|
11613665|NCT00542542|Active Comparator|Paravertebral Block + General Anesthesia|Group 1: Paravertebral Block + General Anesthesia (Ropivacaine)
11613666|NCT00542542|Active Comparator|General Anesthesia Alone|Group 2: General Anesthesia Alone (Propofol, Midazolam, Fentanyl)
11613667|NCT00542529|Placebo Comparator|Cohort 1|Placebo or 2.0 mg/kg of Imprime PGG dosed in 7 different treatment regimens in combination with G-CSF for up to 4 consecutive days.
11613668|NCT00542529|Placebo Comparator|Cohort 2|Placebo or 4.0 mg/kg of Imprime PGG dosed in 7 different treatment regimens in combination with G-CSF for up to 4 consecutive days.
11613669|NCT00542516|Experimental|HES 130/04|Pre-expansion with HES
11613670|NCT00542516|Active Comparator|Ringer's lactate|Pre-expansion with Ringer's lactate
11613671|NCT00542490|Experimental|Vaginal Cuff Brachytherapy|
11613672|NCT00542464|Placebo Comparator|Cohort 1|1.0 mg/kg Imprime PGG administered daily over 1 hr for 7 consecutive days
11613673|NCT00542464|Placebo Comparator|Cohort 2|2.0 mg/kg Imprime PGG administered daily over 1 hr for 7 consecutive days
11613674|NCT00542464|Placebo Comparator|Cohort 3|4.0 mg/kg Imprime PGG administered daily over 2 hr for 7 consecutive days
11613675|NCT00542438|Active Comparator|Physical Activity Recall|Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
11613676|NCT00542438|Active Comparator|Environmental Assessment|Environmental assessments on a palm pilot either 3 times a day or once a day. Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
11613677|NCT00542425|Placebo Comparator|Placebo|
11613678|NCT00542425|Experimental|BA058 20 µg|
11613679|NCT00542425|Experimental|BA058 40 µg|
11613680|NCT00542425|Experimental|BA058 80 µg|
11613681|NCT00542425|Active Comparator|teriparatide|
11613682|NCT00542399|Experimental|1|once a day
11613683|NCT00542399|Experimental|2|twice a day
11613684|NCT00542386|Experimental|1|
11613685|NCT00542386|Placebo Comparator|2|
11613686|NCT00542373|Experimental|Diagnostic (fluorescent/reflectance imaging, spectroscopy)|Participants' oral cavities are inspected by a clinician using a standard white light headlamp. Participants then undergo oral mucosa examination using wide-field reflectance and fluorescence imaging, and/or fluorescence spectroscopy imaging. Standard oral brush biopsies are also performed and examined microscopically. Participants may undergo repeated imaging procedures and biopsy during subsequent follow up visits.
11613687|NCT00542360|Experimental|Social marketing program|Behavioral: Social marketing program to motivate exercise class participation
11613688|NCT00542360|No Intervention|Control|Control: No intervention
11613689|NCT00542347|Active Comparator|1|"esomeprazole 20mg po once per day for 7 days
~24hr pH study on day 7
~followed by washout for 7 days
~generic omeprazole 20mg po once per day for 7 days
~24hr pH study on day 7"
11613690|NCT00542347|Active Comparator|2|"generic omeprazole 20mg po once per day for 7 days
~24hr pH study on day 7
~followed by washout for 7 days
~esomeprazole 20mg po once per day for 7 days
~24hr pH study on day 7"
11613691|NCT00542321|Experimental|Kinetic Therapy Bed|Kinetic Therapy Bed: Continuous automated turning to 45 degrees with head of the bed elevated 30 degrees or more for up to 7 continuous days
11613726|NCT00542113|Experimental|1|Parents of elementary school children in grades 2-6 participating in Program ENERGY -Intervention 1
11613692|NCT00542321|Active Comparator|Manual Turn|Manual Turn: lateral rotation every 2 hours from back to left to back to right to back, with >/= 45 degree lateral rotation angle and 30 degree head of bed elevation
11613693|NCT00542308|Experimental|Zalutumumab 4-16 mg/kg|Zalutumumab iv infusion once weekly. The dose was titrated until grade 2 rash occurred.
11613694|NCT00542295|Experimental|A|
11613695|NCT00542295|Placebo Comparator|B|
11613696|NCT00542282||1, 2, 3|known moderate to severe COPD, known moderate or severe Asthma, suspected obstructive moderate to severe airways disease
11613697|NCT00542269|Experimental|Aliskiren / ramipril / amlodipine|6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
11613698|NCT00542269|Experimental|Aliskiren / amlodipine|6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
11613699|NCT00542269|Active Comparator|Ramipril / amlodipine|6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
11613700|NCT00542256|Active Comparator|1|Each subject will receive 14 days (2 week period: 10 weekdays and 2 weekends) of constraint induced movement therapy. In addition, on the 10 weekdays during the treatment period, the subjects will come into the laboratory and receive up to 6 hours per day of training of the affected arm in a variety of tasks. At the beginning of each of the 10 weekday training sessions, participants will receive 40 minutes of active tDCS over the primary motor cortex.
11613701|NCT00542256|Sham Comparator|2|Each subject will receive 14 days (2 week period: 10 weekdays and 2 weekends) of constraint induced movement therapy. In addition, on the 10 weekdays during the treatment period, the subjects will come into the laboratory and receive up to 6 hours per day of training of the affected arm in a variety of tasks. At the beginning of each training day tDCS will be applied for 40 minutes with the current active for only 30 seconds over the primary motor cortex.
11613702|NCT00542243|Active Comparator|Finasteride|"The recommended dosage of PROSCAR© is one 5 mg tablet daily with or without food. If a tablet is missed at its usual time, an extra dose should not be taken. The next dose should be taken as usual.
~PROSCAR© 5 mg tablets are blue, apple-shaped; film coated with the code MSD 72 on one side and PROSCAR on the other. They will be provided in bottles of 35 tablets."
11613703|NCT00542243|Placebo Comparator|Placebo|Patient will receive a placebo comparator each day for 6 months.
11613704|NCT00542230||Healthy Volunteers|Healthy Volunteers
11613705|NCT00542230||Sickle Cell Trait|Patient with sickle cell trait or disease
11613706|NCT00542217|Placebo Comparator|Cohort 1|Single dose of 0.5 mg/kg Imprime PGG administered over 1 hr
11613707|NCT00542217|Placebo Comparator|Cohort 2|Single dose of 1.0 mg/kg Imprime PGG administered over 1 hr
11613708|NCT00542217|Placebo Comparator|Cohort 3|Single dose of 2.0 mg/kg Imprime PGG administered over 1 hr
11613709|NCT00542217|Placebo Comparator|Cohort 4|Single dose of 4.0 mg/kg Imprime PGG administered over 2 hr
11613710|NCT00542217|Placebo Comparator|Cohort 5|Single dose of 6.0 mg/kg Imprime PGG administered over 3 hr
11613711|NCT00542204|Experimental|Online disease management|The PAMFOnline-mediated Personalized Health Care Program, which couples a multidisciplinary diabetes care management team with an EHR-integrated Online Disease Management (ODM) system.
11613712|NCT00542204|No Intervention|Usual care|Usual medical care. No access to the PHCP electronic system and self-management tools supporting this care management.
11613713|NCT00542191|Experimental|Neoadjuvant metronomic AC followed by weekly TC|Neoadjuvant chemotherapy with metronomic AC followed by weekly TC then surgery
11613714|NCT00542178|Experimental|Intensive glycemia control|A strategy of intensive glycemia treatment to HbA1c less than 6%
11613715|NCT00542178|Active Comparator|Standard glycemia control|A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%
11613716|NCT00542178|Experimental|Intensive BP control|A strategy of BP treatment for SBP less than 120 mm Hg
11613717|NCT00542178|Active Comparator|Standard BP control|A strategy of BP treatment for SBP less than 140 mm Hg
11613718|NCT00542178|Experimental|Fibrate|Blinded fenofibrate + simvastatin 20-40 mg/d
11613719|NCT00542178|Placebo Comparator|Fibrate Placebo|Blinded placebo + simvastatin 20-40 mg/d
11613720|NCT00542152|Active Comparator|CICLO|"Cyclosporine will be administered by continuous intravenous infusion at the initial dose regimen of 2mg/kg per day.
~After 24 hours of treatment, cyclosporine trough level will be measured and the dose adapted in order to obtain a cyclosporinaemia level between 150 and 250 ng/ml. Cyclosporinaemia will be reassessed every 48 hours for the duration of the continuous intravenous treatment."
11613721|NCT00542152|Active Comparator|INFLIXIMAB|"INFLIXIMAB (REMICADE) Infliximab in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution, and slowly infused at the dose of 5mg/kg in 2 hours.
~In patients with clinical response at D7 (Lichtiger Index score < 10 for 2 consecutive days), two additional infliximab infusions will be administered at the dose of 5mg/kg at D14 and D42."
11613722|NCT00542139|Experimental|1|
11613723|NCT00542139|Active Comparator|2|
11613724|NCT00542126|Active Comparator|1|GnRH analog administration following embryo transfer
11613725|NCT00542126|No Intervention|2|
11613818|NCT00541242|Active Comparator|2|latanoprost 0.005% eye drops
11613727|NCT00542113|Experimental|2|Parents of elementary school children in grades 2-6 participating in Program ENERGY -Intervention 2
11613728|NCT00542113|Sham Comparator|3|Parents of elementary school children in grades 2-6 participating in Program ENERGY matched to the intervention groups
11613729|NCT00542100|Experimental|1|
11613730|NCT00542100|Experimental|2|
11613731|NCT00542074|Experimental|1|
11613732|NCT00542074|Active Comparator|2|
11613733|NCT00542061|Experimental|A|Device: monitoring services
11613734|NCT00542061|No Intervention|B|Control group: no monitoring procedures
11613735|NCT00542048|Experimental|1|
11613736|NCT00542035|Experimental|ARRY-371797|
11613737|NCT00542035|Experimental|Placebo, ARRY-371797|
11613738|NCT00542035|Placebo Comparator|Placebo|
11613739|NCT00542009|Experimental|CE-326,597 100 mg QD|
11613740|NCT00542009|Experimental|CE-326,597 50 mg QD|
11613741|NCT00542009|Experimental|CE-326,597 25 mg QD|
11613742|NCT00542009|Placebo Comparator|Placebo|
11613743|NCT00542009|Experimental|CE-326,597 5mg QD|
11613744|NCT00541983|Active Comparator|1|
11613745|NCT00541983|Placebo Comparator|2|
11613746|NCT00541970|Experimental|Cervarix 1/Placebo Group|Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
11613747|NCT00541970|Experimental|Cervarix 1/Placebo/Cervarix 1 Group|Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
11613748|NCT00541970|Experimental|Cervarix 2/Placebo/Cervarix 2 Group|Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
11613749|NCT00541970|Experimental|Cervarix 2 Group|Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.
11613750|NCT00541957|Other|2|Medication prescribed by PCP
11613751|NCT00541957|Experimental|1|Medication prescribed by PCP + behavior therapy
11613752|NCT00541931|Other|Nonsmoker|Nonsmokers Intervention: Dietary Supplement: LifePak Nano
11613753|NCT00541931|Other|Smoker|Smoker arm Intervention: Dietary Supplement: LifePak Nano
11613754|NCT00541918|Active Comparator|1|propofol
11613755|NCT00541918|Experimental|2|sevoflurane
11613756|NCT00541905|Experimental|NT 201 (50-300 Units)|"NT 201 (Xeomin®, also know as IncobotulinumtoxinA or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
11613757|NCT00541892|Experimental|1|Medium with no human serum albumine added
11613758|NCT00541892|Active Comparator|2|Conventional medium
11613759|NCT00541879|Experimental|I|Elementary school children -grades 2-6 participating in Program ENERGY
11613760|NCT00541879|Sham Comparator|II|Elementary school children in grades 2-6 matched to the intervention classes not receiving any intervention
11613761|NCT00541866|Experimental|Voreloxin injection and cytarabine|"Dose-escalation Phase
~Schedule A:
~Schedule B:
~Expansion Phase
~Schedule A:
~Schedule B:"
11613762|NCT00541853|Active Comparator|A|ADPKD patients with blood pressure above 130/85 are enrolled. The patients whose blood pressure is controlled under 130/85 by Candesartan alone are classified into group A.
11613763|NCT00541853|Experimental|B|The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group B, blood pressure is controlled by Candesartan plus Cilnidipine. If blood pressure is not lowered by Candesartan plus Cilnidipine alone, another antihypertensive agents except CCB and ACEI are allowable.
11613764|NCT00541853|Active Comparator|C|The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group C, blood pressure is controlled by Candesartan plus non-CCB agents such as beta- or alpha- adrenergic blockers or another ARB. Any CCB and ACEI are not allowable.
11613765|NCT00541814|Active Comparator|1|CNI [Cyclosporine] minimisation Group. Conversion from azathioprine to Myfortic followed by a three month period of cyclosporine weaning to target blood level of 50-100 ng/ml.
11613766|NCT00541814|Experimental|2|CNI [Cyclosporine] withdrawal Group. Conversion from azathioprine to Myfortic followed by a three month period of cyclosporine weaning to the point of withdrawal.
11613767|NCT00541788|Experimental|1|Administration of Common Sage
11613768|NCT00541775|Experimental|Sitagliptin|sitagliptin 100 mg
11613769|NCT00541775|Active Comparator|Rosiglitazone|rosiglitazone 8 mg
11613770|NCT00541775|Placebo Comparator|Placebo|placebo
11613771|NCT00541762|Other|A, 3; B, 3; C, 3|A, 3: Fat with and without orlistat or placebo. B, 3: LCF vs MCF vs placebo. C, 3: LCF with and without DEXLOX or placebo.
11613772|NCT00541736|Experimental|Patients|GTN-infusion
11613773|NCT00541736|Active Comparator|Controls|GTN-infusion
11613774|NCT00541723|Experimental|IncobutolinumtoxinA (Xeomin), 4-injection scheme|"IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:
~Clostridium Botulinum neurotoxin Type A free of complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl); total volume 0.24 mL per side, i.e. 4 x 0.06 mL (4 x 3 units = 12 units); mode of administration: intramuscular injection."
11613775|NCT00541723|Placebo Comparator|Placebo 4-injection scheme|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; total volume 0.24 mL per side, i.e. 4 x 0.06 mL placebo solution; mode of administration: intramuscular injection.
11613819|NCT00541229|Experimental|1|sitagliptin 100 mg
11613820|NCT00541229|Experimental|2|sitagliptin 200 mg
11613821|NCT00541229|Placebo Comparator|3|Placebo
11613822|NCT00541190|Experimental|cystic fibrosis|Cystic fibrosis patients
11613823|NCT00541190|Experimental|healthy controls|Healthy control subjects
11613776|NCT00541723|Experimental|IncobotulinumtoxinA (Xeomin), 3-injection scheme|"IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:
~Clostridium Botulinum neurotoxin Type A free of complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl); total volume 0.24 mL per side, i.e. 3 x 0.08 mL (3 x 4 units = 12 units); Mode of administration: intramuscular injection."
11613777|NCT00541723|Placebo Comparator|Placebo 3-injection Scheme|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; total volume 0.24 mL per side, i.e. 3 x 0.08 mL placebo solution; mode of administration: intramuscular injection.
11613778|NCT00541710|Placebo Comparator|Lifestyle counseling|Placebo tablets. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
11613779|NCT00541710|Experimental|Genistein|Genistein 54 mg/day in 2 tablets for 12 months. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
11613780|NCT00541671|Placebo Comparator|1|Patients will then be randomized to receive placebo, consisting of 10ml of normal saline solution to be administered intravenously with the narcotic
11613781|NCT00541671|Active Comparator|2|Patients will be randomized to 6.25mg of promethazine, consisting of 0.25ml of promethazine diluted in 9.75ml of normal saline.
11613782|NCT00541658|Active Comparator|5 mg Before Breakfast|5 mg / Immediate-release Risedronate (At Least 30 Minutes Before Breakfast)
11613783|NCT00541658|Experimental|35 mg After Breakfast|35 mg / Delayed-release Risedronate (Immediately Following Breakfast)
11613784|NCT00541658|Experimental|35 mg Before Breakfast|35 mg / Delayed-release Risedronate (At Least 30 Minutes Before Breakfast)
11613785|NCT00541619||A|hypertensives with proteinuria
11613786|NCT00541606|Experimental|Intervention|Received collaborative care including a clinical pharmacist practitioner.
11613787|NCT00541606|Active Comparator|Control|Patients received usual care directed by their physician.
11613788|NCT00541593|Experimental|NOTES pancreatic pseudocystgastrostomy|Patients who undergo pancreatic pseudocystgastrostomy via a NOTES technique.
11613789|NCT00541567|Placebo Comparator|1|
11613790|NCT00541567|Experimental|2|
11613791|NCT00541567|Experimental|3|
11613792|NCT00541567|Experimental|4|
11613793|NCT00541515|Experimental|closed loop system|Device: continuous glucose sensors and insulin pump
11613794|NCT00541489|Placebo Comparator|1|
11613795|NCT00541489|Active Comparator|2|Naproxen 500 mg
11613796|NCT00541489|Experimental|3|Naproxcinod 750 mg
11613797|NCT00541450|Experimental|Sita/Met FDC|"In Phase A (Treatment Day 1 to Week 12), participants were administered 100 mg once daily (q.d.) of sitagliptin and matching placebo to 15 mg pioglitazone q.d. for 6 weeks followed by matching placebo to 30 mg pioglitazone for the next 6 weeks.
~In Phase B (Treatment Week 12-Week 40), participants were switched to the Sita/Met Fixed-Dose Combination (FDC) at a dose of 50/500 mg twice a day (b.i.d.), which was increased to 50/1000 mg b.i.d. over a period of 4 weeks; as well as matching placebo to 45 mg pioglitazone."
11613798|NCT00541450|Active Comparator|Pioglitazone|"In Phase A (Treatment Day 1 up to Week 12), randomized participants in the pioglitazone group were administered 15 mg q.d. of pioglitazone and matching placebo to sitagliptin. At Week 6, participants were up-titrated to 30 mg pioglitazone q.d.
~In Phase B (Treatment Week 12 to Week 40), participants were administered 45 mg pioglitazone q.d.; as well as matching placebo to Sita/Met FDC (50/500 increased to 50/1000 b.i.d. after 4 weeks)."
11613799|NCT00541424||PET/CT Scanning|Patients that have newly diagnosed mantle cell lymphoma will first undergo CT colonography (CT or CTC) and PET followed by conventional colonoscopy.
11613800|NCT00541398|Experimental|A|
11613801|NCT00541398|No Intervention|B|
11613802|NCT00541385|Experimental|1|60mg pyronaridine and 20mg artesunate fixed dose combination granule formulation for 3 consecutive days
11613803|NCT00541385|Active Comparator|2|120mg lumefantrine and 20mg Artemether fixed dose combination crushed tablets, twice a day for 3 days
11613804|NCT00541372|Experimental|1|Needle 5 mm
11613805|NCT00541372|Active Comparator|2|Needle length 8 mm
11613806|NCT00541359|Experimental|Arm I|"PART I (completed as of 09/06/06; all patients enrolled in study after 09/06/06 are enrolled in part II): Patients receive escalating doses of topotecan hydrochloride IV over 30 minutes on days 1 and 8 followed 6 hours later by bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
~PART II: Patients receive bortezomib IV on days 1, 4, 8, and 11 followed 6 hours later by escalating doses of topotecan hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
~In both parts of the study, patients who achieve a response may receive additional courses of treatment."
11613807|NCT00541346|Experimental|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
11613808|NCT00541333|Active Comparator|Copaxone|
11613809|NCT00541333|Sham Comparator|Sham|
11613810|NCT00541307|Experimental|GORE VIABHAN Endoprothesis|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
11613811|NCT00541294||B|M.tb unexposed HIV-infected and uninfected children <15 years of age
11613812|NCT00541294||A|M.tb exposed HIV-infected and uninfected children <15 years of age
11613813|NCT00541281|Active Comparator|A|weekly docetaxel and prednisone
11613814|NCT00541281|Active Comparator|B|weekly docetaxel (35mg/m&) plus prednisone 10mg a day associated with estramustine form day 1to 5 and 8 to 12
11613815|NCT00541268|Experimental|A|Heart Failure nonischemic etiology
11613816|NCT00541268|Active Comparator|B|
11613817|NCT00541242|Active Comparator|1|bimatoprost 0.03% eye drops
11633799|NCT00325351|Experimental|Arm 1|
11613825|NCT00541177|Active Comparator|2|use 0.5% tropicamide everyday
11613826|NCT00541164|Experimental|1|300 mg CoQ10 chewable wafer twice a day
11613827|NCT00541164|Placebo Comparator|2|Chewable placebo wafer twice a day for 24 weeks with crossover to 300mg CoQ10 twice a day for weeks 24-48.
11613828|NCT00541125|Other|FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire|FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire
11613829|NCT00541099|Experimental|Avastin & Docetaxel|Avastin 10.0 mg/kg on days 1 and 15; Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel; Docetaxel 35 mg/m2 on day 1, 8, 15
11613830|NCT00541086|Experimental|A - anastrozole|Up-front adjuvant anastrozole for 5 years
11613831|NCT00541086|Experimental|B - exemestane|Up-front adjuvant exemestane for 5 years
11613832|NCT00541086|Experimental|C - letrozole|Up-front adjuvant letrozole for 5 years
11613833|NCT00541086|Active Comparator|D - tamoxifen followed by anastrozole|Switch adjuvant treatment with tamoxifen for 2 years followed by anastrozole for 3 years
11613834|NCT00541086|Active Comparator|E - tamoxifen followed by exemestane|Switch adjuvant treatment with tamoxifen for 2 years followed by exemestane for 3 years
11613835|NCT00541086|Active Comparator|F - tamoxifen followed by letrozole|Switch adjuvant treatment with tamoxifen for 2 years followed by letrozolefor 3 years
11613836|NCT00541060|Active Comparator|A|250 young patients presenting several carious lesions
11613837|NCT00541060|Placebo Comparator|B|160 young adults totally caries free
11613838|NCT00541047|Experimental|RADICALS-RT: Early RT|
11613839|NCT00541047|Experimental|RADICALS-RT: Salvage RT|
11613840|NCT00541047|Experimental|RADICALS-HD: Radiotherapy Alone|
11613841|NCT00541047|Experimental|RADICALS-HD: Radiotherapy + 6 months|
11613842|NCT00541047|Experimental|RADICALS-HD: Radiotherapy + 24 months|
11613843|NCT00541034|Experimental|cyclophosphamide, pentostatin & rituximab|Patients receive cyclophosphamide IV followed by pentostatin IV on day 1 in course 1. Beginning in course 2 and in all subsequent courses, patients receive cyclophosphamide IV on day 1, pentostatin IV on day 1, and rituximab IV on day 1 or on days 1 and 2. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11613844|NCT00540995|Experimental|Arm I|"PREPARATIVE CHEMOTHERAPY: Patients receive busulfan IV once daily over 2 hours on days -15 and -13 and then every 6 hours on days -12 to -9. Patients also receive etoposide IV on day -3. Patients undergo image-guided intensity-modulated radiation therapy using helical tomotherapy on days -8 to -5.
~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0.
~GRAFT-VS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive GVHD prophylaxis that excludes methotrexate."
11613845|NCT00540982|Experimental|Normal Liver Function|
11613846|NCT00540982|Experimental|Mild Liver Dysfunction|
11613847|NCT00540982|Experimental|Moderate Liver Dysfunction|
11613848|NCT00540982|Experimental|Severe Liver Dysfunction|
11613849|NCT00540969|Experimental|Arm I (percutaneous cryoablation)|Cryoprobes are inserted percutaneously under CT scan or ultrasound guidance, to the malignant soft tissue-bone interface. Patients undergo ablations using a freeze-thaw-freeze cycle lasting approximately 10-5-10 minutes, respectively.
11613850|NCT00540969|Active Comparator|Arm II (external-beam radiotherapy)|Patients undergo external-beam radiotherapy comprising either a single 8 Gy dose or 20 Gy/5 fractions administered over 1 week.
11613851|NCT00540943|Experimental|Single Arm|irinotecan and cetuximab in combination with pazopanib.
11613852|NCT00540917|Experimental|cooling spray|cooling spray during laser treatment
11613853|NCT00540904|Active Comparator|sodium bicarbonate|Solution 154 mEq/L of sodium bicarbonate
11613854|NCT00540904|Active Comparator|Sodium chloride|Solution of 154 mEq/L of NaCl
11613855|NCT00540865|Experimental|A|Participants will receive problem-solving therapy and case management
11613856|NCT00540865|Active Comparator|B|Participants will receive case management
11613857|NCT00540852|Other|Diagnostic Tool|Diffuse Optical Spectroscopy Imaging
11613858|NCT00540839|Experimental|Montelukast|Participants receive montelukast 4 mg oral granules (OG) or 4 mg chewable tablets (CT) once daily (QD) for 24 weeks and placebo to fluticasone 50 mcg inhalation aerosol twice daily (BID) for 24 weeks. Participants aged >6 months to <2 years receive montelukast 4 mg packet of OG QD for 24 weeks. Participants aged >2 years to <64 months receive montelukast 4 mg CT QD for 24 weeks.
11613859|NCT00540839|Active Comparator|Fluticasone|Participants receive fluticasone 50 mcg inhalation aerosol twice daily (BID) for 24 weeks and placebo to montelukast 4 mg QD for 24 weeks. Participants aged >6 months to <2 years receive placebo packet of OG QD for 24 weeks. Participants aged >2 years to <64 months receive placebo CT QD for 24 weeks.
11613860|NCT00540826||A|A: ADHD-patients receiving non-stimulants (e.g. atomoxetine)
11613861|NCT00540826||B|B: ADHD-patients receiving stimulants
11613862|NCT00540813|Experimental|Drug Eluting Balloon|
11613863|NCT00540800|Active Comparator|A|Three-weekly chemotherapy
11613864|NCT00540800|Experimental|B|Weekly chemotherapy
11613865|NCT00540787|Active Comparator|Drug Treatment|
11613866|NCT00540787|Active Comparator|ThermoCool Radiofrequency Catheter|Radiofrequency catheter used.
11613867|NCT00540774||Oral tissue|detection of oral pathology
11613868|NCT00540761|Experimental|OFDI imaging|OFDI catheter advanced to the distal coronary artery
11613869|NCT00540761|Experimental|Intravenous Ultrasound|Randomization to determine whether Intravenous Ultrasound will be conducted before or after OFDI imaging.
11613870|NCT00540748|Experimental|A1|
11613871|NCT00540748|No Intervention|A2|
11613872|NCT00540735|Experimental|1|PDT
11613873|NCT00540735|No Intervention|2|
11613874|NCT00540722|Experimental|Treatment (R-(-)-gossypol acetic acid)|"Patients receive oral R-(-)-gossypol once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
~Laboratory Biomarker Analysis: Patients undergo tumor tissue and blood sample collection at baseline and periodically during study for biomarker correlative studies. Archived tumor tissue samples, if available, are analyzed for Bcl-2 family protein expression (e.g., Bcl-2, Bcl-xL, MCl-1, Bax, Bak, and BH3 domain for BH3 members only) and MGMT gene methylation status. Blood samples are analyzed for apoptotic protein levels (Bcl-2) by enzyme-linked immunosorbent assay."
11634739|NCT00313300|Placebo Comparator|A3|
11613875|NCT00540696|Experimental|darbepoetin alfa|
11613876|NCT00540670|Experimental|1|
11613877|NCT00540670|Experimental|2|
11613878|NCT00540670|Experimental|3|
11613879|NCT00540670|Placebo Comparator|4|
11613880|NCT00540657|Experimental|1|
11613881|NCT00540657|Placebo Comparator|2|
11613882|NCT00540644|Experimental|Revlimid, Cyclophosphamide, Prednisone|"Lenalidomide orally on Days 1-21 followed by 7 days rest, repeated every 28 days.
~Cyclophosphamide twice daily, orally on Days 1-21 followed by 7 days rest, repeated every 28 days.
~Prednisone every other day orally."
11613883|NCT00540631|No Intervention|P|subcutaneous treatment with placebo Placebo- physiological saline containing histamine-dihydrochloride 0.1mL, 0.2mL, 0.4mL, 0.6mL of strength A(1000TU/mL) followed by 0.1mL, 0.4mL, 0.6mL by strength B (10000TU/mL) in weekly intervals
11613884|NCT00540631|Experimental|A|Active treatment with house dust mite extract
11613885|NCT00540618|Active Comparator|1|MEDI-507
11613886|NCT00540618|Placebo Comparator|2|
11613887|NCT00540618|Active Comparator|3|MEDI-507
11613888|NCT00540618|Active Comparator|4|MEDI-507
11613889|NCT00540605|Experimental|1|4g tenofovir 1% gel applied vaginally 2 hours prior to expected time of cesarean delivery
11613890|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 1 Group|Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
11613891|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 2 Group|Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
11613892|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 3 Group|Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
11613893|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 4 Group|Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
11613894|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 5 Group|Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
11613895|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 6 Group|Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
11613896|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 7 Group|Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
11613897|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 8 Group|Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
11613898|NCT00540592|Active Comparator|Fluarix elderly Group|Subjects aged ≥65 years received one dose of Fluarix vaccine.
11613899|NCT00540592|Active Comparator|Fluarix young Group|Subjects aged 18-40 years received one dose of Fluarix vaccine.
11613900|NCT00540579|Experimental|Intervention|All patients received gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of a 28 day cycle. Pomalidomide was administered orally on days 1-21 at doses escalated from 2 mg to 10 mg daily.
11613901|NCT00540566||Optical Biopsy|Optical Biopsy imaging
11613902|NCT00540527|Experimental|1|local intraarterial recombinant tissue plasminogen activator
11613903|NCT00540527|Active Comparator|2|intravenous (IV) rt-PA
11613904|NCT00540514|Experimental|Albumin-bound paclitaxel + Carboplatin|Participants received albumin-bound paclitaxel (ABRAXANE®) 100 mg/m^2 administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. Carboplatin was given at an Area Under the Curve (AUC) = 6 mg*min/mL on Day 1 only of each 21-day cycle, beginning immediately after the completion of albumin-bound paclitaxel administration. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
11613905|NCT00540514|Active Comparator|Paclitaxel + Carboplatin|Participants received 200 mg/m^2 paclitaxel (Taxol®) administered by intravenous infusion followed by carboplatin at AUC = 6 mg*min/mL on Day 1 of a 21 day cycle. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
11613906|NCT00540501|Experimental|Oseltamivir 150mg and zanamivir 50mg/hour|Oseltamivir1 150mg PO q12h for 5 doses + Zanamivir IV continuous infusion at 50mg/hour for 72 hours
11613907|NCT00540501|Experimental|Zanamivir IV 50mg/hour|Zanamivir IV continuous infusion 50mg/hour for 16 hours (total dose of 800mg)
11613908|NCT00540501|Experimental|Oseltamivir 150mg and zanamivir 600mg|Oseltamivir 150mg PO q12h for 5 doses + Zanamivir 600mg IV q12h
11613909|NCT00540501|Active Comparator|Oseltamivir 150mg|Oseltamivir 150mg PO q12h for 3 days
11613910|NCT00540462|No Intervention|1|Medical Group
11613911|NCT00540462|Active Comparator|2|Surgical Group with gastric bypass
11613912|NCT00540462|Active Comparator|3|Sugical Group with Sleeve gastrectomy
11613913|NCT00540449|Active Comparator|Efavirenz|Efavirenz 600mg once daily for 96 weeks
11613914|NCT00540449|Experimental|TMC278|TMC278 25 mg tablet once daily for 96 weeks
11613915|NCT00540436|Experimental|GSK1325760A|Single arm safety and efficacy
11613916|NCT00540423|Experimental|SB-497115-GR group|Subject will initiate treatment with SB-497115-GR 12.5mg once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR may be adjusted at 12.5mg, 25mg or 50mg.
11613917|NCT00540423|Placebo Comparator|placebo group|Subject will initiate treatment with SB-497115-GR 12.5mg matching placebo once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR 12.5mg matching placebo may be increased to 2 tablet of SB-497115-GR 12.5mg matching placebo.
11613918|NCT00540410|Experimental|1|
11613919|NCT00540410|Active Comparator|2|
11613920|NCT00540384|Experimental|NESP - Schedule 1 Part A|Part A - 4.5, 6.75, 9.0 or 13.5 mcg/kg Q3W for 12 weeks
11613921|NCT00540384|Experimental|NESP - Schedule 2 Part A|NESP 9.0, 12.0, 15.0 or 18.0 mcg/kg Q4W for 12 weeks
11613922|NCT00540384|Placebo Comparator|Placebo - Schedule 1 Part A|Placebo Q3W for 12 weeks
11613923|NCT00540384|Experimental|NESP - Schedule 1 Part B|Open-label NESP at the dose of study drug administered at the end of Part A. Increase dose at week 19 if hgb < 13.0g/dL and/or RBC transfusion in previous 2 weeks.
11613924|NCT00540384|Placebo Comparator|Placebo - Schedule 2 Part A|Placebo Q4W for 12 weeks
11634740|NCT00313300|Experimental|A4|
11613925|NCT00540384|Experimental|NESP - Schedule 2 Part B|Open-label NESP at the dose of study drug administered at the end of Part A
11613926|NCT00540371||Port wine stain Birthmark|Port wine stain Birthmark
11613927|NCT00540358|Active Comparator|Arm G/C|Standard chemotherapy with gemcitabine/carboplatin on Days 1 and 8 of 21-day cycle(s)
11613928|NCT00540358|Experimental|Arm G/C/I|Standard chemotherapy with gemcitabine/carboplatin on Days 1 and 8, plus iniparib on Days 1, 4, 8, and 11 of 21-day cycle(s)
11613929|NCT00540345|Active Comparator|A, RVR LD RBV|Patients who have a RVR will be randomized into two groups with a ratio of 1:1 (Arm A & B)B, RVR SD RBV A, RVR LD RBV B, RVR SD RBV
11613930|NCT00540345|Active Comparator|B, RVR SD RBV|Patients who have a RVR will be randomized into two groups with a ratio of 1:1 (Arm A & B)B, RVR SD RBV
11613931|NCT00540345|Active Comparator|C, non-RVR 24w|For patients who do not have a RVR will be randomized into two groups with a ratio of 1:1 (Arm C & D) (C, non-RVR 24w) (D, non-RVR 48w)
11613932|NCT00540345|Active Comparator|D, non-RVR 48w|For patients who do not have a RVR will be randomized into two groups with a ratio of 1:1 (Arm C & D)(C, non-RVR 24w) (D, non-RVR 48w)
11613933|NCT00540332|Placebo Comparator|Placebo|"Approximately 17 subjects to receive palifermin. Subjects will be enrolled as follows:
~PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects
~Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects."
11613934|NCT00540332|Experimental|Palifermin|"Approximately 23 subjects to receive palifermin. Subjects will be enrolled as follows:
~PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects
~Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects."
11613935|NCT00540306||Diagnostic Tool|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
11613936|NCT00540293|Experimental|Treatment group|this patient group consists of dyslipidemia patients with various CVD risk factors
11613937|NCT00540280|Active Comparator|Surgery alone|Surgery alone
11613938|NCT00540267||Schizophrenia|Chronic schizophrenia with aged 18-80 years
11613939|NCT00540254|Active Comparator|Arm 1|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
11613940|NCT00540254|Active Comparator|Arm 2|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
11613941|NCT00540241||Second-line pemetrexed treatment in NSCLC|Patients with NSCLC who will start second-line treatment with pemetrexed.
11613942|NCT00540228|Experimental|GSK1247446A 1 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11613943|NCT00540228|Experimental|GSK1247446A 2 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11613944|NCT00540228|Experimental|GSK1247446A 3 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11613945|NCT00540228|Experimental|GSK1247446A 4 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11613946|NCT00540228|Active Comparator|Fluarix Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11613947|NCT00540215|Active Comparator|1|450 nmol GLP-2 SC
11613948|NCT00540215|Placebo Comparator|2|1 ml isotonic saline SC
11613949|NCT00540202|Experimental|1.Oral quinine|Patients will be given oral quinine at the dose of 10mg/kg 8 hourly for 7 days
11613950|NCT00540202|Active Comparator|2. Coartem|Tablets
11613951|NCT00540189|Other|Initial appendectomy|children with complicated appendicitis will undergo initial appendectomy
11613952|NCT00540189|Other|Interval appendectomy|children with complicated appendicitis will undergo initial antibiotic treatment followed by an interval appendectomy
11613953|NCT00540176|Experimental|Cohort A|Recurrent disease with previous surgery, radiation therapy and/or chemotherapy
11613954|NCT00540176|Experimental|Cohort B|Newly diagnosed disease with no previous therapy
11613955|NCT00540150|Active Comparator|1|Standard specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany
11613956|NCT00540150|Active Comparator|2|Shortened specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany
11613957|NCT00540137|Active Comparator|NRTIs plus NNRTI arm|nevirapine 400 mg once daily (after 12 weeks induction)with a nucleoside backbone
11613958|NCT00540137|Active Comparator|NRTIs plus PI arm|atazanavir 300 mg once daily, ritonavir 100 mg once daily with a nucleoside backbone
11613959|NCT00540124|Experimental|Tadalafil|
11613960|NCT00540124|Placebo Comparator|Placebo|
11613961|NCT00540124|Active Comparator|Tamsulosin|
11613962|NCT00540111|Other|1|"Study of intervention, prospective,uncontrolled Group Number: 1
~Group Type:Other - the subjects of group were compared the initial moment (M0 - moment without soluble fiber supplementation)with the others two moments: M1 (one month after soluble fiber supplementation) and M2 (four months after soluble fiber supplementation).
~Group Description - HIV-positive individuals with hypertriglyceridemia (serum levels ≥ 200 to ≤ 500 mg/dL),who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study.
~Intervention:Received 20g/day of soluble fiber® (partially hydrolyzed guar gum) for 4 months at pre-established times."
11613963|NCT00540098|Experimental|1|Paroxetine + aerobic exercise
11613964|NCT00540098|Active Comparator|2|Paroxetine + relaxation
11613965|NCT00540098|Active Comparator|3|Placebo + aerobic exercise
11613966|NCT00540098|Placebo Comparator|4|Placebo + relaxation
11613967|NCT00540085|Active Comparator|A|Rocuronium dosed after ideal body weight
11613968|NCT00540085|Active Comparator|B|Rocuronium dosed after corrected body weight 20%
11613969|NCT00540085|Active Comparator|C|Rocuronium dosed after corrected body weight 40%
11613970|NCT00540046|Active Comparator|A/Immediate|The patients in the immediate arm will have the Copper T 380A IUD inserted within 15 minutes after delivery of the placenta immediately following procedure
11613971|NCT00540046|Active Comparator|B/Delayed|The delayed group will have the Copper T 380A IUD inserted at the post-operative visit within 2-4 weeks following the procedure.
11613972|NCT00540033|Experimental|2|Study arm was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks; the control arm was fed with breast milk or mixed feeding without probiotics.
11613973|NCT00540020|Experimental|Cognitive-Didactic|Developed by Sohlberg & Mateer to target four cognitive domains often impaired by TBI: attention, memory, executive functions, and pragmatic communication. Subjects practiced progressively more difficult paper-and-pencil or computerized cognitive tasks in 1:1 cognitive therapy sessions (1.5-2.5 hours daily).
11613974|NCT00540020|Experimental|Functional-Experiential|The works of Giles and Clark-Wilson and Hartley guided the basic concepts and treatment of the functional-experiential arm (Functional). The objective of the functional protocol was to use real life performance situations and common tasks to remediate or compensate for functional deficits after brain injury. Functional protocol treatment interventions (1.5-2.5 hours daily) typically occurred in group settings and natural environments (hospital recreation areas, group rooms, simulated home environments in the dining room, community outings, etc.).
11613975|NCT00540007|Experimental|Cohort 1 - Lenalidomide daily on days 1-21|"The first group of participants will be assigned to Cohort 1 and if no unacceptable toxicities occur in Cohort 1 then the second group of participants will be assigned to Cohort 2
~Lenalidomide 25 mg per day PO daily on days 1-21 of a 28 day cycle."
11613976|NCT00540007|Experimental|Cohort 2 - Lenalidomide daily on days 1-28|"The first group of participants will be assigned to Cohort 1 and if no unacceptable toxicities occur in Cohort 1 then the second group of participants will be assigned to Cohort 2
~Lenalidomide 25 mg per day PO daily on days 1-28 of a 28 day cycle."
11613977|NCT00539994|Experimental|Treatment B|200mg BID retapamulin 5 days
11613978|NCT00539994|Placebo Comparator|Treatment C|200mg BID placebo 5 days
11613979|NCT00539994|Experimental|Treatment A|200mg BID retapamulin 3 days and placebo BID 2 days for a total of 5 days
11613980|NCT00539981|Experimental|FluBlok|Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2007/08 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/3/2006(H1N1), A/Wisconsin/67/2005(H3N2), and B/Malaysia/2506/2004
11613981|NCT00539981|Placebo Comparator|Placebo|0.9% Sodium Chloride
11613982|NCT00539968|Experimental|Docetaxel plus lonafarnib (single arm)|Docetaxel plus lonafarnib
11613983|NCT00539955|Other|1|Standard 40 hour state-mandated batterer intervention
11613984|NCT00539955|Other|2|Brief alcohol intervention combined with standard batterer intervention
11613985|NCT00539942|Active Comparator|Intermittent compression devices (ICD)|All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
11613986|NCT00539942|Experimental|Arixtra (fondaparinux sodium)|Patients randomized to treatment arm will initiate Arixtra (fondaparinux sodium) treatment on post-operative day 1 and continue treatment until post-operative day 22 (21 consecutive days). Subjects randomized to this arm are to receive the standard prophylactic dose for major abdominal surgery of 2.5 mg/day for a total of 21 consecutive days (including hospitalization time and after hospital discharge).
11613987|NCT00539929|Experimental|E6201 0.005% BID|Participants applied E6201 0.005% cream to a pre-identified marker lesion twice a day (BID) for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
11613988|NCT00539929|Experimental|E6201 0.01% BID|Participants applied E6201 0.01% cream to a pre-identified marker lesion BID for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
11613989|NCT00539929|Experimental|E6201 0.03% BID|Participants applied E6201 0.03% cream to a pre-identified marker lesion BID for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
11613990|NCT00539929|Experimental|E6201 0.03% QD|Participants applied E6201 0.03% cream to a pre-identified marker lesion once a day (QD) for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
11613991|NCT00539916|Experimental|Jus d'orange|
11613992|NCT00539916|Placebo Comparator|Boisson contrôle|
11613993|NCT00539864|Experimental|FluBlok|"Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
~135μg total"
11613994|NCT00539864|Active Comparator|TIV (Fluzone)|"Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004
~45μg total
~(Fluzone, sanofi pasteur)"
11613995|NCT00539838|Experimental|Ocrelizumab 1000 mg|Ocrelizumab was administered i.v. at a dose on Days 1 and 15, followed by 1000 mg i.v. at Week 16 and then every 16 weeks
11613996|NCT00539838|Experimental|Ocrelizumab 400 mg|Ocrelizumab was administered at a dose 400 mg i.v. on Days 1 and 15, followed by 400 mg i.v. at Week 16 and then every 16 weeks
11613997|NCT00539838|Placebo Comparator|Placebo|Placebo infusions were administered on Days 1 and 15, followed by placebo infusion at Week 16 and then every 16 weeks
11613998|NCT00539812|Other|1|Standard Care only (standard batterer intervention program)
11613999|NCT00539812|Other|2|Brief alcohol intervention combined with standard care
11614000|NCT00539799|Active Comparator|1|Long-term low-dose prednisolone (5 - 7.5 mg/day)
11614001|NCT00539799|Placebo Comparator|2|
11614002|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xa (Cohort 1-5)|Eligible subjects will receive GSK1827771 with the starting dose of 0.3 milligram (mg)
11614003|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xa (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
11614004|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xb (Cohort 1-5)|Eligible subjects will receive GSK1827771 via injection
11614005|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xb (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
11614006|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xc (Cohort 1-5)|Eligible subjects will receive GSK1827771 via injection
11614007|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xc (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
11614008|NCT00539721|Experimental|Rolapitant Dose 1|
11614009|NCT00539721|Experimental|Rolapitant Dose 2|
11614010|NCT00539721|Experimental|Rolapitant Dose 3|
11614011|NCT00539721|Experimental|Rolapitant Dose 4|
11614012|NCT00539721|Active Comparator|Ondansetron|
11614013|NCT00539721|Placebo Comparator|Placebo|
11614014|NCT00539708|Experimental|NIV|Non-invasive ventilation
11614015|NCT00539708|Active Comparator|Control|Oxygen therapy
11614016|NCT00539695|Experimental|IL2 Administration|"SCHEDULE OF IL-2 ADMINISTRATION: Patients will receive a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT.
~Time will be measured as 'week beginning with first IL-2 injection.'
~T cell Induction via IL-2 to reduce GVHD"
11614017|NCT00539656|Experimental|Receive two cord blood units|One cord blood unit will be thawed on day -14 before transplantation and selected using the CliniMACS for primitive cells that express CD133. These cells will be expanded ex vivo for a total of 14 days, using a two-stage procedure. On Day 0 the expanded cells will be harvested, washed three times with CliniMACS buffer (Miltenyi) plus 1% HSA per standard laboratory and clinical practice and the expanded cell product will be infused to a patient who has been prepared with a standard, myeloablative preparative regimen. A second, unexpanded, cord blood product will be infused on Day +1 for safety.
11614018|NCT00539643|Active Comparator|Bead Arm|Hepatic arterial embolization with Bead Block microspheres, beginning with 100 - 300 micron beads, and using larger particles if necessary until stasis is evident.
11614019|NCT00539643|Active Comparator|Bead + Dox Arm|Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
11614020|NCT00539617|Experimental|Tarceva and FOLFOX|"COMBINATION THERAPY PHASE: Patients receive erlotinib hydrochloride orally (PO) once daily (QD) on days 1-56. Patients also receive FOLFOX6 therapy comprising oxaliplatin intravenously (IV) over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1, 15, 29, and 43. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable disease or no evidence of disease after course 2 or subsequent courses continue on to maintenance phase.
~MAINTENANCE PHASE: Patients receive erlotinib hydrochloride PO QD on days 1-42. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity."
11614021|NCT00539591|Experimental|Temozolomide/peginterferon alfa-2b|"Stratum B: Resected Stage IIIC, unresectable Stage III, Stage IV, and recurrent patients
~Stratum B is divided into 2 groups based on the presence (Stratum B1) or absence (Stratum B2) of measurable disease. Subjects will receive 8 weekly doses of peginterferon alfa-2b 0.5 mcg/kg/dose subcutaneously (SQ) in combination with temozolomide 75mg/m2/dose by mouth (PO) daily for 6 weeks followed by 2 week break. The duration of each treatment course will be 8 weeks. Strata B2 (no measurable disease) will proceed with 7 courses as outlined."
11614022|NCT00539591|Experimental|Peginterferon alfa-2b/non-pegylated interferon alfa-2b|Stratum A: Resected Stages IIC, IIIA, and IIIB patients will receive recombinant interferon alfa-2b 20 million units/m2/day intravenously (IV) 5 consecutive days per week for 4 weeks followed by peginterferon alfa-2b 1mcg/kg subcutaneously (SQ) once a week for 48 weeks.
11614023|NCT00539565|Active Comparator|A|oral corticosteroids
11614024|NCT00539565|Placebo Comparator|B|as for active regimen
11614025|NCT00539539|Active Comparator|Feedback On|Automated real-time feedback on CPR Process activated
11614026|NCT00539539|No Intervention|Feedback Off|For the first three to six months, participating EMS agencies will have defibrillators with automated, real-time feedback inactivated. During this period, the baseline rate of ROSC (and secondary outcomes) will be collected. At the end of this baseline period, EMS agencies will be randomized to one of two interventions, with randomization stratified within site by agency, station, or device. All clusters will cross-over to the opposite feedback strategy at least once during the intervention phase.
11614027|NCT00539526|Experimental|1|bimatoprost 0.03%
11614028|NCT00539526|Active Comparator|2|travoprost 0.004%
11614029|NCT00539526|Active Comparator|3|latanoprost 0.005%
11614030|NCT00539513|Experimental|N-Acetylcysteine|Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose titrated to 3000 mg within the first week, in addition to the medication regimen they are on at enrollment
11614031|NCT00539513|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
11614032|NCT00539500|Experimental|Transplantation CD133+ cells|Stem Cell Transplantation of CD133+ cells using the ClinicMACS in combination with Carboplatin + Etoposide + Melphalan
11614033|NCT00539474|Active Comparator|1|Wireguided localisation
11614034|NCT00539474|Experimental|2|Radioguided occult lesion localisation
11614035|NCT00539448|Experimental|1|combination of insulin Glargine & insulin Glulisine as basal bolus regimen
11614036|NCT00539435|Active Comparator|1|Diabetic patients will complete cardiac quality of life questionnaires at baseline and monthly thereafter to monitor and assess progress with complications resulting from their heart disease. Comparisons will be performed on carotid ultrasounds,echocardiograms and lab values performed at baseline and every six months and medication information collected at weekly Pulsatile Intravenous Insulin treatment sessions
11614037|NCT00539422||I|group I of 15 women with benign breast lesion
11614038|NCT00539422||II|group II of 16 women with breast cancer
11614039|NCT00539422||III|13 women were taken as a control group
11614083|NCT00539032|Experimental|Group 1: Menactra® Booster Group|Participants who had received 2 doses of quadrivalent (A, C, Y, and W-135) meningococcal polysaccharide vaccine before age 2 years received a booster vaccination with Menactra® vaccine.
11614781|NCT00533559|Placebo Comparator|Placebo|
11614040|NCT00539409|No Intervention|1|Diabetic patients will complete quality of life questionnaires at baseline and quarterly thereafter to monitor and assess progress with complications resulting from their diabetes. Comparisons will be performed on lab values performed at baseline and every six months and medication information collected at weekly Pulsatile Intravenous Insulin treatment sessions.
11614041|NCT00539409|Active Comparator|Pulsatile Intravenous Insulin Therapy|
11614042|NCT00539383|Experimental|1|
11614043|NCT00539357|Experimental|1|All patients self-administered stimulation for 60 consecutive minutes each day. Participants self-administered the treatment for a period of 6 weeks, 7 days a week between the hours of 15:00 and 19:00. Assessments took place every 2 weeks during the treatment period.
11614044|NCT00539344|Experimental|1|
11614045|NCT00539331|Placebo Comparator|1|Paclitaxel/Carboplatin
11614046|NCT00539331|Experimental|2|Paclitaxel/Carboplatin + AZD2171
11614047|NCT00539318||GI Cancer|
11614048|NCT00539305|Experimental|Study drug; testosterone transdermal gel|Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl
11614049|NCT00539305|Placebo Comparator|2|
11614050|NCT00539292|Experimental|1|Silastic Spring-Loaded Silo
11614051|NCT00539292|Active Comparator|2|Primary Closure of Abdomen
11614052|NCT00539279|Experimental|Prolonged Exposure Therapy (PE)|Prolonged Exposure Therapy (PE)
11614053|NCT00539279|Active Comparator|Relaxation Training (RT)|Relaxation Training (RT)
11614054|NCT00539266|Active Comparator|1|non diabetic patients with Fontaine IIb-IV peripheral artery disease
11614055|NCT00539266|Placebo Comparator|2|non diabetic patients with Fontaine IIb-IV peripheral artery disease
11614056|NCT00539266|Active Comparator|3|diabetic patients with Fontaine IIb-IV peripheral artery disease
11614057|NCT00539266|Placebo Comparator|4|diabetic patients with Fontaine IIb-IV peripheral artery disease
11614058|NCT00539253|Other|Gadobenate Dimeglumine (Multi Hance)|If patient did not participate in this study (by signing consent), they could receive any other contrast used routinely at this facility including the contrast used in this study
11614059|NCT00539240|Placebo Comparator|Rabeprazole morning/evening placebo bedtime|AciPhex 20 mg BID and once daily placebo
11614060|NCT00539240|Placebo Comparator|Rabeprazole breakfast, placebo dinner and bedtime|AcipHex 20 mg once daily and BID placebo
11614061|NCT00539240|Active Comparator|Rabeprazole breakfast, placebo dinner, nortriptyline bedtime|AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily
11614062|NCT00539227||NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC). Questionnaires taking about 20-30 minutes to complete.
11614063|NCT00539188|Experimental|N-Acetylcysteine|Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose (3000 mg daily), in addition to the medication regimen they are on at enrollment
11614064|NCT00539188|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
11614065|NCT00539175|Active Comparator|2|active treatment with infrared light
11614066|NCT00539175|Placebo Comparator|1|sham (placebo) treatment without infrared light
11614067|NCT00539162|Experimental|CA 125 Analysis|"Participants will have blood (about 2-3 tablespoons) drawn for CA-125 testing and other tumor markers.
~Depending on CA-125 level:
~Blood (about 2-3 tablespoons) drawn for CA-125 testing and other tumor markers in 1 year.
~Blood (about 2-3 tablespoons) drawn for CA-125 testing and other tumor markers in 3 months, OR Blood (about 2-3 tablespoons) drawn for CA-125 testing and other tumor markers, and a transvaginal ultrasound in 6 weeks +/- 2 weeks.
~Questionnaires completed at baseline and during each follow up visit."
11614068|NCT00539149|Active Comparator|1|
11614069|NCT00539149|Placebo Comparator|2|
11614070|NCT00539123|Experimental|1|Physician Management (PM): medically focused advice and brief counseling
11614071|NCT00539123|Experimental|2|Physician Management (PM) plus Abstinence Contingent Buprenorphine (ACB) dispensing
11614072|NCT00539123|Experimental|3|PM plus Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
11614073|NCT00539123|Experimental|4|PM plus BDRC plus ACB
11614074|NCT00539110|Experimental|zolpidem|zolpidem or ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
11614075|NCT00539110|Active Comparator|ramelteon|ramelteon or zolpidem dosed at 2200 and 0200 per the feeding tube depending on randomization
11614076|NCT00539097|Experimental|A, treated|treated with Juven po supplement x 3 weeks postop
11614077|NCT00539097|No Intervention|B, control|Usual nutrition therapy received postop
11614078|NCT00539084|Experimental|1|Intradermal injection of Lidocaine followed by a painful stimulus (venipuncture)
11614079|NCT00539084|Placebo Comparator|2|Intradermal injection of placebo followed by a painful stimulus (venipuncture)
11614080|NCT00539071|Active Comparator|Conventional dose|All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks (given as two injections - active 50 mg plus placebo injection).As advised by the package insert for Consta, oral risperidone will be given (3-4 mg qd x 3 days followed by 6mg qd up to Week 3 unless symptoms warrant a quicker titration) along with the injections.Any oral risperidone the patients receive will be discontinued after Week 4.At Week 6, psychopathology will be assessed with a PANSS. Dose will remain at 50 mg q 2 weeks for those in the conventional Consta dose group.
11614081|NCT00539071|Active Comparator|High Dose group|Those who are randomized to high dose Consta will receive Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose after consent. As advised by the package insert for Consta, oral risperidone will be given (3-4 mg qd x 3 days followed by 6mg qd up to Week 4 unless symptoms warrant a quicker titration) along with the injections. Any oral risperidone the patients receive will be discontinued after Week 4.Psychopathology will be assessed with a PANSS at Week 6. If no improvement since baseline, dose will be increased to two 50 mg injections q 2 weeks for the remainder of the study.
11614082|NCT00539045||A|The study population will consist of patients who are admitted to The New York Presbyterian Hospital-Weill Medical College of Cornell University (NYP-WMC) with ST elevation myocardial infarctions (STEMI). STEMI will be established based on standard clinical and ECG criteria.
11614304|NCT00537342|Placebo Comparator|B|
11614084|NCT00539032|Experimental|Group 2: Menactra® Primary Vaccine (Control) Group|Participants who had not previously been given any meningococcal vaccine (meningococcal vaccine naive) received a primary vaccination with Menactra® vaccine.
11614085|NCT00539019||A, observed|measure REE via indirect calorimetry at various time points post burn
11614086|NCT00539006|Active Comparator|FFNS, FPNS|active compound
11614087|NCT00539006|Active Comparator|FPNS, FFNS|active compound
11614088|NCT00539006|Placebo Comparator|placebo FFNS, placebo FPNS|placebo arm
11614089|NCT00539006|Placebo Comparator|placebo FPNS, placebo FFNS|placebo arm
11614090|NCT00538993|Experimental|1|Provider receives cue sheet to assist with counseling.
11614091|NCT00538993|No Intervention|2|Provider does not receive cue sheet.
11614092|NCT00538980|Experimental|All patients|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
11614093|NCT00538967|No Intervention|1|
11614094|NCT00538967|Active Comparator|2|doxycycline 50 mg/day
11614095|NCT00538967|Active Comparator|3|doxycycline 100 mg
11614096|NCT00538967|Active Comparator|4|doxycycline 300 mg
11614097|NCT00538954|Active Comparator|1|Follow a standard Enhanced Recovery After Surgery protocol
11614098|NCT00538954|Experimental|2|Follow a standard Enhanced Recovery After Surgery protocol and will receive 1 g of Magnesium Oxide laxative twice daily from the day after surgery until discharge
11614099|NCT00538954|Experimental|3|Follow a standard Enhanced Recovery After Surgery protocol and will receive preconditioning with carbohydrate and fluid loading prior to surgery (800ml of Nutricia Preop the evening before surgery and 400 the morning of surgery 2 hours prior to anaesthesia) and postoperative nutritional supplements (200 ml Nutricia Fortisip twice daily) after surgery for 30 days
11614100|NCT00538954|Experimental|4|Follow a standard Enhanced Recovery After Surgery protocol and will receive preconditioning with carbohydrate and fluid loading prior to surgery (800ml of Nutricia Preop the evening before surgery and 400 the morning of surgery 2 hours prior to anaesthesia) and postoperative nutritional supplements (200 ml Nutricia Fortisip twice daily) after surgery for 30 days and will receive postoperative laxative in the form of 20 ml of Magnesium Oxide twice daily form the day after surgery until discharge
11614101|NCT00538941|Active Comparator|1|daily intake of 40gr chocolate (Nestlé Noir intense) in the morning and 40gr chocolate in the evening.
11614102|NCT00538941|Placebo Comparator|2|Nestlé Placebo Chocolate 40gr in the morning and 40gr chocolate in the evening.
11614103|NCT00538928|Experimental|1|Intervention: Implantation of the iLA - adaptation of the ventilation strategy, explantation of the iLA after corresponding improvement (see treatment plan for details) - weaning from the ventilation and extubation according to specified criteria.
11614104|NCT00538928|Active Comparator|2|no device: Ventilation strategy based on the concept of lung-protective ventilation without extracorporeal support, weaning from the ventilation and extubation according to specified criteria (see treatment plan for details).
11614105|NCT00538915|Experimental|Nabi-IGIV Infused Every 3- or 4-Weeks|
11614106|NCT00538902|Placebo Comparator|Placebo|Placebo administered subcutaneously every other week
11614107|NCT00538902|Experimental|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously every other week
11614108|NCT00538902|Experimental|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week
11614109|NCT00538863|Experimental|Fentanyl sublingual spray titration|Patients received fentanyl sublingual spray to treat up to a maximum of 4 breakthrough pain episodes per day with a minimum separation of 4 hours between treatments. Patients started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 26 days was reached.
11614110|NCT00538863|Experimental|Fentanyl sublingual spray maintenance|Patients received fentanyl sublingual spray up to a maximum of 4 times per day with a minimum separation of 4 hours between treatments for 90 days. Patients received a dose of 100 to 1600 µg determined in a previous study (INS-05-001, NCT00538850) or in the open-label dose titration period of the current study. The dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects.
11614111|NCT00538850|Experimental|Fentanyl sublingual spray|Participants received fentanyl sublingual spray 7 times or placebo 3 times in random order to treat up to a maximum of 2 breakthrough pain episodes per day with a minimum separation of 2 hours between treatments. Patients received a dose of 100 to 1600 µg determined in the open-label dose titration period of the current study.
11614112|NCT00538824|Experimental|DexTR (all patients)|All patients were treated with the DexTR (dexamethasone / thalidomide, lenalidomide (Revlimid®)), which consisted of lenalidomide 25mg/day during days 1-21, dexamethasone 40mg/day on days 1-4, 9-12, and 17-20, and thalidomide 50mg/day for the first 7 days, followed by 100mg/day for all subsequent days, for a total of 4 cycles of 28 days each.
11614113|NCT00538811|Experimental|1|Interferon alpha, ribavirin, interferon gamma
11614114|NCT00538811|Active Comparator|2|Interferon alpha, ribavirin, amantadine
11614115|NCT00538785|Experimental|Motavizumab|Motavizumab was administered as an intramuscular injection at 15 mg/kg every 30 days during the RSV season for a maximum of 5 scheduled doses. Additionally, children who underwent cardiac surgery with cardiopulmonary bypass through Study Day 150 were to receive a protocol-specified replacement dose of study drug immediately following the surgery when determined by the physician to be medically stable for an IM injection.
11614116|NCT00538785|Active Comparator|Pailvizumab|Palivizumab was administered as an intramuscular injection at 15 mg/kg every 30 days during the RSV season for a maximum of 5 scheduled doses. Additionally, children who underwent cardiac surgery with cardiopulmonary bypass through Study Day 150 were to receive a protocol-specified replacement dose of study drug immediately following the surgery when determined by the physician to be medically stable for an IM injection.
11614117|NCT00538772||Biomarker|
11614118|NCT00538759|Experimental|EBRT|External beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty.
11614887|NCT00532675|Experimental|PAN 25 mg|Panobinostat 25 mg
11614119|NCT00538759|Sham Comparator|Control|Sham external beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty.
11614120|NCT00538746|Experimental|1|BIPAP (Bilevel Positive Airway Pressure) targeted on: TV 6-8 ml/kg, total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92% (with spontaneous RR between 20-40%)
11614121|NCT00538746|Experimental|2|PSV (pressure support ventilation) targeted on: TV 6-8 ml/kg,total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92, a minimum of 7 cmH2O of PS is tolerated.
11614122|NCT00538746|Experimental|3|PSV+CPAP (continuous positive airway pressure) targeted on: PSV: TV 6-8 ml/kg,total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92, a minimum of 7 cmH2O of PS is tolerated, CPAP (5-10 cmH2O) at least 2 hours a day. If during the CPAP periods at least 1 of the criteria T tube test failure occurs, the patients will come back immediately to PSV.
11614123|NCT00538733|Experimental|T-BiRD Therapy|"All patients were treated with the same regimen, starting with T-BIRD therapy (Cycles 1-4).
~After 4 cycles, Patients with disease progression will be taken off study. Patients who achieve maximum response will receive maintenance. Patients who achieve VGPR or PR will be given T-BiRD for 2 cycles (cycles 5-6). After 6 cycles of T-BiRD, Patients who achieve maximum response will receive maintenance; those with disease progression will be taken off study; all other patients will receive BIRD.
~Patients who progress on BiRD will reinitiate T-BiRD. If disease progression continues after 2 cycles, patients will be taken off study.
~Patients in CR/sCR or that achieve a plateau of disease for > 2 cycles on BiRD or T-BiRD therapy will receive maintenance."
11614124|NCT00538720|Experimental|Vitamin D|Vitamin D starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
11614125|NCT00538707|Experimental|Young subjects|
11614126|NCT00538707|Experimental|Older subjects|
11614127|NCT00538681|Experimental|Enzastaurin + Pemetrexed + Cisplatin|
11614128|NCT00538681|Placebo Comparator|Placebo + Pemetrexed + Cisplatin|
11614129|NCT00538668|Experimental|1|20 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
11614130|NCT00538668|Experimental|2|25 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
11614131|NCT00538668|Experimental|3|30 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
11614132|NCT00538668|Experimental|4|35 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
11614133|NCT00538668|Experimental|5|40 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
11614134|NCT00538668|Experimental|6|45 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
11614135|NCT00538668|Experimental|7|50 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
11614136|NCT00538668|Experimental|8|55 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
11614137|NCT00538668|Experimental|9|25 mCi/m2 of 177Lu-J591 will be given every 2 weeks.
11614138|NCT00538655|Experimental|modafinil|
11614139|NCT00538642|No Intervention|Stay on current antipsychotic|Subjects stay on same daily oral antipsychotic treatment as at baseline. Dose adjustments allowable as clinically indicated.
11614140|NCT00538642|Active Comparator|ziprasidone treatment|Subjects switch to daily oral ziprasidone from current antipsychotic(s). Dose titrated to clinically effective level.
11614141|NCT00538629||Schizophrenia|Patients with schizophrenia
11614142|NCT00538629||Bipolar disorder|Patients with bipolar disorder
11614143|NCT00538616|Active Comparator|Precedex-Propofol|Patients received an infusion of precedex for six hours and then a washout and then a propofol infusion for six hours.
11614144|NCT00538616|Active Comparator|Propofol- Precedex|Patients received an infusion of propofol for six hours and then a washout and then a precedex infusion for six hours.
11614145|NCT00538590|Active Comparator|MITOMYCIN-C|Following ethics committee approval, 20 patients with uncontrolled glaucoma will be will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with Mitomycin-C.
11614146|NCT00538590|Experimental|ologen (Oculusgen)|20 patients will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with ologen implant. The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
11614147|NCT00538564|Experimental|Tadalafil|Participants assigned to this arm were given oral 10 mg tadalafil tablets to take 3 times a week for 16 weeks.
11614148|NCT00538564|Placebo Comparator|Placebo|Participants assigned to this arm were given a placebo pill 3 times a week for the first 8 weeks, and then Tadalafil 10 mg 3 times a week for weeks 9-16.
11614149|NCT00538538|Active Comparator|A|Does not receive Gas bubble
11614150|NCT00538538|Active Comparator|B|Does receive gas bubble
11614151|NCT00538525|Active Comparator|Arm 1|Doxorubicin, Docetaxel, Cisplatin
11614152|NCT00538512|Active Comparator|TIV|the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur
11614153|NCT00538512|Active Comparator|LAIV|live-attenuated influenza vaccine Flumist, manufactured by MedImmune
11614154|NCT00538512|Placebo Comparator|Placebo|Physiologic saline administered as a nasal spray or intramuscular injection
11614155|NCT00538499|Other|Fentanyl citrate|
11614156|NCT00538499|Experimental|bupivcaine hydrochloride|
11614157|NCT00538499|Other|videothoracoscopy|
11614158|NCT00538486|Experimental|Group T|Telmisartan
11614159|NCT00538486|Experimental|Group T+M|Telmisartan plus Metformin
11614160|NCT00538486|Experimental|Group C|Candesartan
11614161|NCT00538486|Experimental|Group C+M|Candesartan pus Metformin
11614162|NCT00538486|Active Comparator|Group A|Amlodipine
11614163|NCT00538486|Experimental|Group A+M|Amlodipine plus Metformin
11614164|NCT00538473|Experimental|FluAS25 (GSK576389A) Group|Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A).
11614165|NCT00538473|Active Comparator|Fluarix Group|Subjects received 1 dose of Fluarix™.
11614166|NCT00538434|Experimental|Reslizumab 1 mg/kg|reslizumab 1 mg/kg intravenous (IV) on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
11614167|NCT00538434|Experimental|Reslizumab 2 mg/kg|reslizumab 2 mg/kg IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
11614168|NCT00538434|Experimental|Reslizumab 3 mg/kg|reslizumab 3 mg/kg IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
11614169|NCT00538434|Placebo Comparator|Placebo|saline placebo IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
11614170|NCT00538421|Active Comparator|1|
11614171|NCT00538421|Active Comparator|2|
11614172|NCT00538382|Experimental|Case|Cases are defined as parasitemic pregnant women during the second trimester (22-26 weeks gestation) and the third trimester (32-36 weeks gestation).
11614173|NCT00538382|Active Comparator|Non-pregnant Control|Non-pregnant controls are defined as parasitemic non-pregnant women recruited from the same community as the cases.
11614174|NCT00538382|Active Comparator|Internal Control|Internal controls are defined as the same women(cases)at three months postpartum.
11614175|NCT00538369|Active Comparator|standard-of-care|The standard-of-care group will receive sedation assessment and monitoring with the Ramsay scale, which is the accepted tool at this university
11614176|NCT00538369|Experimental|standard + BIS|Subjects in the standard-of-care + BIS group will receive sedation assessment and monitoring using the Ramsay scale and values from the bispectral index (BIS) monitor.
11614177|NCT00538356|Experimental|Home Monitoring|ICD or CRT-D with Home Monitoring feature activated Home Monitoring data will be analyzed regularly and patients will be contacted and scheduled for additional follow-up after predefined events
11614178|NCT00538356|Active Comparator|Control|ICD or CRT-D with Home Monitoring feature deactivated Patients will be treated as per standard of care in each participating clinic
11614179|NCT00538343|Experimental|RTA 744|
11614180|NCT00538317|Experimental|1|tirofiban bolus + perfusion started at the site of caring
11614181|NCT00538317|Active Comparator|2|tirofiban bolus + perfusion started at the beginning of coronarography (usual use of tirofiban)
11614182|NCT00538304|Experimental|1|bimatoprost eye drops
11614183|NCT00538304|Placebo Comparator|2|placebo
11614184|NCT00538291|Experimental|Arm 1|Cetuximab 400mg/m2 IV on day 1 over 2 hours then 250 mg/m2 over 1 hour weekly + Xeloda(Capecitabine) 1000mg/m2 BID on days 1-14 repeated every 21 days.
11614185|NCT00538265|Active Comparator|A|tacrolimus + steroids
11614186|NCT00538265|Experimental|B|ATG+ tacrolimus without steroids in maintenance therapy
11614187|NCT00538265|Experimental|C|ATG+ Mycophenolate Mofetil + tacrolimus a reduced dosage without steroids in maintenance therapy
11614188|NCT00538239|Experimental|Ridaforolimus|
11614189|NCT00538239|Placebo Comparator|Placebo|
11614190|NCT00538213|Experimental|Adjuvanted influenza vaccine GSK576389A Group|Subjects aged ≥ 66 years who previously received 1 dose of adjuvanted influenza vaccine GSK576389A in NCT00318149 and NCT00386698 studies were administered 1 dose of adjuvanted influenza vaccine GSK576389A.
11614191|NCT00538213|Active Comparator|Fluarix young Group|Subjects aged 19-42 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine.
11614192|NCT00538213|Active Comparator|Fluarix elderly Group|Subjects aged ≥ 66 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine.
11614193|NCT00538200|Other|1|Dietary Advice
11614194|NCT00538200|Other|2|Supplements
11614195|NCT00538187|Experimental|Treatment (obatoclax mesylate, bortezomib)|Patients will receive a 3-hour infusion of obatoclax and an infusion of bortezomib once a week for 4 weeks
11614196|NCT00538174|Experimental|Arm 1|2.5 mg
11614197|NCT00538174|Experimental|Arm 2|10 mg
11614198|NCT00538174|Experimental|Arm 3|20 mg
11614199|NCT00538174|Placebo Comparator|Arm 4|
11614200|NCT00538161|Experimental|Low tidal volume arm|
11614201|NCT00538161|Active Comparator|Conventional tidal volume arm|
11614202|NCT00538135|Experimental|1|"Cognitive Behaviour Therapy plus Treatment as Usual (CBT plus TAU) for borderline personality disorder.
~CBT is a structured, time limited, psycho-social intervention developed to treat Cluster B personality disorder. Patients are encouraged to engage in treatment through a formulation of their problems within a cognitive framework. Interventions focus on the patient's beliefs and behaviour that impair social and adaptive functioning. Thirty sessions of CBT over one year, each lasting up to one hour, are required to work on long-standing problems and develop new ways of thinking and behaving. Priority is given to behaviours that cause harm to self or others. In addition, participants received the usual treatment they would have received if the trial had not been in place"
11614203|NCT00538135|Active Comparator|2|"Treatment as Usual.
~All participants received the standard treatment (TAU) they would have received if the trial had not been in place. Although standard treatment may vary across the three sites, and depend on the specific problems of the individual participant, it was thought that all participants would be in contact with mental health services and would have some contact with Accident and Emergency services for repeated self-harm episodes. TAU will be documented carefully after each patient exits the trial."
11614204|NCT00538122||Thioridazine Group|Patients must have been treated with (Mellaril) thioridazine at least three months at time of enrollment.
11614205|NCT00538096|Experimental|1|MEDI-538
11614206|NCT00538096|Experimental|2|MEDI-538
11614207|NCT00538096|Experimental|3|MEDI-538
11614208|NCT00538083|Experimental|1, 2|acute phase, solid dark chocolate, placebo
11614209|NCT00538083|Experimental|3, 4, 5|acute phase, sugared cocoa, sugar-free cocoa, placebo
11614210|NCT00538083|Experimental|6, 7, 8|sustained phase, sugared cocoa, sugar-free cocoa, placebo
11614211|NCT00538070|Placebo Comparator|Placebo|You will receive two grams of placebo per day. You will take two 500 mg placebo capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
11614212|NCT00538070|Experimental|Sarcosine|You will receive two grams of sarcosine per day. You will take two 500 mg capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
11614213|NCT00538057|Experimental|arm 1|study drug
11614214|NCT00538044|Experimental|1simvastatin group|before the operation, the patient start the simvastatin medication on the dosage of 40mg per day
11614215|NCT00538044|No Intervention|2contral group|just do routin operation with no use of simvastatin, other medication is exact the same as the simvastatin group
11614995|NCT00531778||NYU OCEDP Population|
11614216|NCT00538031|Active Comparator|Arm I|Patients receive oral cyclophosphamide once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11614217|NCT00538031|Experimental|Arm II|Patients receive oral cyclophosphamide once daily and oral celecoxib twice daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11614218|NCT00537979|Active Comparator|Paricalcitol injection|ABT-358 Zemplar
11614219|NCT00537979|Active Comparator|Paricalcitol capsules|ABT-358 Zemplar
11614220|NCT00537966|No Intervention|Control|Patients with primary HIV-1 infection who do not want to undergo early combination antiretroviral treatment
11614221|NCT00537966|Active Comparator|Intervention|In this arm patients with primary HIV-1 infection will receive early combination antiretroviral therapy with standard drugs approved by Swiss Medic.
11614222|NCT00537940|Active Comparator|A|
11614223|NCT00537940|Active Comparator|B|
11614224|NCT00537927|Active Comparator|0|fixation of mesh with a single crown of tacks and absorbable sutures
11614225|NCT00537927|Active Comparator|1|fixation of mesh with a double crown of tacks and no sutures
11614226|NCT00537927|Active Comparator|2|fixation of mesh with a single crown of tacks and non-absorbable sutures
11614227|NCT00537914|Other|1|single-arm non-comparative somatropin safety study (PASS)
11614228|NCT00537875|Active Comparator|1|
11614229|NCT00537875|Placebo Comparator|2|
11614230|NCT00537836|Experimental|ZK 283197, 3 mg|Postmenopausal women with hot flushes received 3 mg (3 x 1 mg tablets) ZK 283197, administered orally once daily over 8 weeks
11614231|NCT00537836|Placebo Comparator|Matching placebo|Postmenopausal women with hot flushes received placebo (3 tablets) orally once daily over 8 weeks
11614232|NCT00537836|Experimental|ZK 283197, 2 mg|Postmenopausal women with hot flushes received 2 mg (2 x 1 mg tablet) ZK 283197 plus 1 placebo tablet, once daily orally over 8 weeks
11614233|NCT00537836|Active Comparator|17ß-estradiol|Postmenopausal women with hot flushes received 1 mg (2 x 0.5 mg tablet) 17ß-estradiol plus 1 placebo tablet, once daily orally over 8 weeks
11614234|NCT00537823|Experimental|Arm 1 - Wildtype|"Neoadjuvant therapy
~Week 1
~Leucovorin 400 mg/m^2 IV
~Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m2 IV
~5FU bolus 400 mg/m^2
~5FU CIVI 1200 mg/m^2/day over 46 hours
~Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly
~Weeks 3, 5, 7
~Leucovorin 400 mg/m^2 IV
~Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
~5FU bolus 400 mg/m^2
~5FU CIVI 1200 mg/m^2/day over 46 hours
~Wait 3-8 weeks after completion of therapy
~Liver resection
~Wait 4 weeks or until clinical status allows
~Adjuvant Therapy
~Week 1, 3, 5, 7, 9, 11, 13, 15
~Leucovorin 400 mg/m^2 IV
~Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV
~5FU bolus 400 mg/m^2
~5FU CIVI 1200 mg/m^2/day over 46 hours
~Weeks 2, 4, 6, 8, 10, 12, 16
~*Cetuximab 250 mg/m^2 IV weekly"
11614235|NCT00537823|Experimental|Arm 2 K-Ras 12/13 codon mutation|"Neoadjuvant Therapy
~Weeks 1, 3, 5
~Leucovorin 400 mg/m^2 IV
~Oxaliplatin 85 mg/m^2 IV
~Bevacizumab 5 mg/kg IV
~5FU bolus 400 mg/m^2
~5FU CIVI 1200 mg/m^2
~Week 7
~Leucovorin 400 mg/m^2 IV
~Oxaliplatin 85 mg/m^2 IV
~5FU bolus 400 mg/m^2
~5FU CIVI 1200 mg/m^2
~Wait 3-8 weeks after completion of therapy
~Liver resection
~Wait 4 weeks or until clinical status allows
~Adjuvant Therapy
~Weeks 1, 3, 5, 9, 11, 13
~Leucovorin 400 mg/m^2 IV
~Oxaliplatin 85 mg/m^2 IV
~Bevacizumab 5 mg/kg IV
~5FU bolus 400 mg/m^2
~5FU CIVI 1200 mg/m^2
~Week 7, 15
~Leucovorin 400 mg/m^2 IV
~Oxaliplatin 85 mg/m^2 IV
~5FU bolus 400 mg/m^2
~5FU CIVI 1200 mg/m^2"
11614236|NCT00537810|Experimental|Sibutramine|Sibutramine 15 mg daily
11614237|NCT00537810|Placebo Comparator|Placebo|Placebo Daily
11614238|NCT00537810|Experimental|Placebo/CBTsh|Placebo and Self-help CBT Placebo daily, Cognitive behavioral self-help manual for binge eating
11614239|NCT00537810|Experimental|Sibutramine/CBTsh|Sibutramine and Self-help CBT 15 mg daily Cognitive behavioral treatment manual for binge eating
11614240|NCT00537797|Experimental|Arm 1|"18-FDG-PET exam with SUV determination
~Thyroid operation to remove nodule
~Pathologic confirmation of nodule histology
~Determine sensitivity and specificity of FDG-PET, correlative studies"
11614241|NCT00537784|Active Comparator|1|Injection of autologous platelet concentrate into repair site
11614242|NCT00537784|Placebo Comparator|2|No injection
11614243|NCT00537771|Experimental|1|Anastrozole (ARIMIDEX)
11614244|NCT00537771|Active Comparator|2|Tamoxifen
11614245|NCT00537758|Experimental|1|Cognitive Behavior Therapy
11614246|NCT00537758|Experimental|2|Behavioral Weight Loss Treatment
11614247|NCT00537758|Experimental|3|CBT + BWL
11614248|NCT00537745|Experimental|Vivitrol|Vivitrol 380 mg/monthly, plus individual compliance enhancement therapy (Medication Management Therapy).
11614249|NCT00537732|Active Comparator|control group|3 tablets, only 20 mg omeprazole, genotype independent
11614250|NCT00537732|Active Comparator|intervention group|20 vs. 60 mg daily, genotype dependent
11614251|NCT00537719|Active Comparator|GSK716155|albiglutide subcutaneous injection
11614252|NCT00537719|Placebo Comparator|placebo|placebo injection
11614253|NCT00537693|Active Comparator|1|CRRT via Convection
11614254|NCT00537693|Active Comparator|2|CRRT via Diffusion
11614255|NCT00537680|Experimental|1|mid dose Idebenone
11614256|NCT00537680|Experimental|2|high dose Idebenone
11614257|NCT00537680|Placebo Comparator|3|
11614258|NCT00537667|Active Comparator|A|anakinra
11614259|NCT00537667|Experimental|B|anakinra and PEGsTNF-R1
11614260|NCT00537654|Experimental|Fasted state|Subjects will be required to fast overnight. Subjects will participate in 3 treatment periods and assigned to one of 12 treatment sequences ( ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) in accordance with the randomization schedule. The three treatment periods will be separated by a minimum washout period of 28 days
11614261|NCT00537654|Experimental|Fed state|Subjects will be served high fat breakfast 30 minutes prior to dosing. Subjects will participate in 3 treatment periods and assigned to one of 12 treatment sequences ( ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) in accordance with the randomization schedule. The three treatment periods will be separated by a minimum washout period of 28 days
11614262|NCT00537602|Experimental|A|Oral miglustat capsules 200 mg t.i.d. for 1 week and a single 200 mg dose on day 8
11614263|NCT00537602|Placebo Comparator|B|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. for 1 week and a single dose on day 8
11614996|NCT00531765|Active Comparator|1|hydration with normal saline
11614264|NCT00537576|Experimental|Low dose LACTIN-V applicator|Low dose LACTIN-V applicator (150 mg LACTIN-V, 5.0 x 10^8 CFU), administered vaginally once a day for 5 consecutive days
11614265|NCT00537576|Experimental|Medium dose LACTIN-V applicator|Medium dose LACTIN-V applicator (300 mg LACTIN-V, 1.0 x 10^9 CFU), administered vaginally once a day for 5 consecutive days
11614266|NCT00537576|Experimental|High dose LACTIN-V applicator|High dose LACTIN-V applicator (600 mg LACTIN-V, 2.0 x 10^9 CFU), administered vaginally once a day for 5 consecutive days
11614267|NCT00537576|Placebo Comparator|Low dose Placebo applicator|Low dose Placebo applicator (150 mg Placebo), administered vaginally once a day for 5 consecutive days
11614268|NCT00537576|Placebo Comparator|Medium dose Placebo applicator|Medium dose Placebo applicator (300 mg Placebo), administered vaginally once a day for 5 consecutive days
11614269|NCT00537576|Placebo Comparator|High dose Placebo applicator|High dose Placebo applicator (600 mg Placebo), administered vaginally once a day for 5 consecutive days
11614270|NCT00537537|Active Comparator|1|Telbivudine
11614271|NCT00537537|Active Comparator|2|Telbivudine
11614272|NCT00537537|Active Comparator|3|Telbivudine
11614273|NCT00537524|Experimental|Arm 1|0.5mL of H5N1 vaccine 7.5ug
11614274|NCT00537524|Active Comparator|Arm 2|0.25 or 0.5mL of H5N1 vaccine
11614275|NCT00537511|Experimental|Dose-finding arm: Pomalidomide + Cisplatin + Etoposide|Oral pomalidomide 1 mg - 5 mg daily (QD) for 14 consecutive days of a 21-day cycle, in combination with intravenous (IV) cisplatin 25 mg/m^2 and IV etoposide 100 mg/m^2 on Days 1, 2 and 3 of each cycle during the dose-finding phase (Treatment and Extension Periods; 6 cycles in total). Dose escalation followed a standard phase 1 3+3 design. Participants continuing took only their pomalidomide dose (monotherapy) for an additional 3-week Recovery Period (14 days of consecutive dosing followed by 7 days of no study medication). Participants continuing took oral pomalidomide 5 mg QD as monotherapy for 14 consecutive days of each 21-day cycle until disease progression in the Maintenance Phase.
11614276|NCT00537498|Experimental|1|Interventional group
11614277|NCT00537485|Experimental|1|
11614278|NCT00537485|Placebo Comparator|2|
11614279|NCT00537472|Experimental|I|
11614280|NCT00537472|Active Comparator|II|
11614281|NCT00537446|Active Comparator|High-level ventilation|Each subject will spend 2 hours receiving high-level noninvasive ventilation.
11614282|NCT00537446|Active Comparator|Low-level ventilation|Each subject will receive 2 hours of low-level noninvasive positive pressure ventilation.
11614283|NCT00537433|No Intervention|Standard counseling|Families in the control group receive standard care, including routine counseling regarding medications prescribed from their physician and post-visit counseling by the pediatric nursing staff. Dosing instruments are given at the discretion of the physician or nurse.
11614284|NCT00537433|Experimental|Pictogram|Parents randomized to the pictogram-based intervention group receive medication counseling utilizing the pictogram-based medication instruction sheets. These sheets help to facilitate medication counseling, including teaching about dosage and adherence.
11614285|NCT00537420|Placebo Comparator|1|Nasal Placebo
11614286|NCT00537420|Placebo Comparator|2|Capsule Placebo
11614287|NCT00537420|Experimental|3|Nasal PYY3-36 200 ug
11614288|NCT00537420|Experimental|4|Nasal PYY3-36 400 ug
11614289|NCT00537420|Experimental|5|Nasal PYY3-36 600 ug
11614290|NCT00537420|Active Comparator|6|Sibutramine 10 mg
11614291|NCT00537407|Experimental|Treatment Arm A|Debio 025 (alisporivir) 400 mg orally once daily + peg-IFNα2a 180 μg subcutaneously (sc) once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
11614292|NCT00537407|Experimental|Treatment Arm B|Debio 025 (alisporivir) 400 mg orally once daily for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
11614293|NCT00537407|Experimental|Treatment Arm C|Debio 025 (alisporivir) 400 mg orally once daily + peg-IFNα2a 180 μg sc once weekly for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
11614294|NCT00537407|Experimental|Treatment Arm D|Debio 025 (alisporivir) 800 mg orally once daily + peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
11614295|NCT00537407|Experimental|Treatment Arm E|Debio 025 (alisporivir) orally at a loading dose of 400 mg twice daily for 7 days followed by 400 mg/day for 22 days + peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
11614296|NCT00537394|Experimental|A|Regimen with higher predicted activity assigned by the study plus at least 2 NRTIs (personalized choice from expert recommendation) for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
11614297|NCT00537394|Experimental|B|Regimen with higher predicted activity assigned by the study without NRTIs for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
11614298|NCT00537394|Other|C|Regimen with lower predicted activity assigned plus at least 2 NRTIs (personalized choice from expert recommendation) for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
11614299|NCT00537381|Active Comparator|Docetaxel + Prednisone + Placebo|Matching placebo as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) every week for initial 6 weeks, then every 3 weeks; along with docetaxel 75 milligram per square meter (mg/m^2) as intravenous infusion every 3 weeks and prednisone 5 mg orally twice daily were administered till 6 months or disease progression.
11614300|NCT00537381|Experimental|Docetaxel + Prednisone + Intetumumab|Intetumumab 10 mg per kilogram (mg/kg) as intravenous infusion every week for initial 6 weeks, then every 3 weeks; along with docetaxel 75 mg/m^2 as intravenous infusion every 3 weeks and prednisone 5 mg orally twice daily were administered till 6 months or disease progression.
11614301|NCT00537355|Active Comparator|TOLAMBA™|
11614302|NCT00537355|Sham Comparator|Histamine|Histamine simulates mild redness/swelling effect seen with active comparator, TOLAMBA™. Prevents study staff from easily identifying subjects who received active comparator.
11614303|NCT00537342|Experimental|A|Biological Vaccine
11614305|NCT00537329|Other|Open|This is an open-label, multi-center, non-comparative 12 week study evaluating the efficacy and safety of anidulafungin in subjects with candidemia.
11614306|NCT00537316|Experimental|Infliximab (IFX)|Part 1: IFX 5 mg/kg of body weight intravenous (IV) infusions was to be administered at Weeks 0, 2, and 6 and placebo to AZA was to be taken orally every day for 16 weeks. Responders to IFX at Week 8, were to receive one more IFX infusion at Week 14; non-responders to IFX were to receive placebo IFX infusions at Weeks 8 and 10 and an additional IFX infusion at Week 14. Part 2: Participants in steroid-free remission at Week 16 of Part 1 were to be randomized to either maintenance (every 8 weeks [q8w]) or intermittent (upon relapse) open-label IFX (last IFX infusion administered at Week 86) plus double-blind oral AZA/placebo treatment as allocated in Part 1 (last dose at the final visit, Week 94). Responders at Week 16 who had not achieved steroid-free remission were to continue to receive IFX infusions every 8 weeks.
11614307|NCT00537316|Active Comparator|Azathioprine (AZA)|AZA 2.5 mg/kg of body weight orally every day for 16 weeks. Responders to AZA monotherapy at Week 8 were to continue on AZA therapy and receive one placebo infusion at Week 14; non-responders to AZA at Week 8 would be eligible to receive an IFX infusion at Weeks 8, 10, and 14. Participants in steroid-free remission at Week 16 were to continue on AZA monotherapy and were to be followed up for safety in Part 2. Participants who experienced a relapse of disease after Week 16 were to continue daily AZA monotherapy and receive 3 infusions of IFX (induction therapy at Weeks 0, 2, and 6) followed by infusions every 8 weeks (maintenance therapy).
11614308|NCT00537316|Experimental|IFX/AZA|IFX 5 mg/kg of body weight IV infusions at Weeks 0, 2, and 6 plus AZA 2.5 mg/kg orally every day for 16 weeks. Responders to IFX/AZA at Week 8 were to receive one more IFX infusion at Week 14; non-responders to IFX/AZA were to receive placebo infusions at Weeks 8 and 10 and one additional IFX infusion at Week 14. Part 2: Participants in steroid-free remission at Week 16 of Part 1 were to be randomized to either maintenance (every 8 weeks [q8w]) or intermittent (upon relapse) open-label IFX (last IFX infusion administered at Week 86) plus double-blind oral AZA/placebo treatment as allocated in Part 1 (last dose at the final visit, Week 94). Responders at Week 16 who had not achieved steroid-free remission were to continue to receive IFX infusions every 8 weeks.
11614309|NCT00537316|Experimental|Maintenance IFX/AZA (during Part 2)|Participants randomized to maintenance IFX/AZA in Part 2 of the study were to receive IFX 5 mg/kg of body weight IV infusions every 8 weeks (beginning at Week 22, Week 6 for direct entry) plus AZA 2.5 mg/kg of body weight daily. Four participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
11614310|NCT00537316|Experimental|Maintenance IFX (during Part 2)|Participants randomized to maintenance IFX were to receive IFX 5 mg/kg of body weight IV infusions every 8 weeks (beginning at Week 22, Week 6 for direct entry) in Part 2 of the study. Placebo to AZA therapy was to continue as allocated in Part 1 of the study. All participants were from Part 1 of the study.
11614311|NCT00537316|Experimental|Intermittent IFX/AZA (during Part 2)|Participants randomized to intermittent IFX/AZA were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained) plus AZA 2.5 mg/kg of body weight daily in Part 2 of the study. Three participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
11614312|NCT00537316|Experimental|Intermittent IFX (during Part 2)|Participants randomized to intermittent IFX were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained). Placebo to AZA therapy was to continue as allocated in Part 1 of the study. One participant was from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
11614313|NCT00537303|Experimental|Advanced|Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the meals with the largest prandial increments and individually adjusted insulin aspart based mainly on postmeal SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
11614314|NCT00537303|Active Comparator|Basic|Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the largest meals and individually adjusted insulin aspart based mainly on pre-meal and bedtime SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
11614315|NCT00537290|Experimental|Rituximab|All patients will receive 1000 milligrams of rituximab by intravenous infusion on Days 1 and 15.
11614316|NCT00537277|Experimental|BIAsp 30|Biphasic insulin aspart 30 administered once daily for 16 weeks. If HbA1c is higher than 7.0 % after 16 weeks of treatment, dose is increased to twice daily for another 16 weeks. If HbA1c is higher than 7.0 % after 32 weeks of treatment, dose is increased to three times daily until week 48 (end of trial).
11614317|NCT00537264|Experimental|Computer|Health-related quality of life questionnaires will be administered using a computerised multimedia touchscreen system.
11614318|NCT00537264|Experimental|Interviewer|Health-related quality of life questionnaire will be administered via face-to-face interviews.
11614319|NCT00537238|Active Comparator|B|
11614320|NCT00537238|Active Comparator|A|
11614321|NCT00537225|Experimental|A-Exercise group|Home based exercise
11614322|NCT00537225|No Intervention|B- Usual Care|Exercise as usually prescribed by provider
11614323|NCT00537212|Active Comparator|1|"Subjects will receive phototherapy and dietary counselling consistent with The South Beach diet."
11614324|NCT00537212|Active Comparator|2|"Subjects will receive phototherapy and dietary counselling consistent with The Ornish Diet."
11614325|NCT00537212|Sham Comparator|3|Subjects will receive phototherapy alone, without dietary counselling.
11614326|NCT00537199|Other|OraTest + Visual Exam|OraTest dye
11614327|NCT00537186|Other|1|Iron oligosaccharide
11614328|NCT00537173||Arm 1|Paclitaxel 90 mg/m2 IV D1, 8, and 15 + Avastin 10 mg/kg IV, day 1 and 15
11614329|NCT00537147|Experimental|1|1 vaccination of a 10^4 plaque-forming units (PFU) dose of WN/DEN4delta30 vaccine administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
11614330|NCT00537147|Experimental|2|1 vaccination of a 10^5 PFU dose of WN/DEN4delta30 vaccine administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
11614378|NCT00536731|Active Comparator|Pulmicort Turbuhaler|Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
11614331|NCT00537147|Placebo Comparator|3|1 vaccination of a placebo administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
11614332|NCT00537134|No Intervention|1|Conservative management (watchful observation)
11614333|NCT00537134|Active Comparator|2|Endovascular treatment
11614334|NCT00537108|Experimental|HV|Intervention arm.
11614335|NCT00537108|No Intervention|Cntr|Usual care control
11614336|NCT00537095|Experimental|vandetanib (ZD6474)|vandetanib (ZD6474) 300 mg per os once daily
11614337|NCT00537095|Placebo Comparator|Placebo|Placebo
11614338|NCT00537082|Experimental|FTY720 0.5 mg|FTY720
11614339|NCT00537082|Experimental|FTY720 1.25 mg|FTY720
11614340|NCT00537082|Placebo Comparator|Placebo|
11614341|NCT00537056|Experimental|F-18 FDG PET/CT and DCE MRI|FDG PET CT F-18 Fluoro-deoxi-glucose: 15 mCi iv Gadolinium-DTPA: 0.1 mmol/kg Sunitinib: 50 mg/day po
11614342|NCT00537030|Experimental|Treatment (chemotherapy)|Patients receive 6 doses of Erwinia asparaginase IM on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase remaining on the original treatment protocol. All other chemotherapy continues according to the original treatment protocol.
11614343|NCT00537017|Experimental|Preladenant 5 mg BID|Preladenant 5 mg twice daily (BID) given open-label for 36 weeks to participants with moderate to severe Parkinson's Disease who are on a long-term and stable L-dopa treatment regimen.
11614344|NCT00537004||PPA (Primary Progressive Aphasia)|Individuals with primary progressive aphasia
11614345|NCT00537004||Control|Individuals with no diagnosis of any type of dementia
11614346|NCT00536991|Experimental|Treatment (calcitriol, ketoconazole, hydrocortisone)|"PHASE I: Patients receive calcitriol PO QD on days 1-3, 8-10, 15-17, and 22-24. Patients also receive ketoconazole PO TID on days 1-24 and therapeutic hydrocortisone PO BID on days -1 to 24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~PHASE II: Patients receive calcitriol and therapeutic hydrocortisone as in phase I. Patients also receive ketoconazole PO TID on days 4-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11614347|NCT00536978|Experimental|NK Cell/T-Cell Infusion|Possible Cell Adback - infusion NK cells or T-cells from donor given after blood stem cell transplantation for either Reduced intensity chemotherapy of campath, modified BEAM regimen of Campath-IH 15 mg intravenous (IV) Daily for 3 Days + BEAM Daily for 4 days (BCNU 300 mg/m^2 IV, Etoposide 100 mg/m^2 IV, Ara-C 100 mg/m^2 IV Daily for 4 days and Melphalan 100 mg/m^2 IV Over 30 Minutes for 1 Day) + Rituximab 375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks]; or Non-myeloablative Preparative Regimen [Fludarabine 30 mg/m^2 IV Daily Over 1 Hour for 3 Days; Cyclophosphamide 1000 mg/m^2 IV Daily Over 1 Hour for 3 Days; Rituximab 375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks; Campath-IH 15 mg IV Daily Over 30 Minutes for 3 Days; plus Total Body radiation (TBI)].
11614348|NCT00536952|Experimental|Arm 1|Pulmozyme
11614349|NCT00536952|Placebo Comparator|Arm 2|Placebo
11614350|NCT00536939|Experimental|Enzastaurin + Bevacizumab + Paclitaxel|"Participants randomized to this arm (Arm A) will receive enzastaurin, paclitaxel and bevacizumab until disease progression.
~Prior to randomization, a safety lead-in will be conducted in 6 participants who will be treated according to Arm A for 2 cycles (1 cycle = 28 days). Only after an acceptable safety analysis of the safety lead-in, will other participants be randomized to Phase 2 (either Arm A or Arm B). In Phase 2, participants from the safety lead-in will continue treatment according to Enzastaurin + Bevacizumab + Paclitaxel (Arm A)."
11614351|NCT00536939|Placebo Comparator|Bevacizumab + Paclitaxel + Placebo|Participants randomized to this arm (Arm B) will receive bevacizumab, paclitaxel and placebo until disease progression.
11614352|NCT00536926|Active Comparator|A|home spirometry alone
11614353|NCT00536926|Experimental|B|Home spirometry with data transfer via cellphone to clinical database
11614354|NCT00536913|Experimental|With Spacer|Budesonide/formoterol pMDI 40/2.25ug + spacer
11614355|NCT00536913|Experimental|Without Spacer|Budesonide/formoterol pMDI 40/2.25 ug
11614356|NCT00536900|Experimental|1|Advisor-Teller Money Manager
11614357|NCT00536900|Active Comparator|2|FIT (finance instruction therapy)
11614358|NCT00536874|Experimental|Gemcitabine And Oxaliplatin|A Phase II Study of Neoadjuvant Gemcitabine And Oxaliplatin In Patients With Potentially Resectable Previously Untreated Pancreatic Adenocarcinoma
11614359|NCT00536861|Experimental|1|
11614360|NCT00536848|Experimental|A|Metronidazole for 10 days, probiotics for 6 months
11614361|NCT00536848|Placebo Comparator|B|Metronidazole for 10 days, placebo for 6 months
11614362|NCT00536835|Experimental|Stage A|Stage A will identify maximum tolerated doses for either Schedule 1 - GSK461364 given once weekly on Day 1, 8 and 15 every 28 days; Schedule 2 - GSK 461364 given twice weekly Days 1, 2, 8, 9, 15 and 16; Schedule 3 Daily on Day 1 to Day 15 every 21 days.
11614363|NCT00536835|Experimental|Stage B|Evaluate safety, PK, pharmacodynamic (PD) & tumor response in expanded cohorts at the MTD for at least one schedule from Stage A.
11614364|NCT00536809|Experimental|Phase I|Dose escalation of lapatinib along with capecitabine and oxaliplatin until the maximum tolerated dose is reached.
11614365|NCT00536809|Experimental|Phase II|Treatinng subjects at the maximum tolerated dose of lapatinib, capecitabine, and oxaliplatin
11614366|NCT00536796||Patients at very high risk|
11614367|NCT00536796||Patients at high risk|
11614368|NCT00536796||Patients at medium risk|
11614369|NCT00536796||Patients at low risk|
11614370|NCT00536770|Placebo Comparator|A|Placebo + gemcitabine
11614371|NCT00536770|Placebo Comparator|B|Placebo + gemcitabine + erlotinib
11614372|NCT00536770|Active Comparator|C|DN-101 + gemcitabine
11614373|NCT00536770|Active Comparator|D|DN-101 + gemcitabine + erlotinib
11614374|NCT00536744|Active Comparator|Active PACE application - 4 applications|Application of acoustical pulse energy (extracorporeal shockwaves) to target ulcer + standard of care
11614375|NCT00536744|Sham Comparator|Inactive, non-energy application|Non-energized (inactive - Sham)) application + standard of care
11614376|NCT00536731|Active Comparator|Symbicort pMDI|Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
11614377|NCT00536731|Active Comparator|Symbicort Turbuhaler|Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
11614469|NCT00535951|Experimental|LBH589|
11614379|NCT00536679|Experimental|Sequence ABC|Subjects will be randomized to sequence ABC, where A=1 milligram (mg) GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
11614380|NCT00536679|Experimental|Sequence ACB|Subjects will be randomized to sequence ACB, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
11614381|NCT00536679|Experimental|Sequence BAC|Subjects will be randomized to sequence BAC, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
11614382|NCT00536679|Experimental|Sequence BCA|Subjects will be randomized to sequence BCA, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
11614383|NCT00536679|Experimental|Sequence CAB|Subjects will be randomized to sequence CAB, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
11614384|NCT00536679|Experimental|Sequence CBA|Subjects will be randomized to sequence CBA, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
11614385|NCT00536666|Other|1|Iron oligosaccharide
11614386|NCT00536653|Active Comparator|Osteporosis Group|Patients with a presenting T score < -2.5 (osteoporosis), treated with bicalutamide and Ca/VitD
11614387|NCT00536653|Active Comparator|Osteopenia Group|Patients with a presenting T score between -1.0 and -2,4 (osteopenia), treated with LHRH agonists and Ca/VitD
11614388|NCT00536653|Active Comparator|Normal Group|Patients with a presenting T score > -1.0(normal BMD), treated with LHRH agonists
11614389|NCT00536640|Experimental|Arm A (Erlotinib, Bevacizumab)|
11614390|NCT00536640|Active Comparator|Arm B (Gemcitabine, Cisplatin, Bevacizumab)|
11614391|NCT00536627|Experimental|1|Patients will receive 5 injections of DNA vaccine at weeks 0, 8, 16, 40, 44.
11614392|NCT00536627|No Intervention|2|
11614393|NCT00536614|No Intervention|A|arm A) gemcitabine/cisplatin in combination with Cetuximab arm B) gemcitabine/cisplatin alone
11614394|NCT00536601|Experimental|Regimen CBV (patients with HL or NHL)|Patients receive etoposide intravenously (IV) continuously over 34 hours on day -8, cyclophosphamide IV over 2 hours on days -7 to -4, and carmustine IV over 2 hours on day -3. Patients undergo ASCT on day 0.
11614395|NCT00536601|Experimental|Regimen M200/M120 (patients with MM or amyloidosis)|Patients receive 200 or 120 mg/m^2 of melphalan IV over 30 minutes on day -2. Patients undergo ASCT on day 0.
11614396|NCT00536601|Experimental|Regimen BuC2iv (patients with ALL, AML, HL, or NHL)|Patients receive busulfan IV over 2 hours then every 6 hours on days -7 to -4 for 16 total doses and cyclophosphamide IV over 2 hours on days -3 and -2. Patients undergo ASCT on day 0.
11614397|NCT00536601|Experimental|Regimen CT6 (patients with ALL)|Patients receive cyclophosphamide IV over 2 hours on days -5 to -4. Patients then undergo TBI twice daily on days -3 to -1. Patients undergo ASCT on day 0.
11614398|NCT00536601|Experimental|Regimen CTtCp (patients with other solid tumors)|Patients receive cyclophosphamide IV continuously, carboplatin IV continuously, and thiotepa IV continuously over 24 hours on days -7 to -4. Patients undergo ASCT on day 0.
11614399|NCT00536601|Experimental|Regimen VCp (patients with testicular cancer)|Patients receive etoposide IV over 2-3 hours and carboplatin IV over 30 minutes on days -6 to -4. Patients undergo ASCT on day 0. At least 4 weeks after the first transplant, patients receive etoposide IV over 2-3 hours and carboplatin IV over 30 minutes on days -6 to -4. Patients then undergo a second ASCT on day 0.
11614400|NCT00536601|Experimental|Regimen TtC1500/ECpM (patients with NBL or SRBCT)|Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 2 hours on days -5 to -2. Patients undergo ASCT on day 0. At least 4 weeks after the first transplant, patients receive carboplatin IV continuously over 24 hours on days -7 to -4, etoposide IV continuously over 24 hours on days -7 to -4, and melphalan IV over 30 minutes on days -7 to -5. Patients undergo a second ASCT on day 0.
11614401|NCT00536588|Experimental|SCH 721015 with SCH 209702|
11614402|NCT00536575|Experimental|Intervention|The trial was designed as a single-arm Phase I/II study of sorafenib and bortezomib with dose optimization in initial patients. Phase I consisted of cohorts of 3 patients at each of three dose levels. Patients received bortezomib (Dose Level 1 - 1.3 mg/m2; Dose Level 2 - 1.6 mg/m2) by IV bolus on days 1, 8, 15, and 22 of each 5-week cycle with continuous oral dosing of sorafenib at 200 mg twice daily. Dose level 3 was planned as bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 with sorafenib 400 mg by mouth twice daily throughout each 5-week cycle.
11614403|NCT00536562|No Intervention|Usual Care|Usual Care as provided through the Stroke Prevention Clinic
11614404|NCT00536562|Active Comparator|Cardiac Rehabilitation|Usual Care plus Comprehensive Cardiac Rehabilitation Program
11614405|NCT00536549|Experimental|A|Guardina RT monitoring
11614406|NCT00536549|Active Comparator|B|
11614407|NCT00536536|Active Comparator|Hospital|Care of Childhood Obesity Clinic (COCO)
11614408|NCT00536536|Active Comparator|Primary Care|Primary care clinics (x2)
11614409|NCT00536523||Patients Receiving Chemotherapy|Patients with newly diagnosed ovarian, fallopian tube or primary peritoneal cancer for which 6 cycles of a taxane and platinum containing regimen is planned
11614410|NCT00536510|Experimental|1|laropiprant/niacin (MK0524A)
11614411|NCT00536510|Placebo Comparator|2|placebo
11614412|NCT00536484|Experimental|Fesoterodine (Double-Blind)|
11614413|NCT00536484|Placebo Comparator|Placebo (Double-Blind)|
11614414|NCT00536471|Experimental|A|duloxetine 60 milligrams (mg) every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months
11614415|NCT00536471|Placebo Comparator|B|placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months
11614416|NCT00536458|Experimental|radiotherapy|minichep + radiotherapy
11614417|NCT00536458|Active Comparator|B|MINI CHEP
11614418|NCT00536419|Placebo Comparator|2|4 days of placebo
11614419|NCT00536419|Experimental|1|MPH-SODAS at day 1 (0.3/mg/kg/day); day 2 (0.7/mg/kg/day);days 3 and 4 (1.0 mg/kg/day)
11614420|NCT00536406|Experimental|A|Participants will receive the BE-ACTIV treatment
11614421|NCT00536406|Active Comparator|B|Participants will receive treatment as usual
11614422|NCT00536393|Active Comparator|Doxorubicine|CHOP 8 courses every 21 days
11614423|NCT00536393|Experimental|Doxorubicine pegylated|CLOP 8 courses every 21 days
11614424|NCT00536380|Experimental|5-mg Desloratadine|5-mg Desloratadine once daily
11614425|NCT00536380|Experimental|10-mg Desloratadine|10-mg Desloratadine once daily
11614426|NCT00536380|Experimental|20-mg Desloratadine|20-mg Desloratadine once daily
11614427|NCT00536367||Patients seen for ADHF at OSUMC|
11614428|NCT00536341|Experimental|lenalidomide, fludarabine, rituximab|"Phase I Non-stratified, dose-escalation: >=3 patients per dose level. Safety and tolerability will be evaluated every 2 weeks during the active treatment. Doses of lenalidomide will be escalated, while the fludarabine and rituximab doses remain fixed.
~Phase II The Phase II regimen will be chosen following a review of the Phase I data. Following selection of the Phase II schedule, 40 treatment naive patients will be enrolled and treated with the Phase II regimen every 28 days for up to 6 courses. For those patients achieving a CR after 3 cycles, one additional cycle of treatment will be administered beyond CR confirmation."
11614429|NCT00536315||COPD|Patients with cough and/or shortness of breath who may have windpipe collapse.
11614430|NCT00536315||Healthy adults|Subjects without symptoms for comparison.
11614431|NCT00536315||Tracheomalacia|Patients with cough and/or shortness of breath who may have windpipe collapse.
11614432|NCT00536302|Experimental|1|Collagen Hydrolysate
11614433|NCT00536302|Placebo Comparator|2|
11614434|NCT00536289|Active Comparator|1|Sharp needles
11614435|NCT00536289|Experimental|2|Blunt tipped needles
11614436|NCT00536263|Active Comparator|PEG 1.0 mcg/kg weekly (QW) * 24 weeks|PegIntron 1.0 mcg/kg weekly (QW) * 24 weeks + 24 weeks follow-up
11614437|NCT00536263|Experimental|PEG 1.5 mcg/kg QW * 24 wks|PegIntron 1.5 mcg/kg QW * 24 wks + 24 wks follow-up
11614438|NCT00536263|Experimental|PEG 1.5 mcg/kg QW * 48 wks|PegIntron 1.5 mcg/kg QW * 48 wks + 24 wks follow-up
11614439|NCT00536224|Active Comparator|2|Minimal counseling
11614440|NCT00536224|Experimental|1|Full counseling
11614441|NCT00536211|Experimental|1|Exercise
11614442|NCT00536211|Active Comparator|2|Metformin
11614443|NCT00536198|Experimental|Sertraline|Participants will take sertraline that is dosed between 50 and 100 mgs during the symptomatic period. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
11614444|NCT00536198|Placebo Comparator|Placebo|Participants will take similar looking placebo during the symptomatic period.
11614445|NCT00536185|Experimental|1|
11614446|NCT00536185|Placebo Comparator|2|
11614447|NCT00536172|Experimental|Escitalopram|Participants will receive treatment with escitalopram
11614448|NCT00536172|Placebo Comparator|Placebo|Participants will receive treatment with placebo
11614449|NCT00536159|Active Comparator|Community Care|Medicaid eligible/insured pregnant women and their infants are eligible for risk assessment and up to 18 home visits (9/pregnancy and 9/infancy) from community professional providers as part of a state-sponsored enhanced prenatal and postnatal Medicaid program.
11614450|NCT00536159|Experimental|Nurse-CHW Team|Nurse-CHW team provided both nursing care, with additional focus on mental health and stress, and intensive relationship-based support from a CHW similar in characteristics to women served in the context of state-sponsored Medicaid program.
11614451|NCT00536133|Experimental|Zinc group|children with recurrent acute lower respiratory infections receiving zinc supplementation
11614452|NCT00536133|Placebo Comparator|Placebo group|children with recurrent acute lower respiratory infections receiving placebo syrup
11614453|NCT00536120|Experimental|Tysabri Plus Vaccinations|Participants receive 9 monthly doses of Tysabri 300 mg intravenous (IV), and receive vaccinations with neoantigen and recall antigen (keyhole limpet hemocyanin [KLH] and tetanus diphtheria toxoid [Td], according to manufacturer's prescribing information) at Month 6 (following the 7th dose of Tysabri) for both KLH and Td, and 14 and 28 days later for KLH.
11614454|NCT00536120|Other|Vaccinations Only|Participants receive only vaccinations with neoantigen and recall antigen (KLH and Td, according to manufacturer's prescribing information) at Month 0 for both KLH and Td, and 14 and 28 days later for KLH. They do not receive any treatment for their MS and remain in the study through Month 2.
11614455|NCT00536107|Active Comparator|Docetaxel|docetaxel
11614456|NCT00536107|Experimental|Gefitinib|Gefitinib (IRESSA)
11614457|NCT00536094|Experimental|1|Participants will receive cognitive behavioral therapy for anxiety that includes exposure
11614458|NCT00536094|Active Comparator|2|Participants will receive treatment as usual as delivered by school-based clinicians
11614459|NCT00536081|Active Comparator|A|Pegfilgrastim during all 6 cycles of chemotherapy
11614460|NCT00536081|Experimental|B|Pegfilgrastim during the first two cycles of chemotherapy
11614461|NCT00536068|Experimental|1, 2, 3, 4|"acetylsalicylic acid 100 mg/po,acetaminophen 3x1g/po
~acetylsalicylic acid 100 mg/po,diclofenac 3x50mg/po
~acetylsalicylic acid 100 mg/po,naproxen 3x250mg/po
~acetylsalicylic acid 100 mg/po,placebo 3x1/po"
11614462|NCT00536042|Experimental|minocycline|addition of minocycline to standard asthma care as add-on therapy: 150 mg bid to 250 mg bid for up to one year
11614463|NCT00536029||A|Subject with pigmented skin lesion suspect for malignant melanoma
11614464|NCT00536003|Experimental|1|
11614465|NCT00536003|Placebo Comparator|2|
11614466|NCT00535977|Experimental|1|Dietary intervention of ITC-enriched broccoli
11614467|NCT00535977|Experimental|2|Dietary intervention of frozen peas
11614468|NCT00535964||1|Psychologically healthy adolescents, evenly divided across the various stages of smoking uptake
11614470|NCT00535938||Naïve to Botox® treatment|Initiating treatment with BOTOX® upon entry to the project.
11614471|NCT00535938||Non-naïve to Botox® treatment|Receiving ongoing treatment with BOTOX® upon entry to the project.
11614472|NCT00535925|Active Comparator|Standard of Care (SoC) therapy|Control group patients will continue their SoC therapy. During the study such patients could receive all the therapeutic modifications according to the good medical practice of the specialist.
11614473|NCT00535925|Experimental|Multifactorial Intensified therapy|"An intensive multifactorial intervention according Scientific Guidelines is performed to achieve the goals for the following risk factors: hypertension, hyperglycaemia, lipids, anaemia.
~In particular, new antihypertensive drugs will be added one by one until the achievement of blood pressure target (<130/80 mmHg)."
11614474|NCT00535912|No Intervention|A|¨Chemotherapy by 12 courses of CHOP
11614475|NCT00535912|Active Comparator|B|¨Chemotherapy by 3 courses of CHOP, intensification and autograft
11614476|NCT00535886|Active Comparator|Elaidic Acid|
11614477|NCT00535886|Experimental|Vaccenic Acid|
11614478|NCT00535886|Placebo Comparator|Oleic Acid|
11614479|NCT00535873|Experimental|Lenalidomide|Lenalidomide starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
11614480|NCT00535860|Experimental|50 mcg|ViaDerm transdermal delivery
11614481|NCT00535860|Experimental|80 mcg|Add Via-Derm transdermal delivery
11614482|NCT00535860|Active Comparator|20 mcg|Subcutaneous injection
11614483|NCT00535847|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 24 weeks.
11614484|NCT00535847|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
11614485|NCT00535847|Experimental|Other|"Subjects received telaprevir 750 mg tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects <75 kg and 1200 mg/day for subjects weighing >=75 kg, discontinued treatment before Week 12 in this study (VX06-950-107 [NCT00535847]) and had a partial response, viral breakthrough, or relapse in the parent study (VX05-950-104 [NCT00336479], VX05-950-104EU [NCT00372385] or VX06-950-106 [NCT00420784]) were included in Other reporting group."
11614486|NCT00535821|Experimental|MiCHO|A 6-hour resuscitation protocol utilizing the esophageal Doppler monitoring (EDM)
11614487|NCT00535821|Active Comparator|EGDT|A 6-hour resuscitation protocol utilizing CVP/ScvO2
11614488|NCT00535808|Experimental|1|Administration of nitroprusside
11614489|NCT00535808|Experimental|2|Administration of nitroglycerine
11614490|NCT00535808|Experimental|3|Administration of sevoflurane
11614491|NCT00535795|Active Comparator|1|Conventional Radiation Therapy (XRT), one fraction per day, from Sunday to Thursday every week.
11614492|NCT00535795|Experimental|2|Conventional Plus accelerated boost Radiation Therapy (XRT), from Sunday to Thursday every week.
11614493|NCT00535782|Experimental|TCZ + MTX|Participants received 8 mg/kg tocilizumab (TCZ) by intravenous infusion (IV) every 4 weeks plus methotrexate (MTX) 7.5-25 mg (oral or parenteral) weekly for the first 24 weeks. From Week 24 to Week 104, participants received open-label TCZ 8 mg/kg every 4 weeks plus 7.5-25 mg MTX weekly.
11614494|NCT00535782|Placebo Comparator|Placebo + MTX|Participants received placebo intravenous infusion (IV) every 4 weeks plus methotrexate (MTX) 7.5-25 mg (oral or parenteral) weekly for the first 24 weeks. From Week 24 to 104, participants received open-label tocilizumab (TCZ) 8 mg/kg every 4 weeks plus 7.5-25 mg MTX.
11614495|NCT00535769|Placebo Comparator|Electronic monitor + no text message|The control or placebo comparator group of subjects will receive the study sunscreen with the attached electronic monitor. They will be instructed to apply sunscreen once a day in the morning to the sun-exposed areas of the body. If the subjects are to have continuous sun exposure (for example, at a beach), they are to re-apply the sunscreen every 3 hours.
11614496|NCT00535769|Experimental|Electronic monitor + Text message|The text message experimental group of subjects will receive the study sunscreen with the attached electronic monitor. In addition, this group will receive daily text messages on their cellular phone to remind them to apply the sunscreen. The text message will also contain the daily weather information. This group will also be instructed to apply sunscreen once a day in the morning to the sun-exposed areas of the body. If subjects are to have continuous sun exposure (for example, at a beach), they are to re-apply the sunscreen every 3 hours.
11614497|NCT00535756|Experimental|1|
11614498|NCT00535756|Placebo Comparator|2|
11614499|NCT00535743|Placebo Comparator|Arm A. Placebo; 3 min after 1 mg/kg Esmeron®|Placebo (single intravenous (IV) bolus) administered 3 minutes (min) after the bolus intubation dose of 1 mg/kg Esmeron®.
11614500|NCT00535743|Experimental|Arm B. 2 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
11614501|NCT00535743|Experimental|Arm C. 4 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
11614502|NCT00535743|Experimental|Arm D. 8 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
11614503|NCT00535743|Experimental|Arm E. 12 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
11614504|NCT00535743|Experimental|Arm F. 16 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
11614505|NCT00535743|Placebo Comparator|Arm G. Placebo; 15 min after 1 mg/kg Esmeron®|Placebo (single intravenous (IV) bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
11614506|NCT00535743|Experimental|Arm H. 2 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
11614997|NCT00531765|Experimental|2|hydration with sodium bicarbonate
11614507|NCT00535743|Experimental|Arm I. 4 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
11614508|NCT00535743|Experimental|Arm J. 8 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
11614509|NCT00535743|Experimental|Arm K. 12 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
11614510|NCT00535743|Experimental|Arm L. 16 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
11614511|NCT00535743|Placebo Comparator|Arm M. Placebo; 3 min after 1.2 mg/kg Esmeron®|Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
11614512|NCT00535743|Experimental|Arm N. 2 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
11614513|NCT00535743|Experimental|Arm O. 4 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
11614514|NCT00535743|Experimental|Arm P. 8 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
11614515|NCT00535743|Experimental|Arm Q. 12 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
11614516|NCT00535743|Experimental|Arm R. 16 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
11614517|NCT00535743|Placebo Comparator|Arm S. Placebo; 15 min after 1.2 mg/kg Esmeron®|Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
11614518|NCT00535743|Experimental|Arm T. 2 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
11614519|NCT00535743|Experimental|Arm U. 4 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
11614520|NCT00535743|Experimental|Arm V. 8 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
11614521|NCT00535743|Experimental|Arm W. 12 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
11614522|NCT00535743|Experimental|Arm X. 16 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
11614523|NCT00535730|Placebo Comparator|1|Placebo Comparator
11614524|NCT00535730|Experimental|2|vaccine
11614525|NCT00535704|Experimental|1|The Strong AFrican American FAmilies-Teen program is a five part educational program has been designed to help teens and their parents create successful futures and avoid the risky behaviors that sometimes keep teens from reaching their goals.
11614526|NCT00535704|Other|2|The FUEL program is a family-based adaptation of a curriculum designed to assist teens to develop lifestyles that prevent health problems such as heart disease, diabetes, and being overweight. This program deals with diet and exercise, the influence of TV and magazines on eating habits, and handling stress.
11614527|NCT00535691|Active Comparator|1|Tacrolimus ointment 0.03% once daily, placebo once daily
11614528|NCT00535691|Active Comparator|2|Tacrolimus ointment 0.03% twice daily
11614529|NCT00535665|Experimental|1: 10 ug, 14 days|
11614530|NCT00535665|Experimental|2: 5 ug, 28 days|
11614531|NCT00535665|Experimental|3: 10 ug, 28 days|
11614532|NCT00535665|Experimental|4: 15 ug, 28days|
11614533|NCT00535652|Experimental|Ertapenem|Administration of 1 gram ertapenem I.V.
11614534|NCT00535626|Other|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell used in revision total hip replacement
11614535|NCT00535613|Experimental|1|propofol
11614536|NCT00535613|Sham Comparator|2|no propofol
11614537|NCT00535587|Experimental|1|
11614538|NCT00535587|Experimental|2|
11614539|NCT00535587|Experimental|3|
11614540|NCT00535587|Experimental|4|
11614541|NCT00535574|Placebo Comparator|Bexarotene (Targretin LGD1069)|
11614542|NCT00535574|Active Comparator|placebo|
11614543|NCT00535561|Active Comparator|1|Oral iron treatment only- for iron deficiency anemia and subclinical hypothyroidism coexisting patients
11614544|NCT00535561|Active Comparator|2|Oral iron plus levothyroxine treatment- for iron deficiency anemia and subclinical hypothyroidism coexisting patients
11614545|NCT00535522|Experimental|TAK-285|
11614546|NCT00535496|Experimental|1|sugammadex 1.0 mg/kg, TOF-Watch® SX (dominant forearm) and PNS (non-dominant forearm)
11614547|NCT00535496|Experimental|2|sugammadex 1.0 mg/kg, TOF-Watch® SX (non-dominant forearm) and PNS (dominant forearm)
11614548|NCT00535496|Experimental|3|sugammadex 4.0 mg/kg, TOF-Watch® SX (dominant forearm) and PNS (non-dominant forearm)
11614549|NCT00535496|Experimental|4|sugammadex 4.0 mg/kg, TOF-Watch® SX (non-dominant forearm) and PNS (dominant forearm)
11614550|NCT00535470|Experimental|1|Open label 0.04% Mechlorethamine gel
11614551|NCT00535457|Experimental|1|"Children will watch tricks (magic) before anesthesia induction"
11614552|NCT00535444|Active Comparator|Control|assisted appointment with physician
11614553|NCT00535431|Experimental|A|AER 001
11614554|NCT00535431|Placebo Comparator|P|sterile saline
11614555|NCT00535418|Experimental|Letrozole|
11614556|NCT00535405|Experimental|1|Each patient will receive 1 active treatment dose & 2 Placebo (Pbo) doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
11614557|NCT00535405|Experimental|2|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
11614558|NCT00535405|Experimental|3|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
11614559|NCT00535405|Experimental|4|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
11614560|NCT00535405|Experimental|5|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
11614561|NCT00535392|Experimental|Levetiracetam|
11614562|NCT00535379|Experimental|1|
11614563|NCT00535366|Experimental|Tiotropium+salmeterol+fluticasone|
11614564|NCT00535366|Experimental|Tiotropium+salmeterol+ciclesonide low|
11614565|NCT00535366|Experimental|Tiotropium+salmeterol+ciclesonide high|
11614566|NCT00535366|Placebo Comparator|Placebo|
11614567|NCT00535314|Experimental|RTA 402 Dose1|Dose1 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
11614568|NCT00535314|Experimental|RTA 402 Dose2|Dose2 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
11614569|NCT00535301|Placebo Comparator|Anterior Colporrhaphy (sutured repair)|Anterior vaginal prolapse repair with anterior colporrhaphy (no graft) using sutures.
11614570|NCT00535301|Active Comparator|Perigee (grafted repair)|Anterior vaginal prolapse repair with graft
11614571|NCT00535288|Placebo Comparator|Placebo|Participants receive encapsulated tablets, orally, once daily (QD) for up to 12 weeks.
11614572|NCT00535288|Experimental|Esmirtazapine 2.25 mg|Participants receive esmirtazapine, 2.25 mg, encapsulated tablets, orally QD for up to 12 weeks.
11614573|NCT00535288|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine, 4.5 mg, encapsulated tablets, orally QD for up to 12 weeks.
11614574|NCT00535288|Experimental|Esmirtazapine 9 mg|Participants receive esmirtazapine, 9 mg, encapsulated tablets, orally QD for up to 12 weeks.
11614575|NCT00535288|Experimental|Esmirtazapine 18 mg|Participants receive esmirtazapine, 18 mg, encapsulated tablets, orally QD for up to 12 weeks.
11614576|NCT00535275|Experimental|A|
11614577|NCT00535275|Active Comparator|B|Docetaxel monotherapy
11614578|NCT00535262|Experimental|EmSam|EmSam will be administered in open-label fashion for 8-weeks during phase I of the study during which symptoms of depression will be assessed weekly. Those whose depression responds after 8-weeks will be entered into an 8-month open-label continuation phase during which they will be maintained on EmSam and be assessed on a monthly basis.
11614579|NCT00535236|Experimental|Autologous HCT-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
11614580|NCT00535236|Placebo Comparator|Autologous HCT-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
11614581|NCT00535236|Experimental|Allogeneic HCT-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
11614582|NCT00535236|Placebo Comparator|Allogeneic HCT-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
11614583|NCT00535236|Experimental|STM-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
11614584|NCT00535236|Placebo Comparator|STM-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
11614585|NCT00535236|Experimental|HM-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
11614586|NCT00535236|Placebo Comparator|HM-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
11614587|NCT00535236|Experimental|HIV-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
11614588|NCT00535236|Placebo Comparator|HIV-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
11614589|NCT00535223|Experimental|Group Based Exposure Therapy|"Behavioral:
~GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking."
11614590|NCT00535223|Experimental|Present Centered Group Therapy|"Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus. This lasted for 16 weeks."
11614591|NCT00535210|Other|1|
11614592|NCT00535210|Other|2|
11614593|NCT00535197|Experimental|CD34+ stem/progenitor cell therapy|Patients presenting within 7 days of onset with severe anterior circulation ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score≥8). CD34+ cells were collected from the bone marrow of the subjects before being delivered by catheter angiography into the ipsilesional middle cerebral artery.
11614726|NCT00534066||Observational|Patients who present to the ED for acute exacerbation of CHF who are transferred to the Observation Unit from the ED for up to 24 hours.
11614998|NCT00531752|Experimental|Flexible Dose|
11614594|NCT00535145|Experimental|001|Treatment as usual (TAU), Paliperidone ERTreatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
11614595|NCT00535132|Experimental|002|Oral Risperidone 4 or 6 mg MG once daily for 0-2 weeks
11614596|NCT00535132|Experimental|001|Paliperidone ER 6, 9 or 12 MG once daily for 4-6 weeks
11614597|NCT00535119|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 3 and veliparib PO twice daily on days 1-7 until the recommended phase II dose is determined. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression or unacceptable toxicity.
11614598|NCT00535106|Active Comparator|Standard resusc|Patients in this arm will be treated with standard resuscitation efforts, including the delivery of an immediate defibrillatory shock for all patients presenting in VF.
11614599|NCT00535106|Experimental|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
11614600|NCT00535106|Active Comparator|Delayed defib|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation. Data is being collected on this population as well, thereby providing a cohort population for comparative purposes.
11614601|NCT00535093|No Intervention|1|All patients fulfilling inclusion criteria will be evaluated for GAS infection using both a rapid streptococcus test and also a standard throat culture
11614602|NCT00535067||Breast Cancer Survivors|
11614603|NCT00535054|Experimental|Tears Again|All subjects shall be treated with Tears Again.
11614604|NCT00535028|Experimental|A|AER 001 s.c. once daily for 28 days
11614605|NCT00535028|Placebo Comparator|P|placebo s.c. once daily for 28 days
11614606|NCT00535002|Other|Cocaine Females, Yohimbine then Placebo|Cocaine dependent females, received yohimbine day 1 and placebo day 2
11614607|NCT00535002|Other|Cocaine Females, Placebo the Yohimbine|Cocaine dependent females, received placebo day 1 and yohimbine day 2
11614608|NCT00535002|Other|Cocaine Males, Yohimbine then Placebo|Cocaine dependent males, received yohimbine day 1 and placebo day 2
11614609|NCT00535002|Other|Cocaine Males, Placebo thenYohimbine|Cocaine dependent males, received placebo day 1 and yohimbine day 2
11614610|NCT00535002|Other|Control Females, Yohimbine then Placebo|Non-dependent females, received yohimbine day 1 and placebo day 2
11614611|NCT00535002|Other|Control Females, Placebo then Yohimbine|Non-dependent females, received placebo day 1 and yohimbine day 2
11614612|NCT00535002|Other|Control Males, Yohimbine then Placebo|Non-dependent males, received yohimbine day 1 and placebo day 2
11614613|NCT00535002|Other|Control Males, Placebo then Yohimbine|Non-dependent males, received placebo day 1 and yohimbine day 2
11614614|NCT00534976|Experimental|Montelukast Sodium|"Participants 4-5 years: A single dose of 4 mg Montelukast chewable tablet daily, crossing over to matching placebo (Pbo) after a 3- to 7-day washout period (no participants 4-5 years were enrolled)
~Participants 6-14 years: A single dose of 5 mg Montelukast chewable tablet daily, crossing over to matching Pbo after a 3- to 7-day washout period"
11614615|NCT00534976|Experimental|Placebo|"Participants 4-5 years: A single dose of 4 mg Pbo chewable tablet daily, crossing over to Montelukast 4 mg chewable tablet after a 3- to 7-day washout period (no participants 4-5 years of age were enrolled)
~Participants 6-14 years: A single dose of 5 mg Pbo chewable tablet daily, crossing over to Montelukast 5 mg chewable tablet after a 3- to 7-day washout period"
11614616|NCT00534937|Active Comparator|Standard compression|Patients in this arm will receive current standard of care (once-weekly short-stretch compression wrapping).
11614617|NCT00534937|Experimental|Flexitouch|Patients in this arm will receive once-a-week short stretch compression wrapping AND once-daily Flexitouch pump application (including Flexitouch application once-a-week in the clinic setting).
11614618|NCT00534924|Placebo Comparator|1|No intervention after IR injury
11614619|NCT00534924|Experimental|2|Postconditioning
11614620|NCT00534924|Experimental|3|Vit. C
11614621|NCT00534911|Experimental|Cognitive Behavioral Therapy|Primary & Secondary Control Enhancement Training (PASCET)
11614622|NCT00534911|Active Comparator|Supportive Non-Directive Therapy (SNDT)|Supportive Non-Directive Therapy
11614623|NCT00534885|Experimental|1: Healive® Lot 1|
11614624|NCT00534885|Experimental|2: Healive® Lot 2|
11614625|NCT00534885|Experimental|3: Healive® Lot 3|
11614626|NCT00534885|Active Comparator|4: control vaccine (Havrix)|
11614627|NCT00534872|Experimental|SB649868|10 mg
11614628|NCT00534846|Placebo Comparator|A placebo|The participants were randomly allocated to receive toremifene (20 mg) or placebo during the luteal phase for three consecutive menstrual cycles.
11614629|NCT00534846|Active Comparator|B toremifene|The participants were randomly allocated to receive toremifene (20 mg) or placebo during the luteal phase for three consecutive menstrual cycles.
11614630|NCT00534833|Experimental|Group 1|DTaP-Hep B-PRP-T + OPV vaccine group
11614631|NCT00534833|Active Comparator|Group 2|Tritanrix-HepB/Hib™ + OPV vaccine group
11614632|NCT00534794|Experimental|Elestat|
11614633|NCT00534794|Active Comparator|Pataday|
11614634|NCT00534781|Experimental|A|plasma microtenotomy
11614635|NCT00534781|Active Comparator|B|Standard Surgical Debridement
11614636|NCT00534768|Active Comparator|1|debridement on 1st, 3-5th and 7th postoperative days
11614637|NCT00534768|Active Comparator|2|
11614638|NCT00534755|Other|Breast database|Database
11614639|NCT00534703|Active Comparator|AAV1/SERCA2A|SERCA gene therapy
11614640|NCT00534703|Placebo Comparator|Placebo|Placebo (saline solution)
11614641|NCT00534690|Other|1|
11614642|NCT00534690|Other|2|
11614643|NCT00534677|Active Comparator|A|
11614644|NCT00534677|Active Comparator|B|
11614727|NCT00534053|Experimental|1|400 patients will be given a mailed educational reminder 10 days after picking up their FOBT cards from the VA laboratory.
11614825|NCT00533104|Experimental|BM-MNC|Patients are implanted with bone marrow - mononuclear cells
11634741|NCT00313248|Experimental|Arm 1|
11614645|NCT00534638|Experimental|Cervarix/Engerix-B A Group|The A group includes subjects from communities where 70% of male and female adolescents were to be vaccinated with Cervarix vaccine. To achieve a Cervarix vaccination coverage of 70%, a 9:1 ratio was used to allocate study participants to receive Cervarix vaccine versus control Engerix-B vaccine (meaning 90% of vaccinated subjects were randomized to Cervarix). Finally, subjects from A group were either vaccinated with Cervarix, Engerix-B (control vaccine), or not vaccinated (enrolled control without vaccination). Vaccines were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
11614646|NCT00534638|Experimental|Cervarix/Engerix-B B Group|The B group includes subjects from communities where 70% of female adolescents were to be vaccinated with Cervarix vaccine. To achieve a Cervarix vaccination coverage of 70%, a 9:1 ratio was used to allocate female participants to receive Cervarix vaccine versus control Engerix-B vaccine (meaning 90% of vaccinated females were randomized to Cervarix). In this group, all male adolescents were to be vaccinated with Engerix-B control vaccine. Finally, subjects from B group were either vaccinated with Cervarix (females) or Engerix-B/not vaccinated (males and females). Vaccines were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
11614647|NCT00534638|Active Comparator|Engerix-B Group|In this control group, all adolescents were to be vaccinated with Engerix-B control vaccine. Finally, subjects from this group were either vaccinated with Engerix-B or not vaccinated. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
11614648|NCT00534625|Placebo Comparator|1|
11614649|NCT00534625|Experimental|2|150 mg zileuton by intravenous injection
11614650|NCT00534625|Experimental|3|300 mg zileuton by intravenous injection
11614651|NCT00534612|Experimental|1|fine needle aspiration biopsy of the parotid gland mass
11614652|NCT00534599|Other|1|Adjunctive Placebo Seroquel XR to anxiety treatment
11614653|NCT00534599|Experimental|2|Adjunctive Seroquel XR to anxiety treatment
11614654|NCT00534586|Active Comparator|1|remifentanil
11614655|NCT00534586|Active Comparator|2|propofol
11614656|NCT00534586|Active Comparator|3|sevoflurane
11614657|NCT00534586|Active Comparator|4|s-ketamine
11614658|NCT00534573|Active Comparator|Moclobemide,|treatment during 2 weeks
11614659|NCT00534573|Active Comparator|Amisulpride|Comparison
11614660|NCT00534560|Experimental|1|
11614661|NCT00534560|Experimental|2|
11614662|NCT00534560|Placebo Comparator|3|
11614663|NCT00534534|Active Comparator|1|All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion. No drugs will be used. In addition, they also will undergo repeated similar interventions at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
11614664|NCT00534534|No Intervention|Standard|All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion. No drugs will be used. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
11614665|NCT00534521|Active Comparator|Active Treatment Arm|Subjects will have their leg and foot draped to remain blinded to the test. They will be in a supine position with the knees abducted and flexed. The medial aspect of the lower extremity is palpated and a needle insertion site is identified. Between the posterior margin of the tibia and the soleus muscle, an acupuncture-like needle is inserted. An adhesive grounding pad is placed on the bottom of the foot just below the smallest toe. The needle and grounding pad are connected to the stimulator and the stimulation is increased as tolerated.
11614666|NCT00534521|Sham Comparator|Sham Arm|"Since subjects with the PTNS will feel foot stimulation, the sham was devised to mimic this feeling without the tibial nerve being stimulated. Again the leg and foot will be draped and out of view from the subject. The medial aspect of the lower extremity is palpated (Figure 4) and the tibial nerve site is identified approximately 5 cm cephalad from the medial malleolus. A Streitberger needle is used at the tibial nerve insertion site to simulate needle placement without puncturing the skin. The needle will be taped in place as in the PTNS procedure. The grounding pad will be a gel electrode pad from a TENS unit device that is placed on the bottom of the foot just below the smallest toe."
11614667|NCT00534495|Experimental|Group 1|Loading dose of rilonacept (4.4mg/kg) at Week 0, followed by rilonacept 2.2 mg/kg/week for the remainder of the study
11614668|NCT00534495|Placebo Comparator|Group 2|Placebo for 4 weeks, followed by rilonacept loading dose (4.4mg/kg), followed by rilonacept 2.2 mg/kg/week for the remainder of the study
11614669|NCT00534482|Experimental|A, 1, I|Practice-level treatment group
11614670|NCT00534482|Active Comparator|A, 1, II|Practice-level comparison group
11614671|NCT00534482|Experimental|B, 1, I|Patient-level treatment group
11614672|NCT00534482|Active Comparator|B, 1, II|Patient-level comparison group
11614673|NCT00534469|Active Comparator|HD ARA-C with Idarubicin|HD ARA-C with Idarubicin Consolidation, Busulfan/FTBI/VP16/PSC/BMT
11614674|NCT00534469|Active Comparator|HD ARA-C without Idarubicin|HD ARA-C Consolidation, Busulfan/FTBI/VP16/PSC/BMT
11614675|NCT00534456|Experimental|Active|
11614676|NCT00534456|Placebo Comparator|Placebo|
11614677|NCT00534443|Experimental|1|A total of 130 patients with peptic ulcer disease and /or chronic gastritis will be enrolled in the study after written informed consent. Patients will be prescribed oral treatment with rabeprazole or esomeprazole according to standard guidelines. Rabeprazole is administered 20mg twice daily and esomeprazole 10 mg once daily. Selection of rabeprazole or esomeprazole is at the discretion of the attending physicians. The drug is administered for four weeks in patients with duodenal ulcers, for eight weeks in patients with gastric ulcers and for four weeks in patients with chronic gastritis.
11614678|NCT00534430|Experimental|Busulfan, FTBI and VP16|IV Busulfan + 12 cGy FTBI + VP16 prior to allogeneic Bone Marrow Transplant
11614679|NCT00534417|Experimental|Capecitabine and fulvestrant|"Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po AM and 500 mg po PM in patients of body weight < 80 kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 kg.
~Fulvestrant will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days."
11614779|NCT00533585|Experimental|BAY 43-9006 + Bevacizumab|BAY 43-9006 (Sorafenib) + Bevacizumab + Paclitaxel + Carboplatin
11614680|NCT00534404|Experimental|NRT Patch, Phone Counseling, Internet|As adjuncts to internet-assisted tobacco treatment (iQuit Smoking website), research participants in this arm will have access to free 8-week supply of nicotine patches, contingent upon participation in proactive telephone counseling. Patch therapy will begin with the 21 mg patch for 4 weeks, followed by 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks.
11614681|NCT00534404|Active Comparator|Nicotine Patches and Internet|As adjuncts to internet-assisted tobacco treatment (iQuit Smoking website), research participants in this arm will have access to free 8-week supply of nicotine patches. Patch therapy will begin with the 21 mg patch for 4 weeks, followed by 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks.
11614682|NCT00534404|Placebo Comparator|Internet|Research participants in this arm will have free access to internet-assisted tobacco treatment (iQuit Smoking website).
11614683|NCT00534391|Placebo Comparator|B|Artificial tear containing antibiotic solution base
11614684|NCT00534391|Experimental|A|combined antibiotic ophthalmic solution (neomycin sulfate, polymyxin B sulfate and gramicidin)
11614685|NCT00534378|No Intervention|1|
11614686|NCT00534365|Active Comparator|1|Tension-free vaginal tape procedure (TVT)
11614687|NCT00534365|Active Comparator|2|TVT-SECUR device
11614688|NCT00534352|Experimental|001|TMC125; darunavir; ritonavirTMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
11614689|NCT00534326|Active Comparator|1|Standard Reaming of femoral shaft fracture prior to intramedullary nailing
11614690|NCT00534326|Active Comparator|2|Reamer/Irrigator/Aspirating of femoral shaft fracture prior to intramedullary nailing
11614691|NCT00534313|Active Comparator|Abatacept (30/10)|Abatacept (30 mg/kg) was administered as intravenous (iv) infusion over approximately 30 minutes on Days 1 and 15, followed by 10 mg/kg (fixed dose) abatacept infusion on Day 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants for dosing on Days 1 and 15 followed by fixed dosing as per rheumatoid arthritis label (participants weighing <60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing >100 kg received 1000 mg) thereafter.
11614692|NCT00534313|Active Comparator|Abatacept (10/10)|Abatacept (10 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141 in the double-blind period and continued for next 18 months in the open-label period till Day 729. All participants received a dose based on their screening visit weight as per rheumatoid arthritis label (participants weighing <60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing >100 kg received 1000 mg).
11614693|NCT00534313|Active Comparator|Abatacept (3/3)|Abatacept (3 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants.
11614694|NCT00534313|Placebo Comparator|Placebo|Placebo solution (5% dextrose in water for injection, 0.9% sodium chloride injection) by iv infusion was administered on Days 1, 15, and 29 and every 28 days thereafter till Day 141.
11614695|NCT00534300|Experimental|A|
11614696|NCT00534300|Placebo Comparator|B|
11614697|NCT00534287|Active Comparator|MeroMono|Monotherapy with meropenem
11614698|NCT00534287|Active Comparator|MeroMoxi|Combination therapy with meropenem + moxifloxacin
11614699|NCT00534274|Experimental|TEP FLT|
11614700|NCT00534261|Experimental|1|patients received Avonex IM injections and be evaluated for quality of life criteria
11614701|NCT00534248|Experimental|Zostavax™|Participants randomized to receive Zoster Vaccine, Live (Zostavax™).
11614702|NCT00534248|Placebo Comparator|Placebo|Participants randomized to receive Placebo.
11614703|NCT00534235|Active Comparator|Posterolateral Fusion w/Pedicle Screws|Control: Posterolateral fusion and implantation of pedicle screws after decompression
11614704|NCT00534235|Active Comparator|coflex Interlaminar Technolgy|Investigative: Implantation of coflex Interlaminar Technology after decompression
11614705|NCT00534222||Quetiapine|
11614706|NCT00534222||Olanzapine|
11614707|NCT00534222||Risperidone|
11614708|NCT00534209|Experimental|Arm I: Allogeneic B7.1/HLA-A1|"Patients will receive Allogeneic B7.1/HLA-A1 vaccine once every other week for 2 courses over 12 weeks, for a maximum of 6 vaccines.
~Given intradermally."
11614709|NCT00534209|Placebo Comparator|Arm II: Placebo|Patients receive a placebo vaccine intradermally once every other week for 2 courses over 12 weeks, for a maximum of 6 vaccines.
11614710|NCT00534196||Group under operation of brachytherapy|Patients with histologically confirmed adenocarcinoma of the prostate and who are planning to undergo brachytherapy with PI (permanent iodine) or combination of PI with other tratement.
11614711|NCT00534183|Experimental|1|Olanzapine
11614712|NCT00534183|Active Comparator|2|Risperidone
11614713|NCT00534183|Active Comparator|3|haloperidol
11614714|NCT00534170|Experimental|A,F,T,K|Two arms are for intervention and two are for control or placebo
11614715|NCT00534144|Active Comparator|Iron Sucrose|
11614716|NCT00534144|Active Comparator|Ferric Gluconate|
11614717|NCT00534131|Active Comparator|Arm 1|Patients for whom a standard abdominal approach is adequate to excise the distal third of the rectum (without jeopardising oncological clearance if appropriate).
11614718|NCT00534131|Experimental|Arm 2|Combined abdominal and trans-perineal approach to excise the distal third of the rectum, while preserving the anal canal
11614719|NCT00534131|Active Comparator|Arm 3|Standard proctectomy to excise the distal third of the rectum and the anal canal
11614720|NCT00534118|Experimental|Infusion|Patients receive up to four donor lymphocyte infusions at least 1 month apart in the absence of disease progression, unacceptable toxicity, or uncontrolled graft-versus-host disease
11614721|NCT00534105||Gestational Diabetics|Patients with Gestational Diabetes
11614722|NCT00534105||2|Normal pregnant women without gestational diabetes
11614723|NCT00534079|Experimental|Dornase alfa|28 days of sinonasal inhalation (Pari Sinus)
11614724|NCT00534079|Placebo Comparator|isotonic saline|28 days of sinonasal inhalation (Pari Sinus)
11614725|NCT00534066||Admitted|Patients presenting to the ED with acute exacerbation of CHF who require admission to the hospital directly from the ED
11614780|NCT00533559|Experimental|buphenyl|
11614728|NCT00534053|No Intervention|2|400 patients will not receive a mailed educational reminder to return their FOBT cards after they have picked up the FOBT cards from the VA laboratory
11614729|NCT00534027|Experimental|Arm 2|Low Dose AMG 655 with paclitaxel/carboplatin
11614730|NCT00534027|Placebo Comparator|Arm 3|Placebo with paclitaxel/carboplatin
11614731|NCT00534027|Experimental|Arm 1|AMG 655 High doseplus paclitaxel/carboplatin
11614732|NCT00534014|Placebo Comparator|A|0 mg of Vitamin C
11614733|NCT00534014|Active Comparator|B|250 mg Vitamin C
11614734|NCT00534014|Active Comparator|C|500 mg Vitamin C
11614735|NCT00534014|Active Comparator|D|1000 mg Vitamin C
11614736|NCT00534001|Experimental|Arm I (1-week run-in)|Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
11614737|NCT00534001|Experimental|Arm II (4-week run-in)|Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
11614738|NCT00533988|No Intervention|5592|Standard triple lumen catheter
11614739|NCT00533988|Active Comparator|5593|Antimicrobial impregnated catheter (chlorhexidine silver-sulfadiazine)
11614740|NCT00533949|Active Comparator|60 Gy RT|60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
11614741|NCT00533949|Experimental|74 Gy RT|74 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
11614742|NCT00533949|Experimental|60 Gy RT + Cetuximab|60 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin
11614743|NCT00533949|Experimental|74 Gy RT + Cetuximab|74 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin
11614744|NCT00533910|Placebo Comparator|Placebo|Will be given placebo and follow the exact procedures as the experimental section
11614745|NCT00533910|Experimental|Drug|
11614746|NCT00533897|Experimental|Abatacept|
11614747|NCT00533897|Placebo Comparator|Placebo|
11614748|NCT00533884||Treatment|Patients undergoing treatment for head and neck, lung, and esophagus cancers
11614749|NCT00533871||Normotensive|Pregnant women in the third trimester with normal blood pressure this pregnancy and no history of HTN or pre-eclampsia in a previous pregnancy
11614750|NCT00533871||Chronic Hypertensive|Pregnant women in their third trimester with known hypertension prior to the current pregnancy
11614751|NCT00533871||Pre-eclampsia|Pregnant women in their third trimester who meet ACOG diagnostic criteria for pre-eclampsia
11614752|NCT00533845|Experimental|On-Q pain pump|Bupivacaine
11614753|NCT00533845|Placebo Comparator|Placebo/control|Saline
11614754|NCT00533832|Active Comparator|1|Patients implanted with the vagus nerve stimulation (VNS) device and receiving VNS Intervention: vagus nerve stimulation (VNS)
11614755|NCT00533832|Placebo Comparator|2|Implanted with vagus nerve stimulation (VNS) device, but not receiving VNS
11614756|NCT00533819|Experimental|1|
11614757|NCT00533819|No Intervention|2|would have routine physical activity
11614758|NCT00533806|Experimental|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy.
11614759|NCT00533806|Active Comparator|Relaxation therapy.|Participants will receive relaxation therapy.
11614760|NCT00533793|Active Comparator|SoC|Standard of Care
11614761|NCT00533793|Active Comparator|SoC plus 0.133 mg/mL|
11614762|NCT00533793|Active Comparator|SoC plus 0.4 mg/mL|
11614763|NCT00533793|Active Comparator|SoC plus 1.0 mg/mL|
11614764|NCT00533741|Experimental|1c (10 mcg)|4 subjects randomized in a 1:3 fashion to receive a two dose regimen of placebo or vaccine with 10 mcg of antigen and no adjuvant.
11614765|NCT00533741|Experimental|2 (dose comparison stage)|54 subjects (9 per vaccine group) randomized 1:1:1:1:1:1 to receive vaccines containing, 2.5, 5.0, or 10.0 mcg of antigen without adjuvant, or 2.5 or 5.0 mcg of antigen with Alum, or placebo.
11614766|NCT00533741|Experimental|1a (2.5 mcg)|7 subjects randomized in a 1:3:3 fashion to receive a 2 dose regimen of placebo, vaccine containing 2.5 mcg of antigen and no adjuvant, or 2.5 mcg of antigen and Alum adjuvant.
11614767|NCT00533741|Experimental|1b (5.0 mcg)|7 subjects randomized in a 1:3:3 fashion to receive a 2 dose regimen of placebo, vaccine containing 5.0 mcg of antigen and no adjuvant, or 5.0 mcg of antigen and Alum adjuvant.
11614768|NCT00533715||>100|"The study included healthy children (2.5-6.5 years old) from a number of public kindergartens. An initial screening questionnaire based on the ATA-DLD-78-A for adults, adapted for children and translated into Hebrew, concerning the child's birth, past and present health status, was completed by the parents.
~Exclusion criteria: Previous symptoms or treatment for asthma, current respiratory symptoms or other present respiratory diseases."
11614769|NCT00533702|Experimental|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab)
11614770|NCT00533702|Active Comparator|IMC-1121B (ramucirumab) + dacarbazine|IMC-1121B (ramucirumab) + dacarbazine
11614771|NCT00533663|Experimental|Healing Touch (HT)|A a gentle, non-invasive form of energy-balancing work that promotes relaxation and can help manage the side effects of chemotherapy. It occurs every other week (during their infusion).
11614772|NCT00533663|Active Comparator|Guided relaxation|Guided relaxation every other week (during their infusion).
11614773|NCT00533663|Active Comparator|standard care|Standard care
11614774|NCT00533637|Experimental|1|NLA Nasal Spray
11614775|NCT00533637|Active Comparator|2|
11614776|NCT00533637|Placebo Comparator|3|
11614777|NCT00533624|Active Comparator|1: Myfortic|Myfortic Group: Myfortic® 1,440 mg/day in two divided doses (induced with either the IL-2 receptor inhibitors or thymoglobulin). Tacrolimus will be dosed to 12-hour trough levels of 8-10 ng/ml. Methylprednisolone is to be given as per our center protocols, weaning to dose levels of <0.1 mg/kg by 3-6 months post-operatively.
11614778|NCT00533624|Active Comparator|2. Cellcept|Cellcept® 2,000 mg/day, in divided doses (induced with either the IL-2 receptor inhibitors or thymoglobulin). Tacrolimus will be dosed to 12-hour trough levels of 8-10 ng/ml. Methylprednisolone is to be given as per our center protocols, weaning to dose levels of <0.1 mg/kg by 3-6 months post-operatively.
11614782|NCT00533546|Experimental|Tier One|Participants will receive APC by intravenous injection, receiving 50% of dose as a bolus and the remainder as an infusion over one ho.
11614783|NCT00533520|Active Comparator|0.5mg ranibizumab|Subjects will be treated with 0.5mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
11614784|NCT00533520|Active Comparator|1.0mg ranibizumab|Subjects will be treated with 1.0mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
11614785|NCT00533520|Active Comparator|2.0mg ranibizumab|Subjects will be treated with 2.0 mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
11614786|NCT00533507|Experimental|Synflorix group|Subjects receiving Synflorix co-administered with Infanrix™ hexa at 1.5, 3 and 6 months of age, and co-administered with Rotarix™ at 1.5 and 3 months of age.
11614787|NCT00533494|Active Comparator|B|Feedback to physicians + reminder letters to patients
11614788|NCT00533494|Active Comparator|A|Feedback information to physicians
11614789|NCT00533442|Active Comparator|Tacrolimus plus MMF plus Steroids|Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Mycophenolate Mofetil (MMF), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.
11614790|NCT00533442|Experimental|Tacrolimus plus Rapamycin plus Steroids|Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Rapamycin (Sirolimus), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.
11614791|NCT00533429|Experimental|A|
11614792|NCT00533429|Placebo Comparator|B|
11614793|NCT00533390|Experimental|EFAVIRENZ 800mg|Efavirenz 800 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin
11614794|NCT00533390|Active Comparator|EFAVIRENZ 600mg|Efavirenz 600 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin
11614795|NCT00533377|Experimental|CP-533,536 Dose Level 2|
11614796|NCT00533377|Placebo Comparator|Placebo|
11614797|NCT00533377|Other|Standard of Care|
11614798|NCT00533377|Experimental|CP-533,536 Dose Level 1|
11614799|NCT00533377|Experimental|CP-533,536 Dose Level 3|
11614800|NCT00533377|Experimental|CP-533.536 Dose Level 4|
11614801|NCT00533351|Experimental|AGN201781|AGN201781 50 mg capsules three-time daily for 2 weeks
11614802|NCT00533351|Placebo Comparator|Placebo|placebo 50 mg capsules three-times daily for 2 weeks
11614803|NCT00533338|Experimental|Weight Gain Prevention Program|Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling. Packet of questionnaires will be completed.
11614804|NCT00533338|Active Comparator|Standard Care Group|Packet of questionnaires will be completed.
11614805|NCT00533299|Experimental|1|Topotecan hydralazine valproate
11614806|NCT00533299|Placebo Comparator|2|Placebo, hydralazine, valproate
11614807|NCT00533286|Placebo Comparator|A|placebo (2 tablets daily)
11614808|NCT00533286|Experimental|B|diazepam (2 x 5 mg)
11614809|NCT00533273|Experimental|AA4500 0.58 mg|
11614810|NCT00533273|Placebo Comparator|Placebo|
11614811|NCT00533221|Active Comparator|Somatotropin|subcutaneous application of somatotropin over 12 weeks followed by 8 weeks wash out period followed by 12 weeks subcutaneous placebo application
11614812|NCT00533221|Placebo Comparator|Placebo|12 weeks placebo subcutaneous application followed by 8 weeks wash out and 12 weeks subcutaneous application of somatotropin
11614813|NCT00533195|Active Comparator|0|5-MOP photochemotherapy. Intake of Geralen capsules (1.2 mg/kg) 2 hours before irradiation. Determination of the minimal phototoxic dose (MPD) and Geralen serum level prior to treatment. Start with 70 % of the MPD, no dose increments in the first treatment week. From the second week increments of the UVA dose by 20 % in the absence of an erythemal reaction, respectively by 10 % in cases of a barely perceptible erythemal response. Increments of the UVA dose at the earliest 96 hours after the last increments. Treatment frequency 3 x week for 5 weeks (=15 exposures). No maintenance therapy except emollients.
11614814|NCT00533195|Experimental|1|UVA1 phototherapy. Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability. No maintenance therapy except emollients.
11614815|NCT00533182||1|Patients with known or suspected influenza infection
11614816|NCT00533182||2|Patients at the Washington Hospital Center
11614817|NCT00533182||3|Healthy Pregnant Women (Control):
11614818|NCT00533169|Experimental|ZD6474 + Retinoic Acid|Part A = ZD6474 Alone, Starting dose 50 mg/m^2 by mouth daily for 28 days; Part B, C = ZD6474 + Retinoic Acid 80 mg/m^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
11614819|NCT00533143|Experimental|2|Non-invasive ventilation
11614820|NCT00533130||1|Pediatric patients under 16 years old with long bones fractures
11614821|NCT00533117|Experimental|Dialectical Behavior Therapy Fluoxetine|Dialectal behavior therapy (DBT) is a form of Cognitive behavior therapy (CBT) targeting suicidal and non-suicidal self injury in borderline personality disorder and is delivered over a 12 month period,and fluoxetine, a selective serotonin reuptake inhibitor (SSRI) that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
11614822|NCT00533117|Placebo Comparator|Dialectical Behavior Therapy placebo|Dialectal behavior therapy and placebo Dialectal behavior therapy (DBT) is a form of Cognitive behavior therapy targeting suicidal and non-suicidal self injury in borderline personality disorder and is delivered over a 12 month period, and placebo for fluoxetine, an SSRI that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
11614823|NCT00533117|Experimental|Supportive therapy Fluoxetine|Supportive psychotherapy and fluoxetine Supportive therapy is a manualized psychotherapy aimed at strengthening coping skills and is delivered over a 12 month period, and fluoxetine, an SSRI that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
11614824|NCT00533117|Active Comparator|Supportive therapy placebo|Supportive psychotherapy and placebo See above for descriptions.
11634742|NCT00313248|Experimental|Arm 2|
11614826|NCT00533104|Experimental|PB-MNC|Patients are implanted with peripheral blood - mononuclear cells
11614827|NCT00533091|Active Comparator|1|MEDI-545
11614828|NCT00533091|Other|2|Placebo
11614829|NCT00533078|Other|1|
11614830|NCT00533052|Experimental|Affective and Cognitive Skills Training|Standard Behavioral Weight Loss Treatment Plus Affective and Cognitive Skills Training
11614831|NCT00533039|Placebo Comparator|Control|Subjects take 2 tablets BID. Placebo tablets are identical to active medication.
11614832|NCT00533039|Experimental|Varespladib (A-002)|Subjects take 250mg tablets BID beginning 3-5 days pre-angioplasty and for 5 days post-angioplasty.
11614833|NCT00533026|Active Comparator|A|Subjects received warfarin QD, PO for approximately 12 days. Subjects with stabilized INR after approximately 12 days continued to receive warfarin QD, PO for an additional 14 days and also received duloxetine 60mg QD, PO for the 14 days. Duloxetine doses were tapered, subjects received 30mg QD, PO for 4 days. No warfarin was received during the taper phase.
11614834|NCT00533026|Active Comparator|B|Subjects received warfarin QD, PO for approximately 12 days. Subjects with stabilized INR after approximately 12 days continued to receive warfarin QD, PO for an additional 14 days and also received duloxetine 60 mg QD, PO for 4 days followed by duloxetine 120 mg QD, PO for 10 days. Duloxetine doses were tapered, subjects received 60mg QD, PO for 4 days followed by 30mg QD, PO for 4 days. No warfarin was received during the taper phase.
11614835|NCT00533013|Active Comparator|Usual care|Management of heart failure is provided by primary practitioners and consultant cardiologists
11614836|NCT00533013|Experimental|Disease Management|Disease management led by nurse specialists in regional Heart Failure Clinics and a national Call Center. Tele-Monitoring of body weight, pulse rate and blood pressure is performed at participants' homes.
11614837|NCT00533000|Experimental|A|Smoking cessation
11614838|NCT00533000|No Intervention|B|
11614839|NCT00532961|Experimental|Zylet|Zylet (loteprednol etabonate and tobramycin)
11614840|NCT00532961|Active Comparator|Tobradex|TobraDex (dexamethasone and tobramycin)
11614841|NCT00532948|Experimental|1|
11614842|NCT00532935|Experimental|1|Sitagliptin phosphate (+) metformin hydrochloride
11614843|NCT00532935|Active Comparator|2|pioglitazone
11614844|NCT00532922||1|Chinese asthma patient prescribed Symbicort® Turbuhaler®
11614845|NCT00532896||bariatric surgery|patients with morbid obesity undergoing a bariatric surgery
11614846|NCT00532896||No bariatric surgery|patients with morbid obesity on a waiting list for a bariatric surgery but who will have their surgery in more than one year.
11614847|NCT00532883|Placebo Comparator|Placebo Pills and Placebo Liquid|
11614848|NCT00532883|Active Comparator|Hydroxyurea Pills and Placebo Liquid|
11614849|NCT00532883|Active Comparator|Placebo Pills and Magnesium Pidolate Liquid|
11614850|NCT00532883|Active Comparator|Hydroxyurea Pills and Magnesium Pidolate Liquid|
11614851|NCT00532870|Active Comparator|1|laparoscopy
11614852|NCT00532857|Experimental|Paclitaxel/Gemcitabine/Trastuzumab|
11614853|NCT00532844|Experimental|6R-BH4|6R-BH4 5 mg/kg BID for 13.5 days
11614854|NCT00532844|Experimental|6R-BH4 + Vitamin C|6R-BH4 5 mg/kg BID + 500 mg Vitamin C BID for 13.5 days
11614855|NCT00532831||Obese asthmatics|Obese subjects with asthma (on inhaled bd only)
11614856|NCT00532831||Non-obese asthmatics|Non-obese subjects with asthma(on inhaled bd only)
11614857|NCT00532818|Placebo Comparator|1|
11614858|NCT00532818|Experimental|2|
11614859|NCT00532792|Experimental|Group 1|
11614860|NCT00532792|Experimental|Group 2|
11614861|NCT00532792|Experimental|Group 3|
11614862|NCT00532792|Experimental|Group 4|
11614863|NCT00532792|Experimental|Group 5|
11614864|NCT00532792|Experimental|Group 6|
11614865|NCT00532792|Experimental|Group 7|
11614866|NCT00532792|Experimental|Group 8|
11614867|NCT00532792|Experimental|Group 9|
11614868|NCT00532792|Placebo Comparator|Group 10|
11614869|NCT00532779|Experimental|NB16|Naltrexone SR 16 mg/Bupropion SR 360 mg /day with ancillary therapy
11614870|NCT00532779|Experimental|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg /day with ancillary therapy
11614871|NCT00532779|Placebo Comparator|Placebo|Placebo with ancillary therapy
11614872|NCT00532766|Experimental|2|Jusline Humulin
11614873|NCT00532740||All Patients|Patients with metastatic cancer of the liver who are not surgical resection candidates and who will be treated with TheraSphere per institutional standard of care.
11614874|NCT00532727|Experimental|Arm A|Carboplatin
11614875|NCT00532727|Active Comparator|Arm B|Docetaxel
11614876|NCT00532714|No Intervention|Irinotecan plus capecitabine|Irinotecan 80 mg/m2 (intravenously once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period) Capecitabine (orally at a dose of 1,000 mg/m2 twice daily 3-week cycles (2 weeks of treatment followed by a 1-week rest period))
11614877|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 16 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-16 in patients with RVR
11614878|NCT00532701|Active Comparator|Peg-IFN + LD RBV for 16 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-6, and then low dose ribavirin (800 mg/day) from weeks 6-16 in patients with RVR
11614879|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 24 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-24 in patients without RVR
11614880|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 48 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-48 in patients without RVR
11614881|NCT00532701|Active Comparator|Peg-IFN + LD RBV for 24 weeks|Low dose ribavirin (800 mg/day) from weeks 1-24 in patients with or without RVR
11614882|NCT00532688|Experimental|1|5 patients: 28 days of n-acetylcysteine (in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period.
11614883|NCT00532688|Placebo Comparator|2|28 days of oral distilled water (5ml) (in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to intervention (N-acetylcysteine 500mg oral bd) for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
11614884|NCT00532675|Experimental|PAN 5 mg|Panobinostat 5 mg
11614885|NCT00532675|Experimental|PAN 10 mg|Panobinostat 10 mg
11614886|NCT00532675|Experimental|PAN 20 mg|Panobinostat 20 mg
11614888|NCT00532662|Experimental|1|epidural s(+)-ketamine for supplementation of caudal anesthesia
11614889|NCT00532662|Active Comparator|2|intravenous ketamine for supplementation of caudal anesthesia
11614890|NCT00532636|Active Comparator|1|Children 1-5 years of age
11614891|NCT00532636|Active Comparator|2|Children 6-10 years of age
11614892|NCT00532623|Active Comparator|Combination|
11614893|NCT00532623|Active Comparator|Seqeuntial|"Gemcitabine monotherapy followed by Vinorelbine monotherapy:
~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."
11614894|NCT00532597|Experimental|O|
11614895|NCT00532597|Active Comparator|L|
11614896|NCT00532584|Experimental|treatment with inhaled beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
11614897|NCT00532584|No Intervention|Control - healthy smokers|Group B will act as control and include healthy smokers who receive no treatment.
11614898|NCT00532584|No Intervention|control - healthy non-smokers|Group C will act as control and include healthy non-smokers who receive no treatment.
11614899|NCT00532558|Experimental|Lapaquistat Acetate 50 mg QD|
11614900|NCT00532558|Placebo Comparator|Placebo QD|
11614901|NCT00532545|Experimental|A|Teriparatide
11614902|NCT00532532|Experimental|1|AV650 low dose
11614903|NCT00532532|Experimental|2|AV650 high dose
11614904|NCT00532532|Experimental|3|Placebo
11614905|NCT00532493|Active Comparator|Prazosin Group|Subjects randomized to this arm will be on prazosin.
11614906|NCT00532493|Placebo Comparator|Placebo Group|Subjects randomized to this arm will be on placebo.
11614907|NCT00532480|Other|Duolxetine|Open-label duloxetine 30 - 60 mg oral administration
11614908|NCT00532454|Other|tamoxifen|observation for clinical efficacy on tamoxifen according to CYP2D6 genotype
11614909|NCT00532441|Experimental|Erlotinib and Docetaxel: Biliary|"Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28
~Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15"
11614910|NCT00532441|Experimental|Erlotinib and Docetaxel: Hepatocellular|"Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28
~Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15"
11614911|NCT00532428|Active Comparator|1|
11614912|NCT00532428|Active Comparator|2|
11614913|NCT00532428|Placebo Comparator|3|
11614914|NCT00532415|Experimental|Triamcinolone|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
11614915|NCT00532389|Experimental|Panobinostat (LBH589)|
11614916|NCT00532363||Obese asthmatics|Obese subjects with asthma (on inhaled corticosteroids)
11614917|NCT00532363||Non obese asthmatics|Non obese subjects with asthma (on inhaled corticosteroids)
11614918|NCT00532350|Experimental|1|QAT370
11614919|NCT00532350|Placebo Comparator|2|Placebo
11614920|NCT00532350|Active Comparator|3|Tiotropium
11614921|NCT00532337|Placebo Comparator|P|
11614922|NCT00532337|Experimental|E1|
11614923|NCT00532337|Experimental|E2|
11614924|NCT00532337|Experimental|E3|
11614925|NCT00532337|Active Comparator|A|
11614926|NCT00532324|No Intervention|A|Pregnant women not receiving CA-MRSA decolonization therapy.
11614927|NCT00532324|Other|B|Pregnant women receiving CA-MRSA decolonization therapy.
11614928|NCT00532311|Experimental|Lapaquistat Acetate 50 mg QD|(and stable statin therapy)
11614929|NCT00532311|Active Comparator|Stable statin therapy|
11614930|NCT00532298|Experimental|GSK576389A- 2006/2007 Season - 1 container Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.
11614931|NCT00532298|Experimental|GSK576389A - 2006/2007 Season - 2 containers Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.
11614932|NCT00532298|Active Comparator|Fluarix 2006/2007 Season Group|Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
11614933|NCT00532298|Experimental|GSK576389A - 2007/2008 Season - 1 container Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.
11614934|NCT00532298|Experimental|GSK576389A - 2007/2008 Season - 2 containers Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.
11614935|NCT00532298|Active Comparator|Fluarix 2007/2008 Season Group|Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
11614936|NCT00532285|Experimental|Paclitaxel/Gemcitabine|paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8) every 3 weeks, 4 cycles
11614937|NCT00532272|Experimental|letrozole|letrozole(2.5mg orally daily)
11614938|NCT00532272|Active Comparator|goserelin plus letrozole|goserelin (3.6mg subcutaneously every 28 days) plus letrozole(2.5mg orally daily)
11614939|NCT00532259|Experimental|CT-011|The monoclonal antibody termed CT-011 (currently, pidilizumab).
11614940|NCT00532246|Experimental|A|raloxifene
11614941|NCT00532246|Placebo Comparator|B|placebo
11614942|NCT00532233|Experimental|1|QAX576
11614943|NCT00532220|Active Comparator|A|
11614944|NCT00532220|Placebo Comparator|B|
11614945|NCT00532207|Experimental|A|
11614946|NCT00532194|Placebo Comparator|A (reference)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral placebo tablet for the duration of chemotherapy and then until protocol defined disease progression occurs.
11614947|NCT00532194|Active Comparator|B (concurrent cediranib)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy only and then an oral daily placebo tablet until protocol defined disease progression occurs.
11614999|NCT00531752|Placebo Comparator|Placebo|
11614948|NCT00532194|Active Comparator|C (concurrent and maintenance cediranib)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy until protocol defined disease progression occurs.
11614949|NCT00532168|Experimental|1|tenofovir plus emtricitabine plus efavirenz
11614950|NCT00532168|Experimental|2|tenofovir plus emtricitabine plus lopinavir-ritonavir
11614951|NCT00532168|Experimental|3|tenofovir plus emtricitabine plus atazanavir-ritonavir
11614952|NCT00532155|Experimental|Placebo/Docetaxel|Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Placebo immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
11614953|NCT00532155|Placebo Comparator|Aflibercept/Docetaxel|Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Aflibercept immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
11614954|NCT00532129|Experimental|Rituximab plus Chlorambucil|Participants will receive combination therapy of rituximab plus chlorambucil for first 6 cycles and then chlorambucil alone for a maximum of 6 additional cycles.
11614955|NCT00532116|Active Comparator|A|EMSAM 6mg
11614956|NCT00532116|Active Comparator|B|EMSAM (Selegiline Transdermal System) 12mg
11614957|NCT00532090|Experimental|1|
11614958|NCT00532090|Experimental|2|
11614959|NCT00532090|Experimental|3|
11614960|NCT00532064||Ancillary-correlative (biospecimen collection)|Patients receive sunitinib malate or sorafenib chemotherapy then undergo blood collection 2 weeks later, and then every 4-6 weeks for up to 6 months to test for troponin I and BNP.
11614961|NCT00532025|Experimental|1|Sorafenib treatment
11614962|NCT00531999|Active Comparator|1|Raltegravir 400 mg twice daily for the first 14 days of the study. Lopinavir/ritonavir 400/100 mg twice daily for the last 14 days of the study
11614963|NCT00531999|Active Comparator|2|"Lopinavir/ritonavir 400/100 mg twice daily for the first 14 days of the study.
~Raltegravir 400 mg twice daily for the last 14 days of the study."
11614964|NCT00531986|Experimental|Monotherapy|Ritonavir-boosted lopinavir (Kaletra®) will be used as monotherapy
11614965|NCT00531986|Active Comparator|Continued ART|Continuation Therapy, conventional triple HAART
11614966|NCT00531973|Experimental|A|Liposomal doxorubicin
11614967|NCT00531973|Active Comparator|B|epirubicin
11614968|NCT00531960|Active Comparator|Bevacizumab, Chemotherapy|Participants received bevacizumab, 15 milligrams (mg) per (/) kilogram (kg), intravenously (IV), on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received 4 to 6 cycles of a standard platinum-containing regimen of chemotherapy: either gemcitabine, 1250 mg/ square meter (m^2), IV, on Days 1 and 8 of Cycles 1 through 4 or 6, and cisplatin 80 mg/m^2, IV, on Day 1 of Cycles 1 through 4 or 6; or paclitaxel, 200 mg/m^2, IV, and carboplatin area under the curve (AUC) 6 mg/ milliliter (ml) multiplied by (*) minute (min) on Day 1 of Cycles 1 through 4 or 6. The chemotherapy regimen and number of cycles was up to the discretion of the investigator.
11614969|NCT00531960|Experimental|Bevacizumab, Erlotinib|Participants received bevacizumab, 15 mg/kg, IV, on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received erlotinib, 150 mg, orally (PO), daily until disease progression, unacceptable toxicity, death, or withdrawal.
11614970|NCT00531947|Experimental|EMSAM|Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg
11614971|NCT00531947|Placebo Comparator|Placebo|Placebo Selegiline Transdermal System 6, 9 or 12
11614972|NCT00531934|Experimental|1|
11614973|NCT00531934|Active Comparator|2|
11614974|NCT00531921||Kidney transplants|patients from 5 specific sites
11614975|NCT00531921||Liver transplants|patients from 5 specific sites
11614976|NCT00531921||Heart transplants|patients from 5 specific sites
11614977|NCT00531921||Lung transplants|patients from 5 specific sites
11614978|NCT00531908|Experimental|A|To compare natriuretic effect of a single dose administration of amiloride (20 mg) in patients with acromegaly
11614979|NCT00531882|Experimental|1-pioglitazone|Pioglitazone
11614980|NCT00531882|Experimental|2-simvasatin|Simvastatin
11614981|NCT00531882|Active Comparator|3-Ibuprofen 1000-1600 mg/day|Ibuprofen 1000-16-- mg/day, maximum 3200 mg/day
11614982|NCT00531856|Experimental|1|5.97 mg/L of carbon monoxide in 30% oxygen
11614983|NCT00531856|Placebo Comparator|2|Oxygen 30% in Nitrogen
11614984|NCT00531843|Experimental|1A|Patients at high risk for venous thromboembolism (criteria: age>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with Abbreviated Injury Scale (AIS) >=3). These patients will receive fondaparinux 2.5mg via subcutaneous administration (SubQ) daily.
11614985|NCT00531843|Active Comparator|1B|Patients at high risk for venous thromboembolism (criteria: age>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with AIS >=3) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure with creatine clearance <30 mL/min, head injury with head AIS >=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression.
11614986|NCT00531843|Experimental|2A|Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days >3, 2 or more high risk factors). These patients will receive fondaparinux 2.5mg SubQ daily and mechanical compression.
11614987|NCT00531843|Active Comparator|2B|Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days >3, 2 or more high risk factors) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure creatine clearance <30 mL/min, head injury with head AIS >=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression and possibly temporary inferior vena cava (IVC) filter(as determined by the patient's care givers).
11614988|NCT00531830||1|Preschool children with PDD
11614989|NCT00531830||2|Preschool children without PDD
11614990|NCT00531817|Experimental|Tocilizumab 8 mg/kg + DMARDs|
11614991|NCT00531817|Placebo Comparator|Placebo + DMARDs|
11614992|NCT00531804|Experimental|1|
11614993|NCT00531791|Active Comparator|1|
11614994|NCT00531791|Experimental|2|
11615001|NCT00531739|No Intervention|A|Colorectal Surgery without use of SurgiWrapTM
11615002|NCT00531739|Active Comparator|B|Colorectal Surgery with use of SurgiWrapTM film secured in two study areas: the posterior pelvic rim and directly below the abdominal incision
11615003|NCT00531726|Sham Comparator|B|
11615004|NCT00531726|Experimental|A|
11615005|NCT00531713|No Intervention|1|Usual T4 dose is given
11615006|NCT00531713|Active Comparator|2|20 microgram of T3 is given and 50 microgram of T4 is withdrawn
11615007|NCT00531700|Experimental|I|Exposure to both tailored/targeted health messages about influenza and also to reports about contextualized influenza risk
11615008|NCT00531700|Experimental|II|Exposure to tailored/targeted health messages
11615009|NCT00531700|Experimental|III|Exposure to reports about influenza related contextualized risk
11615010|NCT00531700|Active Comparator|IV|Comparison group exposed to community level health promotion messages not generated by the study
11615011|NCT00531687|Other|GCT|cisplatin Paclitaxel gemcitabine
11615012|NCT00531674|Experimental|1|Nutritional supplementation for pregnant and lactating women
11615013|NCT00531674|Experimental|2|Nutritional supplementation for children
11615014|NCT00531661|Active Comparator|TREATMENT Group|Standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System
11615015|NCT00531661|Placebo Comparator|CONTROL Group|Standard of care HF management
11615016|NCT00531648||1|Families with toddlers that having feeding disorders and SPD
11615017|NCT00531622|Experimental|Saredudant/Escitalopram|Saredutant 100 mg and Escitalopram 10 mg once daily for a maximum of 8 weeks
11615018|NCT00531622|Active Comparator|Placebo and Escitalopram|Placebo for saredutant and Escitalopram 10 mg once daily for a maximum of 8 weeks
11615019|NCT00531622|Placebo Comparator|Placebo|Placebo for saredutant and Placebo for Escitalopram once daily for one week during the screening phase and for a maximum of 8 weeks during the active phase
11615020|NCT00531596|Active Comparator|A|EMSAM 6mg/24hr
11615021|NCT00531596|Active Comparator|B|EMSAM 9mg/24Hr
11615022|NCT00531596|Active Comparator|C|EMSAM 12mg/24Hr
11615023|NCT00531557|Other|1|Darunavir 600mg BID with ritonavir 100mg BID administered orally.
11615024|NCT00531518|No Intervention|Control group|This is the control arm. Participants will be offered only case management. Participants may seek outside treatment, without guidance from study staff.
11615025|NCT00531518|Experimental|Family-aided Assertive Community Treatment|This is the experimental intervention arm for high-risk-for-psychosis participants. The intervention includes psychiatric drugs (aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine), psychoeducational multifamily group treatment and supported employment and education .
11615026|NCT00531505||2a|Morbid Obese individuals undergoing bariatric surgery (i.e. Laparoscopic Banding, Gastric Bypass). These individuals are a subset population of the greater Longitudinal Assessment of Bariatric Surgery (LABS-1) study population. This subpopulation engaged in memory tests as well as tissue extraction.
11615027|NCT00531492|Experimental|A|
11615028|NCT00531492|Active Comparator|B|
11615029|NCT00531479|Active Comparator|Voriconazole|Voriconazole monotherapy
11615030|NCT00531479|Experimental|Voriconazole and Anidulafungin|Combination therapy with voriconazole and anidulafungin
11615031|NCT00531466|Active Comparator|1|
11615032|NCT00531466|Placebo Comparator|2|
11615033|NCT00531453|Experimental|1|bortezomib, dexamethasone, and thalidomide
11615034|NCT00531453|Experimental|2|bortezomib, dexamethasone, thalidomide, and cyclophosphamide
11615035|NCT00531427|Experimental|1|Buprenorphine transdermal system 10 and 20 applied for 7-day wear
11615036|NCT00531427|Placebo Comparator|2|Placebo transdermal system to match BTDS patches, applied for 7-day wear
11615037|NCT00531362||Patients|All patients (acute or stable) presenting to a cardiovascular clinic and on aspirin.
11615038|NCT00531349|Active Comparator|A|General anesthesia and opioid analgesia for the treatment of pain after surgery.
11615039|NCT00531349|Active Comparator|B|Regional anesthesia and analgesia (epidural) combined with deep sedation or general anesthesia.
11615040|NCT00531336|Experimental|1|Avastin first followed by retreatment of Macugen
11615041|NCT00531336|Active Comparator|2|Avastin intravitreally every 6 weeks
11615042|NCT00531336|Active Comparator|3|Macugen intravitreally every 6 weeks
11615043|NCT00531323|Other|1|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
11615044|NCT00531323|Other|2|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
11615045|NCT00531310|Experimental|Matched Family Donor|Matched Family Donor
11615046|NCT00531310|Experimental|Unrelated Donor|Unrelated Donor Transplant/ Cord Blood Transplant
11615047|NCT00531297|Experimental|Treatment arm|endoscopic posterior mesorectal resection
11615048|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615049|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/27 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 27 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615050|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/36 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615091|NCT00531011|Active Comparator|XIENCE V|Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)
11615051|NCT00531284|Experimental|Phase 2 Solid Tumors: Carfilzomib 20/36 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615052|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 36 mg/m²|Participants received carfilzomib 36 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615053|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 45 mg/m²|Participants received carfilzomib 45 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615054|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/45 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615055|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615056|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615057|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/36 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615058|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/45 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615059|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615060|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615061|NCT00531284|Experimental|Phase 1b Lymphoma: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615062|NCT00531284|Experimental|Phase 1b Lymphoma: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615063|NCT00531284|Experimental|Phase 1b MM: Carfilzomib 20/45 mg/m² + Dexamethasone|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615064|NCT00531284|Experimental|Phase 1b MM: Carfilzomib 20/56 mg/m² + Dexamethasone|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
11615065|NCT00531258|Active Comparator|1|
11615066|NCT00531258|Placebo Comparator|2|
11615067|NCT00531232|Experimental|clofarabine 25 mg/day|
11615068|NCT00531219||1|Group #1 NOTES Appendectomy - Transgastric approach
11615069|NCT00531219||2|Group #2 NOTES Cholecystectomy - Transgastric approach
11615070|NCT00531206||All participants|
11615071|NCT00531193|Other|1|Various protocol-specified doses of BIIB014 will be used (doses to be determined by PET scan results)
11615072|NCT00531180|Experimental|4-DCT Ventilation Validation|
11615073|NCT00531167|Experimental|A|combination therapy
11615074|NCT00531167|Active Comparator|B|entecavir
11615075|NCT00531141||A|examination twice by examiner 1
11615076|NCT00531141||B|examination first by examiner 1 thereafter by examiner 2
11615077|NCT00531141||C|examination first by examiner 2 thereafter by examiner 1
11615078|NCT00531141||D|examination performed twice by examiner 2
11615079|NCT00531115|Experimental|1|
11615092|NCT00531011|Active Comparator|TAXUS® Liberté™|Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System
11615093|NCT00530998||1|Group #1 NOTES Appendectomy - Transvaginal approach
11615080|NCT00531102|Experimental|1|"Resuscitation will proceed as per standard of care and infants are only to receive respiratory support if they remain cyanotic despite 60 seconds of spontaneous regular respirations. All infants will have a pulse oximetry probe placed on the right hand (pre-ductal position) immediately after birth. Infants that meet the entry criteria will be randomized to resuscitation with one of two neonatal T-piece resuscitator circuits:
~GROUP 1 - infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes."
11615081|NCT00531102|Active Comparator|2|"Resuscitation will proceed as per standard of care and infants are only to receive respiratory support if they remain cyanotic despite 60 seconds of spontaneous regular respirations. Infants that meet the entry criteria will be randomized to resuscitation with one of two neonatal T-piece resuscitator circuits:
~GROUP 2 - infants will receive 50% oxygen at a rate of 6 liters per minute continuously for at least 5 minutes using a modified neonatal T-piece resuscitator circuit that does not generate pressure. Fifty percent oxygen was chosen because it reflects the actual inspired oxygen concentration when 100% oxygen is blown towards the infant's face."
11615082|NCT00531089|Experimental|Study group|"All patients in the study will be in the study group and will receive rituximab. There is no control arm."
11615083|NCT00531050|Experimental|Part 1: Sequence A, Part 2: Sequence A|"Part 1: Sequence 'A' consisted of - Period 1, patient received a single inhaled dose of indacaterol 300μg capsule via the Concept1 inhaler device. Period 2, patient received single dose of salmeterol 50μg via Diskus dry powder inhaler (DPI). Period 3, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device.
~Part 2: Sequence 'A' consisted of - Period 1, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 3, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
11615084|NCT00531050|Experimental|Part 1 : Sequence B, Part 2: Sequence B|"Part 1: Sequence 'B' consisted of - Period 1, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 2, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patient received single dose of salmeterol 50μg via Diskus DPI.
~Part 2: Sequence 'B' consisted of - Period 1, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 3, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
11615085|NCT00531050|Experimental|Part 1: Sequence C, Part 2: Sequence C|"Part 1: Sequence 'C' consisted of - Period 1, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patient received single dose of salmeterol 50μg via Diskus DPI. Period 3, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device.
~Part 2: Sequence 'C' consisted of - Period 1, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 2, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 3, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device . In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
11615086|NCT00531050|Experimental|Part 1; Sequence D, Part 2: Sequence D|"Part 1: Sequence 'D' consisted of - Period 1, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 3, patient received single dose of salmeterol 50μg via Diskus DPI.
~Part 2: Sequence 'D' consisted of - Period 1, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 2, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
11615087|NCT00531050|Experimental|Part 1: Sequence E, Part 2: Sequence E|"Part 1: Sequence 'E' consisted of - Period 1, patient received single dose of salmeterol 50μg via Diskus DPI. Period 2, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 3, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device.
~Part 2: Sequence 'E' consisted of - Period 1, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 2, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
11615088|NCT00531050|Experimental|Part 1: Sequence F, Part 2: Sequence F|"Part 1: Sequence 'F' consisted of - Period 1, patient received single dose of salmeterol 50μg via Diskus DPI. Period 2, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device.
~Part 2: Sequence 'F' consisted of - Period 1, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 2, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 3, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
11615089|NCT00531024|Experimental|1|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
11615090|NCT00531024|Placebo Comparator|2|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
11615335|NCT00528905|Placebo Comparator|1|Placebo
11615094|NCT00530998||2|Group #2 NOTES Cholecystectomy - Transvaginal approach
11615095|NCT00530985|Experimental|1|Benefits Counseling
11615096|NCT00530985|Active Comparator|2|VA Orientation
11615097|NCT00530972|Experimental|Peginterferon alfa-2a plus ribavirin|
11615098|NCT00530946|Active Comparator|CI-1038 2.5mg/5mg|
11615099|NCT00530946|Active Comparator|CI-1038 2.5mg/10mg|
11615100|NCT00530946|Active Comparator|CI-1038 5mg/5mg|
11615101|NCT00530946|Active Comparator|CI-1038 5mg/10mg|
11615102|NCT00530933|Sham Comparator|1|Sham tibial nerve stimulation
11615103|NCT00530933|Experimental|2|Percutaneous tibial nerve stimulation
11615104|NCT00530933|Experimental|3|Transcutaneous tibial nerve stimulation
11615105|NCT00530907|Experimental|Valproic Acid + Bevacizumab|"Valproic acid administered at a dose of 5.3 mg/Kg/day on days 1 - 28. Depending on the calculated dose, patients will take capsules once or twice a day per mouth.
~Bevacizumab administered at a dose of 2.5 mg/kg by vein every 2 weeks."
11615106|NCT00530894|Experimental|1|Cohort A: Sapien Valve
11615107|NCT00530894|Active Comparator|2|Cohort A: other surgical valve
11615108|NCT00530894|Experimental|3|Cohort B: Sapien Valve
11615109|NCT00530894|Active Comparator|4|Cohort B: Medical therapy
11615110|NCT00530881|Placebo Comparator|4|
11615111|NCT00530881|Placebo Comparator|3 active, 1 placebo|
11615112|NCT00530868|Experimental|Letrozole + Avastin|
11615113|NCT00530868|Experimental|Letrozole alone|
11615114|NCT00530855|Experimental|Lacosamide|Lacosamide tablets for dosing 100 -800 mg/day
11615115|NCT00530829|Experimental|1|Mothers recieve a blister pack of zinc tablets in home every two months for use when child in home under 5 years has diarrhea. ORS satchets also given. Instructions on when and how to use zinc and ORS and when to take child in clinic are given by community health worker. Zinc will also be given in clinic if child visits clinic with diarrhea and has not yet started zinc at home.
11615116|NCT00530829|Active Comparator|2|Mothers recieve ORS satchets at home every two months for use when child in home under 5 years has diarrhea. Instructions on when and how to use ORS and when to take child in clinic are given by community health worker. Zinc will be given in clinic if child visits clinic with diarrhea.
11615117|NCT00530816|Experimental|Carfilzomib|"Participants received carfilzomib 20 mg/m² intravenous (IV) injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.
~Starting with Amendment 3, if all doses in Cycle 1 were well-tolerated the dose was escalated to 27 mg/m² IV for subsequent cycles."
11615118|NCT00530803|Active Comparator|EMLA Cream|Participants will have a dose of EMLA Cream applied to the venipuncture site 1 hour before the procedure. Dosage based on age and weight: 4-6 years old and heavier than 10kg will receive 10g of EMLA; 7-12 years old and more than 20kg will receive 20g of EMLA.
11615119|NCT00530803|Active Comparator|Synera Patch|Participants will have a Synera Patch applied to the venipuncture site 20 minutes prior to the procedure.
11615120|NCT00530790|Experimental|ropinirole CR-RLS|"Subjects will orally take ropinirole CR-RLS tablet(s) once daily 1-2 hours before the onset of RLS symptoms at about the same time of the day. The time of taking ropinirole must be after 16:00.Adjustment of the Ropinirole CR-RLS tablets should be completed after the Week 1 visit up to the Week 10 visit. The dose will be increased at intervals of at least one week until sufficient efficacy is obtained (use much improved as a guide) without safety problem. Dose escalation will start at the initial dose 0.5 mg/day to 1 mg/day; after 1 mg/day, the dose will be increased by 1 mg/day to the maximum 6 mg/day."
11615121|NCT00530777|Experimental|1|500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
11615122|NCT00530777|Placebo Comparator|2|oral placebo twice daily from 34 weeks gestation to 1 year postpartum
11615123|NCT00530764|Experimental|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
11615124|NCT00530764|Experimental|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
11615125|NCT00530764|Experimental|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
11615126|NCT00530764|No Intervention|Placebo|Range of 1-16 sprays per day of placebo spray.
11615127|NCT00530738|Experimental|1|treatment with Lipoplus & Nutriflex plus (commercially available and marketed 2 Chamber Bag)
11615128|NCT00530738|Active Comparator|2|treatment with Lipofundin MCT & Nutriflex plus (commercially available and marketed 2 Chamber Bag)
11615129|NCT00530725|Active Comparator|chest drainage|This represents the best current standard of care although this is quite controversial
11615130|NCT00530725|Experimental|close observation|This is the novel approach that has some justification in the literature
11615131|NCT00530712|Experimental|PTA and Stenting with EverFlex device|Qualified subjects undergo treatment of atherosclerotic lesions in the native SFA/SFA/PPA with PTA and stenting using the PROTÉGÉ® EverFlex™ Self-Expanding Stent System
11615132|NCT00530634|Experimental|Gemcitabine + Cisplatin|Surgical resection followed by (within 60 days) by chemotherapy (Gemcitabine at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle and Cisplatin at 75 mg/m2 IV over 1 hour on day 8 of a 21 day cycle) followed by radiation therapy (treated using linear accelerator with photon beam energy of 6-21 MV) upon completion of 3 cycles of chemotherapy.
11615133|NCT00530621|Experimental|Pemetrexed + Enzastaurin|
11615134|NCT00530621|Placebo Comparator|Pemetrexed + Placebo|
11615135|NCT00530530|Experimental|1|Dose 1
11615136|NCT00530530|Experimental|2|Dose 2
11615137|NCT00530530|Experimental|3|Dose 3
11615138|NCT00530530|Placebo Comparator|4|
11615139|NCT00530517|Experimental|1|
11615140|NCT00530504|Experimental|Device|Device
11615141|NCT00530491|Active Comparator|1|conventional perioperative management for lung surgery
11615142|NCT00530491|Experimental|2|fast track management for lung surgery
11615143|NCT00530452|Experimental|A|2.0 mg (loading dose, Day 0) followed by 0.3 mg/day (Days 1-20)
11615336|NCT00528905|Experimental|2|AZD3480 oral
11615144|NCT00530452|Experimental|B|4.0 mg (loading dose, Day 0) followed by 0.6 mg/day (Days 1-20)
11615145|NCT00530452|Experimental|C|8.0 mg (loading dose, Day 0) followed by 1.2 mg/day (Days 1-20)
11615146|NCT00530452|Placebo Comparator|D|Placebo (identical number of capsules to active drug groups) (Days 0-20)
11615147|NCT00530439|Experimental|Lifestyle intervention|physical activity, dietetic counselling
11615148|NCT00530439|No Intervention|Control|
11615149|NCT00530413|Experimental|1|Phenobarbital - dose based by weight range
11615150|NCT00530413|Placebo Comparator|2|Placebo group
11615151|NCT00530400|Experimental|1|intravenous 1.5g cefuroxime
11615152|NCT00530400|Placebo Comparator|2|intravenous placebo
11615153|NCT00530374|Active Comparator|1|Each child in this group will receive daily supplementation of Iron Sprinkles with a single sachet for 60 days
11615154|NCT00530374|Placebo Comparator|2|Each child in this group will receive daily supplementation of placebo Sprinkles with a single sachet for 60 days
11615155|NCT00530348|Experimental|Alemtuzumab|
11615156|NCT00530348|Active Comparator|Interferon Beta-1a|
11615157|NCT00530335|Experimental|Atomoxetine|
11615158|NCT00530322||A|"Patients who have had previous open colorectal surgery and are referred for a further operative procedure, at which time a second-look laparoscopy can be performed."
11615159|NCT00530322||B|"Patients who have had a previous laparoscopic colorectal procedure and are having a second-look procedure"
11615160|NCT00530309|Experimental|Subjects receiving GSK716155 + placebo|Eligible subjects will receive GSK716155 with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks. Subjects will also receive placebo.
11615161|NCT00530283||A|Patients with Squamous cell cancer of neck nodes, unknown primary
11615162|NCT00530270|Active Comparator|Dexamethasone|
11615163|NCT00530270|Placebo Comparator|Placebo|
11615164|NCT00530257|Placebo Comparator|Placebo|Placebo (sugar pill);Subjects will be equally randomized and will receive one week of treatment with placebo and compared to subjects who were randomized to receive one week of OROS-methylphenidate.
11615165|NCT00530257|Active Comparator|OROS-methylphenidate|Subjects will be equally randomized and will receive one week of treatment with the optimal dose of OROS methylphenidate compared with subjects randomized to receive one week of placebo.
11615166|NCT00530244|Experimental|1|Infants will be fed formula supplemented with docosahexaenoic acid
11615167|NCT00530244|Placebo Comparator|2|Infants will be fed standard formula (Enfamil)
11615168|NCT00530218|Experimental|All Study Participants|Ganciclovir IV 5 mg/kg/bid x 7 days followed by Ganciclovir Oral 1000 mg tid 7 days per week x 5 weeks
11615169|NCT00530179|Active Comparator|Arm A|"Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined negative for disease intensity patient receives 4 more cycles R-CHOP (total 6 cycles R-CHOP)
~Assigned interventions: Drug: R-CHOP (Rituximab, Cyclophosphamide, Etoposide, Cisplatin, Mesna, G-CSF 6 - 21 DAY Cycles of R-CHOP"
11615170|NCT00530179|Active Comparator|Arm B|"Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined positive for disease intensity the patient receives one cycle or R-DICEP/R-BEAM the autologous blood stem cell transplantation.
~Assigned Interventions: Procedure/Surgery: Autologous Blood Stem Transplantation 2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION"
11615171|NCT00530166|Experimental|002|sham comparator 3(100 mg) tablets once daily for 12 weeks
11615172|NCT00530166|Experimental|001|JNJ-18054478 3(100 mg) tablets once daily for 12 weeks
11615173|NCT00530140|Experimental|A|All patients will receive the same vaccination schedule/formulation
11615174|NCT00530127|Placebo Comparator|A|Placebo solution
11615175|NCT00530127|Experimental|B|Deferiprone oral solution 20 mg/kg/day
11615176|NCT00530127|Experimental|C|Deferiprone oral solution 40 mg/kg/day
11615177|NCT00530127|Placebo Comparator|D|Placebo solution
11615178|NCT00530127|Experimental|E|deferiprone oral solution 60 mg/kg/day
11615179|NCT00530114|Placebo Comparator|Placebo|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
11615180|NCT00530114|Experimental|AMG 223|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
11615181|NCT00530088|Experimental|Porfimer Sodium|Patients receive porfimer sodium subcutaneously followed by photodynamic therapy (PDT) comprising laser light delivered by a single or a diffuser (i.e., for broad areas of dysplasia) fiberoptic lens fiber.
11615182|NCT00530075|Experimental|1|Gusperimus
11615183|NCT00530062|Active Comparator|Albuterol HFA-BAI|Albuterol Hydrofluoroalkane (HFA) Breath-Actuated Inhaler (BAI)
11615184|NCT00530062|Active Comparator|Albuterol HFA-MDI|Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)
11615185|NCT00530049||questionnaires|"The purpose of this study is to develop a PRO instrument that measures quality of life as relates to facial appearance after head and neck cancer reconstruction surgery and after dermatologic surgery for patients with cutaneous skin cancers. . To develop this measure, we will adhere to the following sequential steps recommended by quality of life experts. Thus, the study will have three parts:
~Questionnaire content generation and development of preliminary instrument
~Field-testing the preliminary questionnaire with item reduction and development of final questionnaire
~Psychometric evaluation of final questionnaire"
11615186|NCT00530036||Continent|"54% of 699 patients followed as outpatient by the Fondation des Services d'Aide et de Soins à Domicile in Geneva without urinary incontinence"
11615187|NCT00530036||Incontinent|"46% of 699 patients followed by the Fondation des Services d'Aide et de Soins à Domicile in Geneva and with an urinary incontinence"
11615188|NCT00530023|Active Comparator|1. 722|722 arm: MiniMed Paradigm REAL-Time System
11615189|NCT00530023|No Intervention|2. Multiple Daily Injections (MDI)|MDI arm: Continue with currently prescribed Multiple Daily Injection therapy. No change in treatment or regime for study.
11615190|NCT00529997|Experimental|1|Posterior Dynamic Stabilization with the Stabilimax NZ
11615191|NCT00529997|Active Comparator|2|Posteriolateral instrumented fusion
11615192|NCT00529984|Experimental|Cohort 1|
11615193|NCT00529984|Experimental|Cohort 2|
11615194|NCT00529984|Experimental|Cohort 3|
11615195|NCT00529984|Experimental|Cohort 4|
11615196|NCT00529984|Experimental|Cohort 5|
11615197|NCT00529971|Experimental|1|Participants in the first arm participate in an 8-week MBSR group
11615198|NCT00529971|Active Comparator|2|Participants assigned to the control arm do not receive the MBSR program but may or may not be receiving current psychotherapy or counselling
11615199|NCT00529958|Active Comparator|Patellar Tendon (PT)|ACL reconstruction using a patellar tendon autograft
11615200|NCT00529958|Active Comparator|Hamstring (HT)|ACL reconstruction using a quadruple-strand semitendinosus/gracilis (hamstring) tendon single-bundle autograft
11615201|NCT00529958|Active Comparator|Double-Bundle (DB)|ACL reconstruction using a semitendinosus/gracilis (hamstring) tendon double-bundle autograft
11615202|NCT00529932|Active Comparator|1|Enriched CD133+, bone marrow-derived, autologous progenitor cells for this trial will be infused in the coronary arteries
11615203|NCT00529932|Placebo Comparator|2|Control group patients will receive 3 injections of 0.3 mL each of buffered normal saline (the vehicle used for cell suspension) into comparable vessels. Subjects will have an identical intra-coronary injection procedure to those randomized to autologous CD133+ progenitor cell injections.
11615204|NCT00529919|Active Comparator|1|MCT oil consumption
11615205|NCT00529919|Placebo Comparator|2|Olive oil consumption
11615206|NCT00529867|Active Comparator|A|
11615207|NCT00529867|Active Comparator|B|
11615208|NCT00529854||1|Observational evaluation of current billing and documentation practices
11615209|NCT00529854||2|Use of SIC-IR Billing Module
11615210|NCT00529841|Experimental|1 (Hydrocortisone sodium acetate)|Subcutaneous administration of Hydrocortisone sodium acetate via insulin pump
11615211|NCT00529815|Experimental|1CGM and SBGM|Intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
11615212|NCT00529815|Active Comparator|2 SBGM|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
11615213|NCT00529802|Experimental|Everolimus (RAD001) 10mg daily|All patients were to receive 10mg everolimus (RAD001) daily.
11615214|NCT00529789|Experimental|Duloxetine|
11615215|NCT00529776|Active Comparator|1|Continuous lateral rotation therapy
11615216|NCT00529776|No Intervention|2|Standard manual positioning (Supine position)
11615217|NCT00529763|Experimental|1|
11615218|NCT00529750|Experimental|Irbesartan Group|150 mg p.o. once a day, 30 minutes before breakfast during 12 weeks
11615219|NCT00529750|Active Comparator|Atenolol Group|50 mg p.o. once a day, 30 minutes before breakfast during 12 weeks.
11615220|NCT00529737|Experimental|Group 1|Post Procedure Mammogram Projection View A -- (view same projection as used in the biopsy procedure), then View B (view orthogonal projection to the first view).
11615221|NCT00529737|Experimental|Group 2|Post Procedure Mammogram Projection View B than View A
11615222|NCT00529711|Experimental|Group 1|Hypertonic lactate
11615223|NCT00529711|Active Comparator|Group 2|Ringer's lactate
11615224|NCT00529698|Other|A|Subjects were immunized subcutaneously with Tat, 3 dosage groups (7.5, 15 or 30 micrograms), in association with Alum as adjuvant, or with Saline + Alum, as placebo.
11615225|NCT00529698|Other|B|Subjects were immunized intradermally with Tat, 3 dosage groups (7.5, 15 or 30 micrograms), or with Saline, as placebo.
11615226|NCT00529672|Active Comparator|1|Surgery: crossectomy plus short stripping
11615227|NCT00529672|Active Comparator|2|ultrasound guided sclerotherapy with foam (3% polidocanol)
11615228|NCT00529672|Active Comparator|3|Endovenous laser therapy (940 nm, about 70 J/cm)
11615229|NCT00529659|Experimental|MK-0773|MK-0773
11615230|NCT00529659|Placebo Comparator|Placebo|Placebo
11615231|NCT00529633|Active Comparator|Thalidomide|"12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months
~Serum C reactive protein level of ≥ 0.8 mg/dl
~Serum albumin < 3.8 g/dl (BCG)
~Patients will receive 100mg Thalidomide for a period of 4 weeks; if somnolence tolerated, dosage is increased to 200mg nightly for a period of 20 more weeks -- to total of 24 weeks on Thalidomide."
11615232|NCT00529633|Placebo Comparator|No Drug|"12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months
~Serum C reactive protein level of ≥ 0.8 mg/dl
~Serum albumin < 3.8 g/dl (BCG)
~Patients will receive Placebo (Sugar pill) for a period of 24 weeks."
11615233|NCT00529620|Active Comparator|1|sulfalene pyrimethamine plus amodiaquine
11615234|NCT00529620|Active Comparator|2|dihydroartemisinin piperaquine
11615235|NCT00529620|Active Comparator|3|sulfadoxine-pyrimethamine plus piperaquine
11615236|NCT00529607||1|- patients with acute ST elevation myocardial infarction and consecutive percutaneous coronary intervention of the infarct-related artery
11615237|NCT00529607||2|- 30 patients with stable CAD (control group 1)
11615238|NCT00529607||3|- 30 healthy volunteers regarding cardiovascular diseases (control group 2)
11615239|NCT00529594|Placebo Comparator|Control Group|Patients who received placebo
11615240|NCT00529594|Active Comparator|Treatment Group|Patients who received etoricoxib 120 mg
11615241|NCT00529568|Experimental|eltrombopag|active treatment arm
11615242|NCT00529568|Placebo Comparator|placebo|placebo control arm
11615243|NCT00529555|Sham Comparator|Scaling and root planing + SHAM TX|sham treatment
11615244|NCT00529555|Placebo Comparator|Scaling and root planing + Vehicle|Placebo
11615245|NCT00529555|Active Comparator|Scaling & root planing + Periocline Gel|Minocycline HCL 2.1%
11615246|NCT00529542|Experimental|Atorvastatin|
11615247|NCT00529542|Placebo Comparator|Placebo|
11615248|NCT00529529|Experimental|Indacaterol 300 μg|Patients received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 300 μg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11615293|NCT00529191|Experimental|Atorvastatin|Two out of every three patients will receive atorvastatin.
11615294|NCT00529191|Placebo Comparator|Placebo|One out of three subjects will receive a placebo.
11634865|NCT00311805|Placebo Comparator|3|
11615249|NCT00529529|Experimental|Indacaterol 600 μg|Patients received indacaterol 600 μg (2 x 300 μg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 600 μg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11615250|NCT00529529|Active Comparator|Salmeterol 50 μg|Patients received salmeterol 50 μg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 07:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 μg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11615251|NCT00529516|Experimental|FluAS25 Group|Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.
11615252|NCT00529516|Active Comparator|Fluarix ≥ 65 years age Group|Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.
11615253|NCT00529516|Active Comparator|Fluarix 18-40 years age Group|Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.
11615254|NCT00529503|Experimental|1|SGN-40, rituximab, etoposide, carboplatin, ifosfamide
11615255|NCT00529503|Placebo Comparator|2|placebo, rituximab, etoposide, carboplatin, ifosfamide
11615256|NCT00529490|Experimental|HL|Hypertonic lactate group
11615257|NCT00529490|Active Comparator|RL|Ringer's lactate
11615258|NCT00529477|Active Comparator|1|The Wright Nebulizer will be used to perform the methacholine challenge in arm 1.
11615259|NCT00529477|Active Comparator|2|The Pari LC nebulizer will be used to perform the methacholine challenge in arm 2.
11615260|NCT00529477|Active Comparator|3|The Pari Sinustar nebulizer will be used to perform the methacholine challenge in arm 3.
11615261|NCT00529464|Experimental|Colposcopy|Colposcopy - a direct magnified inspection of cervix
11615262|NCT00529464|Experimental|Colposcopy + Fluorescence Spectroscopy|Colposcopy - a direct magnified inspection of cervix + Fluorescence Spectroscopy - electromagnetic spectroscopy which analyzes fluorescence from a sample.
11615263|NCT00529464|Experimental|Colposcopy + LEEP Procedure|Colposcopy - a direct magnified inspection of cervix + loop electrosurgical excision procedure (LEEP) - thin, low-voltage electrified wire loop to cuts out cervix abnormal tissue.
11615264|NCT00529451|Experimental|Aliskiren 300 mg|Aliskiren 300 mg once daily
11615265|NCT00529451|Experimental|Aliskiren 150 mg|Aliskiren 150 mg once daily
11615266|NCT00529451|Experimental|Aliskiren 75 mg|Aliskiren 75 mg once daily
11615267|NCT00529451|Active Comparator|Ramipril 5 mg|Ramipril 5 mg once daily
11615268|NCT00529438|Experimental|Bardoxolone methyl capsules|"Bardoxolone methyl to be taken orally for 21 consecutive days, once a day, in the morning prior to food intake.
~Patients to continue to receive treatment for the first 21 days of each 28-day cycle until they experience intolerable toxicity, show evidence of disease progression, or receive a maximum of 18 cycles (18 months)."
11615269|NCT00529425|Active Comparator|Ropivacaine|
11615270|NCT00529425|Placebo Comparator|Saline|
11615271|NCT00529412|No Intervention|control|no Seprafilm
11615272|NCT00529412|Active Comparator|Seprafilm|
11615273|NCT00529399|Experimental|1|3 injections of GAD-Alum vaccine
11615274|NCT00529399|Experimental|2|2 injections of GAD-Alum vaccine and one injection with Aluminum hydroxide alone
11615275|NCT00529399|Placebo Comparator|3|3 injections of Aluminum hydroxide alone
11615276|NCT00529386|Experimental|Botox|300 IU botox
11615277|NCT00529373|Experimental|Odanacatib|Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly for 5 years. Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.
11615278|NCT00529373|Placebo Comparator|Placebo|Participants receive blinded placebo to 50 mg of odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly for 5 years. Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.
11615279|NCT00529360|Experimental|Part A|Part A will be the dose escalation phase to determine the MTD and/or safe/tolerated dose of clofarabine.
11615280|NCT00529360|Experimental|Part B|Part B will accrue patients to further define the event free, disease free and overall survival at the MTD or safe/tolerated dose of clofarabine.
11615281|NCT00529334|Experimental|1|CyberKnife Partial Breast Irradiation (PBI)
11615282|NCT00529308|Active Comparator|Active|
11615283|NCT00529308|Sham Comparator|Sham|
11615284|NCT00529295|Experimental|1|Titrated oral misoprostol
11615285|NCT00529295|Active Comparator|2|Vaginal misoprostol
11615286|NCT00529282|Experimental|001|Ceftobiprole Medocaril 500 mg every 8 hours 120-minute infusion [250 mL]
11615287|NCT00529282|Active Comparator|002|Cefepime with or without vancomycin 2 g every 8 hrs-30 min infusion vancomycin 1 000mg every 12 hrs-60 min infusion
11615288|NCT00529256|No Intervention|2|No intervention
11615289|NCT00529243|Experimental|MK-0518 (raltegravir)|Open label, single arm. All patients to receive MK-0518 400mg orally twice a day for 24 weeks, as substitution for enfuvirtide.
11615290|NCT00529230||Chronic opioid therapy + Gonadal function|Males on chronic opioid therapy for cancer-related pain syndromes
11615291|NCT00529217|Experimental|Open-Label Active rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS)
11615292|NCT00529204|Experimental|Exenatide|exenatide 5 µg BID s.c. daily for 28 days, followed by 10 µg BID s.c. daily from day 29 to week 24
11634958|NCT00310544|Experimental|Arm 1|
11615295|NCT00529165|Experimental|A|with injection-meal-interval,cross over after 3 month, than without injection-meal-interval for 3 month
11615296|NCT00529165|Experimental|B|without injection-meal-interval,cross over after 3 month, than with injection-meal-interval for 3 month
11615297|NCT00529152|Other|A|Ferriprox Oral Solution single treatment
11615298|NCT00529139|Active Comparator|A|
11615299|NCT00529139|Active Comparator|B|
11615300|NCT00529126|Experimental|SKY0402 high dose|SKY0402, single administration
11615301|NCT00529126|Experimental|SKY0402 middle dose|SKY0402, single administration
11615302|NCT00529126|Experimental|SKY0402 low dose|SKY0402, single administration
11615303|NCT00529126|Active Comparator|Bupivacaine HCl|Bupivacaine HCl
11615304|NCT00529113|Experimental|Phase 1 Cohort 1|Bardoxolone methyl 150 mg/day x 21 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
11615305|NCT00529113|Experimental|Phase 1 Cohort 2|Bardoxolone methyl 300 mg /day for 21 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
11615306|NCT00529113|Experimental|Phase 1 Cohort 3|Bardoxolone methyl 150 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
11615307|NCT00529113|Experimental|Phase 1 Cohort 4|Bardoxolone methyl 200 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
11615308|NCT00529113|Experimental|Phase 1 Cohort 5|Bardoxolone methyl 250 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
11615309|NCT00529113|Experimental|Phase 1 Cohort 6|Bardoxolone methyl 300 mg/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
11615310|NCT00529113|Experimental|Phase 1 Cohort 7|Bardoxolone methyl 350 mg/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
11615311|NCT00529113|Experimental|Phase 2 Cohort 1|Bardoxolone methyl maximum tolerated dose(as determined in the Phase 1 portion of the study)/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
11615312|NCT00529113|Placebo Comparator|Phase 2 Cohort 2|Placebo capsules/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
11615313|NCT00529100|Experimental|Pemetrexed/Cisplatin/Radiation Phase 1|Treatment included: radiation as 61-65 Gray (Gy) in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent pemetrexed intravenous (IV) bolus with doses escalating from 300 milligrams per square meter (mg/m^2) IV through 500 mg/m^2 IV on Days 1 and 22; concurrent cisplatin 25 mg/m^2 IV on Days 1-3 and 22-24 for Cohorts 1-3 and cisplatin 20 mg/m^2 IV on Days 1-5 and 22-26 for Cohort 4. Participants then received 2 additional consolidation cycles repeated every 3 weeks (q3 weeks) of pemetrexed 500 mg/m^2 IV and cisplatin 75 mg/m^2 IV.
11615314|NCT00529100|Experimental|Pemetrexed/Cisplatin/Radiation Phase 2|Treatment included: radiation, 61-65 Gy in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m^2 IV on Days 1 and 22 ; concurrent cisplatin 20 mg/m^2 IV as determined by Phase 1 trial with cycles commencing on Days 1 and 22; 2 additional consolidation cycles (q3 weeks) of pemetrexed 500 mg/m^2 IV and cisplatin 75 mg/m^2 IV.
11615315|NCT00529087|Placebo Comparator|1|
11615316|NCT00529087|Experimental|2|
11615317|NCT00529087|Experimental|3|
11615318|NCT00529048||T2DM|T2DM patients (WHO-criteria)
11615319|NCT00529048||CTRL|Healthy control subjects matched individually to the cases.
11615320|NCT00529035|Experimental|Interleukin-2|"Interleukin-2 (IL-2) will be given daily through an injection under the skin for a period of 8 weeks. To determine the highest safest dose of IL-2, the dose participants receive will increase as lower doses are determined to be safe. There will be three dose levels:
~Dose Level -A 0.3 x 106 (IU/m2/d) Dose Level -B 1 x 106 (IU/m2/d) Dose Level-C 3 x 106 (IU/m2/d)"
11615321|NCT00529022|Experimental|Azacitidine + Valproic Acid + Carboplatin|Azacitidine 75 mg/m^2 subcutaneous injection or by vein daily for 5 Days. Valproic Acid 40 mg/kg by mouth daily for 7 days. Carboplatin area under the curve (AUC) 2 by vein on Days 3 and 10 over 60 Minutes.
11615322|NCT00528983|Experimental|Subcutaneous (SC) Azacitidine and Oral Azacitidine|Cycle 1 subjects receive SC Azacitidine for first 7 days of 28 day cycle. For Cycle 2 and beyond subjects receive Oral Azacitidine (experimental) for first 7 days of 28 day cycle.
11615323|NCT00528983|Experimental|Oral Azacitidine|Subjects receive Oral Azacitidine (experimental) QD or BID for the first 14 or 21 days of 28 day cycle.
11615324|NCT00528970|Experimental|MOA-728 12 mg|Participants will receive methylnaltrexone (MOA-728) 12 mg as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
11615325|NCT00528970|Experimental|MOA-728 24 mg|Participants will receive MOA-728 24 mg as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
11615326|NCT00528970|Placebo Comparator|Placebo|Participants will receive placebo matching to MOA-728 as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
11615327|NCT00528957|Experimental|Tenofovir DF|
11615328|NCT00528957|Active Comparator|stavudine or zidovudine|
11615329|NCT00528944||Cohort A|Patients with obstructive defects and radiological evidence of emphysema
11615330|NCT00528944||Cohort B|Patients with obstructive ventilatory defects and no radiological evidence of emphysema
11615331|NCT00528944||Cohort C|Non-smokers without obstructive ventilatory defects or history of cardiopulmonary disease
11615332|NCT00528931|Experimental|AA4500 0.58 mg|
11615333|NCT00528918|Active Comparator|Apidra|Direct 1:1 comparison of Apidra and Regular insulin.
11615334|NCT00528918|Active Comparator|Regular|Direct 1:1 comparison of Apidra and Regular insulin.
11615337|NCT00528905|Experimental|3|AZD3480 oral dose
11615338|NCT00528892|Experimental|1|Switch current boosted-PI to raltegravir 400 mg BID.
11615339|NCT00528892|Active Comparator|2|Continue current regimen (ritonavir-boosted PI plus at least 2 other drugs)
11615340|NCT00528879|Placebo Comparator|Placebo + Metformin|Participants received dapagliflozin-matching placebo once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
11615341|NCT00528879|Experimental|Dapagliflozin, 2.5 mg + Metformin|Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
11615342|NCT00528879|Experimental|Dapagliflozin, 5 mg + Metformin|Participants received dapagliflozin, 5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
11615343|NCT00528879|Experimental|Dapagliflozin, 10 mg + Metformin|Participants received dapagliflozin, 10 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
11615344|NCT00528866|Experimental|Androgen suppression + RT + docetaxel|LHRH agonist and oral antiandrogen (flutamide or bicalutamide), radiation therapy (RT), and docetaxel
11615345|NCT00528840|Experimental|AA4500 0.58 mg|
11615346|NCT00528827|Placebo Comparator|1|
11615347|NCT00528827|Experimental|2|5 mcg
11615348|NCT00528827|Experimental|3|2.5
11615349|NCT00528827|Experimental|4|0.5
11615350|NCT00528814|Experimental|Two Step Hand-Hygiene|Hand washing plus hand sanitizer
11615351|NCT00528814|No Intervention|Usual Care Hand Hygiene|
11615352|NCT00528801||Cases (CLOSED)|These are patients diagnosed with sickle cell disease (confirmed by hemoglobin electrophoresis).
11615353|NCT00528801||Controls (CLOSED)|These are persons that do not have sickle cell disease (confirmed by hemoglobin electrophoresis); matched to cases by age, gender, and education level
11615354|NCT00528788|Experimental|Pre and post doxicalciferol|ESRD: all patients with secondary hyperparathyroidism who are vitamin D naive will receive doxercalciferol 2 mcg or 4 mcg 3 times per week fopr 30 days (1 month). Blood work and vascular laboratory studies will be performed pre and post treatment.
11615355|NCT00528775|Experimental|HPPH|Patients will receive 4 mg/m2 HPPH (given light exposure precautions) and approximately 2 days later be treated endoscopically with 150J/cm of 665 +-5nm light.
11615356|NCT00528762||Focus Group|Mexican American or African American females (aged 6-12 years old) and their parents
11615357|NCT00528723|Experimental|A|BDP/salbutamol HFA pMDI
11615358|NCT00528723|Active Comparator|B|BDP/salbutamol CFC pMDI
11615359|NCT00528710|Placebo Comparator|P|Placebo Control Group
11615360|NCT00528697|Experimental|1|Lowest ABT-089 dose
11615361|NCT00528697|Experimental|2|Low-medium ABT-089 dose
11615362|NCT00528697|Experimental|3|Medium-high ABT-089 dose
11615363|NCT00528697|Experimental|4|Highest ABT-089 dose
11615364|NCT00528697|Active Comparator|5|atomoxetine
11615365|NCT00528697|Placebo Comparator|6|placebo
11615366|NCT00528671|Active Comparator|A|Low dose oral anticoagulation, INR self-management once a week
11615367|NCT00528671|Active Comparator|B|very low dose oral anticoagulation, INR self-management once a week
11615368|NCT00528671|Experimental|C|very low dose oral anticoagulation, INR self-management twice a week
11615369|NCT00528658|Experimental|1|
11615370|NCT00528658|Experimental|2|
11615371|NCT00528658|Experimental|3|
11615372|NCT00528645|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily for up to 2 years in the absence of disease progression or unacceptable toxicity. Blood samples are obtained at baseline and periodically during study to determine levels of circulating tumor cells for defined translational studies.
11615373|NCT00528632||Cholesterolosis|I. Patients with gallbladder cholesterolosis and symptomatic cholelithiasis
11615374|NCT00528632||Cholelithiasis|II. Patients without gallbladder cholesterolosis and with symptomatic cholelithiasis
11615375|NCT00528619|Experimental|A|
11615376|NCT00528606|Experimental|AA4500 0.58 mg|
11615377|NCT00528606|Placebo Comparator|Placebo|
11615378|NCT00528593|Active Comparator|1|
11615379|NCT00528580|Experimental|1|Simvastatin 80 mg once daily PO (or via NG or G-tube)
11615380|NCT00528580|Placebo Comparator|2|Identical-appearing placebo PO (or via NG or G-tube)
11615381|NCT00528567|Experimental|Bevacizumab and Chemotherapy|Participants randomized to receive bevacizumab in combination with chemotherapy as prescribed.
11615382|NCT00528567|Active Comparator|Chemotherapy|Participants randomized to receive standard adjuvant chemotherapy as prescribed.
11615383|NCT00528554|Active Comparator|A|Active laser acupuncture
11615384|NCT00528554|Placebo Comparator|B|Placebo laser acupuncture
11615385|NCT00528541|Active Comparator|BOTOX®|botulinum toxin type A (BOTOX®)
11615386|NCT00528541|Active Comparator|Dysport®|botulinum toxin type A (Dysport®)
11615387|NCT00528528|Experimental|Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet|Telaprevir tablets at the dose of 750 milligram (mg) orally administered every 8 hours (hr) for 12 weeks, in combination with standard treatment composed of pegylated interferon (Peg-IFN)-alfa-2a solution for subcutaneous injection at the dose of 180 microgram per week (mcg/week) and ribavirin (RBV) oral tablets at the dose of 1000-1200 mg/day up to 48 weeks.
11615388|NCT00528528|Experimental|Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule|Telaprevir tablets at the dose of 750 mg orally administered every 8 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2b solution for subcutaneous injection at the dose of 1.5 mcg/kilogram/week (mcg/kg/week) and RBV oral capsules at the dose of 800-1200 mg/day up to 48 weeks.
11615389|NCT00528528|Experimental|Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet|Telaprevir tablets at the dose of 1125 mg orally administered every 12 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2a solution for subcutaneous injection at the dose of 180 mcg/week and RBV oral tablets at the dose of 1000-1200 mg/day up to 48 weeks.
11615390|NCT00528528|Experimental|Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule|Telaprevir tablets at the dose of 1125 mg orally administered every 12 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2b solution for subcutaneous injection at the dose of 1.5 mcg/kg/week and RBV oral capsules at the dose of 800-1200 mg/day up to 48 weeks.
11615391|NCT00528515|Active Comparator|1|propofol
11615392|NCT00528515|Experimental|2|desflurane
11615393|NCT00528502|Experimental|Saline|Saline misted into the air breathe during the surgery.
11615394|NCT00528502|Experimental|Lidocaine|Lidocaine misted into the air during the surgery.
11615395|NCT00528489|Experimental|1|PENNVAX-B with 0.8 mg IL-15 administered in both deltoids at Months 0, 1, 3, and 6
11615396|NCT00528489|Experimental|2|PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
11615397|NCT00528489|Experimental|3|PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
11615398|NCT00528489|Experimental|4|PENNVAX-B with 2 mg IL-15 injected into both deltoids at Months 0, 1, 3, and 6
11615399|NCT00528476||1|Patients, who were treated because of recurrent (2 or more urinary tract infections per year) pyelonephritis or cystitis.
11615400|NCT00528476||2|Patients with nonrecurrent urinary tract infections (patients who had no history of more than one urinary tract infections in last year).
11615401|NCT00528463|Experimental|sciatic block|One arm, all patient studied received a block
11615402|NCT00528450|Experimental|Tretinoin and Arsenic Trioxide With or Without Idarubicin|See Outline for details
11615403|NCT00528437|Other|Myeloablative Chemo-Temozolomide, Thiotepa, and Carboplatin.|
11615404|NCT00528424|Experimental|AA4500 0.58 mg|
11615405|NCT00528411|Active Comparator|1|Aspirin + Placebo
11615406|NCT00528411|Active Comparator|2|Aspirin + clopidogrel
11615407|NCT00528411|Experimental|3|Aspirin + Ticagrelor
11615408|NCT00528398|Experimental|Treatment (idarubicin, cytarabine)|Patients receive cytarabine IV over 3 hours every 12 hours on days 1-4 and idarubicin IV over 5-10 minutes on days 1-3. Patients undergo bone marrow aspirate and biopsy 7 days after completion of induction chemotherapy. Patients with > 25% cellular biopsy or > 10% abnormal cells on aspirate receive 4 more doses of cytarabine and 1 dose of idarubicin.
11615409|NCT00528372|Experimental|Group 1: Dapagliflozin, 2.5 mg AM|Participants with hemoglobin A1c (HbA1c) ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each morning for up to 102 weeks.
11615410|NCT00528372|Experimental|Group 1: Dapagliflozin, 10 mg AM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each morning for up to 102 weeks.
11615411|NCT00528372|Experimental|Group 1: Dapagliflozin 2.5 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each evening for up to 102 weeks.
11615412|NCT00528372|Experimental|Group 1: Dapagliflozin, 5 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 5 mg, once each evening for up to 102 weeks.
11615413|NCT00528372|Experimental|Group 1: Dapagliflozin, 10 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each evening for up to 102 weeks.
11615414|NCT00528372|Experimental|Group 2: Dapagliflozin, 5 mg AM|Participants with HbA1c ≥10.1% and ≤12% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
11615415|NCT00528372|Experimental|Group 2: Dapagliflozin, 10 mg AM|Participants with HbA1c ≥10.1% and ≤12% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
11615416|NCT00528372|Experimental|Group 1: Dapagliflozin placebo AM & PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin placebo once each morning and evening for up to 102 weeks.
11615417|NCT00528372|Experimental|Group 1: Dapaglifozon, 5 mg AM|Participants with (HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
11615418|NCT00528359||A|36 lean schizophrenic subjects free of metabolic syndrome(M:F 24:12; Caucasian n=23; North-African n=12; South-Asian n=1)aged 35±9 years
11615419|NCT00528346|Active Comparator|1|Participants will see their own brain activation.
11615420|NCT00528346|Placebo Comparator|2|Participants will see simulated data that does not come from their own brains.
11615421|NCT00528333|Experimental|1|Lintuzumab plus low dose cytarabine
11615422|NCT00528333|Active Comparator|2|Placebo plus low dose cytarabine
11615423|NCT00528307|Active Comparator|1|First 3 months of biventricular pacing, second 3 months right ventricular apical pacing
11615424|NCT00528307|Active Comparator|2|First 3 months of right ventricular apical pacing, second 3 months biventricular pacing
11615425|NCT00528294|Experimental|1|GRID-radiotherapy followed by biological imaging guided IMRT
11615426|NCT00528281|Experimental|Lapatinib + pemetrexed|This is a single-arm, two-stage, multicenter Phase II study to determine the clinical activity of pemetrexed with lapatinib.
11615427|NCT00528268|Experimental|Cohort 1|Family history of SMA type I 0-3 months old Confirmation of no more than 3 SMN2 copies
11615428|NCT00528268|Experimental|Cohort 2|Family history of SMA type II 0-6 months old Confirmation of no more than 4 SMN2 copies
11615429|NCT00528255|Experimental|1|
11615430|NCT00528242|Experimental|1|SLx-2101
11615431|NCT00528242|Placebo Comparator|2|Matching Placebo Dose
11615432|NCT00528190|Experimental|Itraconazole|Itraconazole 5mg/kg/day for 24 weeks
11615433|NCT00528190|Placebo Comparator|Placebo|Placebo/day for 24 weeks
11615434|NCT00528177|Active Comparator|O|This arm will receive intravenous oxycodone at the end of surgery and PCA oxycodone for postoperative pain relief.
11615435|NCT00528177|Active Comparator|M|This arm will receive intravenous morphine at the end of surgery and PCA morphine for postoperative pain relief.
11615436|NCT00528164|Experimental|Team PLAY Group|6-month family-centered intervention to increase physical activity and healthy eating patterns, primarily directed at parents. Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
11615437|NCT00528164|No Intervention|Standard Care Group|Participants receive standard care by primary care physician.
11615438|NCT00528151|Placebo Comparator|2|"curcumin
~placebo"
11615439|NCT00528138||1|Simple appendicitis
11615440|NCT00528138||2|Perforated appendicitis
11615441|NCT00528125|Active Comparator|A|Active laser acupuncture
11615442|NCT00528125|Placebo Comparator|B|placebo laser acupuncture
11615501|NCT00527618|Active Comparator|Standard-dose acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
11615443|NCT00528112|Experimental|LCS12|Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro
11615444|NCT00528112|Experimental|LCS16|Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro
11615445|NCT00528086||1|Parkinson disease patients and their family members or caregivers randomly assigned to receive their PD care in group visit format.
11615446|NCT00528086||2|Parkinson disease patients and their family members or caregivers randomly assigned to receive their PD care in standard of care format (one-on-one physician-patient visits).
11615447|NCT00528073|Experimental|A|Rifaximin-EIR tablet 1x400 mg + Placebo 2 tablets bid
11615448|NCT00528073|Experimental|B|Rifaximin-EIR tablet 2x400 mg + Placebo 1 tablet bid
11615449|NCT00528073|Experimental|C|Rifaximin-EIR tablet 3x400 mg bid
11615450|NCT00528073|Placebo Comparator|D|Placebo 3 tablets bid
11615451|NCT00528047|Experimental|PRLX 93936|
11615452|NCT00528034|Experimental|Lymphoscintigraphy|
11615453|NCT00528021|Active Comparator|1|
11615454|NCT00528021|Active Comparator|2|
11615455|NCT00528021|Active Comparator|3|
11615456|NCT00528021|Placebo Comparator|4|
11615457|NCT00528008|Active Comparator|A|povidone-iodine
11615458|NCT00528008|Active Comparator|B|chlorhexidine gluconate
11615459|NCT00527982|Experimental|Celecoxib treatment|600 mg orally (PO) daily
11615460|NCT00527982|No Intervention|No treatment|
11615461|NCT00527943|Placebo Comparator|Placebo|Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.
11615462|NCT00527943|Experimental|Vorapaxar|Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.
11615463|NCT00527917|Experimental|Uracyst|Sodium chondroitin sulfate
11615464|NCT00527917|Placebo Comparator|Placebo|placebo
11615465|NCT00527904|Experimental|PN 400 (VIMOVO)|500 mg delayed release naproxen/20 mg immediate release esomeprazole
11615466|NCT00527891||Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI Scan
11615467|NCT00527878|Experimental|Placebo/Ranitidine crossover|Patients took placebo for 12 months and then ranitidine for 12 months
11615468|NCT00527878|Experimental|Ranitidine/placebo crossover|Ranitidine for one year followed by placebo for one year
11615469|NCT00527865|Experimental|1|6 subjects DAS181 dosage 0.5 mg; 3 subjects placebo
11615470|NCT00527865|Experimental|2|6 subjects DAS181 dosage 1.0 mg; 3 subjects placebo
11615471|NCT00527865|Experimental|3|6 subjects DAS181 dosage 2.25 mg; 3 subjects placebo
11615472|NCT00527865|Experimental|4|6 subjects DAS181 dosage 4.5 mg; 3 subjects placebo
11615473|NCT00527826|Active Comparator|arm 1|
11615474|NCT00527826|Active Comparator|arm 2|
11615475|NCT00527813|Experimental|A|prone position for at least 16 hours per day
11615476|NCT00527813|No Intervention|B|semi-recumbent position
11615477|NCT00527800|Experimental|1|Treatment for episodes of uncomplicated malaria
11615478|NCT00527800|Active Comparator|2|Treatment for uncomplicated malaria
11615479|NCT00527800|Experimental|A|Prevention of malaria in HIV uninfected, exposed children
11615480|NCT00527800|No Intervention|B|Prevention of malaria in HIV uninfected, exposed children
11615481|NCT00527787|Experimental|PN400|Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily
11615482|NCT00527787|Active Comparator|Naproxen|Naproxen 500 mg dosed twice daily
11615483|NCT00527774||A|HCV(+) maintenance hemodialysis patients
11615484|NCT00527774||B|HCV(-) maintenance hemodialysis patients
11615485|NCT00527761|Experimental|Temozolomide, Docetaxel + Cisplatin|
11615486|NCT00527748|No Intervention|Standard of care|Patient ankle range of motion will be assessed at clinic visit. No stretching exercises with the device, but will be provided standard care through physiotherapist in acute cases, and no stretching exercises for chronic patients. Reassessment will be done at six weeks and 10 weeks.
11615487|NCT00527748|Experimental|Non-Measuring Ankle Exerciser|Subjects will train using only one combination of movement, dorsiflexion with inversion. This is done by manipulating the ring so that the medial and anterior ropes are taut. Subject will start with 3 minute warm-up. Subject will then manipulate the ring so that the foot moves into dorsiflexion with inversion until a point of tolerable discomfort is felt; subject will hold this position for 30 seconds. Stretch will be repeated 10 times, each day, for six weeks. Reassessment will be done at six weeks and 10 weeks.
11615488|NCT00527735|Experimental|Ipilimumab/ placebo + paclitaxel + carboplatin (concurrent)|
11615489|NCT00527735|Experimental|Ipilimumab/ placebo + paclitaxel + carboplatin (sequential)|
11615490|NCT00527735|Active Comparator|Ipilimumab placebo + paclitaxel + carboplatin|
11615491|NCT00527722|Experimental|Pleural Plug|Experimental lung plug after the lung biopsy.
11615492|NCT00527722|Active Comparator|No Pleural Plug|The standard lung biopsy without placement of the plug.
11615493|NCT00527696|Active Comparator|TVT SECURE|sling
11615494|NCT00527696|Active Comparator|TVT O|sling
11615495|NCT00527683|Active Comparator|A|Subjects will receive vigabatrin in escalating doses to 3 grams per day over three weeks, continued for 4 weeks and then tapered to zero over the next 2 weeks.
11615496|NCT00527683|Placebo Comparator|B|Orange juice and administration identical to Arm A.
11615497|NCT00527670||Normal Controls|Healthy patients undergoing laparoscopic surgery for cholelithiasis, appendicitis, and adrenalectomy.
11615498|NCT00527670||Recurrent Hernia|Patients presenting for laparoscopic repair of ventral or incisional hernias.
11615499|NCT00527657|Experimental|Lomustine + Temozolomide + Thalidomide|Lomustine starting dose 30 mg/m^2 by mouth daily on Day 1 and 29. Temozolomide 75 mg/m^2 by mouth daily on Days 1 to 42. Thalidomide 200 mg/m^2 by mouth daily.
11615500|NCT00527644|Other|Spring Clips|Subjects will undergo laparoscopic cholecystectomy with commercially available 5 mm spring clips utilized for the ligation of the cystic duct and artery.
11634959|NCT00310531|Experimental|Arm 1|
11615502|NCT00527618|Experimental|High-dose valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
11615503|NCT00527605|Experimental|A|dutasteride 0.5mg once daily orally
11615504|NCT00527605|Placebo Comparator|B|Placebo matched once daily orally
11615505|NCT00527592|Experimental|Travoprost|Travoprost assigned to one eye, with latanoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.
11615506|NCT00527592|Active Comparator|Latanoprost|Latanoprost assigned to one eye, with travoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.
11615507|NCT00527566|Experimental|Mepolizumab|Subjects will receive open-label mepolizumab
11615508|NCT00527553|Experimental|A|daily consumption of a regular egg
11615509|NCT00527553|Experimental|B|daily consumption of a lutein-enriched egg, eggs laid by chickens on a lutein-enriched feed.
11615510|NCT00527553|Experimental|C|daily consumtion of a zeaxanthin-enriched egg, eggs laid by chickens on a zeaxantin-enriched feed.
11615511|NCT00527553|Experimental|D|daily egg product from enriched eggs
11615512|NCT00527553|No Intervention|E|control subjects were not blinded as they did not receive any aditional supplementation. Only markers measured during the trial period as a control.
11615513|NCT00527527|Active Comparator|1|8 flexion distraction visits
11615514|NCT00527527|Active Comparator|2|12 flexion distraction visits
11615515|NCT00527527|Active Comparator|3|18 flexion distraction visits
11615516|NCT00527527|Placebo Comparator|4|8 placebo control visits
11615517|NCT00527514|Experimental|1|
11615518|NCT00527488|Experimental|Degarelix 16+16 mg|
11615519|NCT00527488|Experimental|Degarelix 32 mg|
11615520|NCT00527488|Experimental|Degarelix 32+32 mg|
11615521|NCT00527488|Experimental|Degarelix 64 mg|
11615522|NCT00527475|Active Comparator|Group I|Group I will receive 0.5 mg. ranibizumab intraocularly initially. This will be repeated monthly for 3 months total and then as needed over the period of one year.
11615523|NCT00527475|Experimental|Group II|Group II will receive Reduced Fluence-PDT (25 Joules) followed by 0.5 mg. of ranibizumab intraocularly on the same day. The second group will receive the combination of ranibizumab and RF-PDT as needed over a period of one year.
11615524|NCT00527436|Other|Dietary Supplement|Fish oil pill
11615525|NCT00527436|Placebo Comparator|Placebo|Placebo matched corn oil pill
11615526|NCT00527423|Experimental|Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye)|
11615527|NCT00527410|Experimental|RTA 744|RTA 744 injection administered intravenously for a maximum of 18 cycles (54 weeks). Dose escalation based on four dose levels and occurance of dose limiting toxicity (DLT).
11615528|NCT00527397|Experimental|B|Type 2 Diabetes Mellitus (DM) who has not yet treated by Insulin
11615529|NCT00527397|Experimental|C|Type 2 DM who has already treated by Insulin
11615530|NCT00527397|Experimental|A|Type 1 DM
11615531|NCT00527371|Experimental|PVP|Photoselective vaporization of the prostate.
11615532|NCT00527371|Active Comparator|TURP|Transurethral resection of the prostate.
11615533|NCT00527358|Experimental|SAFER|"The intervention community will receive 4 services:
~community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;
~youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, and provide education about avoiding violence;
~school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;
~Youth drop-in center: will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training."
11615534|NCT00527358|No Intervention|2|Business as usual.
11615535|NCT00527345||1|children riding retrofitted school buses or private cars
11615536|NCT00527345||2|children riding old buses who will change to retrofitted buses during the first or second year of the study
11615537|NCT00527345||3|children who ride old diesel buses through the study
11615538|NCT00527332|Active Comparator|A|Spinal anesthesia combined with intrathecal morphine. Spinal anesthesia applied in intervertebral space L3/L4 or L2/L3 with hyperbaric bupivacaine 20 mg and morphine 0.2 mg intrathecally. Sedation with propofol.
11615539|NCT00527332|Active Comparator|B|General anesthesia. General anesthesia induced with propofol, fentanyl and rocuronium, and maintained with propofol and oxygen in air. Rocuronium and fentanyl repeated when needed.
11615540|NCT00527319|No Intervention|Group A, control group|Supportive care only
11615541|NCT00527319|Active Comparator|Group B, Low Dose VT-122|VT-122 (dose of etodolac: 400 mg/day) + supportive care
11615542|NCT00527319|Active Comparator|Group C, High Dose VT-122|VT-122 (dose of etodolac: 800 mg/day) + supportive care
11615543|NCT00527306|Experimental|I - Multivitamin|The multivitamin will contain 100% of the US reference daily intakes (recommended daily amounts) of vitamins A, B1, B2, B3, B5, B6, B9, B12, C, D, and E. It also contains several inactive ingredients including sodium bisulfite and gelatin.
11615544|NCT00527306|Placebo Comparator|II - Inactive Medication|The placebo will be a gelatin capsule filled with lactose.
11615545|NCT00527293|Experimental|MammoSite Brachytherapy|Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
11615546|NCT00527293|Experimental|3-dimensional conformal radiotherapy|3-dimensional conformal radiotherapy twice daily for 5-10 days.
11615547|NCT00527280|Experimental|1|
11615548|NCT00527267|Experimental|AMG 073|AMG 073
11615549|NCT00527267|Placebo Comparator|Placebo|Placebo
11615550|NCT00527254|No Intervention|Control group|
11615551|NCT00527254|Active Comparator|Telemedicine group|
11615552|NCT00527241|Experimental|1: A|
11615553|NCT00527241|No Intervention|2 B|wait-listed for intervention to begin in 6 months
11615554|NCT00527228|Active Comparator|A|After 6 months of treatment, and a 3-months wash-out, there is cross-over to Arm B
11615555|NCT00527228|Placebo Comparator|B|After 6 months of treatment, and a 3-months wash-out, there is cross-over to Arm A
11615556|NCT00527215|Experimental|darbepoetin alfa|
11615557|NCT00527202|Experimental|1|active treatment arm
11615558|NCT00527202|Placebo Comparator|2|
11615559|NCT00527150|Other|Cohort 1|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
11615560|NCT00527150|Other|Cohort 2|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
11615561|NCT00527150|Other|Cohort 3|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
11615562|NCT00527150|Other|Optional Cohort 4|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
11615563|NCT00527150|Other|Optional Cohort 5|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
11615564|NCT00527137|Active Comparator|rHuEPO|
11615565|NCT00527137|Experimental|darbepoetin alfa|
11615566|NCT00527124|Experimental|Arm I|Patients receive oral cediranib maleate once daily on days 1-21, docetaxel IV over 1 hour on day 1, and oral prednisone twice daily on days 1-21.
11615567|NCT00527124|Active Comparator|Arm II|Patients receive docetaxel and prednisone as in arm I.
11615568|NCT00527111|Experimental|Chemoradiotherapy plus Cetuximab|Pelvic irradiation plus 5-fluorouracil plus cetuximab
11615569|NCT00527111|Active Comparator|Chemoradiotherapy alone|Pelvic irradiation plus 5-fluorouracil
11615570|NCT00527085|Experimental|AMG 073|
11615571|NCT00527085|Placebo Comparator|Placebo|
11615572|NCT00527072|Experimental|001|infliximabOpen-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
11615573|NCT00527059|Experimental|1|patients with acute heart failure
11615574|NCT00527059|Active Comparator|2|standard therapy for heart failure
11615575|NCT00527033|Experimental|1|Oral
11615576|NCT00527033|Experimental|2|Oral
11615577|NCT00527033|Experimental|3|Oral
11615578|NCT00527033|Placebo Comparator|4|Oral
11615579|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort A|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
11615580|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort B|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
11615581|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort C|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
11615582|NCT00527020|Experimental|Part B: Subjects in 5 period crossover period|Eligible subjects (first 14 subjects) will be randomized to one of the following 14 sequences as a 5 period crossover with sequences; LMNOQ, MNOLQ, NOLMQ, OLMNQ, ONMLQ, NMLOQ, MLONQ, LONMQ, LNMOQ, NMOLQM MOLNQ, OLNMQ, OMNLQ and MNLOQ) (L= 80 milligrams GSK1018921 given in fasted state, M= 200 milligrams GSK1018921 given in fasted state, N= nicotine lozenge, O= placebo and Q= 80 milligrams GSK1018921 in fed state).
11615583|NCT00527020|Experimental|Part B: Subjects in 4 period crossover period|Eligible subjects (last 7 subjects) will be randomized to one of the following 7 sequences as a 4 period crossover with sequences; NLOM, LOMN, OLNM, LNMO, NMOL, MOLN, and MNLO.
11615584|NCT00527007|Experimental|A|
11615585|NCT00527007|No Intervention|B|
11615586|NCT00526994|Experimental|Screened|Screened w/4 questions on intimate partner violence; if positive, receives referral information
11615587|NCT00526994|Active Comparator|Universal education|all participants receive partner violence referral information
11615588|NCT00526994|No Intervention|Control|no screen and no referral
11615589|NCT00526981|Experimental|Treatment|Prone position + all conventional treatment.
11615590|NCT00526981|No Intervention|Control|Conventional treatment
11615591|NCT00526968|Experimental|1|EVT 101 8 mg capsule
11615592|NCT00526968|Experimental|2|EVT 101 15 mg capsule
11615593|NCT00526968|Placebo Comparator|3|Matching placebo capsule
11615594|NCT00526942|No Intervention|I|No contact control (NCC)
11615595|NCT00526942|Experimental|II|Computerized, SAAGE-designed, visual memory-based cognitive training
11615596|NCT00526929|Experimental|darbepoetin alfa|darbepoetin alfa (NESP)
11615597|NCT00526903|Experimental|Fiber|Fiber added to diet for a total of 6 weeks.
11615598|NCT00526903|Placebo Comparator|Placebo|Placebo powder taken for a total of 6 weeks.
11615599|NCT00526890|Experimental|CPSR|Concurrent Carboplatin, Paclitaxel and Selenomethionine in Combination with Radiation
11615600|NCT00526877|Experimental|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
11615601|NCT00526864||Elderly patients|
11615602|NCT00526864||HIV infected patients|
11615603|NCT00526864||Immunosuppressed patients|
11615604|NCT00526838|Experimental|1|once-weekly dosing
11615605|NCT00526838|Experimental|2|twice-weekly dosing
11615606|NCT00526812|Experimental|Group A (RTA 744)|Receive study drug for three consecutive days, Cycle repeated every 21 days.
11615607|NCT00526812|Experimental|Group C (RTA 744 Injection)|Receive study drug once a week for four consecutive weeks. Repeat cycle every 5 weeks.
11615608|NCT00526799|Experimental|Phase I|Topotecan 3.5 mg/m^2 + Sorafenib dose escalation:
11615609|NCT00526799|Experimental|Phase II|Topotecan 3.5 mg/m^2 + Sorafenib 400 mg po daily.
11615610|NCT00526773|Other|1|Telephone management plus a motivational intervention
11615611|NCT00526773|Other|2|Telephone management with standard patient education
11615612|NCT00526760|Experimental|Dexmedetomidine|
11615613|NCT00526747||Epo-resistant|Patients with CKD (estimated GFR < 60cc/min) not on hemodialysis who are receiving greater than or equal to 100IU/kg/week of epoetin alpha and/or 1mcg/kg/week darbepoetin to obtain target hemoglobin or hematocrit.
11615614|NCT00526747||Epo-responsive|Patients with CKD (estimated GFR < 60cc/min) not on hemodialysis who are requiring <100IU/kg/week of epoetin alpha and/or 1mcg/kg/week of darbepoetin to obtain target hemoglobin/hematocrit.
11615615|NCT00526682|Active Comparator|1|Comparison of actives for synergy
11615616|NCT00526656|Experimental|sunitinib malate|Drug
11615617|NCT00526643|Experimental|Arm B|combination chemotherapy
11615618|NCT00526643|Active Comparator|Arm A|monochemotherapy
11615619|NCT00526630|Active Comparator|1. MPD|Randomized to receive active Methylphenidate first. At cross-over, participants will receive placebo.
11615620|NCT00526630|Placebo Comparator|2. Placebo|Randomized to receive placebo first. At cross-over, participants will receive the active Methylphenidate.
11615621|NCT00526617|Experimental|Open Label|Within each dose level, subjects are treated with the same regimen/doses of ABT-888 and TMZ.
11615622|NCT00526604|Active Comparator|2|The control group will have an clinical examination and exercise and then return to general practitioner, which will take decision about sick leave or return to work.
11615623|NCT00526591|Experimental|Low-dose Everolimus Cohort|5mg Everolimus daily continuously for 8 weeks and conventional surgery
11615624|NCT00526591|Active Comparator|High-dose Everolimus Cohort|10mg Everolimus daily continuously for 8 weeks and conventional surgery
11615625|NCT00526578||Questionnaire|Pancreatic cancer patients or family member.
11615626|NCT00526565|Experimental|1|TAT (Tapas Acupressure Technique)
11615627|NCT00526565|Active Comparator|2|SS (Professionally facilitated social support groups)
11615628|NCT00526500|Experimental|P-T|
11615629|NCT00526500|Experimental|P- SAH|
11615630|NCT00526500|Experimental|P- A|
11615631|NCT00526500|Experimental|Control|
11615632|NCT00526487|Other|1|Endovascular Repair
11615633|NCT00526474|Placebo Comparator|Placebo|1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.
11615634|NCT00526474|Experimental|Vorapaxar|one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.
11615635|NCT00526461|Experimental|PDT using HPPH|Patients receive HPPH IV over 1 hour on day 1. Patients then receive photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.
11615636|NCT00526448|Experimental|1|Peginterferon alfa-2a 180 mcg/week + ribavirin 2000 mg/day + epoetin beta 450 UI/week
11615637|NCT00526448|Active Comparator|2|Peginterferon alfa-2a 180 mcg/week + ribavirin 1000-1200 mg/day
11615638|NCT00526435|Experimental|Group WWE|Subjects will participate in a group-assisted 6 week WWE program.
11615639|NCT00526435|Experimental|Self-directed|Subjects will follow the self-directed WWE program.
11615640|NCT00526396|Active Comparator|A|standard fixed doses
11615641|NCT00526396|Experimental|B|toxicity adjusted dosing
11615642|NCT00526383|Experimental|A|antidepressant versus medical dispositive
11615643|NCT00526383|Placebo Comparator|B|
11615644|NCT00526370||A|Women with at least moderate dysplasia in biopsies from cervix uteri
11615645|NCT00526370||B|Women with only normal PAP-smears
11615646|NCT00526357|Other|A|Of the 24 asthmatic subjects, 12 will be enrolled who are taking beta2 agonists alone to treat their asthma
11615647|NCT00526357|Other|B|Of the 24 asthmatic subjects, 12 will be enrolled who are taking beta2 agonists and inhaled steroids to treat their asthma
11615648|NCT00526344||1|Subjects with complete remission of asthma
11615649|NCT00526344||2|Subjects with symptomatic remission of asthma
11615650|NCT00526344||3|Subjects with asthma
11615651|NCT00526344||4|Healthy controls
11615652|NCT00526331|Experimental|Study Group|FloTrac Sensor + Vigileo Monitor used to decide how much fluid to give during surgery.
11615653|NCT00526331|Experimental|Control Group|FloTrac Sensor + Vigileo Monitor only used for data collection during surgery; Standard of Care to decide fluid amount.
11615654|NCT00526292|Experimental|natural killer (NK) cells with salvage chemotherapy|This is a Phase II study, designed to determine the efficacy of natural killer (NK) cells isolated from HLA-haploidentical related donors when infused following a salvage chemotherapy regimen into patients who have relapsed or persistent leukemia following an allogeneic HLA-compatible HSCT and who are ineligible for a second HSCT.
11615655|NCT00526266|Experimental|1|
11615656|NCT00526266|Placebo Comparator|2|
11615657|NCT00526266|No Intervention|3|No Treatment
11615658|NCT00526253|Active Comparator|Low Dose|Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.
11615659|NCT00526253|Active Comparator|High Dose|Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.
11615660|NCT00526253|Placebo Comparator|Control|Patient will undergo biopsy of muscle tissue and biopsy tissue will be sent to lab.
11615661|NCT00526227|Experimental|1|Secura ICD implanted
11615662|NCT00526214|No Intervention|1|In the control group, patients will not take the drug. We do not use placebo drugs.
11615663|NCT00526214|Experimental|2|In the intervention group, patients will take celecoxib.
11615664|NCT00526201|Experimental|Exercise|Subjects will be randomized to exercise (12 week EnhanceFitness class) or a wait-list control group.
11615665|NCT00526201|Other|Control|Wait-list control group will receive intervention after 12-weeks.
11615666|NCT00526188|Experimental|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
11615667|NCT00526162|Experimental|Implantation of Consulta CRT-D|Patients have an implant attempt with a Bi-ventricular Implantable Cardioverter Defibrillator
11615668|NCT00526136|Placebo Comparator|1|Placebo (b.i.d.)
11615669|NCT00526136|Experimental|2|Vernakalant (oral), 150 mg (b.i.d.)
11615670|NCT00526136|Experimental|3|Vernakalant (oral), 300 mg (b.i.d.)
11615671|NCT00526136|Experimental|4|Vernakalant (oral), 500 mg (b.i.d.)
11615672|NCT00526123|Active Comparator|1|symmetric tip catheter
11615673|NCT00526123|Active Comparator|2|conventional split-tip catheter
11615674|NCT00526110|Experimental|5-Fluorouracil + Docetaxel + Oxaliplatin|5-Fluorouracil 2.2 Gm/m^2 intravenously (IV) over 48 hours on Day 1. Docetaxel 20 mg/m^2 IV over 60 minutes. Oxaliplatin 85 mg/m^2 IV over 120 minutes on Day 1.
11615675|NCT00526097|Experimental|Bisacodyl 5 mg x 2 once daily|patient to receive two enteric-coated tablets containing 5 mg bisacodyl
11615676|NCT00526097|Placebo Comparator|Placebo|patient to receive two placebo-to-match enteric-coated tablets 5 mg bisacodyl
11615677|NCT00526071|Experimental|Migalastat|Migalastat was administered orally, 150 mg QOD, 250 mg QD for 3 days, 4 days off per week for 2 months, or 500 mg QD for 3 days, 4 days off per week for up to 10 months, depending on the approval date of the protocol amendments at each site. Participants received migalastat for up to 56 months.
11615678|NCT00526058|Other|A (Secura then Futura)|The Group Randomized first to the approved Plasmat® Secura apheresis system and then to the Plasmat® Futura apheresis system.
11615679|NCT00526058|Other|B (Futura then Secura)|The Group Randomized first to the approved Plasmat® Futura apheresis system and then to the Plasmat® Secura apheresis system.
11615680|NCT00526045|Experimental|Escalation|
11615681|NCT00526045|Experimental|HER2 Positive|
11615682|NCT00526045|Experimental|ER+ breast cancer|
11615683|NCT00526032||Spectroscopic Oblique-Incidence Reflectometry (OIR)|
11615684|NCT00526019||Complete remission of their asthma|Subjects in complete remission of their asthma Subjects in complete remission of their asthma: absence of respiratory symptoms, no rescue asthma medication need and an optimal pulmonary function and normal PC20 methacholine (>16 mg/ml) for more than two years (with no current treatment).
11615685|NCT00526019||Symptomatic remission ofasthma|Subjects in symptomatic remission of their asthma (No asthma symptoms in the last 2 years, no asthma medication, PC20 methacholine <16 mg/ml)
11615686|NCT00526019||Current asthma (mild asthma)|Subjects with current asthma (Mild asthma)
11615687|NCT00526019||Healthy controls|Healthy controls
11615688|NCT00525993|Experimental|A|
11615689|NCT00525993|Active Comparator|B|
11615690|NCT00525980|Experimental|Group 1: Written Materials|One group asked to read educational materials.
11615691|NCT00525980|Experimental|Group 2: Computer Program Only|Group 2 use an educational computer program to learn about breast cancer risk and genetic testing without guidance.
11615692|NCT00525980|Experimental|Group 3: Computer Program + Promotora|Group 3 use the computer program with the guidance of a promotora.
11615693|NCT00525967|Active Comparator|1|Methadone plus Placebo
11615694|NCT00525967|Experimental|2|Methadone plus Acetaminophen
11615695|NCT00525915|Experimental|Arm A: Chemo with Radiation Treatment|For 5 weeks, Chemo of 5-FU 250 mg/m^2 intravenous (IV) over 24 hours for 5 days weekly with Oxaliplatin 40 mg/m^2 IV daily over 2 hours, and Radiation treatment every weekday; then surgery.
11615696|NCT00525915|Experimental|Arm B: Pre-Op Chemo + Chemo with Radiation Treatment|Pre-Operative Chemo 5-FU 2.2 mg/m^2 IV continuous infusion over 48 hours start on day 1 and 15, and Oxaliplatin 100 mg/m^2 IV on day 1 and 15; followed by Surgery + Chemo with Radiation Therapy (same as Arm A)
11615697|NCT00525902|Experimental|Adalimumab|
11615698|NCT00525889|Experimental|Rapamycin/IL-2 combination therapy|IL-2 (Proleukin) was administered at 4.5 3 106 IU s.c., three times per week for 4 weeks for a total of 12 doses. Rapamycin (Rapamune or Sirolimus) was administered without a loading dose at 2 mg/day, with adjustments to maintain trough blood levels of 5-10 ng/mL for 3 months.
11615699|NCT00525876|Experimental|Matched Sibling Transplant|Allogeneic Stem Cell Transplantation With Rituximab Containing Nonablative Conditioning Regimen: Cyclophosphamide 750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.
11615700|NCT00525876|Experimental|Allo MUD & MM|Allo MUD & MM = Allogeneic Stem Cell Transplantation, Matched unrelated donor or mismatched sibling donor transplantations: Cyclophosphamide 1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation. Alemtuzumab 15 mg per day given intravenously days 1 through 3 after transplantation.
11615701|NCT00525850|Other|1|high saturated fat diet
11615702|NCT00525850|Other|2|low calorie low saturated fat low trans fat high fiber diet
11615703|NCT00525837|Other|varenicline|open label varenicline
11615704|NCT00525811|Experimental|A|Interactive decision aid
11615705|NCT00525811|Active Comparator|B|Regular patient information
11615706|NCT00525798|Active Comparator|1|SMC021 - Oral Calcitonin
11615707|NCT00525798|Placebo Comparator|SMC021- Placebo|SMC021 - placebo
11615708|NCT00525785|Experimental|5-Fluorouracil + Folinic Acid + Oxaliplatin|"PreOp Chemotherapy: 2 cycles (each cycle consisting of 4 weeks or 2 treatments) of chemotherapy with oxaliplatin, folinic acid and infusional 5-FU (FOLFOX-48). Oxaliplatin 100 mg/m^2 over 2 hours on day 1, folinic acid intravenous (IV) at 200 mg/m^2 over 30 minutes on day 1, and 5-FU 2,200 mg/m^2 over 48 hours as continuous infusion by outpatient pump starting on day 1. This therapy, FOLFOX-48 repeated every 2 weeks x 4 (8 weeks of induction chemotherapy).
~PreOp Chemoradiotherapy begins 12 days after last dose of PreOp Chemo 5FU plus oxaliplatin; A total of 45 Gy (1.8 Gy fx/d) of radiotherapy concurrent to low-dose continuous infusion of 5-FU (300 mg/m^2/d Monday through Friday) & weekly oxaliplatin 45 mg/m^2 over 2 hours for 5 weeks (oxaliplatin administered on the first day of radiation week).
~Surgical resection 4-6 weeks after completion of chemoradiotherapy"
11615709|NCT00525772|Active Comparator|1|ciclesonide 50 and 200ug
11615710|NCT00525772|Active Comparator|2|ciclesonide 100ug and 400ug
11615711|NCT00525759|Active Comparator|A|Neoadjuvant chemotherapy alone
11615712|NCT00525759|Experimental|B|Neoadjuvant chemotherapy + zoledronic acid
11615713|NCT00525746||Cases|Patients with a confirmed diagnosis of AML or MDS (cases).
11615714|NCT00525746||Controls|Patients treated for a primary malignancy (controls).
11615715|NCT00525733|Active Comparator|3-drug standard therapy|FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ +ritonavir 100 mg QD
11615716|NCT00525733|Experimental|5-drug experimental therapy|FTC 200 mg/TDF 300 mg QD + darunavir 800 mg + ritonavir 100 mg QD + Raltegravir 400 mg BID + Maraviroc 150 mg BID
11615717|NCT00525720|Experimental|Brachytherapy - Participants with < 35% biopsy core|Brachytherapy implant procedure lasting 1-2 hours. Questionnaires taking 30 total minutes.
11615718|NCT00525720|Experimental|Brachytherapy - Participants with > 35% biopsy core|Brachytherapy implant procedure lasting 1-2 hours. Questionnaires taking 30 total minutes.
11615719|NCT00525707|Experimental|1|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
11615720|NCT00525707|Placebo Comparator|2|
11615721|NCT00525694|Other|1|glucose tolerance test solution
11615722|NCT00525694|Other|2|Diet Coke
11615723|NCT00525694|Other|3.|Coke Zero
11615724|NCT00525681|Other|CsA|Investigation of systemic exposure of cyclosporine before and after 2 moths of co-adminiastration of rimonabant.
11615725|NCT00525681|Other|Tac|Investigation of systemic exposure of tacrolimus before and after 2 moths of co-adminiastration of rimonabant.
11615726|NCT00525668|Active Comparator|verum|Sunphenon plus glatiramer acetate
11615727|NCT00525668|Active Comparator|placebo|placebo plus glatiramer acetate
11615728|NCT00525655|Experimental|Multimedia Intervention|
11615729|NCT00525642|Experimental|A|six cycles of adjuvant TAC
11615730|NCT00525642|Experimental|B|four cycles of T followed by 4 cycles of AC
11615731|NCT00525629|Experimental|Walnut Diet|48 Grams of Walnuts Daily
11615732|NCT00525629|Placebo Comparator|Control Diet|Isocaloric Diet with No Walnuts
11615733|NCT00525616|Experimental|Rituximab|Treatment consists of two slow intravenous infusions of rituximab 1000mg to 15 days apart with local corticosteroid .
11615734|NCT00525603|Experimental|CFAR|CFAR = Cyclophosphamide 200 mg/m^2/day 3-5 intravenous (IV) 5-30 minutes, Fludarabine 20 mg/m^2/day 3-5 IV 5-30 minutes, Alemtuzumab 30 mg 1, 3,5 IV 2-4 hours, and Rituximab 375 mg/m^2/day 2 IV 4-6 hours
11615735|NCT00525590|Experimental|1|
11615736|NCT00525577|Experimental|1:A|Placebo
11615737|NCT00525577|Experimental|2:B|AGI-1067 75 mg
11615738|NCT00525577|Experimental|3:C|AGI-1067 150 mg
11615739|NCT00525564|Placebo Comparator|A|Placebo diskus
11615740|NCT00525564|Active Comparator|B|Salmeterol diskus powder
11615741|NCT00525551|Active Comparator|1|
11615742|NCT00525551|Placebo Comparator|2|
11615743|NCT00525525|Experimental|Efficacy Group|Patients treated with the combination of radiation plus temozolomide (75 mg/m2 daily during radiotherapy) plus bevacizumab (10 mg/kg IV every two weeks during radiotherapy) plus tarceva (dose based upon use of EIAED, either 200 mg daily or 500 mg daily; given daily); all treatment begins at the start of radiotherapy and continues until tumor progression, death or excessive toxicity
11615744|NCT00525525|Other|Safety Lead-in Group|"Fractionated radiotherapy in daily doses of 1.8-2.0 Gy delivered 5 days per week over ~6 weeks, to a total dose of 59.4 to 60 Gy.
~Adjuvant temozolomide 200 mg/m^2/d x 5 d per 28-d cycle; Erlotinib 150-200 mg/d (or 500-600 mg/d for patients on enzyme-inducing antiepileptic drugs) on a continuous basis 7 days per week; Bevacizumab 10 mg/kg every 2 weeks"
11615745|NCT00525512|Experimental|tiotropium 18mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
11615746|NCT00525512|Placebo Comparator|Placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
11615747|NCT00525499|Placebo Comparator|1|Vehicle control cream applied topically to the face twice daily for 12 weeks
11615748|NCT00525499|Experimental|2|0.001% ASC-J9 cream applied topically to the face twice daily for 12 weeks
11615749|NCT00525499|Experimental|3|0.005% ASC-J9 cream applied topically to the face twice daily for 12 weeks
11615750|NCT00525499|Experimental|4|0.025% ASC-J9 cream applied topically to the face twice daily for 12 weeks
11615751|NCT00525486|Experimental|A|The treated group of pregnant women, after having successful treatment for PTL
11615752|NCT00525486|No Intervention|B|The no treatment arm of women treated with tocolysis for PTL.
11615753|NCT00525447|Experimental|1|
11615754|NCT00525434|Experimental|A|
11615755|NCT00525421|Experimental|Curcumin|Curcumin C3 Complex
11615756|NCT00525421|Placebo Comparator|Placebo|Placebo
11615757|NCT00525408|Experimental|2|Docetaxel+Mw
11615758|NCT00525408|Active Comparator|1|Docetaxel
11615759|NCT00525395|Experimental|A|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
11615760|NCT00525395|Active Comparator|B|Group B: 6 months non-stop treatment.
11615761|NCT00525356|Active Comparator|1|Anti-hypertensive medical treatment
11615762|NCT00525330|Experimental|KRP-104 120 mg QD|
11615763|NCT00525330|Experimental|KRP-104 60 mg BID|
11615764|NCT00525330|Placebo Comparator|Placebo|
11615765|NCT00525317|Active Comparator|Magnesium tablet suplementation (1)|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"
11615766|NCT00525317|Placebo Comparator|Placebo tablet suplementation (2)|Placebo (3 times daily for 2 weeks)
11615767|NCT00525304|Experimental|1|Participants will receive a self-management program for chronic illness
11615768|NCT00525304|No Intervention|Usaual Care|Usual Care; no additional intervention
11615769|NCT00525291|Experimental|EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
11615770|NCT00525291|Active Comparator|EMG-biofeedback alone|
11615771|NCT00525265|Experimental|1|OPC-41061
11615772|NCT00525265|Placebo Comparator|2|placebo
11615773|NCT00525252|Placebo Comparator|2|A total of 42 alcoholic patients with liver cirrhosis treated with placebo
11615774|NCT00525252|Active Comparator|1|a total of 42 alcoholic patients with liver cirrhosis treated by baclofen
11615775|NCT00525239|Experimental|1: Ritonaivr|Pre and post ritonavir, lopinavir/ritonavir or atazanavir/ritonavir
11615776|NCT00525226||1|Women who have experienced symptoms of depression or anxiety during pregnancy.
11615777|NCT00525213|Active Comparator|A|
11615778|NCT00525213|Active Comparator|B|
11615779|NCT00525213|Active Comparator|C|
11615780|NCT00525213|Placebo Comparator|D|
11615781|NCT00525200|Active Comparator|A|
11615782|NCT00525200|Experimental|B|
11615783|NCT00525174|Active Comparator|Patching|2 hours daily patching of the sound eye plus one hour near activities while patching
11615784|NCT00525174|Active Comparator|Bangerter filters|Bangerter filter worn on sound eye spectacles lens full time plus at least one hour near activities
11615785|NCT00525161|Experimental|Sorafenib & Endocrine Therapy|Sorafenib & Endocrine Therapy
11615786|NCT00525148|Experimental|BIBW 2992|Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop. Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs. After protocol amendment 2 (17 Dec 2008), the starting dose of BIBW 2992 was reduced to a medium dose, with 2 possible dose reductions if needed after discontinuation due to drug-related AEs.
11615787|NCT00525135|Other|1|If a patient exhibits increased radioiodine uptake on the Thyrogen scan post valproic acid therapy, patients will then prepare for ablative treatment and will remain on valproic acid for a total of 16 weeks, until receiving RAI ablation.
11615788|NCT00525135|Other|2|If no increased uptake is seen, patients will continue on valproic acid for 6 additional weeks at an increased dosage, totaling an overall treatment time of 16 weeks as well.
11615789|NCT00525122||1|Patients with hyperthyroidism who are will be treated with radioactive iodine.
11615790|NCT00525109||1|Single family cohort
11615791|NCT00525096|Placebo Comparator|Placebo|Aromasin + placebo in place of Celebrex
11615792|NCT00525096|Experimental|Celebrex|Aromasin + Celebrex
11615793|NCT00525057|Experimental|Treatment (dalteparin)|Participants receive dalteparin SC QD starting 12-24 hours after surgery on post-operative day 1 until hospital discharge, about 7-10 days.
11615794|NCT00525044|Placebo Comparator|Control|
11615795|NCT00525044|Experimental|Ambroxol|
11615796|NCT00525031|Experimental|Temozolomide (TMZ)|Temozolomide = TMZ - 150 mg/m^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.
11615797|NCT00525031|Experimental|Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI)|"Temozolomide = TMZ and PGI = Pegylated Interferon-alpha 2b
~Temozolomide 150 mg/m^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks. Pegylated Interferon-alpha 2b 0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks."
11615798|NCT00525005|Experimental|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
11615799|NCT00524979||Schizophrenia|People who are diagnosed as schizophrenic by DSM-IV
11615800|NCT00524979||Mental diseases|Patients who are deagnosed as having mental disease other then schizophrenia
11615801|NCT00524979||Mentally healthy|People who have no mental disease
11615802|NCT00524953|Experimental|I|10 patients after allogeneic BMT (non T-depleted).
11615803|NCT00524940|Experimental|Study Group|
11615804|NCT00524927|Active Comparator|A|
11615805|NCT00524927|Placebo Comparator|B|
11615806|NCT00524914|Experimental|1|Apomorphine
11615807|NCT00524914|Placebo Comparator|2|Placebo
11615808|NCT00524901|Experimental|1|25 patients undergoing CABG for three vessel disease, receiving a single dose of erythropoietin periprocedural.
11615809|NCT00524901|Placebo Comparator|2|25 patients undergoing CABG for three vessel disease, receiving placebo (NaCl 0.9%) periprocedural.
11615810|NCT00524888|Active Comparator|1|suturing lacerations of the hand
11615811|NCT00524888|Active Comparator|2|using bioadhesive on lacerations of hand
11615812|NCT00524875|Experimental|1|Intravitreal bevacizumab injection 1-2 weeks before surgery
11615813|NCT00524875|Sham Comparator|2|Sham injection (needleless syringe pressed against conjunctiva)
11615814|NCT00524862|Other|1|
11615815|NCT00524862|Other|2|
11615816|NCT00524849|Active Comparator|conventional Zometa|Zometa 4mg IV q4w, in combination with other antitumor agents one month after the initial dosing.
11615817|NCT00524849|Experimental|weekly Zometa|Weekly Zometa in combination with other antitumor agents one month after the initial dosing.
11615818|NCT00524823||1|10 diagnosed men in age 60 - 90 with Prostate Cancer
11615819|NCT00524823||2|10 patients with benign growth
11615820|NCT00524823||3|10 health volunteers
11615821|NCT00524823||4|10 patients diagnosed with other cancer
11615822|NCT00524810|Experimental|Caelyx - Taxotere|
11615823|NCT00524797|Active Comparator|Main|50 patients will receive Profonycia 5 gr/day PO for 7 days
11615824|NCT00524784|Experimental|A|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses
11615825|NCT00524771||1|Users of NuvaRing
11615826|NCT00524771||2|Users of combined oral contraceptives
11615827|NCT00524758|Experimental|Ologen in Trabeculectomy|Ologen in Trabeculectomy
11615828|NCT00524758|Active Comparator|MMC in Trabeculectomy|MMC in Trabeculectomy
11615829|NCT00524745|Active Comparator|0,2,6 month vaccination schedule|
11615830|NCT00524745|Active Comparator|0,3,9 month vaccination schedule|
11615831|NCT00524745|Active Comparator|0,6,12 month vaccination schedule|
11615832|NCT00524745|Active Comparator|0,12,24 month vaccination schedule|
11615833|NCT00524732||1|18 to 30 months since last prior dose of TD/Td vaccine.
11615834|NCT00524732||2|30 to 42 months since last prior dose of TD/Td vaccine.
11615835|NCT00524732||3|42 to 54 months since last prior dose of TD/Td vaccine.
11615836|NCT00524732||4|54 to 66 months since last prior dose of TD/Td vaccine.
11615837|NCT00524732||5|66 to 78 months since last prior dose of TD/Td vaccine.
11615838|NCT00524732||6|78 to 90 months since last prior dose of TD/Td vaccine.
11615839|NCT00524732||7|90 to 102 months since last prior dose of TD/Td vaccine.
11615840|NCT00524732||8|102 to 114 months since last prior dose of TD/Td vaccine.
11615841|NCT00524732||9|Control - over 114 months since last prior dose of TD/Td vaccine.
11615842|NCT00524719|Active Comparator|Open, internal fixation volar plate|Open reduction and internal fixation (ORIF) with volar locked plate
11616086|NCT00522418|Active Comparator|Best Medical Practice|Best Medical Practice
11615843|NCT00524719|Active Comparator|Closed reduction with external fixator|Surgical procedure - Closed reduction and non-spanning external fixation (Ex-FIX)
11615844|NCT00524719|Active Comparator|Closed reduction percutaneous pinning|Surgical procedure - Closed reduction with percutaneous pinning (CRPP) and the application of a cast
11615845|NCT00524693|Active Comparator|1|4mg Singulair© sachets
11615846|NCT00524693|Placebo Comparator|2|
11615847|NCT00524680|Experimental|Arm I|Patients receive 4,000 IU of oral cholecalciferol (vitamin D3) once daily.
11615848|NCT00524680|Experimental|Arm II|Patients receive 6,000 IU of vitamin D3 once daily.
11615849|NCT00524680|Experimental|Arm III|Patients receive 8,000 IU of vitamin D3 once daily.
11615850|NCT00524680|Experimental|Arm IV|Patients receive 10,000 IU of vitamin D3 once daily.
11615851|NCT00524667|Experimental|1|
11615852|NCT00524615|Active Comparator|1|25 mg of Spironolactone oraly once daily
11615853|NCT00524615|Placebo Comparator|2|placebo oraly once daily
11615854|NCT00524589|Experimental|Dexamethasone and Calcitriol|Patients receive oral dexamethasone once on days 1 and 2 and calcitriol IV over 1 hour on day 2. Treatment repeats weekly.
11615855|NCT00524576|Experimental|Engerix 2 Doses + Challenge Dose|Subjects received 2 doses of Engerix™-B (Month 0 and 6) in the primary study and a single dose of Engerix™-B during the booster study.
11615856|NCT00524576|Experimental|Engerix 3 Doses + Challenge Dose|Subjects received 3 doses of Engerix™-B (Month 0, 1 and 6) in the primary study and a single dose of Engerix™-B during the booster study.
11615857|NCT00524537||Adalimumab (Humira) Treatment|Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.
11615858|NCT00524511|Experimental|1|Women receiving Dermabond for skin closure
11615859|NCT00524511|Active Comparator|2|Women receiving standard surgical skin staples
11615860|NCT00524498|Experimental|A|FAIT
11615861|NCT00524498|Active Comparator|B|BST
11615862|NCT00524485|Experimental|Arm 1 - ALA|Patients receive topical ALA topical (aminolevulinic acid) 2 hours before PDT.
11615863|NCT00524485|Experimental|Arm 2|Patients receive topical ALA topical (aminolevulinic acid) 4 hours before PDT
11615864|NCT00524485|Experimental|Arm 3|Patients receive topical ALA (aminolevulinic acid) 24 hours before PDT. Each anatomic area is divided into subunits (e.g., right and left arm, right and left side of the face). The subunits are randomized to receive 1 or 2 pulses of the laser treatment
11615865|NCT00524485|Experimental|Arm 4|Vbeam laser pulse (photodynamic therapy) is applied to the subunit
11615866|NCT00524485|Experimental|Arm 5|Vbeam laser pulses (photodynamic therapy) are applied to the subunit. Patients may receive up to 3 treatments (including pretreatment, ALA, and PDT) at least 1 month apart
11615867|NCT00524472|Experimental|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
11615868|NCT00524472|Other|Insulin at the standard of care levels|Group B will be administered insulin at the standard of care levels established by the participating institution.
11615869|NCT00524446|No Intervention|ST-DI|Standard treatment - delayed intervention. Counselling on complementary feeding + Vitamin A (200,000 IU) every 6 months until 36 months + 1 kg maize / soy flour 2-weekly (71 g / day) between 18 and 30 months of age.
11615870|NCT00524446|Experimental|FSm|Fortified Spread (milk). Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
11615871|NCT00524446|Experimental|FSs|Counselling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
11615872|NCT00524446|Experimental|LP|Likuni Phala. Counseling + Vitamin A as for ST-DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
11615873|NCT00524433|Experimental|1|tezosentan
11615874|NCT00524433|Placebo Comparator|2|
11615875|NCT00524420|Experimental|Active rTMS|Active rTMS involves administration of real rTMS to the patient.
11615876|NCT00524420|Sham Comparator|Sham rTMS|Sham rTMS is a placebo or inactive form of rTMS for study control and comparison purposes.
11615877|NCT00524368|Experimental|DRV/rtv 800/100 mg once daily|Two 400 mg darunavir (DRV) ie, TMC114 tablets + one 100 mg ritonavir (rtv) capsule once daily.
11615878|NCT00524368|Experimental|DRV/rtv 600/100 mg twice daily|One 600 mg TMC114 tablet + one 100 mg capsule of rtv twice daily.
11615879|NCT00524342|Experimental|Oprelvekin, Interleukin 11, IL-11|25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
11615880|NCT00524316|Experimental|Sunitinib|oral sunitinib malate once daily on days 1-7 and 15-35 in course 1 and on days 1-28 in all subsequent courses
11615881|NCT00524303|Active Comparator|Arm 1|Trastuzumab alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles and Paclitaxel for 4 (21 day) cycles then continued trastuzumab until time of definitive surgery
11615882|NCT00524303|Experimental|Arm 2|Lapatinib alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued lapatinib until time of definitive surgery
11615883|NCT00524303|Experimental|Arm 3|Trastuzumab + Lapatinib for 2 weeks then added FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued trastuzumab + lapatinib until time of definitive surgery
11615884|NCT00524277|Experimental|Arm I|HLA-A2-positive patients receive GP2 peptide + GM-CSF vaccine intradermally (ID) every 3-4 weeks for a total of up to 6 inoculations.
11615885|NCT00524277|Active Comparator|Arm II|HLA-A2-positive patients receive GM-CSF ID every 3-4 weeks for a total of up to 6 inoculations.
11615886|NCT00524277|Experimental|Arm III|HLA-A2-negative patients receive AE37 peptide/GM-CSF vaccine ID every 3-4 weeks for a total of up to 6 inoculations.
11615887|NCT00524277|Active Comparator|Arm IV|HLA-A2-negative patients receive GM-CSF ID ID every 3-4 weeks for a total of up to 6 inoculations
11615888|NCT00524264|Experimental|1|
11615889|NCT00524264|Placebo Comparator|2|
11615890|NCT00524238|Other|1|11 hypothyroid patients, newly diagnosed, examined before and after treatment
11615891|NCT00524238|No Intervention|2|10 healthy controls
11616082|NCT00522444|Experimental|nebulized magnesium sulfate|6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
11615892|NCT00524225|Experimental|Neumega (Interleukin 11, IL-11)|Neumega (Oprelvekin, Interleukin 11, IL-11) 25 mcg/kg subcutaneously, given for 4 days preoperatively, and on day 5 preoperatively, and for up to 2 days postoperatively
11615893|NCT00524212||IE confirmed IE rejected|Prospective, controlled, blinded study of clinical/TEE criteria of IE compare to clinical/blood test criteria of IE.
11615894|NCT00524212||IE confirmed IE rejected|
11615895|NCT00524199|Placebo Comparator|Placebo|Saline IV infusion over five minutes at the beginning of dialysis.
11615896|NCT00524199|Active Comparator|Mesna|12 mg/kg mesna IV infusion over five minutes at the beginning of dialysis.
11615897|NCT00524186|Experimental|Oral Sunitinib|Patients receive oral sunitinib malate on day -7 and then once daily on days 2-28 in course 1 and on days 1-28 in all subsequent courses
11615898|NCT00524173|Active Comparator|Tenofovir only|Tenofovir 300mg by mouth daily for 192 weeks
11615899|NCT00524173|Experimental|Tenofovir & emtricitabine|Tenofovir 300mg in combination with emtricitabine 200mg by mouth daily for 192 weeks
11615900|NCT00524134|Experimental|1|Carvedilol-CR up to 80mg daily, used as a P-glycoprotein inhibitor to increase drug concentrations in specific regions of the brain.
11615901|NCT00524121|Experimental|Oral Erlotinib|Patients receive oral erlotinib hydrochloride once daily for 1 year
11615902|NCT00524095|No Intervention|1|standard of care
11615903|NCT00524095|Experimental|2|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
11615904|NCT00524095|Experimental|3|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
11615905|NCT00524056|Experimental|001|Carisbamate two 100 mg tablets twice per day
11615906|NCT00524056|Placebo Comparator|002|Placebo two placebo tablets twice per day
11615907|NCT00524043|Experimental|001|Paliperidone ER 1.5 mg tablet once daily for 6 weeks
11615908|NCT00524043|Active Comparator|002|Paliperidone ER 6 mg tablet once daily for 6 weeks
11615909|NCT00524043|Placebo Comparator|003|Placebo Once daily for 6 weeks
11615910|NCT00524030|Experimental|1|
11615911|NCT00524030|Experimental|2|
11615912|NCT00524017|Experimental|Arm I (treatment)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.
11615913|NCT00524017|No Intervention|Arm II (control)|Patients receive regular follow-up care
11615914|NCT00524004|Experimental|Anti-CsbD Bovine IgG|Anti CsbD Bovine Milk Immunoglobulin
11615915|NCT00524004|Experimental|Placebo|Lacto-free milk supplement
11615916|NCT00524004|Experimental|Anti-CS17 Bovin IgG|Anti-CS17 Bovin Milk Immunoglobulin
11615917|NCT00523991|Placebo Comparator|placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
11615918|NCT00523991|Experimental|tiotropium|Oral inhalation once daily of 18mcg tiotropium via handihaler
11615919|NCT00523978|Experimental|Experimental|Experimental subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci. If necessary, experimental subjects were allowed a previously failed Study Atrial Fibrillation Drug (AF Drug).
11615920|NCT00523978|Active Comparator|Control|Control Subjects were treated with an AF Drug (flecainide, propafenone, or sotalol) that they had not previously failed.
11615921|NCT00523965|Experimental|A|AmBisome 5 mg/kg iv infusion over 2 h x 1 day (single dose) + oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 7 days on day 2-8
11615922|NCT00523965|Experimental|B|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
11615923|NCT00523965|Experimental|C|oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
11615924|NCT00523965|Active Comparator|D|amphotericin B deoxycholate at 1 mg/kg every other day for 15 infusions
11615925|NCT00523952|Experimental|1|
11615926|NCT00523939|Experimental|Lymphomatous|Subjects with Lymphomatous Meningitis
11615927|NCT00523939|Experimental|Leukemic|Subjects with Leukemic Meningitis
11615928|NCT00523900|Experimental|Experimental|Malnourished adults who will be given a dietary supplement.
11615929|NCT00523848|Experimental|Arm 1|Patients receive low-dose oral thalidomide once a day on days 1-28, bortezomib IV on days 1, 4, 15, and 18, and doxorubicin hydrochloride liposome IV over 60-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity
11615930|NCT00523835||KS|Patients with Klinefelter syndrome verified by chromosome analysis
11615931|NCT00523835||Normal|Normal men Age matched to KS patients
11615932|NCT00523809|Experimental|Bevacizumab + Fludarabine + Melphalan|Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m^2 IV Daily over 5 Days; Melphalan 70 mg/m^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.
11615933|NCT00523770||Group A|Non-pneumococcal infected healthy elderly volunteers
11615934|NCT00523757|Experimental|1|Spironolactone
11615935|NCT00523757|Placebo Comparator|2|
11615936|NCT00523744|Experimental|Amlodipine(AML)+olmesartan, AML+valsartan, AML+valsartan+HCTZ|During the Treatment Phase 1, participants received 1 week of treatment with olmesartan 10 mg and amlodipine 5 mg once daily in free combination, followed by three weeks of treatment with olmesartan 20 mg plus amlodipine 10 mg once daily in free combination. During the treatment Phase 2 of the study participants received amlodipine 10 mg plus valsartan 160 mg for 4 weeks. During the Extension Phase, participants received 4 weeks treatment with amlodipine 10 mg plus valsartan 160 mg plus hydrochlorothiazide (HCTZ) 12.5 mg.
11615937|NCT00523718|Experimental|riluzole|Patients randomized to this arm will receive riluzole augmentation, at a standard, fixed dose (50 mg bid), in addition to the medication regimen they are on at enrollment
11615938|NCT00523718|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from riluzole, in addition to the medication regimen they are on at study enrollment.
11616083|NCT00522444|Placebo Comparator|normal saline nebulization|standard of care
11616084|NCT00522431|Experimental|1|2% testosterone gel
11615939|NCT00523705|Experimental|escitalopram|Escitalopram 10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
11615940|NCT00523705|Placebo Comparator|placebo|Placebo tablets matched to drug.
11615941|NCT00523692|Experimental|1|Intensive therapy
11615942|NCT00523692|Active Comparator|2|Standard therapy
11615943|NCT00523666|Active Comparator|1|
11615944|NCT00523666|Placebo Comparator|2|
11615945|NCT00523640|Experimental|I|"Combination of gemcitabine, capecitabine, and bevacizumab
~gemcitabine 1000 mg/m^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle"
11615946|NCT00523627||Healthy Volunteers with normal glucose regulation|Healthy volunteers with normal glucose regulation
11615947|NCT00523614||1: Cases|
11615948|NCT00523614||2: Controls|
11615949|NCT00523575|No Intervention|C|Usual nurse and dietetic care
11615950|NCT00523575|Experimental|I|Intensive nutritional support composed of oral dietary supplement combined with dietetic counselling.
11615951|NCT00523562|Experimental|normal weight male high fructose diet|"Effects of diet intervention  high fructose in normal weight subjects"
11615952|NCT00523562|Experimental|offsprings of T2DM high fructose diet|"Effect of diet intervention high fructose in healthy non-obese offsprings of patients with type 2 diabetes"
11615953|NCT00523562|Experimental|normal weight subjects high fat diet|"effects of diet intervention high fat in healthy male subjects"
11615954|NCT00523562|Experimental|Normal weight high fat+protein diet|"effect of diet intervention high fat + protein subjects in healthy male subjects"
11615955|NCT00523549|Experimental|Standard treatment regimen|(Valsartan + Amlodipine to target SBP of < 140 mmHg)
11615956|NCT00523549|Experimental|Intensive treatment regimen|(Valsartan + Amlodipine to target SBP < 130 mm Hg)
11615957|NCT00523536|Experimental|1|Patient navigator-nurse disease management intervention
11615958|NCT00523536|No Intervention|2|Usual clinical care
11615959|NCT00523523|Experimental|A|This group will complete a 2 week program of functional task practice with auditory rhythm cuing.
11615960|NCT00523523|Active Comparator|F|This group will complete a 2 week program of functional task practice without auditory rhythm cuing.
11615961|NCT00523510|Experimental|Feasibility Study|HIV positive women [and a smaller number of HIV negative/unknown status (1 for every 3 infected women)] to avoid stigmatizing home-based counseling will be recruited at 1-2 postpartum and provided enhanced home-based infant feeding counseling by community health workers to exclusively breastfeed for 6 months. Mothers will also be told about the option to Flash-heat breastmilk during and after the transition from exclusive breastfeeding. Mothers who choose to Flash-heat will be provided continued home-based counseling and support. Feasibility data will be collected during the time mothers Flash-heat.
11615962|NCT00523510|Experimental|Pilot efficacy|We will collect infant health data to monitor and compare health outcomes among 3 groups of infants who had exclusive breast feeding (EBF) for the first months and then either: 1) fed Flash-heated breast milk and complementary foods (n=30), or 2) weaned to replacement foods and NO breast milk (n=15; per standard WHO recommendation for rapid cessation), or 3) continued feeding at the breast and providing other foods and/or fluids, i.e. mixed feeds (n=15; per WHO consensus that breastfeeding continue if replacement feeding is not AFASS94). We will collect infant growth and morbidity data. Infant health outcomes will be compared for the 3 groups noted above. These data will be collected primarily to pilot an efficacy trial.
11615963|NCT00523458|Active Comparator|1|Standard dose nevirapine (200 mg 2x daily) in combination with 2 nucleoside analogs
11615964|NCT00523458|Experimental|2|High dose nevirapine (400 mg in the morning, 200 mg in the evening) in combination with 2 nucleoside analogs
11615965|NCT00523458|Active Comparator|3|Standard dose efavirenz (600 mg at bedtime) in combination with 2 nucleoside analogs
11615966|NCT00523458|Experimental|4|High dose efavirenz (800 mg at bedtime) in combination with 2 nucleoside analogs
11615967|NCT00523445|Experimental|Varenicline|The effect of varenicline on cognitive function of Varenicline(Chantix) is being compared to that of placebo
11615968|NCT00523445|Placebo Comparator|Placebo|The effect of placebo comparator is being compared to that of varenicline
11615969|NCT00523432|Experimental|A|Arm A will consist of subjects without prior pelvic radiation or with radiation to a field smaller than the whole pelvis. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.
11615970|NCT00523432|Experimental|B|Arm A will consist of subjects with prior whole pelvic radiation. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.
11615971|NCT00523419|Experimental|Pemetrexed|Participants received pemetrexed 500 milligrams per square meter (mg/m^2) by intravenous (IV) infusion of 10 minutes on Day 1 of each 21-day cycle.
11615972|NCT00523406|Active Comparator|A|standard fluence photodynamic therapy and intravitreal triamcinolone combination
11615973|NCT00523406|Active Comparator|B|reduced fluence photodynamic therapy and intravitreal triamcinolone combination
11615974|NCT00523393|No Intervention|1|
11615975|NCT00523393|Experimental|2|
11615976|NCT00523393|Active Comparator|3|
11615977|NCT00523380|Experimental|A|
11615978|NCT00523367|No Intervention|esomeprazole|
11615979|NCT00523354|Experimental|1 (open-label)|prospective, open label, uncontrolled trial
11615980|NCT00523341|Experimental|Denosumab|Participants received a 60 mg subcutaneous injection of denosumab every 6 months for seven years.
11615981|NCT00523328|Experimental|BG9924|dosage administered as per Biogen-idec protocol
11615982|NCT00523302|Active Comparator|Active TMS|Since cortical stimulation can be performed non-invasively by active Transcranial Magnetic Stimulation (TMS), Participants in the active TMS group, receive five 20 minute active TMS treatment sessions per week for two weeks.
11616031|NCT00522899|Experimental|Aerobic exercise|Study-specific group exercise classes include 10' warm-up, 30' cardio, 5' cool down, 15' stretching/toning. Target heart rate is 60-75% of maximum. Study participants attend classes 60 min/day, 3 days/week for 12 weeks.
11616032|NCT00522899|Active Comparator|Stretching/toning|Study-specific stretching/toning exercise classes include 10' warm-up, 40' stretching/toning, 10' relaxation. Participants attend classes 60 minutes/day, 3 days/week for 12 weeks.
11615983|NCT00523302|Sham Comparator|Sham TMS|To prevent unwanted cortical activation, Sham TMS will be employed in the Sham TMS group. For the Sham TMS group, a specially designed sham TMS coil will be used for all sham conditions. This sham TMS coil produces auditory signals identical to active TMS coils but is shielded so that actual stimulation does not occur. This approach is currently the state-of-the-art approach to sham TMS procedures and is employed in high-quality clinical TMS trials. Participants in the sham TMS group receive five 20 minute Sham TMS treatment sessions per week for two weeks.
11615984|NCT00523289|Active Comparator|B|Arm number B corresponds to the Bupivacaine group.
11615985|NCT00523289|Active Comparator|R|Arm number R corresponds to the Ropivacaine group.
11615986|NCT00523276||HCWs|Who may/may not have contact with SARS patients
11615987|NCT00523276||Family/close contacts|No illness but household/close contact
11615988|NCT00523276||SARS subjects|Diagnosed with active disease
11615989|NCT00523263|Active Comparator|Dacron|Patients receiving polyester above-knee femoro-popliteal bypass
11615990|NCT00523263|Active Comparator|HUV|patients receiving HUV femoro-popliteal bypass
11615991|NCT00523250|Experimental|AR-102 0.003% Ophthalmic Solution|q.d. ocular
11615992|NCT00523250|Experimental|AR-102 0.005% Ophthalmic Solution|q.d. ocular
11615993|NCT00523250|Experimental|AR-102 0.01% Ophthalmic Solution|q.d. ocular
11615994|NCT00523250|Experimental|AR-102 0.03% Ophthalmic Solution|q.d. ocular
11615995|NCT00523250|Experimental|AR-102 Vehicle Ophthalmic Solution|q.d. ocular
11615996|NCT00523224|Experimental|single arm|open lable,single arm , intervention is Angiogenic Cell Precusors(ACPs)
11615997|NCT00523211|Experimental|Test Arm|Vicriviroc 30 mg QD
11615998|NCT00523211|Placebo Comparator|Placebo Control Arm|Placebo
11615999|NCT00523185|Active Comparator|2|
11616000|NCT00523185|Active Comparator|1|
11616001|NCT00523172|Active Comparator|Group A|"1) Group A will receive 9 manipulative therapy treatments (adjustments) to one area: the hip with pre-manipulative static and post active-assisted stretch of tight hip muscles. After the last (or 9th) treatment these patients will receive general advice and recommendations on managing HOA and how to gently and safely increase general exercise.
~• Based on a previous trial, Group A treatment appears superior than placebo. There will be a 3, 6 and 9 month follow up."
11616002|NCT00523172|Active Comparator|Group B|2) Group B will receive 9 treatments with manipulative therapy treatments (adjustments) to the entire kinetic chain (five areas): the lumbosacral, sacroiliac, hip, knee, ankle and foot joints with pre-manipulative static and post active-assisted stretch of tight hip muscles. There will be a 3, 6 and 9 month follow up.
11616003|NCT00523172|Other|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.
~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
11616004|NCT00523159|Other|1|Pre-treatment with a single low dose of Cyclophosphamide followed by IMA901 vaccination plus GM-CSF as adjuvant
11616005|NCT00523159|Other|2|No pre-treatment with Cyclophosphamide before vaccination with IMA901 and GM-CSF as adjuvant
11616006|NCT00523120|Active Comparator|1|voltaren ophta
11616007|NCT00523120|Active Comparator|2|dexotic
11616008|NCT00523107|Experimental|PG2|PG2 500 mg / 500 ml normal saline will be given t.i.w for 8 weeks.
11616009|NCT00523107|Placebo Comparator|Placebo|500 ml normal saline will be given t.i.w 1-4 weeks, then PG2 500 mg / 500 ml normal saline will be given 5-8 weeks.
11616010|NCT00523081|Experimental|Experimental|Teens in the experimental group will meet with a research counselor for five to nine individual, 50-minute weekly sessions. They will learn ways to deal with stress and feel better. The study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
11616011|NCT00523081|Active Comparator|Active Control|
11616012|NCT00523068|Active Comparator|1|Tension Free Vaginal Tape
11616013|NCT00523068|Active Comparator|2|Tolterodine tartrate 4mg
11616014|NCT00523042|Experimental|A|
11616015|NCT00523042|Active Comparator|B|
11616016|NCT00523029|Experimental|1|Participants will receive a chronic disease self-management program
11616017|NCT00523016|Experimental|Electroacupuncture|Subjects will receive Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP) electroacupuncture protocol for 20 minutes per treatment session; a total of 13 treatments will be administered over 3-4 weeks.
11616018|NCT00523016|Sham Comparator|Sham acupuncture|Subjects will receive simulated acupuncture that includes insertion of acupuncture needles on the head. During each treatment session, needles will be stimulated with electricity for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
11616019|NCT00523003|Experimental|1,|2.2 g protein/kg LBM/day high protein diet
11616020|NCT00523003|Placebo Comparator|2, standard protein|1.1 g protein/kg LBM/day standard protein diet
11616021|NCT00522990|Experimental|1|Refractory Hematological Malignancies
11616022|NCT00522964|Experimental|Intervention|
11616023|NCT00522951|Experimental|Gadobutrol 0.1 mmol/kg bw|Participants received first injection (intravenous [i.v.]) of gadobutrol 0.1 mmol/kg body weight (bw), corresponding to a dose of 0.1 mmol/kg bw
11616024|NCT00522951|Experimental|Gadobutrol 0.2 mmol/kg bw|Participants received second injection (i.v.) of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min
11616025|NCT00522951|Experimental|Gadoteridol (ProHance)|Participants received two injections (i.v.) of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min
11616026|NCT00522925|Placebo Comparator|1|Matching Placebo
11616027|NCT00522925|Experimental|2|
11616028|NCT00522925|Experimental|3|
11616029|NCT00522912|Experimental|A|Immediate posterior lamella tarsal rotation surgery for minor trichiasis
11616030|NCT00522912|Active Comparator|B|Regular epilation by another person
11616085|NCT00522418|Experimental|VNS Therapy|VNS Therapy + Best Medical Practice
11616033|NCT00522899|Experimental|Computer-based mental activity training|Computer-based visual and auditory stimulation training programs developed by Posit Science corporation. Participants perform assigned mental activity on computers in their homes for 60 minutes/day, 3 days/week for 12 weeks.
11616034|NCT00522899|Active Comparator|Educational DVD training|Watching and listening to in-depth, college-level lectures on art, history and science on the computer. Participants perform assigned mental activities 60 minutes/day, 3 days/week for 12 weeks.
11616035|NCT00522873|Experimental|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 13 cycles (28 days per cycle).
11616036|NCT00522873|Active Comparator|0.5mg NETA / 1.0mg E2 (Activella)|One capsule [0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)] per day taken orally for 13 cycles (28 days per cycle).
11616037|NCT00522860|Experimental|Vicryl Suture|Vicryl sutures, 5/0, 3/8 curved cutting needle
11616038|NCT00522860|Active Comparator|Silk Suture|Silk suture, 4/0, 3/8 curved cutting needle
11616039|NCT00522834|Active Comparator|1|Elesclomol (STA-4783) in Combination With Paclitaxel
11616040|NCT00522834|Other|2|Paclitaxel alone
11616041|NCT00522821|Other|Antibiotics|"A: co-trimoxazole prophylactically for 12 months followed by intravenous immunoglobulin treatment for 12 months.
~Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given."
11616042|NCT00522821|Other|intravenous immunoglobulins|"B: intravenous immunoglobulin treatment for 12 months followed by co-trimoxazole prophylactically for 12 months.
~Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given."
11616043|NCT00522795|Experimental|PPX with cisplatin and radiation|PPX 50mg/m2 wk and cisplatin 25mg/m2 wk for 6 weeks with 50.4 GY concurrent radiation
11616044|NCT00522782|Active Comparator|A|Nebulized budesonide
11616045|NCT00522769|Active Comparator|Delayed Intervention|1/2 of participants are randomized to immediate intervention that starts within a week of randomization. The other 1/2 of the participants are randomized to delayed intervention which starts 6 months after randomization.
11616046|NCT00522769|Experimental|Immediate intervention|Immediate intervention starts within two weeks of randomization. Delayed interventions starts 6 months after randomization.
11616047|NCT00522756|Experimental|Intervention|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
11616048|NCT00522756|Active Comparator|Control|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
11616049|NCT00522743|Experimental|1|GH & GNRHa treatment
11616050|NCT00522743|Active Comparator|2|GH treatment
11616051|NCT00522730|Experimental|1|Parenteral nutrition
11616052|NCT00522730|Active Comparator|2|Enteral nutrition
11616053|NCT00522717|Experimental|1|
11616054|NCT00522717|Active Comparator|2|
11616055|NCT00522691|Experimental|A: sacral first|Phase 1: sacral nerve stimulation crossover Phase 2 : sham stimulation
11616056|NCT00522691|Experimental|B: sham first|Phase 1: sham stimulation crossover Phase 2: sacral nerve stimulation
11616057|NCT00522678|Experimental|Cohort A|In Cohort A, subjects will be randomized (3:1) to receive once daily doses of GW685698X 400 microgram (mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
11616058|NCT00522678|Experimental|Cohort B|In Cohort B, subjects will be randomized (3:1) to receive once daily doses of GW685698X (600 mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
11616059|NCT00522678|Experimental|Cohort C|InIn Cohort C, subjects will be randomized (3:1) to receive once daily doses of GW685698X (800 mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
11616060|NCT00522665|Active Comparator|Arm A: Irinotecan + Cetuximab +/- RAD001|
11616061|NCT00522665|Active Comparator|Arm B: Ironotecan + Cetuximab|
11616062|NCT00522652|Experimental|Investigational Drug|Dose Escalation
11616063|NCT00522626||Observational|Opioid exposed pregnancies
11616064|NCT00522587|Experimental|1|Fixed sevoflurane dose 1
11616065|NCT00522587|Experimental|2|Fixed sevoflurane dose 2
11616066|NCT00522587|Experimental|3|Fixed sevoflurane dose 3
11616067|NCT00522587|Experimental|4|Fixed sevoflurane dose 4
11616068|NCT00522587|Experimental|5|Fixed sevoflurane dose 5
11616069|NCT00522587|Experimental|6|Fixed sevoflurane dose 6
11616070|NCT00522587|Experimental|7|Fixed remifentanil dose 1
11616071|NCT00522587|Experimental|8|Fixed remifentanil dose 2
11616072|NCT00522587|Experimental|9|Fixed remifentanil dose 3
11616073|NCT00522587|Experimental|10|Fixed remifentanil dose 4
11616074|NCT00522587|Experimental|11|Fixed remifentanil dose 5
11616075|NCT00522587|Experimental|12|Fixed remifentanil dose 6
11616076|NCT00522561|Other|1|healthy volunteers
11616077|NCT00522548|Active Comparator|Enteric coated mycophenolate sodium|Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) at a target dose of 720 mg orally twice daily for 6 months after transplant.
11616078|NCT00522548|Active Comparator|Mycophenolate mofetil|Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent manufactured by Sandoz, at a target dose of 1000 mg orally twice daily for 6 months after transplant.
11616079|NCT00522535|Active Comparator|Open Surgical Repair|Open surgical repair of abdominal aortic aneurysm. All patient enrollment and 2-year follow-ups completed.
11616080|NCT00522535|Experimental|Endovascular Repair|"Endovascular treatment arm of 160 patients having suitable anatomy for the Aorfix™ AAA Flexible Stent Graft System. Use of stent grafts in aortic angles greater than 60° has not been approved for other devices available in the US. As a result, a minimum of 120 patients in this arm will have an aortic angle between 60° and 90°.
~Patient recruitment completed; 5-year follow-up evaluations continue."
11616081|NCT00522535|Experimental|Continued Access|"Endovascular treatment arm of 50 patients maximum having suitable anatomy for the Aorfix™ AAA Flexible Stent Graft System. This Arm will provide active sites with ongoing device access while FDA reviews the PMA.
~Patient recruitment completed; 5-year patient follow-ups continue."
11616087|NCT00522405|Active Comparator|1|Transarterial Chemoembolisation
11616088|NCT00522405|Active Comparator|2|TACE Plus oral chemotherapy
11616089|NCT00522392|Experimental|Arm A (VRD)|Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib, dexamethasone and lenalidomide. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11; fixed dose of lenalidomide at 15 mg orally on days 1-14; and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15. Aspirin 325 mg/day orally on days 1-21 of each cycle was required unless the patient was treated with alternate prophylaxis of either low molecular weight heparin or coumadin.
11616090|NCT00522392|Active Comparator|Arm B (VD)|Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib plus dexamethasone. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11 and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15.
11616091|NCT00522379|Experimental|Rotigotine 2 mg/24 hr|
11616092|NCT00522379|Experimental|Rotigotine 4 mg/24 hr|
11616093|NCT00522379|Experimental|Rotigotine 6 mg/24 hr|
11616094|NCT00522379|Experimental|Rotigotine 8 mg/24 hr|
11616095|NCT00522379|Placebo Comparator|Placebo|
11616096|NCT00522353|Active Comparator|1|Oligofructose
11616097|NCT00522353|Placebo Comparator|2|Placebo
11616098|NCT00522340|Experimental|Aerobic Exercise Program|
11616099|NCT00522340|No Intervention|Usual Care|
11616100|NCT00522327|Experimental|1|remote simult med interpret
11616101|NCT00522327|Active Comparator|2|Usual & Customary
11616102|NCT00522327|Other|3|comparison group
11616103|NCT00522314|Active Comparator|1|NIV & ACBT
11616104|NCT00522314|Placebo Comparator|2|Active cycle of breathing techniques
11616105|NCT00522301|Experimental|Oral Sorafenib (BAY43-9006)|Sorafenib is supplied as 200-mg tablets. Sorafenib will be administered as 400 mg orally daily x 28 days (continuous). One cycle = 28 days. There is no planned treatment interruption between cycles. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating). In the absence of intolerable toxicity, a patient may continue to receive treatment with sorafenib until disease progression, or until 24 months have elapsed.
11616106|NCT00522288|Experimental|Contact Lens|Soft contact lenses
11616107|NCT00522288|Active Comparator|Spectacle|Spectacles
11616108|NCT00522275|Experimental|Lacosamide|Up to 800 mg/day lacosamide (flexible dosing)
11616109|NCT00522262|Experimental|Exercise|Women randomized to the exercise intervention arm completed a one year aerobic exercise intervention of 225 minutes/week.
11616110|NCT00522262|No Intervention|Control|Women randomized to the control arm were asked to maintain their regular lifestyle which meant no changes to their exercise or dietary intake. Women eligible for this trial were inactive and hence were expected not to increase their levels of physical activity in the control arm.
11616111|NCT00522249|Experimental|1|One cycle of the combination therapy will be 42 days (6 weeks). All patients will receive PEG-Intron given subcutaneously on Day 1 each week. Patients will receive Sunitinib orally on Days 1-28 of each cycle. Patients will receive Tarceva orally on Days 1-42.
11616112|NCT00522236|Experimental|Arm 1|
11616113|NCT00522223||Questionnaire|Questionnaire
11616114|NCT00522210|Experimental|BID insulin with LA analogue|Treatment Group: BID Insulin Regimen with Long Acting Insulin Analogue (Detemir)
11616115|NCT00522210|Active Comparator|Standard TID insulin|Active Control Group: Usual TID Insulin Regimen (intermediate insulin- Humulin N or Novolin NPH)
11616116|NCT00522197|Active Comparator|ACAPHA|
11616117|NCT00522197|Placebo Comparator|Sugar Pill|
11616118|NCT00522184|Experimental|1|patient receiving etanercept intra-articular injection
11616119|NCT00522184|Active Comparator|2|patient receiving steroid intra-articular injection
11616120|NCT00522171||Electro Surgery|Electro Surgical instruments are used to cut and coagulate tissue using alternating electric current at the surgical site. In Electro Surgery, the patient is included in the circuit and current enters the patient's body.
11616121|NCT00522145|Experimental|Group 1|
11616122|NCT00522132|Active Comparator|cohort 1|2.4 mg/kg iv artesunate at 0, 12, 24, 48and 72 hours
11616123|NCT00522132|Experimental|cohort 2|4.0 mg/kg iv Artesunate at 0, 24 and 48 h
11616124|NCT00522106|Experimental|A|Behavioral graded activity
11616125|NCT00522106|Active Comparator|B|Exercise therapy
11616126|NCT00522067|Experimental|Arm 1|FLUAD
11616127|NCT00522054|Other|A|Single group study
11616128|NCT00522041|Experimental|Cellegesic (nitroglycerin 0.4%)|Participants applied Cellegesic 375 mg ointment containing approximately 1.5 mg of nitroglycerin anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
11616129|NCT00522041|Placebo Comparator|Placebo 375 mg|Participants applied placebo 375 mg ointment anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
11616130|NCT00522015|Active Comparator|1|patients take 6 mg rivastigmine daily, if well tolerable increase to 12 mg rivastigmine maximum daily
11616131|NCT00521989|Experimental|CRx-102 (2.7/90)|"2.7 mg prednisolone plus 90 mg dipyridamole
~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
11616132|NCT00521989|Experimental|CRx-102 (2.7/180)|"2.7 mg prednisolone plus 180 mg dipyridamole
~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
11616133|NCT00521989|Experimental|CRx-102 (2.7/360)|"2.7 mg prednisolone plus 360 mg dipyridamole
~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
11616134|NCT00521989|Active Comparator|Prednisolone|"2.7 mg prednisolone
~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM."
11616135|NCT00521989|Placebo Comparator|Placebo|"Placebo
~Subjects were dose twice daily through day 98."
11616136|NCT00521976||Chest pain|Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).
11616138|NCT00521950|Experimental|Intervention, TPMT genotyping|Pre-treatment TPMT genotyping to optimize initial thiopurine treatment dose. Intervention is based on the genotype.
11616139|NCT00521950|Active Comparator|control|Standard thiopurine treatment
11616140|NCT00521937|Experimental|A|Dermagen®
11616141|NCT00521937|Active Comparator|B|Conventional treatment
11616142|NCT00521924|Experimental|Infliximab + basic treatment|3 mg/kg infliximab plus basic treatment
11616143|NCT00521924|Active Comparator|Basic treatment (DMARDs)|Rheumatoid Arthritis basic therapy (disease modifying anti-rheumatic drugs [DMARDs])
11616144|NCT00521911|Active Comparator|1|Cognitive Behavioural Therapy
11616145|NCT00521911|No Intervention|2|Treatment as Usual
11616146|NCT00521898|Experimental|DMEK|DMEK as intervention
11616147|NCT00521885|Active Comparator|Arixtra (Fondaparinox) 2.5 mg SC Daily|Arixtra (Fondaparinox) 2.5 mg SC Daily
11616148|NCT00521885|Active Comparator|Lovenox 40mg SC Daily|Lovenox 40mg SC Daily
11616149|NCT00521859|Experimental|Cloretazine + Fludarabine|
11616150|NCT00521846||1|As part of their routine care, patient's will receive Biomet modular radial head replacement. This study is an observational, prospective study that monitors the patient's pain, functional ability, and patient-reported outcomes.
11616151|NCT00521833|Experimental|1|Temporal (right eye)
11616152|NCT00521833|Experimental|2|Nasal (Left eye)
11616153|NCT00521820|Experimental|Pioglitazone QD|
11616154|NCT00521820|Active Comparator|Glyburide QD|
11616155|NCT00521807|No Intervention|A 1|
11616156|NCT00521807|Experimental|A 2|Treatment group
11616157|NCT00521781|Experimental|1|Treatment will be Abraxane/hormonal therapy (LHRH Agonist) for four nine-week cycles, followed by Total androgen blockade therapy (LHRH Agonist+ Anti-androgen) for 2 years from the time the hormonal therapy was started.
11616158|NCT00521755|Experimental|A|
11616159|NCT00521742|Experimental|Pioglitazone 15 mg to 45 mg QD|
11616160|NCT00521742|Active Comparator|Glyburide 2.5 mg to 15 mg, QD|
11616161|NCT00521742|Experimental|Pioglitazone 15 mg or 30 mg QD|
11616162|NCT00521742|Active Comparator|Glyburide 5 mg or 10 mg, QD|
11616163|NCT00521716|Experimental|A|
11616164|NCT00521703|Experimental|1|group treated
11616165|NCT00521703|Placebo Comparator|2|control group
11616166|NCT00521677|Experimental|1|Procedure: Use of protocol that use special suction connected toothbrush to clean the teeth and the oral cavity, use of non alcoholic antiseptic solution and lubrication of the lips and the oral cavity.
11616167|NCT00521677|Active Comparator|2|The traditional method of oral care with cleaning of the oral cavity with a sponge soaked with antiseptic non alcoholic solution
11616168|NCT00521664|Active Comparator|1|Therapeutic platelet transfusion (TP) strategy versus prophylactic platelet transfusion (PP) strategy. In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
11616169|NCT00521664|Active Comparator|2|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
11616170|NCT00521651||Community Cohort|Men and Women from two Shanghai cohort studies.
11616171|NCT00521638|Experimental|1|
11616172|NCT00521612|Experimental|A|Sevoflurane group, experimental group
11616173|NCT00521612|Active Comparator|B|Isoflurane group, control group
11616174|NCT00521599|Experimental|MF DPI 2 x 100 mcg BID|2 inhalations of mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks
11616175|NCT00521599|Experimental|MF DPI 1 x 200 mcg BID|1 inhalation of mometasone furoate dry powder inhaler (MF DPI) 200 mcg plus 2 inhalations of placebo matching MF DPI 100 mcg twice daily (BID) for 8 weeks
11616176|NCT00521599|Placebo Comparator|Placebo|2 inhalations of placebo matching mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks
11616177|NCT00521586|Other|1|arm 1 = TIV +13vPnC at visit 1, placebo at visit 2 then 13vPnC at year 5
11616178|NCT00521586|Other|2|arm 2 = TIV + placebo at visit 1, then 13vPnC at visit 2 and at year 5
11616179|NCT00521560|Experimental|1|
11616180|NCT00521534||A|CRT programmed to VDD pacing mode
11616181|NCT00521534||B|CRT programmed to DDD with overdrive pacing based on first night average sinus rate.
11616182|NCT00521521|Active Comparator|docetaxel and cisplatin|
11616183|NCT00521521|Experimental|docetaxel|
11616184|NCT00521508|Other|1|Patient affected by Berger's disease confirmed by renal biopsy with increased rate of Ig A
11616185|NCT00521508|Other|2|Patient affected by Berger's disease with normal rate of Ig A
11616186|NCT00521508|Other|3|Healthy volunteers
11616187|NCT00521495|Experimental|A|Surface magnetic field strength at target 450 Gauss permanent magnet
11616188|NCT00521495|Experimental|B|Surface field strength at target 150 Gauss permanent magnet
11616189|NCT00521495|Active Comparator|C|
11616190|NCT00521482|Active Comparator|A|Temozolomide 75 mg/m2 daily for 21 days during each 28-day cycle until tumor progression.
11616191|NCT00521482|Experimental|B|Temozolomide 200 mg/m2 for 5 days during each 28-day cycle plus Thalidomide 100 mg for 2 weeks, thereafter 200 mg daily continuously until tumor progression.
11616192|NCT00521456|Experimental|1|
11616193|NCT00521456|Placebo Comparator|2|
11616194|NCT00521443||Normal|Embryos derived from morphologically normal MII oocytes
11616195|NCT00521443||Irregular Shapes|Embryos derived from irregularly shaped oocytes.
11616196|NCT00521443||Large PVS|Embryos derived from oocytes with large perivitelline space.
11616197|NCT00521443||Dark Zona|Embryos derived from oocytes with dark zona pellucida
11616198|NCT00521443||Dark cytoplasm|Embryos derived from oocytes with dark cytoplasm
11616199|NCT00521443||Vacuolar cytoplasm|Embryos derived from oocytes with vacuolated cytoplasm
11616200|NCT00521443||Central granulation|Embryos derived from oocytes with centrally granulated cytoplasm
11616201|NCT00521443||Double extra|Embryos derived from oocytes with double extracytoplasmic abnormalities
11616202|NCT00521443||Double combined|Embryos derived from oocytes with any combination of one extracytoplasmic and one cytoplasmic anomaly
11616203|NCT00521443||Double cytoplasmic|Embryos derived from oocytes with any two cytoplasmic anomalies
11616204|NCT00521443||Triple extra|Embryos derived from oocytes with triple extracytoplasmic anomaly
11616205|NCT00521443||Triple combined|Embryos derived from oocytes with triple combined anomalies
11616206|NCT00521417|Experimental|short-term dynamic therapy|Group therapy 20 sessions, give insight
11616207|NCT00521417|Active Comparator|long-term dynamic therapy|Group therapy 80 sessions, give insight
11616208|NCT00521404|Experimental|CS-1008 + gemcitabine|CS-1008 + gemcitabine
11616209|NCT00521391|Experimental|A|a tailored physical activity intervention involving moderate-intensity exercise
11616210|NCT00521391|No Intervention|B|
11616211|NCT00521365|Experimental|Quetapine 600 mg|
11616212|NCT00521352|Active Comparator|Active rTMS|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
11616213|NCT00521352|Sham Comparator|Sham rTMS|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
11616214|NCT00521339|Experimental|Apremilast 20 mg BID/ 30 mg BID|Apremilast 20 mg or 30 mg orally twice per day
11616215|NCT00521326||A|Patients with an acute coronary syndrome that are candidates for coronary angiography. Doppler results will be compared to angiographic findings.
11616216|NCT00521300|Experimental|octreotide|6 months preoperative treatment with octreotide before transsphenoidal surgery for acromegaly
11616217|NCT00521300|Active Comparator|standard surgery|Standard transphenoidal surgery soon after the diagnosis of acromegaly
11616218|NCT00521287|Other|Early (E)|Early stage cancer
11616219|NCT00521287|Other|Advanced (A)|Advanced stage cancer (Stage IV without treatment)
11616220|NCT00521287|Other|Terminal (T)|Terminal stage cancer (Stage IV with chemotherapy)
11616221|NCT00521274|Experimental|1|"Patients randomized to Arm 1 will receive treatment cycles of Docetaxel and vaccine.
~PI relocated, data not available."
11616222|NCT00521274|Active Comparator|2|"Patients randomized to Arm 2 will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over).
~PI relocated, data not available."
11616223|NCT00521248|Active Comparator|Oral morphine solution|Oral morphine solution
11616224|NCT00521248|Experimental|Buprenorphine|Sublingual buprenorphine
11616225|NCT00521222|Active Comparator|Arg/Arg genotype on Advair (Fluticasone with Salmeterol) HFA|Asthma patients with the Arg/Arg genotype who are randomized to continue the combination therapy of a specific long-acting beta 2 agonist (salmeterol) and inhaled corticosteroid (fluticasone) in the form of Advair HFA.
11616226|NCT00521222|Active Comparator|Gly/Gly genotype on Advair (Fluticasone with Salmeterol) HFA|Asthma patients with the Gly/Gly genotype who are randomized to continue the combination therapy of a specific long-acting beta 2 agonist (salmeterol) and inhaled corticosteroid (fluticasone) in the form of Advair HFA.
11616227|NCT00521222|Experimental|Arg/Arg genotype on Fluticasone HFA|Asthma patients with the Arg/Arg genotype who are randomized to fluticasone (Flovent HFA) alone.
11616228|NCT00521222|Experimental|Gly/Gly genotype on Fluticasone HFA|Asthma patients with the Gly/Gly genotype who are randomized to fluticasone (Flovent HFA) alone.
11616229|NCT00521209|Experimental|Clinic 1 - intervention|Clinic 1 will feature the Self-Care Stimulating Disease Prevention Program (SCSDPP) intervention
11616230|NCT00521209|Other|Clinic 2 - no intervention|Clinic 2 will continue with standard procedures no intervention
11616231|NCT00521196|No Intervention|Baseline- 1 month|Subjects will be asked to maintain a migraine diary in which they will record the onset of each migraine, migraine-associated symptoms, migraine-associated pain, daily average pain, and daily average anxiety.
11616232|NCT00521196|Experimental|tDCS- 1 month|"There will be 10- twenty minute sessions of the tDCS intervention over a four week period. During each tDCS session, two electrodes are placed over selected areas of the brain. 2 mA of direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The subject may feel a slight itching on the scalp. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.
~During this phase, participants will continue to maintain their migraine diary. In addition, the pain threshold of patients will be measured at the first, fifth, and tenth sessions via Thermal Sensory Analysis and Von Frey Hair tests."
11616233|NCT00521196|No Intervention|Follow Up- 4 months|During the follow up phase, subjects will meet with the study investigators a total of 5 times for follow up monitoring. Participants will continue to maintain their migraine diary during this time.
11616234|NCT00521196|Other|Active tDCS- 1 month|Participants randomized to sham tDCS (placebo) will be given the opportunity to receive the active intervention if the intervention is found to be safe and efficacious.
11616235|NCT00521183|Experimental|CldC + H4U|
11616236|NCT00521157|Experimental|intervention|Experimental group randomised after abstinence oriented treatment
11616237|NCT00521157|No Intervention|2|waiting list control
11616238|NCT00521144|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive obatoclax mesylate IV over 3 hours on day 1 OR days 1 and 3 and topotecan hydrochloride IV over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity
11616239|NCT00521118|Experimental|Treatment (second curettage)|Patients undergo a second curettage rather than standard treatment (immediate chemotherapy) within 14 days of registration.
11616240|NCT00521105|No Intervention|1|Participants will be seen every 3-4 months with a physician-only visit alternating with a multidisciplinary visit (MD, RN and RD). This is the current standard of practice.
11616241|NCT00521105|Experimental|2|Participants will be seen every 3-4 months with a phone contact, with the diabetes nurse educator, alternating with a multidisciplinary visit (MD, RN and RD).
11616242|NCT00521092|Experimental|Arm I|Patients receive oral sunitinib malate 50 mg once daily for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
11616243|NCT00521079|Experimental|vBloc|Subjects implanted with a functional Maestro System device that delivers therapy (Therapy ON).
11616244|NCT00521079|Sham Comparator|Placebo|Subjects implanted with a functional Maestro System device that does NOT deliver therapy (Therapy OFF).
11616245|NCT00521066||1|Prosima Pelvic Floor Repair System
11616246|NCT00521053|Experimental|PV-10|
11634960|NCT00310531|Active Comparator|Arm 2|
11616247|NCT00521027|Other|Treatment|Debridement with Versajet Hydrosurgery system
11616248|NCT00521027|Other|Control|Conventional surgical debridement techniques
11616249|NCT00521014|Experimental|GM-CSF and Rituximab After Autologous Stem Cell Transplant|"GM-CSF: 250 mcg (flat dose) three times per week for 8 weeks, administered on alternate days. Thus, 24 doses of GM-CSF will be administered.
~Rituximab: 375 mg/m2/week for 4 weeks, beginning within 3 days after the first dose of GM-CSF; rituximab. The second course of GM-CSF and rituximab will be administered approximately 22-26 weeks (day +154 to +182) after ASCT."
11616250|NCT00521001|Experimental|everolimus + temozolomide|"Patients receive oral everolimus once a day on days 1-5, 8-12, 15-19, 22-26, and 29-33 and oral temozolomide once a day on days 8-12 for course 1 only. For course 2 and all subsequent courses, patients receive oral everolimus once a day on days 1-5, 8-12, 15-19, and 22-26 and oral temozolomide once a day on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
~All patients undergo blood sample collection periodically for correlative studies. Samples are analyzed for relative numbers of T, B, and NK cells via flow cytometry, quantitative immunoglobulin levels (IgG, IgM, and IgA), Tetramer/ELISPOT CTL frequencies to CMV/EBV immunodominant antigens, V beta T cell spectratyping, and VEGF levels via ELISA.
~After completion of study treatment, patients are followed every 8 weeks."
11616251|NCT00520988|Experimental|1|Usual care plus use of Interactive Voice Recognition system
11616252|NCT00520988|No Intervention|2|Usual care
11616253|NCT00520975|Active Comparator|Arm A (chemotherapy and placebo)|"INDUCTION THERAPY: Patients receive trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22 and paclitaxel IV over 60 minutes with or without carboplatin IV over 60 minutes on days 1, 8, and 15. Patients also receive placebo IV over 30-90 minutes on day 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and placebo IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
11616254|NCT00520975|Experimental|Arm B (chemotherapy and bevacizumab)|"INDUCTION THERAPY: Patients receive trastuzumab and paclitaxel with or without carboplatin as in Arm A. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
11616255|NCT00520962||1,2,3|"First degree relatives of patients with type 2 diabetes
~Patients with cardiovascular disease and stroke
~patients with heart valve disease"
11616256|NCT00520962||4|Healthy controls
11616257|NCT00520949|Experimental|Quadruple Therapy|
11616258|NCT00520936|Experimental|Pemetrexed|
11616259|NCT00520923|Experimental|1|160mg of LY2140023, taken orally as 80mg twice daily, for up to 4 weeks.
11616260|NCT00520923|Experimental|2|80mg of LY2140023, taken orally as 40mg twice daily, for up to 4 weeks.
11616261|NCT00520923|Experimental|3|40mg of LY2140023, taken orally as 20mg twice daily, for up to 4 weeks.
11616262|NCT00520923|Experimental|4|10mg of LY2140023, taken orally as 5mg twice daily, for up to 4 weeks.
11616263|NCT00520923|Placebo Comparator|5|Placebo of LY2140023, taken orally twice daily, for up to 4 weeks.
11616264|NCT00520923|Active Comparator|6|Placebo, taken orally every morning, followed by Olanzapine 15mg taken orally every evening for up to 4 weeks.
11616265|NCT00520910|Experimental|Polypodium leucotomos extract|Subject is given a 7.5 mg/kg dose of Polypodium leucotomos.
11616266|NCT00520910|No Intervention|No intervention|Subject is not given any treatment.
11616267|NCT00520897|Experimental|MK0518 + cART|Raltegravir + standard of care combined antiretroviral therapy
11616268|NCT00520897|Placebo Comparator|Placebo + cART|Placebo + standard of care combined antiretroviral therapy
11616269|NCT00520884|Placebo Comparator|Healthy 70+ Women Placebo Infusion|Healthy and Frail Women 70 and Older Receive a 3 hour Placebo Infusion of Saline administered in a stepwise fashion in amounts equivalent to the ghrelin infusion.
11616270|NCT00520884|Placebo Comparator|Frail 70+ Women Placebo Infusion|Frail Women 70 and Older Receive a 3 hour Placebo Infusion of Saline administered in a stepwise fashion in amounts equivalent to the ghrelin infusion.
11616271|NCT00520884|Active Comparator|Healthy 70+ Women Ghrelin Infusion|Healthy Women 70 and Older are administered a 3 hour graded Ghrelin Infusion (the first hour of the ghrelin infusion a dose of 2.5 pmol/kg/min, increased to a dose of 5.0 pmol/kg/min for one hour, and then increased to the dose of 10 pmol/kg/min for the final hour of the infusion).
11616272|NCT00520884|Active Comparator|Frail 70+ Women Ghrelin Infusion|Frail Women 70 and Older are administered a 3 hour graded Ghrelin Infusion (the first hour of the ghrelin infusion at a dose of 2.5 pmol/kg/min, increased to a dose of 5.0 pmol/kg/min for one hour, and then increased to the dose of 10 pmol/kg/min for the final hour of the infusion).
11616273|NCT00520858|No Intervention|C|
11616274|NCT00520858|Active Comparator|RE|Resistance Exercise
11616275|NCT00520858|Active Comparator|AE|Aerobic Exercise
11616276|NCT00520858|Active Comparator|RAE|Resistance and Aerobic
11616277|NCT00520845|Experimental|Treatment Arm|Either docetaxel or pemetrexed given with celecoxib
11616278|NCT00520832|Experimental|MC-E|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
11616279|NCT00520832|Placebo Comparator|MC-P|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
11616280|NCT00520806|Placebo Comparator|Placebo|48 hour iv infusion of placebo
11616281|NCT00520806|Experimental|Relaxin|48 hour iv infusion of relaxin at 30 ug/kg/day
11616282|NCT00520780|Experimental|1|
11616283|NCT00520780|Placebo Comparator|2|
11616284|NCT00520767|Experimental|Melphalan, Dexamethasone, Bortezomib,|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22; Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23; Melphalan 9 mg/m2/day days 1-4
11616285|NCT00520741|Experimental|Lacosamide 400 mg/day|Lacosamide 400 mg/day
11616286|NCT00520741|Active Comparator|Lacosamide 300 mg/day|Lacosamide 300 mg/day
11616287|NCT00520728|Experimental|A|Experimental arm receives 12 week intervention along with standard care.
11639647|NCT00246571|Experimental|A|
11616288|NCT00520715||Patients at hospital admission|Patients at hospital admission in medical wards on our tertiray care hospital (Hôpital Beaujon, Clichy, France).
11616289|NCT00520702|Active Comparator|3D CRT|3-Dimensional Conformal Radiation Therapy (3D CRT)
11616290|NCT00520702|Active Comparator|IMRT|Intensity-Modulated Radiation Therapy (IMRT)
11616291|NCT00520689|Active Comparator|1|
11616292|NCT00520689|Active Comparator|2|
11616293|NCT00520689|Active Comparator|3|
11616294|NCT00520689|Active Comparator|4|
11616295|NCT00520676|Experimental|pemetrexed plus carboplatin|"Drug: pemetrexed 500 milligrams per square meter (mg/m^2), intravenous (IV), every (q) 21 days x 6 cycles maximum
~Drug: carboplatin Area Under the Curve (AUC) 5 milligram*minute/milliLiter (mg*min/mL), IV, q 21 days x 6 cycles maximum"
11616296|NCT00520676|Active Comparator|docetaxel plus carboplatin|"Drug: docetaxel 75 mg/m^2, IV, q 21 days x 6 cycles maximum
~Drug: carboplatin AUC 5 mg*min/mL, IV, q 21 days x 6 cycles maximum"
11616297|NCT00520663|Experimental|Healthy male subjects|Each subject will receive a single oral dose of 14C-SB649868 (containing approximately 70 microcuries of radiocarbon and 30 milligrams of SB649868).
11616298|NCT00520624|Experimental|1|Treatment 1, for those with high degree of EIL
11616299|NCT00520624|Experimental|2|Treatment 2, for those with high degree of EIL
11616300|NCT00520624|No Intervention|3|Control group of those with high degree of EIL
11616301|NCT00520624|Experimental|4|Treatment 1, for those with low degree of EIL
11616302|NCT00520624|No Intervention|5|Control group of those with low degree of EIL
11616303|NCT00520611|Active Comparator|Lottery|Participants are entered into daily lotteries to win $10 or $100 every day their weight is at or below daily targets.
11616304|NCT00520611|Active Comparator|Deposit|Participants receive $3/day if they are at or below their daily weight goals, plus have opportunity to deposit up to $3/day of their own money, which is then matched 1:1 every day they are at or below their daily weight goals.
11616305|NCT00520611|No Intervention|Control|Participants would receive usual care from their providers and have monthly weigh ins.
11616306|NCT00520598|Active Comparator|1|Arm 1: 0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen.
11616307|NCT00520598|Experimental|2|Arm 2: 0.5 ml injection of V505 formulation 1 as 3 dose regimen.
11616308|NCT00520598|Experimental|3|Arm 3: 0.5 ml injection of V505 formulation 2 as 3 dose regimen
11616309|NCT00520598|Experimental|4|Arm 4: 0.5 ml injection of V505 formulation 2 as 2 dose regimen and 1 Pbo injection
11616310|NCT00520598|Experimental|5|Arm 5: 0.5 ml injection of V505 formulation 3 as 2 dose regimen and 1 Pbo injection
11616311|NCT00520572|Active Comparator|1|Etanercept 50mg, subcutaneous, once weekly
11616312|NCT00520572|Experimental|2|50mg oral, once daily
11616313|NCT00520572|Experimental|3|100 mg oral, once daily
11616314|NCT00520572|Experimental|4|200 mg oral, once daily
11616315|NCT00520572|Experimental|5|400mg once, daily
11616316|NCT00520572|Placebo Comparator|6|oral, once daily
11616317|NCT00520546|Experimental|1|Patients with prostate carcinoma confirmed by needle biopsy, age >50 years, planned radical prostatectomy with lymph-node dissection, fasting for >12 hours before FEC-PET and an interval between biopsy and PET >3 weeks.
11616318|NCT00520533|Experimental|On Study|"Treatment (cycle 1):
~cG250 10mg/m² IV weekly x5 doses (1st & 5th doses trace-labelled with ¹²⁴I)
~Sunitinib 50 mg/day orally x 4 weeks commencing day 8
~Followed by two week break
~Treatment (cycle 2 - investigator discretion):
~cG250 10mg/m² IV weekly x4 doses
~Sunitinib 50 mg/day orally x 4 weeks (commencing concurrently)
~Followed by two week break"
11616319|NCT00520507|Experimental|1|
11616320|NCT00520507|Placebo Comparator|2|
11616321|NCT00520494|Experimental|Vivaglobin|Vivaglobin: 16% (160 mg/mL) liquid formulation of human IgG for SC use. Loading dose: 100 mg/kg for 5 consecutive days; maintenance dose: 100 mg/kg 1 to 2 times a week for 24 weeks.
11616322|NCT00520481|Experimental|IMC-A12|Thirty-one participants will receive IMC-A12 at 10 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). An additional 10 participants will receive IMC-A12 at a dose of 20 mg/kg every three weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Radiographic evaluation of response will be performed every 8 weeks for the participants treated with intravenous (i.v.) IMC-A12 at 10 mg/kg and every 9 weeks for the participants treated with i.v. IMC-A12 at 20 mg/kg.
11616323|NCT00520468|Experimental|Cytokine-Immunotherapy|Erythropoietin 40,000 units subcutaneously (SQ) weekly; G-CSF 300 mcg SQ twice a week; Prednisone 60 mg/Day for 7 days, taper over 1 month; Cyclosporin A 300 mg orally daily
11616324|NCT00520455|No Intervention|Control|Control participants were advised where they could obtain hormonal contraception on a sliding scale basis. Participants were also advised where they could obtain hormonal contraception on a sliding scale basis.
11616325|NCT00520455|Experimental|Intervention|Study subjects were prescribed levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and a package of 30 condoms provided via a commerical pharmacy at no cost to the study subject. The subject could refill this prescription as many times as they wanted for 12 months
11616326|NCT00520442|Experimental|Ibuprofen|
11616327|NCT00520442|Active Comparator|acetamin w codeine|
11616328|NCT00520429|Other|1|This study is an open pilot; therefore all participants were given the opportunity to receive treatment.
11616329|NCT00520416||1|There is no control or experimental group. The same patients undergoing endovascular AAA repair with serve as their own control
11616330|NCT00520403|Experimental|1|
11616331|NCT00520377|Experimental|1|MD05
11616332|NCT00520377|Active Comparator|2|Beta-TCP and autologous bone
11616333|NCT00520364||History of chemotherapy|IVF after chemotherapy
11616334|NCT00520364||IVF without history of chemotherapy|IVF without history of prior chemotherapy
11616335|NCT00520351|Active Comparator|1|
11616336|NCT00520351|Active Comparator|2|
11616337|NCT00520338|Placebo Comparator|2|"placebo
~celecoxib"
11616338|NCT00520338|No Intervention|1|1 placebo
11616339|NCT00520325|Other|0.5 mg/kg|
11616340|NCT00520325|Other|1.0 mg/kg|
11616341|NCT00520299|Experimental|Cohort 1|Subjects received ADI-PEG 20 at a dose of 40 IU/m^2
11616342|NCT00520299|Experimental|Cohort 2|Subjects received ADI-PEG 20 at a dose of 80 IU/m^2
11616343|NCT00520299|Experimental|Cohort 3|Subjects received ADI-PEG 20 at a dose of 160 IU/m^2
11616344|NCT00520286|Active Comparator|Modafinil|Participants will receive a Modafinil 200 mg or 400 mg tablet one time per day for 12 weeks
11616345|NCT00520286|Placebo Comparator|Placebo|Participants will receive a matching Modafinil placebo 200 mg or 400 mg tablet one time per day for 12 weeks
11616346|NCT00520273|Experimental|A|
11616347|NCT00520260|Active Comparator|1|Active treatment arm bromfenac 0.09% BID for 6 weeks
11616348|NCT00520260|Active Comparator|2|ketorolac 0.4% BID for 6 weeks
11616349|NCT00520234|Active Comparator|1 prophylaxis|Caspofungin 50 mg Intravenous (IV) daily up to 28 days of therapy
11616350|NCT00520234|Placebo Comparator|2 placebo|Normal Saline 100 cc IV daily
11616351|NCT00520221||2|"Minocycline group: 300 mg of minocycline hydrochloride was instilled into the pleural space through the catheter.
~Control group consisted of 33 patients who had successful simple aspiration alone between January 2004 and December 2005."
11616352|NCT00520182|Active Comparator|1|ADA 2003 diet
11616353|NCT00520182|Active Comparator|2|Low Glycemic index (LGI) diet
11616354|NCT00520182|Active Comparator|3|MUFA diet
11616355|NCT00520169|Active Comparator|A|oral ketamine
11616356|NCT00520169|Experimental|B|intranasal ketamine
11616357|NCT00520169|Active Comparator|C|intravenous ketamine
11616358|NCT00520130|Experimental|A - Tacrolimus, methotrexate, sirolimus (TMS) Arm|TMS Arm
11616359|NCT00520130|Experimental|B - Cyclosporine (AC) Arm|AC Arm
11616360|NCT00520117||negative pap-smear|
11616361|NCT00520117||positive pap-smear|
11616362|NCT00520104|Experimental|A|intranasal ketamine
11616363|NCT00520104|Experimental|B|oxymetazoline plus intranasal ketamine
11616364|NCT00520104|Experimental|C|intranasal steroid plus intranasal ketamine
11616365|NCT00520091|Active Comparator|Cohort 1|Induction chemotherapy and chemoradiation without celecoxib
11616366|NCT00520091|Experimental|Cohort 2|Induction chemotherapy and chemoradiation with celecoxib
11616367|NCT00520065|Experimental|#1|Diabetes specific enteral product
11616368|NCT00520065|Active Comparator|#2|Standard enteral feeding
11616369|NCT00520052|Active Comparator|LHRH Group|Patients on LHRH agonists and zoledronic acid
11616370|NCT00520052|Active Comparator|Bicalutamide Group|Patients on Bicalutamide and zoledronic acid
11616371|NCT00520039|Experimental|Standard Care Plus OMM|Subjects will receive active intervention with osteopathic manipulative medicine (OMM) using a prescribed standardized treatment protocol which is age appropriate. Subjects will also receive standard care for otitis media from their referring physician.
11616372|NCT00520039|No Intervention|Standard Care Only|Subjects will receive standard care only for otitis media from their regular referring physician
11616373|NCT00520026|Active Comparator|1|Lithium treatment
11616374|NCT00520026|Placebo Comparator|2|Placebo treatment
11616375|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab then bevacizumab|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.
~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.
~Consolidation (A): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 1 year."
11616376|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab then bevacizumab/erlotinib|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.
~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.
~Consolidation (AE): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle and oral erlotinib 150mg daily for 1 year."
11616377|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.
~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.
~Consolidation: None"
11616378|NCT00520000|Active Comparator|Weekly Arm|Carboplatin day 1, abraxane days 1, 8, 15 every 28 day cycle
11616379|NCT00520000|Experimental|Every 3 week Arm|Carboplatin day 1, abraxane day 1, every 21 day cycle
11616380|NCT00520000|Experimental|Arm C|Carboplatin day 1, abraxane day 1, 8 every 21 day cycle
11616381|NCT00519987|Experimental|Treatment A|intranasal ketamine
11616382|NCT00519961|Experimental|A|
11616383|NCT00519961|Experimental|B|
11616384|NCT00519935|Experimental|Multisystemic Therapy|In-home, intensive family therapy
11616385|NCT00519935|No Intervention|Standard Medical Care (TAU)|Standard medical care is provided at Children's Hospital of Michigan consistent with the standards for the care of children with T1D outlined by the American Diabetes Association.
11616386|NCT00519922|Experimental|1|KBA = Kinesthesia, Balance, Agility Exercise Training
11616387|NCT00519922|Active Comparator|2|Standard Lower Extremity Strength Training
11616388|NCT00519909|Other|1|Diet with high content of calcium and high content of fat
11616389|NCT00519909|Other|2|Diet with low content of calcium and high content of fat
11616390|NCT00519909|Other|3|Diet with high content of calcium and normal content of fat
11616391|NCT00519909|Other|4|Diet with low content of calcium and normal content of fat
11616392|NCT00519909|Other|5|Diet with high content of calcium fra supplement and high content of fat
11616393|NCT00519896|Experimental|Treatment (enzyme inhibitor therapy, antiangiogenesis therapy)|Patients receive sunitinib malate PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
11616394|NCT00519883|Active Comparator|A|Arm A: Standard Supportive Care (no supervised exercise)
11616395|NCT00519883|Experimental|B|Arm B: Exercise Intervention
11616396|NCT00519870|Active Comparator|I, II|I: nifedipine II: losartan
11616397|NCT00519857|Active Comparator|1|Tibolone
11616398|NCT00519857|Placebo Comparator|2|Placebo
11616399|NCT00519831|Experimental|Vinflunine + Cetuximab|Patients may receive more than 4 cycles of therapy if they continue to demonstrate response to therapy, have limited toxicity, and if the treating physician determines that they are deriving clinical benefit from the treatment. The decision of continuing therapy beyond 4 cycles must be discussed with the principal investigator.
11616400|NCT00519818|Experimental|Cortef and Chronocort|Cortef 3 times daily(total dose 30 mg)for minimum of 7 days followed by Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
11616401|NCT00519792|Experimental|1|Omega DUROS: Dose 25
11616402|NCT00519792|Experimental|2|Omega DUROS: Dose 50
11616403|NCT00519779|Placebo Comparator|2|Placebo oral Omega-3 fish oil supplementation
11616404|NCT00519779|Experimental|1|oral Omega-3 fish oil supplementation
11616405|NCT00519753|Experimental|DuoTrav|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
11616406|NCT00519727|Experimental|A|50 mg ISIS 325568 vs Placebo, s.c. injection
11616407|NCT00519727|Experimental|B|100 mg ISIS 325568 vs Placebo , s.c. injection
11616408|NCT00519727|Experimental|C|200 mg ISIS 325568 vs Placebo , s.c. injection
11616409|NCT00519727|Experimental|D|400 mg ISIS 325568 vs Placebo, s.c. injection
11616410|NCT00519727|Experimental|AA|50 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
11616411|NCT00519727|Experimental|BB|100 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
11616412|NCT00519727|Experimental|CC|200 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
11616413|NCT00519727|Experimental|DD|400 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
11616414|NCT00519714|Placebo Comparator|1|three placebo capsules PO three times daily.
11616415|NCT00519714|Active Comparator|2|1-MNA 90 mg daily: one active treatment capsule and two placebo capsules PO three times daily
11616416|NCT00519714|Active Comparator|3|1-MNA 270 mg daily: three active treatment capsules PO three times daily.
11616417|NCT00519701|Experimental|1|hydroxyurea
11616418|NCT00519688|Experimental|Thalidomide plus Tegafur/Uracil1|Thalidomide plus Tegafur/Uracil
11616419|NCT00519662|Experimental|Dose escalating cohorts of SNS-314|Sequential groups, starting at a dose of 30 mg/m2, will be escalated according to identification of dose limiting toxicities against various criteria. Doses escalated by doubling the dose until the first observation of clinically significant Grade 2 or greater toxicity related to SNS-314 injection. Results in dosing increments of 67%, 50%, 40%, 33%, and subsequently 25% based on modified Fibonacci schema.
11616420|NCT00519649|Experimental|Group Engerix|Subjects received a single challenge dose of Engerix™ (hepatitis-B [HBV] vaccine)
11616421|NCT00519636|Active Comparator|FFNS, FPNS|fluticasone furoate nasal spray, fluticasone propionate nasal spray
11616422|NCT00519636|Active Comparator|FPNS, FFNS|fluticasone propionate nasal spray, fluticasone furoate nasal spray
11616423|NCT00519636|Placebo Comparator|placebo FFNS, placebo FPNS|placebo nasal spray matching fluticasone furoate nasal spray, placebo nasal spray matching fluticasone propionate nasal spray
11616424|NCT00519636|Placebo Comparator|placebo FPNS, placebo FFNS|placebo nasal spray matching fluticasone propionate nasal spray, placebo nasal spray matching fluticasone furoate nasal spray
11616425|NCT00519623|Experimental|PassPort(R) Transdermal Insulin Delivery System|
11616426|NCT00519610||I|Patients will have charts reviewed for relevant medical information before and after surgery to assess patient outcome after placement of H-graft shunt for the treatment of portal hypertension.
11616427|NCT00519597|Experimental|I|Asymptomatic OSA (CPAP)
11616428|NCT00519597|No Intervention|II|Asymptomatic OSA (no CPAP)
11616429|NCT00519597|Active Comparator|III|Symptomatic OSA (OSAS)
11616430|NCT00519597|No Intervention|IV|Non-OSA
11616431|NCT00519584|Placebo Comparator|Ropivacaine/saline|Ropivacaine 30ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block and 0.9% saline 2 ml (systemic placebo) for intravenous injection with sedation for the block
11616432|NCT00519584|Active Comparator|Ropivacaine/dex|Ropivacaine and local steroid: 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic and 0.9% saline 2ml (systemic placebo) for intravenous injection with sedation for the block;
11616433|NCT00519584|Active Comparator|bupivacaine/dex|bupivacaine and systemic steroid: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block plus dexamethasone 8 mg (2 ml) administered intravenously with sedation administered for the block.
11616434|NCT00519584|Placebo Comparator|bupivacaine/Saline|bupivacaine 30ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block and 0.9% saline 2 ml (systemic placebo) for intravenous injection with sedation for the block
11616435|NCT00519571|Experimental|1|
11616436|NCT00519545|Experimental|1|scripted prayer group (intervention group)
11616437|NCT00519545|No Intervention|2|no prayer intervention group (non-intervention group)
11616438|NCT00519532|Experimental|Rotigotine|Rotigotine Transdermal Patch
11616439|NCT00519519|Active Comparator|2|regular dose versus high dose
11616440|NCT00519493|Active Comparator|Suture|A keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
11616441|NCT00519493|Active Comparator|Clozex|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
11616442|NCT00519480|Placebo Comparator|Subjects receiving treatment P|Eligible subjects will receive placebo twice daily along with metformin twice daily for 13 days.
11616443|NCT00519480|Experimental|Subjects receiving treatment A|Eligible subjects will receive GSK189075 500 milligrams twice daily along with metformin twice daily for 13 days.
11616444|NCT00519480|Experimental|Subjects receiving treatment B|Eligible subjects will receive GSK189075 750 milligrams twice daily along with metformin twice daily for 13 days.
11616445|NCT00519454||Female Lupus patients|Females who are still childbearing age, not on hormones, with Systemic Lupus Erythematosus, still cycling.
11616446|NCT00519441|Other|I|All patients in the study will have pH studies done in order to determine the degree of reflux after laparoscopic Heller myotomies.
11616517|NCT00518921|Placebo Comparator|Arm 4|
11616518|NCT00518908|Experimental|Sevoflurane|Sevoflurane for pharmacological postconditioning
11616447|NCT00519428|Experimental|escitalopram + bupropion|escitalopram plus bupropion extra long (XL) as dual treatment (i.e., this is not a SINGLE treatment arm; all patients assigned this arm received both medications)
11616448|NCT00519428|Active Comparator|escitalopram|escitalopram monotherapy
11616449|NCT00519428|Active Comparator|bupropion|bupropion extra long (XL) monotherapy
11616450|NCT00519415|Experimental|A|
11616451|NCT00519415|Experimental|B|
11616452|NCT00519402||Partial Tonsillectomy|Patients who received a partial tonsillectomy
11616453|NCT00519402||Complete Tonsillectomy|Patients who received a complete tonsillectomy
11616454|NCT00519389|Experimental|Low dose H5N1 VLP Vaccine|
11616455|NCT00519389|Experimental|Mid dose H5N1 VLP Vaccine|
11616456|NCT00519389|Experimental|High dose H5N1 VLP Vaccine|
11616457|NCT00519389|Placebo Comparator|Placebo|
11616458|NCT00519376|Experimental|GW642444M 25mcg|
11616459|NCT00519376|Experimental|GW642444M 50mcg|
11616460|NCT00519376|Experimental|GW642444M 100mcg|
11616461|NCT00519376|Experimental|GW642444H 100mcg|
11616462|NCT00519376|Experimental|placebo|
11616463|NCT00519350||I|Liver surgery
11616464|NCT00519350||II|Colon surgery
11616465|NCT00519350||III|Femur Fracture
11616466|NCT00519337|Active Comparator|1|Ascorbic acid
11616467|NCT00519337|Placebo Comparator|2|Identical placebo
11616468|NCT00519324|Experimental|RAD001|
11616469|NCT00519311|Experimental|School based health intervention|Educational intervention based on health diary + health check
11616470|NCT00519311|No Intervention|Usual care|Normal school curriculum and usual medical care
11616471|NCT00519298|Experimental|1|
11616472|NCT00519298|Placebo Comparator|2|
11616473|NCT00519298|Active Comparator|3|
11616474|NCT00519285|Placebo Comparator|Placebo|Placebo added to standard chemotherapy with docetaxel plus prednisone or prednisolone
11616475|NCT00519285|Experimental|Aflibercept|Aflibercept added to standard chemotherapy with docetaxel plus prednisone or prednisolone
11616476|NCT00519272||Cervical Cancer Care Questionnaires|New cervical cancer patients through stage IVB presenting to the LBJ Gyn-Onc Clinic.
11616477|NCT00519246|Placebo Comparator|I|No drug was delivered.
11616478|NCT00519246|Active Comparator|II|Butorphanol tartrate 1mg was given intravenously.
11616479|NCT00519246|Active Comparator|III|Butorphanol tartrate 2 mg was given intravenously.
11616480|NCT00519246|Active Comparator|IV|Flurbiprofen Axetil 50 mg was given intravenously.
11616481|NCT00519246|Active Comparator|V|Flurbiprofen Axetil 100 mg was given intravenously.
11616482|NCT00519246|Active Comparator|VI|Tramadol Hydrochloride 10 mg was given intravenously.
11616483|NCT00519246|Active Comparator|VII|Tramadol Hydrochloride 20 mg was given intravenously.
11616484|NCT00519233|Experimental|1.AGS-1C4D4|
11616485|NCT00519220||I|Patients will answer symptom questionnaires and have their charts reviewed for relevant medical information.
11616486|NCT00519207|Active Comparator|1|This group will receive lidocaine and sucrose placebo (water).
11616487|NCT00519207|Active Comparator|2|This group will receive lidocaine placebo and sucrose.
11616488|NCT00519207|Active Comparator|3|This group will receive lidocaine and sucrose.
11616489|NCT00519194|Experimental|Epicor Cardiac Ablation|
11616490|NCT00519155|Experimental|1|Open flap debridement + MD05
11616491|NCT00519155|Active Comparator|2|Open flap debridement
11616492|NCT00519142|Placebo Comparator|1|metformin + placebo for mitiglinide
11616493|NCT00519142|Experimental|2|metformin + mitiglinide three times a day with meals
11616494|NCT00519142|Experimental|3|metformin + mitiglinide two times a day with morning and evening meal, placebo for mitiglinide with midday meal
11616495|NCT00519103|Experimental|1|Active resistive excercise for 7 weeks
11616496|NCT00519090|Experimental|Nilotinib (AMN107)|
11616497|NCT00519090|Active Comparator|Imatinib|
11616498|NCT00519077|Experimental|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
11616499|NCT00519064|Active Comparator|Arm 1|
11616500|NCT00519064|Active Comparator|Arm 2|
11616501|NCT00519051|Active Comparator|control group|patients can receive pharmacotherapy and psychotherapy and specialized treatment
11616502|NCT00519038|Experimental|1|Patients treated according to clinical pathways
11616503|NCT00519038|Other|2|Patients treated according to usual care
11616504|NCT00519012|Active Comparator|Arm-1|Sertraline to Paroxetine
11616505|NCT00519012|Active Comparator|2|Paroxetine to Sertraline
11616506|NCT00518999||1|Schizophrenia patients who performed earlier cognitive assessment as part of routine assessment for patients in the Shalvata Mental Health Center.
11616507|NCT00518986|Active Comparator|1|armodafinil 200 mg/day
11616508|NCT00518986|Placebo Comparator|2|Placebo
11616509|NCT00518973|Placebo Comparator|Placebo|The primary outcome was to determine the effect of quetiapine compared with placebo in terms of reducing core eating disorder symptoms on the Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS) and the Eating Disorder Inventory-2 (EDI-2).
11616510|NCT00518973|Experimental|Quetiapine|Secondary outcomes were to determine if quetiapine is superior to placebo in reducing anxiety, depression and obsessionality assessed with the State Trait Anxiety Inventory (STAI), Hamilton Depression Rating Scale (HAM D) and Yale-Brown Obsessive Compulsive Scale, respectively. In addition, another secondary goal was to determine if quetiapine is superior to placebo in terms of weight gain. Adverse events were also determined.
11616511|NCT00518947|Active Comparator|1|Continued-Lithium
11616512|NCT00518947|Experimental|2.|Verapamil
11616513|NCT00518947|Experimental|3.|Verapamil plus Lithium
11616514|NCT00518921|Experimental|Arm 1|
11616515|NCT00518921|Experimental|Arm 2|
11616519|NCT00518908|Experimental|Propofol|Anesthesia maintenance with propofol instead of Sevoflurane postconditioning
11616520|NCT00518895|Experimental|A|Dacarbazine with Genasense
11616521|NCT00518895|Active Comparator|B|Dacarbazine with placebo
11616522|NCT00518882|Experimental|Liraglutide|Liraglutide 1.8 mg once daily + subject's own OAD treatment
11616523|NCT00518882|Active Comparator|Exenatide|Exenatide 10 mcg twice daily + subject's own OAD treatment
11616524|NCT00518869|Experimental|Treatment group|PG2 plus standard chemotherapies
11616525|NCT00518869|Placebo Comparator|Placeo group|Placebo plus standard chemotherapies
11616526|NCT00518856|Experimental|intervention|TBAs who receive training and supplies for the intervention
11616527|NCT00518856|Active Comparator|control|TBAs continuing with current standard of practice
11616528|NCT00518843|Experimental|FBT-BN|Family-based treatment
11616529|NCT00518843|Active Comparator|SPT|Individual Supportive Psychotherapy
11616530|NCT00518830|Experimental|PND-MCI|The multi-component intervention involved a psychoeducational group, treatment adherence support, and pharmacotherapy if needed
11616531|NCT00518830|Active Comparator|usual care|'Usual care' included all services normally available in the clinics, including antidepressant medication, brief psychotherapeutic interventions or referral for specialty treatment
11616532|NCT00518791|Experimental|I|Multidisciplinary Care
11616533|NCT00518791|Other|II|Usual Care
11616534|NCT00518765|Experimental|1|Various sequences of different doses of Aliskiren
11616535|NCT00518765|Experimental|2|Various sequences of different doses of Aliskiren plus placebo
11616536|NCT00518765|Experimental|3|Various sequences of different doses of Aliskiren
11616537|NCT00518765|Experimental|4|Various sequences of different doses of Aliskiren plus placebo
11616538|NCT00518752|Active Comparator|A|Standard Oral Care
11616539|NCT00518752|Experimental|B|Comprehensive Oral Care
11616540|NCT00518726|Experimental|Arm 1|
11616541|NCT00518713|Experimental|Clobazam Low Dose|
11616542|NCT00518713|Experimental|Clobazam Medium Dose|
11616543|NCT00518713|Experimental|Clobazam High Dose|
11616544|NCT00518713|Placebo Comparator|Placebo|
11616545|NCT00518687|Experimental|V710 60 µg|
11616546|NCT00518687|Placebo Comparator|Placebo|
11616547|NCT00518648|Experimental|I|Multifactorial fall prevention program
11616548|NCT00518648|Other|II|Usual care
11616549|NCT00518635|Experimental|A|Growth hormone or Placebo 0.1 mg/day self-administrated once a day.
11616550|NCT00518622|Experimental|1|25 mg b.i.d. MK7009
11616551|NCT00518622|Experimental|2|75 mg b.i.d. MK7009
11616552|NCT00518622|Experimental|3|250 mg b.i.d. MK7009
11616553|NCT00518622|Experimental|4|500 mg b.i.d. MK7009
11616554|NCT00518622|Experimental|5|700 mg b.i.d. MK7009
11616555|NCT00518622|Experimental|6|125 mg q.d. MK7009
11616556|NCT00518622|Experimental|7|600 mg q.d. MK7009
11616557|NCT00518622|Experimental|8|Placebo
11616558|NCT00518609||Indian Neonates|All hospitalized neonates (all live born infants <60 days of age, independent of birth weight and gestational age) brought to hospital, with the diagnosis of suspected sepsis.
11616559|NCT00518596|Experimental|Probiotic Arm|Newborn infants' ≥ 35 weeks of gestation and ≥1800g, given L. plantarum preparations orally once a day starting on day 1, 2, or 3 of life and continuing for seven days thereafter.
11616560|NCT00518596|Placebo Comparator|Control Arm|Newborn infants' ≥ 35 weeks of gestation and ≥1800g, receiving placebo preparations (a control solution of sterile 2.0 cc 5% dextrose-saline)orally once a day starting on day 1, 2, or 3 of life and continuing for seven days thereafter.
11616561|NCT00518570|Experimental|Open-Label treatment|Patients prospectively diagnosed with premenstrual dysphoric disorder.
11616562|NCT00518557|Experimental|1|All patients of this arm are treated by TACE together with Andostatin.
11616563|NCT00518557|Active Comparator|2|All patients of this arm are treated by TACE alone: only mixture of Epirubicin and Lipiodol is injected into the feeding arteries of the tumor, without injection of Andostatin.
11616564|NCT00518531|Other|Treatment Sequence B|When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment Sequences. Subjects randomized to treatment sequence B will receive 70 mg oral alendronate QW for 1-year (Treatment period 1) followed by denosumab 60 mg Q6M SC for 1 year (Treatment Period 2).
11616565|NCT00518531|Other|Treatment Sequence A|When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment sequences. Subjects randomized to treatment sequence A will receive 60 mg denosumab Q6M SC for 1-year (Treatment period 1) followed by oral alendronate 70 mg QW for 1 year (Treatment period 2).
11616566|NCT00518518|Active Comparator|1|
11616567|NCT00518518|Placebo Comparator|2|
11616568|NCT00518505|Other|I|This is a single arm study. All patients will be asked to complete questionnaires and have their medical charts reviewed.
11616569|NCT00518492|Experimental|Arm 1|Includes subjects from a trial involving experimental vaccine and an active comparator vaccine. Comparator is Twinrix (not a MnB vaccine) and thus is comparator for safety but not immunogencity
11616570|NCT00518479|Experimental|1|Neurohormonal stimulatory arm
11616571|NCT00518479|Experimental|2|Neurohormonal inhibitory arm
11616572|NCT00518466|Experimental|treatment 1|"One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.
~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.
~One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Days 4 - 21 of Period 2."
11616573|NCT00518466|Experimental|treatment 2|"Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.
~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.
~One 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsules at Hour 0 on Days 4, 5, and 6 of Period 2.
~Two 7.5 mg phentermine hydrochloride IR capsules (Cardinal) and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2.
~Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2."
11616574|NCT00518466|Experimental|treatment 3|"Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.
~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.
~Two 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsule at Hour 0 on Days 4, 5, and 6 of Period 2.
~Two 7.5 mg phentermine hydrochloride IR capsules and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2.
~Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2."
11616575|NCT00518466|Experimental|treatment 4|"Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Day 1 of Period 1.
~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate IR tablet at Hour 0 on Days 1, 2, and 3 of Period 2.
~Half of a 37.5 mg phentermine hydrochloride IR tablet and two 25 mg topiramate IR tablets at Hour 0 on Days 4, 5, and 6 of Period 2.
~Half of a 37.5 mg phentermine hydrochloride IR tablet and three 25 mg topiramate IR tablets at Hour 0 on Days 7, 8, and 9 of Period 2.
~Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Days 10 - 21 of Period 2."
11616576|NCT00518453|Experimental|Arm 1: Fluvirin|
11616577|NCT00518427|Experimental|1|insulin glargine
11616578|NCT00518414|Active Comparator|Marketed infant formula with DHA and ARA|Marketed milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA)
11616579|NCT00518414|Experimental|Milk-based infant formula with DHA and ARA|Experimental milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA)
11616580|NCT00518414|Experimental|Milk-based formula with DHA, ARA, prebiotics|Experimental milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA) and prebiotic blend
11616581|NCT00518388||Focus Group + Questionnaire|Participants that are self identified as Korean, Filipino, or Vietnamese.
11616582|NCT00518362|Experimental|immunosuppressor|Valsartan,160mg/d,TW 120mg/d
11616583|NCT00518349|Active Comparator|Prototype colonoscope|Colonoscopy using prototype colonoscope with passive bending function
11616584|NCT00518349|Placebo Comparator|Standard colonoscope|Colonoscopy using standard colonoscope with no passive bending function
11616585|NCT00518336|Experimental|Cervarix Group|Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.
11616586|NCT00518336|Placebo Comparator|Placebo Group|Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.
11616587|NCT00518323|Experimental|001|Paliperidone ER 1.5 mg tablet once daily for 6 weeks
11616588|NCT00518323|Experimental|002|Paliperidone ER 3 mg or 6 mg tablet once daily for 6 weeks
11616589|NCT00518323|Experimental|003|Paliperidone ER 6 mg or 12 mg tablet once daily for 6 weeks
11616590|NCT00518323|Placebo Comparator|004|Placebo Once daily for 6 weeks
11616591|NCT00518310|Placebo Comparator|0|Placebo
11616592|NCT00518310|Active Comparator|1|Azathiprine Prednisone
11616593|NCT00518297|Active Comparator|1|
11616594|NCT00518297|Active Comparator|2|
11616595|NCT00518297|Active Comparator|3|
11616596|NCT00518284|No Intervention|No Drug Treatment Control|Following revascularization, participants did not receive any study drug treatment.
11616597|NCT00518284|Experimental|Proximal to Lesion + IV|Participants received an initial intraarterial infusion (proximal to the lesion) of 45 mg/m^2 nanoparticle paclitaxel immediately following revascularization, and a follow-up intravenous injection of 45 mg/m^2 at 7 days.
11616598|NCT00518284|Experimental|During Flow Arrest|Participants received an initial intraarterial infusion (during flow arrest) of 45 mg/m^2 nanoparticle paclitaxel immediately following revascularization.
11616599|NCT00518284|Experimental|During Flow Arrest + IV|Participants received an initial intraarterial infusion (during flow arrest) of 45mg/m^2 nanoparticle paclitaxel immediately following revascularization and a follow-up intravenous injection of 45 mg/m^2 at 7 days.
11616600|NCT00518258||1|Patient Group
11616601|NCT00518258||2|Control Group
11616602|NCT00518245|Experimental|1|
11616603|NCT00518245|No Intervention|2|
11616604|NCT00518219|Experimental|immunosuppressor|TW 120mg/d，Valsartan,160mg/d
11616605|NCT00518206|Experimental|Cohort 1|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
11616606|NCT00518206|Experimental|Cohort 2|Cyclophosphamide (300 mg/m^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
11616607|NCT00518180|Experimental|MenACWY + Tdap + HPV|Subjects received MenACWY concomitantly with Tdap and HPV at study month 0 followed by two injections of HPV at month 2 and 6
11616608|NCT00518180|Experimental|MenACWY →Tdap → HPV|Subjects received MenACWY at study month 0 followed by one injection of Tdap at month 1, followed by three injections of HPV at months 2, 4, and 8
11616609|NCT00518180|Experimental|Tdap →MenACWY → HPV|Subjects received Tdap at month 0 followed by one injection of MenACWY at month 1, followed by three injections of HPV at months 2, 4, and 8
11616610|NCT00518167|Experimental|1|Intensive lifestyle intervention
11616611|NCT00518167|No Intervention|2|Standard counselling at baseline
11616612|NCT00518154|Experimental|A|Patients will be taking oral Pyridostigmine 30mg tid, as well as their usual antiretroviral treatment
11616613|NCT00518141|Experimental|1|FER
11616614|NCT00518141|No Intervention|2|FER
11616615|NCT00518141|Experimental|3|SET
11616616|NCT00518141|No Intervention|4|SET
11616617|NCT00518141|Experimental|5|DET
11616618|NCT00518141|No Intervention|6|DET
11616619|NCT00518128|Active Comparator|1|Surgical OSA Treatment Group: Moderate to Severe OSA patients who are unable to tolerate PAP (Positive Airway Pressure) and elect to proceed with surgical treatment (surgical cohort).
11639648|NCT00246571|Active Comparator|B|
11616620|NCT00518128|Active Comparator|2|Positive Airway Pressure Therapy Comparison Group: Moderate to Severe OSA patients who tolerate PAP (Positive Airway Pressure).
11616621|NCT00518102||001|REGRANEX (becaplermin) A cohort of REGRANEX (becaplermin) users (ie patients treated with REGRANEX (becaplermin) a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
11616622|NCT00518102||002|REGRANEX (becaplermin) comparators A cohort of REGRANEX (becaplermin) nonusers (ie patients who are not treated with REGRANEX [becaplermin]) but are similar in characteristics to patients in the REGRANEX [becaplermin] user cohort)
11616623|NCT00518089|Experimental|Gatifloxacin 0.5% Eye Drops|Gatifloxacin 0.5% Eye Drops
11616624|NCT00518089|Placebo Comparator|Placebo Eye Drops|Placebo Eye Drops
11616625|NCT00518050||Specific Aim 1- Focus Group|"Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:
~Screening, skin self-examination, sun protection, and other cancer preventive practices;
~Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,
~Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment"
11616626|NCT00518050||Specific Aim 2- Survey Study|A separate random sample of melanoma survivors will complete the pilot questionnaire. To enhance completion rates, survey instruments will be developed to be both self-administered and interviewer-administered. The survey will include questions from existing surveys, regarding demographics, sun sensitivity, eye and hair color, color of untanned skin, sun exposure, skin selfexamination, sun protection practices and frequency of sunburns, psychosocial/cognitive factors: skin cancer knowledge, skin awareness, cancer worry, perceived risk of recurrence, cancer risk and screening behaviors, and access to health care and insurance.
11616627|NCT00518037||1|nonmelanoma skin cancer patients
11616628|NCT00518024|Experimental|1|Bilateral theta burst stimulation to the secondary auditory cortex
11616629|NCT00518024|Experimental|2|Bilateral theta burst stimulation to the tertiary auditory cortex
11616630|NCT00518024|Sham Comparator|3|Bilateral theta burst stimulation to a non-cortical region
11616631|NCT00518011|Experimental|Erlotinib + Gemcitabine|Participants received Erlotinib 150 mg/day orally as a continuous schedule with Gemcitabine 1000 (mg/m^2)/day, IV on Days 1, 8, 15 and every 4 weeks for 6 cycles.
11616632|NCT00518011|Active Comparator|Gemcitabine|Participants received Gemcitabine 1000 (mg/m^2)/day, IV on Days 1, 8, 15 and every 4 weeks for 6 cycles.
11616633|NCT00517998|Experimental|Group1|Treatment will be administered in two sessions.
11616634|NCT00517998|Experimental|Group2|Treatment will be administered in a single session.
11616635|NCT00517959|Experimental|1|Stereotactic conformal radiotherapy (SCRT)
11616636|NCT00517959|Other|2|Conventional radiotherapy Patients in this arm will be treated with conventional radiotherapy techniques being used at the moment in the department. This involves patient being immobilised with a customised thermoplastic mask after which they will have a contrast enhanced planning CT scan. The radiation oncologist will draw the tumour on the appropriate CT slices and a margin of 1-2 cms grown for the planning target volume. Beam arrangement will be relatively simple and typically consist of 2-3 coplanar fields using 6 MV photons. Conventional planning optimisation will be carried out by the use of wedges, beam weightage and corner shields as appropriate. Radiotherapy doses, prescription and fractionation schedules will be identical to the SCRT arm
11616637|NCT00517933|Active Comparator|Sildenafil|20 mg of sildenafil 3 times a day (TID) for 12 weeks followed by 20 mg of sildenafil TID for an additional 12 weeks
11616638|NCT00517933|Placebo Comparator|Placebo / Sildanafil|20 mg of placebo TID for 12 weeks followed by 20 mg of sildenafil citrate TID for an additional 12 weeks
11616639|NCT00517920|Experimental|ABT-869|
11616640|NCT00517907|Experimental|1|6 steroid-resistant acute GVHD patients, post-matched BMT (serial)
11616641|NCT00517881|Experimental|C.E.R.A.|
11616642|NCT00517868|Other|Crossover|Placebo Treatment on Visit 1 followed by URG101 Treatment on Visit 2
11616643|NCT00517868|Other|Crossover 2|URG101 Treatment on Visit 1 followed by Placebo Treatment on Visit 2
11616644|NCT00517829|Active Comparator|1- Docetaxel plus Oxaliplatin|Docetaxel as an intravenous (IV) infusion over 1 hour, followed by oxaliplatin IV over 2 hours
11616645|NCT00517829|Active Comparator|2- Docetaxel plus oxaliplatin plus cetuximab|Docetaxel 60 mg/m2 as an IV infusion over 1 ho ur, followed by oxaliplatin 130 mg/m2 IV over 2 hours, followed by cetuximab 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
11616646|NCT00517816|Experimental|1|
11616647|NCT00517816|Experimental|2|
11616648|NCT00517816|Experimental|3|
11616649|NCT00517816|Experimental|4|
11616650|NCT00517816|Experimental|5|
11616651|NCT00517816|Experimental|6|
11616652|NCT00517816|Experimental|7|
11616653|NCT00517816|Experimental|8|
11616654|NCT00517803|Experimental|1|
11616655|NCT00517803|Placebo Comparator|2|
11616656|NCT00517790|Experimental|ABT-869 0.25 mg/kg|Approximately half of the subjects were randomized to receive the high dose
11616657|NCT00517790|Experimental|ABT-869 0.10 mg/kg|Approximately half of the subjects were randomized to receive the Low Dose
11616658|NCT00517777|Experimental|1|continuous positive airway pressure ventilation + dietary and life style recommendations
11616659|NCT00517777|Active Comparator|2|dietary and life style recommendations
11616660|NCT00517764|No Intervention|Healthy control|Healthy matched control, no intervention
11616661|NCT00517764|Active Comparator|Escitalopram|Depressed subjects receiving escitalopram
11616662|NCT00517764|No Intervention|subjects with major depression|Depressed subjects not receiving study treatment, but taking part in study measures.
11616663|NCT00517751|Experimental|X-STOP PEEK|In this arm, patients will undergo X-STOP PEEK surgery.
11616664|NCT00517738|Experimental|Physical training - No encephalopathy|Patients randomized to the physical training program and diet intervention
11616665|NCT00517738|Active Comparator|Control - No encephalopathy|Patients not allocated to exercise program, but undergoing diet intervention
11616666|NCT00517738|Experimental|Physical training - Early encephalopathy|Patients with early hepatic encephalopathy (minimal or clinical grade 1-2) randomized to the physical training program
11616940|NCT00515294|Active Comparator|3Caffeinated Non-Alcoholic Beer|Caffeinated Non-Alcoholic Beer
11616667|NCT00517738|Active Comparator|Control - Early encephalopathy|Patients with early hepatic encephalopathy (minimal or clinical grades 1-2) not allocated to the physical training program, but undergoing diet intervention
11616668|NCT00517725|Active Comparator|Carvedilol|
11616669|NCT00517725|Active Comparator|Bisoprolol|
11616670|NCT00517725|Active Comparator|Nebivolol|
11616671|NCT00517712|Active Comparator|A|Duration of maintenance therapy with single agent ATO of 12 months
11616672|NCT00517712|Active Comparator|B|Duration of maintenance therapy with single agent ATO for 6 months
11616673|NCT00517699|Experimental|1|
11616674|NCT00517686|Experimental|1|The study will use automated databases and PHASE information systems to identify patients and incorporate feedback on a monthly basis into the ongoing reports used by program staff at facilities randomized to this intervention arm (n=4).
11616675|NCT00517686|No Intervention|2|Usual care facilities (n=4) will continue to use current PHASE reports that include information on recent risk factor levels and current use of selected medications but no treatment intensification information, and no information on medication adherence.
11616676|NCT00517673|Experimental|GSK945237|Active Study Drug
11616677|NCT00517673|Placebo Comparator|Sugar Pill|Placebo
11616678|NCT00517634|Experimental|Sequence 1: FP, SFC, Placebo|Fluticasone Propionate (FP) 100 micrograms (mcg) twice daily (BID) in the first treatment period: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID in the second treatment period: Placebo in the third treatment period
11616679|NCT00517634|Experimental|Sequence 2: Placebo, SFC, FP|Placebo in the first treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
11616680|NCT00517634|Experimental|Sequence 3: SFC, FP, Placebo|Salmeterol/Fluticasone Propionate 50/100 Combination mcg BID in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Placebo in the third treatment period
11616681|NCT00517634|Experimental|Sequence 4: SFC, Placebo, FP|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the first treatment period: Placebo in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
11616682|NCT00517634|Experimental|Sequence 5: FP, Placebo, SFC|Fluticasone Propionate 100 mcg BID in the first treatment period: Placebo in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
11616683|NCT00517634|Experimental|Sequence 6: Placebo, FP, SFC|Placebo in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
11616684|NCT00517582|Experimental|HOE-140|Administration of HOE-140 (icatibant) 30 mg at time 0 and at 6 hours
11616685|NCT00517582|Placebo Comparator|Placebo|Administration of placebo at time 0 and 6 hours
11616686|NCT00517569|Experimental|1|GX-12 combined with HAART
11616687|NCT00517556|Experimental|study group (CCOCP)|treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for 168 continuous days through six cycles
11616688|NCT00517556|Active Comparator|control group (traditional OCP)|treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for traditional (21 active days/7 inactive days) regimen through six cycles.
11616689|NCT00517530|Experimental|Phase I, NHL|Participants in this NHL arm received multiple ascending doses between 50 and 2000 mg via intravenous infusion of obinutuzumab.
11616690|NCT00517530|Experimental|Phase I, CLL|Participants in this CLL arm received multiple ascending doses between 400 and 2000 mg via intravenous infusion of obinutuzumab.
11616691|NCT00517530|Experimental|400/400 mg - Phase II, iNHL|Participants in this iNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
11616692|NCT00517530|Experimental|1600/800 mg - Phase II, iNHL|Participants in this iNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
11616693|NCT00517530|Experimental|400/400 mg - Phase II, aNHL|Participants in this aNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
11616694|NCT00517530|Experimental|1600/800 mg - Phase II, aNHL|Participants in this aNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
11616695|NCT00517530|Experimental|1000/1000 mg - Phase II, CLL|Participants in this CLL arm received an intravenous infusion of obinutuzumab 1000 mg on Days 1, 8, and 15 of Cycle 1 and obinutuzumab 1000 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
11616696|NCT00517530|Experimental|Retreated Participants|Participants who might benefit from retreatment who were allowed to be treated again via intravenous infusion of obinutuzumab at the request of the investigator.
11616697|NCT00517517|Experimental|1|Intramuscular injection of whole virion, Vero cell-derived influenza vaccine containing 7.5 µg of H5N1 HA antigen per 0.5 mL in a non-adjuvanted formulation
11616698|NCT00517517|Experimental|2|Intramuscular injection of whole virion, Vero cell-derived influenza vaccine containing 3.75 µg of H5N1 HA antigen per 0.25 mL in a non-adjuvanted formulation
11616699|NCT00517491|Experimental|1|
11616700|NCT00517465|Experimental|1|
11616701|NCT00517465|Experimental|2|
11616702|NCT00517465|Experimental|3|
11616703|NCT00517465|Placebo Comparator|4|
11616704|NCT00517452||Platelet Rich Plasma|Group received platelet rich plasma and observed over a period of 30 days or until wound closure
11616705|NCT00517452||Standard Wound Care|Group was treated as per standard care
11616706|NCT00517439|Experimental|Group 1|Group 1 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1000 po bid) plus PEGASYS (180 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
11616941|NCT00515294|Placebo Comparator|4Non-Caffeinated, Non-Alcoholic Beer|Non-Caffeinated, Non-Alcoholic Beer
11616707|NCT00517439|Experimental|Group 2|Group 2 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (500 mg po bid) plus PEGASYS (180 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
11616708|NCT00517439|Experimental|Group 3|Group 3 will receive HCV polymerase inhibitor pro-drug 500mg po bid plus PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd for 24 weeks; after 24 weeks, those achieving a rapid virological response (RVR) will stop all medication, and non-RVR patients will remain on triple combination for an additional 24 weeks.
11616709|NCT00517439|Experimental|Group 4|Group 4 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1500 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
11616710|NCT00517439|Experimental|Group 5|Group 5 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1000 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
11616711|NCT00517439|Experimental|Group 6|Group 6 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (500 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
11616712|NCT00517439|Active Comparator|Group 7|Standard of care (SOC)
11616713|NCT00517426|Experimental|Active Acetazolamide|
11616714|NCT00517413|Experimental|C.E.R.A|Participants with chronic renal anaemia who were on dialysis and previously treated with intravenous (IV) or subcutaneous (SC) epoetin alfa, epoetin beta or darbepoetin alfa received monthly treatment with Continuous Erythropoietin Receptor Activator (C.E.R.A.) (methoxy polyethylene glycol-epoetin beta [Mircera]). The initial dose of C.E.R.A. was based on the last dose of the previous Erythropoiesis Stimulating Agent (ESA); 120, 200, or 360 micrograms (mcg) C.E.R.A., IV or SC, every 4 weeks for 48 weeks.
11616715|NCT00517400|Active Comparator|Exposure-Stimulation|
11616716|NCT00517400|Active Comparator|Sham exposure - Real stimulation|
11616717|NCT00517400|Active Comparator|Exposure - Sham Stimulation|
11616718|NCT00517387|Active Comparator|1|All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
11616719|NCT00517361|Experimental|Carboplatin + Avastin|
11616720|NCT00517335||1|Women who are healthy controls
11616721|NCT00517335||2|Women who have recovered from bulimia
11616722|NCT00517335||3|Women who have recovered from anorexia
11616723|NCT00517322|Experimental|1|treatment with ramipril
11616724|NCT00517322|Experimental|2|treatment with irbesartan
11616725|NCT00517296|Experimental|Adalimumab with EUS guided therapy|Patients will be randomized to adalimumab treatment with EUS guided therapy decisions. Colorectal surgeon will have access to EUS data prior to EUA with possible seton placement.
11616726|NCT00517296|Active Comparator|Adalimumab|Patients will be randomized to adalimumab treatment. Colorectal surgeon will not have access to EUS data prior to EUA with possible seton placement.
11616727|NCT00517283|Experimental|Sequence 1|Exenatide 5 mcg - Exentatide 10 mcg - Placebo
11616728|NCT00517283|Experimental|Sequence 2|Exenatide 10 mcg - Placebo - Exenatide 5 mcg
11616729|NCT00517283|Experimental|Sequence 3|Placebo - Exenatide 5 mcg - Exenatide 10 mcg
11616730|NCT00517257|Experimental|A|Atorvastatin 80 mg orally once daily for 24 weeks
11616731|NCT00517257|Placebo Comparator|P|Placebo tablet orally once daily for 24 weeks
11616732|NCT00517244||A|Primary anxiety disorder
11616733|NCT00517244||B|Primary obsessive compulsive disorder
11616734|NCT00517244||C|Healthy children with no previous history of an anxiety disorder
11616735|NCT00517166||A|Individuals on whom tourniquet was used.
11616736|NCT00517153|Experimental|1|OGT-918 - Zavesca (miglustat)
11616737|NCT00517153|No Intervention|2|Standard treatment
11616738|NCT00517127|Active Comparator|1|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
11616739|NCT00517127|Active Comparator|2|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
11616740|NCT00517088|Other|Other|Group Description
11616741|NCT00517075|Experimental|A|high frequency rTMS to the left infero-parietal lobe, active/sham condition randomized (2:1), double-blind
11616742|NCT00517075|Active Comparator|B|Active high frequency rTMS to the left dorsolateral prefrontal cortex
11616743|NCT00517075|Sham Comparator|C|Sham (placebo) high frequency rTMS to the left dorsolateral prefrontal cortex or left infero-parietal lobe, active/sham condition randomized (2:1), double-blind
11616744|NCT00517075|Experimental|Open cross over high frequency rTMS|Following the randomization phase with three arms, subjects who did not respond, have the possibility of receiving open active treatment to the target that they did not receive treatment to in the randomization phase. (i.e. randomized to IPL --> open phase DLPFC and vice versa)
11616745|NCT00517062|Active Comparator|A|Growth hormone
11616746|NCT00517062|Placebo Comparator|B|Placebo
11616747|NCT00517049|Experimental|1|
11616748|NCT00517036|Experimental|A|Participants will take EPA
11616749|NCT00517036|Experimental|B|Participants will take DHA
11616750|NCT00517036|Placebo Comparator|C|Participants will take placebo
11616751|NCT00517023|Active Comparator|ILR + Syncope Clinic|Patients will have ILR implanted and follow-up in Syncope Clinic
11616752|NCT00517023|Active Comparator|ILR Only|Patients will have ILR implanted and routine follow up.
11616753|NCT00517023|Active Comparator|Routine Mx + Syncope Clinic|Patients will receive routine care and management plus follow up in Syncope Clinic
11616754|NCT00517023|Active Comparator|Routine Mx|Patients will receive routine care and management
11617002|NCT00514878||1|Adult same-day outpatients scheduled for general anesthesia
11645450|NCT00146107|Experimental|3|Exercise
11616755|NCT00517010|Experimental|proton beam with ranibizumab|Intervention is 24Gy proton radiation in 2 fractions given within 6 weeks of first dose of intravitreal ranibizumab (0.5mg) drug combined with four monthly doses of intravitreal lucentis and monthly prn lucentis thereafter.
11616756|NCT00516984|Placebo Comparator|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
11616757|NCT00516984|Sham Comparator|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
11616758|NCT00516984|Active Comparator|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
11616759|NCT00516958|Experimental|1|Topical Dermacyn
11616760|NCT00516958|Active Comparator|2|Topical Dermacyn and levofloxacin
11616761|NCT00516958|Active Comparator|3|Topical saline and levofloxacin
11616762|NCT00516919|Experimental|1|Xenical + behavioral intervention
11616763|NCT00516919|Active Comparator|2|Placebo + behavioral intervention
11616764|NCT00516906|Placebo Comparator|Transparent Adhesive Dressing|Standard of Care Non-Antimicrobial Transparent Adhesive Dressing
11616765|NCT00516906|Experimental|CHG antimicrobial transparent dressing|Chlorhexidine gluconate antimicrobial transparent adhesive dressing
11616766|NCT00516893|Experimental|Natalizumab High Titer|natalizumab high titer 300 mg administered as intravenous (IV) infusion over 60 minutes once every 4 weeks for up to 9 doses
11616767|NCT00516867|Active Comparator|UVB 0.5%|
11616768|NCT00516867|No Intervention|Controls|
11616769|NCT00516867|Active Comparator|UVB 1.4%|
11616770|NCT00516841|Experimental|volociximab|15 mg/kg volociximab once weekly
11616771|NCT00516828|Experimental|Sorafenib and Cytarabine|Cytarabine: subcutaneously twice daily from day 1 - 10. Sorafenib: Days 2-28; at the dose level assigned at registration. Sorafenib will be given orally twice daily.
11616772|NCT00516802|Experimental|1|DTIC + KU-0059436
11616773|NCT00516737|Experimental|1|Active Drug
11616774|NCT00516737|Placebo Comparator|2|Matching Pbo Comparator
11616775|NCT00516724|Experimental|1|Carboplatin + KU-0059436
11616776|NCT00516724|Experimental|2.|Paclitaxel + KU-0059436
11616777|NCT00516724|Experimental|3.|Paclitaxel, Carboplatin + KU-0059436
11616778|NCT00516698||Group 1|"Patients undergo blood sample collection at baseline and at 1 year after initiation of aromatase inhibitor therapy (anastrozole or exemestane). Samples are analyzed for estrogen and testosterone levels and additional hormone levels and growth factors that have been previously linked with breast density and that could be altered by aromatase inhibitor use (i.e., sex hormone-binding globulin [SHBG], DHEA, DHEA sulfate, progesterone, prolactin, insulin-like growth factor-1 [IGF-1], and insulin-like growth factor binding protein 3 [IGF BP3]). Samples are also analyzed for anastrozole and exemestane levels by HPLC. Pharmacogenetic studies are also performed. Haplotype-tagged single nucleotide polymorphisms in genes in the aromatase pathway are examined.
~Patients also undergo mammogram at baseline (≤ 6 months prior to study registration) and at 1 year after initiation of aromatase inhibitor therapy."
11616779|NCT00516685|Experimental|Vaccine Group|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
11616780|NCT00516685|No Intervention|Control Group|Patients in this arm will only receive Best Supportive Care.
11616781|NCT00516672|Experimental|Arm 1|Pazopanib monotherapy or in combination with lapatinib
11616782|NCT00516659|Active Comparator|Group 1|Group 1 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 37.5µg LT
11616783|NCT00516659|Placebo Comparator|Group 2|Group 2 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 0µg LT (placebo patch containing no LT)
11616784|NCT00516646|Active Comparator|1|ALT-711 200 mg bid
11616785|NCT00516646|Placebo Comparator|2|
11616786|NCT00516633|No Intervention|CG|The control group had regular individual information and support in connection with ordinary clinical follow-ups
11616787|NCT00516633|Experimental|IG|The intervention group had extra support and information in the form of four group discussions with parents
11616788|NCT00516620|Active Comparator|1|Participants receive Health Canada's Food Guide and Physical Activity guide.
11616789|NCT00516620|Active Comparator|2|Participants receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
11616790|NCT00516620|Active Comparator|3|Participants receive intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products.
11616791|NCT00516620|Active Comparator|4|Participants receive intensive dietary counseling for 6 months to decrease intake of sweetened soft drink.
11616792|NCT00516581||no HAART|Patients that no received HAART
11616793|NCT00516581||with HAART|Patients that received HAART
11616794|NCT00516555||A, 07, 001|Pregnant women at term with a baby in breech presentation who will have an external cephalic version.
11616795|NCT00516516|Experimental|I|Oral L-Carnitine, 1g PO twice daily
11616796|NCT00516516|Placebo Comparator|II|Placebo, similar in appearance to experimental drug, given orally twice daily.
11616797|NCT00516503|Experimental|Arm I|Patients apply 1 spoonful of baclofen-amitriptyline hydrochloride-ketamine gel> topically to each> area of pain,> numbness,> and/or tingling> on the> feet and/or hands twice daily> for> 4 weeks.
11616798|NCT00516503|Placebo Comparator|Arm II|Patients apply 1 spoonful of placebo gel topically to each area of pain, numbness, and/or tingling on the feet and/or hands twice daily for 4 weeks.
11616799|NCT00516490|Experimental|1|GnRH agonist administration
11616800|NCT00516490|Placebo Comparator|2|Sterile saline injection
11616801|NCT00516477|Experimental|dose cohort 1|1.5E10 vector genomes voretigene neparvovec-rzyl in 150 microliters administered subretinally
11616802|NCT00516477|Experimental|dose cohort 2|4.8E10 vector genomes voretigene neparvovec-rzyl in 150 microliters administered subretinally
11616803|NCT00516477|Experimental|dose cohort 3|1.5E11 vector genomes voretigene neparvovec-rzyl in 300 microliters administered subretinally
11616804|NCT00516451|Experimental|1|
11616805|NCT00516438|Experimental|1|Topotecan + KU-0059436
11617003|NCT00514865|Experimental|E1|1-2 mg of ONO-2333
11616806|NCT00516412|Experimental|Everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11616807|NCT00516399|Experimental|I:|povidone-iodine 1.25% ophthalmic solution. The associated intervention descriptions contain sufficient information to describe the arm.
11616808|NCT00516399|Active Comparator|II|natamycin ophthalmic suspension, USP 5%. The associated intervention descriptions contain sufficient information to describe the arm.
11616809|NCT00516386|Experimental|Insulin like growth factor- 1 (IGF-1)|Adolescent girls with AN meeting inclusion criteria were administered recombinant human (rh) rhIGF-1 at a dose of 35-40 mcg/k twice daily by subcutaneous injections for a 7-10 day period.
11616810|NCT00516373|Experimental|KU-0059436|KU-0059436 administered orally twice daily
11616811|NCT00516360|Experimental|1|Chlorhexidien as the antibacterial agent used to cleanse the hub of neonatal central lines
11616812|NCT00516360|Active Comparator|2|Isopropyl alcohol as the antibacterial agent used to cleanse the hub of neonatal central lines
11616813|NCT00516295|Experimental|Arm I (Feasibility assessment of VTCB)|Patients receive bevacizumab IV over 30-90 minutes on day 1, vincristine sulfate IV on days 1, 8, and 15, and topotecan hydrochloride IV over 30 minutes and cyclophosphamide IV over 60 minutes on days 1-5. Treatment repeats every 21 days (except during weeks 14, 15 [course 5], 17, 18 [course 6], 26, 27 [course 9], 29, and 30 [course 10] when no chemotherapy is given) for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11616814|NCT00516295|Experimental|Arm II (VTCB)|Patients receive bevacizumab, vincristine sulfate, topotecan hydrochloride, and cyclophosphamide as in Arm I.
11616815|NCT00516295|Active Comparator|Arm III (CTC)|Patients receive vincristine, topotecan hydrochloride, and cyclophosphamide as in arm I.
11616816|NCT00516269|Experimental|Methylphenidate then Placebo|Methylphenidate 18 mg oral daily for 2 weeks then Placebo oral daily for 2 weeks
11616817|NCT00516269|Experimental|Placebo then Methylphenidate|Placebo oral daily for 2 weeks then Methylphenidate 18 mg oral daily for 2 weeks
11616818|NCT00516256|Experimental|CHESS System|CHESS System - Internet-based computer program for 6 months.
11616819|NCT00516256|Experimental|Cancer Information Mentor|Cancer Information Mentor - Phone calls to the patient for 6 months.
11616820|NCT00516256|Experimental|CHESS System + Cancer Information Mentor|CHESS System + Cancer Information Mentor
11616821|NCT00516243|Experimental|Arm I (defined green tea catechin extract)|Patients receive defined green tea catechin extract PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
11616822|NCT00516243|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
11616823|NCT00516217|Experimental|Galaximab|Induction: 500 mg/m^2 by IV over 60 minutes days 1, 8, 15 & 22 Extended Induction: 500 mg/m^2 by IV every 4 weeks until disease progression or unacceptable toxicity
11616824|NCT00516204||Patients at very high risk|
11616825|NCT00516204||Patients at high risk|
11616826|NCT00516204||Patients at medium risk|
11616827|NCT00516204||Patients at low risk|
11616828|NCT00516178|Placebo Comparator|Placebo|Saline (No lipid emulsion)
11616829|NCT00516178|Experimental|Fish oil emulsion|3 infusions of 0.2 g/kg omega-3 PUFA within 24 hours in cardiac surgery (continuous infusion post-PTCA)
11616830|NCT00516165|Experimental|RAD001|Patients will receive RAD001 10 mg/day orally (6 weeks/cycle). Patients will be continued on treatment until disease progression, limiting toxicity, patient withdrawal of consent, or death.
11616831|NCT00516139|Experimental|Lamotrigine|Open-label lamotrigine
11616832|NCT00516126||Point-of-Care managed|This arm includes all patients in which the hemostatic therapy is guided by POC devices e.g. MULTIPLATE (a platelet function analyzer) or ROTEM (thromboelastometry)
11616833|NCT00516126||Conventional hemostasis lab managed|This arm includes all patients in which the hemostatic therapy is guided by conventional hemostasis laboratory data e.g. INR, aPTT, fibrinogen concentration, platelet count but no POC devices e.g. MULTIPLATE (a platelet function analyzer) or ROTEM (thromboelastometry)
11616834|NCT00516113|Active Comparator|1|Paroxetine 20mg during the luteal phase of the menstrual cycle
11616835|NCT00516113|Placebo Comparator|2|Placebo during the luteal phase of the menstrual cycle
11616836|NCT00516087|Experimental|Patients|Patients with NPC in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV genome or antigens have been demonstrated in tissue biopsies.
11616837|NCT00516074|Experimental|Exenatide Arm|This arm will receive 5mcg exenatide for 4 weeks, and then 10mcg exenatide for the remaining 8 weeks of the study.
11616838|NCT00516074|Placebo Comparator|Placebo Arm|This arm will receive placebo injection (volume equivalent to the exenatide injection in the experimental arm).
11616839|NCT00516048|Experimental|Exenatide:Treatment-Emergent Antibody Negative|This arm will receive 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks.
11616840|NCT00516048|Experimental|Exenatide:Treatment-Emergent Antibody Positive|This arm will receive 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks.
11616841|NCT00516035|Experimental|1|0.50 ml (0.25 ml in each nostril) of Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca) administered by nasal spray at two timepoints (at study entry and between Weeks 4 and 8)
11616842|NCT00516022|Experimental|Investigator product|The patients randomized to this arm will receive the IP injections at home 3 times a week (the patients will inject the IP themselves).
11616843|NCT00516022|Other|Control|The patients randomized to this arm will continue to receive chemotherapy as usual without further treatment (unless prescribed by the Doctor).
11616844|NCT00516009|Experimental|1 TREATMENT GROUP|20 PATIENTS WILL RECEIVE DEXAMETHASONE 30 MG IV 3 DAYS AND 20 AND 10 MG FOR THE OTHER TWO DAYS
11616845|NCT00516009|Placebo Comparator|2|20 PATIENTS WILL RECEIVE PLACEBO FOR 5 DAYS
11616846|NCT00515996||2|paroxetine treatment group vs. normal control group
11616847|NCT00515970|Experimental|1|Clinical or histologic diagnosis of nodular BCC
11616848|NCT00515970|Active Comparator|2|Clinical or histologic diagnosis of nodular BCC
11616849|NCT00515970|Experimental|3|Clinical or histologic diagnosis of superficial BCC
11616850|NCT00515970|Active Comparator|4|Clinical or histologic diagnosis of superficial BCC
11616851|NCT00515957|Experimental|Patients|Patients with Nasopharyngeal Carcinoma in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV-genome or antigens have been demonstrated in tissue biopsies
11616852|NCT00515931|Experimental|Radiotherapy|GIST patients who have progressing metastases will be treated with radiotherapy.
11616853|NCT00515918||1|Iron deficient
11616854|NCT00515918||2|Iron sufficient
11616855|NCT00515879|Experimental|CBT plus d-cycloserine|Participants will receive cognitive behavioral therapy plus D-cycloserine
11616856|NCT00515879|Placebo Comparator|CBT plus placebo|Participants will receive cognitive behavioral therapy plus pill placebo
11616857|NCT00515866|Experimental|1|Gemcitabine + KU-0059436
11616858|NCT00515840|Sham Comparator|1|equal time with health care professional (asthma nurse)
11616859|NCT00515827|Experimental|Raltegravir then Placebo (Arm A)|400 mg raltegravir (MK-0518) administered twice daily in addition to optimized background regimen (OBR) from entry to Week 12; halt raltegravir at Week 12 and add placebo twice daily for 12 weeks
11616860|NCT00515827|Experimental|Placebo then Raltegravir (Arm B)|Placebo administered twice daily in addition to OBR from entry until Week 12; halt placebo at Week 12 and add 400 mg raltegravir tablet twice daily for 12 weeks
11616861|NCT00515814|Experimental|1, 2|During measurement/test periods, investigator sets implant into ON or OFF condition without subjects knowledge of when device is active.
11616862|NCT00515801|Experimental|A|Glibenclamide 5 mg tablets
11616863|NCT00515801|Placebo Comparator|B|placebo capsules
11616864|NCT00515788|Experimental|DepoCyt + Temozolomide|DepoCyt Starting 50 mg Intrathecal Day 1 every 14 days for 12 weeks (6 treatments), then every 28 days for 40 weeks (10 treatments). Temozolomide 100 mg/m^2 by mouth daily for 7 days every 14 days.
11616865|NCT00515762|Experimental|1: scalp cooling|scalp cooling
11616866|NCT00515736|Experimental|AOX group|Treatment group - double dose (loading) for 48 hours then single dose (Se 270 mcg, Zn 30 mg, vit C 1.2 g, B1 100 mg, vit E 300 mg enteral)
11616867|NCT00515736|Placebo Comparator|0|Group receiving vehicle solution for 5 days (double dose for 48 hours)
11616868|NCT00515723|Active Comparator|Olanzapine|Participants in this group were randomized to flexibly-dosed treatment with olanzapine.
11616869|NCT00515723|Active Comparator|Risperidone|Participants in this group were randomized to flexibly-dosed treatment with risperidone.
11616870|NCT00515723|Active Comparator|Quetiapine|Participants in this group were randomized to flexibly-dosed treatment with quetiapine.
11616871|NCT00515723|Active Comparator|Ziprasidone|Participants in this group were randomized to flexibly-dosed treatment with ziprasidone.
11616872|NCT00515710||1|Prior gene therapy study subjects receiving AAV2-hFIX16.
11616873|NCT00515697|Experimental|Ramucirumab|Intravenous infusion at 8 milligrams per kilogram (mg/kg) on day 1 of every 14-day cycle.
11616874|NCT00515671|Experimental|Arm 1_IMR|Illness Management and Recovery was offered in small groups (less than 8), co-facilitated by either an experienced masters level clinician or a doctoral level psychologist and by a doctoral student in clinical psychology. Facilitators used the IMR curriculum, incorporating psychoeducation, cognitive-behavioral approaches, relapse prevention, social skills training, and coping skills training. Facilitators worked with groups to set personal recovery goals and address progress towards those goals throughout the intervention. Home assignments helped participants apply newly learned skills and/or make progress on goals. Groups were open to rolling admission across the study period
11616875|NCT00515671|Placebo Comparator|Arm 2_PS|Problem Solving was the active control condition (also offered in groups weekly for 9 months). Participants were encouraged to discuss current concerns and receive group support; we did not use structured problem solving tasks. These groups were led by the same facilitators described above, who helped establish group expectations (attendance, confidentiality), encouraged participation, and provided process-oriented observations; there was no formal curriculum, goal setting, or homework assignments.
11616876|NCT00515645|Experimental|1|
11616877|NCT00515632|Experimental|Balaglitazone 10 mg per day|
11616878|NCT00515632|Experimental|Balaglitazone 20 mg per day|
11616879|NCT00515632|Active Comparator|Pioglitazone 45 mg per day|
11616880|NCT00515632|Placebo Comparator|Placebo|
11616881|NCT00515619|Experimental|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing
11616882|NCT00515580|Experimental|A|Pilot study of 5 patients, with an additional 20 patients with conditional approval by the IRB once the initial 5 patient's data is reviewed.
11616883|NCT00515554|Active Comparator|A|8 cycles BEACOPPesc
11616884|NCT00515554|Experimental|B|8 cycles BEACOPPesc plus rituximab
11616885|NCT00515554|Active Comparator|C|8 cycles BEACOPPesc
11616886|NCT00515554|Experimental|D|4 cycles BEACOPPesc
11616887|NCT00515541|Active Comparator|A|Patient is not on Aspirin, Clopidogrel, or Warfarin and is taking escalating doses of study drug.
11616888|NCT00515541|Active Comparator|B|Patient is on regular dose of Aspirin ( < or = 325mg). Patient is not taking Clopidogrel or Warfarin and is taking the escalating doses of Lovaza
11616889|NCT00515541|Active Comparator|C|Patient is taking regularly 75mg of clopidogrel daily and Aspirin (< or = 325mg) and not taking Warfarin and is taking the escalating doses of Lovaza
11616890|NCT00515541|Active Comparator|D|Patient is regularly taking Warfarin daily and Aspirin (< or = 325mg)and is not taking Clopidogrel and is taking the escalating doses of Lovaza
11616891|NCT00515528|Experimental|1|4-peptide melanoma vaccine, ontak
11616892|NCT00515528|Experimental|2|ontak
11616893|NCT00515502|Active Comparator|Seq 1: UMEC 250 µg, UMEC 500 µg, Tiotropium 18 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: umeclidinium bromide (UMEC) 250 micrograms (µg), UMEC 500 µg, Tiotropium 18 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
11616894|NCT00515502|Active Comparator|Seq 2: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
11616942|NCT00515281|Experimental|INO Treatment|The treatment group will receive iNO, combined with O2 or room air, until 33 weeks corrected age.
11646987|NCT00123292|Experimental|3|
11616895|NCT00515502|Active Comparator|Seq 3: UMEC 250 µg, placebo, UMEC 500 µg, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, UMEC 500 µg and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
11616896|NCT00515502|Active Comparator|Seq 4: UMEC 250 µg, UMEC 500 µg, placebo, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, UMEC 500 µg, placebo and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
11616897|NCT00515502|Active Comparator|Seq 5: Placebo, UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, UMEC 250 µg, UMEC 500 µg and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
11616898|NCT00515502|Active Comparator|Seq 6: UMEC 250 µg, placebo, Tiotropium 18 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, Tiotropium 18 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
11616899|NCT00515502|Active Comparator|Seq 7: Placebo, Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, Tiotropium 18 µg, UMEC 250 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
11616900|NCT00515502|Active Comparator|Seq 8: Tiotropium 18 µg, placebo, UMEC 250 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, placebo, UMEC 250 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
11616901|NCT00515502|Active Comparator|Seq 9: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
11616902|NCT00515502|Active Comparator|Seq 10: Tiotropium 18 µg, UMEC 250 µg, placebo, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, UMEC 250 µg, placebo and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
11616903|NCT00515502|Active Comparator|Seq 11: Placebo, UMEC 250 µg, Tiotropium 18 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, UMEC 250 µg, Tiotropium 18 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
11616904|NCT00515502|Active Comparator|Seq 12: UMEC 250 µg, placebo, UMEC 500 µg, Tiotropium 18 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, UMEC 500 µg and Tiotropium 18 µg. Treatment periods were seperated by a washout period of at least 14 days.
11616905|NCT00515489||001|Risperidone as prescribed
11616906|NCT00515463|Experimental|Denosumab - Vial|Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.
11616907|NCT00515463|Experimental|Denosumab - Prefilled syringe|Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.
11616908|NCT00515450|Experimental|1|
11616909|NCT00515450|Active Comparator|2|
11616910|NCT00515437|Experimental|1|1500U Myobloc
11616911|NCT00515437|Experimental|2|2500U Myobloc
11616912|NCT00515437|Experimental|3|3500U Myobloc
11616913|NCT00515437|Placebo Comparator|4|pooled placebo
11616914|NCT00515411|Active Comparator|Arm A, - Modified DCF|"Drug Dose (mg/m2) Schedule
~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Arm A is repeated every 2 weeks, and a cycle will be considered 6 weeks (eg 3 treatments)."
11616915|NCT00515411|Active Comparator|ARM B - Parent DCF with G-CSF|"Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17
~* 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg"
11616916|NCT00515411|Active Comparator|Arm C - Modifid DCF + Trastuzumab|"Treatment for Her2 Positive Participants
~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes."
11616917|NCT00515398||1|Group 1 (all subjects)
11616918|NCT00515385|Experimental|1a|Cohort 1 completed
11616919|NCT00515385|Placebo Comparator|1b|Cohort 1 placebo completed
11616920|NCT00515385|Experimental|2a|Cohort 2 completed completed
11616921|NCT00515385|Placebo Comparator|2b|Cohort 2 placebo completed
11616922|NCT00515385|Experimental|3a|Cohort 3 active
11616923|NCT00515385|Placebo Comparator|3b|Cohort 3 placebo
11616924|NCT00515385|Experimental|4a|Cohort 4 active
11616925|NCT00515385|Placebo Comparator|4b|Cohort 4 placebo
11616926|NCT00515385|Experimental|5a|Cohort 5 active
11616927|NCT00515385|Placebo Comparator|5b|Cohort 5 placebo
11616928|NCT00515372|Active Comparator|Intervention Group|Weekly phone calls lasting about 30 minutes. Lists of professional resources and referral recommendations will be provided.
11616929|NCT00515372|Other|Usual Care Group|Lists of professional resources and referral recommendations will be provided.
11616930|NCT00515359|Active Comparator|Dose Comparison|continuous versus intermittent bolus dosing
11616931|NCT00515333|Placebo Comparator|1|Placebo: 0 milligrams; t.i.d.
11616932|NCT00515333|Active Comparator|2|Treatment group: 30 milligrams; t.i.d.
11616933|NCT00515333|Active Comparator|3|Treatment group: 60 milligrams; t.i.d.
11616934|NCT00515333|Active Comparator|4|Treatment group: 100 milligrams; t.i.d.
11616935|NCT00515320|Experimental|Fluoxetine|
11616936|NCT00515320|Placebo Comparator|Placebo|
11616937|NCT00515307|Experimental|A|
11616938|NCT00515294|Experimental|1Caffeinated Alcoholic Beer|Caffeinated Alcoholic beer
11616939|NCT00515294|Active Comparator|2Non-Caffeinated Alcoholic Beer|Non-Caffeinated Alcoholic beer
11616943|NCT00515281|Placebo Comparator|INO Control|INO will be given to infants in the control group for the first 7 days of the study gas, then O2 or room air, as clinically appropriate, on the 8th day, until 33 weeks corrected age
11616944|NCT00515268|Experimental|Subjects receiving GSK256066|Eligible subjects will be randomized to receive GSK256066 with inhaled doses of 25 micrograms or 87.5 micrograms once daily for 7 days, administered via an ACCUHALER.
11616945|NCT00515268|Placebo Comparator|Subjects receiving placebo|Eligible subjects will be randomized to receive placebo for 7 days, administered via an ACCUHALER.
11616946|NCT00515242|Experimental|1|Therapeutic massage
11616947|NCT00515242|Active Comparator|2|Thermotherapy
11616948|NCT00515242|Placebo Comparator|3|Relaxation
11616949|NCT00515229|Active Comparator|1|Verum 1: Each individual capsule has a filling volume of 25 mg amitriptyline, given once an day in the evening over 28 days
11616950|NCT00515229|Active Comparator|2|Verum 1: Each individual capsule has a filling volume of 50 mg amitriptyline, given once an day in the evening over 28 days
11616951|NCT00515229|Active Comparator|3|Verum 3: Each individual capsule has a filling volume of 75 mg amitriptyline, given once an day in the evening over 28 days
11616952|NCT00515229|Placebo Comparator|0|Placebo: Each individual capsule has a filling volume of 25 mg placebo (corn starch), given once an day in the evening over 28 days
11616953|NCT00515216|Experimental|Oxaliplatin/Leucovorin/5-FU|"Good risk patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks."
11616954|NCT00515203|Placebo Comparator|II.|5 thrombocytopenic (as defined per protocol) subjects
11616955|NCT00515203|Experimental|I.|15 thrombocytopenic (as defined per protocol) subjects
11616956|NCT00515190|Active Comparator|A|(continuous):S-1 plus oxalipatin will be continued until disease progression, unacceptable toxicity or consent withdrawal.
11616957|NCT00515190|Active Comparator|B|(intermittent arm): Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles.
11616958|NCT00515177|Experimental|MBSR|A Mindfulness-Based Stress Reduction (MBSR) program that includes 8-weeks of group instruction in mindfulness meditation techniques followed by home practice and monitoring.
11616959|NCT00515177|Active Comparator|PCT Sleeping Pills|A pharmacotherapy control arm (PCT Sleeping Pills) consisting of a state-of-the-art prescription sedative hypnotic, eszopiclone - brand name LUNESTA(R), at a dose of one 3 milligram (mg) pill nightly for a duration of 8 weeks followed by use as needed (same dosage) for 3 months. This drug was approved by the Food and Drug Administration as a sedative for more than short term use.
11616960|NCT00515164|Experimental|Group 1|Treatment will be administered in 2 treatment sessions.
11616961|NCT00515164|Experimental|Group 2|Treatment will be administered in a single treatment session.
11616962|NCT00515151|Active Comparator|Oct/Alc|
11616963|NCT00515151|Active Comparator|Alc|
11616964|NCT00515125|Other|Dietary Advice|Dietary Advice
11616965|NCT00515125|Other|Oral Nutritional Supplements|Oral Nutritional Supplements
11616966|NCT00515112|Experimental|A|Twenty subjects will receive testosterone gel
11616967|NCT00515112|Placebo Comparator|B|Twenty subjects will receive the placebo
11616968|NCT00515099|Experimental|Antithymocyte globulin|This group received a total of 6.5 mg/kg of antithymocyte globulin (e.g., Thymoglobulin®) divided into four doses as follows: Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.
11616969|NCT00515099|Placebo Comparator|Placebo|This group received a saline solution to match the Thymoglobulin doses given to the active treatment group, on Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.
11616970|NCT00515086|Experimental|No Surgery (Everolimus 10 mg)|Participants with recurrent Glioblastoma Multiforme (GBM) not scheduled to undergo salvage surgical resection, received a daily oral dose of 10 mg Everolimus (RAD001) until evidence of disease progression or toxicity.
11616971|NCT00515086|Experimental|Everolimus 10 mg + Surgery|Participants scheduled to undergo salvage surgical resection received a daily oral dose of 10 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
11616972|NCT00515086|Experimental|Everolimus 5 mg + Surgery|Participants scheduled to undergo salvage surgical resection received a daily oral dose of 5 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
11616973|NCT00515086|Active Comparator|Everolimus 0 mg + Surgery|Participants scheduled to undergo salvage surgical resection received no treatment with Everolimus prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
11616974|NCT00515073|Experimental|Paclitaxel (Taxol) + Pelvic Radiation|"Paclitaxel (Taxol) 50 mg/m^2 intravenous (IV) weekly over 1 hour for 5 weeks. Radiation therapy to the pelvis daily for 25 treatments.
~Both radiation therapy and paclitaxel chemotherapy on Day 1 or 2, followed by radiation alone for four days, repeated every week for a total of 5 weeks, giving a total dose of 45 Gy with external beam radiation to pelvis and 5 courses of paclitaxel 50 mg/m^2. Four-six weeks after pelvic radiation completed, 4 additional courses of paclitaxel 135 mg/m^2 alone given every 21 days. Vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for additional 3 days. No chemotherapy given with vaginal apex boost."
11616975|NCT00515060||Cancer Therapy-Induced Pain|Patients with advanced cancer entering chemotherapy or have reported pain as a result of cancer treatment.
11616976|NCT00515047||Eczema Herpeticum (EH)|Participants with AD who currently have or have had EH
11616977|NCT00515047||Non-EH|Participants with AD who do not have and have never had EH
11616978|NCT00515047||Healthy Controls|Healthy participants without a history of AD
11616979|NCT00515034|Experimental|001|Doripenem 1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
11617000|NCT00514891|Active Comparator|1|Vitamin A supplementation
11617001|NCT00514891|Placebo Comparator|2|Placebo
11616980|NCT00515034|Active Comparator|002|Imipenem/cilastatin 1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
11616981|NCT00515034|Experimental|003|Doripenem 1 gram infused over 4 hours at 8 hour intervals for patients with complicated intrabdominal infections (cIAI) for 5 to 14 days Vancomycin may be added as adjunctive therapy as per investigator discretion
11616982|NCT00515034|Active Comparator|004|Imipenem/cilastatin 1 gram infused over 1 hour at 8 hour intervals for patients with complicated intrabdominal infections (cIAI) for 5 to 14 days Vancomycin may be added as adjunctive therapy as per investigator discretion
11616983|NCT00515021|Experimental|Daytime then nightime dosing|Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 50mg, by mouth, daily, in the evening x 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks.
11616984|NCT00515021|Experimental|Nighttime then daytime dosing|Eplerenone - 50mg, by mouth, daily, in the evening x 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks then patients cross over to 50mg, by mouth, daily, in the morning x 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks.
11616985|NCT00515008|Experimental|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi 18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
11616986|NCT00515008|Placebo Comparator|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
11616987|NCT00514995|Experimental|1|
11616988|NCT00514982|Other|1/Drug #1|Oral mesalamine will be used as initial therapy in patients who are not taking any medication or have not received any prior treatment for their IBD. Dosing will begin at 2.4 g PO QD and will be increased to 4.8 g QD within 2 weeks. Topical mesalamine (enema 4 g PR HS/BID or suppository 1 g PR HS/BID) may be added for patients with inflammation that is limited to the rectum (proctitis) or who have prominent complaints of urgency, incomplete evacuation or rectal bleeding.
11616989|NCT00514982|Other|1/Drug#2|Add oral corticosteroids (prednisone) to mesalamine. The standard induction dose will be 40 mg/day. After 1 week of therapy, if the total SCCAI score has decreased by greater than or equal to 2 points the patient will continue on another week of therapy. If the SCCAI has not decreased by greater than or equal to 2 points (indicative of a reduction in symptoms) at one week, then the dose will be increased to 60 mg/day. Patients on either dosage will have another SCCAI assessment done a week later (2 weeks after beginning corticosteroids), and if they are found to be in remission (SCCAI less than or equal to 2), a steroid-tapering schedule will be initiated.
11616990|NCT00514982|Other|1/Drug#3|Infliximab and 6-MP will be added to patients with a SCCAI greater than 2 at week 8. The first infusion of infliximab (5 mg/kg) will be given during that week. In addition, 6-MP will be initiated at doses of 1.0-1.5 mg/kg PO QD to reduce the incidence of infliximab antibody formation and facilitate steroid tapering (the target dose of 6-MP will be decreased accordingly if patients are found to have low TMPT levels/activity by genotypic or phenotypic testing). Also, steroids will also be rapidly tapered off at this time.
11616991|NCT00514982|Other|1/Drug#4|Infliximab and 6-MP will be added to patients with a SCCAI greater than 2 at week 8. The first infusion of infliximab (5 mg/kg) will be given during that week. In addition, 6-MP will be initiated at doses of 1.0-1.5 mg/kg PO QD to reduce the incidence of infliximab antibody formation and facilitate steroid tapering (the target dose of 6-MP will be decreased accordingly if patients are found to have low TMPT levels/activity by genotypic or phenotypic testing). Also, steroids will also be rapidly tapered off at this time.
11616992|NCT00514982|Other|1/Drug#5|Subjects with a SCCAI greater than 2 after 3 doses of infliximab will continue 6-MP, discontinue infliximab infusions and start adalimumab injections approximately 2 weeks after the 3rd dose of infliximab. Induction dosing will consist of a 160 Micro/g subcutaneous injection, followed by 80 Micro/g 2 weeks after.
11616993|NCT00514982|Other|1/Drug#6|Patients who have a SCCAI greater than 2 after 2 doses of adalimumab will continue 6-MP, discontinue adalimumab, and start therapy with tacrolimus 0.01 mg/kg PO BID approximately 2 weeks after the second dose of adalimumab.
11616994|NCT00514943|Experimental|BIBW 2992|once daily taken orally
11616995|NCT00514943|Active Comparator|Cetuximab|once every week by intravenous injection
11616996|NCT00514917|Experimental|Docetaxel+Leuprolide+Bicalutamide|Participants received docetaxel 75 milligram per square meter (mg/m^2) intravenous infusion over 1 hour every 3 weeks up to 10 cycles (3 week cycle) along with leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.
11616997|NCT00514917|Active Comparator|Leuprolide+Bicalutamide|Participants received leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.
11616998|NCT00514904|Experimental|Nimenrix Group|Subjects received 1 dose of Nimenrix vaccine at Month 0. Nimenrix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11616999|NCT00514904|Active Comparator|Mencevax ACWY Group|Subjects received 1 dose of Mencevax ACWY vaccine at Month 0. Mencevax ACWY vaccine was administered subcutaneously into the upper region of the non-dominant arm.
11646988|NCT00123292|Experimental|4a|
11617004|NCT00514865|Experimental|E2|5-10 mg of ONO-2333
11617005|NCT00514865|Placebo Comparator|P|placebo comparator
11617006|NCT00514852|Experimental|1|Carboxymethylcellulose and Glycerin based artificial tear
11617007|NCT00514852|Active Comparator|2|Carboxymethylcellulose
11617008|NCT00514839|No Intervention|C|Control group receiving a booklet on health behavior
11617009|NCT00514839|Experimental|MI|Counselling based on Motivational Interviewing plus individualized feedback
11617010|NCT00514813|Experimental|Dynepo (Epoetin delta)|Subjects received Dynepo (Epoetin delta) either twice weekly (BIW), once weekly (QW), once every 2 weeks (Q2W) or once every 4 weeks (Q4W) based on what is appropriate for the subject
11617011|NCT00514800|Experimental|Intervention|"Patients will be given a home blood pressure monitor and taught how to use it and how to respond to the readings using a standardised protocol and blood pressure targets. The study nurse will follow up patients at home after a month with additional telephone support according to a defined protocol. Patients will consult their own GP for medication changes when above target.
~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings."
11617012|NCT00514800|Active Comparator|Control|
11617013|NCT00514774|Experimental|A|
11617014|NCT00514774|Experimental|B|
11617015|NCT00514774|Placebo Comparator|C|
11617016|NCT00514761|Active Comparator|1|Xeloda
11617017|NCT00514761|Experimental|2|AZD6244
11617018|NCT00514748|Active Comparator|1|Patients who receive breast reconstruction with bilateral DIEP flap based on bilateral vessel pedicles
11617019|NCT00514748|Experimental|2|Patient who receive breast reconstruction with vessel interconnected DIEP flap based on one vessel pedicle
11617020|NCT00514735|Experimental|1|Ablation Management
11617021|NCT00514735|Active Comparator|2|Medical Management
11617022|NCT00514709|Experimental|Group 1|DTaP-Hep B-PRP-T + OPV vaccine group
11617023|NCT00514709|Experimental|Group 2|Tritanrix-HepB/Hib™ + OPV vaccine group
11617024|NCT00514696|Experimental|GCS-100|GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
11617025|NCT00514683|Experimental|dose 1|low dose BIBF1120 once daily
11617026|NCT00514683|Experimental|dose 2|low dose BIBF 1120 twice daily
11617027|NCT00514683|Experimental|dose 3|intermediate dose BIBF 1120 twice daily
11617028|NCT00514683|Experimental|dose 4|high dose BIBF 1120 twice daily
11617029|NCT00514683|Placebo Comparator|placebo|placebo
11617030|NCT00514670|Experimental|1|Intervention classrooms received alcohol-based hand sanitizer and disinfecting wipes.
11617031|NCT00514670|No Intervention|2|No hand sanitizer or disinfecting wipes were used.
11617032|NCT00514657|Placebo Comparator|P|
11617033|NCT00514657|Experimental|L|low dose (0.03 %)
11617034|NCT00514657|Experimental|M|medium dose (0.1 %)
11617035|NCT00514657|Experimental|H|high dose (0.3 %)
11617036|NCT00514644|Experimental|Panorama to Ultrasound|100 asymptotic patients that have findings of calcifications in the area of the carotid arteries when examined with panorama. These persons are examined with carotid ultrasound.
11617037|NCT00514644|Experimental|Ultrasound to Panorama|100 patients with a known carotid stenosis seen on ultrasound will be examined with panorama before any intervention is made. These patients must undergo surgery to be finally included.
11617038|NCT00514618|Active Comparator|1|patients will be treated with misoprostol 50 mcg PO
11617039|NCT00514618|Placebo Comparator|2|patients will receive placebo (Vitamin C)
11617040|NCT00514592||All|All patients enter the same group
11617041|NCT00514579|Other|Myeloablative double unit UCBT|Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation
11617042|NCT00514566|Active Comparator|1|Surgical Patient undergoing midline laparotomy closure
11617043|NCT00514540|Experimental|First-Line/Second-Line Chemotherapy|"First-Line (CD) Chemotherapy: Carboplatin area under the curve (AUC) = 5, intravenous (IV) over 30 minutes and Docetaxel 75 mg/m^2 IV over 60 minutes, Day 1. Repeated every 3 weeks.
~Second-Line (EP) Chemotherapy: Etoposide 120 mg/m^2 daily for 3 days and Cisplatin 25 mg/m^2 for 3 days with adequate intravenous hydration mannitol diuresis and supportive care (antiemetics). Repeated every 3 weeks."
11617044|NCT00514527|Experimental|1|
11617045|NCT00514527|Experimental|2|
11617046|NCT00514527|Experimental|3|
11617047|NCT00514514|Active Comparator|CNI standard regimen|Myfortic, Sandimmun Optoral and corticosteroids
11617048|NCT00514514|Experimental|CNI free regimen|"CNI free regimen: comprising the following steps for switching treatment:
~Step 1 at BL2 + 1 day: Myfortic, Certican 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, Certican 3 mg and corticosteroids"
11617049|NCT00514514|Active Comparator|CNI low regimen|"CNI low regimen: comprising the following steps for switching treatment:
~Step 1 at BL2 + 1 day: Certican 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: Certican 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids"
11617050|NCT00514501|Experimental|Iodofiltic Acid I 123|
11617051|NCT00514462|Experimental|A|low level laser instrument (Painless Light PL-830, Advanced Chips & Products Crop., USA)
11617052|NCT00514449|Experimental|Valacyclovir|1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.
11617053|NCT00514449|Placebo Comparator|Sugar pill|2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.
11617054|NCT00514436|No Intervention|Usual care|Usual care consisted of referral back to primary care provider after index hospitalization
11617055|NCT00514436|Experimental|Behavioral|Asthma coaching, inperson contact followed by telephone contact
11617056|NCT00514423|Experimental|2|Psychoeducation by peer-moderators
11617057|NCT00514423|Experimental|1|Psychoeducation by professionals
11617058|NCT00514423|Experimental|3|Video-education
11617059|NCT00514423|Placebo Comparator|4|Control group
11617060|NCT00514410|Experimental|Folic Acid|
11617061|NCT00514410|Placebo Comparator|Placebo|
11617062|NCT00514371|Experimental|tanespimycin and bortezomib|A patient will receive a standard dose of bortezomib followed by a high dose of tanespimycin.
11646989|NCT00123292|Experimental|4b|
11617063|NCT00514371|Experimental|bortezomib and tanespimycin|A patient will receive a standard dose of bortezomib followed by a mid dose of tanespimycin.
11617064|NCT00514371|Experimental|bortezomib tanespimycin|A patient will receive a standard dose of bortezomib followed by a low dose of tanespimycin.
11617065|NCT00514358||gestational age|
11617066|NCT00514332|Experimental|A|primary surgery group
11617067|NCT00514306|Experimental|Schedule 1|OSI-906 days 1-3 every 14 days
11617068|NCT00514306|Experimental|Schedule 2|OSI-906 days 1-5 every 14 days
11617069|NCT00514306|Experimental|Schedule 3|OSI-906 days 1-7 every 14 days
11617070|NCT00514267|Experimental|1. HRPC|
11617071|NCT00514267|Experimental|2. Solid Tumors|
11617072|NCT00514254||case|Participants complete questionnaires about lifestyle factors and their usual diet and measure their waist and hips. Saliva or buccal specimens are collected for future research.
11617073|NCT00514254||control|Participants complete questionnaires about lifestyle factors and their usual diet and measure their waist and hips. Saliva or buccal specimens are collected for future research.
11617074|NCT00514241|Experimental|A|The arm utilizes the GPS™ II Platelet Concentrate Separation Kit.
11617075|NCT00514241|No Intervention|B|This arm utilizes standard leg wound closure procedures.
11617076|NCT00514228|Experimental|Continuous sunitinib treatment|
11617077|NCT00514215|Experimental|Sargramostim, Flow Cytometry, Biopsy. Cryosurgery|Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 & 32 Immunoenzyme technique-Days 1 & 32 CT guided biopsy-Days 1 & 32 Cryosurgery-Days 1 and 32
11617078|NCT00514202|Placebo Comparator|1|Placebo plus cognitive behavioral therapy
11617079|NCT00514202|Experimental|2|Dextroamphetamine SR (60 mg/kg) plus cognitive behavioral therapy
11617080|NCT00514189|Experimental|Autologous Dendritic Cells|
11617081|NCT00514163|Experimental|1|gemcitabine + S-1
11617082|NCT00514163|Active Comparator|2|S-1
11617083|NCT00514150|Active Comparator|1|1075 cc of 154 mEq/L solution of NaCl 0.9% , prepared by adding 75 cc of 154 mEq/L NaCl 0.9 % to 1000 cc of 154 mEq/L NaCl 0.9%
11617084|NCT00514150|Active Comparator|2|1075 cc fluid made by adding 75 cc of sodium bicarbonate 8.4% to 1000 cc of 154 mEq/ L NaCl 0.9%.
11617085|NCT00514137|Experimental|Treatment (kinase inhibitor therapy)|Patients receive 37.5 mg oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11617086|NCT00514111||HVC Patients|HVC patients attended in SAE e HD.
11617087|NCT00514085|Experimental|Recombinant human interleukin-21|
11617088|NCT00514072|Experimental|Arm I|Patients receive ONY-P1 vaccine with BCG intradermally on days 1 and 15. Patients then receive ONY-P1 vaccine alone on day 29 and then every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
11617089|NCT00514072|Placebo Comparator|Arm II|Patients receive placebo vaccine intradermally on days 1, 15, and 29 and then every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
11617090|NCT00514059|Other|1|
11617091|NCT00514046|Experimental|Arm 1|Vandetanib administered as a once daily dose, continuously (1 cycle = 28 days) at a dose of 150 mg/m2/d.
11617092|NCT00514033||Group A|PoliorixTM will be administered according to a 3-dose schedule at 2, 4, 6 months for primary vaccination followed by a booster dose between 4 to 6 years. For the primary vaccination course, 1 to 3 doses of the vaccine will be given depending on previous vaccination history with poliomyelitis vaccine.
11617093|NCT00514020|Experimental|Treatment|
11617094|NCT00514007|Experimental|OSI-906 QD|Once per day
11617095|NCT00514007|Experimental|OSI-906 BID|Twice per day
11617096|NCT00513994|Active Comparator|1|
11617097|NCT00513968|Experimental|I|HB-110 2mg, 4mg or 8mg combined with Adefovir
11617098|NCT00513968|Active Comparator|II|Adefovir
11617099|NCT00513955|Experimental|Bortezomib plus CHOP|"Patients receive bortezomib IV over 3-5 seconds on days 1 and 8; doxorubicin hydrochloride IV, cyclophosphamide IV, and vincristine IV on day 1; and oral prednisolone on days 1-5.
~Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
~Patients complete quality of life questionnaires at baseline, prior to each treatment course, and then at 30 days after completion of treatment.
~After completion of study treatment, patients are followed at 30 days and then every 12 weeks thereafter."
11617100|NCT00513942|No Intervention|A|These women will follow standard antenatal care according to the Norwegian Guidelines
11617101|NCT00513942|Active Comparator|B|Intervention group for Fetal Movement Counting
11617102|NCT00513929|Experimental|X: Zinc sulphate|
11617103|NCT00513916|Experimental|Arm I|"Participants partake in a high soy diet consisting of 2 daily soy servings (approximately 50mg isoflavones).
~The choice of soy foods will include ½ cup of tofu, ¾ cup of soy milk, or ¼ cup of soy nuts. Replacement of currently consumed foods with soy foods will be encouraged."
11617104|NCT00513916|Active Comparator|Arm II|Participants will be asked to keep their soy intake below 3 servings per week. The participants will also receive general nutrition counseling.
11617105|NCT00513903|Active Comparator|Minimal intervention|Minimal intervention group patients will be seen by a clinical pharmacist in the hospital but will not receive followup after hospital discharge.
11617106|NCT00513903|Experimental|Enhanced intervention|Enhanced intervention patients will receive care from a clinical pharmacist during hospitalization and followup by phone after hospitalization.
11617107|NCT00513903|No Intervention|Control|Control arm patients will not be seen by the clinical pharmacist.
11617108|NCT00513877|Experimental|Bortezomib 1.6mg/m2|
11617109|NCT00513864|Active Comparator|CYP2D6-|This arm consists of subjects that are poor metabolizers (PM) and intermediate metabolizers (IM).
11617110|NCT00513864|Active Comparator|CYP2D6+|Extensive metabolizers (EM) of codeine
11617111|NCT00513851|Experimental|1|Once Daily Dosing
11617112|NCT00513851|Experimental|2|Twice Daily Dosing
11617113|NCT00513825|Active Comparator|1|1075 cc of 77 mEq/L solution of NaCl 0.45% , prepared by adding 75 cc of 77 mEq/L NaCl 0.45 % to 1000 cc of 77 mEq/L NaCl 0.45%
11617114|NCT00513825|Active Comparator|2|1075 cc fluid made by adding 75 cc of sodium bicarbonate solution 8.4% to 1000 cc of NaCl 0.45%.
11617226|NCT00512967||IPF|15 IPF patients, partially treated
11617115|NCT00513799|Active Comparator|1: Hygiene Education|"Intensive education on prevention of skin infections through improvements in personal hygiene (also serves as control group)"
11617116|NCT00513799|Active Comparator|2: Hygiene education + mupirocin|Application of mupirocin in the nasal mucosa alone
11617117|NCT00513799|Active Comparator|Education + mupirocin + chlorhexidine|A combination of nasal application of mupirocin and chlorhexidine showers
11617118|NCT00513799|Active Comparator|4: Education + mupirocin + bleach baths|A combination of nasal application of mupirocin and bathing in dilute bleach water
11617119|NCT00513786|Experimental|carboplatin/paclitaxel with bevacizumab|A regimen of Carboplatin and paclitaxel combined with bevacizumab given every 21 days in patients with advanced stage endometrial cancer for a maximum of 6 cycles.
11617120|NCT00513760|Experimental|1|Coingestion of 240 ml of grapefruit juice with 10 mg of montelukast.
11617121|NCT00513760|Active Comparator|2|Coingestion of 240 ml of orange juice with 10 mg of montelukast.
11617122|NCT00513760|Placebo Comparator|3|Coingestion of 240 ml of Gatorade with 10 mg of montelukast.
11617123|NCT00513747|Experimental|Arm I|Patients receive rituximab IV over 4 hours on days 1, 3, and 5 of week 1 and then on day 1 of weeks 5, 9, 13, 17, and 21. Patients also receive fludarabine phosphate IV over 30 minutes on days 1-5 of weeks 1, 5, 9, 13, 17, and 21. After completion of chemoimmunotherapy, patients are followed every 3 months until disease progression. At the time of disease progression, patients receive retreatment with chemoimmunotherapy as above or another treatment regimen.
11617124|NCT00513747|Active Comparator|Arm II|Patients are followed every 3 months until disease progression. At the time of disease progression, patients receive rituximab and fludarabine phosphate as in arm I. Patients are then followed every 3 months until second disease progression. Patients with a second disease progression receive retreatment with chemoimmunotherapy as above or another treatment regimen.
11617125|NCT00513734|Active Comparator|1|Geliperm Hydrogel Dressing
11617126|NCT00513734|Active Comparator|2|Lacrilube ointment
11617127|NCT00513721||III|Prostate specimens with positive surgical margins.
11617128|NCT00513708|No Intervention|Treatment As Usual (TAU)|"Treatment as Usual (TAU): Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during medically managed inpatient detoxification."
11617129|NCT00513708|Experimental|Motivational Enhancement Therapy (MET)|"Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during inpatient detoxification plus a 60-minute Motivational Enhancement Therapy (MET) session delivered by a trained professional."
11617130|NCT00513708|Experimental|Peer-delivered Twelve Step Facilitation|"Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during inpatient detoxification plus a 60-minute Peer-delivered Twelve Step Facilitation (P-TSF)session delivered by individuals from a common self-help program."
11617131|NCT00513695|Experimental|Treatment (neoadjuvant chemotherapy before surgery)|Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
11617132|NCT00513682|Experimental|Ultrase® MT20|
11617133|NCT00513669|Experimental|1 PEV301&302|The vaccine includes two antigens (CSP and AMA1- derived)in combination and formulated with virosomes
11617134|NCT00513669|Active Comparator|2 Influenza vaccine|Inflexal V is the comparator that includes 3 antigens from flu formulated in virosomes
11617135|NCT00513656|Active Comparator|Oxycodone Hydrochloride Tablets|
11617136|NCT00513656|Experimental|Oxycodone Naloxone Tablets|
11617137|NCT00513643|Experimental|1|6 U insulin aspart
11617138|NCT00513643|Experimental|2|12 U insulin aspart
11617139|NCT00513643|Experimental|3|24 U insulin aspart
11617140|NCT00513643|Active Comparator|4|6 IU human regular insulin
11617141|NCT00513643|Active Comparator|5|12 IU human regular insulin
11617142|NCT00513643|Active Comparator|6|24 IU human regular insulin
11617143|NCT00513630|Active Comparator|metformin|
11617144|NCT00513630|Active Comparator|glipizide|
11617145|NCT00513617|Active Comparator|Low Dose|0.05 g/kg/day Arginine
11617146|NCT00513617|Active Comparator|High Dose|0.10 g/kg/day Arginine
11617147|NCT00513617|Placebo Comparator|Placebo|No Arginine
11617148|NCT00513604|Experimental|Cohort 1 - NMA, TIL, aldesleukin|"Cohort 1 - Nonmyeloablative (NMA), tumor infiltrating lymphocytes (TIL), & high dose (HD) aldesleukin:
~Nonmyeloablative chemotherapeutic conditioning regimen followed by bulk young tumor infiltrating lymphocytes and high dose aldesleukin.
~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. Bulk young TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.
~Cohort 1 = unselected TIL"
11617149|NCT00513604|Experimental|Cohort 2 - NMA, CD4+ TIL, aldesleukin|"Cohort 2 - Nonmyeloablative (NMA), cluster of differentiation 4 (CD4+) depleted tumor infiltrating lymphocytes (TIL), aldesleukin:
~Nonmyeloablative chemotherapeutic conditioning regimen followed by CD4+ depleted tumor infiltrating lymphocytes and high dose (HD) aldesleukin.
~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.
~Cohort 2 = CD4+ depleted (selected) TIL"
11617186|NCT00513344|Active Comparator|Control chocolate with no polyphenols|cocoa-free chocolate
11617187|NCT00513331||Algorithm #1|Patients without visable lesions
11617188|NCT00513331||Algorithm #2|Patients with a visable lesion that is less than 1cm
11617189|NCT00513331||Algorithm #3|Patients with a visable lesion greater than 1cm
11617227|NCT00512967||COPD|15 COPD patients within 24 hours after their last exacerbation
11617228|NCT00512967||controls|25 healthy controls, matched for age and gender
11617229|NCT00512941||1|HBV: Carrier
11617230|NCT00512941||2|HBV: cure
11617150|NCT00513604|Experimental|Cohort 3 - NMA, total body irradiation|"Cohort 3 - Nonmyeloablative (NMA), total body irradiation (TBI):
~Nonmyeloablative chemotherapeutic conditioning regimen and 2 gray units (Gy) of total body irradiation followed by cluster of differentiation 4 (CD4+) depleted tumor infiltrating lymphocytes and high dose (HD) aldesleukin.
~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL 2Gy (gray units) of total body irradiation (TBI) twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute using a linear accelerator in Radiation Oncology Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.
~Cohort 3 = CD4 + depleted (selected) TIL + 600Gy radiation"
11617151|NCT00513604|Experimental|Cohort 4 - NMA, young TIL, aldesleukin|"Cohort 4 - Nonmyeloablative (NMA), tumor infiltrating lymphocytes (TIL), aldesleukin:
~Nonmyeloablative chemotherapeutic conditioning regimen followed by bulk young tumor infiltrating lymphocytes and high dose (HD) aldesleukin.
~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. Bulk young TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.
~Cohort 4 = unselected TIL - it is the SAME as cohort 1"
11617152|NCT00513604|Experimental|Cohort 5 - NMA, CD4+TIL, HD aldesleukin|"Cohort 5 - Nonmyeloablative (NMA), cluster of differentiation 4 (CD4+) tumor infiltrating lymphocytes (TIL), high dose (HD) aldesleukin:
~Nonmyeloablative chemotherapeutic conditioning regimen followed by CD4+ depleted tumor infiltrating lymphocytes and high dose aldesleukin.
~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.
~Cohort 5 = CD4 + depleted TIL - it is the SAME as cohort 2"
11617153|NCT00513591||1|Women with lupus
11617154|NCT00513591||2|Health women who are matched to women with lupus by age and race
11617155|NCT00513591||3|Women with other autoimmune diseases
11617156|NCT00513565|Placebo Comparator|placebo arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
11617157|NCT00513565|Experimental|GSK561679 arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
11617158|NCT00513565|Active Comparator|lorazepam arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
11617159|NCT00513552|Experimental|Antibiotics|Antibiotics
11617160|NCT00513539|Active Comparator|Arm A|Biliary Stenting alone
11617161|NCT00513539|Experimental|Arm B|Photodynamic Therapy plus biliary stenting
11617162|NCT00513526|Experimental|Gardasil|Quadrivalent HPV Vaccine (types 6, 11, 16, 18) for intramuscular injection at study entry, week 8, week 24, and week 128.
11617163|NCT00513500|Experimental|1|Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on rapid diagnostic test. For pneumonia, give one half tablet (250mg amoxicillin) for children weighing (5-9.9kg) and one tablet for children weighing (10-20kg) three times a day for five days.
11617164|NCT00513500|Active Comparator|2|Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on clinical diagnosis. For pneumonia, refer to the nearest health facility
11617165|NCT00513474|Experimental|Rasburicase Group|Myeloablative (bone marrow depletion) conditioning protocol as per standard of care at the investigator's discretion followed by granulocyte colony-stimulating factor (GCSF)-mobilized human leukocyte antigen (HLA)-matched, related or unrelated donor allogeneic peripheral blood stem cells (unmanipulated), standard graft-versus-host disease (GVHD) prophylaxis as per standard of care at the investigator's discretion and rasburicase 0.20 mg/kg/day administered by intravenous infusion for 5 consecutive days. If after 5 days of rasburicase the participant's uric acid plasma level remains above 5 mg/dL, rasburicase may be continued for up to 7 days in total.
11617166|NCT00513474|Other|Control Group|Historical chart review of patients from the Blood and Marrow Transplant database who received myeloablative allogeneic stem cell/bone marrow transplantation followed by standard GVHD prophylaxis in the past 10 years. Participants received allopurinol per institutional guidelines.
11617167|NCT00513461|Experimental|Arm I (SAMe)|Patients receive SAMe PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
11617168|NCT00513461|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
11617169|NCT00513435|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO or by PEG tube QD on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
11617170|NCT00513422|Experimental|1|Glucosamine sulfate 1500mg and chondroitin sulfate 800mg (low molecular weight, bovine)
11617171|NCT00513422|Experimental|2|Glucosamine sulfate 1500mg
11617172|NCT00513422|Experimental|3|Chondroitin sulfate 800mg
11617173|NCT00513422|Placebo Comparator|4|Matching glucosamine/chondroitin placebo capsules
11617174|NCT00513409|Experimental|Synflorix Booster Group|Subjects previously primed with Synflorix™ and receiving in the current study Havrix™ co-administered with Infanrix™ hexa (Dose 1) and Synflorix™ (Dose 2).
11617175|NCT00513409|Experimental|Synflorix Catch-up Group|Subjects previously primed with Havrix™ co-administered with Infanrix™ hexa and receiving in the current study Synflorix™ co-administered with Infanrix™ hexa (Dose 1) and Synflorix™ (Dose 2).
11617176|NCT00513396|Experimental|1|
11617177|NCT00513396|Active Comparator|2|
11617178|NCT00513396|Placebo Comparator|3|
11617179|NCT00513383|Experimental|Part A|Determine the best dosing of panitumumab, chemotherapy and radiation.
11617180|NCT00513383|Experimental|Part B|Determine the best dosing of induction chemotherapy combined with panitumumab prior to receiving panitumumab and chemoradiotherapy.
11617181|NCT00513370|Experimental|1|
11617182|NCT00513357|Experimental|Melatonin|20 mg of Melatonin before going to sleep at night for a period of 4 weeks.
11617183|NCT00513357|Placebo Comparator|Placebo|20 mg of Placebo before going to sleep at night for a period of 4 weeks.
11617184|NCT00513344|Experimental|dark chocolate containing polyphenols|dark chocolate
11617185|NCT00513344|Experimental|Milk chocolate containing polyphenols|Bespoke milk chocolate
11617190|NCT00513305|Active Comparator|Low-dose cytarabine plus arsenic trioxide|Cycle 1 cytarabine 10 mg/m^2 was administered subcutaneously (sc) twice daily (bid) on days 1-14. 0.25 mg/kg arsenic trioxide was administered intravenously (iv) on days 1-5 and days 8-12. Cycle 2 A second identical cycle of cytarabine and arsenic trioxide was given to patients with persistent disease. Patients who achieved complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine and arsenic trioxide with the doses and schedule identical to the initial cycle. A recovery period of up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of arsenic trioxide 0.25 mg/kg iv on days 1 and 4 and cytarabine 10 mg/m^2 sc bid on days 1 through 7 of a 28-day cycle.
11617191|NCT00513305|Active Comparator|Low-dose cytarabine alone|Cytarabine was administered at a dose of 10 mg/m^2 sc bid from days 1-14 of cycle 1. A second identical cycle of cytarabine was given to patients with persistent disease. Patients who achieved a complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine with the doses and schedule identical to the initial treatment cycle. Recovery period up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of cytarabine at 10 mg/m^2 sc bid on days 1-7 of a 28-day cycle. Patients started maintenance treatment within 42 days after platelet count recovery. Maintenance treatment continued for 2 years or until unacceptable toxicity or disease progression.
11617192|NCT00513292|Active Comparator|FEC-75 then Paclitaxel/trastuzumab|Patients receive FEC comprising fluoroucacil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks.
11617193|NCT00513292|Experimental|Paclitaxel/trastuzumab then trastuzumab/FEC-75|Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluoroucacil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I.
11617194|NCT00513279|Experimental|Cohort 1|Subjects in Cohort 1 will be randomized to one of the following sequences: ABDFH, BADFH, BDAFH, BDFAH and BDFHA in a 1:1:1:1:1 ratio where A = Placebo, B= GSK618334 dose 1 (2.5 mg), D = GSK618334 dose 3, F = GSK618334 dose 5, H = GSK618334 dose 7. On day 1, subjects will be administered a starting dose of 2.5 milligrams (mg) GSK618334. The planned doses of GSK618334 to be administered in Cohort 1 are 2.5, 25, 100 and 400mg. In each dosing period 2 subjects will receive placebo and 8 subjects will receive GSK618334. Subjects within a cohort will have a washout period of at least two weeks from last dose before receiving another dose.
11617195|NCT00513279|Experimental|Cohort 2|Subjects in Cohort 2 will be randomized to one of the following sequences: ACEGI, CAEGI, CEAGI, CEGAI, CEGIA in a 1:1:1:1:1 ratio where A = Placebo, C= GSK618334 dose 2, E = GSK618334dose 4, G = GSK618334 dose 6, I= GSK618334 dose 8. In each dosing period 2 subjects will receive placebo and 8 subjects will receive GSK618334. Subjects within a cohort will have a washout period of at least two weeks from last dose before receiving another dose.
11617196|NCT00513240|Experimental|EPO group|Patients randomized to receive the 3 doses of erythropoetin.
11617197|NCT00513240|Placebo Comparator|Control group.|Patients randomized to receive 3 doses of normal saline control.
11617198|NCT00513214|Active Comparator|XOMA 052|
11617199|NCT00513214|Placebo Comparator|Placebo|
11617200|NCT00513162|Experimental|Valproate + Etoposide|Valproate Starting Dose of 10 mg/kg By Mouth Daily. Etoposide 25 - 50 mg/m^2 By Mouth Daily.
11617201|NCT00513149|Active Comparator|c6|Clopidogrel 600 mg loading
11617202|NCT00513136|Active Comparator|I|10 week group-based mind body medicine intervention
11617203|NCT00513136|Experimental|II|Group-based mind body medicine intervention with a family focus
11617204|NCT00513123||Digital Colposcopy|Digital Colposcopy for Fluorescence (DCF)
11617205|NCT00513110|Experimental|1|Endotoxin and AMPD1 polymorphism
11617206|NCT00513110|Experimental|2|Endotoxin and intervention with caffeine
11617207|NCT00513110|Placebo Comparator|3|Endotoxin combined with placebo
11617208|NCT00513097|Experimental|Smoking Prevention & Cessation Program|
11617209|NCT00513084|Experimental|SDT Intervention|This arm will follow main experimental intervention, as described elsewhere
11617210|NCT00513084|No Intervention|Comparison Group|Comparison Group receiving standard care health promotion intervention
11617211|NCT00513071|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11617212|NCT00513058|Experimental|lapatinib + vinorelbine|"starting with loading dose of lapatinib per os for 7 days
~then, combining lapatinib (oral daily continuous) + vinorelbine (intravenous, day 1 and 8 every 3 weeks)"
11617213|NCT00513045|Experimental|IRT|Intervention based on Imagery Rehearsal Therapy
11617214|NCT00513045|Active Comparator|Exposure|Treatment based on exposure
11617215|NCT00513045|No Intervention|Nightmare diary|Recording nightmares in a diary
11617216|NCT00513045|No Intervention|Waiting list|Waiting list
11617217|NCT00513032||methylene blue|
11617218|NCT00513032||C|
11617219|NCT00513019|Active Comparator|1|Lamictal (lamotrigine)
11617220|NCT00513019|Placebo Comparator|2|Placebo
11617221|NCT00512993|Active Comparator|Treatment|Patients receive zoledronic acid (4mg) for 5 years. Additionally patients receive standard endocrine, radiologic and trastuzumab treatment, respectively
11617222|NCT00512993|No Intervention|Observation|Patients will be under observation and receive standard endocrine, radiologic and trastuzumab treatment, respectively
11617223|NCT00512980|Active Comparator|1|
11617224|NCT00512980|Active Comparator|2|
11617225|NCT00512967||sarcoidosis|21 onset patients, non-treated
11617233|NCT00512941||5|HCV: anti-HCV positive test
11617234|NCT00512941||6|HBV/HCV co-infection
11617235|NCT00512941||7|Susceptible individuals
11617236|NCT00512915|Active Comparator|1699T (Optisense)|Implantation of the Optisense Lead 1699T, programming of the shortest possible postventricular atrial blanking period (PVAB)
11617237|NCT00512915|Active Comparator|Standard lead|Implantation of a standard bipolar atrial pacing lead. Optimization of the postventricular atrial blanking period (PVAB) after implantation.
11617238|NCT00512902|Experimental|Group 1|SSc patients receiving Imatinib (Gleevec, up to 600 mg) QD PO for up to 1 year.
11617239|NCT00512889|Experimental|Cohort 1|Different dose of CTL
11617240|NCT00512889|Experimental|Cohort 2|Different dose of CTL
11617241|NCT00512889|Experimental|Cohort 3|Combination of CTL with GMCSF +/- radiation
11617242|NCT00512850|Other|Folic acid|Folic acid supplement 1g/day
11617243|NCT00512850|Other|Placebo|Placebo pill once per day
11617244|NCT00512837|Active Comparator|2|
11617245|NCT00512824|Placebo Comparator|1|
11617246|NCT00512824|Active Comparator|2|
11617247|NCT00512824|Active Comparator|3|
11617248|NCT00512824|Active Comparator|4|
11617249|NCT00512798|Experimental|Phase I|
11617250|NCT00512798|Experimental|Phase II|
11617251|NCT00512785|Experimental|E1|
11617252|NCT00512785|Experimental|E2|
11617253|NCT00512759|No Intervention|Standard of care|Standard of care of acute decompensated heart failure will be according to the current guidelines of the European Society of Cardiology (ESC).
11617254|NCT00512759|Experimental|Intervention|Early goal-directed preload and afterload decrement using a fixed therapy schedule including sublingual or nitrospray and transdermal nitrates together with hydralazine, followed by rapid up-titration of ACE-inhibitors , AT-receptor blockers or neprilysin inhibitors/AT-receptor blockers to achieve maximal vasodilatation with a target systolic blood pressure of 90-110 mmHg. All other elements of treatment will be according to the current guidelines of the European Society of Cardiology (ESC)
11617255|NCT00512746|Other|Surveillance|Screened arm
11617256|NCT00512746|Active Comparator|Control|Control arm
11617257|NCT00512707|Experimental|Active Testosterone Gel|Active Testosterone Gel and on demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
11617258|NCT00512707|Placebo Comparator|Placebo Gel|Placebo Gel and on demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
11617259|NCT00512668|Experimental|Treatment (hormone therapy, temsirolimus)|"Patients receive combined androgen ablation therapy comprising a luteinizing hormone-releasing hormone analogue (i.e., leuprolide acetate intramuscularly once monthly or goserelin subcutaneously every 3 months) and an oral anti-androgen drug (i.e., bicalutamide or nilutamide once daily or flutamide 3 times daily) on days 1-90.* Beginning on day 60 of hormonal therapy, patients receive temsirolimus IV over 30 minutes once weekly. Treatment with temsirolimus continues for up to 36 weeks in the absence of disease progression or unacceptable toxicity.
~NOTE: *Patients may receive no more than 3 months of hormonal therapy, including therapy initiated within 2 months of study entry."
11617260|NCT00512655|Experimental|1|Intervention: 5 week training program, 2 sessions per week (total of 10 sessions). Training includes both the patient and the caregiver. The training consists of two components: a cognitive and a physical component.
11617261|NCT00512655|No Intervention|2|Usual care.
11617262|NCT00512642||Patients at increased risk of lung cancer|Patients at increased risk of lung cancer
11617263|NCT00512629|Experimental|Omegaven|Omegaven is a fish based intravenous fat emulsion
11617264|NCT00512629|Active Comparator|Intralipid|
11617265|NCT00512590|Experimental|Experimental|
11617266|NCT00512577|Active Comparator|A|Patients will not receive a pre-operative transfusion.
11617267|NCT00512577|Active Comparator|B|Patients will receive a pre-operative blood transfusion. Those presenting with an admission Hb of less than 9g/dL will receive a simple (also called a 'top-up') transfusion, those presenting with an admission Hb of more than or equal to 9g/dL will undergo a partial exchange transfusion.
11617268|NCT00512564||1|Patients suffering from Sickle cell disease
11617269|NCT00512551||Cervical cancer tumor biopsy + radiation therapy|Cervical cancer tumor biopsy + radiation therapy.
11617270|NCT00512525|Placebo Comparator|2|
11617271|NCT00512499|Placebo Comparator|Group 1|CONTROL GROUP (first year only; maximum 300 patients): patients seen by CHUS orthopedists at the Hotel-Dieu site, where no nurse coordinator is available for inclusion. This is random but not randomized.
11617272|NCT00512499|Active Comparator|Group 2|"MINIMAL INTERVENTION GROUP: 1/2 of patients, randomly selected.
~INTERVENTION: A nurse coordinator will identify patients with fragility fractures and inform the patient about osteoporosis as the cause of the fracture, the benefit of treatment, and the options of treatment adapted to the individual patient. Written information will be sent to his/her family physician containing a presumed osteoporosis diagnosis, investigation to be performed, correct interpretation of any osteodensitometry results in the context of a fragility fracture, the options of treatment, and alternatives if the first prescriptions are not tolerated or stopped. Intervention"
11617273|NCT00512499|Experimental|Group 3|INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
11617274|NCT00512486|Active Comparator|1|MEDI-563
11617275|NCT00512473|Placebo Comparator|A|I.v. saline for 8 hours
11617276|NCT00512473|Experimental|GH|Growth hormone (0.5 mg s.c. at t = 0 hours)
11617469|NCT00510705|Other|1|Regular physical exercise training alone
11617277|NCT00512473|Experimental|Pegvisomant|Pegvisomant injection 30 mg 36 hours prior to the study
11617278|NCT00512460|Experimental|RTA 744|
11617279|NCT00512434|Active Comparator|Control in arm fields|Standard treatment Intervention no'Osteosynthesis'
11617280|NCT00512434|Experimental|IMOCA|Intervention 'Osteosynthesis' Percutaneous autologous bone-marrow grafting - surgical technique (ref: Hernigou Ph et al J Bone Joint Surg Am ,2006; 88 (sup 1 part 2): 322-327
11617281|NCT00512421||A|navigation technique
11617282|NCT00512421||B|conservative surgery
11617283|NCT00512421||C|Historical control
11617284|NCT00512408||A|
11617285|NCT00512408||B|
11617286|NCT00512395|Active Comparator|1|epidural analgesia
11617287|NCT00512395|No Intervention|2|traditional analgesia with opioids
11617288|NCT00512382||A|Babies and small children 1-24 months
11617289|NCT00512382||B|Children 2-18 years old
11617290|NCT00512356|Experimental|Investigational product group|"Anti-Adhesion Product was applied to the rectal stump and the incision line.
~Like in the control group, surgical measures to prevent adhesions were also taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves."
11617291|NCT00512356|No Intervention|Control group|Only surgical measures to prevent adhesions were taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves. No specific additional treatment was applied.
11617292|NCT00512317|Experimental|ganaxolone|active experimental drug
11617293|NCT00512304|Experimental|Preoperative chemoradiotherapy|
11617294|NCT00512304|Experimental|Postoperative chemoradiotherapy|
11617295|NCT00512291|Experimental|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses
11617296|NCT00512278|Experimental|Infliximab|Infliximab: 48 weeks of therapy with the combination of PEG INF-2b/RBV plus adjuvant infliximab
11617297|NCT00512278|Placebo Comparator|Placebo|Placebo: 48 weeks of therapy with Placebo and PEG INF-2b/RBV
11617298|NCT00512265|Active Comparator|1|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
11617299|NCT00512265|Placebo Comparator|2|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
11617300|NCT00512252|Experimental|Phase I Dose Escalation|"AMD3100 SQ on days 0-5
~Mitoxantrone on days 1-5
~Etoposide on days 1-5
~Cytarabine on days 1-5
~Dose Level 1 AMD3100 dose = 80 mcg/kg/d
~Dose Level 2 AMD3100 dose = 160 mcg/kg/d"
11617301|NCT00512252|Experimental|Phase II Dose Treatment|"AMD 3100 SQ on days 0-5
~Mitoxantrone on days 1-5
~Etoposide on days 1-5
~Cytarabine on days 1-5
~Dose Level 3 AMD3100 dose=240 mcg/kg/d (this was the Phase II dose)"
11617302|NCT00512239||EUPA cohort|Consecutive adult patients presenting to receive rheumatological care at the Sherbrooke University Hospital Centre (CHUS) with an immune-mediated inflammatory arthritis affecting at least 3 joints for a duration of more than 4 and less than 52 weeks.
11617303|NCT00512213|Active Comparator|1|Immunonutrition containing RNA, omega-3-FAs, arginine
11617304|NCT00512213|Active Comparator|2|Standard enteral nutrition: isocaloric and isonitrogeneous but w/o active ingredients
11617305|NCT00512200||Case|Patients aged 65 or older
11617306|NCT00512200||Control|Patients aged 20 to 40
11617307|NCT00512200||Control 2|Healthy volunteers aged 65 or older
11617308|NCT00512187|Experimental|first group|patients who adhered to a low-calorie diet associated to sub-optimal cyclosporine dose (2.5 mg/Kg/day)for 24 weeks
11617309|NCT00512148|Experimental|1|Receipt of autologous neo-bladder construct consisting of a device regenerated in the laboratory from the patient's own muscle and urothelial cells
11617310|NCT00512135|Experimental|IncobotulinumtoxinA (Xeomin) (20 units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
11617311|NCT00512122|Experimental|EN only|Withholding PN during the first week of ICU stay
11617312|NCT00512122|Active Comparator|EN plus early PN|Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E Parenteral nutrition targeted at covering calculated needs together with the enteral nutrition intake that is achieved
11617313|NCT00512096|Experimental|Cisplatin + Ifosfamide + Paclitaxel|Cisplatin 25 mg/m^2 IV Days 1-3; Ifosfamide 1200 mg/m^2 IV Days 1-3; Paclitaxel 175 mg/m^2 IV Day 1
11617314|NCT00512070|Experimental|IIA (0.3mg day melatonin)|0.3mg day melatonin
11617315|NCT00512070|Experimental|IIB (3.0 mg/day melatonin)|3.0 mg/day melatonin
11617316|NCT00512057|Experimental|1|
11617317|NCT00512057|Placebo Comparator|2|
11617318|NCT00512044|Active Comparator|A: general|general anesthesia: spinal and general
11617319|NCT00512044|Experimental|B: pudendal|local anesthesia: pudendal block
11617320|NCT00512018|Active Comparator|Isokinetic Exercise only|Individuals were asked to perform a 8-session training, twice a week, in which they trained the knee extensors muscles in an isokinetic dynamometer, 3 sets of 10 repetitions.
11617321|NCT00512018|Experimental|Isokinetic exercise + NMES|In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES).
11617322|NCT00511992|Experimental|Avastin|
11617323|NCT00511979|Experimental|Technosphere insulin inhalation system, 25 units|
11617324|NCT00511979|Experimental|Technosphere insulin inhalation system, 50 units|
11617325|NCT00511979|Experimental|Technosphere insulin inhalation system, 100 units|
11617326|NCT00511979|Active Comparator|Subcutaneous regular human insulin|
11617327|NCT00511966||001|
11617328|NCT00511966||002|
11617329|NCT00511953|Active Comparator|Gabapentin ER|Active drug, Gabapentin extended release
11617330|NCT00511953|Placebo Comparator|Sugar Pill|Comparator arm is Placebo
11617331|NCT00511940|Experimental|1|acamprosate
11617332|NCT00511940|Placebo Comparator|2|sugar pill
11617333|NCT00511927||GHD|Patients with Growth Hormone Deficiency
11617334|NCT00511927||non-GHD|Patients with CHF, without coexisting growth hormone deficiency
11617470|NCT00510705|Other|2|Regular physical exercise training + metformin
11617335|NCT00511914|Experimental|cTIV (Adults)|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
11617336|NCT00511914|Experimental|cTIV (Elderly)|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
11617337|NCT00511901|Placebo Comparator|Placebo & Niferex|Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks
11617338|NCT00511901|Active Comparator|epoetin alpha & Niferex|40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks
11617339|NCT00511875|Experimental|Doxycycline Monohydrate|stratified equally to doxycycline monohydrate 50mg taken once daily for 24 months
11617340|NCT00511875|Placebo Comparator|Placebo|stratified equally to placebo taken once daily for 24 months
11617341|NCT00511862|Experimental|TheraSphere|Single arm, TheraSphere Yttrium 90 glass microspheres at 120 Gy +/- 10%; stratified by type of disease (colorectal cancer, neuroendocrine cancer, non-colorectal/non-neuroendocrine cancer
11617342|NCT00511849|Experimental|1|
11617343|NCT00511836|Experimental|VIVITROL 380 mg|
11617344|NCT00511836|Placebo Comparator|Placebo|
11617345|NCT00511823|Experimental|Subjects in Part A|Subjects will receive 100 milligrams (mg) of oral dolasetron once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 100 mg oral dolasetron once daily on days 1, 2 and 3 along with 150 mg oral casopitant on day 1 and 50 mg oral casopitant on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
11617346|NCT00511823|Experimental|Subjects in Part B|Subjects will receive 2 mg of oral granisetron once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 2 mg oral granisetron once daily on days 1, 2 and 3 along with 150 mg oral casopitant once daily on day 1 and 50 mg oral casopitant once daily on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
11617347|NCT00511823|Experimental|Subjects in Part C|Subjects will receive 4 mg of oral rosiglitazone once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 4 mg oral rosiglitazone once daily on days 1, 2 and 3 along with 150 mg oral casopitant once daily on day 1 and 50 mg oral casopitant once daily on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
11617348|NCT00511810|Experimental|Low Dose Fish Oil|Capsule omega-3 fatty acids 2.4g/day (4 capsules/day)
11617349|NCT00511810|Experimental|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
11617350|NCT00511797|Experimental|DRSP 1 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
11617351|NCT00511797|Experimental|DRSP 2 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
11617352|NCT00511797|Experimental|DRSP 3 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
11617353|NCT00511797|Placebo Comparator|Placebo|1 tablet per day placebo for 28 days in each 28-day cycle
11617354|NCT00511784||OrthoEvra(norelgestromin/ethinylestradiol contraceptive patch)|subjects in insurance claims database who used transdermal patch containing 6 milligrams norelgestromin and 0.75 milligram ethinyl estradiol worn for 1 week for 3 consecutive weeks; the fourth week was patch-free
11617355|NCT00511784||levonorgestrel-containing oral contraceptives|subjects in insurance claims database who were first time users of triphasic levonorgestrel-containing oral contraceptives with 30 micrograms ethinyl estradiol taken for 21 consecutive days followed by no pill or an inert pill for 7 days
11617356|NCT00511758||Digital Imaging Device|Patients with a diagnosis of cervical dysplasia that are scheduled for a colposcopy.
11617357|NCT00511745||001|
11617358|NCT00511732|Experimental|Technosphere Insulin|
11617359|NCT00511732|Placebo Comparator|Technosphere Inhalation Powder|
11617360|NCT00511719|Experimental|Technosphere Insulin|Technosphere Insulin Inhalation Powder
11617361|NCT00511719|Active Comparator|Actrapid|Subcutaneous regular human insulin
11617362|NCT00511706|Experimental|dexamethasone and ranibizumab|Intravitreal injection of dexamethasone 700 µg at Day 1; ranibizumab 500 µg at Day -30 and Day 7-14.
11617363|NCT00511706|Sham Comparator|sham and ranibizumab|Sham injection at Day 1; ranibizumab 500 µg at day -30 and Day 7-14.
11617364|NCT00511693|Experimental|1|hospitals randomly allocated to receive physician and patient osteoporosis recommendations from the regional coordinator
11617365|NCT00511693|Active Comparator|2|hospitals randomly allocated to receive falls prevention advice
11617366|NCT00511680|Experimental|Behavioral based In-home Intervention|This group will recieve up to 10 1-hour sessions over a 4 month period.
11617367|NCT00511667|Experimental|MK0941|
11617368|NCT00511667|Placebo Comparator|Placebo|
11617369|NCT00511654|Experimental|Subjects in Group 1 receiving GW823296|Subjects will receive single dose of GW823296 on Day 1 followed by a wash-out period of 1 week. The subjects will then be administered GW823296 for 28 days in the repeat dosing period.
11617370|NCT00511654|Placebo Comparator|Subjects in Group 1 receiving placebo|Subjects will receive single dose of placebo on Day 1 followed by a wash-out period of 1 week. The subjects will then be administered placebo for 28 days in the repeat dosing period.
11617371|NCT00511654|Experimental|Subjects in Group 2 and 3 receiving GW823296|Subjects will receive single dose of midazolam on Day 1 followed by wash-out period of one day. Further the subjects will be administered GW823296 on Day 3 of single dose period followed by a wash-out period of 1 week. The subjects will then be administered a single dose of GW823296 for 28 days (Day 1 to Day 28 of repeat dosing period) and a single dose of midazolam on Day 29 of repeat dosing period.
11617372|NCT00511654|Placebo Comparator|Subjects in Group 2 and 3 receiving placebo|Subjects will receive single dose of midazolam on Day 1 followed by wash-out period of one day. Further the subjects will be administered placebo on Day 3 of single dose period followed by a wash-out period of 1 week. The subjects will then be administered a single dose of placebo for 28 days (Day 1 to Day 28 of repeat dosing period) and a single dose of midazolam on Day 29 of repeat dosing period.
11617373|NCT00511641||Low Risk OVCA|Patient that is participating in an ovarian cancer (OVCA) screening program.
11617374|NCT00511628||001|Risperidone As prescribed
11646990|NCT00123279|Experimental|1|
11617375|NCT00511615||1|Patients with cervical cancer scheduled to be treated with the LEEP procedure.
11617376|NCT00511602|Experimental|Technosphere Insulin Inhalation Powder|
11617377|NCT00511602|Placebo Comparator|Technosphere Inhalation Powder|
11617378|NCT00511576|Active Comparator|Part 1|In Part 1, cohorts of three to six subjects will receive doses of MGCD0103 administered orally three times per week (TIW) in combination with 60 mg/m2 IV docetaxel administered as a 1-hour infusion on Day 1 of each 3-week (21-day) cycle. The starting dose of MGCD0103 in Part 1 will be 50 mg (approximately 25 mg/m2).
11617379|NCT00511576|Active Comparator|Part 2|Part 2 will begin once the MTD for MGCD0103 in combination with 60 mg/m2 IV docetaxel has been determined and further evaluated in the expansion phase. In Part 2, cohorts of three to six subjects will receive escalating doses of MGCD0103 administered orally TIW in combination with 75 mg/m2 docetaxel administered as a 1-hour IV infusion on Day 1 of each cycle. The starting dose of MGCD0103 administered in combination with 75 mg/m2 IV docetaxel will be the MTD from Part 1 minus 25 mg.
11617380|NCT00511563|Experimental|GW876008 and GSK561679|GW876008 and GSK561679
11617381|NCT00511524|Experimental|Subjects receiving GW842166|Subjects will receive single oral dose of 400 milligram (mg) un-labeled GW842166X. After 2-5 hours subjects will receive [carbonyl-^11C]GW842166.
11617382|NCT00511498|Placebo Comparator|Placebo Arm|Placebo nightly
11617383|NCT00511498|Active Comparator|Drug|Sildenafil 50mg nightly
11617384|NCT00511485|Experimental|Etarfolatide + Vintafolide|Screening: After completion of all screening procedures and confirmation of eligibility, all participants receive a 1- to 2-mL injection of 0.1 mg etarfolatide labeled with 20 to 25 mCi of technetium-99m. Induction phase of treatment: Two 4-week cycles; if stable disease or better at (week 8) computed tomography (CT), participant may proceed into maintenance phase. Maintenance phase of treatment: 4-week cycles with CT every 8 weeks. Participants continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit.
11617385|NCT00511472|Experimental|MK-0941|
11617386|NCT00511472|Placebo Comparator|Placebo|
11617387|NCT00511459|Experimental|A|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 10 mg/kg IV QW
11617388|NCT00511459|Experimental|D|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + Open Label AMG 386 10 mg/kg IV QW
11617389|NCT00511459|Experimental|B|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 3 mg/kg IV QW
11617390|NCT00511459|Active Comparator|C|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 placebo IV QW
11617391|NCT00511446|Experimental|1|docetaxel, oxaliplatin, capecitabine
11617392|NCT00511433|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
11617393|NCT00511433|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
11617394|NCT00511420|Placebo Comparator|1|Cocoa and other ingredients (product type 1). This product is a control of type 2.
11617395|NCT00511420|Placebo Comparator|2|Cocoa plus hazelnuts and other ingredients (product type 2). This product is a control of type 3 and 4.
11617396|NCT00511420|Active Comparator|3|Cocoa plus hazelnuts and other ingredients (cocoa product type 3).
11617397|NCT00511420|Active Comparator|4|Cocoa, hazelnuts and other ingredients called LMN (cocoa product type 4).
11617398|NCT00511407|Experimental|I|RAD Treatment
11617399|NCT00511407|No Intervention|II|Conventional CVVHD
11617400|NCT00511394|Active Comparator|I|Infusion of 100 mL of 20% Albumin
11617401|NCT00511394|Placebo Comparator|II|100 mL Normal Saline
11617402|NCT00511368|Placebo Comparator|1|placebo
11617403|NCT00511368|Experimental|2|Bevirimat
11617404|NCT00511355|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
11617405|NCT00511355|Active Comparator|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets (LNG-EE), 150 mcg LNG and 30 mcg EE
11617406|NCT00511342|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic COC
11617407|NCT00511342|Active Comparator|LNG-EE|Levonorgestrel (LNG) and Ethinyl Estradiol (EE), 0.150 mg LNG and 0.030 mg EE monophasic COC
11617408|NCT00511329|Experimental|Somatropin|
11617409|NCT00511316|Experimental|Drug|20 mg montelukast daily for 6 months
11617410|NCT00511316|Placebo Comparator|Placebo|20 mg daily placebo
11617411|NCT00511238|Experimental|carfilzomib (A0)|
11617412|NCT00511238|Experimental|carfilzomib (A1)|
11617413|NCT00511225|Active Comparator|1|Will receive 10,000 IU of cholecalciferol weekly
11617414|NCT00511225|Placebo Comparator|2|Will receive a identical appearing placebo weekly
11617415|NCT00511199|Experimental|NOMAC-E2|"Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2
~monophasic combined oral contraceptive"
11617416|NCT00511199|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
11617417|NCT00511186|Experimental|Bovine Intestinal AP|"Bovine Intestinal Alkaline Phosphatase (BIAP) Intravenous administration of 10 bolus (67,5U/kg) and 48h continuous infusion (132,5U/kg)"
11617418|NCT00511186|Placebo Comparator|2|"Placebo Intravenous administration of 10 bolus and 48h continuous infusion"
11617419|NCT00511173|Experimental|Clinician dosing of warfarin|Warfarin dose based on clinician dosing without the use of warfarin pharmacogenetics
11617420|NCT00511160|Active Comparator|S|Study arm: Cardiac surgery group
11617421|NCT00511160|Active Comparator|C|Routine cardiology group
11617422|NCT00511147|Experimental|IGIV3I Grifols 10% (All Subjects)|All subjects with Chronic ITP
11617423|NCT00511134|Experimental|Zyban + Lunesta|Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + Lunesta (3 mg qd x 6 weeks)
11617424|NCT00511134|Placebo Comparator|Zyban + Placebo|Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + placebo (1 pill per day x 6 weeks)
11617425|NCT00511108|Experimental|1|Arm 1: drug
11617426|NCT00511108|Active Comparator|2|Arm 2: active comparator
11617427|NCT00511108|Experimental|3|Arm 3: drug + active comparator
11617428|NCT00511108|Placebo Comparator|4|Arm 4: placebo comparator
11617471|NCT00510705|Other|3|Regular physical exercise training + glitazone
11617429|NCT00511095|Experimental|HEPLISAV|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) Intramuscular (IM) injection 0.5mL
11617430|NCT00511082|Experimental|Treatment group|
11617431|NCT00511056||HIVNAT 006|HIVNAT 006 is a long term follow up cohort. The primary objective of this study is to collect and evaluate the long-term clinical outcomes of HIV infected patients have participated in HIV-NAT studies. These subjects will be used to test our hypothesis.
11617432|NCT00511043|Experimental|All pts|PTK787
11617433|NCT00511017|Experimental|Doxercalciferol|
11617434|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole -STD|Standard therapy of DEC (300mg) and albendazole (400mg) yearly
11617435|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole- HD1|High dose of DEC (300mg) and albendazole (800mg) yearly
11617436|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole-HD2|High dose of DEC (300mg) and albendazole (800mg) twice yearly (every 6 months)
11617437|NCT00510991|Experimental|A|NIPPV
11617438|NCT00510978|Active Comparator|1|Bifidobacterium infantis 35624
11617439|NCT00510978|Active Comparator|2|Lactobacillus salivarius UCC118
11617440|NCT00510978|Placebo Comparator|3|Placebo
11617441|NCT00510965|Experimental|A|
11617442|NCT00510952|Experimental|Lispro|Insulin Lispro protamine suspension: Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
11617443|NCT00510952|Active Comparator|Glargine|Insulin glargine: Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
11617444|NCT00510887|Experimental|VR-FND|"Bortezomib (VELCADER) 1.6 mg/m2 IV days 1 and 8 Rituximab 375 mg/m2 IV on day 1 Fludarabine 25 mg/m2 IV on days 1,2,3 Mitoxantrone 10 mg/m2 IV on day 2 Dexamethasone 20 mg orally on days 1,2,3,4,5 On day 1 the sequence of drug administration will be Bortezomib followed by Fludarabine followed by Rituximab.
~Each cycle will be repeated every 28 days for 8 cycles maximum."
11617445|NCT00510874|Experimental|Pumarix Formulation 1 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 1 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
11617446|NCT00510874|Experimental|Pumarix Formulation 2 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 2 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
11617447|NCT00510874|Experimental|Pumarix Formulation 3 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 3 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
11617448|NCT00510874|Experimental|Pandemrix Formulation A Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation A of Pandemrix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
11617449|NCT00510874|Experimental|Pandemrix Formulation B Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation B of Pandemrix ™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
11617450|NCT00510874|Experimental|Pumarix Formulation 4 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 4 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
11617451|NCT00510874|Experimental|Pumarix Formulation 5 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 5 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
11617452|NCT00510848|Experimental|1|Reconstruction with an autograft tendon (hamstrings)
11617453|NCT00510848|Experimental|2|Reconstruction with an allograft tendon (tibialis posterior)
11617454|NCT00510835|Experimental|1|Early Goal Directed Therapy (EGDT) - The study team will insert a central venous catheter (CVC) for continuous monitoring of the subjects' central venous pressure (CVP) and central venous oxygen saturation (Scv02). The study team will use this information to give fluid, blood, and heart medications in a structured fashion. The CVC is FDA approved and routinely used in hospitals.
11617455|NCT00510835|Experimental|2|Protocolized Standard Care (PSC)- The study team will monitor the subjects' blood pressure and blood oxygen level with routine equipment. The study team will use this information to give fluid and heart medications in a structured fashion. CVCs will only be used when standard IVs are unable to give the proper amount of fluids and medicines. Blood transfusions will be given according to currently recommended guidelines.
11617456|NCT00510835|Active Comparator|3|Usual Care - The attending physicians will treat the subjects according to their standard treatment plan and without any influence from the study team. A member of the study team will simply observe and record what happens.
11617457|NCT00510822|Placebo Comparator|Placebo|Placebo + Sertraline
11617458|NCT00510822|Experimental|Cimicoxib|Sertraline + Cimicoxib
11617459|NCT00510809|Active Comparator|1|Policosanol 20mg daily
11617460|NCT00510809|Placebo Comparator|2|
11617461|NCT00510809|Active Comparator|3|Policosanol 20mg daily Plus Statin Therapy Already In Use
11617462|NCT00510796||High Risk Group|Colon and/or Endometrial Cancer
11617463|NCT00510783|Active Comparator|Phenytoin/Fosphenytoin|Patients in the control arm will receive either IV Dilantin (1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals) or IV Fosphenytoin (1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals).
11617464|NCT00510783|Active Comparator|Levetiracetam|Patients in the intervention arm will receive IV Keppra (1 gram of Keppra added to 100 mL diluent infused over 15 minutes).
11617465|NCT00510757||Males|
11617466|NCT00510757||Females|
11617467|NCT00510744|Experimental|pancreatic enzyme supplementation|3 month supplementation in those gastric bypass patients shown to have a fat absorption less than 80%
11617472|NCT00510705|No Intervention|4|Control
11617473|NCT00510692|Experimental|2g/day Eicosapentanoic Acid (EPA)|"Eicosapentanenoic Acid (EPA) as the free fatty acid 2 capsules twice daily for 6 months.
~Endoscopy and biopsies taken as described under intervention."
11617474|NCT00510692|Placebo Comparator|Placebo|Medium chain triglycerides 2 capsules twice daily for six months. Endoscopy and biopsies taken as described under intervention.
11617475|NCT00510666|Experimental|1|Butorphanol basal infusion adjunct to morphine PCA
11617476|NCT00510666|Experimental|2|Saline infusion adjunct to morphine PCA
11617477|NCT00510666|Experimental|3|Premedication of Tramadol
11617478|NCT00510666|Experimental|4|Preemptive saline for morphine PCA
11617479|NCT00510653|Experimental|Imatinib Mesylate|600 mg/day orally for 6 Weeks
11617480|NCT00510640|Experimental|Sunitinib|Sunitinib will be administered orally daily for 4 weeks followed by a 2-week rest; the daily starting dose will be 50 mg with a provision for dose reduction based on tolerability. All patients will receive repeated cycles until disease progression or occurrence of severe toxicity.
11617481|NCT00510627|Experimental|A|Radiofrequency ablation in conjunction with chemotherapy
11617482|NCT00510627|Active Comparator|B|Standard of care chemotherapy regimen
11617483|NCT00510614|Active Comparator|A|1 gram tinidazole twice weekly for 12 weeks
11617484|NCT00510614|Placebo Comparator|B|Placebo twice weekly for 12 weeks
11617485|NCT00510601|Experimental|1|
11617486|NCT00510588|Other|1|regular physical exercise training
11617487|NCT00510588|Other|2|regular physical exercise training + metformin
11617488|NCT00510588|Other|3|regular physical exercise training + glitazon
11617489|NCT00510588|No Intervention|4|Control
11617490|NCT00510575|Active Comparator|1|Subjects in this arm will receive the 5.5mm stainless steel instrumentation rod.
11617491|NCT00510575|Active Comparator|2|Subjects in this arm will receive a 6.35mm stainless steel instrumentation rod.
11617492|NCT00510562|Experimental|1|Assessment for cranial strain patterns, followed by indirect osteopathic treatment of dysfunctions found on assessment, followed by reassessment.
11617493|NCT00510562|Sham Comparator|2|Assessment for cranial strain patterns, followed by laying on of hands, followed by reassessment.
11617494|NCT00510549|Active Comparator|1, PD|Peritoneal Dialysis
11617495|NCT00510549|Active Comparator|2, HD|Hemodialysis
11617496|NCT00510510|Experimental|NVA237 100 µg|
11617497|NCT00510510|Experimental|NVA237 200 µg|
11617498|NCT00510510|Placebo Comparator|Placebo|
11617499|NCT00510497|Experimental|Autologous HIV-1 ApB DC Vaccine|Subjects who will receive ApB Dendritic cell vaccine
11617500|NCT00510484|Experimental|A|
11617501|NCT00510484|Placebo Comparator|B|
11617502|NCT00510458|Other|LFIT™Femoral Heads With X3® Insert|LFIT™ Femoral Heads With X3® Insert
11617503|NCT00510445|Experimental|Single Arm Trial|Patients will be enrolled in the order of confirmation of eligibility. Dose cohorts will be filled sequentially with a minimum of 3 patients. Once assigned to a dose cohort, each patient will continue to be treated at the same dose level throughout the course of the study.
11617504|NCT00510432||s.c. anticoagulant therapy|All patients with s.c. anticoagulant therapy (UFH, LMWH, heparinoids, fondaparinux)
11617505|NCT00510406|Placebo Comparator|A|
11617506|NCT00510406|Active Comparator|B|
11617507|NCT00510406|Active Comparator|C|
11617508|NCT00510406|Active Comparator|D|
11617509|NCT00510406|Active Comparator|E|
11617510|NCT00510406|Active Comparator|F|
11617511|NCT00510406|Active Comparator|G|
11617512|NCT00510406|Active Comparator|H|
11617513|NCT00510393|Experimental|1|drug eluting stent
11617514|NCT00510393|Placebo Comparator|2|Bare Metal Stent
11617515|NCT00510380||growth-restricted Chinese pregnancies|
11617516|NCT00510380||appropriately-grown Chinese pregnancies|
11617517|NCT00510367|Experimental|Multimodality Treatment|"Multimodality (chemotherapy, surgery and radiation therapy) treatment:
~5-Fluorouracil + Doxorubicin + Cyclophosphamide (FAC)"
11617518|NCT00510354|Experimental|RAD001 + Imatinib|
11617519|NCT00510341|Active Comparator|1|CMP program
11617520|NCT00510341|No Intervention|2|Control group
11617521|NCT00510315||Women treated with SCT/TBI|
11617522|NCT00510315||1:1 Matched group of women|"Current age + or - 2 years
~Race and ethnicity
~Cancer diagnosis
~Interval from completion of cancer therapy to study + or - 2 years"
11617523|NCT00510302||Melanoma Risk-Reduction|Patients with melanoma, their spouses/partners, and first-degree relatives (FDRs).
11617524|NCT00510289|Experimental|all patients|sorafenib
11617525|NCT00510276|Experimental|Atomoxetine|
11617526|NCT00510276|Placebo Comparator|Placebo|
11617527|NCT00510263|Experimental|1|
11617528|NCT00510263|Experimental|2|
11617529|NCT00510263|Experimental|3|
11617530|NCT00510263|Placebo Comparator|4|
11617531|NCT00510250|Experimental|Cisplatin and Radiation in Combination with Sorafenib|
11617532|NCT00510237|Experimental|1|5-7 females per group at each of the four sites.
11617533|NCT00510237|Experimental|2|5-7 males per group at each of the four sites.
11617534|NCT00510224|Experimental|1|
11617535|NCT00510211||olanzapine coated tablet|
11617536|NCT00510211||olanzapine orodispersable tablet|
11617537|NCT00510198|Active Comparator|Control Arm 1: SOC and CC with OptiVol|Standard of Care and Cardiac Compass with OptiVol as the Control. Intervention is standard of care, such as symptom assessment with the addition of viewing Cardiac Compass trends and the OptiVol diagnostic.
11617538|NCT00510198|Active Comparator|Control Arm 2: SOC|Intervention is Standard of Care alone, such as assessment of symptoms, only. Device trending information, but OptiVol is not allowed.
11617539|NCT00510185|Experimental|1|Coronary angiography within 72h and revascularization as clinical indicated
11617540|NCT00510185|Sham Comparator|2|Initially conservative treatment with coronary angiography only for recurrent ischemia
11617541|NCT00510172|Active Comparator|1|Active treatment
11617542|NCT00510172|Placebo Comparator|2|Placebo
11617589|NCT00509743|Experimental|A|Low dose Diclofenac
11617543|NCT00510146|Experimental|Olanzapine|During double-blind treatment, participants receive olanzapine at a dose of 5 milligram (mg) which is increased to 10 mg per day no later than 3-7 days after randomization (Baseline). Subsequent dose increases above 10 mg (up to a maximum of 20 mg per day) are permitted in 5 mg per day increments, based upon tolerability and symptoms. Dosing may be decreased by any number of decrements, however dosing below 5 mg requires study discontinuation.
11617544|NCT00510146|Placebo Comparator|Placebo|Matching placebo administered once daily, by mouth during double-blind treatment.
11617545|NCT00510146|Experimental|Olanzapine (open-label treatment period)|During open-label treatment, participants randomized to placebo in double-blind period will receive olanzapine 5 mg starting at Week 6. Participants randomized to olanzapine must be at a 5 mg olanzapine dose at Week 7. Those on higher doses will be reduced between Week 6 and Week 7 (10 mg reduced to 5 mg; 15 mg reduced to 10 mg and then to 5 mg at Week 7; 20 mg reduced to 15 mg and then 10 mg to dosing at 5 mg at Week 7). Dose increases beyond Week 7 are permitted and at the investigator's discretion.
11617546|NCT00510133|Experimental|GRNVAC1|Autologous dendritic cell vaccine
11617547|NCT00510120|Experimental|1|Participants will receive collaborative problem solving.
11617548|NCT00510120|Active Comparator|2|Participants will receive parent management training.
11617549|NCT00510120|Active Comparator|3|Participants assigned to waitlist control will receive one of the two treatments after a 10-weeks waitlist period.
11617550|NCT00510107|Active Comparator|1|Docetaxel 35 mg/m2 will be administered on days 1 and 8. Cisplatin 60 mg/m2 will be administered on day 1 every 3 weeks.
11617551|NCT00510107|Experimental|2|Docetaxel 35 mg/m2 will be administered on days 1 and 8. Oxaliplatin 120 mg/m2 will be administered on day 1 every 3 weeks.
11617552|NCT00510094|Experimental|1|Participants will receive the Friend to Friend program
11617553|NCT00510094|Active Comparator|2|Participants will receive the psychoeducational attention control intervention
11617554|NCT00510081|Experimental|1|subjects will receive filler injections
11617555|NCT00510068|Experimental|Everolimus 10 mg/day|Participants received 10 mg per day of Everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).
11617556|NCT00510068|Placebo Comparator|Placebo|Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).
11617557|NCT00510055|Experimental|A|scars receive subdermal manipulation ONLY
11617558|NCT00510055|Experimental|B|scars receive subdermal manipulation AND injection of a filler
11617559|NCT00510029|Other|GAP-134, IV and Oral|Experimental; Active Comparator; Placebo
11617560|NCT00510016|Experimental|Clonidine treatment|Infants intrauterine exposed to opioids (heroin or methadone) that demonstrate signs and symptoms of withdrawal with withdrawal scores (modified Finnegan score) greater than 9 on to consecutive scores taken 4 hours apart.
11617561|NCT00509977|Experimental|1|Light therapy
11617562|NCT00509977|Experimental|2|Laser Treatment
11617563|NCT00509964|Active Comparator|1|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
11617564|NCT00509964|Active Comparator|2|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and infusional 5-fluorouracil, on day 1 every 2 weeks.
11617565|NCT00509951|Active Comparator|1|One-session exposure treatment (OST)
11617566|NCT00509951|Experimental|2|Family-enhanced (augmented) OST
11617567|NCT00509938|Experimental|1|5mg hLF1-11, single dose iv
11617568|NCT00509925|Experimental|Treatment period 1|Insulin detemir for 16 weeks (treatment period 1) followed by insulin NPH treatment for 16 weeks (treatment period 2) in addition to meal-time insulin aspart
11617569|NCT00509925|Experimental|Treatment period 2|Insulin NPH for 16 weeks (treatment period 1) followed by insulin detemir treatment for 16 weeks (treatment period 2) in addition to meal-time insulin aspart
11617570|NCT00509899|Experimental|Ruxolitinib|All participants received oral ruxolitinib. Patients began treatment with either 10 mg twice a day (bid), 15 mg bid, 25 mg bid, 50 mg bid, 25 mg once a day (qd), 50 mg qd, 100 mg qd, or 200 mg qd, depending on the time period when they entered the study. The doses were titrated based on efficacy and safety to a maximum of 25 mg bid for patients who entered the study after sufficient dosing information had been obtained to define the maximum dose for patients in the study. Patients could continue receiving treatment indefinitely if receiving benefit at a dose that continues to maintain benefit but does not exceed a maximum dose of 25 mg BID.
11617571|NCT00509886|Experimental|1|ARMs were randomized. One side of the body received treatment with one antiperspirant and the contralateral side with a different antiperspirant.
11617572|NCT00509886|Experimental|2|ARMs were randomized. One side of the body received treatment with one antiperspirant and the contralateral side with a different antiperspirant.
11617573|NCT00509873|Experimental|Gatifloxacin 0.5% Eye Drops|Gatifloxacin 0.5% Eye Drops
11617574|NCT00509873|Placebo Comparator|Placebo Eye Drops|Placebo Eye Drops
11617575|NCT00509860|Experimental|Irinotecan|Irinotecan 16 mg/m2 by vein daily over 1 hour for 5 Days
11617576|NCT00509834|Experimental|hLF1-11|hLF1-11 0.5mg
11617577|NCT00509834|Placebo Comparator|Placebo|Placebo formulation is Similar to hLF1-11 iv formulation except for the active component
11617578|NCT00509821|Experimental|Enzastaurin Once Daily (QD)|Enzastaurin given orally (PO) once daily (QD). 1125 mg loading dose D(-)7 then 500 mg PO,QD with concomitant radiotherapy.
11617579|NCT00509821|Experimental|Enzastaurin Twice Daily (BID)|Enzastaurin 1125 mg loading dose D(-)7 then 250 mg twice daily (BID) PO, with concomitant radiotherapy.
11617580|NCT00509808|Sham Comparator|electrostimulation|Use of device for predetermined length
11617581|NCT00509795|Active Comparator|ranibizumab 0.5mg Q4|
11617582|NCT00509795|Experimental|aflibercept injection 2.0mg Q4|
11617583|NCT00509795|Experimental|aflibercept injection 0.5mg Q4|
11617584|NCT00509795|Experimental|aflibercept injection 2.0mg Q8|
11617585|NCT00509782|Experimental|ZIO-101|
11617586|NCT00509769|Experimental|Trastuzumab emtansine 3.6 mg/kg|Patients received trastuzumab emtansine 3.6 mg/kg intravenously on Day 1 of each 21 day cycle for a maximum of 1 year. The total dose was dependent on the patient's weight on Day 1 of each cycle.
11617587|NCT00509756|Active Comparator|1|Drug: FXR-450
11617588|NCT00509756|Placebo Comparator|2|Placebo
11617590|NCT00509743|Experimental|B|High dose Diclofenac
11617591|NCT00509717|Experimental|experimental|
11617592|NCT00509717|Active Comparator|control|
11617593|NCT00509691|Experimental|Single arm study|
11617594|NCT00509665|Experimental|Gemcitabine+doxorubicin|
11617595|NCT00509652|Experimental|Arm 1|Erythrocyte apheresis
11617596|NCT00509652|Active Comparator|Arm 2|Phlebotomy
11617597|NCT00509639|Experimental|Metronidazole 10% ointment|Metronidazole 10% ointment
11617598|NCT00509639|Placebo Comparator|Placebo ointment|Placebo ointment
11617599|NCT00509600|Experimental|Etanercept|0.8 mg/kg subcutaneously weekly for 90 days
11617600|NCT00509587|Experimental|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11617601|NCT00509561|Active Comparator|Chemo-radiotherapy|
11617602|NCT00509561|Experimental|Chemo-radiotherapy plus cetuximab|
11617603|NCT00509548|Experimental|1|Dose 1
11617604|NCT00509548|Experimental|2|Dose 2
11617605|NCT00509496|Experimental|anti-gp100:154-162 TCR PBL + HD IL-2|"fludarabine phosphate-25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days
~cyclophosphamide-60 mg/kg/day x 2 days intravenous
~Anti-gp100:154-162 TCR-engineered peripheral blood lymphocyte (PBL) cell preparation - minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes.
~aldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)"
11617606|NCT00509496|Experimental|anti-gp100:154-162 TCR TIL + HD IL-2|"fludarabine phosphate-25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days
~cyclophosphamide-60 mg/kg/day x 2 days intravenous
~Anti-gp100:154-162 TCR-engineered tumor infiltrating lymphocytes (TIL) cell preparation- minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes
~aldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)"
11617607|NCT00509470|Active Comparator|telmisartan plus low-dose hydrochlorothiazide|12 week combination therapy with telmisartan plus low-dose hydrochlorothiazide
11617608|NCT00509470|Active Comparator|Amlodipine|Amlodipine is continuously administered.
11617609|NCT00509444|Active Comparator|Educational materials|
11617610|NCT00509444|Experimental|Educational materials, plus patient navigation|
11617611|NCT00509431|Experimental|Erlotinib + Sirolimus|This is an open-label,phase I single-arm dose-escalation and phase II study of continuous, once daily doses of erlotinib administered orally in combination with sirolimus in adult patients with malignant glioma at first, second or third recurrence
11617612|NCT00509418|Experimental|A|Viusid, a nutritional supplement, in combination with controlled diet and exercise
11617613|NCT00509418|Active Comparator|B|Controlled diet and exercise
11617614|NCT00509405|Placebo Comparator|Potassium citrate|
11617615|NCT00509392|Active Comparator|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation & ClosureFAST catheter
11617616|NCT00509392|Active Comparator|Endovenous Laser|Treatment invention of venous disease with an Endovenous Laser.
11617617|NCT00509379|Experimental|1|All patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
11617618|NCT00509366|Active Comparator|Cisplatin Sensitive (Post-Amendment)|"Assignment to Treatment Group based on histology and tumor genomics analysis:
~Squamous Cell NSCLC-Cisplatin day 1, Gemcitabine days 1 & 8 Non-Squamous Cell NSCLC-Cisplatin day 1, Pemetrexed day 1
~Per an amendment dated 1/25/2010, post-amendment treatment assignment refers to the further separation of patients into sub-groups, within the cisplatin sensitive arm, based on histology (squamous/non-squamous)."
11617619|NCT00509366|Active Comparator|Cisplatin Resistant (Post-Amendment)|"Assignment to Treatment Group based on histology and tumor genomics analysis:
~Squamous Cell NSCLC-Docetaxel day 1, Gemcitabine days 1 & 8 Non-Squamous Cell NSCLC-Pemetrexed day 1, Gemcitabine days 1 & 8
~Per an amendment dated 1/25/2010, post-amendment treatment assignment refers to the further separation of patients into sub-groups, within the cisplatin resistant arm, based on histology (squamous/non-squamous)."
11617620|NCT00509366|Active Comparator|Cisplatin Sensitive (Pre-Amendment)|"Assignment to Treatment Group based on tumor genomics analysis:
~Cisplatin day 1, Gemcitabine days 1 & 8"
11617621|NCT00509366|Active Comparator|Cisplatin Resistant (Pre-Amendment)|"Assignment to Treatment Group based on tumor genomics analysis:
~Pemetrexed day 1, Gemcitabine days 1 & 8"
11617622|NCT00509340|No Intervention|1|Participants will receive usual clinical care, which may or may not include mental health treatment
11617623|NCT00509340|Experimental|2|Participants will receive cognitive behavioral intervention
11617624|NCT00509327|Active Comparator|1|bisacodyl 10mg twice daily from one day preoperative to day three postoperative
11617625|NCT00509327|Placebo Comparator|2|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
11617626|NCT00509301|Experimental|1|1.5 mCi/cc
11617627|NCT00509301|Experimental|2|2.0 mCi/cc
11617628|NCT00509301|Experimental|3|2.5 mCi/cc
11617629|NCT00509288|Experimental|anti-MART-1 F5 TCR PBL + HD IL-2|Patients treated with peripheral blood lymphocytes (PBL)
11617630|NCT00509288|Experimental|anti-MART-1 F5 TCR TIL + HD IL-2|Patients treated with TIL (tumor infiltrating lymphocytes).
11617631|NCT00509275|Experimental|1|W0027
11617632|NCT00509275|Experimental|2|W0027
11617633|NCT00509275|Experimental|3|W0027
11617634|NCT00509275|Placebo Comparator|4|Placebo
11617635|NCT00509262|Experimental|Sitagliptin|Sitagliptin + Placebo for Glipizide
11617636|NCT00509262|Active Comparator|Glipizide|Glipizide + Placebo for Sitagliptin
11617637|NCT00509249|Experimental|Arm I|Patients will receive aflibercept IV at 4 mg/kg over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11617638|NCT00509236|Experimental|Sitagliptin 25 mg|
11617639|NCT00509236|Active Comparator|Glipizide 2.5 mg - 20 mg|
11617640|NCT00509223|Experimental|Group 1|Lifestyle counseling with Positive Airway Pressure (PAP) therapy
11617970|NCT00506363|Sham Comparator|C|dynamic cooling device
11617641|NCT00509223|Active Comparator|Group 2|Lifestyle counseling without Positive Airway Pressure (PAP) therapy
11617642|NCT00509197|Active Comparator|Active treatment group (A)|Intervention : treatment with inhaled corticosteroids (Fluticasone) will be administered to this group
11617643|NCT00509197|Placebo Comparator|Control group treated with placebo (B)|treatment with placebo
11617644|NCT00509171|Active Comparator|1-Standard reamer|Standard reamer
11617645|NCT00509171|Active Comparator|2-Use of the Reamer-Irrigator Aspirator|Use of the Reamer-Irrigator Aspirator
11617646|NCT00509145|Experimental|Laquinimod|Laquinimod 0.6 mg, oral
11617647|NCT00509145|Placebo Comparator|Placebo|Matching placebo
11617648|NCT00509106|Experimental|Ceftaroline fosamil for injection|Ceftaroline fosamil was administered in two consecutive 300 mg IV infusions over 30 minutes, every 12 hours (q12h).
11617649|NCT00509106|Active Comparator|IV Ceftriaxone|Ceftriaxone was administered as a 1-g IV infusion over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h).
11617650|NCT00509093|Experimental|Imatinib Mesylate|
11617651|NCT00509067|Experimental|A|Participants assigned to receive galantamine and CDP-choline
11617652|NCT00509067|Placebo Comparator|B|Participants assigned to receive placebo
11617653|NCT00509041|Experimental|Dasatinib|Use of dasatinib in treatment of pts with previously treated malignant mesothelioma
11617654|NCT00509028|Experimental|BUD - Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
11617655|NCT00509028|Active Comparator|CONV - Conventional Asthma Therapy|Conventional Asthma Therapy - according to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
11617656|NCT00509015|Active Comparator|1|Sulphadoxine-pyrimethemine (day 1) artesunate (day 1-3) primaquine (day 3)
11617657|NCT00509015|Placebo Comparator|2|Placebo: lactose tablets (Albochin)
11617658|NCT00509002|Experimental|Adenoid Cystic Salivary Gland Carcinoma Group|Participants receive Gefitinib daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
11617659|NCT00509002|Experimental|Other Carcinoma of Salivary Gland Group|Participants receive Gefitinib daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
11617660|NCT00508989|Experimental|1|
11617661|NCT00508989|Placebo Comparator|2|
11617662|NCT00508976|Experimental|3|
11617663|NCT00508976|Experimental|2|
11617664|NCT00508976|Experimental|4|
11617665|NCT00508976|Active Comparator|1|
11617666|NCT00508950|Other|All subjects|All subjects
11617667|NCT00508937|Active Comparator|1|
11617668|NCT00508937|Experimental|2|
11617669|NCT00508937|Experimental|3|
11617670|NCT00508937|Experimental|4|
11617671|NCT00508937|Experimental|5|
11617672|NCT00508924|Experimental|ARG250|
11617673|NCT00508924|Experimental|ARG300|
11617674|NCT00508924|Experimental|ARG350|
11617675|NCT00508924|Placebo Comparator|Heparin|
11617676|NCT00508911|Experimental|Healthy female subjects|Each subject will be administered a monophasic combined oral contraceptive (COC) containing ethinylestradiol 30 micrograms and levonorgestrel 150 micrograms for two complete cycles (Day 8 to Day 28) in Session 1. The subjects will be administered COC on Day 8 to Day 28 and GW876008 125 milligrams on Days 1 to 35 in Session 2.
11617677|NCT00508898|Experimental|treatment group|Patients will receive calcitriol at a fixed dose of 1 mcg twice weekly.
11617678|NCT00508898|Active Comparator|control group|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
11617679|NCT00508885|Experimental|1|Niacinamide starting at 250 mg twice daily titrated up to 750 mg twice daily
11617680|NCT00508885|Placebo Comparator|2|Placebo
11617681|NCT00508872|Experimental|FOLFOX-B|FOLFOX-B: 5-Fluorouracil 400 mg/m^2 IV + Bevacizumab 5 mg/kg IV + Leucovorin 400 mg/m^2 IV + Oxaliplatin 85 mg/m^2 IV
11617682|NCT00508859|Experimental|Active, 1|sertraline
11617683|NCT00508859|Placebo Comparator|Placebo|placebo
11617684|NCT00508846||HNPCC Patients|
11617685|NCT00508820|Experimental|1|Romiplostim
11617686|NCT00508807|Experimental|RTA 402|5 mg PO daily x 21 days
11617687|NCT00508794|Experimental|Group 1 Yoga Program|3 sessions of yoga each week for 6 weeks. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
11617688|NCT00508794|Experimental|Group 2 Stretching Program|3 sessions of stretching each week for 6 weeks. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
11617689|NCT00508794|Other|Group 3 Waitlist Control Group|Option of participating in the yoga or stretching program after the study has ended. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
11617690|NCT00508755|Experimental|Arm 1|stroke
11617691|NCT00508742|Experimental|1|13 valent pneumococcal conjugate vaccine
11617692|NCT00508742|Active Comparator|2|7 valent pneumococcal conjugate vaccine
11617693|NCT00508716|No Intervention|A|Usual Care - Education about CHF by Primary Nurse on discharge. No teach-back is used in this arm.
11617694|NCT00508716|Experimental|B|"Tailored Intervention for patients with low health literacy and nurse-directed teachback: Educational leaflet which has been developed for low-health literacy patients. Adminstered by dedicated Nurse-educator. Nurse-educator asks Patient for teachback after Intervention. This means that the Patient repeats in his/her own words the Information received. Education ends once Patient has been able to repeat the Information back."
11617695|NCT00508703||CT Scan + IMRT Radiation Therapy|
11617696|NCT00508690|Active Comparator|IV|Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
11617697|NCT00508690|Active Comparator|Oral/IV|2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
11617698|NCT00508664|Experimental|A|TP + Radiation (TPF until Feb 2009)
11617699|NCT00508664|Experimental|B|TP + Cetuximab + Radiation (TPF until Feb 2009)
11617864|NCT00507325||Blood Sample + Tumor Sample|Blood samples will be collected. Tumor samples will be collected using a small needle, a punch knife, or a small surgery.
11646991|NCT00123279|Experimental|2|
11617700|NCT00508651|Experimental|Cohort 1 MEDI-560|MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson^TM Luer slip tip syringes. Each 0.2 mL dose contained 10^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
11617701|NCT00508651|Placebo Comparator|Cohort 1 Placebo|Placebo was a frozen preparation filled into Becton Dickinson^TM Luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
11617702|NCT00508625|Other|C|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 of each 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
11617703|NCT00508625|Experimental|E|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (20mg/kg) on days 1-2 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
11617704|NCT00508625|Experimental|B|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus AMG 951 (rhApo2L/TRAIL) (8mg/kg) for 5 days per 21 days cycle until disease progression, study drug intolerability or withdrawal of consent.
11617705|NCT00508625|Other|A|40 subjects will receive up to 6 cycles of Carboplatin (AUC = 6.0mg/ml.min) and Paclitaxel (200mg/m2) only
11617706|NCT00508625|Experimental|D|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (8mg/kg) on days 1-5 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
11617707|NCT00508612|Active Comparator|1|The 12-lesson Williams LifeSkills anger and stress management workshop (WLS) enhances awareness of thoughts and feelings in stressful situations, and provides training in evaluation, deflection, problem-solving, assertion, saying no, speaking, listening, empathy, and emphasizing positives.
11617708|NCT00508612|Placebo Comparator|2|Control group (will attend regular high school classes)
11617709|NCT00508599|No Intervention|1|Study 1 is the control arm in which participants continue with their normal activity.
11617710|NCT00508599|Experimental|2.|Study 2 consists of 48 hours of complete bed rest.
11617711|NCT00508586|Experimental|1|PTC299 with an aromatase inhibitor
11617712|NCT00508573||Lynch Syndrome Registry|Patient that has or is at risk for Lynch Syndrome.
11617713|NCT00508560|Experimental|Arm 1|Experimental
11617714|NCT00508560|Active Comparator|Arm 2|Active Comparator
11617715|NCT00508547||Guselkumab|Participants will receive guselkumab as prescribed by the physician according to standard of care for psoriasis.
11617716|NCT00508547||Infliximab|Participants will receive infliximab as prescribed by the physician according to standard of care for psoriasis.
11617717|NCT00508547||Ustekinumab|Participants will receive ustekinumab as prescribed by the physician according to standard of care for psoriasis.
11617718|NCT00508547||Biological Therapies|Participants will receive biological therapies other than infliximab, ustekinumab, guselkumab, and IL-17 inhibitors as prescribed by physician for psoriasis. Participants will not receive any intervention as a part of this study.
11617719|NCT00508547||Conventional Systemic Agents|Participants will receive conventional systemic agents as prescribed by the physician for psoriasis. Participants will not receive any intervention as a part of this study.
11617720|NCT00508547||IL-17 Inhibitor|Participants will receive an IL-17 inhibitor as prescribed by the physician according to standard of care for psoriasis.
11617721|NCT00508521|Experimental|FES and Motor Learning Training|participants <6 months after first stroke who presented with arm dysfunction were trained using FES and Motor Learning
11617722|NCT00508521|Other|Control group|Subjects in this arm will receive standard care as prescribed by their physician and covered by their insurance
11617723|NCT00508508|Experimental|1|Behavioral: IVR
11617724|NCT00508508|Experimental|2|Behavioral: Nurse-Led Group Visits
11617725|NCT00508495|Experimental|Test drug|
11617726|NCT00508495|Active Comparator|Reference drug|
11617727|NCT00508495|Placebo Comparator|Placebo|
11617728|NCT00508482|Experimental|deep needling group|Acupoints of bilateral Tianshu (ST25), which were located according to WHO Standardized Acupuncture Points Location, were used. After sterilizing the skin, needles of the size of 0.35×0.75mm were inserted into ST25 vertically and slowly without manipulation for about 20~60mm until piercing into the muscle layer. Paired alligator clips of the electric acupuncture (EA) apparatus were attached transversely to the needle holders of bilateral ST25. EA stimulation lasted for 30 minutes with a dilatational wave of 2/15Hz and current intensity of 0.1~1mA. Participant's abdominal muscle twitching mildly showed the proper dose. Patients were treated once a day, five times a week for continuous 4 weeks.
11617729|NCT00508482|Active Comparator|lactulose group|Lactulose Oral Solution was taken orally at the dose of 20~30ml once every morning after breakfast for continuous 4 weeks. Patients should take lactulose for another 3 months if no severe adverse effect was showed.
11617730|NCT00508482|Active Comparator|shallow needling group|Bilateral ST25, the same acupoints as deep needling group, were used. After skin disinfection, needles of the size of 0.30×25mm penetrated the skin uprightly for about 5~9mm into the fat layer without manipulation. The usage of EA apparatus and treatment course were the same as deep needling group.
11617731|NCT00508469|Experimental|Travalert with travoprost/timolol fixed combination|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
11617732|NCT00508469|Experimental|Travalert with travoprost and timolol|One drop travoprost in the study eye at 9 p.m. and one drop of timolol in the study eye twice daily (9 a.m. and 9 p.m.) for six months using a separate Travalert device for each medication.
11617733|NCT00508456|Experimental|Hominex®-2 + Temodar®|Dietary Methionine Restriction (Hominex®-2) Days 1-7 and 15-21 + Temodar® 150 mg/m^2 orally Days 8-15
11617734|NCT00508443|Experimental|Radiation Therapy|Radiation Therapy using CT-on-Rails or Trilogy procedure. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
11617735|NCT00508430|Experimental|1|Low dose group
11617736|NCT00508430|Experimental|2|Middle dose group
11617737|NCT00508430|Experimental|3|High dose group
11617738|NCT00508430|Placebo Comparator|4|
11618542|NCT00500812|Experimental|1 mg|Subjects receiving 1 mg Cethrin
11617739|NCT00508404|Experimental|Panitumumab plus FOLFIRI|Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until diagnosed with radiographic disease progression.
11617740|NCT00508391|Experimental|Simultaneous 1st, Optimized 2nd|Lumax HF-T device programmed to simultaneous biventricular pacing first for 30 days, followed by optimized biventricular pacing for 30 days.
11617741|NCT00508391|Experimental|Optimized 1st, Simultaneous 2nd|Lumax HF-T device programmed to optimized biventricular pacing first for 30 days, followed by simultaneous biventricular pacing for 30 days.
11617742|NCT00508378||Interview & Questionnaires|
11617743|NCT00508365|Experimental|Subjects receiving treatment sequence AB|Eligible subjects will receive treatment sequence AB; A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).
11617744|NCT00508365|Experimental|Subjects receiving treatment sequence BA|Eligible subjects will receive treatment sequence BA; B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).
11617745|NCT00508352|Experimental|Helical tomotherapy|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
11617746|NCT00508339||1|Patients with a diagnosis of soft tissue sarcoma.
11617747|NCT00508326|Experimental|HAI Paclitaxel|Paclitaxel via Hepatic Artery Infusion (HAI)
11617748|NCT00508313||With Lung Cancer|Patients with lung cancer.
11617749|NCT00508313||Healthy Participants|Healthy participants without cancer.
11617750|NCT00508300|Other|A|Epidural Analgesia (EDA) An epidural catheter was inserted at thoracic level (Th8-Th10) before induction of anesthesia. A bolus of 5 mL of bupivacaine 0.5% was started as soon as the epidural catheter was in place, and a continuous perfusion of bupivacaine 0.5% at 5 mL/hr was initiated until the end of surgical procedure.
11617751|NCT00508300|Other|B|Patient controlled analgesia (PCA) was assured by fentanyl (morphine-based) as needed.
11617752|NCT00508287|Experimental|A|
11617753|NCT00508287|Active Comparator|B|
11617754|NCT00508287|Placebo Comparator|C|
11617755|NCT00508274|Experimental|lapatinib in combination with capecitabine|daily oral lapatinib (1250 mg/day) in combination with capecitabine (2000mg/m2/day on days1-14 every 21 days)
11617756|NCT00508261|Experimental|Group A|Meningococcal vaccine GSK134612 co-administered with Infanrix hexa™
11617757|NCT00508261|Experimental|Group B|Meningococcal vaccine GSK134612 followed one month later by Infanrix hexa™
11617758|NCT00508261|Active Comparator|Group C|Infanrix hexa™ followed one month later by Meningococcal vaccine GSK134612
11617759|NCT00508261|Active Comparator|Group D|Meningitec™ vaccination
11617760|NCT00508248|Active Comparator|A1|1 g omega 3 fatty acid supplements
11617761|NCT00508248|Placebo Comparator|A2|
11617762|NCT00508235||Quality of Friendships|Patients with Neurofibromatosis, type 1 (NF-1) between the ages of 8 and 18 years old.
11617763|NCT00508183|Active Comparator|single row fixation|
11617764|NCT00508183|Active Comparator|double row fixation|
11617765|NCT00508170||Patients with Oropharyngeal Cancer|
11617766|NCT00508170||Patients with Non-Oropharyngeal Cancer|
11617767|NCT00508157|Experimental|A|
11617768|NCT00508157|Active Comparator|B|
11617769|NCT00508144|Experimental|Alimta|Alimta 500 mg/m^2 by vein Once Over 10 Minutes Every 3 Weeks.
11617770|NCT00508131|Active Comparator|A|Milk fortified with, iron, zinc and vitamin C
11617771|NCT00508131|Placebo Comparator|B|Milk not fortified
11617772|NCT00508118|Experimental|1|Nicardipine
11617773|NCT00508118|Placebo Comparator|2|0.9% saline
11617774|NCT00508105|Active Comparator|subscapularis peel|
11617775|NCT00508105|Active Comparator|osteotomy|
11617776|NCT00508092|Active Comparator|A|lanz incision appendectomy
11617777|NCT00508092|Active Comparator|B|lanz incision appendectomy
11617778|NCT00508066|Experimental|Arm 1|Subjects in arm 1 will intraoperatively have a continuous infusion catheter placed in the paraspinal musculature of the posterior spinal wound. Post-operatively, the catheter will infuse 0.25 - 0.5% (according to patient's weight) Bupivacaine at a rate of 4ml/hr for 72 hours. This is in addition to the standardized PCA pain management.
11617779|NCT00508066|Placebo Comparator|Arm 2|Subjects in arm 2 will intraoperatively have a continuous infusion catheter placed in the paraspinal musculature of the posterior spinal wound. Post-operatively, the catheter will infuse normal saline at a rate of 4ml/hr for 72 hours. This is in addition to the standardized PCA pain management.
11617780|NCT00508053|Active Comparator|1|Mass closure
11617781|NCT00508053|Experimental|2|Small stitches
11617782|NCT00508040|Experimental|A|To analyse the potential therapeutic effect of Interferon alpha2a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
11617783|NCT00508040|Active Comparator|B|
11617784|NCT00508027|Other|Simvastatin, Dose Escalation|There are no arms in this study. Simvastatin will be given in a dose-escalating fashion to 3 sequential dosage groups (20 mg/day, 40 mg/day, 80 mg/day).
11617785|NCT00508014|Active Comparator|Control|usual care
11617786|NCT00508014|Experimental|Concurrent Peer Review Visit|See description of interventioin
11617787|NCT00508001|Placebo Comparator|1|Best Supportive Care + Placebo
11617788|NCT00508001|Experimental|2|Best Supportive Care + ZD6474 100 mg
11617789|NCT00508001|Experimental|3|Best Supportive Care + ZD6474 300 mg
11617790|NCT00507988|Experimental|A|Complex Problem Solving Training
11617791|NCT00507988|Active Comparator|B|Basic Cognitive Training
11617865|NCT00507312|Active Comparator|1|Healthy subjects (with no evidence of cardiovascular disease).
11617866|NCT00507312|Experimental|2|Patients with risk factors for heart failure
11617792|NCT00507975|Placebo Comparator|A|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
11617793|NCT00507975|Experimental|B|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
11617794|NCT00507962|Experimental|Cisplatin + Liposomal Doxorubicin|Cisplatin 100 mg/m^2 Intraarterial and Liposomal Doxorubicin starting dose 20 mg/m^2 by vein on Day 1 every 4 weeks
11617795|NCT00507949|Experimental|1|Megestrol acetate: sachets of granulated 160 mg. Dose: 160 mg/b.i.d. Duration 8 weeks
11617796|NCT00507949|Placebo Comparator|2|The placebo is the excipient of the experimental drug.
11617797|NCT00507936|Experimental|A|ABT-894 1 mg BID
11617798|NCT00507936|Experimental|B|ABT-894 2 mg BID
11617799|NCT00507936|Experimental|C|ABT-894 4 mg BID
11617800|NCT00507936|Placebo Comparator|D|
11617801|NCT00507936|Active Comparator|E|Duloxetine 60 mg QD
11617802|NCT00507923|Experimental|Group I (Tibetan yoga)|Participants participate in Tibetan yoga sessions consisting of deep breathing or stretching exercises over 90 minutes for 4 sessions either once weekly or every 3 weeks. Participants also wear actigraph activity monitor and complete a sleep diary for 7 days. Participants receive instructional yoga audiotape and printed instructions to use at home upon completion of sessions.
11617803|NCT00507923|Active Comparator|Group II (stretching)|Participants participate in stretching exercise sessions over 90 minutes for 4 sessions either once weekly or every 3 weeks. Participants also wear actigraph activity monitor and complete a sleep diary for 7 days. Participants receive instructional yoga audiotape and printed instructions to use at home upon completion of sessions. Participants have the option to attend Tibetan yoga sessions upon completion of 12-month follow-up.
11617804|NCT00507923|Active Comparator|Group III (usual care)|Participants receive usual care and wear actigraph activity monitor and complete a sleep diary for 7 days. Participants have the option to attend Tibetan yoga sessions upon completion of 12-month follow-up.
11617805|NCT00507897||A|Cohort: Patients with normal blood pressure scheduled to have thyroid nodules surgically removed
11617806|NCT00507897||A1|Patients from group A not receiving any drugs and who lack other pathology, gender and age matched group B1
11617807|NCT00507897||B|Cohort: Patients with increased blood pressure scheduled to have thyroid nodules surgically removed
11617808|NCT00507897||B1|Patients from group B not receiving any drugs and who lack other pathology, gender and age matched group A1
11617809|NCT00507884||3 Tesla MRI|Patients with renal tumors scheduled to have a CT scan of the kidneys and abdomen.
11617810|NCT00507858|Experimental|Pemetrexed|Starting dose 500 mg/m^2 IV once every 3 weeks
11617811|NCT00507858|Experimental|Pemetrexed + IV Dexamethasone|Pemetrexed Starting dose 500 mg/m^2 IV once every 3 weeks + Dexamethasone 20 mg intravenous (IV) Day 1.
11617812|NCT00507858|Experimental|Pemetrexed + Oral Dexamethasone|Pemetrexed starting dose 500 mg/m^2 IV once every 3 weeks + Dexamethasone 4 mg orally twice daily for 3 Days.
11617813|NCT00507832|Active Comparator|I|"Interindividual design:
~active and comparator (one side each) applied twice daily"
11617814|NCT00507832|Active Comparator|II Hydrocortisone|Hydrocortisone, twice daily
11617815|NCT00507819|Active Comparator|Sildenafil, then Placebo|Sildenafil will be given at a dose of 20 mg three times-a-day for six weeks followed by a six week washout period followed by placebo for an additional six weeks.
11617816|NCT00507819|Active Comparator|Placebo, then Sildenafil|Placebo will be given for six weeks followed by a six week washout period followed by Sildenafil which will be given at a dose of 20 mg three times-a-day for six weeks
11617817|NCT00507767|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO or via PEG tube BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11617818|NCT00507754||Latent Tuberculosis Infection|Patients with cancer at risk for developing active tuberculosis (TB).
11617819|NCT00507741|Experimental|Ertafolide + Vintafolide|Screening: After completion of all screening procedures and confirmation of eligibility, all participants receive a 1- to 2-mL injection of 0.1 mg ertafolide labeled with 20 to 25 mCi of technetium-99m Part A: Induction phase of treatment: Two 4-week cycles; if stable disease or better at week 8 computed tomography (CT), participant may proceed into maintenance phase, comprised of 4-week cycles with CT every 8 weeks. Participants continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit. Part B: 4-week cycles with CT every 8 weeks. Participants continue until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit.
11617820|NCT00507728|Experimental|Bupropion|Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).
11617821|NCT00507728|Experimental|Varenicline|Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).
11617822|NCT00507728|Placebo Comparator|Placebo|Placebo by mouth for 12 weeks.
11617823|NCT00507715|Experimental|1|Plantago ovata husk
11617824|NCT00507715|Placebo Comparator|2|hemicellulose crystalline
11617825|NCT00507689|Experimental|FTC/TDF+HBIg|Participants received FTC/TDF+HBIg for up to 24 weeks in the pre-randomization period; those who completed 24 weeks of treatment were then randomized to receive FTC/TDF+HBIg in the randomized period.
11617826|NCT00507689|Experimental|FTC/TDF|Participants received FTC/TDF+HBIg for up to 24 weeks in the pre-randomization period; those who completed 24 weeks of treatment were then randomized to receive FTC/TDF in the randomized period.
11617867|NCT00507312|Experimental|3|Patients with heart failure
11617868|NCT00507299|Experimental|Model Care (SEEK)|Residents in this group received special training on addressing pyschosocial problems. They then used a parent screening questionnaire, and addressed identified problems. A study social worker was also part of this intervention. Thus, this group provided enhanced pediatric primary care.
11617926|NCT00506779|Experimental|Phase I: Paclitaxel + Imatinib Mesylate|Phase I MTD using oral dose Imatinib Mesylate escalation 400, 500, 600 mg daily; Paclitaxel 175 mg/m^2 every 21 days
11646992|NCT00123279|Experimental|3|
11617827|NCT00507676||Group 1|One hundred and sixty healthy infants between 1 and 24 months of age will be evaluated. Subjects will be recruited so that there are 40 subjects within each of four subgroups: 1) Negative ETS exposure and Negative Fm Asthma, 2) Positive ETS exposure and Negative Fm Asthma, 3) Negative ETS exposure and Positive Fm Asthma and 4) Positive ETS exposure and Positive Fm Asthma. Equal numbers of males and females will be recruited. The ethnic composition will be approximately 80% Caucasian and 20% African-American in each of the four groups, which represents the distribution within the cities where infants will be evaluated. Subjects will be excluded if they were born prematurely (<37 weeks gestation), have a history of congenital cardio-respiratory disease, or have history of lower respiratory illness.
11617828|NCT00507676||Group 2|Eighty infants between 1 and 24 months of age scheduled for CT scans of the abdomen or chest will be evaluated. Subjects will be excluded if they are born prematurely (<37 weeks gestation), have history of congenital cardio-respiratory disease, or have history of recurrent wheezing.
11617829|NCT00507676||Group 3|Eighty infants with recurrent wheezing between 1 and 24 months of age will be evaluated when they are not acutely symptomatic for at least 3 weeks. Subjects will be recruited so that there are 20 subjects within each of four subgroups: 1) Negative ETS exposure and Negative Fm Asthma, 2) Positive ETS exposure and Negative Fm Asthma, 3) Negative ETS exposure and Positive Fm Asthma and 4) Positive ETS exposure and Positive Fm Asthma. Equal numbers of males and females will be recruited. Subjects will be excluded if they were born prematurely (<37 weeks gestation) or have history of congenital cardio -respiratory disease.
11617830|NCT00507663|Experimental|Atenolol|Atenolol given prior to and for up to 7 days after surgery
11617831|NCT00507663|No Intervention|routine care|routine clinical care
11617832|NCT00507650|Active Comparator|Prescribed|Fluid volume and type prescribed by MD or provider.
11617833|NCT00507650|Experimental|Supplemental|Fluid volume and type prescribed by physician or provider plus 10 ml/kg X 5 days.
11617834|NCT00507637|Experimental|NT 201 (IncobotulinumtoxinA/Xeomin®)|
11617835|NCT00507611|Other|Single-arm|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
11617836|NCT00507585|Experimental|Oxaliplatin + Fluorouracil + Leucovorin + Avastin|
11617837|NCT00507572||Observational (medical chart review)|Patients' medical records are reviewed prospectively and retrospectively.
11617838|NCT00507559|Experimental|AAA Repair System|
11617839|NCT00507546|Experimental|Ramelteon then placebo|8 mg nightly ramelteon for three weeks, followed by two weeks of nightly placebo (washout), then three weeks of nightly placebo (cross-over)
11617840|NCT00507546|Experimental|Placebo then ramelteon|placebo nightly for three weeks, followed by two weeks of nightly placebo (washout), then three weeks of 8 mg nightly ramelteon (cross-over)
11617841|NCT00507507|Experimental|Tenofovir DF|Participants were randomized to receive tenofovir DF plus placebo to match FTC once daily.
11617842|NCT00507507|Experimental|FTC+Tenofovir DF|Participants were randomized to receive FTC plus tenofovir DF once daily.
11617843|NCT00507455|Placebo Comparator|Placebo|Participants received once daily, oral doses of placebo matching solifenacin succinate and tamsulosin tablets for 12 weeks.
11617844|NCT00507455|Experimental|6 mg Solifenacin + 0.4 mg Tamsulosin|Participants received once daily, oral doses of 6 mg solifenacin succinate and 0.4 mg tamsulosin tablets for 12 weeks.
11617845|NCT00507455|Experimental|9 mg Solifenacin + 0.4 mg Tamsulosin|Participants received once daily, oral doses of 9 mg solifenacin succinate and 0.4 mg tamsulosin tablets for 12 weeks.
11617846|NCT00507442|Experimental|VDR|VELCADE (bortezomib), dexamethasone, and Revlimid (lenalidomide)
11617847|NCT00507442|Experimental|VDCR|VELCADE (bortezomib), dexamethasone, cyclophosphamide, Revlimid (lenalidomide)
11617848|NCT00507442|Experimental|VDC|VELCADE (bortezomib), dexamethasone, cyclophosphamide
11617849|NCT00507442|Experimental|VDC-mod|Modified dosing of VELCADE (bortezomib), dexamethasone, cyclophosphamide
11617850|NCT00507429|Experimental|Arm 1: CA4P + Carboplatin + paclitaxel|Six 21-day cycles: CA4P (60 mg/m2 on Days 1, 8, 15), carboplatin (AUC 6) + paclitaxel (200 mg/m2) on Day 2
11617851|NCT00507429|Active Comparator|Arm 2: Carboplatin + Paclitaxel|Six 21-day cycles of Carboplatin (AUC 6) + paclitaxel (200 mg/m2) given on Day 1
11617852|NCT00507416|Experimental|Bortezomib and Dexamethasone (VD)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
11617853|NCT00507416|Experimental|Bortezomib, Thalidomide, and Dexamethasone (VTD)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance) .
11617854|NCT00507416|Experimental|Bortezomib, Melphalan and Prednisone (VMP)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
11617855|NCT00507403|Active Comparator|Infliximab|Infliximab
11617856|NCT00507403|Experimental|Infliximab +methotrexate|Infliximab +methotrexate
11617857|NCT00507390|Active Comparator|A1|n-3 PUFAs
11617858|NCT00507390|Placebo Comparator|A2|olive oil capsules
11617859|NCT00507351||Cancer Pain Management|Patients receiving chemotherapy for breast, colon, lung, or prostate cancer.
11617860|NCT00507338|Experimental|ARC1779 low dose|0.1 mg/kg
11617861|NCT00507338|Experimental|ARC1779 mid dose|0.3 mg/kg
11617862|NCT00507338|Experimental|ARC1779 high dose|1.0 mg/kg
11617863|NCT00507338|Active Comparator|abciximab|labeled regimen for primary PCI
11617925|NCT00506792|Placebo Comparator|2|Placebo
11617869|NCT00507299|Active Comparator|Standard pediatric primary care|This arm involved residents receiving the regular education through the program. They did not use the screening questionnaire to identify psychosocial problems, and did not have a dedicated social worker to assist them. Instead, residents in this group provided standard pediatric primary care
11617870|NCT00507273||GIST|Patients diagnosed with a gastrointestinal stromal tumor (GIST)
11617871|NCT00507260|Experimental|Control Group|Control Group (Food Record)
11617872|NCT00507260|Experimental|Treatment Group|Treatment Group (Food Record + Nutritional Consults)
11617873|NCT00507247|Experimental|Daptomycin|6mg/kg/day intravenous (IV) for 10 days
11617874|NCT00507221|Experimental|1|Arm 1 will receive an intensive regimen of anti-helminthic therapy consisting of albendazole every three months for two years and praziquantel at enrollment and at one year of follow up.
11617875|NCT00507221|Active Comparator|2|Arm 2 will receive symptomatic diagnosis and treatment of helminth infection as is current standard of care in Kenya.
11617876|NCT00507208|Experimental|Dynasplint|Participants randomized to this arm will be treated with the Dynasplint Trismus System
11617877|NCT00507208|Active Comparator|Control|Participants randomized to this arm will use tongue depressors for 3 months and if there is no improvement in their mouth opening at this timepoint, they will crossover to the Dynasplint Trismus System
11617878|NCT00507182|Experimental|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
11617879|NCT00507156|Experimental|Mek postcon|Re-opening of the infarcted coronary artery by several balloon inflations separated by reperfusion of the vessel.
11617880|NCT00507156|Active Comparator|Standard treatment|Standard treatment (primary PCI)
11617881|NCT00507130|Experimental|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
11617882|NCT00507130|Experimental|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
11617883|NCT00507130|Experimental|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
11617884|NCT00507130|Placebo Comparator|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
11617885|NCT00507117|Active Comparator|PSG|
11617886|NCT00507091|Experimental|ZD6474 (vandetanib) 100mg|
11617887|NCT00507091|Experimental|ZD6474 (vandetanib) 300mg|
11617888|NCT00507065|Experimental|Adderall XR (10 mg)|
11617889|NCT00507065|Experimental|Adderall XR (20 mg)|
11617890|NCT00507065|Experimental|Adderall XR (30 mg)|
11617891|NCT00507065|Experimental|Adderall XR (40 mg)|
11617892|NCT00507065|Placebo Comparator|placebo|
11617893|NCT00507039||grass allergy, bronchial challenge|subjects with known allergy against grass-pollen undergo bronchial challenges
11617894|NCT00507026|Experimental|A|DIC075V (IV diclofenac)
11617895|NCT00507026|Active Comparator|B|IV Ketorolac
11617896|NCT00507026|Placebo Comparator|C|Placebo
11617897|NCT00507013|Other|2|
11617898|NCT00507000|Active Comparator|A, Cholecalciferol|A Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
11617899|NCT00507000|Placebo Comparator|Vitamin D and Tuberculosis|B, Lactose
11617900|NCT00506987|Experimental|SCH 486757|
11617901|NCT00506987|Placebo Comparator|Placebo|
11617902|NCT00506961|Active Comparator|1|10 mg rosuvastatin for 4 weeks followed by 20 m rosuvastatin for another 8 weeks
11617903|NCT00506961|Active Comparator|2|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
11617904|NCT00506948|Experimental|Thymoglobulin + Sirolimus + MMF|Thymoglobulin 1.5 mg/kg intravenous (IV) days -4, -3, -2, -1 before Stem Cell Transplant (Day 0); Sirolimus 6 mg IV on day -2 followed by 2 mg daily to maintain therapeutic levels and Mycophenolate Mofetil (MMF) 15 mg/kg IV or orally every 12 hours starting on day 0 until day+27.
11617905|NCT00506935|Experimental|1|GVG
11617906|NCT00506935|Placebo Comparator|2|placebo
11617907|NCT00506922|Experimental|No Pentostatin|Group 1: No Pentostatin
11617908|NCT00506922|Experimental|Pentostatin 0.5|Group 2: Pentostatin 0.5 mg/m^2
11617909|NCT00506922|Experimental|Pentostatin 1|Group 3: Pentostatin 1 mg/m^2
11617910|NCT00506922|Experimental|Pentostatin 1.5|Group 4: Pentostatin 1.5 mg/m^2
11617911|NCT00506922|Experimental|Pentostatin 2|Group 5: Pentostatin 2 mg/m^2
11617912|NCT00506909|Experimental|Group 1|Group 1: 20 IU BID for the first week, 40IU BID for the following two weeks, 1 week washout, 3 week placebo trial.
11617913|NCT00506909|Experimental|Group 2|Group 2: 3 week placebo trial, 1 week washout, 20 IU BID for the first week, 40IU BID for the following two weeks.
11617914|NCT00506896|Active Comparator|1|
11617915|NCT00506883|Experimental|High Dose Colchicine|After confirmation of a gout flare, patients were to begin standard dosing of colchicine 4.8mg (two capsules (1.8mg) initially followed by additional one capsule doses (0.6mg) every hour for an additional 6 doses).
11617916|NCT00506883|Experimental|Low Dose Colchicine|Within 12 hours of a confirmed gout flare, patients were to begin the low dose colchicine regimen consisting of a total dose of 1.8 mg - two colchicine capsules initially (1.2 mg)followed an hour later by a single additional capsule of active drug(0.6 mg)then by 5 additional hourly doses of an identical looking placebo capsules
11617917|NCT00506883|Placebo Comparator|Placebo|
11617918|NCT00506870|No Intervention|1|Conventional follow-up of anticoagulation
11617919|NCT00506870|Experimental|2|Self-monitoring of anticoagulation
11617920|NCT00506857|Experimental|Busulfan + Fludarabine|Busulfan starting 0.8 mg/kg by vein (IV) every 6 hours for 12 doses; Fludarabine 30 mg/m^2 IV daily for 4 days.
11617921|NCT00506831|Experimental|Imatinib mesylate|100 mg daily and increase by 100mg daily every 2 weeks to a maximum of 400 mg daily as tolerated
11617922|NCT00506818|Active Comparator|2|Intensive risk factor intervention
11617923|NCT00506805|Experimental|Single Arm|
11617924|NCT00506792|Experimental|1|QAU145
11617927|NCT00506779|Experimental|Phase II: Paclitaxel Alone or Pacliataxel + Imatinib Mesylate|"Intended randomization of Paclitaxel alone or Paclitaxel + Imatinib Mesylate; the study was terminated early due to poor enrollment and all patients are no longer being treated or followed. Single treatment arm MTD using oral dose Imatinib Mesylate escalation = 500 mg daily; Paclitaxel 175 mg/m^2 every 21 days
~Phase II, (Arm 1) = Paclitaxel 175 mg/m^2 every 21 days Phase II, (Arm 2) Paclitaxel 175 mg/m^2 every 21 days+ Imatinib Mesylate MTD using oral dose Imatinib Mesylate escalation = 500 mg daily"
11617928|NCT00506753|Experimental|MI/CBT|Motivational Interviewing followed by Cognitive Behavior Therapy
11617929|NCT00506753|Experimental|RT/TU|Relaxation Training followed by Treatment as Usual
11617930|NCT00506740|Active Comparator|Electrocautery|Elesurgical instruments are used to cut and coagulate tissue using alternatig electric current focusing intense heat at the surgical site. In electrosurgery, the patient is included in the circuit and current enters the patient's body.
11617931|NCT00506727|Experimental|Adderall XR|
11617932|NCT00506727|Active Comparator|Atomoxetine hydrochloride|
11617933|NCT00506714|Experimental|Adult subjects with hip osteoarthritis|Walk with and without a single point cane at baseline and after four weeks
11617934|NCT00506714|No Intervention|Healthy Subjects|Healthy adults walking without a cane at baseline
11617935|NCT00506701|Experimental|Tadalafil treatment 40 mg|
11617936|NCT00506675|Active Comparator|Intensive|42 hours per week of patching combined with atropine (1%) once daily in the sound eye, with spectacle correction (if needed)
11617937|NCT00506675|Active Comparator|Weaning|For patients currently patching, reduce patching to two hours daily for four weeks, then no treatment thereafter except spectacle correction (if needed). For patients currently using atropine, reduce atropine to once weekly for 4 weeks, then no treatment thereafter except spectacle correction (if needed)
11617938|NCT00506662|Experimental|Insulin detemir|Individually adjusted dose of insulin detemir once daily
11617939|NCT00506662|Active Comparator|Insulin NPH|Individually adjusted dose of insulin NPH once daily
11617940|NCT00506597|Experimental|Erwinase|6 doses of 25,000 Units/m^2 Erwinase® intramuscular/subcutaneously every other day to replace each dose of Pegylated Asparaginase
11617941|NCT00506584|Experimental|Group 1, arm 1|Human breast milk + Prolact20/Neo20 (as needed) + Prolact+4 (initiated when nutrition volume reaches 100 mL/kg/day, where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
11617942|NCT00506584|Experimental|Group1, Arm 2|Human breast milk + Prolact20/Neo20 (as needed) + Prolact+4 (initiated when nutrition volume reaches 40 mL/kg/day), where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
11617943|NCT00506584|Active Comparator|Group 1, Arm 3|Human breast milk + bovine-based human milk fortifier (initiated when nutrition volume reaches 100 mL/kg/day) + pre-term formula (as needed)
11617944|NCT00506584|Experimental|Group 2, Arm 1|Prolact20/Neo20 + Prolact+4 (initiated when nutrition volume reaches 100 mL/kg/day), where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
11617945|NCT00506584|Active Comparator|Group 2, Arm 2|Pre-term/term formula (minimum 20 cal/oz)
11617946|NCT00506558|Experimental|A|Ventral Decompression and Instrumented Fusion
11617947|NCT00506558|Active Comparator|B|Dorsal Decompression with or without fusion
11617948|NCT00506545|Experimental|SCH 619734|
11617949|NCT00506545|Placebo Comparator|Placebo|
11617950|NCT00506506|Experimental|1|N-acetylcysteine 1200 mg twice daily x 48 hours
11617951|NCT00506506|Placebo Comparator|2|
11617952|NCT00506480|Experimental|OD|patients artificially prepared for OD will undergo a mock cycle consisting of estrogen and later by progesterone. a pipelle sample will be taken after 6 days of progesterone supplementation.
11617953|NCT00506480|Experimental|IVF|A pipelle sample will be taken on day 21 of the cycle before administration of GNRHa. Exact timing will be performed by counting 7 days from the LH surge.
11617954|NCT00506467||VRI System|Vibration Response Imaging (VRI) System
11617955|NCT00506454|Active Comparator|Lipidose|Dosage of 1.5 mL/kg of Lipidose over a 2-hour period.
11617956|NCT00506454|Placebo Comparator|Placebo|Dosage of 1.5 mL/kg of Placebo over a 2-hour period.
11617957|NCT00506441|Experimental|1|
11617958|NCT00506441|Placebo Comparator|2|
11617959|NCT00506415|Experimental|Open label: Rivastigmine (5 cm^2 / 10 cm^2)|Rivastigmine 5 cm^2 transdermal patch once a day during the first 4 weeks of open label treatment followed by rivastigmine 10 cm^2 transdermal patch once a day from week 4 to week 24, 36 or 48.
11617960|NCT00506415|Experimental|Double blind: Rivastigmine (10 cm^2)|Rivastigmine transdermal patch 10 cm^2 and placebo to rivastigmine 15 cm^2 once daily for 48 weeks during the double blind period.
11617961|NCT00506415|Experimental|Double blind: Rivastigmine (15 cm^2)|Rivastigmine transdermal patch 15 cm^2 and placebo to rivastigmine 10 cm^2 once daily for 48 weeks during double blind period.
11617962|NCT00506415|Experimental|Extended open label Rivastigmine (10 cm^2)|Rivastigmine 10 cm^2 transdermal patch once a day during 48 weeks open label treatment running in parallel to the double blind period.
11617963|NCT00506402|Experimental|1|
11617964|NCT00506389|Experimental|Esmirtazapine 3.0 mg|Participants took placebo tablets on Days -7 and -6, esmirtazapine 3.0 mg tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
11617965|NCT00506389|Experimental|Esmirtazapine 4.5 mg|Participants took placebo tablets on Days -7 and -6, esmirtazapine 4.5 mg tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
11617966|NCT00506389|Placebo Comparator|Placebo|Participants took placebo tablets on Days -7 and -6, placebo tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
11617967|NCT00506376||Surgical Treatment Preferences|Assessment of patient's feelings toward risks associated with surgical treatment of cervical cancer.
11617968|NCT00506363|Experimental|A|pulsed dye laser and dynamic cooling device on the day of suture removal
11617969|NCT00506363|Active Comparator|B|pulsed dye laser and dynamic cooling device 2 months after suture removal
11617971|NCT00506350|Experimental|GSK1562902A non-AD F1 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
11617972|NCT00506350|Experimental|GSK1562902A non-AD F2 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
11617973|NCT00506350|Experimental|GSK1562902A non-AD F3 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
11617974|NCT00506350|Experimental|GSK1562902A non-AD F4 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
11617975|NCT00506350|Experimental|GSK1562902A AD F1 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
11617976|NCT00506350|Experimental|GSK1562902A AD F2 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
11617977|NCT00506350|Experimental|GSK1562902A AD F3 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
11617978|NCT00506350|Experimental|GSK1562902A AD Approved F4 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
11617979|NCT00506350|Experimental|Control Group|Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
11617980|NCT00506311|Experimental|Fibrin Sealant|
11617981|NCT00506311|No Intervention|No Fibrin Sealant|
11617982|NCT00506298|Experimental|A|CRx-401 (bezafibrate + diflunisal)
11617983|NCT00506298|Active Comparator|B|bezafibrate + placebo
11617984|NCT00506285|Experimental|A|This arm was 4 weeks long. Subjects were treated using Methylphenidate Transdermal System. Patients were seen weekly, phone contact was made between visits and dosing could be adjusted as a result of the phone contact. MTS was initiated using a 12.5 cm patch. The dose was increased during the first 2 weeks based on treatment response and side effects to the largest tolerated dose/patch size. It was held steady the last 2 weeks.
11617985|NCT00506285|Placebo Comparator|B|This arm was 4 weeks long. Placebo patch was initiated using a 12.5 cm patch and then increased to the largest tolerated patch size during the first 2 weeks and held steady the last two weeks. Subjects were seen weekly, phone contact was made between visits and dosing could be adjusted as a result of the phone visit.
11617986|NCT00506272|Experimental|Standard care|Patients admitted for elective surgery will receive standard diabetes care, including but not limited to finger stick blood glucose determinations, and insulin injections delivered by the nursing staff.
11617987|NCT00506272|Experimental|Patient administered care|Patients will self-monitor and record finger-stick blood glucose measurements, and self administer insulin at doses agreed upon with the consulting endocrinology in-patient service.
11617988|NCT00506246|Experimental|1|Propofol MCT/LCT
11617989|NCT00506246|Active Comparator|2|Propofol LCT
11617990|NCT00506233||Chronic Graft-Versus Host Disease (GvHD)|Participants with chronic graft-versus host disease (GvHD)
11617991|NCT00506194|Experimental|Insulin|Insulin therapy was initiated at a 75% total daily dose in the last day hospitalization with Insulatard. Two third of daily dose was administered before breakfast and the other was administered at bedtime. Insulin doses were titrated every 3 days to achieve target FPG and pre-supper blood glucose values between 90 and 130 mg/dl. Bedtime insulin doses were titrated based on FPG values and the pre-breakfast dose was titrated base on pre-supper blood glucose.
11617992|NCT00506194|Active Comparator|OAD|Subject in other OAD group was visited every two weeks in the two months and the every four weeks. The subjects will start with Gliclazide-MR 30mg before breakfast, The dosage was titrated based on the fasting blood glucose on the visiting day with the same target. Decreased by 30mg if blood glucose was <70mg /dl, decreased by 15 mg if blood glucose was 70-90mg/dl, no change if blood glucose was 90-130mg/dl, increased by 15 mg if blood glucose was 131-160 mg/dl, increased by 30 mg if blood glucose >160mg/dl. When the Gliclazide-MR dose each to the maximum dose of 60 mg twice daily, Metformin was added. The titration of Metformin was use 250mg for an adjust dosage with the same target.
11617993|NCT00506181|Active Comparator|X|receiving probiotics
11617994|NCT00506181|Placebo Comparator|Y|
11617995|NCT00506181|No Intervention|Z|
11618047|NCT00505713|Experimental|1|Dose Level 1 of escalating doses of Rexin-G i.v.
11617996|NCT00506155|Experimental|Neoadjuvant Chemotherapy with M-VAC + Avastin|Avastin 10 mg/kg by vein over 90 minutes. Cisplatin 70 mg/m^2 by vein over 4 hours. Doxorubicin 30 mg/m^2 by vein over 15 minutes. Methotrexate 30 mg/m^2 by vein over 30 minutes. Vinblastine Sulfate 3 mg/m^2 by vein over 30 minutes.
11617997|NCT00506142|Experimental|Cohort 1|Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.
11617998|NCT00506142|Experimental|Cohort 2|Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week.
11617999|NCT00506129|Experimental|Fludarabine + Melphalan with PBPC|Fludarabine 25 mg/m^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant. Melphalan 70 mg/m^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant. Allogeneic transplant given by vein after completion of Fludarabine and Melphalan. Thymoglobulin 2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
11618000|NCT00506090|Experimental|A|pulsed dye laser and dynamic cooling device at 3 weeks intervals
11618001|NCT00506090|Active Comparator|B|pulsed dye laser and dynamic cooling device at 6 weeks intervals
11618002|NCT00506090|Sham Comparator|C|dynamic cooling device
11618003|NCT00506077|Experimental|MK0249|
11618004|NCT00506077|Placebo Comparator|Placebo|
11618005|NCT00506064|Experimental|Melatonin|0.15 mg/kg capsules by mouth daily
11618006|NCT00506064|Placebo Comparator|Placebo|Starch capsules by mouth daily
11618007|NCT00506051|Experimental|ZD6474 (vandetanib) 100mg|
11618008|NCT00506051|Experimental|ZD6474 (vandetanib) 300mg|
11618009|NCT00506025|Active Comparator|Cranberry 2xday|Cranberry juice (C) two times daily, a.m. and p.m.
11618010|NCT00506025|Active Comparator|Cranberry + Placebo|De-Activated Cranberry juice in the am, then placebo (P) in the pm
11618011|NCT00506025|Placebo Comparator|Placebo 2xday|Placebo in the form of juice two times daily in the a.m. and p.m.
11618012|NCT00506012|Experimental|1|T2000
11618013|NCT00505999||Questionnaire|Patients diagnosed with Multiple Myeloma and healthy controls.
11618014|NCT00505960|Experimental|1|
11618015|NCT00505947|Active Comparator|A|"Infliximab 5 mg/Kg body weight by intravenous infusion on visit 1 (week 0), visit 2 (week 2), visit 3 (week 6)and visit 5 (week 14).
~Afterwards, after a washout period of 2 weeks, arm A will receive placebo at visits 6 (week 16), visit 7 (week 18), visit 8 (week 22)and visit 30 (week 30)"
11618016|NCT00505947|Placebo Comparator|B|"Arm B will receive placebo at visit 1 (week 0), visit 2 (week 2), visit 3 (week 6)and visit 5 (week 14).
~Afterwards, after a washout period of 2 weeks, group B will receive infliximab 5 mg/Kg body weight by intravenous infusion at visit 6 (week 16), visit 7 (week 18), visit 8 (week 22)and visit 30 (week 30)"
11618017|NCT00505934|Experimental|Levetiracetam|
11618018|NCT00505921|Experimental|Campath-1H|"3 mg in vivo Day 1; 10 mg Day 2; 30 mg Days 3 and 10 of chemotherapy treatment. Transplantation on Day 0.
~Preparative Regimen For Autologous Stem Cell Transplantation: BEAM (BCNU 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice on day -5 to -2 (total 8 doses), and Melphalan 140 mg/m2 IV on day -1. Beginning on day +5 G-CSF 10 mg/kg sc (in a.m.) and GM-SCF 250 m/m2 on Day +5 (in p.m.)
~Preparative Regimen For Allogenic Stem Cell Transplantation: Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy day 0."
11618019|NCT00505895|Experimental|Fludarabine + Melphalan + Stem Cell Infusion|"Fludarabine 30 mg/m^2 intravenous (IV) daily over 30 minutes for 4 Days (Beginning Day -4).
~Melphalan 140 mg/m^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m^2 IV infused starting on day -5."
11618020|NCT00505895|Experimental|Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion|"Fludarabine 30 mg/m^2 intravenous daily over 30 minutes for 4 Days (Beginning Day -4).
~Lower-Dose Melphalan 100 mg/m^2 intravenous over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m^2 intravenous infused starting on day -5."
11618021|NCT00505882|Active Comparator|Insulin|
11618022|NCT00505882|Experimental|Pramlintide|
11618023|NCT00505869||1|Health & Wellness Intervention + Questionnaire
11618024|NCT00505869||2|Mood Management Intervention + Questionnaire
11618025|NCT00505843|Other|1|7mg MK0657 capsules + >/=1.0 mg/kg/hr dose of levodopa.
11618026|NCT00505843|Other|2|7mg MK0657 Pbo capsules + >/=1.0 mg/kg/hr dose of levodopa.
11618027|NCT00505830||1|50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ >85.
11618028|NCT00505830||2|50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70<IQ<84.
11618029|NCT00505830||3|50 adolescents with psychiatric disorders but no autism syndrom.
11618030|NCT00505830||4|Sample of 50 healthy adolescents selected randomly from 200.
11618031|NCT00505804|Experimental|1|
11618032|NCT00505804|Active Comparator|2|
11618033|NCT00505791|Placebo Comparator|Sugar pill|Lactose, NF (monohydrate)
11618034|NCT00505791|Active Comparator|Nesiritide|Natrecor (nesiritide) is a commercially available B-type natriuretic peptide which is indicated for intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.
11618035|NCT00505778|Active Comparator|Mesalamine (Asacol) Once-Daily|an oral, once daily (QD) mesalamine regimen (1.6 - 2.4 g/day)
11618036|NCT00505778|Active Comparator|Mesalamine (Asacol) Twice-Daily|an oral, twice daily (BID) mesalamine regimen (1.6 - 2.4 g/day)
11618037|NCT00505765|Experimental|AL-108, 30 mg/day|AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
11618038|NCT00505765|Experimental|AL-108, 5 mg/day|AL-108, 5 mg/day- one spray in each nostril once per day
11618039|NCT00505765|Placebo Comparator|Placebo, 3 sprays BID|Placebo- 3 sprays in each nostril, twice per day
11618040|NCT00505765|Placebo Comparator|Placebo, 1 Spray Daily|Placebo- one spray in each nostril, once per day
11618041|NCT00505752|Experimental|AS900672-Enriched 50 mcg|
11618042|NCT00505752|Experimental|AS900672-Enriched 100 mcg|
11618043|NCT00505752|Experimental|AS900672-Enriched 150 mcg|
11618044|NCT00505752|Active Comparator|Follitropin alfa 150 IU|
11618045|NCT00505739|Experimental|Mifepristone|
11618046|NCT00505726||Confocal Microscopy|
11618048|NCT00505713|Experimental|3|Dose Level 3 of escalating doses of Rexin-G i.v.
11618049|NCT00505713|Experimental|4|Dose Level 4 of escalating doses of Rexin-G i.v.
11618050|NCT00505713|Experimental|5|Dose Level 5 of escalating doses of Rexin-G i.v.
11618051|NCT00505713|Experimental|2|Dose Level 2 of escalating doses of Rexin-G i.v.
11618052|NCT00505687|Experimental|Rotigotine|Rotigotine
11618053|NCT00505661|Experimental|Letrozole|2.5 mg by mouth (PO) daily
11618054|NCT00505635|Experimental|Biochemotherapy with Temozolomide|Temozolomide 250 mg/m^2 every 4 hours Day 1; Biochemotherapy of Velban 1.5 mg/m^2 intravenous (IV) Days 1-4; Cisplatin 20 mg/m^2 IV Days 1-4; + Interleukin-2 9 MIU/m^2 IV over 24 Hours for 4 Doses Days 1-4; Intron-A 5 mu/m^2 subcutaneously daily Days 1-5; + Oral Thalidomide 400 mg daily.
11618055|NCT00505622|Experimental|E2007|E2007 2 mg (one 2 mg tablet taken daily in the evening), or 4 mg (two 2 mg tablets daily in the evening).
11618056|NCT00505609|Experimental|A|The Institute for Reproductive Health trained health providers in teaching the Standard Days Method to study subjects and in study procedures. Providers counseled study participants in method use. Participants were followed for up to 13 cycles of method use.
11618057|NCT00505596|Experimental|Computerized decision aid|Participants instructed to view the updated PT Tool and told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study (Informed free choice). They also participate in a baseline pre-randomization interview and one follow-up telephone interview.
11618058|NCT00505596|No Intervention|Usual care|Control group, in which participants receive no intervention beyond a baseline pre-randomization interview and one follow-up telephone interview.
11618059|NCT00505570|No Intervention|Medical Management|
11618060|NCT00505570|Experimental|PFO Closure|
11618061|NCT00505544||Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
11618062|NCT00505544||Questionnaire + Actigraphs|Questionnaires that ask about your sleep, symptoms, and mood. Wear actigraph to collect information on activity levels and sleep patterns for one week.
11618063|NCT00505531||Tramadol ER- 200mg|Tramadol Extended Release capsules Weeks 1 & 6- 100 mg/day Weeks 2-5- 200 mg/day
11618064|NCT00505531||Tramadol ER- 300mg|Tramadol Extended Release capsules Weeks 1 & 7- 100 mg/day Weeks 2 & 6- 200 mg/day Weeks 3-5- 300 mg/day
11618065|NCT00505531||Placebo|Diphenhydramine capsules Weeks 1-6- 25 mg/day
11618066|NCT00505505|Experimental|A|Insulin infusion rate titrated to maintain glycemia between 80 and 100 mg/dl
11618067|NCT00505505|Active Comparator|B|Insulin infusion rate titrated to maintain glycemia between 80 and 220 mg/dl
11618068|NCT00505492|Experimental|Radiation + Chemotherapy|Radiation with weekly Cisplatin 40 mg/m^2 intravenously (IV) Followed by Carboplatin (AUC 5 IV)/Paclitaxel (135 mg/m^2 IV) Chemotherapy every 28 days
11618069|NCT00505466||Pre-Test Genetic Counseling + Genetic Sample|
11618070|NCT00505440|Experimental|Computerized screening and referral|Computerized screening and referral: Intervention is a web-based screening and assessment tool completed by adolescents during primary care visits. Patient reported screening provided to primary care physicians in real time with recommendations for behavioral referrals.
11618071|NCT00505440|Active Comparator|Delayed feedback from screening|Active comparator is Usual pediatric care plus mailed screening results from computerized waiting room screens that arrive three days after screening.
11618072|NCT00505414|Placebo Comparator|Matching Placebo|Oral Tapentadol 100 mg to 250 mg twice daily. Followed by matching placebo in the maintenance (i.e. randomized withdrawal phase).
11618073|NCT00505414|Active Comparator|Morphine Controlled Release|Oral Morphine 45 mg to 90 mg twice daily.
11618074|NCT00505414|Experimental|Tapentadol Extended Release|Oral Tapentadol 100 mg to 250 mg twice daily.
11618075|NCT00505401|Other|A|Subjects were immunized subcutaneously with Tat, 3 dosage groups (7.5, 15 or 30 microgrammi), in association with Alum as adjuvant, or with Saline + Alum, as placebo.
11618076|NCT00505401|Other|B|Subjects were immunized intradermally with Tat, 3 dosage groups (7.5, 15 or 30 microgrammi), or with Saline, as placebo.
11618077|NCT00505375|Experimental|1|Intravenous infusions of CTLA-4 Ig
11618078|NCT00505375|Placebo Comparator|2|Intravenous infusions of placebo
11618079|NCT00505362|Active Comparator|Rectus muscle closure|Two-layer uterine closure, peritoneal closure, fascial and skin closure and reapproximation of the rectus muscles with three-interrupted sutures.
11618080|NCT00505362|No Intervention|Rectus muscle non-closure|Two-layer uterine closure, peritoneal closure, fascial and skin closure, and rectus muscles non-closure.
11618081|NCT00505349|No Intervention|No Intervention Arm|Phase I in this study will involve the evaluation of blood-derived neurotrophic factors in healthy, younger adults (18-30.) Individuals in this group will not undergo computerized, cognitive training.
11618082|NCT00505349|Experimental|Cognitive Training|Phase II of this study will involve an evaluation of the pre- and post- cognitive training levels of blood-derived neurotrophic factors in healthy, mature adults. Participants randomized to this arm will receive SAAGE-based computerized cognitive training.
11618083|NCT00505336|Experimental|1|Eplerenone
11618084|NCT00505336|Active Comparator|3|no additional treatment
11618085|NCT00505336|Experimental|2|Atorvastatin
11618086|NCT00505310|Experimental|Emotional Expression Writing|20 minutes of writing on different topics at four different times. Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
11618087|NCT00505310|Experimental|Neutral Writing|20 minutes of writing on different topics at four different times. Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
11618088|NCT00505297||A|Subjects with potentiall rapidl progressing OA
11618089|NCT00505297||B|Age-matched healthy subjects with no knee pain
11618090|NCT00505284|Placebo Comparator|Placebo|
11618091|NCT00505284|Active Comparator|Perampanel 2mg|
11618092|NCT00505284|Active Comparator|Perampanel 4mg|
11618093|NCT00505284|Active Comparator|Perampanel 6mg|
11618094|NCT00505284|Active Comparator|Perampanel 8mg|
11618095|NCT00505271|Experimental|1|Escalating doses of Rexin-G will be given two or three times a week for four weeks, with a 2 week rest period
11646993|NCT00123279|Experimental|4|
11618096|NCT00505245||Observational (questionnaire, QOL assessment, interview)|Participants complete questionnaires and quality of life assessments, and may also complete interviews over 45 minutes periodically.
11618097|NCT00505232|Experimental|Rituximab-HCVAD,Methotrexate/Cytarabine and Zevalin|Induction Treatment (Rituximab-HCVAD and Methotrexate/Cytarabine) followed by Consolidation Treatment (Rituximab and Y-90 Ibritumomab tiuxetan)
11618098|NCT00505219|Experimental|Ixmyelocel-T|Core decompression & treatment with Tissue Repair Cells (TRCs), demineralized bone matrix bound in autologous plasma
11618099|NCT00505219|Active Comparator|Standard of Care Only|Core decompression, demineralized bone matrix bound in autologous plasma, without any TRCs.
11618100|NCT00505167|Active Comparator|1|Patients randomized to receive memantine
11618101|NCT00505167|Active Comparator|2|Patients randomized to receive donepezil
11618102|NCT00505154|Placebo Comparator|2|Placebo tablets
11618103|NCT00505154|Active Comparator|1|rosuvastatin
11618104|NCT00505128|Other|1|to test the interest of early bile duct decompression by endoscopic sphincterotomy after early non invasive diagnosis by endosonography or MR cholangiography
11618105|NCT00505102|Active Comparator|A|
11618106|NCT00505089|Experimental|1|ACZ885 10mg/kg subcutaneous
11618107|NCT00505089|Experimental|2|ACZ885 5mg/kg intravenous
11618108|NCT00505089|Experimental|3|ACZ885 2mg/kg subcutaneous
11618109|NCT00505089|Experimental|4|ACZ885 1mg/kg intravenous
11618110|NCT00505076|Experimental|MK-0777 8 mg|MK-0777 8 mg tablet by mouth twice daily for 4 weeks
11618111|NCT00505076|Experimental|MK-0777 3 mg|MK-0777 3 mg tablet by mouth twice daily for 4 weeks
11618112|NCT00505076|Placebo Comparator|Placebo|Placebo tablet by mouth twice daily for 4 weeks
11618113|NCT00505063|Other|A|Immunization Schedule patients <7 years.
11618114|NCT00505063|Other|B|Immunization Schedule patients > or = to 7 years and <11 years of age
11618115|NCT00505063|Other|C|Immunization Schedule patients > or = to 11 years of age
11618116|NCT00505050|No Intervention|1|Standard follow-up medical visits and treatment for control group were performed during the study period by the same cardiologist team that was not informed of the randomization.
11618117|NCT00505037|Experimental|ASP1585 dose #1|
11618118|NCT00505037|Experimental|ASP1585 dose #2|
11618119|NCT00505037|Experimental|ASP1585 dose #3|
11618120|NCT00505037|Placebo Comparator|Placebo|
11618121|NCT00505037|Active Comparator|Sevelamer hydrochloride|
11618122|NCT00505024|Experimental|IVRS Only|
11618123|NCT00505024|Experimental|IVRS + Symptoms Report|
11618124|NCT00504998|Experimental|1|Dose Level 1 of escalating doses of Rexin-G i.v.
11618125|NCT00504998|Experimental|2|Dose Level 2 of escalating doses of Rexin-G i.v.
11618126|NCT00504998|Experimental|3|Dose Level 3 of escalating doses of Rexin-G i.v.
11618127|NCT00504998|Experimental|4|Dose Level 4 of escalating doses of Rexin-G i.v.
11618128|NCT00504998|Experimental|5|Dose Level 5 of escalating doses of Rexin-G i.v.
11618129|NCT00504985||Fatigue in Emergency Center Patients|
11618130|NCT00504972|Experimental|Study Treatment|This study is a single arm study
11618131|NCT00504959|Experimental|1|ranibizumab
11618132|NCT00504946|Active Comparator|I|
11618133|NCT00504946|Active Comparator|II|
11618134|NCT00504946|Placebo Comparator|III|
11618135|NCT00504946|Active Comparator|A|
11618136|NCT00504946|Placebo Comparator|B|
11618137|NCT00504933|Experimental|A|Bilastine
11618138|NCT00504933|Active Comparator|B|Cetirizine
11618139|NCT00504933|Placebo Comparator|C|Placebo
11618140|NCT00504920||Symptom Assessment|Drawing blood samples and matching the test results with questionnaire responses for symptoms patients experience from transplant treatment.
11618141|NCT00504907|Experimental|Cohort A|Placebo or BTA9881 -10mg
11618142|NCT00504907|Experimental|Cohort B|Placebo or BTA9881 - 10mg
11618143|NCT00504907|Experimental|Cohort C|Placebo or BTA9881 - 25mg
11618144|NCT00504907|Experimental|Cohort D|Placebo or BTA9881 - 50mg
11618145|NCT00504907|Experimental|Cohort E|Placebo or BTA9881 - 100mg
11618146|NCT00504907|Experimental|Cohort F|Placebo or BTA9881 - 200mg
11618147|NCT00504907|Experimental|Cohort G|Placebo or BTA9881 - 400mg
11618148|NCT00504894|Placebo Comparator|Placebo|Placebo given in low dose to gauge subject's responses to visual stimuli.
11618149|NCT00504894|Active Comparator|Propofol|Propofol give at 0.90 μgml-1 to gauge subject's responses to visual stimuli.
11618150|NCT00504881|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
11618151|NCT00504881|Experimental|Brivaracetam|A flexible dose of Brivaracetam tablets, administered twice a day, starting with a dose of 20 mg/day and could increase to 50 mg/day, 100 mg/day or 150 mg/day
11618152|NCT00504855|Active Comparator|Gortex (Waterproof) Cast Padding|Randomized application of one of two cast padding materials
11618153|NCT00504855|Active Comparator|Cotton/Cotton-Poly Cast Padding|Randomized application of one of two cast padding materials
11618154|NCT00504829|Experimental|LCP-AtorFen|LCP-AtorFen 40/100mg fixed-dose combination tablet of 40mg atorvastatin and 145mg fenofibrate for treatment of mixed dyslipidemia
11618155|NCT00504829|Active Comparator|atorvastatin|atorvastatin 40mg tablet (Lipitor), as an adjunct to diet and exercise for treatment of mixed dyslipidemia
11618156|NCT00504829|Active Comparator|fenofibrate|fenofibrate 145mg tablet (Tricor), as an adjunct to diet and exercise for treatment of mixed dyslipidemia
11618157|NCT00504816|Other|Brevicon|Oral contraceptive used to determine pharmacokinetics when given with GSK189075 to look for interaction.
11618158|NCT00504816|Experimental|GSK189075|Given in conjunction with Brevicon to see if GSK189075 interfered with Brevicon drug levels.
11618159|NCT00504803|Experimental|1|MSC co-infusion with either HLA-mismatched PBSC or cord blood
11618160|NCT00504790|Experimental|GSK923295|anti-mitotic compound under study
11618161|NCT00504777|Experimental|1|
11618162|NCT00504751|Experimental|Study Treatment|This is a single arm study
11618163|NCT00504725|Experimental|Ketamine|Single bolus 0.5mg/kg ketamine IV after induction of anesthesia
11646994|NCT00123279|Experimental|5|
11618164|NCT00504725|Placebo Comparator|Placebo|0.9 % saline bolus of equivalent volume
11618165|NCT00504712|Experimental|Active|Testosterone 200 mg intramuscular every 2 weeks
11618166|NCT00504712|Placebo Comparator|Placebo|Saline
11618167|NCT00504699|Experimental|letrozole|ovarian stimulation after breast cancer diagnosis and before breast cancer treatment
11618168|NCT00504699|No Intervention|control|No ovarian stimulation before breast cancer treatment
11618169|NCT00504686|Active Comparator|1|manual therapy - thoracic spine thrust manipulation
11618170|NCT00504686|Active Comparator|2|therapeutic exercise
11618171|NCT00504660|Active Comparator|1: Anaplastic Tumors|Anaplastic Tumors - 6-TG 80 mg/m^2 orally (PO) every 6 hours Day 1-3; Temozolomide 150 mg/m^2 PO daily Days 4-8, after 6 day rest Capecitabine 825 mg/m^2 and Celebrex 400 mg PO every 12 hours Day 14-27 for 28 day course.
11618172|NCT00504660|Active Comparator|2: Anaplastic Tumors|"Anaplastic Tumors - 6-TG 80 mg/m^2 PO every 6 hours Day 1-3, Lomustine 100 mg/m^2 PO on Day 4; Capecitabine 825 mg/m^2 PO every 12 hours Days 11-24, and Celebrex 400 mg PO every 12 hours Days 11-24.
~Participants if previously received Temozolomide but not Lomustine (CCNU) will receive Lomustine; or if had Gliadel wafers and Temozolomide with radiotherapy (XRT) will receive Temozolomide."
11618173|NCT00504660|Active Comparator|3: Glioblastoma Multiforme|"Glioblastoma Multiforme - 6-TG 80 mg/m^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle.
~Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide."
11618174|NCT00504634|Experimental|Bortezomib|1 mg/m^2 intravenous (IV) Days 1, 4, 8, and 11.
11618175|NCT00504621||sarcoidosis|Sarcoidosis known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009
11618176|NCT00504621||pulmonary fibrosis|Idiopathic pulmonary fibrosis (IPF) patients known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009
11618177|NCT00504595|Experimental|ACZ885|"Healthy Volunteers: Single administration of 600 mg of ACZ885 (Canakinumab) Intravenous (IV) on Day 1.
~Rheumatoid Arthritis (RA) Patients: Dose of 600 mg of ACZ885 (Canakinumab) Intravenous (IV) on Day 1, Day 15, and Day 43."
11618178|NCT00504595|Placebo Comparator|Placebo|"Healthy Volunteers: Single administration of 600 mg of Placebo Intravenous (IV) on Day 1.
~Rheumatoid Arthritis (RA) Patients: Dose of 600 mg of Placebo Intravenous (IV) on Day 1, Day 15, and Day 43."
11618179|NCT00504582|Experimental|Fibrin Sealant|Tisseel applied externally to the dissected axillary area.
11618180|NCT00504582|No Intervention|No Fibrin Sealant|
11618181|NCT00504556|Experimental|1|DU-176b 30mg tablet once daily
11618182|NCT00504556|Experimental|2|DU-176b 60mg once daily
11618183|NCT00504556|Experimental|3|DU-176b 30mg b.i.d.
11618184|NCT00504556|Experimental|4|DU-176b 60mg tablets two times a day
11618185|NCT00504556|Active Comparator|5|warfarin tablets
11618186|NCT00504543|Active Comparator|Neoral|
11618187|NCT00504543|Active Comparator|AEB071 high dose with Cetican reduced dose|
11618188|NCT00504543|Active Comparator|AEB071 low dose with Cetican standard dose|
11618189|NCT00504504|Experimental|Rituximab + ABVD Chemotherapy|Rituximab 375 mg/m^2 by vein (IV) over 3 to 8 hours weekly for 6 weeks in a row. ABVD Chemo: Adriamycin 25 mg/m^2 IV, Bleomycin 10 U/m^2 IV, Vinblastine 6 mg/m^2 IV, DTIC 375 mg/m^2 IV. Each but Rituximab over 3 hours every other week for a total of 12 treatments.
11618190|NCT00504491|Experimental|1|"Four Rituximab - CHOP courses will be given The courses will be given every 21 days Drug Dose Day Rituximab (Mabthera) 500mg/m2 1(*) (**) Cyclophosphamide 750mg/m2 1 Adriamycin 50mg/m2 1 Vincristine 1,4 mg/m2 1 Prednisone 60mg/m2 1 to 5
~(**) 1st course, 375 mg/m2 (*) If lymphocyte count is > 30 X 10 9/l, dose will be split up in two, which will be given in days 0 and 1"
11618191|NCT00504478|Experimental|1|8-weeks of high complex carbohydrate diet
11618192|NCT00504478|Experimental|2|omega-3 fatty acids supplements
11618193|NCT00504439|Experimental|Cohort 1|Subjects in Cohort 1 will receive 20 milligrams (mg) of SB-656933-AAA once daily or matching placebo once daily for 14 days.
11618194|NCT00504439|Experimental|Cohort 2|Subjects will be administered 40 mg simvastatin on day 1 followed by a washout period of two days. From day 3, the subjects will receive 50 mg of SB-656933-AAA once daily or matching placebo once daily for 14 days. On day 17, subjects will be administered 40 mg simvastatin along with SB-656933-AAA to assess statin interaction.
11618195|NCT00504439|Experimental|Cohort 3|Subjects will be administered 100 mg SB-656933-AAA/ day or matching placebo for 14 days. Dosing will initiate after cohort I and II have completed dosing.
11618196|NCT00504426|Placebo Comparator|1|
11618197|NCT00504426|Active Comparator|2|
11618198|NCT00504426|Active Comparator|3|
11618199|NCT00504426|Active Comparator|4|
11618200|NCT00504400|Experimental|A|
11618201|NCT00504387||A: Patients|Patients with a primary burning mouth disorder Pain (VAS 0-10): 3<x<9 Patient understands and speaks german Age: >18 years
11618202|NCT00504387||B: Controls|Age and sex matched persons/patients who do not have any history of an oral burning sensation or a burning mouth disorder.
11618203|NCT00504374||Symptoms Questionnaire|Patients with lung cancer.
11618204|NCT00504361||1: Lung Disease|Individuals with at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) patients with diseases of organs with known association with lung disease; and (7) individuals suspected of history of lung diseased based on history and/or physical examination
11618205|NCT00504361||2: Normal Control|Individuals without a history of lung disease.
11618248|NCT00503984|Experimental|Phase 1 - Aza + Doc|Phase 1 Azacitidine (Aza) and Docetaxel (Doc) with dose escalation/de-escalation design, and Prednisone, with growth factor support; GADD45α methylation and expression analysis, with optional growth factor support (pegfilgrastim/filgrastim).
11646995|NCT00123279|Experimental|6|
11618206|NCT00504348|Experimental|Prospective investigation group|Tacrolimus treatment is to be initiated at the starting dose of 0.075mg/kg/day, adjusted to maintain its whole blood trough levels between 5 and 10 ng/mL for 52 weeks. All patients are to receive glucocorticoids with the starting doses equivalent to between 0.6 and 1.0 mg/kg/day of prednisolone which are to be continued for the first 28 days after which be subsequently tapered according to a predefined guideline. Up to two courses of pulse intravenous glucocorticoid therapy are allowed during that period.
11618207|NCT00504335|Experimental|500 BIO 300 capsule|The first cohort will receive one 500 BIO 300 capsule and pharmacokinetic blood sampling will be conducted over the first 4 days in an outpatient setting
11618208|NCT00504335|Experimental|1000 BIO 300 capsule|the second cohort will be treated with 1000 mg BIO 300 using the same PK sampling program
11618209|NCT00504335|Experimental|1500 BIO 300 capsule|the third cohort will be treated with 1500 mg BIO 300using the same PK sampling program
11618210|NCT00504335|Experimental|2000 BIO 300 capsule|the forth cohort will be treated with 2000 mg BIO 300using the same PK sampling program
11618211|NCT00504322|Placebo Comparator|placebo|The placebo will be the salt water-sugar solution used as a vehicle for the vector.
11618212|NCT00504322|Active Comparator|AdcuCD40L|Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
11618213|NCT00504309|Experimental|4g P-OM3, then 1g P-OM3, then Placebo|4 g/day Dose Prescription Omega-3 acid ethyl esters (P-OM3)capsules(4) for first intervention (8 weeks), followed by 1g/day P-OM3 capsules(4) for 2nd intervention (8 weeks), followed by Placebo corn oil capsules, 4/day, for the 3rd intervention (8 weeks).
11618214|NCT00504309|Experimental|1g P-OM3, then 4g P-OM3, then Placebo|1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks,followed by 6-wk washout. Placebo capsules for 8-wks.
11618215|NCT00504309|Experimental|Placebo, then 4g P-OM3, then 1g P-OM3|Corn Oil placebo capsules for 8-wks, followed by 6-wk washout. 4g P-OM3 capsules for 8-wks, followed by 6-wk washout. 1g P-OM3 for 8-wks.
11618216|NCT00504309|Experimental|4g P-OM3, then Placebo, then 1g P-OM3|4g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 1g capsules for 8 wks.
11618217|NCT00504309|Experimental|1g P-OM3, then Placebo, then 4g P-OM3|1g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
11618218|NCT00504309|Experimental|Placebo, then 1g P-OM3, then 4g P-OM3|Corn oil placebo capsules for 8-wks, followed by 6-wk washout.1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
11618219|NCT00504296|Experimental|SB939|
11618220|NCT00504270|Placebo Comparator|Placebo|po daily
11618221|NCT00504270|Experimental|RG3421 120mg|120mg po daily
11618222|NCT00504270|Experimental|RG3421 20mg|20mg po daily
11618223|NCT00504257|Experimental|Avastin and Docetaxel|Combination Therapy: Immunotherapy (Avastin) and Chemotherapy (Docetaxel) as outlined in Intervention descriptions. Avastin: 15 mg/kg, In 100 ml normal saline (NS) IV infusion over 90 +/- 15 minutes, Day 1, every 21 day cycle. Docetaxel: 40 mg/m^2, In 250 ml 5% dextrose in pure water (D5W) or NS IV infusion over 1 hour in a non-pvc container and through a polyethylene-lined set, Day 1, 8, every 21 day cycle. Response assessment every 3 cycles (9 weeks).
11618224|NCT00504231|Experimental|0.3 mL Influenza Vaccine ID|60% dose - 0.3 mL delivered intradermally with needle and syringe
11618225|NCT00504231|Experimental|0.15 mL twice Influenza Vaccine ID|60% dose - 0.15 mL delivered twice intradermally with needle and syringe
11618226|NCT00504231|Active Comparator|0.5 mL Influenza Vaccine by IM|100% dose - 0.5mL delivered intramuscularly with needle and syringe
11618227|NCT00504231|Experimental|0.3 mL Influenza Vaccine IM|60% dose - 0.3 mL delivered intramuscularly with needle and syringe
11618228|NCT00504166|Active Comparator|alendronate sodium|alendronate sodium 70 mg tablet once a week for 24 months
11618229|NCT00504166|Placebo Comparator|placebo|placebo to match alendronate sodium
11618230|NCT00504153|Experimental|Treatment (tyrosine Kinase Inhibitor)|Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11618231|NCT00504140|Experimental|Interferon Alpha + Etoposide|Interferon Alpha 5x10^6 mu/m^2 subcutaneously and Etoposide 100 mg/m^2 intravenously, both daily for 5 days
11618232|NCT00504127|Experimental|naproxcinod 375 mg bid|
11618233|NCT00504127|Experimental|naproxcinod 750 mg bid|
11618234|NCT00504127|Active Comparator|naproxen 500 mg bid|
11618235|NCT00504127|Placebo Comparator|placebo|
11618236|NCT00504114||1|Healthy volunteers without knee pain.
11618237|NCT00504114||2|Patients with mild arthritic symptoms and radiographic changes (Kellgren Lawrence score of 1, 2)
11618238|NCT00504114||3|Patients with severe pain and functional limitations associated with knee arthritis (Kellgren Lawrence score of 3, 4).
11618239|NCT00504114||4|Patients with acute anterior cruciate ligament (ACL) injuries with associated osseous contusion.
11618240|NCT00504114||5|Patients with posttraumatic knee injury or degenerative condition and will have cartilage resurfacing procedures.
11618241|NCT00504075|Experimental|Gammaplex (intravenous immunoglobulin)|
11618242|NCT00504036|Experimental|Intra-gastric balloon|Patients will receive either an air-filled or water-filled intra-gastric balloon.
11618243|NCT00504036|No Intervention|Usual care|Usual care will be given to the patients.
11618244|NCT00504023|Experimental|imiquimod|This is a pilot study of the use of a topical immunomodulatory agent, imiquimod, for the treatment of recurrent Extramammary Paget's disease (EMPD).
11618245|NCT00504010|Active Comparator|1|arnica containing cream
11618246|NCT00504010|Placebo Comparator|2|carrier cream without arnica
11618247|NCT00503997|Experimental|drug therapy|
11618437|NCT00501943|Placebo Comparator|Placebo|placebo + Avonex
11618438|NCT00501904|Active Comparator|Group A|Short protocol
11618249|NCT00503984|Experimental|Phase 2 - Aza + Doc RPTD|Recommended Phase Two Dose (RPTD) of Azacitidine and Docetaxel; and Prednisone; with optional growth factor support (pegfilgrastim/filgrastim).
11618250|NCT00503971|Experimental|Vorinostat plus erlotinib|Vorinostat plus erlotinib
11618251|NCT00503932|Experimental|Proton Therapy + Capecitabine|Capecitabine 825 mg/m^2 by mouth twice daily on Proton Therapy (radiation) days.
11618252|NCT00503919|Experimental|MDC|Multi-spectral Digital Colposcopy for Fluorescence Spectroscopy
11618253|NCT00503906|Experimental|Abraxane, Avastin and Gemcitabine|"Each treatment cycle is 28 days. Participants will be treated until disease progression:
~Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;
~Abraxane: 150 mg/m2 IV over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;
~Avastin: 10 mg/kg IV on days 1 and 15 of each cycle."
11618254|NCT00503893||Wilm's Tumor PO1|Familial and Sporadic Wilm's tumor, genitourinary anomalies, Beckwith-Wiedemann hemihypertrophy and/or aniridia.
11618255|NCT00503880|Experimental|Treatment|G-CSF 300 μg subcutaneously to begin one day prior to treatment and continued until ANC greater than 1.0 or recovers back to the patients baseline ANC for 3 days in a row subsequent to completion of chemotherapy (SOC) Low-dose Cytarabine 10 mg/m2 subcutaneously daily starting on day 1 for the first 5 consecutive days of the treatment course 2-4 hours following the end of the clofarabine infusion. (SOC) Clofarabine starting at dose level 0. Dose-10 mg/m2 IV over 1 hour daily starting on day 1 for the first 5 consecutive days of the treatment course The G-CSF and cytarabine doses are fixed. The dose of clofarabine is initially fixed. For the subsequent cohort, the dose of clofarabine will be advanced to the next dose level.
11618256|NCT00503854||Observational (questionnaire)|Patients complete a questionnaire on days 1, 2, and 6 regarding fatigue, sleep disturbance, depression, and other symptoms.
11618257|NCT00503841|Experimental|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
11618258|NCT00503828|Active Comparator|naproxen|Naproxen 500 mg/day for 4 weeks
11618259|NCT00503828|Experimental|Derris Scandens Benth|Derris Scandens Benth
11618260|NCT00503802|Active Comparator|1|Active RF treatment
11618261|NCT00503802|Sham Comparator|2|Sham RF treatment
11618262|NCT00503789|Active Comparator|1|cow-milk based infant formula
11618263|NCT00503789|Experimental|2|cow milk based infant formula with prebiotics
11618264|NCT00503789|Other|3|human milk reference group
11618265|NCT00503776|Active Comparator|Arm IA|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
11618266|NCT00503776|Active Comparator|Arm IB|Patients undergo SNT and low weight resistance training (LWRT).
11618267|NCT00503776|Experimental|Arm IIA|Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.
11618268|NCT00503776|Experimental|Arm IIB|Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.
11618269|NCT00503750|Active Comparator|Trastuzumab and Abraxane followed Trastuzumab and Vinorelbine|Patients will be treated sequentially with preoperative trastuzumab and dose-dense ABI-007 followed by trastuzumab in combination with vinorelbine. Trastuzumab will be administered as a one-time loading dose of 4 mg/kg as a 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as a 30 minute infusion. ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8). Growth factor support with pegfilgrastim (Neulasta®) is required 24 to 48 hours following completion of each cycle of ABI-007. Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20). As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52.
11618270|NCT00503737|Active Comparator|Colorectal Cancer Screening Toolkit|Toolbox includes tools and guides designed increase screening by primary care physicians
11618271|NCT00503737|No Intervention|Standard of Care Colorectal Cancer Screening|Primary Care physician will screen for colorectal cancer as per his/her standard practice
11618272|NCT00503711|Experimental|100 mg Vandetanib eod|100 mg Vandetanib every other day dosing
11618273|NCT00503711|Experimental|100 mg Vandetanib od|100 mg Vandetanib once daily dosing
11618274|NCT00503711|Experimental|300 mg Vandetanib od|300 mg Vandetanib once daily dosing
11618275|NCT00503698|Experimental|Somatropin|Somatropin once daily from week 0 to end of trial
11618276|NCT00503698|Placebo Comparator|Placebo|Placebo once daily to end of trial
11618277|NCT00503685|Experimental|IMC-A12|Administered every 2 weeks
11618278|NCT00503685|Experimental|IMC-A12 + cetuximab|Administered every 2 weeks
11618279|NCT00503685|Experimental|IMC-A12 + cetuximab [Kirsten rat sarcoma (K-ras) wild-type]|Participants who have experienced confirmed partial response (PR) or stable disease (SD) ≥ 24 weeks on a prior anti-EGFR-containing therapy followed by disease progression are enrolled in this arm.
11618280|NCT00503659|Active Comparator|A|Methacholine challenge, five-breath dosimeter protocol
11618281|NCT00503659|Active Comparator|B|Methacholine challenge five incremental dosages protocol
11618282|NCT00503594|Experimental|1|Comparative evaluation of the efficiency of a new protocol of the primitive LYMPHOME of the central nervous system ( LPSNC) to the old subject, associating Methotrexate and Temozolomide with regard to a standard protocol associating Methotrexate, Procarbazine, Vincristine and Cytarabine.
11618283|NCT00503594|Active Comparator|bras conventional|bras conventional
11618284|NCT00503581|Experimental|Regimen 1 (megestrol acetate, surgery)|Patients receive oral megestrol twice daily every day for 24 weeks. Approximately twelve weeks after treatment starts, clinical blood tests are obtained and research serum and plasma collected. Twenty-four weeks constitutes one course of treatment and a pill count is performed during the 12-week f/u visit and at the completion of the treatment course to determine compliance. After progestin therapy the patient has an induced-withdrawal bleed. Patients in this arm undergo a re-evaluation biopsy and hysterectomy a minimum of two weeks and a maximum of eight weeks after completing the megestrol treatment.
11618439|NCT00501904|Active Comparator|Group B|Long protocol
11618285|NCT00503581|Experimental|Regimen 2 (megestrol acetate, surgery)|Patients receive oral megestrol twice daily for two weeks continuously followed by no treatment for two weeks. This course is repeated for a total of 24 weeks. Approximately twelve weeks after treatment starts, clinical blood tests are obtained and research serum and plasma collected. Twenty-four weeks constitutes one course of treatment and a pill count is performed during the 12-week f/u visit and at the completion of the treatment course to determine compliance. After progestin therapy the patient has an induced-withdrawal bleed. Patients in this arm undergo a re-evaluation biopsy and hysterectomy a minimum of two weeks and a maximum of eight weeks after the megestrol treatment.
11618286|NCT00503581|Active Comparator|Regimen 3 (surgery/biopsy)|(Closed as of 6/3/2010) Patients do not receive megestrol. At the discretion of the managing physician, patients undergo the re-evaluation biopsy and hysterectomy anytime between 2-20 weeks after enrollment and randomization.
11618287|NCT00503568|Experimental|DS-1: gp96-ig Dose Schedule 1|Dose Schedule 1 (DS-1): Ad100-gp96Ig-HLA A1 Vaccine 4x10^7 cells bi-weekly, maximum 9 vaccines/patient;
11618288|NCT00503568|Experimental|DS-2: gp96-ig Dose Schedule 3|Dose Schedule 2 (DS-2): Ad100-gp96Ig-HLA A1 Vaccine 2X10^7 cells weekly, maximum 18 vaccines/patient;
11618289|NCT00503568|Experimental|DS-3: gp96-ig Dose Schedule 3|Dose Schedule 3 (DS-3): Ad100-gp96Ig-HLA A1 Vaccine 1x10^7 cells twice weekly, maximum 36 vaccines/patient
11618290|NCT00503542|Experimental|Intervention|Patients primarily with itching or irritation are treated for candidal vaginitis. Patients primarily with vaginal odor are treated for bacterial vaginosis. Patients who did not fit either of the previous groups are treated for both candidal vaginitis and bacterial vaginosis.
11618291|NCT00503542|Active Comparator|Control|Patient are examined and a wet mount is prepared. If a definitive diagnosis is made patient is treated for the condition diagnosed. If no diagnosis is made the clinician has the option of either foregoing treatment (watchful waiting) or following the protocol in the experimental group
11618292|NCT00503516|Experimental|1|Megestrol acetate 160 mg b.i.d. during 24 weeks
11618293|NCT00503516|Placebo Comparator|2|1 sachet of powder of placebo b.i.d. during 24 weeks
11618294|NCT00503490|Experimental|1|Inhaled Levofloxacin
11618295|NCT00503490|Placebo Comparator|2|Placebo
11618296|NCT00503451|Experimental|LBH589|
11618297|NCT00503438|Other|Salto Talaris Ankle|This is an Implant Registry of the approved Salto Talaris Ankle replacement device
11618298|NCT00503425|Experimental|1|
11618299|NCT00503399|Experimental|Teriparatide|Teriparatide 20 microgram (µg) subcutaneous (sc) injection once daily (QD).
11618300|NCT00503399|Active Comparator|Risedronate|Risedronate 35 milligrams (mg) oral (po) tablet once weekly (QW)
11618301|NCT00503347|Experimental|1|0.3 mg/kg
11618302|NCT00503347|Experimental|2|1 mg/kg
11618303|NCT00503347|Experimental|3|3 mg/kg
11618304|NCT00503347|Experimental|4|6 mg/kg
11618305|NCT00503334|Experimental|preOP booster|
11618306|NCT00503334|Placebo Comparator|preOP booster placebo|
11618307|NCT00503321|Experimental|Arm B|S-1 plus PSK group
11618308|NCT00503321|Active Comparator|Arm A|S-1 alone
11618309|NCT00503308|Experimental|Abbreviated Consenting|
11618310|NCT00503308|No Intervention|Standard Consenting|
11618311|NCT00503269|Active Comparator|1|30 ml of 1% Lignocaine with 1:10,000 Adrenaline
11618312|NCT00503269|Active Comparator|2|Standard General anaesthesia with Enflurane and Propofol.
11618313|NCT00503256||CLL - Linkage Families|Gene identification related to Chronic lymphocytic leukemia (CLL) development
11618314|NCT00503230|Active Comparator|Standard Care Intervention (SCI)|
11618315|NCT00503230|Active Comparator|Culturally Tailored Intervention (CTI)|
11618316|NCT00503204|Experimental|1|Lomustine + Cediranib (AZD2171)
11618317|NCT00503191|Experimental|Intention-based therapy treatment for autism|NeuroModulation Technique
11618318|NCT00503178|Experimental|Patients undergoing imaging guided radiotherapy.|
11618319|NCT00503152|Experimental|benazepril|
11618320|NCT00503152|Experimental|valsartan|
11618321|NCT00503152|Experimental|benazepril/valsartan|
11618322|NCT00503113|Experimental|1|
11618323|NCT00503113|Experimental|2|
11618324|NCT00503113|Active Comparator|3|
11618325|NCT00503100||NICU full-term early pain group|
11618326|NCT00503100||NICU premature early pain group|
11618327|NCT00503100||NICU premature control group|
11618328|NCT00503100||Soroka- full-term control group|
11618329|NCT00503074|Experimental|1|Parents receive tailored health-behavior change messages designed to reduce their child's exposure to televised food commercials. Intervention is delivered by a case manager, by a website, and by periodic newsletters.
11618330|NCT00503074|Active Comparator|Control|Parents of children ages 2-5 receive behavioral-change counseling around toddler & preschooler safety and injury prevention.
11618331|NCT00503048||1|foster care children
11618332|NCT00503048||2|reference children (living with families)
11618333|NCT00503035|Experimental|Celecoxib|Celecoxib 400 mg orally twice daily for 6 months. Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure.
11618334|NCT00503009|Active Comparator|Arm 1|
11618335|NCT00503009|Active Comparator|Arm 2|
11618336|NCT00503009|Placebo Comparator|Arm 3|
11618337|NCT00502996|Experimental|Rituximab|Eligible participants receiving Rituximab (MabThera/Rituxan) 1 gram/dose (g/dose) intravenously (IV) on Day 1 and Day 15 followed by previous pre-medication (methylprednisolone 100 mg IV, antihistamine and antipyretic) and concomitant treatment of Methotrexate at least 15 mg per oris (PO) weekly were observed during the study period of 24 weeks. After treatment completion, participants were followed-up for safety up to 24 weeks.
11618338|NCT00502983||Interview|AML Patients & Healthy Controls
11618339|NCT00502970|Experimental|1|16 weeks Interferon Tiw with Ribavirin
11618340|NCT00502970|Active Comparator|2|24 weeks Interferon Tiw with Ribavirin
11618341|NCT00502944|Experimental|Counselor-based HIV screening|
11618342|NCT00502944|Active Comparator|Emergency staff member-based HIV screening|
11618343|NCT00502918||1|
11618538|NCT00500851|Active Comparator|2|Endoscopic placement of jejunal feeding tubes fulfilling clinical indication for jejunal feeding.
11618344|NCT00502905|Experimental|Busulfan + Fludarabine|Once a day for four days, Busulfan 130 mg/m^2 through intravenous catheter over 3 hours immediately after Fludarabine 40 mg/m^2 over 1 hour.
11618345|NCT00502892|Experimental|Topotecan + Ifosfamide + Carboplatin|
11618346|NCT00502866||breastfed children|children, 6-15 months old, predominately breastfed for at least 6 months without supplemental vitamin D
11618347|NCT00502853|Experimental|1|
11618348|NCT00502840|Experimental|1|
11618349|NCT00502827|Other|Recommended Standard of Care|Recommended Standard of Care (RSOC) = Physician Advice + Written Materials
11618350|NCT00502827|Other|RSOC + Cell Phone Intervention|Recommended Standard of Care (RSOC) + Cell Phone Intervention
11618351|NCT00502814||1|Patients with Breast Cancer.
11618352|NCT00502801|Experimental|Doripenem|1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
11618353|NCT00502749|Experimental|Exercise program|Daily (Monday-Friday) 45-minute group physical exercise program during each hospital admission for three months or individual 20 minute session bedside.
11618354|NCT00502736|Experimental|1|
11618355|NCT00502723|Active Comparator|2|Radical laparoscopy prostatectomy
11618356|NCT00502723|Experimental|1|Radical retropubic prostatectomy
11618357|NCT00502710|Experimental|RO4876904 1|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
11618358|NCT00502710|Experimental|RO4876904 2|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
11618359|NCT00502710|Experimental|RO4876904 3|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
11618360|NCT00502710|Experimental|RO4876904 4|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
11618361|NCT00502710|Placebo Comparator|Placebo|Placebo po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
11618362|NCT00502697|Experimental|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic visits. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
11618363|NCT00502697|Other|Conventional prenatal/postpartum care|Women assigned to the control arm of the study received conventional prenatal and postpartum clinic care.
11618364|NCT00502684|Experimental|1|Peri-operative etodolac and propranolol as described in protocol
11618365|NCT00502684|Placebo Comparator|2|peri-operative placebo as described in protocol
11618366|NCT00502671|Experimental|1|
11618367|NCT00502632|Experimental|1|"Intrapleural administration of:
~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days
~Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
11618368|NCT00502632|Placebo Comparator|2|"Intrapleural administration of:
~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days
~25ml normal saline, twice daily for 4 days"
11618369|NCT00502619|Experimental|Acupuncture plus Treadmill Exercise|Acupuncture plus Treadmill Exercise
11618370|NCT00502606||patients with provisional crowns|the same patient would serve as control and test
11618371|NCT00502593|Experimental|GSK1562902A-A Lot 1 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
11618372|NCT00502593|Active Comparator|Fluarix-A 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
11618373|NCT00502593|Experimental|GSK1562902A-A Lot 1 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
11618374|NCT00502593|Active Comparator|Fluarix-A 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
11618375|NCT00502593|Experimental|GSK1562902A-B Lot 2 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 2. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
11618376|NCT00502593|Active Comparator|Fluarix-B 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
11618377|NCT00502593|Experimental|GSK1562902A-B Lot 2 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 2. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
11618378|NCT00502593|Active Comparator|Fluarix-B 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
11618379|NCT00502593|Experimental|GSK1562902A-C Lot 3 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 3. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
11618539|NCT00500838|Experimental|1|Transthoracic impedance device implanted.
11646996|NCT00123266|Experimental|Active|
11618380|NCT00502593|Active Comparator|Fluarix-C 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
11618381|NCT00502593|Experimental|GSK1562902A-C Lot 3 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 3. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
11618382|NCT00502593|Active Comparator|Fluarix-C 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
11618383|NCT00502580||1|Patients with lesions of the oral cavity mucosa.
11618384|NCT00502554|No Intervention|1|Observation with standard care (macrolides, exercise, oxygen therapy etc.) alone.
11618385|NCT00502554|Active Comparator|2|2-day cycles of photopheresis every 3 weeks for 3 months
11618386|NCT00502541|Experimental|Fluocinolone acetonide|Fluocinolone acetonide intravitreal implant
11618387|NCT00502541|Active Comparator|Standard of Care|Standard of care
11618388|NCT00502528|Placebo Comparator|1|Placebo
11618389|NCT00502528|Active Comparator|2|BQ-123
11618390|NCT00502515|Experimental|25 mg SSR180575|orally once daily for 24 weeks
11618391|NCT00502515|Experimental|100 mg SSR180575|orally once daily for 24 weeks
11618392|NCT00502515|Placebo Comparator|Placebo|orally once daily for 24 weeks
11618393|NCT00502502||Symptom-Related Cytokines Questionnaire|
11618394|NCT00502411|Experimental|Doxorubicin + Radiation Therapy|Doxorubicin 17.5 mg/m^2 IV bolus infusion, followed by continuous IV infusion on days 1-4. Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
11618395|NCT00502372|Experimental|Enriched product, dietary supplement|Subjects receiving enriched product compared to an unenriched product
11618396|NCT00502372|Active Comparator|1|Subjects not receiving enriched product
11618397|NCT00502320|Experimental|Ramelteon|8 mg
11618398|NCT00502320|Placebo Comparator|Placebo|
11618399|NCT00502307|Experimental|1|Tivozanib (AV-951) administered as a solid dosage form daily for three weeks per month
11618400|NCT00502307|Placebo Comparator|2|solid oral capsule containing excipients dosed daily for three weeks per month
11618401|NCT00502281|Active Comparator|Group A|COS followed by TI
11618402|NCT00502281|Active Comparator|Group B|COS followed by IUI
11618403|NCT00502268|Placebo Comparator|Group 1|Doxercalciferol administration by DOQI and 2nd Gen PTH assay
11618404|NCT00502268|Active Comparator|Group 2|Doxercalciferol administered by 1-84-7-84 ratio between 1.4-1.6
11618405|NCT00502255|Experimental|telemonitoring|Health Buddy in patients home situation
11618406|NCT00502255|Experimental|usual care|patients receive care as usual
11618407|NCT00502242|Active Comparator|A|Capsule - initial treatment is 5 mg (active)- oral - once per day
11618408|NCT00502242|Placebo Comparator|B|Capsule - initial treatment is 5 mg (placebo) - oral - once per day
11618409|NCT00502229|Active Comparator|Group A|Continuing treatment
11618410|NCT00502229|Active Comparator|Group B|Gonadotrophins
11618411|NCT00502216|Experimental|1|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
11618412|NCT00502216|Placebo Comparator|2|Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
11618413|NCT00502203|Experimental|Paclitaxel + Carboplatin|Paclitaxel 175 mg/m^2 intravenously (IV) over 3 hours and Carboplatin AUC 5 IV over 1 hour every 21 Days for 6 courses.
11618414|NCT00502190|Experimental|1|Silicon ring positioned in the vagina, around the cervix
11618415|NCT00502190|Experimental|2|Silicon ring positioned in the vagina, around the cervix
11618416|NCT00502177||Quality of Life Questionnaire|Patients undergoing continuous hyperthermic peritoneal perfusion with cisplatin and their parents/caregivers.
11618417|NCT00502138|Experimental|A|Interventional, continuous pramlintide infusion at 9 micrograms/hr plus 60 microgram meal bolus plus continuous insulin basal-bolus subcutaneous infusion
11618418|NCT00502125||Patients with oral lesions|
11618419|NCT00502112|Experimental|1|lintuzumab and lenalidomide
11618420|NCT00502099|Active Comparator|1|Pegylated interferon alpha 2a plus ribavirin
11618421|NCT00502099|Active Comparator|2|Pegylated interferon alpha 2b plus ribavirin
11618422|NCT00502086|Experimental|I|Viusid, three sachets daily during 96 weeks
11618423|NCT00502086|Placebo Comparator|2|Placebo three sachets daily during 96 weeks
11618424|NCT00502034|Experimental|A-immunotherapy|Immunotherapy with interferon-alpha and interleukin
11618425|NCT00502034|No Intervention|B-follow-up|Wait-and-see
11618426|NCT00502021|Experimental|1|Supplement of flaxseed powder (60 g/day)during 12 weeks
11618427|NCT00502021|Placebo Comparator|2|Placebo powder supplement 60 g/day during 12 weeks
11618428|NCT00502021|Experimental|3|Flaxseed oil 30 ml/day (10 g ALA)during 12 weeks
11618429|NCT00502021|Placebo Comparator|4|Safflower oil 30 ml/day (no ALA) during 12 weeks
11618430|NCT00501995|Experimental|IV Cyclophosphamide (50 mg/kg)|This is an open-labeled single arm study of Cyclophosphamide (50 mg/kg) administered intravenously over 1 hour daily for four consecutive days (200 mg/kg total) through a Hickman catheter .
11618431|NCT00501982|No Intervention|1|N Cpap in delivery room and than rescue curosurf in case of need
11618432|NCT00501982|Experimental|2|Poractant alfa (Curosurf) + N Cpap in delivery room
11618433|NCT00501969|Experimental|Rotigotine|Rotigotine
11618434|NCT00501956|Experimental|Intradialytic parenteral nutrition|Individually compounded intradialytic parenteral nutrition (IDPN) including glucose, amino acids, lipids, L-Carnitine, trace elements and water-soluable vitamins 3x / week over 16 weeks + 12 weeks postinterventional observation.
11618435|NCT00501956|No Intervention|Control Group|Observation over 28 weeks (16 + 12 weeks).
11618436|NCT00501943|Active Comparator|Riluzole|Riluzole + Avonex
11618440|NCT00501891|Experimental|Bevacizumab and Metronomic Temozolomide|Patients will receive up to 12 cycles of bevacizumab (Avastin) and metronomic temozolomide (Temodar), and each cycle is 28 days. Bevacizumab will be administered at 10 mg/kg every other week beginning a minimum of 7 days after a biopsy or 28 days after a craniotomy. Temozolomide will be dosed at 50 mg/m2 daily in a 28-day cycle.
11618441|NCT00501865|Experimental|Sequence AB|Subjects will be randomized to sequence AB, where A represents fasted state and B represents fed state. Subjects will be administered a single oral dose of GW273225 50 milligrams (mg) in the fasted state in dosing period 1. The subjects will receive a single oral dose of GW273225 50 mg immediately after a high fat breakfast in dosing period 2. There will be at least 21 days between doses for the fasted and fed treatment phases of the study.
11618442|NCT00501865|Experimental|Sequence BA|Subjects will be randomized to sequence BA, where A represents fasted state and B represents fed state. Subjects will be orally administered a single dose of GW273225 50 mg immediately after a high fat breakfast in dosing period 1. The subjects will receive a single oral dose of GW273225 50 mg in the fasted state in dosing period 2. There will be at least 21 days between doses for the fed and fasted treatment phases of the study.
11618443|NCT00501852|Experimental|NVA237 12.5 µg|12.5 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
11618444|NCT00501852|Experimental|NVA237 25 µg|25 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
11618445|NCT00501852|Experimental|NVA237 50 µg|50 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
11618446|NCT00501852|Experimental|NVA237 100 µg|100 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
11618447|NCT00501852|Placebo Comparator|Placebo|Placebo via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
11618448|NCT00501852|Active Comparator|Tiotropium 18 µg|18 µg od via Handihaler inhaler. Tiotropium was given open-label. At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
11618449|NCT00501839|Active Comparator|Group A|Cyclic progestogens for nine months
11618450|NCT00501839|Active Comparator|Group B|CC treatment for further three cycles at the same ovulating doses followed by six months of cyclic progestogens
11618451|NCT00501839|Active Comparator|Group C|CC administration at the same ovulating doses for nine cycles
11618452|NCT00501826|Experimental|Treatment (nelarabine and combination chemotherapy)|See Detailed Description
11618453|NCT00501813|Active Comparator|surgery|initial palliative hepatectomy followed by TACE and/or local regional treatment
11618454|NCT00501813|Experimental|no surgery|TACE combined with local regional treatment without hepatectomy
11618455|NCT00501800||Caucasian|
11618456|NCT00501800||African American|
11618457|NCT00501800||Chinese|
11618458|NCT00501800||Latina (Mexican or Central American)|
11618459|NCT00501800||Filipina|
11618460|NCT00501787|Active Comparator|Group B|Non-tailoring
11618461|NCT00501787|Active Comparator|Group A|Tailoring
11618462|NCT00501761||1: Endometrial Cancer Survivors|
11618463|NCT00501761||2: Healthy Participants|Healthy participants that have no history of invasive cancer.
11618464|NCT00501748|Experimental|Rituximab|
11618465|NCT00501709|Experimental|Treatment|Allogenic pancreatic islet transplant using belatacept and raptiva
11618466|NCT00501696|Other|1|A randomized placebo-controlled, parallel-group study, crossover-design
11618467|NCT00501696|Other|2|A randomized placebo-controlled, parallel-group study, crossover-design
11618468|NCT00501670||Group A|Collection of lesion samples and blood sampling from subjects aged >=50 years with clinically diagnosed herpes zoster
11618469|NCT00501657|Experimental|Sitagliptin (100mg)|Active drug (sitagliptin)
11618470|NCT00501657|Placebo Comparator|Placebo (sugar pill)|Inactive drug (placebo)
11618471|NCT00501644|Experimental|Chemoimmunotherapy|GM-CSF Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy + rIFN-g (Interferon Gamma) 0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle) + Paraplatin (Carboplatin) AUC of 5 by 1 hour IV infusion every 28 days
11618472|NCT00501631|Active Comparator|VIVITROL 380 mg|Administered via intramuscular (IM) injection once every 4 weeks.
11618473|NCT00501631|Placebo Comparator|Placebo for VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
11618474|NCT00501618|Other|Fazaclo|open label switch from generic clozapine to Fazaclo
11618475|NCT00501592|Active Comparator|25 mg INT-747|
11618476|NCT00501592|Active Comparator|50 mg INT-747|
11618477|NCT00501592|Placebo Comparator|Placebo|
11618478|NCT00501540|Experimental|Lithium|Lithium carbonate will be dosed on a flat scale of mg/day and not by weight or body surface area (BSA). Lithium carbonate will be provided as a 300mg tablet and will be taken daily without breaks in treatment.
11618479|NCT00501527|Experimental|A: Biological vaccine|The first active arm will receive a dose that is 10x less than the dose of the other arm
11618480|NCT00501527|Experimental|B: biological vaccine|The first active arm will receive a dose that is 10x more than the dose of the other arm
11618481|NCT00501527|Placebo Comparator|C|
11618482|NCT00501462|Other|Mild renal impairmnent|
11618483|NCT00501462|Other|moderate renal impairment|
11618484|NCT00501462|Other|Normal renal function|
11618485|NCT00501449||Multiple Endocrine Neoplasia (MEN)|Patients with multiple endocrine neoplasia (MEN).
11618540|NCT00500825||1|Patients successfully resuscitated after cardiac arrest undergoing therapeutic hypothermia
11650610|NCT00077675|Experimental|Telavancin|
11618486|NCT00501410|Experimental|FOLFOX + Dasatinib + Cetuximab|5-FU 2400 mg/m^2 by vein over 46 Hours On Days 1 & 2. Cetuximab initial dose = 400 mg/m^2 by vein, then 250 mg/m^2 Weekly On Days 1 & 8. Dasatinib 100 mg by mouth daily on days 1-14. Leucovorin 400 mg/m^2 by vein on day 1. Oxaliplatin 85 mg/m^2 by vein on day 1.
11618487|NCT00501371|Active Comparator|MCS|Group A: MCS 30 mg/day for 12 weeks
11618488|NCT00501371|Placebo Comparator|Placebo|Placebo, 2 capsules per day
11618489|NCT00501345|Experimental|Aspirin|
11618490|NCT00501332|Active Comparator|2|
11618491|NCT00501319||1|Patients with Non-Small Cell Lung Cancer.
11618492|NCT00501293|Experimental|1|Methylphenidate Transdermal System
11618493|NCT00501280||MSF Women + their children|Blood and urine samples and interviews of Migrant or seasonal farmworker (MSF) woman + their children
11618494|NCT00501280||Non-MSF Women + their Children|Blood and urine samples and interviews of non-MSF women (women who have never worked in agriculture) and their children
11618495|NCT00501241|Placebo Comparator|1|placebo twice daily
11618496|NCT00501241|Experimental|2|20 mg ATI-7505, BID for 4 weeks
11618497|NCT00501241|Experimental|3|40 mg ATI, BID, 4 weeks
11618498|NCT00501241|Experimental|4|80 mg ATI-4505, BID for 4 weeks
11618499|NCT00501241|Experimental|5|120 mg ATI-7505, BID for 4 weeks
11618500|NCT00501228|Experimental|Filgrastim Injections|
11618501|NCT00501215|Experimental|Parathyroidectomy + Observation|
11618502|NCT00501215|Other|Observation Alone|
11618503|NCT00501202|Placebo Comparator|002|placebo twice daily for 4 weeks
11618504|NCT00501202|Experimental|001|RWJ-333369 (carisbamate) 200 mg tablet twice daily for 4 weeks
11618505|NCT00501189||1|Those getting Gardasil vaccination for low grade Pap abnormality.
11618506|NCT00501189||2|Historical group that did not get Gardasil.
11618507|NCT00501176|Active Comparator|plastic stent|Stent insertion
11618508|NCT00501176|Active Comparator|metalic stent|Stent inserttion
11618509|NCT00501137|Active Comparator|16-26 year olds 3 doses HPV Vaccine|Group 3 - 16-26 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0, 2, 6 mths
11618510|NCT00501137|Active Comparator|3 dose 9-13 HPV Vaccine|Group 2 - 9-13 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0,2,6 mths
11618511|NCT00501137|Active Comparator|2 dose 9-13 yrs HPV Vaccine|Group 1 9-13 year olds 2 doses HPV (Human Papillomavirus) Vaccine at 0 and 6 mths
11618512|NCT00501111|No Intervention|1|Placebo
11618513|NCT00501111|Active Comparator|2|donepezil
11618514|NCT00501111|Experimental|3|AZD3480
11618515|NCT00501098|Experimental|I|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.
~No stratification is planned."
11618516|NCT00501085||LAP-BAND|Patients who receive the LAP-BAND AP Adjustable Gastric Banding System.
11618517|NCT00501072|Experimental|Open|Real-Time Continuous Glucose monitoring System (RT-CGMS) with alarm setting active and ability to view glucose trend profiles
11618518|NCT00501072|No Intervention|Blind|RT-CGMS is applied without alarm setting and without the ability to watch glucose trend profiles
11618519|NCT00501059|Experimental|Acetylsalicylic acid (Aspirin, BAYE4465)|Participants received 1 tablet of enteric-coated acetylsalicylic acid [100 milligram (mg)] orally once daily.
11618520|NCT00501059|Placebo Comparator|Placebo|Participants received 1 tablets of matching placebo orally once daily.
11618521|NCT00501046|Placebo Comparator|Placebo|
11618522|NCT00501046|Experimental|AST-120|
11618523|NCT00501007||Non-psychiatric smokers|Smokers not meeting criteria for Schizophrenia or Schizoaffective Disorder
11618524|NCT00501007||Smokers with Schizophrenia|Smokers meeting criteria for schizophrenia or schizoaffective disorder
11618525|NCT00500994|Experimental|fMRI study|subjects receiving MRI
11618526|NCT00500981|Experimental|Intravenous fluid bolus|Administration of 500 ml of 10% pentastarch
11618527|NCT00500968|Active Comparator|Stent|
11618528|NCT00500968|Active Comparator|conventional distal pancreatectomy|
11618529|NCT00500942||1|Patients having a standard procedure performed in Interventional Radiology.
11618530|NCT00500903|Experimental|PIC Dose Escalation|Alisertib 5, 10, 20, 40, 80, 110 or 150 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 7 to 21 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 51 cycles).
11618531|NCT00500903|Experimental|ECT Dose Escalation|Alisertib 10 or 20 mg, Enteric-coated Tablet (ECT) formulation, orally, once daily (QD) for 7 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 2 cycles).
11618532|NCT00500903|Experimental|Relative Bioavailability|Alisertib 40 mg ECT or PIC formulation, orally, twice daily (BID) for 7 days followed by a 14--day recovery period in cycle 1, followed by alisertib 40 mg in the opposite formulation (PIC or ECT) orally, twice daily (BID) for 7 days followed by a 14--day recovery period in cycle 2, followed by alisertib 50 mg PIC formulation orally, twice daily (BID) for 7 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 9 cycles).
11618533|NCT00500890|Experimental|Carboplatin + Etoposide + Vincristine|Carboplatin 350 mg/m^2 by vein, Over 2 Hours x 2 Days. Etoposide 100 mg/m^2 by vein, Over 1 Hour x 5 Days. Vincristine 1.5 mg/m^2 (by vein)IV Push Over 15 Minutes On Day 5. Radiation treatment over a period of about 6 weeks.
11618534|NCT00500890|Experimental|Cyclophosphamide + Etoposide + Vincristine|Cyclophosphamide 1 g/m^2 by vein, Over 1 Hour x 2 Days. Etoposide 100 mg/m^2 by vein, Over 1 Hour x 5 Days. Vincristine 1.5 mg/m^2 (by vein)IV Push Over 15 Minutes On Day 5. Radiation treatment over a period of about 6 weeks.
11618535|NCT00500877|Active Comparator|Mood Management Phone counseling|Mood management phone counseling for smoking cessation
11618536|NCT00500877|Placebo Comparator|Phone Counseling Standard|Phone counseling standard
11618537|NCT00500851|Active Comparator|1|In case of meeting clinical criteria for jejunal feeding, tubes are placed using CORTRAK (electromagnetic imaging).
11618541|NCT00500812|Experimental|0.3 mg|Subjects Receiving 0.3 mg Cethrin
11618543|NCT00500812|Experimental|3 mg|Subjects receiving 3 mg Cethrin
11618544|NCT00500812|Experimental|6 mg|Subjects receiving 6 mg Cethrin
11618545|NCT00500812|Experimental|9 mg|Subjects receiving 9 mg Cethrin
11618546|NCT00500786|Experimental|100 mcg CYT006-AngQb Healthy Volunteers|
11618547|NCT00500786|Experimental|100 mcg CYT006-AngQb Hypertensives|
11618548|NCT00500786|Experimental|300 mcg CYT006-AngQb Hypertensives|
11618549|NCT00500786|Placebo Comparator|Placebo Healthy Volunteers|
11618550|NCT00500786|Placebo Comparator|Placebo Hypertensives|
11618551|NCT00500760|Experimental|Panitumumab Plus Chemoradiation|Participants received standard radiation therapy for 7 weeks and cisplatin 75 mg/m^2 and panitumumab 9 mg/kg on Days 1, 22 and 43.
11618552|NCT00500760|Active Comparator|Chemoradiotherapy Alone|Participants received standard radiation therapy for 7 weeks and cisplatin 100 mg/m^2 on Days 1, 22, and 43.
11618553|NCT00500747|Experimental|Group C: 100 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 100 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
11618554|NCT00500747|Experimental|Group B: 20 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 20 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
11618555|NCT00500747|Experimental|Group A: 4 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 4 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
11618556|NCT00500734||Heart Disease Patients|
11618557|NCT00500695|Experimental|Motivational Interviewing|Motivational Interviewing
11618558|NCT00500695|Active Comparator|Psychoeducation|Psychoeducation
11618559|NCT00500682|Placebo Comparator|Placebo|
11618560|NCT00500682|Experimental|AST-120|
11618561|NCT00500669|Experimental|Betadine|
11618562|NCT00500669|Active Comparator|Saline|
11618563|NCT00500656|Experimental|Randomized controlled -Icatibant|"Subjects received S.C icatibant+ oral placebo
~Icatibant Form: solution for injection, 3 mL, 10 mg/mL Single dose: 30 mg (3 mL)
~Placebo Form: hard capsule Single dose: 2 capsules Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart"
11618564|NCT00500656|Active Comparator|Randomized controlled-Tranexamic acid|"Subjects received oral Tranexamic acid+ S.C. placebo
~Tranexamic acid Form: over encapsulated film tablet Single dose: 1000 mg (2 capsules) Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart
~Placebo Form: solution for injection, matched to icatibant for injection Single dose: 3 mL Frequency: one subcutaneous injection in the abdominal region"
11618565|NCT00500656|Experimental|Controlled Open-label / laryngeal attack|Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.
11618566|NCT00500656|Experimental|Untreated patients at the baseline|Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing were treated in the open label phase with icatibant
11618567|NCT00500617||segment 1|Gene discovery blood draw
11618568|NCT00500617||sement 2|Assay development blood draw
11618569|NCT00500617||segment 3|Assay validation blood draw
11618570|NCT00500617||segment 4|Additional assay testing blood draw (Note: post discovery diabetic subjects assigned to this group)
11618571|NCT00500604|Experimental|A|"period 1: Hydrochlorothiazide 12.5 mg for 3-5 weeks
~period 2: One 150/12.5mg tablet every morning for 8 weeks.
~period 3: One 300/12.5mg tablet every morning for 8 weeks.
~period 4: Two 150/12.5mg tablets every morning for 8 weeks."
11618572|NCT00500604|Active Comparator|B|"period 1: Hydrochlorothiazide 12.5 mg for 3-5 weeks
~period 2: One 80/12.5mg tablet every morning for 8 weeks.
~period 3: One 160/12.5mg tablet every morning for 8 weeks.
~period 4: Two 80/12.5mg tablets every morning for 8 weeks."
11618573|NCT00500591||Obese Women|
11618574|NCT00500578|Experimental|1: Standard Schedule - Ribavirin|Aerosolized Ribavirin 6 grams over 18 hours every 24 hours
11618575|NCT00500578|Experimental|2: Modified Schedule - Ribavirin|Aerosolized Ribavirin 2 grams over 3 hours every 8 hours
11618576|NCT00500565|Experimental|On-Q pump with Saline|On-Q Pump with Saline
11618577|NCT00500565|Experimental|On-Q Pump with Bupivicaine|On-Q Pump with bupivicaine
11618578|NCT00500526|Experimental|1 Singing Group|Patients who will receive singing classes
11618579|NCT00500526|Other|2 Control group|Patients who will attend hand craft classes
11618580|NCT00500513|Experimental|Implanted Markers + CT + RT|
11618581|NCT00500500|Experimental|EGb 761® (Tanakan®)|EGb 761® (Tanakan®)
11618582|NCT00500500|Placebo Comparator|Placebo|Placebo
11618583|NCT00500487|Experimental|1|
11618584|NCT00500487|Active Comparator|2|
11618585|NCT00500487|Active Comparator|3|
11618586|NCT00500461|Experimental|Subjects receiving GSK233705|Each subject will receive one or more ascending doses given as a constant rate IV infusion over 30 minutes and a single oral dose of 250 microgram GSK233705 solution. IV doses will include 30, 70, 110 microgram of GSK233705 at specified time points.
11618587|NCT00500448|No Intervention|No Treatment|No treatment was delivered to this arm. Participants went about activities of daily living
11618588|NCT00500448|Experimental|Electrical Stimulation|Neuromuscular electrical stimulation treatments 3 times per week for 4 weeks
11618589|NCT00500435||Laparoscopy Procedure|Laparoscopy procedure in abdomen to remove para aortic lymph nodes of patients diagnosed with cervical cancer.
11618590|NCT00500422|Experimental|Doxil + Gemcitabine + Velcade|Doxil Starting dose of 20 mg/m^2 intravenous (IV) over 2 hours on Day 1 and Gemcitabine 500 mg/m^2 IV over 30 minutes on Days 1 and 8; Velcade Starting dose of 0.7 mg/m^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles.
11618591|NCT00500409|Experimental|Drug Group|Osteoform
11618592|NCT00500409|Active Comparator|Control group|SHELCAL
11618593|NCT00500370|Experimental|Group A|
11618594|NCT00500370|Placebo Comparator|Group B|
11618595|NCT00500344|Other|1|
11618596|NCT00500331|Experimental|Arm 1|GSK189075
11618597|NCT00500331|Placebo Comparator|Arm 2|Placebo
11618598|NCT00500331|Other|Arm 3|pioglitazone (active control)
11618599|NCT00500318|Experimental|Aclidinium|
11618600|NCT00500318|Placebo Comparator|Placebo|
11618601|NCT00500292|Placebo Comparator|1|FOLFOX + Placebo vandetanib
11618602|NCT00500292|Experimental|2|FOLFOX + low dose vandetanib
11618603|NCT00500292|Experimental|3|FOLFOX + high dose vandetanib
11618604|NCT00500253|Active Comparator|1|children with asthma with FeNO monitored treatment (study group)
11618605|NCT00500253|Other|2|group of children with treatment monitored by GINA's grade of disease clinical control (control group)
11618606|NCT00500240|No Intervention|Conventional Care|Control Group: Conventional care using blood sugar management with regular human insulin.
11618607|NCT00500240|Other|Intensive Insulin|Intervention Group: Intense blood sugar management with Insulin Aspart + Insulin Glargine
11618608|NCT00500201|Experimental|Subjects in treatment sequence AB|In treatment sequence AB first subjects will be randomized to receive treatment A (two tablets of 60 milligram [mg] of SB-773812) and one placebo tablet. Then subjects will receive treatment B (one tablet of 120 mg of SB-773812) and two placebo tablets . There will be a wash-out period of 20 days between.
11618609|NCT00500201|Experimental|Subjects in treatment sequence BA|In treatment sequence BA first subjects will be randomized to receive treatment B (one tablet of 120 mg of SB-773812) and two placebo tablets. Then subjects will receive treatment A (two tablets of 60 mg of SB-773812) and one placebo tablet. There will be a wash-out period of 20 days between.
11618610|NCT00500188|Experimental|7 Days|Imatinib Mesylate 300 mg orally twice daily starting 7 days before surgery.
11618611|NCT00500188|Experimental|5 Days|Imatinib Mesylate 300 mg orally twice daily starting 5 days before surgery.
11618612|NCT00500188|Experimental|3 Days|Imatinib Mesylate 300 mg orally twice daily starting 3 days before surgery.
11618613|NCT00500162|Active Comparator|1|
11618614|NCT00500162|Active Comparator|2|
11618615|NCT00500149|Experimental|1|
11618616|NCT00500149|Placebo Comparator|2|
11618617|NCT00500110|Experimental|Hormonal Ablation, Imatinib + Docetaxel|Imatinib Mesylate 600 mg by mouth (PO) daily + Docetaxel 30 mg/m^2 by vein (IV) weekly + Hormonal Ablation (Goserelin Acetate or Leuprolide) injections every other month or every 3 months
11618618|NCT00500084|Experimental|Liprotamase|Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units) administered orally with each of three meals and two snacks daily for 12 months
11618619|NCT00500071|Experimental|1|
11618620|NCT00500058|Experimental|SB-485232+Rituximab|Rituximab 375 milligrams per square meter (mg/m^2) will be administered to subjects with CD20+ B cell lymphoma by intravenous (IV) infusion once a week for four consecutive weeks on Day 1 of Weeks 1 to 4. SB-485232 will be administered by IV infusion over a 2 hour period, at doses ranging from 1 microgram (μg)/kilogram (kg) to 100 μg/kg. SB-485232 will be given once a week for 12 consecutive weeks on Day 2 of Weeks 1 to 4 and Day 2 (± 1 day) of Weeks 5 to 12. SB-485232 will be infused at least 24 hours after the Rituximab infusion was started.
11618621|NCT00500045|Experimental|Treatment|Oral niacin
11618622|NCT00500032|Experimental|Arm 1|Active Comparator for all subjects enrolled in 6108A1-500
11618623|NCT00500019||1.|Elective Cesarean sections
11618624|NCT00500019||2.|Non-elective cesarean section
11618625|NCT00500006|Other|A|Arm A: Drug and comparator
11618626|NCT00500006|Other|B|Arm B: Drug and comparator
11618627|NCT00499967|Experimental|Cohort 1|GS-9191 0.01% ointment
11618628|NCT00499967|Experimental|Cohort 2|GS-9191 0.03% ointment
11618629|NCT00499967|Experimental|Cohort 3|GS-9191 0.1% ointment
11618630|NCT00499967|Active Comparator|Cohort 4|GS-9191 0.3%
11618631|NCT00499967|Active Comparator|Cohort 5|GS-9191 1.0%
11618632|NCT00499967|Placebo Comparator|Cohorts 1, 2, 3, 4 & 5|Placebo in all cohorts
11618633|NCT00499915|Experimental|Secondhand Smoke Reduction and Asthma Education|Parents of children in the experimental group will receive asthma education at NICU discharge as well as a secondhand smoke reduction program.
11618634|NCT00499915|Active Comparator|Asthma Education|Parents of children in the active comparator group will receive asthma education at NICU discharge.
11618635|NCT00499902|Other|2 stages|This is a two-stage study. The first stage is in a three-tier dose escalation format, followed by a second stage during which subjects will be randomized in an equal proportion to up to 3 qualifying dose arms.
11618636|NCT00499889|Experimental|Imatinib, Busulfan, Fludara + Antithymocyte Globulin|Oral Imatinib Mesylate 400 mg twice a day for 9 Days; Busulfan 130 mg/m^2 by vein (IV) daily for 2 Days; Fludara 40 mg/m^2 IV daily for 4 Days; Antithymocyte Globulin (ATG) 2.5 mg/kg IV daily for 3 Days; Tacrolimus levels maintained between 5-15 ng/dl, Day -2 to Day 180; Methotrexate 5 mg/m2 on days 1, 3, 6 and 11; and Donor bone marrow or blood stem cells infused on day 0 with possible donor lymphocyte infusion (DLI) for progressive disease.
11618637|NCT00499876|Active Comparator|A|
11618638|NCT00499876|Placebo Comparator|B|
11618639|NCT00499863|Experimental|Methylphenidate Transdermal System|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
11618640|NCT00499863|Placebo Comparator|2|Daily application of matching MTS Placebo Patch
11618641|NCT00499837|Experimental|80 mg/kg AAT inhaled|80 mg/kg AAT inhaled
11618642|NCT00499837|Placebo Comparator|Placebo inhaled|Placebo inhaled
11618643|NCT00500266|Experimental|1|13-valent Pneumococcal Conjugate Vaccine
11618644|NCT00499824|Experimental|1|Medical Practitioners who receive education on diabetes management following the guidelines of the International Diabetes Federation Western Pacific Region
11618645|NCT00499824|No Intervention|2|Medical practitioners who follow standard practice for management of their patients with type 2 diabetes
11618646|NCT00499811|Experimental|Treatment (enzyme inhibitor therapy)|"Vorinostat (SAHA) will be administered as a single oral dose on day -6 for all patients. Blood samples are obtained periodically on day -6 for pharmacokinetic studies.
~One week later (day 1), the first course of oral vorinostat will be initiated on a continuous daily oral regimen. Each treatment course will consist of 21 days of therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
11618647|NCT00499798||patients on temozolimide for brain cancer|
11618648|NCT00499785||patients admitted with acute leukemia|
11618649|NCT00499746|Active Comparator|Tramadol|oral dose, once per day
11618650|NCT00499746|Placebo Comparator|Placebo|oral dose, once per day
11618651|NCT00499746|Active Comparator|hydromorphone|oral dose, once per day
11618652|NCT00499746|Active Comparator|methylphenidate|oral dose, once per day
11618653|NCT00499733|Experimental|Intervention|Participant will receive one time intravenous infusion of cyclophosphamide three days after scheduled cryoablation surgery.
11618654|NCT00499694|Experimental|Bevacizumab and Satraplatin|"Bevacizumab 10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)
~Satraplatin 80 mg/m(2), Orally, Days 1-5, every 35 days"
11618655|NCT00499681|Experimental|Arm I|Patients receive Lapatinib and Letrozole once daily for two weeks, following tumor measurement patients receive Lapatinib and Letrozole once daily for 14 weeks.
11618656|NCT00499681|Experimental|Arm II|Patients receive Letrozole and placebo once daily for 2 weeks, following tumor measurement patients receive Letrozole and Lapatinib once daily for 14 weeks.
11618657|NCT00499668|Experimental|ARM A|
11618658|NCT00499668|Experimental|ARM B|
11618659|NCT00499655|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.
11618660|NCT00499655|Experimental|Arm II|Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily on days 1-28.
11618661|NCT00499629|Active Comparator|1|Arm 1: FXR 450
11618662|NCT00499629|Placebo Comparator|2|Placebo
11618663|NCT00499616|Experimental|Group 2 (chemotherapy, surgery)|2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.
11618664|NCT00499616|Experimental|Group 3 (chemotherapy, surgery)|4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
11618665|NCT00499616|Experimental|Group 4 (chemotherapy, surgery, antineoplastic therapy)|8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients < 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
11618666|NCT00499616|Experimental|Non-intermediate risk enrolled on intermediate risk trial|The no treatment group assignment patients may have received some treatment on ANBL0531 but they were not evaluable on this study due to being non-intermediate risk and hence did not receive a treatment assignment on ANBL0531.
11618667|NCT00499603|Experimental|Paclitaxel + FEC|Paclitaxel 80 mg/m^2 intravenously (IV) on day 1(+/- 2 days) of each week, followed by four cycles of combination 5-Fluorouracil at 500 mg/m^2, Epirubicin at 100 mg/m^2 and Cyclophosphamide at 500 mg/m^2 (FEC) on day 1 every 3 weeks (+/- 7 days).
11618668|NCT00499603|Experimental|Paclitaxel + RAD001 + FEC|Paclitaxel + RAD001 Followed by FEC (5-Fluorouracil + Epirubicin + Cyclophosphamide)
11618669|NCT00499590|Active Comparator|A|Lucentis® (0.5mg) every 4 weeks.
11618670|NCT00499590|Experimental|B|Bevasiranib (2.5mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
11618671|NCT00499590|Experimental|C|Bevasiranib (2.5mg) every 12 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
11618672|NCT00499577|Experimental|Group 1 (HLA-A2 positive)|Patients receive the following peptides emulsified in incomplete Freund's adjuvant VG: I) hTERT I540 peptide; ii) hTERT R572Y peptide; iii) hTERT D988Y peptide; iv) survivin Sur1M2 peptide ; and v) CMV control peptide N495 subcutaneously (SC). Patients also receive sargramostim (GM-CSF) SC and pneumococcal conjugate vaccine intramuscularly.
11618673|NCT00499577|Experimental|Group 2|Patients receive pneumococcal conjugate vaccine intramuscularly and GM-CSF subcutaneously.
11618674|NCT00499577|Experimental|Second group 1|On days 14, 42, and 90 post-transplant, patients receive peptides and GM-CSF subcutaneously and pneumococcal conjugate vaccine intramuscularly.
11618675|NCT00499577|Experimental|Second group 2|On day 14, 42, 90 post-transplant, patients receive pneumococcal conjugate vaccine intramuscularly and GM-CSF subcutaneously.
11618676|NCT00499525|Experimental|Arm I|Patients receive paclitaxel IV over 1 hour once weekly for 3 weeks. Patients also receive oral sorafenib tosylate twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11618677|NCT00499525|Active Comparator|Arm II|Patients receive paclitaxel as in arm I and oral placebo twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11618678|NCT00499512||Spirituality Questionnaire|Patients with newly diagnosed ovarian, primary peritoneal, or fallopian tube cancer.
11618679|NCT00499499|Experimental|1|
11618680|NCT00499486|Experimental|Sirolimus|Sirolimus 5mg. po QD continously (28 days=cycle)
11618681|NCT00499473|Experimental|Stratum 1 (kinase inhibitor therapy)|Non-EIAC patients receive oral sunitinib malate once daily for 4 consecutive weeks followed by 2 weeks of rest.
11618682|NCT00499473|Experimental|Stratum 2 (kinase inhibitor therapy)|EIAC & OSU patients receive oral sunitinib malate as in stratum 1. Patients receive escalating doses of oral sunitinib malate until the maximum tolerated dose (MTD) is determined.
11618683|NCT00499460|Other|Arm I|Two 30-day treatment periods separated by a washout of at least 4 weeks. In Period 1, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29. In Period 2, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
11618718|NCT00499044|Experimental|2|Cognitive Drug Research Computerized Cognitive Assessment System
11618719|NCT00499031|Experimental|Treatment (cetuximab)|Patients receive cetuximab IV over 120 minutes on day 1.
11618684|NCT00499460|Other|Arm II|Two 30-day treatment periods separated by a washout of at least 4 weeks. In Period 1, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29. In Period 2, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
11618685|NCT00499447|Experimental|Radiofrequency Ablation with External Beam Radiation|Radiofrequency Ablation (RFA)under computerized tomography guidance followed 3-4 weeks later with External Beam Radiation Therapy
11618686|NCT00499421||CT Scan|CT Scan with Fiducial markers + external beam radiation therapy
11618687|NCT00499408|Experimental|Soy and Vitamin D|Patients will receive oral supplementation with both 2,000 IU per day of vitamin D (cholecalciferol) and soy (160 mg per day soy isoflavones). Serum PSA and plasma levels of vitamin D will be assessed monthly. Soy isoflavones levels will be assessed every three months.
11618688|NCT00499382||PET/CT scan + NM cardiac scan|
11618689|NCT00499369|Experimental|Arm I (chemotherapy, cetuximab)|Patients receive single-agent irinotecan hydrochloride IV or FOLFIRI IV. They also receive cetuximab IV over 1-2 hours on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
11618690|NCT00499369|Experimental|Arm II (chemotherapy, cetuximab, bevacizumab)|Patients receive single-agent irinotecan hydrochloride or FOLFIRI AND cetuximab as in arm I. Patients also receive bevacizumab IV over 30 minutes on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
11618691|NCT00499369|Experimental|Arm III (closed to accrual as of 4/20/2009)|Patients receive single-agent irinotecan hydrochloride or FOLFIRI AND cetuximab as in arm I. Patients also receive a higher dose of bevacizumab (higher than in arm II) IV over 30 minutes on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
11618692|NCT00499343|Experimental|Rituximab + Ifosfamide + Etoposide + 2 Growth Factors|Growth Factors = granulocyte-colony stimulating factor (G-CSF) + granulocyte macrophage-colony stimulating factor (GM-CSF)
11618693|NCT00499343|Experimental|Rituximab + Ifosfamide + Etoposide + 1 Growth Factor|Growth Factor = granulocyte-colony stimulating factor (G-CSF)
11618694|NCT00499330|Other|Arm A|Patients undergo a standard operation for lung cancer called a lobectomy.
11618695|NCT00499330|Experimental|Arm B|Patents undergo a limited resection (segentectomy or wedge resection), which a smaller portion of the lung is removed.
11618696|NCT00499265|Active Comparator|Gemcitabine|
11618697|NCT00499265|Experimental|Gemcitabine plus 200 mg WX-671|
11618698|NCT00499265|Experimental|Gemcitabine plus 400 mg WX-671|
11618699|NCT00499252|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation (Abraxane®) IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11618700|NCT00499239|Experimental|GS-9219|Escalating doses of GS-9219 (5, 8, 11.5, 16, 22.5, 31.5, 44, and 61.5 mg/m^2) until determination of the maximum tolerated dose (MTD)
11618701|NCT00499200|Experimental|SRA-444 + Placebo|Experimental; Placebo
11618702|NCT00499187||Fanconi Cases|This cohort enrolled participants with evidence of protocol-defined Fanconi syndrome (confirmed creatinine clearance decline and evidence of proximal tubulopathy).
11618703|NCT00499187||Control Cases|This cohort enrolled participants with no evidence of protocol-defined Fanconi syndrome.
11618704|NCT00499174|No Intervention|Active Surveillance|Active surveillance with radical intervention at the time one or more of the following occur: Biochemical progression; Grade progression; Clinical progression
11618705|NCT00499174|Active Comparator|Radical Intervention|Radical prostatectomy or radiotherapy based on patient and physician preference
11618706|NCT00499161|No Intervention|1|Control group received usual care
11618707|NCT00499161|Experimental|2|Received intervention New model of nursing care
11618708|NCT00499135|Experimental|Schedule A|Patients receive sunitinib malate PO QD in weeks 1-4. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
11618709|NCT00499135|Experimental|Schedule B|Patients receive sunitinib malate PO QD in weeks 1, 2, 4, and 5. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
11618710|NCT00499122|Experimental|NOV-002 and Chemotherapy|"NOV-002:
~Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart
~Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration
~Cycle 1 - 8, Days 2 - 21: 60 mg subcutaneous injections
~Cyclophosphamide: 600 mg/m2 IV, Cycles 1 - 4, Day 1
~Doxorubicin: 60 mg/m2 IV, Cycles 1 - 4, Day 1
~Docetaxel: 100 mg/m2 IV, Cycles 5 - 8, Day 1"
11618711|NCT00499109|Experimental|E. Dual Agent Chemotherapy|"Experimental Arm E.
~Patients received treatment according to gene expression strata with four doublet regimens.
~Low ERCC1 and Low RRM1 Group - Gemcitabine (G) and Carboplatin (Cb): GCb Group.
~Low RRM1 and High ERCC1 Group - Gemcitabine (G) and Docetaxel (D): GD Group.
~High RRM1 and Low ERCC1 Group - Docetaxel (D) and Carboplatin (Cb): DCb Group.
~High ERCC1 and High RRM1 Group - Vinorelbine (V) and Docetaxel (D): DV Group."
11618712|NCT00499109|Active Comparator|C. Standard of Care Control Arm|"Control Arm C: Gemcitabine and Carboplatin (GCb).
~All patients in arm C were treated with GCb regardless of gene expression levels. Patients received up to 6 cycles, and no maintenance therapy was allowed."
11618713|NCT00499096|Experimental|Chronic Care Model for Bipolar Disorder|An intervention group of patients with bipolar disorder and 1 or more risk factor for cardiovascular disease; group will receive self-management group sessions, followed by phone contacts by the Care Manager. This is the chronic care model for bipolar disorder
11618714|NCT00499096|No Intervention|Enhanced Usual Care|A group of patients with bipolar disorder and one or more risk factors for cardiovascular disease will be randomized to receive enhanced usual care. This group will receive usual care, plus mailings on wellness topics (attention control), and their providers will receive information on guideline concordant care.
11618715|NCT00499083|Experimental|Vaccine|Patients with HER-2/neu negative tumors will receive IT DCs one week after the first three of four cycles of dose dense T therapy and then four cycles of dose dense AC therapy will be given (i.e. T-AC).
11618716|NCT00499057|Other|single arm study|single arm study
11618717|NCT00499044|Experimental|1|MATRICS Consensus Cognitive Battery
11618720|NCT00499018|Experimental|1|R-MegaCHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT
11618721|NCT00499018|Experimental|1 BIS|R-CHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT
11618722|NCT00499018|Experimental|2|R-MegaCHOP14 x 4 Restaging + R-MegaCHOP x 2
11618723|NCT00499018|Experimental|2 BIS|R-CHOP14 x 4 Restaging + R-CHOP14 x 4
11618724|NCT00499005|Active Comparator|Primi|
11618725|NCT00499005|Active Comparator|Multi|
11618726|NCT00498979|Experimental|recombinant interferon alfa-2b|recombinant interferon alfa-2b
11618727|NCT00498966|Experimental|Group A|Patients in group A will have previously failed a VEGF receptor inhibitor but not an mTOR inhibitor.Intervention: Perifosine.
11618728|NCT00498966|Experimental|Group B|Patients in group B will have failed both a VEGF receptor inhibitor and an mTOR inhibitor. Intervention: Perifosine.
11618729|NCT00498940|Active Comparator|Biventricular Pacing|After weaning from bypass, patients received temporary biventricular pacing for 24 hours. Values obtained from optimization testing determined pacemaker settings (AVD, VVD, heart rate).
11618730|NCT00498940|Active Comparator|Standard of Care|No continuous pacing occurred about surgery. Patients underwent optimization testing.
11618731|NCT00498927|Experimental|Temozolomide|Following diagnosis of tumor recurrence or progression, all patients will receive of daily low dose temozolomide given at 50mg/m2/d without interruption. Brain imaging will be performed at baseline and every 2 months (standard of care). The treatment will be administered until development of toxicity, evidence of progression of disease or death.
11618732|NCT00498914|Experimental|1|
11618733|NCT00498888|Active Comparator|1|Women were prescribed a 3 month supply of Tolterodine SR 4 mg (Detrusitol SR 4 mg, Pfizer Pharmaceuticals Israel LTD) . After the randomization she needs to get the first prescription from her doctor, and followed this protocol every three weeks. Her doctor how already knows this research were explained how to take the drug. After finished this protocol she get the money she pay after sending the receipts and the empty boxes.
11618734|NCT00498888|Active Comparator|2|The Bladder training protocol aims o to increase the time interval between voids, either by a mandatory or self-adjustable schedule, so that incontinence is ultimately avoided and continence regained. It is generally comprised of three components: 1) patient education that includes information about bladder and how continence is usually maintained, 2) scheduled voiding- a 'timetable for voiding' which may fixed or flexible to suit the participant's rate of increase in interval between voids, commonly the aim is to achieve an interval of three to four hours between voids and 3) positive reinforcement- - psychological support and encouragement is generally considered important and usually provided by health care professional . Frequency volume chart (FVC) records the time and volumes of voided for 24 hours by the women between the appointments. Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
11618735|NCT00498888|Active Comparator|3|The Pelvic floor muscle training (PFMT) protocol based on National Institute for health and clinical excellence (NICE clinical guideline 40, 2006), that the PFMT programs should comprise at least eight contractions performed three times per day, and the trial of supervised PFMT of at least 3 months' duration . Each appointment the women maid three sets of eight to 12 slow maximal contractions sustained for 6-8 second, and asked to made this protocol every day, and taught to contract these muscle to suppress urge filling. Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
11618736|NCT00498888|Active Comparator|4|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for pelvic floor muscle training and bladder training and lifestyle advice and information about good bladder and bowel habits.
11618737|NCT00498875||Questionnaire + Depression Intervention|
11618738|NCT00498784|Experimental|Arm 1|
11618739|NCT00498771|Active Comparator|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
11618740|NCT00498771|No Intervention|Control - No Exercise Arm|No exercise will be performed in Control arm. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL) at baseline, 6 week, 6 and 12 month.
11618741|NCT00498719||CTP Group|One-on-one cognitive training
11618742|NCT00498719||Control Group|Standard educational support.
11618743|NCT00498706|Experimental|Telephone-administered CBT|Participants will receive telephone-administered cognitive behavioral therapy.
11618744|NCT00498706|Active Comparator|Face-to-face CBT|Participants will receive face-to-face cognitive behavioral therapy.
11618745|NCT00498680|Active Comparator|Viagra 100mg|
11618746|NCT00498680|Active Comparator|Levitra 20mg|
11618747|NCT00498680|Active Comparator|Viagra 50mg+ Levitra 10mg|
11618748|NCT00498667||PET/CT|all patients with aggressive lymphoma who had a baseline and interim pet/ct study
11618749|NCT00498628|Experimental|1|Quetiapine fumarate plus medical management
11618750|NCT00498628|Placebo Comparator|2|Medical management plus placebo comparator
11618751|NCT00498615|Experimental|Fasudil 80 mg|Subject is given a single dose of 80 mg of Fasudil ( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
11618752|NCT00498615|Experimental|40 mg Fasudil|Subject is given a single dose of 40 mg of Fasudil ( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
11618753|NCT00498615|Placebo Comparator|placebo|Subject is given a single dose of placebo( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
11618754|NCT00498602|Experimental|1|ACC-001
11618755|NCT00498602|Other|2|QS-21
11618756|NCT00498602|Other|3|Diluent: Phosphate Buffered Saline
11618757|NCT00498602|Experimental|4|ACC-001
11618758|NCT00498589|Placebo Comparator|1|Methotrexate IM or SC 25 mg/week vs placebo IM or SC for 24 weeks
11618759|NCT00498589|Placebo Comparator|2|1 IM or SC of placebo per week during 24 weeks
11618760|NCT00498576||1|kidney transplant with hypertension
11618761|NCT00498576||2|hypertensive patients with native kidneys
11618762|NCT00498576||3|healthy controls
11618763|NCT00498550|Experimental|Clozapine|Clozapine, Clozaril
11618764|NCT00498550|Active Comparator|Treatment as usual|Treatment as usual with any antipsychotic other than Clozapine.
11618765|NCT00498537|Other|1|
11618766|NCT00498537|Other|2|
11618767|NCT00498524||1|Sib who has received an ICD
11618768|NCT00498524||2|Sib who has not received an ICD
11618769|NCT00498485|Placebo Comparator|Placebo|Patients were randomized and these received placebo
11618770|NCT00498485|Active Comparator|Sodium Oxybate|Patients were randomized and these received the active drug
11618771|NCT00498472|Active Comparator|A|Pre-discharge NT-ProBNP based
11618772|NCT00498472|No Intervention|B|Discharge date and treatment not based on the knowledge of pre-discharge NT-proBNP levels
11618773|NCT00498459|Experimental|ICAPS|Promotion Physical Activity
11618774|NCT00498459|No Intervention|Control|No specific physical activity promotion Ususal school program
11618775|NCT00498433|Experimental|Aliskiren|"Part 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase (period 1) consisting of treatment with one tablet of placebo to aliskiren once daily (o.d.). This was followed by a 4 week treatment phase (period 2) consisting of treatment with 300 mg aliskiren o.d..
~Part 2: Eligible randomized patients in this arm received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks."
11618776|NCT00498433|Active Comparator|Amlodipine|"Part 1: After aliskiren treatment (period 2), each patient was entered into a second washout period (4 weeks) during which blood pressure was required to be ≤ 140/90 mmHg. If blood pressure exceeded 140/90 mmHg on two consecutive days (home monitoring) and was confirmed at the study center, the patient was entered into the amlodipine treatment period (period 3). In period 3, all patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks.
~Part 2: Eligible patients randomized to part 2 received amlodipine 5 mg o.d. and aliskiren placebo for 12 weeks"
11618777|NCT00498368|Experimental|Rituximab Plus ACE/ARB|Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement
11618778|NCT00498368|Active Comparator|ACE/ARB|ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement
11618779|NCT00498355|Experimental|Ranibizumab|0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
11618780|NCT00498316|Other|Cord Blood Infusion|"Cord blood transplantation performed on day 0. Busulfan 32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4.
~Fludarabine 10 mg/m2 by vein on Days -7 to -4, 40 mg/m2 by vein on Days -6 to -3 or on Days -5 to -2.
~Rituximab 375 mg/m2 by vein on Day -9. ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3, 1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2.
~Cyclophosphamide 50 mg/kg by vein on Day -6. Clofarabine 30 mg/m2 by vein on Days -7 to -4. Total body irradiation (TBI) 200 cGy at 25 cGy/minute delivered on Day -3. Melphalan 140 mg/m2 by vein on Day -2. Tacrolimus 0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present."
11618781|NCT00498290|Experimental|A|received enhanced recovery after surgery (ERAS) protocol in colorectal surgery
11618782|NCT00498290|No Intervention|B|normal recovery protocol in colorectal surgery
11618783|NCT00498277||Spinal MRI|
11618784|NCT00498225|Experimental|1|Gemcitabine plus TS-1
11618785|NCT00498225|Experimental|2|TS-1
11618786|NCT00498225|Active Comparator|3|Gemcitabine
11618787|NCT00498212|Experimental|1018 ISS-HBsAg-Single|Single dose (3000 µg 1018 ISS + 20 µg rHBsAg)
11618788|NCT00498212|Experimental|1018 ISS-HBsAg-Double|Double dose (6000 µg 1018 ISS + 40 µg rHBsAg)
11618789|NCT00498186|Experimental|Rotigotine|Rotigotine trans-dermal patch
11618790|NCT00498173|Experimental|Atomoxetine|Participants will receive flexibly dosed atomoxetine for 8 weeks. Dosage can be increased over the first 4 weeks of study participation and will then be held constant for the remainder of the 8-week trial.
11618791|NCT00498173|Placebo Comparator|Placebo|Participants will receive blinded, matched placebo for 8 weeks. Dosage can be increased over the first 4 weeks of study participation and will then be held constant for the remainder of the 8-week trial.
11618792|NCT00498160|Experimental|Living or Deceased Donor Kidney Allograft|Recipients with the need for a living kidney allograft are treated with an enriched hematopoetic stem cell infusion from the same living donor. Recipients with the need for a deceased donor kidney allograft are treated with an enriched hematopoetic stem cell infusion from the same deceased donor
11618793|NCT00498147||ADEC <6months|Patients new to the ADEC program who will be provided the ADEC interventions (prospective study)
11618794|NCT00498147||ADEC >6months|Patients who have been with the ADEC program as early as 2002 (coincides with ADEC's EMR initiation date) who continue to be provided the ADEC interventions (combined retrospective/prospective study)
11618795|NCT00498121||VAP patient|
11618796|NCT00498069|Active Comparator|1|Injection of autologous bone marrow concentrate into ischemic tissues of the lower extremity
11618797|NCT00498069|Placebo Comparator|2|Injection of placebo into ischemic tissues of the lower extremity
11618798|NCT00498056|Experimental|1|Participants will receive a total of three injections of the DNA vaccine VRC-HIVDNA016-00-VP followed by one injection of the adenovirus vaccine VRC-HIVADV014-00-VP. Injections will occur at study entry and Weeks 4, 8, and 24.
11618799|NCT00498056|Placebo Comparator|2|Participants will receive a total of three injections of the DNA vaccine VRC-HIVDNA016-00-VP placebo followed by one injection of the adenovirus vaccine VRC-HIVADV014-00-VP placebo. Injections will occur at study entry and Weeks 4, 8, and 24.
11618800|NCT00498043|Experimental|R-CHOP-14|R-CHOP14 induction regimen
11618801|NCT00498043|Experimental|R-ACVBP14|R-ACVBP14 induction regimen
11618802|NCT00497978|Active Comparator|1|taurine will be given per capsule
11618803|NCT00497978|Placebo Comparator|2|placebo capsules containing microcrystalline cellulose will be given
11618804|NCT00497952|Experimental|Multiple Sclerosis Patients|Recipients treated with a hematopoetic stem cell infusion from a living donor
11651777|NCT00061633|Experimental|Telavancin|
11618805|NCT00497926|Experimental|Living Kidney Allograft|Recipients with the need for a living kidney allograft are treated with an enriched hematopoietic stem cell infusion from the same living donor
11618806|NCT00497913|Active Comparator|A|
11618807|NCT00497913|Placebo Comparator|B|
11618808|NCT00497900|Experimental|1|Calcium and vitamin D
11618809|NCT00497900|Placebo Comparator|2|Calcium and placebo (cellulose)
11618810|NCT00497874|Experimental|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
11618811|NCT00497874|No Intervention|Usual care|Usual primary care treatment
11618812|NCT00497848|Active Comparator|motivational interviewing|
11618813|NCT00497848|Experimental|The System Orientated Intervention|
11618814|NCT00497809|Experimental|1|AVI-014 2.5mcg/kg
11618815|NCT00497809|Experimental|2|AVI-014 5.0 mcg/kg
11618816|NCT00497809|Experimental|3|AVI014 10.0 mcg/kg
11618817|NCT00497809|Active Comparator|4|Filgrastim 5.0 mcg/kg
11618818|NCT00497796|Experimental|1|
11618819|NCT00497796|Active Comparator|2|
11618820|NCT00497770||Caucasian|Caucasian patients receiving Alimta for 2nd line NSCLC
11618821|NCT00497770||African American|African American patients receiving Alimta for 2nd line NSCLC
11618822|NCT00497770||Asian American|Asian American patients receiving Alimta for 2nd line NSCLC
11618823|NCT00497770||Hispanic|Hispanic patients receiving Alimta for 2nd line NSCLC
11618824|NCT00497757|Experimental|Cardiac Failure Patients|Recipients treated with an enriched hematopoetic stem cell infusion from the heart donor's bone marrow
11618825|NCT00497653|Experimental|DCI|
11618826|NCT00497653|Placebo Comparator|Placebo|
11618827|NCT00497614|Other|No arm|
11618828|NCT00497601|Experimental|A|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 and 3
11618829|NCT00497601|Experimental|B|Amphotericin B in fat emulsion (Amphomul) 10 mg/kg on day 1 and 5 mg/kg on day 3
11618830|NCT00497601|Experimental|C|Amphotericin B in fat emulsion (Amphomul) 12.5 mg/kg on day 1 and 2.5 mg/kg on day 3
11618831|NCT00497601|Experimental|D|Amphotericin B in fat emulsion (Amphomul) 15 mg/kg in a single dose administration on day 1
11618832|NCT00497588|Active Comparator|radiotherapy|patients receive radiotherapy
11618833|NCT00497588|Experimental|surgery|Patients undergo surgery
11618834|NCT00497549|Active Comparator|1|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
11618835|NCT00497549|Active Comparator|2|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
11618836|NCT00497536|Active Comparator|1|≈ bolus protocol.
11618837|NCT00497536|Active Comparator|2|≈ CSII protocol
11618838|NCT00497536|Active Comparator|3|≈ CIII protocol.
11618839|NCT00497523|Experimental|Beclomethasone dipropionate|
11618840|NCT00497523|Experimental|Beclomethasone dipropionate/Salbutamol combination|
11618841|NCT00497523|Active Comparator|Salbutamol|
11618842|NCT00497497|Experimental|1|
11618843|NCT00497497|Experimental|2|
11618844|NCT00497458|Placebo Comparator|Arimidex|Arimidex 1 mg plus placebo
11618845|NCT00497458|Active Comparator|Arimidex test 40mg|Arimidex 1mg and testosterone 40mg
11618846|NCT00497458|Active Comparator|Arimidex plus test 80mg|Arimidex 1mg and testosterone 80mg
11618847|NCT00497445|Experimental|Angioplasty / surgery and exercise therapy|Angioplasty / surgery followed by supervised exercise therapy
11618848|NCT00497445|No Intervention|Angioplasty / surgery|Angioplasty / surgery alone
11618849|NCT00497393|No Intervention|Control|regular use of the 2-bed areas in the Emergency department
11618850|NCT00497380|Experimental|Arginine enriched nutrition|
11618851|NCT00497380|Placebo Comparator|Nutrition|
11618852|NCT00497367|Experimental|TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent|This arm received the TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent.
11618853|NCT00497341|Experimental|1|antibiotic is given before tourniquet inflation and before tourniquet release
11618854|NCT00497341|Placebo Comparator|2|antibiotic is given before tourniquet inflation
11618855|NCT00497328|Other|N-acetylcysteine Group (NAC)|"N-acetylcysteine Group (NAC)
~Intravenous infusion 154mEq/L of sodium chloride (0.9% normal saline) at a rate of 1mL/kg/hour from 12 hours before till 6 hours after cardiac catheterization Oral NAC 1200mg dissolve in 250ml of water twice a day the day before to the day after the procedure (total 6 doses)"
11618856|NCT00497328|Other|Sodium Bicarbonate Group (SOB)|"Sodium Bicarbonate Group (SOB)
~Intravenous infusion154meq/L sodium bicarbonate in 5% dextrose in water at a rate of 3 mL/kg/hour for 1 hour immediately before radiocontrast injection. For patients weighing more than 110 kg, the initial fluid bolus and drip will be limited to those doses administered to a patient weighing 110 kg.
~Intravenous infusion154meq/L sodium bicarbonate in 5% dextrose in water at a rate of 1 mL/kg/hour during the contrast exposure and for 6 hours after the procedure"
11618903|NCT00496795|Other|epirubicin/docetaxel sequential|Epirubicin/docetaxel sequential, i.e. one arm study with Epirubicin 4 cycles 60 mg/m2 q2w, followed by docetaxel 4 cycles, 100 mg/m2 q2w. Each course with pegfilgrastim.
11618904|NCT00496782|Other|Single|
11618905|NCT00496769|Experimental|Apixaban|
11618906|NCT00496769|Active Comparator|Acetylasalicylic acid|
11618857|NCT00497328|Other|Combination Group (COM: NAC and SOB)|"Combination Group (COM: NAC and SOB)
~Intravenous infusion of 154 meq/l sodium bicarbonate at a rate of 3ml/kg/hour for 1 hour before cardiac catheterization and 1 ml/kg/hour till 6 hours after procedure Oral NAC 1200mg dissolve in 250ml of water twice a day the day before to the day after the procedure (total 6 doses). All patients will be monitored regularly for pulmonary congestion and hemodynamics compromise hourly after PCI for 6 hours and every 4 hour thereafter for 24 hours."
11618858|NCT00497315|Experimental|A|pemetrexed + cisplatin (3 cycles) followed by thoracic irradiation + pemetrexed
11618859|NCT00497315|Experimental|B|thoracic irradiation + pemetrexed followed by pemetrexed + cisplatin
11618860|NCT00497302|Experimental|1|receives housing based on drug abstinence
11618861|NCT00497302|Active Comparator|2|Usual care treatment at the Center for Addiction and Pregnancy
11618862|NCT00497289|Experimental|1|Lipidem 20 %
11618863|NCT00497289|Active Comparator|2|Lipofundin MCT/LCT 20%
11618864|NCT00497276|Experimental|I|Ultrasound guided placement of popliteal catheter
11618865|NCT00497276|Experimental|II|Nerve stimulation guided placement of popliteal catheter
11618866|NCT00497250|Other|1|Thoracic RT for patients will start from 54Gy, and then escalate dose at 2Gy increment to 60Gy. At each dose level, 8 patients are required to complete RT without dose limiting toxicity(DLT). Evaluation will be done after 8 patients have completed the treatment.If there are >=2 DLT in the first 8 patients, the maximum tolerated dose (MTD) is achieved. If there is a single DLT revealed, an additional 8 patients will be recruited to that dose level. Should there be severe complication occurred again be at least 1 more DLT, then MTD is thought to be achieved.Hence,MTD will be achieved if at least 2 out of the first 8 patients have a DLT,or if a further 8 patents are recruited, >=2 out of 16 patients have a DLT. Concurrent with RT, patients will be given gefitinib 250 mg/day PO as well as same dose PO for 60 days after the completion of RT.
11618867|NCT00497237|Experimental|1|Foster
11618868|NCT00497237|Active Comparator|2|Seretide
11618869|NCT00497224|Experimental|Erlotinib|Eligible patients will receive erlotinib 150mg PO daily, with dose escalation occurring as tolerated.
11618870|NCT00497198|Experimental|MCI-196|
11618871|NCT00497198|Placebo Comparator|Placebo|
11618872|NCT00497185|Other|A|Mindfulness-Based Cognitive Therapy
11618873|NCT00497185|No Intervention|B|Shared care: Treatment as usual augmented by psychiatric consultation intervention to optimise treatment in the present health care system.
11618874|NCT00497172|Experimental|1|drug-eluting stent
11618875|NCT00497172|Active Comparator|2|bare-metal stent
11618876|NCT00497159|Placebo Comparator|1|Placebo
11618877|NCT00497159|Experimental|2|Dimebon
11618878|NCT00497146|Experimental|Paricalcitol|Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.
11618879|NCT00497146|Placebo Comparator|Placebo|Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.
11618880|NCT00497107|Active Comparator|1|The Control Group (UFT + Calcium Folinate)
11618881|NCT00497107|Experimental|2|The PSK Group (UFT + Calcium Folinate + PSK)
11618882|NCT00497094|Active Comparator|1|Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin irrespective of the baseline cholesterol level) and clopidogrel (75mg daily). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations. Additionally patients will undergo carotid artery stenting using a filter wire protection device.
11618883|NCT00497094|No Intervention|2|Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin daily irrespective of the baseline cholesterol level) and clopidogrel (75mg daily). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations
11618884|NCT00497081|Active Comparator|Mirtazapine|mirtazapine 30 mg daily
11618885|NCT00497081|Placebo Comparator|Placebo|placebo 30 mg daily
11618886|NCT00497068|Experimental|tobacco abstinent contingent voucher|Tobacco abstinent contingent voucher condition
11618887|NCT00497068|Experimental|non-contingent|Participants receive vouchers non-contingent upon tobacco use status
11618888|NCT00497068|Other|no voucher|This is the standard care intervention
11618889|NCT00497055|Experimental|Aripiprazole|Aripiprazole 5mg daily for week one. Aripiprazole 10mg daily for week two. Aripiprazole 20mg daily for weeks three through twelve.
11618890|NCT00497055|Placebo Comparator|Placebo|Placebo (for Aripiprazole) 5mg daily for week one. Placebo (for Aripiprazole) 10mg daily for week two. Placebo (for Aripiprazole) 20mg daily for weeks three through twelve.
11618891|NCT00496990|Active Comparator|control|Participants in this group receive the opportunity to attend a support group
11618892|NCT00496990|Experimental|Enhanced care|Participants in this arm receive the opportunity to have detoxification or methadone treatment as well as receive vouchers contingent upon drug free urine samples and individualized counseling
11618893|NCT00496964|Experimental|1|Injection of Botulinum toxin A into vastus lateralis of study limb plus exercise program
11618894|NCT00496964|Placebo Comparator|2|Placebo injection + exercise
11618895|NCT00496938|Other|1|Observational cohort using an all-comers design
11618896|NCT00496899||1|Women in active labor
11618897|NCT00496873|Experimental|Cytoxan + Rituxan + Nipent|Cytoxan 600 mg/m^2 on Day 1 of 21-day cycle. Rituxan 375 mg/m^2 on Day 1 of 21 Day Cycle. Nipent 4 mg/m^2 on Day 1 of 21 Day Cycle.
11618898|NCT00496847|Experimental|Drug Group|PERIOGEN
11618899|NCT00496847|Active Comparator|Control group|Beta TCP alone
11618900|NCT00496834|Experimental|1|Losartan or Losartan/HCTZ
11618901|NCT00496834|Active Comparator|2|Carvedilol or Carvedilol/HCTZ
11618902|NCT00496808|Experimental|Herceptin|8 mg/kg intravenously (IV) Over 90 Minutes
11618955|NCT00496119|Experimental|Photon Beam Therapy|Proton beam therapy combined with photon radiation therapy where combination improves final dose distribution.
11618907|NCT00496756|Other|Sorafenib|"The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the table below, providing no dose limiting toxicity (Grade 3 or 4) is observed. If grade 3 or 4 toxicity is observed, delay and dose modification will occur as defined in protocol. Once dose level 3 is reached, the patient will remain at that dose as defined in following section.
~Dose Level 1 Day 1-28 400 mg b.i.d. Dose Level 2 Day 29-56 600 mg b.i.d. Dose Level 3 Day 57- 800 mg b.i.d.
~A treatment cycle will be 4 weeks.
~Two 4-week cycles will be administered. At the completion of two cycles (week 8), restaging will occur. Patients will continue on therapy per study protocol."
11618908|NCT00496730|Experimental|Vytorin®|simvastatin (+) ezetimibe 10/20 mg (Vytorin®) ; tablet, once daily, 8 Weeks
11618909|NCT00496730|Active Comparator|atorvastatin|atorvastatin 10 mg; tablet, once daily, 8 Weeks
11618910|NCT00496717||1|There is only one arm and all patients will have their aortic calcium scoring by CT scan.
11618911|NCT00496691|Experimental|1|Parent-child
11618912|NCT00496691|Active Comparator|2|Adolescent only intervention focusing on condom use skills and assertiveness training around sexual discussions
11618913|NCT00496691|Placebo Comparator|3|Health promotion intervention including general health promotion topics such as smoking, diet, exercise, etc.
11618914|NCT00496678|Experimental|Navigation|Navigation through the cancer care system is the intervention
11618915|NCT00496678|Active Comparator|Standard of Care|Cancer patient receives standard of care.
11618916|NCT00496665|Experimental|Vandetenib|Cyclophosphamide 50 mg daily, methotrexate 2.5 mg days 1-2 weekly, and daily vandetanib (zactima) in 3 dose-escalation cohorts (100mg=Cohort 1) (200mg=Cohort 2) (300mg=Cohort3)
11618917|NCT00496652|Active Comparator|1|Radiotherapy (+cisplatin to stage 3+4)
11618918|NCT00496652|Experimental|2|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4) + Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
11618919|NCT00496626|Experimental|1|V501 (Gardasil®)
11618920|NCT00496626|Placebo Comparator|2|Placebo
11618921|NCT00496613||1|Breast cancer survivors (2-6 years post-treatment) who were post-menopausal at the time of diagnosis and treated with a combination of chemotherapy and hormonal therapy, matched on age and education
11618922|NCT00496613||2|Breast cancer survivors (2-6 years post-treatment) who were post-menopausal at the time of diagnosis and treated with hormonal therapy only matched on age and education
11618923|NCT00496613||3|Healthy women matched on age and education
11618924|NCT00496587|Experimental|Capecitabine + Gemcitabine + Bevacizumab|Capecitabine 800 mg/m^2 By Mouth Twice Daily On Days 1-21. Gemcitabine 900 mg/m^2 By Vein Over 30 Minutes on Days 1 and 15. Bevacizumab 10 mg/kg By Vein On Days 1 and 15.
11618925|NCT00496574|Active Comparator|1|
11618926|NCT00496574|No Intervention|2|no intevention
11618927|NCT00496561|Active Comparator|1|subcutaneous immunotherapy (House Dust Mites)
11618928|NCT00496561|Placebo Comparator|2|placebo of subcutaneous immunotherapy (House Dust Mites)
11618929|NCT00496548|Experimental|1|Fecal calprotectin and urinary PGE-M levels will be tested on all participants.
11618930|NCT00496522|Other|Proton Beam Therapy|Proton Beam Therapy - A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
11618931|NCT00496509|Experimental|ZD6474 (vandetanib) 100mg|
11618932|NCT00496509|Experimental|ZD6474 (vandetanib) 300mg|
11618933|NCT00496483|Active Comparator|LCP-Tacro (tacrolimus)|Experimental: LCP Tacro; investigational product LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.
11618934|NCT00496470|Active Comparator|Symbicort+TIO|Symbicort Turbuhaler® (budesonide/formoterol) 320/9 mcg, one inhalation twice daily and Spiriva® (tiotropium) 18 mcg, one inhalation once daily
11618935|NCT00496470|Active Comparator|Spiriva® + Placebo Turbuhaler|Spiriva® (tiotropium) 18 mcg, one inhalation once daily and placebo Turbuhaler one inhalation once daily
11618936|NCT00496457|Experimental|1|TRO19622
11618937|NCT00496457|Placebo Comparator|2|
11618938|NCT00496444|Experimental|Azacitidine + Valproic Acid|
11618939|NCT00496431|Experimental|ITF2357|
11618940|NCT00496418|Experimental|Prophylactic stoma mesh|Mesh
11618941|NCT00496418|Active Comparator|No mesh prophylaxis|No mesh
11618942|NCT00496379|Experimental|ZK219477|
11618943|NCT00496366|Experimental|Capecitabine (Xeloda) + Lapatinib (Tykerb)|"Capecitabine for 2 weeks straight (Days 1-14) followed by 1 week without capecitabine (Days 15-21).
~Lapatinib will be taken daily continuously for 21 days (Days 1- 21)."
11618944|NCT00496340|Experimental|Conditioning Followed by HCT|"Pentostatin/Busulfan/Rituximab/Allogeneic Hematopoietic Cell Transplant (HCT).
~Pre-conditioning therapy:
~All participants will receive pentostatin 4 mg/m^2 on day -28. Patients may receive additional doses on days -21 & -14 depending on cell counts.
~Conditioning:
~Patients will receive anti-seizure prophylaxis with lorazepam 0.5 mg every 6 hours beginning day -6.
~Intravenous Busulfan (1st dose) at a dose of 200mg/m^2 on day -4.
~Patient will then receive pentostatin at a dose of 4 mg/m^2 by intravenous infusion over 1-2 hours on days -4, -3.
~Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600.
~Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.
~Rituximab: Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m^2 according to prescribing and institutional guidelines."
11618945|NCT00496327|Experimental|1|Open label
11618946|NCT00496288|Experimental|prophylactic irradiation|prophylactic contralateral breast irradiation
11618947|NCT00496288|No Intervention|controls|Those that do not opt for prophylactic irradiation or mastectomy
11618948|NCT00496262|Experimental|Human Fibrinogen Concentrate|
11618949|NCT00496223|Experimental|1|
11618950|NCT00496197|Experimental|1.|Subjects receive anidulafungin IV followed by oral therapy with fluconazole or voriconazole.
11618951|NCT00496145|Experimental|treatment|Spanish Diabetes Self-Management Program
11618952|NCT00496145|No Intervention|control|usual-care control group
11618953|NCT00496132|Experimental|1|
11618954|NCT00496119|Experimental|70 Gray (Gy) Proton Beam Therapy|Participants treated to 70 cobalt Gray equivalent (CGE) only (the standard treatment).
11618956|NCT00496106|Experimental|Control Arm|6 telephone counseling sessions
11618957|NCT00496106|Active Comparator|Usual Care Arm|6 telephone counseling sessions
11618958|NCT00496093|Experimental|Pneumococcal Vaccine, Polyvalent (23-valent)|Participants received one 0.5 mL dose of Pneumococcal Vaccine, Polyvalent (23-valent) by intramuscular (deltoid) injection on Day 1.
11618959|NCT00496080|Experimental|DUAO Device|Doppler-guided uterine artery occlusion device (Single-arm study)
11618960|NCT00496067|Experimental|1|DUAO Device
11618961|NCT00496054|Experimental|RotaTeq™ Vaccine (V260)|Evaluation of Safety, Tolerability and Immunogenicity of Vaccination with RotaTeq™ in Healthy Infants in India.
11618962|NCT00496041|Experimental|Smart Stent in the Superficial Femoral Artery .|
11618963|NCT00496028|Experimental|1|AZD0530 + Paclitaxel
11618964|NCT00496028|Experimental|2|AZD0530 + Carboplatin
11618965|NCT00496028|Experimental|3|AZD0530 + Carboplatin + Paclitaxel
11618966|NCT00496015|Experimental|Synflorix I Group|Subjects were vaccinated with 3 primary vaccination doses of Synflorix™ vaccine with prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa along with prophylactic antipyretic treatment.
11618967|NCT00496015|Experimental|Synflorix II Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment
11618968|NCT00496015|Experimental|Synflorix PRE Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study (before the implementation of the protocol amendment) at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment.
11618969|NCT00496015|Experimental|Synflorix POST Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study (after the implementation of the protocol amendment) at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment.
11618970|NCT00496015|Active Comparator|Mencevax + Infanrix Hexa Group|Age-matched pneumococcal vaccine unprimed group receiving a single dose of Mencevax™ vaccine co-administered with Infanrix™ hexa vaccine.
11618971|NCT00495950||Questionnaire|
11618972|NCT00495924||PD|Patients undergoing pancreaticoduodenectomy for pancreatic or peri-ampullary tumours.
11618973|NCT00495898|Experimental|1|CYPHER sirolimus-eluting stent
11618974|NCT00495898|Active Comparator|2|uncoated Bx VELOCITY balloon-expandable stent
11618975|NCT00495885|Experimental|Volinanserin|Volinanserin 2 mg for a maximum of 87 days
11618976|NCT00495885|Placebo Comparator|Placebo|Placebo for volinanserin for a maximum of 106 days
11618977|NCT00495872|Experimental|VN|Valproic Acid + Sorafenib
11618978|NCT00495872|Experimental|VS|Valproic Acid + Sunitinib
11618979|NCT00495872|Experimental|VD|Valproic Acid + Dasatinib
11618980|NCT00495872|Experimental|VT|Valproic Acid + Erlotinib
11618981|NCT00495872|Experimental|VL|Valproic Acid + Lapatinib
11618982|NCT00495872|Experimental|VR|Valproic Acid + Lenalidomide
11618983|NCT00495859|Active Comparator|1|Study group will receive formula enriched with arginine, ω-3 fatty acids, and nucleotides once daily
11618984|NCT00495859|Active Comparator|2|controls receive an isocaloric isonitrogenous non-specific nutritional support
11618985|NCT00495846|Experimental|A|"Patients with cirrhosis without HCC in all liver function classes already receiving specific therapy for cirrhosis who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study
~Patients with cirrhosis with multifocal HCC and clinical and/or radiological signs of persistence or recurrence of HCC in presence or absence of trombosis of the portal vein, with a single nodule of >6 cm in size or multiple nodules of >3 cm in size who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study"
11618986|NCT00495846|Other|B|Historical controls
11618987|NCT00495833|No Intervention|1|
11618988|NCT00495833|Experimental|2|photo and blood pressure personalization
11618989|NCT00495833|Experimental|3|photo personalization only
11618990|NCT00495833|Experimental|4|blood pressure personalization only
11618991|NCT00495833|Experimental|5|no personalization
11618992|NCT00495833|Experimental|A|receives gift card in blood pressure (BP) kit
11618993|NCT00495833|Experimental|B|does not receive gift card in BP kit
11618994|NCT00495820|Experimental|Arm 1|Methylphenidate
11618995|NCT00495820|Placebo Comparator|Arm 2|Placebo
11618996|NCT00495807|No Intervention|1|No Words was delivered during the PCA management
11618997|NCT00495807|Active Comparator|2|Positive words was delivered as a positive control group during the therapy of the pain with PCA
11618998|NCT00495807|Active Comparator|3|Partially negative words was delivered during the PCA pain management
11618999|NCT00495807|Active Comparator|4|Totally negative words was delivered during the PCA pain management
11619000|NCT00495794|Experimental|Pharmacist management|Eligible patients assigned to - adherence counseling and medication management delivered by a clinical pharmacist trained in behavioral counseling approaches (motivational interviewing)
11619001|NCT00495794|No Intervention|Usual care|Eligible patients receive usual care
11619002|NCT00495755|Experimental|Campath (alemtuzumab)|
11619003|NCT00495729|Experimental|Cohort 1|Subjects in Cohort 1 will be randomized to receive 5 milligram (mg) of SB-649868 or Placebo along with 10 mg of simvastatin.
11619004|NCT00495729|Experimental|Cohort 2|Subjects in Cohort 2 will be randomized to receive two or three times higher than the starting dose of SB-649868 or Placebo along with 10 mg of simvastatin.
11619005|NCT00495729|Experimental|Cohort 3|Subjects in Cohort 3 will be randomized to dose higher than that administered in Cohort 2 of SB-649868 or Placebo along with 10 mg of simvastatin.
11619006|NCT00495716|Active Comparator|Episodic Treatment Arm|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
11619007|NCT00495716|Active Comparator|Suppressive Therapy Arm|400 mg acyclovir orally twice daily for 1 year
11619008|NCT00495703|Experimental|1|Exercise
11619009|NCT00495703|Active Comparator|2|Usual Care
11619010|NCT00495677|Active Comparator|PF-00232798 40 mg|
11619011|NCT00495677|Active Comparator|PF-00232798 300 mg|
11619012|NCT00495677|Active Comparator|PF-00232798 400 mg|
11619013|NCT00495677|Active Comparator|PF-00232798 5 mg|
11619014|NCT00495677|Active Comparator|PF-00232798 20 mg|
11619015|NCT00495677|Active Comparator|PF-00232798 150 mg|
11619016|NCT00495664|Experimental|TITANOX|Titanium-nitride-oxide coated stent
11619017|NCT00495664|Active Comparator|PES|Paclitaxel-eluting stent
11619018|NCT00495651|Active Comparator|I|Standard of care
11619019|NCT00495651|Experimental|II|Standard of care+Isoniazid Prophylaxis:
11619020|NCT00495651|Experimental|III|Early Antiretroviral therapy
11619021|NCT00495651|Experimental|IV|Early Antiretroviral therapy + Isoniazid prophylaxis
11619022|NCT00495625|Experimental|Sunitinib Malate (SUO11248) Treatment|
11619023|NCT00495612|Experimental|Omalizumab|Patients received omalizumab via subcutaneous injection either every 2 weeks or every 4 weeks for 16 weeks. The dose administered and the dosing interval were determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
11619024|NCT00495612|Placebo Comparator|Placebo|Patients received placebo as a subcutaneous injection either every 2 weeks or every 4 weeks for 16 weeks. Patients received injections at the same time intervals as the omalizumab group.
11619025|NCT00495586|Placebo Comparator|Placebo|Placebo pills t.i.d. for 8 days
11619026|NCT00495586|Active Comparator|Amoxycillin and clavulanic acid|Amoxycillin and clavulanate t.i.d. for 8 days
11619027|NCT00495573||1|HSV-2 seropositive subjects who will receive a 5-day course of acyclovir for treatment of a genital herpes recurrence.
11619028|NCT00495573||2|HSV-2 seropositive subjects who will be observed during a genital herpes recurrence but not receive acyclovir.
11619029|NCT00495521|Experimental|Active|4-Aminosalicylic acid extended release granules (as volume equivalent of active product), 50 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 50 mg/kg orally two times daily for 2 weeks
11619030|NCT00495521|Placebo Comparator|Placebo|Placebo granules identical in appearance to the active arm (as volume equivalent of active product), 0 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 0 mg/kg orally two times daily for 2 weeks
11619031|NCT00495495|Experimental|Ozone treatment|Ozone treatment of randomly selected study tooth for 60 seconds
11619032|NCT00495495|Placebo Comparator|Placebo, no ozone|Placebo treatment (no ozone) of randomly selected study tooth for 60 seconds.
11619033|NCT00495482||1|Patients receiving palliative care due to incurable illness
11619034|NCT00495469|Experimental|GSK189075|Participants will receive GSK189075 for 12 weeks
11619035|NCT00495469|Placebo Comparator|Placebo|Participants will receive GSK189075 matching Placebo for 12 weeks
11619036|NCT00495417|Active Comparator|1|
11619037|NCT00495417|Active Comparator|2|
11619038|NCT00495404|Other|Arm 1|
11619039|NCT00495404|Other|Arm 2|
11619040|NCT00495391|Active Comparator|1|Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if <75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
11619041|NCT00495391|Placebo Comparator|2|Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if <75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
11619042|NCT00495352|Active Comparator|High-dose NRT, Low-dose NRT, bupropion|
11619043|NCT00495339|Experimental|1|Levofloxacin
11619044|NCT00495326|Experimental|1|Nevirapine-based ART
11619045|NCT00495326|Active Comparator|2|Efavirenz-based ART
11619046|NCT00495313|Active Comparator|Cohort 1: doxycycline|Vibramycin plus metronidazole
11619047|NCT00495313|Active Comparator|Cohort 2|Oracea® delayed release plus metronidazole
11619048|NCT00495300||1|Related or Unrelated Hematopoietic Stem Cell Transplantation Recipients for the National Marrow Donor Program
11619049|NCT00495287|Active Comparator|A|"Remission induction arm A is with conventional chemotherapy cycle (ICE: idarubicin, standard-dose cytarabine, etoposide)"
11619050|NCT00495287|Experimental|B|Remission induction therapy with high-dose cytarabine sequential regimen (HD-Ara-C, idarubicin)
11619051|NCT00495274|Experimental|Healthy male subjects|In Part A each subject will participate in six sessions and will be administered, in randomized order, single doses of five new formulations (formulation B, C, D, E and F) of SB-649868 30 milligrams (mg), in fasted state and a single dose of the original formulation (formulation A), after a standard Food and Drug Administration (FDA) High-Fat breakfast. All dosing sessions will be separated by a washout session of at least 5 ± 2 days after each dose. In Part B a single dose of the selected SB-649868 30 mg formulation will be administered after a standard FDA High-Fat breakfast.
11619052|NCT00495261|Experimental|1|
11619053|NCT00495261|Active Comparator|2|
11619054|NCT00495248|Experimental|1|
11619055|NCT00495248|Active Comparator|2|
11619056|NCT00495235||Endometrial Cancer Group|Participants who have had endometrial cancer (cases).
11619057|NCT00495235||Control Group|Participants who have not had endometrial cancer (controls).
11619058|NCT00495222|Experimental|Tissue plication|The Endoscopic Suturing System (ESS) is used for tissue apposition and reduction of the size of a dilated GJ anastomosis in subjects who are regaining weight after successful weight loss following gastric bypass
11619059|NCT00495209||Qigong|"Pre-surgical Qigong therapy for women with breast cancer
~External Qi Therapy = EQT"
11619060|NCT00495196|Experimental|1|
11619061|NCT00495196|Active Comparator|2|
11619062|NCT00495183|Experimental|1|caffeine + placebo
11619063|NCT00495183|Experimental|2|caffeine + biperiden
11619064|NCT00495183|Placebo Comparator|3|Placebo+placebo
11619065|NCT00495170|Experimental|Concurrent proton and Chemotherapy|Proton Radiotherapy + Carboplatin + Paclitaxel
11653526|NCT00048555|Experimental|1|
11619066|NCT00495157|Experimental|Symptom-based adjustment|Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
11619067|NCT00495157|Experimental|Biomarker-based adjustment|Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
11619068|NCT00495157|Experimental|Guideline-based adjustment|Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
11619069|NCT00495131|Active Comparator|Peginterfron and ribavirin (24 weeks)|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 24 weeks
11619070|NCT00495131|Active Comparator|Peginterferon and ribavirin (48 weeks)|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 48 weeks
11619071|NCT00495105|Experimental|Two Servings of Dairy Snacks|Intervention group received two servings of dairy food per day as a snack at school for 6 months as well as nutrition education.
11619072|NCT00495105|No Intervention|No Dairy Snacks|Control Group did not receive any snacks or education.
11619073|NCT00495092|Experimental|1|This study arm will receive caffeine+placebo
11619074|NCT00495092|Experimental|2|this study arm will receive Caffeine+Biperiden
11619075|NCT00495092|Placebo Comparator|3|this study arm will receive placebo+placebo
11619076|NCT00495079|Experimental|Marqibo|Eligible subjects received study drug at 2.25 mg/m^2 intravenously via peripheral or central venous access over 60 minutes (± 10 minutes).
11619077|NCT00495053|Experimental|hMaxi-K 5000 µg/mL|5000 micrograms (µg)/90 milliliter (mL) intravesical instillation
11619078|NCT00495053|Experimental|hMaxi-K 10000 µg/mL|10000 µg/90 mL intravesical instillation
11619079|NCT00495053|Placebo Comparator|Placebo|Matching placebo (PBS-20% sucrose)
11619080|NCT00495040|Experimental|Proton Radiotherapy|Proton radiotherapy 87.5 CGE with 2.5 Gy/fraction for 35 treatments.
11619081|NCT00494975|Experimental|NB-UVB|Narrow band-Ultraviolet B phototherapy
11619082|NCT00494975|Placebo Comparator|UVA|Ultraviolet A Phototherapy
11619083|NCT00494949|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
11619084|NCT00494949|Active Comparator|Control|Ringer's lactate
11619085|NCT00494936||HIV/HCV|HIV and HCV coinfected
11619086|NCT00494936||HIV infected|HIV monoinfected
11619087|NCT00494936||HIV/HCV nonviremnic|HIV and HCV coinfected with HCV RNA less than 600 copies
11619088|NCT00494936||HCV infected|HCV monoinfected with HCV viremia
11619089|NCT00494910|Experimental|1|Meaning Centered Group Psychotherapy (MCGP)
11619090|NCT00494910|Active Comparator|2|standardized Supportive Group Psychotherapy
11619091|NCT00494871|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period
11619092|NCT00494871|Active Comparator|Warfarin|Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period
11619093|NCT00494858|Active Comparator|CBT-EF|Participants will receive cognitive behavioral therapy - focused
11619094|NCT00494858|Experimental|CBT-EB|Participants will receive cognitive behavioral therapy - broad
11619095|NCT00494845|Experimental|Intervention|8-week Mindfulness Program for chronic low back pain
11619096|NCT00494845|Active Comparator|Comparison|8-week health education program
11619097|NCT00494832|Active Comparator|Dexmedetomidine|Dexmedetomidine infusion
11619098|NCT00494832|Placebo Comparator|Placebo|Normal Saline infusion
11619099|NCT00494806|Experimental|Rocking Group|Patients rocked in a rocking chair in 10-20 minute increments for at least one hour per day beginning on the first day after surgery. Activity was increased each day and continued until passage of first postoperative flatus.
11619100|NCT00494806|No Intervention|Standard Care|Standard care group got out of bed and sat in a non-rocking chair and ambulated beginning the first day after surgery. Activity was increased each day and continued until passage of first postoperative flatus.
11619101|NCT00494793|Other|VAWC and mesh mediated fascial traction|This is a study aiming to evaluate one technique for temporary abdominal closure for open abdomen therapy in all patients applicable according to the inclusion criteria
11619102|NCT00494780|Active Comparator|Active Comparator 1|Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 500mg
11619103|NCT00494780|Active Comparator|Active Comparator 2|Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 1000mg
11619104|NCT00494767|Experimental|GW869682 1000 mg thrice daily (TID)|Subjects will be randomized to receive GW869682 1000 mg TID
11619105|NCT00494767|Experimental|GSK189075 250 mg TID|Subjects will be randomized to receive GSK189075 250 mg TID
11619106|NCT00494767|Placebo Comparator|GW869682-Placebo TID|Subjects will be randomized to receive Placebo matching GW869682 for TID
11619107|NCT00494767|Placebo Comparator|GSK189075-Placebo TID|Subjects will be randomized to receive Placebo matching GSK189075 for TID
11619108|NCT00494741|Experimental|mycophenolate mofetil|
11619109|NCT00494741|Experimental|azathioprine|
11619110|NCT00494728|Other|CBASP + ST|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) + Smoking Cessation Treatment (ST)
11619111|NCT00494728|Other|ST|Smoking Cessation Treatment (ST)
11619112|NCT00494715|Experimental|Benazepril|
11619113|NCT00494715|Experimental|valsartan|
11619114|NCT00494715|Experimental|benazepril/valsartan|
11619115|NCT00494702|Experimental|LOX|Low saturation group of premature infants that will be kept within preset limits of 85-89%
11619116|NCT00494702|Active Comparator|HOX|HOX group of premature infants will be kept within preset saturation limits of 90-93%
11619117|NCT00494676|Experimental|Real prism glasses first, then sham|Participants in this arm will receive high power (57 prism diopter) peripheral prism glasses in the first period of the crossover and low power sham peripheral prism glasses in the second period
11619118|NCT00494676|Experimental|Sham prism glasses first, then real|Participants in this arm will receive low power sham peripheral prism glasses in the first period of the crossover and high power (57 prism diopter) peripheral prism glasses in the second period
11619119|NCT00494663|Experimental|1|150mg DIO-902 + 10mg atorvastatin
11619120|NCT00494663|Experimental|2|300mg DIO-902 + 10mg atorvastatin
11619121|NCT00494663|Experimental|3|450mg DIO-902 + 10mg atorvastatin
11619122|NCT00494663|Placebo Comparator|4|DIO-902 Placebo + 10mg atorvastatin
11619123|NCT00494663|Experimental|5|150mg DIO-902 + atorvastatin placebo
11619124|NCT00494663|Experimental|6|300mg DIO-902 + atorvastatin placebo
11619125|NCT00494663|Experimental|7|450mg DIO-902 + atorvastatin placebo
11619126|NCT00494663|Placebo Comparator|8|DIO-902 placebo + atorvastatin placebo
11619127|NCT00494650|Experimental|1|Participants will receive cognitive behavioral therapy.
11619128|NCT00494650|Active Comparator|2|Participants will receive brief PTSD treatment.
11619129|NCT00494585|Experimental|CEP-701|80 mg orally twice a day for 30 days
11619130|NCT00494572|Sham Comparator|Sterile Water|Sterile water
11619131|NCT00494572|Active Comparator|Montelukast|10mg rapid dissolving granules in sterile water orally once
11619132|NCT00494559|Experimental|Actos|Actos group: pioglitazone 15mg or 30mg
11619133|NCT00494559|Placebo Comparator|Placebo|Placebo group: placebo without active medication
11619134|NCT00494520|Experimental|Errorful training condition|A type of anomia rehabilitation paradigm which allows for errors. The intervention involves providing minimal auditory cues to allow for errors in picture naming.
11619135|NCT00494520|Experimental|Errorless training condition|A type of anomia rehabilitation paradigm in which the situation surrounding the performance of the desired task (i.e., picture naming) is controlled to prevent errors. The intervention involves providing maximal auditory cues to prevent errors in picture naming.
11619136|NCT00494507|Active Comparator|HYP Dichlorphenamide|Hyperkalemic participants were randomized to Dichlorphenamide for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
11619137|NCT00494507|Placebo Comparator|HYP Placebo|Hyperkalemic participants were randomized to Placebo for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
11619138|NCT00494507|Active Comparator|HOP Dichlorphenamide|Hypokalemic participants were randomized to Dichlorphenamide for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
11619139|NCT00494507|Placebo Comparator|HOP Placebo|Hypokalemic participants were randomized to Placebo for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
11619140|NCT00494494|Active Comparator|Standard Treatment|topical antibiotic for 10 days and a topical corticosteroid for 1 month
11619141|NCT00494494|Experimental|Nepafenac|1 drop per study eye three times per day for 30 days in addition to standard care
11619142|NCT00494481|Placebo Comparator|1|Docetaxel + placebo vandetanib
11619143|NCT00494481|Experimental|2|Vandetanib + Docetaxel
11619144|NCT00494455|Active Comparator|1|Continuous subcutaneous glucose monitoring in patients without shock
11619145|NCT00494455|Active Comparator|2|continuous subcutaneous glucose monitoring in patients with shock
11619146|NCT00494442|Experimental|KU-0059436 (AZD2281) 100 mg BID|
11619147|NCT00494442|Experimental|KU-0059436 (AZD2281) 400 mg BID|
11619148|NCT00494429|Experimental|1|Gestational Age< 29 weeks will be administered a loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/hr.
11619149|NCT00494429|Experimental|2|Gestational Age>= 29 weeks will be administered a loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
11619150|NCT00494416|No Intervention|ANC approach|Passive health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.
11619151|NCT00494416|Other|advanced strategies SP|Joint with advanced strategies delivery approach (JAS). In addition to passive delivery of IPT/sulphadoxine pyrimethamine (SP) at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages, such as immunization, health promotion, and even ANC visits.
11619152|NCT00494416|Other|Community based|Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs). Each approach will be implemented in a zone constituted by the catchment area of a number of health centres to achieve the required sample size. The zones will be randomly assigned to a delivery approach. The main outcomes to be measured are: a) the coverage of IPT, b) compliance, c) infection prevalence, d) Hb level, e) difficulties and constraints of each approach, f) the acceptability to population and health staff and g) the performance of each approach to deliver IPT /SP. Coverage by 10%, each group should be composed of n = 3841 pregnant women.
11619153|NCT00494312|Experimental|Pioglitazone QD|
11619154|NCT00494312|Active Comparator|Glyburide QD|
11619155|NCT00494299|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose modification (delayed or reduced) was permitted due to toxicity.
11619156|NCT00494299|Placebo Comparator|Placebo|Sorafenib (Nexavar, BAY43-9006) matching placebo (2 placebo tablets) orally administered bid (twice daily).
11619157|NCT00494286|Experimental|AF-CBT|Participants will receive abused-focused cognitive behavioral therapy
11619158|NCT00494286|Active Comparator|TAU|Participants will receive treatment as usual
11619159|NCT00494260|Experimental|Social learning and cognitive behavioral therapy (SLCBT)|The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques.
11619212|NCT00493792|Other|2|X3 Polyethylene when used with a Triathlon Posterior Stabilized total knee system. This is a fixed- bearing knee intended for use in patients undergoing cemented total knee arthroplasty.
11619160|NCT00494260|Active Comparator|Education Support (ES)|The ES condition focuses on education about GI system anatomy and function, information about the United States Department of Agriculture nutrition guidelines, and additional food-related information such as how to read food product labels. The ES condition was developed to provide a credible alternative condition that would control for therapist and patient time and attention.
11619161|NCT00494234|Experimental|KU-0059436 (AZD2281) 100 mg BID|
11619162|NCT00494234|Experimental|KU-0059436 (AZD2281) 400 mg BID|
11619163|NCT00494221|Active Comparator|FOLFOX + Cediranib 20 mg|FOLFOX + Cediranib 20 mg
11619164|NCT00494221|Active Comparator|FOLFOX + Cediranib 30 mg|FOLFOX + Cediranib 30 mg
11619165|NCT00494221|Placebo Comparator|FOLFOX + Placebo Cediranib|FOLFOX + Placebo Cediranib
11619166|NCT00494208|Active Comparator|1|
11619167|NCT00494208|Active Comparator|2|
11619168|NCT00494208|Active Comparator|3|
11619169|NCT00494208|Active Comparator|4|
11619170|NCT00494208|Active Comparator|5|
11619171|NCT00494195|Experimental|1|The first cohort will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml. The anatomical midline point of the muscle will be identified on the skin and two to six vector injections will be distributed in the direction of an X. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
11619172|NCT00494195|Experimental|2|The second cohort will receive the same dose of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
11619173|NCT00494182|Experimental|Treatment (carboplatin, paclitaxel, sorafenib)|Participants receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1, and sorafenib PO BID on days 2-19. Treatment repeats every 21 days for up to 6 courses. Starting with course 7, participants receive sorafenib PO daily in the absence of disease progression or unacceptable toxicity.
11619174|NCT00494143|Active Comparator|Conventional Prosthetic foot|A conventional prosthetic foot that has limited energy storage and return capabilities. It is standardized and used by all subjects in the study.
11619175|NCT00494143|Active Comparator|Prescribed Prosthetic foot|the Prosthetic foot that the subject had prescribed for them by their clinical providers and was worn prior to study initiation
11619176|NCT00494143|Experimental|CESR foot|the experimental CESR, controlled energy storage prosthetic foot
11619177|NCT00494104|Active Comparator|200 IU/day Vitamin D|200 IU/day Vitamin D
11619178|NCT00494104|Experimental|400 IU/day Vitamin D|400 IU/day Vitamin D
11619179|NCT00494104|Experimental|600 IU/day Vitamin D|600 IU/day Vitamin D
11619180|NCT00494104|Experimental|800 IU/day Vitamin D|800 IU/day Vitamin D
11619181|NCT00494091|Experimental|A.|
11619182|NCT00494091|Experimental|B.|
11619183|NCT00494078|Active Comparator|1|Patients randomised to this arm are treated with intensive insulin therapy guided by the continuous glucose monitoring system.
11619184|NCT00494078|Active Comparator|2|intensive insulin therapy guided by an algorithm
11619185|NCT00494065|Experimental|1|Chiropractic Spinal Manipulative Therapy + Home exercise
11619186|NCT00494065|Active Comparator|2|Home exercise
11619187|NCT00494052|Experimental|1|Heart to Heart intervention
11619188|NCT00494052|No Intervention|2|Usual care
11619189|NCT00494026|Experimental|Pemetrexed + Carboplatin|
11619190|NCT00494013|Experimental|Insulin Lispro Protamine Suspension|Insulin Lispro Protamine Suspension: Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
11619191|NCT00494013|Active Comparator|Detemir|Detemir: Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
11619192|NCT00493987|Active Comparator|Testosterone enanthate|
11619193|NCT00493987|Placebo Comparator|Duatesteride|Duatesteride
11619194|NCT00493974|Active Comparator|Zileuton|Zileuton (Zyflo, 600 mg 4 times a day)
11619195|NCT00493974|Placebo Comparator|Placebo|Placebo
11619196|NCT00493922|Active Comparator|2|Microscopy for diagnosis of malaria
11619197|NCT00493922|Active Comparator|3|Clinical diagnosis for malaria
11619198|NCT00493922|Experimental|1|Rapid Diagnostic Test for Malaria
11619199|NCT00493909|Active Comparator|1|thoracic epidural analgesia
11619200|NCT00493909|Active Comparator|2|intrathecal opioids and thoracic paravertebral analgesia
11619201|NCT00493896|Experimental|Fondaparinux|Fondaparinux treatment - one standard of care option
11619202|NCT00493896|Active Comparator|2|Enoxaparin
11619203|NCT00493883|Other|TheraSphere|"Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver
~--------------------------------------------------------------------------------"
11619204|NCT00493870|Experimental|TC|docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2
11619205|NCT00493870|Active Comparator|TAC|doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 and docetaxel 75 mg/m2
11619206|NCT00493857|Experimental|2|Nimotuzumab 400mg every week or every two weeks
11619207|NCT00493844|Experimental|1|Discharge if clinical risk score <3 points + Nt-proBNP <110 ng/L
11619208|NCT00493844|Active Comparator|2|Discharge if negative exercise testing
11619209|NCT00493805|Experimental|Interventional Study arm (with insulin resistance)|"HOMA IR (homeostasis model assessment-estimated insulin resistance) of > 2
~These participants received PEG-Intron 1.5 μg /kg subcutaneously (SC) once weekly plus weight based Rebetol 800-1400 mg by mouth (PO) administered twice daily (BID) for a variable period depending on their response to treatment."
11619210|NCT00493805|Experimental|Non interventional study arm (without insulin resistance)|"HOMA IR <= 2
~These participants received PEG-Intron 1.5 μg /kg subcutaneously (SC) once weekly plus weight based Rebetol 800-1400 mg PO administered twice daily (BID) for 48 weeks. (Participants are treated according to
~European labeling)."
11619211|NCT00493792|Other|1|Stryker Orthopaedics N2Vac Polyethylene when used with a Triathlon Posterior Stabilized total knee system. This is a fixed- bearing knee intended for use in patients undergoing cemented total knee arthroplasty.
11619480|NCT00490906||1|Patients receive Copaxone
11619213|NCT00493779|No Intervention|1|Effect of Clopidogrel withdrawal on biomarkers will be assessed via blood draws
11619214|NCT00493766|Experimental|oral LBH589 alone|
11619215|NCT00493766|Experimental|oral LBH589 + IV docetaxel + oral prednisone|
11619216|NCT00493727|Other|1|
11619217|NCT00493714||Arm 1 (Patient)|Cancer patient who recently experienced confusion or restlessness.
11619218|NCT00493714||Arm 2 (Caregiver)|Caregivers of cancer patients who recently experienced confusion or restlessness.
11619219|NCT00493701|Other|Lifestyle|Measurement of body weight in a fown with light undercloting (30 minutes) and height.
11619220|NCT00493701|Other|DEXA Scanner|Low-dose X0rays to determine the amount of fat, bone and muscle in your body.
11619221|NCT00493688||Cardiopulmonary Exercise Testing (CPET)|
11619222|NCT00493649|Experimental|TC+H|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel (Taxotere) 75 mg/m2 IV (over 1 hour), plus cyclophosphamide (Cytoxan) 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab (Herceptin) 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter.
11619223|NCT00493636|Active Comparator|A (Sorafenib + Gemcitabine or Capecitabine)|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)
11619224|NCT00493636|Placebo Comparator|B (Placebo + Gemcitabine or Capecitabine)|Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)
11619225|NCT00493623|Experimental|1|
11619226|NCT00493623|Placebo Comparator|2|
11619227|NCT00493610|Other|1|
11619228|NCT00493584|Experimental|1|Primary PCI in patients with acute Non-STEMI
11619229|NCT00493584|Active Comparator|2|Standard medical treatment and coronary angiography after 3 days in patients with Non-STEMI.
11619230|NCT00493571|Experimental|Gimatecan|Gimatecan Starting dose: 0.6 mg capsules administered orally once daily.
11619231|NCT00493480|Active Comparator|carvedilol|
11619232|NCT00493480|Active Comparator|propranolol|Cirrhotic patients treated with propranolol
11619233|NCT00493467|Experimental|Zevalin|Ibritumomab Tiuxetan (Zevalin) + Rituximab
11619234|NCT00493454|Experimental|Ibritumomab tiuxetan + Rituximab|Rituximab 250 mg/m² intravenous (IV) Days 1 and 8, 111In Ibritumomab Tiuxetan (5mCi of 111In, 1.6 mg of Ibritumomab Tiuxetan) IV (over 10 minutes) on Day 1; and 90Y Ibritumomab Tiuxetan 0.3 or 0.4 mCi/kg IV (over 10 minutes) on Day 8 after the Day 8 of Rituximab.
11619235|NCT00493441|Experimental|Treatment|
11619236|NCT00493415|Experimental|1|nitroglycerine iv
11619237|NCT00493415|Placebo Comparator|2|nacl 0.9% 4 ml/h iv in the first 30 minutes, 2 ml/h iv in the next 23 hours and 30 minutes
11619238|NCT00493402|Experimental|combined chemotherapy with embolization|chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, with particle embolization.
11619239|NCT00493402|Experimental|combined chemotherapy without embolization|chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, without particle embolization.
11619240|NCT00493402|Experimental|single agent chemotherapy with embolization|chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
11619241|NCT00493363|Experimental|arm 1|
11619242|NCT00493363|Active Comparator|arm 2|
11619243|NCT00493350||1|Patients with newly diagnosed stage IV breast cancer scheduled to start systemic therapy.
11619244|NCT00493337|No Intervention|Control group|
11619245|NCT00493337|Experimental|Advanced counseling|
11619246|NCT00493337|Active Comparator|Compliance Card only|
11619247|NCT00493324|Experimental|1|
11619248|NCT00493311|Experimental|IV Acetaminophen|1 g of acetaminophen in 100 mL of intravenous solution
11619249|NCT00493311|Placebo Comparator|IV Placebo|100 mL of intravenous placebo solution
11619250|NCT00493298||natalizumab|According to the local prescribing information
11619251|NCT00493285|Active Comparator|1|MEDI-534 at 10^4 TCID50 at 0, 2, and 4 months (Nasal spray)
11619252|NCT00493285|Active Comparator|2|MEDI-534 at 10^5 TCID50 at 0, 2, and 4 months (Nasal Spray)
11619253|NCT00493285|Active Comparator|3|MEDI-534 at 10^6 TCID50 at 0, 2, and 4 months (Nasal Spray)
11619254|NCT00493272|Placebo Comparator|Placebo|Nacl
11619255|NCT00493272|Active Comparator|Fibrinogen|Fibrinogen
11619256|NCT00493246|Experimental|Intravenous (IV) Acetaminophen 15 milligrams/kilogram (mg/kg)|Intravenous Acetaminophen administered 15 milligrams/kilogram (mg/kg) every 8 hours (q8h) or every 6 hours (q6h) based age of subject
11619257|NCT00493246|Experimental|Intravenous (IV) Acetaminophen 12.5 (mg/kg)|Intravenous Acetaminophen administered 12.5 milligrams/kilogram (mg/kg) every 6 hours (q6h) or every 4 hours (q4h)
11619258|NCT00493233|Experimental|1|
11619259|NCT00493233|Placebo Comparator|2|
11619260|NCT00493220|Experimental|HYLENEX SC, Placebo SC, IV|subcutaneous HYLENEX and ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention
11619261|NCT00493220|Experimental|HYLENEX SC, IV, Placebo SC|subcutaneous HYLENEX and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention
11619262|NCT00493220|Experimental|Placebo SC, HYLENEX SC, IV|subcutaneous placebo and ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention
11619263|NCT00493220|Experimental|Placebo SC, IV, HYLENEX SC|subcutaneous placebo and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention
11619264|NCT00493220|Experimental|IV, HYLENEX SC, Placebo SC|IV ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention
11619265|NCT00493220|Experimental|IV, Placebo SC, HYLENEX SC|IV ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention
11619266|NCT00493181|Experimental|Interleukin-11|Starting dose 10 mcg/kg subcutaneously 3 times a week
11619267|NCT00493155|Experimental|1|
11619268|NCT00493142|Experimental|1|Usual care
11619269|NCT00493129|Experimental|Ontak|Ontak administered intravenously on Days 1-5 at the dose of 9 µg/kg/day, with a rest period from Days 6-21.
11619270|NCT00493116|Experimental|1|
11619271|NCT00493077|Experimental|1|
11619272|NCT00493064|Experimental|Prospective active treatment|Niacin 500mg TID PO for treatment of retinal vein occlusions.
11619273|NCT00493051|Other|1|Standardized Wound Care
11619274|NCT00493051|Placebo Comparator|2|Placebo 1 dose
11619275|NCT00493051|Placebo Comparator|3|Placebo 2 doses
11619276|NCT00493051|Active Comparator|4|Active 1 dose
11619277|NCT00493051|Active Comparator|5|Active 2 doses
11619278|NCT00493038|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg tablets once daily (OD) for 7 days and amoxicillin/clavulanate 1000 mg matching placebo tablets three times daily (TID)for 10 days
11619279|NCT00493038|Active Comparator|Amoxicillin/Clavulanate|Amoxicillin/clavulanate 1000 mg tablets three times daily (TID) for 10 days and moxifloxacin 400 mg matching placebo tablets once daily (OD) for 7 days
11619280|NCT00493025|Experimental|Paclitaxel, Cisplatin, ZD1839 and Radiotherapy|Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
11619281|NCT00493012|Experimental|vitamin D oil|oil containing vitamin D (Vigantol oil)
11619282|NCT00493012|Placebo Comparator|placebo oil|oil not containg vitamin D (Migliol oil)
11619283|NCT00492999|Experimental|Group 1|Patients receive hepatic arterial infusion (HAI) therapy comprising floxuridine and dexamethasone continuously on days 1-14. Patients also receive oxaliplatin IV over 2 hours and irinotecan hydrochloride IV over 30 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11619284|NCT00492999|Experimental|Group 2|Patients receive HAI therapy as in group 1. Patients also receive irinotecan hydrochloride IV over 30 minutes and leucovorin calcium IV over 30 minutes on days 1 and 15 and fluorouracil IV continuously over 48 hours on days 1, 2, 15, and 16. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11619285|NCT00492986|Experimental|Arm 1|
11619286|NCT00492973|Active Comparator|Control|Patients in the active comparator group will receive intraoperative injections containing bupivacaine HCl, morphine, epinephrine, clonidine, cefuroxime, and normal saline, as per the surgeon's standard of care.
11619287|NCT00492973|Experimental|Corticosteroid|Patients in the Corticosteroid group will have the same medications as the Control Group with the addition of a corticosteroid (methylprednisolone acetate)
11619288|NCT00492960|Experimental|Larazotide acetate 1 mg|larazotide acetate 1 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
11619289|NCT00492960|Experimental|Larazotide acetate 4 mg|larazotide acetate 4 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
11619290|NCT00492960|Experimental|Larazotide acetate 8 mg|larazotide acetate 8 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
11619291|NCT00492960|Placebo Comparator|Placebo|placebo capsules TID + 900 mg gluten capsules TID for 6 weeks
11619292|NCT00492934|Active Comparator|1|Daily injections with a small dose of gonadotrophins from day 2 of the cycle
11619293|NCT00492934|No Intervention|2|No daily injections with hormones
11619294|NCT00492921|Experimental|Cyclophosphamide 50|Treatment with cyclophosphamide 50 mg/kg/d x 1 days.
11619295|NCT00492921|Experimental|Cyclophosphamide 100|Treatment with cyclophosphamide 50 mg/kg/d x 2 days.
11619296|NCT00492921|Experimental|Cyclophosphamide 150|Treatment with cyclophosphamide 50 mg/kg/d x 3 days.
11619297|NCT00492908|Active Comparator|Titanium Nitride Oxide Coated Stent|Stent
11619298|NCT00492908|Active Comparator|Zotarohlimus Eluting Stent|Stent
11619299|NCT00492895|Other|A|one arm only. Crossover study
11619300|NCT00492856|Experimental|Post-consolidation therapy arm I|Patients receive oral tretinoin twice daily on days 1-7, oral mercaptopurine once daily on days 1-14, and oral methotrexate on day 1. Treatment repeats every 2 weeks for up to 1 year.
11619301|NCT00492856|No Intervention|Post-consolidation therapy arm II|Patients receive no further chemotherapy. Patients are followed every 3 months for 1 year. (Randomization and observation arm closed as of 8/15/10)
11619302|NCT00492843|Experimental|A|Intravenous infusion of either 6mg Bondronat on three consecutive days
11619303|NCT00492843|Active Comparator|B|Intravenous infusion of 6mg Bondronat on one day
11619304|NCT00492817|Experimental|Single Session Stereotactic Body Radiotherapy (SBRT)|On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
11619305|NCT00492804|Other|Neurectomy|
11619306|NCT00492804|Other|Nerve preservation|
11619307|NCT00492791||Endoscopic Capsule|Patient enrolled for performing an endoscopic capsule
11619308|NCT00492778|Experimental|Arm I (brachytherapy, radiation therapy)|Patients undergo EBRT to the pelvis daily on days 1-5 for 5 weeks. After completion of EBRT, patients undergo intracavitary low-dose rate or high-dose rate brachytherapy or low-dose rate interstitial brachytherapy.
11619309|NCT00492778|Experimental|Arm II (brachytherapy, radiation therapy, cisplatin)|Patients undergo EBRT as in Arm I and receive cisplatin IV over 1-2 hours on days 1, 8, 15, 22, and 29. Patients then undergo brachytherapy as in Arm I.
11619310|NCT00492765|Experimental|1|interferon beta-1a and Simvastatin
11619311|NCT00492765|Placebo Comparator|2|Interferon beta-1a and Placebo
11619312|NCT00492752|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib was administered orally at a dose of 400 mg (2 x 200 mg tablets) bid (twice daily); 2 dose reductions to predefined levels of 400 mg (2 x 200 mg tablets) once daily (od) and 400 mg (2 x 200 mg tablets) every 2 days were permitted for treatment-emergent adverse events related to study treatment.
11619313|NCT00492752|Placebo Comparator|Placebo|Placebo tablets matching in appearance were orally administered bid (twice daily).
11619314|NCT00492739|Other|Varicella vaccine|2-3 doses of Varicella vaccine to seronegative patients two months apart
11619315|NCT00492726|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.
11619316|NCT00492726|Active Comparator|Ertapenem|Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.
11619317|NCT00492713|Active Comparator|1|Dark chocolate
11619318|NCT00492713|Active Comparator|2|Milk chocolate 1
11619319|NCT00492713|Active Comparator|3|Milk chocolate 2
11619320|NCT00492661|Experimental|Tacrolimus With Diet and Exercise Intervention|Participants on tacrolimus for immunosuppression (drug which suppresses the body's immune response, used in transplantation and diseases caused by disordered immunity) will be provided with intensive dietary advice and supervised progressive resistance training (PRT) for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
11619321|NCT00492648|Experimental|GSK1437173A 18-30 Years Old Group|Subjects aged 18 to 30 years old receiving 2 doses GSK1437173A vaccine in the primary study.
11619322|NCT00492648|Experimental|GSK1437173A 50-70 Years Old Group|Subjects aged 50 to 70 years old receiving 2 doses GSK1437173A vaccine in the primary study.
11619323|NCT00492635|Experimental|Arm 1|
11619324|NCT00492635|Experimental|Arm 2|
11619325|NCT00492635|Placebo Comparator|Arm 3|
11619326|NCT00492622|Experimental|Immediate-release omeprazole release first|subjects receive immediate release omeprazole for 7 days then delayed release for 7 days
11619327|NCT00492622|Experimental|Delayed-release omeprazole first|subjects receive delayed release omeprazole for 7 days then immediate release for 7 days
11619328|NCT00492609||1|PATIENTS WITH COMPUTER-ASSISTED
11619329|NCT00492609||2|PATIENTS WITHOUT COMPUTER-ASSISTED
11619330|NCT00492596|Experimental|device|insertion of balloon system
11619331|NCT00492596|Sham Comparator|sham|cystoscopy with sham system
11619332|NCT00492583|Placebo Comparator|Placebo|Subjects were provided 4 fluid ounces (112 grams) administered orally per day of placebo drink.
11619333|NCT00492583|Experimental|Bifidobacterium lactis (BB-12)|Subjects were provided 4 fluid ounces (112 grams) administered orally per day of active drink.
11619334|NCT00492557|Experimental|13vPnC+TIV Followed by Placebo 1 month later|
11619335|NCT00492557|Active Comparator|Placebo+TIV Followed by 13vPnC 1 month later|
11619336|NCT00492544|Experimental|Cervarix|Subjects received 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) according to a 0, 1, 6-month schedule.
11619337|NCT00492531|Experimental|Sildenafil|There was a balancing of treatment group assignment across Tricuspid Regurgitant Jet velocity(TRV)measured on Echo.
11619338|NCT00492531|Placebo Comparator|Placebo|There was a balancing of treatment group assignment across Tricuspid Regurgitant Jet velocity(TRV)measured on Echo
11619339|NCT00492492|Other|trans-styloid and intrafocal pinning on the one side|trans-styloid and intrafocal pinning on the one side
11619340|NCT00492492|Other|volar fixed-angle plating on the other side|volar fixed-angle plating on the other side
11619341|NCT00492466|Experimental|1|
11619342|NCT00492453|Active Comparator|1|Laparoscopic cholecystectomy under spinal anesthesia
11619343|NCT00492453|Active Comparator|2|Laparoscopic cholecystectomy under general anesthesia
11619344|NCT00492440|Experimental|CYT107 (r-hIL-7)|
11619345|NCT00492427|Active Comparator|2|
11619346|NCT00492427|Experimental|1|
11619347|NCT00492401|Experimental|Treatment (chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11619348|NCT00492388|Experimental|A|PMI-150 (intranasal ketamine)
11619349|NCT00492388|Placebo Comparator|B|placebo
11619350|NCT00492362|Active Comparator|A|Ergometer during hemodialysis
11619351|NCT00492362|Active Comparator|B|Pedometer use outside of hemodialysis
11619352|NCT00492349|Experimental|1|Varenicline
11619353|NCT00492349|Placebo Comparator|2|Placebo
11619354|NCT00492336|Active Comparator|Rasagiline|Treatment with Rasagiline
11619355|NCT00492336|Placebo Comparator|Inactive pill|Treatment with Placebo
11619356|NCT00492323|Placebo Comparator|002|placebo twice daily for 4 weeks
11619357|NCT00492323|Experimental|001|carisbamate 200 mg tablet twice daily for 4 weeks
11619358|NCT00492310|Experimental|1|Cognitive-behavioral smoking cessation with yoga
11619359|NCT00492310|Active Comparator|2|smoking cessation with twice weekly wellness program
11619360|NCT00492297|Experimental|Sorafenib + Dacarbazine|Dacarbazine 1000 mg/m^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
11619361|NCT00492284|Experimental|1/4 Fluence Triple Therapy|Very low fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
11619362|NCT00492284|Experimental|1/2 Fluence Triple Therapy|Reduced-fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
11619363|NCT00492284|Experimental|1/2 Fluence Double Therapy|Reduced-fluence Visudyne followed by Lucentis double therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
11619364|NCT00492284|Experimental|Ranibizumab|Lucentis monotherapy administered on Day 0, Month 1 and Month 2, and then as required monthly thereafter
11619365|NCT00492271|Experimental|1|Experimental arm with increasing dosage
11619366|NCT00492232|Experimental|Ramelteon 8 mg QD and current Zolpidem therapy|Zolpidem therapy will be reduced by dose, frequency, or both for up to 10 weeks.
11619367|NCT00492232|Placebo Comparator|Placebo QD and current Zolpidem therapy|Zolpidem therapy will be reduced by dose, frequency, or both for up to 10 weeks.
11619368|NCT00492219|Active Comparator|1|Patients undergoing total knee replacement
11619369|NCT00492219|No Intervention|2|Healthy volunteers that are not undergoing knee replacement surgery
11619370|NCT00492219|Experimental|3|Patients undergoing partial knee replacement with the Oxford mobile bearing implant system
11619371|NCT00492219|Experimental|4|Patients undergoing partial knee replacement with the Vanguard M implant system
11619372|NCT00492206|Experimental|Cetuximab|"Cetuximab 400 mg/m2 IV week 0 only
~External beam radiation weeks 1 - 7
~Cetuximab 250 mg/m2 IV weekly thereafter weeks 1 - 7
~Cetuximab 250 mg/m2 IV weekly weeks 8 - 26
~Carboplatin AUC = 6 IV Paclitaxel 200 mg/m2 IV Every 3 weeks x 3 Cycles"
11619373|NCT00492167|Experimental|Beta-Glucan and Monoclonal Antibody 3F8|"This is a dose-escalation study of beta-glucan. Patients receive oral beta-glucan once daily on days -4 to 12 and monoclonal antibody 3F8 IV over 30-90 minutes on days 1-5 and 8-12. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity and with a human antimouse antibody (HAMA) titer < 1,000 U/mL.
~Cohorts of 3-6 patients receive escalating doses of beta-glucan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
~Patients undergo urine, bone marrow, and blood sample collection periodically for biological studies. Samples are analyzed for antibody-dependent cellular cytotoxicity, complement-mediated cytotoxicity, and serum HAMA response via immunohistochemistry.
~After completion of study treatment, patients are followed periodica"
11619374|NCT00492141|Experimental|L9-NC + Temozolomide|Liposomal 9-nitro-20(S)-camptothecin (L9-NC) alone, total 10 ml of 0.4 mg/ml in aerosol reservoir once a day for 5 days in row each 2 weeks, followed by 2 weeks off; then in combination with Temozolomide 100 mg/m^2 oral/day for Cycle 2 Days 1-5.
11619375|NCT00492128|Experimental|Losartan/hydrochlorothiazide|Combination drug with losartan 50mg and hydrochlorothiazide 12.5mg
11619376|NCT00492128|Active Comparator|Losartan/amlodipine|Combination therapy with losartan 50mg and amlodopine 5mg
11619377|NCT00492115|Active Comparator|"therapeutic CPAP Treatment (6 weeks)"|Intervention - The active comparator is an intervention of nightly therapeutic CPAP (continuous positive airway pressure) treatment for 6 weeks. Patients will use CPAP every night for the full duration of the study, i.e., 6 weeks
11619378|NCT00492115|Placebo Comparator|"Sham CPAP/therapetuic CPAP (6 weeks)"|"The placebo comparator is an intervention of placebo CPAP (continuous positive airway pressure) nightly for 3 weeks followed by therapeutic CPAP treatment nightly for 3 weeks.
~Patients will use a sham CPAP (no real pressure) for 3 weeks and then will be switched to real CPAP for 3 weeks."
11619379|NCT00492102|Experimental|1|Nine VLBW pre-term infants older than 7 days will be enrolled in the study and receive one oral dose of Montelukast based on weight. Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.
11619380|NCT00492089|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11619381|NCT00492089|Placebo Comparator|Arm II|Patients receive placebo IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11619382|NCT00492076|Active Comparator|1|Pangramin Plus Dermatophagoides pteronyssinus 100%
11619383|NCT00492076|Placebo Comparator|2|Pangramin Plus placebo
11619384|NCT00492063|Experimental|Cell culture-derived influenza vaccine (cTIV)|
11619385|NCT00492063|Active Comparator|Egg-derived influenza virus vaccine (TIV)|
11619386|NCT00492050|Experimental|Bortezomib + Rituximab|Bortezomib 1.6 mg/m^2 IV Weekly on Days 1, 8, 15 and 22. Rituximab 375 mg/m^2 IV on Day 8 and 22. Valacyclovir 500 mg orally daily (or acyclovir 200 mg orally twice daily).
11619387|NCT00492024|Experimental|Moxifloxacin 400 mg|Moxifloxacin 400mg once daily for 5 days
11619388|NCT00492024|Placebo Comparator|Placebo|Matching placebo for 5 days
11619389|NCT00492011|Experimental|Ramelteon 1 mg QD|
11619390|NCT00492011|Experimental|Ramelteon 4 mg QD|
11619391|NCT00492011|Experimental|Ramelteon 8 mg QD|
11619392|NCT00492011|Placebo Comparator|Placebo|
11619393|NCT00491998|Experimental|2-hourly dosing|6 Doses of IMP at 2-hourly intervals
11619394|NCT00491998|Experimental|3-hourly dosing|4 doses of IMP at 3-hourly intervals
11619395|NCT00491998|Active Comparator|3-hourly dosing plus Entacapone|4 doses of IMP plus Entacapone at 3-hourly intervals
11619396|NCT00491985|Experimental|Study Group 1|Subjects aged 9 to 17 years
11619397|NCT00491985|Experimental|Study Group 2|Subjects aged 3 to 8 years
11619398|NCT00491985|Experimental|Study Group 3|Subjects aged 6 to 35 months
11619399|NCT00491894|Other|Patients with Chronic Drooling|Arm receiving study drug
11619400|NCT00491868|Experimental|1|
11619401|NCT00491868|Experimental|2|
11619402|NCT00491868|Active Comparator|3|
11619403|NCT00491868|Active Comparator|4|
11619404|NCT00491855|Experimental|Bevacizumab + Oxaliplatin + Paclitaxel|One cycle of treatment is 21 days. Bevacizumab starting dose level 2.5 mg/kg given intravenously on day 1. Oxaliplatin starting dose level 25 mg/m^2 given intraperitoneally on day 2. Paclitaxel starting dose level 110 mg/m^2 given continuous infusion on day 1 and 30 mg/m^2 given intraperitoneally on day 8.
11619405|NCT00491842||At-risk|Individuals at-risk for HD
11619406|NCT00491842||Presymptomatic|Presymptomatic carriers of HD
11619407|NCT00491829|Experimental|flibanserin|50 mg qhs
11619408|NCT00491829|Experimental|flibanserin 100mg|100 mg qhs
11619409|NCT00491829|Placebo Comparator|placebo|placebo qhs
11619410|NCT00491816|Experimental|erlotinib with neoadjuvant chemotherapy|Study drug, erlotinib, is administered along with neoadjuvant chemotherapy. Adjuvant therapy given at discretion of treating physician. Once adjuvant therapy is completed, all patients will receive erlotinib 150 mg daily for 1 year.
11619411|NCT00491803|Active Comparator|1|Sildenafil 20mg
11619412|NCT00491803|Active Comparator|2|Sildenafil 40mg
11619413|NCT00491790|Sham Comparator|1|Sterile Water
11619414|NCT00491790|Active Comparator|Montelukast|Dissolved granules in sterile water
11619415|NCT00491764|Experimental|Posaconazole 100 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
11619416|NCT00491764|Experimental|Posaconazole 200 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
11619417|NCT00491764|Experimental|Posaconazole 400 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
11619418|NCT00491764|Experimental|Posaconazole 400 mg QD for 12 weeks.|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
11619419|NCT00491764|Active Comparator|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
11619420|NCT00491764|Placebo Comparator|Placebo|Placebo for 24 weeks.
11619421|NCT00491751|Experimental|Atorvastatin|Atorvastatin 40 or 80 mg/day
11619422|NCT00491751|Experimental|Ascorbic Acid|Ascorbic Acid 500 mg/day
11619423|NCT00491751|Placebo Comparator|Placebo|Placebo atorvastatin and Placebo ascorbic acid
11619424|NCT00491738|Experimental|1|
11619425|NCT00491738|Placebo Comparator|2|
11619426|NCT00491673|Active Comparator|Uncemented|Uncemented primary bipolar hemiarthroplasty of the hip
11619427|NCT00491673|Active Comparator|Cemented|Cemented primary bipolar hemiarthroplasty of the hip
11619428|NCT00491634|Experimental|1|treosulfan
11619429|NCT00491621|Other|1|surgery or biopsy of the kidney tumor
11619430|NCT00491608|Experimental|1|rThrombin
11619431|NCT00491582|No Intervention|Athletes, controls, patients|Sedentary controls: age, BMI, Gender and waist matched (to the growth hormone deficient patients) healthy control subjects Endurance trained athletes: minimal >50 mlO2/KG body weight
11619432|NCT00491556|Experimental|Experimental Arm|Subjects in the experimental group will begin HAART consisting of TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r upon entry or to begin treatment under current DHHS guidelines. Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
11619433|NCT00491556|Other|Standard Care Arm|Subjects randomized to the standard care arm will begin HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care and will be followed for a total of three years. Under these guidelines and under current clinical standards, subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur.
11619434|NCT00491530|Experimental|ABT-335 + rosuvastatin calcium|
11619435|NCT00491530|Experimental|ABT-335 + simvastatin|
11619436|NCT00491530|Experimental|ABT-335 + atorvastatin calcium|
11619437|NCT00491517|Experimental|Sirolimus|
11619438|NCT00491517|Active Comparator|conventional therapy|
11619439|NCT00491504|Experimental|Mometasone Furoate Nasal Spray (MFNS)|MFNS 200 mcg total dose (2 sprays each nostril)
11619440|NCT00491504|Placebo Comparator|Placebo|Placebo (2 sprays each nostril)
11619441|NCT00491491|Experimental|Z-BEAM|ibritumomab tiuxetan (zevalin) BEAM
11619442|NCT00491491|Active Comparator|standard BEAM|standard BEAM chemotherapy
11619443|NCT00491439||Corneal wounds after Epi-LASIK|Corneal wounds after Epi-LASIK
11619444|NCT00491439||penetrating keratoplasty|Corneal wound after penetrating keratoplasty
11619445|NCT00491439||corneal epithelial debridement|Corneal wound after pars plana vitrectioy with corneal epithelial debridement for diabetic retinopathy
11619446|NCT00491426||<26 weeks|Subjects <26 weeks gestational age
11619447|NCT00491426||26-29 weeks|Subjects 26-29 weeks gestational age
11619448|NCT00491426||30-32 weeks|Subjects 30-32 weeks gestational age
11619449|NCT00491400|Active Comparator|Fenofibrate First|Fenofibrate 145 mg/day for 8 weeks First and Atorvastatin 20 mg/day for 8 weeks Second
11619450|NCT00491400|Active Comparator|Atorvastatin First|Atorvastatin 20 mg/day for 8 weeks First and Fenofibrate 145 mg/day for 8 weeks Second
11619451|NCT00491387|Experimental|metoprolol succinate|Subjects will undergo I-123 MIBG testing before and after sustained-release beta-adrenergic blockade.
11619452|NCT00491374|Experimental|MFNS|
11619453|NCT00491374|Placebo Comparator|Placebo|
11619454|NCT00491322|Experimental|Ergocalciferol group|Ergocalciferol 50000 international units once a week for 12 weeks
11619455|NCT00491322|Placebo Comparator|Ergocalciferol Placebo group|Matching placebo once a week for 12 weeks
11619456|NCT00491309|Active Comparator|exercise training group|exercise and respiratory therapy with specific program for pulmonary hypertension (respiratory therapy, dumbbell training, ergometer training, mental training)
11619457|NCT00491309|No Intervention|Control group without exercise training|continuation of sedentary lifestyle without advice for specific exercise training
11619458|NCT00491257|Experimental|Study Group 1|Participants aged 18 to 60 years at enrollment
11619459|NCT00491257|Experimental|Study Group 2|Participants aged 61 years or older at enrollment.
11619460|NCT00491244|Experimental|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
11619461|NCT00491244|Experimental|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
11619462|NCT00491179|Experimental|Pegylated IFN + RBV for HCV genotype 1|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks for HCV genotype 1
11619463|NCT00491179|Experimental|Pegylated IFN + RBV for HCV genotype 2|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks for HCV genotype 2
11619464|NCT00491140||Observation|Colorectal cancer patients
11619465|NCT00491101||1|Children with asthma, both genders, from 7-18 years old.
11619466|NCT00491075|Experimental|Pemetrexed + Gemcitabine|Pemetrexed 500 mg/m^2 intravenous (IV) and Gemcitabine 1500 mg/m^2 IV on Day 1.
11619467|NCT00491062|Active Comparator|Control|
11619468|NCT00491062|Experimental|Parkinson stade 1|
11619469|NCT00491062|Experimental|Parkinson stade2|
11619470|NCT00491062|Experimental|Parkinson stade 3|
11619471|NCT00491036|Active Comparator|Intraaortic balloon pump|Patients in cardiogenic shock get an intraaortic balloon pump in the cath lab
11619472|NCT00491036|No Intervention|No intraaortic balloon pump|Patients in cardiogenic shock in this group get no intraaortic balloon pump
11619473|NCT00490997|Active Comparator|1|Ketamine only arm
11619474|NCT00490997|Active Comparator|2|Ketamine-Propofol arm
11619475|NCT00490971|Experimental|Paliperidone ER|
11619476|NCT00490971|Placebo Comparator|Placebo|
11619477|NCT00490971|Active Comparator|Olanzapine|
11619478|NCT00490919|Experimental|Double-blind BTDS 10 or 20|Buprenorphine transdermal system 10 or 20 mcg/h applied for 7-day wear
11619479|NCT00490919|Placebo Comparator|Double-blind Placebo TDS|Placebo transdermal system to match BTDS patches, applied for 7 days
11653989|NCT00034554|Experimental|4|4.0mg
11619481|NCT00490906||2|Patients receive interferons
11619482|NCT00490854|Experimental|1|
11619483|NCT00490854|Experimental|2|
11619484|NCT00490841|Experimental|RX Herculink Elite|To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.
11619485|NCT00490828|Placebo Comparator|A|
11619486|NCT00490828|Active Comparator|B|Stress doses of hydrocortisone
11619487|NCT00490815|Experimental|1|
11619488|NCT00490815|Experimental|2|
11619489|NCT00490802|Experimental|Intranasal Oxytocin|Subjects were given 24 IU intranasal oxytocin twice daily, in the morning and afternoon for 6 weeks.
11619490|NCT00490802|Placebo Comparator|Placebo|Subjects were given placebo twice daily, in the morning and afternoon for 6 weeks.
11619491|NCT00490776|Experimental|LBH589|
11619492|NCT00490763||Active Surveillance|Patients with low-risk prostate cancer who choose to undergo active surveillance.
11619493|NCT00490750|Active Comparator|Laparoscopic Dor fundoplication|Heller myotomy followed by Dor fundoplication
11619494|NCT00490750|Active Comparator|Laparoscopic Toupet fundoplication|Heller myotomy followed by Toupet fundoplication
11619495|NCT00490737|Experimental|Hemodialysis (HD) Participants|Participants will receive daptomycin 6 mg/kg by intravenous infusion (i.v.) at 48-hours intervals (with dialysis) for a total of 3 doses.
11619496|NCT00490737|Experimental|Continuous Ambulatory Peritoneal Dialysis (CAPD) Participants|Participants will receive daptomycin 6 mg/kg, i.v., at 48-hours intervals for a total of 3 doses.
11619497|NCT00490724|Experimental|Nesiritide (1+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
11619498|NCT00490724|Experimental|Nesiritide (2+0.005)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
11619499|NCT00490724|Experimental|Nesiritide (2+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
11619500|NCT00490698|Experimental|Zoledronate + Atorvastatin|Zoledronate 4 mg intravenous (IV) once every 4 Weeks + Atorvastatin 20 mg orally (PO) daily
11619501|NCT00490672|Other|Control Arm|Conventional Patient Management on Hypertension, Diabetes Mellitus and Hyperlipidaemia by Malaysian GP
11619502|NCT00490672|Active Comparator|CORFIS Arm|Community based Multiple Risk Factor Intervention Strategies
11619503|NCT00490646|Experimental|Arm A|trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.
11619504|NCT00490646|Active Comparator|Arm B|trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + docetaxel 100 mg/m^2 IV over 1 hour once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.
11619505|NCT00490633|Experimental|Facemask and hand hygiene|Facemask and hand hygiene provided for participants.
11619506|NCT00490633|Experimental|Facemask only|Facemask only provided for participants.
11619507|NCT00490633|No Intervention|Control|Control, no intervention.
11619508|NCT00490620|Placebo Comparator|1|blinded placebo control
11619509|NCT00490620|Active Comparator|2|Antiretroviral therapy
11619510|NCT00490581|Experimental|Study group|These patients are assigned to the intervention of early supportive housing with case management integrated into the medical system. These subjects are offerred respite care/interim housing upon discharge from enrolling hospitalizations, followed by stable housing within 90 days. They have a case manager at each stage (hospital, respite/interim housing, and stable housing)
11619511|NCT00490581|No Intervention|Usual Care|These patients receive usual social services for hospital discharge planning.
11619512|NCT00490568|Experimental|Rosiglitazone XR|Investigational drug
11619513|NCT00490555|Placebo Comparator|1|Placebo gel + Placebo pill + placebo injection
11619514|NCT00490555|Active Comparator|2|Testosterone 1% transdermal gel 10 g + placebo pill + placebo injection
11619515|NCT00490555|Active Comparator|3|Testosterone 1% transdermal gel 10 g + dutasteride 0.5 mg Orally + placebo injection
11619516|NCT00490555|Active Comparator|4|Testosterone 1% transdermal gel 10 g + placebo pill + DMPA 300 mg injection (IM)
11619517|NCT00490542|Placebo Comparator|Placebo arm|Participants were instructed by a physician to take a study drug daily. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone. Participants were not informed whether they were receiving sugar pills or Geodon. Participants in this study arm received sugar pills.
11619518|NCT00490542|Active Comparator|Geodon arm|Participants were instructed by a physician to take a study drug daily. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone. Participants were not informed whether they were receiving sugar pills or Geodon. Participants in this study arm received Geodon.
11619519|NCT00490529|Experimental|CpG-MCL Vaccine|An autologous anti-tumor vaccine.
11619520|NCT00490516|Experimental|1|
11619521|NCT00490516|Experimental|2|
11619522|NCT00490516|Placebo Comparator|3|
11619523|NCT00490503||MRI + MRS|Patients with newly diagnosed stage II A-B or III A-C breast cancers who are scheduled to start systemic chemotherapy.
11619524|NCT00490490|Experimental|Tositumomab + XRT + KI|Tositumomab + external beam radiotherapy (XRT) + potassium iodide (KI)
11619525|NCT00490477|No Intervention|CONVENTIONAL|
11653990|NCT00034554|Experimental|5|8.0mg
11619526|NCT00490477|Active Comparator|POLYMYXIN-B|an extracorporeal LPS removal
11619527|NCT00490451|Experimental|LY573636|
11619528|NCT00490412|Experimental|A: tenofovir/vitamin D|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Group A (who are already taking Tenofovir) once every four weeks during study visits.
11619529|NCT00490412|Placebo Comparator|B: tenofovir/placebo|A placebo will be administered orally to subjects in Group B (who are already taking Tenofovir).
11619530|NCT00490412|Experimental|C: no tenofovir/vitamin D|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Group C (who are not taking Tenofovir) once every four weeks during study visits.
11619531|NCT00490412|Placebo Comparator|D: no tenofovir/placebo|A placebo will be administered orally to subjects in Group D (who are not taking Tenofovir).
11619532|NCT00490334||Cancer patients|Children with cancer aged 8 to 16 years
11619533|NCT00490334||Control (non-cancer)|Normal children aged 8 to 16 years, age- and gender-matched to the cancer cohort
11619534|NCT00490295||newborn cardiac surgical study group|
11619535|NCT00490282|Experimental|Image-Guided Adaptive Radiotherapy|Intensity Modulated Radiotherapy (IMRT) + Adaptive Radiotherapy (ART)
11619536|NCT00490269|Active Comparator|Dronabinol|
11619537|NCT00490269|Placebo Comparator|Placebo|
11619538|NCT00490256|No Intervention|Control|Arm 1 is the control arm. This arm will receive the standard cardiopulmonary bypass circuit.
11619539|NCT00490256|Active Comparator|Experimental|This arm is the modified selective perfusion arm. This arm will receive the modified cardiopulmonary circuit.
11619540|NCT00490230|Experimental|WR 279,396|CL lesions treated with WR 279396
11619541|NCT00490230|No Intervention|Natural Healing|CL lesions healed naturally
11619542|NCT00490230|Placebo Comparator|vehicle control|CL lesions were treated with the vehicle alone
11619543|NCT00490152||1|Participants use Vivagel™, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
11619544|NCT00490152||2|Participants use VivaGel™ Placebo, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
11619545|NCT00490152||3|Participants use HEC Placebo Gel (HEC Gel), applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
11619546|NCT00490139|Active Comparator|Arm 1: Trastuzumab|"Design 1: Trastuzumab 8mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks for a total of 52 weeks.
~Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab administered every 3 weeks (6mg/kg IV without loading dose) for an additional 40 weeks (52 weeks total).
~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab (6mg/kg without loading dose) every 3 weeks for an additional 40 weeks (52 weeks total)."
11619547|NCT00490139|Experimental|Arm 2: Lapatinib|"Based on the IDMC results from 18 August 2011, any patient enrolled onto Arm 2 should be considered for a new treatment strategy based on discussion with their physician.
~Design 1: Lapatinib 1500mg oral daily for a total of 52 weeks.
~Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, oral lapatinib administered at 1500mg daily for an additional 40 weeks (52 weeks total).
~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, the dose of lapatinib will be increased to 1500mg oral daily for an additional 40 weeks (52 weeks total)."
11619548|NCT00490139|Experimental|Arm 3: Trastuzumab followed by Lapatinib|"Design 1: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total).
~Design 2: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks administered concomitantly and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles; followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total).
~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) followed by a 6 week treatment-free interval followed by oral lapatinib 1500 mg daily for 28 weeks (52 weeks total)."
11619549|NCT00490139|Experimental|Arm 4: Lapatinib in combination with Trastuzumab|"Design 1: Oral lapatinib 1000 mg daily concurrent with trastuzumab 8 mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks (52 weeks total).
~Design 2: Trastuzumab (4mg/kg loading dose followed by 2mg/kg IV weekly) concurrent with oral lapatinib 750 mg daily and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles (12 weeks). After completion of chemotherapy, the dose of lapatinib will be increased to 1000mg daily concurrently with trastuzumab every 3 weeks (6mg/kg without loading dose) for an additional 40 weeks (52 weeks total).
~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concurrently with oral lapatinib 750mg plus weekly trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV. After the completion of chemotherapy, trastuzumab will be administered every 3 weeks (6mg/kg without loading dose) concurrent with lapatinib 1000mg daily for an additional 40 weeks (52 weeks total)."
11619550|NCT00490126||Laparoscopic Surgery Database|
11619551|NCT00490113|Experimental|1|
11619552|NCT00490100|Experimental|Treatment|Treatment
11619553|NCT00490087|Experimental|Hysteroscopic resection plus IUD|
11619554|NCT00490087|No Intervention|Hysteroscopic resection without IUD|
11619555|NCT00490074|Experimental|3 DNA-C + 1 NYVAC-C|
11619556|NCT00490074|Active Comparator|2 DNA-C + 2 NYVAC-C|
11619557|NCT00490061|Experimental|Radiotherapy and Lapatinib with DCE-MRI|DCE-MRI will precede radiotherpy before and after Lapatinib loading. 1500mg/d once daily oral Lapatinib will be administration for seven days prior to and throughout radiotherapy. Radiotherapy will be delivered as Intensity Modulated Radio Therapy (IMRT) using a G.E. Healthcare 1.5T MR, systems revision 12.0 M5 for a total dose of 70Gy delivered in 2-2.12 Gy/ fraction over the course of 6.5-7 weeks.
11619558|NCT00490035|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
11654048|NCT00031395|Active Comparator|3|
11619559|NCT00490035|Experimental|Brivaracetam 20 mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day
11619560|NCT00490035|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
11619561|NCT00490035|Experimental|Brivaracetam 100 mg/day|Brivaracetam 100 mg/day, 50 mg administered twice a day
11619562|NCT00490022|Active Comparator|1|DHT gel (70 mg/day) for one month
11619563|NCT00490022|Placebo Comparator|2|Placebo gel for one month
11619564|NCT00490009|Experimental|Bexxar + Total Body Irradiation (TBI)|Bexxar will be administered with pre-medications acetaminophen, diphenhydramine, and potassium iodide (KI).
11619565|NCT00489970|Experimental|Boostrix Group|Subjects received in the primary study (NCT00346073) a single dose of Boostrix vaccine [Tdap](GSK776423) intramuscularly in the deltoid region of the non-dominant upper arm and in this study at Year 9 received a second dose of Boostrix vaccine [Tdap](GSK776423).
11619566|NCT00489970|Active Comparator|Adacel Group|Subjects received in the primary study (NCT00346073) a single dose of Adacel vaccine intramuscularly in the deltoid region of the non-dominant upper arm and in this study at Year 9 received a dose of Boostrix vaccine [Tdap](GSK776423).
11619567|NCT00489970|Active Comparator|Control group|Subjects received the first dose of Boostrix vaccine [Tdap](GSK776423) in this study at Year 9.
11619568|NCT00489957||Normals|
11619569|NCT00489957||Cardiomyopathy|
11619570|NCT00489918|Placebo Comparator|Macroflux® placebo|Macroflux® placebo patch
11619571|NCT00489918|Experimental|Macroflux® 20 mcg|Macroflux® 20 mcg patch
11619572|NCT00489918|Experimental|Macroflux® 30 mcg|Macroflux® 30 mcg patch
11619573|NCT00489918|Experimental|Macroflux® 40 mcg|Macroflux® 40 mcg patch
11619574|NCT00489918|Active Comparator|FORTEO®|FORTEO® 20 mcg injection
11619575|NCT00489866|Experimental|Aripiprazole|
11619576|NCT00489866|Placebo Comparator|Placebo|
11619577|NCT00489853|Experimental|Symbicort then Formoterol then Placebo|Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
11619578|NCT00489853|Experimental|Formoterol then Symbicort then Placebo|Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
11619579|NCT00489853|Placebo Comparator|Placebo then Formoterol then Symbicort|Placebo, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily
11619580|NCT00489840|Experimental|anecortave acetate|
11619581|NCT00489827|Active Comparator|Intravenous glutamate|Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
11619582|NCT00489827|Placebo Comparator|Saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
11619583|NCT00489814||1|Patients who are planned to undergo local proton radiotherapy for biopsy-proven, untreated, prostate adenocarcinoma.
11619584|NCT00489801|Other|Exercise intervention|Exercise intervention and lifestyle counseling at centre or exercise intervention at home
11619585|NCT00489736|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets administered twice a day (bid) and matching over-encapsulated tablets of placebo of amiodarone 200mg
11619586|NCT00489736|Active Comparator|Amiodarone 600mg/200mg od|over-encapsulated tablets of amiodarone 200mg (600mg daily for 28 days then 200mg daily) administered once daily (od) and matching placebo of dronedarone 400mg tablets
11619587|NCT00489710|Experimental|Talabostat|Talabostat 600 mcg PO QD x 14 days (21 day cycle); 2 cycles
11619588|NCT00489697|Experimental|1 (single arm)|patient with histologically confirmed colorectal tumor treated in first line by a bevacizumab based chemotherapy
11619589|NCT00489671||pre cancerous condition (pancreatitis)|
11619590|NCT00489645|Placebo Comparator|1|Placebo, euglycemia
11619591|NCT00489645|Experimental|2|Pramlintide, euglycemia
11619592|NCT00489645|Placebo Comparator|3|placebo, hyperglycemia
11619593|NCT00489645|Experimental|4|pramlintide, hyperglycemia
11619594|NCT00489632||Questionnaire|Children with leukemia and their families/caregivers.
11619595|NCT00489593|Experimental|Olanzapine|Olanzapine 2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
11619596|NCT00489567||Group A|Children hospitalised with community-acquired severe RV GE and children acquiring nosocomial severe RV GE.
11619597|NCT00489554|Experimental|Synflorix Vaccine Group|Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.
11619598|NCT00489541|Experimental|TAXUS Element Stent System|
11619599|NCT00489515||patients with gastrointestinal cancer scheduled for surgery|
11619600|NCT00489489|Experimental|Teriflunomide 7 mg + IFN-β|Teriflunomide 7 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
11619601|NCT00489489|Experimental|Teriflunomide 14 mg + IFN-β|Teriflunomide 14 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
11619602|NCT00489489|Placebo Comparator|Placebo + IFN-β|Placebo (for Teriflunomide) once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
11619603|NCT00489476|Experimental|1.25 mg Staccato Loxapine|1.25 mg ADASUVE, single dose
11619604|NCT00489476|Experimental|2.5 mg Staccato Loxapine|2.5 mg ADASUVE, single dose
11619605|NCT00489476|Experimental|5 mg Staccato Loxapine|5 mg ADASUVE, single dose
11619606|NCT00489476|Experimental|Staccato Placebo|Staccato Placebo, 0 mg
11619607|NCT00489424|Experimental|Acetaminophen|2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
11619985|NCT00485433|Active Comparator|Bupivacaine HCl 105mg|Bupivacaine HCl given during hernia repair
11619608|NCT00489424|Experimental|Fluvastatin|2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
11619609|NCT00489424|Placebo Comparator|Placebo|2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
11619610|NCT00489411|Experimental|Arm I/Group A (Duloxetine then Placebo)|Patients receive oral duloxetine hydrochloride once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive an oral placebo once or twice daily in weeks 8-13.
11619611|NCT00489411|Experimental|Arm II/Group B (Placebo then Duloxetine)|Patients receive an oral placebo once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive oral duloxetine hydrochloride once or twice daily in weeks 8-13.
11619612|NCT00489372|Placebo Comparator|Arm I (placebo)|Participants receive oral placebo on day 1.
11619613|NCT00489372|Experimental|Arm II (Se-methyl-seleno-L-cysteine)|Participants receive oral Se-methyl-seleno-l-cysteine (MSC) on day 1. Cohorts of 5 participants receive escalating doses of MSC until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 5 or 2 of 10 patients experience dose-limiting toxicity.
11619614|NCT00489359|Experimental|Pemetrexed/Carboplatin Phase 1|"Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.
~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion."
11619615|NCT00489359|Experimental|Pemetrexed/Carboplatin Phase 2|"Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.
~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion."
11619616|NCT00489307|Active Comparator|Dexamethasone|"Dexamethasone 4 mg orally two times a day for 14 days.
~On day 15 [ ± 3 days], all patients receive dexamethasone 4 mg orally twice a day for 7 days, and then the dose of dexamethasone tapered to 2 mg orally twice a day between days 22 to 28."
11619617|NCT00489307|Placebo Comparator|Placebo|"Placebo by mouth (PO) twice daily for 14 days.
~On day 15 [ ± 3 days], all patients receive dexamethasone 4 mg orally twice a day for 7 days, and then the dose of dexamethasone tapered to 2 mg orally twice a day between days 22 to 28."
11619618|NCT00489281|Experimental|Transplant - 200 cGy|Conditioning regimen with anti-thymocyte globulin, fludarabine, cyclophosphamide, and total body irradiation - 200. Seizure prophylaxis with levetiracetam. Allogeneic bone marrow transplant infusion on Day 0. Graft-vs-host-disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and sirolimus.
11619619|NCT00489281|Experimental|Transplant - 400 cGy|Conditioning regimen with anti-thymocyte globulin, fludarabine, cyclophosphamide, and total body irradiation - 400. Seizure prophylaxis with levetiracetam. Allogeneic bone marrow transplant infusion on Day 0. Graft-vs-host-disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and sirolimus.
11619620|NCT00489268|Active Comparator|Phase I: 6 J/cm2|Subjects randomized to the energy density group of 6 J/cm2 through the HALO Ablation System.
11619621|NCT00489268|Active Comparator|Phase I: 8 J/cm2|Subjects randomized to the energy density group of 8 J/cm2 through the HALO Ablation System.
11619622|NCT00489268|Active Comparator|Phase I: 10 J/cm2|Subjects randomized to the energy density group of 10 J/cm2 through the HALO Ablation System.
11619623|NCT00489268|Active Comparator|Phase I: 12 J/cm2|Subjects randomized to the energy density group of 12 J/cm2 through the HALO Ablation System.
11619624|NCT00489268|Active Comparator|Phase II|All Halo 360 treatments performed at 10 J/cm2 through the HALO Ablation System. All Halo 90 treatments performed at 12 J/cm2 through the HALO Ablation System.
11619625|NCT00489255|Experimental|Trimethobenzamide (Tigan®)|
11619626|NCT00489255|Placebo Comparator|Inactive substance|
11619627|NCT00489216|Experimental|Efalizumab|All patients on study will receive a total of 8 injections of efalizumab
11619628|NCT00489203|Experimental|Arm I|Patients receive oral beclomethasone dipropionate 4 times daily beginning at the start of the conditioning regimen and continuing through day 75 post-transplant. Patients also receive a standard immunosuppressive regimen comprising tacrolimus and methotrexate post-transplant.
11619629|NCT00489203|Active Comparator|Arm II|Patients receive oral placebo 4 times daily beginning at the start of the conditioning regimen and continuing through day 75 post-transplant. Patients also receive a standard immunosuppressive regimen comprising tacrolimus and methotrexate post-transplant.
11619630|NCT00489177|Active Comparator|A|QuickOpt
11619631|NCT00489177|Placebo Comparator|B|Usual care
11619632|NCT00489138|Experimental|1|Noradrenalin infusion
11619633|NCT00489138|No Intervention|2|No adrenalin infusion
11619634|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot A|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot A administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
11619635|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot B|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot B administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
11619636|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot C|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot C administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
11619637|NCT00489099|Active Comparator|V232 Current Process Hepatitis B Vaccine|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) current process administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
11619638|NCT00489086|Other|Tazarotene Cream|Open label
11619639|NCT00489034||Index Participants|HIV-infected females, ages 13- 23 years, recruited from ATN sites in New York, Chicago, Miami, Los Angeles, and New Orleans will undergo quantitative interviewing. A sub-sample of the group will undergo ethnographic and/or gender interviewing.
11619803|NCT00487318|Experimental|Arm 1 Plus statin|The addition of fluvastatin or rosuvastatin or other statins to the standard of care of peginterferon and ribavirin.
11619640|NCT00489034||Network Participants|Closest friends of index participants s and parents/guardians of index participants who know the index participant's HIV status will undergo quantitative interviewing. A sub-sample of the group will undergo ethnographic interviewing.
11619641|NCT00489008|Experimental|Cohort 1|Stereotactic Body Radiation Therapy (SBRT) Stage I NSCLC
11619642|NCT00489008|Experimental|Cohort 2|Stereotactic Body Radiation Therapy (SBRT) Selective Stage II NSCLC
11619643|NCT00489008|Experimental|Cohort 3|Stereotactic Body Radiation Therapy (SBRT) Isolated Peripheral Lung Recurrent NSCLC
11619644|NCT00488982|Experimental|Docetaxel + Observation|Intermittent docetaxel/prednisone with no maintenance therapy: Patients will discontinue docetaxel/prednisone and undergo observation until disease progression at which time they will re-initiate docetaxel/prednisone. Six cycles of docetaxel/prednisone will again be administered before subsequent discontinuation of chemotherapy
11619645|NCT00488982|Experimental|Docetaxel + GM-CSF|Intermittent docetaxel/prednisone with maintenance GM-CSF therapy: Patients will discontinue docetaxel/prednisone and will receive maintenance GM-CSF until disease progression at which time, they will discontinue GM-CSF and resume docetaxel/prednisone. Six cycles of docetaxel/prednisone will again be administered before discontinuation of chemotherapy and GM-CSF therapy is re-initiated. GM-CSF dose/schedule will be as previously described (250 mcg/m2 SQ daily, days 15-28 q28 days)
11619646|NCT00488969|Active Comparator|Modified-release morphine then Placebo|up to a ceiling dose of 120 mg
11619647|NCT00488969|Placebo Comparator|Placebo then modified-release morphine|Matching placebo
11619648|NCT00488904|Experimental|a|
11619649|NCT00488904|Placebo Comparator|b|
11619650|NCT00488891||Paliperidone extended release (ER)|Drug: Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
11619651|NCT00488891||Atypical antipsychotics agent (AAP)|AAP includes quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
11619652|NCT00488878||Ovarian Cancer Data Collection|
11619653|NCT00488865|Other|Intravascular Filter Device|
11619654|NCT00488839|Other|IPX056 20 mg - OLE|A single dose of IPX056 20 mg, Placebo IPX056 40 mg and Placebo Baclofen Tablet (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
11619655|NCT00488839|Other|IPX056 40 mg - OLE|A single dose of IPX056 40 mg, Placebo IPX056 20 mg and Placebo Baclofen Tablet (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
11619656|NCT00488839|Other|Baclofen 20 mg - OLE|A single dose of Encapsulated Baclofen 20 mg, Placebo IPX056 20 mg and Placebo IPX056 40 mg (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
11619657|NCT00488839|Other|Placebo - OLE|A single dose of Placebo Baclofen Tablet, Placebo IPX056 20 mg and Placebo IPX056 40 mg (Part 1), 9 week Open label extension of IPX056 (flexible dose design,IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
11619658|NCT00488787|Experimental|A|Intranasal ketamine low dose
11619659|NCT00488787|Experimental|B|intranasal ketamine medium dose
11619660|NCT00488787|Experimental|C|intranasal ketamine high dose
11619661|NCT00488787|Placebo Comparator|D|placebo
11619662|NCT00488774|Placebo Comparator|Placebo|Matching placebo for golimumab, intravenous (IV) (through a vein in the arm) infusion administered at Week 0
11619663|NCT00488774|Experimental|Golimumab 1 milligram (mg) per kilogram (kg)|Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0.
11619664|NCT00488774|Experimental|Golimumab 2 mg per kg|Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0.
11619665|NCT00488774|Experimental|Golimumab 4 mg per kg|Golimumab 4 mg per kg, intravenous (IV) infusion administered at Week 0.
11619666|NCT00488748|Experimental|MST|Magnetic Seizure Therapy (MST)
11619667|NCT00488748|Active Comparator|ECT|Electroconvulsive Therapy (ECT)
11619668|NCT00488696|Experimental|Interventional|Endovascular Bifurcated Stent Graft: The investigational operation involves placing a stent-graft over the aortic aneurysm.
11619669|NCT00488683|Experimental|MenACWY-CRM and Routine Vaccines (Group 1)|Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 13 months), and 1 dose each of MMR and Hib (booster) at 13 months.
11619670|NCT00488683|Experimental|MenACWY-CRM and Routine Vaccines (Group 2)|"Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 12 months), and 1 dose each of MMR and Hib (booster) at 13 months.
~This group had an additional blood draw at the time of enrollment."
11619671|NCT00488683|Experimental|MenACWY-CRM and Routine Vaccines (Group 3)|"Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 12 months), and 1 dose each of MMR and Hib (booster) at 13 months of age.
~This group had an additional blood draw at 6-7 days after third dose of MenACWY-CRM."
11619672|NCT00488657|Experimental|1|In the ear device to provide altered auditory feedback
11619673|NCT00488644|Experimental|Levothyroxine + Liothyronine|Levothyroxine 75 mcg by mouth (PO) Daily for 8 Weeks + Liothyronine 15 mcg PO Daily for 8 Weeks
11619674|NCT00488631|Placebo Comparator|Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to placebo subcutaneous (under the skin) injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.
11619804|NCT00487318|Active Comparator|2|Administration of the standard of care for hepatitis C of peginterferon and ribavirin.
11619986|NCT00485433|Experimental|SKY0402 low dose|SKY0402 low dose given during hernia repair
11654049|NCT00031395|Placebo Comparator|4|
11619675|NCT00488631|Experimental|GLM-I-Rsp-Golimumab 50 mg Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 50 mg or 100 mg subcutaneous injections every 4 weeks through Week 52.
11619676|NCT00488631|Experimental|GLM-I-Rsp-Golimumab 100 mg Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 100 mg or 200 mg subcutaneous injections every 4 weeks through Week 52.
11619677|NCT00488631|Placebo Comparator|Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance|Participants in clinical response to placebo at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized. Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.
11619678|NCT00488631|Experimental|PBO-I-nonRsp-Golimumab 100 mg Maintenance|Participants not in clinical response to placebo at Week 6 induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.
11619679|NCT00488631|Experimental|GLM-I-nonRsp-Golimumab 100 mg Maintenance|Participants not in clinical response to golimumab at Week 6 of induction study and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.
11619680|NCT00488618|Experimental|Cariprazine|Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
11619681|NCT00488618|Placebo Comparator|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
11619682|NCT00488605|Active Comparator|Treatment Arm A|
11619683|NCT00488605|Experimental|Treatment Arm B|
11619684|NCT00488592|Experimental|WTI: 126-134/ PRI|"Subjects were given 6 doses of PR1:169-177 in Montanide adjuvant and 6 doses of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
11619685|NCT00488579|Active Comparator|routine iron prophylaxis|giving 60 mg ferrous sulphate daily (+folic acid)
11619686|NCT00488579|Active Comparator|screening and therapy|doing Hb measurement on each visit, Hb>9g/dl giving only folic acid, Hb<9g/dl giving 60-120 mg of ferrous sulphate daily (+folic acid)
11619687|NCT00488566|Other|Part 1|Single dose escalation
11619688|NCT00488566|Other|Part 2|Pharmacodynamic assessment
11619689|NCT00488553||Cases|Participants of study with newly diagnosed lymphoma.
11619690|NCT00488553||Control|Participants of study from matched control group.
11619691|NCT00488540|Active Comparator|Paracetamol (Acetaminophen)|Paracetamol (Acetaminophen) given at 2 and 8 hours post birth, measurement of EDIN-Score on day one of life, measurement of stress response after Guthrie-test on day 4 of life.
11619692|NCT00488540|Placebo Comparator|Placebo|Placebo given at 2 and 8 hours post birth, measurement of EDIN-Score on day one of life, measurement of stress response after Guthrie-test on day 4 of life.
11619693|NCT00488527|Experimental|1|
11619694|NCT00488514|Other|Active Drug|Combination Tablet of Treximet (sumatriptan/naproxen sodium)
11619695|NCT00488488||A|
11619696|NCT00488475||Patients with Rheumatoid Arthritis|
11619697|NCT00488462|No Intervention|Control|Clinics will collect data on patients experiencing shock due to obstetrical hemorrhage. In the control arm, half of the study clinics will not use the NASG but the NASG will be available at the referral hospital for patients transported there.
11619698|NCT00488462|Other|Intervention|Clinics will collect data on patients experiencing shock due to obstetrical hemorrhage. In the intervention arm, half of the study clinics will use the NASG on patients before transporting to the referral hospital.
11619699|NCT00488423|Active Comparator|Lap-band|Patient undergoing Lap-band Bariatric Surgery
11619700|NCT00488423|Active Comparator|Gastric Bypass|Patient's undergoing Laparoscopic Roux-N Y Gastric Bypass surgery.
11619701|NCT00488397||1|
11619702|NCT00488384|Other|a|single arm only. Only open label treatment anticipated
11619703|NCT00488345|Experimental|A|0.75 mg/kg (up to a maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Escalation to next dose cohort will occur only after safety and tolerability at preceding dose have been established by sponsor (after tigecycline LDOT data are received) and if at least 5 of 6 PK samples per patient have been received by central laboratory in acceptable condition for 10 to 12 patients in cohort. Treatment period of tigecycline will be a minimum of 3 days (unless patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
11619704|NCT00488345|Experimental|B|1 mg/kg (up to a maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Escalation to next dose cohort will occur only after safety and tolerability at preceding dose have been established by sponsor (after tigecycline LDOT data are received) and if at least 5 of 6 PK samples per patient have been received by the central laboratory in acceptable condition for 10 to 12 patients in the cohort. Treatment period of tigecycline will be a minimum of 3 days (unless the patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
11619927|NCT00486200|Experimental|5|Dosing regimen 3
11619928|NCT00486200|Experimental|6|Dosing regimen 4
11620023|NCT00485108|Active Comparator|1|Prednisolone 1% eye drop
11619705|NCT00488345|Experimental|C|1.25 mg/kg (up to maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Treatment period of tigecycline will be a minimum of 3 days (unless patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
11619706|NCT00488332||OCT + FS + Questionnaire|Optical Coherence Tomography (OCT) + Fluorescence Spectroscopy (FS) and Questionnaire
11619707|NCT00488319|Experimental|001|Paliperidone ER1.5 to 12 mg tablet once daily for 6 months
11619708|NCT00488293|Experimental|Arm 1|Store and forward teledermatology consult process
11619709|NCT00488293|No Intervention|Arm 2|Conventional consult process
11619710|NCT00488280|Experimental|Kids Step Study: Locomotor Training|All children who participate will be in the experimental cohort, KSS-#, and receive 60 sessions of daily locomotor training. This experimental cohort will also undergo clinical and neurophysiological testing pre, during, and post 60 sessions of locomotor training.
11619711|NCT00488267|Experimental|Thermoprofen|ThermoProfen™ (ketoprofen matrix/Controlled Heat Assisted Drug Delivery [CHADD™] patch)
11619712|NCT00488267|Placebo Comparator|Placebo Matrix|Placebo matrix with CHADD patch.
11619713|NCT00488267|Placebo Comparator|Ketoprofen matrix/placebo CHADD|Ketoprofen matrix with placebo CHADD patch (no heat)
11619714|NCT00488241|Active Comparator|1|Topically applied daily for 2 weeks
11619715|NCT00488228|Experimental|1|Participants in the behavioral self-regulation intervention will receive a modified standard treatment that incorporates daily weighing and training in self-regulation methods for weight loss. All treatment modules are adapted for a young adult age group.
11619716|NCT00488228|Experimental|2|Participants in the Standard group will receive a brief version of standard behavioral weight loss treatment with treatment modules tailored to better meet the needs of young adults.
11619717|NCT00488215|Active Comparator|1|Prucalopride
11619718|NCT00488215|Placebo Comparator|2|Placebo
11619719|NCT00488189|No Intervention|1|baseline, collecting rectal swab samples
11619720|NCT00488189|Active Comparator|2|use pipercill/tazobact to replace 3rd generation cephalosporin and collect rectal swab
11619721|NCT00488176|Active Comparator|1|monteluksat sodium
11619722|NCT00488176|Active Comparator|2|cetirizine
11619723|NCT00488176|Active Comparator|3|montelukast sodium and cetirizine
11619724|NCT00488176|Placebo Comparator|4|placebo
11619725|NCT00488163|Active Comparator|Atomoxetine|Atomoxetine 40 mg compounded into capsules.
11619726|NCT00488163|Placebo Comparator|Placebo|Inactive matching compounding of placebo capsules
11619727|NCT00488137|Active Comparator|1|Prucalopride 2 mg
11619728|NCT00488137|Placebo Comparator|3|Placebo
11619729|NCT00488137|Active Comparator|2|Prucalopride 4 mg
11619730|NCT00488111|Active Comparator|1|Participants were treated with normal Ringer's solution 15 min before the operation.
11619731|NCT00488111|Active Comparator|2|6% Starch was used 15min before operation followed epidural anesthesia.
11619732|NCT00488072|Experimental|Mirtazapine|Mirtazapine 15 mg by mouth (PO) daily for 15 days; Day 22-29, increased to 30 mg PO daily.
11619733|NCT00488072|Placebo Comparator|Placebo|One placebo tablet by mouth daily.
11619734|NCT00488059|Experimental|Phase I|Phase 1: ENF 90mg SC BID): In the first phase or cohort phase of day I-1 through Week I-12 of the trial all patients received enfuvirtide (ENF) 90 mg subcutaneously (SC) twice daily (BID) + Isentress® [raltegravir] (RAL) 400-mg orally (PO) BID + optimized background (OB) with at least 1 fully active antiretroviral (ARV) agent excluding nucleoside reverse transcriptase inhibitor (NRTIs).
11619735|NCT00488059|Experimental|Phase II|"In the randomized comparator Phase II of the trial- (Day II-1 through Week II-16): Virologic responders confirmed HIV-1 RNA ≤50 copies/mL from Phase I were randomized to 1 of 2 treatment arms of
~(Phase II Arm A: Phase I then ENF 90mg SC BID): ENF 90 mg SC BID + RAL 400 mg PO BID + OB with at least 1 fully active ARV agent excluding NRTIs or (Phase II Arm B: Phase I then ENF 180mg SC QD): ENF 180 mg SC once daily (QD) + RAL 400 mg PO BID + OB with at least 1 fully active ARV agent excluding NRTIs."
11619736|NCT00488046|Experimental|1|Two, 0.5 ml doses of vaccine in nasal spray form administered at study entry and sometime between 4 and 8 weeks after initial vaccination
11619737|NCT00488033|No Intervention|1|Standard of Care
11619738|NCT00488033|Other|2|CT Angiography
11619739|NCT00488007|Experimental|Active Hearing aids|Active
11619740|NCT00488007|Placebo Comparator|Inactive Hearing aids|Hearing aids turned off
11619741|NCT00487994|Experimental|Lapaquistat Acetate 100 mg QD|
11619742|NCT00487994|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin 10 mg QD|
11619743|NCT00487994|Active Comparator|Atorvastatin 10 mg QD|
11619744|NCT00487981|Other|Spinal Cord Stimulation Group|Spinal Cord Stimulation (SCS) Treatment Group
11619745|NCT00487942|Active Comparator|50 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 50 mg/day armodafinil treatment arm for the double-blind treatment period of the study took one 50 mg armodafinil tablet plus three placebo tablets each morning.
11619746|NCT00487942|Active Comparator|100 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 100 mg/day armodafinil treatment arm for the double-blind treatment period of the study took two 50 mg armodafinil tablets plus two placebo tablets each morning. Subjects began taking 50 mg/day and then titrated to 100 mg/day on Day 2 of the first week of the double-blind treatment period.
11619747|NCT00487942|Active Comparator|200 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 200 mg/day armodafinil treatment arm for the double-blind treatment period of the study took four 50 mg armodafinil tablet and no placebo tablets each morning. Subjects were titrated to this dose by starting treatment at 50 mg/day (1 tablet) and increasing by 50 mg increments on days 2, 4, and 6 until they were taking 200 mg/day.
11619982|NCT00485485|Experimental|Imatinib Mesylate + Docetaxel|Imatinib 400 mg orally daily; Docetaxel 60 mg/m^2 by vein over 1 hour every 3 weeks
11619748|NCT00487942|Placebo Comparator|Placebo|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the placebo treatment arm for the double-blind treatment period of the study took four placebo tablets and no armodafinil tablets each morning.
11619749|NCT00487929|Experimental|CPAP|Continuous positive airway pressure
11619750|NCT00487929|Sham Comparator|Sham CPAP|Sham nasal continuous positive airway pressure
11619751|NCT00487851|Active Comparator|1|Endoscopic treatment strategy
11619752|NCT00487851|Active Comparator|2|Surgical treatment strategy
11619753|NCT00487825|Experimental|Canakinumab + Methotrexate|Canakinumab, human anti-interleukin-1beta monoclonal antibody plus Methotrexate (MTX). Intravenous (IV) Infusion of 600mg canakinumab on Day 1, 15 continuing every 4 weeks up to week 26. MTX was given as variable dosing regimen of 7.5 mg-15 mg weekly.
11619754|NCT00487825|Active Comparator|Methotrexate + placebo|Methotrexate (MTX) was given as variable dosing regimen of 7.5 mg-15 mg weekly. Intravenous (IV) Placebo Solution, given in the same mode of administration as the canakinumab solution.
11619755|NCT00487786|Experimental|A|Each patient receives OGX-427
11619756|NCT00487773|Active Comparator|1|budesonide
11619757|NCT00487773|Active Comparator|2|D3 vitamin
11619758|NCT00487773|Active Comparator|3|montelukast sodium
11619759|NCT00487773|Active Comparator|4|salbutamol
11619760|NCT00487747|Experimental|Peginterferon Alfa-2a|
11619761|NCT00487734|Experimental|1|Subjects in this arm will receive testosterone gel
11619762|NCT00487734|Placebo Comparator|2|
11619763|NCT00487721|Experimental|Silibin-Phytosome|Subjects in this group will take Silibin-Phytosome 13 grams daily, in three divided doses for 2-10 weeks.
11619764|NCT00487721|No Intervention|Control|Patients in this arm will not take any intervention.
11619765|NCT00487708|Experimental|1|ACZ885
11619766|NCT00487695|Active Comparator|CLE followed by standard EGD|Participants are randomized to have either confocal laser endomicroscopy (CLE) or standard endoscopy (EGD) first. Then 6 weeks later, they have the other procedure. This arm is for patients randomized to CLE followed by standard EGD
11619767|NCT00487695|Active Comparator|standard EGD followed by CLE|Patients are randomized to either have standard endoscopy (EGD)or confocal laser endomicroscopy (CLE) first. The second procedure is then completed 6 weeks later. This arm is for patients who had standard endoscopy first.
11619768|NCT00487682|Experimental|1|ASP2151 low dose
11619769|NCT00487682|Experimental|2|ASP2151 middle dose
11619770|NCT00487682|Experimental|3|ASP2151 high dose
11619771|NCT00487682|Active Comparator|4|Valacyclovir hydrochloride
11619772|NCT00487669|Experimental|Paclitaxel Poliglumex with Pemetrexed|The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued.
11619773|NCT00487656|Experimental|ART-123|6 mg/ml ampule solution for injection
11619774|NCT00487656|Placebo Comparator|Placebo|6 mg/mlampule of solution for injection
11619775|NCT00487617|Experimental|fruit juice|300 mL of fruit juice
11619776|NCT00487617|Placebo Comparator|placebo|300 mL of fruit juice without polyphenols
11619777|NCT00487591||Simva+Omacor|
11619778|NCT00487591||Simva + Placebo|
11619779|NCT00487578|Active Comparator|A|Naratriptan 2.5 mg tablet bid x 30 days
11619780|NCT00487578|Placebo Comparator|B|placebo matching naratriptan 2.5 mg tablet
11619781|NCT00487565|Other|LCS Complete Posterior Stabilized knee implant|Total knee arthroplasty with a posterior stabilized implant
11619782|NCT00487552|Experimental|1|palliative treatment of gastric outlet obstruction
11619783|NCT00487539|Placebo Comparator|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
11619784|NCT00487539|Experimental|Golimumab 100 mg -> 50 mg|Golimumab 100 milligram (mg) subcutaneous injection administered at Week 0 and dose is decreased to 50 mg at Week 2.
11619785|NCT00487539|Experimental|Golimumab 200 mg -> 100 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 and dose is decreased to 100 mg at Week 2.
11619786|NCT00487539|Experimental|Golimumab 400 mg -> 200 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 and dose is decreased to 200 mg at Week 2.
11619787|NCT00487500|Experimental|Ultrabrief, Right Unilateral ECT|Right unilateral ECT administered with an ultrabrief pulse width (0.3 ms), at a dose 6 times the initial seizure threshold
11619788|NCT00487500|Experimental|Ultrabrief, Bilateral ECT (2.5 X ST)|Bilateral (frontotemporal) ECT with an ultrabrief pulse width with dosage 2.5 times the initial seizure threshold
11619789|NCT00487500|Active Comparator|Brief Pulse, Right Unilateral ECT|Right unilateral ECT, with a standard brief pulse (1.5 ms), with dosage 6 times the initial seizure threshold
11619790|NCT00487500|Active Comparator|Brief Pulse, Bilateral ECT|Bilateral (frontotemporal) ECT with a standard brief pulse (1.5 ms), with dosage 2.5 times the initial seizure threshold
11619791|NCT00487474||Sculptra|
11619792|NCT00487461|Placebo Comparator|Control Group|Placebo tablet
11619793|NCT00487461|Experimental|Study Group #1|Simvastatin 40 mg
11619794|NCT00487461|Experimental|Study Group #2|Simvastatin 80 mg
11619795|NCT00487435|Experimental|001|Tapentadol (CG5503) Extended Release (ER) 100 150 200 250 mg oral tablet twice daily for 52 weeks
11619796|NCT00487422|Active Comparator|1|Prucalopride
11619797|NCT00487422|Active Comparator|2|Prucalopride
11619798|NCT00487422|Placebo Comparator|3|Placebo
11619799|NCT00487409|Other|Group A|Standard of Care
11619800|NCT00487409|Other|Group B|Standard of Care
11619801|NCT00487357||MATCh Parents' Supplemental Survey|Parent/Guardian Survey
11619802|NCT00487331|Experimental|Acupuncture|Acupuncture sessions 1-3 times per week. 2 pain questionnaires + satisfaction survey completed at beginning and end of treatment.
11619983|NCT00485472|Experimental|Lacosamide|lacosamide (LCM)
11619805|NCT00487305|Experimental|Biological/Vaccine|"Biological/Vaccine: Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.
~--------------------------------------------------------------------------------"
11619806|NCT00487279|Experimental|ICD Group|ICD (Implantable Cardioverter Defibrillator)
11619807|NCT00487279|Other|Control Group|Medial Therapy
11619808|NCT00487253|Active Comparator|Group 1|"Oral administration of Miltefosine, doses: 1,5mg to 2,5mg/kg/day, during 28 days.
~presentation: capsulas 10mg and 50mg Miltefosine (Impavido®)"
11619809|NCT00487253|Active Comparator|Group 2|Administration of Parenteral meglumine antimoniate, Glucantime® Amp 5ml (83mg/ml). Dosage:20mg/kg/day, during 20 days.
11619810|NCT00487240|Experimental|Insulin Lispro Protamine Suspension|Insulin Lispro Protamine Suspension twice daily
11619811|NCT00487240|Active Comparator|Detemir|Insulin Levemir (detemir) subcutaneous (SC) twice daily.
11619812|NCT00487227|Placebo Comparator|Placebo|
11619813|NCT00487227|Experimental|2.5mg caffeine|
11619814|NCT00487227|Experimental|5mg caffeine|
11619815|NCT00487227|Experimental|10mg caffeine|
11619816|NCT00487188|Experimental|ENF + HAART|Participants received Enfuvirtide (ENF) 90 mg administered by subcutaneous injection twice a day for up to 48 weeks in addition to an oral highly active antiretroviral treatment (HAART) regimen for up to 48 weeks.
11619817|NCT00487188|Active Comparator|HAART|Participants received an oral highly active antiretroviral treatment (HAART) regimen, consisting of 3-5 antivirals for up to 48 weeks.
11619818|NCT00487162|Experimental|intensive glycemic control|In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R [Novo Nordisk]) in 50ml of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg / dL on two consecutive samples and will be adjusted to maintain the blood glucose level between 80 and 110 mg / dL. If the glucose level falls below 80 mg / dL, the insulin infusion will be tapered and discontinued.
11619819|NCT00487162|Active Comparator|conventional glycemic control|In this group if the subject's blood glucose level should exceed 200 mg/dL the subject will be treated with a continuous insulin infusion to maintain blood glucose levels between 180-200mg/dL
11619820|NCT00487136|Active Comparator|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
11619821|NCT00487136|Experimental|Warfarin plus ABT-335 plus Rosuvastatin|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
11619822|NCT00487136|Experimental|Warfarin plus ABT-335 mg plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
11619823|NCT00487097|Experimental|Study Group|Enteral Nutrition with Omega 3 (Eicosapentanoic acid, docosahexaenoic acid)
11619824|NCT00487097|No Intervention|Control Group|Patients in control group will receive nutritional support composed of a standard formula
11619825|NCT00487084|Experimental|morphine - 2CP-saline (MCS)|morphine will be administered 30 min prior to epidural anesthesia; 2CP will be used to achieve a T4 level; saline will be administered at skin incision
11619826|NCT00487084|Experimental|saline-2CP-morphine (SCM)|saline will be administered 30 min prior to epidural anesthesia; 2CP will be used to achieve a T4 level;morphine will be administered at skin incision
11619827|NCT00487084|Active Comparator|saline-lidocaine-morphine (SLM)|Saline will be administered 30 min prior to epidural anesthesia; lidocaine will be used to achieve a T4 level; morphine will be administered at skin incision
11619828|NCT00487071|Experimental|Anal fistula plug|
11619829|NCT00487045|Experimental|1|Hem-Avert Perianal Stabilizer, single use, disposable, sterile, individually packaged instrument
11619830|NCT00487045|No Intervention|2|
11619831|NCT00487032|Experimental|1|Prazosin 1mg challenge to block alpha 1 adrenoreceptors
11619832|NCT00487032|Placebo Comparator|2|Placebo to Prazosin
11619833|NCT00487019||1|Neonates aged <72 h and needing antibacterial therapy for early onset neonatal sepsis
11619834|NCT00487019||2|Same as group 1
11619835|NCT00487006|Active Comparator|At risk for CIH/with CIH|In hyperglycemic patients who will be starting insulin infusions to control hyperglycemia, blood will be drawn just prior to initiation of insulin infusion for the following levels: insulin, glucose, and C-peptide. These levels will be re-drawn upon achieving euglycemia, at 24 hours following that, then every three days. Levels will be again drawn once the insulin infusion is stopped/when CIH has resolved, and 24 hours following discontinuation of insulin infusion. At each timepoint the patient's clinical status will be documented and significant interval changes (intubation/extubation, change in pressor need), amount of dextrose (mg/kg/hour) supplied, and other concurrent medicines and doses will be recorded.
11619836|NCT00487006|Active Comparator|At risk for CIH/without CIH|"For comparative controls, insulin, C-peptide, and glucose levels will be drawn from ICU patients aged 2-12 years at similar risk (mechanical ventilation or vasoactive medications) but without CIH. The above labs will be drawn and data gathered near the time of risk, 24 hours later, then in 3 days following, for a total of three timepoints."
11619837|NCT00487006|Active Comparator|Not at risk for CIH/without CIH|"In addition, other ICU patients aged 2-12 years that are deemed NOT at risk for critical illness hyperglycemia will also be evaluated to serve as a group not at risk but admitted to the PICU as a further control population. Like Group B, the above labs will be drawn and data gathered at the time consent is obtained, 24 hours later, then in 3 days following, for a total of three timepoints"
11619838|NCT00486993||asuriesgo|unselected outpatient population
11619839|NCT00486967||Heart Failure|CHF patients were identified from inpatients as well as patients attending outpatient clinics and from the general practice in the community. Diagnosis of CHF was based on the European Society of Cardiology guidelines for CHF. All patients with stable CHF were included in the study. Inpatients with CHF who were hospitalized were also included, except patients with acutely decompensated CHF requiring intravenous therapy. CHF patients with a previous diagnosis of diabetes mellitus were excluded from the study.
11619840|NCT00486967||Controls|A group of healthy subjects were also studied. They were recruited from the community and were clinically healthy based on history, physical examination, and blood laboratory results and were not taking any medication.
11619841|NCT00486954|Experimental|Paclitaxel plus Lapatinib|6 pills of lapatinib at 250 mg each once daily and infusion of paclitaxel at 80 mglm2 weekly
11619842|NCT00486954|Active Comparator|Paclitaxel alone|Infusion of paclitaxel at 80 mglm2 weekly
11619843|NCT00486928||AVR|All consecutive patients in the study period
11619844|NCT00486915|Active Comparator|Left Atrial Appendage Exclusion|
11619845|NCT00486915|No Intervention|Control|
11619846|NCT00486902|Experimental|Ketamine|Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.
11619847|NCT00486902|Placebo Comparator|Placebo|Subjects receive IV Saline 20 mL 5 minutes after infant delivery
11619848|NCT00486889|Experimental|alglucosidase alfa|
11619849|NCT00486876|Placebo Comparator|1|Placebo
11619850|NCT00486876|Experimental|2|100 mg BID
11619851|NCT00486876|Experimental|3|200 mg BID
11619852|NCT00486876|Experimental|4|300 mg BID
11619853|NCT00486863|Placebo Comparator|Control|Placebo at 12-16 weeks gestation.
11619854|NCT00486863|Experimental|Praziquantel|Praziquantel at 12-16 weeks gestation.
11619855|NCT00486837|Experimental|Group 1|Bronchial Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
11619856|NCT00486837|Experimental|Group 2|Peripheral Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
11619857|NCT00486824|Active Comparator|Indomethacin|50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
11619858|NCT00486824|Active Comparator|Nifedipine|30 mg Nifedipine initially followed by 20 mg every 6 hrs for 48 hrs.
11619859|NCT00486811|Placebo Comparator|Matching Placebo (twice daily)|The starting dose of placebo was matched with the active treatment arms taken twice daily for the first 3 days. The dose was then increased to match the active treatments for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days as in the active treatment arms. Dose decreases were allowed without time restrictions.
11619860|NCT00486811|Experimental|Tapentadol ER (100 to 250 mg twice daily)|The starting dose was tapentadol ER 50 mg twice daily for 3 days. The dose was then increased to 100 mg tapentadol ER twice daily for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days. Dose decreases were allowed without time restrictions.
11619861|NCT00486811|Active Comparator|Oxycodone CR (20 to 50 mg twice daily)|The starting dose was oxycodone CR 10 mg twice daily for 3 days. The dose was then increased to 20 mg oxycodone CR twice daily for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days. Dose decreases were allowed without time restrictions.
11619862|NCT00486785|Experimental|1|
11619863|NCT00486759|Experimental|Bevacizumab + rituximab + CHOP|Patients received bevacizumab 5 mg/kg/week on Day 1 of each cycle + rituximab 375 mg/m^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone).
11619864|NCT00486759|Active Comparator|Placebo + rituximab + CHOP|Patients received placebo to bevacizumab on Day 1 of each cycle + rituximab 375 mg/m^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone).
11619865|NCT00486746|Experimental|Lifestyle intervention|
11619866|NCT00486746|Active Comparator|General health counseling|
11619867|NCT00486733|No Intervention|Standard of Care|Standard of Care Treatment; no study treatment
11619868|NCT00486733|Experimental|Standard of Care plus Study Treatment|Standard of Care Treatment plus study treatment
11619869|NCT00486720|Experimental|1|vorinostat 400 mg
11619870|NCT00486720|Experimental|2|vorinostat 200 mg
11619871|NCT00486707||Patients with ovarian cancer|
11619872|NCT00486681||1|period I (warning of the Accu-Check Inform glucose meter on glucose levels not activated)
11619873|NCT00486681||2|period II (warning activated).
11619874|NCT00486668|Active Comparator|Group 1: AC then paclitaxel + trastuzumab|AC followed by paclitaxel plus trastuzumab
11619875|NCT00486668|Experimental|Group 2: AC then paclitaxel + lapatinib|AC followed by paclitaxel plus lapatinib
11619876|NCT00486668|Experimental|Group 3: AC then paclitaxel + trastuzumab + lapatinib|AC followed by paclitaxel plus trastuzumab plus lapatinib
11619877|NCT00486642|Experimental|Arm A (pazopanib hydrochloride)|"Patients receive pazopanib hydrochloride PO QD on days 1-28.
~."
11619878|NCT00486642|Experimental|Arm B (pazopanib hydrochloride, bicalutamide)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Patients also receive bicalutamide PO QD on days 8-28 of course 1 and on days 1-28 in all subsequent courses.
11619879|NCT00486629|Experimental|Intervention|Lifestyle intervention
11619880|NCT00486629|No Intervention|Control|No intervention
11619881|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 200 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT. Starting dose of HCQ is 200mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase
~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.
~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.
~Other: pharmacological study (PK)
~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1
~Radiation (RT)"
11619882|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 400 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 400 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase
~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.
~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.
~Other: pharmacological study (PK)
~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1
~Radiation (RT)"
11619984|NCT00485472|Placebo Comparator|Placebo|Placebo
11619883|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 600 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 600 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase
~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.
~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.
~Other: pharmacological study (PK)
~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1
~Radiation (RT)"
11619884|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 800 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 800 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase
~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.
~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.
~Other: pharmacological study (PK)
~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1
~Radiation (RT)"
11619885|NCT00486603|Experimental|Phase 2: RT + TMZ + HCQ MTD|"Phse 2: daily hydroxychloroquine (HCQ) (MTD 600mg) on 1st day of RT and concomitant temozolomide for 6wks during RT. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase
~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.
~Other: pharmacological study (PK)
~Pts will continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 2
~Radiation (RT)"
11619886|NCT00486577|Experimental|1|
11619887|NCT00486577|Experimental|2|
11619888|NCT00486538|Experimental|Single arm|One oral dose daily
11619889|NCT00486525|Experimental|Arm I: Yoga Therapy|Patients participate in a Hatha yoga session over 90 minutes twice weekly for 12 weeks. Patients are also encouraged to practice yoga at home using the appropriate DVD/video segments for the month.
11619890|NCT00486525|No Intervention|Arm II: Wait-List|Wait-listed women were told to continue performing their usual activities, and to refrain from beginning any yoga practice. After their final assessment they were offered the yoga classes.
11619891|NCT00486512|Experimental|Active Treatment (calcitriol+ASA+CaCO3)|Daily dose of 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol, Rocaltrol; Roche, Basel, Switzerland), 75 mg acetylsalicylic acid (ASA), and 1250 mg calcium carbonate (CaCO3). The daily dose was administered as 1 capsule containing 0.5 mg calcitriol (Rocaltrol; Roche) and 2 tablets containing a 37.5-mg ASA core with a 625-mg calcium carbonate shell (tablet-in-tablet) that was made expressly for this study. Patients should take 1 capsule and 2 tablets daily, together or separately. Timing of the intake is not important; study medication can be taken with or without food. The daily dose should not be exceeded. Before randomization, patients were given the placebo and followed up for a 3-week run-in period. Only patients who showed a placebo medication compliance rate of at least 80% were eligible for randomization. The primary outcome was the proportion of patients with recurrence of any adenomas as detected by colonoscopy after 3 years of treatment.
11619892|NCT00486512|Placebo Comparator|Placebo to calcitriol+ASA+CaCO3|Daily dose of matching placebo to 0.5 mg calcitriol, 75 mg acetylsalicylic acid (ASA), and 1250 mg calcium carbonate (CaCO3). Patients should take 1 capsule and 2 tablets of placebo daily, together or separately. Timing of the intake is not important; study medication can be taken with or without food. The daily dose should not be exceeded. Before randomization, patients were given the placebo and followed up for a 3-week run-in period. Only patients who showed a placebo medication compliance rate of at least 80% were eligible for randomization. The primary outcome was the proportion of patients with recurrence of any adenomas as detected by colonoscopy after 3 years of treatment.
11619893|NCT00486486|Active Comparator|Bimatoprost/Timolol AM therapy|
11619894|NCT00486486|Active Comparator|Bimatoprost/Timolol PM therapy|
11619895|NCT00486447|Experimental|Imaging|General imaging subjects receiving CT exams
11619896|NCT00486434|Active Comparator|1|SMC021 Oral Calcitonin, 0.8 mg twice daily during 24 months
11619897|NCT00486434|Placebo Comparator|2|SMC021 Placebo, orally twice daily during 24 months
11619898|NCT00486421|Experimental|PRED & RITUX|
11619899|NCT00486408|Experimental|1|MRKAd5 HIV-1 gag/pol/nef vaccine administered as 1 ml in either deltoid at study entry and Weeks 4 and 26
11619900|NCT00486395|Active Comparator|1|Mechanical ventilation
11619901|NCT00486395|Experimental|2|CPAP
11619902|NCT00486382|Experimental|Low dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
11619903|NCT00486382|Experimental|Medium dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
11619904|NCT00486382|Experimental|High dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
11619905|NCT00486356|Experimental|Capecitabine, Epirubicin, and Carboplatin|
11619906|NCT00486343|Experimental|1|Zileuton CR
11619907|NCT00486343|Placebo Comparator|2|Placebo
11619908|NCT00486330|Other|Buprenorphine plus Tipranavir/Ritonavir|
11619909|NCT00486304|Experimental|Antioxidant-deficient diet (ADD)|
11619910|NCT00486304|Placebo Comparator|Placebo|
11619911|NCT00486291|Experimental|1|Phentermine 15mg/topiramate 100mg
11619912|NCT00486291|Placebo Comparator|2|Matched placebo
11619913|NCT00486278|Experimental|vatreptacog alfa 5 mcg/kg|
11619914|NCT00486278|Experimental|vatreptacog alfa 10 mcg/kg|
11619915|NCT00486278|Experimental|vatreptacog alfa 20 mcg/kg|
11619916|NCT00486278|Experimental|vatreptacog alfa 40 mcg/kg|
11619917|NCT00486278|Experimental|vatreptacog alfa 80 mcg/kg|
11619918|NCT00486278|Experimental|rFVIIa 90 mcg/kg|
11619919|NCT00486252||This is N/A due to the above description.|This is N/A due to the above description.
11619920|NCT00486226||1 Endovascular|All patients implanted with an CORDIS ENTERPRISE Vascular Reconstruction Device.
11619921|NCT00486213|Active Comparator|Pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
11619922|NCT00486213|Placebo Comparator|Placebo|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
11619923|NCT00486200|Active Comparator|1|Oral administration of active comparator
11619924|NCT00486200|Placebo Comparator|2|Oral administration of placebo
11619925|NCT00486200|Experimental|3|Dosing regimen 1
11619926|NCT00486200|Experimental|4|Dosing regimen 2
11619929|NCT00486187|Experimental|1|"Treatment-naive subjects randomly assigned to rosiglitazone (4 mg/day force titrated to 8 mg/day).
~Subjects taking metformin before randomization were randomly assigned to the addition of rosiglitazone (4 mg/day force titrated to 8 mg/day).
~Subjects taking glyburide before randomization were randomly assigned to the addition of rosiglitazone (4 mg/day)."
11619930|NCT00486187|Active Comparator|2|"Treatment-naive subjects randomly assigned to metformin (250 mg twice per day [BID] titrated to 500 mg BID if baseline A1C ≥7.5% and ≤8.0%, or 500 mg BID titrated to 1 g BID if baseline A1C >8.0%).
~Subjects taking metformin before randomization were randomly assigned to the addition of glyburide (2.5 mg BID titrated to 5 mg BID if baseline A1C ≥7.5% and ≤8.0%, or 5 mg BID titrated to 10 mg BID if baseline A1C >8.0%).
~Subjects taking glyburide before randomization were randomly assigned to the addition of metformin (250 mg BID titrated to 500 mg BID if baseline A1C ≥7.5% and ≤8.0% or 500 mg BID titrated to 1 g BID if baseline A1C >8.0%)."
11619931|NCT00486174|Active Comparator|1|standard sepsis therapy plus Methylene Blue
11619932|NCT00486174|No Intervention|2|standard sepsis therapy
11619933|NCT00486148|No Intervention|"group S"|Breast milk
11619934|NCT00486148|No Intervention|"group A"|Control Infant formula
11619935|NCT00486148|Experimental|"group B"|Infant formula supplemented with 0.4 g/100 ml of oligosaccharides
11619936|NCT00486135|Experimental|1|Daily dosing for 21 days/7 days off
11619937|NCT00486135|Experimental|2|Continuous daily dosing
11619938|NCT00486135|Experimental|3|Continuous daily dosing
11619939|NCT00486044|Experimental|simvastatin|simvastatin 40 mg nightly for 1 month then 80 mg nightly for 8 months
11619940|NCT00486044|Placebo Comparator|Placebo|Matching placebo tablet nightly for 9 months
11619941|NCT00486031|Other|balsalazide disodium tablets,3.3 g BID,|
11619942|NCT00486018|Sham Comparator|Sham injection|
11619943|NCT00486018|Experimental|Ranibizumab injection 0.3 mg|
11619944|NCT00486018|Experimental|Ranibizumab injection 0.5 mg|
11619945|NCT00485979|Experimental|Arm A1|Cohort 1: Her2-ve breast cancer
11619946|NCT00485979|Active Comparator|Arm B1|Cohort 1: Her2-ve breast cancer
11619947|NCT00485979|Experimental|Arm A2|Cohort 2: Her2+ve breast cancer
11619948|NCT00485979|Active Comparator|Arm B2|Cohort 2: Her2+ve breast cancer
11619949|NCT00485953|Experimental|Active Medication Group|risedronate 35 mg weekly
11619950|NCT00485953|No Intervention|Placebo Group|Placebo
11619951|NCT00485940|Active Comparator|1|Prucalopride 2 mg
11619952|NCT00485940|Placebo Comparator|3|Placebo
11619953|NCT00485940|Active Comparator|2|Prucalopride 4 mg
11619954|NCT00485914|Experimental|On-site work evaluation|Participants will receive one-to-one contact with an occupational therapist and an individualized work plan
11619955|NCT00485914|Active Comparator|Educational material|Participants will receive educational materials to develop strategies to compensate for limitations caused by their condition
11619956|NCT00485888|Active Comparator|1|
11619957|NCT00485888|Placebo Comparator|2|
11619958|NCT00485836|Sham Comparator|Sham injection|
11619959|NCT00485836|Experimental|Ranibizumab injection 0.3 mg|
11619960|NCT00485836|Experimental|Ranibizumab injection 0.5 mg|
11619961|NCT00485784|Sham Comparator|control group|control group
11619962|NCT00485784|Experimental|prééclampsies group|prééclampsies group
11619963|NCT00485784|Experimental|RCIU group|RCIU group
11619964|NCT00485784|Experimental|MFIU group|MFIU group
11619965|NCT00485758|Other|1|Arm 1: One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study.
11619966|NCT00485758|Active Comparator|2|Arm 2: stable lipid-modifying regimen, adding Placebo ER niacin/laropiprant in week 4, for the duration of the study.
11619967|NCT00485732|Experimental|Cervarix Group|
11619968|NCT00485732|Placebo Comparator|Placebo Group|
11619969|NCT00485719|Experimental|1|Twice daily (bid) dosing
11619970|NCT00485719|Experimental|2|Once daily (qd) dosing
11619971|NCT00485693|Active Comparator|Bupivacaine HCl|Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000)
11619972|NCT00485693|Other|SKY0402|SKY0402 at various dosage levels. Single administration.
11619973|NCT00485667|Active Comparator|Moxifloxacin tablet|
11619974|NCT00485667|Experimental|Placebo tablet|
11619975|NCT00485667|Experimental|SKY0402 300mg|
11619976|NCT00485667|Experimental|SKY0402 450mg|
11619977|NCT00485667|Placebo Comparator|Placebo injection|
11619978|NCT00485615|Experimental|1|OMEGA 3
11619979|NCT00485589|Placebo Comparator|Placebo|Participants received placebo intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, 76, and 78. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
11619980|NCT00485589|Experimental|Ocrelizumab 200 mg|Participants received ocrelizumab 200 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54 and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
11619981|NCT00485589|Experimental|Ocrelizumab 500 mg|Participants received ocrelizumab 500 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
11619987|NCT00485433|Experimental|SKY0402 Middle dose|SKY0402 middle dose given during hernia repair
11619988|NCT00485433|Experimental|SKY0402 High dose|SKY0402 high dose given during hernia repair
11619989|NCT00485420|Active Comparator|Usual Care|Member with recurrent or chronic depression receives usual specialty mental health care
11619990|NCT00485420|Experimental|Internet-based disease managment program|Usual care is augmented with internet based education, self monitoring and clinical monitoring
11619991|NCT00485394|Experimental|1|OT-551 0.3% ophthalmic solution
11619992|NCT00485394|Experimental|2|OT-551 0.45% ophthalmic solution
11619993|NCT00485394|Placebo Comparator|3|vehicle placebo
11619994|NCT00485355|Active Comparator|1|Conventional Laparoscopic Hysterectomy
11619995|NCT00485355|Active Comparator|2|Robotic Assisted Laparoscopic Hysterectomy
11619996|NCT00485342|No Intervention|standard dose|"the reference strategy : Peg-interferon alpha 2a (180 µg/week) and ribavine (1000 mg/day if weight < 75 kg and 1200 mg/day if weight ≥ 75 kg)"
11619997|NCT00485342|Experimental|adjusted dose|individual dose adjustment of ribavirin dose at D7, based on ribavirin abbreviated AUC-0-4H , estimated itself by two independent methods: multiple linear regression and bayesien estimation based on three ribavirin concentration measurements obtained at 0.5H, 1H, 2H after the first intake of 600 mg at D0.
11619998|NCT00485329|Experimental|Low dose papain|Ratio of drug to placebo treated patients will be 4:1
11619999|NCT00485329|Experimental|Medium dose papain|Ratio of drug to placebo treated patients will be 4:1
11620000|NCT00485329|Experimental|High dose papain|Ratio of drug to placebo treated patients will be 4:1
11620001|NCT00485303|Experimental|Abiraterone|Abiraterone acetate 1000 milligram (mg) (4 oral tablets of 250 mg each) will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-days dosing cycle and will be continued until disease progression or unacceptable toxicity.
11620002|NCT00485264|Experimental|Cohort I|"Participants between the ages of 12 and 18 years; receiving raltegravir poloxamer film coated tablet:
~Stage I starting dose: Weight based dose of ~6 mg/kg based on protocol dosing table, taken orally twice daily.
~Final Selected Dose: 400-mg tablet taken orally twice daily."
11620003|NCT00485264|Experimental|Cohort IIA|"Participants between the ages of 6 and 11 years, receiving raltegravir poloxamer film coated tablet:
~Stage I starting dose: Weight based dose of ~8 mg/kg based on protocol dosing table, taken orally twice daily.
~Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants < 25 kg were switched to a weight-based dose of the chewable tablet."
11620004|NCT00485264|Experimental|Cohort IIB|"Participants between the ages of 6 and 11 years; receiving raltegravir chewable tablet:
~Stage I starting dose: Weight based dose of ~8 mg/kg based on protocol dosing table, taken orally twice daily.
~Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily."
11620005|NCT00485264|Experimental|Cohort III|"Participants between the ages of 2 and 5 years; receiving raltegravir chewable tablet:
~Stage I starting dose: Weight based dose of ~6 mg/kg based on protocol dosing table, taken orally twice daily.
~Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily."
11620006|NCT00485264|Experimental|Cohort IV|"Participants between the ages of 6 and 23 months; receiving raltegravir oral granules for suspension (20 mg/mL):
~Stage I starting dose: Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data."
11620007|NCT00485264|Experimental|Cohort V|"Participants between the ages of 4 weeks and 5 months; receiving raltegravir oral granules for suspension (20 mg/mL):
~Stage I starting dose: Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data."
11620008|NCT00485251|Active Comparator|1|hand assisted right hemicolectomy
11620009|NCT00485251|Active Comparator|2|laparoscopic right hemicolectomy
11620010|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 1|
11620011|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 2|
11620012|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 3|
11620013|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 4|
11620014|NCT00485186||1|
11620015|NCT00485186||2|
11620016|NCT00485173|Experimental|INFUSE® Bone Graft|In this arm, patients will receive implant with INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate.
11620017|NCT00485134|Experimental|Stage 1: Group A, Dolphin 240 µg|240 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of lipopolysaccharides (LPS). 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
11620018|NCT00485134|Experimental|Stage 1: Group B, Dolphin 480 µg|480 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
11620019|NCT00485134|Experimental|Stage 1: Group C, Dolphin 690 µg|690 Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
11620020|NCT00485134|Other|Stage 1: Group D, Pipette 240 µg|240 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. These subjects received 200 μL the vaccine via electronic pipette. This group is for lot bridging only, not included in dose-finding study.
11620021|NCT00485134|Other|Stage 2: Immunized / Challenge|The selected dose was to be administered with the Dolphin™ using the vaccination schedule from stage 1. Immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast.
11620022|NCT00485134|Placebo Comparator|Stage 2: Controls|A control was to be administered with the DolphinTM using the vaccination schedule from Stage 1. Non-immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast.
11620024|NCT00485108|Active Comparator|2|ketorolac 0.5% eye drop
11620025|NCT00485108|Placebo Comparator|3|Artificial Tears (methyl cellulose eye drop)
11620026|NCT00485069|Experimental|Ropinirole Hydrochloride|
11620027|NCT00485056|Placebo Comparator|Placebo|Crossover arm
11620028|NCT00485056|Active Comparator|Pioglitazone|Pioglitazone 45mgs daily
11620029|NCT00485030|Experimental|Cypher|sirolimus-eluting stent
11620030|NCT00485030|Active Comparator|Xience-V|everolimus-eluting stent
11620031|NCT00485017|Experimental|1|THR-4109: 115 mg orally in am, 115 mg orally in pm for 24 weeks
11620032|NCT00485017|Experimental|2|THR-4109: 100 mg orally in am, 100 mg orally in pm for 24 weeks
11620033|NCT00485017|Experimental|3|THR-4109: 15 mg orally in am, 15 mg orally in pm for 24 weeks
11620034|NCT00485017|Placebo Comparator|4|
11620035|NCT00485004|Experimental|Cutting balloon|Cutting balloon
11620036|NCT00485004|Active Comparator|Sirolimus-eluting stent|Sirolimus-eluting stent
11620037|NCT00484939|Experimental|Bevacizumab + capecitabine|Participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3-week treatment cycle. In addition, participants received capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 3-week treatment cycle.
11620038|NCT00484939|Active Comparator|Capecitabine|Participants received capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 3-week treatment cycle.
11620039|NCT00484926|Active Comparator|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
11620040|NCT00484926|Experimental|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
11620041|NCT00484874|Experimental|A Single Dose of I-131 Tositumomab|I-131 Tositumomab therapeutic regimen given to patients with relapsed/refractory Hodgkin's lymphoma who have or have not undergone transplant.
11620042|NCT00484822|Experimental|1|Brazo 1: Bemiparina Sódica 3.500 UI/día.
11620043|NCT00484822|Placebo Comparator|2|Brazo 2: Heparina Cálcica 10.000 UI/día.
11620044|NCT00484796||1|Patients undergoing carotid surgery
11620045|NCT00484783|Experimental|Prospective|Subjects scheduled to receive procedure
11620046|NCT00484783|Other|Historical|Chart review control group
11620047|NCT00484770|Other|Congestion Score Strategy|
11620048|NCT00484770|Other|BNP Strategy|
11620049|NCT00484744|Experimental|Acetaminophen|
11620050|NCT00484744|Experimental|Ibuprofen|
11620051|NCT00484744|Placebo Comparator|Avicel|
11620052|NCT00484731|Placebo Comparator|Injection with Saline|Injection with Saline instead of Bupivacain
11620053|NCT00484731|Active Comparator|Injection with Bupivacaine|Injection with Bupivacaine
11620054|NCT00484718|Active Comparator|A|
11620055|NCT00484718|Active Comparator|B|
11620056|NCT00484718|Placebo Comparator|C|
11620057|NCT00484705|Experimental|Low-frequency electro-acupuncture|
11620058|NCT00484705|Experimental|Physical exercise|
11620059|NCT00484705|Active Comparator|Untreated control|
11620060|NCT00484679|Experimental|1|Patients receiving Triamcinolone Acetonide 10 ml (Kenalog-10) intralesional injections.
11620061|NCT00484614|Active Comparator|1 PEM|
11620062|NCT00484614|Active Comparator|2 MRI|
11620063|NCT00484601|Experimental|Ifosfamide and Doxorubicin|Single arm treatment with Ifosfamide and Doxorubicinin patients with Refractory Nasopharyngeal Carcinoma
11620064|NCT00484575|Active Comparator|propofol|propofol for sedation minimum 2 hours in CTICU after CABG
11620065|NCT00484575|Experimental|sevoflurane|Sevoflurane via AnaConDa for minimum 2 hours in CTICU after CABG
11620066|NCT00484562|Active Comparator|Standard oxygen delivery system|Standard oxygen tank with pulse dose regulator
11620067|NCT00484562|Active Comparator|Homefill oxygen delivery system|Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.
11620068|NCT00484562|Active Comparator|Helios oxygen delivery system|Liquid oxygen portable system pre-filled from a larger liquid oxygen tank
11620069|NCT00484562|Active Comparator|FreeStyle oxygen system|portable battery-powered oxygen concentrator delivery system
11620070|NCT00484536|Experimental|CDP323 1000 mg/day|
11620071|NCT00484536|Experimental|CDP323 500 mg/day|
11620072|NCT00484536|Placebo Comparator|Placebo|
11620073|NCT00484510|Experimental|Ascorbic Acid|
11620074|NCT00484510|Placebo Comparator|Placebo|
11620075|NCT00484484|Experimental|1|Ketamine
11620076|NCT00484484|Experimental|2|Ketamine
11620077|NCT00484471|Experimental|1|
11620078|NCT00484471|Placebo Comparator|2|
11620079|NCT00484458|Experimental|1|Wallis Stabilization System
11620080|NCT00484458|Active Comparator|2|Total Disc Replacement
11620081|NCT00484432|Experimental|A: NGR-hTNF + doxorubicin|NGR-hTNF plus doxorubicin
11620082|NCT00484419|Experimental|colesevelam|colesevelam tablets 625 mg
11620083|NCT00484419|Active Comparator|rosiglitazone|rosiglitazone maleate 4mg
11620084|NCT00484419|Active Comparator|sitagliptin|sitagliptin phosphate tablets
11620085|NCT00484393|Experimental|Tetracaine|Tetracaine 4% gel 1g applied to injection site
11620086|NCT00484393|Placebo Comparator|Placebo|Placebo cream (Aquatain) 1g applied to inejction site
11620087|NCT00484367|Active Comparator|1 AGT|
11620088|NCT00484367|Active Comparator|2 TFT|
11620089|NCT00484354|Active Comparator|1|Bicarbonate administration
11620090|NCT00484354|Placebo Comparator|2|Normal saline administration
11620091|NCT00484341|Experimental|A: low-dose NGR-hTNF|0.8 mcg/m² of NGR-hTNF
11620092|NCT00484341|Experimental|B: high-dose NGR-hTNF|45 mcg/m² of NGR-hTNF
11620093|NCT00484341|Experimental|C: low-dose NGR-hTNF + doxorubicin|0.8 mcg/m² of NGR-hTNF + doxorubicin
11620094|NCT00484341|Experimental|D: high-dose NGR-hTNF + doxorubicin|45 mcg/m² of NGR-hTNF + doxorubicin
11620095|NCT00484328|Experimental|1|
11620096|NCT00484328|Experimental|2|
11620097|NCT00484315|Experimental|TAXUS Element|
11620098|NCT00484315|Active Comparator|TAXUS Express|
11620099|NCT00484302|Experimental|CapOpus|
11620100|NCT00484302|Active Comparator|Treatment as usual|
11620101|NCT00484289|Experimental|Arm 1: Participants from Phase I study (IM101-034)|
11620102|NCT00484289|Experimental|Arm 2: Participants from Phase II study (IM101-071)|
11620103|NCT00484289|Experimental|Arm 3: New Participants with Methotrexate (MTX) Intolerance|
11620104|NCT00484276|Experimental|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every 3 weeks or weekly
11620105|NCT00484263|Active Comparator|1|
11620106|NCT00484211|Experimental|A|
11620107|NCT00484198|Placebo Comparator|1|
11620108|NCT00484198|Experimental|2|Rivoglitazone 1.0 mg
11620109|NCT00484198|Experimental|3|Rivoglitazone 1.5 mg
11620110|NCT00484198|Active Comparator|4|Pioglitazone 45 mg
11620111|NCT00484185||1|
11620112|NCT00484159|Experimental|1|Radiofrequency lumbar facet joint denervation only if positive response to 2 diagnostic facet blocks.
11620113|NCT00484159|Experimental|2|Radiofrequency lumbar facet joint denervation if positive response to single facet joint block.
11620114|NCT00484159|Experimental|3|Radiofrequency lumbar facet denervation without a diagnostic facet block.
11620115|NCT00484120|Experimental|1|3% Diclofenac NE cream
11620116|NCT00484120|Placebo Comparator|2|
11620117|NCT00484094||Rapamune|
11620118|NCT00484055|Active Comparator|treatment|"Use of local CollagenGentamicin and enhanced sternal fixation according to the Clinical routine introduced 4 years earlier as a result of a previous RCT on 2000 patients. In that sense these patients did not receive any intervention but just the standard treatment introduced 4 years earlier.
~The aim of the study was to PROSPECTIVELY include a defined number of patients to compare their complication rate with that from aControl Group of patients från a previous RCT to verify that the effect of the treatment was stable over time.
~As the study did not include any intervention compared to the present standard treatment at that time ethical approval was Exempt."
11620119|NCT00484029|Experimental|1|Nasal Carbon Dioxide
11620120|NCT00484029|Placebo Comparator|2|Air
11620121|NCT00483977|Active Comparator|Oxycodone|
11620122|NCT00483977|Placebo Comparator|Placebo|
11620123|NCT00483977|Experimental|PF-00592379|
11620124|NCT00483964|Experimental|A|The group getting the study drugs, Bacopa monnieri and Nardostachys jatamansi
11620125|NCT00483964|Active Comparator|B|The group getting Olanzapine
11620126|NCT00483951|Other|Patients with known or suspected cardiovascular disease|combination of electrocardiography, chest X-ray, nuclear stress testing, laboratory testing, echocardiography, stress echocardiography, cardiac CT, and cardiac MRI
11620127|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group A)|Participants with HCV RNA levels greater than (>) 15 international units per milliliter (IU/mL) at Week 4, HCV RNA greater than or equal to (>=) 15 IU/mL at Week 8, and either HCV RNA less than (<) 15 IU/mL or >=2 times logarithmic (2 log10) drop at Week 12, will receive pegylated-interferon alfa-2a (Pegasys) 180 micrograms (mcg) subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 milligrams (mg) orally daily for 48 weeks.
11620128|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group B)|Participants with HCV RNA levels >15 IU/mL at Week 4, HCV RNA >=15 IU/mL at Week 8, and either HCV RNA <15 IU/mL or >=2 log10 drop at Week 12, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 72 weeks, and ribavirin 1000 to 1400 mg orally daily for 72 weeks.
11620129|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group C)|Participants with HCV-RNA levels >15 IU/mL at Week 4, and HCV-RNA <15 IU/mL at Week 8, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 36 weeks, and ribavirin 1000 to 1400 mg orally daily for 36 weeks.
11620130|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group D)|Participants with HCV-RNA levels >15 IU/mL at Week 4, and HCV-RNA <15 IU/mL at Week 8, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
11620131|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group E)|Participants with HCV-RNA levels <15 IU/mL at Week 4, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 24 weeks, and ribavirin 1000 to 1400 mg orally daily for 24 weeks.
11620132|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group F)|Participants with HCV-RNA levels <15 IU/mL at Week 4, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
11620133|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group NR)|Participants who do not have any change in HCV-RNA levels at Weeks 4, 8, and 12 will not be randomized (NR) to any of the other groups. Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
11620134|NCT00483899|Experimental|Cohort 1: Part A|Subjects in Cohort 1 will be randomized to receive 0.5, 2 and 6 mg GW870086X and placebo.
11620135|NCT00483899|Experimental|Cohort 2: Part A|Subjects in Cohort 2 will be randomized to receive 3 mg GW870086X or placebo.
11620136|NCT00483899|Experimental|Part B|Subjects will be randomized to receive 1 and 3 mg of GW870086X or placebo.
11620137|NCT00483886|Active Comparator|1|Prucalopride 2 mg
11620138|NCT00483886|Placebo Comparator|3|Placebo
11620139|NCT00483886|Active Comparator|2|Prucalopride 4 mg
11620140|NCT00483860|Experimental|Topotecan|once a day
11620141|NCT00483834|Experimental|Bevacizumab, Irinotecan and Capecitabine|Evaluate the efficacy and toxicity of bevacizumab, irinotecan and capecitabine as first-line treatment for patients with metastatic colorectal cancer
11620142|NCT00483808|Experimental|Denervation|Renal denervation using the Symplicty Catheter
11620143|NCT00483756|Active Comparator|1|Treatment Arm 1 will also receive standard of care medications
11620144|NCT00483756|Experimental|2|Treatment Arm 2 will also receive standard of care medications
11620145|NCT00483756|Experimental|3|Treatment Arm 3 will also receive standard of care medications
11620146|NCT00483743|Experimental|TPI 1020|TPI 1020 500 mcg BID x 42 days
11620147|NCT00483743|Active Comparator|Budosenide cortico|Budesonide 800 mcg BID x 42 days
11620148|NCT00483743|Placebo Comparator|Placebo|Placebo inhaler
11620149|NCT00483717|Placebo Comparator|Placebo|Intranasal Placebo
11620150|NCT00483717|Experimental|Ketorolac tromethamine|Intranasal ketorolac tromethamine
11620151|NCT00483704|Experimental|Telcagepant 140 mg|Telcagepant 140 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 140 mg or placebo.
11620152|NCT00483704|Experimental|Telcagepant 280 mg|Telcagepant 280 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 280 mg or placebo.
11620153|NCT00483704|Placebo Comparator|Control Group 1|Placebo, oral, tablet, across 3 migraine attacks (1st, 2nd, and 4th). Telcagepant 140 mg will be administered for the 3rd migraine attack. Participants will receive placebo for the optional second dose. For migraine attacks 2, 3, and 4, no study medication will be provided as an optional second dose.
11620154|NCT00483704|Placebo Comparator|Control Group 2|Placebo, oral, tablet, across 3 migraine attacks (1st, 2nd, and 3rd). Telcagepant 140 mg will be administered for the 4th migraine attack. Participants will receive placebo for the optional second dose. For migraine attacks 2, 3, and 4, no study medication will be provided as an optional second dose.
11620155|NCT00483678|Experimental|Intimacy-Enhancing Couples Therapy|Patients and their partners receive Intimacy-Enhancing Couples Therapy over 6 weeks comprising the following four 90-minute sessions: the Story of Cancer; Understanding the Couple, Ways of Relating and Key Influences; Intimacy; and Coping, Support, and Adaptation. Patients and their partners complete treatment satisfaction questionnaires after completion of study intervention.
11620156|NCT00483678|Active Comparator|standard psychosocial care|Patients and their partners receive standard psychosocial care. All participants complete questionnaires assessing psychological distress, intimacy, communication patterns, and overall relationship adjustment/satisfaction at baseline and at 1 month after completion of study intervention
11620157|NCT00483652|Placebo Comparator|Placebo|Placebo control
11620158|NCT00483652|Active Comparator|Fampridine-SR|10 mg b.i.d.
11620159|NCT00483600|Experimental|no arms/one group|
11620160|NCT00483574|Experimental|Group 1: Menactra® and Routine Pediatric Vaccines|Participants received Menactra® alone at age 9 months and Menactra® concomitantly with routine pediatric vaccines (measles-mumps-rubella-varicella [MMRV: ProQuad], pneumococcal conjugate [PCV], and hepatitis A [HepA]) at age 12 months.
11620161|NCT00483574|Other|Group 2: Routine Pediatric Vaccines|Participants received routine pediatric vaccines (measles-mumps-rubella-varicella [MMRV: ProQuad], pneumococcal conjugate[PCV], and hepatitis A [HepA]) at age 12 months.
11620162|NCT00483561|Experimental|Gefitinib plus Etoposide|"Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial.
~Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple)."
11620163|NCT00483548|Experimental|Ziprasidone|Active treatment, double-blind, randomized treatment arm
11620164|NCT00483548|Placebo Comparator|Placebo|Inactive, placebo treatment, double-blind, randomized arm
11620165|NCT00483535|Experimental|Sequence ABC|All subjects will receive the treatment sequence ABC where A=combined oral contraceptive pill (COC), B=COC plus GW273225 and C=GW273225. COC will be administered in two cycles that is, cycle 1 (Days 1-21) and cycle 2 (Days 29-49) of the study. The cycles will be separated by a 7 day washout period. GW273225 will be administered at a dose of one 25 milligram tablet once daily on Days 29-75 of the study.
11620166|NCT00483522|Experimental|1|Scheduled telephone counseling over 2 years time.
11620167|NCT00483522|No Intervention|2|This control group will receive standard care after hospital rehabilitation discharge as directed by their physician.
11620168|NCT00483509|Experimental|A: NGR-hTNF + doxorubicin|NGR-hTNF plus doxorubicin
11620169|NCT00483496|Experimental|V0096CR actives and vehicle|"Each patient received each one of the 8 test products on their respective randomly allocated sites on grid (grid to be applied on the back skin; 1 product by grid window).
~Single application of the test materials at the dosage of 2mg/cm² (total of 8 treated sites), prior to irradiation using a solar simulator."
11620170|NCT00483483|Experimental|1|Healthy Relationships Intervention (HRI)
11620171|NCT00483483|Active Comparator|Attention-control group|health education & support
11620172|NCT00483470|Experimental|1|
11620173|NCT00483470|Active Comparator|2|
11620174|NCT00483444|No Intervention|2|Control group were recruited in the emergency department after concussion and received standard care as directed by the ED physician and PCP.
11620175|NCT00483444|Experimental|1|Persons with concussion recruited in the emergency department received 5-6 scheduled telephone counseling calls focused on symptom management and self-management.
11620176|NCT00483431|Placebo Comparator|PLACEBO|MK7 dosage 0 mcg, 4 capsules, orally, daily for 12 weeks.
11620177|NCT00483431|Active Comparator|MK7_10|MK7 dosage 10 mcg, 1 capsule of 10 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
11620178|NCT00483431|Active Comparator|MK7_20|MK7 dosage 20 mcg, 2 capsules of 10 mcg and 2 placebo-capsules, orally, daily for 12 weeks.
11620179|NCT00483431|Active Comparator|MK7_45|MK7 dosage 45 mcg, 1 capsules of 45 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
11620180|NCT00483431|Active Comparator|MK7_90|MK7 dosage 90 mcg, 2 capsules of 45 mcg and 2 placebo-capsules, orally, daily for 12 weeks.
11620181|NCT00483431|Active Comparator|MK7_180|MK7 dosage 180 mcg, 4 capsules of 45 mcg, orally, daily for 12 weeks.
11620182|NCT00483431|Active Comparator|MK7_360|MK7 dosage 360 mcg, 1 capsule of 360 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
11620183|NCT00483405|Other|Single Arm Trial|Single Arm Trial
11620184|NCT00483379|Experimental|alglucosidase alfa 20 mg/kg every week|Participants were treated with alglucosidase alfa 20 mg/kg every week for 52 weeks. This was the 'frequent dose' arm.
11620185|NCT00483379|Experimental|alglucosidase alfa 40 mg/kg every other week|Participants were treated with alglucosidase alfa 40 mg/kg every other week for 52 weeks. This was the 'high dose' arm.
11620231|NCT00482768|No Intervention|2|Control clinics will deliver usual care for patients with diabetes.
11620232|NCT00482742|Other|Lifestyle counseling|
11620233|NCT00482742|Other|Metformin|
11620234|NCT00482729|Experimental|1|Arm 1: drug
11620235|NCT00482729|Active Comparator|2|Arm 2: active comparator
11620236|NCT00482703|Experimental|A|
11620186|NCT00483366|Other|Imatinib/Gemcitabine/Capecitabine|"Patients will be accrued on cohorts of three per dose level starting at dose level 0. Accrual to higher dose levels will depend on toxicity occurrence.
~Dose limiting toxicity (DLT) will be determined after cycle two for each patient.
~Schema: Imatinib days 1 - 5 and days 8 - 12 Gemcitabine on days 3 and 10 Capecitabine on days 1 - 14
~Doses: Imatinib 400 mg/d fixed dose Gemcitabine 450 mg/m2; 550 mg/m2; 675 mg/m2; 825 mg/m2; 1000 mg/m2 Capecitabine 500 mg/m2; 600 mg/m2 bid; 725 mg/m2; 850 mg/m2
~Treatment cycle: 21-days
~Treatment duration: Until disease progression or unacceptable toxicity defined in protocol."
11620187|NCT00483327|Experimental|Megestrol Acetate|80 mg (2 tablets) orally at breakfast, 80 mg at dinner for at least 12 weeks and up to 2 years.
11620188|NCT00483314|Experimental|1|
11620189|NCT00483262|Experimental|CCI779 and Bortezomib Phase I/II|In Phase I part, 15 or 25 mg temsirolimus (CCI-779)and 1·3 or 1·6 mg/m² bortezomib was given once a week.In Phase II, patients received intravenous temsirolimus once a week on days 1, 8, 15, 22, and 29 for a cycle of 35 days, and intravenous bortezomib once a week on days 1, 8, 15, and 22 for a cycle of 35 days, the MTD ascertained in the Phase I part.
11620190|NCT00483249|Experimental|Interventional|Endovascular Branched Stent-Graft: The investigational operation is done making small incisions in both groins and the right arm and placing a graft in the aorta through tubes that are inserted through the femoral and brachial arteries, than fastening it in position with metal springs(stents).
11620191|NCT00483223|Experimental|Single Arm|Cisplatin or carboplatin (1 arm, 2 cohorts)
11620192|NCT00483184|Placebo Comparator|1|(placebo)0 IU IFNa
11620193|NCT00483184|Experimental|2|(Veldona)500 IU IFNα bid
11620194|NCT00483184|Experimental|3|(Veldona)1000 IU IFNα bid
11620195|NCT00483171|Placebo Comparator|Placebo|
11620196|NCT00483171|Other|Non-pharmacological weight loss program (NPP)|
11620197|NCT00483171|Other|Low Calorie Diet|
11620198|NCT00483158|Placebo Comparator|A|Rising Single Dose
11620199|NCT00483158|Placebo Comparator|B|Rising Multiple Dose
11620200|NCT00483158|Experimental|C|Open Label H. pylori cohort
11620201|NCT00483145|Active Comparator|1|Long-pulsed dye laser (Candela)
11620202|NCT00483145|Active Comparator|2|Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)
11620203|NCT00483119|Active Comparator|Group A|IVIg alone (intravenous immunoglobulin)
11620204|NCT00483119|Experimental|Group B|IVIg with cyclophosphamide
11620205|NCT00483106|Placebo Comparator|Ritalin|
11620206|NCT00483106|Placebo Comparator|Placebo|
11620207|NCT00483093|Experimental|A|
11620208|NCT00483080|Experimental|A: NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every 3 weeks or weekly
11620209|NCT00483067|Experimental|2-CdA + Ara-C + G-CSF|2-CdA 12 mg/m^2/day by vein (IV) Continuous Infusion and Ara-C 1 gm/m^2/day IV for 5 Days with G-CSF 5 mcg/kg/day subcutaneously starting Day 9
11620210|NCT00483054|Experimental|Efavirenz|Efavirenz 600 mg/day + stavudine +lamivudine
11620211|NCT00483054|Experimental|Nevirapine|Nevirapine 400 mg/day + stavudine +lamivudine
11620212|NCT00483041|Experimental|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
11620213|NCT00483041|Placebo Comparator|PLACEBO|Placebo administered as a single intravenous infusion
11620214|NCT00483002||Healthy smokers|
11620215|NCT00482989|Experimental|1|MEDI-545
11620216|NCT00482989|Other|2|Placebo
11620217|NCT00482963|Experimental|levonorgestrel, efavirenz|healthy HIV-negative women of reproductive age were given levonorgestrel, efavirenz
11620218|NCT00482924||Overweight/obese|"The cohort consists of age and sex matched normal weighted controls and overweight/obese persons.
~Definition for overweight: BMI >90th and <97th percentile, if under 18 years of age, and BMI >25 and <29.9 kg/m2 if over 18 years of age.
~Definition for obese: BMI >97th percentile, if under 18 years of age, and BMI >30kg/m2, if over 18 years of age."
11620219|NCT00482924||Interventional branch|A lifestyle intervention following a holistic schedule was done in a subgroup of obese juveniles.
11620220|NCT00482911|Experimental|Cohort 1-lenalidomide & cyclophosphamide|Participants first started on 2 Interventions (Dose A-QD) in Cycle 1, with 10 mg Lenalidomide (Len) once daily and 50 mg Cyclophosphamide (Cyc) once daily; 25 mg Sunitinib (Sun) was added once daily as a 3rd Intervention (Dose B-QD) from Cycle 2 onwards. Doses were adjusted in subsequent cycles depending on toxicity, including incremental step downs to 5/25/12.5 mg Len/Cyc/Sun once daily (Dose C-QD) or once every other day (Dose C-QOD).
11620221|NCT00482911|Experimental|Cohort 2-sunitinib & cyclophosphamide|2 participants started Cycle 1 with Dose B as described above and had adjusted-dosing as described for Cohort 1. The remaining 7 participants began Cycle 1 with 10 mg Len, 25 mg Cyc and 12.5 mg Sun once daily (Dose D-QD). Doses were adjusted in subsequent cycles depending on toxicity, including step up to 10/50/12.5 mg Len/Cyc/Sun once daily (Dose E-QD) and step down to Dose D once every other day (Dose D-QOD).
11620222|NCT00482846|Experimental|Palifermin & Melphalen|"Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is >40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3
~Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:
~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;
~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. <60)adm. via I.V.:
~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
11620223|NCT00482833|Experimental|ARM A - ATO/ATRA|
11620224|NCT00482833|Active Comparator|ARM B - ATRA|
11620225|NCT00482820|Experimental|1|attention training away from threat
11620226|NCT00482820|Placebo Comparator|2|placebo attention training
11620227|NCT00482794||1|Individuals with APS who also have one or more of their family members affected specifically by APS
11620228|NCT00482794||2|Individuals with APS who also have one or more of their family members affected by another type of autoimmune disorder, such as lupus or rheumatoid arthritis.
11620229|NCT00482794||3|Individuals with APS and no family or no family affected with APS or another autoimmune disorder
11620230|NCT00482768|Experimental|1|Intervention clinics will receive practice facilitation visits at regular intervals over a 12-month period.
11620237|NCT00482703|Experimental|B|
11620238|NCT00482677|Active Comparator|Temozolomide|Temozolomide and short course radiation
11620239|NCT00482677|Active Comparator|Radiation|Short course radiation alone
11620240|NCT00482664|Experimental|1 mg|
11620241|NCT00482664|Experimental|10 mg|
11620242|NCT00482664|Experimental|3 mg|
11620243|NCT00482664|Placebo Comparator|Placebo|
11620244|NCT00482651|Experimental|UAP, SAP|
11620245|NCT00482625|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.
11620246|NCT00482612|Experimental|Esmirtazapine 1.5 mg|Esmirtazapine 1.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
11620247|NCT00482612|Experimental|Esmirtazapine 3.0 mg|Esmirtazapine 3.0 mg tablet, oral administration in the evening, once daily, for 2 weeks
11620248|NCT00482612|Experimental|Esmirtazapine 4.5 mg|Esmirtazapine 4.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
11620249|NCT00482612|Placebo Comparator|Placebo|Placebo to esmirtazapine
11620250|NCT00482599|Active Comparator|Normal renal function|Org 25969 given to subjects with normal renal function
11620251|NCT00482599|Experimental|Impaired renal function|Org 25969 given to subjects with impaired renal function
11620252|NCT00482586||Image-guided Therapy|Patients undergoing Image-guided Therapy of Hepatic Neoplasms.
11620253|NCT00482573|Experimental|Group LE|Seventeen (54.8%) patients, composed group LE, were randomly assigned for the infusion of 1.8 mL (one cartridge) by the modified anesthesia into the periodontal ligament (PDLm injection) of 2% lidocaine solution with epinephrine 1:100,000. Their ages were ranging from 18 to 44 years (mean:29.6), they were diagnosed as having rheumatic valve disease, in a functional class I or II according to classification of the NYHA. Gestation age ranged from 28 to 36 weeks (mean:31.8), and the BMI from 18.7 to 32.9 (mean:23.8) kg/m2. All the patients had the restauration done in their inferior premolar and/or molar teeth.
11620254|NCT00482573|Active Comparator|Group LNE|Fourteen (45.2%) patients, composed group LNE, were randomly assigned for the infusion of 1.8 mL (one cartridge) by the modified anesthesia into the periodontal ligament (PDLm injection) of 2% lidocaine solution without epinephrine. Their ages were ranging from 22 to 33 years (mean:26.6), they were diagnosed as having rheumatic valve disease, in a functional class I or II according to classification of the NYHA. Gestation age ranged from 29 to 37 weeks (mean:32.1), and the BMI from 18.5 to 38.1 (mean:22.8) kg/m2. All the patients had the restauration done in their inferior premolar and/or molar teeth.
11620255|NCT00482547|Experimental|Silver-coated catheter|Bard Hydrogel Silver Salts Coated Latex Urinary Catheter System
11620256|NCT00482547|Placebo Comparator|Silicone-coated catheter|Bard silicone elastomer coated latex catheter system
11620257|NCT00482521|Experimental|CC-4047|
11620258|NCT00482482|Experimental|Yoga|Yoga was offered twice a week for 8 weeks, 1.5 hours per session
11620259|NCT00482482|Active Comparator|Psychoeducation|Psychoeducation was offered twice a week for 8 weeks, 1.5 hours per session
11620260|NCT00482443|Experimental|1|To assess the efficacy of a Diabetes Interactive Diary in Diabetes Management.
11620261|NCT00482443|Active Comparator|2|Control Arm. Patients will receive standard education programme.
11620262|NCT00482430|Other|1|MK0557 10mg tablet qd, crossing over to MK0557 Pbo tablet qd.
11620263|NCT00482430|Other|2|MK0557 Pbo tablet qd, crossing over to MK0557 10mg tablet qd.
11620264|NCT00482391|Experimental|AC, PACLITAXEL , TRASTUZUMAB & LAPATINIB|The regimen consists of AC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 4 with pegfilgrastim, followed by weekly paclitaxel (80 mg/m2) x 12 + trastuzumab (H) + lapatinib (L). Pegfilgrastim 6mg is given subcutaneously (SQ) on day # 2 of each AC. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion. Trastuzumab will be administered weekly starting with paclitaxel treatment # 1. Near the completion of all chemotherapy, patients may receive trastuzumab on a q 3-weekly schedule, starting as early as with paclitaxel cycle # 12. The total duration of trastuzumab from beginning to end is 52 weeks. Lapatinib will be given orally at 1000 mg daily, starting with trastuzumab for a total duration of 52 weeks. Hormonal therapy such as tamoxifen or an aromatase inhibitor will be given to patients with hormone receptor positive disease at the physician's discretion. Radiation therapy to the breast or chest is recommended to patients as appropriate.
11620265|NCT00482378|Experimental|Sm 153 lexidronam|
11620266|NCT00482352||Ancillary-Correlative (marker identification, molecular test)|Patients undergo blood collection and bone marrow biopsies at baseline and at the end of induction therapy for immunophenotyping for marker identification; molecular testing for translocations; trisomy analysis by fluorescence in situ hybridization (FISH); and DNA ploidy. Immunophenotype results obtained on this study are used to determine the patient's assignment to specific treatment clinical trials (consistent with acute lymphoblastic leukemia).
11620267|NCT00482313|Experimental|Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
11620268|NCT00482313|Placebo Comparator|Sugar pill|Placebo given orally once daily for 5 weeks.
11620269|NCT00482287|Other|1|Dose level 0.3 mg/kg with 6 active and 2 placebo
11620270|NCT00482287|Other|2|Dose level 0.6 mg/kg 6 patients active and 2 placebo
11620271|NCT00482287|Other|3|Dose level 1.2 mg/kg 6 active and 2 placebo
11620272|NCT00482287|Other|4|Dose level 2.4 mg/kg 6 active and 2 placebo
11620273|NCT00482261|Experimental|len-dex|Drug: Lenalidomide 15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards; Drug: dexamethasone 20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
11620274|NCT00482222|Active Comparator|OxMdG / IrMdG chemotherapy|OxMdG / IrMdG chemotherapy for 12 weeks Followed by surgery OxMdG / IrMdG chemotherapy for 12 weeks
11620275|NCT00482222|Experimental|OxMdG / IrMdG chemotherapy with cetuximab|OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks Followed by Surgery OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks
11620276|NCT00482209|Active Comparator|1|200mg mifepristone followed by 400mcg misoprostol
11620277|NCT00482209|Active Comparator|2|200mg mifepristone followed by 800mcg misoprostol
11620278|NCT00482170|Experimental|1|Arm 1: Enbrel 50 mg Prefilled Syringe
11620279|NCT00482170|Active Comparator|2|Arm 2 Enbrel 50 mg Autoinjector
11620280|NCT00482144|Active Comparator|Treatment: PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
11620281|NCT00482144|Active Comparator|Treatment: PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
11620282|NCT00482144|No Intervention|Control|The scar will be randomly divided into three equal fields. One third of the scar will not receive treatment
11620283|NCT00482118||Cases|Non smoking women with lung cancer
11620284|NCT00482118||Controls|Non smoking women without lung cancer
11620285|NCT00482105|Other|A|"This research study proposes to use a non-invasive method to capture superficial cells on pigmented skin lesions that are suspected of being early melanomas. This non-invasive biopsy technology has been developed and patented by DermTech International. RNA in skin cells captured by this method will be profiled in order to diagnose the nature of the lesion (i.e. malignant melanoma or not). A successful outcome of this proposal would create a candidate non-invasive diagnostic assay based on a gene expression profile for identifying early stage melanomas"
11620286|NCT00482092|Placebo Comparator|Placebo|Placebo
11620287|NCT00482092|Active Comparator|Low dose|Low dose (600 million cells total over four infusions in two weeks)
11620288|NCT00482092|Active Comparator|High dose|High dose (1200 million cells delivered in four infusions over two weeks)
11620289|NCT00482066|Active Comparator|1|Abatacept (Orencia)
11620290|NCT00482066|Placebo Comparator|2|saline placebo
11620291|NCT00482053|Experimental|Auto-HCT followed by Allo-HCT for Poor-risk DLBCL|"Participants will have peripheral blood stem cells (PBSC, aka progenitor / stem cells) mobilized to peripheral blood with rituximab, chemotherapy (cyclophosphamide or etoposide), and filgrastim; undergo apheresis to collect (self/autologous PBSC), and receive carmustine, etoposide, and cyclophosphamide as conditioning for PBSC infusion as a hematopoietic cell transplant (auto-HCT).
~Then participants will receive allogeneic HCT (allo-HCT) transplant conditioning [total lymphoid irradiation (TLI) + anti-thymocyte globulin (ATG)] followed by allogenic PBSC (allo-HCT) obtained from a human leukocyte antigen (HLA)-matched or single mismatch filgrastim-mobilized donor. Participant allo-HCT transplant is to occur within 150 days of auto-HCT. Post-allo-HCT treatment includes cyclosporine + mycophenolate mofetil (MMF).
~Subject's participation ends if donor is not identified within 150 days. Pre-medication includes acetaminophen; diphenhydramine; hydrocortisone; & methylprednisolone."
11620292|NCT00482027|Active Comparator|1 AAV-2 HIV Vaccine|64 volunteers receiving AAV-2 HIV vaccine tgAAC09 at 3 dosage levels, dose escalation and dose optimization
11620293|NCT00482027|Placebo Comparator|2|16 volunteers receiving formulation buffer consisting of a buffered salt solution with potassium phosphate, calcium chloride, magnesium chloride, and HEPES
11620294|NCT00482014|Experimental|A: Pemetrexed + Carboplatin|Pemetrexed + Carboplatin
11620295|NCT00482014|Experimental|B: Pemetrexed + Cisplatin|Pemetrexed + Cisplatin
11620296|NCT00482001|Experimental|donepezil|donepezil, capsule, 5mg daily once daily for 14 days
11620297|NCT00482001|Placebo Comparator|placebo|placebo (cornstarch), capsule, once daily for 14 days
11620298|NCT00481988|Active Comparator|transcranial direct current stimulation|The active group of patients will receive active Iomed II Phoresor transcranial direct current stimulation for the first two weeks followed by another two weeks of active transcranial direct current stimulation.
11620299|NCT00481988|Sham Comparator|sham tDCS|The patients in the sham arm receive active Iomed II Phoresor transcranial direct current stimulation for the second two weeks of the clinical trial only. For the first two weeks the Iomed II Phoresor constant current generator is turned on for 10 seconds to produce the tingling sensation on the scalp experienced by the patients in the active arm but the generator is then turned off and the patients receive no stimulation for the remainder of the 20 minute session.
11620300|NCT00481936|Experimental|Dose Escalating|"Patients will be treated with VB6-845 as a monotherapy IV infusion, once weekly in 4-week cycles. Patients will continue to receive treatment up until the treatment stopping criteria or patient withdrawal criteria are met.
~Dose escalation will begin at a dose level of 1.00 mg/kg. Doses will be escalated according to the modified Fibonacci design with dose multipliers of 2.00, 1.67, 1.50, 1.40, and 1.33."
11620301|NCT00481884|Experimental|RadiaPlexRx Gel|RadiaPlexRx Gel for application to one half of irradiated breast skin, determined by a randomization process.
11620302|NCT00481884|Active Comparator|Aquaphor Gel|Aquaphor Gel for application to one half of irradiated breast skin, determined by a randomization process.
11620303|NCT00481871|Experimental|Pralatrexate & Gemcitabine - Sequential Days|
11620304|NCT00481871|Experimental|Pralatrexate & Gemcitabine - Same Day|
11620305|NCT00481845|Experimental|Vandetanib + Anastrozole|Vandetanib and Anastrozole as neoadjuvant therapy
11620306|NCT00481845|Active Comparator|Anastrozole|Anastrozole as neoadjuvant therapy
11620307|NCT00481832|Experimental|T & B Cell Mobilization Auto & Allo HCT|A transplant regimen that conditions the subjects using total lymphoid irradiation (TLI) and anti-thymocyte globulin(ATG) which will reduce acute graft-vs-host disease to negligible rates while maintaining the anti-tumor graft vs lymphoma GvL benefit. Along with TLI/ATG regiment; Solumedrol will be used as pre-medication and anti-emetic for any side effects. For stem cell mobilization, participants will be given either B Cell NLH or T Cell NHL. Before the filgrastim (G-CSF) mobilized PBPC infusion: acetaminophen, diphenhydramine and hydrocortisone will also be given as another set of pre-medications. BCNU, Etoposide, and Cyclophosphamide will be used as a preparative regimen. Cyclosporine and mycophenolate mofetil will be administered as an immunosuppressant after transplantation. Lastly, rituximab will be infused at the end of the transplantation regimen.
11620308|NCT00481819|Experimental|1|In combination with MMF and steroids
11620309|NCT00481819|Active Comparator|2|In combination with MMF and steroids
11620310|NCT00481767|Active Comparator|Cervarix Group|Healthy female subjects who received 3 doses of Cervarix at Months 0, 1 and 6, administered intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.
11620311|NCT00481767|Placebo Comparator|Placebo Group|Healthy female subjects who received 3 doses of placebo at Months 0, 1 and 6, administered intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.
11620312|NCT00481754||Females with ovarian cancer|Recruited from Magee Women's Hospital
11620313|NCT00481728|Experimental|Tolterodine|
11620314|NCT00481715|Experimental|1|Web-based weight loss program
11620315|NCT00481715|Experimental|2|Cash incentive weight loss program
11620316|NCT00481715|Experimental|3|Web-based program plus the cash incentive program
11620317|NCT00481715|No Intervention|4|No intervention
11620318|NCT00481676|Experimental|Omalizumab 75-375 mg|Omalizumab was dosed at 75 to 375 mg according to baseline IgE and body weight as described in dosing tables in the study protocol. Dosing occurred subcutaneously every 2 or 4 weeks depending on dose.
11620319|NCT00481676|Placebo Comparator|Placebo to omalizumab|Placebo to omalizumab was dosed at 75 to 375 mg according to baseline IgE and body weight as described in dosing tables in the study protocol. Dosing occurred subcutaneously every 2 or 4 weeks depending on dose.
11620320|NCT00481663|Experimental|Sitagliptin 25 mg once daily|Sitaglipin (MK-0431), 25 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
11620321|NCT00481663|Experimental|Sitagliptin 50 mg once daily|Sitagliptin, 50 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
11620322|NCT00481663|Experimental|Sitaglipin 100 mg once daily|Sitagliptin, 100 mg, once daily for 158 weeks, orally
11620323|NCT00481663|Experimental|Sitagliptin 50 mg twice daily|Sitagliptin 50 mg, twice daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
11620324|NCT00481663|Placebo Comparator|Placebo to Sitagliptin → Metformin|Placebo to Sitagliptin, once daily, orally for 12 weeks. Participants randomized to the placebo treatment group during the base study were reallocated to treatment with metformin 850 mg twice daily (b.i.d., initiated with 850 mg q.d. for 4 weeks then force titrated to 850 mg b.i.d.) during either the first or initiation of the second extensions study periods.
11620325|NCT00481637||Cancer patients|SCLC and gynecological cancer patients and unrelated cancer patients with presence of PND-specific CTLs.
11620326|NCT00481637||Normal|Normal volunteers
11620327|NCT00481624|Experimental|Epoetin Alfa plus Iron|
11620328|NCT00481572|Experimental|1|Terlipressin
11620329|NCT00481572|Experimental|2|Vasopressin
11620330|NCT00481572|Active Comparator|3|titrated norepinephrine
11620331|NCT00481546|Experimental|Experimental|All clinical trial subjects received the same vector.
11620332|NCT00481520|Experimental|1|
11620333|NCT00481520|Placebo Comparator|2|
11620334|NCT00481507|Placebo Comparator|Placebo|
11620335|NCT00481507|Experimental|Kefir|
11620336|NCT00481481|Experimental|1|
11620337|NCT00481455|Experimental|1|
11620338|NCT00481429||1|Rosiglitazone
11620339|NCT00481429||2|Diet control +/- metformin
11620340|NCT00481390||HIV-1 infected adults|HIV-1 infected adults
11620341|NCT00481364|Active Comparator|Statin|Atorvastatin 40 mg/day
11620342|NCT00481364|Placebo Comparator|Placebo|placebo
11620343|NCT00481351|Experimental|group1 ezetimibe|6 week wash out, followed by 06 week ezetimibe 10mg once a day e then 6 week ezetimibe 10mg plus sinvastatin 20mg for more 6 week.
11620344|NCT00481351|Active Comparator|group 2 simvastatin|6 week simvastatin 20mg once a day followed by 6 week simvastatin 80mg once a day.
11620345|NCT00481338|Experimental|Study specific procedure|X-rays, biological samples and medical information about osteoarthritis
11620346|NCT00481325|Experimental|A1|
11620347|NCT00481325|Active Comparator|A2|
11620348|NCT00481325|Placebo Comparator|A3|
11620349|NCT00481312|Active Comparator|1|Dexmedetomidine
11620350|NCT00481312|Active Comparator|2|Midazolam
11620351|NCT00481286|Experimental|Group Clinic|Patients in Group Clinic arm will meet every 3rd week for 12 weeks, for a total of 4 visits. At each visit, BP will be measured, home BP and glucose measurements collected. Each visit will include group-based education and feedback sessions, with an individualized process of selecting and modifying process of care goals for systolic BP, H1C, and LDL cholesterol. Short-term health behavior change goals will also be discussed.
11620352|NCT00481286|Placebo Comparator|Uusual Care|Older diabetes patients will attend regular clinician visits and one targeted primary care physician visit during the 12 weeks post-enrollment. They will be enrolled in a diabetes education class. Blood pressure, H1C and lipids will be measured at enrollment, 6 weeks , and 12 weeks.
11620353|NCT00481247|Experimental|Dasatinib|
11620354|NCT00481247|Active Comparator|Imatinib|
11620355|NCT00481221||1|Screened pregnant women
11620356|NCT00481195|Active Comparator|Armodafinil|
11620357|NCT00481195|Placebo Comparator|Placebo|
11620358|NCT00481156|Experimental|Patients: Cognitive Remediation|Patients in the cognitive REM condition attended up to 25 h of training in small groups over 4-6 weeks based on the approach to cognitive remediation described by Wexler and Bell (2005). Patients performed tasks designed to train attention and memory from the battery available within a computerized software package (CogPack Marker Software). This training protocol has been shown to improve memory and executive functioning in patients with schizophrenia (Sartory et al, 2005) and tasks chosen were designed to produce improved working memory and attention capacity in the treated group. In addition, patients in the REM group trained on the word N-back one to two times a week and on N-back tasks using a variety of other stimuli (such as faces) one to two times a week to support the generalization of working memory improvements.
11620451|NCT00480207|Experimental|omega-3 placebo, folic acid placebo, vit B12|omega-3 placebo (canola oil),folic acid placebo (starch), vitamin B12 (1000 mcg per day)
11620452|NCT00480181|Experimental|Active|
11620453|NCT00480181|Placebo Comparator|placebo|
11620359|NCT00481156|Active Comparator|Patients: Cognitive-Behavioral Social Skills Training|Patients in the CBSST group also attended up to 25 h of treatment but followed a manualized group therapy protocol (Granholm et al, 2005) using cognitive and behavioral therapy methods to increase patients' skills in symptom recognition, communication, problem solving, and relapse prevention. In both conditions, the facilitators interacted with the clients throughout small group (B4 patients) sessions: in the REM group, this mostly involved brief one-on-one discussions regarding task performance; in the CBSST condition, this interaction was in the context of the group milieu.
11620360|NCT00481156|Other|Controls: Retest control group|Estimate of normal brain functioning and retest effects
11620361|NCT00481143|Experimental|deferasirox|
11620362|NCT00481091|Experimental|Phase 1: Dose Escalation Portion|Participants will receive escalating doses of ABT-263 to determine the recommended phase 2 dose (RPTD). Eligible participants can continue to receive ABT-263 for 11 years in the extension portion.
11620363|NCT00481091|Experimental|Phase 2a: Dose Expansion Portion|Participants will receive ABT-263 at the RPTD determined in Phase 1 portion. Eligible participants can continue to receive ABT-263 for 11 years in the extension portion.
11620364|NCT00481078|Experimental|Arm I (vorinostat, paclitaxel, carboplatin)|Patients receive oral vorinostat (SAHA) at 400 mg once daily on days 1-14 and paclitaxel IV 200 mg/m2 over 3 hours and carboplatin IV dosed to achieve an area under the concentration versus time curve of 6 mg/mLXmin over 30 minutes on day 3.
11620365|NCT00481078|Active Comparator|Arm II (placebo, paclitaxel, carboplatin)|Patients receive an oral placebo once daily on days 1-14 and paclitaxel and carboplatin as in arm l.
11620366|NCT00481065|Experimental|Concomitant alone|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382.
11620367|NCT00481065|Experimental|Concomitant +Mixed|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
11620368|NCT00481065|Experimental|Concomitant +MF59-eH5N1|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
11620369|NCT00481065|Experimental|Mixed|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
11620370|NCT00481065|Experimental|Mixed and mixed|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382
11620371|NCT00481065|Experimental|Mixed+MF59-eH5N1|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
11620372|NCT00481065|Experimental|MF59-eH5N1+eTIV_a|1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
11620373|NCT00481065|Experimental|eTIV_a+MF59-eH5N1|1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
11620374|NCT00481039||1|Patients diagnosed as having abnormal hemoglobin like hemoglobin S and thalassemia in a bedouin village
11620375|NCT00481026|Sham Comparator|Placebo|Placebo tDCS
11620376|NCT00481026|Active Comparator|active tDCS|active tDCS
11620377|NCT00481013|Placebo Comparator|1a|For six months, half of patients are randomized into placebo . After 6 months, all patients are on treatment.
11620378|NCT00481013|Active Comparator|1b|Cohort 1b patients are randomized onto treatment. After 6 months, all patients are on drug.
11620379|NCT00481000|No Intervention|1|Waitlist; Treatment as usual
11620380|NCT00480987|Experimental|Oxaliplatin + Cytarabine + Fludarabine|Oxaliplatin 30 mg/m^2 intravenous (IV) days 1-4, Cytarabine 500 mg/m^2 by IV continuous infusion days 2-6, Fludarabine 30 mg/m^2 IV days 2-6
11620381|NCT00480974||1|Patients with Sickle cell anemia treated by Hydroxyurea
11620382|NCT00480948|Active Comparator|1|Infant formula with InFat™ oil(containing ~49% of C16:0 at sn-2 position).
11620383|NCT00480948|Placebo Comparator|2|Standard vegetable oil based infant formula
11620384|NCT00480935|Experimental|Sunitinib Malate (Sutent)|Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 2 week rest period to comprise a complete cycle of 6 weeks. Patients will then continue on Sutent for another cycle of 4 consecutive weeks
11620385|NCT00480922|Experimental|1|A low glycemic load diet
11620386|NCT00480922|Active Comparator|2|Low fat diet
11620387|NCT00480896|Experimental|1|
11620388|NCT00480896|Placebo Comparator|2|
11620389|NCT00480883|Active Comparator|1|injection meglumine antimoniate 20 mg/kg/day/intramuscular for 21 days.
11620390|NCT00480883|Experimental|2|injection meglumine antimoniate 10 mg/kg/day/intramuscular plus tablet allopurinol 1200 mg/day/6hourly divided doses.
11620391|NCT00480870|Experimental|A|Donepezil treated Alzheimer patients
11620392|NCT00480870|Placebo Comparator|B|Placebo treated Alzheimer patients
11620393|NCT00480857|Experimental|Docetaxel|
11620394|NCT00480844|Experimental|Sertindole|
11620395|NCT00480844|Active Comparator|Risperidone|
11620396|NCT00480831|Experimental|1|
11620397|NCT00480831|Placebo Comparator|2|
11620398|NCT00480792|Active Comparator|A|GenHevac-B 20 microgramme Intramuscular use at M0, M1, M6
11620399|NCT00480792|Experimental|B|GenHevac-B 40 microgramme Intramuscular use at M0, M1, M2, M6
11620400|NCT00480792|Experimental|C|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
11620401|NCT00480779|Other|GLB Group|The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study choose traditional GLB face-to-face group delivery or delivery via DVD. Group members met weekly and completed the program over a 12-15 week period. The face-to-face group meetings were led by a trained lifestyle coach, and participants were encouraged to self-monitor their eating and physical activity behaviors. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
11620454|NCT00480155|Active Comparator|1|FluMist
11620455|NCT00480155|Placebo Comparator|2|Placebo
11620456|NCT00480116|Active Comparator|1|
11620457|NCT00480116|Active Comparator|2|
11620402|NCT00480779|Other|GLB DVD|The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study choose traditional GLB face-to-face group delivery or delivery via DVD. Those who took part via DVD received an overview of the GLB program at the first session, as well as the materials needed for the program. They subsequently watched one session of the program each week, and received a telephone call from a trained lifestyle coach each week to review weight, physical activity minutes and questions/concerns regarding the program. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
11620403|NCT00480740|Experimental|Cardiac Transplant|diagnostic cardiac catheterization in children with a transplanted heart
11620404|NCT00480740|Experimental|Fontan procedure|diagnostic cardiac catheterization in children with a transplanted ventricle
11620405|NCT00480740|Other|Normal Physiology|diagnostic cardiac catheterization in children with normal cardiac physiology
11620406|NCT00480727|Placebo Comparator|Control|No fortnightly re-tensioning. Placebo treatment utilises the re-tensioning procedure, pt experiences clicking sensation, however, the pin is not tightened.
11620407|NCT00480727|Experimental|Treatment (Re-tensioning) Group|Pins are re-tensioned fortnightly back to initial fitting tension of 8lb/inch.
11620408|NCT00480701|Experimental|[123I]-IBVM|To assess [123I] IBVM and SPECT imaging
11620409|NCT00480675|Experimental|1|Trochanteric bursa injections done into the bursa under fluoroscopic guidance
11620410|NCT00480675|Active Comparator|2|Trochanteric bursa injection done with sham fluoroscopy using only landmarks as guidance.
11620411|NCT00480649|Active Comparator|Sal/FP 50/250mcg|SERETIDE 50/250
11620412|NCT00480649|Active Comparator|Sal/FP 50/500mcg|SERETIDE 50/500
11620413|NCT00480636||One cohort of patients treated with dalteparin.|About 100 patients with deep-vein thrombosis and with or without pulmonary embolism will be included in the study.
11620414|NCT00480610|Experimental|1|
11620415|NCT00480610|Placebo Comparator|2|
11620416|NCT00480584|Experimental|GemCap-T Dose Escalation|GemCap-T, capecitabine in combination with gemcitabine. Dose Escalation 6 Cycles @ 28 Days.
11620417|NCT00480571|Experimental|1|BL 1020 low dose
11620418|NCT00480571|Experimental|2|BL 1020 High Dose
11620419|NCT00480558|Active Comparator|1|Group 1: M. tb
11620420|NCT00480558|Active Comparator|2|Group 2: HIV (not on antiretrovirals [ARV])
11620421|NCT00480558|Active Comparator|3|Group 3: M. tb and HIV (not on ARV)
11620422|NCT00480558|Active Comparator|4|Group 4: M. tb and HIV (on ARV)
11620423|NCT00480532|Experimental|Doxycycline 100bid x5 days|
11620424|NCT00480532|Placebo Comparator|placebo bid x 5 days|
11620425|NCT00480532|Experimental|Subantimicrobial doxycycline daily|
11620426|NCT00480532|Placebo Comparator|placebo daily|
11620427|NCT00480493|Experimental|Parent mentor contact|Parent mentor provides face-to-face social support
11620428|NCT00480493|Active Comparator|Control Arm|Parent is given a phone contact
11620429|NCT00480454|Active Comparator|1|Stage 1 would require 12 per group low dose and 12 per group high dose (total 72)
11620430|NCT00480454|Active Comparator|2|Stage 2 would require 48 per group (total 144)
11620431|NCT00480441|Active Comparator|1|Dronabinol+ BRENDA therapy
11620432|NCT00480441|Placebo Comparator|2|Placebo+BRENDA therapy
11620433|NCT00480402|Experimental|400 mg Progesterone|Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 400 mg Progesterone Group vaginal pessaries arm.
11620434|NCT00480402|Experimental|200 mg Progesterone Group|Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 200 mg Progesterone Group vaginal pessaries arm.
11620435|NCT00480402|Active Comparator|Placebo|Approximately one third of the bichoronic biamniotic twin pregnant women were randomized to the placebo vaginal pessaries arm.
11620436|NCT00480389|Experimental|Sorafenib|"All patients on study will be accrued to this arm. Sorafenib (200 mg tablets x 2) will be administered orally twice a day for 12 weeks (full daily dose of 800 mg). Patient visits for safety will be conducted at least every 4 weeks. Sorafenib dose reductions for drug-related toxicity will be applied based on considerable prior clinical experience. Surgery will be performed at the completion of the 13th week, allowing for a one-week washout period. Sorafenib will be continued post operatively (around 6 weeks post surgery or when complete wound healing has occurred) until patient progresses or unacceptable toxicity occurs."
11620437|NCT00480363|Experimental|1|Lenalidomide + Dexamethasone for 9 cycles and maintenance
11620438|NCT00480363|No Intervention|2|Observation
11620439|NCT00480324|Experimental|Rotarix Group|Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.
11620440|NCT00480324|Placebo Comparator|Placebo Group|Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.
11620441|NCT00480311||1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
11620442|NCT00480272|Experimental|group A|"adalimumab 40 mg subcutaneous injections every other week from baseline to month 12
~methotrexate orally weekly at initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.
~prednisone orally 50 mg daily, gradually tapered up to 6.25 mg at week 7 and stopped at month 6"
11620443|NCT00480272|Placebo Comparator|group B|"adalimumab 40 mg subcutaneous injections every other week from baseline to the end of month 12
~methotrexate orally oweekly at an initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.
~placebo orally, stopped at month 6"
11620444|NCT00480259|Active Comparator|Standard Nutrition|
11620445|NCT00480259|Experimental|Hyperprotein Nutrition|
11620446|NCT00480220|Experimental|1|Specific Intervention as Global care and support program
11620447|NCT00480220|No Intervention|2|'No specific intervention'
11620448|NCT00480207|Experimental|omega-3, folic acid, vitB12|folic acid (1600 mcg per day), and omega-3 (2000 mg per day: active docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA), proportion 1:1), vitamin B12 (1000 mcg per day)
11620449|NCT00480207|Experimental|omega-3, folic acid placebo, vit B12|omega-3,folic acid placebo (starch), vitamin B12 (1000 mcg per day)
11620450|NCT00480207|Experimental|omega-3 placebo, folic acid, vit B12|folic acid, omega-3 placebo(canola oil),vitamin B12 (1000 mcg per day)
11620459|NCT00480090|Experimental|Cytarabine|eligible patients will receive cytarabine, starting at 075g/m2 and escalating to a maximum of 1.25g/m2, BID IV for 2 days every three weeks for 6 or more cycles if tolerated.
11620460|NCT00480077|Experimental|Access Arm|HF subjects managed with standard clinical assessment and using the audible OptiVol® Fluid status monitoring alert and the device Cardiac Compass Report
11620461|NCT00480077|Active Comparator|Control arm|HF subjects managed with standard clinical assessment
11620462|NCT00480038|Other|1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
11620463|NCT00480025|Experimental|ASCI Group|
11620464|NCT00480025|Placebo Comparator|Placebo Group|
11620465|NCT00479986|Experimental|Pioglitazone|
11620466|NCT00479986|Active Comparator|placebo|
11620467|NCT00479973|Active Comparator|Cinnamonforce|Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.
11620468|NCT00479973|Placebo Comparator|Placebo|
11620469|NCT00479934|Experimental|1|6 month treatment with Imtinib 400mg/day
11620470|NCT00479934|Placebo Comparator|2|6 month treatment with Placebo 400mg/day
11620471|NCT00479895|Other|1|Occlusion with pre-oxygenated HBOC-201 followed by dry occlusion
11620472|NCT00479895|Other|2|Dry occlusion followed by occlusion with pre-oxygenated HBOC-201
11620473|NCT00479882|Experimental|Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg|After a 2-week placebo run-in, participants will receive MK-0524B (0.9 g/simvastatin 10 mg) for 4 weeks, then MK-0524B 1.8g /20 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 20 mg for 8 weeks.
11620474|NCT00479882|Experimental|Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg|After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 10 mg for 4 weeks, then co-administered MK-0524A 2g +simvastatin 20 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/20 mg combination tablet for 8 weeks.
11620475|NCT00479882|Experimental|Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg|After a 2-week placebo run-in, participants will receive MK-0524B 0.9g/40 mg combination tablet for 4 weeks, then MK-0524B 1.8g /40 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 40 mg for 8 weeks.
11620476|NCT00479882|Experimental|Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg|After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 40 mg for 4 weeks, then co-administration MK-0524A 2g +simvastatin 40 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/40 mg combination tablet for 8 weeks.
11620477|NCT00479856|Experimental|Lapatinib plus Chemotherapy|Lapatinib is administered in combination with one of the following chemotherapies based on the discretion of the investigator : capecitabine, docetaxel or nab-paclitaxel.
11620478|NCT00479830||Group 1|South Asian, Subgroup: Asian Indian, population in the Greater Houston area.
11620479|NCT00479830||Group 2|South Asian, Subgroup: Bangladeshi, population in the Greater Houston area.
11620480|NCT00479830||Group 3|South Asian, Subgroup: Pakistani, population in the Greater Houston area.
11620481|NCT00479830||Group 4|South Asian, Subgroup: Sri Lankan, population in the Greater Houston area.
11620482|NCT00479817|Experimental|Arm A|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 10 mg/kg IV QW
11620483|NCT00479817|Experimental|Arm B|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 3 mg/kg IV QW
11620484|NCT00479817|Active Comparator|Arm C|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 placebo
11620485|NCT00479765|Experimental|1|OncoGel administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel
11620486|NCT00479752|Active Comparator|A|"FOLFOX4:
~Oxaliplatin 85 mg/m² d1
~Leucovorin 200 mg/m² d1+d2, followed by
~Bolus 5FU 400 mg/m², followed by
~Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks
~Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m²."
11620487|NCT00479752|Active Comparator|B|"FOLFOX4:
~Oxaliplatin 85 mg/m² d1
~Leucovorin 200 mg/m² d1+d2, followed by
~Bolus 5FU 400 mg/m² , followed by
~Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks
~Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks."
11620488|NCT00479739|Experimental|Arm 1|
11620489|NCT00479713|Experimental|1|Arm 1: drug
11620490|NCT00479713|Active Comparator|2|Arm 2: active comparator
11620491|NCT00479687|Active Comparator|Supartz|Supartz
11620492|NCT00479687|Placebo Comparator|Phosphate Buffered Saline|Phosphate Buffered Saline
11620493|NCT00479674|Experimental|Abraxane, Carboplatin, Bevacizumab|Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15
11620494|NCT00479661|Experimental|1|Dexmedetomidine
11620495|NCT00479661|Active Comparator|2|Propofol
11620496|NCT00479648|Active Comparator|1|Inactivated trivalent influenza vaccine
11620497|NCT00479648|Experimental|2|CSL412 formulation
11620498|NCT00479648|Experimental|3|CSL412 formulation
11620499|NCT00479648|Experimental|4|CSL412 formulation
11620500|NCT00479635|Experimental|TPI 287|
11620501|NCT00479622|Experimental|1|
11620502|NCT00479622|Experimental|2|
11620503|NCT00479609|Placebo Comparator|1|Placebo gel
11620504|NCT00479609|Active Comparator|2|Transdermal testostrone therapy
11620505|NCT00479583|Active Comparator|A|
11620506|NCT00479583|Active Comparator|B|
11620507|NCT00479570|Experimental|Study period 1, 2 or 3|
11620508|NCT00479570|Placebo Comparator|Placebo Study period 1, 2 or 3|
11620509|NCT00479557|Active Comparator|1|arm 1: ACC-001 (Vanutide Cridificar)+ QS-21
11620510|NCT00479557|Active Comparator|2|arm 2: ACC-001
11620511|NCT00479557|Placebo Comparator|3|arm 3: QS-21
11620512|NCT00479557|Placebo Comparator|4|Drug: Phosphate Buffered Saline (PBS)
11620513|NCT00479505|Experimental|Active|
11620514|NCT00479505|Placebo Comparator|Placebo|
11620515|NCT00479492|Experimental|1|
11620516|NCT00479492|Experimental|2|
11620517|NCT00479492|Experimental|3|
11620519|NCT00479479|Experimental|Cobalamin|An intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
11620520|NCT00479479|No Intervention|No intervention|No intervention
11620521|NCT00479466|Experimental|MK0893 80 mg|MK0893 tablets totaling 80 mg once daily.
11620522|NCT00479466|Experimental|MK0893 60 mg|MK0893 tablets totaling 60 mg once daily.
11620523|NCT00479466|Experimental|MK0893 40 mg|MK0893 40 mg tablet once daily.
11620524|NCT00479466|Experimental|MK0893 20 mg|MK0893 20 mg tablet once daily.
11620525|NCT00479466|Active Comparator|Metformin|Metformin HCL 500 mg tablet twice daily BID titrating up to 1000 mg twice daily over 3 weeks.
11620526|NCT00479466|Placebo Comparator|Placebo|PLA tablets. 12 week treatment period.
11620527|NCT00479427|Experimental|Overall study|overall study population
11620528|NCT00479401|Experimental|Pramipexole Extended Release (PPX ER)|
11620529|NCT00479401|Experimental|Pramipexole Immediate Release (PPX IR)|
11620530|NCT00479401|Placebo Comparator|Placebo|
11620531|NCT00479388|Other|1|One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
11620532|NCT00479388|Active Comparator|2|Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.
11620533|NCT00479362|Experimental|1 Warfarin Uninterrupted|Warfarin therapy is continued without interruption prior to cardiac pacing device implantation
11620534|NCT00479362|Active Comparator|2 Warfarin Interrupted|Warfarin therapy is discontinued 2 days prior to cardiac pacing device implantation
11620535|NCT00479362|Sham Comparator|3 Aspirin Group|Patients with aspirin therapy during implantation
11620536|NCT00479362|Other|4 No Antithrombotic Group|No antithrombotic treatment during operations
11620537|NCT00479349|Active Comparator|1|SAM 531 + placebo
11620538|NCT00479336|Placebo Comparator|1|
11620539|NCT00479336|Experimental|2|
11620540|NCT00479336|Experimental|3|
11620541|NCT00479336|Experimental|4|
11620542|NCT00479323|Other|1|Immunize healthy volunteers with pneumococcal vaccine (Pneumovax 23) to obtain a pool of hyperimmune sera in a quantity sufficient to generate reference sera.
11620543|NCT00479271|Active Comparator|Home Care|"A flexible home-care program tailored to the needs of the individual and the family. The components of the intervention will include:
~Basic education about dementia (what is the disease, its course, its features etc)
~Education about common behaviour problems and how they can be managed
~Support to the carer, for example for an elderly carer living alone with the patient, in activities of daily living
~Referral to specialists when behaviour problems are severe and warrant medication intervention (sedatives)."
11620544|NCT00479271|Other|Wait-list|This group will be put on a waiting list to receive the intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
11620545|NCT00479258|Experimental|Inhaled insulin (Exubera)|
11620546|NCT00479258|Active Comparator|Subcutaneous Insulin (subject's prescribed)|
11620547|NCT00479245|Other|1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
11620548|NCT00479232|Experimental|Cohort 1: Vorinostat (sequential)|"Vorinostat 400 mg capsules once daily given 7, 10 or 14 days in 28 day cycles. Up to 24 months of treatment.
~Decitabine IV 20 mg/m^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment."
11620549|NCT00479232|Experimental|Cohort 2: Vorinostat (concurrent)|"Vorinostat 400 mg capsules once daily given 7 days, 14 days with 8 day break after first 7 days or 14 days without break, out of 28 day cycles.
~Decitabine IV 20 mg/m^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment."
11620550|NCT00479219|Experimental|A|
11620551|NCT00479219|Placebo Comparator|B|
11620552|NCT00479193|Other|1|There is one arm to the study. The same subjects are their own control. One of the investigators will identify two sites that appear to be the same depth on each patient [1 site Polymen and 1 site bacitracin/xeroform )]. One site will be identified for bacitracin/xeroform and one site for Polymen. All burns will be initially debrided and cleaned according to burn unit protocol. Laser Doppler will be utilized to determine burn depth at both the trial and control sites. On each subsequent visit, patients will rate the pain of the dressing change on a 1-10 pain intensity scale.The study will end for each patient when the investigator determines that 95% of their burn has re-epithelized.
11620553|NCT00479180|Experimental|AVG1|Vascugel
11620554|NCT00479180|Placebo Comparator|AVG2|Gelfoam
11620555|NCT00479180|Experimental|AVF3|Vascugel
11620556|NCT00479180|Placebo Comparator|AVF4|Gelfoam
11620557|NCT00479154|Experimental|Botulinum Toxin A|Injection of onabotulinumtoxinA
11620558|NCT00479154|Placebo Comparator|Placebo (saline)|Injection of saline placebo
11620559|NCT00479141|Experimental|1|HIV infected participants and their families
11620560|NCT00479141|Experimental|2|Popular Opinion Leaders (POL) participants
11620561|NCT00479128|Experimental|Bortezomib + Gemcitabine + Doxorubicin|Starting dose of Bortezomib 0.8 mg/m^2 IV Over 3-5 Seconds. Starting dose of Gemcitabine 225 mg/m^2 IV Up to 90 Minutes. Starting dose of Doxorubicin 12.5 mg/m^2 IV Over 15-30 minutes.
11620562|NCT00479115|Experimental|AMD3100|
11620563|NCT00479089|Active Comparator|Weekly Docetaxel|Docetaxel 25 mg/m^2 IV over 30 minutes for 4 weeks with premedication with Dexamethasone, followed by 2 weeks off therapy.
11620564|NCT00479089|Active Comparator|Weekly Docetaxel + ZD1839|Docetaxel 25 mg/m^2 IV over 30 minutes for 4 weeks with premedication with Dexamethasone, followed by 2 weeks off therapy. ZD1839 250 mg by mouth daily, without break.
11620565|NCT00479063||Cases|All subjects screened for this study were aged 30 to 50 years, had been referred to participating Radiology services, and underwent a lumbar MRI. Cases had been referred for a lumbar MRI for LBP lasting > 90 days.
11620566|NCT00479063||Controls|All subjects screened for this study were aged 30 to 50 years, had been referred to participating Radiology services, and underwent a lumbar MRI. Controls were headache patients who had been referred for a cranial MRI, which turned out to be normal, and who either had no history of LBP or had only experienced one episode in their life, which had lasted for less than 7 days.
11620567|NCT00479037|Active Comparator|PTH(1-84)|
11620568|NCT00479037|Active Comparator|Strontium Ranelate|
11620800|NCT00476645|Experimental|Fulvestrant|
11620569|NCT00479024||observation|patients enrolled in previous trial IOP 104; collecting clinical outcome data on these same patients
11620570|NCT00478985|Experimental|1|Imatinib treatment ending
11620571|NCT00478972|Experimental|Rimonabant|Rimonabant 20 mg once daily in addition to diet and exercise
11620572|NCT00478972|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily in addition to diet and exercise
11620573|NCT00478959|Experimental|Lenalidomide|Lenalidomide given as a daily oral dose of 25 mg on days 1 - 21 followed by 7 days of no therapy of a 28 day cycle in the treatment of a population with relapsed or refractory Hodgkin's lymphoma.
11620574|NCT00478946|Experimental|1|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
11620575|NCT00478946|Active Comparator|2|FOLFOX Oxaliplatin 85 mg/m2, as a 2-hour infusion Leucovorin (400 mg/m2 in D5W) and Oxaliplatin. Leucovorin + oxaliplatin will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
11620576|NCT00478933|Experimental|ICD Therapy, blood sampling|Blood sampling Defibrillator, Dual Chamber ; Implantable
11620577|NCT00478881|Experimental|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
11620578|NCT00478881|Placebo Comparator|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
11620579|NCT00478842|Experimental|1|Deep brain stimulation
11620580|NCT00478816|Active Comparator|Group 1|Primed subject with pandemic Vaccine
11620581|NCT00478816|Active Comparator|Group 2|Non Primed subject with pandemic Vaccine
11620582|NCT00478803|Experimental|1, preservation|aortic valve surgery(Remodeling associated with a subvalvular aortic ring annuloplasty or double sub and supra valvular aortic annuloplasty)
11620583|NCT00478803|Sham Comparator|2, Bentall|Mechanical aortic valve replacement(isolated or composite valve and graft replacement);actual surgical standard for dystrophic aortic roots
11620584|NCT00478790|Experimental|1|ologen™ collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy. After operation with ologen™ Collagen Matrix, anti-inflammatory eye-drops will be prescribed
11620585|NCT00478777|Experimental|lenalidomide plus dexamethasone|Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), dexamethasone was to be reduced to 40 mg QD for Days 1-4 of each 28 day-cycle.
11620586|NCT00478738|Other|GSK961081|GSK961081
11620587|NCT00478725|Experimental|Part A|Absorption, Distribution, Metabolism and Elimination of a Single Oral [14C] Labeled Dose of GW786034
11620588|NCT00478725|Experimental|Part B|characterize the pharmacokinetics of a single IV dose of GW786034
11620589|NCT00478712||Families with Hirschsprung Disease|Individuals with Hirschsprung disease and their affected and unaffected relatives.
11620590|NCT00478699|Active Comparator|1|
11620591|NCT00478699|Experimental|2|
11620592|NCT00478686||Severe Toxicity|Patients who experienced severe toxicity (at least one grade 4 side effect) with capecitabine chemotherapy
11620593|NCT00478686||Dose-Limiting Toxicity|Patients who experienced dose-limiting toxicity (at least one grade 3, or recurrent grade 2, side effect)with capecitabine chemotherapy
11620594|NCT00478686||Low/No Toxicity|Patients who have experienced low/no toxicity (none or only side effects at grade 1 & 2) with capecitabine chemotherapy.
11620595|NCT00478647|Experimental|GA-GCB (velaglucerase alfa)|15-60 U/kg, every other week via intravenous infusion
11620596|NCT00478634|Experimental|A1: RAD001 + cetuximab + irinotecan|RAD001 30mg weekly oral, 400mg/m2, loading i.v. (250mg/m2 for subsequent weekly dose i.v.), 350mg/m2 every 3 weeks i.v.
11620597|NCT00478634|Experimental|B1 dose: RAD001 + cetuximab + irinotecan|RAD001 30mg weekly oral, 400mg/m2 loading i.v (250mg/m2 for subsequent weekly dose i.v.), 250mg/m2 every 3 weeks i.v.
11620598|NCT00478621|Experimental|Group A|
11620599|NCT00478621|Experimental|Group B|
11620600|NCT00478621|Experimental|Group C|
11620601|NCT00478621|Experimental|Group D|
11620602|NCT00478621|Experimental|Group E|
11620603|NCT00478621|Active Comparator|Group F|
11620604|NCT00478595|Experimental|Rimonabant|Rimonabant 20 mg once daily
11620605|NCT00478595|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily
11620606|NCT00478569||Parathyroid Hormone (PTH) (1-84)|PTH(1-84) was prescribed in accordance with the terms of the marketing authorization. Participants were observed for 24 months.
11620607|NCT00478556|Active Comparator|1|Gastroview
11620608|NCT00478556|Experimental|2|Omnipaque
11620609|NCT00478543|Experimental|Diuretic|Furosemide
11620610|NCT00478504|Active Comparator|Clomiphene citrate|Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
11620611|NCT00478504|Active Comparator|Letrozole|Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
11620612|NCT00478491||1|Persons with a parent with Alzheimer's disease
11620613|NCT00478491||2|Persons whose parents survived to old age without memory problems
11620614|NCT00478491||3|Persons with diagnosed mild cognitive impairment
11620615|NCT00478491||4|Persons without memory problems
11620616|NCT00478478||Acute Ischemic Stroke patients|Patients presenting with signs and symptoms consistent with a diagnosis of Acute Ischemic Stroke, who are treated with the Merci Retrieval System during a Mechanical Thrombectomy procedure.
11620617|NCT00478452|Experimental|DC Ova|DC Ova vaccine administered day 2 and week 3,6,9
11620618|NCT00478452|Active Comparator|DC Ova with Cyclophosphamide|Cyclophosphomide administered at day 0 prior to administration of DC Ova vaccine administered day 2 and week 3,6,9
11620619|NCT00478439|Placebo Comparator|Placebo Comparator|
11620620|NCT00478426|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11620621|NCT00478400||Participants who have had a TBI|"(recruited by invitation only)
~Must be between 1- and 6-years post-injury
~Closed head injury
~Evidence of loss of consciousness
~Must have an informant (friend, spouse, child etc.)
~Audit-C < 7, PCL < 65 and PHQ-9 < 15"
11620622|NCT00478400||Participants with No history of TBI|"(Recruited by invitation only)
~No history of TBI
~Must have an informant (friend, spouse, child etc.)"
11620623|NCT00478400||Veterans with History of TBI|"Must be between 1- and 6-years post-injury
~Closed head injury
~Evidence of loss of consciousness
~Must have an informant (friend, spouse, child etc.)
~Audit-C < 7, PCL < 65 and PHQ-9 < 15"
11620624|NCT00478400||US Veterans with No history of TBI|"No history of TBI
~Must have an informant (friend, spouse, child etc.)"
11620625|NCT00478374|Experimental|1|
11620626|NCT00478361|Experimental|Gemcitabine, Paclitaxel and Doxorubicin|Paclitaxel 135 mg/m^2 intravenous (IV) over 1 hour; Gemcitabine 900 mg/m^2 IV over 90 min; Doxorubicin 40 mg/m^2 IV over 20 min; treatment may repeat every 2 weeks for up to nine courses. Injection of Pegfilgrastim on day 1.
11620627|NCT00478348|Other|Drain|
11620628|NCT00478348|Other|No drain|
11620629|NCT00478335|Experimental|Active Therapy|4-day treatment with hydrochlorothiazide/amiloride, indomethacin, calcitonin, sildenafil
11620630|NCT00478335|Placebo Comparator|Placebo Control|4-day treatment with hydrochlorothiazide/amiloride, indomethacin, placebo for calcitonin, placebo for sildenafil
11620631|NCT00478322|Experimental|INCB013739|
11620632|NCT00478322|Placebo Comparator|Matching Placebo|
11620633|NCT00478309|No Intervention|Arm I|Participants receive standard primary care.
11620634|NCT00478309|Experimental|Arm II|Participants receive standard primary care followed by the Genetic Epidemiology and Risk Assessment (GERA) intervention. Participants also participate in a discussion session regarding the GERA including the rationale behind methylenetetrahydrofolate reductase mutation detection and folate assessment and its relationship to colorectal cancer risk.
11620635|NCT00478270|Experimental|1|
11620636|NCT00478257|Active Comparator|1 Active Bright White Light Treatment|Intervention: Bright white light, the intervention, was administered via a light box made by Litebook Inc for 30 minutes each morning during four cycles of chemotherapy
11620637|NCT00478257|Active Comparator|2 Comparator Red Light Treatment|Intervention: Dim red light, the intervention, was administered via a light box made by Litebook Inc for 30 minutes each morning during four cycles of chemotherapy
11620638|NCT00478244|Experimental|Epidermolysis Bullosa (EB) Patients|Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant.
11620639|NCT00478231|Experimental|1|
11620640|NCT00478218|Experimental|Lenalidomide/Cyclophosphamide/Dexamethasone|
11620641|NCT00478205|Experimental|1|
11620642|NCT00478205|Experimental|2|
11620643|NCT00478192|Experimental|Regimen 1 Conivaptan QD|20 mg conivaptan once a day
11620644|NCT00478192|Experimental|Regimen 2 Conivaptan BID|20 mg conivaptan two times a day
11620645|NCT00478192|Placebo Comparator|Regimen 3 Placebo|
11620646|NCT00478140|Experimental|Trastuzumab|Participants receive trastuzumab loading dose 8 mg/kg intravenous (IV) over 30-90 minutes on day 1 and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11620647|NCT00478114|Experimental|1|Sorafenib
11620648|NCT00478088|Experimental|1|NeoDisc
11620649|NCT00478088|Active Comparator|2|ACDF
11620650|NCT00478062|Experimental|Cell vaccine after initial therapy for Hodgkin lymphoma|Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.
11620651|NCT00478049|Active Comparator|1|Docetaxel
11620652|NCT00478049|Experimental|2|Gefitinib
11620653|NCT00478036|Active Comparator|Acular LS|Acular LS - 1 drop in treated eye, 4 times a day, for 4 days
11620654|NCT00478036|Active Comparator|Pred Forte|Pred Forte - 1 drop in treated eye, 4 times a day, for 4 days
11620655|NCT00478036|Placebo Comparator|Refresh Tears|Refresh Tears - 1 drop in treated eye, 4 times a day, for 4 days
11620656|NCT00478023|Active Comparator|Morphine|
11620657|NCT00478023|Experimental|Tapentadol 50 mg immediate release|
11620658|NCT00478023|Experimental|Tapentadol 75 mg immediate release|
11620659|NCT00478023|Experimental|Tapentadol 100 mg immediate release|
11620660|NCT00478023|Placebo Comparator|Matched placebo|
11620661|NCT00477997|Placebo Comparator|1|Saline bolus + OGTT
11620662|NCT00477997|Other|2|GH-bolus and OGTT
11620663|NCT00477997|Other|3|GH-bolus
11620664|NCT00477984|Experimental|A|alcohol and placebo
11620665|NCT00477971|Active Comparator|Arm A|"Patients receive low-dose melphalan IV over 15-30 minutes on day
~1 or orally once daily on days 1-7 and oral dexamethasone on days 1-4 and 22-25. Treatment repeats every 6 weeks for 10 courses.
~Study treatment beyond one year is not allowed."
11620666|NCT00477971|Experimental|Arm B|Patients receive filgrastim (G-CSF) on days -7 to -3 and undergo autologous hematopoietic stem cell (HSC) collection. Patients receive high-dose melphalan IV over 1 hour on days -2 and -1 and undergo autologous HSC transplantation on day 0.
11620667|NCT00477958|Experimental|Geriatric Assessment Tool|
11620668|NCT00477919||Weekly assessment by E-MOSAIC|Patients complete a weekly assessment comprising visual analogue scales (VAS) of pain, fatigue, drowsiness, nausea, anxiety, depression, shortness of breath, loss of appetite, and overall well-being; up to 3 optional symptoms selected by the patient; and an estimated nutritional intake using an electronic tool for monitoring symptoms and syndromes associated with advanced cancer (E-MOSAIC). Nurses record the patient's weight, KPS score, body mass index, and assessment of current medication for pain (i.e., morphine-equivalent daily dose), fatigue, and anorexia/cachexia syndromes weekly. A Longitudinal Monitoring Sheet (LoMoS) is printed (comprising VAS of pain, pain medication, fatigue, KPS, medication for fatigue [i.e., methylphenidate hydrochloride or epoetin alfa], anorexia, weight change, nutritional intake, medication, supplements, counseling for anorexia, VAS of individually selected symptoms) and stored.
11620669|NCT00477919||Palm-based monitoring tool|Patients complete a weekly symptom assessment and nutritional intake using a Palm-based monitoring tool. Nurses record weight and Karnofsky performance status (KPS) scores weekly. A proof of electronic transfer sheet is printed and stored.
11620670|NCT00477906|Experimental|1|"MVax + BCG + cyclophosphamide + IL2
~2:1 randomization - MVax:Control"
11620671|NCT00477906|Placebo Comparator|2|Placebo Vaccine + BCG + cyclophosphamide + IL2
11620672|NCT00477893|Placebo Comparator|Placebo|
11620673|NCT00477893|Active Comparator|Adalimumab|
11620674|NCT00477880|Experimental|Cetuximab|Cetuximab lV weekly at an initial loading dose of 400 ml/m2, followed by three weekly maintenance doses of 250 mg/m2. Four infusions of C225 will be defined as a course of therapy.
11620675|NCT00477854|Experimental|Visual Analogue Scale Ratings|Food intake data and its coefficients, including total food intake, food not eaten, duration of the meal, and bite rate. A mixed model analysis of variance will also be conducted on ratings of food cravings and eating atttudes. Changes in hunger and satiety ratings between, before, and after the meals will be compared for difference across treatment conditions.
11620676|NCT00477854|Experimental|Consuming less Lunch allows consumption of more dinner|Test whether chromium picolinate supplementation affects food cravings, eating attitudes, and satiety in healthy, overweight and/or obese, adult women who are determinded to be carbohydrate cravers. Whether participants who eat less at a lunch test meal consume more food at an ad lib dinner test meal with a diversity of foods.
11620677|NCT00477815|Experimental|Rituximab + Zevalin|Determine the dose level that is both tolerable and achieves the greatest B cell recovery in patients with multiple myeloma.
11620678|NCT00477802|Experimental|Botox|Randomized into receiving Botox first. At cross-over, patients will receive placebo.
11620679|NCT00477802|Placebo Comparator|Placebo|Randomized to receive placebo first. At cross-over, patients will receive the active Botox.
11620680|NCT00477776|Active Comparator|a|Mother with diet-controlled diabetes receive Metoclopramide 10 mg 3 times a day for the first 7 days, and 2 times a day for day 8 to 10, and once a day from day 11 to day 12
11620681|NCT00477776|Placebo Comparator|b|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, and once a day for day 11 to 12
11620682|NCT00477776|Active Comparator|c|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, and once a day from day 11 to 12
11620683|NCT00477776|Placebo Comparator|d|Placebo 10 mg 3 times a day for 7 days, 2 times a day for day 8 to 10; and once a day from day 11 to 12
11620684|NCT00477763|Active Comparator|1|
11620685|NCT00477763|Placebo Comparator|2|
11620686|NCT00477750|Experimental|Treatment (Lenalidomide, Melphalan, Prednisone)|"Intervention: Drug: lenalidomide Dose determined by Phase I treatment schedule. Taken orally days 1-21 every 28 days until progression
~Intervention: Drug: melphalan Dose determined by Phase I treatment schedule. Taken orally days 1-4 every 28 days until progression
~Intervention: Drug: prednisone 60mg/m^2, orally days 1-4 every 28 days until progression"
11620687|NCT00477724|Placebo Comparator|sedentary control group|patients are treated by conventional rehabilitation
11620688|NCT00477724|Active Comparator|exercise and respiratory therapy|rehabilitation with exercise and respiratory therapy
11620689|NCT00477711|Experimental|C225+Chemotherapy|
11620690|NCT00477685||OculusGen Collagen Matrix|OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
11620691|NCT00477672|Experimental|2|Pimavanserin tartrate (ACP-103), 10 mg, tablet, once daily by mouth, 6 weeks
11620692|NCT00477672|Experimental|3|Pimavanserin tartrate (ACP-103), 40 mg, tablet, once daily by mouth, 6 weeks
11620693|NCT00477672|Placebo Comparator|1|Placebo tablet, once daily by mouth, 6 weeks
11620694|NCT00477659|Experimental|Donepezil|
11620695|NCT00477646|Experimental|Prevention Care Management|Telephone support over 18 months from trained Prevention Care Managers, to help women overcome barriers to colon, breast, and cervical cancer screening
11620696|NCT00477646|No Intervention|Usual Care|Usual Care. A sample of patients receive a single telephone call to validate claims data and collect basic demographic information.
11620697|NCT00477633|Experimental|Norethindrone/ethinyl estradiol|1 tablet per day
11620698|NCT00477607|Experimental|Arm 1|Receiving alpha-lipoic acid during cisplatin treatment.
11620699|NCT00477607|Placebo Comparator|Arm 2|Receiving placebo during cisplatin treatment
11620700|NCT00477594|Experimental|Mipomersen 200 mg per week|Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.
11620701|NCT00477594|Experimental|Mipomersen 200 mg every other week|Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator's discretion after the first 52 weeks of the treatment period.
11620702|NCT00477581|Experimental|Sequence A|
11620703|NCT00477581|Experimental|Sequence B|
11620704|NCT00477529|Experimental|ABI-008|
11620705|NCT00477516|Experimental|1|
11620706|NCT00477503|Active Comparator|Group A|Ga-67 citrate injection alone for individuals with cancer cells in cerebral spinal fluid (CSF), no earlier treatment for disease.
11620707|NCT00477503|Active Comparator|Group B|Ga-67 + In 111 DTPA injection for individuals who have cancer cells in CSF, no earlier treatment for disease.
11620708|NCT00477503|Active Comparator|Group C|Individuals with tumors in the CSF that have been treated and are now cleared from the CSF, receive standard follow-up care (baseline injection of Ga-67 citrate and In-111 DTPA).
11620709|NCT00477490|Placebo Comparator|Placebo|Participants took a placebo 'melt' for 28 days to complete part 1 of the study. In part 2, placebo patients were randomized to one of the other 4 treatment arms based on assignments predetermined at the initial randomization, to receive active desmopressin melt for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
11620710|NCT00477490|Experimental|desmopressin melt 10 μg|Participants took desmopressin melt 10 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
11620711|NCT00477490|Experimental|desmopressin melt 25 μg|Participants took desmopressin melt 25 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
11620712|NCT00477490|Experimental|desmopressin melt 50 μg|Participants took desmopressin melt 50 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
11620799|NCT00476671||1|HIV infected adults with viral load < 50 copies/ml on NNRTI based HAART
11620713|NCT00477490|Experimental|desmopressin melt 100 μg|Participants will take desmopressin melt 100 μg for 28 days to complete part 1 of the study. Participants will continue on this dose in part 2 of the study for between 1-6 months (until the database for part 1 is locked and treatment is unblinded).
11620714|NCT00477477|Experimental|1|Low glycemic load diet
11620715|NCT00477477|Active Comparator|2|Low fat diet
11620716|NCT00477464|Experimental|Lapatinib+capecitabine|Lapatinib 1250mg once daily +capecitabine 2000mg/m^2 twice daily (14 days out of 21 days)
11620717|NCT00477451|Placebo Comparator|RCT Placebo|Subjects received inhaled placebo after 0.5 mg/kg doxapram IV in the randomized controlled trial
11620718|NCT00477451|Experimental|RCT Alprazolam 1 mg|Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the randomized controlled trial
11620719|NCT00477451|Experimental|Open Label Inhaled Alprazolam 1 mg|Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the open label dose validation
11620720|NCT00477451|Experimental|Initial Inhaled Alprazolam 2 mg|Subjects received 2 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the initial open label dose assessment
11620721|NCT00477412|Experimental|Treatment (combination chemotherapy)|"Participants receive Drug Combination I during courses 1, 3, 5, and 7 (if needed) and Drug Combination II during courses 2, 4, 6, and 8 (if needed) in the absence of disease progression or unacceptable toxicity.
~Drug Combination I: Participants receive rituximab IV over 6 hours on day 1, cyclophosphamide IV over 3 hours BID on days 2-4, doxorubicin IV over 15-30 minutes on day 5, vincristine IV over 15-30 minutes on days 5 and 12, dexamethasone PO or IV on days 2-5 and 12-15, and bortezomib IV over a few seconds after the first dose of cyclophosphamide and immediately after vincristine and doxorubicin have been given on day 5.
~Drug Combination II: Participants receive rituximab IV over 6 hours on day 1, methotrexate IV over 24 hours on day 2, and cytarabine IV over 2 hours every 12 hours on days 3-4."
11620722|NCT00477386|Experimental|Carboplatin combined with Decitabine|Decitabine at escalating dose levels will be given X 5 days followed by Carboplatin given on Day 8.
11620723|NCT00477373|Experimental|1|If the daily dose does not exceed 1000 mg, Depakine CHRONO can be administered once a day. If the dose is greater than 1000 mg/day, Depakine CHRONO will be administered in a bid regimen: one tablet in the morning and one tablet in the evening.
11620724|NCT00477360|Experimental|1|C.A.P
11620725|NCT00477347|Active Comparator|1|Manual administration
11620726|NCT00477347|Experimental|2|Closed-loop administration
11620727|NCT00477334|Experimental|1|Famciclovir 1000 mg; twice a day for one day.
11620728|NCT00477334|Placebo Comparator|2|Placebo; twice a day for one day.
11620729|NCT00477321|Experimental|CYT107|CYT107 vs Placebo (4:1 ratio)
11620730|NCT00477308|Other|salvage therapy|Children with drug resistance were treated using the drug resistant profile
11620731|NCT00477295|Active Comparator|Zonisamide|
11620732|NCT00477295|Active Comparator|Carbamazepine|
11620733|NCT00477282|Experimental|Karenitecin|
11620734|NCT00477282|Active Comparator|Topotecan|
11620735|NCT00477269|Experimental|STI571|STI571
11620736|NCT00477269|Placebo Comparator|Placebo|Placebo
11620737|NCT00477269|Experimental|All Patients|Open label extension
11620738|NCT00477256||Child|Children between 6 and 17 years diagnosed with, and treated for, any type of cancer.
11620739|NCT00477256||Parent|Parent(s) or caregiver(s) of children with cancer.
11620740|NCT00477256||Medical Staff|Medical staff (i.e., physicians, nurse practitioners) involved in the children's medical decision-making.
11620741|NCT00477243||Palliative Care Clinic Patients|Department of Symptom Control and Palliative Care Center Patients
11620742|NCT00477230|Experimental|1|Single ablation procedure with Endoscopic Ablation System
11620743|NCT00477230|Active Comparator|2|Medication
11620744|NCT00477217|Other|1|
11620745|NCT00477204|Active Comparator|Simvastatin|Zocor(simvastatin)(20 mg)daily for 6 months along with Placebo (sugar pill)of active comparator (Vytorin [simvastatin] + Zetia [ezetimibe].
11620746|NCT00477204|Active Comparator|Ezetimibe/Simvastatin|Vytorin(simvastatin [Zocor} + ezetimibe [Zetia])(20 mg)daily for 6 months along with placebo (sugar pill)of comparator (Vytorin [simvastatin]).
11620747|NCT00477191|Experimental|Etanercept|Etanercept
11620748|NCT00477178||chronic non-malignant pain codeine|patients having chronic non-malignant pain, living in Trondheim or the four adjacent counties and treated at the Center for Pain and Complex Disorders at St. Olav University Hospital - on long-term codeine therapy
11620749|NCT00477178||chronic non-malignant pain|patients having chronic non-malignant pain, living in Trondheim or the four adjacent counties and treated at the Center for Pain and Complex Disorders at St. Olav University Hospital - NOT on long-term codeine therapy
11620750|NCT00477178||healthy|healthy controls
11620751|NCT00477165|Experimental|Citalopram|One 20mg capsule per day for 4 weeks, then 2 capsules per day (40mg) for 4 weeks
11620752|NCT00477165|Placebo Comparator|Placebo|Identical to citalopram 20mg capsule. One capsule per day for 4 weeks, then 2 capsules per day for 4 weeks
11620753|NCT00477152|Experimental|HYLENEX-augmented subcutaneous (SC ) rehydration|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
11620754|NCT00477126|Active Comparator|1|start generic product cross over to reference product
11620755|NCT00477126|Active Comparator|2|start reference product cross over to generic product
11620756|NCT00477100||Observational (biospecimen and medical data collection)|Patients complete questionnaires and participate in interview over 30 minutes. Patients also undergo collection of medical data and blood, tissue, and stool samples.
11620757|NCT00477087|Experimental|GM-CSF Plus Mitoxantrone|GM-CSF at 250 micrograms/ m² / day subcutaneously 3 x week for 3 weeks. Participants will also receive mitoxantrone 14 mg/m² on Day 1 of each cycle. Each cycle of therapy consists 21 days.
11620758|NCT00477048|Other|1|Replace Indinavir with SQV in patients with indinavir toxicity
11620759|NCT00477035|Experimental|Autologous Cytokine-induced Killer Cells|
11620760|NCT00477009|Experimental|1|Adjustable mandibular repositioning appliance
11620761|NCT00477009|Placebo Comparator|2|Placebo device in upper jaw
11620762|NCT00476996|Experimental|Ocrelizumab 200 mg x 2 IV + Non-Biologic DMARD Therapy|Participants will receive 2 intravenous (IV) infusions of 200 milligram (mg) of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
11620763|NCT00476996|Experimental|Ocrelizumab 500 mg x 2 IV + Non-Biologic DMARD Therapy|Participants will receive 2 IV infusions of 500 mg of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
11620764|NCT00476996|Placebo Comparator|Placebo x 2 IV + Non-Biologic DMARD Therapy|Participants will receive ocrelizumab matching placebo IV in two infusions, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
11620765|NCT00476983|Experimental|1|SQV/r 1500/100 mg OD + Truvada OD
11620766|NCT00476970|Experimental|Patient Navigation Intervention|Participants randomized to this arm will receive language-concordant patient navigation in the form of an introductory letter with educational material followed by phone or in-person contact to provide individually tailored interventions.
11620767|NCT00476970|No Intervention|Usual Care|Participants randomized to this arm will receive no additional navigation beyond the usual care for the duration of the 9-month intervention. Participants will be offered navigation services after the completion of the intervention period.
11620768|NCT00476957|Active Comparator|1|Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System
11620769|NCT00476957|Active Comparator|2|Cordis Cypher® Sirolimus-eluting Coronary Stent
11620770|NCT00476931|Experimental|1|SB-509
11620771|NCT00476931|Placebo Comparator|2|
11620772|NCT00476905||Spectral-Diagnosis|Method for noninvasive detection of cutaneous malignancies
11620773|NCT00476892|Other|1|"It consists of five outpatient appointments (weeks 0, 2, 6, 11 and 16) with a local trial physiotherapist at a trial centre. At the first appointment a standardised history is taken from the woman, anatomy and function of the pelvic floor muscles are taught, and types of prolapse described, using diagrams and a model pelvis. Women are taught how to contract the muscles, and also how to contract and hold prior to an event that increases intra-abdominal pressure (the Knack). Pelvic floor muscles are assessed by vaginal examination and recorded on a dedicated form at each appointment thus determining the content of a single set of exercises for each woman. At least three sets of exercises daily is recommended. Women use an exercise diary to record compliance. Tailored advice is given on ways of reducing intra-abdominal pressure, e.g. advice on weight loss, chronic cough, heavy lifting and general exercise."
11620774|NCT00476892|No Intervention|2|Women allocated to the control group will be sent a lifestyle advice leaflet only, and will have no planned contact with the centre until their consultant review appointment at six months. The leaflet gives instructions on seeking advice where appropriate about weight loss, constipation, and avoidance of heavy lifting, coughing and high impact exercise, with a view to minimising increases in intra-abdominal pressure which may cause prolapse to worsen.
11620775|NCT00476879|Experimental|1|12 hours of fasting and a GH bolus
11620776|NCT00476879|Experimental|2|36 hours of fasting and a GH bolus
11620777|NCT00476879|Experimental|3|36 hours of fasting and Pegvisomant
11620778|NCT00476879|Experimental|4|36 hours of fasting and NaCl injection
11620779|NCT00476853|Active Comparator|1|NVP 400 mg
11620780|NCT00476853|Active Comparator|2|NVP 600 mg
11620781|NCT00476827|Active Comparator|Bevacizumab / Capecitabine|Bevacizumab 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle.
11620782|NCT00476827|Active Comparator|Bevacizumab / Docetaxel|Docetaxel (taxotere) 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
11620783|NCT00476827|Active Comparator|Bevacizumab /Irinotecan (Camptosar®, CPT-11)|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
11620784|NCT00476827|Active Comparator|Bevacizumab / Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
11620785|NCT00476827|Active Comparator|Bevacizumab /Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle.
11620786|NCT00476827|Active Comparator|Bevacizumab / Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.
11620787|NCT00476801|Experimental|UVA1 irradiation|The dose and scheduling will be similar to those being successfully used in Germany: up to 130J/cm2 from a UVA1 Sellamed irradiation device (German manufactured UVA1 light emitting device) with irradiations up to 5 times per week for up to 14 weeks on one side of the face. Then a cross-over treatment an equal length of time.
11620788|NCT00476801|No Intervention|Control|No treatment on the opposite side of the face as the UVA1 treatment for up to 14 weeks. Then a cross-over treatment an equal length of time.
11620789|NCT00476788|Experimental|Omnipod Device|Patients will be placed on an Omnipod insulin pump
11620790|NCT00476775|Experimental|After school ethnic dance and home-based screen time reduction|After school ethnic dance classes and home-based screen time reduction intervention
11620791|NCT00476775|Active Comparator|Health and Nutrition Education|Health and nutrition education active placebo control intervention
11620792|NCT00476723||1|HIV/Hepatitis coinfected patients who use at least one hepatitis activity drug or medications
11620793|NCT00476710||Normal Glucose Metabolism|Overweight and obese individuals that have normal glucose metabolism and their response to Colesevelam HCl
11620794|NCT00476710||Impaired Glucose Tolerance|Overweight and obese individuals that have impaired glucose tolerance and their response to Colesevelam HCl
11620795|NCT00476710||Frank type 2 diabetes|Overweight and obese individuals that have frank type 2 diabetes and their response to Colesevelam HCl
11620796|NCT00476697|Experimental|UVA1 Irradiation|UVA1 irradiaton up to 5 times per week, for up to 16 weeks using German manufactured UVA1 emitting light system. UVA1 dose will be applied with up to 130 J/cm2.
11620797|NCT00476684|Experimental|radiofrequency neurotomy|Radiofrequency-neurotomy of the medial branch at 80 degr. C for 70 seconds, after diagnostic blocks
11620798|NCT00476684|Sham Comparator|sham controls|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
11620801|NCT00476632||Control|Person with no history of cancer.
11620802|NCT00476619|Placebo Comparator|Erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
11620803|NCT00476606||Long-term pediatric cohort|Long-term follow-up cohort since 2003
11620804|NCT00476593|Experimental|Diclofenac|Preservative- free Diclofenac Na 0.1 % eye drops were applied in one consecutively assigned eye of healthy volunteers four times a day for three days, after which macular thichness was measured in both subjects' eyes with the OCT .
11620805|NCT00476593|Experimental|Dexamethasone|Benzalkonium-reserved Dexamethasone Sodium Phosphate 0.1% was applied in one consecutively assigned eye of healthy volunteers six times a day for three days, after which macular thickness was assessed in both subjects's eyes with the OCT.
11620806|NCT00476580||Sri Lankan Sinhalese|Sri Lankan Sinhalese adults (18 years of age or older) living in the greater Houston area, but born in Sri Lanka.
11620807|NCT00476580||Siblings or Cousins in Sri Lanka|Siblings or the first cousins of the study participants living in Sri Lanka of same sex and of an age plus or minus 10 years.
11620808|NCT00476567|Experimental|exercise|Regular exercise 45-60 minutes minimum three times per week
11620809|NCT00476567|Active Comparator|control|standard antenatal care
11620810|NCT00476554|Experimental|A|low dose
11620811|NCT00476554|Experimental|B|High dose
11620812|NCT00476541|Experimental|1|Gemtuzumab 5 mg / m2 two courses with three week interval
11620813|NCT00476541|No Intervention|2|No further therapy
11620814|NCT00476515|Experimental|Rituximab|this study has only one arm as treatment group.
11620815|NCT00476502||1|patients involved in structured interruption therapy
11620816|NCT00476476|Experimental|Erlotinib|Patients rcvd oral erlotinib 150 mg/day. Cohort 1 pts would have at least 28 days and no more than 42 days of therapy in advance of definitive therapy (surgery or chemoradiation). Cohort 2 pts continued on therapy (28 days per cycle) until disease progression, unacceptable toxicity or withdrawal of consent. Two potential dose reductions were prescribed to 100 and 50 mg/day.
11620817|NCT00476463|Active Comparator|1|AZT+FTC+EFV
11620818|NCT00476463|Active Comparator|2|TDF+FTC+EFV
11620819|NCT00476424|Active Comparator|1|400 mg EFV
11620820|NCT00476424|Active Comparator|2|600 mg EFV
11620821|NCT00476411|Experimental|1|HBV vaccine
11620822|NCT00476398|No Intervention|Diagnostic capsule endoscopy|Patient with non-cardiac chest pain will undergo capsule endoscopy
11620823|NCT00476385|Experimental|somatropine|
11620824|NCT00476372||Parkinson's disease|Pt with parkinsons disease
11620825|NCT00476359|Other|double-boosted PI|double-boosted protease inhibitor combination
11620826|NCT00476346|Active Comparator|Calcium|Daily calcium supplementation Intervention: Calcium 2000mg / daily
11620827|NCT00476346|Experimental|Vitamin D|Daily Calcium and Vitamin D supplementation Intervention: Vitamin D 800IU / daily
11620828|NCT00476294||Group 1: G + Placebo|G-CSF plus Placebo Arm (G + Placebo)
11620829|NCT00476294||Group 2: G + AMD3100|G-CSF plus AMD3100 Arm (G + AMD3100)
11620830|NCT00476281|Other|abnormal glucose tolerance|abnormal glucose tolerance
11620831|NCT00476268|Experimental|beclometasone /formoterol|beclomethasone dipropionate 100 µg plus formoterol 6 µg pMDI
11620832|NCT00476268|Active Comparator|Beclomethasone|Beclomethasone dipropionate (BecotideTM) 250 µg/unit dose pMDI aerosol via CFC propellant.
11620833|NCT00476268|Active Comparator|Formoterol powder 12 µg/unit dose|Formoterol powder 12 µg/unit dose (Foradil™)
11620834|NCT00476255|Active Comparator|Enhanced Standard Care|Instructional materials
11620835|NCT00476255|Experimental|Motivational Intervention|Motivational interview
11620836|NCT00476242|Experimental|Memantine and Vivitrol|intramuscular injection of Vivitrol 380 mg and 20 mg bid Memantine (PO)
11620837|NCT00476242|Placebo Comparator|Placebo and Vivitrol|intramuscular injection of Vivitrol 380 mg and Placebo
11620838|NCT00476229|Experimental|Radiation + Chemotherapy + BSCT|Total Lymphoid Irradiation (2 times) at 80 cGy daily for five days + Thymoglobulin 1.5 mg/kg intravenous 5 days + Rituximab 375 mg/m^2 intravenous on 4 different days + Blood stem cell transplant (BSCT)
11620839|NCT00476216|Experimental|Combination of Arixtra with chemotherapy|Carboplatin 6 AUC q 21 days; Paclitaxel 200 mg/m2 q 21 days. Cohort I: Arixtra 2.5 mg SQ qd x 21 days; Cohort II: Arixtra weight-based dose (D1-2)followed by Arixtra 2.5 SQ q day (D3-21)
11620840|NCT00476203|Experimental|1|Immediate yoga classes offered
11620841|NCT00476203|Other|2|Delayed yoga classes (after 6 months) offered [wait list control group]
11620842|NCT00476190|Experimental|Arm A|Complete remission achieved after Induction Phase
11620843|NCT00476190|Experimental|Arm B|Failure to achieve complete remission after the Induction Phase
11620844|NCT00476164|Experimental|Rituximab|Infusion of 2 x 1g of rituximab, 14 days apart
11620845|NCT00476164|Sham Comparator|2|
11620846|NCT00476151|Placebo Comparator|placebo cream|vehicle cream
11620847|NCT00476151|Active Comparator|amitriptyline 4% ketamine 2% cream|active topical cream
11620848|NCT00476125|Experimental|3 day ketogenic diet|
11620849|NCT00476125|Experimental|12 day ketogenic diet|
11620850|NCT00476125|Experimental|16 hour fast|
11620851|NCT00476112|Experimental|1|Atrial flutter duration of 3 hours to <45 days
11620852|NCT00476099|Experimental|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|
11620853|NCT00476099|Active Comparator|Budesonide 200 µg plus formoterol 6 µg DPI|
11620854|NCT00476099|Active Comparator|Formoterol 12 µg DPI|
11620855|NCT00476086|Experimental|Oxaliplatin/ Gemcitabine Then Radiation|Patients rcvd IV chemotherapy on days 1 and 15 of a 4-week cycle: gemcitabine 1000 mg/m2 and oxaliplatin 65 mg/m2 for up to 3 cycles. Two dose reductions per study drug were permitted. On study, chemotherapy was followed by radiation therapy (RT) within 4-6 weeks of last chemotherapy. RT regimen was tumor-volume directed.
11620856|NCT00476060|Experimental|A|
11620857|NCT00476060|Placebo Comparator|B|
11620858|NCT00476047|Experimental|Treatment (monoclonal antibody therapy)|Patients receive tositumomab and iodine I 131 tositumomab IV over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.
11621086|NCT00473811|Experimental|Low-GI|a low GI dietary education
11620859|NCT00476021|Experimental|Postplacental IUD insertion|immediate postplacental levonorgestrel-releasing IUD (Mirena) insertion
11620860|NCT00476021|Active Comparator|Delayed IUD insertion|delayed levonorgestrel-releasing IUD (Mirena) insertion (6-8 weeks after delivery)
11620861|NCT00476008|Placebo Comparator|Placebo|One tablet placebo morning and evening (BID) for 12 months
11620862|NCT00476008|Active Comparator|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months.
11620863|NCT00475982|Experimental|Arm 1: Weight Loss|Weight Loss Group
11620864|NCT00475982|Active Comparator|Arm 2: No Weight Loss|No Weight Loss Group
11620865|NCT00475956|Experimental|1|AZD2171 Monotherapy
11620866|NCT00475956|Experimental|2|AZD2171 + AZD0530
11620867|NCT00475930|Experimental|1|2% chlorhexidine gluconate impregnated cloths, self applied three times weekly
11620868|NCT00475930|Placebo Comparator|2|Comfort Bath cloths, self applied three times weekly
11620869|NCT00475917|Experimental|1|
11620870|NCT00475904|Active Comparator|amitriptyline 4% ketamine 2% cream, placebo capsules|Np-1 cream and placebo gabapentin
11620871|NCT00475904|Active Comparator|gabapentin capsules, placebo cream|gabapentin caps and placebo cream
11620872|NCT00475904|Placebo Comparator|placebo cream and capsules|placebo cream and capsules
11620873|NCT00475878|Placebo Comparator|placebo|
11620874|NCT00475878|Active Comparator|escitalopram|
11620875|NCT00475865|Placebo Comparator|Placebo + GA|Placebo (for teriflunomide) once daily concomitantly with glatiramer acetate (GA) for 24 weeks
11620876|NCT00475865|Experimental|Teriflunomide 7 mg + GA|Teriflunomide 7 mg once daily concomitantly with glatiramer acetate (GA) for 24 weeks
11620877|NCT00475865|Experimental|Teriflunomide 14 mg + GA|Teriflunomide 14 mg once daily concomitantly with glatiramer acetate (GA) for 24 weeks
11620878|NCT00475852|Experimental|001|Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
11620879|NCT00475852|Placebo Comparator|002|Placebo matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
11620880|NCT00475839|Active Comparator|Tension-free Vaginal Tape|
11620881|NCT00475839|Active Comparator|Monarc Sub-fascial hammock|
11620882|NCT00475787|Experimental|Spinal Manipulative therapy|Spinal manipulation involves high velocity low amplitude manipulation and flexion distraction and mobilization.
11620883|NCT00475787|Sham Comparator|Detuned Ultrasound|"Detuned Ultrasound involves utilizing an ultrasound machine that is set to 0 w/cm2 and US gel is applied to the spine for 11 minutes."
11620884|NCT00475761||Breast Cohort|Primary clinical- patients referred to diagnostic breast biopsy
11620885|NCT00475735|Experimental|MK-0249|Total time in the study will be ~10 weeks.
11620886|NCT00475735|Active Comparator|Concerta|Total time in the study will be ~10 weeks.
11620887|NCT00475735|Placebo Comparator|Placebo|Total time in the study will be ~10 weeks.
11620888|NCT00475722|Active Comparator|1 Healthy Eating|Healthy People 2010 Diet using an exchange list
11620889|NCT00475722|Experimental|2 Mediterranean|Mediterranean Diet using an exchange list
11620890|NCT00475709|Experimental|Trifecta Aortic Heart Valve|All subjects enrolled into the study are implanted with the Trifecta Aortic Heart Valve.
11620891|NCT00475683|Sham Comparator|regular measurments|Mouth wash with chlorexidin
11620892|NCT00475683|Experimental|Curucmol|mouth wash with curcumol and mouth wash with chlorexidin
11620893|NCT00475670|Active Comparator|Trastuzumab Monotherapy|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose on Day 1, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death.
11620894|NCT00475670|Experimental|Trastuzumab, Taxane|Participant received an initial loading dose of 4 mg/kg trastuzumab i.v. on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death; and concomitant taxane, which is either 100 milligrams per square meter (mg/m2) docetaxel i.v. every 3 weeks, or 75 mg/m2 weekly or 175 mg/m2 every 3 weeks paclitaxel for at least 18 weeks, or more at the discretion of the investigator.
11620895|NCT00475657|Experimental|A|
11620896|NCT00475644|Experimental|Enzastaurin|Enzastaurin: 1125 milligram (mg) loading dose then 500 mg, oral daily, up to 3 years
11620897|NCT00475618|Experimental|Fluoride Varnish|Professional cleaning + education + fluoride vanish
11620898|NCT00475618|Active Comparator|Fluoride Toothpaste 500 ppm|Professional cleaning + education + fluoride toothpaste 500 ppm
11620899|NCT00475618|Active Comparator|No fluoride toothpaste|Professional cleaning + education + no fluoride toothpaste
11620900|NCT00475605||1. Protopic Exposure|Pediatric subjects whose ages are/were <16 years at the time of first tacrolimus ointment exposure
11620901|NCT00475592|Experimental|Capsule Endoscopy|
11620902|NCT00475592|Active Comparator|Upper Gastrointestinal Endoscopy|
11620903|NCT00475566|Other|1|This is a prospective, non-randomized, single-arm, multi-center study. A projected 100 patients will receive the stent(s) in this study at approximately 10-15 European sites. The primary objective is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral or proximal popliteal lesions.
11620904|NCT00475553|Other|Group 2|Subject will use the nuvaring and if they developed breakthrough bleeding or spotting for more than 5 days on the 6th day the ring would be removed and would leave it out for 3 full days and reinsert the same ring the next day. All subjects would be filling out a daily diary or calendar which would rate their blood flow, pelvic pain, headaches, moods, how many pain pills were taken and how many pads, liners or tampons would be used.
11620905|NCT00475553|Other|Group 1|Subject is using the nuvaring continuously and it would be changed out monthly. If she develops breakthrough bleeding or spotting she does not remove the ring until it is her time to change it. All subjects would be filling out a daily diary or calendar which would rate their blood flow, pelvic pain, headaches, moods, how many pain pills were taken and how many pads, liners or tampons would be used.
11620906|NCT00475540|Active Comparator|Prolift mesh|vaginal prolapse repair with mesh
11621218|NCT00472381|Experimental|2|Insulin
11620907|NCT00475540|Active Comparator|Prolapse repair without mesh|vaginal prolapse repair without mesh
11620908|NCT00475527|No Intervention|iron only|Only iron therapy
11620909|NCT00475527|Experimental|iron + HP therapy|Iron + 'omeprazole,clarithromycin,amoxicillin (or metronidazole)
11620910|NCT00475501|Experimental|Arm 1|testosterone enanthate
11620911|NCT00475501|Experimental|Arm 2|finasteride
11620912|NCT00475501|Experimental|Arm 3|testosterone enanthate + finasteride
11620913|NCT00475501|Placebo Comparator|Arm 4|placebo
11620914|NCT00475488|Other|Group 1|Radial Artery versus Right Internal Thoracic Artery when used as a coronary conduit in patients undergoing multi-vessel coronary artery bypass grafting.
11620915|NCT00475488|Other|Group 2|Radial Artery versus Saphenous Vein when used as a coronary conduit in patients undergoing multi-vessel coronary artery bypass grafting.
11620916|NCT00475475|Experimental|1|Fructose-sweetened beverage Subjects will be asked to drink 4 servings of a beverage sweetened with 100% fructose per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
11620917|NCT00475475|Experimental|2|Glucose-sweetened beverage Subjects will be asked to drink 4 servings of a beverage sweetened with 100% glucose per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
11620918|NCT00475475|Placebo Comparator|3|Beverage sweetened with a non-caloric sweetener Subjects will be asked to drink 4 servings of a beverage sweetened with a non-caloric sweetener per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
11620919|NCT00475436|Experimental|Arm 1|
11620920|NCT00475423|Experimental|1|
11620921|NCT00475410|Experimental|ASCs|
11620922|NCT00475410|Experimental|ASCs+fibrin glue|
11620923|NCT00475410|Active Comparator|Fibrin glue|
11620924|NCT00475371|Experimental|1|MKC253 Inhalation Powder
11620925|NCT00475319|Placebo Comparator|Placebo|0% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
11620926|NCT00475319|Experimental|1% OPC-12759 ophthalmic suspension|1% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
11620927|NCT00475319|Experimental|2% OPC-12759 ophthalmic suspension|2% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
11620928|NCT00475306|Active Comparator|Metoclopramide 20+diphenhydramine|Metoclopramide 20 mg + diphenhydramine, delivered intravenously over 15 minutes
11620929|NCT00475306|Active Comparator|Metoclopramide 20+placebo|Metoclopramide 20 mg + placebo, delivered intravenously over 15 minutes
11620930|NCT00475306|Active Comparator|Metoclopramide 10 + placebo|Metoclopramide 10mg + placebo, delivered intravenously over 15 minutes
11620931|NCT00475306|Active Comparator|Metoclopramide 10+diphenhydramine|Metoclopramide 10 mg + diphenhydramine 25 mg, delivered intravenously over 15 minutes
11620932|NCT00475293|Experimental|1|
11620933|NCT00475280|Other|Geriatric assessment|
11620934|NCT00475241|Experimental|Prolonged Exposure Therapy|Prolonged exposure therapy for PTSD
11620935|NCT00475241|Active Comparator|Present Centered Therapy|Present centered therapy for PTSD
11620936|NCT00475228|Experimental|Arm I|Levonorgestrel IUD will be inserted immediately after completion of D&E
11620937|NCT00475228|Active Comparator|Arm 2|Levonorgestrel IUD will be inserted at standard time post-procedure (3-6 weeks post D&E procedure)
11620938|NCT00475215|Experimental|Rocuronium + Sugammadex 2.0 mg/kg|After the IV intubation dose (0.6 mg/kg) or last maintenance dose (0.15 mg/kg) of rocuronium, at reappearance of T2, participants will receive IV sugammadex 2.0 mg/kg.
11620939|NCT00475215|Experimental|Rocuronium + Sugammadex 4.0 mg/kg|After the IV intubation dose (0.6 mg/kg) or last maintenance dose (0.15 mg/kg) of rocuronium, at reappearance of T2, participants will receive IV sugammadex 4.0 mg/kg.
11620940|NCT00475189|Active Comparator|1|
11620941|NCT00475189|Active Comparator|II|loestrin 1/20 given 1 tab 21/7
11620942|NCT00475176|Experimental|S-Adenosyl Methionine|
11620943|NCT00475150|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral cediranib maleate QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
11620944|NCT00475137|Experimental|Lamotrigine Plus Antidepressant|Subjects will be randomized to one of two study arms at baseline. Those in the first treatment arm will be prescribed lamotrigine in addition to the antidepressant medication they were prescribed prior to study entry.
11620945|NCT00475137|Active Comparator|2. Lamotrigine Monotherapy|Subjects in the second treatment arm will discontinue their antidepressants and will be prescribed lamotrigine monotherapy. Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily.
11620946|NCT00475124|Experimental|1|Home Monitoring ON
11620947|NCT00475124|Active Comparator|2|Home Monitoring OFF
11620948|NCT00475111|Experimental|1|People in Group 1 will participate in CBT for Pain (CBT-P), which will focus on altering thought processes as a way to cope more effectively with pain.
11620949|NCT00475111|Experimental|2|People in Group 2 will participate in Mindfulness Medication for Emotion Regulation (MM-ER), a type of CBT that focuses on being more aware of one's emotions and regulating them.
11620950|NCT00475111|Experimental|3|Group 3 participants will serve as controls and receive educational information on the causes of, course of, and treatment for RA.
11620951|NCT00475098|Active Comparator|A|
11620952|NCT00475098|Experimental|B|
11620953|NCT00475085|Active Comparator|Arm I|Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
11620954|NCT00475085|Experimental|Arm II|Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
11620955|NCT00475085|Active Comparator|Arm III|Patients receive palonosetron hydrochloride IV and dexamethasone IV once on day 1, oral aprepitant once daily on days 1-3, and oral dexamethasone once daily and oral placebo twice daily on days 2 and 3.
11621219|NCT00472368|Experimental|LBH589|
11620956|NCT00475085|Experimental|Arm IV|Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and oral dexamethasone once daily on days 2 and 3.
11620957|NCT00475072|Experimental|1|
11620958|NCT00475059|Experimental|1|patients who received cimétidine
11620959|NCT00475033|Experimental|1|
11620960|NCT00475033|Active Comparator|2|
11620961|NCT00475020|Experimental|Fludarabine + Busulfan + Thymoglobulin|Fludarabine 40 mg/m^2 by vein daily over 1 hour x 4 days. Busulfan test dose = 32 mg/m^2 by vein x 1 day; 100 mg/m^2 by vein daily over 3 hours x 4 days. Thymoglobulin 2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor.
11620962|NCT00475007|Experimental|1|The experimental group will have an investigational medical device implanted in their lungs with an instrument known as a bronchoscope. This procedure is done without an incision
11620963|NCT00475007|Sham Comparator|2|The sham comparator group will be tested, treated and followed in an identical manner as the experimental group, except that no valves will be placed during the diagnostic bronchoscopy, the sham procedure.
11620964|NCT00474994|Experimental|Group A|Vascular connective tissue neoplasms, leiomyosarcoma, dermatofibrosarcoma protuberans (DFSP), desmoid tumors. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
11620965|NCT00474994|Experimental|Group B|High grade undifferentiated pleomorphic sarcoma (includes the older designation malignant fibrous histiocytoma [MFH]) and other non-GIST connective tissue tumors; may include carcinosarcomas.Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
11620966|NCT00474994|Experimental|Group C|Chordomas. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
11620967|NCT00474981|Experimental|1|IMNCI
11620968|NCT00474981|No Intervention|2|Control
11620969|NCT00474968||Arm 1 - Experimental|e2 Cell Collector [SoftPAP(R)]
11620970|NCT00474968||Arm 2 - Control|Brush/spatula
11620971|NCT00474955|Experimental|Peginterferon Alpha-2a|Eligible participants will be administered peginterferon alpha-2a [Pegasys] (40 kilo Dalton), 180 micrograms as a subcutaneous injection, once in a week, for 48 weeks. Participants with a calculated glomerular filtration rate of <15 milliliter /minute will be administered a reduced dose of 135 mcg as a subcutaneous injection, once in a week, for 48 weeks.
11620972|NCT00474929|Experimental|Multiple Myeloma|Phase I: Dose level 0: Sorafenib 200 mg twice daily, RAD001 5mg every other day; Dose level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day; Dose level 2: Sorafenib 400 mg twice daily, RAD001 5mg every day; Dose level 3: Sorafenib 400 mg twice daily, RAD001 10mg every day; Phase II: Sorafenib 200 mg twice daily, RAD001 5mg every day;
11620973|NCT00474929|Experimental|Lymphoma|Phase I: Dose level 0: Sorafenib 200 mg twice daily, RAD001 5mg every other day; Dose level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day; Dose level 2: Sorafenib 400 mg twice daily, RAD001 5mg every day; Dose level 3: Sorafenib 400 mg twice daily, RAD001 10mg every day; Phase II: Sorafenib 200 mg twice daily, RAD001 5mg every day;
11620974|NCT00474916|Experimental|KRN5500|KRN5500 escalating dose of .6, 1.2, 1.8, or 2.2 mg/m2 in IV infusion of normal saline
11620975|NCT00474916|Placebo Comparator|Normal Saline|Placebo consists of IV infusion of normal saline
11620976|NCT00474903|Active Comparator|Arm I (placebo, esomeprazole magnesium)|Patients receive two oral placebos once daily and oral esomeprazole magnesium (40 mg, twice daily).
11620977|NCT00474903|Experimental|Arm II (low-dose aspirin, esomeprazole magnesium)|Patients receive both an oral placebo and acetylsalicylic acid (81 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
11620978|NCT00474903|Experimental|Arm III (higher-dose aspirin, esomeprazole magnesium)|Patients receive both an oral placebo and acetylsalicylic acid (325 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
11620979|NCT00474851|Experimental|Norethindrone acetate + estrogens|Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + conjugated equine estrogens 0.625 mg by mouth daily for the 12 months of study participation.
11620980|NCT00474851|Placebo Comparator|norethindrone acetate + placebo|Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + a placebo capsule by mouth daily for the 12 months of study participation.
11620981|NCT00474838|Active Comparator|Oral AntiDiabetic Drug|glimepiride and metformin and/or once daily glargine
11620982|NCT00474838|Experimental|intensive insulin group|insulin glargine insulin glulisine
11620983|NCT00474825|Active Comparator|1|Hyperbaric Oxygen twice weekly (Monday & Friday) with Radiation and Chemotherapy
11620984|NCT00474825|Active Comparator|2|Hyperbaric Oxygen three times per week (Monday, Wednesday & Friday) with Radiation and Chemotherapy.
11620985|NCT00474825|Active Comparator|3|Hyperbaric Oxygen Five times per week (Monday through Friday) with Radiation and Chemotherapy
11620986|NCT00474812|Experimental|Dasatinib Treatment|Patients receive oral dasatinib twice daily on days 1-28.
11620987|NCT00474799|Experimental|A|MNS075 7.5mg q1h
11620988|NCT00474799|Experimental|B|MNS075 15mg q3h
11620989|NCT00474786|Experimental|1|
11620990|NCT00474786|Experimental|2|
11620991|NCT00474760|Experimental|1|
11620992|NCT00474708|Experimental|1|1.Effexor XR Group
11620993|NCT00474708|Active Comparator|2|2.SSRI or Conventional Antidepressant Group
11620994|NCT00474695||1|Active approved treatment
11620995|NCT00474669|Experimental|Docetaxel|Intraperitoneal Docetaxel administered with heat
11620996|NCT00474630|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/ day with ancillary therapy
11620997|NCT00474630|Placebo Comparator|Placebo|Placebo with ancillary therapy
11620998|NCT00474617|Experimental|Participants 18 to 64 years old|Participants to receive an intravenous (IV) single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of second twitch (T2) with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
11620999|NCT00474617|Experimental|Participants 65 to 74 years old|Participants to receive an IV single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of T2 with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
11621000|NCT00474617|Experimental|Participants 75 years and older|Participants to receive an IV single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of T2 with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
11621001|NCT00474604|Active Comparator|Participants without breast cancer|
11621002|NCT00474604|Experimental|Participants with breast cancer|
11621003|NCT00474552|Experimental|1|Experimental-Placebo Comparator
11621004|NCT00474539|Experimental|1|
11621005|NCT00474539|Active Comparator|2|
11621006|NCT00474526|Experimental|US1A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:
~MenACWY: 2, 4, 6, and 12 months
~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
~Pneumococcal, HAV, and MMR-V: 12 months"
11621007|NCT00474526|Experimental|US1B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:
~MenACWY: 2, 4, 6, and 13 months
~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
~Pneumococcal, HAV, and MMR-V: 12 months"
11621008|NCT00474526|Experimental|US2 (Infant Vaccines Only)|"Received vaccines:
~MenACWY: 12 and 15 months
~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
~Pneumococcal, HAV, and MMR-V: 12 months"
11621009|NCT00474526|Experimental|US3 (MenACWY-CRM + Infant Vaccines)|"Received vaccines:
~MenACWY: 2, 4, 6, and 12 months
~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
~Pneumococcal, HAV, and MMR-V: 12 months"
11621010|NCT00474526|Experimental|US4A (Infant Vaccines Only)|"Received vaccines:
~MenACWY: 12 and 15 months
~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
~Pneumococcal, HAV, and MMR-V: 12 months"
11621011|NCT00474526|Experimental|US4B (Infant Vaccines Only)|"Received vaccines:
~MenACWY: 13 and 15 months DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
~Pneumococcal, HAV, and MMR-V: 12 months"
11621012|NCT00474526|Experimental|US4C (Infant Vaccines Only)|"Received vaccines:
~MenACWY: 18 months
~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
~Pneumococcal, HAV, and MMR-V: 12 months"
11621013|NCT00474526|Experimental|LA1A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:
~MenACWY: 2, 6, and 12 months
~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months Pneumococcal, HAV, and MMR-V: 12 months"
11621014|NCT00474526|Experimental|LA1B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:
~MenACWY: 2, 6, and 13 months
~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
~Pneumococcal, HAV, and MMR-V: 12 months"
11621015|NCT00474526|Experimental|LA2 (Infant Vaccines Only)|"Received vaccines:
~MenACWY: 12 and 15 months
~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
~Pneumococcal, HAV, and MMR-V: 12 months"
11621016|NCT00474526|Experimental|LA3A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:
~MenACWY: 2, 4, 6, and 16 months
~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
~DTaP, Hib: 16 months
~Pneumococcal, HAV, and MMR-V: 12 months"
11621017|NCT00474526|Experimental|LA3B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:
~MenACWY: 2, 4, 6, and 17 months
~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
~DTaP, Hib: 16 months
~Pneumococcal, HAV, and MMR-V: 12 months"
11621018|NCT00474526|Experimental|LA4 (Infant Vaccines Only)|"Received vaccines:
~MenACWY: 12 and 15 months
~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
~DTaP, Hib: 15 months
~Pneumococcal, HAV, and MMR-V: 12 months"
11621019|NCT00474526|Experimental|LA5 (MenACWY-CRM + Infant Vaccines)|"Received vaccines:
~MenACWY: 2, 4, 6, and 12 months
~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
~Pneumococcal, HAV, and MMR-V: 12 months"
11621020|NCT00474526|Experimental|LA6A (Infant Vaccines Only)|"Received vaccines:
~MenACWY: 12, and 15 months
~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
~Pneumococcal, HAV, and MMR-V: 12 months"
11621021|NCT00474526|Experimental|LA6B (Infant Vaccines Only)|"Received vaccines:
~MenACWY: 13 and 15 months
~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
~Pneumococcal, HAV, and MMR-V: 12 months"
11621022|NCT00474526|Experimental|LA6C (Infant Vaccines Only)|"Received vaccines:
~MenACWY: 18 months
~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months
~Pneumococcal, HAV, and MMR-V: 12 months"
11621023|NCT00474487|Experimental|Novartis MenACWY Vaccine (19 to 55 Years)|Novartis meningococcal ACWY conjugate vaccine administered to subjects 19 years to 55 years
11621024|NCT00474487|Active Comparator|Licensed polysaccharide vaccine|Licensed meningococcal ACWY polysaccharide vaccine
11621025|NCT00474487|Active Comparator|Licensed Conjugate Vaccine|Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
11621026|NCT00474487|Experimental|Novartis MenACWY Vaccine (56 to 65 Years)|Novartis meningococcal ACWY conjugate vaccine administered to subjects 56 years to 65 years
11621027|NCT00474461|Experimental|Treatment group|Patients in this arm received intracoronary expanded autologous c-kit positive cardiac stem cells.
11621028|NCT00474461|No Intervention|Control group|Patients in this arm did not receive any intervention.
11621029|NCT00474383|Experimental|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) tablet or capsule will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study, along with prednisone/prednisolone 5 mg tablet orally twice daily or dexamethasone 0.5 mg tablet orally once daily.
11621030|NCT00474370|Experimental|Test Arm|Vicriviroc 30 mg QD
11621031|NCT00474370|Placebo Comparator|Placebo Control Arm|Placebo
11621032|NCT00474357|Experimental|1|Bipolar patients participating in psychoeducation intervention
11621033|NCT00474357|No Intervention|2|bipolar patients who do not participate in psychoeducation group
11621034|NCT00474357|No Intervention|3|Therapists will complete questionnaires regarding myths about bipolar patients, no intervention
11621035|NCT00474318||Adolescents with severe obesity|Adolescents and young adults with severe obesity
11621036|NCT00474266|Experimental|Nimenrix + Priorix-Tetra Group|Subjects received 1 dose of Nimenrix vaccine and 1 dose of Priorix-Tetra vaccine on Day 0 and a second dose of Priorix-Tetra vaccine on Day 84.
11621037|NCT00474266|Experimental|Nimenrix Group|Subjects received 1 dose of Nimenrix vaccine on Day 0 followed by 2 doses of Priorix-Tetra vaccine, respectively 42 and 84 days later.
11621038|NCT00474266|Active Comparator|Priorix-Tetra Group|Subjects received 1 dose of Priorix-Tetra vaccine on Day 0, 1 dose of Meningitec vaccine on Day 42 and a second dose of Priorix-Tetra vaccine on Day 84.
11621039|NCT00474266|Active Comparator|Meningitec Group|Subjects received 1 dose of Meningitec vaccine on Day 0 followed by 2 doses of Priorix-Tetra vaccine, respectively 42 and 84 days later.
11621040|NCT00474253|Experimental|Rocuronium + Sugammadex|Participants were to receive a single bolus dose of 1.2 mg/kg rocuronium. Three minutes after the start of the rocuronium administration, they were to receive a single bolus dose of 16.0 mg/kg sugammadex.
11621041|NCT00474253|Active Comparator|Succinylcholine|Participants were to receive a single bolus dose of 1.0 mg/kg succinylcholine and allowed to recovery spontaneously from neuromuscular blockade.
11621042|NCT00474240|Placebo Comparator|1|
11621043|NCT00474240|Active Comparator|2|
11621044|NCT00474240|Experimental|3|
11621045|NCT00474240|Experimental|4|
11621046|NCT00474240|Experimental|5|
11621047|NCT00474240|Experimental|6|
11621048|NCT00474227|Experimental|A|behavioral intervention, group therapy including nutritional guidance and physical exercise
11621049|NCT00474227|No Intervention|B|comparison group, one time explanation of importance of proper nutrition. This group receives no group therapy or organized exercise sessions or nutritional guidance. They are wait listed for this program.
11621050|NCT00474201|Sham Comparator|Gemfibrozil PK without LPV/r|"Subjects received a single 600 mg dose of gemfibrozil without concurrent lopinavir-ritonavir 400mg/100mg; this is the control arm of a crossover study design."
11621051|NCT00474201|Experimental|Gemfibrozil PK after 2 weeks of LPV/r|Single dose (600 mg) Gemfibrozil pharmacokinetics (i.e. plasma concentrations collected over time to calculate area under the concentration vs. time curve) assessed after 14.5 days of lopinavir/ritonavir (400/100 mg twice daily) administration.
11621052|NCT00474188|Experimental|Single Arm|
11621053|NCT00474175|Placebo Comparator|1|Placebo control
11621054|NCT00474175|Active Comparator|2|10% benzocaine gel formulation
11621055|NCT00474175|Active Comparator|3|20% benzocaine gel formulation
11621056|NCT00474136|Experimental|1|
11621057|NCT00474136|Experimental|2|
11621058|NCT00474136|Active Comparator|3|
11621059|NCT00474123|Active Comparator|Simvastatin 80 mg|Patients were treated with simvastatin 80 mg for 6 weeks
11621060|NCT00474123|Active Comparator|Ezetimibe 10 mg / Simvastatin 20 mg|Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks
11621061|NCT00474110|Experimental|1|Ketamine and hydromorphone for patient-controlled relief in children's mucositis.
11621062|NCT00474058|Experimental|Rotigotine|Rotigotine transdermal patch
11621063|NCT00474058|Placebo Comparator|Placebo|Placebo transdermal patch
11621064|NCT00474045|Experimental|Insulin detemir|Individually adjusted insulin detemir injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn
11621065|NCT00474045|Active Comparator|Neutral Protamine Hagedorn (NPH) insulin|Individually adjusted NPH insulin injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn
11621066|NCT00474019|Experimental|1|Based on age and/or weight dose of esomeprazole IV qd in milligrams 20,40,10,20,10, 1.0 mg/kg, 0,5 mg/kg
11621067|NCT00474006|Active Comparator|arm I|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 45 mg/m2/d civ x 3 days
11621068|NCT00473980|Experimental|Drug|Treatment with indomethacin or celecoxib
11621069|NCT00473980|Sham Comparator|SHAM|Sham treatment
11621070|NCT00473967|Experimental|10 mcg Na-ASP-2/Alhydrogel|Na-ASP-2 Hookworm Vaccine
11621071|NCT00473967|Active Comparator|Butang hepatitis B vaccine|Hepatitis B Vaccine - comparator vaccine
11621072|NCT00473954|Experimental|EGEN-001|
11621073|NCT00473941|No Intervention|1|Writing in a journal 15 minutes a day
11621074|NCT00473941|No Intervention|2|Control Writing in a journal 15 minutes a day
11621075|NCT00473889|Experimental|1|vorinostat; IV paclitaxel; IV carboplatin
11621076|NCT00473889|Placebo Comparator|2|Placebo; IV paclitaxel; IV carboplatin
11621077|NCT00473876|Active Comparator|1|Receiving Metformin for 4 months
11621078|NCT00473876|Placebo Comparator|2|Matched Placebo for 4 months
11621079|NCT00473863|Experimental|intervention|Receives CCTA
11621080|NCT00473863|No Intervention|Control|
11621081|NCT00473837|Active Comparator|Treatment|Subjects initially treated with Co-arthemeter, and then continued on weekly chloroquine till day 90
11621082|NCT00473837|Placebo Comparator|Control|Subjects initially treated with Co-arthemeter, and then continued on weekly placebo till day 90
11621083|NCT00473824|Experimental|Civacir Treated|Hepatitis C Immune Globulin Intravenous (Human) 5% [Civacir], 18 infusions total, per schedule, of Civacir 300 or 400 mg/kg of body weight, with standard post-transplant site specific routine immunosuppressant therapy .
11621084|NCT00473824|No Intervention|Observational Control|Observation on standard post-transplant site specific routine immunosuppressant therapy without infusions of Hepatitis C Immune Globulin Intravenous (Human) 5% [Civacir].
11621085|NCT00473811|Active Comparator|ADA diet|Patients will be encouarged to consume foods consisted with ADA dietary recommendation
11621087|NCT00473798||A|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
11621088|NCT00473798||A'|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
11621089|NCT00473798||B|Patients who have consented to participate in a randomized trial of optical spectroscopy.
11621090|NCT00473798||C|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
11621091|NCT00473798||D|Health care providers.
11621092|NCT00473772|Active Comparator|Cypher Stent|
11621093|NCT00473772|Experimental|DEBlue Stent|
11621094|NCT00473746|Experimental|Phase I Dose Escalation|
11621095|NCT00473746|Experimental|Phase II Dose Treatment|
11621096|NCT00473720|Experimental|satraplatin abraxane|Satraplatin and abraxane will be given in escalating cohorts on a 3 + 3 design from satraplatin 40mg/m2 and abraxane 80mg/m2
11621097|NCT00473707|Active Comparator|1|Active management of the third stage of labor- oxytocin infusion after delivery of fetus, gentle cord traction, and fundal massage
11621098|NCT00473707|Other|2|Expectant management of the third stage of labor
11621099|NCT00473694|Experimental|rocuronium+sugammadex|Participants received a single bolus dose of 0.60 mg/kg rocuronium prior to intubation. The neuromuscular block was maintained with 0.15 mg/kg rocuronium if needed. At 1-2 post-tetanic counts (PTC) and after the last dose of rocuronium, a single bolus dose of 4.0 mg/kg sugammadex was administered.
11621100|NCT00473694|Active Comparator|rocuronium+neostigmine|Participants received a single bolus dose of 0.60 mg/kg rocuronium prior to intubation. The neuromuscular block was maintained with 0.15 mg/kg rocuronium if needed. At 1-2 PTC and after the last dose of rocuronium, a single bolus dose of 70.0 μg/kg neostigmine (up to a maximum dose of 5 mg) was administered in combination with 14.0 μg/kg glycopyrrolate.
11621101|NCT00473694|Experimental|vecuronium+sugammadex|Participants received a single bolus dose of 0.1 mg/kg vecuronium prior to intubation. The neuromuscular block was maintained with 0.015 mg/kg vecuronium if needed. At 1-2 PTC and after the last dose of vecuronium, a single bolus dose of 4.0 mg/kg sugammadex was administered.
11621102|NCT00473694|Active Comparator|vecuronium+neostigmine|Participants received a single bolus dose of 0.1 mg/kg vecuronium prior to intubation. The neuromuscular block was maintained with 0.015 mg/kg vecuronium if needed. At 1-2 PTC and after the last dose of vecuronium, a single bolus dose of 70.0 μg/kg neostigmine (up to a maximum dose of 5 mg) was administered in combination with 14.0 μg/kg glycopyrrolate.
11621103|NCT00473668|Experimental|TRITANRIX-HEPB/HIBERIX KFT. GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ Kft. vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
11621104|NCT00473668|Active Comparator|TRITANRIX-HEPB/HIBERIX LD GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ low-dose (LD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
11621105|NCT00473668|Active Comparator|TRITANRIX-HEPB/HIBERIX HD GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ high-dose (HD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
11621106|NCT00473642|Experimental|1|Standard Fluence Photodynamic Therapy combined with ranibizumab
11621107|NCT00473642|Experimental|2|Verteporfin at 50% fluence photodynamic therapy combined with ranibizumab
11621108|NCT00473642|Active Comparator|3|Ranibizumab monotherapy
11621109|NCT00473616|Experimental|1|AZD7762 monotherapy followed by AZD7762 + irinotecan
11621110|NCT00473603|Experimental|LHI|to perform an i.v. lipid heparin infusion for 4 h
11621111|NCT00473603|Sham Comparator|SHI|to perform an i.v. saline heparin infusion for 4 h
11621112|NCT00473590|Experimental|Bortezomib + bevacizumab|Participants received bortezomib 1.3 mg/m^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and bevacizumab 15 mg/kg administered by intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. After completion of 8 cycles, participants could continue to receive bevacizumab as monotherapy until disease progression.
11621113|NCT00473590|Active Comparator|Bortezomib + placebo|Participants received bortezomib 1.3 mg/m^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and placebo intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. At the completion of the 8-cycle treatment phase, participants entered the observation phase until disease progression.
11621114|NCT00473564|Experimental|TORS Candidates|Participants who consented to undergo transoral robotic-assisted surgery using the da Vinci® Robotic System
11621115|NCT00473551|Experimental|Anti-Third Party T Lymphocytes + Nonmyeloablative SCT|"Anti-Third Party CTL (Cytolytic T-lymphocytes) with Nonmyeloablative SCT (Stem Cell Transplantation)
~Rituximab 375 mg/m^2 intravenously over several hours on Day -13, followed by 1000 mg/m^2 intravenously on Days -6, 1, and 8; + Cyclophosphamide 50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine; + Fludarabine 40 mg/m^2 intravenously over 30 minutes once per day for 4 days, starting Day -6; + Radiation 2Gy Total body radiation day before transplantation + Stem Cell Transplantation + Intravenous infusion of Anti-third Party CTLs."
11621116|NCT00473525|Placebo Comparator|Placebo|
11621117|NCT00473525|Experimental|PF-00734200 10 mg QD|
11621118|NCT00473525|Experimental|PF-00734200 20 mg QD|
11621119|NCT00473525|Experimental|PF-00734200 5 mg QD|
11621120|NCT00473525|Experimental|PF-00734200 2 mg QD|
11621121|NCT00473512|Experimental|Abiraterone acetate|Abiraterone acetate 250 mg up to a maximum of 2000 mg capsules will be given orally daily for 28-day treatment period to determine the MTD in Phase 1 of the study. Participants will receive MTD of abiraterone acetate for 12 cycles (28 day each) in Phase 2 of the study. Dexamethasone 0.5 mg will be given orally (If participants have disease progression) daily up to 12 cycles.
11621122|NCT00473499|Experimental|DEBlue stent|Paclitaxel coated balloon with CoCr stent mounted on it
11621123|NCT00473499|Active Comparator|Cypher stent|
11621124|NCT00473499|Placebo Comparator|Coroflex Blue stent|
11621220|NCT00472329|No Intervention|Fludarabine and 400cGY TBI|
11621125|NCT00473486|Active Comparator|1|Pemetrexed, Carboplatin plus Sorafenib in the first-line treatment of patients with stage IIIb or IV NSCLC
11621126|NCT00473486|Placebo Comparator|2|Pemetrexed, Carboplatin plus placebo in the first-line treatment of patients with stage IIIb or IV NSCLC
11621127|NCT00473473|Experimental|1|potassium bichromate
11621128|NCT00473473|Placebo Comparator|2|placebo
11621129|NCT00473460|Experimental|Arm 1|
11621130|NCT00473460|Placebo Comparator|Arm 2|
11621131|NCT00473434|Experimental|001|Paliperidone3mg or 6mg or 9mg or 12mg once daily for 52 weeks
11621132|NCT00473382|Experimental|Ranibizumab 0.3 mg|Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
11621133|NCT00473382|Experimental|Ranibizumab 0.5 mg|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
11621134|NCT00473382|Sham Comparator|Sham injection/ranibizumab 0.5 mg|Patients received a sham intravitreal injection monthly for 24 months. Patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
11621135|NCT00473356|Active Comparator|1|to receive amino acid supplement
11621136|NCT00473356|No Intervention|2|no amino acid supplement
11621137|NCT00473330|Experimental|Ranibizumab 0.3 mg|Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
11621138|NCT00473330|Experimental|Ranibizumab 0.5 mg|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
11621139|NCT00473330|Sham Comparator|Sham injection/ranibizumab 0.5 mg|Patients received a sham intravitreal injection monthly for 24 months. Patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
11621140|NCT00473317|Experimental|1|All subjects in this study will be in the active arm
11621141|NCT00473291||Patients with pleural effusion|Patients diagnosed with pleural effusion and presenting for treatment
11621142|NCT00473265|Experimental|PTH(1-84)|100mcg of PTH1-84 every other day, every day, or every three days
11621143|NCT00473252||Hemodialysis patients|
11621144|NCT00473252||Renal transplant patients|
11621145|NCT00473239|Experimental|cholecalciferol|A single dose of 100,000 IU vitamin D
11621146|NCT00473239|No Intervention|Control|No drug was given
11621147|NCT00473200|Active Comparator|S-adenosylmethionine|S-adenosylmethionine
11621148|NCT00473200|Placebo Comparator|Placebo|Placebo
11621149|NCT00473174|Active Comparator|1|Ramipril on awakening
11621150|NCT00473174|Active Comparator|2|Ramipril at bedtime
11621151|NCT00473148|Experimental|1|BNP-guided treatment (Furosemide)
11621152|NCT00473148|No Intervention|2|
11621153|NCT00473135|Experimental|1|Two subcutaneous vaccinations with rDEN1delta30 into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on Day 120.
11621154|NCT00473135|Experimental|2|Two subcutaneous vaccinations with rDEN1delta30 into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on Day 180.
11621155|NCT00473135|Placebo Comparator|3|Two subcutaneous vaccinations with placebo into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on either Day 120 or 180, depending on arm assignment.
11621156|NCT00473122|Other|Delayed-Immediate Breast Reconstruction|Delayed-Immediate Reconstruction: If radiation therapy (XRT) not needed, immediate reconstruction. If XRT is needed, delayed reconstruction until XRT complete.
11621157|NCT00473109|Experimental|Dialysis without systemic heparinization|Dialysis without systemic heparinization
11621158|NCT00473083|Experimental|Arm 1: Prophylactic Treatment|Participants will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
11621159|NCT00473083|Experimental|Arm 2: Reactive Treatment|"Pts will receive treatment at initiation of rash. Tx is dependent on grading of rash as follows:
~Grade 1 or 2A: Topical clindamycin 2%, with hydrocortisone 1% in lotion base applied twice daily until resolution of rash by one grade
~Grade 2B: Topical clindamycin 2%, with hydrocortisone 1% in lotion base applied 2x daily and oral minocycline 100mg 2x daily for a min. of 4 weeks and continuing thereafter, as required, until resolution of rash by 1 grade. Scalp lesions will be treated with a topical clindamycin 2%, triamcinolone acetonide 0.1% soln.
~Grade 3: Pts will discontinue tx with erlotinib 150mg for 1 week and restart at 100mg once daily.
~Tx with topical clindamycin 2%, with hydrocortisone 1% in lotion base applied 2x daily and oral minocycline 100mg 2x daily for a min. of 4 weeks and continuing thereafter, as required, until resolution of rash to Grade 1 or 2A. Scalp lesions will be treated with a topical clindamycin 2%, triamcinolone acetonide 0.1% soln."
11621160|NCT00473083|Experimental|Arm 3: No Treatment Unless Severe (Grade 3)|This is the control group. Patients will be treated only if grade 3 rash develops. For grade 3 rash, treatment will be in accordance with that of Grade 3 rash in Treatment Arm 2.
11621161|NCT00473031|Experimental|1|High Protein
11621162|NCT00473031|Active Comparator|2|Normal Protein
11621263|NCT00471770||2|2.SPN group:enrolled subjects who have no isolated pneumococcal
11621163|NCT00472966|Other|1|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
11621164|NCT00472953|Experimental|A|
11621165|NCT00472953|Active Comparator|B|
11621166|NCT00472862|Experimental|2|Cognitive training
11621167|NCT00472862|Active Comparator|1|OPUS psychosocial treatment alone
11621168|NCT00472849|Experimental|OFAR (Phase I)|Oxaliplatin starting dose 30 mg/m^2/day over 2 hours on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily intravenous (IV) over 30 minutes on days 2-3, 2-4, or 2-5 until maximum tolerated dose reached. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose (MTD) reached. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
11621169|NCT00472849|Experimental|OFAR MTD (Phase II)|Oxaliplatin 25 mg/m^2 IV per day MTD on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily IV over 30 minutes on days 2-4. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after fludarabine dose started, on days 2-4. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
11621170|NCT00472836|Experimental|Normal renal function|
11621171|NCT00472836|Experimental|Severe renal impairment|
11621172|NCT00472823|Experimental|vitamin D3 400 IU daily|vitamin D3 400 IU daily
11621173|NCT00472823|Experimental|vitamin D3 800 IU daily|vitamin D3 800 IU daily
11621174|NCT00472823|Experimental|vitamin D3 1600 IU daily|vitamin D3 1600 IU daily
11621175|NCT00472823|Experimental|vitamin D3 2400 IU daily|vitamin D3 2400 IU daily
11621176|NCT00472823|Experimental|vitamin D3 3200 IU daily|vitamin D3 3200 IU daily
11621177|NCT00472823|Experimental|vitamin D3 4000 IU daily|vitamin D3 4000 IU daily
11621178|NCT00472823|Experimental|vitamin D3 4800 IU daily|vitamin D3 4800 IU daily
11621179|NCT00472823|Placebo Comparator|placebo|matched to vitamin D tablet
11621180|NCT00472810|Experimental|1|20 patients will be recruited according to the enrollment acceptance criteria.Randomisation is performed using a sealed envelope system, where 40 shuffled envelopes designating the surgery to either trabeculectomy with mitomycin-C (MMC) and trabeculectomy with ologen™ Collagen matrix must be open before surgery. Then, patients are allocated and trabeculectomy is performed.If ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
11621181|NCT00472810|Active Comparator|2|Following ethics committee approval, 20 patients with uncontrolled glaucoma will be randomised to trabeculectomy with mitomycin -C. Randomisation is performed. Then, trabeculectomy is performed
11621182|NCT00472797|Active Comparator|1|Rebif New Formulation - Non Titrated
11621183|NCT00472797|Active Comparator|2|Rebif New Formulation - Titrated
11621184|NCT00472758|Active Comparator|1|MEDI 545
11621185|NCT00472758|Placebo Comparator|2|Placebo IV
11621186|NCT00472745|Experimental|WL|weight loss (WL) with nutrition/behavior modification counseling
11621187|NCT00472745|Active Comparator|WM|Weight Maintenance (WM)
11621188|NCT00472732||1|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD
11621189|NCT00472732||2|Healthy males or females without known medical or metabolic disorder (control group)
11621190|NCT00472719|Experimental|1|Participants in this group will receive an injection of the adenoviral vector vaccine VRC-HIVADV027-00VP at study entry and an injection of VRC-HIVADV038-00-VP at Month 3. There will be 9 study visits for this arm.
11621191|NCT00472719|Experimental|2|Participants in this group will receive an injection of VRC-HIVADV038-00-VP at study entry and an injection of VRC-HIVADV027-00-VP at Month 3. There will be 9 study visits for this group.
11621192|NCT00472719|Experimental|3|Participants in this group will receive an injection of the VRC-HIVDNA044-00-VP vaccine at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV027-00-VPat Month 6. There will be 13 study visits for this group.
11621193|NCT00472719|Experimental|4|Participants in this group will receive an injection of VRC-HIVDNA044-00-VP at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV038-00-VP at Month 6. There will be 13 study visits for this group.
11621194|NCT00472706|Active Comparator|1|Excision
11621195|NCT00472706|Active Comparator|2|Photodynamic therapy
11621196|NCT00472693|Experimental|Bevacizumab and ABI-007 (Abraxane)|Bevacizumab and ABI-007 (Abraxane)
11621197|NCT00472680|Experimental|1|High Dietary Protein
11621198|NCT00472680|Active Comparator|2|Normal Dietary Protein
11621199|NCT00472667|Experimental|1|Procalcitonin guided strategy
11621200|NCT00472654|Placebo Comparator|WL|
11621201|NCT00472654|Experimental|WL + D|
11621202|NCT00472654|Placebo Comparator|WM|
11621203|NCT00472654|Active Comparator|WM + D|
11621204|NCT00472641|Experimental|Ziprasidone/Geodon|Ziprasidone/Geodon up to 320 mg per day
11621205|NCT00472589||1|Healthy women
11621206|NCT00472589||2|Women with breast cancer
11621207|NCT00472576|Experimental|Placebo then MK-0657|Double-blind crossover administration of placebo then MK-0657 (4-8 mg/day)
11621208|NCT00472576|Experimental|MK-0657 then Placebo|Double-blind crossover administration of MK-0657 (4-8 mg/day) then placebo
11621209|NCT00472498||1|"Case:
~Patients resuscitated after 2001"
11621210|NCT00472498||2|"Control:
~Patients who suffer cardiac arrests after 2001."
11621211|NCT00472472|Placebo Comparator|1|PTA
11621212|NCT00472472|Active Comparator|2|PTA with Paccocath
11621213|NCT00472446|Experimental|cervical block before surgery|bilateral superficial cervical block, placed before surgery (just before skin incision)
11621214|NCT00472446|Placebo Comparator|placebo cervical block before surgery|placebo bilateral superficial cervical block with saline, placed before surgery (just before skin incision)
11621215|NCT00472446|Experimental|cervical block after surgery|bilateral superficial cervical block, placed after surgery (just after skin closure)
11621216|NCT00472446|Placebo Comparator|placebo cervical block after surgery|placebo bilateral superficial cervical block with saline, placed after surgery (just after skin closure)
11621217|NCT00472420|Experimental|1|
11621221|NCT00472303|Placebo Comparator|Matching Placebo after Tapentadol in Titration Phase|Oral Tapentadol 100 mg to 250 mg twice daily. Participants randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off the tapentadol dose they had received in the Titration Phase. From the 4th day (Day 18) all participants received matching placebo in the maintenance (i.e. randomized withdrawal) phase.
11621222|NCT00472303|Active Comparator|Morphine Controlled Release|Oral Morphine 40 mg to 100 mg twice daily. Capsule taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Maintenance phase: continuing on dose level established in titration phase.
11621223|NCT00472303|Experimental|Tapentadol Prolonged Release|Oral Tapentadol 100 mg to 250 mg twice daily. Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses.
11621224|NCT00472290|Experimental|Open Label Romiplostim (formerly AMG 531)|
11621225|NCT00472264||Single arm study (Healthy volunteers & COPD subjects)|A single arm study PET imaging is carried out twice during the first week of the study and again 4 weeks later in both Healthy volunteers and COPD subjects.
11621226|NCT00472238|Experimental|1, Training|Group for training therapy
11621227|NCT00472238|Active Comparator|2, Control|
11621228|NCT00472225|Experimental|1|Rituximab treatment arm
11621229|NCT00472212|Experimental|Spectacles|Spectacles with hyperopic lenses
11621230|NCT00472212|Placebo Comparator|Control|Spectacles with placebo lenses
11621231|NCT00472199|Experimental|Pramipexole|4 weeks of flexible dose-titration (to optimise efficacy and tolerability), starting at 0.125 mg once daily with the potential to increase or decrease the dose in steps to 0.25 mg, 0.5 mg and 0.75 mg, with the final dose level subsequently fixed for 22 weeks.
11621232|NCT00472199|Placebo Comparator|Placebo|4 weeks of flexible dose-titration as for the investigational product; with the dose subsequently fixed for 22 weeks.
11621233|NCT00472186|Experimental|1|Post-operative administration of Lansoprazole
11621234|NCT00472186|Placebo Comparator|2|Placebo
11621235|NCT00472173|Active Comparator|Calcium hydroxide|
11621236|NCT00472173|Experimental|MTA|
11621237|NCT00472160|Experimental|1|Non Invasive Ventilation
11621238|NCT00472134|Active Comparator|Bupivicaine via Elastomeric pump|Bupivicaine via elastomeric pump
11621239|NCT00472134|Placebo Comparator|Placebo via elastomeric pump|Placebo via elastomeric pump
11621240|NCT00472121||1: AMG|
11621241|NCT00472121||2: MMG|
11621242|NCT00472095|Experimental|diabetes fotonovela|spanish language comic book describing diabetes care and consequences
11621243|NCT00472095|Placebo Comparator|placebo fotonovela|
11621244|NCT00472082|Experimental|1|The study drug Efalizumab will be given as part of a triple drug regimen including mycophenolate mofetil and prednisone. A test dose of Efalizumab 0.7mg/kg will be given at the enrollment visit. Beginning with study visit 2, Efalizumab 1mg/kg will be administered subcutaneously by injection on a weekly basis for 1 year. Mycophenolate mofetil will be given at a dose of 2gm/day which is the same as the standard of care dose. If patient experiences drug toxicity with mycophenolate mofetil they may be reduced and resume a minimum of at least 1gram daily to continue in the study. Patients will be maintained at 10mg of prednisone daily, same as standard of care.
11621245|NCT00472069|Experimental|A|transplantation of the squeletic muscular cells
11621246|NCT00472056|Experimental|BEAM + Standard Rituximab|"Arm 1 BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + Standard Rituximab with Standard Rituximab for Cohort 1 or 2
~Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.
~Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.
~Standard Rituximab: 375 mg/m^2 IV Days +1, +8 after Stem Cell Infusion on Day 0."
11621247|NCT00472056|Experimental|BEAM + High Rituximab|"BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + High Dose Rituximab
~Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.
~Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.
~High Dose Rituximab: 1000 mg/m^2 IV Days +1, +8 after Stem Cell Infusion on Day 0"
11621248|NCT00472030|Experimental|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
11621249|NCT00472030|Active Comparator|Prednisone|The control arm of the study will receive standard prednisone therapy to a maximum dose of 0.5 mg/kg/day.
11621250|NCT00472017|Experimental|Pediatric Diffuse Brainstem Glioma Patients|Patients with newly diagnosed diffuse brainstem gliomas receive vandetanib.
11621251|NCT00472004|Active Comparator|1|17B Estradiol (1mg) / (0.125 mg) Trimegestone (TMG) Continuous combined, 1 Daily, 1 year duration
11621252|NCT00472004|Active Comparator|2|Tibolone 2.5 mg 1 daily, 1 year duration
11621253|NCT00471991|Active Comparator|Arm 1|
11621254|NCT00471991|Experimental|Arm 2|
11621255|NCT00471965|Experimental|A|Oxaliplatin + 5-Fluorouracil/Leucovorin
11621256|NCT00471965|Active Comparator|B|Doxorubicin
11621257|NCT00471952|Experimental|1|Maxalt 10mg with Caffeine 75mg
11621258|NCT00471952|Active Comparator|2|Maxalt 10mg plus Placebo
11621259|NCT00471952|Placebo Comparator|3|Double placebo
11621260|NCT00471887|Experimental|Treatment-Single Arm|See intervention descriptions
11621261|NCT00471848|Experimental|Treatment Arm|Antithymocyte globuline with cyclosporin in first line treatment of patients with acquired severe aplastic anaemia and patients with non-severe aplastic anaemia who are transfusion dependent
11621262|NCT00471770||1|1.Core group: enrolled subjects who have isolated pneumococcal
11621264|NCT00471770||3|3.DCF group: Subjects screened but not enrolled
11621265|NCT00471718|Experimental|Phase I/II: Chemotherapy ABT-751|"Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21.
~Phase II: Patients receive ABT-751 twice daily"
11621266|NCT00471705|Experimental|Miltefosine|Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
11621267|NCT00471705|Active Comparator|Glucantime®|Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
11621268|NCT00471705|Experimental|Thermotherapy|One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
11621269|NCT00471692|Placebo Comparator|placebo|Normal saline placebo
11621270|NCT00471692|Active Comparator|Ropivocaine|Ilioinguinal nerve block with ropivocaine
11621271|NCT00471679|Experimental|Ethanol-Lock Treatment|Ethanol instillation and removal will be carried out by one of the investigating physicians, a pediatric surgical nurse practitioner, or a dedicated research nurse. Syringes containing a 70% ethanol solution will be pre-filled in the PDH pharmacy and dispensed to the nurse caring for a particular patient. The volume of ethanol to be administered into each lumen of the central line will be specific to each patient's catheter and will be determined at enrollment.
11621272|NCT00471640|Active Comparator|1|dexamethasone
11621273|NCT00471640|Placebo Comparator|2|Placebo
11621274|NCT00471614|Experimental|1|NucleomaxX
11621275|NCT00471614|Placebo Comparator|2|Placebo
11621276|NCT00471601|Experimental|Interviews/Questionnaires|The primary intervention in part 1 includes the interview for item generation with 50 women and the pilot-testing with a separate group of n = 30 women. The primary intervention in part 2 and 3 is the administration of the questionnaire. In part 3, along with the questionnaire being developed, the Body Image Scale (BIS), the Life Orientation Test-Revised (LOT-R), and the upcoming MSKCC BREAST-Q will be given to determine convergent and discriminant construct validity. No other therapeutic or diagnostic agents will be administered.
11621277|NCT00471536|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11621278|NCT00471510|Experimental|1|NEOSH101 2%
11621279|NCT00471510|Experimental|2|NEOSH101 1%
11621280|NCT00471510|Experimental|3|NEOSH101 0.5%
11621281|NCT00471510|Placebo Comparator|4|
11621282|NCT00471497|Experimental|nilotinib 300mg bid (investigating arm)|
11621283|NCT00471497|Experimental|Nilotinb 400 mg bid (investigating arm)|
11621284|NCT00471497|Experimental|imatinib 400mg QD (control arm)|
11621285|NCT00471471|Experimental|Peptide Vaccine + GM-CSF + Pfizer 3512676 in-ISA Oil|"The water-in-oil emulsion will consist of peptide (100 mcg/0.1 mL), GM-CSF (80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water), Pfizer PF3512676 (0.6 mg/0.04 mL using 15mg/mL vial) and 0.20 mLl of sterile saline.
~Vaccination will be given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year)."
11621286|NCT00471445|Experimental|ketamine/amitriptyline NP-H cream|Patients apply 4 grams amitriptyline (4%) and ketamine (2%) hydrochloride topical analgesic cream twice daily to areas of pain, numbness, or tingling in the hands and/or feet.
11621287|NCT00471445|Placebo Comparator|Placebo Cream|Patients apply a placebo cream twice daily to areas of pain, numbness, or tingling in the hands and/or feet.
11621288|NCT00471380|Active Comparator|Crossover group ABB|"3 period, 2 treatment cross-over model:
~Participants received Treatment A, which was concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.) for period 1 for 8 weeks. Then participants received Treatment B, which was fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.) for Period 2 (8 weeks) and Period 3 (8 weeks)"
11621289|NCT00471380|Active Comparator|Crossover group BAA|"3 period, 2 treatment cross-over model:
~Participants received Treatment B, which was fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.) for Period 1 (8 weeks). Then participants received Treatment A, which was concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.) for Period 2 (8 weeks) and Period 3 (8 weeks)."
11621290|NCT00471354|Experimental|Atomoxetine|0.5 mg/kg/day once a day (QD), by mouth (PO), starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
11621291|NCT00471328|Experimental|Nilotinib|400mg twice daily in core and extension phases of the study.
11621292|NCT00471328|Active Comparator|Control/cross-over to Nilotinib|"In core study phase, patients in this arm received Best Supportive Care (BSC) with or without imatinib or sunitinib at the last tolerated dose or at the investigator's choice until documented disease progression followed by cross-over to nilotinib arm.
~Patients entering the extension study on this control arm were permitted to cross over to nilotinib arm only upon documented disease progression."
11621293|NCT00471315|No Intervention|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
11621294|NCT00471302||1|Healthy adults in a malaria endemic area in Mali
11621295|NCT00471289|Experimental|1|PTA with primary placement of Drug (paclitaxel) Eluting Stent
11621296|NCT00471289|Active Comparator|2|PTA
11621297|NCT00471276|Experimental|1|
11621298|NCT00471250||1|Healthy Volunteers
11621299|NCT00471250||2|NIH patients with known or suspected susceptibility to infection.
11621300|NCT00471237|No Intervention|Placebo|All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
11621301|NCT00471237|Active Comparator|Alendronate|All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
11621302|NCT00471237|Active Comparator|Teriparatide|Open-label arm. All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
11621354|NCT00470561|Active Comparator|Aspirin|
11621355|NCT00470561|Placebo Comparator|Placebo|
11621303|NCT00471237|Experimental|Ronacaleret|4 arms, 100mg, 200mg, 300mg, 400mg. All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study.
11621304|NCT00471224||Patients who have received drug.|Patients who have received drug.
11621305|NCT00471185|Experimental|A|Subjects will receive progressively increasing doses of 10, 20 and 40 mg of oral acyline, on 3 occasions, each separated by 1 week
11621306|NCT00471146|Experimental|A|
11621307|NCT00471146|Active Comparator|B|
11621308|NCT00471133|Experimental|Xenogeneic Tyrosinase|
11621309|NCT00471120|Experimental|P2x7 Assay|Compare assay results with biopsy
11621310|NCT00471107|Sham Comparator|Sham TDCS|
11621311|NCT00471107|Experimental|Surface-anodal direct current|0.08 mA/cm2
11621312|NCT00471107|Active Comparator|Surface-cathodal direct current|0.08 mA/cm2
11621313|NCT00471094|Experimental|Ilaprazole 5 mg QD|
11621314|NCT00471094|Experimental|Ilaprazole 20 mg QD|
11621315|NCT00471094|Experimental|Ilaprazole 40 mg QD|
11621316|NCT00471094|Active Comparator|Lansoprazole 30 mg QD|
11621317|NCT00471081|Experimental|Group A|Single dose GSK134612.
11621318|NCT00471081|Experimental|Group B|Two doses of GSK134612.
11621319|NCT00471068|Experimental|Travatan|Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
11621320|NCT00471068|Active Comparator|Cosopt|treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
11621321|NCT00471055|Experimental|A|Capsaicin and placebo controlled,Cross-over design study
11621322|NCT00471055|Placebo Comparator|B|Capsaicin and placebo controlled,Cross-over design study
11621323|NCT00471003||Arm 1|
11621324|NCT00470977|Experimental|(Ranibizumab) Lucentis|(Ranibizumab)Lucentis 0.5%
11621325|NCT00470951|Active Comparator|open rectal resection|conventional open resection
11621326|NCT00470951|Active Comparator|laparoscopic rectal resection|laparoscopic rectal resection
11621327|NCT00470925|Experimental|Access [123I]MZINT and SPECT Imaging|
11621328|NCT00470899|Experimental|placental drainage|
11621329|NCT00470899|No Intervention|no drainage of fetal blood|
11621330|NCT00470886||Group 1|
11621331|NCT00470873||Group 1|
11621332|NCT00470847|Other|Lapatinib,Whole Brain Radiation,Herceptin|Lapatinib before and during Whole Brain Radiation Therapy (WBRT), then Herceptin 4mg/kg IV weekly
11621333|NCT00470834|Experimental|Arm 1|50 mg bicalutamide and 3.5 mg Dutasteride (IP)
11621334|NCT00470834|Placebo Comparator|Arm 2|50 mg bicalutamide and placebo
11621335|NCT00470821|Placebo Comparator|A - placebo|Identical tablets without the active principles. Each evening, nurses are requested to give 2 tablets at 8 PM and 12 PM
11621336|NCT00470821|Active Comparator|B - melatonin|Identical tablets containing melatonin 3 mg Nurses are requested to give two tablets daily, at 8 PM and 12 PM.
11621337|NCT00470795|Experimental|A|Acupuncture - 2 treatments weekly, 4 weeks (8 treatment)
11621338|NCT00470795|Placebo Comparator|B|Placebo/sham treatment; twice weekly for 4 weeks (total 8 treatments)
11621339|NCT00470756||evertors, invertors|
11621340|NCT00470743|Experimental|Ibuprofen|Compare ibuprofen
11621341|NCT00470743|Placebo Comparator|Normal saline|Compared against ibuprofen -- placebo
11621342|NCT00470704|Other|Lapatinib and Herceptin|1000 mg daily Lapatinib and 2 mg/kg weekly or the 6 mg/kg every 3 week dose of trastuzumab
11621343|NCT00470691|Experimental|complete plaster cast|reduction and a complete plaster cast,
11621344|NCT00470691|Active Comparator|dorsal plaster splint|reduction and a dorsal plaster splint.
11621345|NCT00470678|Experimental|1|Ranibizumab
11621346|NCT00470652||1|Pre-intervention patients admitted to our ED in the month prior to the intervention, before the 'computer-assisted decision support' is turned on (the intervention)
11621347|NCT00470652||2|Short-term post-intervention cohort of patients admitted in the month following the initiation of the 'computer-assisted decision support' for pain management
11621348|NCT00470652||3|long-term post-intervention cohort of patients admitted on the 6th month following the initiation of the 'computer-assisted decision support' for pain management
11621349|NCT00470626|Experimental|1|Vena Cava Filter
11621350|NCT00470613|Experimental|SGT-53|SGT-53 (2.4mg DNA/infusion) will be administered in a standard 3x3 dose escalation design in combination with docetaxel 40mg/m2 starting dose, cohort 1, cycle 1. This protocol will allow for both inter- and intra-patient dose escalations. SGT-53 will be administered weekly, day 1 except weeks 1, 4 & 7 when it will be administered biweekly on days 1 & 4. Docetaxel will be administered every 3 weeks (weeks 1, 4 & 7) on day 3. Patients completing cohort 1, cycle 1 without DLT at docetaxel 40mg/m2 will be allowed to dose escalate to 60mg/m2 in cycles 2 and 3. Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60mg/m2. Cohort 3 (3.6mg DNA/infusion; 75mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4mg DNA/infusion and docetaxel 75mg/m2. If necessary, the dose of docetaxel in cycle 2 and 3 may be reduced to 60mg/m2.
11621351|NCT00470600|Placebo Comparator|Normal Saline|250 milliliters normal saline as a placebo comparator was administered every 6 hours for a total of five doses over the first 24 hours. Those patients who received the initial five doses could continue to receive additional doses as needed every 6 hours through the 120-hour treatment period.
11621352|NCT00470600|Experimental|Intravenous ibuprofen|800 mg of intravenous ibuprofen diluted in 250 milliliters normal saline was administered every 6 hours for a total of five doses over the first 24 hours. Those patients who received the initial five doses could continue to receive additional doses as needed every 6 hours through the 120-hour treatment period.
11621353|NCT00470574|Experimental|Vaccine Therapy and QS21|"Patients receive sialyl Lewisª -keyhole limpet hemocyanin conjugate vaccine subcutaneously (SC) and QS21 immunoadjuvant SC once in weeks 1, 2, 3, 7, and 19 in the absence of disease progression or unacceptable disease.
~Blood samples are collected periodically and evaluated for circulating tumor cells and reactivity against sialyl Lewisª antigen in ELISA and/or immunoprecipitation-western blot assays.
~After completion of study treatment, patients are followed every 3 months"
11621356|NCT00470548|Experimental|Phase I: Abraxane and Alimta|Three dose levels were tested. Pemetrexed 500mg/m2 day 1 and nab-paclitaxel day 1 at 180, 220, and 260 mg/m2 every 21 days.
11621357|NCT00470548|Experimental|Phase II: Abraxane and Alimta|Pemetrexed 500mg/m2 day 1 and nab-paclitaxel day 1 at 260 mg/m2 every 21 days.
11621358|NCT00470535|Experimental|Arm 1 - Oral Erlotinib hydrochloride|Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity
11621359|NCT00470509|Experimental|Adalimumab|adalimumab (2 subcutaneous 40 mg injections on day 0 and 7)
11621360|NCT00470509|Placebo Comparator|Placebo|2 placebo injections on day 0 and 7
11621361|NCT00470496|Experimental|Treatment (intraoperative PDT)|Patients receive HPPH IV over 1 hour on day 1. Patients undergo surgery followed by laser light exposure to the entire tumor bed on day 2.
11621362|NCT00470483|Active Comparator|arm 1|Paroxetine treatment during 8 weeks
11621363|NCT00470483|Placebo Comparator|arm 2|Placebo treatment during 8 weeks
11621364|NCT00470470|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral imatinib mesylate twice daily for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
11621365|NCT00470444|Active Comparator|1|Liberal transfusion strategy
11621366|NCT00470444|Active Comparator|2|Restrictive transfusion strategy
11621367|NCT00470418|Other|NIC5-15|Subjects with Alzheimer's Disease
11621368|NCT00470418|Placebo Comparator|Placebo|Subjects with Alzheimer's Disease
11621369|NCT00470405|Experimental|Therapeutic Intervention|
11621370|NCT00470392|Other|Imiquimod|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
11621371|NCT00470392|Other|Clobetasol|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
11621372|NCT00470379|Experimental|Immunization with NY-ESO-1b|Efficacy of maximal dose of topical resiquimod as immune adjuvant to intradermally administered NY-ESO-1b peptide vaccine.
11621373|NCT00470366|Experimental|Paclitaxel, Ifosfamide, and Cisplatin|-Paclitaxel is administered first, 120 mg/m2 on days 1 and 2 every three weeks for four cycles. Cisplatin is administered at 20 mg/m2 over approximately 30 minutes daily for five days every three weeks for four courses. -The ifosfamide is given last with 1200 mg/m2 daily for five days every three weeks for four cycles.
11621374|NCT00470340|Experimental|1|Oxaliplatin, gemcitabine, cisplatin, lipiodol
11621375|NCT00470340|Experimental|2|Oxaliplatin, gemcitabine, cisplatin, lipiodol
11621376|NCT00470301|Experimental|Arm I|Tipifarnib plus sequential weekly paclitaxel followed by doxorubicin plus cyclophosphamide
11621377|NCT00470275|Experimental|Cytarbine|Cytarabine IV every 12 hours days 1-5 of 21 day cycle. Response evaluation after 6 cycles of therapy.
11621378|NCT00470262|Other|Fenofibrate 145 mg PO QD and Pioglitazone 45 mg PO QD|Treatment with pioglitazone and fenofibrate in subjects with pre diabetes
11621379|NCT00470262|Other|Fenofibrate 145 mg PO QD|Treatment with fenofibrate in subjects with pre diabetes
11621380|NCT00470236|Active Comparator|Arm 1 (Standard WB Fractionation)|Whole Breast RT alone - Standard fractionation schedule (50GY/25 Fractions/35days)
11621381|NCT00470236|Experimental|Arm 2 (Shorter WB Fractionation)|Whole Breast RT alone - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days)
11621382|NCT00470236|Active Comparator|Arm 3 (Standard WB fractionation+Boost)|Whole Breast RT + tumor bed boost - Standard fractionation schedule (50 Gy/25 fractions/35 days; Boost 16 Gy/8 fractions/10 days)
11621383|NCT00470236|Experimental|Arm 4 (Shorter WB fractionation + Boost)|Whole breast RT + tumour bed boost - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days; Boost 16 Gy/8 fractions/10 days)
11621384|NCT00470223|Experimental|Chemotherapy + zoledronic acid|
11621385|NCT00470223|Active Comparator|chemotherapy|
11621386|NCT00470210|Experimental|1|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week Ribavirin (Copegus®) 1600 mg/day Epoetin β (450 UI/kg/week)
11621387|NCT00470197|Experimental|Arm I|Patients receive flavopiridol IV over 30 minutes on days 1, 2, and 3. Patients receive cytarabine IV continuously over 72 hours beginning on day 6 and mitoxantrone hydrochloride IV over 60-120 minutes on day 9.
11621388|NCT00470184|Experimental|Chemo|Oxaliplatin 85 mg/m2 will be administered IV on days 1, 15 and 29. Capecitabine 1250 mg/m2 will be administered in 2 divided daily doses P0 or via enteral tube, on radiation days only (Monday- Friday/ weekly). Capecitabine will be continued until the final dose of radiotherapy
11621389|NCT00470158|Experimental|combined iron and zinc|Iron and zinc together
11621390|NCT00470158|Experimental|Separate iron and zinc|Iron and zinc on separate days
11621391|NCT00470158|Experimental|iron alone|Iron
11621392|NCT00470158|Experimental|zinc alone|Zinc
11621393|NCT00470158|Placebo Comparator|placebo|
11621394|NCT00470119|No Intervention|Control|
11621395|NCT00470119|Other|Caloric Restriction|Nutritionist-delivered weight loss intervention though diet modification with an aim of 10% weightloss over a year long intervention based on the DPP and LookAHEAD interventions. Participants meet with a nutritionist individually and in small groups. Participants receive general information about diet and behavior strategies such as self-monitoring, goal-setting, stimulus-control, problem-solving, and relapse-prevention training. Participants learn to set a calorie goal and a fat gram goal and how to achieve the goal calorie reduction. Meetings are held weekly during the first 6 months of the diet program but taper off over the course of the study.
11621396|NCT00470119|Other|Exercise Intervention|Participants exercise 3 days per week under the supervision of a physiologist and 2 days per week independently at home, for a total of 5 exercise sessions (at least 45 minutes of moderate-intensity exercise per session) weekly over 12 months
11621827|NCT00465283|Placebo Comparator|placebo|
11621397|NCT00470119|Other|Caloric Restriction AND Exercise Intervention|Combined caloric restriction & exercise intervention
11621398|NCT00470106|Active Comparator|Cognitive Remediation|cognitive remediation
11621399|NCT00470106|Experimental|Social Cognitive Skills Training|social cognitive skills training
11621400|NCT00470106|Active Comparator|Hybrid Intervention|combined social cognitive and cognitive remediation training
11621401|NCT00470106|Other|Skills Training|control training
11621402|NCT00470093|Experimental|Interleukin-6 and Interferon-α|Subjects will be started on recombinant interferon-α at a dose of 3 million units SQ daily, escalating the dose by 1 million units every week as tolerated to a maximum dose of 3 million units/m2/day. Following a minimum of one month of interferon therapy with two weeks on a stable dose, subjects will begin recombinant interleukin-6 therapy at a dose of 2.5 ug/kg/day.
11621403|NCT00470080|Experimental|1|venepuncture
11621404|NCT00470067|Experimental|Doxorubicin and carboplatin|Patients receive doxorubicin hydrochloride liposome IV over 1 hour on day 1 and carboplatin IV over 30 minutes on day 1
11621405|NCT00470054|Experimental|Treatment (dasatinib)|Patients receive oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11621406|NCT00470015|Experimental|MART1 Analog, gp100 and Survivin|
11621407|NCT00469963|Experimental|SIR-SPHERES|
11621408|NCT00469937|Experimental|Therapeutic Intervention|
11621409|NCT00469924|Experimental|Alerting system ON|Alerting system is ON
11621410|NCT00469924|No Intervention|Alerting system OFF|Alerting system is OFF
11621411|NCT00469911|Experimental|Magnetic Resonance Spectroscopy|Patients will have Magnetic Resonance Spectroscopy to measure in vivo accumulation of triglycerides in myocardial tissue
11621412|NCT00469911|Experimental|Ex vivo heart biopsy|Patients will have their normal routine clinical heart biopsy of myocardial heart tissue.
11621413|NCT00469898|Experimental|Therapeutic Intervention|Lung cancer patients will be treated for four 3-week cycles (12 weeks) in the absence of progressive disease, unacceptable toxicity, or withdrawal of patient consent. Up to two additional cycles may be administered at the discretion of the treating physician. If at treatment withdrawal the disease has responded or is stable, the patient will continue to be followed for efficacy (i.e. until progressive disease)at 8 week intervals. Following the diagnosis of progressive disease, patients will be followed every two months for survival.
11621414|NCT00469885|Other|1|Usual care
11621415|NCT00469885|Other|2|Reduction
11621416|NCT00469872|Active Comparator|Child Focused|Occupational and physical therapy focused on improving child's skills and abilities through rehabilitation to improve child functioning
11621417|NCT00469872|Experimental|Context Focused|Occupational and physical therapy focused on improving child's skills and abilities through rehabilitation to change the task or environment around a child
11621418|NCT00469859|Experimental|Group 1 (Lestaurtinib dose 50 mg/m2|"DOSE-FINDING PHASE:
~COURSE 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2. Cohorts of 6 patients receive escalating doses of lestaurtinib until a TBAD is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by PIA assay.
~COURSE 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy.
~CONTINUATION THERAPY: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~Continued (see detailed description)"
11621419|NCT00469859|Experimental|Group 2 (Lestaurtinib: Dose 62.5 mg/m2|"DOSE-FINDING PHASE:
~COURSE 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2. Cohorts of 6 patients receive escalating doses of lestaurtinib until a TBAD is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by PIA assay.
~COURSE 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy.
~CONTINUATION THERAPY: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~Continued (see detailed description)"
11621420|NCT00469833|Experimental|Arm 1|Intervention: Insulin glargine treatment. The study is designed as a within subjects comparison of insulin secretion in type 2 diabetic patients before and after 2 months of insulin treatment to reduce blood glucose. Insulin secretion will be determined with a hyperglycemic clamp using 20% dextrose, and ingestion of an oral glucose solution (75 g).
11621421|NCT00469781|Active Comparator|1|
11621422|NCT00469781|Other|2|
11621423|NCT00469768|Experimental|A|
11621424|NCT00469768|Experimental|B|
11621425|NCT00469768|Placebo Comparator|C|
11621426|NCT00469755|Active Comparator|1|Differin® Gel, 0.1% for 12 weeks
11621427|NCT00469755|Active Comparator|2|Tazorac® Cream, 0.1% for 12 weeks
11621428|NCT00469755|Active Comparator|3|Differin® Gel, 0.1% for 6 weeks switched to Tazorac® Cream, 0.1% for 6 weeks
11621429|NCT00469729|Experimental|StemEx|
11621430|NCT00469690|Other|1|
11621431|NCT00469690|Other|2|
11621432|NCT00469651|Experimental|1|15 microgramme candidate vaccine
11621433|NCT00469651|Active Comparator|2|Hepatitis B vaccine
11621434|NCT00469651|Experimental|3|30 microgramme MSP3 candidate malaria vaccine
11621435|NCT00469651|Active Comparator|4|Hepatitis B control vaccine
11621436|NCT00469638|Experimental|Agilis sheeth group|
11621437|NCT00469638|Active Comparator|Non-steerable sheeth group|
11621438|NCT00469612|Experimental|A|NeuroVision's NVC treatment for low myopia
11621439|NCT00469612|No Intervention|B|The subjects in this group will serve as controls and will be the no intervention group.
11621440|NCT00469599|Active Comparator|1|alfacalcidol 16 weeks, 6 weeks wash out, paricalcitol 16 weeks
11621828|NCT00465270|Experimental|Device|AMPLATZER PFO Occluder
11621441|NCT00469599|Active Comparator|2|paricalcitol ´16 weeks, 6 weeks wash out, alfacalcidol 16 weeks
11621442|NCT00469586|Experimental|A|
11621443|NCT00469586|Experimental|B|
11621444|NCT00469586|Active Comparator|C|
11621445|NCT00469573|Other|1.|
11621446|NCT00469560|Experimental|Deferasirox|
11621447|NCT00469547|Experimental|1|62% ethanol in emollient gel
11621448|NCT00469547|Placebo Comparator|2|15% ethanol in emollient gel
11621449|NCT00469508|Active Comparator|Modafinil|Modafinil 400mg oral dose taken daily for 12 weeks
11621450|NCT00469508|Placebo Comparator|Placebo|Modafinil 0mg (sugar pill) oral dose taken daily for 12 weeks
11621451|NCT00469482|Active Comparator|Sedation, RASS Targeted|Patient sedation utilizing standard of care methods (RASS Targeted)
11621452|NCT00469482|Active Comparator|Sedation,RASS Targeted plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring.
11621453|NCT00469456|Active Comparator|1|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
11621454|NCT00469456|Placebo Comparator|2|Placebo oral administration twice daily for 12 weeks
11621455|NCT00469443|Experimental|1|FOLFIRI/Avastin
11621456|NCT00469443|Experimental|2|XELIRI/Avastin
11621457|NCT00469430|No Intervention|Op|traditional surgery
11621458|NCT00469430|Experimental|Ab|antibiotic treatment
11621459|NCT00469391|Experimental|GI Sleeve|medical device that mimics gastric bypass mechanism for weight-loss
11621460|NCT00469391|Sham Comparator|Sham Control|
11621461|NCT00469378|Experimental|firategrast|900 (females) or 1200 (males) mg twice daily for 24 weeks
11621462|NCT00469339||cohort of Mexican-American households|cohort of Mexican-American households
11621463|NCT00469326|Active Comparator|atorvastatin|atorvastatin pre-treatment group (80mg atorvastatin two days before PCI)
11621464|NCT00469326|No Intervention|control|PCI without atorvastatin pretreatment
11621465|NCT00469274|Active Comparator|Antibiotic PEP|Subjects who did receive PEP following pertussis exposure
11621466|NCT00469274|No Intervention|No PEP|Subjects who did not receive PEP following pertussis exposure
11621467|NCT00469261|Experimental|Doxycycline|Active drug 100 mg bid for seven days in pts with AMI treated with Primary PCI and current medical therapy
11621468|NCT00469261|Active Comparator|Standard Therapy|Pts with AMI treated with Primary PCI and current medical therapy
11621469|NCT00469235|Placebo Comparator|1|50ng dose group
11621470|NCT00469235|Placebo Comparator|2|200ng dose group
11621471|NCT00469209|Active Comparator|No Bortezomib|Arm 1: Melphalan 100 mg/m^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
11621472|NCT00469209|Active Comparator|Bortezomib 1.0 mg/m^2|Arm 2: Bortezomib (Level 1) 1.0 mg/m^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
11621473|NCT00469209|Active Comparator|Bortezomib 1.5 mg/m^2|Arm 3: Bortezomib (Level 2) 1.5 mg/m^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
11621474|NCT00469170|Experimental|A|vaginal ring first 12 weeks & observational safety last 12 weeks
11621475|NCT00469170|Experimental|B|observational safety first 12 weeks & vaginal ring last 12 weeks
11621476|NCT00469157|Other|1.|
11621477|NCT00469144|Experimental|Fixed-Dose Busulfan + Fludarabine|Busulfan Fixed Dose = 130 mg/m^2 IV Daily Over Three Hours x 4 Days. Fludarabine 40 mg/m^2 IV Daily Over 1 Hour x 4 Days.
11621478|NCT00469144|Experimental|Adjusted Dose Busulfan + Fludarabine|Busulfan Adjusted Dose = 32 mg/m^2 IV Over 2 Hours Test Dose x 1 Day. Fludarabine 40 mg/m^2 IV Daily Over 1 Hour x 4 Days.
11621479|NCT00469131|Active Comparator|1 Drug:|tacrolimus + steroid
11621480|NCT00469131|Active Comparator|2 Drug:|tacrolimus + mycophenolate mofetil
11621481|NCT00469118|Experimental|DRX Treatment|20 treatments of spinal decompression over a six week period. Each session lasts about 45 minutes and consists of a 28-minute treatment on the DRX9000™ machine followed by 15 minutes of cold therapy to the lumbar paravertebral muscles.
11621482|NCT00469118|No Intervention|Conservative Care|Conservative non surgical therapy for 6 weeks prior to beginning DRX9000 treatment
11621483|NCT00469105|Active Comparator|Control|Control Arm receives standard diabetes disease management
11621484|NCT00469105|Experimental|Intervention Arm|Receives numeracy/literacy sensitive diabetes management
11621485|NCT00469092|Experimental|BIAsp 30|
11621486|NCT00469092|Active Comparator|Glargine|
11621487|NCT00469079|Active Comparator|1|Nicotine gum or nicotine lozenge; Dosage: 2 or 4 mg; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
11621488|NCT00469079|Experimental|2|Taboka - oral tobacco product Dosage: 0.84 to 1.26 mg free nicotine per g dry weight; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
11621489|NCT00469079|Experimental|3|Camel Snus - oral tobacco product Dosage: 6.09 to 9.16 mg dry weight; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
11621490|NCT00469040|Experimental|GW642444M 25mcg|In Cohort 1 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 25 mcg.
11621491|NCT00469040|Experimental|GW642444M 50mcg|Subjects after randomization will receive two inhalations of 25 mcg GW642444M in Cohort 1.
11621492|NCT00469040|Experimental|GW642444M 100mcg|In Cohort 2 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 100 mcg.
11621493|NCT00469040|Experimental|GW642444M 200mcg|Subjects after randomization will receive two inhalations of 100 mcg GW642444M in Cohort 2.
11621494|NCT00469040|Experimental|GW642444M 400mcg|Subjects after randomization will receive two inhalations of 200 mcg GW642444M in Cohort 3.
11621495|NCT00469027|Experimental|eNOS transfected EPCs|eNOS transfected EPCs will be delivered by injection via a PA line, incremental doses over three days
11621496|NCT00469014|Active Comparator|Arm 1: Busulfan + Fludarabine (30 mg/m^2) + Clofarabine|Busulfan 30 mg/m^2 intavenous (IV) Daily + Fludarabine 30 mg/m^2 IV Daily; + Clofarabine 10 mg/m^2 IV Daily
11621497|NCT00469014|Experimental|Arm 2: Busulfan + Fludarabine (20 mg/m^2) + Clofarabine|Busulfan 20 mg/m^2 IV + Fludarabine 20 mg/m^2 IV Daily + Clofarabine 20 mg/m^2 IV Daily
11621587|NCT00468091|Active Comparator|saline-exendin(9-39)amide|"saline IV
~+ exendin(9-39)amide IV"
11621498|NCT00469014|Experimental|Arm 3: Busulfan + Fludarabine (10 mg/m^2) + Clofarabine|Busulfan 10 mg/m^2 IV Daily + Fludarabine 10 mg/m^2 IV Daily + Clofarabine 30 mg/m^2 IV Daily
11621499|NCT00469014|Experimental|Arm 4: Busulfan + Clofarabine|Busulfan 40 mg/m^2 IV Daily + Clofarabine 40 mg/m^2 IV Daily
11621500|NCT00468949||1|Patients undergoing excision surgery for their dupuytren's contracture
11621501|NCT00468949||2|Patients not undergoing surgery for their excision surgery
11621502|NCT00468936|No Intervention|1|Usual medications (Cellcept)
11621503|NCT00468936|Active Comparator|2|Patients taking Myfortic
11621504|NCT00468923|Placebo Comparator|Rosuvastatin|Rosuvastatin 10 mg vs placebo
11621505|NCT00468923|Placebo Comparator|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 mg vs placebo
11621506|NCT00468910|Experimental|Arm I|Patients receive oral acetylsalicylic acid (aspirin) once daily.
11621507|NCT00468910|Placebo Comparator|Arm II|Patients receive oral placebo once daily.
11621508|NCT00468897|Experimental|Treatment Arm AB|A will be a single tablet RSG XR 8 milligram (mg) manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm AB subject will receive A regimen in Period 1 and B regimen in Period 2.There will be wash-out period of 5 days between doses.
11621509|NCT00468897|Experimental|Treatment Arm BA|A will be a single tablet RSG XR 8 mg manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm BA subject will receive B regimen in Period 1 and A regimen in Period 2. There will be wash-out period of 5 days between doses.
11621510|NCT00468871|Experimental|Fluocinolone acetonide|Intravitreal fluocinolone acetonide implant
11621511|NCT00468871|Active Comparator|Standard care|Standard of Care
11621512|NCT00468858|Experimental|T-DEN-Post-Transfection F17|Post-Transfection F17, full dose
11621513|NCT00468858|Experimental|T-DEN-Post-Transfection F19|Post-Transfection F19, full dose
11621514|NCT00468858|Placebo Comparator|Placebo|Control
11621515|NCT00468845|Experimental|1|
11621516|NCT00468845|Experimental|2|
11621517|NCT00468845|Placebo Comparator|3|
11621518|NCT00468832||Ongoing Duchenne Muscular Dystrophy (DMD) Cohort|340 patients currently enrolled participants with DMD.
11621519|NCT00468832||New Young Duchenne Muscular Dystrophy (DMD) Cohort|Additional 100 confirmed DMD participants aged 4-7 years old to be recruited.
11621520|NCT00468832||Typically Developing Control Cohort|Up to 370 typically developing male children and adults aged 6-30 years old to be recruited.
11621521|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 2 to 6 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
11621522|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 7 to 11 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
11621523|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 12 to 17 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
11621524|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 2 to 17 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
11621525|NCT00468793|Active Comparator|2|Fluid therapy guided by blood pressure and urine production
11621526|NCT00468793|Experimental|1|ScvO2 guided fluid therapy
11621527|NCT00468767|Experimental|1|Atrial fibrillation (AF) duration of 3 hours to 7 days.
11621528|NCT00468767|Experimental|2|AF duration of >7 days to <45 days
11621529|NCT00468754|Experimental|A|
11621530|NCT00468754|Experimental|B|
11621531|NCT00468741|No Intervention|1|subjects receive internet access and computer
11621532|NCT00468741|Experimental|2|CHESS informational services only
11621533|NCT00468741|Experimental|3|CHESS social support and informational services
11621534|NCT00468741|Experimental|4|Full CHESS
11621535|NCT00468728|Active Comparator|1|Vancomycin
11621536|NCT00468728|Experimental|2|PAR-101/OPT-80
11621537|NCT00468715|Experimental|bicalutamide|This is a multicenter, open-label, phase II study to evaluate the antitumor activity and safety of bicalutamide administered orally daily to patients with ER(-)/PR(-)/AR(+) metastatic breast cancer. Eligible patients who have consented to trial participation will receive bicalutamide at a dose of 150mg PO daily.
11621538|NCT00468676|Active Comparator|B|Treatment as usual
11621539|NCT00468676|Experimental|A|Case management intervention
11621540|NCT00468650|Active Comparator|Open label|Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive Patrex® 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to Patrex® 100 mg PRN for the following four weeks.
11621541|NCT00468611|Experimental|1|
11621542|NCT00468611|Placebo Comparator|2|
11621543|NCT00468585|Experimental|1 Capecitabine and Bevacizumab|The Phase II trial has a Simon mini-max two-stage design. Twenty-seven patients will be enrolled to the first stage of the Phase II trial, with a target accrual of 40 patients. The treatment dose of capecitabine as determined in the Phase I portion of this trial will be administered orally in two divided doses daily on Days 1 through 7 and Days 15 through 21 in a 28 day cycle. Phase II patients will receive bevacizumab 10 mg/kg intravenously every 2 weeks concurrently with oral capecitabine. Patients will be evaluated for toxicity between Days 3 to 5 (complete blood count only), Day 8, Day 15, and Day 22 during cycle #1. Thereafter, toxicity will be assessed on Days 1 and 15. Efficacy will be assessed with every other week physical examination and radiographic scans of measurable disease every 12 weeks.
11621544|NCT00468572|Experimental|1|Participants will receive treatment with affectionate writing
11621545|NCT00468572|Active Comparator|2|Participants will receive treatment with meaningless writing
11621546|NCT00468559|Experimental|Open Label Esomeprazole|This is an open label, run-in phase. All patients received Esomeprazole.
11621547|NCT00468559|Experimental|Double Blind Esomeprazole|This is the double blind withdrawal phase. Patients are randomized to active drug or placebo.
11621548|NCT00468559|Placebo Comparator|Double Blind Placebo|This is the double blind withdrawal phase. Patients are randomized to active drug or placebo.
11621549|NCT00468546|Placebo Comparator|Placebo Plus Methotrexate|Participants will be administered placebo by intravenous infusion on Days 1 and 15 along with MTX 10-25 mg per os (p.o.) or parenterally once a week up to 24 weeks and will be followed up to Week 104.
11621550|NCT00468546|Experimental|Rituximab plus Methotrexate|Participants will be administered rituximab 1000 mg as intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to Week 24 and will be followed up to Week 104.
11621551|NCT00468481|Experimental|Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)|1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks
11621552|NCT00468481|Active Comparator|Drospirenone (DRSP)/Ethinylestradiol (EE)|1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks
11621553|NCT00468468|Experimental|CHESS Condition|Subjects who receive the CHESS (Comprehensive Health Enhancement Support System)
11621554|NCT00468468|Experimental|Mentor Condition|Subjects who receive access to a Human Cancer Mentor only
11621555|NCT00468468|Experimental|CHESS + Mentor|Subjects who receive the CHESS system plus a Human Cancer Mentor
11621556|NCT00468468|No Intervention|Internet Only|Subjects receive routine care and nothing else
11621557|NCT00468442|Experimental|Allogeneic Pancreatic Islet Cells|Participants will receive up to three islet transplants and maintenance immunosuppressive therapy.
11621558|NCT00468403|Experimental|Allogeneic Pancreatic Islet Cells|Participants will receive up to three islet transplantations and continuous immunosuppressive therapy including belatacept
11621559|NCT00468338||BIS monitor used for all subjects|BIS monitor applied to all subjects
11621560|NCT00468325|Active Comparator|Multi-slice Computed Tomography|Patients admitted to the ED with chest pain and/or anginal equivalent symptoms are randomized to a multi-slice computed tomography arm where they will receive a CT scan of their heart.
11621561|NCT00468325|Active Comparator|Standard of Care|Patients admitted to the ED with chest pain and/or anginal equivalent symptoms are randomized to the Standard of Care arm and receive rest-stress nuclear myocardial perfusion imaging test.
11621562|NCT00468312|Experimental|Mometasone Furoate Nasal Spray (MFNS)|200 mcg daily
11621563|NCT00468312|Placebo Comparator|Placebo|Two sprays in each nostril in the morning
11621564|NCT00468299|Active Comparator|Misoprostol and placebo|Women in this arm receive placebo and misoprostol 800 mcg buccally
11621565|NCT00468299|Experimental|Mifepristone and misoprostol|Womwn in this group receive mifepristone 200 mg orally and misoprostol 800 mcg buccally
11621566|NCT00468286|Experimental|A|Treatment group A: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months.
11621567|NCT00468286|Experimental|B|Treatment group B: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months.
11621568|NCT00468273|Experimental|Intravenous Immune Globulin|Subjects with primary humoral immunodeficiency
11621569|NCT00468247|Active Comparator|1|Device , Navigator used for guiding haemodynamic care
11621570|NCT00468247|Placebo Comparator|2|Conventional care
11621571|NCT00468208|Experimental|1|Participants will receive abatacept intravenously at study visits on Days 1, 15, and 29, and then once a month thereafter.
11621572|NCT00468182||1|MS patients or patients with CIS (Clinically isolated syndrome) who decided to be treated with IFN-beta for 3 months (with the option to continue Rx)
11621573|NCT00468182||2|MS patients or patients with CIS(Clinically isolated syndrome)who decided to postpone the treatment with IFN-beta
11621574|NCT00468169|Experimental|A: Cetuximab+FHX|Cetuximab [250mg/m2 (day 1, weekly x10)] + FHX (5-FU [CI: 600mg/m2/day; days 0-5 (120h total) every other week x5], Hydroxyurea [500 mg PO BID, days 0-5 (=11 doses), every other week x5] and twice-daily radiation [150 cGy per fraction - days 1-5, every other week x5 (70-72 Gy total dose)]). Total duration is 10 weeks.
11621575|NCT00468169|Experimental|B: Cetuximab + PX|Cetuximab [250 mg/m2 (day 1, weekly x7)] + PX (Cisplatin [100mg/m2 (week 1 & 4 on day 1 (or 2))], Accelerated fraction radiotherapy with concomitant boost [AFX-CB (72 Gy/42 F/6 W) (3-D or IMRT based)]). Total duration: 7 weeks.
11621576|NCT00468156|Active Comparator|1|written materials only
11621577|NCT00468156|Experimental|2|written materials plus asked to form implementation intentions
11621578|NCT00468156|Experimental|3|same as arm 2 plus telephone support
11621579|NCT00468143|Experimental|Adderall Extended Release First|This group was treated with Adderall extended release, either during phase 2 of the trial, or during phase 3 (this subset received Adderall immediate release during phase 2 and then underwent a washout period). This was a counterbalanced crossover study, with a washout period in between treatment periods. Participants were randomized in a 1:1 ratio to one of two schedules Adderall IR followed by Adderall XR, or Adderall XR followed by Adderall IR.
11621580|NCT00468143|Experimental|Adderall Immediate Release First|This group was treated with Adderall immediate release, either during phase 2 of the trial, or during phase 3 (this subset received Adderall extended release during phase 2 and then underwent a washout period). This was a counterbalanced crossover study, with a washout period in between treatment periods. Participants were randomized in a 1:1 ratio to one of two schedules Adderall IR followed by Adderall XR, or Adderall XR followed by Adderall IR.
11621581|NCT00468130|Experimental|Aripiprazole|Subjects in the experimental group will receive Aripiprazole
11621582|NCT00468130|Placebo Comparator|Placebo|Subjects in the control group will receive placebo
11621583|NCT00468117|Experimental|Islet transplantation|Up to three separate islet transplants will occur and a regimen of immunosuppressive medications consisting of antithymocyte globulin (ATG) and etanercept throughout study.
11621584|NCT00468104|Active Comparator|Alteplase, Placebo- intapleural instillation|Either 25 mg of Alteplase or Placebo instilled daily. Response to therapy after three days. cross over to the other drug if no response was noted.
11621585|NCT00468104|Active Comparator|Placebo, Alteplase -2nd arm|If the first arm fails then the 2nd arm ( cross over to either Placebo or Alteplase not used in the first arm) instilled intrapleurally daily for three days
11621586|NCT00468091|Placebo Comparator|saline-saline|"saline IV
~+ saline IV"
11621941|NCT00463970|Placebo Comparator|4|Soy oil
11621588|NCT00468091|Active Comparator|saline-atropine|"saline IV
~+ atropine IV"
11621589|NCT00468091|Active Comparator|exendin(9-39)amide-atropine|"exendin(9-39)amide IV
~+ atropine IV"
11621590|NCT00468078|Experimental|A|Parkinson's disease
11621591|NCT00468078|Active Comparator|B|ET+Normal
11621592|NCT00468065|Experimental|A|TO use Veinviewer to improve the effectiveness of IV starts in children
11621593|NCT00468065|No Intervention|B|Standard approach to placing IV s in children
11621594|NCT00468052|Active Comparator|fentanyl|fentanyl bolus 1ug.kg-1
11621595|NCT00468052|Experimental|dexmedetomidine|dexmedetomidine 2ug.kg-1 over 10 min followed by 0.7ug.kg-1.h-1
11621596|NCT00468039|Experimental|vildagliptin + metformin|
11621597|NCT00468013|Experimental|1|Computer-based exercises to be executed at home.
11621598|NCT00468013|Sham Comparator|2|Computer-based exercises to be executed at home.
11621599|NCT00468000|Experimental|Ixmyelocel-T|The treatment arm of the study will receive injections of the study cellular product.
11621600|NCT00468000|Placebo Comparator|Placebo|The control arm of the study will receive placebo injections.
11621601|NCT00467987|Experimental|androgel|androgel
11621602|NCT00467987|Placebo Comparator|placebo|placebo gel
11621603|NCT00467987|No Intervention|no treatment|eugonadal comparison arm
11621604|NCT00467974|Experimental|1|TEA with LEM
11621605|NCT00467974|Active Comparator|2|TACE
11621606|NCT00467961|Experimental|Miltenyi system transplant recipients|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach. Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. Determine appropriate level of post transplant immunosuppression
11621607|NCT00467896|Experimental|Iloprost|The study enrolled patients who were already using iloprost (10 µg/mL) standard dose (5 µg) delivered by I-neb® Adaptive Aerosol Delivery (AAD) System with Power Disc-6 (PD-6) without any safety or tolerability concerns, thereby facilitating a direct comparison with the Power Disc-15 (PD-15). The single arm design allowed each patient to serve as his/her own control.
11621608|NCT00467883|Experimental|amphotericin B|Treatment with high dosage of amphotericin B liposomal 10 mg/kg/day during 4 weeks
11621609|NCT00467870|Experimental|1|750 mg dose of testosterone undecanoate
11621610|NCT00467870|Experimental|2|1000 mg dose testosterone undecanoate
11621611|NCT00467857|Active Comparator|InteguSeal* and standard surgical preparation solutions|InteguSeal* microbial skin sealant was applied to surgical sites prior to incision after standard surgical skin preparation in patients undergoing coronary artery bypass graft (CABG) surgery
11621612|NCT00467857|Other|Standard surgical skin preparation alone|Prior to incision, standard surgical skin preparation in patients undergoing coronary artery bypass graft (CABG) surgery
11621613|NCT00467844|Experimental|1|1 mg GTx-024
11621614|NCT00467844|Experimental|2|3 mg GTx-024
11621615|NCT00467844|Placebo Comparator|3|Placebo
11621616|NCT00467831|Experimental|Multi-Drug Regimen|Losartan, 25 mg by mouth every night at bedtime; Zileuton, 1200 mg by mouth twice daily; N-acetylcysteine, 600 mg by mouth three times daily; Pravastatin, 20 mg by mouth every night at bedtime; Erythromycin, 333 mg by mouth three times daily.
11621617|NCT00467818|Experimental|Omega 3 fatty Acids|Omega 3 Fatty acids will be dispensed to subjects in the active experimental group of the study.
11621618|NCT00467818|Placebo Comparator|Placebo|The placebo will be dispensed to subjects in the control group
11621619|NCT00467779|Experimental|Stage 1: Cobimetinib Dose Escalation (21/7 Schedule)|Participants will receive cobimetinib (GDC-0973/XL518) at the starting dose of 0.05 mg/kg via solution or capsule, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment [21/7 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
11621620|NCT00467779|Experimental|Stage 1A: Cobimetinib Dose Escalation (14/14 Schedule)|Participants will receive cobimetinib at the starting dose of 60 mg via solution or capsule, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment [14/14 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
11621621|NCT00467779|Experimental|Stage 2: Cobimetinib Expansion (21/7 Schedule)|Participants will receive cobimetinib at the maximum tolerated dose (MTD) established in Stage 1, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment [21/7 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
11621622|NCT00467779|Experimental|Stage 2 A: Cobimetinib Expansion (14/14 Schedule)|Participants will receive cobimetinib at the MTD established in Stage 1A, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment [14/14 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
11621623|NCT00467779|Experimental|Stage 3: Cobimetinib+Midazolam+Dextromethorphan|Participants will receive a single dose of midazolam (2 mg of midazolam syrup) and dextromethorphan (30 mg tablet) on Cycle 1 Day 1, in the absence of cobimetinib. After a 2-day washout period, participants will receive 21 consecutive daily doses of cobimetinib (60-mg) followed by a 7-day washout period. Participants will receive another single dose of midazolam and dextromethorphan on Cycle 1 Day 15, in the presence of steady-state cobimetinib concentrations. In Cycle 2 and beyond participants will receive cobimetinib alone, administered as a 60-mg daily dose for 21 consecutive days in 28-day cycles (21/7 schedule).
11621624|NCT00467753|Experimental|Oxcarbazepine|Oxcarbazepine is the active drug to be given to subjects in the experimental arm
11621625|NCT00467753|Placebo Comparator|Sugar Pill|Patients are given either active or inactive intervention.
11621626|NCT00467727|Experimental|1|Phase Contrast Mammography Exam
11621627|NCT00467714|No Intervention|1|2.5 cm Cartilage as columella strut
11621628|NCT00467688|No Intervention|A,1|Real time access to current measured glucose values; hyperglycemic or hypoglycemic alerts
11621629|NCT00467688|No Intervention|A,2|Retrospective analysis of glucose values
11621630|NCT00467649|Experimental|Group A|
11621631|NCT00467649|Active Comparator|Group B|
11621632|NCT00467636|Experimental|Insulin Glulisine|Blood glucose monitoring and treatment of hyperglycaemia with insulin. Insulin to be with-held if pre meal blood glucose < 4 mmol/l.
11621633|NCT00467636|Active Comparator|2|Blood glucose monitoring for comparison with treatment arm (1)
11621634|NCT00467610|Experimental|Panhematin|
11621635|NCT00467597||Group 1|
11621636|NCT00467584|Active Comparator|High Dose Aspirin|High Dose Aspirin; 1300 milligrams of aspirin per day, taken by mouth as two tablets, twice per day for 8 weeks
11621637|NCT00467584|Active Comparator|Low Dose Aspirin|Low Dose Aspirin; 162 milligrams of aspirin per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
11621638|NCT00467584|Placebo Comparator|Placebo|Placebo tablets, matching the active aspirin tablets in appearance, taken by mouth twice per day for 8 weeks
11621639|NCT00467571|Experimental|I|Drug: lansoprazole, clarithromycin, amoxycillin
11621640|NCT00467558|Active Comparator|Naltrexone|Naltrexone 50mg-150mg by mouth per day.
11621641|NCT00467558|Placebo Comparator|Placebo|Placebo pills (1-3 pills daily) depending upon dose prescribed by study physician
11621642|NCT00467519|Experimental|Group 1|DAPTACEL primed participants
11621643|NCT00467519|Experimental|Group 2|Pentacel primed participants
11621644|NCT00467493|Experimental|Anastrozole - A|Treatment for 26 consecutive days
11621645|NCT00467493|Experimental|Anastrozole -B|Treatment for 7 consecutive days early in menstrual cycle
11621646|NCT00467493|Experimental|Anastrozoe - C|Treatment for 7 consecutive days mid follicular phase
11621647|NCT00467493|Experimental|Anastrozole - D|Treatment for 7 consecutive days - mid cycle
11621648|NCT00467493|Experimental|Anastrozole - E|Treatment for 7 consecutive days - luteal
11621649|NCT00467493|Placebo Comparator|Anastrozole - F|Treatment with placebo for 26 consecutive days
11621650|NCT00467454|Active Comparator|1|Naltrexone
11621651|NCT00467454|Placebo Comparator|2|Placebo
11621652|NCT00467402|Experimental|1|
11621653|NCT00467402|Experimental|2|
11621654|NCT00467402|Placebo Comparator|3|
11621655|NCT00467389|Experimental|Oral Placebo First|Three days of daily treatment with oral placebo, followed by three days of daily treatment with 5 mg of donepezil
11621656|NCT00467389|Experimental|Donepezil First|Three days of daily treatment with 5 mg of donepezil, followed by three days of daily treatment with oral placebo.
11621657|NCT00467376|Experimental|1|Administration of Insulin Glulisine
11621658|NCT00467376|Active Comparator|2|Administration of Lispro
11621659|NCT00467363|Active Comparator|Aspirin|81mg of low-dose aspirin plus 400micrograms of folic acid.
11621660|NCT00467363|Placebo Comparator|Placebo|400micrograms of folic acid.
11621661|NCT00467350|Active Comparator|enema|Rectal enema containing mixture of milk and molasses
11621662|NCT00467350|Active Comparator|PEG 3350|Medication to be taken orally once each day for three consecutive days
11621663|NCT00467298|Experimental|Self-management|Novel intensive self-management education and exercise program of four weeks
11621664|NCT00467298|No Intervention|Usual care|Usual care- cardiac or pulmonary rehabilitation exercise program of 8 weeks duration
11621665|NCT00467285||Group 1|140 subjects with type 2 diabetes on pioglitazone.
11621666|NCT00467285||Group 2|140 subjects with type 2 diabetes not on pioglitazone.
11621667|NCT00467272|Experimental|Daptomycin|Daptomycin 6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria.
11621668|NCT00467259|Placebo Comparator|Placebo|28 cm² Placebo patch
11621669|NCT00467259|Experimental|Testosterone|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
11621670|NCT00467233|Experimental|1|Laser Treatment
11621671|NCT00467233|Experimental|2|Acid peel
11621672|NCT00467220|No Intervention|Control|Subjects will follow all study tasks but will not be required to follow a calorie-restricted meal plan.
11621673|NCT00467220|Other|Alternate Day Fasting Arm|Subjects in this arm will be asked to alternate between one day of eating as they wish versus one day on a calorie-restricted meal plan. Subjects will follow this alternating meal plan for 3 months.
11621674|NCT00467220|Other|Calorie Restriction|Subjects in this arm will be asked to follow a calorie-restricted meal plan, daily, for three months.
11621675|NCT00467207|Active Comparator|BoNT A|Botulinum toxin A injections in muscles of the arm (biceps brachii and brachialis)
11621676|NCT00467207|Experimental|Resistance training|8 weeks resistance training
11621677|NCT00467194|Experimental|Phase I study of rapamycin and bevacizumab|"Rapamycin (available as 1mg per tablet; Wyeth) will be given orally once in the morning before meal. The starting dose of rapamycin will be 1mg administered once daily. All doses of rapamycin will be preceded by an oral loading dose three times the maintenance dose on day 1. The dose of rapamycin will be increased at each dose level.
~Bevacizumab (100mg/4ml; Roche) will start concurrently with rapamycin. It will be diluted in a total of 100ml of 0.9% sodium chloride given via intravenous injection. The first dose will be infused over 90 minutes. If the first infusion is tolerated without any adverse infusion-related events (fever and/or chills), the second infusion may be delivered over 60 minutes. If the 60- minute infusion is well tolerated, the subsequent doses may be delivered over 30 minutes."
11621678|NCT00467116|Experimental|Therapeutic Intervention|
11621679|NCT00467103||Chronic Stroke patients with Nonfluent Aphasia|patients with left hemisphere (LH) stroke who have chronic nonfluent aphasia
11621680|NCT00467077|Experimental|Gefitinib and PEG-IFNa Treatment|Gefitinib administered at a dose of 250 mg orally once daily for 12 weeks. PEG-IFNa at 4.0 µg/kg/wk administered subcutaneously once weekly for 6 weeks (cycle repeated once for a total of 2 cycles).
11621681|NCT00467064|Experimental|Arthritis self-management workshop|Comparison of two-week, lay led, scripted self-management workshop emphasizing action planning, problem-solving, and content specific to arthritis.
11621682|NCT00467064|Other|Delayed treatment control|After 4 month delay, participants in Control Group receive Experimental intervention.
11621773|NCT00465894|Active Comparator|Extended Release Tolterodine LA|An anti-muscarinic drug that is used for symptomatic treatment of urinary incontinence.
11621683|NCT00467051|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously or IV once daily until blood count returns to normal. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
11621684|NCT00467038|Other|Dialectical Behavior Therapy|Dialectical Behavior Therapy
11621685|NCT00467038|No Intervention|Healthy Controls|Healthy controls
11621686|NCT00467025|Experimental|Arm A|
11621687|NCT00467025|Experimental|Arm B|
11621688|NCT00467025|Active Comparator|Arm C|
11621689|NCT00467012|Experimental|step 1|6 enrollment for 1 cycle(4 weeks)
11621690|NCT00467012|Experimental|step 2|114 enrollment through to meet the stopping criteria
11621691|NCT00466999|Active Comparator|surgery|standard surgical treatment (either dilation and curettage or manual vacuum aspiration)
11621692|NCT00466999|Active Comparator|misoprostol|400 mcg misoprostol
11621693|NCT00466973|Active Comparator|Dry bipolar radiofrequency (RF) clamp|used for ablation during surgical procedure
11621694|NCT00466973|Active Comparator|Unipolar microwave antenna|used for ablation during surgical procedure
11621695|NCT00466973|Active Comparator|Unipolar cryothermic probe|used for ablation during surgical procedure
11621696|NCT00466973|Active Comparator|Irrigated unipolar RF antenna|used for ablation during surgical procedure
11621697|NCT00466973|Active Comparator|Irrigated bipolar RF clamp|used for ablation during surgical procedure
11621698|NCT00466973|Active Comparator|Hi-intensity focused ultrasound wand|used for ablation during surgical procedure
11621699|NCT00466960|Experimental|Treatment (colony stimulating factor and chemotherapy)|"INDUCTION THERAPY: Patients receive GM-CSF SC once daily on days 16-26. Patients also receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Beginning 14 days after last GM-CSF injection, patients receive GM-CSF SC once daily on days 1-15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
11621700|NCT00466947|Experimental|Synflorix Group|Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).
11621701|NCT00466947|Active Comparator|Control Group|Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.
11621702|NCT00466921|Experimental|Lenalidomide|
11621703|NCT00466895|Experimental|Stratum 1 Acute Leukemias|Patients must have a diagnosis of Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia(ALL)according to the WHO (World Health Organization) classification.
11621704|NCT00466895|Experimental|Stratum 2 Chronic lymphocytic leukemia|Patients must have diagnosis of B-Cell, Chronic Lymphocytic Leukemia(CLL) or Small Lymphocytic Leukemia (SLL) (including Waldenstrom's Macroglobulinemia) requiring therapy (see eligibility criteria for definition of this) and have previously received treatment with one or more prior chemotherapy regimens.
11621705|NCT00466882||Inamed Lap-Band System|The LAPBAND is positioned laparoscopically around the stomach and requires an overnight hospitalization and an upper GI swallow the next morning. The device can be gradually adjusted to increase stomach constriction by the physician in an office setting so that the patient loses approximately 1-2 pounds per week over two years.
11621706|NCT00466856|Experimental|Sir-Spheres|
11621707|NCT00466843|Experimental|1|Participants will be treated with ATG
11621708|NCT00466817|Experimental|Valganciclovir|Six months of oral Valganciclovir.
11621709|NCT00466817|Placebo Comparator|Placebo|Six weeks of oral Valganciclovir followed by placebo to complete the six month time period.
11621710|NCT00466804||Heart Transplant Recipients|People who will have a heart transplant
11621711|NCT00466791|Active Comparator|Methylphenidate Transdermal System|Transdermal patch, 27.5mg, 41.3mg, 55mg, and 82.5mg, daily for 11 weeks
11621712|NCT00466791|Placebo Comparator|Placebo|Transdermal patch, 0mg, daily for 11 weeks
11621713|NCT00466765|Experimental|Single Arm|Use Brava system for pre-expansion of breast prior to fat grafting
11621714|NCT00466752|Experimental|Treatment (enzyme inhibitor) 48hr stop|Patients receive sorafenib tosylate PO BID on days 1-14. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 days after completion of sorafenib tosylate, patients undergo radical prostatectomy on approximately day 43.
11621715|NCT00466752|Experimental|Treatment (enzyme inhibitor) 24hr stop|tients receive sorafenib tosylate PO BID on days 1-14. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 day after completion of sorafenib tosylate, patients undergo radical prostatectomy on approximately day 43.
11621716|NCT00466687|Experimental|Therapeutic Intervention|"Tarceva and Avastin:
~Tarceva: 150mg PO, days 1-28
~Avastin: 10mg/kg, IV infusion, days 1,15 Regimen will be repeated every 28 days = 1 course"
11621717|NCT00466674|Experimental|Allogenic Transplant|
11621718|NCT00466661|Experimental|Acamprosate|666 mg p.o. TID
11621719|NCT00466661|Placebo Comparator|Placebo|Matching placebo
11621720|NCT00466622|Experimental|1|Metformin 1000mg x 2 daily. Orally. From Weifa
11621721|NCT00466622|Placebo Comparator|2|Placebo 2 tablets x 2 daily. Orally From Weifa
11621722|NCT00466609|Experimental|Quetiapine (fluoxetine plus quetiapine)|fluoxetine up to 40mg once a day plus Quetiapine up to 200mg once a day, during 12 weeks
11621723|NCT00466609|Active Comparator|Clomipramine (fluoxetine plus clomipramine)|Fluoxetine up to 40mg once a day plus clomipramine up to 75mg once a day, during 12 weeks
11621724|NCT00466609|Placebo Comparator|Placebo (fluoxetine plus placebo)|Fluoxetine up to 80 mg once a day plus placebo 3 pills once a day, during 12 weeks
11621774|NCT00465894|Active Comparator|Intra Vaginal Estradiol Cream|For topical application to the vaginal area to treat symptoms of urgency or irritation with urination.
11621725|NCT00466531|Experimental|Patients with CLL or indolent B-cell lymphoma|The first stage is a standard 3-step phase I dose escalation trial to assess the safety of 19-28z CAR expressing autologous T cells with or without prior conditioning chemotherapy.Step 1, a cohort of pts will receive the lowest planned dose of 19-28z+ modified T cells. Step 2, a cohort of pts will receive cyclophosphamide conditioning chemotherapy followed by the lowest planned dose of 19-28z+ modified T cells. If less than 33% of pts in the cohort experience unanticipated dose-limiting toxicity,Step 3, a cohort of pts will be treated with the investigator's choice conditioning chemotherapy followed by the higher dose of 19-28z+ modified T cells. If less than 33% of pts in the initial cohort (Step 3) experience unanticipated dose-limiting toxicity, the cohort in Step 3 may be expanded to include up to 15 pts. In Step 3, an additional cohort of Waldenstrom's Macroglobulinemia (WM) pts will be treated with the investigator's choice conditioning chemotherapy followed by 19-28z+ T cells.
11621726|NCT00466518|Experimental|1|
11621727|NCT00466505|Experimental|Therapeutic Intervention|
11621728|NCT00466492|Other|No sedatation intervention|The intervention group is the normal care in our institution, the control group is the golden standard
11621729|NCT00466466|Experimental|Daily dosing RAD001|
11621730|NCT00466466|Experimental|Weekly dosing RAD001|
11621731|NCT00466440|Experimental|docetaxel + prednisone + enzastaurin|Regimen A: docetaxel 75 milligrams per square meter (mg/m^2), intravenous (IV) is administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 milligrams (mg) oral (po), twice daily (BID) every day. In Cycle 1, enzastaurin is given as a loading dose of 1125 mg on the day prior to docetaxel and prednisone therapy, followed by enzastaurin 500 mg po, daily (QD) for the remaining Period 2 (chemotherapy) and Period 3 (maintenance).
11621732|NCT00466440|Placebo Comparator|docetaxel + prednisone + placebo|Regimen B: docetaxel 75 mg/m^2, IV is administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 mg po, BID every day. In Cycle 1, placebo is given as a loading dose on the day prior to docetaxel and prednisone therapy, followed by po, QD placebo for the remaining Period 2 (chemotherapy) and Period 3 (maintenance), until unblinding.
11621733|NCT00466440|Experimental|docetaxel + prednisone + enzastaurin (modified Regimen A)|Modified Regimen A, including pharmacokinetic (PK) characterization: Participants were treated with a modified investigational regimen with no dose escalation: docetaxel 75 mg/m2, IV was administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 mg po, BID every day. In Cycle 1, enzastaurin was given as a loading dose of 1125 mg starting on Day 4, followed by enzastaurin 500 mg po, QD for the remaining Period 2 (chemotherapy) and Period 3 (maintenance).
11621734|NCT00466375||A|Patients with a hemangioma.
11621735|NCT00466375||B.|Patients with a vascular anomaly.
11621736|NCT00466323|Experimental|FMPO Condition|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
11621737|NCT00466323|Active Comparator|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
11621738|NCT00466310|Active Comparator|Aripiprazole for 4 weeks|Blood is drawn for baseline. 20 Subjects are randomly assigned to receive Aripiprazole for weeks weeks with a starting dose of 10mg/day and the dose will be titrated to a maximum of 30mg /day based on effectiveness and tolerability. After 4 weeks of treatment, blood will be drawn again for metabolomics.
11621739|NCT00466310|Active Comparator|Risperidone for 4 weeks|Blood will be drawn for baseline evaluation. 20 Subjects will be randomly assigned to receive risperidone at a starting dose of 2mg/day, and can be increased to 6mg/day based on response of the subject. After 4 weeks of medication, blood is drawn again.
11621740|NCT00466310|Other|Healthy volunteers|Fasting blood samples will be drawn from healthy volunteers to match age, race and gender with the research subjects for comparison.
11621741|NCT00466245|Experimental|A|Previously vaccinated for smallpox, 1x10-8 dose
11621742|NCT00466245|Experimental|B|Smallpox vaccine naive, 1x10-8 dose
11621743|NCT00466245|Experimental|C|Previous smallpox vaccination, 1x10-7 dose
11621744|NCT00466245|Experimental|D|Smallpox vaccine naive, 1x10-7 dose
11621745|NCT00466245|Experimental|E|Previous smallpox vaccination, 1x10-6 dose
11621746|NCT00466245|Experimental|F|Smallpox vaccine naive, 1x10-6 dose
11621747|NCT00466245|Experimental|G|Previous smallpox vaccination, placebo dose
11621748|NCT00466245|Experimental|H|Smallpox vaccine naive, placebo dose
11621749|NCT00466232|Experimental|1|Weekly Topetecan in combination with Sorafenib
11621750|NCT00466206|Experimental|3MP - Treatment Arm|Magnetic Mini-Mover Procedure using the Magnimplant and Magnatract
11621751|NCT00466193|Experimental|Zolpidem 3.5mg|
11621752|NCT00466193|Placebo Comparator|Placebo|
11621753|NCT00466167|Other|Pramipexole ER|
11621754|NCT00466167|Other|Pramipexole IR|
11621755|NCT00466167|Placebo Comparator|Placebo|
11621756|NCT00466102|Active Comparator|1|Patients with stable disease after 8 week run in randomized to RAD001 (blinded)
11621757|NCT00466102|Placebo Comparator|2|Patients with stable disease after 8 week run in receive placebo (blinded)
11621758|NCT00466089|Experimental|1|RT + Tarceva
11621759|NCT00466089|No Intervention|2|RT
11621760|NCT00466063||ICL670|ICL670
11621761|NCT00466024|Experimental|1|Health coach and 2 HEPA air cleaners
11621762|NCT00466024|Active Comparator|2|Standard asthma education and 2 HEPA air cleaners
11621763|NCT00466024|Active Comparator|3|Standard asthma education and delayed receipt of 2 HEPA air cleaners
11621764|NCT00465985|Experimental|Part I, Part II-arm1, & Part III|
11621765|NCT00465985|Placebo Comparator|Part II - arm 2|
11621766|NCT00465972|Placebo Comparator|Placebo|Placebo
11621767|NCT00465972|Active Comparator|2|Doxepin
11621768|NCT00465972|Active Comparator|3|Temazepam
11621769|NCT00465959|Experimental|400 mg TrIP|
11621770|NCT00465959|Experimental|800 mg TrIP|
11621771|NCT00465959|Placebo Comparator|Placebo|
11621772|NCT00465907|Experimental|Paclitaxel, Carboplatin and Irinotecan|Study of Weekly Paclitaxel, Carboplatin and Irinotecan in patients with Non-Small Cell Lung Carcinoma
11621826|NCT00465283|Active Comparator|Donepezil|
11621775|NCT00465855|Active Comparator|Hyperbaric Oxygen (HBO2) - 3 sessions|Subjects undergo 3 hyperbaric oxygen sessions within 24 hours following carbon monoxide poisoning.
11621776|NCT00465855|Sham Comparator|Hyperbaric Oxygen (HBO2) - 1 session|Subjects undergo 1 hyperbaric oxygen session and then 2 sham chamber sessions within 24 hours of carbon monoxide poisoning.
11621777|NCT00465842||A - Normal Volunteers|"Normal volunteers without any history of liver disease and with normal liver functions test (LFT), including total protein/Albumin, LDH, ALT, AST, GGT, total bilirubin, direct and indirect bilirubin and do not belong to group B.
~Volunteers will be screened using questionnaires. Those deemed suitable will then be asked to have the blood test done. All blood tests are done free of charge to subjects."
11621778|NCT00465842||B - Hepatitis B or C carriers with normal liver functions|
11621779|NCT00465842||C - Hepatitis B or C carriers with abnormal liver functions|
11621780|NCT00465842||D - Liver Cirrhosis|Liver cirrhosis, proven by liver biopsy or on clinical evidences, such as varices on CT scan indicative of portal hypertension.
11621781|NCT00465842||E - Hepatocellular Carcinoma (HCC) with Resection|HCC patients with resection.
11621782|NCT00465842||F - Unresectable HCC|Unresectable HCC patients with treatment
11621783|NCT00465842||G - Malignant HCC|HCC patients with active malignant disease and only palliative care are offered.
11621784|NCT00465816|Experimental|Nimenrix + Twinrix Group|Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.
11621785|NCT00465816|Active Comparator|Nimenrix Group|Subjects received 1 dose of Nimenrix™ vaccine at Month 0.
11621786|NCT00465816|Active Comparator|Twinrix Group|Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.
11621787|NCT00465803|Other|DuoTrav|One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months, as recorded by dosing aid
11621788|NCT00465803|Other|Travatan/Timolol|One drop Timolol in the study eye(s) once daily at 8 AM; one drop of Travatan in the study eye(s) once daily at 8 PM. Both products dosed for twelve months, as recorded by separate dosing aid for each product.
11621789|NCT00465764|Experimental|Protein formula|Feed as per HCP direction
11621790|NCT00465764|Active Comparator|Standard infant formula|Feed as per HCP instructions
11621791|NCT00465751|Active Comparator|A|chenodeoxycholic acid treatment
11621792|NCT00465751|Placebo Comparator|B|placebo treatment
11621793|NCT00465738|Experimental|incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 5.0 mL of sterile sodium chloride [NaCl] 0.9% solution without preservatives. Dilution with 5.0 mL resulted in a dose of 20 units per 1.0 mL."
11621794|NCT00465738|Active Comparator|incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 mL sterile of NaCl 0.9% solution without preservatives. Dilution with 2.0 mL resulted in a dose of 50 units per 1.0 mL."
11621795|NCT00465725|Experimental|1|two-period crossover, open label study in which a single dose (Cycle 1) of picoplatin will be given either IV or PO, followed 4 weeks later by a single dose (Cycle 2) of picoplatin given by the route not used for Cycle 1. Subjects subsequently may continue to receive IV picoplatin commencing with Cycle 3 in a Continuation Study.
11621796|NCT00465712|Experimental|A|Transabdominal amnioinfusion performed before external cephalic version
11621797|NCT00465712|No Intervention|V|Without transabdominal amnioinfusion
11621798|NCT00465686|Experimental|A|
11621799|NCT00465647|Experimental|≥ 28 Days to < 13 Months|infant and toddler
11621800|NCT00465647|Experimental|≥ 13 months to < 5 years|young child
11621801|NCT00465647|Experimental|≥ 5 years to < 12 years|older child
11621802|NCT00465647|Experimental|≥ 12 years to < 17 years|adolescent
11621803|NCT00465608|Experimental|1|propranolol
11621804|NCT00465595|Experimental|Low Dose First, High Dose Second|The Low-Dose-1st Group received the low dose of psilocybin on the first session and the high dose on the second session
11621805|NCT00465595|Experimental|High Dose First, Low Dose Second|The High-Dose-1st Group received the high dose of psilocybin on the first session and the low dose on the second session
11621806|NCT00465569|Experimental|Active Treatment|Pre-measured doses of dry, nonfat powered milk prepared by the clinical research-registered dieticians
11621807|NCT00465569|Placebo Comparator|Placebo|
11621808|NCT00465556|Experimental|1|Dove Intervention
11621809|NCT00465556|Active Comparator|2|Intimate Partner Violence (IPV) Protocol
11621810|NCT00465543|Placebo Comparator|II|Arm 2 receives 4 weeks of placebo mint tea (consumed twice a day) followed by 4 weeks of washout and then a further 4 weeks of treatment with study mint tea (consumed twice a day).
11621811|NCT00465543|Placebo Comparator|I|Arm 1 receives 4 weeks of treatment with mint tea high in rosmarinic acid, consumed twice a day. Treatment is followed by a 4 week wash-out phase. Subjects then enter a 4 week phase of placebo mint tea (low in rosmarinic acid), to be consumed twice a day.
11621812|NCT00465530|Experimental|2|Saline plus Gentamycin
11621813|NCT00465530|Placebo Comparator|1|Saline
11621814|NCT00465517|Experimental|ganaxolone|active study drug
11621815|NCT00465517|Placebo Comparator|non-active drug|placebo
11621816|NCT00465491|Experimental|1|Picoplatin
11621817|NCT00465491|Other|2|BSC
11621818|NCT00465465|Active Comparator|1|Dose of 1 x 10^7
11621819|NCT00465465|Active Comparator|2|Dose of 1 x 10^8
11621820|NCT00465426||1|HIV Positive men and women 18-65 years of age
11621821|NCT00465426||2|HIV negative men and women 18-65 years of age
11621822|NCT00465361|No Intervention|Baseline Performance|Observation of baseline performance
11621823|NCT00465361|Experimental|Post-intervention Performance|Observation of performance post-intervention
11621824|NCT00466388|Experimental|Cevimeline|Evoxac tid for xerostomia
11621825|NCT00466388|Placebo Comparator|Placebo|sugar pill
11621829|NCT00465270|Active Comparator|Standard or Care - Medical Management|Medical treatment with Aspirin alone, Coumadin alone, Clopidogrel alone, or Aspirin combined with dipyridamole.
11621830|NCT00465244|Experimental|1|Levetiracetam 1 g IV + Lorazepam 2 mg IV
11621831|NCT00465244|Other|2|Placebo + Lorazepam 3 mg IV
11621832|NCT00465231|Active Comparator|1|Epidural
11621833|NCT00465231|Placebo Comparator|2|Epidural - saline solution
11621834|NCT00465218||1|High dose aspirin (325 mg)
11621835|NCT00465218||2|Low dose aspirin (81 mgs) plus warfarin
11621836|NCT00465205|Experimental|I|
11621837|NCT00465179|Experimental|Sunitinib Malate|Sunitinib Malate 50 mg by mouth daily for 4 weeks, then 2 weeks off.
11621838|NCT00465166||1|Patients who had a documented, accidental dural puncture during placement of their labor epidural.
11621839|NCT00465153|Experimental|1|Flax oil
11621840|NCT00465153|Placebo Comparator|2|corn oil
11621841|NCT00465101|Other|GreenLight HPS|
11621842|NCT00465088|Experimental|1|
11621843|NCT00465088|Experimental|2|
11621844|NCT00465049|Experimental|primary closure|suture after I&D
11621845|NCT00465049|Placebo Comparator|SECONDARY CLOSURE|LEAVE TO HEAL BY SECONDARY INTENTIN AFTER I&D
11621846|NCT00465023|Experimental|Proton Beam Radiation|Proton radiation therapy
11621847|NCT00464984|Active Comparator|ILI-group|Intensive lifestyle intervention at a tertiary care rehabilitation center. Treatment included changes in both dietary habits (calori restriction) and physical activity with particularly high intensity the first 3 months.
11621848|NCT00464984|Active Comparator|MLI|Moderate lifestyle intervention at a secondary care outpatient center. Treatment included moderate changes in dietary habits (calori restriction) and physical activity.
11621849|NCT00464958|Experimental|Sublingual tizanidine|Once nightly dosing of 12 mg sublingual tizanidine tablet
11621850|NCT00464945|Experimental|1|
11621851|NCT00464945|Active Comparator|2|
11621852|NCT00464919|Experimental|A|
11621853|NCT00464893|Active Comparator|catumaxomab arm|Patients will get first the chemotherapeutic regimen (Epirubicin, Cisplatin and Capecitabine or 5-Fluorouracil) consisting of three 21-day cycles, starting on the weeks 1, 4 and 7. Four weeks after CTx the D2 surgery will take place. Treatment with catumaxomab will consist of an initial dose of 10µg given intraoperatively as in intraperitoneal bolus and of four postoperative ascending doses.
11621854|NCT00464841|Experimental|1|Tsui test for combined spinal-epidural
11621855|NCT00464841|Experimental|2|Tsui test for intrathecal catheter
11621856|NCT00464815|Experimental|Group A|Subjects of 11-17 years of age who will receive GSK134612
11621857|NCT00464815|Active Comparator|Group B|Subjects of 11-17 years of age who will receive MencevaxTM ACWY
11621858|NCT00464776|Experimental|1|Various sequences of 3 doses of Aliskiren plus placebo
11621859|NCT00464776|Experimental|2|Various sequences of 3 doses of Aliskiren plus placebo
11621860|NCT00464776|Experimental|3|Various sequences of 3 doses of Aliskiren plus placebo
11621861|NCT00464776|Experimental|4|Various sequences of 3 doses of Aliskiren plus placebo
11621862|NCT00464763|Experimental|Dexmedetomidine|
11621863|NCT00464763|Placebo Comparator|Placebo (PBO)|
11621864|NCT00464737|Placebo Comparator|Placebo|Placebo
11621865|NCT00464737|Experimental|Rotigotine 4 mg|4 mg/24 hrs
11621866|NCT00464737|Experimental|Rotigotine 8 mg|8 mg/24 hrs
11621867|NCT00464724|Experimental|3T MRSI Prostate|3T Magnetic Resonance Spectroscopic Imaging
11621868|NCT00464711|Other|Escitalopram|single arm
11621869|NCT00464698|Experimental|All Study Participants|Duloxetine 30mg: Dose level 1 (Week 1) Duloxetine 60mg: Dose level 2 (Wks 2-4) Duloxetine 120mg: Dose level 3 (Wks 3-7)
11621870|NCT00464685|Experimental|700 µg Dexamethasone Implant and Laser Photocoagulation|Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
11621871|NCT00464685|Sham Comparator|Sham Implant and Laser Photocoagulation|Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
11621872|NCT00464672|Experimental|Influenza virus vaccine|
11621873|NCT00464672|Active Comparator|Comparator influenza vaccine|
11621874|NCT00464659|Experimental|Effective CPAP treatment|Effective Continuous Positive Airway Pressure treatment (CPAP) applied for 6 weeks
11621875|NCT00464659|Sham Comparator|Sham CPAP treatment|Ineffective Continuous Positive Airway Pressure treatment (sham CPAP) applied for 6 weeks
11621876|NCT00464646|Experimental|1|"Cohort A: Women with unresected locally advanced breast cancer (clinical Stage IIIA, IIIB, and IIIC)
~Cohort B: Women with resected pN2 or pN3 (pathologic Stage III) breast cancer"
11621877|NCT00464633|Experimental|Alvocidib|Cycles with 4-week treatment with alvocidib followed by 2-week rest period for up to a maximum of 6 cycles
11621878|NCT00464620|Experimental|Dasatinib, 70 mg, twice daily|Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
11621879|NCT00464555|Experimental|Islet Transfusion and LSF|Participants assigned to this group will receive an islet transfusion and an immunosuppressive medication regimen containing LSF.
11621880|NCT00464542|Other|Metronidazole|Observational before and after treatment Drug: Metronidazole 500 mg, taken by mouth, two times a day, 7 days
11621881|NCT00464516|Experimental|estetrol|
11621882|NCT00464516|Placebo Comparator|placebo|
11621883|NCT00464490|No Intervention|Standard Hospital Ventilation Weaning Protocol|Control. Hospital weaning protocol
11621884|NCT00464490|Experimental|Dexmedetomidine for Extubation|Dexmedomidine infusion to facilitate extubation
11621885|NCT00464464|Active Comparator|1|cognitive-behavioral therapy
11621886|NCT00464464|No Intervention|2|standard medical care
11621887|NCT00464451|Experimental|1|Dexmedetomidine sedated pediatric patients undergoing EEG study.
11621888|NCT00464451|Active Comparator|2|Chloral hydrate sedated pediatric patients undergoing sedated EEG study.
11621889|NCT00464438|Experimental|1|
11621890|NCT00464438|Active Comparator|2|
11622645|NCT00455429|Experimental|JNJ-26113100 (100 mg) once daily|
11621891|NCT00464425|Experimental|Electroacupuncture (EA)|EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles
11621892|NCT00464425|Sham Comparator|Sham Acupuncture (SA)|Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used
11621893|NCT00464425|No Intervention|No Acupuncture (NA)|Control
11621894|NCT00464386|No Intervention|POC Glucose Testing|Hourly blood glucose monitoring with point of care glucometer (i.e., current standard of care).
11621895|NCT00464386|Experimental|Continuous Glucose Monitoring|Continuous arterial glucose monitoring with Guardian sensor + hourly blood glucose monitoring with point of care glucometer (i.e., current standard of care).
11621896|NCT00464373|Experimental|1|Botulinum Toxin Type A 200 U in 4ml NaCl 0.9%
11621897|NCT00464373|Placebo Comparator|2|4ml NaCl 0.9%
11621898|NCT00464334|Experimental|Placebo to V950/IMX 0 mcg|Participants receive Placebo to V950/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
11621899|NCT00464334|Experimental|Placebo to V950/IMX 16 mcg|Participants receive Placebo to V950/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
11621900|NCT00464334|Experimental|V950 0.5 mcg/IMX 0 mcg|Participants receive V950 0.5 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
11621901|NCT00464334|Experimental|V950 0.5 mcg/IMX 16 mcg|Participants receive V950 0.5 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
11621902|NCT00464334|Experimental|V950 0.5 mcg/IMX 47 mcg|Participants receive V950 0.5 mcg/IMX 47 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
11621903|NCT00464334|Experimental|V950 0.5 mcg/IMX 94 mcg|Participants receive V950 0.5 mcg/IMX 94 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
11621904|NCT00464334|Experimental|V950 5 mcg/IMX 0 mcg|Participants receive V950 5 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
11621905|NCT00464334|Experimental|V950 5 mcg/IMX 16 mcg|Participants receive V950 5 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
11621906|NCT00464334|Experimental|V950 5 mcg/IMX 47 mcg|Participants receive V950 5 mcg/IMX 47 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
11621907|NCT00464334|Experimental|V950 50 mcg/IMX 0 mcg|Participants receive V950 50 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
11621908|NCT00464334|Experimental|V950 50 mcg/IMX 16 mcg|Participants receive V950 50 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
11621909|NCT00464321|Experimental|Cohort A|Dose Group
11621910|NCT00464321|Experimental|Cohort B|Dose Group
11621911|NCT00464321|Experimental|Cohort C|Dose Group
11621912|NCT00464321|Experimental|Cohort D|Dose Group
11621913|NCT00464308|Active Comparator|001|Esomeprazole 40mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
11621914|NCT00464308|Active Comparator|002|Esomeprazole 20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
11621915|NCT00464308|Active Comparator|003|Rabeprazole 20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
11621916|NCT00464269|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period.
11621917|NCT00464269|Experimental|Brivaracetam 5 mg/day|Brivaracetam 5 mg/day, 2.5 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 5 mg /day in a double-blinded way for the 12-week Treatment Period.
11621918|NCT00464269|Experimental|BRV 20mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period.
11621919|NCT00464269|Experimental|BRV 50mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day, in a double-blinded way for the 12-week Treatment Period.
11621920|NCT00464243|Experimental|Volinanserin|2 mg volinanserin tablets orally once daily
11621921|NCT00464243|Placebo Comparator|Placebo|tablets orally once daily
11621922|NCT00464204|Experimental|Voluven® Arm|
11621923|NCT00464204|Active Comparator|0.9 % NaCl|
11621924|NCT00464178|Experimental|Bortezomilb and bevacizumab|Bortezomilb will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
11621925|NCT00464139||1|"The electronic files of all patients who consulted the LUFC since 2003 were searched to select women with at least 1 year of infertility, a regular cycle (variation 21 - 35 days), whose partner had normal sperm according to World Health Organization (WHO) criteria (n = 304).
~After exclusion of 83 (27,3%) patients with a previous laparoscopic diagnosis of endometriosis before referral to our centre, 221 (72,7%) infertile women were included in our study."
11621926|NCT00464126|Active Comparator|Colloid|5% albumin for volume resuscitation
11621927|NCT00464126|Placebo Comparator|Crystalloid|Saline for volume resuscitation
11621928|NCT00464113|Experimental|1|once-weekly dosing
11621929|NCT00464113|Experimental|2|twice-weekly dosing
11621930|NCT00464087|Active Comparator|Heparin|Patients are switched from fondaparinux to heparin, receiving a dose of 60 U/Kg IV during the PCI
11621931|NCT00464087|Active Comparator|Bivalirudin|Patients switched from fondaparinux to bivalirudin, received a bolus of 0.75 mg/kg IV followed by infusion of 1.75 mg/g per hour infusion during the PCI.
11621932|NCT00464061|Experimental|Volinanserin|
11621933|NCT00464061|Placebo Comparator|Placebo|
11621934|NCT00464009|Active Comparator|A|Group A practices (n=39) received didactic training and course materials in oral health screening, referral, counseling and application of fluoride varnish.
11621935|NCT00464009|Active Comparator|B|Group B practices (n=41) received the same as Group A and were offered weekly conference calls providing advice and support.
11621936|NCT00464009|Active Comparator|C|Group C practices (n=41) received the same as Group B and were also offered in-office follow-up visits providing hands-on advice and support.
11621937|NCT00463983|Experimental|octreotide|octreotide SR 30 mg intra muscularly every 4 weeks
11621938|NCT00463970|Active Comparator|1|Brief Intervention
11621939|NCT00463970|Experimental|2|Cognitive Behavioural Therapy
11621940|NCT00463970|Experimental|3|Seal oil
11621942|NCT00463905|No Intervention|1|Current management for identifying postmenopausal women with osteoporotic vertebral fractures in primary care i.e. nothing
11621943|NCT00463905|Experimental|2|Intervention arm: simple clinical assessment to identify high risk 30% (approximately) who will then be offered lateral thoraco-lumbar X-rays
11621944|NCT00463853|Experimental|Arm 1|direct intramyocardial injection of cells as adjunct to CABG
11621945|NCT00463840|Experimental|Oxaliplatin+ 5FU+ radiation (RT) /surgery /FOLFOX 6|"Concurrent chemoradiation before surgery and FOLFOX6 regimen after surgery
~Radiation (RT) 180cGy daily x 5 days/week x 5 weeks, then additional 540 cGy in 3 fractions over a half week to pancreatic portal;
~Combined with :
~5FU 200 mg/m^2 daily by continuous intravenous infusion (CIV) x 5 weeks and weekly Oxaliplatin 60 mg/m^2, IV for 5 weeks (in Phase I, 30, 40, 50, and 60 mg/m^2 Oxaliplatin were tested).
~Observation for 2 weeks to assess dose-limiting toxicity (DLT)/Response. Surgery if deemed resectable.
~Then modified FOLFOX 6 for 6 cycles (2 weeks/cycle):
~Day 1 hour 0: Oxaliplatin 85 mg/m^2 intravenously (IV) + Leucovorin 350 mg IV over 2 hours; hour 2: 5FU 400 mg/m^2 IV bolus followed by 2400 mg/m^2 IV over 46 hours."
11621946|NCT00463827|Active Comparator|2|Atorvastatin 40
11621947|NCT00463827|Placebo Comparator|placebo|matched placebo
11621948|NCT00463814|Experimental|AZD6244|
11621949|NCT00463801|Experimental|Daptomycin|350 mg of Daptomycin was supplied as sterile lyophilized powder in glass vials. Each vial was to be reconstituted with 7 mL of normal saline or water for injection, to give a 50 mg/mL drug concentration. Daptomycin was to be administered as a 30-minute intravenous infusion, once daily for at least 7 days, at the dose of 4 mg/Kg, up to a maximum of 14 days.
11621950|NCT00463788|Experimental|cisplatin and cetuximab|
11621951|NCT00463788|Active Comparator|cisplatin|
11621952|NCT00463749|Active Comparator|1|High-dose N-Acetylcystein during percutaneous coronary intervention and for 2 days post intervention 2 x/day
11621953|NCT00463749|Placebo Comparator|2|Placebo (NaCl)
11621954|NCT00463736|Active Comparator|Magnesium sulfate|x 48 hours IV
11621955|NCT00463736|Placebo Comparator|Normal saline|x 48 hours IV
11621956|NCT00463697|Experimental|GW642444M 25mcg|Subject will inhale single dose of GW642444M 25 mcg via a DISKUS device in morning.
11621957|NCT00463697|Experimental|GW642444M 100mcg|Subject will inhale single dose of GW642444M 100 mcg via a DISKUS device in morning.
11621958|NCT00463697|Experimental|GW642444M 400mcg|Subject will inhale single dose of GW642444M 400 mcg via a DISKUS device in morning.
11621959|NCT00463697|Experimental|GW642444H 100mcg|Subject will inhale single dose of GW642444H 100 mcg via a DISKUS device in morning.
11621960|NCT00463697|Placebo Comparator|placebo|Subject will inhale single dose of Placebo via a DISKUS device in morning.
11621961|NCT00463684|Experimental|All subjects|Healthy infants 9 months of age (plus or minus 2 weeks) that met the eligibility criteria. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV) and one dose of live, attenuated measles vaccine.
11621962|NCT00463658|Experimental|1|Subjects in the interdisciplinary group received home care services from a team of professional service providers (CCAC Case Manager, Registered Nurse, Occupational Therapist, Physiotherapist, Registered Dietician) with experience and training in falls prevention. The team provided a comprehensive, coordinated and evidence based approach to falls prevention through regular home visits, weekly case conferencing, a single accessible fall prevention plan,and joint client visits.
11621963|NCT00463658|No Intervention|2|Participants allocated to the control group received standard home care services arranged by the CCAC. These include routine follow-up by the CCAC case manager whose focus is on assessing client's eligibility for in-home health services, arrangement and coordination of professional (i.e. nursing, occupational therapy, physiotherapy, social work, speech-language pathology, nutrition) and non-professional HSS, information and referral to community agencies, and ongoing monitoring and evaluating the plan of care through in-home assessments with clients.
11621964|NCT00463606|Experimental|ABT-335 and Rosuvastatin Calcium|ABT-335 135mg in combination with rosuvastatin calcium 5mg administered orally, once daily for 12 weeks
11621965|NCT00463606|Active Comparator|ABT-335|ABT-335 135mg monotherapy administered orally, once daily for 12 weeks
11621966|NCT00463606|Active Comparator|Rosuvastatin Calcium|Rosuvastatin calcium 5mg monotherapy administered orally, once daily for 12 weeks
11621967|NCT00463593||2|children enrolled in formal schools and children not enrolled in formal schools
11621968|NCT00463580|Experimental|Infliximab|Participants in this arm will receive an infusion of infliximab.
11621969|NCT00463580|Placebo Comparator|Placebo|Participants in this arm will receive an infusion of normal saline.
11621970|NCT00463567|Experimental|Indacaterol 150 µg (Continued Into Stage 2)|"In the morning, Indacaterol 150 µg once daily orally inhaled via a single dose dry powder inhaler (SDDPI) + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
~Daily Inhaled Corticosteroid (ICS) monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
11621971|NCT00463567|Experimental|Indacaterol 300 µg (Continued Into Stage 2)|"In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
11621972|NCT00463567|Active Comparator|Tiotropium 18 µg (Continued Into Stage 2)|"Tiotropium 18 µg dry powder capsules delivered (open label) via manufacturer's proprietary SDDPI, (Handihaler®). Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2.
~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
11622060|NCT00462384|Experimental|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 micrograms per kilogram (mcg/kg) body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
11621973|NCT00463567|Placebo Comparator|Placebo (Continued Into Stage 2)|"In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.
~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
11621974|NCT00463567|Experimental|Indacaterol 75 µg (Not Continued into Stage 2)|"In the morning, Indacaterol 75 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.
~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
11621975|NCT00463567|Experimental|Indacaterol 600 µg (Not Continued Into Stage 2)|"In the morning, 2 capsules of Indacaterol 300 µg once daily orally inhaled via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.
~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
11621976|NCT00463567|Active Comparator|Formoterol 12 µg (Not Continued Into Stage 2)|"In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Formoterol 12 µg delivered via Aerolizer. In evening, Formoterol 12 µg delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.
~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
11621977|NCT00463541|Experimental|1|
11621978|NCT00463489|Active Comparator|Mail-based|Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
11621979|NCT00463489|Experimental|Individualized Lifestyle Intervention|Women randomized to the individualized lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
11621980|NCT00463476|Experimental|2-year olds|Healthy children 2 years of age (±3 months) who had previously received all vaccinations recommended under the Sri Lankan childhood immunization schedule according to their age. Subjects must have previously received inactivated mouse brain-derived Japanese Encephalitis vaccine (IMBV) at the recommended 12 and 13 months of age. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV).
11621981|NCT00463476|Experimental|5-year olds|Healthy children 5 years of age (±3 months) that met all other eligibility criteria. Subjects must have previously received inactivated mouse brain-derived Japanese Encephalitis vaccine (IMBV) at the recommended 12, 13, and 24 months of age. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV).
11621982|NCT00463450|Experimental|Arm 1|
11621983|NCT00463450|Active Comparator|Arm 2|
11621984|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany & Poland and Infanrix™ IPV Hib in Spain) and Wyeth's Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.
11621985|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany & Poland and Infanrix™ IPV Hib in Spain) and Baxter's Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.
11621986|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany & Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
11621987|NCT00463437|Active Comparator|Prevenar™ + Menitorix™|Subjects receiving a booster dose of Wyeth's pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany & Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
11621988|NCT00463398||Patients operated at the LUFc|All patients operated at the Leuven University Fertility Centre (LUFc) between september 2006 and August 2008.
11621989|NCT00463385|Experimental|Prednisone|"Participants received oral prednisone from Day 1-28 of each 28-day cycle for up to 3 cycles (84 days), 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day, and pomalidomide placebo tablets on Days 1-28 for up to 12 cycles in the Double-Blind Treatment Phase.
~After the completion of cycle 12 and upon unblinding, participants were discontinued from the study."
11621990|NCT00463385|Experimental|Pomalidomide|"Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and prednisone placebo tablets on Days 1-28 for the first 3 cycles in the Double-Blind Treatment Phase.
~After the completion of Cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
11621991|NCT00463385|Experimental|Pomalidomide 2 mg + Prednisone|"Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase.
~After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
11621992|NCT00463385|Experimental|Pomalidomide 0.5 mg + Prednisone|"Participants received 0.5 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase.
~After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 0.5 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
11621993|NCT00463346|Experimental|Acamprosate|Acamprosate
11621994|NCT00463346|Placebo Comparator|placebo|placebo
11621995|NCT00463294|Active Comparator|On Pump Arm|
11621996|NCT00463294|Experimental|Off Pump Arm|
11621997|NCT00463268|Active Comparator|1|Alendronate 70 mg every 2 weeks
11621998|NCT00463268|Placebo Comparator|2|Alendronate 70 mg placebo tablet every 2 weeks
11621999|NCT00463242|Experimental|Agomelatine|Dosing for each subject in this extension study began with the same dose (25 mg or 50 mg of agomelatine orally once daily) the subject was receiving at the end of Week 8, the week before this study began.
11622000|NCT00463242|Active Comparator|2|
11622001|NCT00463242|Placebo Comparator|3|
11622002|NCT00463229|Experimental|Interprofessional Team Approach|Participants in the experimental group will receive home care services from a team of professional service providers [Community Care Access Centre (CCAC) Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist] and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
11622003|NCT00463229|No Intervention|Usual Home Care Services|Participants allocated to the control group received standard home care services arranged by the CCAC. These include routine follow-up by the CCAC case manager whose focus is on assessment and referral to community agencies, and ongoing monitoring and evaluating the plan of care through in-home assessment with clients.
11622004|NCT00463151|Placebo Comparator|1|0mg rebamipide
11622005|NCT00463151|Experimental|2|60mg rebamipide
11622006|NCT00463151|Experimental|3|150mg rebamipide
11622007|NCT00463151|Experimental|4|300mg rebamipide
11622008|NCT00463086|Experimental|1.Isoniazid (INH)|A self-administered daily dose of 5mg/kg of Isoniazid (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
11622009|NCT00463086|Placebo Comparator|2. Placebo|A self-administered daily dose of 5mg/kg of placebo for 12months (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
11622010|NCT00463060|Experimental|Treatment|Participants treated with chemotherapy and radiotherapy
11622011|NCT00463047|Experimental|Fentanyl Buccal Tablets (FBT)|This study includes a screening period, 2 open-label dose titration periods (in randomized order), and 2 double-blind treatment periods (in randomized order).
11622012|NCT00463047|Active Comparator|Oxycodone|This study includes a screening period, 2 open-label dose titration periods (in randomized order), and 2 double-blind treatment periods (in randomized order).
11622013|NCT00462995|Active Comparator|Erlotinib|Erlotinib 150mg once a day p.o
11622014|NCT00462982|Experimental|Sunitinib|Patients will be treated with 50 mg daily for four out of every six weeks.
11622015|NCT00462969|Experimental|1|pre-surgical SHG
11622016|NCT00462956|Experimental|lapatinib 1500mg daily|Subjects will self-administer lapatinib 1500 mg orally once daily.
11622017|NCT00462943|Experimental|OMA|"Omacetaxine mepesuccinate (OMA) Induction: 1.25mg/m^2 subcutaneously twice daily for 14 consecutive days, every 28 days for up to six cycles.
~Omacetaxine mepesuccinate (OMA) Maintenance: 1.25mg/m^2 subcutaneously twice daily for 7 consecutive days, every 28 days for up to 24 months."
11622018|NCT00462917|Experimental|Pleiotropic info, in-person disclosure|Incidental pleiotropic risk information, in addition to AD risk information, is disclosed in-person during an APOE-based genetic risk assessment
11622019|NCT00462917|Experimental|AD-only info, phone disclosure|Alzheimer's disease risk information only is disclosed via telephone during an APOE-based genetic risk assessment
11622020|NCT00462917|Experimental|Pleiotropic info, phone disclosure|Incidental pleiotropic risk information, in addition to AD risk information, is disclosed via telephone during an APOE-based genetic risk assessment
11622021|NCT00462917|Active Comparator|AD-only info, in-person disclosure|Alzheimer's disease risk information only is disclosed in-person during an APOE-based genetic risk assessment
11622022|NCT00462904|Experimental|BPI infusion group|BPI will be infused by bolus for 30 minutes followed by continuous infusion for 47.5 hours
11622023|NCT00462891|Experimental|IT System|IT system to send reminder letters to patients overdue for breast cancer screening.
11622024|NCT00462891|No Intervention|Usual Care|
11622025|NCT00462865|Experimental|Gemcitabine and Capecitabine and Avastin|Avastin administered concurrently with chemotherapy (Gemcitabine + Capecitabine) for six cycles followed by single agent Avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
11622026|NCT00462839|Experimental|Calibrated drapes viewed first|Caregivers were shown calibrated drape demonstrating level of blood and asked to estimate amount of blood in collection bag. These same individuals were then crossed over and shown non-calibrated drapes and asked to estimate the amount of blood they contained.
11622027|NCT00462839|Active Comparator|Non-calibrated drapes viewed first|Standard vaginal delivery drape (non-calibrated) was shown to caregiver who was asked to estimate amount of blood. These same individuals were then crossed over and shown calibrated delivery drapes and asked to estimate the amount of blood they contained.
11622028|NCT00462826|Experimental|Treatment (aflibercept)|Patients receive VEGF Trap IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11622061|NCT00462358|Experimental|ARRY-520|
11622062|NCT00462358|Experimental|ARRY-520 + G-CSF support|
11622101|NCT00461851|Experimental|Chemotherapy plus sorafenib|Gemcitabine 1000 mg/m2 weekly x 2 weeks plus carboplatin AUC (Area under curve) 5 every 3 weeks plus sorafenib x 6 cycles then maintenance sorafenib alone
11622029|NCT00462787|Experimental|Clofarabine|This is a single arm phase I clinical trial to assess safety (morbidity and mortality) of a novel leukemia re-induction regimen. The first component of this trial is a phase I dose escalation study to determine the maximum tolerated dose (MTD) of the novel agent Clofarabine, when used in combination with topotecan, vinorelbine, thiotepa and dexamethasone. A total of three dose levels will be explored in this study.
11622030|NCT00462761|Experimental|AC220|Determine safety, tolerability and pharmacokinetic (PK) parameters of AC220
11622031|NCT00462748|Experimental|1|Arm 1: Drug
11622032|NCT00462748|Active Comparator|2|Arm 2: Active comparator
11622033|NCT00462748|Active Comparator|3|Arm 3: Active comparator
11622034|NCT00462735|Experimental|Advanced Head and Neck Cancer|Patients with stage IVA and IVB or high-risk stage III squamous cell carcinomas of the head and neck
11622035|NCT00462722|Placebo Comparator|Placebo pre and post exercise|placebo before and after musculoskeletal-loading exercise
11622036|NCT00462722|Experimental|Placebo pre and ibuprofen post exercise|placebo before and ibuprofen after musculoskeletal-loading exercise
11622037|NCT00462722|Experimental|Ibuprofen pre and placebo post exercise|ibuprofen before and placebo after musculoskeletal-loading exercise
11622038|NCT00462709|Experimental|Open-label C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 7 days.
11622039|NCT00462670|Placebo Comparator|1|0mg
11622040|NCT00462670|Experimental|2|15mg OPC-41061
11622041|NCT00462644|Active Comparator|Etomidate|Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications
11622042|NCT00462644|Active Comparator|Fentanyl-Midazolam|Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.
11622043|NCT00462631|Experimental|1|paclitaxel eluting balloon followed by bare metal stent
11622044|NCT00462631|Active Comparator|2|Paclitaxel eluting stent
11622045|NCT00462618|Active Comparator|CBT|
11622046|NCT00462605|Experimental|Arm I|Patients receive oral MS-275 on days 1, 8, 15, and 22. Patients also receive sargramostim (GM-CSF) subcutaneously once daily on days 1-42 in courses 3 and 5 and on days 1-35 in courses 1, 2, 4, and 6. Treatment repeats every 6 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. After completion of 2 courses of study therapy, patients who achieve a complete or partial response may receive an additional 4 courses. Patients who maintain stable disease for more than 2 months after completion of 6 courses of study therapy may receive an additional 6 courses at the time of disease progression, provided they meet original eligibility criteria.
11622047|NCT00462592|Active Comparator|1|montelukast - montelukast 5 mg ( < 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening
11622048|NCT00462592|Active Comparator|2|budesonide - inhaled budesonide turbuhaler 200ug (& matching placebo) taken 1 puff morning & 1 puff evening.
11622049|NCT00462592|Placebo Comparator|3|placebo
11622050|NCT00462592|Active Comparator|4|montelukast budesonide combination - montelukast 5mg ( < 15 years) or 10 mg (& matching placebo)will be taken 1 tab in the evening together with inhaled budesonide turbuhaler 200 ug (& matching placebo) taken 1 puff morning & 1 puff evening.
11622051|NCT00462553|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 OR on days 1, 8, and 15. Patients also receive oral sunitinib malate once daily on days 1-21 OR days 1-28. Treatment repeats every 21 days OR every 28 days in the absence of disease progression or unacceptable toxicity.
11622052|NCT00462501|Experimental|Chemotherapy and Bevacizumab With or Without Radiation|FOLFOX/Bevacizumab will be given for 4 cycles over 8 weeks; FOLFOLX6 without Bevacizumab will be given for an additional 2 cycles over 4 weeks. Oxaliplatin will be given on Day 1 of each cycle over 2 hours at 85 mg/m2 IV. Leucovorin will be given Day 1 of each cycle over 2 hours at 400 mg/m2 IV. Fluorouracil will be given on Day 1 of each cycle at 400 mg/m2 IVP, then Fluorouracil will be given at 1200 mg/m2 IVCI over Day 1 and 2. Bevacizumab will be given at 5mg/kg over 10 minutes on day 1. Patients will undergo re-staging within 3 weeks of completing their 6th cycle of FOLFOX. If the reassessment reveals that there has been no disease progression as compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection. If the surgical oncologist's reassessment is that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous infusional 5-fluorouracil.
11622053|NCT00462488|Active Comparator|Treatment Schedule A -|"Induction Phase is a single intravesical dose of Vicinium at 30 mg in 40 mL PBS once per week for 6 weeks. If free of disease at 12 weeks after the first instillation, the subject enters Maintenance dosing in which 30 mg of Vicinium is administered once per week for 3 weeks followed by 9 weeks of no therapy.
~If the subject had histologically confirmed disease that is stage <T2, they repeat the Induction phase dosing. If the subject is free of disease, the subject enters the maintenance dosing phase of every 12 weeks (3 weeks of therapy followed by 9 weeks of no therapy until disease recurrence is confirmed by positive biopsy or up to a maximum of Week 51 (end-of-study [EOS])."
11622054|NCT00462488|Active Comparator|Treatment Schedule B|"Induction Phase is a single intravesical dose of Vicinium at 30 mg in 40 mL PBS once per week for 12 weeks followed by 1 week of no therapy.
~If 13 weeks after the first instillation of Vicinium the subject is free of disease, they have a break from therapy before entering Maintenance dosing in which 30 mg of Vicinium is administered once weekly for 3 weeks followed by 9 weeks of no therapy. If the subject is free of disease, additional maintenance cycle(s) are repeated every 12 weeks (3 weeks of therapy followed by 9 weeks of no therapy until disease recurrence is confirmed by positive biopsy or up to a maximum of Week 57 (EOS)."
11622055|NCT00462462|Experimental|1|Ethanol gel
11622056|NCT00462462|Active Comparator|2|Ethanol solution
11622057|NCT00462449|No Intervention|1|Individuals randomized into this group will only receive specialized therapy associated with this population.
11622058|NCT00462449|Experimental|2|In addition to appropriate therapy, this group will receive the FES device and be given instruction on how to complete specialized exercises utilizing this device.
11622059|NCT00462423|Experimental|Single Arm, Open Label|Single Arm, Open Label trial of Abraxane and Avastin
11622099|NCT00461903|Placebo Comparator|Placebo (for perindopril)|Sugar pill manufactued to mimic perindopril
11622100|NCT00461903|Active Comparator|Perindopril|Perindopril (coversyl) 4 mg tablets
11622232|NCT00460564|Active Comparator|Low-Dose BTX|
11622063|NCT00462345|Experimental|Rituximab, Methotrexate|Participants received rituximab 1000 milligrams (mg), intravenously (IV), on Day 1 and Day 15. Participants also received methylprednisolone 100 mg, IV, 30 minutes before the infusion of rituximab. Participants also received methotrexate (MTX) 10 to 25 milligrams per week (mg/week), orally (PO) or parenterally, and folate greater than or equal to (≥) 5 mg/week, PO, folate greater than or equal to (≥) 5 mg/week, PO, either as a single dose or as divided daily doses from Day 1 through Week 24. Participants also received prednisone less than or equal to (≤) 10 milligrams per day (mg/day), PO, OR equivalent corticosteroid, OR non-steroidal anti-inflammatory drugs (NSAIDs), PO, from Day 1 through Week 24. Eligible participants who completed the first 24-week course were entered into a second course.
11622064|NCT00462332|Experimental|High risk patientes|Category of risk will be defined according to biological features.
11622065|NCT00462332|Experimental|Low risk patients|Category of risk will be defined according to biological features.
11622066|NCT00462306||Pregnant population|The study group consisted of pregnant women, presenting to Prentice Women's Hospital of Northwestern Memorial Hospital for spontaneous labor, induction of labor, and scheduled cesarean delivery.
11622067|NCT00462306||Non-Pregnant Population|The study group consisted of non-pregnant females, presenting to Northwestern Memorial Hospital for ambulatory surgery
11622068|NCT00462280|Experimental|Two matched nevi group - Lovastatin|Patients with two matched nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
11622069|NCT00462280|Placebo Comparator|Two Matched Nevi Group - Placebo|Patients with two matched nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
11622070|NCT00462280|Experimental|One large nevi group - Lovastatin|Patients who have one large nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
11622071|NCT00462280|Placebo Comparator|One Large Nevi Group - Placebo|Patients who have one large nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
11622072|NCT00462267|No Intervention|Usual care|
11622073|NCT00462267|Experimental|Enriched lifestyle intervention|
11622074|NCT00462254|Other|A|Day 1-3: placebo run-in - 8 mg of placebo orally 30 minutes before bedtime. Days 4-11: true drug - 8 mg of Ramelteon orally 30 minutes before bedtime. Days 12-14: crossover - 8 mg of placebo orally 30 minutes before bedtime. Days 15-22: continue placebo.
11622075|NCT00462254|Other|B|Day 1-3: Placebo run-in - 8 mg of placebo orally 30 minutes before bedtime. Days 4-11: continue placebo. Days 12-14: crossover - 8 mg of placebo orally 30 minutes before bedtime. Days 15-22: true drug - 8 mg of Ramelteon orally 30 minutes before bedtime.
11622076|NCT00462241|Experimental|chiropractic treatment|Individualised chiropractic treatment, pragmatic approach
11622077|NCT00462241|Sham Comparator|self-management|Self-management: Minimal intervention - practice as usual.
11622078|NCT00462228|Experimental|Memantine|Subjects will be titrated up to 20 mg of memantine per day for 12 weeks, followed by placebo for 12 weeks
11622079|NCT00462228|Placebo Comparator|Placebo|Subjects will be titrated up to 20 mg of placebo per day for 12 weeks, followed by memantine for 12 weeks
11622080|NCT00462215|Experimental|1|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
11622081|NCT00462215|Experimental|2|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
11622082|NCT00462215|Experimental|3|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
11622083|NCT00462215|Experimental|4|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
11622084|NCT00462215|Experimental|5|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
11622085|NCT00462215|Experimental|6|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
11622086|NCT00462202|Experimental|Sulodexide|Open label extension to original trial
11622087|NCT00462176||1|All women (n=45) who had undergone CO2 laser laparoscopic radical excision of deep infiltrating endometriosis with active involvement of the colorectal surgeon performing a bowel resection were selected retrospectively from the list of all patients (n=more than 400) operated at the Leuven University Fertility Centre (LUFc) between September 2004 and July 2006.
11622088|NCT00462137||1|control group
11622089|NCT00462137||2|hypnotic group
11622090|NCT00462124|Other|Balloon|Implantation of a biodegradable balloon spacer (absorbable perirectal spacer)
11622091|NCT00462098|Experimental|HBO|Subject receives 40 HBO sessions at 2 atmospheres of pressure over 4 weeks
11622092|NCT00462098|Active Comparator|Control|non-HBO comparison group
11622093|NCT00462020|Active Comparator|1|5 days of IV antibiotics after appendectomy
11622094|NCT00462020|Experimental|2|home on oral antibiotics to complete 7 days of treatment when tolerating PO's
11622095|NCT00462007|Experimental|1|Stalevo
11622096|NCT00461981|Experimental|FluMist, Influenza Virus Vaccine Live|FluMist, Influenza Virus Vaccine Live, Intranasal
11622097|NCT00461981|Active Comparator|TIV, Trivalent Inactivated Influenza Virus Vaccine|TIV, Trivalent Inactivated Influenza Virus Vaccine, Intramuscular
11622098|NCT00461955|Experimental|1|autologous peripheral blood stem cell transplantation
11622102|NCT00461838||1|All women (n=56) who had undergone CO2 laser laparoscopic radical excision of deep infiltrating endometriosis with active involvement of colorectal surgeon and/or urologist were selected retrospectively from the list of all patients (n=more than 2000) operated at the Leuven University Fertility Centre (LUFc) between September 1996 and July 2004.
11622103|NCT00461812|Experimental|Mometasone|
11622104|NCT00461812|Experimental|Advair|
11622105|NCT00461786|Experimental|Pemetrexed|
11622106|NCT00461773|Active Comparator|1|brief exposure bevacizumab
11622107|NCT00461773|Active Comparator|2|brief exposure bevacizumab and letrozole
11622108|NCT00461760|Active Comparator|1|Women with normal cytology at recruitment will be recalled for their next routine screen at 2 years and if negative again, for their exit screen at 4 years, all according to current provincial guidelines.
11622109|NCT00461760|Active Comparator|2|Women with abnormal cytology at recruitment or at the 2 year screen will be followed according to provincial guidelines based on their cytology results.
11622110|NCT00461747|Active Comparator|A|"Four alternating cycles of VBMCP/VBAD + Velcade VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalán, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.
~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20. The interval between VBMCP and VBAD is 5 weeks and between VBAD and VBMCP is 4 weeks. The patients will received two cycles of VBMCP and two cycles of VBAD. After 4 weeks of last cycle of VBAD, patients will received two cycles of Velcade, 1,3 mg/ m2 iv twice a week (days 1, 4, 8 and 11), followed by 10 days without treatment"
11622111|NCT00461747|Experimental|B|"Six cycles of 4 weeks of Thalidomide/Dexamethasone. Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity < grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.
~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
11622112|NCT00461747|Experimental|C|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is < grade 2, the dose will be increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.
~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.
~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days."
11622113|NCT00461734|Active Comparator|RV Apex|
11622114|NCT00461734|Experimental|RV High Septum|
11622115|NCT00461708|Experimental|Rash, Grade <2|Participants with a rash graded less than (<) 2 according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version (v.) 3.0 received erlotinib, 100 milligrams (mg), orally (PO), once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg per (/) square meter (m^2), intravenously (IV), over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.
11622116|NCT00461708|Experimental|Rash, Grade ≥2|Participants with a rash graded greater than or equal to (≥) 2 according to the NCI-CTC v. 3.0 received erlotinib, 100 mg, PO, once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg/m^2, IV, over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.
11622117|NCT00461695|Other|CMV-seropositive|Cytomegalovirus-seropositive individuals at screening (week 0). Intervention: Intervention: Vaccination against tick-borne encephalitis by intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
11622118|NCT00461695|Other|CMV-seronegative|Cytomegalovirus-seronegative individuals at screening (week 0). Intervention: Vaccination against tick-borne encephalitis by intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
11622119|NCT00461643|Active Comparator|Strategy A|clomiphene followed by clomiphene plus metformin followed by gonadotropins
11622120|NCT00461643|Active Comparator|Strategy B|metformin followed by metformin plus clomiphene followed by gonadotropins
11622121|NCT00461643|Active Comparator|Strategy C|metformin plus clomiphene followed by gonadotropins
11622122|NCT00461630|Experimental|ER niacin/laropiprant|1 g ER niacin plus 20 mg laropiprant per tablet. 2 tablets orally per day. With either 40 mg simvastatin tablet or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily
11622123|NCT00461630|Active Comparator|Placebo|Placebo (for ER niacin/laropiprant) 2 tablets orally per day. With either 40 mg simvastatin tablet orally per day or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily
11622124|NCT00461617|Active Comparator|2|Nateglinide 120 mg TID
11622125|NCT00461591|Experimental|Apaziquone|TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
11622126|NCT00461591|Placebo Comparator|Placebo|TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT
11622127|NCT00461565|Active Comparator|Part A1|
11622128|NCT00461565|Placebo Comparator|Part A2|
11622129|NCT00461565|Experimental|Part B1|
11622130|NCT00461565|Placebo Comparator|Part B2|
11622131|NCT00461552|Active Comparator|Leptin|Leptin weight and gender based dose, sub-cutaneous, twice daily. Leptin versus placebo for entire 6 months double-blind.
11622132|NCT00461552|Placebo Comparator|Placebo|Placebo , sub-Q injection twice daily.
11622133|NCT00461539|Active Comparator|2|Participants will receive treatment as usual
11622134|NCT00461539|Experimental|1|Participants will receive the behavioral health intervention
11622135|NCT00461526|Experimental|125 mg crofelemer|
11622136|NCT00461526|Placebo Comparator|placebo|
11622233|NCT00460564|Active Comparator|Low-Dose Placebo|
11622234|NCT00460551|Experimental|Zalutumumab 8 mg/kg|
11622235|NCT00460538|Placebo Comparator|2|
11622236|NCT00460538|Active Comparator|1|
11622237|NCT00460525|Active Comparator|Rabies Vaccine|Rabies vaccine administered on Days 0, 30, and 60.
11622238|NCT00460525|Experimental|FMP2.1/AS02A|50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.
11622239|NCT00460512|Experimental|Paliperidone Extended Release (ER)|
11622137|NCT00461513||Intervention|The PCDM intervention will include evaluation of CHF care by the collaborative care team, with diagnostic and therapeutic treatment recommendations based on current ACC/AHA national clinical practice guidelines, daily telemonitoring and patient self-care support utilizing the VA telemonitoring system, and screening and treatment for comorbid depression. The Collaborative Care (CC) team at each site will consist of a primary care provider, cardiologist, and psychiatrist, who are local opinion leaders, as well as a nurse site coordinator and pharmacist. For a given intervention patient, there will be an initial assessment of care by the CC team following the enrollment visit. Each intervention patient will be re-reviewed by the CC team a minimum of 2 additional times (at 6-weeks and 6 months). In addition, patients will have daily telemonitoring, and their care will be reviewed by the CC team if the telemonitoring data suggests clinical deterioration.
11622138|NCT00461513||Usual Care|Patients randomized to the usual care arm will continue to receive care at the discretion of their regular VA providers (for a given patient, this could include cardiology specialty care in addition to PCP care, participation in site-specific CHF programs such as CHF patient education classes, etc.), in direct continuity with the care they were receiving prior to enrollment. Patients in the usual care group will also be given information sheets that outline self-care for CHF, and will be provided with a scale, if needed, at the enrollment visit. Patients in the usual care group will have the same amount of interaction with the study team as the intervention patients (i.e. complete questionnaires at the same frequency; have the same study visits). PCPs of usual care patients will be notified of the results of all screening studies (patient survey results, lab tests) as we have done in previous studies.
11622139|NCT00461487|Experimental|1|Participants will receive sex education information during the physical exam
11622140|NCT00461487|Active Comparator|2|Participants will receive information on hygiene and nutrition during the physical exam
11622141|NCT00461487|No Intervention|3|Passive control participants will not receive any additional information during the physical exam
11622142|NCT00461448|Active Comparator|1 Potassium supplement|Patients received an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)
11622143|NCT00461448|Placebo Comparator|2 Grape Juice|Patients received same amount of grape juice for 28 days.
11622144|NCT00461422|Experimental|1|Standard Flexible antagonist protocol Addition of Ganirelix at first 3 days of the cycle
11622145|NCT00461422|No Intervention|2|Standard Flexible antagonist protocol
11622146|NCT00461396||Group 1|
11622147|NCT00461331|Active Comparator|Insulin 1|Either insulin Aspart or insulin Lispro were randomized to be insulin 1.
11622148|NCT00461331|Active Comparator|Insulin 2|Between insulin Aspart and insulin Lispro, the one that was not used as insulin 1 was then used as the second insulin for the second arm of the study.
11622149|NCT00461305|Experimental|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
11622150|NCT00461305|Experimental|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
11622151|NCT00461292|Experimental|1|botulinum toxin Type A (200U)
11622152|NCT00461292|Experimental|2|botulinum toxin Type A (300U)
11622153|NCT00461292|Other|3|placebo; botulinum toxin Type A (200U)
11622154|NCT00461292|Other|4|placebo; botulinum toxin Type A (300U)
11622155|NCT00461279|Other|1|
11622156|NCT00461279|Other|2|
11622157|NCT00461266|Experimental|1|
11622158|NCT00461266|Active Comparator|2|
11622159|NCT00461253||1|Breast Cancer Cases
11622160|NCT00461253||2|Matched Controls for Breast Cancer Cases
11622161|NCT00461240||acromegaly|
11622162|NCT00461240||growth hormone deficiency|
11622163|NCT00461175||1|Mirena®
11622164|NCT00461175||2|Copper IUD
11622165|NCT00461162|Experimental|1: i-DSMP|Internet Dyspnea Self-management Program (i-DSMP)
11622166|NCT00461162|Experimental|2: f-DSMP|Face-to-Face Dyspnea Self-management Program (f-DSMP)
11622167|NCT00461162|Active Comparator|3: AC|Attention Control (AC)
11622168|NCT00461123|Experimental|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
11622169|NCT00461123|Placebo Comparator|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
11622170|NCT00461110|Experimental|1|Active
11622171|NCT00461110|Experimental|2|Active
11622172|NCT00461097|Experimental|Egg Oral Immunotherapy (OIT)|Subjects ingest egg white solid (EWS) on Visit 1 (initial day dose escalation up to 50 mg), followed by a build-up phase (escalating daily egg doses every 2 wks, achieving a maintenance dose by 32-40 wks). Thereafter, subjects are on a maximally tolerated daily egg dose (306 mg to 2 gm) for ≥8 wks. After wk 44, subjects are given a 5 gm Oral Food Challenge (OFC) using EWS to identify desensitized [1] subjects. Subjects/study staff are unblinded following this OFC and either continue on their egg OIT maintenance dose of 2 gm/day or are allowed to attempt escalation up to 2 gm/day for the remainder of the study (1-3 years). A 10 gm OFC to identify desensitized [1] subjects occurs at specified intervals under prescribed conditions (yrs 2 - 4). Subjects who pass this 1st 10 gm OFC stop study therapy for 4-6 wks, then have a 2nd 10 gm OFC. Subjects that pass this 2nd 10 gm OFC are considered tolerant [2], stop EWS dosing and add egg to their diet.
11622240|NCT00460499|Active Comparator|B Low dose GIK|This group will have low doses of glucose and insulin
11622241|NCT00460499|Active Comparator|C High Dose GIK|This group will have high doses of insulin and glucose
11622242|NCT00460499|Active Comparator|A Insulin|This group will receive only an intravenous insulin infusion
11622243|NCT00460473|Experimental|Dexmedetomidine|
11622244|NCT00460473|Placebo Comparator|Placebo (PBO)|
11622245|NCT00460434|Experimental|1|Tension-free Vaginal Tape (TVT) surgery
11622246|NCT00460434|Sham Comparator|2|Sham Tension-free Vaginal Tape (TVT) surgery
11622646|NCT00455429|Experimental|JNJ-26113100 (100 mg) twice daily|
11622173|NCT00461097|Placebo Comparator|Control Group|Subjects ingest placebo (cornstarch) during Visit 1 (initial day of dose escalation up to 50 mg), followed by a build-up phase (escalating daily placebo doses every 2 wks, achieving a maintenance dose by 32-40 wks). Thereafter, subjects were on a maximally tolerated daily placebo dose (306 mg to 2 gm) for ≥8 wks. After wk 44, subjects were given a 5 gm Oral Food Challenge (OFC) using egg white solid to identify desensitized [1] subjects. Subjects/study staff were unblinded following this initial 5 gm OFC. After unblinding, subjects discontinued further placebo dosing and continued on an egg-restricted diet. A 10 gm OFC was administered under prescribed conditions to subjects if their egg-specific serum IgE level was below 2 kUA/L. They were followed in the study up to 2 years. [1] Desensitized: Subject does not react to egg during OFC while taking daily doses of therapy. [2] Tolerant: Subject does not react to egg during OFC 4-6 wks after abstinence from egg consumption.
11622174|NCT00461084||1|lymphoma follicular
11622175|NCT00461084||2|lymphoma non-follicular
11622176|NCT00461071|Active Comparator|Internet-based self-help|Internet-based self-help behavioural
11622177|NCT00461071|Active Comparator|Bibliotherapy|bibliotherapy
11622178|NCT00461058|Active Comparator|Actos|
11622179|NCT00461058|Experimental|Aleglitazar|
11622180|NCT00461045|Experimental|MRZ 0.5 mg/m^2|Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles
11622181|NCT00461032|Experimental|1|montelukast
11622182|NCT00461032|Placebo Comparator|2|Placebo
11622183|NCT00461019|Experimental|Implantation of the CardioFit system|
11622184|NCT00461006|Experimental|Aleglitazar|
11622185|NCT00461006|Active Comparator|Actos|
11622186|NCT00460993|Experimental|Group 1|Lunesta Active drug (eszopiclone) 1 mg during 1st week of active drug. If sleep efficiency does not improve does increases to 2 mg for 2nd week of active drug administration.
11622187|NCT00460993|Placebo Comparator|Group 2|"Sugar pill packaged and supplied by Sepracor. One pill weeks one and two of intervention.
~Weeks 3 and 4 this Placebo group crosses over to active drug. 1 mg week 3 increasing to 2mg week 4 if sleep efficiency does not improve."
11622188|NCT00460980|Other|Virtual reality laparoscopic simulator|"Virtual reality laparoscopic simulator training:
~Residents will participate in a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience."
11622189|NCT00460967|Experimental|1|Rheopheresis treatment
11622190|NCT00460967|Sham Comparator|2|Sham treatment
11622191|NCT00460941|Placebo Comparator|Placebo|sc weekly
11622192|NCT00460941|Experimental|Taspoglutide 20mg|sc weekly
11622193|NCT00460941|Experimental|Taspoglutide 20mg-30mg|sc weekly
11622194|NCT00460941|Experimental|Taspoglutide 20mg-40mg|sc weekly
11622195|NCT00460928|Experimental|intravenous immune globulin (IVIG)|
11622196|NCT00460902|Experimental|Deep TMS stimulation|
11622197|NCT00460902|Experimental|DTMS with positive cognitive-emotional provocation|
11622198|NCT00460902|Experimental|DTMS with negative cognitive-emotional provocation|
11622199|NCT00460850|Experimental|1|
11622200|NCT00460837|Active Comparator|1 A|gastrofin & Picolax
11622201|NCT00460837|Active Comparator|2|senna
11622202|NCT00460811|Active Comparator|72 ug linaclotide acetate|
11622203|NCT00460811|Active Comparator|145 ug linaclotide acetate|
11622204|NCT00460811|Active Comparator|290 ug linaclotide acetate|
11622205|NCT00460811|Active Comparator|579 ug linaclotide acetate|
11622206|NCT00460811|Placebo Comparator|Matching Placebo|
11622207|NCT00460798||Non-Interventional Study|
11622208|NCT00460759|Experimental|Moxifloxacin and Rifapentine|
11622209|NCT00460746|Experimental|001|TMC125, Darunavir; RitonavirTMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
11622210|NCT00460733|Experimental|1|
11622211|NCT00460733|Active Comparator|2|
11622212|NCT00460720||001|
11622213|NCT00460707|Experimental|Cohort 1|All subjects in Cohort 1 will receive ketoconazole 400 milligrams (mg) once daily on Day 1 to 9 and oral casopitant 150 mg on Day 4 and 50 mg on Day 5 and Day 6 of treatment period 1. After a washout period of 21 days, subjects will be administered oral casopitant 150 mg on Day 1 and 50 mg on Day 2 and Day 3 of treatment period 2.
11622214|NCT00460707|Placebo Comparator|Cohort 2, Group A|Subjects will receive placebo once daily on Day 1 to Day 3 in treatment period 1. Subjects will receive ketoconazole 400 mg once daily on Day 1 to Day 9 and oral placebo once daily on Days 4, 5 and 6 in treatment period 2. There will be a 14-day washout period between treatment periods 1 and 2.
11622215|NCT00460707|Experimental|Cohort 2, Group B|In treatment period 1, subjects will receive oral casopitant 150 mg on Day 1 and 50 mg on Days 2 and 3. In treatment period 2, they will be administered ketoconazole 400 mg once daily on Day 1 to Day 9 and oral casopitant 150 mg on Day 4 and 50 mg on Days 5 and 6. There will be a 14-day washout period between treatment periods 1 and 2.
11622216|NCT00460668|Experimental|Pulmonary rehabilitation post-thoracotomy|Pulmonary rehabilitation post-thoracotomy
11622217|NCT00460668|No Intervention|Control|Control
11622218|NCT00460655|Active Comparator|BTX|
11622219|NCT00460655|Placebo Comparator|Placebo|
11622220|NCT00460616||1|Patients already receiving treatment with cabergoline.
11622221|NCT00460616||2|healthy controls sex and age-matched with the patients
11622222|NCT00460603|Active Comparator|B|bevacizumab 5 mg/kg every 2 weeks + FOLFOX
11622223|NCT00460603|Experimental|C|AG-013726 5 mg bid+ bevacizumab 2 mg/kg every 2 weeks + FOLFOX
11622224|NCT00460603|Experimental|A|AG-013736 5 mg bid starting dose + FOLFOX
11622225|NCT00460590|Experimental|1|12 adults with prior BCG
11622226|NCT00460590|Experimental|2|12 adults without prior BCG
11622227|NCT00460590|Experimental|3|12 Adolescents
11622228|NCT00460577|Active Comparator|Formoterol (Foradil®)|Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.
11622229|NCT00460577|Active Comparator|Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg|Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.
11622230|NCT00460564|Active Comparator|High-Dose BTX|
11622231|NCT00460564|Placebo Comparator|High-Dose Placebo|
11622247|NCT00460421|Experimental|Palifermin Dose Escalation|A 3 dose escalation design. Sucessive cohorts of patient (9 patients per group) will each be administered Palifermin as an IV bolus injection (40, 60 or 80 µg) once daily for 3 consecutive days before the start of conditioning regimen (chemotherapy and total body irradiation) and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).
11622248|NCT00460408||Observational study, no comparator|Observational study of patients with AMD treated with Macugen, no comparator
11622249|NCT00460369|Active Comparator|1|sulfadoxine-pyrimethamine
11622250|NCT00460369|Active Comparator|2|artemether-lumefantrine
11622251|NCT00460369|Active Comparator|3|amodiaquine-artesunate coformulation
11622252|NCT00460356||Ancillary-Correlative (glycoprotein and glycan profiling)|Primary and metastatic tumor specimens are collected during lymphadenectomy and used for tissue microarray analysis, mutational analysis of T-synthase and Cosmc, immunohistochemical staining of Tn antigen and sialyl Tn antigen, and customized gene expression array analysis of 400 genes associated with glycobiology. Pre-lymphadenectomy blood is collected from patients at baseline for customized glycan array analysis of 300 carbohydrates.
11622253|NCT00460343|Experimental|max|
11622254|NCT00460343|Active Comparator|min|
11622255|NCT00460317|Placebo Comparator|Arm B|All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and placebo 125mg QD orally
11622256|NCT00460317|Active Comparator|Arm A|All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and AMG 706 125mg QD orally.
11622257|NCT00460265|Active Comparator|ARM 2|Arm 2 consists of Cisplatin and 5-FU
11622258|NCT00460265|Experimental|ARM 1|ARM 1 Consists of Panitumumab plus Cisplatin and 5-FU
11622259|NCT00460239|Experimental|Placebo|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
11622260|NCT00460239|Experimental|Morphine 15|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
11622261|NCT00460239|Experimental|Morphine 30|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
11622262|NCT00460239|Experimental|Buprenorphine 8|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
11622263|NCT00460239|Experimental|Buprenorphine 16|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
11622264|NCT00460239|Experimental|Buprenorphine 32|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
11622265|NCT00460239|Experimental|Buprenorphine 48|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
11622266|NCT00460239|Experimental|Buprenorphine 60|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
11622267|NCT00460226||lamotrigine|there is only one group.
11622268|NCT00460213|Experimental|Valsartan|
11622269|NCT00460174|Experimental|Treatment Arm|Concurrent gemcitabine, bevacizumab, and radiation therapy
11622270|NCT00460161|Active Comparator|1|true acupuncture
11622271|NCT00460161|Placebo Comparator|2|placebo/sham acupuncture
11622272|NCT00460135|Experimental|RT|resistance training
11622273|NCT00460135|No Intervention|Routine care|General counseling on increasing physical exercise
11622274|NCT00460109|Experimental|rituximab + denileukin diftitox|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients also receive denileukin diftitox IV over 15-60 minutes on days 1-5. Treatment with denileukin diftitox repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11622275|NCT00460083|Active Comparator|Elidel(r)|
11622276|NCT00460083|Experimental|Epiceram(r)|
11622277|NCT00460057|Placebo Comparator|Alendronate, Placebo|All subjects were given 600 mg of calcium and 400 IU of vitamin D supplements. The subjects were randomized to receive weekly alendronate 20 mg (n = 31) or placebo (n = 32).
11622278|NCT00460031|Experimental|Ketoconazole Plus Lenalidomide|
11622279|NCT00460018|Experimental|Intervention|Women receiving the DEBI Intervention
11622280|NCT00460018|No Intervention|No intervention|Women receiving standard care
11622281|NCT00459979|Experimental|Sunitinib|
11622282|NCT00459953|Experimental|Extended treatment|extended cognitive behavioral treatment for smoking cessation; Participants receive an additional 9 sessions of cognitive behavior therapy
11622283|NCT00459953|No Intervention|Control group|Monthly follow-up phone calls for assessment purposes and to control for potential therapeutic effects associated with continued contact
11622284|NCT00459914|Active Comparator|1 CPAP|Nasal continuous positive airway pressure
11622285|NCT00459914|No Intervention|2|Pharmacological treatment alone
11622286|NCT00459875|Experimental|Sunitinib|The treatment will include Sunitinib malate 50 mg self-administered orally, once daily in the evening, without regard to meals, for 4 consecutive weeks (28 days) followed by 2 weeks (14 days) off, to comprise a complete cycle of 6 weeks.
11622287|NCT00459862|Experimental|Arm I|Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
11622288|NCT00459823|Experimental|1|
11622289|NCT00459797|Active Comparator|Conventional Glidescope|
11622290|NCT00459797|Experimental|Single-use Glidescope|
11622291|NCT00459771|Placebo Comparator|Placebo|Placebo
11622292|NCT00459771|Active Comparator|Candesartan|Candasartan
11622293|NCT00459745|Active Comparator|Pravastatin|Pravastatin 40 mg
11622294|NCT00459745|Active Comparator|Fenofibrate|Fenofibrate 160 mg
11622295|NCT00459745|Experimental|Pravafen (Parvastatin and Fenofibrate)|Combined Therapy of Pravastatin 40 mg and Fenofibrate 160 mg.
11622296|NCT00459732|Placebo Comparator|Placebo Capsule|placebo capsule, similar in size, shape and color to zinc capsule, taken once daily for 18 months
11622297|NCT00459732|Active Comparator|Zinc (25 mg/d)|25 mg of elemental Zinc as zinc sulphate taken once daily for 18 months
11622298|NCT00459719|Experimental|1|In combination with steroids
11622299|NCT00459719|Active Comparator|2|In combination with steroids
11622300|NCT00459706|Experimental|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
11622301|NCT00459706|Experimental|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
11622302|NCT00459680|Experimental|Acupuncture|
11622303|NCT00459680|Experimental|Laser Acupoint|
11622304|NCT00459667|Experimental|IFNB-1b 500 mcg|Interferon beta 1b ([IFNB 1b] Betaseron) 500 mcg administered s.c. every other day (double blind)
11622305|NCT00459667|Experimental|IFNB-1b 250 mcg|Interferon beta 1b ([IFNB 1b] Betaseron) 250 mcg administered s.c. every other day (double blind)
11622306|NCT00459667|Experimental|IFNB-1b 250 mcg*|"Interferon beta 1b ([IFNB 1b] Betaseron) 250 mcg administered s.c. every other day
~*(Subjects who were administered Copaxone and subjects who had prematurely discontinued medication during BEYOND study.)"
11622307|NCT00459654|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Each subject receives local filed external beam radiotherapy (EBR) and repeated injections of the investigational drug radium-223 (EBR+Radium-223)
11622308|NCT00459654|Placebo Comparator|Saline|Each subject receives local filed external beam radiotherapy (EBR) and repeated injections of saline (EBR+placebo)
11622309|NCT00459641|Experimental|1|I-040302 doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
11622310|NCT00459641|Active Comparator|2|Standard of care (bone marrow aspirate or steroids)
11622311|NCT00459628|Active Comparator|Conventional radiotherapy|Conventional Long schedule Radiotherapy Arm
11622312|NCT00459628|Experimental|Tomotherapy|Short course schedule by tomotherapy
11622313|NCT00459602||Laparoscopic incisional hernia repair|Subjects with an incisional, ventral, umbilical, or spigelian hernia no larger tham 15 cm at the largest measurement, who are candidates for laparoscopic repair of the hernia, and who are able to commit to long-term followup. Laparoscopic repair will proceed as per the standard technique, using polyester mesh.
11622314|NCT00459589|Experimental|1|nutritional intervention with dietician at each cycle of chemotherapy in 6 first cycles to maintain 30 kcal/kg/d and 1.2 protein/kg/d
11622315|NCT00459589|Active Comparator|2|
11622316|NCT00459563|Placebo Comparator|Placebo|
11622317|NCT00459563|Active Comparator|Cholecalciferol|Cholecalciferol
11622318|NCT00459563|Active Comparator|Calcitriol|Calcitriol
11622319|NCT00459550|Experimental|Part A|Part A will be a single-blind, single dose, placebo controlled, dose escalation study in up to five consecutive cohorts of Alzheimers Disease subjects. Each subject will receive a single infusion of GSK933776 or placebo. The dose for the first cohort will be 0.001 mg/kg. The proposed nominal doses for subsequent cohorts are 0.01, 0.1, 0.5 and 3 mg/kg, but these may be altered based on the outcome of the safety, tolerability, pharmacodynamic and pharmacokinetic data of the preceding group(s). The maximum possible dose will be 20 mg/kg, although the planned top dose is 18 mg/kg
11622320|NCT00459550|Experimental|Part B|"Part B will be a single-blind, repeat dose, placebo controlled dose escalation design. It is proposed that there will be initially 3 cohorts of AD subjects. However up to 5 cohorts may be recruited if required in order to characterise GSK933776 fully.Each cohort will consist of eight subjects (six active, two placebo) who will each receive a maximum of three infusions of GSK933776 or placebo. Dosing in Part B may proceed in parallel with Part A following satisfactory review of minimum data sets as below:
~First cohort in Part B: at least 3 weeks' data from the Part A dose that is the same dose level as that planned for Part B Second cohort in Part B: at least 3 weeks PK data and 8 weeks safety data following the first dose from all the subjects on active treatment in the preceding Part B cohort plus a satisfactory outcome of the PIB Subsequent cohorts in Part B: at least 3 weeks PK data and 8 weeks safety data follow"
11622321|NCT00459537|Experimental|Terbinafine|10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.
11622322|NCT00459537|Active Comparator|Amorolfine|5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.
11622323|NCT00459524||Questionnaire|AML and MDS Patients
11622324|NCT00459485|Experimental|Zinc supplement (20 mg)|Daily intake of 20 mg supplementary zinc
11622325|NCT00459485|Experimental|Zinc supplement (10 mg)|Daily intake of 10 mg supplementary zinc
11622326|NCT00459485|Placebo Comparator|Placebo supplement|Daily intake of placebo supplement
11622327|NCT00459472|Other|Training|laparoscopic training curriculum: all general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
11622328|NCT00459433|Experimental|1|psychosocial intervention
11622329|NCT00459433|Active Comparator|2|Usual care
11622330|NCT00459420|Placebo Comparator|Placebo|
11622331|NCT00459420|Experimental|Caffeine|
11622332|NCT00459407|Experimental|Arm I (green tea catechin extract)|"Patients receive oral defined green tea catechin extract daily for 4-7 weeks.
~All patients undergo surgery one day after the last dose of study agent."
11622333|NCT00459407|Placebo Comparator|Arm II (placebo)|"Patients receive oral placebo daily for 4-7 weeks.
~All patients undergo surgery one day after the last dose of study agent."
11622334|NCT00459381|Experimental|Treatment (pazopanib hydrochloride)|"Patients receive oral pazopanib hydrochloride daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
~Other: laboratory biomarker analysis"
11622335|NCT00459368|Experimental|I|In this cluster-randomized trial physicians practicing at intervention clinic sites will receive adherence information on their patients with asthma who are currently taking an inhaled corticosteroid medication. This information will be available to them via our electronic prescribing software to discuss with patients at the time of the visit. Physicians at these sites also receive standardized training in how to interpret and intervene when poor adherence is identified.
11622647|NCT00455429|Experimental|JNJ-26113100 (250 mg) twice daily|
11622336|NCT00459368|Active Comparator|II|Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
11622337|NCT00459355|Experimental|Home Safety Toolkit|Intervention group receives home safety tool-kit with education and self-efficacy materials to promote competence to make home safety modifications.
11622338|NCT00459355|No Intervention|Conventional Safety Checklist|Comparison group received a conventional home safety checklist
11622339|NCT00459342|Experimental|Arm I|Patients received oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11622340|NCT00459316|Experimental|Group 1|Participants ≤11 to <25 years of age with CD4% at screening ≥15%. All received Quadrivalent meningococcal conjugate vaccine at entry, those who were eligible were randomized at week 24, with Group 1B receiving a second Quadrivalent meningococcal conjugate vaccine at week 24. Those who were eligible received a booster dose of Quadrivalent meningococcal vaccine at 3.5 years.
11622341|NCT00459316|Experimental|Group 2|Participants ≤11 to <25 years of age with CD4% at screening <15%; All receiving Quadrivalent meningococcal conjugate vaccine at entry, with those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24 and 3 years.
11622342|NCT00459316|Experimental|Group 3|Participants >=2 to <11 years of age with CD4% at screening ≥ 25%; All received Quadrivalent meningococcal conjugate vaccine at entry, with those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24 and 3 years.
11622343|NCT00459303|Active Comparator|intraocular lens|patients with bilateral clinical significant cataract reisiceved cataract surgeries and recieved spherial intraocuar lens(SA60AT, Alcon) in one eye and aspherical intraocular lens(Tecnis Z9000, AMO)in the other respectively.
11622344|NCT00459290|Experimental|Mifepristone 200 mg PO daily|Mifepristone 200 mg PO daily administered on a continuous basis (every 4 weeks is considered one cycle) until disease progression or adverse effects prohibit further therapy.
11622345|NCT00459277|Experimental|Nasalfent, Fentanyl Citrate Nasal Spray|
11622346|NCT00459277|Placebo Comparator|Placebo Spray|
11622347|NCT00459264|Active Comparator|1|Folic Acid
11622348|NCT00459264|Placebo Comparator|2|Matching placebo for folic acid
11622349|NCT00459225|Active Comparator|1|The parent/guardian will be educated on the iron study and provided the opportunity to ask questions. If the parent/guardian chooses to participate in the study, the parent/guardian will give informed consent for the patient to be placed in either Group I or Group II, based upon guardian/parents' choice for participation in the iron arm of the study. Group I will be randomized in a 1:1 ratio in this open label trial to either receive or not receive iron. Group II will not receive iron but will be a participant in the study and follow the course of the non-iron randomized patients.
11622350|NCT00459225|No Intervention|2|Group II will not receive iron but will be a participant in the study and follow the course of the non-iron randomized patients.
11622351|NCT00459212|Experimental|Arm I|Patients receive GTI-2040 IV continuously on days 1-4 and 15-18.
11622352|NCT00459186|Experimental|RAD001 Followed by RAD001 + Docetaxel|RAD001 10 mg daily for 2 weeks, followed by RAD001 + Docetaxel at one of three doses: 5 mg RAD001 and docetaxel at 60 mg/m2, 10 mg RAD001 and docetaxel at 60 mg/m2, and 10 mg RAD001 and docetaxel at 70 mg/m2. RAD001 was given daily. Docetaxel was given every 3 weeks by intravenous infusion. Patients also received prednisone 5 mg by mouth twice daily.
11622353|NCT00459160|Experimental|Low MAP Group|Hypotensive Group with a target minimum MAP of 50 mmHg
11622354|NCT00459160|No Intervention|High MAP group|Non experimental group: These patients will have a target minimum MAP of 65 mm Hg
11622355|NCT00459134|Experimental|Arm I: ArginMax|ArginMax® 3 pills twice daily
11622356|NCT00459134|Placebo Comparator|Arm II: Placebo|Patients receive oral placebo 3 pills twice daily
11622357|NCT00459121|Experimental|Zactima, Paclitaxel, Carboplatin|"Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.
~Neoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment."
11622358|NCT00459108|Experimental|Oral Dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11622359|NCT00459056|Experimental|Carvediolol CR + Lisinopril, then Lisinopril + HCTZ|Subjects were randomly assigned to Carvedilol CR + Lisinopril for three months, then had a washout period of one month, and then were given Lisinopril + HCTZ for the final three months.
11622360|NCT00459056|Active Comparator|Lisinopril + HCTZ, then Carvedilol CR + Lisinopril|Subjects were randomally assigned to Lisinopril + HCTZ for three months, then had a washout period for one month, and then were given Carvedilol CR + Lisinopril for the final three months.
11622361|NCT00459043|Active Comparator|1|Docetaxel Alone
11622362|NCT00459043|Active Comparator|2|Docetaxel with ZD6474
11622363|NCT00459030|Experimental|Print Communication|Cancer screening educational information mailed to patient's home one time after signing consent.
11622364|NCT00459030|Experimental|Electronic communication|Cancer screening educational information delivered via a password protected internet site.
11622365|NCT00459030|Active Comparator|No Health Communication|No additional cancer screening education information sent to patient.
11622366|NCT00458978|Experimental|Treatment (enzyme inhibitor)|Patients receive oral cediranib maleate once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11622367|NCT00458952|Experimental|Dose Escalation|Dosing of Ultratrace iobenguane I 131 began at 6.0 mCi/kg and escalated in 1.0 mCi/kg increments in order to establish the MTD. The MTD is the dose immediately below the level at which escalation stops due to dose-limiting toxicity (DLT). An additional 3 patients are to be treated at the MTD, for a total of 6.
11622368|NCT00458900|Experimental|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
11622449|NCT00457977|Active Comparator|Prevnar (PCV7)|diphtheria protein-conjugated vaccine (PCV7) (Prevnar) 1.0 mL dose
11622450|NCT00457964|Experimental|Administration of RAD001|
11622369|NCT00458887||Ancillary/Correlative (ototoxicity assessment)|"Patients undergo hearing tests (conventional, otoscopy, ultrahigh frequency, and otoacoustic emission testing) for management of therapy complications before the first course of planned cisplatin, before each subsequent course of cisplatin, and 4 weeks after the last dose of cisplatin.
~Patients who are scheduled to receive hematopoietic progenitor stem cell transplantation undergo hearing tests for management of therapy complications before the transplantation and 4 weeks after transplantation."
11622370|NCT00458874|Experimental|Receive CIMT Results (R-CIMT)|This group will receive visual feedback of their CIMT results on a weekly basis.
11622371|NCT00458874|No Intervention|Withhold CIMT Results (W-CIMT)|The W-CIMT group will not receive their CIMT results until the end of their study participation.
11622372|NCT00458861|Experimental|BG9924|Subcutaneous administration of BG9924 given every other week for 12 weeks
11622373|NCT00458861|Placebo Comparator|Placebo|Subcutaneous administration of placebo given every other week for 12 weeks
11622374|NCT00458822|Experimental|All Patients|All patients treated with Melphalan with Stem Cell Transplant and Adjuvant Bortezomib and Dexamethasone for Recently Diagnosed Untreated Patients with Systemic Light-Chain (AL) Amyloidosis
11622375|NCT00458809|Experimental|Hyperthermic Chemoperfusion with Oxaliplatin 200 mg/m2|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin 200 mg/m2
11622376|NCT00458809|Experimental|Hyperthermic Chemoperfusion with Oxaliplatin 250 mg/m2|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin 250 mg/m2
11622377|NCT00458783|Active Comparator|Prolonged RBC storage|Transfusion with oldest available matching RBCs.
11622378|NCT00458783|Active Comparator|Short RBC storage|Transfusion with youngest available matching RBCs.
11622379|NCT00458731|Experimental|Treatment (cediranib maleate and bevacizumab)|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral cediranib maleate once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of bevacizumab and cediranib maleate until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
11622380|NCT00458705|Experimental|Combination therapy|Combination therapy with bortezomib, pegylated liposomal doxorubicin and dexamethasone (BDD) followed by either thalidomide and dexamethasone (TD) or bortezomib, thalidomide and dexamethasone in patients with symptomatic untreated high-risk or primary resistant multiple myeloma. Three cycles of BDD will be administered. Patients who respond after three cycles will receive two cycles of TD. Patients with stable or progressive disease after three cycles of BDD receive two cycles of bortezomib, thalidomide and dexamethasone. If at any point during the study a patient achieves a complete response (CR), the patient will be given the option to discontinue treatment on-study.
11622381|NCT00458679|Experimental|Vaccine|autologous B-CLL vaccine expressing CD40L and IL2
11622382|NCT00458653|Experimental|Group A|Post-transplant vaccination
11622383|NCT00458653|Experimental|Group B|Pre- and post-transplant vaccination
11622384|NCT00458601|Experimental|CDX-110 with GM-CSF|
11622385|NCT00458575|Experimental|CNTO 2476|Participants 1 to 4: advanced retinitis pigmentosa (RP) with light perception only (LP); Participant 5: combination visual acuity of LP in the treated eye and no better than hand motion (HM) in the fellow eye; and Participants 6 to 9: advanced RP with hand motion (HM) will receive different dose levels of CNTO 2476.
11622386|NCT00458562||HIV+, <CIN2|HIV positive women without CIN2-3 or worse
11622387|NCT00458562||HIV-, no >=CIN3 biopsy, HR HPV+|HIV negative women without biopsy-proven CIN3 or worse, and with high risk HPV infection
11622388|NCT00458562||HIV-, <=CIN1, HPV- at screening|HIV negative women who are <= CIN1 and HPV negative at screening
11622389|NCT00458549|Experimental|omega-3 fatty acids|omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
11622390|NCT00458549|Placebo Comparator|Corn Oil|Oral 8g once a day for 21 days prior to (biopsy) surgery
11622391|NCT00458510|Experimental|Fentanyl, Open-Label treatment|All patients take NasalFent at effective dose to treat up to four episodes of breakthrough cancer pain per day
11622392|NCT00458497|Experimental|1|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
11622393|NCT00458497|Placebo Comparator|2|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric.
11622394|NCT00458484|Experimental|Series 1: Stereotactic radiosurgery|Series I: Radiation will be delivered in 4 fractions. The initial dose level will be 6 Gy per fraction to a total dose of 24 Gy in 4 fractions. Doses will be escalated at 2 Gy per fraction increments to 12 Gy per fraction to a total dose of 48 Gy.
11622395|NCT00458484|Experimental|Series 2: Stereotactic radiosurgery|Series II: The initial dose level will be 48 Gy to the target volume (tumor) in 3 fractions of 16 Gy per fraction. If acute toxicity is acceptable, then the next four patients will be escalated to 54 Gy in 3 fractions of 18 Gy. Finally if a dose limit has not been reached, the last group of four patients will be treated to 60 Gy in 3 fractions of 20 Gy each.
11622396|NCT00458458|Active Comparator|NA alone|Norethindrone Acetate (NA) 5mg taken 1-3 tabs orally every night for duration of treatment
11622397|NCT00458458|Active Comparator|LD then NA|Lupron Depot(LD) given intramuscularly every 12 weeks for total of 24 weeks then switched to Norethindrone Acetate (NA) taken 1-3 tablets orally every night for remainder of treatment
11622398|NCT00458419|Placebo Comparator|A: naloxone; B: normal saline|Arm A: IV naloxone Arm B: IV normal saline
11622399|NCT00458406|Active Comparator|Bi-Flex|"Subjects randomized to this arm will undergo a clinical Bi-Flex sleep study. Following a baseline polysomnography, subjects in this arm will undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.
~In this randomized, double-blinded clinical trial, patients with obstructive sleep apnea will be randomized to Bi-Flex or CPAP, and repeat polysomnography will be performed on pressure at 3 months. Objective adherence data will be obtained at 1 and 3 months."
11622451|NCT00457951|Experimental|Open Label|Initial six subjects treated with ODSH open-label to confirm safety in subjects with an acute exacerbation of COPD; six additional patients will be enrolled following safety review.
11622452|NCT00457951|Placebo Comparator|0.9% Sodium Chloride|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride Solution bolus; dose of 0.375mg/kg/hr over 96 hours.
11622400|NCT00458406|Active Comparator|CPAP|"Subjects randomized to this arm will undergo a clinical CPAP titration sleep study.
~Subjects in this arm received standard continuous positive airway pressure (CPAP) therapy.
~In this randomized, double-blinded clinical trial, patients with obstructive sleep apnea will randomized to CPAP or Bi-Flex, and repeat polysomnography will be performed on pressure at 3 months. Objective adherence data will be obtained at 1 and 3 months."
11622401|NCT00458393|Experimental|TDF/FTC|Drug. Daily oral tablet of co-formulated 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate (TDF/FTC).
11622402|NCT00458393|Placebo Comparator|Placebo|Drug. Daily oral placebo
11622403|NCT00458367||001|Open label risperidone long acting injectable intramuscular injections every 2 weeks for 26 weeks flexible dose 25 to 50 mg
11622404|NCT00458354|Experimental|Spinal Sealant|Dural repair with the Spinal Sealant System.
11622405|NCT00458354|Active Comparator|Standard Methods|Dural repair with standard methods such as the closing of the dura with stitches.
11622406|NCT00458341|Experimental|Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg|During Cycle 1, participants will receive ataluren at 4 mg/kg in the morning, 4 mg/kg at midday, and 8 mg/kg in the evening for 14 days, followed by a 14-day follow-up period without treatment. Then, the participants will crossover to the other ataluren dose regimen (ataluren 10, 10, and 20 mg/kg) for Cycle 2.
11622407|NCT00458341|Experimental|Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg|During Cycle 1, participants will receive ataluren at 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 14 days, followed by a 14-day follow-up period without treatment. Then, the participants will crossover to the other ataluren dose regimen (ataluren 4, 4, and 8 mg/kg) for Cycle 2.
11622408|NCT00458302|Experimental|darunavir monotherapy|darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
11622409|NCT00458302|Experimental|darunavir + 2 NRTI|darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
11622410|NCT00458289|No Intervention|1|P-containing meal alone
11622411|NCT00458289|Active Comparator|2|P-containing meal AND single 1 g oral dose of chewed lanthanum carbonate
11622412|NCT00458289|Active Comparator|3|P-containing meal and single 1 g oral dose of lanthanum carbonate crushed into a fine powder
11622413|NCT00458276|Experimental|1|Tezosentan
11622414|NCT00458276|Placebo Comparator|2|Placebo
11622415|NCT00458263|Experimental|single arm|
11622416|NCT00458237|Experimental|Ph I: Everolimus L1 + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 5 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
11622417|NCT00458237|Experimental|Ph I: Everolimus L2 + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 10 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
11622418|NCT00458237|Experimental|PhII: Everolimus MTD + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus at the MTD by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
11622419|NCT00458224|Experimental|Parental counseling|Life style counseling
11622420|NCT00458211|Experimental|Experimental|Open label change to ziprasidone
11622421|NCT00458198|Experimental|1|Participants will receive integrated behavioral therapy
11622422|NCT00458198|Active Comparator|2|Participants will receive integrated behavioral therapy after a 12-week waitlist period
11622423|NCT00458159|Experimental|1|
11622424|NCT00458146|Experimental|1|MM-093
11622425|NCT00458146|Placebo Comparator|2|Placebo
11622426|NCT00458133|Experimental|1|We randomly assigned 72 individuals to an aerobic exercise training only group.
11622427|NCT00458133|Experimental|2|We randomly assigned 73 individuals to an resistance exercise training only group.
11622428|NCT00458133|Experimental|3|We randomly assigned 76 individuals to a combination of aerobic plus resistance training group.
11622429|NCT00458133|Placebo Comparator|4|We randomly assigned 41 individuals to a stretching and relaxation group.
11622430|NCT00458120|Experimental|1|Participants previously vaccinated with rDEN4delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN1delta30 vaccine into the deltoid region of either arm.
11622431|NCT00458120|Experimental|2|Participants previously vaccinated with rDEN4delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN2/4delta30(ME) into the deltoid region of either arm.
11622432|NCT00458120|Experimental|3|Participants previously vaccinated with rDEN2/4delta30(ME) will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN1delta30 vaccine into the deltoid region of either arm.
11622433|NCT00458120|Experimental|4|Participants previously vaccinated with rDEN1delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN2/4delta30(ME) vaccine into the deltoid region of either arm.
11622434|NCT00458120|Placebo Comparator|5|One subcutaneous vaccination with placebo into the deltoid region of either arm.
11622435|NCT00458094|Experimental|1|Participants will receive the peer-supported physical activity intervention
11622436|NCT00458094|Active Comparator|2|Participants will receive physical activity without peer support
11622437|NCT00458081|Experimental|Rimonabant|
11622438|NCT00458081|Placebo Comparator|Placebo|
11622439|NCT00458029|Experimental|School based intervention|Integration of activities, events, and programs affecting total school food service environment, physical education class, behavior change, promotion, and communications
11622440|NCT00458029|No Intervention|Control|Observational control
11622441|NCT00458016|Experimental|1|
11622442|NCT00458016|Experimental|2|
11622443|NCT00458016|Experimental|3|
11622444|NCT00458016|Experimental|4|
11622445|NCT00458016|Placebo Comparator|5|
11622446|NCT00458003|Experimental|Phenylephrine|Subject will receive a phenylephrine infusion to prevent and to treat hypotension associated with spinal anesthesia
11622447|NCT00458003|Active Comparator|Ephedrine|Subject will receive an ephedrine infusion to prevent and to treat hypotension associated with spinal anesthesia
11622448|NCT00457977|Active Comparator|Pneumovax (PPSV23)|pneumococcal capsular polysaccharide vaccine (PPSV23) (Pneumovax)
11622453|NCT00457951|Active Comparator|Randomized, Blinded, ODSH Arm|Subjects will receive standard of care treatment. ODSH is administered in bolus doses estimated to inhibit inflammatory mediators randomized 1:1 to ODSH 8mg/kg or placebo. The continuous infusion dose will be 0.375 mg/kg/hr over 96 hours.
11622454|NCT00457938|Other|"Low fat diet is the drug"|Diet 10% fat versus 35% fat
11622455|NCT00457873|Experimental|A|0.9% saline in 5% dextrose (intravenous)
11622456|NCT00457873|Active Comparator|B|0.45% saline in 5% dextrose (intravenous)
11622457|NCT00457821|Experimental|Ivacaftor Group A|Subjects in Part 1 who first received 25 mg or 75 mg of ivacaftor every 12 hours (q12h) for 14 days, then crossed over to receive the alternate dose for another 14 days.
11622458|NCT00457821|Experimental|Ivacaftor Group B|Subjects in Part 1 who first received 75 mg or 150 mg of ivacaftor q12h for 14 days then crossed over to receive the alternate dose for another 14 days.
11622459|NCT00457821|Experimental|Ivacaftor Group C|Subjects in Part 2 who received 150 mg or 250 mg of ivacaftor q12h for 28 days.
11622460|NCT00457821|Placebo Comparator|Placebo|Subjects who received placebo in Part 1 and subjects who received placebo in Part 2.
11622461|NCT00457795|Experimental|brimonidine 0.1%|brimonidine 0.1%
11622462|NCT00457782|Experimental|I|Intravenous KW-2478 (ascending dose cohorts)
11622463|NCT00457769|Experimental|Aricept- A|Half of subjects are randomized to immediate treatment with donepezil 5mg orally daily following baseline testing, with retesting at 12 and 24 weeks.
11622464|NCT00457769|Experimental|A2-12-week waiting period|The remaining nine subjects are randomized to testing followed by a 12-week waiting period. After the 12 week wait, this group of subjects is retested and begins taking donepezil, 5 mg orally daily, with retesting at 24 weeks
11622465|NCT00457756|Active Comparator|I|Cohort I subjects will take supplement for 12 weeks
11622466|NCT00457756|Placebo Comparator|II|Cohort II will take placebo for 12 weeks
11622467|NCT00457743|Experimental|SU011248|25 , 50 or 75 mg/day of SU011248
11622468|NCT00457730|Experimental|Duloxetine|subjects will be randomized to study drug (Duloxetine) or Placebo. Subjects will take 30 mg (10 capsules) titrate up to 60 mg( 40 capsules) and titrate back down to 30 mg.
11622469|NCT00457730|Placebo Comparator|placebo|matched placebo medication
11622470|NCT00457691|Experimental|1|
11622471|NCT00457691|Placebo Comparator|2|
11622472|NCT00457665|Active Comparator|Nelfinavir (Viracept)|
11622473|NCT00457665|Active Comparator|Efavirenz (Sustiva)|
11622474|NCT00457652|Active Comparator|1|7 day treatment rosuvastatin
11622475|NCT00457652|Placebo Comparator|2|7 day treatment placebo
11622476|NCT00457639|Experimental|Cholic Acid active capsules|Cholic Acid weight based dose for 6 months double-blind
11622477|NCT00457639|Placebo Comparator|Placebo for Cholic Acid|Placebo for Cholic Acid for 6 months double-blind
11622478|NCT00457626|Experimental|Valsartan|
11622479|NCT00457509|Experimental|Group 1|Dose 1 with Adjuvant
11622480|NCT00457509|Experimental|Group 2|Dose 2 with adjuvant
11622481|NCT00457509|Experimental|Group 3|Dose 3 with adjuvant
11622482|NCT00457509|Experimental|Group 4|Dose 4 with adjuvant
11622483|NCT00457509|Active Comparator|Group 5|Control
11622484|NCT00457496|Active Comparator|A|
11622485|NCT00457457|Active Comparator|Comparator|Tamsulosin 0.4 mg prolonged release
11622486|NCT00457457|Experimental|Treatment Arm|There are 5 possible UK-369,003 arms as follows: UK-369,003 MR (10mg, 25mg, 50mg & 100mg), UK-369,003 IR (40mg),
11622487|NCT00457431|No Intervention|Control|Standard therapy as used in the hospital's ICU
11622488|NCT00457431|Active Comparator|Hypothermia|Standard therapy as used in the hospital's ICU plus Hypothermia
11622489|NCT00457418|Experimental|PEG-Intron|"6 ug/kg/week, SC (first 8 weeks)
~3 ug/kg/week, SC (252 weeks [weeks 9-260], maintenance)"
11622490|NCT00457405|Active Comparator|1|first 7 day treatment with dipyridamol and at least two weeks later 7 day treatment with placebo
11622491|NCT00457405|Active Comparator|2|first 7 day treatment with placebo and at least two weeks later 7 day treatment with atorvastatin
11622492|NCT00457392|Experimental|1|
11622493|NCT00457392|Active Comparator|2|
11622494|NCT00457366|Active Comparator|Quetiapine|Quetiapine is being used in an ER setting on agitated patients, being administered orally.
11622495|NCT00457366|Active Comparator|Haloperidol|"Haloperidol is being used in an ER setting on agitated patients, administered IM. This is being used in combination with lorazepam and cogentin. We are comparing the use of this cocktail to quetiapine alone."
11622496|NCT00457366|Active Comparator|Lorazepam|"Lorazepam is being used in an ER setting on agitated patients, administered IM.This is being used in combination with haloperidol, and cogentin. We are comparing the use of this cocktail to quetiapine alone."
11622497|NCT00457366|Active Comparator|Cogentin|"Cogentin is being used in an ER setting on agitated patients, administered IM.
~This is being used in combination with haloperidol, and lorazepam. We are comparing the use of this cocktail to quetiapine alone."
11622498|NCT00457353|Active Comparator|1|Administration of oral rehydration therapy with Bacillus clausii probiotic strain (1 vial twice daily, each vial containing 2 billion spores of Bacillus clausii)
11622499|NCT00457353|Placebo Comparator|2|Administration of Oral rehydration therapy
11622500|NCT00457314|Experimental|1|Participants will partake in regular exercise training for 6 months. After 6 months, they will switch to no exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
11622501|NCT00457314|Experimental|2|Participants will not partake in regular exercise training for 6 months. After 6 months, they will switch to exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
11622502|NCT00457301||Control|
11622503|NCT00457249|Experimental|Adacel Vaccine Group|
11622504|NCT00457249|Active Comparator|DECAVAC Vaccine Group|
11622505|NCT00457223|Experimental|1Fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®)
11622506|NCT00457223|Active Comparator|2 Suture|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using continuous suture with nylon 10-0
11622642|NCT00455455|Active Comparator|ReNu Multiplus Multipurpose Solution|
11622507|NCT00457197|Placebo Comparator|Placebo|This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
11622508|NCT00457197|Active Comparator|Quetiapine|This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
11622509|NCT00457158|Experimental|1|ALN optional filter
11622510|NCT00457158|No Intervention|2|No ALN optional filter
11622511|NCT00457119|Experimental|Step 1 Arm 1|5mg/day RAD001 + Carboplatin + Paclitaxel
11622512|NCT00457119|Experimental|Step 1, Arm 2|30mg/week RAD001 + Carboplatin + Paclitaxel
11622513|NCT00457119|Experimental|Step 2, Arm 1|5mg/day RAD001 + Carboplatin + Paclitaxel + Bevacizumab
11622514|NCT00457119|Experimental|Step 2, Arm 2|30mg/week RAD001 + Carboplatin + Paclitaxel + Bevacizumab
11622515|NCT00457015|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections.
11622516|NCT00457015|Placebo Comparator|Placebo|Placebo, Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.
11622517|NCT00457002|Experimental|Arm 1|"While hospitalized, Apixaban plus Placebo
~Apixaban (Tablets, Oral, 2.5 mg), Placebo (Syringes, SC)
~After hospital discharge, Apixaban
~Apixaban (Tablets, Oral, 2.5 mg)"
11622518|NCT00457002|Active Comparator|Arm 2|"While hospitalized, Enoxaparin plus Placebo
~Enoxaparin (Syringes, SC, 40 mg), Placebo (Tablets, Oral)
~After hospital discharge: Placebo
~Placebo (Tablets, Oral)"
11622519|NCT00456989|Experimental|Taxotere and Doxil|Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively. Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
11622520|NCT00456963|Experimental|Diet, exercise and Enalapril|one Enalapril 10mg tablet and one Losartan placebo tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet and one Losartan placebo tablet once daily until the end of the randomized treatment phase. After this one Enalapril placebo tablet and one Losartan placebo tablet once daily for six months.
11622521|NCT00456963|Active Comparator|Diet, Exercise and Losartan|one Losartan 50mg tablet and one Enalapril placebo tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet and one Enalapril placebo tablet once daily until the end of the randomized treatment phase. After this one Losartan placebo tablet and one Enalapril placebo tablet once daily for six months.
11622522|NCT00456963|Placebo Comparator|Diet, exercise and Placebo|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
11622523|NCT00456885|Placebo Comparator|Exenatide First|Started on Exenatide, 3 week washout, start placebo
11622524|NCT00456885|Experimental|Placebo First|Started on placebo, 3 week washout, start exenatide
11622525|NCT00456872|Experimental|buffered lidocaine|Sodium bicarbonate is a buffering additive that decreases the pH of the solution allowing for decrease in pain upon filtration.
11622526|NCT00456872|Experimental|unbuffered lidocaine|lidocaine is injected without sodium bicarbonate added
11622527|NCT00456846|Experimental|ABI-007|100 mg/m^2 ABI-007 was administered by intravenous (IV) infusion over 30 minutes weekly for 3 weeks followed by 1 week rest. Therapy continued until disease progression or unacceptable toxicity.
11622528|NCT00456833|Experimental|RAD 5mg/day + erlotinib|
11622529|NCT00456833|Active Comparator|erlotinib 150mg/day|
11622530|NCT00456807|Experimental|Cervarix Group|Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).
11622531|NCT00456807|Placebo Comparator|Placebo Group|Subjects who received 3 doses of placebo during the primary study (NCT00294047).
11622532|NCT00456781|Experimental|Augmentation|Rotator Cuff Repair augmented with the Graft Jacket Device
11622533|NCT00456781|Active Comparator|No Augmentation|Rotator Cuff RFepair
11622534|NCT00456755|Active Comparator|Shi-Bi-Lin|Consist of 6 herbal. 7.5 g Xanthium sibiricum Patrin ex Widder (Asteraceae, Fructus), 20 g Angelica dahurica (Fisch. ex Hoffm.) Benth. (Apiaceae, Radix), 7.5 g Saposhnikovia divaricata (Turcz.) Schischk. (Apiaceae, Radix),15 g Magnolia biondii Pamp., (Magnoliaceae, Flos), 5 g Gentiana scabra Bunge (Gentianaceae, Radix) and 5 g Verbena officinalis L. (Verbenaceae, Herba).
11622535|NCT00456755|Placebo Comparator|Placebo|The placebo contained brown colored starch resembling the SBL powder
11622536|NCT00456703|Active Comparator|restriction|In this group, the fluids will be restricted compared to a standard procedure
11622537|NCT00456690|Experimental|1|Thalassemia Mayor Patients
11622538|NCT00456677|Experimental|Minocycline|Addition of minocycline 150 mg po twice daily to current asthma treatment regimen.
11622539|NCT00456677|Placebo Comparator|Placebos|Addition of placebo capsules po twice daily to current asthma treatment regimen
11622540|NCT00456638|Experimental|Depodur|Depodur arm
11622541|NCT00456638|Active Comparator|Traditional|traditional management
11622542|NCT00456625|Experimental|Group Engerix™-B|Subjects received a dose of Hepatitis B vaccine approximately 20 years after the primary neonatal vaccination
11622543|NCT00456612|Other|Cyberknife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
11622544|NCT00456599|Experimental|Oxaliplatin & gemcitabine with radiation|This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer.
11622545|NCT00456547||Postpartum hysterectomy|Women that require postpartum hysterectomy for post-delivery bleeding.
11622546|NCT00456547||Cesarean delivery case controls|Women that deliver by cesarean that presented with risk factors for bleeding but did not require post delivery hysterectomy
11622547|NCT00456521|Experimental|NB32|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day with intensive group lifestyle modification counseling
11622548|NCT00456521|Placebo Comparator|Placebo|Placebo with intensive group lifestyle modification counseling
11622549|NCT00456508|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) Patients were treated with DX-88 (ecallantide) when they experienced an HAE attack. 30 mg dose of ecallantide given via 3 SC injections; a second 30 mg dose can be administered if needed. Patients were to be assessed until 4 hrs post-dose. Patients were asked to return for 3 follow-up visits: 7 days, 28 days and 90 days post-dose.
11622643|NCT00455429|Placebo Comparator|Placebo|
11622550|NCT00456495|Experimental|Subconjunctival ranibizumab|Patients will receive subconjunctival ranibizumab every 2-4 weeks.
11622551|NCT00456482|Experimental|Fluocinolone Acetonide 0.59mg|Fluocinolone acetonide intravitreal implant 0.59mg
11622552|NCT00456482|Experimental|Fluocinolone Acetonide 2.1mg|Fluocinolone acetonide intravitreal implant 2.1mg
11622553|NCT00456482|No Intervention|No Intervention|Fellow eye
11622554|NCT00456378|Experimental|DIAM™ spinal stabilization system|Implantation of the DIAM Spinal Stabilization System
11622555|NCT00456378|Active Comparator|Conservative care|Conservative Care
11622556|NCT00456365|Experimental|Pravastatin|Pravastatin
11622557|NCT00456365|Placebo Comparator|Placebo|Placebo
11622558|NCT00456326||HIT Patients|Patients at Brigham and Women's Hospital diagnosed with Heparin Induced Thrombocytopenia.
11622559|NCT00456313|Active Comparator|arm 1|
11622560|NCT00456300|Experimental|Exenatide 1.25 mcg + Insulin|In each intervention arm the participant receives a different dose of Exenatide along with Insulin as a single subcutaneous injection
11622561|NCT00456300|Experimental|Exenatide 2.5 mcg + Insulin|In each intervention arm the participant receives a different dose of Exenatide along with Insulin as a single subcutaneous injection
11622562|NCT00456300|Active Comparator|Insulin|Each subject received a baseline study with insulin alone
11622563|NCT00456274|Other|1|
11622564|NCT00456261|Experimental|Cohort A|Cohort A, will receive bevacizumab 10mg/kg by vein over 30-90 minutes followed by pemetrexed 500 mg/m2 by vein over 10 minutes followed by gemcitabine 1500 mg/m2 by vein over 30-60 minutes. This regimen will be given on day 1 and day 15 of each treatment cycle. Each cycle is 28 days long. As long as their disease does not worsen patients can receive up to a maximum of 6 cycles of this combination chemotherapy. Following that they can receive bevacizumab alone once every 2 weeks as long as their disease does not worsen.
11622565|NCT00456261|Experimental|Cohort B|Cohort B, will receive bevacizumab 15mg/kg by vein over 30-90 minutes followed by pemetrexed 500 mg/m2 by vein over approximately 10 minutes followed by carboplatin AUC=5 by vein over 30-60 minutes. This regimen will be given on day 1 of each treatment cycle. Each cycle is 21 days long. As long as their disease does not worsen patients can receive up to a maximum of 6 cycles of this combination chemotherapy. Following that they can receive bevacizumab alone once every 3 weeks as long as their disease does not worsen.
11622566|NCT00456248|Experimental|1|Infergen 15 ug QD plus RBV for 36 weeks
11622567|NCT00456248|Experimental|2|Infergen 15 ug QD plus RBV for 48 weeks
11622568|NCT00456248|Active Comparator|3|
11622569|NCT00456235|Experimental|adjument MMF|adjusting the dose according to the MMF AUC of mycophenolic acid
11622570|NCT00456235|Active Comparator|continued treatment|Continued treatment empirically usual
11622571|NCT00456222||Luteal|
11622572|NCT00456222||Follicular|
11622573|NCT00456144||Group 1|GnRH agonist for 24 months
11622574|NCT00456144||Group 2|GnRH agonist for 6 months
11622575|NCT00456131|Experimental|Intervention|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
11622576|NCT00456118||repeated miscarriages|60 womens for repeated miscarriages will be included
11622577|NCT00456118||Preeclampsia|70 women for pre-eclampsia will be included
11622578|NCT00456118||intervillites|20 women for intervillites will be included
11622579|NCT00456105|Active Comparator|1|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician, post operatively until hospital discharge and post discharge in the community.
11622580|NCT00456105|Experimental|2|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team post operatively until hospital discharge and post discharge in the community. The Diabetes Action team will consist of a nurse coordinator who is a Certified Diabetes Educator (CDE) and a team of physicians specialized in the management of diabetes.
11622581|NCT00456105|Placebo Comparator|3|Subjects without diabetes will have their blood glucose levels monitored while in the hospital.
11622582|NCT00456092|Experimental|Apremilast 40 mg QD|"Participants received 40 mg apremilast orally once a day (QD) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 40 mg apremilast QD for an additional 12 weeks.
~The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 40 mg QD thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication."
11622583|NCT00456092|Experimental|Apremilast 20 mg BID|Participants received 20 mg apremilast orally twice a day (BID) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 20 mg apremilast BID for an additional 12 weeks. The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 20 mg BID thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication.
11622584|NCT00456092|Placebo Comparator|Placebo|Participants received matching placebo to apremilast orally BID for 12 weeks during the Treatment Phase. Participants who entered the Extension Phase were re-randomized on Day 85 to receive either 40 mg apremilast QD or 20 mg apremilast BID for 12 weeks.
11622585|NCT00456014|Experimental|1 - SSRI|Participants will receive standardized pharmacotherapy with the SSRI escitalopram over 8 weeks. Non-remitters after 8 weeks will be offered standardized pharmacotherapy with desipramine
11622586|NCT00455975|Experimental|Weekly Avastin|Bevacizumab 15mg/kg IV weekly until progressive disease or toxicity
11622587|NCT00455975|Experimental|Bi-weekly Avastin|Bevacizumab 15mg/kg IV every 2 weeks until progressive disease or toxicity
11622588|NCT00455962|Active Comparator|African American women 18-35 yo|intervention: estradiol steroid infusion and progesterone steroid infusion
11622589|NCT00455962|Active Comparator|Caucasian women 18-35 yo|intervention: estradiol steroid infusion intervention: progesterone steroid infusion
11622590|NCT00455936|Experimental|study arm|Gefitinib 250mg table/QD, daily every 3 weeks
11622591|NCT00455936|Active Comparator|control arm|gemcitabine 1250mg/m2 iv on D1 & D8 every 3 weeks Cisplatin 80mg/m2 iv on D1 every 3 weeks
11622644|NCT00455429|Experimental|JNJ-26113100 (50 mg) once daily|
11622592|NCT00455923|Experimental|Seretide|Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.
11622593|NCT00455923|Experimental|Flixotide|Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.
11622594|NCT00455897|Experimental|GMCSF-RCHOP|
11622595|NCT00455871|Active Comparator|Lucentis plus Reduced Fluence PDT same day|
11622596|NCT00455871|Active Comparator|Lucentis plus reduced fluence PDT 1-2 weeks later|
11622597|NCT00455858|Active Comparator|insulin detemir|
11622598|NCT00455845|Active Comparator|1 levonorgestrel IUD|
11622599|NCT00455845|No Intervention|2 control|
11622600|NCT00455793||1|HIV
11622601|NCT00455793||2|Non-HIV infected controls
11622602|NCT00455780|Experimental|MR-/REDE-|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy for weight loss maintenance.
11622603|NCT00455780|Experimental|MR+/REDE-|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy and use of meal replacements for weight loss maintenance.
11622604|NCT00455780|Experimental|MR-/REDE+|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy as well as Reduced Energy Density Education for weight loss maintenance.
11622605|NCT00455780|Experimental|MR+/REDE+|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy, as well as Reduced Energy Density Education and continued meal replacement use, for weight loss maintenance.
11622606|NCT00455767|Active Comparator|1|Depelestat
11622607|NCT00455767|Placebo Comparator|2|Placebo
11622608|NCT00455741|Active Comparator|Young postmenopausal women|Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women.
11622609|NCT00455741|Active Comparator|Older postmenopausal women|Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women..
11622610|NCT00455702|Experimental|D-cycloserine|50 mg d-cycloserine
11622611|NCT00455702|Placebo Comparator|Placebo|50 mg placebo
11622612|NCT00455689|Experimental|Developed hot flashes|Subjects who developed hot flashes after receiving leuprolide acetate (3.75 mg intramuscular injection)
11622613|NCT00455689|Experimental|Did not develop hot flashes|Subjects who did not develop hot flashes after receiving leuprolide acetate (3.75 mg intramuscular injection)
11622614|NCT00455663|Experimental|Cognitive Adaptation Training|In home treatment using environmental supports such as signs, labels, alarms, checklists and the organization of belongings to bypass cognitive impairment, cue and sequence adaptive behavior and improve a wide range of functional outcomes.
11622615|NCT00455663|Experimental|Pharm-Cognitive Adaptation Training|Uses Supports from Cognitive Adaptation Training designed only to promote adherence to medication and treatment follow up.
11622616|NCT00455663|Active Comparator|Treatment As Usual|Medication follow up and limited case management provided by local mental health authority
11622617|NCT00455650|Active Comparator|Schizophrenia, Mecamylamine|
11622618|NCT00455650|Active Comparator|Schizophrenia, Varenicline|
11622619|NCT00455650|Placebo Comparator|Schizophrenia, Placebo|
11622620|NCT00455650|Active Comparator|Control, Mecamylamine|
11622621|NCT00455650|Active Comparator|Control, Varenicline|
11622622|NCT00455650|Placebo Comparator|Control, placebo|
11622623|NCT00455637|Experimental|Dysport 5 units|
11622624|NCT00455637|Experimental|Dysport 10 units|
11622625|NCT00455637|Experimental|Dysport 15 units|
11622626|NCT00455598|Placebo Comparator|A|Sulfonylurea + 100 mg/week ISIS 113715 or placebo
11622627|NCT00455598|Placebo Comparator|B|Sulfonylurea + 200 mg/week ISIS 113715 or placebo
11622628|NCT00455572|Experimental|Cohort 1|Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will receive chemo-and immunotherapy in parallel.
11622629|NCT00455572|Experimental|Cohort 2|Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will first receive chemotherapy and then immunotherapy
11622630|NCT00455572|Experimental|Cohort 3|Patients with resected stage IB, II or IIIA tumors who are not due for chemotherapy. These patients will receive immunotherapy only.
11622631|NCT00455572|Experimental|Cohort 4|Patients with unresectable stage III tumors, following standard chemotherapy and/or radiotherapy. These patients will receive immunotherapy only.
11622632|NCT00455559|Experimental|Perifosine 100 mg/d + imatinib mesylate|Perifosine 100 mg/d x 28 days Oral daily dose of perifosine 100 mg and oral daily dose of imatinib mesylate (current dose at time of progression of disease [PD] without interruption). Both drugs will be taken on a continuous basis and should be taken with food. Each cycle will be defined as 28 days.
11622633|NCT00455559|Experimental|Perifosine 900 mg/d + imatinib mesylate|Perifosine 900 mg/d (300 mg tid), 1 x weekly Oral once-weekly dose of perifosine 900 mg (300 mg tid) + oral daily dose of imatinib mesylate (current dose at time of PD without interruption). Perifosine will be taken on days 1, 8, 15, and 22 of a 28-day cycle. Both medications should be taken with food.
11622634|NCT00455533|Experimental|A|
11622635|NCT00455533|Active Comparator|B|
11622636|NCT00455520|Placebo Comparator|Placebo|placebo matching placebo twice daily for 12 weeks
11622637|NCT00455520|Experimental|CG5503|CG5503 100, 150, 200, 250mg twice daily given for up to 15 weeks
11622638|NCT00455507|Experimental|1|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
11622639|NCT00455507|Experimental|2|40mg KW-6002 per day (two 20 mg KW-6002 tablets orally once daily for 12 weeks)
11622640|NCT00455507|Placebo Comparator|3|Two placebo tablets once daily for 12 weeks
11622641|NCT00455455|Active Comparator|Optifree RepleniSH Multipurpose Disinfecting Solution|
11622648|NCT00455403|Experimental|Chloroquine Subjects|Participants will receive 80 mg of chloroquine on a daily basis.
11622649|NCT00455403|Placebo Comparator|Placebo Subjects|Participants will receive a placebo comparator tablet on a daily basis.
11622650|NCT00455351|Experimental|A I|Study drug
11622651|NCT00455325|Placebo Comparator|Placebo Comparator Limb 1|Chloroquine placebo one tablet daily for 3 weeks
11622652|NCT00455325|Active Comparator|Chloroquine Limb 2|80mg chloroquine or placebo tablet weekly for Weeks 1-3
11622653|NCT00455325|Active Comparator|Chloroquine Limb 3|80mg tablet daily for 3 weeks
11622654|NCT00455325|Active Comparator|Chloroquine Limb 4|250mg tablet daily for 3 weeks
11622655|NCT00455312|Experimental|Patients with DC|Patients with dyskeratosis congenita (DC). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, total body irradiation and stem cell transplantation.
11622656|NCT00455312|Experimental|Patients with SAA|Patients with severe aplastic anemia (SAA). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, antithymocyte globulin, total body irradiation and stem cell transplantation.
11622657|NCT00455299|Active Comparator|a|a: suture anchoring + tackers and approximation of defect
11622658|NCT00455299|Active Comparator|b|b: suture anchoring + tackers without approximation of defect
11622659|NCT00455299|Active Comparator|c|c: only tacker fixation and approximation of defect
11622660|NCT00455299|Active Comparator|d|d: only tacker fixation without approximation of defect
11622661|NCT00455221|Experimental|Peptide Vaccine|
11622662|NCT00455195|Experimental|Alglucosidase Alfa/Alglucosidase Alfa|Participants who received alglucosidase alfa during the double-blind study and, if they completed the double-blind study, continued that treatment during the extension study. Participants received an intravenous (IV) infusion of 20 mg/kg of alglucosidase alfa every other week (qow) until their participation in both the AGLU02704 (NCT00158600) and AGLU03206 studies combined equaled a minimum of 104 weeks.
11622663|NCT00455195|Experimental|Placebo/Alglucosidase Alfa|Participants given placebo during the double-blind study, completed the double-blind study (study AGLU02704, NCT00158600), and qualified to continue into the extension study on alglucosidase alfa. Participants received an intravenous (IV) infusion of 20 mg/kg of alglucosidase alfa every other week (qow) for up to 52 weeks. Only the alglucosidase alfa treatment experience is included in this extension study.
11622664|NCT00455182|Placebo Comparator|1|Standard medical care
11622665|NCT00455182|Experimental|2|Acupuncture
11622666|NCT00455182|Sham Comparator|3|Sham acupuncture
11622667|NCT00455169||1|Premature infants
11622668|NCT00455169||2|Full term infants
11622669|NCT00455156|Experimental|150/15 NES/EE CVR|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
11622670|NCT00455143|Experimental|Dexmedetomidine|Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
11622671|NCT00455143|Placebo Comparator|Placebo|Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively or until discharge from the PACU.
11622672|NCT00455117|Placebo Comparator|1|placebo (2 ml normal saline) administered intravenously at dural closure during craniotomy
11622673|NCT00455117|Active Comparator|2|parecoxib 40 mg in 2 ml normal saline administered intravenously at dural closure during craniotomy
11622674|NCT00455104||National Registry|To maintain an established national registry which will collect information related to the identification and monitoring of all persons with Fabry disease in Canada.
11622675|NCT00455052|Experimental|XMT-1001|XMT-1001 is administered I.V. every 21 days. Groups of 3 patients are given one dose and the dose increases for each group. The first dose level is 17 mg/m^2, the next dose level is 30 mg/m^2, followed by dose levels: 50 mg/m^2, 80 mg/m^2, 120 mg/m^2, 150 mg/m^2, and 190 mg/m^2 until disease progressions or unacceptable side effects are experienced.
11622676|NCT00455026|Placebo Comparator|1|0 ng/ml target effect site concentration remifentanil
11622677|NCT00455026|Active Comparator|2|2 ng/ml target concentration remifentanil
11622678|NCT00455026|Active Comparator|3|4 ng/ml target effect site concentration remifentanil
11622679|NCT00455013|Experimental|belatacept, mycophenolate mofetil (MMF)|thymoglobulin 1.5mg/kg for 4 days;IV belatacept: 10 mg/kg Days 1 and 5, then every other week through Month 3 (Weeks 2,4,6,8,10,12), and then every 4 weeks through Month 6 (Weeks 16, 20, 24),after 6 months, 5 mg/kg every 4 weeks until 12 months; MMF 1g twice daily(bis in die, BID)
11622680|NCT00455013|Experimental|belatacept, sirolimus|thymoglobulin 1.5mg/kg for 4 days;IV belatacept: 10 mg/kg Days 1 and 5, then every other week through Month 3 (Weeks 2,4,6,8,10,12), and then every 4 weeks through Month 6 (Weeks 16, 20, 24),after 6 months, 5 mg/kg every 4 weeks until 12 months;sirolimus 5 mg/day on Day 1 (day of transplant)and continued through Day 2, dosing to be adjusted to keep pre-dose C0 levels at 7-12 ng/mL for first 6 months, followed by 5 - 10 ng/mL until 12 months.
11622681|NCT00455013|Other|tacrolimus, MMF|(IMPs as comparator regimen)thymoglobulin 1.5mg/kg for 4 days; oral tacrolimus 0.1 mg/kg/day in 2 divided doses with initial targeted trough level of 8-12 ng/mL for Days 1 - 30 with dose reduction to achieve 12 hour trough target of 5-10 ng/mL for 12 months; MMF (mycophenolate mofetil) 1g BID.
11622682|NCT00455000|Experimental|Active treatment|5 possible active doses
11622683|NCT00455000|Placebo Comparator|Placebo|
11622684|NCT00454987|Experimental|Menitorix Group|Previously primed in infancy with Menitorix™ and Infanrix-IPV™ and boosted with Menitorix™ (Priorix™ co-administered). All UK subjects received a booster dose of Infanrix-IPV™ at 40 to 43 months of age, intramuscularly in the deltoid region.
11622685|NCT00454987|Active Comparator|Meningitec Group|Previously primed in infancy with Meningitec™ and Pediacel™ and boosted with Menitorix™ (Priorix™ co-administered). All UK subjects received a booster dose of Infanrix-IPV™ at 40 to 43 months of age, intramuscularly in the deltoid region.
11622729|NCT00454584|Experimental|CNTO 1275 90 mg|Patients will receive CNTO 1275 90 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.
11622788|NCT00453999|Experimental|Arm 1: Peramivir 200 mg|Peramivir 200 mg administered intravenously once daily for 5 days (5 doses)
11622686|NCT00454987|Active Comparator|Meningitec+Hiberix Group|"Previously primed (according to the routine UK immunisation schedule) with 3 doses of a Meningitec™ conjugate vaccine and a Hiberix™ containing vaccine before the age of 8 months without booster dose at 12 months of age (only for UK). All subjects received a booster dose of Infanrix-IPV™ and Menitorix™ at 40 to 43 months of age, intramuscularly in the deltoid region.
~This group was added only at year 2 in UK (Meningitec+Hiberix Group) to comply with UK Hib Catch-up vaccination programme."
11622687|NCT00454922|Active Comparator|1|education
11622688|NCT00454922|Placebo Comparator|2|standard of care
11622689|NCT00454909|Experimental|Group A|Subjects aged 10 years (< 11 years) vaccinated with meningococcal vaccine GSK134612.
11622690|NCT00454909|Experimental|Group B|Subjects aged 11 to 25 years vaccinated with meningococcal vaccine GSK134612.
11622691|NCT00454909|Active Comparator|Group C|Subjects aged 11 to 25 years vaccinated with Menactra®.
11622692|NCT00454896|Experimental|1|
11622693|NCT00454896|Placebo Comparator|2|
11622694|NCT00454883||1 cohort of patients treated with ziprasidone|
11622695|NCT00454857||Patients with ITP|Participants with ITP and currently treated for ITP were followed prospectively for a period of 12 months.
11622696|NCT00454831|Active Comparator|HEP 400mg TID|HEP-40 400 mg three times a day
11622697|NCT00454831|Active Comparator|HEP 800mg BID|HEP-40 800 mg twice a day
11622698|NCT00454831|Active Comparator|HEP 800mg TID|HEP-40 800 mg three times a day
11622699|NCT00454831|Active Comparator|HEP 2400mg QD|HEP-40 2400 mg once a day
11622700|NCT00454831|Placebo Comparator|Placebo|Placebo, three times a day
11622701|NCT00454818|Experimental|MYDICAR Very Low Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1.4x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) only.
11622702|NCT00454818|Experimental|MYDICAR Low Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
11622703|NCT00454818|Experimental|MYDICAR Mid Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3x10e12 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study).
11622704|NCT00454818|Experimental|MYDICAR High Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1x10e13 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study).
11622705|NCT00454818|Placebo Comparator|Placebo infusion|A single dose of placebo (Sodium Chloride Injection, USP) administered by antegrade epicardial coronary artery infusion.
11622706|NCT00454805|Active Comparator|2|Fulvestrant Monotherapy
11622707|NCT00454805|Experimental|3|AZD2171 + Fulvestrant
11622708|NCT00454792|Active Comparator|Exercise and advise to stay active|The exercise group received exercises for the stabilising muscles in the low back and abdomen together with dynamic exercises, exercises for postural instability and light physical fitness training.
11622709|NCT00454792|Experimental|Rest and use of flexible lumbar belt|The rest group was instructed to avoid hard physical activity and to rest twice daily for one hour, by lying down
11622710|NCT00454779|Experimental|Arm 1|Panitumumab + Docetaxel + Cisplatin
11622711|NCT00454779|Other|Arm 2|control
11622712|NCT00454766||Questionnaire|Questionnaire Regarding Tailored Educational Materials
11622713|NCT00454740|Experimental|1|
11622714|NCT00454714|Active Comparator|A|Sildenafil arm
11622715|NCT00454714|Placebo Comparator|B|Placebo arm
11622716|NCT00454701||1. Amevive Exposure|Patients treated with alefacept for chronic plaque psoriasis
11622717|NCT00454688|Placebo Comparator|Placebo|
11622718|NCT00454688|Experimental|Asimadoline 0.15 mg|
11622719|NCT00454688|Experimental|Asimadoline 0.5 mg|
11622720|NCT00454688|Experimental|Asimadoline 1.0 mg|
11622721|NCT00454662|Active Comparator|1|olmesartan medoxomil, Calcium channel blockers (amlodipine, azelnidipine)
11622722|NCT00454662|Active Comparator|2|AT1 subtype angiotensin II receptor antagonist/low dose diuretic
11622723|NCT00454649|Experimental|Axitinib [AG-013736] + chemotherapy combination|"The following separate groups were included:
~axitinib
~plus carboplatin/paclitaxel in three different schedules
~plus paclitaxel
~plus docetaxel/carboplatin
~plus docetaxel
~plus capecitabine
~plus gemcitabine/cisplatin
~plus pemetrexed/cisplatin"
11622724|NCT00454636|Experimental|Cisplatin / Capecitabine|Cisplatin, 80 mg/m2/day, intravenous (IV), every 3 weeks; capecitabine, 1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks.
11622725|NCT00454636|Experimental|Epirubicin / Cisplatin / Capecitabine|Epirubicin, 50 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capecitabine, 625mg/m2, orally, twice daily per 3-week cycle. Study drugs were administered for at least 24 weeks.
11622726|NCT00454636|Experimental|Epirubicin / Oxaliplatin / Capecitabine|Epirubicin, 50 mg/m2/day, IV, every 3 weeks; oxaliplatin, 130 mg/m2/day, IV, every 3 weeks; capecitabine, 625mg/m2 orally, twice daily per 3-week cycle. Study drugs were administered for at least 24 weeks.
11622727|NCT00454636|Experimental|Docetaxel / Cisplatin / Capecitabine|Docetaxel, 60 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capecitabine, 825 mg/m2, orally, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks.
11622728|NCT00454584|Experimental|CNTO 1275 45 mg|Patients will receive CNTO 1275 45 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on Physician's Global Assessment (PGA) response at Week 12 and initial treatment assignment.
11622787|NCT00454025||Healthy Patients|Patients without glaucoma
11622730|NCT00454584|Active Comparator|Etanercept 50 mg|Patients will receive Etanercept 50 mg twice weekly through Week 12. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.
11622731|NCT00454571|Experimental|Pazopanib|Patients receive pazopanib hydrochloride PO QD on days 1-28 after treatment with leuprolide acetate and goserelin acetate. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11622732|NCT00454571|Active Comparator|Observation|Patients undergo observation after treatment with leuprolide acetate and goserelin acetate.
11622733|NCT00454558|Experimental|Arm 1|
11622734|NCT00454519|Experimental|A|cytoreductive surgery, IPHC, cisplatin 20 mg/m2/L, Mitomycin C 4 mg/m2/L, postoperative chemotherapy.
11622735|NCT00454519|Active Comparator|B|cytoreductive surgery alone, postoperative chemotherapy.
11622736|NCT00454493|Active Comparator|fish oil|
11622737|NCT00454493|Placebo Comparator|placebo|
11622738|NCT00454454||No treatment|
11622739|NCT00454389|Experimental|A|Epi-Rad90™ Ophthalmic System procedure + Lucentis
11622740|NCT00454389|Active Comparator|B|Lucentis only
11622741|NCT00454363|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
11622742|NCT00454337|Experimental|Intensification arm|emtricitabine/TDF + efavirenz or lopinavir/ritonavir + enfuvirtide
11622743|NCT00454337|Active Comparator|Standard arm|emtricitabine/TDF + efavirenz or lopinavir/ritonavir
11622744|NCT00454324|Experimental|Arm A|Carboplatin + Abraxane (240mg/m2) on Day 1 of a 21 Day cycle, up to 6 cycles
11622745|NCT00454324|Experimental|Arm B|Carboplatin + Abraxane (80mg/m2)given on Days 1, 8 and 15 of a 21 Day Cycle, up to 6 cycles
11622746|NCT00454311|Active Comparator|One cell biopsy|
11622747|NCT00454311|Other|Two cell biopsy|
11622748|NCT00454298|Active Comparator|A|AGG-523 1800 mg QD PO (12 capsules) for 28 days
11622749|NCT00454298|Active Comparator|B|AGG-523 900 mg BID PO (12 capsules) for 28 days
11622750|NCT00454298|Placebo Comparator|C|Placebo QD PO (12 capsules) for 28 days
11622751|NCT00454298|Placebo Comparator|D|Placebo BID PO (12 capsules) for 28 days
11622752|NCT00454272|Active Comparator|1, Vancomycin|Vancomycin
11622753|NCT00454272|Active Comparator|2, Teicoplanin|Teicoplanin
11622754|NCT00454259|Experimental|1|0,5 µg/kg
11622755|NCT00454259|Experimental|2|0,05 µg/kg
11622756|NCT00454259|Experimental|3|0,005 µg/kg
11622757|NCT00454259|Placebo Comparator|4|NaCl 0,9 %
11622758|NCT00454246|Experimental|methoxy polyethylene glycol-epoetin beta|"120-360 micrograms methoxy polyethylene glycol-epoetin beta subcutaneous (sc) monthly starting dose, for a minimum of 5 months to a maximum of 18 months.
~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
11622759|NCT00454246|Active Comparator|Epoetin alfa|"Patients randomized to the reference arm continued to receive their standard of care dose and regimen of epoetin alfa subcutaneous once per week for a minimum of 5 months to a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.
~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
11622760|NCT00454246|Active Comparator|Darbepoetin alfa|"Patients randomized to the reference arm continued to receive their standard of care dose and regimen of darbepoetin subcutaneous once every two weeks for a minimum of 5 months and a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.
~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
11622761|NCT00454233|Experimental|1|Dose 1
11622762|NCT00454233|Experimental|2|Dose 2
11622763|NCT00454233|Experimental|3|Dose 3
11622764|NCT00454233|Experimental|4|Dose 4
11622765|NCT00454233|Active Comparator|5|
11622766|NCT00454233|Placebo Comparator|6|
11622767|NCT00454220|Placebo Comparator|Placebo|
11622768|NCT00454220|Experimental|0.01 mg MRrhTSH + 131-I arm|
11622769|NCT00454220|Experimental|0.03 mg MRrhTSH + 131-I arm|
11622770|NCT00454207|Experimental|sildenafil citrate (UK-92,480)|sildenafil citrate 20 mg TID
11622771|NCT00454194|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily on days 1-21 and pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11622772|NCT00454194|Active Comparator|Arm II|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11622773|NCT00454181|Experimental|IFN lozenges|500 IU Interferon-alpha lozenges for oral dissolution
11622774|NCT00454181|Placebo Comparator|placebo lozenges|200 mg lozenges containing anhydrous crystalline maltose
11622775|NCT00454168|Experimental|Arm I|Patients receive PR1 leukemia peptide vaccine and sargramostim (GM-CSF) subcutaneously.
11622776|NCT00454168|Active Comparator|Arm II|Patients receive placebo vaccine and GM-CSF subcutaneously.
11622777|NCT00454155|Experimental|Opebacan|
11622778|NCT00454142|Experimental|Treatment (pazopanib hydrochloride)|"Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Pharmacological study will be done on Day 1 and Day 28. Computed tomography will be done at baseline and day 28."
11622779|NCT00454116|Placebo Comparator|1|FOLFIRI + placebo vandetanib
11622780|NCT00454116|Experimental|2|FOLFIRI + low dose vandetanib
11622781|NCT00454116|Experimental|3|FOLFIRI + high dose vandetanib
11622782|NCT00454064|Active Comparator|1|cognitive-behavioral treatment
11622783|NCT00454064|Active Comparator|2|cognitive-behavioral treatment with biofeedback elements
11622784|NCT00454051|Active Comparator|Omalizumab|Omalizumab was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level.
11622785|NCT00454051|Placebo Comparator|Placebo|Placebo was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks.
11622786|NCT00454025||Glaucoma|Patients with Glaucoma
11622789|NCT00453999|Experimental|Arm 2: Peramivir 400 mg|Peramivir 400 mg administered intravenously once daily for 5 days (5 doses)
11622790|NCT00453999|Experimental|Arm 3: Oseltamivir|Oseltamivir 75 mg oral suspension administered orally twice daily for 5 days (10 doses)
11622791|NCT00453986|Experimental|Nimenrix A Group|subjects received 1 dose of Nimenrix™ Lot A at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
11622792|NCT00453986|Experimental|Nimenrix B Group|subjects received 1 dose of Nimenrix™ Lot B at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
11622793|NCT00453986|Experimental|Nimenrix C Group|subjects received 1 dose of Nimenrix™ Lot C at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
11622794|NCT00453986|Active Comparator|Mencevax ACWY Group|subjects received 1 dose of Mencevax™ ACWY vaccine at Month 0. Mencevax™ ACWY vaccine was administered by subcutaneous injection in the non-dominant upper arm.
11622795|NCT00453986|Experimental|Nimenrix+Fluarix Group|subjects received 1 dose of Nimenrix™ Lot A co-administered with Fluarix™ vaccines at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm. Fluarix™ vaccine was administered by intramuscular injection in the deltoid region of the dominant arm.
11622796|NCT00453973|Experimental|Maintenance Switch in Dialysis Participants|"Participants were from a prior Affymax peginesatide treatment study conducted in participants who were on dialysis and had been on Epoetin at study entry, and who were switched to peginesatide (NCT00434330). This group is categorized as Maintenance Switch in Dialysis Participants regardless of dialysis status at the start of or during this study."
11622797|NCT00453973|Experimental|Treatment Initiation in Non-Dialysis Participants|"Participants were from a prior Affymax peginesatide treatment study conducted in participants who were not on dialysis and not on erythropoiesis stimulating agents (ESAs), and who received peginesatide (NCT00228436). This group is categorized as Initiation of Treatment in Non-Dialysis Participants regardless of dialysis status at the start of or during this study."
11622798|NCT00453960|Experimental|Genistein|Genistein 54 mg/day
11622799|NCT00453960|Active Comparator|Norethisterone Acetate|Norethisterone Acetate 10mg/day
11622800|NCT00453960|Placebo Comparator|Placebo|Placebo tablets, daily
11622801|NCT00453921|Placebo Comparator|1|Placebo Capsule and Placebo Memory and Attention Training (Placebo as both conditions)
11622802|NCT00453921|Active Comparator|2|Methylphenidate capsules and Memory and Attention Training (Active Med/Active therapy)
11622803|NCT00453921|Active Comparator|3|Methylphenidate capsules and Placebo Memory and Attention Training (Active Med/Placebo therapy)
11622804|NCT00453921|Active Comparator|4|Placebo capsules and Memory and Attention Training (Placebo Med/Active therapy)
11622805|NCT00453895|Experimental|Sunitinib|"Sunitinib will be administered 50 mg per day for 4 weeks followed by 2 weeks off.
~treatment will continue until progressive disease or unacceptable toxicity"
11622806|NCT00453843|Experimental|proximal to distal training|
11622807|NCT00453843|Experimental|distal to proximal|
11622808|NCT00453843|Experimental|proximal and distal on alternate days|
11622809|NCT00453843|Experimental|proximal and distal same day|
11622810|NCT00453817|Experimental|Study subjects|One-arm observational study
11622811|NCT00453791|Experimental|Subjects receiving treatment sequence 1: Part 1|Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using Metered Dose Inhaler (MDI).
11622812|NCT00453791|Experimental|Subjects receiving treatment sequence 2: Part 1|Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.
11622813|NCT00453791|Experimental|Subjects receiving treatment sequence 1: Part 2|Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using MDI.
11622814|NCT00453791|Experimental|Subjects receiving treatment sequence 2: Part 2|Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.
11622815|NCT00453791|Experimental|Subjects receiving GW805858: Part 3|Eligible subjects will receive GW805858 1200 micrograms twice daily administered using MDI.
11622816|NCT00453791|Experimental|Subjects receiving placebo: Part 3|Eligible subjects will receive placebo administered using MDI.
11622817|NCT00453765|Experimental|A|montelukast
11622818|NCT00453765|Placebo Comparator|B|placebo
11622819|NCT00453700||serological testing|In Latin American immigrants diagnosed with nonischemic cardiomyopathy in Los Angeles, serological testing for Trypanosoma cruzi was performed at enrollment.
11622820|NCT00453687|Experimental|Arm 1|Drug
11622821|NCT00453674||Adrenocortical carcinoma|Adrenocortical carcinoma
11622822|NCT00453661||Intervention Group|Patient Navigator (PN) + Educational Materials + Annual Questionnaires
11622823|NCT00453661||Comparison Group|Educational Materials + Exit Questionnaire
11622824|NCT00453648|Placebo Comparator|White-fleshed Sweet Potato|0 ug retinol activity equivalents (RAE)/d as boiled white-fleshed sweet potatoes (WFSP) and a corn oil capsule, 6d/wk for 10 wk
11622825|NCT00453648|Experimental|Orange-fleshed Sweet Potato (boiled)|600 ug RAE/d as boiled orange-fleshed sweet potato and a corn oil capsule, 6d/wk for 10 wk
11622826|NCT00453648|Experimental|Orange-fleshed Sweet Potato (fried)|600 ug RAE/d as fried orange-fleshed sweet potato and a corn oil capsule, 6d/wk for 10 wk
11622827|NCT00453648|Active Comparator|White-fleshed Sweet Potato and retinyl palmitate capsule|0 ug RAE/d as white-fleshed sweet potato and 600 ug retinol/d as retinyl palmitate, 6d/wk for 10 wk
11622828|NCT00453635|Experimental|1|Docetaxel + Carboplatin + Herceptin (D/Carbo/Her)
11622829|NCT00453635|Experimental|2|Vinorelbine + Herceptin (VHer)
11622830|NCT00453570|Experimental|1|DTacP IPV// PRP~T combined vaccine at 2, 3 and 4 months of age, and a booster dose at 18-20 months of age.
11622831|NCT00453570|Experimental|2|DTacP-IPV// PRP~T combined vaccine at 3, 4 and 5 months of age and a booster dose at 18-20 months of age.
11622832|NCT00453570|Active Comparator|3|Control vaccines at 3, 4 and 5 months of age and a booster dose at 18-20 months of age
11622833|NCT00453544|Experimental|Enhanced consent - A|The intervention was an enhanced consent process, including a multimedia aid for a moderate risk hypothetical protocol
11622834|NCT00453544|Experimental|Enhanced consent - B|The intervention was an enhanced consent process, including multimedia aide for a higher risk hypothetical protocol
11622835|NCT00453544|Active Comparator|Routine consent - A|This was a comparison condition - a routine consent process, including a printed consent document, for a moderate risk hypothetical protocol
11622836|NCT00453544|Active Comparator|Routine consent - B|This was a comparison condition - a routine consent process, including a printed consent document, for a higher risk hypothetical protocol
11622837|NCT00453531|Experimental|Healthy Volunteers|
11622838|NCT00453505|Active Comparator|1|Healthy adults
11622839|NCT00453453|Experimental|Nesiritide|Subjects who come into the ED with CHF will be treated with nesiritide
11622840|NCT00453453|No Intervention|Standard care|Subjects who come into the ED with CHF will receive standard care treatment
11622841|NCT00453388|Experimental|Arm I (2 vs 2.5 vs 3 Gy TBI dose-escalation)|Patients with a history of hematologic malignancy and HLA-haploidentical donor receive fludarabine phosphate (FLU) intravenously (IV) over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF orally (PO) thrice daily (TID) on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
11622842|NCT00453388|Experimental|Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)|Patients with no history of hematological malignancy and HLA-haploidentical donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
11622843|NCT00453388|Experimental|Arm III (2 vs 2.5 vs 3 Gy TBI dose-escalation)|Patients with history of hematologic malignancy and HLA-matched unrelated donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
11622844|NCT00453388|Experimental|Arm IV (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)|Patients with no history of hematological malignancy and HLA-matched unrelated donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
11622845|NCT00453375|Experimental|1|BHT-3021
11622846|NCT00453375|Placebo Comparator|2|BHT-Placebo
11622847|NCT00453362|Experimental|Erlotinib|"Erlotinib 150 mg/day taken orally at approximately the same time of day with 200 mL (6-8 Ounces) of water on an empty stomach. Participants received Erlotinib for 1 year or until they developed progressive disease or intolerable toxicity.
~After 14 days and after 56 days of treatment with Erlotinib participants underwent FDG-PET and FLT-PET scans."
11622848|NCT00453349|Experimental|Moxifloxacin|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
11622849|NCT00453349|Active Comparator|Levofloxacin plus Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
11622850|NCT00453336|Experimental|Single Arm|
11622851|NCT00453323|Experimental|study arm|
11622852|NCT00453310|Experimental|sunitinib malate|The dose of sunitinib malate will be a continuous daily dose of 37.5 mg administered orally for 6 weeks. The cycle of therapy is 42 days (or 6 weeks)
11622853|NCT00453271|Experimental|NB-002 0.25% BID|
11622854|NCT00453271|Experimental|NB-002 0.5% QD|
11622855|NCT00453271|Experimental|NB-002 0.5% BID|
11622856|NCT00453271|Sham Comparator|Vehicle control|
11622857|NCT00453258||Study Subject|Subjects receiving eye examination
11622858|NCT00453219||1|Women ages 18-35 years with regular ovulatory menstrual cycles
11622859|NCT00453219||2|Women ages 18-35 years with irregular or absent menstrual periods due to functional hypothalamic amenorrhea (FHA) also called stress-induced anovulation
11622860|NCT00453219||3|Women ages 18-35 years with irregular or absent menstrual periods due to polycystic ovary syndrome(PCOS).
11622861|NCT00453193|Experimental|Alemtuzumab + Pentostatin|Alemtuzumab 30 mg intravenous (IV) three times weekly; Pentostatin 4 mg/m^2 IV weekly for 4 weeks then every 2 weeks
11622862|NCT00453180|Experimental|1|Target dose for n-acetylcysteine is 60 mg/kg/day. Capsules available in 300 mg and 600 mg strengths.
11622863|NCT00453180|Placebo Comparator|2|Subjects randomized to placebo arm will receive capsules identical in size and appearance to those subjects receiving study drug. Placebo capsules contain inactive ingredients.
11622864|NCT00453167|Experimental|study arm|
11622865|NCT00453154|Experimental|Arm I (Combination Chemotherapy + Sunitinib Maintenance)|"Participants will receive the following combination chemotherapy for 4-6 cycles (21 days):
~Cisplatin 80 mg/m^2 by IV over 1 hour on day 1 every cycle OR Carboplatin AUC = 5* by IV Etoposide 100 mg/m^2 by IV over 1 hour on days 1, 2, and 3 every cycle
~Maintenance: Following 4-6 cycles of combination chemotherapy, start sunitinib at 150 mg on day 1, then 37.5 daily until disease progression."
11622866|NCT00453154|Active Comparator|Arm II (Combination Chemotherapy + Placebo Maintenance)|"Participants will receive the following combination chemotherapy for 4-6 cycles (21 days):
~Cisplatin 80 mg/m^2 by IV over 1 hour on day 1 every cycle OR Carboplatin AUC = 5* by IV Etoposide 100 mg/m2 by IV over 1 hour on days 1, 2, and 3 every cycle
~Maintenance: Following 4-6 cycles of combination chemotherapy, start placebo at 150 mg on day 1, then 37.5 daily until disease progression."
11622867|NCT00453115|Experimental|study arm|GemOx
11622868|NCT00453102|Experimental|Zevalin + Rituximab|Ibritumomab Tiuxetan (Zevalin) + Rituximab
11622869|NCT00453076|Experimental|Paclitaxel eluting covered metal stent|Paclitaxel eluting covered metal stent group
11622870|NCT00453076|Active Comparator|Control covered metal stent|Control covered metal stent group
11622871|NCT00453063|Experimental|MFNS 200 mcg QD|
11622872|NCT00453063|Placebo Comparator|Placebo|
11622922|NCT00452426|Experimental|Sedation System|Computer-Assisted Personalized Sedation (CAPS) device used for delivery of sedation
11622923|NCT00452426|Active Comparator|Current Standard of Care|Site's current standard used for delivery of sedation
11623053|NCT00450424|No Intervention|Counseling|Participants will be given one of two counseling interventions regarding MSI testing: standard counseling or a CD-ROM intervention.
11622873|NCT00453037|Active Comparator|group I (early intervention)|"We refer to the results of the DAFNE-study. This study showed the merits of an educational program in diabetics. In accordance to the protocol of DAFNE, we developed a design as follows: For each participating center patients are randomly assigned to two groups. Group I receives an early educational intervention at time of randomization, which should lead to better control of blood pressure after 6 months compared to the control group. The protocol design was chosen for proving an independent effect of the educational program despite optimal management by the GP. Group II is designated to receive the educational intervention 6 months after enrollment into the study.
~for further details please see brief description section"
11622874|NCT00453037|Other|delayed education|"delayed educational intervention
~for further details please see brief description section"
11622875|NCT00452985||1|"Injection of Docetaxel
~3-hour gap
~Injection of carboplatin"
11622876|NCT00452907|Experimental|1|Arsucam® (AS 50mg/Aq153mg),oad, per os, 3 days of treatment
11622877|NCT00452907|Active Comparator|2|Arsumax (AS 50mg) + Sulfadoxine-Pyrimethamine (SP=SDX 500mg/PYR 25mg), oad, per os
11622878|NCT00452907|Active Comparator|3|Coartem (arthemether 20mg+ lumefantrine 120 mg), bid, per os. Duration of treatment: 3 days
11622879|NCT00452881|Experimental|study arm|GemOx
11622880|NCT00452881|Active Comparator|control arm|GemCis
11622881|NCT00452868|Experimental|Donepozil|Donepezil 5 milligrams a day for 6 weeks
11622882|NCT00452829|Experimental|Study Group|5 mg folic acid (the standard UK supplement for pregnancies at high risk of NTD) and 1 g inositol,
11622883|NCT00452829|Placebo Comparator|Control Group|5 mg folic acid (the standard UK supplement for pregnancies at high risk of NTD)and 1 g placebo
11622884|NCT00452816|Experimental|Intervention|Intervention Group - Workplace Solutions Consulting
11622885|NCT00452816|Active Comparator|2|Delayed Intervention
11622886|NCT00452803|Active Comparator|study arm|pre-operative chemotherapy (Pac/Cis)
11622887|NCT00452803|Active Comparator|study arm 2|Pre-operative concurrent chemoradiation therapy
11622888|NCT00452790|Experimental|A|
11622889|NCT00452790|Active Comparator|B|
11622890|NCT00452777|Experimental|BVT.115959|Capsules containing 7 mg BVT.115959 administered orally three times daily
11622891|NCT00452777|Placebo Comparator|Placebo|Placebo capsules administered orally three times daily
11622892|NCT00452699|Active Comparator|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
11622893|NCT00452699|Active Comparator|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
11622894|NCT00452673|Experimental|50 mg BID dasatinib + 825 mg/m^2 BID capecitabine|Twice a day (BID) for 2 weeks of a 3-week cycle
11622895|NCT00452673|Experimental|70 mg BID dasatinib + 825 mg/m^2 BID capecitabine|BID for 2 weeks of a 3-week cycle
11622896|NCT00452673|Experimental|70 mg BID dasatinib + 1000 mg/m^2 BID capecitabine|BID for 2 weeks of a 3-week cycle
11622897|NCT00452673|Experimental|100 mg QD dasatinib + 1000 mg/m^2 BID capecitabine|2 weeks of a 3-week cycle
11622898|NCT00452660|Experimental|evaluating the effect of -Exjade|evaluating the effect of -Exjade (Deferasirox)_on oxidative stress parameters of blood cells in patients with Low risk Mylodysplastic syndrome ( MDS) with Iron over load
11622899|NCT00452634|Experimental|study arm|
11622900|NCT00452608|Placebo Comparator|amido pill|
11622901|NCT00452608|Experimental|atorvastatina|atrovastatina 80 mg/d by mouth for 10 days
11622902|NCT00452582|Experimental|Sildenafil|Orally administered sildenafil in addition to usual care.
11622903|NCT00452582|Active Comparator|Usual post-stroke care|Usual post-stroke treatment including physical, occupational, and speech therapy.
11622904|NCT00452569|Experimental|A|Oral thalidomide (100mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
11622905|NCT00452569|Experimental|B|Oral thalidomide (200mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
11622906|NCT00452569|Experimental|C|Oral thalidomide (400mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
11622907|NCT00452569|Active Comparator|D|High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
11622908|NCT00452556|Active Comparator|Standard Radiotherapy Sequence Arm|Standard sequence of radiotherapy = whole pelvic lymphatics, proximal seminal vesicles, prostate (or prostate bed) first, then prostate/prostate bed last
11622909|NCT00452556|Experimental|Experimental Radiotherapy Sequence Arm|Experimental sequence of radiotherapy = whole pelvic lymphatics, proximal seminal vesicles, prostate (or prostate bed) last, prostate/prostate bed first
11622910|NCT00452543|Experimental|Escitalopram plus acamprosate|
11622911|NCT00452543|Placebo Comparator|Escitalopram plus placebo|
11622912|NCT00452530|Experimental|Apixaban, 2.5 mg BID + Placebo|Participants received apixaban, 2.5-mg tablets twice daily (BID), plus a matching enoxaparin-placebo injection 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
11622913|NCT00452530|Active Comparator|Enoxaparin, 40 mg QD + Placebo|Participants received enoxaparin, 40-mg subcutaneous injection once daily (QD), plus a matching apixaban-placebo tablet 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
11622914|NCT00452491|Experimental|1|
11622915|NCT00452491|Active Comparator|2|
11622916|NCT00452478|Experimental|1|
11622917|NCT00452465|Experimental|Intervention|A research nurse will meet with participants, complete a detailed nursing assessment and develop of a care plan to help connect participants with resources to allow them to stay in their homes longer.
11622918|NCT00452465|No Intervention|Control|Usual Care
11622919|NCT00452452|Experimental|A|
11622920|NCT00452439|Active Comparator|Actonel|Actonel (Risedronate) + Vitamin D + Calcium
11622921|NCT00452439|Placebo Comparator|Placebo|Placebo + Vitamin D + Calcium
11623186|NCT00448851|Experimental|1|inhaled allergen challenge
11622924|NCT00452413|Experimental|Enzastaurin and erlotinib combination therapy|"Enzastaurin:
~Phase 1, Dose Level 1: 500 milligram (mg) oral loading dose Day 1, 250 mg oral, daily Day 2-28, 28-day cycle until disease progression
~Phase 1, Dose Level 2: 1125 mg oral loading dose Day 1, 500 mg oral, daily until disease progression
~Phase 2: Dose determined from Phase 1, oral, daily, 28-day cycles until disease progression
~Erlotinib:
~• 150 mg, oral, daily, 28-day cycles until disease progression"
11622925|NCT00452374|Experimental|Oxaliplatin, Fludarabine, Cytarabine + Rituximab|Starting dose oxaliplatin 17.5mg/m^2/day intravenous (IV) for 4 days; Fludarabine 30 mg/m^2 IV and Cytarabine 1 g/m^2 IV for two days, + Rituximab 375 mg/m^2 IV on Day 3, Cycle 1 then Day 1 following cycles.
11622926|NCT00452361|Experimental|1|Sirolimus therapy
11622927|NCT00452361|Active Comparator|2|Calcineurin Inhibitor therapy (either cyclosporine or tacrolimus)
11622928|NCT00452348|Active Comparator|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
11622929|NCT00452348|Active Comparator|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
11622930|NCT00452335|Experimental|Lubiprostone 12 mcg QD|Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (<6 years of age and able to swallow capsules) who are at least 12 kg body weight
11622931|NCT00452335|Experimental|Lubiprostone 12 mcg BID|Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight
11622932|NCT00452335|Experimental|Lubiprostone 24 mcg BID|Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight
11622933|NCT00452257|Experimental|A|
11622934|NCT00452244|Experimental|study arm|Iressa (gefitinib) + simvastatin
11622935|NCT00452244|Active Comparator|control arm|Iressa (gefitinib) only
11622936|NCT00452218|Experimental|Open|
11622937|NCT00452153|Experimental|Characterization Legionnella|Characterization Legionnella by polymerase chain reaction (PCR)
11622938|NCT00452127|Experimental|1|
11622939|NCT00452114|Active Comparator|Assignment to In-Exsufflator Cough Assist Device|In-Exsufflator Cough Assist Device augments the expiratory flow and force of the patient's cough with the addition of a cycle of positive and negative inspiratory pressure when used daily
11622940|NCT00452114|Active Comparator|Assignment to flutter valve device|flutter valve device delivers expiratory low-pressure vibratory pulse to the patient's airway when used daily
11622941|NCT00452088|Experimental|1|15 microgramme candidate vaccine group
11622942|NCT00452088|Active Comparator|2|Hepatitis B comprator group
11622943|NCT00452088|Experimental|3|30 microgrammes candidate vaccine group
11622944|NCT00452088|Active Comparator|4|Hepatitis B vaccine group
11622945|NCT00452075|Experimental|arm 1 medicine|erlotinib daily
11622946|NCT00452036||Minor head injury|patients with minor head injury
11622947|NCT00452036||minor head injury|patients with minor head injury
11622948|NCT00452023|Experimental|IFN-alpha2a|Starting dose 90 microgram (mcg) injection under the skin once a week.
11622949|NCT00452010|Experimental|1|transcutaneous electrical nerve stimulation
11622950|NCT00452010|Placebo Comparator|2|No transcutaneous electrical nerve stimulation
11622951|NCT00451997|Experimental|Gleevec + Low-Dose Ara-C|
11622952|NCT00451958|Experimental|Degarelix 80 mg / Degarelix 80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.
11622953|NCT00451958|Experimental|Degarelix 160 mg / Degarelix 160 mg|"The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days.
~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
11622954|NCT00451958|Experimental|Leuprolide 7.5 mg / Degarelix 80 mg|"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
~Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
11622955|NCT00451958|Experimental|Leuprolide 7.5 mg / Degarelix 160 mg|"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.
~Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.
~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
11622956|NCT00451906|Experimental|Bevacizumab + Chemotherapy|Participants with advanced or recurrent NSCLC will be administered bevacizumab infusions at a dose of 7.5 milligram per kilogram (mg/kg) or 15 mg/kg (investigator's choice) on Day 1 and then every 3 weeks, intravenously (IV) for a maximum of 6 cycles in combination with the standard of care NSCLC first-line chemotherapy in line with the licensed national prescribing information, during the treatment period. The initial dose of bevacizumab will be administered following chemotherapy; all subsequent doses could be given before or after chemotherapy.
11622957|NCT00451893|Active Comparator|Heavy-weight|Lichtenstein operation performed with a heavy-weight mesh.
11622958|NCT00451893|Active Comparator|Light-weight|Lichtenstein operation performed with a light-weight mesh.
11622959|NCT00451880|Experimental|Arm 1|XL281 administered once a day
11622960|NCT00451880|Experimental|Arm 2|XL281 administered twice a day
11623187|NCT00448825|Experimental|Topiramate|Topiramate + Cognitive Behavioral Therapy
11622961|NCT00451880|Experimental|Arm 3|XL281 administered once a day. Subjects in this arm will be dosed under fed conditions, fasted conditions, and with a concomitant single dose of 40 mg famotidine, during the second, third, and fourth week of the first cycle.
11622962|NCT00451867|Active Comparator|A|2000 mg per day of CellCept (MMF) divided into 2 equal doses.
11622963|NCT00451867|Placebo Comparator|B|Placebo
11622964|NCT00451841||1|Chronic cough caused by GERD
11622965|NCT00451841||2|Chronic cough without GERD
11622966|NCT00451776|Experimental|1|patients who received etomidate
11622967|NCT00451776|Active Comparator|2|patients who received propofol
11622968|NCT00451698|Placebo Comparator|3|acyanotic placebo
11622969|NCT00451698|Experimental|4|acyanotic erythropoietin
11622970|NCT00451646|Experimental|1|SMOFlipid
11622971|NCT00451646|Active Comparator|2|Intralipid
11622972|NCT00451620|Experimental|2.|GlucoNorm
11622973|NCT00451620|Experimental|1.|Glyburide
11622974|NCT00451568|Active Comparator|1|metformin
11622975|NCT00451568|Active Comparator|2|desorelle
11622976|NCT00451568|Active Comparator|3|desorelle + metformin
11622977|NCT00451555|Experimental|Enzastaurin + Fulvestrant|"Participants received Enzastaurin loading dose of 1125 mg, on Day 1 of Cycle 1 only then received Enzastaurin 500 mg orally (QD) once daily in a 28-day cycle.
~Participants received enzastaurin loading dose of 1125 mg, on Day 1 of Cycle 1 only then received Enzastaurin 250 mg orally (BID) twice daily in a 28-day cycle.
~Fulvestrant was given intramuscularly at a loading dose of 500 mg on Day 1 and 250 mg on Day 15 in Cycle 1. Subsequent doses of Fulvestrant 250 mg were given on Day 1 of Cycle 2 and every 28 days thereafter."
11622978|NCT00451555|Placebo Comparator|Fulvestrant + Placebo|Participants received fulvestrant: 500 mg, IM, day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression. Then, participants received placebo, oral, daily.
11622979|NCT00451503|Experimental|1|surgery
11622980|NCT00451451|Experimental|BG00012 240 mg Twice Daily (BID)|Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
11622981|NCT00451451|Experimental|BG00012 240 mg 3 Times Daily (TID)|Participants received two 120 mg BG00012 capsules orally three times daily (TID)
11622982|NCT00451451|Placebo Comparator|Placebo|Participants received two placebo capsules orally three times daily (TID)
11622983|NCT00451451|Active Comparator|Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)|Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)
11622984|NCT00451425|No Intervention|control|standard maternity care
11622985|NCT00451412|Experimental|Certoparin|
11622986|NCT00451412|Active Comparator|Unfractionated Heparin|
11622987|NCT00451321|Experimental|otelixizumab|
11622988|NCT00451308|Experimental|1|Foley balloon wih 60cc fluid
11622989|NCT00451308|Active Comparator|2|Foley balloon with 30cc
11622990|NCT00451295|Placebo Comparator|1|
11622991|NCT00451295|Experimental|2|
11622992|NCT00451282|Experimental|Stepped Preventive Care|Receiving Stepped Preventive Care intervention - at least 2 brief assessments with nurse and/or social worker (1) during hospital admission , and (2) approximately 2 weeks post-discharge. Additional interventions provided as needed, based on manual.
11622993|NCT00451282|No Intervention|Treatment as usual|Medical and psychosocial care per usual hospital protocols, which may include social work support.
11622994|NCT00451217|Experimental|Rocuronium + Sugammadex|After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered
11622995|NCT00451217|Active Comparator|Rocuronium + Neostigmine|After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered
11622996|NCT00451217|Experimental|Vecuronium + Sugammadex|After the last dose of vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered
11622997|NCT00451217|Active Comparator|Vecuronium + Neostigmine|After the last dose of vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered
11622998|NCT00451204|Active Comparator|Estriol plus Copaxone injections QD|Estriol Capsules (daily) plus Copaxone injections (daily). Progestin capsules given for 2 weeks every 3 months to avoid unopposed estrogens.
11622999|NCT00451204|Placebo Comparator|Placebo plus Copaxone injections QD|Placebo Capsules (daily) plus Copaxone injections (daily). A second placebo capsule given for 2 weeks every 3 months.
11623000|NCT00451191|Active Comparator|1|100 units botulinum toxin type A (BoNT/A)
11623001|NCT00451191|Active Comparator|2|300 units botulinum toxin type A (BoNT/A)
11623002|NCT00451178|Experimental|R-CHOP and Enzastaurin|R-CHOP includes rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment therapies.
11623003|NCT00451178|Active Comparator|R-CHOP|R-CHOP includes rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment therapies.
11623004|NCT00451165||colon|
11623005|NCT00451165||rectum|
11623006|NCT00451152|Experimental|Anecortave Acetate Depot|
11623007|NCT00451152|Placebo Comparator|Anecortave Acetate Vehicle|
11623008|NCT00451100|Experimental|Sugammadex|2.0 mg/kg Org 25969 (sugammadex)
11623009|NCT00451100|Active Comparator|Neostigmine|50 ug/kg neostigmine
11623010|NCT00451087|Experimental|1|
11623011|NCT00451087|Active Comparator|2|
11623012|NCT00451048|Experimental|Arm I|Patients will receive sunitinib malate (SU11248) by mouth once a day. Treatment may continue for as long as benefit is shown.
11623013|NCT00451035|Experimental|1|
11623014|NCT00451022||Cohort 1|Subjects previously participating in gene transfer or other immunotherapy studies at the NCI or extramural sites receiving therapeutic agents as part of a multi-site trial.
11623015|NCT00450970|Experimental|1|Prednisone and Satraplatin (INN / USAN), also known as JM-216, or OC-6-43-bis(acetato-O)ammine dichloro (cyclohexanamine)-platinum (IV), is a member of a novel class of platinum (IV) compounds that are absorbed by the oral route. The lipophilic properties of these compounds, and hence their absorption, are largely determined by the nature of the axial acetate ligands.
11623016|NCT00450970|Experimental|2|Prednisone (17 alpha, 21-dihydroxypregna-1, 4-diene-3, 11, 20-trione) is commercially formulated as the acetate salt (prednisone 21-acetate). It is a biologically inert glucocorticoid, which is converted to active prednisolone in the liver.
11623017|NCT00450957|Experimental|Arm I (high-dose lycopene)|Participants receive high-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive high-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days.
11623018|NCT00450957|Experimental|Arm II (low-dose lycopene)|Participants receive low-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive low-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days
11623019|NCT00450892|Other|arm 1|
11623020|NCT00450892|Other|arm 2|
11623021|NCT00450892|Experimental|arm 3|
11623022|NCT00450879|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD for 12-20 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgical resection of tumor between days 13 and 21 (24 hours after completion of pazopanib hydrochloride).
11623023|NCT00450866|Experimental|Epothilone B|
11623024|NCT00450853|Experimental|Granisetron SC-Granisetron IV|Granisetron SC followed by Granisetron IV
11623025|NCT00450827|Experimental|Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab|Patients will be administered a therapeutic doses of intravenous (IV) 131I-3F8 given in a single dose per the dose escalation regimen on day 0 of study. This will be followed by blood draws for pharmacokinetic and dosimetry studies and by gamma camera scan, where feasible. Bevacizumab will be administered at a fixed dose of 15mg/kg on days 1 and 15. Thyroid protection is commenced 10 days prior to administration of 131I-3F8 and continued for 28 days after the therapeutic dose of 131I-3F8. ASCR will be carried out if ANC < 500/ul on day 28 (blood radioactivity will be confirmed to be <1 uCi/ml prior to ASCR). ASCR will be carried out sooner in the case of life-threatening infection in the setting of neutropenia (ANC<500). G-CSF can be used to maintain ANC>500/ul but should not be used for 24 hours immediately before and after ASCR. Blood product support will be provided with platelet and red cell transfusions as required.
11623026|NCT00450814|Experimental|Stage 1 (MV-NIS alone)|Patients receive MV-NIS IV over 1 hour on day 1. (Closed to accrual on 12/17/2009 and reopened 10/13/2011)
11623027|NCT00450814|Experimental|Stage 2 (MV-NIS and cyclophosphamide)|Patients receive cyclophosphamide IV over 30 minutes and then MV-NIS IV over 1 hour 2 days later. (Temporarily closed to accrual on 10/13/11)
11623028|NCT00450801|Experimental|R-MACLO-IVAM-T|Rituximab, Methotrexate, Doxorubicin, Cyclophosphamide and Vincristine (cycle 1), followed by Rituximab, Ifosfamide (and Mesna), Etoposide and Cytarabine (cycle 2). These two cycles are repeated once, and patients achieving complete repose receive maintenance Thalidomide.
11623029|NCT00450788||Golestan Cohort|Cohort of adults from Golestan region in Iran
11623030|NCT00450775|Other|1|
11623031|NCT00450749|Placebo Comparator|Arm I (placebo)|Patients receive placebo PO QD for 4-7 weeks, and then undergo radical prostatectomy.
11623032|NCT00450749|Experimental|Arm II (low-dose lycopene)|Patients receive low-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy.
11623033|NCT00450749|Experimental|Arm III (high-dose lycopene)|Patients receive high-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy.
11623034|NCT00450736|Experimental|Single Arm|
11623035|NCT00450723|Experimental|Sentinel Lymph Node Biopsy|
11623036|NCT00450697||observation|
11623037|NCT00450684|Experimental|Group A|Implantation and testing of CRT
11623038|NCT00450684|Experimental|Group B|IImplantation and testing of CRT
11623039|NCT00450658|Experimental|1|HZT-501: Ibuprofen 800mg/Famotidine 26.6mg
11623040|NCT00450658|Active Comparator|2|Ibuprofen 800mg
11623041|NCT00450619|Experimental|Arm A -EDTMP Alone|Patients receive samarium Sm 153 lexidronam pentasodium 1 mCi/Kg intravenous (IV) over 1 minute on day 8. Treatment repeats every 12 weeks in the absence of disease progression or unacceptable toxicity.
11623042|NCT00450619|Experimental|Arm B - 153SmEDTMP with vaccine|Patients receive recombinant vaccinia-TRICOM vaccine 2 x 10^8 PFU subcutaneously (SC) on day 1. Patients also receive recombinant fowlpox-TRICOM vaccine 1 x 10^9 PFU SC on days 15 and 29 and sargramostim (GM-CSF)100 mcg/injection SC x 4 days. Treatment with recombinant fowlpox-TRICOM vaccine and GM-CSF* repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive samarium Sm 153 lexidronam pentasodium 1 mCi/Kg as in arm I.
11623043|NCT00450580|Experimental|Arm A|Fosamprenavir/ritonavir 1400mg/100mg QD + ABC/3TC FDC 600/300mg QD
11623044|NCT00450580|Active Comparator|Arm B|Fosamprenavir/ritonavir 700mg/100mg BID + ABC/3TC FDC 600/300mg QD
11623045|NCT00450541||Fatigue Questionnaire + Interview|
11623046|NCT00450515|Experimental|vinflunine + capecitabine|"Patients receive vinflunine IV over 20 minutes on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
~Quality of life is assessed at baseline, every other course, and at the completion of study treatment.
~After completion of study treatment, patients are followed periodically for up to 5 years."
11623047|NCT00450463|Active Comparator|Flutamide Alone|Patients receive flutamide orally 3 times a day on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After 3 months of treatment, patients who do not develop clinical progression, but develop biochemical recurrence (e.g., rising prostatic specific antigen (PSA) levels) without metastatic disease (as evidenced on scans), may receive vaccine treatment as defined in arm II beginning 4 weeks after flutamide therapy is discontinued.
11623048|NCT00450463|Experimental|Flutamide + Vaccine + Sargramostim|Patients receive flutamide orally 3 times a day on days 1-28. Patients also receive recombinant vaccinia PSA vaccine subcutaneously (SC) on day 1 of course 1 only and recombinant fowlpox PSA vaccine SC on day 1 of all subsequent courses. Patients receive sargramostim (GM-CSF) SC on days 1-4. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After 3 months of treatment, patients who do not develop clinical progression, but develop biochemical recurrence (e.g., rising PSA levels), discontinue flutamide but may continue to receive vaccine treatment.
11623049|NCT00450450|Experimental|Arm I|Patients undergo filgrastim (G-CSF)-stimulated allogeneic bone marrow transplantation on day 0.
11623050|NCT00450450|Active Comparator|Arm II|Patients undergo conventional allogeneic bone marrow transplantation on day 0.
11623051|NCT00450437|Active Comparator|Licensed Meningococcal Vaccine|Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
11623052|NCT00450437|Experimental|Novartis MenACWY Conjugate Vaccine|Novartis meningococcal ACWY conjugate Vaccine
11623054|NCT00450411|Experimental|Brachytherapy|Prostate brachytherapy delivered using either 125-iodine (I-125) or 103-palladium (Pd-103)
11623055|NCT00450398|Experimental|1|YSPSL (rPSGL-Ig)
11623056|NCT00450398|Placebo Comparator|2|
11623057|NCT00450385|Experimental|R-CHOP|"Patients will receive R-CHOP for 6 to 8 cycles:
~Rituximab 375 mg/m2 on day 1
~Cyclophosphamide 750 mg/m2 IV on day 1
~Doxorubicin 50 mg/m2 on day 1
~Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1
~Prednisone 100 mg orally days 1-5, repeated every 21 days."
11623058|NCT00450372|Experimental|ADI-PEG 20|
11623059|NCT00450333|Active Comparator|1|Erythropoietin(EPO)-naive BIW
11623060|NCT00450333|Active Comparator|2|EPO-naive QW
11623061|NCT00450333|Active Comparator|3|EPO QW
11623062|NCT00450333|Active Comparator|4|EPO Q2W
11623063|NCT00450320|Active Comparator|Rapamycin|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen.
11623064|NCT00450307|Experimental|3F8 and GM-CSF|One cycle has 5 days of 3F8 treatment. Each day, patients receive GM-CSF subcutaneously ~1.5 hr before the start 3F8 infusion. To limit side-effects, patients receive analgesics, antihistamines, and a small dose (IV, over ~5 minutes) of heat-modified 3F8. Cycles can be repeated after a 2-4 week interval, up to a total of two cycles.
11623065|NCT00450281||Male, Never-smokers|Male subjects who smoked less than 100 cigarettes during their lifetime.
11623066|NCT00450281||Male, Ever-smokers|Male subjects who have smoked at least 100 cigarettes during their lifetime.
11623067|NCT00450281||Female, Ever-smokers|Female subjects who have smoked less than 100 cigarettes during their lifetime.
11623068|NCT00450281||Female, Never-smokers|Female subjects who have smoked at least 100 cigarettes during their lifetime.
11623069|NCT00450255|Experimental|Arm I|Patients receive Aflibercept IV at 4 mg/kg over 1 hour on day 1. Treatment repeats every 14 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
11623070|NCT00450242|Experimental|5% Lidocaine cream|5% topical lidocaine cream.
11623071|NCT00450242|Placebo Comparator|Placebo cream|
11623072|NCT00450229|Experimental|Arm I|Patients receive low-dose, nutritional-grade oral diindolylmethane (DIM) twice daily for 21-28 days in the absence of disease progression or unacceptable toxicity. Treatment may continue for up to 60 days, if surgery is delayed.
11623073|NCT00450229|Experimental|Arm II|Patients receive high-dose, nutritional-grade oral DIM twice daily as in arm I.
11623074|NCT00450229|Placebo Comparator|Arm III|Patients receive oral placebo twice daily for 21-28 days in the absence of disease progression or unacceptable toxicity. Treatment may continue for up to 60 days, if surgery is delayed.
11623075|NCT00450216|Experimental|1|HZT-501: Ibuprofen 800mg/famotidine 26.6mg
11623076|NCT00450216|Active Comparator|2|Ibuprofen 800mg
11623077|NCT00450203|Experimental|ECX + Bevacizumab|ECX + Bevacizumab
11623078|NCT00450203|Active Comparator|Epirubicin, Cisplatin and Capecitabine|ECX chemotherapy
11623079|NCT00450203|Experimental|ECX + Lapatinib|ECX + Lapatinib
11623080|NCT00450190|Experimental|Saizen® E-Device|
11623081|NCT00450177|Experimental|Iron Group|Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
11623082|NCT00450177|Placebo Comparator|Placebo Group|Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
11623083|NCT00450138|Experimental|1|Radiation + vandetanib
11623084|NCT00450138|Experimental|2|Radiation + cisplatin + vandetanib
11623085|NCT00450125||Six-Minute Walk Test|Two Six-minute walk tests where total distance walked measured. Tests performed within 15 days of an exercise stress test.
11623086|NCT00450099|Experimental|1|Epidural, bupivacaine
11623087|NCT00450086|Experimental|A|
11623088|NCT00450086|Experimental|B|
11623089|NCT00450086|Placebo Comparator|C|
11623090|NCT00450073|Active Comparator|Vitamin D3|Vitamin D3=cholecalciferol 50,000 IU weekly
11623091|NCT00450073|Active Comparator|vitamin D2|The intervention is an oral tablet of vitamin D2 (ergocaliferol 50,000 IU weekly) for 12 weeks.
11623092|NCT00450073|Active Comparator|Sunlamp|The intervention is the use of a Sunlamp (Sperti) to the skin 5 times a week for 12 weeks
11623093|NCT00450034|Experimental|1|
11623094|NCT00450008|Other|A|Combination therapy of GM-CSF, Thalidomide plus Docetaxel in patients with prostate cancer with a rising PSA
11623095|NCT00449969|Experimental|1. Extended feedback|
11623096|NCT00449969|Active Comparator|2. Limited feedback|
11623097|NCT00449956|Experimental|1|combination of dorzolamide hydrochloride and timolol maleate
11623098|NCT00449956|Active Comparator|2|Concomitant use of dorzolamide hydrochloride and timolol maleate
11623099|NCT00449956|Active Comparator|3|timolol maleate
11623100|NCT00449930|Experimental|1|Drug
11623101|NCT00449930|Active Comparator|2|Active comparator
11623102|NCT00449904|Experimental|Liprotamase|Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units) administered orally with each of three meals and two snacks daily for 12 months.
11623103|NCT00449878|Experimental|Liprotamase|"Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units).
~Open Label Period: Liprotamase administered orally with each of three meals and two snacks daily for 21 days.
~Double Blind Treatment Period: Administered orally with each of three meals and two snacks daily for 6 days.
~Second Open Label Period: Administered orally with each of three meals and two snacks daily for 7 days."
11623104|NCT00449878|Placebo Comparator|Placebo|Double Blind Treatment Period: Placebo (microcrystalline cellulose) administered orally with each of three meals and two snacks daily for 6 days.
11623105|NCT00449865|Placebo Comparator|Placebo|
11623106|NCT00449865|Active Comparator|creatine|
11623107|NCT00449852|Experimental|Interactive Voice Response Group|
11623108|NCT00449852|No Intervention|Usual Care Group|
11623109|NCT00449839|Other|A, CSII without bolus|Period A: A constant subcutaneous infusion rate of insulin aspart (0.5 U/hr) is given for 8 hours. Following 3 hours of blood sampling.
11623188|NCT00448825|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy
11623963|NCT00440869|Experimental|N-acetylcysteine|Active
11623110|NCT00449839|Other|B; CSII with bolus|Period B: A constant subcutaneous infusion of insulin aspart (0.5 U/hr) is given for 8 hours and upon start a s.c.bolus (1.4 U)of insulin aspart is given. Hereafter follows 3 hours of blood sampling.
11623111|NCT00449839|Other|C; CSII with bolus, optional|A constant subcutaneous insulin aspart infusion is given for 8 hours and upon start a bolus of insulin aspart is given. The bolus in arm C is of a different size then arm B. After the 8 hours of constant infusion follows 3 hours of blood sampling. Period C are optional and it is evaluated if it will be conducted after period A and B has been performed.
11623112|NCT00449813|Active Comparator|1.|40 mg Pantoprazole
11623113|NCT00449787|Active Comparator|Sumatriptan|Sumatriptan 100 mg tablet
11623114|NCT00449787|Active Comparator|Naproxen|Naproxen 500 mg tablet
11623115|NCT00449774|Experimental|Subjects in Treatment regimen C|Subjects in treatment regimen C will receive 200 milligram (mg) orally disintegrating tablets (ODT) of lamotrigine disintegrate in mouth without water in fasting condition.
11623116|NCT00449774|Experimental|Subjects in Treatment regimen D|Subjects in treatment regimen D will receive 200 mg Immediate Release (IR) tablets of lamotrigine with water in fasting condition.
11623117|NCT00449774|Experimental|Subjects in Treatment regimen E|Subjects in treatment regimen E will receive 200 mg ODT disintegrate of lamotrigine in mouth without water in fed state.
11623118|NCT00449774|Experimental|Subjects in Treatment regimen F|Subjects in treatment regimen F will receive 200 mg ODT of lamotrigine, that subjects will swallow with water in fasting condition.
11623119|NCT00449761|Experimental|Panobinostat|
11623120|NCT00449748|Experimental|RAD001|Oral 10 mg daily for 30 days
11623121|NCT00449696|Experimental|Gel-200|
11623122|NCT00449696|Placebo Comparator|PBS|
11623123|NCT00449683|Experimental|terazosin|open-label treatment group
11623124|NCT00449670|Experimental|H5N1 Adjuvanted Group|Subjects received 2 doses of H5N1 adjuvanted split virus vaccine (lot 1, 2, 3 or 4) containing A/Vietnam/1194/2004 strain at Day 0 and Day 21 during Primary Phase. A subset of these subjects (Boosted sub-cohort) received a single dose of heterologous H5N1 adjuvanted vaccine containing A/Indonesia/05/2005 strain at Month 6 during Booster Phase. The remaining subjects (Non-Boosted sub-cohort) received a single booster dose at Month 12 or 36 after initial priming in study 111443 (NCT00652743).
11623125|NCT00449670|Active Comparator|H5N1 Un-adjuvanted Group|Subjects received 2 doses of a H5N1 non-adjuvanted split virus vaccine containing A/Vietnam/1194/2004 strain at Day 0 and Day 21 and two booster doses of heterologous H5N1 adjuvanted vaccine containing A/Indonesia/05/2005 strain at Month 6 and Month 6 + 21 days.
11623126|NCT00449644|Experimental|TMC207 Stage 1|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 weeks in addition to Background Regimen (BR) for multi-drug resistant tuberculosis (MDR-TB).
11623127|NCT00449644|Placebo Comparator|Placebo Stage 1|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 weeks in addition to BR for MDR-TB.
11623128|NCT00449644|Experimental|TMC207 Stage 2|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 22 weeks in addition to BR for MDR-TB.
11623129|NCT00449644|Placebo Comparator|Placebo Stage 2|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 22 weeks in addition to BR for MDR-TB.
11623130|NCT00449618|Active Comparator|1|Aspirin 100 mg on awakening
11623131|NCT00449618|Active Comparator|2|Aspirin 100 mg at bedtime
11623132|NCT00449618|Placebo Comparator|3|Placebo on awakening
11623133|NCT00449618|Placebo Comparator|4|Placebo at bedtime
11623134|NCT00449605|Experimental|Rimonabant|Rimonabant 20 mg once daily on top of metformin
11623135|NCT00449605|Active Comparator|Glimepiride|Glimepiride from 1 mg up to 6 mg once daily on top of metformin
11623136|NCT00449592|Experimental|1|Oral zinc therapy, intervention
11623137|NCT00449592|Placebo Comparator|2|oral placebo
11623138|NCT00449553||Pioglitazone 15 mg QD + Sulphonylurea|
11623139|NCT00449553||Pioglitazone 30 mg QD + Sulphonylurea|
11623140|NCT00449553||Pioglitazone 15 mg QD + Metformin|
11623141|NCT00449553||Pioglitazone 30 mg QD + Metformin|
11623142|NCT00449540|Active Comparator|Active Transcranial Magnetic Stimulation (TMS) Device|Both arms of participants receive identical looking devices and were instructed use the same treatment protocol. Participants in each group were instructed to treat with the device within one hour of onset of migraine aura.
11623143|NCT00449540|Sham Comparator|Sham TMS Device|Both arms of participants receive identical looking devices and were instructed use the same treatment protocol. Participants in each group were instructed to treat with the device within one hour of onset of migraine aura.
11623144|NCT00449488|No Intervention|Control|
11623145|NCT00449488|Active Comparator|Epoetin alfa|i.v bolus 60.000 IU epoetin alfa
11623146|NCT00449293|Active Comparator|1|
11623147|NCT00449293|Active Comparator|2|
11623148|NCT00449280|Experimental|A|Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken once a week until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.
11623149|NCT00449280|Experimental|B|Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.
11623150|NCT00449280|Experimental|C|Rapamycin once a week starting on Day 1. Beginning on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.
11623151|NCT00449280|Experimental|D|Rapamycin every day beginning on Day 1. Starting on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.
11623152|NCT00449267|Experimental|1|
11623153|NCT00449176|Experimental|001|tapentadol (CG5503) ER 50 100 150 200 250 mg twice daily for 15 weeks
11623154|NCT00449176|Active Comparator|002|oxycodone CR 10 20 30 40 50 mg twice daily for 15 weeks
11623155|NCT00449176|Placebo Comparator|003|placebo matching placebo twice daily for 15 weeks
11623156|NCT00449163|Experimental|Combination Chemotherapy and Bevacizumab|"Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:
~Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;
~Irinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;
~Leucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;
~Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29."
11623157|NCT00449150|Experimental|Treatment Group A: CET 78 mg + 78 mg|"Treatment course 1: Cetrorelix 78 mg + 78 mg
~Week 0: 52 mg CET (2 injections)
~Week 2: 26 mg CET (1 injection)
~Treatment course 2:
~Week 26: 52 mg CET (2 injections)
~Week 28: 26 mg CET(1 injection)
~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
11623158|NCT00449150|Experimental|Treatment Group B: CET 78 mg + 52 mg|"Treatment course 1: Cetrorelix 78 mg + 52 mg
~Week 0: 52 mg CET (2 injections)
~Week 2: 26 mg CET (1 injection)
~Treatment course 2:
~Week 26: 52 mg CET (2 injections)
~Week 28: Placebo (1 injection)
~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
11623159|NCT00449150|Placebo Comparator|Treatment Group C: Placebo|"Treatment course 1:
~Week 0: placebo (2 injections)
~Week 2: placebo (1 injection)
~Treatment course 2:
~Week 26: placebo (2 injections)
~Week 28: placebo (1 injection)
~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
11623160|NCT00449137|Experimental|Single Arm|
11623161|NCT00449124|Experimental|Part I-group 1|Part I/Group 1: Cycle 1-TG4040 10^6 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14; Cycle 3-Placebo days 0, 7 and 14.
11623162|NCT00449124|Experimental|Part IIa-group 1|Part IIa/Group 1: Cycle 1-TG4040 10^8 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14.
11623163|NCT00449124|Experimental|Part IIa-group 2|Part IIa/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^8 PFU days 0, 7 and 14.
11623164|NCT00449124|Experimental|Part I-group 3|Part I/Group 3: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14; Cycle 3-TG4040 10^8 PFU days 0, 7 and 14.
11623165|NCT00449124|Experimental|Part I-group 2|Part I/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^7 PFU days 0, 7 and 14; Cycle 3-Placebo days 0, 7 and 14.
11623166|NCT00449124|Experimental|Part IIb-group 1|Part IIb/Group 1: Cycle 1-TG4040 10^8 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14.
11623167|NCT00449124|Experimental|Part IIb-group 2|Part IIa/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^8 PFU days 0, 7 and 14.
11623168|NCT00449098|Experimental|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
11623169|NCT00449098|Active Comparator|MMC|Trabeculectomy with MMC
11623170|NCT00449072|Placebo Comparator|Placebo|"3 to 9 year old participants with Perennial Allergic Rhinitis (PAR) administered
~Placebo in the baseline/screening period to demonstrate administration of investigational product (IP) with the nasal spray bottle
~Placebo in the double-blind treatment period
~All participants were provided Children's Claritin® Syrup as a rescue medication."
11623171|NCT00449072|Active Comparator|TAA-AQ|"3 to 9 year old participants with Perennial Allergic Rhinitis (PAR) administered
~Placebo in the baseline/screening period to demonstrate administration of IP with the nasal spray bottle
~Triamcinolone acetonide (TAA-AQ) in the double-blind treatment period
~All participants were provided Children's Claritin® Syrup as a rescue medication."
11623172|NCT00449033|Experimental|Sorafenib (Nexavar, BAY43-9006) + GC|Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with sorafenib. Day 1: gemcitabine 1250 mg/ m^2 infusion (IV), followed by cisplatin 75 mg/ m^2 IV; Day 8: gemcitabine 1250 mg/ m^2 IV; Days 1-21: sorafenib 2 tablets (200 mg) taken orally (po) twice daily (bid). If the patient had radiological evidence of stable disease (SD) or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which sorafenib was administered 400 mg bid until criteria for withdrawal were met.
11623173|NCT00449033|Placebo Comparator|Placebo + GC|Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with placebo. Day 1: gemcitabine 1250 mg/ m^2 infusion (IV), followed by cisplatin 75 mg/ m^2 IV; Day 8: gemcitabine 1250 mg/ m^2 IV; Days 1-21: placebo 2 tablets po bid. If the patient had radiological evidence of SD or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which 2 placebo tablets were administered bid until criteria for withdrawal were met.
11623174|NCT00449007|Active Comparator|1|fluoxetine -- 6 months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention; patients will also be encouraged to attend daily Alcoholics Anonymous meetings
11623175|NCT00449007|Active Comparator|2|bupropion -- 6 months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention; patients will also be encouraged to attend daily Alcoholics Anonymous meetings
11623176|NCT00448929|Experimental|Trabeculectomy with Oculusgen|
11623177|NCT00448929|No Intervention|Trabeculectomy without Oculusgen or antifibrotic agents|
11623178|NCT00448916|Experimental|Pregabalin|Orally-administered pregabalin
11623179|NCT00448903|Experimental|A|Bemiparin
11623180|NCT00448903|Placebo Comparator|2|Placebo
11623181|NCT00448890|Experimental|GSK729327|Dose escalation from 1.0mg to 6 mg.
11623182|NCT00448890|Placebo Comparator|Placebo|
11623183|NCT00448864|Experimental|Ecallantide - Low Dose Regimen|Participants received a maximum of 15 milligrams (mg) ecallantide in stages. Intravenous (IV) infusion of 0.6 milligrams per milliliter (mg/mL) ecallantide was administered at 2.92 milliliters per minute (mL/min) for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of cardiopulmonary bypass (CPB), whichever came first. At the termination of the initial infusion, a second infusion of 0.4 mg/mL ecallantide was started at 38 milliliters per hour (mL/hr) for 4 hours.
11623184|NCT00448864|Experimental|Ecallantide - High Dose Regimen|Participants received a maximum of 91 mg ecallantide in stages. IV infusion of 0.6 mg/mL ecallantide was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, an infusion of normal saline was started at 38 milliliters per hour (mL/hr) for 4 hours.
11623185|NCT00448864|Placebo Comparator|Placebo|Participants received placebo in stages. IV infusion placebo was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, a second infusion of placebo was started at 38 mL/hr for 4 hours.
11623189|NCT00448786|Other|Arm C|Arm C - AMG 706 75 mg BID 5-days on and 2-days off
11623190|NCT00448786|Other|Arm B|Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
11623191|NCT00448786|Other|Arm A|Arm A = AMG 706 125 mg PO daily continuously
11623192|NCT00448760|Experimental|Neoadjuvant + Adjuvant Chemotherapy|
11623193|NCT00448747|Experimental|AEZS-130 ( formerly ARD-07)|A single oral administration of AEZS-130 (0.5 mg/kg po) as Growth Hormone Stimulation Test
11623194|NCT00448747|Active Comparator|L-ARG+GHRH|This trial was set up as a multi-center, randomized, cross-over study investigating AEZS-130 as a Growth Hormone Stimulation Tests in terms of safety and efficacy compared to L-ARG+GHRH. When GHRH became unavailable on the US market, this comparator arm was no longer available, which was addressed by Amendment No. 3 (version 27-March-2010). Control subject enrolled under Amendment No. 3 were not randomized as there was no cross-over due to unavailability of L-ARG+GHRH. These control subjects received only AEZS-130
11623195|NCT00448734|Experimental|1|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.
~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
11623196|NCT00448734|Active Comparator|2|Docetaxel
11623197|NCT00448721|Experimental|Perifosine|Perifosine will be administered orally at 100mg PO daily with food. One treatment cycle will consist of 42 days (6 weeks).
11623198|NCT00448708|Experimental|Vascular Wrap and Graft|Lifespan® ePTFE Vascular Graft and Vascular WrapTM Paclitaxel-Eluting Mesh: The Lifespan® ePTFE Vascular Graft is implanted as an arteriovenous graft in an upper extremity to provide a hemodialysis access. The Vascular WrapTM Paclitaxel-Eluting Mesh is positioned on the vein and placed around the venous anastomosis to include both the toe and the heel of the anastomosis, and is sutured in place.
11623199|NCT00448708|No Intervention|Lifespan® ePTFE Vascular Graft|Lifespan® ePTFE Vascular Graft Only: The Lifespan® ePTFE Vascular Graft is implanted as an arteriovenous graft in an upper extremity to provide a hemodialysis access.
11623200|NCT00448682|Experimental|FUdR + Leucovorin + Oxaliplatin + Docetaxel (Taxotere)|"Treatment will be administered on an outpatient basis. Chemotherapy will be administered weekly, 3 out of 4 weeks, on days 1, 8 and 15:
~Day 1 and Day 15 Chemotherapy Administration: Patients will be administered oxaliplatin (85 mg/m2) and docetaxel (25 mg/m2) followed by FUdR/Leucovorin (110 mg/kg//500 mg/m2) on Day 1 and Day 15 of each cycle.
~Day 8 Chemotherapy Administration On Day 8, treatment will consist of docetaxel (25 mg/m2) followed by FUdR/Leucovorin (110mg/kg//500mg/m2).
~There will be no treatment delivered week 4 (Day 22). For the purpose of this study, one cycle equals four weeks. There will be a maximum of 6 cycles."
11623201|NCT00448669|Active Comparator|TDF-FTC,condoms,adh/risk counseling|Eligible participants were randomized to oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet. The ratio of randomization was 1:1. Participants randomized to the active arm received male and female condoms, risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
11623202|NCT00448669|Placebo Comparator|Placebo,condoms,adh/risk counseling|Eligible participants were randomized to the placebo arm and received placebo oral tablets that were visually identical to the TDF-FTC tablet and taken once daily. The placebo tablets contained no active ingredients. The ratio of randomization was 1:1. Participants randomized to the placebo arm received male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
11623203|NCT00448643|Experimental|Whole-Abdominal Radiation Therapy and Chemotherapy|
11623204|NCT00448630||Atypical Antispychotics (or second generation antipsychotics)|Patients with schizophrenia who are currently receiving or are going to start a new treatment with atypical antipsychotics, ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, amisulpride.
11623205|NCT00448591|Experimental|1|
11623206|NCT00448539|Experimental|Rufinamide (Rufinamide During Core Study)|
11623207|NCT00448539|Experimental|Rufinamide (Placebo During Core Study)|
11623208|NCT00448513|Experimental|catechin|catechin capsule group
11623209|NCT00448461|Active Comparator|1|heparin
11623210|NCT00448461|Active Comparator|2|bivalirudin
11623211|NCT00448448|Active Comparator|Brace|This study involves full-time, rigid TLSO's only. Braced subjects are followed every six months with radiography, clinical exam and self-reported evaluations of health and functioning. Orthotic evaluations are conducted every 6 months as as necessary to maintain brace fit and function.
11623212|NCT00448448|Active Comparator|Observation|Observation. Observed subjects are followed every six months with radiography, clinical exam and self-reported evaluations of health and functioning.
11623213|NCT00448435|Active Comparator|SLM+FP First|SLM(salmeterol) 25mcg + FP(fluticasone propionate) 50mcg twice daily in first intervention period and SFC(salmeterol/fluticasone propionate) 25/50mcg twice daily in second intervention period and (after washout period).
11623214|NCT00448435|Active Comparator|SFC First|SFC (Salmeterol/Fluticasone propionate combination) 25/50mcg twice daily in first intervention period and SLM (Salmeterol) 25mcg + FP (Fluticasone Propionate) 50mcg twice daily in second intervention period (after washout period).
11623215|NCT00448435|Experimental|SFC|SFC (salmeterol/fluticasone propionate combination) 25/50mcg twice daily in Extension period (after cross-over period).
11623216|NCT00448422|Experimental|1|Tablet
11623217|NCT00448422|Placebo Comparator|2|Tablet
11623218|NCT00448409|Experimental|1|TroVax alone
11623219|NCT00448409|Experimental|2|TroVax plus GM-CSF
11623220|NCT00448396|Experimental|Patupilone|
11623221|NCT00448383|Experimental|1|Open-label adalimumab
11623222|NCT00448357|Experimental|GVHD prophylaxis|"Subjects with matched-related donors (MRDs) were treated with tacrolimus and methotrexate with or without alemtuzumab for graft vs host disease prophylaxis Subjects also receive busulfan and fludarabine .
~Matched unrelated donor (MUD) or mismatched related donor (MMRD) subjects receive GVHD prophylaxis with rabbit anti-thymocyte globulin (ATG) + Methotrexate Subjects also receive busulfan, fludarabine, and tacrolimus."
11623223|NCT00448344|Experimental|Arm 1|Family-supported smoking cessation
11623224|NCT00448344|Other|Arm 2|Standard smoking cessation
11623964|NCT00440869|Placebo Comparator|placebo|placebo
11623225|NCT00448331||positive screen, negative screen|Positive screens are those who received positive feedback regarding their answers to a mental illness screening assessment. Negative screens received feedback stating that they did not screen positive for any mental illness.
11623226|NCT00448305|Experimental|1|EndoTAG-1 + Paclitaxel
11623227|NCT00448305|Experimental|2|EndoTAG-1
11623228|NCT00448305|Active Comparator|3|Paclitaxel
11623229|NCT00448292|Experimental|1|PRX-00023 taken twice daily, escalating from 40 mg to 80 mg to 120 mg
11623230|NCT00448292|Placebo Comparator|2|Placebo taken twice daily, escalating from 40 mg to 80 mg to 120 mg
11623231|NCT00448279|Active Comparator|Chemotherapy Alone|Chemotherapy, schedule and dose at the investigator's discretion.
11623232|NCT00448279|Experimental|Chemotherapy, Trastuzumab|Trastuzumab, at the investigator's discretion, either 2 milligrams per kilogram (mg/kg) intravenous (i.v.) every 7 days or 6 mg/kg i.v. every 3 weeks. Chemotherapy, schedule and dose at the investigator's discretion.
11623233|NCT00448266|Experimental|2|1 course ddAc, 2 courses IAA with PBPC support
11623234|NCT00448266|Active Comparator|1|3 courses ddAC
11623235|NCT00448253|Experimental|1|Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA. And a Fourth Cohort at 840 units TNA with 2 additional product lots.
11623236|NCT00448253|Placebo Comparator|2|Saline (equal volume to 210 U, 420 U, or 840 U TNA dose)
11623237|NCT00448227|Experimental|Famciclovir|Famciclovir was administered orally as a suspension in OraSweet® on Day 1. Patients received a single, individualized dose between 25-200 mg based on body weight.
11623238|NCT00448214|Experimental|1|Low dose
11623239|NCT00448214|Experimental|2|Middle dose
11623240|NCT00448214|Experimental|3|High dose
11623241|NCT00448214|Active Comparator|4|
11623242|NCT00448201|Active Comparator|Methotrexate Only Arm|GVHD Prophylaxis with Methotrexate
11623243|NCT00448201|Active Comparator|2 Doses ATG + Methotrexate|GVHD prophylaxis with antithymocyte globulin (ATG) + Methotrexate
11623244|NCT00448201|Active Comparator|2 Doses ATG|GVHD prophylaxis with 2 doses ATG
11623245|NCT00448201|Active Comparator|3 Doses ATG|GVHD prophylaxis with 3 doses ATG
11623246|NCT00448175|Experimental|Urgent PC treatment arm|
11623247|NCT00448149|Experimental|1|To establish the maximally tolerated dose (MTD) of RAD001 in combination with Nexavar®
11623248|NCT00448136|Experimental|1|
11623249|NCT00448136|Experimental|2|
11623250|NCT00448123|Placebo Comparator|Placebo|Placebo
11623251|NCT00448123|Active Comparator|Tamsulosin|Intervention - Tamsulosin
11623252|NCT00448110|Experimental|A|intravenous diclofenac dosage level 1
11623253|NCT00448110|Experimental|B|intravenous diclofenac dosage level 2
11623254|NCT00448110|Active Comparator|C|intravenous ketorolac
11623255|NCT00448110|Placebo Comparator|D|placebo
11623256|NCT00448097|Other|Data not available PI relocated|No verifiable data available, PI relocated
11623257|NCT00448058|Experimental|GSK372475|flexible-dose design from GSK372475 1.0 mg/day to GSK372475 2.0 mg/day
11623258|NCT00448058|Active Comparator|Venlafaxine|Flexible- dose design from Venlafaxine XR 75 mg/day to Venlafaxine XR 225 mg/day
11623259|NCT00448058|Placebo Comparator|placebo|
11623260|NCT00448045|Experimental|Manual and mechanical assisted cough|Individuals will be given a pulse oximeter and taught both manually assisted and mechanically assisted coughing techniques to maximize their cough peak flow. Manually assisted coughing consists of air stacking to deep insufflations. An abdominal thrust is then applied upon glottic opening to augment the cough peak flow. Subjects will also have rapid access to a mechanical in-exsufflator (CoughAssistTM) and will be trained on how to access and use this device. Mechanically assisted coughing (MAC) involves the use of the CoughAssistTM to expand the lungs and then quickly reverse the pressure to rapidly empty the lungs with expiratory (cough) flows of 600 L/m. An abdominal (manual) thrust is applied in conjunction with the negative pressure (exsufflation) to further increase cough.
11623261|NCT00448045|Active Comparator|Incentive spirometry|The active control group will consist of individuals assigned to the oximetry with incentive spirometry group. These individuals will be given a pulse oximeter and an incentive spirometer (AirLife Company) and taught how to use them.
11623262|NCT00448019|Experimental|FCR + Bevacizumab|FCR = Fludarabine 25 mg/m^2 intravenous (IV) , Cyclophosphamide 250 mg/m^2 IV daily for 3 days, Rituximab 375 mg/m^2 IV Day 1, followed by 500 mg/m^2 IV. FCR daily for 3 days. Bevacizumab 10 mg/Kg IV on Day 3, course 1.
11623263|NCT00447993|Experimental|1 NT-501|High Dose Implant
11623264|NCT00447993|Experimental|2 NT-501|Low Dose Implant
11623265|NCT00447980|Experimental|1 NT-501 implant|High Dose
11623266|NCT00447980|Experimental|2 NT-501 implant|Low Dose
11623267|NCT00447967|Experimental|1|IOX
11623268|NCT00447967|Experimental|2|FLOX
11623269|NCT00447954|Experimental|1 high dose NT-501 implant|
11623270|NCT00447954|Experimental|2 low dose NT-501 implant|
11623271|NCT00447954|Sham Comparator|3 sham procedure|No implant
11623272|NCT00447915|Experimental|1|
11623273|NCT00447915|Experimental|2|
11623274|NCT00447915|Active Comparator|3|
11623275|NCT00447876|Experimental|Botulinum type A toxin (Dysport®)|
11623276|NCT00447876|Placebo Comparator|Placebo|
11623277|NCT00447837|Experimental|1|
11623278|NCT00447837|Experimental|2|
11623279|NCT00447837|Placebo Comparator|3|
11623280|NCT00447798|Experimental|Prevention Care Advocate|Prevention Care Advocate (PCA) intervention contains elements based on cognitive-behavioral theories and strengths-based case management. Intervention arm participants will undergo an 8 session intervention comprised of three components: 1) An individual strengths-based case management approach aimed at motivating participants to seek or maintain their engagement with HIV primary care and drug treatment; 2) A cognitive-behavioral, skills-building approach to increase participants' risk reduction knowledge, skills, and perceived self-efficacy as well as intention to change high risk transmission behaviors; and 3) A community placement in which study participants will have the opportunity to practice their advocacy skills in prevention and care setting.
11623384|NCT00446654|Experimental|CGC-11047 once every 2 weeks|16.5 mg CGC-11047 as a subconjunctival injection once every two weeks.
11623965|NCT00440856|No Intervention|Control|
11623281|NCT00447798|No Intervention|Standard of Care|"Standard of Care (SOC) condition involves standard practice, consisting of usual inpatient/hospital services provided within normal clinical practice, plus a brief educational session consisting of the review of the topics in the Living with HIV brochure published by the Centers for Disease Control and Prevention (CDC)."
11623282|NCT00447772|Experimental|1|
11623283|NCT00447759|Experimental|Celecoxib|Celecoxib. Celebrex 200-400mg daily in divided doses
11623284|NCT00447759|Active Comparator|Diclofenac|continue usual nsNSAID
11623285|NCT00447733|Experimental|Integrated treatment|Evidence-based psychosocial and pharmacological treatment of both the substance use disorder and the mental health disorder is provided at the same time and by the same therapists in a comprehensive way.
11623286|NCT00447733|Active Comparator|Treatment as usual|Non-manualized clinic-based treatment provided by therapists without formal training in integrated treatment of co-occurring disorders.
11623287|NCT00447720|Experimental|PATH counseling|These participants received the PATH intervention
11623288|NCT00447720|Active Comparator|Treatment as Usual|These individuals receive treatment as they normally would receive in the community
11623289|NCT00447694|Experimental|deferasirox every day for 77 weeks|participants will be given oral deferasirox 30mg/kg/day for 77 weeks.
11623290|NCT00447668|Experimental|1|
11623291|NCT00447668|Active Comparator|2|Exercise
11623292|NCT00447668|Active Comparator|3|Self-care book recommendations
11623293|NCT00447642|Experimental|LX201 0.50 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.50 inch in length
11623294|NCT00447642|Experimental|LX201 0.75 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.75 inch by length
11623295|NCT00447642|Placebo Comparator|Placebo 0.75 inch implant|Silicone implant not containing cyclosporine A, 0.75 inch in length
11623296|NCT00447603|Active Comparator|Losartan 50 mg|Losartan 50 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg once daily for 4 weeks
11623297|NCT00447603|Active Comparator|Losartan 100 mg|Losartan 100 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 100 mg/hydrochlorothiazide (HCTZ) 12.5 mg once daily for 4 weeks
11623298|NCT00447603|Experimental|Losartan 50 mg/HCTZ 12.5 mg|Losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 50 mg once daily for 4 weeks
11623299|NCT00447603|Experimental|Losartan 100 mg/HCTZ 12.5 mg|Losartan 100 mg/hydrochlorothiazide (HCTZ) 12.5 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 100 mg once daily for 4 weeks
11623300|NCT00447590|Experimental|LAP-BAND|All subjects who received the LAP-BAND System.
11623301|NCT00447577|Experimental|Zylet|Loteprednol etabonate and tobramycin ophthalmic suspension, 0.5%/0.3% (Zylet)
11623302|NCT00447577|Active Comparator|Tobradex|Tobradex (tobramycin and dexamethasone ophthalmic suspension, 0.3%/0.1%), US marketed product (Alcon) from commercial lots.
11623303|NCT00447564|Active Comparator|Group A|
11623304|NCT00447564|Placebo Comparator|Group B|
11623305|NCT00447551|Experimental|single group|
11623306|NCT00447525|Experimental|1|
11623307|NCT00447525|Active Comparator|2|
11623308|NCT00447499|Experimental|Somatuline Autogel (lanreotide acetate)|Somatuline Autogel (lanreotide acetate) Injection
11623309|NCT00447473|Other|A|GM-CSF given in combination with ketoconazole and mitoxantrone in patients with progressive prostate cancer despite androgen deprivation and prior taxane containing chemotherapy
11623310|NCT00447421|Experimental|A|
11623311|NCT00447408|Active Comparator|A|Education in the hemodialysis diet.
11623312|NCT00447408|Experimental|B|Education in the hemodialysis diet. Behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
11623313|NCT00447395||GROUP 1|Recurrent miscarriage, <40 year-old-men, < 38 year-old-women, normal or mild affected sperm, normal parents karyotype, no thrombophilia, normal uterus, no endocrinopathy
11623314|NCT00447395||GROUP 2|•Recurrent miscarriage, <40 year-old-men, < 38 year-old-women, oligozoospermia (1-5 mill/ml), normal parents karyotype, no thrombophilia, normal uterus, no endocrinopathy
11623315|NCT00447395||GROUP 3|•Oligozoospermia (1-5 mill/ml), < 40 year-old-men, no recurrent miscarriages
11623316|NCT00447395||GROUP 4|•Healthy young sperm donors
11623317|NCT00447382|Active Comparator|NN304|Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
11623318|NCT00447382|Experimental|NN729|Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
11623319|NCT00447343||Treatment group|"Patients with cervical myelopathy undergoing decompressive cervical spine surgery will have two scans (pre-operatively and 6 months post-operatively).
~A blinded investigator will administer questionnaires at each time point."
11623320|NCT00447343||Control group|"Healthy Volunteers will have two scans 6 months apart.
~A blinded investigator will administer questionnaires at each time point."
11623321|NCT00447330|Experimental|1|
11623322|NCT00447317|Experimental|A|Intervention
11623323|NCT00447317|Other|B|Attention control, standard dietary education
11623324|NCT00447278|Experimental|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
11623325|NCT00447278|Active Comparator|OEST|Other Early Standard Treatment (OEST): any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
11623326|NCT00447265|Experimental|Etanercept|Participants in this group will self-administer 50 mg etanercept injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).
11623385|NCT00446654|Experimental|CGC-11047 once every four weeks|16.5 mg CGC-11047 as a subconjunctival injection once every four weeks.
11623386|NCT00446641|Experimental|1 Cilostazol|100mg of Cilostazol twice a day
11623327|NCT00447265|Placebo Comparator|Placebo|Participants in this group will self-administer 50 mg placebo injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).
11623328|NCT00447226|Experimental|Lapatinib Oral Tablets|
11623329|NCT00447226|Placebo Comparator|Placebo Control|
11623330|NCT00447213|Experimental|1|
11623331|NCT00447213|Experimental|2|
11623332|NCT00447187|Experimental|LX201 0.50 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.50 inch in length
11623333|NCT00447187|Experimental|LX201 0.75 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.75 inch by length
11623334|NCT00447187|Placebo Comparator|Placebo 0.75 inch implant|Silicone implant not containing cyclosporine A, 0.75 inch in length
11623335|NCT00447174|Experimental|treatment|treatment manual
11623336|NCT00447174|No Intervention|control group|
11623337|NCT00447161|Experimental|1|Bacillus Clausii Multi ATB Resist
11623338|NCT00447161|Placebo Comparator|2|Placebo
11623339|NCT00447148|No Intervention|1|Paired comparison of 2 angiographic techniques
11623340|NCT00447122|Experimental|treatment|lapatinib, 1,500 mg/day, and Gemcitabine, 1 gm/m2/week for 3 weeks followed by 1 week off, until disease progression
11623341|NCT00447096|Experimental|Treatment Arm|Treatment arm will receive treatment 5 days a week for 6 weeks. Repetitive transcranial magnetic stimulation (rTMS) treatment.
11623342|NCT00447096|Sham Comparator|Sham Arm|Sham Arm will not receive any stimulation 5 days a week for 6 weeks. Sham transcranial magnetic stimulation.
11623343|NCT00447083|Experimental|UVB First|Subjects with fibromyalgia will undergo 6 tanning sessions (3/week x 2 weeks) at which they will be exposed in tanning beds with UV. The dose of UV (time of exposure) will be progressively increased from 3 minutes to 9 minutes over the 6 visits to acclimate subjects to UV light. Before and after every tanning session the subject will complete the pain questionnaire. Subjects in this group will be randomized to receive UVB tanning bed treatment first, then switch to the non-UVB treatment.
11623344|NCT00447083|Placebo Comparator|Non-UVB First|Subjects with fibromyalgia will undergo 6 tanning sessions (3/week x 2 weeks) at which they will be exposed in tanning beds with non-UV bulbs. The time of exposure will be progressively increased from 3 minutes to 9 minutes over the 6 visits to mirror UVB treatment. Before and after every tanning session the subject will complete the pain questionnaire. Subjects in this group will be randomized to receive non-UVB tanning bed treatment first, then switch to the UVB treatment.
11623345|NCT00447083|Experimental|UVB|The subjects who complete the acclimation phase of the study will then be randomized to 3 times/week treatments for 6 weeks with a fixed dose (10 min) of UVB.
11623346|NCT00447083|Placebo Comparator|Non-UVB|The subjects who complete the acclimation phase of the study will then be randomized to 3 times/week treatments for 6 weeks with a fixed dose (10 min) of non-UVB exposure
11623347|NCT00447057|Experimental|Pemetrexed (Nonsquamous)|Group of participants with non-small cell lung cancer (NSCLC) of nonsquamous histology who were assigned to Pemetrexed arm
11623348|NCT00447057|Experimental|Pemetrexed + Erlotinib (Nonsquamous)|Group of participants with NSCLC of nonsquamous histology who were assigned to Pemetrexed + Erlotinib arm
11623349|NCT00447057|Experimental|Pemetrexed (Squamous)|Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed arm
11623350|NCT00447057|Experimental|Pemetrexed + Erlotinib (Squamous)|Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed + Erlotinib arm
11623351|NCT00447044|Experimental|2|Subjects drink essential amino acid supplement 3x day for 2 days.
11623352|NCT00447044|Placebo Comparator|1|Subjects receive inert substance versus protein supplement.
11623353|NCT00447044|Experimental|3|Resistance exercise.
11623354|NCT00447005|Experimental|Open|
11623355|NCT00446992|Experimental|Open Trial Group|The patients were newly diagnosed with psychosis and were recruited at their first clinical contact for psychosis.
11623356|NCT00446979|Experimental|1|UC 781 0.1% carbomer gel
11623357|NCT00446979|Experimental|2|UC 781 0.25% carbomer gel
11623358|NCT00446979|Placebo Comparator|3|Placebo vaginal gel
11623359|NCT00446966|Experimental|fish oil , corn oil|Highly purified pharmaceutical grade omega three polyunsaturated fatty acids
11623360|NCT00446966|Placebo Comparator|placebo|olive oil
11623361|NCT00446953|Experimental|1|2x 12 mg betamethazone
11623362|NCT00446953|Placebo Comparator|2|no drugs
11623363|NCT00446901|Placebo Comparator|Placebo|Placebo
11623364|NCT00446901|Experimental|Selenium (selenized yeast)|Selenium (selenized yeast) tablets, 300 ug/day
11623365|NCT00446888|Active Comparator|1|"these subjects will get a standard protein supplement milkshake during thei study."
11623366|NCT00446888|Experimental|2|"these subjects will receive an enhanced protein supplement milkshake during their study. Product 4808."
11623367|NCT00446875|Experimental|Sucrose|Participants received oral sucrose (0.6mL/Kg) 2 minutes prior to the combind DTaP, IPV, and Hep B (Hib and PCV7) vaccine.
11623368|NCT00446875|Placebo Comparator|Placebo|Participants received Placebo (sterile water, 0.6mL/Kg) 2 minutes prior to the combind DTaP, IPV, and Hep B (Hib and PCV7) vaccine.
11623369|NCT00446849|Experimental|MMX Mesalamine|
11623370|NCT00446836|Other|Single arm|Open label use of Xyotax
11623371|NCT00446810|Active Comparator|A1|Benfotiamine
11623372|NCT00446810|Active Comparator|A2|
11623373|NCT00446797|Active Comparator|Non-Selective NSAIDS|nsNSAIDs used in real-life standard practice for treatment of pain due to ankle sprain.
11623374|NCT00446797|Experimental|Celecoxib|
11623375|NCT00446758|Experimental|Zinc|zinc (as zinc sulphate) 12.5 mg orally per day (6.25 mg in children < 12 mo)
11623376|NCT00446758|Placebo Comparator|Placebo|
11623377|NCT00446745||Abdominal obesity|60 males were recruited according to waist circumference, from lean to obese values
11623378|NCT00446732|Active Comparator|1|
11623379|NCT00446732|No Intervention|2|
11623380|NCT00446693|Experimental|I|Use of EndoFast Reliant System
11623381|NCT00446680|Experimental|1|
11623382|NCT00446680|Placebo Comparator|2|
11623383|NCT00446667|Experimental|1|
11623387|NCT00446641|Placebo Comparator|Placebo|matching placebo to cilostazol
11623388|NCT00446628|Experimental|intervention|Five elementary school received intervention consistin of training in hand and respiratory hygiene, and access to hand sanitizer
11623389|NCT00446628|No Intervention|control|Five elementary school received no training or hand sanitizer.
11623390|NCT00446602|Experimental|001|Epoetin alfa Type=exact unit=units number=80 000 form=solution for injection route=subcutaneous use once every week or once every 2 weeks.
11623391|NCT00446589|Experimental|F|HD pts suffering from osteoporosis and adynamic bone disease who received teriparatide
11623392|NCT00446589|Experimental|I|Hemodialysis pts suffering from osteoporosis who received iv ibandronate
11623393|NCT00446563|Experimental|Amlodipine + Valsartan|Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
11623394|NCT00446563|Active Comparator|Losartan + Hydrochlorothiazide|Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
11623395|NCT00446550|Experimental|Afegostat Tartrate Treatment Regimen 1|For the first 2 weeks, afegostat tartrate was administered orally at a dose of 225 milligrams (mg) once daily (QD) for 7 consecutive days, followed by no study medication for 7 consecutive days. After 2 weeks, participants then took 225 mg afegostat tartrate QD for 3 consecutive days, followed by no study medication for 4 consecutive days. This 3-days-on/4-days-off treatment regimen was followed for 22 weeks.
11623396|NCT00446550|Experimental|Afegostat Tartrate Treatment Regimen 2|Afegostat tartrate was administered orally at a dose of 225 mg QD for 7 consecutive days, followed by no study medication for 7 consecutive days. This 7-days-on/7-days-off treatment regimen was followed for 24 weeks.
11623397|NCT00446524|Experimental|Valsartan + Amlodipine 80/5 mg|Valsartan 80 mg or Amlodipine 5 mg ---> Valsartan + Amlodipine 80 / 5 mg
11623398|NCT00446524|Experimental|Valsartan + Amlodipine 80/5 mg + Diuretic|Valsartan + Amlodipine 80 / 5 mg + Diuretic
11623399|NCT00446511|Experimental|CKD patients: Valsartan+enalapril|
11623400|NCT00446511|Active Comparator|CKD patients: Enalapril|
11623401|NCT00446511|Experimental|Non-CKD patients: Valsartan|
11623402|NCT00446511|Active Comparator|Non-CKD patients: Enalapril|
11623403|NCT00446485|Active Comparator|1|Ginkgo Biloba standardized extract 24/6
11623404|NCT00446485|Placebo Comparator|3|placebo
11623405|NCT00446472|Experimental|1|Randomized to Regranex gel
11623406|NCT00446472|Active Comparator|2|Placebo hydrogel will be used for a total of 16 weeks
11623407|NCT00446446|Experimental|Panitumumab|articipants received panitumumab as an intravenous infusion at a dose of 9 mg/kg every 21 days until disease progression, unacceptable toxicity, withdrawal of consent, death, or end of study.
11623408|NCT00446420|Active Comparator|1|These patients will only receive intravenous propofol which will be titrated to an OAA/S score of 3. They will not receive fentanyl, midazolam or any other drugs
11623409|NCT00446420|Active Comparator|2|These patients will receive propofol plus midazolam and/or fentanyl. Midazolam and fentanyl will be given in fixed doses first and propofol will be titrated to effect. All drugs will be given intravenously.
11623410|NCT00446407|Experimental|Collaborative Stepped Care|Screening, Antidepressants, Psychosocial interventions (psychoeducation, IPT, adherence management) by Health Counselor, support and supervision by Psychiatrist.
11623411|NCT00446407|Active Comparator|Enhanced Usual Care|
11623412|NCT00446394|Experimental|1|
11623413|NCT00446394|Active Comparator|2|
11623414|NCT00446381|Experimental|1|Patients with Proliferative Diabetic Retinopathy
11623415|NCT00446381|Experimental|2|Patients with Clinically Significant Macular Edema
11623416|NCT00446368|Experimental|RAD001|Subjects will take RAD001 (Everolimus) 10mg by mouth daily.
11623417|NCT00446342|Experimental|Dose-escalation of SNS-032 injection|Patients escalated to MTD starting in Cohort 1 of 15 mg/m2 of SNS-032 injection, with 1.5-fold increase each cohort and a maximum loading dose increase of 10 mg/m2. Each dose cohort will have a minimum of 3 patients each with advanced CLL or MM. Dose escalation continues in the absence of Cycle 1 DLT criteria until an MTD is achieved for each disease type to a maximum of 7 cohorts at a high dose of 70 mg/m2. Stage 2 tests at MTD in larger group.
11623418|NCT00446316|Experimental|Gleevec plus antacids|Gleevec® will be administered at a dose of 400 mg, and the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide). Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1.
11623419|NCT00446316|Experimental|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
11623420|NCT00446290|Experimental|Docetaxel, Capecitabine and Oxaliplatin|
11623421|NCT00446264|Experimental|islet transplantation|Each participant received up to three sequential fresh islet infusions within three months.
11623422|NCT00446238|Experimental|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
11623423|NCT00446238|Active Comparator|Standard of Community Care Treatment|Standard of Community Care Treatment
11623424|NCT00446225|Experimental|A|Erlotinib (Tarceva)150 mg /day
11623425|NCT00446225|Active Comparator|B|"4 cycles of Chemotherapy:
~Cisplatin / Gemcitabine; Cisplatin /Docetaxel; Carboplatin / Gemcitabine; Carboplatin / Docetaxel."
11623426|NCT00446212|Active Comparator|1|Propofol based anaesthetic maintenance with propofol effect-site steered target-controlled infusion, in addition to fentanyl and non-opioid analgesics
11623427|NCT00446212|Active Comparator|2|Desflurane based anaesthetic maintenance with manually controlled administration in 100% oxygen in addition to fentanyl and non-opioid analgesics
11623467|NCT00445705|Experimental|AGN 203818 3 mg|Part A: 3 mg AGN 203818 every 12 hours for 4 weeks
11623428|NCT00446199|Experimental|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
11623429|NCT00446199|Experimental|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
11623430|NCT00446199|Experimental|Estradiol (E2 0.3mg)|One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).
11623431|NCT00446199|Placebo Comparator|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
11623432|NCT00446173|Experimental|Busulfan + Cyclophosphamide + G-CSF + GM-CSF|
11623433|NCT00446147|Placebo Comparator|Placebo|one tablet twice per day, which is identical to pyridoxine
11623434|NCT00446147|Experimental|Pyridoxine|100 mg twice per day
11623435|NCT00446134|Experimental|Group 1: Drug|Oral taribavirin tablet 20 mg/kg/day (Actual doses were 20-24 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
11623436|NCT00446134|Experimental|Group 2: Drug|Oral taribavirin tablet 25 mg/kg/day (Actual doses were 25-29 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
11623437|NCT00446134|Experimental|Group 3: Drug|Oral taribavirin 30 mg/kg/day (Actual doses were 30-34 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
11623438|NCT00446134|Active Comparator|Group 4: Drug|Oral ribavirin 800 mg/day (body weight <65 kg), 1000 mg/day (body weight 65-84 kg), 1200 mg/day (body weight 85-104 kg) or 1400 mg/day (body weight greater than or equal to 105 kg) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
11623439|NCT00446095|Experimental|fostamatinib|
11623440|NCT00446082|Experimental|SOM230 LAR|
11623441|NCT00446069|Experimental|Egalet® morphine|
11623442|NCT00446069|Active Comparator|MST Continus®|
11623443|NCT00446030|Experimental|Stratum 1: TAC + Bevacizumab|"Human epidermal growth factor receptor-2 (HER2) negative participants stratified at registration, were administered chemotherapy with docetaxel, doxorubicin and cyclosphosphamide (TAC) + bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.
~All participants were administered prophylactic recombinant Granulocyte Colony Stimulating Factor (G-CSF) during chemotherapy, based on a dose recommended by the manufacturer. For participants with estrogen receptor (ER) or progesterone receptor (PR) positive tumors, anti-estrogen therapy was recommended. Participants could receive radiation therapy at the discretion of the treating medical and radiation oncologist."
11623444|NCT00446030|Experimental|Stratum 2: TCH + Bevacizumab|"HER2 positive participants stratified at registration, were administered chemotherapy with docetaxel, carboplatin and trastuzumab (TCH) + bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks.
~All participants were administered prophylactic recombinant Granulocyte Colony Stimulating Factor (G-CSF) during chemotherapy, based on a dose recommended by the manufacturer. For participants with estrogen receptor (ER) or progesterone receptor (PR) positive tumors, anti-estrogen therapy was recommended. Participants could receive radiation therapy at the discretion of the treating medical and radiation oncologist."
11623445|NCT00446004|Other|A|On an 18-day schedule, Omeprazole (PPI) once daily on days 10 through 16; and Gleevec® once daily on days 1 and 15 (i.e., Gleevec® alone on day 1, and combination of Gleevec® and PPI on day 15).
11623446|NCT00446004|Other|B|On an 18-day schedule, Omeprazole (PPI) once daily on days -4 through 1; and Gleevec® once daily on days 1 and 15 (i.e., combination of Gleevec® and PPI on day 1, Gleevec® alone on day 15).
11623447|NCT00445978|Experimental|6R-BH4|2.5, 5, 10, 20 mg/kg/day of 6R-BH4 during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks, with an optional extension phase at the highest tolerated dose for up to a total of 2 years.
11623448|NCT00445965|Experimental|131I-3F8|This is a phase II single-arm open-label study that will define responses to therapy with weekly intrathecal 131I-3F8 in patients with central nervous system/leptomeningeal GD2-expressing disease.
11623449|NCT00445939|Experimental|Adalimumab 160 mg/80 mg|
11623450|NCT00445939|Experimental|Adalimumab 80 mg/40 mg|
11623451|NCT00445939|Placebo Comparator|Placebo|
11623452|NCT00445913|Experimental|control dendritic cells|autologous dendritic cells that are not treated
11623453|NCT00445913|Experimental|AS ODN dendrtitic cells|autologous dendritic cells treated ex vivo with the mixture of the antisense oligonucleotides
11623454|NCT00445887|Experimental|Arm I (levonorgestrel)|Patients receive oral levonorgestrel once daily.
11623455|NCT00445887|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily.
11623456|NCT00445848|Experimental|Erlotinib and Bevacizumab|
11623457|NCT00445835|Other|BA :Active arm|A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
11623458|NCT00445835|Other|BC: Conservative arm|Conservative medical approach
11623459|NCT00445809||1|High Risk population for developing AKI during/after CABG surgery.
11623460|NCT00445809||2|Medium Risk population for developing AKI during/after CABG surgery.
11623461|NCT00445770|Experimental|1|
11623462|NCT00445770|Experimental|2|
11623463|NCT00445770|Active Comparator|3|
11623464|NCT00445744|Experimental|Treatment (cyclophosphamide, busulfan, transplant)|"CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.
~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.
~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11."
11623465|NCT00445718||Observational|Patients undergo an abdominal CT or MRI scan on weeks 0, 6, and 42 and an abdominal sonogram on weeks 0, 3, 6, 12, 18, 30, 42, 66, and 90. Urinary catecholamine levels are also measured on the same weeks as the abdominal sonogram. Patients with an increase in tumor volume or catecholamine levels undergo sonographic evaluation and urine catecholamine sampling every 3 weeks until stabilization. Patients with a continued increase in catecholamine levels or a 50% increase in tumor volume undergo surgical resection off protocol therapy.
11623466|NCT00445705|Placebo Comparator|Placebo|Part A: Placebo every 12 hours for 4 weeks
11623568|NCT00444678|Experimental|Cetuximab, Capecitabine and Oxaliplatin|
11623468|NCT00445705|Experimental|AGN 203818 20 mg|Part A: 20 mg AGN 203818 every 12 hours for 4 weeks
11623469|NCT00445705|Experimental|AGN 203818 60 mg|Part A: 60 mg AGN 203818 every 12 hours for 4 weeks
11623470|NCT00445692|Experimental|Treatment (clarithromycin, dexamethasone, lenalidomide)|"Patients receive clarithromycin orally (PO) twice daily and dexamethasone PO once a week. Treatment with clarithromycin and dexamethasone continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO once daily on days 1-14. Courses with lenalidomide repeat every 21 days in the absence of disease progression or unacceptable toxicity. Lenalidomide is taken 4 hours or more after last dose of daily clarithromycin.
~NOTE: *After one year of treatment, dexamethasone is tapered for an additional 4 weeks."
11623471|NCT00445679|Experimental|A|DVS SR 50mg/day
11623472|NCT00445679|Experimental|B|DVS SR 100mg/day
11623473|NCT00445679|Experimental|C|DVS SR 200mg/day
11623474|NCT00445679|Active Comparator|D|Paroxetine 20mg/day
11623475|NCT00445627||Healthy Lean Controls|Cross-sectional analyses of continuous variables (e.g. hormonal measurements, inflammatory markers, lipids, BMI, and body composition measurements) will be compared using ANOVA
11623476|NCT00445627||Overweight Obese Controls|Cross-sectional analyses of continuous variables (e.g. hormonal measurements, inflammatory markers, lipids, BMI, and body composition measurements) will be compared using ANOVA
11623477|NCT00445627||Type 1 Diabetes|Cross-sectional analyses of continuous variables (e.g. hormonal measurements, inflammatory markers, lipids, BMI, and body composition measurements) will be compared using ANOVA
11623478|NCT00445614|Experimental|Marine trout|150 g/day of trout fed on marine based feed
11623479|NCT00445614|Experimental|Vegetable trout|150 g/d of trout fed on vegetable based feed
11623480|NCT00445614|Other|Poultry|150 g/d of poultry (for comparison)
11623481|NCT00445601|Experimental|Arm I|Patients receive intravesical gemcitabine hydrochloride over 1 hour.
11623482|NCT00445601|Placebo Comparator|Arm II|Patients receive intravesical placebo over 1 hour.
11623483|NCT00445588|Experimental|Treatment|"Patients receive oral erlotinib hydrochloride 150mg once daily and oral sorafenib tosylate 400mg twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
~Other: pharmacological study"
11623484|NCT00445575|Experimental|1|treatment duration: 1 year
11623485|NCT00445575|Placebo Comparator|2|treatment duration: 1 year
11623486|NCT00445575|Experimental|3|duration treatment: 3 years
11623487|NCT00445575|Placebo Comparator|4|treatment duration: 3 years
11623488|NCT00445549|Experimental|Vandetanib treatment|300 mg daily oral dose, 28 day cycle
11623489|NCT00445523|Experimental|1|TroVax® alone
11623490|NCT00445523|Experimental|2|TroVax® plus IFN-α
11623491|NCT00445484|Experimental|Group 1|Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
11623492|NCT00445484|Experimental|Group 2|Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
11623493|NCT00445471|Other|A|Mifne Approach to PDD
11623494|NCT00445471|Other|B|Treatment as usual
11623495|NCT00445458|Experimental|HKI-272 dose level 1|Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 160 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
11623496|NCT00445458|Experimental|HKI-272 dose level 2|Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
11623497|NCT00445458|Experimental|HKI-272 expanded MTD cohort, arm A|Part 2: Subjects with metastatic breast cancer who have not received more than 1 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
11623498|NCT00445458|Experimental|HKI-272 expanded MTD cohort, arm B|Part 2: Subjects with metastatic breast cancer who have not received more than 3 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
11623499|NCT00445445||Patients|Histologically confirmed breast cancer that was diagnosed between the years 2002-2004
11623500|NCT00445445||Healthy participants|Healthy participant who is receiving routine medical care (e.g., screening mammograms. Healthy participants are frequency-matched by age (± 2 years) and ethnicity.
11623501|NCT00445432|Experimental|DB Adalimumab 40 mg eow|Subjects received double-blind (DB) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the DB treatment period lasting 52 weeks.
11623502|NCT00445432|Placebo Comparator|Placebo eow|Subjects received placebo subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
11623503|NCT00445432|Experimental|OL Adalimumab 40 mg eow|Subjects received open-label (OL) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
11623504|NCT00445367||Case|
11623505|NCT00445367||Control|
11623506|NCT00445341|Experimental|Flavopiridol in lymphoma patients|Flavopiridol 30 mg/m^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
11623507|NCT00445328|Active Comparator|B|
11623508|NCT00445328|Experimental|A|
11623509|NCT00445315|Experimental|2|
11623510|NCT00445315|Experimental|3|
11623511|NCT00445315|Experimental|1|
11623512|NCT00445315|Experimental|4|
11623513|NCT00445315|Placebo Comparator|5|
11623514|NCT00445302|Active Comparator|Normal renal function|Participants with normal renal function (creatinine clearance (CLcr) > 90 ml/min) who serve as the study control. Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
11623515|NCT00445302|Experimental|Mild renal impairment|Participants have mild renal impairment (creatinine clearance (CLcr) = 51 to 80 mL/min). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
11623516|NCT00445302|Experimental|Moderate renal impairment|Participants have moderate renal impairment (creatinine clearance (CLcr) = 31 to 50 mL/min). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
11623517|NCT00445302|Experimental|Severe renal impairment|Participants have severe renal impairment (creatinine clearance (CLcr) < 31 mL/min, not requiring dialysis). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
11623518|NCT00445263|Experimental|Early Invasive strategy|Tirofiban and coronarography within 6 hours
11623519|NCT00445263|Active Comparator|Delayed invasive strategy|Coronarography after 6 hours
11623520|NCT00445224|Experimental|Hip Progressive Resistive Exercises|Exercises targeting hip musculature such as hip abduction and hip external rotation that was progressed by increased resistance following typical progressive resistive exercise approach.
11623521|NCT00445224|Active Comparator|Quad Progressive Resistive Exercises|Exercises targeting quadriceps musculature such as quadriceps isometric setting, terminal knee extensions, and straight leg raises that was progressed by increased resistance following typical progressive resistive exercise approach..
11623522|NCT00445211|Active Comparator|Intra-Aortic balloon Pump with Heparin|Intra-Aortic Balloon Pump (IABP) with Heparin
11623523|NCT00445211|Active Comparator|Intra-Aortic balloon Pump without Heparin|Intra-Aortic balloon Pump (IABP) without Heparin
11623524|NCT00445198|Experimental|Phase 1 and Phase 2a|
11623525|NCT00445185|Experimental|1|Henogen Hepatitis B vaccine for uremic patients
11623526|NCT00445185|Active Comparator|2|Fendrix hepatitis B vaccine for uremic patients
11623527|NCT00445172|Experimental|1|
11623528|NCT00445146|Experimental|EVG+RTV|"EVG 85 mg or 150 mg + RTV + ARV regimen
~Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their ARV regimen will receive EVG 85 mg and all other participants will receive EVG 150 mg.
~Some participants may receive EVG 300 mg during the course of protocol amendment 2."
11623529|NCT00445120|Experimental|1|
11623530|NCT00445120|Placebo Comparator|2|
11623531|NCT00445081|Active Comparator|1|
11623532|NCT00445081|Active Comparator|2|
11623533|NCT00445068|Experimental|Panobinostat|
11623534|NCT00445055|Experimental|1|Intravenous injection of 0,625 mg Droperidol, 30 min before the end of anesthesia
11623535|NCT00445055|Experimental|2|Intravenous injection of 2,5 mg Droperidol, 30 min before the end of anesthesia
11623536|NCT00445055|Placebo Comparator|3|Intravenous injection of NaCl 9% (Placebo), 30 min before the end of anesthesia
11623537|NCT00445042|Experimental|A|Intrapatient dose escalation study of sorafenib
11623538|NCT00445003|Experimental|Sham injection plus laser|Sham injection at baseline and 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
11623539|NCT00445003|Experimental|0.5mg Ranibizumab plus laser|Intravitreal injections of 0.5mg Ranibizumab at baseline and at 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
11623540|NCT00445003|Active Comparator|4-mg Triamcinolone Acetonide plus Laser|4-mg Triamcinolone Acetonide at baseline and sham injection at 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
11623541|NCT00444977|Experimental|Case-management linkage intervention|"The intervention represents a brief, real world intervention that could easily be adopted by HIV care clinics to facilitate linkage and increase use of oral services by their HIV+ patients (if shown to be effective). We are seeking to compare this intervention to usual practice in these clinics."
11623542|NCT00444977|No Intervention|Standard of Care|Subjects will receive standard of care services.
11623543|NCT00444951|Experimental|Menactra® group|Have received previously a dose of an A, C, Y, W 135 and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, will receive a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.
11623544|NCT00444951|Experimental|Mencevax® group|Have received previously a dose of an A, C, Y, W 135 and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, will receive a booster dose of Mencevax ACWY (serogroups A, C, Y, W-135) polysaccharide meningococcal vaccine.
11623545|NCT00444951|Experimental|Control group|Participants have not previously received any meningococcal vaccine, will receive a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.
11623546|NCT00444925|Experimental|Fesoterodine|Tablets
11623547|NCT00444925|Placebo Comparator|Placebo|Tablets and capsules
11623548|NCT00444925|Active Comparator|Tolterodine|Capsules
11623549|NCT00444912|Experimental|G-CSF plus plerixafor|Participants with CD20- lymphoma
11623550|NCT00444912|Experimental|G-CSF plus plerixafor and rituximab|Participants with CD20+ lymphoma
11623551|NCT00444899|Experimental|Intensive treatment|Submitted to an intensive follow-up by the dietician.
11623552|NCT00444899|Active Comparator|Usual treatment|Subjects will remain under the care of their endocrinologist and/or general practitioner.
11623553|NCT00444886|Active Comparator|1|To assess the effect of BOTOX injection to the scalene muscles on the severity of pain from TOS.
11623554|NCT00444886|Active Comparator|2|To assess the effect of BOTOX injection on numbness and tingling and quality of life.
11623555|NCT00444873|Experimental|28 day dose interval|
11623556|NCT00444873|Experimental|42 day dose interval|
11623557|NCT00444873|Experimental|56 day dose interval|
11623558|NCT00444860|Experimental|1|Zostavax
11623559|NCT00444834|Experimental|1|Egalet carvedilol
11623560|NCT00444834|Active Comparator|2|Coreg
11623561|NCT00444821|No Intervention|Surveillance|
11623562|NCT00444821|Experimental|Early Endovascular Repair|
11623563|NCT00444795||1|patients diagnosed as GIST after disease progression on or intolerance to imatinib mesylate
11623564|NCT00444795||2|patients diagnosed as advanced RCC
11623565|NCT00444795||3|patients diagnosed as unresectable, well-differentiated advanced and/or metastatic pancreatic neuroendocrine carcinoma
11623566|NCT00444743|Active Comparator|1|
11623567|NCT00444743|Placebo Comparator|2|
11623569|NCT00444639|Experimental|1|triptorelin 11.25mg given 12 weekly by subcutaneous formulation
11623570|NCT00444639|Active Comparator|2|triptorelin 11.25mg given 12 weekly by intramuscular injection
11623571|NCT00444626|Experimental|DGE|Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. Participants who continued into the Repeat Treatment period were treated with DGE as an open-label treatment.
11623572|NCT00444626|Active Comparator|Restylane|Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period.
11623573|NCT00444613|Experimental|E0302 25 mg|
11623574|NCT00444613|Experimental|E0302 50 mg|
11623575|NCT00444613|Placebo Comparator|3|
11623576|NCT00444600|Experimental|0.5mg Ranibizumab plus laser|
11623577|NCT00444600|Experimental|0.5 mg Ranibizumab plus deferred laser|
11623578|NCT00444600|Experimental|4 mg Triamcinolone plus laser|
11623579|NCT00444600|Active Comparator|Sham plus laser|
11623580|NCT00444587|Experimental|Trastuzumab + 2nd Line Chemotherapy|
11623581|NCT00444587|Active Comparator|Only Chemotherapy|
11623582|NCT00444574|Active Comparator|Methylphenidate Transdermal System|Methylphenidate 2.7mg, 41.3mg, 55mg, and 82.5mg patches for 7 weeks
11623583|NCT00444574|Placebo Comparator|Placebo|Placebp matching MTS and Concerta for 7 weeks
11623584|NCT00444574|Active Comparator|Concerta|Methylphenidate HCL 18mg tablet 7 weeks
11623585|NCT00444561|Active Comparator|Pramlintide acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC administration. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
11623586|NCT00444535|Experimental|Oral lapatinib tablets in combination with IV bevacizumab|1500 mg oral lapatinib (once daily) plus 10 mg/kg intravenous bevacizumab (every two weeks)
11623587|NCT00444509|Experimental|Treatment 1|Subjects will receive GW685698X 800 microgram (mcg) single inhaled dose via a DISKUS inhaler. There will be a wash-out period of at least 5 days between doses.
11623588|NCT00444509|Experimental|Treatment 2|Subjects will receive GW685698X 800 mcg containing magnesium stearate inhaled dose via a DISKUS inhaler. There will be a wash-out period of at least 5 days between doses.
11623589|NCT00444470|Active Comparator|A|Active drug being tested in this study is Tranexamic Acid
11623590|NCT00444470|Placebo Comparator|B|Normal saline was used as the Placebo
11623591|NCT00444457|Experimental|1|
11623592|NCT00444457|Experimental|2|
11623593|NCT00444457|Experimental|3|
11623594|NCT00444457|Active Comparator|4|
11623595|NCT00444418|Experimental|1|Active medication (Naltrexone) combined with Modified Behavioral Self-Control Psychotherapy
11623596|NCT00444418|Experimental|2|Placebo combined with Modified Behavioral Self-Control Psychotherapy
11623597|NCT00444418|Experimental|3|Active medication (Naltrexone) combined with Brief Behavioral Compliance Enhancement Therapy
11623598|NCT00444418|Placebo Comparator|4|Placebo + Brief Behavioral Compliance Enhancement Therapy
11623599|NCT00444379|Active Comparator|PI-based HAART regimen|PI-based HAART regimen (lopinavir/ritonavir plus emtricitabine/tenofovir)
11623600|NCT00444379|Active Comparator|non-nucleoside reverse transcriptase inhibitor|non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART regimen (efavirenz plus emtricitabine/tenofovir)
11623601|NCT00444314|Experimental|A|
11623602|NCT00444314|Experimental|B|
11623603|NCT00444275|Experimental|Esomeprazole 20 mg Once Daily (initial phase)|
11623604|NCT00444275|Experimental|Esomeprazole 40 mg Once Daily (initial phase)|
11623605|NCT00444275|Experimental|Esomeprazole 20 mg Once Daily (Maintenance Phase)|
11623606|NCT00444275|Experimental|Esomeprazole 20 mg on Demand (Maintenance Phase)|
11623607|NCT00444275|Experimental|Antacid Treatment (Maintenance Phase)|
11623608|NCT00444262|Active Comparator|1|conventional treatment
11623609|NCT00444262|Experimental|2|stroke volume optimisation
11623610|NCT00444249|Active Comparator|1|White Alcon IOL
11623611|NCT00444249|Active Comparator|2|Yellow Alcon IOL
11623612|NCT00444249|Active Comparator|3|White Hoya IOL
11623613|NCT00444249|Active Comparator|4|Yellow Hoya IOL
11623614|NCT00444236|Active Comparator|1|
11623615|NCT00444236|Placebo Comparator|2|
11623616|NCT00444223|Experimental|fluorine F 18 FEQA + positron emission tomography|
11623617|NCT00444184|Active Comparator|Travoprost/Timolol therapy|24-hour pressure monitoring after 3 months of chronic dosing with travoprost/timolol drops
11623618|NCT00444184|Active Comparator|Travoprost therapy|24-hour pressure monitoring after 3 months of chronic dosing with travoprost drops
11623619|NCT00444145|Experimental|Patients with documented GERD or laryngopharyngeal reflux|Patients who have documented GERD as evidenced by erosive esophagitis or those patients who have newly diagnosed laryngopharyngeal reflux as diagnosed by endoscopy.
11623620|NCT00444106|Experimental|Artemether-lumefantrine (Coartem)|Artemether-lumefantrine (Coartem) tablets containing 20 mg artemether and 120 mg lumefantrine twice a day for 3 days, dosage dependent on body weight.
11623621|NCT00444106|Active Comparator|Atovaquone-proguanil (Malarone)|Atovaquone-proguanil (Malarone) tablets containing 250 mg atovaquone and 100 mg proguanil hydrochloride once daily for 3 days, dosage dependent on body weight.
11623622|NCT00444106|Active Comparator|Artesunate-mefloquine|Artesunate-mefloquine tablets containing 50 mg artesunate (Plasmotrim) and 250 mg mefloquine (Mephaquin). Artesunate 4 mg/kg/day (for 3 days) and mefloquine 25 mg/kg/day (days 2 and 3) total dose was given once daily dependent upon body weight.
11623623|NCT00444093|Experimental|Opii normata treatment|Treamtment with opii normata in case of diarrhea
11623624|NCT00444093|Experimental|Loperamid Treatment|Treatment with Loperamid in case of diarrhea
11623625|NCT00444080|Active Comparator|Control Arm|Subjects undergoing trabeculectomy with the use of Mitomycin C
11623626|NCT00444080|Experimental|Treatment Arm|Subjects undergoing Ex-PRESS Under Scleral Flap implantation procedure with the use of Mitomycin C
11623627|NCT00444067|Experimental|Spinal Sealant System|Spinal Sealant System
11623628|NCT00444067|Active Comparator|Standard of Care|Standard of care methods as an adjunct to sutured dural repair
11623629|NCT00444054|Experimental|Dietary modification|Patients are placed on a low carbohydrate diet (<30 grams/day) for 28 days.
11623630|NCT00444041|Experimental|Xelox, Bev|
11623631|NCT00444028|Experimental|Cohort A: Inhaled Loxapine 0.625 mg or Placebo|Single 0.625 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
11623632|NCT00444028|Experimental|Cohort B: Inhaled Loxapine 1.25 mg or Placebo|Single 1.25 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
11623633|NCT00444028|Experimental|Cohort C: Inhaled Loxapine 2.5 mg or Placebo|Single 2.5 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
11623634|NCT00444028|Experimental|Cohort D: Inhaled Loxapine 5 mg or Placebo|Single 5 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
11623635|NCT00444028|Experimental|Cohort E: Inhaled Loxapine 10 mg or Placebo|Single 10 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
11623636|NCT00444015|Experimental|Dose Escalation|
11623637|NCT00444002||Hepatitis C - Steatosis|Patients with chronic Hep C infection undergoing liver biopsy with >=5% steatosis on liver biopsy
11623638|NCT00444002||Hepatitis C - no steatosis|Patients with chronic Hep C infection without steatosis on liver biopsy (<5% of hepatocytes involved)
11623639|NCT00443976|Experimental|AT9283|
11623640|NCT00443963|Experimental|PPI|PPI Medication
11623641|NCT00443963|Experimental|H2RA|H2RA Medication
11623642|NCT00443924|Placebo Comparator|1|Arm 1
11623643|NCT00443924|Experimental|2|Arm 2
11623644|NCT00443924|Experimental|3|Arm 3
11623645|NCT00443924|Experimental|4|Arm 4
11623646|NCT00443924|Experimental|5|Arm 5
11623647|NCT00443898|Experimental|1|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks
11623648|NCT00443898|Placebo Comparator|2|vehicle (placebo) applied once daily for 48 weeks
11623649|NCT00443898|Experimental|3|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks
11623650|NCT00443898|Placebo Comparator|4|vehicle (placebo) applied once daily for 24 weeks
11623651|NCT00443872|Other|orally disintegrating selegiline|This is a one arm open label study of patients who are experiencing a dopamine agonist (DA) related adverse effects (AE) of either one or more of the following: excessive daytime sleepiness, hallucinations, pedal edema, impulse control disorder. All subjects received orally disintegrating selegiline.
11623652|NCT00443859||PPHN|Infants with persistent pulmonary hypertension (PPHN)
11623653|NCT00443846|Experimental|Group 1: Concomitant Administration|Participants received 2 concomitant doses of RotaTeq® and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age and a third dose of RotaTeq® at 24-25 weeks of age (and 28 to 42 days after the vaccine administration at 20-21 weeks of age).
11623654|NCT00443846|Active Comparator|Group 2: Sequential Administration|Participants received 3 doses of RotaTeq® at 6-7 weeks of age, 15-16 weeks of age, and 24-25 weeks of age (and 28 to 42 days after the MMC vaccine administered at 20-21 weeks of age), and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age.
11623655|NCT00443820|Experimental|1|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks
11623656|NCT00443820|Placebo Comparator|2|Vehicle (placebo) for 48 weeks
11623657|NCT00443820|Experimental|3|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks
11623658|NCT00443820|Placebo Comparator|4|Vehicle (placebo) for 24 weeks
11623659|NCT00443794|Experimental|1, POLYCAP|Combination of 3 anti hypertensives, lipid lowering agent and anti platelet agent
11623660|NCT00443794|Active Comparator|2 B|Diuretic antihypertensive
11623661|NCT00443794|Active Comparator|3 C|Thiazide plus Angiotensis converting enzyme inhibitor - combination antihypertensive.
11623662|NCT00443794|Active Comparator|4 D|Diuretic with Beta blocker combination antihypertensive
11623663|NCT00443794|Active Comparator|5, E|ACE inhibitor plus Beta blocker combination antihypertensive
11623664|NCT00443794|Active Comparator|6, F|Combination antihypertensive of ACE inhibitor, diuretic and beta blocker
11623665|NCT00443794|Active Comparator|7,G|Combination of ACE inhibitor, betablocker, diuretic and Antiplatelet
11623666|NCT00443794|Active Comparator|8,H|Lipid lowering agent
11623667|NCT00443794|Active Comparator|9,A|Antiplatelet
11623668|NCT00443781|Other|PD and F.A.D. diagnostic testing|
11623669|NCT00443768||1|
11623670|NCT00443768||2|
11623671|NCT00443755|Active Comparator|Insulin Sensitizer Therapy|Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily.
11623672|NCT00443755|Placebo Comparator|Placebo|Placebo tablets were used to match the active comparator drugs and dosing regimen.
11623673|NCT00443729|Experimental|1|Raltegravir & Placebo
11623674|NCT00443729|Active Comparator|2|Lopinavir (+) Ritonavir & Placebo
11623675|NCT00443703|Experimental|1|Arm 1: MK0518 (raltegravir) + placebo to KALETRA™ (lopinavir (+) ritonavir )
11623676|NCT00443703|Active Comparator|2|Arm 2: KALETRA™ (lopinavir (+) ritonavir) + placebo to MK0518 (raltegravir)
11623677|NCT00443690|Placebo Comparator|2|placebo control
11623678|NCT00443690|Experimental|1|KW-3902IV
11623679|NCT00443677|Active Comparator|abvd|
11623680|NCT00443677|Experimental|beacopp|
11623681|NCT00443677|Experimental|coppebvcad|
11623682|NCT00443651|Experimental|Rituximab 1000 mg (Stage I patients)|Stage I patients received 2 doses of rituximab 1000 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 1000 mg given 14 days apart. Concomitant non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
11623735|NCT00443235|Active Comparator|A|"One cycle:
~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
11623683|NCT00443651|Experimental|Rituximab 500 mg (Stage II patients)|Stage II patients received 2 doses of rituximab 500 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 500 mg given 14 days apart. Concomitant biological and non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
11623684|NCT00443638|No Intervention|Control Group|Control Group
11623685|NCT00443638|Experimental|Home visitation through pregnancy|Nurse home visitation through pregnancy
11623686|NCT00443638|Experimental|Home visitation through age 2|Nurse home visitation through child age 2.
11623687|NCT00443612|Experimental|1|"12 weeks on treatment 1
~2 week washout period
~12 weeks on treatment 2"
11623688|NCT00443612|Experimental|2|"12 weeks on treatment 2
~2 week washout period
~12 weeks on treatment 1"
11623689|NCT00443599|Experimental|Insulin|Insulin was infused to target a blood glucose concentration of 80-110 mg/dL
11623690|NCT00443599|Active Comparator|Usual Care|Insulin was infused according to the discretion of the treating clinical team.
11623691|NCT00443586|Active Comparator|Developmental Screening|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age.
11623692|NCT00443586|Active Comparator|Screening plus Transportation|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two).
11623693|NCT00443586|Active Comparator|Screening, Transport, Prenatal Visits|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy.
11623694|NCT00443586|Experimental|Screen, Transport, Prenatal/Inf Visits|Participants received regular sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy and through child age two.
11623695|NCT00443560||Instrumental Vaginal Delivery (IVD)|Instrumental vaginal delivery (IVD) is attempted to prevent fetal hypoxia if the second stage of labor is prolonged. It includes forceps and vacuum extractions.
11623696|NCT00443560||Spontaneous Vaginal Delivery (SVD)|The control group consisted of parturients who had a spontaneous vaginal delivery (SVD)in the same 24 hour period who were case-matched for gravidity and parity.
11623697|NCT00443547||1-level|Patients needing a single level cervical fusion with Vectra-T
11623698|NCT00443547||2-level|Patients needing cervical fusion at two consecutive levels with Vectra-T
11623699|NCT00443547||3-level|Patients needing cervical fusion at three consecutive levels with Vectra-T
11623700|NCT00443547||4-level|Patients needing cervical fusion at four consecutive levels with Vectra-T
11623701|NCT00443534|Experimental|1|
11623702|NCT00443469|Experimental|Magnetic Stimulation|
11623703|NCT00443469|Placebo Comparator|Magnetic Stimulation with tilted coil|Magnetic Stimulation with tilted coil
11623704|NCT00443456|Experimental|Single|
11623705|NCT00443430|Active Comparator|Methotrexate Arm|Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus placebo etanercept and placebo prednisolone
11623706|NCT00443430|Active Comparator|Methotrexate-Etanercept-Prednisolone Arm|Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus etanercept 0.8 mg/kg given by subcutaneous injection once per week, plus prednisolone by mouth daily with decreasing dose tapered over 16 weeks
11623707|NCT00443417|Placebo Comparator|1|
11623708|NCT00443417|Active Comparator|2|200mg qd
11623709|NCT00443417|Active Comparator|3|200mg bid
11623710|NCT00443417|Active Comparator|4|400mg qd
11623711|NCT00443404|Active Comparator|1|perioperative epidural analgesia
11623712|NCT00443404|Active Comparator|2|Iv PCA Fentanyl preoperative, Epidural analgesia postoperative
11623713|NCT00443404|Active Comparator|3|perioperative IV PCA Fentanyl, epidural anesthesia
11623714|NCT00443404|Active Comparator|4|perioperative IV PCA Fentanyl general anesthesia
11623715|NCT00443404|Placebo Comparator|5|IV PCA with saline 0.9% and sc saline 0.9%in the L3-L4 area. IM meperidine, po codeine/acetaminophen, IV acetaminophen and IV parecoxib
11623716|NCT00443391|Experimental|1|
11623717|NCT00443378|Experimental|1|"Arm 1, CARE+ arm is the study arm that receives the CARE+ computer intervention."
11623718|NCT00443378|No Intervention|2|Arm 2, the control arm, is the study arm that receives computerized risk assessment only.
11623719|NCT00443365|No Intervention|1|Coronary Artery Bypass Grafting with no Mitral Valve intervention
11623720|NCT00443365|Active Comparator|2|Coronary Artery Bypass Grafting + Mitral Annuloplasty
11623721|NCT00443352|Experimental|Duloxetine|Duloxetine 120mg daily for 12 weeks.
11623722|NCT00443326|Experimental|AMG 714|AMG 714 will be given as a multiple dose regimen
11623723|NCT00443300||Protective environment|Participants in a Protective environment
11623724|NCT00443300||Not a protective environment|Participants not in a protective environment
11623725|NCT00443287|Placebo Comparator|1|
11623726|NCT00443287|Experimental|2|dose level 1
11623727|NCT00443287|Experimental|3|dose level 2
11623728|NCT00443287|Experimental|4|dose level 3
11623729|NCT00443287|Active Comparator|5|
11623730|NCT00443274||NBIR placeholder|Once the US National Breast Implant Registry is established, subjects will be transferred to this database for follow up
11623731|NCT00443274||410 Arm|Anatomically shaped silicone gel-filled breast implants.
11623732|NCT00443274||BIFs|Round silicone gel-filled breast implants and saline-filled breast implants
11623733|NCT00443261|Experimental|1 (SCCHN)|Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Patients will receive Azacitidine and cisplatin.
11623734|NCT00443248|Experimental|Vaginal Heat Wash-Out Device|
11623826|NCT00442351|Placebo Comparator|Placebo inhaler|
11623736|NCT00443235|Experimental|B|"One cycle:
~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity < grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)
~Five cycles:
~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
11623737|NCT00443209|Experimental|Telcagepant 280 mg/300 mg|Participants receive telcagepant 300 mg soft gel capsules or telcagepant 280 mg tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of telcagepant, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of telcagepant per month for up to 18 months.
11623738|NCT00443209|Active Comparator|Rizatriptan 10 mg|Participants receive rizatriptan tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of rizatriptan, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of rizatriptan per month for up to 18 months.
11623739|NCT00443196|Experimental|Experimental|
11623740|NCT00443183|Experimental|Brief Negotiation Interview|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
11623741|NCT00443183|Placebo Comparator|Discharge Instructions|Scripted discharge instructions to be read by emergency practitioner and designed to be less than 1 minute in length.
11623742|NCT00443131|Experimental|Group A|
11623743|NCT00443131|Experimental|Group B|
11623744|NCT00443131|Experimental|Group C|
11623745|NCT00443118|Active Comparator|Neopuff TM with PEEP|Newborns ventilated for neonatal resuscitation using Neopuff TM with PEEP
11623746|NCT00443118|Active Comparator|Self Inflating Bag with PEEP|Newborns ventilated for neonatal resuscitation using Self Inflating Bag with PEEP valve attached
11623747|NCT00443118|Active Comparator|Self Inflating Bag without PEEP|Newborns ventilated for neonatal resuscitationusing Self Inflating Bag without PEEP valve attached
11623748|NCT00443092|Experimental|1|proprietary tart cherry juice blend (8 oz., BID)
11623749|NCT00443092|Placebo Comparator|2|control juice (color matched kool aid blend),(8 oz., BID)
11623750|NCT00443053|Active Comparator|Fondaparinux 2.5mg|
11623751|NCT00443053|Placebo Comparator|Placebo|
11623752|NCT00443040|Placebo Comparator|Placebo|
11623753|NCT00443040|Active Comparator|Asimadoline 1.0 mg|Asimadoline 1.0 mg b.i.d.
11623754|NCT00443040|Active Comparator|Asimadoline 3.0 mg|Asimadoline 3.0 mg b.i.d.
11623755|NCT00443027|Experimental|Vaginal Heat Wash-Out Device|
11623756|NCT00443014|Experimental|A Cognitive stimulation therapy|Patients with recently diagnosed dementia in five of the study municipality.
11623757|NCT00443014|No Intervention|B Care as usual|
11623758|NCT00442962|Experimental|EFV + FTC/TDF|Participants will efavirenz (600mg in pill form, taken orally, once daily) and emtricitabine/tenofovir disoproxil fumarate (200/300mg in pill form, taken orally, once daily), for 48 weeks
11623759|NCT00442949|Active Comparator|2|Catheterization immediate PCI
11623760|NCT00442949|Experimental|1|delayed PCI
11623761|NCT00442936|Experimental|Telcagepant 150 mg|Participants receive telcagepant 150 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 150 mg or placebo) or one dose of non-study rescue medication.
11623762|NCT00442936|Experimental|Telcagepant 300 mg|Participants receive telcagepant 300 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 300 mg or placebo) or one dose of non-study rescue medication.
11623763|NCT00442936|Active Comparator|Zolmitriptan 5 mg|Participants receive zolmitriptan 5 mg tablets, one tablet administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (placebo) or one dose of non-study rescue medication.
11623764|NCT00442936|Placebo Comparator|Placebo|Participants receive placebo matching capsules or tablets, one capsule or tablet administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (placebo) or one dose of non-study rescue medication.
11623765|NCT00442923|Placebo Comparator|CTRL|
11623766|NCT00442923|Experimental|TREAT|
11623767|NCT00442910|Active Comparator|3% SPL7013|Intravaginal application of 3.5 g SPL7013 gel twice daily for 14 days
11623768|NCT00442910|Placebo Comparator|Placebo for SPL7013 Gel|Intravaginal application of 3.5 g placebo gel twice daily for 14 days
11623769|NCT00442910|Placebo Comparator|HEC Placebo Gel|Intravaginal application of 3.5 g HEC placebo gel twice daily for 14 days
11623770|NCT00442897|Experimental|1|
11623771|NCT00442897|Active Comparator|2|
11623772|NCT00442871|Experimental|Eltrombopag|Eltrombopag 50 mg oral (single dose)
11623773|NCT00442832|Experimental|TD-1792|
11623774|NCT00442832|Active Comparator|Vancomycin|
11623775|NCT00442806|Placebo Comparator|Placebo|Placebo is injected
11623776|NCT00442806|Experimental|Treatment|ADRC's are injected
11623777|NCT00442793|Experimental|1|
11623778|NCT00442793|Active Comparator|2|
11623779|NCT00442780|Placebo Comparator|1|Dose Level A of BIIB014
11623780|NCT00442780|Placebo Comparator|2|Dose Level B of BIIB014
11623781|NCT00442780|Placebo Comparator|3|Dose Level C of BIIB014
11623782|NCT00442780|Placebo Comparator|4|Dose Level D of BIIB014
11623783|NCT00442767|Active Comparator|Rapid acting Insulin therapy - before meal|Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal
11623784|NCT00442767|Experimental|Pre-meal Pramlintide and Post-meal Insulin therapy|30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
11623785|NCT00442741|Experimental|Patupilone + Midazolam|
11623786|NCT00442741|Experimental|Patupilone + Omeprazole|
11623787|NCT00442702|Experimental|Mircera|Participants received Mircera by subcutaneous injection once every month during the dose titration (7 months) and evaluation period (2 months). The starting dose was based on the weekly dose of darbepoetin alfa administered prior to the switch to Mircera, and was either 120, 200 or 360 µg Mircera per month. The dose was then adjusted to maintain Hemoglobin levels within the defined target range and also according to the need for red blood cell transfusions (due to worsening anemia), or for toxicity related to Mircera.
11623788|NCT00442702|Active Comparator|Darbepoetin alfa|Participants continued to receive the same dose of darbepoetin alfa as before screening by subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling during the dose titration (7 months) and the evaluation period (2 months).
11623789|NCT00442689|Experimental|1|oral contraceptive (35 mg ethinyl estradiol)
11623790|NCT00442689|Experimental|2|Flutamide 250 mg twice daily
11623791|NCT00442689|Placebo Comparator|3|Placebo
11623792|NCT00442676|Experimental|1|Celecoxib, 200 mg/day
11623793|NCT00442676|Placebo Comparator|2|Placebo
11623794|NCT00442637|Experimental|1|observation
11623795|NCT00442637|Active Comparator|2|capecitabine plus bevacizumab
11623796|NCT00442624||1|Patients with chronic insomnia
11623797|NCT00442624||2|age, sex, bmi matched healthy controls
11623798|NCT00442611|Experimental|Abatacept|Abatacept (dosed based upon weight) administered intravenously (IV) on days 1, 15, 30 and monthly thereafter for a total of 7 doses.
11623799|NCT00442611|Placebo Comparator|IV fluid|Placebo to match abatacept (IV fluid) administered on days 1, 15, 30 and monthly thereafter for a total of 7 doses.
11623800|NCT00442598|Experimental|Glufosfamide q21 days|1-hour infusion of glufosfamide at a dose of 5,000 mg/m2 on Day 1 of a 21-day cycle
11623801|NCT00442598|Experimental|Glufosfamide q7 days low|1-hour infusion of glufosfamide at a dose of 1,660 mg/m2 on Days 1, 8 and 15 of a 21-day cycle
11623802|NCT00442598|Experimental|Glufosfamide q7 days high|1-hour infusion of glufosfamide at a dose of 2,500 mg/m2 on Days 1, 8 and 15 of a 21-day cycle
11623803|NCT00442572|Experimental|PEGASYS|Participants received 4 treatment cycles of continuous intermittent treatment with PEGASYS® (Peginterferon alfa-2a) . Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
11623804|NCT00442572|No Intervention|No Intervention|Participants were on non- specific anti-viral treatment.
11623805|NCT00442559|Experimental|Montelukast|Participants were treated for 12 months after randomization: Participants 2 to 5 years of age took one 4 mg chewable tablet and 6 to 14 years of age took one 5 mg chewable tablet daily in the evening. If participants had exacerbated from mild to moderate within 12 weeks, inhaled corticosteroids (ICS) was added to Montelukast and ICS, respectively and those participants were excluded in the efficacy evaluation at 12 weeks.
11623806|NCT00442559|Active Comparator|Inhaled Corticosteroids (ICS)|Participants were treated for 12 months after randomization: Each participant's physician selected the ICS agent, dose, and regimen. If participants had exacerbated from mild to moderate within 12 weeks, ICS was added to Montelukast and ICS, respectively and those participants were excluded in the efficacy evaluation at 12 weeks.
11623807|NCT00442546|Experimental|1|
11623808|NCT00442546|Experimental|2|
11623809|NCT00442546|Placebo Comparator|3|
11623810|NCT00442533|Experimental|Indium-111 pentetreotide|4 cycles of 500 mCi treatments every 10-12 weeks
11623811|NCT00442520||2|colorectal cancer patients
11623812|NCT00442520||3|head and neck cancer patients
11623813|NCT00442520||1|lung cancer patients
11623814|NCT00442507|Experimental|1|Patients will be treated with erlotinib 150 mg oral daily and Avastin 15 mg/kg intravenously each cycle of therapy (each cycle is 21 days or every 3 weeks). The first infusion of Avastin will be administered over 90 minutes. If tolerated, the second infusion will be given over 60 minutes and in 30 minutes for the subsequent treatments. Treatment will be administered until disease progression or intolerable side effects.
11623815|NCT00442494|Other|Study couldn´t start due to investigator|Study couldn´t start due to investigator
11623816|NCT00442468||All participants|This is a cross-sectional, non-interventional study. All enrolled subjects were asked to complete a questionnaire and pulmonary function test to assess the prevalence of airflow obstruction.
11623817|NCT00442455|Experimental|Erlotinib, radiotherapy.|There are three cohorts of patients in whom the dose of Erlotinib chlorhydrate(100 and 150 mg) and Cisplatin (30 and 40 mg / m2) will be increase, and the doses of Radiation therapy being fixed (63 Gy during 5 days a week during 7 weeks)
11623818|NCT00442442|No Intervention|1|No treatment control
11623819|NCT00442442|Active Comparator|2|LLIN Nets
11623820|NCT00442442|Experimental|3|Mosquito Coils
11623821|NCT00442442|Experimental|4|Mosquito coils & LLIN
11623822|NCT00442416|Experimental|RO0503821|Eligible participants will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) subcutaneously (SC) every month for eight months (6 months of titration period [TP] and two months of evaluation period [EP] and 15-days following the final study visit (9 months post randomization). The first dose of Mircera (120, 200, or 360 mcg) will be based upon the dose of epoetin alfa received 1 to 2 weeks prior to administration of study drug, while subsequent doses will be adjusted to maintain haemoglobin (Hb) concentrations within target of >=10.0 gram per decilitre (g/dL) and <=12.0 g/dL. Participants who self-administered/visited to clinics for erythropoiesis stimulating agent (ESA) dosing prior to randomization will continue to do so.
11623823|NCT00442416|Active Comparator|Epoetin Alfa|Eligible participants will be administered epoetin alfa SC as per the standard of care for eight months (TP and EP), and will be followed-up for 15 days following the final study visit. Participants who self-administered/visited to clinics for ESA dosing prior to randomization will continue to do so.
11623824|NCT00442364|Experimental|1|Polidocanol (1%) Microfoam (Varisolve)
11623825|NCT00442351|Experimental|Asmanex Twisthaler|
11623827|NCT00442338|Experimental|Montelukast 7 mg|Montelukast 7 mg IV administration
11623828|NCT00442338|Experimental|Montelukast 14 mg|Montelukast 14 mg IV administration
11623829|NCT00442338|Active Comparator|Aminophylline 250 mg|Aminophylline 250 mg IV drip administration
11623830|NCT00442286|Experimental|On|Subject will be randomized to a 2:1 allocation to the Rheos ON or OFF arms at the time of Rheos System activation (time point 0). After the six month follow up evaluation, all subjects will have therapy activated, though subjects and treating physicians will not be informed of randomized treatment assignment.
11623831|NCT00442286|Experimental|Off|Subject will be randomized to a 2:1 allocation to the Rheos ON or OFF arms at the time of Rheos System activation (time point 0). After the six month follow up evaluation, all subjects will have therapy activated, though subjects and treating physicians will not be informed of randomized treatment assignment.
11623832|NCT00442260|Experimental|Abraxane dose escalation + fixed dose DOXIL|Limited dose-escalation study of Abraxane and fixed dose of DOXIL in order to identify correct dose and side effect profile of the combination.
11623833|NCT00442195||1|Healthy Volunteers
11623834|NCT00442169|Experimental|Group 1: WN02 Low Dose (Part 1)|Low Dose in healthy adults in Part 1 against a placebo control.
11623835|NCT00442169|Experimental|Group 2: WN02 Medium Dose (Part 1)|Medium dose level in part one healthy subjects against a placebo control.
11623836|NCT00442169|Experimental|Group 3: WN02 High Dose (Part 1)|High dose level in part one healthy subjects against a placebo control
11623837|NCT00442169|Placebo Comparator|Group 4: Placebo (Part 1)|Participants will receive a single dose of saline in Part 1 on Day 0
11623838|NCT00442169|Experimental|Group 5: WNO2 High Dose (Part 2)|Participants enrolled in Part 2 and received a single dose of West Nile Virus vaccine.
11623839|NCT00442169|Placebo Comparator|Group 6: Placebo (part 2)|Participants will receive a single dose of saline in Part 2 on Day 0
11623840|NCT00442156||Laser|People with diabetic macular edema involving the center of the macula (OCT central subfield thickness >250 microns), who were already intended to receive focal photocoagulation
11623841|NCT00442130|Experimental|GM-K562 Vaccine|"Biological/Vaccine: GM-K562 vaccine The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.
~Procedure/Surgery: stem cell transplantation Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation"
11623842|NCT00442117|Experimental|MF-DPI|MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day)
11623843|NCT00442117|Active Comparator|BUD-DPI|Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day)
11623844|NCT00442104|Experimental|ganaxolone|
11623845|NCT00442091|Other|10 ml of dandelion juice twice daily|
11623846|NCT00442065|Active Comparator|Open label, single arm|A prospective, open label, single-arm (non-randomized) multi-center, international clinical device investigation to collect safety and performance data concerning the Aorfix™ Stent Graft System in the treatment of abdominal aortic aneurysm and aorto-iliac aneurysm where a significant degree of vessel angulation exists
11623847|NCT00442039|Experimental|Lithium dosing 1|The starting dose of lithium was 300 mg for patients weighing < 20 kg [no patients were enrolled that weighed less than 20 kg] and 600 mg for patients weighing ≥ 20 kg.
11623848|NCT00442039|Experimental|Lithium dosing 2|"The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability."
11623849|NCT00442039|Experimental|Lithium dosing 3|"The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patients response and tolerability."
11623850|NCT00442039|Placebo Comparator|Placebo|
11623851|NCT00442026|Experimental|1|DG
11623852|NCT00442026|Experimental|2|G
11623853|NCT00442013|Experimental|Lansoprazole|Participants in this group will receive lansoprazole on a daily basis for 6 months. There are two doses of Lansoprazole solutab provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
11623854|NCT00442013|Placebo Comparator|Matching placebo|Participants in this group will receive a matching placebo on a daily basis for 6 months. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
11623855|NCT00441974|Experimental|Single arm adefovir dipivoxil|adefovir dipivoxil once daily orally 10 mg
11623856|NCT00441935||Interstim Neuromodulation|Subjects undergoing implantation of an Interstim device for neuromodulation.
11623857|NCT00441922|Experimental|1|D
11623858|NCT00441922|Experimental|2|V
11623859|NCT00441909|Experimental|1A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 8 hours
11623860|NCT00441909|Placebo Comparator|1B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 8 hours
11623861|NCT00441909|Experimental|2A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 4 hours
11623862|NCT00441909|Placebo Comparator|2B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 4 hours
11623863|NCT00441909|Experimental|3A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 2 hours
11623864|NCT00441909|Placebo Comparator|3B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 2 hours
11623865|NCT00441909|Experimental|4A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 0 hours
11623866|NCT00441909|Placebo Comparator|4B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 0 hours
11623867|NCT00441896|Experimental|ganaxolone|ganaxolone
11623868|NCT00441896|Placebo Comparator|non-active drug|placebo
11623869|NCT00441883|Experimental|PF-03187207 and Latanoprost Vehicle|One drop of each, once daily in study eye for 28 days
11623870|NCT00441883|Active Comparator|Latanoprost 0.005% and PF-03187207 Vehicle|One drop of each, once daily in study eye for 28 days
11623871|NCT00441792|Experimental|Etomidate|
11623872|NCT00441792|Experimental|midazolam|
11623873|NCT00441779||1|Traumatic injury
11623874|NCT00441779||2|Elective orthopedic surgery
11623875|NCT00441779||3|Burn injury
11623876|NCT00441766|Experimental|AGN 203818 3 mg|Part A: AGN 203818 3mg capsule every 12 hours for 4 weeks
11623877|NCT00441766|Experimental|AGN 203818 20 mg|Part A: AGN 203818 20mg capsule every 12 hours for 4 weeks
11623878|NCT00441766|Experimental|AGN 203818 60 mg|Part A: AGN 203818 60mg capsule every 12 hours for 4 weeks
11623879|NCT00441766|Placebo Comparator|Placebo|Part A: Placebo capsule every 12 hours for 4 weeks
11623880|NCT00441740|Experimental|1|VG
11623881|NCT00441740|Experimental|2|DG
11623882|NCT00441727|Experimental|Esomeprazole 40 mg|Esomeprazole 40 mg
11623883|NCT00441727|Experimental|Esomeprazole 20 mg|Esomeprazole 20 mg
11623884|NCT00441727|Placebo Comparator|Placebo|Placebo
11623885|NCT00441701|Experimental|Part 1: Navarixin 3 mg|Cohort 1: Participants receive navarixin 3 mg (three 1 mg capsules) once daily (QD) for up to 12 weeks
11623886|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 3 mg|Cohort 1: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
11623887|NCT00441701|Experimental|Part 1: Navarixin 10 mg|Cohort 2: Participants receive navarixin 10 mg (one 10 mg capsule and two placebo capsules) QD for up to 12 weeks
11623888|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 10 mg|Cohort 2: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
11623889|NCT00441701|Experimental|Part 1: Navarixin 30 mg|Cohort 3: Participants receive navarixin 30 mg (three 10 mg capsules) QD for up to 12 weeks
11623890|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 30 mg|Cohort 3: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
11623891|NCT00441701|Experimental|Part 2: Navarixin 3 mg|Cohort 4: Participants receive navarixin 3 mg (three 1 mg capsules) QD for up to 12 weeks
11623892|NCT00441701|Experimental|Part 2: Navarixin 10 mg|Cohort 4: Participants receive navarixin 10 mg (one 10 mg capsule and two placebo capsules) QD for up to 12 weeks
11623893|NCT00441701|Experimental|Part 2: Navarixin 30 mg|Cohort 4: Participants receive navarixin 30 mg (three 10 mg capsules) QD for up to 12 weeks
11623894|NCT00441701|Placebo Comparator|Part 2: Placebo to navarixin|Cohort 4: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
11623895|NCT00441688|Experimental|GI265235|
11623896|NCT00441675||Salmeterol/Fluticasone|Previous Salmeterol/Fluticasone treatment
11623897|NCT00441675||Fluticasone|Previous Fluticasone propionate treatment
11623898|NCT00441636|Experimental|CPAP treatment|Continuous Positive Airway Pressure (CPAP)for 4 weeks
11623899|NCT00441636|No Intervention|No CPAP|routine psychiatric care for 4 weeks followed by CPAP titration and initiation after followup measures.
11623900|NCT00441636|No Intervention|Control group|No obstructive sleep apnea detected.
11623901|NCT00441610|Experimental|Gimatecan|
11623902|NCT00441597|Active Comparator|1|first 3 day treatment placebo and 4 weeks later three day treatment with atorvastatin 80 mg
11623903|NCT00441597|Active Comparator|2|first 3 day treatment atorvastatin 80 mg and 4 weeks later three day treatment with placebo
11623904|NCT00441597|No Intervention|3|3 days treatment with placebo twice
11623905|NCT00441584|Experimental|PegIntron plus Rebetol|PegIntron 1.5 μg/kg/week plus Rebetol 800-1400 mg/day administered for 48 weeks
11623906|NCT00441558|Experimental|flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
11623907|NCT00441545|Experimental|1|Fosrenol (Lanthanum carbonate)
11623908|NCT00441545|Active Comparator|2|Sevelamer hydrochloride
11623909|NCT00441480|Active Comparator|Plant sterol esters|plant sterols esterified to fish oil fatty acids
11623910|NCT00441480|Placebo Comparator|placebo|Corn oil
11623911|NCT00441467|Experimental|Glufosfamide|Glufosfamide
11623912|NCT00441454|Active Comparator|A|Retropubic Tension-free Vaginal Tape (TVT)
11623913|NCT00441454|Active Comparator|B|Transobturator Tension-free Vaginal Tape (TVT-O)
11623914|NCT00441441|Experimental|Fluticasone propionate/salmeterol 100/50 HFA|Fluticasone propionate/salmeterol 100/50 HFA (2 inhalations of 50/25mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate 100mcg HFA inhaler (2 inhalations) twice daily
11623915|NCT00441441|Experimental|Fluticasone propionate 100mcg HFA|Fluticasone propionate 100mcg HFA (2 inhalations of 50mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate/salmeterol 100/50 HFA inhaler (2 inhalations ) twice daily
11623916|NCT00441376|Experimental|ThermoDox + RFA|ThermoDox administered as single dose intravenously over 30 minutes in combination with radiofrequency ablation. Dose is determined by dose cohort patient enters study.
11623917|NCT00441363|Active Comparator|Bromocriptine Mesylate|Bromocriptine mesylate 0.8 mg
11623918|NCT00441363|Placebo Comparator|Placebo|Bromocriptine mesylate 0.8 mg matching placebo
11623919|NCT00441350|Active Comparator|OM 40|Olmesartanmedoxomil (OM)40 mg tablets.
11623920|NCT00441350|Experimental|OM/HCTZ 40/12.5|Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets.
11623921|NCT00441337|Experimental|0.3 mg/kg MDX-1106 drug|0.3 milligrams (mg) MDX-1106 drug (nivolumab) per kilogram (kg) of body weight (mg/kg) was administered in a single intravenous (IV) infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
11623922|NCT00441337|Experimental|1 mg/kg MDX-1106 drug|1 mg MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
11623923|NCT00441337|Experimental|3 mg/kg MDX-1106 drug|3 mgs MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
11623924|NCT00441337|Experimental|10 mg/kg MDX-1106 drug|10 mgs MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
11623925|NCT00441311|Experimental|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
11623926|NCT00441311|No Intervention|Service-as-Usual|Control Arm
11623927|NCT00441298|Experimental|1|Tenofovir gel (a reverse transcriptase inhibitor)
11623928|NCT00441298|Placebo Comparator|2|Universal HEC placebo
11623929|NCT00441285|Active Comparator|I. ABZ + ABZ Placebo + PZQ|Albendazole 15 mg / kg / d (until 800 mg / d) + Placebo of Albendazole ( 7.5 mg / Kg / d )+ Praziquantel 50 mg / kg / d (until 3600 mg / d)
11623930|NCT00441285|Active Comparator|II.- ABZ + ABZ Placebo + PZQ Placebo|Albendazole 15 mg / kg / d ( until 800 mg / d ) + Placebo of Albendazole ( 7.5 mg / Kg / d ) + Placebo of Praziquantel ( 50 mg / kg / d )
11623931|NCT00441285|Active Comparator|III .- Albendazole + PZQ Placebo|"Albendazole 22.5 mg / kg / d (until 1200 mg / d) + Placebo of Praziquantel ( 50 mg / kg / d )
~This arm was not used in the first substudy ( initial part and guide to the design of the parent study ) however it will be used henceforward."
11623932|NCT00441259|Experimental|JE-CV Group|Participants will receive Japanese encephalitis chimeric virus vaccine (JE-CV)
11623933|NCT00441259|Active Comparator|MBDV Group|Participants will receive the mouse brain-derived vaccine (MBDV)
11623934|NCT00441220||A|Patients must have lupus nephritis and previously had therapy with intravenous cyclophosphamide.
11623935|NCT00441220||B|Patients must have lupus nephritis and are currently receiving therapy with intravenous cyclophosphamide.
11623936|NCT00441168|Active Comparator|VAD Treatment|vincristine in combination with adriamycin and dexamethasone
11623937|NCT00441168|Experimental|PAD Treatment|bortezomib in combination with adriamycin and dexamethasone
11623938|NCT00441155|Experimental|Monotherapy: AMN107|initial dose of imatinib (dose level 1) was 400 mg bid was administered orally on a continuous daily schedule and was not escalated during the study
11623939|NCT00441155|Active Comparator|Combination Therapy: AMN107 + Imatinib|six possible doses of Nilotinib (100 mg once daily (qd), 200 mg qd, 400 mg qd, 200 mg bid, 300 mg bid, and 400 mg bid). four possible doses of Imatinib (0 mg, 400 mg qd, 600 mg qd, and 400 mg bid).the initial dose of nilotinib (dose level 1) was 200 mg qd and could have been escalated up to 400 mg bid
11623940|NCT00441142|Active Comparator|Phase II: Arm A (Control Group: RT + TMZ)|"The Induction Phase:
~Temozolomide (75 mg/m2 daily for 6 weeks) with concurrent fractionated radiation therapy for approximately 6 weeks (XRT must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy), followed by 4-6 weeks rest.
~Followed by the Maintenance Phase:
~12 cycles of adjuvant temozolomide [at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle; if 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given]."
11623941|NCT00441142|Experimental|Phase I + Phase II: Arm B (RT + TMZ + Vandetanib)|"The Induction Phase:
~ZD6474 (Vandetanib) daily (to begin 5-7 days prior to starting participant's RT) Temozolomide (75 mg/m2 daily for 6 weeks) with concurrent fractionated radiation therapy for approximately 6 weeks (XRT must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy), followed by 4-6 weeks rest.
~Followed by the Maintenance Phase:
~12 cycles of adjuvant temozolomide [at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle; if 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given].
~ZD6474 (Vandetanib) daily for the twelve (12) 28-day cycles of adjuvant temozolomide, with the option to continue until participant experiences an unacceptable toxicity or his/her tumor progresses."
11623942|NCT00441129|Active Comparator|Conventional insulin pump therapy|Conventional insulin pump therapy or continuous subcutaneous insulin infusion (CSII)
11623943|NCT00441129|Experimental|Minimed paradigm Real Time Sytem|Minimed paradigm Real Time Sytem
11623944|NCT00441116|Placebo Comparator|Dutasteride|Dutasteride
11623945|NCT00441103|Experimental|Rebif® New Formulation (IFN-beta-1a, RNF)|
11623946|NCT00441103|Placebo Comparator|Placebo/RNF|
11623947|NCT00441090|Experimental|Avatrombopag tablets|"2.5, 5, 10 or 20 mg tablets
~1 tablet taken orally once daily for 28 days"
11623948|NCT00441090|Placebo Comparator|Placebo tablet|"2.5, 5, 10, or 20 mg tablets
~1 tablet taken orally once daily for 28 days"
11623949|NCT00441064|Experimental|Diet Sequence Low/High Sodium|Patients on low sodium diet ( <= 100 mmol/day) for the first 4 weeks and high sodium (>= 200 mmol/day) diet for the next 4 weeks. [with Aliskiren 300 mg]
11623950|NCT00441064|Experimental|Diet Sequence High/Low Sodium|Patients on high sodium (>= 200 mmol/day) diet for the first 4 weeks and on low sodium diet ( <= 100 mmol/day) for the next 4 weeks. [with Aliskiren 300 mg]
11623951|NCT00441038|Active Comparator|1|Education on postural hygiene and handout of The Back Guide
11623952|NCT00441038|Active Comparator|2|Education on active management and handout of The Back Book
11623953|NCT00441038|Active Comparator|3|Education on cardiovascular and general health
11623954|NCT00441025|Active Comparator|1|1 Alemtuzumab
11623955|NCT00441012|Experimental|1|Modified process Hib/Hep B vaccine
11623956|NCT00441012|Active Comparator|2|COMVAX™
11623957|NCT00440973|Other|treatment arm|PI relocated, currently data is no longer available
11623958|NCT00440947|Other|Simplification|Atazanavir (ATV) 400 mg QD + abacavir (ABC) 600 mg/lamivudine (3TC) 300 mg fixed dose combination (FDC) QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.
11623959|NCT00440947|Other|Continuation|Atazanavir (ATV) 300 mg QD + ritonavir (/r) 100 mg QD + abacavir (ABC) 600mg/lamivuidine (3TC )300 mg FDC QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.
11623960|NCT00440895|Experimental|1 intracoronary + infusion|Bolus abciximab i.c. (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
11623961|NCT00440895|Active Comparator|2 intravenous|Bolus abciximab i.v. (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
11623962|NCT00440895|Placebo Comparator|3 Placebo|Bolus of placebo followed by 12 h infusion (placebo).
11623966|NCT00440856|Experimental|experimental|Participants are given their disc fragments following their operation
11623967|NCT00440843|Experimental|OLZ|
11623968|NCT00440843|Active Comparator|Typicals|
11623969|NCT00440830|Experimental|Smokers-nicotine|Smokers who were treated with nicotine
11623970|NCT00440830|Experimental|Nonsmokers-nicotine|Nonsmokers who were treated with nicotine
11623971|NCT00440830|Placebo Comparator|Smokers-placebo|Smokers who were treated with placebo
11623972|NCT00440830|Placebo Comparator|Nonsmokers-placebo|Nonsmokers who were treated with placebo
11623973|NCT00440817||Patients with lymphoma|Lymphoma Occurring in Patients with Rheumatoid Arthritis or Crohn's Disease
11623974|NCT00440778|Experimental|Gr 1 - intracoronary + infusion|abciximab bolus 0.25 mg/kg ic + 12 hrs iv infusion
11623975|NCT00440778|Experimental|Gr 2 - intracoronary|100% abciximab bolus dose 0.3 mg/kg ic
11623976|NCT00440778|Active Comparator|Gr 3 - intravenous|abciximab bolus dose 0.25 mg/kg iv + 12 hrs iv infusion
11623977|NCT00440778|Experimental|Gr 4 - intravenous|100% abciximab bolus dose 0.3 mg/kg iv
11623978|NCT00440765||001|bortezomib dose as determined (observational study) by treating physician
11623979|NCT00440752||AL|Cohort of study participants receiving treatment with artemether-lumefantrine
11623980|NCT00440739|Placebo Comparator|1|1=placebo
11623981|NCT00440739|Active Comparator|2|2= etoricoxib
11623982|NCT00440739|Active Comparator|3|3=falvoxate
11623983|NCT00440739|Active Comparator|4|etoricoxib and flavoxate
11623984|NCT00440726|Experimental|Ph 1 Dose Escalation|Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. 3+3 escalation design.
11623985|NCT00440726|Experimental|Ph 2 Efficacy and Safety|Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. Patients receive bortezomib at maximum tolerated dose (as established in the Phase 1 portion of the study) and are assessed for response and toxicity.
11623986|NCT00440700|Experimental|Patient-directed music|Patients select preferred music for listening through headphones whenever they like for as long as they like whenever feeling anxious, desire some rest and quiet time, or for listening enjoyment while mechanically ventilated in the ICU.
11623987|NCT00440700|Active Comparator|Headphones|Noise-canceling headphones only (no music) are applied by the patient to block out noise/sound in the ICU whenever desired.
11623988|NCT00440700|Other|Standard of Care|Patients receive usual care for the ICU and are encouraged to self-initiate rest periods twice daily.
11623989|NCT00440674|Experimental|1|Direct stenting technique
11623990|NCT00440674|Experimental|2|Conventional stenting with pre-dilatation strategy
11623991|NCT00440648|Other|1|sevelamer carbonate w(1-8) sevelamer hydrochloride w(9-16)
11623992|NCT00440648|Other|2|sevelamer hydrochloride w(1-8) sevelamer carbonate w(9-16)
11623993|NCT00440622|Experimental|1|GHer
11623994|NCT00440622|Experimental|2|CapHer
11623995|NCT00440609|Active Comparator|0.5mg transitioning to 2.0mg|Ranibizumab-intravitreal injection
11623996|NCT00440609|Active Comparator|1.0 mg transitioning to 2.0mg|Ranibizumab-intravitreal injection
11623997|NCT00440596|Experimental|Mindfulness based stress reduction|Mindfulness based stress reduction
11623998|NCT00440596|Active Comparator|Progressive Muscle Relaxation|Progressive Muscle Relaxation
11623999|NCT00440583|Experimental|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
11624000|NCT00440557|Experimental|TIW: Epoetin alfa 3 injections Weekly/Once Weekly|Participants will be administered with epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)
11624001|NCT00440557|Experimental|QW: Epoetin alfa once weekly|Participants will be administered with epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU).
11624002|NCT00440557|Experimental|Q2W: Epoetin alfa once every two weeks|Participants will be administered with epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU).
11624003|NCT00440544|Experimental|1|100 ug H1 antigen alone in BCG naive subjects
11624004|NCT00440544|Experimental|2|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
11624005|NCT00440544|Experimental|3|50 ug H1 antigen in BCG immunized subjects
11624006|NCT00440544|Experimental|4|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
11624007|NCT00440544|Experimental|5|100 ug H1 antigen in BCG immunized subjects
11624008|NCT00440544|Experimental|6|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
11624009|NCT00440531|Active Comparator|1|RECOMBIVAX HB™
11624010|NCT00440531|Experimental|2|Modified Process Hepatitis B Vaccine
11624011|NCT00440531|Active Comparator|3|ENGERIX-B™
11624012|NCT00440518|Placebo Comparator|Placebo|Placebo
11624013|NCT00440518|Experimental|Lacosamide 100mg|100mg lacosamide
11624014|NCT00440518|Experimental|Lacosamide 300mg|300mg lacosamide
11624015|NCT00440505|Placebo Comparator|Placebo|Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
11624016|NCT00440505|Experimental|Nicotine (5 mg)|Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
11624017|NCT00440505|Experimental|Nicotine (10 mg)|Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
11624018|NCT00440479||001|Bortezomib dose as determined (observational study) by treating physician
11624019|NCT00440466|Experimental|001|epoetin alfa Continue pre-study once weekly dose of epoetin alfa for 36 weeks
11624020|NCT00440466|Experimental|003|epoetin alfa Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
11624021|NCT00440466|Experimental|002|epoetin alfa Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
11624022|NCT00440453|No Intervention|1|Normal hospital food
11624023|NCT00440453|Experimental|2|Nutritional treatment
11624024|NCT00440440|Active Comparator|1|testosterone gel
11624025|NCT00440440|Placebo Comparator|2|placebo gel
11624026|NCT00440414|Experimental|1|Alimta
11624027|NCT00440414|Experimental|2|Tarceva
11624028|NCT00440401|Active Comparator|TachoSil®|
11624029|NCT00440401|Active Comparator|Standard Treatment|Standard Treatment of haemorrhage in cardiovascular surgery
11624030|NCT00440362|Active Comparator|T1|
11624031|NCT00440362|Active Comparator|T2|
11624032|NCT00440362|Active Comparator|T3|
11624033|NCT00440362|Active Comparator|T4|
11624034|NCT00440362|Active Comparator|T5|
11624035|NCT00440362|Active Comparator|T6|
11624036|NCT00440362|Active Comparator|T7|
11624037|NCT00440362|Active Comparator|T8|
11624038|NCT00440362|Placebo Comparator|C1|
11624039|NCT00440362|Placebo Comparator|C2|
11624040|NCT00440362|Placebo Comparator|C3|
11624041|NCT00440362|Placebo Comparator|C4|
11624042|NCT00440323|Experimental|ADBC sequence|In ADBC sequence A is Placebo, B is SB-649868 10 milligram (mg), C is SB-649868 30 mg, and D is Zolpidem 10 mg. Subject will receive placebo tablets, then two 5 mg tablets of SB-649868, then 25 mg and 5 mg tablet of SB-649868. There will be wash-out period of 7 days.
11624043|NCT00440323|Experimental|BACD sequence|In BACD sequence subject will receive SB-649868 two tablets of 5 mg each (10 mg, B), Placebo tablets (A), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), and Zolpidem 10 mg (D). There will be wash-out period of 7 days.
11624044|NCT00440323|Experimental|CBDA sequence|In CBDA sequence subject will receive SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), SB-649868 two tablets of 5 mg each (10 mg, B), Zolpidem 10 mg (D) and Placebo tablet (A). There will be wash-out period of 7 days.
11624045|NCT00440323|Experimental|DCAB sequence|In DCAB sequence subject will receive Zolpidem 10 mg (D), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), Placebo tablet (A), and SB-649868 two tablets of 5 mg each (10 mg, B). There will be wash-out period of 7 days.
11624046|NCT00440310|Experimental|Litx + Chemotherapy|
11624047|NCT00440310|Active Comparator|Chemotherapy alone|
11624048|NCT00440297|Experimental|Modified process hepatitis B vaccine|Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
11624049|NCT00440297|Active Comparator|ENGERIX-B™2|ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
11624050|NCT00440271|Other|Standard of Care (SoC)|Standard of Care (SOC) Arm = Tipranavir/ritonavir (TPV/r) capsules taken orally at a dose of 500 mg/200 mg twice a day (BID) plus optimized background regimen (OBR). No TPV/r dose changes were permitted.
11624051|NCT00440271|Other|Therapeutic Drug Monitoring (TDM)|Therapeutic Drug Monitoring (TDM) Arm = Patients began by receiving standard of care (SOC) tipranavir/ritonavir (TPV/r) capsules orally at a dose of 500 mg/200 mg twice a day (BID) plus optimized background regimen (OBR) followed, if needed, by TPV or ritonavir (RTV) dose adjustments at Week 4, 6, 10, 14, 18, 22, 26 and 30 based on viral response, phenotypic inhibitory quotient (IQ), and TPV trough concentrations.
11624052|NCT00440245|Other|salbutamol|There are two groups, asthma and COPD, which are being compared with respect to bronchoprotection from an active treatment (salbutamol).
11624053|NCT00440232|Experimental|Frovatriptan|5.0 mg of Frovatriptan given as single dose
11624054|NCT00440232|Placebo Comparator|placebo|
11624055|NCT00440219|Experimental|Prednisone group|Prednisone 50 mg daily for 10 days immediately pre-op
11624056|NCT00440219|Placebo Comparator|Placebo group|Placebo pill for 10 days immediately pre-operative
11624057|NCT00440193|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants were to receive rivaroxaban 15 mg oral tablet twice daily for 3 weeks, followed by 20 mg once daily
11624058|NCT00440193|Active Comparator|Enoxaparin/VKA|Participants were to receive 1.0 mg/kg enoxaparin twice daily (subcutaneous) for at least 5 days, plus vitamin K antagonist (VKA) (oral) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 to 3.0)
11624059|NCT00440180|Placebo Comparator|Group B|Placebo
11624060|NCT00440180|Experimental|Group A|Anastrozole
11624061|NCT00440167|Active Comparator|Arm A|
11624062|NCT00440167|Active Comparator|Arm B|
11624063|NCT00440154|Experimental|1|oral administration 5 mg breakfast timing
11624064|NCT00440154|Experimental|2|oral administration 25 mg breakfast timing
11624065|NCT00440154|Experimental|3|oral administration 50 mg breakfast timing
11624066|NCT00440154|Experimental|4|oral administration 100 mg breakfast timing
11624067|NCT00440154|Experimental|5|oral administration 25 mg dinner timing
11624068|NCT00440154|Placebo Comparator|6|oral administration
11624069|NCT00440154|Active Comparator|7|oral administration 10mg breakfast timing
11624070|NCT00440141|Experimental|1|
11624071|NCT00440141|Active Comparator|2|
11624072|NCT00440128|Active Comparator|Docetaxel|Docetaxel
11624073|NCT00440128|Experimental|Docetaxel/Casopitant|Docetaxel/Casopitant
11624074|NCT00440115|Experimental|High intensity disease management|High intensity disease management, free nicotine replacement therapy or bupropion
11624075|NCT00440115|Experimental|Low intensity disease management|Low intensity disease management, free nicotine replacement therapy or bupropion
11624076|NCT00440115|Other|Comparison group|Comparison group, free nicotine replacement therapy or bupropion
11624077|NCT00440102|Active Comparator|1|ketamine
11624078|NCT00440102|Active Comparator|2|Etomidate
11624079|NCT00440050|Experimental|1.|DHA
11624080|NCT00440050|Placebo Comparator|2.|Placebo
11624081|NCT00440037|Experimental|AMG 531|
11624082|NCT00440024|Experimental|Cell A|Study controlled daily skin care regimen during 'rest period' consisting of Dove Mild Cleanser, Dove Facial Moisturizer with SPF 15 followed by Tazorac
11624083|NCT00440024|Placebo Comparator|Cell B|Subject controlled normal skin care regimen during 'rest period, followed by study controlled daily skin care regime consisting of Dove Mild Cleanser, Dove Facial Moisturizer with SPF 15 followed by Tazorac
11624084|NCT00440011|Experimental|1|
11624085|NCT00440011|Active Comparator|2|
11624086|NCT00439985|Other|Behavioral: Cognitive Behavior Therapy|
11624087|NCT00439972|Active Comparator|Group 1|Visits 2-6: Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: extended use of Ortho Evra (R)
11624088|NCT00439972|Active Comparator|Group 2|Visits 2-6: Ortho Evra (R) Visits 6-11: extended use Ortho Evra (R) Visits 11-15: Ortho Cyclen (R)
11624089|NCT00439972|Active Comparator|Group 3|Visits 2-6: Ortho Cyclen (R) Visits 6-11: Ortho Evra (R) Visits 11-15: extended use of Ortho Evra (R)
11624090|NCT00439972|Active Comparator|Group 4|Visits 2-6: Ortho Cyclen (R) Visits 6-11: extended use of Ortho Evra (R) Visits 11-15: Ortho Evra (R)
11624091|NCT00439972|Active Comparator|Group 5|Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Evra (R) Visits 11-15: Ortho Cyclen (R)
11624092|NCT00439972|Active Comparator|Group 6|Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: Ortho Evra (R)
11624093|NCT00439946|Experimental|treprostinil|IV treprostinil continuous infusion via Crono Five infusion pump.
11624094|NCT00439920|Experimental|High-dose anthracycline|
11624095|NCT00439907|Active Comparator|End-to-end|End-to-end repair
11624096|NCT00439907|Active Comparator|Overlap|Overlap repair
11624097|NCT00439894||blood draw|One time blood draw
11624098|NCT00439868|Experimental|Treatment Group 1|Subjects in Period 1 of treatment group 1 will receive oral doses of extended release WELLBUTRIN XL tablets for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD. In Period 2 subject will receive placebo for 2 weeks.
11624099|NCT00439868|Experimental|Treatment Group 2|Subjects in Period 1 of Treatment group 2 will receive Placebo for 2 weeks and in Period 2 subject will receive oral doses of extended release WELLBUTRIN XL for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD.
11624100|NCT00439842|Experimental|HF group clinic appointments|HF group clinic appointments Heart failure multidisciplinary group clinic appointments (Arm 1 - HFcareGroup) includes 6 teaching sessions with patients led by nurse practitioner.
11624101|NCT00439842|No Intervention|Standard HF care|Standard HF care Standard heart failure education includes cardiologists instructions and hospital discharge information.
11624102|NCT00439829|Experimental|1|Initiation of ovarian stimulation therapy on day 1 (i.e., first day of menses)
11624103|NCT00439829|Active Comparator|2|Initiation of ovarian stimulation therapy on day 4 (day 1= first day of menses)
11624104|NCT00439816|Other|Arm 1|
11624105|NCT00439803|Active Comparator|T1|
11624106|NCT00439803|Placebo Comparator|C1|
11624107|NCT00439803|Active Comparator|T2|
11624108|NCT00439803|Placebo Comparator|C2|
11624109|NCT00439803|Active Comparator|T3|
11624110|NCT00439803|Placebo Comparator|C3|
11624111|NCT00439803|Active Comparator|T4|
11624112|NCT00439803|Placebo Comparator|C4|
11624113|NCT00439777|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)
11624114|NCT00439777|Active Comparator|Enoxaparin/VKA|Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)
11624115|NCT00439764|Active Comparator|1|Routine clinical practice and talk on general health
11624116|NCT00439764|Active Comparator|2|Talk on back health and handout of The Back Book
11624117|NCT00439764|Active Comparator|3|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
11624118|NCT00439751|Other|Immediate ADT|
11624119|NCT00439751|Other|Deferred ADT|
11624120|NCT00439738|Experimental|valsartan/HCTZ|
11624121|NCT00439738|Active Comparator|HCTZ +Amlodipine|
11624122|NCT00439725|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants were to receive rivaroxaban 20 mg oral tablet once daily
11624123|NCT00439725|Placebo Comparator|Placebo|Participants were to receive matching placebo oral tablet once daily
11624124|NCT00439712|Experimental|Treatment Group 1|
11624125|NCT00439712|Placebo Comparator|Treatment Group 2|
11624126|NCT00439699|Experimental|Memantine|Tremor reduction
11624127|NCT00439686|Experimental|Single Arm|
11624128|NCT00439647|Experimental|Zoledronic Acid|5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.
11624129|NCT00439647|Placebo Comparator|Placebo|100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The i.v. infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.
11624130|NCT00439634|Placebo Comparator|Placebo|
11624131|NCT00439634|Experimental|AVE1625 dose level 1|
11624132|NCT00439634|Experimental|AVE1625 dose level 2|
11624133|NCT00439634|Experimental|AVE1625 dose level 3|
11624134|NCT00439621|Experimental|1|
11624135|NCT00439621|Experimental|2|
11624136|NCT00439621|Experimental|3|
11624137|NCT00439621|Placebo Comparator|4|
11624138|NCT00439608|Experimental|Treatment|Cetuximab, paclitaxel, and carboplatin weekly for 6 weeks with 50.4 Gy radiation.
11624139|NCT00439595|Experimental|1|Hemocue 210 meter
11624140|NCT00439595|Experimental|2|Copack HBCS
11624141|NCT00439595|No Intervention|3|Control
11624142|NCT00439582|Experimental|1|
11624143|NCT00439582|Experimental|2|
11624144|NCT00439569|Experimental|Single Arm|Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first three subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The dosage of the next cohort was determined by the Modified Continual Re-assessment Method (MCRM) calculation and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage.
11624598|NCT00434876|Experimental|1|Quetiapine XR
11624145|NCT00439556|Experimental|Treatment (chemotherapy, transplant, filgrastim, tacrolimus)|See Detailed Description
11624146|NCT00439517|Experimental|1|UFOX + Cetuximab
11624147|NCT00439517|Active Comparator|2|FOLFOX4 + Cetuximab
11624148|NCT00439465|Other|Ex-vivo expanded effector cells|Infusing IL-2 and GM-CSF post-Hematopoietic Stem Cell Transplant (HSCT)
11624149|NCT00439452|Active Comparator|Telemedicine-Based Collaborative Care|Telemedicine-Based Collaborative Care - Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
11624150|NCT00439452|Active Comparator|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
11624151|NCT00439439|Sham Comparator|A|Sham Procedure
11624152|NCT00439439|Active Comparator|B|Verum Beamer ablation of heterotopic gastric mucosa
11624153|NCT00439426|Experimental|1|
11624154|NCT00439413|Active Comparator|Selegiline Transdermal Patch|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -4 week Screening/Baseline Phase.
~During treatment, subjects received Selegiline Transdermal System, 6mg -20cm(2) patch, one time per day for 9 weeks
~Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks"
11624155|NCT00439413|Placebo Comparator|Placebo|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -4 week Screening/Baseline Phase.
~During treatment, subjects received matched placebo 20cm(2) patch transdermal patch one time per day for 9 weeks
~Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks"
11624156|NCT00439400|Active Comparator|A|
11624157|NCT00439400|Placebo Comparator|B|
11624158|NCT00439374|Active Comparator|17 alpha-hydroxyprogesterone caproate|250 mg of 17 alpha-hydroxyprogesterone caproate given by weekly injection until 37 weeks gestation or delivery
11624159|NCT00439374|Placebo Comparator|Placebo|Placebo oil given by weekly injection until 37 weeks gestation or delivery.
11624160|NCT00439361|Experimental|Bortezomib + ICE|"Bortezomib + ICE (Ifosfamide, Carboplatin, Etoposide):
~Bortezomib 1.0 mg/m^2 intravenous (IV) over 5 Seconds on Days 1 and 4; + ICE (Ifosfamide 5 Gm/m^2 IV continuous infusion on Day 1, Carboplatin 5 AUC IV over 1 Hour Day 1, Etoposide 100 mg/m^2 IV over 2 Hours Days 1-3) + Mesna 5 mg/m^2 IV continuous infusion Day 1; 2 Gm/m^2 IV continuous infusion over 12 Hours."
11624161|NCT00439348|Experimental|Electronic prescription|Patients receive a prescription for specific over-the-counter medications.
11624162|NCT00439348|Active Comparator|Verbal advice|
11624163|NCT00439335|Experimental|H5 HA IM|Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.
11624164|NCT00439335|Experimental|H5 HA ID|Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.
11624165|NCT00439322||Group 1|
11624166|NCT00439309|Experimental|VascuSeal|Consists of two liquids that when mixed together in situ rapidly cross-link to form a biocompatible absorbable sealant that is tissue adherent. These liquids are sprayed onto tissues using the Dual Liquid Applicator. The formed Sealant remains intact for approximately 2 to 7 days. During this period the Sealant undergoes hydrolysis where it is absorbed into the circulatory system and is excreted through the kidneys.
11624167|NCT00439309|Active Comparator|GELFOAM/THROMBIN|GELFOAM/THROMBIN description - GELFOAM Sterile Compressed Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified porcine Skin Gelatin USP Granulates and Water for Injection, USP. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids. Although not necessary, GELFOAM can be used either with or without thrombin to obtain hemostasis.
11624168|NCT00439296|Experimental|Dose Level 1|"Treatment Dose of ABT-751 is 80 mg/m2/day
~Tx Course 1:
~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate
~Tx Course 2:
~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751
~Tx Courses 3-12 (maintenance courses):
~• ABT-751, IT Methotrexate"
11624169|NCT00439296|Experimental|Dose Level 2|"Treatment Dose of ABT-751 is 100 mg/m2/day
~Tx Course 1:
~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate
~Tx Course 2:
~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751
~Tx Courses 3-12 (maintenance courses):
~• ABT-751, IT Methotrexate"
11624170|NCT00439296|Experimental|Dose Level 3|"Treatment Dose of ABT-751 is 125 mg/m2/day
~Tx Course 1:
~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate
~Tx Course 2:
~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751
~Tx Courses 3-12 (maintenance courses):
~• ABT-751, IT Methotrexate"
11624171|NCT00439296|Experimental|Dose Level 4|"Treatment Dose of ABT-751 is 150 mg/m2/day
~Tx Course 1:
~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate
~Tx Course 2:
~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751
~Tx Courses 3-12 (maintenance courses):
~• ABT-751, IT Methotrexate"
11624172|NCT00439296|Experimental|Dose Level 5|"Treatment Dose of ABT-751 is 175 mg/m2/day
~Tx Course 1:
~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate
~Tx Course 2:
~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751
~Tx Courses 3-12 (maintenance courses):
~• ABT-751, IT Methotrexate"
11624173|NCT00439296|Experimental|Dose Level 0|"Treatment Dose of ABT-751 is 65 mg/m2/day
~Tx Course 1:
~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate
~Tx Course 2:
~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751
~Tx Courses 3-12 (maintenance courses):
~• ABT-751, IT Methotrexate"
11624599|NCT00434876|Placebo Comparator|2|Placebo
11624174|NCT00439296|Experimental|Dose Level -1|"Treatment Dose of ABT-751 is 50 mg/m2/day
~Tx Course 1:
~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate
~Tx Course 2:
~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751
~Tx Courses 3-12 (maintenance courses):
~• ABT-751, IT Methotrexate"
11624175|NCT00439270|Active Comparator|Dasatinib, 50 mg + Docetaxel, 60 mg/m^2|Participants received dasatinib, 50 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 60 mg/m^2.
11624176|NCT00439270|Active Comparator|Dasatinib, 50 mg + Doxetaxel, 75 mg/m^2|Participants received dasatinib, 50 mg administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
11624177|NCT00439270|Active Comparator|Dasatinib, 70 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 70 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
11624178|NCT00439270|Active Comparator|Dasatinib, 100 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 100 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
11624179|NCT00439270|Active Comparator|Dasatinib, 120 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 120 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
11624180|NCT00439257||Group 1|
11624181|NCT00439244|Active Comparator|Zoledronic acid plus teriparatide|Zoledronic acid 5.0 mg/100 mL was administered via a peripheral intravenous site at Visit 2 (once at randomization) as a slow 15-minute infusion. Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. The pen device delivers 20 μg of teriparatide concurrently as daily subcutaneous injections for 52 weeks.
11624182|NCT00439244|Experimental|Zoledronic acid|Zoledronic acid 5.0 mg/100 mL was administered via a peripheral intravenous site at Visit 2 (once at randomization) as a slow 15-minute infusion.
11624183|NCT00439244|Active Comparator|Placebo zoledronic acid plus teriparatide|Placebo zoledronic acid 100 mL intravenous (i.v.) (once at randomization) plus teriparatide 20 μg (daily subcutaneous injections administered concurrently through 52 weeks). Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. The pen device delivers 20 μg of teriparatide concurrently as daily subcutaneous injections for 52 weeks.
11624184|NCT00439231|Experimental|Lenalidomide (Revlimid) subjects|Lenalidomide regimen testing to determine efficacy for CLL/ SLL subjects
11624185|NCT00439218|Experimental|Subject Enrollments|Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first three subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The dosage of the next cohort was determined by the Modified Continual Re-assessment Method (MCRM) approach and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage.
11624186|NCT00439205||MDM + FastEEM4|Multispectral digital microscope (MDM) + FastEEM4 Systems
11624187|NCT00439179|Experimental|Cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
11624188|NCT00439179|Experimental|Cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
11624189|NCT00439179|Experimental|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
11624190|NCT00439179|Experimental|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
11624191|NCT00439166|Experimental|1 AD combined doxycycline + rifampin|Doxycycline 100 mg b.i.d. plus rifampin 300 mg o.d. for 12 months.
11624192|NCT00439166|Experimental|2 AD Doxycycline only|Doxycycline 100 mg b.i.d. plus placebo matched to rifampin o.d. for 12 months.
11624193|NCT00439166|Experimental|3 Rifampin only|Rifampin 300 mg o.d. plus placebo matched to doxycycline b.i.d. for 12 months.
11624194|NCT00439166|Placebo Comparator|4 Double Placebo|Placebo matched to Doxycycline b.i.d. plus placebo matched to rifampin o.d. for 12 months.
11624195|NCT00439140|Experimental|botulinum toxin Type A 200U|Botulinum toxin Type A 200U injection into the detrusor on Day 1 followed by a repeat botulinum toxin Type A 200U injection after a minimum of 12 weeks (if applicable).
11624196|NCT00439140|Experimental|botulinum toxin Type A 300U|Botulinum toxin Type A 300U injection into the detrusor on Day 1 followed by a repeat botulinum toxin Type A 300U injection after a minimum of 12 weeks (if applicable).
11624197|NCT00439140|Other|Placebo/botulinum toxin Type A 200U|Placebo (Normal Saline) injection into the detrusor on Day 1 followed by a botulinum toxin Type A 200U injection after a minimum of 12 weeks (if applicable).
11624198|NCT00439140|Other|Placebo/botulinum toxin Type A 300U|Placebo (Normal Saline) injection into the detrusor on Day 1 followed by a botulinum toxin Type A 300U injection (200U after discontinuation of 300U) after a minimum of 12 weeks (if applicable).
11624199|NCT00439101|Experimental|1|
11624200|NCT00439101|Placebo Comparator|2|Placebo
11624201|NCT00439075|Experimental|CPAP|positive airway pressure
11624202|NCT00439075|Active Comparator|standard medical therapy|conventional oxygen therapy
11624203|NCT00439049||A|Cocaine Dependent Subjects
11624204|NCT00439036|Experimental|Behavior Therapy: Acceptance and Commitment Therapy|"The Act-ODT intervention consists of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
~--------------------------------------------------------------------------------"
11624205|NCT00439036|Active Comparator|Drug Counseling|The Drug Counseling intervention consists of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
11624206|NCT00438984|Experimental|Treatment (chemotherapy, immunosuppressive, lymphocytes)|"All patients receive high-dose cyclophosphamide IV on days -3 and -2 and autologous antigen-specific cytotoxic CD8+ T-lymphocyte clones IV over 30-60 minutes on day 0.
~COHORT I: Beginning within 6 hours of T cell infusion, patients receive low-dose aldesleukin SC twice daily on days 0-14.
~COHORT II: Beginning within 6 hours of T cell infusion, patients receive high-dose aldesleukin IV 3 times daily on days 0-5."
11624207|NCT00438971|Experimental|Duloxetine|
11624208|NCT00438958|Active Comparator|Arm I|Patients undergo filgrastim (G-CSF)-mobilized sibling donor peripheral blood SCT on day 0.
11624209|NCT00438958|Experimental|Arm II|Patients undergo G-CSF-mobilized sibling donor bone marrow transplantation on day 0.
11624210|NCT00438932|Active Comparator|Lanthanum Carbonate and Low Phosphorus Diet|25% of subjects will receive binders plus a phosphate restricted diet.
11624211|NCT00438932|Active Comparator|Lanthanum Carbonate and Unrestricted Phosphorus Diet|25% binders + unrestricted phosphate diet.
11624212|NCT00438932|Active Comparator|Placebo and Low Phosphorus Diet|25% placebo + phosphate restricted diet.
11624213|NCT00438932|Active Comparator|Placebo and Unrestricted Phosphorus Diet|25% placebo + unrestricted phosphate diet.
11624214|NCT00438919|Experimental|1|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
11624215|NCT00438893|Other|A portfolio of cholesterol-lowering foods|Dietary advice to consume a dietary portfolio of cholesterol-lowering foods
11624216|NCT00438880|Experimental|Arm I|See Detailed Description
11624217|NCT00438867|Experimental|1|
11624218|NCT00438867|Experimental|2|
11624219|NCT00438867|Placebo Comparator|3|
11624220|NCT00438854|Experimental|Dasatinib treatment|All patients were treated with dasatinib pills by mouth as treatment.
11624221|NCT00438828|Experimental|Dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
11624222|NCT00438815|Experimental|Open-label C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously. If there was no response to treatment 60 minutes after the first dose, a second 1,000 U dose could be administered.
11624223|NCT00438802|Experimental|alefacept|Determine both the maximum tolerated dose level as well as the optimal immunologic dose and toxicity.
11624224|NCT00438776|Active Comparator|olanzapine|active zyprexa (olanzapine)
11624225|NCT00438776|Placebo Comparator|sugar pill|Placebo (fake pill)
11624226|NCT00438763||1|Subjects using the neoprene splint.
11624227|NCT00438763||2|Subjects using the orthoplast splint.
11624228|NCT00438750|Experimental|Independent Home Exercises|Subjects who learn their therapy exercises from the surgeon and practice them independently at home.
11624229|NCT00438750|Experimental|Formal Therapy|Subjects who follow the conventional protocol of seeing a therapist to learn and guide them in their exercises.
11624230|NCT00438698|Experimental|Low Glycemic Index Diet|Diet with low glycemic index carbohydrates
11624231|NCT00438698|Active Comparator|High Fiber Diet|Diet with high cereal fibre choices
11624232|NCT00438672|Active Comparator|Dequervains|The de Quervain's injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and DeQuervain's is also fairly uncommon. Therefore, the trial wasn't feasible for this diagnosis.
11624233|NCT00438672|Active Comparator|Lateral Epicondylitis|
11624234|NCT00438672|Active Comparator|CMC Arthritis|The CMC Arthritis injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and it was decided that the trial wasn't feasible for this diagnosis.
11624235|NCT00438659|Experimental|Mometasone|Patients apply 2.5 mL mometasone furoate cream once daily to the treatment area (breast or chest wall) for the duration of planned radiotherapy.
11624236|NCT00438659|Placebo Comparator|Placebo|Patients apply 2.5 mL of an identical-appearing placebo cream to the treatment area as in arm I.
11624237|NCT00438633||Early Therapy|Subjects who begin therapy immediately after diagnosis of injury.
11624238|NCT00438633||Late Therapy|Subjects who delay therapy for 3 weeks after diagnosis of injury.
11624239|NCT00438607|Other|1|BIIB014 at MTD from Part A
11624240|NCT00438607|Other|2|BIIB014 at dose immediately below MTD from Part A
11624241|NCT00438607|Placebo Comparator|3|
11624242|NCT00438594|No Intervention|Control group|Control group
11624243|NCT00438594|Experimental|Paraprofessional home visits|home visitation by Paraprofessional
11624244|NCT00438594|Experimental|Nurse home visits|home visitation by Nurse
11624245|NCT00438568|Placebo Comparator|1|saline
11624246|NCT00438568|Experimental|2|10 Units
11624247|NCT00438568|Experimental|3|20 Units
11624248|NCT00438555|Experimental|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
11624249|NCT00438555|Experimental|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
11624250|NCT00438555|No Intervention|Control group|control group, no intervention, medical follow up only
11624251|NCT00438516|No Intervention|1|Control group
11624252|NCT00438516|Experimental|2|Nurse home visitation
11624253|NCT00438490|Experimental|recombinant human prolactin|Recombinant Human Prolactin 60 mcg/kg once daily subcutaneous injection
11624254|NCT00438490|Placebo Comparator|Placebo|Normal saline placebo subcutaneous injection
11624255|NCT00438477|Experimental|Injection Methods|One injection site with radioactive tracer intraparenchymal/peritumoral (around the tumor), and other subareolar (around the nipple)
11624256|NCT00438464|Experimental|Arm I (Finasteride)|Finasteride 5 mg once daily for 4-6 weeks, then undergo prostatectomy.
11624257|NCT00438464|Placebo Comparator|Arm II (Placebo)|Placebo once daily for 4-6 weeks, then undergo prostatectomy.
11624258|NCT00438451|Active Comparator|Levetiracetam|Levetiracetam
11624259|NCT00438451|Active Comparator|Carbamazepine|Carbamazepine
11624260|NCT00438451|Active Comparator|Lamotrigine|Lamotrigine
11624261|NCT00438425|Experimental|Intensive Portfolio|The portfolio dietary advice will conform to current therapeutic diets appropriate for hypercholesterolemic subjects (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal. Participants received 7 visits during a 6-month period with the study dietitian.
11624383|NCT00437229|Experimental|Subjects in Part B|In PART B, subjects received Regimen D: oral casopitant alone (150 mg QD Day 1, 50 mg QD Days 2 and 3); Regimen E: IV dexamethasone (8 mg single-dose Day 1 only) and oral ondansetron (8 mg BID Days 1 to 3); and Regimen F: oral casopitant regimen as in Regimen D, and IV dexamethasone and oral ondansetron as in Regimen E.
11624262|NCT00438425|Experimental|Routine Portfolio|The portfolio dietary advice will conform to current therapeutic diets appropriate for hypercholesterolemic subjects (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal. Participants received 2 visits during a 6-month period with the study dietitian.
11624263|NCT00438425|Active Comparator|Control|Advice focused on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
11624264|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 1|"Clobetasol propionate Shampoo:
~Dose or Concentration: Clobetasol propionate 0.05% shampoo
~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes
~Duration of Treatment: 4 weeks as a maximum
~Wash-out up to 8 weeks
~Corticosteroid 1:
~Dose or Concentration: Corticosteroid 1 Foam
~Mode and Frequency of Administration:Twice daily, a golf-ball sized amount to be massaged into the affected area of the scalp
~Duration of Treatment: 4 weeks as a maximum"
11624265|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 2|"Clobetasol propionate Shampoo:
~Dose or Concentration: Clobetasol propionate 0.05% shampoo
~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes
~Duration of Treatment: 4 weeks as a maximum
~Corticosteroid 2:
~Dose or Concentration: Corticosteroid 2 Lotion
~Mode and Frequency of Administration: Twice daily, a thin film to be applied to the affected area of the scalp and massaged gently and thoroughly into the skin
~Duration of Treatment: 4 weeks as a maximum"
11624266|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 3|"Clobetasol propionate Shampoo:
~Dose or Concentration: Clobetasol propionate 0.05% shampoo
~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes
~Duration of Treatment: 4 weeks as a maximum
~Corticosteroid 3:
~Dose or Concentration: Corticosteroid 3 Scalp application
~Mode and Frequency of Administration: Twice daily, a thin film to be applied into the affected area of the dry scalp and rubbed gently into the scalp
~Duration of Treatment: 4 weeks as a maximum"
11624267|NCT00438399|Active Comparator|Corticosteroid 1-Wash out-C. propionate|"Clobetasol propionate Shampoo:
~Dose or Concentration: Clobetasol propionate 0.05% shampoo
~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes
~Duration of Treatment: 4 weeks as a maximum
~Corticosteroid 1:
~Dose or Concentration: Corticosteroid 1 Foam
~Mode and Frequency of Administration:Twice daily, a golf-ball sized amount to be massaged into the affected area of the scalp
~Duration of Treatment: 4 weeks as a maximum"
11624268|NCT00438399|Active Comparator|Corticosteroid 2-Wash out-C. propionate|"Clobetasol propionate Shampoo:
~Dose or Concentration: Clobetasol propionate 0.05% shampoo
~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes
~Duration of Treatment: 4 weeks as a maximum
~Corticosteroid 2:
~Dose or Concentration: Corticosteroid 2 Lotion
~Mode and Frequency of Administration: Twice daily, a thin film to be applied to the affected area of the scalp and massaged gently and thoroughly into the skin
~Duration of Treatment: 4 weeks as a maximum"
11624269|NCT00438399|Active Comparator|Corticosteroid 3-Wash out-C. propionate|"Clobetasol propionate Shampoo:
~Dose or Concentration: Clobetasol propionate 0.05% shampoo
~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes
~Duration of Treatment: 4 weeks as a maximum
~Corticosteroid 3:
~Dose or Concentration: Corticosteroid 3 Scalp application
~Mode and Frequency of Administration: Twice daily, a thin film to be applied into the affected area of the dry scalp and rubbed gently into the scalp
~Duration of Treatment: 4 weeks as a maximum"
11624270|NCT00438360|Active Comparator|Cyclosporine A|Oral soft gelatin capsules of cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
11624271|NCT00438360|Placebo Comparator|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
11624272|NCT00438347||group 1|Intervention Group- aerobic exercise
11624273|NCT00438347||group 2|Control Group- stretching and toning
11624274|NCT00438321|Placebo Comparator|Placebo|Placebo injection, gel and pill
11624275|NCT00438321|Active Comparator|Testosterone only|Zoladex 3.6 mg IM injection Testosterone 7.5 g gel (AndroGel) transdermally daily Anastrozole 10 mg (Arimidex) orally daily
11624276|NCT00438321|Active Comparator|Testosterone and Estrogen|Zoladex 3.6 mg IM injection Testosterone 7.5 g gel (AndroGel) transdermally Placebo pill orally daily
11624277|NCT00438308||1|Subjects who begin therapy immediately after fracture.
11624278|NCT00438308||2|Subjects delay therapy for 3 weeks after injury.
11624279|NCT00438282|No Intervention|1|Control group
11624280|NCT00438282|Experimental|2|Paraprofessional home visits
11624281|NCT00438282|Experimental|3|Nurse home visitation
11624282|NCT00438256|Experimental|Group 1|10 Radiation Sessions over 2 weeks
11624283|NCT00438256|Experimental|Group 2|5 Radiation sessions: 3 in week 1 and 2 in week 2
11624284|NCT00438256|Experimental|Group 3|5 Radiation sessions: 4 in week 1 and 1 in week 2
11624285|NCT00438256|Experimental|Group 4|5 Radiation Sessions in one week
11624286|NCT00438243|Placebo Comparator|1|1 drop affected eye twice daily.
11624287|NCT00438243|Experimental|2|Bromfenac (Xibrom) 1 drop to affected eye twice a day.
11624288|NCT00438204|Experimental|Bevacizumab, gemcitabine hydrochloride|"Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days
~Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed disodium every 14 days
~Pemetrexed 400 mg/m2 intravenously over 10 minutes every 14 days."
11624289|NCT00438191||1|Subjects who wear the splint whenever the feel the need.
11624290|NCT00438191||2|Subjects who wear the splint whenever possible.
11624291|NCT00438165|No Intervention|1|Control group
11624292|NCT00438165|Experimental|2|Nurse home visits
11624293|NCT00438152|Active Comparator|Invirase® tablets|
11624294|NCT00438152|Active Comparator|Kaletra® tablets|
11624384|NCT00437216||1|Monotherapy - Subjects who are not currently being treated with anti-psoriatic medication and start using Clobex®
11624295|NCT00438113|Active Comparator|Aggressive Blood Pressure control|"The experimental arm will receive open label therapy to achieve a target systolic blood pressure less than or equal to 120 mmHg.
~If the average BP is found to be > 120 mmHg at the baseline, telephone or clinic followup visits, treatment will be recommended based on the following regimen (For details, please see Appendix 4):
~Step 1 - Accupril, titrated to maximum tolerated dose, beginning at 20 mg po od followed by 40 mg successively Step 2 - combination of Accupril with Hydrochlorothiazide 12.5 mg po od. Step 3 - Addition of Atenolol 50 mg po od. Step 4 - Addition of Norvasc 2.5-10 mg po od. Step 5 - Addition of Terazosin 1 mg po od."
11624296|NCT00438113|No Intervention|Standard Blood Pressure control|Treatment will be carried out as per the CHEP guidelines. These patients may require ACEi or ARBs for their treatment. No changes to their drug regimen will be made as long as BP measurements are congruent with current guidelines. These modifications will be made as per standard practice by the physician who is primarily involved with their care (this may be a family physician or a specialist, depending on the patient). Patients with diabetes in the standard arm will be treated to a target BP of <130/80 as per the CHEP guidelines.
11624297|NCT00438100|Active Comparator|Capecitabine arm|Capecitabine (Xeloda): 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
11624298|NCT00438100|Experimental|S-1 arm|S-1: 80 mg/m2 orally bid daily for day 1 through day28 followed by 14-day washout; repeat this as a course.
11624299|NCT00438087|Placebo Comparator|2|placebo versus methylprednisolone
11624300|NCT00438087|Experimental|1|placebo versus methylprednisolone
11624301|NCT00438048|Active Comparator|a,b|Compare Pilocarpine and Artificial saliva
11624302|NCT00438022||1|Group 1 will include participants with AD, EH, and recurrent herpes simplex virus (HSV)
11624303|NCT00438022||2|Group 2 will include participants with AD and recurring HSV infections but without EH
11624304|NCT00438022||3|Group 3 will include participants with AD but without EH or HSV infection
11624305|NCT00438022||4|Group 4 will include participants in good general health without AD, EH, or HSV infection
11624306|NCT00438009|Experimental|CAVATAK|
11624307|NCT00437983|Active Comparator|PS-Omega3|Phosphatidylserine-Omega3, 300mg/day 15 wk
11624308|NCT00437983|Placebo Comparator|Placebo|Cellulose tainted with fishy odor, 3 capsules/day
11624309|NCT00437970|Active Comparator|A|Arm A- Metformin
11624310|NCT00437970|Active Comparator|B|Arm B- Pioglitazone
11624311|NCT00437957|Experimental|Temazolomide, Valproic Acid and Radiation|Temazolomide, Valproic Acid and Whole Brain Radiation Therapy
11624312|NCT00437931||A|patients with subclinical hypothyroidism
11624313|NCT00437931||B|patients with subclinical hyperthyroidism
11624314|NCT00437931||C|patient with normal thyroid function.
11624315|NCT00437892|Experimental|Atorvastatin and lipid lowering diet|
11624316|NCT00437892|Active Comparator|lipid lowering diet|
11624317|NCT00437840|Experimental|Treatment Arm A|In Arm A dosing subject will receive Placebo in Week 1, 10 milligram (mg) of GSK598809 in Week 2, 25 mg of GSK598809 in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
11624318|NCT00437840|Experimental|Treatment Arm B|In Arm B dosing subject will receive 10 mg of GSK598809 in Week 1, Placebo in Week 2, 25 mg of GSK598809 in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
11624319|NCT00437840|Experimental|Treatment Arm C|In Arm C dosing subject will receive 10 mg of GSK598809 in Week 1, 25 mg of GSK598809 in Week 2, Placebo in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
11624320|NCT00437840|Experimental|Treatment Arm D|In Arm D dosing subject will receive 10 mg of GSK598809 in Week 1, 25 mg of GSK598809 in Week 2, 75 mg of GSK598809 in Week 3, Placebo in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
11624321|NCT00437827|Active Comparator|1|Each subject in this arm will receive depression therapy similar to that used by the Star*D study - a major depression study conducted in the United States (Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Am J Psychiatry 2006; 163:1905-1917)
11624322|NCT00437827|Experimental|2|Each subject in this arm will receive therapy based upon an individualized rEEG report which provides one or more treatment options with the highest probability of success.
11624323|NCT00437762|Experimental|1|Botulinum Toxin A Injection
11624324|NCT00437762|Placebo Comparator|2|Placebo injection
11624325|NCT00437749|Active Comparator|CBT-1|
11624326|NCT00437749|Placebo Comparator|Placebo|
11624327|NCT00437736|Experimental|Single arm dose escalation|
11624328|NCT00437723|Experimental|1|
11624329|NCT00437723|No Intervention|2|
11624330|NCT00437684|Experimental|A|LPV/r: LPV/r monotherapy and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
11624331|NCT00437684|Active Comparator|B|LPV/r+ selected NUCS and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
11624332|NCT00437671|Experimental|Entered study|
11624333|NCT00437658|Experimental|Elagolix 75 mg BID|Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12.
11624334|NCT00437658|Experimental|Elagolix 150 mg QD|Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12.
11624335|NCT00437658|Active Comparator|DMPA-SC|Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12.
11624528|NCT00435708|No Intervention|1|
11624336|NCT00437645|Experimental|Valsartan/amlodipine 160/5 mg|Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.
11624337|NCT00437645|Active Comparator|Amlodipine 10 mg|Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.
11624338|NCT00437632|Experimental|Subjects in Cohort-1 of Section 1|Subjects will be randomized to receive either GSK598809 10 mg or Placebo.
11624339|NCT00437632|Experimental|Subjects in Cohort-2 of Section 1|Subjects will be randomized to receive either GSK598809 25 mg or Placebo.
11624340|NCT00437632|Experimental|Subjects in Cohort-3 of Section 1|Subjects will be randomized to receive either GSK598809 25 mg or Placebo.
11624341|NCT00437632|Experimental|Subjects in Cohort-4 of Section 1|Subjects will be randomized to receive either GSK598809 40 mg or Placebo.
11624342|NCT00437632|Experimental|Subjects in Cohort-5 of Section 2|Subjects will be randomized to receive either ascending doses of GSK598809 75, 120 and 175 mg or Placebo. There will be a washout period of 6 days between the doses.
11624343|NCT00437632|Experimental|Subjects in Cohort-6 of Section 3|Subjects will receive caffeine on day -1 and after randomization subject will either receive GSK598809 or Placebo on Day 1. After washout period of 1-week subject will either receive GSK598809 or Placebo for 28 days.
11624344|NCT00437619|Experimental|1|
11624345|NCT00437606|Experimental|1|
11624346|NCT00437606|Experimental|2|
11624347|NCT00437606|Experimental|3|
11624348|NCT00437567|Active Comparator|Prebiotics|Babies randomized to this arm will receive galacto-oligosaccharide supplements
11624349|NCT00437567|Placebo Comparator|Placebo|Babies randomized to this arm will receive placebo
11624350|NCT00437502|Experimental|tumor peptide vaccine|2 cohorts: High and low dose tumor peptide vaccine
11624351|NCT00437489|Active Comparator|Control|
11624352|NCT00437489|Experimental|Experimental|
11624353|NCT00437476|Experimental|A|LPV/r + selected NRTIs for 26 weeks, followed by LPV/r monotherapy and anti HCV drugs for 48 weeks. All the patients will be followed-up for 24 weeks after the end of anti-HCV drugs for the evaluation of SVR.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day . At the end of week 12 of combined therapy, only patients who will reach an early virological response will continue anti-HCV drugs.
11624354|NCT00437476|Active Comparator|B|LPV/r+ selected NRTIs for 24 weeks, followed by the same HAART and anti-HCV drugs for 48 weeks. At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decision. All the patients will be followed-up for 24 weeks after the end of anti-HCV drugs for the evaluation of SVR.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day . At the end of week 12 of combined therapy, only patients who will reach an early virological response will continue anti-HCV drugs.
11624355|NCT00437463|Experimental|1|Ramipril
11624356|NCT00437463|No Intervention|2|
11624357|NCT00437437|Experimental|1|
11624358|NCT00437424|Experimental|1|
11624359|NCT00437411|Experimental|Workshop|Affective Self Awareness intervention
11624360|NCT00437411|No Intervention|Control|Waiting-list control.
11624361|NCT00437398|Experimental|Islet Transplant|Subjects will receive standard intraportal transplantation or portal venous system infusion via laparotomy of purified pancreatic islets.
11624362|NCT00437385|Active Comparator|1|Continuation-Medication with Antidepressants (after WBS Guidelines)
11624363|NCT00437385|Experimental|2|Continuation-ECT with Antidepressants
11624364|NCT00437385|Experimental|3|"Continuation-Psychotherapy (Cognitive Behavioral Group Psychotherapy including the Situational Analysis of CBASP)"
11624365|NCT00437372|Experimental|Sunitinib plus Radiation|Sunitinib plus Radiation
11624366|NCT00437359|Other|Fareston|Toremifene citrate: 40-mg tablets by mouth once daily.
11624367|NCT00437359|Other|Arimidex|Anastrozole: 1-mg tablets by mouth once daily.
11624368|NCT00437346|Active Comparator|Group A|Patients is given thorough information based on the tests taken plus medical treatment.
11624369|NCT00437346|Active Comparator|Group B|Patients receive simple written information based on the tests taken plus medical treatment.
11624370|NCT00437320|Experimental|1|
11624371|NCT00437320|Placebo Comparator|2|
11624372|NCT00437307|Active Comparator|1|Topotecan: 0,75 mg/m²/d, Tage 1-3 und Carboplatin: AUC 5 (after Cockroft and Gault formula) am Tag 3 nach Topotecan, q 21d.
11624373|NCT00437307|No Intervention|2|Paclitaxel 175 mg/m2/d, day 1 and Carboplatin: AUC 5 (after Cockroft and Gault formula), day 1, q21d OR gemcitabine 1000 mg/m2/d, day 1 and 8 and Carboplatin AUC 4 (after Cockroft and Gault formula), day 1, q 21d.
11624374|NCT00437294|Experimental|Capecitabine + Enzastaurin|
11624375|NCT00437294|Placebo Comparator|Capecitabine + Placebo|
11624376|NCT00437281|Placebo Comparator|Placebo|
11624377|NCT00437281|Experimental|Pregabalin|
11624378|NCT00437268|Experimental|enzastaurin + irinotecan + cetuximab|
11624379|NCT00437268|Active Comparator|irinotecan + cetuximab|
11624380|NCT00437255|Active Comparator|1|Clobex® Spray
11624381|NCT00437255|Active Comparator|2|Taclonex® Ointment
11624382|NCT00437229|Experimental|Subjects in Part A|In PART A, subjects received Regimen A: oral casopitant alone (150 mg once daily [QD] Day 1, 50 mg QD Days 2 and 3); Regimen B: oral dexamethasone (20 mg QD Day 1 and 8 mg twice daily [BID] Days 2 and 3) and intravenous (IV) ondansetron (32 mg single-dose Day 1); and Regimen C: oral casopitant as in Regimen A, IV ondansetron as in Regimen B and a lower dose oral dexamethasone than in Regimen B (12 mg QD Day 1, 8 mg QD Days 2 and 3).
11624385|NCT00437216||2|Add-on therapy - Subjects who are taking some form of anti-psoriatic medication and add Clobex® treatment
11624386|NCT00437203|Experimental|1|
11624387|NCT00437190|Active Comparator|Anterior Cervical Discectomy Fusion|
11624388|NCT00437190|Experimental|BRYAN Cervical Disc Prosthesis|BRYAN Cervical Disc Prosthesis is a cervical intervertebral disc prosthesis designed to provide for motion like the normal cervical functional spinal unit.
11624389|NCT00437151|Active Comparator|1|More frequent than normal office visits
11624390|NCT00437151|Active Comparator|2|Electronic reminders (voice, e-mail, text messages)
11624391|NCT00437151|Active Comparator|3|Parental involvement / intervention reminders
11624392|NCT00437151|Active Comparator|4|No intervention or reminders
11624393|NCT00437125|Experimental|Duloxetine|Participants received duloxetine 30 milligram (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg orally QD for 11 weeks
11624394|NCT00437112|Experimental|1|"4 week pretreatment phase consists of continuation of usual OAM therapy
~24 week treatment period with insulin glargine and OAM continuation followed by 24 week treatment period with HIIP and OAM continuation
~8 week follow up period"
11624395|NCT00437112|Experimental|2|"4 week pretreatment phase consists of continuation of usual OAM therapy
~24 week treatment period with HIIP and OAM continuation followed by 24 week treatment period with insulin glargine and OAM continuation
~8 week follow up period"
11624396|NCT00437099|Experimental|1|subjects with BPD receiving Omacor 1.680 mg/d
11624397|NCT00437099|Experimental|2|BPD patients randomized to Omacor 3.360 mg/d
11624398|NCT00437099|Placebo Comparator|3|patients with BPD randomized to Placebo
11624399|NCT00437086|Experimental|PS-341|Designed to assess the toxicity and pilot response of PS-341 in patients with advanced myeloproliferative diseases.
11624400|NCT00437073|Experimental|lapatinib plus capecitabine|A total of 55 isubjects will be enrolled into this arm. Subjects with progression of CNS and/or non-CNS disease will be considered progressors. At the time of radiographically-documented CNS and/or non-CNS disease progression, a subject randomized to this arm will be allowed to cross over to the alternative arm.
11624401|NCT00437073|Experimental|lapatinib + topotecan|A total of 55 isubjects will be enrolled into this arm. Subjects with progression of CNS and/or non-CNS disease will be considered progressors. At the time of radiographically-documented CNS and/or non-CNS disease progression, a subject randomized to this arm will be allowed to cross over to the alternative arm.
11624402|NCT00437060||Ancillary/Correlative (neurocognitive assessment, biomarkers))|"Patients complete neurocognitive tests to assess thinking, memory, attention, and concentration. The baseline test is administered during the consolidation phase of chemotherapy and further tests are done at 1 year from baseline and 1 year after* the completion of study therapy.
~Patients undergo blood and cerebrospinal fluid collection periodically for biomarker, genotypic polymorphisms, and pharmacokinetic analysis. Patients undergo MRI diffusion-tensor imaging to correlate imaging with neuropsychological outcomes."
11624403|NCT00437034|Experimental|Treatment (antiangiogenesis therapy)|Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11624404|NCT00437021|Active Comparator|Group C|Dryvax® vaccine or placebo on Day 0. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
11624405|NCT00437021|Experimental|Group D|Standard dose IMVAMUNE® vaccine or placebo on Day 0 and Dryvax® vaccine or placebo on Day 7. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
11624406|NCT00437021|Experimental|Group E|Dryvax® vaccine and standard dose IMVAMUNE® vaccine or 2 placebos on Day 0. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
11624407|NCT00437021|Experimental|Group F|Standard dose IMVAMUNE® vaccine or placebo on Day 0.
11624408|NCT00437021|Experimental|Group B|Standard dose IMVAMUNE® vaccine or placebo on Days 0 and 28.
11624409|NCT00437021|Experimental|Group A|Standard dose IMVAMUNE® vaccine or placebo on Days 0 and 7.
11624410|NCT00436995|Other|Single|
11624411|NCT00436982|Active Comparator|Cemented Triathlon total knee system|The Triathlon total knee system is the successor of the Duracon total knee system and was observed in a prospective randomised, parallel, double-blind study.
11624412|NCT00436982|Active Comparator|Cemented Duracon total knee system|The Duracon total knee system is the predecessor of the Triathlon total knee system and was observed in a prospective randomised, parallel, double-blind study.
11624413|NCT00436969|Active Comparator|Control|Subjects randomized to the control arm injection of prescribed anesthetic and corticosteroid, shall receive an equivalent volume (8 mL's).
11624414|NCT00436969|Experimental|Investigational|Subjects randomized to the active treatment in this study will receive a one-time dose of 8 mL's of Orthovisc derived from non-animal source bacterial fermentation, S. Equi.
11624415|NCT00436956|Experimental|AZD2171 in Prostate Cancer|Cohort 1 (n=35) received 20 mg AZD2171 (Cediranib) orally daily. Cohort 2 (n=23) received prednisone 10 mg orally daily with 20 mg AZD2171.
11624416|NCT00436943||A|Smokers
11624417|NCT00436930|Experimental|Arm I|Patients receive irradiated autologous tumor cells subcutaneously (SC) and sargramostim (GM-CSF) SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.
11624418|NCT00436930|Experimental|Arm II|Patients receive autologous dendritic cells loaded with irradiated autologous tumor cells SC and GM-CSF SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.
11624419|NCT00436917|Experimental|zoledronic acid|4 mg 15 minutes IV infusion. If creatinine clearance is ≤ 60, dosage should be adjusted as follows:CrCl 50-60: 3.5 mg; CrCl 40-49: 3.3 mg; CrCl 30-39: 3.0 mg.
11624420|NCT00436904|Experimental|Alemtuzumab + Rituximab|Alemtuzumab 30mg Monday, Wednesday, and Friday x 5 weeks, Rituximab 375/mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
11624421|NCT00436878|Experimental|Portion Size|Each experiment manipulated food portion size of beverages, entrees, and side dishes
11624422|NCT00436865|Other|PCOS|PCOS women receiving weight loss intervention
11624423|NCT00436865|Other|Control|Non-PCOS women receiving weight loss intervention
11624529|NCT00435708|Experimental|2|5 portions fruit and vegetables/day
11624424|NCT00436852|Experimental|Measurable disease by CT or MRI scan (ABT-751 chemotherapy)|Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.
11624425|NCT00436852|Experimental|Evaluable by I-MIBG scintigraphy (ABT-751)|Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.
11624426|NCT00436839|Experimental|1|Docetaxel 75mg/m² intravenously (day 1) every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle
11624427|NCT00436839|Active Comparator|2|Mitoxantrone 12mg/m² intravenously every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle
11624428|NCT00436826|Experimental|Cladribine 3.5 mg/kg, IFN-beta (DB period)|Participants received cladribine tablets orally as cumulative dose of 0.875 mg/kg over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 milligram per kilogram (mg/kg) along with interferon (IFN)-beta therapy (Rebif® new formulation [RNF] 44 mcg three times a week, subcutaneously; Avonex® 30 microgram (mcg) every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during the Double blind period (DBP) of 96 weeks.
11624429|NCT00436826|Placebo Comparator|Placebo, IFN-beta (DB period)|Participants received matching placebo tablets orally over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during the DB period of 96 weeks.
11624430|NCT00436826|Experimental|Cladribine 3.5 mg/kg, IFN-beta, Cladribine 3.5 mg/kg (OL Ext)|Participants who received cladribine 3.5 mg/kg initially and completed DB period entered in the open label (OL) extension (Ext.) period. In OL Ext. period, participant who met the eligibility criteria received OL oral cladribine 3.5 mg/kg over maximum of 48 weeks along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
11624431|NCT00436826|Placebo Comparator|Placebo, IFN-beta, Cladribine 3.5 mg/kg (OL Ext)|Participants who received placebo initially and completed DB period entered in the OL Ext. period. In OL Ext. period, participant who met the eligibility criteria received OL oral cladribine 3.5 mg/kg over maximum of 48 weeks along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
11624432|NCT00436826|Experimental|Cladribine 3.5 mg/kg, IFN-beta (Safety follow up)|Participants who received cladribine 3.5 mg/kg initially and completed DB period entered in the OL ext. safety follow up period. In this period, participants who did not meet eligibility criteria received only IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
11624433|NCT00436826|Placebo Comparator|Placebo, IFN-beta (Safety follow up)|Participants who received placebo initially and completed DB period entered in the OL ext. safety follow up period. In this period, participants who did not meet eligibility criteria received only IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
11624434|NCT00436800|Experimental|1|Gemcitabine on Day 1 followed by Oxaliplatin on Day 2. The regimen is given every 2 weeks to a maximum of 12 cycles.
11624435|NCT00436748|Experimental|Darbepoetin Alfa QW|Participants received darbepoetin alfa once a week (QW) for 24 weeks. The initial dose was 0.45 μg/kg; thereafter, active doses were administered to achieve and then maintain hemoglobin levels within a target range of 10.0 to 12.0 g/dL. Participants not on dialysis or who were receiving peritoneal dialysis were administered darbepoetin alfa subcutaneously; participants receiving hemodialysis were administered darbepoetin alfa intravenously.
11624436|NCT00436748|Experimental|Darbepoetin Alfa Q2W|Participants received darbepoetin alfa every 2 weeks (Q2W) and a placebo every other 2 weeks to maintain the blind for 24 weeks. The initial dose was 0.75 μg/kg; thereafter, active doses were administered to achieve and then maintain hemoglobin levels within a target range of 10.0 to 12.0 g/dL. Participants not on dialysis or who were receiving peritoneal dialysis were administered darbepoetin alfa subcutaneously; participants receiving hemodialysis were administered darbepoetin alfa intravenously.
11624437|NCT00436696||Ancillary-correlative (SNP analysis)|DNA samples are derived from participants' banked blood or uninvolved bone marrow. A whole genome scan of DNA samples is employed to identify candidate single nucleotide polymorphisms (SNPs). The candidate SNPs are investigated, using a gene-centric haplotyping approach, to identify 10-20 true disease-associated alleles. The disease-associated alleles are again investigated, using a gene-centric haplotyping approach, to validate 5-10 disease-associated SNPs. SNPs are then analyzed for heritable predisposition.
11624438|NCT00436683|Experimental|1|Dose titration on active
11624439|NCT00436683|Active Comparator|2|Dose titration
11624440|NCT00436670|Experimental|AMG 317 75 mg|75 subjects
11624441|NCT00436670|Placebo Comparator|Placebo Arm|75 subjects
11624442|NCT00436670|Experimental|AMG 317 300 mg|75 subjects
11624443|NCT00436670|Experimental|AMG 317 150 mg|75 subjects
11624444|NCT00436657|Experimental|Surgery + CHPP of Escalating Cisplatin|Abdominal Surgery + CHPP of Escalating Cisplatin (Starting dose of 100 mg/m^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.)
11624445|NCT00436644|Experimental|Lapatinib + Topotecan|Assess biological effects of topotecan and lapatinib in patients with epithelial ovarian cancer and primary peritoneal carcinoma.
11624446|NCT00436631|Experimental|diet|
11624447|NCT00436618|Experimental|Relapsed aggressive non-Hodgkin lymphoma|Study 1. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
11624448|NCT00436618|Experimental|Relapsed indolent non-Hodgkin lymphoma|Study 2. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
11624530|NCT00435695|Active Comparator|GSK163090|one infusion only
11624449|NCT00436618|Experimental|Uncommon lymphomas|Study 3. Includes Hodgkin's lymphomas. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
11624450|NCT00436605|Experimental|Treatment (kinase inhibitor therapy)|Patients receive oral dasatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11624451|NCT00436592|Experimental|1|
11624452|NCT00436579|Experimental|Arm I (higher-dose enzyme inhibitor therapy)|Patients receive higher-dose oral sorafenib tosylate twice daily on days 15-36.
11624453|NCT00436579|Active Comparator|Arm II (standard-dose enzyme inhibitor therapy)|Patients receive standard-dose oral sorafenib tosylate three times daily on days 15-36.
11624454|NCT00436579|Active Comparator|Arm III (standard-dose enzyme inhibitor therapy)|Patients receive standard-dose oral sorafenib tosylate twice daily on days 15-36. (closed to accrual as of 4/29/2009)
11624455|NCT00436553|Experimental|Verteporfin With Standard Fluence Rate Plus Ranibizumab|Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin photodynamic therapy (PDT) with standard fluence (SF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.
11624456|NCT00436553|Active Comparator|Ranibizumab Monotherapy|Patients received monthly ranibizumab injections for 12 months and thereafter as needed based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. Retreatments were determined based on study specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA).
11624457|NCT00436553|Experimental|Verteporfin With Reduced Fluence Rate Plus Ranibizumab|Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT with reduced fluence (RF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.
11624458|NCT00436540|Active Comparator|1|clobetasol propionate (Clobex®) spray
11624459|NCT00436540|Active Comparator|2|clobetasol propionate (Olux®) foam
11624460|NCT00436527|Other|1|
11624461|NCT00436501|Experimental|Treatment (VEGF Trap, Docetaxel)|"Phase I (closed to accrual as of 3/14/2008): Patients receive VEGF Trap IV over 1 hour on day 1 of course 1. Patients then receive VEGF Trap IV over 1 hour and docetaxel IV over 1 hour on day 1 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of VEGF Trap until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 or 6 patients experience dose-limiting toxicity."
11624462|NCT00436501|Experimental|Phase II Treatment (VEGF Trap, Docetaxel)|Phase II (opened to accrual as of 5/9/2008): Patients receive VEGF Trap at the MTD determined in phase I and docetaxel as in phase I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11624463|NCT00436475|Other|1|Vitamin D3 2,000 IU daily plus Calcium Carbonate 400 mg twice daily
11624464|NCT00436475|Other|2|Vitamin D3 2,000 IU daily plus Calcium-Placebo twice daily
11624465|NCT00436475|Other|3|Vitamin D3-Placebo plus Calcium Carbonate 400 mg twice daily
11624466|NCT00436475|Other|4|Vitamin D3-Placebo plus Calcium-Placebo
11624467|NCT00436436|Experimental|O6-benzylguanine & Temozolomide in Glioblastoma|Patients receive O6-benzylguanine intravenous over 1 hour and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11624468|NCT00436423|Experimental|1|Gemcitabine with TS-1
11624469|NCT00436371|Experimental|1|Amisulpride 400-800mg per day on a twice-a-day regimen
11624470|NCT00436358||Group A|IS case deemed children
11624471|NCT00436358||Group B|LRTI-related post-neonatal deaths deemed Children
11624472|NCT00436358||Group C|A random sample of children from an annual birth cohort within the electronic IMSS dataset
11624473|NCT00436358||Group D|All children from a single annual birth cohort with IS identified in their electronic IMSS data
11624474|NCT00436358||Group E|A sample of children from the electronic IMSS dataset selected to match the selected IS cases on age, gender, and hospital of birth.
11624475|NCT00436345|Experimental|Remifentanil|remifentanil
11624476|NCT00436345|Active Comparator|Propofol|Propofol infusion
11624477|NCT00436332|Experimental|Erlotinib and Bevacizumab|
11624478|NCT00436319|No Intervention|1|In the control group (group 1) the initiation of the ovarian stimulation will be realized according to the typical long luteal protocol, two weeks after the initiation of the GnRH agonist administration.
11624479|NCT00436319|Other|2|In the study group (group 2) the initiation of the ovarian stimulation will be effectuated on the second day of the menstrual period.
11624480|NCT00436306|Experimental|Individualized Intervention: stage-matched/tailored counseling|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
11624481|NCT00436306|Placebo Comparator|Control: Enhanced usual care counseling|The Enhanced Usual Care arm was the control group. It provided computer-based information regarding contraceptive methods, but was not individualized or tailored to the participant stage of change.
11624482|NCT00436293|Experimental|1|Neo-adjuvant Taxotere followed by cisplatin and radiotherapy
11624483|NCT00436293|Active Comparator|2|Cisplatin and radiotherapy alone without neo-adjuvant chemotherapy
11624484|NCT00436280|Experimental|Enzastaurin + Gemcitabine Rituximab Oxaliplatin (R-GEMOX)|
11624485|NCT00436254|Experimental|Arm I|Patients receive pNGVL3-hICD vaccine admixed with GM-CSF intradermally once a month for 3 months in the absence of disease progression or unacceptable toxicity.
11624486|NCT00436241|Experimental|1|
11624487|NCT00436215|Experimental|BAY 43-9006 + Bevacizumab|BAY 43-9006 (sorafenib) + Bevacizumab
11624488|NCT00436176|Experimental|1|Intervention clinicians receive monthly performance reports, cultural competency training, and health navigation training
11624489|NCT00436176|No Intervention|2|Control clinicians function within the context of the generic chronic care model.
11624490|NCT00436163|Experimental|Peginterferon Alfa-2a|Participants received peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once per week for 48 weeks.
11624491|NCT00436150|Experimental|A|Participants will receive interpersonal therapy-based treatment
11624492|NCT00436150|Active Comparator|B|Participants will receive standard care
11624493|NCT00436137|Experimental|1|Patients will receive a mailing recommending colonoscopy, followed by a telephone outreach
11624494|NCT00436098|Experimental|1|physical training
11624495|NCT00436098|No Intervention|2|
11624496|NCT00436046|Active Comparator|Group 1: 0.6 ml of IVV|30 subjects to receive 0.6 ml of inactivated influenza virus vaccine (IVV).
11624497|NCT00436046|Experimental|Group 3: 0.7 ml of IVV + 10M units of IFN|30 subjects to receive 0.7 ml of IVV containing 10M units of interferon (IFN).
11624498|NCT00436046|Experimental|Group 2: 0.6 ml of IVV + 1M unit of IFN|30 subjects to receive 0.6 ml of IVV containing 1M units of interferon (IFN).
11624499|NCT00436033|Placebo Comparator|Placebo|
11624500|NCT00436033|Experimental|Minalcipran|
11624501|NCT00436020|Active Comparator|1|Active
11624502|NCT00436020|Placebo Comparator|2|Sham TMS
11624503|NCT00436007|Experimental|GSK 257049 1 Group|"Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib, Polio Sabin™ and GSK 257049 vaccines at Months 0, 1 and 2, and a single dose of Rouvax™ and Stamaril™ vaccines at Month 7.
~The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. The Stamaril™ vaccine was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania."
11624504|NCT00436007|Experimental|GSK 257049 2 Group|Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib and Polio Sabin™ at Months 0, 1 and 2, 3 doses of GSK 257049 vaccine at Months 0, 1 and 7, and a single dose of Rouvax™ and Stamaril™ at Month 7. The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. Stamaril™ was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania.
11624505|NCT00436007|Active Comparator|Tritanrix™ HepB/Hiberix™ Group|Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib and Polio Sabin™ at Months 0, 1 and 2, and a single dose of Rouvax™ and Stamaril™ at Month 7. The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. The Stamaril™ vaccine was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania.
11624506|NCT00435994|Other|Infants with viral lower respiratory infections|Infants between the ages of 2-24 month, with viral lower respiratory infection defined as first episode of wheezing and shortness of breath preceded by an upper respiratory tract infection, including hospitalized infants
11624507|NCT00435994|Other|Healthy Control|Healthy infants between the ages of 2-24 month
11624508|NCT00435994|Other|Bronchiolitis-Nasal wash only|Infants 2 months to 24 months who were diagnosed with bronchiolitis received nasal wash only
11624509|NCT00435942|Experimental|1|Endovascular Treatment arm to be implanted with Relay device
11624510|NCT00435942|Active Comparator|2|Surgical Control, underwent open repair
11624511|NCT00435929|Experimental|1|
11624512|NCT00435929|Experimental|2|
11624513|NCT00435916|Experimental|1|
11624514|NCT00435890|No Intervention|1|No triage liaison physician
11624515|NCT00435864|Other|allogeneic donor from a file|
11624516|NCT00435864|Other|Registry geno-identical donor family|
11624517|NCT00435864|Other|transplantation of HSCs derived from placental blood|
11624518|NCT00435825|Experimental|peginterferon alfa-2a 90 μg_24 Weeks|Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.
11624519|NCT00435825|Experimental|peginterferon alfa-2a 180 μg_24 Weeks|Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.
11624520|NCT00435825|Experimental|peginterferon alfa-2a 90 μg_48 Weeks|Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.
11624521|NCT00435825|Experimental|peginterferon alfa-2a 180 μg_48 Weeks|Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.
11624522|NCT00435812|Experimental|HEPLISAV and/or Placebo|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
11624523|NCT00435812|Active Comparator|Engerix-B|1.0 mL Engerix-B
11624524|NCT00435799|Active Comparator|A|
11624525|NCT00435760|Active Comparator|Tiotropium|1 puff, 1 day treatment
11624526|NCT00435760|Placebo Comparator|Placebo|Tiotropium or Aclidinium Placebo, 1 day treatment
11624527|NCT00435760|Experimental|Aclidinium bromide|200 micrograms, once daily, 1 day treatment
11624531|NCT00435643|Active Comparator|A|10 patients with severe OSAS (Apnea Hypopnea Index of more than 30 events per hour of sleep) were treated with nCPAP for three months and all mentioned measurements above were repeated.
11624532|NCT00435630|Other|1|Completing simulator training sessions
11624533|NCT00435617|Experimental|A|Hand Mentor
11624534|NCT00435591|Experimental|Dose Regimen 1|Placebo loading dose + 20mg/day continuous infusion conivaptan per ampoule
11624535|NCT00435591|Experimental|Dose Regimen 2|Conivaptan loading dose (20mg)+ 20mg/day continuous infusion conivaptan per ampoule
11624536|NCT00435591|Experimental|Dose Regimen 3|Placebo loading dose + 20mg/day continuous infusion conivaptan per premix bag
11624537|NCT00435591|Experimental|Dose Regimen 4|Conivaptan loading dose (20mg) + 20mg/day continuous infusion conivaptan per premix bag
11624538|NCT00435539|Experimental|ocriplasmin 75µg single injection|Ocriplasmin 75µg single injection versus sham injection
11624539|NCT00435539|Experimental|ocriplasmin 125µg single injection|Ocriplasmin 125µg single injection versus sham injection
11624540|NCT00435539|Experimental|ocriplasmin 175µg single injection|Ocriplasmin 175µg single injection versus sham injection
11624541|NCT00435539|Experimental|ocriplasmin 125µg multiple injections|Ocriplasmin 125µg multiple injections. Subjects who did not achieve resolution of VMT by the day 28 visit (i.e. non-responders) were given an open-label injection of ocriplasmin 125µg. Subjects who still did not achieve resolution of VMT by the day 56 visit were given a second open-label injection of ocriplasmin 125µg.
11624542|NCT00435539|Sham Comparator|sham injection|sham injection
11624543|NCT00435513||Transsexual group|Female-to-male and male-to-female transsexuals
11624544|NCT00435513||Controls|Healthy blood donors
11624545|NCT00435487|Experimental|A|
11624546|NCT00435487|Active Comparator|B|
11624547|NCT00435474|Active Comparator|1|Silver product
11624548|NCT00435474|Experimental|2|Honey product
11624549|NCT00435409|Experimental|A|
11624550|NCT00435409|Active Comparator|B|
11624551|NCT00435396|Experimental|Group A|
11624552|NCT00435383||Observational|Group 1 received a presurgical caudal block and group 2 received a intravenous narcotics.
11624553|NCT00435370|Experimental|Tropisetron|Tropisetron (10mg/day) + risperidone(6mg/day)
11624554|NCT00435370|Placebo Comparator|Placebo|Placebo + risperidone (6mg/day)
11624555|NCT00435357|Experimental|mobile-bearing TKA|
11624556|NCT00435357|Active Comparator|fixed- bearing TKA|
11624557|NCT00435331|Experimental|1|Open Label
11624558|NCT00435292|Experimental|flavocoxid 250 mg|flavonoid mixture
11624559|NCT00435292|Active Comparator|flavocoxid 500 mg|flavonoid mixture
11624560|NCT00435292|Active Comparator|naproxen|nonsteroidal antiinflammatory drug
11624561|NCT00435279|Experimental|Eszopiclone|
11624562|NCT00435279|Experimental|Placebo|
11624563|NCT00435266|Experimental|1|Remote ischemic preconditioning
11624564|NCT00435266|No Intervention|2|
11624565|NCT00435253|Experimental|BLVR Treatment|BLVR Treatment
11624566|NCT00435227|Experimental|1|MEDI-524
11624567|NCT00435227|Placebo Comparator|2|Placebo
11624568|NCT00435188|Experimental|Arm 1|Behavioral: Multi-component physical activity counseling program A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
11624569|NCT00435188|No Intervention|Arm 2|Usual care
11624570|NCT00435162|Experimental|Low Dose|
11624571|NCT00435162|Experimental|Medium Dose|
11624572|NCT00435162|Experimental|High Dose|
11624573|NCT00435149|Active Comparator|1|
11624574|NCT00435149|Active Comparator|2|
11624575|NCT00435123|Active Comparator|A|Patients are randomly assigned to receive either Active Comparator (ProStat 64) or placebo for the first 3 months. At the end of this, all patients receive open label ProStat64.
11624576|NCT00435123|Placebo Comparator|B|Patients are randomly assigned to Placebo Comparator or Active Comparator (ProStat 64). At the end of 3 months, all patients receive active ProStat 64
11624577|NCT00435084|Experimental|Single-arm mono therapy|APO866 will be administered by civ infusion at 0.126 mg/m2/hr for 4 consecutive days (96 hours). This constitutes 1 cycle.
11624578|NCT00435071|Active Comparator|1|
11624579|NCT00435071|Active Comparator|2|
11624580|NCT00435045|Active Comparator|atorvastatin arm|atorvastatin + placebo
11624581|NCT00435045|Experimental|Lovaza arm|Lovaza + atorvastatin
11624582|NCT00435032|Active Comparator|1|Early appendectomy
11624583|NCT00435032|Active Comparator|2|Interval appendectomy
11624584|NCT00435019|Experimental|insulin detemir|insulin detemir + insulin aspart
11624585|NCT00435019|Experimental|NPH insulin|NPH insulin + insulin aspart
11624586|NCT00434993|Active Comparator|Albuterol Sulfate|
11624587|NCT00434993|Placebo Comparator|Placebo|
11624588|NCT00434980|Experimental|Treatment|Participant and family take part in FCA treatment program.
11624589|NCT00434967|No Intervention|4|Placebo
11624590|NCT00434967|Active Comparator|2|Candesartan cilexetil
11624591|NCT00434967|Active Comparator|3|Hydrochlorothiazide (HCT)
11624592|NCT00434967|Experimental|1|Candesartan cilexetil + Hydrochlorothiazide Combination
11624593|NCT00434954|Experimental|Exenatide Twice Daily (BID)|
11624594|NCT00434954|Active Comparator|Premixed Insulin Aspart Twice Daily (BID)|
11624595|NCT00434941|Experimental|Radiotherapy + Capecitabine|Radiotherapy (for 25 days; Dose: 50 Gy) + Capecitabine (for 35 days; Dose: 825 mg/m2 twice per day p.o.) Experimental treatment consists of administration of 825 mg/m2 x 2 daily p.o., for 7 days simultaneously with daily radiotherapy treatment.Capecitabine will be administered for 35 days as maximum.
11624596|NCT00434889||1|Memory problems
11624597|NCT00434889||2|No memory problems
11624600|NCT00434850|Experimental|Allogeneic Pancreatic Islet Cells|Participants in this study can receive up to three separate islet transplants. They will begin receiving antithymocyte globulin (ATG) and sirolimus 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant. Participants will continue taking sirolimus for the duration of the study. On the day of transplant, participants will receive DSG and etanercept, in addition to ATG and sirolimus. The DSG infusion will be administered over 3 hours and will immediately precede the islet transplant. Participants will continue receiving daily 3-hour infusions of DSG through Day 6 post-transplant. Etanercept will also be administered on Days 3, 7, and 10 post-transplant. Tacrolimus will be administered on Day 1 post-transplant and continued throughout the study.
11624601|NCT00434837|Experimental|Low-tension|Patients recruited to study the initial graft tension during ACL reconstruction surgery who were randomized to the Low-tension group will receive the low-tension treatment with initial graft tension set so that the anterior-posterior (A-P) displacement of the reconstructed knee is equal to that of the uninjured knee.
11624602|NCT00434837|Experimental|High-tension|Patients recruited to study the initial graft tension during ACL reconstruction surgery who were randomized to the High-tension group will receive the high-tension treatment with the initial graft tension set to reduce A-P displacement by 2 millimeters relative to that of the uninjured knee.
11624603|NCT00434837|No Intervention|Uninjured Control Group|Uninjured age, sex, and race matched control group
11624604|NCT00434824|Active Comparator|Arm 1|Oral testosterone undecanoate (Andriol)
11624605|NCT00434824|Placebo Comparator|Arm 2|Placebo
11624606|NCT00434811|Experimental|Islet Transplantation|Participants will receive up to three separate islet transplants and a regimen of immunosuppressive medications consisting of antithymocyte globulin (ATG), sirolimus, and low-dose tacrolimus.
11624607|NCT00434759|Active Comparator|SCP|SCP is a stepped-care program with a self-help module with minimal therapist contact (8 sessions) as first step, followed by therapist-guided intervention depending on status of remission (8 sessions up to a maximum of 16 sessions).
11624608|NCT00434759|Active Comparator|ST|A standard therapy which means a therapist-guided intervention with 16 sessions face-to-face therapy.
11624609|NCT00434655|Active Comparator|1 LAP BAND|
11624610|NCT00434655|Experimental|2 Sleeve gastrectomy|
11624611|NCT00434642|Experimental|Carboplatin and gemcitabine + bevacizumab|Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.
11624612|NCT00434642|Active Comparator|Carboplatin and gemcitabine + placebo|Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.
11624613|NCT00434616|Placebo Comparator|1|saline injections
11624614|NCT00434616|Active Comparator|2|autologous bone marrow transplantation into the ischemic leg
11624615|NCT00434590|Experimental|Full Dose Myfortic® and Reduced Dose Neoral®|The administration of gradual dose increased to reach 1440 mg/day (V4) of enteric-coated mycophenolate sodium (Myfortic®, EC-MPS) with simultaneous dose reduction of micro emulsion cyclosporine (Neoral®, CsA-ME) given to maintenance kidney transplant patients previously treated with reduced-dose mycophenolate mofetil (MMF) and standard dose CsA-ME
11624616|NCT00434590|Active Comparator|Standard Dose of Myfortic® and Standard Dose of CsA-ME|Patients received unchanged dose of Myfortic® (equimolar to the prior established dose MMF) and unchanged standard dose of CsA-ME.
11624617|NCT00434577|Experimental|GSK1437173A _LD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) low dose (LD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by intramuscular injection (IM) in the upper deltoid site of the left arm.
11624618|NCT00434577|Experimental|GSK1437173A _MD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) medium dose (MD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
11624619|NCT00434577|Experimental|GSK1437173A _HD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
11624620|NCT00434577|Placebo Comparator|Placebo + GSK1437173A _HD Group|Healthy male or female subjects aged 60 years or older, who received a 1st dose of saline solution and a 2nd dose of GSK1437173A high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
11624621|NCT00434577|Active Comparator|GSK1437173A_MODIFIED GROUP|Healthy male or female subjects aged 60 years or older, who received 2 doses of GSK1437173A modified formulation vaccine reconstituted with saline solution, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
11624622|NCT00434551||1|Patients with suspected Crohn's disease
11624623|NCT00434525|Experimental|1 Sleeve gastrectomy with omentectomy|
11624624|NCT00434525|Active Comparator|2 Sleeve gastrectomy|
11624625|NCT00434512|Experimental|SB732461 adjuvanted_LD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted low-antigen dose [LD] (10 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
11624626|NCT00434512|Experimental|SB732461 adjuvanted_MD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted medium-antigen dose [MD] (30 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
11624627|NCT00434512|Experimental|SB732461 adjuvanted_HD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted high-antigen dose [HD] (90 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
11624758|NCT00433199|Experimental|T-Gel 1.62%|Testosterone (T) gel 1.62%
11624628|NCT00434512|Experimental|SB732461 non-adjuvanted_LD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted low-antigen dose [LD] (10 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
11624629|NCT00434512|Experimental|SB732461 non-adjuvanted_MD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted medium-antigen dose [MD] (30 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
11624630|NCT00434512|Experimental|SB732461 non-adjuvanted_HD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted high-antigen dose [HD] (90 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
11624631|NCT00434499|Active Comparator|placebo first|placebo first then crossover to EGCG
11624632|NCT00434499|Active Comparator|EGCG first|EGCG first then crossover to placebo
11624633|NCT00434473|Placebo Comparator|Placebo|
11624634|NCT00434473|Experimental|A-001|
11624635|NCT00434460||1|Patients receiving invasive mechanical ventilation > 48 hours.
11624636|NCT00434447|Experimental|Zoledronic Acid|ZOL446
11624637|NCT00434434|Experimental|1|
11624638|NCT00434434|Experimental|2|
11624639|NCT00434434|Placebo Comparator|3|
11624640|NCT00434421|Experimental|German Cockroach Allergen Dosing Group|Glycerinated German Cockroach Allergenic Extract
11624641|NCT00434408|Experimental|1|4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth
11624642|NCT00434408|Experimental|2|4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth
11624643|NCT00434408|Active Comparator|3|dry cord care
11624644|NCT00434356|Experimental|1|
11624645|NCT00434356|Placebo Comparator|2|
11624646|NCT00434330|Experimental|Cohort 1, Q4W, SC, No Transition|
11624647|NCT00434330|Experimental|Cohort 2, Q4W, IV, No Transition|
11624648|NCT00434330|Experimental|Cohort 3, Q4W, SC, Transition|
11624649|NCT00434330|Experimental|Cohort 4, Q4W, IV, Transition|
11624650|NCT00434330|Experimental|Cohort 5, Q4W, SC, Transition|
11624651|NCT00434330|Experimental|Cohort 6, Q4W, IV, Transition|
11624652|NCT00434317|Experimental|ZOL446|
11624653|NCT00434304|Experimental|Ropinirole PR/XR|
11624654|NCT00434278|Placebo Comparator|Placebo|
11624655|NCT00434278|Experimental|Dornase alfa|
11624656|NCT00434252|Placebo Comparator|Carboplatin+Paclitaxel+Placebo|
11624657|NCT00434252|Experimental|Carboplatin+Paclitaxel+Bevacizumab|
11624658|NCT00434239|Experimental|Treatment: Lenalidomide and Ancestim|Drug: Lenalidomide + Ancestim Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
11624659|NCT00434226|Experimental|Bevacizumab + Carboplatin/Paclitaxel + Sunitinib|
11624660|NCT00434226|Placebo Comparator|Bevacizumab + Carboplatin/Paclitaxel|
11624661|NCT00434213|Experimental|Methylphenidate Transdermal System|To characterize the dermal reactions seen with the use of DAYTRANA
11624662|NCT00434174|Experimental|everolimus + Pemetrexed - daily|Daily treatment
11624663|NCT00434174|Experimental|everolimus + Pemetrexed - weekly|Weekly treatment
11624664|NCT00434161|Active Comparator|Palifermin before only|Subjects received palifermin before-high dose chemotherapy (total 3 doses) and matched placebo after-high dose chemotherapy (total 3 doses)
11624665|NCT00434161|Placebo Comparator|Placebo (suger pill)|Subjects received matched placebo before- and after-high dose chemotherapy
11624666|NCT00434161|Active Comparator|Palifermin before and after|Subjects received palifermin before- and after-high dose chemotherapy (total of 6 doses)
11624667|NCT00434148|Experimental|Pasireotide 600 ug|At randomization, participants received 600 ug subcutaneously (sc) twice daily (bid). Participants continued at this dose until month 6 if their month 3 mean urinary free cortisol (mUFC) was <= 2 x the upper limit of normal (ULN) and the mUFC was below or equal to their baseline mUFC. Participants not meeting the mUFC criteria at month 3 were unblinded and required to increase their dose to 900ug bid on an open label basis. Participants had the option to continue in the extension phase as long as they did not meet any discontinuation criteria or until pasireotide was available commercially in their country.
11624668|NCT00434148|Experimental|Pasireotide 900 ug|At randomization, participants received 900 ug subcutaneously (sc) twice daily (bid). Participants continued at this dose until month 6 if their month 3 mean urinary free cortisol (mUFC) was <= 2 x the upper limit of normal (ULN) and the mUFC was below or equal to their baseline mUFC. Participants not meeting the mUFC criteria at month 3 were unblinded and required to increase their dose to 1200 ug bid on an open label basis. Participants had the option to continue in the extension phase as long as they did not meet any discontinuation criteria or until pasireotide was available commercially in their country.
11624669|NCT00434135|Experimental|A|Gemcitabine 1,250 mg/sqm days 1 and 8 + Alimta 500 mg/sqm day 8, every 3 weeks
11624670|NCT00434135|Active Comparator|B|Paclitaxel 120 mg/sqm days 1 and 8 + Gemcitabine 1,000 mg/sqm days 1 and 8, every 3 weeks
11624671|NCT00434122|Experimental|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
11624672|NCT00434122|Placebo Comparator|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.
~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
11624673|NCT00434109|Experimental|Sunitinib Malate and Hepatic Artery Embolizations|Sunitinib Malate and Selective Hepatic Artery Embolizations: Sunitinib malate (Sutent) at a dose of 37.5mg. 1-3 selective hepatic artery embolizations.
11624674|NCT00434096|Experimental|1|
11624675|NCT00434096|Placebo Comparator|2|
11624676|NCT00434057|Other|Biopsied Pigmented Skin Lesions|Pigmented skin lesions for which clinical management was prospectively determined to be biopsy of the lesion in toto
11624756|NCT00433212|Active Comparator|B|Non-invasive respiratory support via nasal Continuous Positive Airway Pressure
11624677|NCT00434018|Other|Wheelchair Skills Training Program|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs. The WSP is a set of assessment and training protocols related to wheelchair skills. The WSP includes the Wheelchair Skills Test (WST), the Wheelchair Skills Training Program (WSTP) and related materials.
11624678|NCT00434018|Other|Basic Health Education|Basic health educational training sessions: Five sessions are held with subjects to provide them additional information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
11624679|NCT00434005|Experimental|Diesel Exhaust|
11624680|NCT00434005|Sham Comparator|Filtered Air|
11624681|NCT00433992||ABC/3TC|HIV-infected subjects were given Abacavir-Lamuvidine
11624682|NCT00433992||TDF/FTC|HIV-infected patients were given tenofovir DF-emtricitabine
11624683|NCT00433966|Active Comparator|Pharmacology Arm|"To establish the safety and efficacy of the use of bivalirudin in patients with acute myocardial infarction undergoing a primary angioplasty strategy by showing that compared to unfractionated heparin plus routine use of GP IIb/IIIa inhibitors, bivalirudin (with use of GP IIb/IIIa inhibitors reserved for angioplasty complications) results in:
~reduced rates of major bleeding events at 30 days
~similar rates of major adverse ischemic cardiac events at 30 days
~reduced rates of the composite of major adverse ischemic cardiac events + major bleeding at 30 days."
11624684|NCT00433966|Active Comparator|Stent Arm|"To establish the safety and efficacy of the paclitaxel-eluting TAXUS™ stent by showing that compared to an otherwise identical bare metal EXPRESS2™ stent, the TAXUS™ stent results in:
~reduced rates of target lesion revascularization for ischemia at 1 year
~similar rates of death, reinfarction, stroke or stent thrombosis at 1 year
~lower rates of analysis segment binary angiographic restenosis at 13 months"
11624685|NCT00433940||Infantile Hemangioma Patients|Infants with infantile hemangioma being treated clinically with oral prednisolone sodium phosphate suspensions.
11624686|NCT00433927|Active Comparator|Arm A|FOLFIRI plus Cetuximab
11624687|NCT00433927|Active Comparator|Arm B|FOLFIRI plus Bevacizumab
11624688|NCT00433914|Experimental|rMenB|6-8 months-old infants received 3 doses of rMenB vaccine without OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
11624689|NCT00433914|Experimental|rMenB+OMV|6-8 months-old infants received 3 doses of rMenB vaccine with OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
11624690|NCT00433888|Experimental|1|
11624691|NCT00433888|Experimental|2|
11624692|NCT00433849|Experimental|1|
11624693|NCT00433849|Experimental|2|
11624694|NCT00433836|Experimental|Valsartan 80 mg|
11624695|NCT00433836|Experimental|Valsartan 160 mg|
11624696|NCT00433836|Experimental|Valsartan 320 mg|
11624697|NCT00433836|Active Comparator|Enalapril 10 mg|
11624698|NCT00433836|Active Comparator|Enalapril 20 mg|
11624699|NCT00433836|Active Comparator|Enalapril 40 mg|
11624700|NCT00433797|Experimental|1|Tomato
11624701|NCT00433797|Experimental|2|Multi-diet
11624702|NCT00433797|Active Comparator|3|Control
11624703|NCT00433771|Experimental|WallFlex Biliary Fully Covered stent|Single arm, biliary stenting, using WallFlex Biliary Fully Covered stent
11624704|NCT00433745|Experimental|WT1 Peptide Vaccine|WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
11624705|NCT00433719|Experimental|1|Combivir, efavirenz for 12 months
11624706|NCT00433719|Placebo Comparator|2|Placebo for 2 months followed by Combivir and efavirenz for 10 months
11624707|NCT00433706|Experimental|Control position by 3DOBI daily|
11624708|NCT00433706|Active Comparator|Standard imaging|
11624709|NCT00433693|Experimental|1|
11624710|NCT00433654|Active Comparator|MRI group|The MRI group underwent a one-hour MRI scan at the 9-12 weeks post-implant follow-up.
11624711|NCT00433654|Other|Control group|The control group waited for one hour (no MRI) at the 9-12 weeks post-implant follow-up.
11624712|NCT00433641|Placebo Comparator|1|placebo tablet
11624713|NCT00433641|Experimental|2|sibutramine
11624714|NCT00433641|Experimental|3|sibutramine
11624715|NCT00433615|Experimental|1|
11624716|NCT00433615|Experimental|2|
11624717|NCT00433589|Active Comparator|Arm I (anthracycline-based)|"FEC 100
~Canadian CEF
~CAF
~FAC
~E-CMF"
11624718|NCT00433589|Experimental|Arm II (docetaxel and capecitabine)|"Docetaxel
~Capecitabine"
11624719|NCT00433576|Experimental|Treatment (resveratrol, colorectomy)|"STAGE I: Patients undergo an colorectal endoscopy. Patients whose biopsies confirm colorectal adenocarcinoma histology and require surgical resection continue on study stage 2.
~STAGE II: Patients receive oral resveratrol on days 1-8. Patients undergo colorectomy on day 9. A tumor biopsy is performed during endoscopy and colorectomy for research purposes."
11624720|NCT00433563|Experimental|Once daily radiotherapy|Once daily radiotherapy
11624721|NCT00433563|Active Comparator|Twice daily radiotherapy|Twice daily radiotherapy
11624722|NCT00433550|Experimental|Group 1 (6/6 UGT1A1 genotype)|Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 2-15
11624723|NCT00433550|Experimental|Group 2 (6/7 UGT1A1 genotype)|Patients receive irinotecan hydrochloride as in group 1. They also receive oxaliplatin and capecitabine as in group 1 but at lower doses.
11624724|NCT00433550|Experimental|Group 3 (7/7 UGT1A1 genotype)|Patients receive irinotecan hydrochloride, oxaliplatin, and capecitabine as in group 1 but at lower doses.
11624725|NCT00433537|Experimental|VcR-CVAD induction followed by maintenance rituximab|"VcR-CVAD induction: Patients receive VcR-CVAD comprising bortezomib IV over 3-5 seconds on days 1 and 4; rituximab IV over 3-4 hours on day 1; doxorubicin hydrochloride IV over 48 hours on days 1 and 2; cyclophosphamide IV over 3 hours every 12 hours on days 1-3; vincristine IV over 3-5 seconds on day 3; and dexamethasone IV or orally once daily on days 1-4. Patients also receive filgrastim (G-CSF) subcutaneously (SC) or IV once daily beginning on day 5 or 6 and continuing until blood counts recover OR pegfilgrastim SC on day 5 or 6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~Maintenance rituximab: Beginning 4-8 weeks after completion of induction therapy, patients receive rituximab IV over 3-4 hours once weekly for 4 weeks. Treatment repeats every 6 months for up to 4 courses in the absence of disease progression or unacceptable toxicity."
11624726|NCT00433537|Experimental|VcR-CVAD induction followed by ASCT|"VcR-CVAD induction: Patients receive VcR-CVAD comprising bortezomib IV over 3-5 seconds on days 1 and 4; rituximab IV over 3-4 hours on day 1; doxorubicin hydrochloride IV over 48 hours on days 1 and 2; cyclophosphamide IV over 3 hours every 12 hours on days 1-3; vincristine IV over 3-5 seconds on day 3; and dexamethasone IV or orally once daily on days 1-4. Patients also receive filgrastim (G-CSF) SC or IV once daily beginning on day 5 or 6 and continuing until blood counts recover OR pegfilgrastim SC on day 5 or 6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~ASCT: After completion of induction therapy, patients who are eligible may have the option to receive consolidation therapy for autologous stem cell transplantation (off-study). These patients undergo stem cell harvest during courses 4, 5, or 6 of induction therapy."
11624727|NCT00433511|Active Comparator|Arm I (chemotherapy, placebo)|Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV over 20-30 minutes, and placebo IV over 30-90 minutes on day 1. Treatment repeats every 2 or 3 weeks for 4 courses. Beginning 3 weeks later, patients then receive paclitaxel IV over 1 hour on days 1, 8, and 15 and placebo IV over 30-90 minutes on day 1. Treatment with paclitaxel and placebo repeats every 3 weeks for 4 courses.
11624728|NCT00433511|Experimental|Arm II (chemotherapy, bevacizumab)|Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 2 or 3 weeks for 4 courses. Beginning 3 weeks later, patients then receive paclitaxel as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment with paclitaxel and bevacizumab repeats every 3 weeks for 4 courses.
11624729|NCT00433511|Experimental|Arm III (chemotherapy, bevacizumab monotherapy)|Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I and bevacizumab as in arm II. Treatment repeats every 2 or 3 weeks for 4 courses. Beginning 3 weeks later, patients then receive paclitaxel as in arm I and bevacizumab as in arm II. Treatment with paclitaxel and bevacizumab repeats every 3 weeks for 4 courses. Beginning 2 months later, patients then receive bevacizumab IV over 30-90 minutes on day 1. Treatment with bevacizumab alone repeats every 3 weeks for 10 courses.
11624730|NCT00433498|Experimental|Carboplatin/cisplatin and Etoposide with Pravastatin|
11624731|NCT00433498|Placebo Comparator|Carboplatin/cisplatin and Etoposide with Placebo|
11624732|NCT00433472|Other|MRI -|"MRI scan to be complete to look at RSR13 on measurement of T2 and T2* on MRI
~Procedure/surgery magnetic resonance imaging (MRI)"
11624733|NCT00433459|Active Comparator|COPP|procarbazine-containing consolidation chemotherapy arm
11624734|NCT00433459|Experimental|COPDAC|procarbazine-free consolidation chemotherapy arm
11624735|NCT00433446|Experimental|CNTO 328|
11624736|NCT00433433|Active Comparator|Favorable - Standard - any PET outcome|ABVDx3 cycles + Involved node RT (IN-RT) 30 Gy (+boost of 6Gy to residual lesions); FDG-PET after two cycles of ABVD for comparison with the experimental arm will be performed but no treatment adaptation will take place.
11624737|NCT00433433|Experimental|Favorable - Experimental - PET negative|"ABVDx2 cycles; then FDG-PET evaluation:
~PET negative: ABVDx2 without further RT (total of 4 cycles!)"
11624738|NCT00433433|Experimental|Favorable - Experimental - PET positive|"ABVDx2 cycles; then FDG-PET evaluation:
~PET positive: presumed poor-risk: switch to escalated BEACOPPx2 + INRT30Gy (+boost 6Gy to residual lesions)."
11624739|NCT00433433|Active Comparator|Unfavorable - Standard - Any PET outcome|ABVDx4 cycles + IN-RT 30Gy (+boost 6Gy to residual lesions). FDG-PET after two cycles of ABVD for comparison with the experimental arm will be performed but no treatment adaptation will take place.
11624740|NCT00433433|Experimental|Unfavorable - Experimental - PET negative|"ABVDx2 cycles; then FDG-PET evaluation:
~PET negative: ABVDx 4 cycles, without RT (total of 6 cycles)"
11624741|NCT00433433|Experimental|Unfavorable - Experimental - PET positive|"ABVDx2 cycles; then FDG-PET evaluation:
~PET positive: presumed poor-risk: switch to escalated BEACOPPx2 + INRT 30Gy (+boost 6Gy to residual lesions)."
11624742|NCT00433407|Experimental|trastuzumab|blood sample collected on different days from patients receiving trastuzumab
11624743|NCT00433394|Experimental|Stratum 1: No Consent for personal identification|Data to be collected for this stratum include histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries.
11624744|NCT00433394|Experimental|Stratum 2: Consent for personal identification - No Contact|Data will be collected for this study include:child's name, parent's name, address, telephone number, child's date of birth, race, ethnicity, histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries. No contact for future to ask me to consider taking part in Research Network approved studies
11624745|NCT00433394|Experimental|Stratum 3: Consent for personal identification - Contact|Data will be collected for this study include:child's name, parent's name, address, telephone number, child's date of birth, race, ethnicity, histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries Someone from the Childhood Cancer Research Network may contact me in the future to ask me to consider taking part in Research Network approved studies
11624746|NCT00433381|Experimental|Arm I (bevacizumab and temozolomide)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral temozolomide once daily on days 1-21.
11624747|NCT00433381|Experimental|Arm II (bevacizumab & irinotecan hydrochloride)|Patients receive bevacizumab IV as in Arm I followed by irinotecan hydrochloride IV over 90 minutes on days 1 and 15.
11624748|NCT00433342|Experimental|I|Flucloxacillin
11624749|NCT00433342|No Intervention|II|
11624750|NCT00433329|Experimental|Bosentan|Oral bosentan 62.5 mg twice daily (BID) first 4 weeks, followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated, with the addition of sildenafil 20 mg thrice daily (TID) in patients who do not reach the 6-MWT distance threshold at Week 16
11624751|NCT00433316|Experimental|study|Receiving 10ml of 1% ropivacaine
11624752|NCT00433316|Placebo Comparator|Control|Receiving 10ml of saline
11624753|NCT00433290|Experimental|A|
11624754|NCT00433290|Placebo Comparator|B|
11624755|NCT00433212|Active Comparator|A|Non-invasive respiratory support via nasal intermittent positive pressure ventilation
11624757|NCT00433199|Placebo Comparator|Placebo|Placebo
11624759|NCT00433186|Experimental|A|Mycophenolate
11624760|NCT00433173|Placebo Comparator|1|1) Group 1: Placebo
11624761|NCT00433173|Active Comparator|2|2) Group 2: Depot GnRH agonist (Zoladex) + Testosterone + placebo
11624762|NCT00433173|Active Comparator|3|3) Group 3: (Zoladex + Testosterone + aromatase inhibitor (anastrozole)
11624763|NCT00433160|Experimental|Teriparatide|20 micrograms for 104 weeks
11624764|NCT00433160|Placebo Comparator|Placebo|Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks
11624765|NCT00433147|Experimental|Afegostat tartrate 25 milligrams (mg) once per day|Afegostat tartrate was administered orally during the 4-week treatment period.
11624766|NCT00433147|Experimental|Afegostat tartrate 150 mg once per day|Afegostat tartrate was administered orally once per day during the 4-week treatment period.
11624767|NCT00433147|Experimental|Afegostat tartrate 150 mg once every four days|Afegostat tartrate was administered orally once every 4 days during the 4-week treatment period.
11624768|NCT00433147|Experimental|Afegostat tartrate 150 mg once every seven days|Afegostat tartrate was administered orally once every 7 days during the 4-week treatment period.
11624769|NCT00433121|Experimental|A|Discontinuation of neuroleptic or anti depressants
11624770|NCT00433069|Experimental|Intervention|Pioglitazone 15 mg QD + pegylated interferon Alfa-2a 180 μg QW + ribavirin 1000-1200 mg QD for 12 weeks, to be continued to a total of 48 weeks in case of complete early virological response, defined as undetectable serum HCV RNA after 12 weeks of triple therapy
11624771|NCT00433056|Experimental|1|STI
11624772|NCT00433056|Active Comparator|2|stable HAART, Any registered regimen containing NRTIs (AZT or D4T or 3TC or TDF or DDI), NNRTIs (EFV or NVP) or PIs (RTV-boosted ATV; IDV; LPV, fosAPV, SQV; unboosted ATV or NFV)is allowed according to international guidelines
11624773|NCT00433043|Active Comparator|1|CRT and b-blocker uptitration to target dose
11624774|NCT00433043|Active Comparator|2|CRT and continuation of entry b-blocker dose to 6 month evaluation
11624775|NCT00433017|Experimental|Verteporfin + Ranibizumab|Verteporfin (6 mg/m^2) photodynamic therapy (PDT) and ranibizumab (0.5 mg). Patients received three consecutive monthly ranibizumab injections starting on Day 1, and then as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).
11624776|NCT00433017|Active Comparator|Ranibizumab Monotherapy|Patients received three consecutive monthly ranibizumab injections starting on Day 1 and then as needed from Month 3 based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).
11624777|NCT00433004|No Intervention|1|No advance supply of emergency contraception
11624778|NCT00433004|Active Comparator|2|Advance supply of emergency contraception is given
11624779|NCT00432991|Placebo Comparator|Saline Placebo|Drug: Saline Placebo 0.5 mL, IM (in the muscle), one time
11624780|NCT00432991|Experimental|IM Ephedrine|Drug: Ephedrine [Synonyms: Ephedra, Ephedrinum] 25 mg, IM (in the muscle), one time
11624781|NCT00432965|Experimental|VAC Therapy|Treatment of Diabetic Foot Ulcers with VAC Therapy
11624782|NCT00432965|Active Comparator|Moist Wound Therapy|Moist Wound Therapy (standard of care)
11624783|NCT00432926|Experimental|1|Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
11624784|NCT00432926|Experimental|2|Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
11624785|NCT00432926|Active Comparator|3|An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
11624786|NCT00432913|Active Comparator|1g EPA per day|
11624787|NCT00432913|Active Comparator|2g EPA per day|
11624788|NCT00432913|Placebo Comparator|Placebo|
11624789|NCT00432900|Active Comparator|Healthy Volunteer|Healthy Volunteers
11624790|NCT00432900|Experimental|Patient|Multiple Sclerosis Patients
11624791|NCT00432874|Experimental|1|"Anterior stromal hydration (Wong method)"
11624792|NCT00432874|Active Comparator|2|Traditional lateral wound hydration
11624793|NCT00432861|Active Comparator|1|Pancrecarb(R) MS-16 Capsules
11624794|NCT00432861|Placebo Comparator|2|
11624795|NCT00432835|Active Comparator|Gastric Stimulation Days1-4/Sham5-8|The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days
11624796|NCT00432835|Active Comparator|Sham1-4/Gastric Stimulation Days5-8|The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.
11624797|NCT00432809|No Intervention|Medical therapy|Intensive medical therapy for diabetes
11624798|NCT00432809|Active Comparator|Gastric Bypass|Procedure/Surgery: Bariatric surgery laparoscipic Roux-en-Y Gastric Bypass (RYGB) plus intensive medical therapy
11624799|NCT00432809|Active Comparator|Sleeve Gastrectomy|Procedure/Surgery: Bariatric surgery - laparoscopic sleeve gastrectomy plus intensive medical therapy
11624800|NCT00432796|Active Comparator|1|"patients are randomized post-operative to receive either active treatment or placebo.
~Active treatment is Dalteparin injectable. Patients randomized to active treatment will receive Dalteparin 5,000 iu or 200 iu/kg once daily depending on the type of surgery they have had."
11624801|NCT00432796|Experimental|2|patients will be randomized post-operative to receive either active treatment or placebo
11624802|NCT00432744|Active Comparator|CoenzymeQ10|CoenzymeQ10: patients will be randomized to receive CoenzymeQ10 in either Period #1 (Months 0-6) or Period #2 (Months 7-12).
11624803|NCT00432744|Placebo Comparator|Placebo|Placebo: patients will be randomized to receive placebo either ion Period #1 (months 1-6) or Period #2 (months 7-12).
11624804|NCT00432679|Experimental|arm 1|study drug
11624805|NCT00432666|Experimental|IncobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection"
11624806|NCT00432666|Placebo Comparator|Placebo|
11624807|NCT00432640|Experimental|1|Endoscopic ultrasound staging
11624808|NCT00432640|Active Comparator|2|Surgical staging
11624809|NCT00432627|Experimental|Mild hepatic impaired|
11624810|NCT00432627|Experimental|Moderate hepatic impaired|
11624811|NCT00432627|Experimental|Severe hepatic impaired|
11624812|NCT00432627|Experimental|Healthy volunteers|Controlled group
11624813|NCT00432614|Experimental|Group 1|SR58611A 350mg twice daily with escitalopram 10mg once daily
11624814|NCT00432614|Active Comparator|Group 2|placebo with escitalopram 10mg once daily
11624815|NCT00432614|Placebo Comparator|Group 3|placebo
11624816|NCT00432601|Experimental|Arm 1|Patients will receive Michigan Cancer Consortium decision aid.
11624817|NCT00432601|Active Comparator|Arm 2|Patients will receive National Comprehensive Cancer Network decision aid.
11624818|NCT00432575|Placebo Comparator|1|
11624819|NCT00432575|Active Comparator|2|surinabant 2,5 mg/day
11624820|NCT00432575|Active Comparator|3|surinabant 5 mg/day
11624821|NCT00432575|Active Comparator|4|surinabant 10 mg/day
11624822|NCT00432510|Experimental|Single Dose|1,000 Units (U) of C1INH-nf administered intravenously (IV).
11624823|NCT00432510|Experimental|First Dose Followed by Second Dose|1,000 U of C1INH-nf administered IV, followed by a second 1,000 U dose 60 minutes later.
11624824|NCT00432484|Placebo Comparator|1|Placebo with Lingzhi(Granoderma Lucidum) and Sen Miao San
11624825|NCT00432471|Experimental|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
11624826|NCT00432458|Experimental|Arm I: Thal/ZLD|Thalidomide (Thal) + Zolendronic acid (ZLD)
11624827|NCT00432458|Experimental|Arm II: ZLD|Zoledronic acid (ZLD)
11624828|NCT00432445|Experimental|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks. Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
11624829|NCT00432432|Placebo Comparator|2|placebo with infliximab
11624830|NCT00432406|Active Comparator|1|infliximab
11624831|NCT00432406|Active Comparator|2|etanercept
11624832|NCT00432380|Experimental|PLACEBO-ROTARIX-ROTARIX GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 2 oral doses of Rotarix™ liquid vaccine at Month 1 and Month 2, and a single oral dose of placebo at Day 0. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
11624833|NCT00432380|Experimental|ROTARIX-PLACEBO-ROTARIX GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 2 oral doses of Rotarix™ liquid vaccine at Day 0 and Month 2, and a single oral dose of placebo at Month 1. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
11624834|NCT00432380|Placebo Comparator|PLACEBO GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 3 oral doses of placebo at Day 0, Month 1 and Month 2. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
11624835|NCT00432367|Experimental|1|OptiMAL® antigen screening and treatment with SP plus LLIN
11624836|NCT00432367|Experimental|2|OptiMAL® antigen screening and treatment with AQ+AS plus LLIN
11624837|NCT00432367|Active Comparator|3|SP-IPTp plus LLIN
11624838|NCT00432341|Experimental|BOTOX®|Botulinum toxin type A (BOTOX®)
11624839|NCT00432341|Active Comparator|Dysport®|Botulinum toxin type A (Dysport®)
11624840|NCT00432315|Experimental|1|Resectable NSCLC
11624841|NCT00432315|Experimental|2|Unresectable NSCSC
11624842|NCT00432302|Experimental|Sagopilone|Subjects received 28 mg ZK 219477, containing 14 kBq/7.8 µg [14C]-ZK 219477 in the first infusion (Treatment course 1) followed by subsequent infusions (Treatment courses 2 to n [till disease progression]) of 16 mg/m2 ZK 219477 without radioactive label. Interval between the treatments was at least 21 days.
11624843|NCT00432276|Experimental|Alogliptin 25 mg + Pioglitazone 30 mg add-on to Metformin|Alogliptin 25 mg, tablets, orally, once daily; pioglitazone 30 mg, tablets, orally, once daily; and the maximum tolerated dose of metformin, tablets, orally, for up to 52 weeks.
11624844|NCT00432276|Active Comparator|Pioglitazone 45 mg add-on to Metformin|Alogliptin placebo-matching tablets, orally, once daily; pioglitazone 45 mg, tablets, orally, once daily; and the maximum tolerated dose of metformin, tablets, orally, for up to 52 weeks.
11624845|NCT00432237|Experimental|MK0974 50 mg|MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack
11624846|NCT00432237|Experimental|MK0974 150 mg|MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack
11624847|NCT00432237|Experimental|MK0974 300 mg|MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack
11624848|NCT00432237|Placebo Comparator|Placebo|Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack
11624849|NCT00432211|Placebo Comparator|1|Complete Scar Excision
11624850|NCT00432211|Placebo Comparator|2|Staged Excision of scar
11624851|NCT00432198|Experimental|1|Oral
11624852|NCT00432198|Experimental|2|Oral
11624853|NCT00432198|Placebo Comparator|3|Oral
11624854|NCT00432185|Active Comparator|1|One day treatment
11624855|NCT00432185|Active Comparator|2|Two day treatment
11624856|NCT00432172|Active Comparator|Group 1 (Luminal A) Standard treatment|Standard treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv every 21 days for 4 cycles.
11624857|NCT00432172|Experimental|Group 1 (Luminal A) Selective treatment|"Selective treatment:
~Postmenopausal patients: exemestane x 6 months Premenopausal patients: goserelin x 6 months + exemestane x 6 months"
11624858|NCT00432172|Active Comparator|Group 2 (Basal) Standard treatment|Standard treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv every 21 days for 4 cycles.
11624859|NCT00432172|Experimental|Group 2 (Basal) Selective treatment|Selective treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv and carboplatin (Cb) (area under the curve = 6 mg/mL) iv every 21 days for 4 cycles.
11624860|NCT00432159|Experimental|1-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at a single level of the cervical spine, C3 to C7 inclusive.
11624861|NCT00432159|Active Comparator|1-level ACDF with plate|Anterior Cervical Discectomy and Fusion with plate (ACDF with plate) using allograft spacer and the SLIM-LOC™ Anterior Cervical Plate System at a single level of the cervical spine, C3 to C7 inclusive.
11624862|NCT00432159|Experimental|2-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at two adjacent levels of the cervical spine, C3 to C7 inclusive.
11624863|NCT00432159|Active Comparator|2-level ACDF|Anterior Cervical Discectomy and Fusion with plate (ACDF with plate) using allograft spacer and the SLIM-LOC™ Anterior Cervical Plate System at two adjacent levels of the cervical spine, C3 to C7 inclusive.
11624864|NCT00432159|Experimental|Training: 1 & 2-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at a single level or multiple levels of the cervical spine, C3 to C7 inclusive. Training cohort.
11624865|NCT00432133|Experimental|1|Protection motivation theory-based tailored intervention to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
11624866|NCT00432133|Experimental|2|Environmental access and awareness intervention to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
11624867|NCT00432133|Experimental|3|Combination intervention combining protection motivation and environmental intervention components to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
11624868|NCT00432120|Active Comparator|A|"nonselective - clopidogrel 600 mg >6 hours before coronary angiography;"
11624869|NCT00432120|Active Comparator|B|"selective - clopidogrel 600 mg in the cath-lab after coronary angiography, only in case of percutaneous coronary intervention"
11624870|NCT00432107|Experimental|2-stage mono therapy of APO866|The treatment period consists of 3 consecutive 28 day cycles. Each cycle starts with a 4 day continuous infusion of the study medication followed by a 24 day break
11624871|NCT00432094|Experimental|2 Transplants|Patients with Germ Cell Tumors (GCT) treated with a second tandem autologous stem cell transplant (AuSCT) with non-cross-resistant conditioning regimens.
11624872|NCT00432094|Active Comparator|1 Transplant|Patients with Germ cell tumors who receive one transplant only.
11624873|NCT00432068|Experimental|Octreotide pamoate|
11624874|NCT00432055|Experimental|I|Botox
11624875|NCT00432055|Placebo Comparator|II|
11624876|NCT00432042|Experimental|ProQuad® + Infanrix® hexa|Pediatric (12 to 23 months of age) participants received ProQuad® and Infanrix® hexa (booster dose) concomitantly on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
11624877|NCT00432042|Active Comparator|ProQuad®|Pediatric (12 to 23 months of age) participants received ProQuad® on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
11624878|NCT00432042|Active Comparator|Infanrix® hexa|Pediatric (12 to 23 months of age) participants received Infanrix® hexa (booster dose) on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
11624879|NCT00432029|Other|1|IDDM
11624880|NCT00432029|Other|2|Hypercholesterolemia and/or Hypertension
11624881|NCT00432029|Other|3|age/sex matched healthy control subjects
11624882|NCT00431964|Active Comparator|Active|azithromycin 250 mg tablets
11624883|NCT00431964|Placebo Comparator|Placebo|placebo tablets (matched to active drug in appearance)
11624884|NCT00431951|Experimental|ST-246|250 mg, 400 mg or 800 mg of ST-246 given once daily for 21 days
11624885|NCT00431951|Placebo Comparator|placebo|Placebo to match ST-246
11624886|NCT00431912|Experimental|Single-arm, trinomial 2-stage design|
11624887|NCT00431873|Experimental|1|MGCD0103 administered orally three times per week.
11624888|NCT00431847||Group 1|Soldiers with one or more severely injured, mangled or amputated limbs from the Iraq/Afghanistan war aggressively treated with regional anesthesia for pain control.
11624889|NCT00431847||Group 2|Soldiers with one or more severely injured, mangled or amputated limbs from the Iraq/Afghanistan war receiving standard treatment for pain control.
11625165|NCT00428935|Experimental|High Dose|High Dose - 1.0E11 vg/kg
11624890|NCT00431821|Other|Arm 1|Home-based exercise prescriptions with weekly motivational telephone calls.
11624891|NCT00431821|Other|Arm 2|Stroke education program with matched attention phone calls
11624892|NCT00431808|Experimental|I, AMA1 vaccine|20 volunteers will receive 3 doses of the vaccine
11624893|NCT00431795|Experimental|1|Epi
11624894|NCT00431795|Experimental|2|Cael
11624895|NCT00431769|Experimental|Bortezomib|
11624896|NCT00431704|Experimental|vinorelbine, carboplatin, trastuzumab|
11624897|NCT00431691|Active Comparator|1|
11624898|NCT00431691|Placebo Comparator|2|
11624899|NCT00431678|Experimental|Arm 1|
11624900|NCT00431678|Active Comparator|Arm 2|
11624901|NCT00431639|Active Comparator|Comparison|For the comparison condition, subjects will be asked to choose one of four topics that will be determined thatday with a recreational therapist for 20 minutes.
11624902|NCT00431639|Active Comparator|Treatment|The treatment condition will consist of a 20-minute visit by a therapy dog and its owner. Therapy dogowners will be instructed to limit conversation with the patient to topics of the therapy dog, thepatients pets, and pets in general.
11624903|NCT00431626|Experimental|Laser TURP with dutasteride|Prior to and after standard treatment with laser TURP, dutasteride is applied to each patient
11624904|NCT00431626|Placebo Comparator|Laser TURP with placebo|Prior to and after standard treatment with laser TURP, placebo is applied to each patient
11624905|NCT00431613|Experimental|1|DG -> RT
11624906|NCT00431613|Experimental|2|DG -> RT -> DCarbo
11624907|NCT00431600|Experimental|1|12 healthy male subjects
11624908|NCT00431561|Experimental|AP 12009 10 µM|
11624909|NCT00431561|Experimental|AP 12009 80 µM|
11624910|NCT00431561|Active Comparator|Chemotherapy|
11624911|NCT00431496|Experimental|Cinacalcet|Cinacalcet was administered orally at a starting dose of 30 mg/day for 23 weeks. Possible sequential doses during the study were 30, 60, 90, 120, and 180 mg. Dose escalation of cinacalcet occurred if the intact parathyroid hormone (iPTH) level from the previous study visit was > 31.8 pmol/L (300 pg/mL) unless the participant had either reached the maximum dose (180 mg/day), the serum corrected total calcium was < 2.1 mmol/L (8.4 mg/dL), or the participant experienced an adverse event that precluded a dose increase.
11624912|NCT00431483|Other|Pharmaceutical counseling|
11624913|NCT00431457|Active Comparator|Implantation intracranial electrode with immediate stimulation|
11624914|NCT00431457|Placebo Comparator|Implantation intracranial electrode without stimulation|
11624915|NCT00431457|Active Comparator|Resective surgery: amygddohyppocampertomy|
11624916|NCT00431444|Active Comparator|Zoledronic Acid|Zoledronic acid 5 mg (single i.v. infusion) + daily oral placebo for 6 months (zoledronic acid group)
11624917|NCT00431444|Active Comparator|Raloxifene|Placebo (single i.v. infusion) + oral raloxifene 60 mg/day for 6 months (raloxifene group)
11624918|NCT00431431|Experimental|1|tibolone
11624919|NCT00431431|Active Comparator|2|raloxifene
11624920|NCT00431418|Active Comparator|1|Sildenafil oral solution.
11624921|NCT00431418|Placebo Comparator|2|Placebo oral solution.
11624922|NCT00431353|Experimental|1|
11624923|NCT00431353|Experimental|2|
11624924|NCT00431301||Case|PSP Cases
11624925|NCT00431301||Control|Healthy Controls
11624926|NCT00431275|Experimental|Commercial Formulation|Commercial Formulation
11624927|NCT00431275|Experimental|Current Formulation|Current Formulation
11624928|NCT00431249|Other|one|
11624929|NCT00431223|Active Comparator|Active Group|7 patients were assigned to Cognitive Remediation Therapy..
11624930|NCT00431223|No Intervention|Control Group|4 patients were assigned to Control group or no cognitive remediation therapy.
11624931|NCT00431210|Experimental|Biological/Vaccine|Epstein-Barr virus-specific adoptive T-cells immunotherapy given intravenously on Days 1 and 14
11624932|NCT00431184|Active Comparator|Pentazocine then Lorazepam|In the first leg of the study, pentazocine will be given to subjects randomly assigned to this group. On Day 1, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later. On Day 2, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two hours later.
11624933|NCT00431184|Active Comparator|Lorazepam then Pentazocine|In the first leg of the study, lorazepam will be given to subjects randomly assigned to this group. On Day 3, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two hours later. On Day 2, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later.
11624934|NCT00431158|Active Comparator|1|ARDSnet Protocol
11624935|NCT00431158|Active Comparator|2|OLA Protocol
11624936|NCT00431132|Experimental|Vagifem® 10 mcg|One 10 mcg (microgram) vaginal tablet of intravaginal estradiol (Vagifem®) once daily for two weeks followed by one 10 mcg vaginal tablet twice weekly for 50 weeks
11624937|NCT00431106|Active Comparator|1|Vinorelbine/Gemcitabine (VG)
11624938|NCT00431106|Active Comparator|2|Capecitabine (Cap)
11624939|NCT00431093|Experimental|1|tibolone
11624940|NCT00431093|Active Comparator|2|low-dose estradiol/noresterone
11624941|NCT00431080|Experimental|1|FEC -> TXT
11624942|NCT00431080|Experimental|2|FEC -> TXL
11624943|NCT00431067|Experimental|BIBW 2992|BIBW 2992 (Afatinib) once daily until progression
11624944|NCT00431054|Experimental|Perifosine + Docetaxel|
11624945|NCT00431041|Experimental|Solifenacin|Solifenacin succinate: 5 mg tablets, taken orally, once daily
11624946|NCT00431041|Active Comparator|Oxybutynin IR|Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day
11624947|NCT00431028|No Intervention|colirio|prednisolone 1% eye drops + ciprofloxacin 0,3% eye drops
11624948|NCT00430989|Other|70% Nitrous Oxide|General anaesthesia using 70% Nitrous Oxide with fraction of inspired oxygen at 30%
11624949|NCT00430989|Other|No Nitrous Oxide|General anaesthesia not containing Nitrous oxide with fraction of inspired oxygen at 30%
11624950|NCT00430963|Placebo Comparator|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
11625395|NCT00426166|Experimental|1|Low Level Laser Therapy
11624951|NCT00430963|Experimental|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
11624952|NCT00430950|Experimental|1|olmesartan medoximil (OM)/ hydrochlorothiazide (HCTZ) 40/25 mg + OM/HCTZ 20/25 mg matching placebo
11624953|NCT00430950|Experimental|2|olmesartan medoximil (OM)/ hydrochlorothiazide (HCTZ)20/25 mg + OM/HCTZ 40/25 matching placebo
11624954|NCT00430937|Experimental|Daptomycin|4 mg/kg intravenous (i.v.) once daily
11624955|NCT00430937|Active Comparator|Pooled Comparator|
11624956|NCT00430924|Active Comparator|1|Eplerenone
11624957|NCT00430924|No Intervention|2|Control
11624958|NCT00430898|Placebo Comparator|1. Placebo|Placebo to mimic 40 mg of Simulect
11624959|NCT00430898|Experimental|2. 40 mg Simulect|40 mg of Simulect
11624960|NCT00430885|Placebo Comparator|Saline|
11624961|NCT00430885|Experimental|Octagam (IVIG)|Octagam (IVIg) is intravenous immunglobulin
11624962|NCT00430872||MDASI-Spine Tumor Module Survey|M. D. Anderson Symptom Inventory-Spine (survey) of patients with a tumor on the spine or spinal cord.
11624963|NCT00430859|Experimental|1|BIAP
11624964|NCT00430859|Placebo Comparator|Placebo|Placebo, saline
11624965|NCT00430846|Experimental|A|
11624966|NCT00430820||1|30 patients
11624967|NCT00430820||2|30 patients
11624968|NCT00430820||3|30 patients
11624969|NCT00430781|Experimental|Combination arm|Pazopanib plus lapatinib
11624970|NCT00430781|Active Comparator|Lapatinib monotherapy|Lapatinib
11624971|NCT00430781|Active Comparator|Pazopanib monotherapy|Pazopanib
11624972|NCT00430768|Experimental|Group 1 Low Dose|"rAAV1-CB-hAAT 6.9 x10e12 vector genomes (vg) administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
11624973|NCT00430768|Experimental|Group 2 Middle Dose|"rAAV1-CB-hAAT 2.2 x 10e13 vg administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
11624974|NCT00430768|Experimental|Group 3 High Dose|"rAAV1-CB-hAAT 6.0 x10e13 vg administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
11624975|NCT00430755|Other|Inpatients of hospital|"All patients who were admitted to the departments of nephrology or cardiology in a tertiary hospital in Germany.
~The intervention was use of an expert system to acquire medical histories by direct interview of patients.
~Description of the software program - The program tested in this study consisted of a data acquisition [history-taking] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
11624976|NCT00430742|Experimental|1|Arm 1: MK0364 0.5 mg capsule once daily
11624977|NCT00430742|Experimental|2|Arm 2: MK0364 1 mg capsule once daily
11624978|NCT00430742|Experimental|3|Arm 3: MK0364 2 mg capsule once daily
11624979|NCT00430742|Placebo Comparator|4|Arm 4: Pbo capsule once daily
11624980|NCT00430716|Experimental|Sildenafil High dose|
11624981|NCT00430716|Experimental|Sildenafil Low dose|
11624982|NCT00430716|Experimental|Sildenafil medium dose|
11624983|NCT00430716|Experimental|Sildenafil - Open label Phase|Open label extension from week 12 to week 24.
11624984|NCT00430703|Experimental|1|Patients with severe traumatic brain injury
11624985|NCT00430703|Experimental|2|Healthy volunteers
11624986|NCT00430690||1|Cocaine dependent subjects
11624987|NCT00430690||2|Healthy controls
11624988|NCT00430690||3|Siblings of cocaine dependent subjects
11624989|NCT00430677|Experimental|Abatacept 30 mg/kg+Corticosteroids+MMF|Short-term Period
11624990|NCT00430677|Experimental|Abatacept 10 mg/kg+Corticosteroids+MMF|Short-term Period
11624991|NCT00430677|Experimental|Placebo+Corticosteroids+MMF|Short-term Period
11624992|NCT00430677|Experimental|Abatacept 10mg/kg|Long-term Extension Period
11624993|NCT00430651|Experimental|1|Docetaxel + Carboplatin
11624994|NCT00430651|Experimental|2|Docetaxel
11624995|NCT00430638|Experimental|Treatment|Olmesartan medoxomil, plus hydrochlorothiazide, if necessary
11624996|NCT00430638|Placebo Comparator|Placebo|Placebo tablets were taken once daily for 12 weeks
11624997|NCT00430625|Experimental|VPRIV®-45 U/kg, IV, every other week|VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB)
11624998|NCT00430625|Experimental|VPRIV®-60 U/kg, IV, every other week|VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase,GA-GCB)
11624999|NCT00430612||1|Non-voluntary registry of consecutive patients diagnosed as having a MI at each study site
11625000|NCT00430586|Experimental|20 U NT 201|
11625001|NCT00430586|Placebo Comparator|Placebo|
11625002|NCT00430586|Experimental|10 U NT 201|
11625003|NCT00430586|Experimental|30 U NT 201|
11625004|NCT00430573|Experimental|DCS-augmented CBT-IC|D-cycloserine-augmented CBT-IC
11625005|NCT00430573|Placebo Comparator|Placebo-augmented CBT-IC|Placebo-augmented CBT-IC
11625006|NCT00430560|Active Comparator|1|work therapy
11625007|NCT00430560|Experimental|2|work therapy plus cognitive remediation
11625008|NCT00430521|Experimental|GSK1562902A V/I/6 Group|Subjects received 1 dose of vaccine formulated from VT strain at Day 0 and 1 dose of the vaccine including IN at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
11625009|NCT00430521|Experimental|GSK1562902A V/V/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
11625162|NCT00428948|Experimental|Tolvaptan|Participants received the highest tolerated split-dose regimen (upon awakening and 9 hours later) of tolvaptan 45/15 mg, 60/30 mg, or 90/30 mg orally for 36 months.
11625010|NCT00430521|Experimental|GSK1562902A 2V/I/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN strain at Month 6.The vaccine was administered in the deltoid region of the non-dominant arm.
11625011|NCT00430521|Experimental|GSK1562902A 2V/V/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
11625012|NCT00430521|Experimental|GSK1562902A V/I/12 Group|Subjects received 1 dose of vaccine formulated from VT strain at Day 0 and 1 dose of the vaccine including IN strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
11625013|NCT00430521|Experimental|GSK1562902A V/V/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
11625014|NCT00430521|Experimental|GSK1562902A 2V/I/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.
11625015|NCT00430521|Experimental|GSK1562902A 2V/V/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.
11625016|NCT00430508|Experimental|4|olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
11625017|NCT00430508|Experimental|1|olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
11625018|NCT00430508|Experimental|3|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
11625019|NCT00430508|Experimental|2|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
11625020|NCT00430495|Experimental|Atacicept 25 mg|
11625021|NCT00430495|Experimental|Atacicept 75 mg|
11625022|NCT00430495|Experimental|Atacicept 150 mg|
11625023|NCT00430495|Placebo Comparator|Placebo|
11625024|NCT00430482|Experimental|1|Cognitive Behavioral Therapy
11625025|NCT00430482|Active Comparator|2|Individual Counseling
11625026|NCT00430456|Other|Arm 1|Higher Intensity, Shorter Duration Treadmill Training
11625027|NCT00430456|Active Comparator|Arm 2|Lower Intensity, Longer Duration Treadmill Training
11625028|NCT00430430|Experimental|High MUFA|high monounsaturated fat background diet to portfolio diet
11625029|NCT00430430|Active Comparator|Low MUFA|low monounsaturated fat background diet to portfolio diet
11625030|NCT00430417||3 groups|Group 1: post-partum breastfeeding women
11625031|NCT00430417||Group 2|Group 2: post-partum bottlefeeding women
11625032|NCT00430417||Group 3|Group 3: normal non-pregnant controls who are age and race-matched to Group 1
11625033|NCT00430404|No Intervention|Usual care (controlled group)|Usual care for management of depression
11625034|NCT00430404|Experimental|collaborative care (Intervention)|Collaborative care for management of depression for intervention group. We provided multidisciplinary groups of care from psychiatrist, psychologist, social counselor, general practitioners and case managers for intervention group.
11625035|NCT00430391|Experimental|DVD patient high risk|Patients with a diagnosis of schizophrenia/schizoaffective disorder randomized to the DVD, high risk version
11625036|NCT00430391|Experimental|DVD patient low risk|Patient with a diagnosis of schizophrenia/schizoaffective disorder randomized to DVD consent, low risk version
11625037|NCT00430391|Experimental|DVD normal high risk|Participants with no psychiatric diagnosis randomized to DVD consent, high risk version
11625038|NCT00430391|Experimental|DVD normal low risk|Participants with no psychiatric diagnosis randomized to DVD consent, low risk version
11625039|NCT00430391|Experimental|Routine control high risk|Participants with no psychiatric diagnosis randomized to routine consent, high risk version
11625040|NCT00430391|Experimental|Routine control low risk|Participants with no psychiatric diagnosis randomized to routine consent, low risk version
11625041|NCT00430391|Experimental|Routine patient low risk|Participants with schizophrenia/schizoaffective disorder randomized to routine consent, low risk version
11625042|NCT00430391|Experimental|Routine patient high risk|Participants with schizophrenia/schizoaffective disorder randomized to routine consent, high risk version
11625043|NCT00430378|Experimental|Acupuncture|Acupuncture Before the Radiation Treatment
11625044|NCT00430378|Experimental|Standard Care|Standard Care Without Acupuncture
11625045|NCT00430365|Placebo Comparator|placebo group|Administration of oral placebo
11625046|NCT00430365|Experimental|lenalidomide group|Administration of lenalidomide
11625047|NCT00430352|Experimental|1|
11625048|NCT00430313|Experimental|Electro-Stimulation (Active Site)|Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
11625049|NCT00430313|Experimental|Electro-Stimulation (Inactive Site)|"Electro-stimulation at a inactive site on the bottom of the foot (a placebo site)."
11625050|NCT00430300|Experimental|150mcg, 450mcg or 1350mcg|Active treatment given BID via a double pin monodose capsule inhaler device
11625051|NCT00430300|Placebo Comparator|Placebo|Placebo treatment given BID via a single pin monodose inhaler device
11625052|NCT00430287||1: Primary open angle glaucoma|Patients with a form of primary open angle glaucoma
11625053|NCT00430287||2: No known eye disease (controls)|Patients with no known eye disease (controls)
11625054|NCT00430248|Experimental|Febuxostat 40 mg QD|
11625055|NCT00430248|Experimental|Febuxostat 80 mg QD|
11625056|NCT00430248|Active Comparator|Allopurinol 200 mg or 300 mg QD|(dependent on renal function)
11625104|NCT00429702|Experimental|Benadryl® Ativan® Decadron® (BAD) Pump|Patients receive ondansetron hydrochloride IV twice daily and saline IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive diphenhydramine hydrochloride, lorazepam, and dexamethasone by continuous infusion pump.
11625163|NCT00428948|Placebo Comparator|Placebo|Participants received placebo (upon awakening and 9 hours later) orally for 36 months.
11625057|NCT00430183|Experimental|Arm A: docetaxel + LHRH agonist + surgical intervention|"Patients receive six cycles of docetaxel administered every 3 weeks combined with 18-24 weeks of androgen deprivation therapy. During each cycle of chemotherapy, all patients should undergo premedication with dexamethasone 8 mg orally prior to docetaxel. Dexamethasone may also be given intravenously according to institutional guidelines.
~Patients will also receive androgen deprivation for 18-24 weeks of an LHRH agonist (eg, leuprolide acetate, goserelin acetate). Additional premedication and antiemetics may be given at the physician's discretion and as defined by the protocol.
~Patients will undergo standard surgical intervention. The surgical procedures will be performed within 60 days of the completion of neoadjuvant therapy. Patients are allowed to receive adjuvant external beam radiation at the discretion of the treating physician and as defined per the protocol. It must be initiated within 6 months of the date of surgery."
11625058|NCT00430183|Other|Arm B: surgical intervention|All patients undergo standard surgical intervention. The surgical procedures will be performed within 60 days of randomization. Patients are allowed to receive adjuvant external beam radiation at the discretion of the treating physician and as defined per the protocol. Adjuvant radiation must be initiated within 6 months of the date of surgery.
11625059|NCT00430170|Active Comparator|1|dipyridamol during 7 days and before ischemic exercise caffeine 4mg/kg
11625060|NCT00430170|Placebo Comparator|2|dipyridamol during 7 days and before ischemic exercise placebo
11625061|NCT00430144|Experimental|CKD-602|
11625062|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction Prot III|
11625063|NCT00430118|Experimental|Induction Prot I/Pred - reinduction Prot III|
11625064|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction Prot II|
11625065|NCT00430118|Active Comparator|Induction Prot I/Pred - reinduction Prot II|
11625066|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 2x Prot III|
11625067|NCT00430118|Experimental|Induction Prot I/Pred - reinduction 2x Prot III|
11625068|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 3 HR courses + 3x Prot III|
11625069|NCT00430118|Experimental|Induction Prot I/Pred - reinduction 3 HR courses + 3x Prot III|
11625070|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 6 HR courses + Prot II|
11625071|NCT00430118|Active Comparator|Induction Prot I/Pred - reinduction 6 HR courses + Prot II|
11625072|NCT00430092|Experimental|Difluprednate 0.05% BID|Difluprednate 0.05% 1 drop BID for 14 days
11625073|NCT00430092|Experimental|Difluprednate 0.05% QID|Difluprednate 0.05% 1 drop QID for 14 days
11625074|NCT00430092|Placebo Comparator|Placebo|Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.
11625075|NCT00430079|Experimental|Diagnostic (etanidazole)|Patients receive etanidazole derivative EF5 IV over 1-2½ hours once within 1-2 days before surgical resection or biopsy. Tumor tissue, normal tissue, and/or tumor-infiltrated lymph node samples are collected during surgery and stained for biological markers. Fluorescent immunohistochemistry techniques are used to determine the presence, distribution, and levels of EF5 binding.
11625076|NCT00430066|Experimental|Imatinib Mesylate|400 mg/day by mouth for 6 months (+ 6 months in case of responsiveness)
11625077|NCT00430040|Experimental|carvedilol|carvedilol
11625078|NCT00430040|Active Comparator|lisinopril|lisinopril
11625079|NCT00430027|Experimental|Capecitabine, oxaliplatin, cetuximab, and radiation therapy|Patients enrolled on the trial will receive neoadjuvant combined capecitabine, oxaliplatin, cetuximab, and radiation therapy. This will be followed by surgical resection and adjuvant capecitabine, oxaliplatin, and cetuximab
11625080|NCT00430014|Experimental|Atiprimod|
11625081|NCT00429962|Experimental|A|intravitreal ranibizumab used in combination with verteporfin photodynamic therapy
11625082|NCT00429962|Active Comparator|B|intravitreal ranibizumab
11625083|NCT00429949|Experimental|Dasatinib|"Dasatinib will be administered continuously at an oral dose of 70 mg BID on Days 1-28 of each 28 day cycle.
~In patients with stable disease after 8 weeks on therapy the dasatinib will be increased to 100 mg BID on Days 1-28 on each 28 day cycle."
11625084|NCT00429936|Active Comparator|100 mg fenretinide softgel capsules|Three (3) 100-mg fenretinide softgel capsules
11625085|NCT00429936|Active Comparator|Fenretinide and placebo softgel capsules|One (1) 100-mg fenretinide softgel capsule and two (2) placebo softgel capsules
11625086|NCT00429936|Placebo Comparator|Placebo softgel capsules|Three (3) placebo softgel capsules
11625087|NCT00429923|Experimental|Difluprednate 0.05% BID|Difluprednate 0.05% 1 drop BID for 14 days.
11625088|NCT00429923|Experimental|Difluprednate 0.05% QID|Difluprednate 0.05% 1 drop QID for 14 days.
11625089|NCT00429923|Placebo Comparator|Placebo|Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.
11625090|NCT00429871|Experimental|1|DF
11625091|NCT00429871|Experimental|2|DC
11625092|NCT00429858|Experimental|Targeted therapy group|Gemcitabine monotherapy until disease progression, followed by gemcitabine + S-1
11625093|NCT00429806|Placebo Comparator|Placebo|Placebo suppository; once daily for 7 days.
11625094|NCT00429806|Experimental|DHEA 0.50%|DHEA 0.50% (6.5 mg) suppository; once daily for 7 days.
11625095|NCT00429806|Experimental|DHEA 1.0%|DHEA 1.0% (13 mg) suppository; once daily for 7 days.
11625096|NCT00429806|Experimental|DHEA 1.8%|DHEA 1.8% (23.4 mg) suppository; once daily for 7 days.
11625097|NCT00429793|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11625098|NCT00429780|No Intervention|Alum-ALM + BCG|Alum-ALM + BCG
11625099|NCT00429780|No Intervention|Placebo|BCG diluent
11625100|NCT00429754|Other|aprepitant|Aprepitant treatment
11625101|NCT00429715|Experimental|Alum-ALM + BCG|Alum-ALM + BCG
11625102|NCT00429715|Active Comparator|BCG|BCG
11625103|NCT00429715|Placebo Comparator|BCG diluent|Diluent
11625161|NCT00428974|Placebo Comparator|Placebo|
11625164|NCT00428935|Experimental|Low Dose|Low dose cohort - 2.0E10 vg/kg
11625105|NCT00429702|Active Comparator|Control Arm Saline|Patients receive ondansetron hydrochloride IV twice daily and dexamethasone IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive saline by continuous infusion pump.
11625106|NCT00429663|Other|IM Nails|Reamed, Interlocking Intramedullary Nail - Randomized treatment
11625107|NCT00429663|Other|Plate Fixation|Locking Periarticular Plate - Randomized Treatment
11625108|NCT00429650|Experimental|1|Increased amount of exercise to maintain weight loss.
11625109|NCT00429650|Experimental|2|Combination of Exercise and Diet to maintain weight loss
11625110|NCT00429650|Active Comparator|3|Use diet alone to maintain weight loss.
11625111|NCT00429585|Other|Randomized Treatment - Nail|Randomized Treatment - Nail
11625112|NCT00429585|Other|Randomized Treatment - Plate|Randomized Treatment - Plate
11625113|NCT00429572|Experimental|Allogeneic Transplantation|Intravenous Fludarabine 30 mg/m^2 daily on days 1-5, and Melphalan 70 mg/m^2 on days 4 and 5 followed by blood stem cell transplant on day 7.
11625114|NCT00429559|Experimental|A|
11625115|NCT00429546|Experimental|Intervention|Participants will receive a cognitive-behavioral intervention designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child
11625116|NCT00429546|Active Comparator|Control|Participants will receive treatment as usual
11625117|NCT00429507|Experimental|Samarium 153-EDTMP + Stem Cell Transplant|Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) by vein On Day 1. If enough study drug goes to bones, will receive a higher dose of 153 Sm-EDTMP, called a therapy dose, 7-14 days after the tracer dose. Stem Cell Transplant on Day 0, about 14-21 days after Samarium 153-EDTMP. Questionnaires taking about 15 minutes to complete.
11625118|NCT00429494|Experimental|Leuprolide Acetate|Leuprolide Acetate 22.5 mg intramuscular (IM) injection 2 months before hematopoietic stem cell transplantation (HSCT) transplant and 3 months post-transplant.
11625119|NCT00429455||Survey Participants|Female patients who had a hematopoietic stem cell transplantation between January 1987 and September 2004 at M. D. Anderson Cancer Center.
11625120|NCT00429442|Active Comparator|1|
11625121|NCT00429442|Placebo Comparator|2|
11625122|NCT00429429|Experimental|Peanut protein solution|Subjects receiving the peanut sublingual peanut protein drops. Sublingual Immunotherapy.
11625123|NCT00429416|Experimental|LLME to Decrease GVHD Following HSC T|To determine if an experimental agent, LLME, can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).
11625124|NCT00429403|Experimental|Goserelin|3.6 mg subcutaneously 1 week before chemotherapy, then once a month until 3 weeks after chemotherapy.
11625125|NCT00429403|No Intervention|No Goserelin|
11625126|NCT00429364|Active Comparator|Atenolol|Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.
11625127|NCT00429364|Active Comparator|Losartan|Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).
11625128|NCT00429338|Experimental|AIR-MRSI|Endorectal MRSI with Air
11625129|NCT00429338|Experimental|PFC-MRSI|Endorectal MRSI with PFC
11625130|NCT00429312|Experimental|Single Arm|Intratumoral injection(s) of Recombinant Vaccinia GM-CSF, JX-594
11625131|NCT00429299|Active Comparator|Arm A|Chemotherapy plus trastuzumab
11625132|NCT00429299|Experimental|Arm B|Chemotherapy plus lapatinib
11625133|NCT00429299|Active Comparator|Arm C|Chemotherapy plus trastuzumab plus lapatinib
11625134|NCT00429273|Active Comparator|Group 1: Guan-Guan+Placebo|weeks 1-4: Guanfacine weeks 5-8: Guanfacine + Placebo
11625135|NCT00429273|Active Comparator|Group 2: Placebo-Placebo+DMPH|weeks 1-4: Placebo weeks 5-8: Placebo+DMPH
11625136|NCT00429273|Experimental|Group 3: Guan-Guan+DMPH (Comb)|weeks 1-4: Guanfacine weeks 5-8: Guanfacine+DMPH
11625137|NCT00429247|Experimental|1|Her
11625138|NCT00429247|No Intervention|2|Follow up
11625139|NCT00429234|Experimental|Dasatinib + Gemcitabine|Dasatinib starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks. Gemcitabine starting dose of 800 mg/m^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
11625140|NCT00429182|Experimental|High-dose chemotherapy|Carboplatin + Cyclophosphamide + Thiotepa
11625141|NCT00429169|Active Comparator|Paroxetine|Participants will receive paroxetine for 8 weeks
11625142|NCT00429169|Active Comparator|Bupropion|Participants will receive bupropion for 8 weeks
11625143|NCT00429156|Active Comparator|1|Home non-invasive ventilation
11625144|NCT00429156|Sham Comparator|2|Home sham non-invasive ventilation with CPAP 5 cm H2O
11625145|NCT00429143|Experimental|Haploidentical Allogeneic Transplantation|Patients undergoing hematopoietic stem cell transplant from a partially matched related donor
11625146|NCT00429117||Survey|Physician members of the International Gynecologic Oncologists Society or the Society of Gynecologic Oncologists.
11625147|NCT00429104|Experimental|HER2+ Metastatic Breast Cancer|Herceptin 4 mg/kg IV Over 90 Minutes + GM-CSF 250 mcg/m^2 subcutaneously
11625148|NCT00429091|Placebo Comparator|1|
11625149|NCT00429091|Experimental|2|
11625150|NCT00429091|Active Comparator|3|
11625151|NCT00429026|Experimental|Fludarabine + Cyclophosphamide with ASCT|ASCT=Allogeneic Hematopoietic Stem Cell Transplantation
11625152|NCT00429026|Experimental|Fludarabine + Melphalan with ASCT|ASCT=Allogeneic Hematopoietic Stem Cell Transplantation
11625153|NCT00429013|No Intervention|2|no medical device
11625154|NCT00429013|Experimental|1|medical device
11625155|NCT00428987||lean|Normal weight men and women over the age of 18 years with BMI greater than 18.5 and less than 25, who are reasonably healthy
11625156|NCT00428987||obese|Obese men and women over the age of 18 years with BMI greater than 30, who are reasonably healthy
11625157|NCT00428987||overweight|Overweight men and women over the age of 18 years with BMI greater than 25 and less than 30, who are reasonably healthy
11625158|NCT00428974|Experimental|CF101 1 mg|
11625159|NCT00428974|Experimental|CF101 2mg|
11625160|NCT00428974|Experimental|CF101 4mg|
11625166|NCT00428922|Experimental|Trastuzumab, Bevacizumab, and Docetaxel|Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M²]
11625167|NCT00428909|Other|Drug-Drug interaction|
11625168|NCT00428896|Experimental|1|ZD1839
11625169|NCT00428870|Experimental|Arthroscopic acromioplasty|Arthroscopic acromioplasty
11625170|NCT00428870|Placebo Comparator|Sham surgery|Shoulder arthroscopy without active treatment and subacromial arthroscopy without bursectomy, decompression or other active interventions
11625171|NCT00428870|Active Comparator|Conservative treatment|Standardized exercise rehabilitation (supervised by physiotherapist)
11625172|NCT00428844|Experimental|Daptomycin 6 mg/kg|Daptomycin (6 mg/kg every 24 hours [q24h]) as a 30 minute intravenous (IV) infusion for 6 weeks (± one week).
11625173|NCT00428844|Experimental|Daptomycin 8 mg/kg|Daptomycin (8 mg/kg q24h) as a 30 minute IV infusion for 6 weeks (± one week).
11625174|NCT00428844|Active Comparator|Comparator|Vancomycin was administered at 1 gram every 12 hours (q12h) as a 60-minute infusion and teicoplanin was administered 6 mg/kg q24h as a 30-minute infusion also for 6 weeks (±1 week). Semi-synthetic penicillin (nafcillin, oxacillin, or flucloxacillin) was administered according to standard of care for 6 weeks (±1 week).
11625175|NCT00428831||1|Patients with respiratory illnesses.
11625176|NCT00428805|Experimental|intervention 1|This transcommunity study has one intervention and one control group. The intervention, described elsewhere has 6 components--classroom curriculum, family component,grocery store component, health care provider component, training for Head Start food service workers,and training for Head Start teachers/aides.
11625177|NCT00428805|No Intervention|control 2|measurement only control arm
11625178|NCT00428792|Experimental|Very light breakfast (VLB) then standard breakfast (SB)|Very light breakfast (VLB) for one week then crossover to standard breakfast (SB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12.
11625179|NCT00428792|Experimental|Standard breakfast (SB) then very light breakfast (VLB)|Standard breakfast (SB) for one week then crossover to very light breakfast (VLB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12.
11625180|NCT00428779|Experimental|1|patients running during 24 hours without sleep
11625181|NCT00428779|Placebo Comparator|2|patients without sleep during 24 hours
11625182|NCT00428727|Experimental|1|Nitric oxide patches
11625183|NCT00428727|Placebo Comparator|2|Placebo patches
11625184|NCT00428714|Experimental|Enzastaurin-Cohort 1|Chemo-naive participants who had androgen-independent prostate cancer with rising prostate-specific antigen (PSA) levels but no clinical or radiographic evidence of metastatic disease. Participants were given 1125 mg loading dose of enzastaurin on Day 1 of Cycle 1 (28-day cycle) only, and thereafter 500 mg enzastaurin once daily.
11625185|NCT00428714|Experimental|Enzastaurin-Cohort 2|Participants with progressed, metastatic prostate cancer who had received prior treatment with a docetaxel-containing agent. Participants were given 1125 mg loading dose of enzastaurin on Day 1 of Cycle 1 (28-day cycle) only, and thereafter 500 mg enzastaurin once daily.
11625186|NCT00428649|Experimental|1|20 µg selenium as selenomethionine
11625187|NCT00428649|Experimental|2|40 µg selenium as selenomethionine
11625188|NCT00428649|Experimental|3|60 µg selenium as selenomethionine
11625189|NCT00428649|Experimental|4|80 µg selenium as selenomethionine
11625190|NCT00428649|Experimental|5|100 µg selenium as selenomethionine
11625191|NCT00428649|Experimental|6|120 µg selenium as selenomethionine
11625192|NCT00428649|Placebo Comparator|7|placebo
11625193|NCT00428610|Experimental|LY573636|LY573636-sodium (LY573636) is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
11625194|NCT00428597|Experimental|A|
11625195|NCT00428597|Placebo Comparator|B|
11625196|NCT00428584|Experimental|1|interferon beta-1a
11625197|NCT00428584|Active Comparator|2|interferon beta-1b
11625198|NCT00428571|Placebo Comparator|Intensive Medical Management|Medical management of obesity including medication optimization and lifestyle and dietary advice.
11625199|NCT00428571|Active Comparator|Laparoscopic Gastric Bypass|
11625200|NCT00428571|Active Comparator|Laparoscopic Adjustable Gastric Band|
11625201|NCT00428558|Active Comparator|2|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
11625202|NCT00428558|Experimental|1|BRAS INDUCTION SEQUENTIAL
11625203|NCT00428545|Experimental|Bevacizumab + Bortezomib|Bevacizumab starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days. Bortezomib starting Dose 0.7 mg/m^2 By Vein On Days 1 and 8 Every 21 Days.
11625204|NCT00428519|Placebo Comparator|1|
11625205|NCT00428519|Active Comparator|2|
11625206|NCT00428519|Active Comparator|3|
11625207|NCT00428480|Experimental|1|Daily reinforcement of walking speed
11625208|NCT00428480|Active Comparator|2|No reinforcement of walking speed
11625209|NCT00428454|Experimental|Zotarolimus eluting stent|Zotarolimus eluting stent
11625210|NCT00428454|Active Comparator|Sirolimus eluting stent|Sirolimus eluting stent
11625211|NCT00428428|Placebo Comparator|1|Saline irrigation
11625212|NCT00428428|Active Comparator|2|ISO irrigation
11625213|NCT00428402||Focus Group|Participant is a 4th-8th grade student in select schools from Bastrop Independent School District (BISD).
11625246|NCT00428038||1|"Group 1:
~Infants born prematurely at a gestational age < 32 weeks with a diagnosis of chronic lung disease. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:
~Oxygen requirements
~Congenital heart disease"
11625393|NCT00426231|Active Comparator|Information control|Information control
11625394|NCT00426218|Experimental|1|ACZ885
11625214|NCT00428389|Experimental|Immediate Switch|Patients randomized to the immediate switch group continued treatment with donepezil through the evening prior to Day 8 of the study. On Day 8, all patients began open-label treatment with 5 cm^2 rivastigmine patch formulation. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm^2 patch and continued on their best tolerated dose for the remainder of the study.
11625215|NCT00428389|Experimental|Delayed Switch|Patients randomized to the delayed switch group were switched to 5 cm^2 rivastigmine patch formulation on Day 8, following a 7-day withdrawal period from donepezil. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm^2 patch and continued on their best tolerated dose for the remainder of the study.
11625216|NCT00428337|Experimental|1|Participants will receive one injection of DNA vaccine EP-1233 or placebo in each shoulder on Days 0 and 28 and one injection of MVA-mBN32 or placebo in each arm on Days 84 and 168
11625217|NCT00428337|Experimental|2|Participants will receive one injection of DNA vaccine EP-1233 or placebo in each shoulder on Days 0, 28, 84, and 168
11625218|NCT00428337|Experimental|3|Participants will receive one injection of MVA-mBN32 or placebo in each arm on Days 0, 28, 84, and 168
11625219|NCT00428298|Experimental|Active Treatment Valacyclovir|Subjects dispensed 500 mg capsules. Subjects take two 500 mg capsules twice daily for 16 weeks.
11625220|NCT00428298|Placebo Comparator|Placebo Treatment|Subjects dispensed 500 mg capsules. Subjects take two 500 mg capsules twice daily for 16 weeks.
11625221|NCT00428285|Experimental|Single Arm|
11625222|NCT00428272|Experimental|1|Lexatumumab alone dose escalation
11625223|NCT00428272|Experimental|2|Lexatumumab with interferon - dose escalation
11625224|NCT00428272|Other|3|Lexatumumab 10mg/kg with interferon expansion at
11625225|NCT00428246|Active Comparator|1|1 mcg paricalcitol
11625226|NCT00428246|Active Comparator|2|2 mcg paricalcitol
11625227|NCT00428246|Placebo Comparator|3|Placebo
11625228|NCT00428233|No Intervention|Leukemia Cell Harvest|Procedure/Surgery: Leukemia cell harvest Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
11625229|NCT00428220|Experimental|A|"Sunitinib will be administered in a continuous daily dose (oral, once per day). Starting dose will be 37.5 mg daily unless the patient was on a different dose (25 mg or 50 mg daily) on the previous trial. In that case, they will begin treatment on this study at the same dose used at the end of the previous study.
~The protocol now allows for patients on dosing regimens other than only continuous dosing (e.g. 4/2, etc.) to be enrolled if eligible."
11625230|NCT00428207|Active Comparator|Insulin Aspart Versus Insulin Lispro|Insulin aspart will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Insulin aspart doses will be adjusted by the principal investigator as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Lispro).
11625231|NCT00428207|Active Comparator|Insulin Lispro Versus Insulin Aspart|Insulin lispro will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Dose will be adjusted as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Aspart).
11625232|NCT00428194|Experimental|Cohort 1|Erlotinib 100 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
11625233|NCT00428194|Experimental|Cohort 2|Erlotinib 125 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
11625234|NCT00428194|Active Comparator|Cohort 3|Erlotinib 150 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
11625235|NCT00428181|Active Comparator|1 Brief Intervention|The primary purpose of the proposed research is to compare the effectiveness of brief intervention, brief intervention plus a booster and treatment as usual for adult patients with an alcohol related injury.
11625236|NCT00428181|Active Comparator|2) Booster|The primary purpose of the proposed research is to compare the effectiveness of brief intervention, brief intervention plus a booster and treatment as usual for adult patients with an alcohol related injury.
11625237|NCT00428168|Experimental|Betahistine 24 mg|
11625238|NCT00428168|Placebo Comparator|Placebo|
11625239|NCT00428142|Experimental|Bortezomib + BCVP-R|BCVP-R - q 21 days x 4 cycles Bortezomib: 1.3 mg/m2 Days 1 & 8 Cyclophosphamide: 750 mg/m2 IV Day 1 Vincristine: 1.4 mg/m2 IV Day 1 (dose capped at 2 mg) Prednisone: 40 mg/m2 po Days 1-5 Rituximab: 375 mg/m2 IV Day 1
11625240|NCT00428129|Experimental|1|
11625241|NCT00428116|No Intervention|Interrupted HAART|After 24 months of treatment with HAART, half the eligible infants will be randomized to interrupted treatment and followed for 18 months.
11625242|NCT00428116|Active Comparator|Continued HAART|After 24 months of treatment with HAART, half the eligible infants will be randomized to continued treatment with HAART for 18 months.
11625243|NCT00428090|Experimental|Rosiglitazone|XR (extended release) oral tablets
11625244|NCT00428090|Other|Placebo|Placebo (Double-Dummy to Match)
11625245|NCT00428051||All eligible patients|
11625346|NCT00426647|Experimental|Buprenorphine|Norspan transdermal patch
11625347|NCT00426647|Active Comparator|Tramadol|Tramadol SR tablets
11625247|NCT00428038||2|"Group 2:
~Infants born prematurely at a gestational age < 32 weeks without a diagnosis of chronic lung disease. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:
~Oxygen requirements
~Congenital heart disease"
11625248|NCT00428038||3|"Group 3:
~Infants born full term at a gestational age > 37 weeks. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:
~Hospitalization for a respiratory illness
~History of wheezing, asthma, or treatment with asthma medications
~Congenital heart disease"
11625249|NCT00428025|Placebo Comparator|placebo suppository|
11625250|NCT00428025|Active Comparator|diclofenac suppository|
11625251|NCT00428012|Experimental|QOLT|Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions
11625252|NCT00428012|Active Comparator|ST|Supportive Therapy (ST) 8 weekly individual counseling sessions
11625253|NCT00428012|No Intervention|Standard Care|
11625254|NCT00427999|Experimental|STI571+ pioglitazone+ etoricoxib + dexamethasone + treosulfane|STI571 (imatinib) 400mg po daily + pioglitazone 60mg po daily + etoricoxib 60mg po daily + dexamethasone 1mg po daily + treosulfane 500mg po daily for 24 weeks
11625255|NCT00427973|Experimental|AZD2171|Patients will receive AZD2171 (cediranib maleate) 30mg by mouth once a day. Treatment may continue for as long as benefit is shown. Patients will undergo MRI and CT scan of the liver before beginning treatment, 3 days after the first dose of AZD2171, and after finishing course one. Patients will also undergo blood collection periodically for laboratory studies. Laboratory biomarker analysis, computed tomography, dynamic contrast-enhanced magnetic resonance imaging, and pharmacological study will be performed.
11625256|NCT00427960|Active Comparator|rosuvastatin|rosuvastatin 5 mg
11625257|NCT00427960|Active Comparator|atorvastatin|atorvastatin 10 mg
11625258|NCT00427947|Experimental|1|Continuous sciatic nerve bloc : ropivacaine infusion
11625259|NCT00427947|Placebo Comparator|2|Continuous sciatic nerve bloc : NaCl Infusion
11625260|NCT00427934|Placebo Comparator|2|
11625261|NCT00427934|Experimental|1|This study was divided into two components: safety/pharmacokinetic (PK) and proof-of-concept (POC). In the safety/PK component either 150 mg or 300 mg tablets of maraviroc was administered twice a day (BID) to 16 rheumatoid arthritis subjects for 4 weeks.
11625262|NCT00427921|Experimental|1|Open Label
11625263|NCT00427908|Experimental|Group A|All subjects received GSK Biolgicals' meningococcal vaccine 134612.
11625264|NCT00427908|Active Comparator|Group B|Subjects including and above two years of age received Mencevax™ ACWY, subjects below two years of age received Meningitec™.
11625265|NCT00427895|Experimental|13vPnC Cohort 1, Vaccination 1|Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.
11625266|NCT00427895|Active Comparator|23vPS Cohort 1, Vaccination 1|Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.
11625267|NCT00427895|Experimental|13vPnC Cohort 2, Vaccination 1|Participants aged 50-59 years given a 0.5 mL dose administered on day 1.
11625268|NCT00427895|Experimental|13vPnC Cohort 3, Vaccination 1|Participants aged 18-49 years given a 0.5 mL dose administered on day 1.
11625269|NCT00427895|Experimental|13vPnC Cohort 1, Vaccination 2|Participants aged 60-64 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.
11625270|NCT00427895|Active Comparator|23vPS Cohort 1, Vaccination 2|Participants aged 60-64 years who received 23vPS at vaccination 1 receive a 0.5 mL dose of 23vPS administered 3-4 years after dose 1.
11625271|NCT00427895|Experimental|13vPnC Cohort 2, Vaccination 2|Participants aged 50-59 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.
11625272|NCT00427856|Experimental|Obatoclax mesylate 40mg|40 mg over 3 hrs q/weekly for 12 weeks, 4 weeks combo with rituximab, another 8 weeks single-agent obatoclax
11625273|NCT00427856|Experimental|Obatoclax mesylate 60mg|60 mg obatoclax mesylate over 24 hours, q/weekly for 12 weeks, 4 weeks combo with rituximab, another 8 weeks single-agent obatoclax
11625274|NCT00427843|Experimental|Exercise Home-Based Program|Patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. The exercise program will be performed 3 times per week for 8 weeks.
11625275|NCT00427804|Experimental|Calcitriol|Calcitriol 0.25 mcg orally twice a day for 7 days or calcitriol 0.50 mcg orally twice a day for 7 days.
11625276|NCT00427791|Experimental|Etoposide + Total Body Irradiation + Rituximab|Etoposide 60 mg/kg intravenous (IV) Daily Over 4 Hours for 1 Day + Total Body Irradiation (TBI) 3 Gy Daily for 4 Days + Rituximab 375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks
11625277|NCT00427791|Experimental|Etoposide + Total Body Irradiation|Etoposide 60 mg/kg IV Daily Over 4 Hours for 1 Day + TBI 3 Gy Daily for 4 Days
11625278|NCT00427778|Experimental|Incontinence ring then no intervention|Participants first were fitted with an incontinence ring, which they wore continuously for 4 weeks. The ring wa then removed and a washout period of 2 weeks followed. Then the second 4-week period with no ring was completed.
11625279|NCT00427778|Experimental|No intervention then incontinence ring|Participants spend the first study 4-week period with no intervention. Then, a wasout period of 2 weeks followed. Participants were then fitted with an incontinence ring, which they wore continuously for 4 weeks.
11625280|NCT00427765|Experimental|Busulfan + Melphalan|Busulfan 32 mg/m^2 intravenous (IV) for 1 Day then 130 mg/m^2 IV for 4 Days; and Melphalan 70 mg/m^2 IV for 2 Days
11625281|NCT00427752|Experimental|Whipple|Patients with pancreatic cancer who will proceed to a Whipple procedure.
11625282|NCT00427739||CCT exam|
11625283|NCT00427700|Active Comparator|Clomiphene|Uso of 100mg of clomiphene citrate during days 5-9 of the menstrual cycle
11625284|NCT00427700|Experimental|Raloxifene|Use of 100mg of raloxifene during days 5-9 of the menstrual cycle
11625285|NCT00427674|Experimental|injection of 5 mCi of 123-I mZINT|
11625286|NCT00427661|Other|AHCT in High Risk SCD|Intervention: Busulfan; Fludarabine; cyclosporine A and MMF
11625287|NCT00427648|Active Comparator|1|xylocaine
11625288|NCT00427648|Placebo Comparator|2|normal saline
11625289|NCT00427609|Placebo Comparator|1|
11625290|NCT00427609|Active Comparator|2|
11625291|NCT00427583|Experimental|STI571|
11625292|NCT00427557|Experimental|Cellular Therapy with Cord Blood Cells|Fludarabine 30 mg/m^2 intravenous (IV) for 4 Days + Melphalan 140 mg/m^2 IV for 1 Day + Rituximab 375 mg/m^2 IV once weekly + Cord Blood Transplantation + Stem Cell Transplantation Infusion
11625293|NCT00427492|Active Comparator|Magnesia|Medical laxative
11625294|NCT00427492|Placebo Comparator|Placebo|Placebo
11625295|NCT00427440|Experimental|AMG 102 at 10 mg/kg Dose Level|Up to 40 subjects will be treated at this dose level based upon investigator assessment of responses observed.
11625296|NCT00427440|Experimental|AMG 102 at 20 mg/kg Dose Level|Up to 40 subjects will be treated at this dose level based upon investigator assessment of responses observed.
11625297|NCT00427414|Experimental|liposomal daunorubicin citrate|40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
11625298|NCT00427388|Experimental|Treatment|500 mg of methylprednisolone divided into two intravenous doses of 250 mg each, one during anesthetic induction and the other on CPB initiation
11625299|NCT00427388|Placebo Comparator|Placebo|500 mg of matching placebo (normal saline solution) divided into two intravenous doses of 250 mg each, one during anesthetic induction and the other on CPB initiation
11625300|NCT00427375|Experimental|1|New surgical option in good responders after neoadjuvant treatment for low rectal cancer
11625301|NCT00427375|Active Comparator|2|Standard surgery
11625302|NCT00427349|Experimental|AMG 706+Octreotide|"Patients receive oral AMG 706 and octreotide acetate intramuscularly (IM) once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
~AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the morning. AMG 706 was taken daily without breaks in treatment.
~One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles."
11625303|NCT00427336|Experimental|Fludarabine + Cyclophosphamide + ATG|Fludarabine 30 mg/m^2/day by vein (IV), Cyclophosphamide IV 300 mg/m^2/day, ATG (Antithymocyte Globulin) IV 3.75 mg/kg/day
11625304|NCT00427310|Experimental|Arm 1: Postoperative 5 FU + sodium heparin|Continuous portal vein infusion with 5 FU 600 mg/m2 + 5000 units sodium heparin per day given for a total of 7 consecutive days.
11625305|NCT00427310|Active Comparator|Arm 2: Postoperative observation|
11625306|NCT00427297|Experimental|NVP-containing|Infants randomized to this arm will receive nevirapine-containing HAART regimen
11625307|NCT00427297|Active Comparator|NVP-sparing|Infants randomized to this arm will receive nevirapine-sparing HAART
11625308|NCT00427219|Placebo Comparator|Placebo run-in phase|Eligible patients entered a placebo run-in phase in which placebo was administered twice over a 2 week period (Day -28 and Day -14) and patients were assessed to establish baseline values approximately 14 days following the second placebo injection
11625309|NCT00427219|Experimental|Ozarelix/Placebo|All patients completing the placebo run in period were randomized to enter the treatment phase of the study and received either placebo or ozarelix on Day 0 and Day 14
11625310|NCT00427206|Active Comparator|1|acetaminophen 4 g/day
11625311|NCT00427206|Placebo Comparator|2|placebo undistinguishable from active drug
11625312|NCT00427193|Experimental|Caloric Restriction (CR)|25% caloric restriction
11625313|NCT00427193|Active Comparator|Control, Ad libitum (AL)|Ad libitum energy intake
11625314|NCT00427154|Active Comparator|A|
11625315|NCT00427154|Active Comparator|B|
11625316|NCT00427089|Experimental|1|2L gut cleansing solution
11625317|NCT00427089|Active Comparator|2|
11625318|NCT00427076|Experimental|A|Cotrimoxazole
11625319|NCT00427076|Active Comparator|B|Vancomycin
11625320|NCT00427037|Placebo Comparator|Placebo|Placebo
11625321|NCT00427037|Active Comparator|Cholecalciferol|D3
11625322|NCT00427011|Experimental|1|
11625323|NCT00426907|Experimental|1|Full postoperative weightbearing
11625324|NCT00426907|Active Comparator|2|Partial weightbearing 6 weeks postoperative
11625325|NCT00426881|Experimental|1|Twice weekly resistance training for 52 weeks.
11625326|NCT00426881|Experimental|2|Once weekly resistance training for 52 weeks.
11625327|NCT00426881|Experimental|3|Twice weekly balance and tone training for 52 weeks.
11625328|NCT00426868|Experimental|Treatment|
11625329|NCT00426868|Placebo Comparator|Placebo|
11625330|NCT00426855|Experimental|Bendamustine and Bortezomib|Combination Chemotherapy of Bendamustine and Bortezomib as described in the intervention section
11625331|NCT00426842|Experimental|Arm 1|Blood pressure response during HUT following administration of Midodrine Hydrochloride compared with no drug.
11625332|NCT00426829|Experimental|Proton Therapy + Bevacizumab|Proton Therapy + Bevacizumab
11625333|NCT00426816|Experimental|Crossover population|All study population receive placebo and doses of SB-649868 at 10mg, 30mg and 60mg in a crossover desing
11625334|NCT00426777|Active Comparator|risedronate|
11625335|NCT00426777|Placebo Comparator|placebo|
11625336|NCT00426764|Experimental|Romidepsin|Participants received romidepsin 14 mg/m^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.
11625337|NCT00426751|Active Comparator|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
11625338|NCT00426751|Experimental|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mcg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
11625339|NCT00426725|Experimental|A|This group uses the EasyLabour device according to the protocol
11625340|NCT00426725|No Intervention|Control|
11625341|NCT00426712|Experimental|1|Low dose
11625342|NCT00426712|Experimental|2|Middle dose
11625343|NCT00426712|Experimental|3|High dose
11625344|NCT00426712|Active Comparator|4|
11625345|NCT00426660|Experimental|1|
11625348|NCT00426621|Experimental|1|
11625350|NCT00426608|Experimental|Session 1|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 gram per kilogram (g/kg) and Dose 2 of AEBCD sequence. In AEBCD sequence A is placebo, E Alprazolam, B GSK6561679 10 milligram (mg), C GSK6561679 50 mg and D GSK6561679 400 mg. Wash-out period will be of 7 days.
11625351|NCT00426608|Experimental|Session 2|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of BACED sequence. In BACED sequence B is GSK6561679 10 mg, A placebo, C GSK6561679 50 mg, E Alprazolam, and D GSK6561679 400 mg. Wash-out period will be of 7 days.
11625352|NCT00426608|Experimental|Session 3|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of CBEAD sequence. In CBEAD sequence C is GSK6561679 50 mg, B GSK6561679 10 mg, E Alprazolam, A placebo, and D GSK6561679 400 mg. Wash-out period will be of 7 days.
11625353|NCT00426608|Experimental|Session 4|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of ECABD sequence. In ECABD sequence E is Alprazolam, C is GSK6561679 50 mg, A placebo, B GSK6561679 10 mg and D GSK6561679 400 mg. Wash-out period will be of 7 days.
11625354|NCT00426608|Experimental|Session 5|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of GSK561679 400 mg and alprazopam placebo. Wash-out period will be of 7 days.
11625355|NCT00426582|Experimental|Patupilone only|Cycle 1 patupilone alone Cycle 2 and onward patupilone and carboplatin
11625356|NCT00426582|Active Comparator|Carboplatin alone|Cycle 1 Carboplatin alone Cycle 2 and onward patuilone and carboplatin
11625357|NCT00426556|Experimental|Phase I - RAD001 5mg + PT, daily|Daily dosing schedule of EPT = Paclitaxel & Trastuzumab verolimus 5mg plus Paclitaxel plus Trastuzumab.
11625358|NCT00426556|Experimental|Phase I - RAD001 10mg + PT, daily|Daily dosing schedule of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab
11625359|NCT00426556|Experimental|Phase I - RAD001 30mg + PT, weekly|Weekly dosing schedule of Everolimus 30mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab.
11625360|NCT00426556|Experimental|Phase II - RAD001 10mg + PT, daily|Daily dosing schedule of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab
11625361|NCT00426530|Experimental|RAD001 Daily Schedule|5mg or 10mg
11625362|NCT00426530|Experimental|RAD001 Weekly Schedule|30mg
11625363|NCT00426517|Other|Group 1|All Sibling BMT
11625364|NCT00426517|Other|Group 2|MUD or Cord Blood Unit BMT
11625365|NCT00426517|Other|Group 3|Sibling Donors for Group 1
11625366|NCT00426504|Experimental|radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
11625367|NCT00426491|Active Comparator|A|Four 200 ug tablets of Misoprostol
11625368|NCT00426491|Placebo Comparator|B|
11625369|NCT00426439|Experimental|1 Coartem|Treatment of documented malaria in children following the dosages recommended by the manufacturer.
11625370|NCT00426439|Active Comparator|2 Chloroquine|The antimalarial actually used in Guinea-Bissau is the dosage of 50 mg/kg given twice a day for 3 days.
11625371|NCT00426426|Active Comparator|Meta-Cognitive Therapy|first Meta-cognitive therapy then Cognitive Behaviour Therapy
11625372|NCT00426426|Active Comparator|Cognitive Behaviour Therapy|first Cognitive Behaviour Therapy then Meta-cognitive therapy
11625373|NCT00426426|Other|Waiting List|Waiting List
11625374|NCT00426413||1|Obese AA subjects with DKA or severe hyperglycemia
11625375|NCT00426413||2|obese nondiabetic subjects, age 19-65.
11625376|NCT00426413||3|Any subjects with recurrent DKA. Recurrent DKA is defined as more than one admission to Grady Memorial Hospital.
11625377|NCT00426361|Experimental|Cervarix Group|Subjects who received GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 0, 1 and 6.
11625378|NCT00426361|Experimental|Boostrix Polio → Cervarix Group|Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 1, 2 and 7.
11625379|NCT00426361|Experimental|Cervarix + Boostrix Polio Group|Subjects who received GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.
11625380|NCT00426348|Active Comparator|1|In arm 1,Valsartan(80-160mg/day) is given to patients in combination with Placebo
11625381|NCT00426348|Experimental|2|Valsartan(80-160mg/day) + Probucol(750mg/day)
11625382|NCT00426322|Active Comparator|1|small particles
11625383|NCT00426322|Active Comparator|2|large particles
11625384|NCT00426283|Experimental|Flovent 1760 mcg|Fluticasone propionate 880 mcg twice daily for 3 months
11625385|NCT00426283|Placebo Comparator|Placebo|Placebo twice daily for 3 months
11625386|NCT00426270|Experimental|Octagam 10% 1 g/kg/day|Participants received Octagam 10% (human normal immunoglobulin) 1 g/kg intravenously once a day for 2 days.
11625387|NCT00426257|Experimental|1|Secondary debulking surgery with hyperthermic intraperitoneal chemotherapy
11625388|NCT00426257|Active Comparator|2|Secondary debulking surgery
11625389|NCT00426244|Sham Comparator|Placebo Ultrasound|"In addition to controlling for physician attention during the treatment visit, the SUT used a nonfunctional ultrasound therapy unit that was modified for research purposes to provide both visible and auditory cues that could potentially elicit a placebo response. The physician provided the SUT by placing the applicator head over the subject's clothing and applying sufficient pressure for tactile stimulation of the skin and underlying tissues in the same anatomical distributions as would generally be addressed if the subject were being treated with OMT.
~The subjects assigned to the UOBC only group did not receive any study treatments beyond conventional obstetrical care; however, they were expected to complete data collection forms on the same schedule as all other trial subjects."
11625390|NCT00426244|Active Comparator|Osteopathic Manipulative Treatment|OMT is a complementary and alternative body-based treatment method in which the patient is evaluated and treated including the musculoskeletal system to improve physiologic functioning and remove impediments to optimal health and functioning.
11625391|NCT00426244|No Intervention|Standard Care|Subject only receives care from her OB provider. Subjects were allowed to receive conventional obstetrical care with the exception of OMT, massage therapy, physical therapy, chiropractic manipulation, or therapeutic ultrasound intended to treat musculoskeletal disorders.
11625392|NCT00426231|Experimental|Patient Navigator intervention|Patient Navigator intervention
11625396|NCT00426166|No Intervention|2|No Laser Therapy. Outcome Measures the same.
11625397|NCT00426153|Active Comparator|Octreotide|Participants received Octreotide LAR® Depot injections (up to 40 mg) intramuscularly every 28 days (+/- 5 days) for one year
11625398|NCT00426153|Placebo Comparator|Placebo|Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
11625399|NCT00426140|Experimental|EPO906|
11625400|NCT00426127|Experimental|Docetaxel and Liposomal Doxorubicin Combined with Enoxaparin|Docetaxel 75 mg/m^2 + Doxil 30 mg/m^2 + Enoxaparin 1.5 mg/kg
11625401|NCT00426101|Experimental|Etoposide, Dexamethasone, Cyclosporin A plus IT MTX & Steroids|"As compared to the HLH-94 treatment, the main changes are that
~Cyclosporin A is administered from day 1 and
~Intrathecal steroids are added to the intrathecal methotrexate.
~Drugs, dosage, frequency and duration are described in the paragraph Interventions below."
11625402|NCT00426023|Experimental|1|this group of patients is treated with the experimental drug (Cyclosporine A 0,05% eye drops) 2 times daily
11625403|NCT00426023|Active Comparator|2|
11625404|NCT00426010|Active Comparator|1|overt then covert caffeine
11625405|NCT00426010|Active Comparator|2|covert then overt caffeine
11625406|NCT00426010|Active Comparator|3|overt then covert placebo
11625407|NCT00426010|Active Comparator|4|covert then overt placebo
11625408|NCT00425945|Placebo Comparator|Placebo|Placebo delivered as four tablets matching the active product once daily orally.
11625409|NCT00425945|Active Comparator|Pine Bark Extract|Flavangenol 200 mg Flavangenol is a brand of Pine Bark Extract manufactured by Toyo Shinyaku of Saga, Japan. Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day.
11625410|NCT00425932|No Intervention|Rituximab/Placebo|Patients will be randomized at Baseline to either Placebo or Rituximab. At Week 24 and up to Week 48 if patient DAS28 score is >2.6, patient will be retreated with open label Rituximab.
11625411|NCT00425932|Active Comparator|Open Label|At Week 24 or any time up to Week 48 if the Patient DAS 28 > 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
11625412|NCT00425906|Experimental|Nicotine inhaler|
11625413|NCT00425906|Placebo Comparator|Placebo inhaler|
11625414|NCT00425893|Active Comparator|1|health education
11625415|NCT00425893|Experimental|2|hand hygiene
11625416|NCT00425893|Experimental|3|masks and hand hygiene
11625417|NCT00425880||Pregnant Asthmatics|
11625418|NCT00425880||Pregnant Smokers|
11625419|NCT00425880||Healthy Pregnant Controls|
11625420|NCT00425854|Experimental|BIBW 2992|high dose once daily
11625421|NCT00425815|Experimental|Org 24448 250 mg|Two capsules (one Org 24448 250 mg capsule and one placebo capsule that is identical to the active treatment) will be ingested orally daily for eight weeks.
11625422|NCT00425815|Experimental|Og 244448 500 mg|Two capsules (two Org 24448 250 mg capsules) will be ingested orally daily for eight weeks.
11625423|NCT00425815|Placebo Comparator|Inactive Capsule|Two capsules (two placebo capsules that are identical to the active treatment) will be ingested orally daily for eight weeks.
11625424|NCT00425802|Other|treatment|This is a phase 2 study of a treatment regimen consisting of a non-myeloablative (NMA) conditioning regimen incorporating low dose chemotherapy and low dose radiation as well as peri-transplant Rituximab and the transplantation of peripheral blood stem cells (PBSC) or bone marrow if PBSC collection not possible from an HLA compatible related or unrelated donor in patients with B cell lymphoid malignancies including diffuse large cell (DLC) and mantle cell non-Hodgkin's lymphoma (NHL), indolent B cell NHL, or chronic lymphocytic leukemia (CLL).
11625425|NCT00425776|Active Comparator|Real acupuncture|
11625426|NCT00425776|Sham Comparator|Sham acupuncture|
11625427|NCT00425776|No Intervention|No intervention|
11625428|NCT00425763|Experimental|AQAS|
11625429|NCT00425750|Experimental|Treatment|"Docetaxel (40 mg/m2) IV Infusion over 30 minutes every 3 weeks (Day 1 and 8 of 21 day cycle)except the first dose is held on Day 1 of Cycle 1.
~Bortezomib (1.6mg/m2) IV 3-5 second push every 3 weeks (Day 1 and 8 of 21 day cycle).Bortezomib is given as a single agent only on Day 1 of Cycle 1."
11625430|NCT00425711|Experimental|DUI Court Participants|Individuals enrolled in the DUI Court treatment site will be recruited for the 13 week open-label trial of acamprosate.
11625431|NCT00425698|Active Comparator|intravenous erythropoietin|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
11625432|NCT00425698|Placebo Comparator|intravenous placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
11625433|NCT00425672|Experimental|Arm I|Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11625434|NCT00425659|Active Comparator|3|
11625435|NCT00425659|Experimental|1|
11625436|NCT00425659|Other|2|usual practice
11625437|NCT00425620|Experimental|Amphotericin B|
11625438|NCT00425607|Experimental|Lonafarnib|All subjects initiated oral Lonafarnib twice daily at a dose of 115mg/m2 and escalated to 150 mg/m2. Two subjects de-escalated to 115mg/m2 following toxicity.
11625439|NCT00425555|Experimental|Previously treated with oral bexarotene|
11625440|NCT00425555|Experimental|No prior oral bexarotene treatmemt|
11625441|NCT00425542|Experimental|Outpatient treatment|
11625442|NCT00425542|No Intervention|Inpatient care|
11625443|NCT00425516|No Intervention|standard (A)|3 FEC100 followed 3 Taxotere
11625444|NCT00425516|Experimental|Modulated (B)|possibility treatments receive: 2 FEC100 followed by 4 Taxotere 4 FEC100 followed by 2 Taxotere 6 FEC 100
11625445|NCT00425477|Experimental|Bexarotene + GM-CSF|BEX and GM-CSF were administered in 4 week cycles. BEX was given orally with food daily for 28 days at the FDA-approved dose for treatment of CTCL of 300 mg/m2 and GM-CSF was given at a daily dose of 125 µg/m2 subcutaneously for 28 days.
11625446|NCT00425464|Experimental|Synchrony® Dual Optic Intraocular Lens|
11625447|NCT00425464|Active Comparator|Standard Monofocal Intraocular Lens|
11625448|NCT00425451|Experimental|PerioChip Plus|
11625449|NCT00425451|Experimental|Flurbiprofen Chip|
11625450|NCT00425451|Active Comparator|PerioChip|
11625451|NCT00425451|Placebo Comparator|Placebo Chip|
11625452|NCT00425438|Experimental|Mycophenolate Mofetil|Participants received mycophenolate mofetil (MMF) 0.5 grams (g), orally (PO), twice daily (BID) from Day 0 to the end of Week 1, followed by 1.0 g, PO, BID from Weeks 2 through 24, and 0.75 g, PO, BID from Weeks 32 to 48. Participants also received prednisolone 0.75 to 1.0 milligrams per kilogram (mg/kg), PO, once per day, up to a maximum of 60 mg per day from Weeks 1 through 4, reduced by 10 mg per day every 2 weeks until dose reaches 40 mg per day, followed by a reduction of 5 mg per day every 2 weeks until dose reaches 10 mg per day up to Week 48.
11625453|NCT00425438|Active Comparator|Cyclophosphamide/Azathioprine|Participants received cyclophosphamide 0.75 grams per square meter (g/m^2), intravenously (IV), every 4 weeks from Weeks 1 through 4, and 0.5 to (-) 1.0 g/m^2, IV, to maintain a minimum white blood cell (WBC) count of greater than or equal to (≥) 2500 per cubic millimeter (mm^3) every 4 weeks from Weeks 5 through 24. Participants also received azathioprine 100 mg, PO, daily for participants with a body weight of 50 to 70 kg and 150 mg, PO, daily for subjects with a body weight of more than 70 kg from Weeks 25 through 48. Participants also received prednisolone 0.75 to 1.0 mg/kg, PO, once per day, up to a maximum of 60 mg per day from Weeks 1 through 4, reduced by 10 mg per day every 2 weeks until dose reaches 40 mg per day, followed by a reduction of 5 mg per day every 2 weeks until dose reaches 10 mg per day up to Week 48.
11625454|NCT00425386|Experimental|Erlotinib and Sunitinib|"Drug: erlotinib hydrochloride Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;
~100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;
~150 mg/day, continuous daily
~Drug: sunitinib malate Will be administered at 50 mg daily, 4 weeks on, 2 weeks off"
11625455|NCT00425373|Experimental|Valsartan + amlodipine 40/2.5 mg|
11625456|NCT00425373|Experimental|Valsartan + amlodipine 40/5 mg|
11625457|NCT00425373|Experimental|Valsartan + amlodipine 80/2.5 mg|
11625458|NCT00425373|Experimental|Valsartan + amlodipine 80/5 mg|
11625459|NCT00425373|Active Comparator|Valsartan 40 mg|
11625460|NCT00425373|Active Comparator|Valsartan 80 mg|
11625461|NCT00425373|Active Comparator|Amlodipine 2.5 mg|
11625462|NCT00425373|Active Comparator|Amlodipine 5 mg|
11625463|NCT00425373|Placebo Comparator|Placebo|
11625464|NCT00425334|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
11625465|NCT00425334|Active Comparator|Control|Ringer's lactate
11625466|NCT00425321|Experimental|RWJ-445380 100 mg|
11625467|NCT00425321|Experimental|RWJ-445380 200 mg|
11625468|NCT00425321|Experimental|RWJ-445380 300 mg|
11625469|NCT00425321|Placebo Comparator|Placebo|
11625470|NCT00425308|Active Comparator|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|Everolimus dose has been adjusted to reach in Group 2, assessment of everolimus dose/trough level (C0), between 6 and 10 ng/ml plus Enteric-coated Mycophenolate Sodium (EC-MPS) 720 mg/d (360mg the morning and 360 mg the evening) plus steroids
11625471|NCT00425308|Active Comparator|Everolimus + Cyclosporine|Everolimus dose has been adjusted to reach in Group 1, assessment of everolimus dose/trough level (C0), between 3 and 8 ng/ml plus Cyclosporine in which Group 1 dose adjusted to reach, assessment of Cyclosporine dosage and blood concentration (C2), between 200 and 450 ng/ml plus steroids
11625472|NCT00425295|Active Comparator|1|
11625473|NCT00425295|Experimental|2|
11625474|NCT00425269|Experimental|Intervention|The intervention group was divided into nine subgroups of ten to twelve women who were offered six educational sessions, each lasting 2 h, during a 7 +- 1-month period. The main focus was on the physiological importance of blood glucose and its regulation by diet and physical activity, and on knowledge about the Pakistani lifestyle in Pakistan and Norway
11625475|NCT00425269|No Intervention|Control|One lesson recieved after post-test
11625476|NCT00425204|Experimental|Open Label|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
11625477|NCT00425191|Experimental|1|
11625478|NCT00425191|Experimental|2|
11625479|NCT00425191|Experimental|3|
11625480|NCT00425113|Experimental|Metronidazole|Metronidazole added to background TB treatment regimen during initial 2 months
11625481|NCT00425113|Placebo Comparator|Placebo|Placebo added to background TB treatment regimen during initial 2 months
11625482|NCT00425100|Experimental|Open Label-fesoterodine|Single treatment study arm.
11625483|NCT00425074|Experimental|SR-ASA|slow release acetylsalicylic acid 150 mg
11625484|NCT00425074|Active Comparator|ASA|normal release acetylsalicylic acid
11625485|NCT00425061|Experimental|1|
11625486|NCT00425061|Experimental|2|
11625487|NCT00425061|Placebo Comparator|3|
11625488|NCT00424983|Experimental|Zometa q 4 weeks|
11625489|NCT00424983|Active Comparator|Zometa q 12 weeks|
11625490|NCT00424970|Placebo Comparator|acetazolamide|acetazolamide 250mg /day oral administration, for 6 months
11625491|NCT00424944|Experimental|I, GMZ2 vaccine arm|20 volunteers will receive GMZ2 vaccine on days 0, 28, and 56
11625492|NCT00424944|Active Comparator|II, Rabies vaccine arm|20 volunteers will receive standard vaccine against rabies on the similar schedule on days 0, 28, and 56
11625493|NCT00424931|Experimental|001|JNJ-17216498 10mg one time
11625494|NCT00424931|Experimental|002|JNJ-17216498 50mg one time
11625495|NCT00424931|Active Comparator|003|Modafinil 200 mg X 2
11625496|NCT00424905|Experimental|1|Enterogermina® vials containing 2×109 spores of polyantibiotic resistant Bacillus clausii (test drug)
11625497|NCT00424905|No Intervention|2|No treatment (reference group)
11625498|NCT00424866|Placebo Comparator|Placebo|The dosing groups correspond to total doses of 0 µg/kg of FGF-1.
11625499|NCT00424866|Active Comparator|Human FGF-1|The dosing groups correspond to total doses of either 3, 10 or 30 µg/kg of FGF-1.
11625500|NCT00424853|Experimental|A|
11625501|NCT00424853|Experimental|B|
11625502|NCT00424840|Experimental|Bortezomib 1.3 mg/m2|Level 1 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
11625503|NCT00424840|Experimental|Bortezomib 1.6 mg/m2|Level 2 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
11625504|NCT00424840|Experimental|Bortezomib 1.8 mg/m2|Level 3 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
11625505|NCT00424827|Experimental|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of Gemcitabine/Fluorouracil with External Beam Radiation in patients with non-metastatic, locally advanced pancreatic carcinoma.
11625506|NCT00424814|Experimental|1|Kaletra (lopinavir/ritonavir)
11625507|NCT00424814|Active Comparator|2|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)
11625508|NCT00424801|Experimental|Vasodilatory|Patients in this arm will receive intensive vasodilatory treatment to lower blood pressure
11625509|NCT00424762|Experimental|rosiglitazone|4mg titrated to 8mg daily
11625510|NCT00424762|Placebo Comparator|Placebo|blinded matching placebo treatment
11625511|NCT00424749|Experimental|Rituximab|375 mg/m^2/week for 4 weeks
11625512|NCT00424710|Other|Single Arm study|"Single arm study:
~Drug: ranibizumab intravitreal injection liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year"
11625513|NCT00424645|Experimental|Voraxaze|Voraxaze administered 50 units/kg intravenously (IV) repeated a maximum of 2 times in a given cycle of chemotherapy.
11625514|NCT00424645|Placebo Comparator|Placebo|Placebo administered IV following Voraxaze arm.
11625515|NCT00424632|Experimental|Single arm dose escalation|
11625516|NCT00424619|Active Comparator|1|50 000 IU Vitamin D2
11625517|NCT00424619|Active Comparator|2|100 000 IU Vitamin D2
11625518|NCT00424619|Placebo Comparator|3|Placebo
11625519|NCT00424606|Experimental|1|
11625520|NCT00424606|Experimental|2|
11625521|NCT00424593|Experimental|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
11625522|NCT00424593|Placebo Comparator|Placebo|every day (QD), by mouth (PO), 13 weeks
11625523|NCT00424554|Experimental|Temozolomide treatment|
11625524|NCT00424554|No Intervention|No treatment|
11625525|NCT00424528|Active Comparator|Arformoterol 15 mcg twice daily|Arformoterol 15 mcg twice daily/Placebo Inhalation Powder
11625526|NCT00424528|Active Comparator|Tiotropium 18 mcg once daily|Tiotropium 18 mcg once daily/Placebo Inhalation Solution
11625527|NCT00424528|Experimental|Arformoterol /Tiotropium|Arformoterol 15 mcg twice daily/Tiotropium 18 mcg once daily
11625528|NCT00424515|Experimental|Treatment Arm|Imatinib
11625529|NCT00424502|Experimental|1|
11625530|NCT00424489|Experimental|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation will be performed after conditioning
11625531|NCT00424476|Placebo Comparator|Placebo|Placebo
11625532|NCT00424476|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg
11625533|NCT00424476|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg
11625534|NCT00424463|Experimental|1|
11625535|NCT00424463|Placebo Comparator|2|
11625536|NCT00424450||PAD patients|30 PAD patients
11625537|NCT00424398|Experimental|Bepreve|Bepotastine Besilate Ophthalmic Solution 1.5%
11625538|NCT00424398|Placebo Comparator|Placebo|sterile ophthalmic solution
11625539|NCT00424398|Experimental|Bepotastine Besilate|sterile ophthalmic solution 1.0%
11625540|NCT00424385|Experimental|Arm 1|Only 1 arm for the study - this arm gets both drugs, gleevec and sorafenib
11625541|NCT00424372|Experimental|pregabalin|
11625542|NCT00424346|Experimental|Canakinumab 600 mg IV + 300 mg q2wk|Participants received canakinumab 600 mg intravenous (IV) loading dose on Day 1 and 300 mg subcutaneous injections every 2 weeks (q2wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg every 4 weeks.
11625543|NCT00424346|Experimental|Canakinumab 300 mg q2wk|Participants received canakinumab 300 mg subcutaneous injections every 2 weeks (q2wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
11625544|NCT00424346|Experimental|Canakinumab 150 mg q4wk|Participants received canakinumab 150 mg subcutaneous injections every 4 weeks (q4wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
11625545|NCT00424346|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections every 2 weeks for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
11625546|NCT00424294|Active Comparator|Celecoxib|Celecoxib with placebo therapy.
11625547|NCT00424294|Other|Methotrexate|Background Methotrexate taken in both CP-195,543/Celecoxib and Celecoxib only arms.
11625548|NCT00424294|Experimental|CP-195,543|CP-195,543 and Celecoxib dual therapy.
11625549|NCT00424268|Active Comparator|Roflumilast|"Roflumilast 500 µg
~underlying medication: tiotropium 18 µg, once daily, inhaled"
11625550|NCT00424268|Placebo Comparator|Placebo|"Placebo
~underlying medication: tiotropium 18 µg, once daily, inhaled"
11625551|NCT00424255|Experimental|Lapatinib+Chemoradiation|"Adjuvant concurrent chemoradiotherapy plus lapatinib 1500 mg once daily for 6 to 7 weeks, followed by lapatinib 1500 mg once daily for one year.
~Chemoradiotherapy=total dose of 66Gy over 6-7 weeks plus cisplatin 100mg/m2 on days 1,2 and 43 of the course of radiotherapy. Lapatinib is also given at 1500 mg once daily for 3-7 days prior to the start of chemoradiotherapy."
11625552|NCT00424255|Placebo Comparator|Placebo+Chemoradiation|"Adjuvant concurrent chemoradiotherapy plus placebo once daily for 6 to 7 weeks, followed by placebo once daily for one year.
~Chemoradiotherapy = total dose of 66Gy over 6-7 weeks plus cisplatin 100mg/m2 on days 1,2 and 43 of the course of treatment. Placebo is also given once daily for 3-7 days prior to the start of chemoradiotherapy."
11625553|NCT00424242|Experimental|Escalating doses of Pemetrexed|Escalating doses of Pemetrexed beginning at 500 mg/m2
11625554|NCT00424203|Experimental|Myocet, Endoxan|
11625555|NCT00424190|Experimental|Ceftaroline for Injection|
11625556|NCT00424190|Active Comparator|IV Vancomycin and IV Aztreonam|
11625557|NCT00424177|Experimental|eltrombopag|
11625558|NCT00424164|Experimental|Tamoxifen-lapatinib|Tamoxifen alone at cycle 1 and as of cycle 2 in combination with Lapatinib.
11625559|NCT00424164|Experimental|Lapatinib-tamoxifen|Lapatinib will be given alone for 2 weeks during cycle 1. As of cycle 2, you will receive the combined treatment Lapatinib and Tamoxifen
11625560|NCT00424138|Experimental|Group A - 3 FDG-PET/CT Scans|Two FDG-PET/CT scans prior to 1st cycle of chemotherapy, plus 2 optional volumetric CT scans. One FDG-PET/CT after 1st cycle of chemotherapy, plus 1 optional volumetric CT scan.
11625561|NCT00424138|Experimental|Group B - 2 FDG-PET/CT + 1 Optional|One FDG-PET/CT prior to 1st cycle of chemotherapy; 1 FDG-PET/CT after the 1st cycle of chemotherapy; 1 optional FDG-PET/CT after the 2nd cycle of chemotherapy. All three with optional volumetric CT scans.
11625562|NCT00424138|Experimental|Group C - Test-Retest|Test-retest sequence for FDG-PET/CT; two scans with optional volumetric CT to be completed prior to 1st cycle of chemotherapy.
11625563|NCT00424125|Experimental|Enhanced Pharmacy Care|Received enhanced community pharmacy based services.
11625564|NCT00424099|Experimental|Group 1: Methylphenidate + NTI|Methylphenidate 5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days + Nursing Telephone Intervention (NTI). NTI calls from study nurse 3 times weekly to ask about side effects and other symptoms.
11625565|NCT00424099|Placebo Comparator|Group 2: Placebo + NTI|Placebo capsule orally as needed for 14 days + NTI, calls from study nurse 3 times weekly to ask about side effects and other symptoms.
11625566|NCT00424099|Experimental|Group 3: Methylphenidate + Non NTI|Methylphenidate 5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days + Non NTI, calls from research staff 3 times weekly.
11625567|NCT00424099|Experimental|Group 4: Placebo + Non NTI|Placebo capsules as needed with Non NTI, calls from research staff 3 times weekly.
11625568|NCT00424047|Experimental|CC-5013 plus dexamethasone|Arm A: Oral CC-5013 is initiated on Day 1 of Cycle 1 at a dose of 25 mg daily for 21 days every 28 days. Therefore, the subject will take a placebo identical in appearance to the CC-5013 capsule for week 4 of every 28 days. Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral CC-5013 placebo capsules will be administered for 28 days of every cycle.
11625569|NCT00424047|Experimental|Dexamethasone plus placebo|Arm B: Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
11625570|NCT00424008|Experimental|MF/F MDI 200/10 mcg BID|Mometasone furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily.
11625571|NCT00424008|Active Comparator|F/SC DPI 250/50 mcg BID|Fluticasone propionate/salmeterol (F/SC) 250/50 mcg BID
11625572|NCT00423982|Active Comparator|Rifampicin-combination therapy|Cloxacillin or vancomycin in combination with Rifampicin. Treatment of early staphylococcal prosthetic joint infections in addition to debridement and retention of the prosthesis.
11625573|NCT00423982|Active Comparator|Monotherapy|Cloxacillin or vancomycin in the treatment of early staphylococcal prosthetic joint infections in addition to debridement and retention of the prosthesis.
11625574|NCT00423956|Sham Comparator|Sham Comparator|One side is experimental and the opposite side is Sham control.
11625575|NCT00423943|Experimental|D|modafinil
11625576|NCT00423943|Placebo Comparator|Placebo|placebo
11625577|NCT00423930|Experimental|IMRT + cisplatin + bevacizumab|This is a single-institution phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab.
11625578|NCT00423917|Experimental|fulvestrant + bevacizumab|"Patients receive fulvestrant intramuscularly on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
~Quality of life is assessed at baseline, prior to every other course, and at the completion of study treatment.
~After completion of study treatment, patients are followed every 3-6 months for 5 years."
11625579|NCT00423891|Experimental|Arm 1: Entecavir|
11625580|NCT00423878|Experimental|1|Participants will switch to aripiprazole with a cross-titration from the current antipsychotic over 3-4 weeks. Allowed final dosage range for aripiprazole was 5-30 mg/day
11625581|NCT00423878|Active Comparator|2|Participants will continue with their current antipsychotic treatment, either olanzapine 5-20 mg/day, quetiapine 200-1200 mg/day, or risperidone 1-16 mg/day.
11625582|NCT00423865|Experimental|cisplatin & RAD001|This will be a single institution phase I study of low dose weekly cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15) plus escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle) for patients with advanced solid tumors
11625583|NCT00423852|Experimental|chemotherapy with Stem Cell Support|This is a phase I/II trial of sequential accelerated chemotherapy cycles with paclitaxel/ifosfamide and paclitaxel/ifosfamide and carboplatin administered with G-CSF and PBSC support. During phase I, carboplatin, ifosfamide, and paclitaxel will be dose escalated to determine the MTD. Additional patients will be enrolled in the Phase II portion of the study following the determination of the MTD of Ifosfamide and paclitaxel, to bring the total possible number of patients treated at the MTD to 38.
11625584|NCT00423813|Placebo Comparator|1|
11625585|NCT00423813|Experimental|2|
11625586|NCT00423800|Experimental|Pegetron® - 24 Weeks|Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 16 weeks of treatment
11625587|NCT00423800|Active Comparator|Pegetron®- 48 Weeks|Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 40 weeks of treatment.
11625588|NCT00423787|Experimental|Ragweed MATA MPL|modified Ragweed pollen allergen absorbed to Tyrosine and containing MPL adjuvant
11625589|NCT00423787|Placebo Comparator|Placebo|4 injections of placebo 0.5 ml (2% tyrosine)
11625590|NCT00423735|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
11625591|NCT00423722|Experimental|Hydration: Normal Saline (salt water)|Group 1: 1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily
11625592|NCT00423722|Placebo Comparator|Placebo: Lower Saline|Group 2: Lower Amount of Normal Saline (salt water); 100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
11625593|NCT00423683|Experimental|1- Arixtra Alone|Arixtra Alone
11625594|NCT00423683|Active Comparator|2 Arixtra+ filter|Arixtra + filter
11625595|NCT00423670|Active Comparator|Arm 1. PEG +RBV for 48 Wks (Part I)|"Participants treated with PegIntron (1.5 μg/kg, once weekly [QW]) and Ribavirin (800 to 1400 mg/day) for 48 weeks.
~Participants with detectable HCV-RNA levels after 24 weeks of treatment had the option of crossing over to receive 24 weeks of PegIntron (1.5 μg/kg, QW), Ribavirin (800 to 1400 mg/day), and boceprevir (800 mg three times daily [TID]) for 24 additional weeks. The participants that crossed over to receive boceprevir formed Arm 8. The total treatment duration was up to 54 weeks."
11625596|NCT00423670|Experimental|Arm 2. PEG + RBV + BOC for 28 Wks (Part I)|Participants receiving boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 28 weeks.
11625597|NCT00423670|Experimental|Arm 3. PEG + RBV + BOC (from Wk 4) for 24 Wks (Part I)|Participants receiving a lead-in treatment with PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks, followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 24 weeks.
11625598|NCT00423670|Experimental|Arm 4. PEG +RBV + BOC for 48 Wks (Part I)|Participants receiving boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 48 weeks.
11625599|NCT00423670|Experimental|Arm 5. PEG + RBV + BOC (from Wk 4) for 44 Wks (Part I)|Participants receiving a lead-in treatment with PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks, followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 44 weeks.
11625600|NCT00423670|Experimental|Arm 6. PEG + RBV + BOC for 48 Wks (Part II)|Participants receiving PegIntron (1.5 μg/kg QW), ribavirin (800 to 1400 mg/day) and boceprevir (800 mg TID) for up to 48 weeks during Part II of the study. Part II was initiated after participants were fully enrolled for Part I.
11625601|NCT00423670|Experimental|Arm 7. PEG +Low-dose RBV + BOC for 48 Wks (Part II)|Participants receiving PegIntron (1.5 μg/kg QW), low-dose ribavirin (400 to 1000 mg/day) and boceprevir (800 mg TID) for up to 48 weeks (Arm 7) during Part II of the study. Part II was initiated after participants were fully enrolled for Part I.
11625602|NCT00423670|Experimental|Arm 8. PEG + RBV + BOC (from Wk 24) for 48 Wks (Part I)|"Participants that started in Arm 1 and had detectable HCV-RNA levels after 24 weeks of treatment had the option of receiving boceprevir (800 mg TID) with
~PegIntron (1.5 μg/kg QW), and ribavirin (800 to 1400 mg/day). Participants that took the option of crossing over to receive PegIntron, ribavirin, and boceprevir (800 mg TID) for 24 additional weeks constitute Arm 8. The total treatment duration was up to 54 weeks."
11625603|NCT00423657|Experimental|Ceftaroline fosamil for Injection|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
11625604|NCT00423657|Active Comparator|IV Vancomycin plus IV Aztreonam|Vancomycin 1 g administered over 60 minutes every 12 hours followed by aztreonam 1 g administered over 60 minutes every 12 hours.
11625605|NCT00423644|Experimental|Single Arm|
11625606|NCT00423631|Experimental|Standard Care and Web|Standard care plus a web site based on cognitive behavioral principals.
11625607|NCT00423631|Active Comparator|Standard Care|Subject recieve standard care from their primary care provider.
11625608|NCT00423618|Active Comparator|Control arm|Radiotherapy Conventional treatment arm A total of 33 fractions each of 2Gy should be given once a day for 5 days per week over 6 weeks and 3 days in week 7, totalling 66Gy. The first 50 Gy in 25 fractions will be given to CTV1 and subsequent 16 Gy in 8 fractions will be delivered to CTV2.
11625609|NCT00423618|Experimental|Research arm|Radiotherapy Research arm A total of 33 fractions each of 2Gy should be given once a day for 5 days per week over 6 weeks and 3 days in week 7, totalling 66Gy. The 66Gy in 33 fractions will be delivered to CTV2 alone. No attempt will be made to include drain/biopsy sites or the surgical scar.
11625610|NCT00423605|Experimental|1|
11625611|NCT00423579|Experimental|Ezetimibe/Simvastatin 10/20 mg + Simvastatin placebo|Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin 10/20 mg. The second tablet is simvastatin placebo. Subjects will receive a maximum of 6 weeks of treatment
11625612|NCT00423579|Active Comparator|Ezetimibe/Simvastatin placebo + Simvastatin 40 mg|Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin placebo. The second tablet is simvastatin 40 mg. Subjects will receive a maximum of 6 weeks of treatment.
11625613|NCT00423514|Experimental|cytoreduction regimen & stem cell transplant|This is a single arm phase I/II clinical trial to assess efficacy (the antileukemic potential and relapse rate), and safety (peri-transplant morbidity and mortality) of a novel cytoreduction regimen in preparation for allogeneic hematopoietic stem cell transplantation (HSCT).
11625614|NCT00423501|Experimental|1|
11625615|NCT00423501|Experimental|2|
11625616|NCT00423501|Experimental|3|
11625617|NCT00423501|Experimental|4|
11625618|NCT00423501|Experimental|5|
11625619|NCT00423501|Placebo Comparator|6|
11625620|NCT00423488|Experimental|Ezetimibe 10 mg + Simvastatin Placebo + Simvastatin 20 mg|Participants were instructed to take one 10-mg ezetimibe tablet and one simvastatin placebo tablet orally in the evening every day for six weeks in addition to their daily, oral, open-label, 20-mg simvastatin tablet.
11625621|NCT00423488|Active Comparator|Ezetimibe Placebo + Simvastatin 40 mg|Participants were instructed to take one ezetimibe placebo tablet and one simvastatin 20-mg tablet orally in the evening every day for six weeks in addition to their daily, oral, open-label, 20-mg simvastatin tablet.
11625622|NCT00423475|Active Comparator|I|Exclusive Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) in treating patients who have undergone surgery for recurent or refractory Prostate Cancer
11625623|NCT00423475|Experimental|II|Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) and GOSERELIN ACETATE in treating patients who have undergone surgery for recurent or refractory Prostate Cancer
11625624|NCT00423449|Experimental|Vorinostat + Gemcitabine + Platinum-based agent|
11625672|NCT00422968|Active Comparator|coronary artery bypass graft|coronary artery bypass graft
11625625|NCT00423436|Experimental|IVR Assessment Plus Triage|Interactive Voice Response Telephone System (IVR) Plus Triage (Participants report symptoms to telephone system and doctor/nurse notified when symptom is severe) + Questionnaire
11625626|NCT00423436|Experimental|IVR Assessment Only|IVR (Phone calls twice weekly) + Questionnaire
11625627|NCT00423410|Experimental|EPC2407 (crinobulin)|
11625628|NCT00423384|Experimental|1|Ibandronate
11625629|NCT00423384|Placebo Comparator|2|
11625630|NCT00423371|Experimental|EUFLEXXA™|
11625631|NCT00423371|Placebo Comparator|Placebo|
11625632|NCT00423358|Active Comparator|vitamin D|ergocalciferol 50,000 IU Twice monthly
11625633|NCT00423358|Placebo Comparator|placebo|matching placebo tablet
11625634|NCT00423332|Placebo Comparator|1|Cediranib placebo
11625635|NCT00423332|Experimental|2|Cediranib
11625636|NCT00423319|Active Comparator|Apixaban, 2.5 mg BID plus placebo|Participants received apixaban, 2.5 mg twice daily (BID), as oral tablets, and matching enoxaparin-placebo injection once daily (QD)
11625637|NCT00423319|Experimental|Enoxaparin, 40 mg QD plus placebo|Participants received enoxaparin, 40 mg QD subcutaneously, and matching apixaban-placebo tablets BID
11625638|NCT00423306|Experimental|Single Arm|
11625639|NCT00423293|Other|5-FU + Mitomycin + IMRT|5-FU + Mitomycin + IMRT
11625640|NCT00423280|Active Comparator|1|700mg/day 6R-BH4
11625641|NCT00423280|Active Comparator|2|400mg/day 6R-BH4
11625642|NCT00423280|Placebo Comparator|3|Placebo
11625643|NCT00423267|Experimental|Posaconazole|Eligible subjects will be stratified at Baseline by disease site (skeletal, lung, or soft tissue) and by immune status (immunocompromised or non-immunocompromised) and will then be randomly assigned to receive Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months.
11625644|NCT00423267|Active Comparator|Fluconazole|Eligible subjects will be stratified at Baseline by disease site (skeletal, lung, or soft tissue) and by immune status (immunocompromised or non-immunocompromised) and will then be randomly assigned to receive Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months. Fluconazole treatment or placebo only occurred during Period A.
11625645|NCT00423254|Experimental|Low Dose Cohort|
11625646|NCT00423254|Experimental|High Dose Cohort|
11625647|NCT00423241|Experimental|SEMPERFLO Pain Management System|
11625648|NCT00423241|Active Comparator|ON-Q PainBuster Post-Op Pain Relief System|
11625649|NCT00423228|Experimental|ZT-1|ZT-1 (investigational product)
11625650|NCT00423228|Active Comparator|Donepezil|Donepezil
11625651|NCT00423215||Patients with Type II diabetes|
11625652|NCT00423189|Active Comparator|Ranibizumab only|drug - intravitreal ranibizumab
11625653|NCT00423189|Experimental|40% fluence PDT/procedure|40% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab
11625654|NCT00423189|Experimental|20% fluence photodynamic therapy|20% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab
11625655|NCT00423176|Experimental|MFNS + Antibiotic|Mometasone furoate nasal spray (MFNS) twice daily (BID) for 29 days, plus antibiotic. Appropriate antibiotic therapy amoxicillin/clavulanic acid BID.
11625656|NCT00423176|Placebo Comparator|Placebo|Matching placebo nasal spray BID for 29 days, plus amoxicillin/clavulanic acid BID
11625657|NCT00423150|Experimental|Temozolomide|
11625658|NCT00423124|Experimental|A|
11625659|NCT00423098|Experimental|Standard dose|Mycophenolate sodium was administered orally in combination with a standard dose of corticosteroids (CS) administered as prednisone or prednisone equivalent (PRED). Mycophenolate sodium was administered in divided doses at a daily dose of 1440 mg during the first 2 weeks of the study and then at 2160 mg daily for the next 22 weeks. The dose of Prednisone was started at 1 mg per kg body weight and subsequently tapered according to the patient's weight. The planned treatment duration was 24 weeks.
11625660|NCT00423098|Active Comparator|Low dose|Mycophenolate sodium was administered in combination with a reduced dose of corticosteroids (CS) administered as prednisone or prednisone equivalent (PRED). Mycophenolate sodium was administered in divided doses at a daily dose of 1440 mg during the first 2 weeks of the study and then at 2160 mg daily for the next 22 weeks. The dose of Prednisone was started at 0.5 mg per kg body weight and subsequently tapered according to the patient's weight. The planned treatment duration was 24 weeks.
11625661|NCT00423085|Placebo Comparator|Placebo|Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
11625662|NCT00423085|Experimental|rivastigmine 5 cm^2|During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks and thereafter daily rivastigmine 5 cm^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
11625663|NCT00423085|Experimental|Rivastigmine 10 cm^2|During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks, rivastigmine 5 cm^2 patch for the next 4 weeks, rivastigmine 7.5 cm^2 patch for the next 4 weeks and then rivastigmine 10 cm^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
11625664|NCT00423072||1|children with cleft palate birth-24 months of age
11625665|NCT00423046|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals human papillomavirus [HPV]16/18 vaccine 580299 (CervarixTM) at Months 0, 1 and 6 and a dose of placebo at Month 2. All doses were administered by intramuscular injection in the deltoid muscle of the upper arm.
11625666|NCT00423046|Active Comparator|Gardasil Group|Subjects received 3 doses of Gardasil® (Merck's human papillomavirus [HPV] vaccine) at Months 0, 2 and 6 and a dose of placebo at Month 1. All doses were administered by intramuscular injection in the deltoid muscle of the upper arm.
11625667|NCT00423007|Experimental|Bromfenac|Ophthalmic Solution
11625668|NCT00423007|Placebo Comparator|Placebo|Vehicle ophthalmic solution
11625669|NCT00422981|Active Comparator|AL-108 5 mg|5 mg QD
11625670|NCT00422981|Active Comparator|AL-108 15 mg|15 mg BID
11625671|NCT00422981|Placebo Comparator|Placebo|Placebo
11625673|NCT00422968|Experimental|percutaneous coronary intervention|Using silorimus eluting stent
11625674|NCT00422955|Experimental|Arm 1|
11625675|NCT00422942|Experimental|1|
11625676|NCT00422929||chronic otitis media with effusion (OME)|history of chronic effusion (3 months if both ears, 6 months if one ear, or 3 episodes of effusion each lasting for 2 months or longer)
11625677|NCT00422929||recurrent AOM|recurrent acute otitis media (3 episodes in 6 months or 4 episodes in 1 year)
11625678|NCT00422929||no OM|no history of significant otitis media (i.e., does not meet criteria for chronic OME or recurrent AOM)
11625679|NCT00422916|Experimental|intervention arm|Lifestyle Intervention based on Nutrition Treatment, exercise Treatment and behavorial treatment
11625680|NCT00422916|No Intervention|waiting list|waiting 6 months for Intervention without any intervention
11625681|NCT00422903|Placebo Comparator|Letrozole plus placebo|Letrozole 2.5 mg administered orally fro 6 mos. plus placebo 1500 mg administered orally throughout the study until definitive surgery
11625682|NCT00422903|Experimental|Letrozole plus lapatininb|Letrozole 2.5 mg administered orally fro 6 mos. plus lapatinib 1500 mg administered orally throughout the study until definitive surgery
11625683|NCT00422877|Experimental|Taxoprexin|Starting dose of 500 mg/m2 (400 mg/m2 for patients with an elevated bilirubin at baseline) administered intravenously by a 1-hour infusion weekly for the first 5 weeks of a 6 week cycle.
11625684|NCT00422851||1|Normal tympanic membrane
11625685|NCT00422851||2|tympanosclerosis
11625686|NCT00422851||3|dimeric (atrophic)
11625687|NCT00422838||1|Chronic HCV Genotype 1 monoinfection, never had interferon and ribavirin treatment
11625688|NCT00422838||2|Chronic HCV Genotype 2 or 3 monoinfection,never had interferon and ribavirin treatment
11625689|NCT00422825|Experimental|Imatinib 800mg|
11625690|NCT00422825|Active Comparator|Imatinib 400mg|
11625691|NCT00422812|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo
11625692|NCT00422812|Experimental|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
11625693|NCT00422812|Experimental|Inhaled PCZ 7.5 mg|Inhaled Staccato Prochlorperazine 7.5 mg
11625694|NCT00422812|Experimental|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
11625695|NCT00422799|Experimental|bortezomib and rituximab|bortezomib and rituximab
11625696|NCT00422786|Experimental|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period.
11625697|NCT00422773|Experimental|Cetuximab+ FOLFOXIRI|Cetuximab and Irinotecan, Oxaliplatin, 5FU and Folinic acid
11625698|NCT00422747|Experimental|beclomethasondipropionate|2 x 100 ug dd for two months, via aerochamber
11625699|NCT00422734|Placebo Comparator|1|Placebo
11625700|NCT00422734|Active Comparator|2|5 mg tadalafil
11625701|NCT00422695||HIV +|Groups divided according to CD4 counts
11625702|NCT00422695||Healthy Controls|HIV -ve subjects
11625703|NCT00422682|Experimental|1|BSI-201 + topotecan
11625704|NCT00422682|Experimental|2|BSI-201 + temozolomide
11625705|NCT00422682|Experimental|3|bsi-201 + gemcitabine
11625706|NCT00422682|Experimental|4|bsi-201 + carboplatin/paclitaxel
11625707|NCT00422669|Active Comparator|RV Mid-Septal Pacing|Pacing lead is placed in the right ventricle at the middle of the muscle separating the right and left sides of the heart
11625708|NCT00422669|Active Comparator|RV Apical Pacing|Pacing lead is placed at the bottom of the right ventricle of the heart, in the right ventricular apex
11625709|NCT00422656|Experimental|Perifosine|Patients receive oral perifosine (150 mg) daily each cycle. Cycle duration is 28 days. After cycle 2, response is assessed and patients with stable or responding disease can continue for another 4 cycles or until disease progression (PD). Protocol treatment duration is 6 cycles but patients may receive perifosine maintenance per investigator discretion in absence of PD.
11625710|NCT00422630|Active Comparator|Average American Diet|
11625711|NCT00422630|Active Comparator|The DASH diet|
11625712|NCT00422630|Active Comparator|The Low Glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
11625713|NCT00422591|Experimental|Idarubicin + Cytarabine|Idarubicin 12 mg/m2 IV over 1 hour daily x 3 (days 1-3). Cytarabine 1.5 g/m2 IV over 24 hours daily on day 1-4 (age <60 years) or days 1-3 (age > 60 years).
11625714|NCT00422565|Experimental|Endeavor|Zotarolimus-eluting stent
11625715|NCT00422565|Active Comparator|Cypher|Sirolimus-eluting stent
11625716|NCT00422565|Active Comparator|Taxus|Paclitaxel-eluting stent
11625717|NCT00422513|Experimental|methoxy polyethylene glycol-epoetin beta|120-360 micrograms (iv) monthly, starting dose
11625718|NCT00422513|Active Comparator|Epoetin Alfa|As prescribed, (iv), 3 times weekly
11625719|NCT00422500||Chemotherapy Symptoms|Study participants with advanced-stage lung cancer.
11625720|NCT00422487|Experimental|MBX-2044 1.5 mg|
11625721|NCT00422487|Experimental|MBX-2044 4.5 mg|
11625722|NCT00422487|Experimental|MBX-2044 15 mg|
11625723|NCT00422487|Experimental|MBX-2044 30 mg|
11625724|NCT00422487|Experimental|MBX-2044 60 mg|
11625725|NCT00422487|Experimental|MBX-2044 90 mg|
11625726|NCT00422487|Placebo Comparator|Placebo|
11625727|NCT00422461|Experimental|PF-00489791 4 mg|
11625728|NCT00422461|Experimental|PF-00489791 10 mg|
11625729|NCT00422461|Experimental|PF-00489791 20 mg titrated to 40 mg|
11625730|NCT00422461|Placebo Comparator|Placebo|
11625731|NCT00422448|Experimental|Nevi from participants|Benign nevi dermoscopically sub-classified into 4 dermoscopic types (i.e., with globular, reticular, mixed pattern with globules in the center and mixed pattern with globules at the periphery) were excised from healthy volunteers for further genetical analysis
11625732|NCT00422435|Experimental|Drug eluting stent|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter
11625733|NCT00422422|Experimental|Brivaracetam|
11625734|NCT00422383|Experimental|1|
11625737|NCT00422344|Experimental|RAD001 AND SUNITINIB|RAD001 AND SUNITINIB IN METASTATIC RENAL CELL CARCINOMA PATIENTS
11625738|NCT00422305||1-Healthy Infants|"Group 1: The investigators will recruit 80 healthy infants born at > 37 weeks gestation, and between 2 and 36 months of age. Infants will be excluded for any of the following reasons:
~Congenital cardio-respiratory disease
~Hospitalization for respiratory illness
~Treatment with asthma medications
~Small for gestational age at birth"
11625739|NCT00422305||2-Healthy Infants computerized Tomography|"Group 2: The investigators recruited 4 infants born at > 37 weeks gestation and they were evaluated between 2 and 36 months of age when scheduled for high resolution computed tomography (HRCT) imaging for non-respiratory medical problems. Subjects were enrolled and HRCT of the chest were obtained. Infants were excluded for the following reasons:
~Congenital cardio-respiratory disease
~Hospitalization for respiratory illness
~Treatment with asthma medications"
11625740|NCT00422305||3-Premature Infants|"Group 3: The investigators have recruited 45 infants born prematurely at 23-35 weeks gestation. Subjects were evaluated at corrected age at between 2 and 24 months. The subjects had no oxygen requirements, and were clinically stable outpatients when evaluated. Infants were excluded for any of the following reasons:
~Congenital cardio-respiratory disease
~Severe developmental delay"
11625741|NCT00422292|Experimental|Menactra® at 9 and 12 Months|Participants will received Menactra® vaccination at 9 and 12 months of age.
11625742|NCT00422292|Experimental|Menactra® at 9 Months and Menactra® + MMRV at 12 Months|Participants will receive Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV) vaccine at 12 months of age
11625743|NCT00422292|Experimental|Menactra® at 9 Months and Menactra® + PCV at 12 Months|Participants will receive Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age
11625744|NCT00422292|Active Comparator|MMRV + PCV at 12 Months|Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age
11625745|NCT00422279|Experimental|supraalevolar|Bone inductive implant (Nobel Replace Tapered Groovy) placed in the supralveolar position
11625746|NCT00422279|Experimental|Other|Bone inductive implant (Nobel Replace Tapered Groovy) placed in extraction socket
11625747|NCT00422227|Active Comparator|1|Etanercept + Methotrexate
11625748|NCT00422227|Active Comparator|2|DMARD therapy Methotrexate + Sulfasalazine/Hydroxychloroquine/Leflunomide
11625749|NCT00422201|Experimental|Prospective, open-label, study of mifepristone|Eligible subjects will start study treatment at the dose of 600 mg/day (given as one 200 mg tablet tid, per os). Total duration of treatment will not exceed 12 months. At the end of 12-month treatment, investigators may petition to extend treatment on a case-by-case basis.
11625750|NCT00422188|Experimental|Deoxycholic Acid Injection 0.5%|Participants received 0.5% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
11625751|NCT00422188|Experimental|Deoxycholic Acid Injection 1.0%|Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
11625752|NCT00422188|Experimental|Deoxycholic Acid Injection 2.0%|Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
11625753|NCT00422188|Experimental|Deoxycholic Acid Injection 4.0%|Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
11625754|NCT00422188|Placebo Comparator|Placebo|Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
11625755|NCT00422162|Experimental|Duloxetine Hydrochloride (60 mg)|"Up to Week 4: 60 milligrams (mg) every morning and placebo every evening, by mouth (PO).
~Week 4 to Week 8: Responders continued on same dose as before; Nonresponders received 60 mg every morning and 60 mg every evening added to the placebo"
11625756|NCT00422162|Experimental|Duloxetine Hydrochloride (120 mg)|"Up to Week 4: 60 mg every morning and 60 mg every evening, PO.
~Week 4 to Week 8: Responders continued on same dose as before; Nonresponders continued as before with a placebo capsule added to the evening dose"
11625757|NCT00422149|Active Comparator|1|SUBLIVAC® Grasses treatment
11625758|NCT00422149|Placebo Comparator|2|Placebo treatment
11625759|NCT00422097|Experimental|Ixabepilone, 5 mg/d|If none of first 3 participants experiences a dose-limiting toxicity (DLT) during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the maximum tolerated dose (MTD). If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
11625760|NCT00422097|Experimental|Ixabepilone, 10 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
11625761|NCT00422097|Experimental|Ixabepilone, 15 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
11625803|NCT00421759|Experimental|1|85 elderly individuals with somatosensory deficits
11625804|NCT00421759|Experimental|2|85 elderly individuals with recurrent falls
11625805|NCT00421733|Active Comparator|Paricalcitol 1 mcg|One paricalcitol 1 mcg capsule and one matching placebo capsule per dose
11625762|NCT00422097|Experimental|Ixabepilone, 20 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
11625763|NCT00422097|Experimental|Ixabepilone, 25 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
11625764|NCT00422097|Experimental|Ixabepilone, 30 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
11625765|NCT00422097|Experimental|Ixabepilone, 25 mg, with famotidine|Following identification of MTD, participants who completed Cycle 1 and treated at the ixabepilone MTD (25 mg/d) will crossover to Cycle 2 in which they receive famotidine, 40 mg on Day 1.
11625766|NCT00422097|Experimental|Ixabepilone, 25 mg, with food|Following identification of MTD, participants who completed Cycle 1 and treated at the ixabepilone MTD (25 mg/d) will crossover to Cycle 2 in which they receive a low-fat meal on Day 1.
11625767|NCT00422084|Experimental|1|Pyronaridine artesunate
11625768|NCT00422084|Active Comparator|2|Arthemether lumefantrine
11625769|NCT00422058|Placebo Comparator|Lira placebo/Lira 2.4 mg/Lira 3.0 mg|Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
11625770|NCT00422058|Experimental|Lira 1.2 mg/Lira 3.0 mg|Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
11625771|NCT00422058|Experimental|Lira 1.8 mg/Lira 3.0 mg|Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
11625772|NCT00422058|Experimental|Lira 2.4 mg/Lira 3.0 mg|Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
11625773|NCT00422058|Experimental|Liraglutide 3.0 mg|Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
11625774|NCT00422058|Active Comparator|Orlistat|Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)
11625775|NCT00422045|No Intervention|2|No Laser done. All outcome measures are the same.
11625776|NCT00422045|Experimental|1|Low Level Laser Therapy
11625777|NCT00422032|Experimental|15 mg/m^2 Clofarabine|Lower Dose Clofarabine Group A: 15 mg/m^2 intravenous (IV) over 1 hour daily for 5 days
11625778|NCT00422032|Experimental|30 mg/m^2 Clofarabine|Higher Dose Clofarabine Group B: 30 mg/m^2 IV over 1 hour daily for 5 days
11625779|NCT00422019|Experimental|AMG 102 at 20 mg/kg Dose Level|Up to 40 subjects will be treated at 20 mg/kg of AMG 102 Q2W (every 2 weeks) depending upon the stage of the study and number of responses observed.
11625780|NCT00422019|Experimental|AMG 102 at 10 mg/kg Dose Level|Up to 40 subjects will be dosed at 10mg/kg of AMG 102 Q2W (every two weeks) based upon the stage of the study and number of responses observed.
11625781|NCT00422006|Experimental|1|Non diabetic non dyslipidemic patient
11625782|NCT00422006|Experimental|2|Patient with metabolic syndrome
11625783|NCT00422006|Experimental|3|Patients with type II diabetes
11625784|NCT00422006|Experimental|4|Patient with a single lipidic anomaly
11625785|NCT00421993|Experimental|1|Adapalene/Benzoyl Peroxide Topical Gel
11625786|NCT00421993|Active Comparator|2|Adapalene Topical Gel
11625787|NCT00421993|Active Comparator|3|Benzoyl Peroxide Topical Gel
11625788|NCT00421993|Placebo Comparator|4|Topical Gel Vehicle
11625789|NCT00421967|Experimental|1|
11625790|NCT00421967|Active Comparator|2|
11625791|NCT00421954|Experimental|Ziprasidone|
11625792|NCT00421928|Experimental|001|tapentadol (CG5503) 50 100 150 200 250mg twice a day (BID) during 15 weeks
11625793|NCT00421928|Active Comparator|002|oxycodone 10 20 30 40 50mg twice a day (BID) during 15 weeks
11625794|NCT00421928|Placebo Comparator|003|placebo matching placebo twice a day (BID) during 15 weeks
11625795|NCT00421902|Experimental|Acupuncture|Acupuncture of the patients
11625796|NCT00421889|Experimental|Single arm|"Belinostat: 1000 mg/m2 days 1-5 in a 21 day cycle; IV Paclitaxel: Administered IV 2-3 hours after belinostat infusion on day 3 in a 21-day cycle
~Carboplatin: Administered IV infusion after paclitaxel on day 3 in a 21-day cycle"
11625797|NCT00421863|Other|Intensive Strategy|
11625798|NCT00421863|Other|Usual Strategy|
11625799|NCT00421837||controls|household and other close contacts
11625800|NCT00421837||cases|elderly (>55) subjects hospitalized with Influenza
11625801|NCT00421824|Experimental|A|
11625806|NCT00421733|Active Comparator|Paricalcitol 2 mcg|Two paricalcitol 1 mcg capsules per dose
11625807|NCT00421733|Placebo Comparator|Placebo|Two placebo capsules per dose
11625808|NCT00421707|Experimental|GW876008|GW876008
11625809|NCT00421707|Placebo Comparator|Placebo|Placebo
11625810|NCT00421681|Experimental|A|"Treatment Arm A will develop tailored/negotiated contracts with the exercise instructor to maintain post intervention exercise adherence at home or in the community. Half of the participants in this negotiated maintenance arm will be randomly assigned to receive telephone calls to reinforce adherence and half will be assigned to a no telephone calls group."
11625811|NCT00421681|Experimental|B|"Treatment Arm B will be mainstreamed into an ongoing facility-based exercise program for post intervention exercise adherence. Persons in this mainstream follow up arm will be randomly assigned such that half will receive regular telephone reinforcement follow up and half will not."
11625812|NCT00421668|Experimental|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate, and B12
11625813|NCT00421668|Experimental|Multivitamins + Zinc|Vitamins C, E, B1, B2, niacin, B6, folate and B12, and zinc
11625814|NCT00421668|Experimental|Zinc|zinc
11625815|NCT00421668|Placebo Comparator|Placebo|placebo
11625816|NCT00421655|Experimental|1|
11625817|NCT00421655|Placebo Comparator|2|
11625818|NCT00421603|Active Comparator|Adderall-XR and Topiramate|Adderall-XR (60 mg/day) and Topiramate (300mg/day)
11625819|NCT00421603|Placebo Comparator|Placebo|Placebo
11625820|NCT00421551|Experimental|1|
11625821|NCT00421551|Active Comparator|2|
11625822|NCT00421538|Active Comparator|LMWH|Therapeutic dose of Nadroparin
11625823|NCT00421538|Placebo Comparator|Placebo|Injectable placebo
11625824|NCT00421525|Active Comparator|Multiple Doses|Multiple Dose levels
11625825|NCT00421447||Breast Cancer patients|A group of women with breast cancer prescribed Anastrozole
11625826|NCT00421447||Healthy women wit no breast Cancer|A group of healthy women wit no breast cancer prescribed Anastrozole
11625827|NCT00421434|Experimental|Nitazoxanide-Peginterferon|One oral nitazoxanide 500 mg tablet with food twice daily for 12 weeks followed by 36 weeks of one oral nitazoxanide 500 mg tablet plus weekly injections of 180 µg peginterferon alfa-2a.
11625828|NCT00421434|Experimental|Nitazoxanide-Peginterferon-Ribavirin|One oral nitazoxanide 500 mg tablet with food twice daily for 12 weeks followed by 36 weeks of one oral nitazoxanide 500 mg tablet plus weekly injections of 180 µg peginterferon alfa-2a plus oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses.
11625829|NCT00421434|Active Comparator|Peginterferon-Ribavirin|Weekly injections of 180 µg peginterferon alfa-2a plus oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
11625830|NCT00421408|Experimental|Protein powder|Participants will receive a protein supplement daily (40 g whey protein supplement).
11625831|NCT00421408|Placebo Comparator|Placebo carbohydrate|Participants will receive a placebo supplement daily (40 g maltodextrin).
11625832|NCT00421395|Experimental|multi|escalating in increments of 2.5 mCi/m2
11625833|NCT00421356||Transfemoral Power Knee group|Transfemoral amputees who used the power assisted Ossur Power Knee who used the knee daily without adjustments for at least 90 days prior to the study.
11625834|NCT00421356||Transfemoral C-Leg knee group|Transfemoral amputees who used the stance control Otto Bock C-Leg who used the knee daily without adjustments for at least 90 days prior to the study.
11625835|NCT00421356||Transfemoral Mauch knee group|Transfemoral amputees who used the mechanical fluid controlled Mauch Swing and Stance Knee who used the knee daily without adjustments for at least 90 days prior to the study.
11625836|NCT00421356||Non amputee control group|Healthy, non-amputee control group
11625837|NCT00421343|Other|Treatment for osteoporosis and falls|calcium, vitamin D, a weekly oral bisphosphonate, and falls prevention measures. No comparator group. All participants received the same intervention
11625838|NCT00421330|Active Comparator|OR|Open Aneurysm Repair
11625839|NCT00421330|Experimental|EVAR|Endovascular Aneurysm Repair
11625840|NCT00421304|Experimental|1|MEDI-524 or Motavizumab
11625841|NCT00421304|Experimental|2|MEDI-524 or Motavizumab
11625842|NCT00421304|Placebo Comparator|3|Placebo
11625843|NCT00421278|Experimental|1|Arm 1: Drug
11625844|NCT00421252|Active Comparator|Clopidogrel 600 mg pre-treatment|Patients will receive 600 mg Clopidogrel load >2 hours pre-angiography with possibility for ad hoc PCI based on angiographic results
11625845|NCT00421252|Active Comparator|No clopidogrel 600 mg pretreatment|Patients will receive 600 mg Clopidogrel load after PCI, if performed
11625846|NCT00421252|Active Comparator|5Fr arterial access sheath|Patients will have angiography performed using 5Fr sheath. If PCI required, sheath will be upsized.
11625847|NCT00421252|Active Comparator|6Fr arterial access sheath|Patients will have angiography performed using 6Fr sheath
11625848|NCT00421239||A|
11625849|NCT00421239||B|
11625850|NCT00421213|Experimental|Single Arm|
11625851|NCT00421200|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
11625852|NCT00421200|Active Comparator|Control|Voluven (HES 130/0.4)
11625853|NCT00421187|Experimental|1|AmBisome® will be given on day 0 (10 mg/kg), day 2 (5 mg/kg), and day 5 (5 mg/kg)
11625854|NCT00421187|Active Comparator|2|AmBisome as a constant daily dose of 3 mg/kg for a maximum of 14 days or until the resolution of fever and neutropenia
11625855|NCT00421174|Experimental|Etanercept|Etanercept plus corticosteroids
11625856|NCT00421174|Active Comparator|Placebo|Placebo plus Corticosteroids
11625857|NCT00421148|Experimental|Sugammadex 0.5 mg/kg|Participants are to receive an intravenous (IV) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex is to be given.
11625858|NCT00421148|Experimental|Sugammadex 1 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex is to be given.
11625859|NCT00421148|Experimental|Sugammadex 2 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex is to be given.
11625909|NCT00420680|Experimental|Arm 1|Sugammadex 2.0 mg/kg
11625860|NCT00421148|Experimental|Sugammadex 4 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex is to be given.
11625861|NCT00421148|Placebo Comparator|Placebo|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single 3-mL bolus dose of placebo (sodium chloride 0.9% solution) is to be given.
11625862|NCT00421135|Experimental|Single Arm|ZIO-201
11625863|NCT00421122|Active Comparator|1|Bricasol®
11625864|NCT00421122|Experimental|2|Bricasol® + Pulmicort®
11625865|NCT00421122|Experimental|3|Bricasol® + Symbicort®
11625866|NCT00421109|Experimental|1|Bilastine 20 mg
11625867|NCT00421109|Active Comparator|2|Levocetirizine 5 mg
11625868|NCT00421109|Placebo Comparator|3|Placebo
11625869|NCT00421096|Experimental|patient with cervix cancer|will receive gemcitabine + cisplatin + radiotherapy
11625870|NCT00421070|No Intervention|Treatment as usual|Observational component
11625871|NCT00421070|Active Comparator|Intervention|Massage therapy adjunct comparator
11625872|NCT00421057||Exercise Group|Taught to perform a specific regimen for strength-training and walking exercises.
11625873|NCT00421057||Nonexercise Group|Follow usual routines of standard care but not taught to perform a specific regimen for strength-training and walking exercises; will keep record of any exercises done that are not a part of this study.
11625874|NCT00421044|Experimental|Arm A (Normal liver function)|
11625875|NCT00421044|Experimental|Arm B (Mild liver dysfunction)|
11625876|NCT00421044|Experimental|Arm C (Moderate liver dysfunction)|
11625877|NCT00421018|Sham Comparator|Symptom-guided group|Anti-inflammatory treatment is guided conventionally according to symptoms and beta-2-agonist use.
11625878|NCT00421018|Active Comparator|FeNO-guided group|Anti-inflammatory treatment is guided according to the level of exhaled nitric oxide
11625879|NCT00421005|Experimental|1|Fluvastatin 80mg
11625880|NCT00421005|Active Comparator|2|Fluvastatin 20, tapered up according to LDL concentration
11625881|NCT00420992|Experimental|ALO-01|Up to 80 mg twice a day (bid)
11625882|NCT00420992|Placebo Comparator|Placebo|Twice a day (bid)
11625883|NCT00420940|Experimental|90 Hz whole-body vibration|20-minute daily whole-body vibration at 90 Hz and 0.3g
11625884|NCT00420940|Experimental|30 Hz whole-body vibration|20-minute daily whole-body vibration at 90 Hz and 0.3g
11625885|NCT00420940|No Intervention|control|control group (receiving no vibration)
11625886|NCT00420927|Experimental|ADA+MTX/PBO+MTX (Arm 1)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2
11625887|NCT00420927|Experimental|ADA+MTX/ADA+MTX (Arm2)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2
11625888|NCT00420927|Experimental|ADA+MTX/OL ADA+MTX (Arm 3)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA + MTX during Period 2
11625889|NCT00420927|Experimental|PBO+MTX/PBO+MTX (Arm 4)|Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2
11625890|NCT00420927|Experimental|PBO+MTX/OL ADA+MTX (Arm 5)|Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2.
11625891|NCT00420888|Experimental|Safety group|6-12 patients
11625892|NCT00420888|Experimental|1|
11625893|NCT00420888|Other|2|Standard treatment with IFN-alpha without add-on of ABR-217620/naptumomab estafenatox
11625894|NCT00420849|Experimental|Lenalidomide plus Dexamethasone|Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
11625895|NCT00420823|Placebo Comparator|Placebo pill|4 placebo pills daily for 3 months
11625896|NCT00420823|Experimental|Taurine 4g|Taurine 4g daily comprising four 1g pills
11625897|NCT00420784|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 24 weeks.
11625898|NCT00420784|Experimental|Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week|Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
11625899|NCT00420784|Experimental|Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week|Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.
11625900|NCT00420784|Placebo Comparator|PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
11625901|NCT00420771|Experimental|Gabapentin|gabapentin treatment 1200 mg three times daily
11625902|NCT00420771|Placebo Comparator|Placebo|Placebo condition received pills identical in appearance to experimental arm.
11625903|NCT00420758|No Intervention|Control|
11625904|NCT00420758|Experimental|LNS|Lipid-based nutrient supplement
11625905|NCT00420758|Experimental|CSB|Corn-soy blend supplement
11625906|NCT00420745|Experimental|Rotarix Group|All subjects received 2 oral doses of Rotarix vaccine, 1 dose at Day 0 and 1 dose at Month 1 or 2 depending on the country.
11625907|NCT00420745|Placebo Comparator|Placebo Group|All subjects received 2 oral doses of placebo, 1 dose at Day 0 and 1 dose at Month 1 or 2 depending on the country.
11625908|NCT00420732|Experimental|Vaccine Group|
11625910|NCT00420680|Experimental|Arm 2|Sugammadex 4.0 mg/kg
11625911|NCT00420680|Placebo Comparator|Arm 3|Placebo
11625912|NCT00420654|Active Comparator|A1|
11625913|NCT00420654|Placebo Comparator|A2|
11625914|NCT00420654|Other|A3|
11625915|NCT00420641|Experimental|GSK372475 Arm|GSK372475 1.0- 1.5 mg/day
11625916|NCT00420641|Experimental|Paroxetine Arm|Paroxetine 20-30 mg/day
11625917|NCT00420641|Other|Placebo|Placebo to Match
11625918|NCT00420628|Experimental|Loteprednol/Tobramycin|0.5% loteprednol etabonate with 0.3% tobramycin opthalmic suspension
11625919|NCT00420628|Placebo Comparator|Vehicle|Vehicle
11625920|NCT00420615|Experimental|Patupilone and Omeprazole|patupiloe + omeprazole
11625921|NCT00420615|Experimental|patupilone + midalzolam|patupilone + midalzolam
11625922|NCT00420602|Other|Single Arm, Open Label|Single Arm, Open Label
11625923|NCT00420589|Placebo Comparator|1|Arm 1: MK0364 Pbo capsules once daily
11625924|NCT00420589|Experimental|2|Arm 2: MK0364 0.5 mg capsule once daily
11625925|NCT00420589|Experimental|3|Arm 3: MK0364 1 mg capsule once daily
11625926|NCT00420589|Experimental|4|Arm 4: MK0364 2 mg capsule once daily
11625927|NCT00420576|Experimental|1|Low Dose Danggui Buxue Tang (1.5g)
11625928|NCT00420576|Experimental|2|Middle Dose Danggui Buxue Tang(3g)
11625929|NCT00420576|Experimental|3|High Dose Danggui Buxue Tang (6g)
11625930|NCT00420563|Experimental|CYCLOPHOSPHAMIDE|
11625931|NCT00420563|Active Comparator|MEGESTROL|
11625932|NCT00420537|Active Comparator|mycophenolate|Mycophenolate mofetil with cyclosporine trough levels between 100 and 150
11625933|NCT00420537|Active Comparator|Everolimus|Everolimus with cyclosporine trough levels between 40 and 90 ng/ml
11625934|NCT00420524|Experimental|Arm A (Normal liver function)|
11625935|NCT00420524|Experimental|Arm B (Mild liver dysfunction)|
11625936|NCT00420524|Experimental|Arm C (Moderate liver dysfunction)|
11625937|NCT00420511|Experimental|Sitagliptin|Sitagliptin 100mg once a day (od) by mouth (po)
11625938|NCT00420511|Placebo Comparator|Placebo arm|Placebo once a day (od) by mouth (po)
11625939|NCT00420485|Experimental|Daily times five schedule|
11625940|NCT00420485|Experimental|Continuous schedule, twice daily|
11625941|NCT00420459|Experimental|Aripiprazole|
11625942|NCT00420433||1|Patients with breast cancer that has spread to the bones.
11625943|NCT00420420|Experimental|MK0249|
11625944|NCT00420420|Placebo Comparator|placebo|
11625945|NCT00420407|Experimental|I|Vasopressin
11625946|NCT00420407|Placebo Comparator|2|bolus of NS (normal saline) followed by continuous infusion of NS, no vasopressin added
11625947|NCT00420381|Experimental|A|
11625948|NCT00420355|Experimental|Arm A|Subjects on atazanavir/ritonavir will add lopinavir/ritonavir.
11625949|NCT00420355|Experimental|Arm B|Subjects on lopinavir/ritonavir will add atazanavir.
11625950|NCT00420342|Experimental|0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)|0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
11625951|NCT00420342|Experimental|2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)|2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
11625952|NCT00420342|Active Comparator|1.5 mg MPA / 0.3 mg CEE (Prempro)|1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
11625953|NCT00420316|Experimental|Rotarix Group|Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.
11625954|NCT00420316|Placebo Comparator|Placebo Group|Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.
11625955|NCT00420303|Experimental|A|
11625956|NCT00420303|Placebo Comparator|B|
11625957|NCT00420290|Active Comparator|Kineret|Interleukin-1 receptor antagonist
11625958|NCT00420290|Placebo Comparator|Placebo|
11625959|NCT00420277|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
11625960|NCT00420277|Active Comparator|Control|Voluven (HES 130/0.4)
11625961|NCT00420238|Experimental|A|
11625962|NCT00420238|Placebo Comparator|B|
11625963|NCT00420212|Placebo Comparator|Placebo|Participants received two placebo capsules orally three times daily (TID)
11625964|NCT00420212|Experimental|BG00012 240 mg Twice Daily (BID)|Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
11625965|NCT00420212|Experimental|BG00012 240 mg 3 Times Daily (TID)|Participants received two 120 mg BG00012 capsules orally three times daily (TID)
11625966|NCT00420199|Active Comparator|Abatacept + Methotrexate (Double-blind period)|
11625967|NCT00420199|Placebo Comparator|Placebo + Methotrexate (Double-blind period)|
11625968|NCT00420186|Experimental|1|
11625969|NCT00420173||Patients with CLE|
11625970|NCT00420160|Experimental|Exercise|3x/wk 50 minutes of moderate intensity walking on treadmills + health education videos
11625971|NCT00420160|Other|Health Education|Contact control group attending 3x/wk 50 minutes of health education videos
11625972|NCT00420147|Experimental|Wedged Orthosis|Subjects were given a wedged inshoe orthosis
11625973|NCT00420147|Placebo Comparator|Neutral Orthosis|Subjects were given a neutral inshoe orthosis.
11625974|NCT00420095|Active Comparator|1|Human insulin mix 30/70
11625975|NCT00420095|Experimental|2|Insulin lispro low mix
11625976|NCT00420082|Experimental|1|Bilastine 20 mg
11625977|NCT00420082|Active Comparator|2|Fexofenadine 120 mg
11625978|NCT00420082|Active Comparator|3|Cetirizine 10 mg
11625979|NCT00420082|Placebo Comparator|4|Placebo
11625980|NCT00420056|Experimental|PD-0332991|
11625981|NCT00420043|Experimental|imatinib 800mg|
11625982|NCT00420043|Active Comparator|imatinib 400mg|
11625983|NCT00420030|Active Comparator|1|Arm 1 - routine upfront administration of Reopro (Abciximab)
11625984|NCT00420030|Other|2|Reopro (Abciximab) only if needed - according to physician
11625985|NCT00420017|Experimental|Amiodarone|Intravenous amiodarone
11625986|NCT00420017|Other|Control|Control
11625987|NCT00420004|Experimental|LY2216684|"LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks.
~For the first week of treatment, participants received a starting dose of 3 mg/day. Then, based on tolerability, for the next 7 weeks, the dose could remain at 3 mg/day; it could be increased 3 mg at a time (scheduled visit) to a maximum dose of 12 mg/day; or it could be decreased 3 mg at any time (scheduled or unscheduled visits) to a minimum dose of 3 mg/day.
~All participants were required to take an equal number of tablets (2) and capsules (2) per day. Therefore, participants on 3 mg/day and 6 mg/day of LY2216684 also received 1 LY2216684-matching placebo tablet + 2 escitalopram-matching placebo capsules. Participants on 9 mg/day and 12 mg/day of LY2216684 also received 2 escitalopram-matching placebo capsules."
11625988|NCT00420004|Placebo Comparator|Placebo|Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks.
11625989|NCT00420004|Active Comparator|Escitalopram|"Escitalopram: flexible dose of 10 or 20 milligram (mg), capsules, administered orally, once daily for 8 weeks.
~For the first week of treatment, participants received a starting dose of 10 mg/day. Then, based on tolerability, for the next 7 weeks, the dose could remain at 10 mg/day; it could be increased up to a maximum dose of 20 mg/day; or it could be decreased back to 10 mg/day.
~All participants were required to take an equal number of tablets (2) and capsules (2) per day. Therefore, participants on 10 mg/day of escitalopram also received 1 escitalopram-matching placebo capsule + 2 LY2216684-matching placebo tablets. Participants on 20 mg/day of escitalopram also received 2 LY2216684-matching placebo tablets."
11625990|NCT00419991|No Intervention|1 Tigecycline|
11625991|NCT00419952|Experimental|Symbicort|Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
11625992|NCT00419952|Experimental|Budesonide|Budesonide HFA pMDI 160 ug x 2 actuations BID
11625993|NCT00419939||1|ab 10 patientsr with acquired severe brain injury (GCS 3 - 9), >18 år, PTA phase at the end (GOAT scoring), RLAS score at minimum 4 and informed consent in writing
11625994|NCT00419926|Experimental|Intensified Mycophenolate Sodium (Myfortic) dosing regimen|In patients randomized to the intensified Myfortic dosing regimen, the initial dose was 2-fold of the labeled dose (i.e. 2880 mg/day). The dosage was reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
11625995|NCT00419926|Active Comparator|Standard Mycophenolate Sodium (Myfortic) dosing regimen|In patients randomized to the standard Myfortic dosing regimen, the initial dose of 1440 mg/day had to be maintained throughout the whole study.
11625996|NCT00419913|Experimental|A|Dehydroepiandrosterone (DHEA) 25mg tid
11625997|NCT00419913|Placebo Comparator|B|
11625998|NCT00419861||Group 1|Adults >/= 50 years of age, hospitalized for respiratory illness in Davidson County, TN.
11625999|NCT00419848|Experimental|1|
11626000|NCT00419848|Active Comparator|2|
11626001|NCT00419822|Active Comparator|Acupuncture|
11626002|NCT00419822|Sham Comparator|Sham Acupuncture|
11626003|NCT00419822|Placebo Comparator|Standard of Care|
11626004|NCT00419783|Experimental|1|Bilastine 20 mg
11626005|NCT00419783|Experimental|2|Bilastine 100 mg
11626006|NCT00419783|Active Comparator|3|Bilastine 20 mg + Ketoconazole 400 mg
11626007|NCT00419783|Active Comparator|4|Moxifloxacin 400 mg
11626008|NCT00419783|Placebo Comparator|5|Placebo
11626009|NCT00419770|Experimental|B|Deferasirox
11626010|NCT00419770|Placebo Comparator|A|
11626011|NCT00419757|Active Comparator|Symbicort|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
11626012|NCT00419757|Active Comparator|Budesonide|budesonide HFA pMDI 160 μg x 2 actuations twice daily
11626013|NCT00419731|Active Comparator|1|Bupropion+Placebo
11626014|NCT00419731|Experimental|2|Bupropion+Naltrexone
11626015|NCT00419705|Experimental|Transcranial Laser Therapy|
11626016|NCT00419705|Sham Comparator|Sham control procedure|
11626017|NCT00419692|Experimental|Sequence WAXBYZCDE|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), C: 1 x 6 mg CR-RLS (fasted), D: 1 x 6 mg CR-RLS (high fat fed) and E: 2 x 3 mg CR-RLS (fasted).
11626018|NCT00419692|Experimental|Sequence WAXBYZCED|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), C: 1 x 6 mg CR-RLS (fasted), E: 2 x 3 mg CR-RLS (fasted) and D: 1 x 6 mg CR-RLS (high fat fed).
11626019|NCT00419692|Experimental|Sequence WAXBYZDCE|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), D: 1 x 6 mg CR-RLS (high fat fed), C: 1 x 6 mg CR-RLS (fasted) and E: 2 x 3 mg CR-RLS (fasted).
11626020|NCT00419692|Experimental|Sequence WAXBYZDEC|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), D: 1 x 6 mg CR-RLS (high fat fed), E: 2 x 3 mg CR-RLS (fasted) and C: 1 x 6 mg CR-RLS (fasted).
11626021|NCT00419692|Experimental|Sequence WAXBYZECD|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), E: 2 x 3 mg CR-RLS (fasted),C: 1 x 6 mg CR-RLS (fasted) and D: 1 x 6 mg CR-RLS (high fat fed).
11626022|NCT00419692|Experimental|Sequence WAXBYZEDC|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), E: 2 x 3 mg CR-RLS (fasted), D: 1 x 6 mg CR-RLS (high fat fed) and C: 1 x 6 mg CR-RLS (fasted).
11626255|NCT00417105||3|nocturnal hemodialysis, 8 hours every other night
11626023|NCT00419666|Experimental|Calcitriol 3mcg/g|Participants receive calcitriol 3 micrograms per gram (mcg/g) ointment applied topically twice daily for 56 days.
11626024|NCT00419653|Experimental|1|
11626025|NCT00419653|Active Comparator|2|
11626026|NCT00419653|Active Comparator|3|Haloperidol
11626027|NCT00419640|Experimental|LAS + DAO ON|The right atrial lead is placed in the low atrial septal position and the DAO algorithm is turned ON.
11626028|NCT00419640|Experimental|LAS + DAO OFF|The right atrial lead is placed in the low atrial septal position and the DAO algorithm is turned OFF.
11626029|NCT00419640|Experimental|RAA + DAO ON|The right atrial lead is placed in the right atrial appendage position and the DAO algorithm is turned ON.
11626030|NCT00419640|Active Comparator|RAA + DAO OFF|The right atrial lead is placed in the right atrial appendage position and the DAO algorithm is turned OFF.
11626031|NCT00419601|Active Comparator|2|Fentanyl
11626032|NCT00419601|Experimental|1|Remifentanyl
11626033|NCT00419588||1-Healthy Infants|"Group 1: We have recruited 50 healthy infants born >37 weeks gestation, and between 2 and 36 months of age. Infants were excluded for any of the following reasons.
~Congenital cardio-respiratory disease
~Hospitalization for respiratory illness
~Treatment with asthma medications for more than one time
~Small for gestational age at birth
~More than one respiratory illness
~More than one episode of wheezing"
11626034|NCT00419588||3-Premature Infants|"Group 3: We will recruit 115 infants born prematurely, 23-35 weeks gestation. Subjects will be evaluated at the corrected age between 2 and 24 months. The subjects will have no oxygen requirements, and be clinically stable outpatients when evaluated. Infants will be excluded for any of the following reasons.
~Congenital cardio-respiratory disease
~Severe developmental delay"
11626035|NCT00419588||2-Healthy Infants CT|"Group 2: The investigators recruited 50 infants born at > 37 weeks gestation and they were evaluated between 2 and 36 months of age when scheduled for high resolution computed tomography (HRCT) imaging for non-respiratory medical problems. Subjects were enrolled and HRCT of the chest were obtained. Infants were excluded for the following reasons:
~Congenital cardio-respiratory disease
~Hospitalization for respiratory illness
~Treatment with asthma medications"
11626036|NCT00419562|Experimental|Oral Insulin|7.5 mg oral insulin capsules given before breakfast on a daily basis.
11626037|NCT00419562|Placebo Comparator|Placebo|Placebo capsule designed to match appearance of treatment capsule
11626038|NCT00419549|Active Comparator|1|Valdecoxib
11626039|NCT00419549|Active Comparator|2|
11626040|NCT00419549|No Intervention|3|
11626041|NCT00419497|Active Comparator|Paleolithic diet vs Mediterranean diet|Prudent diets with or without grains and dairy
11626042|NCT00419471|Experimental|Escitalopram|
11626043|NCT00419471|Placebo Comparator|Placebo pill|
11626044|NCT00419445|Active Comparator|GTS21 25 mg tid/Placebo 25 mg tid|
11626045|NCT00419445|Active Comparator|GTS21 75 mg tid/Placebo 75 mg tid|
11626046|NCT00419445|Active Comparator|GTS21 150 mg tid/Placebo 150 mg tid|
11626047|NCT00419432|Active Comparator|Group A (standard pre-operative analysis)|
11626048|NCT00419432|Experimental|Group B (additional pre-operative analysis)|
11626049|NCT00419406|Experimental|A: UVA1|
11626050|NCT00419406|Experimental|B: NB UVB|
11626051|NCT00419393|Experimental|Keppra XR (Levetiracetam XR)|1000 - 3000 mg/day Keppra XR (Levetiracetam XR), flexible dosing, throughout the duration of the study (planned: approximately 6 months-3 years)
11626052|NCT00419380|Active Comparator|dornase alfa (Pulmozyme®)|dornase alfa - Pulmozyme®: 5 drops twice daily for 7 days to the affected ear.
11626053|NCT00419380|Active Comparator|Ofloxin|Ofloxin : 5 drops twice daily for 7 days to the affected ear.
11626054|NCT00419341|Experimental|IgPro20|Human Normal Immunoglobulin for Subcutaneous Administration (IgPro20) is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
11626055|NCT00419328|Experimental|A|
11626056|NCT00419315|Experimental|Alcohol Care Management|Care management for alcohol dependence delivered in primary care
11626057|NCT00419315|Active Comparator|Usual Care|Usual care included a referral to specialty addiction treatment
11626058|NCT00419276|Experimental|Prolonged infusion|At least 100 hours of femoral perineural ropivacaine infusion.
11626059|NCT00419276|Placebo Comparator|Standard-of-Care|Overnight femoral perineural ropivacaine infusion followed by a femoral perineural normal saline infusion (placebo) until postoperative day 4.
11626060|NCT00419263|Experimental|Peramivir 150 mg|
11626061|NCT00419263|Experimental|Peramivir 300 mg|
11626062|NCT00419263|Placebo Comparator|Placebo|
11626063|NCT00419250|Experimental|dose-escalation to 5 mg lenalidomide (len)|escalate up to 5 mg once daily / 28-day cycle
11626064|NCT00419250|Experimental|dose-escalation to 10 mg lenalidomide (len)|escalate up to 10 mg once daily / 28-day cycle
11626065|NCT00419250|Experimental|dose-escalation to 15 mg lenalidomide (len)|escalate up to 15 mg once daily / 28-day cycle
11626066|NCT00419250|Experimental|dose-escalation to 20 mg lenalidomide (len)|escalate up to 20 mg once daily / 28-day cycle
11626067|NCT00419250|Experimental|dose-escalation to 25 mg lenalidomide (len)|escalate up to 25 mg once daily / 28-day cycle
11626068|NCT00419237|Active Comparator|Healthy subjects|Subjects with normal liver function test will be administered a single oral inhaled dose of 400 micrograms (mcg) GW685698X in the morning of the study day. Each healthy subject will be matched as closely as possible for age, gender, bodyweight and race to a subject with impaired liver function.
11626069|NCT00419237|Experimental|Subjects with hepatic impairment|Subjects with Child Pugh B hepatic dysfunction will be administered a single oral inhaled dose of 400 mcg GW685698X in the morning of the study day.
11626070|NCT00419211|Experimental|Lifestyle counseling|Tailored exercise program
11626071|NCT00419211|No Intervention|No Intervention|Usual care group
11626072|NCT00419198|Experimental|1|Post-conditioning during angioplasty
11626073|NCT00419198|Active Comparator|2|standard angioplasty
11626074|NCT00419159|Experimental|Everolimus (RAD001) 70 mg/week|
11626075|NCT00419159|Experimental|Everolimus (RAD001) 10 mg/day|
11626076|NCT00419146|Experimental|Ethyl EPA (active) and Vitamins E + C (active)|
11626077|NCT00419146|Experimental|Ethyl EPA (active) and Vitamins E+C (placebo)|
11626078|NCT00419146|Experimental|Ethyl EPA (placebo) and Vitamins E+C (active)|
11626079|NCT00419146|Placebo Comparator|Ethyl EPA (placebo) and Vitamins E+C (placebo)|
11626080|NCT00419133|Experimental|1|Cholera Vaccine
11626081|NCT00419133|Placebo Comparator|2|Placebo
11626082|NCT00419120|Experimental|Neo-bladder construction|Surgical implantation of autologous neo-bladder construct
11626083|NCT00419094|Experimental|Keppra XR 1000 mg/day|1000 mg/day once daily for 18 weeks (administered as two levetiracetam XR tablets and two placebo tablets once daily)
11626084|NCT00419094|Experimental|Keppra XR 2000 mg/day|2000 mg/day once daily for 18 weeks (administered as four levetiracetam XR tablets once daily)
11626085|NCT00419055||1 Control|Patients are discharged the day after PCI
11626086|NCT00419055||2 Study group|Patients will be discharged 4-6 hrs after PCI
11626087|NCT00419029|Active Comparator|control|brief telephone check-in (no motivational interviewing)
11626088|NCT00419029|Experimental|telephone-administered motivational interviewing|motivational interviewing sessions
11626089|NCT00419003|Experimental|Lamotrigine Pre-Treatment|Patients who met enrolment criteria for phase 1 were randomly allocated to lamotrigine or placebo by a permuted block procedure consisting of blocks of two or four patients. The randomization list was created by a biostatistician with no patient contact. 300 mg of lamotrigine 2 hrs prior to ketamine infusion. Responders were randomized to one of two continuation pharmacotherapy groups, receiving either two capsules of riluzole 50 mg each (100 mg/d) or matching pill placebo under double-blind conditions.
11626090|NCT00419003|Placebo Comparator|Placebo Pre-Treatment|2 hours prior to ketamine infusion each patient received three capsules of placebo identical in size, weight, appearance, and taste to the lamotrigine tablets. Responders were randomized to one of two continuation pharmacotherapy groups, receiving either two capsules of riluzole 50 mg each (100 mg/d) or matching pill placebo under double-blind conditions.
11626091|NCT00418977|Experimental|Family Based Therapy|Participants will receive family based therapy (FBT)
11626092|NCT00418977|Active Comparator|Individual Supportive Psychotherapy|Participants will receive individual supportive psychotherapy (ISP)
11626093|NCT00418964|Experimental|Single bundle hamstring|
11626094|NCT00418964|Experimental|Double bundle hamstring|
11626095|NCT00418964|Active Comparator|Bone patellar tendon bone|
11626096|NCT00418951|Experimental|Liposomal amphotericin B: 3 mg/kg|3 mg/kg intravenously (IV) three times per week
11626097|NCT00418951|Experimental|Liposomal amphotericin B: 9 mg/kg|9 mg/kg IV once per week
11626098|NCT00418951|Experimental|Voriconazole: 400 mg|400 mg oral twice daily day 1 followed by 200 mg twice daily
11626099|NCT00418938|Experimental|Arm A|FOLFIRI + Panitumumab
11626100|NCT00418938|Experimental|Arm B|FOLFIRI + Bevacizumab
11626101|NCT00418899||GLIOGENE|International Multi-Center, Multidisciplinary Study Consortium
11626102|NCT00418886|Placebo Comparator|1|Placebo Vandetanib + Pemetrexed
11626103|NCT00418886|Experimental|2|Vandetanib + Pemetrexed
11626104|NCT00418873|Experimental|1. Zotepine|
11626105|NCT00418873|Active Comparator|2. Risperidone|
11626106|NCT00418860|Experimental|A|
11626107|NCT00418847|Experimental|1|
11626108|NCT00418834|Active Comparator|1|
11626109|NCT00418834|Active Comparator|2|
11626110|NCT00418782|Active Comparator|1|
11626111|NCT00418782|Experimental|2|
11626112|NCT00418782|Placebo Comparator|3|
11626113|NCT00418769|Experimental|Nilotinib Tablet Formulations|
11626114|NCT00418769|Active Comparator|Established Nilotinib Capsule Formulation|
11626115|NCT00418756|Experimental|Rifampin + nilotinib|
11626116|NCT00418730|Experimental|1|
11626117|NCT00418730|Active Comparator|2|
11626118|NCT00418730|Placebo Comparator|3|
11626119|NCT00418717|Experimental|1|Arm 1: Period A-25mg BW; Arm 1: Period B-50mg QW
11626120|NCT00418691|Active Comparator|Immediate Release (IR) Methylphenidate|10 mg by mouth (PO) twice daily for 4 Weeks
11626121|NCT00418691|Active Comparator|Sustained Release (SR) Methylphenidate|200 mg PO once daily for 4 Weeks
11626122|NCT00418691|Active Comparator|Modafinil|18 mg PO once daily for 4 Weeks
11626123|NCT00418665|Active Comparator|750 mcg AMG 531|750 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
11626124|NCT00418665|Placebo Comparator|Placebo Part B|Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
11626125|NCT00418665|Placebo Comparator|Placebo Part A|Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
11626126|NCT00418665|Active Comparator|500 mcg AMG 531|500 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
11626127|NCT00418665|Active Comparator|750 mcg AMG531 Part B|750 μg AMG 531 biweekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
11626128|NCT00418652|No Intervention|No TMS stimulation|The patients performed 2 tasks: a study and a control assignments with no TMS stimulation.
11626129|NCT00418652|Experimental|TMS over the dorsal stream|The patients performed 2 tasks: a study and a control assignments under TMS stimulation over the dorsal stream area (PO3 EEG site).
11626130|NCT00418652|Sham Comparator|TMS over the vertex|The patients performed 2 tasks: a study and a control assignments under TMS stimulation over the vertex area.
11626131|NCT00418626|Experimental|Nilotinib|
11626132|NCT00418613|Experimental|1|MK0633
11626133|NCT00418613|Placebo Comparator|2|Placebo
11626134|NCT00418600|Other|1|Hectorol capsules at 1.0 times current injection dose
11626135|NCT00418600|Other|2|Hectorol capsules at 1.5 times current injection dose
11626136|NCT00418600|Other|3|Hectorol capsules at 2.0 times current injection dose
11626137|NCT00418587|Experimental|1|800 IU oral daily dose level
11626138|NCT00418587|Experimental|2|2000 IU oral daily dose level
11626139|NCT00418587|Experimental|3|4000 IU oral daily dose level
11626140|NCT00418574|Experimental|Abagovomab|
11626141|NCT00418574|Placebo Comparator|Placebo|
11626142|NCT00418561|Experimental|rhASA|
11626143|NCT00418522|Active Comparator|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
11626144|NCT00418522|Experimental|Exubera|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
11626145|NCT00418496|Experimental|Aldekleukin Plus Dose Escalation Sorafenib|Patients will be admitted to a dedicated nursing unit for HD aldesleukin administration. Patients will receive bolus aldesleukin at a dose of 600,000 IU/Kg every eight hours on days 1-5 with a goal of 10-12 doses.
11626146|NCT00418483|Experimental|Plasmin (Human) 25 mg|Plasmin (Human) 25 mg
11626147|NCT00418483|Experimental|Plasmin (Human) 50 mg|Plasmin (Human ) 50 mg
11626148|NCT00418483|Experimental|Plasmin (Human) 75 mg|Plasmin (Human) 75 mg
11626149|NCT00418483|Experimental|Plasmin (Human) 100 mg|Plasmin (Human) 100 mg
11626150|NCT00418483|Experimental|Plasmin (Human) 125 mg|Plasmin (Human) 125 mg
11626151|NCT00418483|Experimental|Plasmin (Human) 150 mg|Plasmin (Human) 150 mg
11626152|NCT00418483|Experimental|Plasmin (Human) 175 mg|Plasmin (Human) 175 mg
11626153|NCT00418470|Experimental|A|Higher concentration of antibiotic in NS
11626154|NCT00418470|Experimental|B|Lower concentration of antibiotic in NS
11626155|NCT00418457|Active Comparator|General anesthesia and opioid|General anesthesia followed by opioid administration
11626156|NCT00418457|Active Comparator|Regional analgesia and propofol|Regional anesthesia and analgesia (either epidural or paravertebral) combined with propofol
11626157|NCT00418418|Active Comparator|A|Patient group receiving the stem cell injections during the CABG
11626158|NCT00418418|Placebo Comparator|B|The patient group receiving autologous serum injections during the CAGB operation
11626159|NCT00418392|Experimental|Minocycline group|After successful simple aspiration, minocycline pleurodesis will be performed.
11626160|NCT00418392|Placebo Comparator|Control group|After successful simple aspiration, nothing will be performed.
11626161|NCT00418379|Experimental|300 IR (4M)|300 IR grass pollen allergen extract tablet, treatment starting 4 months before the pollen season
11626162|NCT00418379|Experimental|300 IR (2M)|300 IR grass pollen allergen extract tablet, treatment starting 2 months before the pollen season
11626163|NCT00418379|Placebo Comparator|Placebo|Placebo tablet
11626164|NCT00418314|Experimental|QuickOpt (Treatment)|Frequent optimization using QuickOpt to optimize the AV/PV and VV Delays.
11626165|NCT00418314|Active Comparator|Control|Empiric programming or one-time optimization using a non-IEGM method.
11626166|NCT00418288|Active Comparator|A|
11626167|NCT00418288|Placebo Comparator|P|
11626168|NCT00418262|Experimental|Atomoxetine HCL (Strattera)|Teatment of children with fetal alcohol syndrome and ADHD with Atomoxetine HCL (Strattera)
11626169|NCT00418210|Experimental|Accelerated partial breast irradiation|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)
11626170|NCT00418184|Experimental|1|
11626171|NCT00418184|Placebo Comparator|2|
11626172|NCT00418145|Experimental|megadose oral methylprednisolone|1400 mg qd/5 days
11626173|NCT00418145|Experimental|IV methylprednisolone|1000 mg/qd/5 days
11626174|NCT00418132|Experimental|1|Participants will receive thalidomide.
11626175|NCT00418132|Placebo Comparator|2|Participants will receive placebo thalidomide.
11626176|NCT00418106||1|Mothers who are pumping breast milk and who are willing to kangaroo hold their infant.
11626177|NCT00418093|Experimental|Chemotherapy|All patients received oxaliplatin, gemcitabine, and bevacizumab
11626178|NCT00418067|Active Comparator|Cypher|Sirolimus-eluting stent
11626179|NCT00418067|Active Comparator|Taxus Liberte|Paclitaxel-eluting stent
11626180|NCT00418067|Experimental|Endeavor|Zotarolimus-eluting stent
11626181|NCT00418028|Active Comparator|A Cint|Capecitabine will be administered orally at a dose of 1250 mg/m2 twice-daily (in the morning and in the evening, the equivalent of a total daily dose of 2500 mg/m2) for 14 days, in 3 week cycles with a resting period of 7 days,until disease progression or severe toxicity. Dose adjustments were made in patients with grade 3 or greater diarrhea or hand and food syndrome.
11626182|NCT00418028|Experimental|B Ccont|Capecitabine 800 mg/m2 orally twice-daily (in the morning and in the evening the equivalent of one dose of 1600 mg/m2) for 21 days, in 3 week cycles without resting period, until disease progression or severe toxicity. Dose adjustments were made in patients with grade 3 or greater diarrhea or hand and food syndrome.
11626183|NCT00418015||Labor analgesia|Labor analgesia receiving fentanyl labor analgesia
11626184|NCT00418015||Cesarean delivery analgesia|Cesarean delivery analgesia consisting of spinal fentanyl and morphine
11626185|NCT00417989|Experimental|722 sensor augmented pump|722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year
11626186|NCT00417989|No Intervention|Multiple Daily Injections (MDI)|MDI arm: Continue with current MDI therapy using Lantus and NovoLog/NovoRapid for 1 year
11626187|NCT00417976|Experimental|Bevacizumab|
11626188|NCT00417963|Experimental|stent placement in the carotid artery|placement of a bare metal stent for treatment of carotid artery stenosis
11626189|NCT00417937|Active Comparator|1|Azelaic acid 15 % gel once daily
11626190|NCT00417937|Active Comparator|2|Azelaic acid 15 gel twice daily
11626191|NCT00417911|Active Comparator|No treatment|
11626192|NCT00417911|Experimental|Bortezomib consolidation|Bortezomib consolidation : 20 injections starting 3 months after ASCT
11626193|NCT00417885|Experimental|A|sunitinib + exemestane
11626194|NCT00417859|Active Comparator|TKA mobile|TKA mobile
11626195|NCT00417859|No Intervention|TKA|TKA fix
11626196|NCT00417807|Experimental|Gleevec/Glivec|
11626197|NCT00417794|Active Comparator|1|Atomoxetine HCL (Strattera)
11626198|NCT00417794|Placebo Comparator|2|
11626199|NCT00417768|Active Comparator|Tissue Plasminogen Activator|tPA administered by drainage tube into abscess, allowed to dwell for one hour and then drained into drainage bag. Dose of tPA administered to be determined by the volume of drainage immediately post drain insertion. This intervention is done on day 0, 1 and 2.
11626256|NCT00417105||4|nocturnal hemodialysis, 8 hours, six times per week
11626200|NCT00417768|Sham Comparator|Instillation of Normal Saline|Insertion of abdominal drainage tube to drain intra-abdominal abscess. Normal Saline administered immediately post drain insertion. Normal Saline (10 cc) allowed to dwell for one hour, then allowed to drain into drainage bag.
11626201|NCT00417729|Active Comparator|acarbose, glibenclamide|acarbose vs. glibenclamide (background metformin therapy)
11626202|NCT00417690|Experimental|A|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
11626203|NCT00417690|Placebo Comparator|P|One packet of oral granules administered three times daily for 2 weeks followed by one packet two times daily for two weeks
11626204|NCT00417638|Experimental|patients with acute STEMI - treatment with Hypothermia +PCI|"Hypothermia using endovascular cooling with the Celsius Control System as an adjunct therapy.
~Hypothermia before reperfusion by a combination of infusion of cold saline and endovascular catheter cooling as an adjunct therapy in patients with a STEMI scheduled to undergo primary percutaneous coronary intervention (PCI)."
11626205|NCT00417638|Active Comparator|Patients with an acute STEMI eligible for primary PCI|Standard of care treatment or the control group Patients with an acute STEMI eligible for primary PCI
11626206|NCT00417612|Experimental|1|Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
11626207|NCT00417612|Placebo Comparator|2|Participants given placebo capsule to match for comparison
11626208|NCT00417599|Experimental|Lifestyle intervention|Behavioral lifestyle intervention versus control group. The Behavioral intervention consists of behavioral lessons delivered over the internet.
11626209|NCT00417599|Experimental|control|The intervention for the waiting list control group was usual care.
11626210|NCT00417560|Experimental|Influenza A/H5N1 Vaccine|Two 90ug Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine
11626211|NCT00417521|Experimental|Family therapy|
11626212|NCT00417508|Experimental|Nutritional supplement|2 packages/day with nutritional supplement containing a total of 600 kcal and 40 g protein
11626213|NCT00417508|Active Comparator|Dietary advice|ordinary dietary advice with a recommendation of four meals per day or similar dietary advice
11626214|NCT00417482|Other|Risperidone-risperidone|Risperidone for 16 weeks followed by risperidone for 16 weeks
11626215|NCT00417482|Other|Risperidone-Placebo|Risperidone for 16 weeks followed by placebo for 16 weeks
11626216|NCT00417482|Other|Placebo-Placebo|Placebo for 16 weeks followed by placebo for 16 weeks
11626217|NCT00417456|Active Comparator|1|Office Visits
11626218|NCT00417456|Experimental|2|Evisit
11626219|NCT00417417|Experimental|Rilonacept|Rilonacept 320 mg subcutaneous at each treatment visit
11626220|NCT00417417|Sham Comparator|Placebo|Normal saline subcutaneously at each treatment visit.
11626221|NCT00417404|Active Comparator|vitamin A|
11626222|NCT00417404|Sham Comparator|sham injection|
11626223|NCT00417391|Experimental|1 mg RR110|1 mg RR110
11626224|NCT00417391|Experimental|4 mg RR110|4 mg RR110
11626225|NCT00417378|Active Comparator|1|Intraaortic balloon counterpulsation (IABP)
11626226|NCT00417378|Experimental|2|Left Ventricular Assist Device (Impella LP2.5)
11626227|NCT00417339||hemodialysis, 4h, twice weekly|hemodialysis, four hours, twice weekly
11626228|NCT00417339||hemodialysis, 8h, twice weekly|hemodialysis, eight hours, twice weekly
11626229|NCT00417339||hemodialysis, 8h, every other day|hemodialysis, eight hours, every other day
11626230|NCT00417339||hemodialysis, 8h, six days per week|hemodialysis, eight hours, six days per week
11626231|NCT00417326|Placebo Comparator|P|
11626232|NCT00417326|Experimental|E|
11626233|NCT00417287|Active Comparator|High dose|128 mg/m2
11626234|NCT00417287|Active Comparator|Low dose|54 mg/m2
11626235|NCT00417274|Experimental|Quinacrine|Uncontrolled treatment arm
11626236|NCT00417261|Experimental|1|ATF936
11626237|NCT00417261|Experimental|2|AXT914
11626238|NCT00417261|Placebo Comparator|3|Placebo
11626239|NCT00417248|Experimental|Investigational Treatment|Cisplatin/Etoposide/Radiotherapy followed by Sorafenib in patients with inoperable stage III non-small cell lung cancer
11626240|NCT00417235|Experimental|3-days dressing frequency/CHX sponge|"Interventions:
~Device: 'Chlorhexidine Sponge (Biopatch TM)' on the insertion site"
11626241|NCT00417235|Experimental|7-days dressing frequency/CHX sponge|"Interventions:
~Behavioural: 7-day catheter dressing frequency Device: 'Chlorhexidine Sponge (Biopatch TM)' on the insertion site"
11626242|NCT00417235|No Intervention|3-days dressing frequency/No CHX sponge|No intervention, classical protocol of dressing frequency every 3-days and no other device
11626243|NCT00417235|Experimental|7-days dressing change/No CHX sponge|Interventions:Behavioural: 7-day catheter dressing frequency
11626244|NCT00417222|Active Comparator|Olmesartan medoxomil|olmesartan medoxomil
11626245|NCT00417222|No Intervention|Standard therapy|Standard therapy
11626246|NCT00417209|Experimental|Larotaxel (XRP9881)|
11626247|NCT00417209|Active Comparator|5-Fluorouracil or capecitabine|Each Investigator must choose either IV 5-FU or oral capecitabine regimen before the first participant begins the study and has to consistently use the chosen regimen throughout the study for all participants treated at her/his site.
11626248|NCT00417170|Experimental|Aliskiren 300 mg|Eligible participants received oral Aliskiren 300 mg + Placebo Amlodipine once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed.
11626249|NCT00417170|Active Comparator|Amlodipine 5 mg|Eligible participants received oral Amlodipine 5 mg + Placebo Aliskiren once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed.
11626250|NCT00417118|Experimental|Saredutant 100 mg|Saredutant 100 mg once daily in the morning for a maximum of 8 weeks
11626251|NCT00417118|Active Comparator|Escitalopram 10 mg|Escitalopram 10 mg once daily in the morning for a maximum of 8 weeks
11626252|NCT00417118|Placebo Comparator|Placebo|Placebo for one week during the run in period and for a maximum of 8 weeks during the active period
11626253|NCT00417105||1|hemodialysis twice weekly 4 hours
11626254|NCT00417105||2|nocturnal dialysis twice weekly 8 hours
11626257|NCT00417079|Active Comparator|Mitoxantrone + Prednisone|Mitoxantrone + Prednisone
11626258|NCT00417079|Experimental|Cabazitaxel + Prednisone|Cabazitaxel + Prednisone
11626259|NCT00417040|Other|(Internet-based STAR database)|"Patients are registered into the STAR database, obtain a password, undergo STAR training, and complete a patient-STAR questionnaire after seeing their clinician (baseline self-report) on day 1 of course 2* of chemotherapy. Patients are reminded to complete online STAR questionnaire before seeing their clinician on day 1 of courses 3, 4, 5, and 6* of chemotherapy. Clinicians review these patient reports before creating their own assessment. Patients also complete a patient feedback survey on day 1 of course 4* of chemotherapy. Clinicians complete feedback survey at study completion.
~NOTE: *All time points are based on scheduled therapy with clinical trial CALGB-90401, CALGB-30607, CALGB-30704, CALGB-40601, CALGB-40603, CALGB-40502, CALGB-70604, CALGB-80405, or CALGB-40503."
11626260|NCT00417027|Active Comparator|2.5 mL bolused every 15 minutes|
11626261|NCT00417027|Active Comparator|5ml bolused every 30 minutes|
11626262|NCT00417027|Active Comparator|10ml bolused every 60 minutes|
11626263|NCT00416975|Other|Breast Cancer Risk Assessment Screening|Counseling Intervention and Eduation Intervention
11626264|NCT00416949|Experimental|Patient-specific 3D-RD Dosimetry|Applied a patient-specific dosimetry calculation method to the imaging data collected to calculate tumor absorbed doses, using 3D-RD method.
11626265|NCT00416923|Experimental|intrathecal rituximab|3 dose levels of intrathecal rituximab, 10mg, 25mg, 50mg
11626266|NCT00416910|Active Comparator|FCM|Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) q28d, max. 6 cycles
11626267|NCT00416910|Experimental|FCM + G-CSF|Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) Filgrastim (G-CSF) s.c. (5 µg/kg/d beginning on day +6 until neutrophil recovery above 1500/µl.) q28d, max. 6 cycles
11626268|NCT00416884|Experimental|TBI, Campath, Fludarabine T-cell Deplete|(Campath) 30 mg on day -8 over 5-6 hours, Fludarabine 30 mg/m^2 on day -4 through day -2, Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0., Stem cells will be T cell depleted and given on day 0
11626269|NCT00416819|Experimental|methotrexate, leucovorin calcium, rituximab, and temozolomide|Determine the rate of toxicity, in terms of percentage of patients with grade 4 neurotoxicity, in patients with untreated primary CNS lymphoma treated with induction therapy comprising high-dose methotrexate, leucovorin calcium, rituximab, and temozolomide followed by consolidation therapy comprising cytarabine and etoposide phosphate.
11626270|NCT00416793|Experimental|Treatment|Patients receive bortezomib IV on days 1, 4, 8, and 11 and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11626271|NCT00416767|Experimental|FOLFIRI|
11626272|NCT00416741||1 Usual Care-Lifestyle counseling|Metabolic syndrome
11626273|NCT00416741||2 Intensive care-Lifestyle counseling|Metabolic Syndrome Implementation of guidelines
11626274|NCT00416715|Experimental|Treatment (letrozole)|Patients receive letrozole PO QD. Patients, who experience muscle pain, joint pain, or joint stiffness that requires an intervention and who are found to be vitamin D deficient, also receive calcium and vitamin D3 PO. Treatment continues for up to 28 weeks in the absence of disease progression or unacceptable toxicity.
11626275|NCT00416702|Experimental|1|QAB149
11626276|NCT00416689||Breast or lung CA pt undergoing chemoTx|
11626277|NCT00416663|Experimental|single arm|open label,single arm,intervention is Angiogenic Cell Precusors(ACPs)
11626278|NCT00416650|Experimental|Therapeutic Intervention|Patients will receive erlotinib (OSI-774) 150 mg daily by mouth. If specified toxicities occurs, the dose may be reduced.
11626279|NCT00416637|Experimental|Bevacizumab (Avastin)|Bevacizumab given and then BP checked and skin biopsies obtained.
11626280|NCT00416624|Experimental|Epoetin alfa - 40000 units|40,000 Units
11626281|NCT00416624|Experimental|Epoetin alfa - 80000 units|80,000 Units
11626282|NCT00416624|Experimental|Epoetin alfa - 120000 Units|120,000 Units
11626283|NCT00416624|Experimental|Darbepoetin alfa***|500 mcg
11626284|NCT00416598|Experimental|Treatment (chemotherapy, PBSC or bone marrow transplantation)|See Detailed Description.
11626285|NCT00416572|Experimental|Education Intervention|Participants attended 4 2-hr education sessions. The overall goal of the sessions was to provide information that would reduce participants' uncertainty about their illness and its treatment, to enhance coping in productive ways with the issues and problems confronting them, and to facilitate communication between the participants and their partners.
11626286|NCT00416572|Experimental|Nutrition Education Intervention|Participants attended 4 2-hr nutrition education sessions. Each session provided information and encouragement on setting and attaining measurable goals for healthy eating and on the benefits of thinking positively about dealing adaptively with problems in life and living a healthy lifestyle.
11626287|NCT00416572|No Intervention|Control Condition|Participants received care as usual.
11626288|NCT00416520|Experimental|1|
11626289|NCT00416520|Placebo Comparator|2|
11626290|NCT00416520|Active Comparator|3|
11626291|NCT00416494|Experimental|Initial Cohort|
11626292|NCT00416494|Experimental|Second cohort|
11626293|NCT00416481||Patient assessment|"Patients undergo assessments of cognition and performance status using the healthcare professional-rated Karnofsky performance scale. These assessments are performed by healthcare personnel. Body mass index and the percentage of unintentional weight loss and the number of falls in the past 6 months are also assessed.
~Patients also complete self-administered questionnaires that measure level of functioning and need for services. It also includes questionnaires that measure higher levels of physical functioning, performance related to survival and clinically significant illness and measures of comorbidity and the impact on daily activities. Lastly, questionnaires are administered to measure the impact of cancer on patients' social functioning and perceived availability of social support.
~Patients then begin planned treatment."
11626332|NCT00415805|Active Comparator|2|
11626333|NCT00415766|Active Comparator|rHCG 250 ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
11626334|NCT00415766|Active Comparator|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
11626335|NCT00415766|Active Comparator|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
11626336|NCT00415701|Experimental|1|Etomidate as a single induction dose
11626294|NCT00416455|Experimental|Treatment (diagnostic scans, surgery, chemotherapy, radiation)|Patients receive fludeoxyglucose F 18 (FDG) IV followed 60 minutes later by positron emission tomography (PET)/CT scanning on day 1. Patients also receive ferumoxtran-10 IV over 30-45 minutes on day 1 (or 24-36 hours before MRI) and undergo MRI on day 2. Patients undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy with pelvic and abdominal lymph node biopsy within 2 weeks after PET/CT scan. Patients diagnosed with metastatic disease prior to lymph node biopsy proceed directly to primary treatment. Patients with cervical cancer undergo chemoradiotherapy within 4 weeks of PET/CT scan.
11626295|NCT00416403|Experimental|Arm I|Patients receive oral fluvastatin sodium once daily for 3-6 weeks in the absence of disease progression or unacceptable toxicity.
11626296|NCT00416403|Experimental|Arm II|Patients receive oral fluvastatin sodium as in arm I at a higher dose.
11626297|NCT00416403|Experimental|Arm III|Patients do not receive fluvastatin sodium. breast Cancer surgery only
11626298|NCT00416364||1|
11626299|NCT00416364||2|
11626300|NCT00416364||3|
11626301|NCT00416364||4|
11626302|NCT00416351|Experimental|Clofarabine|Patients will receive intravenous clofarabine once daily for three consecutive days. Doses of clofarabine will start at 4 mg/m2/day and will be escalated to higher dose levels.
11626303|NCT00416312||Conventional & Patient-Specific Dosimetry|Tumor absorbed dose calculations determined using both conventional dosimetry and 3D-RD patient-specific dosimetry software.
11626304|NCT00416273|Experimental|Treatment group|Participants in the treatment group will receive Bortezomib at a dosage of 1.6 mg/m2.
11626305|NCT00416273|Experimental|Observation group|Participants in the observation group will not receive any consolidation therapy.
11626306|NCT00416260|Experimental|HFO-TGI|Patients with severe Acute Respiratory Distress Syndrome receiving sessions of high frequency oscillation and tracheal gas insufflation according to the study protocol
11626307|NCT00416260|No Intervention|CMV|Patients with severe Acute Respiratory Distress Syndrome receiving only conventional mechanical ventilation according to the study protocol
11626308|NCT00416234|Active Comparator|1|Laparoendoscopic Rendez vous (one stage management of cholelithiasis/choledocholithiasis)
11626309|NCT00416234|Active Comparator|2|preoperative ERCP and CBD clearance followed by lap cholecystectomy (two stage management of cholelithiasis/choledocholithiasis)
11626310|NCT00416208|Experimental|Bortezomib|Bortezomib 1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
11626311|NCT00416208|No Intervention|Observation|Observational arm
11626312|NCT00416195|Experimental|E2007|2 mg E2007 once daily for 2 weeks (Days 1 to 14), then 4 mg E2007 once daily for 2 weeks (Days 15 to 28), then 6 mg E2007 once daily for 2 weeks (Days 29 to 42), then 8 mg E2007 once daily for 2 weeks (Days 43 to 56), then 10 mg E2007 once daily for 2 weeks (Days 57 to 70), then 12 mg E2007 once daily for 6 weeks (Days 71 to 112).
11626313|NCT00416195|Placebo Comparator|Placebo|Matching placebo once daily for 16 weeks (Days 1 to 112)
11626314|NCT00416182|Experimental|Pulmozyme|2.5 mg Pulmozyme (dornase alfa) delivered intranasally once daily
11626315|NCT00416182|Placebo Comparator|placebo|2.5 mg/2mL placebo administered intranasally once daily
11626316|NCT00416130|Experimental|Vorinostat|A phase I portion that will determine the safety of 400mg Vorinostat once a day, continuously in the Asian population. A pre-determined dose reduction schema will be followed in the event of significant dose-limiting toxicities at this dose. Phase II will recruit additional patients at the determined dose with the goal of evaluating drug efficacy.
11626317|NCT00416078|Experimental|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
11626318|NCT00416078|Active Comparator|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
11626319|NCT00416039|Experimental|1|Midazolam and morphine
11626320|NCT00416039|Placebo Comparator|2|placebo, Nacl 0.9 %, morphine 0.5 mg/kg
11626321|NCT00415974|Other|Enhanced Usual Care|"Enhanced Usual Care Arm: This group will receive 2 face-to-face sessions with a health educator for dietary and health counseling in addition to an initial physician-patient visit. Educational materials that a patient might receive at his/her physician's office will also be provided at the initial health educator visit and monthly thereafter. This condition is called Enhanced Standard Care because it is, in fact, more than most obese adolescents currently receive in primary care offices in San Diego."
11626322|NCT00415974|Experimental|Stepped Care|"PACE-PC is a 1-year stepped-care intervention (subdivided into three 4-month blocks) utilizing multiple modalities including clinician and tailored health educator counseling, phone counseling, mailed content for overweight adolescents and their family to promote improved diet and physical activity behaviors aimed at weight loss and weight loss maintenance.
~PACE-PC is designed to be based in the primary care setting and promotes involvement, management, and decision-making by the primary care provider about the level of PACE-PC step for each enrolled patient
~Participants randomized to the PACE-PC condition will be enrolled in Step 1 (the most intensive) for the first 4 months. Depending upon response at the end of Step 1, for the next 4 months adolescents will be triaged to Step 2 (less intensive) or will repeat Step 1. At 8 months, again based upon treatment response, triage will occur to either Step 3 (least intensive) or repetition of the previous step."
11626323|NCT00415961|Experimental|1|CoStar Paclitaxel drug eluting stent
11626324|NCT00415909|Experimental|TALL-104 + IM|TALL-104 cells and imatinib mesylate (IM) therapy
11626325|NCT00415870|Experimental|PACE|Received text messages and counseling calls
11626326|NCT00415870|No Intervention|Control|
11626327|NCT00415857|Experimental|PR1 + Imatinib|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses. Continue receiving imatinib by mouth at the same dose received during the last 6 months. GM-CSF 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
11626328|NCT00415857|Experimental|PR1 + Imatinib + Interferon|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses. Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination. GM-CSF 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
11626329|NCT00415818|Experimental|Arm 1|MVA-MUC1-IL2 in combination with 1st line Chemotherapy
11626330|NCT00415818|Active Comparator|Arm 2|1st line Chemotherapy without a MVA-MUC1-IL2 combination
11626331|NCT00415805|Experimental|1|
11626337|NCT00415701|Active Comparator|2|Propofol as a single induction dose
11626338|NCT00415701|Other|3|Hydrocortisone substitution or placebo (50-50%) in etomidate-group
11626339|NCT00415675||Respiratory Tumor + Normal Tissue Motion|
11626340|NCT00415649|Experimental|A|DNA vaccine at baseline, Month 1, and Month 2, and the adenoviral vector vaccine at Month 6.
11626341|NCT00415649|Placebo Comparator|B|Placebo vaccine
11626342|NCT00415636|Experimental|LY2603618 40 mg/m^2 (4.5-hour infusion)|LY2603618 40 milligrams per square meter (mg/m^2) was administered over the duration of 4.5 hours (30-minute bolus followed by a 4-hour infusion). Dose modifications were not allowed.
11626343|NCT00415636|Experimental|LY2603618 40 mg/m^2 (1-hour infusion)|Based on pharmacokinetic (PK) data from Cohort 1 (LY2603618 40 mg/m^2 [4.5-hour infusion]), the LY2603618 40 mg/m^2 dose in Cohort 2 (LY2603618 40 mg/m^2 [1-hour infusion]) was repeated, but the dose was administered over the duration of 1 hour. Dose modifications were not allowed.
11626344|NCT00415636|Experimental|LY2603618 70 mg/m^2|Beginning with Cohort 3 (LY2603618 70 mg/m^2), dose modifications were allowed. LY2603618 70 mg/m^2 was administered over the course of 1 hour.
11626345|NCT00415636|Experimental|LY2603618 105 mg/m^2|Cohort 4: LY2603618 105 mg/m^2 administered over the duration of 1 hour.
11626346|NCT00415636|Experimental|LY2603618 150 mg/m^2|Cohort 5: LY2603618 150 mg/m^2 administered over the duration of 1 hour.
11626347|NCT00415636|Experimental|LY2603618 195 mg/m^2|Cohort 6: LY2603618 195 mg/m^2 administered over the duration of 1 hour.
11626348|NCT00415623|Active Comparator|Amlodipine 5mg|
11626349|NCT00415623|Experimental|Amlodipine 10mg|
11626350|NCT00415610|Other|Tier 1|"Dose escalation:
~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 170 to 200 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
11626351|NCT00415610|Other|Tier 2|"Dose escalation:
~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 140 to 170 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
11626352|NCT00415610|Other|Tier 3|"Dose escalation:
~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 110 to 140 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
11626353|NCT00415597|Experimental|ALO-01|Doses given once or twice daily
11626354|NCT00415545|Experimental|1|Fluid Watchers LITE program
11626355|NCT00415545|Experimental|2|Fluid Watchers PLUS program
11626356|NCT00415545|No Intervention|3|Usual care control group
11626357|NCT00415532|Experimental|Romiplostim|Romiplostim administered by subcutaneous injection once weekly at a starting dose of 3 μg/kg, adjusted to a maximum dose of 10 μg/kg to maintain a platelet count between 50 and 200 x 10^9/L for up to 52 weeks.
11626358|NCT00415532|Other|Standard of Care|Medical standard of care treatments were selected and prescribed by the investigator according to standard institutional practices or therapeutic guidelines and administered for up to 52 weeks.
11626359|NCT00415519|Experimental|1|
11626360|NCT00415519|Placebo Comparator|2|
11626361|NCT00415506|Experimental|Scleritis|Subjects with Scleritis
11626362|NCT00415506|Experimental|Orbital Inflammation|Subjects with Orbital Inflammation
11626363|NCT00415493|Experimental|Order 1|Cold-dry air provocation followed (on a separate day) by Warm-moist air provocation
11626364|NCT00415493|Experimental|Order 2|Warm-moist air provocation followed (on a separate day) by Cold-dry air provocation
11626365|NCT00415467|Experimental|GliaSite Radiation Therapy System (RTS)|Surgical removal of brain tumor followed by GliaSite RTS targeted brachytherapy to the specific brain tumor site
11626366|NCT00415454|Experimental|Gene therapy|Adenovirus injection followed by 3 weeks of 5-FC + vGCV prodrug therapy and a 6 week course of capecitabine-based chemoradiation
11626367|NCT00415441|Experimental|Active physiotherapy|Manual therapy and home exercise program
11626368|NCT00415441|Placebo Comparator|Placebo physiotherapy|Manual therapy and home exercise program
11626369|NCT00415428||1.|
11626370|NCT00415402|Placebo Comparator|placebo|non vitamin D containing sugar granules
11626371|NCT00415402|Experimental|Vitamin D3|vitamin D granules
11626372|NCT00415389|Active Comparator|1|interactive educational program
11626373|NCT00415389|Active Comparator|2|usual medical care
11626374|NCT00415363|Experimental|A|
11626375|NCT00415363|Placebo Comparator|B|
11626376|NCT00415350|Active Comparator|Azithromycin treatment 1|
11626377|NCT00415350|Placebo Comparator|Placebo 2|
11626378|NCT00415324|Experimental|Arm 1|Patients receive eribulin mesylate IV over 5 minutes on days 1, 8, and 15 and cisplatin IV over 30-60 minutes on day 1.
11626379|NCT00415311|Other|0 mg/kg|
11626380|NCT00415311|Other|0.5 mg/kg|
11626381|NCT00415311|Other|1.0 mg/kg|
11626382|NCT00415259|Experimental|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
11626383|NCT00415259|Other|Flat control insoles|
11626384|NCT00415233|Experimental|1.1Gbq with rhTSH|Patients receive 1.1GBq dose of radioactive iodine and rhTSH
11626385|NCT00415233|Experimental|3.2 GBq with rhTSH|Patients receive 3.2GBq dose of radioactive idodine and rhTSH
11626386|NCT00415233|Experimental|1.1GBq without rhTSH|Patients only receive 1.1GBq dose of radioactive iodine and no rhTSH
11626387|NCT00415233|Experimental|3.2GBq without rhTSH|Patients only receive 3.2GBq dose of radioactive iodine and no rhTSH
11626439|NCT00414648|Experimental|1|Participants will receive sirolimus daily for 1 year followed with serial pulmonary functional tests and 6-minute walk tests over a 2-year period.
11626388|NCT00415194|Experimental|Pemetrexed/Cisplatin|"Pemetrexed 500 milligrams per meter square (mg/m^2) administered intravenously (IV) plus cisplatin 75 mg/m^2 IV on Day 1 every 21 days. Pretreatment, Both Treatment Arms: Dexamethasone administered orally (po): 4 milligrams (mg) twice daily (BID) taken on the day before, the day of, and day after study treatment.
~Vitamin B12 administered intramuscularly (im): 1000 micrograms (μg) taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks after last treatment dose. Folic Acid administered orally (po): 350 μg to 1000 μg taken 1 to 2 weeks before treatment and continue daily until 3 weeks after last treatment dose."
11626389|NCT00415194|Placebo Comparator|Placebo/Cisplatin|"Placebo (approximately 100 mL normal saline) administered intravenously (IV) plus cisplatin 75 mg/m^2 on Day 1 every 21 days.
~Pretreatment - Both Treatment Arms: Dexamethasone administered orally (po): 4 milligrams (mg) twice daily (BID) taken on the day before, the day of, and day after study treatment. Vitamin B12 administered intramuscularly (im): 1000 micrograms (μg) taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks after last treatment dose.
~Folic Acid administered orally (po): 350 μg to 1000 μg taken 1 to 2 weeks before treatment and continue daily until 3 weeks after last treatment dose."
11626390|NCT00415168|Experimental|Pemetrexed + Cisplatin|
11626391|NCT00415155|Experimental|A|
11626392|NCT00415142|Experimental|Saredutant 100 mg|Saredudant100 mg once daily for a maximum of 32 weeks
11626393|NCT00415142|Active Comparator|Escitalopram 10 mg|Escitalopram 10 mg once daily for a maximum of 32 weeks
11626394|NCT00415142|Placebo Comparator|Placebo|Placebo once daily for one week during screening phase and a maximum of 8 weeks during the acute phase
11626395|NCT00415129|Experimental|Study Group 1|Vaccine with adjuvant
11626396|NCT00415129|Experimental|Study Group 2|Vaccine without adjuvant
11626397|NCT00415103|Experimental|1|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days Palonosetrón: 0.25 mg iv every 48 horas starting day 1
11626398|NCT00415103|Active Comparator|2|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment.
11626399|NCT00415090|No Intervention|1|Follow with same ARV treatment
11626400|NCT00415090|Experimental|2|Switch one of ARV drugs to Nevirapine
11626401|NCT00415077|Active Comparator|2|LASEK- laser-assisted subepithelial keratectomy
11626402|NCT00415077|Active Comparator|3|Mitomycin C PRK
11626403|NCT00415077|Active Comparator|1|PRK- Photorefractive keratectomy
11626404|NCT00415051|Experimental|Single Group Assignment|RVF MP-12
11626405|NCT00415038|Experimental|Rostafuroxin 50 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
11626406|NCT00415038|Experimental|Rostafuroxin 150 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
11626407|NCT00415038|Experimental|Rostafuroxin 500 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
11626408|NCT00415038|Experimental|Rostafuroxin 1.5 mg capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
11626409|NCT00415038|Experimental|Rostafuroxin 5 mg capsule|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
11626410|NCT00414986|Experimental|1|Practice in this arm will receive the Chronic Care Improvement intervention
11626411|NCT00414986|Experimental|2|Practices in this arm will receive the standard CQI intervention. An in-practice CQI coordinator will assist the practices in implement a chronic disease registry.
11626412|NCT00414986|Active Comparator|3|Practice in this arm will have access to all chronic care tools, but will not have an in-practice change agent.
11626413|NCT00414973|Experimental|A|
11626414|NCT00414973|Active Comparator|B|
11626415|NCT00414960|Experimental|Enzastaurin|Treatment with enzastaurin 500 milligrams (mg) orally (po) once daily (QD) given as 4 tablets (125 mg each).
11626416|NCT00414960|Placebo Comparator|Placebo|Treatment with placebo po QD appearing identical to enzastaurin.
11626417|NCT00414934||metastatic bone lesion for patients with cancer|
11626418|NCT00414921|Active Comparator|1|clonidine
11626419|NCT00414921|Active Comparator|2|methylphenidate
11626420|NCT00414921|Active Comparator|3|methylphenidate and clonidine
11626421|NCT00414921|Placebo Comparator|4|
11626422|NCT00414908|Experimental|A|
11626423|NCT00414908|Placebo Comparator|B|
11626424|NCT00414869|Experimental|NCX-1000|Experimental drug under evaluation
11626425|NCT00414869|Placebo Comparator|Placebo|Placebo powder
11626426|NCT00414817|Experimental|Automated Phone-Based Refill Reminders|Intervention Arm: Participants randomly assigned to this study arm may receive up to 8 automated phone calls from the BREATH EASY Medication Reminder Program over the course of the 19 month intervention period.
11626427|NCT00414817|No Intervention|Usual Care|"Usual Care: Participants randomly assigned to this arm received the same introductory letter as those in the intervention arm, giving them the opportunity to opt out, but were subsequently selected to be in the usual care study arm, and therefore, receive no intervention."
11626428|NCT00414804|Active Comparator|Spinal Cord Stimulation (SCS) Group|Spinal Cord Stimulation (SCS) Treatment Group
11626429|NCT00414804|Active Comparator|Nerve Blocks and PT|
11626430|NCT00414765|Experimental|Aldesleukin|
11626431|NCT00414726|Active Comparator|NBO (Normobaric Oxygen)|Oxygen, inhaled at 30-45L/min via a facemask for 8 hours
11626432|NCT00414726|Placebo Comparator|Room Air|Room Air, inhaled at 30-45L/min via a facemask for 8 hours
11626433|NCT00414713|Active Comparator|1|Regular transfusion
11626434|NCT00414713|Active Comparator|2|Restricted transfusion
11626435|NCT00414700|Experimental|ChondroCelect|
11626436|NCT00414700|Active Comparator|Microfracture|
11626437|NCT00414687|Experimental|Arm 1|
11626438|NCT00414661||Study group|All enrolled subjects
11626440|NCT00414648|Placebo Comparator|2|Participants will receive placebo sirolimus daily for 1 year followed with serial pulmonary functional tests and 6-minute walk tests over a 2-year period.
11626441|NCT00414635|Other|Control Arm with Week 24 Crossover|Subjects randomized to the control arm will remain on daily dosing of the pre-study regimen of 600mg efavirenz and 1 coformulated tablet of 300mg tenofovir df + 200 mg emtricitabine by mouth daily, or the equivalent coformulated single tablet of 600mg efavirenz + 300mg tenofovir df + 200 mg emtricitabine by mouth daily for 24 weeks. After 24 weeks of daily therapy subjects on this arm may be eligible to cross over to the experimental arm regimen of the coformulated single tablet of 600 mg efavirenz +300 mg tenofovir df +200 mg of emtricitabine on the 5/2 intermittent dosing treatment schedule for the remainder of the study.
11626442|NCT00414635|Experimental|5/2 Intermitent Treatment Arm|Subjects randomized to the 5/2 intermittent dosing treatment schedule regimen will be prescribed the pre-study regimen of 600mg efavirenz and 1 coformulated tablet of 300mg tenofovir df + 200 mg emtricitabine by mouth daily, or the equivalent coformulated single tablet of 600mg efavirenz + 300mg tenofovir df + 200 mg emtricitabine by mouth daily, for 5 consecutive days per week followed by 2 days off of these medications, 600 mg efavirenz, 300 mg tenoforvir dt and 200 mg emtricitabine, for 48 weeks.
11626443|NCT00414609|Experimental|Aliskiren|"Core Study: Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for next 34 weeks orally once daily in the morning.
~Extension Study: Patients from both the core arms who completed core study and signed informed consent form were included in this arm of extension study.
~Patients received 150 mg aliskiren tablet orally once a day for two weeks. Patients were then up-titrated to 300 mg aliskiren orally once a day at the discretion of the principal investigator based on their clinical condition for the duration of the study."
11626444|NCT00414609|Placebo Comparator|placebo|Core study: placebo for 36 weeks once daily in the morning
11626445|NCT00414596|Experimental|DRX Group|Patients using the device DRX9000™.
11626446|NCT00414583||Observation|all adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology
11626447|NCT00414570|Experimental|[18]F-FLT PET scan|Radioactive dose of 2.59 MBq/kg (range 100 - 350 MBq) [18]F-FLT per injection prior to Positron Emission Tomography (PET) imaging. [18]F-FLT PET scans at baseline/pre-treatment and at disease progression, up to a maximum of two separate [18]F-FLT PET scans per participant.
11626448|NCT00414544|Experimental|CosmetaLife|Test Article was given at start and two week follow up if necessary, up to a maximum dose of 2 cc to achieve optimal correction as determined by investigator.
11626449|NCT00414544|Active Comparator|Restylane|Control Article was given at start and two week follow up if necessary, up to a maximum dose of 2 cc to achieve optimal correction as determined by investigator.
11626450|NCT00414531|Other|SIM|Patients diagnosed to have or not to have Statin induced Myopathy
11626451|NCT00414518|Experimental|Treatment interruption|Oral Tenofovir disoproxil fumarate/Emtricitabine and Lopinavir/Ritonavir for 12 weeks followed by treatment interruption if CD4 count is 450 mm^3 or higher. When CD4 count is less than 350 mm^3 on two separate, consecutive measurements during treatment interruption, therapy will be resumed.
11626452|NCT00414518|Experimental|CD4 T cell guided therapy|Anti Retroviral Therapy initiated when AIDS-defining illness occurs or if CD4 count is confirmed at less than 350 mm^3 at two separate, consecutive measurements
11626453|NCT00414479||children 9-12 years of age|Children with schistosomiasis, malaria and anaemia
11626454|NCT00414466|Placebo Comparator|Placebo (0mg/day)|Intraspinal Placebo delivered continuously for 29 days via an implantable infusion system
11626455|NCT00414466|Active Comparator|Gabapentin Low (1mg/day)|Intraspinal Gabapentin Low delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
11626456|NCT00414466|Active Comparator|Gabapentin Medium (6mg/day)|Intraspinal Gabapentin Medium delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
11626457|NCT00414466|Active Comparator|Gabapentin High (30mg/day)|Intraspinal Gabapentin High delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
11626458|NCT00414453|Active Comparator|Lidocaine 5% + placebo patch, ER and placebo pills|5% lidocaine patch used as intervention placebo patch used with extended release oxycodone or with placebo pills and placebo patches a randomized subjects given extended release oxycodone and placebo patches during this treatment placebo pills used with lidocaine 5% patch group and with placebo patch/placebo pill group period
11626459|NCT00414440|Experimental|Everolimus|Patients in the everolimus group initially received 5 mg/day everolimus divided in 2 equal doses (i.e. 2.5 mg b.i.d.). Dose adjustments were performed to achieve a blood trough level of 3-8 ng/mL (maximum daily dose: 10 mg/day [5 mg b.i.d.]).
11626460|NCT00414440|Placebo Comparator|Placebo|Placebo tablets equivalent to the dosage of everolimus 5 mg/day, divided in 2 equal doses.
11626461|NCT00414414|Active Comparator|prednisone|
11626462|NCT00414414|Placebo Comparator|placebo|
11626463|NCT00414401|Other|Arm 1|
11626464|NCT00414388|Experimental|Single agent Sorafenib|Oral Single agent Sorafenib 400mg twice daily
11626465|NCT00414375|Active Comparator|1|Drainage with interval appendectomy
11626466|NCT00414375|Experimental|2|appendectomy on presentation
11626467|NCT00414349|Experimental|1|
11626468|NCT00414349|Active Comparator|2|
11626469|NCT00414349|Experimental|3|
11626470|NCT00414310|Experimental|Decitabine|Decitabine 20 mg/m^2 intravenous (IV) over 1 hour daily for 5 days.
11626471|NCT00414310|Experimental|Decitabine + Valproic Acid|Decitabine 20 mg/m^2 intravenous (IV) over 1 hour daily for 5 days. Valproic Acid 50 mg/kg orally daily for 7 days.
11626472|NCT00414297|Active Comparator|1 ECP|active ECP Therapy
11626473|NCT00414297|Placebo Comparator|2|Sham ECP Treatment
11626474|NCT00414271|Experimental|Docetaxel and Capecitabine in gastric cancer|Intravenous docetaxel 60 mg/m2 on day 1 and oral capecitabine 900 mg/m2 two times per day from day 1 to day 14 every 3 weeks for 2 cycles.
11626475|NCT00414206|Active Comparator|1% mecamylamine|
11626476|NCT00414206|Active Comparator|0.3% mecamylamine|
11626477|NCT00414206|Placebo Comparator|Placebo|
11626478|NCT00414167|Experimental|1|Bupropion
11626479|NCT00414167|Placebo Comparator|2|Placebo
11626480|NCT00414141|Experimental|1|Grass MATA MPL
11626481|NCT00414141|Placebo Comparator|2|
11626482|NCT00414128|Experimental|mycophenolate mofetil|Mycophenolate mofetil for 3-6 months until in stable remission, dose 2-3g/day
11626483|NCT00414128|Active Comparator|cyclophosphamide|pulsed intravenous cyclophosphamide 15mg/kg for 3-6 months (6-10 doses)until in stable remission
11626484|NCT00414102|Experimental|Ramelteon 8 mg QD|
11626485|NCT00414102|Placebo Comparator|Placebo QD|
11626486|NCT00414076|Active Comparator|Letrozole|Letrozole 2.5 mg Tablet By Mouth Daily for 12 Weeks.
11626487|NCT00414076|No Intervention|Standard of Care|Patients receive no treatment. Follow up every 3 months.
11626488|NCT00414050|Experimental|Modified Process Hepatitis B vaccine 5 μg|Infants received a primary series of 3 doses of experimental vaccine (5 μg per dose) at 2, 4 and 6 months of age.
11626489|NCT00414050|Active Comparator|RECOMBIVAX HB™ Hepatitis B Vaccine|Infants received a primary series of 3 doses of currently licensed vaccine (5 μg per dose) at 2, 4 and 6 months of age.
11626490|NCT00414050|Experimental|Modified Process Hepatitis B vaccine 10 μg|Infants received a primary series of 3 doses of experimental vaccine (10 μg per dose) at 2, 4 and 6 months of age.
11626491|NCT00414050|Active Comparator|ENGERIX-B®|Infants received a primary series of 3 doses of currently licensed vaccine (10 μg per dose) at 2, 4 and 6 months of age.
11626492|NCT00414037|Experimental|eszopiclone (Lunesta) 3mg|Subchronic (1-week) administration of 3mg Lunesta (eszopiclone)
11626493|NCT00414037|Placebo Comparator|Placebo|Placebo-treated group
11626494|NCT00414011|Experimental|Moxifloxacin|Moxifloxacin eye drops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
11626495|NCT00414011|Experimental|Gatifloxacin|Gatifloxacin eyedrops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
11626496|NCT00413998|Experimental|CABG + Mitral valve repair|
11626497|NCT00413998|Active Comparator|CABG only|
11626498|NCT00413972|Experimental|Vytorin 10/10|Ezetimibe 10 mg with Simvastatin 10 mg
11626499|NCT00413972|Experimental|Vytorin 10/20|Ezetimibe 10 mg with Simvastatin 20 mg
11626500|NCT00413972|Experimental|Vytorin 10/40|Ezetimibe 10 mg with Simvastatin 40 mg
11626501|NCT00413972|Placebo Comparator|Placebo|
11626502|NCT00413959|Experimental|Velcade, Rituximab,Cyclophosphamide & Decadron|Velcade 375 mg/m^2 given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
11626503|NCT00413946|Experimental|Erythropoietin|Three doses of rErythropoietin (3000 U/kg body weight) intravenously at 3, 12-18 and 36-42 hours after birth.
11626504|NCT00413946|Placebo Comparator|saline|Three doses of placebo (0.9% saline 1 ml/kg body weight) intravenously at 3, 12-18 and 36-42 hours after birth
11626505|NCT00413933|Experimental|Intrevention group|each subject in intervention group will get 15 weekly sessions (each session - 45 minutes) of specified exercise from a physical therapist that specializes in fall prevention and walking device recommendations. All subjects will get brochure for home exercise. It will be expected for intervention group to exercise twice daily, each time for 20 minutes in addition to the PT sessions
11626506|NCT00413933|No Intervention|Control group|"Those who agree to participate in the study will fill in questionnaire about falls (causes, circumstance, results). All will pass through: cognitive assessment by the Mini-Mental State Examination (MMSE), affective assessment by the 15-item Geriatric Depression Scale (GDS), functional assessment by Barthel Index (BI), visual assessment by Snellen charts and basic gait assessment by a Timed get Up and Go test (TU&G).
~Participants that fulfill inclusion criteria will be randomly assigned to the intervention group or the control group"
11626507|NCT00413920|Experimental|Without Steroids|Patients received Enteric-coated Mycophenolate Sodium (EC-MPS), administered orally 2 times a day for 6 months. Patients also received cyclosporine and a dose of methylprednisolone immediately after transplantation, but did not subsequently receive oral corticosteroids for the remainder of the study.
11626508|NCT00413920|Active Comparator|With Steroids|Patients received Enteric-coated Mycophenolate Sodium (EC-MPS), administered orally 2 times a day for 6 months. Patients also received cyclosporine and a dose of methylprednisolone immediately after transplantation, and subsequently continued to receive daily oral prednisone.
11626509|NCT00413894|Experimental|1|
11626510|NCT00413881|Active Comparator|2|Conventional LASIK Enhancement
11626511|NCT00413881|Experimental|1|Wavefront guided LASIK Enhancement
11626512|NCT00413829|Other|1|
11626513|NCT00413803|Other|1|Four-hour dialysis session, blood flow rate 300-400 ml/min
11626514|NCT00413803|Active Comparator|2|Eight-hours dialysis session, blood flow rate 200-250 ml/min
11626515|NCT00413790|Experimental|1|Darifenacin
11626516|NCT00413790|Active Comparator|2|Tolterodine
11626517|NCT00413790|Placebo Comparator|3|Placebo
11626518|NCT00413777|Experimental|Tolvaptan 45/15 mg/day orally for up to 4 years|Participants received tolvaptan 45 mg orally in the morning and 15 mg orally 8 hours later for up to 4 years.
11626519|NCT00413777|Experimental|Tolvaptan 60/30 mg/day orally for up to 4 years|Participants received tolvaptan 60 mg orally in the morning and 30 mg orally 8 hours later for up to 4 years.
11626520|NCT00413764|Experimental|1|tibolone
11626521|NCT00413764|Active Comparator|2|transdermal continuous combined E2-NETA (estradiol-norethisterone)
11626522|NCT00413725|Experimental|1|Three doses of MRKAd5 HIV-1 gag/pol/nef vaccine
11626523|NCT00413725|Placebo Comparator|2|Placebo
11626524|NCT00413699|Experimental|Open-Label Active Treatment Enrolled from Phase 2|Patients enrolling from Phase 2 studies
11626525|NCT00413699|Experimental|Open-Label Active Treatment Enrolled from Phase 3|Patients enrolling from Phase 3 studies
11626526|NCT00413686|Experimental|1|AZD7762 monotherapy followed by AZD7762 + gemcitabine
11626527|NCT00413673|Experimental|1|PRK
11626528|NCT00413660|Experimental|CP 690,550 1 mg BID|
11626529|NCT00413660|Experimental|CP 690,550 10 mg BID|
11626530|NCT00413660|Experimental|CP 690,550 15 mg|
11626531|NCT00413660|Experimental|CP 690,550 3 mg BID|
11626532|NCT00413660|Experimental|CP 690,550 5 mg BID|
11626533|NCT00413660|Experimental|CP-690,550 20 mg QD|
11626534|NCT00413660|Placebo Comparator|Placebo|Dummy tablets
11626535|NCT00413647|Experimental|CardioPET|
11626536|NCT00413634|Experimental|1|
11626537|NCT00413608|Experimental|1|Clopidogrel
11626538|NCT00413608|Experimental|2|Clopidogrel
11626539|NCT00413595||Observation|Adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology and the genetic diagnosis (a-galactosidase defect) of Fabry disease
11626540|NCT00413582|Active Comparator|1|Epidural analgesia
11626541|NCT00413582|Experimental|2|IV narcotic analgesia
11626542|NCT00413556|Active Comparator|1|
11626543|NCT00413556|Placebo Comparator|2|
11626544|NCT00413543|Experimental|interventional, rehabilitation|'early pulmonary lung rehabilitation'
11626545|NCT00413543|No Intervention|control|"standard care"
11626546|NCT00413491|Experimental|1|Comparison of MR and mammography
11626547|NCT00413478|Experimental|5-Azacytidine|5-Azacytidine 75mg/m^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
11626548|NCT00413452|Experimental|50 mg|50 mg once weekly
11626549|NCT00413439|Experimental|Low dose isavuconazole intravenous solution|
11626550|NCT00413439|Experimental|High dose isavuconazole intravenous solution or oral capsules|
11626551|NCT00413413|Experimental|Valsartan/amlodipine 80/5 mg|
11626552|NCT00413413|Active Comparator|Valsartan 80 mg|
11626553|NCT00413413|Active Comparator|Valsartan 160 mg|
11626554|NCT00413400|Placebo Comparator|Placebo|
11626555|NCT00413400|Active Comparator|Etanercept|
11626556|NCT00413387|Experimental|1|chf1535
11626557|NCT00413387|Active Comparator|2|Symbicort
11626558|NCT00413374|Other|Enoxaparin|
11626559|NCT00413361|Placebo Comparator|A|placebo
11626560|NCT00413361|Experimental|B|versus hydroxychloroquine
11626561|NCT00413335|Active Comparator|1|Subject undergoes ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, NMR and DEXA scan. Subject then receives Rosiglitazone. Subjects are followed every 2 weeks. Imaging repeated at 2 months. 12 week follow up. And then all tests are repeated at 4 months.
11626562|NCT00413335|Placebo Comparator|2|Subject has ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, DEXA, NMR. Subject is randomized (double-blind) to placebo. Is followed every 2 weeks, repeats imaging at 2 months, is seen at 12 weeks and then repeats all tests at 2 months.
11626563|NCT00413322|Experimental|Single-arm dose escalation|
11626564|NCT00413296|Placebo Comparator|1|Tablets, no active ingredient, 1-6 tablets/day for 12 wks in the 2 nd phase of the trial.
11626565|NCT00413296|Active Comparator|2|Levetiracetam, 500mg (1-6 tablets /day) for 12 wks in the 2nd phase of the study.
11626566|NCT00413283|Placebo Comparator|Placebo|Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
11626567|NCT00413283|Experimental|Romiplostim 250 μg|Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
11626568|NCT00413283|Experimental|Romiplostim 500 μg|Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
11626569|NCT00413283|Experimental|Romiplostim 750 μg|Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
11626570|NCT00413257|Experimental|1|nefopam infusion will start before the surgical incision, at the induction time of anesthesia and will be continued until postoperative H48
11626571|NCT00413257|Experimental|2|nefopam administration will start at the end of the surgery and will be continued until postoperative H48
11626572|NCT00413257|Placebo Comparator|3|control group that will receive a placebo from the induction time of anesthesia until H48
11626573|NCT00413244|Experimental|Androgel treatment|"Androgel 5 grams
~Androgel treatment - subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
11626574|NCT00413244|Placebo Comparator|Placebo|Placebo - will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
11626575|NCT00413231|Experimental|Valiant Thoracic Stent Graft System|"160 subjects were enrolled into the study, including 157 subjects treated with the study device and three subjects classified as intent-to-treat who did not receive the study device.
~There were no other arms for this study."
11626576|NCT00413218|Experimental|Isavuconazole (ISA)|Participants received 3 intravenous (IV) loading doses of 200 mg of isavuconazole on days 1 and 2, followed by an IV maintenance dose of 200 mg once daily from day 3 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV to oral therapy. Oral therapy consisted of 200 mg isavuconazole twice daily.
11626577|NCT00413218|Active Comparator|Caspofungin (CAS)/Voriconazole|Participants received 1 intravenous (IV) loading dose of 70 mg CAS on day 1, followed by an IV maintenance dose of 50 mg CAS from day 2 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV CAS to oral voriconazole comprising of a loading dose of 400 mg twice daily (BID) on the first day of oral therapy followed by standard dosing of 200 mg BID thereafter.
11626578|NCT00413205|Placebo Comparator|Placebo|po daily
11626579|NCT00413205|Experimental|RAR Gamma|5mg po daily
11626580|NCT00413192|Experimental|1|
11626581|NCT00413166|Experimental|Induction ATRA + ATO + Idarubicin|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO)
~ATRA 45 mg/m2 daily by mouth beginning day 1; ATO 0.15 mg/kg by vein daily beginning on day 1; Idarubicin 12 mg/m2 x 1 dose; Methylprednisolone 50 mg daily for 5 days starting on day 1."
11626582|NCT00413166|Experimental|Maintenance|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO)
~ATO 0.15 mg/kg by vein over 2 hours Monday-Friday for 4 weeks, then a 4-week break. ATRA 45 mg/m2 by mouth every day for 2 weeks, followed by 2 additional weeks of no study drug. Continue ATRA until treatment with ATO complete."
11626583|NCT00413166|Experimental|Induction ATRA + ATO + GO|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO) + Gemtuzumab Ozogamicin (GO)
~ATRA 45 mg/m2 daily po (in 2 divided doses) beginning day 1; ATO 0.15 mg/kg IV daily beginning on day 1; GO 9 mg/m2 on day 1 Methylprednisolone 50 mg daily for 5 days followed by rapid taper starting on day 1.
~Theophylline 100mg p.o. bid days 1-3, 200 mg p.o. bid days 4-6, and 300 mg p.o. bid thereafter during periods when patient is receiving ATRA or ATO. Theophylline administration continues until therapy with ATO and ATRA is completed."
11626584|NCT00413153|Active Comparator|1|Boosted Reyataz (300mg atazanavir + 100mg ritonavir)
11626585|NCT00413153|Active Comparator|2|Kaletra (pre-study dose)
11626586|NCT00413127|Experimental|1|Lidocaine i.v
11626587|NCT00413127|Active Comparator|2|intraoperatively lidocaine epidural postoperatively lidocaine i.v.
11626588|NCT00413127|Active Comparator|3|intraoperatively lidocaine i.v. postoperatively lidocaine epidural
11626589|NCT00413127|Active Comparator|4|lidocaine epidural
11626590|NCT00413127|Placebo Comparator|5|placebo i.v.
11626591|NCT00413114|Experimental|Obatoclax Mesylate|Obatoclax Mesylate 30mg
11626592|NCT00413101|Experimental|1|
11626593|NCT00413075|Experimental|oral belinostat|
11626594|NCT00413062|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
11626595|NCT00413062|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
11626596|NCT00413049|Experimental|Valsartan/amlodipine 80/5 mg|
11626597|NCT00413049|Active Comparator|Amlodipine 5 mg|
11626598|NCT00413036|Experimental|lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
11626599|NCT00413010|Placebo Comparator|Arm 2|
11626600|NCT00413010|Experimental|Arm 1|
11626601|NCT00412997|Experimental|LBH589|
11626602|NCT00412984|Active Comparator|1|
11626603|NCT00412984|Experimental|2|
11626604|NCT00412971|Active Comparator|Hexvix cystoscopy group|
11626605|NCT00412971|Other|White light|Standard White light cystoscopy
11626606|NCT00412958|Experimental|Ocriplasmin 25µg|25µg of ocriplasmin intravitreal injection
11626607|NCT00412958|Experimental|Ocriplasmin 75µg|75µg of ocriplasmin intravitreal injection
11626608|NCT00412958|Experimental|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
11626609|NCT00412958|Placebo Comparator|Placebo|Intravitreal injection of placebo
11626610|NCT00412893|Experimental|Isavuconazole|Participants received a loading dose of isavuconazole, 200 mg three times a day by intravenous infusion (IV) for the first 2 days followed by a maintenance dose from Day 3 of 200 mg once daily either IV or orally until they reached a treatment endpoint or for a maximum of 84 days.
11626611|NCT00412893|Active Comparator|Voriconazole|Participants received a loading dose of voriconazole, 6 mg/kg every 12 hours IV for the first 24 hours, followed by a maintenance dose of 4 mg/kg every 12 hours by IV on Day 2. Beginning on Day 3, participants received 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they reached a treatment endpoint or for a maximum of 84 days.
11626612|NCT00412867|Experimental|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
11626613|NCT00412841|Experimental|Atorvastatin|Atorvastatin 40mg
11626614|NCT00412841|Placebo Comparator|Placebo|Tablets identical to atorvastatin 40mg
11626615|NCT00412802|Experimental|1|dose adaptation of Enoxaparine at the renal deficient patients
11626616|NCT00412802|Active Comparator|2|No dose adaptation of Enoxaparine at renal normal patients
11626617|NCT00412789|Experimental|EPO906|
11626618|NCT00412776|Experimental|1|Proxinium plus Best Supportive Care
11626619|NCT00412776|No Intervention|2|Best Supportive Care
11626620|NCT00412750|Experimental|LdT+ PEG-INF|Telbivudine (LdT) 600 mg orally once a day for 104 weeks in combination with peginterferon alpha-2a (PEG-INF)180 μg subcutaneous injection once a week for 52 weeks.
11626621|NCT00412750|Experimental|LdT Monotherapy|Telbivudine (LdT) monotherapy: 600 mg orally once daily for 104 weeks.
11626622|NCT00412750|Active Comparator|PEG-INF Monotherapy|Peginterferon alpha-2a (PEG- INF) monotherapy: 180 μg subcutaneous injection once a week for 52 weeks.
11626623|NCT00412737|Experimental|Oseltamivir|
11626624|NCT00412737|Placebo Comparator|Placebo|
11626625|NCT00412698|Experimental|1|
11626626|NCT00412698|Placebo Comparator|2|
11626627|NCT00412685||TGA group|The TGA group consists of 15 patients treated withMustard or Senning procedures for surgical repaired of D-TGA atrial switch operation.
11626628|NCT00412685||TOF group|The TOF group consists of 15 patients with surgically corrected TOF.
11626629|NCT00412685||Control group|The control group C consists of 15 control subjects (AH) with normal Doppler Echocardiographic echocardiographic examinations.
11626630|NCT00412659|Active Comparator|Midline excision|Midline excision for pilonidal sinus disease.
11626631|NCT00412659|Active Comparator|Karydakis|Karydakis operation for pilonidal sinus disease.
11626632|NCT00412620|Placebo Comparator|Sugar Pill|
11626633|NCT00412620|Experimental|Group 1 Part 1 - ABT-925|
11626634|NCT00412620|Experimental|Group 1 Part 2 - ABT-925|
11626635|NCT00412620|Experimental|Group 2 - ABT-925|
11626636|NCT00412607|Experimental|NaviStar ThermoCool Catheter|
11626637|NCT00412594|Experimental|Treatment (cladribine and rituximab)|Patients receive cladribine IV over 2 hours QD on days 1-5 and rituximab IV once weekly for 8 weeks beginning on day 28 in the absence of disease progression or unacceptable toxicity.
11626638|NCT00412581|Experimental|Lenalidomide + Dacarbazine|
11626639|NCT00412568|Active Comparator|1|PRK control group
11626640|NCT00412555|Experimental|1|
11626641|NCT00412542|Experimental|Thalidomide + CPT-11|Oral Thalidomide 100 mg daily for 8 weeks + CPT-11 125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest.
11626642|NCT00412529|Experimental|Telbivudine|
11626643|NCT00412529|Active Comparator|Entecavir|
11626644|NCT00412516|Other|Group 1|JE live attenuated SA 14-14-2 vaccine then measles vaccine after one month
11626645|NCT00412516|Experimental|Group 2|JE live attenuated SA 14-14-2 vaccine and measles vaccine concurrently
11626646|NCT00412516|Other|Group 3|Measles vaccine then JE live attenuated SA 14-14-2 vaccine after one month
11626647|NCT00412490||Smoking Behavior Group|Individuals Having Surgery for Oral Cavity Cancer.
11626648|NCT00412477|Experimental|Group 1 - LFn-p24 ISOug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).
~Placebo recipients will receive a saline preparation in similar volume given IM.
~Immunizations given at 0, 4 and 16 weeks"
11626649|NCT00412477|Experimental|Group 2 - LFn-p24 300ug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).
~Placebo recipients will receive a saline preparation in similar volume given IM.
~Immunizations given at 0, 4 and 16 weeks"
11626650|NCT00412477|Experimental|Group 3 - LFn-p24 450ug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).
~Placebo recipients will receive a saline preparation in similar volume given IM.
~Immunizations given at 0, 4 and 16 weeks"
11626651|NCT00412451|Experimental|Ocriplasmin 25µg|25µg ocriplasmin intravitreal injection versus sham injection
11626652|NCT00412451|Experimental|Ocriplasmin 75µg|75µg ocriplasmin intravitreal injection versus sham injection
11626653|NCT00412451|Experimental|Ocriplasmin 125µg|125µg ocriplasmin intravitreal injection versus sham injection
11626654|NCT00412451|Sham Comparator|sham injection|Sham injection
11626655|NCT00412425|Active Comparator|2 Days Palonosetron|2 Days Palonosetron 0.25 mg intravenous (IV)
11626656|NCT00412425|Active Comparator|3 Days Palonosetron|3 Days Palonosetron 0.25 mg IV
11626657|NCT00412412|Experimental|A|Patients with HER2- Breast Cancer
11626658|NCT00412412|Experimental|B|Patients with HER2+ Breast Cancer
11626659|NCT00412386||BAV|patients with BAV
11626660|NCT00412386||Normal control|normal patients
11626661|NCT00412373|Experimental|001|Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
11626662|NCT00412373|Experimental|003|Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
11626663|NCT00412373|Placebo Comparator|002|Placebo for 6 weeks
11626664|NCT00412360|Experimental|Single Cord Blood Transplant|Unrelated donor, single umbilical cord blood unit transplant; conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil
11626665|NCT00412360|Experimental|Double Cord Blood Transplant|Unrelated donor, double umbilical cord blood unit transplant; Conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil
11626666|NCT00412334|Experimental|1|
11626667|NCT00412334|Experimental|2|
11626668|NCT00412334|Experimental|3|
11626669|NCT00412334|Experimental|4|
11626670|NCT00412321|Experimental|Cohort 1 (CNTO 328)|Patients will receive 4 administrations of 3 mg/kg CNTO 328 every 2 weeks till Day 43.
11626671|NCT00412321|Experimental|Cohort 2 (CNTO 328)|Patients will receive 4 administrations of 6 mg/kg CNTO 328 every 2 weeks till Day 43.
11626672|NCT00412321|Experimental|Cohort 3 (CNTO 328)|Patients will receive 3 administrations of 12 mg/kg CNTO 328 every 2 weeks till Day 43.
11626673|NCT00412321|Experimental|Cohort 4 (CNTO 328)|Patients will receive 7 administrations of 6 mg/kg CNTO 328 every week till Day 43.
11626674|NCT00412321|Experimental|Cohort 5 (CNTO 328)|Patients will receive 4 administrations of 12 mg/kg CNTO 328 every 2 weeks till Day 43.
11626675|NCT00412321|Experimental|Cohort 6 (CNTO 328)|Patients will receive 3 administrations of 12 mg/kg CNTO 328 every 3 weeks till Day 43.
11626676|NCT00412321|Experimental|Cohort 7a (CNTO 328)|Patients responding to CNTO 328 treatment will receive 9 mg/kg CNTO 328 every 3 weeks.
11626677|NCT00412321|Experimental|Cohort 7b (CNTO 328)|Patients responding to CNTO 328 treatment will receive 12 mg/kg CNTO 328 every 3 weeks as extended administration.
11626678|NCT00412243|Experimental|Clofarabine + Cyclophosphamide|Clofarabine 40 mg/m^2 daily for 3 Days + Cyclophosphamide starting 200 mg/m^2 every 12 hours for 3 days
11626679|NCT00412230||no treatment|
11626680|NCT00412230||2|
11626681|NCT00412217|Experimental|Erlotinib|Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive erlotinib tablets as 150 mg PO daily for 1 year until disease progression or intolerable toxicity.
11626682|NCT00412217|Placebo Comparator|Placebo|Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive placebo treatment for 1 year until disease progression or intolerable toxicity.
11626683|NCT00412204|Active Comparator|1|Tiotropium
11626684|NCT00412204|Placebo Comparator|2|Placebo
11626685|NCT00412191|Experimental|Subjects in treatment regimen A|Subjects in treatment regimen A will receive 100 and 200 mg lamotrigine XR in fasting condition.
11626686|NCT00412191|Experimental|Subjects in treatment regimen B|Subjects in treatment regimen B will receive 100 mg lamotrigine XR in fasting condition.
11626687|NCT00412191|Experimental|Subjects in treatment regimen C|Subjects in treatment regimen C will receive 100 mg lamotrigine XR in fed condition.
11626773|NCT00411281|Other|Group II|Patients are observed. If symptoms of intermediate- or high-risk disease develop, patients may crossover to group I.
11626774|NCT00411242|Experimental|1|
11626775|NCT00411242|Experimental|2|
11626688|NCT00412165|No Intervention|usual care|Usual care arm receives standard physical activity, nutrition and weight loss information from their primary care provider. The study offers and pays for a series of weight management sessions provided by Rady's Children's Hospital and Health Center's Nutrition Dept.
11626689|NCT00412165|Experimental|Intervention - Web|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition.
11626690|NCT00412165|Experimental|Intervention - Group|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition and has access to monthly group session with other teen and parent participants.
11626691|NCT00412165|Experimental|Intervention - Cell Phone|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition and are provided with cell phones to use during the program. The cell phone allows for the transfer of text messages from the study to the participant that are tailored to their health goals. In addition, self-monitoring and uploading capabilities to the program website are included.
11626692|NCT00412113|Active Comparator|Norvasc 5 mg|Blinded amlodipine 5 mg and amlodipine/atorvastatin single pill combination 5/20 mg placebo dosed once daily for 6 weeks.
11626693|NCT00412113|Experimental|Caduet 10/20mg|Blinded amlodipine/atorvastatin single pill combination 10/20 mg dosed once daily for 6 weeks and amlodipine besylate 10 mg placebo.
11626694|NCT00412113|Active Comparator|Norvasc 10 mg|Blinded amlodipine 19 mg and amlodipine/atorvastatin single pill combination 10/20 mg placebo dosed once daily for 6 weeks.
11626695|NCT00412113|Experimental|Caduet 5/20mg|Blinded amlodipine/atorvastatin single pill combination 5/20 mg and amlodipine besylate 5 mg placebo dosed once daily for 6 weeks .
11626696|NCT00412087|Experimental|Cholecalciferol 2000 IU|Women at 12-16 weeks' gestation are enrolled into the study to receive 2000 IU/day vitamin D3 for one month. After the run-in dose, the subjects are randomized to one of two treatment groups: either 2000 or 4000 IU/day to be taken throughout pregnancy until delivery.
11626697|NCT00412087|Experimental|Cholecalciferol 4000 IU|Women are randomized to one of 2 treatment groups: 2000 or 4000 IU vitamin D3/day
11626698|NCT00412074|Active Comparator|Control 400 IU vitamin D3|400 IU vitamin D3/day given to lactating women and 400 IU vitamin D3/day given as oral supplement to infant in dyad
11626699|NCT00412074|Experimental|2400 IU vitamin D3 (cholecalciferol)|2400 IU vitamin D3 given to lactating mother: 400 IU vitamin D3 from a prenatal vitamin and 2000 IU vitamin D3 and 0 IU vitamin D3 (placebo) given to her breastfeeding infant
11626700|NCT00412074|Experimental|6400 IU vitamin D3 (cholecalciferol)|6400 IU vitamin D3 given to lactating mother: 400 IU vitamin D3 from a prenatal vitamin and 6000 IU vitamin D3 and 0 IU vitamin D3 (placebo) given to her breastfeeding infant
11626701|NCT00412061|Experimental|Octreotide+ Everolimus|Everolimus was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity. Each treatment cycle lasted 28 days. Patients received their first dose of everolimus at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1, Day 1.
11626702|NCT00412061|Placebo Comparator|Octreotide+ Placebo|Matching placebo was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity; Each treatment cycle lasted 28 days. Patients received their first dose of matching placebo at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1 Day 1.
11626703|NCT00412048|Other|ALZHEIMER DISEASE|
11626704|NCT00412048|Other|MOLD COGNITIVE IMPAIRMENT|
11626705|NCT00412048|Other|CONTROLS|
11626706|NCT00412035|Active Comparator|Botox|Botulinum toxin A injection
11626707|NCT00412035|Placebo Comparator|Placebo|saline injection
11626708|NCT00412022|Active Comparator|A|Triptorelin 3.75 mg IM every 4 weeks and Tamoxifen 20 mg daily, for 5 years
11626709|NCT00412022|Active Comparator|B|Triptorelin 3.75 mg IM every 4 weeks and Letrozole 2.5 mg daily, for 5 years
11626710|NCT00412022|Experimental|C|Triptorelin 3.75 mg IM every 4 weeks and Letrozole 2.5 mg daily for 5 years + zoledronic acid 4 mg every 6 months.
11626711|NCT00411996|Other|1|IDV/r 600/100 mg + rifampicin
11626712|NCT00411957|Active Comparator|1|ATV/r 300/100 mg
11626713|NCT00411957|Active Comparator|2|ATV/r 200/100 mg OD
11626714|NCT00411892|Experimental|A|
11626715|NCT00411892|Active Comparator|B|
11626716|NCT00411879|Placebo Comparator|Control Group|Patients with refractory cardiac arrest (as defined in methods) treated according to the latest guidelines for resuscitation and receiving placebo instead of vasopressin and corticosteroids
11626717|NCT00411879|Experimental|Study Group|Patients with refractory cardiac arrest treated with combined vasopressin, epinephrine, and methylprednisolone during resuscitation. Patients receive stress-dose hydrocortisone for postresuscitation shock
11626718|NCT00411866|Experimental|Subjects receiving ketoconazole for 8 days|In Session 1, subjects will receive a single oral dose of SB-773812 20 milligrams (mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 8 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.
11626719|NCT00411866|Experimental|Subjects receiving ketoconazole for 14 days|In Session 1, subjects will receive a single oral dose of SB-773812 (20mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 12 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.
11626720|NCT00411827|Active Comparator|1|PRK
11626721|NCT00411827|Active Comparator|2|LASIK
11626722|NCT00411814|Placebo Comparator|Placebo|Saline
11626723|NCT00411814|Active Comparator|Active|GSK679586
11626724|NCT00411801|Experimental|Uniplas|Participants will receive Uniplas intravenously in 4 cycles of 7 to 9 days each for 1 month. The first cycle will consist of 1.5 plasma volume exchanges (= 75 mL/kg) for 3 consecutive days, followed by a minimum of 4 and a maximum of 6 daily single volume plasma exchanges (= 50 mL/kg). Subsequent treatment will depend upon the response of the participant to the first cycle, as assessed by a blinded assessor.
11626776|NCT00411242|Placebo Comparator|3|
11626725|NCT00411801|Active Comparator|Cryosupernatant plasma|Participants will receive cryosupernatant plasma intravenously in 4 cycles of 7 to 9 days each for 1 month. The first cycle will consist of 1.5 plasma volume exchanges (= 75 mL/kg) for 3 consecutive days, followed by a minimum of 4 and a maximum of 6 daily single volume plasma exchanges (= 50 mL/kg). Subsequent treatment will depend upon the response of the participant to the first cycle, as assessed by a blinded assessor.
11626726|NCT00411788|Experimental|sirolimus and trastuzumab|Patients received oral sirolimus 6 mg daily in combination with weekly trastuzumab administered intravenously with a loading dose of 4 mg/kg followed by 2 mg/kg weekly in a 28-day cycle. A subsequent amendment allowed trastuzumab to be administered every 3 weeks for patient convenience, with a loading dose of 8 mg/kg followed by a 6 mg/kg in a 21-day cycle. Sirolimus was administered at a 6 mg oral daily dose. Cycles were repeated on an every 21 or 28-day schedule until disease progression, unacceptable toxicity, or the development of any of the criteria for study removal. Doses were reduced or discontinued based on tolerability.
11626727|NCT00411762|Experimental|PHY906 Administration|PHY906 800mg, orally, twice a day for days 1-4 and capecitabine 1500mg/m^2 days 1-7 of a 14-day cycle
11626728|NCT00411749|Experimental|V501|"V501 vaccination Quadrivalent HPV (Types 6, 11, 16,
~18) L1 VLP Vaccine Injection
~cervix cancer exgenlesion Vaccination at Day 1, Month 2, and Month 6. Total 3 vaccinations. 0.5 mL intramuscular dose of V501 (HPV L1 Virus-Like Particle [VLP] Type 6,
~Type 11, Type 16, Type 18) or placebo at Day 1, Month 2 and Month 6."
11626729|NCT00411749|Placebo Comparator|Placebo|Placebo vaccination, Placebo 0.5 ml injection in 3 dosing regimen
11626730|NCT00411736|Experimental|A|Stratification group: Age under 8 years, no CF siblings at home.
11626731|NCT00411736|Experimental|B|Stratification group: Age >/= 8 years, no CF siblings at home.
11626732|NCT00411736|Experimental|C|Stratification group: Age >/= 8 years, CF siblings at home.
11626733|NCT00411723|Experimental|1|
11626734|NCT00411723|Placebo Comparator|2|
11626735|NCT00411697|Experimental|Group A|
11626736|NCT00411684|Experimental|Exp arm|A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of CBD-2914 as Emergency Contraception When Taken Between 48 Hours and 120 Hours of Unprotected Intercourse
11626737|NCT00411671|Experimental|Sorafenib|Sorafenib 400 mg By Mouth Twice Daily for 28 Days.
11626738|NCT00411658|Experimental|Investigational Device|
11626739|NCT00411658|Active Comparator|Cryopreserved|
11626740|NCT00411645|Experimental|A|
11626741|NCT00411645|Placebo Comparator|B|
11626742|NCT00411632|Experimental|Bexarotene + Erlotinib|Bexarotene 400 mg/m^2 by mouth daily x 28 Days. Erlotinib 150 mg by mouth daily x 28 Days.
11626743|NCT00411619|Experimental|Everolimus|As this was a non-randomized, open-label, single arm study, all patients in the study received treatment with everolilmus
11626744|NCT00411606||1|Subjects with no allergies
11626745|NCT00411593|Experimental|Avastin® + Bortezomib|"Phase I - 3 * 3 design, enrolling patients to receive Avastin® at a fixed dose of 15 mg/kg every 3 weeks and Bortezomib dosed at 1.6 mg/m2 weekly for 2 weeks out of 3.
~Phase II - The MTD for Bortezomib from the weekly schedule that is chosen will be combined with Avastin® to estimate the rate of progression-free survival."
11626746|NCT00411580|Experimental|1|CAD106
11626747|NCT00411580|Placebo Comparator|2|Placebo
11626748|NCT00411554|Experimental|Sitagliptin 50 mg QD|sitagliptin 50 mg orally once daily (QD=once daily)
11626749|NCT00411554|Active Comparator|Voglibose 0.2 mg TID|voglibose 0.2 mg orally three times daily (TID= three times daily)
11626750|NCT00411528|Experimental|1: 8 mg/m2 study drug + prednisone|Patupilone 8 mg/m2 + prednisone 5 mg bid daily
11626751|NCT00411528|Experimental|2: study drug + prednisone days 1 -8|Patupilone 10 mg/m2 + prednisone days 1 -8 at 25 mg bid, day 9 at 20 mg bid, day 10 at 15 mg bid, day 11 at 10 mg bid, day 12 - 21 at 5 mg bid
11626752|NCT00411528|Experimental|3: Study drug + prednisone days 1 - 4|Patupilone 10 mg/m2 + prednisone days 1 - 4 at 5 mg bid, days 5 -12 at 25 mg bid, day 13 at 20 mg bid, day 14 at 15 mg bid, day 15 at 10 mg bid, day 16 - 21 at 5 mg bid
11626753|NCT00411528|Active Comparator|4: Docetaxel 75 mg/m2 + prednisone 5 mg bid daily|Docetaxel 75 mg/m2 once every 3 weeks + prednisone 5 mg bid daily
11626754|NCT00411463|Experimental|Psychotherapy|Subjects randomized to the Psychotherapy arm will receive Interpersonal and Social Rhythm Therapy (IPSRT-BPII)
11626755|NCT00411463|Experimental|Medication|Subjects randomized to the medication arm will receive the FDA approved medication Seroquel (quetiapine)
11626756|NCT00411450|Experimental|Panitumumab plus FOLFIRI|Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until disease progression, intolerability, death, or study withdrawal.
11626757|NCT00411424|Experimental|1|
11626758|NCT00411424|Placebo Comparator|2|
11626759|NCT00411411|Placebo Comparator|Placebo|Placebo treatment, administered as tablets.
11626760|NCT00411411|Experimental|Januvia|Active treatment
11626761|NCT00411398|Experimental|Memantine 5-20mg/d flexible dose|Memantine tablets 5-20mg/d flexible dose
11626762|NCT00411385|Experimental|1|900 mcg alb-IFN every 2 weeks (12 doses) + Ribavirin 800 micrograms per day
11626763|NCT00411385|Experimental|2|1200 mcg alb-IFN every 2 weeks (12 doses) + Ribavirin 800 micrograms per day
11626764|NCT00411385|Active Comparator|3|180 mcg PEG-IFNx2a every 1 week (24 doses)+ Ribavirin 800 micrograms per day
11626765|NCT00411359|Experimental|Cardiac rehabilitation|8-week cardiac rehabilitation programme
11626766|NCT00411359|No Intervention|Monitoring|Carry on life as normal
11626767|NCT00411320|Active Comparator|Group 1|Smokers with asthma
11626768|NCT00411320|Active Comparator|Group 2|Ex-smokers with asthma
11626769|NCT00411320|Active Comparator|Group 3|Non-smokers with asthma
11626770|NCT00411320|No Intervention|Group 4|Non smokers without asthma
11626771|NCT00411320|No Intervention|Group 5|Smokers without asthma or COPD
11626772|NCT00411281|Experimental|Group I|Patients receive very low-dose cytarabine subcutaneously twice daily on days 1-7. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or complete or hepatic clinical remission undergo observation.
11626777|NCT00411229|Active Comparator|1|Capecitabine + Oxalipatin
11626779|NCT00411216|Experimental|exercises for gaze stabilization|Experimental group performed vestibular adaptation and substitution exercises
11626780|NCT00411216|Placebo Comparator|Control exercises|Saccadic eye movements against a Ganzfeld to prevent retinal slip error signal; no head movements
11626781|NCT00411203|Active Comparator|Tamoxifen Citrate|
11626782|NCT00411203|Placebo Comparator|Placebo|
11626783|NCT00411190|Experimental|Session 1|Subjects will receive 500 mg acetaminophen on Day 1, 400 mg ibuprofen on Day 2, 40 mg atorvastatin on Day 3.
11626784|NCT00411190|Experimental|Session 2|Subjects will be randomized to receive relacatib 60 mg or 120 mg from Day 1-14. On Day 15 subjects will receive 500 mg acetaminophen, 400 mg ibuprofen on Day 16 and 40 mg atorvastatin on Day 17 with usual dose of relacatib.
11626785|NCT00411177|Active Comparator|Post-dilution on-line hemodiafiltration|Post-dilution on-line hemodiafiltration
11626786|NCT00411177|Other|High-flux hemodialysis|High-flux hemodialysis
11626787|NCT00411138|Active Comparator|Radiation Therapy|Pelvic Radiotherapy alone
11626788|NCT00411138|Experimental|Radiation Therapy and Chemotherapy|Pelvic Radiation plus 2 concurrent cycles cisplatin followed by 4 adjuvant cycles carboplatin and paclitaxel
11626789|NCT00411099|Experimental|1|
11626790|NCT00411099|Experimental|2|
11626791|NCT00411099|Placebo Comparator|3|
11626792|NCT00411086|Experimental|Rituximab + GM-CSF|Rituximab 375 mg/m^2 By Vein Weekly on Days 1, 8, 15, and 22. Sargramostim (GM-CSF) 250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
11626793|NCT00410982|Experimental|Gemcitabine + Busulfan + Melphalan + HCT|HCT = Hematopoietic Cell Transplantation
11626794|NCT00410956|Experimental|UNRESECTABLE PRIMARY HEPATIC MALIGNANCY|All patients enrolled in the study will receive HAI FUDR (0.16 mg/kg X pump volume / pump flow rate), Dexamethasone (1 mg/m2/day) and IV Bevacizumab at 5mg/kg. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days post surgical placement of HAI pump; patients will receive their first treatment with Bevacizumab no sooner than 28 days post surgical placement of HAI pump.
11626795|NCT00410904|Experimental|Arm I|Patients receive oral AZD2171 once daily on days 1-28 in course 1 and on days 1-21 in course 2 and all subsequent courses. Patients also receive pemetrexed disodium IV over 10 minutes on day 8 in course 1 and on day 1 in course 2 and all subsequent courses. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
11626796|NCT00410891|Experimental|topical antibiotic|topical gatifloxacin 4 times per day
11626797|NCT00410865|Experimental|INGN 201|INGN201 injection + oral rinse, day 1, courses 1-6. Twice-daily oral rinses, days 2-5, courses 1-6.
11626798|NCT00410852|Experimental|A|
11626799|NCT00410852|Experimental|B|
11626800|NCT00410852|Active Comparator|C|
11626801|NCT00410826|Experimental|Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer)|Patients receive cisplatin IV on days 1, 22, and 43 and undergo 3-dimensional conformal or intensity modulated radiotherapy once daily, 5 days per week, on days 1-47. Patients also receive erlotinib hydrochloride PO once daily on days -7 to 47.
11626802|NCT00410826|Active Comparator|Arm II (chemotherapy, radiotherapy)|Patients receive cisplatin and radiotherapy as in Arm I.
11626803|NCT00410813|Experimental|Arm I|Patients receive oral dasatinib once daily.
11626804|NCT00410813|Experimental|Arm II|Patients receive oral dasatinib twice daily.
11626805|NCT00410761|No Intervention|1|Placebo vandetanib
11626806|NCT00410761|Experimental|2|Vandetanib
11626807|NCT00410735|Placebo Comparator|P|
11626808|NCT00410735|Experimental|E|
11626809|NCT00410722|Experimental|Full-Dose Nut|Subjects will be given tree nuts (almonds, hazelnuts, pistachios, macadamia nuts, pecans, walnuts, and cashews) and peanuts (at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
11626810|NCT00410722|Experimental|Half-Dose Nut|Subjects will be given tree nuts (almonds, hazelnuts, pistachios, macadamia nuts, pecans, walnuts, and cashews) and peanuts as well as the control supplement (wheat bran muffin)(at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
11626811|NCT00410722|Active Comparator|Control|Subjects will be given a control supplement (wheat bran muffin)(at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
11626812|NCT00410696|Active Comparator|Filgrastim|Filgrastim administration starting 1 day after autologous stem-cell reinfusion up to hemopoietic reconstitution (defined as more than 500/mm3 for 2 days)
11626813|NCT00410696|Experimental|Pegfilgrastim|Pegfilgrastim administered the day after autologous stem-cell reinfusion
11626814|NCT00410683|Experimental|Radiotherapy|Beginning within 4-8 weeks after surgery or 2-6 weeks after chemotherapy, patients undergo adjuvant thoracic conformal radiotherapy once daily, 5 days per week, for 6 weeks.
11626815|NCT00410683|Active Comparator|No radiotherapy|Patients do not undergo adjuvant thoracic radiotherapy. After completion of study therapy, patients are followed periodically for up to 10 years.
11626816|NCT00410605|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11626817|NCT00410579||Patients treated in NSABP R-02, R-03, C-05, C-06 or C-07|Study population to be interviewed comprises patients who were treated at least 5 years ago for colon or rectal cancer in NSABP trials R-02, R-03, C-05, C-06 or C-07
11626818|NCT00410566|Experimental|1|
11626819|NCT00410566|Experimental|2|
11626820|NCT00410566|Experimental|3|
11626821|NCT00410566|Experimental|4|
11626822|NCT00410566|Experimental|5|
11626823|NCT00410553|Experimental|Treatment (combination chemotherapy)|Patients receive eribulin mesylate IV and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 OR on days 1 and 8. Courses repeat every 28 or 21 days* in the absence of disease progression or unacceptable toxicity.
11626824|NCT00410514|Placebo Comparator|Placebo|Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.
11626825|NCT00410514|Experimental|Mirabegron 50 mg|Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.
11626826|NCT00410514|Experimental|Mirabegron 100 mg|Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.
11626827|NCT00410488|Active Comparator|Palonosetron - 1 Dose|"Arm 1: Palonosetron 0.25 mg intravenous (IV) for 1 dose (day 0).
~Dexamethasone: IV piggyback daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy. Chemotherapy treatment regimen: Zinecard: 750 mg/m2 as an IV bolus; Doxorubicin: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0. Mesna: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hours for days 0, 1, 2, and 3 (infusion completing on day 4); Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2); Vincristine: 2 mg IV by rapid administration on day 0 (for patients with small cell histology)."
11626828|NCT00410488|Active Comparator|Palonosetron - 3 Doses|"Arm 2: Palonosetron 0.25 mg IV for 3 doses (days 0, 2, 4).
~Dexamethasone: IV piggyback daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy. Chemotherapy treatment regimen: Zinecard: 750 mg/m2 as an IV bolus; Doxorubicin: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0. Mesna: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hours for days 0, 1, 2, and 3 (infusion completing on day 4); Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2); Vincristine: 2 mg IV by rapid administration on day 0 (for patients with small cell histology)."
11626829|NCT00410475||U.S. radiologic technologists|Radiologic technologists certified by the American Registry of Radiologic Technologists (ARRT) during 1923-1980 and residing in any U.S. state or territory.
11626830|NCT00410436|Experimental|Resistance Training Group|Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM).
11626831|NCT00410436|Active Comparator|Control Group|Subjects will not be performing resistance exercise but will continue performing aerobic exercise at the same volume, duration and intensity as they did at baseline.
11626832|NCT00410423|Experimental|Bortezomib 0.7mg/m^2|Bortezomib in combination with mitoxantrone, etoposide and cytarabine
11626833|NCT00410423|Experimental|Bortezomib 1.0mg/m^2|
11626834|NCT00410423|Experimental|Bortezomib 1.3mg/m^2|
11626835|NCT00410410|Experimental|Abatacept (ABA)|"Induction Period; 3 arms for Cohort 1: ABA 30/~10 mg/kg (ABA administered at 30 mg/kg followed by ABA at ~10 mg/kg), ABA ~10 mg/kg, ABA 3 mg/kg
~Induction Period; 2 arms for Cohort 2: ABA 30/~10 mg/kg and Second Cohort ABA ~10 mg/kg
~1 arm for maintenance period (ABA ~10 mg/kg)"
11626836|NCT00410410|Placebo Comparator|Placebo|"1 arm for induction period
~1 arm for maintenance period"
11626837|NCT00410410|Other|abatacept|1 arm for open-label extension phase (ABA ~10 mg/kg)
11626838|NCT00410397|Experimental|A|Osteopathic Manipulative Medicine
11626839|NCT00410397|Placebo Comparator|B|
11626840|NCT00410384|Placebo Comparator|Placebo|Placebo
11626841|NCT00410384|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg
11626842|NCT00410384|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg
11626843|NCT00410371|Experimental|GI267119|25 mg ODT tablet strength
11626844|NCT00410358|Experimental|LBQ707|
11626845|NCT00410345|Experimental|Pitocin|Treatment with Pitocin after mifegine
11626846|NCT00410345|Active Comparator|Cytotec|Treatment with cytotec after mifegine
11626847|NCT00410332|Active Comparator|A|TRAUMEEL S
11626848|NCT00410332|Placebo Comparator|B|
11626849|NCT00410306||Group 1|
11626850|NCT00410280|Other|1|
11626851|NCT00410241||A1|Self-referred individuals 45-65 at enrollment, 25% of whom had coronary artery disease
11626852|NCT00410241||A2|Individuals 45-65 at enrollment who self identified as African, African-American or Afro-Caribbean
11626853|NCT00410241||A3|Adults aged 18-65 at the time of enrollment, including subjects of both sexes, who have been identified as likely to return for follow up
11626854|NCT00410241||B|Family members of Group A1, A2, or A3
11626855|NCT00410215|Active Comparator|1|sodium phosphate
11626856|NCT00410215|Active Comparator|2|picosalax
11626857|NCT00410215|Active Comparator|3|picosalax plus bisacodyl
11626858|NCT00410202|Active Comparator|Entecavir|With the option of adding tenofovir at week 48. (This does not apply to Korea)
11626859|NCT00410202|Active Comparator|Adefovir + Lamivudine|
11626860|NCT00410202|Active Comparator|Entecavir + Adefovir|
11626861|NCT00410189|Experimental|ZD6474|ZD6474 300 mg by mouth daily for 28 Days.
11626862|NCT00410163|Active Comparator|Active Comparator 1|Each patient will receive a total of 6 infusions with ofatumumab every 4 weeks in combination with fludarabine and cyclophosphamide. The first infusion will be 300mg followed by 5 infusions of 500mg
11626863|NCT00410163|Active Comparator|Active Comparator 2|Each patient will receive a total of 6 monthly infusions with ofatumumab in combination with fludarabine and cyclophosphamide. The first infusion will be 300mg followed by 5 infusions of 1000mg
11626864|NCT00410150|Experimental|Group 1 (Heliox-powered albuterol)|Group 1 (Heliox-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 70:30 Heliox.
11626865|NCT00410150|Active Comparator|Group 2 (Oxygen-powered albuterol)|Group 2 (Oxygen-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 100% oxygen per usual standard of care.
11626866|NCT00410124|Experimental|RAD001 +BSC|The study drugs were self administered by the patients. Patients were instructed to take the study drug as specified in the protocol. Patients were instructed to take two tablets (5 mg each) by mouth every day. Tablets were to be taken one tablet after another with a glass of water, at the same time each day in a fasting state or with a light fat-free meal. If disease progression occurred, patients were unblinded and if they were receiving RAD001, they would discontinue the study. Otherwise, they would be given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
11626867|NCT00410124|Placebo Comparator|Placebo (plus BSC)|Patients received matching placebo of RAD001 tablets twice a day along with Best Supportive Care. With the documented disease progression, the investigator could unblind the patient. If unblinded patient was receiving placebo treatment, they were given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
11626868|NCT00410072|Experimental|TDF 0.5 mg|TDF=tenofovir
11626869|NCT00410072|Experimental|ETV 0.5 mg +TDF 300 mg|ETV=entecavir; TDF=tenofovir
11626870|NCT00410059|Experimental|Erlotinib|Erlotinib 150 mg by mouth daily x 28 days.
11626871|NCT00410046|Experimental|Etanercept (ETN)|Patients received ETN dose 50 mg once weekly or Sulphasalazine dose 3 g daily in study 402 for 16 weeks. Upon enrollment into study 405, all received subcutaneous injections of etanercept 50 mg once weekly for 36 weeks.
11626872|NCT00410007|Other|Patients with ADPKD, HS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
11626873|NCT00410007|Other|Patients with ADPKD, LS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
11626874|NCT00410007|Other|Healthy Control Subjects, HS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
11626875|NCT00410007|Other|Healthy Control Subjects, LS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
11626876|NCT00409994|Experimental|Rapamycine|rapamycine 6 mg dd
11626877|NCT00409968||Screening Study|Screening study to find out if Patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body are eligible to take part in 1 of 4 different research studies.
11626878|NCT00409942|Experimental|1|Torasemide prolonged released
11626879|NCT00409942|Active Comparator|2|Furosemide
11626880|NCT00409916|Placebo Comparator|Standard Care Arm|In the Standard Care Arm, the treating clinician will adjust therapy according only to the clinical assessment of signs and symptoms of heart failure since the ICG information is blinded to the treating clinician.
11626881|NCT00409916|Active Comparator|ICG Arm|In the ICG Arm, the treating clinician will adjust therapy according to the clinical assessment of signs and symptoms of heart failure, in addition to the ICG hemodynamic information obtained from the printed report.
11626882|NCT00409864|Active Comparator|PTBD|percutaneous biliary drainage
11626883|NCT00409864|Active Comparator|Endoscopic stenting|ERCP and stenting
11626884|NCT00409838|Experimental|Abatacept and Methotrexate|
11626885|NCT00409838|Placebo Comparator|Placebo and Methotrexate|(standard of care)
11626886|NCT00409838|Experimental|Abatacept - Open Label|Open-label extension phase
11626887|NCT00409825|Experimental|Part 1|Part 1 done after 4 weekly 17-OHPC injections completed, between 20 6/7 to 24 6/7 weeks gestation. 10 cc blood drawn pre-5th injection. 10 cc blood drawn 12 hours post-dose and 7 consecutive days. 24-hour urine collected days 4-5 within 7 days post-injection. Part 2 done 31 0/7 to 34 6/7 or at 35 0/7 weeks. 10 cc blood drawn pre weekly injection, 12 hours post-dose, and 7 consecutive days. 24-hour urine collected between days 4-5 within 7 days post-injection. A subject in whom Part 2 is performed during the last scheduled injection of 17-OHPC (at or around 35 0/7 weeks) will have the option to participate in Part 3, in which 10 cc of blood will be drawn serially over 21 days after completing Part 2. Blood will be drawn on days 9, 11, 14, 17, 20, 24, 28 after the last injection. Part 4: At the time of labor and delivery, subject will have 10cc of blood removed from a maternal peripheral vein. 10cc of blood will be collected from the placenta/umbilical cord after delivery.
11626888|NCT00409799|Experimental|1|Experimental - high dose
11626889|NCT00409799|Experimental|2|Experimental - low dose
11626890|NCT00409799|Active Comparator|3|Autograft
11626891|NCT00409773|Other|1|Arm 1: drug + comparator + Placebo
11626892|NCT00409773|Other|2|Arm 2: drug + comparator + Placebo
11626893|NCT00409773|Other|3|Arm 3: drug + comparator + Placebo
11626894|NCT00409773|Other|4|Arm 4: drug + comparator + Placebo
11626895|NCT00409773|Other|5|Arm 5: drug + comparator + Placebo
11626896|NCT00409747|Experimental|Minocycline|
11626897|NCT00409734||Children with pyloric stenosis|Male or female children age two to nine weeks with history of vomiting and feeding intolerance, and abdominal sonogram showing presence of pyloric stenosis
11626898|NCT00409734||Children without pyloric stenosis|Male or female children age two to nine weeks without pyloric stenosis admitted to the hospital for other reasons
11626899|NCT00409721|Experimental|Memantine Low Dose|
11626900|NCT00409721|Experimental|Memantine High Dose|
11626901|NCT00409708|Active Comparator|1|
11626902|NCT00409708|Other|2|
11626903|NCT00409695|Experimental|High Dose Thymoglobulin (ATG)|High Dose Thymoglobulin (ATG): 1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
11626904|NCT00409695|Experimental|Low Dose Thymoglobulin (ATG)|Low Dose Thymoglobulin (ATG): 2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
11626905|NCT00409682|Active Comparator|Open-label adalimumab (Week 0 to Week 4)|All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
11626906|NCT00409682|Active Comparator|Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52)|Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
11626958|NCT00409149|Active Comparator|DASH|standard dietary DASH approach in hypertensive patients
11626959|NCT00409136||Alert|Physicians alerted about their high risk patients who are not receiving any VTE prophylaxis.
11626960|NCT00409136||No Alert|Physicians not alerted about their high risk patients who are not receiving any VTE prophylaxis.
11626961|NCT00409084|Active Comparator|1|endoscopic variceal band ligation
11626962|NCT00409084|Active Comparator|2|subjects will receive nadolol (beta blocker) at 20mg/day with dose titration
11626963|NCT00409071|Experimental|1|cocculine
11626907|NCT00409682|Active Comparator|High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52)|Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
11626908|NCT00409617|Experimental|Open Label|
11626909|NCT00409604|Experimental|1|Standard PCI procedure + pacing post conditioning
11626910|NCT00409604|No Intervention|2|Standard PCI procedure
11626911|NCT00409591|Active Comparator|1|"NVP-NVP:
~In women, one NVP 200 mg tablet at onset of labor;
~In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours"
11626912|NCT00409591|Experimental|2|"PL-NVP:
~In women, one placebo tablet at onset of labor;
~In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours"
11626913|NCT00409591|Experimental|3|"LPV/r:
~In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery"
11626914|NCT00409578|Placebo Comparator|Placebo|Placebo tablets and capsules
11626915|NCT00409578|Experimental|Aliskiren 300 mg|Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.
11626916|NCT00409578|Experimental|Valsartan 320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.
11626917|NCT00409578|Experimental|Aliskiren/valsartan 300/320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.
11626918|NCT00409565|Experimental|Cetuximab plus bevacizumab|Cetuximab plus bevacizumab
11626919|NCT00409552|Experimental|1|Virtual Reality with head display
11626920|NCT00409552|Active Comparator|2|Virtual Reality with flat projection display
11626921|NCT00409552|Active Comparator|3|non-interactive video with head display
11626922|NCT00409552|Active Comparator|4|non-interactive video with flat projection display
11626923|NCT00409552|No Intervention|5|No distraction
11626924|NCT00409539|Placebo Comparator|1|Placebo run-in phase. 2 week duration.
11626925|NCT00409539|Placebo Comparator|2|To be taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
11626926|NCT00409539|Experimental|3|20mg dose of SMP-986 to be taken once daily for 8 week duration.
11626927|NCT00409539|Experimental|4|40mg dose of SMP-986 to be taken for 8 week duration.
11626928|NCT00409539|Experimental|5|80mg dose of SMP-986 to be taken for 8 week duration.
11626929|NCT00409539|Experimental|6|120mg dose of SMP-986 to be taken for 8 week duration.
11626930|NCT00409487|Experimental|1|8 weeks of Valsartant treatment, 4 weeks of washout, 8 weeks of CPAP and 8 weeks of Valsartant plus CPAP treatments
11626931|NCT00409487|Experimental|2|8 weeks of CPAP , 4 weeks of washout, 8 weeks of Valsartant treatment and 8 weeks of Valsartant plus CPAP treatments
11626932|NCT00409448|Experimental|CAPS|Participants will receive the Internet-based counselor-assisted problem-solving group treatment
11626933|NCT00409448|Active Comparator|IRC|Participants will receive the Internet resource comparison group treatment
11626934|NCT00409435|Active Comparator|pyridostigmine|Active study drug
11626935|NCT00409435|Placebo Comparator|Placebo|Control
11626936|NCT00409409|Experimental|300 IR|300 IR grass pollen allergen extract tablet
11626937|NCT00409409|Placebo Comparator|Placebo|Placebo tablet
11626938|NCT00409396|Experimental|1|Fecal calprotectin and urinary PGEm levels will be tested on all participants.
11626939|NCT00409344|Placebo Comparator|1|Normal Saline
11626940|NCT00409344|Active Comparator|Dexmedetomidine|Dexmedetomidine is a highly specific a2 agonist with prominent central nervous system and cardiovascular effects. A postoperative sedative-hypnotic agent for intensive care patients for use up to 24 hours.
11626941|NCT00409331|Experimental|IMRT + Amifostine|Intensity-Modulated Radiation Therapy (IMRT) 2.0 to 2.2 Gy delivered in 30 fractions + Amifostine 500 mg, 2 divided doses subcutaneously 30-60 minutes prior to IMRT.
11626942|NCT00409318|Active Comparator|1|Etanercept
11626943|NCT00409318|Placebo Comparator|2|Placebo
11626944|NCT00409292|Experimental|RAD001|"RAD001 was administered continuously at a dose of 10 mg daily by mouth until disease progression, unacceptable toxicity, or withdrawal of consent.
~Four weeks of study drug was considered to be one cycle of treatment."
11626945|NCT00409279|Experimental|1|multi-component psychosocial intervention
11626946|NCT00409279|No Intervention|2|
11626947|NCT00409253|Active Comparator|Urapidil|
11626948|NCT00409253|Active Comparator|Nicardipine|
11626949|NCT00409240|Experimental|MEDIC Intervention|Receives pharmacist-led behavioral and pharmacologic group intervention for cardiac risk reduction
11626950|NCT00409240|No Intervention|Usual Care|Patient continued on usual care
11626951|NCT00409227|Active Comparator|1|double blind placebo control
11626952|NCT00409227|Placebo Comparator|2|placebo control blinded arm
11626953|NCT00409188|Experimental|Tecemotide (L-BLP25)|
11626954|NCT00409188|Placebo Comparator|Placebo|
11626955|NCT00409175|Experimental|1.|Fx-1006A
11626956|NCT00409175|Placebo Comparator|2.|Placebo
11626957|NCT00409149|Experimental|CALM BP|dietary approach, education on cooking and food consumption choices, walking physical exercise, Qi Gong - a form of Chinese slow movement exercise combined with relaxation breathing and imagery and group therapy coaching in stress management techniques and mind-body balancing techniques.
11626964|NCT00409071|Placebo Comparator|2|placebo
11626965|NCT00409058|Experimental|Teen Online Problem Solving|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
11626966|NCT00409058|Experimental|Internet Resources Comparison|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
11626967|NCT00409019|Experimental|1|Study cancelled: Withdrawn before enrollment of any participants
11626968|NCT00409019|Experimental|2|Study cancelled: Withdrawn before enrollment of any participants
11626969|NCT00409019|Experimental|3|Study cancelled: Withdrawn before enrollment of any participants
11626970|NCT00409006|Experimental|Pemetrexed/Cisplatin/Gefitinib|Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity.
11626971|NCT00409006|Experimental|Pemetrexed/Cisplatin|Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity.
11626972|NCT00408993|Experimental|Duloxetine|60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)
11626973|NCT00408993|Placebo Comparator|Placebo|Placebo every day (QD), by mouth (PO) for 12 weeks
11626974|NCT00408967|Experimental|Tucotuzumab celmoleukin (EMD 273066)|
11626975|NCT00408954|Placebo Comparator|Placebo|
11626976|NCT00408954|Active Comparator|UK-369,003|
11626977|NCT00408928|Experimental|Bortezomib for Treatment of GHVD|To determine if bortezomib (VELCADE®) will successfully inhibit T-cell responses in clinically acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
11626978|NCT00408902|Experimental|TandutinibTreatment|Patients receive oral tandutinib 500 mg twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11626979|NCT00408876|Experimental|Duloxetine 20 mg|duloxetine 20 mg once a day (QD), by mouth (PO) for 13 weeks
11626980|NCT00408876|Experimental|Duloxetine 60 mg|duloxetine 30 mg once a day (QD), by mouth (PO) for 1 week then duloxetine 60 mg QD, PO for 12 weeks
11626981|NCT00408876|Experimental|Duloxetine 120 mg|duloxetine 30 mg once a day (QD), by mouth (PO) for 1 week followed by duloxetine 60 mg QD, PO for 1 week, then duloxetine 120 mg QD, PO for 11 weeks
11626982|NCT00408876|Placebo Comparator|Placebo|placebo once a day (QD), by mouth (PO) for 13 weeks
11626983|NCT00408863|Active Comparator|Tibolone|Tibolone 2.5 mg/day
11626984|NCT00408863|Placebo Comparator|Placebo|Placebo
11626985|NCT00408850|Active Comparator|Pioglitazone|pioglitazone 15 mg for 6 weeks followed by 30 mg for 6 weeks
11626986|NCT00408850|Placebo Comparator|sugar pill|Placebo comparator
11626987|NCT00408785|Experimental|A|Injection
11626988|NCT00408785|Placebo Comparator|B|Injection
11626989|NCT00408772|Experimental|Unresectable colorectal liver mets|
11626990|NCT00408733|No Intervention|1|
11626991|NCT00408733|Experimental|2|Intervention
11626992|NCT00408694|Experimental|Treatment (bevacizumab, cisplatin, fluorouracil, IMRT, 3D-CRT)|"BEVACIZUMAB AND CHEMORADIOTHERAPY: Patients receive bevacizumab IV over 30-90 minutes and cisplatin IV over 20-30 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 1, patients also undergo three-dimensional conformal radiotherapy or intensity-modulated radiotherapy once daily 5 days a week for a total of 33 fractions.
~ADJUVANT THERAPY: Beginning in week 10, patients receive fluorouracil IV continuously over 96 hours on days 1-4, cisplatin IV over 20-30 minutes on day 1 OR days 1 and 2, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
11626993|NCT00408681|Experimental|Arm I|Patients receive oral lithium carbonate once or twice daily. Treatment continues for up to 8 weeks in the absence of disease progression or unacceptable toxicity.
11626994|NCT00408655|Experimental|Arm I|"PART A: Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1 and temsirolimus IV over 30 minutes on days 8 and 15. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
~PART B: Patients receive paclitaxel and carboplatin as in part A. They also receive temsirolimus IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
11626995|NCT00408642|Experimental|1|enhanced adherence support for patients initiating antiretroviral therapy
11626996|NCT00408642|Active Comparator|2|standard adherence support
11626997|NCT00408629|Experimental|adalimumab group|
11626998|NCT00408629|Experimental|placebo group|
11626999|NCT00408616|Experimental|1|Grazax treatment
11627000|NCT00408616|Placebo Comparator|2|Grazax Placebo
11627001|NCT00408603|Experimental|All study patients|All patients will receive voreloxin injection
11627002|NCT00408590|Experimental|Experimental Arm|
11627049|NCT00408083|Active Comparator|2|Magnevist contrast agent for MRA
11627050|NCT00408070|Experimental|I|This is a single Arm study. Two of the study drugs used are non-experimental. One of the study drugs is experimental.
11627003|NCT00408564|Experimental|Gemcitabine,Oxaliplatin and Cetuximab|"Gemcitabine will be given on day 1 of every 2 week cycle. Oxaliplatin will be given day 2 of every 2 week cycle. Cetuximab will be given every week for 12 weeks.
~After chemotherapy, patient will be assessed for resectability. Patients will have either surgery or daily radiation and capceitabine Monday-Friday for a total of 5 and a half weeks."
11627004|NCT00408551|Experimental|FOLFOX6|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continously over 46 hours beginning on day 1.
11627005|NCT00408551|Experimental|FOLFIRI|Patients receive irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1.
11627006|NCT00408551|Experimental|FUDR|Patients receive floxuridine IV continuously on days 1-14.
11627007|NCT00408525|Experimental|1|Donepezil
11627008|NCT00408512|Active Comparator|Thiazides|Thiazidic diuretic
11627009|NCT00408512|Active Comparator|Non Tiazidic|Non tiazidic diuretic treatment: Any other therapy can be considered in this arm: example: CCB, BB, ACEi, ARB
11627010|NCT00408499|Experimental|Erlotinib + Cetuximab|Daily erlotinib combined with weekly cetuximab
11627011|NCT00408460|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive paclitaxel IV on days 3, 10, and 17 and imatinib mesylate PO QD on days 1-4, 8-11, and 15-18. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
11627012|NCT00408447|Other|SCD group|Sickle Cell Disease patients receiving chemotherapy (Busulfan, Fludarabine and Alemtuzumab) will undergo allogeneic stem cell transplant.
11627013|NCT00408447|Other|BT group|Beta Thalassemia patients receiving chemotherapy (Busulfan, Fludarabine and Alemtuzumab) will undergo allogeneic stem cell transplant.
11627014|NCT00408434|Experimental|CS-7017|CS-7017 from 0.05 to 3.2 mg bid
11627015|NCT00408421|Experimental|A|duloxetine 30 mg, daily (QD), by mouth (PO) for 1 week then duloxetine 60 mg QD, PO for 6 weeks then duloxetine 60 mg or 120 mg QD, PO for 6 weeks
11627016|NCT00408421|Placebo Comparator|B|placebo daily (QD), by mouth (PO) for 13 weeks
11627017|NCT00408408|Active Comparator|Arm 1A: Docetaxel then AC|Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
11627018|NCT00408408|Experimental|Arm 1B Docetaxel + Bev then AC + Bev|Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
11627019|NCT00408408|Experimental|Arm 2A: Docetaxel + Capecitabine then AC|Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
11627020|NCT00408408|Experimental|Arm 2B: Docetaxel + Cape + Bev then AC + Bev|Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
11627021|NCT00408408|Experimental|Arm 3A: Docetaxel + Gem then AC|Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
11627022|NCT00408408|Experimental|Arm 3B: Docetaxel + Gem + Bev then AC + Bev|Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
11627023|NCT00408395|Experimental|1: Trivalent Seasonal Influenza Vaccine|
11627024|NCT00408395|Experimental|2: Adjuvanted Trivalent Seasonal Influenza Vaccine|
11627025|NCT00408330|Active Comparator|1|azelaic acid 15%
11627026|NCT00408330|Placebo Comparator|2|Inactive 15% gel base
11627027|NCT00408317|Experimental|Ultrase® MT20|
11627028|NCT00408317|Placebo Comparator|Placebo|
11627029|NCT00408291||1|Winsta PH osteosynthesis device (Fischer Medical)for treatment of humeral fracture
11627030|NCT00408252|Experimental|Arm A|patients will receive SU011248 in monotherapy
11627031|NCT00408239|Experimental|1|Dose regimen 1
11627032|NCT00408239|Active Comparator|2|
11627033|NCT00408239|Experimental|3|Dose regimen 2
11627034|NCT00408226|Experimental|1|
11627035|NCT00408213|Experimental|1|
11627036|NCT00408213|Placebo Comparator|2|
11627037|NCT00408200|Other|AAD:YES|Subjects receive membrane-active anti-arrhythmic medication after ablation. See intervention list below.
11627038|NCT00408200|Other|AAD:NO|Subjects do not receive membrane-active anti-arrhythmic medications after ablation.
11627039|NCT00408187|Active Comparator|1.|
11627040|NCT00408187|Placebo Comparator|3.|
11627041|NCT00408187|Active Comparator|2.|
11627042|NCT00408161|Active Comparator|1|prize contingency management (CM) plus standard case management treatment -- patients earn the chance to win prizes by submitting negative breath samples and by complying with steps toward treatment goals
11627043|NCT00408161|Active Comparator|2|standard case management treatment
11627044|NCT00408148|Placebo Comparator|2|Administration of one rimonabant placebo tablet once daily in the morning
11627045|NCT00408148|Experimental|1|Administration of one tablet containing 20 mg of active rimonabant once daily in the morning
11627046|NCT00408096|Active Comparator|1|The Copeland uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact area used as a treatment for shoulder osteoarthritis
11627047|NCT00408096|Active Comparator|2|The Global Cap uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact area used as a treatment for shoulder osteoarthritis
11627048|NCT00408083|Experimental|1|MultiHance MRI contrast agent
11627051|NCT00408031|Experimental|1|Randomization to 2 treatment groups. One group receives adjuvant treatment with D-cycloserine, up to 1 g/day. The second group receives adjuvant treatment with placebo, up to 1 g/day.
11627052|NCT00408005|Experimental|Group 0 Induction Therapy|All patients (T-ALL and T-LLy) receive cytarabine intrathecally (IT) on day 1; vincristine sulfate IV on days 1, 8, 15, and 22; prednisone IV or PO twice daily BID on days 1-28; pegaspargase IM (may give IV over 1 to 2 hours) on day 4, 5, or 6; daunorubicin hydrochloride IV on days 1, 8, 15 and 22; and methotrexate IT on days 8 and 29 (and days 15 and 22 for patients with CNS3 disease).
11627053|NCT00408005|Active Comparator|Group 1 Arm IV (Consolidation chemotherapy)|Patients receive nelarabine IV over 60 minutes on days 1-5 and 43-47; methotrexate IT on days 15, 22, 57, and 64; cyclophosphamide IV over 30 minutes on days 8 and 50; cytarabine IV over 15-30 minutes or SC on days 8-11, 15-18, 50-53 and 57-60; mercaptopurine PO on days 8-21 and 50-63; vincristine sulfate IV on days 22, 29, 64, and 71; and pegaspargase IM or IV over 1-2 hours on days 22 and 64. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 15, 22-26, and 29-33 (DS patients excluded as of 09/29/10). (Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT QD on days 22-28 and 29-35.
11627054|NCT00408005|Active Comparator|Group I Arm I (Consolidation chemotherapy)|Patients receive methotrexate IT on days 1, 8, 15, and 22; cyclophosphamide IV over 30 minutes on days 1 and 29; cytarabine IV over 15-30 minutes or SC on days 1-4, 8-11, 29-32, and 36-39; mercaptopurine PO on days 1-14 and 29-42; vincristine sulfate IV on days 15, 22, 43 and 50; and pegaspargase IM or IV over 1-2 hours on days 15 and 43. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 11-12, 15-19, and 22-26. (DS patients excluded as of 09/29/10.) Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT (1,200 cGy/dose) QD on days 15-21 and 22-28. Patients with low-risk disease do not undergo CRT. Patients with standard risk T-LLy received Arm I, and those with high risk T-LLy were randomized between Arm I and Arm II combination chemotherapy.
11627055|NCT00408005|Active Comparator|Group I Arm I (Delayed intensification chemotherapy|Patients receive vincristine sulfate IV on days 1, 8, 15, 43, and 50; dexamethasone IV or PO BID on days 1-21 (for patients < 10 years of age) OR on days 1-7 and 15-21 (for patients >= 10 years of age and for patients with DS); doxorubicin hydrochloride IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6, AND day 43; methotrexate IT on days 1, 29, and 36; cyclophosphamide IV over 30 minutes on day 29; cytarabine IV over 15-30 minutes or SC on days 29-32 and 36-39; and thioguanine PO on days 29-42. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose (DS patients excluded as of 09/29/10). Standard risk T-LLy patients were assigned to Arm I and those with high risk were randomized between Arm I and Arm II.
11627056|NCT00408005|Active Comparator|Group I Arm I (Maintenance chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; prednisone PO BID on days 1-5, 29-33, and 57-61; mercaptopurine PO QD on days 1-84; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; and methotrexate IT on day 1. Treatment repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 119) (for girls with T-ALL), all patients with T-LLy, and 3 years from the start of interim maintenance therapy (approximately week 171) (for boys with T-ALL).
11627057|NCT00408005|Active Comparator|Group I Arm I (Interim maintenance chemotherapy)|"Patients receive vincristine sulfate IV and escalating doses of methotrexate IV on days 1, 11, 21, 31, and 41; pegaspargase* IM or IV over 1-2 hours on days 2 and 22; and methotrexate IT on days 1 and 31. Patients with DS also receive leucovorin calcium PO 48 and 60 hours after each methotrexate IT dose (DS patients excluded as of 09/29/10).
~Note: *Patients with an allergy to pegaspargase receive Erwinia asparaginase on days 2, 4, 6, 8, 10, 12, 22, 24, 26, 28, 30, and 32."
11627058|NCT00408005|Active Comparator|Group I Arm II (Consolidation chemotherapy)|Patients receive nelarabine IV over 60 minutes on days 1-5 and 43-47; methotrexate IT on days 15, 22, 57, and 64; cyclophosphamide IV over 30 minutes on days 8 and 50; cytarabine IV over 15-30 minutes or SC on days 8-11, 15-18, 50-53 and 57-60; mercaptopurine PO on days 8-21 and 50-63; vincristine sulfate IV on days 22, 29, 64, and 71; and pegaspargase IM or IV over 1-2 hours on days 22 and 64. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 15, 22-26, and 29-33 (DS patients excluded as of 09/29/10). (Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT QD on days 22-28 and 29-35. Patients with high risk T-LLy were either randomized to Arm I or Arm II. Patients with T-LLy who failed induction therapy were assigned to Arm II.
11627059|NCT00408005|Active Comparator|Group I Arm II (Delayed intensification chemotherapy)|Patients receive vincristine sulfate IV on days 1, 8, 15, and 50; dexamethasone IV or PO BID on days 1-21 (for patients < 10 years of age) OR on days 1-7 and 15-21 (for patients >= 10 years of age); doxorubicin hydrochloride IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6 AND day 50; methotrexate IT on days 1, 36, and 43; nelarabine IV over 60 minutes on days 29-33; cyclophosphamide IV over 30 minutes on day 36; cytarabine IV over 15-30 minutes or SC on days 36-39 and 43-46; and thioguanine PO on days 36-49.
11627060|NCT00408005|Active Comparator|Group I Arm II (Interim maintenance chemotherapy)|"Patients receive vincristine sulfate IV and escalating doses of methotrexate IV on days 1, 11, 21, 31, and 41; pegaspargase* IM or IV over 1-2 hours on days 2 and 22; and methotrexate IT on days 1 and 31.
~Note: *Patients with an allergy to pegaspargase receive Erwinia asparaginase on Monday, Wednesday and Friday for two consecutive weeks starting the day of asparaginase substitution."
11627061|NCT00408005|Active Comparator|Group I Arm II (Maintenance chemotherapy)|Patients receive vincristine sulfate, prednisone, mercaptopurine, methotrexate PO, methotrexate IT, and nelarabine in Cycles 1, 2 and 3. Patients then receive treatment (without nelarabine) as follows: vincristine sulfate, prednisone, mercaptopurine, methotrexate PO, and methotrexate IT as in arm II. Treatment (without nelarabine) repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 121) (for girls with T-ALL), and for those with T-LLY, and 3 years from the start of interim maintenance therapy (approximately week 173) (for boys with T-ALL).
11627171|NCT00406536|Active Comparator|1|
11627172|NCT00406536|Placebo Comparator|2|
11627173|NCT00406484|Experimental|1|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
11627174|NCT00406484|Active Comparator|2|Standard drug counseling
11627175|NCT00406471|Active Comparator|1|500 micrograms of ranibizumab
11627062|NCT00408005|Active Comparator|Group I Arm III (Consolidation chemotherapy)|Patients receive methotrexate IT on days 1, 8, 15, and 22; cyclophosphamide IV over 30 minutes on days 1 and 29; cytarabine IV over 15-30 minutes or SC on days 1-4, 8-11, 29-32, and 36-39; mercaptopurine PO on days 1-14 and 29-42; vincristine sulfate IV on days 15, 22, 43 and 50; and pegaspargase IM or IV over 1-2 hours on days 15 and 43. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 11-12, 15-19, and 22-26. (DS patients excluded as of 09/29/10.) Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT (1,200 cGy/dose) QD on days 15-21 and 22-28. Patients with low-risk disease do not undergo CRT.
11627063|NCT00408005|Active Comparator|Group I Arm III (Delayed intensification chemotherapy)|Patients receive vincristine sulfate IV on days 1, 8, 15, 43, and 50; dexamethasone IV or PO BID on days 1-21 (for patients < 10 years of age) OR on days 1-7 and 15-21 (for patients >= 10 years of age and for patients with DS); doxorubicin hydrochloride IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6, AND day 43; methotrexate IT on days 1, 29, and 36; cyclophosphamide IV over 30 minutes on day 29; cytarabine IV over 15-30 minutes or SC on days 29-32 and 36-39; and thioguanine PO on days 29-42. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose (DS patients excluded as of 09/29/10).
11627064|NCT00408005|Active Comparator|Group I Arm III (Interim maintenance chemotherapy)|Patients receive HDMTX IV over 24 hours and vincristine sulfate IV on days 1, 15, 29, and 43; mercaptopurine PO on days 1-56; and methotrexate IT on days 1 and 29. Beginning 42 hours after the start of HDMTX, patients also receive leucovorin calcium IV or PO once every 6 hours for 3 doses.
11627065|NCT00408005|Active Comparator|Group I Arm III (Maintenance chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; prednisone PO BID on days 1-5, 29-33, and 57-61; mercaptopurine PO QD on days 1-84; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; and methotrexate IT on day 1. Treatment repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 119) (for girls with T-ALL) and all patients with T-LLy, and 3 years from the start of interim maintenance therapy (approximately week 171) (for boys with T-ALL).
11627066|NCT00408005|Active Comparator|Group I Arm IV (Delayed intensification chemotherapy)|Patients receive vincristine sulfate IV on days 1, 8, 15, and 50; dexamethasone IV or PO BID on days 1-21 (for patients < 10 years of age) OR on days 1-7 and 15-21 (for patients >= 10 years of age); doxorubicin IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6 AND day 50; methotrexate IT on days 1, 36, and 43; nelarabine IV over 60 minutes on days 29-33; cyclophosphamide IV over 30 minutes on day 36; cytarabine IV over 15-30 minutes or SC on days 36-39 and 43-46; and thioguanine PO on days 36-49.
11627067|NCT00408005|Active Comparator|Group I Arm IV (Interim maintenance chemotherapy)|Patients receive HDMTX IV over 24 hours and vincristine IV on days 1, 15, 29, and 43; mercaptopurine PO on days 1-56; and methotrexate IT on days 1 and 29. Beginning 42 hours after the start of HDMTX, patients also receive leucovorin calcium IV or PO once every 6 hours for 3 doses.
11627068|NCT00408005|Active Comparator|Group I Arm IV (Maintenance chemotherapy)|Patients receive vincristine sulfate, prednisone, mercaptopurine, methotrexate PO, methotrexate IT, and nelarabine in Cycles 1, 2 and 3. Patients then receive treatment (without nelarabine) as follows: vincristine, prednisone, mercaptopurine, methotrexate PO, and methotrexate IT as in arm II. Treatment (without nelarabine) repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 121) (for girls with T-ALL), and for those with T-LLY, and 3 years from the start of interim maintenance therapy (approximately week 173) (for boys with T-ALL).
11627069|NCT00407992|Experimental|Occipital nerve stimulation ON|
11627070|NCT00407992|Other|Occipital nerve stimulation OFF|
11627071|NCT00407979||People with Atopic Dermatitis|
11627072|NCT00407979||People with Psoriasis|
11627073|NCT00407979||Generally healthy people|
11627074|NCT00407979||People with Atopic Dermatitis and Eczema Herpeticum|
11627075|NCT00407966|Experimental|Treatment (alvocidib, cytarabine, mitoxantrone hydrochloride)|"Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Beginning 35-63 days after completion of course 1, patients achieving complete or partial remission may receive a second course of treatment as above.
~Patients age 50 and over with core binding factor acute myeloid leukemia (AML) (e.g., t[8;21], inv[16], or t[16;16]) achieving a complete remission after course 1 of treatment may receive 3-4 courses of consolidation therapy comprising high-dose cytarabine at the discretion of the investigator."
11627076|NCT00407914|Experimental|1|Aquamid
11627077|NCT00407914|Active Comparator|2|Restylane
11627078|NCT00407901||A, B|A: High functioning visually challenged (legally blind) B: Low-functioning visually challenged (legally blind)
11627079|NCT00407888|Experimental|Arm I|Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 week later, patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity.
11627080|NCT00407875|Active Comparator|Permanent interstitial prostate brachytherapy (PIPB)|patient will undergo permanent interstitial prostate brachytherapy (PIPB) using a transperineal approach to deliver 125Iodine Rapidstrand® seeds at the facilities of the British Columbia Cancer Agency (BCCA) by one or more of the certified prostate brachytherapists in the BCCA Prostate Brachytherapy Program. The minimum peripheral dose (MPD) to the prostate gland of the implant will be 144 Gy as per TG 43 protocol. A modified peripheral loading technique will be utilized in an effort to maintain the periurethral dose to < 150% of the MPD. Within 48 hours of the implant, the patient will undergo a day 0 CT scan of the pelvis to assess post implant dosimetry using the standard BCCA protocol.
11627176|NCT00406471|Active Comparator|2|300 microgram ranibizumab
11627177|NCT00406458|Experimental|SB-509|60 mg SB-509 injected IM into lower limbs every 2 months
11627178|NCT00406458|Placebo Comparator|Normal Saline|Normal saline injected IM into lower limbs every 2 months
11627081|NCT00407875|Experimental|Intensity modulated external beam radiation therapy (IMRT)|patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) to a volume encompassing the prostate gland. The total radiation dose will be 70 Gy delivered in 28 fractions, so that the minimum dose to the PTV is 70 Gy, with CT simulation used for planning the treatment. Prior to starting the course of IMRT, fiducial markers will be placed in the prostate to assist in localization of the prostate for planning and quality assurance during treatment.
11627082|NCT00407836|Experimental|Vaccination|One arm of open label T cell vaccination in which all participants will receive the T cell vaccine
11627083|NCT00407797|Experimental|Pregabalin|
11627084|NCT00407745|Placebo Comparator|matched placebo|
11627085|NCT00407745|Experimental|pregabalin|flexible dosing over 4 weeks followed by 12 weeks maintenance and one week taper period
11627086|NCT00407732|No Intervention|SC|standard care
11627087|NCT00407732|Experimental|INT|psychosocial intervention
11627088|NCT00407667|Experimental|1|patients receive 20 min of anodal transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
11627089|NCT00407667|Experimental|2|patients receive 20 min of cathodal transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
11627090|NCT00407667|Sham Comparator|3|patients receive 20 min of sham transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
11627091|NCT00407654|Experimental|Arm I|Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
11627092|NCT00407641|Experimental|Tinzaparin|Patients will receive Tinzaparin as anticoagulant during the HD session.
11627093|NCT00407641|Active Comparator|Heparin|Patients will receive Heparin as an anticoagulant during the HD session
11627094|NCT00407602|Active Comparator|Implant of Argus II Retinal Prosthesis|This is a single group study where the status and performance of the implanted eye prior to surgery serves as the comparator.
11627095|NCT00407589|Experimental|BOL-303224-A|Systemic exposure of BOL-303224-A following single and multiple topical doses
11627096|NCT00407550|Experimental|Gemzar x2|Treat subjects with 2 dosings/cycle of Gemzar x6 cycles.
11627097|NCT00407550|Experimental|Gemzar x1|Treat subjects with 1 dosing/cycle of Gemzar x9 cycles.
11627098|NCT00407537|Experimental|Caduet|Open label caduet added to usual care regimen followed by investigators.
11627099|NCT00407511|Experimental|Pregabalin|
11627100|NCT00407485|Experimental|Treatment (ziv-aflibercept)|Patients receive 4 mg/kg VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
11627101|NCT00407420|Experimental|Mandometer|Active intervention - one meal eaten per day off Mandometer
11627102|NCT00407420|Active Comparator|Control|Nutritional and activity advice alone
11627103|NCT00407381|Experimental|Ranibizumab|Ranibizumab (RBZ) intravitreal injection alone
11627104|NCT00407381|Active Comparator|Laser|Laser photocoagulation
11627105|NCT00407381|Experimental|Laser with Ranibizumab|Laser following intravitreal injection of RBZ
11627106|NCT00407355|Active Comparator|RBZ 0.3|RBZ at the 0.3 mg dose intravitreal injection
11627107|NCT00407355|Active Comparator|RBZ 0.5|RBZ dose level .5 for ITV injection
11627108|NCT00407303|Experimental|1|30mg obatoclax, 1.0mg/m2 bortezomib
11627109|NCT00407303|Experimental|2|obatoclax 30 mg, bortezomib 1.3 mg/m2
11627110|NCT00407303|Experimental|3|Obatoclax 45 mg, Bortezomib 1.3 mg/m2
11627111|NCT00407277|Experimental|1A|
11627112|NCT00407277|Placebo Comparator|1B|
11627113|NCT00407277|Experimental|2A|
11627114|NCT00407186|Experimental|1chemoradiotherapy|5 weeksadjuvant treatment; radiotherapy and concomitant chemotherapy with cisplatin and capecitabine.
11627115|NCT00407186|Active Comparator|2chemotherapy|3 adjuvant courses epirubicin, cisplatin, capecitabine.
11627116|NCT00407173|Experimental|1|HCV-796 1000mg single dose
11627117|NCT00407160||Group 1 Standard Immunosuppression|"Anti-thymocyte Globulin (Rabbit)] ,tacrolimus, mycophenolate mofetil and prednisone
~Patients with End Stage Renal Disease (ESRD) and high Panel Reactive Antibody (PRA) who randomize to the control group. These patients will get induction therapy prior to transplant with Thymoglobulin 1.5 mg/kg/day for 4 days to a total dose of 6mg/kg.
~They will receive maintenance immunosuppression with three drugs : tacrolimus, cellcept and prednisone."
11627118|NCT00407160||Group 2 Campath Immunosuppression|"Alemtuzumab,tacrolimus
~Patients with ESRD and high PRA who randomize to the study group. These patients will get induction therapy prior to reperfusion of the kidney, during the transplant operation, with Campath (Alemtuzumab) 30mg, one dose. They will receive maintenance immunosuppression with tacrolimus alone (monotherapy)."
11627119|NCT00407147|No Intervention|Control|Standard treatment
11627120|NCT00407147|Experimental|PCT|PCT guided arm
11627121|NCT00407095|Experimental|1|
11627122|NCT00407082|Experimental|Fluocinolone acetonide 0.59mg|Fluocinolone acetonide ocular implant 0.59mg
11627123|NCT00407082|Experimental|Fluocinolone acetonide 2.1mg|Fluocinolone acetonide ocular implant 2.1mg
11627124|NCT00407082|No Intervention|No intervention|Fellow eye
11627125|NCT00407069||Active Atopic Dermatitis (AD)|Pediatric and adult subjects who fulfill the criteria for AD, a chronic inflammatory skin disease.
11627126|NCT00407069||Inactive Atopic Dermatitis (AD)|Adult subjects with a prior history of active AD that has been quiescent for at least 1 year.
11627127|NCT00407069||Psoriatics|Adult subjects who fulfill the criteria for plaque psoriasis, a chronic inflammatory skin disease.
11627128|NCT00407069||Asthmatics (without a history of AD)|Adult subjects who fulfill the criteria for asthma (reactive airway disease) and have a negative history of skin disease.
11627129|NCT00407069||Eczema Herpeticum (EH|Pediatric and adult AD subjects with a history of EH.
11627130|NCT00407069||Healthy Volunteers|Healthy individuals with no history of skin or respiratory disease.
11627179|NCT00406445||carrier LFS family members|96 carrier LFS family members
11627180|NCT00406445||non-carrier LFS family members or normal|60 non-carrier LFS family members or normal
11627181|NCT00406445||non-carrier mitochondrial disorder family members or normal co|20 non-carrier mitochondrial disorder family members or normal controls
11627131|NCT00407030|Experimental|incobotulinumtoxinA (Xeomin) (240 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 240 units, total volume 4.8mL; Mode of administration: intramuscular injection"
11627132|NCT00407030|Experimental|incobotulinumtoxinA (Xeomin) (120 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 120 units, total volume 4.8 mL; Mode of administration: intramuscular injection"
11627133|NCT00407030|Placebo Comparator|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 4.8 mL; Mode of administration: intramuscular injection
11627134|NCT00406978|Experimental|MPTD|
11627135|NCT00406913|Experimental|Mupirocin ointment|
11627136|NCT00406913|Active Comparator|Standard of Care sterilization|
11627137|NCT00406848|Experimental|Duloxetine|
11627138|NCT00406848|Placebo Comparator|Placebo|
11627139|NCT00406809|Experimental|Phase 1a and 1b|Relapsed or refractory lymphoid malignancies
11627140|NCT00406809|Experimental|Arm A (Phase 2a)|Relapsed or refractory follicular lymphoma
11627141|NCT00406809|Experimental|Arm B (Phase 2a)|Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma
11627142|NCT00406809|Experimental|Extension Study|Relapsed or refractory follicular lymphoma or Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma
11627143|NCT00406796|Active Comparator|1|0.5mg Ranibizumab
11627144|NCT00406796|Active Comparator|2|0.3mg Ranibizumab
11627145|NCT00406783|Experimental|5-mg Desloratadine tablet|
11627146|NCT00406783|Placebo Comparator|Placebo tablet|
11627147|NCT00406757|Active Comparator|Pediatric Arm 1|"Cycle 1: Nelarabine 400mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.
~Cycle 2 and subsequent Cycles: Nelarabine 650mg2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose."
11627148|NCT00406757|Active Comparator|Pediatric Arm 2|Cycle 1 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.
11627149|NCT00406757|Active Comparator|Adult Arm 1|"Cycle 1: Nelarabine 1000mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.
~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose."
11627150|NCT00406757|Active Comparator|Adult Arm 2|Cycle 1 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.
11627151|NCT00406757|Active Comparator|Pediatric Arm 3|Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
11627152|NCT00406718|Experimental|PharmCAT|Participants will receive PharmCAT in addition to Treatment as usual, Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
11627153|NCT00406718|Active Comparator|Med-eMonitor|Participants will receive Med-eMonitor™ in addition to treatment as usual. Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
11627154|NCT00406718|Active Comparator|Treatment as Usual|Participants will receive standard treatment as usual which is medication management and limited case management provided by the CMHC.
11627155|NCT00406692|Experimental|Zonisamide|In open-label non-placebo controlled trial subjects are treatment with zonisamide 400 mg during the maintenance phase of this study
11627156|NCT00406679|Experimental|1|
11627157|NCT00406679|Placebo Comparator|2|
11627158|NCT00406679|Active Comparator|3|
11627159|NCT00406653|Experimental|1|"4 arms for induction period
~2 arms for maintenance period"
11627160|NCT00406653|Placebo Comparator|2|"4 arms for induction period
~2 arms for maintenance period"
11627161|NCT00406653|Other|abatacept|1 arm for open-label extension phase
11627162|NCT00406640|Active Comparator|A|
11627163|NCT00406640|Active Comparator|B|
11627164|NCT00406614|Experimental|1|Literacy-focused high blood pressure intervention. The intervention group will receive the health literacy -focused hypertension management intervention that will be delivered through 6 weeks of highly interactive group sessions in a classroom setting, followed by telephone counseling once a month for 12 months. Also, the intervention group will concurrently use home blood pressure monitoring with telephone transmission for 12 months.
11627165|NCT00406614|Active Comparator|2|Wait-list control group will initially receive usual care from a regular medical provider. Participants in the control group will take part in the intervention once the study has been completed.
11627166|NCT00406588|Experimental|1|
11627167|NCT00406588|Placebo Comparator|2|
11627168|NCT00406575|Placebo Comparator|Placebo|Participants receive diluent via continuous IV infusion for 48 hours.
11627169|NCT00406575|Experimental|Low Dose rhRlx|Participants receive recombinant human relaxin (rhRlx) via continuous IV infusion for 48 hours at a rate of 100 µg/kg/day (corresponding to a dose of 4.2 µg/kg/hr).
11627170|NCT00406575|Experimental|High Dose rhRlx|Participants receive recombinant human relaxin (rhRlx) via continuous IV infusion for 48 hours at a rate of 500 µg/kg/day (corresponding to a dose of 21.0 µg/kg/hr).
11627182|NCT00406445||normal controls for MR spectroscopy study|30 normal controls for MR spectroscopy study
11627183|NCT00406445||subjects with mitochondrial disorders|20 subjects with mitochondrial disorders
11627184|NCT00406432|Experimental|Subjects receiving paroxetine|Eligible subjects will receive single dose of paroxetine 25 milligrams controlled release formulation followed by wash-out period of 5 days. Subjects will receive multiple doses of paroxetine 25 milligrams for further 14 days.
11627185|NCT00406419|Placebo Comparator|Placebo × 2 IV + MTX|Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.
11627186|NCT00406419|Experimental|Ocrelizumab 200 mg × 2 IV + MTX|Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
11627187|NCT00406419|Placebo Comparator|Ocrelizumab 500 mg × 2 IV + MTX|Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
11627188|NCT00406393|Active Comparator|Tacrolimus/Methotrexate|Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.
11627189|NCT00406393|Experimental|Tacrolimus/Sirolimus|Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.
11627190|NCT00406367|Experimental|incobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to 50 Units per eye; Open-Label Extension Period: up to 5 injections, up to 50 Units per eye per injection session; Mode of administration: intramuscular injection"
11627191|NCT00406367|Placebo Comparator|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
11627192|NCT00406354|Experimental|Atomoxetine Fast Titration|0.5 milligram per kilogram (mg/kg) daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 8 weeks
11627193|NCT00406354|Experimental|Atomoxetine Slow Titration|0.5 mg/kg daily dose taken orally for 1 week, then 0.8 mg/kg daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 7 weeks
11627194|NCT00406354|Placebo Comparator|Placebo|matching placebo daily dose taken orally
11627195|NCT00406315|Other|A1|atypical antipsychotic for the treatment of schizophrenia
11627196|NCT00406276|Experimental|RAD001+Docetaxel|RAD001 in combination with Docetaxel.
11627197|NCT00406250|Experimental|Bevacizumab|
11627198|NCT00406237|Experimental|1|
11627199|NCT00406133|No Intervention|Standard intensive glucose monitoring|Patients in the control group were given blood glucose meters and test strips and asked to perform home blood glucose monitoring at least four times daily.
11627200|NCT00406133|Active Comparator|Continuous Glucose Monitoring (CGM)|Patients in the CGM group were instructed to use the CGM device on a daily basis and to verify the accuracy of the glucose measurement with a home blood glucose meter (provided by the study) before making management decisions (as per the regulatory labeling of the devices).
11627201|NCT00406107|Active Comparator|Pegaptanib Sodium 0.3mg (Macugen)|Intravitreous injections of Macugen 0.3mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.
11627202|NCT00406107|Active Comparator|Pegaptanib Sodium 1 mg (Macugen)|Intravitreous injections of Macugen 1.0mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.
11627203|NCT00406094|Experimental|1|montelukast
11627204|NCT00406094|Placebo Comparator|2|placebo
11627205|NCT00406081||Participants with AD|Children with AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit (including a group of AD subjects with eczema herpeticum)
11627206|NCT00406081||Nonatopic controls|Children without AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit
11627207|NCT00406068|Experimental|Mycobacterial cell wall-DNA complex|Mycobacterial cell wall-DNA complex
11627208|NCT00406055||1|Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
11627209|NCT00406029|Experimental|Preladenant 1 mg BID|Participants received preladenant 1 mg twice daily (BID) during the 12-week treatment period.
11627210|NCT00406029|Experimental|Preladenant 2 mg BID|Participants received preladenant 2 mg BID during the 12-week treatment period.
11627211|NCT00406029|Experimental|Preladenant 5 mg BID|Participants received preladenant 5 mg BID during the 12-week treatment period.
11627212|NCT00406029|Experimental|Preladenant 10 mg BID|Participants received preladenant 10 mg BID during the 12-week treatment period.
11627213|NCT00406029|Placebo Comparator|Placebo BID|Participants received preladenant matching placebo BID during the 12-week treatment period.
11627214|NCT00406016|Experimental|1|
11627215|NCT00406003|Experimental|Subjects receiving treatment sequence ABC|Eligible subjects will receive treatment sequence ABC; A= paroxetine 12.5 milligrams, B= paroxetine 25 milligrams, and C= paroxetine 37.5 milligrams separated by a wash-out period of 10 days.
11627216|NCT00406003|Experimental|Subjects receiving treatment sequence BAC|Eligible subjects will receive treatment sequence BAC; B= paroxetine 25 milligrams, A= paroxetine 12.5 milligrams and C= paroxetine 37.5 milligrams separated by a wash-out period of 10 days.
11627217|NCT00406003|Experimental|Subjects receiving treatment sequence CBA|Eligible subjects will receive treatment sequence CBA; C= paroxetine 37.5 milligrams, B= paroxetine 25 milligrams and A= paroxetine 12.5 milligrams separated by a wash-out period of 10 days.
11627218|NCT00406003|Experimental|Subjects receiving treatment sequence BCA|Eligible subjects will receive treatment sequence BCA; B= paroxetine 25 milligrams, C= paroxetine 37.5 milligrams and A= paroxetine 12.5 milligrams separated by a wash-out period of 10 days.
11627439|NCT00403611|Experimental|Praziquantel 60mg/kg|Praziquantel (Distocide) 60mg/kg single oral dose
11627674|NCT00401401|Experimental|Zalutumumab 12 mg/kg|Zalutumumab 8 weekly infusions
11627219|NCT00406003|Experimental|Subjects receiving treatment sequence CAB|Eligible subjects will receive treatment sequence CAB; C= paroxetine 37.5 milligrams, A= paroxetine 12.5 milligrams and B= paroxetine 25 milligrams separated by a wash-out period of 10 days.
11627220|NCT00406003|Experimental|Subjects receiving treatment sequence ACB|Eligible subjects will receive treatment sequence ACB; A= paroxetine 12.5 milligrams, C= paroxetine 37.5 milligrams and B= paroxetine 25 milligrams separated by a wash-out period of 10 days.
11627221|NCT00405977|Placebo Comparator|Physiologic saline|
11627222|NCT00405977|Active Comparator|Magnesium sulphate|
11627223|NCT00405964|Experimental|5-mg Desloratadine tablet|
11627224|NCT00405964|Placebo Comparator|Placebo tablet|
11627225|NCT00405951|Experimental|Obatoclax Mesylate + Docetaxel|Obatoclax Mesylate 250mL in combination with Docetaxel
11627226|NCT00405938|Experimental|Bevacizumab/anastrozole|Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] and anastrozole (1 mg orally daily). Treatment will be given in 4-week cycles.
11627227|NCT00405938|Experimental|Bevacizumab/fulvestrant|Bevacizumab/fulvestrant (with trastuzumab in HER2+ patients). Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant). Treatment will be given in 4-week cycles.
11627228|NCT00405925|Active Comparator|combivir/kaletra|All patients started with combivir/Kaletra and were randomized if they reached undetectable viral load (2 times) within 24 weeks into continuation of the same regimen or Trizivir (2 arms)
11627229|NCT00405925|Experimental|Trizivir|patients who reach undetectable HIV-RNA within 24 weeks are randomized to switch to trizivir or continuation of combivir/kaletra
11627230|NCT00405912|Placebo Comparator|Placeo|Placebo pill was identical in appearance to the active medication.
11627231|NCT00405912|Experimental|St. John's Wort-900 mg/day|St. John's Wort - 300 mg tablets, 3 times a day.
11627232|NCT00405912|Experimental|St. John's Wort-1800 mg/day|St. John's Wort - 600 mg 3 times per day
11627233|NCT00405899||Immunotherapy|Patients starting immunotherapy
11627234|NCT00405899||Non-immunotherapy|Patients being treated using methods other than immunotherapy
11627235|NCT00405886|Experimental|Neramexane 25mg/d|
11627236|NCT00405886|Experimental|Neramexane 50mg/d|
11627237|NCT00405886|Experimental|Neramexane 75mg/d|
11627238|NCT00405886|Placebo Comparator|Placebo|
11627239|NCT00405873|Experimental|AMT2003|
11627240|NCT00405821|Active Comparator|Acyclovir 400mg tablet twice daily|
11627241|NCT00405821|Placebo Comparator|Placebo tablet twice daily|
11627242|NCT00405808|Experimental|1|Administration of one tablet containing 20 mg of Rimonabant
11627243|NCT00405808|Placebo Comparator|2|Administration of one Rimonabant placebo tablet.
11627244|NCT00405782|Active Comparator|Immediate Exercise Group|Exercise Intervention begins immediately
11627245|NCT00405782|Active Comparator|Delayed Exercise Group|Exercise intervention delayed by 16 weeks
11627246|NCT00405769|Placebo Comparator|1|placebo control
11627247|NCT00405769|Active Comparator|2|red yeast rice
11627248|NCT00405756|Experimental|MPR+R|Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
11627249|NCT00405756|Experimental|MPR+p|Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
11627250|NCT00405756|Other|MPp+p|Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
11627251|NCT00405743|Experimental|Arm A|CP4055, 2 and 4 hour IV infusion
11627252|NCT00405743|Experimental|Arm B|CP-4055, Continuous IV infusion
11627253|NCT00405730|Experimental|Nepafenac|One drop in the study eye 3 times daily for 23 days
11627254|NCT00405730|Active Comparator|Ketorolac Trometamol|One drop in the study eye 3 times daily for 23 days
11627255|NCT00405730|Placebo Comparator|Nepafenac Vehicle|One drop in the study eye 3 times daily for 23 days
11627256|NCT00405704|Active Comparator|Trimethoprim-Sulfamethoxazole|Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
11627257|NCT00405704|Placebo Comparator|Placebo|Cherry-flavored liquid suspension matched to active comparator.
11627258|NCT00405678|Experimental|1|Subjects receiving chemo and exercise training
11627259|NCT00405678|Experimental|2|Subjects receiving chemo only
11627260|NCT00405665|Experimental|1|
11627261|NCT00405665|Experimental|2|
11627262|NCT00405652|Experimental|Enteric-coated Mycophenolate sodium|Enteric-coated Mycophenolate sodium (EC-MPS), administered orally twice a day to achieve a dose equimolar to the dose of Mycophenolate mofetil (MMF) the patient was taking at the time of study entry up to a maximum dose of 1440 mg.
11627263|NCT00405639|Active Comparator|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is >90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
11627576|NCT00402337|Active Comparator|72 ug linaclotide acetate|
11627264|NCT00405639|Placebo Comparator|Placebo|Subjects randomized to this arm will receive self administered SQ placebo (normal saline) injections to match those of the study drug group. That is, first dose on Day 1, second dose 12 hours after the first dose, third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
11627265|NCT00405600|Active Comparator|Device|Device used in surgery with or without instrumentation
11627266|NCT00405587|Experimental|PLX4032|Open-label, sequential dose escalation
11627267|NCT00405574|Experimental|High Dose|ATN-224 dose 300mg
11627268|NCT00405574|Experimental|Low Dose|ATN-224 dose: 30mg
11627269|NCT00405561|Experimental|AMT2003|
11627270|NCT00405548|Active Comparator|BNP (nesiritide)|BNP 10 micrograms/Kg twice per day given subcutaneously for 12 weeks
11627271|NCT00405548|Placebo Comparator|Placebo|Saline solution given subcutaneously twice per day for 12 weeks (packaged to match active comparator)
11627272|NCT00405535|Experimental|A|glycine powder
11627273|NCT00405535|Placebo Comparator|B|placebo powder
11627274|NCT00405522|Experimental|Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg|
11627275|NCT00405522|Experimental|Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg|
11627276|NCT00405509||Confirmed respiratory virus|
11627277|NCT00405509||Unconfirmed respiratory infection|
11627278|NCT00405483|Active Comparator|Minimally invasive exposure|Surgical technique, minimal incision
11627279|NCT00405483|Active Comparator|Standard exposure|Standard Incision
11627280|NCT00405470|Active Comparator|Medial Pivot|
11627281|NCT00405470|Active Comparator|Posterior Stabilized|
11627282|NCT00405457|Other|A|
11627283|NCT00405444|Experimental|1|
11627284|NCT00405444|Placebo Comparator|2|
11627285|NCT00405431|Active Comparator|1|Patients received restasis eyedrops during 6 month post-operative period
11627286|NCT00405431|Placebo Comparator|2|Patients receive artificial tears (Endura) during 6 month post-operative period
11627287|NCT00405418|Experimental|1|Insulin Glargine
11627288|NCT00405418|Active Comparator|2|Insulin Detemir
11627289|NCT00405405|Experimental|Treatment|A combination of Cisplatin, Docetaxel, Bevacizumab, Erlotinib, and Radiotherapy
11627290|NCT00405366|Other|Single Arm Study|
11627291|NCT00405353|Experimental|crossover treatment with Androgel|6 months pretreatment, 12 months treatment intervention with Androgel 10 grams of gel containing 100mg of testosterone
11627292|NCT00405340|Experimental|Drug|Rituximab
11627293|NCT00405327|Experimental|DC vaccine therapy|Tumor lysate-pulsed dendritic cell (DC) vaccine following HSCT
11627294|NCT00405301|Other|Arm 1|Arm 1: will receive Isoniazide(5mg/kg/day), Rifampicin(10mg/kg/day) and Pyrazinamide(25mg/kg/day) in full doses on day 1 and continued further
11627295|NCT00405301|Other|Arm 2|Arm 2 : will receive Rifampicin(10mg/kg/day) in full dose on day 1 and continued, Isoniazide(5mg/kg/day)in full dose on day 8 and continued, Pyrazinamide(25mg/kg/day)on day 15 and continued
11627296|NCT00405301|Other|Arm 3|Arm 3 will receive 100 mg/day of Isoniazide on day 1 which is gradually increased to maximum dose (5mg/kg/day) by day 4 and continued. Rifampicin is introduced on day 8 in a dose of 150 mg/day which is gradually increased to maximum dose (10mg/kg/day) by day 11 and continued. Pyrazinamide is introduced on day 15 in a dose of 500mg/day which is gradually increased to maximum dose (25mg/kg/day) by day 18 and continued.
11627297|NCT00405288||Proctofoam-HC®|Women in the third trimester of pregnancy prescribed Proctofoam-HC® aerosol foam canister for 36 applications for treatment of symptoms of hemorrhoids. One applicatorful is to be applied into the anus (or on the perianal area) two or three times daily and after bowel evacuation.
11627298|NCT00405288||Control|Control group of women in the third trimester of pregnancy who were not exposed to any teratogens during the course of the pregnancy, and to Proctofoam-HC any of its components, or any other topical corticosteroids or local anaesthetics during the course of their pregnancy.
11627299|NCT00405275|Active Comparator|Arm 1|Etanercept and Methotrexate. Participants also received placebo hydroxychloroquine and sulfasalazine
11627300|NCT00405275|Active Comparator|Arm 2|Hydroxychloroquine, sulfasalazine and methotrexate. Participants also received placebo etanercept.
11627301|NCT00405262|Active Comparator|1|
11627302|NCT00405262|Experimental|2|
11627303|NCT00405262|Experimental|3|
11627304|NCT00405080|Experimental|Treatment Period 1|Subject will receive single oral dose of 150 milligram (mg) of Casopitant. There will be wash out period of 7 days.
11627305|NCT00405080|Experimental|Treatment Period 2|Subjects will receive rifampin 600 mg once daily on Days 1 - 9. On Day 8 subjects will receive a single dose of oral casopitant 150 mg along with rifampin.
11627306|NCT00405054|Other|1|continuous infusion every 14 days
11627307|NCT00405041|Experimental|A|
11627308|NCT00405015|Experimental|1|Placebo first
11627309|NCT00405015|Experimental|2|Rosiglitazone first
11627310|NCT00405002||1|ALI/ARDS patients
11627311|NCT00404924|Placebo Comparator|1|Best Supportive Care
11627312|NCT00404924|Experimental|2|Vandetanib + Best Supportive Care
11627313|NCT00404911|Experimental|MFG therapy|Participants will receive multi-family group therapy
11627314|NCT00404911|Active Comparator|Standard of Care|Participants will receive standard care
11627315|NCT00404885|Placebo Comparator|Placebo|
11627316|NCT00404885|Active Comparator|LX211, 0.2 mg/kg|
11627317|NCT00404885|Active Comparator|LX211, 0.4 mg/kg|
11627318|NCT00404885|Active Comparator|LX211, 0.6 mg/kg|
11627319|NCT00404820|Experimental|Zoledronic acid 5 mg|Patients received zoledronic acid 5 mg in 100 ml solution in a 15 minute intravenous (iv) infusion once per year. The peripheral iv infusion was preceded by and followed by a 10 ml normal saline flush of the intravenous line. In addition to study therapy, all participants received 1200 mg elemental calcium and 800 IU of vitamin D daily. Calcium and vitamin D were supplied in a chewable tablet that was to be taken twice daily.
11627577|NCT00402337|Active Comparator|145 ug linaclotide acetate|
11627578|NCT00402337|Active Comparator|290 ug linaclotide acetate|
11627579|NCT00402337|Active Comparator|579 ug linaclotide acetate|
11627320|NCT00404820|Active Comparator|Alendronate 70 mg|Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal. Patients were to remain in an upright position for 30 minutes after swallowing the tablet. In addition to study therapy, all participants received 1200 mg elemental calcium and 800 IU of vitamin D daily. Calcium and vitamin D were supplied in a chewable tablet that was to be taken twice daily.
11627321|NCT00404781|Experimental|optimal antiplatelet|cilostazol in addition to aspirin and clopdidogrel for pts with clopidogrel resistance
11627322|NCT00404781|Active Comparator|standard antiplatelet|aspirin and clopidogrel for all patients
11627323|NCT00404768|Experimental|Treatment|GSK221149A
11627324|NCT00404768|Placebo Comparator|Placebo|Placebo
11627325|NCT00404755|Experimental|escitalopram|escitalopram 10 mg/d for 1 week, then increasing by 10 mg/week if tolerated and not remitted to maximal dose of 40 mg/d
11627326|NCT00404755|Experimental|bupropion|bupropion extended release (XL) 150 mg/d for a week, then 300 mg/d for a week and then 450 mg/d; all dose increases if tolerated and not remitted
11627327|NCT00404755|Experimental|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then by 50 mg/week to a maximum dose of 300 mg/d; all dose increases if tolerated and not remitted
11627328|NCT00404742|Placebo Comparator|Placebo|
11627329|NCT00404742|Active Comparator|LX211, 0.2 mg/kg|
11627330|NCT00404742|Active Comparator|LX211, 0.4 mg/kg|
11627331|NCT00404742|Active Comparator|LX211, 0.6 mg/kg|
11627332|NCT00404703|Experimental|1|
11627333|NCT00404690|Active Comparator|1|Operative attempt at closure
11627334|NCT00404690|Experimental|2|bedside silo
11627335|NCT00404677|Placebo Comparator|Standard|Methacholine challenges are performed using the standardized two minute tidal breathing method
11627336|NCT00404677|Active Comparator|Modified|Five deep inhalation maneouvers are incorporated into the standardized methacholine challenge
11627337|NCT00404651|Experimental|Group 1|Participants receive vaccine Batch A
11627338|NCT00404651|Experimental|Group 2|Participants receive vaccine Batch B
11627339|NCT00404651|Experimental|Group 3|Participants receive vaccine Batch C
11627340|NCT00404651|Active Comparator|Group 4|Participants receive Infanrix hexa™
11627341|NCT00404612|Placebo Comparator|Placebo|
11627342|NCT00404612|Active Comparator|LX211, 0.2 mg/kg|
11627343|NCT00404612|Active Comparator|LX211, 0.4 mg/kg|
11627344|NCT00404612|Active Comparator|LX211, 0.6 mg/kg|
11627345|NCT00404586|Experimental|Treatment period 1|In treatment period subjects will receive once daily 100 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
11627346|NCT00404586|Experimental|Treatment period 2|In treatment period subjects will receive once daily 200 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
11627347|NCT00404586|Experimental|Treatment period 3|In treatment period subjects will receive once daily 400 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
11627348|NCT00404586|Placebo Comparator|Treatment period 4|In treatment period subjects will receive once daily Placebo and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive Placebo and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
11627349|NCT00404560||healthy blood relatives|relatives not ill with a known or suspected infection susceptibility syndrome
11627350|NCT00404560||Patients|patients who either have, or are suspected of having, an infection or infection susceptibility in order to further characterize such conditions
11627351|NCT00404547|Active Comparator|Alvesco|Alvesco 320mcg / Alvesco 640mcg
11627352|NCT00404547|Active Comparator|Usual Care|
11627353|NCT00404534|Experimental|1|Amoxicillin 1000 mg BID, clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
11627354|NCT00404534|Placebo Comparator|2|Placebo of Amoxicillin 1000 mg BID, placebo of clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
11627355|NCT00404521|Experimental|Arm 1|
11627356|NCT00404495|Experimental|Temozolomide + Irinotecan|
11627357|NCT00404469|Active Comparator|CORT|Peritendinous corticosteroid injections at 0 and 4 weeks. 12 weeks total
11627358|NCT00404469|Experimental|ECC|12 weeks of eccentric unilateral decline squats
11627359|NCT00404469|Experimental|HSR|Heavy slow resistance training. 3/week. 12 weeks
11627360|NCT00404443|Sham Comparator|1|arm 1: placebo needle
11627361|NCT00404430||Exacerbated COPD patients|Patients with exacerbated COPD
11627362|NCT00404430||Stable COPD patients|Patients with stable COPD
11627363|NCT00404417|Experimental|1|Botox/Placebo
11627364|NCT00404417|Experimental|2|Botox/Botox
11627365|NCT00404417|Experimental|3|Placebo/Botox
11627366|NCT00404417|Placebo Comparator|4|Placebo/Placebo
11627367|NCT00404391|Experimental|Arm 1: hydrocodone/acetaminophen extended release|
11627368|NCT00404391|Experimental|Arm 2: hydrocodone/acetaminophen extended release|
11627369|NCT00404391|Placebo Comparator|placebo|
11627370|NCT00404378|Experimental|Cohort 1 Treatment Period 1|Subjects will receive single oral dose of 100 milligram (mg) of Casopitant. There will be wash out period of 7 days.
11627371|NCT00404378|Experimental|Cohort 1 Treatment Period 2|Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 100 mg along with ketoconazole.
11627372|NCT00404378|Experimental|Cohort 2 Treatment Period 1|Subjects will receive single oral dose of 50 mg of Casopitant. There will be wash out period of 7 days.
11627373|NCT00404378|Experimental|Cohort 2 Treatment Period 2|Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 50 mg along with ketoconazole.
11627580|NCT00402337|Placebo Comparator|Matching Placebo|
11627581|NCT00402324|Experimental|1|olanzapine and divalproex
11627582|NCT00402324|Placebo Comparator|2|placebo and divalproex
11627374|NCT00404365|Experimental|Arm I (control)|Arm I (control): Patients complete screening questionnaires about their mood and experience with lung cancer once before and once after a visit with their physician. Neither the patient nor physician receives the screening results before the visit.
11627375|NCT00404365|Experimental|Arm II|Arm II: Patients complete screening questionnaires as in arm I. Only the patient receives the screening results before their visit with the physician; the physician remains blinded to the results.
11627376|NCT00404365|Experimental|Arm III|Arm III: Patients complete screening questionnaires as in arm I. Only the physician receives the screening results before their visit with the patient; the patient remains blinded to the results.
11627377|NCT00404365|Experimental|Arm IV|"Arm IV: Patients complete screening questionnaires as in arm I. Both physician and patient receive the screening results before the visit.
~All patients and physicians are notified of the screening results before the patient leaves the clinic. All patients are offered supportive counseling."
11627378|NCT00404352|Active Comparator|RNF 44 mcg three times weekly|
11627379|NCT00404352|Active Comparator|RNF 44 mcg once weekly and placebo twice weekly for blinding|
11627380|NCT00404352|Placebo Comparator|Placebo three times weekly|
11627381|NCT00404313|Experimental|1|MK0633 10 mg
11627382|NCT00404313|Experimental|2|MK0633 50 mg
11627383|NCT00404313|Experimental|3|MK0633 100 mg
11627384|NCT00404313|Placebo Comparator|4|placebo
11627385|NCT00404287|Active Comparator|fluvastatin|fluvastatin 80 mg
11627386|NCT00404287|Placebo Comparator|placebo|
11627387|NCT00404274|Experimental|Treatment regimen A|In treatment regimen A subject will co-administer casopitant and warfarin over three-day period (Day 1 150 milligram per day [mg/day], Day 2 50 mg/day, Day 3 50 mg/day) and from Days 4 to 10 subject will administer only warfarin.
11627388|NCT00404274|Experimental|Treatment regimen B|In treatment regimen B subject will co-administer casopitant 60 mg/day and warfarin for 14 days.
11627389|NCT00404274|Experimental|Treatment regimen C|In treatment regimen C subject will co-administer warfarin and casopitant 30 mg/day for 14 days.
11627390|NCT00404261|Other|Arm 1|Fluticasone/Salmeterol HFA MDI without counter
11627391|NCT00404261|Other|Arm 2|Fluticasone/Salmeterol HFA MDI with counter
11627392|NCT00404248|Active Comparator|With Enzyme-inducing antiseizure drugs (+EIASD)|"subjects on the +EIASD treatment arm were taking one of these antiseizure drugs: phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine.
~Subjects will take terameprocol for 5 consecutive days each month by IV. Starting dose is 750mg/day. Dose escalation is 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, and 9300. NO intrasubject dose escalation.
~PK (pharmacological study) data will be collected on day one of cycle one infusion"
11627393|NCT00404248|Active Comparator|With Non enzyme-inducing antiseizure drugs (-EIASD)|"Subjects in the -EIASD group were either not being treated with antiseizure drugs or were taking ones that did not significantly induce hepatic enzymes such as gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine, topiramate, zonisamide and felbamate.
~Subjects will take terameprocol for 5 consecutive days each month by IV. Starting dose is 750mg/day. Dose escalation is 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, and 9300. NO intrasubject dose escalation.
~PK (pharmacological study) data will be collected on day one of cycle one infusion"
11627394|NCT00404235|Experimental|paclitaxel + carboplatin|"Patients receive paclitaxel albumin-stabilized nanoparticle formulation (ABI-007) IV over 30 minutes followed by carboplatin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for at least 8 courses in the absence of disease progression or unacceptable toxicity.
~Blood and tumor tissue samples are collected periodically to evaluate secreted protein acidic and rich in cysteine (SPARC) content of tumor tissue by immunohistochemistry and to explore the impact of therapy on immune homeostasis. Samples are also analyzed by immunoenzyme techniques for angiogenesis markers.
~After completion of study treatment, patients are followed periodically for up to 2 years."
11627395|NCT00404222|Experimental|hydrocodone / acetaminophen extended release|
11627396|NCT00404222|Active Comparator|Hydrocodone/Acetaminophen Immediate Release (Norco ®)|
11627397|NCT00404222|Placebo Comparator|Placebo|
11627398|NCT00404183|Experimental|hydrocodone/acetaminophen extended release|
11627399|NCT00404183|Placebo Comparator|Placebo|
11627400|NCT00404170|Experimental|B-CIT and SPECT imaging|To assess B-CIT injection and SPECT scanning. Optional ongoing B-CIT SPECT imaging scans at follow-up visits
11627401|NCT00404144|Experimental|Drug Eluting Balloon|treatment of small vessel with drug eluting balloon
11627402|NCT00404092|Experimental|1st cohort|70mg caspofungin 1x/day
11627403|NCT00404092|Experimental|2nd cohort|100mg caspofungin 1x/day
11627404|NCT00404092|Experimental|3rd cohort|150mg caspofungin 1x/day
11627405|NCT00404092|Experimental|4th cohort|200mg caspofungin 1x/day
11627406|NCT00404079|Experimental|Glucosamine Sulphate|
11627407|NCT00404079|Placebo Comparator|Placebo|
11627408|NCT00404066|Experimental|Neoadjuvant Chemotherapy|Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles, followed by docetaxel + lapatinib for four 21-day cycles, followed by surgery. Dexamethasone was administered twice-a-day for 3 days, starting 24 hours before the docetaxel infusions. After surgery +/- radiation, participants may receive trastuzumab (Herceptin) for a year.
11627409|NCT00404014|Active Comparator|AL-208|1 dose of 300 mg
11627410|NCT00404014|Placebo Comparator|Placebo|
11627411|NCT00403949|Active Comparator|Azelaic acid 15% Gel|Azelaic acid 15%
11627412|NCT00403949|Placebo Comparator|Placebo|Non-active base from Azelaic acid 15% gel
11627413|NCT00403923||Patients with known lactose intolerance|
11627414|NCT00403897|Experimental|1|Ages 2 - 6: Day 1= 1 sachet/day; Day 3= 1 sachet BID; Day 5= 1 sachet TID Ages 7 - 11: Day 1= 1 sachet BID; Days 3 & 5 = 2 sachets BID;
11627415|NCT00403845|Experimental|Placebo-indacaterol 150μg-indacaterol 300μg-indacaterol 600μg|In treatment period, 1 patients received 2 placebo capsules; in treatment period 2, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; in treatment period 3, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; and in treatment period 4, patients received 2 indacaterol 300 μg capsules. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
11627416|NCT00403845|Experimental|Indacaterol 150μg-indacaterol 600μg-placebo-indacaterol 300μg|In treatment period 1, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; in treatment period 2, patients received 2 indacaterol 300 μg capsules; in treatment period 3, patients received 2 placebo capsules; and in treatment period 4, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
11627417|NCT00403845|Experimental|Indacaterol 300μg-placebo-indacaterol 600μg-indacaterol 150μg|In treatment period 1, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 2, patients received 2 placebo capsules; in treatment period 3, patients received 2 indacaterol 300 μg capsules; and in treatment period 4, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
11627418|NCT00403845|Experimental|Indacaterol 600μg-indacaterol 300μg-indacaterol 150μg-placebo|In treatment period 1, patients received 2 indacaterol 300 μg capsules; in treatment period 2, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 3, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; and in treatment period 4 patients received 2 placebo capsules. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
11627419|NCT00403806|Active Comparator|1|Intravenous dexamethasone 0.05 mg per kg bodyweight
11627420|NCT00403806|Active Comparator|2|Intravenous dexamethasone 0.15 mg per kg bodyweight
11627421|NCT00403806|Active Comparator|3|Intravenous dexamethasone 0.5 mg per kg bodyweight
11627422|NCT00403806|Placebo Comparator|4|Intravenous saline
11627423|NCT00403793|Active Comparator|Arm 1|etonogestrel with testosterone undecanoate
11627424|NCT00403793|Placebo Comparator|Arm 2|Placebo
11627425|NCT00403780|Active Comparator|A|Active intervention with pregabalin
11627426|NCT00403780|Placebo Comparator|B|placebo arm with capsule Lyrica Placebo
11627427|NCT00403767|Experimental|Rivaroxaban|
11627428|NCT00403767|Active Comparator|Warfarin|
11627429|NCT00403754|Experimental|Placebo-Ind 150 μg-Ind 300 μg-Ind 600 μg-Salmeterol|"In treatment period 1: patients received 2 placebo capsules; in treatment period 2: patients received 1 indacaterol (Ind) 150 μg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 indacaterol 300 μg capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.
~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
11627430|NCT00403754|Experimental|Ind 150 μg-Ind 600 μg-Placebo-Ind 300 μg-Salmeterol|"In treatment period 1: patients received 1 indacaterol (Ind) 150 μg capsule + 1 placebo capsule; in treatment period 2: patients received 2 indacaterol 300 μg capsules; in treatment period 3: patients received 2 placebo capsules; and in treatment period 4: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.
~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
11627431|NCT00403754|Experimental|Ind 300 μg-Placebo-Ind 600 μg-Ind 150 μg-Salmeterol|"In treatment period 1: patients received 1 indacaterol (Ind) 300 μg capsule + 1 placebo capsule; in treatment period 2: patients received 2 placebo capsules; in treatment period 3: patients received 2 indacaterol 300 μg capsules; and in treatment period 4: patients received 1 indacaterol 150 μg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation, device on Day 1.
~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
11627432|NCT00403754|Experimental|Ind 600 μg-Ind 300 μg-Ind 150 μg-Placebo-Salmeterol|"In treatment period 1: patients received 2 indacaterol (Ind) 300 μg capsules; in treatment period 2: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 placebo capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.
~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
11627433|NCT00403689|Experimental|x|capsules containing beta glycan
11627434|NCT00403689|Placebo Comparator|y|capsules containing placebo (waxy maize starch)
11627435|NCT00403676|Experimental|Follow up by nurse|Patient randomized for follow-up by a nurse
11627436|NCT00403676|Experimental|follow up by medical doctor|Patients randomized for follow up by a medical doctor
11627437|NCT00403650|Experimental|1|
11627438|NCT00403611|Active Comparator|Praziquantel 40mg/kg|Praziquantel (Distocide) 40mg/kg single oral dose
11627440|NCT00403546|Experimental|High-Dose Ziprasidone|Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take ziprasidone oral capsule twice daily added to their regular open-label ziprasidone dose (total of 240 mg/d). After the first week, the study drug will be increased to a total ziprasidone dose of 320 mg/d for 7 weeks.
11627441|NCT00403546|Placebo Comparator|Placebo, Standard Treatment Ziprasidone|Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take matching placebo oral capsule twice daily added to their regular open-label ziprasidone dose of 160 mg/d. After the first week, the matching placebo will be increased to two capsules twice daily and their regular open-label ziprasidone will remain the same (160 mg/d) for 7 weeks.
11627442|NCT00403520|Experimental|Experimental 1|
11627443|NCT00403520|Placebo Comparator|Placebo Comparator|
11627444|NCT00403507|No Intervention|Clean Control|Probable Alzheimer's disease in the context of no excluding medical conditions.
11627445|NCT00403507|No Intervention|CoMorbid Control|Probable Alzheimer's disease in the context of well-controlled comorbid medical conditions.
11627446|NCT00403507|Experimental|Clean Exercise|Probable Alzheimer's disease in the context no comorbid medical conditions.
11627447|NCT00403507|Experimental|CoMorbid Exercise|Probable Alzheimer's disease in the context of well-controlled comorbid medical conditions.
11627448|NCT00403494|Experimental|6R-BH4|800 mg/day of 6R-BH4, divided into two doses each day, for 24 weeks
11627449|NCT00403494|Placebo Comparator|Placebo|Placebo to be administered in the same manner as that of the investigational product, 6R-BH4
11627450|NCT00403494|Experimental|6R-BH4 + Vitamin C|800 mg/day of 6R-BH4, divided into two doses, plus 1000mg/day Vitamin C, divided into two doses, for 24 weeks
11627451|NCT00403494|Placebo Comparator|Placebo + Vitamin C|Placebo to be administered in the same manner as that of the investigational product, plus 1000mg/day Vitamin C, divided into two doses
11627452|NCT00403481|Experimental|Active treatment|Blood pressure (BP) measurements were taken every three weeks for 12 weeks. In accordance with their BP results, participants either stayed on their current medication or were started on the next higher regimen at the 3, 6, or 9 week visits. All participants began at 20 mg olmesartan, once daily for 3 weeks. The next higher regimen was olmesartan 40 mg, followed by olmesartan 40 mg + 12.5 mg hydrochlorothiazide, followed by olmesartan 40 mg + 25 mg of hydrochlorothiazide.
11627453|NCT00403455|Other|Paroxetine Arm|This is a single arm, single site, open-label clinical trial to treat veterans with PTSD. It is a 12-week trial to investigate the efficacy of paroxetine in reducing PTSD symptoms, with the primary outcome measure using CAPS. Genetic information is included to understand why some respond and some do not respond to paroxetine treatment.
11627454|NCT00403429|Experimental|Capecitabine|
11627455|NCT00403416|Active Comparator|Mycophenolic Acid / tacrolimus|
11627456|NCT00403416|Experimental|AEB071 / tacrolimus arm 1|
11627457|NCT00403416|Experimental|AEB071 / tacrolimus arm 2|
11627458|NCT00403403|Placebo Comparator|Placebo+Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide
11627459|NCT00403403|Experimental|Bevacizumab+Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide
11627460|NCT00403390|Experimental|Brand name levothyroxine (Synthroid)|Dose previously demonstrated to normalize thyroid function given daily for 2 months
11627461|NCT00403390|Active Comparator|Generic formulation of Levothyroxine|Dosage previously determined to normalize thyroid function given daily for 2 months
11627462|NCT00403377|Experimental|Intervention|Phase II include two arms. In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
11627463|NCT00403377|No Intervention|Control|Phase II include two arms. In the control arm, a souvenir photograph is taken of the participants and they then receive product samples that are irrelevant to skin cancer risk reduction (e.g., skin moisturizer, hair gel, chewing gum). Participants also receive educational materials at the completion of the study.
11627464|NCT00403351||ARM-CAD 1|Cross-sectional analysis using coronary angiogram results
11627465|NCT00403351||ARM-CAD 2|Prospective cohort for incident cardiovascular events and mortality
11627466|NCT00403286|Experimental|C 10/1|
11627467|NCT00403286|Experimental|C 5/2|
11627468|NCT00403286|Experimental|C 5/1|
11627469|NCT00403286|Experimental|FP 1000|
11627470|NCT00403286|Experimental|FF 20|
11627471|NCT00403286|Active Comparator|AD 250/50|
11627472|NCT00403286|Placebo Comparator|Plc|
11627473|NCT00403286|Experimental|C 10/2|
11627474|NCT00403273|Experimental|A|Single Intra-articular Injection of 100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
11627475|NCT00403273|Placebo Comparator|B|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
11627476|NCT00403260|Experimental|1|Pyronaridine artesunate (180:60 mg tablets)
11627477|NCT00403260|Active Comparator|2|Mefloquine plus artesunate
11627478|NCT00403247|Experimental|A|vitamin capsule
11627479|NCT00403247|Placebo Comparator|B|placebo capsule
11627480|NCT00403234|Experimental|BTDS 10|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
11627481|NCT00403234|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
11627482|NCT00403234|Experimental|BTDS 30|Buprenorphine transdermal patch 30 mcg/h applied for 7-day wear
11627483|NCT00403234|Placebo Comparator|Placebo TDS|Placebo patches were similar to BTDS 10 and 20.
11627484|NCT00403169|Experimental|Lenalidomide for Advanced RCC|25 mg/day Lenalidomide for 21 days per cycle.
11627485|NCT00403130|Experimental|Phase II 3-drug regimen|Gemcitabine + Paclitaxel + Bevacizumab
11627486|NCT00403117|Placebo Comparator|Placebo, Marijuana (0% THC)|During each session, one capsule containing placebo was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
11627635|NCT00401856|Placebo Comparator|2|This group will receive the placebo
11627792|NCT00400166|No Intervention|0|No Recovery Mentor, services as usual
11627487|NCT00403117|Experimental|Placebo, Marijuana (3.27% THC)|During each session, one capsule containing placebo was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
11627488|NCT00403117|Experimental|Naltrexone (12mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (12 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
11627489|NCT00403117|Experimental|Naltrexone (12mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (12 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
11627490|NCT00403117|Experimental|Naltrexone (25mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (25 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
11627491|NCT00403117|Experimental|Naltrexone (25mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (25 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
11627492|NCT00403117|Experimental|Naltrexone (50mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (50 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
11627493|NCT00403117|Experimental|Naltrexone (50mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (50 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
11627494|NCT00403117|Experimental|Naltrexone (100mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (100 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
11627495|NCT00403117|Experimental|Naltrexone (100mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (100 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
11627496|NCT00403104|Experimental|E|ONO-2506PO in the presence of Riluzole
11627497|NCT00403104|Placebo Comparator|P|Placebo in the presence of Riluzole
11627498|NCT00403091|Experimental|Intervention|
11627499|NCT00403091|Active Comparator|Control|
11627500|NCT00403052|Experimental|1|Low dose of 1018 ISS
11627501|NCT00403052|Experimental|2|Middle dose of 1018 ISS
11627502|NCT00403052|Experimental|3|High dose of 1018 ISS
11627503|NCT00403039|Other|Open-label ranibizumab|Subjects will receive open-label intravitreal injections of ranibizumab administered every 28 ± 7 days for a total of 3 injections. Thereafter they are to be evaluated monthly for re-treatment until Month 48.
11627504|NCT00403013|Experimental|1|lateral, head-down position during axillary plexus block
11627505|NCT00403013|Active Comparator|2|standard position during axillary plexus block
11627506|NCT00402987|Experimental|celecoxib 50 mg/50 mg|
11627507|NCT00402987|Experimental|celecoxib 100 mg/placebo|
11627508|NCT00402987|Experimental|celecoxib 100 mg/50 mg|
11627509|NCT00402987|Placebo Comparator|Placebo|
11627510|NCT00402961|Active Comparator|1|Acupuncture is the insertion of needles at certain body points.
11627511|NCT00402961|Sham Comparator|2|sham acupuncture
11627512|NCT00402948|Experimental|TPI ASM8|ASM8 0.25mg
11627513|NCT00402948|Experimental|ASM8 as TPI ASM8|TPI ASM8 0.5mg
11627514|NCT00402896|Experimental|ZD6474|300 mg/day orally for 10 weeks.
11627515|NCT00402883|Experimental|Intervention|Induction treatment included: carboplatin AUC=5, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg each administered intravenously weeks 1 and 4. Radiation was administered concurrently at a dose of 1.8 Gy/d weeks 1 to 7 to a total of 61.2 Gy per institutional guidelines. Consolidative therapy, following an 8-week break from chemoradiotherapy, included carboplatin AUC=6, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg each administered intravenously on week 16, repeated weeks 19 and 22. Folic acid (350 to 1,000 ug or equivalent) supplementation was administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinued study therapy. Vitamin B12(1,000ug) was administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinued therapy.
11627516|NCT00402857|Experimental|1|Participants will receive the Incredible Years Program, a group parenting intervention
11627517|NCT00402857|Other|2|Participants assigned to the waitlist condition will receive the Incredible Years Program after a 1-year waiting period
11627518|NCT00402831|Experimental|Intramuscular ProQuad®|Participants will receive doses of ProQuad® by IM injection on Day 1 and Day 30 into the deltoid muscle perpendicular to the skin, with the first dose in the right arm and the second dose in the left arm.
11627519|NCT00402831|Active Comparator|Subcutaneous ProQuad®|Participants will receive doses of ProQuad® by SC injection on Day 1 and Day 30 in the deltoid area at a 45° angle to the skin, with the first dose in the right arm and second dose in the left arm.
11627520|NCT00402792|Experimental|Arm 1: hydrocodone / acetaminophen extended release|
11627521|NCT00402792|Experimental|Arm 2: hydrocodone / acetaminophen extended release|
11627522|NCT00402792|Placebo Comparator|Arm 3: Placebo|
11627523|NCT00402779|Experimental|Erlotinib|Balanced randomization: Erlotinib 150 mg continuous administration for 1 year.
11627524|NCT00402779|Placebo Comparator|Placebo|Balanced randomization: Placebo continuous administration for 1 year.
11627793|NCT00400153|Experimental|COMBIVENT Respimat 20/100 mcg|
11627525|NCT00402766|Experimental|Cisplatin + Imatinib + Pemetrexed|Cisplatin 60 mg/m^2 by vein, Over 2 Hours. Imatinib 300 mg PO Daily. Pemetrexed 500 mg/m^2 by vein, Over 40 Minutes. Dexamethasone 20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
11627526|NCT00402753|Experimental|Group 1|Physical exercise group: Combined supervised physical activity: Endurance and Resistive strength
11627527|NCT00402753|No Intervention|Group 2|Usual care control group
11627528|NCT00402727|Experimental|Moxifloxacin|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
11627529|NCT00402727|Active Comparator|PIP/TAZ-AMC|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
11627530|NCT00402714|Active Comparator|1|Extracorporeal photopheresis, pentostatin and total body irradiation
11627531|NCT00402714|Active Comparator|2|Pentostatin and total body irradiation
11627532|NCT00402701|Experimental|1|Students in school with active walk-to-school promotion programs.
11627533|NCT00402701|No Intervention|2|Students in schools with access to standard school district transportation resources.
11627534|NCT00402688|Active Comparator|001|levofloxacin 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
11627535|NCT00402688|Active Comparator|002|levofloxacin 750mg tablet once daily for 3 weeks followed by 1 week of placebo.
11627536|NCT00402688|Active Comparator|003|levofloxacin 500mg tablet once daily for 4 weeks.
11627537|NCT00402675|Active Comparator|Immediate Intervention|Patients with NSTEMI undergo immediate invasive angiography (< 2 hours)
11627538|NCT00402675|Active Comparator|Early Intervention|Patients with NSTEMI undergo early invasive angiography (12-48 hours)
11627539|NCT00402675|Active Comparator|Selective invasive angiography|Patients with NSTEMI undergo selective invasive angiography
11627540|NCT00402649|Experimental|1|All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.
11627541|NCT00402636|Experimental|1|rapamycin plus 17beta estradiolvalerat-eluting stent
11627542|NCT00402636|Experimental|2|rapamycin-eluting stent
11627543|NCT00402623|Placebo Comparator|1|placebo
11627544|NCT00402623|Active Comparator|2|quercetin (food supplement)
11627545|NCT00402597|Experimental|001|Rivaroxaban 1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
11627546|NCT00402597|Experimental|002|Rivaroxaban/Placebo 1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
11627547|NCT00402597|Placebo Comparator|003|Placebo 1 placebo tablet twice daily for 6 months.
11627548|NCT00402558|Experimental|Thymoglobulin + Busulfan + Fludarabine|"Thymoglobulin 1.5 mg/kg by vein for 3 days. Busulfan 130 mg/m^2 by vein for 4 days. Fludarabine 40 mg/m^2 by vein for 4 days. Alloreactive NK infusion from haploidentical donor on Day -8. Alloreactive NK cell infusion given at one of 4 dose levels 10e6, 5 x 10e6, 3 x 10e7 cells/kg and 3 x10e7 NK Cells plus systemic interleukin-2 treatment. The 4th dose level is 3 x 107 NK cells/kg plus systemic interleukin-2 at a dose of 0.5 million units per day subcutaneously starting on Day -8 (day of the NK cell infusion) to Day -4.
~G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count is > 500 x 109/L for 3 consecutive days. Tacrolimus starting dose of 0.015 mg/kg daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present. Methotrexate 5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant."
11627549|NCT00402532|Active Comparator|Everolimus|
11627550|NCT00402532|Active Comparator|Mycophenolatmofetil|
11627551|NCT00402519|Experimental|APBI|Accelerated Partial Breast Irradiation with multicatheter brachytherapy
11627552|NCT00402519|Active Comparator|EBRT|Standard External Beam Whole Breast Irradiation
11627553|NCT00402493|Active Comparator|Latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
11627554|NCT00402493|Active Comparator|Brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
11627555|NCT00402493|Active Comparator|ibuprofen|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
11627556|NCT00402467|Experimental|Arm 6|
11627557|NCT00402467|Experimental|Arm 1|
11627558|NCT00402467|Experimental|Arm 2|
11627559|NCT00402467|Experimental|Arm 3|
11627560|NCT00402467|Experimental|Arm 4|
11627561|NCT00402467|Experimental|Arm 5|
11627562|NCT00402428|Active Comparator|1|180 mcg PEG-IFNx2a every 1 week (48 doses) + Ribavirin 1000 or 1200 mg/day
11627563|NCT00402428|Experimental|2|900 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
11627564|NCT00402428|Experimental|3|1200 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
11627565|NCT00402415|Experimental|1|
11627566|NCT00402389|Experimental|1|Participants assigned to take omega-3 fatty acids
11627567|NCT00402389|Placebo Comparator|2|Participants assigned to take placebo
11627568|NCT00402363|Experimental|omega-3-acid ethyl esters|
11627569|NCT00402363|Placebo Comparator|Placebo|
11627570|NCT00402350|Placebo Comparator|Placebo|Subjects (2) from each of the 4 dose escalation arms
11627571|NCT00402350|Experimental|25 mcg IV and Inhaled Crossover|Single dose crossover (IV vs Inhaled)
11627572|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 2|Inhaled Staccato fentanyl, 25 mcg x 2
11627573|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 4|Inhaled Staccato fentanyl, 25 mcg x 4
11627574|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 6|Inhaled Staccato fentanyl, 25 mcg x 6
11627575|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 12|Inhaled Staccato fentanyl, 25 mcg x 12
11627583|NCT00402298|Experimental|1|Participants will receive an initial dose of 125 mg MDMNA followed 2.5 hours later by a supplemental dose of 62.5 mg MDMA during the course of two day-long psychotherapy sessions.
11627584|NCT00402298|Active Comparator|2|25 and 12.5 mg MDMA
11627585|NCT00402285|Active Comparator|lycopene supplement|Two 15mg lycopene capsules daily for 3 months.
11627586|NCT00402285|Active Comparator|fish oil supplement|1g fish oil capsule daily for 3 months.
11627587|NCT00402285|Placebo Comparator|placebo|placebos for lycopene and fish oil.
11627588|NCT00402272|Experimental|1|XIENCE V® Everolimus Eluting Coronary Stent System
11627589|NCT00402246|Experimental|Remote Arm|Remote Management
11627590|NCT00402246|Active Comparator|In-office Arm|In-Office Care
11627591|NCT00402233|Other|Placebo|
11627592|NCT00402233|Other|Pramipexole 0.5 mg Tid|Pramipexole 0.5 mg tid (three times a day)
11627593|NCT00402233|Other|Pramipexole 0.5 mg Bid|Pramipexole 0.5 mg bid (bis in die (two times a day))
11627594|NCT00402233|Other|Pramipexole 0.75 mg Bid|Pramipexole 0.75 mg bid (bis in die (two times a day))
11627595|NCT00402220|Active Comparator|1|active TMS
11627596|NCT00402220|Placebo Comparator|2|Sham TMS
11627597|NCT00402181|Experimental|Treatment Plan A|Siltuximab 6 milligram per kilogram (mg/kg) as intravenous (directly into the vein) infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days (if participant have complete or partial response) along with dexamethasone (starting from Cycle 2, If participant do not have complete or partial response) 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles.
11627598|NCT00402181|Experimental|Treatment Plan B|Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks along with dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles (duration of each cycle is 28 days) after that on Day 1 to 4 up to 12 cycles.
11627599|NCT00402168|Experimental|A: Belatacept|
11627600|NCT00402168|Active Comparator|B: calcineurin inhibitor (CNI)-based immunosuppressive regimen|
11627601|NCT00402155||1|Normal subjects
11627602|NCT00402155||2|Reading discomfort subjects
11627603|NCT00402142|Active Comparator|Pulsed dendritic cells untreated patients|Untreated patients receiving a dendritic cell based vaccine pulsed with autologous heat iactivated virus
11627604|NCT00402142|Placebo Comparator|non pulsed dendritic cells untreated patients|
11627605|NCT00402142|Active Comparator|pulsed dendritic cell treated patient|treated patients will be immunized with a dendritic cell vaccine pulsed with heat inactivated autologous virus immediately before art interruption
11627606|NCT00402142|Active Comparator|pulsed dendritic cell in treated patients|patients will be immunized with a dendritic cell vaccine pulsed with heat inactivted autologous virus immediately after interruption of art
11627607|NCT00402142|Placebo Comparator|non pulsed dendritic cells|
11627608|NCT00402116|Experimental|A|The Phase 1 consisted of the dose escalation of enzastaurin in 2 cohorts of up to 6 patients to assess maximum tolerated dose (MTD). Cohort 1 = radiotherapy/enzastaurin 250 mg per day/temozolomide 75 mg/m^2 therapy. The 6 initial cohort patients were clinically evaluated for dose-limiting toxicities (DLT). If no more than 1 of 6 patients experienced a DLT or tumor progression, patients continued 1 complete adjuvant enzastaurin/temozolomide 28-day cycle. If there was no significant toxicity after the first adjuvant cycle, participants received subsequent adjuvant enzastaurin/temozolomide cycles. If no more than 1 of the 6 initial cohort participants treated at 250 mg of enzastaurin experienced a DLT during radiotherapy and the first adjuvant cycle, up to 6 more participants could be entered at 500 mg of enzastaurin. The Phase 2, using the MTD determined in the Phase 1 (250 mg), evaluated the combination's safety and measured OS.
11627609|NCT00402103|Experimental|Aliskiren/Amlodipine|
11627610|NCT00402103|Experimental|Aliskiren/Amlodipine/HCTZ|
11627611|NCT00402077|Experimental|1|
11627612|NCT00402077|Experimental|2|
11627613|NCT00402077|Experimental|3|
11627614|NCT00402077|Placebo Comparator|4|
11627615|NCT00402051|Experimental|Pemetrexed + Cisplatin|
11627616|NCT00402051|Experimental|Pemetrexed + Carboplatin|
11627617|NCT00402038|Experimental|Arm 1|
11627618|NCT00402038|Placebo Comparator|Arm 2|
11627619|NCT00402025|Experimental|Talimogene Laherparepvec|Participants received 3 doses of talimogene laherparepvec administered by direct injection 3 weeks apart. At the discretion of the investigator, treatment with talimogene laherparepvec could continue beyond the third dose until week 15 in a regimen of at least 3 weeks between doses.
11627620|NCT00402012|No Intervention|1|
11627621|NCT00402012|Experimental|2|
11627622|NCT00401986||Alair Treatment|Alair Treated subject6s from PREDECESSOR STUDY
11627623|NCT00401973|Experimental|Olanzapine|olanzapine plus behavioral information
11627624|NCT00401973|Experimental|Olanzapine + Amantadine|Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information
11627625|NCT00401973|Experimental|Olanzapine + Metformin|Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information
11627626|NCT00401960|Experimental|Daptomycin adjunctive group|Patients with enterococcal endocarditis who elect to receive daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving
11627627|NCT00401960|No Intervention|standard of care|Patients with enterococcal endocarditis who elect to receive standard of care therapy as prescribed by their primary physician
11627628|NCT00401921|Placebo Comparator|Minocycline arm|Minocycline 100mg/Placebo 0mg Minocycline 100mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
11627629|NCT00401921|Placebo Comparator|Placebo arm|Placebo 0mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
11627630|NCT00401895|Active Comparator|1|patients treated with 10 mm stent
11627631|NCT00401895|Active Comparator|2|patients treated with 8 mm stent
11627632|NCT00401882|Active Comparator|Standard Of Care Drug Epinephrine|Additional doses of Epinephrine (1 mg) given as part of standard of care during cardiac arrest
11627633|NCT00401882|Active Comparator|IV Metoprolol instead Epinephrine|IV metoprolol 5 mg. up to 2 times (only) during cardiac arrest will be given instead of additional Epinephrine doses
11627634|NCT00401856|Experimental|1|This arm will receive eplerenone
11627636|NCT00401843|Experimental|Part 1: Siltuximab Plus Bortezomib|Siltuximab 6 milligram per kilogram (mg/kg) will be administered as intravenous infusion once every 2 weeks along with bortezomib 1.3 milligram per square meter (mg/m^2) during cycle 1.
11627637|NCT00401843|Experimental|Part 2: Bortezomib + Placebo|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period along with matching placebo administered as intravenous infusion once every 2 weeks during 42-day treatment phase. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) along with matching placebo once every 2 weeks during 35-day Maintenance Phase. Dexamethasone tablet will be administered at first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 milligram per day (mg/day) will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles.
11627638|NCT00401843|Experimental|Part 2: Bortezomib + Siltuximab|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period along with Siltuximab administered as intravenous infusion once every 2 weeks during 42-day treatment phase. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) along with Siltuximab administered as intravenous infusion once every 2 weeks for 35-day Maintenance Phase. Dexamethasone tablet will be administered at first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles.
11627639|NCT00401830|Placebo Comparator|Placebo|
11627640|NCT00401830|Experimental|Lacosamide|Lacosamide Tablet 400mg daily
11627641|NCT00401817|Experimental|Study Treatment Arm|Bevacizumab-R-CHOP therapy included bevacizumab administered at 15 mg/kg on day 1, and standard dose R-CHOP on day 3, for six 21-day cycles
11627642|NCT00401791|Experimental|1|
11627643|NCT00401791|No Intervention|2|
11627644|NCT00401778|Active Comparator|1|RAD001 5 mg/day for 21 days sequentially.
11627645|NCT00401778|Active Comparator|3|RAD001 10 mg/day for 21 days sequentially.
11627646|NCT00401778|No Intervention|Control|Patients who are eligible for the study but choose not to receive RAD001 treatment.
11627647|NCT00401765|Experimental|Cohort 1A (Docetaxel and CNTO 328)|In cohort 1A, 75 mg/m2 docetaxel will be administered in run-in phase and 75 mg/m2 docetaxel every 3 weeks and 6 mg/kg CNTO 328 every 2 weeks will be administered in the treatment phase.
11627648|NCT00401765|Experimental|Cohort 1B (Docetaxel and CNTO 328)|In cohort 1B, 6 mg/kg CNTO 328 will be administered in run-in phase and 75 mg/m2 docetaxel will be administered every 3 weeks plus 6 mg/kg CNTO 328 will be administered every 2 weeks in the treatment phase.
11627649|NCT00401765|Experimental|Cohort 2 (Docetaxel and CNTO 328)|In cohort 2, 75 mg/m2 docetaxel will be administered in run-in phase and 75 mg/m2 docetaxel plus 9 mg/kg CNTO 328 will be administered every 3 weeks in treatment phase.
11627650|NCT00401765|Experimental|Cohort 3 (Doctaxel and CNTO 328)|In cohort 3, 75 mg/m2 docetaxel will be administered in the run-in phase and 75 mg/m2 docetaxel plus 12 mg/kg CNTO 328 will be administered every 3 weeks in treatment phase.
11627651|NCT00401739|Experimental|I|Treatment with CSL360
11627652|NCT00401674|Experimental|SINGLE ARM|
11627653|NCT00401661|Experimental|1|Alfuzosin for 24 weeks
11627654|NCT00401622|Experimental|OneTouch® Ultra®2 system|Test care group assigned to OneTouch® Ultra®2 system
11627655|NCT00401622|Active Comparator|Standard care|Control group receiving standard care with a traditional blood glucose monitoring system
11627656|NCT00401583|Experimental|Pazopanib receivers|During Days 1 and 2 subjects will be dosed with only probe drugs, and with no drugs on Days 3-5. During Days 6 to the end of the study, subjects will receive 800 mg daily pazopanib, and on Days 23-24 subjects will receive probe drugs in addition to pazopanib
11627657|NCT00401570|Experimental|Cohort 1|Volociximab (10 mg/kg every other week (qowk)) and Gemcitabine
11627658|NCT00401570|Experimental|Cohort 2|Volociximab (15 mg/kg weekly (qwk)) and Gemcitabine
11627659|NCT00401544|Experimental|Darbepoetin alfa 300 μg plus IV Iron|Darbepoetin alfa 300 μg subcutaneous injection plus intravenous (IV) iron 400 mg, every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
11627660|NCT00401544|Experimental|Darbepoetin alfa 300 μg|Darbepoetin alfa 300 μg subcutaneous injection every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
11627661|NCT00401544|Experimental|Darbepoetin alfa 500 μg|Darbepoetin alfa 500 μg subcutaneous injection every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
11627662|NCT00401544|Active Comparator|Darbepoetin alfa 500 μg plus IV Iron|Darbepoetin alfa 500 μg subcutaneous injection plus intravenous (IV) iron 400 mg, every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
11627663|NCT00401531|Experimental|Group 1: DTaP IPV Hep B PRP T + Prevnar™|
11627664|NCT00401531|Active Comparator|Group 2: Infanrix hexa™ + Prevnar™|
11627665|NCT00401518|Experimental|ACADIA®|Investigational surgical treatment using the ACADIA Facet Replacement system
11627666|NCT00401518|Active Comparator|Control Instrumented PLF|Control surgical treatment using an instrumented posterolateral fusion
11627667|NCT00401466|Experimental|1|Prolonged follow-up intervals every 12 months
11627668|NCT00401466|Active Comparator|2|Standard follow-up intervals of 3 months
11627669|NCT00401440|Active Comparator|A|400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
11627670|NCT00401440|Active Comparator|B|400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
11627671|NCT00401414|Experimental|Warfarin|We will develop a nomogram for warfarin dosing that uses rapid turnaround genetic testing and monthly nomogram modification (if necessary) to achieve effective and safe warfarin induction and maintenance. More than 70% of the time, we will maintain warfarin naïve patients within the target therapeutic range. The percent of time in the therapeutic range will be analyzed beginning 2 weeks after initiation of warfarin. Analyses will be stratified by the indication for anticoagulation.
11627672|NCT00401401|Experimental|Zalutumumab 4 mg/kg|Zalutumumab 8 weekly infusions
11627673|NCT00401401|Experimental|Zalutumumab 8 mg/kg|Zalutumumab 8 weekly infusions
11627675|NCT00401401|Experimental|Zalutumumab 16 mg/kg|Zalutumumab 8 weekly infusions
11627676|NCT00401388|Experimental|Group A: chondrosarcoma|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of chondrosarcoma.
~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
11627677|NCT00401388|Experimental|Group B: alveolar soft part sarcoma|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of alveolar soft part sarcoma.
~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
11627678|NCT00401388|Experimental|Group C: extra-skeletal myxoid|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of extra-skeletal myxoid chondrosarcoma.
~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
11627679|NCT00401375|Experimental|MNTX 12 mg|Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) as an intravenous (IV) infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
11627680|NCT00401375|Experimental|MNTX 24 mg|Participants will receive MNTX 24 mg as an IV infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
11627681|NCT00401375|Placebo Comparator|Placebo|Participants will receive placebo matching to MNTX as an IV infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
11627682|NCT00401362|Experimental|Arm 1|
11627683|NCT00401362|Placebo Comparator|Arm 3|
11627684|NCT00401362|Experimental|Arm 2|
11627685|NCT00401336|Experimental|Magnetic Resonance Imaging|New magnetic resonance imaging multiecho gradient-echo sequence
11627686|NCT00401323|Experimental|docetaxel plus cisplatin|Taxotere 75 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by cisplatin 75 mg/m² administered as a 30-minute to 3-hour infusion on Day 1
11627687|NCT00401323|Active Comparator|cisplatin plus 5-FU|Cisplatin 100 mg/m², 30-minute to 3-hour infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 1000 mg/m²/day from Day 1 to Day 5
11627688|NCT00401323|Experimental|docetaxel plus 5-FU|"Taxotere 85 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 750 mg/m²/day from Day 1 to Day 5
~Arm only in the phase II part of the study"
11627689|NCT00401310|Placebo Comparator|1|Placebo
11627690|NCT00401310|Experimental|2|MK0724
11627691|NCT00401258|Other|1|12-week, open-label trial of duloxetine in subjects with IBS.
11627692|NCT00401245|Active Comparator|A|
11627693|NCT00401245|Active Comparator|B|
11627694|NCT00401245|Active Comparator|C|
11627695|NCT00401245|Active Comparator|D|
11627696|NCT00401245|Active Comparator|E|
11627697|NCT00401245|Active Comparator|F|
11627698|NCT00401245|Active Comparator|G|
11627699|NCT00401245|Placebo Comparator|H|
11627700|NCT00401232|Other|Arm 1|
11627701|NCT00401193|Experimental|1|
11627702|NCT00401193|Experimental|2|
11627703|NCT00401193|Placebo Comparator|3|
11627704|NCT00401154|Experimental|Intervention Stationary Cycling|Subjects receiving the intervention performed stationary cycling 3 times a week for 30 sessions over 12 weeks.
11627705|NCT00401115|Experimental|1|Subconjunctival injection
11627706|NCT00401115|Experimental|2|Intraocular injection
11627707|NCT00401102|Other|Interpersonal psychotherapy|All participants received interpersonal psychotherapy adapted for self-injury
11627708|NCT00401089|Experimental|Ginsana-115|Ginsana-115 (Panax Ginseng formulation obtained from Boehringer Ingelheim Pharmaton Inc. Switzerland )is available in oral dosage form of capsules. Two dosages of Ginsana-115 will be tested: 100 mg once daily oral dosage ( 1 100-mg Ginsana-115 capsule) and 200 mg once daily dosage ( 2 100-mg Ginsana-115 capsule). The total duration of each dosage is 8 weeks.
11627709|NCT00401089|Placebo Comparator|Sugar Pill|Placebo capsules formulated identical to the active drug: Ginsana-115 are to be obtained from Boehringer Ingelheim Pharmaton, Switzerland. Two dosages of Placebo capsules will be administered once daily for 8 weeks : a) Placebo 100 mg capsule: 1 placebo capsule daily; b) Placebo 200 mg capsule: 2 placebo-capsule daily
11627710|NCT00401076|Experimental|1|
11627711|NCT00401063|Other|Single arm|Acupuncture treatment
11627712|NCT00401024|Experimental|Treatment|Imatinib mesylate 600mg orally once a day for seven consecutive days prior to surgery with last dose taken one day prior to surgery
11627713|NCT00401011|Experimental|Phase II: Perifosine + Bortezomib|All patients will start with perifosine at bedtime daily and Bortezomib IV on days 1, 4, 8, and 11 q 21 days. Patients will be evaluated at q 3 weeks. If the patient has a CR, PR, MR or stable disease, they will continue treatment.
11627714|NCT00401011|Experimental|Phase II: Perifosine + Bortezomib + Dexa|If the patient shows progressive disease, dexamethasone 20 mg will be added on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
11627715|NCT00401011|Experimental|Phase I: Dose 1: Perifosine + Bortezomib|Perifosine 50 mg at bedtime and bortezomib 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks.
11627794|NCT00400153|Experimental|COMBIVENT CFC-MDI 36/206 mcg|
11627716|NCT00401011|Experimental|Phase I: Dose 2: Perifosine + Bortezomib|Perifosine 100 mg at bedtime and bortezomib 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
11627717|NCT00401011|Experimental|Phase I: Dose 3: Perifosine + Bortezomib|Perifosine 50 mg at bedtime and bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
11627718|NCT00401011|Experimental|Phase I: Dose 4: Perifosine + Bortezomib|Perifosine 100 mg at bedtime and bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
11627719|NCT00400998|Placebo Comparator|Vienna Challenge Chamber in season (Phase 3)|"Phase 3 will consist of two treatment periods each lasting 8 days, with a 10 day wash-out between each treatment period.
~Subjects will administer 200micrograms (μg) fluticasone propionate or fluticasone propionate matched placebo nasal spray, once daily for 8 days. Dosing will be supervised on the first and last days of each treatment period (Day 1 and Day 8).
~Immediately following the last dose received on Day 8 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy."
11627720|NCT00400998|Placebo Comparator|Vienna Challenge Chamber out of season (Phase 1)|"Phase 1 will consist of two treatment periods each lasting 8 days, with a 10 day wash-out between each treatment period.
~Subjects will administer 200μg fluticasone propionate or fluticasone propionate matched placebo nasal spray, once daily for 8 days. Dosing will be supervised on the first and last days of each treatment period (Day 1 and Day 8).
~Immediately following the last dose received on Day 8 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy.
~An intermediate study follow-up visit will take place 7-14 days after the last dose is received in treatment period 2."
11627721|NCT00400998|Placebo Comparator|Park In Season (Phase 2)|"Phase 2 will consist of 2 treatment periods lasting either 8 to 14 days (D) (depending on out-door conditions). There will be a 10D wash-out between this treatment period in Phase 2 and that in Phase 3.
~Subjects will administer 200μg fluticasone propionate (or fluticasone propionate matched placebo nasal spray, once daily up to 14D, with dosing supervised on the first and last days of each treatment period (D1 and either D8 or up to D14).
~Immediately following the last dose received on either D8 or up to D14 baseline measures will be taken (time = 0). The subject is then taken by bus to the Park and the first measurement will be taken 15 minutes after the subjects leave the bus and enter the Park.
~Immediately following the last dose received on D8 or up to D14 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy"
11627722|NCT00400985|Other|Implantable Device diagnostics|All enrolled subjects were implanted with a device. Audible Device diagnostics turned on or off
11627723|NCT00400946|Active Comparator|Intramuscular native E coli L-asparaginase (IM-EC)|Patients in this arm were randomized to intramuscular native E coli L-asparaginase 25 000 IU/m2 weekly for 30 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.
11627724|NCT00400946|Experimental|Intravenous PEG-asparaginase (IV-PEG)|Patients in this arm were randomized to intravenous PEG-asparaginase 2500 IU/m2 every 2 weeks for 15 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.
11627725|NCT00400933|Experimental|psycho-education|six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
11627726|NCT00400881|No Intervention|Continuous PAP (CPAP)|CPAP (continuous positive airway pressure). 5 cm H2O.
11627727|NCT00400881|Experimental|Automatic tube compensation (ATC)|ATC is a new mode of ventilation being compared with traditional one (CPAP). ATC is a mode of ventilation of the same device (mechanical ventilator), not a new device. The pressure in this modes varies according the mechanical parameters of the respiratory system that are automatically calculated by this mode. This is the intervention arm.
11627728|NCT00400868|Active Comparator|standard joint protection education|psycho-educational joint protection vs. usual care (standard joint protection education)
11627729|NCT00400855|Experimental|Arm 1|study drug
11627730|NCT00400842|Experimental|L|
11627731|NCT00400842|Experimental|H|
11627732|NCT00400842|Placebo Comparator|P|
11627733|NCT00400829|Experimental|Arm I|Patients receive 1.4 mg/m2 eribulin mesylate IV over 1-2 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11627734|NCT00400816|Experimental|Temozolomide|Temozolomide, 150 mg/m2/d x days 1-7 and 15-21
11627735|NCT00400803|Experimental|Patients with Stage IIIb/IV Non-Small Cell Lung Cancer|Patients treated with Gemcitabine 2000mg/m^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
11627736|NCT00400764|Experimental|Phase Ib: Dulanermin 4 mg/kg|Participants received 4.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
11627737|NCT00400764|Experimental|Phase Ib: Dulanermin 8 mg/kg|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
11627738|NCT00400764|Active Comparator|Phase II: Rituximab|Participants received rituximab administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
11627739|NCT00400764|Experimental|Phase II: Combination Therapy|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
11627740|NCT00400764|Experimental|Phase II: Dulanermin|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles.
11627741|NCT00400738|Experimental|1|different dose per arm
11627742|NCT00400738|Experimental|2|different dose per arm
11627743|NCT00400738|Experimental|3|different dose per arm
11627744|NCT00400738|Experimental|4|different dose per arm
11627745|NCT00400725|Experimental|1|
11627746|NCT00400725|Placebo Comparator|2|
11627747|NCT00400712|No Intervention|Control|natural progression post-stroke
11627748|NCT00400712|Experimental|Intervention|two weeks of goal directed intensive physical rehabilitation therapy at 6 months (and one year)
11627749|NCT00400699|Other|REview|
11627750|NCT00400686|Experimental|Epoetin Alfa - 80,000 U sc|Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels
11627751|NCT00400673|Other|Chemotherapy|Risk-oriented chemotherapy for remission induction (application of sequential high-dose cytarabine course to patients unresponsive to standard chemotherapy course 1) and postremission consiolidation(standard risk: blood stem cell supported high-dose cytarabine course [x3]; high risk: allogeneic SCT)
11627752|NCT00400660|Experimental|Subjects receiving treatment sequence 1: Part 1|Eligible subjects will receive placebo followed by GSK615915A with a starting dose of 250 micrograms.
11627753|NCT00400660|Experimental|Subjects receiving treatment sequence 2: Part 1|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms followed by placebo.
11627754|NCT00400660|Experimental|Subjects receiving treatment sequence 1: Part 2|Eligible subjects will receive placebo followed by GSK615915A with a starting dose of 250 micrograms.
11627755|NCT00400660|Experimental|Subjects receiving treatment sequence 2: Part 2|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms followed by placebo.
11627756|NCT00400660|Experimental|Subjects receiving GSK615915A: Part 3|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms.
11627757|NCT00400660|Experimental|Subjects receiving placebo: Part 3|Eligible subjects will receive placebo.
11627758|NCT00400647|Experimental|EC MPS|Up to 1440mg taken in two doses
11627759|NCT00400647|Active Comparator|Mycophenolate mofetil|250 mg or 500 mg in two equal doses
11627760|NCT00400634|Experimental|1|Intracerebral administration of CERE-120
11627761|NCT00400634|Sham Comparator|2|Sham Neurosurgery
11627762|NCT00400595|Experimental|1|Polysporin tRIPLE ointment (topical ointment in widespread use for other skin lesions)
11627763|NCT00400595|Active Comparator|2|Mupirocin
11627764|NCT00400569|Experimental|Sunitinib Malate (SU011248) Treatment|Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks
11627765|NCT00400517|Experimental|GM-CSF Injections and Oral Thalidomide|taught to administer an injection of GM-CSF under your skin (subcutaneous injection) and will administer this medicine to yourself every Monday, Wednesday and Friday for 4 weeks at time. Thalidomide will be taken orally (by mouth) every evening at bed time. You will continue these injections 3 times a week and the daily oral medicine for up to 2 months if the therapy appears to be helping your disease.
11627766|NCT00400491|Experimental|1|
11627767|NCT00400491|Placebo Comparator|2|
11627768|NCT00400478|Active Comparator|A|Treatment
11627769|NCT00400478|No Intervention|B|Observation
11627770|NCT00400465|Active Comparator|Control group|Pressure dressing
11627771|NCT00400465|Experimental|Experimental group|Normal dressing
11627772|NCT00400439|Experimental|dalcetrapib (RO4607381)|
11627773|NCT00400439|Placebo Comparator|placebo|
11627774|NCT00400400|Experimental|Enteric-coated mycophenolate sodium|Enteric-coated mycophenolate sodium tablets taken orally twice a day (in the morning and in the evening) at a dose equimolar to the dose of mycophenolate mofetil the participant was taking prior to start of the study + Placebo to mycophenolate mofetil capsules taken orally twice a day for 30 days. Participants remained on their standard immunosuppressive regimen of calcineurin inhibitors (CNI) (Cyclosporin A or Tacrolimus) administered with or without corticosteroids throughout the study.
11627775|NCT00400400|Active Comparator|Mycophenolate mofetil|Mycophenolate mofetil capsules taken orally twice a day (in the morning and in the evening) at the dose the participant was taking prior to study start + Placebo to mycophenolate sodium tablets taken twice a day for 30 days. Participants remained on their standard immunosuppressive regimen of calcineurin inhibitors (CNI) (Cyclosporin A or Tacrolimus) administered with or without corticosteroids throughout the study.
11627776|NCT00400387|Other|Multivitamin supplement|
11627777|NCT00400387|Experimental|Multivitamin supplement + dalteparin sodium|
11627778|NCT00400374|Experimental|Erlotinib, Celecoxib|
11627779|NCT00400361|Experimental|1|
11627780|NCT00400309|Experimental|REPEVAX® after REVAXIS®|REVAXIS® at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28).
11627781|NCT00400309|Active Comparator|REPEVAX® after Placebo|Placebo at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28).
11627782|NCT00400296|Experimental|1|
11627783|NCT00400257||1|People at high risk of heart failure.
11627784|NCT00400231|Active Comparator|1|Metformin
11627785|NCT00400231|Active Comparator|2|Fenofibrate
11627786|NCT00400231|Active Comparator|3|Fenofibrate and Metformin
11627787|NCT00400231|Placebo Comparator|4|
11627788|NCT00400205|Experimental|Recipients of Docetaxel, Cisplatin, 5-Fluorouracil|Participants with squamous cell carcinoma receiving chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil.
11627789|NCT00400179|Active Comparator|A|In Arm A, S-1 25 mg/m² was administered orally BID from Day 1 through Day 21 followed by a recovery period from Days 22 through Day 28. On Day 1, the morning dose of S-1 was administered before cisplatin 75 mg/m2 administration as a 1- to 3-hour IV infusion. This regimen was repeated every 4 weeks. S-1 was administered one hour before or one hour after a meal with a glass of water (approximately 100 mL).
11627790|NCT00400179|Active Comparator|B|In Arm B, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion (CIV) over 120 hours (on Days 1 through 5). This regimen was repeated every 4 weeks. 5-FU CIV followed cisplatin infusion on Day 1. All 5-FU used in this study was commercially available product.
11627791|NCT00400166|Experimental|1|Recovery Mentor: peer-based supportive care
11627795|NCT00400153|Experimental|Ipratropium Respimat 20 mcg|
11627796|NCT00400140|Experimental|A|
11627797|NCT00400127|Experimental|amputee|
11627798|NCT00400114|Experimental|sunitinib|
11627799|NCT00400088|Experimental|lithium group|Start at 600 mg po hs. Dose titrated up to a serum level of between 0.6 and 1.1 mmol/l.
11627800|NCT00400088|Active Comparator|paroxetine group|Start dose at 20 mg po od. If no clinical improvement(<20% reduction in MADRS score) by week 4 dose to be increased to 40 mg po od.
11627801|NCT00400062||ICU survivors|The investigators will measure the independent contribution of risk factors such as delirium and exposure to sedative and analgesic medications to the incidence of long-term CI.
11627802|NCT00400023|Experimental|1|"During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive one of the following treatment sequences:
~Sequence A: Single dose of 50 mg S-1 (2 capsules of 25 mg) on Day 1 followed by a single dose of 800 mg FT (8 capsules of 100 mg) on Day 8
~Sequence B: Single dose of 800 mg FT on Day 1 followed by a single dose of 50 mg S-1 on Day 8"
11627803|NCT00400023|Active Comparator|2|"During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive one of the following treatment sequences:
~Sequence A: Single dose of 50 mg S-1 (2 capsules of 25 mg) on Day 1 followed by a single dose of 800 mg FT (8 capsules of 100 mg) on Day 8
~Sequence B: Single dose of 800 mg FT on Day 1 followed by a single dose of 50 mg S-1 on Day 8"
11627804|NCT00400010|Experimental|Expert System Intervention|Computerized Expert System Intervention based on the Transtheoretical Model of Change: 1. Normative feedback and feedback on motivational variables during the first week of hospital stay 2. Ipsative feedback on drinking behavior and motivation to change after three months
11627805|NCT00400010|No Intervention|Control group|Controls received a brochure on health behavior
11627806|NCT00399984|Experimental|1|
11627807|NCT00399984|No Intervention|2|
11627808|NCT00399971|Experimental|Hemathera|Patients will receive cell-based immunotherapy.
11627809|NCT00399919|Experimental|PLC|Investigational drug
11627810|NCT00399919|Placebo Comparator|Placebo|
11627811|NCT00399906|Active Comparator|A1|10 mg
11627812|NCT00399906|Active Comparator|A2|30 mg
11627813|NCT00399906|Active Comparator|A3|100 mg
11627814|NCT00399906|Placebo Comparator|P1|10 or 100 mg
11627815|NCT00399893|Experimental|Octreotide|Octreotide to be administered by subcutaneous injection three times daily while on study
11627816|NCT00399893|Placebo Comparator|Placebo|Placebo to be administered by subcutaneous injection three times daily while on study
11627817|NCT00399880|Experimental|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
11627818|NCT00399880|No Intervention|Usual care|
11627819|NCT00399841|Active Comparator|1|Stimulation will occur at the T7 during the trial implant period
11627820|NCT00399841|Active Comparator|2|Stimulation will occur at the T8 level during the trial implant period
11627821|NCT00399802|Active Comparator|Single IV infusion of ZA 4 mg|Participants will receive a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks.
11627822|NCT00399802|Experimental|Odanacatib 5 mg|Participants will receive a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment.
11627823|NCT00399789|Active Comparator|Perifosine 150 mg qd|A daily dose of 150 mg to be given in one dose at bedtime. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 200 mg to be given in one dose at bedtime.
11627824|NCT00399789|Active Comparator|Perifosine 900 mg per week|A weekly dose of 900 mg to be divided into three doses of 300 mg each. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 1,200 mg divided into four doses of 300 mg.
11627825|NCT00399789|Active Comparator|Perifosine 50 mg tid|A daily dose of 150 mg to be divided into three doses of 50 mg each. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 200 mg divided into four doses of 50 mg.
11627826|NCT00399776||Group A|Adolescents taking haloperidol, risperidone, or olanzapine
11627827|NCT00399776||Group B|Healthy adolescents
11627828|NCT00399763|Placebo Comparator|1|placebo plus individual cognitive behavioral therapy
11627829|NCT00399763|Experimental|2|atomoxetine plus individual cognitive behavioral therapy
11627830|NCT00399685|Active Comparator|A|
11627831|NCT00399685|Active Comparator|B|
11627832|NCT00399685|Active Comparator|C|
11627833|NCT00399685|Active Comparator|D|
11627834|NCT00399672|Active Comparator|1|The 4 participating sites are designated either High Intensity or Low Intensity. High Intensity sites have access to: full time specialist physicians, access to full time nurses and counselors. All weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
11627835|NCT00399672|Active Comparator|2|The 4 participating sites are designated either High Intensity or Low Intensity. In the Low intensity group, all patients will have access to: full time primary care physicians, specialist physicians and access to part time nurse or counselor by appointment. Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
11627836|NCT00399607||Aim 1|Participants previously randomized for the parent study will be eligible for a portion of the adjunct biomarker study.
11627837|NCT00399607||All aims|Participants entering the parent study will be eligible for all sample collections of the adjunct biomarker study.
11627838|NCT00399594|Experimental|A|Targeted LV lead placement
11627839|NCT00399594|Active Comparator|B|Usual LV lead placement
11627840|NCT00399581|Experimental|HFOV-Lo|High Frequency Oscillatory Ventilation using lower mean airway pressures and higher FiO2s.
11627841|NCT00399581|Experimental|HFOV-Hi|High Frequency Oscillatory Ventilation using higher mean airway pressures
11627842|NCT00399568|Experimental|IV acetaminophen 1 g/100 mL solution|
11627843|NCT00399568|Placebo Comparator|IV Placebo 100 mL solution|
11627908|NCT00398827|Experimental|Dexmedetomidine 1 mcg/kg load|
11627909|NCT00398827|Placebo Comparator|Placebo|
11627844|NCT00399555||One|Patients with HLHS that have had surgical palliation with the Norwood procedure (Stage I palliation) at Children's Healthcare of Atlanta after January 1, 2001. These patients must be between the ages of 2.5 years and 6 years of age.
11627845|NCT00399529|Experimental|Allo GM-CSF-secreting vaccine, Trastuzumab, Cyclophosphamide|"Allogeneic GM-CSF-secreting breast cancer vaccine : the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 10^8 cells for each patient and each vaccination cycle) given intradermally every 4-6 weeks for 3 cycles and then a 4th dose given 6-8 months after beginning the study.
~Trastuzumab : An initial loading dose of 4 mg/kg for participants beginning treatment with Trastuzumab, otherwise 2 mg/kg given every week intravenously
~Cyclophosphamide : 300 mg/m^2 given intravenously every 4-6 weeks for 3 cycles and then once 6-8 months after beginning the study"
11627846|NCT00399490|Experimental|1|
11627847|NCT00399477|Active Comparator|Rasagiline mesylate|
11627848|NCT00399477|Experimental|Rasagiline mesylate plus adjunct therapy|Rasagiline mesylate with one of three adjunct therapies
11627849|NCT00399438|Other|1|0 mg
11627850|NCT00399438|Other|2|25 mg
11627851|NCT00399438|Other|3|100 mg
11627852|NCT00399412||LQTS|Long QT syndrome
11627853|NCT00399412||HF|Heart Failure
11627854|NCT00399412||CRT|Cardiac Resynchronization Therapy
11627855|NCT00399412||Wide QRS|QRS > 120 milliseconds
11627856|NCT00399373||Quality Improvement Initiative|The initial step in the quality improvement initiative was a letter sent from JHHC Care Management Department to the quality improvement initiative group, inviting them to take advantage of the case management services that are part of their current benefits in the Priority Partners MCO. It is similar to the standard letter sent to PPMCO members who are appropriate for a JHHC disease or case management program. A substance abuse outreach staff initiated telephonic contact with the members in the intervention group. The staff member then refered to substance abuse treatment when possible and appropriate and refered to medical case management.
11627857|NCT00399373||Control group|No additional improvement modalities
11627858|NCT00399360|Placebo Comparator|Group 1|No Lifestyle Modification and Placebo
11627859|NCT00399360|Active Comparator|Group 2|Lifestyle Modification and Placebo
11627860|NCT00399360|Active Comparator|Group 3|No Lifestyle Modification and Metformin
11627861|NCT00399360|Active Comparator|Group 4|Lifestyle Modification and Metformin
11627862|NCT00399334||001|
11627863|NCT00399308|Active Comparator|Control|Multi-layer compression bandaging (Profore)
11627864|NCT00399308|Experimental|Celaderm, Bi-Weekly|Celaderm, bi-weekly applications, up to a maximum of four applications
11627865|NCT00399308|Experimental|Celaderm, Weekly|Celaderm, applied weekly, up to a maximum of four applications
11627866|NCT00399204|Active Comparator|Control|Metformin
11627867|NCT00399204|Experimental|Experimental|Pioglitazone
11627868|NCT00399165|Active Comparator|1|Oral Testosterone enanthate in sesame oil, 400 mg po (orally), BID (twice daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once
11627869|NCT00399165|Active Comparator|2|Oral Testosterone sesame oil, 800 mg po (orally), qd (in am daily) + placebo sesame oil (in pm daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once
11627870|NCT00399152|Experimental|Perifosine+Sunitinib malate|
11627871|NCT00399087|Experimental|Perifosine D1 + Docetaxel|
11627872|NCT00399087|Experimental|Perifosine D1+ Docexatel+Prednisone|
11627873|NCT00399087|Experimental|Perifosine+ D1,8 and 15+Docetaxel+Prednisone|
11627874|NCT00399074|No Intervention|chloroquine|Weekly CQ
11627875|NCT00399074|No Intervention|Sulfadoxine-pyrimethamine|Monthly SP
11627876|NCT00399061|Active Comparator|1|Systane
11627877|NCT00399061|Active Comparator|2|Optive
11627878|NCT00399061|Placebo Comparator|3|Restasis
11627879|NCT00399035|Placebo Comparator|FOLFOX + placebo Cediranib|FOLFOX + placebo Cediranib
11627880|NCT00399035|Placebo Comparator|Xelox + placebo Cediranib|Xelox + placebo Cediranib
11627881|NCT00399035|Experimental|FOLFOX + Cediranib|FOLFOX + Cediranib
11627882|NCT00399035|Experimental|XELOX + Cediranib|XELOX + Cediranib
11627883|NCT00398996|Active Comparator|1 - Early integrated-therapy group|antiretroviral therapy to be initiated within 4 weeks of starting tuberculosis treatment
11627884|NCT00398996|Active Comparator|2 - Late integrated-therapy group|antiretroviral therapy to be initiated within 4 weeks of completing the intensive phase of tuberculosis treatment
11627885|NCT00398996|Active Comparator|3 - Sequential-therapy group|Antiretroviral therapy to be initiated within 4 weeks after completing tuberculosis treatment
11627886|NCT00398983|Experimental|Decitabine 20 mg/m^2|20 mg/m^2 intravenous (IV) daily for 5 days
11627887|NCT00398983|No Intervention|No Study Drug|Continue current therapy.
11627888|NCT00398970|Active Comparator|Traditional flouroscopy guided sampling|
11627889|NCT00398970|Experimental|Ultrasound guide sampling|
11627890|NCT00398918|Experimental|Zonisamide|
11627891|NCT00398918|Placebo Comparator|Placebo|
11627892|NCT00398905|Experimental|Arm 1|
11627893|NCT00398905|Experimental|Arm 2|
11627894|NCT00398905|Experimental|Arm 3|
11627895|NCT00398905|Experimental|Arm 4|
11627896|NCT00398905|Experimental|Arm 5|
11627897|NCT00398905|Active Comparator|Arm 6|
11627898|NCT00398892|Other|1|Crossover - placebo then active
11627899|NCT00398892|Other|2|Crossover - active then placebo
11627900|NCT00398879|Experimental|Arm 1: Perifosine + Capecitabine|Perifosine 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks until progression
11627901|NCT00398879|Placebo Comparator|Arm 2: Perifosine Placebo + Capecitabine|Perifosine Placebo 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks until progression
11627902|NCT00398866|Active Comparator|1|Bupivicaine (local anesthetic)
11627903|NCT00398866|Active Comparator|2|Corticosteroid (trimcinolone (Kenalog) 40 mg)
11627904|NCT00398866|Experimental|3|Synvisc
11627905|NCT00398853|Experimental|Chromium Picolinate|Chromium
11627906|NCT00398853|Other|Placebo|Placebo
11627907|NCT00398827|Experimental|Dexmedetomidine 0.5 mcg/kg load|
11627910|NCT00398814|Experimental|Perifosine + Sorafenib|
11627911|NCT00398749||Epoetin alfa|Epoetin alfa 40 000 IU once weekly variable treatment length
11627912|NCT00398723|Experimental|Vitiligo|adult patients (age 18 or greater) with extensive vitiligo warranting treatment with whole body NB-UVB
11627913|NCT00398710|Experimental|Perifosine|Patients will receive perifosine orally at 150 mg daily after food for 28-d cycles.
11627914|NCT00398684|Experimental|1|One dose maternal NVP treatment at onset of labor, and one dose of infant NVP treatment 48-72 hours after birth (NVP-NVP)
11627915|NCT00398684|Experimental|2|One dose maternal NVP treatment at onset of labor, and one dose of infant placebo 48-72 hours after birth. (NVP-Placebo)
11627916|NCT00398684|Placebo Comparator|3|One dose maternal placebo at onset of labor, and one dose of infant placebo 48-72 hours after birth. This was the reference study arm. (Placebo-Placebo)
11627917|NCT00398645|Experimental|Arm 1|
11627918|NCT00398632|Experimental|Duloxetine|Duloxetine 60 mg, by mouth, once daily or twice daily (as needed to control symptoms of major depression)
11627919|NCT00398567|Experimental|Part 1 - dose level 1 (160 mg)|All subjects receiving HKI-272 dose level 1 in combination with trastuzumab
11627920|NCT00398567|Experimental|Part 1 - dose level 2 (240 mg)|All subjects receiving HKI-272 dose level 2 in combination with trastuzumab
11627921|NCT00398567|Experimental|Part 2 - expanded MTD cohort|All subjects receiving HKI-272 in combination with trastuzumab
11627922|NCT00398554|Experimental|VECOPA|dose and time intensified consoloditation chemotherapy cycle
11627923|NCT00398515|Experimental|Treatment (antiangiogenesis, chemotherapy, enzyme inhibitor)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
11627924|NCT00398476|Active Comparator|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
11627925|NCT00398476|Active Comparator|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
11627926|NCT00398463|Experimental|1|Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus tirofiban infusion given at high bolus dose
11627927|NCT00398463|Placebo Comparator|2|Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus placebo
11627928|NCT00398411|Experimental|Moxifloxacin|moxifloxacin 400 mg tablets once daily
11627929|NCT00398411|Placebo Comparator|Placebo|identical appearing placebo
11627930|NCT00398398|Experimental|Capecitbine, oxaliplatin, cetuximab|Capecitbine, oxaliplatin and cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
11627931|NCT00398359|Experimental|1|
11627932|NCT00398333|Experimental|Eicosapentaenoic acid enriched nutritional supplement|
11627933|NCT00398333|No Intervention|No supplementation|
11627934|NCT00398320|Experimental|Bevacizumab (Avastin), Oxaliplatin (Eloxatin)|
11627935|NCT00398281|Experimental|Arm I|Patients receive oral dutasteride once daily on days 1-14.
11627936|NCT00398281|Placebo Comparator|Arm II|Patients receive oral placebo once daily on days 1-14.
11627937|NCT00398229|Active Comparator|A|receiving hCG injection
11627938|NCT00398229|Placebo Comparator|B|
11627939|NCT00398190|Active Comparator|Control|Students receive standard anti-tobacco education
11627940|NCT00398190|Experimental|Media Literacy|Students receive media literacy based anti-smoking education
11627941|NCT00398138|Experimental|vaccine|Six vaccinations of the WT-1 peptide (1.0 ml of emulsion) will be administered on weeks 0, 4, 6, 8, 10 & 12. Vaccinations will be administered subcutaneously with sites rotated among extremities. Injection sites will be pre-stimulated with Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 & -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) if they have been appropriately instructed on SQ injection administration. Patients will keep a logbook noting the time & placement of the injection. Note: during each vaccination, the Sargramostim (GM-CSF) & the vaccine emulsion will be administered to the same anatomical site. This site will be marked by the patient or treating healthcare professional by a permanent marker pen. For patients who have a clinical, molecular, or immunologic response & have not had disease progression, they may receive up to 6 more vaccinations administered approximately every month.
11627942|NCT00398112|Experimental|Arm I|Patients receive oral sunitinib malate daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11627943|NCT00398086|Experimental|100 mg/m^2|Participants received albumin-bound paclitaxel 100 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level one). Treatment continued until progressive disease or unacceptable toxicity.
11627944|NCT00398086|Experimental|125 mg/m^2|Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level two). Treatment continued until progressive disease or unacceptable toxicity.
11627945|NCT00398086|Experimental|150 mg/m^2|Participants received albumin-bound paclitaxel 150 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level three). Treatment continued until progressive disease or unacceptable toxicity.
11627946|NCT00398073|Experimental|mouse gp100 DNA via PMED|patients will be randomized to mouse gp100 DNA delivered via gold particles using the PowderMed delivery system (ND10, described above). Two actuations/day will be administered every two weeks for 4 months for a total of 16 actuations. Each actuation consists of 2 μg of plasmid DNA coated onto 1000 μg of gold. The total dose of plasmid DNA given will be 32 μg DNA on 16,000 μg gold.
11627947|NCT00398073|Experimental|mouse gp100 DNA injections intramuscularly|patients will be injected with 1000 μg of mouse gp100 plasmid DNA intramuscularly. Two injections/day will be administered every two weeks for 4 months (4000 ug of mouse gp100 plasmid/month) for 16 vaccinations.
11627948|NCT00398060|Experimental|A|
11627949|NCT00398047|Experimental|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine andHematopoietic Growth Factors
11627950|NCT00398008|Experimental|1|DC-HIV plus buprenorphine maintenance.
11627951|NCT00398008|Experimental|2|DC-HIV plus naltrexone maintenance
11627952|NCT00397982|Experimental|Treatment (enzyme inhibitor, monoclonal antibody)|Patients receive temsirolimus IV over 30 minutes on days 1 and 8 and bevacizumab IV over 30-90 minutes on day 8. Treatment repeats every 14 days for a maximum of 26 courses in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection on day 9 of course 2.
11627953|NCT00397943|Experimental|M72/AS01B Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of M72/AS01B vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
11627954|NCT00397943|Experimental|M72/AS02A Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of M72/AS02A vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
11627955|NCT00397943|Active Comparator|Mtb72F/AS02A Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the comparator Mtb72F/AS02A vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
11627956|NCT00397943|Active Comparator|Non-adjuvanted Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the comparator GSK Biologicals' candidate recombinant M. tuberculosis vaccine, non-adjuvanted, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
11627957|NCT00397943|Placebo Comparator|Control Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the adjuvant system alone, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
11627958|NCT00397930|Experimental|Yoga Intervention (YOCAS)|Standardized Yoga for Cancer Survivors (YOCAS)
11627959|NCT00397930|Experimental|Standard Care Control Condition|Standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses.
11627960|NCT00397917|Active Comparator|400 micrograms of folic acid|Blinded study with two arms one of 400ug in arm 1
11627961|NCT00397917|Active Comparator|4mg of folic acid|Second arm is 4mg of folic acid in arm 2
11627962|NCT00397904|Experimental|Cetuximab, Cisplatin, and Irinotecan|Cetuximab will be combined with weekly irinotecan and cisplatin. Patients will receive cetuximab 400 mg/m2 on day 1, week 1. Following this loading dose, patients will receive weekly cetuximab 250 mg/m2 (day 8, 15, 22, etc.) until disease progression or unacceptable toxicity. Patients will continue to receive irinotecan and cisplatin weekly on day 1 and day 8, on an every 21 day cycle. The standard maximum doses are irinotecan 65 mg/m2 and cisplatin 30 mg/m2.
11627963|NCT00397891|Experimental|1|bapineuzumab 0.15 mg/kg or placebo
11627964|NCT00397891|Experimental|2|bapineuzumab 0.5 mg/kg or placebo
11627965|NCT00397891|Experimental|3|bapineuzumab 1.0 mg/kg or placebo
11627966|NCT00397878|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11627967|NCT00397865|Experimental|A|
11627968|NCT00397839|Placebo Comparator|Placebo|
11627969|NCT00397839|Experimental|Ibandronate|
11627970|NCT00397826|Other|MK0733,simvastatin|20 patients with total cholesterol ≧ 240 mg/dL or LDL-C > 160 mg/dL for primary hypercholesterolemia; LDL-C ≧ 130 mg/dL for secondary hypercholesterolemia with identifiable risk factors will be enrolled into study to receive simvastatin 40 mg once daily for 12 weeks.
11627971|NCT00397813|Experimental|Arm A - Dose Level 1|"Arm A - patients with MPD or MDS-RA/RARS Dose Level 1 - 300 cGy TBI
~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.
~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.
~IMMUNOSUPPRESSION:
~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.
~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
11627972|NCT00397813|Experimental|Arm A - Dose Level 2|"Arm A - patients with MPD or MDS-RA/RARS Dose Level 2 - 400 cGy TBI
~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.
~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.
~IMMUNOSUPPRESSION:
~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.
~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
11627973|NCT00397813|Experimental|Arm A - Dose Level 3|"Arm A - patients with MPD or MDS-RA/RARS Dose Level 3 - 450 cGy TBI
~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.
~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.
~IMMUNOSUPPRESSION:
~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.
~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
11627974|NCT00397813|Experimental|Arm B - Dose Level 1|"Arm B - patients with MDS-RAEB or CMML Dose Level 1 - 300 cGy TBI
~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.
~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.
~IMMUNOSUPPRESSION:
~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.
~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
11628010|NCT00397215|Experimental|GSK1562902A 1 Group|Subjects aged 61 years or older at the time of first vaccination received 1 dose of GSK1562902A adjuvanted vaccine at Day 0. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm.
11627975|NCT00397813|Experimental|Arm B - Dose Level 2|"Arm B - patients with MDS-RAEB or CMML Dose Level 2 - 400 cGy TBI
~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.
~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.
~IMMUNOSUPPRESSION:
~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.
~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
11627976|NCT00397813|Experimental|Arm B - Dose Level 3|"Arm B - patients with MDS-RAEB or CMML Dose Level 3 - 450 cGy TBI
~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.
~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.
~IMMUNOSUPPRESSION:
~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.
~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
11627977|NCT00397787|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
11627978|NCT00397774|Active Comparator|Exercise|Physical exercise twice a week for 8 weeks, and best supportive care
11627979|NCT00397774|Other|No exercise|Best supportive care, no exercise
11627980|NCT00397735|Experimental|N-Acetylcysteine|The subjects enrolled in our research protocol must have evidence of infection/inflammation at amniocentesis in order to receive N-acetylcysteine. Women with positive amniocentesis results The dose of N-acetylcysteine is the one recommended to be used in humans to prevent acetaminophen toxicity: 150 mg/kg loading dose (60 min), followed by 50mg/kg IV continuous infusion rate for 4 hours, and followed by 100 mg/kg IV continuous infusion rate for the following 16 hours. Acetadote (Cumberland Pharmaceuticals) is the only FDA-approved intravenous N-acetylcysteine formulation and will be used in our study.
11627981|NCT00397735|Placebo Comparator|Placebo|The subjects enrolled in our research protocol must have infection/inflammation in order to be randomized to receive N-acetylcysteine or placebo. Placebo-assigned patients will receive sodium chloride solution without N-acetylcysteine
11627982|NCT00397696|Experimental|[123I] 5-IA|To assess [123I] 5IA and SPECT imaging
11627983|NCT00397657|Active Comparator|Extended release niacin|
11627984|NCT00397657|Active Comparator|Ezetimibe|
11627985|NCT00397631|Experimental|1|sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.
11627986|NCT00397631|Active Comparator|2|sitagliptin 100 mg placebo q.d./pioglitazone 30 mg q.d.
11627987|NCT00397605|Experimental|Crossover|
11627988|NCT00397579|Experimental|SL-401|Patients will be treated with a maximum of five doses of approximately 15min IV infusions of DT388IL3/SL-401 over a ten day period at a maximum of once daily.
11627989|NCT00397553|Experimental|Insulin Glulisine|
11627990|NCT00397540|Active Comparator|percutaneous ethanol injection therapy|Patients with hepatocellular carcinoma who will be treated with PEIT (percutaneous ethanol injection therapy)
11627991|NCT00397540|Active Comparator|radiofrequency thermal ablation|Patients with hepatocellular carcinoma who will be treated with RFTA (radiofrequency thermal ablation)
11627992|NCT00397514||Congenital Heart Surgery Patients|Pacing protocol prior to patient's extubation with 20 min. of either conventional right ventricular (RV) or biventricular (BiV) pacing, preceded and followed by 10 min. of recovery time.
11627993|NCT00397501|Active Comparator|HER-2 positive subjects|HER-2 positive subjects treated with trastuzumab
11627994|NCT00397501|Active Comparator|HER-2 negative subjects|HER-2 negative subjects not treated with trastuzumab
11627995|NCT00397488|Experimental|Sunitinib|This is a phase II trial of Sunitinib in patients with metastatic urothelial carcinoma. Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks followed by a two-week rest period for the initial population. A second cohort of patients will be enrolled, who will receive 37.5 mg of sunitinib orally, on a continuous dosing schedule. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Re-staging imaging studies will be performed after every cycle of treatment during the first 4 cycles and subsequently after every other cycle. Patients may continue on study as long as they are tolerating therapy and in the absence of disease progression.
11627996|NCT00397462|No Intervention|Control|No change to usual behavior
11627997|NCT00397462|Experimental|Low dose|Request that calf muscle pump stimulation be used less than four hours per day
11627998|NCT00397462|Experimental|High dose|Request that calf muscle pump stimulation be used at least four hours per day
11627999|NCT00397449|Experimental|1, 2, 3|
11628000|NCT00397436|Experimental|1|Comparing irradiated skin to non irradiated skin.
11628001|NCT00397423|Active Comparator|1|1,G-CSF,intervention
11628002|NCT00397423|Placebo Comparator|2|2,NS,intervention
11628003|NCT00397384|Experimental|Treatment (cetuximab and erlotinib hydrochloride)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and erlotinib hydrochloride PO QD on days 8-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11628004|NCT00397345|Experimental|Trovax|
11628005|NCT00397345|Placebo Comparator|Placebo|
11628006|NCT00397280||1|Any healthy donors meeting inclusion/exclusion criteria
11628007|NCT00397254|Active Comparator|Clinical Limit|"Eligible patients were randomized to one of two treatment regimens in a 1:1 ratio. Those randomized to receive a clinical limit of study medication received Rizatriptan 10mg ODT: 27 tablets per month."
11628008|NCT00397254|Active Comparator|Formulary Limit|"Eligible patients were randomized to one of two treatment regimens in a 1:1 ratio. Those randomized to receive a formulary limit of study medication received Rizatriptan 10mg ODT: 9 tablets per month."
11628009|NCT00397228|Experimental|ALTROPANE®|ALTROPANE® dosing
11628160|NCT00395707|Active Comparator|2|Lucentis 0.5mg/0.05 ml
11628161|NCT00395694|Experimental|lamictal|
11628011|NCT00397215|Experimental|GSK1562902A 2 Group|Subjects aged 61 years or older at the time of first vaccination received 1 dose of GSK1562902A non-adjuvanted vaccine at Day 0. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm.
11628012|NCT00397215|Experimental|GSK1562902A 3 Group|Subjects aged 61 years or older at the time of first vaccination received 2 doses of GSK1562902A adjuvanted vaccine at Days 0 and 21. The vaccine was administered in the deltoid region of each arm.
11628013|NCT00397215|Experimental|GSK1562902A 4 Group|Subjects aged 61 years or older at the time of first vaccination received 2 doses of GSK1562902A non-adjuvanted vaccine at Days 0 and 21. The vaccine was administered in the deltoid region of each arm.
11628014|NCT00397202|Active Comparator|The DivaCupTM|
11628015|NCT00397189|Experimental|Circadin|
11628016|NCT00397189|Placebo Comparator|placebo|
11628017|NCT00397163|Active Comparator|Remote preconditioning|Simultaneous inflation (5min) and deflation (5min) of cuffs placed on upper arm and thigh - cycle repeated 2 times
11628018|NCT00397163|Placebo Comparator|Placebo|Deflated cuffs placed on upperarm and thigh for 20 minutes
11628019|NCT00397150|Experimental|Intervention|Peer-support for exclusive breastfeeding
11628020|NCT00397150|No Intervention|No intervention|No intervention
11628021|NCT00397137|Experimental|Stapled Anopexy|Circular stapled anopexy
11628022|NCT00397137|Active Comparator|Conventional Haemorrhoidectomy|Closed diathermy haemorrhoidectomy
11628023|NCT00397111||Healthy Volunteer|Healthy Volunteer/control group
11628024|NCT00397111||Major Depressive Disorder|Individuals with Major Depressive Disorder
11628025|NCT00397072|Experimental|ZK-EPO|administered iv for 3 h every 21 days; dose reductions to 12 or 9 mg/m2 ZK-EPO were allowed in order to manage any treatment-related toxicity.
11628026|NCT00397046|Experimental|Neratinib 80 mg|
11628027|NCT00397046|Experimental|Neratinib 160 mg|
11628028|NCT00397046|Experimental|Neratinib 240 mg|
11628029|NCT00397046|Experimental|Neratinib 320 mg|
11628030|NCT00397033|Experimental|002|Paliperidone ER 12mg/day paliperidone er for 6 weeks
11628031|NCT00397033|Experimental|001|Paliperidone ER 6mg/day paliperidone er for 6 weeks
11628032|NCT00397033|Placebo Comparator|003|Placebo Placebo for 6 weeks
11628033|NCT00397020|Experimental|1 Divalproex ER|Divalproex ER
11628034|NCT00397020|Active Comparator|2 Quetiapine Fumarate|quetiapine fumarate
11628035|NCT00396994|Experimental|Low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz
11628036|NCT00396994|Placebo Comparator|2|10 minutes per day standing on sham low mechanical stimulation platform
11628037|NCT00396981|Active Comparator|Matrix 2® Coils|Matrix 2® Coils for endovascular aneurysm occlusion
11628038|NCT00396981|Active Comparator|GDC® Coils|GDC® Coils for endovascular aneurysm occlusion
11628039|NCT00396877|Placebo Comparator|Placebo|
11628040|NCT00396877|Experimental|Clopidogrel 0.2 mg/kg/day|
11628041|NCT00396864|Experimental|NPI-0052|Advanced Solid Tumor Malignancies and Refractory Lymphoma
11628042|NCT00396825|Experimental|Active treatment|Subjects randomized to this arm will receive the Family Caregiver Kit composed of the Williams LifeSkills Family Caregiver Video and Workbook and will also receive telephone coaching
11628043|NCT00396825|No Intervention|Control|Subjects randomized to this arm will receive no intervention and serve as wait list controls. They will undergo the same evaluations as the Intervention arm subjects at comparable times. In a crossover design, once subjects have finished serving as controls, they will be given the video, workbook, and telephone calls from a social worker and tested one more time.
11628044|NCT00396812|Experimental|Rituximab|
11628045|NCT00396786|Experimental|Arm 1|
11628046|NCT00396786|Experimental|Arm 2|
11628047|NCT00396786|Experimental|Arm 3|
11628048|NCT00396786|Experimental|Arm 4|
11628049|NCT00396786|Experimental|Arm 5|
11628050|NCT00396786|Active Comparator|Arm 6|
11628051|NCT00396747|Active Comparator|A|Methotrexate
11628052|NCT00396747|Active Comparator|B|MTX + MP
11628053|NCT00396747|Active Comparator|C|MTX + IFX
11628054|NCT00396721|Active Comparator|A|
11628055|NCT00396721|Experimental|B|
11628056|NCT00396669|Experimental|Dopamine release|
11628057|NCT00396656|Experimental|Valsartan followed by atenolol + hydrochlorothiazide (HCTZ)|"After a 2-week washout period, patients were treated with valsartan for 20 weeks followed by one week in which it was tapered off. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. The valsartan dose was then tapered off to 80 mg for one week. Patients took valsartan film coated tablets orally once a day (od) in the morning.
~After a second 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning."
11628058|NCT00396656|Experimental|Atenolol + hydrochlorothiazide (HCTZ) followed by valsartan|"After a 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks followed by one week in which atenolol was tapered off and HCTZ was discontinued. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning.
~After a second 2-week washout period, patients were treated with valsartan for 20 weeks. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. Patients took valsartan film coated tablets orally once a day (od) in the morning."
11628059|NCT00396643|Experimental|A|
11628060|NCT00396643|Placebo Comparator|B|Coconut oil
11628061|NCT00396630|Experimental|Rotarix Group|"All subjects received 2 oral doses of Rotarix vaccine at Day 0 (Visit 1) and Week 7 (Visit 2).
~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3)."
11628062|NCT00396630|Placebo Comparator|Placebo Group|"All subjects received 2 oral doses of placebo at Day 0 (Visit 1) and Week 7 (Visit 2).
~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3)."
11628063|NCT00396591|Experimental|Aflibercept|Participants with advanced ovarian epithelial cancer (including fallopian tube and primary peritoneal adenocarcinoma) treated with Aflibercept every 2 weeks until a criterion for treatment discontinuation was met
11628064|NCT00396565|Experimental|ER OROS paliperidone|Extended Release (ER) Osmotic Controlled-Release Oral Delivery System (OROS) paliperidone
11628065|NCT00396565|Placebo Comparator|Placebo|
11628066|NCT00396565|Active Comparator|Olanzapine|
11628067|NCT00396552|Experimental|1|
11628068|NCT00396552|Sham Comparator|2|
11628069|NCT00396474||SGA patients|Infants born small for SGA who either received GH, no GH, or growth within normal ranges.
11628070|NCT00396461|Active Comparator|TPN A (Group I)|Emulsion based on 20% MCT/LCT (50:50 ratio)
11628071|NCT00396461|Experimental|TPN B (Group II)|Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides
11628072|NCT00396448|Experimental|CP-945,598 Treatment B|
11628073|NCT00396448|Experimental|CP-945,598 Treatment A|
11628074|NCT00396448|Placebo Comparator|Placebo|
11628075|NCT00396435|Experimental|Group A|High Hb target
11628076|NCT00396435|Active Comparator|Group B|Low Hb Target
11628077|NCT00396409|Experimental|Depigold+Omalizumab|Xolair® (Omalizumab, double-blind core study period only), Depigoid® (grass/rye pollen 50/50)
11628078|NCT00396409|Experimental|Depigoid+Placebo|Depigoid® (grass/rye pollen 50/50) + Placebo
11628079|NCT00396383|Experimental|Participants with Multiple Myeloma (MM)|Participants with MM who were eligible for autologous peripheral blood stem cell transplantation.
11628080|NCT00396370|Experimental|Group A: BCG ID/Placebo PO; Placebo ID/Placebo PO|Primary vaccination: BCG ID (Danish)/Placebo PO; secondary vaccination (1 year later): Placebo ID/Placebo PO.
11628081|NCT00396370|Experimental|Group B: BCG ID/Placebo PO; BCG ID/Placebo PO|Primary vaccination: BCG ID (Danish)/Placebo PO; secondary vaccination (1 year later): BCG ID (Danish)/Placebo PO.
11628082|NCT00396370|Experimental|Group C: Placebo ID/BCG PO; Placebo ID/Placebo PO|Primary vaccination: Placebo ID/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/Placebo PO.
11628083|NCT00396370|Experimental|Group D: Placebo ID/BCG PO; Placebo ID/BCG PO|Primary vaccination: Placebo ID/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/BCG PO (Danish).
11628084|NCT00396370|Experimental|Group E: BCG ID/BCG PO; Placebo ID/Placebo PO|Primary vaccination: BCG ID (Danish)/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/Placebo PO.
11628085|NCT00396370|Experimental|Group F: BCG ID/BCG PO; BCG ID/BCG PO|Primary vaccination: BCG ID (Danish)/BCG PO (Danish); secondary vaccination (1 year later): BCG ID (Danish)/BCG PO (Danish).
11628086|NCT00396370|Experimental|Group G: Connaught strain BCG ID|Primary vaccination: Connaught strain BCG ID; secondary vaccination (1 year later): none.
11628087|NCT00396357|Experimental|vildagliptin + metformin|
11628088|NCT00396357|Active Comparator|Metformin|
11628089|NCT00396344|Placebo Comparator|1|Saline control
11628090|NCT00396344|Experimental|2|
11628091|NCT00396344|Experimental|3|
11628092|NCT00396331|Experimental|G-CSF plus Plerixafor|
11628093|NCT00396318|Experimental|Tenecteplase|
11628094|NCT00396305|Experimental|Group 2, Control Double Dose|12 elderly and 6 young participants. This group will be vaccinated with a double dose of vaccine without booster on Day 0. These subjects will receive a double-dose of vaccine administered as 2 consecutive injections (2 injections of 0.5 mL) in the same deltoid. The control group for Group 2 is group 1, Cohort 2.
11628095|NCT00396305|Experimental|Group 3-Control late booster|12 elderly and 6 young participants. This group will be vaccinated with the standard dose of vaccine (0.5 mL) on Day 0 and with a booster dose of vaccine (0.5 mL) on Day 21. The control for Group 3 is Group 1, Cohort 3.
11628096|NCT00396305|Active Comparator|Group 1, Control|12 elderly and 8 young participants. Group 1 will be further divided into 4 equal cohorts (each containing 3 elderly and 2 young adults). Cohorts 2, 3, and 4 will receive the standard dose of vaccine and placebo (0.5 mL saline) on Day 0, 21, or 7 respectively. Cohort 1 will be vaccinated with the standard dose of vaccine without placebo/vaccine booster.
11628097|NCT00396305|Experimental|Group 4-Control early booster|12 elderly and 6 young participants. This group will be vaccinated with the standard dose of vaccine (0.5 mL) on Day 0 and with a booster dose of vaccine (0.5 mL) on Day 7. The control for Group 4 is Group 1, Cohort 4.
11628098|NCT00396292|Experimental|VIT-45|A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
11628099|NCT00396292|Active Comparator|Oral iron tablets|325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
11628100|NCT00396279|Experimental|Denosumab|Participants received denosumab 120 mg once every 4 weeks (Q4W), with an additional 120 mg doses on Days 8 and 15 of the first month of treatment. All participants were instructed to take daily supplements of at least 500 mg of calcium and 400 IU of vitamin D. Participants were to continue to receive denosumab until one of the following occurred: complete tumor resection, disease progression without clinical benefit, or decision by the participant to discontinue for any reason.
11628101|NCT00396266|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
11628102|NCT00396266|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
11628156|NCT00395733|Experimental|Gadopentate, dimeglumine then Gadobutrol|Period 1: Participant received Gadopentate 0.5 M (iv), at a dose of 0.4 mL/kg BW, up to 0.6 mL/kg BW if 3 FOVs to be imaged; Period 2: Participant received Gadobutrol 1.0 M (iv: intravenous injection), at a dose of 0.2 mL/kg BW, up to 0.3 mL/kg BW if 3 Fields of View (FOVs) to be imaged
11628157|NCT00395720|Active Comparator|1|Group 1 (10 volunteers): 5 x 10^7 pfu
11628103|NCT00396253|Experimental|Tenecteplase|At each treatment, subjects had 2 mL (2 mg) of tenecteplase instilled into each lumen of their HD catheter. Subjects could receive up to three treatments with tenecteplase, the first two as part of the initial treatment course and one additional treatment as part of the retreatment (RT) course. The first treatment, followed by a 1-hour dwell time, was given to all subjects at Visit 1. At the end of hemodialysis at Visit 1, eligible subjects had a second treatment instilled for an extended dwell time until the start of Visit 2 (up to 72 hours).
11628104|NCT00396227|Experimental|1|Vildagliptin 100mg + Met
11628105|NCT00396227|Active Comparator|TZD|TZD + metformin
11628106|NCT00396214|Experimental|1|
11628107|NCT00396214|Experimental|2|
11628108|NCT00396214|Active Comparator|3|
11628109|NCT00396201|Experimental|Participants with Hodgkin's Disease (HD)|Participants with Hodgkin's Disease who were eligible for autologous peripheral blood stem cell transplantation.
11628110|NCT00396188||Normals|"Patients seeking initial laser vision correction that were screened to be good candidates for the procedure.
~No history of refractive or other ocular surgery.
~No corneal pathologies.
~Normal corneal topography.
~Contact lens wearers should discontinue use at least 2 weeks for hard contacts, and 3 days for soft lenses prior to imaging."
11628111|NCT00396188||Keratoconus|"An irregular cornea determined by distorted keratometry mires, distortion of the retinoscopic, or ophthalmoscopic red reflex (or a combination of these)
~At least one of the following biomicroscopic signs: Vogt's striae, Fleischer's ring of >2 mm arc, or corneal scarring consistent with keratoconus.
~Contact lens wearers should discontinue use preferably 1 day or at least half an hour prior to imaging."
11628112|NCT00396188||Myopic Laser Vision Correction|"Patients who have undergone myopic:
~LASIK
~PRK
~LASEK"
11628113|NCT00396188||Hyperopic Laser Vision Correction|"Patients who have undergone hyperopic:
~LASIK
~PRK
~LASEK"
11628114|NCT00396188||Orthokeratology|1. Patients using specially designed rigid contact lenses to reshape the cornea to temporarily reduce or eliminate refractive error.
11628115|NCT00396188||Others|1. Corneal conditions (diseases/ pathologies/surgeries) that can potentially affect the corneal surface that are not listed above (e.g. pellucid marginal degeneration; postoperative corneal transplant, intra-corneal ring segments, refractive keratotomy, conductive keratoplasty; peripheral ulcerative keratitis, Terrien's marginal degeneration; etc.).
11628116|NCT00396162|Placebo Comparator|Placebo pill|Placebo pills on same schedule as active intervention.
11628117|NCT00396162|Active Comparator|Probiotic|L. rhamnosus R0011 strain
11628118|NCT00396149|Placebo Comparator|Placebo|Placebo group
11628119|NCT00396149|Experimental|Active group|rBet v 1 tablets
11628120|NCT00396097|Active Comparator|Standard|Standard daily HGH treatment
11628121|NCT00396097|Active Comparator|Formula-based|Formula-based dose regimen
11628122|NCT00396084|Experimental|Gatifloxacin|10 subjects to receive gatifloxacin 400 mg orally once daily for 7 days.
11628123|NCT00396084|Active Comparator|Isoniazid|20 subjects to receive isoniazid 300 mg orally once daily for 7days.
11628124|NCT00396084|Experimental|Levofloxacin|10 subjects to receive levofloxacin 1000 mg orally once daily for 7days.
11628125|NCT00396084|Experimental|Linezolid every 12 hours|10 subjects to receive linezolid 600 mg orally every 12 hours daily for 7 days.
11628126|NCT00396084|Experimental|Linezolid once daily|10 subjects to receive linezolid 600 mg orally once daily for 7days.
11628127|NCT00396084|Experimental|Moxifloxacin|10 subjects to receive moxifloxacin 400 mg orally once daily for 7 days.
11628128|NCT00396071|Experimental|1|Vildagliptin 100 mg qd
11628129|NCT00396071|Placebo Comparator|2|Matching placebo
11628130|NCT00396032|Experimental|1|
11628131|NCT00396032|Placebo Comparator|2|
11628132|NCT00395993|Experimental|Ferric Carboxymaltose (FCM)|Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
11628133|NCT00395993|Active Comparator|Ferrous Sulfate tablets|325 mg tablets TID on Days 0 through Day 42
11628134|NCT00395967|Experimental|All Patients|Patients who were predicted to be unable to mobilize a minimum number of cells (≥2*10^6 CD34+ cells/kg) in 3 apheresis days when given granulocyte colony-stimulating factor (G-CSF) alone and who were eligible for autologous peripheral blood stem cell transplantation.
11628135|NCT00395941|Active Comparator|Control|Acitretin
11628136|NCT00395941|Experimental|Experimental|Pioglitazone
11628137|NCT00395889|Experimental|Rehabilitation + Lifestyle Counseling|Multicomponent Pulmonary Rehabilitation Program including structured exercise training
11628138|NCT00395889|Active Comparator|Lifestyle Counseling|
11628139|NCT00395876|Placebo Comparator|Placebo + Tenecteplase + Tenecteplase (PTT)|
11628140|NCT00395876|Experimental|Tenecteplase + Tenecteplase + Placebo (TTP)|
11628141|NCT00395863|Active Comparator|MultiHance|0.5 M MultiHance at a single injection
11628142|NCT00395863|Active Comparator|Magnevist|0.5 M Magnevist at a single injection
11628143|NCT00395850|Placebo Comparator|1|microcrystalline cellulose
11628144|NCT00395850|Experimental|2|disulfiram at 250 mg/day
11628145|NCT00395850|Experimental|3|Disulfiram at 375 mg/day
11628146|NCT00395850|Experimental|4|Disulfiram at 500 mg/day
11628147|NCT00395772|Active Comparator|Arm 4|
11628148|NCT00395772|Experimental|Arm 1|
11628149|NCT00395772|Experimental|Arm 2|
11628150|NCT00395772|Experimental|Arm 3|
11628151|NCT00395746|Experimental|0.6 mg + SU|Liraglutide 0.6 mg + sulphonylurea
11628152|NCT00395746|Experimental|0.9 mg + SU|Liraglutide 0.9 mg + sulphonylurea
11628153|NCT00395746|Placebo Comparator|SU Mono - 1|Liraglutide placebo 0.6 mg + sulphonylurea
11628154|NCT00395746|Placebo Comparator|SU Mono - 2|Liraglutide placebo 0.9 mg + sulphonylurea
11628155|NCT00395733|Experimental|Gadobutrol, then Gadopentate dimeglumine|Period 1: Participant received Gadobutrol 1.0 M (iv: intravenous injection), at a dose of 0.2 mL/kg BW, up to 0.3 mL/kg BW if 3 Fields of View (FOVs) to be imaged; Period 2: Participant received Gadopentate 0.5 M (iv), at a dose of 0.4 mL/kg BW, up to 0.6 mL/kg BW if 3 FOVs to be imaged
11628158|NCT00395720|Active Comparator|2|Group 2 (10 volunteers): 1 x 10^8 pfu
11628159|NCT00395707|Active Comparator|1|Lucentis 0.3mg/0.05 ml
11628162|NCT00395681|Active Comparator|propofol|propofol 200 mg versus 350 mg
11628163|NCT00395681|Active Comparator|Propofol|Propofol 350 mg versus 200 mg
11628164|NCT00395642|Experimental|HM with weight and BP remote monitoring|Device based Home Monitoring and weight and blood pressure remote monitoring
11628165|NCT00395629|Experimental|ICL670 (Deferasirox)|Three dose cohorts: 5 mg/kg/day, 10 mg/kg/day, 15 mg/kg/day
11628166|NCT00395551|Active Comparator|ranibizumab|ranibizumab 0.5mg intravitreal injection
11628167|NCT00395538|Other|Biopsy|Subjects are randomized to have the second bone biopsy done 1,2, or 4 years after the start of PTH.
11628168|NCT00395512|Experimental|Alogliptin 25 mg QD|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
11628169|NCT00395512|Active Comparator|Pioglitazone 30 mg QD|Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
11628170|NCT00395512|Experimental|Alogliptin 25 mg QD+ Pioglitazone 30 mg QD|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
11628171|NCT00395512|Active Comparator|Alogliptin 12.5 mg QD + Pioglitazone 30 mg QD|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
11628172|NCT00395486|Experimental|Rosuvastatin|
11628173|NCT00395486|Active Comparator|Atorvastatin|
11628174|NCT00395460|Experimental|Gadobutrol 0.1 mmol/kg Body Weight (BW) (Gadavist, BAY86-4875)|Participant received 0.1 mmol/kg BW Gadobutrol (= 0.1 mL/kg BW by intravenous injection at a rate of 1.0 mL/sec)
11628175|NCT00395460|Active Comparator|GD 0.1 mmol/kg BW (Magnevist, BAY86-4882)|Participant received 0.1 mmol/kg BW Gadopentetate Dimeglumine (GD) (= 0.2 mL/kg BW by intravenous injection at a rate of 2.0 mL/sec
11628176|NCT00395447||Straight-forward Device Replacement|Subject with a straight-forward device replacement without lead revisions or additions.
11628177|NCT00395447||Device Replacement with Upgrade|Subjects with a device replacement and planned lead upgrade, revision, or addition.
11628178|NCT00395421|Experimental|A|NM283(200 mg QD)plus Peg-IFNα-2a (180 µg QW)
11628179|NCT00395382|Active Comparator|1|Alendronate
11628180|NCT00395382|Placebo Comparator|2|Placebo
11628181|NCT00395343|Experimental|1|sitagliptin
11628182|NCT00395343|Placebo Comparator|2|Placebo
11628183|NCT00395317|Placebo Comparator|Arm 1|placebo (4 tablets)
11628184|NCT00395317|Experimental|Arm 2|SB-683699 150 mg bid (1 x 150mg + 3 placebo tablets)
11628185|NCT00395317|Experimental|Arm 3|SB-683699 600 mg bid (2 x 300mg + 2 placebo tablets)
11628186|NCT00395317|Experimental|Arm 4|SB-683699 900 mg bid (3 x 300 mg + 1 placebo tablet)
11628187|NCT00395317|Experimental|Arm 5|SB-683699 1200 mg bid, male subjects only (4 x 300 mg tablets)
11628188|NCT00395304|Experimental|Sequence #1|fluticasone propionate + montelukast, followed by fluticasone propionate, followed by fluticasone propionate + salmeterol
11628189|NCT00395304|Experimental|Sequence #2|fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol, followed by followed by fluticasone propionate
11628190|NCT00395304|Experimental|Sequence #3|fluticasone propionate + salmeterol, followed by fluticasone propionate, followed by fluticasone propionate + montelukast
11628191|NCT00395304|Experimental|Sequence #4|fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast, followed by fluticasone propionate
11628192|NCT00395304|Experimental|Sequence #5|fluticasone propionate, followed by fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast
11628193|NCT00395304|Experimental|Sequence #6|fluticasone propionate, followed by fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol
11628194|NCT00395291|Experimental|MK-0677 then Placebo|MK-0677 and Placebo - All subjects were given MK-0677 for a 30 +/- 7 days and then they were given a placebo for 30 +/- 7 days.
11628195|NCT00395291|Experimental|Placebo then MK-0677|MK-0677 and Placebo - All subjects were given Placebo for a 30 +/- 7 days and then they were given MK-0677 for 30 +/- 7 days.
11628196|NCT00395278||HIV negative|HIV negative without Kaposi sarcoma
11628197|NCT00395278||HIV positive|HIV positive without Kaposi sarcoma
11628198|NCT00395278||HIV positive KS|HIV positive with Kaposi sarcoma
11628199|NCT00395252|Experimental|one arm study|Cetuximab (Erbitux®) and Gemcitabine treatment over 6 months
11628200|NCT00395239|Experimental|1|
11628201|NCT00395226|Experimental|Zinc sulfate|220 mg of zinc sulfate
11628202|NCT00395226|Placebo Comparator|Lactose|270 mg lactose
11628203|NCT00395213||1|Children and adolescents with a pre-specified anxiety disorder, depressive disorder, eating disorder, or obsessive-compulsive disorder
11628204|NCT00395200|Experimental|MSC Treatment|
11628205|NCT00395174|Experimental|FluBlok|"Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2005-2006 formulation containing 45μg of each hemagglutinin derived from A/New Caledonia (H1N1), A/Wisconsin (H3N2) and B/Ohio
~135μg total"
11628206|NCT00395174|Active Comparator|TIV (Fluzone)|"Licensed trivalent influenza vaccine (TIV): 2005-2006 formulation containing 15μg of each hemagglutinin derived from A/Wisconsin (H3N2), A/New Caledonia (H1N1) and B/Malaysia
~45μg total
~(Fluzone, sanofi pasteur)"
11628207|NCT00395161|Experimental|zinc selenium glutamine metoclopramide|metoclopramide, zinc, selenium, and glutamine
11628208|NCT00395161|Placebo Comparator|enteral whey protein and IV saline|saline, sterile water, whey protein
11628209|NCT00395135|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
11628210|NCT00395135|Placebo Comparator|Matching Placebo BID|Matching placebo tablet each morning and evening
11628211|NCT00395083|No Intervention|Group 1|Patients allocated to the control arm will receive standardized care that incorporates guide-line based recommendations including influenza vaccination, a short-acting bronchodilator, and either a long-acting bronchodilator or inhaled corticosteroid inhaler.
11628212|NCT00395083|Experimental|Group 2|The comprehensive group will receive an initial, intense education program with development of an action plan, and regular telephone contacts by a case manager in addition to standardized COPD care.
11628213|NCT00395070|Experimental|Treatment Arm|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
11628214|NCT00395070|Active Comparator|Control Arm|DTIC 1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR TMZ 150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
11628215|NCT00395057|Experimental|AGN 211745 Solution 1000 ug|AGN 211745 Solution 1000 ug
11628216|NCT00395057|Experimental|AGN 211745 Solution 300 ug|AGN 211745 Solution 300 ug
11628217|NCT00395057|Experimental|AGN 211745 Solution 100 ug|AGN 211745 Solution 100 ug
11628218|NCT00395057|Active Comparator|Ranibizumab 500 ug|Ranibizumab 500 ug
11628219|NCT00395044|Experimental|Gabapentin|1200 mg/daily of Gabapentin
11628220|NCT00395044|Placebo Comparator|Placebo|1200mg/d of Placebo
11628221|NCT00395031|Other|Ziprasidone|Open label
11628222|NCT00395018|Experimental|entecavir|
11628223|NCT00394992|Active Comparator|1 oxaliplatin+capecitabine|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
11628224|NCT00394992|Experimental|2 oxaliplatin+capecitabine+bevacizumab|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
11628225|NCT00394966|Experimental|SCH 619734 Dose 1|
11628226|NCT00394966|Experimental|SCH 619734 Dose 2|
11628227|NCT00394966|Experimental|SCH 619734 Dose 3|
11628228|NCT00394966|Experimental|SCH 619734 Dose 4|
11628229|NCT00394966|Placebo Comparator|Placebo|
11628230|NCT00394953|Experimental|MIRCERA|Eligible participants with anemia in CKD who were on hemodialysis will receive methoxy polyethylene glycol-epoetin beta (MIRCERA [RO0503821]) IV once every month up to 52 weeks. The starting dose of MIRCERA which will be administered during the treatment period will depend on the dose of darbepoetin alfa administered during screening period i.e., 120, 200 and 360 mcg for weekly darbepoetin alfa doses of <40, 40-80, and >80 mcg, respectively.
11628231|NCT00394953|Active Comparator|Darbepoetin Alfa|Eligible participants with anemia in CKD who were on hemodialysis will receive darbepoetin alfa (Aranesp) IV once every two weeks up to 26 weeks and darbepoetin alfa IV twice the dose than earlier, once every month from Week 27 up to Week 52.
11628232|NCT00394914|Experimental|Pleconaril|Participants will receive Pleconaril nasal spray 4 sprays per nostril twice daily (BID), 24 mg/day for 1 week during the Treatment Period for a total of 14 doses.
11628233|NCT00394914|Placebo Comparator|Placebo|Participants will receive placebo nasal spray 4 sprays per nostril BID for 1 week during the Treatment Period for a total of 14 doses.
11628234|NCT00394901|Placebo Comparator|Placebo|
11628235|NCT00394901|Experimental|Pregabalin 150mg/day|
11628236|NCT00394901|Experimental|Pregabalin 300mg/day|
11628237|NCT00394901|Experimental|Pregabalin 600mg/day|
11628238|NCT00394888|Other|Facial Hemangioma|Patients with large facial hemangioma.
11628239|NCT00394888|Other|Lumbosacral Hemangioma|Patients with lumbosacral hemangioma.
11628240|NCT00394888|Other|Multiple Hemangiomas|patients with multiple hemangiomas (>5)
11628241|NCT00394849|Experimental|suture one tonsillar fossa|Intervention: one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
11628242|NCT00394849|No Intervention|One side not sutured|Intervention: one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
11628243|NCT00394810|Experimental|1|
11628244|NCT00394771|Experimental|Low Dose DR-1031|42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
11628245|NCT00394771|Experimental|Midrange Dose DR-1031|21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
11628246|NCT00394771|Experimental|High Dose DR-1031|21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
11628247|NCT00394771|Active Comparator|Seasonale|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.
11628248|NCT00394706|Experimental|1|Use of Impedance Threshold Device (ITD)
11628249|NCT00394706|Sham Comparator|2|Sham ITD
11628250|NCT00394706|Other|3|Analyze early. Upon EMS (emergency medical services) arrival at the scene of a non-traumatic cardiac arrest, the EMS providers assess the cardiac rhythm as soon as possible. Approximately thirty seconds of CPR (cardiopulmonary resuscitation) may be done prior to an assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
11628251|NCT00394706|Other|4|Analyze late. Upon the EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is done prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
11628252|NCT00394654|Experimental|MEDI528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
11628253|NCT00394654|Placebo Comparator|PLACEBO|Placebo administered as a single intravenous infusion
11628254|NCT00394602||Patients|Patients receiving chemoradiation for abdominal-pelvic tumors.
11628255|NCT00394602||Caregiver Controls|Healthy controls with no prior cancer diagnosis.
11628256|NCT00394589|Experimental|Increased Frequency|Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks
11628257|NCT00394589|Experimental|Increased Dose|3 mg/kg infliximab + 1 extra vial (100 mg) infliximab, every 8 weeks
11628258|NCT00394589|Active Comparator|Control|Continuation of infliximab 3 mg/kg every 8 weeks
11628259|NCT00394576|Experimental|usual care plus Internet-based nutrition module|usual care plus Internet-based nutrition module
11628260|NCT00394576|Active Comparator|usual care|usual care
11628261|NCT00394563|Experimental|1|monoclonal antibody
11628262|NCT00394563|Experimental|2|
11628263|NCT00394563|Experimental|3|
11628264|NCT00394563|Experimental|4|
11628265|NCT00394563|Experimental|5|
11628266|NCT00394563|Placebo Comparator|placebo|
11628267|NCT00394550|No Intervention|control|If laryngomalacia is found, then in the control group, no supraglottoplasty will be performed. Only the tonsils and adenoids will be removed.
11628268|NCT00394550|Experimental|Treatment|"If laryngomalacia is found, then in the Treatment group, a supraglottoplasty with laser will be performed, as well as removal of the tonsils and adenoids.
~Intervention: supraglottoplasty with laser"
11628269|NCT00394524|Experimental|Computer assisted IV insulin infusion|Subjects in this group will receive continuous intravenous (IV) Insulin Infusion using glucommander computer guided system. All patients in the study will receive Glulisine(Apidra R ) a rapid acting insulin approved by Food and Drug Administration (FDA)
11628270|NCT00394524|Active Comparator|Standard insulin infusion algorithm|Subjects in this group will receive Insulin using Standard insulin infusion algorithm. All patients in the study will receive Glulisine(Apidra R ) a rapid acting insulin approved by Food and Drug Administration (FDA)
11628271|NCT00394511|Experimental|Arm I|Radiotherapy. Irradiation of the prostatic bed using megavoltage equipment with effective photon energies of greater than 4 MV.
11628272|NCT00394511|No Intervention|Arm II|No further treatment.
11628273|NCT00394459|Active Comparator|A|Perifix Standard
11628274|NCT00394459|Experimental|B|Perifix New
11628275|NCT00394433|Experimental|Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA)|Patients received bevacizumab 10 mg/kg IV on day 1 every 3 weeks while on study. Additionally, they received docetaxel 30 mg/m2 IV over 30 minutes, followed by cisplatin 25 mg/m2 IV over 30 minutes, followed by irinotecan 50 mg/m2 IV over 30 minutes on days 1 and 8 of each 3-week cycle until disease progression or unacceptable toxicity. Dose reductions were not permitted for bevacizumab although treatment could be held up to 2 months. If bevacizumab was discontinued, treatment with other agents could continue. When docetaxel, cisplatin, or irinotecan was held on day 1 of a cycle, all agents were held.
11628276|NCT00394407|Active Comparator|sliding scale regular insulin|sliding scale insulin given acqhs
11628277|NCT00394407|Active Comparator|glargine insulin and glulisine insulin|glargine basal insulin once a day with prandial glulisine insulin tid
11628278|NCT00394381|Experimental|CIK infusion|Infusion of autologous CIK cells in study group. There is only one arm to this study
11628279|NCT00394355|Experimental|Group 1|MF DPI 400 mcg once a day (QD) in the evening (PM)
11628280|NCT00394355|Experimental|Group 2|MF DPI 200 mcg QD PM
11628281|NCT00394355|Active Comparator|Group 3|Fluticasone propionate (FP) metered dose inhaler (MDI) 250 mcg twice a day (BID)
11628282|NCT00394355|Active Comparator|Group 4|ML 10 mg QD PM
11628283|NCT00394329|Experimental|Daily ICS + Rescue ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) one puff bid + beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed + albuterol sulfate HFA (ProAir®™ 90 mcg Inhalation Aerosol) rescue puffs as needed
11628284|NCT00394329|Active Comparator|Daily ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) one puff bid + albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
11628285|NCT00394329|Experimental|Rescue ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed + albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
11628286|NCT00394329|Placebo Comparator|Placebo|Albuterol sulfate administered via a hydrofluoroalkane (HFA) inhaler (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
11628287|NCT00394303|Experimental|1|Intervention
11628288|NCT00394303|No Intervention|2|Control
11628289|NCT00394290|Experimental|PPC|Night time device for positive pulmonary pressure
11628290|NCT00394277|Experimental|PEG-IFN 180 µg + Ribavirin 1200 mg|
11628291|NCT00394277|Experimental|PEG-IFN 180 µg + Ribavirin 1400/1600 mg|
11628292|NCT00394277|Experimental|PEG-IFN 360/180 µg + Ribavirin 1200 mg|
11628293|NCT00394277|Experimental|PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg|
11628294|NCT00394251|Experimental|AC --> ABI-007|Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 260 mg/m^2 ABI-007 (Abraxane) plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
11628295|NCT00394251|Experimental|AC --> Taxol|Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 175 mg/m^2 Taxol plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
11628296|NCT00394212|Experimental|1|Transoral suturing of the dilated gastrojejunostomy
11628297|NCT00394212|Sham Comparator|2|Sham Endoscopy (suturing not performed)
11628298|NCT00394199|Experimental|1|FlutiForm 100/10ug
11628299|NCT00394199|Experimental|2|Fluticasone 100
11628300|NCT00394199|Active Comparator|3|Formoterol 10
11628301|NCT00394173|Experimental|1|
11628302|NCT00394173|Placebo Comparator|2|
11628303|NCT00394134|Other|Interview|Interviews to describe the sun exposure and sun protection practices of patients and their children.
11628304|NCT00394095|Experimental|Topiramate Group|Patients' initial dose of topiramate 25mg bid, which was titrated over 18 days to 150 mg bid (with flexibility to titrate to 200mg bid) as tolerated.
11628305|NCT00394095|Placebo Comparator|Placebo Group|Sugar pill
11628306|NCT00394082|Experimental|ABI-007 plus Bevacizumab|ABI-007 is administered on days 1, 8 and 15 at 125 mg/m^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If a patient develops intolerable toxicity to only one of the drugs, the other drug may be continued as single agent therapy in the absence of progression, as long as the treating physician feels this is in the best interests of the patient.
11628307|NCT00394069|Experimental|Montelukast sodium|Participants receive montelukast sodium for 14 days.
11628308|NCT00394056|Other|Period 1|
11628309|NCT00394056|Other|Period 2|
11628310|NCT00394056|Other|Period 3|
11628311|NCT00394043|Experimental|Osteopathic Manipulative Treatment|A protocol of specific osteopathic manipulative techniques was applied.
11628312|NCT00394043|Placebo Comparator|Placebo ultrasound|Sub-therapeutic ultrasound was applied.
11628313|NCT00394043|No Intervention|Standard Medical care|Subjects did not receive either study treatment, but continued to receive standard medical care.
11628314|NCT00394030|Experimental|Group A|In Group A healthy subjects will be randomized to receive 16 milligram (mg) of GSK716155 to abdomen.
11628315|NCT00394030|Experimental|Group B|In Group B healthy subjects will be randomized to receive 64 mg of GSK716155 to abdomen.
11628316|NCT00394030|Experimental|Group C|In Group C Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to abdomen.
11628317|NCT00394030|Experimental|Group D|In Group D Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to arm.
11628318|NCT00394030|Experimental|Group E|In Group E Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to leg.
11628319|NCT00394030|Experimental|Group F|In Group F Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to abdomen.
11628320|NCT00394030|Experimental|Group G|In Group G Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to arm.
11628321|NCT00394030|Experimental|Group H|In Group H Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to leg.
11628322|NCT00394017|Active Comparator|Intervention group|Reminder letters and usual implementations vs. usual implementation
11628323|NCT00394017|No Intervention|Control group|usual implementations
11628324|NCT00393991|Experimental|1|FlutiForm 100/10 μg
11628325|NCT00393991|Active Comparator|2|Fluticasone 100 μg
11628326|NCT00393991|Active Comparator|3|Formoterol 10 μg
11628327|NCT00393991|Placebo Comparator|4|Placebo
11628328|NCT00393978|Placebo Comparator|Quetiapine and Placebo|Quetiapine and Placebo
11628329|NCT00393978|Active Comparator|Quetiapine and Topiramate|Quetiapine and Topiramate
11628330|NCT00393952|Experimental|1|FlutiForm 250/10
11628331|NCT00393952|Active Comparator|2|FlutiForm 100/10
11628332|NCT00393952|Active Comparator|3|Fluticasone 250
11628333|NCT00393952|Active Comparator|4|Formoterol 10
11628334|NCT00393952|Placebo Comparator|5|Placebo
11628335|NCT00393939|Experimental|A|
11628336|NCT00393939|Active Comparator|B|
11628337|NCT00393913||Continuous Positive Airway Pressure (CPAP)|Participants will use a CPAP machine if they are found to have sleep apnea.
11628338|NCT00393900||1|Children with tympanostomy tubes for chronic OME
11628339|NCT00393887|Experimental|1|Biodesign IHM Graft placement
11628340|NCT00393887|Active Comparator|2|Polypropylene mesh placement
11628341|NCT00393874|Active Comparator|Medication|Treatment will be conducted under double blind conditions and will last a total of 8 weeks. Participants will also receive printed educational material about sleep hygiene developed by the American Academy of Sleep Medicine. Items include going to bed when drowsy, avoiding clock watching while awake in bed, avoidance of caffeine and alcohol, engaging in moderate exercise, and ensuring comfortable sleep environment. Clinical ratings will be obtained weekly throughout the trial.Medications will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose. The research pharmacy will prepare each dose in identical gelatin capsules to prevent identification.
11628342|NCT00393874|Active Comparator|Behavioral|"Participants randomized to BSI will receive the intervention aimed at reducing nightmares, insomnia, and sleep avoidance behavior. The treatment will be administered over 8 weeks. The intervention sessions will consist of two individual, 45-minute treatment sessions, delivered on Weeks 1 and 3. A 45-minute booster session will be conducted on Week 5. Thirty-minute face-to-face contacts will be scheduled on other weeks (i.e., Weeks 2, 4, 6, 7 and 8) to address any difficulty with the treatment instructions and techniques, to answer questions that may have occurred, and to complete weekly clinical ratings (CGI-I/SR and ASES)."
11628343|NCT00393874|Placebo Comparator|Placebo|Participants randomized to PLA will take 4 capsules each night, and capsule will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed. A placebo pill condition is included for several reasons. First, there is no approved treatment approach currently recognized as being effective for sleep disturbances associated with combat-related PTSD, and which is being withheld from subjects assigned to the placebo arm of the study. We will monitor subjects carefully and on a weekly basis.
11628344|NCT00393861|Experimental|oxaliplatin & bevacizumab|
11628345|NCT00393848|Experimental|Experiment 2 - Experimental Group|
11628346|NCT00393848|No Intervention|Experiment 1 - Standard of care Group|
11628347|NCT00393848|Experimental|Experiment 1 - Experimental Group|
11628348|NCT00393848|Placebo Comparator|Experiment 2 - Placebo Group|
11628349|NCT00393822|Experimental|Palifermin|50 subjects to receive palifermin 3 days prior to the first day (day 1) of each cycle of 5-FU/ LV chemotherapy.
11628350|NCT00393822|Placebo Comparator|Control Group|50 subjects to receive matched placebo 3 days prior to the first day (day 1) of each cycle of 5-FU/ LV chemotherapy.
11628351|NCT00393796|Active Comparator|SUTENT|Study participants randomized to received SUTENT will receive a dose of 50 mg PO (capsules) as a single agent to be taken once daily for four consecutive weeks followed by a two week rest period to form a complete cycle of six weeks.
11628352|NCT00393796|Placebo Comparator|Placebo|Study participants randomized to receive placebo will receive 50 mg/day PO (capsules) of an inactive substance to be taken once daily for four consecutive weeks followed by a two week rest period to form a complete cycle of six weeks.
11628353|NCT00393783|Experimental|1|HER2 ECD DNA.
11628354|NCT00393770|Experimental|L-acetylcarnitine|
11628355|NCT00393744|Experimental|1|
11628356|NCT00393744|Active Comparator|2|
11628357|NCT00393718|Experimental|Liraglutide|Liraglutide 0.9 mg + glibenclamide placebo
11628358|NCT00393718|Active Comparator|Glibenclamide|Glibenclamide 1.25-2.5 mg + liraglutide placebo
11628359|NCT00393705|Experimental|insulin lispro LM + insulin lispro MM|Three times per day subcutaneous injection of insulin lispro mid mixture (MM) with the possibility to change the evening injection of MM to insulin lispro low mixture (LM) if fasting blood glucose target is not achieved.
11628360|NCT00393705|Active Comparator|Insulin Biphasic Aspart 30/70 or Insulin Lispro LM|Twice daily subcutaneous injection of either insulin biphasic aspart 30/70 or insulin lispro low mixture (LM) (continuation of analogue formulation used before study enrollment).
11628361|NCT00393679|Experimental|1|AS-AQ
11628386|NCT00393380|Experimental|Parathyroid Hormone (teriparatide)|Parathyroid hormone after double umbilical cord blood transplant.
11628647|NCT00390585|Experimental|A|Iodixanol 320
11628362|NCT00393679|Experimental|2|"DHAPQ
~TO BE NOTED: since the batches of the study drug DHAPQ expire at the end of October 2008, and because of the unavailability of a new batch of DHAPQ from the manufacturer, the recruitment in the DHAPQ arm had to be discontinued on 30th October 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities."
11628363|NCT00393679|Experimental|3|AL
11628364|NCT00393679|Experimental|4|"Lapdap + AS
~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008."
11628365|NCT00393640|Active Comparator|A|Breast pump given and used on regular intervals
11628366|NCT00393640|No Intervention|B|
11628367|NCT00393640|Active Comparator|c|Breast pump given to be used on regular interval
11628368|NCT00393640|No Intervention|D|
11628369|NCT00393627|Experimental|1|Sleep Education Program: The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
11628370|NCT00393627|Placebo Comparator|2|Routine medical care
11628371|NCT00393575|Experimental|Community Mobilization|The intervention population is defined as the community each site is attempting to mobilize.
11628372|NCT00393523|Active Comparator|5 µg Modified Process Hepatitis B Vaccine Booster (Group 1)|"Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.
~During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine (Booster Dose)."
11628373|NCT00393523|Active Comparator|10 µg ENGERIX-B™ Booster (Group 2)|"Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.
~During this study, participants received a dose of 10µg/per 0.5 ml ENGERIX-B™ (Booster Dose)"
11628374|NCT00393523|Active Comparator|5 µg Modified Process Hepatitis B Vaccine Booster (Group 3)|"Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.
~During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine, (Booster Dose)."
11628375|NCT00393523|Active Comparator|10 µg ENGERIX-B™ Booster (Group 4)|"Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.
~During this study, participants received a 10µg/0.5 ml dose of ENGERIX-B™ (Booster Dose)."
11628376|NCT00393523|Experimental|5 µg Modified Process Hepatitis B Vaccine (Group 5)|"Participants did not receive a prior vaccination with a hepatitis B vaccine.
~During the study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine."
11628377|NCT00393510|Active Comparator|Traditional Chinese Medicine|12 herbals formulation was given as an adjuvant therapy for the patients orally twice a day.
11628378|NCT00393510|Placebo Comparator|Placebo|Placebo was made with starch and colouring materials. Given to patient orally twice a day
11628379|NCT00393484|Experimental|Arm A|"Entecavir + Lamivudine placebo (0-96 weeks)
~Entecavir (96-240 weeks)"
11628380|NCT00393484|Active Comparator|Arm B|"Lamivudine + Entecavir placebo (0-96 weeks)
~Lamivudine (96-240 weeks)"
11628381|NCT00393458|Experimental|Indacaterol 300 μg plus placebo to formoterol|Patients inhaled indacaterol 300 μg once daily via a single-dose dry-powder inhaler (SDDPI), placebo to indacaterol once daily via a SDDPI, and placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Indacaterol, placebo to indacaterol, and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11628382|NCT00393458|Experimental|Indacaterol 600 μg plus placebo to formoterol|Patients inhaled indacaterol 600 μg (two 300 μg capsules) once daily via single-dose dry-powder inhalers (SDDPI) plus placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11628383|NCT00393458|Active Comparator|Formoterol 12 μg plus placebo to indacaterol|Patients inhaled formoterol 12 μg twice daily via the manufacturer's proprietary inhalation device (Aerolizer®) plus placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI). Formoterol and placebo to indacaterol were taken in the morning between 8:00 and 10:00 AM; formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11628384|NCT00393458|Placebo Comparator|Placebo to indacaterol plus placebo to formoterol|Patients inhaled placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI) plus placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Placebo to indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
11628385|NCT00393445|Experimental|Intravenous infusion|intravenous infusion of test substances
11628648|NCT00390585|Active Comparator|B|Iomeprol 350
11628387|NCT00393367|Placebo Comparator|Saline Placebo|All subjects will receive 3 albuterol sulfate doses, 2 ipratropium bromide doses, and systemic corticosteroids. All patients will receive both the systemic corticosteroids and one dose of a mixture of albuterol and ipratropium bromide while guardians are approached for consent. Patients randomized to this placebo comparator arm will then receive 2 nebulized albuterol doses mixed with 8mL of normal saline. Finally, all patients will receive the second nebulized ipratropium dose.
11628388|NCT00393367|Experimental|Budesonide Inhalaiton Suspension|All subjects will receive 3 albuterol sulfate doses, 2 ipratropium bromide doses, and systemic corticosteroids. All patients will receive both the systemic corticosteroids and one dose of a mixture of albuterol and ipratropium bromide while guardians are approached for consent. Patients randomized to this intervention arm will then receive 2 nebulized albuterol doses mixed with 8mL of budesonide inhalation suspension (BIS). Finally, all patients will receive the second nebulized ipratropium dose.
11628389|NCT00393341||Case|Women with breast cancer
11628390|NCT00393341||Control|Women without breast cancer
11628391|NCT00393328|Active Comparator|A|
11628392|NCT00393328|Active Comparator|B|
11628393|NCT00393302||1 & 2|"Retrospective chart review: HIV testing rates
~Prospective cohort group: HIV testing rates"
11628394|NCT00393276|Experimental|A|HCV-infected defined as a positive result using polymerase chain reaction (PCR) without previous HCV-based therapy and without the presence of Child's B or C cirrhosis. These participants will be HIV-uninfected.
11628395|NCT00393276|Experimental|B|HIV-infected and ARV naive, with a CD4 cell count of 300 cells/mm3 or greater, with no prior or current opportunistic infection, and with no indication for HIV therapy. These participants will be HCV-uninfected.
11628396|NCT00393276|Experimental|C|HCV/HIV-coinfected as defined above in Arms A and B.
11628397|NCT00393263|Experimental|1|pimecrolimus
11628398|NCT00393263|Active Comparator|2|clobetasol
11628399|NCT00393250|Experimental|1|Hypnosis
11628400|NCT00393250|Active Comparator|2|Control
11628401|NCT00393224||cohort|hospital based family cohort
11628402|NCT00393198|Experimental|Arm 1|
11628403|NCT00393198|Placebo Comparator|Arm 2|
11628404|NCT00393198|Active Comparator|Arm 3|
11628405|NCT00393172|Experimental|exercise|5 days per week exercise for 4 months
11628406|NCT00393172|No Intervention|no exercise|
11628407|NCT00393120|Experimental|Treatment A - INCB009471 100mg IR|INCB009471, 100 mg IR orally once daily
11628408|NCT00393120|Experimental|Treatment B - INCB009471 300mg SR|INCB009471, 300 mg SR orally once daily
11628409|NCT00393120|Placebo Comparator|Treatment C - Placebo|Placebo matching INCB009471
11628410|NCT00393094|Experimental|Bevacizumab & Irinotecan Patients|Bevacizumab - 10 mg/kg intravenous injection Irinotecan - 125 mg/m^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
11628411|NCT00393068|Experimental|Treatment|"Prior to surgery study treatment will be given over a 6 weeks (Days 1-42) period. Beginning Day 1 and continuing through Day 35 patients will receive a continuous infusion of 5-FU by vein. A small portable pump will be used to administer this drug into a tube that has been surgically inserted into the patient's vein. On Day 1 and 22 patients will also receive the drugs paclitaxel, carboplatin and bevacizumab by vein. Erlotinib is given by mouth beginning on Day 1 and continuing through Day 45. Patients will receive radiation therapy daily, Monday through Friday, beginning Day 1-35 (approximately 5 weeks).
~Surgery will be performed approximately 12-14 weeks after beginning this combined treatment."
11628412|NCT00393055|Experimental|xylitol lozenge|1g xylitol lozenge. Five/day, dissolved in mouth
11628413|NCT00393055|Placebo Comparator|inactive lozenge|1g placebo lozenge. Five/day, dissolved in mouth
11628414|NCT00393042|Experimental|Focalin XR then Adderall XR|Subjects are given the Focalin XR first (dexmethylphenidate) for four weeks with a randomized placebo week followed by Adderall XR (mixed amphetamine salts) for four weeks with a randomized placebo week.
11628415|NCT00393042|Experimental|Adderall XR then Focalin XR|Subjects are given the Adderall XR (mixed amphetamine salts) for four weeks with a randomized placebo week followed by Focalin XR first (dexmethylphenidate) for four weeks with a randomized placebo week.
11628416|NCT00393029|Experimental|Patients with metastatic melanoma|Melanoma is a serious form of skin cancer that develops in the skin cells that make our skin color (melanocytes).
11628417|NCT00393029|Experimental|Patients with other metastatic cancers|
11628418|NCT00392990|Experimental|Alternating doxil/Magrath regimen & rituximab/Magrath regimen|Patients are stratified between high risk and low risk disease status. Low risk patients receive 3 cycles of rituximab (500 mg/m2) R-CODOX-M chemotherapy IV over 2-4 hours with intrathecal chemotherapy (Regimen A). High risk patients receive 1 cycle of R-CODOX-M chemotherapy IV followed by R-IVAC chemotherapy over 30 minutes(Regimen B); regimens A and B are then repeated.
11628419|NCT00392951|Experimental|Sirolimus treatment|Sirolimus treatment
11628420|NCT00392925|Experimental|Placebo and Metreleptin|Placebo-pramlintide 600 microliters (µL) twice a day (BID) and metreleptin (recombinant-methionyl human leptin) 5 milligram (mg) BID, 20 weeks
11628421|NCT00392925|Experimental|Pramlintide Acetate and Placebo|Lead-in period: 2 weeks pramlintide acetate 180 mcg BID, then 2 weeks pramlintide acetate 360 mcg BID Study period: Pramlintide acetate 360 mcg BID and placebo-metreleptin 1 mL BID, 20 weeks
11628422|NCT00392925|Experimental|Pramlintide Acetate and Metreleptin|Lead-in period: 2 weeks pramlintide acetate 180 mcg BID, then 2 weeks pramlintide acetate 360 mcg BID Study period: Pramlintide acetate 360 mcg BID and metreleptin (recombinant-methionyl human leptin) 5 mg BID, 20 weeks
11628423|NCT00392925|Other|Lead-In Period|During the Lead-In Period before a participant was randomized to a study arm, the participant received 180 mcg pramlintide acetate twice a day (BID) for 2 weeks, followed by 360 mcg pramlintide acetate BID for 2 weeks (total of 4 weeks in the Lead-In Period).
11628424|NCT00392899|Active Comparator|UFT adjuvant therapy group|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year. During protocol treatment, clinical findings and laboratory values are evaluated every month. After the completion of protocol treatment, patients are followed-up, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
11628745|NCT00389558|Active Comparator|1|Amukin
11628425|NCT00392899|No Intervention|Observation group|Patients are followed-up without adjuvant treatment, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
11628426|NCT00392886|Experimental|Regimen C|Patients receive induction therapy of vincristine IV on days 1, 8, and 15 of courses 1-3, oral temozolomide once daily on days 1-5, and carboplatin IV over 4 hours on days 1 and 2. Patients also receive G-CSF SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients receive consolidation therapy of carboplatin IV over 4 hours on days -8 to -6 and thiotepa IV over 3 hours on days -5 to -3, undergo reinfusion of bone marrow or peripheral blood stem cells on day 0, and receive G-CSF SC beginning on day 1 and continuing until blood counts recover. Beginning within 6 weeks after transplantation, some patients undergo radiotherapy once daily 5 days a week for 4-6 weeks in the absence of disease progression or unacceptable toxicity and some patients undergo radiotherapy if there is evidence of tumor remaining after completion of induction chemotherapy.
11628427|NCT00392886|Experimental|Regimen D2|In courses 1, 3, and 5, patients receive cisplatin IV over 6 hours on day 1, cyclophosphamide IV over 1 hour and etoposide IV over 2 hours on days 2 and 3, high-dose methotrexate IV over 4 hours on day 4, vincristine IV on days 1, 8, and 15 (in courses1 and 3), and filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until blood counts recover. In courses 2 and 4, patients receive oral temozolomide once daily on days 1-5, oral etoposide once daily on days 1-10, cyclophosphamide IV over 1 hour on days 11 and 12, vincristine IV on days 1, 8, and 15 (in course 2), and G-CSF SC beginning on day 13 and continuing until blood counts recover. Patients receive consolidation therapy as in regimen C in combination with etoposide IV over 3 hours on days -5 to -3 and undergo autologous bone marrow or peripheral blood stem cell transplantation, receive G-CSF, and undergo radiotherapy as in regimen C.
11628428|NCT00392873|Experimental|EAMD+Calories|This group contains women with exercise-associated menstrual disturbances (EAMD) and receives an intervention of increased caloric intake during the 12-month intervention. The targeted increase in caloric intake is 20-30% of baseline energy expenditure.
11628429|NCT00392873|No Intervention|EAMD Control|This group contains women with exercise-associated menstrual disturbances (EAMD) and undergoes the same procedures as the EAMD+Calories group. However, this group is instructed to maintain exercise and eating habits.
11628430|NCT00392873|No Intervention|Heathy Control|This group contains exercising women with regular, ovulatory menstrual cycles. this group is instructed to maintain body weight and exercise and eating habits.
11628431|NCT00392860|Experimental|PalmRim Experimental|Participants will have PalmRim installed on their wheelchair.
11628432|NCT00392860|Experimental|Natural-Fix Experiment|Participants will have a Natural-Fit installed on their wheelchair.
11628433|NCT00392860|Placebo Comparator|Handrim Control|Participants in this arm had a new standard handrim installed on their wheelchair as a control.
11628434|NCT00392847|Active Comparator|2|The first group will receive routine follow-up as currently provided by national community health and social services.
11628435|NCT00392847|Experimental|1|will receive home visits by community workers. These visits will start during pregnancy and will continue up to the child's second birthday.
11628436|NCT00392834|Experimental|Regimen A (R-CODOX-M chemotherapy)|Patients receive rituximab IV and doxorubicin hydrochloride IV over 15 minutes on day 1, cyclophosphamide IV over 30-60 minutes on days 1 and 2, pegfilgrastim SC on day 3, vincristine IV on days 1 and 8, high-dose methotrexate IV over 2-4 hours on day 15, and leucovorin calcium IV beginning 24 hours after the start of methotrexate and continuing every 6 hours until level is adequate. Patients receive CNS prophylaxis of methotrexate IT, cytarabine IT, and hydrocortisone IT on day 1. Patients with high-risk disease receive an additional dose of cytarabine IT on day 3. Patients also receive G-CSF SC once daily on days 3-9. Once the methotrexate levels drops below 50 nmol/L, patients resume G-CSF SC once daily beginning on approximately day 18 and continuing until blood counts recover.
11628437|NCT00392834|Experimental|Regimen B (rituximab and IVAC chemotherapy)|Patients receive rituximab IV on day 1, ifosfamide IV continuously and etoposide IV continuously over 24 hours on days 1-5, and high-dose cytarabine IV over 1-3 hours twice daily on days 1-2. Patients receive CNS prophylaxis comprising methotrexate IT and hydrocortisone IT on day 5. Patients also receive pegfilgrastim SC once 24-48 hours after completion of chemotherapy OR G-CSF SC beginning on day 6 and continuing until blood counts recover. Patients with CNS involvement (leptomeningeal and/or intraparenchymal) at diagnosis do not receive CNS prophylaxis as above. Instead, these patients receive a combination of sequential liposomal cytarabine and methotrexate IT or via an Ommaya reservoir on day 1 and then every 14 days as tolerated until completion of systemic chemotherapy.
11628438|NCT00392821|Experimental|RAD001 and Sorafenib|RAD001 and Sorafenib
11628439|NCT00392808|Experimental|MENC-CRM/MENC-CRM|Children primed with 3 doses of MenC-CRM vaccine, Intervention: boosted with one dose of MenC-CRM vaccine
11628440|NCT00392808|Experimental|MENC-CRM/MENC-TT|Children Primed with three doses of MenC-CRM vaccine. Intervention: boosted with one dose of MenC-TT
11628441|NCT00392808|Experimental|MENC-TT/MENC-CRM|Children primovacccinated with two MenC-TT vaccine doses. Intervention: boosted with one dose MenC-CRM vaccine
11628442|NCT00392808|Experimental|MENC-TT/MENC-TT|Children primovacccinated with two MenC-TT vaccine doses. Intervention boosted with one dose MenC-TT vaccine
11628443|NCT00392782|Experimental|Natural Killer Cell Kir Epitope|
11628444|NCT00392769|Experimental|Cetuximab|400 mg/m^2 intravenous (IV) over 120 Minutes, followed by weekly infusions at 250 mg/m^2 IV over 60 minutes.
11628445|NCT00392756|No Intervention|off treatment|Subjects undergo the baseline evaluation off treatment
11628446|NCT00392756|Experimental|GnRH Treatment|Subjects receive long term pulsatile GnRH therapy
11628447|NCT00392743||pet/spect scan|
11628448|NCT00392730||1|Preterm infants in NICU and age-matched controls
11628449|NCT00392730||2|Term infants in NICU and age-matched controls
11628450|NCT00392730||3|Children on home PN (to age 6) and age-matched controls
11628485|NCT00392314|Experimental|advanced disease IPS 3-7|Patients with advanced disease IPS score 3-7 will start chemotherapy with escalated beacopp. following 2 cycles PET/CT will be carried out and according to results further chemotherapy will be given
11628486|NCT00392288|Placebo Comparator|Placebo MDI|double-blind
11628487|NCT00392288|Experimental|Ciclesonide MDI 40 µg BID|double-blind
11628488|NCT00392288|Experimental|Ciclesonide MDI 80 µg BID|double-blind
11628451|NCT00392704|Experimental|Intervention|"All patients initially received treatment with paclitaxel 200 mg/m2, 3 hour IV infusion days 1 and 22; carboplatin area under the curve (AUC) 6.0 IV, days 1 and 22; 5-fluorouracil (5-FU) 200 mg/m2 daily by 24-hour continuous IV infusion, days 1 to 43; bevacizumab 15 mg/kg IV infusion days 1 and 22.
~One to three weeks after completing neoadjuvant therapy, patients began treatment with concurrent chemoradiation, bevacizumab, and erlotinib. Radiation therapy began on day 1, with 1.8-Gy single daily doses, Monday through Friday, to a total dose of 68.4 Gy. Paclitaxel 50 mg/m2 was administered by 1-hour IV infusion on days 1 and 22. Erlotinib 150 mg by mouth daily began concurrently with radiation therapy and continued daily during the 7-week course of radiation."
11628452|NCT00392691|Experimental|Zevalin, Rituximab, Melphalan|
11628453|NCT00392678|Placebo Comparator|Placebo|Placebo, appearance matched to active drug
11628454|NCT00392678|Active Comparator|3 gram|Salsalate 3.0 grams daily, divided
11628455|NCT00392678|Active Comparator|3.5 gram|Salsalate 3.5 g daily, divided
11628456|NCT00392678|Active Comparator|4 gram|Salsalate 4.0 g daily, divided
11628457|NCT00392665|Active Comparator|Erlotinib + Bevacizumab|erlotinib plus bevacizumab
11628458|NCT00392665|Active Comparator|Erlotinib + Sulindac|erlotinib plus sulindac
11628459|NCT00392652|Experimental|Arm I (low-dose oral diindolylmethane)|Participants receive low-dose oral diindolylmethane (BR-DIM) twice daily for 4 weeks.
11628460|NCT00392652|Experimental|Arm II (high-dose oral diinolylmethane)|Participants receive high-dose oral BR-DIM twice daily for 4 weeks.
11628461|NCT00392639|Experimental|1-2|Comparison of 2 cooling procedures
11628462|NCT00392574|Experimental|1|Prulifloxacin
11628463|NCT00392574|Placebo Comparator|2|Placebo
11628464|NCT00392561|Experimental|1|Selenium
11628465|NCT00392561|Experimental|2|Vitamin E
11628466|NCT00392561|Experimental|3|Vitamin E + Selenium
11628467|NCT00392561|No Intervention|Arm 4|
11628468|NCT00392535|Active Comparator|Control arm|conventional radiotherapy (74 Gy delivered in 37 fractions over 7·4 weeks)
11628469|NCT00392535|Experimental|Hypofractionated arm 1|Hypofractionated radiotherapy (60 Gy in 20 fractions over 4 weeks)
11628470|NCT00392535|Experimental|Hypofractionated arm 2|Hypofractionated radiotherapy (57 Gy in 19 fractions over 3·8 weeks)
11628471|NCT00392509|Experimental|2|Unfractionated Autologous Mononuclear Bone Marrow
11628472|NCT00392496|Experimental|Arm I|This is a non-randomized, open-label, multicenter study. Patients receive sunitinib malate orally once daily on days 1-28. Treatment repeats every 4 weeks for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity.
11628473|NCT00392444|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
11628474|NCT00392392|Experimental|Intervention|Patients received treatment with nab-paclitaxel (100 mg/m2 IV days 1, 8, 15) and carboplatin (AUC 6 IV day 1) every 28 days for 6 cycles. Trastuzumab (4 mg/kg loading dose, followed by 2 mg/kg) and bevacizumab (5 mg/kg IV) were administered weekly for 23 weeks, beginning concurrently with chemotherapy. Patients then underwent either mastectomy or breast conserving surgery and pathologic treatment responses were assessed. After surgery, trastuzumab 6 mg/kg and bevacizumab 15 mg/kg were administered at 3 week intervals for a total of 52 weeks.
11628475|NCT00392379|Experimental|A|4 mg nicotine lozenges for 3 months
11628476|NCT00392379|Placebo Comparator|B|Placebo nicotine lozenges for 3 months
11628477|NCT00392353|Experimental|Treatment (azacitidine, vorinostat)|Patients receive azacitidine SC QD on days 1-7 and vorinostat PO 2-3 times daily on days 3-5, 3-9, or 3-16. Treatment repeats every 28 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
11628478|NCT00392327|Active Comparator|Arm A (chemoradiotherapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy QD five days a week for 6 weeks. Patients also receive vincristine sulfate IV over 1 minute once weekly for 6 weeks. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.
~MAINTENANCE THERAPY: Patients receive cisplatin IV over 6 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 8, and cyclophosphamide IV over 1 hour on days 2 and 3. Patients also receive filgrastim SC or IV beginning on day 4 and continuing until blood counts recover (at least 10 days).
~Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity."
11628479|NCT00392327|Experimental|Arm B (chemoradiotherapy)|"CHEMORADIOTHERAPY: Patients receive vincristine sulfate and undergo radiation therapy as in Arm A. Patients also receive carboplatin IV over 15 minutes on each day of radiation therapy. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.
~MAINTENANCE THERAPY: Patients receive maintenance therapy as in Arm A."
11628480|NCT00392327|Experimental|Arm C (chemoradiotherapy, isotretinoin-CLOSED TO ACCRUAL)|"CHEMORADIOTHERAPY: Patients undergo chemoradiotherapy as in Arm A. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.
~MAINTENANCE THERAPY: Patients receive isotretinoin PO BID on day 1 and days 16-28 and cisplatin, vincristine sulfate, cyclophosphamide, and filgrastim as in Arm A maintenance therapy. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to continuation therapy.
~CONTINUATION THERAPY: Patients receive isotretinoin PO BID on days 15-28 every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
11628481|NCT00392327|Experimental|Arm D (chemoradiotherapy, isotretinoin-CLOSED TO ACCRUAL)|"CHEMORADIOTHERAPY: Patients undergo chemoradiotherapy as in Arm B. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.
~MAINTENANCE THERAPY: Patients receive maintenance therapy as in Arm C. Patients then proceed to continuation therapy.
~CONTINUATION THERAPY: Patients receive continuation therapy as in Arm C."
11628482|NCT00392314|Experimental|Early favorable|patients with early favorable disease Ia IIA will have a PET/CT following 2 cycles of ABVD
11628483|NCT00392314|Experimental|Early Unfavorable|Patients with early favorable disease Ia or IIa with risk factors :large mediastinal mass extra nodal disease elevated esr, three or more involved areas, age equal or >50 , lymphocytic depleted or mixed cellularity
11628484|NCT00392314|Experimental|advanced disease|patients with advanced disease low IPS score 0-2 will start chemotherapy with ABVD for 2 cycles followed by PET/CT further therapy will be given according to PET/CT results
11628646|NCT00390598|Active Comparator|4 L PEG|Bowel preparation with 4 L PEG prior to colonoscopy.
11628489|NCT00392236|Experimental|A|Participants will receive treatment as usual and a 2-way pager for 6 months
11628490|NCT00392236|Active Comparator|B|Participants will receive treatment as usual
11628491|NCT00392223|Experimental|Treatment Group A|
11628492|NCT00392223|Experimental|Treatment Group B|
11628493|NCT00392210|No Intervention|Spontaneous Fill|
11628494|NCT00392210|Active Comparator|Retrograde Fill|
11628495|NCT00392184|Experimental|APBI|Accelerated Partial Breast Irradiation with interstitial Brachytherapy
11628496|NCT00392171|Experimental|Temozolomide|Temozolomide will be administered at a dose of 50 mg/m^2 for cycles of 28 days for 12 months or until progression.
11628497|NCT00392145|Active Comparator|1|
11628498|NCT00392145|Experimental|2|
11628499|NCT00392106|Active Comparator|Control|Class I or III anti-arrhythmic drug for the treatment of AF
11628500|NCT00392106|Experimental|Treatment|Pulmonary vein ablation with HIFU
11628501|NCT00392080|Placebo Comparator|3|
11628502|NCT00392080|Experimental|1|75 mg BID
11628503|NCT00392080|Experimental|2|
11628504|NCT00392054|Experimental|Catheter Ablation|Pulmonary vein isolation performed by catheter ablation for the prevention of recurrence of symptomatic atrial fibrillation
11628505|NCT00392054|Active Comparator|Antiarrhythmic Drug Therapy|Conventional antiarrythmic drug therapy for the prevention of recurrence of symptomatic atrial fibrillation
11628506|NCT00392041|Experimental|Eszopiclone|
11628507|NCT00392041|Placebo Comparator|Placebo|
11628508|NCT00392015|Experimental|Dose-escalation|NMRC-M3V-Ad-PfCA
11628509|NCT00392015|Experimental|Regimen-comparison|NMRC-MV-Ad-PfC, NMRC-MV-Ad-PfA
11628510|NCT00391976|Experimental|Tobramycin 300 mg for 28 days|Patients inhaled tobramycin 300 mg bis in die (bid, twice a day) for 28 days using the PARI LC PLUS™ jet nebulizer and a suitable compressor. The 2 daily doses were taken approximately 12 hours apart and no less than 6 hours apart.
11628511|NCT00391976|Experimental|Tobramycin 300 mg for 56 days|Patients inhaled tobramycin 300 mg bis in die (bid, twice a day) for 56 days using the PARI LC PLUS™ jet nebulizer and a suitable compressor. The 2 daily doses were taken approximately 12 hours apart and no less than 6 hours apart.
11628512|NCT00391937|Experimental|1|ASR prosthesis placed using CAS
11628513|NCT00391937|Active Comparator|2|ASR prosthesis placed by conventional method
11628514|NCT00391911|Active Comparator|NAC and CRRT|N-Acetylcysteine and CRRT Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label,
11628515|NCT00391911|Other|NAC and non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
11628516|NCT00391911|Other|Placebo and CRRT|Patients are assigned to placebo treatment and CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT is open label.
11628517|NCT00391911|Other|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. This is the standard of care arm. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
11628518|NCT00391898|Experimental|Levodopa/carbidopa/entacapone|
11628519|NCT00391898|Active Comparator|Levodopa/carbidopa|
11628520|NCT00391872|Active Comparator|Clopidogrel|Oral treatment
11628521|NCT00391872|Experimental|Ticagrelor|Oral treatment
11628522|NCT00391859|Experimental|Health service provision|Health service provision within the first few months of diagnosis which includes physical examination, radiographs, education, exercise, weight loss, assistive devices and pharmacologic therapy.
11628523|NCT00391846|Other|Guided by NT-proBNP|Treatment guided by clinical symptoms and signs + NTproBNP
11628524|NCT00391846|Other|Not Guided by NT-proBNP|Treatment guided by clinical symptoms and signs
11628525|NCT00391807|Experimental|study drug|Norethindrone/Ethinyl Estradiol
11628526|NCT00391794|Experimental|ESSG|eight weekly 90-minute sessions
11628527|NCT00391794|Active Comparator|ES|one 4-hour educational program
11628528|NCT00391768|Experimental|oseltamivir (Tamiflu®)|
11628529|NCT00391755|Active Comparator|1|ramelteon 8 mg po qhs with sleep and migraine journal
11628530|NCT00391755|Placebo Comparator|2|Placebo po qhs with sleep and migraine journal
11628531|NCT00391729|Placebo Comparator|1|
11628532|NCT00391729|Experimental|2|
11628533|NCT00391716|Experimental|gabapentin 900mg daily|900mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.
11628534|NCT00391716|Experimental|gabapentin 1800mg daily|1800 mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks
11628535|NCT00391716|Placebo Comparator|placebo daily|placebo capsules daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.
11628536|NCT00391703|Experimental|1|Quadriceps electrostimulation program, performed prior to an endurance retraining program using a cycloergometer
11628537|NCT00391703|Active Comparator|2|Usual sport activity, performed prior to an endurance retraining program using a cycloergometer
11628538|NCT00391677|Experimental|1|Participants will receive social skills training with attention shaping procedures
11628539|NCT00391677|Active Comparator|2|Participants will receive social skills training without attention shaping procedures
11628540|NCT00391651|Active Comparator|1|Nitrofurantoin 100mg BID x 5 days
11628541|NCT00391651|Active Comparator|2|TMP/SMX DS BID x 3 days
11628542|NCT00391638|Experimental|HIV antiretroviral therapy, TRUVADA , PEGASYS 180μg|Week-8 up Week0: HIV antiretroviral therapy Week 0 up Week 48: HIV antiretroviral therapy + TRUVADA + PEGASYS 180μg Week 48 up Week 72: HIV antiretroviral therapy + TRUVADA Week 72 up Week 144: HIV antiretroviral therapy
11628543|NCT00391625|Experimental|GA-GCB|15-60 U/kg every other week via intravenous infusion
11628544|NCT00391612|Sham Comparator|2|subject receives optimal medical management, supervised pulmonary rehabilitation therapy and undergoes bronchoscopy but no stents are placed
11628545|NCT00391612|Experimental|1|subject receives optimal medical management, supervised pulmonary rehabilitation therapy and undergoes bronchoscopy during which up to six Exhale drug-eluting stents are placed in the lungs
11628546|NCT00391599|Experimental|Study Group|a fleet enema (250 cc of sodium biphosphate 16 gr and sodium phosphate 6 gr per 100 cc) the night before cesarean section
11628547|NCT00391599|Active Comparator|Control Group|no preoperative intestinal preparation.
11628548|NCT00391586|Experimental|Erlotinib followed by chemotherapy|"Erlotinib: 150 mg orally once daily,
~Platinum-based chemotherapy regimen selections include:
~Carboplatin (Carbo) area under the curve (AUC) 6, or cisplatin (Cis) 60-100 mg/m2, day (D)1, administered with one of the following:
~Docetaxel 75 mg/m2, D1
~Docetaxel 35 mg/m2, D1,8,15
~Paclitaxel 200-225 mg/m2, D1
~Paclitaxel 80-100 mg/m2, D1,8,15
~Carbo AUC 5-6, or Cis 60-100 mg/m2, D1, administered with one of the following:
~Etoposide 100 mg/m2 D1-3
~Etoposide 200 mg/m2 orally D1-3
~Pemetrexed 500 mg/m2, D 1
~Irinotecan 50 mg/m2 D1,8,15
~Other regimens:
~Gemcitabine 1000 mg/m2-1250 mg/m2, D1,8 + Carbo AUC 6, or Cis 60-100 mg/m2, D1 or 8
~Vinorelbine 25 mg/m2 D1,8 + Carbo AUC 5, or Cis 80 mg/m2 D1"
11628549|NCT00391560|Experimental|Group 1 on Perifosine|"Patients with AML, MDS, CML-BP non-lymphoid, CMML, or Agnogenic Myeloid Metaplasia (AMM).
~After a one-time loading dose of 600 mg (150 mg x 4 at least 4 hours apart) during the first cycle, perifosine will be given orally at 100 mg once a day continuously. Cycles are 28 days in length.
~Intra-patient dose escalation for the maintenance dose to 150 mg daily will be done in the second cycle if no non-hematological toxicities beyond grade 0-1 occurred during the first cycle are observed."
11628550|NCT00391560|Experimental|Group 2 on Perifosine|"Patients with CLL, ALL, or CML-BP lymphoid. After a one-time loading dose of 600 mg (150 mg x 4 at least 4 hours apart) during the first cycle, perifosine will be given orally at 100 mg once a day continuously. Cycles are 28 days in length.
~Intra-patient dose escalation for the maintenance dose to 150 mg daily will be done in the second cycle if no non-hematological toxicities beyond grade 0-1 occurred during the first cycle are observed."
11628551|NCT00391534|Experimental|Oxcarbazepine MR|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
11628552|NCT00391534|Active Comparator|Oxcarbazepine IR|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
11628553|NCT00391521|Active Comparator|1|Regimen 1
11628554|NCT00391521|Active Comparator|2|Regimen 2
11628555|NCT00391521|Active Comparator|3|Regimen 3
11628556|NCT00391469|No Intervention|control treatment|
11628557|NCT00391443|Experimental|Bosentan|Subjects receive bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg b.i.d (if body weight > 40 kg) or bosentan 62.5 mg b.i.d. (if body weight < 40 kg)
11628558|NCT00391443|Placebo Comparator|Placebo|Subjects receive placebo matching the bosentan treatment regimen
11628559|NCT00391430|No Intervention|Control|Participants assigned to the control condition will receive no treatment
11628560|NCT00391430|Active Comparator|Sertraline|Participants will receive treatment with sertraline
11628561|NCT00391430|Active Comparator|CBT|Participants will receive cognitive behavioral therapy
11628562|NCT00391404|Active Comparator|Alendronate|Oral alendronate 70 mg weekly
11628563|NCT00391404|Placebo Comparator|Placebo|Conventional drug treatment
11628564|NCT00391391|Experimental|1|Split, Inactivated, Trivalent Influenza Vaccine
11628565|NCT00391391|Experimental|2|Split, Inactivated, Trivalent Influenza Vaccine
11628566|NCT00391391|Active Comparator|3|Split, Inactivated, Trivalent Influenza Vaccine
11628567|NCT00391391|Active Comparator|4|Split, Inactivated, Trivalent Influenza Vaccine
11628568|NCT00391365||Group 1|Subjects undergoing ankle arthrodesis (fusion) for treatment of ankle arthritis
11628569|NCT00391365||Group 2|Subjects undergoing ankle arthroplasty (replacement) for treatment of ankle arthritis
11628570|NCT00391352||MS|MS patient is matched to healthy volunteer
11628571|NCT00391352||Control|
11628572|NCT00391287||erythropoietin treatment in CRF|Patients exposed to EPREX or other marketed erythropoietin products administered by the subcutaneous route of administration for the treatment of anemia of Chronic Renal Failure
11628573|NCT00391274|Experimental|Pemetrexed|
11628574|NCT00391274|Active Comparator|Docetaxel|
11628575|NCT00391235||BPD|Children with bipolar disorder
11628576|NCT00391235||HC|Healthy comparison children
11628577|NCT00391222|Experimental|001|Risperidone Long Acting Injectable (LAI) Intramuscular injections of risperidone LAI (25 37.5 or 50 mg) every 2 weeks and oral placebo daily
11628578|NCT00391222|Placebo Comparator|002|Placebo Intramuscular injections of placebo every 2 weeks and oral placebo daily
11628579|NCT00391222|Active Comparator|003|Olanzapine Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily
11628580|NCT00391209|Experimental|1|
11628581|NCT00391209|Experimental|2|
11628582|NCT00391196|Placebo Comparator|Placebo|
11628583|NCT00391196|Experimental|CP-945,598|
11628584|NCT00391196|Experimental|CP-945,598 Treatment B|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
11628585|NCT00391183|Active Comparator|Endoscopic stenting|patients with biliary obstruction will undergo endoscopic stenting.
11628586|NCT00391183|No Intervention|Best supportive care|
11628587|NCT00391170|Experimental|Active|Dexamethasone 0.01%
11628588|NCT00391170|Placebo Comparator|Placebo|Placebo oral rinse
11628589|NCT00391131|Experimental|Ig NextGen 16%|
11628590|NCT00391118|Experimental|A (Part A)|"Enzastaurin: 1125 milligram (mg) loading dose then 500 mg oral tablet, daily for six 21-day cycles or up to 3 years
~Carboplatin: Area under the concentration time curve (AUC) 5 intravenous (IV), every (q) 21 days for six 21-day cycles
~Paclitaxel:175 milligrams/square meter (mg/m²) IV, q21 days for six 21-day cycles"
11628591|NCT00391118|Placebo Comparator|B (Part B)|"Carboplatin: AUC5 IV, q21 days for six 21-day cycles
~Paclitaxel: 175 mg/m², IV, q21 days for six 21-day cycles
~Placebo: oral tablet"
11628592|NCT00391092|Experimental|1|
11628593|NCT00391092|Active Comparator|2|
11628594|NCT00391079|Experimental|A|
11628595|NCT00391079|Placebo Comparator|B|
11628596|NCT00391066|Active Comparator|1|"FCR
~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks
~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks
~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
11628597|NCT00391066|Experimental|2|"FCR + Lumiliximab (L)
~L (Lumiliximab): Day 2 50 mg/m2, Day 4 450 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks.
~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks
~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks
~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
11628598|NCT00391053|Experimental|Study Group 1|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 1
11628599|NCT00391053|Experimental|Study Group 2|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 2
11628600|NCT00391053|Experimental|Study Group 3|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 3
11628601|NCT00391053|Active Comparator|Group 4|Participants will receive the Standard Fluzone® vaccine
11628602|NCT00391027|Active Comparator|Insulin Glargine (Lantus®)|
11628603|NCT00391027|Active Comparator|Inhaled Human Insulin (Exubera®)|
11628604|NCT00391014|Experimental|1|"AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.
~If patient required ALO-TPH, the prophylaxis should be followed."
11628605|NCT00391001|Experimental|1|
11628606|NCT00391001|Placebo Comparator|2|
11628607|NCT00390949|Experimental|Intervention arm|Peer education with female sex workers and potential male clients. Strengthened syndromic management of STIs with community-based promotion activities
11628608|NCT00390949|No Intervention|Control|Standard of care
11628609|NCT00390936|No Intervention|1|4 dosages
11628610|NCT00390923|Experimental|1|
11628611|NCT00390923|Placebo Comparator|2|
11628612|NCT00390910|Experimental|Synflorix™ + Infanrix™ hexa Group I|Very preterm infants born after a gestation period of 27-30 weeks (189-216 days)
11628613|NCT00390910|Experimental|Synflorix™ + Infanrix™ hexa Group II|Mild pretem infants born after a gestation period of 31-36 weeks (217-258 days)
11628614|NCT00390910|Experimental|Synflorix™ + Infanrix™ hexa Group III|Infants born after a gestation period of more than 36 weeks (more than 258 days)
11628615|NCT00390884|Experimental|Fluzone®-Primed Group|Participants had received two doses of the 2005-2006 formulation of Fluzone® vaccine in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.
11628616|NCT00390884|Experimental|Fluzone®-Naive Group|Participants had never received Influenza vaccine and had received two doses of placebo in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.
11628617|NCT00390871|Active Comparator|Fentanyl/Propofol sedation first|Patient given fentanyl only first, then sedated with fentanyl/propofol as needed to have Richmond Agitation Sedation Scale (RASS) Score 0 to -1. After washout with fentanyl only, patient sedated with fentanyl/dexmedetomidine to have RASS Score 0 to -1.
11628618|NCT00390871|Active Comparator|Fentanyl/Dexmedetomidine sedation first|Patient given fentanyl only first, then sedated with fentanyl/dexmedetomidine as needed to have RASS Score 0 to -1. After washout with fentanyl only, patient sedated with fentanyl/propofol to have RASS Score 0 to -1.
11628619|NCT00390858|Experimental|Deferasirox|Initial dose of 10 mg/kg, dose modifications of ± 5 or 10 mg/kg were based on participant response.
11628620|NCT00390845|Experimental|SB681323|Patients with pain associated with peripheral nerve injury and/or compression will be recruited for this study.
11628621|NCT00390845|Experimental|Placebo|Patients with pain associated with peripheral nerve injury and/or compression will be recruited for this study.
11628622|NCT00390832|Active Comparator|A|recombinant human erythropoietin beta
11628623|NCT00390832|Placebo Comparator|B|0.9% NaCl solution
11628624|NCT00390806|Experimental|topotecan plus radiation|topotecan 1.1 mg/m2 followed by whole brain radiation 3 Gy/day for 10 days, followed by optional continuation therapy with topotecan 2.3 mg/m2 for 5 days Q21 days as monotherapy.
11628625|NCT00390806|Active Comparator|Whole brain radiation|Whole brain radiation 3 Gy/day for 10 days
11628626|NCT00390793|Experimental|Treatment (chemotherapy, dasatinib)|See detailed description in outline.
11628627|NCT00390780|Active Comparator|Clotrimazole|Clotrimazole troches, 10 mg, 5 times per day for 14 days
11628628|NCT00390780|Experimental|miconazole Lauriad|Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days
11628629|NCT00390767|Experimental|MultiGeneAngio|Escalating doses of MultiGeneAngio
11628630|NCT00390754|Experimental|Pregnancy Test Group|Group got free home pregnancy test kits
11628631|NCT00390754|No Intervention|2|Group did not receive free home pregnancy test kits
11628632|NCT00390741|Active Comparator|1|Home-based exercise program
11628633|NCT00390741|No Intervention|2|Usual care
11628634|NCT00390702|Experimental|VSD occluder|transcatheter implantation of a VSD occluder (Nitinol coil)
11628635|NCT00390689|Experimental|Pramipexole 0.25 mg once daily|Pramipexole 0.25 mg given once daily
11628636|NCT00390689|Experimental|Pramipexole 0.5 mg once daily|Pramipexole 0.5 mg given once daily
11628637|NCT00390689|Experimental|Pramipexole 0.75 mg once daily|Pramipexole 0.75 mg given once daily
11628638|NCT00390637|Experimental|1|Low Protein, Low GI Diet
11628639|NCT00390637|Experimental|2|Low Protein, High Glycemic Index Diet
11628640|NCT00390637|Experimental|3|High Protein, Low Glycemic Index diet
11628641|NCT00390637|Experimental|4|High Protein, High glycemic index diet
11628642|NCT00390637|Experimental|5|Control diet (current recommendations)
11628643|NCT00390611|Active Comparator|Paclitaxel/Carboplatin/Sorafenib|Paclitaxel 175 mg/m2 1-3 hour IV infusion, Day 1 Carboplatin AUC 6 infused over 20 minutes IV, Day 1 Sorafenib 400mg PO bid
11628644|NCT00390611|Active Comparator|Paclitaxel/carboplatin|Paclitaxel 175 mg/m2 1-3 hour IV infusion, Day 1 Carboplatin AUC 6 infused over 20 minutes IV
11628645|NCT00390598|Active Comparator|senna 36 mG + PEG 2L|Bowel preparation with senna tablets 36 mG and PEG 2L prior to colonoscopy.
11628649|NCT00390572|Experimental|Sleep Specialty Consultation|Participants randomized to receive a one-time sleep consultation at beginning of study
11628650|NCT00390572|No Intervention|Treatment as Usual|Participants randomized to receive a one-time sleep consultation after completing study procedures (after 10 month study wait-list period).
11628651|NCT00390559|Experimental|ActiveP/ActiveC|21 mg patch/Nicotine-containing cigarette
11628652|NCT00390559|Experimental|PlaceboP/ActiveC|0 mg patch/nicotine-containing cigarette
11628653|NCT00390559|Experimental|Active P/PlaceboC|21 mg patch/no nicotine cigarette
11628654|NCT00390559|Experimental|PlaceboP/PlaceboC|0 mg patch/no nicotine cigarette
11628655|NCT00390546|Experimental|Propranolol|Single dose of 0.5 mg/kg per dose and increased to 1.0 mg/kg per dose ITD for the second and subsequent doses.
11628656|NCT00390546|Experimental|Digoxin|First 2 doses at 0.010 mg/kg per dose TID, then 0.0035 mg/kg per dose TID for the third and subsequent doses
11628657|NCT00390533|Experimental|Saredutant 30 mg|Saredutant 30 mg once daily for a maximum of 8 weeks
11628658|NCT00390533|Experimental|Saredutant 100 mg|Saredutant 100 mg once daily for a maximum of 8 weeks
11628659|NCT00390533|Placebo Comparator|Placebo|Placebo for saredutant once daily for one week during the screening phase and for a maximum of 8 weeks during the acute phase
11628660|NCT00390481|Other|Intervention|EC-IC Bypass
11628661|NCT00390481|No Intervention|Control|Best Medical Therapy
11628662|NCT00390468|Experimental|Tandutinib (MLN518)|500 mg twice daily, a small-molecule inhibitor of the type III receptor tyrosine kinases. Tandutinib (MLN518) previously known as CT53518.
11628663|NCT00390455|Experimental|Arm I (lapatinib)|Patients receive lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 and 15 of course 1 and on day 1 of each subsequent course. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11628664|NCT00390455|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28 and fulvestrant as in Arm I. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11628665|NCT00390429|Experimental|Phase I, Group I (completed)|Patients receive docetaxel IV over 1 hour on day 1 and oral erlotinib hydrochloride once on days 2, 9, and 16. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression. Patients may then continue to receive erlotinib hydrochloride alone in the absence of unacceptable toxicity or disease progression.
11628666|NCT00390429|Experimental|Phase I, Group II (completed)|Patients receive docetaxel as in group I and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression. Patients may then continue to receive erlotinib hydrochloride alone in the absence of unacceptable toxicity or disease progression.
11628667|NCT00390429|Experimental|Phase II|Patients receive docetaxel IV over 1 hour on day 1 and oral erlotinib hydrochloride at the MTD determined in group II of phase I once daily on days 2-16. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may then continue to receive erlotinib hydrochloride alone in the absence of disease progression or unacceptable toxicity.
11628668|NCT00390416|Experimental|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
11628669|NCT00390338|Experimental|peptide-pulsed type-1-polarized dendritic cells|intralymphatic vaccination with peptide-pulsed type-1-polarized dendritic cells (aDC1)
11628670|NCT00390338|Experimental|peptide-pulsed mature non-polarized dendritic cells (cDCs)|intralymphatic vaccination with peptide-pulsed mature non-polarized dendritic cells (cDCs)
11628671|NCT00390325|Experimental|Treatment (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity.
11628672|NCT00390312|Active Comparator|4|Intravenous morphine
11628673|NCT00390312|Experimental|1|Intranasal morphine 7.5 mg
11628674|NCT00390312|Experimental|2|Intranasal morphine 15 mg
11628675|NCT00390312|Active Comparator|3|Oral morphine 60 mg
11628676|NCT00390312|Placebo Comparator|5|Intranasal placebo
11628677|NCT00390312|Placebo Comparator|6|Oral placebo
11628678|NCT00390312|Placebo Comparator|7|Intravenous placebo
11628679|NCT00390299|Experimental|Arm A (resection cavity administration)|Patients undergo en block resection of their tumor (after confirming diagnosis) on day 1, followed by MV-CEA administered into the resection cavity.
11628680|NCT00390299|Experimental|Arm B (intratumoral and resection cavity administration)|Patients undergo stereotactic biopsy (to confirm the diagnosis) and placement of a catheter within the tumor, followed by MV-CEA IT through the catheter over 10 minutes on day 1. Patients then undergo en block resection of their tumor with computer-assisted stereotactic techniques on day 5, followed by MV-CEA administered around the tumor bed.
11628681|NCT00390234|Experimental|Treatment (ziv-aflibercept)|Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
11628682|NCT00390221|Placebo Comparator|Placebo|Participants will receive 3 subcutaneous (SC) injections of placebo every 4 weeks for up to 52 weeks.
11628683|NCT00390221|Experimental|150 mg DAC HYP|Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.
11628684|NCT00390221|Experimental|300 mg DAC HYP|Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.
11628685|NCT00390208|Other|Group 1|Combination triple therapy of Lucentis, Dexamethasone and Visudyne Therapy
11628686|NCT00390208|Other|Group 2|Monotherapy: One 0.5 mg intravitreal Ranibizumab injection
11628687|NCT00390195|Experimental|1. Daily|Taking orally the investigational drug daily
11628688|NCT00390195|Experimental|2. Weekly|Taking orally the investigational drug weekly
11628689|NCT00390182|Experimental|Single Arm|"Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.
~Radiation: External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy."
11628690|NCT00390143|Experimental|Group A|Subjects previously primed with meningococcal vaccine 134612.
11628691|NCT00390143|Active Comparator|Group B|Subjects previously primed with Mencevax™ ACWY.
11628692|NCT00390130|Active Comparator|Pentacel|The subjects in this arm will be vaccinated with Pentacel
11628693|NCT00390130|Active Comparator|Prevnar|The subjects in this arm will be vaccinated with Prevnar
11628694|NCT00390117|Experimental|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
11628695|NCT00390078|Active Comparator|1|20 Subjects, 1x 10E8_TCID50 MVA-mBN32
11628696|NCT00390078|Placebo Comparator|2|10 Subjects 1x 10E8_TCID50 IMVAMUNE
11628697|NCT00390065|Experimental|Study group|Hypoxemic Respiratory Failure treated by Nitric Oxide;
11628698|NCT00390065|Placebo Comparator|Control|Hypoxemic Respiratory Failure control (Placebo);
11628699|NCT00390065|No Intervention|Reference|Reference (Non hypoxemic respiratory failure)
11628700|NCT00390052|Experimental|Arm I|Patients will receive a 2-hour infusion of 3-AP once in week 1. Beginning in week 2, they will receive 3-AP by mouth twice a day 3 days a week for 3 weeks. Treatment with 3-AP by mouth may repeat every 4 weeks for as long as benefit is shown.
11628701|NCT00390039|Experimental|A|MNS075 7.5mg
11628702|NCT00390039|Placebo Comparator|B|Placebo
11628703|NCT00390039|Active Comparator|C|IV Morphine
11628704|NCT00390039|Experimental|E|MNS075 15mg
11628705|NCT00390039|Placebo Comparator|D|Placebo
11628706|NCT00390039|Placebo Comparator|F|Placebo
11628707|NCT00390013|Active Comparator|Gabapentin|Gabapentin (Neurontin) titration and dosing for total of 8 weeks (Cross over)
11628708|NCT00390013|Placebo Comparator|Placebo oral capsule|Placebo titration and dosing for total of 8 weeks (Cross over)
11628709|NCT00390000|Experimental|Arm I|See Detailed Description
11628710|NCT00389974|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO daily for 4 weeks. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or PR may receive 2 courses after CR or PR is reached.
11628711|NCT00389935|Experimental|Treatment|
11628712|NCT00389922|Experimental|A (Daily Dosing)|"Oral lapatinib given daily for 28 days plus IV vinorelbine given weekly (3 out of 4 weeks)
~Cohorts of 3-6 patients receive escalating doses of lapatinib ditosylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during course 1. At least 6 patients are treated at the MTD. Once the MTD of lapatinib has been determined, patients may be accrued to group B or to a separate pharmacokinetics cohort in group A."
11628713|NCT00389922|Experimental|B (Intermittent Dosing)|"Oral lapatinib given days 2-5, 9-12 and 16-25 plus IV vinorelbine given weekly (3 out of 4 weeks)
~Cohorts of 3-6 patients receive escalating doses of lapatinib ditosylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during course 1. At least 6 patients are treated at the MTD. Once the MTD of lapatinib has been determined, patients may be accrued to group B or to a separate pharmacokinetics cohort in group A."
11628714|NCT00389909|Active Comparator|1|Treatment based on patient weight;
11628715|NCT00389909|Active Comparator|2|Treatment based on a chart taking into account weight, age and gender
11628716|NCT00389883|Active Comparator|1|propofol et remifentanil
11628717|NCT00389883|Experimental|2|sevoflurane et sufentanil
11628718|NCT00389857|Experimental|Influenza vaccine-naive group|Participants have never received Influenza virus vaccine in the past. They will receive a single dose of Fluzone vaccine on Day 0 and Day 28, respectively.
11628719|NCT00389857|Experimental|Influenza vaccine-primed group|Participants have received Influenza virus vaccine in the past. They will receive a single dose of Fluzone vaccine on Day 0.
11628720|NCT00389844|No Intervention|1|Routine care
11628721|NCT00389844|Active Comparator|2|Exercise only
11628722|NCT00389844|Active Comparator|3|Motivation only
11628723|NCT00389844|Experimental|4|Exercise plus motivation
11628724|NCT00389831|Placebo Comparator|Placebo|Subjects receiving a single dose of placebo nasal spray on all 4 treatment days
11628725|NCT00389831|Experimental|Rotigotine Nasal Spray|Subjects receiving doses of placebo nasal spray on Day 1 or Day 2, Rotigotine nasal spray 62µg on Day 1 or Day 2, Rotigotine nasal spray 124µg on Day 3, and Rotigotine nasal spray 247µg on Day 4
11628726|NCT00389818|Experimental|DR-COP|Single arm interventional study: all subjects receive DR-COP regimen.
11628727|NCT00389792|No Intervention|ATI-2042 200 mg|
11628728|NCT00389792|No Intervention|ATI-2042 400 mg|
11628729|NCT00389792|No Intervention|ATI-2042 600 mg|
11628730|NCT00389792|No Intervention|ATI-2042 Placebo|
11628731|NCT00389779|Experimental|Darusentan|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily for 14 weeks
11628732|NCT00389779|Active Comparator|Guanfacine|Placebo to match darusentan for 2-week placebo run-in period, followed by guanfacine 1 mg capsules administered orally once daily for 14 weeks
11628733|NCT00389779|Placebo Comparator|Darusentan Placebo|Placebo to match darusentan for 2-week placebo run-in period, followed by placebo to match darusentan administered orally once daily for 14 weeks
11628734|NCT00389727|Experimental|Group 1 Patients|Radiotherapy Patients
11628735|NCT00389727|No Intervention|Group 2|
11628736|NCT00389675|Experimental|Darusentan|Darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily
11628737|NCT00389675|Active Comparator|Guanfacine|Guanfacine 1 mg capsules administered orally once daily
11628738|NCT00389636|Active Comparator|1|TheraGauze alone
11628739|NCT00389636|Active Comparator|2|Theragauze + Regranex
11628740|NCT00389610|Experimental|Stratum I|Patients receive booster vaccination comprised of an allogenic GM-CSF plasmid-transfected pancreatic tumor cell vaccine, given subcutaneously (SC). Treatment repeats every 6 months.
11628741|NCT00389610|Experimental|Stratum II|Patients receive priming vaccinations comprised of allogenic GM-CSF plasmid-transfected pancreatic tumor cell vaccine, given SC once a month for 3 months and then receive booster vaccinations as in stratum I.
11628742|NCT00389597|Experimental|1 Level|Cervical artificial disc (investigational device) at 1 level compared with control procedure (ACDF) at one level
11628743|NCT00389597|Experimental|2 Level|Cervical artificial disc (investigational device) at 2 levels compared with control procedure (ACDF) at two levels
11628744|NCT00389558|Active Comparator|2|Biseptine
11628746|NCT00389532|Experimental|1|aged 19 to 59 years
11628747|NCT00389532|Experimental|2|aged ≥ 60 years
11628748|NCT00389519|Placebo Comparator|Placebo|once per day
11628749|NCT00389519|Experimental|ramipril low dose|0.3125, 0.625, or 1.25 mg once a day, based on subject weight
11628750|NCT00389519|Experimental|ramipril mid dose|1.25, 2.5, or 5 mg once a day, based on subject weight
11628751|NCT00389519|Experimental|ramipril high dose|5, 10, or 20 mg once a day, based on subject weight
11628752|NCT00389493|Active Comparator|1|Participants will receive treatment with risperidone
11628753|NCT00389493|Active Comparator|2|Participants will receive exposure and ritual prevention therapy (EX/RP)
11628754|NCT00389493|Placebo Comparator|3|Participants will receive treatment with the placebo
11628755|NCT00389480|Experimental|I|Dose escalating
11628756|NCT00389467|Active Comparator|1 Mechanical Embolectomy|Participants will be randomized to receive mechanical embolectomy treatment either with the Merci Retriever or Penumbra System and standard medical care or treatment with standard medical care alone.
11628757|NCT00389467|No Intervention|2|standard medical care
11628758|NCT00389441|Experimental|A|
11628759|NCT00389376|Other|Group 1|Placebo and 140 mg single dose + every 8 hours
11628760|NCT00389376|Other|Group 2|Placebo and 280 mg single dose
11628761|NCT00389376|Other|Group 3|Placebo and 280mg every 8 hours
11628762|NCT00389376|Other|Group 4|Placebo and 280 single dose + every 8 hours
11628763|NCT00389376|Other|Group 5|Placebo and 560 mg single dose + every 8 hours
11628764|NCT00389376|Other|Group 6|Placebo and 560 mg single dose + every 8 hours
11628765|NCT00389376|Other|Group 7|Placebo and 700 mg single dose + every 8 hours
11628766|NCT00389324|Experimental|Immune Globulin Intravenous (Human)|Immune Globulin Intravenous (Human), 10%, Caprylate/Chromatography Purified
11628767|NCT00389311|Active Comparator|Nonoxynol-9|Gynol-II, 2% N-9, 5 mL
11628768|NCT00389311|Other|Normosol-R|Normosol-R, 5 mL, single administration, negative control
11628769|NCT00389311|Experimental|Normosol with simulation, endoscopy and biopsy|Normosol-R, 5 mL following simulation, endoscopy and biopsy
11628770|NCT00389259|Experimental|A|IV Scopolamine 0.25mg in adults and 0.006mg/kg in children Q4h
11628771|NCT00389259|Placebo Comparator|B|IV Look alike drug Q 4h
11628772|NCT00389233|Experimental|1|2L gut cleansing solution
11628773|NCT00389233|Active Comparator|2|4L preparation
11628774|NCT00389220|Active Comparator|BioMatrix Flex stent|Coronary stent placement with Biolimus A9 coated stent with biodegradable polymer
11628775|NCT00389220|Active Comparator|Cypher Select stent|Coronary stent placement with Sirolimus coated stent with durable polymer
11628776|NCT00389207|Active Comparator|NVP bid|nevirapine (NVP) 200 mg BID in combination with emtricitabine (FTC) and tenofovir DF (TDF)
11628777|NCT00389207|Experimental|NVP qd|nevirapine (NVP) 400 mg QD in combination with emtricitabine (FTC) and tenofovir DF (TDF)
11628778|NCT00389207|Active Comparator|ATZ/r|ritonavir-boosted atazanavir in combination with emtricitabine (FTC) and tenofovir DF (TDF)
11628779|NCT00389181|Experimental|Medical management|Patients with unruptured BAVMs will receive symptomatic medical management alone.
11628780|NCT00389181|Active Comparator|Interventional therapy|Patients with unruptured BAVMs will receive symptomatic medical management with invasive therapies (any combination of surgery, endovascular embolization, or radiotherapy).
11628781|NCT00389168|Experimental|Irbesartan|Irbesartan per os titrated to 300 mg od, 48 weeks
11628782|NCT00389168|Active Comparator|Atenolol|Atenolol per os titrated to 100 mg od, 48 weeks
11628783|NCT00389155|Experimental|vinflunine and gemcitabine|solution for injection, IV, vinflunine: 280/320 mg/m2 + gemcitabine: 1000 mg/m2, every 3 wks, variable duration
11628784|NCT00389155|Placebo Comparator|placebo and gemcitabine|solution for injection, IV, placebo + gemcitabine, 1000 mg/m2, every 3 wks, variable duration
11628785|NCT00389116|Experimental|1|
11628786|NCT00389116|Placebo Comparator|2|
11628787|NCT00389103|Placebo Comparator|placebo|
11628788|NCT00389090|Experimental|Temozolomide + O6BG|
11628789|NCT00389077|Experimental|Perifosine Daily Dose|Daily dose perifosine 50 mg.
11628790|NCT00389077|Experimental|Perifosine Twice Daily Dose|Twice daily dose perifosine 50 mg.
11628791|NCT00389064|Experimental|Quetapine XR|Tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily.
11628792|NCT00389064|Placebo Comparator|Placebo|Matching placebo tablets orally administered once daily.
11628793|NCT00389038|Active Comparator|Coping Skills Training + Amitriptyline|Behavioral coping skills training--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.
11628794|NCT00389038|Active Comparator|Headache Education + Amitriptyline|Behavioral headache education
11628795|NCT00388999|Other|0 mg/kg|
11628796|NCT00388999|Other|0.5 mg/kg|
11628797|NCT00388999|Other|1.0 mg/kg|
11628798|NCT00388986|Experimental|1|
11628799|NCT00388986|Experimental|2|
11628800|NCT00388986|Experimental|3|
11628801|NCT00388960|Experimental|Amrubicin|Amrubicin 45mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
11628802|NCT00388960|Experimental|Amrubicin plus Cisplatin|Amrubicin 40mg/m<2> IV days 1, 2, 3 plus cisplatin 60mg/m<2> IV day 1 of each 21-day cycle until disease progression.
11628803|NCT00388960|Active Comparator|Cisplatin plus etoposide|Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 each 21-day cycle until disease progression.
11628804|NCT00388947||1|AMS Prolapse Product (AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family)
11628805|NCT00388934|Experimental|Drug eluting stent (Cypher)|Percutaneous coronary intervention with implantation of drug eluting coronary stent (Cypher)
11629334|NCT00382915||3|Smokers without any mental illness
11628806|NCT00388934|Experimental|Drug eluting stent (Taxus)|Percutaneous coronary intervention with implantation of drug eluting coronary stent (Taxus)
11628807|NCT00388908|Experimental|A|Multifaceted intervention
11628808|NCT00388908|Active Comparator|B|Usual Care
11628809|NCT00388843||Dose Increased|Patients presenting with symptoms of coronary artery disease or stroke/suspected stroke, with carotid plaque > 1.1 mm, and whose statin dose is increased to moderate to high dose by their clinicians.
11628810|NCT00388843||Dose Maintained|Patients presenting with symptoms due to coronary artery disease or stroke/suspected stroke, with carotid plaque > 1.1 mm, on no statins or whose statin dose was unchanged by their clinicians.
11628811|NCT00388804|Active Comparator|RT Group 1|Radiation Therapy (RT) over 8 1/2 weeks: 42 treatments, 5 days per week with 2 days rest in between.
11628812|NCT00388804|Active Comparator|RT Group 2 + Hormone Therapy|Radiation Therapy over 8 1/2 weeks; + Hormone Therapy (Bicalutamide 50 mg orally/day or Flutamide 250 mg orally 3 times daily on first 21-30 Days) + Leuprolide (22.5 mg Intramuscularly (IM)/every 3 months or 7.5 mg IM monthly) or Goserelin (10.8 mg subcutaneously every 3 months or 3.6 mg subcutaneously monthly)
11628813|NCT00388739|Active Comparator|Usual care|Systemic steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day). Subjects will also receive standardized discharge medication instructions for using albuterol nebulizer treatments: they will receive a prescription for 2.5mg of albuterol in 3cc Normal Saline for aerosol use via compressor every 3 times a day as a chronic care regimen if they are either in the treatment arm and 1-5 years of age or if they are in the control group and already own a nebulization compressor. Children in the control group that do not own a nebulization compressor will be given a prescription for an albuterol MDI with mask and spacer with instructions to deliver 2 puffs (90mcg per actuation) 3 times a day as a standard chronic care regimen. Instructions to follow-up with their primary care physician in 3-5 days (as is standard care practice) will be given at discharge for patients in the control or treatment arm.
11628814|NCT00388739|Experimental|Usual care + 6 months of inhaled steroids|In addition to the usual care described above, patients randomized to the intervention/experimental arm will also be given a one month supply as well as a prescription (for a 6 month supply) for Budesonide respules (children with mild persistent disease will receive 0.25 mg bid whereas children with moderate or severe persistent disease will receive 0.5 mg bid).
11628815|NCT00388726|Experimental|1|
11628816|NCT00388726|Active Comparator|2|
11628817|NCT00388700|Experimental|GM-CT-01|
11628818|NCT00388674||A|
11628819|NCT00388674||B|
11628820|NCT00388661|Active Comparator|Melatonin|melatonin 3mg
11628821|NCT00388661|Placebo Comparator|Placebo|
11628822|NCT00388609|Experimental|T|5 mg (ST) to 50 mg (LT)
11628823|NCT00388609|Experimental|U|10 mg (ST) to 50 mg (LT)
11628824|NCT00388609|Experimental|V|25 mg (ST) to 50 mg (LT)
11628825|NCT00388609|Experimental|W|50 mg (ST and LT)
11628826|NCT00388609|Experimental|X|25 mg/d (X1 wk), 5 mg/d (X11 wks) (ST) to 50 mg (LT)
11628827|NCT00388609|Experimental|Z|"Open label: 50 mg/d (X 4 wks) 100 mg/wk (X8 wks) (ST) to 50 mg (LT)
~Once daily (x 4 weeks), once daily (x 8 weeks)"
11628828|NCT00388609|Placebo Comparator|Y|0 mg (ST and LT)
11628829|NCT00388583|Experimental|Fluzone Intradermal (ID) Vaccine Group|Participants received a dose of Fluzone Intradermal (ID) Influenza Vaccine
11628830|NCT00388583|Active Comparator|Fluzone Intramuscular (IM) Vaccine Group|Participants received a dose of Fluzone Intramuscular (IM) Influenza Vaccine.
11628831|NCT00388557|Experimental|1|
11628832|NCT00388544|Experimental|1|
11628833|NCT00388544|Experimental|2|
11628834|NCT00388544|Experimental|3|
11628835|NCT00388544|No Intervention|4|Recreational activities are not tailored to either style of interest or function
11628836|NCT00388518|Active Comparator|Actos|
11628837|NCT00388518|Experimental|Aleglitazar 1|
11628838|NCT00388518|Experimental|Aleglitazar 2|
11628839|NCT00388518|Experimental|Aleglitazar 3|
11628840|NCT00388518|Experimental|Aleglitazar 4|
11628841|NCT00388518|Placebo Comparator|Placebo|
11628842|NCT00388505|Experimental|Tobramycin inhalation powder (TIP)|Participants received four 28 mg capsules of tobramycin inhalation powder (TIP) delivered with the T-326 inhaler twice daily for 28 days followed by 28 days off therapy (one cycle) for a total of three cycles.
11628843|NCT00388505|Active Comparator|Tobramycin solution for inhalation (TOBI)|Participants received one 300 mg (in 5 mL) ampoule of tobramycin solution for inhalation (TOBI) delivered with a nebulizer twice daily for 28 days followed by 28 days off therapy (one cycle) for a total of three cycles.
11628844|NCT00388453|Active Comparator|1|Healthy volunteers with no history of GERD or EERD or Proton Pump Inhibitor (PPI) use
11628845|NCT00388453|Experimental|2|subject is known to have GERD based on symptoms and previous positive response to PPI
11628846|NCT00388453|Experimental|3|subject is known to have EERD based on symptoms and previous positive response to PPI
11628847|NCT00388427|Other|Advanced Solid Malignancies|
11628848|NCT00388414|Placebo Comparator|Placebo - sugar pill|
11628849|NCT00388414|Experimental|Duloxetine|
11628850|NCT00388388|Experimental|1|Losartan treatment
11628851|NCT00388388|Active Comparator|2|Hydrochlorothiazide, 12.5-25 mg per day once a day for 6 months
11628852|NCT00388375|No Intervention|CVC Internal Jugular or Subclavian Vein|
11628853|NCT00388362|Experimental|Sirolimus Therapy|Administration of Sirolimus and Prednisone
11628854|NCT00388349|Experimental|Gemcitabine + Autologous HCT|Gemcitabine and high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue. Chemotherapy includes Gemcitabine + Vinorelbine + Carmustine + Etoposide + Cyclophosphamide.
11628855|NCT00388323|Experimental|1|
11628856|NCT00388310|Active Comparator|Cephalexin|Cephalexin 250 mg PO q6h x5 days
11628857|NCT00388310|Active Comparator|Clindamycin|Clindamycin 300 mg PO q6h x5 days
11628858|NCT00388310|Active Comparator|trimethoprim/sulfamethoxazole|trimethoprim/sulfamethoxazole 160 mg/800 mg PO q12h x 5 days
11628859|NCT00388310|Placebo Comparator|Placebo|
11628860|NCT00388297|Experimental|Levothyroxine for Subclinical Hypothyroidism|100 µg of Levothryoxine for participants with subclinical hypothyroidism
11628861|NCT00388297|Placebo Comparator|Placebo for Levothyroxine - Subclinincal Hypothyroidism|Placebo for Levothyroxine for participants with subclinical hypothyroidism
11628862|NCT00388297|Experimental|Levothyroxine for Hypothyroxinemia - Hypothyroxinemia|50 µg of Levothyroxine for participants with hypothyroxinemia
11628863|NCT00388297|Placebo Comparator|Placebo for Levothyroxine|Placebo for Levothyroxine for participants with hypothyroxinemia
11628864|NCT00388271|Active Comparator|1|xatral
11628865|NCT00388271|Placebo Comparator|2|standard treatment
11628866|NCT00388193|Experimental|1|
11628867|NCT00388167||1|Caspofungin
11628868|NCT00388154|Experimental|Gemcitabine + Cisplatin|Gemcitabine 900 mg/m^2 by vein (IV) over 1 hour on Day 1 and Day 8. Cisplatin 30 mg/m^2 by vein over 1 hour on Day 1 and Day 8.
11628869|NCT00388141|Experimental|NIDCAP|In the intervention NIDCAP group the staff has been introduced and trained in the principles of the NIDCAP-care, where main core is to see, organize and conduct the care of the preterm infant on behalf of the childs actually resources and competences
11628870|NCT00388128|Placebo Comparator|A|
11628871|NCT00388115|Experimental|RFA prior to surgery|
11628872|NCT00388076|Experimental|Part 1|pazopanib and paclitaxel
11628873|NCT00388076|Experimental|Part 2|pazopanib, paclitaxel, and carboplatin
11628874|NCT00388076|Experimental|Part 3|pazopanib, paclitaxel, and lapatinib
11628875|NCT00388050|Experimental|Diabetes Medication Choice decision aid|Patients in this arm will discuss diabetes medication for glucose control with the help of a decision aid that covers five commonly prescribed anti-hyperglycemic medications.
11628876|NCT00388050|Other|Usual Care|Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
11628877|NCT00388037|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11628878|NCT00388024||cancer patients about to be treated with radiation therapy|Patienta with histologically confirmed squamous cell or lymphoepithelioma of oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, or unknown primary of the head and neck about to be treated with radiation therapy
11628879|NCT00388011|Experimental|1|Intranasal morphine 3.75 mg
11628880|NCT00388011|Experimental|2|Intranasal morphine 7.5 mg
11628881|NCT00388011|Experimental|3|Intranasal morphine 15 mg
11628882|NCT00388011|Experimental|4|Intranasal morphine 30 mg
11628883|NCT00388011|Active Comparator|5|Intravenous morphine 7.5 mg
11628884|NCT00388011|Placebo Comparator|6|Intranasal placebo
11628885|NCT00387998|Experimental|Risk primer|"Booklet written by investigators know your chances"
11628886|NCT00387998|Active Comparator|Control booklet|AHRQ staying healthy booklet
11628887|NCT00387959|Experimental|Unrelated Donor Umbilical Cord Transplant|Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and the Transplantation of Unrelated Donor Umbilixal Cord Blood
11628888|NCT00387933|Experimental|Gleevec + PTK787/ZK 22584 + Hydroxyurea|Patients with recurrent or relapsing glioblastoma multiforme (GBM) will be given daily doses of Gleevec and PTK787/ZK 22584 orally in combination with fixed doses of hydroxyurea.
11628889|NCT00387920|Experimental|Treatment (enzyme inhibitor therapy)|"PART A: Patients receive oral sunitinib malate once daily on days 1-28 days. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
~PART B: Patients receive sunitinib malate capsule contents sprinkled over applesauce or yogurt once daily on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. After the first course, patients may switch to capsule formulation for convenience."
11628890|NCT00387907|Experimental|Larotaxel + Trastuzumab|
11628891|NCT00387894|Experimental|erlotinib hydrochloride (Tarceva)|During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
11628892|NCT00387881|Placebo Comparator|Placebo|
11628893|NCT00387881|Experimental|Treximet|
11628894|NCT00387868|Other|Registration|Cisplatin, Etoposide & concurrent radiotherapy
11628895|NCT00387868|Other|Surgical Resection|No distant Progression post Registration Arm
11628896|NCT00387868|Other|Post Resection|Assessment post surgical procedure to determine if at higher risk of recurrence or if complete resection could not be achieved.
11628897|NCT00387855|Experimental|1|receive SOS program
11628898|NCT00387829|Active Comparator|1|Use of DuraGen Plus Adhesion Barrier Matrix as an adhesion barrier in the spine
11628899|NCT00387829|No Intervention|2|Control arm is surgery alone (no adhesion barrier)
11628900|NCT00387790|Experimental|Arm I|Patients receive motexafin gadolinium IV over 5-10 minutes once daily (prior to radiotherapy) 5 days a week for 6 weeks. Patients undergo focal cranial radiotherapy once daily 5 days a week for 6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
11628901|NCT00387764|Experimental|pazopanib arm|This was a single arm study, therefore no control arm.
11628902|NCT00387751|Experimental|Arm I|Patients receive oral sorafenib tosylate on days 1-5, 8-12, 15-19, and 22-26 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression.
11628903|NCT00387738|Experimental|1|TOLAMBA™ dose-intense regimen
11628904|NCT00387738|Experimental|2|TOLAMBA™ lower-dose regimen
11628905|NCT00387738|Placebo Comparator|3|
11628906|NCT00387725|Experimental|Group A|20ug Experimental
11628907|NCT00387725|Experimental|Group 2|60ug Experimental
11628908|NCT00387725|Experimental|Group 3|200ug Experimental
11628909|NCT00387725|Active Comparator|Group 4|Active comparator
11628992|NCT00386724|Active Comparator|Precision Spinal Cord Stimulation|Single arm Precision Spinal Cord Stimulation System with Artisan Surgical Lead
11629888|NCT00376090|Placebo Comparator|Group II Placebo|
11628910|NCT00387712|Experimental|Velocity based treadmill training|6 month of progressive treadmill walking with treadmill speed gradually progressed to meet the training heart rate goals for moderate intensity aerobic exercise, when hemiparetic gait velocity can no longer be safely progressed, incline is added to achieve the heart rate training goals.
11628911|NCT00387712|Experimental|Duration based treadmill training|6 month of progressive treadmill walking with duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress.
11628912|NCT00387686|Experimental|A|1.0 mg/mL rhBMP-2/CPM + surgical fixation
11628913|NCT00387686|Experimental|B|2.0 mg/mL rhBMP-2/CPM + surgical fixation
11628914|NCT00387686|Active Comparator|C|Buffer/CPM + surgical fixation Intervention
11628915|NCT00387686|Other|D|Standard of Care: Surgical fixation intervention
11628916|NCT00387673|Experimental|Arm 1|6 weeks of upper extremity training for 3 sessions/week, as follows: a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session);
11628917|NCT00387673|Active Comparator|Arm 2|a 6-week period of 2 hours somatosensory stimulation of the hand, without training
11628918|NCT00387673|Placebo Comparator|Arm 3|a 6-week period of 2 hours sham somatosensory stimulation of the hand, followed by 1 hour of activity-based training
11628919|NCT00387660|Experimental|Metastatic SCLC|Irinotecan 200 mg/m2, every 21 days (intravenous) + Carboplatin AUC = 5 mg/ml x min (intravenous), every 21 days for 6 cycles
11628920|NCT00387660|Experimental|Relapsed SCLC|Irinotecan 150 mg/m2 (intravenous), every 21 days + Carboplatin AUC = 5 mg/ml x min (intravenous, every 21 days for 6 cycles
11628921|NCT00387647|Experimental|Azacitidine Treatment|Azacitidine 50 mg/m^2 subcutaneously daily for 5 days (Monday through Friday) on days 1 through 5, every 28 days for 6-12 cycles.
11628922|NCT00387634|Active Comparator|Arm 1|Blood draw only, no vaccine
11628923|NCT00387634|Active Comparator|Arm 2|Blood draw only, no vaccine
11628924|NCT00387634|Active Comparator|Arm 3|Blood draw only, no vaccine
11628925|NCT00387634|Active Comparator|Arm 4|Blood draw only, no vaccine
11628926|NCT00387621|Experimental|Placebo First, then Nesiritide (Arm A)|In the first intervention period the subjects received subcutaneous placebo given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered. There was a 2 week washout period. In the second intervention period, the subjects received subcutaneous nesiritide given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered.
11628927|NCT00387621|Experimental|Nesiritide First, then Placebo (Arm B)|In the first intervention period the subjects received subcutaneous nesiritide given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered. There was a 2 week washout period. In the second intervention period, the subjects received subcutaneous placebo given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered.
11628928|NCT00387582|Experimental|I|Lucentis injections for the first three months of the study and then per the protocol for the duration of the trial.
11628929|NCT00387582|Active Comparator|II|Argon Laser treatment at enrollment and then per the protocol for the duration of the study.
11628930|NCT00387569|Experimental|Cohort 1|Experimental (20ug); Active Comparator/Placebo
11628931|NCT00387569|Experimental|Cohort 2|Experimental (60ug); Active Comparator/Placebo
11628932|NCT00387569|Experimental|Cohort 3|Experimental (200ug); Active Comparator/Placebo
11628933|NCT00387556|Experimental|Ketamine + Ondansetron|ketamine 1 mg/kg IV (maximum single dose 100 mg)+ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
11628934|NCT00387556|Placebo Comparator|Ketamine + Placebo|ketamine 1 mg/kg IV (maximum single dose 100 mg)+2 ml normal saline solution IV (placebo
11628935|NCT00387530|Other|Single Arm Study of Biopsy|
11628936|NCT00387478|Experimental|1|modified Tree pollen allergen absorbed to Tyrosine and containing MPL adjuvant
11628937|NCT00387478|Experimental|2|modified Tree pollen allergen absorbed to Tyrosine
11628938|NCT00387478|Placebo Comparator|Placebo|4 injections of placebo 0.5 ml (2% tyrosine)
11628939|NCT00387465|Experimental|Phase I - 30mg/m2 Azacitidine|Patients receive Azacitidine 30mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.
11628940|NCT00387465|Experimental|Phase I - 40mg/m2 Azacitidine|Patients receive azacitidine 40mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.
11628941|NCT00387465|Experimental|Phase II Arm|Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11628942|NCT00387452|Active Comparator|1|
11628943|NCT00387452|Active Comparator|2|
11628944|NCT00387452|No Intervention|3|No intervention, only testing during 6 months.
11628945|NCT00387439|Experimental|standard medical treatment|standard medical treatment
11628946|NCT00387439|Experimental|standard medical treatment + anoperineal physiotherapy|standard medical treatment + anoperineal physiotherapy
11628947|NCT00387426|Experimental|Arm I|Patients receive oral sunitinib malate once daily for 6 weeks.
11628948|NCT00387413|Experimental|Treatment Arm A1|In treatment Arm A1 Period 1 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. In treatment Arm A1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2.
11628949|NCT00387413|Experimental|Treatment Arm A2|In treatment Arm A2 Period 1 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. In treatment Arm A2 Period 2 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. There will be a washout of approximately one week between periods 1 and 2.
11628950|NCT00387413|Experimental|Treatment Arm B1|In treatment Arm B1 Period 1 subject will receive 30 milligram (mg) Duloxetine plus GSK189254 Placebo in Week 1, in Week 2 60 mg Duloxetine plus GSK189254 Placebo and in Week 3 30 mg Duloxetine plus GSK189254 Placebo. In treatment Arm B1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2.
11629270|NCT00383513|Experimental|Epratuzumab|
11628951|NCT00387413|Experimental|Treatment Arm B2|In treatment Arm B2 Period 1 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. In treatment Arm B2 Period 2 subject will receive 30 milligram (mg) Duloxetine plus GSK189254 Placebo in Week 1, in Week 2 60 mg Duloxetine plus GSK189254 Placebo and in Week 3 30 mg Duloxetine plus GSK189254 Placebo. There will be a washout of approximately one week between periods 1 and 2.
11628952|NCT00387387|Experimental|FOLFOX 6 + Pazopanib|Subjects will receive escalating doses of Pazopanib in combination with FOLFOX 6.
11628953|NCT00387387|Experimental|CapeOx + Pazopanib|Subjects will receive escalating doses of Pazopanib in combination with CapeOx. CapeOx treatment consisted of IV oxaliplatin (130 mg/m^2) on Day 1 plus oral capecitabine (1000 mg/m^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment was administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine was reduced to 850 mg/m^2 twice daily.
11628954|NCT00387374|Experimental|Stratum I (radiotherapy, bevacizumab, chemotherapy)|Patients undergo prophylactic radiotherapy on days 1-5 and 8-12. Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 15. Patients also receive paclitaxel IV over 3 hours or carboplatin IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 36 (course 2).
11628955|NCT00387374|Experimental|Stratum II (radiotherapy, chemotherapy, bevacizumab)|Patients undergo prophylactic radiotherapy and receive paclitaxel and carboplatin as in stratum I. Patients also receive bevacizumab IV over 30-90 minutes on day 15 (course 1). In both strata, treatment with paclitaxel, carboplatin, and bevacizumab repeats every 21 days for 5-6 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response or stable disease may continue to receive single-agent bevacizumab every 21 days in the absence of disease progression or unacceptable toxicity.
11628956|NCT00387361|Experimental|1|
11628957|NCT00387361|No Intervention|2|
11628958|NCT00387348|Placebo Comparator|Placebo-Placebo|Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and placebo once daily for the second 4 weeks
11628959|NCT00387348|Other|Placebo-Escitalopram|Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and escitalopram oxalate 10 mg once daily for the second 4 weeks
11628960|NCT00387348|Other|Escitalopram-Placebo|Participants in this arm were randomzied to receive escitalopram 10 mg once daily for the first 4 weeks and placebo once daily for the second 4 weeks
11628961|NCT00387335|Experimental|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11628962|NCT00387322|Experimental|Group 1|Patients receive oral erlotinib hydrochloride once on days 2, 9, and 16 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of unacceptable toxicity or disease progression
11628963|NCT00387322|Experimental|Group 2|Patients receive oral erlotinib hydrochloride once daily on days 2-16 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of unacceptable toxicity or disease progression.
11628964|NCT00387270|Experimental|A|Dimebon
11628965|NCT00387244|Active Comparator|Precision for Spinal Cord Stimulation|Single arm Precision for Spinal Cord Stimulation
11628966|NCT00387205|Experimental|Arm 1|Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
11628967|NCT00387179|Experimental|Dim Light Melatonin and/or methylxanthine|Dim Light Melatonin and/or methylxanthine
11628968|NCT00387179|Experimental|Placebo and Dim Light or bright light|Placebo and Dim Light or bright light
11628969|NCT00387179|Experimental|Bright light melatonin and/or methylxanthine|Bright light, melatonin, and/or methylxanthine
11628970|NCT00387166||1|Mexican-American women, aged 40-65
11628971|NCT00387127|Experimental|Lapatinib|1500mg lapatinib orally daily
11628972|NCT00387127|Placebo Comparator|Placebo|orally daily
11628973|NCT00387088|Other|Tiotropium|Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
11628974|NCT00387088|Other|Placebo|Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
11628975|NCT00387075|Experimental|[123I]β-CIT and SPECT imaging|To Assess [123I]β-CIT and SPECT imaging
11628976|NCT00387049|Experimental|Anxiety-specific smoking cessation care|
11628977|NCT00387049|Active Comparator|Standard smoking cessation care|
11628978|NCT00387036|Other|1|Arm 1: drug, crossing over to Pbo comparator
11628979|NCT00387036|Other|2|Arm 2: Pbo comparator, crossing over to drug
11628980|NCT00387023|Experimental|Zevalin + Rituximab|Rituximab 250 mg/m^2 intravenous (IV) over 4-6 hours for 2 weeks, + Zevalin 5 millicurie (mCi)/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
11628981|NCT00387010|Experimental|fentanyl buccal tablets|Successful dose strength for each participant was determined during a titration period of no more than 10 days. Participants used the successful dose of 100, 200, 400, 600, or 800 mcg during the four week open-label treatment period.
11628982|NCT00386971|Active Comparator|1|L-carnitine
11628983|NCT00386971|Placebo Comparator|2|Placebo
11628984|NCT00386945|Other|1|Non-Experiment Intervention consisting of an intervention based on the Clinical Practice Guideline: Treating Tobacco Use and Dependence and modified for use in chiropractic settings.
11628985|NCT00386906|Other|Sentinel Lymph Node (SLN) Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
11628986|NCT00386893|Other|Treatment as usual|simultaneous EEG/fMRI
11628987|NCT00386880||Subjects with episodic migraine with allodynia|These are subjects with episodic migraine with allodynia
11628988|NCT00386880||Subjects with episodic migraine without allodynia|Subjects with episodic migraine without allodynia
11628989|NCT00386841|Active Comparator|A Escitalopram 10 mg|Escitalopram 10 mg
11628990|NCT00386841|Placebo Comparator|Placebo|Placebo
11628991|NCT00386776|Experimental|'Computer-based medical history|A computer-based medical history to take in their homes via the Internet. The history is divided into 24 modules- family history, social history, cardiac history, pulmonary history, and the like.
11629382|NCT00382187|Experimental|MF59 adjuvant H5N1 influenza vaccine 15 micrograms|
11628993|NCT00386672|Experimental|Lite OJ with Ca and VitD|240ml of reduced energy (lite) OJ beverage fortified with 350mg Ca and 100U VitD, 3 times per day.
11628994|NCT00386672|Active Comparator|Lite OJ without Ca and VitD|240ml of reduced energy (lite) OJ beverage, 3 times per day.
11628995|NCT00386633|Other|1|Lower dosage: 10E7_TCID50
11628996|NCT00386633|Active Comparator|2|10E8_TCID50
11628997|NCT00386620||Survey + ED|"Part 1: Survey + Electronic Diaries (ED)
~Part 2: 3 Month, 6 Month Survey + ED"
11628998|NCT00386607|Experimental|Core Treatment|Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combination for 52-weeks, optional addition of Hydrochlorothiazide (HCTZ) 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (mean sitting Systolic Blood Pressure ≥ 140 and/or mean sitting Diastolic Blood Pressure ≥ 90 mmHg). The dose of Hydrochlorothiazide (HCTZ) 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.
11628999|NCT00386607|Experimental|Extension Treatment|"For patients entering into extension, those previously treated with Hydrochlorothiazide (HCTZ) 12.5 or 25 mg in addition to aliskiren 300 mg/valsartan 320 mg were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 25 mg in the extension. Those patients who had not received HCTZ during the core study were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 12.5 mg.
~The HCTZ 12.5 mg dose could be increased to HCTZ 25 mg if the mean sitting Systolic Blood Pressure (msSBP) was ≥140 mmHg and/or the mean sitting Diastolic Blood Pressure (msDBP) was ≥90 mmHg for 2 consecutive visits."
11629000|NCT00386542|Experimental|ID-JI-0.1|"Group ID-JI-0.1 (n = 16) - reduced 0.1 mL INF doses administered intradermally (ID) by needle-free jet injector (JI) (Biojector® 2000 subcutaneous syringe no. 2 [green color code], with 2 cm investigational spacer, Bioject Medical Technologies, Inc., Portland, OR, USA)"
11629001|NCT00386542|Active Comparator|IM-NS-0.1|"Group IM-NS-0.1 (n = 16) - reduced 0.1 mL INF doses administered intramuscularly (IM) needle-syringe (NS) (via 22-25 gauge needle, minimum 25 mm/1-inch length)"
11629002|NCT00386542|Active Comparator|IM-NS-0.25 control|"Group IM-NS-0.25 (controls) (n = 16) - full 0.25 mL INF doses administered intramuscularly (IM) by needle-syringe (NS) (22-25 gauge needle, minimum 25 mm/1-inch length)"
11629003|NCT00386516|Experimental|GM-CT-01, 5-FU|GM-CT-01 (280 mg/m2) combined with 5-FU (600 mg/m2) given 4 consecutive days in a 28 days cycle until disease progression.
11629004|NCT00386490|Experimental|Larazotide acetate 0.25 mg|larazotide acetate 0.25 mg capsule TID for 10 days
11629005|NCT00386490|Experimental|Larazotide acetate 1 mg|larazotide acetate 1 mg capsule TID for 10 days
11629006|NCT00386490|Experimental|Larazotide acetate 4 mg|larazotide acetate 4 mg capsule TID for 10 days
11629007|NCT00386490|Experimental|Placebo|Placebo capsule TID for 10 days
11629008|NCT00386477|Experimental|Vag prep|Vagina cleansed prior to performing cesarean
11629009|NCT00386425|Experimental|Standard therapy|24 microgram/kilogram/hour (mcg/kg/hr) for 24 hours, followed by 24 mcg/kg/hr for an additional 72 hours
11629010|NCT00386425|Experimental|Alternative therapy:moderate protein C deficiency|24 mcg/kg/hr for 24 hours, followed by 24 mcg/kg/hr for an additional 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)
11629011|NCT00386425|Experimental|Alternative therapy:severe protein C deficiency|24 mcg/kg/hr for 24 hours, followed by 30 or 36 mcg/kg/hr for 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)
11629012|NCT00386399|Experimental|Arm 1|Patients with BRCA2 gene will be treated with Mitomycin-C (MMC) on Day 1 at a dose of 10mg/m2 intravenously. This will be repeated every 28 days, which is one cycle. Treatment will continue until disease progression, serious toxicity, patient withdrawal or maximum cumulative dose of 60 mg/m2
11629013|NCT00386386|Other|1|Subject receives two infusions: One by EASI Access and one by IV access, at different sites
11629014|NCT00386373|Experimental|Imatinib Mesylate|
11629015|NCT00386360|Placebo Comparator|Placebo|Placebo dose
11629016|NCT00386360|Experimental|Risedronate|35 mg risedronate, orally, once weekly
11629017|NCT00386334|Placebo Comparator|Placebo|Week -2 to day 0 single blind one tablet placebo in the evening. Double blind period: Day 1 to Week 12 double blind one tablet placebo in the evening. Follow up period: two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.
11629018|NCT00386334|Experimental|Eszopiclone|Week -2 to day 0 single blind one tablet placebo in evening. Double Blind period: Day 1 to Week 12 double blind one tablet 2 mg of eszopiclone in evening. Follow up period consists of two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.
11629019|NCT00386308|Experimental|1|
11629020|NCT00386308|Placebo Comparator|2|
11629021|NCT00386282|Other|mifepristone-misoprostol treatment|200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone
11629022|NCT00386256|Experimental|Health Buddy outpatient|Received home telehealth monitoring by Health Buddy
11629023|NCT00386256|Experimental|Telephone outpatient|
11629024|NCT00386256|Experimental|health buddy inpatient|
11629025|NCT00386256|Experimental|telephone inpatient|
11629026|NCT00386243|No Intervention|Usual Care|Study subjects randomized to this arm would receive usual care from their provider(s). No study intervention is undertaken on subjects in this arm. Participants in Usual Care would complete the same four outcome assessments (surveys) throughout the course of the study that members of the intervention complete.
11629027|NCT00386243|Experimental|Stepped Care|Study subjects randomized to this arm would receive stepped care for their pain. Stepped care involves FDA-approved analgesic therapy, a 12-week pain self-management program, and if pain does not improve, a 12-week cognitive behavioral therapy program.
11629028|NCT00386230|Experimental|1|Maternal ZDV treatment starting at 35 weeks Gestational Age (GA) and continuing through labor and delivery, and three days of infant ZDV treatment starting at birth (Smother-Sinfant)
11629029|NCT00386230|Experimental|2|Maternal ZDV treatment starting at 35 weeks Gestational Age (GA) and continuing through labor and delivery, and six weeks of infant ZDV treatment starting at birth (Smother-Linfant)
11629030|NCT00386230|Experimental|3|Maternal ZDV treatment starting at 28 weeks Gestational Age (GA) and continuing through labor and delivery, and three days of infant ZDV treatment starting at birth (Lmother-Sinfant)
11629335|NCT00382863|Experimental|Treatment|HeartNet and Optimal Medical/Device Therapy (e.g., medications and cardiac resynchronisation therapy)
11629031|NCT00386230|Active Comparator|4|Maternal ZDV treatment starting at 28 weeks Gestational Age (GA) and continuing through labor and delivery, and six weeks of infant ZDV treatment starting at birth (Lmother-Linfant). This study arm was the reference regimen.
11629032|NCT00386217||Telephone Survey|90 minute Telephone survey of female cancer survivors
11629033|NCT00386191|Experimental|1|50 mg
11629034|NCT00386191|Experimental|2|75 mg
11629035|NCT00386178|Experimental|1|Vitamin E supplement rich in gamma tocopherol
11629036|NCT00386165|Experimental|Larazotide acetate|Larazotide acetate capsules: 12 mg QD x 3 days
11629037|NCT00386165|Placebo Comparator|Placebo|Placebo capsules: QD x 3 days
11629038|NCT00386152|Experimental|epoetin alfa (120,000 Units)|epoetin alfa (PROCRIT) 120,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
11629039|NCT00386152|Experimental|epoetin alfa (80,000 Units)|epoetin alfa (PROCRIT) 80,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
11629040|NCT00386152|Active Comparator|darbepoetin alfa (500 mcg)|darbepoetin alfa (ARANESP) 500 mcg injected subcutaneously the skin once every 3 weeks for up to 13 weeks
11629041|NCT00386100|Placebo Comparator|Metformin|MET began at a total daily dose of 500 mg and could be increased up to a maximum dose of MET 2000 mg. The dose level was to be increased unless a tolerability issue existed at the current dose level.
11629042|NCT00386100|Active Comparator|Avandamet (Rosiglitazone maleate/metformin hydrochloride)|AVM began at a total daily dose of 4 mg/500 mg and could be increased up to a maximum dose of AVM 8 mg/2000 mg
11629043|NCT00386048||Standard of Care Observation Group|This group is randomized to continue their current medical management strategies for pain as recommended/prescribed by health care providers. Primary and secondary outcomes are collected at the same time intervals as the biopsychosocial intervention group.
11629044|NCT00386048||Biopsychosocial Intervention Group|This group continues all standard of care procedures for managing pain and adds to this additional cognitive-behavioral treatment (CBT) strategies for managing pain. The intervention explicitly frames the CBT strategies as added, complimentary pain management methods to add to the standard of care treatment.
11629045|NCT00386035||1: DC Group|HIV infected participants who will stop or defer ART until the CD4 cell count drops below 250 cells/mm3 and who discontinue ART when CD4 cell count reaches above 350 cells/mm3. Participants are followed by episodic ART based on CD4 cell count.
11629046|NCT00386035||2: VS Group|HIV infected participants who continue ART to keep viral loads as low as possible, regardless of CD4 cell count.
11629047|NCT00386022|Experimental|Young postmenopausal women|intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
11629048|NCT00386022|Experimental|Older postmenopausal women|intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
11629049|NCT00386009|Placebo Comparator|1|Placebo
11629050|NCT00386009|Active Comparator|2|tadalafil
11629051|NCT00385996|Experimental|Erlotinib|Erlotinib 150mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
11629052|NCT00385970|Active Comparator|1|UFT+LV Group: The group treated with UFT and LV
11629053|NCT00385970|Experimental|2|UFT+PSK Group: The group treated with of UFT and PSK
11629054|NCT00385944|Experimental|Prasugrel|Open label lead-in one time dose of Clopidogrel 900 mg oral tablets (a single or cumulative dose) and 250 mg to 500 mg aspirin loading dose (LD), either orally or intravenously. Patients are then assigned to maintenance dose (MD) prasugrel 10 mg and two placebo tablets, matched to clopidogrel, and 100 mg aspirin, all taken orally once a day for 14 days. Patients cross-over to MD of clopidogrel two 75 mg tablets and one placebo matched to prasugrel and 100 mg aspirin, all taken orally once a day for the next 14 days.
11629055|NCT00385944|Active Comparator|Clopidogrel|Open label lead-in one time dose of Clopidogrel 900 mg oral tablets (a single or cumulative dose) and 250 mg to 500 mg aspirin loading dose (LD), either orally or intravenously. Patients are then assigned to maintenance dose (MD) Clopidogrel two 75 mg and one placebo tablet, matched to prasugrel, and 100 mg aspirin, all taken orally once a day for 14 days. Patients cross-over to MD of prasugrel one 10 mg tablet and two placebo tablets matched to clopidogrel and 100 mg aspirin, all taken orally once a day for the next 14 days.
11629056|NCT00385918|Experimental|Lokomat training|Subjects will receive active exercise treatment in the Lokomat device 3 times per week for 3 months. Each session will last approximately 45 minutes.
11629057|NCT00385918|Active Comparator|Home stretching then Lokomat training|Patients will participate in a home stretching program for 3 months. They will then be crossed over to an active Lokomat treatment for a subsequent 3 months.
11629058|NCT00385866|Active Comparator|Comparison Group|The control or lesser intervention group, will receive cancer screening information on a quarterly basis, with no facilitation of services.
11629059|NCT00385866|Active Comparator|Intervention group|The intervention group are those participants who were randomly assigned to receive facilitation of services in the form of patient navigation for the duration of the study.
11629060|NCT00385853|Experimental|PTK787|Single arm study of PTK787
11629061|NCT00385840|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of re-vaccination, who previously received 1 dose of the Fluarix™ vaccine in study NCT00321763, received 1 dose of Fluarix™ vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11629062|NCT00385840|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of re-vaccination, who previously received 1 dose of the GSK1247446A vaccine in study NCT00321763, received 1 dose of adjuvanted GSK1247446A vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11629063|NCT00385827|Experimental|Mitoxantrone+Prednisone+Siltuximab (CNTO 328) (Part 1)|In Part 1, mitoxantrone 12 milligram per square meter (mg/m^2) will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with siltuximab 6 mg/kilogram (mg/kg) intravenously as a 2 hour-infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year; and prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
11629889|NCT00376090|Experimental|Group III Vaccine|
11629064|NCT00385827|Experimental|Mitoxantrone+Prednisone+Siltuximab (Part 2)|In Part 2, mitoxantrone 12 mg/m^2 will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with siltuximab 6 mg/kg intravenously as a 2-hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year; and prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
11629065|NCT00385827|Active Comparator|Mitoxantrone+Prednisone (Part 2)|In Part 2, mitoxantrone 12 mg/m^2 will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
11629066|NCT00385801|Placebo Comparator|Placebo|Identical placebo tablets and injections
11629067|NCT00385801|Active Comparator|risperidone consta|Risperidone 1-2 mg tablets and Risperidone 25 mg injections
11629068|NCT00385788|Experimental|Gemcitabine + Fludarabine + Melphalan|Gemcitabine 800 mg/m^2 intravenous (IV) over 30 minutes for one day; Fludarabine 33 mg/m^2 IV for 4 days; Melphalan 70 mg/m^2 IV over 30 minutes for 2 days. Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation. If receiving transplant from matched unrelated donor (not blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant, infusion of stem cells on Day 0. Tacrolimus 0.03 mg/kg by vein over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.
11629069|NCT00385788|Experimental|Fludarabine + Melphalan|Fludarabine 33 mg/m^2 IV for 4 days; Melphalan 70 mg/m^2 IV over 30 minutes for 2 days. Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation. If receiving transplant from matched unrelated donor (not blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant, infusion of stem cells on Day 0. Tacrolimus 0.03 mg/kg by vein over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.
11629070|NCT00385736|Experimental|Adalimumab 80/40|
11629071|NCT00385736|Experimental|Adalimumab 160/80/40|
11629072|NCT00385736|Placebo Comparator|Placebo|
11629073|NCT00385723|Experimental|1|1.25 g/d
11629074|NCT00385723|Experimental|2|2.496 g/d
11629075|NCT00385723|Placebo Comparator|3|
11629076|NCT00385710|Experimental|valproic acid|Depakine
11629077|NCT00385710|Placebo Comparator|Placebo|Placebo
11629078|NCT00385697|Experimental|1|
11629079|NCT00385697|Experimental|2|
11629080|NCT00385697|Experimental|3|
11629081|NCT00385697|Placebo Comparator|4|
11629082|NCT00385684|Experimental|A1: hydrocodone/APAP w placebo PRN|This is a fully crossed study, each participant serves as his own control. Phase A (closed label) has two arms: A1 is the experimental and A2 is the placebo comparator. Participants are randomized to either A1 for 1 week then A2 for 1 week OR A2 for 1 week then A1 for one week. A1: hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID, with liquid placebo available PRN. A2: liquid placebo TID with hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid PRN.
11629083|NCT00385684|Placebo Comparator|A2: placebo w hydrocodone/APAP PRN|This is a fully crossed study, each participant serves as his own control. Phase A: Participants are randomized to either A1 for 1 week then A2 for 1 week OR A2 for 1 week then A1 for one week. A1: hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID, with liquid placebo available PRN. A2: liquid placebo TID with hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid PRN.
11629084|NCT00385684|Active Comparator|B: Open label hydrocodone/acetaminophen|Phase B: If tolerated study medication during Phase A (i.e., the closed label, double-blind phase of the trial) then enter a six-week, open-label phase. Participants judged as responders during Phase A continue the same dose of study medication. Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
11629085|NCT00385671|Active Comparator|Pregabalin|Pregabalin (PGB) 50 milligram (mg) three times a day (TID) (US & Germany) or 75 mg twice daily (BID) (Canada), orally (PO) for 2 weeks, then PGB 100 mg TID (US & Germany) or 150 mg BID (Canada), PO for 10 weeks.
11629086|NCT00385671|Experimental|Duloxetine|Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then DLX 60 mg QD, PO for 11 weeks.
11629087|NCT00385671|Experimental|Gabapentin + Duloxetine|Stable Gabapentin (GAB) + Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then stable GAB + DLX 60 mg QD, PO for 11 weeks.
11629088|NCT00385632||1|Participants following a drug conservation (DC) regimen in which ART was stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count was at least 350 cells/mm3, and then followed by episodic ART based on CD4 cell count
11629089|NCT00385632||2|Participants following a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count
11629090|NCT00385580|Experimental|1|
11629091|NCT00385580|Experimental|2|
11629092|NCT00385541|Active Comparator|A|Patients receive morphine 1mg/dose PCA for postsurgical pain; max 10 mg/hr; lockout 6 minutes.
11629093|NCT00385541|Active Comparator|B|Patients receive hydromorphone 0.2mg/dose PCA for postsurgical pain; max 10mg/hr; lockout 6 minutes.
11629094|NCT00385515|Experimental|1|SNX-1012 (meclocyline sulfosalicylate) tablets dissolved in water for oral swish and expectorate; 30 mg 4 times daily for 10 days
11629095|NCT00385515|Placebo Comparator|2|placebo (matched to SNX-1012) tablets dissolved in water for oral swish and expectorate; 4 times daily for 10 days
11629096|NCT00385502|Experimental|EcoNail™|econazole 5%/SEPA® 18% nail lacquer
11629097|NCT00385476||Patient Medication Knowledge Tool|Assessment of Cancer patients' knowledge of their medications in an outpatient acute care setting
11629098|NCT00385450|Experimental|Nelfinavir/placebo|
11629099|NCT00385411|Experimental|valproate|
11629100|NCT00385346|Experimental|A 1|Expressive writing
11629101|NCT00385268|Experimental|Active medication Acamprosate|1998mg/day for 8 weeks
11629102|NCT00385268|Placebo Comparator|Placebo|placebo pills for 8 weeks
11629890|NCT00376090|Placebo Comparator|Group III Placebo|
11629103|NCT00385255|Experimental|BOOSTRIX+FLUARIX GROUP|Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Boostrix® vaccine co-administered with Fluarix® vaccine at Day 0, injected intramuscularly in the left and right upper deltoid regions, respectively.
11629104|NCT00385255|Experimental|FLUARIX BOOSTRIX GROUP|Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Fluarix® vaccine at Day 0 and Boostrix® vaccine at Month 1, both injected intramuscularly in the upper left deltoid region.
11629105|NCT00385242|Active Comparator|PET guided Therapy|Patients will be randomized to undergo positron emission tomography aspart of their clinical work up
11629106|NCT00385242|Active Comparator|Standard care|Patients will be randomized to standard care will under go other types of imaging or work up for revascularization without PET imaging.
11629107|NCT00385229|Experimental|Induction|induction of labor at gestational age 289(41 weeks+2 days)
11629108|NCT00385229|No Intervention|expectant management|expectant management at gestational age 289(41 weeks+2 days)
11629109|NCT00385216|Active Comparator|Nicotine nasal spray|In one sitting the subject will receive a nicotine nasal spray, 3 mg, one application.
11629110|NCT00385216|Placebo Comparator|Placebo spray|In one sitting the subject will receive a placebo nasal spray (0 mg), one application.
11629111|NCT00385177|Experimental|A|SN2310 Injectable Emulsion
11629112|NCT00385138|Experimental|Cangrelor|cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion
11629113|NCT00385138|Active Comparator|Clopidogrel|placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion
11629114|NCT00385086|Experimental|TNF-alpha blocker|Treatment with TNF-alpha blocker
11629115|NCT00385086|Active Comparator|Placebo|Treatment with placebo
11629116|NCT00385047|Experimental|Group A|FMP 2.1 50 μg FMP2.1/AS01B
11629117|NCT00385047|Experimental|Group B|FMP 2.1 50 μg FMP2.1/AS02A
11629118|NCT00385008|Other|Arm 1|open-label active drug
11629119|NCT00385008|Other|Arm 2|open-label active drug
11629120|NCT00384995|Experimental|Bicarbonate|Bicarbonate solution infusion
11629121|NCT00384995|Active Comparator|Saline|Standard volume expansion
11629122|NCT00384982|Experimental|A, B, C, D|Early or late; percutaneous intracoronary or combined (intramyocardial and intracoronary) administration of BM-MNCs
11629123|NCT00384969|Experimental|1|RAD001 and Sorafenib
11629124|NCT00384956|Experimental|Azacitidine|Azacitidine 75 mg/m2 IV on days 1-5 of each 28 day cycle. Patients that do not respond after two cycles will have the dose increased to 100 mg/m2. Patients who achieve a CR will receive 3 additional 28 day cycles and then begin treatment on days 1-5 of a 56 day cycle. Individuals who demonstrate a loss of response will resume 28 day cycles.
11629125|NCT00384930|Placebo Comparator|1|placebo tablet
11629126|NCT00384930|Active Comparator|2|2.5 mg tadalafil tablet
11629127|NCT00384930|Active Comparator|3|5 mg tadalafil tablet
11629128|NCT00384930|Active Comparator|4|10 mg tadalafil tablet
11629129|NCT00384930|Active Comparator|5|20 mg tadalafil tablet
11629130|NCT00384904|No Intervention|A1|
11629131|NCT00384904|Experimental|A2|
11629132|NCT00384904|Experimental|A3|
11629133|NCT00384904|No Intervention|B1|
11629134|NCT00384904|Experimental|B2|
11629135|NCT00384904|Experimental|B3|
11629136|NCT00384891|Experimental|Synergo + MMC|Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
11629137|NCT00384891|Active Comparator|Bacillus Calmette-Guérin|Intravesical instillation with BCG (Bacillus Calmette-Guérin)
11629138|NCT00384865|Active Comparator|Aspirin 81 mg + Simvastatin 40 mg|"Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months
~Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months"
11629139|NCT00384865|Active Comparator|Aspirin 81 mg + Placebo|"Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months
~Placebo taken orally, once a day for 6 months"
11629140|NCT00384865|Active Comparator|Placebo + Simvastatin 40 mg|"Placebo taken orally, once a day for 6 months
~Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months"
11629141|NCT00384865|Placebo Comparator|Placebo + Placebo|"Placebo taken orally, once a day for 6 months
~Placebo taken orally, once a day for 6 months"
11629142|NCT00384852|Experimental|A|1.0 mg/mL rhBMP-2/CPM + SOC
11629143|NCT00384852|Experimental|B|2.0 mg/mL rhBMP-2/CPM + SOC
11629144|NCT00384852|Active Comparator|C|Buffer/CPM + SOC
11629145|NCT00384852|Other|D|Standard of Care Alone (SOC)
11629146|NCT00384839|Experimental|1|azacitidine for injectable suspension
11629147|NCT00384826|Experimental|1|
11629148|NCT00384826|Experimental|2|
11629149|NCT00384813|Experimental|1: Home-based family intervention|Home-based family intervention
11629150|NCT00384813|Active Comparator|2: ETAU|Enhanced Treatment As Usual (1 home visit)
11629151|NCT00384787|Experimental|1|Group 1 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost intramuscularly at Month 6.
11629152|NCT00384787|Experimental|2|Group 2 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost intradermally at Month 6.
11629153|NCT00384787|Experimental|3|Group 3 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost subcutaneously at Month 6.
11629154|NCT00384774|Experimental|Lasmiditan|Participants received escalating doses of 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 45 mg of lasmiditan as intravenous injection.
11629155|NCT00384774|Placebo Comparator|Placebo|Participants received intravenous infusion of placebo solution.
11629271|NCT00383500|Experimental|Flexitouch device|Participants will self-administer lymphedema management via daily use of the Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump)
11629156|NCT00384748|Experimental|Tele-visit Group|TR intervention targets safe functional mobility within a home environment and consists of: 1) exercise targeting underlying stroke-related impairment and 2) adaptive strategies targeting external factors to help compensate for disability. TR uses a combination of tele-video visits, an in-home messaging device, and telephone contact over a 3-month study period. A video camera is used in the home to provide visual and audio to a therapist located at the base hospital. An interactive, in-home messaging device is used to facilitate adherence with treatment recommendations and to screen for depression, falls, and difficulty with self-care. This allows evaluations of problem areas during tele-visits, rapid response to new functional problems.
11629157|NCT00384748|Active Comparator|Usual Care Group|Patients randomized to the Usual Care group receive routine VA care, as directed by their physicians. Therapy services are tracked via a weekly diary for the entire 6 month study period. In this weekly diary, patients in both the usual care and intervention group will record receipt of therapy. Usual Care group will be asked whether they exercised, and if so how frequently. They will be administered telephone interviews at baseline, 3-and 6-months. The interview outcome measures are FONEFIM, Late-Life Function and Disability Instrument, Falls Self Efficacy Scale and Stroke Specific Patient Satisfaction with Care. In addition, sociodemographics, stroke severity, length of time since stroke onset, and depression at baseline will be measured.
11629158|NCT00384735||1A|Intensive - 3 monthly follow up
11629159|NCT00384735||1B|Intensive - 6 monthly follow up
11629160|NCT00384735||IIA|Cost Effective - 3 monthly follow up
11629161|NCT00384735||IIB|Cost Effective - 6 monthly follow up
11629162|NCT00384696||Smoking Cessation|Treatment to help quit smoking, including written self-help materials, counseling, and 4 week supply of nicotine patch plus 5 MD Anderson Visits.
11629163|NCT00384683||Endothelial Dysfunction|Participants are scheduled for major chest (lung or esophagus) surgery or are a healthy volunteer. A blood test will quantify the number of cells that are destined to become endothelial cells.
11629164|NCT00384670|Experimental|Dengue and Japanese Encephalitis vaccine|1 mL subcutaneous injection Dengue Vaccine Formulation 17 on Day 0 and Day 60. 0.5 mL subcutaneous injection Licensed Japanese Encephalitis (JE) Vaccine on months 7 and 7.5.
11629165|NCT00384657|Experimental|Group I|iv iron sucrose
11629166|NCT00384657|No Intervention|Group II|Patients will receive conventional treatment of Chronic Heart Failure.
11629167|NCT00384644||1|sepsis, septic shock ptients
11629168|NCT00384644||2|cardiogenic shock patients
11629169|NCT00384631|Sham Comparator|2|
11629170|NCT00384631|Experimental|1|
11629171|NCT00384605|Experimental|1|Arm 1: MK0364 2 mg capsule once daily
11629172|NCT00384605|Experimental|2|Arm 2: MK0364 1 mg capsule once daily
11629173|NCT00384605|Experimental|3|Arm 3: MK0364 0.5 mg capsule once daily.
11629174|NCT00384605|Placebo Comparator|4|Arm 4: Pbo capsule once daily.
11629175|NCT00384579|Experimental|1|Botulinum Toxin B
11629176|NCT00384579|Placebo Comparator|2|Placebo
11629177|NCT00384566|Experimental|1|
11629178|NCT00384566|Active Comparator|2|
11629179|NCT00384540|Other|Cardiovascular events vs Dobutamine stress echocardiography|
11629180|NCT00384527|Experimental|1|
11629181|NCT00384527|Active Comparator|2|
11629182|NCT00384462||1|Premature Infants (32-35 wks. GA) who are less than six months of age at start of RSV season and followed until May of the following year.
11629183|NCT00384462||2|Premature newborns (32-35 wks. GA) who are born during the current RSV season and discharged from the hospital after 01 Dec and followed until May of the next year.
11629184|NCT00384449|Experimental|Lucentis (ranibizumab)|Lucentis (ranibizumab)
11629185|NCT00384397|Experimental|Group 1: Menactra® Vaccine|Participants will receive Menactra® vaccine at age 9 months and 12 months, respectively.
11629186|NCT00384397|Experimental|Group 2: Menactra® + MMRV|Participants will receive Menactra® at age 9 months followed by Menactra® and Measles-Mumps-Rubella-Varicella (MMRV) vaccines at Age 12 Months
11629187|NCT00384397|Experimental|Group 3: Menactra® + PCV|Participants will receive Menactra® at age 9 months followed by Menactra® and Pneumococcal Conjugate (PCV) vaccines at Age 12 Months
11629188|NCT00384371|Experimental|1|Botulinum Toxin A
11629189|NCT00384371|Placebo Comparator|2|Placebo
11629190|NCT00384358|Experimental|A|1.0 mg/mL rhBMP-2/CPM + surgical fixation
11629191|NCT00384358|Experimental|B|2.0 mg/mL rhBMP-2/CPM + surgical fixation
11629192|NCT00384358|Other|C|Control: Surgical fixation
11629193|NCT00384332|Experimental|Arm 1|Orally disintegrating olanzapine
11629194|NCT00384332|Experimental|Arm 2|regular olanzapine
11629195|NCT00384293|Experimental|1|MK0524A
11629196|NCT00384293|Placebo Comparator|2|placebo
11629197|NCT00384267||Neonates|Inpatient
11629198|NCT00384254|No Intervention|1|Usual Care Control: Patients receive treatment as usual
11629199|NCT00384254|Experimental|2|"5 A Intervention Condition: Patients in this condition receive all five A components (Ask, Advise, Assess, Assist, Arrange) recommended in the Clinical Practice Guideline: Treating Tobacco Use and Dependence."
11629200|NCT00384254|Experimental|3|"3 A Condition: Patients receive Ask, Advise, Arrange intervention consisting of the first two A components recommended by the Clinical Practice Guideline: Treating tobacco Use and Dependence, plus Fax-to-Quit referral to a tobacco quit line."
11629201|NCT00384241||Children|Children age 15-19, self reported as African American of European Origin, healthy non-smoker, with normal blood pressure, exposed to an activity to that results in induced stress
11629202|NCT00384241||Parents|Collection of buccal swab Parent of participants in the Children Arm
11629203|NCT00384228|Experimental|Nilotinib|
11629204|NCT00384202|Experimental|1|
11629205|NCT00384189|Active Comparator|Ciclesonide 40 µg|Placebo-matching ciclesonide, inhaled via a metered-dose inhaler (MDI) with 1,1,1,2-hydrofluoroalkane (HFA)-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 40 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
11629332|NCT00382915||1|Smokers with schizophrenia
11629333|NCT00382915||2|Smokers with bipolar disorder
11629206|NCT00384189|Active Comparator|Ciclesonide 80 µg|Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 80 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
11629207|NCT00384189|Active Comparator|Ciclesonide 160 µg|Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 160 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
11629208|NCT00384189|Placebo Comparator|Placebo|Placebo-matching Ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 2 to 4 week in the Baseline period followed by placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
11629209|NCT00384176|Active Comparator|1|Bevacizumab + FOLFOX
11629210|NCT00384176|Experimental|2|Cediranib + FOLFOX
11629211|NCT00384137|Experimental|1|
11629212|NCT00384111|Experimental|1|R-CVP plus Zevalin Therapeutic Regimen
11629213|NCT00384111|Active Comparator|2|R-CVP
11629214|NCT00384085|Experimental|Lantus/Apidra-3|Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.
11629215|NCT00384085|Experimental|Lantus/Apidra-1|Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.
11629216|NCT00384085|Experimental|Novolog Mix 70/30|Premixed insulin (Novolog® Mix 70/30) added to oral agents.
11629217|NCT00384059|Experimental|1|13-valent pneumococcal vaccine
11629218|NCT00384059|Active Comparator|2|7-valent pneumococcal vaccine
11629219|NCT00384046|Experimental|1|300mcg/day testosterone
11629220|NCT00384046|Placebo Comparator|2|Placebo arm
11629221|NCT00384033|Experimental|Desvenlafaxine succinate sustained-release 50 mg|
11629222|NCT00384033|Experimental|Desvenlafaxine succinate sustained-release 100 mg|
11629223|NCT00384033|Placebo Comparator|Placebo|
11629224|NCT00384033|Other|Duloxetine 60mg|Active control to assess assay sensitivity
11629225|NCT00383994|Experimental|Immunotherapy with NK Cell, Rituximab + GM-CSF|"Immunotherapy in Non-myeloablative Allogeneic Stem Cell Transplantation
~GM-CSF = Granulocyte-Macrophage Colony-Stimulating Factor"
11629226|NCT00383942|Active Comparator|Misoprostol|Patients randomized to this arm will receive 25 micrograms of misoprostol every four hours.
11629227|NCT00383942|Experimental|EASI Catheter|Patients randomized to this arm will receive extra amniotic saline infusion (EASI) administered via catheter
11629228|NCT00383929|Experimental|1|Candesartan Cilexetil (CC) /HCT 32/12.5mg
11629229|NCT00383929|Experimental|2|Candesartan Cilexetil (CC) /HCT 32/25mg
11629230|NCT00383929|Experimental|3|Candesartan Cilexetil monotherapy
11629231|NCT00383890|Experimental|Dexmedetomidine|Dexmedetomidine 1 mcg/kg load for 10 minutes and Dexmedetomidine Maintenance (0.7 mcg/kg/hr) for 15 min
11629232|NCT00383890|Placebo Comparator|Placebo (PBO)|Placebo load for 10 min and Placebo maintenance for 15 min
11629233|NCT00383799|Active Comparator|Group 1|IV procainamide (single dose: 10 mg/kg over 20 min)
11629234|NCT00383799|Active Comparator|Group 2|IV Amiodarone (single dose: 5 mg/kg over 20 min)
11629235|NCT00383786|Experimental|GR205171|selective neurokinin-1 receptor antagonist, fixed 5 mg dose every day, for 8 weeks.
11629236|NCT00383786|Placebo Comparator|placebo|sugar pill
11629237|NCT00383760|Experimental|Treatment (eribulin mesylate)|Patients receive E7389 IV on days 1 and 8.
11629238|NCT00383747|Active Comparator|Nicotine Patch|
11629239|NCT00383747|Placebo Comparator|Placebo Nicotine Patch|
11629240|NCT00383734|Experimental|1|newfill
11629241|NCT00383734|Experimental|2|Eutrophill
11629242|NCT00383721|Experimental|MF/F MDI 400/10 mcg BID|
11629243|NCT00383721|Experimental|MF/F MDI 200/10 mcg BID|
11629244|NCT00383721|Experimental|MF MDI 400 mcg BID|
11629245|NCT00383721|Active Comparator|Formoterol MDI 10 mcg BID|
11629246|NCT00383721|Placebo Comparator|Placebo MDI BID|
11629247|NCT00383708|Experimental|1|
11629248|NCT00383669|Active Comparator|Multiple RDA multivitamins|Multivitamins (including B, C, and E)
11629249|NCT00383669|Active Comparator|Single RDA Multivitamins|Multivitamins (including B, C, and E)
11629250|NCT00383656|Experimental|Pulsatile GnRH|All participants will be administered GnRH intravenously by means of a portable infusion pump that delivers boluses at specific intervals.
11629251|NCT00383643|Placebo Comparator|Placebo|Eligible subjects randomized to this arm received placebo as gelatin capsule and a liquid capsule to fully maintain the blind.
11629252|NCT00383643|Active Comparator|Zolpidem tartrate|Eligible subjects randomized to this arm received zolpidem as gelatin capsule and a placebo liquid capsule to fully maintain the blind.
11629253|NCT00383643|Active Comparator|Sodium oxybate|Eligible subjects randomized to this arm received placebo as gelatin capsule and a sodium oxybate capsule to fully maintain the blind.
11629254|NCT00383630|Experimental|Group 1|Intramyocardial injection of bone marrow mononuclear cells + LVAD
11629255|NCT00383630|Experimental|Group 2|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells + LVAD
11629256|NCT00383630|Other|Group 3|LVAD alone
11629257|NCT00383578|Experimental|Vildagliptin|
11629258|NCT00383578|Active Comparator|Metformin|
11629259|NCT00383565|Experimental|Arm I|Patients receive FR901228 IV over 4 hours on days 1, 8, and 15.
11629260|NCT00383552|Experimental|MF/F MDI 100/10 mcg BID|
11629261|NCT00383552|Experimental|MF MDI 100 mcg BID|
11629262|NCT00383552|Experimental|F MDI 10 mcg BID|
11629263|NCT00383552|Placebo Comparator|Placebo BID|
11629264|NCT00383539|Experimental|1|Lot 1
11629265|NCT00383539|Experimental|2|Lot 2
11629266|NCT00383539|Experimental|3|Lot 3
11629267|NCT00383539|Active Comparator|4|Control
11629268|NCT00383526|Experimental|Study Group 1|
11629269|NCT00383526|Active Comparator|Study Group 2|
11629272|NCT00383500|Experimental|Manual Lymphatic Drainage (MLD)|Participants will self-administer lymphedema management via daily manual lymphatic massage therapy, using a Class 1 compression garment
11629273|NCT00383500|No Intervention|Observational Control (no intervention)|Control group, no intervention. No Flexitouch or manual massage therapy
11629274|NCT00383474|Experimental|Arm I|Patients will receive an infusion of bortezomib twice a week for 2 weeks. They will also receive tipifarnib by mouth twice a day for 2 weeks.
11629275|NCT00383448|Experimental|Treated Patients|Patients receiving chemotherapy (Hydroxyurea, Alemtuzumab, Clofarabine, Melphalan), Hematopoietic Stem Cell Transplantation and radiation therapy (Total body Irradiation) mycophenylate mofetil and cyclosporine A.
11629276|NCT00383435|Experimental|MF/F MDI 400/10 mcg BID|
11629277|NCT00383435|Experimental|MF/F MDI 200/10 mcg BID|
11629278|NCT00383435|Experimental|MF MDI 400 mcg BID|
11629279|NCT00383435|Active Comparator|Formoterol MDI 10 mcg BID|
11629280|NCT00383435|Placebo Comparator|Placebo MDI BID|
11629281|NCT00383422|Experimental|1|
11629282|NCT00383422|Active Comparator|2|
11629283|NCT00383370|Experimental|ITV-1|VEGF Trap formulation 1
11629284|NCT00383370|Experimental|ITV-2|VEGF Trap formulation 2
11629285|NCT00383370|Experimental|ITV-2 OL|VEGF Trap formulation 2 open label, higher concentration
11629286|NCT00383331|Experimental|A|
11629287|NCT00383331|Experimental|B|
11629288|NCT00383292|Experimental|Tasisulam|
11629289|NCT00383266|Experimental|Pemetrexed + Carboplatin|"Pemetrexed 500 mg/m^2 IV over 10 minutes
~Carboplatin AUC 5 IV over 30 minutes on day 1 of each cycle
~Each cycle will last 21 days."
11629290|NCT00383253|Experimental|10%|
11629291|NCT00383253|Experimental|25%|
11629292|NCT00383253|Experimental|50%|
11629293|NCT00383253|Placebo Comparator|Control|
11629294|NCT00383240|Experimental|MF/F MDI 200/10 mcg BID|
11629295|NCT00383240|Experimental|MF MDI 200 mcg BID|
11629296|NCT00383240|Experimental|F MDI 10 mcg BID|
11629297|NCT00383240|Placebo Comparator|Placebo BID|
11629298|NCT00383214|Active Comparator|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
11629299|NCT00383214|Placebo Comparator|Placebo|Intravenous
11629300|NCT00383188|Placebo Comparator|1|
11629301|NCT00383188|Experimental|2|
11629302|NCT00383188|Experimental|3|
11629303|NCT00383188|Experimental|4|
11629304|NCT00383188|Experimental|5|
11629305|NCT00383162|Other|Combination Product - Placebo|Combination product (sumatriptan and naproxen sodium) [Attack 1] followed by placebo [Attack 2]
11629306|NCT00383162|Other|Placebo - Combination Product|Placebo [Attack 1] followed by Combination Product (sumatriptan and naproxen sodium) [Attack 2]
11629307|NCT00383149|Experimental|Ixabepilone plus Cetuximab|All participants were administered ixabepilone at a starting dose of 32 mg/m^2 as a 3-hour intravenous (IV) infusion every 3 weeks. In addition, all participants were administered an initial dose of cetuximab (400 mg/m^2 IV over 2 hours) followed by a weekly lower dose (250 mg/m^2 IV over 1 hour).
11629308|NCT00383136|Experimental|1|Tirofiban
11629309|NCT00383136|Active Comparator|2|Abciximab
11629310|NCT00383123|Experimental|Fluarix Group|"Subjects in this group received Fluarix™ and will be further stratified by 3 age groups
~1:1 in 6 months to < 36 months
~1:1 in 3 to < 5 years
~3:1 in 5 to < 18 years"
11629311|NCT00383123|Active Comparator|Fluzone Group|"Subjects in this group received Fluzone and will be further stratified by 3 age groups
~1:1 in 6 months to < 36 months
~1:1 in 3 to < 5 years
~3:1 in 5 to < 18 years"
11629312|NCT00383110||Group 1|Adults (age 18 or older) with type 2 diabetes.
11629313|NCT00383084|Experimental|1|Group 1 participants will take part in 30 minutes total of self-selected lifestyle physical activity throughout the day, 5 to 7 days per week. Twice a month, they will attend group sessions designed to help participants develop and maintain a more physically active lifestyle. Goal setting, self-monitoring, and pain management will be discussed at these sessions.
11629314|NCT00383084|Active Comparator|2|Group 2 participants will attend monthly fibromyalgia educational sessions, which will focus on understanding the symptoms of FM, learning to manage pain and fatigue, and developing self-help strategies.
11629315|NCT00383071|Active Comparator|Cohort 1|H5N1 vaccine - 90 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
11629316|NCT00383071|Active Comparator|Cohort 2|H5N1 vaccine - 120 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
11629317|NCT00383071|Active Comparator|Cohort 3|H5N1 vaccine - 180 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
11629318|NCT00383071|Active Comparator|Cohort 4|H5N1 vaccine - 180 mcg IM every 4 weeks x 2 doses, injection site randomized to either deltoid or gluteus Apheresis - if HAI titer above 1:160
11629319|NCT00382993|Other|Combination Product - Placebo|Combination Product (sumatriptan and naproxen sodium) [Attack 1] followed by Placebo [Attack 2]
11629320|NCT00382993|Other|Placebo - Combination Product|Placebo [Attack 1] followed by Combination Product (sumatriptan and naproxen sodium) [Attack 2]
11629321|NCT00382980|Experimental|7.5-|7.5 mcg of vaccine without adjuvant administered on Days 0 and 28.
11629322|NCT00382980|Experimental|45-|45 mcg of vaccine without adjuvant administered on Days 0 and 28.
11629323|NCT00382980|Placebo Comparator|Placebo|Placebo administered on Days 0 and 28.
11629324|NCT00382980|Experimental|15+|15 mcg of vaccine with aluminum hydroxide adjuvant administered on Days 0 and 28.
11629325|NCT00382980|Experimental|7.5+|7.5 mcg of vaccine with aluminum hydroxide adjuvant administered on Days 0 and 28.
11629326|NCT00382980|Experimental|15-|15 mcg of vaccine without adjuvant administered on Days 0 and 28.
11629327|NCT00382967|Experimental|Datscan Product|
11629328|NCT00382967|No Intervention|Control|
11629329|NCT00382954|Experimental|Phase 1 escalation|
11629330|NCT00382928|No Intervention|Standard of Care Group|Patients will receive standard of care measures in case of cardiac arrest. They will not receive AECD monitoring or intervention
11629331|NCT00382928|Experimental|AECD Monitoring + Standard of Care Group|Patients will receive AECD monitoring and intervention in addition to standard of care in case of cardiac arrest during admission to the hospital. Defibrillation of pulseless VT/VF by AECD.
11629336|NCT00382863|Active Comparator|Control|Optimal Medical/Device Therapy alone (e.g., medications and/or cardiac resynchronisation therapy) (Note: For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of angiotensin converting enzyme (ACE) inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as cardiac resynchronization therapy (CRT) or cardiac resynchronization therapy-defibrillator (CRT-D) for at least three months prior to study enrollment, when indicated.)
11629337|NCT00382850|Active Comparator|open nissen fundoplication|open repair through surgical midline incision
11629338|NCT00382850|Active Comparator|laparoscopic nissen fundoplication|use of laparoscope to do repair
11629339|NCT00382824|Active Comparator|CoQ10|Half of the enrolled patients will be randomized into the the CoQ10 arm and will receive a dosage of 2400mg/day of Coenzyme Q10
11629340|NCT00382824|Placebo Comparator|Placebo|Half of the enrolled patients will be randomized into the the Placebo arm and will receive a matching dose of placebo that resembles the 2400mg/day dose of the CoQ10 arm.
11629341|NCT00382811|Experimental|1|Daily Phenoxodiol + weekly carboplatin
11629342|NCT00382811|Active Comparator|2|Daily phenoxodiol placebo + weekly carboplatin
11629343|NCT00382785|Experimental|moderated online support|12-week online support led by a healthcare professional
11629344|NCT00382785|Experimental|peer-led support|12-week online support group in a peer-led format
11629345|NCT00382720|Experimental|TE (Taxotere and Eloxatin)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin). Each chemotherapy cycle was repeated every 21 days.
~Participants received either the optimal or non-optimal dose for Taxotere and Eloxatin. Participants who received the optimal dose for Taxotere and Eloxatin were analyzed in this study."
11629346|NCT00382720|Experimental|TEF (Taxotere, Eloxatin and 5-FU)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and 5-FU (5-Fluorouracil). Each chemotherapy cycle was repeated every 14 days.
~Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and 5-FU. Participants who received the optimal dose for Taxotere, Eloxatin and 5-FU were analyzed in this study."
11629347|NCT00382720|Experimental|TEX (Taxotere, Eloxatin and Xeloda)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and capecitabine (Xeloda). Each chemotherapy cycle was repeated every 21 days.
~Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and Xeloda. Participants who received the optimal dose for Taxotere, Eloxatin and Xeloda were analyzed in this study."
11629348|NCT00382681|Experimental|FID 107027|Contact lens solution used as instructed for 90 days.
11629349|NCT00382681|Active Comparator|ReNu MultiPlus|Contact lens solution used as instructed for 90 days.
11629350|NCT00382668||A|
11629351|NCT00382668||B|
11629352|NCT00382668||C|
11629353|NCT00382642|Experimental|Ondansetron|Arm 1 = Ondansetron 4 mcg/kg b.i.d.+ Cognitive behavioral therapy
11629354|NCT00382642|Placebo Comparator|Placebo|Arm 2 = Placebo + Cognitive behavioral therapy
11629355|NCT00382590|Active Comparator|5-Aza + VPA|5-Azacytidine (5-Aza) 75 mg/m^2 subcutaneously daily + Valproic Acid (VPA) 50 mg/m^2 orally daily, each for 7 days
11629356|NCT00382590|Active Comparator|Ara-C|Low-Dose Ara-C 20 mg twice daily subcutaneously for 10 days.
11629357|NCT00382525||Patients with Cardiac Rhythm Management device|Patients receiving a Medtronic Cardiac Rhythm Device, worldwide
11629358|NCT00382499|Experimental|Lidocaine|IV lidocaine in OR as described in methods
11629359|NCT00382473|Experimental|exercise|
11629360|NCT00382447|Experimental|1|Standard nebulizer versus standard breath actuated nebulizer
11629361|NCT00382434||EPh Present|the emergency pharmacist is present in the ED when the medical care is provided
11629362|NCT00382408|Experimental|Vaccine|Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).
11629363|NCT00382408|Placebo Comparator|Placebo|Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).
11629364|NCT00382395|Experimental|1|SOLX Gold Shunt
11629365|NCT00382395|Active Comparator|2|Control Ahmed FP7 Shunt
11629366|NCT00382382|Other|Children with Autism|A diffusion tensor imaging (DTI) will be done to examine the integrity of the white matter pathways in high functioning austistic children.
11629367|NCT00382382|Other|Healthy Volunteers|A diffusion tensor imaging (DTI) will be done to examine the integrity of the white matter pathways in healthy volunteers.
11629368|NCT00382356|Experimental|study drug|Open label, single arm
11629369|NCT00382343|Experimental|sulfamethoxazole/trimethoprim|Antibiotic prophylaxis with sulfamethoxazole/trimethoprim [1-2 mg/kg trimethoprim and 5-10 mg/kg sulfamethoxazole once daily]; in case of intolerance (leucopoenia) and for children younger than 6 months: nitrofurantoin [2 mg/kg once daily]
11629370|NCT00382343|No Intervention|No prophylaxis|
11629371|NCT00382291|Experimental|Regular Titration|Regular titration of Sertraline plus cognitive behavioral therapy. The titration schedule used a flexible upward titration from 25 mg/day to 200 mg/day over 9 weeks unless higher doses were not tolerated, after which the dosage was adjusted as a function of tolerability. If tolerated, maximum dose could be achieved in 5 weeks.
11629372|NCT00382291|Placebo Comparator|Placebo|Placebo plus cognitive behavioral therapy
11629373|NCT00382291|Experimental|Slow Titration|Slow titration of Sertraline plus cognitive behavior therapy. The titration schedule utilized a slower titration schedule relative to the RegSert arm. Unless unable to tolerate higher doses, children remained on 25mg/day for the first two weeks, 50mg/day from weeks 3-4, 75mg/day for weeks 5-6, 100mg/day for week 7, 150mg/day for week 8, and 200mg/day for week 9 until the end of the study.
11629374|NCT00382265|Active Comparator|Tamsulosin|Tamsulosin 0.4mg PO qd for 28 days
11629375|NCT00382265|Placebo Comparator|Placebo|Placebo PO qd for 28 days
11629376|NCT00382239|Experimental|Exenatide 5 mcg/exenatide 10 mcg|
11629377|NCT00382239|Experimental|Exenatide 5 mcg/exenatide 5 mcg|
11629378|NCT00382239|Experimental|Exenatide 2.5 mcg/exenatide 2.5 mcg|
11629379|NCT00382239|Placebo Comparator|Placebo/placebo|
11629380|NCT00382200|Experimental|Decitabine and All-Trans Retonoic Acid (Tretinoin)|Decitabine and All-Trans Retonoic Acid (Tretinoin)
11629381|NCT00382187|Experimental|MF59 adjuvant H5N1 influenza vaccine 7.5 micrograms|
11629891|NCT00376090|Experimental|Group IV Vaccine|
11629383|NCT00382187|Experimental|non-adjuvanted influenza vaccine 15 micrograms of H5N1 antigen|
11629384|NCT00382174|Placebo Comparator|1|0.00% thymosin beta 4 w/w administered topically once daily for up to 84 days
11629385|NCT00382174|Active Comparator|2|3 doses of thymosin beta 4: 0.01% w/w, 0.02% w/w, and 0.1% w/w, administered topically once daily for up to 84 days
11629386|NCT00382148|Experimental|1|
11629387|NCT00382135|Placebo Comparator|1|placebo tablet
11629388|NCT00382135|Active Comparator|2|20 mg tadalafil tablet
11629389|NCT00382109|Experimental|Tacro-MTX/Sirolimus GVHD Prophylaxis Regimen|Preparative regimen of total body irradiation (TBI) 200 cGy BID days -8,-7, & -6, Thiotepa IV (dose 5 mg/kg/day on days -5 & -4) & cyclophosphamide IV (dose 60 mg/kg/day on days -3 & -2). Tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily on day -2 with a taper starting on day 42 - day 98 (patients undergoing matched sibling donor transplantation) OR tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily beginning on day -2 followed by a taper on day 100 through day 180 (patients undergoing other related, unrelated, or cord blood donor transplantation) in the absence of GVHD. Patients also receive methotrexate IV (5 mg/m2/dose) on days 1,3, & 6 (patients with matched sibling and umbilical cord blood donors) OR days 1,3 6, & 11 (patients with other related/unrelated bone marrow and peripheral blood stem cell donors) and oral sirolimus (dose 2.5mg/m2/day - 4 mg max starting dose) daily starting on day 0 followed by a taper starting on day 180 through day 207.
11629390|NCT00382109|Active Comparator|Tacro-MTX GVHD Prophylaxis|Preparative regimen of total body irradiation (TBI) 200 cGy BID days -8,-7, & -6, Thiotepa IV (dose 5 mg/kg/day on days -5 & -4) & cyclophosphamide IV (dose 60 mg/kg/day on days -3 & -2). Tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally (when able) daily on day -2 with a taper starting on day 42 - day 98 (patients undergoing matched sibling donor transplantation) OR tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily beginning on day -2 followed by a taper on day 100 through day 180 (patients undergoing other related, unrelated, or cord blood donor transplantation) in the absence of GVHD. Patients also receive methotrexate IV (5 mg/m2/dose) on days 1,3, & 6 (patients with matched sibling and umbilical cord blood donors) OR days 1,3 6, & 11 (patients with other related/unrelated bone marrow and peripheral blood stem cell donors).
11629391|NCT00382096|Experimental|Vildagliptin + Metformin Dose 1|
11629392|NCT00382096|Experimental|Vildagliptin + Metformin Dose 2|
11629393|NCT00382096|Active Comparator|Vildagliptin|
11629394|NCT00382096|Active Comparator|Metformin|
11629395|NCT00382070|Experimental|Group 2 Letrozole|Patients receive oral letrozole once daily for up to 5 years.
11629396|NCT00382070|Placebo Comparator|Group 1 Placebo|Patients receive oral placebo once daily for up to 5 years.
11629397|NCT00382031|Active Comparator|zalutumumab|Zalutumumab in combination with Best Supportive Care
11629398|NCT00382031|Other|Control|Best Supportive Care
11629399|NCT00382018|Active Comparator|Group 1|Patients continue to receive regular treatment without change at the discretion of the physician. Patients are eligible for other first-line chemotherapy trials. No further blood is collected.
11629400|NCT00382018|Experimental|Group 2|Patients continue to receive their current chemotherapy regimen without change.
11629401|NCT00382018|Active Comparator|Group 3, Arm I|Patients continue with their current chemotherapy regimen without change.
11629402|NCT00382018|Experimental|Group 3, Arm II|Patients switch to a different chemotherapy regimen. Selection of a new chemotherapy regimen is made by the patient's doctor.
11629403|NCT00381979|Experimental|1|set
11629404|NCT00381966|Experimental|Robotic placement device|The intervention involves use of a robotic template to assist in placement of needles for prostate brachytherapy.
11629405|NCT00381953|Active Comparator|360 PEG IFN|360 mug peginterferon alfa-2a QW
11629406|NCT00381953|Active Comparator|9 MU + 180 PEG IFN|9 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
11629407|NCT00381953|Active Comparator|4,5 MU IFN + 180 PEG IFN|4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
11629408|NCT00381940|Experimental|Treatment (enzyme inhibitor therapy, chemotherapy)|"Patients receive ifosfamide IV continuously over days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, bortezomib IV on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.
~Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy."
11629409|NCT00381914|Experimental|1|400 IU / day vitamin D
11629410|NCT00381914|Experimental|2|800 IU / day vitamin D
11629411|NCT00381914|Experimental|3|1200 IU / day vitamin D
11629412|NCT00381888|Experimental|Patients Treated with Fondaparinux|Patients treated with at least one dose of Fondaparinux (2.5 mg subcutaneous, Days 1-28 by mouth).
11629413|NCT00381862|Experimental|Aprepitant and Palonosetron|
11629414|NCT00381849|Active Comparator|Cystone then sugar pill|Subject will take Cystone for 6 weeks, then have a 1 week wash out period followed by the sugar pill for another 6 weeks
11629415|NCT00381849|Placebo Comparator|Sugar pill then Cystone|Subject will take sugar pill for 6 weeks, then a 1 week wash out followed by the Cystone for another 6 weeks
11629416|NCT00381849|Experimental|Open-label Cystone|All subjects will receive Cystone for 46 weeks in the open-label period.
11629417|NCT00381810|Experimental|Rituximab 1000 mg|Participants will receive rituximab 1000 mg intravenously twice, 14 days apart at study entry and again 6 months later. Participants will also receive methylprednisolone 100 or 125 mg IV, acetaminophen 1000 mg orally, and diphenhydramine 50 mg orally prior to study drug infusion.
11629418|NCT00381797|Experimental|Arm I|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and irinotecan hydrochloride IV over 90 minutes on day 16 or 17 for course 1. Patients receive bevacizumab and irinotecan hydrochloride on days 1 and 15 for all subsequent courses. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.
~Patients undergo MRIs of the brain, magnetic resonance perfusion/diffusion, and fludeoxyglucose F 18 positron emission tomography at baseline and periodically during treatment."
11629419|NCT00381784|Experimental|Community PROMISE|Community PROMISE is a community level HIV/STD prevention program that relies on role model stories and peer advocates from the community. Sites will adapt PROMISE for local use remaining faithful to the core elements.
11629420|NCT00381784|Experimental|Mpowerment|MPowerment is a community level HIV/STD prevention program that relies on peer advocates from the community to lead outreach activities including discussion groups (Mgroups), venue-based outreach, social events and a publicity campaign. Sites will adapt MPowerment for local use remaining faithful to the core elements.
11629421|NCT00381771||Objective salivary function|"Based on the salivary scintigraphy,
~Objective salivary normo-function
~Objective salivary dysfunction"
11629422|NCT00381732|Placebo Comparator|1|placebo tablet
11629423|NCT00381732|Active Comparator|2|2.5 mg tadalafil tablet
11629424|NCT00381732|Active Comparator|3|5 mg tadalafil tablet
11629425|NCT00381719|Experimental|1|3 mg
11629426|NCT00381719|Experimental|2|20 mg
11629427|NCT00381719|Experimental|3|60 mg
11629428|NCT00381719|Placebo Comparator|4|Placebo
11629429|NCT00381706|Experimental|Arm A (ECF + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab IV on days 1, 8 and 15. Patients receive epirubicin 50 mg/m^2 IV after cetuximab on day 1 followed by cisplatin 60 mg/m^2 IV over 60 minutes. On days 1-21, patients receive 5-fluorouracil 200 mg/m^2/day continuous IV infusion. Treatment repeats every 21 days in the absence of disease progression and unacceptable toxicity.
11629430|NCT00381706|Experimental|Arm B (IC + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab on days 1, 8 and 15. Patients receive cisplatin 30 mg/m^2 IV over 30 minutes on days 1 and 8 after cetuximab. Patients also receive irinotecan 65 mg/m^2 IV over 90 minutes on days 1 and 8 after receiving cisplatin.Treatment repeats every 21 days in the absence of disease progression and unacceptable toxicity.
11629431|NCT00381706|Experimental|ARM C (FOLFOX + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab on days 1 and 8. On Day 1, patients also receive oxaliplatin 85 mg/m^2 IV over 120 minutes and leucovorin 400 mg/m^2 IV over 120 minutes either concurrently with oxaliplatin via a separate infusion line or post oxaliplatin administration. Following leucovorin, patients will receive 5-fluorouracil 400 mg/m^2 IV bolus injection, then 5-fluorouracil 2400 mg/m^2 IV infusion over 46-48 hours. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
11629432|NCT00381680|Active Comparator|Regimen A: Standard vincristine dosing|See detailed description.
11629433|NCT00381680|Experimental|Arm B: Randomized High Dose Vincristine regimen|See detailed description. Closed to accrual as of 09/2010).
11629434|NCT00381667|Experimental|GW642444M 12.5|
11629435|NCT00381667|Experimental|GW642444M 100mcg|
11629436|NCT00381667|Experimental|GW642444M 400mcg|
11629437|NCT00381667|Experimental|GW642444H 100mcg|
11629438|NCT00381667|Experimental|Placebo|
11629439|NCT00381654|Experimental|A|Daily oral administration of AV-412
11629440|NCT00381641|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity
11629441|NCT00381628||Stable subjects with CF|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro.
11629442|NCT00381628||Exacerbating subjects with CF|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) at the beginning and end of treatment for a pulmonary exacerbation. These cells will be studied in vitro.
11629443|NCT00381628||Stable subjects with asthma|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro. This is the disease control group.
11629444|NCT00381628||Healthy volunteers|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro. This is the control group
11629445|NCT00381615|Experimental|rMenB|"Infants received 4 doses of recombinant meningococcal serogroup B (rMenB) vaccine without outer membrane vesicle (OMV-NZ) at 2, 4, 6 and 12 months of age.
~Infants also received routine vaccines - 3 doses each of Diphtheria Tetanus Pertussis-Haemophilus influenzae type b-Inactivated Polio Vaccine (DTaP-Hib-IPV) (at 2, 3, and 4 months) and Heptavalent Pneumococcal Conjugate (PC7) (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and Measles Mumps Rubella (MMR) (at 13 months)."
11629446|NCT00381615|Experimental|rMenB+OMV|"Infants received 4 doses of rMenB vaccine with OMV-NZ at 2, 4, 6 and 12 months of age.
~Infants also received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months)."
11629447|NCT00381615|Experimental|Routine|"Infants received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months).
~Infants also received single dose of rMenB vaccine without OMV-NZ at 12 months of age."
11629448|NCT00381615|Experimental|Routine+OMV|"Infants received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months).
~Infants also received single dose of rMenB vaccine with OMV-NZ at 12 months of age."
11629449|NCT00381589|Experimental|A|Random assignment to investigational spray
11629450|NCT00381576|Experimental|A|12 weeks of resistance training
11629451|NCT00381563|Other|Intervention to placebo|Participants will wear the patellofemoral realigning knee brace for 6 weeks, followed by the non-aligning knee brace for 6 weeks.
11629551|NCT00380055|Experimental|Treatment Navigation|Individuals with a study cancer who receive navigation services.
11629452|NCT00381563|Other|Placebo to intervetion|Participants will wear the non-aligning knee brace for 6 weeks, followed by the patellofemoral realigning knee brace for 6 weeks.
11629453|NCT00381550|Experimental|Arm I|Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11629454|NCT00381485|Experimental|MF/F MDI 400/10 mcg BID|"Mometasone Furoate 400 mcg and formoterol 10 mcg fixed dose combination taken twice daily
~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
11629455|NCT00381485|Experimental|MF/F MDI 200/10 mcg BID|"Mometasone Furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily
~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
11629456|NCT00381485|Active Comparator|MF MDI 400 mcg BID|"Mometasone Furoate 400 mcg taken twice daily
~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
11629457|NCT00381420|Experimental|1|sirolimus-coated Bx Velocity stent
11629458|NCT00381420|Active Comparator|2|uncoated Bx Velocity stent
11629459|NCT00381407|Experimental|1|Participants will receive organizational skills training program
11629460|NCT00381407|Experimental|2|Participants will receive contingency management program
11629461|NCT00381407|No Intervention|3|Participants will receive wait list condition
11629462|NCT00381381|Experimental|1|
11629463|NCT00381342|Experimental|Exenatide 5 mcg/exenatide 5 mcg|Exenatide 5 mcg; then exenatide 5 mcg
11629464|NCT00381342|Experimental|Exenatide 5 mcg/exenatide 10 mcg|Exenatide 5 mcg, then exenatide 10 mcg
11629465|NCT00381342|Placebo Comparator|Placebo|Placebo in volumes equivalent to exenatide
11629466|NCT00381329|Active Comparator|1|Motivational Interviewing (MI)
11629467|NCT00381329|Active Comparator|2|Structured Brief Advice (SBA)
11629468|NCT00381316|Active Comparator|1|Thallous Chloride T1-201
11629469|NCT00381316|Active Comparator|2|Technetium Tc99m Tetrofosmin injections
11629470|NCT00381303|Experimental|001|darunavir 600mg bid for 48 wks,ritonavir 100mg bid for 48 wks
11629471|NCT00381290|Active Comparator|1|Participants will follow an exercise regimen
11629472|NCT00381290|Active Comparator|2|Participants will follow a calorie-restricted diet
11629473|NCT00381290|Active Comparator|3|Participants will follow a calorie-restricted diet and an exercise regimen
11629474|NCT00381238|Experimental|rosiglitazone|Extended Release Tablets
11629475|NCT00381225|Experimental|Ultra-sound guided radio-frequency ablation|
11629476|NCT00381212|Experimental|1|AGS-004 immunotherapeutic injections.
11629477|NCT00381173|Experimental|1|
11629478|NCT00381160|Experimental|1|Provision of non-caloric beverages to home
11629479|NCT00381160|No Intervention|2|
11629480|NCT00381121||Kidney disease cohort|Individuals with a clinically indicated biopsy are recruited and/or surplus tissue that remains from past clinical interventions is obtained.
11629481|NCT00381108|Experimental|Pomegranate Tablet|
11629482|NCT00381108|Placebo Comparator|Placebo Tablet|
11629483|NCT00381095|Experimental|1|flexible dosing
11629484|NCT00381095|Placebo Comparator|2|
11629485|NCT00381043|Active Comparator|1- Acamprosate|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
11629486|NCT00381043|Placebo Comparator|2 - Sugar Pill - Placebo|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
11629487|NCT00381004|Experimental|FCR + Sargramostim|Fludarabine + Cyclophosphamide + Rituximab (FCR) = Fludarabine - Course 1: 25 mg/m^2 IV Days 2-4; Course 2-6: 25 mg/m^2 IV Days 1-3. Cyclophosphamide - Course 1: 250 mg/m^2 intravenous (IV) Days 2-4; Course 2-6: 250 mg/m^2 Days 1-3. Rituximab - Course 1: 375 mg/m^2 IV over 2-6 hours Day 1; Course 2-6: 500 mg/m^2 IV Day 1. Sargramostim - Course 1: 250 mcg/m^2 subcutaneous (SQ) Days -1 and 5-11; Course 2-6: 250 mcg/m^2 SQ Days -1 and 4-10.
11629488|NCT00380978|Active Comparator|early analgesia:combined-spinal epidural|
11629489|NCT00380978|Active Comparator|late analgesia (systemic)|
11629490|NCT00380874|Experimental|1|flexible dosing
11629491|NCT00380874|Placebo Comparator|2|
11629492|NCT00380861|Active Comparator|PFC Sigma RP-F|PFC® Sigma™ RP-F knee implant is a posterior stabilized cemented component cemented that is implanted with a standard posterior stabilized surgical technique.
11629493|NCT00380861|Active Comparator|PFC Sigma RP|P.F.C.® Sigma™ Rotating Platform (RP) Cruciate Retaining Knee System has a special insert that helps the knee move more like it did before the knee replacement.
11629494|NCT00380809|Active Comparator|Rotational Atherectomy + PES|Elective lesion preparation with rotational atherectomy priot to stent implantation
11629495|NCT00380809|Active Comparator|Standard Treatment (PES without Rotational Atherectomy)|Stenting without prior rotational atherectomy, usually preceeded with balloon dilatation
11629496|NCT00380796||Cohort 1|
11629497|NCT00380770|Experimental|HAART alone|Arm 1. HAART These patients will be given one tablet twice daily of Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
11629498|NCT00380770|Active Comparator|Combination HAART and chemotherapy|Arm 2. CTX PLUS HAART. HAART will be given as above. In addition, CTX will be administered at 2 weekly intervals in the Oncology Dept at KEH VIII Hospital and will consist of:- Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
11629499|NCT00380757|Active Comparator|CPR 30:2|30 chest compressions to 2 ventilations
11629500|NCT00380757|Active Comparator|CPR 15:2|15 chest compressions to 2 ventilations
11629501|NCT00380744|Experimental|Part A LY2189102 0.1 mg/kg/wk|"Part A: 2 times (x) 0.1 milligrams/kilogram/week (mg/kg/wk) Loading dose, then 0.1 mg/kg/wk) X 4 weeks (wks), intravenous (IV)
~Part B: 2 x 0.02 mg/kg/wk Loading dose, then 0.02 mg/kg/wk X 4 wks, IV"
11629502|NCT00380744|Experimental|Part A LY2189102 0.3 mg/kg/wk|"Part A: 2 x 0.3 mg/kg/wk Loading dose, then 0.3 mg/kg/wk X 4 wks, IV
~Part B: 2 x 0.15 mg/kg/wk Loading dose, then 0.15 mg/kg/wk X 4 wks, IV"
11629503|NCT00380744|Experimental|Part A LY2189102 1.0 mg/kg/wk|"Part A: 2 x 1.0 mg/kg/wk Loading dose, then 1.0 mg/kg/wk X 4 wks, IV
~Part B: 2 x 1.0 mg/kg/wk Loading dose, then 1.0 mg/kg/wk X 4 wks, IV"
11629504|NCT00380744|Experimental|Part A LY2189102 2.5 mg/kg/wk|"Part A: 2 x 2.5 mg/kg/wk Loading dose, then 2.5 mg/kg/wk X 4 wks, IV
~Part B: 2 x 2.5 mg/kg/wk Loading dose, then 2.5 mg/kg/wk X 4 wks, IV"
11629505|NCT00380744|Placebo Comparator|Placebo|IV, once weekly x 4 wks
11629506|NCT00380731|Experimental|1|Participants will receive immediate cognitive behavioral therapy
11629507|NCT00380731|Experimental|2|Participants will receive cognitive behavioral therapy with a 16-week delayed start
11629508|NCT00380718|Experimental|Pemetrexed|
11629509|NCT00380692|Experimental|Atomoxetine|atomoxetine 0.5 mg/kg/day every day (QD), by mouth (PO) for 1 week, atomoxetine 0.8mg/kg/day QD, PO for 1 week, 1.2mg/kg/day QD, PO for 6 weeks then atomoxetine 0.5-1.2 mg/kg/day QD, PO for up to 20 weeks
11629510|NCT00380692|Placebo Comparator|Placebo|"placebo every day (QD), by mouth (PO) for 8 weeks
~Then patients can take atomoxetine 0.5-1.2 mg/kg/day QD, PO up to 20 weeks"
11629511|NCT00380640|Experimental|1|
11629512|NCT00380640|Experimental|2|
11629513|NCT00380601|Experimental|1|
11629514|NCT00380588|Experimental|Gemcitabine + Cisplatin|"Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.
~Cisplatin: 25 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal."
11629515|NCT00380588|Experimental|Gemcitabine|Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1,8 and 15 every 28 days x 12 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.
11629516|NCT00380562|Experimental|Volunteer|High intensity volunteering (15 hours a week or greater) in Baltimore City Schools with children in grades K-3
11629517|NCT00380562|No Intervention|Control|Usual activities
11629518|NCT00380549|Active Comparator|CONSERVE® A-Class THA BFH|CONSERVE® A-Class Total Hip with BFH technology. Patients in this arm will undergo a unilateral total hip replacement with the CONSERVE® acetabular component and the CONSERVE® A-Class BFH femoral head. Blood ion levels will be collected and analyzed.
11629519|NCT00380549|Active Comparator|CONSERVE® Plus Total Resurfacing Hip System|CONSERVE® Plus Total Resurfacing Hip System. Patients in this arm will undergo a unilateral total hip replacement with the CONSERVE® Plus Total Resurfacing Hip System. Blood ion levels will be collected and analyzed.
11629520|NCT00380536|Experimental|1|Participants will participate in peer-led medical illness self-management group sessions.
11629521|NCT00380536|No Intervention|2|Participants will receive treatment as usual.
11629522|NCT00380497|Experimental|Pico-Salax|
11629523|NCT00380497|Active Comparator|PEGlyte|
11629524|NCT00380484|Experimental|1|Budesonide
11629525|NCT00380484|Active Comparator|2|Montelukast
11629526|NCT00380419|Experimental|1|Participants will receive 16 sessions of interpersonal psychotherapy
11629527|NCT00380406|Placebo Comparator|Placebo|Placebo
11629528|NCT00380406|Active Comparator|depot GnRHa (Leuprolide acetate (LA) 11.25 mg intramuscularly)|
11629529|NCT00380393|Experimental|GSK257049 Group|Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of GSK257049 vaccine administered intramuscularly in the left deltoid muscle at Days 0, 30 and 60.
11629530|NCT00380393|Active Comparator|Rabipur Group|Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine administered intramuscularly in the left deltoid muscle at Days 0, 30 and 60.
11629531|NCT00380367|Experimental|Quadrivalent HPV VLP Vaccine (Types 6, 11, 16, 18)|Participants who enroll receive a total of 3 intramuscular injections of Quadrivalent HPV VLP vaccine (types 6, 11, 16, 18) given on Day 1, Month 2 and Month 6.
11629532|NCT00380276|Other|Open Label Arm|Treatment is open-label
11629533|NCT00380250|Experimental|Lubiprostone|8 mcg capsule twice daily (BID)
11629534|NCT00380250|Placebo Comparator|Placebo|Matching placebo capsule twice daily (BID)
11629535|NCT00380237|Experimental|1|Two vaccinations with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops. The second vaccination will be given 4 to 12 weeks after the first.
11629536|NCT00380185||1|Subjects with no hemodynamically significant disease (NHSD) of the coronary or peripheral arteries
11629537|NCT00380185||2|Subjects with coronary artery disease only
11629538|NCT00380185||3|Subjects with both coronary artery disease and peripheral arterial disease
11629539|NCT00380146|Experimental|SP plus artesunate|SP (Fansidar®, Roche South Africa) at a dose of 25/1.25mg/kg of sulfadoxine/pyrimethamine respectively on day 0 only, and artesunate (Arsumax®, Sanofi-Aventis, South Africa) at a dose of 4mg/kg on days 0, 1, and 2
11629540|NCT00380133|Experimental|Randomised, double-blind, five-way crossover|A randomised, double-blind, double-dummy, placebo-controlled, five-way crossover study to assess the effects of single oral doses of SB-681323 (7.5 mg and 25 mg) and prednisolone (10 mg and 30 mg) on biomarkers in induced sputum and blood in COPD patients.
11629541|NCT00380120|Experimental|1|Tailoring the duration of anticoagulation according to the ultrasound persistence of residual vein thrombosis
11629542|NCT00380120|Active Comparator|2|Administering a fixed duration of anticoagulation (i.e., discontinue it at the time of randomization in patients with secondary DVT, and prolong it for 3 additional months in patients with idiopathic DVT)
11629543|NCT00380081|Experimental|placebo/zolpidem 3.5/zolpidem 1.75|
11629544|NCT00380081|Experimental|placebo/zolpidem 1.75/zolpidem 3.5|
11629545|NCT00380081|Experimental|zolpidem 3.5/placebo/zolpidem 1.75|
11629546|NCT00380081|Experimental|zolpidem 3.5/zolpidem 1.75/placebo|
11629547|NCT00380081|Experimental|zolpidem 1.75/placebo/zolpidem 3.5|
11629548|NCT00380081|Experimental|zolpidem 1.75/zolpidem 3.5/placebo|
11629549|NCT00380068|Experimental|Ambrisentan|
11629550|NCT00380055|Experimental|Screening Navigation|Individuals without a study cancer who receive services of a navigator.
11629552|NCT00380055|Active Comparator|Screening Education|Rather than receiving navigation, these participants receive general cancer education appropriate to Medicare enrollees.
11629553|NCT00380055|Active Comparator|Treatment Education|Rather than receiving navigation services, these participants receive cancer education appropriate to Medicare recipients.
11629554|NCT00380042|Active Comparator|Active Stimulation|
11629555|NCT00380042|Sham Comparator|Sham|
11629556|NCT00380029|Experimental|Erlotinib|erlotinib given before and after transurethral resection of a bladder tumor, TURBT
11629557|NCT00379990|Experimental|GW274150 60 mg once daily for 28 days|60 mg GW274150 taken once daily for 28 days
11629558|NCT00379990|Active Comparator|Prednisolone 7.5 mg once daily for 28 days|7.5 mg prednisolone taken once daily for 28 days
11629559|NCT00379990|Placebo Comparator|Placebo once daily for 28 days|Placebo taken once daily for 28 days
11629560|NCT00379951|Experimental|1|Arm 1: ertapenem sodium
11629561|NCT00379938|Experimental|1|25 micrograms + MF59 (n=26)
11629562|NCT00379938|Experimental|3|2.5 micrograms + MF59 (n=26)
11629563|NCT00379938|Placebo Comparator|4|saline (n=11)
11629564|NCT00379938|Experimental|2|25 micrograms alone (n=26)
11629565|NCT00379925|Experimental|Behavioral|Participants will take part in the Physical Activity and Dietary Health Promotion Program.
11629566|NCT00379912|Experimental|Investigational Arm A|Azacitidine + Erythropoietin
11629567|NCT00379912|Experimental|Investigational Arm B|Azacitidine
11629568|NCT00379899|Active Comparator|Control|Standard of care, without use of cinacalcet.
11629569|NCT00379847|Experimental|1|Lower dose
11629570|NCT00379847|Experimental|2|Higher dose
11629571|NCT00379834|Active Comparator|Cosopt|Cosopt twice daily in both eyes
11629572|NCT00379821|Experimental|CQ Monotherapy|N=160: treat with Chloroquine (CQ) alone.
11629573|NCT00379821|Experimental|CQ plus atovaquone proguanil|N=160: treat with CQ plus atovaquone proguanil.
11629574|NCT00379821|Experimental|CQ plus artesunate|N=160: treat with CQ plus artesunate.
11629575|NCT00379821|Experimental|CQ plus azithromycin|N=160: treat with CQ plus azithromycin.
11629576|NCT00379808|Placebo Comparator|Placebo|1 lactose-containing capsule daily for 1 month
11629577|NCT00379808|Active Comparator|Montelukast 10 mg|1 montelukast 10 mg tablet (masked by capsule) daily for 1 month
11629578|NCT00379795|Experimental|Ranibizumad 0.5 mg|Ranibizumab 0.5 mg intravitreal injection 0.5 mg in the study eye on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment.
11629579|NCT00379769|Experimental|rosiglitazone in addition to background metformin|Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
11629580|NCT00379769|Experimental|rosiglitazone in addition to background sulfonylurea|Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
11629581|NCT00379769|Active Comparator|Sulfonylurea in addition to background metformin|Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.
11629582|NCT00379769|Active Comparator|Metformin in addition to background sulfonylurea|Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
11629583|NCT00379756|Active Comparator|Levitra|10mg x 4 weeks, with option to increase to 20mg aat that time if desired
11629584|NCT00379756|Placebo Comparator|placebo|
11629585|NCT00379743|Active Comparator|2|Individuals randomized to this arm receive the following interventions: 1) educational materials on recommended cancer-preventive services, plus 2) a health coordinator (patient navigator) who helps the participant schedule and keep appointments for cancer screening and/or treatment.
11629586|NCT00379678||Information not available|
11629587|NCT00379665|Experimental|Cisplatin|1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
11629588|NCT00379652|Active Comparator|A|Patient-based intervention
11629589|NCT00379652|Active Comparator|B|Health center-based intervention
11629590|NCT00379652|Active Comparator|C|Combination of patient and health center-based intervention
11629591|NCT00379652|No Intervention|D|Control group: Neither patient-based nor center-based intervention
11629592|NCT00379639|Experimental|Romidepsin / Gemcitabine|Participants were to receive 7, 10 or 12 mg/m^2 of romidepsin intravenously on either Days 1, 8 and 15 (Schedule A) or Days 1 and 15 (Schedule B) of each 28-day cycle, followed by 800 or 1000 mg/m^2 of gemcitabine. Subsequent doses of both drugs were based on treatment-related toxicities. The planned duration of study therapy was 6 cycles or until disease progression occurred. Patients who responded could continue beyond 6 cycles until disease progression or until a withdrawal criterion was met.
11629593|NCT00379626|Experimental|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
11629594|NCT00379613|Placebo Comparator|1|rocuronium + 16.0 mg/kg Org 25969
11629595|NCT00379613|Experimental|2|rocuronium + 2.0 mg/kg Org 25969
11629596|NCT00379613|Experimental|3|rocuronium + 4.0 mg/kg Org 25969
11629597|NCT00379613|Experimental|4|rocuronium + 8.0 mg/kg Org 25969
11629598|NCT00379613|Experimental|5|rocuronium + 12.0 mg/kg Org 25969
11629599|NCT00379574|Experimental|Bortezomib + CHOP every 2 weeks|Bortezomib + CHOP(Cycloophosphamide, vincristine, doxorubicin,and predinisolone) every 2 weeks
11629600|NCT00379561|Experimental|Intervention PSA-PAH1|Determination of the therapeutic activity of different concentrations of PSA-PAH1 at increasing doses of per gram of prostate.
11629601|NCT00379548|No Intervention|1|Control group- subjects are on the Asian diet for the entire duration of the study
11629602|NCT00379548|Experimental|2|Asian and Caucasian subjects switch from an Asian Diet to a Western Diet midway through the study.
11629603|NCT00379535|Experimental|1|Daily dose of 200 µg of potassium iodide
11629604|NCT00379535|Placebo Comparator|2|Daily dose of placebo
11629605|NCT00379522|Active Comparator|Vasopressin|Vasopressin, 10 I.U./4 ml, Solution for Injection
11629606|NCT00379522|Placebo Comparator|Saline|Saline placebo 4 ml, Solution for Injection
11629607|NCT00379509|Experimental|GW572016|
11629608|NCT00379483|Experimental|Arm 1|
11629609|NCT00379470|Active Comparator|Best Standard of Care|Patients randomized to the BSC group will be treated with one chemotherapy according to the BSC practiced at each center.
11629610|NCT00379470|Experimental|NovoTTF-100A|
11629611|NCT00379431|Experimental|Administration of rituximab and methylprednisolone|
11629612|NCT00379405|Experimental|A|Saquinavir (Invirase): 2 capsules (500 mg) / 12 hours
11629613|NCT00379405|No Intervention|2|IP o NNUCS + 2 NUCS as a HAART therapy .
11629614|NCT00379392|Experimental|Mental Imagery and CIT|Mental Imagery and Constraint Induced Therapy
11629615|NCT00379392|Active Comparator|Mental Imagery only|Mental Imagery only
11629616|NCT00379366|Active Comparator|1|14 Gy ionizing radiations
11629617|NCT00379366|No Intervention|2|
11629618|NCT00379353|Active Comparator|Group 1: Thalidomide|100 mg capsules orally, once a day for 14 days
11629619|NCT00379353|Placebo Comparator|Group 2: Placebo|Two placebo capsules orally, once a day for 14 days.
11629620|NCT00379340|Experimental|Stage IV and rapid complete response (RCR) of lung metastases|Stage IV and rapid complete response (RCR) of lung metastases continuously treated with DD4A after 6 weeks of DD4A
11629621|NCT00379340|Experimental|Stage IV and slow incomplete response (SIR) of lung metastases|Stage IV and slow incomplete response (SIR) of lung metastases treated with Regimen M after 6 weeks of DD4A
11629622|NCT00379340|Other|Stage III/IV with LOH 1p and 16q treated with Regimen M|Stage III/IV with LOH 1p and 16q treated with Regimen M
11629623|NCT00379340|Other|Stage IV with non-lung disease treated with Regimen M|Stage IV with non-lung disease treated with Regimen M
11629624|NCT00379340|Other|Stage IV with lung metastases|Stage IV with lung metastases treated with DD4A for less than 6 weeks and/or response inevaluable at week 6
11629625|NCT00379327|Experimental|Real Accupuncture|Acupuncture with a real needle that punctures the skin versus acupuncture needle that does not puncture the skin.
11629626|NCT00379327|Placebo Comparator|Non-puncturing Acupuncture|Acupuncture needle that touches but does not puncture the skin
11629627|NCT00379301|Active Comparator|Group 1|Pulmonary vein isolation (PVI) combined with ablation of documented non-PV triggers of atrial fibrillation --- (sites away from the pulmonary veins where consistent abnormal impulses that can trigger AF are identified during the procedure)
11629628|NCT00379301|Active Comparator|Group 2|PVI combined with ablation at documented sites of non-PV triggers, PLUS ablation at sites where non-PV triggers are commonly found
11629629|NCT00379301|Active Comparator|Group 3|PVI combined with ablation at documented sites of non-PV triggers and ablation at sites in the left atrium that demonstrate disorganized electrical impulses called complex fractionated electrograms (CFE).
11629630|NCT00379288|Experimental|MF/F 200/10 mcg BID|
11629631|NCT00379288|Experimental|MF/F 400/10 mcg BID|
11629632|NCT00379288|Active Comparator|F/SC 250/50 mcg BID|
11629633|NCT00379288|Active Comparator|F/SC 500/50 mcg BID|
11629634|NCT00379262|Experimental|1A|Concurrent-Adjuvant CRT using P-PF regimen and conventional fractionation radiotherapy
11629635|NCT00379262|Experimental|1B|Concurrent-Adjuvant CRT using P-PF regimen and accelerated fractionation radiotherapy
11629636|NCT00379262|Experimental|2A|Induction-Concurrent CRT using PF-P regimen and conventional fractionation radiotherapy
11629637|NCT00379262|Experimental|2B|Induction-Concurrent CRT using PF-P regimen and accelerated fractionation radiotherapy
11629638|NCT00379262|Experimental|3A|Induction-Concurrent CRT using PX-P regimen and conventional fractionation radiotherapy
11629639|NCT00379262|Experimental|3B|Induction-Concurrent CRT using PX-P regimen and accelerated fractionation radiotherapy
11629640|NCT00379236|Experimental|EUFLEXXA™ Double-blind|Each subject received 3 single-dose injections of EUFLEXXA™ into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
11629641|NCT00379236|Placebo Comparator|Placebo Double-blind|Each subject received 3 single-dose injections of placebo into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
11629642|NCT00379236|Experimental|EUFLEXXA™ Open Label|All patients who participated in the 26 week double-blind study (including participants randomized to the placebo treatment group) and elected to participate in the open label extension, received three injections of EUFLEXXA™ in the target knee. Injections were given once a week on weeks 26, 27 and 28.
11629643|NCT00379223|No Intervention|1|Standard treatment of central retinal vein occlusion : the rheologic correction
11629644|NCT00379223|Experimental|2|Standard treatment of central retinal vein occlusion : the rheologic correction and surgery associating pars plana vitrectomy and radial optic neurotomy
11629645|NCT00379210|Experimental|1|"Meditation training group-- received Mindfulness Based Stress Management from the Penn Program for Stress Management.
~The meditation practice initially emphasized attention to a single focus. For most concentrative exercises, this focus was the breath. The sensations of breathing were to be examined closely, and when attention wandered it was to be redirected back to the breath. In other exercises, the focus of attention was to be directed to sensations within specific body parts (body scan exercise) and sensations of walking (walking meditation). During the 5th week of classes, the mindfulness training was expanded to include some explicit training in receptive attention."
11629646|NCT00379210|Active Comparator|2|"Nutrition education group
~An active comparison condition involving nutrition education was offered. This course matched the mindfulness course in all dimensions including course duration, homework, psychosocial support, and teacher expertise. The course was taught by a nurse who had expertise in nutrition and offered a program described in the book, Nutrition for Life by Lisa Hark."
11629647|NCT00379197|Experimental|Naltrexone|Naltrexone 50 mg will be taken orally once a day every day of a 28 day treatment course (cycle 1) and continue for another identical 28 day treatment (cycle 2) . PET scan will be performed after cycle 1 and cycle 2 complete.
11629648|NCT00379184||A|Osteoarthritis patients scheduled for Total Knee Arthroplasty.
11629649|NCT00379184||B|Osteoarthritis patients not scheduled for Total Knee Arthroplasty.
11629650|NCT00379184||C|Healthy volunteers
11629651|NCT00379145|Experimental|Trabectedin|Trabectedin IV over 24 hours every 3 weeks
11629652|NCT00379106|Active Comparator|Group1|
11629653|NCT00379106|Experimental|Group 2|
11629654|NCT00379080|Experimental|Arm I - Feasibility|"Patients receive oral tandutinib twice daily for 7 days. Patients then undergo biopsy or surgery to remove the tumor. Within 2 weeks after biopsy or surgery, patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~conventional surgery
~oral tandutinib
~Pharmacological study
~Tissue samples"
11629655|NCT00379080|Experimental|Arm 2 - Dose Escalation (Phase 1)|"Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
~the starting dose for tandtinib is 500mg BID
~oral tandutinib
~Pharmacological study
~Tissue samples"
11629656|NCT00379080|Experimental|Arm 3 - Phase 2|"Patients receive tandutinib as in phase I at the MTD determined in phase I.
~600mg was the determined MTD in Dose Escalation
~oral tandutinib
~Pharmacological study
~Tissue samples"
11629657|NCT00379067|Active Comparator|1|Tamsulosin OCAS tablet
11629658|NCT00379067|Placebo Comparator|2|Placebo tablet
11629659|NCT00379015|Experimental|HER2 over-expressing primary breast cancer group|"Patients receive epirubicin hydrochloride and cyclophosphamide in week 1-3. Treatment with epirubicin hydrochloride and cyclophosphamide repeats every 3 weeks for 4 courses. Patients then receive docetaxel in week 13 and trastuzumab (Herceptin®) in weeks 13-15. Treatment with docetaxel and trastuzumab repeats every 3 weeks for 4 courses.
~Patients then undergo appropriate surgery. After surgery, patients with hormone receptor-positive disease receive trastuzumab once weekly and either tamoxifen with or without a luteinizing hormone-releasing hormone agonist or an aromatase inhibitor. Treatment continues for 40 weeks."
11629660|NCT00378989|Active Comparator|Intervention|A letter with personal feedback of the results of a health risk appraisal and invitation to a consultation at the occupational health services.
11629661|NCT00378989|No Intervention|Control|Care as usual
11629662|NCT00378976|Experimental|1|
11629663|NCT00378976|Placebo Comparator|2|
11629664|NCT00378950|Active Comparator|1|Participants will receive a 1-hour education session about CHF, symptom recognition, diet, exercise, and daily check ups.
11629665|NCT00378950|Experimental|2|Participants will receive a 1-hour education session about CHF, symptom recognition, diet, exercise, and daily check ups, as well as additional information on diuretic self adjustment. This group will then get several follow-up phone calls over the course of the year to reinforce these topics and help them master the knowledge and encourage behavior and lifestyle changes to align with these topics.
11629666|NCT00378911|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11629667|NCT00378898|Active Comparator|EGD with proximal BRAVO capsule|Subjects have a second BRAVO capsule placed 10cm proximal to prior BRAVO capsule placement. Fluoroscopy is used to confirm detachment of the monitor 7 days after investigational deployment.
11629668|NCT00378898|Sham Comparator|EGD with sham BRAVO capsule placement|Subjects have a EGD with BRAVO delivery introducer positioned 10cm proximal to prior BRAVO capsule placement with no BRAVO placed.
11629669|NCT00378781|Experimental|Arm I|Minocycline hydrochloride + Edetate Calcium Disodium (M-EDTA) flush solution into CVC once daily.
11629670|NCT00378781|Experimental|Arm II|Heparin flush solution into CVC once daily.
11629671|NCT00378742||Participants|Participants with eye disease or their unaffected relatives.
11629672|NCT00378729|Active Comparator|A|
11629673|NCT00378729|Active Comparator|B|
11629674|NCT00378716|Active Comparator|Group 1|5-FU + Leucovorin
11629675|NCT00378716|Experimental|Group 2|Uracil/Ftorarur + leucovorin
11629676|NCT00378703|Active Comparator|Arm A (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15.
11629677|NCT00378703|Experimental|Arm B (bevacizumab and temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and bevacizumab as in Arm A.
11629678|NCT00378703|Experimental|Arm C (bevacizumab and sorafenib tosylate)|Patients receive bevacizumab as in Arm A and sorafenib tosylate PO BID on days 1-5, 8-12, 15-19, and 22-26.
11629679|NCT00378703|Experimental|Arm D (sorafenib tosylate and temsirolimus)|Patients receive sorafenib tosylate PO BID on days 1-28 and temsirolimus as in Arm B.
11629680|NCT00378690|Active Comparator|Continuous Androgen Deprivation (CAD)|
11629681|NCT00378690|Experimental|Intermittent Androgen Deprivation (IAD)|
11629682|NCT00378664|Experimental|Intervention|All enrollees are included in the intervention - lumbar to sacral ventral nerve re-routing procedure surgical nerve re-routing procedure.
11629683|NCT00378612|Experimental|Cypher® sirolimus eluting coronary stent|All pts were given the Cypher sirolimus eluting coronary stent in this open-label, single-arm, non-randomized trial
11629684|NCT00378599|Experimental|PEG-Intron plus Rebetol (RBV)|PEG-Intron plus RBV treatment for up to 48 weeks with 24-week follow up. SCH 54031 PEG-Intron 1.5 ug/kg SC per week plus SCH 18908 REBETOL twice daily (BID) PO with food, dosed as followed: Weeks 1 and 2, RBV Dose 400 mg (2 capsules, 1 AM and 1 PM). At the end of Weeks 2 and 4 of Treatment (tx), a complete blood count (CBC) was performed. An increase in RBV dose was permitted only if the hemoglobin was >10 g/dL. At Weeks 3 and 4, RBV dose was 800 mg (4 capsules, 2 AM and 2 PM). From Weeks 5 to 48, RBV doses could be increased based on subject body weight. For subjects weighing <65 kg, maximum dose of RBV was to be 800 mg (4 capsules, 2 AM and 2 PM), for subjects weighing 65-85 kg, max dose of RBV was 1000 mg/day (5 capsules, 2 AM and 3 PM), for subjects weighing >85 kg, max dose of RBV was 1200 mg/day, 6 capsules, 3 AM and 3 PM).
11629685|NCT00378573|Experimental|docetaxel, gemcitabine and bevacizumab|Single arm treatment with docetaxel, gemcitabine and bevacizumab
11629686|NCT00378560|Placebo Comparator|1|Placebo
11629687|NCT00378560|Experimental|2|Vaccine
11629688|NCT00378547|Placebo Comparator|Paracetamol|Oral paracetamol 1 g + placebo + placebo
11629689|NCT00378547|Experimental|Paracetamol + Pregabalin|Oral paracetamol 1g + oral pregabalin 300 mg + placebo
11629690|NCT00378547|Experimental|Paracetamol + pregabalin + dexamethasone|Oral paracetamol 1g + oral pregabalin 300 mg + IV dexamethasone 8 mg
11629691|NCT00378534|Experimental|Miltenyi reagent system|"The protocol will evaluate survival at day +200 in subjects with hematological malignancies receiving myeloablative conditioning regimen of cyclophosphamidem fludarabine and total body irradiation followed by an infusion of a stem cell prodict prepared using the Miltenyi CliniMacs system for CD34 selection and a delayed T cell depletion add back as donor lymphocyte infusion (DLI) at day 90.
~The objective is to determine the overall survival rate at day +200 following allogeneic peripheral blood stem cell allotransplantation (PBSCT)"
11629692|NCT00378508|Experimental|1|The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2 over a 14 day treatment period.
11629693|NCT00378508|Placebo Comparator|2|Normal saline infusion
11629694|NCT00378482|Experimental|1|Drug: CP-675,206 (Tremelimumab)
11629695|NCT00378404|Experimental|1|
11629696|NCT00378378|Experimental|MFNS 100 mcg QD for subjects 6 to less than 12 years|Mometasone Furoate nasal Spray (MFNS) 100 mcg once per day (QD) for subjects 6 to less than 12 years of age
11629697|NCT00378378|Placebo Comparator|Placebo QD for subjects 6 to less than 12 years|
11629698|NCT00378378|Experimental|MFNS 200 mcg QD for subjects 12 to less than 18 years|
11629699|NCT00378378|Experimental|MFNS 200 mcg BID for subjects 12 to less than 18 years|
11629700|NCT00378378|Placebo Comparator|Placebo QD for subjects 12 to less than 18 years|
11629701|NCT00378378|Experimental|MFNS 100 mcg BID for subjects 6 to less than 12 years|
11629702|NCT00378378|Placebo Comparator|Placebo BID for subjects 6 to less than 12 years|
11629703|NCT00378378|Placebo Comparator|Placebo BID for subjects 12 to less than 18 years|
11629704|NCT00378365|Experimental|1|Arsenic trioxide
11629705|NCT00378352|Placebo Comparator|Dose Escalation Safety|The objective of the first phase is to evaluate the safety of escalating doses of Epoetin alfa in patients with STEMIs.
11629706|NCT00378352|Placebo Comparator|Single Dose Efficacy|Single parenteral administration of 60000 U of epoetin alfa. The objectives of the second phase are to investigate the effects of the highest safe dose on infarct size, left ventricular remodeling and endothelial progenitor cells.
11629707|NCT00378326|Experimental|Tacrolimus|Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
11629708|NCT00378248|Experimental|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group- and individual psychotherapy
11629709|NCT00378248|Active Comparator|Outpatient individual psychotherapy|Eclectic individual psychotherapy in outpatient private practice
11629710|NCT00378209|Experimental|lenalidomide, dexamethasone, bortezomib combination|Participants took the study medication in the clinic on Cycle 1 day 1. Each treatment cycle lasted three weeks. They took the lenalidomide (capsules) every day for the first two weeks only (days 1-14). They took the dexamethasone (tablets) on Day 1, 2, 4, 5, 8, 9, 11 and 12 and came to the outpatient treatment center for intravenous bortezomib on Day 1, 4, 8 and 11. The third week of the cycle was a rest period and the participant did not take any study medication.
11629711|NCT00378196|Experimental|A|0.3 mg/0.05 ml dose of ranibizumab
11629712|NCT00378196|Experimental|B|0.5 mg /0.05 ml dose of ranibizumab
11629713|NCT00378144|Experimental|1|Pseudoephedrine/Paracetamol
11629714|NCT00378131|Placebo Comparator|1|
11629715|NCT00378131|Experimental|2|RC-1291 50mg
11629716|NCT00378131|Experimental|3|RC-1291 100mg
11629717|NCT00378105|Experimental|lenalidomide, dexamethasone, bortezomib combination|In this study each cycle will be 21 days and participants will begin the study medication in the clinic on Cycle 1 Day 1. Lenalidomide (capsules) will be taken daily for the first 2 weeks only (Day 1-14). Dexamethasone (tablets) will be taken on Day 1, 2, 4, 5, 8, 9, 11 and 12. Bortezomib will be given intravenously in the outpatient treatment clinic on Day 1, 4, 8 and 11. The third week is a rest period and no study medication will be given.
11629718|NCT00378092|Experimental|Risperidone Long-Acting Injection (RLAI) (Period 1)|Participants will receive 25 milligram (mg) to 50 mg of RLAI intramuscularly (into the muscle) which will be tapered and discontinued over a period of up to 6 weeks. Participants will be followed-up until their first disease relapse or maximum of 36 months.
11629719|NCT00378092|Experimental|Oral risperidone and RLAI (Period 2)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus (a muscle) for up to 24 months. Supplementation with oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injections becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
11629720|NCT00378079|Experimental|3|
11629721|NCT00378079|Active Comparator|1|
11629722|NCT00378079|Experimental|2|
11629723|NCT00378066|Active Comparator|Bevacizumab|Bevacizumab, capecitabine and oxaliplatin for metastatic colorectal cancer, 1st line treatment
11629724|NCT00378027||Stable Acute Pulmonary Embolism|Administer weight dosed Fondaparinux
11629725|NCT00378014|Experimental|Everolimus|Basiliximab plus everolimus-based immunosuppressive regimen following the reduction and cessation of initial CNI regimen plus optional steroids according to local best practice
11629726|NCT00378014|Active Comparator|Calcineurin Inhibitor (CNI)|Basiliximab plus CNI-based immunosuppressive regimen according to local best practice plus optional steroids according to local best practice
11629727|NCT00377988||001|Transdermal Contraceptive System In each 4-week period exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
11629843|NCT00376675|Placebo Comparator|Arm II|Patients receive oral placebo daily on days 1-28.
11629728|NCT00377988||002|Norgestimate-containing oral contraceptives with EE NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days then no pill or a drug-free pill 7 days.
11629729|NCT00377962|Experimental|Everolimus + CNI reduction|Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level < 75 ng/mL or a tacrolimus trough level < 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice.
11629730|NCT00377962|Active Comparator|Control|CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.
11629731|NCT00377936|Active Comparator|1|Gemcitabine
11629732|NCT00377936|Experimental|2|EndoTag-1 + Gemcitabine
11629733|NCT00377936|Experimental|3|EndoTag-1 + Gemcitabine
11629734|NCT00377936|Experimental|4|EndoTag-1 + Gemcitabine
11629735|NCT00377910|Active Comparator|1, drug|Injections of polidocanol
11629736|NCT00377910|Placebo Comparator|2 drug|injections of lidocaine
11629737|NCT00377871|Active Comparator|1|Valve design 1
11629738|NCT00377871|Active Comparator|2|Valve design 2
11629739|NCT00377871|No Intervention|Control|Healthy control
11629740|NCT00377858|Experimental|Insulin Lispro Mid Mixture|Insulin lispro mid mixture (MM) up to three times a day (TID)
11629741|NCT00377858|Active Comparator|Insulin Glargine|Insulin glargine daily with insulin lispro at mealtime (up to 3 injections) as needed.
11629742|NCT00377832|No Intervention|1|
11629743|NCT00377832|Active Comparator|2|Acetaminophen 975 mg once
11629744|NCT00377819|Experimental|denosumab|
11629745|NCT00377819|Active Comparator|alendronate|
11629746|NCT00377793|Experimental|Arm 1|
11629747|NCT00377793|Placebo Comparator|Arm 2|
11629748|NCT00377780|Experimental|1|Myocet + docetaxel + trastuzumab
11629749|NCT00377741|Experimental|1|
11629750|NCT00377715|Experimental|Dimebon|Dimebon 20 mg three times a day x 26 weeks
11629751|NCT00377715|Placebo Comparator|Placebo|Placebo 20 mg three times a day x 26 weeks
11629752|NCT00377676|Experimental|Usual Diabetes Therapy plus placebo|Usual diabetes therapy plus placebo
11629753|NCT00377676|Experimental|Drug Cycloset|
11629754|NCT00377663|Experimental|1|Participants will use the AsthmaNet web site.
11629755|NCT00377663|No Intervention|2|Participants will not use the AsthmaNet Web site.
11629756|NCT00377637|Experimental|Induction Phase: Mycophenolate mofetil|Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24 weeks of the Induction Phase.
11629757|NCT00377637|Active Comparator|Induction Phase: Cyclophosphamide|Participants received monthly infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.
11629758|NCT00377637|Experimental|Maintenance Phase: Mycophenolate mofetil|Participants received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.
11629759|NCT00377637|Active Comparator|Maintenance Phase: Azathioprine|Participants received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.
11629760|NCT00377611|Experimental|FLUARIX 50-64 YEARS GROUP|Adult subjects aged between and including 50-64 years who received a single dose of Fluarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm, were enrolled for investigation of influenza and influenza-related complications.
11629761|NCT00377611|Experimental|FLUARIX 65+ YEARS GROUP|Elderly subjects aged 65 and over who received a single dose of Fluarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm, were enrolled for investigation of influenza and influenza-related complications.
11629762|NCT00377598|Experimental|TAK-583 5 mg QD|
11629763|NCT00377598|Experimental|TAK-583 25 mg QD|
11629764|NCT00377598|Experimental|TAK-583 50 mg QD|
11629765|NCT00377598|Experimental|TAK-583 100 mg QD|
11629766|NCT00377598|Placebo Comparator|Placebo QD|
11629767|NCT00377572|Experimental|Omalizumab (Xolair) + Conventional Therapy|Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.
11629768|NCT00377572|Placebo Comparator|Placebo + Conventional Therapy|Placebo was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.
11629769|NCT00377559|Experimental|1.|Myocet+docetaxel
11629770|NCT00377520|Experimental|Pemetrexed|
11629771|NCT00377507|Experimental|catechin|mask containing catechins
11629772|NCT00377481|Experimental|1|
11629773|NCT00377481|Active Comparator|2|
11629774|NCT00377455|Experimental|Bosentan|
11629775|NCT00377455|Placebo Comparator|Placebo|
11629776|NCT00377442|Experimental|1|
11629777|NCT00377442|Experimental|2|
11629778|NCT00377442|Experimental|3|
11629779|NCT00377429|Experimental|catumaxomab|
11629780|NCT00377416|Experimental|1|rAAV2-CB-hAAT Gene Vector
11629781|NCT00377403|Experimental|Intervention Arm|Amoxicillin 500mg three times a day (tid) for 10 days in addition to symptomatic treatments
11629782|NCT00377403|Placebo Comparator|Symptomatic treatments only|Placebo for 10 days in addition to symptomatic treatments
11629783|NCT00377390||Cockroach sensitive|
11629784|NCT00377390||Control (cockroach insensitive)|
11629785|NCT00377364|Experimental|Acetaminophen|Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days.
11629786|NCT00377364|Placebo Comparator|Placebo|Participants will be given an identical appearing placebo (two 500 mg tablets) four times daily for 7 days.
11629787|NCT00377325|Experimental|1|Participants will receive full dose cyclosporin.
11629788|NCT00377325|Experimental|2|Participants will receive active drug full dose until cleared, then one dose every 4 days.
11629789|NCT00377325|Placebo Comparator|3|Participants will receive active drug full dose until clear, then full dose every 4 days with placebo on the intervening days.
11629790|NCT00377312|Experimental|Group 1|Parathyroid Hormone (PTH) (1-34) 2 picomols/kg/hr for one week.
11629791|NCT00377312|Experimental|Group 2|Parathyroid Hormone (PTH) (1-34)4 picomols/kg/hr for one week.
11629792|NCT00377299|Experimental|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
11629793|NCT00377299|Placebo Comparator|Placebo|Placebo matching active medication.
11629794|NCT00377286|Placebo Comparator|2|1500 mg of lite lemonade
11629795|NCT00377286|Active Comparator|1|1500 mg glucosamine in 16 oz lite lemonade 1 time daily for 6 months
11629796|NCT00377260|Experimental|Amoxicillin-clavulanate|Reconstituted amoxicillin-clavulanate at 90/6.4 mg/kg/day in 2 divided doses for 10 days.
11629797|NCT00377260|Placebo Comparator|Placebo|Reconstituted placebo in 2 divided doses for 10 days.
11629798|NCT00377247|Experimental|Dendritic Cells w/Tumor DNA|
11629799|NCT00377234|Experimental|1|
11629800|NCT00377234|Active Comparator|2|
11629801|NCT00377208|Active Comparator|Intervention Condition|Receives web-based feedback specific to their blood-pressure and other health-related conditions.
11629802|NCT00377208|No Intervention|Control Condition|The control group receives preventative feedback, general to the population.
11629803|NCT00377195|Experimental|1|
11629804|NCT00377182|Active Comparator|PEGASYS with COPEGUS|
11629805|NCT00377182|Experimental|RO5024048 1500mg in combination with PEGASYS|
11629806|NCT00377182|Experimental|RO5024048 3000mg in combination with PEGASYS|
11629807|NCT00377182|Experimental|RO5024048 in combination with PEGASYS and COPEGUS|
11629808|NCT00377156|Active Comparator|Arm I|Patients undergo stereotactic radiosurgery (SRS)
11629809|NCT00377156|Experimental|Arm II|Patients undergo SRS as in arm I. Within 14 days, patients then undergo whole-brain radiotherapy 5 days a week for 2.5 weeks.
11629810|NCT00377130|No Intervention|Arm I- Usual psychological care|Usual psychological care- no intervention
11629811|NCT00377130|Experimental|Self administered Stress Management|Self-Administered Stress Management Training Plus Usual Psychosocial Care
11629812|NCT00377104|Experimental|Treatment (chemotherapy)|Patients receive alvocidib IV over 30 minutes (loading dose), followed by alvocidib IV over 4 hours on days 1, 8, and 15. Treatment repeats every 5 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11629813|NCT00377052|Experimental|Bortezomib + Gemcitabine|
11629814|NCT00377026|Experimental|lifestyle|participants receive lifestyle intervention
11629815|NCT00376961|Experimental|R-CHOP + Velcade|6 21-day cycles of standard R-CHOP with 1.3 mg/m^2 Bortezomib given on days 1 and 4 of each cycle. This is followed by 8 3-month cycles of maintenance with 1.3 mg/m^2 Bortezomib on days 1, 4, 8 and 11 of each cycle.
11629816|NCT00376948|Experimental|Novasoy®, Gemcitabine & Erlotinib|Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, & 15; Erlotinib 150 mg day 1 until day 28
11629817|NCT00376935|Placebo Comparator|1|Participants will receive palifermin placebo injection on Days 1, 2, and 3
11629818|NCT00376935|Experimental|2|Participants will receive palifermin 20 mcg/kg injection on Days 1, 2, and 3
11629819|NCT00376935|Experimental|3|Participants will receive palifermin 40 mcg/kg injection on Days 1, 2, and 3
11629820|NCT00376935|Experimental|4|Participants will receive palifermin 60 mcg/kg injection on Days 1, 2, and 3
11629821|NCT00376922|No Intervention|usual care|
11629822|NCT00376922|Experimental|Music therapy|
11629823|NCT00376909|Experimental|Intervention|Series of telephone support calls from a trained prevention care manager
11629824|NCT00376909|No Intervention|Usual Care|Usual care
11629825|NCT00376896|Experimental|GW876008 20mcg|GW876008 20mcg
11629826|NCT00376896|Experimental|GW876008 200mcg|GW876008 200mcg
11629827|NCT00376896|Placebo Comparator|Placebo|Placebo
11629828|NCT00376870|Active Comparator|Pioglitazone|Pioglitazone 30mg/d
11629829|NCT00376870|Placebo Comparator|Placebo|
11629830|NCT00376844|Active Comparator|External Beam Radiation Therapy|Postoperative pelvic radiotherapy
11629831|NCT00376844|Experimental|Vaginal Brachytherapy|Postoperative vaginal brachytherapy
11629832|NCT00376831|Active Comparator|0|fentanyl
11629833|NCT00376831|Active Comparator|1|ketamine
11629834|NCT00376805|Experimental|All Treated Patients|All patients with advanced metastatic breast cancer treated with natural killer cells after receiving fludarabine, cyclosphosphamide and total body irradiation.
11629835|NCT00376740|Experimental|Immediate zoledronic acid|Patients on this arm will receive zoledronic acid every 6 months during 2.5 years of letrozole therapy starting within 3 months of the start of letrozole therapy. (5 doses of zoledronic acid)
11629836|NCT00376740|Active Comparator|Delayed zoledronic acid|Patients on this arm will receive zoledronic acid during the 2.5 years of letrozole treatment only after the T-score on bone mineral density testing falls below minus 2.0.
11629837|NCT00376727|Experimental|Phase I dose escalation study|
11629838|NCT00376701|Experimental|1|Reduced fluence PDT plus intravitreal Kenalog (2 mg) plus intravitreal Avastin 1.25 mg
11629839|NCT00376701|Experimental|2|Reduced fluence PDT plus intravitreal Avastin
11629840|NCT00376701|Experimental|3|Intravitreal Avastin and sham reduced fluence PDT
11629841|NCT00376688|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11629842|NCT00376675|Experimental|Arm I|Patients receive oral methylphenidate hydrochloride daily on days 1-28.
11629844|NCT00376597|Experimental|Arm I (lymphedema education)|Six weeks after surgery, patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction and written materials. Patients complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months. Patients are also contacted by telephone at 9 and 15 months.
11629845|NCT00376597|Experimental|Arm II (lymphedema education, physical therapy)|Description Patients receive lymphedema education and complete physical assessments and questionnaires as in Arm I. Patients also complete a personalized physical therapy intervention, receive a refrigerator magnet, and a 15-minute video that reinforces information and exercises.
11629846|NCT00376584|Placebo Comparator|Placebo → MK-0524A 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A Placebo for 5 days (drug holiday) followed by MK-0524A 2 g for the remainder of the study (7 days).
11629847|NCT00376584|Active Comparator|Placebo → Extended Release (ER)-Niacin 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A Placebo for 5 days (drug holiday) followed by ER-Niacin 2g for the remainder of the study (7 days)
11629848|NCT00376584|Experimental|MK-0524A 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A 2g for the remainder of the study (approximately 2 weeks).
11629849|NCT00376571|Experimental|Stenting of main vessel and side branch|Percutaneous coronary intervention
11629850|NCT00376571|Experimental|No side branch treatment|Percutaneous coronary intervention
11629851|NCT00376558|Active Comparator|Contingency Management w/ CRA|Cocaine users: Contingency management w/ Community Reinforcement Approach
11629852|NCT00376558|No Intervention|Healthy Control|A group of healthy matched comparison subjects with no DSM-IV axis I Disorder was included; they were matched for cigarette smoking, gender, and ethnicity.
11629853|NCT00376532||ICD pacing or shock event|Subjects who experienced a device treatment, defined as a pacing event or a shock event
11629854|NCT00376532||No ICD pacing or shock event|Subjects who did not experience a treatment defined as a pacing event or a shock event
11629855|NCT00376519|Experimental|Transplant with Treg Cells|Patients receive preparative therapy with Fludarabine, cyclophosphamide, total body irradiation and Treg infusion followed by umbilical cord blood transplantation.
11629856|NCT00376506|Experimental|Implanted Device|Implanted intramuscular neurostimulator device
11629857|NCT00376506|Active Comparator|External Device|External vibrotactile device
11629858|NCT00376493|Active Comparator|1|Use of antibiotics after hospital discharge
11629859|NCT00376493|Placebo Comparator|2|Use of placebo
11629860|NCT00376480|Experimental|administration of adoptive donor lymphocyte infusion|administration of donor lymphocytes made using costimulatory blockade ex vivo
11629861|NCT00376415|Experimental|Lessertia Fructescens|Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
11629862|NCT00376415|Placebo Comparator|Placebo|Participants received an identical placebo capsule twice daily for 3 months.
11629863|NCT00376363|Active Comparator|Ahmed implant,1|Ahmed glaucoma drainage implant for intraocular pressure control
11629864|NCT00376363|Active Comparator|Baerveldt implant|Baerveldt glaucoma drainage implant for intraocular pressure control
11629865|NCT00376350|Experimental|High dose manipulation|High dose spinal manipulation + ultrasound
11629866|NCT00376350|Experimental|Moderate dose manipulation|Moderate dose manipulation + low dose massage + ultrasound
11629867|NCT00376350|Experimental|Low dose manipulation|low dose spinal manipulation + moderate dose massage + ultrasound
11629868|NCT00376350|Other|High dose masssage|high dose massage + ultrasound
11629869|NCT00376337|Active Comparator|1|infusion for 3-12 weeks
11629870|NCT00376337|Experimental|2|infusion for 3-12 weeks
11629871|NCT00376272|Experimental|1|
11629872|NCT00376272|Placebo Comparator|2|
11629873|NCT00376259|Experimental|Combination therapy|Combination therapy: 600 mg of telbivudine (LdT) by mouth plus 10 mg of adefovir (ADV) by mouth once daily for 96 weeks.
11629874|NCT00376259|Active Comparator|Adefovir monotherapy|Adefovir monotherapy: 10 mg of adefovir by mouth once daily for 96 weeks.
11629875|NCT00376246|Other|Group 1|1st group will receive Ezetimibe for 2 weeks followed by washout (no medication) period for 4 weeks and followed by placebo for 2 weeks.
11629876|NCT00376246|Other|Group 2|2nd group will receive Ezetimibe and placebo in reverse order with interspaced 4-week washout period.
11629877|NCT00376220|Experimental|1|"Drug: Riluzole Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) < 12) the dose will not be increased further unless clinical symptoms recur.
~Other Names:
~• Rilutek"
11629878|NCT00376220|Placebo Comparator|2|Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS < 12) the dose will not be increased further unless clinical symptoms recur.
11629879|NCT00376181|Experimental|Pioglitazone 45 mg/Azilsartan 20 mg QD|
11629880|NCT00376181|Experimental|Pioglitazone 45 mg/Azilsartan 40 mg QD|
11629881|NCT00376181|Active Comparator|Pioglitazone 45 mg QD|
11629882|NCT00376168|Experimental|prGCD 30 Units/kg|
11629883|NCT00376168|Experimental|prGCD 60 Units/kg|
11629884|NCT00376129|Experimental|I|
11629885|NCT00376090|Experimental|Group I Vaccine|
11629886|NCT00376090|Placebo Comparator|Group I Placebo|
11629887|NCT00376090|Experimental|Group II Vaccine|
11629892|NCT00376090|Placebo Comparator|Group IV Placebo|
11629893|NCT00376077|Active Comparator|Placebo and IVIG|"The trial site is blinded to the randomization process. Patients are assigned an arm by a research pharmacist. Patients on this arm receive an infusion of placebo (0.9% NaCl) over one hour. Immediately following this dosing, 1 g/kg IVIG (Gammunex ©) is infused over 2 - 3 hours. Following this treatment, complete blood counts are drawn at:
~completion of IVIG infusion,
~8 hours following the start of the placebo/solumedrol infusion
~24 hours following the start of the placebo/solumedrol infusion
~72 hours following the start of the placebo/solumedrol infusion
~7 days post infusion
~21 days post infusion"
11629894|NCT00376077|Experimental|Methylprednisolone and IVIG|"The trial site is blinded to the randomization process. Patients are assigned an arm by a research pharmacist.Patients on this arm receive IV Methylprednisolone 30 mg/kg (1 gram maximum) infused over one hour. Immediately following this dosing, 1 g/kg IVIG Gammunex © is infused over 2 - 3 hours. Following this treatment, complete blood counts are drawn at:
~completion of IVIG infusion,
~8 hours following the start of the placebo/solumedrol infusion
~24 hours following the start of the placebo/solumedrol infusion
~72 hours following the start of the placebo/solumedrol infusion
~7 days post infusion
~21 days post infusion"
11629895|NCT00376064|Experimental|SMS995 + Carbegolin, Somavert + SMS995|
11629896|NCT00376012|Active Comparator|1|2EHRZ3/4RH3
11629897|NCT00376012|Experimental|2|2EHRZ3/7RH3
11629898|NCT00375999|Experimental|docetaxel and epirubicin|salvage docetaxel and epirubicin
11629899|NCT00375973|Experimental|Duloxetine|Duloxetine po 60-120 mg/day for 12 weeks
11629900|NCT00375973|Placebo Comparator|Placebo|Placebo comparator to Duloxetine
11629901|NCT00375947|Experimental|1|Home-based hand exercise program
11629902|NCT00375947|Placebo Comparator|2|Sham hand cream
11629903|NCT00375934|Experimental|1|
11629904|NCT00375934|Placebo Comparator|2|
11629905|NCT00375895|Experimental|Ciclosporin|
11629906|NCT00375882|Other|cochlear implantation with mild hypothermia|
11629907|NCT00375869|Active Comparator|Darbopoeitin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
11629908|NCT00375869|Placebo Comparator|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
11629909|NCT00375856|No Intervention|1|DePuy P.F.C.® SigmaTM Posterior Cruciate Substituting Knee
11629910|NCT00375856|Experimental|2|Rotating Platform Knee
11629911|NCT00375843|Active Comparator|Level 1 Treatment: Escitalopram|Level 1 participants who are assigned to escitalopram
11629912|NCT00375843|Active Comparator|Level 2: Sertraline|Participants from Level 1 who do not achieve remission with escitalopram enter Level 2 and switch to sertraline
11629913|NCT00375830|Experimental|Cohort 1 Pilot-WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET scans|Preliminary pilot assessment to confirm feasibility & improved diagnostic accuracy of the combined 18F-NaF CT & 18F-FDG PET scan procedures, as compared to the regular medical care procedure, 99mTc MDP bone scans.
11629914|NCT00375830|Experimental|Cohort 2 WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET scans|Assessment to define the accuracy of the combined 18F-NaF CT & 18F-FDG PET/CT scan procedures compared to 99mTc MDP bone scan.
11629915|NCT00375830|Experimental|Cohort 3 Combined 18F-NaF / 18F-FDG PET/WB-MRI scan|Assessment to define the utility of 18F-NaF & 18F-FDG as the radiolabels in a single combined PET / WB-MRI procedure.
11629916|NCT00375791|Experimental|Perifosine daily|Patients will take three 50 mg tablets of perifosine daily at bedtime with food. Patients will be examined every three weeks. If patients have no progression it is allowed to receive 8 cycles of perifosine
11629917|NCT00375791|Experimental|Perifosine daily + Dexa twice per week|Patients will take three 50 mg tablets of perifosine daily at bedtime with food until progression. If progressive disease is confirmed by a second measurement at least one week later the patient will receive a combination of 20 mg twice per week dexamethasone (dexa) and 150 mg perifosine daily at bedtime.
11629918|NCT00375752|Active Comparator|Letrozole|Letrozole 2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvent treatment
11629919|NCT00375752|Experimental|Zolendronic Acid + Letrozole|2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvant treatment plus zoledronic acid 4 mg i.v. q4w
11629920|NCT00375726|Experimental|1|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^3 PFU dose) into the deltoid region of either arm.
11629921|NCT00375726|Experimental|2|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
11629922|NCT00375726|Experimental|3|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
11629923|NCT00375726|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
11629924|NCT00375713|Experimental|Levocetirizine|Levocetirizine + Cetirizine-Placebo + Standard Topical Steroid (1% hydrocortisone) Ointment for 14 days
11629925|NCT00375713|Active Comparator|Cetirizine|Cetirizine + Levocetirizine-Placebo + Standard Topical Steroid (1% hydrocortisone) Ointment for 14 days
11629926|NCT00375674|Experimental|A|
11629927|NCT00375674|Placebo Comparator|B|
11629928|NCT00375661|No Intervention|interferon|
11629929|NCT00375648|Experimental|zoledronate|
11629930|NCT00375609|Experimental|Betrixaban 15 mg|Betrixaban 15 mg oral twice daily for 10 to 14 days
11629931|NCT00375609|Experimental|Betrixaban 40 mg|Betrixaban 40 mg oral twice daily for 10 to 14 days
11629932|NCT00375609|Experimental|Enoxaparin|Enoxaparin 30 mg administered subcutaneously every 12 hours for 10 to 14 days
11629933|NCT00375570|Experimental|1|ME-609
11629934|NCT00375557|Active Comparator|1|Quetiapine
11629935|NCT00375557|Active Comparator|2|Divalproex ER
11629936|NCT00375518|Active Comparator|1|Atorvastatin
11629937|NCT00375518|Placebo Comparator|2|placebo
11629938|NCT00375505|Experimental|Zometa|Zoledronic acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).
11629939|NCT00375505|Placebo Comparator|Placebo|Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).
11629940|NCT00375492|Experimental|Group A|
11629941|NCT00375492|Placebo Comparator|Group B|
11629942|NCT00375466|Experimental|Tranexamic Acid|
11629943|NCT00375466|Placebo Comparator|placebo|
11629944|NCT00375453|Experimental|Arm 1|
11629945|NCT00375427|Experimental|Every 3 months|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every three months. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized patients will receive a maximum of 4 infusions in this group.
11629946|NCT00375427|Experimental|Every 4 weeks|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every 4 weeks. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Patients randomized to this group will receive up to 12 infusions.
11629947|NCT00375401|Experimental|CP-945,598 Treatment A|
11629948|NCT00375401|Experimental|CP-945,598 Treatment B|
11629949|NCT00375401|Placebo Comparator|Placebo|
11629950|NCT00375336||1|Patients with aortic stenosis (mean transvalvular aortic gradient ≥30 mm Hg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
11629951|NCT00375336||2|Patients with nonobstructive aortic sclerosis (mean gradient ≤10 mmHg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
11629952|NCT00375336||3|Patients with normal aortic valve plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
11629953|NCT00375310|Experimental|Gemcitabine + Sorafenib & radiotherapy|"Induction: Gemcitabine with Sorafenib for 4 weeks (1 cycle). Chemo-radiotherapy: Gemcitabine with Sorafenib and Radiotherapy for 5 weeks. Sorafenib will be given in escalating dose cohorts.
~Sorafenib only: Sorafenib alone for 4 weeks. Consolidation: Gemcitabine with Sorafenib for 16 weeks (4 cycles). Maintenance: Sorafenib alone until disease progression."
11629954|NCT00375258|Experimental|1|Active
11629955|NCT00375258|Placebo Comparator|2|
11629956|NCT00375245|Experimental|Rapamycin + Grapefruit juice|
11629957|NCT00375219|Experimental|omacetaxine|Treatment was the same for all cohorts: induction therapy was subcutaneous (SC) administration of omacetaxine at 1.25 mg/m^2 twice a day (BID), administered for 14 consecutive days every 28 (±3) days for up to 6 cycles. Maintenance therapy was subcutaneous (SC) administration of omacetaxine at 1.25 mg/m^2 twice a day (BID), administered for 7 consecutive days every 28 (±3) days for up to 3 years.
11629958|NCT00375193|Experimental|1|Amrubicin 40mg/m<2> IV days 1, 2, 3 of each 21-day cycle until cycle 6 or no longer beneficial.
11629959|NCT00375167|Experimental|Recovery Workbook Intervention|12-week Recovery Intervention: The intervention is a 12-week group-based intervention. The intervention is informed by the Recovery Workbook- a validated intervention for people with serious mental illness. The intervention includes 2 hour sessions for 12 weeks that focus on the following areas: Introduction to the intervention; Recovery; Knowledge and Control; Managing life stress; Enhancing personal meaning; Building personal support; and Setting personal goals. The total time period of the intervention is 24 hours. Participants in this arm also receive treatment as usual.
11629960|NCT00375167|No Intervention|Treatment as usual|The participants in the control arm will continue to receive treatment as usual. TAU is Assertive Community Treatment. Assertive Community Treatments are structured to meet set fidelity standards that are evidence-based. This arm did not receive any intervention.
11629961|NCT00375102|Experimental|Acup|Acupuncture
11629962|NCT00375102|Experimental|RR|Relaxation Response
11629963|NCT00375102|No Intervention|UC|Usual Care
11629964|NCT00375089||Group 1|Individuals with Prader-Willi syndrome.
11629965|NCT00375089||Group 2|Individuals with Early-onset Morbid Obesity
11629966|NCT00375050|Experimental|Riluzole|
11629967|NCT00375050|Placebo Comparator|Placebo|
11629968|NCT00375037|Experimental|Hand hygiene|Hand hygiene promotion
11629969|NCT00375037|Active Comparator|Usual care|usual care
11629970|NCT00375024|Other|1: Patient Navigator|Patients will meet with a Patient Navigator regarding their treatment and any related concerns.
11629971|NCT00375024|Other|2: Without Navigator|Patient will work with existing clinic staff, which does not include a Patient Navigator.
11629972|NCT00374985|Experimental|one arm|
11629973|NCT00374972||combined contraceptives|combined contraceptives
11629974|NCT00374972||pregesterone only contraceptives|pregesterone only contraceptives
11629975|NCT00374946||A|THA. Bearing of Zirconia head and UHMWPE liner
11629976|NCT00374946||B|THA. Bearing of CO-Cr-Mo head and liner
11629977|NCT00374946||C|THA. Head og Zirconia head and UHMWPE moulded in shell (Asian)
11629978|NCT00374946||D|THA. Head and shell og Alumina ceramic
11629979|NCT00374933|Experimental|1|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
11629980|NCT00374907|Experimental|Saxagliptin (A)|Metformin 500-1500 mg (open-label, as needed for rescue in LT)
11629981|NCT00374907|Placebo Comparator|Placebo (ST) / Metformin (LT) (B)|Metformin 500-1500 mg (open-label, as needed for rescue in LT)
11629982|NCT00374881|Active Comparator|1|Morphine High Dose
11629983|NCT00374881|Placebo Comparator|2|Morphine Low Dose
11629984|NCT00374881|Placebo Comparator|3|Sorbitol Phenylephrine
11629985|NCT00374881|Experimental|4|Sorbitol high concentration+Phenylephrine+Morphine
11629986|NCT00374881|Experimental|5|Sorbitol low concentration+Phenylephrine+Morphine
11629987|NCT00374868|Experimental|Pemetrexed + Cisplatin|
11629988|NCT00374842|Experimental|GSK1247446A Formulation 1 Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the GSK1247446A vaccine adjuvanted with a full dose of adjuvant at Day 0. The adjuvanted GSK1247446A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11629989|NCT00374842|Experimental|GSK1247446A Formulation 2 Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the GSK1247446A vaccine adjuvanted with a half dose of adjuvant at Day 0. The adjuvanted GSK1247446A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11629990|NCT00374842|Active Comparator|Fluarix Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11629991|NCT00374803|Experimental|Mycophenolic Acid (Myfortic) Preload|Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter
11629992|NCT00374803|Active Comparator|Mycophenolic Acid (Myfortic) Standard|Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day).
11629993|NCT00374777|Experimental|1|
11629994|NCT00374777|Experimental|2|
11629995|NCT00374777|Active Comparator|3|
11629996|NCT00374777|Placebo Comparator|4|
11629997|NCT00374751|Experimental|Samarium (153SM)|Injection of Samarium (153SM)
11629998|NCT00374738|Experimental|GIFT Intervention|Guided Imagery for Trauma (GIFT)
11629999|NCT00374738|No Intervention|Music Control|Relaxing Music Audio control; same music used in guided imagery, with no narrative voice.
11630000|NCT00374673|Experimental|transcranial magnetic stimulation|repetitive transcranial magnetic stimulation of the motor cortex
11630001|NCT00374673|Sham Comparator|placebo stimulation|repetitive placebo stimulation of the motor cortex
11630002|NCT00374660|Experimental|1|
11630003|NCT00374634|Active Comparator|"Individual or standard rFSH dose"|"Patients were randomized to recieve individual (50, 75 or 100 IU/day) or standard (75 IU/day) rFSh dose. The individual dose was prescribed according to a dosage nomogram based on the patient's body weight (kg) and the total antral follicle count (Freiesleben NC et al., RBMOnline 2009;17:632-64)."
11630004|NCT00374634|Active Comparator|"Standard rFSH dose"|"Standard dose of rFSH"
11630005|NCT00374621|Active Comparator|Misoprostol|
11630006|NCT00374621|Active Comparator|Misoprostol with Isosorbide Mononitrate|
11630007|NCT00374569|Experimental|Gymnastics|Gymnasts stand on a computerized dynamic posturography Force Plate and Stability is measured and gymnastic routines performed
11630008|NCT00374569|Experimental|Non Gymnasts|Non Gymnasts stand on a computerized dynamic posturography Force Plate and Stability is measured and gymnastic routines performed
11630009|NCT00374556|Experimental|Eszopiclone|Eszopiclone 3mg capsules, once daily at bedtime for 12 weeks
11630010|NCT00374556|Placebo Comparator|Placebo|3mg placebo capsule, once daily at bedtime for 12 weeks
11630011|NCT00374543|Experimental|Ziprasidone|Ziprasidone will be dosed on a twice daily (BID) basis, with flexible dosing based on tolerability, with a total daily dose in the range of 40 to 160 mg/day, for 8 weeks. This time period reflects the rapid onset of effect seen in studies of atypical antipsychotics, but allows time for a potentially longer response for some anxiety symptoms.
11630012|NCT00374543|Placebo Comparator|Placebo Capsules|Identical placebo capsules will be dosed on a BID basis, with flexible dosing based on tolerability, with a total daily dose in the range of 40 to 160 mg/day.
11630013|NCT00374452|Experimental|ATHENA-CDS-HTN plus Guideline Link|ATHENA-CDS-HTN plus Guideline Link. ATHENA-CDS-HTN display on the cover sheet of electronic health record, plus link to the guidelines
11630014|NCT00374452|Other|Guideline Link Only|Guideline Link Only. Link to The Seventh Report of the Joint National Committee on Prevention Detection and Treatment of High Blood Pressure (JNC7) and to VA-Department of Defense (DoD) hypertension guidelines
11630015|NCT00374439|Experimental|Cognitive-behavioral|Participants in this arm received a cognitive-behavioral program
11630016|NCT00374439|Experimental|Interpersonal Therapy|Participants in this arm received a prevention program based on interpersonal therapy for depression
11630017|NCT00374439|No Intervention|No intervention|Participants in this arm did not receive an intervention, but complete assessments only
11630018|NCT00374413|Experimental|Kineflex-C|
11630019|NCT00374413|Active Comparator|ACDF|
11630020|NCT00374361||Caucasian Adolescents|Caucasian Adolescents
11630021|NCT00374361||African-American Adolescents|African-American Adolescents
11630022|NCT00374335|Other|infants with cutaneous hemangiomas|
11630023|NCT00374322|Placebo Comparator|Placebo|6 tablets daily for 12 months
11630024|NCT00374322|Experimental|Lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
11630025|NCT00374296|No Intervention|1|Elderly (≥65 years) untreated arm
11630026|NCT00374296|Experimental|2|Relapsed/Refractory Arm
11630027|NCT00374244|Placebo Comparator|1|placebo pimozide
11630028|NCT00374244|Active Comparator|2|active pimozide
11630029|NCT00374231|Experimental|Immunosuppression|All the patients who enroll in this study will receive the same medications (tacrolimus, mycophenolate mofetil, and a short course of steroids) to prevent rejection of the liver transplant. All participants will be gradually taken off prednisone if they are 90 days or longer post liver transplant and have not had a rejection in the last 30 days.
11630030|NCT00374205|Experimental|AL|Artemether plus Lumefantrine 6 dose 3 days treatment
11630031|NCT00374205|Active Comparator|ASAQ|Artesunate plus Amodiaquine
11630032|NCT00374192|Experimental|1|Eszopiclone
11630033|NCT00374192|Placebo Comparator|2|Placebo
11630034|NCT00374166|Experimental|SSR149415 - 250 mg|SSR149415 250 mg, twice daily for a maximum of 8 weeks
11630035|NCT00374166|Experimental|SSR149415 - 100 mg|SSR149415 100 mg and additional placebo capsules in order that all patients are being administered three capsules twice daily for a maximum of 8 weeks
11630036|NCT00374166|Active Comparator|Paroxetine|Paroxetine 20 mg and additional placebo capsules in order that all patients are being administered three capsules twice daily for a maximum of 8 weeks
11630037|NCT00374166|Placebo Comparator|Placebo|Placebo for a maximum of 9 weeks
11630038|NCT00374153|Experimental|1|Online personal feedback report.
11630039|NCT00374153|Experimental|2|In-person Motivational Interview with personal feedback report
11630040|NCT00374153|Experimental|3|In-person Motivational Interview only (without a personal feedback report)
11630041|NCT00374153|No Intervention|4|Assessment only
11630042|NCT00374153|No Intervention|5|Delayed Assessment
11630043|NCT00374140|Experimental|RAD001 (Everolimus)|RAD001 (Everolimus)10 mg by mouth daily without interruption
11630044|NCT00374127|Experimental|marijuana blunt|marijuana blunt (0%, 1.8%, or 3.6% THC)
11630045|NCT00374127|Experimental|marijuana cigarette|marijuana cigarette (0%, 1.8%, or 3.6% THC)
11630046|NCT00374088|Placebo Comparator|Placebo|These patients receive a placebo infusion of D5W prior to and after surgery
11630047|NCT00374088|Experimental|N-Acetylcysteine|These patients receive a loading dose of N-Acetylcysteine 100 mg/kg in D5W IV 1 hour prior to surgery. They receive a maintenance infusion of N-Acetylcysteine 10 mg/kg/hr in D5W IV for 24 hours after surgery.
11630048|NCT00374062|Experimental|I|relaxation tape 1
11630049|NCT00374062|Experimental|II|relaxation tape 2
11630050|NCT00374062|Placebo Comparator|III|relaxation tape 3
11630051|NCT00374049|Experimental|One|MUC1 vaccine in conjunction with GM-CSF and Poly-ICLC (Hiltonol)in Arm ONE
11630052|NCT00374036|Experimental|1|ECC
11630053|NCT00374036|Experimental|2|FOLFIRI
11630054|NCT00373958|Experimental|13vPnC vaccine|
11630055|NCT00373958|Active Comparator|7vPnC vaccine|
11630056|NCT00373932|Experimental|MOBILE-A|Coached exercise persistence intervention
11630057|NCT00373932|Active Comparator|MOBILE-B|Self-monitored exercise persistence intervention
11630058|NCT00373880|Experimental|Aripiprazole (15mg) + Cocaine|Aripiprazole (15 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg).
11630059|NCT00373880|Placebo Comparator|Placebo + Cocaine|Placebo (0 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg)
11630060|NCT00373867|Active Comparator|Standard|Standard treatment-based classification physical therapy
11630061|NCT00373867|Active Comparator|Graded exercise|Treatment-based classification physical therapy plus graded exercise
11630062|NCT00373867|Experimental|Graded exposure|Treatment-based classification physical therapy plus graded exposure
11630063|NCT00373789|Experimental|Botox A|up to two injections of 200 Units of intra-detrusor Botulinum Toxin A , which must be separated by at least eight weeks and no more than 52 weeks
11630064|NCT00373789|Placebo Comparator|Placebo|up to two injections of inactive injection (carrier saline), which must be separated by at least eight weeks and no more than 52 weeks
11630065|NCT00373750|Experimental|Family Spirit Intervention|The Family Spirit Intervention included 43 structured lessons and followed a culturally congruent format. Positive parenting lessons were focused on reducing behaviors (i.e., poor monitoring; coercive interactions;harsh, unresponsive, or rejecting parenting; and abuse/ neglect) associated with early childhood behavior problems, including externalizing, internalizing, and dysregulation problems.
11630066|NCT00373750|No Intervention|Optimized Standard Care Control Group|Optimized standard care consisted of transportation to recommended prenatal and well-baby clinic visits, pamphlets about child care and community resources, and referrals to local services. It also addressed access barriers to health care for young mothers and children, and it overcame concerns that home-visiting programs have operated in parallel, not in partnership, with pediatric care. Family health liaisons conducted the optimized standard care and were not trained in the Family Spirit intervention, to avoid contamination of the control condition.
11630067|NCT00373698|Experimental|Three Component Model|Three Component Model of Collaborative Care: Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
11630068|NCT00373698|No Intervention|Usual Care|"Patients randomized to Usual Care will receive care as usual by VA clinicians."
11630069|NCT00373685|Experimental|Celecoxib|dosing as per USPI label
11630070|NCT00373685|Active Comparator|NSAIDs|
11630071|NCT00373672|Active Comparator|1|armodafinil (Nuvigil) 150 mg
11630072|NCT00373672|Placebo Comparator|2|identical in appearance to active comparator
11630073|NCT00373633|Experimental|Continuous extra-pleural intercostal local anesthesia|intra-operatively placed extrapleural intercostal catheter
11630074|NCT00373633|Active Comparator|Thoracic Epidural|gold standard
11630075|NCT00373607|Experimental|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin, Hualijian Pharmaceutical Co. Ltd., Guangzhou, China). Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
11630076|NCT00373607|Active Comparator|Mefloquine + Artesunate (MAS3)|The MAS3 regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
11630077|NCT00373581|Experimental|Vigabatrin, cocaine|
11630078|NCT00373581|Placebo Comparator|placebo, cocaine|
11630079|NCT00373529|Experimental|Clofarabine|Participants received an induction cycle of clofarabine 30 mg/m^2/day intravenous infusion for 5 consecutive days. Participants could then receive up to 5 additional cycles, repeated minimally every 28 days, of clofarabine 20 mg/m^2/day intravenous infusion for 5 consecutive days.
11630080|NCT00373503|Experimental|lofexidine, dronabinol, marijuana|lofexidine (.6 mg qid), dronabinol (20 mg tid)
11630081|NCT00373490|Experimental|Vorinostat 600 mg|600 mg daily (300 mg twice daily [b.i.d.]) for 3 consecutive days followed by 4 days of rest.
11630082|NCT00373490|Experimental|Vorinostat 400 mg|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
11630083|NCT00373451|Experimental|Abciximab+UFH|Abciximab and unfractionated heparin as bolus given during PCI and abciximab-perfusion for 12 hours after PCI
11630084|NCT00373451|Active Comparator|Bivalirudin|Bivalirudin given only during PCI
11630085|NCT00373438|No Intervention|A|
11630086|NCT00373438|Experimental|B|Fetoscopic tracheal occlusion
11630087|NCT00373425|Experimental|Erlotinib|Participants received 150 mg/day erlotinib orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.
11630088|NCT00373425|Placebo Comparator|Placebo|Participants received matching placebo tablets orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.
11630089|NCT00373399|Placebo Comparator|Inactive Marijuana (0, 1.8, or 3.9% THC)|In this randomized, placebo-controlled study, every participant received all 3 treatment interventions in randomized order. Inactive marijuana (0% THC) served as a placebo comparator. Participants received an inactive marijuana cigarette (0% THC; provided by NIDA) in 1 of the 3 outpatient sessions in randomized order.
11630090|NCT00373399|Experimental|Active Marijuana|In this randomized, placebo-controlled study, every participant received all 3 treatment interventions in randomized order. Participants received active marijuana cigarettes (1.8, or 3.9% THC; provided by NIDA) over 2 of 3 outpatient sessions in randomized order.
11630091|NCT00373386|Experimental|Growth Hormone|Growth hormone treatment 0.3 mg/kg/min
11630092|NCT00373373|Placebo Comparator|A|Chemotherapy + Placebo
11630093|NCT00373373|Active Comparator|B|Chemotherapy + Sorafenib
11630094|NCT00373360|Experimental|1|
11630095|NCT00373334|Experimental|1|
11630096|NCT00373334|Experimental|2|
11630097|NCT00373334|Sham Comparator|3|
11630098|NCT00373295|Experimental|Baclofen 60 mg, Placebo, Baclofen 90 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
11630099|NCT00373295|Experimental|Baclofen 90 mg, Placebo, Baclofen 60 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
11630100|NCT00373295|Experimental|Baclofen 60 mg, Baclofen 90 mg, Placebo|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
11630101|NCT00373295|Experimental|Baclofen 90 mg, Baclofen 60 mg, Placebo|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
11630102|NCT00373295|Experimental|Placebo, Baclofen 90 mg, Baclofen 60 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
11630103|NCT00373295|Experimental|Placebo, Baclofen 60 mg, Baclofen 90 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
11630104|NCT00373269||Diabetic subject|Subjects with acute stroke, hyperglycemia and history of diabetes.
11630105|NCT00373269||Normoglycemic Control|Subjects with acute stroke and normal blood glucose.
11630106|NCT00373256|Experimental|A|
11630107|NCT00373256|Active Comparator|B|
11630108|NCT00373243|Experimental|Subjects receiving GW406381|Subjects will receive single oral dose of 20 milligram (mg) of GW406381.
11630109|NCT00373230|Experimental|1|Internet based telemedicine weight maintenance program
11630110|NCT00373230|Active Comparator|2|In person weight maintenance monthly consultations
11630111|NCT00373217|Experimental|Group 1|Patients in group one will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin in week 1. Treatment may repeat every 3 weeks for up to four courses. They will then undergo surgery to remove as much of the tumor as possible. Within 2 weeks after surgery, patients will receive an injection of the vaccine once a week for 3 weeks. Treatment may repeat every 14 weeks for two courses. After finishing the first course of vaccine therapy, patients will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin every 3 weeks for up to four courses.
11630112|NCT00373217|Experimental|Group 2|Patients in group two will undergo surgery to remove as much of the tumor as possible. Within 2 weeks after surgery, patients will receive an injection of the vaccine once a week for 3 weeks. Treatment may repeat every 14 weeks for two courses. After finishing the first course of vaccine therapy, patients will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin every 3 weeks for up to eight courses. Some patients may undergo a second surgery within 6 weeks after completing the fourth course of chemotherapy and undergo tumor and/or lymph node tissue collection.
11630113|NCT00373204|Experimental|Xcytrin® (motexafin gadolinium)|
11630114|NCT00373178|Active Comparator|Metformin,lifestyle counselling|
11630115|NCT00373152|Experimental|RadioFrequency Ablation for Breast Cancer|
11630116|NCT00373113|Active Comparator|A|1250 mg/m^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
11630117|NCT00373113|Experimental|B|37.5 mg daily, continuous dosing
11630118|NCT00373100|Experimental|Zinc|Zinc acetate
11630119|NCT00373100|Placebo Comparator|Placebo|Placebo
11630120|NCT00373087|Active Comparator|L-dopa + entacapone|L-dopa + entacapone
11630121|NCT00373087|Experimental|L dopa / placebo|L dopa / placebo
11630122|NCT00373074|Active Comparator|15 cc|15 cc of blood used for Epidural Blood Patch
11630123|NCT00373074|Active Comparator|20 cc|20 cc of blood used for Epidural Blood Patch
11630124|NCT00373074|Active Comparator|30 cc|30cc of blood used for Epidural Blood Patch
11630125|NCT00373061||Pregnant Women Exposed to Xolair®|Women who are exposed to at least one dose of Xolair® within 8 weeks prior to conception or at any time during their pregnancy will be followed to completion of their pregnancies.
11630126|NCT00373048|Placebo Comparator|Placebo, tablet|
11630127|NCT00373048|Experimental|mefloquine, tablet|
11630128|NCT00373009|Experimental|Core stabilization and psychosocial education|A core stabilization exercise program (CSEP) is used in this group and has sound biomechanical and anatomical rationale. In addition, a psychosocial education program (PSEP) will be used for this group.
11630129|NCT00373009|Active Comparator|Core stabilization exercise only|A core stabilization exercise program (CSEP) is used in this group and has sound biomechanical and anatomical rationale.
11630130|NCT00373009|Active Comparator|Psychosocial education class only.|A psychosocial education program (PSEP) will be used in this group.
11630131|NCT00373009|Other|Traditional Army training|Traditional Army training will be used in this group.
11630132|NCT00372996|Experimental|1|CP-751,871 + exemestane Treatment until progression or toxicity
11630133|NCT00372996|Active Comparator|2|
11630134|NCT00372970|Active Comparator|Botulinum Toxin A|200 U of Botox injected endoscopically into pylorus
11630135|NCT00372970|Placebo Comparator|Placebo|saline into pylorus.
11630136|NCT00372957|Placebo Comparator|Placebo|Participants received two capsules of matching placebo orally once daily in the morning with 150 milliliter (mL) of water at least 15 minutes prior to breakfast for 7 Days.
11630137|NCT00372957|Experimental|GW823093C 15 mg|Participants received one 15 milligrams (mg) of GW823093C capsule and one placebo capsule orally once daily in the morning with 150 mL of water at least 15 minutes prior to breakfast for 7 Days.
11630138|NCT00372957|Experimental|GW823093C 30 mg|Participants received 30 mg (2x15 mg) of GW823093C capsules orally once daily in the morning with 150 mL of water at least 15 minutes prior to breakfast for 7 Days.
11630139|NCT00372944|Active Comparator|1|Xeloda
11630140|NCT00372944|Experimental|2|AZD6244
11630141|NCT00372918|Other|1|Transnasal Esophagoscopy
11630142|NCT00372905|Experimental|bortezomib, Ibritumomab tiuxetan, rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
11630143|NCT00372892|Active Comparator|A|Rituximab
11630144|NCT00372892|Placebo Comparator|B|Saline placebo iv infusion
11630145|NCT00372879|Experimental|Crossover group 1|Vitamin E first and placebo second
11630146|NCT00372879|Experimental|Crossover group 2|Placebo first then vitamin E
11630147|NCT00372853|Experimental|Arm A|
11630148|NCT00372853|Experimental|Arm B|
11630149|NCT00372840|Experimental|Arm I|Patients receive a specific print intervention manual entitled Facing Forward Series: Life After Cancer Treatment and a general print intervention fact sheet entitled The Cancer Information Service, Questions and Answers.
11630150|NCT00372840|Active Comparator|Arm II|Patients receive the general print intervention fact sheet entitled The Cancer Information Service, Questions and Answers.
11630151|NCT00372814|Experimental|Multisystemic Therapy (MST)|Adolescents receiving MST will receive Intensive Home-Based Family Therapy which will consist of home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their daily diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
11630152|NCT00372814|Active Comparator|Telephone Support Calls|Adolescents receiving Supportive Telephone Calls (TS) will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
11630153|NCT00372788|Active Comparator|1|Pemetrexed
11630154|NCT00372788|Experimental|2|AZD6244
11630155|NCT00372775|Experimental|Sunitinib|
11630156|NCT00372762|Active Comparator|Furosemide|Patients will be assigned to furosemide therapy (20mg to 80mg) orally, once or twice daily for an 8-week period.
11630157|NCT00372762|Active Comparator|Bumetanide|Patients will be assigned to bumetanide therapy at an equipotent dose to furosemide therapy (1mg bumetanide is equivalent to 40mg furosemide)for an 8-week period.
11630158|NCT00372697|Experimental|Octreotide 30 mg every 21 days|Patients received octreotide 30 mg every 21 days intramuscularly (im) for 6 months, a total of 8 doses. At each study visit, octreotide was administered only after completion of all scheduled efficacy and safety evaluations for that visit. Octreotide was injected im into the right or left gluteal regions. The injections were initially administered by a trained and authorized member of the investigational team. When no study visit at the investigational site was required, the injections were given by a trained nurse or the family doctor.
11630159|NCT00372697|Experimental|Octreotide 60 mg every 28 days|Patients received octreotide 60 mg every 28 days intramuscularly (im) for 6 months, a total of 6 doses. Octreotide mg was administered as two 30 mg injections. At each study visit, octreotide was administered only after completion of all scheduled efficacy and safety evaluations for that visit. Octreotide was injected im into the right or left gluteal regions. The injections were initially administered by a trained and authorized member of the investigational team. When no study visit at the investigational site was required, the injections were given by a trained nurse or the family doctor.
11630160|NCT00372684||1|with severe malaria hospitalized in ICU
11630161|NCT00372684||2|with uncomplicated malaria
11630162|NCT00372645|Experimental|Diet|200 µg folate per day from folate-rich foods
11630163|NCT00372645|Experimental|Folic acid supplement|200 µg folate per day from supplemental folic acid
11630164|NCT00372645|Experimental|Metfolin supplement|200 µg folate per day from supplemental Metafolin®
11630165|NCT00372645|Placebo Comparator|Placebo|Placebo
11630166|NCT00372632|Placebo Comparator|placebo|
11630167|NCT00372632|Experimental|sulfadoxine-pyrimethamine|
11630226|NCT00371969|Active Comparator|1 - enhanced MI|Enhanced brief motivational interview (including an IVR component for alcohol self-monitoring purposes)
11630227|NCT00371969|Active Comparator|2- standard MI|The intervention consists of a standard motivational interview or viewing a DVD on HIV self-care.
11630228|NCT00371956|Active Comparator|1|raloxifene
11630229|NCT00371956|Placebo Comparator|2|placebo arm
11630230|NCT00371904|Experimental|1|
11630168|NCT00372619|Experimental|Clofarabine 40 mg/m² to assess feasibility in ALL patients.|Clofarabine 40 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
11630169|NCT00372619|Experimental|Clofarabine 40 mg/m² to assess feasibility in AML patients.|Clofarabine 40 mg/m² to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
11630170|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess feasibility in ALL patients.|Clofarabine 52 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
11630171|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy in ALL patients.|Clofarabine 52 mg/m² to assess efficacy in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
11630172|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess feasibility in AML patients.|Clofarabine 52 mg/m² to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
11630173|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy in AML patients|Clofarabine 52 mg/m² to assess efficacy in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
11630174|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy - ambiguous lineage pt|Clofarabine 52 mg/m² to assess efficacy in acute leukemia of ambiguous lineage patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
11630175|NCT00372593|Active Comparator|Arm A: Standard Arm - No GMTZ, AML Pts w/out Down Syndrome|"Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.
~After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.
~After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5.
~After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9."
11630176|NCT00372593|Experimental|Arm B: Experimental - with GMTZ, AML Pts w/out Down Syndrome|Pts receive IT ARA-C at diagnosis or on day 1 of treatment or twice a week for up to six doses. They also receive an infusion of ARA-C on days 1-10; a 6-hr infusion of daunorubicin on days 1, 3, & 5; a 4-hr infusion of etoposide on days 1-5; and a 2-hr infusion of GMTZ - gemtuzumab ozogamicin (Mylotarg) on day 6. After 3 wks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5. After 3 wks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hr infusion of mitoxantrone hydrochloride on days 3-6. They also receive a 2-hr infusion of gemtuzumab on day 7. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9.
11630177|NCT00372593|Active Comparator|Arm A: Standard Arm - No GMTZ, AML Patients with Down Syndrome|"Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.
~After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.
~After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5.
~After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9."
11630178|NCT00372567|Experimental|A|
11630179|NCT00372567|Active Comparator|B|
11630180|NCT00372528|Experimental|pregabalin|open label treatment
11630181|NCT00372515|Experimental|High dose gefitinib|
11630182|NCT00372502|Active Comparator|1|
11630183|NCT00372502|Experimental|2|
11630184|NCT00372489|Experimental|Peginesatide|
11630185|NCT00372476|Experimental|Imatinib + Vinorelbine|
11630186|NCT00372437|Experimental|1|
11630187|NCT00372424|Experimental|1|Combination of SU011248 (37.5 mg once daily [Schedule 2/1]) with docetaxel (75 mg/m2 every 3 weeks) and trastuzumab (therapeutic dose)
11630188|NCT00372411|Experimental|Arm 1|Robot-Assisted Therapy - MIT-MANUS System
11630189|NCT00372411|Active Comparator|Arm 2|Intensive Comparison Therapy
11630190|NCT00372411|Other|Arm 3|Usual Care
11630191|NCT00372385|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
11630192|NCT00372385|Experimental|Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet orally thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks.
11630193|NCT00372385|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 12 weeks.
11630194|NCT00372385|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 12 weeks.
11630195|NCT00372294|Active Comparator|1|Classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon)
11630196|NCT00372294|Active Comparator|2|Intravitreal Clindamycin & Dexamethasone
11630197|NCT00372281|Experimental|Cliavist|
11630198|NCT00372268|Active Comparator|B|Administration of ropivacaïne 0,2% by direct intra-abdominal administration at the end of the surgery
11630199|NCT00372268|Active Comparator|C|Administration of ropivacaïne 0,75% by nebulization in the insufflated gas during all the surgical procedure with direct intra-abdominal administration of Nacl 0,9%
11630200|NCT00372268|Placebo Comparator|A|Administration of Nacl 0,9% by nebulization in the insufflated gas during all the surgical procedure with direct intra-abdominal administration of Nacl 0,9%
11630201|NCT00372268|Placebo Comparator|D|Administration of Nacl 0,9% by direct intra-abdominal administration at the end of the surgery
11630202|NCT00372255|Experimental|Influsplit SSW® 2005/2006 6-9 years Group|Subjects aged 6 to 9 years who received 2 doses of Influsplit SSW® 2005/2006 vaccine at an interval of 4 weeks (Day 0 and Day 28 ± 2).
11630203|NCT00372255|Active Comparator|Influsplit SSW® 2005/2006 10-13 years Group|Subjects aged 10 to 13 years who received 1 dose of Influsplit SSW® 2005/2006 vaccine at Day 0.
11630204|NCT00372229|Experimental|Valganciclovir Cytomegalovirus (CMV) Prophylaxis|
11630205|NCT00372229|Active Comparator|Pre-emptive CMV Therapy|
11630206|NCT00372216|Active Comparator|1|Pre-hospital loading dose of 600 mg Clopidogrel as early as possible (in addition to standard infarction therapy)
11630207|NCT00372216|No Intervention|2|Standard infarction therapy (without study-specific additions, no Clopidogrel before angiography)
11630208|NCT00372203|Experimental|Endobronchial ultrasound|
11630209|NCT00372190|Experimental|Mesh surgery|Trocar guided tension free vaginal mesh insertion by Prolift mesh kit
11630210|NCT00372190|Active Comparator|Conventional vaginal surgery|Classical vaginal prolapse surgery (fascia plication)
11630211|NCT00372177|Active Comparator|EP1645|Single-Dose
11630212|NCT00372151|Experimental|L-Theanine|
11630213|NCT00372151|Placebo Comparator|Placebo|
11630214|NCT00372138|Experimental|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
11630215|NCT00372125|Active Comparator|Norditropin SimpleXx|0.3 mg/day or 0.4 mg/day if bodyweight was below or above 100 kg,for 4 weeks, 0.6 mg/day or 0.8 mg/day, for 11 months.
11630216|NCT00372125|Placebo Comparator|Placebo|Placebo for 12 months
11630217|NCT00372112|Active Comparator|100 mcg GW642444H|Twice daily in the morning.
11630218|NCT00372112|Active Comparator|400 mcg GW642444H|Twice daily in the morning.
11630219|NCT00372112|Active Comparator|50 mcg salmeterol|Twice daily.
11630220|NCT00372112|Placebo Comparator|placebo|Twice daily
11630221|NCT00372073|Active Comparator|1|seliciclib
11630222|NCT00372073|Placebo Comparator|2|
11630223|NCT00372060|Experimental|1|MK0431 + pioglitazone
11630224|NCT00372060|Placebo Comparator|2|Placebo/MK0431 + pioglitazone
11630225|NCT00371995|Experimental|1|"Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.
~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)"
11630232|NCT00371865|Active Comparator|Cognitive Behavioral Therapy|8 group-administered sessions of Cognitive-Behavioral Therapy
11630233|NCT00371865|Experimental|Acceptance-Based Therapy|8 group-administered sessions of Acceptance-based therapy
11630234|NCT00371839|Active Comparator|Mild Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz of 20-39 decibels hearing level (dBHL)
11630235|NCT00371839|Active Comparator|Moderate Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz of 40-49 decibels hearing level (dBHL)
11630236|NCT00371839|Active Comparator|Moderate-Severe Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz greater than 50 decibels hearing level (dBHL)
11630237|NCT00371826|Experimental|Calcineurin Inhibitor (CNI) Withdrawal|"Every randomized patient in this group received
~Day 1 - Day 14: cyclosporine as Calcineurin Inhibitor (CNI) 5 mg/kg twice daily (b.i.d.), dose adjusted to achieve C2 target of 1,500 ng/mL (range 1,400-1,600 ng/mL) + mycophenolate sodium (MPA)720 mg b.i.d. + methylprednisone/prednisone 500 mg intra-operatively, 250 mg on day 1, then 10-30 mg/day prednisone
~Day 15 - Day 60: everolimus 1.5 mg b.i.d. to achieve target 6-10 ng/mL + cyclosporine decrease dose as per protocol guideline + MPA 720 mg b.i.d. until everolimus trough >6 ng/mL, then MPA was stopped + prednisone 10-30mg/day
~Day 61 - Day 120: everolimus dose adjusted to achieve target 6-10 ng/mL + cyclosporine 25% dose reduction per fortnight, to be discontinued by day 120 as per protocol (or commence reduction by day 120 at discretion of investigator, to be completed within 2 months of commencement) + prednisone 10-30mg/day Day 121 - Month 36: everolimus dose adjusted to achieve target 8-12 ng/mL + prednisone 5-10 mg/day"
11630238|NCT00371826|Experimental|Steroid Withdrawal|"Every randomized patient in this group received
~Day 1 -14: cyclosporine 5 mg/kg b.i.d., dose adjusted to achieve C2 target as per protocol + mycophenolate sodium (MPA) 720 mg b.i.d. + methylprednisone/prednisone 500 mg intra-operatively, 250 mg on day 1, then 10-30 mg prednisone per day
~Day 15 - 60: everolimus 1.5 mg b.i.d. to achieve target 6-10 ng/mL + cyclosporine decrease dose as per protocol guideline + MPA 720 mg b.i.d. until everolimus trough >6 ng/mL, then MPA was stopped + prednisone 10-30mg per day
~Day 61 - 120: Everolimus dose adjusted + cyclosporine adjust dose according protocol guideline (or commence reduction by day 120 at discretion of Investigator, to be completed within 2 months of commencement) + gradual withdrawal of prednisone by 1 mg/week to be discontinued by Day 120.
~Day 121 - Month 36: At Day 121, Month 7 and Month 13 Everolimus dose was adjusted to achieve target 6-10 ng/mL + Cyclosporine adjust dose to achieve C2 target as per protocol"
11630239|NCT00371826|Active Comparator|CNI+MPA+ Steroid|"Patients randomized to this group received:
~Day 1 - Month 36: cyclosporine 5 mg/kg b.i.d., dose adjusted to achieve the protocol defined C2 Targets + mycophenolate sodium 720mg b.i.d. + Methylprednisone/prednisone 500mg intra-operatively, 250mg on day 1, 10-30mg prednisone per day until month 12 (as per local practice), 5-10mg/day months 13-36."
11630240|NCT00371787|Experimental|soft contact lens|
11630241|NCT00371787|No Intervention|non-lens wear|control group
11630242|NCT00371774||1|Dermatologic patients in Canada for which Amevive is clinically indicated
11630243|NCT00371761|Experimental|PegIntron|PegIntron, 1.5 micrograms/kg weekly, for up to 24 weeks followed by a 48-week observation phase
11630244|NCT00371761|Active Comparator|Adefovir|Adefovir, 10 mg daily, for up to 48 weeks followed by a 24-week observation phase
11630245|NCT00371748|Experimental|Arm 1|
11630246|NCT00371748|Other|Arm 2|Historical Comparator: control data derived from a TAXUS V de novo lesion and stent size-matched cohort randomized to receive a single, planned 2.25 mm DES
11630247|NCT00371748|Other|Arm 3|Historical Comparator: control data derived from a TAXUS V de novo lesion size-matched cohort randomized to receive a 2.25 mm or 2.5 mm BMS
11630248|NCT00371735|Experimental|Arm 1|
11630249|NCT00371709|Experimental|Arm 1|
11630250|NCT00371709|Other|Arm 2|Historical Comparator: control data derived from the TAXUS IV and TAXUS V studies
11630251|NCT00371683|Active Comparator|A1|+ placebo
11630252|NCT00371683|Experimental|A2|+ placebo
11630253|NCT00371644|Experimental|Arm 1|Participants receive 12 biweekly sessions of Cognitive Processing Therapy (CPT).
11630254|NCT00371644|Active Comparator|Arm 2|Participants receive 12 biweekly sessions of Present Centered Therapy (PCT).
11630255|NCT00371631|Other|Arm 1|insertion of E. coli coated catheter
11630256|NCT00371592|Experimental|1|Participants will receive acyclovir for 24 weeks
11630257|NCT00371592|Placebo Comparator|2|Participants will receive acyclovir placebo for 24 weeks
11630258|NCT00371566|Experimental|Lapatinib|
11630259|NCT00371566|Placebo Comparator|Placebo|
11630260|NCT00371540|No Intervention|I|Routine care in the clinic
11630261|NCT00371540|Experimental|II|Follow-up in clinic every 3 months, home visits monthly
11630262|NCT00371501|Active Comparator|treatment arm 1|
11630263|NCT00371501|Placebo Comparator|Treatment arm 2|
11630264|NCT00371501|Active Comparator|treatment arm 3|aspirin
11630265|NCT00371501|Placebo Comparator|treatment arm 4|placebo
11630266|NCT00371488|Experimental|GW572016 in combination with trastuzumab|"Lapatinib:
~A specified dose of lapatinib will be orally taken once daily, at least one hour before or one hour after the morning meal. Lapatinib should be taken at the same time of day wherever possible.
~The starting dose of lapatinib should be 750 mg/day, which will be increased to 1000 mg/day (dose escalation group) according to the dose escalation criteria.
~Trastuzumab:
~Trastuzumab (4 mg/kg/day in the first week and 2 mg/kg/day for the 2nd and subsequent weeks) will be administered by intravenous infusion over at least 90 minutes immediately after administration of lapatinib. The fifth (Day 36) and subsequent doses may be administered up to 3 days after the scheduled date. In this case, however, the all following doses should be administered at one-week intervals."
11630267|NCT00371475|Experimental|Arm 1|
11630268|NCT00371475|Other|Arm 2|Historical Comparator: control data derived from the TAXUS IV and TAXUS V clinical trials
11630269|NCT00371462|Active Comparator|Arm 1|MOVE! level 2 group weight loss counseling, the VA standard of care alone (Standard Care);
11630270|NCT00371462|Experimental|Arm 2|MOVE! level 2 + Personal Digital Assistant decision support tool (PDA) (Treatment)
11630271|NCT00371449||hearing aid users|hearing aid users
11630330|NCT00370916|Experimental|Arm 1|Physician-initiated medication reconciliation
11630331|NCT00370916|Experimental|Arm 2|Pharmacist-initiated medication reconciliation
11630272|NCT00371436|Active Comparator|Progressive Audiologic Tinnitus Management (PATM)|"The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment."
11630273|NCT00371436|Other|Usual Care (UC)|Typical audiologic care that would be received in a VA Audiology Clinic.
11630274|NCT00371423|Experimental|Arm 1|
11630275|NCT00371423|Other|Arm 2|Control data derived from ATLAS Workhorse Trial
11630276|NCT00371397|Experimental|Hatha yoga classes|Groups consisted of novices or experts. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
11630277|NCT00371397|Sham Comparator|Movement Control|Non-Hatha yoga gentle movement. Groups consisted of novices or experts. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
11630278|NCT00371397|No Intervention|Passive Video Control|Another control condition, a neutral video that did not include any music, allowed us to contrast the effects of yoga with no activity.The session included a sequence on how to design physics experiments for a high school classroom, as well as segments from two lectures on polymers and quantum mechanics. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
11630279|NCT00371384|Experimental|2|structural massage
11630280|NCT00371384|Experimental|1|relaxation massage
11630281|NCT00371371|Experimental|BM-MNC|autologous bone marrow-derived mononuclear cells
11630282|NCT00371371|Placebo Comparator|Placebo|Placebo
11630283|NCT00371345|Experimental|Dasatinib|Participants with either a Human epidermal growth factor (Her2/neu)-amplified tumor type or ER and/or PgR positive tumor types received oral dasatinib twice daily (BID).
11630284|NCT00371319|Active Comparator|Tacrolimus|Tacrolimus treatment
11630285|NCT00371319|Active Comparator|mycophenolate mofetil|mycophenolate mofetil
11630286|NCT00371293|Active Comparator|1|Participants will receive CPAP therapy.
11630287|NCT00371293|Active Comparator|2|Participants will take part in a weight loss program.
11630288|NCT00371293|Experimental|3|Participants will receive CPAP therapy and take part in a weight loss program.
11630289|NCT00371280|Active Comparator|1|Pegged unpegged hydroxyapatite orbital implantation
11630290|NCT00371280|Active Comparator|2|Unpegged hydroxyapatite orbital implantation
11630291|NCT00371267|Experimental|Arm 1: Telephone-delivered CBT|Telephone-delivered cognitive behavior therapy for pain management
11630292|NCT00371267|Active Comparator|Arm 2: Telephone patient education|Telephone-delivered patient education regarding management of chronic pain
11630293|NCT00371254|Experimental|1|
11630294|NCT00371254|Experimental|2|
11630295|NCT00371228|Experimental|1|Umbilical cord not cut until pulsation stops, in order to provide additional blood to newborn.
11630296|NCT00371228|No Intervention|2|Umbilical cord cut soon after birth without waiting for pulsing to stop.
11630297|NCT00371215|Experimental|1|rThrombin
11630298|NCT00371189|Experimental|Group C: Ad35.CS.01-10^10 vp/ml|15 subjects will receive dosage 10^10 vp/mL; 3 subjects will receive placebo.
11630299|NCT00371189|Experimental|Group D: Ad35.CS.01-10^11 vp/ml|15 subjects will receive dosage 10^11 vp/mL; 3 subjects will receive placebo.
11630300|NCT00371189|Experimental|Group A: Ad35.CS.01-10^8 vp/ml|15 subjects will receive dosage 10^8 vp/mL; 3 subjects will receive placebo.
11630301|NCT00371189|Experimental|Group B: Ad35.CS.01-10^9 vp/ml|15 subjects will receive dosage 10^9 vp/mL; 3 subjects will receive placebo.
11630302|NCT00371176|Experimental|D-Cycloserine|Brief imaginal exposure therapy plus DCS pill
11630303|NCT00371176|Placebo Comparator|Placebo|Brief imaginal exposure therapy plus Placebo pill
11630304|NCT00371163||Contact Dermatitis|Males or females with contact dermatitis
11630305|NCT00371163||Psoriasis|Males or females with psoriasis
11630306|NCT00371163||No skin disease|Males or females with no skin diseases
11630307|NCT00371163||Atopic Dermatitis|Males of females with atopic dermatitis
11630308|NCT00371150|Experimental|Arm1|
11630309|NCT00371137|Placebo Comparator|1|
11630310|NCT00371137|Experimental|2|
11630311|NCT00371111|Active Comparator|1|Intravitreal injection of Triamcinolone
11630312|NCT00371111|Active Comparator|2|Intravitreal injection of Avastin
11630313|NCT00371098|Experimental|active vaccine|patients received active influenza vaccine for season 2004/2005
11630314|NCT00371098|Placebo Comparator|placebo vaccine|patients received placebo influenza vaccine for season 2004/2005 containing all vaccine compounds except viral antigens
11630315|NCT00371085|Experimental|1|Video-based patient education on heart failure self care
11630316|NCT00371033|Active Comparator|1|Pregabalin
11630317|NCT00371033|Placebo Comparator|2|Placebo
11630318|NCT00370994|Active Comparator|Caudal epidural injection|Caudal epidural with placement of catheter in sacral canal with injection of 5 mL of 2% preservative-free lidocaine, followed by 6 mL of 0.9% sodium chloride solution and 6 mg of non-particulate Betamethasone and 1 mL of sodium chloride solution
11630319|NCT00370994|Active Comparator|Percutaneous adhesiolysis|Pecutaneous adhesiolysis and targeted placement of Racz catheter with injection of 5 mL of 2% preservative-free lidocaine, followed by 6 mL of 10% sodium chloride solution and 6 mg of non-particulate Betamethasone and 1 mL of sodium chloride solution
11630320|NCT00370981|Experimental|0.15 mg|
11630321|NCT00370981|Experimental|0.30 mg|
11630322|NCT00370981|Experimental|0.60 mg|
11630323|NCT00370981|Placebo Comparator|PBO|
11630324|NCT00370955|Active Comparator|High vacuum group|Those patients who underwent phacoemulsification using high hydrodynamic parameter: 400 mmHg vacuum and 40 ml/min flow rate.
11630325|NCT00370955|Active Comparator|Low vacuum group|Patients who underwent phacoemulsification using low hydrodynamic parameters: 200 mmHg vacuum and 20 ml/min flow rate.
11630326|NCT00370942|Placebo Comparator|GW823093C A|A=45 mg
11630327|NCT00370942|Placebo Comparator|GW823093C B|B=30 mg
11630328|NCT00370942|Placebo Comparator|GW823093C C|C=15 mg
11630329|NCT00370929|Experimental|Meditation|
11630332|NCT00370916|No Intervention|Arm 3|No formal medication reconciliation
11630333|NCT00370890|Experimental|A|Adjuvant chemotherapy and then clinical follow-up and surveillance
11630334|NCT00370890|No Intervention|B|Clinical follow-up and surveillance only
11630335|NCT00370877|Active Comparator|Standard care for post-partum hemorrhage|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage.
11630336|NCT00370877|Experimental|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
11630337|NCT00370851|Experimental|1|Intravitreal injection of Avastin
11630338|NCT00370851|Sham Comparator|2|
11630339|NCT00370838|Experimental|Levetiracetam|"Levetiracetam (Keppra) is used in one phase of this cross-over study.
~The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase."
11630340|NCT00370838|Active Comparator|Clonidine|"Clonidine is used in one phase of this cross-over study.
~The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase."
11630341|NCT00370812|Active Comparator|A|AMT with conventional medical therapy
11630342|NCT00370812|Active Comparator|B|Medical treatment alone
11630343|NCT00370799|Active Comparator|local anesthetic|Group 1. local anesthetics only
11630344|NCT00370799|Active Comparator|Local anesthetic with generic Celestone|Group 2. local anesthetic with 6mg of non-particulate Celestone
11630345|NCT00370799|Active Comparator|Local anesthetic with Celestone|Group 3. local anesthetic with 6 mg of brand nameCelestone
11630346|NCT00370799|Active Comparator|Local anesthetic with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
11630347|NCT00370786|Experimental|1|
11630348|NCT00370760|Active Comparator|1|
11630349|NCT00370760|Placebo Comparator|2|
11630350|NCT00370747|Experimental|Ecabet|Ophthalmic solution in the Study eye four times daily for 90 days.
11630351|NCT00370747|Placebo Comparator|Placebo|Ophthalmic solution in the Study eye four times daily for 90 days.
11630352|NCT00370721|Experimental|I|
11630353|NCT00370695|Active Comparator|Precision Spinal Cord Stimulation System|Single arm Precision Spinal Cord Stimulation System.
11630354|NCT00370682|Experimental|T-DEN F17|Full Dose (0.5 mL) 0 and 6 months
11630355|NCT00370682|Experimental|T-DEN F19|Full Dose (0.5 mL) at 0 and 6 months
11630356|NCT00370682|Placebo Comparator|Placebo Comparator|0.5 mL sterile buffer at 0 and 6, subcutaneous injection
11630357|NCT00370604|Experimental|1|19g needle, 23g catheter
11630358|NCT00370604|Active Comparator|2|traditional =>18g needle
11630359|NCT00370591|Experimental|Arm 1|
11630360|NCT00370552|Experimental|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|
11630361|NCT00370552|Experimental|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|
11630362|NCT00370552|Active Comparator|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|
11630363|NCT00370513|Experimental|Pazopanib Arm|Different doses of oral pazopanib once daily for the duration of the study starting on Day 1 of Treatment Period 1. Treatment continues until disease progression or withdrawl from study.
11630364|NCT00370500|Experimental|A|There is only one arm in this study. All probands receive quetiapine.
11630365|NCT00370448|Experimental|1|Training gatekeeper recruited from students and tutors and counselors
11630366|NCT00370448|Active Comparator|2|
11630367|NCT00370448|No Intervention|3|
11630368|NCT00370409|Experimental|1|Cryotherapy
11630369|NCT00370409|Placebo Comparator|2|
11630370|NCT00370396|Experimental|Synflorix-Synflorix Group|This group consisted of subjects previously vaccinated with the Synflorix™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Synflorix™ vaccine at 2, 3 and 4 months of age (injected intramuscularly [IM] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Synflorix™ vaccine, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
11630371|NCT00370396|Active Comparator|Prevenar-Prevenar Group|This group consisted of subjects previously vaccinated with the Prevenar™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Prevenar™ vaccine at 2, 3 and 4 months of age (injected intramuscularly [IM] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Prevenar™ vaccine, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
11630372|NCT00370396|Experimental|Prevenar-Synflorix Group|This group consisted of subjects previously vaccinated with the Prevenar™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Synflorix vaccine at 2, 3 and 4 months of age (injected intramuscularly [IM] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Synflorix™, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
11630373|NCT00370383|Experimental|Satraplatin|Satraplatin administered orally once daily for 5 consecutive days followed by erlotinib for 14 consecutive days
11630374|NCT00370383|Experimental|Erlotinib|Erlotinib administered orally once daily. Erlotinib - [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-y]- (3-ethynyl-phenyl)amine hydrochloride, molecular weight 393.4. This is a small molecule that competes with the binding of ATP to the intracellular tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and blocking downstream signal transduction.
11630375|NCT00370370|Active Comparator|1|Injection of intravitreal bevacizumab
11630376|NCT00370370|Active Comparator|2|Injection of bevacizumab + triamcinolone acetonide
11630377|NCT00370344|Active Comparator|Laparoscopic cholecystectomy|Operation by experts in laparoscopy.
11630378|NCT00370344|Active Comparator|Small-incision open cholecystectomy|Operation by experts in small-incision cholecystectomy.
11630379|NCT00370331|Experimental|Treatment arm plus standard of care|Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
11630380|NCT00370331|Placebo Comparator|placebo plus standard of care|Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
11630381|NCT00370305|Experimental|Rosiglitazone treatment|Rosiglitazone will be given to the subjects. All subjects will be analyzed before and after treatment
11630382|NCT00370292|Experimental|Pemetrexed - Before Protocol Amendment|
11630383|NCT00370292|Experimental|Pemetrexed - After Protocol Amendment|
11630384|NCT00370279|Active Comparator|1|scleral buckling
11630385|NCT00370279|Active Comparator|2|Primary vitrectomy without encircling band
11630386|NCT00370279|Active Comparator|3|Primary vitrectomy with encircling band
11630387|NCT00370279|Active Comparator|4|Triamcinolone assisted vitrectomy
11630388|NCT00370253|Active Comparator|2|Terlipressin
11630389|NCT00370253|Experimental|1|Noradrenalin
11630390|NCT00370240|Experimental|Ropivacaïne|
11630391|NCT00370240|Placebo Comparator|placebo|
11630392|NCT00370149|Active Comparator|Antibiotic-impregnated Catheters (M/R)|Interventions is insertion intra-operatively of catheters impregnated with minocycline and rifampin to determine if their is a therapeutic difference between this catheter and the placebo (non-impregnated) catheter. The catheters are sized to accommodate children in different size ranges: Cook Inc. Double Lumen 4 Fr., 8 cm long, (C-UDLM-401J-ABRM-HC), 5 Fr., 8 cm long, (C-UDLM-501J-ABRM-HC), and 5 Fr., 12 cm long, (C-UDLMY-501J-RSC-ABRM-HC).
11630393|NCT00370149|Placebo Comparator|Non-impregnated Catheter (C/S)|Intervention is insertion intra-operatively of conventional, non-impregnated catheters. There are two sizes to accommodate children in different size ranges: Cook Incorporated Double Lumen Polyurethane Central Venous Catheters, 4 Fr., 8 cm long, (C-UDLM-401J), 5 Fr., 8 cm long, (C-UDLM-501J), and 5 Fr., 12 cm long (C-UDLM-501J-RSC).
11630394|NCT00370110|Experimental|Itopride|
11630395|NCT00370110|Other|Placebo|
11630396|NCT00370097|Experimental|Subjects receiving HFA|Subjects in Session 1 will receive two inhalations of placebo HFA by meter-dose inhaler (MDI) twice daily and in Session 2 subjects will receive two inhalations of fluticasone propionate (FP) HFA MDI 44 mcg twice daily
11630397|NCT00370084|Placebo Comparator|Placebo|
11630398|NCT00370084|Experimental|Itopride|
11630399|NCT00370071|Experimental|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
11630400|NCT00369967|Experimental|Quick start|Start contraceptive method (NuvaRing) day of enrollment
11630401|NCT00369967|Active Comparator|Traditional start|Start contraceptive method (NuvaRing) after next menses (per package insert)
11630402|NCT00369941|Experimental|MK-0518 400 mg b.i.d.|MK-0518 400 mg, which can be taken by mouth (PO) twice a day (b.i.d.) without regard to food, and placebo to efavirenz, which will be taken PO at bedtime (q.h.s.) on an empty stomach preferably at bedtime. All participants will take one tablet of TRUVADA® (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) with food, daily with the morning dose of MK-0518. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
11630403|NCT00369941|Active Comparator|Efavirenz 600 mg q.h.s.|Efavirenz 600 mg, which will be taken by mouth (PO) at bedtime (q.h.s.) on an empty stomach preferably at bedtime, and placebo to MK-0518, which will be taken PO twice a day (b.i.d.) without regard to food. All participants will take one tablet of TRUVADA® with food, daily with the morning dose of placebo. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
11630404|NCT00369928|Placebo Comparator|Placebo|Placebo, oral dose, BID
11630405|NCT00369928|Experimental|25 mg PG-760564|25 mg BID, of oral PG-760564
11630406|NCT00369928|Experimental|100 mg PG-760564|100 mg BID, of oral PG-760564
11630407|NCT00369915|Experimental|Plac/Scop|Placebo then scopolamine
11630408|NCT00369915|Experimental|Scop/Plac|Scopolamine then placebo
11630409|NCT00369850|Experimental|Tamoxifen for 5 years|Patients treated with tamoxifen for 5 years after randomisation.
11630410|NCT00369850|Experimental|Letrozole for 5 years|Patients treated with letrozole for 5 years after randomisation.
11630411|NCT00369850|Experimental|Tamoxifen 2 years plus letrozole 3 years|Patients treated with tamoxifen for 2 years and afterwards with letrozole for 3 years.
11630412|NCT00369850|Experimental|Letrozole 2 years plus tamoxifen 3 years|Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.
11630413|NCT00369837|Experimental|clevidipine|A patient-specific blood pressure target range (TR) of ≥20 mm Hg and ≤40 mm Hg SBP was prespecified by the investigator. Once established, clevidipine (0.5 mg/mL in 20% lipid emulsion) intravenous infusion was initiated at 2.0 mg/h and maintained for the first 3 minutes. Clevidipine was up-titrated, as tolerated by the patient, by doubling the dose every 3 minutes until the prespecified systolic blood pressure (SBP) target range was achieved and could continue to be titrated up or down to maintain the desired long-term SBP reduction.
11630414|NCT00369824|Experimental|Cervarix + Boostrix/Menactra Group|Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.
11630415|NCT00369824|Experimental|Cervarix + Menactra/Boostrix Group|Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.
11630601|NCT00367679|Experimental|Single Arm|800 mg pazopanib oral daily
11630416|NCT00369824|Experimental|Cervarix + Boostrix + Menactra Group|Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.
11630417|NCT00369824|Experimental|Boostrix/Cervarix Group|Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.
11630418|NCT00369824|Experimental|Menactra/Cervarix Group|Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.
11630419|NCT00369824|Experimental|Cervarix Group|Subjects received Cervarix at Months 0, 1 and 6.
11630420|NCT00369785|Experimental|Arm I - Donepezil|Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day
11630421|NCT00369785|Placebo Comparator|Arm II - Control|Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day
11630422|NCT00369759||1|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
11630423|NCT00369759||2|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
11630424|NCT00369759||3|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
11630425|NCT00369746||Alcohol and major depression, citalopram|Patients with alcohol use disorder and major depression, treated with citalopram tablets, 20-60 mg, once daily, for 12 weeks
11630426|NCT00369746||Major Depression, citalopram|Patients with major depression, treated with citalopram tablets 20-60 mg daily, for 12 weeks
11630427|NCT00369733|Experimental|Single arm|Aranesp adminsitered every other week for 52 weeks
11630428|NCT00369707|Experimental|Bortezomib and Rituximab|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
11630429|NCT00369694|Active Comparator|1|72 hours of Terlipressin
11630430|NCT00369694|Placebo Comparator|2|24 hours of Terlipressin & then next 48 hours of Dummy of Terlipressin
11630431|NCT00369681|Experimental|R-ABVD|ABVD (doxorubicin; vinblastine; bleomycin; dacarbazine) given as standard for 6-8 cycles. Rituximab given 375 mg/m^2 Cycle 1 Days -6, 1, 8, 15, and 22. Rituximab given 375 mg/m^2 Cycles 2, 4, and 6 Day 1.
11630432|NCT00369668|Experimental|High Intensity|Bilateral training moving both arms coupled with neuromuscular electrical stimulation; four 90-minute sessions/week for 2 weeks.
11630433|NCT00369668|Active Comparator|Low Intensity|Bilateral training moving both arms coupled with neuromuscular electrical stimulation; two 90-minute sessions/week for 2 weeks.
11630434|NCT00369668|Active Comparator|Control|Bilateral training moving both arms coupled with sham neuromuscular electrical stimulation
11630435|NCT00369655|Experimental|Treatment (ziv-afibercept)|Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11630436|NCT00369629|Experimental|Cohort 1|"Pemetrexed at a dose of 400 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.
~Gemcitabine at a dose of 800 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
11630437|NCT00369629|Experimental|Cohort 2|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.
~Gemcitabine at a dose of 800 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
11630438|NCT00369629|Experimental|Cohort 3|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.
~Gemcitabine at a dose of 1000 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
11630439|NCT00369629|Experimental|Cohort 4|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.
~Gemcitabine at a dose of 1200 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
11630440|NCT00369616|Experimental|NicQb vaccine|
11630441|NCT00369616|Placebo Comparator|Placebo vaccine|
11630442|NCT00369603|Experimental|Razadyne ER|galantamine treatment group
11630443|NCT00369603|Experimental|Aricept|Aricept Treatment Group
11630444|NCT00369590|Experimental|All Study Patients|"Patients receive VEGF Trap (ziv-aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
~Other: pharmacological study; laboratory biomarker analysis."
11630445|NCT00369577|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo, single dose
11630446|NCT00369577|Experimental|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, single dose
11630447|NCT00369577|Experimental|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, single dose
11630448|NCT00369564|Experimental|Arm I Glutamic Acid|Patients receive oral glutamic acid 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).
11630449|NCT00369564|Placebo Comparator|Arm II Placebo|Patients receive oral placebo 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).
11630450|NCT00369551|Experimental|Treatment (paclitaxel, carboplatin, bevacizumab, radiation)|"Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, 36, and 43 and bevacizumab IV over 30-90 minutes on days 1, 15, 29, and 43. Patients also undergo chest radiotherapy 5 days a week for 7 weeks beginning on day 1.
~Consolidation therapy: Beginning 4-5 weeks after completion chemoradiotherapy, patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 1 hour followed by bevacizumab IV over 30 minutes. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
11630451|NCT00369538|Active Comparator|1|losartan, hydrochlorothiazide
11630452|NCT00369538|Active Comparator|2|hydrochlorothiazide, losartan
11630453|NCT00369512|Experimental|Erlotinib|Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
11630454|NCT00369486|Active Comparator|1|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study (ETDRS) technique)
11630455|NCT00369486|Experimental|2|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
11630456|NCT00369486|Experimental|3|Anterior peribulbar injection of 20 mg triamcinolone
11630457|NCT00369486|Experimental|4|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
11630458|NCT00369486|Experimental|5|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
11630459|NCT00369473|Experimental|1|350
11630460|NCT00369473|Experimental|2|350
11630461|NCT00369447|Experimental|1|200 mg dose
11630462|NCT00369447|Placebo Comparator|2|
11630463|NCT00369421||Unique Disorders|Unique Disorders
11630464|NCT00369408|Experimental|1|naltrexone (50 mg orally) for 12-week treatment period
11630465|NCT00369408|Placebo Comparator|2|placebo for 12-week treatment period
11630466|NCT00369395|Experimental|Volociximab|Volociximab 15 mg/kg
11630467|NCT00369382|Active Comparator|1|Group 1: Continuation of CNI regimen
11630468|NCT00369382|Experimental|2|Group 2: (CNI-Free) Conversion to SRL-based regimen
11630469|NCT00369356|Sham Comparator|1|Bare Metal Stenting
11630470|NCT00369356|Active Comparator|2|Stenting with DES
11630471|NCT00369356|Experimental|3|Bare metal stenting and administration of prednisone
11630472|NCT00369343|Experimental|A|
11630473|NCT00369343|Placebo Comparator|B|
11630474|NCT00369317|Experimental|Treatment (combination chemotherapy)|"INDUCTION THERAPY COURSE I: Patients receive cytarabine IT on day 1 and cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV continuously, and oral thioguanine BID on days 1-4. COURSE II: Patients receive high-dose cytarabine IV over 3 hours BID on days 1, 2, 8, and 9 and asparaginase (IM) on days 2 and 9.
~COURSE III: Patients receive treatment as in course I. COURSE IV: Patients receive cytarabine IV, daunorubicin hydrochloride IV, and oral thioguanine as in course I
~INTENSIFICATION THERAPY: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity."
11630475|NCT00369291|Experimental|CpG 7909|Patients treated with CpG 7909 oligodeoxynucleotides (ODNs) after autologous transplantation to enhance immune reconstitution.
11630476|NCT00369278|Experimental|Intensified Mycophenolate sodium|Enteric-coated mycophenolate sodium was given according to the following dosing regimen: Day 1-14: 2880 mg/day (2 x 1440 mg), then day 15-42: 2160 mg/day (2 x 1080 mg), then day 43-End of study (month 6): 1440 mg/day (2 x 720 mg). Total duration of treatment was 180 days.
11630477|NCT00369278|Active Comparator|Standard Mycophenolate sodium|Enteric-coated mycophenolate sodium was given according to the following dosing regimen: Day 1 - End of Study(month 6): 1440 mg/day (2 x 720 mg). Total duration of treatment was 6 months.
11630478|NCT00369265|Experimental|Lansoprazole|Lansoprazole 30 mg Twice Daily
11630479|NCT00369265|Placebo Comparator|Sugar pill|placebo
11630480|NCT00369226|Experimental|Bortezomib/Tacrolimus/Methotrexate post HSCT|
11630481|NCT00369200|Experimental|Arm I|"Patients receive AFP464 IV over 3 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
~Cohorts of 2-6 patients receive escalating doses of AFP464 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which ≤ 1 of 6 patients experience dose-limiting toxicity. An additional 10 patients whose tumor is amenable to biopsy are treated at the MTD.
~Patients undergo blood collection periodically for pharmacokinetic and pharmacodynamic studies. Patients treated at the MTD also undergo tumor tissue biopsies periodically for additional pharmacodynamic and correlative biomarker studies.
~After completion of study treatment, patients are followed for 4 weeks."
11630482|NCT00369174|Experimental|Treatment (rosiglitazone maleate)|Patients receive oral rosiglitazone once daily. Treatment continues for 12 weeks in the absence of unacceptable toxicity.
11630483|NCT00369161|Active Comparator|Very low dose tacrolimus|The first dose of everolimus was to be administered not later than 24 hours after transplantation with a starting dose of 1.5 mg bis in diem/twice a day (b.i.d.) thereafter adjusted to maintain the trough blood levels between 3 and 8 ng/ml. Tacrolimus was to be initiated within 24 hours after reperfusion of the graft with a starting dose of 0.1 mg/kg/day thereafter adjusted to maintain the trough blood levels between 4 and 7 ng/ml. Up to months three all patients received the same treatment and after three months patients in this arm received tacrolimus to reach a trough blood level between 1.5 and 3 ng/ml. All patients received two doses of 20 mg basiliximab, administered as an intravenous bolus injection. The first dose was given on the day of transplantation, with the second dose being administered on the fourth day post-transplant. Intravenous (i.v.) prednisone (or equivalent) was given pre- or intra-operatively according to center practice.
11630484|NCT00369161|Active Comparator|Low dose tacrolimus|The first dose of everolimus was to be administered not later than 24 hours after transplantation with a starting dose of 1.5 mg bis in diem/twice a day (b.i.d.) thereafter adjusted to maintain the trough blood levels between 3 and 8 ng/ml. Tacrolimus was to be initiated within 24 hours after reperfusion of the graft with a starting dose of 0.1 mg/kg/day thereafter adjusted to maintain the trough blood levels between 4 and 7 ng/ml. Up to months three all patients received the same treatment and after three months patients in this arm received tacrolimus to reach a trough blood level between 4 and 7 ng/ml. All patients received two doses of 20 mg basiliximab, administered as an intravenous bolus injection. The first dose was given on the day of transplantation, with the second dose being administered on the fourth day post-transplant. Intravenous (i.v.) prednisone (or equivalent) was given pre- or intra-operatively according to center practice.
11630485|NCT00369122|Experimental|Treatment (radiation therapy, bevacizumab, cisplatin)|"Patients undergo pelvic EBRT once daily, 5 days a week, for 5 weeks for a total of 45 Gy.
~Some patients also undergo low-dose rate brachytherapy twice, 1-3 weeks apart, beginning >= 4 weeks after initiating EBRT or high-dose rate brachytherapy 5 times, >= 48 hours apart, beginning >= 2 weeks after initiating EBRT. EBRT and chemotherapy are halted on the day of high-dose rate brachytherapy. Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29 and cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, and 35."
11630486|NCT00369070|Experimental|A|AMG 706 125 mg once daily (QD) and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.
11630487|NCT00369070|Experimental|B|AMG 706 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.
11630602|NCT00367666|Experimental|Patients Diagnosed with Breast Cancer|
11630488|NCT00369070|Active Comparator|C|Bevacizumab 15 mg/kg bevacizumab, delivered via intravenous (IV) infusion once every 3 weeks and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.
11630489|NCT00369031|Experimental|1|Human Immunodeficiency Virus glycoprotein 140 (vaccine)
11630490|NCT00369031|Active Comparator|2|Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant
11630491|NCT00369031|Active Comparator|3|Labile Toxin mutant LTK63 adjuvant
11630492|NCT00369018|Active Comparator|MAL 3|
11630493|NCT00369018|Active Comparator|MAL 12|
11630494|NCT00369018|Active Comparator|HAL 10, 3|
11630495|NCT00369018|Active Comparator|HAL 10, 12|
11630496|NCT00369018|Active Comparator|HAL 40, 3|
11630497|NCT00369018|Active Comparator|HAL 40, 12|
11630498|NCT00368992|Experimental|Treatment (cetuximab, paclitaxel, bevacizumab)|"INDUCTION THERAPY: Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE THERAPY: Patients receive cetuximab IV over 1 hour on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
11630499|NCT00368979|Active Comparator|Dutasteride|
11630500|NCT00368979|Placebo Comparator|Placebo|
11630501|NCT00368966|Experimental|1|
11630502|NCT00368966|Active Comparator|2|
11630503|NCT00368953|Experimental|1|
11630504|NCT00368953|Active Comparator|2|
11630505|NCT00368940|Experimental|PATH|Participants will receive PATH for 12 weeks
11630506|NCT00368940|Active Comparator|ST-CI|Participants will receive ST-CI for 12 weeks
11630507|NCT00368927|Experimental|Arm I|Patients receive oral sulindac twice daily for 6 months.
11630508|NCT00368927|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 6 months.
11630509|NCT00368901|Experimental|Single arm|Every other week dosing of Aranesp SC
11630510|NCT00368875|Experimental|vorinostat, paclitaxel, bevacizumab|Vorinostat BID on days 1-3, 8-10, and 15-17, paclitaxel IV over 1 hour on days 2, 9, and 16, bevacizumab IV over 30-90 minutes on days 2 and 16, repeat every 28 days.
11630511|NCT00368849|Experimental|40 milligram twice a day atomoxetine|Participants received 40 milligram twice a day atomoxetine for 4 weeks.
11630512|NCT00368849|Placebo Comparator|Twice a day matching placebo|Participants received twice a day matching placebo for 4 weeks.
11630513|NCT00368836|Experimental|1|Breath Screen PE device + D-dimer
11630514|NCT00368784||1|Individuals ages 12-85 with an immune mediated skin disease, such as psoriasis, scleroderma, or mycosis fungoides. Peripheral blood and/or check swabs will be collected from participants ages 12- 85 years old. These samples will then be used to characterize the inflammatory cells as described above.
11630515|NCT00368784||2|Age-Matched Controls without immune mediated skin diseases. Peripheral blood and/or check swabs will be collected from participants ages 12- 85 years old. These samples will then be used to characterize the inflammatory cells as described above.
11630516|NCT00368771|Active Comparator|1|IBS Stress Management
11630517|NCT00368771|Active Comparator|2|IBS Symptom Management
11630518|NCT00368771|Active Comparator|3|IBS Educational Training
11630519|NCT00368745|Active Comparator|Pregabalin|Pregabalin treatment for GAD during 6 week taper/discontinuation from alprazolam treatment; followed by 6 weeks pregabalin treatment 'alprazolam free'.
11630520|NCT00368745|Placebo Comparator|Placebo|Placebo treatment of GAD during 6 week taper/discontinuation of alprazolam treatment followed by 6 weeks continuation of placebo treatment 'alprazolam free'.
11630521|NCT00368719|No Intervention|1|
11630522|NCT00368706|Experimental|1|
11630523|NCT00368706|Active Comparator|2|
11630524|NCT00368654|Active Comparator|A|Monotherapy with Raptiva alone
11630525|NCT00368654|Experimental|B|Combination therapy with both Raptiva and Methotrexate
11630526|NCT00368654|Experimental|C|Continue Raptiva, discontinue methotrexate
11630527|NCT00368654|Experimental|D|Continue combination therapy with both Raptiva and Methotrexate
11630528|NCT00368641|Experimental|Intervention|peritoneal dialysis
11630529|NCT00368641|No Intervention|Standard of Care|
11630530|NCT00368615||1|Subjects ages 18-85 years old with biopsy proven melanoma. Peripheral blood will be collected from adults ages 18-85 years old. These samples will then be used for PCR analysis and to generate melanoma-specific T cell clones. If the participant requires a palliative resection of a melanoma tumor(s) then tissue from the tumor will be used to characterize the melanoma's interaction with the immune system and to generate melanoma-specific cell lines. T cell clones isolated from participant's peripheral blood will then be assayed for in-vitro responsiveness to these cell lines. All experiments will be conducted in-vitro.
11630531|NCT00368615||2|Age-matched controls (no evidence of melanoma)
11630532|NCT00368602|Experimental|1|This group receives topical beta adrenergic antagonists (Timoptic) plus standard of care.
11630533|NCT00368602|Placebo Comparator|2|The group will be given standard of care with placebo medication.
11630534|NCT00368550|Experimental|1|Oral sertraline, cognitive-behavioral counseling to maintain abstinence from alcohol
11630535|NCT00368550|Placebo Comparator|2|Placebo, cognitive-behavioral counseling to maintain abstinence from alcohol
11630536|NCT00368537|Active Comparator|1|Arm 1: Tigecycline
11630537|NCT00368537|Active Comparator|2|Arm 2: Ampicillin-Sulbactam or Amoxicillin-Clavulanate plus or minus a glycopeptide
11630538|NCT00368511|No Intervention|1|Listening to music and posture changes
11630539|NCT00368472|Experimental|Perampanel|Participants previously receiving placebo/perampanel in the double blind study, were titrated to receive perampanel 2 mg to 12 mg, once daily during the OLE study
11630540|NCT00368459|Experimental|raloxifene|oral raloxifene 120 mg once daily
11630541|NCT00368459|Placebo Comparator|placebo|identical appearing oral placebo
11630542|NCT00368446||1|Normal
11630543|NCT00368446||2|Patients with Genetic Disorders of Mucociliary Clearance
11630603|NCT00367653|Experimental|1|
11630604|NCT00367653|Experimental|2|
11630544|NCT00368381|Active Comparator|Hydrocortision and fludrocortisone|Study is comparing hydrocortisone alone versus the combination of hydrocortisone and fludrocortisone in the treatment of adrenal insufficiency of septic patients.
11630545|NCT00368368|Experimental|1|
11630546|NCT00368368|Experimental|2|
11630547|NCT00368368|Experimental|3|
11630548|NCT00368355|Experimental|CLINIMACS Device|Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device
11630549|NCT00368355|Experimental|ISOLEX Device|Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device
11630550|NCT00368316|Experimental|S. sonnei conjugate vaccine|Shigella sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa
11630551|NCT00368316|Experimental|S. flexneri 2a conjugate vaccine|Shigella flexneri 2a O-specific polysaccharide covalently bound to recombinant exoprotein A of pseudomonas aeruginosa
11630552|NCT00368290|Experimental|1|modafinil plus CBT
11630553|NCT00368290|Placebo Comparator|2|placebo plus CBT
11630554|NCT00368277|Experimental|Aliskiren-based regimen|Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg
11630555|NCT00368277|Active Comparator|Ramipril-based regimen|Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg
11630556|NCT00368264|Experimental|1|azathioprine plus 4 infusions of infliximab (5 mg/kg)
11630557|NCT00368264|Placebo Comparator|2|azathioprine plus 4 placebo infusions
11630558|NCT00368251|Placebo Comparator|Placebo|Placebo Placebo twice a day (bid), 14 weeks (2 week Up-Titration Period + 12 week Maintenance Period)
11630559|NCT00368251|Experimental|Brivaracetam 5 mg/day|Brivaracetam (BRV) 5 mg/day 5 mg twice a day (bid) using 2.5 mg tablets for 12 weeks (after 2 week Up- Titration Period)
11630560|NCT00368251|Experimental|Brivaracetam 150 mg/day|Brivaracetam (BRV) 150 mg/day 150 mg twice a day (bid) using 25 mg and 50 mg tablets for 12 weeks (after 2 week Up-Titration Period)
11630561|NCT00368212|Experimental|1|"Participants will receive psychoeducational counseling (termed health care counseling)"
11630562|NCT00368212|Active Comparator|2|Participants will receive relaxation response training
11630563|NCT00368160|Experimental|1|eszopiclone 3 mg
11630564|NCT00368160|Placebo Comparator|2|Placebo tablet
11630565|NCT00368121|Experimental|Cetuximab + Dexamethasone|
11630566|NCT00368108|Experimental|2 mg perampanel|The Perampanel 2mg dosage was fixed for the entire double-blind study. Subjects taking perampanel 2mg were to take the dose orally once every day in the evening.
11630567|NCT00368108|Experimental|4 mg perampanel|The Perampanel 4mg group first were subjected to a 4 week titration period, followed by a maintenance period for the remaining weeks. Subjects taking perampanel 4mg had a titration period of 4 weeks, starting at 2mg per day adding 1mg of perampel every two weeks up to 4mg. The dosages were to be taken orally once every day in the evening.
11630568|NCT00368108|Placebo Comparator|placebo|The placebo dosage was a fixed dosage for the entire double-blind study. Subjects receiving the placebo were to take one dose orally once every day in the evening.
11630569|NCT00368082|Experimental|TGFbeta resistant LMP-specific CTLs|"CTLs be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.
~If patients with active disease have stable disease or a partial response at their 6 week or subsequent evaluations they will be eligible to receive up to 6 additional doses of CTLs at 1-2 monthly intervals-each of which will consist of the same cell number as their second injection."
11630570|NCT00368069|Experimental|Keppra® XR|Keppra® extended release formulation -XR
11630571|NCT00368069|Placebo Comparator|Placebo|placebo
11630572|NCT00368056|Experimental|1|eszopiclone 3 mg
11630573|NCT00368056|Placebo Comparator|2|Placebo tablet
11630574|NCT00368030|Experimental|A|Eszopiclone 3 mg QD
11630575|NCT00368030|Placebo Comparator|B|Placebo tablet
11630576|NCT00368017|Active Comparator|1|
11630577|NCT00368017|Placebo Comparator|2|
11630578|NCT00367991|Active Comparator|A|recombinant human erythropoietin 200 U/kg IV daily for 3 days
11630579|NCT00367991|Placebo Comparator|B|Normal saline volume to match active treatment IV daily for 3 days
11630580|NCT00367965|Experimental|1|eszopiclone 3 mg
11630581|NCT00367965|Placebo Comparator|2|placebo tablet
11630582|NCT00367952|Experimental|ATC 800mg BID|800mg ATC BID
11630583|NCT00367900||NIH-AARP Diet and Health Study sub study: PAGE|Diet and Health Study members who self-reported a Parkinson's disease (PD) diagnosis on a follow-up questionnaire, and randomly selected controls, will participate in the PAGE sub study.
11630584|NCT00367887|Active Comparator|1|
11630585|NCT00367887|Active Comparator|2|
11630586|NCT00367887|Active Comparator|3|
11630587|NCT00367861|Experimental|interruption of Glivec®|
11630588|NCT00367835|Experimental|SPD503 (Guanfacine hydrochloride)|
11630589|NCT00367835|Placebo Comparator|Placebo|
11630590|NCT00367809|Experimental|1|
11630591|NCT00367809|Active Comparator|2|
11630592|NCT00367809|No Intervention|3|
11630593|NCT00367770|Experimental|Tracleer|The starting dose for all patients will be 62.5 mg b.i.d. At the Week 4 visit, patients who were started on 62.5 mg b.i.d. will be uptitrated to 125 mg b.i.d. if the 62.5 mg b.i.d. dose was well-tolerated.
11630594|NCT00367757|Other|PVI group|Trigger-based ablation guided by pulmonary vein antrum isolation
11630595|NCT00367757|Other|CFAE group|Substrate-based ablation using an approach targeting CFAEs
11630596|NCT00367757|Other|Combined group|Combined trigger and substrate based approach
11630597|NCT00367744|Active Comparator|Rosigitazone arm|Rosiglitazone active 4 mg BID
11630598|NCT00367744|Placebo Comparator|Placebo arm|Matching Placebo BID
11630599|NCT00367705|Active Comparator|T|VSL-#3
11630600|NCT00367705|Placebo Comparator|P|
11630605|NCT00367640|Experimental|100 IR|100 IR grass pollen allergen extract tablet
11630606|NCT00367640|Experimental|300 IR|300 IR grass pollen allergen extract tablet
11630607|NCT00367640|Experimental|500 IR|500 IR grass pollen allergen extract tablet
11630608|NCT00367640|Placebo Comparator|Placebo|Placebo tablet
11630609|NCT00367601|Experimental|1|Bevacizumab + erlotinib; if no progressive disease observed, combination or single-agent treatment will continue until unacceptable toxicity or progressive disease.
11630610|NCT00367484|Experimental|Rebif® (clone 484-39)|Rebif® 44 mcg, three times per week (tiw), subcutaneously (s.c.) During the first 4 weeks of the study, subjects underwent a dose titration regimen of 40% of Rebif® 22 mcg or 20% of Rebif® 44 mcg tiw (8.8 mcg per injection) in the first and second week followed by 100% of Rebif® 22 mcg or 50% of Rebif® 44 mcg (22 mcg per injection) in the third and fourth week. After 4 weeks, subjects received 44 mcg injected s.c. tiw.
11630611|NCT00367471|Active Comparator|Group A|Subjects in Treatment Group A (in cohorts of three) will receive oral lapatinib QD (Days 1 to 28). Following lapatinib administration on Day 1, paclitaxel will be administered intravenously over one hour followed immediately by an IV infusion of carboplatin over not less than 15 minutes. Carboplatin will be followed by an initial loading dose of trastuzumab by 90 minute IV infusion (first dose only) with subsequent IV doses of trastuzumab to be given weekly over 30 minute infusion. Doses of paclitaxel and carboplatin will be administered weekly (Day 1, 8, and 15). Trastuzumab is administered on Day 1, 8, 15, and 22. Treatment cycles are repeated every four weeks.
11630612|NCT00367471|Active Comparator|Group B|Subjects in Treatment Group B (in cohorts of three) will receive oral lapatinib QD (Days 1 to 28). Following lapatinib administration on Day 1, paclitaxel will be administered intravenously over one hour followed immediately by a ≥15 minute intravenous infusion of carboplatin. Doses of paclitaxel, and carboplatin will be administered weekly (Day 1, 8, and 15) for three weeks with cycles repeated every four weeks.
11630613|NCT00367458|Experimental|Atorvastatin, then Placebo|Patients were randomized to receive Atorvastatin first for 8 weeks, followed by 4 weeks wash out, and then cross over to placebo for 8 weeks.
11630614|NCT00367458|Experimental|Placebo, Then Atorvastatin|Patients were randomized to receive placebo first for 8 weeks, followed by 4 weeks wash out, and then cross over to 80 mg atorvastatin daily for 8 weeks.
11630615|NCT00367432|Experimental|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
11630616|NCT00367406|Experimental|Treatment with a Gamma 3 nail.|
11630617|NCT00367393|Experimental|1|Pimecrolimus cream 1%
11630618|NCT00367380|Experimental|Group 1|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 413ABM
11630619|NCT00367380|Experimental|Group 2|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 414WRR
11630620|NCT00367380|Experimental|Group 3|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 418JAL
11630621|NCT00367341|Other|Escitalopram|
11630622|NCT00367341|Other|Cognitive Behavioral Therapy|
11630623|NCT00367328|Active Comparator|A|Oral Antibiotics in standard care vs. Laser treatment
11630624|NCT00367302|Experimental|1|Buprenorphine maintenance
11630625|NCT00367302|Active Comparator|2|Methadone maintenance
11630626|NCT00367276|Experimental|Arm 1|
11630627|NCT00367237|Experimental|Infliximab + methotrexate (IFX + MTX)|Remicade (infliximab [IFX]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week
11630628|NCT00367237|Active Comparator|Methotrexate (MTX)|Oral methotrexate (MTX) 15 mg/week
11630629|NCT00367198|Active Comparator|1|30 ml per serving
11630630|NCT00367198|Active Comparator|2|60 ml per serving
11630631|NCT00367198|No Intervention|3|chronic hemodialysis patients
11630632|NCT00367198|No Intervention|4|healthy subjects
11630633|NCT00367133|Active Comparator|1|Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
11630634|NCT00367133|Experimental|2|Intravitreal injection of 1mg of triamcinolone acetonide
11630635|NCT00367133|Experimental|3|Intravitreal injection of 4mg of triamcinolone acetonide
11630636|NCT00367042|No Intervention|1|
11630637|NCT00367029|Active Comparator|1|Print-based, individually tailored motivational program
11630638|NCT00367029|Experimental|2|Enhanced version of the print-based, individually tailored motivational program
11630639|NCT00367016|Placebo Comparator|A|The subjects will be randomized to a treatment group and a placebo group. Prior to Omalizumab administration, all subjects will undergo screening studies, including spirometry, blood test and skin test. Blood test includes comprehensive metabolic panel, CBC, and total and free IgE levels. Skin test will be done with a panel of 7 common allergens
11630640|NCT00367016|Active Comparator|B|The subjects will be randomized to a treatment group and a placebo group. Prior to Omalizumab administration, all subjects will undergo screening studies, including spirometry, blood test and skin test. Blood test includes comprehensive metabolic panel, CBC, and total and free IgE levels. Skin test will be done with a panel of 7 common allergens
11630641|NCT00367003|Experimental|Deep Brain Stimulation|Participants with treatment resistant depression will have a device implanted for deep brain stimulation.
11630642|NCT00366990|Active Comparator|weight loss and sodium intake reduction|Behavioral and weight loss intervention, including a low sodium diet. Study goals are a 10% weight loss, 200 minutes of moderate physical activity a week, such as walking, and a 50% reduction in sodium intake.
11630643|NCT00366990|Placebo Comparator|weight loss and normal sodium intake|Behavioral and weight loss intervention, with regular sodium intake. Study goals are a 10% weight loss, 200 minutes of moderate physical activity a week, such as walking.
11630644|NCT00366964|No Intervention|Device|
11630645|NCT00366899|Experimental|1|13-valent pneumococcal conjugate vaccine
11630646|NCT00366899|Active Comparator|2|7-valent pneumococcal conjugate vaccine
11630647|NCT00366873|Active Comparator|1|cow-milk based infant formula
11630648|NCT00366873|Experimental|2|cow-milk based infant formula with prebiotics
11630649|NCT00366860|Experimental|Soy bread|Soy bread (75-100 mg isoflavone/day) for 12 weeks
11630650|NCT00366860|Active Comparator|Wheat bread|Wheat bread for 12 weeks
11631022|NCT00362427|Active Comparator|Group C|
11630651|NCT00366834|Placebo Comparator|Control|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV on Day 1 + placebo
11630652|NCT00366834|Experimental|Single dose oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV + casopitant 150 mg on Day 1
11630653|NCT00366834|Experimental|3-day oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV + casopitant 150 mg on Day 1 + 50 mg on days 2 & 3
11630654|NCT00366834|Experimental|3-day IV/oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV on Day 1 + 90 mg IV casopitant on day 1 and 50 mg oral casopitant on days 2 & 3
11630655|NCT00366821||1|Examine the outcomes following cardiac surgery in those newborns with genetic abnormalities.
11630656|NCT00366821||2|Examine the outcomes following cardiac surgery in newborns without genetic abnormalities.
11630657|NCT00366795|Experimental|Satavaptan|
11630658|NCT00366795|Placebo Comparator|Placebo|
11630659|NCT00366782|Experimental|1|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to adults 18 to 49 years of age
11630660|NCT00366782|Experimental|2|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to HPIV3-seropositive children 15 to 59 months of age). This arm may enroll after Arm 1 depending on the effect of the vaccine on Arm 1.
11630661|NCT00366782|Experimental|3|One vaccination with rB/HPIV3 vaccine (at lower dose) given as nose drops to seronegative children or infants 6 to 36 months of age. This arm may enroll after Arm 2.
11630662|NCT00366782|Experimental|4|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to seronegative children or infants 6 to 36 months of age. This arm may enroll after Arm 2.
11630663|NCT00366782|Placebo Comparator|5|One vaccination with placebo vaccine given as nose drops to adults, HPIV3-seropositive children, or seronegative children or infants
11630664|NCT00366704|Experimental|A|
11630665|NCT00366704|Active Comparator|B|
11630666|NCT00366678|Experimental|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
11630667|NCT00366678|Active Comparator|7-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine
11630668|NCT00366639||001|
11630669|NCT00366626|Experimental|1.|Naltrexone one capsule a day
11630670|NCT00366626|Placebo Comparator|2|One capsule a day match to naltrexone
11630671|NCT00366548|Experimental|1|
11630672|NCT00366548|Active Comparator|2|
11630673|NCT00366535|Active Comparator|Placebo first, then Neurotropin (G-1)|Double blind cross-over study: receive Placebo for 12 weeks and then Neurotropin for 12 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
11630674|NCT00366535|Active Comparator|Neurotropin first, then Placebo (G-2)|Double blind cross-over study: receive Neurotropin for 12 weeks and then Placebo for 12 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others
11630675|NCT00366509||1|Lung Disease
11630676|NCT00366509||2|Healthy volunteer
11630677|NCT00366470|Experimental|A|Vitamin D in doses of 100,000 IU
11630678|NCT00366470|Placebo Comparator|B|
11630679|NCT00366457|Other|Gemcitabine, Bevacizumab and Erlotinib|single-arm, no masking
11630680|NCT00366444|Experimental|1|
11630681|NCT00366444|Placebo Comparator|2|
11630682|NCT00366379|Experimental|1|
11630683|NCT00366379|Experimental|2|
11630684|NCT00366379|Experimental|3|
11630685|NCT00366379|Experimental|4|
11630686|NCT00366379|Experimental|5|
11630687|NCT00366353|Other|1|Sedation suring a spontaneous breathing trial.
11630688|NCT00366353|Other|2|No sedation during spontaneous breathing trial
11630689|NCT00366340|Experimental|1|13-valent pneumococcal conjugate vaccine
11630690|NCT00366340|Active Comparator|2|7-valent pneumococcal conjugate vaccine
11630691|NCT00366327|Experimental|A|
11630692|NCT00366301|Placebo Comparator|Placebo pill|Placebo pill
11630693|NCT00366301|Active Comparator|Metformin Pill|Metformin pill
11630694|NCT00366301|Active Comparator|Insulin Glargine plus placebo pill|Insulin glargine plus placebo pill
11630695|NCT00366301|Active Comparator|Insulin Glargine plus metformin pill|Insulin Glargine plus metformin pill
11630696|NCT00366288||1|
11630697|NCT00366288||2|
11630698|NCT00366288||3|
11630699|NCT00366288||4|
11630700|NCT00366288||5|
11630701|NCT00366288||6|
11630702|NCT00366288||7|
11630703|NCT00366275|Experimental|In vivo purging autotransplant|
11630704|NCT00366249|Active Comparator|A|
11630705|NCT00366249|Active Comparator|B|
11630706|NCT00366210|Experimental|Expanded CI therapy|3.5 hours of training for the more-affected arm set in the laboratory for 15 consecutive weekdays
11630707|NCT00366210|Placebo Comparator|Placebo Control|Stretching, movement exercises, and EMG biofeedback for the same duration as the experimental intervention.
11630708|NCT00366210|No Intervention|Usual & Customary Care Control|Treatments available to participants as part of their regular medical care, such as conventional physical or occupational therapy. For some participants, this would involve no treatment, since all participants were more than one year post stroke.f standard clinical care.
11630709|NCT00366158|Experimental|1|Ventricular Instrinsic Preference (VIP) turned ON
11630710|NCT00366158|Active Comparator|2|Ventricular Instrinsic Preference (VIP) turned OFF
11630711|NCT00366145|Active Comparator|Prochymal|Patients who receive standard of care plus treatment with ex vivo cultured adult human Mesenchymal Stem Cells
11630712|NCT00366145|Placebo Comparator|Placebo|Patients who receive standard of care and do not receive treatment with ex vivo cultured adult human mesenchymal stem cells.
11630713|NCT00366093|Experimental|1|eszopiclone 3 mg
11630714|NCT00366093|Placebo Comparator|2|Placebo tablet
11630715|NCT00366041|Experimental|Cellularised LG002|Cellularised LG002
11630716|NCT00366041|Experimental|UnCellularised LG002|UnCellularised LG002
11630748|NCT00365716|Experimental|Placebo (mcg) (Aluminum Adjuvant) 225|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 4 received placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
11630717|NCT00366028|Other|Organizational Model|Organizational Model: Participants in this arm of the study will receive information regarding the organizational model and work closely with the research team throughout the project to implement various aspects of the model. Participants in this arm of the study will be interviewed and participate in the data feedback portion of the study as well.
11630718|NCT00366028|Other|Data Feedback|Data Feedback Only: Participants in this arm will be interviewed periodically and participate in the data feedback portion of the study.
11630719|NCT00366002|Experimental|1|Darifenacin
11630720|NCT00365989|Experimental|ExAblate Enhanced Sonication Test Arm|The intervention to be administered is ExAblate Enhanced Sonication. The purpose of this study is to examine the safety profile of the ExAblate Enhanced Sonication mode to insure that no new safety issues are introduced compared to the normal focused ultrasound mode.
11630721|NCT00365976|Placebo Comparator|1|Placebo
11630722|NCT00365976|Active Comparator|2|Eszopiclone
11630723|NCT00365937|Experimental|Group A|The eight HLA-A2 peptides
11630724|NCT00365937|Experimental|Group B|The eight HLA-A2 peptides + immunological adjuvant Montanide ISA51
11630725|NCT00365937|Experimental|Group C|the eight peptides HLA-A2 + IMP321
11630726|NCT00365937|Experimental|Group D|The eight HLA-A2 peptides + the 2 immunological adjuvants (Montanides ISA 51 and IMP321)
11630727|NCT00365924|Other|Forteo|
11630728|NCT00365885|Experimental|1|electronic mail notifications to care managers about sentinel health events
11630729|NCT00365885|Experimental|2|feedback reports with notifications to clinic managers about sentinel health events
11630730|NCT00365885|Experimental|3|letters to patients with notifications about sentinel health events
11630731|NCT00365885|No Intervention|4|electronic mail notifications to care managers about sentinel health events -- generated but withheld
11630732|NCT00365885|No Intervention|5|feedback reports with notifications to clinic managers about sentinel health events -- generated but withheld
11630733|NCT00365885|No Intervention|6|letters to patients with notifications about sentinel health events -- generated but withheld
11630734|NCT00365872|Experimental|EBRT + DC Injection + Resection|Single Arm: EBRT + DC Injection + Resection. Prior to the fourth DC Injection, participants were assigned to 3 cohorts as outlined in that intervention.
11630735|NCT00365859|Experimental|De Novo|De novo participants (those who did not participate in protocol (CN138-178 [NCT00332241] or CN138-179 [NCT00337571]) assigned to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
11630736|NCT00365859|Experimental|Rollover Placebo|Participants who completed participation in protocol (CN138-178 [NCT00332241] or CN138-179 [NCT00337571]) on placebo treatment and continued to meet all of the inclusion criteria and none of the exclusion criteria. Assigned in this study to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
11630737|NCT00365859|Experimental|Rollover Aripiprazole|Participants who completed participation in protocol CN138-178 [NCT00332241] or CN138-179 [NCT00337571] on aripiprazole treatment and continued to meet all of the inclusion criteria and none of the exclusion criteria. Assigned in this study to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
11630738|NCT00365846|Experimental|Campath 1H induction w/ Sirolimus immunosuppression|Campath 1H at day -1 and 0 of kidney transplant followed by long term CNI free immunosuppressive therapy with Sirolimus,
11630739|NCT00365833||Recipients of Kidney Transplant|Patients Transplanted with Live or Deceased Donor's Kidney. Standard of Care treatment pre- and post-transplant.
11630740|NCT00365807|Active Comparator|Brief Family Intervention (Primarily education)|Behaviorally based family group intervention using standard education and nutrition counseling. Three hours of client contact
11630741|NCT00365807|Experimental|Positively Fit|12 week (90 minute per session) behavioral group intervention for children and their parents. Children and parent attend parallel group with identical (but developmentally appropriate) information presented.
11630742|NCT00365794|Experimental|Single arm|Open label treatment without masking with each participant serving as his own control. Measurements are compared before and after treatment.
11630743|NCT00365768|Experimental|Arm I: Glutamine|Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.
11630744|NCT00365768|Placebo Comparator|Arm II: Placebo|Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.
11630745|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 1 received a 20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
11630746|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 2 received a 40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
11630747|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 3 received a 80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
11630749|NCT00365716|Experimental|Placebo (mcg) (Aluminum Adjuvant) 450|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 5 received placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
11630750|NCT00365703|Experimental|1|Orogastric feeding tube.
11630751|NCT00365703|Experimental|2|Nasogastric feeding tube.
11630752|NCT00365690|Active Comparator|1|Participants will receive individual therapy upon request
11630753|NCT00365690|Active Comparator|2|Participants will receive telephone-administered supportive-expressive group therapy
11630754|NCT00365690|Experimental|3|Participants will receive telephone-administered coping improvement group therapy
11630755|NCT00365677|Experimental|Zyoptix Tissue Saving Aspheric|The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm is used for treatment with LASIK for the correction of myopia and myopic astigmatism.
11630756|NCT00365677|Active Comparator|Zyoptix Tissue Saving|The Bausch & Lomb Zyoptix Tissue Saving algorithm is used for treatment with LASIK for the correction of myopia and myopic astigmatism.
11630757|NCT00365599|Experimental|Vorinostat and Tamoxifen|As outlined in Intervention descriptions
11630758|NCT00365547|Experimental|Patients Treated With Topotecan and Avastin in NSCLC|Weekly topotecan hydrochloride and bi-weekly Avastin (bevacizumab) in patients with non-small cell lung cancer (NSCLC) who have failed prior systemic chemotherapy.
11630759|NCT00365508|Experimental|Arm I|Participants apply a transdermal nicotine patch at 3 different time periods during weeks 3-14; a higher-dose patch is applied for weeks 3-8, a medium-dose patch is applied for weeks 9-10, and a lower-dose patch is applied for weeks 11-14.
11630760|NCT00365508|Experimental|Arm II|Participants receive one oral nicotine lozenge every 1-2 hours in weeks 3-8 (≥ 9 lozenges per day), one lozenge every 2-4 hours in weeks 9-11 (≥ 5 lozenges per day), and 1 lozenge every 4-8 hours in weeks 12-14 (≥ 3 lozenges per day).
11630761|NCT00365469|Experimental|Probiotic|Commercially available cow's milk based infant formula with Bifidobacterium longum [BL999} and Lactobacillus rhamnosus [LPR]
11630762|NCT00365469|Placebo Comparator|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
11630763|NCT00365456|Experimental|PTH (1-84)|
11630764|NCT00365456|Active Comparator|Risedronate|
11630765|NCT00365417|Experimental|Doxorubicin+Cyclophosphamide+Bevacizumab|
11630766|NCT00365391|Experimental|Treatment (monoclonal antibody, enzyme inhibitor)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory studies to determine EGFR and phosphorylated-EGFR protein levels using initial diagnostic biopsy specimens by IHC for correlation with clinical outcome. Levels of proteins through which EGFR signals, including Akt, phosphorylated-Akt, MAPK, and phosphorylated-MAPK, are also determined using initial diagnostic biopsy specimens by IHC and correlated with clinical outcome. Total and free serum vascular endothelial growth factor levels are determined at the start of study and prior to course 3 by ELISA.
11630767|NCT00365378|Experimental|1|HPV 16 L1 VLP vaccine
11630768|NCT00365378|Placebo Comparator|2|Placebo
11630769|NCT00365365|Experimental|Stratum 1 (AC->T + bevacizumab)|"HER2-negative participants administered
~doxorubicin and cyclophosphamide (AC) + bevacizumab for 4 cycles followed by
~docetaxel (T) + bevacizumab for 4 cycles followed by
~bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
11630770|NCT00365365|Experimental|Stratum 2 (TAC + bevacizumab)|"HER2-negative participants administered
~docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab for 6 cycles followed by
~bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
11630771|NCT00365365|Experimental|Stratum 3 (TCH + bevacizumab)|"All HER2-positive participants administered
~docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab for 6 cycles followed by
~bevacizumab and trastuzumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
11630772|NCT00365352|Experimental|XP13512 600MG|XP13512 600MG ONCE DAILY
11630773|NCT00365352|Experimental|XP13512 1200MG|XP13512 1200MG ONCE DAILY
11630774|NCT00365352|Placebo Comparator|Placebo|PLACEBO ONCE DAILY
11630775|NCT00365339|Active Comparator|A|
11630776|NCT00365339|Experimental|B|
11630777|NCT00365339|Experimental|C|
11630778|NCT00365339|Experimental|D|
11630779|NCT00365339|Experimental|E|
11630780|NCT00365300|Active Comparator|Pantoprazole|
11630781|NCT00365300|Placebo Comparator|Placebo|
11630782|NCT00365274|Experimental|SGN-30 + Combination Chemotherapy|"Monoclonal antibody SGN-30 monotherapy: SGN-30 12 mg/kg weekly intravenously(IV) over 2 hours once weekly for 3 weeks.
~SGN-30 and CHOP chemotherapy: Beginning 1 week after completion of monoclonal antibody SGN-30 monotherapy, SGN-30 12 mg/kg IV over 2 hours on day 1 and CHOP chemotherapy comprising cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, and vincristine IV over 15 minutes on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 6-8 courses."
11630783|NCT00365261|Active Comparator|eszopiclone|active drug
11630784|NCT00365261|Placebo Comparator|placebo|placebo
11630785|NCT00365222|Experimental|1|
11630786|NCT00365209|Experimental|2g (curcumin)|Patients receive 2 grams of oral curcumin once daily. Treatment continues for up to 30 days in the absence of unacceptable toxicity or disease progression.
11630787|NCT00365209|Experimental|4g (curcumin)|Patients receive 4 grams of oral curcumin once daily. Treatment continues for up to 30 days in the absence of unacceptable toxicity or disease progression.
11630788|NCT00365183|Experimental|Xcytrin® (motexafin gadolinium)|
11630789|NCT00365157|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 1-2 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11630790|NCT00365144|Experimental|Bevacizumab Plus Erlotinib Hydrochloride|"A treatment cycle is 21 days:
~bevacizumab 15 mg/kg as a 60-90 min infusion once every 21 days, with erlotinib hydrochloride 150 mg by mouth daily"
11630791|NCT00365105|Active Comparator|Zoledronic acid|Zoledronic acid, vitamin D and calcium supplements.
11630792|NCT00365105|Experimental|Zoledronic acid + Radiopharmaceuticals|Zoledronic acid, vitamin D and calcium supplements, plus Sr-89 or Sm-153.
11630793|NCT00365053|Experimental|Treatment (belinostat)|Patients receive PXD101 IV at 1000 mg/m2 over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11630794|NCT00365014||Blood disease patients|People with blood diseases presenting at Shanghai hospitals
11630795|NCT00365001|Experimental|1|
11630796|NCT00365001|Active Comparator|2|
11630797|NCT00364910|Experimental|Cognitive behavioral therapy (CBT)|Participants will receive cognitive behavioral therapy
11630798|NCT00364910|Active Comparator|Educational session and treatment as usual|Participants will receive an educational session and treatment as usual
11630799|NCT00364871|Experimental|1|Bupropion SR (400 mg/day) plus Naltrexone (48 mg/day)
11630800|NCT00364871|Experimental|2|Bupropion SR (400 mg/day) plus Naltrexone (16 mg/day)
11630801|NCT00364871|Active Comparator|3|Bupropion SR (400 mg/day)
11630802|NCT00364871|Active Comparator|4|Naltrexone (48 mg/day)
11630803|NCT00364871|Placebo Comparator|5|B-Placebo plus N-Placebo
11630804|NCT00364871|Placebo Comparator|6|B-Placebo plus N-Placebo
11630805|NCT00364871|Experimental|7|Bupropion SR (400 mg/day) plus Naltrexone (32 mg/day)
11630806|NCT00364858|Other|Q2 Cerezyme|Patients receiving Cerezyme one infusion every 2 weeks (Q2).
11630807|NCT00364858|Other|Q4 Cerezyme|Patients receiving Cerezyme one infusion every 4 weeks (Q4).
11630808|NCT00364845|Active Comparator|Darbepoetin alfa|Single-blind darbepoetin alfa administered by subcutaneous injection (SC) every other week until hemoglobin (Hgb) was stable (2 consecutive Hgb values between 120 and 135 g/L), then every month for up to 9 months.
11630809|NCT00364845|Placebo Comparator|Placebo|Single-blind placebo administered by subcutaneous injection (SC) every other week until week 16, then every month for up to 9 months.
11630810|NCT00364832|Experimental|Cohort A (0.4/150, 1x/ Week)|Eligible participant will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) SC using a dose conversion factor of 0.4/150 microgram (mcg)/ kilogram (kg) of the previous weekly erythropoiesis stimulating agents (ESA) dose, (equal to 50% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
11630811|NCT00364832|Experimental|Cohort B (0.4/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.4/150 mcg/kg of the previous weekly ESA dose, (equal to 50% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
11630812|NCT00364832|Experimental|Cohort C (0.4/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.4/150 mcg/kg of the previous weekly ESA dose, (equal to 50% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
11630813|NCT00364832|Experimental|Cohort D (0.8/150, 1x/ Week)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
11630814|NCT00364832|Experimental|Cohort E (0.8/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
11630815|NCT00364832|Experimental|Cohort F (0.8/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
11630816|NCT00364832|Experimental|Cohort G (1.2/150, 1x/ Week)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
11630817|NCT00364832|Experimental|Cohort H (1.2/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
11630818|NCT00364832|Experimental|Cohort I (1.2/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
11630819|NCT00364819|Experimental|1|rituximab 1000 mg IV on days 1 and 15, given over 5 - 6 hours
11630820|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 3 months to < 6 months|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
11630821|NCT00364793|Experimental|EFV+ddI+FTC in patients >=6 months to < 2 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
11630870|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 3|Eligible subjects will receive GSK159802 300 micrograms, placebo, GSK159802 1200 micrograms and salmeterol.
11630822|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 2 years to < 3 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
11630823|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 3 years to <= 6 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
11630824|NCT00364780|Experimental|1|Patients received XL647 at an intermittent dosing schedule receiving drug for 5 days followed by 9 days without drug.
11630825|NCT00364780|Experimental|2|Patients received drug at a daily dosing schedule
11630826|NCT00364767|Experimental|A|Whiskey (32 gram of alcohol/day)
11630827|NCT00364767|Placebo Comparator|B|Water (0 gram alcohol/day)
11630828|NCT00364741|Active Comparator|A|Fraction of inspired oxygen (FiO2) = 0.30
11630829|NCT00364741|Active Comparator|B|FiO2 = 0.80
11630830|NCT00364689|Experimental|lactulose given with a placebo (sugar pill)|
11630831|NCT00364689|Experimental|lactulose given with rifaximin|
11630832|NCT00364689|Active Comparator|rifaximin given alone|
11630833|NCT00364676|Experimental|1|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
11630834|NCT00364676|Experimental|2|Patients are dosed on Day 1 of a 21-day cycle.
11630835|NCT00364650|Placebo Comparator|I|Placebo
11630836|NCT00364650|Experimental|II|Probiotic supplement
11630837|NCT00364637|Active Comparator|Total intravenous anesthesia|
11630838|NCT00364637|Experimental|sevoflurane|
11630839|NCT00364611|Experimental|Docetaxel and Bevacizumab|Stratum 1: HER2 Negative participants with metastatic breast cancer treated with DB (docetaxel and bevacizumab) intravenously (IV) every 3 weeks (q3w) until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met
11630840|NCT00364611|Experimental|Docetaxel, Bevacizumab and Trastuzumab|Stratum 2: HER2 Positive participants with metastatic breast cancer treated with DBT (docetaxel, bevacizumab, and trastuzumab) IV q3w until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met
11630841|NCT00364572|Placebo Comparator|1|Two injections of epidural saline 2 weeks apart
11630842|NCT00364572|Experimental|Epidural injection of etanercept|Two injections of epidural etanercept 2 weeks apart
11630843|NCT00364559|Experimental|B|A, Active B, Historical Register
11630844|NCT00364533|Placebo Comparator|003|Placebo Fixed Dose Matching placebo for 3 days
11630845|NCT00364533|Active Comparator|002|Oxycodone HCL IR Fixed Dose 10 mg BID for 3 days
11630846|NCT00364533|Experimental|001|Tapentadol IR (CG5503) Fixed Dose 50, 75, & 100 mg BID for 3 days
11630847|NCT00364533|Other|004|Tapentadol IR (CG5503) Flexible Dose q4-6 hr Tapentadol IR 50 & 100 mg BID for 9 days
11630848|NCT00364520||Shanghai Workers|Shanghai Workers
11630849|NCT00364442|Experimental|Arm 1|investigational drug
11630850|NCT00364416||001|
11630851|NCT00364403|Experimental|1|Low glycemic load diet
11630852|NCT00364403|Active Comparator|2|Low fat diet
11630853|NCT00364377|Active Comparator|Sitagliptin|People with impaired fasting glucose randomized to treatment with sitagliptin 100 mg once daily.
11630854|NCT00364377|Placebo Comparator|Placebo|People with impaired fasting glucose randomized to treatment with placebo once daily.
11630855|NCT00364351|Active Comparator|1|Erlotinib
11630856|NCT00364351|Experimental|2|Vandetanib
11630857|NCT00364325||001|
11630858|NCT00364286|Experimental|Dasatinib|Dasatinib 50mg Orally twice daily.
11630859|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 1|Eligible subjects will receive placebo, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms.
11630860|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, placebo, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms.
11630861|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, placebo, GSK159802 900 micrograms and GSK159802 1200 micrograms.
11630862|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, placebo and GSK159802 1200 micrograms.
11630863|NCT00364273|Experimental|Subjects receiving treatment sequence 5 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and placebo.
11630864|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 2|Eligible subjects will receive placebo, salmeterol, GSK159802 low dose (LD) and GSK159802 maximum tolerated dose (MTD).
11630865|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 2|Eligible subjects will receive salmeterol, GSK159802 MTD, placebo and GSK159802 LD.
11630866|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 2|Eligible subjects will receive GSK159802 LD, placebo, GSK159802 MTD and salmeterol.
11630867|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 2|Eligible subjects will receive GSK159802 MTD, GSK159802 LD, salmeterol and placebo.
11630868|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 3|Eligible subjects will receive placebo, salmeterol, GSK159802 300 micrograms and GSK159802 1200 micrograms.
11630869|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 3|Eligible subjects will receive salmeterol, GSK159802 1200 micrograms, placebo and GSK159802 300 micrograms.
11631018|NCT00362440|Experimental|Leptin|Leptin replacement therapy
11631076|NCT00361894|Active Comparator|Arm 2|
11630871|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 3|Eligible subjects will receive GSK159802 1200 micrograms, GSK159802 300 micrograms, salmeterol and placebo.
11630872|NCT00364273|Experimental|Subjects receiving treatment sequence 5 : Cohort 3|Eligible subjects will receive GSK159802 1200 micrograms, salmeterol, GSK159802 300 micrograms and placebo.
11630873|NCT00364182|Experimental|A|
11630874|NCT00364182|Experimental|B|
11630875|NCT00364156|Experimental|Extended Patch Treatment|Participants in this treatment arm receive 24 weeks of 21mg nicotine patch in addition to 8 smoking cessation counseling sessions.
11630876|NCT00364156|Active Comparator|Standard Patch Treatment|Participants receive 8 weeks of 21mg nicotine patch followed by 16 weeks of placebo patch.
11630877|NCT00364130|Active Comparator|Active Low Magnitude Mechanical Stimulus|Active Low Magnitude Mechanical Stimulus
11630878|NCT00364130|Placebo Comparator|Inactive Low Magnitude mechanical Stimulus|Inactive, or placebo low magnitude mechanical stimulus
11630879|NCT00364104|Experimental|A|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
11630880|NCT00364104|Experimental|B|The 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
11630881|NCT00364104|Experimental|C|6-weeks of iron supplementation only plus 10-days of matching placebo of Hp infection eradication therapy
11630882|NCT00364104|Placebo Comparator|D|
11630883|NCT00364013|Experimental|FOLFOX + Panitumumab|Participants received panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.
11630884|NCT00364013|Active Comparator|FOLFOX|Participants received FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
11630885|NCT00364000|Active Comparator|I|Calcium acetate 670 mg tablets
11630886|NCT00364000|Experimental|II|label sevelamer (RenagelR) 800 mg tablets
11630887|NCT00363987|Experimental|1|
11630888|NCT00363987|Other|2|
11630889|NCT00363961|Experimental|1|resistance exercise
11630890|NCT00363961|Sham Comparator|2|flexibility exercises
11630891|NCT00363948|Placebo Comparator|P|
11630892|NCT00363948|Experimental|E|
11630893|NCT00363922|Experimental|1|Rehabilitation in institution
11630894|NCT00363922|Active Comparator|2|Rehabilitation at home
11630895|NCT00363909|Experimental|low-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in weeks 2-7.
~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
11630896|NCT00363909|Experimental|medium-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in week 2 and 2 tablets once daily in weeks 3-7.
~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
11630897|NCT00363909|Experimental|high-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in week 2, 2 tablets once daily in week 3, and 3 tablets once daily in weeks 4-7.
~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
11630898|NCT00363909|Placebo Comparator|placebo|"Patients receive 1-3 placebo tablets once daily in weeks 2-7.
~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
11630899|NCT00363896|Experimental|Aclidinium 200 μg once-daily|Aclidinium bromide 200 μg once-daily by inhalation
11630900|NCT00363896|Placebo Comparator|Placebo|Placebo once-daily via inhalation
11630901|NCT00363883|Experimental|Treatment (vorinostat)|Patients receive oral vorinostat (SAHA) twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11630902|NCT00363844|Experimental|E|
11630903|NCT00363831|Experimental|1|Oxaliplatin
11630904|NCT00363805|Experimental|Green Tea|Patients receive green tea beverage and placebo capsules for 6 months.
11630905|NCT00363805|Experimental|Polyphenon E|Patients receive placebo beverage and Polyphenon E capsules daily for 6 months.
11630906|NCT00363805|Placebo Comparator|Placebo|Patients receive placebo beverage and placebo capsules daily for 6 months.
11630907|NCT00363779|Experimental|LGL Patients administered cyclosporine|Large Granular Lymphocyte Leukemia (LGL) is a low grade non-Hodgkins lymphoma characterized by tissue invasion of the marrow, spleen, and liver. Cyclosporine 5-10 mg/kg/day was administered as an oral preparation given every 12 hours. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml.
11630908|NCT00363766|Experimental|LY573636|
11630909|NCT00363714|Experimental|1|Single intravitreal injection
11630910|NCT00363714|Experimental|2|Single intravitreal injection
11630911|NCT00363714|Experimental|3|Single intravitreal injection
11630912|NCT00363714|Experimental|4|Single intravitreal injection
11630913|NCT00363714|Experimental|5|Single intravitreal injection
11630914|NCT00363714|Experimental|6|Single intravitreal injection
11630915|NCT00363675|Experimental|All study participants|Children with hand burns
11630916|NCT00363649|Experimental|Arm A|Patients will receive injections of interferon alfa and sargramostim once a day for 6 months. Some patients may receive treatment for up to 1 year. After 1 year, some patients may receive treatment as in arm II.
11630917|NCT00363649|Experimental|Arm B|Patients will receive an injection of GM-K562 cell vaccine every 3 weeks for at least 6 months. Some patients may receive treatment for up to 1 year. After 1 year, some patients may receive treatment as in arm I. NOTE: Study Arm B is not available to newly accrued and enrolled subjects based on the interim analysis directing all new subjects to the combination of Interferon + sargramostim (Arm A).
11630918|NCT00363636|Experimental|1|
11630919|NCT00363636|Active Comparator|2|
11630920|NCT00363597|Experimental|A|
11630921|NCT00363545|Experimental|Liquid Rotarix Group|Healthy male and female infants, between and including 6-12 weeks of age, who received two oral doses of the liquid formulation of the Rotarix™ vaccine, according to a 0, 2 month schedule.
11631019|NCT00362440|Placebo Comparator|Pioglitazone or metformin|Diabetes treatment therapy
11630922|NCT00363545|Experimental|Lyophilized Rotarix Group|Healthy male and female infants, between and including 6-12 weeks of age, who received two oral doses of the lyophilized formulation of the Rotarix™ vaccine, according to a 0, 2 month schedule.
11630923|NCT00363519|Placebo Comparator|P|
11630924|NCT00363519|Experimental|E|
11630925|NCT00363480|Experimental|SFC 50/250 mcg|Participants received the combination product, fluticasone 250 microgram (mcg) plus salmeterol 50 mcg (SFC 50/250 mcg) for 12 weeks. Study treatment was received using DISKUS™ powder inhalers, one dose in morning and evening. Study medication was dispensed at visits 3, 4, and 5 for 30 days each. The participants were provided with salbutamol rescue medication if they developed acute asthmatic symptoms. This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol. Use of rescue medications was recorded in the participant's asthma diaries. Stable dosages of other concomitant medications were allowed if they had no impact on the outcome criteria.
11630926|NCT00363467|Other|Autologous Hematopoietic Progenitor Cell Transplantation|G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion
11630927|NCT00363454|Experimental|Dose Escalation|Phase I: Triciribine Phosphate Monohydrate
11630928|NCT00363428|Placebo Comparator|Control|Receive standard care and educational material on exercise and lifestyle choices of well-being
11630929|NCT00363428|Experimental|Lifestyle intervention|
11630930|NCT00363415|Experimental|A|
11630931|NCT00363415|Active Comparator|B|
11630932|NCT00363376|Experimental|Sugar pill|"olanzapine and placebo (sugar pill)"
11630933|NCT00363376|Experimental|Zonisamide|olanzapine and zonisamide (active drug)
11630934|NCT00363363|Experimental|1|
11630935|NCT00363363|Active Comparator|2|
11630936|NCT00363311|Active Comparator|Dutasteride|Dutasteride 0.5mg
11630937|NCT00363311|Placebo Comparator|Placebo|Matching placebo
11630938|NCT00363298|Experimental|d-amphetamine|dextro-amphetamine capsules, 15 mg per capsule, in Bottles A and B, dose: one from Bottle A each morning and 1 from Bottle B each morning
11630939|NCT00363298|Sham Comparator|Sham comparison|caffeine in capsules identical to those containing d-amphetamine, with 200 mg of caffeine in Bottle A capsules, and 100 mg of caffeine in Bottle B capsules, dose was 1 capsule from Bottle A and 1 capsule from Bottle B each morning
11630940|NCT00363272|Experimental|Arm I|Patients receive ispinesib IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
11630941|NCT00363246||Group 1|Older veterans who use a wheelchair for their primary means of mobility.
11630942|NCT00363194|Experimental|Lead-In cohort|In Part 1 of Lead-In cohort, subjects will be dosed with a single dose of pazopanib with a high-fat breakfast to establish safety and tolerability.
11630943|NCT00363168|Experimental|A|0.3 mg/0.05 ml dose of ranibizumab
11630944|NCT00363168|Experimental|B|0.5 mg/0.05 ml dose of ranibizumab
11630945|NCT00363142|Active Comparator|FPV/r200|Fosamprenavir/ritonavir (either 700/100mg BID or 1400/200mg QD)
11630946|NCT00363142|Experimental|FPV/r100|Fosamprenavir/ritonavir 1400/100mg QD
11630947|NCT00363129|Experimental|Arm I|Patients receive oral vitamin E twice daily beginning within 4 days of the start of chemotherapy course 1 and continuing until 1 month after completion of chemotherapy.
11630948|NCT00363129|Placebo Comparator|Arm II|Patients receive oral placebo twice daily beginning within 4 days of the start of chemotherapy course 1 and continuing until 1 month after completion of chemotherapy.
11630949|NCT00363116|Active Comparator|5 Dose Daclizbumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
11630950|NCT00363116|Active Comparator|2 Dose Daclizaumab|daclizumab 2 mg/kg/dose every 14 days for 2 doses
11630951|NCT00363116|Active Comparator|Control|no antibody induction
11630952|NCT00363077|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11630953|NCT00363077|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11630954|NCT00363051|Experimental|Everolimus 10 mg|"Stratum 1 patients who were not receiving regular Octreotide Depot therapy. These patients were to receive everolimus monotherapy at 10 mg/day.
~Stratum 2 patients who were to receive everolimus 10 mg/day in addition to continuing their entry dose of Octreotide Depot therapy.
~Patients were instructed to take two 5 mg tablets of everolimus orally with a glass of water, once daily (preferably in the morning). Dosing was strongly recommended to occur at the same time every day."
11630955|NCT00363038|Experimental|Bruising|Bruises at three time points: immediate after bruise creating, and at 1 and 2 weeks.
11630956|NCT00362986|Experimental|sunscreen|"Patients apply sunscreen generously to the entire body twice daily for 4 weeks.
~Patients complete self-reported questionnaires regarding their rash status at baseline and then weekly for 8 weeks.
~After completion of study treatment, patients are followed for 8 weeks."
11630957|NCT00362986|Placebo Comparator|placebo|"Patients apply placebo generously to the entire body twice daily for 4 weeks.
~Patients complete self-reported questionnaires regarding their rash status at baseline and then weekly for 8 weeks.
~After completion of study treatment, patients are followed for 8 weeks."
11630958|NCT00362973||Hormone Receptor Positive Breast Cancer|Patients with hormone receptor positive primary, recurrent or metastatic breast cancer with a treatment plan that involves (neoadjuvant) administration of aromatase inhibitor and ovarian suppression (if premenopausal).
11630959|NCT00362973||HER-2/neu Positive Breast Cancer|Patients with HER-2/neu positive primary, recurrent or metastatic breast cancer with a treatment plan that involves (neoadjuvant) administration of trastuzumab.
11630960|NCT00362947|Placebo Comparator|A|A - Parnaparin 8.500 UI aXa od (therapeutic doses) for 10 days followed by placebo for 20 days
11630961|NCT00362947|Active Comparator|B|B - Parnaparin 8.500 UI aXa od for 10 days followed by 6.400 UI aXa once daily (intermediate therapeutic doses) for 20 days
11630962|NCT00362947|Active Comparator|C|C - Parnaparin 4.250 UI aXa od (prophylactic doses) for 30 days
11630963|NCT00362934|Experimental|1|
11630964|NCT00362934|Active Comparator|2|
11630965|NCT00362921|Experimental|Gliadel wafers in combination with O6-benzylguanine|
11631020|NCT00362427|Experimental|Group A|
11630966|NCT00362908|Active Comparator|Group 1|"Subjects consume study diets in the following order:
~Diet 1 (20% fat diet) for 1 month with all food provided,
~American Heart Association Step I Diet for 1 month at home, and
~Diet 2 (40% fat diet) for 1 month with all food provided and then continue to follow this diet for an additional 4 months at home."
11630967|NCT00362908|Active Comparator|Group 2|"Subjects consume study diets in the following order:
~Diet 2 (40% fat diet) for 1 month with all food provided,
~American Heart Association Step I Diet for 1 month at home, and
~Diet 1 (20% fat diet) for 1 month with all food provided and then continue to follow this diet for an additional 4 months at home."
11630968|NCT00362895|Experimental|Tobradex AF|
11630969|NCT00362895|Active Comparator|TOBRADEX|
11630970|NCT00362882|Experimental|Arm 1|Patients receive docetaxel IV over 60 minutes on day 1 and bortezomib IV over 3-5 seconds on days 1 and 8.
11630971|NCT00362882|Experimental|Arm 2|Patients receive docetaxel as in arm I and bortezomib IV over 3-5 seconds on days 2 and 8.
11630972|NCT00362869|Experimental|1|Dosage 1X10^9 given orally in a sodium bicarbonate solution
11630973|NCT00362869|Experimental|2|Dosage 5X10^9 given orally in a sodium bicarbonate solution
11630974|NCT00362869|Placebo Comparator|5|Sodium bicarbonate placebo solution
11630975|NCT00362869|Experimental|4|Dosage 5X10^10 given orally in a sodium bicarbonate solution
11630976|NCT00362869|Experimental|3|Dosage 1X10^10 given orally in a sodium bicarbonate solution
11630977|NCT00362856|Placebo Comparator|Placebo + Gluten|placebo TID + gluten 800 mg TID administered orally in capsules
11630978|NCT00362856|Placebo Comparator|Placebo + Gluten placebo|placebo TID + gluten placebo TID administered orally in capsules
11630979|NCT00362856|Other|Larazotide acetate 8 mg + Gluten placebo|Safety Control Arm. Larazotide acetate 8 mg TID + gluten placebo TID administered orally in capsules
11630980|NCT00362856|Active Comparator|Larazotide acetate 0.25 mg + Gluten|Larazotide acetate 0.25 mg TID + gluten 800 mg TID administered orally in capsules
11630981|NCT00362856|Active Comparator|Larazotide acetate 1 mg + Gluten|Larazotide acetate 1 mg TID + gluten 800 mg TID administered orally in capsules
11630982|NCT00362856|Active Comparator|Larazotide acetate 4 mg + Gluten|Larazotide acetate 4 mg TID + gluten 800 mg TID administered orally in capsules
11630983|NCT00362856|Active Comparator|Larazotide acetate 8 mg + Gluten|Larazotide acetate 8 mg TID + gluten 800 mg TID administered orally in capsules
11630984|NCT00362843||healthy volunteers|healthy volunteers
11630985|NCT00362843||patients|Patients with Fragile X Syndrome
11630986|NCT00362830|Experimental|1|
11630987|NCT00362817|Experimental|Temozolomide & Intra-Arterial (IA) carboplatin|Patients will be administered Temozolomide orally once a day for 5 consecutive days and and will receive Intra Arterial Carboplatin
11630988|NCT00362778|Sham Comparator|Serum saline|
11630989|NCT00362765|Experimental|1|
11630990|NCT00362765|Active Comparator|2|
11630991|NCT00362765|Active Comparator|3|
11630992|NCT00362765|Placebo Comparator|4|
11630993|NCT00362752|Placebo Comparator|Placebo|
11630994|NCT00362752|Experimental|Norfloxacin 400 mg bid|
11630995|NCT00362739||1: Lung Disease|Individuals with at least one of the following: (1)symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) patients with diseases of organs with known association with lung disease; (7) individuals suspected of history of lung diseased based on history and/or physical examination
11630996|NCT00362739||2: Normal Controls|Individuals without a history of lung disease
11630997|NCT00362726|Active Comparator|A|
11630998|NCT00362726|Active Comparator|B|
11630999|NCT00362726|Active Comparator|C|
11631000|NCT00362726|Active Comparator|D|
11631001|NCT00362726|Active Comparator|E|
11631002|NCT00362713|Experimental|A|3 mg/kg or 10 mg/kg
11631003|NCT00362687|Experimental|1|Truvada 1 tablet once a day.
11631004|NCT00362687|Experimental|2|Emtricitabine 1 capsule once a day
11631005|NCT00362648|Experimental|1|RotaTeq™
11631006|NCT00362648|Placebo Comparator|2|Placebo
11631007|NCT00362609|Active Comparator|Low dose|
11631008|NCT00362609|Active Comparator|High dose|
11631009|NCT00362518|Placebo Comparator|1|Study Arm A - Control: no vitamins (placebo only).
11631010|NCT00362518|Active Comparator|2|Study Arm B - Low Dose: Vitamin C 250 mg, Vitamin E 200 IU
11631011|NCT00362518|Active Comparator|3|Study Arm C - Medium Dose: Vitamin C 500 mg, Vitamin E 400 IU
11631012|NCT00362518|Active Comparator|4|Study Arm D - High Dose: Vitamin C 1000 mg, Vitamin E 800 IU.
11631013|NCT00362479|Experimental|1|
11631014|NCT00362466|Active Comparator|A|50-180 mg once daily (QD)
11631015|NCT00362466|Active Comparator|B|200-800 mg QD
11631016|NCT00362453|Experimental|Tai Chi|The Tai Chi program was based on the classical Yang Style. Patients participated in 60-minute Tai Chi sessions twice a week for 12 weeks. Each session included warm up and review of Tai Chi principles and techniques; Tai Chi exercises; breathing techniques; and various relaxation methods. The classes were taught by a Tai Chi master with over 20 years' experience conducting Tai Chi Mind-Body exercise programs. Several modifications were developed to achieve the physical and mental goals of the study for knee OA, accommodate knee OA symptoms and limit dropouts. Subjects were instructed to practice Tai Chi at least 20 minutes a day at home and encouraged to maintain their usual physical activities, but not to participate in additional new strength training other than their Tai Chi exercises.
11631017|NCT00362453|Placebo Comparator|Wellness Education and Stretching|The wellness education and stretching program provided an active control for the attention being paid to the Tai Chi group. The control group attended two 60-minute class sessions per week for 12 weeks. Each session started with 40 minutes of didactic lessons on OA knowledge, nutrition, and physical and mental health education. The final 20 minutes consisted of stretching exercises involving the upper body, trunk and lower body, each stretch being held for 10 to 15 seconds. Participants were also instructed to practice at least 20 minutes of stretching exercises per day at home. They were encouraged to maintain their usual physical activities, but not to participate in additional strength and mind-body exercise programs other than their stretching exercise.
11631023|NCT00362414|Experimental|Dual Growth Factor|All patients received erythropoietin and beta-hCG. This was the only treatment arm in the study, i.e., all enrollees received active therapy.
11631024|NCT00362375|Experimental|Healthy Love Workshop|Single-session, small-group HIV prevention intervention
11631025|NCT00362375|Active Comparator|HIV101|Single-session, small-group intervention providing facts regarding HIV/AIDS
11631026|NCT00362349|Experimental|1|IVIg
11631027|NCT00362336|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|
11631028|NCT00362336|Experimental|Group 2: CombAct-HIB™ + OPV|
11631029|NCT00362336|Active Comparator|Group 3: DTaP-IPV-Hep B-PRP-T (ENGERIX B™ at birth)|
11631030|NCT00362323|Experimental|1|
11631031|NCT00362323|Active Comparator|2|
11631032|NCT00362297|Active Comparator|Standard dose|
11631033|NCT00362297|Experimental|High-dose|
11631034|NCT00362284|Experimental|NYUCI-AC group|Adult children in this arm received the NYUCI-AC intervention, which consisted of 6 individual and family counseling sessions, the offering of an adult child specific support group, and the provision of ad hoc, or ongoing, consultation throughout the duration of participation.
11631035|NCT00362284|No Intervention|Usual care control|Adult children randomly assigned to the usual care control did not receive the NYUCI-AC intervention. If they were in crisis or required support, the NYUCI-AC counselors provided information and referral on an as-needed basis.
11631036|NCT00362271|Other|1|
11631037|NCT00362232|Experimental|Rivaroxaban 10 mg Once Daily (OD) ((Xarelto, BAY59-7939))|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening plus placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
11631038|NCT00362232|Active Comparator|Enoxaparin 30 mg twice a day (bid)|Placebo tablet of rivaroxaban administered once daily in the evening plus syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
11631039|NCT00362219|Placebo Comparator|Placebo|Gel with no active ingredient
11631040|NCT00362219|Active Comparator|Morphine .25 mg|Gel with 0.25 mg morphine per 100cm2 square of wound
11631041|NCT00362219|Active Comparator|Morphine - .75 mg.|Gel with 0.75 mg morphine per 100cm2 square of wound.
11631042|NCT00362219|Active Comparator|Morphine 1.25 mg.|Gel with 1.25 mg morphine per 100cm2 square of wound.
11631043|NCT00362206|Experimental|1|
11631044|NCT00362206|Experimental|2|
11631045|NCT00362206|Active Comparator|3|
11631046|NCT00362180|Experimental|Cohort A: mipomersen|Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
11631047|NCT00362180|Placebo Comparator|Cohort A: placebo|Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
11631048|NCT00362180|Experimental|Cohort D: mipomersen|Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
11631049|NCT00362180|Placebo Comparator|Cohort D: placebo|Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
11631050|NCT00362180|Experimental|Cohort E: mipomersen|Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.
11631051|NCT00362180|Placebo Comparator|Cohort E: placebo|Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.
11631052|NCT00362180|No Intervention|Cohort F: no intervention|A reference group of participants with familial hypobetalipoproteinemia (FBHL) who did not receive a study intervention. Data gathered for 15 weeks.
11631053|NCT00362180|Experimental|Cohort G: mipomersen|Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.
11631054|NCT00362180|Placebo Comparator|Cohort G: placebo followed by mipomersen|Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.
11631055|NCT00362115|Experimental|Azilsartan Medoxomil 5 mg QD|
11631056|NCT00362115|Experimental|Azilsartan Medoxomil 10 mg QD|
11631057|NCT00362115|Experimental|Azilsartan Medoxomil 20 mg QD|
11631058|NCT00362115|Experimental|Azilsartan Medoxomil 40 mg QD|
11631059|NCT00362115|Experimental|Azilsartan Medoxomil 80 mg QD|
11631060|NCT00362115|Active Comparator|Olmesartan 20 mg QD|
11631061|NCT00362115|Placebo Comparator|Placebo QD|
11631062|NCT00362089|Active Comparator|Marinol|Intervention group with Marinol D40 fish oil capsules
11631063|NCT00362089|No Intervention|Nutrition counseling|Control group
11631064|NCT00362063|Experimental|growth hormone|children with proven growth hormone deficiency
11631065|NCT00362063|No Intervention|healthy controls|No growth hormone is given
11631066|NCT00361985|Experimental|1|Nexium group
11631067|NCT00361972|Active Comparator|Lansoprazole therapy|Lansoprazole 30 mg orally twice daily
11631068|NCT00361972|Placebo Comparator|Placebo|placebo orally twice daily
11631069|NCT00361946||lean subjects|BMI <85th for age, normal glucose tolerance
11631070|NCT00361946||obese subjects|BMI> 95th for age normal glucose tolerance
11631071|NCT00361946||Type diabetes|BMI > 85th for age , history of Type 2 diabetes as per ADA criteria
11631072|NCT00361933|Experimental|1|
11631073|NCT00361907|Active Comparator|2|Diabetic patients who meet inclusion criteria will be enrolled to start Pulsatile Intravenous Insulin Therapy on a weekly basis. Baseline testing will be performed and measured against continued testing every twelve months.
11631074|NCT00361907|Placebo Comparator|1|Circulating blood markers will be performed on diabetic control patients at baseline and every twelve months to compare and measure against patients treated with Pulsatile intravenous insulin therapy
11631075|NCT00361894|Experimental|Arm 1|
11631078|NCT00361881|Active Comparator|2|Acyclovir in ME-609 vehicle
11631079|NCT00361881|Placebo Comparator|3|Vehicle
11631080|NCT00361868|Experimental|1|
11631081|NCT00361868|Active Comparator|2|
11631082|NCT00361829||Ecologic/Community|Married women, infants, caregivers, Japanese-American, Argentine-American
11631083|NCT00361803|Experimental|All treated subjects|All subjects received Topotecan, administered intravenously over 30 minutes at 4 milligrams per meter^2 weekly for 3 weeks every 28 days.
11631084|NCT00361790|Other|1|
11631085|NCT00361777||Possible Cushing's|Patients with possible cushion's syndrome
11631086|NCT00361712|Experimental|Preemptive epidural analgesia|Parturients will receive epidural analgesia immediately upon arrival in the labor ward before onset of painful contractions (VAS<3).
11631087|NCT00361712|Active Comparator|Standard of care|Parturients with cervical dilatation and painful labor (VAS >5) will receive epidural analgesia as soon as possible
11631088|NCT00361699|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
11631089|NCT00361699|No Intervention|No intervention|Patient has no intervention.
11631090|NCT00361660|Experimental|1|Therapy is provided every other day 3 days per week (Monday, Wednesday, Friday).
11631091|NCT00361660|Active Comparator|2|The same therapy is provided daily Monday through Friday
11631092|NCT00361634|Experimental|Etanercept|Etanercept 50 mg administered by subcutaneous injection once weekly for up to 12 weeks.
11631093|NCT00361595|Experimental|open label|5 mg zoledronic acid in a single 15 minute IV
11631094|NCT00361569|Experimental|1|
11631095|NCT00361569|Experimental|2|
11631096|NCT00361569|Placebo Comparator|3|
11631097|NCT00361569|Placebo Comparator|4|
11631098|NCT00361556|Active Comparator|1|The Back Book
11631099|NCT00361556|Active Comparator|2|The Back Guide
11631100|NCT00361556|Active Comparator|3|General health book
11631101|NCT00361543|Active Comparator|1|Raloxifene Hydrochloride
11631102|NCT00361543|Placebo Comparator|2|placebo tablet
11631103|NCT00361530|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
11631104|NCT00361530|No Intervention|No intervention|Patient has no intervention.
11631105|NCT00361517|Experimental|GM test|Twice weekly blood draws from the patients in this arm for serial GM monitoring. They will be given standard antifungal prophylaxis but no antifungal therapy unless two consecutive GM readings are positive.
11631106|NCT00361517|No Intervention|no GM monitoring|in this arm the patients will not have any GM monitoring and they will be given standard antifungal prophylaxis and treatment according to the published guidelines.
11631107|NCT00361504|Experimental|Tapentadol (CG5503)|Tapentadol (CG5503) extended release (ER) 100 to 250 mg twice daily (BID) for up to one year.
11631108|NCT00361504|Active Comparator|Oxycodone|Oxycodone controlled release (CR) 20 to 50 mg twice daily (BID) for up to one year.
11631109|NCT00361478|Experimental|1|"Mother and Baby Program comprising exercise and education."
11631110|NCT00361478|Active Comparator|2|Education only
11631111|NCT00361465||Parkinsonian patients presenting of the dystonia|15 Parkinsonian patients presenting of the dystonia of ONE or OFF at the time of the phases of driving fluctuations. These patients must present a dystonia of the upper limb, mainly localised than the level of the segment brachial or in distality.
11631112|NCT00361465||patients carrying a primary education dystonia affecting|15 patients carrying a primary education dystonia affecting at least one of the two upper limbs, without excessive involuntary movements
11631113|NCT00361465||patients carrying a secondary dystonia|15 patients carrying a secondary dystonia (consecutive with a perinatal suffering) affecting at least one of the two upper limbs, without excessive involuntary movements
11631114|NCT00361465||pilot subjects|30 healthy pilot subjects paired in sex, age (± 5 years), dominant laterality and level of schooling (15 subjects paired with the Parkinsonian patients and 15 subjects paired with the patients dystonic
11631115|NCT00361439|Active Comparator|Mometasone|Mometasone intranasal steroid therapy daily for 2 weeks
11631116|NCT00361439|Placebo Comparator|Placebo|2 puffs of placebo spray in each nostril once daily
11631117|NCT00361413|Experimental|1|Alefacept
11631118|NCT00361413|Placebo Comparator|2|
11631119|NCT00361374|Experimental|EPA|Eicosapentaenoic acid (EPA) Omega-3, 1g/day
11631120|NCT00361374|Experimental|DHA|Docosahexaenoic acid (DHA) Omega-3, 1g/day
11631121|NCT00361374|Placebo Comparator|Placebo|Placebo capsule (980mg soybean oil)
11631122|NCT00361348|Active Comparator|Palifermin|A single 60µg/kg IV bolus dose of palifermin on Day 1 of the treatment period
11631123|NCT00361348|Experimental|Palifermin + Heparin|A single 60µg/kg IV bolus dose of palifermin on Day 1 of the treatment period + unfractionated heparin for a 2 to 3 day heparin titation/maintenance period and continuing through a 3 day treatment period
11631124|NCT00361348|Active Comparator|Heparin|unfractionated heparin for a 2 to 3 day heparin titation/maintenance period and continuing through a 3 day treatment period
11631125|NCT00361335|Experimental|Group I: 2mg/kg Golimumab + MTX|Intravenous (IV) infusions of 2mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (an additional 2mg/kg IV infusion of golimumab) and dose regimen adjustment (switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of subcutaneous (SC) injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive methotrexate (MTX) at the same dose as that before study entry
11631217|NCT00360243|Experimental|flibanserin 25 mg b.i.d|25 mg twice daily for 24 weeks
11631218|NCT00360243|Experimental|flibanserin 50mg qhs|50 mg taken once daily at bedtime for 24 weeks
11631219|NCT00360243|Experimental|flibanserin 50mg b.i.d.|50 mg twice daily for 24 weeks
11631220|NCT00360243|Placebo Comparator|placebo|twice daily for 24 weeks
11631442|NCT00357682|Experimental|Arm D|80mg Esomeprazole + 300mg Aspirin
11631126|NCT00361335|Experimental|Group II: 2mg/kg Golimumab only|IV infusions of 2mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX or switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules
11631127|NCT00361335|Experimental|Group III: 4mg/kg Golimumab + MTX|IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter for a minimum of 48 weeks followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive MTX at the same dose as that before study entry.
11631128|NCT00361335|Experimental|Group IV: 4mg/kg Golimumab only|IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules.
11631129|NCT00361335|Placebo Comparator|Group V: IV Placebo + MTX|IV infusions of placebo at Week 0 and Week 12 with early escape (switch to 4mg/kg IV golimumab) and dose regimen adjustment (switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (placebo plus golimumab) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition patients will receive MTX at the same dose as that before study entry. Participants still receiving placebo injections at Week 48 are not eligible to enter the Extension Study.
11631130|NCT00361309|Experimental|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks). Patients will be continued on treatment until disease progression, limiting toxicity, or patient withdrawal of consent.
11631131|NCT00361296|Experimental|K562/GM-CSF cell vaccine|Vaccinations of 1x10^8 cells are given to participants at weeks 0, 3, 6, 9, and 17.
11631132|NCT00361283|Other|atorvastatin|80mg of atorvastatin given once daily for 16 weeks
11631133|NCT00361270|Experimental|Arm 1 Hyp-8|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour hypnosis with hypnotherapist without audio recordings
11631134|NCT00361270|Experimental|Arm 2 Hyp-8 w recordings|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour hypnosis with hypnotherapist with audio recordings
11631135|NCT00361270|Experimental|Arm 3 Hyp-2 w recordings|Single-site study at MEDVA-Houston Behavioral: 2 weeks 1-hour hypnosis with hypnotherapist with audio recordings
11631136|NCT00361270|Active Comparator|Arm 4 BIO|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour EMG biofeedback without audio recordings
11631137|NCT00361257|Experimental|Arm 1: Minocycline|100 mg orally every 12 hours
11631138|NCT00361257|Placebo Comparator|Arm 2: Matching placebo|orally every 12 hours
11631139|NCT00361231|Experimental|Bevacizumab, Gemcitabine, Oxaliplatin|"The chemotherapy drugs are given twice every 28 days. This 28 day period is called a cycle of study treatment.
~Bevacizumab will be administered by IV over 90 minutes on day 1 and day 15. Gemcitabine will be administered by IV over 1 hour and 40 minutes on days 1 and 15 of each cycle. Oxaliplatin will be administered by IV for 2 hours on days 1 and 15 of each cycle.
~Participants will continue to receive cycles of study treatment as long as their disease does not progress and they are not experiencing any serious side effects."
11631140|NCT00361218|Other|open-label selective serotonin reuptake inhibitor (SSRI)|citalopram or escitalopram
11631141|NCT00361153|Active Comparator|1|Colesevelam hydrochloride
11631142|NCT00361153|Placebo Comparator|2|placebo
11631143|NCT00361140|Experimental|AUC 6000|"Busulfan AUC Level 1: 6000 +/- 600 uM-min
~Fludarabine 40mg/m2 IV over 1 hour"
11631144|NCT00361140|Experimental|AUC 7500|"Busulfan AUC Level 2: 7500 +/- 750 uM-min
~Fludarabine 40mg/m2 IV over 1 hour"
11631145|NCT00361140|Experimental|AUC 9000|"AUC Level 3: 9000 +/- 900 uM-min
~Fludarabine 40mg/m2 IV over 1 hour"
11631146|NCT00361127|Experimental|CMPD patients|Patients with CMPD with evaluation of ACE I/D polymorphism
11631147|NCT00361114|Active Comparator|A|SP in symptomatic children aged 6-59 months
11631148|NCT00361114|Experimental|B|SP to asymptomatic infected children aged 2-10 months
11631149|NCT00361114|Experimental|C|Chlorproguanil/dapsone in symptomatic 6-59 month old children
11631150|NCT00361088|Experimental|Phase I|
11631151|NCT00361088|Experimental|Phase II|
11631152|NCT00361036|Experimental|1|BeadBlock treatment arm
11631153|NCT00361036|Active Comparator|2|Embospheres control arm
11631154|NCT00360997|Other|Behavioural|Conventional UK physical therapy (Con UK PT)
11631155|NCT00360997|Experimental|Con UK PT + MTS|Con UK PT + 30/60 or 120 minutes MTS
11631156|NCT00360971|Experimental|Palifermin|Concurrent radiation therapy, cisplatin, and palifermin followed by neck dissection for indicated patients.
11631157|NCT00360971|Placebo Comparator|Placebo|Concurrent radiation therapy, cisplatin, and placebo followed by neck dissection for indicated patients.
11631158|NCT00360958|Experimental|Ultrafiltration|Ultrafiltration treatment
11631159|NCT00360958|Active Comparator|Usual treatment|Usual HF treatment
11631160|NCT00360919|Experimental|A|Cheese
11631161|NCT00360919|Placebo Comparator|B|Fruits and vegetables
11631162|NCT00360867|Other|1|Single Arm
11631163|NCT00360841|Experimental|A|The subjects in arms A and B will receive auricular acupuncture. The subjects in arms A will receive auricular acupuncture (at 2nd and 4th chemotherapy courses) as well as the sham auricular acupuncture (at the 3rd chemotherapy course).
11631164|NCT00360841|Sham Comparator|B|The subjects in arms A and B will receive auricular acupuncture. The subjects in arm B will receive the sham auricular acupuncture (at the 2nd and 4th chemotherapy courses) and auricular acupuncture (at the 3rd chemotherapy course).
11631165|NCT00360841|No Intervention|C|No treatment received.
11631443|NCT00357669|Placebo Comparator|Placebo|
11631166|NCT00360828|Experimental|Irinotecan Treatment|Participants were given irinotecan at a fixed dose: [350 mg/m2 in patients either not on anti-seizure drugs or on anti-seizure drugs which do not interfere with the metabolism of Irinotecan; 600 mg/m2 in patients on anti-seizure drugs which interfere with the metabolism of Irinotecan] once every 21 days. Depending on how many side effects were experienced with the first cycle [first 21 days], the dose of both drugs may remain the same or may be decreased to make the treatment better tolerated with less side effects. The irinotecan was given to through a vein over 90 minutes.
11631167|NCT00360802|Active Comparator|CBT|Cognitive Behavioral Treatment
11631168|NCT00360802|Active Comparator|MBSR|Mindfulness Based Stress Reduction
11631169|NCT00360776|Experimental|Arm I|"Patients will receive tipifarnib by mouth twice a day for 3 weeks. Treatment may repeat every 4 weeks for up to eight courses.
~Patients will undergo blood collection periodically for laboratory studies. After finishing treatment, patients will be evaluated every 6 months for 5 years."
11631170|NCT00360737|Active Comparator|NP-018|Subjects received one or two vials of NP-018 administered intravenously.
11631171|NCT00360724|Experimental|duloxetine (cymbalta)|Duloxetine medication: a medication currently marketed in the USA that is reported to have pharmacological effects including reuptake blockage for serotonin and norepinephrine
11631172|NCT00360724|Placebo Comparator|Placebo treatment|placebo treatment: treatment with placebo capsules that match active medication capsules
11631173|NCT00360698|Other|insulin glulisine+insulin glargine+metformin+glimepiride|Bolus arm
11631174|NCT00360698|Other|insulin glargine+metformin+glimepiride|Control arm
11631175|NCT00360685|Other|TAC + MMF|Tacrolimus and Mycophenolate
11631176|NCT00360685|Other|TAC+MTX|Tacrolimus and Methotrexate
11631177|NCT00360672|Experimental|Revlimid|Revlimid 25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
11631178|NCT00360646||Subjects with liver injury|
11631179|NCT00360646||Subjects without liver injury|
11631180|NCT00360594|Experimental|1|Acamprosate
11631181|NCT00360594|Placebo Comparator|2|Placebo
11631182|NCT00360568|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants received LCIG, delivered through a percutaneous endoscopic gastrostomy with jejunal extension (PEG-J), administered for up to 12 months (52 weeks).
~Starting dose of LCIG was based on the participant's optimized oral levodopa-carbidopa dose that the subject was receiving just prior to randomization in Study S187.3.001 (NCT00357994) or Study S187.3.002 (NCT00660387), administered in the morning of the first day following Study Day 86 of either of these 2 previous studies. The LCIG infusion was expected to infuse over approximately16 hours each day with a rate of infusion within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances."
11631183|NCT00360555|Experimental|flibanserin|flibanserin 25 mg b.i.d
11631184|NCT00360555|Experimental|flibanserin 50mg|flibanserin 50mg qhs/b.i.d
11631185|NCT00360555|Experimental|flibanserin 100mg|flibanserin 50mg b.i.d./100mg qhs
11631186|NCT00360555|Placebo Comparator|placebo|placebo comparator
11631187|NCT00360529|Experimental|fibanserin|flibanserin 50 mg q.h.s.
11631188|NCT00360529|Experimental|flibanserin|flibanserin 100 mg q.h.s.
11631189|NCT00360529|Placebo Comparator|placebo|placebo q.h.s.
11631190|NCT00360490|Experimental|Levonorgestrel Intrauterine System (LNG IUS) 20µg per 24 hours|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
11631191|NCT00360490|Active Comparator|Medroxyprogesterone acetate (MPA)|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
11631192|NCT00360477|Active Comparator|1|Floseal
11631193|NCT00360477|Active Comparator|2|Cope-Loop/Nephrostomy Tube
11631194|NCT00360477|Active Comparator|3|Fascial Stitch
11631195|NCT00360451|Experimental|1|Adolescent only Penn Resiliency Program
11631196|NCT00360451|Experimental|2|Adolescent plus parent Penn Resiliency Program
11631197|NCT00360451|No Intervention|3|Control
11631198|NCT00360438|Experimental|Rasburicase|
11631199|NCT00360412|Experimental|E2007|During the first two weeks of the study, Patients received 1 x 2mg E2007 tablet. At the week 2 visit, patients who tolerated the 2 mg/day dose were up-titrated to receive 4mg/day (2 x 2 mg E2007 tablets). Patients not tolerating the 4 mg dose were allowed to down titrate to 2 mg. Patients who did not tolerate the 2 mg dose were withdrawn from the study. Patients returned at week 4, if their tolerance to the 4 mg/day dose was acceptable they remained on this dose for the maintenance phase of the study. If at any time their tolerance declined, they were to return for an unscheduled visit and the daily dose was reduced to 2 mg. If at any stage, 2 mg day wass not tolerated, the patient was withdrawn from the study.
11631200|NCT00360399|Active Comparator|Escitalopram|Participants will receive treatment with escitalopram for 12 weeks
11631201|NCT00360399|Active Comparator|Duloxetine|Participants will receive treatment with duloxetine for 12 weeks
11631202|NCT00360399|Active Comparator|CBT|Participants will receive 16 one-hour sessions of cognitive behavioral therapy delivered over 12 weeks
11631203|NCT00360360|Experimental|Bevacizumab/Paclitaxel/Carboplatin/Erlotinib|Bevacizumab 15mg/kg IV infusion,Day 1 Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1 Carboplatin AUC 6.0 IV Day 1 Erlotinib 150 mg by mouth daily
11631204|NCT00360334|Experimental|1|
11631205|NCT00360334|Active Comparator|2|
11631206|NCT00360308|Placebo Comparator|Placebo|matching E2007 and matching entacapone
11631207|NCT00360308|Active Comparator|E2007|2 mg once daily in the evening, Weeks 0→2 (2 weeks) and 4 mg once daily in the evening, Weeks 2→18.
11631208|NCT00360308|Active Comparator|Entacapone|200 mg with each dose of Levodopa.
11631209|NCT00360282|Other|With Vertigo; Placebo - Rizatriptan|This group received placebo on visit 1 and Rizatriptan on visit 2.
11631210|NCT00360282|Other|With Vertigo; Rizatriptan - Placebo|These subjects received Rizatriptan on visit 1 and placebo on visit 2.
11631211|NCT00360282|Other|Without Vertigo; Placebo - Rizatriptan|This group received placebo on visit 1 and Rizatriptan on visit 2.
11631212|NCT00360282|Other|Without Vertigo; Rizatriptan-Placebo|This group received Rizatriptan on visit 1 and placebo on visit 2.
11631213|NCT00360269|Experimental|Active|Atomoxetine plus Motivational Enhancement Therapy
11631214|NCT00360269|Placebo Comparator|Placebo|Placebo plus Motivational Enhancement Therapy
11631221|NCT00360230|Experimental|SB257049 F2 0-1 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1-month schedule administered intramuscularly (IM) in the left deltoid muscle.
11631222|NCT00360230|Experimental|SB257049 F1 0-1 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1-month schedule administered intramuscularly (IM) in the left deltoid muscle.
11631223|NCT00360230|Experimental|SB257049 F2 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
11631224|NCT00360230|Experimental|SB257049 F1 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
11631225|NCT00360230|Experimental|SB257049 F2 0-1-7 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1, 7-month schedule administered intramuscularly (IM) in the left deltoid muscle.
11631226|NCT00360230|Active Comparator|SB257049 F1 0-1-7 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1, 7-month schedule administered intramuscularly (IM) in the left deltoid muscle.
11631227|NCT00360230|Active Comparator|Rabipur 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
11631228|NCT00360152|Active Comparator|Positive Axillary Ultrasound|Positive Axillary Ultrasound -> Fine Needle Aspiration Biopsy -> Cytopathology and Reverse Transcription-Polymerase Chain Reaction (RT-PCR) -> Positive Cyto=Axillary Lymph Node Dissection, Negative Cyto=Sentinel Lymph Node Biopsy -> Pathology
11631229|NCT00360152|Active Comparator|Negative Axillary Ultrasound|Negative Axillary Ultrasound -> Sentinel Lymph Node Biopsy/Fine Needle Aspiration Biopsy -> Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Pathology
11631230|NCT00360035|Experimental|GX15-070MS|Obatoclax mesylate 60mg
11631231|NCT00360022|Experimental|Joint Visits|Transition patients will have 2 joint visits performed with the pediatric GI specialist and the adult GI specialist as they transfer care to an adult GI provider.
11631232|NCT00360022|No Intervention|Control|Transition patients in the control group will transfer care to adult GI provider in typical manner.
11631233|NCT00360009|Active Comparator|STN DBS|Patients who underwent deep brain stimulation (DBS) of the subthalamic nucleus (STN) to treat Parkinson's disease (PD)
11631234|NCT00360009|Active Comparator|GPI DBS|Patients who underwent deep brain stimulation (DBS) of the globus pallidus interna (GPi) to treat Parkinson's disease (PD)
11631235|NCT00360009|No Intervention|no DBS|non-DBS PD patient control group
11631236|NCT00359996|Active Comparator|Health disparities collaborative|The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.
11631237|NCT00359996|Active Comparator|Control|No additional educational sessions added to usual care of patients.
11631238|NCT00359983|Experimental|MenHibrix 4-dose group|Subjects received in the primary study (NCT00129129) 3 doses of MenHibrix co-administered with Pediarix and Prevnar and a 4th dose of MenHibrix co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
11631239|NCT00359983|Active Comparator|ActHIB 4-dose group|Subjects received in the primary study (NCT00129129) 3 doses of ActHIB co-administered with Pediarix and Prevnar and a 4th dose of ActHIB co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
11631240|NCT00359983|Experimental|ActHIB 3-dose + MenHibrix 4th-dose group|Subjects received in the primary study (NCT00129129) 3 doses of ActHIB co-administered with Pediarix and Prevnar and a dose of MenHibrix co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
11631241|NCT00359970|Active Comparator|Azithromycin 500 mg plus Placebo|a single 500 mg dose of Azitrhomycin at the start of treatment; a single loading dose of placebo at the start of treatment and then a dose of placebo after each loose stool
11631242|NCT00359970|Active Comparator|Azithromycin 1000 mg plus Placebo|a single 1000 mg dose of Azitrhomycin at the start of treatment; a single loading dose of placebo at the start of treatment and then a dose of placebo after each loose stool
11631243|NCT00359970|Experimental|Azithromycin 500 mg plus Loperamide|a single 500 mg dose of Azitrhomycin at the start of treatment; a single 4 mg loading dose of Loperamide at the start of treatment and then 2 mg Loperamide after each loose stool
11631244|NCT00359957|Experimental|1|ADDED condition - behavioral intervention for modifying diet and physical activity, with greater emphasis on physical activity than the STANDARD condition
11631245|NCT00359957|Active Comparator|2|STANDARD condition - behavioral intervention for modifying diet, with little emphasis on physical activity
11631246|NCT00359944|Experimental|AC-3933|AC-3933, 5mg twice daily
11631247|NCT00359944|Experimental|AC-3933, 20 mg twice daily|AC-3933, 20 mg twice daily
11631248|NCT00359944|Placebo Comparator|Placebo|Sugar Pill twice daily
11631249|NCT00359918|Experimental|Prehospital facilitated PCI|
11631250|NCT00359918|Active Comparator|Primary PCI|
11631251|NCT00359905|Experimental|Silodosin|
11631252|NCT00359905|Active Comparator|Tamsulosin|
11631253|NCT00359905|Placebo Comparator|Placebo|
11631254|NCT00359892|Experimental|Obatoclax Mesylate|Obatoclax Mesylate 60mg
11631255|NCT00359879|Experimental|1 - exenatide before breakfast and dinner|
11631256|NCT00359879|Active Comparator|2 - exenatide before lunch and dinner|
11631293|NCT00359398|Experimental|Platelet sequestration|Sequestration of platelet rich plasma before cardiopulmonary bypass
11631294|NCT00359398|No Intervention|Standard care|No platelet rich plasma sequestration undertaken before cardiopulmonary bypass (usual practice)
11631295|NCT00359385|Active Comparator|Alendronate 70mg weekly|Alendronate 70mg weekly
11631257|NCT00359866|Experimental|Pelvic IMRT with Tomotherapy|"Helical tomotherapy will be used to plan and deliver the radiation treatment.
~Treatment volume will include the upper third of the vagina and para-vaginal tissue and the common, external and internal iliac nodal regions.
~External beam radiation will be delivered in 160-180 cGy daily fractions to a total dose of 4500-5120 cGY.
~Receive treatment once a day for five days a week for approximately 6 weeks.
~Treating physician will make determination if patient is to receive intracavitary brachytherapy.
~Treating physician will make determination if patient is to receive chemotherapy (allowed but not mandated)."
11631258|NCT00359814|Experimental|1|Azathioprine administration: was stopped at day 0; Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily; Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
11631259|NCT00359801|Experimental|Exubera|
11631260|NCT00359801|Active Comparator|Usual Diabetes Care|
11631261|NCT00359762|Experimental|Exenatide|
11631262|NCT00359762|Active Comparator|Glimepiride|
11631263|NCT00359736|Experimental|Sildenafil|Sildenafil 20 mg tid orally
11631264|NCT00359736|Placebo Comparator|Placebo|Identical Placebo 20 mg tid orally
11631265|NCT00359723|Experimental|Methylphenidate 0.4 mg/kg TID followed by placebo TID|As above
11631266|NCT00359723|Experimental|Placebo TID followed by methylphenidate 0.4 mg/kg TID|As above
11631267|NCT00359684||Cystinosis|Patients with a diagnosis of cystinosis
11631268|NCT00359671|Experimental|1|Arm 1: study drug
11631269|NCT00359671|Other|2|Arm 2: study drug + comparator
11631270|NCT00359658|Experimental|1|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal; Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily; Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 mg/ml
11631271|NCT00359645|No Intervention|Control|Annual auto questionnaire
11631272|NCT00359645|Experimental|Screening|Annual screening of Head and Neck cancer
11631273|NCT00359632|Experimental|Linezolid|Subjects have received at least 6 weeks of linezolid therapy (600 mg BID). Continued duration of linezolid treatment is based on treating physician's benefit/risk assessment. A matching control who did not receive linezolid will be selected for each linezolid treated subject.
11631274|NCT00359632|Active Comparator|Matched control|Control subjects individually matched to linezolid subjects (on age, gender and type of infection) who received at least 6 weeks of antibiotics other than linezolid. Control group assessed only at baseline visit to assess presence of background abnormalities in the study test panel.
11631275|NCT00359619|Active Comparator|Cervarix Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11631276|NCT00359619|Experimental|Cervarix 1 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 1 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11631277|NCT00359619|Experimental|Cervarix 2 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 2 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11631278|NCT00359619|Experimental|Cervarix 3 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 3 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11631279|NCT00359619|Experimental|Cervarix 4 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 4 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11631280|NCT00359619|Experimental|Cervarix 5 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 5 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11631281|NCT00359619|Experimental|Cervarix 6 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 6 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11631282|NCT00359606|Experimental|Treatment (5-fluoro-2-deoxycytidine, tetrahydrouridine)|Patients receive tetrahydrouridine PO on day 1; 5-fluoro-2-deoxycytidine PO on days 1 and 8; tetrahydrouridine IV over 3 hours on days 2-5, 8, and 9-12; and 5-fluoro-2-deoxycytidine IV over 3 hours on days 2-5 and 9-12 of course 1. For all subsequent courses, patients receive tetrahydrouridine IV over 3 hours and 5-fluoro-2-deoxycytidine IV over 3 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11631283|NCT00359580||AGDB|Those individuals who are listed in the Fisher Family History and other genealogy books ordatabases will be included in the AGDB.
11631284|NCT00359567|Experimental|1|palonosetron
11631285|NCT00359567|Active Comparator|2|granisetron hydrochloride
11631286|NCT00359476|Experimental|1|
11631287|NCT00359463|Active Comparator|Healthy subjects|Subjects will receive a single 50 mg oral dose of eltrombopag.
11631288|NCT00359463|Experimental|Subjects with hepatic impairment|Subjects with mild, moderate or severe hepatic impairment will receive a single 50 mg oral dose of eltrombopag.
11631289|NCT00359437|Experimental|Satavaptan|
11631290|NCT00359437|Placebo Comparator|Placebo|
11631291|NCT00359424|Active Comparator|intravenous (IV) rt-PA alone|Group one will receive the standard dose of intravenous (IV) rt-PA alone given over an hour.
11631292|NCT00359424|Experimental|Endovascular therapy|Group two will receive a lower dose or a standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose (based on the location and extent of the blood clot) a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery.
11631296|NCT00359385|Placebo Comparator|placebo of alendronate 70mg weekly|placebo of Alendronate 70mg weekly
11631297|NCT00359359|Experimental|Sagopilone and cisplatin|The study drug sagopilone was administered in combination with a fixed dose of cisplatin
11631298|NCT00359333|Experimental|Single Group|
11631299|NCT00359320|Experimental|Mucosa-to-jejunal mucosa technique of pancreaticojejunosto|Determine whether a duct mucosa-to-jejunal mucosa technique of pancreaticojejunostomy will improve the pancreatic fistula rate
11631300|NCT00359294|Experimental|Arm 1|
11631301|NCT00359268||1|Any patient with a condition or disease whose etiology is unknown.
11631302|NCT00359255|Active Comparator|1|
11631303|NCT00359255|Experimental|2|
11631304|NCT00359242|Experimental|1|Soothing and Calming instructions given at 2 weeks of life
11631305|NCT00359242|Experimental|2|Repeated food exposure instructions given between 4 and 6 months of life
11631306|NCT00359242|Experimental|3|Receive both interventions: Soothing and Calming and Repeated food exposure
11631307|NCT00359242|No Intervention|4|Group receiving neither of the interventions.
11631308|NCT00359229|Experimental|1|For 3 weeks
11631309|NCT00359216|Experimental|Mometasone furoate nasal spray|
11631310|NCT00359216|Placebo Comparator|Placebo nasal spray|
11631311|NCT00359203|Placebo Comparator|Dual chamber pacemaker|Dual chamber pacemaker programmed ODO (switched OFF)
11631312|NCT00359203|Active Comparator|Dual chamber pacemeker|Medtronic dual chamber pacemaker programmed ON and with Rate Drope Response programmed ON
11631313|NCT00359190|Experimental|Lapatinib receivers|Subjects with treatment-naïve breast tumors will be administered lapatinib 1500 mg once daily, 1000 mg once daily, or 500 mg twice daily for a minimum of 9 days and maximum of 15 days prior to surgical resection..
11631314|NCT00359177|Experimental|Healthy subjects receiving GW679769|Healthy Subjects will receive single 100 milligram (mg) oral doses of GW679769 for five consecutive days.
11631315|NCT00359177|Experimental|Subjects with hepatic impairment receiving GW679769|Subjects with hepatic impairment will receive single 100 mg oral doses of GW679769 for five consecutive days.
11631316|NCT00359164|Active Comparator|1|Bevacizumab with verteporfin at Low Fluence Photodynamic Therapy.
11631317|NCT00359164|Active Comparator|2|Bevacizumab with verteporfin at Very Low Photodynamic Therapy.
11631318|NCT00359164|Sham Comparator|3|Bevacizumab with verteporfin with Sham Photodynamic Therapy.
11631319|NCT00359151|Experimental|Celecoxib|Celecoxib
11631320|NCT00359151|Placebo Comparator|Placebo|Placebo
11631321|NCT00359138|Experimental|Desloratadine 5 mg tablet + Levocetirizine placebo capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
11631322|NCT00359138|Active Comparator|Desloratadine placebo tablet + Levocetirizine 5 mg capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
11631323|NCT00359138|Placebo Comparator|Desloratadine placebo tablet + Levocetirizine placebo capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
11631324|NCT00359125|Active Comparator|1|RU-486, 600 mg/day for 1 week.
11631325|NCT00359125|Placebo Comparator|2|Placebo, 600 mg/day for 1 week
11631326|NCT00359086|Experimental|1|
11631327|NCT00359073|Active Comparator|Montelukast|montelukast (10 mg everyday)
11631328|NCT00359073|Placebo Comparator|Placebo|Placebo comparator
11631329|NCT00359047|Experimental|Documentation|Written educational material on osteoporosis for the participant and the physician.
11631330|NCT00359047|Experimental|Video|A 15-minute educational video on osteoporosis as well as written documentation on osteoporosis for the participant and the physician.
11631331|NCT00359021|Experimental|001|TMC125 200 mg twice daily until commercially available
11631332|NCT00359008||1|Intermediate AMD
11631333|NCT00359008||2|New untreated CNV subject
11631334|NCT00358995|Active Comparator|1|Cognitive Behavior Therapy (CBT) may include keeping a diary of significant events and associated feelings, thoughts and behaviors; questioning and testing cognitions, assumptions, evaluations and beliefs that might be unhelpful and unrealistic; gradually facing activities which may have been avoided; and trying out new ways of behaving and reacting and using relaxation and distraction techniques.
11631335|NCT00358995|Active Comparator|2|Stress Management Therapy (SMT) includes relaxation, interaction, biofeedback, exercises, such as muscle stretching exercises, yoga, meditation, time management techniques, and many more.
11631336|NCT00358982|Experimental|1|
11631337|NCT00358956|Experimental|1|
11631338|NCT00358943||Patients in ICGG Gaucher Registry|No experimental intervention is given. A patient with Gaucher Disease will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.
11631339|NCT00358943||Pregnant women with confirmed diagnosis of Gaucher disease|No experimental intervention is given. Pregnant women with confirmed diagnosis of Gaucher disease who are participating in the ICGG Gaucher Registry and consented to participate in the Gaucher Pregnancy Sub-registry, regardless of whether she is receiving disease-specific therapy and irrespective of the commercial product with which she may be treated.
11631340|NCT00358917|Experimental|LPV/r 800/200 mg QD Tablet|
11631341|NCT00358917|Active Comparator|LPV/r 400/100 mg BID Tablet|
11631342|NCT00358878|Experimental|Satavaptan|
11631343|NCT00358878|Placebo Comparator|Placebo|
11631344|NCT00358852||Patients with Schizophrenia|
11631345|NCT00358826|Experimental|VIA-2291 25 mg|VIA-2291 25 mg
11631346|NCT00358826|Experimental|VIA-2291 50 mg|VIA-2291 50 mg
11631347|NCT00358826|Experimental|VIA-2291 100 mg|VIA-2291 100 mg
11631348|NCT00358826|Placebo Comparator|Placebo|Placebo
11631349|NCT00358813|Experimental|Subjects receiving casopitant|Eligible subjects will receive a 100 milligrams oral dose of casopitant once daily for five consecutive days.
11631350|NCT00358787|Active Comparator|1|Crossed K wire orientation for surgical management of a type III Supracondylar fracture.
11631351|NCT00358787|Active Comparator|2|Lateral K wire orientation for surgical management of a type III Supracondylar fracture.
11631439|NCT00357682|Experimental|Arm A|20mg Esomeprazole
11631440|NCT00357682|Experimental|Arm B|80mg Esomeprazole
11631352|NCT00358735|Experimental|ActiveCare CECT|The ActiveCare CECT device is a mobile compression device used to prevent venous thromboembolic events, used after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery.
11631353|NCT00358735|Active Comparator|LMWH (Enoxaparin)|Enoxaparin (LMWH) will be used, following a protocol that is considered a standard of care for this patient population. 40mg QD for the remainder of the 10 days.
11631354|NCT00358722|Experimental|Fermagate|
11631355|NCT00358670|Active Comparator|Maintenance Infliximab|Infliximab 5 mg/kg by body weight every 8 weeks
11631356|NCT00358670|Experimental|Intermittent Infliximab|Infliximab 5 mg/kg by body weight at Weeks 0, 2, 6 and 14 following a 50% reduction in Psoriasis Area and Severity Index (PASI) from the Study P04271 Baseline
11631357|NCT00358657|Experimental|Treatment (chemo, total-body irradiation, transplant)|See Detailed Description
11631358|NCT00358644|Experimental|1|
11631359|NCT00358579|Active Comparator|Adrenaline|
11631360|NCT00358579|Active Comparator|Vasopressin|
11631361|NCT00358566|Active Comparator|Gemcitabine|Gemcitabine alone treatment.
11631362|NCT00358566|Experimental|GV1001|GV1001 in sequential combination with Gemcitabine
11631363|NCT00358540|Experimental|Group B|Group B is a dose escalation phase designed to determine the optimal biological dose of eltrombopag in subjects with sarcoma who received chemotherapy treatment with Adriamycin and Ifosfamide
11631364|NCT00358540|Experimental|Group A|Group A will be used for further exploration of the optimal biological dose (as initially established by completion of Group B), by using 2 different dosing schedules of eltrombopag.
11631365|NCT00358527|Experimental|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray 200 mcg, once daily.
11631366|NCT00358527|Placebo Comparator|Matching placebo nasal spray|
11631367|NCT00358501|Experimental|Defibrotide|Defibrotide treatment
11631368|NCT00358501|No Intervention|Historical Control|Historical control group
11631369|NCT00358488|Experimental|GSK159797 (10, 15, and 20mcg)|GSK159797 (10, 15, and 20mcg)
11631370|NCT00358488|Experimental|salbutamol|salbutamol
11631371|NCT00358488|Experimental|salmeterol 50mcg|salmeterol 50mcg
11631372|NCT00358488|Placebo Comparator|placebo|placebo
11631373|NCT00358462|Active Comparator|Active azithromycin+placebo doxycycline|Active azithromycin (1g) and placebo doxycycline
11631374|NCT00358462|Active Comparator|Active doxycycline+placebo azithromycin|Active doxycycline and placebo azithromycin
11631375|NCT00358449|Experimental|Mepolizumab 0.55 mg/kg|Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
11631376|NCT00358449|Experimental|Mepolizumab 2.5 mg/kg|Participants received mepolizumab 2.5 mg/kg by IV infusion for 30 minutes on Day 1, Week 4 and Week 8.
11631377|NCT00358449|Experimental|Mepolizumab 10 mg/kg|Participants received mepolizumab 10 mg/kg by IV infusion for 30 minutes on Day 1, Week 4 and Week 8.
11631378|NCT00358436|Experimental|Aclidinium 200 μg once-daily|Aclidinium bromide 200 μg once-daily by inhalation
11631379|NCT00358436|Placebo Comparator|Placebo|Placebo by inhalation
11631380|NCT00358423|Experimental|A|
11631381|NCT00358423|Placebo Comparator|B|
11631382|NCT00358410|Experimental|GW679769|120mg once a day
11631383|NCT00358410|Placebo Comparator|Placebo|Placebo once a day
11631384|NCT00358397|Experimental|Treatment arm|
11631385|NCT00358384|Experimental|Subjects receiving treatment A|Eligible subjects will receive 0.1 percent pazopanib ointment.
11631386|NCT00358384|Experimental|Subjects receiving treatment B|Eligible subjects will receive 0.5 percent pazopanib ointment.
11631387|NCT00358384|Experimental|Subjects receiving treatment C|Eligible subjects will receive 1 percent pazopanib ointment.
11631388|NCT00358384|Placebo Comparator|Subjects receiving treatment D|Eligible subjects will receive pazopanib vehicle as negative control.
11631389|NCT00358384|Placebo Comparator|Subjects receiving treatment E|Eligible subjects will receive 0.1 percent betamethasone valerate ointment as steroid positive control.
11631390|NCT00358384|Placebo Comparator|Subjects receiving treatment F|Eligible subjects will receive 0.005 percent calcipotriol ointment as vitamin D agonist positive control.
11631391|NCT00358371|Experimental|Subjects receiving flucloxacillin 250 mg|Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
11631392|NCT00358371|Experimental|Subjects receiving flucloxacillin 500 mg|Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
11631393|NCT00358345||1|Intermediate AMD
11631394|NCT00358345||2|Newly diagnosed CNV
11631395|NCT00358332|Experimental|Group 1: FMP2.1/AS02A 10 mcg dose or rabies vaccine.|20 children will be randomized to receive either the 10 mcg dose of FMP2.1/AS02A (n=15) or rabies vaccine (n=5) on study days 0, 30 +/- 7, and 60 +/- 7.
11631396|NCT00358332|Experimental|Group 2: FMP2.1/AS02A 25 mcg dose or rabies vaccine.|40 children will be randomized to receive either the 25 mcg dose of FMP2.1/AS02A (n=30) or rabies vaccine (n=10) on study days 0, 30 +/- 7, and 60 +/- 7.
11631397|NCT00358332|Experimental|Group 3: FMP2.1/AS02A 50 mcg dose or rabies vaccine.|40 children will be randomized to receive either the 50 mcg dose of FMP2.1/AS02A (n=30) or rabies vaccine (n=10) on study days 0, 30 +/- 7, and 60 +/- 7.
11631398|NCT00358319|Experimental|Phase I|Dose escalation phase
11631399|NCT00358319|Experimental|Phase II|All patients enrolled in the Phase II will be treated with Valproic Acid (VPA) and Karenitecin using the dosing schedule determined to be the Maximum Tolerated Dose (MTD) in Phase I.
11631400|NCT00358306||a|those with previous history of Acute kidney injury
11631401|NCT00358267|Active Comparator|RFA|Radiofrequency Ablation (RFA) involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
11631402|NCT00358267|Active Comparator|PRIT|Partial Resection of Inferior Turbinate (PRIT) involves surgically removing a small piece off the turbinate, which also reduces its size.
11631441|NCT00357682|Experimental|Arm C|20mg Esomeprazole + 300mg Aspirin
11631403|NCT00358215|Experimental|Darbepoetin alfa|Starting dose of 0.75 µg/kg subcutaneously every 2 weeks until hemoglobin concentrations reach 13.0 g/dL on 2 consecutive visits, then monthly dosing, titrated to achieve hemoglobin target of 13.0 g/dL, not to exceed 14.5 g/dL.
11631404|NCT00358215|Placebo Comparator|Placebo|Participants received dose and administration schedule (every 2 weeks or once a month) changes that simulated the changes for participants receiving darbepoetin alfa.
11631405|NCT00358202|Active Comparator|1 cefepime|
11631406|NCT00358202|Active Comparator|2 ceftriaxone|
11631407|NCT00358150|Experimental|Eliglustat tartrate|
11631408|NCT00358072|Experimental|1|Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
11631409|NCT00358033|Experimental|group intervention|pharmacist-led group intervention in behavioral and pharmacologic therapy
11631410|NCT00358033|Active Comparator|individual|pharmacist-based individual clinic visits with behavioral and pharmacologic intervention for cardiac risk reduction
11631411|NCT00358033|No Intervention|usual care|usual care
11631412|NCT00358007|Experimental|Cone Beam CT|
11631413|NCT00357994|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG) + Placebo Capsules|Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
11631414|NCT00357994|Active Comparator|Placebo Gel + Levodopa-Carbidopa Capsules|Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.
11631415|NCT00357981|Experimental|ORTHO EVRA|"The approximate first two months of women's participation will be spent documenting baseline information about their health and well-being, work patterns and performance, and the economic impact of their menstruation. Subjects will then initiate two, two month intervals of continuous use of ORTHO EVRA.
~Over this four month treatment period, subjects will document their health and well-being, work patterns and performance, and the economic impact of their menstruation while being treated with ORTHO EVRA. This will allow us to compare subjects' experiences pre- and post-treatment. The study's instruments will focus on eliciting information on the personal and economic costs of menstruation such as measuring time missed from work, changes in productivity and work satisfaction, and impact on quality of life."
11631416|NCT00357968|Experimental|Prasugrel to Clopidogrel|One time oral loading dose (LD) of 60-mg Prasugrel and placebo matched to clopidogrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 10-mg Prasugrel and placebo matched to clopidogrel taken orally once a day for 14 days. Patients cross-over to 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for the next 14 days.
11631417|NCT00357968|Active Comparator|Clopidogrel to Prasugrel|One time oral LD of 600 mg clopidogrel and placebo matched to prasugrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for 14 days. Patients cross-over to 10 mg prasugrel and placebo tablets matched to clopidogrel taken orally once a day for the next 14 days.
11631418|NCT00357955|Experimental|MEDIC|Multidisciplinary education and diabetes intervention for cardiac risk reduction
11631419|NCT00357955|No Intervention|usual care|usual care
11631420|NCT00357942|Experimental|C group I|Morphine mouthwash and placebo i.v.(24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
11631421|NCT00357942|Active Comparator|C group II|Placebo mouthwash and morphine i.v.(24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
11631422|NCT00357942|Placebo Comparator|C group III|Placebo mouthwash and placebo i.v. (24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
11631423|NCT00357903|Other|1|
11631424|NCT00357890|Experimental|Pump therapy (CSII)|Use of pump therapy
11631425|NCT00357890|Active Comparator|Multiple daily injections (MDI)|Use of MDI (basal bolus therapy with glargine)
11631426|NCT00357877|Placebo Comparator|Placebo Dental Coating|Dental coating with all ingredients except Chlorhexidine topically applied by dental professional supragingivally to the full dentition
11631427|NCT00357877|Active Comparator|Active Dental Coating|10% w/v chlorhexidine acetate coating FDA IND #45466. Dental coating with all ingredients including Chlorhexidine topically applied by dental professional supragingivally to the full dentition
11631428|NCT00357799|Active Comparator|VeinViewer Arm|Attempts at IV placement will be made with use of the VeinViewer Machine
11631429|NCT00357799|No Intervention|Conventional Method|IV attempted with conventional method
11631430|NCT00357786|Experimental|A|Enzyme replacement for Fabry's Disease
11631431|NCT00357760|Experimental|Arm A (higher dose of VEGF Trap)|Patients receive a higher dose of ziv-aflibercept (VEGF Trap) IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11631432|NCT00357760|Experimental|Arm B (lower dose of VEGF Trap)|Patients receive a lower dose of ziv-aflibercept (VEGF Trap) IV over 1 hour on day 1. In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. At the time of disease progression, the dose of ziv-aflibercept (VEGF Trap) may be escalated to the higher dose in Arm A.
11631433|NCT00357747|Experimental|AEG35156 plus docetaxel|
11631434|NCT00357734|Experimental|Gefitinib (ZD1839)|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
11631435|NCT00357721|Active Comparator|A1|
11631436|NCT00357721|Active Comparator|A2|
11631437|NCT00357721|Active Comparator|A3|
11631438|NCT00357708|Experimental|Treatment (decitabine, vorinostat)|"Patients receive decitabine IV over 1 hour on days 1-5 and oral vorinostat (SAHA) three times daily on days 6-19. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 6 patients receive escalating doses of decitabine and SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose."
11631444|NCT00357669|Experimental|Brivaracetam 50 mg/day|BRV 50 mg/day
11631445|NCT00357669|Experimental|Brivaracetam 150 mg/day|BRV 150 mg/day
11631446|NCT00357656|Experimental|BI|Bolus infusion of rAHF-PFM
11631447|NCT00357656|Experimental|CI|Continuous infusion of rAHF-PFM
11631448|NCT00357604|Active Comparator|A1|
11631449|NCT00357604|Experimental|A2|
11631450|NCT00357591|Active Comparator|Control|
11631451|NCT00357565|Experimental|Double Unit UCB Transplantation|Patients that receive 2 units of umbilical cord blood transplantation (UCBT).
11631452|NCT00357565|Experimental|Single Unit UCB Transplantation|Patients that receive one unit of umbilical cord blood transplantation (only if 2 adequate size and matched units are not available).
11631453|NCT00357552|Experimental|LPV/r monotherapy|Participants will receive lopinavir/ritonavir twice daily for up to 104 weeks. Upon confirmation of virologic failure, emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) once a day will be added to their regimen.
11631454|NCT00357500|Experimental|5-drug metronomic antiangiogenic regimen|Thalidomide: Start at 3 mg/kg (rounded to nearest 50 mg), increasing dose weekly by 50 mg as tolerated to 24 mg/kg (max 1,000 mg); Celecoxib: < 20 kg at 100 mg; 20-50 kg at 200 mg; > 50 kg at 400 mg; Fenofibrate: 90 mg/m2 (max 200 mg); Etoposide: 50 mg/m2; Cyclophosphamide: 2.5 mg/kg (max 100 mg); Patients receive oral etoposide once daily on days 1-21 and 43-63 (weeks 1-3 and 7-9) and oral cyclophosphamide once daily on days 22-42 (weeks 4-6). Patients also receive oral thalidomide once daily, oral celecoxib twice daily, and oral fenofibrate once daily in weeks 1-9. Treatment repeats approximately every 9 weeks for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients receive alternating etoposide and cyclophosphamide pulses (i.e., etoposide-cyclophosphamide-etoposide during courses 1 and 3 and cyclophosphamide-etoposide-cyclophosphamide during course 2).
11631455|NCT00357474|Active Comparator|chemotherapy|Transarterial chemoembolization (TACE)
11631456|NCT00357474|Active Comparator|ethanol|Percutaneous ethanol injection therapy (PEIT)
11631457|NCT00357448|Experimental|Arm I|Patients receive intraperitoneal denileukin diftitox over at least 15 minutes on days 1-3. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11631458|NCT00357422|Active Comparator|surgery|
11631459|NCT00357422|Active Comparator|local therapy|
11631460|NCT00357396|Experimental|Chemo followed by DSCT|"Myeloablative preparative regimen: Patients receive busulfan IV over 2 hours every 6 hours on days -8 to -6, melphalan IV over 20 minutes on days -5 to -3, and thiotepa IV over 4 hours on day -2.
~Allogeneic hematopoietic stem cell transplant: Patients undergo allogeneic bone marrow or T-cell depleted peripheral blood stem cell transplantation on day 0.
~Graft-vs-host disease (GVHD) prophylaxis: Patients receive treatment according to institutional guidelines and are given treatment against infection.
~After completion of study treatment, patients are followed periodically for at least 3 years."
11631461|NCT00357370|Experimental|Cohort 1|20 mg
11631462|NCT00357370|Experimental|Cohort 2 - Arm 1|10 mg
11631463|NCT00357370|Experimental|Cohort 2 - Arm 2|20 mg
11631464|NCT00357370|Placebo Comparator|Cohort 2 - Arm 3|
11631465|NCT00357357|Placebo Comparator|Group1|4x 7 day rising dose
11631466|NCT00357357|Placebo Comparator|Group2|4x, 7 day rising dose
11631467|NCT00357357|Placebo Comparator|Group3|28 day fixed lower dose
11631468|NCT00357357|Placebo Comparator|Group4|28 day fixed upper dose
11631469|NCT00357331|Experimental|Potassium Citrate|Potassium Citrate 20 meq twice daily
11631470|NCT00357331|Placebo Comparator|Placebo|Placebo
11631471|NCT00357318|Experimental|Treatment (sunitinib malate, bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29 and oral sunitinib malate (SU11248) once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11631472|NCT00357305|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive oral SAHA two or three times daily on days 1-7 and cytarabine IV over 3 hours twice daily and etoposide IV over 1 hour once daily on days 11-14. Treatment repeats approximately every 6-7 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11631473|NCT00357279|Placebo Comparator|1|Placebo
11631474|NCT00357279|Experimental|2|
11631475|NCT00357240|Active Comparator|A1|
11631476|NCT00357240|Active Comparator|A2|
11631477|NCT00357240|Experimental|A3 I|
11631478|NCT00357240|Experimental|A3 II|
11631479|NCT00357240|Active Comparator|B1|
11631480|NCT00357240|Active Comparator|B2|
11631481|NCT00357240|Experimental|B3 I|
11631482|NCT00357240|Experimental|B3 II|
11631483|NCT00357214|Active Comparator|potassium bicarbonate|Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
11631484|NCT00357214|Active Comparator|Sodium bicarbonate|Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
11631485|NCT00357214|Active Comparator|Potassium chloride|Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.
11631486|NCT00357214|Placebo Comparator|microcrystalline cellulose|Participants will receive placebo is microcrystalline cellulose. This compound has no other name.
11631487|NCT00357188|Active Comparator|A|
11631488|NCT00357188|Active Comparator|B|
11631489|NCT00357162|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11631490|NCT00357149|Active Comparator|A|Cisplatin from day 1 to day 4 and 5-FU for 4 days starting immediately after the end of cisplatin infusion on day 1. Both drugs were administered during week 1 and 6 of irradiation, starting from day 1 of weekly radiotherapy.
11631491|NCT00357149|Experimental|B|Docetaxel followed by cisplatin and 5-FU from day 1 to day 4 starting after the end of cisplatin infusion. The cycle was repeated every 3 weeks up to a total of 3 cycles. After 3-6 weeks from the end of neoadjuvant chemotherapy, patients will receive with the same modality of arm A (reference arm).
11631492|NCT00357110|Active Comparator|1|Anastrozole monotherapy
11631493|NCT00357110|Experimental|2|Anastrozole + Fulvestrant
11631537|NCT00356460|Experimental|1 - Part 1|Dose Group
11631538|NCT00356460|Experimental|2 - Part 1|Dose Group
11631494|NCT00357032|Experimental|Treatment (belinostat)|Patients receive PXD101 IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 6-12 months in the absence of disease progression or unacceptable toxicity.
11631495|NCT00357006|Active Comparator|1|100 mcg Estradiol
11631496|NCT00357006|Active Comparator|2|200 mcg Estradiol
11631497|NCT00357006|Placebo Comparator|3|adjunctive transdermal placebo
11631498|NCT00356993|Experimental|NRT + Behavioural Support|Nicotine Replacement Therapy plus Behavioural Intervention
11631499|NCT00356941|Experimental|Chemoradiation Treated Patients|Patients receiving Docetaxel, Oxaliplatin and radiotherapy.
11631500|NCT00356928|Experimental|Cyclophosphamide + T cells|Conditioning regimen with cyclophosphamide followed by donor T cells on Day 0.
11631501|NCT00356915|Experimental|Itraconazole tablets|Itraconazole 200 mg tablets
11631502|NCT00356915|Active Comparator|Itraconazole capsules|Two Itraconazole 100 mg capsules were taken daily.
11631503|NCT00356915|Placebo Comparator|Placebo tablets|The itraconazole 200-mg tablets and placebo tablets exactly matched one another and were white to slightly grey in color, were oblong and biconvex in shape, and were melt-extrusion, film-coated.
11631504|NCT00356889|Experimental|Bevacizumab and Erlotinib Hydrochloride|"Patients receive 5 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15 and 150 mg oral erlotinib hydrochloride daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
~Tumor tissue and blood specimens are collected periodically for correlative studies. Specimens are examined by immunohistochemistry for epidermal growth factor receptor (EGFR) and P-EGFR protein levels; AKT p-AKT, mitogen-activated protein kinase (MAPK) and P-MAPK protein levels; and vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR-2 protein levels. EGFR mutations are detected by laser capture microdissection. Enzyme-linked immunosorbent assay is used to measure total and free serum VEGF levels."
11631505|NCT00356863|Experimental|Explanation on cardiac rehabilitation|Intervention: Increasing awareness to cardiac rehabilitation programs: Patients received a written and oral short explanation on the importance and benefits of cardiac rehabilitation (CR) participation, and information on available programs. They were telephoned 2 weeks after hospital discharge to encourage them to enroll at a cardiac rehabilitation program (CRP). In addition, physicians and nurses at the cardiothoracic units participated in a 1-hour seminar on CR. A recommendation to the general physician to refer the patient to CRP was added to the letter of discharge from hospital.
11631506|NCT00356863|No Intervention|Usual care with no intervention|Patients recruited to the study received the usual care without any additional explanation on cardiac rehabilitation, and no effort to increase their awareness or the ward's awareness to cardiac rehabilitation was done.
11631507|NCT00356837|Experimental|A|Those with extremity fractures.
11631508|NCT00356824||1|HIV-infected children in Uganda
11631509|NCT00356811|Experimental|Single arm|Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
11631510|NCT00356759|Sham Comparator|12-weekly INR|Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times
11631511|NCT00356759|No Intervention|Standard management|Dosing warfarin every 4 weeks, all INRs true values
11631512|NCT00356746||1|elective CABG only patients
11631513|NCT00356746||2|elective ICD replacement surgical patients requiring general anesthesia
11631514|NCT00356733|Experimental|EPO rise|EPO administration
11631515|NCT00356733|Experimental|EPO stable|EPO and stable Hemoglobin
11631516|NCT00356733|No Intervention|control|standard treatment
11631517|NCT00356707||1|This cohort comprises women from the Black Women's Health Study, a prospective study of African American women, who lived in the Los Angeles, New York, or Chicago metropolitan areas at the time of completion of the 1995, 1997, or 1999 questionnaires.
11631518|NCT00356681|Placebo Comparator|Arm A Placebo|Blinded AMG 706 placebo plus paclitaxel
11631519|NCT00356681|Experimental|Arm B Experimental|Blinded AMG 706 plus paclitaxel
11631520|NCT00356681|Active Comparator|Arm C Comparator|Open-label bevacizumab plus paclitaxel
11631521|NCT00356642|Experimental|Single dose 1 cohort|Subjects with body surface area (BSA) disease involvement between 10 and 15% will be included. Subjects will receive either 100 milligrams (mg) GW842470X or placebo in a ratio of 2:1.
11631522|NCT00356642|Experimental|Repeat dose 1 cohort|Subjects with BSA disease involvement between 10 and 15% will be included. Subjects will receive either 100-150 mg GW842470X or placebo in a ratio of 3:1
11631523|NCT00356642|Experimental|Repeat dose 2 cohort|Subjects with BSA disease involvement between 30 and 40% will be included. Subjects will receive either 300-400 mg GW842470X or placebo in a ratio of 3:1
11631524|NCT00356642|Experimental|Repeat dose 3 cohort|Subjects with BSA disease involvement >=50% will be included. Subjects will receive either 500-1000 mg GW842470X or placebo in a ratio of 2:1
11631525|NCT00356616|Experimental|A|Trizivir+ Tenofovir 2/day
11631526|NCT00356616|No Intervention|B|antiretroviral treatment optimizated by genotyp
11631527|NCT00356603|Experimental|Sumatriptan|Sumatriptan
11631528|NCT00356590|Other|1|
11631529|NCT00356525|Experimental|Less Than One Year: Pemetrexed|Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
11631530|NCT00356525|Experimental|Less Than One Year: Pemetrexed + Gemcitabine|Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
11631531|NCT00356525|Experimental|One Year or Greater: Pemetrexed + Carboplatin|Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
11631532|NCT00356525|Experimental|One Year or Greater: Pemetrexed + Gemcitabine|Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
11631533|NCT00356486|Experimental|A|Peginterferon alfa-2a (40 KD) (270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (40 KD) (180 µg/week) + Ribavirin (1000-1200 mg/day) for 8 weeks
11631534|NCT00356486|Experimental|B|Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
11631535|NCT00356473|Placebo Comparator|Placebo|Placebo
11631536|NCT00356473|Experimental|Atorvastatin|Atorvastatin
11631539|NCT00356460|Experimental|3 - Part 1|Dose Group
11631540|NCT00356460|Experimental|4 - Part 1|Dose Group
11631541|NCT00356460|Experimental|5 - Part 1|Dose Group
11631542|NCT00356460|Experimental|6 - Part 1|Dose Group
11631543|NCT00356460|Experimental|1 (Part 2)|
11631544|NCT00356460|Experimental|2 (part 2)|
11631545|NCT00356447|Active Comparator|Arm 1|
11631546|NCT00356447|Placebo Comparator|Arm 2|
11631547|NCT00356434|Active Comparator|1|Patients will have the Kendall, A-V foot impulse pump, model 6060 applied to their lower extremities to prevent DVT
11631548|NCT00356434|Active Comparator|2|Patients will have the Kendall,sequential compression device, model 9525 applied to the lower extremities to prevent DVT
11631549|NCT00356421|Active Comparator|Control|
11631550|NCT00356421|Experimental|Experimental|
11631551|NCT00356408|Experimental|CDP870 400 mg|Certolizumab pegol (CDP870) 400 mg (2 injections of 1 mL) every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2
11631552|NCT00356369|Experimental|Nimenrix Group|Subjects receiving GSK Biologicals' meningococcal vaccine 134612
11631553|NCT00356369|Active Comparator|Mencevax Group|Subjects receiving Mencevax™ ACWY
11631554|NCT00356356|Experimental|All subjects|257 subjects
11631555|NCT00356343|Experimental|NMES Strengthening Group|Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
11631556|NCT00356343|No Intervention|Control Group|No Intervention Control Group
11631557|NCT00356343|Active Comparator|Volitional Strengthening|Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
11631558|NCT00356317|Experimental|1|Participants will receive a 15-week family therapy
11631559|NCT00356317|Active Comparator|2|Participants will receive a 3-week family therapy (treatment as usual)
11631560|NCT00356304|Experimental|1|Participants will receive motivational interviewing in addition to their antidepressant therapy
11631561|NCT00356304|Active Comparator|2|Participants will receive treatment as usual
11631562|NCT00356291|Experimental|1|Participants will receive Skill-Building and Motivational Interviewing.
11631563|NCT00356291|Active Comparator|2|Participants will receive Skill-Building.
11631564|NCT00356278|Experimental|A|Participants will receive VRE therapy and D-cycloserine
11631565|NCT00356278|Active Comparator|B|Participants will receive VRE therapy and alprazolam
11631566|NCT00356278|Placebo Comparator|C|Participants will receive VRE therapy and placebo
11631567|NCT00356265|Experimental|CKD|
11631568|NCT00356265|Active Comparator|Hypertension group|
11631569|NCT00356265|Active Comparator|Normotensive group|
11631570|NCT00356213|Experimental|A|laparoscopic sleeve gastrectomy
11631571|NCT00356213|Active Comparator|B|laparoscopic gastric bypass
11631572|NCT00356200|Experimental|Fluphenazine treated|Treated with fluphenazine
11631573|NCT00356200|Placebo Comparator|Placebo|Treated with Placebo
11631574|NCT00356187|Experimental|Propranol Treatment|
11631575|NCT00356187|No Intervention|Standard of Care|
11631576|NCT00356174||Children with food allergy|340 longitudinally followed children with egg and/or milk allergy without elevated peanut specific Immunoglobulin E (IgE), less than 5 kUA/L
11631577|NCT00356174||Full sibling controls for genetic studies|Approximately 250 not age matched full siblings (i.e., non-step siblings, non-half siblings) will be recruited as an additional control group for genetic studies.
11631578|NCT00356174||Full sibling controls for mechanistic studies|Approximately 50 not age matched full siblings (i.e., non-step siblings, non-half siblings) will be recruited as an additional control group for mechanistic studies. A subset of this cohort will be without food allergy,
11631579|NCT00356148|Active Comparator|Prophylaxis Group|patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis
11631580|NCT00356148|No Intervention|No Prophylaxis Group|Patients who are BMI over 25 and do not receive antibiotic prophylaxis
11631581|NCT00356135|Experimental|Prasugrel 10/10 mg|Open label (lead-in) dose of clopidogrel 75 milligram (mg) for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 10 mg and placebo, followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.
11631582|NCT00356135|Experimental|Clopidogrel 75/75 mg|Open label (lead-in) dose of clopidogrel 75 mg for 10 to 14 days. Upon completion, assignment to a single loading dose of clopidogrel 75 mg and placebo, followed by maintenance dose of clopidogrel 75 mg taken for 13 to 15 days.
11631583|NCT00356135|Experimental|Prasugrel 60/10 mg|Open label (lead-in) dose of clopidogrel 75 mg for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 60 mg and placebo followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.
11631584|NCT00356122|Experimental|Docetaxel/Oxaliplatin/Bevacizumab|Participants with advanced, recurrent, or metastatic Non Small Cell Lung Cancer (NSCLC), treated with the combination of docetaxel, followed by oxaliplatin, and then bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.
11631585|NCT00356109|Experimental|1|
11631586|NCT00356109|Active Comparator|2|
11631587|NCT00356083|Experimental|switch from morphine to methadon|
11631588|NCT00356057|Active Comparator|1|Biventricular pacing group with Closed Loop Stimulation rate adaptation (Protos CLS device)
11631589|NCT00356057|Active Comparator|2|Biventricular pacing group with accelerometer based rate adaption (Stratos LV device)
11631590|NCT00356057|Active Comparator|3|Right Ventricular pacing group with accelerometer based rate adaption (Stratos LV device)
11631591|NCT00356031|Experimental|Bevacizumab, Radiation, and Surgery|Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)
11631592|NCT00356005|Experimental|Azithromycin + Artesunate|Azithromycin + Artesunate treatment
11631593|NCT00356005|Active Comparator|Artesunate|Artesunate treatment controls
11631635|NCT00355550|Placebo Comparator|Matching Placebo to AC-1202|Placebo formulation, once daily. Administered orally
11631594|NCT00355966|Active Comparator|A|In group A, immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
11631595|NCT00355966|Active Comparator|B|In Group B immediate induction of labour will be done by application of vaginal PGE2 gel 0.5 gm at an interval of 6 hours , a maximum of 2 doses.
11631596|NCT00355940|Experimental|1|
11631597|NCT00355940|Active Comparator|2|
11631598|NCT00355914|Active Comparator|Group 1 Without Steroids|Lumbar Facet Joint Nerve Block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin)
11631599|NCT00355914|Experimental|Group 2 With Steroids|Lumbar Facet Joint Nerve Block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin) and 0.15 mg of non-particulate betamethasone)
11631600|NCT00355888|Experimental|Open label study of MBP-426|Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
11631601|NCT00355862|Active Comparator|1|Center specific immunosuppressive regimen (mTOR inhibitor free)
11631602|NCT00355862|Experimental|2|Sirolimus containing regimen
11631603|NCT00355849|Experimental|1|Intensified Glargine
11631604|NCT00355849|Experimental|2|HIIP
11631605|NCT00355849|Experimental|3|Intensified Glargine plus HIIP
11631606|NCT00355810|Experimental|placebo followed by probiotic|placebo, then washout period, then Lactobacillus plantarum MF1298
11631607|NCT00355810|Experimental|probiotic followed by placebo|Lactobacillus plantarum MF1298, then washout period, then placebo
11631608|NCT00355797|Active Comparator|Closed Loop Stimulation (CLS)|Pacemaker programmed with Closed Loop Stimulation rate adaptive technology for long-term follow-up data collection.
11631609|NCT00355797|Active Comparator|Standard Rate Adaptive Technology (R)|Pacemaker programmed with standard rate adaptive technology (R, accelerometer) for long-term follow-up data collection.
11631610|NCT00355797|Active Comparator|Non-rate adaptive pacing (DDD)|Pacemaker programmed with no rate adaption (DDD mode) for long-term follow-up data collection.
11631611|NCT00355784|Other|Control|9 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and their plasma growth hormone concentration was allowed to decline naturally.
11631612|NCT00355784|Experimental|Growth Hormone Treatment|8 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and received exogenous growth hormone treatment administered in 4 daily injections to mimic physiological growth hormone secretion throughout the 2-week overeating period.
11631613|NCT00355784|Experimental|High Growth Hormone Treatment|5 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and received a relatively high daily dose of growth hormone.
11631614|NCT00355771|Experimental|Treatment Group 1|
11631615|NCT00355771|Placebo Comparator|Treatment Group 2|
11631616|NCT00355719|Experimental|Nevirapine-atazanavir|Atazanavir/ritonavir 300/100 mg once daily for ≥2 weeks. Nevirapine was added at a dose of 200 mg once daily from days 0 to 14, and 200 mg twice daily from days 14 to 28.
11631617|NCT00355706|Active Comparator|Group I - without Steroids|Thoracic Facet Joint Nerve Blocks with Local Anesthetic(0.25% Bupivacaine)
11631618|NCT00355706|Active Comparator|Group II - with steroid|Thoracic Facet Joint Nerve Blocks with Local Anesthetic (0.25% Bupivacaine) and Sterioids(0.15 mg of non-particulate betamethasone)
11631619|NCT00355680|Experimental|1|Aurolab Green Laser
11631620|NCT00355680|Active Comparator|2|Available Green Laser
11631621|NCT00355667|Active Comparator|A|Patients with chronic heart failure with NYHA II or III are given furosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with furosemide 20-40 mg/day, without a placebo run-in period. The dose of each diuretic was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.
11631622|NCT00355667|Active Comparator|B|Patients with chronic heart failure with NYHA II or III are given azosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with azosemide 30-60 mg/day without a placebo run-in period. The dose of azosemide was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.
11631623|NCT00355654|Experimental|Group 1|Participants will receive PEDIACEL with Prevenar at Visit 1 and ENGERIX-B Kinder at Visit 2
11631624|NCT00355654|Active Comparator|Group 2|Participants will receive Infanrix hexa with Prevenar at Visit 1
11631625|NCT00355641|Experimental|Open Label|All subjects will receive ropinirole XR in this study. The total daily dose range of ropinirole XR will be 0.5mg to 6.0mg daily
11631626|NCT00355628|Experimental|1|KW-2246 (fentanyl citrate)
11631627|NCT00355615|Active Comparator|rosuva 5|rosuvastatin 5 mg
11631628|NCT00355615|Active Comparator|rosuva 10|rosuvastatin 10 mg
11631629|NCT00355615|Active Comparator|rosuva 20|rosuvastatin 20 mg
11631630|NCT00355615|Placebo Comparator|Placebo|Placebo
11631631|NCT00355615|Other|rosuva ol|rosuvastatin open label
11631632|NCT00355576|Experimental|Minocycline + Creatine|Minocycline 100 mg BID and Creatine 10 g BID
11631633|NCT00355576|Experimental|Celecoxib + Creatine|Celecoxib 400 mg BID and Creatine 10 g BID
11631634|NCT00355550|Active Comparator|AC-1202|Tricaprilin formulation, once daily. Administered orally
11631636|NCT00355537|Experimental|Active|
11631637|NCT00355537|Placebo Comparator|Placebo|
11631638|NCT00355524|Experimental|Group A with >= 20 kg to < 30 kg body weight|300 milligram (mg) of TMC114 tablet with 50 mg (which is equivalent to 0.625 milliliter [mL]) of ritonavir liquid (80 milligram/milliliter [mg/ml]) will be administered orally twice daily.
11631639|NCT00355524|Experimental|Group A with >= 30 kg to < 40 kg body weight|300 mg of TMC114 tablet with 50 mg (which is equivalent to 0.625 milliliter [mL]) of ritonavir liquid (80 milligram/milliliter [mg/ml]) will be administered orally twice daily.
11631640|NCT00355524|Experimental|Group A with >= 40 kg to < 50 kg body weight|450 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
11631641|NCT00355524|Experimental|Group B with >= 20 kg to < 30 kg body weight|375 mg of TMC114 tablet with 50 mg (which is equivalent to 0.625 mL) of ritonavir liquid (80 mg/mL) will be administered orally twice daily.
11631642|NCT00355524|Experimental|Group B with >= 30 kg to < 40 kg body weight|450 mg of TMC114 tablet with 60 mg (which is equivalent to 0.75 mL) of ritonavir liquid (80 mg/mL) will be administered orally twice daily.
11631643|NCT00355524|Experimental|Group B with >= 40 kg to < 50 kg body weight|600 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
11631644|NCT00355524|Experimental|Participants with >= 50 kg body weight|600 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
11631645|NCT00355498||1|Controls
11631646|NCT00355498||2|Mild Cognitive Impairment
11631647|NCT00355498||3|Alzheimer's disease
11631648|NCT00355498||4|FTD
11631649|NCT00355485|Experimental|Microdermabrasion Treatment|Bilateral, split-face comparison in which one half of the face will be randomly assigned to receive the microdermabrasion treatment(s) while the other half of the face will not. Subjects will receive a series of microdermabrasion treatment sessions (up to 6) spaced one to two weeks apart. In all cases, microdermabrasion treatment parameters will be within those accepted in cosmetic work.
11631650|NCT00355472|Experimental|1|KW-0761
11631651|NCT00355394|Placebo Comparator|Placebo|Standard care including intravenous fluid, but no metoclopramide.
11631652|NCT00355394|Active Comparator|Metoclopramide|Standard care including intravenous fluid PLUS metoclopramide.
11631653|NCT00355368|Active Comparator|Succinylcholine|
11631654|NCT00355368|Active Comparator|Rocuronium|
11631655|NCT00355355|Experimental|Litx|Drug: Talaporfin Sodium (1 mg/kg iv), Device: Interstitial Light Emitting Diodes (200 J/cm) 3 treatments within 6 months
11631656|NCT00355355|Active Comparator|Standard Care|The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
11631657|NCT00355342|Experimental|Salmeterol 50 mcg BID|Participants randomized to this arm received salmeterol 50 microgram (mcg), formulated with lactose via the DISKUS™ inhaler one inhalation twice daily (BID) one inhalation in the morning and one inhalation in the evening for 156 Weeks. Each DISKUS contained 60 doses of study medication. Participant were provided with albuterol/salbutamol as relief medication. DISCUS is registered trademark product of GlaxoSmithKline.
11631658|NCT00355342|Experimental|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Participants randomized to this arm received Fluticasone propionate/salmeterol combination product 250/50 mcg, formulated with lactose via the DISKUS inhaler one inhalation BID, one inhalation in the morning and one inhalation in the evening for 156 Weeks. Each DISKUS contained 60 doses of study medication. Participant were provided with albuterol/salbutamol as relief medication.
11631659|NCT00355316|Experimental|Stage IV Breast Cancer|Blood draws at baseline before systemic therapy. Blood draw then every 6 weeks for approximately 12 weeks.
11631660|NCT00355316|Other|Healthy Volunteers|Baseline blood draw.
11631661|NCT00355303|Active Comparator|Misoprostol tablet, PGE2 gel|participants are assigned to one of two arms for the duration of the study In one group induction of labour is done by intravaginal misoprostol tablets at 4 hrly interval with maximum of five doses.In other group PGE2 gel is applied in poaterior fornix at six hourly interval.
11631662|NCT00355264|Experimental|Single Arm on Active Drug|"5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
~Outcomes were also evaluated by the subject's type of BH4 deficiency either defects in the genes encoding the enzymes involved in biosynthesis or defects in the genes encoding the enzymes involved in recycling."
11631663|NCT00355251|Experimental|A|4 semanas manteniendo el tratamiento antirretroviral e iniciar atorvastatina 40 mg/día. A la semana 4 interrupción HAART y aumentar a 80 mg/día de atorvastatina hasta la semana 32 de seguimiento
11631664|NCT00355251|No Intervention|B|4 semanas manteniendo el tratamiento antirretroviral. A la semana 4 interrupción HAART hasta la semana 32 de seguimiento
11631665|NCT00355238|Experimental|1|no comparator to brivanib
11631666|NCT00355199|Experimental|R-HDS|R-HDS : Rituximab supplemented high-dose (Cyclophosphamide,Ara-C, Methotrexate, Etoposide, Cis-Platin) sequential chemotherapy with autografting.
11631667|NCT00355199|Active Comparator|R-CHOP|Rituximab-CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone).
11631668|NCT00355186|No Intervention|Control|
11631669|NCT00355186|Experimental|Early|
11631670|NCT00355186|Experimental|Late|
11631671|NCT00355147|Experimental|Arm 1 Secondary Risk Factor Management|Patient Secondary Stroke Risk Factor Program including Stroke Self Management and Stroke Peer Support and Physician Stroke Guideline Adherence
11631672|NCT00355147|Placebo Comparator|Attention Control Group|Received Phone Calls from Staff to Control for Attention
11631673|NCT00355134|Experimental|Fingolimod 1.25 mg|"Participants received 1.25 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 1.25 mg fingolimod orally once a day.
~Note: Upon implementation of a protocol amendment all patients taking 1.25 mg fingolimod were switched to 0.5 mg fingolimod orally once a day."
11631674|NCT00355134|Experimental|Fingolimod 0.5 mg|Participants received 0.5 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 0.5 mg fingolimod orally once a day.
11631757|NCT00354159|Placebo Comparator|Control Arm|Physicians do not have access to device-based hemodynamic monitor information to guide patient management
11631795|NCT00353613|Other|2|Ben Taub Hospital
11631675|NCT00355134|Experimental|Placebo|"Participants received placebo capsules orally once a day for up to 24 months during the core phase. In the Extension phase participants received either 1.25 or 0.5 mg fingolimod orally once a day.
~Note: Upon implementation of a protocol amendment all patients taking 1.25 mg fingolimod were switched to 0.5 mg fingolimod orally once a day. Upon implementation of a protocol amendment, all patients taking placebo were switched to 0.5 mg fingolimod orally once a day."
11631676|NCT00355121|Experimental|Group 1|DAPTACEL® + IPOL on Day 0 and Menactra on Day 30
11631677|NCT00355121|Experimental|Group 2|DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30
11631678|NCT00355121|Experimental|Group 3|Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30
11631679|NCT00355095|Active Comparator|1|erythropoietin
11631680|NCT00355095|No Intervention|2|Placebo
11631681|NCT00355082|Experimental|lamotrigine 300|300 mg/day treatment
11631682|NCT00355082|Experimental|lamotrigine 250|250 mg/day treatment
11631683|NCT00355069|Experimental|1|Received the Basic Pediatric Chronic Care Model AND the Medication Assessment Prompt AND family education
11631684|NCT00355069|Experimental|2|Received the Basic Pediatric Chronic Care Model AND the Medication Assessment Prompt but NOT family education
11631685|NCT00355069|Experimental|3|Received the Basic Pediatric Chronic Care Model AND family education but NOT the Medication Assessment Prompt
11631686|NCT00355069|Placebo Comparator|4|Received the Basic Pediatric Chronic Care Model only (NO Medication Assessment Prompt and NO family education)
11631687|NCT00355056|Sham Comparator|Medical Management|Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure).
11631688|NCT00355056|Experimental|PFO Closure|Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and undergo PFO device closure procedure with the AMPLATZER PFO Occluder.
11631689|NCT00355030|Experimental|1|
11631690|NCT00355030|Experimental|2|
11631691|NCT00354991|Experimental|1|Losartan/HCTZ
11631692|NCT00354978|Experimental|FOLFIRI plus Bevacizumab|FOLFIRI [folinic acid (leucovorin) 400 mg/m^2 by vein (IV) Day 1; 5-FU 400 mg/m^2 IV injection Day 1 immediately followed by 2.4 g/m^2 IV over 46 hours over Days 1-3; Irinotecan 180 mg/m^2 IV on Day 1] + Bevacizumab 5 mg/kg over 90 minutes on Day 1 administered alone then 5 mg/kg IV on Day 1 of 14 day cycle.
11631693|NCT00354965|Experimental|ARM 1|
11631694|NCT00354926|Experimental|AME 133v|All subjects will receive weekly intravenous infusions of AME-133v. Each subject will receive a total of 4 infusions administered once a week for 3 consecutive weeks.
11631695|NCT00354913|Experimental|Imatinib mesylate+hydroxyurea|All patients receive imatinib mesylate and hydroxyurea orally on a daily, continuous basis. Dosing of imatinib mesylate is adjusted for patients who are also receiving p450-inducing anti-epileptic drugs.
11631696|NCT00354887|Experimental|Oxaliplatin + Capecitabine|Intravenous Oxaliplatin 130 mg/m^2, Day 1 + Oral Capecitabine 750 mg/m^2 twice daily Days 1-14.
11631697|NCT00354874|Experimental|GW642444 50mcg|
11631698|NCT00354874|Experimental|GW642444 100mcg|
11631699|NCT00354874|Experimental|GW642444 200mcg|
11631700|NCT00354874|Active Comparator|salmeterol 50mcg|
11631701|NCT00354874|Placebo Comparator|placebo|
11631702|NCT00354861|Experimental|A|IMP321
11631703|NCT00354861|Placebo Comparator|B|Saline
11631704|NCT00354861|Active Comparator|C|Engerix B
11631705|NCT00354835|Active Comparator|VAC|Patients receive VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
11631706|NCT00354835|Experimental|VAC Alternating with VI|Patients receive VAC chemotherapy alternating with VI chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 13, 22, 28, 34, and 40; cyclophosphamide IV over 1 hour on day 1 of weeks 1,10, 13, 22, 28, 34, and 40; and irinotecan hydrochloride IV over 1 hour on days 1-5 of weeks 4, 7, 16, 19, 25, 31, and 37. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
11631707|NCT00354770|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine
11631708|NCT00354770|Placebo Comparator|2|Placebo
11631709|NCT00354757|Active Comparator|2 arms|PPI 1
11631710|NCT00354757|Active Comparator|PPI|PPI 2
11631711|NCT00354744|Experimental|High Risk Rhabdomyosarcoma|Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20. Weeks 1-6: vincristine sulfate and irinotecan hydrochloride. Weeks 7-34: vincristine sulfate and irinotecan hydrochloride, Cyclophosphamide with MESNA, Doxorubicin hydrochloride, Etoposide, Ifosfamide with MESNA. Weeks 35-54: vincristine sulfate, Dactinomycin, irinotecan hydrochloride and Cyclophosphamide with MESNA and Filgrastim. Radiation therapy beginning at Week 20. Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients.
11631712|NCT00354731|Active Comparator|corticosteroid|Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
11631713|NCT00354731|Experimental|Pentoxifylline + corticosteroid|Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M + oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
11631714|NCT00354705||Colon Cancer Patients|Patients with colon cancer recently removed by surgery.
11631715|NCT00354692|Experimental|Experimental|
11631758|NCT00354133|Active Comparator|DBS treatment|Patients in this arm are treated with Deep Brain Stimulation (DBS) of the Nucleus subthalamicus with the device Kinetra and Soletra (neurostimulator, Medtronic) and addtionally get best medical treatment
11631759|NCT00354133|Active Comparator|BMT treatment|Patients in this arm get best medical treatment only.
11631760|NCT00354120|Experimental|1|Alentuzumab
11631761|NCT00354120|Active Comparator|2|Globulina antilinfocitaria
11631716|NCT00354679|Experimental|Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, & Surger|"Induction therapy: Patients receive cisplatin IV over 30 minutes and irinotecan hydrochloride IV over 30 minutes on days 1, 8, 22, and 29. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 22.
~Combination therapy and radiotherapy: Patients receive cisplatin and irinotecan hydrochloride as in induction chemotherapy on days 43, 50, 64, and 71. Patients also receive bevacizumab IV over 30-90 minutes on days 43 and 64. Patients undergo external beam radiotherapy 5 days a week for 6 weeks beginning on day 43. Surgery: Patients undergo surgery 6-8 weeks after finishing combination therapy and radiotherapy.
~Maintenance therapy: Approximately 6 weeks after surgery, patients receive bevacizumab IV over 30-90 minutes every 3 weeks for 6 months"
11631717|NCT00354640|Experimental|Anastrozole and Simvastatin|This is a pharmacological study for women on anastrozole as adjuvant therapy for breast cancer to receive concurrent simvastatin for up to 14 days.
11631718|NCT00354627|Experimental|TMC125|TMC125 200 mg b.i.d. till commercially available.
11631719|NCT00354601|Experimental|Weekly Docetaxel and Capecitabine|Weekly Docetaxel and Capecitabine
11631720|NCT00354575|Experimental|A|Chinese Herb (CCH1)
11631721|NCT00354575|Placebo Comparator|B|Starch powder as placebo
11631722|NCT00354562|Active Comparator|A|Docetaxel + ABT-751
11631723|NCT00354562|Placebo Comparator|B|Docetaxel + placebo
11631724|NCT00354536|Active Comparator|albiglutide|albiglutide injection
11631725|NCT00354536|Placebo Comparator|albiglutide placebo|placebo injection
11631726|NCT00354523|Experimental|Capecitabine + Dacarbazine + Imatinib|Capecitabine starting Dose 500 mg/m^2 twice a day Days 1-14 of 21 Day Cycle. Dacarbazine starting Dose 250 mg/m^2 a day on Days 1-3 of 21 Day Cycle. Imatinib starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
11631727|NCT00354484|Experimental|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
11631728|NCT00354484|Active Comparator|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
11631729|NCT00354458|Placebo Comparator|1|
11631730|NCT00354458|Experimental|2|
11631731|NCT00354432|Active Comparator|Arm I - Placebo|Patients receive oral placebo pill and oral placebo powder once daily.
11631732|NCT00354432|Active Comparator|Arm II - Soy|Patients receive oral placebo pill and oral soy protein/isoflavones powder once daily.
11631733|NCT00354432|Experimental|Arm III - Venlafaxine|Patients receive oral Venlafaxine pill and placebo powder once daily.
11631734|NCT00354432|Placebo Comparator|Arm IV - Soy + Venlafaxine|Patients receive oral Venlafaxine pill and soy protein/isoflavones powder once daily.
11631735|NCT00354419|Experimental|Arm I|See Detailed Description
11631736|NCT00354406|Experimental|A|Patients in Arm A (Early abciximab arm) will receive abciximab at time of STEMI diagnosis, before transfer to the Cath Lab to undergo primary angioplasty.
11631737|NCT00354406|Active Comparator|B|Patients in Arm B (Late abciximab arm) will receive abciximab at time of primary angioplasty, directly in the Cath Lab.
11631738|NCT00354354|Experimental|1|Combivent
11631739|NCT00354354|Placebo Comparator|2|Saline Solution (0.9% NaCl)
11631740|NCT00354341|Experimental|Group 1 (Early Epoetin Beta)|Along with their standard treatment participants will receive epoetin beta at a starting dose of 2000 International Units (IU) subcutaneously (SC) once weekly to reach and maintain target hemoglobin (Hb) between 13 and 15 grams per deciliter (g/dL), for 15 months. Epoetin beta doses will be adjusted according to individual participant's Hb level. Standard treatment will be as per investigator discretion.
11631741|NCT00354341|Active Comparator|Group 2 (No/Late Epoetin Beta)|Participants will receive their standard treatment for 15 months but no treatment for anemia correction unless Hb level will be less than (<) 10.5 g/dL on 2 consecutive visits of 2 weeks interval or the Hb level will be <10 g/dL on a single determination. In such cases participants could receive epoetin beta at a starting dose of 2000 IU SC once weekly to reach and maintain a target Hb level of 10.5 to 11.5 g/dL. Standard treatment will be as per investigator discretion.
11631742|NCT00354315|Experimental|1|Immediate Continuous medical education (CME)
11631743|NCT00354315|No Intervention|2|control, 6 months delay CME intervention
11631744|NCT00354263|Placebo Comparator|A|PBS injected alone in step 1 or mixed with Aggripal in step 2
11631745|NCT00354263|Experimental|B|
11631746|NCT00354250|Experimental|Treatment (ispinesib)|Patients receive ispinesib (SB-715992) IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11631747|NCT00354237|Other|B|No intensive treatment
11631748|NCT00354237|Experimental|A|Intensive insulin treatment
11631749|NCT00354224|Experimental|Oxaliplatin + Capecitabine|Patients will receive Oxaliplatin 85 mg/m2/d on day 1, given as a 2-hour infusion in 250 mL of dextrose 5% repeated every 2 weeks. Capecitabine will be administered orally at a dose of 850 mg/m2 twice a day.
11631750|NCT00354211||1|FLOTRAC™ SYSTEM
11631751|NCT00354211||2|Control Group
11631752|NCT00354198|Active Comparator|corticosteroids|[intravenous pulse methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses
11631753|NCT00354198|Experimental|pentoxifylline + corticosteroids|[intravenous pulse methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses + intravenous infusion of pentoxifylline (0.33-0.66 mg/kg/h) x 7 days + oral pentoxifylline (400-800 mg/day) from days 8 to 90
11631754|NCT00354185|Experimental|Treatment (tanespimycin, belinostat)|"Patients receive 17-AAG IV over 2 hours on days 1, 4, 8, and 11 and PXD101 IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of 17-AAG and PDX101 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD.
~Patients undergo blood collection on days 1 and 4 of course 1 for pharmacokinetic studies."
11631755|NCT00354172|Experimental|Treated Patients|All patients receiving treatment with chemotherapy and radiation, along with natural killer cells, aldesleukin and umbilical cord blood transplant.
11631756|NCT00354159|Experimental|Treatment Arm|Physicians have access to device-based hemodynamic monitor information to guide patient management
11631762|NCT00354107|Experimental|Treatment (monoclonal antibody therapy, chemotherapy)|"Patients receive monoclonal antibody SGN-30 IV alone on day 1 in weeks 1-8. Beginning in week 5, patients receive ICE chemotherapy comprising ifosfamide IV over 2 hours on days 1-3, carboplatin IV over 1 hour on day 1, and etoposide IV over 1 hour on days 1-3. Treatment with ICE repeats every 3 weeks for 6 courses** in the absence of unacceptable toxicity. Patients also receive intrathecal therapy comprising methotrexate, cytarabine, and hydrocortisone once on day 29 (week 5).
~Cohorts of 3-6 patients receive a pre-determined dose of monoclonal antibody SGN-30 with possible dose de-escalation to 1 dose level below in the event of ≥ 2 of 6 patients experience dose-limiting toxicity (DLT). The dose at which ≤ 1 of 6 patients experience DLT will be used in a phase II study."
11631763|NCT00354081|Active Comparator|1|folic acid (0.8 mg) plus vitamin B12 (0.4 mg) and vitamin B6 (40 mg)
11631764|NCT00354081|Active Comparator|2|folic acid (0.8 mg) plus vitamin B12 (0.4 mg)
11631765|NCT00354081|Active Comparator|3|vitamin B6 (40 mg)
11631766|NCT00354081|Placebo Comparator|4|placebo
11631767|NCT00354029|Placebo Comparator|Placebo|Saline 0,9%
11631768|NCT00354029|Active Comparator|S (+) Ketamine|
11631769|NCT00353977|Experimental|ALVAC-CMV (vCP260) Vaccinated group|Patients who were vaccinated with ALVAC-CMV (vCP260)
11631770|NCT00353938|Experimental|3,4-methylenedioxymethamphetamine 125 mg & Psychotherapy|3,4-methylenedioxymethamphetamine 125 and 62.5 m
11631771|NCT00353938|Active Comparator|3,4-methyelendioxymethamphetamine 25 mg & Psychotherapy|3,4-methylenedioxymethamphetamine 25 and 12.5 mg MDMA
11631772|NCT00353873|Active Comparator|Fluticasone propionate (FLIXOTIDE™)|Fluticasone propionate (FLIXOTIDE™) at a dose of 200μg twice daily
11631773|NCT00353873|Experimental|Fluticasone propionate/salmeterol (SERETIDE™)|Salmeterol/fluticasone propionate combination (SERETIDE™) at a dose of 50/100μg twice daily
11631774|NCT00353834|Active Comparator|Glargine insulin|Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve fasting blood glucose of 100 mg/dl and avoid hypoglycemia.
11631775|NCT00353834|Experimental|Exenatide|Exenatide 5ug twice daily for 4 weeks followed by 10 ug twice daily for 8 weeks.
11631776|NCT00353808|Experimental|s, s reboxetine|
11631777|NCT00353782||Dyslipidemia|Dyslipidemia
11631778|NCT00353743|Active Comparator|1|Patients that receive up to 10 days of doxycycline 200mg/day and metronidazole 500mg/day
11631779|NCT00353743|Placebo Comparator|2|Patients that do not receive antibiotics, only placebo
11631780|NCT00353717|Experimental|1|
11631781|NCT00353704|Active Comparator|Pregabalin|150 mg Pregabalin per orally about one hour before surgery
11631782|NCT00353704|Placebo Comparator|Placebo|One capsule of saccharose (placebo) was administered orally about one hour before surgery.
11631783|NCT00353665|Experimental|1 - active|memantine + riluzole
11631784|NCT00353665|Placebo Comparator|2|riluzole + placebo
11631785|NCT00353652|Active Comparator|Study#1: chlorthalidone (CTD) first then spironolactone (SP)|Participants in study #1 only received 2 interventions. All subjects are randomized to receive 3 months of chlorthalidone first (12.5-25 mg/d), using a single-blind 2-phase crossover design. Then, the subject is transitioned to treatment with spironolactone (25-75 mg/d)without washout period for 3 months. Following 3 month treatment period, the procedures listed below were performed. After completion of the study procedures, the medication is discontinued.
11631786|NCT00353652|Active Comparator|Study #1: spironolactone (SP) first, then chlorthalidone (CTD)|Participants in study #1 only received 2 interventions. All subjects are randomized to receive 3 months spironolactone first (25-75 mg/d), using a single-blind 2-phase crossover design. Then, the subject is transitioned to treatment with chlorthalidone(12.5-25 mg/d) without washout period. Following 3 month treatment period, the procedures listed below were performed. After completion of the study procedures, the medication is discontinued.
11631787|NCT00353652|Active Comparator|Study# 2 CTD alone 1st, CTD+ SP 2nd, CTD+IR 3rd|Subjects are randomized to receive 3 months of fixed-dose chlorthalidone (CTD, 25 mg/d) alone first, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD (25 mg/d) plus fixed-dosespironolactone (SP) 25 mg daily for 3 months, then fixed-dose CTD (25 mg/d) plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months. After completion of the study procedures, the medication is discontinued.
11631788|NCT00353652|Active Comparator|Study# 2 CTD alone 1st, CTD+IR 2nd, CTD+SP3rd|Subjects are randomized to receive 3 months of fixed-dose chlorthalidone (CTD, 25 mg/d) alone first, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, followed by fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months. After completion of the study procedures, the medication is discontinued.
11631789|NCT00353652|Active Comparator|Study# 2 CTD+SP1st, CTD alone 2nd, CTD+IR 3rd|Subjects are randomized to receive fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d alone for 3 months, then fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months. After completion of the study procedures, the medication is discontinued.
11631790|NCT00353652|Active Comparator|Study# 2 CTD+SP1st, CTD+IR 2nd, CTD alone 3rd|Subjects are randomized to receive fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, then fixed-dose CTD 25 mg/d alone for 3 months. After completion of the study procedures, the medication is discontinued.
11631791|NCT00353652|Active Comparator|Study# 2 CTD+IR 1st, CTD alone 2nd, CTD+SP 3rd|Subjects are randomized to receive fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d alone for 3 months, then fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months. After completion of the study procedures, the medication is discontinued.
11631792|NCT00353652|Active Comparator|Study# 2 CTD+IR 1st, CTD+SP 2nd, CTD alone 3rd|Subjects are randomized to receive fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, followed by fixed-dose CTD 25 mg/d alone for 3 months. After completion of the study procedures, the medication is discontinued.
11631793|NCT00353639||IBD subjects|Subjects with Inflammatory Bowell Disease
11631796|NCT00353587|Experimental|MBX-102 200 mg|MBX-102 200 mg once daily for 16 weeks
11631797|NCT00353587|Experimental|MBX-102 400 mg|MBX-102 400 mg once daily for 16 weeks
11631798|NCT00353587|Experimental|MBX-102 600 mg|MBX-102 600 mg once daily for 16 weeks
11631799|NCT00353587|Placebo Comparator|Sugar Pill|Placebo comparator once daily for 16 weeks
11631800|NCT00353587|Active Comparator|Actos|Actos 30 mg once daily for 16 weeks
11631801|NCT00353574|Experimental|Darusentan 50 mg|Darusentan 50 mg administered orally once daily
11631802|NCT00353574|Experimental|Darusentan 100 mg|Darusentan 100 mg administered orally once daily
11631803|NCT00353574|Experimental|Darusentan 300 mg|Darusentan 300 mg administered orally once daily
11631804|NCT00353561|Active Comparator|1, Boric acid|600 mg vaginal pessaries for 14 days
11631805|NCT00353561|Other|2, Fluconazole|
11631806|NCT00353548||1-Anorexia Nervosa|Women ages 16-50 who meet DSM-IV criteria for anorexia nervosa
11631807|NCT00353548||2-Bulimia Nervosa|Women age 16-50 who meet DSM-IV criteria for bulimia nervosa
11631808|NCT00353548||3-Binge Eating Disorder|Women with binge eating disorder
11631809|NCT00353548||4-Healthy Controls|Healthy control subjects ages 16-50 of normal weight
11631810|NCT00353548||5-Obese Controls|Healthy obese control subjects
11631811|NCT00353522|Experimental|Dalcetrapib|Dalcetrapib 900mg po daily for 24 weeks
11631812|NCT00353522|Placebo Comparator|Placebo|Placebo po daily for 24 weeks
11631813|NCT00353496|Experimental|lanreotide (Autogel formulation)|
11631814|NCT00353496|Placebo Comparator|Placebo|
11631815|NCT00353483||Tissue, blood, and bone marrow (optional) collection|"Undergo neoadjuvant systemic therapy
~initial surgery for sentinel lymph node biopsy/portacath placement
~definitive cancer surgery (if applicable)
~when portacath is removed (1 year, if available)
~if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis
~Undergo Adjuvant Systemic Therapy
~initial surgery for a sentinel lymph node biopsy/portacath placement
~when portacath is removed (1 year, if available)
~If metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis.
~Undergone neoadjuvant systemic therapy
~during definitive cancer surgery/portacath removal (if available)
~if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis"
11631816|NCT00353470|Experimental|1|Participants will receive panic focused psychodynamic psychotherapy for 12 weeks
11631817|NCT00353470|Active Comparator|2|Participants will receive cognitive behavioral therapy-panic control treatment for 12 weeks
11631818|NCT00353470|Active Comparator|3|Participants will receive applied relaxation training for 12 weeks
11631819|NCT00353457|Experimental|Arm 1|Capecitabine, Oxaliplatin and Cetuximab
11631820|NCT00353431|Active Comparator|1|"Conventional insulin group:
~In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician."
11631821|NCT00353431|Experimental|2|"Intensive insulin therapy algorithm:
~The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake."
11631822|NCT00353418|Experimental|PEG-IFN Alfa-2a 180 μg + Ribavirin 800 mg|
11631823|NCT00353418|Active Comparator|PEG-IFN Alfa-2a 180 μg + Ribavirin 1000 or 1200 mg|
11631824|NCT00353405|Experimental|1|Participants receiving social skills training and mass media messages
11631825|NCT00353405|Experimental|2|Participants receiving social skills training and no mass media messages
11631826|NCT00353405|Experimental|3|Participants receiving mass media messages and no social skills training
11631827|NCT00353405|Experimental|4|Participants receiving no social skills training and no mass media messages
11631828|NCT00353379|Experimental|guanfacine|Participants will take guanfacine.
11631829|NCT00353379|Placebo Comparator|placebo|Participants will take placebo.
11631830|NCT00353366||Cohort Group|Subjects received two oral doses of the Rotarix vaccine at the age of 6 weeks
11631831|NCT00353301|Experimental|Erlotinib and Sirolimus|"Erlotinib hydrochloride (Tarceva) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single-agent Tarceva, 150 mg/day.
~Sirolimus (Rapamune) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day."
11631832|NCT00353275|Other|1|Strict glycemic control with a blood glucose target range of 80-110 mg/dL
11631833|NCT00353275|Other|2|Conventional glycemic control with blood glucose target range of 110-140 mg/dL
11631834|NCT00353262|Experimental|1|
11631835|NCT00353249|Experimental|1|Participants will receive adapted cognitive behavioral therapy treatment
11631836|NCT00353249|No Intervention|2|Participants will receive no treatment for the course of the study; they will be offered courtesy PTSD 5 weeks after the experimental intervention.
11631837|NCT00353223|Experimental|A|Participants will receive combined interpersonal and behavioral psychotherapy aimed at reducing depression in patients with heart failure.
11631838|NCT00353223|Active Comparator|B|Participants will receive the attention control condition.
11631839|NCT00353158|Active Comparator|A|Subjects currently on or previously on chronic voriconazole or subjects who are scheduled to begin voriconazole
11631840|NCT00353158|Experimental|B|100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
11631841|NCT00353145|Experimental|Gemcitabine + Oxaliplatin|Gemcitabine 1000 mg/m^2, infused at 10 mg/m^2/min on Day 1 and Oxaliplatin 100 mg/m^2 by vein infused on Day 2 over two hours. Repeated every 14 days (one cycle).
11631842|NCT00353119|Placebo Comparator|Placebo then etanercept|Patients randomized to initiate the study with placebo for the first 12 weeks - Group 1 then crossed over to etanercept 50mg twice weekly for weeks 12 to 24
11631843|NCT00353119|Active Comparator|Etanercept|Patients randomized to etanercept - Group 2. Patients received etanercept 50 mg subcutaneously twice weekly for 24 weeks
11631844|NCT00353106||Patients|Patients with chronic GVHD
11631845|NCT00353106||Content Expert Panel|Content expert panel with 5 years experience caring for patients with cGVHD.
11631846|NCT00353106||Caregivers|Caregivers of patients with cGVHD
11631847|NCT00353028|Experimental|F|
11631848|NCT00353028|Placebo Comparator|P|
11631849|NCT00353015|Experimental|Irinotecan plus Cisplatin|Irinotecan 65 mg/m2 and Cisplatin 25 mg/m2 intravenous (IV) days 1, 8 of a 21-day cycle
11631850|NCT00352976|Experimental|Treatment with TBI|Patients treated with total body irradiation, Fludarabine, Cyclophosphamide, Bone Marrow Transplantation, Mycophenolate Mofetil, and Sirolimus.
11631851|NCT00352924||Cohort of Agricultural Workers|Cohort of Agricultural Workers
11631852|NCT00352911|Active Comparator|VGX-410 (Mifepristone)|150mg twice daily of VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of VGX-410 for 14 days
11631853|NCT00352911|Placebo Comparator|Placebo for VGX-410 (Mifepristone)|150mg twice daily of placebo for VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of placebo for VGX-410 for 14 days
11631854|NCT00352885|Experimental|Escitalopram|Participants will receive escitalopram and IL-2 treatment
11631855|NCT00352885|Placebo Comparator|Placebo|Participants will receive placebo and IL-2 treatment
11631856|NCT00352859|Experimental|Arm 1|
11631857|NCT00352859|Experimental|Arm 2|
11631858|NCT00352846|Experimental|Vitamin D + Calcium Carbonate|Oral Vitamin D 400 mg daily + Calcium 1200 mg daily
11631859|NCT00352846|Experimental|Vitamin D + Calcium Carbonate + Zoledronic Acid|Oral Vitamin D 400 mg daily and Calcium 1200 mg daily; Zoledronic Acid 4 mg/m^2 intravenous at baseline and 6 months.
11631860|NCT00352820||Interview + Questionnaire|
11631861|NCT00352794|Experimental|Lenalidomide + Prednisone|Lenalidomide oral 10 mg daily/days 1-21 of 28 day cycle. Prednisone starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
11631862|NCT00352781|Experimental|Nicotine Replacement + Behaviour Therapy|Nicotine Replacement Therapy as per monograph & behavioural intervention
11631863|NCT00352768|Experimental|F|
11631864|NCT00352768|Placebo Comparator|P|
11631865|NCT00352755|Experimental|Peritonectomy + IP5FU + FOLFOX|"Surgical debulking with peritonectomy
~IP 5FU 600 mg/m^2 over 30-60 minutes with patient rotating every 15 minutes. Repeated every 2 weeks for a total of 9 cycles.
~FOLFOX (oxaliplatin, 5FU, leucovorin) will follow IP therapy. Oxaliplatin 85 mg/m^2 over 2 hours with leucovorin at 400 mg/m^2 and IV 5-FU at 2400 mg/m^2 over 46 hours. Repeated every 2 weeks for a total of 8 cycles."
11631866|NCT00352742|Experimental|1|ATN-224 + bortezomib
11631867|NCT00352729|Active Comparator|A|
11631868|NCT00352703|Experimental|Kepivance (palifermin) 60 μg/kg/day IV|60 μg/kg/day IV for 3 consecutive days before the conditioning regimen and 3 consecutive days after the peripheral blood stem cell transplantation.
11631869|NCT00352690|Other|Cohort 1 (first 12 eligible patients)|"Paclitaxel poliglumex 135 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.
~Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.
~Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.
~Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.
~Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles."
11631870|NCT00352690|Experimental|Cohort 2 (remaining patients)|"Paclitaxel poliglumex 175 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.
~Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.
~Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.
~Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.
~Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles."
11631871|NCT00352664|Active Comparator|Donepezil|Oral Donepezil 5 mg daily x 7 days
11631872|NCT00352664|Placebo Comparator|daily x 7 days|Placebo tablet daily x 7 days
11631873|NCT00352612|Placebo Comparator|cephalexin|
11631874|NCT00352612|Active Comparator|clindamycin|
11631875|NCT00352599|Active Comparator|Lovastatin|Lovastatin
11631876|NCT00352599|Placebo Comparator|Placebo pill|Placebo pill
11631877|NCT00352573||Normal Volunteers|Adults over 21 years old
11631878|NCT00352560|Active Comparator|A|
11631879|NCT00352560|Placebo Comparator|B|
11631880|NCT00352534|Experimental|Nephrectomy and re-evaluation (very low-risk disease)|Patients undergo nephrectomy only. If they meet criteria, they are then observed periodically for 5 years. Patients with recurrent disease undergo surgery (immediate or delayed) and receive chemotherapy as in stratum III. Patients with no metachronous renal disease receive radiotherapy. Patients with metachronous disease undergo renal-sparing surgery and chemotherapy as in stratum III, but no radiotherapy. Treatment continues for up to 25 weeks.
11631881|NCT00352534|Experimental|Nephrectomy, chemotherapy (standard-risk, stg I or II)|Patients undergo nephrectomy. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1, every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 doses of doxorubicin. Treatment continues for up to 25 weeks.
11631882|NCT00352534|Experimental|Nephrectomy/biopsy, chemotherapy (standard-risk, stage III)|Patients undergo nephrectomy, if feasible, or biopsy. For patients who undergo biopsy only, definitive surgery is undertaken at week 7 or 13. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1 every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 dose of doxorubicin hydrochloride. Patients undergo radiotherapy over 5-7 days after nephrectomy. Treatment continues for up to 25 weeks.
11631916|NCT00352001|Experimental|Lenalidomide and Azacitidine|
11631917|NCT00351988||African American caregivers|African American caregivers for patients with advanced non-small cell lung cancer or breast cancer.
11631883|NCT00352521|Experimental|Bevacizumab and irinotecan|The bevacizumab will be dosed at 10 mg/kg every 14 days (days 1, 15 and 29) and the irinotecan on days 2, 15, and 29 of the first six week schedule. The irinotecan dose will depend on whether the patient is on an enzyme-inducing antiepileptic drug (EIAED). If the patient is on an EIAED, the patient will receive 340 mg/m2 on days 2, 15, and 29 of the first six week schedule. If the patient is not on an EIAED, the dose of irinotecan will be 125 mg/m2 on days 2, 15, and 29 of the first six week schedule. After the first cycle, the irinotecan and bevacizumab will be given on days 1, 15 and 29.
11631884|NCT00352495|Experimental|Vinblastine sulfate and carboplatin|The MTD of vinblastine in combination with a monthly dose of carboplatin will be determined during the first cycle of therapy. Each 4-week cycle will consist of carboplatin once every 4 weeks on day 1. Vinblastine will be given once a week for 3 weeks followed by a one week break. Doses of carboplatin and vinblastine sulfate will be assigned at study enrollment. Patients may receive eleven additional four week cycles, barring tumor progression or unacceptable toxicity. The total duration of therapy will be approximately 48 weeks.
11631885|NCT00352469|Placebo Comparator|2|Subjects will be randomized to receive either Seroquel SR or placebo
11631886|NCT00352443|Experimental|everolimus/lapatinib|Part 1, dose finding: everolimus and lapatinib at assigned dose daily Part 2, cohort A: Everolimus MTD from Part I: 5 mg PO 1-28 Daily Lapatinib MTD from Part I: 1,250 mg PO Cycle 1, Daily Days 8-28** Subsequent Cycles, Days 1-28 Part 2, cohort B: Lapatinib MTD from Part I: 1,250 mg PO 1-28 Daily Everolimus MTD from Part I: 5 mg PO Cycle 1, Daily Days 8-28** Subsequent Cycles, Days 1-28
11631887|NCT00352417|Experimental|VIA-2291|
11631888|NCT00352417|Placebo Comparator|Placebo|Matching Placebo
11631889|NCT00352391||Vanguard Study|Patients with Head and Neck or Non-Small Cell Lung Cancer who are Current or Former Smokers.
11631890|NCT00352378|Experimental|Adriamycin plus Cyclophosphamide|Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1.
11631891|NCT00352378|Experimental|Taxotere plus Xeloda|Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14
11631892|NCT00352365|Experimental|Treatment (lenalidomide)|"INDUCTION THERAPY: Patients receive oral lenalidomide once daily on days 1-14, 1-21, or 1-28 (course 1). Patients undergo bone marrow biopsy on day 28 or 35 to assess treatment efficacy. Patients with stable or improving disease (i.e., a decrease in blast percentage) without progressive disease proceed to maintenance therapy.
~MAINTENANCE THERAPY: Beginning within 42 days after completion of induction therapy, patients receive oral lenalidomide once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11631893|NCT00352339|Experimental|Aripiprazole|switching group (from risperidone to aripiprazole)
11631894|NCT00352339|Active Comparator|Risperidone|Start with risperidone and keep it through the end of study
11631895|NCT00352339|Active Comparator|Abilify|Start with aripiprazole and keep it through the end of study
11631896|NCT00352326|Experimental|Children (with dystonia and controls)|"Participants sat in a chair or their own wheelchair in front of a table whose surface height was adjusted at the midpoint between the hip and the Xiphoid process. They placed the hand that was not used for the task on their lap.
~An iPad® (Apple Inc, Cupertino, California) was located on the table in portrait mode in front of the participants at a distance that ranged between 40 and 55 cm. An adjustable metal bookstand supported the iPad® to allow the participants a comfortable screen view. The size of the screen was 19.5 × 14.6 cm. Custom software was developed for the experimental task (XCode 3.2 development environment, iOS 4.2 operating system; Apple Inc, Cupertino, California)."
11631897|NCT00352313|Experimental|Phase I|Patients receive ATN-161 IV over 10 minutes 3 times weekly in weeks 1-6 and carboplatin IV over 20 minutes in week 3 during course 1. Beginning in course 2, patients receive carboplatin IV over 20 minutes in week 1 and ATN-161 IV over 10 minutes 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
11631898|NCT00352313|Experimental|Phase II|Patients receive carboplatin IV in week 1 and ATN-161 IV, at the MTD determined in phase I, 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11631899|NCT00352300|Experimental|Treatment (carboplatin, paclitaxel, pegfilgrastim)|Patients receive carboplatin IV and paclitaxel IV over 3 hours on day 1. Patients also receive pegfilgrastim subcutaneously on day 2.
11631900|NCT00352196|Experimental|Magnetic Resonance Spectroscopy|Subjects will receive a baseline MRS prior to and within 7 day of completing 12 weeks of standard treatment with.
11631901|NCT00352196|Other|NO-MRS|Subjects will receive 12 weeks of standard treatment of risperidone 0.25 to 11 mg per day, or early termination. Dose titration will based on response and tolerability.
11631902|NCT00352183|Experimental|1|
11631903|NCT00352183|Active Comparator|2|
11631904|NCT00352170|Experimental|1|calcium supplementation
11631905|NCT00352170|Experimental|2|calcium and vitamin D3 supplementation
11631906|NCT00352170|Experimental|3|placebo
11631907|NCT00352144|Experimental|1|eszopiclone 3 mg tablet
11631908|NCT00352144|Placebo Comparator|2|Placebo tablet
11631909|NCT00352118|Experimental|Chemotherapy + Low Dose Radiation|Patients receiving chemotherapy and Low Dose (60 Gy) Radiation per protocol.
11631910|NCT00352105|Experimental|Concurrent Chemotherapy and ZD1839|
11631911|NCT00352079|Active Comparator|Intravesicle BCG|"Induction:
~q weekly x 6 (cycle 1)
~Maintenance:
~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months postrandomization (cycles 2 - 8)"
11631912|NCT00352079|Active Comparator|Iressa and Intravesicle BCG|"Intravesical BCG:
~Induction:
~q weekly x 6 (cycle 1)
~Maintenance:
~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)
~Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)"
11631913|NCT00352053|Experimental|OBR + Tenofovir DF|Tenofovir DF administered orally, one tablet daily without regard to meals
11631914|NCT00352053|Placebo Comparator|OBR + Tenofovir DF Placebo|Placebo to match tenofovir DF administered orally, one tablet daily without regard to meals
11631915|NCT00352027|Experimental|All Participants|Participants receive 12 weeks of Stanford V chemotherapy which includes Adriamycin®, Vinblastine, Nitrogen Mustard (or Cyclophosphamide), Vincristine, Bleomycin, Etoposide, Prednisone, and G-CSF. After completion of 12 weeks of Stanford V chemotherapy, participants receive radiotherapy.
11631918|NCT00351988||Latino caregivers|Latino caregivers for patients with advanced non-small cell lung cancer or breast cancer.
11631919|NCT00351988||White non-Latino caregivers|White non-Latino caregivers for patients with advanced non-small cell lung cancer or breast cancer.
11631920|NCT00351975|Experimental|Arm I (chemotherapy)|Patients receive azacitidine SC on days 1-5.
11631921|NCT00351975|Experimental|Arm II (chemotherapy, enzyme inhibitor therapy)|Patients receive azacitidine as in arm I and belinostat at the MTD IV over 30 minutes on days 1-5.
11631922|NCT00351962|Experimental|Schedule I (10 fractions)|Subjects will receive a total of 10 stereotactic radiation treatments, given over 3 weeks.
11631923|NCT00351962|Experimental|Schedule II (4 fractions)|Subjects will receive a total of 4 stereotactic radiation treatments, given over 2 weeks.
11631924|NCT00351936|Active Comparator|Aripiprazole|aripiprazole 15mg/day
11631925|NCT00351936|Placebo Comparator|placebo|matched placebo for aripiprazole 15mg/day
11631926|NCT00351884|Experimental|vildagliptin am|
11631927|NCT00351884|Experimental|vildagliptin pm|
11631928|NCT00351884|Placebo Comparator|placebo|
11631929|NCT00351819|Active Comparator|Androgel (testosterone gel)|Testosterone replacement therapy
11631930|NCT00351819|Placebo Comparator|Placebo|Placebo gel
11631931|NCT00351806|Experimental|Chinese herbal medicine|
11631932|NCT00351806|Placebo Comparator|placebo|
11631933|NCT00351793||Combined Deformity <30 degrees|
11631934|NCT00351793||Combined Deformity >30 degrees|
11631935|NCT00351767|Experimental|1|
11631936|NCT00351767|Experimental|2|
11631937|NCT00351767|Experimental|3|
11631938|NCT00351767|Placebo Comparator|4|
11631939|NCT00351741|Experimental|High Frequency|Provide standard ventilatory support for burn patients utilizing high frequency percussive ventilation
11631940|NCT00351741|Active Comparator|Conventional|Standard ventilator support for non burned patients utilizing lung protective low tidal volume ventilation
11631941|NCT00351715|Experimental|Pharmacokinetic|One episode of breakthrough pain was to be evaluated per patient. Clinical status and bloodwork was evaluated prior to entering into this phase of the trial, and patients were eligible if bloodwork demonstrated a HgB of >90 g/L with no concurrent bleeding. A peripheral intravenous catheter was inserted and saline locked. When breakthrough pain was experienced, methadone was administered, and the patient completed a pain intensity numeric rating scale at time 0 and every 10 minutes for one hour. A 10 cc specimen of blood was collected prior to administration of methadone, and again every 10 minutes for one hour. Blood was collected without anticoagulant, allowed to clot, separated by centrifugation, and serum samples flash frozen. Serum methadone levels were quantified by LC/MS/MS with comparison to isotopically labeled internal standards
11631942|NCT00351702|Active Comparator|Isoniazid|Isoniazid (300mg) daily for 36 months
11631943|NCT00351663|Active Comparator|IV by weight|intravenous dose of 0.5 mg/kg enoxaparin once daily
11631944|NCT00351663|Active Comparator|SC fixed dose|subcutaneous fixed dose of 40 mg enoxaparin once daily
11631945|NCT00351663|Active Comparator|SC by weight|subcutaneous dose of 0.5 mg/kg enoxaparin once daily
11631946|NCT00351624|Active Comparator|DHA|
11631947|NCT00351624|Placebo Comparator|placebo|
11631948|NCT00351611|Experimental|Active|Active drug
11631949|NCT00351611|Placebo Comparator|Placebo|placebo comparator
11631950|NCT00351598||1|Patients with loco-regional, NSCLC treated by definitive radiotherapy.
11631951|NCT00351533|Experimental|1|Enteral fish oil
11631952|NCT00351533|Placebo Comparator|2|Enteral saline
11631953|NCT00351468|Experimental|Eltrombopag|Open-label eltrombopag
11631954|NCT00351442||1|Inidividuals who have been exposed to HIV but remain uninfected.
11631955|NCT00351442||2|HIV infected regular sexual partners of Group 1 participants.
11631956|NCT00351442||3|HIV uninfected individuals or couples who have not been exposed to HIV.
11631957|NCT00351429|Experimental|1|
11631958|NCT00351416|Experimental|Aromatase inhibitor EFP|"Letrozole administration (20 mg) on day 2-4 (EFP; early follicular phase) of cycle 2 and
~Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted."
11631959|NCT00351416|Experimental|Aromatase inhibitor LFP|"Letrozole administration (20 mg daily x 2) at follicle size of > 16 mm (LFP; late follicular phase) in cycle 2.
~Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted."
11631960|NCT00351403|Experimental|Individualized therapy|Lengh of therapy depends on time point when no HCV RNA is detectable in blood with Versant HCV Qualitative assay.
11631961|NCT00351403|Other|Historical control|48 week standard therapy
11631962|NCT00351390|Placebo Comparator|SOC|Standard of care HF therapy without NT-proBNP guidance
11631963|NCT00351390|Active Comparator|NT-proBNP arm|NT-proBNP plus standard HF management
11631964|NCT00351377|Experimental|Enteric-coated Mycophenolate Sodium|Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily in a dose that was equimolar to the dose of Mycophenolate mofetil the participant was taking at the time of study entry. The planned duration of treatment 6 to 8 weeks.
11631965|NCT00351364|Active Comparator|Montelukast sodium|Drug arm - Montelukast as a single dose 100 mg. To test the hypothesis of leukotriene inhibition.
11631966|NCT00351364|Placebo Comparator|2|No drug given - no placebo available. To compare with active drug.
11631967|NCT00351351|Experimental|A|Cyberwand
11631968|NCT00351351|Active Comparator|B|Currently available lithotripsy technology
11631969|NCT00351325|Experimental|dose escalation|
11631970|NCT00351299|Experimental|Infusion of dexmedetomidine|infusion 0.3-0.7 dexmedetomidine
11631971|NCT00351299|Other|Standard of Care|Standard of care per treating physician preference
11631972|NCT00351273|Active Comparator|Azithromycin and Rifampin|Participants received Azithromycin and Rifampin
11631973|NCT00351273|Active Comparator|Doxycycline and Rifampin|Participants received Doxycycline and Rifampin
11631974|NCT00351273|Placebo Comparator|received placebo|Participants received placebo
11631975|NCT00351143|Experimental|Interventional group: Period 2|Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training in Period 2
11631976|NCT00351143|Active Comparator|Control group: Period 2|Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg in treatment Period 2
11631977|NCT00351143|Experimental|Subjects receiving salmeterol/fluticasone propionate: Period 1|All subjects treated with salmeterol/fluticasone propionate 50/250 µg b.i.d without any other intervention will be included in Period 1
11631978|NCT00351117|Experimental|1|St. John's wort 300mg PO TID
11631979|NCT00351117|Placebo Comparator|2|Lactose in capsule matching the St. John's wort. 300mg PO TID
11631980|NCT00351078|Experimental|PTC124 PO|4-, 4-, and 8-mg/kg TID first 14 days of cycle 10-, 10-, and 20-mg/kg TID second 14 days of cycle 28 day study
11631981|NCT00351052|Experimental|1|Pimecrolimus
11631982|NCT00351052|Placebo Comparator|2|Vehicle
11631983|NCT00351039|Experimental|Bevacizumab, Erlotinib, Pemetrexed|Single Arm Phase II trial in elderly patients with advanced stage Non-Squamous Non-Small Cell Lung Cancer
11631984|NCT00351026|Active Comparator|1|25 HIV negative opiate dependent patients all treated with methadone
11631985|NCT00351026|Active Comparator|2|25 HIV positive opiate dependent patients all treated with methadone
11631986|NCT00351013|Experimental|1|
11631987|NCT00350987|Experimental|PCT|PCT guidance
11631988|NCT00350987|Active Comparator|Guidelines|enforced guidelines
11631989|NCT00350974||End-stage Renal Disease|on maintenance hemodialysis 3 x per week for more than 12 months
11631990|NCT00350974||No kidney disease|eGFR greater than 60 ml/Min
11631991|NCT00350974||Hypertensive group|Blood pressure greater than 130/80
11631992|NCT00350948|Experimental|Telcyta + Liposomal Doxorubicin|Telcyta at 1000 mg/m2 followed by Liposomal Doxorubicin at 50 mg/m2 on Day 1 of each four-week treatment cycle
11631993|NCT00350948|Active Comparator|Liposomal Doxorubicin|Liposomal Doxorubicin at 50 mg/m2 on Day 1 of each four-week treatment cycle
11631994|NCT00350935||Healthy volunteers|Healthy controls
11631995|NCT00350935||Patients|Patients with schizophrenia
11631996|NCT00350909|Experimental|1|One arm was a 2-session brief intervention with both sessions involving only the adolescent. Each session was a 60 minute individual session with the counselor.
11631997|NCT00350909|Active Comparator|2|The other arm was a 3-session brief intervention, with 2 sessions involving the adolescent and one session with the parent. Each of these individual sessions were 60 minutes.
11631998|NCT00350883|Other|Treatment as Usual|
11631999|NCT00350883|Experimental|Cognitive Therapy|
11632000|NCT00350870|Placebo Comparator|Placebo|Placebo (plus Cognitive Behavioral Therapy- CBT)
11632001|NCT00350870|Active Comparator|Disulfiram|Disulfiram (plus CBT)
11632002|NCT00350870|Placebo Comparator|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance (in addition to CBT).
11632003|NCT00350870|Active Comparator|Disulfiram plus Contingency Management|Disulfiram plus Contingency Management for cocaine abstinence and medication compliance (in addition to CBT).
11632004|NCT00350857|Active Comparator|Equetro active|
11632005|NCT00350844|Experimental|Hydroxyurea|
11632006|NCT00350818|Experimental|Azacitidine|Azacitidine after Allogeneic Transplantation
11632007|NCT00350805||Healthy volunteers|
11632008|NCT00350805||Patients|
11632009|NCT00350792|Experimental|Pemetrexed + Carboplatin|"Pemetrexed: 500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 6 cycles.
~Carboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles."
11632010|NCT00350779|Experimental|1|Sitagliptin
11632011|NCT00350779|Placebo Comparator|2|Placebo
11632012|NCT00350766|Experimental|Treated Group|Intracoronary injection in the infarcted-related artery of 100 million bone marrow mononuclear cells resuspended in a 10 ml solution of saline with autologous serum.
11632013|NCT00350766|Placebo Comparator|Control Group|Intracoronary injection in the infarcted-related artery of placebo solution consisting of a saline containing autologous blood serum.
11632014|NCT00350753|Experimental|Erlotinib and bevacizumab|
11632015|NCT00350727|Experimental|Combination|Pazopanib and Lapatinib in combination. Subjects remain on treatment until disease progression or withdrawal from study.
11632016|NCT00350714|Experimental|MBT|C13 methacetin dissolved in water to be ingested after breath baseline collected. Metabolism to measured in real time.
11632017|NCT00350701|Experimental|androgel 5g|androgel 5g
11632018|NCT00350701|Experimental|androgel 10g|androgel 10g
11632019|NCT00350701|Placebo Comparator|placebo|placebo
11632020|NCT00350688|Other|Helical tomotherapy IMRT|Helical tomotherapy IMRT
11632021|NCT00350662|Experimental|Deferiprone + Desferrioxamine|
11632022|NCT00350662|Experimental|Deferiprone single agent|
11632023|NCT00350662|Active Comparator|Desferrioxamine single agent|
11632024|NCT00350649|Experimental|1|manualized delivery of CBT by trained clinicians
11632025|NCT00350649|Active Comparator|2|CBT with Contingency Management reinforcement for attendance and completing homework (CBT+CM/adherence)
11632026|NCT00350649|Experimental|3|Contingency Management for abstinence alone (CM/abstinence)
11632027|NCT00350649|Active Comparator|4|Contingency Management integrated with CBT (CM/abstinence+CBT)
11632028|NCT00350636|Experimental|Oxybutynin topical gel|Oxybutynin topical gel
11632029|NCT00350636|Placebo Comparator|Placebo topical gel|placebo topical gel
11632030|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
11632031|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
11632032|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
11632033|NCT00350610|Active Comparator|1|Standard treatment as usual (TAU) in a community based clinic consisting of individual and group therapy sessions and regular urine monitoring.
11632109|NCT00349596|Experimental|Decitabine|Decitabine administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
11632110|NCT00349492|Active Comparator|EP|etoposide + cisplatin
11632111|NCT00349479|Active Comparator|Intervention|
11632034|NCT00350610|Experimental|2|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping cocaine use and increasing coping skills twice weekly for 8 weeks.
11632035|NCT00350584|Experimental|Mindfulness Telehealth for PTSD|Participants receive two in-person sessions and 6 sessions over the phone. Participants are introduced to mindfulness concepts. CDs with guided meditation exercises are given to participants and they are asked to practice between sessions.
11632036|NCT00350584|Active Comparator|Psychoeducation Telehealth for PTSD|Participants receive two in-person sessions and six telehealth sessions with education about symptoms of PTSD and coping strategies. In addition, participants are asked to read short homework assignments and think about them during the week; these are discussed in weekly sessions.
11632037|NCT00350571|Active Comparator|Standard care follow up|Standard care counselor follow up care phone calls or letters.
11632038|NCT00350571|Experimental|Drop out reengagement motivational intervention|Single session office based or phone based motivational counseling session designed to promote participant re-engagement in standard treatment.
11632039|NCT00350545|Experimental|rituximab + prednisone arm|Rituximab will be given as an IV fusion as initial treatment, followed by predisone (given during registration) which will be continued through-out trial and tapered off by physician. Cyclosporine A and tacrolimus will be used if chances of new diagnosis of chronic GVHD occur. Both drugs have no interaction with Rituxan, but will be tapered off after predisone is completely tapered.
11632040|NCT00350532|Active Comparator|Neuropathic Pain Subjects|Chronic Pain Participants will be trained to accurately estimate pain by way of thermal heat testing. Next a small amount of spinal fluid will be withdrawn from each participant to measure the amounts of naturally-made chemicals in the participants' cerebrospinal fluid. Participants then will receive an injection of clonidine. After the injection, additional samples of spinal fluid will be taken to measure chemical changes in the fluid.
11632041|NCT00350532|Active Comparator|Healthy Subjects|Healthy Participants will be trained to accurately estimate pain by way of thermal heat testing. Next a small amount of spinal fluid will be withdrawn from each participant to measure the amounts of naturally-made chemicals in the participants' cerebrospinal fluid. Participants then will receive an injection of clonidine. After the injection, additional samples of spinal fluid will be taken to measure chemical changes in the fluid.
11632042|NCT00350519|Experimental|PROCRIT (epoetin alfa)|Participants will receive PROCRIT (epoetin alfa).
11632043|NCT00350519|Experimental|STANDARD THERAPY|Participants will receive standard of care.
11632044|NCT00350506|Experimental|64 Channel VCT|All subjects underwent Coronary Computed Tomographic Angiography (CCTA) after receiving an intravenous (IV) administration of Visipaque (320 mgI/mL), to be followed by catheter coronary angiography (CATH).
11632045|NCT00350454|Active Comparator|A|Drug eluting stent using biodegradable polymer BP stent
11632046|NCT00350454|Active Comparator|B|polymer-free drug eluting stent PF stent
11632047|NCT00350454|Active Comparator|C|permanent polymer using stents PP stent
11632048|NCT00350415|Experimental|1|Asacol 2.4 g/day (400 mg tablet)
11632049|NCT00350415|Active Comparator|2|Asacol 4,8 g/day (800 mg tablet), oral, for 6 weeks
11632050|NCT00350402|Active Comparator|High Intensity Muscle Strength Training|This arm involved high intensity muscle strength training at 75% maximum inspiratory pressure (MIP). Training took place for 4 weeks, 5 days a week. Each daily session involved 5 sets of breathing exercises that required participants to take deep breaths (i.e., inspire) using use a breathing device. Settings on the breathing device were determined by obtaining the individual's maximal inspiratory pressure (MIP)using a specialized breathing gauge. The MIP was determined at the beginning of each week and the training device was adjusted and set at 75% MIP. Exercises took place in home setting, with weekly visit by staff. Participants kept daily exercise log.
11632051|NCT00350402|Sham Comparator|Sham MST|This arm (low intensity MST) was identical to the real intervention in all ways except that the training device was set at 5% maximum inspiratory pressure (MIP). Thus less muscle and breathing effort was required during this sham treatment.
11632052|NCT00350389|Experimental|1|Provision of single lens glasses, glasses aids, counselling, updated multifocal glasses if required
11632053|NCT00350389|No Intervention|2|Usual care, updated multifocal glasses if required
11632054|NCT00350363|Active Comparator|1 hour gatifloxacin|presence of conjunctival bacteria 1 hour after administration of topical gatifloxacin
11632055|NCT00350350||elderly people|elderly people over 70 years residents of old's people homes with symptoms of dry mouth
11632056|NCT00350337|Experimental|Pre-transfection F17|"4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.
~Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine"
11632057|NCT00350337|Experimental|Post-transfection F17|"4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.
~Lyophilized, single dose vials and sterile water for injection"
11632058|NCT00350337|Experimental|Post-transfection F19|"4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.
~Lyophilized, single dose vials and sterile water for injection"
11632059|NCT00350337|Placebo Comparator|Placebo|A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine.
11632060|NCT00350298|Active Comparator|1|GS-CDA1 and MDX-1388
11632061|NCT00350298|Placebo Comparator|2|normal saline (0.9% sodium chloride)
11632062|NCT00350285|Experimental|1|Motivational enhancement therapy
11632063|NCT00350285|Active Comparator|2|Marijuana education
11632064|NCT00350285|No Intervention|3|Delayed treatment control condition
11632112|NCT00349479|No Intervention|Control|
11632065|NCT00350272|Experimental|Elvucitabine, Efavirenz,Tenofovir|"Elvucitabine (blinded) 10 mg/day in combination with open-label efavirenz 600 mg daily and open-label tenofovir 300 mg daily, all administered orally, over 12 weeks. Eligible subjects continued with an additional 84 weeks of open-label treatment (through Week 96).
~Subjects who experienced at least a 2 log10 decrease in HIV-1 RNA from Baseline or who had an HIV-1 RNA level of less than 400 copies/mL at Week 10 and had not experienced any Grade 3 or 4 hematological toxicity as of the Week 10 measurement were considered eligible for an additional 84 weeks of open-label treatment after Week 12."
11632066|NCT00350272|Active Comparator|Lamivudine,Efavirenz,Tenofovir|"Lamivudine (blinded) 300 mg daily in combination with open-label efavirenz 600 mg daily and open-label tenofovir 300 mg daily, all administered orally, over 12 weeks. Eligible subjects continued with an additional 84 weeks of open-label treatment (through Week 96).
~Subjects who experienced at least a 2 log10 decrease in HIV-1 RNA from Baseline or who had an HIV-1 RNA level of less than 400 copies/mL at Week 10 and had not experienced any Grade 3 or 4 hematological toxicity as of the Week 10 measurement were considered eligible for an additional 84 weeks of open-label treatment after Week 12."
11632067|NCT00350233|Experimental|ExAblate MRgFUS|
11632068|NCT00350220|Active Comparator|1|High Hemoglobin group; goal Hb >13g/dl. 10cc/kg RBCs are transfused for any hemoglobin value under 13g/dl regardless whether clinical indication for transfusion exists.
11632069|NCT00350220|Active Comparator|2|Low Hb transfusion group; goal to not transfuse unless the Hb <9.0 g/dl. 10cc/kg RBCs are transfused only if the Hemoglobin is under 9.0g/dl and clinical indications for transfusion exist.
11632070|NCT00350194|Placebo Comparator|1|Omega-3 fatty acid vs. placebo comparator
11632071|NCT00350142|Experimental|Stereotactic Body Radiotherapy|Patients will have a 4D pancreatic protocol CT and a FDG PET scan scan, both for planning purposes. An SBRT treatment plan will be developed based on tumor geometry and location. All patients will receive a single fraction of 25 Gy dose of Stereotactic Body Radiotherapy on Trilogy Linear Accelerator, followed by weekly Gemcitabine.
11632072|NCT00350129||1|healthy vasospastic subjects
11632073|NCT00350129||2|healthy non-vasospastic subjects
11632074|NCT00350051|Experimental|Arm 1|
11632075|NCT00350025|Other|Cetuximab alone|Cetuximab 250mg/m2 IV weekly during each 28 day cycle. Arm A closed to accrual June 11, 2009 for lack of efficacy
11632076|NCT00350025|Other|Cetuximab with Paclitaxel|Paclitaxel 80 mg/m2 IV weekly for every 28 day cycle. Cetuximab 250mg/m2 IV weekly for every 28 day cycle.
11632077|NCT00350012||1|Persons who have had a stroke and either have, or do not have, a pathological asymmetry of perception, attention and action causing functional disability (spatial neglect; Barrett and Burkholder, 2006).
11632078|NCT00350012||2|Healthy age- and education-matched volunteers
11632079|NCT00349999||1|18 males and non pregnant females, ages 18-45, with acute cholera.
11632080|NCT00349973|Experimental|1|Dipyridamole
11632081|NCT00349973|Active Comparator|2|Olanzapine
11632082|NCT00349947|Active Comparator|1|Participants will take part in an exercise program.
11632083|NCT00349947|No Intervention|2|Participants will take part in a usual activity group.
11632084|NCT00349934|Experimental|A|IMP321
11632085|NCT00349921|Active Comparator|clonidine first, then adenosine|clonidine given in first injection adenosine given in second injection
11632086|NCT00349921|Active Comparator|adenosine first, then clonidine|adenosine given in first injection clonidine given in second injection
11632087|NCT00349921|Placebo Comparator|clonidine given first, then placebo|placebo
11632088|NCT00349921|Placebo Comparator|adenosine given first, then placebo|placebo
11632089|NCT00349908|Experimental|Group 1: Atherosclerosis Arm|Implant of Cordis Neurovascular ENTERPRISE Self Expanding Stent System
11632090|NCT00349908|Active Comparator|Group 2: Aneurysm Arm|Implant of Cordis Neurovascular ENTERPRISE Self Expanding Stent System
11632091|NCT00349869|Experimental|1|8-week yoga program
11632092|NCT00349869|No Intervention|2|Usual care control
11632093|NCT00349856|Active Comparator|1|
11632094|NCT00349804|Other|Air cooled (COOL)|Subjects will complete the intermitent exercise protocol with cool dry air blown under the shoulder pads during the rest periods and recovery session
11632095|NCT00349791|Placebo Comparator|1|placebo patch replaced twice a week for two years
11632096|NCT00349791|Experimental|2|testosterone patch replaced twice a week for two years
11632097|NCT00349778|Experimental|High-Dose Sequential Therapy|Cyclophosphamide + Etoposide + Melphalan + Carmustine with Filgrastim
11632098|NCT00349752|Experimental|Certolizumab pegol 400 mg|Certolizumab pegol 400 mg
11632099|NCT00349752|Placebo Comparator|Placebo|Placebo
11632100|NCT00349726|Experimental|Inositol low volume|Single dose of intravenous inositol 5%, 60 mg/kg (1.2ml/kg) given over 20 minutes
11632101|NCT00349726|Experimental|Inositol high volume|Single dose of intravenous inositol 5%, 120 mg/kg (2.4ml/kg) given over 20 minutes
11632102|NCT00349726|Placebo Comparator|Placebo low volume|Placebo (5% glucose) at a volume equal to 60 mg/kg (1.2 ml/kg) given via IV over 20 minutes.
11632103|NCT00349726|Placebo Comparator|Placebo high volume|Placebo (5% glucose) at a volume equal to 120 mg/kg (2.4 ml/kg) given via IV over 20 minutes
11632104|NCT00349713|Experimental|Cohort 1: 25ug FMP2.1 / AS02A|20 subject to receive 25ug of FMP2.1 vaccine in 0.25mL of GSK Biologicals' adjuvant AS02A
11632105|NCT00349713|Experimental|Cohort 2: 50ug FMP2.1 / AS02A|20 subjects to receive 50ug of FMP2.1 vaccine in 0.5mL of GSK Biologicals' adjuvant AS02A
11632106|NCT00349713|Active Comparator|Cohorts 1 and 2: Rabies vaccine (RabAvert)|"20 subjects to receive Rabies vaccine (RabAvert). 10 subjects from Cohort 1 and 10 subjects from Cohort 2
~Rabies vaccine (RabAvert): RabAvert Rabies vaccine"
11632107|NCT00349622|Active Comparator|Ceftriaxone|"Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
~Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day."
11632108|NCT00349622|Placebo Comparator|Placebo|"One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
~Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day."
11632113|NCT00349466|Experimental|1|CF101 1 mg given orally every 12 hours for 12 weeks
11632114|NCT00349466|Placebo Comparator|2|Placebo given orally every 12 hours for 12 weeks
11632115|NCT00349453|Experimental|Deferiprone (L1) monotherapy|Deferiprone (L1) monotherapy
11632116|NCT00349453|Experimental|Combination therapy|Deferiprone (L1) and desferrioxamine combination treatment
11632117|NCT00349440|Active Comparator|1|
11632118|NCT00349440|Placebo Comparator|2|
11632119|NCT00349427|Experimental|Rosiglitazone|4mg
11632120|NCT00349427|Placebo Comparator|Rosiglitazone placebo|4mg
11632121|NCT00349388|Experimental|Asacol once a day dosing|Asacol total dose in mg/kg given once a day
11632122|NCT00349388|Active Comparator|Asacol BID/TID dosing|Asacol total dose split BID or TID
11632123|NCT00349375|Experimental|1|
11632124|NCT00349375|Experimental|2|
11632125|NCT00349375|Active Comparator|3|
11632126|NCT00349362|Experimental|Testosterone|Testosterone injections- 200mg- every 2 weeks
11632127|NCT00349362|Placebo Comparator|Placebo|Normal saline injections- every two weeks
11632128|NCT00349349|Experimental|ofatumumab|Anti-CD20 antibody therapy
11632129|NCT00349336|Experimental|1|
11632130|NCT00349336|Experimental|2|
11632131|NCT00349271|Experimental|Stem Cell therapy|Stem Cell therapy
11632132|NCT00349271|Active Comparator|Standart therapy|Standart therapy
11632133|NCT00349219|Experimental|1|erlotinib followed at progression by gemcitabine and cisplatin
11632134|NCT00349219|Active Comparator|2|cisplatin and gemcitabine chemotherapy for 6 cycles, followed at progression by erlotinib
11632135|NCT00349206|Experimental|Arm 1|Patients receive temsirolimus IV over 30 minutes on days 1, 8,15, and 22 and oral sorafenib once or twice daily on days 1-28.
11632136|NCT00349193|Active Comparator|Laquinimod 0.3 mg|Laquinimod 0.3 mg
11632137|NCT00349193|Active Comparator|Laquinimod 0.6 mg|Laquinimod 0.6 mg
11632138|NCT00349193|Placebo Comparator|Placebo|Blinded Placebo
11632139|NCT00349167|Experimental|PR-104|PR104 was administered as a 1-hr IV infusion every 21 days at doses ranging from 135 to 1400 mg/m2
11632140|NCT00349102|Active Comparator|A|Free breathing during conformal radiation
11632141|NCT00349102|Experimental|B|Breath holding during conformal radiation
11632142|NCT00349089|Active Comparator|1|Cisplatin/Vinorelbine
11632143|NCT00349089|Experimental|2|Cisplatin/Pemetrexed
11632144|NCT00349076|Experimental|1|"Preoperative simultaneous radiochemotherapy: 5-Fluorouracil und Oxaliplatin:
~Radiotherapy starts on day 1 of chemotherapy; 28 fractions; single dose: 1,8 Gy once per day, monday through friday; Total dose: 50,4 Gy; Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35
~Adjuvant Chemotherapy:
~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours; repeat day 15, 8 cycles"
11632145|NCT00349076|Active Comparator|2|"Preoperative simultaneous radiochemotherapy: 5-Fluorouracil Radiotherapy starts on day 1 of chemotherapy; 28 fractions; single dose: 1,8 Gy once per day, monday through friday; Total dose: 50,4 Gy; 5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d
~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
11632146|NCT00349050|Active Comparator|1|laboratory pain assessment
11632147|NCT00349050|Active Comparator|2|transcranial magnetic stimulation
11632148|NCT00348985|Experimental|PXD101 in Combination with Bortezomib (PS-341)|Patients receive PXD101 IV over 30 minutes on days 1-5 and bortezomib IV on days 1, 4, 8, and 11 (2, 5, 8, and 11 during course 1).
11632149|NCT00348946|Active Comparator|1|
11632150|NCT00348946|Placebo Comparator|2|
11632151|NCT00348933|Experimental|1|Participants will receive two daily doses of Metafolin, betaine, and creatine, and one daily dose of vitamin B12 for 12 months.
11632152|NCT00348920|No Intervention|1- General Anesthesia|General Anesthesia includes administration of a routine cardiac anesthetic as per institutional norms.
11632153|NCT00348920|Experimental|2- High Spinal and General Anesthesia|High Spinal and General Anesthesia includes a high dose intrathecal anesthetic administered prior to the induction of a standardized cardiac general anesthetic.
11632154|NCT00348907|Active Comparator|1|immediate thermal cure (1st year)
11632155|NCT00348907|Sham Comparator|2|late thermal cure (2 years)
11632156|NCT00348894|Experimental|Open Treatment|[S,S]-reboxetine
11632157|NCT00348894|Other|Standard Care|Standard Care
11632158|NCT00348881|Experimental|Group 1: DTaP-Hep B-PRP-T + OPV vaccine|Participants received 3 doses of the DTaP-Hep B-PRP-T concomitantly with OPV vaccine, 1 dose each at 6, 10, and 14 weeks of age.
11632159|NCT00348881|Active Comparator|Group 2: Tritanrix-HepB/Hib™ + OPV vaccine|Participants received 3 doses of the Tritanrix-HepB/Hib™ concomitantly with OPV vaccine, 1 dose each at 6, 10, and 14 weeks of age.
11632160|NCT00348868|Experimental|1|enhanced behavioral motivation counseling
11632161|NCT00348868|Active Comparator|2|
11632162|NCT00348855|Experimental|1|"Intervention with one day training, electronic device to measure bood pressure, leaflet with goals and drug strategies according to guidelines, six specific cardiovascular consultations during two years, feed back on results of the intervention group at inclusion, year 1 and year 2.
~Specific consultations will be focused on goals to be reach, compliance, exercise and diet."
11632163|NCT00348855|No Intervention|2|
11632164|NCT00348829|Active Comparator|1|Surgical mitral valve reconstruction
11632165|NCT00348829|No Intervention|2|conservative treatment
11632166|NCT00348816|Experimental|Docetaxel (Single Arm)|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Prednisone 5mg twice a day Radical prostatectomy as standard of care Radiation therapy will be used as standard of care Post radiation Doxcetaxel
11632167|NCT00348790|Experimental|Vatalanib|"Patients will be treated with 500 mg of vatalanib, administered orally, twice a day for 28 days (1 cycle). Patients will start at a dose of 250 mg twice a day and increase by 250 mg per day every 7 days until 500 mg twice a day is reached.
~Patients who are responding may remain on study treatment for 12 months."
11632168|NCT00348777|Active Comparator|1|group with 18 days thermal cure
11632222|NCT00347776|Active Comparator|Control|topical tetracycline
11632169|NCT00348777|Sham Comparator|2|group with no thermal cure but only access 3 days to watering place 6 months after inclusion
11632170|NCT00348738|Experimental|1|Patients assigned to this group are receiving Erythropoietin medication
11632171|NCT00348738|No Intervention|2|control group receiving no treatment
11632172|NCT00348712|Active Comparator|A|
11632173|NCT00348712|Active Comparator|B|
11632174|NCT00348699|Experimental|Treatment (AFP464)|Patients receive AFP464 IV over 3 hours on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11632175|NCT00348686|Experimental|Candesartan|Subjects were treated for 24 weeks with Candesartan 16mg once daily as initial dose. Subjects were modified investigational product dose to Candesartan 32mg, Candesartan 32mg + Felodipine 5mg, Candesartan 32mg + Felodipine 10mg, sequentially according to their blood pressures.
11632176|NCT00348673|Experimental|Stage 1|
11632177|NCT00348673|Experimental|Stage 2|
11632178|NCT00348621|Active Comparator|Visual impairment intervention program|enhanced access to eye care services
11632179|NCT00348621|No Intervention|Usual care|family and nursing home was apprised of ocular exam results; eye care services left to family/nursing home arrangements
11632180|NCT00348608|Experimental|Visipaque Injection|All participants will receive intravenous (IV) administration of 80 mL Visipaque (iodixanol) 320 mg-I/mL at a rate of 4-5 mL per second via power injector followed by a saline injection of 40-50 mL 0.9% sodium chloride solution at a rate of 4-5 mL per second.
11632181|NCT00348595|Active Comparator|1|5mg/day Arm: one 5 mg active Revlimid capsule and one 25 mg matched placebo capsules PO QAM (every morning) (at approximately the same time) days 1-21 days (28-day cycles).
11632182|NCT00348595|Active Comparator|2|25 mg/day Arm: one 25 mg active Revlimid capsule and one 5 mg matched placebo capsule PO QAM (every morning) (at approximately the same time) days 1-21 (28 day cycles).
11632183|NCT00348569|Experimental|64 Channel VCT|All subjects underwent Coronary Computed Tomographic Angiography (CCTA) after receiving an intravenous (IV) administration of Visipaque (320 mgI/mL), to be followed 2 to 21 days later by catheter coronary angiography (CATH).
11632184|NCT00348556|Experimental|Nesiritide|Subjects received an intrarenal infusion of nesiritide at 0.005 microgram/kg/min for 6 hours, 0.01 microgram/kg/min for 6 hours, 0.02 microgram/kg/min for 6 hours, and 0.03 microgram/kg/min for 6 hours.
11632185|NCT00348517|Experimental|Systane|
11632186|NCT00348517|Active Comparator|Refresh|
11632187|NCT00348439|Experimental|Plasmin Injection|human-derived plasmin
11632188|NCT00348439|Placebo Comparator|Vehicle|Plasmin formulation, without active ingredient.
11632189|NCT00348387|Experimental|Group 1|
11632190|NCT00348387|Active Comparator|Group 2|
11632191|NCT00348374|Active Comparator|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
11632192|NCT00348374|Experimental|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
11632193|NCT00348348|Active Comparator|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5%
11632194|NCT00348348|Experimental|Besifloxacin Suspension|Besifloxacin hydrochloride ophthalmic suspension 0.6%
11632195|NCT00348335|Active Comparator|1: Restasis|
11632196|NCT00348335|Active Comparator|2: Refresh Endura|
11632197|NCT00348309|Experimental|Arm 1|Rosiglitazone Extended Release 2mg OD
11632198|NCT00348309|Experimental|Arm 2|Rosiglitazone Extended Release 8mg OD
11632199|NCT00348309|Placebo Comparator|Arm 3|Placebo
11632200|NCT00348283|Placebo Comparator|Double Blind|Blinded study through Week 52. Adalimumab compared to placebo during blinded portion.
11632201|NCT00348283|Other|Open Label|Note: No comparator was used in Open-Label portion of study. From Week 8, subjects could have switched to open-label (OL) adalimumab 40mg administered subcutaneously (SC) every other week (eow)or OL adalimumab 40 mg SC every week (ew) dosing to treat disease flare or non-response. At Week 52, all remaining subjects were allowed to switch to the Open-Label portion of the study.
11632202|NCT00348205|Experimental|Technolas 217z Zyoptix System|Bausch & Lomb Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software.
11632203|NCT00348153|Experimental|Adalimumab + corticosteroids + immunosuppressive treatments|Adalimumab 40 mg eow, stable immunosuppression, corticosteroids in 1 mg/kg/Bodyweight (max. 80 mg) and taper
11632204|NCT00348153|Active Comparator|immunosuppressive treatment + corticosteroids|corticosteroids upped to 1mg/kg/Bodyweight and taper, stable immunosuppressive treatment
11632205|NCT00348140|Experimental|Arm 1|Rosiglitazone Extended Release 2mg OD
11632206|NCT00348140|Experimental|Arm 2|Rosiglitazone Extended Release 8mg OD
11632207|NCT00348140|Placebo Comparator|Arm 3|Placebo
11632208|NCT00348075|Experimental|Neurovision|
11632209|NCT00348036|Experimental|Group therapy|Participants will receive interpersonal group therapy.
11632210|NCT00348036|Active Comparator|Control|Participants will receive information only on PTSD.
11632211|NCT00347997|Experimental|LASIK|LASIK correction of myopia and myopic astigmatism
11632212|NCT00347958|Experimental|Adacel vaccine group|Participants 15 to 69 years of age who received a dose of Adacel vaccine in one of three previous studies (Td501, or Td502, or Td505), revaccinated in Study Td518.
11632213|NCT00347932|Experimental|ISV-403|0.6% ISV-403 ophthalmic suspension
11632214|NCT00347932|Placebo Comparator|Vehicle|Vehicle of ISV-403 ophthalmic suspension
11632215|NCT00347919|Experimental|monotherapy arm|1500 mg (6 x 250 mg tablets) oral lapatinib once daily
11632216|NCT00347919|Experimental|Cohort 1 combination arm|1000 mg (4 x 250 mg tablets) of oral lapatinib and 400 mg (4 x 100 mg tablets) of oral pazopanib taken together once daily
11632217|NCT00347919|Experimental|Cohort 2 combination arm|1500 mg (6 x 250 mg tablets) of oral lapatinib and 800 mg (1 x 500 mg tablets plus 3 x 100 mg tablets) of oral pazopanib taken together once daily
11632218|NCT00347854|Experimental|FID 105783|
11632219|NCT00347854|Active Comparator|Visine|
11632220|NCT00347854|Active Comparator|Refresh Liquigel|
11632221|NCT00347854|Active Comparator|Refresh Plus|
11632223|NCT00347776|Active Comparator|Intervention 1|oral azithromycin, single 1g dose to subject
11632224|NCT00347776|Active Comparator|Intervention 2|single oral azithromycin dose to subject and immediate family members
11632225|NCT00347763|No Intervention|control|no active fly spray intervention
11632226|NCT00347763|Active Comparator|intervention|aerial spray of permethrin daily for two weeks and weekly as needed by assessment of fly density
11632227|NCT00347737|Experimental|1|Teriparatide
11632228|NCT00347672|Experimental|1|Two vaccinations of H5N1 VN 2004/AA vaccine at the highest dose
11632229|NCT00347672|Experimental|2|One vaccination of H5N1 VN 2004/AA vaccine at a dose in-between the lowest and highest doses
11632230|NCT00347672|Experimental|3|One vaccination of H5N1 VN 2004/AA vaccine at the lowest dose
11632231|NCT00347659|Experimental|Single Treatment|Experimental Treatment
11632232|NCT00347646|Experimental|Plasmin|Human-derived plasmin reconstituted with sterile sodium chloride for intravitreal injection.
11632233|NCT00347594|Experimental|Next Generation Diagnostic Instrument|Next Generation Diagnostic Instrument (NGDI)
11632234|NCT00347594|Active Comparator|Zyoptix Diagnostic Workstation|Zyoptix Diagnostic Workstation (ZDW)
11632235|NCT00347555|Experimental|Group D|18 subjects 160 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
11632236|NCT00347555|Experimental|Group A|18 subjects 5 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
11632237|NCT00347555|Experimental|Group B|18 subjects 20 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
11632238|NCT00347555|Experimental|Group C|18 subjects 80 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
11632239|NCT00347438|Experimental|Capecitabine|Capecitabine will be given at 1000mg/m2 twice daily for 2 weeks x 8 cycles, with a one-week pause in-between cycles.
11632240|NCT00347425|Other|A|
11632241|NCT00347425|Other|B|
11632242|NCT00347412|Experimental|A|NOV-002 Injection in combination with Carboplatin and Paclitaxel
11632243|NCT00347412|Active Comparator|B|Paclitaxel and Carboplatin Alone
11632244|NCT00347386|Experimental|Zinc|Administration of zinc sulphate every day during illness
11632245|NCT00347386|Placebo Comparator|Placebo|Placebo tablet
11632246|NCT00347360|Experimental|lisinopril|lisinopril
11632247|NCT00347360|Experimental|carvedilol|carvedilol controlled release formulation
11632248|NCT00347321|Experimental|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
11632249|NCT00347269|Experimental|CALM Intervention|"Participant choice of:
~Cognitive Behavioral Therapy (CBT) Psychotropic (anti-anxiety) medication optimization"
11632250|NCT00347269|Active Comparator|Treatment as Usual (TAU)|Participants assigned to TAU with their primary care provider (PCP)
11632251|NCT00347152|Active Comparator|2|Slow Progressive Divalproex DR to Divalproex ER switch
11632252|NCT00347152|Active Comparator|1|Immediate, Progressive Divalproex DR to Divalproex ER switch
11632253|NCT00347139|Experimental|GW642444|
11632254|NCT00347139|Active Comparator|Salmeterol|
11632255|NCT00347100|Experimental|1|Administration of Insulin Glargine and Sulfonylurea or Metformin
11632256|NCT00347100|Active Comparator|2|Administration of Sulfonylurea or Metformin + a second Oral Anti Diabetic (OAD) among Glyburide, Glyclazide,Glimiperide,Glipizide or Metformin
11632257|NCT00347048|Experimental|1|
11632258|NCT00347048|Placebo Comparator|2|
11632259|NCT00347022|Experimental|Xenetix|The patient receive one injection of Xenetix 300 (300 mg of iodine/ml)
11632260|NCT00347022|Active Comparator|Visipaque|The patient receive one injection of Visipaque 270 (270 mg of iodine/ml)
11632261|NCT00347009|Other|Adefovir Dipivoxil|10mg once daily in patients with CHB related advanced fibrosis/cirrhosis.
11632262|NCT00346996|Active Comparator|1|HUman Insulin
11632263|NCT00346996|Experimental|2|Analogue insulin
11632264|NCT00346983|Experimental|A|
11632265|NCT00346983|Placebo Comparator|B|
11632266|NCT00346970|Experimental|1|Extended-release Niacin
11632267|NCT00346970|Placebo Comparator|2|Placebo
11632268|NCT00346957|Experimental|Anecortave Acetate 30|
11632269|NCT00346957|Experimental|Anecortave Acetate 15|
11632270|NCT00346957|Experimental|Anecortave Acetate 3|
11632271|NCT00346957|Placebo Comparator|Anecortave Acetate Vehicle|
11632272|NCT00346944|Experimental|Treatment group|
11632273|NCT00346944|No Intervention|Reference group|
11632274|NCT00346918|Active Comparator|1|Treatment of hypertension, cyst infections and flank pain
11632275|NCT00346918|Active Comparator|2|Sirolimus plus Standard Treatment
11632276|NCT00346905|Experimental|Single Arm|Those receiving Enteryx treatment
11632277|NCT00346853|Experimental|1|
11632278|NCT00346853|Placebo Comparator|2|saline
11632279|NCT00346840|Experimental|MVI 25|Misoprostol vaginal insert 25 mcg
11632280|NCT00346840|Experimental|MVI 50|Misoprostol vaginal insert 50 mcg
11632281|NCT00346840|Experimental|MVI 100|Misoprostol vaginal insert 100 mcg
11632282|NCT00346840|Experimental|MVI 200|Misoprostol vaginal insert 200 mcg
11632283|NCT00346801|Experimental|CPT-11 + Celecoxib/Cisplatin with RT|CPT-11 + Celecoxib + Cisplatin + Radiation Therapy (RT)
11632284|NCT00346788|Experimental|MIS|minimally invasive incision
11632285|NCT00346788|Active Comparator|Standard|Standard incision length
11632286|NCT00346762||1|HIV infected former commercial blood donors (FBDs) in Fuyang, Anhui Province
11632287|NCT00346749|Experimental|Arm 1|
11632288|NCT00346697|Experimental|LOVAZA|4 g/d of omega-3 fatty acid esters, plus dietary counseling
11632289|NCT00346697|Placebo Comparator|Placebo|Corn oil placebo, plus dietary counselling
11632290|NCT00346671|Placebo Comparator|Supine Rest|30min supine rest listening to soft music
11632291|NCT00346671|Sham Comparator|Sham Reiki|30 min intervention by sham practitioner
11632292|NCT00346671|Experimental|Reiki|30 min session with Reiki practitioner
11632293|NCT00346632|Experimental|KW-2449|Treatment with ascending doses of KW-2449
11632294|NCT00346567|Active Comparator|1|AZT from week 28 or asap thereafter. Intrapartum AZT and 3TC + Single dose NVP Postpartum Combivir tail for 7 days twice daily
11632295|NCT00346567|Experimental|2|AZT from week 28 or asap thereafter. Intrapartum Single dose Truvada + Single dose NVP
11632296|NCT00346528|Experimental|NGOIS|
11632297|NCT00346528|Active Comparator|BSS Plus|
11632298|NCT00346502|Experimental|Ointment|Treatment will consist of four weeks of daily application of 20% BA ointment to the dysplastic nevi, after which it will be removed surgically and examined. A similar dysplastic nevi will be removed as a control. Four groups of patients will be enrolled. The first group will apply the ointment once a day, the second twice a day, the third three times a day, and the fourth four times a day.
11632299|NCT00346476||Participants|Individuals in the Masiphumelele Township of Cape Town, South Africa, who have been potentially exposed to TB and/or HIV
11632300|NCT00346437|Experimental|1|Ad5FGF-4
11632301|NCT00346437|Experimental|2|Ad5FGF-4
11632302|NCT00346437|Placebo Comparator|3|Placebo
11632303|NCT00346398|Experimental|Oral mucosal immunoprophylaxis (OMIP)|Participants are administered oral mucosal immunoprophylaxis (OMIP) daily for 12 months.
11632304|NCT00346398|Placebo Comparator|Placebo|Participants are administered, via the same route as the experimental group, an oral placebo solution daily for 12 months.
11632305|NCT00346333|Experimental|Lutein plus 15,000 IU/d Vitamin A|Daily intake of 12mg of Lutein plus 15,000 IU/d of Vitamin A palmitate
11632306|NCT00346333|Placebo Comparator|Control plus 15,000 IU/d Vitamin A|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
11632307|NCT00346320|Experimental|Radiotherapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
11632308|NCT00346294|Other|Single-Arm|Open-lable Single Arm Study
11632309|NCT00346268|Active Comparator|Morphine plus Parecoxib|
11632310|NCT00346268|Active Comparator|Morphine and Placebo|
11632311|NCT00346229|Experimental|Thermodox|ThermoDox20-40mg/m2 every 21-35 days followed by Chest Wall Hyperthermia
11632312|NCT00346216|Experimental|celecoxib|subject receives celecoxib and dummy (placebo) ibuprofen and naproxen
11632313|NCT00346216|Active Comparator|ibuprofen|subject receives ibuprofen and dummy (placebo) celecoxib and naproxen
11632314|NCT00346216|Active Comparator|naproxen|subject receives naproxen and dummy (placebo) celecoxib and ibuprofen
11632315|NCT00346177|Active Comparator|1|Stem Cells
11632316|NCT00346177|Placebo Comparator|2|Placebo
11632317|NCT00346164|Experimental|Arm A: No adjuvant treatment|Patients with low-grade tumor with either negative or positive microscopic margins or high-grade tumor ≤ 5 cm (in maximum diameter) with negative microscopic margins are assigned to arm A: (observation only).
11632318|NCT00346164|Experimental|Arm B: Low risk; adjuvant radiotherapy|Patients with high-grade tumor ≤ 5 cm (in maximum diameter) with positive microscopic margins are assigned to arm B: (adjuvant radiotherapy). Beginning between 6-42 days after surgical resection, patients undergo a total of 31 fractions of adjuvant radiotherapy.
11632319|NCT00346164|Experimental|Arm C: Intermediate & High risk; adjuvant chemoradiotherapy|High risk [metastatic, resected, incompletely resected, or unresected disease] patients with high-grade, grossly resected primary tumor, with metastases are assigned to receive arm C: (adjuvant chemoradiotherapy). Patients receive ifosfamide IV; doxorubicin hydrochloride IV; beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy.
11632320|NCT00346164|Experimental|Arm D: Intermediate & High Risk; Neoadjuvant chemoradiotherapy|High risk [metastatic, resected, incompletely resected, or unresected disease] patients with unresected, high-grade metastatic tumor are assigned to receive treatment as in arm D: (neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy): Patients receive ifosfamide IV; doxorubicin hydrochloride IV. Beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy. Patients undergo surgical resection in week 13.
11632321|NCT00346151|Experimental|Belatacept|Immunosuppressive protocol consisting of belatacept, glucocorticoids, antithymocyte globulin (ATG), and sirolimus.
11632322|NCT00346125|Active Comparator|Preferred Standard Regimen|Subjects with soft tissue sarcoma who are receiving pegylated liposomal doxorubicin hydrochloride, Ifosfamide with mesna and pegfilgrastim - Repeat every 28 days for 4 cycles total
11632323|NCT00346125|Active Comparator|Alternative Treatment Regimen|Subjects with soft tissue sarcoma who are receiving Doxorubicin hydrochloride, Ifosfamide with mesna and pegfilgrastim - Repeat every 28 days for 4 cycles total
11632324|NCT00346073|Experimental|Boostrix Group|Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Boostrix® vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
11632325|NCT00346073|Experimental|Adacel Group|Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Adacel™ vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
11632326|NCT00346047|Placebo Comparator|0|
11632327|NCT00346047|Experimental|1|
11632328|NCT00346034|Experimental|1|
11632329|NCT00346021|Experimental|Sun Protection Intervention|School based sun protection education, provision of free hats.
11632330|NCT00346021|No Intervention|Control arm|Usual sun protection practices
11632331|NCT00345982|Experimental|A|Sertindole 16 mg
11632332|NCT00345982|Placebo Comparator|B|Placebo
11632333|NCT00345969|Active Comparator|Transdermal Testosterone gel (1%)|Transdermal testosterone 1% gel (Androgel) provided as 2.5 gm and/or 5 gm gel packets with dose titration and monthly dose adjustments to achieve and maintain serum total testosterone level between 500-900 mg/dL. Gel to be applied daily by participants. Participants are blinded to the contents of the gel packets. Participants in this arm also perform supervised exercise training for 6 months.
11632334|NCT00345969|Placebo Comparator|Placebo gel|Inactive topical gel identical in appearance to the active medication, provided in packets identical to the packaging for the active medication. Gel to be applied daily by participants. Participants are blinded to the contents of the gel packets. Participants in this arm also perform supervised exercise training for 6 months.
11632335|NCT00345943||Adolescents with Bulimia Nervosa or subclinical BN|Adolescents with Bulimia Nervosa or subclinical Bulimia Nervosa
11632336|NCT00345943||Healthy control adolescents|Healthy control adolescents
11632337|NCT00345930||2|Individuals without drug induced liver disease
11632338|NCT00345930||1|Individuals with drug induced liver disease
11633100|NCT00334568|Placebo Comparator|Placebo|Placebo (matched)
11632339|NCT00345878|Experimental|Cervarix Group|Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.
11632340|NCT00345878|Placebo Comparator|Placebo Group|Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.
11632341|NCT00345865|Experimental|NHL with irradiation|Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
11632342|NCT00345865|Experimental|HL without irradiation|Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
11632343|NCT00345865|Experimental|NHL - HIV infected with irradiation|Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
11632344|NCT00345865|Experimental|NHL - HIV infected without irradiation|Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
11632345|NCT00345865|Experimental|NHL without radiation and cyclosporine|Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
11632346|NCT00345839|Experimental|Cinacalcet|
11632347|NCT00345839|Placebo Comparator|Placebo|
11632348|NCT00345826|Experimental|Dasatinib|
11632349|NCT00345813|Experimental|Arm I|Patients receive oral soy supplementation daily for 4 weeks. Patients undergo radical prostatectomy within 21 days after completion of soy supplementation.
11632350|NCT00345813|Placebo Comparator|Arm II|Patients receive oral placebo supplementation daily for 4 weeks. Patients undergo radical prostatectomy within 21 days after completion of placebo supplementation.
11632351|NCT00345800|Experimental|Sodium Oxybate|Active Substance: Sodium Oxybate Pharmaceutical form: Oral Solution Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks Route of administration: Oral
11632352|NCT00345787|Placebo Comparator|0|
11632353|NCT00345787|Experimental|1|
11632354|NCT00345761|Experimental|Step 1|
11632355|NCT00345761|Experimental|Step 2|
11632356|NCT00345761|Experimental|Step 3|
11632357|NCT00345748|Active Comparator|Abatacept 2 mg/kg|
11632358|NCT00345748|Active Comparator|Abatacept 10 mg/kg|
11632359|NCT00345748|Placebo Comparator|Placebo|
11632360|NCT00345709||National Research Registry Enrollment|Patient, living or deceased, with a pathologically-confirmed diagnosis of Ovarian Cancer.
11632361|NCT00345683|Experimental|Menhibrix Group|Subjects received 3 doses of Menhibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course in the study NCT00345579 and a fourth dose of Menhibrix vaccine at 12-15 months of age in this study (study Month 10-13). Menhibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
11632362|NCT00345683|Active Comparator|ActHIB Group|Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course in the study NCT00345579 and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in this study (study Month 10-13). ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
11632363|NCT00345670|Experimental|1|MEDI-534
11632364|NCT00345670|Experimental|2|MEDI-534
11632365|NCT00345670|Experimental|3|MEDI-534
11632366|NCT00345644|Experimental|1|
11632367|NCT00345644|Placebo Comparator|2|
11632368|NCT00345631|Active Comparator|Manual Compression|Manual compression (MC)
11632369|NCT00345631|Experimental|Vascular Closure Device|Vascular Closure Device (VCD)
11632370|NCT00345618|Experimental|Idrabiotaparinux|"Idrabiotaparinux sodium, 3.0 mg, once-weekly for 3 or 6 months depending on the stratum, after enoxaparin, 1.0 mg/kg, every 12 hours for at least 5 days.
~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or over-dosage)."
11632371|NCT00345618|Active Comparator|Warfarin|"Warfarin, INR-adjusted dose, started 24 hours after the start of enoxaparin, 1.0 mg/kg, every 12 hours for at least 5 days, and continued for 3 or 6 months depending on the stratum.
~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or over-dosage)."
11632372|NCT00345605|Experimental|HDA|"High Dose Arm
~Wash-out then 7 days of:
~Arg 500 mg/kg/d or 10 g/m2 BSA Placebo instead of NaPBA"
11632373|NCT00345605|Experimental|LDA|"Low Dose Arm
~Wash-out followed by 7 days of:
~Arg 100 mg/kg/d or 2 g/m2 BSA NaPBA 500 mg/kg/d or 10 g/m2 BSA"
11632374|NCT00345592|Experimental|Device managed arm|Device-managed therapy arm. Shock therapy for atrial arrhythmias is delivered automatically from the device.
11632375|NCT00345592|Active Comparator|Traditional arm|Traditional therapy arm. In this arm, therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment. Therefore, patients who will experience symptoms at home, will refer to their center, eventually hospitalized and treated for atrial arrhythmias.
11632376|NCT00345579|Experimental|Menhibrix Group|Subjects received 3 doses of Menhibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of Menhibrix vaccine at 12-15 months of age in the study NCT00345683. Menhibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
11632377|NCT00345579|Active Comparator|ActHIB Group|Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
11632378|NCT00345553||1|Biliary atresia subjects who have their native liver
11632379|NCT00345553||2|Biliary atresia subjects who have had a liver transplant
11632380|NCT00345540|Experimental|NOV-002 plus Carboplatin|NOV-002 is given by IV bolus on lead-in day -1 at cycle 1, and on day 1 at subsequent cycles, followed by Carboplatin AUC 5. NOV-002 is then continued via daily SC injection, with 28 day cycles.
11632381|NCT00345514|No Intervention|1|
11632382|NCT00345514|Active Comparator|2|
11632383|NCT00345514|Active Comparator|3|
11632384|NCT00345501|Experimental|1|Iloprost
11632385|NCT00345501|Placebo Comparator|2|Placebo
11632386|NCT00345475||AED treatment|Women being treated with UCB AEDs while pregnant.
11632387|NCT00345397|Experimental|Subjects Receiving PEC Tube|Percutaneous Endoscopic Colostomy Tube (PEC) Placement
11632388|NCT00345384|Placebo Comparator|Normal Saline|One group (placebo comparator) will receive a normal saline infusion, set at a rate as if it were the active drug.
11632389|NCT00345384|Active Comparator|Dexmedetomidine|The second group (the study group) will receive a continuous infusion of dexmedetomidine titrated from 0.1 - 0.5 mics/kg/h to control pain for up to 24 hours after they are admitted to an open nursing unit after discharge from the PACU or ICU
11632390|NCT00345371|Active Comparator|Topiramate|Subjects will receive topiramate (in tablet form) up to 200 mg/day for 13 weeks.
11632391|NCT00345371|Placebo Comparator|Placebo Oral Tablet|After randomization subjects will receive topiramate matched placebo (in tablet form), up to 200 mg/day for 13 weeks.
11632392|NCT00345358|Active Comparator|Synflorix <6M Group|This group consisted of subjects up to 6 months of age at first vaccination who received 3 doses of Synflorix™ vaccine co-administered with Infanrix™ IPV/Hib at 3, 4 and 5 months of age and a booster dose of the same vaccines at 12-15 months of age. Vaccines were administrated intramuscularly in the right (Synflorix™) or the left (Infanrix™ IPV/Hib ) thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
11632393|NCT00345358|Experimental|Synflorix 7-11M Group|This group consisted of subjects 7 to 11 months of age at first vaccination who received 2 doses of Synflorix™, one first dose at enrolment followed by a second dose one month later, and a booster dose at 12-15 months of age. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
11632394|NCT00345358|Experimental|Synflorix 12-23M Group|This group consisted of subjects 12 to 23 months inclusive at first vaccination who received 2 doses of Synflorix™, one first dose at enrolment followed by a second dose 2 months later. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
11632395|NCT00345358|Experimental|Synflorix >=24M Group|This group consisted of subjects aged between 24 months (inclusive) to 5 years (inclusive) at vaccination who received one dose of Synflorix™. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
11632396|NCT00345345|Experimental|1|Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.
11632397|NCT00345332|Placebo Comparator|1|Placebo
11632398|NCT00345332|Experimental|2|Botox
11632399|NCT00345319|Active Comparator|Group 1|
11632400|NCT00345319|Active Comparator|Group 2|
11632401|NCT00345293|Experimental|DC/PC3 vaccine|3 subcutaneous injections of ex vivo-generated autologous dendritic cell vaccine: 1) pulsed with apoptotic PC3 cells; 2) pulsed with apoptotic PC3-M1 cells, and 3) pulsed with keyhole limpet hemocyanin (KLH, control antigen)
11632402|NCT00345254|Experimental|severing cord|The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
11632403|NCT00345254|No Intervention|Untouched cord|The cord was untouched after delivery of the anterior shoulder and prior to extraction of the body.
11632404|NCT00345189|Other|Dosing Schedule 1|Starting dose of 25 mg, with dosing twice a week for 3 weeks out of a 4-week course (Schedule 1). Dosing for schedule 1 is currently closed.
11632405|NCT00345189|Other|Dosing Schedule 2|Starting dose of 600 mg, with dosing twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).
11632406|NCT00345176|Active Comparator|Lutein/Zeaxanthin|lutein (10mg)/zeaxanthin (2 mg)
11632407|NCT00345176|Active Comparator|DHA/EPA|DHA (350 mg)/EPA (650 mg)
11632408|NCT00345176|Active Comparator|Lutein/Zeaxanthin + DHA/EPA|lutein (10 mg)/zeaxanthin (2 mg) + DHA (350 mg)/EPA (650 mg)
11632409|NCT00345176|Placebo Comparator|Placebo/Control|Considered control because all participants received the AREDS formulation
11632410|NCT00345163|Experimental|1|
11632411|NCT00345163|Experimental|2|
11632412|NCT00345059|Active Comparator|docetaxel|single agent docetaxel
11632413|NCT00345059|Experimental|docetaxel + vinorelbine OR gemcitabine|docetaxel in combination with either vinorelbine or with gemcitabine
11632414|NCT00345059|Experimental|docetaxel + capecitabine|docetaxel in combination with capecitabine
11632415|NCT00345046|Active Comparator|Pred Forte 1%|Pred Forte 1% dosed four times daily decreasing to once daily over four weeks.
11632416|NCT00345046|Active Comparator|EconoPred Plus 1%|EconoPred Plus 1% dosed four times daily decreasing to once daily over four weeks.
11632417|NCT00345046|Active Comparator|Prednisolone Acetate 1%|Prednisolone Acetate 1% dosed four times daily decreasing to once daily over four weeks.
11632418|NCT00345033|Experimental|1|Participants will take aripiprazole 15mg/day for 8 weeks.
11632419|NCT00345033|Placebo Comparator|2|Participants will take placebo for 8 weeks.
11632420|NCT00344968|Experimental|1|
11632421|NCT00344968|Experimental|2|
11632422|NCT00344968|Sham Comparator|3|
11632423|NCT00344942|Experimental|1|
11632424|NCT00344942|Placebo Comparator|2|
11632425|NCT00344890|Experimental|Preservon|
11632426|NCT00344890|Active Comparator|Control|
11632427|NCT00344825||Group 1|
11632428|NCT00344786|Experimental|CNF2024|
11632429|NCT00344773|Experimental|Gefitinib|Gefitinib 250mg tablet once daily
11632430|NCT00344760|Active Comparator|Standard Treatment|Efavirenz 600mg once daily, Lamivudine 300mg once daily and Tenofovir 300mg once daily
11632470|NCT00344175|Active Comparator|Simvastatin 40mg/80mg|Simvastatin 40 mg or 80 mg once daily
11632431|NCT00344760|Experimental|Standard Treatment Plus Enfuvirtide|Efavirenz 600mg once daily, Lamivudine 300mg once daily, Tenofovir 300mg once daily and enfuvirtide 90mg subcutaneously twice a day until the viral load is less than 50copies for 2 consecutive visits or 12 weeks (whichever comes first).
11632432|NCT00344721|Active Comparator|EPA/DHA/flaxseed|Study patients in the active comparator arm will take four soft-gel capsules containing omega-3 fatty acids (a nutritional supplement) orally daily for 3 months. Each daily dose contains eicosapentaenoic acid (450 mg), docosahexaenoic acid (300 mg) and flaxseed oil (1000 mg).
11632433|NCT00344721|Placebo Comparator|Wheat germ oil|Study patients in the placebo arm will take four doses of soft-gel capsules containing wheat germ oil orally daily for 3 months.
11632434|NCT00344682|Experimental|memantine|memantine (5-20mg a day)
11632435|NCT00344682|Placebo Comparator|Placebo|placebo (5-20mg a day)
11632436|NCT00344656||Subjects and Controls|Patients with DSM-IV Anorexia Nervosa
11632437|NCT00344591|Experimental|Tailored SET program|tailored SET program for reducing sexual and drug-related HIV transmission risk factors and increasing HIV treatment adherence in HIV infected men who have recently been released from prison
11632438|NCT00344591|Active Comparator|Individually focused therapy|Individually focused therapy program for reducing sexual and drug-related HIV transmission risk factors and increasing HIV treatment adherence in HIV infected men who have recently been released from prison
11632439|NCT00344565|Placebo Comparator|Placebo|Placebo, was matched to modafinil up to 400 mg/day. Patients also receive motivational interviewing and Cognitive Behavioral Therapy-Relapse Prevention (CBT-RP)
11632440|NCT00344565|Active Comparator|Modafinil|Modafinil (Active comparator). Patients received motivational interviewing and Cognitive Behavioral Therapy--relapse prevention (CBT-RP)
11632441|NCT00344552|Experimental|1|
11632442|NCT00344539|Experimental|B|80 mcg AMA1-C1/Alhydrogel® with 368 mcg Aluminum and 500 mg CPG 7909.
11632443|NCT00344539|Experimental|C|80 mcg AMA1-C1/Alhydrogel® with 368 mcg Aluminum alone.
11632444|NCT00344539|Experimental|A|20 mcg AMA1-C1/Alhydrogel® with 377 mcg Aluminum and 500 mg CPG 7909.
11632445|NCT00344500|No Intervention|Usual Care|Usual Care
11632446|NCT00344500|Active Comparator|Lifestyle Balance|Behavioral Weight Loss Program
11632447|NCT00344487|Experimental|lopinavir/ritonavir (Kaletra)|lopinavir/ritonavir (Kaletra)400/100mg tablets by mouth twice a day for 48 weeks.
11632448|NCT00344474|Experimental|learning to cope with your impulsivity|cognitive behavioural intervention teaching high impulsive youth how to manage their impulsive thinking and behaviours
11632449|NCT00344474|Experimental|learning to cope with your sensation seeking|cognitive-behavioural intervention teaching high sensation seeking youth how to manage their need for stimulation and excitement
11632450|NCT00344474|Experimental|learning to cope with your anxiety sensitivity|cognitive behavioural intervention targeting catastrophic thinking in high anxiety sensitive youth
11632451|NCT00344474|Experimental|learning to manage your negative thinking|cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
11632452|NCT00344461|Experimental|Nevirapine, FTC, Tenofovir|Open Label Drugs- Nevirapine 200 mg twice a day, FTC 200 mg once a day and Tenofovir 300 mg once a day for 96 weeks.
11632453|NCT00344448|Experimental|Raptiva|At the beginning of the first (week 1) and second (week 13) phases, all patients will receive reduced dose of the study medication determined at 0.7 mg/kg/week. During all the subsequent administrations, all patients will receive full dose of the study medication determined at 1 mg/kg/week.
11632454|NCT00344448|Placebo Comparator|placebo|Weekly subcutaneous injection of a placebo (formulated to match the commercial vial of Raptiva in appearance and content except for the active ingredient) for the first 12 weeks of the study.
11632455|NCT00344370|Experimental|Pitavastatin|Pitavastatin 4 mg QD
11632456|NCT00344370|Active Comparator|Atorvastatin|Atorvastatin 40 mg
11632457|NCT00344331||Patients with a diagnosis of Niemann-Pick type C (NPC)|Patients with a diagnosis of Niemann-Pick type C (NPC) of either sex and any ageParticipants may range from neurologically asymptomatic to severe and may have liverdisease or unrelated comorbidities, but must be stable enough to safely travel and toleratemedical evaluations.
11632458|NCT00344318|Experimental|Synflorix 1 Group|Subjects aged 6-12 weeks from the Philippines receiving Synflorix™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Polio Sabin™ vaccines at 6, 10, 14 weeks of age.
11632459|NCT00344318|Experimental|Synflorix 2 Group|Subjects aged 6-12 weeks from Poland receiving Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 2, 4, 6 months of age.
11632460|NCT00344318|Active Comparator|Prevenar 1 Group|Subjects aged 6-12 weeks from the Philippines receiving the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Polio Sabin™ at 6, 10, 14 weeks of age.
11632461|NCT00344318|Active Comparator|Prevenar 2 Group|Subjects aged 6-12 weeks from Poland receiving the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ at 2, 4, 6 months of age.
11632462|NCT00344305|Experimental|Cohort 1: Participants Between 6 to < 24 Months Age|Participants received a single, intranasal dose of 0.2 millilitre (mL) (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 fluorescent focus units (FFU) of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
11632463|NCT00344305|Experimental|Cohort 2: Participants Between 24 to < 60 Months Age|Participants received a single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 FFU of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
11632464|NCT00344253|Experimental|1|Interferon beta 3x weekly
11632465|NCT00344253|Active Comparator|2|Methotrexate sc 20 mg weekly
11632466|NCT00344214|Experimental|1|Participants will receive the tri-focal cognitive behavioral therapy - social skills training counseling program
11632467|NCT00344214|Active Comparator|2|Participants will receive the standard care comparison condition
11632468|NCT00344188||1|This population of patients are referred from their physicians both regionally and nationally.
11632469|NCT00344175|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
11632471|NCT00344149|Experimental|Rituximab|I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
11632472|NCT00344149|Placebo Comparator|Placebo|I.V infusion of NaCl 0.9%
11632473|NCT00344123|Other|Tipranavir/ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin.
~Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).
~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
11632474|NCT00344045|Active Comparator|A|
11632475|NCT00344045|Placebo Comparator|B|
11632476|NCT00344032|Experimental|Cervarix|Subjects who received 3 doses of HPV-16/18 VLP/AS04 Vaccine (Cervarix TM) (at 0, 1, 6 months).
11632477|NCT00344032|Placebo Comparator|Placebo|Subjects who received 3 doses of Placebo (at 0, 1, 6 months).
11632478|NCT00344019|Active Comparator|atorvastatin 80 mg|80 mg atorvastatin on average of 2-4 hours pre angio/PCI for ACS
11632479|NCT00344019|Placebo Comparator|placebo oral tablet|placebo on average of 2-4 hours pre angio/PCI for ACS
11632480|NCT00344019|No Intervention|Screening|Patients signed consent if willing to participate. Patients will continue onto randomization if appropriate per inc/exc (i.e. stent placement) otherwise screen fail
11632481|NCT00344006|Experimental|Arm 1|
11632482|NCT00343980|Experimental|A|
11632483|NCT00343980|Active Comparator|B|
11632484|NCT00343928|Experimental|1|
11632485|NCT00343915|Experimental|2-Dose Engerix|subjects received 2 doses of adult (thiomersal-free) HBV formulation, one at 0 and 6 months, respectively and placebo (physiological saline) at 1 month.
11632486|NCT00343915|Active Comparator|3-Dose Engerix|subjects received 3 doses of paediatric (preservative-free) HBV formulation one at 0, 1 and 6 months, respectively.
11632487|NCT00343889|Experimental|Group 1: DTaP-Hep B-PRP-T + Oral Polio Vaccine (OPV) vaccine|Participants received 3 doses of the DTaP-Hep B-PRP~T concomitantly with Oral Polio Vaccine (OPV), 1 dose each at 6, 10, and 14 weeks of age.
11632488|NCT00343889|Active Comparator|Group 2: Tritanrix-HepB/Hib™ + OPV vaccine|Participants received 3 doses of Tritanrix-Hep B/Hib™ concomitantly with Oral Polio Vaccine (OPV) at 6, 10, and 14 weeks of age.
11632489|NCT00343863|Active Comparator|Dexamethasone + Ondansetron IV on Day 1|"All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
~Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)."
11632490|NCT00343863|Experimental|Dexamethasone + Palonosetron IV on Day 1|"All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.
~Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)."
11632491|NCT00343824|Experimental|aquacel AG hydrofiber|
11632492|NCT00343824|Experimental|Acticoat burn dressing|
11632493|NCT00343798|Experimental|Treatment (umbilical cord blood transplant)|"MYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1.
~TRANSPLANTATION : Patients undergo double-unit umbilical cord blood transplantation comprising unmanipulated umbilical cord blood unit IV over 20-30 minutes, and 4-6 hours later patients receive ex vivo-expanded umbilical cord blood cells IV over 30 minutes on day 0.
~GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS: Patients receive cyclosporine IV every 8 or 12 hours on days -3 to 100, followed by a taper to at least day 180. Patients also receive MMF IV every 8 hours on days -3 to 5 and then PO, if tolerated, on days 6-30."
11632494|NCT00343785|Experimental|Treatment (conditioning regimen, transplant, GVHD prophylaxis)|Patients receive a conditioning regimen comprising cyclophosphamide IV on days -5 to -2 and anti-thymocyte globulin IV over 4-10 hours on days -4 to -2. Patients undergo allogeneic bone marrow transplantation on day 0. Patients then receive GVHD prophylaxis comprising methotrexate IV on days 1, 3, 6, and 11 and cyclosporine IV over 1 hour or PO twice daily on days -1 to 50, followed by a taper until 6 months after grafting.
11632495|NCT00343681|Experimental|1|
11632496|NCT00343642|Placebo Comparator|1|Time and attention + fructooligosaccharide placebo
11632497|NCT00343642|Active Comparator|2|Dietary therapy + fructooligosaccharide placebo
11632498|NCT00343642|Experimental|3|Time and attention + active fructooligosaccharide supplement.
11632499|NCT00343616|Experimental|Tamoxifen for 5 years|Patients treated with tamoxifen for 5 years after randomization.
11632500|NCT00343616|Experimental|Letrozole for 5 years|Patients treated with letrozole for 5 years after randomization.
11632501|NCT00343616|Experimental|Tamoxifen 2 years plus letrozole 3 years|Patients treated with tamoxifen for 2 years and afterwards with letrozole for 3 years.
11632502|NCT00343616|Experimental|Letrozole for 2 years plus tamoxifen for 3 years|Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.
11632503|NCT00343564|Experimental|Phase 1 Dose Escalation|Phase 1 dose escalation without and with GCSF support
11632504|NCT00343564|Experimental|Phase 2 Fixed Dose|Phase 2 fixed dose based on Phase I findings stratified by NHL type
11632505|NCT00343512|Experimental|Therapeutic Intervention|
11632506|NCT00343460|Active Comparator|Arm I|Patients receive palonosetron hydrochloride IV, placebo subcutaneously (SC), and dexamethasone IV on day 1 of chemotherapy course 1. Patients in the high-risk (level 5) stratum also receive oral dexamethasone on days 2-4 of all treatment courses.
11632507|NCT00343460|Experimental|Arm II|Patients receive APF530 SC, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
11632508|NCT00343460|Experimental|Arm III|Patients receive APF530 SC at a higher dose, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC (at the same higher dose) and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
11632509|NCT00343421|Experimental|Group 1|PEDIACEL co-administered with Prevenar
11632510|NCT00343421|Active Comparator|Group 2|Infanrix-IPV+Hib co-administered with Prevenar
11632511|NCT00343395|Active Comparator|Avandamet|AVANDAMET 2/500 mg
11632512|NCT00343395|Placebo Comparator|Placebo|
11632552|NCT00342563|Placebo Comparator|Placebo-Smoker|
11632553|NCT00342563|Experimental|Mecamylamine- Non-Smoker|
11632554|NCT00342563|Placebo Comparator|Placebo-Non-Smoker|
11632513|NCT00343382|Experimental|Arm I|Patients receive oral pilocarpine hydrochloride once a day for 3 days, twice a day for 3 days, three times a day for 3 days, and then 4 times a day for up to 6 weeks in the absence of unacceptable toxicity.
11632514|NCT00343382|Experimental|Arm II|Patients receive oral pilocarpine hydrochloride once a day for 3 days and then twice a day for up to 6 weeks in the absence of unacceptable toxicity.
11632515|NCT00343382|Placebo Comparator|Arm III|Patients receive oral placebo once a day for 3 days, twice a day for 3 days, three times a day for 3 days, and then 4 times a day for up to 6 weeks in the absence of unacceptable toxicity.
11632516|NCT00343382|Placebo Comparator|Arm IV|Patients receive oral placebo once a day for 3 days and then twice a day for up to 6 weeks in the absence of unacceptable toxicity.
11632517|NCT00343291|Active Comparator|Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)|"Cycles 1-6:
~Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week
~Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle
~Paclitaxel 200 mg/m² on day 1 of every 3 week cycle
~Carboplatin area under curve (AUC=6 min*mg/mL) on day 1 of every 3 week cycle
~Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
11632518|NCT00343291|Active Comparator|Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)|"Cycles 1-6:
~Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week
~Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle
~Cycles 1-3:
~Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles
~Carboplatin AUC=6 min*mg/mL on day 1 of each 3 week cycle for the first 3 cycles
~Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
11632519|NCT00343265|Active Comparator|1|Progesterone gel
11632520|NCT00343265|Placebo Comparator|2|Vaginal gel with no medication
11632521|NCT00343252|Experimental|Teriparatide|Teriparatide 20 micrograms (ug)/day, subcutaneous, 18 months plus once weekly oral placebo
11632522|NCT00343252|Active Comparator|Risedronate|Risedronate 35 milligrams (mg)/once weekly, oral, 18 months plus daily subcutaneous injection placebo
11632523|NCT00343239|Experimental|Docetaxel/Cisplatin/Fluorouracil (DCF)|DCF combination for three 21-day cycles unless a disease progression is observed at the tumor assessment scheduled after the second cycle or due to patient intolerability
11632524|NCT00343200|Placebo Comparator|Placebo|
11632525|NCT00343200|Experimental|Sildenafil|
11632526|NCT00343135|Experimental|ARM 1|
11632527|NCT00343109|Experimental|Arm I|Patients receive HER-2/neu intracellular domain peptide-based vaccine mixed with GM-CSF intradermally once monthly for 6 months in the absence of disease progression or unacceptable toxicity.
11632528|NCT00343083|Experimental|Cetuximab comparison for Head and Neck Cancer|"To report the mature data of a prospective Phase II trial designed to evaluate the efficacy of an epidermal growth factor receptor inhibitor cetuximab (CTX) added to the concurrent therapy of weekly paclitaxel/carboplatin (PC) and daily radiation therapy (RT).
~Both chemotherapy and radiation will be given on a weekly basis (see interventions for details)."
11632529|NCT00343044|Experimental|Treatment|Subjects received standard topotecan with the addition of bevacizumab. Cycles were 28 days and continued until toxicity, progression or subject wish to discontinue treatment. Topotecan administered 4 mg/m2 IV on days 1, 8 and 15 and bevacizumab IV 10 mg/kg, days 1 and 15 of each cycle.
11632530|NCT00343031||Pregnant women delivering male infants|Male newborns and their mothers living in Tapachula (Chiapas, Mexico) and surrounding areas exposed to DDT through house spraying programs to control malaria, grouped by level of DDT exposure.
11632531|NCT00342992||Healthy Volunteers|Male smokers in Southwestern Finland
11632532|NCT00342953||Cohort|Women receiving implants and other plastic surgery.
11632533|NCT00342927||Volunteers|Volunteers for a genetic study of diabetes and nephropathy
11632534|NCT00342888||Childhood Leukemia Cases|Cases were diagnosed at 9 hospitals in Northern California
11632535|NCT00342888||Matched Controls|Controls were matched on age, gender and race/ethnicity from birth certificates in Northern California
11632536|NCT00342875||Population Controls|Control subjects were selected randomly from state Department of Motor Vehicle and Centers for Medicare and Medicaid Services (CMS) beneficiary records.
11632537|NCT00342875||Urinary Bladder Cases|patients with histologically confirmed carcinoma of the urinary bladder
11632538|NCT00342862||1. Amevive Exposure|Pregnant women with psoriasis exposed to AMEVIVE® at any point within 8 weeks prior to conception, or at any time during pregnancy, where the outcome of the pregnancy is unknown prospectively
11632539|NCT00342849|Experimental|1|Scuccimer Treatment Group
11632540|NCT00342849|Placebo Comparator|2|In order to provide placebo with an odor comparable to that of succimer, the Drug Distribution Center will place a small canister containing 200 mg of active drug into each bottle of placebo drug. A canister containing 200 mg of placebo will be placed inside each bottle of succimer so that all bottles will appear the same.
11632541|NCT00342797||Retinoblastoma cohort|Retinoblastoma patients treated at two hospitals in New York and one hospital in Boston from 1914-2006 who survived at least one year after their retinoblastoma diagnosis.
11632542|NCT00342771||NCI Maryland pop-based controls|population-based controls
11632543|NCT00342771||NCI-Maryland Prostate Cancer Cases|prostate cancer cases
11632544|NCT00342732||non-diabetic volunteers|non-diabetic volunteers aged 18-65 who are healthy as determined by medical history, physical examination, and laboratory tests
11632545|NCT00342667||1|patients with preterm labor/contractions and preterm premature rupture of membranes
11632546|NCT00342628|Experimental|Vi-rEPA plus DTP|Vi-rEPA and DTP at 2, 4, 6 months, and Vi-rEPA at 12 months
11632547|NCT00342628|Active Comparator|Hib-TT plus DTP|Hib-TT and DTP at 2,4 and 6 months, Hib-TT at 12 months
11632548|NCT00342628|Active Comparator|EPI|DTP at 2,4 and 6 months
11632549|NCT00342589||Healthy Volunteers|Individuals exposed to environmental or person- to-person sources of organisms, including healthy volunteers, health care professionals, patient families, or other patients in health care facilities
11632550|NCT00342589||Patients|Patients immunosuppressed with acute pneumonia and are undergoing or have undergone a clinically indicated procedure to obtain a respiratory sample for diagnostic purposes.
11632551|NCT00342563|Experimental|Mecamylamine- Smoker|
11632555|NCT00342550||Pregnant Women|Pregnant women aged 15 and older between 20 and 35 weeks with singleton gestation
11632556|NCT00342472||1|Two of the oldest individuals (a male and a female greater than 18 years of age) from each of 10-15 nonsmoking households from the high-risk region of Linxian, China
11632557|NCT00342433||Localized Prostate Cancer cases|Cases enrolled between Jan 2000 and Apr 2004 at five locations. Study subject eligibility: Age >=18; scheduled for radical prostatectomy; and newly diagnosed with localized prostate cancer.
11632558|NCT00342407||Cohort|Female flight attendants
11632559|NCT00342381|Active Comparator|3.4 diaminopyridine|Single dose 3,4 diaminopyridine
11632560|NCT00342381|Placebo Comparator|Placebo|Two tablets identical to active treatment
11632561|NCT00342368|Active Comparator|1|CPAP through an helmet
11632562|NCT00342368|No Intervention|2|O2 therapy with conventional face mask
11632563|NCT00342355|Active Comparator|AZT+DDI+EFV|Zidovudine,Didanosine,Efavirenz ( Zidovudine 600 mg once daily,Didanosine <60 kg/125 mg twice daily or >60kg/200 mg twice daily,Efavirenz 600 mg once daily)
11632564|NCT00342355|Active Comparator|AZT+DDI+r/LPV|Zidovudine,Didanosine,Lopinavir/Ritonavir(AZT 600 mg once daily,DDI 100 mg twice daily,r/LPV 400mg/100mg twice daily)
11632565|NCT00342355|Active Comparator|d4T+3TC+EFV|Stavudine,Lamivudine,Efavirenz(d4T 40 mg twice daily,3TC 300 mg once daily,EFV 600 mg once daily)
11632566|NCT00342355|Active Comparator|d4T+3TC+r/LPV|Stavudine,Lamivudine,Lopinavir/Ritonavir(d4T 40m mg twice daily,3TC 300 mg once daily,r/LPV 400mg/100mg twice daily)
11632567|NCT00342342||Beaver Dam Eye Study|Individuals over 45 years of age enrolled in Beaver Dam Wisconsin
11632568|NCT00342342||Framingham Eye Study|Subset of individuals from the Framingham Heart Study who received eye examinations
11632569|NCT00342316|Experimental|Stem cell transplant (RICT)|Receiving intervention consisting of Reduced Intensity Conditioning Stem Cell Transplantation
11632570|NCT00342316|No Intervention|Control arm|Treatment according to standard of care, i.e. not undergoing RICT
11632571|NCT00342277||Pregnant Women|Consecutive pregnant women admitted with either: Preterm labor/delivery/PROM. Termdelivery without labor/spontaneous labor /chorioamnionitis/failed labor leading to c-section
11632572|NCT00342264||1|The study cohort will be comprised of underground, and surface workers (excluding administrative workers) who have been employed in the candidate non-metal mines for at least one year during the period between the date of dieselization of each mine and December 31, 1996.
11632573|NCT00342173||Women in Costa Rica|Examining the natural history of HPV and cervical neoplasia in Costa Rican women.
11632574|NCT00342147||1|This is a high risk population of families for NPC
11632575|NCT00342121||1|Corn farmers enrolled in the Agricultural Health Study who are non-smokers, and who plan to apply specific pesticides.
11632576|NCT00342121||2|Control subjects selected from agricultural extension workers in Iowa who are non-smokers
11632577|NCT00342108|Experimental|1|Diagnosis: CP, moderate to severe MR and CVI
11632578|NCT00342108|Experimental|2|Diagnosis: CP, Moderate to severe MR, no visual impairment
11632579|NCT00342004||Healthy Volunteers|Healthy female urban residents in Shanghai between ages of 40-70.
11632580|NCT00341991||1|Cases from hospitals
11632581|NCT00341991||2|Controls from the general populations
11632582|NCT00341991||3|Biological Samples
11632583|NCT00341952||Cases|individuals diagnosed with incident, first primary non-Hodgkin lymphoma
11632584|NCT00341952||Controls|individuals identified in the same geographical areas without non-Hodgkin lymphoma or othercancers
11632585|NCT00341939||1/Cancer Patients|Cancer patients previously enrolled on IRB approved clinical trials at NCI
11632586|NCT00341900||Case|Male pilots with high cosmic radiation exposure
11632587|NCT00341874||1|Subjects with hearing loss consisting of both nonsyndromic and syndromic forms of deafness of genetic etiology
11632588|NCT00341835||High risk lung cancer families|Individuals from families with a high risk of lung cancer, both affected and unaffected family members
11632589|NCT00341692||Samples of normal breast tissue|Samples of normal breast tissue from organ donors for assessment of histology.
11632590|NCT00341679||Family Members|Family members need to be blood relatives of the proband with the diagnosis of anautoimmune disease
11632591|NCT00341679||IIM Patient|Adult and pediatric patients with diagnosis of myositis or a related autoimmune or rheumatic disorder (by Bohan and Peter criteria, American College of Rheumatology, or other criteria).
11632592|NCT00341679||Normal volunteers|gender and race-matched to a subset of autoimmune subjects as controls. Should bewithout any autoimmune disease.
11632593|NCT00341627||1|Population-based sampling of individuals affected with Chordoma
11632594|NCT00341588||Cases|Male U.S. serviceman, age 18-45 years old with TGCT
11632595|NCT00341588||Controls|Male U.S. serviceman, age 18-45 years old without TGCT
11632596|NCT00341549||Myopia|The subject population will be adult individuals and their children, in good health with the exception of myopia.
11632597|NCT00341523||1|Adult patients with Esophageal squamous cell carcinoma (ESCC)
11632598|NCT00341497||Cohort|Persons seen at dental clinics at 6 Veterans Affairs Medical Centers who had clinically visibleoral lesions
11632599|NCT00341458||Cancer Cases|Women 20-74 years old, residents of Warsaw and Lodz that were newly diagnosed with confirmed in situ or invasive breast cancer or ovarian or endometrial cancer
11632600|NCT00341406||Healthy volunteers|healthy, non-overweight or other medical conditions
11632601|NCT00341406||Patients overweight|Those who are generally healthy but overweight
11632602|NCT00341406||Patients with health conditions|Those with diabetes and cardiovascular disease.
11632603|NCT00341380||Patients|Undergoing resection of lung tumor
11632604|NCT00341328|Experimental|1|In one arm the patient will receive intradermal Mycobacterium W Vaccine along with Category I ATT drugs according to RNTCP guidelines
11632605|NCT00341328|Placebo Comparator|2|In this Arm patient will receive Placebo along with Category I ATT drugs according to RNTCP guidelines
11632606|NCT00341315||Cohort|A primarily African-American population living in the vicinity of a DDT production plant inAlabama.
11632607|NCT00341302||Cohort 1|HIV Infected Pregnant Women
11632608|NCT00341302||Pediatric Cohort 2|HIV exposed , uninfected children born to HIV infected women
11632609|NCT00341302||Pediatric Cohort 3|HIV exposed, uninfected children 6 months to 5 years of age
11632610|NCT00341276||1|First, several hundred cases of esophageal cancer and gastric cancer (both cardia and body) ascertained in Taiyuan at the Shanxi Cancer Hospital.
11632611|NCT00341263||Cases - twin pregnancies|Maternal and cord hormones in twins
11632612|NCT00341263||Controls - singleton pregnancies|Maternal and cord hormones in singletons
11632613|NCT00341237||polymorphisms|Specimens are available to investigators in coded form to anonymously screen for the presence of single-nucleotide polymorphisms (SNPs) and other mutations in DNA.
11632614|NCT00341094||Main UkrArm|Subjects exposed to I131 before the age of 18 years
11632615|NCT00341094||Ukraine in utero|Subjects exposed to I131 in utero
11632616|NCT00341068||Cleft|children and adults with a cleft lip and/or cleft palate and their parents residing in the Republic of Ireland, Northern Ireland and the United Kingdom
11632617|NCT00341068||NTD|children and adults with an NTD (neural tube defects) and their parents residing in the Republic of Ireland, Northern Ireland and the United Kingdom
11632618|NCT00341016||Cohort of Chernobyl cleanup workers (liquidators) in Ukraine|Cases with leukemia and related diseases, and matched controls in the cohort
11632619|NCT00340977||Case-Control Parent-Triad|Norwegian infants born with cleft lip or palate over a 5 year period
11632620|NCT00340899||Pregnant women|Pregnant women with gestational age between 6 and 22 weeks
11632621|NCT00340873||Cases|Individuals exposed to digoxin
11632622|NCT00340873||Controls|Individuals not exposed to digoxin
11632623|NCT00340860||Norweigian Population-Based Pregnancy Cohort|Norwegian-speaking pregnant women, their children born post enrollment, and enrolled children's fathers
11632624|NCT00340834|Experimental|Fingolimod 1.25 mg|
11632625|NCT00340834|Experimental|Fingolimod 0.5 mg|
11632626|NCT00340834|Active Comparator|Interferon β-1a 30 µg|
11632627|NCT00340808||endometrial cancer cases|endometrial cancer cases
11632628|NCT00340704|Experimental|1. Low dose group|
11632629|NCT00340704|Experimental|2. Medium dose group|
11632630|NCT00340704|Experimental|3. High dose group|
11632631|NCT00340678|Experimental|Normoalbuminuria Losartan|Subjects with normal urinary albumin excretion were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
11632632|NCT00340678|Placebo Comparator|Normoalbuminuria Placebo|Subjects with normal urinary albumin excretion were treated with placebo corresponding to each dose of losartan.
11632633|NCT00340678|Experimental|Microalbuminuria Losartan|Subjects with microalbuminuria were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
11632634|NCT00340678|Placebo Comparator|Microalbuminuria Placebo|Subjects with Microalbuminuria were treated with placebo corresponding to each dose of losartan.
11632635|NCT00340626||Control|healthy individuals with no history of oral cleftsto serve as controls
11632636|NCT00340626||Oral Cleft Family Members|individuals with unilateral or bilateral cleft lip with or without cleft palate and their unaffected relatives
11632637|NCT00340600||DES Exposed|DES-exposed mothers, daughters and sons, and identified subjects
11632638|NCT00340600||DES Unexposed|DES-unexposed mothers, daughters and sons, and identified subjects
11632639|NCT00340535||Individuals|Individuals recruited at U of Pittsburgh
11632640|NCT00340457||Cases|African American patients with renal cancer from two geographic areas of the US
11632641|NCT00340457||Controls|African American participants without renal cancer from two geographic areas of the US
11632642|NCT00340405||Tin Miners in China at risk of lung cancer|Tin Miners in China at risk of lung cancer
11632643|NCT00340379|Active Comparator|Ziprasidone|Subjects in this arm received ziprasidone with a placebo to maintain the blind
11632644|NCT00340379|Active Comparator|Sertraline/Haloperidol|Subjects in this arm received a combination of sertraline and haloperidol with a placebo to maintain the blind. Sertraline dosage was 150-200mg/day and haloperidol was 6-8mg/day based on tolerance.
11632645|NCT00340340||Cases|Newly diagnosed lung cancer cases
11632646|NCT00340340||Controls|Population-based controls
11632647|NCT00340288||Premenopausal fibroid cases|Premenopausal women (18 years or older) with at least one uterine leiomyoma diagnosis confirmed by ultrasound
11632648|NCT00340262||FIT Participants|
11632649|NCT00340210||Serum Bank Participants|The Columbia MO Serum Bank recruited 6915 women living in and around Columbia MO between 1977-1987 who were cancer-free except for non-melanoma skin cancer and at least 18 years of age.
11632650|NCT00340171||Pregnant women and infants|pregnant women with singleton pregnancy and their newborns
11632651|NCT00340132||Adult volunteers|Volunteers aged 18-55 who are healthy as determined by medical history, physical examination, and laboratory tests
11632652|NCT00340028||Women in Early Pregnancy|Women enrolled in the University of North Carolina's Right from the Start study are followed while trying to become pregnant and through 9 weeks of pregnancy
11632653|NCT00340015||AARP|Members of the AARP, aged 50-71 years, and who resided in one of six states
11632654|NCT00340002||Pregnant women|Pregnant women aged 18 years and older
11632655|NCT00339989||Women undergoing colposcopy|women attending the University of Oklahoma Colposcopy Clinic
11632656|NCT00339950||1|Asymptomatic women between the ages of 40 and 75 referred to regional military medical centers for routine colorectal screening
11632657|NCT00339937||Cases|Adults in Italy with Kaposi's sarcoma
11632658|NCT00339937||Controls|Adults in Italy without Kaposi's sarcoma
11632659|NCT00339924||Physicians|Currently practicing, board certified general internists, both allopathic and osteopathic, whose offices are in the United States.
11632660|NCT00339911||1/ single cohort|Healthy NCI Frederick Cancer Research and Development Center employees
11632661|NCT00339885||AADM|Family and Population based individuals
11632662|NCT00339885||Action-LADA|Population based individuals
11632663|NCT00339885||D2D 2004|Population based individuals
11632664|NCT00339885||DIAGEN (Dresden Biobank)|Population based individuals
11632665|NCT00339885||FINRISK 1987|Population based individuals
11632666|NCT00339885||FINRISK 2002|Population based individuals; Test DNA
11632667|NCT00339885||Fusion 1|Affected-sib pair (ASP) families and elderly controls
11632668|NCT00339885||Fusion 2|275 Replication ASP Families; Trios
11632669|NCT00339885||Fusion 3|Siblings of FUSION1 families; Spouses, Offspring of 291 FUSION 1 families; Spouses, Offspring of Elderly Controls; Other F1 relatives
11632670|NCT00339885||Fusion 4/5|Spouses, Offspring of FUSION 1 and 2 Families
11632671|NCT00339885||FUSION Finnish Groups|Family and Population based (including METSIM and DR's EXTRA): Tissue samples
11632672|NCT00339885||Health-2000|Population based individuals
11632673|NCT00339885||HUNT 2|Population based individuals
11632674|NCT00339885||METSIM|Population based individuals
11632675|NCT00339885||Savitaipale|Population based individuals
11632676|NCT00339885||UEF - Laakso|Monogenic disease individuals and family members
11632677|NCT00339859||1|The population controls are collected from DMV records in the Baltimore region of MD. The cases are patients at the University of Maryland Medical System, including the associated Veterans' Association Hospital.
11632678|NCT00339833|Experimental|Salsalate|Salsalate (3g/day) for 7 days
11632679|NCT00339833|Placebo Comparator|Placebo|Placebo
11632680|NCT00339768|Experimental|Amox/omepr|2 weeks; placebo controlled
11632681|NCT00339768|Experimental|Garlic|Supplement for 7 years; placebo controlled
11632682|NCT00339768|Experimental|Vitamins|Supplement for 7 years; placebo controlled
11632683|NCT00339742||Clinic Referral controls|Controls referred by the endoscopy clinic
11632684|NCT00339742||Esophageal Cancer cases|Histologically confirmed squamous cell cancer of the esophagus
11632685|NCT00339742||Neighborhood controls|Controls recruited from the neighborhood
11632686|NCT00339716||Belarus in utero|subjects exposed to I131 in utero
11632687|NCT00339716||Main BelAm|subjects exposed to I131 at age less than 18 year
11632688|NCT00339690|Experimental|Test Kit Homes|Households assigned to use the in-home test kit.
11632689|NCT00339677||Volunteers|Volunteers
11632690|NCT00339664||1/ patients|Patients on approved clinical trials
11632691|NCT00339651||Cases|Women in one large U.S. health care plan. Cases will consist of women who developed endometrial carcinoma or censored complex atypical hyperplasia at least 1 year after receiving a diagnosis of endometrial hyperplasia.
11632692|NCT00339651||Controls|Women in one large U.S. health care plan. Controls will consist of individually matched women who received a diagnosis of endometrial hyperplasia at the same age and date as the cases and were cancer-free and hysterectomy-free until the date at which the index cases were diagnosed with endometrial carcinoma or censored complex atypical hyperplasia.
11632693|NCT00339625|Experimental|1|low fat, high fiber, high fruit and vegetable eating plan
11632694|NCT00339625|No Intervention|2|Usual Diet
11632695|NCT00339612||HIV-infected children who acquired HIV infection through mothe|HIV-infected children in who acquired HIV infection through mother-to-child transmission (MTCT).
11632696|NCT00339573||National Housing Stock|The target population of this study was the national housing stock (1998-1999) ofapproximately 95 million housing units.
11632697|NCT00339560||Cases will bile duct CA|Patients with bile duct cancer
11632698|NCT00339560||Cases with Gallbladder CA|Patients with gallbladder cancer
11632699|NCT00339560||Controls with gall stones|Patients undergoing cholecystectomy for gall stones
11632700|NCT00339560||Controls without cancer|Hospital controls with cancer
11632701|NCT00339534||Cases|Cases were recruited at Korle Bu Teaching Hospital in Accra, Ghana, between 2008 and 2012.
11632702|NCT00339534||Controls|Controls were selected in a population-based component using a probability sample designed with the 2000 Ghana Population and Housing Census data between 2004 and 2006.
11632703|NCT00339521||Case-Parent Triad|Childhood Asthmatics (aged 4-17) are Cases; biologic parents of cases are genetic Controls.
11632704|NCT00339495||Non-Screening|Participants received their usual care
11632705|NCT00339495||Screening|Participants received trial-provided screening examinations for prostate, lung, colorectal, andovarian cancer
11632706|NCT00339482||American Indians|Residents of the Gila River Indian Community
11632707|NCT00339469|Other|2|Controlled feeding study.
11632708|NCT00339365|Experimental|1|Promoting first relationships group
11632709|NCT00339365|Active Comparator|2|Early education support group
11632710|NCT00339352||1|Cases
11632711|NCT00339352||2|Controls
11632712|NCT00339352||3|first-degree relatives of cases/controls
11632713|NCT00339326||Cases with Kaposi's Sarcoma|Cases with Kaposi's Sarcoma from Southern Italy.
11632714|NCT00339326||Controls without KS|Controls from Southern Italy.
11632715|NCT00339287||Healthy Volunteers|Healthy volunteers between ages 21 and 65
11632716|NCT00339235||Non-pregnant women|Non-pregnant women aged 18 years and older
11632717|NCT00339235||Pregant women|Pregnant women aged 18 years and older
11632718|NCT00339222||1|Melanoma-prone families from dermatology clinics.
11632719|NCT00339196|Experimental|1|5-azacytidine VALPROIC acid and ATRA
11632720|NCT00339183|Experimental|Panitumumab Plus FOLFIRI|Participants received panitumumab as an intravenous (IV) infusion at a dose of 6 mg/kg plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-fluorouracil (5-FU), leucovorin and irinotecan. Treatment was administered in cycles every two weeks.
11632721|NCT00339183|Active Comparator|FOLFIRI Alone|Participants received standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment is administered in cycles every two weeks.
11632722|NCT00339170|Experimental|1|Participants receive a 12-month cognitive enhancement training program plus a 12-month work therapy program.
11632723|NCT00339170|Active Comparator|2|Participants receive a 12-month work therapy program alone.
11632724|NCT00339144|Experimental|Dasatinib (100 mg)|
11632725|NCT00339144|Experimental|Dasatinib (150 mg)|
11632726|NCT00339144|Experimental|Dasatinib (200 mg)|
11632727|NCT00339092|Experimental|Treatment|Participants who receive storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals
11632728|NCT00339092|Active Comparator|Control|Participants who receive standard care
11632780|NCT00338520||Healthy Controls (HC)|Healthy control children will be enrolled from out-patient well-baby visits.
11632729|NCT00339079|Experimental|Cognitive Behavioral Therapy (CBT)|Patients in this arm only received Cognitive Behavioral Therapy (CBT). Six, 60 minute weekly sessions were followed by 4 bi-weekly sessions and 3 monthly booster sessions.
11632730|NCT00339079|Placebo Comparator|Placebo|Patients only received placebo pills accompanied by medication management supportive therapy; including non-specific encouragement, support and explanation similar to that provide in a physician's office.
11632731|NCT00339079|Experimental|Fluoxetine|Patients only received the SSRI Fluoxetine. Medication was adminstered on a fixed-flexible dosing regimen, beginning at 10mg/day for 2 weeks, then 20 mg/day for 2 weeks, 40 mg/day for two weeks, 60 mg/day for 2 weeks, and 80 mg/day (the target dose) thereafter. This was accompanied by medication management supportive therapy; including non-specific encouragement, support and explanation similar to that provide in a physician's office.
11632732|NCT00339079|Experimental|Combined CBT and Fluoxetine|Patients in this arm received both CBT and the fluoxetine medication. Both interventions were administered in the same way as when adminstered alone in the other arms.
11632733|NCT00339040|Active Comparator|Arm A: QHPV|QHPV at week 0, 8, 24, 96.
11632734|NCT00339040|Other|Arm B: Placebo/QHPV|Placebo at week 0, 8, 24; QHPV at week 96, 104, 120.
11632735|NCT00339014|Active Comparator|Group 1|Zonisamide SR 120 mg/day plus Bupropion SR 280 mg/day
11632736|NCT00339014|Active Comparator|Group 2|Zonisamide SR 120 mg/day plus Bupropion SR 360 mg/day
11632737|NCT00339014|Active Comparator|Group 3|Zonisamide SR 240 mg/day plus Bupropion SR 280 mg/day
11632738|NCT00339014|Active Comparator|Group 4|Zonisamide SR 240 mg/day plus Bupropion SR 360 mg/day
11632739|NCT00339014|Active Comparator|Group 5|Zonisamide SR 360 mg/day plus Bupropion SR 280 mg/day
11632740|NCT00339014|Active Comparator|Group 6|Zonisamide SR 360 mg/day plus Bupropion SR 360 mg/day
11632741|NCT00339014|Placebo Comparator|Group 7|
11632742|NCT00338988|Experimental|Capecitabine + Oxaliplatin|Combination of intravenous (IV) oxaliplatin 100 mg/m^2 Day 1 and oral (PO) capecitabine 750 mg/m^2 twice daily (total daily dose 1500 mg/m2) on Days 1-14.
11632743|NCT00338975|Experimental|1|Cognitive Behavioral Social Skills Training (CBSST)
11632744|NCT00338975|Active Comparator|2|Goal-Focused Supportive Contact (GFSC)
11632745|NCT00338962|Active Comparator|Paroxetine and naltrexone|Paroxetine was started at 10 mg per day and the dose was gradually increased over 2 weeks to 40 mg per day. Naltrexone was started at 25 mg the first day and 50 mg per day for the rest of the treatment.
11632746|NCT00338962|Active Comparator|paroxetine and placebo|Paroxetine was started at 10 mg per day and the dose was gradually increased over 2 weeks to 40 mg per day.
11632747|NCT00338962|Active Comparator|Desipramine and naltrexone|Desipramine was started at a dose of 25 mg per day. The dose was gradually increased over 2 weeks to 200 mg per day. Naltrexone was started at 25 mg the first day and 50 mg per day for the rest of the treatment.
11632748|NCT00338962|Active Comparator|Desipramine and placebo|Desipramine was started at a dose of 25 mg per day. The dose was gradually increased over 2 weeks to 200 mg per day.
11632749|NCT00338949|Active Comparator|Control|Participants on risperidone or olanzapine who will remain on risperidone or olanzapine and do not switch to ziprasidone
11632750|NCT00338949|Experimental|Switch|Participants who enter on risperidone or olanzapine and switch to ziprasidone
11632751|NCT00338923|Active Comparator|Treatment arm|One Arm - Active Compound (HO/03/03)
11632752|NCT00338884|Experimental|SUNITINIB MALATE.|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
11632753|NCT00338871|Experimental|study|home exercise
11632754|NCT00338871|No Intervention|control|regular therapy
11632755|NCT00338858|Active Comparator|1|TD
11632756|NCT00338858|Experimental|2|TBI
11632757|NCT00338858|Experimental|a|Cerebral palsy
11632758|NCT00338845|Experimental|1|Participants will receive the Share Safer Sex counseling program
11632759|NCT00338845|Active Comparator|2|Participants will receive a standard didactic safer-sex counseling session
11632760|NCT00338832|Experimental|1|Participants will receive the Physically Ready for Invigorating Movement Every Day program
11632761|NCT00338832|Active Comparator|2|Participants will receive the Program for Activity, Leisure Skills, and Socialization
11632762|NCT00338806|Experimental|Interpersonal Psychotherapy-Prevention|Participants will receive interpersonal psychotherapy for prevention with adolescents
11632763|NCT00338806|Active Comparator|Educational and Clinical Monitoring|Participants will receive educational clinical monitoring
11632764|NCT00338767|Experimental|Treatment|Participants receiving storefront directly observed therapy of anti-depressants (Fluoxetine)
11632765|NCT00338767|No Intervention|Control|Participants receiving referral to mental health follow-up with the UCSF AIDS Health Project
11632766|NCT00338741||1|Rebif exposed pregnancies
11632767|NCT00338741||2|Non-Rebif exposed pregnancies
11632768|NCT00338728|Experimental|Treatment (imatinib mesylate, letrozole)|Participants receive imatinib mesylate PO BID and letrozole PO QD for 8 weeks in the absence of disease progression or unacceptable toxicity.
11632769|NCT00338715|Experimental|A|Prophylactic Pulmonary Vein Isolation in Addition to CABG for the prevention of postoperative Atrial Fibrillation
11632770|NCT00338689|Experimental|Lower protein formula|"Intervention: Infant formula with relatively low protein content (1.25 g/ 100 ml) during the first year of life; described as Lower protein formula"
11632771|NCT00338689|Placebo Comparator|Higher protein formula|"Intervention: Infant formula with a relatively high protein content (2.05 g/ 100 ml) during the first year of life; described as Higher protein formula"
11632772|NCT00338689|No Intervention|Breastfed reference group|Non-randomized breastfed group of infants at least 3 months exclusively breastfed
11632773|NCT00338598|Experimental|Glycine|Glycine, 0.8 gr per kg given in two daily doses
11632774|NCT00338598|Placebo Comparator|placebo|placebo will be administered.
11632775|NCT00338572|Active Comparator|1|12-week exercise program
11632776|NCT00338572|Experimental|2|12-week combined exercise and diet program
11632777|NCT00338572|No Intervention|3|Non-intervention group
11632778|NCT00338559||LMA group|Patients in which laryngeal mask airway (LMA) is used.
11632779|NCT00338559||ET group|Patients in which endotracheal tube (ET) is used.
11632781|NCT00338520||Uncomplicated Malaria (UM)|Febrile children admitted to the hospital with Plasmodium falciparum parasitemia, no other cause of fever identified, no evidence of severe malaria (as listed in Study Protocol, Section 5.2 under exclusion criteria for UM), and no co-infection with other malaria species will be enrolled in the UM group.
11632782|NCT00338520||Cerebral Malaria (CM)|Comatose children admitted to the hospitals will be evaluated by the house physician and/or member of the study team. If lumbar puncture is obtained, the parent or guardian will be approached for permission to enroll the child into the study. Parasitemic children with no other cause of coma identified will included in the CM group.
11632783|NCT00338520||Non-malaria CNS disease (NMC)|Children without parasitemia and diagnosed with a non-malaria cause of coma or CNS disease will be enrolled in the non-malaria CNS disease group.
11632784|NCT00338494|Experimental|1|
11632785|NCT00338481|Active Comparator|1|
11632786|NCT00338481|Active Comparator|2|
11632787|NCT00338455|Experimental|001|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min
11632788|NCT00338455|Placebo Comparator|002|Placebo+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min
11632789|NCT00338429|Experimental|Treatment: FHP Sleep Program|Stratified with or without behavior Disorder Diagnosis (ADHD): 50% randomized to receive Better Days, Better Nights- sleep distance intervention
11632790|NCT00338429|No Intervention|Control: Usual Care|Stratified with/without behavior diagnosis (ADHD): 50% randomized to receive usual care for sleep disorder
11632791|NCT00338390|No Intervention|1|Maintain antiretroviral treatment
11632792|NCT00338390|Experimental|2|Change tenofovir to abacavir and increase didanosine dose to 400 mg/day if weight is > 60 Kg. or to 250mg/day if weight is < 60 kg.
11632793|NCT00338390|Experimental|3|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
11632794|NCT00338377|Experimental|Group A: Chemotherapy + IL-2 plus T-cells|"Cyclophosphamide 60 mg/kg/d by vein (IV) over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
~Group A has been closed to new patient entry as of January 14, 2016."
11632795|NCT00338377|Experimental|Group B: Chemotherapy + IL-2 plus T-Cells + Vaccine|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
11632796|NCT00338377|Experimental|Group C: Prior Treatment with BRAF Inhibitor|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
11632797|NCT00338377|Experimental|Group D: Leptomeningeal Disease|"T-cells: 5.0x109 TIL administered on Day 1 and 10x109 TIL on Day 15.
~IL-2: 1.2 MIU of IL- 2 on Days 2, 4, 9, 11, 16 and 18 as tolerated. After this period, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks, patients switched to IL-2."
11632798|NCT00338377|Experimental|Group E: Chemotherapy + IL-2 plus T-Cells + Vaccine|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
11632799|NCT00338364|Experimental|Treatment|50% randomized to receive distraction during painful procedure
11632800|NCT00338364|No Intervention|Control|50% randomized to receive no distraction during painful procedure
11632801|NCT00338325|Experimental|Treatment|50% randomized to receive treatment: reading pre-operatively
11632802|NCT00338325|No Intervention|Control|50% randomized to receive no intervention pre-operatively: no reading
11632803|NCT00338312|Placebo Comparator|1|Placebo patch
11632804|NCT00338312|Experimental|2|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
11632805|NCT00338286|Experimental|001|epoetin alfa + packed RBC transfusion 40 000 IU SC once a week.
11632806|NCT00338286|Other|002|Standard supportive care (packed RBC transfusion) Per doctor prescription
11632807|NCT00338273|Active Comparator|A1|
11632808|NCT00338273|Placebo Comparator|A2|
11632809|NCT00338234||Cardiac surgery|Successive cardiac surgery patients
11632810|NCT00338234||Surgical ICU|Successive patients admitted to the surgical ICU for more than 7 days, and experiencing anemia
11632811|NCT00338208|No Intervention|No training|Subjects will be fitted with low vision devices; no extra training will be provided.
11632812|NCT00338208|Experimental|Training in the Use of Low Vision Devices|Subjects will be fitted with low vision devices and will receive 6 training sessions with prescribed devices for up to 1 hour each time
11632813|NCT00338195|No Intervention|Delayed intervention control|
11632814|NCT00338182|Experimental|AZD1152|AZD1152 treatment given for 2 days every 14 days (2 treatment days followed by 12 days off treatment)
11632815|NCT00338130|Active Comparator|1|Temozolomide
11632816|NCT00338130|Experimental|2|AZD6244
11632817|NCT00338104|Experimental|40% Glargine|Patients will receive a dose of glargine insulin equal to 40% of insulin drip rate.
11632818|NCT00338104|Experimental|60% Glargine|Patients will receive a dose of glargine insulin equal to 60% of insulin drip rate.
11634351|NCT00318565|Experimental|Navistar ThermoCool Catheter|
11632819|NCT00338104|Experimental|80% Glargine|Patients will receive a dose of glargine insulin equal to 80% of insulin drip rate.
11632820|NCT00338065|Experimental|Subjects with autonomic dysfunction|"Subjects with known autonomic dysfunction diagnoses as defined by the General Clinical Research Center (GCRC) such as pure autonomic failure, Postural orthostatic tachycardia syndrome (POTS), and Multiple System Atrophy( MSA).
~Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes
~Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
11632821|NCT00338065|Experimental|Primary open-angle glaucoma subjects|"Subjects diagnosed with primary open-angle glaucoma following a glaucoma specialist's examination.
~Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes
~Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
11632822|NCT00338065|Experimental|Subjects with normal-pressure glaucoma|"Subjects with open-angle glaucoma damage following a glaucoma specialist's examination without ever an intraocular pressure recording greater than 21 mm Hg.
~.1. Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes
~2. Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
11632823|NCT00338065|Active Comparator|Normal subjects|"Subjects without evidence of glaucoma or autonomic dysfunction.
~..1. Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes
~2. Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
11632824|NCT00338039|Experimental|Chemotherapy + Chemoradation|Systemic chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. Cetuximab 500 mg/m^2 intravenous (IV)/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy. Induction Therapy Gemcitabine 1 gm/m^2 over 100 minutes every 2 weeks +/-1 day for 4 doses; Induction Chemotherapy Oxaliplatin 100 mg/m^2 over 120 minutes every 2 weeks +/-1 day for 4 doses. Capecitabine Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m^2 by mouth (PO) twice daily Monday-Friday throughout radiation. Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.
11632825|NCT00338026|Experimental|ECO-4601|
11632826|NCT00337974|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
11632827|NCT00337974|Active Comparator|Active Control|Educational DVDs
11632828|NCT00337974|No Intervention|No Contact Control|
11632829|NCT00337935|Experimental|Epoetin Alfa|
11632830|NCT00337935|Other|Group 2|Standard treatment of anemia excluding use of erythropoetin stimulating agents (ESAs).
11632831|NCT00337909|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
11632832|NCT00337909|Active Comparator|Active Control|Educational DVDs
11632833|NCT00337909|No Intervention|No Contact Control|
11632834|NCT00337896||observation|healthy adults ages 18-64 years, enrolled at Stanford University Hospital and participating in another clinical trial (DMID Protocol 04-062)
11632835|NCT00337870|Experimental|Treatment|50% randomized to receive distraction intervention during painful procedure
11632836|NCT00337870|No Intervention|Control|50% RANDOMIZED TO RECEIVE NO INTERVENITON
11632837|NCT00337818|Experimental|Cervarix New Process|Subjects aged 15 to 25 years received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the new manufacturing process.
11632838|NCT00337818|Experimental|Cervarix Old Process Group|Subjects aged 15 to 25 years who received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the old manufacturing process.
11632839|NCT00337818|Experimental|Cervarix Young/Lot 1 Group|Subjects aged 10 to 14 years, who received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the new manufacturing process (Lot 1).
11632840|NCT00337805|Active Comparator|1 colloid|Boluses of fluids are a pentastarch (up to 1000 ml)
11632841|NCT00337805|Active Comparator|2. Crytalloid|Boluses are given as normal saline
11632842|NCT00337779|Active Comparator|glatiramer acetate 40 mg|
11632843|NCT00337779|Active Comparator|glatiramer acetate 20 mg|
11632844|NCT00337766|Active Comparator|Desmopressin (DDAVP)|
11632845|NCT00337766|Placebo Comparator|Placebo|
11632846|NCT00337753|Active Comparator|Cognitive Behavioral Therapy|Weekly Cognitive Behavior therapy
11632847|NCT00337753|Other|Wait-list|Subjects in wait-list for six-weeks
11632848|NCT00337727|Other|1|Arm 1: Day 1: aprepitant 125 mg capsule; ondansetron 8 mg capsule prior to chemotherapy and 1 8mg capsule 12 hrs after first dose; dexamethasone 12 mg tablets + 2 dexamethasone Pbo tablets. Day 2: Aprepitant 80 mg capsule; Ondansetron 8 mg capsule every 12 hours Day 3: Aprepitant 80 mg capsule Ondansetron 8 mg capsule every 12 hours.
11632849|NCT00337727|Other|2|Arm 2: Day 1: Aprepitant 125 mg Pbo capsule; Ondansetron 8 mg capsule prior to chemotherapy and 8 mg capsule 12 hours after first dose; Dexamethasone 20 mg tablets. Day 2: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours; Day 3: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours. 3 Day treatment period Optional cycle 2 is being offered to patients. Optional cycle 2 will substitute aprepitant with fosaprepitant dimeglumine 115 mg or Pbo on day 1. All other dosing regimen will remain the same as cycle 1.
11632850|NCT00337714|Placebo Comparator|A|in this arm conventional CVCs will be inserted
11632851|NCT00337714|Active Comparator|B|group B will receive medicated silver nanoparticles CVC
11632852|NCT00337701|Experimental|1|
11632853|NCT00337701|Experimental|2|
11632854|NCT00337675|Active Comparator|Arm 1: drug + episodic supplemental placebo|Montelukast once a day (qd) + episode driven supplemental placebo qd for 12 days for a 52-wk treatment period
11632855|NCT00337675|Active Comparator|Arm 2: placebo comparator + episodic supplemental drug|Placebo qd + episode driven supplemental Montelukast qd for 12 days for a 52-wk treatment period
11632856|NCT00337675|Placebo Comparator|Arm 3: placebo comparator + episodic supplemental placebo|Placebo qd + episode driven supplemental placebo qd for 12 days for a 52-wk treatment period
11632857|NCT00337662|Experimental|1|Olanzapine for Not Early Onset response (NEO) patients
11632858|NCT00337662|Active Comparator|2|Risperidone for Not Early Onset response (NEO) patients
11632859|NCT00337662|Active Comparator|3|Risperidone for Early Onset response (EO) patients
11632860|NCT00337649|Experimental|1|
11632861|NCT00337636|Experimental|HuCNS-SC|human central nervous system stem cells
11632862|NCT00337610|Experimental|sitagliptin 100 mg once a day (q.d.)/metformin ≥1500 mg a day|
11632863|NCT00337610|Placebo Comparator|sitagliptin 100 mg placebo q.d./ metformin ≥ 1500 mg/day|
11632864|NCT00337571|Experimental|A1|5 mg
11632865|NCT00337571|Experimental|A2|10 mg
11632866|NCT00337571|Experimental|A3|15 mg
11632867|NCT00337571|Placebo Comparator|B1|
11632868|NCT00337558|Experimental|1|Solifenacin succinate
11632869|NCT00337558|Experimental|2|Solifenacin succinate and simplified bladder training
11632870|NCT00337532|Active Comparator|paclitaxel-cisplatin combination regimen|
11632871|NCT00337519|Experimental|1|see detailed description
11632872|NCT00337493|Experimental|1|
11632873|NCT00337493|Experimental|2|
11632874|NCT00337493|Experimental|3|
11632875|NCT00337480|No Intervention|conventional|This arm is the conventional way of taking care of patients after an acute coronary syndrome
11632876|NCT00337480|Active Comparator|structured|This arm is an active way to monitor and educate patients after their acute coronary syndrome, with the intervention of health members in a House of Education
11632877|NCT00337467|Experimental|A1|
11632878|NCT00337454|Experimental|A1|
11632879|NCT00337454|Experimental|A2|
11632880|NCT00337454|Experimental|A3|
11632881|NCT00337454|Experimental|B1|
11632882|NCT00337454|Experimental|B2|
11632883|NCT00337454|Experimental|B3|
11632884|NCT00337428|Experimental|Group 1|Concomitant/CMF
11632885|NCT00337428|Experimental|Group 2|Non-Concomitant/CMF
11632886|NCT00337428|Experimental|Group 3|Concomitant/FMF
11632887|NCT00337428|Experimental|Group 4|Non-Concomitant/FMF
11632888|NCT00337389|Experimental|1|CoFactor, 5-FU, Avastin
11632889|NCT00337389|Active Comparator|2|Leucovorin, 5-FU, Avastin
11632890|NCT00337376|Experimental|1|
11632891|NCT00337350|Active Comparator|rosiglitazone|rosiglitazone 4mg/day
11632892|NCT00337350|Placebo Comparator|placebo|matched placebo for 4mg rosiglitazone
11632893|NCT00337298|Experimental|1|Crossover design. Arm is same all the way
11632894|NCT00337285|Experimental|1|
11632895|NCT00337272|Placebo Comparator|1 (Placebo)|Patients will take placebo 30 minutes before bedtime days 1-28 of treatment period.
11632896|NCT00337272|Active Comparator|2 (Ramelteon)|Patients will take 8 mgs of ramelteon 30 minutes before bedtime days 1-28 of treatment period.
11632897|NCT00337259|Experimental|Gemcitabine|"histologically confirmed marginal zone lymphoma
~gemcitabine 1,250 mg/m2 on days 1 and 8 of each cycle, repeated every 3 weeks and continued for 6 cycles, until disease progression, withdrawal due to toxicity, or withdrawal of consent."
11632898|NCT00337207|Experimental|Avastin|
11632899|NCT00337194|Experimental|Arm I (SGN-30, chemotherapy)|"Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
~No prior stem cell transplant:
~SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 20 mg/m^2 IV days 1 & 8, gemcitabine: 1000 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 & 8.
~Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 15 mg/m^2 IV days 1 & 8, gemcitabine: 800 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 & 8."
11632900|NCT00337194|Active Comparator|Arm II (placebo, chemotherapy)|"Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.
~No prior stem cell transplant:
~SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 20 mg/m^2 IV days 1 & 8, gemcitabine: 1000 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 & 8.
~Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 15 mg/m^2 IV days 1 & 8, gemcitabine: 800 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 & 8."
11632901|NCT00337181||Vaccine Group|Received vaccination in RV144
11632902|NCT00337181||Placebo Group|Received placebo in RV144
11632903|NCT00337168|Experimental|Induc, ReInduc, Consol, clofarabine, cytarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
11632904|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 1|25 kBq/kg b.w., 3 times at 6 week intervals
11632905|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 2|50 kBq/kg b.w., 3 times at 6 week intervals
11632906|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 3|80 kBq/kg b.w., 3 times at 6 week intervals
11632907|NCT00337129|Experimental|eribulin mesylate|eribulin mesylate
11632908|NCT00337103|Experimental|1|
11632909|NCT00337103|Active Comparator|2|
11632910|NCT00337077|Experimental|Eribulin mesylate|Patients receive eribulin mesylate IV over 5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11632911|NCT00337051|Experimental|S|General Anesthesia with sevoflurane (inhalation) as hypnotic
11632912|NCT00337051|Active Comparator|P|General Anesthesia With Propofol TCI
11632913|NCT00336973|Experimental|1|
11632914|NCT00336960|Experimental|treatment intervention|
11632915|NCT00336934|Experimental|Arm I|Patients receive oral pomegranate extract daily.
11632916|NCT00336934|Placebo Comparator|Arm II|Patients receive oral placebo daily.
11632917|NCT00336921|Active Comparator|1|Alfuzosin 10mg
11632918|NCT00336921|Placebo Comparator|2|Placebo
11632919|NCT00336895|Experimental|Liver Transplant Subjects|All subjects in this study will receive Myfortic 360mg or 720 mg BID for 90 days.
11632920|NCT00336882|Active Comparator|1|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
11632921|NCT00336882|Experimental|2|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
11632922|NCT00336856|Experimental|IRINOTECAN AND CETUXIMAB|Cetuximab will be administered at the dose of 500 mg/m2 intravenously (IV) over 120 minutes, followed by 500 mg/m2 every 2 weeks, IV over 2 hours at an infusion rate not to exceed 5 ml/min. Followed immediately by Irinotecan administered at a dose of 180 mg/m2 IV over 60 minutes every two weeks.
11632923|NCT00336843|Experimental|Zevalin-BuCyE|histologically confirmed, relapsed or refractory CD20 positive B-cell NHL including diffuse large B-cell, follicular, mantle cell, and Burkitt lymphomas.
11632924|NCT00336830|Active Comparator|Usual Care|Comparator without MD endorsement of Cardiac Rehabilitation
11632925|NCT00336830|Experimental|MD Endorsment of CR|Provided with MD endorsement of participation in Cardiac Rehabilitation
11632926|NCT00336817|Active Comparator|Myfortic Group|Subjects in the Myfortic arm will receive Myfortic 360mg or 720 mg BID for 90 days
11632927|NCT00336817|Active Comparator|CellCept Group|Subjects in the CellCept arm will receive CellCept 500mg or 1000mg BID for 90 days
11632928|NCT00336791|Experimental|Paclitaxel + Additional FAC/FEC|"12 weekly Paclitaxel treatments 80 mg/m^2 by vein (IVPB) over 1 hour + 4 additional FAC or FEC combination chemotherapy treatments; FAC or FEC treatments given once every 3 weeks.
~FAC Chemotherapy: 5-Fluorouracil 500 mg/m^2 intravenous (IV) day 1 & 4 + Doxorubicin 50 mg/m^2 IV day 1 over 72 hour continuous infusion or IV bolus + Cyclophosphamide 500 mg/m^2 IV day 1.
~FEC Chemotherapy: 5-Fluorouracil 500 mg/m^2 IV day 1 + Epirubicin 100 mg/m^2 IV day 1 + Cyclophosphamide 500 mg/m^2 IV day 1."
11632929|NCT00336791|Active Comparator|FAC/FEC|"6 courses FAC or FEC Combination Chemotherapy
~FAC Chemotherapy: 5-Fluorouracil 500 mg/m^2 intravenous (IV) day 1 & 4 + Doxorubicin 50 mg/m^2 IV day 1 over 72 hour continuous infusion or IV bolus + Cyclophosphamide 500 mg/m^2 IV day 1.
~FEC Chemotherapy: 5-Fluorouracil 500 mg/m^2 IV day 1 + Epirubicin 100 mg/m^2 IV day 1 + Cyclophosphamide 500 mg/m^2 IV day 1."
11632930|NCT00336752|Active Comparator|1|Non operative treatment of Weber B ankle fracture. Use of cast, with no surgical intervention
11632931|NCT00336752|Active Comparator|2|Operative treatment of Weber B ankle fracture. Open reduction and internal fixation to repair a broken bones.
11632932|NCT00336713|Experimental|Saredutant 100 mg|Saredutant 100 mg once daily in the morning for a maximum of 64 weeks
11632933|NCT00336713|Placebo Comparator|Placebo|Placebo for Saredutant once daily in the morning during the maintenance phase for a maximum of 52 weeks
11632934|NCT00336700|Experimental|Gemcitabine and Erlotinib|Erlotinib (oral) 150 mg/day x 12 months Gemcitabine 1500 mg/m2 IV over 150 minutes q 2 weeks x 4 months
11632935|NCT00336674|Active Comparator|DV001|Recombinant human intranasal insulin formulation in a buffered solution of benzalkonium chloride and glycerol presented in multi-dose nasal spray devices with actuators (Pfeiffer) designed to deliver 100ul spray doses to nasal mucosa. The product is formulated at a dose strength of 1100 IU / mL (40mg/mL) manufacturing formulation. The product will be self administered by eligible participants as two 100 microlitre spray doses per nostril. Treatment will be administered daily for 7 consecutive days then on one day each week for 12 months. Participants will be followed until they develop diabetes or until 5 years after the last participant has been randomised (maximum period of follow up is expected to be 10 years.
11632936|NCT00336674|Placebo Comparator|Placebo|Placebo insulin carrier solution of benzalkonium chloride and glycerol presented in multi-dose nasal spray devices with actuators (Pfeiffer) designed to deliver 100ul spray doses to nasal mucosa. The product will be self administered by participants as two 100 microlitre spray doses per nostril. Treatment will be administered daily for 7 consecutive days then on one day each week for 12 months. Participants will be followed until they develop diabetes or until 5 years after the last participant has been randomised (maximum period of follow up is expected to be 10 years.
11632937|NCT00336648|Experimental|Gemcitabine + Avastin + Surgery|Gemcitabine plus Avastin-based chemoradiation followed by pancreaticoduodenectomy
11632938|NCT00336622|Experimental|Experimental|Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises
11632939|NCT00336622|Active Comparator|Control|Off-the-shelf splint
11632940|NCT00336583|Experimental|Oxaliplatin, response|relapsed or refractory non-Hodgkin's lymphoma
11632941|NCT00336557||Regularly Scheduled NAb Testing Arm|Subjects will be scheduled for 5 study visits over the course of 12 months and any NAbs test results will be available to the investigator during the study.
11632942|NCT00336557||Usual Care Arm|Subjects will be scheduled for 2 study visits over the course of 12 months and any NAbs test results will be unknown by the investigator until the conclusion of the subject's study participation.
11632943|NCT00336544|Experimental|Cethromycin|
11632944|NCT00336544|Active Comparator|Clarithromycin|
11632945|NCT00336505|Active Comparator|Clarithromycin|
11632946|NCT00336505|Experimental|Cethromycin|
11632947|NCT00336492|Experimental|002|infliximab infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
11632948|NCT00336492|Experimental|001|infliximab infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
11632949|NCT00336479|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
11632950|NCT00336479|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
11632951|NCT00336479|Experimental|Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks.
11632952|NCT00336479|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 12 weeks.
11634352|NCT00318487|Experimental|Bilateral sinus augmentation|
11632953|NCT00336453|Experimental|FluBlok-22.5 μg, 6-35 months old|6-35 months old, FluBlok-22.5 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
11632954|NCT00336453|Experimental|FluBlok-45 μg, 6-35 months old|6-35 months old, FluBlok-45 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
11632955|NCT00336453|Active Comparator|TIV-7.5 μg, 6-35 months old|6-35 months old, 2006-2007 formulation of Fluzone, (sanofi-pasteur, Swiftwater, PA)-7.5 μg of each hemagglutinin antigen: A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Malaysia/2506/2004 like viruses
11632956|NCT00336453|Active Comparator|TIV-15 μg, 36-59 months old|36-59 months old, 2006-2007 formulation of Fluzone (sanofi-pasteur, Swiftwater, PA)-15 μg of each hemagglutinin antigen: A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Malaysia/2506/2004 like viruses
11632957|NCT00336453|Experimental|FluBlok-45 μg, 36-59 months old|36-59 months old, FluBlok-45 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
11632958|NCT00336375|Experimental|1|All treatment doses accompanied with intake of fatty food
11632959|NCT00336375|Active Comparator|2|All treatment doses not-accompanied with intake of fatty food.
11632960|NCT00336362|Active Comparator|1|Participants will receive hydroxyurea pretreatment.
11632961|NCT00336362|No Intervention|2|Participants will not receive hydroxyurea pretreatment.
11632962|NCT00336336|Experimental|1|N-3PUFA
11632963|NCT00336336|Placebo Comparator|2|
11632964|NCT00336336|Experimental|3|Rosuvastatin
11632965|NCT00336336|Placebo Comparator|4|
11632966|NCT00336323|Active Comparator|1|Laser photocoagulation at baseline
11632967|NCT00336323|Experimental|2|1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks
11632968|NCT00336323|Experimental|3|2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks
11632969|NCT00336323|Experimental|4|1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
11632970|NCT00336323|Experimental|5|1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
11632971|NCT00336284|Active Comparator|Home Monitoring|Home Monitoring programmed on.
11632972|NCT00336284|Other|In-Office Conventional Follow-up|Home Monitoring programmed off.
11632973|NCT00336245|Experimental|Copper T Intrauterine Contraceptive Device|
11632974|NCT00336245|Active Comparator|Hormonal Contraception|
11632975|NCT00336232|Experimental|Diet Intervention|28 day diet low vitamin K, 28 day diet high vitamin K
11632976|NCT00336219|Active Comparator|1|Pantoprazole 40 mg
11632977|NCT00336193|Experimental|Home visitation|In the intervention condition, nurse home visitors receive enhanced training to improve delivery of parenting interventions to mothers
11632978|NCT00336180|Experimental|HW|The experimental group (HW) receives 18 classroom-based lessons on leisure motivation, life skills, and skills to avoid substance use and sexual risk.
11632979|NCT00336141|Experimental|Vorinostat|
11632980|NCT00336102||Group 1 Breast Cancer Patient Cases|"Patients between the ages of 25 and 75, diagnosed with primary, operable, stage I-III B breast cancer with planned chemotherapy regimen Adriamycin / Cytoxan (AC) plus a taxane are trial candidates.
~Will have physiologic testing at baseline to assess thyroid function and fatigue assessment and management inventory. Will follow-up on management of therapy complications for thyroid disorder if one identified or until off study."
11632981|NCT00336102||Group 2 Healthy Controls|"Controls will be women from the same general demographic area as Group 1 Cases, have no prior history of cancer and be within 5 years of the Group 1 case's age (+/- 5 years).
~Will have physiologic testing at baseline to assess thyroid function and fatigue assessment and management inventory. Will follow-up on management of therapy complications for thyroid disorder if one identified or until off study."
11632982|NCT00336076||Participants evaluated for mastocytosis|Observational study of all patients referred for suspected mast cell disease. Collection of blood or bone marrow for analysis during diagnostic procedures.
11632983|NCT00336063|Experimental|Treatment (azacitidine, vorinostat)|Patients receive azacitidine SC on days 1-10 and vorinostat PO BID on days 1-14. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11632984|NCT00336024|Active Comparator|Arm I (induction+consolidation chemotherapy, autologous PBSC))|"Patients receive vincristine sulfate IV on days 1, 8, and 15; etoposide IV over 1 hour on days 1-3; cyclophosphamide IV over 1 hour on days 1 and 2; cisplatin IV over 6 hours on day 3. Treatment repeats every 3 weeks for 3 courses.
~Within 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and filgrastim (G-CSF) IV or SC beginning on day 5 and continuing until blood counts recover. Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity."
11632985|NCT00336024|Experimental|Arm II (induction+consolidation chemotherapy, autologous PBSC)|"Patients receive vincristine sulfate IV on days 1, 8, and 15; high-dose methotrexate IV over 4 hours on day 1; and leucovorin calcium IV or orally every 6 hours beginning on day 2 and continuing until methotrexate levels are in a safe range. Patients then receive etoposide IV over 1 hour on approximately days 4, 5, and 6, cyclophosphamide IV over 1 hour on approximately days 4 and 5, and cisplatin IV over 6 hours on approximately day 6. Treatment repeats every 3 weeks for 3 courses.
~Within 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and filgrastim (G-CSF) IV or SC beginning on day 5 and continuing until blood counts recover. Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity."
11633091|NCT00334646|Experimental|Arm B|cyclophosphamide + dexamethasone + ondansetron + GW679769
11633092|NCT00334633|Active Comparator|control|metronidazole 500 BID for 7 days
11633093|NCT00334633|Active Comparator|tinidazole 500|tinidazole 500 BID for 7 days
11633094|NCT00334633|Active Comparator|tinidazole 1 gm|tinidazole 1 gm BID for 7 days
11633095|NCT00334594|Active Comparator|No radiotherapy|
11633096|NCT00334594|Experimental|Radiotherapy|
11632986|NCT00335998|Experimental|Treatment (triapine)|"Group 1: Patients undergo external-beam pelvic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33. Patients also receive 3-AP IV over 2 hours on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33 and cisplatin IV over 1½ hours on day 2, 9, 16, 23, and 30.
~Group 2: Patients undergo external-beam pelvic radiotherapy and receive 3-AP as in group 1.
~In both groups, patients undergo intracavitary or interstitial brachytherapy at least once weekly for 3-5 weeks during or after external-beam radiotherapy as per standard of care."
11632987|NCT00335985|Experimental|1|
11632988|NCT00335985|Placebo Comparator|2|
11632989|NCT00335972|Active Comparator|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
11632990|NCT00335972|Active Comparator|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
11632991|NCT00335959|Experimental|Chemotherapy, Chemoradiation, Surgery|"Chemotherapy: Oxaliplatin, 130 mg/m2, 2 hour IV infusion on Days 1 and 22; Capecitabine 850 mg/m2/dose, PO q 12 hours on Days 1-14 and 22-35 Chemoradiation: Capecitabine 650 mg/m2/dose, PO q 12 hours on days 43-77; Radiation therapy 180 cGy/day, 5 days/week beginning on Day 43.
~Surgery: Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy"
11632992|NCT00335829|Experimental|single arm, received bevacizumab and TACE|
11632993|NCT00335816|Experimental|Group 1 (Closed to Enrollment)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil intravenously continuously over 24 hours 7 days a week for 6 weeks. Patients undergo standard surgical resection after completion of chemoradiation therapy..
11632994|NCT00335816|Experimental|Group 2 (Closed to Enrollment)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1-2. Treatment repeats every 14 days for 2 courses. After the last week of post-radiation chemotherapy, patients undergo standard surgical resection.
11632995|NCT00335816|Experimental|Group 3 (chemotherapy, FOLFOX, conventional surgery)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy as in group II. Treatment repeats every 14 days for 4 courses. After the last week of post-radiation chemotherapy, patients undergo standard surgical resection.
11632996|NCT00335816|Experimental|Group 4 (chemotherapy, FOLFOX, conventional surgery)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy as in group II. Treatment repeats every 14 days for 6 courses. After the last week of post- radiation chemotherapy, patients undergo standard surgical resection. Patients then receive 3 additional courses of FOLFOX-6 chemotherapy or other chemotherapy off study as directed by the physician.
11632997|NCT00335777|Experimental|Migranal treatment first treatment phase|All subjects were asked to treat one headache at 1 hour (early) and one headache at 4 hours after onset of throbbing (late). Dose of nasal spray constant for both time points. The subject could determine the order in which they could treat the headaches (early (first treatment phase) then late (second treatment phase), or late (first treatment phase) then early (second treatment phase).
11632998|NCT00335777|Experimental|Migranal second treatment phase|All subjects were asked to treat one headache at 1 hour (early) and one headache at 4 hours after onset of throbbing (late). Dose of nasal spray constant for both time points. The subject could determine the order in which they could treat the headaches (early (first treatment phase) then late (second treatment phase), or late (first treatment phase) then early (second treatment phase).
11632999|NCT00335764|Experimental|Group 1|Patients receive oral sorafenib tosylate twice daily and oral erlotinib hydrochloride once daily on days 1-28.
11633000|NCT00335764|Experimental|Group 2|Patients receive sorafenib tosylate as in group 1. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
11633001|NCT00335764|Experimental|Group 3|Patients receive sorafenib tosylate as in group 1. Patients also receive oral tipifarnib twice daily on days 1-21.
11633002|NCT00335751|Experimental|positron emission tomography computed tomography (PET/CT)|The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
11633003|NCT00335738|Experimental|Group 1 (identified by central review as high risk)|Includes patients who may or may not require chemotherapy. Patients who require chemotherapy receive vincristine IV and carboplatin IV over 1 hour on day 1 and etoposide IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity and patients who complete chemotherapy are followed after completion of therapy periodically for at least 5 years. Patients who do not require chemotherapy undergo observation periodically for at least 5 years.
11633004|NCT00335738|No Intervention|Group 2 (identified by central review as not high risk)|Patients undergo observation periodically for at least 5 years.
11633005|NCT00335725|Experimental|Fostimon|Fostimon is an highly purified FSH preparation.
11633006|NCT00335725|Active Comparator|Gonal-F|Gonal-F is a recombinant FSH preparation.
11633007|NCT00335686|No Intervention|1|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
11633008|NCT00335686|No Intervention|2|Nevirapine (Viramune): 1 comp (200mg)/12h
11633009|NCT00335595|Active Comparator|1|XELOXA
11633010|NCT00335595|Experimental|2|XELOXA-A
11633011|NCT00335556|Experimental|Surgery|Patients with completely resectable stage I-IV RCC undergo surgical resection. Patients with incompletely resectable stage III-IV RCC undergo treatment as per physician's choice.
11633097|NCT00334581|Experimental|1|Irbesartan 150mg
11633012|NCT00335556|Experimental|Treatment (UH-1)|Patients receive combination chemotherapy comprising vincristine, doxorubicin hydrochloride, cyclophosphamide, etoposide, and carboplatin. Patients whose primary tumors were initially resected undergo radiotherapy once daily 5 days a week for 4-5½ weeks beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13. Patients with unresectable clear cell sarcoma of the kidney (CCSK) receive no further study therapy.
11633013|NCT00335556|Experimental|Treatment (window/UH-1)|Patients receive vincristine IV on days 1 and 8 and irinotecan hydrochloride IV over 30 minutes on days 1-5 and 8-12 (course 1). Patients with progressive disease (PD) are treated with regimen UH-1. Patients with stable disease (SD), partial response (PR), or complete response (CR) receive another course of irinotecan hydrochloride/vincristine window therapy beginning on day 22. After the second course, patients with SD or PD are treated with regimen UH-1 and patients with PR or CR are treated with regimen UH-2.
11633014|NCT00335556|Experimental|Treatment (UH-2)|Patients receive combination chemotherapy comprising vincristine, doxorubicin hydrochloride, cyclophosphamide, etoposide, carboplatin, and irinotecan hydrochloride. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 7. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 7.
11633015|NCT00335556|Experimental|Treatment (regimen I)|Patients receive vincristine, doxorubicin hydrochloride, cyclophosphamide, and etoposide. Patients whose primary tumors were initially resected (except those with stage I CCSK) undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13.
11633016|NCT00335556|Experimental|Treatment (regimen DD-4A)|Patients receive dactinomycin, vincristine, and doxorubicin hydrochloride. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13.
11633017|NCT00335517|Experimental|10mg Depodur|
11633018|NCT00335517|Experimental|15mg DepoDur|
11633019|NCT00335504|Experimental|Arm I (atorvastatin calcium)|Patients receive oral atorvastatin once daily.
11633020|NCT00335504|Experimental|Arm II (sulindac)|Patients receive oral sulindac twice daily.
11633021|NCT00335504|Experimental|Arm III (oligofructose-enriched inulin)|Patients receive oral oligofructose-enriched inulin (Raftilose Synergy 1) twice daily.
11633022|NCT00335504|Placebo Comparator|Arm IV (placebo)|Patients receive an oral placebo twice daily.
11633023|NCT00335478|Experimental|Daptomycin|
11633024|NCT00335452|Experimental|Clopidogrel high dose treatment regimen + ASA high dose|
11633025|NCT00335452|Experimental|Clopidogrel high dose treatment regimen + ASA low dose|
11633026|NCT00335452|Active Comparator|Clopidogrel standard treatment regimen + ASA high dose|
11633027|NCT00335452|Active Comparator|Clopidogrel standard treatment regimen + ASA low dose|
11633028|NCT00335374|Experimental|1|
11633029|NCT00335348|Experimental|Bortezomib and Dexamethasone|
11633030|NCT00335335|Experimental|Visipaque Injection|All participants will receive intravenous (IV) administration of 80 mL Visipaque (iodixanol) 320 mg-I/mL at a rate of 4-5 mL per second via power injector followed by a saline injection of 40-50 mL 0.9% sodium chloride solution at a rate of 4-5 mL per second.
11633031|NCT00335322|Active Comparator|1|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin efavirenz)
11633032|NCT00335322|Active Comparator|2|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)
11633033|NCT00335322|Experimental|3|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
11633034|NCT00335309|Experimental|1|The Investigational arm is treated with sinus irrigation with normal saline 0.9% and intravenous antibiotics of Augmentin 1 gram 3 times a day for 4 days, and then per os (PO) Augmentin 875mg twice a day (BID) for another 10 days. The treatment is done while the patient is admitted to the otolaryngology - head and neck surgery department.
11633035|NCT00335309|Active Comparator|2|The control arm is treated with the same intravenous antibiotics of Augmentin 1 gram 3 times a day for 4 days, and then per os (PO) Augmentin 875mg twice a day (BID) for another 10 days. There is no sinus irrigation with normal saline for this arm. The treatment is done while the patient is admitted to the otolaryngology - head and neck surgery department.
11633036|NCT00335283|Active Comparator|Lansoprazole|
11633037|NCT00335283|Placebo Comparator|Sugar Pill|
11633038|NCT00335257||1|Users of OCs containing DRSP
11633039|NCT00335257||2|Users of OCs containing other progestins
11633040|NCT00335244|Experimental|1|Intravenous L-citrulline
11633041|NCT00335244|Placebo Comparator|2|Placebo of intravenous L-citrulline
11633042|NCT00335231|Experimental|gatifloxacin|one group will receive topical application of gatifloxacin prior to surgery,
11633043|NCT00335231|No Intervention|no eye drops|this group will receive no eye drops.
11633044|NCT00335218|Experimental|Arm 1|
11633045|NCT00335218|Placebo Comparator|Arm 2|
11633046|NCT00335192|Experimental|1|"Phase I: 3TC + TDF + NVP or LPV/rtv
~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + LPV/rtv"
11633047|NCT00335192|Experimental|2|"Phase I: ABV + TDF + NVP or LPV/rtv
~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: ABV + LPV/rtv"
11633048|NCT00335192|Experimental|3|"Phase I: 3TC + ABV + TDF + NVP or LPV/rtv
~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + ABV + LPV/rtv"
11633049|NCT00335179|Active Comparator|Imiquimod cream|Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream Applied 3 times per week for 4 weeks
11633050|NCT00335179|Placebo Comparator|Vehicle cream|Vehicle cream 250 mg Applied 3 times per week for 4 weeks
11633051|NCT00335166|Experimental|1|
11633052|NCT00335166|Active Comparator|2|
11633053|NCT00335166|Placebo Comparator|3|
11633098|NCT00334581|Experimental|2|Irbesartan 300mg
11633054|NCT00335153|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants were to receive LCIG, via the NJ tube during the nasojejunal (NJ) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.
~The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the Post-PEG-J Long-Term Treatment Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour), in most instances."
11633055|NCT00335140|Experimental|Rituximab + standard chemotherapy|Rituximab + high dose methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine. Patients with meningeal involvement will receive additional methotrexate and leucovorin.
11633056|NCT00335075|Experimental|Temodal group|Subjects treated with temozolomide.
11633057|NCT00335075|Active Comparator|Semustine group|Subjects treated with semustine.
11633058|NCT00335049|Experimental|PAL|Progressive Addition Spectacle Lenses (PALs) with a +2.00 D add worn for first year off study. Single Vision Lenses worn for second year of study.
11633059|NCT00335049|Active Comparator|SVL|Single Vision Lenses (SVLs) worn both years of the study.
11633060|NCT00335036|Active Comparator|Thin leads|Thin (less than or equal to 7 French introducer) isodiametric ICD leads
11633061|NCT00335036|Active Comparator|Gore PTFE-coated|ICD lead with PTFE-coated coils
11633062|NCT00335023|Active Comparator|Red blood cell transfusion|At least one unit of red blood cells will be administered.
11633063|NCT00335023|No Intervention|Control|No red blood cell transfusion. Iron suppletion is allowed and can be administered according to local protocol. If suppletion is prescribed, the type and duration will be registered
11633064|NCT00334971|Other|1|Healthy Caucasian women 18-35 years old
11633065|NCT00334971|Other|2|Healthy African-American women 18-35 years old
11633066|NCT00334971|Other|3|Healthy Caucasian women 36-45 years old
11633067|NCT00334971|Other|4|Female fragile X premutation carriers 18-45 years old
11633068|NCT00334958|Placebo Comparator|Placebo|
11633069|NCT00334958|Active Comparator|Rufinamide|
11633070|NCT00334945||Growth Hormone|Patient ages 3-14 years receiving growth hormone for growth hormone deficiency or short stature
11633071|NCT00334945||Healthy Children|Children with normal stature ages 3-18 years.
11633072|NCT00334893|Experimental|Treatment (chemotherapy)|Patients receive eribulin mesylate IV over 15 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11633073|NCT00334867|Active Comparator|Arm I|Patients receive vincristine sulfate IV over 1 minute once a week on day 1 in weeks 1-3, 7-9, and 13-15; doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in weeks 1, 7, and 13; cyclophosphamide IV over 1 hour on day 1 in weeks 1, 7, and 13; and ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 in weeks 4, 10, and 16. Patients undergo local therapy comprising conventional surgery (surgical resection) in approximately week 18 and/or radiation therapy beginning in approximately week 19.
11633074|NCT00334867|Experimental|Arm II|Patients receive vincristine sulfate IV over 1 minute once a week on day 1 in weeks 1-3, 7-9, and 13-16; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 13; cyclophosphamide IV over 30 minutes on days 1-5 in weeks 1 and 13 and IV over 1 hour on day 1 in weeks 7 and 16; ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 in weeks 4 and 10; and doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in weeks 7 and 16. Patients also undergo local therapy comprising of conventional surgery (surgical resection) in approximately week 18 and/or radiation therapy beginning in approximately week 19. Patients then proceed to combination chemotherapy.
11633075|NCT00334828|Experimental|1|
11633076|NCT00334828|Placebo Comparator|2|
11633077|NCT00334815|Experimental|Group 1 (cisplatin, etoposide, radiotherapy)|Patients receive cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Patients undergo concurrent thoracic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47.
11633078|NCT00334815|Experimental|Group 2 (cisplatin, etoposide, radiotherapy, bevacizumab)|Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 15, 36, and 57.
11633079|NCT00334815|Experimental|Group 3 (cisplatin, etoposide, radiotherapy, bevacizumab)|Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 22, and 43.
11633080|NCT00334802|Experimental|A|
11633081|NCT00334789|Experimental|Treatment (belinostat, isotretinoin)|"Patients receive belinostat IV over 30 minutes on days 1-5 and isotretinoin PO QD on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of belinostat until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of therapy.
~Once the MTD is determined, an expanded cohort of 10 patients are enrolled and treated at the MTD. These patients also undergo blood collection periodically during treatment for pharmacokinetic studies.
~All patients undergo blood collection, buccal scrapings, and tumor biopsies periodically for biomarker, pharmacodynamic, gene expression, and laboratory studies."
11633082|NCT00334750||There is no intervention in this study|This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
11633083|NCT00334737|Experimental|Darbepoetin alfa injection|Darbepoetin alfa 10 mics/kg/week subcutaneous injection x 10 weeks or until 35 completed weeks Drug: Darbepoetin alfa Other names: Aranesp Darbe SC injection
11633084|NCT00334737|Active Comparator|erythropoietin alfa injection|Epo 400 units/kg three times a week SC x 10 weeks or until 35 completed weeks Drug: erythropoietin other names: epogen Epo SC injection
11633085|NCT00334737|Placebo Comparator|placebo/control|Sham injection
11633086|NCT00334724|Active Comparator|1|Home blood pressure group
11633087|NCT00334724|Active Comparator|2|Office blood pressure group
11633088|NCT00334685|Experimental|[S,S]-Reboxetine + Pregabalin|
11633089|NCT00334685|Active Comparator|Pregabalin|
11633090|NCT00334646|Experimental|Arm A|cyclophosphamide + dexamethasone + ondansetron
11633099|NCT00334568|Experimental|Rosi XR|Rosi XR
11633101|NCT00334555|Active Comparator|usual care|patient told to refer her partner for treatment
11633102|NCT00334555|Active Comparator|partner delivered|patient given medication to deliver to her partners
11633103|NCT00334555|Active Comparator|field intervention|field intervention to find partners
11633104|NCT00334542|Experimental|Simvastatin|Simvastatin 40 mg for 24-28 weeks
11633105|NCT00334490|Active Comparator|1|Oral Sildenafil 12.5 mg
11633106|NCT00334490|Placebo Comparator|2|Placebo in 5 mls distilled water
11633107|NCT00334438|Other|Zevalin + Velcade Single Arm Study|Zevalin (Ibritumomab Tiuxetan) and Velcade (Bortezomib)
11633108|NCT00334373|Experimental|Post conditioning|Balloon inflations-deflations
11633109|NCT00334373|Placebo Comparator|Standard care|No balloon inflations
11633110|NCT00334360|Experimental|1|dexmedetomidine
11633111|NCT00334360|Experimental|2|Buspirone
11633112|NCT00334360|Experimental|3|Buspirone and dexmedetomidine
11633113|NCT00334360|Placebo Comparator|Control|No drug
11633114|NCT00334347|Active Comparator|Depakote ER|
11633115|NCT00334347|Active Comparator|Depakote DR|
11633116|NCT00334321|Experimental|IMRT with chemotherapy|"IMRT (upper third of vagina & para-vaginal tissue and the common, external and internal iliac nodal regions) 160-180 cGy daily fractions for a total dose of 4500-5120 cGy. Once a day treatment four to five days a week for approximately 6 weeks.
~Intracavitary vaginal brachytherapy - some patients will be given this and it will be decided by the treating physician.
~Carboplatin - AUC 6, IV over 30-60 minutes following completion of paclitaxel, given once every 3 weeks (3 weeks=1 cycles) for a total of 6 cycles
~Paclitaxel - 175 mg/m2, 3 hour continuous IV infusion, administered prior to carboplatin, given once every 3 weeks (3 weeks=1 cycles) for a total of 6 cycles"
11633117|NCT00334282|Placebo Comparator|placebo arm|matching placebo (800 mg tablet) once daily
11633118|NCT00334282|Experimental|pazopanib arm|Oral pazopanib tablet 800 mg once daily continuously
11633119|NCT00334217|Experimental|1|PSS CogRehab exercises
11633120|NCT00334217|No Intervention|2|On-line computer games
11633121|NCT00334204|Other|Measure Platelet Function Analyser -100 (PFA-100)|measuring Platelet Function Analyser (PFA)-100 test (an in vitro platelet function test, in addition to the rest of the routine/uusal clinical care)
11633122|NCT00334139|Experimental|zoledronic acid|
11633123|NCT00334113|Experimental|Arm 1|Participants in this arm will meet with an exercise physiologist and obtain an exercise prescription for a walking program. In addition, they will recieve an intervention that will be delivered over an automated telephone system (TLC-PED). These automated phone calls with voice response and voice recognition capabilities will occur weekly over a 6 month period. During these calls, participants' physical activity will be monitored, new physical activities goals will be set, information about physical activity and the associated health benefits will be provided, and barriers to physical activity will be explored.
11633124|NCT00334113|No Intervention|Arm 2|"This is the treatment as usual condition. Participants in this condition will also have 2 sessions with an exercise physiologist and will receive an exercise prescription for a home based walking program. The will not receive the automated phone calls each week that are designed to motivate physical activity."
11633125|NCT00334100|Other|Arm 1|
11633126|NCT00334074|Experimental|Clofarabine and Cytarabine|Five consecutive days of clofarabine 40 mg/m^2 IVI over 1 hour followed 4 hours later by cytarabine 1000 mg/m^2 IVI over 2 hours
11633127|NCT00334022|Placebo Comparator|Did not receive enfuvirtide|patients were randomized to either receive enfuviratide or not receive it
11633128|NCT00334022|Active Comparator|enfuvirtide|enfuvirtide 1ml BID
11633129|NCT00333983|Experimental|Arm 1|Robot Exercise Group
11633130|NCT00333983|Active Comparator|Arm 2|Traditional Upper Extremity Exercise Group
11633131|NCT00333970|Experimental|cognitive remediation|cognitive remediation
11633132|NCT00333970|No Intervention|treatment as usual|treatment as usual
11633133|NCT00333918|Experimental|1-bromfenac ophthalmic solution|sterile ophthalmic solution
11633134|NCT00333918|Placebo Comparator|2-placebo comparator|sterile ophthalmic solution
11633135|NCT00333879|Other|Virtual Sound System|Efficacy of using a virtual sound system to simulate street crossing conditions.
11633136|NCT00333866|Experimental|1|
11633137|NCT00333866|Experimental|2|
11633138|NCT00333866|Experimental|3|
11633139|NCT00333866|Placebo Comparator|4|
11633140|NCT00333840|Experimental|imatinib (STI571)|In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injection for 10 days every month. Maximum study duration was 11.5 years.
11633141|NCT00333840|Active Comparator|IFN-a+Ara-C|In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.
11633142|NCT00333827|Active Comparator|Optimal Therapy|Optimal therapy for cardiac failure
11633143|NCT00333827|Experimental|cell therapy|stem cell
11633144|NCT00333814|Active Comparator|1|Dexamethasone 350 µg
11633145|NCT00333814|Active Comparator|2|Dexamethasone 700 µg
11633146|NCT00333814|Sham Comparator|3|Sham
11633147|NCT00333801|Active Comparator|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP). VRP is the treatment as usual, which mostly consisted of transitional work program (TWP) in which client is placed in a set-aside noncompetitive job for time-limited period and then pursues competitive employment at time of discharge from VRP. Limited integration with treatment team and limited follow-along supports that are time-limited.
11633148|NCT00333801|Experimental|Individual Placement and Support (IPS)|Inidividual Placement and Support (IPS). IPS Supported Employment involves an IPS specialists working with client to identify job preferences, rapidly begin community-based job search, engage in competitive employment, sustain employment via open-ended IPS follow-along supports, and integrate IPS within the PTSD treatment team.
11633149|NCT00333788|Experimental|Certolizumab pegol 400 mg|400 mg subcutaneous injection of certolizumab pegol every 2 (Q2W) or 4 (Q4W) weeks
11633150|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus placebo|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
11633151|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
11633152|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
11633153|NCT00333762|Experimental|SPAM and SWCS|Smart Power Assistance Module (SPAM) Smart Wheelchair Component System (SWCS)
11633154|NCT00333749|Experimental|1|55 children < 5 years with acute oral ulcer disease.
11633155|NCT00333749|Placebo Comparator|2|55 Children < 5 years with acute oral ulcer disease.
11633156|NCT00333710|Experimental|Individual face-to-face contact|Individual face-to-face contact treatment
11633157|NCT00333710|Experimental|Individual telephone contact|Individual telephone contact treatment
11633158|NCT00333710|No Intervention|Control condition/treatment as usual|Control condition/treatment as usual
11633159|NCT00333684|Active Comparator|receive bioalcamid at baseline|half subjects received bioalcamid at baseline
11633160|NCT00333684|Active Comparator|Receive bioalcamid at 24 weeks|other half of subjets received bioalcamid at 24 weeks
11633161|NCT00333658|Experimental|1|Intervention
11633162|NCT00333658|No Intervention|2|Work Services
11633163|NCT00333619|Experimental|Nonpharmacological sleep intervention|The intervention will combine: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies.
11633164|NCT00333619|Active Comparator|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
11633165|NCT00333606|Experimental|Verum acupuncture|Acupuncture of specific acupuncture points
11633166|NCT00333606|Sham Comparator|Sham acupuncture|Acupuncture of non-specific acupuncture points
11633167|NCT00333580||Group 1|
11633168|NCT00333554|Experimental|DHA Treatment Group|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
11633169|NCT00333554|Placebo Comparator|Control Group|Placebo for DHA given to nursing mother (breast milk), study formula, or capsules (removing content and mixing with food)depending on age of child.
11633170|NCT00333541|Experimental|Treatment|follow-up via e-mail link to survey
11633171|NCT00333541|No Intervention|Control|standard follow-up by phone and in-person interview
11633172|NCT00333528|Experimental|1|Administration of one dose of the active drug (6 volunteers)
11633173|NCT00333528|Placebo Comparator|2|Administration of placebo (2 volunteers)
11633174|NCT00333515|Experimental|1|Administration of one of 3 doses (dose escalation) of the active drug (HuBChE). (Dose-escalation proceeds only after safety evaluation and after the previous dosage has been found to be acceptable by an independent Data Safety Monitoring Board.)
11633175|NCT00333515|Placebo Comparator|2|Administration of placebo
11633176|NCT00333502|Experimental|CRLX101 (formerly known as IT-101)|CRLX101 dosing per protocol dose escalation cohorts to MTD, then expansion cohort treated at MTD of CRLX101 15mg/m2
11633177|NCT00333463||Intervention group|The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
11633178|NCT00333463||Non-Intervention Group|The control group was told to take drops as prescribed and received no additional intervention.
11633179|NCT00333437|Experimental|Treatment|Mycophenolate Mofetil
11633180|NCT00333424|Placebo Comparator|Placebo|placebo containing diluent alone
11633181|NCT00333411|Experimental|BIRT 2584 XX high dose|
11633182|NCT00333411|Experimental|BIRT 2584 XX medium dose|
11633183|NCT00333411|Experimental|BIRT 2584 XX low dose|
11633184|NCT00333411|Placebo Comparator|Placebo|
11633185|NCT00333398|Experimental|1|250 subjects-Lot #1 multiple-dose vial (thimerosal-containing).
11633186|NCT00333398|Experimental|2|250 subjects-Lot #2 multiple-dose vial (thimerosal-containing).
11633187|NCT00333398|Experimental|3|250 subjects-Lot #3 multiple-dose vial (thimerosal-containing).
11633188|NCT00333398|Placebo Comparator|4|250 subjects-multiple-dose vial placebo (thimerosal-containing).
11633189|NCT00333398|Experimental|5|250 subjects-Prefilled Lot #1, #2, or #3 (TBD) (thimerosal-free).
11633190|NCT00333359|Experimental|XP13512 (GEn)|1200 mg XP13512, orally, once daily for 52 weeks
11633191|NCT00333333||SGA infants|Infants who are thought to be small for gestational age (SGA)
11633192|NCT00333333||Pre-eclampsia exposed|Infants who are born to mothers who had pre-eclampsia
11633193|NCT00333320|Placebo Comparator|- Control|
11633194|NCT00333320|Experimental|-postconditioning group|
11633195|NCT00333268|Experimental|NGOIS|
11633196|NCT00333268|Active Comparator|BSS Plus|
11633242|NCT00332670|Active Comparator|1|10.000lux bright blue light 1hour every morning 1 hour after wake-up time during three weeks
11633197|NCT00333229|Experimental|Zoledronic Acid|Patients randomized into the Zometa arm received a total of 8 study drug infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.
11633198|NCT00333229|Placebo Comparator|Placebo|Patients randomized into the Placebo Arm received a total of 8 placebo infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.
11633199|NCT00333216|Experimental|15 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 30 mg/mL, one injection of 0.5 mL in the study eye every 6 months for 48 months
11633200|NCT00333216|Experimental|30 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 60 mg/mL, one injection of 0.5 mL in the study eye every 6 months for 48 months
11633201|NCT00333216|Sham Comparator|Anecortave Acetate Vehicle|Anecortave Acetate Vehicle, one sham injection in the study eye every 6 months for 48 months
11633202|NCT00333203|Experimental|NGOIS|
11633203|NCT00333203|Active Comparator|BSS Plus|
11633204|NCT00333177|Experimental|Cog Remediation, risperidone injection|Participants will receive cognitive remediation training plus risperidone, administered via injection.
11633205|NCT00333177|Active Comparator|Healthy Behavior Training, risperidone injection|Participants will receive health behavior training plus risperidone, administered via injection.
11633206|NCT00333177|Experimental|Cog Remediation, oral risperidone|Participants will receive cognitive remediation training plus risperidone administered orally.
11633207|NCT00333177|Active Comparator|Healthy Behavior Training, oral risperidone|Participants will receive health behavior training plus risperidone administered orally.
11633208|NCT00333138|Experimental|Fingolimod (FTY720) 1.25 mg/day|Core study: patients received fingolimod 1.25 mg, once daily for 6 months. Extension: In dose -blind period and open label, fingolimod 1.25 mg once daily for 9-18 months (6 months to 24 months). Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
11633209|NCT00333138|Placebo Comparator|Placebo/Fingolimod (FTY720)|Core study: patients received placebo, once daily for 6 months. Extension: In dose-blind period patients were re-randomized into either fingolimod 1.25 mg or 5.0 mg once per day for 6-15 months. In open-label period patients received fingolimod 1.25 mg once per day for 15 to 24 months. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
11633210|NCT00333138|Experimental|Fingolimod (FTY720) 5.0 mg/day|Core study: patients received fingolimod 5.0 mg, once daily for 6 months. Extension: In dose-blind period fingolimod 5.0 mg once daily for 6-15 months. For open-label phase 15 to 24 months 1.25mg once daily. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
11633211|NCT00333125|Experimental|Travoprost/Timolol|
11633212|NCT00333125|Active Comparator|Dorzolamide/Timolol|
11633213|NCT00333112|Experimental|1|
11633214|NCT00333112|Placebo Comparator|2|
11633215|NCT00333099|Placebo Comparator|nutrition|study of immuno-modulating enteral nutrition
11633216|NCT00333073|Experimental|Bulkamid|Submucosal injection of Bulkamid into urethra
11633217|NCT00332969|Experimental|Sandostatin|
11633218|NCT00332956|Active Comparator|Group 1|Volunteers will be vaccinated with 80 mcg rF1V vaccine on Study Days 0 , 28, 182
11633219|NCT00332956|Active Comparator|Group 2|Volunteers will be vaccinated with 80 mcg of rF1V vaccine at Study Days 0, 56, 182
11633220|NCT00332956|Active Comparator|Group 3|Volunteers will be vaccinated with 160 mcg rF1V vaccine given on Study Days 0, 28, 182
11633221|NCT00332956|Active Comparator|Group 4|Volunteers will be vaccinated with 160 mcg rf1V vaccine on Study Days 0, 56, 182
11633222|NCT00332917|Experimental|1|
11633223|NCT00332904|Active Comparator|beta|patients with liver cirrhosis, treated with betablocker
11633224|NCT00332904|Active Comparator|spiron|patients with liver cirrhosis, treated with aldosterone antagonist
11633225|NCT00332904|No Intervention|control|patients with liver cirrhosis, no treatment
11633226|NCT00332878|Experimental|1|Stepping Stones
11633227|NCT00332878|Active Comparator|2|A 3 hour intervention on HIV and safer sex
11633228|NCT00332852|Experimental|Letrozole|
11633229|NCT00332839|Active Comparator|Calcineurin Inhibitor (CNI) group|Participants received Cyclosporine A (CsA) plus Enteric Coated Mycophenolate Sodium (EC-MPS) plus corticosteroids, or Tacrolimus A (CsA) plus Enteric Coated Mycophenolate Sodium (EC-MPS) plus corticosteroids.
11633230|NCT00332839|Experimental|Certican group|Participants were switched in a step-wise fashion from the CNI based regimen to Everolimus (RAD001).
11633231|NCT00332774|Experimental|Nevanac|
11633232|NCT00332774|Active Comparator|Acular|
11633233|NCT00332774|Placebo Comparator|Vehicle|
11633234|NCT00332722|Active Comparator|Group 1- without steroid|Cervical Facet Joint Nerve block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin)
11633235|NCT00332722|Active Comparator|Group 2 - with steroid|Cervical Facet Joint nerve block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin) and 0.15 mg of non-particulate betamethasone)
11633236|NCT00332709|Experimental|Letrozole|Letrozole orally 2.5 mg/day for 3 years
11633237|NCT00332709|Experimental|Letrozole + Zoledronic Acid|Letrozole orally 2.5mg/day for 3 years; Zoledronic acid 4mg every 6 months by infusion
11633238|NCT00332696|Experimental|Octreotide|Participants received Octreotide long-acting release (LAR) 30 mg intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received immediate-release Octreotide 600 µg/day (administered subcutaneously 2 or 3 times a day or via continuous intravenous (IV) or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.
11633239|NCT00332696|Placebo Comparator|Placebo|Participants received physiologic saline solution intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received physiologic saline solution (administered subcutaneously 2 or 3 times a day or via continuous intravenous or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.
11633240|NCT00332683|Active Comparator|Control|Patients randomly assigned to this group will have no changes in the ETT during surgery
11633241|NCT00332683|Experimental|Treatment group|Patients in this group will undergo same surgery as control group but with a monitoring and manipulation of ETT pressure
11633243|NCT00332670|Placebo Comparator|2|50lux dim red light 1 hour every morning 1 hr after wake-up time during 3 weeks
11633244|NCT00332657|Experimental|Anecortave Acetate, 15 mg|One 0.5 mL injection of 30 mg/mL Anecortave Acetate Sterile Suspension into the posterior juxtascleral depot (PJD) at 6-month intervals for 42 months.
11633245|NCT00332657|Experimental|Anecortave Acetate, 30 mg|One 0.5 mL injection of 60 mg/mL Anecortave Acetate Sterile Suspension into the posterior juxtascleral depot (PJD) at 6-month intervals for 42 months.
11633246|NCT00332657|Sham Comparator|Anecortave Acetate Vehicle|One sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.
11633247|NCT00332644|Experimental|1|nicotine patch alone treatment
11633248|NCT00332644|Experimental|2|nicotine lozenge alone treatment
11633249|NCT00332644|Experimental|3|nicotine patch + lozenge combination treatment
11633250|NCT00332644|Experimental|4|bupropion alone treatment
11633251|NCT00332644|Experimental|5|bupropion + nicotine lozenge combination treatment
11633252|NCT00332644|Placebo Comparator|6|placebo control (no active medication) treatment
11633253|NCT00332605|Experimental|Naltrexone plus N-Acetyl Cysteine|"Naltrexone tablets
~N-Acetyl Cysteine: 600mg tablets, daily"
11633254|NCT00332605|Placebo Comparator|Placebo|
11633255|NCT00332579|Active Comparator|A|Naltrexone
11633256|NCT00332579|Placebo Comparator|B|Placebo
11633257|NCT00332566|Experimental|Group A|
11633258|NCT00332566|Active Comparator|Group B|
11633259|NCT00332514|Other|Patients offered follow-up phone call|Patients offered follow-up telephone call
11633260|NCT00332488|Experimental|1|Technosphere Insulin
11633261|NCT00332488|Active Comparator|2|Metformin & Secretagogues
11633262|NCT00332488|Experimental|3|Technosphere & Metformin
11633263|NCT00332462|Experimental|Cyclosporine (Sandimmun®)|Period 1: Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days followed by Period 2: Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
11633264|NCT00332397|Active Comparator|A|Rapamycin-eluting Stent (Cypher)
11633265|NCT00332397|Active Comparator|B|Zotarolimus-eluting Stent (Endeavor)
11633266|NCT00332397|Active Comparator|C|Rapamycin-eluting Stent
11633267|NCT00332371|Experimental|1|
11633268|NCT00332371|No Intervention|2|
11633269|NCT00332332|Experimental|etanercept|Open label etanercept 50 mg twice weekly subcutaneously (SC) for 3 months followed by 50 mg twice a week week SC for 9 months, for a total treatment period of 12 months.
11633270|NCT00332306|Experimental|2|Didanosine + Lamivudine + Nevirapine
11633271|NCT00332306|Active Comparator|1|Didanosine + Lamivudine + Efavirenz
11633272|NCT00332293|Experimental|Moxifloxacin|
11633273|NCT00332293|Active Comparator|VIGAMOX|
11633274|NCT00332280|Experimental|AMT2003|
11633275|NCT00332254|Experimental|1|Intra-articular IL-1Ra
11633276|NCT00332254|Placebo Comparator|2|Intra-articular saline
11633277|NCT00332241|Experimental|A1|Active Abilify
11633278|NCT00332241|Placebo Comparator|A2|
11633279|NCT00332228|Active Comparator|CE plus oral +depot naltrexone|Compliance enhancement (CE), simulating standard treatment with oral naltrexone plus two depot naltrexone;
11633280|NCT00332228|Placebo Comparator|CE plus oral naltrexone+ placebo|CE with oral naltrexone plus two placebo injections
11633281|NCT00332228|Experimental|BNT plus Depot naltrexone|BNT plus two doses of depot naltrexone prior to hospital discharge
11633282|NCT00332228|Placebo Comparator|BNT plus PBO injection|BNT plus two placebo injections
11633283|NCT00332202|Experimental|A|
11633284|NCT00332202|Placebo Comparator|B|
11633285|NCT00332176|Experimental|1|
11633286|NCT00332176|Experimental|2|
11633287|NCT00332176|Active Comparator|3|
11633288|NCT00332163|Experimental|Pre-emptive Skin Treatment|Participants received either FOLFIRI and panitumumab 6 mg/kg once every 2 weeks (Q2W) or irinotecan and panitumumab 9 mg/kg once every 3 weeks (Q3W), and pre-emptive skin treatment which included skin moisturizer, sunscreen, 1% hydrocortisone cream, and an oral antibiotic for 6 weeks starting 24 hours prior to chemotherapy.
11633289|NCT00332163|Experimental|Reactive Skin Treatment|Participants received either FOLFIRI and panitumumab 6 mg/kg Q2W or irinotecan and panitumumab 9 mg/kg Q3W. Participants were treated for each individual skin toxicity occurrence according to prespecified guidelines and based on the type and severity. Treatment could include emollient, sunscreen, topical or oral steroids, antibiotics, or antihistamines, as required.
11633290|NCT00332124|Placebo Comparator|1|Participants will take placebo
11633291|NCT00332124|Active Comparator|2|Participants will take choline
11633292|NCT00332098|Experimental|1|Family-Focused Treatment Plus Pharmacotherapy
11633293|NCT00332098|Active Comparator|2|Enhanced Care Plus Pharmacotherapy
11633294|NCT00332020|Experimental|Arm 1|
11633295|NCT00332020|Active Comparator|Arm 2|
11633296|NCT00332007|Experimental|1|Tonabersat 40 mg daily
11633297|NCT00332007|Placebo Comparator|2|
11633298|NCT00331994|Experimental|1|
11633299|NCT00331994|Active Comparator|2|
11633300|NCT00331955|Experimental|Treatment (vorinostat, doxorubicin hydrochloride)|Patients receive oral vorinostat twice daily for 5 doses on days 1-3, 8-10, and 15-17 and doxorubicin hydrochloride IV on days 3, 10, and 17. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 6 courses of treatment may continue to receive vorinostat alone in the absence of disease progression.
11633301|NCT00331929|Experimental|A|Cohort of school children that evaluated with questionnaire and spirometry with MINATO 500 JAPAN spirometer
11633302|NCT00331890|Experimental|Active|Receives active drug
11633303|NCT00331890|Placebo Comparator|Placebo|Receives a placebo
11633339|NCT00331422|Experimental|Patients Who Received Treatment|All patients receiving treatment with Paclitaxel and Carboplatin followed by surgery to remove cancerous tissue.
11633340|NCT00331409|Experimental|Everolimus and Imatinib Mesylate|Everolimus: 2.5 mg daily by mouth Imatinib Mesylate: 600 mg daily by mouth
11633304|NCT00331864|Experimental|Ranibizumab|Ranibizumab-naïve (Non-ANCHOR) patients received up to 12 intravitreal injections (Month 0 through Month 11). The dose of 0.3 mg ranibizumab was administered monthly for three consecutive months. From Month 3 through Month 11, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab were injected as individually needed based on re-treatment criteria described in the protocol. For patients who had participated in the ANCHOR study, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab was injected if the patient met re-treatment criteria described in the protocol. Ranibizumab was administered no sooner than 14 days after the previous treatment.
11633305|NCT00331838|Experimental|Semuloparin 5 mg|Semuloparin sodium 5 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
11633306|NCT00331838|Experimental|Semuloparin 10 mg|Semuloparin sodium 10 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
11633307|NCT00331838|Experimental|Semuloparin 20 mg|Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
11633308|NCT00331838|Experimental|Semuloparin 40 mg|Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
11633309|NCT00331838|Experimental|Semuloparin 60 mg|Semuloparin sodium 60 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
11633310|NCT00331838|Active Comparator|Enoxaparin 40 mg|Enoxaparin sodium 40 mg + Placebo (for Semuloparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
11633311|NCT00331838|Experimental|Placebo pre-op / Semuloparin 20 mg|"Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,
~Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery"
11633312|NCT00331838|Experimental|Placebo pre-op / Semuloparin 40 mg|"Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,
~Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery"
11633313|NCT00331799|Active Comparator|1|Open label treatment with Duloxetine for 8 weeks with dosing from 30-60 mg.
11633314|NCT00331773|Active Comparator|Conventional 3D-CRT|Conventional 3D-CRT or IMRT to 73.8 Gy in 41 fractions
11633315|NCT00331773|Experimental|Hypofractionated 3D-CRT|Hypofractionated 3D-CRT or IMRT to 70 Gy in 28 fractions
11633316|NCT00331760|Other|Endometrial Cancer: IMRT|Endometrial Cancer patients receive Intensity Modulated Radiation Therapy (IMRT) 28 fractions over 5.5 weeks.
11633317|NCT00331760|Other|Cervical Cancer: IMRT + Chemotherapy (cisplatin)|Cervical patients receive Intensity Modulated Radiation Therapy (IMRT) 28 fractions over 5.5 weeks and concurrent weekly cisplatin 40 mg/m^2 for five weeks.
11633318|NCT00331721|Active Comparator|1|Enecadin
11633319|NCT00331721|Placebo Comparator|2|Placebo
11633320|NCT00331708|Experimental|Artesunate plus sulphadoxine-pyrimethamine|
11633321|NCT00331695|Experimental|1|17 alpha-hydroxyprogesterones caproate
11633322|NCT00331682|Experimental|Treatment (docetaxel and alvocidib)|Patients receive docetaxel IV over 30 minutes followed 4-6 hours later by flavopiridol IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11633323|NCT00331669|Placebo Comparator|1|device
11633324|NCT00331643|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.
11633325|NCT00331630|Experimental|Treatment arm|30 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11633326|NCT00331604|Experimental|A|
11633327|NCT00331604|Active Comparator|B|
11633328|NCT00331604|Active Comparator|C|
11633329|NCT00331565|Experimental|Surgery|Bariatric surgery
11633330|NCT00331552|Experimental|Arm I|Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician.
11633331|NCT00331513|Active Comparator|Arm I (vorinostat, idarubicin)|Patients receive oral SAHA three times daily on days 1-14 and idarubicin IV over 15 minutes once daily on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy or who reach the maximum cumulative dose of idarubicin or an equivalent anthracycline and achieve clinical benefit may continue treatment with SAHA alone 3 times daily on days 1-14 of each course, in the absence of disease progression or unacceptable toxicity.
11633332|NCT00331513|Active Comparator|Arm II (vorinostat, idarubicin)|Patients receive oral SAHA three times daily and idarubicin IV over 15 minutes once daily on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy or who reach the maximum cumulative dose of idarubicin or an equivalent anthracycline and achieve clinical benefit may continue treatment with SAHA alone 3 times daily on days 1-14 of each course, in the absence of disease progression or unacceptable toxicity.
11633333|NCT00331500|Experimental|Olopatadine Hydrochloride 0.2%|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop in each eye, once-daily in the morning for 6 weeks
11633334|NCT00331500|Placebo Comparator|Vehicle|Olopatadine hydrochloride ophthalmic solution vehicle, 1 drop in each eye, once-daily in the morning for 6 weeks
11633335|NCT00331487|Experimental|Pioglitazone QD|
11633336|NCT00331487|Active Comparator|Rosiglitazone QD|
11633337|NCT00331435|Active Comparator|1|FA-guided PDT
11633338|NCT00331435|Experimental|2|ICG-guided PDT
11633488|NCT00329563|No Intervention|control, standard of care|
11633341|NCT00331344|Experimental|Treatment (combination chemotherapy)|Patients receive mitoxantrone hydrochloride IV over 30 minutes and ixabepilone IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
11633342|NCT00331331||Participants|Participants who were previously enrolled as part of the MUST study and patients who participate in other intramural NIH studies and agreed to participate in this study.
11633343|NCT00331279|Active Comparator|Cinnamon Extract|A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
11633344|NCT00331279|Placebo Comparator|Placebo|
11633345|NCT00331214|Sham Comparator|Placebo|placebo patch for 6 months
11633346|NCT00331214|Experimental|Testosterone|Testosterone patch
11633347|NCT00331162|Active Comparator|1|Alemtuzumab
11633348|NCT00331162|Active Comparator|2|Anti-Thymocyte Globulin
11633349|NCT00331136|Experimental|1|Pyronaridine artesunate 6:2 mg/kg
11633350|NCT00331136|Experimental|2|Pyronaridine artesunate 9:3 mg/kg
11633351|NCT00331136|Experimental|3|Pyronaridine artesunate 12:4 mg/kg
11633352|NCT00331123|Placebo Comparator|Placebo|Placebo patch
11633353|NCT00331123|Experimental|Testosterone Patch|
11633354|NCT00331097|Active Comparator|A|Standard chemotherapy with CMF
11633355|NCT00331097|Experimental|B|Weekly docetaxel
11633356|NCT00331084|Experimental|antibiotic steroid drops/single vial|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having cataract surgery
11633357|NCT00331084|Active Comparator|antibiotic steroids drops|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having cataract surgery
11633358|NCT00331071||001|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE worn for 1 week and replaced for 3 consecutive weeks fourth week is patch free
11633359|NCT00331071||002|Monophasic or triphasic Oral contraceptive tablet 35 mcg EE for 21 consecutive days followed by no or drug-free tablet for 7 days
11633360|NCT00331058|Other|healthy volunteers|control group not receiving prednisolone
11633361|NCT00331058|Other|asthmatic volunteers|receive prednisolone for 14-16 days
11633362|NCT00331045|Placebo Comparator|Placebo|
11633363|NCT00331045|Experimental|Alvimopan 0.25 mg/yday|
11633364|NCT00331045|Experimental|Alviompan 0.5 mg/day|
11633365|NCT00331045|Experimental|Alvimopan 1 mg/day|
11633366|NCT00331032|Experimental|1: 3% w/w SPL7013 Gel|40 subjects VivaGel™.
11633367|NCT00331032|Placebo Comparator|2: Placebo|20 subjects placebo.
11633368|NCT00331006|Experimental|Rituximab|Rituximab administered at a dose of 375 mg/m2 by slow intravenous infusion once per week for 4 weeks
11633369|NCT00330980|Experimental|1|Participants will receive 20 mg of simvastatin for 6 months.
11633370|NCT00330980|Experimental|2|Participants will receive 40 mg of pravastatin for 6 months.
11633371|NCT00330980|Placebo Comparator|3|Participants will receive placebo for 6 months.
11633372|NCT00330967||Group 1|healthy subjects
11633373|NCT00330967||Group 2|healthy subjects different from group 1
11633374|NCT00330928|Experimental|1|Subjects undergoing elective percutaneous coronary intervention
11633375|NCT00330915|Experimental|A|
11633376|NCT00330902|Active Comparator|1|Sulfadoxine pyrimethamine plus three daily doses of artesunate
11633377|NCT00330902|Experimental|2|Sulfadoxine pyrimethamine plus artesunate plus primaquine
11633378|NCT00330876|Experimental|Pitavastatin 2 mg QD|Pitavastatin 2 mg once daily
11633379|NCT00330876|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
11633380|NCT00330863|Experimental|Injectable|Participants assigned to receive long-acting injectable risperidone
11633381|NCT00330863|Active Comparator|Oral|"Participants assigned to receive oral atypical antipsychotic medication"
11633382|NCT00330824|Experimental|antibiotic steroid (single vial)|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having LASIK surgery
11633383|NCT00330824|Active Comparator|antibiotic / steroid (2 vials)|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having LASIK surgery
11633384|NCT00330798|Experimental|Nevanac|One drop, three times daily, in the assigned eye for the first three postoperative days
11633385|NCT00330798|Placebo Comparator|Acular LS|One drop, three times daily, in the assigned eye for the first three postoperative days
11633386|NCT00330759|Active Comparator|zoledronic acid|denosumab placebo with active zoledronic acid
11633387|NCT00330759|Experimental|denosumab|active denosumab with zoledronic acid placebo
11633388|NCT00330746|Experimental|A|cetuximab and gemcitabine combination
11633389|NCT00330746|Experimental|B|gemcitabine followed by cetuximab (sequential)
11633390|NCT00330733|Placebo Comparator|Placebo|Matching placebo
11633391|NCT00330733|Active Comparator|Salsalate Therapy|Salsalate
11633392|NCT00330694|Experimental|I|Implementation of ParkNet within 8 regions
11633393|NCT00330694|Other|II|Usual Care in 8 regions
11633394|NCT00330681|Experimental|1|MCI-186
11633395|NCT00330681|Placebo Comparator|2|Placebo of MCI-186
11633396|NCT00330668|Experimental|All rhIGF-1 Subjects|"All subjects entering MS306 began recombinant human insulin-like growth factor-1 (rhIGF-1) twice a day (BID) treatment. Each subject treated in MS301 had an MS306 starting dose that was based on their dose at the completion of MS301 (i.e. subcutaneous injections of rhIGF-1 at 40, 80, or 120 micrograms [μg]/ kilogram [kg] BID).
~MS301 untreated control subjects were randomised in MS306 in a 1:1 ratio to a dose of either 80 or 120 μg/kg rhIGF-1 BID.
~Following Protocol Amendment 1, all subjects received either 80 or 120 μg/kg rhIGF-1 BID until the implementation of Protocol Amendment 2.
~Following Protocol Amendment 2, all subjects were first switched to receive subcutaneous injections of 160 μg/kg rhIGF-1 once a day (QD), followed by individual dose-escalation first to 200 μg/kg rhIGF-1 QD and subsequently to a targeted maximum dose of 240 μg/kg rhIGF-1 QD. Subjects were treated QD until the early termination of the study."
11633397|NCT00330629|Active Comparator|Standard Behavioral Treatment|"Goal setting: daily/weekly goals for calorie and fat consumption, exercise time, and behavior change.
~Self-monitoring: systematically observing and recording one's behavior,45,46 which will be reviewed by the therapists, and written feedback will be provided to reinforce positive behaviors.
~Feedback: therapists monitor the recorded behavior changes and provide feedback/encouragement."
11633398|NCT00330629|Active Comparator|SBT+LOV Group|In addition to SBT, participants will aim to eliminate all meat, poultry, and fish from their diet over the first 6 weeks, and will be taught how to select appropriate substitutes for these foods, such as low- or no-fat dairy products (cheeses, milk), and protein-containing vegetable sources (soy products, legumes). .
11633399|NCT00330564|Experimental|SU011248 (Sutent, Sunitinib Malate)|50 mg/day orally for 4 weeks
11633400|NCT00330551|Experimental|Long-acting injectible risperidone|Participants who are randomly assigned to this arm will be administered the long-acting injectible form of risperidone (Risperdal Consta) every two weeks, plus group skills training and case management, for 12 months.
11633401|NCT00330551|Active Comparator|Oral risperidone|Participants who are randomly assigned to this arm will be treated with the oral version of risperidone (Risperdal) daily, plus group skills training and case management, for 12 months.
11633402|NCT00330499|Experimental|A|Synchronous chemo / radiation therapy
11633403|NCT00330499|Active Comparator|B|Radiation Alone
11633404|NCT00330473|Experimental|1|Treatment options available on the market plus the option of taking Human Insulin Inhalation Powder.
11633405|NCT00330473|Active Comparator|2|Treatment Options available on the market.
11633406|NCT00330460|Active Comparator|Alendronate|Subjects in this arm will receive active ALN and placebo denosumab
11633407|NCT00330460|Experimental|Denosumab|Subjects in this arm will receive active denosumab and placbo ALN
11633408|NCT00330447||Studygroup|Cancer in Pregnancy - all diagnoses and treatments Children born from mothers diagnosed with cancer during pregnancy
11633409|NCT00330447||Control group|Children from the general population
11633410|NCT00330434|Other|Trial Withdrawn 2|Trial Withdrawn 2
11633411|NCT00330434|Other|Trial Withdrawn 1|Trial Withdrawn 1
11633412|NCT00330421|Experimental|Group I (sarcomas of extremity, closed accrual as of 5/30/07)|Patients receive oral sorafenib twice daily on days 1-14. Patients undergo surgical resection of the tumor on approximately day 15. Once patients recover from surgery (and radiotherapy if indicated), patients who demonstrate a clinically and pathologically significant response (≥ 25% reduction in tumor size or ≥ 25% necrosis in the surgical specimen) may continue sorafenib as above for a maximum of 6 months in the absence of disease progression or unacceptable toxicity and at the discretion of the principal investigator. Biopsy tissue and blood samples are examined for biomarkers and interstitial fluid pressure (IFP) is measured at baseline and immediately before surgery.
11633413|NCT00330421|Experimental|Group II (metastatic or inoperable sarcomas)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for 2 courses. Patients with responding or stable disease may continue sorafenib in the absence of disease progression or unacceptable toxicity. Biopsy tissue and blood samples are examined for biomarkers and IFP is measured at baseline and on days 28 and 56.
11633414|NCT00330382|Experimental|Arm I (Bowman-Birk inhibitor concentrate)|Patients receive oral Bowman-Birk inhibitor concentrate twice daily for 6 months
11633415|NCT00330382|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo twice daily for 6 months
11633416|NCT00330369|Placebo Comparator|Darusentan Placebo|Placebo to match darusentan for 2-week placebo run-in period, followed by placebo to match darusentan administered orally once daily for 14 weeks
11633417|NCT00330369|Experimental|Darusentan 50 mg|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 50 mg administered orally once daily for 14 weeks
11633418|NCT00330369|Experimental|Darusentan 100 mg|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 100 mg administered orally once daily for 14 weeks
11633419|NCT00330369|Experimental|Darusentan 300 mg|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 300 mg administered orally once daily for 14 weeks
11633420|NCT00330343|Experimental|Naloxone|continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour
11633421|NCT00330317|Experimental|Letrozole|
11633422|NCT00330304|Experimental|Isoniazid preventive therapy|HIV infected children living in a high TB prevalence area receive isonaizid prophylaxis daily, together with cotrimoxazole prohpylaxis either 3 times a week or daily.
11633423|NCT00330304|Placebo Comparator|Placebo|HIV infected children living in a high TB prevalence area receive placebo once daily
11633424|NCT00330265|Experimental|1|KC-002
11633425|NCT00330265|Other|2|Conventional Wound Therapy
11633426|NCT00330252|Experimental|Alemtuzumab & Rituximab|"Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks)
~Rituximab- Given intravenously on day 1 of every week for eight weeks (or 16 weeks)"
11633427|NCT00330226||Psychopharmacotherapy|patients under antipsychotic or mood stabilizer treatment
11633428|NCT00330187|Experimental|Bupropion SR + Contingency Management|Bupropion SR capsules, with goal dose of 300 mg/day, for 6 weeks of treatment. Contingency Management, with escalating rewards for abstinence (and re-sets for non-abstinence) at twice-weekly visits.
11633429|NCT00330187|Active Comparator|Placebo + Contingency Management|Placebo capsules, matched in appearance to Bupropion SR capsules, for 6 weeks of treatment. Contingency Management, with escalating rewards for abstinence (and re-sets for non-abstinence) at twice-weekly visits.
11633430|NCT00330187|Active Comparator|Bupropion SR + No Contingency Management|Bupropion SR capsules, with goal dose of 300 mg/day, for 6 weeks of treatment. Contingency Management is not provided in this arm.
11633431|NCT00330187|Placebo Comparator|Placebo + No Contingency Management|Placebo capsules, matched in appearance to Bupropion SR capsules, for 6 weeks of treatment. Contingency Management is not provided in this arm.
11633432|NCT00330174|Experimental|1|Acamprosate tablets
11633433|NCT00330174|Placebo Comparator|2|Matching placebo tablets
11633585|NCT00328367|Placebo Comparator|B|clozapine plus placebo
11633434|NCT00330161|Experimental|Treatment (vorinostat)|"Patients receive oral vorinostat (SAHA) once daily on days 1-21. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (CR) after 4 courses receive an additional 3 courses. All other patients may continue treatment in the absence of disease progression or unacceptable toxicity.
~Blood samples are taken on day 15 of course 1, day 1 of course 2, during the last week of course 4, and at completion of study treatment. Blood is examined for interleukin (IL)-6, IL-6 receptor, and gp130 levels."
11633435|NCT00330135|Experimental|1|Sodium hyaluronate 2.5 ml - 1 injection
11633436|NCT00330135|Placebo Comparator|2|Placebo injection - 1 injection
11633437|NCT00330096|Experimental|Hesperidin-rich food|
11633438|NCT00330096|Placebo Comparator|No intervention: Placebo|
11633439|NCT00330044|Experimental|Drug|Carboplatin and Pemetrexed
11633440|NCT00330018|Experimental|1|PO Valganciclovir
11633441|NCT00330018|Active Comparator|2|PO Acyclovir
11633442|NCT00329992|Experimental|Treatment group|16 sessions Brief Eclectic Psychotherapy
11633443|NCT00329992|Placebo Comparator|Control group|Minimal attention waitlist group
11633444|NCT00329979||1|Radial access
11633445|NCT00329979||2|Femoral access
11633446|NCT00329940|Experimental|Letrozole|to evaluate the rheumatological tolerability of Femara
11633447|NCT00329914|Placebo Comparator|Placebo|
11633448|NCT00329914|Active Comparator|Progesterone|
11633449|NCT00329901|Experimental|Tdap + MenACWY-CRM|Subjects received Tdap and MenACWY-CRM vaccines concomitantly, in separate arms
11633450|NCT00329901|Experimental|Tdap + saline|Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms
11633451|NCT00329901|Experimental|MenACWY-CRM + saline|Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms
11633452|NCT00329849|Experimental|MenACWY-CRM|Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)
11633453|NCT00329849|Active Comparator|MenACWY-PS|Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal polysaccharide (PS) vaccine (MenACWY-PS)
11633454|NCT00329836||Subjects with cluster headache|Subjects with both episodic and chronic cluster (as defined by the International Headache Society-IHS) were enrolled.
11633455|NCT00329810|Experimental|Switch|
11633456|NCT00329797|Experimental|Zoledronic Acid|Zoledronic acid q 6 months plus Vitamin D and calcium supplement for 3 years in addition to concurrent radiation therapy and LHRH therapy.
11633457|NCT00329797|Active Comparator|Control|Vitamin D and calcium supplement everyday for 3 years in addition to concurrent radiation therapy and LHRH therapy.
11633458|NCT00329784|Experimental|Peanut Consumption Group|Participants on this arm will consume peanut protein.
11633459|NCT00329784|No Intervention|Peanut Avoidance Group|Participants on this arm will avoid peanut as per United Kingdom (UK) public health recommendations.
11633460|NCT00329771||Episodic migraineurs|Eligible subjects with episodic migraine (with or without aura)
11633461|NCT00329758|Active Comparator|1|
11633462|NCT00329758|Placebo Comparator|2|
11633463|NCT00329745|Experimental|Rotarix Group|During the primary study (NCT00197210) subjects received two oral doses of Rotarix™ vaccine.
11633464|NCT00329745|Placebo Comparator|Placebo Group|During the primary study (NCT00197210) subjects received two oral doses of placebo.
11633465|NCT00329732|Active Comparator|Lidocaine/Bupivicaine|
11633466|NCT00329732|Placebo Comparator|saline|matching volume of saline injected
11633467|NCT00329719|Experimental|Group I (sorafenib tosylate, temsirolimus)|Patients receive sorafenib tosylate and temsirolimus as in Phase I.
11633468|NCT00329719|Experimental|Group II (sorafenib tosylate, temsirolimus, surgery)|Patients receive sorafenib tosylate PO BID on days 1-8 and temsirolimus IV over 30 minutes on day 1. Patients undergo surgery on day 8. After recovering from surgery, patients receive sorafenib tosylate and temsirolimus as in Phase I.
11633469|NCT00329719|Experimental|Group III (sorafenib tosylate, temsirolimus, anti-VEGF)|Patients who have received prior anti-VEGF therapy and are not undergoing surgery receive sorafenib tosylate and temsirolimus as in Phase I.
11633470|NCT00329706|Experimental|1|Experimental arm will have an immediate release of the PET report
11633471|NCT00329706|Active Comparator|2|Active Comparator arm will have a delayed release of 2 years
11633472|NCT00329693|Placebo Comparator|1|Daily Tablets Dosing
11633473|NCT00329693|Experimental|2|Daily Tablets Dose
11633474|NCT00329693|Experimental|3|Daily Tablets Dosing
11633475|NCT00329693|Experimental|4|Daily Tablets Dosing
11633476|NCT00329680|Experimental|1|Experimental arm will receive an enteral diet enriched with EPA, GLA and Antioxidant vitamins
11633477|NCT00329680|Placebo Comparator|2|"This arm will receive an enteral diet considered as a standard ICU diet, isocaloric to the control diet but not enhanced with EPA, GLA and antioxidant vitamins"
11633478|NCT00329654|Experimental|Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation.
11633479|NCT00329641|Experimental|Treatment (carboplatin, paclitaxel, sorafenib)|"Patients receive carboplatin IV and paclitaxel IV once on day 1 and oral sorafenib twice daily on days 2-19. Treatment repeats every 21 days for up to 6 courses.* After 6 courses, patients continue to receive oral sorafenib alone twice daily in the absence of disease progression or unacceptable toxicity.
~[Note: *If sorafenib is discontinued prior to course 6, patients may continue to receive carboplatin and paclitaxel for up to 6 courses; if carboplatin and paclitaxel are discontinued prior to course 6, patients may continue to receive sorafenib alone twice daily on days 1-21 of each course in the absence of disease progression or unacceptable toxicity. ]"
11633480|NCT00329628|Experimental|Arm 1|
11633481|NCT00329628|Active Comparator|Arm 2|
11633482|NCT00329602|Placebo Comparator|Double-blind for 12 to 26 Weeks|Double-blind (Ropinirole:Placebo) for 12 to 26 weeks
11633483|NCT00329602|Other|Open-label ropinirole for 40-Weeks|Open label ropinirole for 40 weeks
11633484|NCT00329589|Experimental|CNS|Velcade (bortezomib)
11633485|NCT00329589|Experimental|Head and Neck|Velcade (bortezomib)
11633486|NCT00329589|Experimental|Cervix|Velcade (bortezomib)
11633487|NCT00329563|Experimental|Cold fluid|
11633489|NCT00329550|Experimental|CZP 400 mg / Placebo|Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)
11633490|NCT00329550|Experimental|CZP 400 mg / CZP 200 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)
11633491|NCT00329550|Experimental|CZP 400 mg / CZP 400 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)
11633492|NCT00329537|Experimental|Arm 1|
11633493|NCT00329537|Placebo Comparator|Arm 2|
11633494|NCT00329524|Sham Comparator|Active versus Sham Treatment|Subjects randomly assigned to active and sham TMS separated by one week interval.
11633495|NCT00329511|Active Comparator|A|methyldopa
11633496|NCT00329511|Active Comparator|B|clonidine patch
11633497|NCT00329472|Experimental|Gem/Cis|neoadjuvant chemotherapy: gemcitabine 1250mg/m2 D1,D8 & cisplatin 70mg/m2 , 2 cycles
11633498|NCT00329472|No Intervention|no neoadjuvant chemotherapy|
11633499|NCT00329459|Experimental|arm 1|Treximet (sumatriptan/naproxen sodium)
11633500|NCT00329459|Placebo Comparator|arm 2|placebo to match
11633501|NCT00329433|Active Comparator|Heparin|Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
11633502|NCT00329433|Experimental|Desirudin (Iprivask™)|Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
11633503|NCT00329420|Experimental|CZP 400 mg / Placebo|Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)
11633504|NCT00329420|Experimental|CZP 400 mg / CZP 200 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)
11633505|NCT00329420|Experimental|CZP 400 mg / CZP 400 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)
11633506|NCT00329407|Active Comparator|Topiramate Treatment|In this open label non-placebo controlled trial all subjects received topiramate, the active medication. Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM & 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM & 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM & 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
11633507|NCT00329381|Placebo Comparator|1|Placebo will be compared to Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
11633508|NCT00329381|Experimental|2|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
11633509|NCT00329342|Experimental|1|
11633510|NCT00329342|No Intervention|2|
11633511|NCT00329303|Experimental|Certolizumab Pegol (CZP) 200 mg|Subcutaneous injections of 400 mg initial dose at Week 0 with 200 mg every 2 weeks thereafter.
11633512|NCT00329303|Experimental|Certolizumab Pegol (CZP) 400 mg|Subcutaneous injections of 400 mg every 2 weeks.
11633513|NCT00329238|Experimental|Dabigatran|Patient to receive 1 capsule containing dabigatran 150 mg twice daily plus placebo tablets for warfarin as decided by sham INR measurements
11633514|NCT00329238|Active Comparator|Warfarin (INR of 2.0-3.0)|Patient to receive warfarin tablets to target INR 2.0-3.0 plus placebo capsules for dabigatran twice daily
11633515|NCT00329108|Experimental|A|
11633516|NCT00329108|Active Comparator|B|
11633517|NCT00329082|Experimental|1|
11633518|NCT00329082|Experimental|2|
11633519|NCT00329082|Experimental|3|
11633520|NCT00329082|Experimental|4|
11633521|NCT00329082|Placebo Comparator|5|
11633522|NCT00329056|Experimental|1|40 mg MitoQ OD
11633523|NCT00329056|Experimental|2|80 mg MitoQ OD
11633524|NCT00329056|Placebo Comparator|3|Placebo
11633525|NCT00329043|Experimental|Sunitinib + Hormonal Ablation Before Prostatectomy|Sunitinib Malate 25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles. LHRH Agonist intramuscular injection either monthly for 3 months or in a single 3-month dose. Radical prostatectomy after completion of Sunitinib and LHRH agonist.
11633526|NCT00329030|Active Comparator|Rituxan/BEAM|Autologous transplantation using rituxan/BEAM
11633527|NCT00329030|Experimental|Bexxar/BEAM|Autologous transplantation using Bexxar/BEAM
11633528|NCT00329017||1|Post-menopausal women who are at increased risk for development of breast cancer on the basis of family or personal history.
11633529|NCT00329004|Experimental|1|
11633530|NCT00328965|Other|Lacidipine|All subjects who meet eligiblity criteria receive 2mg for the first 4 weeks in an open manner. If target systolic blood pressure is not ahcieved, subject can increase the dose to 4mg and then 6mg consequently.
11633531|NCT00328926|Active Comparator|Luveris® 75 IU|
11633532|NCT00328926|Active Comparator|Luveris® 25 IU|
11633533|NCT00328926|Placebo Comparator|Placebo|
11633534|NCT00328887|Experimental|CD40 Gene Transfer|Recruitment will be random from the referral base of the investigators from the popula¬tion of individuals with esophageal cancer defined by the protocol inclu¬sion/exclusion criteria.
11633535|NCT00328874|Placebo Comparator|Placebo|
11633536|NCT00328874|Active Comparator|Coenzyme Q10|
11633537|NCT00328861|Experimental|NK Cells + IL-2: Melanoma|Melanoma (skin cancer). Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7. Fludarabine 25 mg/m^2 day intravenous on days -6 through -2. IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days. Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
11633538|NCT00328861|Experimental|NK Cells + IL-2: Renal Cell|Renal cell (kidney cancer). Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7. Fludarabine 25 mg/m^2 day intravenous on days -6 through -2. IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days. Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
11633539|NCT00328848|Experimental|Intervention care management|post dischsrge care management by a nurse care manager who performs in-home vistis and reports to a interdisciplinary team. Team generates care recommendations based on patient goals. PCP and care manager implement the care plan that is based on patient goals. Includes education, behavioral interventions, and coaching.
11633540|NCT00328822|Experimental|A|Quetiapine
11633541|NCT00328822|Placebo Comparator|B|Placebo
11633542|NCT00328809|Experimental|Spirnolactone|
11633543|NCT00328783|Experimental|Active Breathing Coordinator|Patients breathe through the ABC device
11633544|NCT00328770|Experimental|Sirolimus based immunosuppression|Sirolimus given intravenously or orally to achieve serum level of 12-20ug/l
11633545|NCT00328744|Experimental|1|Behavioral: Behavioral weight loss (Standard)
11633546|NCT00328744|Experimental|2|Behavioral: Behavioral weight loss (Limited Variety)
11633547|NCT00328692|Experimental|2|
11633548|NCT00328692|Placebo Comparator|1|
11633549|NCT00328679|Experimental|A|
11633550|NCT00328627|Placebo Comparator|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
11633551|NCT00328627|Experimental|Alogliptin 12.5 + Placebo|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
11633552|NCT00328627|Experimental|Alogliptin 25 + Placebo|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
11633553|NCT00328627|Active Comparator|Placebo + Pioglitazone 15|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
11633554|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 15|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
11633555|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 15|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
11633556|NCT00328627|Active Comparator|Placebo + Pioglitazone 30|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
11633557|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 30|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
11633558|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 30|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
11633559|NCT00328627|Active Comparator|Placebo + Pioglitazone 45|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
11633560|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 45|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
11633561|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 45|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
11633562|NCT00328614|Experimental|Samarium-153 (0.25 mCi/kg)|Cohort 1: Patients receive 0.25 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
11633563|NCT00328614|Experimental|Samarium-153 (0.5 mCi/kg)|Cohort 2: Patients receive 0.5 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
11633564|NCT00328614|Experimental|Samarium-153 (0.75 mCi/kg)|Cohort 3: Patients receive 0.75 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
11633565|NCT00328614|Experimental|Samarium-153 (1.0 mCi/kg)|Cohort 4: Patients receive 1.0 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
11633566|NCT00328614|Experimental|Samarium-153 (1.5 mCi/kg)|Cohort 5: Patients receive 1.5 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
11633567|NCT00328614|Experimental|Samarium-153 (2.0 mCi/kg)|Cohort 6: Patients receive 2.0 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
11633568|NCT00328588|Experimental|1|7 days continuous infusion
11633569|NCT00328575|Experimental|Intensity-Modulated Radiotherapy (IMRT)|Patients with brain metastases will be enrolled in one of three dose levels based on tumor size. For tumor size of 3 cm or less (maximum diameter in any dimension), doses of 47.5Gy, 52.5Gy, and 54.5Gy will be tested. For tumor size of greater than 3 cm (maximum diameter in any dimension), doses of 42.5Gy, 47.5Gy, and 52.5Gy will be tested.
11633570|NCT00328562|Experimental|Iressa and RT|"Iressa plus thoracic RT at the following dose levels:
~Level 1: 42.0 Gy in 10 fractions of 4.2 Gy
~Level 2: 50.4 Gy in 12 fractions of 4.2 Gy
~Level 3: 63.0 Gy in 15 fractions of 4.2 Gy"
11633571|NCT00328510|Experimental|GTC Frame|Participant undergoes SRT using a GTC frame to immobilize the participant's heading during radiation therapy
11633572|NCT00328510|Experimental|BrainLab thermoplastic mask|Participant undergoes SRT using the BrainLab thermoplastic mask to immobilize the participant's head during radiation therapy
11633573|NCT00328497|Experimental|1|Panzem NCD will be dosed orally at a level of 1,000 mg, four times daily for 28 consecutive days and bevacizumab will be administered at a dose of 5 mg/kg as an intravenous bolus on Day 1 and Day 15 of the Treatment Period
11633574|NCT00328484|Experimental|1|Eleven month lifestyle activity program
11633575|NCT00328484|Active Comparator|2|Three month exercise program
11633576|NCT00328458|Experimental|Cohort 1 Brain Tumors|The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.
11633577|NCT00328458|Experimental|Cohort 2 Head and Neck Tumors|The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.
11633578|NCT00328445|No Intervention|Control|Business as usual
11633579|NCT00328445|Experimental|Treatment|Positive Action
11633580|NCT00328419|Experimental|1|photoprotected parenteral nutrition
11633581|NCT00328419|Active Comparator|2|Non-photoprotected parenteral nutrition
11633582|NCT00328393|Active Comparator|Pioglitazone|Pioglitazone 45 mg, 8 weeks
11633583|NCT00328393|Placebo Comparator|Placebo|Placebo
11633584|NCT00328367|Experimental|A|clozapine plus aripiprazole
11633586|NCT00328263|Experimental|1|Bio-K Cl1285 Bio-K Cl1285 contains 50 billion of live bacteria.
11633587|NCT00328263|Placebo Comparator|2|placebo devoid of bacteria
11633588|NCT00328250|Experimental|1|Participants will receive the online CBT intervention immediately and will use the online program for 8 weeks
11633589|NCT00328250|Active Comparator|2|Participants will receive the online CBT intervention after a 4-month waiting period
11633590|NCT00328211|Experimental|Bile Acid|To assess the role of bile acid pool size changes on cholesterol absorption, synthesis and intralumenal cholesterol solubilization.
11633591|NCT00328211|Experimental|Cholesterol Absorption|To determine whether cholesterol absorption, synthesis and solubilization will be significantly altered by changes in phospholipid content, specifically sphingolipids and phosphatidylcholine in the intestinal lumen.
11633592|NCT00328211|Experimental|Intralumenal|To assess intralumenal solubilization and absorption of biliary and dietary cholesterol.
11633593|NCT00328198|Experimental|Dose escalation|Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated).
11633594|NCT00328198|Experimental|No escalation|Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered subcutaneously at alternating injection sites 3 times per week for up to 18 weeks.
11633595|NCT00328172|Placebo Comparator|Placebo|Placebo tablets matching BI 1356
11633596|NCT00328172|Experimental|BI 1356 0.5 mg|BI 1356 dose 1 once daily
11633597|NCT00328172|Experimental|BI 1356 2.5 mg|BI 1356 dose 2 once daily
11633598|NCT00328172|Experimental|BI 1356 5.0 mg|BI 1356 dose 3 once daily
11633599|NCT00328172|Active Comparator|Metformin|Metformin
11633600|NCT00328146||Observation of Sternal Re-entry|All subjects.
11633601|NCT00328107|Experimental|Low Dose|Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2004/05 formulation containing 45μg of each hemagglutinin derived from A/Wyoming/3/03(H3N2) and 15μg from A/New Caledonia/20/99(H1N1) and B/Jiangsu/10/03
11633602|NCT00328107|Experimental|Full Dose|Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2004/05 formulation containing 45μg of each hemagglutinin derived from A/Wyoming/3/03(H3N2), A/New Caledonia/20/99(H1N1) and B/Jiangsu/10/03
11633603|NCT00328107|Placebo Comparator|Placebo|0.9% Sodium Chloride
11633604|NCT00328094|Experimental|CII, Continuous Insulin Infusion|Continuous intravenous insulin infusion to control glucose to <150 mg/dL in patients undergoing open peripheral vascular bypass surgery
11633605|NCT00328094|Active Comparator|IIB, Intermittent insulin boluses|Intermittent intravenous insulin insulin boluses to a blood glucose target of <150mg/dL in patients undergoing peripheral vascular bypass surgery
11633606|NCT00328068||Back pain / peripheral arthritis|Patients with chronic back pain of unknown origin and onset of back pain <45 years of age or patients with peripheral arthritis / enthesitis / dactylitis of unknown origin and onset <45 years of age
11633607|NCT00328042|Experimental|Self-Management Workshop|
11633608|NCT00328042|Active Comparator|Information Only|
11633609|NCT00328016|Experimental|Device Guided Breathing|Individual breathing rate was determined from an expandable band around the torso connected to a commercially available device (RESPeRATE, Lod, Israel) that presented distinctive tones via earphones.
11633610|NCT00328016|Placebo Comparator|Control Group|Control group were instructed to sit in the same manner passively attend to their breathing, and silently repeat 'one' during each exhalation. If other thoughts came to mind, they were instructed to calmly attend to their breathing.
11633611|NCT00327964||study population|601 children enrolled in an on-going longitudinal antimalarial treatment efficacy trial in Kampala, Uganda.
11633612|NCT00327912|Experimental|1|Laparoscopic Biliopancreatic diversion with Duodenal switch
11633613|NCT00327912|Active Comparator|2|Laparoscopic Roux-en-Y Gastric Bypass
11633614|NCT00327873|Experimental|A|Oxygen
11633615|NCT00327873|Active Comparator|B|Medical Air
11633616|NCT00327860||Cohort 1|"Age between 1 and 16 years (before 17th birthday) and estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min|1.73m2"
11633617|NCT00327860||Cohort 2|"Age between 1 and 16 years (before 17th birthday), estimated GFR between 45 and 90 ml/min|1.73m2 based on the updated Schwartz formula, and an equal distribution of children with glomerular and non-glomerular causes of disease were enrolled (i.e., 150 within each) and the study placed an upper limit of 60% for the percent of enrolled with non-glomerular disease."
11633618|NCT00327860||Cohort 3|Age between 6 months and 16 years (before 17th birthday) with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled.
11633619|NCT00327808|Experimental|Inhaler|TPI 1020
11633620|NCT00327808|Active Comparator|Inhaler cortico.|Budesonide inhaler
11633621|NCT00327769|Active Comparator|1|Anastrozole
11633622|NCT00327769|Experimental|2|Anastrozole + Fulvestrant
11633623|NCT00327743|Experimental|larotaxel + Capecitabine|
11633624|NCT00327717|Experimental|Zonisamide 100 mg tablet|
11633625|NCT00327717|Placebo Comparator|Placebo|
11633626|NCT00327704|Active Comparator|Albumin|
11633627|NCT00327704|Placebo Comparator|Saline|
11633628|NCT00327665|Experimental|Group A|
11633629|NCT00327665|Experimental|Group B|
11633630|NCT00327665|Experimental|Group C|
11633631|NCT00327665|Active Comparator|Group D|
11633632|NCT00327665|Active Comparator|Group E|
11633633|NCT00327600|Experimental|imexon + DTIC|
11633634|NCT00327535|Experimental|Mircera 6.3 micrograms/kg|
11633635|NCT00327535|Experimental|Mircera 9 micrograms/kg|
11633636|NCT00327535|Experimental|Mircera 12 micrograms/kg|
11633637|NCT00327535|Active Comparator|Darbepoetin alfa|
11633638|NCT00327509||1-HTG|high tension glaucoma highest IOP > 21 mmHg
11633639|NCT00327509||2-NTG|normal tension glaucoma highest measured IOP < 21 mmHg
11633640|NCT00327509||3-PEX|pseudoexfoliation glaucoma PEX material visible
11633641|NCT00327509||4-Juvenile|juvenile glaucoma
11633642|NCT00327509||5-Control1|healthy subjects (age group 1)
11633643|NCT00327509||6-Control2|healthy subjects (age group 2)
11633644|NCT00327470|Experimental|Open Label|
11633739|NCT00326183|Active Comparator|2|Arm 2: Active comparator
11633645|NCT00327444|Placebo Comparator|Placebo|"Participants with advanced ovarian cancer administered placebo in the double-blind (DB) period.
~In the open-label (OL) period, participants had the option to receive aflibercept or be withdrawn from the study."
11633646|NCT00327444|Experimental|Aflibercept|"Participants with advanced ovarian cancer administered aflibercept in the double-blind (DB) period.
~In the open-label (OL) period, participants had the option to continue to receive aflibercept or be withdrawn from the study."
11633647|NCT00327379|Experimental|Arm 1|
11633648|NCT00327379|Placebo Comparator|Arm 2|
11633649|NCT00327340|Experimental|OGX-011 / mitoxantrone/prednisone|OGX-011 / mitoxantrone/prednisone: OGX-011 administered in combination with mitoxantrone and prednisone
11633650|NCT00327340|Experimental|OGX-011/docetaxel/prednisone|OGX-011/docetaxel/prednisone: OGX-011 administered in combination with docetaxel and prednisone
11633651|NCT00327288|Experimental|A|Docetaxel plus imexon
11633652|NCT00327223|Experimental|imexon|Dose escalation of imexon
11633653|NCT00327210|Experimental|BGATHome|Blood Glucose Awareness Training at Home Internet Intervention
11633654|NCT00327210|No Intervention|Control|No intervention
11633655|NCT00327197|Experimental|Intermittent mild steroid-naïve asthmatic group|Asymptomatic subjects receiving only beta-agonist inhaler with predicted FEV1 >=80% and normal peak expiratory flow between attacks will be included.
11633656|NCT00327197|Experimental|Mild to moderate persistent asthmatic group|Subjects with mild to moderate persistent asthma on low to moderate dose of inhaled corticosteroid (200-500 microgram fluticasone propionate daily or equivalent), an FEV1 >= 80% predicted (post-bronchodilator), and less than 20% variability in peak expiratory flow.
11633657|NCT00327197|Experimental|Severe asthma group|Subjects with severe persistent asthma. They will be on either: high inhaled corticosteroid (CS >=1000 microgram fluticasone daily or equivalent) or on high dose inhaled CS plus oral CS (no more than 20 milligrams predisolone a day). The subjects should have at least one ( if on oral steroids) or two (if only on inhaled steroids) of the following: 1) FEV1<80% and FEV1/FVC ratio <70% 2) more than 25% variability in peak expiratory flow 3) daily symptoms ± nocturnal symptoms 4) severe exacerbations of >= twice a year in at least one of the last two years.
11633658|NCT00327197|Placebo Comparator|Healthy subjects group|Non-asthmatic and non-smokers with FEV1 > 85% predicted, on no regular medication.
11633659|NCT00327184|Experimental|Group Hib-MenC|Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of Hib-MenC + Infanrix™ penta vaccines.
11633660|NCT00327184|Active Comparator|Group NeisVac-C|Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of NeisVac-C™ + Infanrix™ hexa vaccines.
11633661|NCT00327171|Experimental|Aflibercept 2.0 mg/kg|Participants with advanced ovarian epithelial adenocarcinoma administered 2.0 mg/kg Aflibercept.
11633662|NCT00327171|Experimental|Aflibercept 4.0 mg/kg|Participants with advanced ovarian epithelial adenocarcinoma administered 4.0 mg/kg Aflibercept.
11633663|NCT00327132|Experimental|Experimental Arm|
11633664|NCT00327106|Active Comparator|1|Exacyl
11633665|NCT00327106|Placebo Comparator|2|Physiologic serum
11633666|NCT00327093|Experimental|1|Bevacizumab
11633667|NCT00327093|Experimental|2|Cetuximab
11633668|NCT00327054|Experimental|Nigella sativa seed|
11633669|NCT00327054|No Intervention|Control|
11633670|NCT00327015|Experimental|Saxagliptin and Metformin (A)|PLUS open-label pioglitazone (as needed as rescue medication)
11633671|NCT00327015|Experimental|Saxagliptin and Metformin (B)|PLUS open-label pioglitazone (as needed as rescue medication)
11633672|NCT00327015|Experimental|Saxagliptin and Placebo (C)|PLUS open-label pioglitazone (as needed as rescue medication)
11633673|NCT00327015|Active Comparator|Metformin and Placebo (D)|PLUS open-label pioglitazone (as needed as rescue medication)
11633674|NCT00326989|Active Comparator|Low-dose shock wave treatment & Placebo|
11633675|NCT00326989|Active Comparator|low-dose shock-wave treatment & Cell therapy|
11633676|NCT00326989|Active Comparator|High-dose shock-wave treatment & Placebo|
11633677|NCT00326989|Active Comparator|High-dose shock-wave treatment & cell therapy|
11633678|NCT00326989|Active Comparator|Placebo shock-wave treatment & cell therapy|
11633679|NCT00326976|Experimental|1|400 mg injected in 2 divided boluses
11633680|NCT00326976|Placebo Comparator|2|Matching placebo
11633681|NCT00326963|Experimental|Enfuvirtide+PI+ARV's|"Eligible participants received Fuzeon® (enfuvirtide) 90 milligram (mg) subcutaneously (SC) two times a day (bid) for 24 weeks plus new protease inhibitor (PI) (darunavir/ritonavir) plus other investigator-choice antiretrovirals (ARVs). Participants selected their preferred injection device among the following three options: 27 gauge (G) ½ needle/syringe, 31G 8 millimeter (mm) needle/syringe or Biojector 2000 (B2000) needle-free injection device (NFID)."
11633682|NCT00326950|Experimental|1|
11633683|NCT00326924|Experimental|Biological|PRBCs that are less than 7 days old are considered 'fresh'.
11633684|NCT00326924|Experimental|Standard PRBCs|PRBCs 'stored' as per hospital policy.
11633685|NCT00326911|Experimental|cetuximab + bevacizumab + gemcitabine|Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks, and gemcitabine 1000 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks. All medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab, bevacizumab, and gemcitabine. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.
11633686|NCT00326911|Active Comparator|cetuximab + bevacizumab|Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks. Both medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab and bevacizumab. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.
11633687|NCT00326898|Experimental|Arm A (sunitinib malate, placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive sunitinib malate PO QD for 4 weeks and placebo sorafenib tosylate PO QD or BID for 6 weeks.
11633797|NCT00325364|Experimental|1|
11633688|NCT00326898|Experimental|Arm B (sorafenib tosylate, placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive sorafenib tosylate PO QD or BID for 6 weeks and placebo sunitinib malate PO QD for 4 weeks followed.
11633689|NCT00326898|Placebo Comparator|Arm C (placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive placebo sorafenib tosylate as in Arm A and placebo sunitinib malate as in Arm B.
11633690|NCT00326885|Experimental|Catumaxomab|
11633691|NCT00326872|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for 26 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue treatment beyond 26 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, prior to course 2, prior to course 4, and every 6 courses thereafter.
11633692|NCT00326820|Experimental|Ibandronic Acid|50mg tablet once daily over 96 weeks
11633693|NCT00326820|Active Comparator|Zoledronic Acid|4 mg via intravenous infusion (iv) over a minimum of 15 minutes in at least 100mls of saline every 4 weeks over 96 weeks
11633694|NCT00326781|Active Comparator|Nicotine Nasal Spray|
11633695|NCT00326781|Active Comparator|Transdermal Nicotine patch|
11633696|NCT00326716|Experimental|Treatment|
11633697|NCT00326664|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
11633698|NCT00326638|Other|Arm A: 3D-Conformal Radiation|"Intervention: Standard radiation treatment for high risk prostate cancer. Once daily Monday to Friday for 8 weeks.
~3DCRT 7800 cGY/39 Fractions/ STD Technique*
~Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23
~Boost 6 F 3DCRT to Prostate 3,200 cGy/16"
11633699|NCT00326638|Experimental|Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy|"Intervention: Helical Tomotherapy Intensity Modulated Radiotherapy (IMRT) once daily Monday to Friday for 8 weeks.
~IMRT using Helical Tomotherapy* 7800 cGY/39 Fractions Boost IMRT to Prostate 3,200 cGy/16"
11633700|NCT00326625|Experimental|40 mg glatiramer acetate (GA)|Pre-filled syringe of 40 mg glatiramer acetate (GA) for injection, administered subcutaneously once a day.
11633701|NCT00326625|Placebo Comparator|Placebo|Pre-filled syringe of matching placebo, administered subcutaneously once a day.
11633702|NCT00326612|Active Comparator|Intranasal Midazolam 0.2mg/kg|GIve once for seizure longer than 5 minutes
11633703|NCT00326612|Active Comparator|Rectal Diazepam 0.3-0.5 mg/kg|Given once for seizure longer than 5 minutes
11633704|NCT00326599|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and oral AZD2171 once daily on days 1-21. Treatment repeats every 21 days for up to 6 courses. Patients achieving stable disease, partial response, or complete response after 6 courses of therapy receive AZD2171 alone as above. Treatment with AZD2171 repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11633705|NCT00326599|Active Comparator|Arm II|Patients receive gemcitabine and carboplatin as in arm I. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11633706|NCT00326586|Experimental|1|
11633707|NCT00326534||Controls|Patients without sarcoidosis, but requiring a fiberoptic bronchoscopy
11633708|NCT00326534||Sarcoidosis patients|Patients with newly diagnosed sarcoidosis
11633709|NCT00326495|Experimental|BAY 43-9006 & Cetuximab|BAY 43-9006: Administered orally at a dose of 400 mg twice a day (BID). Cetuximab will be given intravenously (IV) at a dose of 400 mg/m^2 initially as a loading dose on week 2, followed by 250 mg/m^2 weekly starting on week 3
11633710|NCT00326482||Prior Liver Biopsy|HIV+ historical liver biopsy history
11633711|NCT00326482||Prospective Liver Biopsy with ARV|HIV+ taking c/ARV medications
11633712|NCT00326482||Prospective Liver Biopsy without ARV|HIV+ not taking c/ARV medications
11633713|NCT00326469|Experimental|1|
11633714|NCT00326456|Experimental|carboplatin and liposomal doxorubicin|
11633715|NCT00326456|Active Comparator|carboplatin and paclitaxel|
11633716|NCT00326443|Experimental|1|14 subjects Oral CVD 909 with buffer on Day 0. Parental Vi polysaccharide vaccine on Day 21.
11633717|NCT00326443|Placebo Comparator|2|14 subjects oral buffer placebo. Parental Vi polysaccharide vaccine on Day 21.
11633718|NCT00326417|Experimental|Cyclophosphamide 150mg|Fludarabine plus 150 mg/kg Cyclophosphamide (total dose)
11633719|NCT00326417|Experimental|Cyclophosphamide 100mg|Fludarabine plus 100 mg/kg Cyclophosphamide (total dose)
11633720|NCT00326417|Experimental|Cyclophosphamide 50mg|Fludarabine plus 50 mg/kg Cyclophosphamide (total dose)
11633721|NCT00326417|Experimental|Fludarabine|Fludarabine only (no Cyclophosphamide administered)
11633722|NCT00326404|Experimental|1|
11633723|NCT00326404|Active Comparator|2|
11633724|NCT00326378|Active Comparator|CCRT arm without consolidation chemotherapy|Docetaxel 20mg/m2 & Cisplatin 20mg/m2 (D1,8,15,22,29,36) during radiotherapy
11633725|NCT00326378|Experimental|CCRT arm with consolidation chemotherapy|docetaxel 20mg/m2 & cisplatin 20mg/m2 (D1,8,15,22,29,36) during radiotherapy, and followed by consolidation chemotherapy with 3-weekly docetaxel 35mg/m2 & cisplatin 35mg/m2 (D1,8) every 3 weeks (#3).
11633726|NCT00326339|Experimental|1|R788 50 mg PO bid
11633727|NCT00326339|Experimental|2|R788 100 mg PO bid
11633728|NCT00326339|Experimental|3|R788 150 mg PO bid
11633729|NCT00326339|Placebo Comparator|4|Placebo PO bid
11633730|NCT00326287|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d
11633731|NCT00326287|Active Comparator|Ceftriaxone with or without Linezolid|Ceftriaxone 2g qd as 0.5h infusions with or without Linezolid 600mg q12h as 1h infusions, 7-14d
11633732|NCT00326248|Experimental|Arm 1|
11633733|NCT00326222|Experimental|1|Lifestyle counseling
11633734|NCT00326222|No Intervention|2|Usual care
11633735|NCT00326209|Experimental|Encapsulated Mesalamine Granules (eMG)|Participants will receive eMG 1.5 grams (4 capsules of eMG 0.375 grams each) QD orally in the morning for up to 24 months.
11633736|NCT00326196|Active Comparator|PCI|Percutaneous coronary intervention
11633737|NCT00326196|Active Comparator|CABG|Coronary artery bypass graft (CABG)
11633738|NCT00326183|Active Comparator|1|Arm 1: vaccine
11633740|NCT00326170|Experimental|VPA + 5-aza + ATRA|Daily for 7 days, Valproic acid (VPA) starting dose 75 mg/m^2 subcutaneously in combination with 5-azacytidine (5-aza) 50 mg/kg orally; and all-trans retinoic acid (ATRA) 45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3.
11633741|NCT00326157|Experimental|1|AmBisome® will be administered for a duration of 8 weeks
11633742|NCT00326118|Active Comparator|Meningitec + Hiberix Group|Subjects received a single dose of Meningitec™ vaccine co-administered with Hiberix™ and Priorix™ vaccines. The Meningitec vaccine was administered intramuscularly in the left deltoid region, the Hiberix vaccine was administered intramuscularly in the left thigh region and the Priorix vaccine was administered subcutaneously in the right upper arm.
11633743|NCT00326118|Experimental|Menitorix Group|Subjects received a single dose of Menitorix™ vaccine co-administered with Priorix™ vaccine. Menitorix vaccine was administered intramuscularly in the left deltoid region and the Priorix vaccine was administered subcutaneously in the right upper arm.
11633744|NCT00326079|Active Comparator|1|
11633745|NCT00326079|Active Comparator|2|
11633746|NCT00326066|Active Comparator|1|
11633747|NCT00326066|Placebo Comparator|2|
11633748|NCT00326040|Experimental|A|
11633749|NCT00326027|Active Comparator|1|Pantoprazole 20 mg
11633750|NCT00326027|Active Comparator|2|Pantoprazole 40 mg
11633751|NCT00326014|Experimental|A|
11633752|NCT00326001|Experimental|Gold tip catheter|Gold tip catheter
11633753|NCT00326001|Active Comparator|Platinum-iridium tip catheter|Platinum-iridium tip catheter
11633754|NCT00325949|Experimental|arm label (1) hydrocodone/acetaminophen extended release|
11633755|NCT00325949|Experimental|arm label (2) hydrocodone/acetaminophen extended release|
11633756|NCT00325949|Placebo Comparator|Arm label (3) placebo|
11633757|NCT00325936|Active Comparator|Nifedipine|parrallel design
11633758|NCT00325936|Experimental|Cilnidipine|
11633759|NCT00325897|Active Comparator|Azithromycin, 250 mg|Macrolide Antibiotic (Azithromycin)
11633760|NCT00325897|Placebo Comparator|Placebo|Inactive
11633761|NCT00325819|Active Comparator|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
11633762|NCT00325819|Placebo Comparator|Placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
11633763|NCT00325780|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
11633764|NCT00325754|Active Comparator|E-Cylinder|22-lb E-cylinder towed on a cart
11633765|NCT00325754|Active Comparator|Lightweight Cylinder|3.6-lb lightweight cylinder that can be carried
11633766|NCT00325728|Experimental|Ramelteon 8 mg QD|
11633767|NCT00325728|Placebo Comparator|Placebo|
11633768|NCT00325715|Experimental|1|
11633769|NCT00325715|Active Comparator|2|
11633770|NCT00325689|Active Comparator|Quetiapine or Risperidone + Aripiprazole|
11633771|NCT00325689|Placebo Comparator|Quetiapine or Risperidone + placebo|
11633772|NCT00325650|Experimental|Rimonabant|Rimonabant 20 mg once daily
11633773|NCT00325650|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
11633774|NCT00325637|Active Comparator|A,1,III|To compare the effect of cilnidipine (calcium channel blocker) and losartan (angiotension II receptor blocker) on CBF in patients with ischemic stroke
11633775|NCT00325598|Experimental|Cohort 1 (36 Gy)|36 Gy in 9 fractions BID x 4 1/2 treatment days
11633776|NCT00325598|Experimental|Cohort 2 (40 Gy)|40 Gy in 10 fractions BID over 5 treatment days
11633777|NCT00325572|Active Comparator|Oral zinc and vitamin C supplementation|Participant will receive oral zinc and vitamin C supplementation based on the child's weight. Blood levels of zinc, copper, liver and renal function as well as blood counts will be measured. Copper to zinc ratio will be calculated at 6 and 16 weeks
11633778|NCT00325572|Placebo Comparator|Oral Placebo|Participant will receive placebo liquid with volume based on child's weight to match the amount given to participants in the experimental group.
11633779|NCT00325533|Experimental|Screening & Enhanced Intervention|After an intensive 10-week baselne screening, the enhanced intervention group barbers will be trained to measure blood pressure and deliver health messages related to blood pressure control during each customer's visit.
11633780|NCT00325533|Active Comparator|Screening|After the intensive 10-week baseline BP screening (an intervention in itself), the barbershops in the comparison arm received a continual supply of American Heart Association pamphlets on Hypertension in African Americans.
11633781|NCT00325520||Anorexia nervosa|Individuals with anorexia nervosa receiving inpatient treatment
11633782|NCT00325520||Healthy controls|
11633783|NCT00325507|Experimental|TroVax|TroVax given as first or second line treatment in conjuntion with low dose IL-2.
11633784|NCT00325494|Experimental|Cohort 1|MORAb-009 weekly dose of 12.5 mg/m^2
11633785|NCT00325494|Experimental|Cohort 2|MORAb-009 weekly dose of 25 mg/m^2
11633786|NCT00325494|Experimental|Cohort 3|MORAb-009 weekly dose of 50 mg/m^2
11633787|NCT00325494|Experimental|Cohort 4|MORAb-009 weekly dose of 100 mg/m^2
11633788|NCT00325494|Experimental|Cohort 5|MORAb-009 weekly dose of 200 mg/m^2
11633789|NCT00325494|Experimental|Cohort 6|MORAb-009 weekly dose of 400 mg/m^2
11633790|NCT00325468|Experimental|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
11633791|NCT00325442|Active Comparator|Active|Subjects assigned to active therapy with UT-15C 0.25, 0.5, 1, or 5 mg oral tablets.
11633792|NCT00325442|Placebo Comparator|Placebo Arm|Subjects assigned to placebo 0.25, 0.5, 1, or 5 mg oral tablets.
11633793|NCT00325416|Experimental|Age Group A - Melphalan and Topotecan plus Stem Cell Rescue|Participants 18 - 60 years of age. Intensive-Dose Melphalan and Topotecan (MT) followed by Stem Cell transplant.
11633794|NCT00325416|Active Comparator|Age Group B - Melphalan and Topotecan plus Stem Cell Rescue|Participants 61 years of age or older. Intensive-Dose Melphalan and Topotecan (MT) followed by Stem Cell transplant.
11633795|NCT00325403|Active Comparator|UT-15C (oral treprositnil)|Subjects receive UT-15C (oral treprostinil) twice daily.
11633796|NCT00325403|Placebo Comparator|Placebo|Subjects receive placebo (sugar pill) twice daily.
11633800|NCT00325286|Experimental|1|Treatment with lithium and extended release carbamazepine
11633801|NCT00325273|Experimental|probiotics & allergy|"To understand the preventive effect of probiotics in neonatal peroid
~To investate the possible mechanism"
11633802|NCT00325234|Experimental|Pemetrexed/Carboplatin|"Pemetrexed 600 mg/m^2 was administered intravenously over approximately 10 minutes on Day 1.
~Carboplatin was given over approximately 30 minutes on Day 1 beginning after the end of the Pemetrexed infusion, consistent with a target of AUC (Area under the plasma drug concentration versus time curve) 5.0 mg*min/mL. The cycle of treatment was 21 days."
11633803|NCT00325234|Active Comparator|Gemcitabine/Vinorelbine|Vinorelbine 30 mg/m^2 was given over approximately 6-10 minutes on Day 1 and Day 8. Gemcitabine 1200 mg/m^2 was given over approximately 30 minutes on Day 1 and Day 8 beginning after the end of the Vinorelbine infusion. The cycle of treatment was 21 days.
11633804|NCT00325221|Experimental|Home Monitoring On|Home Monitoring activated after implantation (Intervention HM On)
11633805|NCT00325221|Experimental|Home Monitoring Off|Home Monitoring activated 9 months after implantation (Intervention HM Off)
11633806|NCT00325195|Experimental|q2 wks|8 mg pegloticase every 2 weeks
11633807|NCT00325195|Experimental|q4 wks|8 mg pegloticase every 4 weeks (alternating with placebo every 4 weeks)
11633808|NCT00325195|Placebo Comparator|placebo|placebo every 2 weeks
11633809|NCT00325182|Experimental|Intervention: Levetiracetam|Levetiracetam dose schedule Days 1-4 250 mg bid Days 5- 19 500 mg bid Days 20 -70 1000 mg bid Days 71-78 500 mg bid Days 79-85 250 mg bid Days 86-91
11633810|NCT00325182|Placebo Comparator|Historical controls|Historical controls from COMBINE study who receive a placebo
11633811|NCT00325156|Experimental|Group A|
11633812|NCT00325143|Experimental|Infanrix Hexa Group|Healthy male or female subjects between and including 11 to 17 weeks of age, who were previously vaccinated with Rotarix™ in study 444563/028 (NCT00197210), additionally received 2 doses of Infanrix™-IPV/Hib vaccine (at 3 and 4 months of age), 2 doses of Rotarix™ vaccine (at 2 and 4 months of age) and one dose of Infanrix Hexa™ vaccine (at 5 months of age) as a primary vaccination course, followed by administration of a booster dose of Infanrix™-IPV/Hib vaccine (at 18 months of age). The Infanrix™-IPV/Hib and Infanrix Hexa™ vaccines were administered intramuscularly into the right antero-lateral thigh, while the Rotarix™ vaccine was given orally.
11633813|NCT00325130|Experimental|Group 1|Concomitant Administration
11633814|NCT00325130|Experimental|Group 2|Non-concomitant administration
11633815|NCT00325078|Experimental|Treatment|Study drug (TNFa inhibitor-infliximab or adalimumab) treated group.
11633816|NCT00325078|No Intervention|Observation|Subjects with IBD without TNFa inhibitor treatment
11633817|NCT00325039|Active Comparator|1|retropubic mid-urethral sling (TVT) The specific TVT used was the Tension-free Vaginal Tape (Gynecare)
11633818|NCT00325039|Active Comparator|2|"transobturator mid-urethral sling (TVT-O and the Monarc) Two transobturator slings were used: the Tension-free Vaginal Tape Obturator (Gynecare), which is placed starting inside the vagina and coming out through the obturator foramen (in-to-out) or the Monarc (American Medical System), which is placed starting in the groin area, passing through the obturator foramen, and then into the vagina (out-to-in)."
11633819|NCT00325013|Experimental|II|
11633820|NCT00324987|Experimental|Arm I (CLOSED TO ACCRUAL 10/1/2009) (imatinib and bevacizumab)|Patients receive imatinib mesylate PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11633821|NCT00324987|Active Comparator|Arm II (CLOSED TO ACCRUAL 10/1/2009) (imatinib)|Patients receive imatinib mesylate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11633822|NCT00324974|Experimental|Lansoprazole QD|
11633823|NCT00324974|Placebo Comparator|Placebo QD|
11633824|NCT00324961|Experimental|Single arm open label adefovir dipivoxil|adefovir dipivoxil once daily 10 mg orally
11633825|NCT00324922|Active Comparator|1|trimethoprim-sulfamethoxazole
11633826|NCT00324922|Active Comparator|2|vancomycin
11633827|NCT00324896|Experimental|eszopiclone|eszopiclone. Those under 65yo received 3mg of eszoplicone ( or randomized to matching placebo)and those 65yo or older received 2mg of eszoplicone ( or randomized to matching placebo)taken each night at bedtime
11633828|NCT00324896|Placebo Comparator|placebo|Those randomly assigned to matching placebo, took their dose each night at bedtime
11633829|NCT00324870|Experimental|Arm I|"Phase I: Patients receive oral SAHA twice daily on days 1-14 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.
~Phase II: Patients receive SAHA at the MTD determined in phase I and bevacizumab as in phase I."
11633830|NCT00324857|Placebo Comparator|Arm 1/Attention Control|Subjects randomized to the attention control arm received a patient educational booklet about OA published by the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This booklet provides a brief educational program that summarizes how to live with knee OA but does not specifically mention joint replacement
11633831|NCT00324857|Active Comparator|Arm 2/Decision Aid (DA)|"Decision Aid Video: The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option."
11633832|NCT00324857|Active Comparator|Arm 3/ Motivational Interview (MI)|Motivational Interviewing: The research intervention will conduct the fact-to-face MI session with the participant. This was used as a mechanism to help patients confront their thoughts about TKR and how to engage their primary care doctors about knee pain
11633864|NCT00324350|Active Comparator|1|intensive glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level below 6.0%)
11633865|NCT00324350|Active Comparator|2|standard glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level of 7 to 7.9%)
11633866|NCT00324324|Active Comparator|moxifloxacin hydrochloride|Moxifloxacin 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
11633833|NCT00324857|Active Comparator|Arm 4/ DA and MI|"Decision Aid Video: The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option.
~Motivational Interviewing: The research intervention will conduct the fact-to-face MI session with the participant. This was used as a mechanism to help patients confront their thoughts about TKR and how to engage their primary care doctors about knee pain"
11633834|NCT00324805|Active Comparator|Arm I (chemotherapy)|"Patients receive one of the following. For all, treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~REGIMEN 1: Vinorelbine ditartrate 30 mg/m2 IV on days 1 and 8, cisplatin 75 mg/m2 IV over 60 minutes on day 1 REGIMEN 2: Docetaxel 75 mg/m2 IV and cisplastin 75 mg/m2 IV on day 1 REGIMEN 3: Gemcitabine hydrochloride 1200 mg/m2 IV on days 1 and 8, cisplatin 75 mg/m2 IV on day 1 REGIMEN 4 (non-squamous histology only): Pemetrexed disodium 500mg/m2 IV and cisplatin 75 mg/m2 IV on day 1"
11633835|NCT00324805|Experimental|Arm II (chemotherapy, bevacizumab)|Patients receive chemotherapy as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment with bevacizumab repeats every 21 days for up to 1 year.
11633836|NCT00324766|Active Comparator|1|levosimendan
11633837|NCT00324766|Placebo Comparator|2|Placebo, 1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
11633838|NCT00324753|Experimental|Intervention|Communication sheet
11633839|NCT00324753|Other|Control|Standard of care brochures
11633840|NCT00324740|Experimental|Treatment (vorinostat and isotretinoin)|Patients receive oral vorinostat (SAHA) twice daily and oral isotretinoin twice daily on days 3-5, 10-12, 17-19, and 24-26. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11633841|NCT00324727|Experimental|Arm I|"Patients undergo an isolated hepatic arterial infusion of melphalan over 30 minutes on day 1. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response undergo 2 additional courses
~in the absence of ongoing or increasing toxicity."
11633842|NCT00324727|Active Comparator|Arm II|"Patients receive the best alternative therapy comprising supportive care, systemic or regional chemotherapy, hepatic artery (chemo)-embolization, or any other appropriate therapy at the National Cancer Institute or therapy at the discretion of their physician.
~Patients may cross over to arm I if they have evidence of disease progression."
11633843|NCT00324701|Experimental|Telepsychology|therapy done at patients house
11633844|NCT00324701|Active Comparator|Face-to-face therapy|therapy delivered at the VAMC
11633845|NCT00324675|Active Comparator|Rosiglitazone|
11633846|NCT00324675|Placebo Comparator|placebo|
11633847|NCT00324649|Experimental|Truvada|Truvada + NNRTI or PI.
11633848|NCT00324649|Active Comparator|Zidovudine/lamivudine|Zidovudine/lamivudine + NNRTI or PI.
11633849|NCT00324623|Experimental|Lymphodepletion, vaccine, IMP321 adjuvant|
11633850|NCT00324558|Experimental|1|Bemiparin 3,500 IU
11633851|NCT00324558|No Intervention|Control|
11633852|NCT00324519|Active Comparator|Misoprostol Drug|This is the misoprostol drug.
11633853|NCT00324519|Experimental|The Foley Bulb|This is the experimental portion to test the Foley Bulb.
11633854|NCT00324506|Active Comparator|Cellcept and Avonex|
11633855|NCT00324480|Experimental|Treatment (chemotherapy, enzyme inhibitor)|Before beginning course 1 of study therapy, patients receive oral SAHA on days 1-3 in order to ensure tolerability of the drug. Beginning 1 week later, patients receive oral SAHA once daily on days 1-3 and 8-10 and fixed-dose alvocidib IV over 1 hour on days 2 and 9. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11633856|NCT00324467|Active Comparator|R-CHOP (Negative Mid-Treatment PET Scan)|"All participants will receive 4 cycles of standard dose R-CHOP chemotherapy administered at 3-weekly intervals. Non-progressing participants will undergo a mid-treatment PET scan along with routine restaging investigations after 4 cycles of R-CHOP. Patients with a negative mid-treatment PET scan (no evidence of abnormal 18F-FDG uptake) will complete therapy with two additional cycles of R-CHOP for a total of 6 cycles of chemotherapy. Patients with a mid-treatment PET scan interpreted to be indeterminate or equivocal will be recorded as such, but should be considered negative for the purpose of treatment planning and should not prompt a change in therapy."
11633857|NCT00324467|Active Comparator|R-ICE (Positive Mid-Treatment PET Scan|"All participants will receive 4 cycles of standard dose R-CHOP chemotherapy administered at 3-weekly intervals. Non-progressing participants will undergo a mid-treatment PET scan along with routine restaging investigations after 4 cycles of R-CHOP. Patients with a mid-treatment PET scan (abnormal 18F-FDG uptake) will be switched to R-ICE chemotherapy and receive 4 cycles of R-ICE for a total of 8 cycles of chemotherapy.
~Following completion of R-ICE chemotherapy, patients will undergo a post-treatment PET scan along with routine restaging investigations. The post-treatment PET scan will be performed between days 28 and 35 following the final cycle of R-ICE. Patients with a negative post-treatment PET scan will undergo no further therapy. Patients with a positive post-treatment PET scan corresponding to persistent abnormalities on CT scan will be considered for radiation therapy to PET positive sites."
11633858|NCT00324428|Experimental|Transcranial Magnetic Stimulation (TMS)|This arm provides active 1Hz repetitive TMS (rTMS) applied to SII
11633859|NCT00324428|Sham Comparator|Transcranial Magnetic Stimulation Sham|This arm provides sham 1Hz repetitive TMS (rTMS) applied to SII
11633860|NCT00324415|Experimental|CMT with Radiation Therapy|"All patients will receive combined modality therapy (CMT) with 2 cycles of cisplatin and 5-FU chemotherapy, given concurrently with radiation therapy. CMT consists of:
~Cetuximab 400 mg/m2 IV Day -7 (1 week before the cycle 1, Day 1 cisplatin/5-FU and RT), then 250 mg/m2 IV Days 1, 8, 15, 22, 29, 36 and 43 (a minimum of 6 and a maximum of 8 doses of cetuximab will be administered, including the loading dose).
~Cisplatin 75 mg/m2 IV on Day 1 (cycle 1) and Day 29 (cycle 2)
~5-FU 1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)"
11633861|NCT00324402||1|Healthy pregnant women, 18-40
11633862|NCT00324363|Experimental|Exenatide|Placebo lead-in; exenatide 5 mcg for 4 weeks; exenatide 10 mcg for 12 weeks
11633863|NCT00324363|Placebo Comparator|Placebo|Placebo in volume equal to exenatide
11633957|NCT00323362|Experimental|Gemcitabine hydrochloride and imatinib mesylate|
11633867|NCT00324324|Placebo Comparator|Sugar pill|Placebo 1 capsule orally once a day through D+100 after bone marrow transplant, then discontinue
11633868|NCT00324311|Experimental|DGD|
11633869|NCT00324311|Active Comparator|SOC|
11633870|NCT00324272|Experimental|Groin dissection: sealant used.|
11633871|NCT00324272|Active Comparator|Groin dissection: no sealant used.|
11633872|NCT00324272|Experimental|Axillary dissection: sealant used.|
11633873|NCT00324272|Active Comparator|Axillary dissection: no sealant used.|
11633874|NCT00324259|Active Comparator|Arm 1 (6 mg estradiol)|6 mg of estradiol daily (2 mg tid).
11633875|NCT00324259|Active Comparator|Arm 2 (30 mg estradiol)|30 mg of estradiol. (10 mg tid)
11633876|NCT00324233|Active Comparator|SC|Speedicath (SC) catheter is a catheter for intermittent catherisation
11633877|NCT00324233|Experimental|SCCM|SpeediCath Compact Male (SCCM) is a compact catheter for intermittent catherisation to be used by males
11633878|NCT00324220|Experimental|1|MGCD0103 oral administration 3 times per week.
11633879|NCT00324194|Experimental|1|MGCD0103 oral dose 2 times per week.
11633880|NCT00324168|Active Comparator|1|
11633881|NCT00324168|Placebo Comparator|2|
11633882|NCT00324155|Experimental|Arm A: Ipilimumab and Dacarbazine|In Maintenance phase: Ipilimumab will be continued. Dacarbazine was given up to Week 22 and is not given in the Maintenance phase
11633883|NCT00324155|Active Comparator|Arm B: Placebo and Dacarbazine|
11633884|NCT00324129|Experimental|1|
11633885|NCT00324116|Experimental|Active|
11633886|NCT00324038|Experimental|buprenorphine transdermal system|Buprenorphine transdermal 7 day analgesic patch
11633887|NCT00324038|Active Comparator|codeine paracetamol tablets|codeine paracetamol combination tablets
11633888|NCT00324025|Experimental|1|Mycograb
11633889|NCT00324025|Active Comparator|2|biological
11633890|NCT00324012|Experimental|treatment|taxotere and cisplatin day one every three weeks
11633891|NCT00323973|Experimental|1|
11633892|NCT00323973|Placebo Comparator|2|Placebo
11633893|NCT00323960|Active Comparator|MPDN+PDN+CSA|MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A
11633894|NCT00323960|Active Comparator|MPDN+PDN+MTX|MPDN= methylprednisolone pulse PDN= prednisone or equivalent MTX= methotrexate
11633895|NCT00323960|Active Comparator|MPDN+PDN|MPDN+PDN MPDN= methylprednisolone PDN= prednisone or equivalent
11633896|NCT00323947|Active Comparator|1|Participants will take OROS-MPH then switch to placebo
11633897|NCT00323947|Placebo Comparator|2|Participants will take placebo then switch to OROS-MPH
11633898|NCT00323934|Experimental|1|MGCD0103 Oral 2 times weekly
11633899|NCT00323908||1|Women at high risk for developing breast cancer
11633900|NCT00323895|Experimental|1|group with intra-Cypher™ restenosis
11633901|NCT00323895|Active Comparator|2|group with intra-Taxus™ restenosis
11633902|NCT00323895|Active Comparator|3|group with intra-BMS restenosis
11633903|NCT00323882|Experimental|MDX-010|
11633904|NCT00323869|Experimental|Bevacizumab + carboplatin + gemcitabine|"Bevacizumab in combination with carboplatin and gemcitabine:
~•Carboplatin, administered IV at area under the curve (AUC) of 5, every 3 weeks on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles.
~Carboplatin was administered before the gemcitabine infusion:
~•Gemcitabine, administered 1000 mg/m² IV on days 1 and 8 of each 3-week cycle (twice per cycle) for up to 6 cycles
~Bevacizumab was administered 1 hour after end of all chemotherapy infusions:
~•Bevacizumab was administered 15 mg/kg IV on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles in combination with chemotherapy, then continuing until evidence of progressive disease or significant treatment-related toxicity"
11633905|NCT00323856|Experimental|Coagulation factor VIII (Human)|Anti-Hemophilic coagulation factor VIII (Human) Alphanate SD/HT
11633906|NCT00323830|Experimental|capecitabine/cisplatin/radiotherapy|postoperative XP/RT
11633907|NCT00323830|Active Comparator|capecitabine/cisplatin|postoperative XP
11633908|NCT00323804|Experimental|Randomised PegIFN alfa 2b + ribavirin (RBV) arm|Combination of ribavirin capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
11633909|NCT00323804|Placebo Comparator|Randomised PegIFN alfa 2b + ribavirin-placebo arm|Combination of ribavirin-placebo capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
11633910|NCT00323739|Experimental|Bevacizumab and RAD001|Bevacizumab 10mg/kg, IV infusion, every 2 weeks RAD001 10 mg by mouth daily
11633911|NCT00323713|Experimental|VLPD diet|Adavnced CKD patients (stage 4-5) on a very low protein diet
11633912|NCT00323713|Active Comparator|LPD diet|Adavnced CKD patients (stage 4-5) on a low protein diet
11633913|NCT00323674|Active Comparator|Light Weight Mesh|
11633914|NCT00323674|Active Comparator|Polysoft Mesh|
11633915|NCT00323661|Experimental|1|Rate-adaptation by Closed Loop Stimulation
11633916|NCT00323661|Active Comparator|2|Accelerometer based pacing rate adaptation
11633917|NCT00323648|Experimental|postoperatively antibiotics|
11633918|NCT00323635|Experimental|Tolterodine|Tolterodine 4 mg q.d. X 8 weeks
11633919|NCT00323635|Placebo Comparator|Placebo|A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine
11633920|NCT00323622|Experimental|Cohort 1-RTS,S/AS02A <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
11633921|NCT00323622|Experimental|Cohort 1-RTS,S/AS02A ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
11634068|NCT00322114|Experimental|Arm I|Participants receive an oral tomato dietary supplement containing lycopene twice daily for 3 weeks.
11633922|NCT00323622|Experimental|Cohort 2-RTS,S/AS02A <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
11633923|NCT00323622|Experimental|Cohort 2-RTS,S/AS02A ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 of the NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
11633924|NCT00323622|Active Comparator|Cohort 1-Prevnar-Hiberix <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 2 doses of Prevnar™ vaccine at Months 0 and 2 and 1 dose of Hiberix® vaccine at Month 1 in the Primary NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
11633925|NCT00323622|Active Comparator|Cohort 1-Engerix-B ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of Engerix®-B vaccine at Months 0, 1 and 2 in the Primary NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
11633926|NCT00323622|Active Comparator|Cohort 2-Prevnar- Hiberix <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 2 doses of Prevnar™ vaccine at Months 0 and 2 and 1 dose of Hiberix® vaccine at Month 1 in the Primary NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
11633927|NCT00323622|Active Comparator|Cohort 2-Engerix-B ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of Engerix®-B vaccine at Months 0, 1 and 2 in the Primary NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
11633928|NCT00323609|Active Comparator|Kyphoplasty|
11633929|NCT00323609|Active Comparator|Vertebroplasty|
11633930|NCT00323557|Experimental|Pneumococcal Vaccine + GM-CSF|Vaccine subcutaneously + GM-CSF (3 Doses of 250 mg subcutaneously) given either Pre Vaccine at Day -7, Day -1 and Day 0 (day of pneumococcal vaccine) or Post Vaccine given at Day 0, Day +3 and Day +7.
11633931|NCT00323557|Experimental|Pneumococcal Vaccine Alone|First vaccine dose subcutaneously, Day 0.
11633932|NCT00323531|Active Comparator|1|Video assisted thoracoscopic decortication
11633933|NCT00323531|Experimental|2|Fibrinolysis through the chest tube
11633934|NCT00323518|Placebo Comparator|1|placebo
11633935|NCT00323518|Experimental|2|30 mcg/kg velafermin
11633936|NCT00323518|Experimental|3|10 mcg/kg velafermin
11633937|NCT00323518|Experimental|4|60 mcg/kg velafermin
11633938|NCT00323492|Experimental|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization
11633939|NCT00323492|Active Comparator|Maintain Baseline Regimen|Maintain baseline regimen
11633940|NCT00323492|Experimental|Delayed Truvada|Truvada once daily with NNRTI or PI (participants from the comparator group who switched to Truvada during Study Phase 2)
11633941|NCT00323492|Experimental|All Truvada|Truvada once daily with NNRTI or PI (all participants who received Truvada during the study, i.e., participants in the Truvada and Delayed Truvada groups)
11633942|NCT00323466|Experimental|IMRT|
11633943|NCT00323453|Experimental|Experimental Arm|The experimental arm will undergo open appendectomy utilizing the Alexis® retractor (wound protection device utilized intraoperatively), followed by standardized wound closure.
11633944|NCT00323453|Placebo Comparator|Control Arm|Open appendectomy and standardized wound closure
11633945|NCT00323440||Group 1|FMF patients in remission
11633946|NCT00323440||Group 2|FMF patients during attack
11633947|NCT00323440||Group 3|FMF patients without colchicine in remission
11633948|NCT00323440||Group 4|FMF patients without colchicine in attack
11633949|NCT00323427|Experimental|Arm 1|Group Aural Rehabilitation session, two hours in length, approximately 6 participants plus Group Facilitator
11633950|NCT00323427|Active Comparator|Arm 2|Veterans receive new VA issued digital hearing aids per Standard VA Audiology Hearing Aid services
11633951|NCT00323414|Active Comparator|Polyunsaturated fatty acid (Opti-EPA)|Polyunsaturated fatty acid will consist of purified EPA:DHA (360 mg EPA and 240 mg DHA) 6 gelcaps-3 capsules by mouth 2x per day x 48 weeks
11633952|NCT00323414|Placebo Comparator|Placebo|Gelcaps containing corn oil as placebo 6 capsules 3 capsules by mouth 2 x per day for 48 weeks
11633953|NCT00323401|Experimental|Interventon|Antenatal classes for the parents
11633954|NCT00323401|No Intervention|Control|No programme are offered
11633955|NCT00323375|Experimental|AQ-13 (Investigational 4-Aminoquinoline)|Arm: Experimental: AQ-13 AQ-13 capsules with 350 mg AQ-13 base per capsule. Two capsules orally on days 1 and 2, one capsule orally on day 3.
11633956|NCT00323375|Active Comparator|CQ (Chloroquine)|Arm: Active Comparator: CQ CQ Capsules with 300 mg CQ base per capsule per capsule. Two capsules orally on days 1 and 2, one capsule orally on day 3.
11633958|NCT00323323|Experimental|Alemtuzumab/CHOP|For all patients enrolled, the study will begin with a stepped-up schedule of single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5. Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose
11633959|NCT00323310|Experimental|Gadobenate Dimeglumine|
11633960|NCT00323297|Placebo Comparator|placebo|
11633961|NCT00323297|Experimental|Active|
11633962|NCT00323284|Active Comparator|A--iStent plus Cataract Surgery|iStent plus Cataract Surgery
11633963|NCT00323284|Active Comparator|B--Cataract Surgery Only|Cataract Surgery only
11633964|NCT00323271|Experimental|Arm 1|Behavioral: Cognitive-behavior therapy
11633965|NCT00323271|Active Comparator|Arm 2|Interventional: Educational intervention
11633966|NCT00323258|Experimental|Intervention|Patients enrolled in the intervention arm received inpatient education on the importance of medication and assessment of barriers to adherence. A pill box, pocket medication card, and tips for remembering to take medications were provided. The community pharmacist was notified of the subject's enrollment. The community pharmacist was asked to reinforce importance of evidence-based medications and assess the subject's medication adherence every 6 weeks for 6 months. If a problem was noted, the subject's health care team will be notified.
11633967|NCT00323258|Active Comparator|Usual Care|The usual care group received routine discharge counseling performed by the patient-care nurse and a letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations. Enrolled patients in the usual care arm were not disclosed to the community pharmacy until the end of the study period when refill records were requested.
11633968|NCT00323206|Experimental|Intra-tumoral Electroporation of pIL-12|Participants will receive intra-tumoral injection of pIL-12 followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid DNA into tumor cells. For each lesion selected for therapy, a total of three electroporation treatments will be performed.
11633969|NCT00323193|Experimental|Arm 1|The intervention group completes approximately 8 individual level sessions with a MOVE specialist as well as approximately 8 group level intervention sessions.
11633970|NCT00323193|No Intervention|Arm 2|The control group offers basic information about diet and exercise every month for six months.
11633971|NCT00323141|Active Comparator|Ventralex|
11633972|NCT00323141|Active Comparator|Leight Weight Vypro II prothesis|
11633973|NCT00323115|Experimental|Vaccine|
11633974|NCT00323089|Experimental|Surgical Arm|Preoperative CT-Guided Microcoil Localization (CTML) and Fluoroscopic-Guided Video-Assisted Thoracoscopic (VATS) Wedge Resection of Small Peripheral Pulmonary Nodules (SPPN)
11633975|NCT00323076|Experimental|1|18F-FAZA PET Imaging
11633976|NCT00323063|Active Comparator|Arm I (Gemcitabine Hydrochloride)|Patients receive gemcitabine hydrochloride IV on days 3 and 10.
11633977|NCT00323063|Experimental|Arm II (Gemcitabine Hydrochloride + Imatinib)|Patients receive gemcitabine hydrochloride IV on days 3 and 10 and oral imatinib mesylate once daily on days 1-5 and 8-12.
11633978|NCT00323037|Active Comparator|1|
11633979|NCT00323037|Active Comparator|2|
11633980|NCT00323011|Active Comparator|Arm A: 5-FU/LV/CPT-11/Bevacizumab|5-FU 400 mg/m2, days 1, 15, & 29 Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29
11633981|NCT00323011|Experimental|Arm B: 5-FU/LV/CPT-11/Bevacizumab + Dalteparin|5-FU 400 mg/m2, days 1, 15, & 29 5-FU 2400 continuous infusion days 1-2, 15-16, 29-30. Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29 Dalteparin 5000 IU subcutaneous starting cycle 2, days 1, 15, & 29
11633982|NCT00323011|Experimental|5-FU/LV/CPT-11/Bevacizumab+Dalteparin daily|5-FU 400 mg/m2, days 1, 15, & 29 5-FU 2400 continuous infusion days 1-2, 15-16, 29-30. Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29 Dalteparin 5000 IU subcutaneous starting cycle 2, daily
11633983|NCT00322972|Other|A|Annual mass treatment
11633984|NCT00322972|Other|B|Biannual mass treatment
11633985|NCT00322972|Experimental|C|Mass administration of antibiotic; treatment of children (1-10 years of age) only
11633986|NCT00322972|No Intervention|D|Delayed initiation of mass administration of antibiotic
11633987|NCT00322972|Other|F|One-time mass administration only
11633988|NCT00322972|Experimental|G|One-time mass administration of antibiotics, plus intensive latrine construction
11633989|NCT00322946|Experimental|1|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^5 PFU dose) into the deltoid region of either arm.
11633990|NCT00322946|Experimental|2|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^3 PFU dose) into the deltoid region of either arm. This arm will enroll after Arm 1.
11633991|NCT00322946|Experimental|3|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm will enroll after Arms 1 and 2.
11633992|NCT00322946|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
11633993|NCT00322881|Experimental|Carboplatin/Paclitaxel|Patients received chemotherapy on day 1 of a 21 day cycle for 6 cycles. Paclitaxel was given via peripheral or central IV catheter at the dose of 175 mg/m2 over 3 hours. IV carboplatin followed using a dose of Area Under the Curve (AUC) equal to 5 with creatinine clearance based on Jelliffe formula.
11633994|NCT00322868|Experimental|Pioglitazone|All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily Other names: Actos, Takeda
11633995|NCT00322855||Chart Review|patients diagnosed with soft tissue sarcoma
11633996|NCT00322842|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
11634069|NCT00322114|Experimental|Arm II|Participants receive an oral tomato dietary supplement containing lycopene at a higher dose twice daily for 3 weeks.
11633997|NCT00322842|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
11633998|NCT00322777|Experimental|Spirituality Group|Arm where participants began the intervention (the Spirituality Teaching Program) upon recruitment for an 8 week period. Therefore, the program was initiated at week 1 of the trial.
11633999|NCT00322777|Active Comparator|Waitlist Control Group|Arm where participants began the intervention (the Spirituality Teaching Program) after an 8 week wait period. Therefore, the program was initiated at week 8 of the trial. Between week 1 and week 8, participants did not complete the program and were instructed to carry out their day to day activities as before.
11634000|NCT00322699|Experimental|A single arm, non-randomized Phase II Study|Non-Randomized Phase II,Single Arm Study evaluating the efficacy of whole bladder photodynamic therapy as an alternative to radical cystectomy.
11634001|NCT00322686|Experimental|Oglemilast followed by placebo|
11634002|NCT00322686|Experimental|Placebo followed by Oglemilast|
11634003|NCT00322621|Experimental|Duloxetine|All subjects receive 30 mg once daily (QD), by mouth (per os - PO) for 1 week followed by duloxetine 60 mg QD, PO for 7 weeks, then maintenance at 60 mg QD, PO for responders to 6 months and rescue at 120 mg QD, PO for non-responders to 6 months. Patients beginning maintenance at the 60 mg QD dose could be increased to the 120 mg QD level if they did not maintain appropriate level of response throughout the maintenance period.
11634004|NCT00322608|Experimental|Dose escalation|
11634005|NCT00322569|Experimental|1|Corio™ Pimecrolimus-Eluting Cobalt Chromium Coronary Stent System
11634006|NCT00322569|Experimental|2|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System
11634007|NCT00322569|Active Comparator|Control Arm|Costar ™ Paclitaxel-Eluting Coronary Stent System
11634008|NCT00322556|Experimental|IgPro10|See Intervention Description
11634009|NCT00322543|Experimental|Drug eluting stent|Corio™ Pimecrolimus-eluting stent
11634010|NCT00322530|Active Comparator|SLED|
11634011|NCT00322530|Active Comparator|CVVHD|
11634012|NCT00322517|Experimental|SU014813|
11634013|NCT00322491|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
11634014|NCT00322491|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
11634015|NCT00322478|Other|GlucoMON-ADMS enabled|Patients who are equipped with the automated technology vs. standard/conventional care
11634016|NCT00322465|Experimental|Doxycycline|Doxycycline 100 mg orally twice daily (2 pills/day = 200 mg/day) for 7 days plus placebo azithromycin orally single dose and placebo tinidazole.
11634017|NCT00322465|Experimental|Doxycycline + Tinidazole|Doxycycline 100 mg orally twice daily for 7 days plus placebo azithromycin single dose plus tinidazole 2 gm orally single dose (4 tablets at 500 mg each).
11634018|NCT00322465|Experimental|Azithromycin|Azithromycin 1 gram (gm) orally single dose (2 tablets at 500 milligrams (mg) each) plus doxycycline placebo twice daily for 7 days plus tinidazole placebo single dose.
11634019|NCT00322465|Experimental|Azithromycin + Tinidazole|Azithromycin 1 gm orally single dose (2 tablets at 500 mg each) plus doxycycline placebo twice daily for 7 days plus tinidazole single dose (4 tablets at 500 mg each).
11634020|NCT00322452|Experimental|1|gefitinib
11634021|NCT00322452|Active Comparator|2|Carboplatin/Paclitaxel
11634022|NCT00322439||Etanercept|Participants received etanercept (Enbrel) treatment at the dose and regimen determined by the investigator and were evaluated for up to 5 years at 6-month intervals. During this period, participants may have discontinued etanercept therapy, may have switched to another anti-psoriatic therapy, may have used etanercept in combination with other anti-psoriatic therapies, or may have discontinued any or all antipsoriatic treatments.
11634023|NCT00322400|Experimental|B1|AMG 706 50 mg daily + Docetaxel (100 mg/m2 D1 every 21 days)
11634024|NCT00322400|Experimental|A4|75 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8 and D15 every 28 days)
11634025|NCT00322400|Experimental|A1|AMG 706 50 mg daily + Paclitaxel (90 mg/m2 D1, D8, D15 every 28 days)
11634026|NCT00322400|Experimental|B4|75 mg AMG 706 daily + Docetaxel (100 mg/m2, D1 every 21 days)
11634027|NCT00322400|Experimental|B5|MTD of AMG 706 + Docetaxel (75mg/m2 D1 every 21 days)
11634028|NCT00322400|Experimental|B3|100 mg AMG 706 daily + Docetaxel (100 mg/m2 on D1 every 21 days)
11634029|NCT00322400|Experimental|B2|AMG 706 125 mg daily + Docetaxel (100 mg/m2 D1 every 21 days)
11634030|NCT00322400|Experimental|A2|AMG 706 125 mg daily + paclitaxel 90 mg/m2 D1, D8, D15 every 28 days
11634031|NCT00322400|Experimental|A3|100 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8, and D15 every 28 days)
11634032|NCT00322387|Experimental|Plerixafor PM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. After the first apheresis, plerixafor (240 µg/kg) was administered each evening (approximately 10pm) followed by apheresis 10 to 11 hours later for up to 4 consecutive days.
~Called 'Cohort A' in protocol, study report and publications."
11634070|NCT00322114|Placebo Comparator|Arm III|Participants receive oral placebo twice daily for 3 weeks.
11634105|NCT00321802|Experimental|1|Patients randomized to active drug, then AF burden and CRP values will be compared to those in placebo arm.
11634106|NCT00321802|Placebo Comparator|2|Patients take placebo once daily for 6 Months, then AF burden and CRP values will be compared to those in experimental arm.
11634152|NCT00321308|Experimental|A|Standard of care chemotherapy plus experimental intervention (PF-3512676)
11634033|NCT00322387|Experimental|Plerixafor AM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. The morning of the second day after the first apheresis, plerixafor (240 µg/kg) was administered followed by apheresis 6 hours later. Plerixafor (240 µg/kg) was administered in the morning followed by apheresis 6 hours later for up to 4 consecutive days.
~Called 'Cohort B' in protocol, study report and publications."
11634034|NCT00322387|Experimental|Low CD34+ Count/ Plerixafor PM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. If participants had a CD34+ count of >=10 cells/µL but <20 cells/µL on 2 consecutive days, plerixafor (240 µg/kg) was given in the evening. G-CSF was administered and apheresis performed in the morning. Plerixafor (240 µg/kg) administered in the evening followed by G-CSF and apheresis 10 to 11 hours later was repeated for up to 4 consecutive days.
~Called 'Cohort C' in protocol, study report and publications."
11634035|NCT00322387|Experimental|Plerixafor After Chemo|"This investigational cohort evaluated the effect of administering plerixafor before white blood cell recovery.
~Participants received mobilizing chemotherapy, followed by 5 consecutive days of G-CSF (10 µg/kg). Starting on the sixth day, participants received G-CSF (10 µg/kg) plus plerixafor (240 µg/kg) daily for up to 3 consecutive days. If CD34+ counts reached >= 20 cells/µL 6 hours after any of the 3 plerixafor doses, apheresis began. If not, G-CSF administration continued until the participant qualified for one of the other treatment arms.
~Called 'Investigational Cohort' in protocol, study report and publications."
11634036|NCT00322374|Experimental|25 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
11634037|NCT00322374|Experimental|30 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
11634038|NCT00322374|Experimental|35 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 35 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
11634039|NCT00322361|Experimental|1|Modified Process Hepatitis B Vaccine
11634040|NCT00322361|Active Comparator|2|Recombivax HB™
11634041|NCT00322348|Experimental|ZOLADEX 10.8 mg|ZOLADEX (goserelin acetate) 10.8 mg intramuscular depot for injection every 12 weeks
11634042|NCT00322348|Experimental|ZOLADEX 3.6 mg|ZOLADEX (goserelin acetate) 3.6 mg intramuscular depot for injection every 4 weeks
11634043|NCT00322335|Experimental|Menitorix/Pediarix Group|Subjects were primed with 3 doses of Pediarix™ co-administered intramuscularly with Menitorix™ in the right and left thigh respectively in the primary study (NCT00352963) at 2, 4 and 6 months of age. This was followed by a booster dose of Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
11634044|NCT00322335|Active Comparator|Infanrix hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group|Subjects were either primed in the primary study (NCT00352963) with 3 doses of Infanrix™ hexa administered intramuscularly in the right thigh at 2, 4 and 6 months of age and 2 doses of NeisVac-C™ administered intramuscularly in the left thigh at 2 and 4 months of age or with Engerix-B at birth intramuscularly in the right thigh, Infanrix™ hexa intramusculary in the right thigh at 2 and 6 months of age and NeisVac-C™ intramuscularly in the left thigh at 2 and 4 months of age, Infanrix™ IPV/Hib was administered intramuscularly in the right thigh at 4 months of age. All subjects were boosted with Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
11634045|NCT00322335|Active Comparator|Infanrix hexa/Meningitec Group|Subjects were primed with Infanrix™ hexa co-administered intramuscularly with Meningitec™ in the right and left thigh respectively at 2, 4 and 6 months of age during the primary study (NCT00352963), followed by a booster dose of Infanrix™ hexa intramuscularly in the right thigh between 13 and 14 months of age in study (NCT00323050). No vaccines were administered during this long-term persistence phase of the study.
11634046|NCT00322322|Experimental|1|L-Carnitine
11634047|NCT00322309|Experimental|Mirtazapine|"Mirtazapine administration as follows:
~Days 1-4 15mg of mirtazapine daily Days 5-9 30mg of mirtazapine daily Days 10-78 45mg of mirtazapine daily Days 79-81 30mg of mirtazapine daily Days 82-84 15mg of mirtazapine daily"
11634048|NCT00322309|Placebo Comparator|Placebo- Sugar pill|Matched Placebo given daily days 1-84
11634049|NCT00322283|Experimental|Oglemilast|
11634050|NCT00322283|Placebo Comparator|Placebo|
11634051|NCT00322257|Experimental|A|
11634052|NCT00322257|Active Comparator|B|
11634053|NCT00322231|Experimental|ZOSTAVAX™ / Placebo|Zoster vaccine live on Day 1 (Period 1), placebo on Week 4 (Period 2)
11634054|NCT00322231|Experimental|Placebo / ZOSTAVAX™|Placebo on Day 1 (Period 1), zoster vaccine live on Week 4 (Period 2)
11634055|NCT00322218|Experimental|1|Zevalin Therapeutic Regimen: Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
11634056|NCT00322218|Other|2|Observation
11634057|NCT00322179||Obese|
11634058|NCT00322179||Non-Obese|
11634059|NCT00322166|Active Comparator|Group A, Sunlight|Participants in this arm are required to sit in the sun most days of the week for 15 minutes
11634060|NCT00322166|Active Comparator|Group B, sunlight and calcium|Participants in this group receive sunlight and a calcium supplement
11634061|NCT00322166|No Intervention|Group C|Control group
11634062|NCT00322153|Placebo Comparator|Placebo|Oral administration, once daily.
11634063|NCT00322153|Active Comparator|Memantine ER|28mg, once daily. Oral administration for 24 weeks.
11634064|NCT00322127|Experimental|1|AMD3100 given as a single 240 g/kg dose followed 14-90 days later by a single 320 g/kg dose
11634065|NCT00322127|Experimental|2|AMD3100 given as a single 320 g/kg dose followed 14-90 days later by a single 400 g/kg dose
11634066|NCT00322127|Experimental|3|AMD3100 given as a single 400 g/kg dose followed 14-90 days later by a single 480 g/kg dose.
11634067|NCT00322127|Experimental|4|randomized to either receive 240 g/kg first followed by 480 g/kg after a washout period or 480 g/kg first followed by 240 g/kg after a washout period.
11634071|NCT00322101|Experimental|Arm I (Nonmyeloablative regimen)|"CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0.
~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0.
~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96."
11634072|NCT00322101|Experimental|Arm II (Myeloablative regimen)|"CONDITIONING: Patients are assigned to 1 of 2 treatment groups.
~Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2.
~Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4.
~TRANSPLANTATION: Patients undergo PBSC infusion on day 0.
~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
11634073|NCT00322062|Experimental|1|"1 pack (contains 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets)= 2L NRL994 . 2 sachets (one of each) will be dissolved in 1L of water. Each litre will be drunk within 1 hour. Furthermore, at least 1000ml (or more) of any additional clear fluid (except milk) has to be drunk after the 2L of NRL994."
11634074|NCT00322062|Active Comparator|2|1 pack consists of 2 flasks of 45ml. Each flask has to be dissolved within 125ml of water. Each intake of NaP solution has to be preceded and followed by 250ml (or more if necessary)of clear liquids(excluding milk)and a delay of at least 12 hours between the intake of the 2 x 45ml of NaP solution has to be completed. In addition, 750ml more of clear liquids (excluding milk)or more if needed must be drunk between the 2 intakes.
11634075|NCT00322049|Experimental|Cohort A: Dengue Vaccine- Full Dose (T-DEN F17 )|"Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years;
~DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection. All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection."
11634076|NCT00322049|Active Comparator|Cohort B: Control vaccines|Control vaccines: Hemophilus influenza type b (Hib) vaccine and varicella vaccine
11634077|NCT00322049|Experimental|Cohort C: Dengue Vaccine - 1/10 Dose (T-DEN F17 )|Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years
11634078|NCT00322036|Experimental|1|Oral 800 mg BID dosing
11634079|NCT00322036|Placebo Comparator|2|Oral BID dosing
11634080|NCT00322023|Experimental|D-serine 30 mg/kg|D-serine 30 mg/kg
11634081|NCT00322023|Experimental|D-serine 60 mg/kg|D-serine 60 mg/kg
11634082|NCT00322023|Experimental|D-serine 120 mg/kg|D-serine 120 mg/kg
11634083|NCT00322010|Experimental|Early PT OT|Early PT/OT Therapy assessments to begin on the first day that consent is obtained. Therapy is delivered by a team consisting of a physical and occupational therapist and coordinated with daily sedative interruption.
11634084|NCT00322010|No Intervention|Standard Care|PT/OT delivered as ordered by the primary ICU team
11634085|NCT00321984|Experimental|Dexlansoprazole MR 30 mg QD|
11634086|NCT00321984|Experimental|Dexlansoprazole MR 60 mg QD|
11634087|NCT00321984|Placebo Comparator|Placebo|
11634088|NCT00321971|Experimental|PST-MCI/AD Caregiving|The experimental Intervention (PST-MCI/AD Caregiving) focuses on training in adaptive problem-solving attitudes and skills (Problem-Solving Therapy or PST). It was adapted from a manualized protocol for PST use in primary care. Our adaptation sought to enhance problem-solving skill levels of family caregivers as they began to face a variety of potential caregiving stressor.
11634089|NCT00321971|Active Comparator|NT-MCI/AD Caregiving|"The comparison Intervention (Caregiver Nutritional Training (NT-MCI/AD) was based on the United States Department of Health and Human Services (USDHHS) 2005 My Pyramid Dietary Guidelines for Americans over Age 50. We chose a nutrition-based comparison intervention because information about dietary practices is not likely to affect mental health outcomes. The NT intervention was matched to the PST-based intervention in terms of number and duration of sessions."
11634090|NCT00321932|Active Comparator|Arm I (control)|Patients receive oral cholecalciferol (vitamin D) and oral calcium once a day for 12 months.
11634091|NCT00321932|Experimental|Arm II (treatment)|Patients receive vitamin D and calcium as in arm I. Patients also receive zoledronic acid intravenously (IV) over 15-30 minutes at 28 days prior to stem cell transplantation and at 3 and 6 months after transplantation.
11634092|NCT00321919|Experimental|Early Epoetin Beta Therapy|Participants received immediate epoetin beta therapy starting at 2000 IU, subcutaneously once weekly up to four years to reach a target Hb level of 13-15 g/dL; with an individual Hb increase of at least 2 g/dL within approximately 3 months.
11634093|NCT00321919|Active Comparator|Late Epoetin Beta Therapy|Participants received epoetin beta treatment starting at 2000 IU, subcutaneously once weekly up to four years only when a decline in Hb levels to <10.5 g/dL had occurred in order to reach a target Hb of 10.5-11.5 g/dL.
11634094|NCT00321906|Active Comparator|Azathioprine|(tacrolimus,azathioprine/prednisone)
11634095|NCT00321906|Active Comparator|Sirolimus|tacrolimus/sirolimus/prednisone
11634096|NCT00321893|Experimental|Arm I: Budesonide|Inhaled Budesonide 800 ug twice daily for 1 year
11634097|NCT00321893|Placebo Comparator|Arm II: Placebo|Inhaled placebo twice daily for 1 year
11634098|NCT00321867|Active Comparator|1|Native tissue repair
11634099|NCT00321867|Experimental|2|Posterior repair with graft
11634100|NCT00321854|Experimental|Early Pramipexole|Patients were treated with pramipexole for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
11634101|NCT00321854|Experimental|Delayed Pramipexole|Patients were treated with placebo for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
11634102|NCT00321828|Experimental|Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab|Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab
11634103|NCT00321815|Experimental|A|Standard of Care chemotherapy plus experimental intervention (PF-3512676)
11634104|NCT00321815|Active Comparator|B|Standard of Care chemotherapy
11634151|NCT00321308|Active Comparator|B|Standard of care chemotherapy
11634107|NCT00321789|Experimental|Spouse-assisted intervention|Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse developed a plan to support patient goal achievement.
11634108|NCT00321789|No Intervention|Usual care|Couples assigned to this arm received educational materials at baseline and usual care thereafter, with no contact from the study interventionist.
11634109|NCT00321763|Experimental|GSK1247446A Lot 1 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11634110|NCT00321763|Experimental|GSK1247446A Lot 2 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11634111|NCT00321763|Experimental|GSK1247446A Lot 3 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
11634112|NCT00321763|Experimental|GSK1247446A Pooled Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.
11634113|NCT00321763|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.
11634114|NCT00321737|Experimental|Dexlansoprazole MR 30 mg QD|
11634115|NCT00321737|Experimental|Dexlansoprazole MR 60 mg QD|
11634116|NCT00321737|Placebo Comparator|Placebo|
11634117|NCT00321724|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11634118|NCT00321711|Active Comparator|Dose level 1 500 AMG 531 (Part A - azacitidine)|500 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
11634119|NCT00321711|Active Comparator|Dose level 1 750 AMG 531 (Part B - decitabine)|750 mcg AMG 531 weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
11634120|NCT00321711|Active Comparator|Dose level 2 750 AMG 531 (Part A - azacitidine)|750 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
11634121|NCT00321711|Placebo Comparator|Placebo (Part A - azacitidine)|Placebo weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
11634122|NCT00321711|Placebo Comparator|Placebo (Part B - decitabine)|Placebo weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
11634123|NCT00321698|Experimental|Phase I Dose 1-4|"Group 1=radiation only; Group 2=Docetaxel IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=Docetaxel IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=Docetaxel IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation
~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
11634124|NCT00321698|Experimental|Phase II MTD Dose|"Phase II with no phase I dose-limiting toxicities=Docetaxel IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation
~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
11634125|NCT00321685|Experimental|Treatment (bevacizumab and chemoradiotherapy)|See Detailed Description
11634126|NCT00321672|Experimental|NGX-4010, 60 minutes|
11634127|NCT00321672|Experimental|NGX-4010, 30 minutes|
11634128|NCT00321672|Other|0.04% conc. capsaicin patch, 60 min.|
11634129|NCT00321672|Other|0.04% conc. capsaicin patch, 30 min.|
11634130|NCT00321659|Experimental|Aerobic and flexibility exercise|16 weeks of aerobic and flexibility exercise. Three days per week for 1 hour of walking and cycling.
11634131|NCT00321659|Experimental|Strength, aerobic, and flexibility|16 weeks of strength training, aerobic, and flexibility exercise (ST) intervention;
11634132|NCT00321659|Experimental|Fibromyalgia Self-Help Course|7 weeks of FSHC behavior change education
11634133|NCT00321659|Experimental|a Combination of ST and FSHC|16 wks of a combination of ST and FSHC (ST-FSHC) exercise and behavior change education
11634134|NCT00321646|Experimental|chemotherapy|docetaxel and bevacizumab prior to prostatectomy
11634135|NCT00321620|Active Comparator|zoledronic acid|
11634136|NCT00321620|Experimental|denosumab|
11634137|NCT00321594|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11634138|NCT00321555|Experimental|LMB-2 to Treat Hairy Cell Leukemia|LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
11634139|NCT00321516|Experimental|1|
11634140|NCT00321464|Active Comparator|zoledronic acid|
11634141|NCT00321464|Experimental|denosumab|
11634142|NCT00321451|Experimental|1|
11634143|NCT00321451|Sham Comparator|2|
11634144|NCT00321451|Active Comparator|3|
11634145|NCT00321412|Placebo Comparator|2|Celphere® CP-305, stained to match appearance of AST-120, in 2g sachets
11634146|NCT00321412|Experimental|1|AST-120, 2 gram sachets
11634147|NCT00321373|Experimental|GSK1247446A-AS03 Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11634148|NCT00321373|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11634149|NCT00321373|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
11634150|NCT00321334|Active Comparator|Docetexel|Chemotherapy+Surgery
11634153|NCT00321269|Active Comparator|Single Illness Managment|This intervention includes standard disease self-management coaching for heart failure and helps patients set goals for fluid management, restricted salt-intake, and medication adherence.
11634154|NCT00321269|Experimental|Comorbid Illness Management|This intervention includes the same self-management coaching found in the comparator arm, but also includes discussion of ways to cope and manage mood.
11634155|NCT00321191|Experimental|N2O|
11634156|NCT00321191|Placebo Comparator|No N2O|
11634157|NCT00321178|Experimental|SR4/CR4|after 4 weeks of standard treatment with streptomycin and rifampicin, patients in the experimental arm switch to oral treatment consisting of rifampicin and clarithromycin
11634158|NCT00321178|Active Comparator|SR8|standard treatment consisting of 8 weeks of streptomycin and rifampicin
11634159|NCT00321152|Experimental|1|Deplin/Deplin = participants will receive 7.5 mg/day of Deplin (6(S)-5-MTHF)for the first 4 weeks, and then 15 mg/day of Deplin for the next 4 weeks.
11634160|NCT00321152|Experimental|2|placebo/Deplin = participants will receive placebo for the first 4 weeks, and then 7.5 mg/day of Deplin (6(S)-5-MTHF) for the next 4 weeks.
11634161|NCT00321152|Placebo Comparator|3|placebo/placebo = both tablets of study medication will be placebo during both phases of the study.
11634162|NCT00321113|Active Comparator|1|oral
11634163|NCT00321113|Experimental|2|oral
11634164|NCT00321100|Active Comparator|A|Cetuximab 250mg/m2 IVweekly of each 21 day cycle; Oxaliplatin 130mg/m2 IVday 1 of each 21 day cycle; Capecitabine 850mg/m2 PO days 1-14 of each 21 day cycle; Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
11634165|NCT00321100|Active Comparator|B|Cetuximab 250mg/m2 IV weekly for each 21 day cycle
11634166|NCT00321087|Experimental|1|T2000 dose escalation
11634167|NCT00321087|Experimental|2|Placebo followed by T2000 dose escalation
11634168|NCT00321087|Experimental|3|Placebo followed by T2000 dose escalation
11634169|NCT00321074|Active Comparator|1|
11634170|NCT00321074|Experimental|2|
11634171|NCT00321048|Experimental|ABC (Active Breathing coordinator)|Patients are randomized to ABC arm will receive radiation with ABC. Cardiac perfusion will be assessed at baseline and 6 months after treatment and the difference will be compared to that seen in the No ABC arm.
11634172|NCT00321048|No Intervention|No Active Breathing Coordinator|Patients randomized to the No ABC arm will receive radiation without ABC.Cardiac perfusion will be assessed at baseline and 6 months after treatment and the difference will be compared to that seen in the ABC arm.
11634173|NCT00320814|Experimental|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
11634174|NCT00320801|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h, applied for 7-day wear
11634175|NCT00320801|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h, applied for 7-day wear
11634176|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q4|
11634177|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q12|
11634178|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q4|
11634179|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q12|
11634180|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 4.0mg q12|
11634181|NCT00320775|Experimental|Part A|Part A: An open label study in which six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye. The total volume of each injection will be 100 μL. Enrollment in new dose levels will not begin until all patients in the preceding dose level have completed Visit 5 (Day 15).
11634182|NCT00320775|Active Comparator|Part B|Part B: A controlled, prospective, randomized, double-masked study in which up to 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive a single ITV injection of2.0 mg/eye VEGF Trap (or the MTD if reached prior to 2.0 mg) followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later. Enrollment into Part B will begin 2 weeks after the last subject to receive the 2.0 mg/eye dose in Part A has been observed for 15 days and it has been determined that the safety profile of VEGF Trap at this dose level is adequate to support expansion of dosing at this dose level. The dose of pegaptanib sodium will be 0.3 mg, according to the package insert.
11634183|NCT00320775|Active Comparator|Part C|Part C: A controlled, prospective, randomized, double-masked study in which approximately 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap. Initiation of Part C is contingent upon the 4.0 mg dose being adequately tolerated in Part A.
11634184|NCT00320749|Experimental|capecitabine, docetaxel, gemcitabine|Dose escalation study of mGTX using three dose levels (DL1-3). Patients received docetaxel on days 1 and 8, gemcitabine on days 8 and 15, and capcitabine on days 8 through 21. Gemcitabine fixed dose at 750 mg/m2 over 75 min, capecitabine twice daily and escalated from 500 to 650 mg/m2 at DL2 and docetaxel increased from 30 to 36 mg/m2 at DL3.
11634185|NCT00320710|Experimental|Zoledronic acid every (q) 4 weeks|Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.
11634186|NCT00320710|Experimental|Zoledronic acid q 12 weeks|Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.
11634187|NCT00320710|Experimental|Placebo / zoledronic acid|Participants randomized to this arm received placebo but the arm was later dropped and participants in this arm were swithced to the zoledronic acid q 4 weeks according to a study amendment.
11634188|NCT00320697|Other|Bupropion + Nicotine patch + Nicotine gum or lozenges|Open label phase All enrolled subjects received weekly CBT group sessions, bupropion 300 mg/daily (if medically eligible), nicotine patch 21 mg/day, and up to 20 mg/day of nicotine gum or lozenge for prn use. Subjects set a quit date between weeks 3 and 4; a ½ hour individual CBT session to help prepare them for the quit date. The open phase groups consisted of 8 weekly CBT meetings.
11634226|NCT00320255|Active Comparator|Cohort 1: Apixaban, 20 mg|Participants received apixaban as tablet, 20 mg, once daily
11634455|NCT00317239|Experimental|Ferric Carboxymaltose (FCM)|A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
11634189|NCT00320697|Active Comparator|Bupropion + Nicotine Patch|Randomized phase: Subjects who achieved 2 weeks continuous abstinence at the end of the open intervention and who are medically eligible for bupropion were eligible for the double blind, relapse prevention trial.Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
11634190|NCT00320697|Placebo Comparator|Placebo pill + placebo patch|Randomized phase: Subjects who achieved 2 weeks continuous abstinence at the end of the open intervention and who are medically eligible for bupropion were eligible for the double blind, relapse prevention trial. Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
11634191|NCT00320684||1|Women who have had anorexia nervosa but are now maintaining a healthy weight
11634192|NCT00320684||2|Women who have never had anorexia nervosa and are maintaining a healthy weight
11634193|NCT00320671|Experimental|Participants will take aripiprazole|Participants will take aripiprazole
11634194|NCT00320671|Experimental|Participants will take risperidone|Participants will take risperidone
11634195|NCT00320658|Experimental|A|3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm B.
11634196|NCT00320658|Experimental|B|3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel and CPG7909 given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm A.
11634197|NCT00320658|Experimental|C|3 vaccinations with a dose of 160 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm D after review of the results from Arms A and B.
11634198|NCT00320658|Experimental|D|3 vaccinations with a dose of 160 mcg MSP1 42-C1/Alhydrogel and CPG7909 given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm C after review of the results from Arms A and B.
11634199|NCT00320619|Experimental|1|Participants will receive either EACA.
11634200|NCT00320619|Placebo Comparator|2|Participants will receive placebo.
11634201|NCT00320606|Experimental|Immunosuppression Withdrawal|"Recipients of parental living donor liver transplants 4 or more years prior to trial enrollment, who also had stable allograft function during the preceding 6 months while taking a single immunosuppressive drug were permitted to undergo withdrawal of immunosuppression therapy. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.
~Participants are carefully evaluated/monitored throughout the study by assessments including but not limited to liver biopsy, liver tests and clinic visits, alloantibodies, autoantibodies and quantitative immunoglobulin G test results."
11634202|NCT00320593|Active Comparator|Progressive addition lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
11634203|NCT00320593|Active Comparator|Single vision lenses (SVLs)|Single vision lenses
11634204|NCT00320580|Experimental|001|norelgestromin/ethinyl estradiol
11634205|NCT00320567|Experimental|001|norgestimate/ethinyl estradiol
11634206|NCT00320541|Active Comparator|paclitaxel plus bevacizumab (PB)|paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days
11634207|NCT00320541|Experimental|paclitaxel plus bevacizumab plus gemcitabine (PB+G)|paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by gemcitabine 1500 mg/m2 IV on days 1 and 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days
11634208|NCT00320528|Experimental|Pure ADHD|Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
11634209|NCT00320528|Experimental|ADHD+Internalizing Disorders|Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
11634210|NCT00320528|Experimental|ADHD+Externalizing Disorders|Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
11634211|NCT00320515|Experimental|A|
11634212|NCT00320489|Experimental|Olanzapine Pamoate Depot|Olanzapine pamoate depot
11634213|NCT00320489|Active Comparator|Olanzapine|Oral olanzapine
11634214|NCT00320411|Experimental|Lapatinb|Lapatinib 1500mg QD
11634215|NCT00320385|Experimental|Arm 1: Lapatinib plus Trastuzumab|Lapatinib 1000mg once daily in combination with trastuzumab 4mg/kg loading dose followed by 2mg/kg weekly
11634216|NCT00320385|Experimental|Arm 2: Lapatinib|Lapatinib 1500mg once daily
11634217|NCT00320372||1. 500 VNS Patients|VNS Patients - Treatment-resistant depression patients treated with VNS Therapy.
11634218|NCT00320372||2. 300 Non-VNS Patients|Non-VNS Patients - Treatment-resistant depression patients not receiving VNS Therapy.
11634219|NCT00320359|Active Comparator|Arm A|Cisplatin 75 mg/m2 i.v., day 1, Etoposide 100 mg/m2 i.v., days 1-3
11634220|NCT00320359|Experimental|Arm B|Topotecan 1 mg/ m2, i.v., days 1-5 Cisplatin 75 mg/m2 i.v., days 5
11634221|NCT00320281|Placebo Comparator|placebo|Normal saline injections were used for placebo injections. Injections were based on treatment plan determined in clinical setting by study PI and physical therapist. 25 cc syringe was used and amount of saline injected was unit based on muscles to be injected according to the treatment plan.
11634222|NCT00320281|Active Comparator|Botulinum toxin A|Botulism toxin A dosage was based on plan developed in clinical setting with study PI and physical therapist. Drug was dosed in 25 cc syringe,diluted with normal saline and injections occured based on treatment plan.
11634223|NCT00320255|Placebo Comparator|Cohort 1: Placebo|Participants received placebo tablets once daily
11634224|NCT00320255|Placebo Comparator|Cohort 1: Apixaban, 5 mg|Participants received apixaban as tablet, 5 mg, once daily
11634225|NCT00320255|Active Comparator|Cohort 1: Apixaban, 10 mg|Participants received apixaban as tablet, 10 mg, once daily
11634227|NCT00320255|Placebo Comparator|Cohort 2: Placebo|Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.
11634228|NCT00320255|Active Comparator|Cohort 2: Apixaban, 5 mg|Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.
11634229|NCT00320242|Active Comparator|1 mo baseline|1 mo baseline before visual cue: Cane or walker, no laserlight visual cue x 1 mo; + laserlight visual cue for 2nd mo
11634230|NCT00320242|No Intervention|2 month baseline|Cane or walker, no laserlight visual cue x 2 mo, + laserlight visual cue for 3rd mo
11634231|NCT00320216|Placebo Comparator|Group I (Placebo)|Patients in the placebo group will receive placebo at Weeks 0, 1, 2, 3, and 16. At week 20, all patients will receive a single dose of ustekinumab 90 mg.
11634232|NCT00320216|Experimental|Group II (Ustekinumab 45 mg)|Patients will receive single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.
11634233|NCT00320216|Experimental|Group III (Ustekinumab 90 mg)|Patients will receive 90 mg single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16 patients with PGA greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.
11634234|NCT00320216|Experimental|Group IV|Patients will receive 45 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.
11634235|NCT00320216|Experimental|Group V|Patients will receive 90 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16 patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.
11634236|NCT00320203|Experimental|Anecortave Acetate 3 mg Depot|Single injection, anterior juxtascleral depot (AJD)
11634237|NCT00320203|Experimental|Anecortave Acetate 15 mg Depot|Single injection, anterior juxtascleral depot (AJD)
11634238|NCT00320203|Experimental|Anecortave Acetate 30 mg Depot|Single injection, anterior juxtascleral depot (AJD)
11634239|NCT00320203|Other|Anecortave Acetate Vehicle|Single injection, anterior juxtascleral depot (AJD)
11634240|NCT00320190|Active Comparator|Dasatinib|Participants with chronic phase chronic myeloid leukemia (CML) who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.
11634241|NCT00320190|Active Comparator|Imatinib|Participants with chronic phase CML who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.
11634242|NCT00320164||Group A: Leukapheresis|Subject's peripheral blood mononuclear cells are collected via leukapheresis.
11634243|NCT00320164||Group B: Buffy Coats Collection|Subject's peripheral blood mononuclear cells are collected via the buffy coats from blood.
11634244|NCT00320138|Active Comparator|Acupuncture|
11634245|NCT00320138|No Intervention|Wait List|Usual Care
11634246|NCT00320125|No Intervention|1|Usual diet
11634247|NCT00320125|Active Comparator|2|Orange juice fortified with calcium
11634248|NCT00320125|Active Comparator|3|Dairy products
11634249|NCT00320112|Experimental|Reciprocal Diabetes Peer Support program|peers are paired during the group visit and are encouraged to speak with their partner at least once a week for the 6 month duration of the study.
11634250|NCT00320112|Other|Nurse Case Management|patients are not paired in the NCM arm. they are provided with educational session on diabetes management and informed of case management services.
11634251|NCT00320099|Active Comparator|1|Hydrocortisone and convention glycemic control
11634252|NCT00320099|Experimental|2|Hydrocortisone and fludrocortisone and conventional glucose control
11634253|NCT00320099|Experimental|3|Hydrocortisone and intensive insulin therapy
11634254|NCT00320099|Experimental|4|hydrocortisone, fludrocortisone and intensive insulin therapy
11634255|NCT00320073|Experimental|Arm A|Pemetrexed, Vinflunine, Folate, B12, Dexamethasone, Ondansetron, Midazolam
11634256|NCT00320073|Experimental|Arm B|Vinflunine, Erlotinib, Ondansetron, Midazolam
11634257|NCT00320047|Experimental|1|Participants will take baclofen for 10 weeks.
11634258|NCT00320008|Active Comparator|Standard Treatment Arm|This arm will at any time during the active intervention period follow treatment guidelines by the Danish Medical Association for the treatment of type 2 diabetes.
11634259|NCT00320008|Experimental|Intensive Treatment Arm|This arm will during the active intervention period be treated according to intensified multiple risk factor intervention following strict guidelines set out by the study protocol.
11634260|NCT00319982|Experimental|I- Diltiazem|Diltiazem- study medication
11634261|NCT00319982|Placebo Comparator|II- Placebo|Placebo Comparator
11634262|NCT00319969|Experimental|1|Amrubicin 40mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
11634263|NCT00319969|Active Comparator|2|Topotecan 1.5mg/m<2> IV, days 1, 2, 3, 4, 5 of each 21-day cycle until disease progression.
11634264|NCT00319956|Active Comparator|Azithromycin Group|Group receives azithromycin
11634265|NCT00319956|Placebo Comparator|Placebo Group|Group receives placebo
11634266|NCT00319917|Experimental|1|
11634267|NCT00319917|Placebo Comparator|2|
11634268|NCT00319878|Experimental|1|Participants will be treated with sirolimus and cyclosporine. In phase I, each dose cohort will initially enroll three patients. If no dose-limiting toxicity (DLT) is observed by Day 28 in any patient of a cohort, then 3 patients will be treated with the next highest sirolimus dose. If 1 out of 3 patients in any cohort experiences a DLT, then 3 more patients will be enrolled in that cohort. If no more patients have a DLT by Day 28, then sirolimus dose escalation will proceed. If one or more patients experience a DLT then that dose level will be considered to be the maximum tolerated sirolimus dose, and Phase II patients will be treated at the next lowest level. Cyclosporine will be given as a twice daily oral dose.
11634269|NCT00319852|Experimental|1|
11634270|NCT00319852|Active Comparator|2|
11634304|NCT00319280|Active Comparator|3|Local autograft in the osteotomysite serves as control
11634271|NCT00319839|Experimental|Abraxane plus Cetuximab|Drug: Abraxane-260 mg/m2 IV over 30 minutes every 3 weeks. Drug: Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles.
11634272|NCT00319826||1|Subjects with Staphylococcus Bacteremia
11634273|NCT00319826||2|Healthy (Non-infected) Control Subjects in the Nasal Carriage Group
11634274|NCT00319748|Experimental|Intent-To-Treat|Patients treated with at least one dose - 852A subcutaneous injection.
11634275|NCT00319748|Experimental|Evaluable Cohort|Patients who received all 24 doses of 852A per protocol.
11634276|NCT00319735|Experimental|Investigational Treatment|"Cetuximab 400 mg/m2 IV over 120 minutes Day -14 (Loading Dose)
~Cetuximab 250 mg/m2 IV over 60 minutes Day -7
~Cetuximab 250 mg/m2 IV over 60 minutes Days 1, 8, 15, 22, 29 and 36
~Combined with radiation therapy for six weeks.
~Surgery for esophageal resection after 6 to 8 week rest period.
~Subjects who consent will provide tissue samples."
11634277|NCT00319696|Experimental|Bosentan|Bosentan 62.5 mg tablets b.i.d. for the first 4 weeks followed by bosentan 125 mg b.i.d. thereafter
11634278|NCT00319657|Experimental|Immune tolerance, kidney transplantation|Intervention: Participants will receive hematopoietic cell transplantation and Total lymphoid irradiation. The intervention is intended to induce immune tolerance in HLA-matched living donor kidney transplantation, to allow withdrawal of the immunosuppressive drugs. Immune tolerance is achieved through the development of donor/recipient mixed chimerism following combined kidney and hematopoietic stem cell transplantation from the living donor.
11634279|NCT00319644|Experimental|Minibal Arm|Using Mini bronchoalveolar lavage
11634280|NCT00319644|No Intervention|Tracheal Aspirates|standard of care for ICU.
11634281|NCT00319592|Experimental|ChimeriVax™-JE|Subjects received 2 injections of placebo (normal saline), 1 each on Days 0 and 7, and 1 injection of ChimeriVax™-JE on Day 28.
11634282|NCT00319592|Active Comparator|JE-VAX®|Subjects received 1 injection of JE-VAX® each on Days 0, 7, and 28.
11634283|NCT00319579||Observation|Living Kidney Donors with controls who have not donated a kidney and meet certain criteria at the time of the donor's donation (i.e. no hypertension, no kidney disease, etc.).
11634284|NCT00319553|Experimental|Adacel® Vaccine Group|
11634285|NCT00319553|Active Comparator|BOOSTRIX® Vaccine Group|
11634286|NCT00319527||Observation|Living Kidney Donors with controls who have not donated a kidney or had certain criteria at the time of the donor's donation (i.e. no hypertension, no kidney disease, etc.).
11634287|NCT00319501|Placebo Comparator|Placebo|During the Double-blind Period, participants received a single, age- and weight-appropriate dose of placebo solution as a deep intramuscular injection in the mid to outer thigh. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of acute repetitive seizures (ARS).
11634288|NCT00319501|Experimental|Diazepam|During the Double-blind Period, participants received a single, age- and weight-appropriate dose of diazepam solution, ranging from 0.2 to 0.5 mg/kg, as a deep intramuscular injection in the mid to outer thigh. Additional doses were permissible during the Open-label Period. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of ARS.
11634289|NCT00319488|Active Comparator|1|Active ICS plus placebo LTRA plus albuterol inhalation treatments four times daily
11634290|NCT00319488|Active Comparator|2|Active LTRA plus placebo ICS plus albuterol inhalation treatment four times daily
11634291|NCT00319488|Placebo Comparator|3|Placebo ICS plus placebo LTRA plus albuterol inhalation treatments four times daily
11634292|NCT00319449|Experimental|Ezetimibe 10 mg|Participants treated with 10 mg/day ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.
11634293|NCT00319449|Placebo Comparator|Placebo 10 mg|Participants treated with 10 mg/day matching placebo to ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.
11634294|NCT00319436|Experimental|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
11634295|NCT00319436|Active Comparator|Standard Parent Education for Substance Using Mothers|This 12 session comparison intervention was designed to match the Maternal Mentalizing Therapy on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child care and child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
11634296|NCT00319423|Active Comparator|Patient education|Patient education according to Klassbo et al 2003
11634297|NCT00319423|Experimental|Patient education and supervised exercise|Patient education according to Klassbo et al 2003. Supervised exercise containing strengthening, functional and flexibility exercises.
11634298|NCT00319371||1|women with vasospasm and difficulties of initiating sleep
11634299|NCT00319371||2|women without vasospasm and no difficulties of initiating sleep
11634300|NCT00319358|Active Comparator|Antioxidants|Intervention was done with antioxidants
11634301|NCT00319358|Placebo Comparator|Placebo|
11634302|NCT00319280|Experimental|1|Minced Iliac Crest autograft in osteotomysite
11634303|NCT00319280|Experimental|2|Injectable calcium phosphate cement in osteotomysite
11634305|NCT00319267|Experimental|Bosentan|The initial dose of bosentan was 2 mg/kg b.i.d. for 4 weeks. After 4 weeks, the initial dose was up-titrated to the maintenance dose of 4 mg/kg b.i.d. up to the end of the study treatment at Week 12. If the maintenance dose was not well tolerated, the dose could be down-titrated to the initial dose.
11634306|NCT00319254|Experimental|Advanced breast cancer|
11634307|NCT00319228|Experimental|Antithrombin III|
11634308|NCT00319202|Experimental|1|
11634309|NCT00319202|Placebo Comparator|2|
11634310|NCT00319150|No Intervention|Standard of Care|Epo dose to remain constant throughout study
11634311|NCT00319150|Active Comparator|Dosage Decrease Arm|Arm 2 is to have an decrease of erythropoietin at regular intervals.
11634312|NCT00319124||Case|Patients with hip Osteoarthritis
11634313|NCT00319124||Control|Healthy controls without hip osteoarthritis
11634314|NCT00319111|Experimental|Bosentan|Open label bosentan treatment
11634315|NCT00319098|Experimental|GSK1562902A Group|Male and female subjects aged 18 or over received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm. The group was further stratified by age for analyses.
11634316|NCT00319098|Active Comparator|Fluarix+Placebo Group|Male and female subjects aged 18 or over received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm. The group was further stratified by age for analyses.
11634317|NCT00319046|Experimental|Open-label miglustat|Oral administration of miglustat 100 mg t.i.d. for a period of 2 years
11634318|NCT00319020|Experimental|Bosentan|Bosentan was administered at 4 mg/kg twice daily (b.i.d.) until the end of the study. It could be down-titrated to 2 mg/kg b.i.d. if not well tolerated.
11634319|NCT00318955|Experimental|Dexmedetomidine group|
11634320|NCT00318955|Active Comparator|Propofol group|
11634321|NCT00318942|Active Comparator|1|Crystalloids, any type of Crystalloids including isotonic or hypertonic saline, Ringer Lactates either modified or not
11634322|NCT00318942|Experimental|2|Colloids, including albumin, gelatines, starch any other synthetic colloids
11634323|NCT00318903|Experimental|Taxotere/Irinotecan|Taxotere and Irinotecan is given intravenously for 3 consecutive weeks with a one-week break before radiotherapy for 5-6 weeks. A combination of Taxotere and Irinotecan will then be administered simultaneously with the radiotherapy.
11634324|NCT00318890|Experimental|Docetaxel + cisplatin followed by radiation|Docetaxel with cisplatin is given for three cycles, followed by concomitant therapy with weekly docetaxel for 4 weeks. Radiation therapy is given 5 days each week on Days 64-106 with a concomitant boost in the last 2 weeks of treatment. Amifostine is given as an injection on a daily basis during radiotherapy.
11634325|NCT00318877|Experimental|After school sports|After school team sports
11634326|NCT00318877|Active Comparator|Health and Nutrition Education|Health and Nutrition Education Active Placebo Control
11634327|NCT00318851|Experimental|Carotid Artery Stenting|
11634328|NCT00318838|Placebo Comparator|1|Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
11634329|NCT00318838|Experimental|2|125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
11634330|NCT00318812|Experimental|Heme Iron|Heme Iron Polypeptide 11mg PO tid for 6 months
11634331|NCT00318812|Active Comparator|Venofer|Venofer q month IV x 6 months
11634332|NCT00318799|Experimental|Arm 1|
11634333|NCT00318799|Active Comparator|Arm 2|
11634334|NCT00318760|Experimental|ARM 1|
11634335|NCT00318760|Placebo Comparator|ARM 2|
11634336|NCT00318721|Experimental|Intervention|
11634337|NCT00318721|No Intervention|control|
11634338|NCT00318708|Experimental|clarithromycin + fluticasone|clarithromycin 500 mg twice daily (Biaxin) + fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
11634339|NCT00318708|Active Comparator|placebo + fluticasone|placebo clarithromycin twice daily + fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
11634340|NCT00318695|Experimental|Probiotics|Bifidobacterium longum [BL999] and Lactobacillus rhamnosus [LPR]
11634341|NCT00318695|Placebo Comparator|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
11634342|NCT00318643|Experimental|Cohort 1: MMC plus Chemophase|On Day 1 of Week 1, all participants will receive mitomycin C (MMC) 40 milligrams (mg)/20 milliliter (mL) monotherapy via intravesical administration. In Weeks 2 through 6, participants will receive weekly intravesical administrations of a combination of MMC 40 mg/20 mL and 20,000 Units Chemophase.
11634343|NCT00318643|Experimental|Cohort 2: MMC plus Chemophase|On Day 1 of Week 1, all participants will receive MMC 40 mg/20 mL monotherapy via intravesical administration. In Weeks 2 through 6, participants will receive weekly intravesical administrations of a combination of MMC 40 mg/20 mL and 60,000 Units Chemophase.
11634344|NCT00318643|Experimental|Cohort 3: MMC plus Chemophase|On Day 1 of Week 1, all participants will receive MMC 40 mg/20 mL monotherapy via intravesical administration. In Weeks 2 through 6, participants will receive weekly intravesical administrations of a combination of MMC 40 mg/20 mL and 200,000 Units Chemophase.
11634345|NCT00318643|Experimental|Cohort 4: MMC plus Chemophase|On Day 1 of Week 1, all participants will receive MMC 40 mg/20 mL monotherapy via intravesical administration. In Weeks 2 through 6, participants will receive weekly intravesical administrations of a combination of MMC 40 mg/20 mL and 400,000 Units Chemophase.
11634346|NCT00318643|Experimental|Cohort 5: MMC plus Chemophase|On Day 1 of Week 1, all participants will receive MMC 40 mg/20 mL monotherapy via intravesical administration. In Weeks 2 through 6, participants will receive weekly intravesical administrations of a combination of MMC 40 mg/20 mL and 800,000 Units Chemophase.
11634347|NCT00318630|Experimental|Subjects receiving treatment 1|Eligible subjects will receive rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily administered orally for 28 days followed by placebo oral tablet.
11634348|NCT00318630|Experimental|Subjects receiving treatment 2|Eligible subjects will receive placebo oral tablet followed by rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily for 28 days.
11634349|NCT00318591|Experimental|SpeediCath|hydrophilic-coated intermittent catheter
11634350|NCT00318591|Experimental|Conveen Uncoated|uncoated urinary intermittent catheter
11634353|NCT00318474|Active Comparator|Mycophenolate Mofetil (MMF)|Dose is based on body size (between 25mg/kg/day and 36mg/kg/day with a maximum dose 1gm BID; initial dose to be used in the first 2 weeks of therapy will be approximately 1/2-2/3 of the full dose). Route of administration is oral. Frequency is daily. MMF will be administered up to 12 months.
11634354|NCT00318474|Placebo Comparator|MMF Placebo|Subjects receive MMF placebo.
11634355|NCT00318461|Experimental|Lira 0.6 + Met|Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
11634356|NCT00318461|Experimental|Lira 1.2 + Met|Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
11634357|NCT00318461|Experimental|Lira 1.8 + Met|Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
11634358|NCT00318461|Active Comparator|Met Mono|Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo
11634359|NCT00318461|Active Comparator|Met + Glim|Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo
11634360|NCT00318409|Active Comparator|Bupropion|buproprion XL 300mg daily
11634361|NCT00318409|Placebo Comparator|Placebo|placebo 300mg daily
11634362|NCT00318396|Experimental|Compaction|The bone is pressed very hard together before implantation of femoral component.
11634363|NCT00318396|Active Comparator|Conventional technique|The bone is broached before implantation of femoral component.
11634364|NCT00318383|Experimental|1|200 mcg NicVAX in each of 4 doses
11634365|NCT00318383|Experimental|2|200 mcg NicVAX in each of 5 doses
11634366|NCT00318383|Experimental|3|400 mcg NicVAX in each of 4 doses
11634367|NCT00318383|Experimental|4|400 mcg NicVAX in each of 5 doses
11634368|NCT00318383|Placebo Comparator|5|Placebo in 4 or 5 doses
11634369|NCT00318383|Experimental|6|200 mcg NicVAX formulation 2 in each of 5 doses
11634370|NCT00318370|Experimental|Far Only|Farletuzumab only (Far Only): farletuzumab, 100 milligrams (mg)/square meter (m2).
11634371|NCT00318370|Experimental|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
11634372|NCT00318357||CRT in CARE-HF|"In the CARE-HF study patients treated with standard medical treatment plus CRT were compared to patients treated with standard medical treatment. In the CARE-HF Long Term Follow-up part, all patients received CRT therapy on top of Optimal Medical Treatment. The CARE-HF LTFU study aims to further investigate mortality.
~CARE-HF LTFU study continued ot follow up the original CARE-HF CRT group patients."
11634373|NCT00318357||Control in CARE-HF|"In the CARE-HF study patients treated with standard medical treatment. In the CARE-HF Long Term Follow-up part, almost all patients received CRT therapy on top of Optimal Medical Treatment. The CARE-HF LTFU study aims to further investigate mortality.
~CARE-HF LTFU study continued to follow up the original CARE-HF control group patients."
11634374|NCT00318331|Active Comparator|A|Will receive enteral glutamine
11634375|NCT00318331|No Intervention|B|No enteral glutamine given
11634376|NCT00318292|Experimental|PLA|Active preemptive local analgesia.
11634377|NCT00318292|Placebo Comparator|Placebo|Placebo for preemptive local analgesia.
11634378|NCT00318266||patients with suerficial transitional cell carcinoma|
11634379|NCT00318240|Experimental|1|High Intensity Focused
11634380|NCT00318227|Active Comparator|Liberal Red cell transfusion arm|Transfusion if Hgb <100g/L
11634381|NCT00318227|Active Comparator|Restrictive Red Cell transfusion|Transfusion if Hgb <70g/L
11634382|NCT00318214|Experimental|1|
11634383|NCT00318214|Placebo Comparator|2|
11634384|NCT00318201|Experimental|1|Altered efficacy for drug to drug interaction of diltiazam with erythromycin
11634385|NCT00318188|Experimental|Intervention group|The patients in this group will do a personalized standardized rehabilitation program on the quality of life.
11634386|NCT00318188|No Intervention|Control group|Habitual care
11634387|NCT00318149|Experimental|Fluarix 18-40 Y Group|Subjects (aged 18-40 years [Y]) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
11634388|NCT00318149|Experimental|Fluarix ≥65 Y Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
11634389|NCT00318149|Experimental|Fluarix-AS25 Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.
11634390|NCT00318149|Experimental|Fluarix-AS50 Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.
11634391|NCT00318149|Experimental|Fluarix- AS01B Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.
11634392|NCT00318149|Experimental|Fluarix- AS01E Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.
11634393|NCT00318136|Experimental|Treated with Bevacizumab|
11634394|NCT00318123|Experimental|A|Abacavir 600mg + lamivudine 300mg in on table QD + efavirenz 600mg QD
11634395|NCT00318123|Experimental|B|Abacavir 600mg + lamivudine 300mg in ine tablet QD * lopinavir/ritonavir 400/100 mg BID
11634396|NCT00318110|Experimental|MUD treatment|NST using MUD for metastatic renal cell carcinoma
11634397|NCT00318097||MAS patients|patient with clinical diagnosis of MAS
11634398|NCT00318097||controls|age matched, tanner stage matched controls
11634399|NCT00318071|Experimental|Treatment|Treatment arm patients had at least one Merci Retriever deployed
11634400|NCT00318032|Other|Intensive Treatment|Frequent specialised diabetes clinician contact. DESMOND self-management programme
11634401|NCT00318019|Experimental|OPC Factor(TM)|
11634402|NCT00318019|Placebo Comparator|Placebo|
11634403|NCT00318006|Active Comparator|Spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
11634404|NCT00318006|Experimental|Irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
11634405|NCT00317980|Experimental|Low dose|Meglumine antimoniate 5 mg/kg/d for 20 days
11634406|NCT00317980|Active Comparator|Standard dose|Meglumine antimoniate 15 mg/kg/d for 20 days
11634407|NCT00317967|Experimental|1|Atorvastatin
11634408|NCT00317967|Placebo Comparator|2|Placebo
11634409|NCT00317941|Experimental|IFNB-1b 250 mcg (Betaseron) via Betaject|Interferon beta 1b ([IFNB-1b] Betaseron, BAY86-5046) 250 mcg (8 MIU) administered every other days by subcutaneous injection using Betaject
11634410|NCT00317941|Experimental|IFNB-1b 250 mcg (Betaseron) via Betaject light|Interferon beta 1b ([IFNB-1b] Betaseron, BAY86-5046) 250 mcg (8 MIU) administered every other days by subcutaneous injection using Betaject Light
11634411|NCT00317941|Active Comparator|IFNB-1a 44 mcg (Rebif) via Rebiject II|Interferon beta-1a ([IFNB-1a] Rebif) 44 mcg (12 MIU) three times per week by subcutaneous injection using Rebiject II
11634412|NCT00317889|Experimental|Compaction|Compaction technique for femoral bone preparation prior to cementless femoral stem insertion.
11634413|NCT00317889|Active Comparator|Broaching|Broaching technique for femoral bone preparation prior to cementless femoral stem insertion.
11634414|NCT00317837|Active Comparator|1|Patients treated with a cemented modular hemiarthroplasty, with a unipolar head
11634415|NCT00317837|Active Comparator|2|Patients treated with a modular cemented hemiarthroplasty with a bipolar head.
11634416|NCT00317772|Experimental|Topotecan + Gefitinib|"Phase I: Topotecan: 2.0, 3.0, or 4.0 mg/m^2 by vein Days 1, 8 and 15 of 28 day cycle.
~Gefitinib: 250 mg by mouth daily.
~Phase II: Topotecan starting dose: MTD from Phase I by vein Days 1, 8, and 15 of 28 day cycle.
~Gefitinib: 250 by mouth daily for 28 Days."
11634417|NCT00317746|Placebo Comparator|Placebo|Placebo + PEG-interferon-alfa2b + ribavirin
11634418|NCT00317746|Experimental|Citalopram|Citalopram + PEG-interferon-alpha2b + ribavirin
11634419|NCT00317720|Experimental|Trastuzumab + RAD001|Trastuzumab loading dose is 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle. Starting RAD001 dose 10 mg by mouth daily.
11634420|NCT00317707|Experimental|N-3 PUFA|
11634421|NCT00317707|Placebo Comparator|Olive oil|
11634422|NCT00317694|Experimental|1|
11634423|NCT00317694|Placebo Comparator|2|
11634424|NCT00317642|Experimental|clofarabine (IV formulation) and cytarabine|"Participants received clofarabine (40 mg/m^2) administered as a 1-hour infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour infusion. Participants could receive up to 3 cycles of treatment (induction, re-induction, and consolidation)
~Complete induction cycle = 5 consecutive days of treatment
~Re-induction cycle = 5 consecutive days of treatment at the original or modified dose
~Consolidation cycle = 4 consecutive days of treatment at the original or modified dose"
11634425|NCT00317642|Experimental|placebo and cytarabine|Participants received placebo administered as a 1-hour infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour infusion. Patients could receive up to 3 cycles of treatment (induction, re-induction, and consolidation)
11634426|NCT00317629|Active Comparator|1|
11634427|NCT00317629|Experimental|2|
11634428|NCT00317603|Experimental|Vaccine|"Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately 1x10 7 , 4x10 6 ,
~1x10 6 , or 1x10 5 depending on the final cell yield."
11634429|NCT00317512|Active Comparator|1|Voluven will be administered at 7.7 ml/min over 15 minutes,followed by Voluven at 7.7 ml/min over 15 minutes
11634430|NCT00317512|Active Comparator|2|HBOC-201 will be administered at 7.7 ml/min over 15 minutes,followed by Voluven at 7.7 ml/min over 15 minutes
11634431|NCT00317512|Experimental|3|HBOC-201 will be administered at 7.7 ml/min over 15 minutes,followed by HBOC-201 at 7.7 ml/min over 15 minutes
11634432|NCT00317499|Experimental|Etanercept|
11634433|NCT00317499|Placebo Comparator|Placebo|
11634434|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 10ug|Subject vaccinated with 10 ug of FMP1/AS02A on days 0, 29 and 57
11634435|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 25 ug|Subject vaccinated with 25 ug of FMP1/AS02A on days 14, 42, and 70
11634436|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 50 ug|Subject vaccinated with 50 ug of FMP1/AS02A on days 28, 56 and 84
11634437|NCT00317473|Active Comparator|Imovax Rabies Vaccine|Subject vaccinated with Imovax Rabies Vaccine on corresponding FMP1/AS021 vaccination days
11634438|NCT00317460|Active Comparator|1|Physician Management
11634439|NCT00317460|Experimental|2|Physician Management and counseling (drug counseling and medication adherence)
11634440|NCT00317395|Experimental|Otamixaban Dose 1|dosage regimen 1
11634441|NCT00317395|Experimental|Otamixaban Dose 2|dosage regimen 2
11634442|NCT00317395|Experimental|Otamixaban Dose 3|dosage regimen 3
11634443|NCT00317395|Experimental|Otamixaban Dose 4|dosage regimen 4
11634444|NCT00317395|Experimental|Otamixaban Dose 5|dosage regimen 5
11634445|NCT00317395|Active Comparator|UFH/Eptifibatide|
11634446|NCT00317382|No Intervention|No Ultrasound|Standard LP without ultrasound use
11634447|NCT00317382|Experimental|Ultrasound Use|Ultrasound used to assess spine and best location for lumbar puncture.
11634448|NCT00317304|Experimental|MBSR|
11634449|NCT00317291|Experimental|Acupuncture/Moxibustion|Acupuncture/Moxibustion for Peripheral Neuropathy in HIV
11634450|NCT00317291|Sham Comparator|Sham acupuncture/Placebo moxibustion|Sham acupuncture/Placebo moxibustion for Peripheral Neuropathy in HIV
11634451|NCT00317278|Experimental|A,1|Massage therapy
11634452|NCT00317278|Sham Comparator|A,2|
11634453|NCT00317252|Experimental|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held >= 24 hours pre-cardiac catheterization and restarted post-catheterization after creatinine measurement (48-96 hours post)
11634454|NCT00317252|Other|Continue ACE1 or ARB|Randomized to continue on prescribed ACE1 or ARB
11634694|NCT00313885|Experimental|1|1 mg daily
11634456|NCT00317239|Active Comparator|Ferrous Sulfate tablets|325 mg/TID x 8 weeks
11634457|NCT00317226|Experimental|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
11634458|NCT00317200|Active Comparator|1|Paclitaxel + Devacizumab in patients with chemosensitive relapsed small cell lung cancer.
11634459|NCT00317187|Experimental|Hib-MenAC Lot 1 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 1 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
11634460|NCT00317187|Experimental|Hib-MenAC Lot 2 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 2 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
11634461|NCT00317187|Experimental|Hib-MenAC Lot 3 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 3 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
11634462|NCT00317187|Active Comparator|Hiberix Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB vaccine mixed extemporaneously with conjugate vaccine Hiberix at 2, 4 and 6 months of age as intramuscular injection in the anterolateral part of the thigh.
11634463|NCT00317148|Experimental|Placebo|
11634464|NCT00317148|Experimental|DHEA|
11634465|NCT00317135|Experimental|Hib-MenAC Lot 1 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 1 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
11634466|NCT00317135|Experimental|Hib-MenAC Lot 2 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 2 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
11634467|NCT00317135|Experimental|Hib-MenAC Lot 3 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 3 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
11634468|NCT00317135|Active Comparator|Hiberix Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB vaccine mixed extemporaneously with conjugate vaccine Hiberix at 2, 4 and 6 months of age as intramuscular injection in the anterolateral part of the thigh.
11634469|NCT00317109|Experimental|AC primed Group|
11634470|NCT00317109|Active Comparator|AC unprimed Group|
11634471|NCT00317096|Active Comparator|FCM|"All patients underwent a central randomization procedure. Randomization was done by a Computer program stratified for histology, Response to the preceding chemotherapy, and the number of previous chemotherapies using the method of permutuated blocks.
~The FCM combination comprised:
~25 mg/m2 fludarabine per day iv over 30 minutes, days 1 to 3 200 mg/m2 cyclophosphamide per day as a 4-hour-infusion, days 1 to 3 8 mg/m2 mitoxantrone per day iv over 30 minutes, day 1 4 treatment Cycles á 4 weeks per cycle In patients with peripheral lymphocyte Counts more than 20.000/mm3 and/or a large Tumor mass (ie, bulky disease more than 10 cm) a cytoreductive pre-phase could be performed, comprising cyclophosphamide at a dose of 200 mg/m2 as a 1-hour-infusion over 3 to 5 days."
11634472|NCT00317096|Experimental|R-FCM|"All patients underwent a central randomization procedure. Randomization was done by a Computer program stratified for histology, Response to the preceding chemotherapy, and the number of previous chemotherapies using the method of permutuated blocks.
~The R-FCM combination comprised:
~375 mg/m2 rituximab on the day before the respective FCM course. 25 mg/m2 fludarabine per day iv over 30 minutes, days 1 to 3 200 mg/m2 cyclophosphamide per day as a 4-hour-infusion, days 1 to 3 8 mg/m2 mitoxantrone per day iv over 30 minutes, day 1 4 treatment Cycles á 4 weeks per cycle In patients with peripheral lymphocyte Counts more than 20.000/mm3 and/or a large Tumor mass (ie, bulky disease more than 10 cm) a cytoreductive pre-phase could be performed, comprising cyclophosphamide at a dose of 200 mg/m2 as a 1-hour-infusion over 3 to 5 days."
11634473|NCT00317096|Other|Observation only|"Patients achieving a complete or partial remission after FCM or R-FCM underwent a subsequent randomization for 2 courses of rituximab to be given 3 and 6 months after completion of salvage therapy versus observation only.
~This second randomization was stratified for the type of salvage therapy with FCM or R-FCM, the Response to this Treatment (CR or PR), and histology."
11634474|NCT00317096|Other|rituximab maintenance|"Patients achieving a complete or partial remission after FCM or R-FCM underwent a subsequent randomization for 2 courses of rituximab to be given 3 and 6 months after completion of salvage therapy versus observation only.
~Courses of rituximab consisted of 4 doses of 375 mg/m2 per day given at 4 consecutive weeks.
~This second randomization was stratified for the type of salvage therapy with FCM or R-FCM, the Response to this Treatment (CR or PR), and histology."
11634475|NCT00317070|Active Comparator|DMSO|Intravesical installation
11634476|NCT00317070|Experimental|Cocktail|
11634477|NCT00317044|Experimental|Esomeprazole 40 mg twice daily|
11634478|NCT00317044|Experimental|Esomeprazole 40 mg once daily|
11634479|NCT00317044|Placebo Comparator|Placebo|
11634480|NCT00317031|Active Comparator|1|Acamprosate
11634481|NCT00317031|Active Comparator|2|Naltrexone
11634482|NCT00317031|Placebo Comparator|3|Placebo
11634483|NCT00317018|Other|Arm 1|Implementation Group
11634484|NCT00317018|No Intervention|Arm 2|Control Group
11634485|NCT00316992|Experimental|Ramelteon 8 mg and Placebo|
11634486|NCT00316953|Experimental|Stratum 1 (solid tumors)|Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11634487|NCT00316953|Experimental|Stratum 2 (leukemia)|Patients receive dasatinib as in stratum 1. Cohorts of 3-12 patients receive escalating or de-escalating doses of dasatinib. The MTD is defined as the dose preceding that at which 7 of 12 patients experience DLT.
11634488|NCT00316914|Experimental|Ca/Mg|Patients receive calcium gluconate (Ca) and magnesium sulfate (Mg) IV over 30 minutes immediately before and after each oxaliplatin administration (once every 2 weeks) of their assigned chemotherapy regimen.
11634489|NCT00316914|Placebo Comparator|Placebo|Patients receive a placebo IV over 30 minutes immediately before and after each oxaliplatin administration (once every 2 weeks) of their assigned chemotherapy regimen.
11634490|NCT00316888|Experimental|Arm I (closed to accrual as of 11/3/2008)|Patients receive cisplatin IV over 60 minutes on days 1, 29, 57, and 85 and fluorouracil IV continuously over 96 hours on days 1-4, 29-32, 57-60, and 85-88. Patients also receive cetuximab IV over 120 minutes on day 50 and then IV over 60 minutes on days 57, 64, 71, 78, 85, 92, and 99 and undergo radiotherapy once daily 5 days a week for 5 weeks, beginning on day 57. Treatment continues in the absence of disease progression or unacceptable toxicity.
11634491|NCT00316888|Experimental|Arm II (open to accrual on 8/18/2009)|Patients receive cetuximab IV over 120 minutes on day 1 and then IV over 60 minutes on days 8, 15, 22, 29, 36, 43, and 50. Patients also receive cisplatin IV over 60 minutes on days 1 and 36, fluorouracil IV continuously over 96 hours on days 8-11 and 36-39, and undergo radiotherapy once daily 5 days a week for 5 weeks beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
11634492|NCT00316875|Experimental|Lapatinib Ditosylate and Doxil|
11634493|NCT00316862|Experimental|Treatment (chemotherapy, chemoradiotherapy, surgery)|"INDUCTION CHEMOTHERAPY (COURSES 1-2): Patients receive cisplatin intravenously (IV) over 30 minutes and irinotecan hydrochloride IV over 30-90 minutes on days 1 and 8 of courses 1 and 2. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
~CHEMORADIOTHERAPY (COURSES 3-4): Beginning 2 weeks after completion of induction chemotherapy, patients receive cisplatin and irinotecan hydrochloride as in induction chemotherapy on days 1 and 8 of courses 3 and 4 and undergo radiotherapy daily 5 days a week in course 3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
~SURGERY: Approximately 4-8 weeks after completion of chemoradiotherapy, patients undergo surgery to remove the tumor."
11634494|NCT00316849|Experimental|Treatment (temsirolimus, temozolomide, radiation therapy)|GROUP 1: (temsirolimus with radiation and temozolomide) Patients receive temsirolimus IV over 30 minutes once weekly. Beginning 7-10 days later, patients also receive oral temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients with stable or responding disease proceed to adjuvant therapy. GROUP 2: (radiation and temozolomide) Patients receive oral temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients with stable or responding disease proceed to adjuvant therapy. ADJUVANT THERAPY: Beginning 4-6 weeks after the completion of chemoradiotherapy patients receive oral temozolomide on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11634495|NCT00316836||Group 1|Patients complete a 10-minute questionnaire about factors that might affect changes in breast density at baseline and another questionnaire at 1 year and 2 years post registration. Blood samples are collected at baseline (before initiation of treatment ) and at 1 year post registration for hormone and drug level analysis. Mammograms taken prior to registration (within 12 months prior to enrollment) and at approximately 1 and 2 years post-registration to this study are retrieved and digitized for determination of percent breast density and dense area.
11634496|NCT00316810|Experimental|Campath|"Day 0: Before revascularisation patients are given 500 mg of Methylprednisolone i.v. followed by Campath 30 mg i.v. infusion over 3-6 hours.
~Day 1: No treatment
~Day 2: Initial dose of Tacrolimus 0.05 - 0.1 mg/kg/d orally.
~till Month 6: Aim at blood level of 12-15 ng/ml (try to prevent the Tacrolimus trough level falling below 12 ng/ml in the first 6 months).
~Month 7-12: Maintain the Tacrolimus blood level at 6-12 ng/ml after 6 months."
11634497|NCT00316810|Active Comparator|ATG|"Day 0: Prior to revascularisation patients are given 500 mg of Methylprednisolone i.v. followed by a single shot of a polyclonal antilymphocyte preparation. Tacrolimus will be given immediately after transplantation(0.05-0.1 mg/kg/d) orally. Preoperative loading dose MMF: 2 g orally.
~From Day 1: Total initial daily dose of 0.05-0.1 mg/kg administered orally in 2 doses. Blood trough levels 12-15 ng/ml during the first 6 months and maintain blood levels 6-12 ng/ml after 6 months. Total daily dose of MMF is 2 g administered orally in 2 doses. Patients will receive Methylprednisolone 250 mg IV 12h post surgery and 125 mg of Methylprednisolone 24 h post transplantation.
~Steroid taper (orally):
~Day 2: 100 mg of Prednisolon Day 3: 80 mg of Prednisolon Day 4: 60 mg of Prednisolon Day 5: 40 mg of Prednisolon Day 6: 25 mg of Prednisolon Day 21: 20 mg of Prednisolon
~Reduction by 5 mg in two week intervals/complete withdrawal by 3 months post-tx."
11634498|NCT00316797|Experimental|123-I INER|To assess 123-I INER
11634499|NCT00316771|Experimental|P38 Inhibitor (4) 150mg|
11634500|NCT00316771|Experimental|P38 Inhibitor (4) 25mg|
11634501|NCT00316771|Experimental|P38 Inhibitor (4) 300mg|
11634502|NCT00316771|Experimental|P38 Inhibitor (4) 50mg|
11634503|NCT00316771|Experimental|P38 Inhibitor (4) 75mg|
11634504|NCT00316771|Placebo Comparator|Placebo|
11634505|NCT00316758|Experimental|1|
11634506|NCT00316745|Active Comparator|1|mFOLFOX6 （ → IRIS ( Irinotecan and S-1) ）
11634507|NCT00316745|Experimental|2|IRIS ( Irinotecan and S-1 ) → mFOLFOX6
11634508|NCT00316719|Experimental|Adefovir Dipivoxil (ADV)|
11634509|NCT00316719|Active Comparator|Lamivudine (LAM)|
11634510|NCT00316706|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals' HPV-16/18 Vaccine (Cervarix™) during the primary study (NCT00196924). Subjects from this group continued the long-term follow-up study until Month 48.
11634511|NCT00316706|Active Comparator|Havrix Group|Subjects received 3 doses of Havrix™ (hepatitis A vaccine [HAV]) during the primary study (NCT00196924). Subjects from the this group completed the study at Month 24.
11634512|NCT00316693|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.
11634513|NCT00316693|Active Comparator|Aimmugen Group|Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.
11634695|NCT00313885|Experimental|2|5 mg daily
11634514|NCT00316602|Experimental|Healthy Participants|Healthy, vaccinia naive subjects without Atopic Dermatitis, receiving two doses of MVA-BN (IMVAMUNE)
11634515|NCT00316602|Experimental|Atopic Dermatitis Participants|"Vaccinia naive subjects with diagnosed Atopic Dermatitis. Diagnosed AD included subjects with either history of or subjects with currently active AD (defined as scoring AD [SCORAD] <= 30), receiving two doses of MVA-BN (IMVAMUNE)"
11634516|NCT00316589|Experimental|Healthy subjects|Control group with and without a history of previous smallpox vaccination IMVAMUNE (MVA-BN)
11634517|NCT00316589|Experimental|HIV-infected, vaccinia-naive|Subjects without a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)
11634518|NCT00316589|Experimental|HIV-infected, vaccinia-experienced|Subjects with a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)
11634519|NCT00316563|Active Comparator|1|
11634520|NCT00316563|Placebo Comparator|2|
11634521|NCT00316524|Experimental|GP 1: two x 1x10E08 TCID, MVA-BN® s.c., vaccinia naive|vaccinia naive subjects receiving two subcutanenous vaccinations with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID)
11634522|NCT00316524|Experimental|GP 2: 1x10E08 TCID, MVA-BN®, 1x Placebo, s.c., vaccinia naive|vaccinica naive subjects receiving one vaccination with 0.5ml MVA-BN® IMVAMUNE(1x10E08 TCID), followed by one vaccination Placebo (0.5ml Tris Buffer)
11634523|NCT00316524|Placebo Comparator|GP 3: two x Placebo, s.c., vaccinia naive|vaccinia naive subjects, receiving two subcutaneous vaccinations with Placebo (0.5ml Tris Buffer).
11634524|NCT00316524|Experimental|GP 4: 1x10E08 TCID, MVA-BN®, s.c., vaccinia experienced|vaccinia experienced subjects, receiving one subcutaneous vaccination with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID).
11634525|NCT00316355|Active Comparator|Traditional CBT|Cognitive-behavioral therapy (CBT) that incorporates exposure with ritual prevention (EX/RP)
11634526|NCT00316355|Experimental|Stepped-Care CBT|Stepped-care CBT
11634527|NCT00316316|Active Comparator|1|Participants will receive motivational interviewing plus exposure and response prevention
11634528|NCT00316316|Active Comparator|2|Participants will receive exposure and response prevention only
11634529|NCT00316303|Experimental|1|Participants will receive screening, testing, immunization, and risk reduction. Screening and testing will take place at study entry, immunization will occur at entry and after 3 and 6 months, and risk reduction will take place at study entry and after 3 and 6 months.
11634530|NCT00316303|Placebo Comparator|2|Participants will receive enhanced treatment as usual.
11634531|NCT00316290|Experimental|1|Participants will receive integrated parent training.
11634532|NCT00316290|Active Comparator|2|Parents will receive behavioral parent training.
11634533|NCT00316277|Experimental|Buprenorphine/Nx with EMM|
11634534|NCT00316277|Active Comparator|Buprenorphine/Nx with SMM|
11634535|NCT00316264|Experimental|Motavizumab followed by Palivizumab|2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)
11634536|NCT00316264|Experimental|Palivizumab followed by motavizumab|2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)
11634537|NCT00316264|Experimental|Motavizumab control|5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)
11634538|NCT00316225|Experimental|Pemetrexed|Pemetrexed 500 mg/m^2 intravenous (IV) every 21 days for 6 cycles
11634539|NCT00316199|Experimental|A|
11634540|NCT00316186|Experimental|Single arm, open label|
11634541|NCT00316173|Experimental|Single-arm|HYCAMTIN at a dose of 2.0 - 2.5mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1, every 21 days
11634542|NCT00316134||Pts scheduled to remove pleural fluid|
11634543|NCT00316121|Experimental|1|
11634544|NCT00316121|Active Comparator|2|
11634545|NCT00316108|Experimental|Arm 1|
11634546|NCT00316082|Experimental|Saxagliptin 2.5 mg QAM (A)|PLUS open-label metformin (as needed as rescue medication)
11634547|NCT00316082|Experimental|Saxagliptin 2.5 mg titrated to 5 mg QAM (B)|PLUS open-label metformin (as needed as rescue medication)
11634548|NCT00316082|Experimental|Saxagliptin 5 mg QAM (C)|PLUS open-label metformin (as needed as rescue medication)
11634549|NCT00316082|Experimental|Saxagliptin 5 mg QPM (D)|PLUS open-label metformin (as needed as rescue medication)
11634550|NCT00316082|Placebo Comparator|Placebo (E)|PLUS open-label metformin (as needed as rescue medication)
11634551|NCT00316017|Experimental|1|7.5% hypertonic saline/6% Dextran-70 (HSD)
11634552|NCT00316017|Experimental|2|7.5% hypertonic saline (HS)
11634553|NCT00316017|Placebo Comparator|3|0.9% normal saline
11634554|NCT00316004|Experimental|7.5% hypertonic saline/6% dextran (HSD)|250 ml intravenous bolus administration of 7.5% saline/6% dextran 70
11634555|NCT00316004|Experimental|7.5% hypertonic saline (HS)|250 ml intravenous bolus administration of 7.5% hypertonic saline
11634556|NCT00316004|Placebo Comparator|0.9% normal saline (NS)|250 ml intravenous bolus administration of 0.9% saline
11634557|NCT00315991|Experimental|BGAT Intervention|Blood Glucose Awareness Training for Parents
11634558|NCT00315991|No Intervention|Control|Enter PDA data and complete questionnaires only. No intervention received.
11634559|NCT00315939|Experimental|Group A Order: SMBG, IBMF-1, IBMF-2|Group A performed routine self-monitored blood glucose (SMBG) alone (level 1), followed sequentially by Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1) level 2 and Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2) level 3. Each level continued for 3 months.
11634560|NCT00315939|Experimental|Group B Order: IBMF-1, IBMF-2, SMBG|Group B began with Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1) level 2, followed by level 3, Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2) and then level 1 (SMBG only). Each level continued for 3 months.
11634561|NCT00315926|Experimental|Melatonin|
11634562|NCT00315926|Placebo Comparator|Placebo|
11634563|NCT00315913|Experimental|IV Propranolol|IV dose propranolol
11634564|NCT00315913|Placebo Comparator|IV Placebo|IV Placebo of saline solution equal to propranolol in volume
11634565|NCT00315900|Experimental|Depakote ER|Depakote ER
11634566|NCT00315900|Active Comparator|Seroquel|Seroquel
11634696|NCT00313885|Placebo Comparator|3|
11634567|NCT00315822|Placebo Comparator|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
11634568|NCT00315822|Active Comparator|80% oxygen|Subject undergoing surgery will receive supplemental oxygen
11634569|NCT00315757|Active Comparator|A|Bortezomib
11634570|NCT00315757|Experimental|B-10|Bortezomib and Mapatumumab 10 mg/kg
11634571|NCT00315757|Experimental|B-20|Bortezomib and Mapatumumab 20 mg/kg
11634572|NCT00315744|Experimental|Subjects receiving salmeterol/fluticasone|Eligible subjects will receive 60 individual doses of the salmeterol 50 microgram/ fluticasone 100 microgram combination. Subjects will also receive placebo.
11634573|NCT00315744|Active Comparator|Subjects receiving fluticasone|Eligible subjects will receive 60 individual fluticasone 100 microgram doses each.
11634574|NCT00315731|Experimental|tositumomab and iodine I 131 tositumomab|Subjects participating in this study will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I-131 tositumomab, immediately following an infusion of 450 mg of unlabeled tositumomab. Using the dosimetric data from three of the six imaging time points and the subject's weight, a patient-specific activity (mCi) of Iodine I-131 will be calculated to deliver the desired total body dose of radiation (75 cGy). All subjects will then receive an infusion of unlabeled tositumomab (450 mg) immediately followed by an infusion of the subject specific dose of tellurium-derived Iodine I-131 tositumomab (35 mg) to deliver a total body dose (TBD) of 75 cGy.
11634575|NCT00315705|Experimental|clofarabine, etoposide, cyclophosphamide|"Phase 1: escalating dosage of the three drugs delivered intravenously. Clofarabine dosage from 20-40 mg/m^2, etoposide dosage from 75-100 mg/m^2, cyclophosphamide dosage from 340-440 mg/m^2.
~Phase 2: The recommended phase 2 doses (RP2D) were clofarabine 40 mg/m^2, etoposide 100 mg/m^2 and cyclophosphamide 440 mg/m^2 delivered intravenously"
11634576|NCT00315692||Premenopausal women|
11634577|NCT00315692||Postmenopausal women|
11634578|NCT00315640|Experimental|Anecortave Acetate 3 mg Depot|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
11634579|NCT00315640|Experimental|Anecortave Acetate 15 mg Depot|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
11634580|NCT00315640|Experimental|Anecortave Acetate 30 mg Depot|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
11634581|NCT00315640|Other|Anecortave Acetate Vehicle|
11634582|NCT00315627|Experimental|islet transplantation|Islet Alone Transplantation under Alentuzumab (Campath1H) induction.
11634583|NCT00315614|Experimental|Islet Transplantation and Bone Marrow|Administration of islets and infusion of CD34 enriched Bone Marrow cells in subjects with type 1 diabetes, impaired awareness of hypoglycemia and severe hypoglycemia.
11634584|NCT00315588|Experimental|Islet Transplantation|Islet Transplantation in subjects with a previous kidney transplant.
11634585|NCT00315575||1|Individuals with high risk for Alzheimer's disease
11634586|NCT00315575||2|Individuals with low risk for Alzheimer's disease
11634587|NCT00315562|Experimental|Early|Early
11634588|NCT00315562|Active Comparator|Delayed|Delayed
11634589|NCT00315458|Experimental|BTDS|Buprenorphine transdermal patches 10 or 20 mcg/h
11634590|NCT00315458|Placebo Comparator|Placebo|Placebo to match buprenorphine transdermal patch 10 or 20
11634591|NCT00315445|Placebo Comparator|Placebo|Placebo oxycodone (OXY)/acetaminophen (APAP) tablets and placebo transdermal patch (TDS) 5, 10, or 20
11634592|NCT00315445|Active Comparator|OXY/APAP|5 mg oxycodone/325 mg acetaminophen tablets
11634593|NCT00315445|Experimental|BTDS|Buprenorphine transdermal patch 5, 10, or 20 mcg/hour
11634594|NCT00315354|Experimental|1|Low glycemic index diet
11634595|NCT00315354|Active Comparator|2|Low fat diet
11634596|NCT00315354|Active Comparator|3|Very low carbohydrate diet
11634597|NCT00315341|Experimental|Buprenorphine/Nx|For the BUP/NX group, all participants will receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg buprenorphine increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.
11634598|NCT00315341|Active Comparator|Methadone|For the MET group, all participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.
11634599|NCT00315328|Active Comparator|Patching|Patching 2 hours per day plus near activities for one hour while patching (with increase to 4 hours per day for moderate amblyopes and >4 hours per day for severe amblyopes at 5 weeks if acuity not improved at least 5 letters)
11634600|NCT00315328|Active Comparator|Atropine|Atropine 1% once each weekend day in the sound eye plus near activities for at least one hour every day (with increase to daily atropine at 5 weeks if acuity not improved by at least 5 letters)
11634601|NCT00315302|Active Comparator|Atropine|Atropine 1% once each weekend day in the sound eye
11634602|NCT00315302|Active Comparator|Atropine plus plano|Atropine 1% once each weekend day in the sound eye plus a plano lens for the sound eye
11634603|NCT00315250|Experimental|[123I]β-CIT|To assess B-CIT and SPECT imaging
11634604|NCT00315237|Experimental|1|
11634605|NCT00315237|No Intervention|2|best supportive care for 18 week duration
11634606|NCT00315211|Other|Arm A|Weekly intravenous topotecan with intravenous docetaxel
11634607|NCT00315198|Active Comparator|Near activities|2 hours of daily patching combined with near visual activities while patching
11634608|NCT00315198|Active Comparator|Distance activities|2 hours of daily patching combined with distance visual activities while patching
11634609|NCT00315159|No Intervention|No intervention|Patients with negative SLN will be followed on no intervention arm
11634610|NCT00315146|Placebo Comparator|Hypocaloric diet (and placebo)|
11634611|NCT00315146|Active Comparator|Hypocaloric diet, resist. training to maximize power, placebo|
11634697|NCT00313872|Experimental|FOLFIRI|
11634612|NCT00315146|Active Comparator|Hypocaloric diet and a PPAR- γ agonist (pioglitazone/Actos™)|
11634613|NCT00315146|Active Comparator|Hypocaloric diet,resistance training, pioglitazone/Actos™|
11634614|NCT00315133|Experimental|Transplant arm|This is a single arm study. The intervention is immunosuppression and autologous stem cell transplantation.
11634615|NCT00315120|Other|A (Active OMT and active (UST)|Subjects in this group received active osteopathic manipulation and active ultrasound physical therapy
11634616|NCT00315120|Other|B (Sham OMT and active UST)|Subjects in this group received sham osteopathic manipulation and active ultrasound physical therapy
11634617|NCT00315120|Other|C (Active OMT and sham UST)|Subjects in this group received active osteopathic manipulation and sham ultrasound physical therapy
11634618|NCT00315120|Other|D (Sham OMT and sham UST)|Subjects in this group received sham osteopathic manipulation and sham ultrasound physical therapy
11634619|NCT00315094|Experimental|1|
11634620|NCT00315094|No Intervention|2|After a control period, this group crosses over to experimental interventions (Arm 1)
11634621|NCT00315055|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|Participants will receive 3 vaccinations with Diphtheria (D) and tetanus (T) toxoids, acellular pertussis (2-component) (aP), recombinant Hepatitis B surface antigen (HBsAg), inactivated poliomyelitis virus (IPV), and Hemophilus influenzae type b (Hib) polysaccharide conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T); One dose each at 2, 3, and 4 months of age.
11634622|NCT00315055|Active Comparator|Group 2: PENTAXIM™ and ENGERIX B® PEDIATRIC|Participants will receive 3 vaccinations with DTaP-IPV-PRP~T (PENTAXIM™ ) and recombinant Hepatitis B (ENGERIX® PEDIATRIC) vaccines. One dose each at 2, 3, and 4 months of age.
11634623|NCT00315029|Experimental|1|Receives combined patient centred intervention
11634624|NCT00315029|No Intervention|2|Standard treatment
11634625|NCT00315016|Placebo Comparator|1|placebo (double dummy)
11634626|NCT00315016|Active Comparator|2|eplerenone
11634627|NCT00315016|Active Comparator|3|doubling of fosinopril dose
11634628|NCT00314977|Experimental|A|Cycles 1-4 q 3 weeks: doxorubicin plus cyclophosphamide Cycles 5-8 q 3 weeks: docetaxel
11634629|NCT00314977|Experimental|B|Cycles 1-6 q 3 weeks: doxorubicin, cyclophosphamide and docetaxel
11634630|NCT00314951|Experimental|fidaxomicin|Participants receiving fidaxomicin 200 mg capsules orally two times daily (every 12 hours [q12h] regimen) with intermittent matching placebo to fidaxomicin
11634631|NCT00314951|Active Comparator|Vancomycin|Participants receiving vancomycin 125 mg capsules orally four times daily (every 6 hours [q6h] regimen).
11634632|NCT00314925|Experimental|1|
11634633|NCT00314847|No Intervention|Control|IABP, inotropic drugs, antiplatelet agents according to site habits.
11634634|NCT00314847|Experimental|Experimental|ECLS +/- IABP, inotropic drugs, antiplatelet agents according to site habits.
11634635|NCT00314808|Experimental|Dronabinol|
11634636|NCT00314795|Experimental|Peginesatide|"Peginesatide 0.05 mg/kg injection, subcutaneously as a starting dose followed by peginesatide 0.1 mg/kg injection, subcutaneously once every 4 weeks for up to 6 months.
~Individual dose of peginesatide injection was modified based on hemoglobin levels. Dose adjustments were made in order to achieve and maintain hemoglobin in the target range of 10.0-12.0 g/dL."
11634637|NCT00314782|Experimental|Part A|Part A (dose-finding): ZD4054 (Zibotentan) 10 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
11634638|NCT00314782|Experimental|Part A (ZD4054 (Zibotentan) 15 mg + docetaxel)|Part A (dose-finding): ZD4054 (Zibotentan) 15 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
11634639|NCT00314782|Experimental|Part B|Part B (randomised, placebo-controlled): ZD4054 (Zibotentan) Maximum Tolerated Dose (MTD), 15mg, oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
11634640|NCT00314782|Experimental|Part B (placebo)|Part B (randomised, placebo-controlled): Matching placebo oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
11634641|NCT00314743|Active Comparator|Control (No aprepitant)|"Regimen #1 (BEAM; NHL and HL)
~Carmustine 300 mg/m2 IV on day -7 (premedicate with ondansetron 32 mg IV and dexamethasone 20 mg IV)
~Etoposide 100 mg/m2 IV Q 12 hours x 8 doses on days -6 to -3 (premedicate first daily dose ondansetron 32 mg IV and dexamethasone 20 mg IV)
~Cytarabine 100 mg/m2 IV Q 12 hours x 8 doses on days -6 and -3 (no additional premedication)
~Melphalan 140 mg/m2 IV on day -2 (premedicate with ondansetron 32 mg IV and dexamethasone 20 mg IV)
~Regimen #2 (MM and Amyloidosis)
~Melphalan 100 mg/m2 IV on days -3 and -2 (premedicate each dose with ondansetron 32 mg IV and dexamethasone 20 mg IV)"
11634642|NCT00314743|Experimental|Experimental (with aprepitant)|"Aprepitant 125 mg PO will be given 30 minutes prior to the first dose of chemotherapy followed by Aprepitant 80 mg PO QD for the remainder of chemotherapy and continuing for a total of 2 days after completing the regimen.
~Regimen #1 (BEAM; NHL and HL)
~Carmustine 300 mg/m2 IV on day -7 (premedicate with ondansetron 32 mg IV and dexamethasone 10 mg IV)
~Etoposide 100 mg/m2 IV Q 12 hours x 8 doses on days -6 to -3 (premedicate first daily dose ondansetron 32 mg IV and dexamethasone 10 mg IV)
~Cytarabine 100 mg/m2 IV Q 12 hours x 8 doses on days -6 and -3 (no additional premedication)
~Melphalan 140 mg/m2 IV on day -2 (premedicate with ondansetron 32 mg IV and dexamethasone 10 mg IV)
~Regimen #2 (MM and Amyloidosis)
~Melphalan 100 mg/m2 IV on days -3 and -2 (premedicate each dose with ondansetron 32 mg IV and dexamethasone 10 mg IV)"
11634643|NCT00314626|Experimental|A|abacavir 600 mg + lamivudine (3TC) 300 mg in 1 tablet + efavirenz 600 mg 1/24h
11634644|NCT00314626|No Intervention|B|efavirenz + 2 NUCS
11634645|NCT00314574|Experimental|Xolair|"The subcutaneous dose of Xolair administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.
~Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.
~Participants were permitted to use albuterol as rescue medicine throughout the study."
11634698|NCT00313872|Experimental|DP|"D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr, D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr
~D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan"
11634699|NCT00313846|Experimental|BTDS|Buprenorphine transdermal patch 5, 10 or 20 micrograms/hour (mcg/h)
11634646|NCT00314574|Placebo Comparator|placebo|"The subcutaneous dose of placebo administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.
~Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.
~Participants were permitted to use albuterol as rescue medicine throughout the study."
11634647|NCT00314548|Experimental|Cases|PGE1 drug
11634648|NCT00314548|Placebo Comparator|Placebo|normal saline via same nebulizer
11634649|NCT00314366|Active Comparator|Stem Cell Therapy|Subjects are randomized to receive Stem Cell Therapy (treatment) at the time of enrollment where cells are delivered after NOGA mapping and cells injected with the Myostar catheter.
11634650|NCT00314366|Placebo Comparator|Control|"Placebo patients will receive injections of plasma (control) instead of stem cells. Placebo patients are able to crossover and receive active treatment at 6 months if they meet the criteria.
~At 6 months, subject is offered stem cell therapy and then followed for 12 months."
11634651|NCT00314353|Experimental|1|
11634652|NCT00314353|Experimental|2|
11634653|NCT00314340|Active Comparator|extended-release morphine|"Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity
~On one of three study dates, subjects received ER morphine tablets, 45 mg (Mallinckrodt Pharmaceuticals, St. Louis, MO). The dose of ER morphine sulfate (45 mg) was selected because of its approximate equianalgesic effect to the dose of hydrocodone-acetaminophen (30/925 mg)."
11634654|NCT00314340|Active Comparator|hydrocodone|"Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity
~On the day of the study session, patients received hydrocodone 30 mg plus N-acetyl-para-aminophenol 975 mg (APAP;Qualitest Pharmaceuticals Inc, Huntsville, AL)."
11634655|NCT00314340|Placebo Comparator|placebo|Subjects received a placebo pill if randomized to this arm. Both opioid medications and the placebo were administered in identical capsules.
11634656|NCT00314327|Experimental|long-acting injectable risperidone|One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.
11634657|NCT00314314|Experimental|1|
11634658|NCT00314314|Placebo Comparator|2|
11634659|NCT00314275|Experimental|ENDEAVOR|Drug Eluting Stent
11634660|NCT00314262|Experimental|Erlotinib & Celecoxib|
11634661|NCT00314249|Placebo Comparator|Placebo|Placebo, oral administration, twice daily for 12 weeks
11634662|NCT00314249|Experimental|Milnacipran|Milnacipran 100mg/day (50mg BID [twice a day])
11634663|NCT00314236|Experimental|Microfracture with BST-CarGel|BST-CarGel applied to a Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle
11634664|NCT00314236|Active Comparator|Microfracture without BST-CarGel|Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle
11634665|NCT00314171|Experimental|Brinzolamide + Timolol|
11634666|NCT00314171|Active Comparator|Dorzolamide + Timolol|
11634667|NCT00314158|Experimental|Brinzolamide +Timolol|
11634668|NCT00314158|Active Comparator|Brinzolamide|
11634669|NCT00314158|Active Comparator|Timolol|
11634670|NCT00314145|Experimental|ChimeriVax™-JE|Participants received dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine and saline placebo into different arms.
11634671|NCT00314145|Active Comparator|JE-VAX®|Participants received 1 dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a dose of saline placebo into a different arm on Day 30.
11634672|NCT00314132|Placebo Comparator|Placebo|All subjects received a single injection of placebo on Day 0.
11634673|NCT00314132|Experimental|ChimeriVax™ JE 4 log10 PFU Vaccine|All participants received a single injection of ChimeriVax™ JE 4 log10 Plaque-forming unit (PFU) Vaccine on Day 0.
11634674|NCT00314119||1|Men and women between 20 and 50 years of age diagnosed with NF1 and their biological parents are eligible for this study.
11634675|NCT00314106|Experimental|TBI 1200 cGy + TIL +HD IL-2, prior IL-2|Patients that received prior interleukin 2 (IL-2) therapy will receive a myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x 2 days intravenous (IV)), fludarabine (25mg/m^2/day IV X 5 days) and 1200 cGy total body irradiation (TBI). Following the lymphodepleting regimen, patient will receive intravenous adoptive transfer of tumor reactive lymphocytes (minimum 3 X 10 (9) and up to a maximum of 3 X 10(11) lymphocytes) followed by high-dose intravenous (IV) IL-2 (720,000 IU/kg/dose every 8 hours for up to 15 doses).
11634676|NCT00314106|Experimental|TBI 1200 cGy + TIL +HD IL-2, no prior IL-2|Patients that have not received prior interleukin 2 (IL-2) therapy will receive a myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x 2 days intravenous (IV)), fludarabine (25mg/m^2/day IV X 5 days) and 1200 cGy total body irradiation (TBI). Following the lymphodepleting regimen, patient will receive intravenous adoptive transfer of tumor reactive lymphocytes (minimum 3 X 10 (9) and up to a maximum of 3 X 10(11) lymphocytes) followed by high-dose intravenous (IV) IL-2 (720,000 IU/kg/dose every 8 hours for up to 15 doses)
11634677|NCT00314067|Experimental|1|
11634678|NCT00314067|Experimental|2|
11634679|NCT00314067|Active Comparator|3|
11634680|NCT00314054|Experimental|1|HCV-796 1000mg single dose
11634681|NCT00314028|Active Comparator|1|Standard of care treatment
11634682|NCT00314028|Experimental|2|Educational program designed to motivate and provide information on the correct use of condoms
11634683|NCT00314015|Experimental|Patients with immediately loaded implants.|
11634684|NCT00313989|Experimental|Evaluation of implants of patients receiving radiotherapy.|
11634685|NCT00313976|Experimental|Arm 1|
11634686|NCT00313976|Experimental|Arm 2|
11634687|NCT00313963|Experimental|1|
11634688|NCT00313963|Placebo Comparator|2|
11634689|NCT00313950|Experimental|Group 1|
11634690|NCT00313950|Experimental|Group 2|
11634691|NCT00313950|Experimental|Group 3|
11634692|NCT00313911|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|
11634693|NCT00313911|Active Comparator|Group 2: Tritanrix-Hep B/Hib™+OPV|
11634700|NCT00313846|Placebo Comparator|Placebo|Placebo to match BTDS 5, 10 or 20 mcg/h
11634701|NCT00313820|Active Comparator|Pregabalin|The change from in pain scores from baseline to endpoint among stroke subjects receiving pregabalin will be compared to change in pain scores from baseline to endpoint among stroke subjects receiving matched placebo.
11634702|NCT00313820|Placebo Comparator|Placebo|The change in pain scores from baseline to endpoint will be compared among the two treatment groups- ie subjects receiving 12 weeks of pregabalin treatment vs subjects receiving 12 weeks of placebo treatment.
11634703|NCT00313807|Active Comparator|1|Intravenous saline infusion plus amino acid infusion
11634704|NCT00313807|Placebo Comparator|2|Intravenous saline infusion plus placebo infusion
11634705|NCT00313794|Experimental|1|single arm
11634706|NCT00313781|Experimental|A|For patients treated with docetaxel and prednisone only, who progress during treatment, CP-751,871 will be added to the regimen to test reversibility of chemoresistance.
11634707|NCT00313781|Active Comparator|B|
11634708|NCT00313768|Active Comparator|B|Standard of care chemotherapy
11634709|NCT00313768|Experimental|A|Standard of care chemotherapy plus experimental intervention (PF-3512676)
11634710|NCT00313729|Experimental|Temozolomide|Temozolomide
11634711|NCT00313716|Active Comparator|Epo1 and TT10|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, at 24 and 48 hrs after injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger of 10gm/dl
11634712|NCT00313716|Active Comparator|Epo1 and TT7|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, at 24 and 48 hrs after injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 7gm/dl
11634713|NCT00313716|Active Comparator|Epo2 and TT10|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 10gm/dl
11634714|NCT00313716|Active Comparator|Epo2 and TT7|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 7gm/dl
11634715|NCT00313716|Placebo Comparator|Placebo and TT10|Placebo administration and transfusion threshold 10 gm/dl
11634716|NCT00313716|Placebo Comparator|Placebo and TT7|Placebo administration and transfusion threshold 7 gm/dl
11634717|NCT00313612|Experimental|Treatment (oxaliplatin plus topotecan)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.
11634718|NCT00313599|Experimental|Lapatinib and Paclitaxel|Lapatinib will be self-administered orally on days 1 and 2 of weeks 1, 2, and 3 of a 4-week cycle. Lapatinib is the experimental therapy and is being administered using a dose escalation design guided by careful monitoring of toxicities. Abraxane will be administered IV weekly on day 3 of weeks 1, 2, and 3 of a 4-week cycle. Abraxane is being administered at the well tolerated and effective standard dose and schedule of 100mg/m2 weekly 3 out of 4 weeks as defined by previous phase I and II studies. Patients will continue on therapy as long as they are not experiencing toxicities and there is no evidence of disease progression.
11634719|NCT00313586|Experimental|Arm A (azacitidine)|Patients receive azacitidine SC QD on days 1-10. Treatment repeats every 28 days for 6-24 courses in the absence of disease progression or unacceptable toxicity.
11634720|NCT00313586|Experimental|Arm B (azacitidine, entinostat)|Patients receive azacitidine as in Arm A and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 6-24 courses in the absence of disease progression or unacceptable toxicity.
11634721|NCT00313560|Experimental|Erlotinib and EBRT after pancreatectomy|"Adjuvant treatment with erlotinib 100 mg plus Capecitabine 800 mg/m2 PO BID (5 days on/ 2 days off regimen) and External Beam Radiation Therapy (EBRT) at doses of 50.4 Gy in 28 fractions after pancreatectomy (Dosing for capecitabine and erlotinib was amended after considering the toxicity profile of the first 6 patients).
~Approximately 4-8 weeks after the conclusion of chemoradiation, it is recommended patients will continue treatment with 4 cycles of gemcitabine 1000 mg/m2 days 1, 8, and 15 every 28 days plus daily erlotinib 100 mg."
11634722|NCT00313508|Experimental|A: Peptide-pulsed DC, ALI and Low Dose Fludarabine|Fludarabine: 5 mg/m^2/day, Auto Lymphocyte Infusion, DC Infusion
11634723|NCT00313508|Experimental|B: Peptide-pulsed DC, ALI and High Dose Fludarabine|Fludarabine: 25 mg/m^2/day, Auto Lymphocyte Infusion, DC Infusion
11634724|NCT00313443|Experimental|Amiodarone, long-term|Unique arm: all patients were taking amiodarone for more than 6 months and all patietns underwent amiodarone dosage in blood and fat tissue samplings
11634725|NCT00313430||Dialysis patients|
11634726|NCT00313430||with or wthout glucose added to dialysis fluid|
11634727|NCT00313417|Active Comparator|1|
11634728|NCT00313417|Placebo Comparator|2|
11634729|NCT00313404|Experimental|Norovirus in groundwater|We dosed volunteers with safety tested infectious norovirus in groundwater (that met EPA standards for drinking water). The length of time norovirus remained in groundwater varied by volunteer.
11634730|NCT00313378|Experimental|ketamine|This study compares two groups of patients undergoing thoracotomy for partial pneumonectomy, one receiving intravenous ketamine since the beginning of procedure and then during 48 hours, the other receiving inactive normal saline (placebo).
11634731|NCT00313378|Other|placebo|This study compares two groups of patients undergoing thoracotomy for partial pneumonectomy, one receiving intravenous ketamine since the beginning of procedure and then during 48 hours, the other receiving inactive normal saline (placebo).
11634732|NCT00313339|No Intervention|Control Group|A concurrent group meeting eligibility criteria but not receiving CD34+cells will be evaluated similar to the study group to assess the extent, if any, of significant improvement in cardiac perfusion/function without the CD34+cell product infusion.
11634733|NCT00313339|Experimental|Treatment Group|Intra-coronary infusion of an autologous bone marrow derived CD34+ stem cell product.
11634734|NCT00313313|Experimental|Saxagliptin 2.5 mg + Glyburide 7.5 mg (A)|Metformin 500-2500 mg (as needed)
11634735|NCT00313313|Experimental|Saxagliptin 5 mg + Glyburide 7.5 mg (B)|Metformin 500-2500 mg (as needed)
11634736|NCT00313313|Placebo Comparator|Placebo + Glyburide 7.5 mg (C)|Metformin 500-2500 mg (as needed)
11634737|NCT00313300|Active Comparator|A1|
11634738|NCT00313300|Experimental|A2|
11634743|NCT00313235|Experimental|DC Vaccine and Cyclophosphamide|"Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).
~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.
~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure."
11634744|NCT00313209|Active Comparator|Roflumilast|"Roflumilast 500 µg
~underlying medication: salmeterol 50 μg, twice daily, inhaled"
11634745|NCT00313209|Placebo Comparator|Placebo|"Placebo
~underlying medication: salmeterol 50 μg, twice daily, inhaled"
11634746|NCT00313196|No Intervention|1|
11634747|NCT00313196|Experimental|2|
11634748|NCT00313183|Experimental|1|single doses of pramlintide acetate or placebo, given in three different sequences to three cohorts of subjects
11634749|NCT00313170|Experimental|1|Fulvestrant 250 mg (intramuscular injection 250 mg)
11634750|NCT00313170|Experimental|2|Fulvestrant 250 mg (+ 250 mg loading regimen)
11634751|NCT00313170|Experimental|3|Fulvestrant 500 mg (intramuscular injection 500 mg)
11634752|NCT00313157|Active Comparator|Metoprolol|Treatment with Metoprolol 100 mg x 1 for three weeks
11634753|NCT00313157|Active Comparator|Diltiazem|Treatment with Diltiazem 360 mg x 1 for three weeks
11634754|NCT00313157|Active Comparator|Verapamil|Treatment with Verapamil 240 mg x 1 for three weeks
11634755|NCT00313157|Active Comparator|Carvedilol|Treatment with Carvedilol 25 mg x 1 for three weeks
11634756|NCT00313105|Experimental|Smokeless Tobacco|Smokeless Tobacco and individual visits
11634757|NCT00313105|Active Comparator|Nicotine tablets|Nicotine tablets
11634758|NCT00313105|Placebo Comparator|3|7-mg nicotine patch acts as placebo
11634759|NCT00313053|Experimental|Human mAb 216|
11634760|NCT00313014|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
11634761|NCT00313014|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
11634762|NCT00313014|Experimental|Oxycodone Immediate-Release|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
11634763|NCT00312975|Experimental|Arm A|
11634764|NCT00312975|Active Comparator|Arm B|
11634765|NCT00312962|Active Comparator|1|Participants will use commercially available computer games
11634766|NCT00312962|Experimental|2|Participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation
11634767|NCT00312949|Experimental|1|Participants will use the interactive website
11634768|NCT00312949|Active Comparator|2|Participants will read written materials and watch a video
11634769|NCT00312936|No Intervention|Wait List|
11634770|NCT00312936|Experimental|MBSR|8 week mindfulness based stress reduction
11634771|NCT00312923|Experimental|Policosanol|20 mg daily of policosanol
11634772|NCT00312923|Placebo Comparator|Placebo|20 mg of microcrystalline cellulose daily
11634773|NCT00312897|Placebo Comparator|corn oil|as stated
11634774|NCT00312897|Experimental|Omega 3 Fatty Acids|as stated
11634775|NCT00312884|Active Comparator|Usual Care|Recieved usual hospital and community care
11634776|NCT00312884|Experimental|Intervention Arm|Recieved telemonitoring
11634777|NCT00312858|Active Comparator|1|Arm 1: VAQTA™ 0.5 mL injection (2 doses 6 months apart), ProQuad™ 0.5 mL injection (2 doses 6 months apart), Prevnar™ 0.5 mL injection (one dose), all vaccines administered concomitantly. 28 weeks of study duration.
11634778|NCT00312858|Active Comparator|2|Arm 2: ProQuad™ 0.5 mL injection (2 doses ~8 months apart), Prevnar™ 0.5 mL injection (one dose), both administered concomitantly, VAQTA™ 0.5 mL injection (2 doses 6 months apart) administered alone. 34 weeks of study duration.
11634779|NCT00312845|Experimental|Bortezomib + Rituximab|
11634780|NCT00312845|Active Comparator|Rituximab|
11634781|NCT00312780|Experimental|Arm 1: XL784|
11634782|NCT00312780|Placebo Comparator|Arm 2: Placebo Gel capsules|
11634783|NCT00312728|Experimental|bevacizumab|
11634784|NCT00312702|Experimental|10µg dose FMP011|Falciparum Malaria Protein 11 with AS02A adjuvant
11634785|NCT00312702|Experimental|50µg dose FMP011|Falciparum Malaria Protein 11 with AS02A adjuvant
11634786|NCT00312663|Experimental|10ug dose FMP011|Falciparum Malaria Protein 11 with AS01B adjuvant
11634787|NCT00312663|Experimental|50ug dose FMP011|Falciparum Malaria Protein 11 with AS01B adjuvant
11634788|NCT00312598||aripiprazole|observational measures of metabolic parameters of subjects who are making clinically determined medication switch to aripiprazole
11634789|NCT00312585|Experimental|Acupuncture|
11634790|NCT00312585|Sham Comparator|Sham Acupuncture|
11634791|NCT00312585|No Intervention|Usual care only|
11634792|NCT00312572|Experimental|BTDS10/20|Initial doses (Level 1) of BTDS 10. Subjects were allowed to have their doses adjusted to BTDS 20 (Level 2) on or after day 4.
11634793|NCT00312572|Experimental|BTDS 20|Initial doses (Level 1) of BTDS 20.
11634794|NCT00312546|Experimental|2A|Discontinuation of VPA and enfuvirtide administered for 24 weeks. As of 05/20/08 this step was discontinued.
11634795|NCT00312546|Experimental|2B|Continuation of VPA for up to 96 weeks. As of 05/20/08 this step was discontinued.
11634796|NCT00312546|Experimental|3A|VPA may be added to enfuvirtide for 16 weeks. VPA and enfuvirtide will be continued for up to 96 weeks in responders, and the study will be discontinued in nonresponders.
11634797|NCT00312546|Experimental|3B|Enfuvirtide may be continued for up to 96 weeks. As of 05/20/08 this step was discontinued.
11634798|NCT00312494|Placebo Comparator|Placebo|
11634799|NCT00312494|Experimental|Ziprasidone 20-40mg twice a day (BID)|
11634800|NCT00312494|Experimental|Ziprasidone 60-80mg BID|
11634801|NCT00312481|Experimental|1|MOVIPREP
11634802|NCT00312481|Active Comparator|2|Picolax
11634803|NCT00312455|Experimental|1|Drug Treatment
11634804|NCT00312455|Placebo Comparator|2|Placebo treatment
11634805|NCT00312442|Experimental|WST 09|Treatment with WST09-mediated VTP
11634806|NCT00312403|Other|1|Patients with primary open angle glaucoma
11634807|NCT00312403|Other|2|Age- and sex-matched control subjects
11634808|NCT00312390|Other|Healthy Control Subjects|
11634809|NCT00312390|Other|Subjects with amblyopia|
11634810|NCT00312377|Active Comparator|1|Docetaxel monotherapy
11634811|NCT00312377|Experimental|2|Vandetanib + Docetaxel
11634812|NCT00312338|Experimental|Infected Patient treated with Vigamox|Conjunctivitis-Infected Patient receiving Vigamox 0.5% in both eyes three times daily for 7 days.
11634813|NCT00312338|No Intervention|Healthy Subjects|Healthy Subjects receiving no treatment
11634814|NCT00312299|Experimental|Arm 1 A - Square edge PMMA IOL|50 patientes will recieve square edge PMMA IOL
11634815|NCT00312299|Active Comparator|1B|In group 1, 50 eyes will receive round edge PMMA IOL
11634816|NCT00312299|Experimental|2A|In group 2, 50 eyes will receive square edge PMMA IOL
11634817|NCT00312299|Active Comparator|2B|In group 2, 50 eyes will receive acrysof IOL
11634818|NCT00312286|Experimental|1|
11634819|NCT00312286|Experimental|2|
11634820|NCT00312286|Experimental|3|
11634821|NCT00312286|Experimental|4|
11634822|NCT00312286|Experimental|5|
11634823|NCT00312286|Experimental|6|
11634824|NCT00312286|Experimental|7|
11634825|NCT00312286|Placebo Comparator|8|
11634826|NCT00312286|Placebo Comparator|9|
11634827|NCT00312286|Placebo Comparator|10|
11634828|NCT00312286|Placebo Comparator|11|
11634829|NCT00312260|Experimental|1|
11634830|NCT00312260|Active Comparator|2|
11634831|NCT00312247||Boys taking steroids|Boys who are taking prednisone or deflazacort
11634832|NCT00312247||Boys who are steroid naive|Boys who are not taking steroids for a variety of reasons
11634833|NCT00312221|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
11634834|NCT00312221|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
11634835|NCT00312221|Experimental|Oxycodone Immediate-Release (Oxy IR) 40 mg|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
11634836|NCT00312208|Experimental|1|Doxorubicin in combination with cyclophosphamide followed by docetaxel (AC -> T)
11634837|NCT00312208|Experimental|2|Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)
11634838|NCT00312195|Experimental|BTDS (5, 10 or 20)|Buprenorphine transdermal patch
11634839|NCT00312195|Placebo Comparator|Placebo to match BTDS|Placebo to match buprenorphine transdermal patch
11634840|NCT00312091|Experimental|A, Stage 1|Tablet containing d4T, 3TC, and NVP taken orally twice daily for the first 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for the final 4 weeks
11634841|NCT00312091|Experimental|A, Stage 2|Tablet containing d4T, 3TC, and NVP taken orally twice daily for 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 4 weeks
11634842|NCT00312091|Experimental|B, Stage 1|Liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 2 weeks, then tablet containing d4T, 3TC, and NVP taken orally twice daily for 2 weeks
11634843|NCT00312091|Experimental|B, Stage 2|Liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 4 weeks, then tablet containing d4T, 3TC, and NVP taken orally twice daily for 4 weeks
11634844|NCT00312065|Experimental|Patient|Once stabilized, a trimmed reflective shield to cover only the probe itself will be placed over the thermistor probe. Changes in measured skin temperature and warmer power output will be recorded non-invasively, as well as the time taken to reestablish baseline status. A full-sized reflective shield will then be placed over the thermistor probe and the same observations recorded, then repeated 15 minutes later. At the time of a subsequent routine change in thermistor position, the same procedure will be followed, but omitting the intermediate step of using the smaller trimmed shield. Continuous core temperatures will be monitored via a short rectal probe during the study periods.
11634845|NCT00312052|Experimental|E5555 50 mg|Participants received one 50 mg E5555 and two 100 mg placebo tablets, once orally daily for 24 weeks.
11634846|NCT00312052|Experimental|E5555 100 mg|Participants received one 50 mg placebo, one 100 mg E5555 and one 100 mg placebo tablets, once orally daily for 24 weeks.
11634847|NCT00312052|Active Comparator|E5555 200 mg|Participants received one 50 mg placebo and two 100 mg E5555 tablets were taken orally once daily for 24 weeks.
11634848|NCT00312052|Placebo Comparator|Placebo|Participants received one 50 mg placebo and two 100 mg placebo tablets, once orally daily for 24 weeks.
11634849|NCT00312039|Experimental|A|
11634850|NCT00312039|Active Comparator|B|
11634851|NCT00312013|No Intervention|No Nadroparin|Patients will receive all standard anticancer treatment. Patients in this arm will not receive nadroparin
11634852|NCT00312013|Experimental|Nadroparin|Patients will be randomized to receive standard anticancer treatment. Nadroparin patients will be treated with therapeutic doses of subcutaneous (s.c). nadroparin for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2-week periods of therapeutic doses of nadroparin will be given for a total of 6 cycles each separated by a 4-week wash-out. The study treatment period ends at week 46 regardless of number of cycles achieved at that moment.
11634853|NCT00312000|Active Comparator|1Capecitabine-irinotecan|1st line- 2nd line (3rd line oxaliplatin plus capecitabine)
11634854|NCT00312000|Experimental|2capecitabine plus irinotecan|1st line (2nd line oxaliplatin plus capecitabine)
11634855|NCT00311948|Active Comparator|Telephone counseling + interactive website|Teen has access to interactive website and receives tailored telephone counseling
11634856|NCT00311948|Other|Control with interactive website|Teen only has access to interactive website.
11634857|NCT00311922|Active Comparator|Control|Active Control Arm receives Comprehensive Diabetes Education
11634858|NCT00311922|Experimental|Intervention Arm|Receives comprehensive education that is literacy/numeracy sensitive
11634859|NCT00311896|Experimental|Bemiparin|
11634860|NCT00311896|Placebo Comparator|Placebo|
11634861|NCT00311831|Active Comparator|1|
11634862|NCT00311831|Experimental|2|
11634863|NCT00311805|Active Comparator|1|
11634864|NCT00311805|Active Comparator|2|
11634866|NCT00311792|Experimental|1|Simulator training
11634867|NCT00311792|Active Comparator|2|Traditional Clinical education at operating room
11634868|NCT00311766|Placebo Comparator|1|Placebo comparator gel does not contain any active drug. Topical administration of 0.0% Thymosin Beta 4 gel, once a day (qd) up to 56 days
11634869|NCT00311766|Active Comparator|2|Topical Administration of 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel once a day (qd) up to 56 days
11634870|NCT00311753|Experimental|1|Certoparin
11634871|NCT00311753|Active Comparator|2|Heparin
11634872|NCT00311727|Experimental|Influenza A/H5N1|232 subjects receiving Influenza A/H5N1 vaccine.
11634873|NCT00311688||1|Individuals will follow the schedule of the study they are participating in
11634874|NCT00311675|Experimental|1|
11634875|NCT00311662|Experimental|1|Tonabersat 40mg
11634876|NCT00311662|Placebo Comparator|2|
11634877|NCT00311623|Active Comparator|Control group|"Men >18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.
~Receive no intervention on Days 1-14. Surgery performed on Day 15."
11634878|NCT00311623|Experimental|Low-dose Rapamycin (3mg)|"Men >18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.
~Must have adequate hepatic, renal and bone marrow function, no allergy to rapamycins, avoid medications interfering with rapamycin metabolism, no active infection, no prior therapies for prostate cancer.
~Will receive rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) oral (PO) once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15)."
11634879|NCT00311623|Experimental|High-dose Rapamycin (6mg)|"Men >18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.
~Must have adequate hepatic, renal and bone marrow function, no allergy to rapamycins, avoid medications interfering with rapamycin metabolism, no active infection, no prior therapies for prostate cancer.
~Will receive rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) oral (PO) once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15)."
11634880|NCT00311610|Experimental|SN-38 liposome|"Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
~After completion of study treatment, patients are followed every 3 months for up to 3 years."
11634881|NCT00311597|Experimental|Single fractionated radiation adjusted for tumor size|Single fractionated radiation adjusted for volume of tumor tissue encompassed by desired isodose line
11634882|NCT00311584|Experimental|Disease measurable by CT or MRI scan (Irinotecan/Temozolomide)|Measurable by CT scan (Computed Tomography) or MRI scan (Magnetic Resonance Imaging). Patients receive irinotecan hydrochloride IV (10 mg/m2/dose) over 1 hour on days 1-5 and 8-12 and oral temozolomide (100 mg/m2/dose) on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11634883|NCT00311584|Experimental|Disease eval by bone marrow or MIBG (Irinotecan/Temozolomide)|Evaluation by bone marrow or MIBG scan (metaiodobenzylguanidine scan, a radiopharmaceutical). Patients receive irinotecan hydrochloride IV (10 mg/m2/dose) over 1 hour on days 1-5 and 8-12 and oral temozolomide (100 mg/m2/dose) on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11634884|NCT00311558|Experimental|SSG & INF|1 arm study: SSG & interferon
11634885|NCT00311545|Experimental|CNTO 328|CNTO 328, anti-IL-6 monoclonal antibody; 6 mg/kg, IV, q 2wks x 12 cycles (1 cycle = 2 wks)
11634886|NCT00311467|Active Comparator|Capecitabine and Interferon|Combined Chemo-Immunotherapy Chemotherapy: Mo-Fr Immunotherapy
11634887|NCT00311467|Active Comparator|Interferon|"Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.
~Efficacy evaluations will be performed every 14 weeks of treatment in both groups"
11634888|NCT00311415|Experimental|Group 1: 2+4 Months (2-doses)|
11634889|NCT00311415|Experimental|Group 2: 2 Months (1-dose)|
11634890|NCT00311415|Experimental|Group 3: 6 Months (1-dose)|
11634891|NCT00311415|Active Comparator|Group 4: 12-16 Months (1 dose in the second year of life)|
11634892|NCT00311402|Other|Aggrenox Capsule|
11634893|NCT00311402|Other|Acetylsalicylic Acid (ASA) 81 mg Tablet|
11634894|NCT00311389|Experimental|Travoprost/Timolol|1 drop in the affected eye(s) once daily in the morning for 12 months
11634895|NCT00311389|Active Comparator|Latanoprost/Timolol|1 drop in the affected eye(s) once daily in the morning for 12 months
11634896|NCT00311376|Experimental|1|botulinum toxin Type A (200U)
11634897|NCT00311376|Experimental|2|botulinum toxin Type A (300U)
11634898|NCT00311376|Other|3|placebo; botulinum toxin Type A (200U)
11634899|NCT00311376|Other|4|placebo; botulinum toxin Type A (300U)
11634900|NCT00311363|Experimental|GEn (XP13512) 1200 mg|GEn (XP13512) 1200 mg
11634901|NCT00311363|Placebo Comparator|Placebo|Placebo
11634902|NCT00311324|Experimental|Special Intervention|One individual counseling visit, twelve group sessions, three postcards, and twelve telephone calls.
11634903|NCT00311324|Experimental|Delayed Intervention|"Direct mailing of two American Dietary Association pamphlets (Healthy Eating and Staying Alive) and three bimonthly newsletters providing general health information and study updates."
11634904|NCT00311311|Active Comparator|1|Tacrolimus + MMF + Steroids
11634905|NCT00311311|Experimental|2|Tacrolimus + MMF + Steroids with conversion from Tacrolimus to Sirolimus at 3-4 months post-transplant
11634906|NCT00311298|Placebo Comparator|No micronutrients|Biscuit without additional micronutrients
11634907|NCT00311298|Experimental|Micronutrients|Biscuit with additional micronutrients
11634908|NCT00311298|Active Comparator|1 biscuit|1 biscuit with micronutrients
11634909|NCT00311298|Experimental|6 biscuits|1 biscuit with micronutrients, plus 5 biscuits without additional micronutrients
11634910|NCT00311246|Experimental|An open-label|Patients received adalimumab 40 mg weekly for 45 weeks, with a final follow-up at Week 52
11634911|NCT00311181|Experimental|2.5/3.5/4.5 ms defibrillation waveform|
11634912|NCT00311155|Experimental|1|"Olmesartan medoxomil oral tablets for 4 weeks followed by, if necessary:
~Olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets for 8 weeks, followed by, if necessary:
~Olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets + amlodipine oral tablets for 8 weeks"
11634913|NCT00311129|Experimental|Arm 1|
11634914|NCT00311129|Active Comparator|Arm 2|
11634915|NCT00311103|No Intervention|Care in the Control Group (CG)|Care in the Control Group (CG): was that provided by the General Practitioners, with basic diagnostic and therapeutic procedures without specified protocols.
11634916|NCT00311103|Experimental|Early Intervention Programa (IG)|Early Intervention Programa (IG): Patients assigned to the intervention group after the randomization were offered an immediate appointment. Patients, who voluntarily accepted, were attended by 2 rheumatologists. The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
11634917|NCT00311090|Experimental|Idrabiotaparinux|"Idrabiotaparinux sodium , 3.0 mg, once-weekly for 6 months.
~In avidin sub-study, participants receive on Day 183, avidin 100 mg or placebo (for avidin) (4 hours after Idrabiotaparinux administration)"
11634918|NCT00311090|Active Comparator|Idraparinux|"Idraparinux sodium, 2.5 mg, once-weekly for 6 months
~In avidin sub-study, participants receive on Day 183, placebo (for avidin) (4 hours after Idrabiotaparinux administration)"
11634919|NCT00310895|Experimental|Dose escalation|Treatment Schedule 3 will consist of dosing on Days 1, 4, 8, and 11 of each 21 day cycle (3 weeks equals 1 cycle) and Treatment Schedule 4 will consist of dosing on Day 1 of each 28 day cycle (4 weeks equals 1 cycle)
11634920|NCT00310869|Experimental|E|
11634921|NCT00310856|Experimental|MenACWY-CRM_6-12 M|Subjects received 2 doses of MenACWY-CRM (1 dose at 6 and 12 months of age). Subjects also received routine vaccines: 2 doses of PC7 (1 dose at 6 and 12 months of age), 1 dose of DTaP-Hib-IPV (at 6 months of age) and 1 dose of MMR+Varicella (at 13 months of age)
11634922|NCT00310856|Experimental|MenACWY-CRM_12 M|Subjects received 1 dose of MenACWY-CRM at 12 months of age. Subjects also received routine vaccines: 2 doses of PC7 (1 dose at 6 and 12 months of age), 1 dose of DTaP-Hib-IPV (at 6 months of age) and 1 dose of MMR+Varicella (at 13 months of age)
11634923|NCT00310856|Experimental|MenC-CRM_12 M_MenACWY-CRM_18 M|"Subjects received 1 dose of MenC-CRM (at 12 months of age) and 1 dose of MenACWY-CRM (at 18 months of age).
~Subjects also received routine vaccines: 1 dose of PCV7 (at 12 months), MMR+Varicella (at 13 months) and DTaP-Hib-IPV (at 18 months)"
11634924|NCT00310843||All study population|
11634925|NCT00310830|No Intervention|1|
11634926|NCT00310830|Experimental|2|
11634927|NCT00310817|Experimental|MenACWY-CRM(Ad+) 12 to 35 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine with adjuvant (Ad+) on day 1 and second dose at 28 days or at 6 months or at 12 months after the first vaccination.
11634928|NCT00310817|Experimental|MenACWY-CRM(Ad-) 12 to 35 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine without adjuvant (Ad-) on day 1 and second dose either at 28 days or at 6 months or at 12 months after the first vaccination.
11634929|NCT00310817|Experimental|MenACWY-CRM(Ad-) 36 to 59 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine without adjuvant on day 1 and second dose on day 169 or day 337.
11634930|NCT00310817|Active Comparator|MenACWY-PS (36 to 59 Months)|Subjects received one dose of MenACWY polysaccharide (PS) vaccine on day 1 and second dose of MenACWY-CRM conjugate vaccine without adjuvant on day 169 or day 337.
11634931|NCT00310804|Experimental|cTIV_lot 1|
11634932|NCT00310804|Experimental|cTIV_lot 2|
11634933|NCT00310804|Experimental|cTIV_lot 3|
11634934|NCT00310804|Active Comparator|TIV group|
11634935|NCT00310791|Placebo Comparator|Sugar Pill|Placebo (sugar pill); identical to treatment medication capsule
11634936|NCT00310791|Experimental|DHEA + Hormone replacement therapy (estrogen/progestin)|Combined therapy of dehydroepiandrosterone (DHEA) and hormone replacement therapy (ERT). Patients randomized to the DHEA + HRT arm will receive micronized oral DHEA in a dose of 50 mg daily + HRT (0.3 mg Premarin, 1 tablet daily for 3 months, follow by Alesse (20 mg ethinyl estradiol + 0.1 mg levonorgestrel for 15 months). The estrogen/progestin component of the regimen has been chosen to maximize patient compliance, as patients with AN may experience bloating or nausea if higher estrogen doses (> 20 g) are initiated too rapidly. The DHEA capsule strength will be 50 mg, the total daily dose to be studied in combination with HRT. The micronized DHEA preparation achieves more constant DHEA and DHEA-S levels. Fifty milligrams appears to be a physiological replacement dose for these young women, determined both from our pilot (10) and longitudinal studies (7).
11634937|NCT00310778|Experimental|1|treatment
11634938|NCT00310765|Active Comparator|1|75-150 mg of pregabalin po BID
11634939|NCT00310765|Placebo Comparator|2|Placebo 75 or 150 mg po BID
11634940|NCT00310726|Experimental|Abrupt Weaning|Women were counseled to abruptly wean their child at 4 months of age.
11634941|NCT00310726|Active Comparator|Exclusive breastfeeding per WHO guidelines|Women were counseled to adhere to the WHO recommendations for duration of exclusive breastfeeding.
11634942|NCT00310713|Experimental|Group 1|
11634943|NCT00310713|Experimental|Group 2|
11634944|NCT00310713|Experimental|Group 3|
11634945|NCT00310713|Experimental|Group 4|
11634946|NCT00310713|Experimental|Group 5|
11634947|NCT00310661|Placebo Comparator|Placebo|Placebo hard gelatin capsules matching the investigational medication
11634948|NCT00310661|Experimental|Sarizotan HCI|Sarizotan HCI is administered at various doses ranging from 2-7mg.
11634949|NCT00310609|Experimental|Arm 1|
11634950|NCT00310596|Experimental|Arm 1|
11634951|NCT00310596|Experimental|Arm 2|
11634952|NCT00310596|Experimental|Arm 3|
11634953|NCT00310596|Experimental|Arm 4|
11634954|NCT00310596|Active Comparator|Arm 5|
11634955|NCT00310596|Placebo Comparator|Arm 6|
11634956|NCT00310557|Experimental|Arm 1|
11634957|NCT00310544|Experimental|Arm 2|
11634961|NCT00310492|Active Comparator|Subcutaneous immunotherapy|Subcutaneous injections with ALK-depot SQ mites to 100,000 SQ-U
11634962|NCT00310492|Placebo Comparator|Subcutaneous injections|placebo injections
11634963|NCT00310466|Active Comparator|Sublingual immunotherapy|sublingual immunotherapy with drops applied once daily by single dose containers (200 STU per dose)
11634964|NCT00310466|Placebo Comparator|Placebo|placebo sublingual drops
11634965|NCT00310440|Experimental|Bone graft substitute|Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with P-15 synthetic osteoconductive bone substitute (investigational device).
11634966|NCT00310440|Active Comparator|Autologous Bone|Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with local autologous bone.
11634967|NCT00310427|Experimental|LY686017|Subjects received 50 mg of the NK1 antagonist LY686017 orally on a daily basis.
11634968|NCT00310427|Placebo Comparator|Placebo|Subjects received placebo orally on a daily basis
11634969|NCT00310401|Experimental|Albuterol|Albuterol sulfate 5 mg dissolved in normal saline administered every 4 hours by nebulization
11634970|NCT00310401|Placebo Comparator|Saline|Saline administered every 4 hours by nebulization
11634971|NCT00310388|Experimental|Retigabine (INN), Ezogabine (USAN)|Retigabine (Ezogabine): all subjects
11634972|NCT00310375|Experimental|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets - 50mg, 100mg or 300mg
11634973|NCT00310362|Experimental|Usual Care with nurse phone call|Usual Care--Nurses telephoned patients 7 days prior to appointment to remind patients about scheduled GI appointment and to answer any questions.
11634974|NCT00310362|Experimental|interactive voice response 3 days prior|Interactive voice response system was used to remind patients 3 days before a scheduled appointment and to educate them about preparation procedures for the appointment (IVR3)
11634975|NCT00310362|Experimental|interactive voice response 7 days prior|Interactive voice response system was used to remind patients 7 days before a scheduled appointment and to educate them about preparation procedures for the appointment (IVR7)
11634976|NCT00310323|Experimental|1|Children with OSAS identified via sleep study
11634977|NCT00310310|Placebo Comparator|Usual Care|Usual sleep apnea and cpap care
11634978|NCT00310310|Experimental|Self-Management|sleep apnea self-management program - 4 sessions, group-based
11634979|NCT00310219|Experimental|Arm 1|Two radiation oncologists are randomly assigned to develop either a 3DCRT plan using CT only, or a 3DCRT plan using fused PET/CT
11634980|NCT00310206|Experimental|ID injection-9 mcg|25 subjects to receive 9 mcg of inactivated influenza A/H5N1 vaccine intradermally on Days 0 and 28.
11634981|NCT00310206|Experimental|IM injection-15 mcg|25 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine intramuscularly on Days 0 and 28.
11634982|NCT00310206|Experimental|IM injection-45 mcg|25 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine intramuscularly on Days 0 and 28.
11634983|NCT00310206|Experimental|ID injection-3 mcg|25 subjects to receive 3 mcg of inactivated influenza A/H5N1 vaccine intradermally on Days 0 and 28.
11634984|NCT00310180|Experimental|Group 1 (Oncotype DX recurrence score =< 10)|Patients in this group receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.
11634985|NCT00310180|Experimental|Group 2, Arm I (experimental)|Patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.
11634986|NCT00310180|Active Comparator|Group 2, Arm II (standard)|Patients receive standard combination chemotherapy at the discretion of the treating physician. Within 4 weeks after the last dose of chemotherapy, patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.
11634987|NCT00310180|Experimental|Group 3 (Oncotype DX recurrence score >= 26)|Patients in this group receive combination chemotherapy followed by hormone therapy similar to the patients in group two who are assigned to receive both types of treatment.
11634988|NCT00310167|Experimental|4 Gy|4 Gy in 2 fractions
11634989|NCT00310167|Active Comparator|24 Gy|24 Gy in 12 fractions
11634990|NCT00310141|Active Comparator|Standard Care Group|Written self-help materials, counseling, and 6-week nicotine patch supply
11634991|NCT00310141|Active Comparator|Computer Treatment Group (CDT)|Written self-help materials, counseling, 6-week nicotine patch supply and 6 weeks of computer-delivered treatment
11634992|NCT00310141|Experimental|CDT Pilot|Written self-help materials, counseling, 6-week nicotine patch supply and 6 weeks of computer-delivered treatment
11634993|NCT00310115||Smoking Prevention Usual Care|Arm I (usual care): Self-help materials and brief relapse prevention advice based on Treating Tobacco Use and Dependence Clinical Practice Guideline.
11634994|NCT00310115||MRP|Arm II (motivational relapse prevention [MRP]): Same intervention as usual care, plus 30 minutes telephone counseling at 34 & 36 weeks gestation then at 2, 4, 7, & 16 weeks postpartum.
11634995|NCT00310115||Enhanced MRP +|Arm III (enhanced MRP [MRP+]): Same intervention as usual care and telephone counseling as MRP, plus 1 hour in-person counseling at 30-33 weeks gestation & 8 weeks postpartum.
11634996|NCT00310076|Experimental|Chemo therapy followed by thalidomide|After cytoreductive surgery with intraperitoneal hyperthermic chemotherapy, patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
11634997|NCT00310063|Experimental|Arm I|Sea Band elastic acupressure wristband
11634998|NCT00310063|Sham Comparator|Arm II|Sham wristband
11634999|NCT00310050|Experimental|Pemetrexed in combination with concomitant radiotherapy|Patients will receive Pemetrexed plus Radiotherapy.
11635000|NCT00310037|Experimental|Arm A maintenance therapy|Patients receive bortezomib 1.6 mg/m^2 IV on days 1, 8, 15, and 22 once daily for 4 weeks. There will be a 4 week rest period. One cycle is a total of 8 weeks. A total of 10 cycles of bortezomib will be given in the absence of disease progression or unacceptable toxicity.
11635001|NCT00310037|Experimental|Arm B consolidation therapy|Patients receive bortezomib 1.3 mg/m^2 IV on days 1, 4, 8, and 11 once daily for 3 weeks. One cycle is a total of 3 weeks. A total of 4 cycles of bortezomib will be given in the absence of disease progression or unacceptable toxicity.
11635095|NCT00308854|Placebo Comparator|2|Placebo-PDT
11635002|NCT00310024|Experimental|Treatment (vorinostat, bortezomib)|"Patients receive bortezomib IV on days 1, 4, 8, and 11 followed by oral SAHA twice daily on days 4-11. Beginning in course 3, some patients may receive low-dose oral dexamethasone on days 4-8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional cohort of 10 patients receive treatment at the MTD.
~Patients undergo blood collection and tumor biopsies periodically during study for pharmacologic and biomarker correlative studies."
11635003|NCT00309985|Experimental|Androgen-Deprivation Therapy and Docetaxel|Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone [LHRH] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11635004|NCT00309985|Active Comparator|Androgen-Deprivation Therapy alone|Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone [LHRH] agonist therapy, LHRH antagonist therapy, or surgical castration) alone.
11635005|NCT00309972|Active Comparator|Sequential arm (SEQ)|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
11635006|NCT00309972|Experimental|Experimental arm (CON)|Concurrent chemo-radiotherapy [55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20] followed by two cycles of cisplatinum/vinorelbine.
11635007|NCT00309959|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive ABI-007 IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11635008|NCT00309946|Experimental|Treatment (enzyme inhibitor therapy)|Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.
11635009|NCT00309907|Experimental|Etanercept and corticosteroid therapy|Patients receive etanercept IV (dose 0.4 mg/kg- max 25 mg) over 30 minutes on day 0 and subcutaneously (dose 0.4 mg/kg- max 25 mg) on days 3, 7, 10, 14, 17, 21, and 24. Treatment continues in the absence of an infectious pathogen, disease progression, or unacceptable toxicity. Patients also receive methylprednisolone (or corticosteroid equivalent) IV (dose 2.0 mg/kg/day) on days 0-2 and then orally with a taper beginning day 7. Dose on days 7-20 (1.0 mg/kg/day), days 21-34 (0.5 mg/kg/day), days 35-48 (0.25 mg/kg/day) and days 49-56 (0.25 mg/kg/every other day) discontinuing on day 56.
11635010|NCT00309855|Placebo Comparator|Double Placebo|(i.m. vehicle 0.5 mL weekly x three injections and oral placebo once daily x 21 days)
11635011|NCT00309855|Other|Testosterone IM and oral placebo|IM injections weekly x three injections and oral placebo once daily x 21 days
11635012|NCT00309855|Other|Testosterone and Oral Anastrozole|IM injections weekly x 3 injections and oral daily x 21 days
11635013|NCT00309855|Other|Testosterone and Dutasteride|IM injections weekly x 3 injections and oral once daily x 21 days
11635014|NCT00309842|Experimental|Unrelated UCBT for Blood Cancers|Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.
11635015|NCT00309777|Experimental|Pitavastatin 2 mg|Pitavastatin 2 mg once daily
11635016|NCT00309777|Active Comparator|Simvastatin 20 mg|Simvastatin 20 mg once daily
11635017|NCT00309777|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
11635018|NCT00309777|Active Comparator|Simvastatin 40 mg|Simvastatn 40 mg once daily
11635019|NCT00309751|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
11635020|NCT00309751|Active Comparator|Atorvastatin 20 mg QD|Atorvastatin 20 mg once daily
11635021|NCT00309738|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
11635022|NCT00309738|Active Comparator|Simvastatin 40 mg QD|Simvastatin 40 mg once daily
11635023|NCT00309699|Placebo Comparator|003|Placebo Daily for 3 weeks
11635024|NCT00309699|Active Comparator|002|Quetiapine 400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
11635025|NCT00309699|Experimental|001|Paliperidone ER 3 to 12 mg daily, flexibly dosed, for 12 weeks
11635026|NCT00309647|Experimental|H5N1 Formulation 1 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 1 vaccine at a 21-day interval
11635027|NCT00309647|Experimental|H5N1 Formulation 2 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 2 vaccine at a 21-day interval
11635028|NCT00309647|Experimental|H5N1 Formulation 3 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 3 vaccine at a 21-day interval
11635029|NCT00309647|Experimental|H5N1 Formulation 4 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 4 vaccine at a 21-day interval
11635030|NCT00309647|Active Comparator|H5N1 Formulation 5 Group|Subjects in this group received 2 doses of H5N1 formulation 5 vaccine at a 21-day interval
11635031|NCT00309647|Active Comparator|H5N1 Formulation 6 Group|Subjects in this group received 2 doses of H5N1 formulation 6 vaccine at a 21-day interval
11635032|NCT00309647|Active Comparator|H5N1 Formulation 7 Group|Subjects in this group received 2 doses of H5N1 formulation 7 vaccine at a 21-day interval
11635033|NCT00309647|Active Comparator|H5N1 Formulation 8 Group|Subjects in this group received 2 doses of H5N1 formulation 8 vaccine at a 21-day interval
11635034|NCT00309608|Experimental|Linagliptin low dose|Patients receive Linagliptin low dose tablets once daily
11635035|NCT00309608|Experimental|Linagliptin medium dose|Patients receive Linagliptin medium dose tablets once daily
11635036|NCT00309608|Experimental|Linagliptin high dose|Patients receive Linagliptin high dose tablets once daily
11635037|NCT00309608|Placebo Comparator|Placebo|Patients receive tablets identical to those containing Linagliptin low, medium and high dose
11635038|NCT00309608|Active Comparator|Glimepiride|Patients receive Glimepiride tablets once daily
11635039|NCT00309595|Experimental|1|Cordis SMART™ nitinol self expandable stent
11635040|NCT00309595|Active Comparator|2|balloon
11635041|NCT00309569|Experimental|A (pre- + postoperative chemotherapy)|3 cycles CMF (cyclophophamide + Methotrexat + 5-Fluorouracil) followed by surgery. Subsequently node-positive patients received 3 cycles anthracycline-based chemotherapy regime EC (epirubicin + cyclophosphamide) and node-negative patients another 3 cycles CMF.
11635042|NCT00309569|Experimental|B (conventional postoperative chemotherapy)|Surgery followed by 3 cycles CMF (cyclophophamide + Methotrexat + 5-Fluorouracil). Subsequently node-positive patients received 3 cycles anthracycline-based chemotherapy regime EC (epirubicin + cyclophosphamide) and node-negative patients another 3 cycles CMF.
11635043|NCT00309556|Active Comparator|A (experimental group)|Epirubicin/Docetaxel/Capecitabine-containing chemotherapy ± trastuzumab in HER-2 positive disease
11635044|NCT00309556|Active Comparator|B (control group)|Epirubicin/Docetaxel-containing chemotherapy ± trastuzumab in HER-2 positive disease
11635045|NCT00309491|Experimental|Group I|Tamoxifen alone
11635046|NCT00309491|Experimental|Group II|Tamoxifen + Aminoglutethimide
11635047|NCT00309478|Experimental|2 (CMF scheme)|6 cycles CMF scheme (cyclophosphamide, methotrexate, fluorouracil)
11635048|NCT00309478|Experimental|1 (Nol + Zol)|Zoladex (3 years) combined with Nolvadex (5 years)
11635049|NCT00309465|Experimental|1|Patients in Group 1 will administer 80% of their usual insulin glargine dose.
11635050|NCT00309465|Active Comparator|2|Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose.
11635051|NCT00309465|Experimental|3|Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
11635052|NCT00309452|Active Comparator|Treatment as usual|Referral to community providers.
11635053|NCT00309452|Experimental|STEP Care|Integrated and comprehensive treatment provided by a specialized team in a public mental health center.Interventions include pharmacotherapy, family education, cognitive behavioral group and individual psychotherapy and case management focused on vocational rehabilitation.
11635054|NCT00309413|Active Comparator|1|Cannabidiol/Placebo
11635055|NCT00309413|Placebo Comparator|2|Placebo/Cannabidiol
11635056|NCT00309387|Experimental|Centrum|multivitamin-mineral supplement. RDA dosage. 1 tablet a day for the whole study duration.
11635057|NCT00309387|Placebo Comparator|placebo|placebo pills. One tablet a day for the whole study duration.
11635058|NCT00309348|Experimental|Weekly measurement of graft flow|The surveillance group was measured with the FloMon instrument weekly, and all procedures related to their access-grafts recorded
11635059|NCT00309348|No Intervention|Control|The control group was questioned weekly with regard to their graft status and whether there had been any graft-related procedures
11635060|NCT00309296|Experimental|Longitudinal Care|One year of combined behavioral and pharamcological tobacco dependence treatment, with interim smoking reduciton for smokers who fail initial quit attempt.
11635061|NCT00309296|Active Comparator|Usual Care|Evidence based, state-of-the-science tobacco treatment; combined behavioral and pharmacological treatment for 8 weeks
11635062|NCT00309283|Experimental|somatostatin|
11635063|NCT00309283|Placebo Comparator|Saline solution|
11635064|NCT00309257|Experimental|ACE inhibitor, ATA II antagonists and Statins|
11635065|NCT00309244|Experimental|TI + Insulin glargine|Technosphere® Insulin Inhalation Powder + insulin glargine
11635066|NCT00309244|Active Comparator|BPR 70/30|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
11635067|NCT00309218|Active Comparator|A|Steroid withdrawal
11635068|NCT00309218|Placebo Comparator|B|continuos Steroid treatment
11635069|NCT00309179|Experimental|1|
11635070|NCT00309166|Experimental|Cervarix Group|Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.
11635071|NCT00309166|Active Comparator|Engerix-B Group|Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Engerix-B™ (HBV) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.
11635072|NCT00309140|Experimental|Enzastaurin|
11635073|NCT00309114|Experimental|Interventions for Experimental Arm|Bacterial Interference with Escherichia coli 83972. Each bladder inoculation contains the study organism, E. coli 83972, suspended as a clear solution in sterile physiological saline.
11635074|NCT00309114|Placebo Comparator|Interventions for Control Arm|Each bladder inoculation contains sterile physiological saline that does not contain the study organism.
11635075|NCT00309101|Experimental|1. tacrolimus|
11635076|NCT00309088|Experimental|1|
11635077|NCT00309088|Placebo Comparator|2|
11635078|NCT00309075|Experimental|Arm 1|
11635079|NCT00309049|Active Comparator|A1|
11635080|NCT00309049|Active Comparator|A2|
11635081|NCT00309049|Active Comparator|A3|
11635082|NCT00309023|Experimental|dose escalation|
11635083|NCT00308997|Experimental|1|Active 1-hertz Repetitive Transcranial Magnetic Stimulation to Wernicke's area and right homologous area
11635084|NCT00308997|Sham Comparator|2|sham rTMS to Wernicke's area and a right homologous area
11635085|NCT00308971|Active Comparator|1|
11635086|NCT00308971|Placebo Comparator|2|
11635087|NCT00308945|Experimental|2|cross-over comparison of two substances
11635088|NCT00308945|Experimental|1|
11635089|NCT00308919|Experimental|WST 09|Treatment with WST09 Vascular Photodynamic therapy
11635090|NCT00308906||1|Hospitalized, untreated infants and children
11635091|NCT00308906||2|Aminoglycoside treated infants and children without renal injury
11635092|NCT00308906||3|Aminoglycoside treated infants with renal injury
11635093|NCT00308893|Experimental|Escitalopram|Treatment response after 3 and 6 weeks
11635094|NCT00308854|Active Comparator|1|PD P 506 A-PDT
11635096|NCT00308789|Experimental|1|Biphasic NCPAP
11635097|NCT00308789|Active Comparator|2|Continuous CPAP
11635098|NCT00308776|Experimental|Cholecystokinin|Participants will receive intravenous saline plus cholescystokinin.
11635099|NCT00308776|Placebo Comparator|Saline|Participants will receive intravenous saline only.
11635100|NCT00308763|Active Comparator|1|Nicotine patch plus placebo sustained-release bupropion
11635101|NCT00308763|Active Comparator|2|Placebo nicotine patch plus sustained-release bupropion
11635102|NCT00308763|Active Comparator|3|Nicotine patch plus sustained-release bupropion
11635103|NCT00308750|Experimental|A|
11635104|NCT00308750|Experimental|B|
11635105|NCT00308750|Active Comparator|C|
11635106|NCT00308737|Experimental|TI Inhalation Powder|Technosphere® Insulin Inhalation Powder
11635107|NCT00308737|Other|Usual care|Usual care
11635108|NCT00308737|No Intervention|Non-diabetes|Subjects without abnormalities in glucose control (Note: Hypoglycemia and HbA1c were not reported for this group)
11635109|NCT00308724|Experimental|1|Cognitive Behavior Therapy
11635110|NCT00308724|Active Comparator|2|Usual Care
11635111|NCT00308711|Experimental|MVI 100|Misoprostol vaginal insert 100 mcg over 24h
11635112|NCT00308711|Experimental|MVI 50|Misoprostol vaginal insert 50 mcg over 24h
11635113|NCT00308711|Active Comparator|Cervidil 10 mg vaginal insert|Cervidil 10 mg over 24h
11635114|NCT00308685|Experimental|Albuterol HFA BAI|ProAir(TM) HFA, Breath Actuated Inhalation Aerosol
11635115|NCT00308685|Placebo Comparator|Placebo HFA BAI|Placebo
11635116|NCT00308620|Experimental|Chloroquine|Chloroquine 205mg or 500mg orally once daily (Results pooled)
11635117|NCT00308620|Placebo Comparator|Placebo|Placebo once daily for 8 weeks
11635118|NCT00308581|Experimental|Active 1|"Q4W regimen
~- every 4 weeks: alternatively placebo and 400mg Certolizumab Pegol"
11635119|NCT00308581|Experimental|Active 2|"Q2W regimen
~- every 2 weeks: 400 mg Certolizumab Pegol"
11635120|NCT00308555|Other|Cannabis|
11635121|NCT00308516|Experimental|Cohort A - Preoperative|"Each patient enrolled in the preoperative cohort received 5-fluorouracil (5-FU) 225 mg/m2 as a continuous infusion (IVCI) on days 1-42 through a portable infusion pump and central venous catheter. Bevacizumab 5 mg/kg was administered intravenously (IV) on days 1 and 15. Additionally these patients received radiation therapy to 50.4 Gy (1.8 Gy/day or 28 fractions) Monday through Friday during weeks 1-6.
~At least 8 weeks after surgery, patients in cohort A began 4 months of chemotherapy and bevacizumab. This adjuvant treatment consisted of 5-FU 400 mg/m2 IV bolus over 2-4 minutes followed by 2400 mg/m2 IVCI over 46 hours, leucovorin 350 mg as a 2-hour infusion, oxaliplatin 85 mg/m2 IV (modified FOLFOX6) and bevacizumab 5 mg/kg IV all on days 1 and 15 of each cycle."
11635122|NCT00308516|Experimental|Cohort B - Combined Modality|"All patients enrolled in cohort B received 5-fluorouracil (5-FU) 225 mg/m2 IVCI on days 1-42. Bevacizumab was administered at 5 mg/kg IV on day 1 every 2 weeks. These patients also received radiation to 50.4 Gy (1.8 Gy/day or 28 fractions)Monday through Friday during weeks 1-6.
~Six weeks after the completion of adjuvant 5-FU/radiation, patients began treatment with 5-FU 400 mg/m2 IV bolus over 2-4 minutes followed by 2400 mg/m2 IVCI over 46 hours, leucovorin 350 mg as a 2-hour infusion, oxaliplatin 85 mg/m2 IV (modified FOLFOX6) and bevacizumab 5 mg/kg IV all on days 1 and 15 of each cycle."
11635123|NCT00308503|Experimental|1|5 mg/day
11635124|NCT00308503|Placebo Comparator|2|
11635125|NCT00308438|Experimental|1|All subjects in the study dosed at 0.1 mg/kg teduglutide
11635126|NCT00308412|Experimental|1|Two 10^5 PFU doses of rHPIV3cp45 vaccine given as nose drops to healthy infants and children aged 6 to 36 months of age. The two doses are given 4 to 10 weeks apart.
11635127|NCT00308412|Placebo Comparator|2|Two placebo vaccinations given as nose drops to healthy infants and children aged 6 to 36 months of age. The two doses are given 4 to 10 weeks apart.
11635128|NCT00308334|Experimental|Domperidone|Domperidone
11635129|NCT00308334|Placebo Comparator|placeob- Sugar pill|
11635130|NCT00308308|Experimental|1|Technosphere Insulin
11635131|NCT00308308|Active Comparator|2|Rapid-acting analogue insulin plus basal insulin glargine
11635132|NCT00308282|Experimental|A|
11635133|NCT00308282|Placebo Comparator|B|
11635134|NCT00308269|Experimental|Vintafolide 1.2 mg IV Bolus|Vintafolide 1.2 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
11635135|NCT00308269|Experimental|Vintafolide 2.5 mg IV Bolus|Vintafolide 2.5 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
11635136|NCT00308269|Experimental|Vintafolide 4.0 mg IV Bolus|Vintafolide 4.0 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
11635137|NCT00308269|Experimental|Vintafolide 2.5 mg IV Infusion|Vintafolide 2.5 mg administered by a 1-hour IV infusion on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
11635138|NCT00308269|Experimental|Vintafolide 3.0 mg IV Infusion|Vintafolide 3.0 mg administered by a 1-hour IV infusion on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
11635139|NCT00308256|Experimental|Nurse counseling|Phone calls performed by nurse 15 days after each monthly visit
11635140|NCT00308256|No Intervention|Control|Normal monthly follow-up without phone calls
11635141|NCT00308230|Placebo Comparator|Normal Heart|Control Group with Normal Heart
11635142|NCT00308230|Active Comparator|Congenital Heart Disease|Tetralogy of Fallot, DTGA, CCTGA
11635143|NCT00308230|Active Comparator|Heart Failure|Left ventricular heart failure, no congestive heart disease
11635144|NCT00308204|Experimental|Raptiva|raptiva injection
11635145|NCT00308165|Experimental|Topotecan|Once a plastic catheter is placed, within 24 hours of placement, the catheter will be connected to a small pump at the bedside, and the convection-enhanced delivery of the Topotecan will begin. The Topotecan will be infused for 4 to 5 days after which time the catheters will simply be pulled out. Patients will be monitored with blood tests and MRI scans during the treatment and at different time periods during the following months.
11635146|NCT00308152|No Intervention|Control|Observation only
11635147|NCT00308152|Active Comparator|Active|Infusion of 1 liter normal saline before sedated colonoscopy
11635148|NCT00308139|Experimental|Exenatide Once Weekly|Subcutaneous injection (SC), once a week of long acting release (LAR) exenatide.
11635310|NCT00306475|Placebo Comparator|2|
11635149|NCT00308139|Active Comparator|Exenatide Twice Daily|"subcutaneous injection (SC), twice a day for the first 30 weeks, followed by exenatide LAR SC injection weekly for the remainder of the study.
~Sub-study: Exenatide 2 mg subcutaneous injection, Administered Using the Exenatide Once Weekly Single-Dose Tray , once a week for 11 visits, switch to Exenatide 2 mg subcutaneous injection, Administered Using the Dual chamber pen device. Exenatide 2mg SC injection administered using the Dual chamber pen device."
11635150|NCT00308113|Active Comparator|1|CoenzymeQ10 taken once a day each morning by mouth.
11635151|NCT00308113|Active Comparator|2|Prednisone taken once a day each morning by mouth
11635152|NCT00308113|Active Comparator|3|CoenzymeQ10 and prednisone each taken once a day in the morning by mouth.
11635153|NCT00308113|No Intervention|4|Enhanced standard of care.
11635154|NCT00308100|Experimental|1|
11635155|NCT00308100|Active Comparator|2|
11635156|NCT00308087|Active Comparator|Rituximab|
11635157|NCT00308087|Experimental|Rituximab + Sargramostim|
11635158|NCT00308074|Experimental|Aripiprazole|aripiprazole monotherapy, begun at 2.5 mg or 5.0 mg based on clinical impression and severity of aggression and agitation. Dose to be adjusted in not more than 5 mg increments, weekly. The lowest effective dose will be used up to a maximum daily dose of 20 mg.
11635159|NCT00308061|Experimental|FMP1/AS02A Vaccine|500 uL of FMP1/AS02A is given to subject on days 0, 30+7, and 60+7 in the left deltoid muscle
11635160|NCT00308061|Active Comparator|Imovax Rabies Vaccine|1 mL of Imovax Rabies Vaccine is given to subject on days 0, 30+7, and 60+7 in the left deltoid muscle
11635161|NCT00308009|Active Comparator|1|Group I, Prolapse repair and TVT concomitantly
11635162|NCT00308009|Active Comparator|2|Group II, Prolapse repair and TVT 3 months afterwards if necessary
11635163|NCT00307931|Experimental|Certolizumab pegol|certolizumab pegol 400 mg
11635164|NCT00307905|Active Comparator|A|TRAUMEEL S
11635165|NCT00307905|Placebo Comparator|B|placebo remedy
11635166|NCT00307892|Active Comparator|A|TRAUMEEL S
11635167|NCT00307892|Placebo Comparator|B|comparable placebo remedy (injection and oral)
11635168|NCT00307866|Experimental|Arm 1|
11635169|NCT00307853|Active Comparator|1|TraumeelS
11635170|NCT00307853|Placebo Comparator|Placebo|
11635171|NCT00307827|Experimental|Arm 1|Visilizumab low dose level
11635172|NCT00307827|Experimental|Arm 2|Visilizumab middle dose level
11635173|NCT00307827|Experimental|Arm 3|Visilizumab high dose level
11635174|NCT00307801|Experimental|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|A blister consists of 28 tablets taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo.
11635175|NCT00307801|Placebo Comparator|Placebo|Matching placebo to be taken orally daily.
11635176|NCT00307762|Experimental|1|Gait trainer exercise actively for 20 minutes + 55 minutes other gait-oriented physiotherapy
11635177|NCT00307762|Active Comparator|2|Overground walking exercises actively for 20 minutes + 55 minutes other gait-oriented physiotherapy
11635178|NCT00307762|No Intervention|3|Control patients with ordinary therapy
11635179|NCT00307749|Placebo Comparator|1|
11635180|NCT00307749|Experimental|2|
11635181|NCT00307749|Experimental|3|
11635182|NCT00307749|Experimental|4|
11635183|NCT00307736|Experimental|Chemotherapy and radiation|Continuous infusion 5-fluorouracil 225 mg/M2/d, bevacizumab 5 mg/kg IV q 14 days, erlotinib 50-150 mg orally daily for duration of radiation.
11635184|NCT00307723|Experimental|Regimen Level 1|Radiation/Oxaliplatin/5-FU
11635185|NCT00307723|Experimental|Regimen Level 2|Radiation/Oxaliplatin/Bevacizumab/5-FU
11635186|NCT00307710|Experimental|A: Trivalent Subvirion Vaccine|Group A: Trivalent subvirion vaccine - standard inactivated influenza vaccine by intramuscular injection.
11635187|NCT00307710|Experimental|B: Vaccine 15 μg|Group B: Trivalent rHA0 vaccine 15 μg per rHA0 (total 45 μg rHA0)
11635188|NCT00307710|Experimental|C: Vaccine 45 μg|Group C: Trivalent rHA0 vaccine 45 μg per rHA0 (total 135 μg rHA0)
11635189|NCT00307710|Experimental|D: Vaccine 135 μg|Group D: Trivalent rHA0 vaccine 135 μg per rHA0 (total 405 μg rHA0)
11635190|NCT00307684|Experimental|001|open label PR OROS methylphenidate Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
11635191|NCT00307684|Experimental|002|double blind PR OROS methylphenidate 18 36 54 72 or 90 mg/day once daily for 4 weeks
11635192|NCT00307684|Placebo Comparator|003|double blind placebo matching placebo tablets once daily for 4 weeks
11635193|NCT00307671|Other|A|conventional treatment
11635194|NCT00307671|Experimental|B|reduction dose
11635195|NCT00307632|Experimental|Norelgestromine (NLGM)/Ethinyl Estradiol (EE)|
11635196|NCT00307593|Active Comparator|1|Rituximab
11635197|NCT00307593|Active Comparator|2|Infliximab
11635198|NCT00307528|Active Comparator|Group A|
11635199|NCT00307528|Experimental|Group B|
11635200|NCT00307528|Experimental|Group C|
11635201|NCT00307528|Experimental|Group D|
11635202|NCT00307528|Experimental|Group E|
11635203|NCT00307528|Experimental|Group F|
11635204|NCT00307515|Experimental|1|Fibrin Sealant 2 (FS2)
11635205|NCT00307515|Active Comparator|2|Oxidized Regenerated Cellulose (Surgicel)
11635206|NCT00307502|Experimental|NVP|Nevirapine
11635207|NCT00307502|Experimental|EFV|Efavirenz
11635208|NCT00307502|Experimental|INV|Indinavir/ritonavir
11635209|NCT00307502|Experimental|NFV|Nelfinavir
11635210|NCT00307502|Experimental|SQV|Saquinavir/ritonavir
11635211|NCT00307502|Experimental|LPV|Lopinavir/ritonavir
11635212|NCT00307502|Experimental|ATV|Atazanavir
11635213|NCT00307502|Experimental|ATV/rtv|Atazanavir/ritonavir
11635214|NCT00307502|Experimental|Fos-APV|Fos-amprenavir/ritonavir
11635215|NCT00307502|Experimental|TPV|Tipranavir/ritonavir
11635216|NCT00307502|Experimental|DRV|Darunavir/ritonavir
11635217|NCT00307489|Experimental|1|TDF
11635218|NCT00307489|Experimental|2|FTC/TDF
11635311|NCT00306462|Active Comparator|1|Intravenous magnesium sulfate or placebo
11635219|NCT00307463|Active Comparator|strict volume control policy|strict volume control policy: Antihypertensive medicine will be stopped and strict volume control policy will be applied.
11635220|NCT00307463|Other|antihypertensive drugs administration|antihypertensive drugs administration: Antihypertensive medicine will be continued. Target BP will be 130/80 mmHg in both groups.
11635221|NCT00307437|Placebo Comparator|Group I: Placebo|
11635222|NCT00307437|Experimental|Group II: Ustekinumab 45 mg|
11635223|NCT00307437|Experimental|Group III: Ustekinumab 90 mg|
11635224|NCT00307398|Experimental|AL-3789|One injection to the study eye by the posterior juxtascleral depot procedure at 6-month intervals for 42 months.
11635225|NCT00307398|Sham Comparator|Anecortave Acetate Vehicle|One sham injection to the study eye at 6-month intervals for 42 months. Syringe containing AA vehicle was not inserted into the eye.
11635226|NCT00307333|Experimental|1|Very low birth weight infants with their HRC index continuously displayed. Clinicians can utilize the HRC score to develop treatment plan.
11635227|NCT00307333|No Intervention|2|Very low birth weight infants for whom the HRC index is not displayed. Infants receive standard of care treatment.
11635228|NCT00307320|No Intervention|1|
11635229|NCT00307320|Experimental|2|Relaxation techniques
11635230|NCT00307294|Experimental|thalidomide and doxil|Combination of Thalidomide and Doxil
11635231|NCT00307281||Registry|10 pack year tobacco smoking history required, current or former smokers accepted.
11635232|NCT00307216|Experimental|1|Participants will receive Graduated Recovery Intervention Program plus treatment as usual
11635233|NCT00307216|Active Comparator|2|Participants will receive treatment as usual
11635234|NCT00307203|Experimental|I|Experiment group received 300 mgs of bupropion, in addition to weekly CBT and nicotine replacement therapy
11635235|NCT00307203|Placebo Comparator|II|Placebo group received placebo, in addition to weekly CBT and nicotine replacement therapy
11635236|NCT00307190||Binge Eating Disorder|Women with Binge Eating Disorder
11635237|NCT00307190||Controls|Weight, age, and gender-matched control subjects
11635238|NCT00307177|Experimental|Arm D|25 subjects receive Recombinant rHA0 vaccine at 135 mcg per rHA0, via IM injection on Day 0
11635239|NCT00307177|Experimental|Arm C|25 subjects receive Recombinant rHA0 vaccine at 45 mcg per rHA0, via IM injection on Day 0
11635240|NCT00307177|Experimental|Arm B|25 subjects receive Recombinant rHA0 vaccine at 15 mcg per rHA0, via IM injection on Day 0
11635241|NCT00307177|Active Comparator|Arm A|25 subjects receive Standard TIV at 15 mcg HA per virus, in a total volume of 0.5 mL, by deep intramuscular (IM) injection on Day 0
11635242|NCT00307164|Active Comparator|NucleomaxX|Participants received NucleomaxX for 48 weeks
11635243|NCT00307164|Placebo Comparator|Placebo|Participants received NucleomaxX placebo for 48 weeks
11635244|NCT00307151|Experimental|Coh I: NVP|Cohort I: Previously received single dose nevirapine (SD NVP). Randomly assigned to receive an NNRTI-based regimen.
11635245|NCT00307151|Experimental|Coh I: LPV/r|Cohort I: Previously received SD NVP. Randomly assigned to receive a PI-based regimen.
11635246|NCT00307151|Experimental|Coh II: NVP|Cohort II: Did not previously receive SD NVP. Randomly assigned to receive an NNRTI-based regimen
11635247|NCT00307151|Experimental|Coh II: LPV/r|Cohort II: Did not previously receive SD NVP. Randomly assigned to receive a PI-based regimen
11635248|NCT00307125|Experimental|Pilot Phase-Rituximab plus immunosuppression|"Enrollment into a Stage 2 pilot treatment study will occur after Stage 1. Adult Rituximab Dosing (Subjects > 18 years): 1000 mg on days 0 and 14; Pediatric Rituximab Dosing (Subjects <\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).
~Standard immunosuppression is site-specific."
11635249|NCT00307125|Placebo Comparator|Pilot Phase-Placebo plus immunosuppression|"Adult Placebo Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Placebo Dosing (Subject <\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).
~Standard immunosuppression is site-specific."
11635250|NCT00307099|Experimental|Meropenem|Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.
11635251|NCT00307099|Active Comparator|Standard antibiotic therapy|Standard intravenous antibiotic therapy for a minimum of 8 days.
11635252|NCT00307086|Other|Autologous PBSCT|bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous peripheral blood stem cell transplant (PBSCT)
11635253|NCT00307047|Experimental|XIENCE V®|
11635254|NCT00307047|Active Comparator|TAXUS™ EXPRESS2™|
11635255|NCT00307034|Experimental|2-dose group|Subjects receiving GSK Biologicals' 10-valent pneumococcal conjugate vaccine at 2-4-11 months of age, co-administered with DTPa-combined vaccine (Infanrix hexa or Infanrix IPV/Hib) at 2-4-11 months of age.
11635256|NCT00307034|Experimental|Comparator group|Subjects receiving GSK Biologicals' 10-valent pneumococcal conjugate vaccine at 2-3-4-11 months of age, co-administered with DTPa-combined vaccine (Infanrix hexa or Infanrix IPV/Hib) at 2-4-11 months of age.
11635257|NCT00307021|Active Comparator|Group A|
11635258|NCT00307021|Experimental|Group B|
11635259|NCT00307008|Experimental|Group A|
11635260|NCT00306995|Experimental|SB218352_15 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 1 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
11635261|NCT00306995|Experimental|SB218352_8 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 2 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
11635262|NCT00306995|Experimental|SB218352_4 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 3 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
11635263|NCT00306995|Experimental|SB218352_2 Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 4 non-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
11635312|NCT00306462|Active Comparator|2|Oral nifedipine or placebo
11635264|NCT00306995|Experimental|SB218352_8AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 2 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
11635265|NCT00306995|Experimental|SB218352_4AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 3 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
11635266|NCT00306995|Experimental|SB218352_2AL Group|Male and female subjects over 60 years of age, healthy or with underlying disease, received 2 doses of SB218352 pandemic influenza A formulation 4 aluminium-adjuvanted vaccine, administered in the deltoid region of the non-dominant arm, at Day 0 and Day 21.
11635267|NCT00306956|Experimental|A|Recommendation to offer a pacifier to 15 days old newborn infants with successful breastfeeding
11635268|NCT00306956|Active Comparator|B|Recommendation not to offer a pacifier to normal newborn infant with successful breastfeeding at 15 days of age
11635269|NCT00306930|Other|A|Acetabular cup replacement with total hip arthroplasty
11635270|NCT00306917|Active Comparator|1|DuoFix HA
11635271|NCT00306917|Active Comparator|2|Porocoat porous coated
11635272|NCT00306904|Experimental|1|3.0 mg/eye dose group
11635273|NCT00306904|Experimental|2|1.5 mg/eye dose group
11635274|NCT00306904|Experimental|3|0.2 mg/eye dose group
11635275|NCT00306891|Experimental|Cediranib 45 mg Fed|Part A: Cediranib 45 mg Fed State
11635276|NCT00306891|Experimental|Cediranib 45 mg Fasted|Part A: Cediranib 45 mg Fasted State
11635277|NCT00306891|Experimental|Cediranib 45 mg Fixed Dose|Part B: Cediranib 45 mg Fixed Dose
11635278|NCT00306891|Experimental|Cediranib 30 - 90 mg Dose Escalation|Part B: Cediranib 30 - 90 mg Dose Escalation
11635279|NCT00306852|Active Comparator|Trabeculectomy|Trabeculectomy with mitomycin C
11635280|NCT00306852|Active Comparator|Implant|Baerveldt Implant
11635281|NCT00306839|Other|1|Tissel group
11635282|NCT00306839|Other|2|Suture group
11635283|NCT00306787|Experimental|Famciclovir|Patients received Famciclovir 1000 mg (2 x 500 mg tablets) twice a day for one day. The first dose was to be taken within 6 hours after onset of prodromal symptoms or genital herpes lesions and the second dose approximately 12 hours later. Patients also received 1 valacyclovir placebo capsule, beginning with the first famciclovir dose, twice a day for 3 days, each taken about 12 hours apart.
11635284|NCT00306787|Active Comparator|Valacyclovir|Patients received Valacyclovir 500 mg capsule twice a day approximately 12 hours apart for 3 consecutive days. The first dose was to be taken within 6 hours after onset of prodromal symptoms or genital herpes lesions. On the first day patients also received 2 famciclovir placebo tablets taken with the first 2 doses of Valacyclovir.
11635285|NCT00306774|Experimental|1|Participants will receive vitamin D (cholecalciferol)
11635286|NCT00306774|Placebo Comparator|2|Participants will receive a matched placebo
11635287|NCT00306735|Experimental|Palonosetron|
11635288|NCT00306709|Experimental|Teaching|
11635289|NCT00306670|Experimental|Rituximab|Patients will receive rituximab.
11635290|NCT00306670|Active Comparator|Oral cyclophosphamide|Patients will receive oral cyclophosphamide.
11635291|NCT00306644|Experimental|Arm 1|study drug
11635292|NCT00306631|Experimental|1|
11635293|NCT00306592|Experimental|Natalizumab|All study participants in 101-MS-322 (NCT00306592) and 101-MS-321 (NCT00297232) received open label 300 mg intravenous (IV) natalizumab 60-minute infusion once every 4 weeks (28 days ±7 days) for up to 48 weeks. After 48 weeks, participants from 101-MS-322 (NCT00306592) entering study 101-MS-321 (NCT 00297232; considered the Long-Term Treatment Period of 101-MS-322) were continued on treatment from Week 52 through Week 480.
11635294|NCT00306540|Active Comparator|1|Placebo Seroquel + existing therapy
11635295|NCT00306540|Experimental|2|Seroquel + existing therapy
11635296|NCT00306527|Active Comparator|cTIV\cTIV (adults)|Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.
11635297|NCT00306527|Active Comparator|cTIV\TIV (adults)|Subjects (18-60 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
11635298|NCT00306527|Active Comparator|cTIV\cTIV (elderly)|Subjects (≥61 years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of cell-derived trivalent influenza vaccine (cTIV) one year later, in this study.
11635299|NCT00306527|Active Comparator|cTIV\TIV (elderly)|Subjects (≥61years of age) previously vaccinated with cell-derived influenza vaccine (cTIV), received one dose of an egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
11635300|NCT00306527|Active Comparator|TIV\TIV (adults)|Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
11635301|NCT00306527|Active Comparator|TIV\cTIV (adults)|Subjects (18-60 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.
11635302|NCT00306527|Active Comparator|TIV\TIV (elderly)|Subjects (≥61 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of egg-derived trivalent influenza vaccine (TIV) one year later, in this study.
11635303|NCT00306527|Active Comparator|TIV\cTIV (elderly)|Subjects (≥61 years of age) previously vaccinated with egg-derived influenza vaccine (TIV), received one dose of cell-derived trivalent influenza (cTIV) one year later, in this study.
11635304|NCT00306501|Other|Button Press|Training with button press
11635305|NCT00306501|Other|Vibtrotactile|Sensory Stimulation - Vibrotactile device with button press to initiate swallowing during retraining
11635306|NCT00306501|Other|Cortical Stimulation|Training with Cortical stimulation - cortical stimulation during training with button press
11635307|NCT00306501|Other|Combined|Combined vibrotactile and cortical stimulation with button press training
11635308|NCT00306488|Experimental|OT-551 antioxidant eye drop|The fellow eye was treated with OT-551 antioxidant eye drops over the course of the study.
11635309|NCT00306475|Active Comparator|1|
11635313|NCT00306397|Active Comparator|A|Rapamycin - MMF after 3 months
11635314|NCT00306397|Active Comparator|B|Low dose tacrolimus - MMF - Rapamycin after 3 months
11635315|NCT00306384|Experimental|Alogliptin 12.5 mg|Alogliptin 12.5 tablet, orally, once daily for up to 4 years.
11635316|NCT00306384|Experimental|Alogliptin 25 mg|Alogliptin 25 mg tablet, orally, once daily for up to 4 years.
11635317|NCT00306228|Active Comparator|bare-metal stent without tirofiban|implantation of a bare-metal stent with no tirofiban infusion after fibrinolysis
11635318|NCT00306228|Active Comparator|bare-metal stent with tirofiban|implantation of a bare-metal stent with tirofiban infusion after fibrinolysis
11635319|NCT00306228|Active Comparator|paclitaxel-eluting stent without tirofiban|implantation of a paclitaxel eluting-stent with no tirofiban after fibrinolysis
11635320|NCT00306228|Active Comparator|paclitaxel-eluting stent with tirofiban|implantation of a paclitaxel eluting-stent with tirofiban infusion after fibrinolysis
11635321|NCT00306215|Experimental|1|Blinded study arm
11635322|NCT00306215|Experimental|2|Blinded study arm
11635323|NCT00306215|Experimental|3|Blinded study arm
11635324|NCT00306215|Experimental|4|Blinded study arm
11635325|NCT00306202|Experimental|Stratum 1 (Ph+ CP-CML)|Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP)
11635326|NCT00306202|Experimental|Stratum 2/3 (Ph+ ALL or AP/BP-CML)|Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML)
11635327|NCT00306202|Experimental|Stratum 4 (Ph- ALL/AML)|Participants with second or subsequent relapse of Ph- ALL or Ph- AML
11635328|NCT00306189|Active Comparator|100 mg AMG 162|
11635329|NCT00306189|Active Comparator|60 mg AMG 162|
11635330|NCT00306189|Placebo Comparator|Placebo|
11635331|NCT00306189|Active Comparator|14 mg AMG 162|
11635332|NCT00306163|Active Comparator|1|Ciclesonide 160 µg
11635333|NCT00306163|Active Comparator|2|Fluticasone 100 µg
11635334|NCT00306150|Experimental|Arm 1|
11635335|NCT00306150|Placebo Comparator|Arm 2|
11635336|NCT00306137|Experimental|Arm 1|
11635337|NCT00306137|Placebo Comparator|Arm 2|
11635338|NCT00306111|Experimental|Pegfilgrastim|Pegfilgrastim for stem cell mobilization (single arm)
11635339|NCT00306098|Experimental|Islet transplantation|
11635340|NCT00306059|Experimental|patients having acute kidney injury|
11635341|NCT00306007||English prenatal|English speaking women recruited from the general OB/GYN clinic
11635342|NCT00306007||Spanish prenatal|Spanish speaking (monolingual) women recruited from the general OB/GYN clinic
11635343|NCT00306007||English abortion clinic|English speaking women recruited from the abortion clinic
11635344|NCT00306007||Spanish abortion clinic|Spanish speaking (monolingual) women recruited from the abortion clinic
11635345|NCT00305942|Experimental|1|"Topotecan 4mg/m2 IV on days 1, 8.
~Carboplatin AUC=5 IV day 1 only .
~- Cycles are repeated every 21 days for > 4 cycles of topotecan and carboplatin (maximum 6 courses). Restaging studies will be performed every 2 cycles (or 6 weeks.)"
11635346|NCT00305929|Experimental|1|Treatment with Tookad VTP
11635347|NCT00305916|Active Comparator|1|conventional coronary angiography
11635348|NCT00305916|Experimental|2|multislice spiral computed tomography coronary angiography
11635349|NCT00305890|Experimental|1|Participants will partake in a lifestyle behavioral weight management program for 24 weeks.
11635350|NCT00305890|Experimental|2|Participants will partake in pain-coping skills training for 24 weeks.
11635351|NCT00305890|Experimental|3|Participants will partake in lifestyle behavioral weight management program plus pain-coping skills training for 24 weeks.
11635352|NCT00305890|Active Comparator|4|Participants will receive standard care for 24 weeks.
11635353|NCT00305877|Experimental|Arm I (cetuximab, gemcitabine, capecitabine, radiation)|Patients receive cetuximab IV over 60-120 minutes on day 1, once weekly, in weeks 1-24; gemcitabine hydrochloride IV over 30 minutes on day 1, once weekly, in weeks 1-3, 13-15, 17-19, and 21-23; oral capecitabine twice daily on days 1-5, 5 days a week, in weeks 5-10. Patients also undergo radiotherapy once daily, 5 days a week, beginning in week 5 and continuing for approximately 5½ weeks (25 fractions).
11635354|NCT00305877|Experimental|Arm II (bevacizumab, gemcitabine, capecitabine, radiation)|Patients receive bevacizumab IV over 60-90 minutes on day 1 in weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, and 23. Patients also receive gemcitabine hydrochloride and capecitabine and undergo radiotherapy as in arm I.
11635355|NCT00305864|Experimental|Phase I: MGd 3 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11635356|NCT00305864|Experimental|Phase I: MGd 4 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40.Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11635422|NCT00304954|Active Comparator|Intravenous Daclizumab|Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
11635423|NCT00304954|Active Comparator|Intravenous Infliximab|Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
11635357|NCT00305864|Experimental|Phase I: MGd 5 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5.Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11635358|NCT00305864|Active Comparator|Phase II: MGd 5 mg/kg|Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Beginning the night before the first dose of radiotherapy and ending the night before the last dose of radiotherapy, patients receive concurrent oral temozolomide once daily on days 0-39. Patients also receive MGd IV over 30 minutes prior to radiotherapy once daily on days 1-5 and 8-12 and then on days 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, 38, and 40. Beginning 28 days after the completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11635359|NCT00305851|Experimental|"Low Dose Control Books on Tape"|Individuals randomly assigned to low-dose control group will have the same amount and timing of contacts as TMV group. A trained music therapist delivers the low-dose intervention (music therapy). Low-dose control group AYA initially choose up to three books-on-CD from a library selection of popular recordings. During the six sessions with the music therapist, AYA listens to the book and/or discusses their impressions and thoughts about he contents. Our rationale for having options of either listening to or discussing is to ensure the intervener has activities that will provide comparable contact time compared to the TMV group. As a parallel activity to the TMV protocol during which participants can work on their music video between sessions, AYA in the low-dose control group are provided with a portable CD player to listen to the books anytime during their hospitalization. As books ar e completed, or if the AYA changes their mind about the choice, the intervener offers other books.
11635360|NCT00305851|Experimental|"Experimental Music Video"|Intervention includes six 1-hour sessions (two sessions per week over 3 weeks) designed specifically for the pre-transplant and acute phase of treatment. The initial TMV session with the therapist occurs within 3 days of hospital admission. The phases of the intervention that require patient participation include song writing, recording the song with a digital accompaniment track, completing a video layout work sheet (determining the contents of the video), taking photos or making drawings for the video, and viewing clip art and pictures on a computer. The protocol concentrates many of these cognitive and active components to produce the video at the beginning, when patients experience less fatigue and malaise
11635361|NCT00305825|Experimental|Study intervention|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral letrozole once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11635362|NCT00305773|Experimental|Arm I (once daily vorinostat)|Patients receive oral vorinostat (SAHA) once a day on days 1-21. In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
11635363|NCT00305773|Experimental|Arm II (thrice daily vorinostat)|Patients receive oral SAHA three times a day on days 1-14. In both arms, treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
11635364|NCT00305760|Experimental|Cyclophosphamide, Pancreatic Tumor Vaccine, Cetuximab|
11635365|NCT00305747|Experimental|BR-DIM|BR-DIM will be administered at a starting dose of 75 mg po twice daily. Patients will be instructed to take tablets twice daily with 8 ozs. of water, with/without food. A study calendar will be provided and patients will be asked to fill the appropriate boxes when they take their study capsules. One treatment cycle is 28 days.
11635366|NCT00305734|Experimental|Treatment (bortezomib, gemcitabine hydrochloride)|"Patients receive bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses of treatment with bortezomib.
~Patients who experience disease progression on single-agent bortezomib and did not receive prior gemcitabine hydrochloride may begin combination therapy within 10-28 days of the last dose of bortezomib. Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and bortezomib IV on days 1, 4, 8, 11. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond the confirmed CR."
11635367|NCT00305695|Experimental|Arm I (zoledroic acid)|Beginning 60-90 days after surgery, patients receive zoledronate IV over 15 minutes once in months 3, 9, and 15.
11635368|NCT00305695|No Intervention|Arm II (clinical observation)|Patients are observed for 18 months after surgery.
11635369|NCT00305682|Active Comparator|Arm 1-Previous Autologous Transplant|Arm 1 - hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
11635370|NCT00305682|Active Comparator|Arm 2 - No Prior Autologous Transplant|Arm 2 - hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
11635371|NCT00305682|Active Comparator|Arm 3 - Refractory Leukemia/Lymphoma|Arm 3 - patients with refractory leukemia or lymphoma who have been rendered aplastic either by induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
11635372|NCT00305682|Active Comparator|Arm 4: MT2006-01 coenrolling patients|Arm 4 - hematologic malignancy patients enrolled in MT2006-01. Conditioning Fludarabine dose of 40 mg/m2/day x 5, cyclophosphamide and total body irradiation with or without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
11635373|NCT00305682|Active Comparator|Arm 5 - Previous Autologous Transplant|Arm 5 - hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycle of multiagent chemotherapy within the last 3 months previous to umbilical cord blood transplant (UCBT). Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation without anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
11635374|NCT00305682|Active Comparator|Arm 6 - No prior autologous transplant|Arm 6 - hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplant (UCBT), and who should receive anti-thymocyte globulin as conditioning regimen. Conditioning Fludarabine dose of 30 mg/m2/day x 5, cyclophosphamide and total body irradiation with anti-thymocyte globulin followed by umbilical cord blood transplantation, and peri-transplant Mycophenolate Mofetil and Sirolimus.
11635375|NCT00305669|Experimental|GM-CSF before surgery|GM-CSF dose prior to surgery- Cohort 1-GM-CSF 250mcg/m2 for 2 weeks Cohort 2-GM-CSF 250mcg/m2 for 3 weeks Cohort 3-GM-CSF 250mcg/m2 for 4 weeks Cohort 4-GM-CSF 125mcg/m2 for 4 weeks
11635376|NCT00305656|Experimental|Arm I|Patients receive oral AZD2171 once daily on days 1-28.
11635377|NCT00305643|Experimental|Arm I: Celecoxib + Capecitabine|Celecoxib 200 mg given orally twice/day along with standard capecitabine treatment (Initial dose of 750-1500 mg/m^2 orally twice/day).
11635378|NCT00305643|Placebo Comparator|Arm II: Placebo + Capecitabine|Placebo with standard capecitabine treatment (Initial dose of 750-1500 mg/m^2 orally twice/day)
11635379|NCT00305604|Active Comparator|1|sitagliptin
11635380|NCT00305604|Placebo Comparator|2|Placebo
11635381|NCT00305578|Placebo Comparator|Placebo|Placebo daily
11635382|NCT00305578|Active Comparator|Memantine|Daily dose Memantine
11635383|NCT00305565|Other|Low Dose|
11635384|NCT00305565|Other|Medium Dose|
11635385|NCT00305565|Other|High Dose|
11635386|NCT00305552|Experimental|1|THALIDOMIDE
11635387|NCT00305539|Active Comparator|1|
11635388|NCT00305539|Placebo Comparator|2|placebo
11635389|NCT00305461|Active Comparator|1|Ciclesonide 160µg
11635390|NCT00305461|Active Comparator|2|Ciclesonide 320µg
11635391|NCT00305448|Experimental|1|Fulvestrant 250 mg intramuscular injection
11635392|NCT00305448|Experimental|2|Fulvestrant 250mg (Plus 250mg Loading Regimen)
11635393|NCT00305448|Experimental|3|Fulvestrant 500 mg
11635394|NCT00305435|Experimental|romiplostim (AMG-531)|
11635395|NCT00305344|Active Comparator|Cord Blood|Umbilical Cord Blood
11635396|NCT00305279|Active Comparator|1|
11635397|NCT00305279|Active Comparator|2|
11635398|NCT00305279|Active Comparator|3|
11635399|NCT00305253|No Intervention|Pre-Intervention|The Pre-Intervention Phase served as the Control / Baseline group.
11635400|NCT00305253|Experimental|Post-Intervention|Intervention used in this phase and outcomes compared to the Pre-Intervention phase.
11635401|NCT00305227|Experimental|Lactin-V|Vaginal capsule containing Lactobacillus crispatus in high concentration. Self-administered once daily for 5 days during the 1st week. Self-administered once weekly for 10 weeks.
11635402|NCT00305227|Placebo Comparator|Placebo|Vaginal capsule - placebo. Self-administered once daily for 5 days during the 1st week. Self-administered once weekly for 10 weeks.
11635403|NCT00305188|Experimental|Xaliproden (SR57746A)|
11635404|NCT00305188|Placebo Comparator|Placebo|
11635405|NCT00305175||Patients With Prior Hydroxyurea|Patients who have received hydroxyurea therapy before entering the study.
11635406|NCT00305175||Patients Without Prior Hydroxyurea|Patients who have not received hydroxyurea before study entry.
11635407|NCT00305162|Experimental|Cangrelor|placebo capsules (to match) + cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + active clopidogrel (600mg) post infusion
11635408|NCT00305162|Active Comparator|Clopidogrel|clopidogrel capsules (600 mg) + placebo bolus & infusion (to match) + placebo capsules (to match) post infusion
11635409|NCT00305123||1|12,000 children 5 to 16 years of age attending the 4 public elementary schools in Djikoroni-para-Sébénikoro, Bamako, Mali.
11635410|NCT00305110|Experimental|2 mg IV hydromorphone|2 mg IV hydromorphone administered over 2-3 minutes
11635411|NCT00305097|Experimental|Caffeinated coffee|Caffeinated coffee
11635412|NCT00305097|Experimental|Decaffeinated coffee|Decaffeinated coffee
11635413|NCT00305097|Active Comparator|No coffee|
11635414|NCT00305084|Experimental|A|
11635415|NCT00305058|Experimental|Hydromorphone|0.0075 mg/kg IV hydromorphone
11635416|NCT00305058|Active Comparator|Morphine|0.05 mg/kg IV morphine
11635417|NCT00305045|Active Comparator|High-frequency Left (HFL)|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Subjects under age 65 will have treatment delivered at 100% of the RMT; those over age 65 will have treatment delivered at 120% of the RMT.
~Site of Stimulation: left hemisphere of DLPFC.
~Frequency: 10 Hz.
~Duration: 29 - 5 second trains with 30 second inter-train interval."
11635418|NCT00305045|Active Comparator|Bilateral|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Subjects under age 65 will have treatment delivered at 100% of the RMT; those over age 65 will have treatment delivered at 120% of the RMT.
~Sites of Stimulation: right and left hemispheres of the DLPFC.
~Frequency: 1 Hz over the right DLPFC followed by 10 Hz over the left DLPFC.
~Duration: i) low-frequency right: 4 trains of 100 second duration and one train of 65 second duration, with a 30 second inter-train interval, followed by ii) HFL: 15 - 5 second trains with 30 second inter-train interval."
11635419|NCT00305045|Sham Comparator|Sham Stimulation|Stimulation will occur over the site of active treatment, but with only the side-edge resting on the scalp. It will be administered as HFL for 17 minutes, with the coil angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
11635420|NCT00305032|Experimental|1|
11635421|NCT00305006|Experimental|A|CIMT
11635932|NCT00298623|Experimental|XP13512 (GSK1838262)|
11635424|NCT00304954|Active Comparator|Oral Rapamycin|Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
11635425|NCT00304954|Other|Observation|Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
11635426|NCT00304915|Experimental|Arm 1: Collaborative Care Intervention|HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received collaborative care intervention.
11635427|NCT00304915|No Intervention|Arm 2: Usual Care|HIV patients were screened for depression and the screener results were available to HIV clinicians. Depressed HIV patients received usual care.
11635428|NCT00304863|No Intervention|Arm 1|This are will not receive Lactobacillus
11635429|NCT00304863|Experimental|Arm 2|This arm will receive lactobacillus
11635430|NCT00304850|Experimental|R+ / K+|
11635431|NCT00304850|Experimental|R+ / K-|
11635432|NCT00304850|Experimental|R- / K+|
11635433|NCT00304850|Placebo Comparator|R- /K-|
11635434|NCT00304798|Experimental|Admission|Admission
11635435|NCT00304798|No Intervention|Discharge|Discharge
11635436|NCT00304772|Active Comparator|1|
11635437|NCT00304772|Active Comparator|2|
11635438|NCT00304759|Experimental|1|6000 cGy / 20 fractions in 4 weeks
11635439|NCT00304759|Active Comparator|2|7800 cGy / 39 fractions in 8 weeks
11635440|NCT00304746|Active Comparator|testosterone gel|AndroGel (1% testosterone transdermal gel), 2.5 g to 10 g daily
11635441|NCT00304746|Placebo Comparator|placebo gel|Placebo gel
11635442|NCT00304707|Experimental|2|participants in this arm receive bupropion
11635443|NCT00304707|Placebo Comparator|1|placebo
11635444|NCT00304603||Patients from previous topiramate obesity and diabetes studies|The patients from previous topiramate obesity and diabetes studies (PRI/TOP-INT-31 or PRI/TOP-INT-33 or a subset of patients with diabetes mellitus who were randomized within the PRI/TOP-INT-34 study at sites that also participated in the PRI/TOP-INT-31 study.
11635445|NCT00304564|Experimental|geriatric community|Subject will stand on a computerized posturography force plate and stability scores are measured
11635446|NCT00304551|Experimental|1|
11635447|NCT00304551|Experimental|2|
11635448|NCT00304551|No Intervention|3|
11635449|NCT00304525|Experimental|RAF265 - Arm 1|Patients received 10mg RAF265 as a once weekly dose until progressive disease was confirmed.
11635450|NCT00304525|Experimental|RAF265 - Arm 2|"RAF265 is given as a single PK run-in dose, a single loading dose on day 1 of cycle 1, followed by once daily maintenance doses."
11635451|NCT00304525|Experimental|RAF265 - Arm 3|Patients were treated with once weekly dosing of RAF265
11635452|NCT00304525|Experimental|RAF265 - Arm 4|Patients with locally advanced or metastatic melanoma will utilize a dose close to or at the MTD/RPTD of the liquid formulation that was determined in Arm 2.
11635453|NCT00304525|Experimental|RAF265 - Arm 5|RAF265 was administered as a continuous dose for 2 weeks followed by a dose holiday of 1 week.
11635454|NCT00304512|Experimental|Migalastat Low Dose 50 mg|Migalastat 50 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
11635455|NCT00304512|Experimental|Migalastat Middle Dose 150 mg|Migalastat 150 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
11635456|NCT00304512|Experimental|Migalastat High Dose 250 mg|Migalastat 250 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week treatment extension period.
11635457|NCT00304434|Other|1|
11635458|NCT00304382|Experimental|PPV-PCV|Patients receive Pneumovax, and 6 months later Prevnar
11635459|NCT00304382|Experimental|PCV-PPV|Patients receive Prevnar, and 6 months later Pneumovax
11635460|NCT00304382|Experimental|PCV-PCV|Patients receive Prevnar, and 6 months later Prevnar again
11635461|NCT00304382|Experimental|PCV only|Patients receive Prevnar only
11635462|NCT00304356|Other|active drug|500 mg nitazoxanide bid given to patient
11635463|NCT00304317|Experimental|I|Celecoxib
11635464|NCT00304317|Placebo Comparator|II|Placebo
11635465|NCT00304304|Active Comparator|Intervention - asthma education|CCC received asthma education in the first 6 months of the study
11635466|NCT00304304|Placebo Comparator|Wait-list control|CCC received asthma education in second 6 months of study
11635467|NCT00304278|Experimental|RADPLAT and Tarceva|"All patients will receive RADPLAT and Tarceva:
~Drug: Erlotinib (Tarceva)
~150 mg daily X 7 weeks
~Other Names:
~Tarceva
~Drug: Intra-arterial Cisplatin (PLAT)
~1 dose (150 mg/sq) per week X 4 weeks
~Other Names:
~Cisplatin
~Radiation: Radiation Therapy (RAD)
~5 days per week X 7 weeks"
11635468|NCT00304265|Experimental|6th Dose Pertussis Vaccine Group|Participants received 6th dose of pertussis vaccine
11635469|NCT00304265|Experimental|5th Dose Pertussis Vaccine Group|Participants received 5th dose of pertussis vaccine
11635470|NCT00304200|Experimental|Single arm, Open Label|Single arm, Open Label Temodar and Sutent
11635471|NCT00304187|Experimental|Erythromycin|Subjects with Bulimia Nervosa will take erythromycin.
11635472|NCT00304187|Placebo Comparator|Placebo|Participants will take matched placebo.
11635473|NCT00304174||Subjects with bulimia nervosa|Participants with bulimia nervosa
11635474|NCT00304174||Controls between 80-120% of ideal weight|Controls without bulimia nervosa
11635475|NCT00304161|Active Comparator|Atomoxetine|Participants will receive 40-80mgs of atomoxetine orally once daily.
11635476|NCT00304161|Placebo Comparator|Placebo|Participants will receive placebo treatment once daily; the pill (taken orally) will resemble the atomoxetine pill but will not contain an active drug.
11635477|NCT00304148||CRIC Cohort|
11635478|NCT00304148||CRIC Subcohort|
11635479|NCT00304135|Active Comparator|Radio-chimiothérapie|Radio-chimiothérapie
11635480|NCT00304135|Experimental|GEMOX|GEMOX
11635481|NCT00304096|Experimental|Stratum 1: Receiving Hormone Therapy|Patients treated with 9 peptide vaccine who received hormone therapy
11636068|NCT00296647|Active Comparator|patch + lozenge|
11635482|NCT00304096|Experimental|Stratum 2: Not receiving hormone therapy|Patients receiving 9 peptide vaccine who did not receive hormone therapy
11635483|NCT00304083|Experimental|Chemotherapy and local control by radiotherapy and surgery|Patients receive doxorubicin hydrochloride and ifosfamide (IA) chemotherapy. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity. Patients then receive etoposide and ifosfamide (IE) chemotherapy. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim (G-CSF) subcutaneously (SC) after each chemotherapy course. After recovery from chemotherapy, patients undergo radiotherapy and receive 2 more courses of IE during radiotherapy followed by 2 more courses of IA after completion of radiotherapy. Some patients may then undergo surgery.
11635484|NCT00304083|Experimental|Chemotherapy and local control by surgery|Patients receive 2 courses of IA followed by 2 courses of IE as above. After recovery from chemotherapy, patients undergo surgery. After recovery from surgery, patients receive 2 more courses of IA followed by 2 more courses of IE in the absence of disease progression or unacceptable toxicity.
11635485|NCT00304070|Experimental|Stratum I (surgery, observation)|Patients undergo conventional surgery (primary tumor resection and retroperitoneal lymph node sampling) followed by observation. Patients who have undergone prior surgery without nodal sampling undergo observation only.
11635486|NCT00304070|Experimental|Stratum II (exploratory surgery, observation)|Patients undergo conventional surgery (primary tumor resection and extended regional lymph node dissection) followed by observation. Patients who have undergone prior surgery with simple resection of the primary tumor undergo exploratory surgery with extended regional lymph node dissection followed by observation.
11635487|NCT00304070|Experimental|Stratum III (chemotherapy, surgery)|Patients receive combination chemotherapy with a total of 8 cycles of chemotherapy with cisplatin, etoposide and doxorubicin hydrochloride, filgrastim (G-CSF). The first 2 to 4 cycles are called the induction phase, followed by mitotane alone for an additional 2 months. Some patients undergo conventional surgery after chemotherapy course 2 or 4. Some patients undergo additional conventional surgery after finishing all chemotherapy.
11635488|NCT00304031|Active Comparator|Conventional adjuvant TMZ|Concurrent radiation therapy with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle.
11635489|NCT00304031|Experimental|Dose-dense adjuvant TMZ|Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Starting four weeks after completion of RT, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle.
11635490|NCT00304031|Other|No adjuvant TMZ (not randomized )|Concurrent radiation therapy (RT) with concurrent temozolomide (75 mg/m2) up to 49 doses. Not randomized to either adjuvant TMZ arm.
11635491|NCT00304018|Experimental|cord blood transplant|
11635492|NCT00303992|Experimental|Trastuzumab and Irinotecan|
11635493|NCT00303979||Cohort A (longitudinal)|Longitudinal Cohort: Approximately 15,000 patients followed at baseline, 12 months and 24 months
11635494|NCT00303979||Cohort B (6 Month)|6 Month Cohort: Approximately 10,000 patients reviewed at single time point
11635495|NCT00303979||Cohort C (18 Month)|18 Month Cohort: Approximately 10,000 patients reviewed at single time point
11635496|NCT00303966|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11635497|NCT00303953|Experimental|Arm I|"Patients will receive an infusion of PXD101 once a day for 5 days. Treatment may repeat every 3 weeks for up to 2 years. Some patients will also undergo core biopsy and blood collection for laboratory studies before and after treatment.
~After finishing treatment, patients will be evaluated every 3-6 months for up to 3 years."
11635498|NCT00303901|Experimental|cryosurgery|cryoprobe is placed in the proper position using CT imaging guidance, and as internal tissue is being frozen, the physician avoids damaging healthy tissue by viewing the movement of the probe on CT images transmitted to a monitor similar to a television screen. Living tissue, healthy or diseased, cannot withstand extremely cold conditions.
11635499|NCT00303888|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on days 1, 8, and 15 and oral placebo three times daily on days 1-21.
11635500|NCT00303888|Experimental|Arm II|Patients receive oral phenoxodiol three times daily on days 1-21 and docetaxel IV over 1 hour on days 1, 8, and 15.
11635501|NCT00303875|No Intervention|Wait-list control|Wait-list control received diet & exercise counseling during year 2 as a courtesy
11635502|NCT00303875|Experimental|Lifestyle counseling|subjects randomized to receive diet & exercise counseling for one year
11635503|NCT00303862|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 4 weeks. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
11635504|NCT00303849|Experimental|Treatment (etoposide, mannitol, melphalan, carboplatin, STS)|Patients receive etoposide phosphate IV over 10 minutes, mannitol IA over 30 seconds, melphalan IA over 10 minutes, and carboplatin IA over 10 minutes on days 1 and 2. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Courses repeat every 4 to 6 weeks for up to 12 months.
11635505|NCT00303836|Experimental|Arm I|Patients undergo apheresis and in-vitro depletion of T-regulatory cells. Patients then receive a nonmyeloablative, lymphocyte-depleting preparative regimen comprising cyclophosphamide IV over 1 hour on days -8 and -7 and fludarabine IV over 15-30 minutes on days -6 to -2 followed by autologous T-regulatory-depleted lymphocytes IV over 20-30 minutes on day 0. Patients receive vaccination with gp100:209-217 (210M) and MART-1:27-35 peptides emulsified in Montanide ISA-51 subcutaneously (SC) on days 0-3, 20-23, 41-44, and 62-65. Patients also receive filgrastim (G-CSF) SC beginning on day 1 and continuing until blood counts recover.
11635506|NCT00303836|Experimental|Arm II|Patients receive treatment as in arm I. Patients also receive high-dose IL-2 IV over 15 minutes every 8 hours on days 0-4, beginning after the lymphocyte infusion. IL-2 treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11635507|NCT00303823|Experimental|Arm I|Patients receive oral green tea extract once daily for 16 weeks in the absence of unacceptable toxicity.
11635508|NCT00303823|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 16 weeks in the absence of unacceptable toxicity.
11635640|NCT00302211|Experimental|DB inhaled iloprost 6x/day|inhaled iloprost (5 μg) 6 times per day (6×/day) plus sildenafil with or without bosentan during the double blind period
11635509|NCT00303797|Experimental|Treatment (bortezomib, sorafenib tosylate)|"GROUP I (solid tumors-dose-escalation group): Patients receive oral sorafenib twice daily on days 1-21 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of sorafenib and bortezomib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
~GROUP II (multiple myeloma or chronic lymphocytic leukemia-maximum tolerated dose [MTD] group): Patients receive oral sorafenib at the MTD twice daily on days 3-21 of course 1 and on days 1-21 of each subsequent course. Patients also receive bortezomib IV over 3-5 seconds at the MTD on days 1, 4, 8, and 11.
~Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
11635510|NCT00303784|Active Comparator|LHRH agonists|"Patients randomised to the control arm will receive continuous treatment with LHRH agonists as per local practice. Treatment should continue for at least 3 years. LHRH antagonists, such as degarelix, are not allowed on the trial. The recommended anti-flare medication is bicalutamide and should be prescribed according to local practice. Control arm medication should be obtained from the hospital pharmacy or GP as per local practice."
11635511|NCT00303784|Experimental|Oestrogen Patches|Patients randomised to the investigational arm will receive transcutaneous oestrogen patches (100 micrograms/24 hours). Treatment should be planned to continue for at least 3 years. For patients prescribed bicalutamide or flutamide prior to randomisation, this treatment should be discontinued before treatment with the patches can commence (no washout period is needed).
11635512|NCT00303771|Active Comparator|LV5FU2 classique|LV5FU2 classique
11635513|NCT00303771|Experimental|LV5FU2 classique + irinotécan|LV5FU2 classique + irinotécan
11635514|NCT00303771|Active Comparator|LV5FU2 simplifié|LV5FU2 simplifié
11635515|NCT00303771|Experimental|LV5FU2 simplifié+ irinotécan|LV5FU2 simplifié + irinotécan
11635516|NCT00303758|Active Comparator|LV5FU2 simplifié + cisplatine puis gemcitabine si progression|LV5FU2 simplifié + cisplatine puis gemcitabine si progression
11635517|NCT00303758|Experimental|gemcitabine puis LV5FU2 simplifié + cisplatine si progression|gemcitabine puis LV5FU2 simplifié + cisplatine si progression
11635518|NCT00303732|Experimental|PTK787, RAD001|PTK787 (vatalinib) 1000 mg daily, RAD001 (everolimus) 5 mg daily
11635519|NCT00303719|Experimental|High Risk Patients|Nonmyeloablative conditioning using fludarabine, cyclophosphamide and low dose Total Body Irradiation with or without anti-thymocyte globulin followed by allogeneic hematopoietic stem cell transplantation, immunosuppressive cyclosporine and mycophenolate mofetil and post-transplant use of bone marrow-stimulating filgrastim.
11635520|NCT00303719|Experimental|Standard Risk Patients|Nonmyeloablative conditioning using fludarabine, cyclophosphamide and low dose Total Body Irradiation with or without anti-thymocyte globulin followed by allogeneic hematopoietic stem cell transplantation, immunosuppressive cyclosporine and mycophenolate mofetil and post-transplant use of bone marrow-stimulating filgrastim.
11635521|NCT00303667|Experimental|SCT w/Donor Natural Killer Cells - short schema|Patients with high risk myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation, receiving fludarabine phosphate (daily dose of 40mg/m^2), cyclophosphamide (administered on Day -15 only), cyclosporin A, total body irradiation, natural killer cells, aldesleukin, and thymoglobulin.
11635522|NCT00303667|Experimental|SCT w/Donor Natural Killer Cells - extended schema|Patients with high risk myeloid malignancies undergoing allogeneic hematopoietic stem cell transplantation, receiving fludarabine phosphate (daily dose of 35mg/m^2), cyclophosphamide (administered on Days -15 and -16), cyclosporin A, total body irradiation, natural killer cells, aldesleukin, and thymoglobulin.
11635523|NCT00303628|Active Comparator|Arm I|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 2 weeks for up to 12 courses.
11635524|NCT00303628|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive oxaliplatin, leucovorin calcium, and fluorouracil as in arm I.
11635525|NCT00303602|Experimental|A|Sublingual orally disintegrating olanzapine (SODO)
11635526|NCT00303602|Active Comparator|B|Oral olanzapine
11635527|NCT00303589|Experimental|1|
11635528|NCT00303589|Experimental|2|
11635529|NCT00303589|Active Comparator|3|
11635530|NCT00303563|Experimental|1|
11635531|NCT00303563|Experimental|2|
11635532|NCT00303563|Experimental|3|
11635533|NCT00303563|Placebo Comparator|4|
11635534|NCT00303524|Experimental|1|Zoladex 3-month depot
11635535|NCT00303524|Experimental|2|Zoladex 1-month depot
11635536|NCT00303498|Experimental|Sitaxsentan sodium|
11635537|NCT00303498|Placebo Comparator|Placebo|
11635538|NCT00303485|Experimental|Ibandronate|Participants received Ibandronate 150 mg tablet once-monthly along with a combination dietary supplement containing vitamin D 200 international units (IU) and elemental calcium 500 mg twice daily with meals for 6 months.
11635539|NCT00303485|Placebo Comparator|Placebo|Participants received a matching placebo tablet to Ibandronate once-monthly along with a combination dietary supplement containing vitamin D 200 IU and elemental calcium 500 mg twice daily with meals for 6 months.
11635540|NCT00303472|Experimental|Part A: 300 µg romiplostim|Cohort 1 in Part A, participants received romiplostim 300 µg subcutaneously once weekly for 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
11635541|NCT00303472|Experimental|Part A: 700 µg romiplostim|Cohort 2 in Part A, participants received romiplostim 700 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
11635542|NCT00303472|Experimental|Part A: 1000 µg romiplostim|Cohort 3 in Part A, participants received romiplostim 1000 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
11635543|NCT00303472|Experimental|Part A: 1500 µg romiplostim|Cohort 4 in Part A, participants received romiplostim 1500 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
11636069|NCT00296647|Active Comparator|buproion + lozenge|
11635544|NCT00303472|Experimental|Part B: 750 µg romiplostim SC QW|Part B participants received romiplostim 750 µg subcutaneously (SC) once weekly (QW) for 8 weeks. Participants who complete Part B could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.
11635545|NCT00303472|Experimental|Part B: 750 µg romiplostim SC Q2W|Part B participants received romiplostim 750 µg subcutaneously every two weeks (Q2W) for 8 weeks. Participants who complete Part B could continue to receive injections of romiplostim for up to 1 year in the extension treatment phase.
11635546|NCT00303472|Experimental|Part B: 750 µg romiplostim IV Q2W|Part B participants received romiplostim 750 µg intravenously (IV) once every two weeks for 8 weeks. Participants who complete Part B could continue to receive romiplostim for up to 1 year in the extension treatment phase.
11635547|NCT00303459|Experimental|A|Bosentan
11635548|NCT00303459|Placebo Comparator|B|Placebo
11635549|NCT00303446|Active Comparator|Dutasteride|Dutasteride 0.5 mg/day
11635550|NCT00303446|Placebo Comparator|Placebo|Matched placebo
11635551|NCT00303420|Active Comparator|1|Alteplase used by normal dwell procedure
11635552|NCT00303420|Experimental|2|"Alteplase given by an new push protocol"
11635553|NCT00303381|Experimental|Interferon-beta-1a, 44 microgram|
11635554|NCT00303381|Experimental|Interferon-beta-1a, 66 microgram|
11635555|NCT00303381|Placebo Comparator|Placebo|
11635556|NCT00303342|Experimental|mind body treatment|regulation of attention, respiration and posture
11635557|NCT00303342|Active Comparator|desensitization|mentation on insomnia behaviors and cognitive activity
11635558|NCT00303329|Experimental|Deferasirox|Deferasirox daily oral dose between 5-40 mg/kg/day
11635559|NCT00303316|Experimental|DTacP IPV HepB PRP-T Combined Vaccine Group|Participant will receive a booster dose of PENTAXIM™ having received DTacP-IPV-HepB-PRP-T (primary series) in Study A3L02.
11635560|NCT00303316|Active Comparator|PENTAXIM™ and ENGERIX B® Vaccine Group|Participant will receive a booster dose of PENTAXIM™ having received ENGERIX B® and PEDIATRICO in Study A3L02 (Primary series)
11635561|NCT00303303|Experimental|1|Active initial and maintenance therapy
11635562|NCT00303303|Experimental|2|Active initial therapy; placebo maintenance therapy.
11635563|NCT00303303|Placebo Comparator|3|Placebo initial and maintenance therapy.
11635564|NCT00303290|Experimental|PEG-Intron + ARA-C|Peg Interferon Alpha 2b (Peg Intron) 4.5 micrograms/kg once a week. ARA-C 10 mg under the skin daily.
11635565|NCT00303277|Active Comparator|1|simvastatin
11635566|NCT00303277|Active Comparator|2|pravastatin
11635567|NCT00303251|Experimental|TKI258|
11635568|NCT00303212|No Intervention|UC|Usual HF guideline-base care
11635569|NCT00303212|Experimental|TM|Telemonitoring group plus usual guideline-based HF care
11635570|NCT00303199|Experimental|Single Arm|
11635571|NCT00303134|Experimental|Islet Cell Transplantation|
11635572|NCT00303108|Experimental|Arm 1|Patients will receive IV Doxil 30 mg/m2 and carboplatin AUC=5 on Day 1 of each cycle. A cycle consists of 28 days. In addition, HER2+ (IHC3+ and FISH+) patients only will receive a one-time loading dose of Herceptin 8 mg/kg IV on Day 1 of Cycle 1 and 4 mg/kg on Day 1 and Day 15 of every cycle thereafter.
11635573|NCT00303069|Experimental|V710 5 μg|V710 S. aureus vaccine
11635574|NCT00303069|Experimental|V710 30 μg|V710 S. aureus vaccine
11635575|NCT00303069|Experimental|V710 90 μg|V710 S. aureus vaccine
11635576|NCT00303069|Placebo Comparator|Placebo|Placebo
11635577|NCT00303043||1|
11635578|NCT00303030|Active Comparator|1. Anal injection|
11635579|NCT00303030|Active Comparator|2. Biofeedback|
11635580|NCT00303017|Experimental|flavocoxid|medical food
11635581|NCT00303017|Active Comparator|naproxen|NSAID
11635582|NCT00302952|Experimental|Lovastatin|Participants are randomized to take two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. For toxicity, the dose could either be adjusted to one 40 mg lovastatin tablet or treatment could be discontinued. In addition to the active ingredient lovastatin, each tablet contained the following ingredients: microcrystalline cellulose, lactose monohydrate, magnesium stearate, and pregelatinized starch. Butylated hydroxyanisole (BHA) was added as a preservative and D&C Yellow #10, FD&C Blue #1, and Yellow #6 were added as dyes.
11635583|NCT00302952|Placebo Comparator|Placebo|Participants are randomized to take two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion. For toxicity, the dose could either be adjusted to one placebo tablet or treatment could be discontinued. The placebo tablets contained microcrystalline cellulose, NF (Avicel PH 102) and Supro AA Swedish Orange Opaque Capsule Shells, Color 4188.
11635584|NCT00302900|Experimental|1|Pre-donation water and muscle tension during donation
11635585|NCT00302900|Experimental|2|Pre-donation water
11635586|NCT00302900|Sham Comparator|3|Pre-donation muscle tension
11635587|NCT00302900|No Intervention|4|Standard donation
11635588|NCT00302848||Users of Drospirenone (DRSP)|
11635589|NCT00302848||Users of Levonorgestrel (LNG)|
11635590|NCT00302848||Users of other oral contraceptives (OCs)|
11635591|NCT00302822|Experimental|Intensification|lopinavir or efavirenz and emtricitabine/tenofovir and intensification with enfuvirtide (week 0 to 24)
11635592|NCT00302822|Active Comparator|Standard|lopinavir or efavirenz and emtricitabine/tenofovir
11635593|NCT00302796|Experimental|Group A, Antibiotic|1 antibiotic tablet 45 patients Group
11635594|NCT00302796|Placebo Comparator|Group B: 1 placebo|1 placebo tablet
11635595|NCT00302796|Experimental|Group C: Antibiotics|2 antibiotic tablets 45 patients
11635596|NCT00302796|Placebo Comparator|Group D, Placebo|2 placebo tablets 36 patients
11635597|NCT00302744|Other|1|Each subject functions as their own control (one placebo session/one active drug session)
11635641|NCT00302211|Experimental|DB inhaled iloprost 4x/day|Inhaled iloprost (5 μg) 4×/day plus inhaled placebo 2x/day plus sildenafil with or without bosentan during the double blind period
11635642|NCT00302211|Placebo Comparator|DB inhaled placebo 6x/day|Inhaled placebo 6×/day plus sildenafil with or without bosentan during the double blind period
11635643|NCT00302211|Experimental|OL inhaled iloprost 6x/day|Inhaled iloprost (5 μg) 6 times per day (6×/day) plus sildenafil with or without bosentan during the Open-Label treatment period
11635598|NCT00302731|Active Comparator|1 equine estrogens m-progesteroneacetate|Menopausal women in first seven years of menopause randomized to arm 1 receive conjugated equine estrogens 0.45 mg combined with medroxyprogesteroneacetate 1.5 mg placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
11635599|NCT00302731|Experimental|2 estradiol estriol progesterone|Menopausal women in first seven years of menopause randomized to arm 2 estradiol .5mg, estriol 2.0mg, progesterone 100mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
11635600|NCT00302731|Experimental|4 estradiol progesterone|Menopausal women in first seven years of menopause randomized to arm 4 estradiol 0.5 mg, progesterone 100 mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
11635601|NCT00302731|Experimental|3 estriol progesterone|Menopausal women in first seven years of menopause randomized to arm 3 estriol 2.5mg, progesterone 100mg dosed orally / day placed in a placebo capsule to disguise contents from participant and study team. Drug dosed daily for 1 year. Screening FSH and PAP. Baseline mammogram, bone density, pelvic ultrasound, EKG, blood work for cholesterol panel (surrogate marker for cardiovascular disease), BUN/Creatinine. Repeated at 12 months. Safety check at 6 months includes BUN/creatinine, EKG, cholesterol panel, estradiol, progesterone levels.
11635602|NCT00302718|Experimental|Physician-level incentives|Examines the effect of physician-level financial incentives on hypertension quality of care
11635603|NCT00302718|Experimental|Practice-level incentives|Examines the effect of practice-level financial incentives on hypertension quality of care
11635604|NCT00302718|Experimental|Physician- and practice-level incentives|Examines the effect of physician- and practice-level financial incentives on hypertension quality of care
11635605|NCT00302718|No Intervention|No incentives (control)|Physician participants in this arm received only audit and feedback performance reports as did the participants in the intervention arms.
11635606|NCT00302705|Active Comparator|Valsartan|160 mg/day on awakening
11635607|NCT00302705|Active Comparator|Enalapril|10-20 mg/day on awakening
11635608|NCT00302666|Sham Comparator|Arm 1|
11635609|NCT00302666|Sham Comparator|Arm 2|
11635610|NCT00302653|Experimental|1|Rasburicase 0,20mg/Kg/Day once a day 3-7 days
11635611|NCT00302640|Active Comparator|Nitazoxanide|7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days
11635612|NCT00302640|Placebo Comparator|Placebo|7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days
11635613|NCT00302627|Experimental|Pamidronate, Vitamin D, and Calcium|"60mg or 90mg given at baseline, 6,12,18, and 24 months
~vitamin D 800 units/day
~calcium carbonate 1500 milligrams/day"
11635614|NCT00302601|Other|None relevant|Not relevant
11635615|NCT00302549|Active Comparator|FK506|
11635616|NCT00302536|Experimental|Tacrolimus|
11635617|NCT00302523|Active Comparator|FK506|
11635618|NCT00302510|Placebo Comparator|immunoadsorption|
11635619|NCT00302471|Experimental|1600 mg twice a day|MK0429
11635620|NCT00302471|Experimental|200 mg twice a day|MK0429
11635621|NCT00302471|Experimental|800 mg twice a day|MK0429
11635622|NCT00302471|Experimental|400 mg twice a day|MK0429
11635623|NCT00302458|Experimental|OROS-MPH + OROS-MPH|OROS-Methylphenidate Will be administered during the first part of the day, and again during the separate part of the day.
11635624|NCT00302458|Experimental|IR MPH + IR MPH|Immediate release methylphenidate will be administered in the first part of the day followed by Immediate release methylphenidate in the second part of the day.
11635625|NCT00302458|Placebo Comparator|Plabebo + Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
11635626|NCT00302458|Experimental|OROS MPH+ IR MPH|Concerta will be administered in the first part of the day, followed by Immediate Release Methylphenidate in the second part of the day.
11635627|NCT00302458|Experimental|IR MPH + OROS MPH|Immediate release Methylphenidate will be administered in the first part of the day, followed by Concerta in the second part of the day
11635628|NCT00302419|Experimental|1|Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given
11635629|NCT00302419|Active Comparator|2|Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed
11635630|NCT00302393|Active Comparator|IR-MPH|Immediate Release Methylphenidate administered before PET Scan
11635631|NCT00302393|Active Comparator|Concerta|OROS Methylphenidate (Concerta) administered before PET Scan
11635632|NCT00302380||un-medicated subjects with ADHD|
11635633|NCT00302380||subjects without ADHD|
11635634|NCT00302341|Experimental|1|pafuramidine maleate, oral tablet, 100 mg bid X 14 days
11635635|NCT00302341|Active Comparator|2|TMP/SMX oral tablet, 15 mg/kg, split tid X 21 days
11635636|NCT00302328|No Intervention|macular hole operation no peeling|
11635637|NCT00302328|Active Comparator|Macular hole operation ICG peeling|
11635638|NCT00302328|Experimental|Macular hole operation TB peeling|
11635639|NCT00302237||1|1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
11635732|NCT00300950|Experimental|2|Gemcitabine with GI-4000
11635733|NCT00300937|Experimental|A|
11635644|NCT00302211|Experimental|OL inhaled iloprost 4x/day|Inhaled iloprost (5 μg) 4 times per day (4×/day) plus sildenafil with or without bosentan during the Open-Label treatment period
11635645|NCT00302185|Active Comparator|Nurse-led supportive care|Visit with a Palliative Care nurse once weekly for 4 weeks
11635646|NCT00302185|Experimental|Acupuncture|Patients received acupuncture once a week for 4 weeks.
11635647|NCT00302172|Experimental|ARQ 197|
11635648|NCT00302159|Experimental|Valproic Acid|Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.
11635649|NCT00302146||Asymptomatic|Unaffected at-risk individuals with or without a first degree family member with parkinsonism, GD with and without a family history of PD, Gaucher carriers with and without a family history of PD.
11635650|NCT00302146||Control|Controls will include subjects without GBA mutations, with sporadic PD and healthy volunteers who do not have a family history of parkinsonism or Gaucher disease.
11635651|NCT00302146||PD|Subjects with parkinsonism to better characterize the parkinsonian phenotype (e.g.,GD/PD, Sporadic PD, Gaucher carrier PD).
11635652|NCT00302133|Experimental|Naltrexone add on to valproate|Naltrexone hydrochloride 50 mg capsule daily for 12 weeks add on to valproate
11635653|NCT00302133|Placebo Comparator|Placebo add on to valproate|Placebo comparator one capsule daily for 12 weeks add on to valproate
11635654|NCT00302107|Active Comparator|Arm 1|Mirtazapine
11635655|NCT00302107|Placebo Comparator|Arm 2|Placebo
11635656|NCT00302081|Active Comparator|PEG2b 1.5/R (24 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg daily for 24 weeks
11635657|NCT00302081|Experimental|PEG 2b 1.0/R (24 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 24 weeks
11635658|NCT00302081|Experimental|PEG2b 1.5/R (16 weeks)|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 mcg/kg QW SC plus ribavirin (SCH 18908) 800-1200 mg/day for 16 weeks
11635659|NCT00302068|Experimental|1|Supervised aerobic exercise, three times per week for 16 weeks.
11635660|NCT00302068|Active Comparator|2|Sertraline (Zoloft), for 16 weeks.
11635661|NCT00302068|Placebo Comparator|3|Placebo control, for 16 weeks.
11635662|NCT00302055|Active Comparator|one-on-one lifestyle|Clinical referral to diabetes prevention lifestyle intervention at School of Medicine campus
11635663|NCT00302055|Experimental|group-based community lifestyle|Clinical referral to group diabetes prevention lifestyle intervention program in community
11635664|NCT00302042|Experimental|1: Brief Counseling Plus Group Lifestyle|Brief counseling plus group diabetes prevention in community
11635665|NCT00302042|Active Comparator|2: Brief Counseling Alone|Brief Counseling for pre-diabetes alone
11635666|NCT00302029||CMV positive|CMV +, N=500/167
11635667|NCT00302029||CMV negative|CMV -, N=500/167
11635668|NCT00302003|Experimental|Doxorubicin, Vincristine, Cyclophosphamide and Filgrastim|Treatment consists of 3 cycles of Doxorubicin hydrochloride IV (25 mg/m2) days 1 & 2, Vincristine sulfate IV (1.4 mg/m2 [max 2.8 mg]) Days 1 & 8, Prednisone orally (40 mg/m2) Days 1-7, Cyclophosphamide IV (600 mg/m2) Days 1 & 2, Filgrastim by mouth or IV (5 micrograms/kg/dose) 24 hours after Cyclophosphamide complete. See detailed description for remainder of therapy.
11635669|NCT00301964|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
11635670|NCT00301951|Experimental|cord blood transplant|
11635671|NCT00301938|Experimental|Arm I (enzyme inhibitor, chemotherapy)|Patients receive a loading dose of oral perifosine every 6 hours on day 1 followed by a maintenance dose once daily on days 2-28 of course 1 and then once daily on days 1-28 in all subsequent courses. Patients also receive 7-hydroxystaurosporine IV over 3 hours on day 4. Cohorts of 3-6 patients receive escalating doses of 7-hydroxystaurosporine until the MTD is determined.
11635672|NCT00301938|Experimental|Arm 2 (enzyme inhibitor, chemotherapy)|Patients receive 7-hydroxystaurosporine IV over 3 hours on day 1 at the MTD determined in group I. Patients also receive oral perifosine as a loading dose every 6 hours on day 4 followed by a maintenance dose once daily on days 5-28 of course 1 and then once daily on days 1-28 in all subsequent courses.
11635673|NCT00301925|Active Comparator|Epi-CMF|
11635674|NCT00301925|Experimental|Accelerated Epi-CMF|
11635675|NCT00301925|Experimental|Epi-Capecitabine|
11635676|NCT00301925|Experimental|Accelerated Epi-Capecitabine|
11635677|NCT00301886|Experimental|zoledronate|zoledronate
11635678|NCT00301886|Experimental|ibandronate|ibandronate
11635679|NCT00301873|Experimental|IV Zometa|Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
11635680|NCT00301847|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11635681|NCT00301834|Experimental|Single arm - conditioning and transplant|Alemtuzumab 0.5 mg/kg (maximum 15 mg) daily for 3 days; Busulfan i.v. every 6 hours from day -9 to day -6 for 16 total doses; Fludarabine phosphate from day -5 for 4 days at 1.3 mg/kg (if patient was less than 12 kg) or 40 mg/m*2 per dose; Cyclosporine continuous infusion 3 mg/kg/Day beginning day -1 for GVHD prophylaxis; Methotrexate at 15 mg/m*2 on day +1, 10 mg/m*2 on days +3, +6, and (only for MUDs) day +11 also for GVHD prophylaxis; Methylprednisolone only as required for GVHD prophylaxis; allogeneic bone marrow transplantation or allogeneic hematopoietic stem cell transplantation or peripheral blood stem cell transplantation or umbilical cord blood transplantation.
11635682|NCT00301821|Experimental|Epratuzumab + Rituximab + CHOP|One arm open label.
11635683|NCT00301808|Experimental|Cisplatin, Docetaxel & Radiation Therapy|Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43; Docetaxel 75 mg/m2 on day 1 of each cycle; Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
11635684|NCT00301795|Experimental|Treatment (oblimersen sodium and rituximab)|"Induction therapy (month 1): Patients receive oblimersen IV continuously on days 1-7 and 15-21 and rituximab IV on days 3, 10, 17, and 24 in month 1.
~Extended induction therapy (months 3, 5, 7, and 9): Patients receive oblimersen IV continuously on days 22-28 and rituximab IV on day 24 in months 3, 5, 7, and 9.
~Treatment continues for 9 months in the absence of disease progression or unacceptable toxicity."
11635734|NCT00300898|Active Comparator|Nucleoplasty|Procedure/Surgery: Nucleoplasty
11635735|NCT00300898|Active Comparator|Percutaneous decompression|Procedure/Surgery: Percutaneous decompression
11635685|NCT00301769|Experimental|Arm I|Patients receive SJG-136 IV over 15 minutes on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients receive escalating doses of SJG-136 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD.
11635686|NCT00301756|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11635687|NCT00301652|Experimental|mycophenolate mofetil|
11635688|NCT00301613|Active Comparator|Mycophenolate mofetil|
11635689|NCT00301600|Active Comparator|Mycophenolate mofeti|
11635690|NCT00301561|Experimental|1|Simplify treatment follow-up
11635691|NCT00301561|Active Comparator|2|Standard treatment follow-up
11635692|NCT00301535|Experimental|1|
11635693|NCT00301535|No Intervention|2|
11635694|NCT00301522|Experimental|Arm 1|
11635695|NCT00301522|Active Comparator|Arm 2|
11635696|NCT00301483|Experimental|1|HBOC-201 followed by standard therapy
11635697|NCT00301483|Active Comparator|2|Standard Therapy
11635698|NCT00301457|Experimental|1|6 years adjuvant anastrozole therapy
11635699|NCT00301457|Experimental|2|3 years adjuvant anastrozole therapy
11635700|NCT00301418|Experimental|Tarceva (Erlotinib)|
11635701|NCT00301405|Active Comparator|Thalidomide|Open Label drug
11635702|NCT00301392|Other|Pitavastatin|Administration of Pitavastatin
11635703|NCT00301379||1|Patients with unresectable cholangiocarcinoma.
11635704|NCT00301366|Experimental|Alpha-1 Proteinase Inhibitor (Human), modified process|Study the safety and tolerability of weekly infusions of Alpha-1 Proteinase Inhibitor (Human), modified process (Alpha-1 MP, 60 mg/kg) over 20 weeks of therapy in adult Alpha-1 antitrypsin deficient subjects.
11635705|NCT00301249||Family Investigation of Nephropathy and Diabetes (FIND)|Individuals with diabetic nephropathy, their parents, and selected siblings
11635706|NCT00301249||African American MALD|Case-control study of African American patients with nephropathy (cases) and their spouses (controls) unaffected by diabetes and nephropathy; offspring were genotyped when available to provide haplotype data.
11635707|NCT00301249||Mexican American MALD|Case-control study of unrelated individuals of Mexican American heritage in which both cases and controls had diabetes, but only the case had nephropathy
11635708|NCT00301210|Experimental|1|tramadol dose 1
11635709|NCT00301210|Experimental|2|tramadol dose 2
11635710|NCT00301184|Experimental|1A|One 0.3 mg dose of DNA HIV vaccine or placebo administered at study entry and Month 2, followed by one dose of 1x10^7 TCID50 MVA or placebo at Months 4 and 6
11635711|NCT00301184|Experimental|1B|One 3.0 mg dose of DNA HIV vaccine or placebo administered at study entry and Month 2, followed by one dose of 1x10^8 TCID50MVA or placebo administered at Months 4 and 6
11635712|NCT00301184|Experimental|2A|One MTD (determined in Part 1) of DNA HIV vaccine or placebo administered at study entry. One dose of placebo or MTD of MVA at Months 2 and 6
11635713|NCT00301184|Experimental|2B|One dose of placebo or MTD of MVA administered at study entry and Months 2 and 6
11635714|NCT00301119||lung cancer screening cohort|observational only. no intervention. current, former and never smokers over age 50 without history of cancer, except for non melanoma skin cancer, no previous treatment with chemotherapy.
11635715|NCT00301119||r/o lung cancer|observational only. no intervention. patients with CT findings suspicious for lung cancer who are undergoing bronchoscopy and/or surgery.
11635716|NCT00301106|Experimental|adenovirus-mediated human interleukin-12|starting dose of ADV-hIL12 - 1 x 10 to the 10th power vp (virus particles) per patient, escalating in half-log increments up to 1 x 10 to the 13th power vp per patient, after which dose escalation will be at lower increments of 2 x 10 to the 13th power vp, to a maximum of 3.0 x 10 to the 13th power vp per patient.
11635717|NCT00301080|Placebo Comparator|Placebo (original version)|Placebo administered orally twice per day for 4 weeks.
11635718|NCT00301080|Active Comparator|D-cycloserine 200mg|D-cycloserine administered orally at a dose of 200 mg twice per day for 12 weeks.
11635719|NCT00301080|Active Comparator|D-cycloserine 50 mg|D-cycloserine administered orally at a dose of 50 mg twice per day for 12 weeks.
11635720|NCT00301080|Active Comparator|D-cycloserine 250mg|This was the original active comparator arm (before the design was changed): D-cycloserine administered orally at a dose of 250 mg twice per day for 4 weeks.
11635721|NCT00301080|Placebo Comparator|Placebo (revised version)|Placebo administered orally twice per day for 12 weeks.
11635722|NCT00301067|Experimental|Cohort 1 - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.
~Calcitriol dose of 0.2 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
11635723|NCT00301067|Experimental|Cohort 2 - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.
~Calcitriol dose of 0.3 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
11635724|NCT00301067|Experimental|Cohort 3 - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.
~Calcitriol dose of 0.5 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
11635725|NCT00301067|Experimental|Expansion - Temozolomide and Calcitriol|"Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days.
~Calcitriol dose of 0.5 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days."
11635726|NCT00301028|Experimental|Cetuximab + Carboplatin/Paclitaxel|Cetuximab beginning weekly dose 400 mg/m^2 intravenous (IV), and 250 mg/m^2 weeks 2-6; Weekly Carboplatin area under the curve (AUC) 2 and Paclitaxel 135 mg/m^2 for 6 courses.
11635727|NCT00301015|Experimental|1|Malaria diagnosis aided with rapid diagnostic test
11635728|NCT00301015|Active Comparator|2|Malaria diagnosis based on clinical judgement only
11635729|NCT00300976|Experimental|Intensive therapy|
11635730|NCT00300976|Active Comparator|Conventional therapy|
11635731|NCT00300950|Active Comparator|1|Gencitabine
11635925|NCT00298766|Experimental|1|VELCADE
11635736|NCT00300898|Active Comparator|Electrothermal disc decompression (IDET)|Procedure/Surgery: Intervertebral electrothermal disc decompression (IDET)
11635737|NCT00300898|Experimental|Behavioral:Conservative treatment|Conservative treatment with oral medications, physical therapy, epidural steroid injections
11635738|NCT00300885|Experimental|Sorafenib + C/P|Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
11635739|NCT00300885|Active Comparator|Placebo + C/P|Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
11635740|NCT00300872|Active Comparator|1|Continuous positive airway pressure (CPAP)
11635741|NCT00300872|Sham Comparator|2|Sham Continuous positive airway pressure (CPAP)
11635742|NCT00300846|Active Comparator|A1|
11635743|NCT00300846|Placebo Comparator|A2|
11635744|NCT00300781|Experimental|Neratinib 240 mg, with prior trastuzumab|Neratinib administered with 80 mg capsules and 40 mg coated tablets taken orally in prescribed dose of 240 mg daily, as long as tolerated and disease does not worsen.
11635745|NCT00300781|Experimental|Neratinib 240 mg, no prior trastuzumab|Neratinib administered with 80 mg capsules and 40 mg coated tablets taken orally in prescribed dose of 240 mg daily, as long as tolerated and disease does not worsen.
11635746|NCT00300768|Experimental|2 mg moxidectin|2 mg moxidectin (Dose-escalation 1st step)
11635747|NCT00300768|Active Comparator|Ivermectin 150 mcg/kg|Active comparator arm (ivermectin 150 mcg/kg).
11635748|NCT00300768|Experimental|4 mg moxidectin|4 mg moxidectin (dose escalation second step)
11635749|NCT00300768|Experimental|8 mg moxidectin|8 mg moxidectin (dose escalation third step)
11635750|NCT00300755|Active Comparator|1|Arm 1- Low Dose pantoprazole
11635751|NCT00300755|Active Comparator|2|Arm 2- Medium Dose pantoprazole
11635752|NCT00300755|Active Comparator|3|Arm 3- High Dose pantoprazole
11635753|NCT00300742|Experimental|Topiramate|Drug: Topiramate Other Name for Topiramate: Topamax
11635754|NCT00300729|Active Comparator|Celecoxib|Four cycles of combination chemotherapy, usually with carboplatin + gemcitabine or carboplatin + vinorelbine, plus celecoxib 400 mg b.i.d. Treatment with celecoxib is continued after completion of chemotherapy. Maximum treatment duration is one year.
11635755|NCT00300729|Placebo Comparator|Placebo|Chemotherapy as in arm 1 plus placebo capsules, b.i.d.
11635756|NCT00300677|Experimental|voriconazole|voriconazole twice daily
11635757|NCT00300638||1- MRI and interviews|In our research, we are trying to understand where in the brain these emotional behaviors take place, and whether or not the brain functions differently for alcoholic and nonalcoholic individuals. We present emotional words and pictures on a computer screen, and using Magnetic Resonance Imaging (MRI) scans, we observe how the brain works when people purposefully respond to the words and pictures. Interviews, cognitive tests, and emotional measurements will also be done. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
11635758|NCT00300612|Experimental|vaccine group|
11635759|NCT00300599|Active Comparator|A|Continue positive airway pressure
11635760|NCT00300599|Placebo Comparator|B|Placebo
11635761|NCT00300586|Sham Comparator|A (supervision)|medical supervision, second line chemotherapy if progression
11635762|NCT00300586|Active Comparator|B (gemcitabicine)|Maintenance treatment (gemcitabicine 1250 mg/m² J1, J8 (repeated cycles every 21 days), second line chemotherapy if progression
11635763|NCT00300586|Experimental|C (Erlotinib)|Treatment by erlotinib 150 mg/day (sequential treatment), second line chemotherapy if progression
11635764|NCT00300573|Experimental|Dexelvucitabine (DFC)|200 mg once daily
11635765|NCT00300573|Active Comparator|lamivudine (3TC)|300 mg once daily
11635766|NCT00300534|No Intervention|Abbott Laboratories Determine test for syphilis|Abbott Laboratories Determine rapid test for syphilis
11635767|NCT00300495|Experimental|1 - Amiodarone|Perioperative amiodarone
11635768|NCT00300495|Active Comparator|2 - Control|Control arm, standard care with no perioperative amiodarone
11635769|NCT00300482|Active Comparator|A|ABT-335 + 10 mg rosuvastatin
11635770|NCT00300482|Active Comparator|B|ABT-335 + 20 mg rosuvastatin
11635771|NCT00300482|Placebo Comparator|C|ABT-335 monotherapy
11635772|NCT00300482|Placebo Comparator|D|10 mg rosuvastatin monotherapy
11635773|NCT00300482|Placebo Comparator|E|20 mg rosuvastatin monotherapy
11635774|NCT00300482|Placebo Comparator|F|40 mg rosuvastatin monotherapy
11635775|NCT00300469|Active Comparator|A|ABT-335 + 20 mg atorvastatin
11635776|NCT00300469|Active Comparator|B|ABT-335 + 40 mg atorvastatin
11635777|NCT00300469|Placebo Comparator|C|ABT-335 monotherapy
11635778|NCT00300469|Placebo Comparator|D|20 mg atorvastatin monotherapy
11635779|NCT00300469|Placebo Comparator|E|40 mg atorvastatin monotherapy
11635780|NCT00300469|Placebo Comparator|F|80 mg atorvastatin monotherapy
11635781|NCT00300456|Active Comparator|A|ABT-335 + 20 mg simvastatin
11635782|NCT00300456|Active Comparator|B|ABT-335 + 40 mg simvastatin
11635783|NCT00300456|Placebo Comparator|C|ABT-335 monotherapy
11635784|NCT00300456|Placebo Comparator|D|20 mg simvastatin monotherapy
11635785|NCT00300456|Placebo Comparator|E|40 mg simvastatin monotherapy
11635786|NCT00300456|Placebo Comparator|F|80 mg simvastatin monotherapy
11635787|NCT00300430|Active Comparator|A|20 mg drug and ABT-335
11635788|NCT00300430|Active Comparator|B|40 mg drug and ABT 335
11635789|NCT00300430|Active Comparator|C|40 mg drug and ABT-335
11635790|NCT00300391|Experimental|haloperidol|Once diagnosed as delirious, randomized to haloperidol 5 mg IV
11635791|NCT00300391|Placebo Comparator|placebo|once diagnosed as delirious, received 5 mg saline placebo
11635792|NCT00300365|Experimental|Active Pioglitazone + Open-Label Niacin|Intervention: Pioglitazone, initially 30mg, then titrated to 45mg + niacin ER 2.0 g/day + aspirin 325 mg/day
11635793|NCT00300365|Placebo Comparator|Placebo +Open-Label Niacin|Intervention: Pioglitazone Placebo + 2.0 g/day Open-Label Niacin + 325 mg/day Aspirin
11635794|NCT00300326|No Intervention|1|Using the same knee implant with a conventional surgical technique.
11635795|NCT00300326|Active Comparator|2|Using the same knee implant using a computer-assist surgery group is the comparator
11635796|NCT00300313|Active Comparator|1|
11635797|NCT00300313|Placebo Comparator|2|
11635798|NCT00300300|No Intervention|1|applying a patellar graft using conventional surgical technique.
11635799|NCT00300300|No Intervention|2|applying a hamstring graft using conventional surgical technique.
11635800|NCT00300300|Experimental|3|applying a patellar graft using a computer-assisted surgy technique.
11635801|NCT00300300|Experimental|4|hamstring graft CAOS
11635802|NCT00300274|Experimental|everolimus 1.5 mg|Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
11635803|NCT00300274|Experimental|everolimus 3.0 mg|"Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.
~Randomization of new patients in this arm was prematurely stopped as of 27 March 2008 due to high mortality rate, as per Data Monitoring Committee."
11635804|NCT00300274|Active Comparator|mycophenolate mofetil|Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.
11635805|NCT00300261|No Intervention|1|receives home care
11635806|NCT00300261|Experimental|2|receives telehealth monitoring in addition to home care
11635807|NCT00300235||1|200 subjects ages 5 to 9.9 years with a diagnosis of HbSS/HbSβ0
11635808|NCT00300235||2|400 subjects ages 10 to 14.9 years with a diagnosis of HbSS/HbSβ0
11635809|NCT00300235||3|400 subjects ages 15 to 24.9 years with a diagnosis of HbSS/HbSβ0
11635810|NCT00300235||4|400 subjects over the age of 25 with a diagnosis of HbSS/HbSβ0
11635811|NCT00300235||5|250 subjects age 15 and older with a diagnosis of HbSC or HbSβ+
11635812|NCT00300196|Experimental|Intravenous ancrod|Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
11635813|NCT00300196|Placebo Comparator|Intravenous Placebo|Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.
11635814|NCT00300131||1|Bioabsorbable Vascular Solutions (BVS) Everolimus Eluting Coronary Stent System
11635815|NCT00300118|Experimental|A|
11635816|NCT00300118|Active Comparator|B|
11635817|NCT00300092|No Intervention|No antibioitcs|Group 1 received no antibiotics
11635818|NCT00300092|Active Comparator|Cephalexin|Group 2 received cephalexin at 50 mg/kg divided 3 times daily for 7 days
11635819|NCT00300040|Experimental|1|Hemoglobin glutamer 250 - bovine
11635820|NCT00300040|Active Comparator|2|6% Hydroxyethylstarch
11635821|NCT00299988|Experimental|IVIG|ivig
11635822|NCT00299988|Placebo Comparator|Placebo|
11635823|NCT00299975|Experimental|MaZiRenWan (MZRW) Low dose|MaZiRenWan (MZRW) Low dose 2.5g sachet by mouth, twice daily for 8 weeks
11635824|NCT00299975|Experimental|MaZiRenWan (MZRW) Median dose|MaZiRenWan (MZRW) Median dose 5.0g sachet by mouth, twice daily for 8 weeks
11635825|NCT00299975|Experimental|MaZiRenWan (MZRW) High dose|MaZiRenWan (MZRW) High dose 7.5g sachet by mouth, twice daily for 8 weeks
11635826|NCT00299962|Experimental|Dose level 4|
11635827|NCT00299962|Experimental|Dose level 5|
11635828|NCT00299962|Experimental|Dose Level 1|on Days 1 and 15
11635829|NCT00299962|Experimental|Dose Level 2|On Days 1 and 15
11635830|NCT00299962|Experimental|Dose Level 3|On Days 1 and 15
11635831|NCT00299884||1|Lipitor 20 mg
11635832|NCT00299884||2|Lipidil Supra 160 mg and Ezetrol 10 mg
11635833|NCT00299858|Active Comparator|Study Group|Patients will be given theophylline, titrated to optimal blood levels, for a period of 4 weeks.
11635834|NCT00299858|Placebo Comparator|Placebo group|Patients will receive placebo pills for a period of 4 weeks.
11635835|NCT00299819|Active Comparator|1|MEDI-545
11635836|NCT00299819|Active Comparator|2|MEDI-545
11635837|NCT00299819|Active Comparator|3|MEDI-545
11635838|NCT00299819|Active Comparator|4|MEDI-545
11635839|NCT00299819|Active Comparator|5|MEDI-545
11635840|NCT00299741|Experimental|1|Sunitinib
11635841|NCT00299702|Active Comparator|002|
11635842|NCT00299702|Experimental|001|
11635843|NCT00299689|Experimental|Intervention|Single-arm: Ontak
11635844|NCT00299676||001|Galantamine (Reminyl) Use of Reminyl according to approved NZ data sheet
11635845|NCT00299650|Placebo Comparator|A|
11635846|NCT00299650|Active Comparator|B|
11635847|NCT00299611|Active Comparator|1|Levetiracetam
11635848|NCT00299611|Placebo Comparator|2|there is no active ingredient in the pills.
11635849|NCT00299559|Other|1|cross over application of both specimen
11635850|NCT00299546|Placebo Comparator|Group 1: Placebo|Placebo Subcutaneous (SC) injections every 4 weeks (wks) thru Wk 20 (unless early escape at Wk 16); Golimumab - if early escape, 50 mg SC injections from Wk 16 up to 5 yrs; Golimumab - 50 mg SC injections beginning Wk 24 up to 5 yrs (unless early escape); Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-24 database lock.
11635926|NCT00298740|Experimental|Aventis U-400 Insulin|
11635927|NCT00298727|Active Comparator|1|SHIPS: Face-to-Face Workshop
11635928|NCT00298727|Active Comparator|2|ePBL: Online Problem-Based Course
11635929|NCT00298675|Experimental|Iniparib|
11635851|NCT00299546|Experimental|Group 2: Golimumab 50 mg|Golimumab 50 mg SC injections every 4 wks from Wk 0 up to 5 yrs (unless early escape at Wk 16); Golimumab - if early escape, 100 mg SC injections every 4 wks beginning Wk 16 up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-24 database lock.
11635852|NCT00299546|Experimental|Group 3: Golimumab 100 mg|Golimumab 100 mg SC injections every 4 wks from Wk 0 up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50 mg. Duration of the blinded period will be until the week-24 database lock.
11635853|NCT00299507|Experimental|15 mg Anecortave Acetate, 3 month intervals|Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 3 month intervals (0, 3, 6, 9, 12, 15, 18 months).
11635854|NCT00299507|Experimental|15 mg Anecortave Acetate, 6 month intervals|Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months).
11635855|NCT00299507|Experimental|30 mg Anecortave Acetate, 6 month intervals|Anecortave Acetate Sterile Suspension, 60 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months).
11635856|NCT00299507|Sham Comparator|Anecortave Acetate Vehicle|One 0.5 mL sham injection of Anecortave Acetate Vehicle at 6 month intervals (3, 9, 15, 21 months).
11635857|NCT00299494|Experimental|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (FOLLICULAR)|Follicular
11635858|NCT00299494|Experimental|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (DLBCL)|Diffuse Large B-cell Lymphoma
11635859|NCT00299494|Experimental|INOTUZUMAB OZOGAMICIN MTD + RITUXIMAB (REFRACTORY)|Refractory Aggressive NHL
11635860|NCT00299455|Experimental|1|Reconstituted amoxicillin-clavulanate at 40/5.7 mg/kg/day in 2 divided doses for 7 days.
11635861|NCT00299455|Placebo Comparator|2|Reconstituted placebo in 2 divided doses for 7 days.
11635862|NCT00299442|Experimental|1|Self-help Triple P Behavioural Family Intervention
11635863|NCT00299442|No Intervention|2|Wait-list control
11635864|NCT00299429|Active Comparator|MIDCAB Surgery|MIDCAB Surgery
11635865|NCT00299429|Experimental|PCI with drug-eluting stent|PCI with DES
11635866|NCT00299403|Active Comparator|1|Right frontal low frequency rTMS
11635867|NCT00299403|Active Comparator|2|electroconvulsive therapy (ECT). Right unilateral ECT 3 time a week in 3 weeks
11635868|NCT00299390|Experimental|Sagopilone|
11635869|NCT00299325|Experimental|Rimonabant|Rimonabant 20 mg once daily with mild hypocaloric diet
11635870|NCT00299325|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily with mild hypocaloric diet
11635871|NCT00299286|Experimental|Lapatinib|lapatinib oral 1500mg daily taken as 6 tablets as one dose 10-14 days presurgery
11635872|NCT00299286|Placebo Comparator|Lapatinib-Placebo|placebo comparator 6 tablets taken as one dose daily
11635873|NCT00299273|Experimental|Low calorie high fat/protein diet|Low calorie high fat/protein diet
11635874|NCT00299260|Active Comparator|vaccine|glycoprotein B plus MF59 adjuvant
11635875|NCT00299260|Placebo Comparator|placebo|normal saline
11635876|NCT00299234|Placebo Comparator|2|placebo
11635877|NCT00299234|Experimental|1|atomoxetine
11635878|NCT00299221|Active Comparator|Monotherapy|Tacrolimus alone
11635879|NCT00299221|Active Comparator|Combination therapy|tacrolimus with mycophenolate mofetil
11635880|NCT00299195|Experimental|1|sulindac
11635881|NCT00299195|Placebo Comparator|2|placebo
11635882|NCT00299182|Experimental|1 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.
~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)
~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
11635883|NCT00299182|Experimental|3 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.
~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)
~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
11635884|NCT00299182|Experimental|10 mcg/ kg AMG531 Pre & Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.
~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days -5 and 5 (Arm A)
~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
11635885|NCT00299182|Placebo Comparator|Placebo (Arm A & Arm B) with Chemotherapy|"Placebo Pre and Post (Arm A), or Post (Arm B) Chemotherapy
~Cycle 1, Chemotherapy (R-HyperCVAD) alone.
~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by placebo subcutaneously on days -5 and 5 (Arm A) or days 5 and 7 (Arm B)
~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
11635886|NCT00299182|Experimental|1 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.
~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 1 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)
~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
11635887|NCT00299182|Experimental|3 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.
~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 3 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)
~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
11635930|NCT00298675|Experimental|Iniparib/irinotecan|
11635931|NCT00298623|Placebo Comparator|Placebo|
11635888|NCT00299182|Experimental|10 mcg/ kg AMG531 Post Chemotherapy|"Cycle 1, Chemotherapy (R-HyperCVAD) alone.
~Cycle 2, Chemotherapy (R-Ara-C/MTX), followed by 10 mcg/ kg AMG 531 subcutaneously on days 5 and 7 (Arm B)
~R-HyperCVAD alternating with R-Ara-C/MTX where R-HyperCVAD is Rituximab 375 mg/m^2; plus Cyclophosphamide 300 mg/m^2, Vincristine 1.4 mg/m^2, Doxorubicin (Adriamycin) 50 mg/m^2, and Dexamethasone 40 mg (CVAD), Mesna 600mg/m^2; and, R-Ara-C/MTX is Rituximab 375 mg/m^2, Cytarabine 3 g/m^2 and Methotrexate 200 mg/m^2."
11635889|NCT00299169|Experimental|1|N of 1 trials of statin therapy
11635890|NCT00299169|Other|2|usual care
11635891|NCT00299156|Experimental|Oral Clofarabine|10 mg (Group 1) or 20 mg (Group 2) tablets once a day for 5 days in a row and repeated every 4-8 week cycle.
11635892|NCT00299130|Active Comparator|Placebo + methotrexate (MTX)|"Participants received placebo intravenous infusion on Days 1 and 15. From Week 16 onwards, participants could switch to receive rituximab 0.5 g (on Days 1 and 15) every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Placebo and rituximab infusions were preceded with 100 milligrams (mg) intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of MTX and ≥ 5 mg/week folic acid for the duration of their participation in the study.
~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
11635893|NCT00299130|Experimental|Rituximab 2 x 0.5 g + MTX|"Participants received 0.5 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.
~Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.
~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
11635894|NCT00299130|Experimental|Rituximab 2 x 1.0 g + MTX|"Participants received 1.0 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone.
~Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study.
~All participants entered a 48-week safety follow-up (SFU) period following the treatment period."
11635895|NCT00299104|Experimental|Rituximab (0.5 g x 2) + Methotrexate|Rituximab intravenously at a dose of 0.5 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
11635896|NCT00299104|Experimental|Rituximab (1.0 g x 2) + Methotrexate|Rituximab intravenously at a dose of 1.0 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
11635897|NCT00299104|Placebo Comparator|Placebo + Methotrexate|"Placebo intravenously on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.
~From Week 104 participants were eligible to receive Rituximab 2 X 0.5 g or Rituximab 2 X 1.0 g every 24 weeks."
11635898|NCT00299091|No Intervention|Control|Efavirenz capsules 600 mg
11635899|NCT00299091|Experimental|Experimental|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
11635900|NCT00299052|Active Comparator|A|Bone reamings with 5cc of DMB putty
11635901|NCT00299052|Active Comparator|B|Bone reamings
11635902|NCT00299039|Active Comparator|1|
11635903|NCT00299039|Active Comparator|2|
11635904|NCT00299013|Active Comparator|1|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
11635905|NCT00299013|Experimental|2|COLAL-PRED 40mg oral capsule, once daily for 8 weeks.
11635906|NCT00299013|Experimental|3|COLAL-PRED 60mg oral capsule, once daily for 8 weeks.
11635907|NCT00299013|Experimental|4|COLAL-PRED 80mg oral capsule, once daily for 8 weeks.
11635908|NCT00299000|Other|Naglazyme, 1.0 mg/kg|Dose comparison
11635909|NCT00299000|Other|Naglazyme, 2.0 mg/kg|Dose Comparison
11635910|NCT00298987|Experimental|A1|
11635911|NCT00298974|Experimental|hydrocodone/acetaminophen extended release|
11635912|NCT00298974|Placebo Comparator|Placebo|
11635913|NCT00298922|Active Comparator|Azithromycin|participants taking 500 mg tablets orally thrice weekly for 24 weeks
11635914|NCT00298922|Placebo Comparator|Placebo|Participants taking 500 mg tablets orally thrice weekly for 24 weeks
11635915|NCT00298909|Experimental|1|niacin
11635916|NCT00298909|Active Comparator|2|physical exercise
11635917|NCT00298909|Placebo Comparator|3|control
11635918|NCT00298896|Experimental|SNS-595|SNS-595; 48 mg/m2 administered IV once every 21 days for up to 6 cycles.
11635919|NCT00298883|Experimental|Treatment|This is a single arm, interventional trial.
11635920|NCT00298870|Experimental|PGx-treatment|NAT2 genotype-guided treatment with stratified isoniazid dose (approx. 7.5 mg/kg b.w., patients homozygous for NAT2*4: rapid acetylators; 5 mg/kg, patients heterozygous for NAT2*4: intermediate acetylators; 2.5 mg/kg, patientes without NAT2*4: slow acetylators)
11635921|NCT00298870|Active Comparator|STD-treatment|Treatment with conventional standard isoniazid dose (approx. 5 mg/kg b.w.)
11635922|NCT00298831|Experimental|Sugammadex|Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was administered. At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg MK-8616 was administered.
11635923|NCT00298792|Experimental|Individualized Assessment & treatment|Individualized treatment for alcohol dependent persons, based on momentary assessment of high-risk situations and recorded coping abilities.
11635924|NCT00298792|Active Comparator|Packaged Cognitive-Behavioral Treatment|Manualized cognitive-behavioral treatment for alcohol dependent persons.
11635933|NCT00298610|Experimental|Artesunate and Malarone|Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
11635934|NCT00298558|Active Comparator|Memory Training|Memory training focused on verbal episodic memory. Participants were taught mnemonic strategies for remembering lists and sequences of items, text material, and main ideas and details of stories and other text-based information.
11635935|NCT00298558|Active Comparator|Reasoning Training|Reasoning training focused on the ability to solve problems that follow a serial pattern. Participants were taught strategies to identify the pattern or sequence required to solve a problem.
11635936|NCT00298558|Active Comparator|Speed of Processing Training|Speed of processing training focused on visual search and the ability to identify and locate visual information quickly in a divided attention format. Participants practiced increasingly complex speeded tasks on a computer.
11635937|NCT00298558|Placebo Comparator|Control|This group did not complete any cognitive training interventions
11635938|NCT00298545|Placebo Comparator|placebo and Calcitriol|placebo tablets together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
11635939|NCT00298545|Active Comparator|2|calcium together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
11635940|NCT00298532|No Intervention|standard therapy|"The use of a before-after controlled study design and 36-month time periods will mirror the approach of our Adult OPALS Study. The Control (before) Period represents the 36 months immediately prior to the introduction of ALS programs at each study community. The Intervention (after) Period is comprised of the 36 months immediately after each community has met all standards for a full ALS program, as defined below. Data will be pooled across communities but the start date for the periods will vary for each community as each will require different amounts of time to prepare their ALS program. A 6- to 36-month Run-in period will separate the Control and Intervention Periods and will allow for training and implementation of the ALS program. Data from the Run-in period will not be considered in the primary analysis. The study periods may be summarized as follows: a) Control (Before) Period b) Run-in Period c) Intervention (After) Period."
11635941|NCT00298506|Active Comparator|FK506+MMF|
11635942|NCT00298428|Other|SPACE group|
11635943|NCT00298415|Active Comparator|A|Chemotherapy (mono)
11635944|NCT00298415|Experimental|B|Chemotherapy (doublet)
11635945|NCT00298389||Non smokers|Non smokers included no history of respiratory or allergic disease, normal baseline spirometry
11635946|NCT00298389||Smokers|Smoking history of at least 10 pack years
11635947|NCT00298389||COPD|Patients with stable COPD
11635948|NCT00298363|Experimental|Tenofovir DF|TDF 300 mg + FTC/TDF placebo + ETV placebo once daily (QD)
11635949|NCT00298363|Experimental|FTC/TDF|FTC 200 mg/TDF 300 mg + TDF placebo + ETV placebo QD
11635950|NCT00298363|Experimental|Entecavir|ETV 0.5 mg or 1 mg + TDF placebo + FTC/TDF placebo QD
11635951|NCT00298324|Active Comparator|Myfortic|Patients in this arm will receive Myfortic + Prednisone + Cyclosporine
11635952|NCT00298324|Other|Standard Care/ Placebo|In this arm patients will receive Prednisone + Cyclosporine + Placebo or Prednisone + Cyclosporine
11635953|NCT00298311|Experimental|mci guidance & peer social support|home visits to promote maternal-child interaction & social support
11635954|NCT00298311|Sham Comparator|peer social support|social support
11635955|NCT00298298|Experimental|1|5 million autologous, DNP-modified NSCLC cells
11635956|NCT00298298|Experimental|2|2.5 million autologous, DNP-modified NSCLC cells
11635957|NCT00298298|Experimental|3|0.5 million autologous, DNP-modified NSCLC cells
11635958|NCT00298272|Experimental|Double-blind/Open Label Rituximab|"The double-blind rituximab treatment group received rituximab 500 mg by intravenous (IV) infusion on Day 1 and Day 15. After 24 weeks (primary endpoint completion), participants continued post-treatment follow-up (PTFU) visits through Week 56, and entered a 48-week Safety Follow-Up (SFU). At any time between Week 24 and Week 40 of PTFU, eligible participants could enter the rituximab open label (OL) arm, and restart the 56-week treatment/follow-up schedule (rituximab 500 mg by IV infusion on Day 1 and Day 15) prior to the 48-week SFU.
~Prior to rituximab infusion, participants were premedicated with methylprednisolone 100 mg IV. Participants received folate ≥5 mg weekly. Background therapy (stable dose for the duration of the study) included: a tumor necrosis factor (TNF) inhibitor; either etanercept 50 mg subcutaneous injection (SC) weekly or adalimumab 40 mg SC once every 2 weeks; methotrexate (MTX) 15 to 25 mg by mouth or by intramuscular injection (IM) weekly."
11635959|NCT00298272|Other|Double-blind Placebo/Open Label Rituximab|"The double-blind placebo treatment group received saline solution IV on Day 1 and Day 15. After 24 weeks (primary endpoint completion), participants continued post-treatment follow-up (PTFU) visits through Week 56, and entered a 48-week Safety Follow-Up (SFU). At any time between Week 24 and Week 40 of PTFU, eligible participants could enter the rituximab open label (OL) arm, and restart the 56-week treatment/follow-up schedule (rituximab 500 mg by IV infusion on Day 1 and Day 15) prior to the 48-week SFU.
~Prior to each infusion of placebo, participants were premedicated with methylprednisolone 100 mg IV. Participants received folate ≥5 mg weekly. Background therapy (stable dose for the duration of the study) included: a tumor necrosis factor (TNF) inhibitor; either etanercept 50 mg subcutaneous injection (SC) weekly or adalimumab 40 mg SC once every 2 weeks; methotrexate (MTX) 15 to 25 mg by mouth or by intramuscular injection (IM) weekly."
11635960|NCT00298259|Active Comparator|ORIF|open reduction internal fixation of fractured ribs in flail chest patients
11635961|NCT00298259|No Intervention|conservative management|current standard conservative management
11635962|NCT00298233|Active Comparator|Standard Dose oseltamivir adult cohort|All participants >= 15 years will receive standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
11635963|NCT00298233|Active Comparator|Double Dose oseltamivir Adult cohort|All participants >= 15 years will receive high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
11635964|NCT00298233|Active Comparator|Standard Dose Oseltamivir child cohort|All participants <15 years will receive standard-dose oseltamivir (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
11636070|NCT00296634|Experimental|1|45 microgram dose Hemagglutinin (HA), 120 subjects receiving Aluminum hydroxide and 120 not receiving Aluminum hydroxide.
11635965|NCT00298233|Active Comparator|Double Dose Oseltamivir child cohort|All Participants <15 years will receive high-dose oseltamivir (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) for 5 to 10 days.
11635966|NCT00298220|Active Comparator|training|tailored multi-component implementation program
11635967|NCT00298220|No Intervention|control|
11635968|NCT00298168|Experimental|1|
11635969|NCT00298168|Experimental|2|
11635970|NCT00298168|Placebo Comparator|3|
11635971|NCT00298155|Active Comparator|Group 1|Goserelin + dutasteride
11635972|NCT00298155|Active Comparator|Group 2|Bicalutamide for one week, begin goserelin plus dutasteride, continue bicalutamide for the full 12 weeks
11635973|NCT00298155|Active Comparator|Group 3|Begin bicalutamide for one week, goserelin injection; begin dutasteride, ketoconazole (and replacement hydrocortisone), continue bicalutamide for the full 12 weeks
11635974|NCT00298090||StO2 values|StO2 monitoring
11635975|NCT00298051|No Intervention|Early umbilical cord clamping (control)|"Umbilical cord was clamped immediately, or as close as possible, after delivery of the infant's shoulders. (This was standard practice in the study hospital, thus it served as the control group)."
11635976|NCT00298051|Experimental|Delayed umbilical cord clamping|Umbilical cord was clamped at 2 minutes after delivery of the infant's shoulder's with the infant held at the level of the mother's uterus.
11635977|NCT00298038|Experimental|Rifaximin|Participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
11635978|NCT00298038|Placebo Comparator|Placebo|Participants were administered a single matching placebo tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
11635979|NCT00298025|Experimental|Cetrotide®|
11635980|NCT00298025|Active Comparator|Antagon ™|
11635981|NCT00297986||1|healthy subjects
11635982|NCT00297947|Experimental|600 mg/day quetiapine (Group B)|Patients qualifying for the Double Blind Phase will be randomly assigned to 600 mg quetiapine (Group B) daily and treated on the assigned dose in a double-blind fashion for 8 weeks
11635983|NCT00297947|Experimental|1200 mg/day quetiapine (Group A)|Patients qualifying for the Double Blind Phase will be randomly assigned to high dose 1200 mg quetiapine daily (Group A) on the assigned dose in a double-blind fashion for 8 weeks
11635984|NCT00297895|Active Comparator|Ultrasound observation + delayed CLND if recurrence detected|
11635985|NCT00297895|Active Comparator|CLND|
11635986|NCT00297882|Active Comparator|1 Artemether-Lumefantrine|
11635987|NCT00297882|Active Comparator|2 Amodiaquine-Artemether|
11635988|NCT00297869|No Intervention|1|
11635989|NCT00297869|Experimental|2|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
11635990|NCT00297856||Boostrix cohort|
11635991|NCT00297856||Historical Td cohort|
11635992|NCT00297830|Experimental|Active Zoledronic Acid & Placebo Alendronate|Group 1 will receive an infusion of active zoledronic acid 5 mg during the first 4 weeks after transplantation. Placebo alendronate 70 mg once weekly will be initiated at the same time as the first zoledronic acid infusion.
11635993|NCT00297830|Experimental|Placebo Zoledronic Acid & Active Alendronate|Group 2 will receive an infusion of placebo zoledronic acid during the first 5 weeks after transplantation. Active alendronate 70 mg once weekly will be initiated at the same time as the placebo infusion.
11635994|NCT00297817|Experimental|Arm 1: rMenB|
11635995|NCT00297817|Experimental|Arm 2: rMenB + OMV|
11635996|NCT00297817|Placebo Comparator|Arm 3: Placebo|
11635997|NCT00297804|Experimental|Arm 1|
11635998|NCT00297804|Active Comparator|Arm 2|
11635999|NCT00297791|Other|1|surgery (open or laparoscopic) and observation
11636000|NCT00297778|Experimental|pramipexole|A daily dose of pramipexole 0.125 mg t.i.d.; titration-to-response up to 1.0 mg t.i.d.
11636001|NCT00297778|Placebo Comparator|placebo|Placebo (matching) tablets
11636002|NCT00297752|Active Comparator|'ceriumnitrate silversulfadiazine (flammacerium)|facial burns treatment with Cerium nitrate silver sulfadiazine
11636003|NCT00297752|Active Comparator|flammazine|facial burns treatment with silver sulfadiazine
11636004|NCT00297648|Experimental|CDP870 400 mg|Certolizumab pegol (CDP870) 400 mg
11636005|NCT00297596|Experimental|Intervention|Patients with HER2 positive breast cancer received treatment with oxaliplatin 130 mg/m2 IV day 1 and trastuzumab 6 mg/kg (following 8 mg/kg loading dose during cycle 1). Cycles were repeated every 21 days.
11636006|NCT00297492|Experimental|Gradual reduction|Intervention: Reduction Phone Counseling. Intervention: Pre-Quit Nicotine Lozenges. Intervention: Post-Quit Nicotine Lozenges.
11636007|NCT00297492|Active Comparator|Abrupt cessation|Intervention: Abrupt Phone Counseling. Intervention: Post-Quit Nicotine Lozenges.
11636008|NCT00297492|Active Comparator|Minimal intervention|Intervention: Minimal Abrupt Phone Counseling. Intervention: Post-Quit Nicotine Lozenges.
11636009|NCT00297479|Experimental|Mindfulness-Based Treatment Group (MBAT)|MBAT is 6 weeks of nicotine patch therapy; a Self-help guide; and In-person group therapy/counseling (8 sessions over 8 weeks) using a Mindfulness-Based Addiction Treatment for nicotine dependence.
11636010|NCT00297479|Active Comparator|Standard Care Group|Standard Care Group (ST) is 6 weeks of nicotine patch therapy, a Self-help guide and In-person group therapy/counseling (8 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
11636011|NCT00297479|Active Comparator|Usual Care Group|Usual Care (UC) is 6 weeks of nicotine patch therapy, a Self-help guide and In-person individual counseling (4 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
11636012|NCT00297453|Experimental|Internet|Individual counseling + nicotine replacement. 6 sessions across a 3 month period.
11636013|NCT00297453|Experimental|Counseling|Individual counseling plus nicotine replacement treatment.
11636014|NCT00297453|Active Comparator|Self-Help|Self-help Manual plus nicotine replacment treatment.
11636071|NCT00296634|Experimental|2|15 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
11636015|NCT00297427|Experimental|Acupuncture|Subjects will 12 acupuncture treatments over 6 weeks; treatment sessions occur twice a week. A total of 12 acupuncture needles will be inserted bilaterally at two leg points and four back points. Needles are manually inserted through a standard guide tube contained within a fitted sheath and the basal ring secured to the skin by double-sided tape. The needles remain in place for 25 minutes and are manually stimulated twice during each treatment.
11636016|NCT00297427|Sham Comparator|Sham acupuncture|Subjects will receive 12 sham acupuncture treatments (delivered twice a week) over 6 weeks. The sham needle is blunted needle whose shaft telescopes into the handle when tapped. While the needle appears to have been inserted, it does not actually penetrate the skin. It is held in place by the same standard guide tube used in the true acupuncture group. The acupuncture points and duration of treatment are the same as for the true acupuncture group.
11636017|NCT00297414||Patients with mild cognitive impairment|Patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
11636018|NCT00297401|Experimental|1|
11636019|NCT00297401|Placebo Comparator|2|
11636020|NCT00297362||Galantamine hydrobromide|
11636021|NCT00297349||001|
11636022|NCT00297336||001|
11636023|NCT00297323||001|
11636024|NCT00297271||Mild cognitive impairment or dementia|Patients with mild cognitive impairment or dementia.
11636025|NCT00297232|Experimental|Natalizumab|300 mg intravenous (IV) infusions once every 4 weeks for up to 480 weeks
11636026|NCT00297219|Active Comparator|2|high dialysate calcium
11636027|NCT00297219|Active Comparator|1|low dialysate calcium
11636028|NCT00297206|Experimental|Cohort 1|Subjects in the age group of 2 to less than 6 years will be included
11636029|NCT00297206|Experimental|Cohort 2|Subjects in the age group of 1 to less than 2 years will be included
11636030|NCT00297206|Experimental|Cohort 3|Subjects in the age group of 6 months to less than 1 year will be included
11636031|NCT00297206|Experimental|Cohort 4|Subjects in the age group of 3 months to less than 6 months will be included
11636032|NCT00297206|Experimental|Cohort 5|Subjects in the age group of 1 month to less than 3 months will be included
11636033|NCT00297193|Experimental|Transplant Arm|Hematopoietic stem cell mobilisation followed, within 4 weeks, by high dose immunoablation and autologous stem cell transplantation
11636034|NCT00297193|Experimental|Delayed Transplant|Hematopoietic stem cell mobilisation followed, after 59 weeks, by high dose immunoablation and autologous hematopoietic stem cell transplantation
11636035|NCT00297167|Experimental|EUR-1008 (APT-1008) First, Then Placebo|
11636036|NCT00297167|Experimental|Placebo First, Then EUR-1008 (APT-1008)|
11636037|NCT00297154|No Intervention|Control|Patients continue receive a single educational session and continue medical managment of heart failure as per their physician
11636038|NCT00297154|Experimental|Lifestyle modification|Patients recieve weekly sessions with dietician, replace 2 meals/day with meal replacement beverage, and initiate a walking program.
11636039|NCT00297141|Experimental|single arm (radiochemotherapy)|single arm study (capecitabine, oxaliplatin)
11636040|NCT00297128|Active Comparator|1|
11636041|NCT00297115|Active Comparator|Roflumilast|500 mcg, once daily, oral administration in the morning
11636042|NCT00297115|Placebo Comparator|Placebo|once daily
11636043|NCT00297102|Active Comparator|Roflumilast|500 mcg, once daily, oral administration in the morning
11636044|NCT00297102|Placebo Comparator|Placebo|once daily
11636045|NCT00297089|Active Comparator|A|Pemetrexed + ABT-751
11636046|NCT00297089|Placebo Comparator|B|Pemetrexed + placebo
11636047|NCT00297037|Active Comparator|1|"During the 6-week double-blind phase, all patients will be randomly assigned to receive either pimecrolimus 1% cream or its vehicle twice daily with occlusion on the affected areas. Topical application of pimecrolimus1% cream for oral erosive lichen planus for a duration of 6 weeks; ¼ gram of cream will be applied to each of the 2 sides of the mouth BID with a 2x2 gauze."
11636048|NCT00297037|Placebo Comparator|2|"During the 6-week double-blind phase, all patients will be randomly assigned to receive either pimecrolimus 1% cream or its vehicle twice daily with occlusion on the affected areas. Topical application of pimecrolimus1% cream for oral erosive lichen planus for a duration of 6 weeks; ¼ gram of cream will be applied to each of the 2 sides of the mouth BID with a 2x2 gauze."
11636049|NCT00297024|Experimental|MRI for brain mets|
11636050|NCT00296907|Experimental|Psychological Intervention|2-session psychological intervention
11636051|NCT00296894|Experimental|1|Drug - adalimimab sc
11636052|NCT00296894|Placebo Comparator|2|Placebo
11636053|NCT00296855|Experimental|Arm 1|
11636054|NCT00296816|Experimental|Oxaliplatin/Docetaxel/Bevacizumab|Participants with International Federation of Gynecology and Obstetrics (FIGO) stage IB through IV ovarian, primary peritoneal, or fallopian tube carcinoma treated with Oxaliplatin, Docetaxel, and Bevacizumab - 28 days after initial surgery
11636055|NCT00296777|Experimental|escitalopram|escitalopram 10 mg/d, increasing by 10 mg/week if tolerated and not remitted to maximum dose of 40 mg/d
11636056|NCT00296777|Experimental|bupropion|bupropion XL 150 mg/d, increasing by 150 mg/d if tolerated and not remitted to maximum dose of 450 mg/d
11636057|NCT00296777|Experimental|imipramine|imipramine 50 mg/d for 3 days, then 100 mg/d for 4 days, then 150 mg/d for 3 days then 200 mg/d for 4 days then 250 mg/d for a week and then 300 mg/d thereafter, all dose increases if tolerated and not remitted
11636058|NCT00296725|Experimental|fluoxetine / Imipramine|fluoxetine or Imipramine
11636059|NCT00296712|Experimental|escitalopram + bupropion|patients begin on escitalopram 10 mg/d, then bupropion 150 mg/d is added and each is alternately increased as tolerated to maximal dose of escitalopram of 40 mg/d and of bupropion of 450 mg/d
11636060|NCT00296686|Experimental|tranylcypromine|sequential tranylcypromine (TC) followed by TC + dextroamphetamine followed by TC + T3
11636061|NCT00296660||1|Proven acute HIV-1 infection
11636062|NCT00296660||1A|Sexual partners of members of Group 1
11636063|NCT00296660||2|Established HIV-infection
11636064|NCT00296660||3|HIV-1 uninfected
11636065|NCT00296647|Active Comparator|patch|
11636066|NCT00296647|Active Comparator|nicotine lozenge|
11636067|NCT00296647|Active Comparator|bupropion|
11636072|NCT00296634|Experimental|4|3.75 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
11636073|NCT00296634|Experimental|3|7.5 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
11636074|NCT00296621|Experimental|1|
11636075|NCT00296621|Placebo Comparator|2|
11636076|NCT00296608|Active Comparator|Radiotherapy|RT was delivered with photons from a linear accelerator with an energy level of 8MVor above.
11636077|NCT00296608|Experimental|Chemotherapy and radiotherapy|The first CT cycle was administered from days 1 to 5 of the RT treatment. LV 20 mg/m2/d was delivered intravenously immediately before administration of FU. FU 350 mg/m2/d was delivered during 20 minutes in 100 mL of saline infusion, 1 hour before RT. The second cycle was administered from days 29 to 33 of the RT treatment using the same schedule.
11636078|NCT00296595|Placebo Comparator|Placebo|Placebo capsules + 500 mL/day of placebo juice
11636079|NCT00296595|Experimental|Cranberry Juice|Placebo capsules + 500 mL/day of cranberry juice
11636080|NCT00296595|Experimental|Fish Oil|2 g/day of fish oil + 500 mL/day of placebo juice
11636081|NCT00296595|Experimental|Cranberry Juice + Fish Oil|2 g/day of fish oil + 500 mL/day of cranberry juice
11636082|NCT00296517|Placebo Comparator|Placebo|Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
11636083|NCT00296517|Experimental|Bupropion SR|Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
11636084|NCT00296491|Active Comparator|Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON)|Fluticasone propionate/salmeterol DISKUS combination product (FSC) twice daily (BID) plus vehicle placebo nasal spray once daily (QD) plus montelukast capsule 10mg (MON) QD
11636085|NCT00296491|Active Comparator|Fluticasone Propionate/Salmeterol (FSC)|FSC BID plus vehicle placebo nasal spray QD plus placebo capsule QD
11636086|NCT00296491|Active Comparator|Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS)|Fluticasone propionate/salmeterol DISKUS combination product (FSC)100/50mcg BID plus fluticasone propionate aqueous nasal spray 200mcg (FPANS) QD plus placebo capsule QD
11636087|NCT00296491|Active Comparator|Montelukast (MON)|Placebo DISKUS BID plus vehicle placebo nasal spray QD plus MON QD
11636088|NCT00296478|Experimental|1|Endometrin 100mg BID
11636089|NCT00296478|Experimental|2|Endometrin 100mg TID
11636090|NCT00296478|Active Comparator|3|Crinone
11636091|NCT00296465|Experimental|Lutrepulse® 5mcg IV|5.0 mcg Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
11636092|NCT00296465|Experimental|Lutrepulse® 10 mcg IV|10.0 mcg Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
11636093|NCT00296465|Experimental|Lutrepulse® 20 mcg SC|20.0 mcg Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
11636094|NCT00296465|Placebo Comparator|Placebo IV|Placebo Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
11636095|NCT00296465|Placebo Comparator|Placebo SC|Placebo Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
11636096|NCT00296465|Active Comparator|Clomiphene Citrate/Placebo IV|Oral clomiphene citrate (over encapsulated) for 5 days and Placebo Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
11636097|NCT00296465|Active Comparator|Clomiphene Citrate / Placebo SC|Oral clomiphene citrate (over encapsulated) for 5 days and Placebo Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
11636098|NCT00296426|No Intervention|Usual Care|control patients admitted to hospital floors received usual care
11636099|NCT00296426|Experimental|Intervention|computerized medication reconciliation tool and process redesign involving physicians, nurses, and pharmacists
11636100|NCT00296413||1|Valproate monotherapy
11636101|NCT00296413||2|Valproate monotherapy with combined oral contraceptive
11636102|NCT00296413||3|Lamotrigine monotherapy
11636103|NCT00296413||4|Lamotrigine monotherapy with combined oral contraceptive
11636104|NCT00296374|Experimental|1|Rosuvastatin 10 mg
11636105|NCT00296374|Experimental|2|Rosuvastatin 40 mg
11636106|NCT00296374|Active Comparator|3|Atorvastatin 80 mg
11636107|NCT00296361|Active Comparator|1|
11636108|NCT00296361|Experimental|2|
11636109|NCT00296348|Active Comparator|1|
11636110|NCT00296348|Experimental|2|
11636111|NCT00296335|Active Comparator|Mitomycin and doxifluridine|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
11636112|NCT00296335|Experimental|Mitomycin, doxifluridine and cisplatin|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
11636113|NCT00296322|Active Comparator|Mitomycin-C, Doxifluridine|Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)
11636114|NCT00296322|Active Comparator|Mitomycin-C, Doxifluridine, Cisplatin|iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)
11636115|NCT00296309|Active Comparator|1|
11636116|NCT00296309|Experimental|2|
11636168|NCT00295646|Active Comparator|AZ (Arimidex+Zoledronate)|Study Drugs Arimidex (Anastrozole), Zometa (Zoledronate; zoledronic acid)
11636117|NCT00296296|Active Comparator|Cyclosporin|Patients receive cyclosporin (dose-adjusted to pre-established targets) as immunosuppressive calcineurin inhibitor (CNI) and Diabetes Education / Management (therapeutic adjustment to target American Diabetes Association (ADA) criteria)
11636118|NCT00296296|Active Comparator|Tacrolimus|Patients receive tacrolimus (dose-adjusted to pre-established targets) as CNI and Diabetes Education / Management (therapeutic adjustment to target ADA criteria)
11636119|NCT00296244|Other|Steroid -free immunosuppression|Study group - Basiliximab, Tacrolimus, Enteric-coated Mycophenolic acid (EC-MPA)
11636120|NCT00296244|Other|Steroid containing immunosuppression|Control group- Basiliximab, Tacrolimus, EC-MPA, steroids
11636121|NCT00296231|Experimental|Nasal High Frequency Ventilation|Stable infants born at less than 1501 g who are at least 7 days old and undergoing nasal continuous positive airway pressure treatment.
11636122|NCT00296192|Placebo Comparator|Placebo 1|Placebo nasal spray 1 - 4 puffs
11636123|NCT00296192|Experimental|Rotigotine 1|Rotigotine Nasal Spray 1 puff (0.25 mg Rotigotine)
11636124|NCT00296192|Experimental|Rotigotine 2|Rotigotine Nasal Spray - 2 puffs (0.49 mg Rotigotine)
11636125|NCT00296192|Experimental|Rotigotine 3|Rotigotine Nasal Spray - 3 puffs (0.74 mg Rotigotine)
11636126|NCT00296192|Experimental|Rotigotine 4|Rotigotine Nasal Spray - 4 puffs (0.99 mg Rotigotine)
11636127|NCT00296153|Active Comparator|1|Omacor 1000mg x 4 / day
11636128|NCT00296153|Placebo Comparator|2|
11636129|NCT00296140|Other|self management of PSD symptoms|
11636130|NCT00296140|Other|screening and treatment of PSD|
11636131|NCT00296049|Active Comparator|vancomycin|
11636132|NCT00296049|Experimental|daptomycin|
11636133|NCT00296036|Experimental|Arm I (closed to accrual as of 10/24/2007)|Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily and oral pyridoxine once daily on days 1-21.
11636134|NCT00296036|Experimental|Arm II (closed to accrual as of 10/24/2007)|Patients receive topical urea/lactic acid-based cream as in arm I (closed to accrual as of 10/24/2007) and oral placebo once daily on days 1-21.
11636135|NCT00296036|Experimental|Arm III (closed to accrual as of 10/24/2007)|Patients receive placebo cream applied to palms and soles twice daily and pyridoxine as in arm I (closed to accrual as of 10/24/2007).
11636136|NCT00296036|Placebo Comparator|Arm IV (closed to accrual as of 10/24/2007)|Patients receive placebo cream as in arm III and oral placebo as in arm II (closed to accrual as of 10/24/2007).
11636137|NCT00296036|Experimental|Arm V|Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily on days 1-21.
11636138|NCT00296036|Placebo Comparator|Arm VI|Patients receive placebo cream applied to palms and soles twice daily on days 1-21.
11636139|NCT00296023|Experimental|stem cell transplant|
11636140|NCT00296010|Experimental|CASA-nil PLD|Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
11636141|NCT00296010|Active Comparator|CASA-Nil|No adjuvant therapy
11636142|NCT00296010|Experimental|CASA-CM PLD|Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
11636143|NCT00296010|Active Comparator|CASA-CM CM|Low-dose, metronomic cyclophosphamide and methotrexate (CM) for 16 weeks
11636144|NCT00295971|Experimental|Single arm of transplant|Receiving haplocompatible T cell depleted peripheral blood stem cell transplant
11636145|NCT00295945||PCA|Patient-controlled intravenous analgesia
11636146|NCT00295945||PCEA|Perioperative patient-controlled epidural analgesia
11636147|NCT00295932|Experimental|Arm I|Patients receive cyclophosphamide IV and rituximab IV on day 1, oral prednisone on days 2-6, and bortezomib IV (at the MTD determined in phase I) on days 2, 5, 9, and 12. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
11636148|NCT00295932|Experimental|Arm II|Patients receive cyclophosphamide IV and rituximab IV on day 1, oral prednisone on days 2-6, and bortezomib IV (at the MTD determined in phase I) on days 2 and 8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
11636149|NCT00295893|Active Comparator|Arm I|Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV, and docetaxel IV on day 1. Treatment repeats every 21 days for 6 courses.
11636150|NCT00295893|Experimental|Arm II|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; treatment repeats every 2 weeks for 4 courses. Patients then receive carboplatin IV on day 1 and paclitaxel IV on days 1, 8, and 15; treatment with carboplatin and paclitaxel repeats every 4 weeks for 3 courses.
11636151|NCT00295893|Experimental|Arm III|Patients receive chemotherapy as in arm II. They also receive trastuzumab (Herceptin®) IV weekly, beginning with the first doses of paclitaxel and carboplatin.
11636152|NCT00295880|Experimental|Transplant Patients|Patients receiving umbilical cord blood transplantation.
11636153|NCT00295867|Experimental|Zoledronic Acid|Patients women with early stage breast cancer and evidence of occult malignant cells in bone marrow aspirates following adjuvant chemotherapy will receive zoledronic acid (Zometa) 4mg, given intravenously over 15 minutes, once a month for two years.
11636154|NCT00295854|Experimental|MN-001|
11636155|NCT00295854|Placebo Comparator|MN-001 once daily|placebo tablets
11636156|NCT00295828|Active Comparator|1|Panretinal Photocoagulation (PRP)
11636157|NCT00295828|Active Comparator|2|Panretinal Photocoagulation and Macugen Intravitreal Injection
11636158|NCT00295815|Experimental|A|
11636159|NCT00295815|Active Comparator|B|
11636160|NCT00295802|Experimental|HIFU|Integrated Imaging High Intensity Focused Ultrasound using the Ablatherm Device
11636161|NCT00295802|Active Comparator|Cryotherapy|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)
11636162|NCT00295789|Active Comparator|1|Drug: chemotherapy: Paclitaxel/Cisplatin
11636163|NCT00295789|Experimental|2|Drug: chemotherapy: Paclitaxel/Carboplatin
11636164|NCT00295763|Other|1|
11636165|NCT00295750|Experimental|degarelix 240/160 mg|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.
11636166|NCT00295750|Experimental|degarelix 240/80 mg|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.
11636167|NCT00295750|Active Comparator|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5 mg IM (in the muscle) every 28 days starting at day 0.
11636169|NCT00295646|Active Comparator|TZ (Tamoxifen+Zoledronate)|Study Drugs Nolvadex (Tamoxifen), Zometa (Zoledronate; zoledronic acid)
11636170|NCT00295646|Active Comparator|AC (Arimidex Control)|Study Drug Arimidex (Anastrozole)
11636171|NCT00295646|Active Comparator|TC (Tamoxifen Control)|Study Drug Nolvadex (Tamoxifen)
11636172|NCT00295633|Experimental|Saxagliptin plus open-label TZD (A)|"Saxagliptin PLUS pioglitazone OR rosiglitazone
~PLUS open-label metformin (as needed as rescue medication)"
11636173|NCT00295633|Experimental|Saxagliptin plus open-label TZD (B)|"Saxagliptin PLUS pioglitazone OR rosiglitazone
~PLUS open-label metformin (as needed as rescue medication)"
11636174|NCT00295633|Placebo Comparator|Placebo plus open-label TZD (C)|"Placebo PLUS pioglitazone OR rosiglitazone
~PLUS open-label metformin (as needed as rescue medication)"
11636175|NCT00295620|Experimental|Arm A: Anastrozol|1 mg per day for 2 years
11636176|NCT00295620|Experimental|Arm B: Anastrozol|1 mg per day for 5 years
11636177|NCT00295607|Active Comparator|1|
11636178|NCT00295607|Experimental|2|
11636179|NCT00295594|Active Comparator|1|
11636180|NCT00295594|Experimental|2|
11636181|NCT00295542|Active Comparator|1|Treatment on awakening
11636182|NCT00295542|Active Comparator|2|Treatment at bedtime
11636183|NCT00295529|Experimental|Multifaceted Educational Intervention|Intervention group received an interactive workshop, portfolio of primary care appropriate genomics tools, and Gene Messengers
11636184|NCT00295529|No Intervention|No education|Educational materials at end of study
11636185|NCT00295503|Experimental|1|cisplatin, pemetrexed, and bevacizumab
11636186|NCT00295490|Experimental|240mg Devil claw|Sub clinical dose if the 3 doses employed
11636187|NCT00295490|Experimental|960mg Devil Claw|Active dose
11636188|NCT00295490|Experimental|1920 mg Devil claw|Active dose
11636189|NCT00295490|Placebo Comparator|Placebo|Comparator for all active intervention arms
11636190|NCT00295438|Experimental|Robot-Based Tele-Echography (TER)|ultrasound performed according to the method Tele-Echography
11636191|NCT00295438|Active Comparator|ultrasound method FAST|ultrasound performed according to the method FAST (Focused Assessment Sonography for Trauma)
11636192|NCT00295308|Experimental|Arm 1|
11636193|NCT00295308|Placebo Comparator|Arm 2|
11636194|NCT00295295|Experimental|Vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
11636195|NCT00295295|Active Comparator|Standing|Standing 10 min/day
11636196|NCT00295282|Experimental|1|patients will receive active MDX-1100
11636197|NCT00295191|Active Comparator|1|high-flux dialyser
11636198|NCT00295191|Active Comparator|2|low-flux dialyser
11636199|NCT00295191|Active Comparator|3|conventional dialysate
11636200|NCT00295191|Active Comparator|4|ultrapure dialysate
11636201|NCT00295165|Experimental|Arm 1|
11636202|NCT00295165|Placebo Comparator|Arm 2|
11636203|NCT00295139|Experimental|1|Behavioral Treatment for Substance Abuse in SPMI (BTSAS)
11636204|NCT00295139|Experimental|2|Behavioral Treatment for Substance Abuse in SPMI (BTSAS) + Critical Time Intervention (CTI)
11636205|NCT00295139|Active Comparator|3|Supportive Treatment in Addiction Recovery (STAR)
11636206|NCT00295061|Experimental|1 Alpha-1 MP|Sequential, blinded treatment periods of Alpha-1 MP (experimental), then crossed-over to Prolastin (active comparator), followed by open-label Alpha-1 MP
11636207|NCT00295061|Active Comparator|2 Prolastin|Sequential, blinded treatment periods of Prolastin (active comparator), then crossed-over to Alpha-1 MP (experimental), followed by open-label Alpha-1 MP
11636208|NCT00295022|Placebo Comparator|Placebo (PBO)|Placebo was administered orally on Days 1 and 2.
11636209|NCT00295022|Experimental|Montelukast (MLKT)|10 mg of Montelukast (MLKT) was administered orally on Days 1 and 2.
11636210|NCT00295022|Experimental|Levocetirizine (LCTZ)|5 mg of Levocetirizine (LCTZ) was administered orally on Days 1 and 2.
11636211|NCT00295009|Active Comparator|1-Level Fusion|Spinal fusion at a single lumbar level.
11636212|NCT00295009|Experimental|1-Level ProDisc|Total disc replacement with the ProDisc device at one spinal lumbar level.
11636213|NCT00295009|Active Comparator|2-Level Fusion|Spinal fusion at two adjacent lumbar levels.
11636214|NCT00295009|Experimental|2-Level ProDisc|Total disc replacement with the ProDisc device at two adjacent lumbar levels.
11636215|NCT00295009|Experimental|1-level ProDisc (non-randomized)|Total disc replacement with the ProDisc device for non-randomized subjects at one spinal lumbar level.
11636216|NCT00295009|Active Comparator|2-Level ProDisc (Continued Access)|Total disc replacement with the ProDisc device for non-randomized subjects at two spinal lumbar levels (only followed out to 24 months)
11636217|NCT00294970||PTSD|Patients with diagnosis of PTSD
11636218|NCT00294970||OCD|Patients with diagnosis of OCD
11636219|NCT00294970||PTSD/OCD|Patients with diagnosis of comorbid PTSD and OCD
11636220|NCT00294918|Experimental|Serostim® (1 mg)|
11636221|NCT00294918|Experimental|Serostim® (2 mg)|
11636222|NCT00294918|Experimental|Serostim® (4 mg)|
11636223|NCT00294892|Active Comparator|Carbamazepine|An oral dose of 400mg Carbamazepine is added to the 200mg oral dose Nevirapine intake prior delivery
11636224|NCT00294892|Placebo Comparator|Nevirapine|Standard therapy of 200mg Nevirapine oral prior to delivery
11636225|NCT00294866|Active Comparator|A|Receive Paricalcitol
11636226|NCT00294866|No Intervention|B|Paricalcitol on hold
11636227|NCT00294827|Experimental|Liver transplantation|
11636228|NCT00294762|Experimental|Erlotinib|150 mg erlotinib daily
11636229|NCT00294762|Experimental|Erlotinib + chemotherapy (intercalated)|carboplatin AUC 6 on Day 1 to 21 days, paclitaxel 200 mg/m2 on Day 1 to 21 days, erlotinib 150 mg Days 2-15 for 4 cycles then erlotinib 150 mg daily until progression, withdrawal of consent, or unacceptable toxicity
11636230|NCT00294736|Experimental|Arm A|Arm A (Tarceva MTD established in Part I)
11636231|NCT00294736|Experimental|Arm B|Arm B (150 mg Tarceva daily).
11636232|NCT00294723|Experimental|Lira 1.8|Liraglutide 1.8 mg once daily + glimepiride placebo 8 mg once daily, weeks 0-52 (double-blinded period) and open-label liraglutide 1.8 mg once daily in the extension periods (weeks 52-195).
11636233|NCT00294723|Experimental|Lira 1.2|Liraglutide 1.2 mg once daily + glimepiride placebo 8 mg once daily, weeks 0-52 (double-blinded period) and open-label liraglutide 1.2 mg once daily in the extension periods (weeks 52-195).
11636234|NCT00294723|Active Comparator|Glimepiride - 1|Glimepiride 8 mg once daily + liraglutide placebo 200 mcl, weeks 0-52 (double-blinded period) and open-label glimepiride 8 mg once daily in the extension periods (weeks 52-195).
11636235|NCT00294723|Active Comparator|Glimepiride - 2|Glimepiride 8 mg once daily + liraglutide placebo 300 mcl, weeks 0-52 (double-blinded period) and open-label glimepiride 8 mg once daily in the extension periods (weeks 52-195).
11636236|NCT00294684|Experimental|Corticosteroids|
11636237|NCT00294684|Placebo Comparator|Placebo|
11636238|NCT00294671|Active Comparator|Diflunisal|Diflunisal 250 mg po bid
11636239|NCT00294671|Placebo Comparator|Placebo|Placebo 1 po bid
11636240|NCT00294658|Active Comparator|Thymectomy plus prednisone|Procedure: Extended Transsternal Thymectomy plus prednisone treatment
11636241|NCT00294658|Placebo Comparator|Prednisone alone|Drug: prednisone alone protocol
11636242|NCT00294645|Active Comparator|Control|Transtelephonic monitoring at 2 month intervals
11636243|NCT00294645|Active Comparator|Remote|Medtronic CareLink® Network remote pacemaker interrogation at 3 month intervals
11636244|NCT00294632|Experimental|Lenalidomide + Rituximab|Lenalidomide Starting Dose 10 mg oral daily on Days 1-21 + Rituximab 375 mg/m^2 intravenous weekly for 4 weeks
11636245|NCT00294619|Experimental|LB03002|
11636246|NCT00294619|Placebo Comparator|Placebo|
11636247|NCT00294567|Active Comparator|1|Amlodipine
11636248|NCT00294567|Active Comparator|2|Azelnidipine
11636249|NCT00294554|Active Comparator|Active Memantine|Memantine tablets, formulated in appearance to match the placebo comparator, were initiated at 5 mg daily and advanced by 5mg /week to 20 mg/week by week 4 with dosing at 10 mg bid over the remaining 20 weeks of the trial. Over the 6 month duration of the trial, dosage could be titrated downward in increments of 5 mg to a minimum dose of 5mg/day in the event of intolerance.
11636250|NCT00294554|Placebo Comparator|Placebo Oral Tablet|Placebo tablets were formulated to match active 5mg memantine tablets. Dosing same as the active comparator with initiation at 5 mg daily and advancing by 5mg /week to 20 mg/week by week 4 with dosing at 10 mg bid over the remaining 20 weeks of the trial. Over the 6 month duration of the trial, dosage could be titrated downward in increments of 5 mg to a minimum dose of 5mg/day in the event of intolerance.
11636251|NCT00294515|Experimental|Valganciclovir up to 100 days|Valganciclovir for up to 100 days post kidney transplant
11636252|NCT00294515|Active Comparator|Valganciclovir up to 200 days|Valganciclovir for up to 200 days post kidney transplant
11636253|NCT00294437|Experimental|zoledronic acid|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
11636254|NCT00294437|No Intervention|no intervention|no reference therapy
11636255|NCT00294398|Other|Standard Asthma ED Discharge Therapy|Standard asthma therapy including oral corticosteroids, albuterol, education and discharge instructions.
11636256|NCT00294398|Experimental|ICS Prescription + Standard Asthma ED Discharge Therapy|"Subjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age:
~1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily"
11636257|NCT00294385|Active Comparator|Gemcitabine, Docetaxel|Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
11636258|NCT00294385|Active Comparator|Docetaxel|Arm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
11636259|NCT00294320|Experimental|1|250mg of Imiquimod cream application once daily 3 times per week.
11636260|NCT00294320|Placebo Comparator|2|250mg vehicle cream for application once daily 3 times per week.
11636261|NCT00294307||Advanced Practice Nurse Care (APNC)|Hospital to Home
11636262|NCT00294307||Augmented Standard Care (ASC)|Hospital only
11636263|NCT00294307||Resource Nurse Care (RNC)|Hospital only
11636264|NCT00294281|Experimental|1|Participants will undergo surgical implantation of the VNS system. This will be followed by a 2-week recovery period, then a 2-week period of gradually increasing the electrical output of the VNS system, and finally a 12-week VNS treatment period during which the electrical output level will remain constant. Follow-up will occur until Month 24.
11636265|NCT00294268|Other|1|20 weekly sessions of CBT integrated with motivational enhancement strategies
11636266|NCT00294255|Experimental|Risperidone|patients will receive risperidone for up to 20 weeks
11636267|NCT00294203|Active Comparator|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
11636268|NCT00294203|Placebo Comparator|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
11636269|NCT00294190|Experimental|Topotecan|
11636270|NCT00294164|Experimental|Serostim® 4 mg daily|
11636271|NCT00294164|Experimental|Serostim® 4 mg alternate days|
11636272|NCT00294164|Placebo Comparator|Placebo|
11636273|NCT00294125|Experimental|1|Participants will receive daily flavocoxid for 12 weeks.
11636274|NCT00294125|Placebo Comparator|2|Participants will receive placebo for 12 weeks.
11636275|NCT00294112|Experimental|High dose|High dose (8 million cells per kg of body weight)
11636276|NCT00294112|Experimental|Low dose|Low dose: 2 million cells per kg body weight
11636277|NCT00294099|Experimental|2|120 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
11636278|NCT00294099|Experimental|3|60 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
11636279|NCT00294099|Experimental|4|60 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
11636280|NCT00294099|Experimental|8|60 subjects to receive 3.75 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
11636281|NCT00294099|Experimental|7|60 subjects to receive 3.75 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
11636282|NCT00294099|Experimental|1|120 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
11636283|NCT00294099|Experimental|5|60 subjects to receive 7.5 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
11636284|NCT00294099|Experimental|6|60 subjects to receive 7.5 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
11636285|NCT00294047|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
11636286|NCT00294047|Placebo Comparator|Aluminium Hydroxide Group|Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
11636287|NCT00294008||001|Risperdal Consta flexible dosage for 24 months
11636288|NCT00293956||1|Full-term and near-term infants with respiratory distress in the first 24 hours of life
11636289|NCT00293852|No Intervention|Usual Care|
11636290|NCT00293852|Experimental|Collaborative Care|
11636291|NCT00293826|Experimental|1|196 subjects
11636292|NCT00293826|Experimental|3|196 subjects
11636293|NCT00293826|Experimental|2|196 subjects
11636294|NCT00293826|Placebo Comparator|4|196 subjects
11636295|NCT00293813|Placebo Comparator|3|Placebo for denosumab and placebo for alendronate
11636296|NCT00293813|Experimental|1|denosumab and placebo for alendronate
11636297|NCT00293813|Active Comparator|2|Placebo for denosumab and alendronate
11636298|NCT00293800|Experimental|Travoprost/Timolol|One drop Travoprost 0.004%/Timolol 0.5% in the study eye(s) each morning at 8 a.m. and one drop Timolol vehicle in the study eye(s) each evening at 8 p.m. for 3 months
11636299|NCT00293800|Active Comparator|Xalatan + Timolol 0.5%|One drop Timolol 0.5% in the study eye(s) each morning at 8 a.m. and one drop Xalatan in the study eye(s) each evening at 8 p.m. for 3 months
11636300|NCT00293787|Experimental|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5% in both eyes each morning at 8 a.m. and Timolol vehicle in both eyes each evening at 8 p.m. for 3 months
11636301|NCT00293787|Active Comparator|Xalatan + Timolol 0.5%|Timolol 0.5% in both eyes each morning at 8 a.m. and Xalatan in both eyes each evening at 8 p.m. for 3 months
11636302|NCT00293774||Standard|Standard hip replacement subjects (polyethylene)
11636303|NCT00293774||Alternative Bearing|Subjects with ceramic on ceramic total hip replacement or metal on metal hip resurfacing.
11636304|NCT00293761|Experimental|Travatan, Investigational|
11636305|NCT00293761|Active Comparator|Travatan|
11636306|NCT00293735|Active Comparator|1. Labetolol|
11636307|NCT00293735|Active Comparator|2. Magnesium Sulfate|
11636308|NCT00293722||Patients with Psoriatic Arthritis|
11636309|NCT00293709||Patients with Psoriatic Arthritis|
11636310|NCT00293644|Experimental|Pre-emptive Treatment Group|As soon as a patient becomes aware of the pregnancy, and before the Nausea and Vomiting of Pregnancy (NVP) starts, she will begin taking Diclectin®. When NVP starts, the dose will be adjusted to match symptoms.
11636311|NCT00293644|Active Comparator|Standard Treatment Group|Women randomised to this arm will not receive any Diclectin® before symptoms appear, and will be advised to commence treatment only at first sign of nausea. The starting dose of Diclectin® will be 20mg (2 tablets) at bedtime.
11636312|NCT00293644|No Intervention|Natural Course Group|A third group will be randomly matched from Motherisk NVP callers who did not participate in our pre-emptive intervention and experienced severe Nausea and Vomiting of Pregnancy/Hyperemesis Gravidarum (NVP/HG) in their previous pregnancy. This group will serve as a control group for the potential effect of the early counselling. (These women will have called for the first time after NVP symptoms (of any degree) started in the current pregnancy).
11636313|NCT00293618|Experimental|Intervention|Arm of anesthesiologists and senior residents who receive a patient's individual predicted PONV risk intraoperatively
11636314|NCT00293618|Active Comparator|Usual Care|Anesthesiologists and senior residents who provide usual care: they provide PONV prophylaxis as they always have
11636315|NCT00293605||1|C-stem implant
11636316|NCT00293605||2|Charnley Implant
11636317|NCT00293605||3|Exeter Implant
11636318|NCT00293592|Active Comparator|Dexamethasone|
11636319|NCT00293592|Placebo Comparator|Placebo|
11636320|NCT00293579|Experimental|Pemetrexed|pemetrexed 500 mg/m2 administered iv, every three weeks, for 6 cycles
11636321|NCT00293540|Active Comparator|A|Surgical oophorectomy in history-estimated mid-luteal phase of menstrual cycle plus Tamoxifen
11636322|NCT00293540|Active Comparator|B|Surgical oophorectomy in history-estimated mid-follicular phase of menstrual cycle plus Tamoxifen
11636323|NCT00293475|Experimental|Treatment (rituximab, mannitol, methotrexate, carboplatin)|Patients receive rituximab IV over 5 hours on day 1, mannitol IA, methotrexate IA over 10 minutes, and carboplatin IA over 10 minutes on days 2 and 3. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats monthly for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11636324|NCT00293462|Active Comparator|Arm I: GM-CSF Group (GG)|Arm I: Patients were randomized to receive oral sargramostim (GM-CSF) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving GM-CSF treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
11636367|NCT00292747|Active Comparator|Drotaverine placebo + ibuprofen|Drotaverine placebo plus ibuprofen 400 mg orally
11636325|NCT00293462|Active Comparator|Arm II: Salt & Soda Group (SS)|Arm II: Patients were randomized to receive salt and soda (SS) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving SS treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
11636326|NCT00293462|Active Comparator|Arm III: Salt & Soda Switched to GM-CSF (SG)|Arm III: Patients were randomized to receive oral salt and soda (SS) mouthwash as a prevention, holding it in their mouths and swallowing it in intervals over 1 hour once daily. If they develop mucositis, they continue receiving GM-CSF treatment continues during 6-7 weeks of radiotherapy and until the mucositis heals.
11636327|NCT00293423|Experimental|Vaccine with Chemotherapy|Single-arm,(HSPPC-96) administered in combination with temozolomide following standard treatment with radiation and temozolomide.
11636328|NCT00293397|Experimental|Drug-eluting bead transarterial chemoembolization (DEB-TACE)|Patients undergo DEB-TACE procedures utilizing LC Beads, polyvinyl alcohol microspheres with diameters of 100-300um or 300-500um, which are loaded with 100mg of doxorubicin hydrochloride and mixed with an equal volume of nonionic contrast media.
11636329|NCT00293384|Experimental|Aprepitant, Dexamethasone, Cytoxan & Kytril|"Day 1: 1 mg of Kytril orally or I.V., 10 mg of Dexamethasone orally, and Aprepitant 125 mg orally, 1 hour prior to cyclophosphamide administration.
~Cyclophosphamide 4gm/m2 I.V. over 90 - 120 minutes.
~Days 2 & 3: Aprepitant 80 mg once daily in the morning."
11636330|NCT00293345|Experimental|Treatment (gemcitabine hydrochloride, triapine)|Patients receive 3-AP (TriapineÃÂ®) IV over 24 hours followed by gemcitabine hydrochloride IV over 100-125 minutes on days 1 and 8. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
11636331|NCT00293293|Active Comparator|Chemotherapy Alone|Patients receiving 6 cycles of taxane and platinum therapy for ovarian, fallopian tube or primary peritoneal cancer by their treating physician. Chemotherapy administration is not administered as part of this protocol.
11636332|NCT00293293|Experimental|Standard Chemotherapy + CAM|Patients receiving 6 cycles of taxane and platinum therapy for ovarian, fallopian tube or peritoneal cancer with additional complementary alternative medicine - CAM (healing touch, hypnosis and massage therapy). Chemotherapy administration is not administered as part of this protocol.
11636333|NCT00293267|Experimental|1|raltegravir potassium
11636334|NCT00293267|Placebo Comparator|2|Placebo
11636335|NCT00293254|Experimental|1|raltegravir potassium
11636336|NCT00293254|Placebo Comparator|2|Placebo
11636337|NCT00293241|Other|MVP ON|Managed Ventricular Pacing programmed on
11636338|NCT00293241|Other|MVP OFF|Managed Ventricular Pacing programmed off: conventional pacing
11636339|NCT00293228|Experimental|A|Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment.
11636340|NCT00293228|Active Comparator|B|B. Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.
11636341|NCT00293228|Experimental|C|C. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment
11636342|NCT00293228|Active Comparator|D|D. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.
11636343|NCT00293215|Experimental|Cohort 1 (1.0 mg/m^2)|Subjects received 111-In-CMD-193 on Day 1 of Cycle 1. Subjects received CMD-193 at a dose of 1.0 mg/m^2 on Day 1 of subsequent 21-day cycles.
11636344|NCT00293215|Experimental|Cohort 2 (2.6 mg/m^2)|Subjects received 111-In-CMD-193 on Day 1 of Cycle 1. Subjects received CMD-193 at a dose of 2.6 mg/m^2 on Day 1 of subsequent 21-day cycles.
11636345|NCT00293202|Active Comparator|A|Etanercept 25 mg injection twice a week
11636346|NCT00293202|Placebo Comparator|B|Saline injection twice a week
11636347|NCT00293176|Experimental|1|
11636348|NCT00293176|Placebo Comparator|2|
11636349|NCT00293150|Active Comparator|Eplerenone|Eplerenone 25mg daily for 2 weeks Titrated to Eplerenone 50mg daily
11636350|NCT00293150|Placebo Comparator|Placebo|Placebo dosed daily
11636351|NCT00293137||1|Patients enrolled into the trial must have left ventricular ejection fraction of <40% by echocardiogram within 6 months of enrollment
11636352|NCT00293085|Active Comparator|Docetaxel|"Docetaxel (Taxotere ) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.
~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.
~Premedication:
~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.
~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.
~Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
11636353|NCT00293085|No Intervention|Comparative arm|No chemotherapy will be administered. No specific salvage therapy after progression is defined.
11636354|NCT00293059|Experimental|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|A blister card consists of 28 pills taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo
11636355|NCT00293059|Placebo Comparator|Placebo|Matching placebo to be taken orally daily
11636356|NCT00293033|Placebo Comparator|Placebo|Placebo
11636357|NCT00293033|Experimental|BEMA™ Fentanyl|BioErodible MucoAdhesive (BEMA) Fentanyl
11636358|NCT00293020|Experimental|1|BEMA Fentanyl
11636359|NCT00292981|Experimental|C1 Esterase Inhibitor|
11636360|NCT00292942|Experimental|2 mg/kg Intravenous Artesunate|2 mg/kg of Intravenous artesunate
11636361|NCT00292942|Experimental|4 mg/kg Intravenous Artesunate|4 mg/kg of Intravenous artesunate
11636362|NCT00292942|Experimental|8 mg/kg Intravenous Artesunate|8 mg/kg of Intravenous artesunate
11636363|NCT00292942|Placebo Comparator|Placebo|Mannitol (200 mg/vial) diluted in phosphate buffer and delivered in an equivalent volume by subject's weight as artesunate.
11636364|NCT00292903|Experimental|A|
11636365|NCT00292903|Active Comparator|B|
11636366|NCT00292747|Experimental|drotaverine + Ibuprofen placebo|Drotaverine 80 mg plus ibuprofen placebo orally
11636368|NCT00292747|Active Comparator|Drotaverine + ibuprofen|Drotaverine 80 mg plus ibuprofen 400 mg orally
11636369|NCT00292721|No Intervention|Control|
11636370|NCT00292721|Active Comparator|Celecoxib|
11636371|NCT00292695|Experimental|chemoradiation|Chemoradiation: IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1
11636372|NCT00292591|Active Comparator|cholecalciferol-400 IU|Control group receiving 400 IU/day plus 0 IU vitamin D3 as placebo/day
11636373|NCT00292591|Experimental|cholecalciferol 2000 IU|Experimental group receiving 2000 IU total vitamin D3/day.
11636374|NCT00292591|Experimental|cholecalciferol 4000 IU|Experimental group receiving 4000 IU/day cholecalciferol
11636375|NCT00292552||COPD subjects|Subjects with GOLD stage II-IV COPD
11636376|NCT00292552||Smoker controls|Subjects with smoking history but normal lung function
11636377|NCT00292552||Non-smoker controls|Normal healthy non-smokers
11636378|NCT00292526|Experimental|enalapril arm|treatment with enalapril
11636379|NCT00292500|No Intervention|C-Port|Automated distal anastomotic device
11636380|NCT00292474|Experimental|TAXUS Express|
11636381|NCT00292474|Placebo Comparator|Express Bare|
11636382|NCT00292461|Active Comparator|zonisamide|tablet
11636383|NCT00292461|Active Comparator|lamotrigine|tablet
11636384|NCT00292396|Active Comparator|1|Anti IL-12 monoclonal antibody/ABT-874, up to 12 weeks, 200 mg every week for 12 weeks
11636385|NCT00292396|Active Comparator|2|Anti IL-12 monoclonal antibody/ABT-874, 200 mg QOW for 12 weeks
11636386|NCT00292396|Active Comparator|3|Anti IL-12 monoclonal antibody/ABT-874, 100 mg QOW in 12 weeks
11636387|NCT00292396|Active Comparator|4|Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 4 doses in 12 weeks
11636388|NCT00292396|Active Comparator|5|Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 1 dose in 12 weeks
11636389|NCT00292396|Placebo Comparator|6|placebo, 12 doses
11636390|NCT00292370|Other|Arm 1: Open Label (OL) Paroxetine|Open-label Paroxetine In Phase I, eligible participants will take open-label (OL) Paroxetine (up to 60 mg) daily for 8 weeks. Participants who are refractory (less than 30% reduction in CAPS scores or a minimum CAPS of 50 at week 8) and have PTSD symptoms of at least moderate severity on CGI-S will be eligible for Phase II.
11636391|NCT00292370|Placebo Comparator|Arm 2 OL Paroxetine + DB Placebo|In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of placebo for 8 weeks in a double-blind (DB) fashion.
11636392|NCT00292370|Experimental|Arm 3: OL Paroxetine + DB Quetiapine|In Phase II, participants will continue taking open label paroxetine and will be randomized to the addition of quetiapine (up to 800 mg daily) for 8 weeks in a double blind fashion.
11636393|NCT00292318|Active Comparator|Arm 1|Control group of patients with fecal incontinence which would be given medical therapy and exercises to perform as treatment.
11636394|NCT00292318|Experimental|Arm 2|Study group of patients with fecal incontinence which would be given biofeedback therapy and exercises to perform as treatment.
11636395|NCT00292305|Experimental|T-crush stenting|Percutaneous coronary intervention with implantation of a stent
11636396|NCT00292305|Active Comparator|Culotte stenting|Percutaneous coronary intervention with stent
11636397|NCT00292292|Experimental|Kineflex Lumbar Artificial Disc|Treatment arm
11636398|NCT00292292|Active Comparator|Charite|
11636399|NCT00292279|Experimental|A|
11636400|NCT00292279|Active Comparator|B|
11636401|NCT00292266|Experimental|Rebif®|
11636402|NCT00292266|Active Comparator|Avonex®|
11636403|NCT00292253|Experimental|Rebif® with Rebiject™Mini|
11636404|NCT00292253|Active Comparator|Rebif® without Rebiject™Mini|
11636405|NCT00292227|Experimental|Rotigotine|Rotigotine Patch
11636406|NCT00292227|Placebo Comparator|Placebo|Placebo patch
11636407|NCT00292201|Experimental|1|Atorvastatin
11636408|NCT00292201|Placebo Comparator|2|Placebo Pill
11636409|NCT00292188|Experimental|Active|
11636410|NCT00292188|Placebo Comparator|Placebo|
11636411|NCT00292162|Active Comparator|medical therapy|Standard therapy for heart failure with angiotensin converting enzyme inhibitors(ACE) - (Ramipril, enalapril, lisinopril, captopril, perindopril), beta-blocker (BB) - (carvedilol, bisoprolol, metoprolol), Aldosterone antagonists (spironolactone) +/- diuretics and digoxin
11636412|NCT00292162|Active Comparator|Radiofrequency ablation (RFA)|Isolation of the pulmonary veins using radiofrequency ablation
11636413|NCT00292110|Active Comparator|Arm Four|
11636414|NCT00292110|Experimental|Arm One|
11636415|NCT00292110|Active Comparator|Arm Three|
11636416|NCT00292110|Active Comparator|ArmTwo|
11636417|NCT00292097|Experimental|1|Early conversion from endotracheal intubation to percutaneous tracheostomy for ventilator support of trauma patients with severe brain injury
11636418|NCT00292097|Active Comparator|2|Conventional conversion from endotracheal intubation to percutaneous tracheostomy for ventilator support of trauma patients with severe brain injury
11636419|NCT00292071|Other|1|IV caspofungin acetate (50 mg/m²/day)
11636420|NCT00292071|Other|2|IV caspofungin acetate (70 mg/m²/day)
11636421|NCT00292032||Cardiac Arrest Survivors or Post Mortem Unexplained Cardiac|Probands - Unexplained Cardiac Arrest Survivors and Post Mortem Unexplained Cardiac Arrest Cases
11636422|NCT00292032||First Degree Family Members|First Degree Family Members of those affected by Sudden Unexplained Cardiac Arrest
11636423|NCT00292019||Robotic prostatectomy|Patients who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robotics.
11636424|NCT00291980|Experimental|1|HB-AS02V vaccine
11636425|NCT00291980|Active Comparator|2|HBVAXPRO vaccine
11636426|NCT00291954|Experimental|1|Henogen hepatitis B vaccine
11636427|NCT00291954|Active Comparator|2|HBVAXPRO hepatitis B vaccine
11636428|NCT00291941|Experimental|1|Henogen HB vaccine
11636429|NCT00291941|Active Comparator|2|Fendrix vaccine
11636430|NCT00291928|Placebo Comparator|Dose ranging|A double-blind, placebo controlled, dose escalation part randomized within each of 3 sequential cohorts (Part A),
11637026|NCT00283855|Active Comparator|Online Self-Management|RAHelp.org
11636431|NCT00291928|Placebo Comparator|Parallel Arm RCT|a parallel group part with randomization into one of 4 treatment arms (Part B).
11636432|NCT00291876|Experimental|Havrix Group|Subjects who received during the primary study 2 doses of Havrix™ at Day 0 and at Month 12.
11636433|NCT00291733|Active Comparator|1|500mg levetiracetam for one week and 1000mg levetiracetam for one week
11636434|NCT00291733|Placebo Comparator|2|placebo
11636435|NCT00291733|Active Comparator|3|After crossover arm 3 equals arm 1
11636436|NCT00291733|Placebo Comparator|4|After crossover arm 4 equals arm 2
11636437|NCT00291720|Active Comparator|Spironolactone|25mg spironolactone daily
11636438|NCT00291720|Placebo Comparator|Placebo|matching placebo medication for the control group
11636439|NCT00291694|Active Comparator|1|Oral Celecoxib 400 mg twice daily for 12 months
11636440|NCT00291694|Placebo Comparator|2|Matched blinded placebo twice daily for 12 months
11636441|NCT00291668|Experimental|Certolizumab pegol 200 mg|Subjects received one subcutaneous (sc) injection of 200 mg CZP and one injection of Placebo to maintain the study blind on Weeks 0 (first dose), 2 and 4.
11636442|NCT00291668|Experimental|Certolizumab pegol 400 mg|Subjects received two subcutaneous (sc) injections of 200 mg CZP on Weeks 0 (first dose), 2 and 4.
11636443|NCT00291668|Placebo Comparator|Placebo|Subjects received two subcutaneous (sc) injections of Placebo on Weeks 0 (first dose), 2 and 4.
11636444|NCT00291655|Experimental|Levetiracetam (LEV)|
11636445|NCT00291642|Placebo Comparator|Placebo (PBO)|A single dose of placebo was administered orally on Day 1.
11636446|NCT00291642|Experimental|Levocetirizine (LCTZ) 2.5 mg|A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.
11636447|NCT00291642|Experimental|Levocetirizine (LCTZ) 5 mg|A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.
11636448|NCT00291642|Experimental|Cetirizine (CTZ) 5 mg|A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.
11636449|NCT00291642|Experimental|Cetirizine (CTZ) 10 mg|A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.
11636450|NCT00291616|Active Comparator|1|Pegylated Interferon-alpha2a
11636451|NCT00291616|Active Comparator|2|Thymosin alpha1 & Pegylated Interferon-alpha2a
11636452|NCT00291577|Experimental|1|
11636453|NCT00291525|Experimental|AVR Low Risk without warfarin|AVR Low Risk without warfarin
11636454|NCT00291525|Active Comparator|AVR low risk with standard warfarin|AVR low risk with standard warfarin
11636455|NCT00291525|Experimental|AVR High risk with lower warfarin|AVR High risk with lower warfarin
11636456|NCT00291525|Active Comparator|AVR High Risk with standard warfarin|AVR High Risk with standard warfarin
11636457|NCT00291525|Experimental|MVR with lower warfarin|MVR with lower warfarin
11636458|NCT00291525|Active Comparator|MVR with standard warfarin|MVR with standard warfarin
11636459|NCT00291499|Active Comparator|Chondroitin 4&6 sulfate (Condrosulf)|
11636460|NCT00291499|Placebo Comparator|placebo|
11636461|NCT00291486|Experimental|Assigned Dose Level|
11636462|NCT00291343|Experimental|TRITANRIX™-HEPB/HIB-MENAC +MENCEVAX™ ACWY GROUP|Subjects previously primed with 3 doses of Tritanrix™-HepB/Hib-MenAC vaccine in study NCT00290303, were administered in the current study one booster dose of Tritanrix™-HepB/Hiberix™, intramuscularly in the left anterolateral thigh, at 15-24 months of age and one booster dose of Mencevax™ ACWY by subcutaneous injection in the upper region of the left arm, at 24-30 months of age.
11636463|NCT00291343|Active Comparator|TRITANRIX™-HEPB/HIBERIX™+MENCEVAX™ ACWY GROUP|Subjects previously primed with 3 doses Tritanrix™-HepB/Hiberix™ vaccine in study NCT00290303, were administered in the current study one booster dose of Tritanrix™-HepB/Hiberix™, intramuscularly in the left anterolateral thigh, at 15-24 months of age and one dose of Mencevax™ ACWY by subcutaneous injection in the upper region of the left arm, at 24-30 months of age.
11636464|NCT00291330|Experimental|dabigatran etexilate 150 mg|twice daily
11636465|NCT00291330|Active Comparator|warfarin (INR 2-3)|prn to maintain INR (2-3)
11636466|NCT00291317|Experimental|RT 300-P FES Cycle|Participants exercised using functional electrical stimulation cycling (FES) using the RT 300-P FES cycle (Restorative Therapies, Baltimore, MD).
11636467|NCT00291226|Experimental|Glycine|Glycine dosing was fixed at an initial dose of 0.2 g/kg q.h.s for 3 days, then 0.2 g/kg b.i.d. for 4 days, then 0.2 g/kg in the a.m. and 0.4 g/kg in the p.m. for 4 days, and finally 0.4 g/kg b.i.d. Subjects weighing > 100 kg were limited to a total daily dose of 80 g daily. Glycine was dispensed under IND 33,515 (DCJ).
11636468|NCT00291226|Placebo Comparator|Placebo Group|Placebo was dispensed as a proprietary formulations developed by Glytech, Inc, consisting of microencapsulated sucrose. Recommended administration of the sprinkles was to spoon them onto pudding or applesauce and swallow them with minimal chewing. Since earlier product testing by Glytech revealed that a few individuals did not like the somewhat granular texture of the sprinkles, subjects could switch to a second Glytech placebo formulation, consisting of proprietary pre-flavored sugar powders to be dissolved in 8 ounces of water.
11636469|NCT00291213|Experimental|Levetiracetram Administration|
11636470|NCT00291213|Placebo Comparator|Placebo|
11636471|NCT00291200||1|Participants with basic symptoms of psychosis
11636472|NCT00291200||2|Control participants
11636473|NCT00291187|Placebo Comparator|Placebo|Take orally 30 minutes prior to bedtime.
11636474|NCT00291187|Experimental|20 mg VEC-162|20 mg taken orally 30 minutes prior to bedtime.
11636475|NCT00291187|Experimental|50 mg VEC-162|50 mg taken orally 30 minutes prior to bedtime.
11636476|NCT00291187|Experimental|100 mg VEC-162|100 mg taken orally 30 minutes prior to bedtime.
11636477|NCT00291161|Experimental|Partners in Dementia Care|"PDC is telephone-based care consultation intervention jointly delivered by care consultants in the VA and local Alzheimer's Association. The steps in care consultation included 1) Assessment of medical and non-medical care needs; 2) Development of a care plan that addresses needs of patients and caregivers; 3) on-going monitoring of the status, progress, and barriers encountered; and 4) Reassessment of care needs for patients and caregivers.
~PDC assisted families by: 1) providing disease-related education and information, 2) offering emotional support and coaching, 3) linking families to medical and non-medical services and resources, and 4) mobilizing and organizing the informal care network."
11637192|NCT00282009|Experimental|Enhanced Internet|Enhanced Internet
11636478|NCT00291161|No Intervention|Usual Care|Patients and caregivers at the three control VA settings were given a packet of educational materials on dementia and usual-care community resources.
11636479|NCT00291148|Active Comparator|Paroxetine|
11636480|NCT00291148|Active Comparator|pregabalin|
11636481|NCT00291135|Experimental|1|Oral Letrozole 2.5 mg daily for six months
11636482|NCT00291057|Experimental|1|MALG
11636483|NCT00291031|Experimental|IRT|Patients randomly assigned to the IRT condition receive Imagery Rehearsal Therapy after 4 weeks since the entrance into the trial next to their treatment as usual.
11636484|NCT00291031|No Intervention|TAU|Patients that are randomly assigned to the waiting list control condition get treatment as usual (TAU) and complete the daily nightmare logs for a period of three months. These patients get the IRT intervention after waiting for 6 months.
11636485|NCT00291018|Experimental|ProDisc-C|ProDisc-C total disc replacement device intended to treat single level SCDD in the cervical spine from C3-C7
11636486|NCT00291018|Active Comparator|Control|ACDF
11636487|NCT00290888|Active Comparator|ACR|Arthroscopic rotator cuff repair without acromioplasty
11636488|NCT00290888|Experimental|ACR-A|Arthorscopic rotator cuff repair with acromioplasty
11636489|NCT00290875|Other|Arm 1|We randomly allocated sites to either intervention or control. At the intervention sites, active strategies were employed to implement the rule into practice, including education, policy, and real-time reminders on radiology requisitions.
11636490|NCT00290862|Experimental|CORTOSS|Patients prospectively randomized to be treated with Cortoss constitute treatment group.
11636491|NCT00290862|Active Comparator|PMMA|Patients prospectively randomized to be treated with PMMA constitute active control group.
11636492|NCT00290823|Experimental|1|Participants will receive 6 mg dexamethasone daily for 10 days Participants will also receive albendazole and omeprazole.
11636493|NCT00290823|Experimental|2|Participants will receive 6 mg dexamethasone daily for 10 days, then 8 mg dexamethasone daily for 4 weeks with a 2-week taper. Participants will also receive albendazole and omeprazole.
11636494|NCT00290810|Experimental|Treatment (monoclonal antibody therapy)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11636495|NCT00290771|Experimental|Imatinib 600 mg + hydroxyurea 1000 mg|Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.
11636496|NCT00290771|Experimental|Imatinib 1000 mg + hydroxyurea 1000 mg|Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.
11636497|NCT00290758|Experimental|Arm I (genistein)|Patients receive oral genistein once daily for up to 6 months.
11636498|NCT00290758|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily for up to 6 months.
11636499|NCT00290745|Active Comparator|tamoxifen or letrozole|tamoxifen or letrozole work in treating women with ductal carcinoma in situ
11636500|NCT00290732|Experimental|Intraductal arm|Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.
11636501|NCT00290732|Active Comparator|Intravenous arm|Participants receiving standard intravenous administration of pegylated liposomal doxorubicin prior to breast biopsy for drug concentrations.
11636502|NCT00290706|Experimental|Gemcitabine 800 mg/m2 + Bortezomib IVP over 3-5 seconds|Gemcitabine dose of 800 mg/m2 over 30 minutes followed by Bortezomib IVP given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
11636503|NCT00290693|Experimental|CapTere (Capecitabine + Docetaxel)|Capecitabine + Docetaxel (Taxotere)
11636504|NCT00290667|Active Comparator|Interventional: CHOP-14 + 8 x 2-weekly rituximab|Arm I (2-weekly rituximab): Patients receive rituximab IV 375 mg/m^2 (females) and 500 mg/m^2 (males) over 4 hours on days 0, 14, 28, 42, 56, 70, 84, and 98. Patients also receive pegfilgrastim subcutaneously on day 4 of each course.
11636505|NCT00290667|Active Comparator|Interventional: CHOP-14 + 8 x dose-dense rituximab|Arm II (pharmacokinetic-based dose-dense rituximab): Patients receive rituximab IV 375 mg/m^2 (females) and 500 mg/m^2 (males) over 4 hours on days -1, 0, 3, 7, 14, 21, 28, and 42. Patients also receive pegfilgrastim subcutaneously on day 4 of each course.
11636506|NCT00290654|Experimental|Lumpectomy with Brachytherapy|Patients with ductal carcinoma in situ (DCIS, a non-invasive form of breast cancer) treated with standard lumpectomy/brachytherapy following by radiation using the MammoSite (FDA approved a balloon-catheter device placed in the lumpectomy cavity through which high dose radiation is delivered). Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient.
11636507|NCT00290615|Experimental|Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab|"Capecitabine - oral administration of 850 mg/m2 every 12 hours on days 1-14. Oxaliplatin - IV administration of 130 mg/m2 over 2 hours on day 1 of a cycle. Bevacizumab- IV administration of 7.5 mg/kg over 30-90 minutes on day 1 of a cycle.
~Cetuximab at an initial dose of 400 mg/m2 over 120 minutes and subsequently 250 mg/m2 over 60 minutes on day 1 of a cycle.
~Cycles are 21 days."
11636508|NCT00290589|Experimental|Intramuscular methylprednisolone acetate|Methylprednisolone acetate 160mg intramuscular injection
11636509|NCT00290589|Placebo Comparator|Placebo|Placebo intramuscular injection
11636510|NCT00290550|Other|1|MK-0457
11636511|NCT00290537|Experimental|Part One: ZD6474|First part of two part treatment, Part One: three 3-week cycles 300 mg of ZD6474 daily. Second part, Part Two: participants randomized to receive 300 mg of ZD6474 daily, or 100 mg of ZD6474 daily plus carboplatin AUC 6.0 intravenous (IV) over 15-30 minutes and paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 every 3 weeks.
11636512|NCT00290537|Experimental|Part Two A: ZD6474 300 mg|Second part of study where participants randomized to receive 300 mg of ZD6474 daily (group A)
11636684|NCT00288444|Active Comparator|Docetaxel 30 mg/ m2and Lonafarnib 150 mg|Docetaxel 30 mg/ m^2 Intravenously weekly and Lonafarnib 150 mg by mouth twice a day daily.
11636513|NCT00290537|Experimental|Part Two B: ZD6474 100 mg + Carboplatin + Paclitaxel|Second part of study where participants randomized to receive 100 mg of ZD6474 daily plus carboplatin AUC 6.0 IV over 15-30 minutes and paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 every 3 weeks (group B).
11636514|NCT00290511|Experimental|R-FIND + Zevalin|Fludarabine 25 mg/m^2 intravenous (IV) over 5-30 minutes on Days 2-4. Mitoxantrone 10 mg/m^2 IV over 5-30 minutes on Day 2. Rituximab 375 mg/m^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total). Zevalin 0.3 mCi/kg IV after 4 cycles of R-FND. Dexamethasone 20 mg by mouth (PO) or IV daily on Days 2-6.
11636515|NCT00290498|Experimental|Arm A|R-HCVAD + R-MTX/Ara-C ((Rituximab-HCVAD (rituximab, doxorubicin, cyclophosphamide, vincristine, and dexamethasone) alternating with Rituximab-Methotrexate-Cytarabine))
11636516|NCT00290498|Active Comparator|Arm B|"R-CHOP ((Rituximab-CHOP (Rituximab, cyclophosphamide, vincristine, and prednisone))
~No longer recruiting for this study arm."
11636517|NCT00290472|Experimental|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 8 weeks.
11636518|NCT00290433|Experimental|HCVIDDOXIL Regimen|"Cycle 1: Cyclophosphamide by vein two times a day on Days 1,2, and 3. Mesna by vein nonstop over Days 1 through 3. Pegylated liposomal doxorubicin by vein over 1 hour on Day 2. Vincristine by vein on Days 4 and 11. Dexamethasone by mouth on Days 1 through 4 and 11 through 14.
~Cycle 2: Methotrexate by vein over 2 hours on Day 1 and over 22 hours on day 1. Cytarabine by vein twice a day on Days 2 and 3."
11636519|NCT00290420|Experimental|Chloroquine profilaxis|"Prevention: chloroquine profilaxis
~Prevention of malaria attacks with chloroquine profilaxis taken once a week"
11636520|NCT00290420|No Intervention|No prevention|Treatment of malaria attack with chloroquine when they occur
11636521|NCT00290355|Experimental|GSK 249553 Group|Male and female patients at least 18 years of age, with resectable non-small-cell lung cancer (NSCLC), who received 13 doses of GSK 249553 vaccine, administered intramuscularly in the deltoid or lateral regions of the thighs, alternatively on the right and left sides, according to the following schedule: 5 doses at 3-week intervals, followed by 8 doses at 3-month intervals.
11636522|NCT00290355|Placebo Comparator|Placebo Group|Male and female patients at least 18 years of age, with resectable non-small-cell lung cancer (NSCLC), who received 13 doses of placebo, administered intramuscularly in the deltoid or lateral regions of the thighs, alternatively on the right and left sides, according to the following schedule: 5 doses at 3-week intervals, followed by 8 doses at 3-month intervals.
11636523|NCT00290342|Experimental|Infanrix-IPV Group|Healthy male or female subjects between and including 8 to 12 weeks (56-90 days) of age at the time of the first vaccination, who were born after a gestation period of 36 to 42 weeks, received 3 doses of the GSK Biologicals' combined Infanrix™-IPV (DTPa-IPV) vaccine at 2, 4 and 6 months of age, intramuscularly into the antero-lateral thigh.
11636524|NCT00290342|Active Comparator|Infanrix + IMOVAX Polio Group|Healthy male or female subjects between and including 8 to 12 weeks (56-90 days) of age at the time of the first vaccination, who were born after a gestation period of 36 to 42 weeks, received 3 doses of the GSK Biologicals' Infanrix™ (DTPa) vaccine co-administered with Sanofi-Pasteur's IMOVAX Polio® (IPV) vaccine at 2, 4 and 6 months of age, intramuscularly into the antero-lateral sides of opposite thighs.
11636525|NCT00290329|Experimental|Group A|
11636526|NCT00290290|Active Comparator|povidone-iodine|preoperative skin preparation with povidone-iodine
11636527|NCT00290290|Experimental|chlorhexidine-alcohol|preoperative skin preparation with scrub and paint technique
11636528|NCT00290251|Active Comparator|ulipristal acetate -20 mg|20 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days in each study phase
11636529|NCT00290251|Active Comparator|ulipristal acetate - 10 mg|10 mg daily dose ulipristal acetate for three menstrual cycles or up to 102 days in each study phase
11636530|NCT00290251|Placebo Comparator|Placebo|Placebo taken daily for three menstrual cycles or up to 102 days in each study phase
11636531|NCT00290238|Experimental|PNT|
11636532|NCT00290238|Sham Comparator|TENS|
11636533|NCT00290199|Experimental|Transcervical Foley Catheter|
11636534|NCT00290199|No Intervention|No Foley|
11636535|NCT00290186|Experimental|Hyperbaric Oxygen Treatment (HBO)|100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
11636536|NCT00290186|Active Comparator|Hyperbaric Air Treatment (HBA)|14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
11636537|NCT00290147|Experimental|1.0 mg of D1ME100 vaccine|1.0 mg dose of DME100 vaccine delivered by Biojector IM injections at 0, 1 and 5 months
11636538|NCT00290147|Experimental|5.0 mg of D1ME100 vaccine|5.0 mg dose of DME100 vaccine delivered by Biojector IM injections at 0, 1 and 5 months
11636539|NCT00290121|Active Comparator|Olanzapine|
11636540|NCT00290082|Active Comparator|loxapine|agitated patients were randomly assigned either to loxapine, either to midazolam group
11636541|NCT00290082|Active Comparator|midazolam|midazolam is compared to loxapine in terms of efficacy and tolerance
11636542|NCT00289991|Active Comparator|Itraconazole|
11636543|NCT00289991|Experimental|Voriconazole|
11636544|NCT00289978|Experimental|Fingolimod 1.25 mg|
11636545|NCT00289978|Experimental|Fingolimod 0.5 mg|
11636546|NCT00289978|Placebo Comparator|Placebo|
11636547|NCT00289965|Active Comparator|1|in-person brief motivational intervention
11636548|NCT00289965|Active Comparator|2|Alcohol 101plus
11636549|NCT00289965|Active Comparator|3|AlcoholEdu (a Web-based tutorial).
11636550|NCT00289952|Experimental|Group 1|HAART + valproic acid for 16 weeks followed by HAART alone for 32 weeks.
11636551|NCT00289952|Experimental|Group 2|HAART alone for 16 weeks followed by HAART + valproic acid for 32 weeks.
11636552|NCT00289926|Experimental|dehydroepiandrosterone|50.0mg dehydroepiandrosterone capsule, by mouth, daily for 12 months
11636553|NCT00289926|Placebo Comparator|Placebo|Placebo capsule consists of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF manufactured to mimic dehydroepiandrosterone capsule
11636554|NCT00289913|Experimental|VAQTA™, PedvaxHIB™ and Infanrix™/VAQTA™ (Stage 1)|"Day 1: VAQTA™ (first dose), PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.
~Week 24: The second dose of VAQTA™ was administered."
11636555|NCT00289913|Experimental|PedvaxHIB™ and Infanrix™/VAQTA™/VAQTA™ (Stage 1)|"Day 1: PedvaxHIB™ and Infanrix™ were administered concomitantly at different injection sites.
~Week 4: The first dose of VAQTA™ was administered.
~Week 28: The second dose of VAQTA™ was administered."
11636556|NCT00289913|Experimental|VAQTA™, PedvaxHIB™/VAQTA™ (Stage 1)|"Day 1: VAQTA™ (first dose) and PedvaxHIB™ were administered concomitantly at different injection sites.
~Week 24: The second dose of VAQTA™ was administered."
11636557|NCT00289913|Experimental|PedvaxHIB™/VAQTA™/VAQTA™ (Stage 1)|"Day 1: PedvaxHIB™ was administered.
~Week 4: The first dose of VAQTA™ was administered.
~Week 28: The second dose of VAQTA™ was administered."
11636558|NCT00289913|Experimental|VAQTA™/VAQTA™ (Stage 2)|"Day 1: The first dose of VAQTA™ was administered.
~Week 24: The second dose of VAQTA™ was administered."
11636559|NCT00289900|Experimental|MK-0524B 2g/20 mg|Co-administration of one tablet of MK-0524A (Extended Release [ER] niacin/laropiprant [LRPT] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks
11636560|NCT00289900|Experimental|MK-0524B 2g/40mg|Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin 20 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 40 mg for 8 weeks
11636561|NCT00289900|Active Comparator|Atorvastatin 10 mg|Atorvastatin 10 mg, orally, once daily for 12 weeks
11636562|NCT00289900|Active Comparator|Atorvastatin 20 mg|Atorvastatin 20 mg, orally, once daily for 12 weeks
11636563|NCT00289900|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg, orally, once daily for 12 weeks
11636564|NCT00289900|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg, orally, once daily for 12 weeks
11636565|NCT00289887|Experimental|1|Losartan
11636566|NCT00289887|Placebo Comparator|2|Placebo
11636567|NCT00289874|Experimental|1|montelukast
11636568|NCT00289874|Placebo Comparator|2|placebo
11636569|NCT00289861|Active Comparator|risperdone|
11636570|NCT00289861|Placebo Comparator|placebo|
11636571|NCT00289848|Experimental|1|sitagliptin 100 mg
11636572|NCT00289848|Placebo Comparator|2|placebo
11636573|NCT00289835|Experimental|PCI-stenting|Stenting the moderate SVG lesion with the paclitaxel stent
11636574|NCT00289835|Other|Standard medical treatment|
11636575|NCT00289796|Active Comparator|Infanrix hexa Group|Subjects received a dose of hepatitis B vaccine at birth followed by immunization with 3 doses of Infanrix hexa™ (2, 4 and 6 months of age) and one booster dose of Infanrix hexa™ between 12 and 23 months of age. All vaccines were administered by deep intramuscular injection into the left anterolateral thigh.
11636576|NCT00289783|Experimental|Menhibrix A Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot A co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
11636577|NCT00289783|Experimental|Menhibrix B Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot B co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
11636578|NCT00289783|Experimental|Menhibrix C Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot C co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
11636579|NCT00289783|Experimental|Menhibrix Group|Subjects were primed with 3 doses of Menhibrix vaccine Lot A, B or C co-administered with Pediarix and boosted with 1 dose of Menhibrix vaccine, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. Menhibrix and Pediarix vaccines were administered intramuscularly in the right or left upper thigh, respectively. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
11636580|NCT00289783|Active Comparator|ActHIB Group|Subjects were primed with 3 doses of ActHIB co-administered with Pediarix and boosted with 1 dose of PedvaxHIB, with co-administration of M-M-R II and Varivax. Subjects received vaccination at approximately 2, 4, 6 months and the fourth dose at 12-15 months of age. ActHIB, PedvaxHIB vaccines were administered intramuscularly in the right upper thigh and Pediarix vaccine in the left upper thigh. M-M-R II and Varivax vaccines were administered subcutaneously respectively in the upper left arm and the upper right arm.
11636581|NCT00289770|Experimental|Group A|Was vaccinated with Lot A in the primary study.
11636582|NCT00289770|Experimental|Group B|Was vaccinated with Lot B in the primary study.
11636583|NCT00289770|Experimental|Group C|Was vaccinated with Lot C in the primary study.
11636584|NCT00289757|Experimental|Havrix Group|"Subjects who received 2 doses of Havrix™ (lot A, B or C) in the primary study.
~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Havrix Group for data analyses during the long term follow-up."
11636585|NCT00289744|Experimental|Twinrix Group|Subjects who received 2 doses (at Day 0 and Month 6) of Twinrix in the primary study (208127/076)
11636586|NCT00289744|Experimental|Engerix-B Additional Dose (Adult)|Subjects aged 16 years and above who received an additional dose of EngerixTM-B (adult dose).
11636587|NCT00289744|Experimental|Engerix-B Additional Dose (Pediatric)|Subjects under the age of 16 years who received an additional dose of EngerixTM-B (pediatric dose).
11636588|NCT00289731|Experimental|Twinrix Group|Healthy and non-healthy male or female subjects, aged 41 years or older, who received combined Twinrix™ (720/20) vaccine, administered intramuscularly in the left deltoid region, according to a 0, 1 and 6 month schedule.
11636830|NCT00286728|Experimental|Arm 1|Intensive referral to dual-focused self-help groups
11636589|NCT00289731|Active Comparator|Engerix-B+Havrix Group|Healthy and non-healthy male or female subjects, aged 41 years or older, who received separate administrations of Engerix™-B (20 μg) vaccine, administered intramuscularly in the left deltoid region, according to a 0, 1 and 6 month schedule and Havrix™ (1440 EL.U) vaccine, administered intramuscularly in the right deltoid region, according to a 0 and 6 month schedule.
11636590|NCT00289731|Active Comparator|HB VAX PRO+Vaqta Group|Healthy and non-healthy male or female subjects, aged 41 years or older, who received separate administrations of HB VAX PRO™ (10 μg) vaccine, administered intramuscularly in the left deltoid region, according to a 0, 1 and 6 month schedule and Vaqta™ (50 IU) vaccine, administered intramuscularly in the right deltoid region, according to a 0 and 6 month schedule.
11636591|NCT00289718|Experimental|Twinrix Group|"Subjects who received 2 doses of Twinrix™ (lot A, B or C) in the primary study.
~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Twinrix Group for data analyses during the long term follow-up."
11636592|NCT00289705|Experimental|Surgery|Laparoscopic gastric bypass
11636593|NCT00289705|No Intervention|2|Traditional treatment for obesity
11636594|NCT00289653|Experimental|single open-label treatment arm|Adult smokers willing to quit were treated with escalating doses of transdermal nicotine patch (Nicoderm) and brief counselling if they continued to smoke over a 9-week treatment period.
11636595|NCT00289640|Experimental|1|
11636596|NCT00289640|Experimental|2|
11636597|NCT00289640|Experimental|3|
11636598|NCT00289627|Experimental|ipilimumab (MDX-010, BMS-734016)|
11636599|NCT00289536|Experimental|Low Dose|
11636600|NCT00289536|Experimental|Medium Dose|
11636601|NCT00289536|Experimental|High Dose|
11636602|NCT00289523||Escitalopram|
11636603|NCT00289523||Bupropion XL|
11636604|NCT00289523||Combination Therapy|Escitalopram and Bupropion XL
11636605|NCT00289471||Cognitive Screening|Cognitive screening
11636606|NCT00289458|Experimental|Aquatic Education|Exercise combined with education
11636607|NCT00289458|Experimental|Aquatic|
11636608|NCT00289458|Placebo Comparator|Control|
11636609|NCT00289432|Experimental|1|Behavioral: Psychoeducative intervention
11636610|NCT00289432|Active Comparator|2|The Hospitals standard follow-up support group
11636611|NCT00289419|Active Comparator|A|
11636612|NCT00289419|Experimental|B|
11636613|NCT00289380||Nutrition support|Nutrition support cohort means accept nutrition support，it was defined as ≥15kal/kg/d and < 30kal/kg/d of non-protein calories (carbohydrate and/or fat) and amino acids or protein≥1g/kg/d for 5~28 consecutive days.
11636614|NCT00289380||Without nutritional support|Group received only intravenous 5 to 10% glucose and electrolyte infusions
11636615|NCT00289341|Placebo Comparator|Placebo|12 patients in the placebo Arm for 8 weeks followed by DC/LNCAP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks.
11636616|NCT00289341|Experimental|DC/LNCaP|12 patients, receiving DC/LNCaP, DC/LNCaP-M1 and DC/KLH immunizations over 8 weeks
11636617|NCT00289315|Experimental|Arm 1|Primary (Environmental) Prevention of Weight Gain
11636618|NCT00289315|Experimental|Arm 2|Primary (Envrironmental) and Secondary (Behavioral) Weight Gain Prevention Program
11636619|NCT00289315|Experimental|Arm 3|Control - no Environmental or Behavioral Program intervention
11636620|NCT00289289|Active Comparator|On-Off|Subjects have intervention pacing features turned On according to randomization assignment in the first crossover period then Off in the second period.
11636621|NCT00289289|Active Comparator|Off-On|Subjects have intervention pacing features turned Off according to the randomization assignment for the first crossover period and then On in the second period.
11636622|NCT00289289|No Intervention|Non-randomized|Subjects that did not have device recorded episodes of atrial tachycardia/atrial fibrillation during the 3 month observation period post-implant did not qualify for randomization but were continued to be followed in the study. There were no programming requirements and symptom activations were not collected.
11636623|NCT00289237|Experimental|High intensity intervention group|"Lifestyle intervention consisted of 15-30 minutes of individual lifestyle counselling + offer of participation in group-based lifestyle counselling (½ year). This offer was given at baseline to all participants in the group.
~Persons at high risk of IHD: offer additionally given at 1- and 3-year follow-up"
11636624|NCT00289237|Experimental|Low intensity intervention group|"Lifestyle intervention consisted of 15-30 minutes of individual lifestyle counselling. This offer was given at baseline to all participants in the group.
~Persons at high risk of IHD: offer additionally given at 1- and 3-year follow-up"
11636625|NCT00289237|No Intervention|Control group|"Questionnaires regarding lifestyle and general health were sent to all participants in this group.
~The importance of healthy lifestyle was not mentioned, and no intervention was offered."
11636626|NCT00289224|Experimental|1|Cholera Vaccine
11636627|NCT00289224|Placebo Comparator|2|Placebo
11636628|NCT00289211|Experimental|C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously (IV). If there was no response to treatment 60 minutes after the first dose, a second 1,000 U dose could be administered.
11636629|NCT00289211|Placebo Comparator|Placebo|Matching placebo (saline) administered IV. If there was no response to treatment 60 minutes after the first dose, a second placebo (saline) dose could be administered.
11636630|NCT00289198|Experimental|Fluticasone furoate|Participants were instructed to administer two sprays into each nostril once daily every morning of fluticasone furoate 110 μg
11636631|NCT00289198|Placebo Comparator|Placebo|Participants were instructed to administer two sprays into each nostril once daily every morning of placebo
11636632|NCT00289185|Experimental|RTS,S/AS02D Group|Subjects aged between 6 and 10 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of the RTS,S/AS02D vaccine co-administered with the TETRActHib™ vaccine at Week 0, Week 4 (Month 1) and Week 8 (Month 2). The RTS,S/AS02D vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
11636685|NCT00288444|Active Comparator|Docetaxel 36 mg/ m2 and Lonafarnib 100 mg|Docetaxel 36 mg/ m^2 Intravenously weekly and Lonafarnib 100 mg by mouth twice a day daily
11636686|NCT00288444|Active Comparator|Docetaxel 30 mg/m2 and Lonafarnib 100 mg|Docetaxel30 mg/m^2 Intravenously weekly and Lonafarnib 100 mg by mouth twice a day daily.
11636633|NCT00289185|Active Comparator|Engerix-B Group|Subjects aged between 6 and 10 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of Engerix-B® vaccine co-administered with the TETRActHib™ vaccine at Week 0, Week 4 (Month 1) and Week 8 (Month 2). The Engerix-B® vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh..
11636634|NCT00289133|Active Comparator|GVF|Gamma Vacuum Foil polyethylene tibial insert
11636635|NCT00289133|Active Comparator|P.F.C.|Cross-linked polyethylene tibial insert
11636636|NCT00289120|Experimental|Cola beverage|Subjects will be given 500cc of Cola twice daily.
11636637|NCT00289120|Placebo Comparator|Deionized water|Subjects will be given 500cc of deionized water.
11636638|NCT00289107|Active Comparator|1|P.F.C.® Sigma™ Rotating Platform Cruciate Substituting Knee System
11636639|NCT00289107|Active Comparator|2|P.F.C.® Sigma™ Fixed Cruciate Substituting Knee System
11636640|NCT00289094|Active Comparator|1|P.F.C.® Sigma™ Rotating Platform (RP) Cruciate Retaining Knee System
11636641|NCT00289094|Active Comparator|2|P.F.C.® Sigma™ Fixed Cruciate Retaining Knee System
11636642|NCT00289081|Active Comparator|1|Rotating Platform Cruciate Retaining Knee implant
11636643|NCT00289081|Active Comparator|2|Rotating Platform Cruciate Substituting Knee implant.
11636644|NCT00289068||Phacoemulsification Sleeve 2.2mm|Phacoemulsification Sleeve setting 2.2 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
11636645|NCT00289068||Phacoemulsification Sleeve 2.8mm|Phacoemulsification Sleeve setting 2.8 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
11636646|NCT00289068||Phacoemulsification Sleeve 3.0mm|Phacoemulsification Sleeve setting 3.0 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
11636647|NCT00289055|Experimental|1|Cordis SMART™ Nitinol Stent
11636648|NCT00289055|Active Comparator|2|balloon angioplasty
11636649|NCT00289016|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec at an initial dose of 10⁶ plaque forming units (PFU)/mL injected into 1 or more tumors with maximum total volume of 4 mL (up to 2 mL per tumor). Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks for up to 15 weeks. After the initial 8 doses, if indications of biological activity were observed, treatment could continue for up to 16 additional doses.
11636650|NCT00288990||1|subjects who are NAb positive
11636651|NCT00288990||2|Subjects who are antibody negative
11636652|NCT00288990||3|subjects who are BAb positive
11636653|NCT00288977|Experimental|islet cell transplant|
11636654|NCT00288912|Active Comparator|Health Education Intervention|Health Education Intervention
11636655|NCT00288912|No Intervention|Usual Medical Care|Usual Medical Care
11636656|NCT00288912|Experimental|Osteoarthritis Self-Management|Osteoarthritis Self-Management
11636657|NCT00288899|Other|Arm 1|standard VA surgical iMedConsent process
11636658|NCT00288899|Experimental|Arm 2|enhanced version of VA surgical iMedConsent process (repeat-back)
11636659|NCT00288886|Experimental|Contracts, Prompts and Reinforcement arm|Participants were provided with contracting, prompting and reinforcement of continuing care attendance and substance use abstinence.
11636660|NCT00288886|Active Comparator|Control Arm|Participants were provided with routine care- they did not receive contracting, prompting and reinforcement of continuing care attendance and substance use abstinence.
11636661|NCT00288860|Experimental|Telephone Monitoring|Biweekly monitoring and support by telephone (up to 6 calls over 3 months) as augmentation to mental health care as usual.
11636662|NCT00288860|Active Comparator|Treatment-As-Usual|Mental health Treatment As Usual, potentially including case management, pharmacotherapy, and individual and/or group psychotherapy.
11636663|NCT00288795|No Intervention|1|Standard Care
11636664|NCT00288795|Other|2|Massage Treatment
11636665|NCT00288795|Other|3|Polarity Treatment
11636666|NCT00288769|Other|2|
11636667|NCT00288730|Experimental|001|nesiritide
11636668|NCT00288704|Placebo Comparator|Placebo|Some subjects were treated with Placebo in the Study. This occurred (if subject randomized to Placebo) either during the first 6 weeks of the study or during the randomized withdrawal (weeks 15-24).
11636669|NCT00288704|Active Comparator|rilonacept 160 mg|"If randomized to rilonacept, subjects received this treatment during the first 6 weeks of the study or during the randomized withdrawal (weeks 15-24). All subjects received rilonacept 160 mg during weeks 6-14 (between Parts A and B).
~Study drug is administered as a 2.0 mL subcutaneous injection once a week. At baseline (week 0) subjects receive a loading dose of rilonacept 320 mg."
11636670|NCT00288704|Other|Open-Label rilonacept 160 mg|"After week 24 (the end of part B), all subjects went into weekly dosing of open label rilonacept 160 mg. During this phase of the study, adolescents aged 7 and above were entered into the study and rilonacept was dosed as 2.2 mg/kg injections, up to 160 mg, per week.
~Study drug is administered as a 2.0 mL subcutaneous injection once a week."
11636671|NCT00288691|Experimental|Arm 1|
11636672|NCT00288691|Experimental|Arm 2|
11636673|NCT00288691|Experimental|Arm 3|
11636674|NCT00288691|Placebo Comparator|Arm 4|
11636675|NCT00288626|Experimental|MS Treatment|Autologous peripheral blood stem cell grafts were CD34+ selected; the participants then received high-dose treatment with carmustine, etoposide, cytarabine, and melphalan as well as rabbit antithymocyte globulin before autologous HCT.
11636676|NCT00288600|Experimental|Experimental group|Intravenous Immunoglobulin
11636677|NCT00288600|Placebo Comparator|CONTROL GROUP|Normal Saline solution
11636678|NCT00288587|Active Comparator|Ultrafiltration|Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
11636679|NCT00288587|Active Comparator|Usual & Customary|Patients treated with conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
11636680|NCT00288574|Experimental|fluoxetine|fluoxetine up to 80 mg per day
11636681|NCT00288574|Placebo Comparator|Placebo|Placebo
11636682|NCT00288509|Experimental|Dysport|250-1000 units
11636683|NCT00288444|Active Comparator|Docetaxel 36 mg/ m2 IV weekly and Lonafarnib 150 mg|Docetaxel 36 mg/ m^2 Intravenously weekly and Lonafarnib 150 mg by mouth twice a day daily.
11636831|NCT00286728|No Intervention|Arm 2|Usual care
11636687|NCT00288431|Experimental|1|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
11636688|NCT00288418|Active Comparator|ARROWgard Blue® CVC|7-French x 20-cm, triple lumen, short-term CVC
11636689|NCT00288418|Experimental|Angiotech CVC|A 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
11636690|NCT00288366|Active Comparator|1|aripiprazole (Abilify)
11636691|NCT00288366|Active Comparator|2|ziprasidone (Geodon)
11636692|NCT00288353|Active Comparator|1|aripiprazole (Abilify)
11636693|NCT00288353|Active Comparator|2|ziprasidone (Geodon)
11636694|NCT00288340|Active Comparator|1,2|
11636695|NCT00288327|Experimental|1|Enhanced New Leaf Intervention
11636696|NCT00288327|Other|2|Minimum Intervention
11636697|NCT00288314||PTSD|
11636698|NCT00288314||CONTROLS|
11636699|NCT00288301|Experimental|1|Special Intervention
11636700|NCT00288301|Experimental|2|Delayed intervention
11636701|NCT00288288||1|Epicardial left ventricular lead placement during a clinically indicated open chest surgery
11636702|NCT00288288||2|Transvenous left ventricular lead implant during a clinically indicated CRT system implant
11636703|NCT00288249|Experimental|Arm 2|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
11636704|NCT00288249|Experimental|Arm 3|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
11636705|NCT00288249|Experimental|Arm 4|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
11636706|NCT00288249|Experimental|Arm 1|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
11636707|NCT00288223|Experimental|1|telithromycin
11636708|NCT00288184|Experimental|Allopurinol|Hypertensive children received both placebo and allopurinol in a cross over design.
11636709|NCT00288184|Placebo Comparator|Placebo|
11636710|NCT00288171|Experimental|Allopurinal|Hypertensive renal transplant recipients with elevated uric acid will the treated with allopurinol and placebo in an randomized cross over fashion. Subjects will serve as their own controls.
11636711|NCT00288171|Placebo Comparator|Placebo|
11636712|NCT00288158|Experimental|Allopurinol|
11636713|NCT00288158|Experimental|Probenecid|
11636714|NCT00288158|Active Comparator|Placebo|
11636715|NCT00288145|Active Comparator|T|Treatment arm comprises one worksite in a matched site pair; one site assigned to treatment, the other site assigned to comparison. Treatment site worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
11636716|NCT00288132|Active Comparator|Usual Care|
11636717|NCT00288132|Experimental|Intervention|
11636718|NCT00288119||Cases|Patients with Barrett's esophagus undergoing surveillance or patients with esophageal adenocarcinoma and esophagogastric junctional adenocarcinoma undergoing EGD
11636719|NCT00288119||EGD Screening|Patients scheduled for clinically indicated EGD for GERD who meet ACG criteria for BE screening
11636720|NCT00288119||Colon Screening|Patients scheduled for screening colonoscopy who have not had EGD and meet clinically indicated criteria for BE screening
11636721|NCT00288119||Controls|Patients scheduled for EGD who do not meet criteria for screening
11636722|NCT00288106||Long Term Follow-Up|Follow-up data collection study for men who developed prostate cancer after participation in SWOG-9217 (PCPT)
11636723|NCT00288093|Experimental|Treatment (triapine, radiation therapy)|Patients undergo radiotherapy once daily, 5 days a week, for approximately 5.5 weeks (a total of 28 fractions). Patients also receive 3-AP (Triapine) IV over 2 hours 3 days a week every other week for 5.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of 3-AP (Triapine) until the maximum tolerated dose (MTD) is determined.
11636724|NCT00288080|Active Comparator|Androgen suppression + Radiation Therapy|Androgen suppression (AS; LHRH agonist and oral antiandrogen) for 8 weeks followed by radiation therapy and concurrent AS. LHRH continues for 24 months after initiation of any treatment, oral antiandrogen discontinues at the end of radiation therapy (RT).
11636725|NCT00288080|Experimental|Androgen suppression + Radiation Therapy + Chemotherapy|Androgen suppression (AS; LHRH agonist and oral antiandrogen) for 8 weeks followed by radiation therapy and concurrent AS. LHRH continues for 24 months after initiation of any treatment, oral antiandrogen discontinues at the end of RT. Following completion of RT, 6 cycles of docetaxel (premedicated with dexamethasone) and prednisone are delivered concurrently with androgen suppression.
11636726|NCT00288067|Experimental|Treatment (fenretinide, rituximab)|"PHASE I: Patients receive fenretinide PO BID on days 1-5. Treatment repeats weekly for at least 4 weeks in the absence of disease progression or unacceptable toxicity.
~PHASE II: Patients receive fenretinide PO BID on days 1-5 in weeks 1-8 and rituximab IV once weekly in weeks 5-8. Treatment continues in the absence of disease progression or unacceptable toxicity."
11636727|NCT00288054|Experimental|Cetuximab + Radiotherapy (no Docetaxel)|
11636728|NCT00288054|Experimental|Cetuximab + Radiotherapy + Docetaxel|
11636729|NCT00288041|Experimental|Treatment (bortezomib, paclitaxel, carboplatin)|Patients will receive an infusion of bortezomib twice in week 1 and once in week 2. They will also receive a 3-hour infusion of paclitaxel and an infusion of carboplatin once in week 1. Treatment may repeat every 3 weeks for as long as benefit is shown.
11636825|NCT00286754|Experimental|Stage-matched intervention (SMI)|Stage-matched intervention (SMI)
11637262|NCT00281255|Placebo Comparator|placebo|
11636730|NCT00288028|Experimental|Bortezomib|Bortezomib is administered as a 5 second IV bolus on days 1, 4, 8,11 or 1,8 and 15 of a 21-35 days cycle (Depending on the Dosing schedule). The dosage will be calculated based on actual weight of the patient unless the actual weight is greater than 40% above the ideal body weight. In this instance the dosage will be based on the adjusted ideal body weight. The Adjusted IBW (kg) = IBW + 0.25 x (actual body weight - IBW). The dosage will be adjusted based on the safety and toxicity profile, until a MTD is determined.
11636731|NCT00288015|Experimental|Bevacizumab|Bevacizumab treatment until disease progression or intolerance
11636732|NCT00287989|Experimental|150 PRE|Erlotinib 150mg on days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200 mg/m2
11636733|NCT00287989|Experimental|1,500 PRE|Erlotinib 1500mg on Days 1 and 2 of a 21 day cycle and Carboplatin AUC6 and Paclitaxel 200mg/m2
11636734|NCT00287989|Experimental|1,500 POST|Carboplatin AUC6, Paclitaxel 200 mg/m2 followed by Erlotinib 1500mg days 2 and 3.
11636735|NCT00287963|Experimental|Vinorelbine + topotecan|
11636736|NCT00287937|Experimental|Treatment (vorinostat, paclitaxel, carboplatin)|Patients receive oral SAHA once or twice daily on days 1-14* and paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have stable disease after the completion of 6 courses may receive single-agent SAHA at the discretion of the treating physician.
11636737|NCT00287911|Experimental|Combo Chemotherapy and Radiation|"Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36. Some patients may also undergo brachytherapy. Patients also receive cisplatin intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36 and topotecan IV continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36. Treatment continues in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
11636738|NCT00287898|Experimental|Telephone Genetic Counseling|Participants randomized to this arm will receive all genetic counseling via telephone.
11636739|NCT00287898|Active Comparator|Usual Care|Participants randomized to usual care will receive standard in-person genetic counseling.
11636740|NCT00287885|Experimental|Metronomic Docetaxel|Docetaxel will be administered by daily injection via pre-filled syringes into the patient's accessed subcutaneous port.
11636741|NCT00287872|Experimental|Bortezomib and Thalidomide|The patients will receive Bortezomib on days 1, 4, 8 and 11 of each 21 day cycle in combination with daily oral Thalidomide.
11636742|NCT00287859|Experimental|Escalating Cohorts|"Patients receive topotecan intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 6 patients will be treated at the MTD."
11636743|NCT00287846|Experimental|Imatinib|400 to 800 mg/day for a maximal 12 months study duration.
11636744|NCT00287833|Experimental|Arm I (Bowman-Birk inhibitor concentrate)|Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
11636745|NCT00287833|Placebo Comparator|Arm II (placebo)|Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
11636746|NCT00287820|Active Comparator|1|olanzapine
11636747|NCT00287820|Active Comparator|2|risperidone
11636748|NCT00287768|Experimental|1|Docetaxel + S-1
11636749|NCT00287768|Active Comparator|2|S-1
11636750|NCT00287755|Experimental|1|
11636751|NCT00287729|Active Comparator|2403 mg/day pirfenidone|2403 mg/day pirfenidone dose group.
11636752|NCT00287729|Placebo Comparator|placebo|Placebo equivalent.
11636753|NCT00287716|Active Comparator|2403 mg/day pirfenidone|Active arm 1, 2403 mg/day pirfenidone dose group.
11636754|NCT00287716|Active Comparator|1197 mg/day pirfenidone|Active arm 2, 1197 mg/day pirfenidone.
11636755|NCT00287716|Placebo Comparator|placebo|Placebo equivalent.
11636756|NCT00287703|Experimental|1|Active Pulsating Electro Magnetic Fields (PEMF) treatment
11636757|NCT00287703|Sham Comparator|2|5 days a week for 5 weeks for 30 minutes Sham PEMF
11636758|NCT00287690|Experimental|Genistein|Supro drink once daily for 3 days
11636759|NCT00287690|Placebo Comparator|Placebo|Drink identical to Supro but containing no genistein, once daily for 3 days
11636760|NCT00287677|Experimental|A|growth hormone + vaccination + HAART
11636761|NCT00287677|Experimental|B|growth hormone + HAART
11636762|NCT00287677|Experimental|C|vaccination + HAART
11636763|NCT00287677|Active Comparator|D|control healthy HIV negative + vaccination
11636764|NCT00287651|Active Comparator|2|Patients with diagnosed Diabetic Retinopathy are enrolled as treated with pulsatile intravenous insulin or as a control patient with weekly treatment sessions. Baseline and quarterly fundus photography is performed to measure and monitor progress.
11636765|NCT00287651|No Intervention|1|Patients diagnosed with Diabetic Retinopathy are enrolled as control patients that do not receive the pulsatile intravenous insulin therapy. Control patients come into the center receive baseline fundus photography and quarterly fundus photography to measure progress and outcomes of diabetic retinopathy and are compared to the patients who receive pulsatile intravenous insulin therapy.
11636766|NCT00287638|Active Comparator|1|CPAP
11636767|NCT00287638|Placebo Comparator|2|no CPAP
11636768|NCT00287625|Active Comparator|1|PRP
11636769|NCT00287625|No Intervention|2|control
11636770|NCT00287612|Active Comparator|1|Arms:Lap. Fundo. with Mobilization of the Esophageal Junction
11636771|NCT00287612|Experimental|2|
11636826|NCT00286754|Active Comparator|Health Education Intervention (HEI)|Health Education Intervention (HEI)
11636827|NCT00286754|No Intervention|Usual Care (UC)|Usual Care (UC)
11636828|NCT00286741|Experimental|Medical group visits|Medical group visits
11636772|NCT00287586|Active Comparator|Testosterone|Participants received 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years. Dose adjustments were made by an unblinded observer. (Serum testosterone level measured on treatment day 15 was measured in a sample sent separately to the laboratory such that the results were reported directly to unblinded physician, who then communicated the decision about dose adjustment (or not) directly to the research pharmacist through e-mail.)
11636773|NCT00287586|Placebo Comparator|Placebo|Participants received placebo-matching testosterone gel daily for 3 years.
11636774|NCT00287573|Experimental|Arm 1|
11636775|NCT00287573|Active Comparator|Arm 2|
11636776|NCT00287534|Experimental|1|Anastrozole
11636777|NCT00287534|Active Comparator|2|Tamoxifen
11636778|NCT00287521|Experimental|AL-37807 Suspension|
11636779|NCT00287521|Active Comparator|Xalatan|
11636780|NCT00287521|Placebo Comparator|AL-37807 Vehicle|
11636781|NCT00287521|Experimental|Timolol Maleate|
11636782|NCT00287495|Experimental|A|Patients with AIDS-KS receiving ritonavir will be given 200 mg BAY 43-9006 once daily with dose escalation up to 400 mg twice daily
11636783|NCT00287495|Experimental|B|Patients with AIDS-KS not receiving ritonavir will be given 200 mg BAY 43-9006 once daily with dose escalation up to 400 mg twice daily
11636784|NCT00287469|Experimental|20mcg Recombinant HEV|20mcg of recombinant HEV antigen administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule
11636785|NCT00287469|Placebo Comparator|Placebo|PBS buffer placebo containing alum was administered intramuscularly in the deltoid according to a 0, 1 and 6 month schedule.
11636786|NCT00287378|Experimental|1|
11636787|NCT00287365|Experimental|1-ozone|Mildly asthmatic subjects with GSTM1 null genotype compared to GSTM1 sufficient subjects
11636788|NCT00287352|Placebo Comparator|Double-Blind Treatment|Olanzapine continuing with placebo
11636789|NCT00287352|Active Comparator|Olanzapine, Amantadine|Standard combine with Amantadine
11636790|NCT00287339|Experimental|1|40mg Esomeprazole BID
11636791|NCT00287339|Placebo Comparator|2|placebo capsules
11636792|NCT00287287|Experimental|Lenalidomide (Revlimid)|Treatment will be initated at 25 mg/day taken in the morning. Dose adjustments may be made to alleviate toxicities.
11636793|NCT00287261|Experimental|zometa|3-weekly infusion of zometa (zoledronic acid) 4 mg
11636794|NCT00287248|Experimental|Assess [123I] IMPY & SPECT Imaging|To assess [123I] IMPY & SPECT Imaging
11636795|NCT00287235|Experimental|Group 1: Standard Medical Therapy + MARS|Patients who were randomized to Group 1 received daily MARS treatments in addition to Standard Medical Therapy for 5 consecutive days.
11636796|NCT00287235|Active Comparator|Group 2: Standard Medical Therapy Only|Patients who were randomized to Group 2 received standard medical treatment only.
11636797|NCT00287222|Experimental|1 - Bevacizumab/Erlotinib|Subjects will be treated with bevacizumab and erlotinib
11636798|NCT00287196|Active Comparator|Post-operative RADIOTHERAPY|Immediate post-operative RADIOTHERAPY
11636799|NCT00287196|Experimental|Delayed Radiotherapy|OBSERVATION with delayed radiotherapy for relapse
11636800|NCT00287183|Active Comparator|PF-04494700 (TTP488)|
11636801|NCT00287183|Placebo Comparator|Placebo|
11636802|NCT00287118|Experimental|Efalizumab|
11636803|NCT00287105|Other|Good risk Ph+ALL|For protocols which adopt a steroid prephase: patients who are Prednisone-good responder and achieve CR after the induction course. For protocols which do not adopt steroid prephase: patients who have M1/M2 BM at day 15 or M1 BM at day 21 and achieve CR after the induction course. Expected stratification in this group: 70-75%.
11636804|NCT00287105|Other|Poor risk Ph+ALL|For protocols which adopt a steroid prephase: patients who are Prednisone poor-responders. For protocol which do not adopt a steroid prephase: patients who have M3 BM at day 15 or M2/M3 BM at day 21. For all protocols: patients who do not achieve CR after the induction course. Expected stratification: 25-30%.
11636805|NCT00287092|Experimental|Group 1|Participants will receive PEDIACEL vaccine
11636806|NCT00287092|Active Comparator|Group 2|Participants will receive Infanrix-IPV+Hib vaccines
11636807|NCT00287079|Experimental|Rebif®|
11636808|NCT00287079|Other|No Treatment|
11636809|NCT00287053|Experimental|Placebo|Divalproex Sodium
11636810|NCT00287053|Placebo Comparator|Placebo Comparator|Placebo Comparator
11636811|NCT00287040|No Intervention|1 - Usual Care|This arm looks at mammogram adherence in those individuals who at this time are not receiving booster mammogram interventions.
11636812|NCT00287040|Experimental|2. DVD Intervention|This arm will receive the initial information provided in usual care and will also receive booster mammography interventions via DVD.
11636813|NCT00287040|Experimental|3. Telephone Counseling|This arm will receive the initial information provided in usual care and receive boosters through tailored telephone counseling.
11636814|NCT00287001|Other|1|1= cool air cooling
11636815|NCT00286962|Experimental|CIPII|Intraperitoneal insulin infusion by means of an implanted insulin pump
11636816|NCT00286962|Active Comparator|CSII/ MDI|Optimized subcutaneous insulin infusion by means of continuous subcutaneous insulin infusion (CSII) or by multiple daily injections (MDI)
11636817|NCT00286949|Other|Atomoxetine (Strattera)|Open-Label Uncontrolled Active Drug Intervention, No comparator
11636818|NCT00286845||II|
11636819|NCT00286845||1|
11636820|NCT00286832||Single group study|
11636821|NCT00286819|Experimental|the FEC75 regimen|"Arm A: the FEC75 regimen will be given at the following doses:
~Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles."
11636822|NCT00286819|Experimental|FEC90 regimen|"Arm B: the FEC90 regimen will be given at the following doses:
~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.
~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.
~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle."
11636823|NCT00286793|Experimental|SIngle Arm Study of AT-101 in combination with Docetaxel|
11636824|NCT00286780|Experimental|1|
11636829|NCT00286741|No Intervention|Treatment as Usual control|control
11636832|NCT00286624|Experimental|1|Allogeneic islet transplantation with anti-thymocyte globulin induction and cyclosporine and RAD maintenance immunosuppression
11636833|NCT00286611||Amifostine|Those individuals enrolled who have received amifostine as part of standard care.
11636834|NCT00286598|Experimental|Feet First|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
11636835|NCT00286598|No Intervention|Control|Usual care
11636836|NCT00286585|Active Comparator|Inhalational anesthetic|Sevoflurane will be used as the main anesthetic in this arm, and no propofol will be administered
11636837|NCT00286585|Active Comparator|Intravenous anesthetic, propofol|Propofol will be used as the main anesthetic in this arm, and no inhalational anesthetic will be administered
11636838|NCT00286533|Experimental|Placed implants|
11636839|NCT00286507|Active Comparator|ILM peeling|Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with ILM peeling
11636840|NCT00286507|Active Comparator|No ILM peeling|combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas without ILM peeling
11636841|NCT00286494|Active Comparator|Placebo|
11636842|NCT00286494|Experimental|Alogliptin 12.5 mg QD|
11636843|NCT00286494|Experimental|Alogliptin 25 mg QD|
11636844|NCT00286481|Experimental|Lapaquistat Acetate 50 mg QD + Simvastatin|
11636845|NCT00286481|Experimental|Lapaquistat Acetate 100 mg QD + Simvastatin|
11636846|NCT00286481|Active Comparator|Simvastatin|
11636847|NCT00286468|Experimental|Alogliptin 12.5 mg QD|
11636848|NCT00286468|Experimental|Alogliptin 25 mg QD|
11636849|NCT00286468|Active Comparator|Placebo|
11636850|NCT00286455|Experimental|Alogliptin 12.5 mg QD|
11636851|NCT00286455|Experimental|Alogliptin 25 mg QD|
11636852|NCT00286455|Placebo Comparator|Placebo QD|
11636853|NCT00286442|Experimental|Alogliptin 12.5 mg QD|
11636854|NCT00286442|Experimental|Alogliptin 25 mg QD|
11636855|NCT00286442|Placebo Comparator|Metformin|
11636856|NCT00286429|Placebo Comparator|Insulin|
11636857|NCT00286429|Experimental|Alogliptin 12.5 mg QD|
11636858|NCT00286429|Experimental|Alogliptin 25 mg QD|
11636859|NCT00286325|Experimental|Treatment Rituximab|Open label study all subjects treated with rituximab
11636860|NCT00286299|Experimental|Aerobic interval training (AIT)|AIT is 4x4 minutes interval training on a treadmill at 85 to 95 % HRpeak interspersed with 3 min of active resting periods at a work load corresponding to 70 % HRpeak between each interval. Patients performed the intervals walking or running with a minimum of 5 % inclination.
11636861|NCT00286299|Active Comparator|Computer game training (CG)|36 minutes playing supervised computer games, Tetris, Xbox
11636862|NCT00286299|Experimental|Maximal strength training (MST)|MST is performed in a leg press machine. The weight is lowered in a controlled manner in the eccentric phase until the patient reached 90 degrees in the knee joint. Then the patients has a short stop (~0.5 second) before the weight is moved as rapidly as possible to complete extension. The training volume is 4 sets of 4RM (i.e. 85-90 % 1RM). The training load is increased with 2.5-5 kg each time patients managed to perform 4 sets with the determined load or each training session.
11636863|NCT00286273|Active Comparator|citrate|regional anticoagulation with citrate
11636864|NCT00286273|Active Comparator|nadroparin|nadroparin is a low molecular weight heparin
11636865|NCT00286234|Placebo Comparator|1|Dual placebo
11636866|NCT00286234|Experimental|2|niaspan
11636867|NCT00286234|Experimental|3|lovaza
11636868|NCT00286234|Experimental|4|combined therapy
11636869|NCT00286221|Experimental|Supratentorial PCA fentanyl|
11636870|NCT00286221|Active Comparator|Supratentorial PRN fentanyl|
11636871|NCT00286221|Experimental|Infratentorial PCA fentanyl|
11636872|NCT00286221|Active Comparator|Infratentorial PRN fentanyl|
11636873|NCT00286208|Active Comparator|Sublingual Misoprostol|400 mcg of sublingual misoprostol
11636874|NCT00286208|Active Comparator|Oral Misoprostol|Misoprostol administered orally
11636875|NCT00286195|No Intervention|I|Consecutive patients, open label
11636876|NCT00286182|Experimental|Erythropoietin alpha|Subcutaneous erythropoietin will be administered once weekly to achieve a target hemoglobin of 13 g/dL. Subjects will be dosed with the study drug for 24 weeks. The administration of study drug will be performed according to a pre-specified treatment algorithm that adjust erythropoietin dosages based on the rate of rise of the hemoglobin.
11636877|NCT00286182|Placebo Comparator|Placebo|Placebo consists of saline injections.
11636878|NCT00286156|Experimental|1|Arm 1 Rapamune dose 2-6mg aimed at maintaining trough levels 5-8 ng/ml
11636879|NCT00286156|Experimental|2|Arm 2 Rapamune dose 2-6 mg aimed at maintaining trough levels of 2-5ng/ml
11636880|NCT00286156|No Intervention|3|Standard Care
11636881|NCT00286143|Active Comparator|A|Fentanyl added to Bupivacaine via epidural catheter.
11636882|NCT00286130|Active Comparator|FOLFOX 6|"FOLFOX 6:
~Oxaliplatin 100 mg/m² d1 concurrent with
~Leucovorin 400 mg/m², followed by
~Bolus 5FU 400 mg/m² , followed by
~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
11636883|NCT00286130|Active Comparator|FOLFIRI|"FOLFIRI:
~Irinotecan 180 mg/m² day 1 concurrent with
~Leucovorin 400 mg/m² followed by
~Bolus 5FU 400 mg/m², followed by
~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
11636884|NCT00286117|Experimental|1|Anastrozole
11636885|NCT00286117|Active Comparator|2|Tamoxifen
11636886|NCT00286104|Active Comparator|1|Bactiseal ventricular catheter (Rifampicin- and Clindamycin-impregnated)
11636887|NCT00286104|Placebo Comparator|2|Plain ventricular catheter
11636888|NCT00286091|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
11636941|NCT00285207|Placebo Comparator|Placebo|Placebo administered topically to the cervix via intravaginal applicator for 5 consecutive days of a 28-day cycle for 2 cycles.
11636889|NCT00286091|Experimental|Denosumb|Participants received 120 mg denosumab administered by subcutaneous injection every 4 weeks during the double-blind treatment phase. Participants then received open-label denosumab 120 mg by subcutaneous injection every 4 weeks during the open-label extension phase.
11636890|NCT00286078|Experimental|Treatment|Active occipital nerve stimulation (stimulation on)
11636891|NCT00286078|Sham Comparator|Control|Sham occipital nerve stimulation from activation to 12 weeks post-activation. Active occipital nerve stimulation from 12 weeks post-activation on.
11636892|NCT00286026|Experimental|Arm 1|Subjects residing in villages assigned to treatment arm 1 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0); will be treated with Azithromycin at Day 30; will be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60; and again at Day 360.
11636893|NCT00286026|Experimental|Arm 2|Subjects residing in villages assigned to treatment arm 2 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0), as well as receive an initial treatment with Azithromycin; will receive a second dose of Azithromycin at Day 30; will be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60; and again at Day 360.
11636894|NCT00285974|Experimental|hip prosthesis|
11636895|NCT00285935|Experimental|Treatment with SSRI|"Depressed participants will receive 8 weeks of treatment with one of the following serotonin-specific reuptake inhibitors:
~fluoxetine (Prozac®), sertraline (Zoloft®), paroxetine (Paxil®), citalopram (Celexa®), escitalopram (Lexapro®)
~The specific drug used for treatment will be selected by the study clinician based on clinical interviews and the participants preferences. Participants will be monitored for response and side effects by study clinician and will return after 8 weeks for a follow up study visit."
11636896|NCT00285896|Active Comparator|Active|GLP-1
11636897|NCT00285896|Placebo Comparator|Placebo|Placebo
11636898|NCT00285857|Experimental|Lovastatin 80 mg/day|Lovastatin 80 mg/day as 40 mg orally twice daily, for 6 months.
11636899|NCT00285844|Experimental|pioglitazone|IR and IS subjects will be randomized to pioglitazone 45 mg daily for 16 wks for comparison with dietary weight loss intervention
11636900|NCT00285844|Experimental|Dietary Weight Loss|IR and IS subjects will be randomized to dietary weight loss for 16 wks for comparison to pioglitazone intervention
11636901|NCT00285818|Active Comparator|Mifepristone|Patients receive mifepristone one day before and for 5 additional days after starting ECT
11636902|NCT00285818|Placebo Comparator|Placebo Oral Capsule|Patients receive a placebo capsule one day before and for 5 additional days after starting ECT
11636903|NCT00285805|Other|Rosiglitazone-placebo|
11636904|NCT00285805|Other|placebo-rosiglitazone|
11636905|NCT00285779|Placebo Comparator|Placebo injection|patients receive normal saline injection twice weekly for weeks 1-12
11636906|NCT00285779|Experimental|Etanercept|patients receive etanercept injection twice weekly for weeks 1-12.
11636907|NCT00285688||1|Gastroscope positive for H. pylori and resistant to clarithromycin
11636908|NCT00285688||2|Gastroscope positive for H. pylori and not resistant to clarithromycin
11636909|NCT00285662|Active Comparator|1|1 day Sulfadoxine/Pyrimethamine + 3 days Amodiaquine
11636910|NCT00285662|Active Comparator|2|1 day of Sulfadoxine/Pyrimthamine and 3 days of Artesunate
11636911|NCT00285662|Placebo Comparator|3|children of this gorup will receive only placebo dugs
11636912|NCT00285649|Experimental|HVLA-SM|HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
11636913|NCT00285649|Experimental|LVVA-SM|LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation
11636914|NCT00285649|Active Comparator|Usual Medical Care|Usual Medical Care, Active Comparator, advice, exercises and medications
11636915|NCT00285584|Active Comparator|Bupropion|Participants in this arm received bupropion.
11636916|NCT00285584|Placebo Comparator|Placebo|Participants in this arm received placebo that looked identical to the active comparator medication.
11636917|NCT00285558|Experimental|CBT with peer-enhanced activities|Cognitive behavioral treatment (CBT) with peer-enhanced adventure therapy. The peer intervention, ''adventure therapy,'' is based on the principles of Outward Bound and was expected to affect weight status through a positive effect on self-concept.
11636918|NCT00285558|Active Comparator|CBT with supervised aerobic exercise|Cognitive behavioral treatment (CBT) with supervised aerobic exercise. Activities for the supervised exercise intervention included use of treadmills, stationary bicycles, and other aerobic activities selected by participants, including dance videos and brisk walking within the clinic setting.
11636919|NCT00285545||Good blood flow|Group with normal blood flow to small intestine
11636920|NCT00285545||Poor blood flow|Group with partial ischemia to small intestine
11636921|NCT00285532||Home test kit|
11636922|NCT00285467|Experimental|Doxercalciferol|doxercalciferol 1 mcg capsule orally daily for 3 months. This is a form of vitamin D that does not require activation by enzymes in the liver and kidney.
11636923|NCT00285467|Active Comparator|Cholecalciferol|cholecalciferol 4000 IU capsule orally daily for one month, then 2000 IU capsule daily orally for 2 months. this form of vitamin D requires activation by cells of the body.
11636924|NCT00285428|Experimental|Dose level 1|120 mg/m2
11636925|NCT00285428|Experimental|Dose level 2|200 mg/m2
11636926|NCT00285428|Experimental|Dose Level 3|375 mg/m2
11636927|NCT00285428|Experimental|Dose level 1B|80 mg/m2
11636928|NCT00285415|Other|1|
11636929|NCT00285402|Experimental|A|
11636930|NCT00285402|Experimental|B|
11636931|NCT00285402|Placebo Comparator|C|
11636932|NCT00285389|Experimental|VAD Clorambucil Rituximab|
11636933|NCT00285376|Experimental|1|vilazodone
11636934|NCT00285376|Placebo Comparator|2|
11636935|NCT00285298|Experimental|Pentoxifylline|
11636936|NCT00285298|Placebo Comparator|Placebo|
11636937|NCT00285259|Experimental|VCL-CB01|
11636938|NCT00285259|Placebo Comparator|Placebo|PBS
11636939|NCT00285246||Group 1|Army Reserve and National Guard soldiers deploying to a hazardous deployment from Fort Dix, NJ and Camp Shelby, MS
11636940|NCT00285233|Experimental|1|
11636996|NCT00284154|Experimental|Intervention|Patients received vinflunine 320 mg/m2 every 21 days as a 15- to 20-minute infusion.
11636942|NCT00285207|Experimental|A007|0.25% A007 administered topically to the cervix via intravaginal applicator for 5 consecutive days of a 28-day cycle for 2 cycles.
11636943|NCT00285168||1 - Control|Usual Bone Density Report
11636944|NCT00285168||2 - Intervention|Bone Density Report with Absolute 10-year Fracture Risk Decision Aide
11636945|NCT00285090|Experimental|Early Treatment|
11636946|NCT00285090|Experimental|LateTreatment|
11636947|NCT00285090|Experimental|Total Treatment|
11636948|NCT00285090|Placebo Comparator|No Treatment|
11636949|NCT00285012|Placebo Comparator|placebo|
11636950|NCT00285012|Experimental|varenicline|
11636951|NCT00284986|Experimental|PROCHYMAL™|PROCHYMAL™
11636952|NCT00284947|Experimental|Maintenance immunosuppression|"40mg Simulect i.v, once every 28 days for 24 weeks (treatment periods)
~1g MMF or 720mg EC-MPS p.o twice daily
~Oral corticosteroids"
11636953|NCT00284934|Active Comparator|Standard dose EC-MPS|Patients received 720 mg/day (360 mg twice a day (bid) orally) Enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus dose (twice a day orally) adjusted to maintain the trough blood level (C0) contained between 5.5 and 10 ng/mL. The randomization was stratified on 1 factor: treatment with or without steroids. Prednisone (or oral equivalent) was administrated to patients as before entering the study and as per center's standard practice, but at a dose of at least 5 mg/day.
11636954|NCT00284934|Experimental|High EC-MPS|Patients received 1440 mg/day (720 mg twice a day (bid) orally) Enteric-coated mycophenolate sodium (EC-MPS) and tacrolimus dose (twice a day orally) tapered to reach a trough blood level target contained between 2 and 4.5 ng/mL within 15 days after randomization at the most. The randomization was stratified on 1 factor: treatment with or without steroids. Prednisone (or oral equivalent) was administrated to patients as before entering the study and as per center's standard practice, but at a dose of at least 5 mg/day.
11636955|NCT00284908|Experimental|I STU-Na|Cross-over study with escalating doses
11636956|NCT00284856|Experimental|1|Arm 1: Montelukast
11636957|NCT00284856|Active Comparator|2|Arm 2: Fluticasone
11636958|NCT00284856|Placebo Comparator|3|Arm 3: Placebo
11636959|NCT00284830|Active Comparator|1|dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
11636960|NCT00284830|No Intervention|2|conventional dual-chamber pacing
11636961|NCT00284817|Experimental|1|MEDI-522
11636962|NCT00284817|Experimental|2|MEDI-522
11636963|NCT00284817|Experimental|3|MEDI-522
11636964|NCT00284817|Experimental|4|MEDI-522
11636965|NCT00284817|Experimental|5|MEDI-522
11636966|NCT00284804|Experimental|MDX-060 plus standard of care|MDX-060 in combination with gemcitabine
11636967|NCT00284804|Active Comparator|Standard of care|Gemcitabine
11636968|NCT00284752|Experimental|ABI-007|
11636969|NCT00284739|Experimental|Alteplase|Multiple Alteplase injection into the abscess collection to improve percutaneous drainage
11636970|NCT00284739|Placebo Comparator|Saline|Multiple normal saline injection into the abscess collection to improve percutaneous drainage
11636971|NCT00284661|Experimental|FAST FIX|Inetrvention is Fast Fix repair of meniscal tear
11636972|NCT00284661|Experimental|Meniscal suturing|Intervention is Standard suturing of meniscal tear
11636973|NCT00284609|Experimental|1|
11636974|NCT00284609|Active Comparator|2|
11636975|NCT00284557|Experimental|Group-based behavioral intervention|"The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter."
11636976|NCT00284557|Active Comparator|Health education materials only|Those allocated to Group 2 were provided with a standardized packet of health education materials addressing the recommended items from the expert committee guidelines (e.g., dietary recommendations using the Food Guide Pyramid and the Traffic Light Diet, a general prescription to increase physical activity to 60 minutes daily). They were also given a community resource list that provides contact and program information for community-based obesity treatment activities in their area.
11636977|NCT00284518|Experimental|botulinum toxin Type A 300 U|Botulinum toxin Type A 300 U transperineal or transrectal injection on Day 1.
11636978|NCT00284518|Experimental|botulinum toxin Type A 200 U|Botulinum toxin Type A 200 U transperineal or transrectal injection on Day 1.
11636979|NCT00284518|Experimental|botulinum toxin Type A 100 U|Botulinum toxin Type A 100 U transperineal or transrectal injection on Day 1.
11636980|NCT00284518|Placebo Comparator|Placebo (Normal Saline)|Placebo (Normal Saline) transperineal or transrectal injection on Day 1.
11636981|NCT00284492|Active Comparator|Lifestyle advice|
11636982|NCT00284492|Experimental|Lifestyle advice and acupuncture therapy|
11636983|NCT00284453||1|Forty(40)subjects that have received >2 appropriate ICD shock therapies
11636984|NCT00284453||2|Twenty(20)subjects that have received 1-2(low level)appropriate ICD therapies
11636985|NCT00284453||3|Ten(10)subjects that received inappropriate therapies from their ICD
11636986|NCT00284427|Experimental|1|Vitamin C
11636987|NCT00284310|Experimental|wrist surgery|
11636988|NCT00284297|Experimental|knee arthrodesis|
11636989|NCT00284258|Experimental|1|CPT-11 and TS-1
11636990|NCT00284258|Active Comparator|2|CPT-11, 5-FU and l-LV
11636991|NCT00284219|Active Comparator|Real high frequency rTMS|The patients will undergo a series of treatments of high frequency rTMS
11636992|NCT00284219|Sham Comparator|Sham high frequency rTMS|The patients will receive a series of sham treatments.
11636993|NCT00284193|Experimental|feiba-VIIa, hemophilia A-inhibitor therapy|COMBINED PATIENT- TAILORED THERAPY WITH CONCOMITANT ADMINISTRATION OF BOTH DRUGS , FOLLOWING EX VIVO THROMBIN GENERATION PREDICTING ASSAYS
11636994|NCT00284180|Experimental|HER2 Negative Intervention|Vinflunine 320 mg/m2 intravenously day 1 over 20 minutes, repeated every 21 days
11636995|NCT00284180|Experimental|HER2 Positive Intervention|Vinflunine 280 mg/m2 every 21 days with trastuzumab administered with a loading dose of 8 mg/kg, followed by 6 mg/kg IV on day 1 of each subsequent cycle, repeated every 21 days. If no grade 3/4 adverse events were encountered after the first cycle of vinflunine/trastuzumab, the dose of vinflunine could be escalated to 320 mg/m2.
11636997|NCT00284141|Experimental|aflibercept 4.0 mg/kg|Participants with metastatic non-small-cell lung adenocarcinoma administered 4.0 mg/kg Aflibercept every 2 weeks until a study withdrawal criterion was met.
11636998|NCT00284128|Experimental|ilepatril (2.5 mg ) once daily|AVE7688 oral administration
11636999|NCT00284128|Experimental|ilepatril (10 mg) once daily|AVE7688 oral administration
11637000|NCT00284128|Experimental|ilepatril (35 mg) once daily|AVE7688 oral administration
11637001|NCT00284128|Experimental|ilepatril (50 mg) once daily|AVE7688 oral administration
11637002|NCT00284128|Other|Losartan-potassium (100 mg) once daily|oral administration
11637003|NCT00284115|Experimental|Mechanical gait repetitive training|Body weight support treadmill training technique enabling nonambulatory patients to have the repetitive practice of a gate-like movement
11637004|NCT00284115|Active Comparator|Conventional rehabilitation program|Physiotherapeutic conventional rehabilitation program
11637005|NCT00284102|Experimental|1|ALI/ARDS patients
11637006|NCT00284089|Experimental|Group A: Ranibizumab 0.3 mg|In the single dose phase, all patients randomized in Group A received a single intravitreal injection of 0.3 mg of ranibizumab into the study eye. Those patients who successfully completed this phase entered the multiple dose phase, where they received an intravitreal injection of 0.3 mg of ranibizumab once a month for an additional 11 months. Subsequently patients enrolling in the extension phase received an intravitreal injection of 0.3 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.70 years.
11637007|NCT00284089|Experimental|Group A: Ranibizumab 0.5 mg|In the single dose phase, all patients randomized in Group A received a single intravitreal injection of 0.5 mg of ranibizumab into the study eye. Those patients who successfully completed this phase entered the multiple dose phase, where they received an intravitreal injection of 0.5 mg of ranibizumab once a month for an additional 11 months. Subsequently Group A patients enrolling in the extension phase received an intravitreal injection of 0.5 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.93 years.
11637008|NCT00284089|Experimental|Group B: Ranibizumab 0.3 mg|Group B patients received a total of 12 monthly intravitreal injections of 0.3 mg of ranibizumab into the study eye in the multiple dose phase of the study. Group B patients who enrolled in the extension phase received an intravitreal injection of 0.3 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.45 years.
11637009|NCT00284089|Experimental|Group B: Ranibizumab 0.5 mg|Group B patients received a total of 12 monthly intravitreal injections of 0.5 mg of ranibizumab into the study eye in the multiple dose phase of the study. Group B patients who enrolled in the extension phase received an intravitreal injection of 0.5 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.36 years.
11637010|NCT00284063|Active Comparator|Group 1: N; SPP; N|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
11637011|NCT00284063|Active Comparator|Group 2: N; SMT; N|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
11637012|NCT00284063|Active Comparator|Group 3: N; SMT; SP|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
11637013|NCT00284063|No Intervention|Group 4: N and SP|N = neutral MRI SP = side posture MRI SPP = side posture position SMT = side posture manipulation
11637014|NCT00284050|Experimental|Ranibizumab 0.3 mg|Participants received monthly intravitreal injections with 0.3 mg ranibizumab (6 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 0.6 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
11637015|NCT00284050|Experimental|Ranibizumab 0.5 mg|Participants received monthly intravitreal injections with 0.5 mg ranibizumab (10 mg/ml) for up to 12 months. At each monthly visit from month 1 and onwards, the evaluating physician decided whether an increase in the dose to 1.0 mg was needed according to set criteria. If the dose was increased, all subsequent administrations were of the higher dose unless treatment had been withheld for more than 45 days (for any reason), in which case injections restarted with the initial dose. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
11637016|NCT00284050|Sham Comparator|Sham injection|Participants in the control group received 12 monthly sham intravitreal injections. The evaluation was performed using the same criteria for dose doubling as in active treatment groups. The injection was a mimicked by an empty syringe without a needle. Laser photocoagulation was permitted as rescue treatment for the study eye after 3 consecutive monthly injections.
11637017|NCT00284011|Active Comparator|SAMe|Two 400 mg pills.
11637018|NCT00284011|Placebo Comparator|Placebo|Two placebo pills (identical in appearance to SAMe).
11637019|NCT00283959|Experimental|Migalastat|Migalastat 150 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week extension period.
11637020|NCT00283946|Experimental|1|
11637021|NCT00283946|Active Comparator|2|
11637022|NCT00283933|Experimental|Migalastat|Migalastat 150 milligrams (mg) was administered orally QOD during the 24-week treatment period and then during the optional 24-week extension period.
11637023|NCT00283868||Telemedicine|Patients randomized to this group were evaluated using the digital observation camera and DICOM evaluations for telemedicine
11637024|NCT00283868||Telephone|Patients randomized to this group were evaluated using telephone only and no use of the digital observation camera or DICOM
11637025|NCT00283855|No Intervention|Control Group|No intervention
11637027|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 50mg|
11637028|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 100mg|
11637029|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 200mg|
11637030|NCT00283842|Experimental|desvenlafaxine succinate sustained-release (DVS SR) 400mg|
11637031|NCT00283842|Placebo Comparator|Placebo|
11637032|NCT00283829|Other|I|Docetaxel followed by IL-2
11637033|NCT00283816|Active Comparator|1|metformin
11637034|NCT00283816|Placebo Comparator|0|placebo
11637035|NCT00283803|Experimental|IAS and Exisulind|Patients will receive intermittent dosing of hormone therapy with commercially supplied luteinizing hormone-releasing hormone (LHRH) agonist and anti-androgen to be chosen by physician per standard of care. Exisulind will be started 3 months prior to the end of the second cycle of hormone therapy. Patients will continue treatment with Exisulind beyond the completion of the second cycle of hormone therapy until they meet criteria for discontinuation.
11637036|NCT00283738|Active Comparator|1|
11637037|NCT00283738|Placebo Comparator|2|Sham control
11637038|NCT00283725||Galantamine|
11637039|NCT00283725||No Alzheimer's disease (AD) treatment|
11637040|NCT00283712|Experimental|Infliximab|"Participants are randomized to receive intravenous infusions of infliximab (5mg/kg reconstituted in 10 mL of Sterile Water for Injection, USP ) at Weeks 0, 2, 6, and 14 over a time period of no less than two hours in a masked (blinded) fashion. Refer to section titled, Detailed Description for additional treatment information."
11637041|NCT00283712|Placebo Comparator|Placebo Comparator|"Participants are randomized to receive intravenous infusions of placebo (5 mg/kg comprised of a white lyophilized powder reconstituted in 10 mL of Sterile Water for Injection, USP) at Weeks 0, 2, 6, and 14 over a time period of no less than two hours in a masked (blinded) fashion. Refer to section titled, Detailed Description for additional treatment information."
11637042|NCT00283699|Active Comparator|1|"albendazole, 15 mg/kg/day for those less than 50 kg in weight. For those more than 50 kg, 800 mg was administered. All got standard symptomatic therapy
~placebo plus standard symptomatic therapy"
11637043|NCT00283699|Placebo Comparator|2|
11637044|NCT00283686|Active Comparator|Study A, Arm 1|Lisinopril + Telmisartan (ACE-I + ARB) and standard blood pressure control of 120-130/70-80 mm Hg
11637045|NCT00283686|Active Comparator|Study A, Arm 2|Lisinopril + Telmisartan (ACE-I + ARB) and low blood pressure control of 95-110/60-75 mm Hg
11637046|NCT00283686|Placebo Comparator|Study A, Arm 3|Lisinopril + Placebo (ACE-I + Placebo) and standard blood pressure control of 120-130/70-80 mm Hg
11637047|NCT00283686|Placebo Comparator|Study A, Arm 4|Lisinopril + Placebo (ACE-I + Placebo) and low blood pressure control of 95-110/60-75 mm Hg
11637048|NCT00283660|Experimental|Active|Dietary Supplement: 10 mg zinc oxide
11637049|NCT00283660|Placebo Comparator|Placebo|Placebo (double blinded)
11637050|NCT00283621|Experimental|Growth Factors + Adriamycin/Ifosfamide|Growth Factors = Aranesp (Darbepoetin Alfa) and Pegfilgrastim (Neulasta)
11637051|NCT00283608||Anastrozole|Blood draws for baseline and six to twelve weeks.
11637052|NCT00283608||Exemestane|Blood draws for baseline and six to twelve weeks
11637053|NCT00283595|Active Comparator|1|Treatment with rHGH
11637054|NCT00283595|Placebo Comparator|2|Treatment with Placebo
11637055|NCT00283556|Experimental|Cohort #1|"Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes every (Q) 3 weeks x 15 patients.
~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
11637056|NCT00283556|Experimental|Cohort #2|"Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.
~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
11637057|NCT00283556|Experimental|Cohort #3|"Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.
~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
11637058|NCT00283517||001|
11637059|NCT00283504|Experimental|all patients received Xolair/active drug|One arm:active drug
11637060|NCT00283491|Active Comparator|A|
11637061|NCT00283491|Placebo Comparator|B|
11637062|NCT00283452|Experimental|Intervention Group|Participation in phone/mail-based intervention to maintain physical activity.
11637063|NCT00283452|No Intervention|Control|No intervention; participation in surveys only
11637064|NCT00283439|Experimental|Single Arm: AMG 531 Dose-Escalating Cohort Study|
11637065|NCT00283413|Experimental|1|Symbiot Covered Stent System
11637066|NCT00283413|Active Comparator|2|Commercially available bare metal stent
11637067|NCT00283400|Active Comparator|dosage tier 1|0.625 g/kg 25% human albumin
11637068|NCT00283400|Active Comparator|dosage tier 2|1.25 g/kg 25% human albumin
11637069|NCT00283400|Active Comparator|dosage tier 3|1.875 g/kg 25% human albumin
11637070|NCT00283400|Active Comparator|dosage tier 4|2.5 g/kg 25% human albumin
11637071|NCT00283387|Experimental|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral lactose placebo, in two doses daily, for 2 months.
11637072|NCT00283387|Placebo Comparator|Placebo|Subjects were randomly assigned to receive oral lactose placebo, in two doses daily, for 2 months. This was followed by a 2 month washout period. Subjects then received the alternative study medication, oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
11637073|NCT00283335|Active Comparator|Gemfibrozil|1200 mg slow-release gemfibrozil (Lopid-SR) once per day
11637074|NCT00283335|Placebo Comparator|Placebo|Matching placebo tablets taken once per day
11637075|NCT00283322||Medical ICU patients|Patients admitted to a medical intensive care unit
11637076|NCT00283322||Surgical ICU patients|Patients admitted to a surgical-trauma intensive care unit
11637077|NCT00283322||Neuro ICU patients|Patients admitted to a neuro-trauma intensive care unit
11637078|NCT00283309|Active Comparator|Memantine|Memantine is used to determine if patients given pretreatment to corticosteroid therapy for inflammatory illnesses will show lesser declarative memory impairment than those receiving placebo. Baseline 10mg x 3 days, then 10mg BID x 4 days.
11637079|NCT00283309|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
11637080|NCT00283309|Active Comparator|Riluzole|Riluzole is given to patients receiving corticosteroid therapy for inflammatory illnesses pretreatment to determine if they show lesser declarative memory impairment than those receiving placebo. Baseline 50mg x 3 days, then 50mg BID x 4 days.
11637081|NCT00283296|Experimental|Endeavor Wheelchair|Participants will receive an introduction to the Endeavor wheelchair, and will complete the Activities of Daily Living Course with their own personal wheelchair and with the Endeavor chair.
11637082|NCT00283283|Experimental|Male, Age 18 -49, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
11637083|NCT00283283|Experimental|Male, Age 50 -64, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
11637084|NCT00283283|Experimental|Female, Age 18 - 49, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
11637085|NCT00283283|Experimental|Female, Age 18 - 49, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
11637086|NCT00283283|Experimental|Male, Age 18 - 49, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinia per strain
11637087|NCT00283283|Experimental|Male, Age 50 -64, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
11637088|NCT00283283|Experimental|Female, Age 50 -64, Full Dose|0.5ml, 15µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
11637089|NCT00283283|Experimental|Female, Age 50 -64, Half Dose|0.25ml, 7.5µg Fluzone® (Aventis Pasteur inactivated influenza vaccine) hemagglutinin antigen per strain
11637090|NCT00283244|Active Comparator|Arm A|Patients receive gemcitabine hydrochloride 1200mg/m2 IV on days 1 and 8. Patients with progressive disease may cross over to arm B.
11637091|NCT00283244|Experimental|Arm B|Patients receive oral erlotinib hydrochloride 150mg p.o. daily on days 1-21.
11637092|NCT00283244|Experimental|Arm C|Patients receive gemcitabine hydrochloride 1000mg/m2 IV on days 1 and 8 and erlotinib hydrochloride 100mg p.o. daily
11637093|NCT00283166|Experimental|A|Tailored Coaching and Education
11637094|NCT00283166|Other|B|Active Control
11637095|NCT00283153|Experimental|FAR|Facial affect recognition training (with computer assistance)
11637096|NCT00283153|Experimental|SEI|Stories of Emotional Inference
11637097|NCT00283114|Experimental|1|
11637098|NCT00283101|Experimental|1|SGN-40
11637099|NCT00283088|Active Comparator|Group 1|Groups 1 and 2: Parallel groups, randomized to hypothermia or no hypothermia. Both groups receive tPA as a part of standard of care.
11637100|NCT00283088|Active Comparator|Group 2|Groups 1 and 2: Parallel groups, randomized to hypothermia or no hypothermia. Both groups receive tPA as a part of standard of care.
11637101|NCT00283088|No Intervention|Group 3|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
11637102|NCT00283088|Active Comparator|Group 4|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
11637103|NCT00283088|Active Comparator|Group 5|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
11637104|NCT00283088|Active Comparator|Group 6|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
11637105|NCT00283075|Experimental|Cancer macrobeads|Cancer Macrobead placement in abdominal cavity
11637106|NCT00283062|Experimental|Docetaxel / Leuprolide Acetate - Immediate Treatment (I-CHT)|Participants administered docetaxel every three weeks (q3w) for 6 cycles in combination with leuprolide acetate every 3 months for 18 months immediately following prostatectomy.
11637107|NCT00283062|Active Comparator|Leuprolide Acetate - Immediate Treatment (I-HT)|Participants administered leuprolide acetate every 3 months for 18 months immediately following prostatectomy.
11637108|NCT00283062|Experimental|Docetaxel / Leuprolide Acetate - Deferred Treatment (D-CHT)|Participants in whom treatment was deferred from randomization until first progression - i.e. PSA progression and/or radiologically or histologically documented progression. Participants were treated with docetaxel every three weeks (q3w) for 6 cycles in combination with leuprolide acetate every 3 months for 18 months.
11637109|NCT00283062|Active Comparator|Leuprolide Acetate - Deferred Treatment (D-HT)|Participants in whom treatment was deferred from randomization until first progression - i.e. PSA progression and/or radiologically or histologically documented progression. Participants were treated with with leuprolide acetate every 3 months for 18 months.
11637110|NCT00283049|Experimental|Insulins + Sulfonylurea (SU) + Thiazolidinedione (TZD)|Arm 1: Insulin glargine administered subcutaneously once daily plus a sulfonylurea and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
11637111|NCT00283049|Experimental|Insulins + Metformin (MET) + Thiazolidinedione (TZD)|Arm 2: Insulin glargine administered subcutaneously once daily plus metformin and a TZD. Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
11637112|NCT00283049|Experimental|Insulins + Metformin (MET) + Sulfonylurea (SU)|Arm 3: Insulin glargine administered subcutaneously once daily plus metformin and a sulfonylurea. Insulin glulisine will be added arms after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
11637113|NCT00283023|Experimental|A|Progenitor cells from the patinets with Craniotomy with V-P Shunt or ventriculostomy will be collected and cultured.
11637114|NCT00283010|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
11637115|NCT00283010|Active Comparator|Active Control|Educational DVDs
11637116|NCT00282984|Placebo Comparator|placebo|
11637117|NCT00282984|Experimental|varenicline|
11637118|NCT00282971|Experimental|Inhaled Insulin|Inhaled insulin plus oral therapy
11637119|NCT00282971|Other|Standard of Care|Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
11637120|NCT00282919|Experimental|Azithromycin plus chloroquine|Single Arm, Open label study
11637121|NCT00282906|Experimental|PET-CT|
11637122|NCT00282893|Experimental|pTBA|Prophylactic Transluminal Ballooning Angioplasty
11637123|NCT00282893|Active Comparator|Control|currently existing therapies for the treatment of vasospasm
11637124|NCT00282867|Active Comparator|tight control group|target glucose level 70-110 mg/dL
11637125|NCT00282867|Active Comparator|loose control group|target glucose level 70 - 200 mg/dL
11637126|NCT00282867|Active Comparator|usual care group|target level 70 - 300 mg/dL
11637127|NCT00282854||Group I: Cases|Children with rolandic epilepsy
11637128|NCT00282854||Group II: Controls|Individuals group matched to cases for ethnicity, sex and area of residence but lacking a primary brain disorder.
11637129|NCT00282841|Experimental|All stroke code patients|After written informed consent Code Stroke patients will undergo a contrast-enhanced transcranial ultrasound study to visualize the intracranial arteries. To do so, an ultrasound contrast agent (Definity) will be administered intravenously and transcranial ultrasound will be applied via the temporal bone window on both sides. Goal is to visualize and assess the intracranial arteries bilaterally. This includes the following vessel segments on both sides: middle cerebral artery (M1,M2,M3 segments), anterior cerebral artery (A1,A2 segments), posterior cerebral artery (P1,P2 segments), internal carotid artery (C1/2,C3/4 segments).
11637130|NCT00282828|Experimental|Sertraline & Clonazepam|"Phase I non-responders randomized to this group remained on sertraline at the same dose level as at entry into Phase 2 with the addition of clonazepam up to 3.0mg per day.
~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 0.5mg of clonazepam per day in order to remain in the study."
11637131|NCT00282828|Experimental|Venlafaxine|"Phase I non-responders randomized to this group switched to venlafaxine with flexible titration up to 225 mg per day.
~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 75 mg venlafaxine per day in order to remain in the study."
11637132|NCT00282828|Experimental|Sertraline & Placebo|"Phase I non-responders randomized to this group remained on sertraline at the same dose level as at entry into Phase 2 with the addition of placebo.
~Dosing was flexible, permitting clinicians to slow or suspend the titration of the medication because of side effects or response, but patients had to receive no less than 1 capsule of placebo per day in order to remain in the study."
11637133|NCT00282815|Active Comparator|1|CPAP
11637134|NCT00282815|Sham Comparator|2|sham CPAP (placebo)
11637135|NCT00282802||1|National Academy of Sciences/National Resource Council (NAS/NRC) World War II Veteran Twins Cohort
11637136|NCT00282776|Active Comparator|TAU|Participants will receive treatment as usual
11637137|NCT00282776|Experimental|DCM|Participants will receive care management for postpartum depression
11637138|NCT00282711||1|Standard Exercise treadmill test
11637139|NCT00282711||2|Exercise treadmill testing with nuclear imaging
11637140|NCT00282672|Sham Comparator|LGD Sham Procedure first then LGD Radiofrequency Ablation|"Sham procedure plus anti-secretory medication. Subjects with Low Grade Dysplasia (LGD) receive proton pump inhibitor (PPI) with dose of Esomeprazole 40 mg BID.
~At 12 month, subjects crossover to receive radiofrequency ablation."
11637141|NCT00282672|Active Comparator|LGD:Radiofrequency ablation|Ablation System plus anti-secretory medication. Subjects with Low Grade Dysplasia (LGD) undergo an upper endoscopy with sizing of the esophageal diameter followed by radiofrequency ablation plus standard anti-secretory therapy (proton pump inhibitor, PPI-dose: Esomeprazole 40 mg BID.)
11637142|NCT00282672|Sham Comparator|HGD Sham Procedure first then HGD Radiofrequency Ablation|"Sham procedure plus anti-secretory medication. Subjects with High Grade Dysplasia (HGD) with proton pump inhibitor (PPI) dose: Esomeprazole 40 mg BID.
~At 12 month, subjects crossover to receive radiofrequency ablation."
11637143|NCT00282672|Active Comparator|HGD:Radiofrequency ablation|Ablation System plus anti-secretory medication. Subjects with High Grade Dysplasia (HGD) undergo an upper endoscopy with sizing of the esophageal diameter followed by radiofrequency ablation plus standard anti-secretory therapy (proton pump inhibitor, PPI-dose: Esomeprazole 40 mg BID.)
11637144|NCT00282646|Active Comparator|1|intraarterial application of bone marrow mononuclear cells
11637145|NCT00282646|Placebo Comparator|2|intraarterial application of placebo
11637146|NCT00282581|Placebo Comparator|placebo|
11637147|NCT00282568|Experimental|Tacrolimus Modified Release|Participants were enrolled into the study on their stable twice-daily (bid) dose of tacrolimus on Day 1 and continued to receive a stable bid dose of tacrolimus through Day 7. Participants then converted to Tacrolimus Modified Release (MR), administered once daily at an equivalent dose to the patient's previous stable total daily dose of tacrolimus. Participants who completed the 4-week pharmacokinetic treatment period with tacrolimus MR could continue receiving tacrolimus MR as part of the extended treatment period of the study. Dose adjustments were allowed in order to maintain tacrolimus trough concentrations within the target range of 5 to 15 ng/mL and for clinical reasons.
11637148|NCT00282503|Active Comparator|methylprednisolone equivalent.|2mg/kg daily will be administered initially and may be tapered according to a tapering schedule provided in the protocol.
11637149|NCT00282503|Experimental|Uvadex+ECP|"Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:
~Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),
~Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days"
11637150|NCT00282464|Active Comparator|Ziprasidone 20 and 60mg|For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
11637151|NCT00282464|Placebo Comparator|Placebo|
11637152|NCT00282438|Experimental|Autologous hematopoietic stem cell transplantation|Autologous stem cells will be injected after conditioning
11637153|NCT00282438|Experimental|Allogeneic stem cell transplantation|Allogeneic stem cells will be injected after conditioning
11637154|NCT00282425|Experimental|Allogeneic Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation will be performed on eligible patients
11637560|NCT00277043|Experimental|1 Test Dose|
11637155|NCT00282412|Experimental|Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation will be performed on eligible patients diagnosed with RA
11637156|NCT00282399|Experimental|DACO-019 2mg/m^2|DACO-019 2mg/m^2 twice daily (BID)
11637157|NCT00282399|Experimental|DACO-019 5mg/m^2|DACO-019 5mg/m^2 BID
11637158|NCT00282399|Experimental|DACO-019 10mg/m^2|DACO-019 10mg/m^2 BID
11637159|NCT00282347|Experimental|Rituximab|Participants received rituximab 1000 mg intravenously (IV) on Days 1, 15, 168, and 182. They also received mycophenolate mofetil, methylprednisolone, diphenhydramine, acetaminophen, and prednisone; see the Detailed Description for details.
11637160|NCT00282347|Placebo Comparator|Placebo|Participants received placebo intravenously (IV) on Days 1, 15, 168, and 182. They also received mycophenolate mofetil, methylprednisolone, diphenhydramine, acetaminophen, and prednisone; see the Detailed Description for details.
11637161|NCT00282334|Experimental|Home blood pressure telemonitoring|
11637162|NCT00282334|No Intervention|Conventional blood pressure monitoring|
11637163|NCT00282308|Experimental|Rituximab + methotrexate (Group A)|Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.
11637164|NCT00282308|Active Comparator|Methotrexate (Group B)|Patients received methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.
11637165|NCT00282295|Experimental|Boostrix + Menactra Group|Subjects, 11 through 18 years of age, received a booster dose of Boostrix® co-administered with Menactra™ at Day 0. The Boostrix® vaccine was administered intramuscularly into the left deltoid region and Menactra™ vaccine was administered intramuscularly into the right deltoid region.
11637166|NCT00282295|Experimental|Boostrix-Menactra Group|Subjects, 11 through 18 years of age, received one dose of Boostrix® vaccine at Day 0, followed by one dose of Menactra™ vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.
11637167|NCT00282295|Experimental|Menactra-Boostrix Group|Subjects, 11 through 18 years of age, received one dose of Menactra™ vaccine at Day 0 followed by one dose of Boostrix® vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.
11637168|NCT00282256|Experimental|Tacrolimus MR|Participants continued to receive their stable twice daily dose of tacrolimus twice daily on Day 1 through Day 7 and on Day 8 were converted to tacrolimus modified release (MR) once-daily in the morning for 7 days on a 1:1 (mg:mg) basis for their total daily dose. Patients who completed the 2-week pharmacokinetic treatment period were eligible to continue receiving tacrolimus MR as part of the extension treatment period of the study. The extended treatment period began on Day 15 and consisted of a single dose of tacrolimus MR once every morning through the end of the study.
11637169|NCT00282243|Experimental|Tacrolimus MR|"After enrollment in the pharmacokinetic period, patients were maintained on their usual dose of tacrolimus twice daily on Day 1 through Day 14 and on Day 15 were converted to tacrolimus modified release (MR) once-daily in the morning for 14 days, converted back to tacrolimus twice daily for 14 days and then converted back to tacrolimus MR formulation once-daily in the morning for 14 days, all based on a 1:1 mg for mg total daily dose conversion. The extended treatment period began on day 57 and consisted of a single dose of tacrolimus extended-release formulation once every morning through the end of the study.
~Dose adjustments were allowed in order to maintain the target tacrolimus trough level within the range of 5 to 20 ng/mL and for clinical reasons."
11637170|NCT00282204|No Intervention|Control|Usual care control
11637171|NCT00282204|Experimental|Hypnosis + CD|Hypnosis plus audio cd on hypnosis
11637172|NCT00282204|Active Comparator|Audio CD on Hypnosis|Audio CD on hypnosis sessions weekly on three occasions after 34 weeks gestation
11637173|NCT00282178|Active Comparator|1|Candesartan 16-32 mg once daily
11637174|NCT00282178|Active Comparator|2|Hydrochlorothiazide 25-50 mg once daily
11637175|NCT00282178|Placebo Comparator|3|
11637176|NCT00282165|Placebo Comparator|placebo|four week double blind placebo treatment phase
11637177|NCT00282165|Active Comparator|naratriptan|four week double blind experimental treatment using daily naratriptan tablets
11637178|NCT00282152|Active Comparator|ODT|Optimal drug therapy: The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary.
11637179|NCT00282152|Experimental|DBS+ODT|"Subjects receive bilateral subthalamic nucleus (B-STN) DBS and continue to take optimal drug therapy as prescribed by their treating neurologist.
~B-STN DBS: Deep brain stimulation (DBS) of both the right and left sub-thalamic nucleus (STN) is an FDA approved treatment for mid- and advanced PD. DBS is not approved for early stage PD. In mid- and advanced stage Parkinson's disease, using DBS in this area of the brain lessens symptoms and allows patients to take less drug to control the disease. Dosage and frequency are not applicable to the DBS. Once the DBS is placed, unless deemed necessary, it will not be removed.
~Optimal drug therapy: The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary."
11637180|NCT00282126|Experimental|1|Participants will receive 90 meq of potassium citrate.
11637181|NCT00282126|Experimental|2|Participants will receive 60 meq of potassium citrate.
11637182|NCT00282126|Placebo Comparator|3|Participants will receive placebo.
11637183|NCT00282113|Active Comparator|ProBioPlus|
11637184|NCT00282113|Active Comparator|Culturelle|
11637185|NCT00282113|Placebo Comparator|Placebo|
11637186|NCT00282100|Experimental|Gefitinib (Iressa)|Open label single arm study of Gefitinib (Iressa) 250mg daily as adjuvant therapy in patients with resectable Hepatocellular Carcinoma
11637187|NCT00282087|Other|gemcitabine/docetaxel then doxorubicin|Gemcitabine 900 mg/m2 IV over 90 minutes days 1 and 8 Docetaxel 75 mg/m2 IV day 8 (pre-medication dexamethasone 4-8 mg p.o. bid for 3 days, starting 12-24 hours prior to docetaxel). Doxorubicin 60 mg/m2 IVP every 21 days for 4 cycles (recommend use of central venous catheter access).
11637188|NCT00282048|Experimental|AG-013736 (axitinib)|AG-013736 single agent in continuous dosing until disease progression or unacceptable toxicity
11637189|NCT00282035|Experimental|APBI utilizing 3D-CRT radiation|Accelerated partial breast irradiation utilizing 3D-CRT
11637190|NCT00282035|Other|Whole breast irradiation|Whole breast irradiation
11637191|NCT00282009|Active Comparator|Basic Internet|Basic Internet
11637193|NCT00282009|Experimental|Enhanced Internet plus Phone|Enhanced Internet + proactive telephone counseling
11637194|NCT00281983|Experimental|Allogeneic stem cell transplantation|"Cytoreductive therapy for inducing a state of partial remission:
~FC or FC-R or alternative salvage regimens (e.g. Alemtuzumab)
~Conditioning regimen:
~FC +/- ATG (Arm A) or FC/Busulfan +/- ATG (Arm C: refractory patients only)
~allogeneic-PBSCT (from HLA-identical donor)
~GVHD prophylaxis: CSA + MTX or MMF
~+/- DLI (Donor lymphocyte infusions)"
11637195|NCT00281957|Experimental|Arm I (sorafenib, temsirolimus)|Patients receive oral sorafenib twice daily on days 1-28 and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
11637196|NCT00281957|Experimental|Arm II (sorafenib, tipifarnib)|Patients receive oral sorafenib as in arm I and oral tipifarnib twice daily on days 1-21
11637197|NCT00281944|Experimental|Treatment (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 followed by fluorouracil IV continuously over 46 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
11637198|NCT00281918|Experimental|Fludarabine+Cyclophosphamide+Rituximab (FCR)|
11637199|NCT00281918|Active Comparator|Fludarabine+Cyclophosphamide (FC)|
11637200|NCT00281892|Experimental|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
11637201|NCT00281892|Active Comparator|fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.
~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
11637202|NCT00281879|Active Comparator|Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI)|
11637203|NCT00281879|Active Comparator|Busulfan and Cyclophosphamide (Cytoxan)|
11637204|NCT00281879|Active Comparator|BEAM Regimen|On the day of your admission, you will start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. Chemotherapy will begin on Day -6 with carmustine (BCNU), followed by etoposide (VP-16), cytosine arabinoside (ARA-C), and melphalan. This conditioning regimen is known as the BEAM regimen. The dose of this therapy is high enough to kill cancer cells but will also kill all of your normal blood forming cells. Subjects undergoing the BEAM regimen will not have total body irradiation (TBI).
11637205|NCT00281879|Active Comparator|Low-Dose Fludarabine and TBI(for second stem cell donation)|A conditioning regimen of low-dose fludarabine and TBI is used in the event that a second donation of hematopoietic stem cells is necessary. Chemotherapy with Fludarabine will begin 4 days prior to your transplant. This drug will be given through the catheter in your chest daily for 3 days. TBI (radiation) will be given to you on the day of your transplant. After your TBI, your donor's stem cells / bone marrow will be given to you through your catheter. The drugs cyclosporine and mycophenolate mofetil (MMF) will be given orally to help you accept your donor's cells.
11637206|NCT00281879|Active Comparator|Busulfan, Cyclophosphamide, and Fludarabine (Pediatric only)|On the day of your admission you will start to take a drug called Dilantin which is used to help prevent seizures while you receive your chemotherapy drugs. You will also start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. On the next day, you will then begin your conditioning therapy with a drug called busulfan. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm four times per day for four days. After the busulfan treatment, you will receive 4 doses each of two drugs, cyclophosphamide (also known as Cytoxan) and fludarabine, over 2 hours into your vein.
11637207|NCT00281879|Active Comparator|ATG For Cord Blood Transplants|If you are undergoing a pre-transplant conditioning regimen prior to undergoing a cord blood transplant, you will receive a drug called ATG to improve your chances of engraftment and decrease your risk of graft versus host disease. You may receive ATG 3 times during your transplant regimen on days -3 through days -1 in addition to your pre-transplant conditioning therapy. Methylprednisolone will also be given during each dose of ATG to help reduce any reactions during infusion.
11637208|NCT00281879|Active Comparator|DLI (Donor Leukocyte Infusion)|Donor Leukocyte Infusions: You will receive DLI from your original transplant donor. This will be given through a vein , usually in your arm. It will be similar to getting a platelet or blood transfusion. You may require more than one DLI. The decision to give you another infusion will be determined by your condition, relapse status, GVHD and how much DLI you were given before. You may need chemotherapy and/or radiation to improve your disease status prior to additional DLI's.
11637209|NCT00281879|Active Comparator|Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric only)|On the day after your admission, you will start receiving radiation therapy (TBI). Radiation will be given to you 2 times a day for 3 days. On the next day, you will then begin your chemotherapy with a drug called etoposide. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm for one day. After the etoposide treatment, on the next day you will receive cyclophosphamide (also known as Cytoxan) for 2 days. When you are given cyclophosphamide, you will also be given a medication called MESNA to help protect your bladder from damage. After you have completed the cyclophosphamide you will rest one day without any anti-cancer therapy. This allows your body time to remove and inactivate the chemotherapy. After a day of rest, you will be given your donor's cells.
11637210|NCT00281840|Experimental|bevacizumab with docetaxel and radiation therapy|
11637211|NCT00281827|Experimental|Treatment Arm|Chemotherapy treatment (carboplatin, gemcitabine and thalidomide) every 21 days for 3 courses.
11637212|NCT00281736|Experimental|Arm I|Patients receive HPPH IV over 1 hour on day 1. Approximately 24 hours later, the lesion is exposed to laser light endoscopically.
11637213|NCT00281736|Experimental|Arm II|Patients receive HPPH as in arm I, but at a higher dose, followed by laser light exposure.
11637263|NCT00281242||Research subjects|All participants undergo the same testing in this observational trial. There is no randomization, and no interventions other than blood drawing.
11637214|NCT00281697|Experimental|Standard chemotherapy + bevacizumab|Patients received one of several standard chemotherapies for metastatic breast cancer plus bevacizumab in a dose of either 10 mg/kg intravenously (IV) every 2 weeks or 15 mg/kg IV every 3 weeks depending upon the schedule of chemotherapy chosen.
11637215|NCT00281697|Placebo Comparator|Standard chemotherapy + placebo|Patients received one of several standard chemotherapies for metastatic breast cancer plus placebo to bevacizumab administered IV either every 2 weeks or every 3 weeks depending upon the schedule of chemotherapy chosen.
11637216|NCT00281684|Experimental|Placebo|Eligible participants received a single dose of SB705498 matching placebo capsules (4 placebo capsules) via oral route and were followed up to a maximum of 14 days.
11637217|NCT00281684|Experimental|SB705498 400 mg|Eligible participants received a single dose of SB705498 400 milligram (mg) capsules (2 x 200 mg capsules plus 2 placebo capsules) via oral route and were followed up to a maximum of 14 days.
11637218|NCT00281684|Experimental|SB705498 1000 mg|Eligible participants received a single dose of SB705498 1000 mg capsules (2 x 200 mg capsules plus 2 x 300 mg capsules) via oral route and were followed up to a maximum of 14 days.
11637219|NCT00281684|Experimental|Co-Codamol|Eligible participants received a single dose of Co-codamol capsules (2 x Paracetamol Ph Eur 500 mg, codeine phosphate hemihydrate Ph Eur 12.8 mg plus two placebo capsules) via oral route and were followed up to a maximum of 14 days.
11637220|NCT00281671|Placebo Comparator|Placebo|In this crossover pilot study, patients are randomly assigned to receive either nesiritide or placebo infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.
11637221|NCT00281671|Experimental|Nesiritide|In this crossover pilot study, patients are randomly assigned to receive either nesiritide or placebo infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.
11637222|NCT00281658|Experimental|Combination|Paclitaxel and Lapatinib (Blinded)
11637223|NCT00281658|Active Comparator|Paclitaxel|Paclitaxel and Placebo (Blinded)
11637224|NCT00281658|Other|Monotherapy Extension|Open-label monotherapy lapatinib
11637225|NCT00281632|Experimental|Pazopanib|800 mg GW786034 administered orally on a daily basis.
11637226|NCT00281619||Mycophenolic Acid (CellCept)|purpose of this study is to determine how fast children, who have had a recent kidney transplant, absorb, breakdown and eliminate mycophenolic acid (CellCept) following their prescribed dose
11637227|NCT00281606|Active Comparator|LPV/r (800/200 mg) 10 ml liquid|Once daily Lopinovir/ritonavir (800/200 mg) taken as a 10 ml liquid
11637228|NCT00281606|Active Comparator|LPV/r (800/200 mg) 6 gel capsules|Once daily Lopinavir/ritonavir (800/200 mg) as 6 gel capsules
11637229|NCT00281580|Placebo Comparator|Placebo|Placebo once daily for eight weeks
11637230|NCT00281580|Experimental|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
11637231|NCT00281580|Experimental|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
11637232|NCT00281580|Experimental|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
11637233|NCT00281580|Experimental|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
11637234|NCT00281580|Experimental|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
11637235|NCT00281580|Active Comparator|Amlodipine 10 mg|Amlodipine 5 mg for two weeks and forced titrated to amlodipine 10 mg for six weeks once daily
11637236|NCT00281580|Experimental|Telmisartan 20 / Amlodipine 2.5|Telmisartan 20/ Amlodipine 2.5 mg once daily for eight weeks
11637237|NCT00281580|Experimental|Telmisartan 20 / Amlodipine 5|Telmisartan 20 / Amlodipine 5 mg once daily for eight weeks
11637238|NCT00281580|Experimental|Telmisartan 20 / Amlodipine 10|Telmisartan 20 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
11637239|NCT00281580|Experimental|Telmisartan 40 / Amlodipine 2.5|Telmisartan 40 / Amlodipine 2.5 for eight weeks
11637240|NCT00281580|Experimental|Telmisartan 40 / Amlodipine 5|Telmisartan 40 / Amlodipine 5 for eight weeks
11637241|NCT00281580|Experimental|Telmisartan 40 / Amlodipine 10|Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
11637242|NCT00281580|Experimental|Telmisartan 80 / Amlodipine 2.5|Telmisartan 80 / Amlodipine 2.5 for eight weeks
11637243|NCT00281580|Experimental|Telmisartan 80 / Amlodipine 5|Telmisartan 80 / Amlodipine 5 mg for eight weeks
11637244|NCT00281580|Experimental|Telmisartan 80 / Amlodipine 10|Telmisartan 40 / Amlodipine 5 for two weeks and forced titrated to amlodipine 10 mg for six weeks
11637245|NCT00281554|Experimental|1|
11637246|NCT00281528|Experimental|260 mg/m^2 ABI-007 every 3 weeks|260 mg/m^2 every 3 weeks and 15 mg/kg bevacizumab every 3 weeks
11637247|NCT00281528|Experimental|260 mg/m^2 ABI-007 every 2 weeks|260 mg/m^2 ABI-007 every 2 weeks and 10 mg/kg bevacizumab every 2 weeks
11637248|NCT00281528|Experimental|130 mg/m^2 ABI-007 weekly|130 mg/m^2 ABI-007 weekly (without a week of 'rest') and 10 mg/kg bevacizumab every 2 weeks
11637249|NCT00281515|Experimental|Lonafarnib / Paclitaxel /Carboplatin|
11637250|NCT00281515|Other|Paclitaxel/Carboplatin|Standard Chemotherapy
11637251|NCT00281489|Experimental|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
11637252|NCT00281489|Active Comparator|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
11637253|NCT00281463|Experimental|Pushrim Activated Power Assist Wheelchair|Participants will be asked to propel both their own chair and a pushrim activated power assist wheelchair on a computer controlled wheelchair dynamometer.
11637254|NCT00281424|No Intervention|control|no pedometer
11637255|NCT00281424|Experimental|pedometer|given pedometer
11637256|NCT00281359|Experimental|With heat|heat applied to contracted tissues prior to using the active stretching orthosis.
11637257|NCT00281359|Placebo Comparator|Without heat|No heat applied to the contracted tissues prior to using the stretching orthosis
11637258|NCT00281346|Experimental|transthoracic Doppler echocardiography|
11637259|NCT00281320|Experimental|Asenapine 2-10 mg BID|Dose titration from 2 mg to 5 mg to 10 mg twice daily (BID)
11637260|NCT00281320|Experimental|Asenapine 5-10mg BID|Dose titration from 5 mg to 10 mg BID
11637261|NCT00281255|Experimental|allopurinol|
11637264|NCT00281203||healthy smokers|Must be free of serious diseases that might make it dangerous to undergo bronchoscopy.
11637265|NCT00281190||Healthy smokers|Smokers with normal pulmonary function
11637266|NCT00281190||COPD patients|COPD patients
11637267|NCT00281099|Active Comparator|VVI 40 pacing|Backup ventricular pacing (VVI) at 40 beats per minute
11637268|NCT00281099|Active Comparator|MVP pacing|Managed ventricular pacing (MVP) at 60 beats per minute
11637269|NCT00281073|Active Comparator|TEE and ICE|Serial use of TEE and ICE for comparative analysis
11637270|NCT00281073|Active Comparator|ICE or TEE|
11637271|NCT00281034||OASIS Study Group|
11637272|NCT00281021|Experimental|Erlotinib and Digoxin|Erlotinib plus Digoxin
11637273|NCT00281008|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
11637274|NCT00281008|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
11637275|NCT00281008|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
11637276|NCT00281008|Experimental|Cohort D|Loading doses followed by extended weekly maintenance doses
11637277|NCT00280995|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
11637278|NCT00280995|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
11637279|NCT00280995|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
11637280|NCT00280995|Experimental|Cohort D|Loading doses followed by extended weekly maintenance doses
11637281|NCT00280969|Experimental|atazanavir arm|Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
11637282|NCT00280969|Active Comparator|efavirenz arm|Patients are treated with efavirenz 300mg along with Epzicom.
11637283|NCT00280826|Experimental|Efalizumab|
11637284|NCT00280813|Active Comparator|Supportive Treatment in Alcohol Recovery (STAR)|
11637285|NCT00280800|Active Comparator|1|constant CPAP
11637286|NCT00280800|Experimental|2|automatic CPAP
11637287|NCT00280761||1|Single Arm Trial
11637288|NCT00280748|Other|Single Arm Study|Single Arm Study
11637289|NCT00280735|Other|Single Arm Trial|adjuvant carboplatin plus docetaxel carboplatin area under curve (AUC) = 6 IV on day 1 every 3 weeks for 4 cycles docetaxel 75 mg/m² IV on day 1 every 3 weeks for 4 cycles
11637290|NCT00280709|Active Comparator|1|Covered metal stent
11637291|NCT00280709|Active Comparator|2|Uncovered metal stent
11637292|NCT00280696|Experimental|Lev 0.5 g|Levetiracetam 0.5 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
11637293|NCT00280696|Experimental|Lev 1 g|Levetiracetam 1 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
11637294|NCT00280696|Experimental|Lev 2 g|Levetiracetam 2 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
11637295|NCT00280696|Experimental|Lev 3 g|Levetiracetam 3 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
11637296|NCT00280696|Placebo Comparator|Placebo|Placebo tablets as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
11637297|NCT00280683|Active Comparator|Arginine|Enrolled subjects will take L-arginine orally, at 0.1 g/kg/day. Subjects will take three to four 1 g capsules (based on weight) of L-arginine twice daily for three months. L-arginine capsules were obtained from Jarrow Pharmaceuticals.
11637298|NCT00280683|Placebo Comparator|Placebo|Enrolled subjects took three to four placebo capsules that matched color and size of the intervention twice daily for three months. Matching placebo capsules were obtained from Jarrow Pharmaceuticals.
11637299|NCT00280670|Experimental|Cognitive Behavioral Therapy|
11637300|NCT00280670|No Intervention|Waitlist|
11637301|NCT00280657|Experimental|Arm 1|
11637302|NCT00280657|Active Comparator|Arm 2|
11637303|NCT00280657|Placebo Comparator|Arm 3|
11637304|NCT00280631|Experimental|1|Dose Escalation Study of TLK199 Tablets From 200 mg Per day To 6000 mg Per Day
11637305|NCT00280592|Placebo Comparator|Placebo|
11637306|NCT00280592|Experimental|Cranberry|Cranberry
11637307|NCT00280579||Cases|Cases would have had their blood cyanide concentration measured
11637308|NCT00280566|Experimental|Ziprasidone|Active treatment, double-blind, randomized arm
11637309|NCT00280566|Placebo Comparator|Placebo|Placebo treatment, double-blind, randomized arm
11637310|NCT00280553|No Intervention|patient controlled analgesia (PCA) only|
11637311|NCT00280553|Other|PCA and pump with saline infusion for up to five days|
11637312|NCT00280553|Other|PCA and bupivicaine infusion for up to five days|
11637313|NCT00280501|Active Comparator|1|Quetiapine
11637314|NCT00280501|Active Comparator|2|Sulpiride
11637315|NCT00280501|Placebo Comparator|3|Placebo
11637316|NCT00280488|Active Comparator|1) MI with SO|Motivational Interviewing (MI), a brief, directive, non-confrontational intervention, with inclusion of a significant other (SO) in prolonged, intensive alcohol treatment.
11637317|NCT00280488|Active Comparator|2) MI with patient only|Motivational Interviewing (MI), a brief, directive, non-confrontational intervention, with the individual patient
11637318|NCT00280488|Active Comparator|3) Assessment only|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
11637319|NCT00280475|Active Comparator|1|Device: Whole brain radiation therapy arm
11637320|NCT00280475|Experimental|2|Device: Salvage stereotactic radiosurgery arm
11637321|NCT00280462|Active Comparator|1|Nifedipine
11637322|NCT00280462|Active Comparator|2|L-Arginin
11637323|NCT00280462|Placebo Comparator|3|Placebo
11637324|NCT00280397|Experimental|1|
11637325|NCT00280384|Active Comparator|E2014 (Botulinum toxin type B)|
11637326|NCT00280384|Placebo Comparator|E2014 (Botulinum toxin type B) Placebo|
11637327|NCT00280332||A|colonic adenoma
11637328|NCT00280332||B|colonic without adenoma
11637329|NCT00280319|Experimental|IPT arm|interpersonal psychotherapy for groups (IPT-G). this consists of psychotherapy provided to participants in a group format.
11637330|NCT00280319|Experimental|CP arm|Creative Play therapy consists of play activities provided to participants in groups.
11637331|NCT00280319|No Intervention|control|those who are wait-list controls
11637332|NCT00280293|Placebo Comparator|1|Placebo
11637333|NCT00280293|Active Comparator|2|LAmotrigine
11637334|NCT00280280|Experimental|1|This study will explore the safety and effectiveness of Botox versus baclofen in treatment subjects with upper-limb spasticity due to neurological damage or a stable neurological disorder. Subjects will be randomized to one of two treatment groups: intramuscular Botox plus oral placebo or intramuscular placebo plus oral baclofen.
11637335|NCT00280241|Experimental|FLUDARABINE, CYCLOSPHOSPHAMIDE AND RITUXIMAB|
11637336|NCT00280228|Experimental|1|Home Based Treatment
11637337|NCT00280228|Active Comparator|2|Treatment as Usual
11637338|NCT00280215|Active Comparator|1|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker. Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
11637339|NCT00280215|Placebo Comparator|2|Patients will take placebo for 24 months.
11637340|NCT00280150|Experimental|Cohort 1|Bevacizumab 10 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
11637341|NCT00280150|Experimental|Cohort 2|Bevacizumab 10 mg + Erlotinib 100 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
11637342|NCT00280150|Experimental|Cohort 3|Bevacizumab + Erlotinib 150 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
11637343|NCT00280150|Experimental|Phase II|Bevacizumab + Erlotinib 100 mg + Chemoradiotherapy (carboplatin, paclitaxel, and 3-dimensional conformal radiation therapy)
11637344|NCT00280111|Experimental|1|116E AGMK
11637345|NCT00280111|Experimental|2|I321 AGMK
11637346|NCT00280111|Placebo Comparator|3|Placebo
11637347|NCT00280098|Experimental|single group|
11637348|NCT00280059|Experimental|1|
11637349|NCT00280059|Active Comparator|2|
11637350|NCT00280033|Placebo Comparator|9|Saline administered on days 0 and 28.
11637351|NCT00280033|Experimental|8|45 mcg alone administered on days 0 and 28.
11637352|NCT00280033|Experimental|7|30 mcg plus aluminum hydroxide administered on days 0 and 28.
11637353|NCT00280033|Experimental|6|30 mcg alone administered on days 0 and 28.
11637354|NCT00280033|Experimental|5|15 mcg plus aluminum hydroxide administered on days 0 and 28.
11637355|NCT00280033|Experimental|4|15 mcg plus MF59 administered on days 0 and 28.
11637356|NCT00280033|Experimental|3|15 mcg alone administered on days 0 and 28.
11637357|NCT00280033|Experimental|2|7.5 mcg plus aluminum hydroxide administered on days 0 and 28.
11637358|NCT00280033|Experimental|1|7.5 mcg plus MF59 administered on days 0 and 28.
11637359|NCT00280020|Experimental|CBT|
11637360|NCT00280020|Experimental|TCC|
11637361|NCT00280020|Active Comparator|SS|
11637362|NCT00280007|Experimental|1|bevacizumab infusion evey 2 weeks
11637363|NCT00280007|Placebo Comparator|2|placebo infusion
11637364|NCT00279942|Active Comparator|Soy|A shake that contained 20 g of soy protein and 160 mg of soy isoflavone.
11637365|NCT00279942|Placebo Comparator|Placebo|A shake that contained 20 g of milk-based protein (casein) and no isoflavone.
11637366|NCT00279916|Active Comparator|Triamcinolone acetonide|"Triamcinolone acetonide nasal spray; Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms) for 6 weeks duration.
~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms) for 6 weeks duration."
11637367|NCT00279916|Sham Comparator|Placebo|"Placebo nasal spray; Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily for 6 weeks duration.
~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily for 6 weeks duration."
11637368|NCT00279903|Active Comparator|Cortisone|
11637369|NCT00279903|Experimental|Low Dose Btx-A|
11637370|NCT00279903|Experimental|High Dose Btx-A|
11637371|NCT00279877|Active Comparator|vertebroplasty|vertebroplasty
11637372|NCT00279877|Active Comparator|kyphoplasty|kyphoplasty
11637373|NCT00279825|Other|Sequence 1|Subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR.
11637374|NCT00279825|Other|Sequence 2|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo.
11637375|NCT00279825|Other|Sequence 3|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Third treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo.
11637557|NCT00277160|Experimental|Treatment Group 1 (Primary Prophylaxis)|Neulasta 6mg single administration per cycle of chemotherapy starting with cycle 1
11637376|NCT00279825|Other|Sequence 4|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo.
11637377|NCT00279812|Placebo Comparator|Placebo|Placebo
11637378|NCT00279812|Experimental|50ug selenium enriched yeast|50ug/d selenium enriched yeast (containing 60% selenomethionine)
11637379|NCT00279812|Experimental|100ug selenium enriched yeast|100ug/d selenium enriched yeast (containing 60% selenomethionine)
11637380|NCT00279812|Experimental|200ug selenium enriched yeast|200ug/d selenium enriched yeast (containing 60% selenomethionine)
11637381|NCT00279812|Experimental|Control onion|3 meals/wk containing un-enriched onions equivalent to 4ug/d Se
11637382|NCT00279812|Experimental|Enriched onion|3 meals/wk containing enriched onions equivalent to 50ug/d Se
11637383|NCT00279799|Experimental|Afiya group intervention + HIV prevention phone sessions|Afiya group-based intervention plus individually tailored HIV prevention phone sessions
11637384|NCT00279799|Active Comparator|Afiya group session + nutrition phone sessions|Afiya group-based intervention plus individually tailored nutrition phone sessions
11637385|NCT00279773|Experimental|TKI258 - dose escalation|Dose-Escalation
11637386|NCT00279773|Experimental|TKI258 - dose expansion|Dose-Expansion
11637387|NCT00279734|Experimental|Group 1|
11637388|NCT00279734|Active Comparator|Group 2|
11637389|NCT00279734|Active Comparator|Group 3|
11637390|NCT00279734|Active Comparator|Group 4|
11637391|NCT00279708|Active Comparator|Intervention Arm (Atorvastatin)|Atorvastatin: Subjects were assigned to the treatment intervention by way of double blind masking. Atorvastatin 80 mg/day was the initial treatment given, as tolerated for a 12 month period. During the study, a 50% dose reduction was applied for subjects meeting pre-specified criteria.
11637392|NCT00279708|Placebo Comparator|Control Arm (Placebo)|Placebo: In a double-blind fashion, subjects were assigned to receive the sham intervention which appeared the same as the intervention agent. For subjects meeting pre-specified criteria, a 50% dose reduction was applied during the 12 month treatment phase of the study: Placebo vs. Atorvastatin
11637393|NCT00279695||1|Subjects with glaucoma and age-matched normals
11637394|NCT00279695||2|normal volunteers, two age groups, one 18-25 years old, one 50 years and older.
11637395|NCT00279695||3|subjects with tumors of the iris and ciliary body
11637396|NCT00279695||4|subjects with age-related macular degeneration and age-matched normals
11637397|NCT00279630|Experimental|type of exericse|type of exercise
11637398|NCT00279617|Active Comparator|Levetricetam|open label treatment
11637399|NCT00279591|Active Comparator|Continuous Blood Pressure Monitoring|Patients received continuous blood pressure monitoring the entire time they were in med flight to the hospital.
11637400|NCT00279591|Placebo Comparator|Standard of care blood pressure monitoring|Patients received the normal standard of care for blood pressure monitoring during the course of the med flight to the hospital.
11637401|NCT00279500|Experimental|single arm study|Argus 16 Retinal Stimulation System-single arm study.
11637402|NCT00279487|Active Comparator|Arm 1|Patients will receive 1200mg gabapentin 1-2 hours prior to surgery.
11637403|NCT00279487|Placebo Comparator|Arm 2|Patients will receive placebo 1-2 hours prior to surgery.
11637404|NCT00279461|Experimental|A,|Arm A: Vitamin D 2,000 units daily all in one capsule for 6 months
11637405|NCT00279461|Placebo Comparator|B|Arm B: matching placebo one capsule daily for 6 months
11637406|NCT00279448|Experimental|A|
11637407|NCT00279448|Active Comparator|B|
11637408|NCT00279435|Placebo Comparator|placebo|
11637409|NCT00279435|Experimental|visilizumab|
11637410|NCT00279422|Placebo Comparator|placebo|
11637411|NCT00279422|Experimental|visilizumab|
11637412|NCT00279409|Active Comparator|aripiprazole|"This treatment arm (also called the combination arm) consists of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus augmentation with aripiprazole. Aripiprazole pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis. Dosing will start at 2.5 mg and will be titrated up to 5 mg by week 1, and up to 10 mg by week 2 and for the remainder of the trial."
11637413|NCT00279409|Placebo Comparator|Sugar pill|"This treatment arm (also called the simple treatment arm) will consist of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus a placebo matching aripiprazole. Placebo pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis."
11637414|NCT00279318||General Population, First Degree Relative|Newborns with high risk HLA in the general population or having a first-degree relative affected with T1DM.
11637415|NCT00279305|Experimental|Rituximab Intravenous Infusion|Participants will receive active rituximab (anti-CD20 monoclonal antibody) as an intravenous infusion, with 4 administrations at weeks 0, 1, 2, and 3 at a dose of 375mg/m2
11637416|NCT00279305|Placebo Comparator|Placebo Intravenous Infusion|Participants will receive placebo given as an intravenous infusion with 4 administrations at weeks 0, 1, 2, and 3.
11637417|NCT00279201|Active Comparator|Insulin glargine|Initiation Phase: Insulin glargine for 24 weeks Maintenance: Up to an additional 2 years of insulin glargine if glycosylated hemoglobin (HbA1c) less than or equal to 7.0 at 24 weeks.
11637418|NCT00279201|Experimental|Lispro Low Mix|Initiation Phase: Lispro Low Mix (LM) for 24 weeks Maintenance Phase: Up to an additional 2 years of Lispro LM if HbA1c less than or equal to 7.0 at 24 weeks.
11637419|NCT00279201|Experimental|Lispro Mid Mix prior Lispro Low Mix addendum|Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Mid Mix for 24 weeks in the Intensification Addendum Phase.
11637558|NCT00277160|Active Comparator|Treatment Group 2 (Secondary Prophylaxis)|Per Investigator's discretion
11637420|NCT00279201|Experimental|Lispro Low Mix prior Glargine addendum|Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Lispro Low Mix for 24 weeks in the Intensification Addendum Phase
11637421|NCT00279201|Active Comparator|Basal bolus prior Lispro Low Mix addendum|Following Lispro LM Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.
11637422|NCT00279201|Active Comparator|Basal bolus prior Glargine addendum|Following Insulin Glargine Initiation Phase, if HbA1c greater than 7.0 after 24 weeks, then instead of entering Maintenance Phase, participants could be randomized to receive Basal Bolus therapy (combination of insulin glargine and lispro) for 24 weeks in the Intensification Addendum Phase.
11637423|NCT00279175|Experimental|BMC|Intracoronary infusion of autologous bone marrow derived cells
11637424|NCT00279175|Placebo Comparator|Placebo|Intracoronary infusion of Placebo medium
11637425|NCT00279149|Experimental|surgery|surgery
11637426|NCT00279110|Experimental|A|
11637427|NCT00279110|No Intervention|B|
11637428|NCT00279019|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive treatment sequence 1; GSK233705 20 micrograms, GSK233705 100 micrograms, tiotropium and placebo.
11637429|NCT00279019|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive treatment sequence 2; GSK233705 20 micrograms, Placebo, GSK233705 50 micrograms and tiotropium.
11637430|NCT00279019|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive treatment sequence 3; GSK233705 20 micrograms, tiotropium, Placebo and GSK233705 50 micrograms.
11637431|NCT00279019|Experimental|Subjects receiving treatment sequence 4|Eligible subjects will receive treatment sequence 4; GSK233705 20 micrograms, placebo, tiotropium and GSK233705 50 micrograms.
11637432|NCT00279019|Experimental|Subjects receiving treatment sequence 5|Eligible subjects will receive treatment sequence 5; Placebo, tiotropium, GSK233705 20 micrograms and GSK233705 50 micrograms.
11637433|NCT00279019|Experimental|Subjects receiving treatment sequence 6|Eligible subjects will receive treatment sequence 6; Placebo, GSK233705 20 micrograms, GSK233705 50 micrograms and tiotropium.
11637434|NCT00279019|Experimental|Subjects receiving treatment sequence 7|Eligible subjects will receive treatment sequence 7; tiotropium, GSK233705 20 micrograms, GSK233705 50 micrograms and Placebo.
11637435|NCT00279019|Experimental|Subjects receiving treatment sequence 8|Eligible subjects will receive treatment sequence 8; tiotropium, GSK233705 20 micrograms, Placebo and GSK233705 50 micrograms.
11637436|NCT00279019|Experimental|Subjects receiving treatment sequence 9|Eligible subjects will receive treatment sequence 9; GSK233705 20 micrograms, tiotropium, GSK233705 50 micrograms and Placebo.
11637437|NCT00279019|Experimental|Subjects receiving treatment sequence 10|Eligible subjects will receive treatment sequence 10; GSK233705 20 micrograms, GSK233705 100 micrograms, Placebo and tiotropium.
11637438|NCT00279019|Experimental|Subjects receiving treatment sequence 11|Eligible subjects will receive treatment sequence 11; Placebo, GSK233705 20 micrograms, tiotropium, and GSK233705 50 micrograms.
11637439|NCT00279019|Experimental|Subjects receiving treatment sequence 12|Eligible subjects will receive treatment sequence 12; Tiotropium, Placebo, GSK233705 20 micrograms and GSK233705 50 micrograms.
11637440|NCT00279019|Experimental|Subjects receiving treatment sequence 13|Eligible subjects will receive treatment sequence 13; Placebo, GSK233705 20 micrograms, GSK233705 50 micrograms and GSK233705 100 micrograms.
11637441|NCT00279019|Experimental|Subjects receiving treatment sequence 14|Eligible subjects will receive treatment sequence 14; GSK233705 20 micrograms, placebo, GSK233705 50 micrograms and GSK233705 100 micrograms.
11637442|NCT00279019|Experimental|Subjects receiving treatment sequence 15|Eligible subjects will receive treatment sequence 15; GSK233705 20 micrograms, GSK233705 100 micrograms, Placebo and GSK233705 50 micrograms.
11637443|NCT00279019|Experimental|Subjects receiving treatment sequence 16|Eligible subjects will receive treatment sequence 16; GSK233705 20 micrograms, GSK233705 100 micrograms, GSK233705 50 micrograms and Placebo.
11637444|NCT00278993|Active Comparator|1|With stratification
11637445|NCT00278954|Other|Gammaplex|Gammaplex
11637446|NCT00278915|Experimental|1|
11637447|NCT00278902|Experimental|ARRY-334543|
11637448|NCT00278889|Active Comparator|1|Bevacizumab + FOLFOX
11637449|NCT00278889|Experimental|2|AZD2171 + FOLFOX
11637450|NCT00278876|Experimental|imatinib mesylate|patients receiving adjuvant imatinib mesylate
11637451|NCT00278863|Active Comparator|S-1|
11637452|NCT00278863|Active Comparator|Capecitabine|
11637453|NCT00278837|Experimental|Mindfulness based meditation program|Meditation and Breast Cancer: Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress reduction and cognitive-affective-behavioral learning.
11637454|NCT00278824|Experimental|50 mcg/hr matrix fentanyl patch|active 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch (20 cm2)
11637455|NCT00278824|Placebo Comparator|Placebo Patch|placebo (20 cm2) will be indistinguishable in size, shape, and appearance to the active matrix fentanyl patch
11637456|NCT00278785|No Intervention|1|Control group to receive informational pamphlet on alcohol use and list of self referral agencies
11637457|NCT00278785|Experimental|2|Intervention group receives pamphlet on alcohol and self referral information in addition to brief motivational interview
11637458|NCT00278772|Experimental|1|Divalproex
11637459|NCT00278772|Placebo Comparator|2|
11637460|NCT00278746|Experimental|1|Zinc and ORS were promoted for treatment of diarrhea in underfive children
11637461|NCT00278746|Other|2|Promoted routine management of diarrhea in underfive with ORS
11637462|NCT00278694|Experimental|Chemoradiation|Neoadjuvant chemotherapy and chemoradiation
11637463|NCT00278681|Experimental|I|Zinc and ORS
11637464|NCT00278655|Experimental|Hematopoietic stem cell transplantation|All participants will undergo hematopoietic stem cell transplantation after receiving conditioning regimen.
11637465|NCT00278642|Experimental|stem cell transplantation|
11637561|NCT00277043|Active Comparator|2) Non test dose arm|
11637466|NCT00278629|Experimental|Hematopoietic Stem Cell Transplantation in CIDP|Autologous hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide 200 mg/kg/intravenously(IV), rATG(thymoglobulin) 5.5 mg/kg/IV and rituximab 1000mg/IV.
11637467|NCT00278590|Experimental|allogeneic stem cell transplantation|allogeneic stem cell transplantation will be performed
11637468|NCT00278577|Experimental|Autologous Hematopoietic Stem Cell Transplant|
11637469|NCT00278564|Experimental|Hematopoietic stem cell transplantation|Intervention as hematopoietic stem cells transplantation after conditioning regimen: Autologous hematopoietic stem cells will be injected after conditioning regimen
11637470|NCT00278551|Experimental|heatopoietic stem cell transplant|
11637471|NCT00278538|Experimental|Hematopoietic Stem Cell Transplant Regimen 2|Autologous Hematopoietic Stem Cell Transplantation: Rituximab, rATG and Cyclophosphamide regimen
11637472|NCT00278525|Experimental|stem cell trasplantation|intervention as stem cell transplantation after conditioning regimen
11637473|NCT00278525|Active Comparator|standard of care|medication as standard of care will be given
11637474|NCT00278512|Experimental|Autologous Stem Cell Transplant|Autologous Stem Cell Transplant will be performed on eligible patients
11637475|NCT00278512|Experimental|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant will be performed on eligible patients
11637476|NCT00278499||1|Female sex workers
11637477|NCT00278499||2|Female sex workers' clients (miners)
11637478|NCT00278486|Experimental|stem cell transplantation|
11637479|NCT00278473|Experimental|Meta-Cognitive Therapy|Cognitive behavioral group. Cognitive behavioral therapy focuses on changing patterns of thinking and behavior. Each group consists of 6 to 8 members and sessions are led by a psychologist.
11637480|NCT00278473|Active Comparator|Supportive Therapy|Social support problem-solving group. Social support problem-solving focuses on general support, problem solving, and information sharing. Each group consists of 6 to 8 members and sessions are led by a psychologist.
11637481|NCT00278447|Active Comparator|1) CDM|Chronic Disease Management
11637482|NCT00278447|Active Comparator|2) Standard care|Standard care
11637483|NCT00278434|Experimental|Zoledronate|"100 cc of saline with 4 mg of zoledronate intravenous (IV), over 20 minutes, for 3 doses one week apart
~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.
~After completion of study treatment, patients are followed at week 10 by telephone."
11637484|NCT00278434|Placebo Comparator|Saline|"100 cc of saline IV, over 20 minutes, for 3 doses one week apart
~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.
~After completion of study treatment, patients are followed at week 10 by telephone."
11637485|NCT00278421|Active Comparator|Interventional: 6 R-CHOP-21|Arm I: Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin hydrochloride IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 3 more courses of R-CHOP.
11637486|NCT00278421|Active Comparator|Interventional: 4 R-CHOP-21 + 2 x R|Arm II: Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 1 more course of R-CHOP followed by 2 courses of rituximab alone.
11637487|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-21|Arm I (R-CHOP-21): Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11637488|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-21 + radiotherapy|Arm II (R-CHOP-21 and radiotherapy): Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve a complete remission (CR) undergo radiotherapy 5 days a week for approximately 5½ weeks.
11637489|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-14|Arm III (R-CHOP-14): Patients receive R-CHOP as in arm I. Patients also receive filgrastim (G-CSF) subcutaneously once daily on days 4-13 or until blood counts recover. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11637490|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-14 and radiotherapy|Arm IV (R-CHOP-14 and radiotherapy): Patients receive R-CHOP as in arm I. Patients also receive G-CSF an in arm III. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve CR undergo radiotherapy as in arm II.
11637491|NCT00278395|Experimental|Arm I|Patients receive oral vorinostat (SAHA) twice daily on days 1-3, 8-10, 15-17, and 22-24. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Patients may have the option of continuing treatment beyond 52 weeks at the discretion of the investigator.
11637492|NCT00278382|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily in the absence of disease progression or unacceptable toxicity.
11637493|NCT00278369|Experimental|A|6 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course
11637494|NCT00278369|Experimental|B|9 mcg/kg Denileukin Diftitox administered IV/daily on days -4 to -2 of standard interleukin 2 dose course
11637495|NCT00278369|Experimental|C|9 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course
11637496|NCT00278343|Experimental|Treatment (cediranib maleate)|Patients receive cediranib maleate PO QD every 4 weeks in the absence of disease progression or unacceptable toxicity.
11637497|NCT00278330|Experimental|Arm I|Patients will receive a 1-hour infusion of flavopiridol on 5 days in week 1 and vorinostat by mouth three times a day in weeks 1 and 2. Treatment may repeat every 3 weeks for as long as benefit is shown.
11637559|NCT00277095|Experimental|ProACT (Adjustable Continence Therapy)|Implantation with ProACT (Adjustable Continence Therapy), Single Arm
11637498|NCT00278278|Experimental|Arm I|"Patients receive high-dose methotrexate IV over 24 hours on days 1 and 15 and leucovorin calcium IV every 6 hours on days 2-3 an 16-17. Four weeks later, patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.
~Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Beginning seven days prior to completion of radiotherapy, patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5."
11637499|NCT00278278|Active Comparator|Arm II|"Patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.
~Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Beginning seven days prior to completion of radiotherapy, patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5."
11637500|NCT00278265|Experimental|MTX followed by fludarabine|MTX is given with a dose of 10-20mg weekly Fludarabine is dosed with 25mg/m2 day 1-3 of 28 days, up to 4 cycles
11637501|NCT00278200|Experimental|EBV Seronegative|Inactivated EBV-infected vaccine given at Week 0 and Week 4. This arm included all participants who were negative for Epstein-Barr Virus (EBV) at baseline.
11637502|NCT00278200|Experimental|EBV Seropositive|Inactivated EBV-infected vaccine given at Week 0 and Week 4. This arm included all participants who were positive for Epstein-Barr Virus (EBV) at baseline.
11637503|NCT00278161|Experimental|R-HiCy|Rituximab (R) and high-dose cyclophosphamide (HiCy) with pegfilgrastim support.
11637504|NCT00278148|Experimental|Dose Level A|"Erlotinib, Paclitaxel, and Carboplatin with Radiation
~Dose Level A: 50 mg OSI-774/50 mg/m2 Paclitaxel/2 AUC Carboplatin"
11637505|NCT00278148|Experimental|Dose Level B|"Erlotinib, Paclitaxel, and Carboplatin with Radiation
~Dose Level B: 100 mg OSI-774/50 mg/m2 Paclitaxel/2 AUC Carboplatin"
11637506|NCT00278148|Experimental|Dose Level C|"Erlotinib, Paclitaxel, and Carboplatin with Radiation
~Dose Level C: 150 mg OSI-774/50 mg/m2 Paclitaxel/2 AUC Carboplatin"
11637507|NCT00278135|Active Comparator|1|
11637508|NCT00278135|Placebo Comparator|2|
11637509|NCT00278109|Experimental|PBI with Concurrent Chemotherapy|Phase I Single Arm study of PBI with concurrent chemotherapy. Primary endpoint is radiation toxicity. The intervention is partial breast radiation with doxorubicin and cyclophosphamide.
11637510|NCT00278070|Active Comparator|1|
11637511|NCT00278070|Active Comparator|2|
11637512|NCT00278070|Active Comparator|3|
11637513|NCT00277888|Experimental|Femoral route|
11637514|NCT00277888|Experimental|Jugular route|
11637515|NCT00277862|Active Comparator|1|"Pegylated IFN- alpha 2b
~Ribavirin for 24 weeks (patients with RVR)"
11637516|NCT00277862|Active Comparator|2|"Pegylated IFN- alpha 2b
~Ribavirin for 36 weeks (patients with complete EVR)"
11637517|NCT00277862|Active Comparator|3|"Pegylated IFN- alpha 2b
~Ribavirin for 48 weeks (patients with partial EVR)"
11637518|NCT00277862|Active Comparator|4|"Pegylated IFN- alpha 2b
~Ribavirin for 48 weeks (control)"
11637519|NCT00277810|Experimental|A|
11637520|NCT00277810|Experimental|B|
11637521|NCT00277810|Experimental|C|
11637522|NCT00277797|Active Comparator|Biowave first|First Treatment: Biowave; Second Treatment: TENS
11637523|NCT00277797|Active Comparator|TENS first|First Treatment: TENS; Second Treatment: Biowave
11637524|NCT00277784||1|Individuals with age related macular degeneration
11637525|NCT00277758|Experimental|1|Interventions: 12 weeks of interleukin-2 administration, followed by 48 weeks of interleukin-2 + Ribavirin + interferon-alpha therapy, followed by 24 weeks off therapy
11637526|NCT00277758|Active Comparator|2|48 weeks of therapy with Ribavirin + interferon-alpha, followed by 24 weeks off therapy
11637527|NCT00277706|Experimental|FORTEO|
11637528|NCT00277706|Placebo Comparator|Placebo|
11637529|NCT00277654|Active Comparator|Risperidone|
11637530|NCT00277654|Placebo Comparator|Sugar pill|
11637531|NCT00277641|Experimental|1|lamotrigine
11637532|NCT00277641|Placebo Comparator|2|
11637533|NCT00277589|Experimental|1|
11637534|NCT00277589|Active Comparator|2|
11637535|NCT00277589|Active Comparator|3|
11637536|NCT00277589|Placebo Comparator|4|
11637537|NCT00277537|Experimental|1|
11637538|NCT00277537|Other|2|
11637539|NCT00277524||Overall|All patients enrolled in OMNI. Patient sub-groups include device type, history of atrial fibrillation (AF), history of investigate atrioventricular (AV) block, implant indication, and managed ventricular pacing (MVP) enabled.
11637540|NCT00277472|Experimental|valsartan HCTZ|
11637541|NCT00277472|Active Comparator|HCTZ|
11637542|NCT00277433||Atopic Dermatitis|
11637543|NCT00277433||Non-atopic control|
11637544|NCT00277394|Experimental|innohep®|innohep® 175 anti-Xa IU/kg once daily
11637545|NCT00277394|Active Comparator|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
11637546|NCT00277368||001|
11637547|NCT00277355|Experimental|Minocycline|Minocycline (3:1 randomization) 100 mg capsules taken by mouth twice daily, 200 mg per day total for 18 months treatment duration.
11637548|NCT00277355|Placebo Comparator|Matching placebo|Sugar pill manufactured to mimic minocycline, 1 capsule taken by mouth twice daily for 18 months treatment duration.
11637549|NCT00277238|Experimental|CPG10101 (0.2) + pegylated inteferon + ribavirin|
11637550|NCT00277238|Experimental|CPG10101 (0.5) + pegylated inteferon + ribavirin|
11637551|NCT00277238|Active Comparator|Pegylated interferon + ribavirin|
11637552|NCT00277238|Experimental|CPG10101 + pegylated interferon + ribavirin (rollover)|
11637553|NCT00277212|Experimental|A1|Phase 1: Single-Blind Treatment, Lamotrigine + Aripiprazole ; Phase 2 Double-Blind Treatment: Lamotrigine + Aripiprazole
11637554|NCT00277212|Placebo Comparator|A2|Phase 2 Double-Blind Treatment: Lamotrigine + Placebo
11637555|NCT00277186|Active Comparator|Intervention|Patients entering new care continuum
11637556|NCT00277186|Active Comparator|Control|Patient enter existing conventional approach
11637562|NCT00276991|Other|"Kallunk oxide (Immunotherapy)"|"The participants were received a daily regimen of Kallunk oxide(Immunotherapy) ."
11637563|NCT00276978|Experimental|Aripiprazole|Aripiprazol augmentation therapy
11637564|NCT00276965|Experimental|A|Participants will take lithium only.
11637565|NCT00276965|Experimental|B|Participants will take lithium and sertraline.
11637566|NCT00276965|Experimental|C|Participants will take sertraline only.
11637567|NCT00276939|Experimental|1|Low-fat, low-Glycemic Index, vegan diet
11637568|NCT00276939|Active Comparator|2|ADA diet
11637569|NCT00276874|Experimental|Aripiprazole|Subjects receive oral aripiprazole.
11637570|NCT00276874|Placebo Comparator|Placebo|Subjects receive oral placebo
11637571|NCT00276848|Active Comparator|Fludarabine plus Cyclophosphamide|
11637572|NCT00276848|Active Comparator|Fludarabine|
11637573|NCT00276835|Experimental|Genistein and Interleukin-2|
11637574|NCT00276783|Experimental|Treatment Arm|Pemetrexed 900 mg/m2 every 21 days until disease progression.
11637575|NCT00276744|Experimental|Arm 1|"PART A: Participants will have their tumors collected at the time of conventional surgery. Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Patients will then proceed to receive adjuvant treatment based on physician discretion and will be followed until disease progression.
~Capecitabine 1,5 mmol/kg Oral gavage 1- 5 days x 2 weeks Cetuximab 500 mg IP Twice a week x 2 weeks Docetaxel 20 mg/kg IV Once at week x 4 weeks Erlotinib 75 mg/kg IP 1-5 days x 2 weeks Gemcitabine 100 mg/kg IP Twice a week x 4 weeks Irinotecan 50 mg/kg IV Twice a week Mitomycin C 5 mg/kg IP One dose Rapamycin 4 mg/kg IP 1-5 days x 2 weeks
~PART B: At the time of progression, patients will be evaluated for Part B of the study and treated with the drug selected in Part A as the most active using approved doses and schedules of administration."
11637576|NCT00276640|Active Comparator|vincristine, carboplatin|standard chemotherapy group
11637577|NCT00276640|Active Comparator|vincristine, carboplatin, etoposide|intensified induction chemotherapy group
11637578|NCT00276640|Active Comparator|radiation|radiation therapy group
11637579|NCT00276640|No Intervention|Control|Control group: wait and see strategy
11637580|NCT00276627|Active Comparator|communication lecture|
11637581|NCT00276627|Experimental|lecture plus CD-ROM|
11637582|NCT00276614|Experimental|Velcade|Velcade IV twice a week for two weeks on Days 1, 4, 8 and 11 of each cycle. A 10 day-rest period (Days 12-21) with no Velcade will follow the 2 weeks of treatment in each cycle. one cycle = 21 days
11637583|NCT00276575|Experimental|Bevacizumab, Everolimus, and Erlotinib|"Dose Level Dose Bevacizumab (mg/kg q2wks) Everolimus (mg daily) Erlotinib (mg daily) -1 5 5 ---
~10 5 ---
~10 10 ---
~10* 10* 75
~10* 10* 150"
11637584|NCT00276549|Experimental|Gemcitabine and Docetaxel i|
11637585|NCT00276536|Experimental|Treatment|IFN weekly
11637586|NCT00276523|Active Comparator|Control|Control (no treatment), conventional surgery.
11637587|NCT00276523|Experimental|PEG-Intron 0.5 mg/kg|PEG-interferon alfa-2b 0.5 mg/kg subcutaneously (SQ) once a week for 3 weeks, plus surgery.
11637588|NCT00276523|Experimental|PEG-Intron 2.5 mg/kg|PEG-interferon alfa-2b 2.5 mg/kg SQ once a week for 3 weeks, plus surgery.
11637589|NCT00276523|Experimental|PEG-Intron 5.0 mg/kg|PEG-interferon Alfa-2b 5 mg/kg SQ once a week for 3 weeks, plus surgery.
11637590|NCT00276510|Experimental|1|
11637591|NCT00276510|Placebo Comparator|2|
11637592|NCT00276484|Active Comparator|1|Atorvastatin 80 mg
11637593|NCT00276484|Experimental|2|Atorvastatin 40 mg + ezetimibe 10 mg
11637594|NCT00276458|Active Comparator|1|Atorvastatin 40mg tablet + Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day).
11637595|NCT00276458|Experimental|2|Atorvastatin 40mg Pbo tablet + Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day).
11637596|NCT00276419|Experimental|Placebo First, then Diclofenac (Arm A)|Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks, then compounded topical Diclofenac cream applied to the skin three times daily for 10 weeks.
11637597|NCT00276419|Experimental|Diclofenac First, then Placebo (Arm B)|Compounded topical Diclofenac cream applied to the skin three times daily for 10 weeks, then placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks.
11637598|NCT00276406|Experimental|Pyridostigmine|Oral pyridostigmine, starting with 60 mg capsules three times per day (TID), increasing by 60 mg every third day (i.e., over 10 days) up to the maximum tolerated dose or 120 mg TID (a total of 360 mg per day). This dose was maintained for 7 days.
11637599|NCT00276406|Placebo Comparator|Placebo|Placebo (sham) capsules, matching the appearance of the active drug comparator and taken TID.
11637600|NCT00276380|Experimental|EGb761®|"EGb761® 240 milligrams (mg)/day for 6 months administered orally, in association with acetylsalicylic acid (325 mg/day).
~The test treatment consists of 6 tablets/day. 2 tablets (each containing 40 mg EGb761®) taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch."
11637601|NCT00276380|Placebo Comparator|Placebo|"6 months, administered orally, in association with acetylsalicylic acid (325 mg/day).
~The placebo consists of 6 tablets/day. 2 tablets taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch."
11637602|NCT00276302|Experimental|1|Schedule A: Doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration.
11637603|NCT00276302|Experimental|2|Schedule B: Doses occur on Days 1, 4, 8, 11, 15, and 18 (twice weekly for 3 weeks continuously).
11637604|NCT00276263|Experimental|1|
11637605|NCT00276250|Experimental|Efalizumab Followed by Abatacept Regimen|Participants with Type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years received efalizumab-based immunosuppression regimen after islet-cell transplantation. During the course of the study, efalizumab was withdrawn from the US market due to safety concerns. The protocol was subsequently amended to alter the immunosuppressive regimen to abatacept for these participants.
11637606|NCT00276250|Experimental|Abatacept Regimen|Participants with Type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years received abatacept immunosuppresion regimen after islet-cell transplantation.
11637733|NCT00273780|Active Comparator|Counseling and alarm|Participants in this arm will receive both education counseling and a pocket alarm device.
11637607|NCT00276250|Experimental|Belatacept Regimen|Participants with Type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years received Belatacept immunosuppresion regimen after islet-cell transplantation.
11637608|NCT00276198|Experimental|1|Supplementation with daily sprinkle package
11637609|NCT00276198|Active Comparator|2|Supplementation with Iron tonic 15mg, vitamins A 300 micrograms, vitamin D 10 micrograms. According to Ministry of Health routine recommendations.
11637610|NCT00276198|No Intervention|3|No intervention except for checking outcomes at approprite times.
11637611|NCT00276172|Experimental|Natalizumab|Open-label natalizumab
11637612|NCT00276159|Experimental|852A Treatment|Patients receiving at least one dose of 852A.
11637613|NCT00276094|Experimental|Ospemifene 30 mg/day and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of ospemifene 30 mg each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
11637614|NCT00276094|Experimental|Ospemifene 60 mg/day and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of ospemifene 60 mg each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
11637615|NCT00276094|Placebo Comparator|Placebo tablets and nonhormonal vaginal lubricant|Subjects will receive a single dose (1 tablet) of placebo each morning with food for 12 weeks. The vaginal lubricant (K-Y® Brand Jelly) should be applied as needed and its use should be recorded in the medication diary. The first dose of the study drug will be administered at the clinic at Visit 2.
11637616|NCT00276055|Experimental|Cohort 1|1000mg/m2 gemcitabine
11637617|NCT00276055|Experimental|Cohort 2|1250 mg/m2 gemcitabine
11637618|NCT00276055|Experimental|Cohort 3|1500 mg/m2 gemcitabine
11637619|NCT00276016|Experimental|Phenylephrine, Pseudoephedrine, Placebo|"Phenylephrine: Immediate-release 12 mg capsules for oral administration.
~Pseudoephedrine: 60 mg immediate-release tablets for oral administration.
~Placebo: Placebo capsules."
11637620|NCT00276016|Experimental|Pseudoephedrine, Placebo, Phenylephrine|"Pseudoephedrine: 60 mg immediate-release tablets for oral administration.
~Placebo: Placebo capsules.
~Phenylephrine: Immediate-release 12 mg capsules for oral administration."
11637621|NCT00276016|Experimental|Placebo, Phenylephrine, Pseudoephedrine|"Placebo: Placebo capsules.
~Phenylephrine: Immediate-release 12 mg capsules for oral administration.
~Pseudoephedrine: 60 mg immediate-release tablets for oral administration."
11637622|NCT00276016|Experimental|Phenylephrine, Placebo, Pseudoephedrine|"Phenylephrine: Immediate-release 12 mg capsules for oral administration.
~Placebo: Placebo capsules.
~Pseudoephedrine: 60 mg immediate-release tablets for oral administration."
11637623|NCT00276016|Experimental|Pseudoephedrine, Phenylephrine, Placebo|"Pseudoephedrine: 60 mg immediate-release tablets for oral administration.
~Phenylephrine: Immediate-release 12 mg capsules for oral administration.
~Placebo: Placebo capsules."
11637624|NCT00276016|Experimental|Placebo, Pseudoephedrine, Phenylephrine|"Placebo: Placebo capsules.
~Pseudoephedrine: 60 mg immediate-release tablets for oral administration.
~Phenylephrine: Immediate-release 12 mg capsules for oral administration."
11637625|NCT00275990|Experimental|thrombectomy before stenting|thrombectomy before stenting
11637626|NCT00275990|Active Comparator|directing stenting alone|directing stenting alone
11637627|NCT00275951|Experimental|Cetuximab Plus P-HDFL|Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
11637628|NCT00275834|Experimental|A|Zonisamide 400 mg
11637629|NCT00275834|Experimental|B|Zonisamide 200 mg
11637630|NCT00275834|Placebo Comparator|C|matching placebo
11637631|NCT00275821|Experimental|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|
11637632|NCT00275821|Experimental|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|
11637633|NCT00275821|Active Comparator|Ranibizumab 0.3 mg monthly|
11637634|NCT00275756|Experimental|1|
11637635|NCT00275756|Experimental|2|
11637636|NCT00275756|Experimental|3|
11637637|NCT00275613|Experimental|Rituximab, IV infusion|The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
11637638|NCT00275574|Experimental|acupuncture|four acupuncture treatments over a period of two weeks
11637639|NCT00275561|Experimental|Fluticasone|Aerosolized swallowed fluticasone 880 mcg bid for 6 weeks
11637640|NCT00275561|Placebo Comparator|Placebo|Placebo inhaler swallowed bid for 6 weeks
11637641|NCT00275548|Other|The Preventative (Prophylaxis) Group:|This group of patients will receive study drugs for the treatment of recurring (or returning) hepatitis C before they actually develop clinical symptoms of hepatitis C.
11637642|NCT00275548|Other|The Observational Group:|This group of patients will receive the study drugs for the treatment of recurring hepatitis C only if they develop the clinical symptoms of hepatitis C infection.
11637643|NCT00275535|Active Comparator|Tacrolimus|Calcineurin inhibitor arm, consisting of treatment with tacrolimus, mycophenolate mofetil, and prednisone.
11637644|NCT00275535|Active Comparator|Sirolimus|Calcineurin inhibitor-free arm, consisting of treatment with rapamycin, mycophenolate mofetil, and prednisone.
11637645|NCT00275509|Experimental|Thymoglobulin|Thymoglobulin was administered as 1.5 mg/kg prior to reperfusion followed by 6 post-operative doses on days 1 through 6.
11637646|NCT00275509|Experimental|Daclizumab|Daclizumab was administered as 2 mg/kg prior to reperfusion followed by 1 mg/kg every other week for 8 weeks post-operatively (4 post-operative doses).
11637647|NCT00275496|Active Comparator|WEX only|
11637648|NCT00275496|Active Comparator|WEX + SLND|
11637649|NCT00275496|Active Comparator|WEX+SLND+CLND|
11637650|NCT00275392|Experimental|Vestibular Rehabilitation|vestibular exercises plus standard balance and gait exercises
11637651|NCT00275392|Placebo Comparator|Placebo|placebo exercises plus standard balance and gait exercises
11637652|NCT00275366|Other|1|
11637653|NCT00275301|Experimental|Open-label Olanzapine.|Open-label Olanzapine.
11637654|NCT00275288||Healthy Normal|
11637655|NCT00275288||Active Disease|
11637656|NCT00275275|Experimental|1|Conversion factor of Mirapex to Requip 24-Hour of 1:3. This was a switch study in which the conversion factor was being investigated to assist in the conversion from Mirapex to Requip PR. In this group, the dose of Requip PR was 3 times the dose of Mirapex.
11637657|NCT00275275|Experimental|2|Conversion factor of Mirapex to Requip 24-Hour of 1:4
11637658|NCT00275275|Experimental|3|Conversion factor of Mirapex to Requip 24-Hour of 1:5
11637659|NCT00275262|Experimental|LAD 11.25 mg 3 Month Depot|Three intramuscular injections LAD 11.25 mg 3 Month treatment administered approximately 3 months apart.
11637660|NCT00275262|Placebo Comparator|Placebo Comparator|Three intramuscular injections of matched placebo administered approximately 3 months apart.
11637661|NCT00275171|Active Comparator|rhTSH|proceeded by 0.1 mg rhTSH
11637662|NCT00275171|Placebo Comparator|Placebo|1 ml isotonic saline
11637663|NCT00275145|Experimental|Resistance Training|8 months of Resistance Exercise Training
11637664|NCT00275145|Experimental|Aerobic Exercise|8 months of Aerobic Exercise Training
11637665|NCT00275145|Experimental|Combination RT & AT|8 months of Combined Aerobic and Resistance Exercise Training
11637666|NCT00275145|Experimental|Control|Control/sedentary intervention
11637667|NCT00275132|Experimental|Erlotinib|Tarceva (OSI-774, erlotinib) PO 150mg daily
11637668|NCT00275132|Placebo Comparator|Matched placebo|Matched placebo PO daily
11637669|NCT00275093|Experimental|Treatment (temsirolimus)|"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD."
11637670|NCT00275080|Experimental|Treatment (enzyme inhibitor, chemotherapy)|"Regimen 1 (sequential dosing): Patients receive oral vorinostat two or three times daily on days 6-21 or days 6-12 (patients with solid tumors or NHL only) and decitabine IV over 1 hour on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Regimen 2 (concurrent dosing): Patients receive oral vorinostat two or three times daily on days 1-21, days 1-14 (patients with hematological malignancies only), or two times daily on days 1-12 (patients with solid tumors or NHL only) and decitabine IV over 1 hour on days 1-5."
11637671|NCT00275067|Experimental|Radiation + temozolomide and arsenic trioxide|Radiation therapy followed by the combination of temozolomide and arsenic trioxide at the maximum tolerated dose determined in phase 1
11637672|NCT00275054|Experimental|Cohort I (FCR)|Patients with 2 or more risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) who are randomized into cohort I receive Fludarabine, Cyclophosphamide and Rituximab (FCR) chemoimmunotherapy.
11637673|NCT00275054|No Intervention|Cohort II (W&W)|Patients with 2 or more risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) who are randomized into cohort II receive no treatment at all (watch & wait).
11637674|NCT00275054|No Intervention|Cohort III (W&W)|Patients with less than 2 risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) are assigned directly to cohort III and receive no treatment at all (watch & wait).
11637675|NCT00275041|Experimental|cetuximab + irinotecan|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and irinotecan hydrochloride IV over 1½ hours on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~After completion of study treatment, patients are followed periodically for up to 5 years."
11637676|NCT00275028|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11637677|NCT00275015|Experimental|High dose therapy + autologous PBSCT|"Cytoreductive treatment: (preferentially) FC (2-4 cycles)
~Mobilization: Dexa-BEAM + G-CSF (1-2 cycles)
~Myeloablation:
~fractionated TBI (e.g. 6x2Gy) + Cyclophosphamide (2 x 60 mg/kg; d -4 to -3)
~autologous peripheral blood stem cell transplantation (PBSCT) (d 0)"
11637678|NCT00275002|Experimental|O6-BG and TMZ|O6-benzylguanine (O6-BG) and temozolomide (TMZ)
11637679|NCT00274989|Experimental|Bendamustine plus Rituximab|
11637680|NCT00274937|Experimental|Stratum I - AJCC Stages I-IIa|Patients undergo radiation therapy 5 days a week for 8 weeks. Patients also receive amifostine trihydrate subcutaneously on the same days they undergo radiation therapy.
11637681|NCT00274937|Experimental|Stratum II - AJCC Stages IIb-IV|Patients receive cisplatin IV over 6 hours on day 1 and fluorouracil IV continuously on days 1-4. Treatment repeats every 3 weeks for 3 courses. In weeks 10-18, patients undergo radiation therapy and receive amifostine trihydrate as in stratum I. Patients also receive 3 courses of cisplatin as before.
11637682|NCT00274924|Experimental|Group I (PET negative)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1, and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
11637683|NCT00274924|Experimental|Group II (PET positive)|Patients receive R-ICE comprising rituximab IV on day 1, ifosfamide IV continuously over 24 hours and carboplatin IV over 30 minutes on day 2, and etoposide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously once daily starting on day 4 and continuing until blood counts recover. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11637684|NCT00274846|Experimental|Intent-to-Treat|All patients treated with natural killer (NK) cells (at a dose of 1.5-8 x 10^7/kg.)
11637685|NCT00274833|Experimental|Radiation Therapy, Temozolomide, and Erlotinib|
11637686|NCT00274794|Other|Rituxan + Etoposide + G-CSF|
11637687|NCT00274794|Other|Etoposide + G-CSF|
11637688|NCT00274781|Experimental|ATO + GO|Arsenic Trioxide 0.25 mg/kg D1-5 Week 1/Twice Weekly W2-12 + Gemtuzumab Ozogamicin 3 mg/m^2 D8 for 1 or 2 Cycles of 12 Weeks each
11637734|NCT00273780|No Intervention|Control|
11637735|NCT00273767|Experimental|1|epoetin beta
11637736|NCT00273767|Placebo Comparator|2|placebo of NaCl
11637737|NCT00273754|Placebo Comparator|Placebo|Saline
11637689|NCT00274768|Experimental|Capecitabine|26 patients received the pre-defined starting dose of capecitabine of 3,000 mg orally daily given in two divided doses. Two thirds of the patients received either the same dose or a 500 mg lower dose compared to what would have been administered with a commonly used body surface area (BSA)-dosing schedule (2,000 mg/m2 with rounding down to nearest 500 mg multiple).
11637690|NCT00274742|Experimental|Blinatumomab|Patients received blinatumomab as continuous intravenous infusion for 4 weeks. Participants with clinical benefit were permitted to continue for another 4 weeks for a total of 8 weeks. Participants with a clinical benefit 4 weeks after completion of the first cycle of treatment could also receive additional treatment approximately 3 months ater the end of infusion at the same dose level.
11637691|NCT00274716|Experimental|High BMI:MK-0736 2mg→Placebo|Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
11637692|NCT00274716|Experimental|High BMI:MK-0736 7mg→Placebo|Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)
11637693|NCT00274716|Experimental|High BMI:MK-0916 6mg→MK-0916 6mg|Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
11637694|NCT00274716|Placebo Comparator|High BMI:Placebo→Placebo|Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
11637695|NCT00274716|Experimental|Low BMI:MK-0916 6mg→MK-0916 6mg|Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
11637696|NCT00274716|Placebo Comparator|Low BMI:Placebo→Placebo|Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)
11637697|NCT00274677|Placebo Comparator|Placebo|
11637698|NCT00274677|Experimental|lamotrigine|
11637699|NCT00274651|Experimental|Arm A|PXD101 1000 mg/m2 once daily for 5 days every 21 days
11637700|NCT00274651|Experimental|Arm B|PXD101 1000 mg/m2 once daily for 5 days every 21 days
11637701|NCT00274625|Experimental|1|Surgisis Gold Graft
11637702|NCT00274625|Active Comparator|2|Control
11637703|NCT00274469|Experimental|1|Fulvestrant
11637704|NCT00274469|Active Comparator|2|Anastrozole
11637705|NCT00274456|Experimental|ABI-007 300 mg/m^2 q3w|ABI-007 300 mg/m^2 administered once every third week (q3w).
11637706|NCT00274456|Experimental|ABI-007 100 mg/m^2 weekly|ABI-007 100 mg/m^2 once weekly for 3 weeks followed by 1 week of rest
11637707|NCT00274456|Experimental|ABI-007 150 mg/m^2 weekly|ABI-007 150 mg/m^2 once weekly for 3 weeks followed by 1 week of rest
11637708|NCT00274456|Active Comparator|Docetaxel 100 mg/m^2, q3w|Docetaxel (Taxotere) 100 mg/m^2 administered once every third week (q3w).
11637709|NCT00274443|Experimental|ABI-007 and Carboplatin|ABI-007 and Carboplatin in patients with Advanced Non-Small Cell Lung Cancer.
11637710|NCT00274287|Experimental|GM-CSF|Once patients have finished receiving the chemotherapy and no signs of disease progression they may receive GM-CSF as outlined in the protocol
11637711|NCT00274261|Experimental|A|C31G vaginal gel contains 35mg (1% concentration) of C31G in 3.5 mL volume of gel
11637712|NCT00274261|Active Comparator|B|Conceptrol® Vaginal gel contains 100mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
11637713|NCT00274209||IBD patients at risk for neoplasia|Patients with long-standing ulcerative colitis or Crohn's colitis at risk for neoplasia.
11637714|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ (vortex)|gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
11637715|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (vortex)|gp100:209-217(210M) peptide emulsified in MONTANIDE ISA-51 or Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.
11637716|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in saline ID|gp100:209-217(210M) in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
11637717|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in saline ID + Imiquimod|gp100:209-217(210M) peptide in 0.9% Sodium Chloride Injection injected intradermally on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of the injection daily for 5 days.
11637718|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ (2 Syringe)|gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks).
11637719|NCT00273910|Experimental|Adj-3 A2 gp209(2M) in IFA SQ + Imiquimod (2 Syringe)|gp100:209-217(210M) peptide emulsified in Montanide ISA 51 VG injected subcutaneously on day one every three weeks (1 cycle) for a total of twelve cycles (33 weeks); following the injection patients will apply imiquimod to the skin at the site of injection daily for 5 days.
11637720|NCT00273858||etanercept|Patients already prescribed to receive etanercept for the first time for treatment of Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis according to the Summary of Product Characteristics (SmPC).
11637721|NCT00273845|Experimental|1|One session of motivational interviewing
11637722|NCT00273845|Experimental|2|Five sessions of strengths-based case management
11637723|NCT00273806|Experimental|1|Medical assistant identification and referral for behavioral risk factors.
11637724|NCT00273806|No Intervention|2|Usual care for behavioral risk factors.
11637725|NCT00273793|Experimental|1|Shaping intervention for hard-to-treat smokers
11637726|NCT00273793|Active Comparator|2|fixed criterion intervention for hard-to-treat smokers
11637727|NCT00273793|Other|3|Non contingent incentives available to hard to treat smokers
11637728|NCT00273793|Experimental|4|Ascending incentives values used in Smokers with Early Success
11637729|NCT00273793|Active Comparator|5|fixed value incentives are used in Smokers with Early Success
11637730|NCT00273793|Other|6|Non contingent incentives are available to Smokers with Early Success
11637731|NCT00273780|Active Comparator|Adherence counseling|
11637732|NCT00273780|Active Comparator|Alarm device|
11637738|NCT00273754|Active Comparator|Caffeine|Caffeine benzoate
11637739|NCT00273741|Experimental|1|methylphenidate at 20mg per day during 7 days, at 20mg or 40mg per day during 7 days and 20, 40 or 60mg per day during 14 days
11637740|NCT00273741|Placebo Comparator|2|placebo capsules
11637741|NCT00273728|Active Comparator|HES, Septic shock, resuscitation|study group with HES 6%
11637742|NCT00273715|No Intervention|Staples|
11637743|NCT00273689|Other|I|This is a crossover trial- Patients get randomly assign to albuterol or singulair and then cross overed to the alternate active medication.
11637744|NCT00273650|Active Comparator|A|Methyl-B12
11637745|NCT00273650|Placebo Comparator|B|Saline placebo
11637746|NCT00273624|Experimental|olanzapine|10 mg Olanzapine
11637747|NCT00273624|Placebo Comparator|placebo|Placebo
11637748|NCT00273611|Experimental|Pharmacist education|Pharmacist education about vitamin D
11637749|NCT00273611|No Intervention|Usual care|Usual care
11637750|NCT00273572|Active Comparator|Moderate lifestyle intervention|Moderate lifestyle intervention including two group sessions and one individual counselling session with a nutritionist, at recruitment. Individual sessions with a nutritionist after 6 and 12 months on follow-up.
11637751|NCT00273572|Experimental|Intensive lifestyle intervention|Intensive lifestyle intervention, including bi-monthly group sessions with a physical activity instructor; a monthly group session with a nutritionist, and a monthly individual session with a nutritionist.
11637752|NCT00273559||1|subjects who remain on steroids after discharge
11637753|NCT00273559||2|Subjects will be off steroids at the time of discharge
11637754|NCT00273364|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with Cyclophosphamide and rATG
11637755|NCT00273364|Active Comparator|Standard therapy for MS|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), Gilenya (fingolimod) or Dimethyl fumarate (Tecfidera or BG-12)
11637756|NCT00273351|Experimental|[123I]B-CIT|[123I]B-CIT and SPECT imaging
11637757|NCT00273312|Experimental|Patupilone|was administered at 10 mg/m2, as a single intravenous infusion over 20 minutes, once every 3 weeks
11637758|NCT00273286|Experimental|family diabetes management intervention|A trained health advisor will be responsible for interactions with parents and patients prior to each diabetes clinic visit (Preparation Phase), at the time of the diabetes clinic visit (Consolidation Phase) and by phone, e-mail, etc. after the clinic visit (Follow-up Phase). Using educational modules developed for the study, families will be engaged in problem identification and solving activities to improve shared parent-youth responsibility for diabetes management and foster increased adolescent's independent management capabilities.
11637759|NCT00273182||Cohort|Patients implanted with InSync Model 8040, InSync III Model 8042 , or Medtronic CRT-D system. A total of 1999 subjects were enrolled in the study. Of them, 1738 had successful post market implants of InSync Model 8040 (601 subjects), InSync III Model 8042 (512 subjects) and CRT-D devices (625 subjects). The rest 262 subjects came from two pre-market studies: the MIRACLE study added 141 subjects to InSync Model 8040, and the InSync III study added 121 subjects to the InSync III Model 8042. A total of 1014 subjects completed the study through 36 month follow up. Follow-up of 1000 subjects was required by the FDA to satisfy the conditions of approval.
11637760|NCT00273104|Active Comparator|Bariatric surgery|Bariatric surgery (gastric bypass) offered to patients after informed consent and shared decision. The surgical procedure was performed at Vestfold Hospital Trust by experienced bariatric surgeons.
11637761|NCT00273104|Active Comparator|Intensive lifestyle intervention|Intensive lifestyle intervention (1-year endurance) at a rehabilitation centre. The intervention consisted of motivation for behaviour change including calorie restriction and increased physical activity.
11637762|NCT00273052|Experimental|Carvedilol Phosphate modified release formulation|
11637763|NCT00273052|Active Comparator|metoprolol succinate|
11637764|NCT00273013|Experimental|Sequence 1|Subjects will receive Placebo in period 1, Singulair 10 milligrams (mg) in period 2 and GW274150 90 mg in period 3.
11637765|NCT00273013|Experimental|Sequence 2|Subjects will receive Placebo in period 1, GW274150 90 mg in period 2 and Singulair 10 mg in period 3.
11637766|NCT00273013|Experimental|Sequence 3|Subjects will receive Singulair 10 mg in period 1, Placebo in period 2 and GW274150 90 mg in period 3.
11637767|NCT00273013|Experimental|Sequence 4|Subjects will receive Singulair 10 mg in period 1, GW274150 90 mg in period 2 and Placebo in period 3.
11637768|NCT00273013|Experimental|Sequence 5|Subjects will receive GW274150 90 mg in period 1, Placebo in period 2 and Singulair 10 mg in period 3.
11637769|NCT00273013|Experimental|Sequence 6|Subjects will receive GW274150 90 mg in period 1, Singulair 10 mg in period 2 and Placebo in period 3.
11637770|NCT00272987|Experimental|Arm 1|Open label safety phase. All patients received paclitaxel + trastuzumab + lapatinib.
11637771|NCT00272961|Placebo Comparator|placebo|
11637772|NCT00272961|Experimental|ARM 1|
11637773|NCT00272961|Experimental|ARM 2|
11637774|NCT00272961|Experimental|ARM 3|
11637775|NCT00272961|Experimental|ARM 4|
11637776|NCT00272948|Experimental|Prophylaxis Arm|
11637777|NCT00272948|Active Comparator|Control Arm|
11637778|NCT00272935|Experimental|1|
11637779|NCT00272935|Placebo Comparator|2|
11637780|NCT00272909|Experimental|1|piclozotan IV infusion, low dose, for 72 hours.
11637781|NCT00272909|Experimental|2|piclozotan IV infusion, high dose, for 72 hours.
11637782|NCT00272909|Placebo Comparator|3|placebo (normal saline) IV infusion, for 72 hours.
11637783|NCT00272857|Experimental|Single arm|
11637784|NCT00272844|Experimental|Cholesterol supplementation|
11637785|NCT00272831|Active Comparator|Cilostazol|Cilostazol 100 mg twice daily
11637786|NCT00272831|Placebo Comparator|Placebo|
11637787|NCT00272792|Experimental|Sapropterin Dihydrochloride|Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
11638223|NCT00266799|Experimental|Pegylated liposomal doxorubicin|
11637788|NCT00272792|Placebo Comparator|Placebo|Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
11637789|NCT00272779|Active Comparator|Atazanavir (ATV) + Ritonovir (RTV)|Participants were administered an oral dose of ATV 300 mg and RTV 100 mg once daily along with food on a background of fixed dose combination TDF 300 mg plus FTC 200 mg (TDF/FTC) once daily. Doses of ATV and RTV were taken 24 hours apart at the same time as the background TDF/FTC, up to 96 Weeks.
11637790|NCT00272779|Active Comparator|Lopinavir (LPV) + RTV|Participants were administered an oral dose of LPV 400 mg and RTV 100 mg once daily along with food on a background of fixed dose combination TDF 300 mg plus FTC 200 mg (TDF/FTC) once daily. Doses of LPV and RTV were taken 24 hours apart at the same time as the background TDF/FTC, up to 96 Weeks.
11637791|NCT00272662|Experimental|Cohort 1|Peginesatide starting dose of 0.1 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 3 weeks (Q3W) for a total of 4 doses.
11637792|NCT00272662|Experimental|Cohort 2|Peginesatide starting dose of 0.15 mg/kg administered SC Q3W for a total of 4 doses.
11637793|NCT00272662|Experimental|Cohort 3|Peginesatide starting dose of 0.2 mg/kg administered SC Q3W for a total of 4 doses.
11637794|NCT00272662|Experimental|Cohort 4|Peginesatide starting dose of 0.05 mg/kg administered SC Q3W for a total of 4 doses.
11637795|NCT00272649|Experimental|Single Arm|Single Arm study
11637796|NCT00272597|Other|Risperidone LAI|"Subjects treated with any antipsychotic can be switched to Risperidone LAI.
~If the subject is currently treated with an antipsychotic other than risperidone, the dosage will be tapered gradually and discontinued. Simultaneously, oral risperidone will be started at 2 mg/day and increased to no more than 6 mg/day. The subject will be treated with risperidone monotherapy for at least five days prior to entering the stabilization phase of the study.
~On the other hand, if the patient has already been treated for more than 5 days with risperidone monotherapy then he/she may enter the stabilization phase of the study immediately."
11637797|NCT00272545|Experimental|1|Participants will receive the normalization of eating program
11637798|NCT00272545|Active Comparator|2|Participants will receive treatment as usual
11637799|NCT00272519|Experimental|Adolescent/caregiver dyads|Eight to ten adolescent/caregiver dyads
11637800|NCT00272493|Active Comparator|A|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
11637801|NCT00272493|Experimental|B|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
11637802|NCT00272480|Placebo Comparator|Placebo|Placebo in HAM/TSP 24
11637803|NCT00272480|Active Comparator|Zidvoudine plus lamivudine|Zidvoudine plus lamivudine in HAM/TSP 24
11637804|NCT00272467|Experimental|Rebamipide|"Dosage (1) The eradication therapy period (for all cases) Amoxicillin 2,000mg/day, clarithromycin 1,000 mg/day and omeprazole 40 mg/day. b.i.d. (morning and evening), oral administration. (2) The ulcer treatment period (on a double-blind basis) Rebamipide 100mg, t.i.d. (before breakfast, evening, before bed).
~Drug period (1) The eradication therapy period: 1 week (2) The ulcer treatment period: 7 weeks"
11637805|NCT00272467|Active Comparator|Omeprazole|"Dosage (1) The eradication therapy period (for all cases) Amoxicillin 2,000mg/day, clarithromycin 1,000 mg/day and omeprazole 40 mg/day. b.i.d. (morning and evening), oral administration. (2) The ulcer treatment period (on a double-blind basis) omeprazole 20mg, once daily (before breakfast)
~Drug period (1) The eradication therapy period: 1 week (2) The ulcer treatment period: 7 weeks"
11637806|NCT00272415|Experimental|1|
11637807|NCT00272402|Other|1|Simulated case-based learning
11637808|NCT00272402|Other|2|EMR clinical decision support tool.
11637809|NCT00272402|No Intervention|3|Control group
11637810|NCT00272337|Active Comparator|1|81 mg Aspirin
11637811|NCT00272337|Active Comparator|2|162 mg Aspirin
11637812|NCT00272337|Active Comparator|3|325 mg Aspirin
11637813|NCT00272337|Active Comparator|4|650 mg Aspirin
11637814|NCT00272337|Active Comparator|5|1300 mg Aspirin
11637815|NCT00272311|Active Comparator|1|81 mg Aspirin
11637816|NCT00272311|Active Comparator|2|162 mg Aspirin
11637817|NCT00272311|Active Comparator|3|325 mg Aspirin
11637818|NCT00272311|Active Comparator|4|650 mg Aspirin
11637819|NCT00272311|Active Comparator|5|1300 mg Aspirin
11637820|NCT00272285|Experimental|1|Intravenous (IV)
11637821|NCT00272285|Active Comparator|2|Intravenous (IV)
11637822|NCT00272272|Experimental|Balance and Music Listening|Music therapy
11637823|NCT00272220|Experimental|1|receive 6-week intervention of peer-delivered mDOT
11637824|NCT00272220|No Intervention|2|
11637825|NCT00272181|Experimental|Dose Determination|The recommended dose (RD) for Proxinium is to be determined based on the rate of Dose Limiting Toxicities (DLT) within each dose cohort. The RD is to be established as the highest dose at which one or fewer patients out of six within a dose cohort experienced a DLT. The initial dose level is 500 μg of Proxinium in PBS (the amount of PBS used will be based on the estimated volume of the target tumour). Doses are to be escalated to a maximum of 700 μg or de-escalated to a minimum of 260 μg according to the prescribed algorithm outlined in the study protocol.
11637826|NCT00272168|Experimental|Arm 1: MPROVE|The Maryland Program for Vocational Effectiveness (MPROVE)
11637827|NCT00272168|Active Comparator|Arm 2: Control|Supportive Treatment for SMI (control)
11637828|NCT00272116|Experimental|1|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children and Vitamin A 100,000 IU to infants and 200,000 IU to older children
11637829|NCT00272116|Placebo Comparator|2|
11637830|NCT00272064|Other|1|Telecare system
11637831|NCT00272064|Other|2|Self Monitoring Blood Glucose (SMBG)system.
11637832|NCT00272038|Experimental|Tarceva|Tarceva 150 mg QD
11637833|NCT00272025|Active Comparator|1|There is a 50% chance of being randomized to Escitalopram in addition to current atypical antipsychotic (minimum dose risperidone 3mg, olanzapine 10mg or seroquel 400mg) or mood stabilizer (lithium, epival or lamotrigine)
11637834|NCT00272025|Placebo Comparator|2|to be filled in
11637835|NCT00271999|Active Comparator|1|Three times a week conventional at home hemodialysis
11637836|NCT00271999|Experimental|2|Six times a week nocturnal home hemodialysis
11637837|NCT00271960|Active Comparator|Individual Care|Participants will receive usual care for their prenatal visits
11637838|NCT00271960|Active Comparator|CenteringPregnancy|Participants will receive CenteringPregnancy(R) group prenatal care
11637839|NCT00271960|Experimental|CenteringPregnancyPlus|Participants will receive CenteringPregancy with an HIV/STD prevention component
11637840|NCT00271947|Experimental|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after the conditioning regimen
11637841|NCT00271908||Cohort #1|Venue-tracking survey subjects recruited annually for 4 years: N= 320-640 (10-20 members of the population of focus per site, per year). The purpose of this cohort is to identify and track venues at which the population of focus congregates.
11637842|NCT00271908||Cohort #2|HIV-related risk survey subjects recruited annually for 4 years: N = 1280-2880 (20-30 members of the population of focus per 2-3 congregation venues, per site, per year). These subjects will complete a survey designed to assess HIV-related risk. In the fourth and final year only, HIV Antibody [Ab] assays will also be conducted with survey participants to assess HIV serostatus. The survey and HIVAb assay data will be used to evaluate the intervention within and across sites.
11637843|NCT00271856|Experimental|0|Mindfulness Based Stress Reduction (MBSR)
11637844|NCT00271856|Active Comparator|1|HIV education/self-management workshop
11637845|NCT00271817|Active Comparator|Part 1 - Arm 1|ezetimibe/simvastatin combination tablet + niacin (ER)
11637846|NCT00271817|Active Comparator|Part 1 -Arm 2|ezetimibe/simvastatin
11637847|NCT00271817|Active Comparator|Part 1 - Arm 3|Niacin (ER)
11637848|NCT00271817|Active Comparator|Part 2 - Arm 1|ezetimibe/simvastatin combination tablet + niacin (ER)
11637849|NCT00271817|Placebo Comparator|Part 2 - Arm 2|ezetimibe/simvastatin combination tablet + niacin (Pbo)
11637850|NCT00271791|Experimental|1|Prednisone
11637851|NCT00271791|Placebo Comparator|2|Placebo
11637852|NCT00271752|Experimental|PCT guided|Procalcitonin guided treatment of infections in the ICU. Intervention: Intensification of antibiotics, surgery, microbiologic testing and diagnostic imaging, when Procalcitonin levels are increasing
11637853|NCT00271752|Sham Comparator|Control|"These patients receive Standard of Care which is the recommended treatment in the given ICU"
11637854|NCT00271739|Experimental|Telemedicine case management|Telemedicine visits conducted by a registered nurse (RN) with remote monitoring of blood pressure (BP) and blood glucose through the use of a telemedicine home unit (HTU).
11637855|NCT00271739|Active Comparator|Usual care|usual care by primary care provider
11637856|NCT00271713|Active Comparator|ibandronate|150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily
11637857|NCT00271713|Placebo Comparator|2|placebo monthly plus 500mg calcium and 800 UI vitamin D daily
11637858|NCT00271700|No Intervention|Usual Care|admission to medical team floor to usual care
11637859|NCT00271700|Experimental|Intervention|consists of usual care as well as an admission order set built into BWH's proprietary computer provider order entry (CPOE) system
11637860|NCT00271635|Experimental|1|Ascorbic acid
11637861|NCT00271635|Placebo Comparator|2|Placebo
11637862|NCT00271622||Healthy volunteers|Healthy Volunteers
11637863|NCT00271622||individuals with risk for psychiatric disorders or neurodevelo|individuals with risk for psychiatric disorders or neurodevelopmental disorders, such as autism spectrum disorders.
11637864|NCT00271609|Other|Anaplastic Glioma (AG)|Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic mixed oligoastrocytoma Malignant astrocytoma (not otherwise specified) 10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
11637865|NCT00271609|Other|Glioblastoma Multiforme (GBM)|Glioblastoma multiforme Gliosarcoma 10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
11637866|NCT00271596|Experimental|Citalopram|20mg daily citalopram
11637867|NCT00271596|Placebo Comparator|Placebo|Matching daily placebo
11637868|NCT00271570|Active Comparator|Second Dose of IVIG (2g/kg)|Subjects who did not respond to the first dose of IVIG received a 2nd dose of IVIG in this arm (2g/kg)
11637869|NCT00271570|Experimental|Infliximab (5mg/kg)|Remicade (5mg/kg) single dose
11637870|NCT00271544|Experimental|4196 Lead|Non-randomized study.
11637871|NCT00271531||1|150 subjects greater than 48 weeks post-conception and less than 18 years of age who are mechanically ventilated and have presumed bacterial pulmonary infection.
11637872|NCT00271518|Experimental|LB03002, sustained release human hGH|LB03002
11637873|NCT00271505|Experimental|Avastin + Docetaxel + Carboplatin|Avastin 15 mg/kg intravenously (IV) every 3 weeks. Docetaxel 75 mg/m2 IV every 3 weeks. Carboplatin AUC 6 IV every 3 weeks.
11637874|NCT00271492|Active Comparator|I|Qualifying patients took Atrasentan, 1 pill per day for 6 months, to determine if it had a favorable affect on patients who took it over those who were randomized to placebo.
11637875|NCT00271492|Placebo Comparator|2|placebo group to be compared to the actual medication
11637876|NCT00271440|Experimental|CHX 1.0%|1.0% CHX wiping
11637877|NCT00271440|Experimental|CHX 0.5%|0.5% Chlorhexidine
11637878|NCT00271440|Experimental|CHX 0.25%|chlorhexidine cleansing with pre-soaked pre-sealed wipe
11637879|NCT00271401|Experimental|Angioplasty With Abciximab Plus Low-Dose Heparin|Participants will receive conventional angioplasty/atherectomy along with bolus abciximab 0.25 milligram per kilogram (mg/kg) of body weight followed by a 0.125 microgram per kilogram per minute (mcg/kg/minute) infusion for 12 hours plus 7 unit per kilogram per hour (U/kg/hr) continuous infusion of heparin.
11637880|NCT00271401|Experimental|Intracoronary Stent With Reo Pro Plus Low Dose Heparin|Participants will receive intracoronary stent along with receive bolus abciximab 0.25 mg/kg of body weight followed by a 0.125 mcg/kg/minute infusion for 12 hours plus 7 U/kg/hr continuous infusion of heparin (low dose).
11637881|NCT00271401|Placebo Comparator|Intracoronary Stent With Placebo Plus Standard Dose Heparin|Participants will receive intracoronary stent along with bolus placebo followed by placebo infusion for 12 hours plus 10 U/kg/hr continuous infusion of heparin (standard dose).
11637882|NCT00271388|Experimental|Parameter Determination|Testing potential effects of GVS on the symptoms of neglect
11637883|NCT00271375|Experimental|Arm 1: Caring for you, Caring for me Educational Intervention|Educational Intervention
11637884|NCT00271375|Experimental|Arm 2: Caring for you, caring for me + social worker|Educational + Social Work Intervention
11637885|NCT00271375|Placebo Comparator|Arm 3: Control group usual care|Control group usual care
11637886|NCT00271362|Active Comparator|1|comparing 2 surgical procedures
11637887|NCT00271336|Placebo Comparator|A|
11637888|NCT00271336|Experimental|B|
11637889|NCT00271323|Experimental|1|Induction chemotherapy followed by concurrent chemoradiotherapy
11637890|NCT00271323|Active Comparator|2|Concurrent chemo-radiotherapy followed by consolidation chemotherapy
11637891|NCT00271284|Experimental|I|
11637892|NCT00271284|Active Comparator|II|
11637893|NCT00271245|Experimental|1|200 µg selenium as selenate
11637894|NCT00271245|Experimental|2|400 µg selenium as selenate
11637895|NCT00271245|Experimental|3|200 µg selenium as selenomethionine
11637896|NCT00271245|Placebo Comparator|4|placebo
11637897|NCT00271219|Experimental|Buprenorphine|Buprenorphine
11637898|NCT00271219|Active Comparator|Methadone|Methadone
11637899|NCT00271206|Active Comparator|Progesterone|200 mg to 400mg of progesterone
11637900|NCT00271206|Placebo Comparator|Sugar Pill|Will mirror active medication
11637901|NCT00271193|No Intervention|1|Control group, receives physician advice for weight loss and materials
11637902|NCT00271193|Active Comparator|2|Active treatment group, receives physician advice, materials, and brief weight loss counseling
11637903|NCT00271154|Placebo Comparator|CRT OFF|Cardiac Resynchronization Therapy (CRT) turned OFF in conjunction with optimal medical therapy
11637904|NCT00271154|Active Comparator|CRT ON|Cardiac Resynchronization Therapy (CRT) turned ON in conjunction with optimal medical therapy
11637905|NCT00271115|Other|Moms w/preterm infants|Mothers of preterm infants who are admitted to the newborn intensive care unit.
11637906|NCT00271102|Active Comparator|Anterior colporrhaphy|Anterior vaginal wall colporrhaphy (repair) for cystocele (dropped bladder)
11637907|NCT00271102|Active Comparator|Paravaginal defect repair|Abdominal paravaginal defect repair cystocele (dropped bladder)
11637908|NCT00271050|Experimental|1|
11637909|NCT00271024|Experimental|Male Naltrexone|50 mg Naltrexone tablet
11637910|NCT00271024|Experimental|Female Naltrexone|Females receiving either naltrexone (50 mg)
11637911|NCT00271024|Placebo Comparator|Male Placebo|Males receiving Placebo (sugar pill)
11637912|NCT00271024|Placebo Comparator|Female Placebo|Females receiving placebo (sugar pill)
11637913|NCT00271011|Experimental|Mitomycin C, Irinotecan and Cetuximab|"Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.
~Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.
~Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1*28 allele will receive irinotecan 110 mg/m2."
11637914|NCT00270998|Experimental|Intravaginal Pessary|Pessary restores continence by stabilization of the proximal urethra and urethrovesical junction, facilitating pressure transmission to the proximal urethra.
11637915|NCT00270998|Experimental|Behavioral Therapy|Pelvic floor muscle training and exercise which includes strong contraction of the pelvic floor muscles to prevent incontinence by occluding the urethra and regular practice can improve pelvic muscle support.
11637916|NCT00270998|Experimental|Pessary combined with behavioral therapy|Combination of the explanations above.
11637917|NCT00270985|Active Comparator|nut free diet|ADA recommended diabetes diet without any nuts
11637918|NCT00270985|Experimental|almond group|calorie controlled diet with prescribed daily amount of almonds
11637919|NCT00270959|Experimental|1|Stepped collaborative care (combination of behavioral therapy and drug therapy)
11637920|NCT00270959|Active Comparator|2|Standard care provided to injured trauma survivors
11637921|NCT00270907|Experimental|CT-2103 + Gemcitabine|CT-2103 135 mg/m^2 intravenous (IV) on Day 1. Gemcitabine 1000 mg/m^2 IV on Day 1 and 8.
11637922|NCT00270894|Experimental|Neoadjuvant therapy|Neoadjuvant therapy will consist of epirubicin (100 mg/m^2) + cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles; followed by a 3-week break; followed by docetaxel (75 mg/m^2) every 2 weeks for 4 cycles + trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments.
11637923|NCT00270855|Other|Arm Crank Ergometer|Upper body Cycle ergometer Exercise: 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
11637924|NCT00270855|Other|FESLCE|Functional Electrical Stimulation Leg Cycle Ergometer Exercise: 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
11637925|NCT00270842|Placebo Comparator|Education Control Group|Education group that is the control group for the study. Is a 10 week course with diverse health education topics.
11637926|NCT00270842|Experimental|Functional Balance Training|Exercise group that participated in functional balance training
11637927|NCT00270842|Experimental|Tai chi|Exercise Group that participated in tai chi training classes
11637928|NCT00270829|Experimental|1|Nesiritide given intrarenally
11637929|NCT00270829|No Intervention|2|No intrarenal drug administration
11637930|NCT00270816|Experimental|interferon beta cyclical administration|Interferon ß-1b Treatment by Cyclical Administration
11637931|NCT00270816|Active Comparator|Interferon ß-1b Treatment|Interferon ß-1b Treatment
11637932|NCT00270803|Placebo Comparator|A|Low nicotine cigarettes without THC
11637933|NCT00270790|Experimental|AMIFOSTINE +CARBOPLATIN, TAXOL +RT|EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.
11637934|NCT00270764||Full cohort|Adult ART patients at 3 treatment facilities in South Africa
11637935|NCT00270738|Experimental|1|TrA training group
11637936|NCT00270738|Active Comparator|2|PFMT group
11637937|NCT00270738|Active Comparator|3|control group (PFM exercise at home)
11637938|NCT00270712||Retrospective Cohort|537 transplant recipient records used retrospectively
11637939|NCT00270712||Prospective Cohort|3137 transplant recipients enrolled prospectively
11637940|NCT00270699|Experimental|1|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^5 PFU dose) into the deltoid region of either arm.
11637941|NCT00270699|Experimental|2|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^3 PFU dose) into the deltoid region of either arm. This arm will enroll after Arm 1.
11637942|NCT00270699|Experimental|3|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm will enroll after Arms 1 and 2.
11637943|NCT00270699|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
11637944|NCT00270647|Experimental|Vitamin E|Active or placebo vitamin E
11637945|NCT00270647|Experimental|Vitamin C|Active or placebo vitamin C
11637946|NCT00270647|Experimental|Multivitamin|Active or placebo multivitamin
11637947|NCT00270647|Experimental|Beta-carotene|Active or placebo beta-carotene
11637948|NCT00270634|Active Comparator|Low Dose Voclosporin|Low dose voclosporin
11637949|NCT00270634|Active Comparator|Mid Dose Voclosporin|Mid Dose Voclosporin
11637950|NCT00270634|Active Comparator|High Dose Voclosporin|High Dose Voclosporin
11637951|NCT00270634|Active Comparator|Tacrolimus|Standard Dose Tacrolimus
11637952|NCT00270621|Experimental|Treatment|FHP Night time Enuresis intervention
11637953|NCT00270621|No Intervention|Control|To receive standard/usual care for Nocturnal Enuresis- No FHP Night time Enuresis INtervention
11637954|NCT00270439|Experimental|single arm|Removed omentum of patients with type 2 diabetes
11637955|NCT00270413|Experimental|1|sutent
11637956|NCT00270413|No Intervention|2|
11637957|NCT00270400|Experimental|001|nesiritide
11637958|NCT00270387|Experimental|001|Natrecor (nesiritide)
11637959|NCT00270374|Experimental|001|nesiritide
11637960|NCT00270361|Experimental|001|nesiritide
11637961|NCT00270361|Experimental|002|nesiritide
11637962|NCT00270361|Active Comparator|003|usual long term cardiac medications
11637963|NCT00270335|Active Comparator|A|General anesthesia titrated according to a cerebral state monitor
11637964|NCT00270335|Active Comparator|B|General anesthesia titrated according to usual clinical criteria
11637965|NCT00270296|Experimental|Trizivir (TZV) Arm|Participants in the TZV Arm (Arm 1A) will be pregnant women who have CD4 counts of 200 cells/mm3 or more. As the intervention, they will receive TZV twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
11637966|NCT00270296|Experimental|Kaletra Arm|Participants in the Kaletra Arm (Arm 1B) will be pregnant women who have CD4 counts of 200 cells/mm3 or more. As the intervention, they will receive Lamivudine/Zidovudine (3TC/ZDV) and Lopinavir/Ritonavir (LPV/RTV) twice daily. Once in labor, these participants will continue to take TZV twice daily and will also be given additional ZDV.
11637967|NCT00270296|Experimental|Nevirapine (NVP) Arm|Participants in the NVP Arm (Arm 2) will be pregnant women who have have CD4 counts less than 200 cells/mm3. These participants will receive NVP once daily for the first 14 days, then twice daily, and 3TC/ZDV twice daily; these women will be in the observational group.
11637968|NCT00270257|Experimental|Long term medication assisted treatment (LT-MAT)|Participants will receive BUP/NX under the tongue daily for a maximum of three weeks(until dose stabilization) and then three times a week for 52 weeks in addition to weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52
11637969|NCT00270257|Experimental|Short term medication assisted treatment (ST-MAT)|Participants will receive short-term BUP/NX; dosage and length of treatment will be determined by the investigator.Additionally, participants will undergo weekly drug and risk reduction counseling for 12 weeks, and then every 4 weeks through Week 52.
11637970|NCT00270244|Active Comparator|1|Participants will receive treatment as usual
11637971|NCT00270244|Experimental|2|Participants will receive group interpersonal psychotherapy for depressed adolescents
11637972|NCT00270231|Active Comparator|Naltrexone|"All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.
~Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg."
11637973|NCT00270231|Placebo Comparator|Placebo|"All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.
~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule."
11637974|NCT00270218|Experimental|1|Arm 1 participants will be given an injection of VRC-HIVADV014-00-VP vaccine on Days 0 and 168.
11637975|NCT00270218|Placebo Comparator|2|Arm 2 participants will be given an injection of final formulation buffer (FFB) on Days 0 and 168.
11637976|NCT00270218|Experimental|3|Arm 3 participants will be given an injection of VRC-HIVDNA009-00-VP vaccine on Days 0 and 28. Participants will also be given an injection of VRC-HIVADV014-00-VP on Day 168.
11637977|NCT00270218|Placebo Comparator|4|Arm 4 participants will be given an injection of phosphate buffered saline (PBS) on Days 0 and 28 and an injection of FFB on Day 168.
11637978|NCT00270205|Experimental|A: 0.1 mg DNA/participant vaccination at weeks 1,7,13|Participants receiving three separate low-dose vaccinations of LC002 (0.1 mg DNA/participant, 0.8 ml total, administered over two skin sites [on the left and right upper back] of 80 cm^2 each, 0.4 ml/site) at weeks 1, 7, and 13.
11637979|NCT00270205|Experimental|B|Participants receiving three separate vaccinations of LC002 placebo (0.8 ml total, administered over two skin sites [on the left and right upper back] of 80 cm^2 each, 0.4 ml/site) at weeks 1, 7, and 13.
11637980|NCT00270205|Experimental|C: 0.4 mg DNA/participant vaccination at weeks 1, 7, 13|Participants receiving three separate high-dose vaccinations of LC002 (0.4 mg DNA/participant, 3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at weeks 1, 7, and 13.
11637981|NCT00270205|Experimental|D|Participants receiving three separate vaccinations of LC002 placebo (3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at weeks 1, 7, and 13.
11637982|NCT00270205|Experimental|E: 0.4 mg DNA/participant vaccination at weeks 0,1,6,7,12,13|Participants receiving six separate high-dose vaccinations of LC002 (0.4 mg DNA/participant, 3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at study entry and weeks 1, 6, 7, 12, and 13.
11637983|NCT00270205|Experimental|F|Participants receiving six separate vaccinations of LC002 placebo (3.2 ml total, administered over four skin sites [on the left and right upper back and left and right upper ventral thigh] of 80 cm^2 each, 0.8 ml/site) at study entry and weeks 1, 6, 7, 12, and 13.
11637984|NCT00270153|Placebo Comparator|enalapril|
11637985|NCT00270153|Placebo Comparator|Placebo|
11637986|NCT00269919|Experimental|Risperidone Long-Acting Injectable (RLAI)|The RLAI 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 2 years.
11637987|NCT00269906|Experimental|Abciximab (c7E3 Fab)|Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight abciximab as bolus intravenous injection followed by continuous infusion of abciximab at rate of 10 microgram per minute for at least 18 hours but not longer than 26 hours.
11637988|NCT00269906|Placebo Comparator|Placebo|Participants will receive matching placebo as bolus IV injection followed by continuous infusion of matching placebo for at least 18 hours but no longer than 26 hours.
11637989|NCT00269893|Placebo Comparator|Placebo|Participants will receive matching placebo solution bolus followed by matching placebo solution infusion up to 12 hours.
11637990|NCT00269893|Experimental|Abciximab and Placebo|Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight of abciximab (c7E3 Fab) bolus injection followed by followed by placebo solution infusion up to 12 hours.
11637991|NCT00269893|Experimental|Abciximab|Participants will receive 0.25 mg/kg of body weight of abciximab bolus followed by abciximab (c7E3 Fab) infusion up to 12 hours.
11637992|NCT00269880|Placebo Comparator|Placebo and Standard Dose of Heparin|Participants will receive bolus placebo followed by 12-hour infusion of placebo and bolus heparin at a dose of 100 units per kilogram of body weight.
11637993|NCT00269880|Active Comparator|Abciximab and Low Dose of Heparin|Participants will receive bolus abciximab at a dose of 0.25 milligram per kilogram (mg/kg) of body weight followed by 12-hour infusion of 0.125 microgram per kilogram per minute (mcg/kg/min) and bolus heparin at a dose of 70 units per kilogram of body weight.
11637994|NCT00269880|Active Comparator|Abciximab and Standard Dose Heparin|Participants will receive bolus abciximab at a dose of 0.25 mg/kg of body weight followed by 12-hour infusion of 0.125 mcg/kg/min and bolus heparin at a dose of 100 units per kilogram of body weight.
11637995|NCT00269867|Placebo Comparator|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
11637996|NCT00269867|Experimental|Infliximab 3 mg/kg every 8 weeks|Infliximab 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
11637997|NCT00269867|Experimental|Infliximab 3 mg/kg every 4 weeks|Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.
11637998|NCT00269867|Experimental|Infliximab 10 mg/kg every 8 weeks|Infliximab 10 mg/kg will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
11637999|NCT00269867|Experimental|Infliximab 10 mg/kg every 4 weeks|Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.
11638000|NCT00269854|Experimental|Infliximab 5 mg/kg|
11638001|NCT00269854|Experimental|Infliximab 10 mg/kg|
11638002|NCT00269854|Experimental|Infliximab 20 mg/kg|
11638003|NCT00269854|Placebo Comparator|Placebo|
11638004|NCT00269841|Experimental|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
11638005|NCT00269841|Experimental|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
11638006|NCT00269841|Placebo Comparator|Placebo|Matching placebo will be administered at Week 0, 2 and 6.
11638007|NCT00269815|Experimental|001|methylphenidate HCl
11638008|NCT00269802|Experimental|001|OROS methylphenidate HCl
11638009|NCT00269802|Active Comparator|002|Ritalin
11638010|NCT00269802|Placebo Comparator|003|Placebo
11638011|NCT00269789|Experimental|001|OROS Methylphenidate HCl
11638012|NCT00269789|Active Comparator|002|Ritalin
11638013|NCT00269789|Placebo Comparator|003|Placebo
11638014|NCT00269776|Experimental|001|OROS (methylphenidate HCl) Treatment A: 1 2 or 3 OROS methylphenidate 18-mg tablets + 0 1 or 2 OROS placebo tablets (3 tablets in total) once daily + 1 placebo capsule 3x/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
11638015|NCT00269776|Experimental|002|Ritalin (methylphenidate) Treatment B: 5 10 or 15-mg tablets (encapsulated/single capsule) 3 times a day + 3 OROS placebo tablets once daily for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
11638016|NCT00269776|Experimental|003|Placebo Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
11638017|NCT00269633|Placebo Comparator|Red Light Box 657 nm|Red Light Box 657 nm
11638018|NCT00269633|Active Comparator|Blue Light Box 467 nm|Blue Light Box 467 nm
11638019|NCT00269620|Experimental|2|OrthoEvra
11638020|NCT00269620|Experimental|1|NuvaRing
11638021|NCT00269581|Other|1|Educational CD-Rom
11638022|NCT00269581|Experimental|2|Headstrong CD-rom
11638023|NCT00269542|Experimental|1|
11638024|NCT00269542|Placebo Comparator|2|
11638025|NCT00269516|Experimental|1|
11638026|NCT00269516|Experimental|2|
11638027|NCT00269516|Experimental|3|
11638028|NCT00269516|Placebo Comparator|4|
11638029|NCT00269477|Experimental|Menactra® Vaccine Group 1|Participants had previously received a dose of Menactra® vaccine in Study MTA02,did not participate in Study MTA19 (NCT 00777790). They provided a pre-vaccination blood sample on Day 0, received one booster dose of Menactra® vaccine on Day 0 and provided 3 additional blood samples on Day 3, Day 7, and Day 28 post-vaccination.
11638030|NCT00269477|Experimental|Menactra® Vaccine Group 2|Participants had previously received a dose of Menactra® vaccine in Study MTA02,did not participate in Study MTA19 (NCT 00777790). They provided a pre-vaccination blood sample on Day 0, received one booster dose of Menactra® vaccine on Day 0 and provided 3 additional blood samples on Day 5, Day 14, and Day 28 post-vaccination
11638031|NCT00269477|Active Comparator|Meningococcal Vaccine-naive Group 3|Participants have never received Meningococcal vaccine and provided one blood sample pre-vaccination on Day 0, received a dose of Menactra® vaccine on Day 0, and provided 3 additional blood samples on Day 3, Day 7, and Day 28 post-vaccination.
11638032|NCT00269477|Active Comparator|Meningococcal Vaccine-naive Group 4|Participants have never received Meningococcal vaccine and provided one blood sample pre-vaccination on Day 0, received a dose of Menactra® vaccine on Day 0, and provided 3 additional blood samples on Day 5, Day 14, and Day 28 post-vaccination.
11638033|NCT00269425|Experimental|Mediterranean diet,|
11638034|NCT00269425|Experimental|American Heart Association Step 2 diet|
11638035|NCT00269425|No Intervention|Case controlled|
11638036|NCT00269399|Experimental|Rifaximin Treatment Arm|rifaximin 400mg taken 3 times a day
11638037|NCT00269399|Active Comparator|Vancomycin Comparator Arm|vancomycin 125mg taken 4 times a day
11638038|NCT00269386|Active Comparator|1 (i)|Clarithromycin S/R 1g od From April 2004, clarithromycin S/R (Klaricid XL) ceased to be available and subsequent patients will receive either standard clarithromycin 500mg bd or placebo tables of identical size, colour and taste
11638039|NCT00269386|Placebo Comparator|2 (ii)|placebo tablets of identical size, colour and taste
11638040|NCT00269360|Experimental|1|
11638041|NCT00269360|Experimental|2|
11638042|NCT00269360|Active Comparator|3|
11638043|NCT00269321|Experimental|1|
11638044|NCT00269321|Experimental|2|
11638045|NCT00269321|Active Comparator|3|
11638046|NCT00269308|Experimental|1|Chiropractic Manual Treatment + Home Exercise
11638047|NCT00269308|Experimental|2|Supervised Rehabilitative Exercise + Home Exercise
11638048|NCT00269308|Active Comparator|3|Home Exercise
11638049|NCT00269295|Experimental|Cohort 1: Arm 1|12 subjects to receive vaccine dose 1: 5 X 10^7 cfu.
11638050|NCT00269295|Placebo Comparator|Cohort 1: Arm 2|6 subjects to receive placebo.
11638051|NCT00269295|Experimental|Cohort 2: Arm 1|12 subjects to receive vaccine dose 2: 5 X 10^8 cfu.
11638052|NCT00269295|Experimental|Cohort 3: Arm 1|12 subjects to receive vaccine dose 3: 5 X 10^9 cfu.
11638053|NCT00269295|Placebo Comparator|Cohort 3: Arm 2|6 subjects to receive placebo.
11638054|NCT00269295|Placebo Comparator|Cohort 2: Arm 2|6 subjects to receive placebo.
11638055|NCT00269282|Active Comparator|1|Self-Management (SM) (Standard Care Group)
11638056|NCT00269282|Experimental|2|Motivational Interviewing plus Self-Management Training (MI+SM)
11638057|NCT00269152|Experimental|A: Pemetrexed + Cisplatin|
11638058|NCT00269152|Experimental|B: Pemetrexed + Carboplatin|
11638059|NCT00269113|Experimental|1|
11638060|NCT00269113|Active Comparator|2|
11638061|NCT00269048|Experimental|Arm 1|SB-480848
11638062|NCT00269048|Placebo Comparator|Arm 2|placebo
11638063|NCT00269035|Experimental|Treatment Group 1|Subjects in group 1 will receive SB-773812 tablet once daily till still steady Cp
11638064|NCT00269035|Experimental|Treatment Group 2|Subjects in group 2 will receive SB-773812 tablets once daily over 6 weeks. Risperidone tablets 6 mg once daily from Days 1-7 two tablets of 3 mg and days 8 until stable Cp 6 mg tablets
11638065|NCT00268996|Experimental|Subjects with ACS and evidence of MN:SB-480848|Enrolled subjects (subjects with ACS and evidence of myocardial necrosis) will receive 160mg of SB-480848 once daily with food for 52 weeks
11638066|NCT00268996|Placebo Comparator|Subjects with ACS and evidence of MN: placebo|Enrolled subjects (subjects with ACS and evidence of myocardial necrosis) will receive SB-480848 matching placebo once daily with food for 52 weeks
11638067|NCT00268996|Experimental|Non-ACS and ACS subjects without evidence of MN: SB-480848|Enrolled subjects (non-ACS subjects and those ACS subjects without evidence of myocardial necrosis) will receive 160mg of SB-480848 once daily with food for 52 weeks
11638068|NCT00268996|Placebo Comparator|Non-ACS and those ACS subjects without evidence of MN: placebo|Enrolled subjects (non-ACS subjects and those ACS subjects without evidence of myocardial necrosis) will receive SB-480848 matching placebo once daily with food for 52 weeks
11638069|NCT00268983|Experimental|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes
~Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes."
11638070|NCT00268983|Active Comparator|Rituximab|Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.
11638071|NCT00268957|Experimental|1|sevelamer carbonate powder
11638072|NCT00268957|Active Comparator|2|Sevelamer hydrochloride
11638073|NCT00268944|Experimental|1|
11638074|NCT00268931|No Intervention|True Control|This group is being enrolled as a true control group. This group will not participate in the movement training or social training however, they will be evaluated in the same way.
11638075|NCT00268931|Experimental|Social Training|This group underwent specific social interactions two times each day with their parents.
11638076|NCT00268931|Experimental|Movement Training|This group of preterm infants underwent movement training two times per day with their parents.
11638077|NCT00268918|Experimental|Docetaxel / PTK787|"Docetaxel: Lead In: Given intravenously on Day 1 and Day 14 Afer Lead in: Given intravenously on day 1, 8, 15, 22 of each 28-day cycle.
~PTK787: Lead In: Given orally on day 4 and day 14 After Lead In: Given orally once a day."
11638078|NCT00268905|Experimental|1|
11638079|NCT00268905|Experimental|2|
11638080|NCT00268905|Experimental|3|
11638081|NCT00268892|Experimental|Degarelix 240/240@40(1-3-6-9)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (40 mg/mL) at months 1, 3, 6, and 9) in the extension study (240 mg (40 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
11638172|NCT00267566|Experimental|Treatment|50% random assignment to receive Family Help Anxiety Treatment
11638082|NCT00268892|Experimental|Degarelix 240/240@60(1-3-6-9)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (60 mg/mL) at months 1, 3, 6, and 9) in the extension study (240 mg (60 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
11638083|NCT00268892|Experimental|Degarelix 240/240@60(1-4-7-10)|Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (60 mg/mL) at months 1, 4, 7, 10) in the extension study (240 mg (60 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
11638084|NCT00268879|Placebo Comparator|1|Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
11638085|NCT00268879|Experimental|2|Renzapride 4 mg QD. Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
11638086|NCT00268879|Experimental|3|Renzapride 2 mg BID: Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
11638087|NCT00268853|Experimental|1|
11638088|NCT00268853|Active Comparator|2|
11638089|NCT00268840|Experimental|unique|Taxotère - Gemzar
11638090|NCT00268814|Experimental|MTF, Psycho-education, Heroin|Stratum: Methadone treatment failures (MTF) Intervention: Psycho-education and Counselling, Drug: Diacetylmorphine (i.v.)
11638091|NCT00268814|Experimental|MTF, Case management, Heroin|Stratum: Methadone treatment failures (MTF) Intervention: Case Management and Motivational Interviewing, Drug: Diacetylmorphine (i.v.)
11638092|NCT00268814|Active Comparator|MTF, Psycho-education, Methadone|Stratum: Methadone treatment failures (MTF) Intervention: Psycho-education and Counselling, Drug: Methadone (p.o.)
11638093|NCT00268814|Active Comparator|MTF, Case management, Methadone|Stratum: Methadone treatment failures (MTF) Intervention: Case Management and Motivational Interviewing, Drug: Methadone (p.o.)
11638094|NCT00268814|Experimental|NIT, Psycho-education, Heroin|Stratum: Not in treatment (NIT) Intervention: Psycho-education and Counselling, Drug: Diacetylmorphine (i.v.)
11638095|NCT00268814|Experimental|NIT, Case management, Heroin|Stratum: Not in treatment (NIT) Intervention: Case Management and Motivational Interviewing, Drug: Diacetylmorphine (i.v.)
11638096|NCT00268814|Active Comparator|NIT, Psycho-education, Methadone|Stratum: Not in treatment (NIT) Intervention: Psycho-education and Counselling, Drug: Methadone (p.o.)
11638097|NCT00268814|Active Comparator|NIT, Case management, Methadone|Stratum: Not in treatment (NIT) Intervention: Case Management and Motivational Interviewing, Drug: Methadone (p.o.)
11638098|NCT00268788|Active Comparator|1|Subcutaneous Ig given twice a week.
11638099|NCT00268788|Active Comparator|2|Intravenous Ig
11638100|NCT00268762|Experimental|Intervention|Argatroban IV Infusion 1 mcg/kg/min for 48 hours
11638101|NCT00268749|Experimental|1|
11638102|NCT00268723|Experimental|1|levalbuterol HFA MDI 90 mcg QID
11638103|NCT00268723|Placebo Comparator|2|Placebo MDI QID
11638104|NCT00268697|Experimental|Lapaquistat Acetate 100 mg QD|
11638105|NCT00268697|Experimental|Lapaquistat Acetate 100 mg QD + Ezetimibe|
11638106|NCT00268697|Active Comparator|Ezetimibe|
11638107|NCT00268593|Experimental|130 mg PI-88 + docetaxel|130 mg PI-88 7 days/week + docetaxel 75 mg/m2
11638108|NCT00268593|Experimental|250 mg PI-88 + docetaxel|250 mg PI-88 4 days/week + docetaxel 75 mg/m2
11638109|NCT00268580|Experimental|Intervention|Asthma care provided using care pathway
11638110|NCT00268580|No Intervention|Control|Standard of care provided
11638111|NCT00268528||Health service research (electronic pill monitoring system)|Patients receive an electronic pill monitoring system comprising an empty MEMS^? medication bottle with TrackCap? CR. The mercaptopurine prescription is filled using this system. Beginning on day 1 of the third or later course of maintenance therapy, patients take all doses of mercaptopurine from the MEMS^? medication bottle with TrackCap? CR for at least 169 days. The MEMS^? TrackCap? CR is mailed to the Coordinating Center at the end of study. Patients also receive methotrexate PO as indicated by their individual chemotherapy regimen.
11638112|NCT00268489|Experimental|pemetrexed + bevacizumab|"Patients receive pemetrexed disodium IV over 10 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~After completion of study treatment, patients are followed periodically for 5 years."
11638113|NCT00268476|Active Comparator|Arm A: Standard of Care|Androgen Deprivation Therapy [ADT] (plus Radiotherapy for newly-diagnosed non-metastatic disease, plus or minus Docetaxel, plus or minus Abiraterone)[Control]
11638114|NCT00268476|Experimental|Arm B: Zoledronic Acid|(ADT + zoledronic acid) NO LONGER RECRUITING
11638115|NCT00268476|Experimental|Arm C: Docetaxel|(ADT + docetaxel + prednisolone) NO LONGER RECRUITING
11638116|NCT00268476|Experimental|Arm D: Celecoxib|(ADT + celecoxib) NO LONGER RECRUITING
11638117|NCT00268476|Experimental|Arm E: Zoledronic Acid & Docetaxel|(ADT + zoledronic acid + docetaxel + prednisolone) NO LONGER RECRUITING
11638118|NCT00268476|Experimental|Arm F: Zoledronic Acid & Celecoxib|(ADT + zoledronic acid + celecoxib) NO LONGER RECRUITING
11638119|NCT00268476|Experimental|Arm G: Abiraterone|(ADT + abiraterone acetate + prednisolone) NO LONGER RECRUITING
11638120|NCT00268476|Experimental|Arm H: M1 RT|(ADT + radiotherapy to the prostate) NO LONGER RECRUITING
11638121|NCT00268476|Experimental|Arm J: Abiraterone * Enzalutamide|(ADT + abiraterone + enzalutamide + Prednisolone) NO LONGER RECRUITING
11638122|NCT00268476|Experimental|Arm K: Metformin|(ADT + Metformin) RECRUITING IN SELECTED SITES
11638123|NCT00268476|Experimental|Arm L: tE2|(Transdermal oestradiol) RECRUITING
11638124|NCT00268463|Active Comparator|Arm 1: Capecitabine + Oxaliplatin|Within 4-6 weeks after surgery and/or ablation, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
11638169|NCT00267592|Experimental|enzyme-inducing antiseizure drug|A single-arm study with all subjects assigned to one treatment (radiation + temozolomide + talampanel) but subjects receiving concomitant anti-seizure drugs which could increase study drug elimination had a slightly modified dose/schedule of study drug. The primary endpoint is analyzed as a single group.
11638125|NCT00268463|Experimental|Arm 2: Floxuridine + Oxaliplatin + Capecitabine|Within 4-6 weeks after surgery and/or ablation, patients receive a continuous hepatic arterial infusion of floxuridine on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 42 days for 4 cycles in the absence of unacceptable toxicity. Beginning with cycle 5, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment with oxaliplatin and capecitabine repeats every 21 days for 4 cycles.
11638126|NCT00268450|Experimental|study intervention|Neo-adjuvant cisplatin, gemcitabine and bevacizumab followed by radical cystectomy. Patients without residual disease will enter follow up after surgery. Patients with residual disease will receive adjuvant therapy with bevacizumab and ciaplatin.
11638127|NCT00268437|Experimental|Pemetrexed/Carboplatin|Pemetrexed+Carboplatin+Radiation
11638128|NCT00268398|Active Comparator|FOLFOX4|
11638129|NCT00268398|Experimental|FOLFOX7 followed by FOLFIRI|
11638130|NCT00268385|Experimental|Treatment (vorinostat, temozolomide)|"PART I: Patients receive vorinostat PO QD or BID on days 1-7 and 15-21 OR QD or BID on days 1-7. Patients also receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Treatment may continue beyond 13 courses at the discretion of the investigator.
~PART II: Patients receive vorinostat and temozolomide as in part I*.
~[Note: Beginning in course 2, some patients may receive a higher dose of temozolomide.]"
11638131|NCT00268372|Active Comparator|cisplatin/RT alone|cisplatin and radiation therapy
11638132|NCT00268372|Experimental|induction chemo followed by cisplatin/RT|docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by surgery and/or cisplatin and radiation therapy
11638133|NCT00268346|Experimental|ZD1839|
11638134|NCT00268307|Experimental|Cell therapy|Intracoronary, one time infusion of autologous, unfractionated bone marrow mononuclear cells.
11638135|NCT00268242|Experimental|Gemcitabine + Mitoxantrone|Gemcitabine Hydrochloride as administered as a continuous intravenous infusion (I.V.) at 10mg/m^2/minute for 12 hours, starting on Day 1. Mitoxantrone Hydrochloride was given at a dose of 12mg/m^2/day I.V. on days 1, 2, and 3.
11638136|NCT00267969|Experimental|ustekinumab 45 mg|Patients received ustekinumab 45 mg at Weeks 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 45 mg every 12 week maintenance therapy.
11638137|NCT00267969|Experimental|ustekinumab 90 mg|Patients received ustekinumab 90 mg at Week 0, 4 and 16. Treatments after Week 16 were dependent on clinical response. At Week 40, patients who achieved PASI 75 at both Week 28 and Week 40 were re-randomized to withdraw from therapy (placebo) or continue 90 mg every 12 week maintenance therapy.
11638138|NCT00267969|Placebo Comparator|Placebo|Patients received placebo at Weeks 0 and 4. At Weeks 12 and 16, placebo crossed over to receive ustekinumab 45 mg or 90 mg. Treatments after Week 16 were dependent on clinical response.
11638139|NCT00267956|Experimental|CNTO1275 (ustekinumab)|Group 1: Patients will receive CNTO 1275 63 mg at Weeks 0, 1, 2, and 3. At Weeks 12 and 16, patients will receive placebo to maintain the blind.
11638140|NCT00267956|Placebo Comparator|Placebo|Group 2: Patients will receive placebo at Weeks 0, 1, 2, and 3. At Weeks 12 and 16, patients will receive CNTO 1275 63 mg.
11638141|NCT00267930|Placebo Comparator|1|Tier 1: 1 placebo capsule b.i.d Tier 2: 2 placebo capsules b.i.d
11638142|NCT00267930|Experimental|2|Tier 1: Vernakalant (oral) 1 x 300 mg capsule b.i.d
11638143|NCT00267930|Experimental|3|Tier 2: Vernakalant (oral) 2 x 300 mg (600 mg) b.i.d
11638144|NCT00267904|Experimental|Healthy Volunteer for Banana|Ingestion of a single banana
11638145|NCT00267904|Experimental|Healthy Volunteer for Coffee|Ingestion of caffeinated coffee on one day and decaffeinated coffee on another day
11638146|NCT00267904|Experimental|Healthy Volunteer for Olive|Ingestion of olives
11638147|NCT00267904|No Intervention|Healthy Volunteer for Quality Control Plasma|Arm venous blood is drawn via an indwelling i.v. catheter from HVs to obtain quality control plasma
11638148|NCT00267904|Experimental|Healthy Volunteer for Temp. Manip.|Manipulation of temperature at skin of the back
11638149|NCT00267865|Experimental|Rituximab, High-Dose Methotrexate & Leucovorin Treatment|Induction treatment cycles with rituximab, high-dose methotrexate and leucovorin will be administered every 2 weeks for 6 cycles. Two additional consolidation cycles of high-dose methotrexate without rituximab will be administered at 4 weeks and 8 weeks following completion of the combined therapy.
11638150|NCT00267852||1.0|As per routinary clinical practice
11638151|NCT00267826|Experimental|1|Patients with atopic dermatitis.
11638152|NCT00267774|Experimental|FFR guided PCI|
11638153|NCT00267774|Active Comparator|Angio-guided PCI|
11638154|NCT00267748|Experimental|C|
11638155|NCT00267748|Experimental|A|
11638156|NCT00267735|No Intervention|Module 1 Only|
11638157|NCT00267735|Experimental|Modules 1, 2, and 3|
11638158|NCT00267696|Experimental|Gemcitabine/carboplatin/bevacizumab|A regimen consisting of gemcitabine(1000 mg/m2)/carboplatin(AUC 3) / bevacizumab(Avastin®)(10mg/kg) will be administered on day 1 and day 15 of a 28 day cycle.
11638159|NCT00267670|Experimental|Pentoxifylline|400mg PO TID
11638160|NCT00267670|Placebo Comparator|Placebo|1 pill PO TID
11638161|NCT00267644||Hydrated patients|Group 1 (n=63) were pediatric patiens that wer hydrated.
11638162|NCT00267644||Dehydrated Group|Group 2 (n=13) were pediatric patients that were dehydrated.
11638163|NCT00267631||At Risk Body Weight|Children with a BMI greater and equal to 85%
11638164|NCT00267631||Normal Body Weight|Children with a BMI of 25 to 75%
11638165|NCT00267618|Experimental|Treatment|50% randomized to receive FHP Pain intervention
11638166|NCT00267618|No Intervention|control|50% randomized to receive standard/usual care for recurrent headache/abdominal pain
11638167|NCT00267605|Experimental|Treatment|FHPADHD 50% randomized to receive Strongest Families (formerly Family Help Program): behavioural distance intervention
11638168|NCT00267605|Active Comparator|Control|ADHD Standard Care 50% randomized to receive standard/usual care for ADHD
11638170|NCT00267579|Experimental|Treatment|50% randomized to receive Strongest Families (formerly Family Help Program): Behaviour treatment
11638171|NCT00267579|Active Comparator|Control|50% randomized to control group: standard/usual care for behaviour disorder
11638173|NCT00267566|Experimental|Control|50% random assignment to control group to receive usual/standard care for anxiety
11638174|NCT00267514|Other|1|sevelamer carbonate powder x 4 weeks then, sevelamer hydrochloride x 4 weeks
11638175|NCT00267514|Other|2|sevelamer hydrochloride x 4 weeks then, sevelamer carbonate powder x 4 weeks
11638176|NCT00267371|Active Comparator|Test Arm with Premere investigational|PFO Closure with Premere investigational device.
11638177|NCT00267371|Active Comparator|Medical management/current medications|Patients in the control group arm will not receive the medical device and will continue medical management.
11638178|NCT00267358|Active Comparator|RC-1291 HCl|50 mg
11638179|NCT00267358|Placebo Comparator|Placebo|
11638180|NCT00267319|Experimental|single group|
11638181|NCT00267293|Active Comparator|A|At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg)
11638182|NCT00267293|Experimental|B|At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) and an appropriate dose of Acetaminophen (15 mg/kg)
11638183|NCT00267293|Experimental|C|At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) and at time 3 hours is given an appropriate dose of Acetaminophen (15 mg/kg)
11638184|NCT00267241|Experimental|1|ALI/ARDS patients
11638185|NCT00267202|Placebo Comparator|Placebo|The dose of placebo was determined according to the omalizumab US product label using a dosing table nomogram that ensures patients receive at least 0.016 mg/kg/IgE (IU/ml) per 4 weeks. The study drug was administered by subcutaneous injection every 2 or 4 weeks according to the dosing table nomogram.
11638186|NCT00267202|Experimental|Omalizumab|The dose of omalizumab was determined according to the omalizumab US product label using a dosing table nomogram that ensures patients receive at least 0.016 mg/kg/IgE (IU/ml) per 4 weeks. The study drug was administered by subcutaneous injection every 2 or 4 weeks according to the dosing table nomogram.
11638187|NCT00267189|Active Comparator|Reduced CNI dose + everolimus ± steroids|Reduced CNI dose + everolimus (1.5 mg twice daily (b.i.d)) ± steroids
11638188|NCT00267189|Experimental|CNI continuation ± MPA/AZA ± Steroids|Standard CNI dose ± MPA/AZA ± steroids
11638189|NCT00267163|Experimental|1.|
11638190|NCT00267163|Placebo Comparator|2.|
11638191|NCT00267150|Experimental|1|
11638192|NCT00267124||1|elderly people who have normal cognition
11638193|NCT00267124||2|elderly people who have mild to moderate Alzheimer's disease
11638194|NCT00267111|Experimental|Amethocaine gel 4% Group|1 g of topical amethocaine gel 4%
11638195|NCT00267111|Placebo Comparator|Placebo Group|
11638196|NCT00267098|Experimental|Biventricular pacing|
11638197|NCT00267098|Active Comparator|Right ventricular pacing|
11638198|NCT00267085|Experimental|CML Vaccine|Imatinib mesylate subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months
11638199|NCT00267059|Experimental|Lenalidomide|
11638200|NCT00267046|Experimental|Palifermin|"Palifermin + Chemotherapy (Adriamycin (Doxorubicin)+ Ifosfamide (AI) or Adriamycin (Doxorubicin) + Cisplatin (AP) Regimen); Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.
~AP=Doxorubicin (Adriamycin) + Cisplatin:
~Palifermin 180 mcg/kg 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0."
11638201|NCT00267046|Placebo Comparator|Placebo|"Placebo + Chemotherapy (AI or AP Regimen);
~AI = Doxorubicin (Adriamycin) + Ifosfamide:
~A single dose placebo prior to chemotherapy; Adriamycin 30 mg/m^2 intravenous (IV) for 72 hours starting Days 0 for total 90 mg/m^2. Ifosfamide 2.5 g/m^2 IV bolus Days 0-3 (total 10 g/m^2); Vincristine 2 mg IV Day 0.
~AP=Doxorubicin (Adriamycin) + Cisplatin:
~A single dose placebo 3 days prior to chemotherapy; Adriamycin 30 mg/m^2 IV continuous infusion for 72 hours starting Day 0(total = 90 mg/m^2); Cisplatin 120 mg/m^2 on day 0."
11638202|NCT00267033|Experimental|1|injection of orthopaedic cement into vertebral bodies
11638203|NCT00267020|Experimental|Enzastaurin+Gemcitabine|
11638204|NCT00267020|Active Comparator|Gemcitabine|
11638205|NCT00267007|Experimental|001|PROCRIT 40 000 IU QW Epoetin alpha (PROCRIT) 40 000 IU every week (QW) for 18 weeks (IV or SC)
11638206|NCT00267007|Placebo Comparator|002|Placebo Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
11638207|NCT00266929||Surgical|Subjects receiving surgical treatment for Type II odontoid fracture per discretion of investigator (non-randomized allocation)
11638208|NCT00266929||Non-surgical|Subjects treated with non-operative treatment options
11638209|NCT00266877|Experimental|Prior Tarceva or Iressa With EGFR Mutation|HKI-272 administered to patients whose disease has progressed following > or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor with an EGFR mutation demonstrated at screening
11638210|NCT00266877|Experimental|Prior Tarceva or Iressa w/o EGFR Mutation|HKI-272 administered to patients whose disease has progressed following > or = 12 weeks of treatment with Tarceva or Iressa and who have a tumor without an EGFR mutation demonstrated at screening
11638211|NCT00266877|Experimental|No Prior EGFR Tyrosine Kinase Inhibitor Treatment|HKI-272 administered to patients with no prior EGFR tyrosine kinase inhibitor treatment, adenocarcinoma, < or = 20 pack-year smoking history, and current non-smoker (no requirement for EGFR mutation)
11638212|NCT00266864|Experimental|Testosterone Replacement Therapy|Subjects with Low Testosterone (Hypogonadal) Receive Testosterone Transdermal System (Androderm 5 mg patch)
11638213|NCT00266864|No Intervention|No Intervention|Subjects with normal testosterone levels (eugonadal) participated in identical outcome measurements at parallel time points.
11638214|NCT00266851|Active Comparator|Azithromycin|Active adjunctive treatment
11638215|NCT00266851|Placebo Comparator|Placebo|Adjunctive placebo
11638216|NCT00266851|Other|Observational Cohort|Eligible participants who declined randomization, offered enrollment in parallel, open-label azithromycin treatment arm
11638217|NCT00266838|Placebo Comparator|Lacrystat|Lacrystat
11638218|NCT00266838|Active Comparator|Maxidex|Applying Maxidex
11638219|NCT00266825|Experimental|DHA capsules|DHA capsules
11638220|NCT00266825|Placebo Comparator|Placebo capsules|Placebo capsule
11638221|NCT00266812|Experimental|Chemotherapy with temozolomide and radiotherapy|
11638222|NCT00266812|Active Comparator|Radiotherapy alone|
11638224|NCT00266799|Active Comparator|Capecitabine|
11638225|NCT00266786|Experimental|Intranasal Ketorolac Tromethamine|
11638226|NCT00266786|Placebo Comparator|Intranasal Placebo|
11638227|NCT00266773|No Intervention|1|Control - standard care only
11638228|NCT00266773|Experimental|2|Attention Control - standard care plus 6 months TIVR receiving minimal monthly feedback
11638229|NCT00266773|Experimental|3|Standard care plus 6 months TIVR receiving detailed monthly feedback
11638230|NCT00266708|Experimental|Risedronate|subjects received Risedronate for one year
11638231|NCT00266708|Placebo Comparator|subjects received placebo|subjects received placebo for 1 year
11638232|NCT00266695|Experimental|Ruboxistaurin|
11638233|NCT00266656|Experimental|Experimental 1 Control|"No drug administration in B9R-US-GDFG (NCT00406926).
~Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given."
11638234|NCT00266656|Experimental|Experimental 2 Humatrope|Humatrope according to investigator's clinical practice and guided by the approved package insert on whether treatment is given.
11638235|NCT00266630|Experimental|Olanzapine Monotherapy|"Olanzapine extension for Study BMAC patients who completed Visit 8.
~Patients received olanzapine 5-20 mg for 18 weeks."
11638236|NCT00266630|Experimental|Olanzapine + Mood Stabilizer|"Olanzapine extension for Study BMAC patients who discontinued at Visit 4 or 5.
~Patients received an initial dose of olanzapine 10 mg for 1 week and subsequent doses of olanzapine 5-20 mg for 17 weeks.
~Patients received one (1) mood stabilizer (lithium, valproate or carbamazepine) for 18 weeks."
11638237|NCT00266565|Experimental|Anti-IL5 (Mepolizumab)|The purpose of the study is to assess the toxicity of anti-IL-5 (Mepolizumab), and to see whether it lowers eosinophils in peripheral blood and/or tissue and whether it has a steroid and/or interferon sparing effect.
11638238|NCT00266474||Cross sectional CF study|Multicentric study, including 187 CF patients of all age groupr in 5 CF centres.
11638239|NCT00266461|Experimental|TU-100 7.5g/day|Subjects will be randomized to TU-100 7.5g, 15g, or no active treatment group. Subjects will take a daily dose divided into 3 times a day.
11638240|NCT00266461|Experimental|TU-100 15g/day|Subjects will be randomized to TU-100 7.5g, 15g, or no active treatment group. Subjects will take a daily dose divided into 3 times a day.
11638241|NCT00266461|No Intervention|Water|Subjects will be randomized to TU-100 7.5g, 15g, or no active treatment group. Subjects will take a daily dose divided into 3 times a day.
11638242|NCT00266409|Experimental|Panic: Niravam+SSRI/SNRI|Panic Disorder: Niravam plus a newly prescribed SSRI or SNRI
11638243|NCT00266409|Experimental|Panic: SSRI/SNRI alone|Panic Disorder: Newly prescribed SSRI or SNRI alone
11638244|NCT00266409|Experimental|GAD: Niravam+SSRI/SNRI|Generalized Anxiety Disorder: Niravam plus a newly prescribed SSRI or SNRI
11638245|NCT00266409|Experimental|GAD: SSRI/SNRI alone|Generalized Anxiety Disorder: Newly prescribed SSRI or SNRI alone
11638246|NCT00266396|Experimental|weight-bearing recommendation|Weight-bearing recommendation after THA and TKA
11638247|NCT00266331|Active Comparator|Group A, RayGel Topical Cream|RayGel Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
11638248|NCT00266331|Placebo Comparator|Arm B Placebo Topical Cream|Placebo Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
11638249|NCT00266305|Experimental|Fish oil|
11638250|NCT00266305|Placebo Comparator|Olive oil|Control group
11638251|NCT00266305|No Intervention|High fish|Reference group
11638252|NCT00266279|Experimental|Treatment with Study Drugs|Treatment with combination of oxaliplatin and capecitabine using study dose and schedule.
11638253|NCT00266253|Experimental|1|
11638254|NCT00266253|Experimental|2|
11638255|NCT00266253|Experimental|3|
11638256|NCT00266253|Experimental|4|
11638257|NCT00266253|Experimental|5|
11638258|NCT00266253|Active Comparator|6|
11638259|NCT00266240|Experimental|1|
11638260|NCT00266240|Experimental|2|
11638261|NCT00266240|Experimental|3|
11638262|NCT00266240|Experimental|4|
11638263|NCT00266240|Placebo Comparator|5|
11638264|NCT00266227|Experimental|Arm A: Rituximab Retreatment|1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.
11638265|NCT00266227|Placebo Comparator|Arm B: Placebo Retreatment|1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by retreatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/week methotrexate.
11638266|NCT00266214|Experimental|Lidocaine Patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.
11638267|NCT00266214|Placebo Comparator|Placebo|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.
11638268|NCT00266110|Experimental|Dendritic Cell Vaccine|Therapeutic autologous dendritic cells (Dendritic Cell Vaccine) i.d. injection, 20 x 106 DCs given per treatment Trastuzumab infusion Vinorelbine ditartrate infusion
11638269|NCT00266097|Experimental|Part I|Oxaliplatin + Gemcitabine + Radiation
11638270|NCT00266097|Experimental|Part II|Erlotinib + Oxaliplatin + Gemcitabine + Radiation
11638271|NCT00266058|Active Comparator|Lopinavir/ritonavir, artemethr/lumefantrine|Determination of the antimalarial drug levels artemether/lumefantrine in the absence and in the presence of co-administered antiretrovirals lopinavir and ritonavir.
11638272|NCT00266058|Active Comparator|efavirenz, artemether, lumefantrine|Determination of the antimalarial drug levels artemether/lumefantrine in the absence and in the presence of co-administered antiretroviral efavirenz.
11638310|NCT00265616|Active Comparator|1|propofol, 2mg/kg as bolus, then titrated up to EEG burst-suppression as a continuous infusion; no maximum doses defined
11638311|NCT00265616|Active Comparator|2|thiopental/pentobarbital, 2mg/kg as bolus, then titrated up to EEG burst-suppression as a continuous infusion; no maximum doses defined
11638357|NCT00265122|Experimental|Population 2: Ustekinumab IV|Ustekinumab 4.5 mg given as one intravenous (IV) infusion at Week 0 during Intervention Period 1. No intervention given during Intervention Period 2.
11638273|NCT00266032|Experimental|Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
11638274|NCT00266032|Experimental|Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
11638275|NCT00266032|Active Comparator|Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
11638276|NCT00265993|Experimental|1|enoxaparin
11638277|NCT00265980|No Intervention|Weight initial|Subjects undergo studies at their usual body weight which is used as a baseline against which to compare subjects following weight loss with or without leptin repletion.
11638278|NCT00265980|Placebo Comparator|Weight -10% placebo|Subjects are studied while at a 10% reduced body weight and receiving placebo injections for 5 weeks.
11638279|NCT00265980|Experimental|Weight -10% leptin|Subjects are studied while at a 10% reduced body weight and receiving leptin injections for 5 weeks.
11638280|NCT00265967|Experimental|1|Irbesartan
11638281|NCT00265954|Experimental|1|Individuals in this arm receive a 6 month behavioral weight loss intervention delivered on-line. Groups meet via a web chat weekly for 24 weeks and monthly for the following 12 months.
11638282|NCT00265954|Experimental|2|In-person; Individuals in the in-person condition attend weekly group behavioral weight loss sessions for 24 weeks and then monthly sessions for the following 12 months.
11638283|NCT00265954|Experimental|3|In-person+internet; Individuals in this condition receive a behavioral weight loss intervention over the internet weekly for 24 weeks and monthly for the following 12 months. Every month during the first 24 weeks and every third month during the following year they have an in-person meeting.
11638284|NCT00265941|Active Comparator|RT + cisplatin|Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin
11638285|NCT00265941|Experimental|RT + cisplatin + cetuximab|Radiation therapy (RT) as accelerated fractionation by concomitant boost (AFX-CB) or intensity-modulated radiation therapy (IMRT) plus cisplatin plus cetuximab
11638286|NCT00265889|Experimental|Poor Risk|Primary progressive, recurrent, or resistant relapse patients
11638287|NCT00265889|Experimental|Good Risk|First recurrence patients
11638288|NCT00265876|Experimental|AZD0530 + Gemcitabine|
11638289|NCT00265863|Experimental|Patients with Malignant Ascites|Patients meeting protocol criteria enrolled with malignant ascites.
11638290|NCT00265850|Active Comparator|Arm A: FOLFOX or FOLFIRI + bevacizumab|Patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
11638291|NCT00265850|Experimental|Arm B: FOLFOX or FOLFIRI + cetuximab|Patients receive cetuximab 400mg/m^2 IV over 2 hours on the first day of treatment, then 250 mg/m^2 IV over 1 hour weekly thereafter. Patients also receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
11638292|NCT00265850|Experimental|Arm C: FOLFOX or FOLFIRI + cetuximab + bevacizumab|Patients receive cetuximab 400mg/m^2 IV over 2 hours on the first day of treatment, then 250 mg/m^2 IV over 1 hour weekly thereafter. Also, patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.
11638293|NCT00265824|Active Comparator|bevacizumab alone|
11638294|NCT00265824|Experimental|Bevacizumab + erlotinib|
11638295|NCT00265811|Experimental|Folfox+Cetuximab|FOLFOX-4 Cetuximab alone every 2 weeks
11638296|NCT00265811|Active Comparator|Folfox|FOLFOX-4 alone every 2 weeks
11638297|NCT00265798|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11638298|NCT00265785|Experimental|Pemetrexed|pemetrexed
11638299|NCT00265759|Experimental|Arm I|Patients receive oral exemestane once daily for up to 16-18 weeks.
11638300|NCT00265759|Experimental|Arm II|Patients receive oral letrozole once daily for up to 16-18 weeks.
11638301|NCT00265759|Experimental|Arm III|Patients receive oral anastrozole once daily for up to 16-18 weeks.
11638302|NCT00265733|Experimental|paclitaxel + capecitabine|"Patients receive paclitaxel poliglumex IV (CT-2103; Xyotax™) over 10-20 minutes on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~After completion of study treatment, patients are followed every 6 months for up to 5 years."
11638303|NCT00265720|Placebo Comparator|Control|Written materials only
11638304|NCT00265720|Experimental|Reduced out-of-pocket expense|Reimbursed up to $500 out-of-pocket expense for colorectal cancer screening
11638305|NCT00265720|Experimental|One-on-one education|Individual education with a health educator on CRC screening
11638306|NCT00265720|Experimental|Group Education|Education on CRC screening in a small group with a health educator
11638307|NCT00265642|Experimental|group verum|Drug: Irbesartan
11638308|NCT00265642|Placebo Comparator|group placebo|
11638309|NCT00265629|Experimental|1|RF ablation
11638358|NCT00265109|Other|open label|Open-label trial; all participants received levetiracetam
11638312|NCT00265603|Experimental|1 Arm|The investigators plan to have approximately 16 persons participate in the study of transimmunization. Transimmunization uses a device, called a UVAR-XTS instrument, to remove a portion of blood, part of which is returned, and part of which is incubated overnight before being returned to the bloodstream the next day
11638313|NCT00265564|Active Comparator|Seeking Safety|Seeking Safety is a manualized, empirically supported, cognitive behavioral therapy that treats substance use disorders and comorbid PTSD. Participants assigned to the Seeking Safety arm attend two one hour sessions of group therapy for 12 weeks.
11638314|NCT00265564|Active Comparator|Usual Care|Usual Care Condition. Patients randomized to usual care will receive standard outpatient SUD treatment.
11638315|NCT00265538|No Intervention|Arm 1 (Pure Control Group)|Pure control (no intervention letter);
11638316|NCT00265538|No Intervention|Arm 2 (Contaminated Control Group)|Intervention control (patient does not receive intervention letter, but provider sees other patients who may bring in letter);
11638317|NCT00265538|Experimental|Arm 3 (Intervention Group A)|Intervention group A (the intervention is a letter only mailed to the subject); This intervention group receives an educational letter, which is the intervention. It is an educational intervention only.
11638318|NCT00265538|Experimental|Arm 4 (Intervention Group B)|Intervention group B (intervention letter A + financial incentive for discussion w/ provider and 6 month copay reimbursement); This group receives the same educational intervention as Group A, but also receives the Financial incentive, which is an added intervention.
11638319|NCT00265538|Experimental|Arm 5 (Intervention Group C)|Intervention group C (intervention letter A, financial incentive for discussion w/ provider + copay reimbursement, PLUS reminder phone call 1-3 days prior to primary care visit). This group receives the same intervention as Group B, but with the added intervention of a reminder phone call to test whether additional prompting is needed to make the intervention more effective.
11638320|NCT00265525|Experimental|Cardio fit|
11638321|NCT00265525|No Intervention|Usual Care|
11638322|NCT00265512|Active Comparator|Telephone Case Monitoring Aftercare|Telephone Case Monitoring Aftercare
11638323|NCT00265512|Active Comparator|Continuing Care as Usual|Continuing Care as Usual
11638324|NCT00265473|Experimental|Allogeneic Islets of Langerhans|Islet infusion
11638325|NCT00265447|Active Comparator|Strength training|3 months of strength training
11638326|NCT00265447|Active Comparator|Aerobic conditioning|3 months of aerobic conditioning
11638327|NCT00265447|Other|Delayed exercise|delayed exercise control group
11638328|NCT00265434|Active Comparator|Dornase alfa|DBPC-cross over trial
11638329|NCT00265434|Placebo Comparator|isotonic saline|
11638330|NCT00265408|Experimental|aspirin|
11638331|NCT00265408|Experimental|warfarin|
11638332|NCT00265395|Active Comparator|Standard therapy|Slow responders (defined as being polymerase chain reaction [PCR] positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to stop treatment at Week 48.
11638333|NCT00265395|Experimental|Extended therapy|Slow responders (defined as being PCR positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to continue treatment to Week 72.
11638334|NCT00265382|Other|Open|
11638335|NCT00265356|Experimental|1|PET diagnostic imaging
11638336|NCT00265356|No Intervention|2|No PET
11638337|NCT00265343|Experimental|1|asenapine
11638338|NCT00265343|Active Comparator|2|olanzapine
11638339|NCT00265330|Experimental|Open|
11638340|NCT00265317|Experimental|A|
11638341|NCT00265317|Active Comparator|B|
11638342|NCT00265239|Active Comparator|1|Edaravone Group
11638343|NCT00265239|No Intervention|2|Placebo Group
11638344|NCT00265226|Experimental|1|In one arm the patient will receive intradermal Mycobacterium W Vaccine along with Category II ATT according to RNTCP guidelines
11638345|NCT00265226|Placebo Comparator|2|In this Arm patient will receive Placebo along with Category II ATT drugs according to RNTCP guidelines
11638346|NCT00265200|Experimental|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
11638347|NCT00265148|Experimental|Rosiglitazone|4 mg once a day for 1 month increasing to 8 mg once a day (Extended Released Tablets)
11638348|NCT00265148|Other|Placebo|Placebo dummy to match
11638349|NCT00265135|Experimental|Part 1 (CNTO 328)|In Part 1 of the study, 4 intravenous infusions (IV) [injection of a substance into a vein] of CNTO 328 will be administered to patients in 4 dose levels ranging from 1, 3, 6, and 12 mg/kg on days 1, 29, 43, and 57 to determine the maximum tolerated dose for Part 2 of the study.
11638350|NCT00265135|Experimental|Part 2 (CNTO 328)|In Part 2 of the study, 2 well tolerated dose levels of CNTO 328 from Part 1 of the study will be administered every 3 weeks as 4 IV infusions to patients.
11638351|NCT00265135|Experimental|Part 3 (CNTO 328)|In Part 3 of the study, CNTO 328 at a dose level of 6 mg/kg will be administered as IV infusion every 2 weeks for at least 6 doses.
11638352|NCT00265122|Experimental|Population 1: Placebo SC followed by ustekinumab SC|Placebo injected subcutaneously (SC) once a week for 4 weeks (Weeks 0-3) during Intervention Period 1 followed by ustekinumab 90 mg SC once a week for 4 weeks (Weeks 8-11) during Intervention Period 2.
11638353|NCT00265122|Experimental|Population 1: Ustekinumab SC followed by Placebo SC:|Ustekinumab 90 mg injected subcutaneously (SC) once a week for 4 weeks (Weeks 0-3) during Intervention Period 1 followed by ustekinumab 90 mg SC once a week for 4 weeks (Weeks 8-11) during Intervention Period 2.
11638354|NCT00265122|Experimental|Population 1: Placebo IV followed by ustekinumab IV|Placebo given as 1 intravenous (IV) infusion at Week 0 during Intervention Period 1 and ustekinumab 4.5 mg/kg given as one IV infusion at Week 8 during Intervention Period 2.
11638355|NCT00265122|Experimental|Population 1: Ustekinumab IV followed by Placebo IV:|Ustekinumab 4.5 mg/kg given as one intravenous(IV) infusion at Week 0 during Intervention Period 1 followed by placebo given as one IV infusion at Week 8 during Intervention Period 2.
11638356|NCT00265122|Experimental|Population 2: Ustekinumab SC|Ustekinumab 90 mg injected subcutaneously (SC) once a week at Weeks 0-3 during Intervention Period 1. No intervention given during Intervention Period 2.
11638410|NCT00264576|Experimental|cTIV|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
11638359|NCT00265096|Experimental|002|golimumab 50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
11638360|NCT00265096|Experimental|001|Placebo; golimumab SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
11638361|NCT00265096|Experimental|003|golimumab 100 mg sc injections every 4 wks from wk 0 up to 5 yrs
11638362|NCT00265083|Experimental|003|golimumab 100 mg sc injections every 4 wks from wk 0 up to 5 yrs
11638363|NCT00265083|Placebo Comparator|001|Golimumab (CNTO 148); placebo SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
11638364|NCT00265083|Experimental|002|golimumab 50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
11638365|NCT00265044|Other|Arm 1|
11638366|NCT00265018|Active Comparator|Arm A|
11638367|NCT00265018|Experimental|Arm B|
11638368|NCT00265018|Experimental|Arm C|
11638369|NCT00265018|Experimental|Arm D|
11638370|NCT00265005|Experimental|All|All subjects receive active drug up to a total of 3 doses
11638371|NCT00264979|Other|1|Simultaneous surgery of colorectal cancer and synchronous liver metastases
11638372|NCT00264979|Other|2|Sequential surgeries of colorectal cancer and synchronous liver metastases
11638373|NCT00264953|Active Comparator|A|4x ABVD plus 30Gy IF-RT
11638374|NCT00264953|Experimental|C|4x BEACOPP baseline plus 30Gy IF-RT
11638375|NCT00264953|Experimental|B|4x ABVD plus 20Gy IF-RT
11638376|NCT00264953|Experimental|D|4x BEACOPP baseline plus 20Gy IF-RT
11638377|NCT00264875|Experimental|1|
11638378|NCT00264849|Experimental|OAT + Omalizumab|During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. During the treatment phase, participants continued to receive optimized asthma therapy (OAT), plus omalizumab add on therapy for 32 weeks, administered by subcutaneous injection once every 4 weeks. The dosage received was individualized based on body weight and serum IgE level.
11638379|NCT00264849|Active Comparator|Optimized Asthma Treatment (OAT)|During the 8-week Run-in phase, asthma therapy was evaluated and optimized according to Global Initiative for Asthma (GINA) guidelines. In the treatment phase, participants continued to receive optimized asthma therapy (OAT) established during the run-in period of the study for 32 weeks.
11638380|NCT00264823|Experimental|1 - Experimental|
11638381|NCT00264823|No Intervention|2 - Control|
11638382|NCT00264810|Active Comparator|Treatment Group (stimulation ON)|Group of subjects that have undergone RNS® System implantation that are randomized to receive RNS® System responsive stimulation (i.e. responsive stimulation enabled or turned ON) during the Blinded Evaluation Period. Stimulation is enabled during the Stimulation Optimization Period (second month post-implant) and may continue throughout the subject's participation in the study.
11638383|NCT00264810|Sham Comparator|Sham Group (stimulation OFF)|Group of subjects that have undergone RNS® System implantation that are randomized to receive sham-stimulation (i.e. responsive stimulation disabled or turned OFF) during the Blinded Evaluation Period. Stimulation is enabled after transition into the Open Label Period (sixth month post-implant) and may continue for the remainder of the subject's participation in the study.
11638384|NCT00264797|Active Comparator|Methylphenidate|
11638385|NCT00264797|Placebo Comparator|Methylphenidate (Placebo)|
11638386|NCT00264758|Active Comparator|Conventional hemodialysis|Three times per week in-center hemodialysis
11638387|NCT00264758|Experimental|Frequent hemodialysis|Six times per week in-center hemodialysis
11638388|NCT00264745|Experimental|1|
11638389|NCT00264745|Active Comparator|2|
11638390|NCT00264732|Experimental|1|
11638391|NCT00264732|Experimental|2|
11638392|NCT00264732|Placebo Comparator|3|
11638393|NCT00264719|Active Comparator|A|Mothers with pre-term deliveries will receive metoclopramide 10 mg three times a day for the first 7 days and 2 times a day for the 8th to 10th day, and once a day for the 11th to 12th day
11638394|NCT00264719|Placebo Comparator|B|Mothers with pre-term deliveries will receive metoclopramide 10 mg 3 times a day, 2 times a day from 8th to 10th day and once a day from 11th to 12th day
11638395|NCT00264719|Active Comparator|C|Mothers with full term deliveries will receive 10 mg metoclopramide, 3 times a day for the first 7 days, 2 times a day from 8th to 10th day, and once a day for day 11 to 12
11638396|NCT00264719|Placebo Comparator|D|Mothers with full term deliveries will receive the placebo 10 mg three times a day, for 7 days, and two times a day from day 8 to day 10, and once a day from 11th to 12th day
11638397|NCT00264706|Other|Participant|Internal control study
11638398|NCT00264693||P - A|Prophylactic Dosage, GFR >= 60 mL/min/1.73m^2
11638399|NCT00264693||P - B|Prophylactic Dosage, GFR 30-59 mL/min/1.73m^2
11638400|NCT00264693||P - C|Prophylactic Dosage, GFR < 30 mL/min/1.73m^2
11638401|NCT00264693||P - CAPD|Prophylactic Dosage, CAPD
11638402|NCT00264693||T - A|Therapeutic Dosage, GFR >= 60 mL/min/1.73m^2
11638403|NCT00264693||T - B|Therapeutic Dosage, GFR 30-59 mL/min/1.73m^2
11638404|NCT00264693||T - C|Therapeutic Dosage, GFR < 30 mL/min/1.73m^2
11638405|NCT00264693||T - CAPD|Therapeutic Dosage, CAPD
11638406|NCT00264641|Experimental|High RAS activity|10 healthy men were characterized by having high basal RAS activity.
11638407|NCT00264641|Experimental|Low RAS activity|10 healthy men were characterized by having either a low basal RAS activity.
11638408|NCT00264602|Experimental|Near Infrared Imaging|The intervention to be administered is indocyanine green dye.
11638409|NCT00264589|Other|Study Population|"non-diabetic obese subjects and type 2 diabetic subjects
~Intervention: 8 weeks individualized training program"
11638411|NCT00264576|Active Comparator|TIV|Received one dose of egg-derived trivalent vaccine (TIV).
11638412|NCT00264563||Behavioral|The intervention is basically by letting the care givers to be aware that there is active recording of iatrogenesis
11638413|NCT00264550|Placebo Comparator|Group 1: Placebo + Methotrexate|Placebo subcutaneous (SC) injections every 4 weeks from Week 0 to Week 20 (early escape at Week 16); Methotrexate - 15 to 25mg weekly from Week 0 up to 5 yrs; Golimumab - if early escape, 50mg SC injections every 4 weeks from Week 16 up to 5 years; Golimumab - 50 mg SC injections every 4 weeks from Week 24 up to 5 yrs (unless early escape); Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
11638414|NCT00264550|Experimental|Group 2: Golimumab 100 mg + Placebo|Golimumab 100 mg SC injections every 4 weeks from Week 0 up to 5 yrs; Placebo - 7-10 capsules weekly during blinded period (or Week 16 if early escape); Methotrexate - if early escape, 15 to 25mg weekly from Week 16 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
11638415|NCT00264550|Experimental|Group 3: Golimumab 50 mg + Methotrexate|Golimumab 50 mg SC injections every 4 weeks from Week 0 up to 5 yrs (unless early escape at Week 16); Methotrexate - 15 to 25 mg weekly from Week 0 up to 5 years; Golimumab - if early escape, 100 mg SC injections every 4 weeks from Week 16 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to100mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
11638416|NCT00264550|Experimental|Group 4: Golimumab 100 mg + Methotrexate|Golimumab100 mg SC injections every 4 weeks from Week 0 up to 5 yrs; Methotrexate - 15 to 25 mg weekly from Week 0 up to 5 yrs; Methotrexate - Dr's discretion, weekly dose adjusted after unblinding; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
11638417|NCT00264537|Experimental|Group 1: Placebo + Methotrexate|Placebo subcutaneous injections (SC) every 4 weeks from Week 0 for up to 5 years (unless early escape at week 28); Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - if early escape, 50 mg SC injections every 4 weeks from Week 28 up to 5 years; Golimumab - Dr's discretion after unblinding (in participants receiving methotrexate plus placebo), 50 mg SC injections every 4 weeks up to 5 years; Golimumab- Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
11638418|NCT00264537|Experimental|Group 2: Golimumab 100 mg + Placebo|Golimumab 100 mg SC injections every 4 weeks from Week 0 for up to 5 years; placebo capsules weekly from Week 0 for up to 5 years (unless early escape at Week 28); Methotrexate - if early escape, 10 to 20 mg weekly from Week 28 up to 5 years; Methotrexate - Dr's discretion after unblinding (in participants receiving golimumab plus placebo) 10 to 20 mg weekly for up to 5 years; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
11638419|NCT00264537|Experimental|Group 3: Golimumab 50 mg + Methotrexate|Golimumab 50 mg SC injections every 4 weeks from Week 0 for up to 5 years (unless early escape at week 28); Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - if early escape, 100 mg SC injections every 4 weeks from Week 28 for up to 5 yrs; Golimumab - Dr's discretion after unblinding, dose adjusted from 50 to 100 mg and from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
11638420|NCT00264537|Experimental|Group 4: Golimumab 100 mg + Methotrexate|Golimumab 100 mg SC injections every 4 weeks from Week 0 for up to 5 years; Methotrexate - 10 to 20 mg weekly from Week 0 for up to 5 years; Golimumab - Dr's discretion after unblinding, dose adjusted from 100 to 50mg. Duration of the blinded period will be until the week-52 database lock.
11638421|NCT00264511|Experimental|Hyperbaric oxygenation|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
11638422|NCT00264511|No Intervention|No hyperbaric oxygenation|Patients randomised to this group will receive standard trauma care.
11638423|NCT00264498|Active Comparator|1|Gemcitabine + Carboplatin
11638424|NCT00264498|Experimental|2|Gefitinib
11638425|NCT00264459|Placebo Comparator|Placebo|Placebo was given the same way as a sublingual preparation.
11638426|NCT00264459|Experimental|Liquid formulation of an extract of a 6 grass pollen mixture|"Sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.
~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter. Initial treatment was applied on the first day of treatment with a starting dose of 25% of the maintenance dose. Increasing doses of 50% were applied with the second and 100% with the third dose to give the maximum (=maintenance) dose. This was followed by a daily patient selfadministered treatment with the maintenance dose."
11638427|NCT00264420|Experimental|1|zoledronic acid plus radiation therapy
11638428|NCT00264394|Experimental|Updated CHD risk profiles|Provision of regularly updated CHD risk profiles
11638429|NCT00264394|Active Comparator|Guidelines|Physicians received guidelines only
11638430|NCT00264381|Active Comparator|Ibuprofen|Ibuprofen 800mg tid X 7 days + additional 7 days determined by protocol
11638431|NCT00264303|Experimental|Levocetirizine|Levocetirizine, once daily, 4 week duration
11638432|NCT00264303|Active Comparator|Desloratadine|Desloratadine, once daily, 4 week duration
11638433|NCT00264290|Experimental|Valganciclovir|900mg PO qd
11638434|NCT00264290|Placebo Comparator|Placebo|900mg PO qd
11638435|NCT00264264|Active Comparator|Direct Compression|
11638436|NCT00264264|Active Comparator|Closure Device|
11638437|NCT00264238|Experimental|Memantine open label|All subjects knowingly received (open label) memantine for up to 12 weeks with a target dose of 10 mg twice a day (20mg/d) taken orally.
11638438|NCT00264199|Active Comparator|1|
11638439|NCT00264199|Placebo Comparator|2|
11638440|NCT00264160|Experimental|AMN107|
11638441|NCT00264147|Experimental|Period I: 1|etoricoxib
11638442|NCT00264147|Experimental|Period I: 2|etoricoxib
11638443|NCT00264147|Experimental|Period I: 3|etoricoxib
11638444|NCT00264147|Experimental|Period I: 4|etoricoxib
11638445|NCT00264147|Placebo Comparator|Period I: 5|Placebo
11638446|NCT00264147|Experimental|Period II: 1|etoricoxib
11638447|NCT00264147|Active Comparator|Period II: 2|diclofenac
11638448|NCT00264108||1|Epoetin alfa 40 000 IU once weekly variable treatment length.
11638449|NCT00264108||2|Darbepoetin alfa Either 150 ug once weekly or 500 ug once every 3 wks variable treatment length.
11638450|NCT00264095||001|
11638451|NCT00264069||001|
11638452|NCT00264069||002|
11638453|NCT00264043|Experimental|1|AngioGuard™ device and Bx Velocity™ stent
11638454|NCT00264030|Other|1|PTCA
11638455|NCT00264030|Other|2|PTCA with angioguard
11638456|NCT00264004|Experimental|1|30 mg AZD2171
11638457|NCT00264004|Experimental|2|45 mg AZD2171
11638458|NCT00263939|Experimental|1 - In home intervention|In home (face to face) delivery of the study intervention, Homing in on Health
11638459|NCT00263939|Experimental|2 - Telephone intervention|Telephone delivery of the study intervention, Homing in on Health
11638460|NCT00263939|No Intervention|3 - Usual care|Patients receiving the care their usual health providers supply, without an study intervention
11638461|NCT00263887|Experimental|Group 1|Prolastin
11638462|NCT00263887|Placebo Comparator|Group 2|
11638463|NCT00263809|Experimental|1|Treatment, Mirasol-treated platelets
11638464|NCT00263809|No Intervention|2|Reference, Untreated platelets
11638465|NCT00263796|Experimental|Pitocin|
11638466|NCT00263796|Placebo Comparator|Placebo|
11638467|NCT00263783|Experimental|1|MEDI-522
11638468|NCT00263770|Other|Positive airway pressure (PAP)|which is air delivered by a mask worn over the nose during sleep
11638469|NCT00263770|Active Comparator|outpatient surgical procedure|where small fabric rods are inserted into the soft palate (the fleshy portion of the roof of the mouth) to stiffen the tissues.
11638470|NCT00263770|Sham Comparator|Sham surgery|an outpatient surgical procedure identical to #2 except that no rods are inserted into the soft palate.
11638471|NCT00263757|Experimental|Therapeutic Positive Airway Pressure|Subjects randomized to this arm received nightly Adaptive Servo-Ventilation during sleep for 12 months.
11638472|NCT00263757|Other|Usual Care|Subjects randomized to this arm received medical management for 12 months as prescribed by their cardiologist.
11638473|NCT00263744|Experimental|1|MEDI517
11638474|NCT00263744|Active Comparator|2|Aluminum hydroxide
11638475|NCT00263731||Group 1 (Experimental Group)|250 subjects with suspected or confirmed lung cancer undergoing surgical resection, will receive 13-C-glucose prior to surgery
11638476|NCT00263731||Group 2 (Control Group)|250 subjects with suspected or confirmed lung cancer undergoing surgical resection, will not receive 13-C-glucose prior to surgery
11638477|NCT00263731||Group 3 (Healthy Subjects)|250 healthy subjects (must be at least 30 years of age and have no prior history of diagnosed lung cancer) will provide 1 blood sample and 1 urine sample.
11638478|NCT00263705|Experimental|capecitabine|capecitabine 2000 mg/m² daily
11638479|NCT00263666|Experimental|Rotarix Group|Subjects received 3 doses of Rotarix vaccine co-administered with routine Tritanrix HepB Hib and Polio Sabin vaccines.
11638480|NCT00263666|Placebo Comparator|Placebo Group|Subjects received 3 doses of placebo co-administered with routine Tritanrix HepB Hib and Polio Sabin vaccines.
11638481|NCT00263640|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Children received lifestyle counselling.
11638482|NCT00263640|Experimental|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
11638483|NCT00263627|Placebo Comparator|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
11638484|NCT00263627|Experimental|Specific Immunotherapy|Subcutaneous injections with birch pollen allergoid were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
11638485|NCT00263601|Experimental|Allergovit 6-grasses immunotherapy|Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.
11638486|NCT00263601|Placebo Comparator|Placebo|Placebo injections was given the same way: Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.
11638487|NCT00263588|Experimental|single arm|750 mg lapatinib administered orally twice daily
11638488|NCT00263575|Experimental|sublingual fentanyl tablet|
11638489|NCT00263562|Experimental|Steroid arm|Receipt of methyprednisolone pulse dose: 15mg/kg to a maximum of 1 gram; following this, the patients also received a steroid taper with oral prednisone:Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily
11638490|NCT00263562|Placebo Comparator|Comparison Group|Patients receiving usual care, with receipt of placebo (saline in lieu of intravenous methylprednisolone infusion or a number of placebo pills equivalent in number to what would have been received for the prednisone.
11638491|NCT00263484|Experimental|"dtZ regimen, Initial therapy"|"To test the efficacy of the dtZ regimen in previously untreated patients with multiple myeloma."
11638492|NCT00263458|Experimental|Integrated|Buprenorphine maintenance treatment delivered at an HIV primary care clinic
11638493|NCT00263458|Active Comparator|Non-integrated|Buprenorphine maintenance treatment delivered at a public health substance use disorder clinic
11638494|NCT00263432|Experimental|1|Implantation of fresh human allogenic chondrocytes
11638495|NCT00263393|Other|Algorithm-based care|An algorithm based approach to increase the identification of high-risk individuals in the community through encouraging opportunistic screening, and to increase the use of appropriate evidence based prevention strategies.
11638496|NCT00263393|Other|Health-promotion|The health promotion arm has been designed to increase knowledge of the causes of cardiovascular disease and enhance use of preventive behaviours in the general population
11638497|NCT00263367|Other|hyperbaric oxygen at 1.3 ATA|Hyperbaric Oxygen at 1.3 ATA for one hour followed by measurement of glutathione in the blood
11638498|NCT00263328|Active Comparator|Treatment group 1|Standard of care
11638499|NCT00263328|Experimental|Treatment group 2|Treatment group 2 also receives mycophenolate mofetil
11638500|NCT00263328|Experimental|Treatment group 3|Treatment group 3 does not receive mycophenolate mofetil
11638501|NCT00263276|Experimental|Arm 1|
11638502|NCT00263276|Experimental|Arm 2|
11638503|NCT00263276|Experimental|Arm 3|
11638504|NCT00263276|Experimental|Arm 4|
11638505|NCT00263276|Experimental|Arm 5|
11638506|NCT00263276|Placebo Comparator|Arm 6|
11638507|NCT00263276|Active Comparator|Arm 7|
11638508|NCT00263211|Experimental|Plavix and Aspirin|Patients will receive a 300 mg loading dose of Plavix on day 1, followed by 75 mg/day, and aspirin 81 mg per day starting day 1. Treatment will be continued until the treating physician elects to resume systemic therapy for the treatment of breast cancer or until unacceptable toxicity is observed. A pill diary will be collected monthly to monitor patients' compliance with the medication regimen.
11638509|NCT00263211|No Intervention|Observation only|Observation by treating physician
11638510|NCT00263198|Experimental|Letrozole + PTK787/ZK222584|"Letrozole 2.5 mg PO daily for 28 days (patients who have already been treated with letrozole for at least 28 days can skip this part)
~Start cycle 1 with:
~Letrozole 2.5 mg PO once daily
~PTK787/ZK222584 250 mg BID PO for 1 week, then 500 mg BID PO for the 2nd week followed by 500 mg qAM and 750 mg QPM PO for the subsequent 2 weeks.
~Subsequent cycles:
~PTK787/ZK222584 500 mg qAM and 750 mg qPM PO daily
~Letrozole 2.5 mg PO once daily"
11638511|NCT00263185|Experimental|Active Treatment Group|"Patients with baseline 25OH vitamin D level of 10-19 ng/ml.
~Calcium carbonate 1000 mg/day
~Vitamin D 400 units daily.
~Vitamin 50,000 IU/wk x 16 weeks and then once a month for a total of 6 months.
~Patients with baseline 25OH vitamin D level of 20-29 ng/ml.
~Calcium carbonate 1000 mg/day
~Vitamin D 400 units daily.
~Vitamin 50,000 IU/wk x 8 weeks and then once a month for a total of 6 months."
11638512|NCT00263185|Placebo Comparator|Control Group|"Patients with baseline 25OH vitamin D level of 10-19 ng/ml.
~Calcium carbonate 1000 mg/day
~Vitamin D 400 units daily.
~Placebo once per week x 16 weeks and then once a month for a total of 6 months.
~Patients with baseline 25OH vitamin D level of 20-29 ng/ml.
~Calcium carbonate 1000 mg/day
~Vitamin D 400 units daily.
~Placebo once per week x 8 weeks and then once a month for a total of 6 months."
11638513|NCT00263185|Other|Observational Group|"Patients with a baseline Vitamin D level below 10 ng/ml.
~Calcium carbonate 1000 mg/day
~Vitamin D 400 units daily."
11638514|NCT00263081|Experimental|Lapaquistat Acetate QD|(and current lipid-lowering treatment)
11638515|NCT00263081|Placebo Comparator|Current lipid-lowering treatment|
11638516|NCT00263068|Experimental|1|Up to 6.75 mg/day (optimal dosing)
11638517|NCT00263042|Experimental|Rimonabant|Rimonabant 20 mg once daily
11638518|NCT00263042|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
11638519|NCT00263029|Experimental|1|
11638520|NCT00262990|Experimental|Patupilone|
11638521|NCT00262990|Active Comparator|doxorubicin|
11638522|NCT00262964|Experimental|NAFLD-Niacin|Subjects, having previously diagnosed with NAFLD, were given Niacin for 16 weeks. The dosage was 500mg/day for week 1, 1000mg/day for week 2, 1500mg/day for week three and 2000mg/day for weeks 4 through 16.
11638523|NCT00262964|No Intervention|Control|Subjects were found to have intrahepatic triglyceride levels below the threshold for Non-Alcoholic Fatty Liver Disease (NAFLD). For this study that threshold was set at 10% intrahepatic triglyceride content as determined by magnetic resonance spectroscopy. These control subjects did not participate in any intervention. Only baseline features were characterized for this arm.
11638524|NCT00262964|Experimental|NAFLD-fenofibrate|Subjects diagnosed with NAFLD were randomized to fenofibrate, an oral medication, nightly for eight weeks. Subjects will be given a dose of 200mg/day.
11638525|NCT00262964|Placebo Comparator|NAFLD-placebo|These subjects were diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD) and received an 8 week course of a placebo pill. Their baseline characteristics were averaged into the overall NAFLD baseline characteristics along with the baseline data for the two intervention groups.
11638526|NCT00262951|Experimental|Pancreatic Adenocarcinoma Patients|Pancreatic Adenocarcinoma Patients treated with chemotherapy regimen and radiation (and or surgery).
11638527|NCT00262938|Active Comparator|Lifestyle counseling|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling.Patients undergo quality of life, exercise, and clinical assessments at baseline and at 3, 6, and 12 months.
11638528|NCT00262938|Active Comparator|Without Counseling|Patients undergo quality of life, exercise, and clinical assessments at baseline and at 3, 6, and 12 months.
11638529|NCT00262925|Experimental|Treatment (chemotherapy, enzyme inhibitor therapy)|"INDUCTION THERAPY: Patients receive methotrexate IV; vincristine IV and asparaginase IM ; oral dexamethasone ; and alemtuzumab SC.
~CONSOLIDATION THERAPY: Patients receive methotrexate IV and asparaginase IM.
~CYTOREDUCTION THERAPY: Patients receive vincristine IV and methotrexate IV; leucovorin calcium IV; and oral dexamethasone.
~MAINTENANCE THERAPY: Patients receive oral mercaptopurine; oral methotrexate; vincristine IV; and oral dexamethasone."
11638530|NCT00262899|Experimental|Rapid genetic counseling|Following randomization, participants will be informed about whether they are assigned to Usual Care (UC) or Rapid Genetic Counseling (RGC). Participants in the UC arm can schedule a genetic counseling appointment at any time during the study if they wish. Participants in the RGC agree to obtain genetic counseling as soon as possible, before they make a definitive surgery decision. RGC can be accomplished by telephone or in-person. The RGC intervention is delivered by highly experienced genetic counselors at each site. This counseling is identical to our standard genetic counseling procedure for newly diagnosed patients. Immediate DNA collection via blood or buccal cell collection is available following counseling. Phone counseling participants will be been mailed a kit for DNA collection or have the option of having the sample collected at at LCCC.
11638531|NCT00262899|No Intervention|Usual Care|Usual Care (UC) for newly diagnosed breast cancer patients does not typically include a pre-surgical genetic referral. These patients may obtain genetic counseling at their own discretion.
11638532|NCT00262873|Experimental|Bortezomib|
11638533|NCT00262860|Experimental|Bortezomib, Gemcitabine Hdrochloride|
11638534|NCT00262847|Active Comparator|Arm I (placebo, paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Beginning in course 2, patients also receive placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive placebo alone IV over 30-90 minutes on day 1. Treatment with placebo repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
11638535|NCT00262847|Experimental|Arm II (placebo, paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel and carboplatin as in arm I. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive placebo alone IV over 30-90 minutes on day 1. Treatment with placebo repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
11638536|NCT00262847|Experimental|Arm III (paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel and carboplatin as in arm I. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses. Beginning in course 7, patients receive bevacizumab alone IV over 30-90 minutes on day 1. Treatment with bevacizumab repeats every 21 days for up to 22 courses in the absence of disease progression or unacceptable toxicity.
11638537|NCT00262834|Experimental|Arm I|Patients receive oral vorinostat twice daily on days -3 to 0. Approximately 2 hours after the final dose of vorinostat, patients undergo conventional surgery of the tumor on day 0. After completion of study treatment, patients are followed for 30 days.
11638538|NCT00262821|Active Comparator|Arm I (cisplatin)|Patients receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6).
11638539|NCT00262821|Experimental|Arm II (cisplatin, tirapazamine)|Patients receive tirapazamine IV over 2 hours on days 1, 8, 10, 12, 15, 22, 24, 26, and 29 and cisplatin IV over 1 hour on days 1, 15, and 29.
11638540|NCT00262795|Experimental|F|Fludarabine
11638541|NCT00262795|Active Comparator|CLB|Chlorambucil
11638542|NCT00262782|Experimental|Fludarabine|
11638543|NCT00262782|No Intervention|watch & wait|
11638544|NCT00262769|Experimental|A - Gemcitabine|Gemcitabine alone
11638545|NCT00262769|Experimental|B - Gemcitabine and Cisplatin|Gemcitabine and Cisplatin
11638546|NCT00262743|Experimental|polyphenon E|Designed to assess toxicity, treatment response, and pertinent laboratory measurements in patients with previously untreated, asymptomatic, Rai Stage 0-II CLL.
11638547|NCT00262730|Experimental|Treatment Arm|"RT + TMZ 6wks, followed by
~poly ICLC, temozolomide, radiation: radiation therapy"
11638548|NCT00262704|No Intervention|Group A|Control group
11638549|NCT00262704|Active Comparator|Group B|Simulated case-based customized learning
11638550|NCT00262704|Active Comparator|Group C|Simulated case based customized learning + leader feedback
11638551|NCT00262665|Experimental|Org 24448|ampa receptor potentiator for the treatment of MDD
11638552|NCT00262665|Placebo Comparator|Placebo|matching placebo pill
11638553|NCT00262639|Experimental|I|2 mg flumazenil given over 20 minutes on Day 1 and Day 2. Gabapentin 300 mg Day 1; gabapentin 600 mg Day 2; gabapentin 900 mg Day 3; gabapentin 1200 mg Day 4 to 30; gabapentin 900 mg day 31-33; gabapentin 600 mg day 34-36; gabapentin 300 mg day 37-39.
11638554|NCT00262639|Placebo Comparator|II|20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
11638555|NCT00262600|Active Comparator|Dabigatran dose 2|twice a day
11638556|NCT00262600|Active Comparator|Warfarin|once a day
11638557|NCT00262600|Active Comparator|Dabigatran dose 1|twice a day
11638558|NCT00262587|Placebo Comparator|Placebo|Placebo inhaler (sugar powder)
11638559|NCT00262587|Active Comparator|Seretide|Seretide inhaler
11638560|NCT00262561|Active Comparator|Aspirin|All participants get Aspirin, and platelet reactivity measurements are performed.
11638561|NCT00262522|Experimental|LPV/r 800/200 mg QD Tablet|
11638562|NCT00262522|Experimental|LPV/r 800/200 mg QD SGC (Through Week 8)|
11638563|NCT00262522|Active Comparator|LPV/r 400/100 mg BID Tablet|
11638564|NCT00262522|Active Comparator|LPV/r 400/100 mg BID SGC (Through Week 8)|
11638565|NCT00262509|Experimental|Egress Badge Performance|Blind subjects are walked into a building to a specific location, and then are asked to find their way out of the building.
11638566|NCT00262509|No Intervention|Baseline Egress Performance|Blind subjects are walked into a building to a particular location and then asked to find their way out of the building.
11638567|NCT00262470|Experimental|1|Acetazolamide
11638568|NCT00262470|Experimental|2|Atomoxetine
11638569|NCT00262470|Experimental|3|NO Drug
11638570|NCT00262470|Experimental|4|Clonidine
11638571|NCT00262470|Experimental|5|Entacapone
11638572|NCT00262470|Experimental|6|Indomethacin
11638573|NCT00262470|Experimental|7|Isosorbide Dinitrate
11638574|NCT00262470|Experimental|8|Mecamylamine
11638575|NCT00262470|Experimental|9|Memantine
11638576|NCT00262470|Experimental|10|Melatonin
11638577|NCT00262470|Experimental|11|Midodrine
11638578|NCT00262470|Experimental|12|Modafinil
11638579|NCT00262470|Experimental|13|Octreotide
11638580|NCT00262470|Placebo Comparator|14|Placebo (lactose tablet)
11638581|NCT00262470|Experimental|15|Propranolol
11638582|NCT00262470|Experimental|16|Sertraline
11638583|NCT00262470|Experimental|17|Normal Saline (0.9%) 1 liter
11638584|NCT00262470|Experimental|18|Drinking Water
11638585|NCT00262470|Experimental|19|Dead Space Breathing Device
11638586|NCT00262470|Experimental|Abdominal Binder|Abdominal binder with inflatable pressure over abdomen
11638587|NCT00262457|Other|Arm 1|
11638588|NCT00262431|Active Comparator|Early (A)|Patients of the EARLY group (A) will be submitted to tracheostomy on day 3-5 from oro/nasotracheal intubation.
11638589|NCT00262431|Active Comparator|Late (B)|Patients of the LATE group (B) will undergo tracheostomy on day 10-12 from oro/nasotracheal intubation.
11638590|NCT00262405|Experimental|zileuton|Zileuton
11638591|NCT00262405|Active Comparator|azathioprine/prednisone|azathioprine/prednisone
11638592|NCT00262392|Experimental|Pamidronate|Pamidronate
11638593|NCT00262392|Active Comparator|radiation|radiation
11638594|NCT00262379|No Intervention|Group A|HCV treatment with peginterferon plus ribavirin during 48 weeks
11638595|NCT00262379|Active Comparator|Groupb|HCV treatment with peginterferon plus ribavirin during 48 weeks plus epoetin beta under anemia conditions
11638596|NCT00262340|Experimental|1|This arm will have treatment changed based on measures of inflammation
11638597|NCT00262340|Active Comparator|2|Treatment will be changed on the basis of reported asthma symptoms
11638598|NCT00262301|Experimental|"100 IU/kg rhC1INH"|100 IU/kg recombinant human C1 inhibitor
11638599|NCT00262301|Placebo Comparator|Saline|Saline solution
11638600|NCT00262288|Experimental|Recombinant Human C1INH|
11638601|NCT00262223|Active Comparator|1) Seeking Safety + Sertraline|Seeking Safety + Sertraline
11638602|NCT00262223|Placebo Comparator|2) Seeking Safety + Placebo|Seeking Safety + Placebo;
11638603|NCT00262119|Active Comparator|Control Group|PM programming according to actual clinical practice
11638604|NCT00262119|Active Comparator|MVP Only|PM programming according to actual clinical practice + MVP algorithm ON
11638605|NCT00262119|Active Comparator|DDDRP|PM programming according to actual clinical practice + MVP algorithm ON + Atrial fibrillation therapies ON
11638606|NCT00262106|Placebo Comparator|Placebo|placebo
11638607|NCT00262106|Active Comparator|PRO 2000/5 Gel 0.5%|PRO 2000/5 Gel 0.5%
11638608|NCT00262080|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections.
11638609|NCT00262080|Placebo Comparator|Placebo|Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.
11638610|NCT00262067|Experimental|Bevacizumab + chemotherapy|Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle plus one of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
11638611|NCT00262067|Placebo Comparator|Placebo + chemotherapy|Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + 1 of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
11638612|NCT00262054|Experimental|A|bivalirudin is to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
11638613|NCT00262054|Active Comparator|B|UFH given as an intravenous bolus of 140 units/kg. Double blinding will be maintained by using a double-dummy technique consisting of identical UFH and bivalirudin syringes and bivalirudin or placebo infusion bags.
11638614|NCT00262041|Experimental|MenACWY-CRM(Ad+)|Subjects received one single dose of adjuvanted formulation of conjugate vaccine.
11638615|NCT00262041|Experimental|MenACWY-CRM(Ad-)|Subjects received one single dose of unadjuvanted formulation of conjugate vaccine.
11638616|NCT00262041|Active Comparator|MenACWY- PS|Subjects received one single dose of the polysaccharide vaccine.
11638617|NCT00262028|Experimental|MenACWY-CRM (2-10 years)|Subjects received one dose of investigational MenACWY-CRM conjugate vaccine
11638618|NCT00262028|Experimental|MenACWY-CRM (12-23 months)|Subjects received one dose of investigational MenACWY-CRM conjugate vaccine
11638619|NCT00262028|Active Comparator|MenACWY-PS (2-10 years)|Subjects received one dose of licensed comparator MenACWY polysaccharide (MenACWY-PS) vaccine
11638620|NCT00262028|Experimental|MenACWY-CRM+PnC (12-15 months)|Subjects received one dose of MenACWY-CRM vaccine alone or concomitantly with PnC
11638621|NCT00262028|Experimental|MenACWY-CRM+DTaP (16-23 months)|Subjects received one dose of MenACWY-CRM vaccine alone or concomitantly with DTaP
11638622|NCT00262002|Experimental|UK234+ (MenACWY Ad+ at 2, 3, 4 m)|Three doses of MenACWY Ad+ vaccine were given at 1-month intervals concomitantly with DTaPHibIPV at 2, 3, and 4 months of age in the UK group. A fourth dose of MenACWY Ad+ was given at 12 months of age.
11638623|NCT00262002|Experimental|UK24+ (MenACWY Ad+ at 2, 4 m)|Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad+ vaccine was given at 12 months of age.
11638624|NCT00262002|Experimental|UKMenC (Menjugate at 2, 4 m)|Two doses of Menjugate were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. One dose of MenACWY Ad+ vaccine was given at 12 months of age.
11638625|NCT00262002|Experimental|CA246+ (MenACWY Ad+ at 2, 4, 6 m)|Three doses of MenACWY Ad+ vaccine were given at 2-month intervals concomitantly with DTaPHibIPV, HBV, and Prevnar at 2, 4, and 6 months of age of the Canadian group (Prevnar at 6 months was optional and was given if available).One subgroup of subjects was given a reduced dose (1/5) of MenACWY PS vaccine concomitantly with MMR (and Prevnar, if available) at 12 months of age. Another subgroup was administered one dose of MMR (and Prevnar, if available) at 12 months of age.
11638626|NCT00262002|Experimental|CA24+ (MenACWY Ad+ at 2, 4 m)|Two doses of MenACWY Ad+ vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad+ vaccine or one reduced dose (1/5) of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.
11638627|NCT00262002|Experimental|UK24- (MenACWY Ad- at 2, 4 m)|Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV at 2 and 4 months of age. A third dose of MenACWY Ad- vaccine was given at 12 months of age.
11638628|NCT00262002|Experimental|CA24- (MenACWY Ad- at 2, 4 m)|Two doses of MenACWY Ad- vaccine were given at a 2-month interval concomitantly with DTaPHibIPV, HBV, and Prevnar at 2 and 4 months of age.One dose of MenACWY Ad- vaccine or one reduced dose of MenACWY PS vaccine was given concomitantly with MMR (and Prevnar, if available) at 12 months of age.
11638629|NCT00261976||Patients in infliximab clinical studies|All patients enrolled in selected Centocor sponsored infliximab clinical studies.
11638630|NCT00261950|Experimental|Cinacalcet|All subjects were enrolled into the single arm to receive Cinacalcet. There was no comparator arm.
11638631|NCT00261924|Experimental|Intercept Platelets|Study patients receiving platelets that have been processed with the INTERCEPT pathogen inactivation system
11638632|NCT00261924|Active Comparator|Conventional Platelets|Study patients receiving platelets processed by standard method without the INTERCEPT pathogen inactivation system
11638633|NCT00261859|No Intervention|SCA|Standard Care with Assessment
11638634|NCT00261859|No Intervention|SCNA|Standard Care No Assessment
11638635|NCT00261859|Experimental|BNI|Brief Negotiated Interview
11638636|NCT00261859|Experimental|EBNI|Enhanced Brief Negotiated Interview
11638637|NCT00261846|Experimental|SKI-606|
11638638|NCT00261833|Experimental|Zemaira®|
11638639|NCT00261833|Placebo Comparator|Placebo|
11638640|NCT00261807|Other|Single ARM Study|It was a single arm study with daptomycin use at a higher dose for patients with severe skin and soft tissue infections.
11638641|NCT00261794|Experimental|1|computer-assisted cognitive remediation (CACR)
11638642|NCT00261794|Active Comparator|2|computer-based cognitive activity
11638643|NCT00261781|Experimental|Treadmill training|Home-based treadmill training
11638644|NCT00261781|No Intervention|Usual care|Control group
11638645|NCT00261768|Experimental|1|Noise reduction on
11638646|NCT00261755|Experimental|Acupuncture Group|Acupuncture treatment during labor
11638647|NCT00261755|Active Comparator|TENS Group|Transcutaneous Electric Nerve Stimulation (TENS treatment)during labor
11638648|NCT00261755|Active Comparator|Traditional Group|Traditional pain treatment during labor
11638649|NCT00261729|Experimental|1|paroxetine
11638650|NCT00261729|Placebo Comparator|2|placebo
11638651|NCT00261729|Experimental|3|prazosin
11638652|NCT00261716|Experimental|IPS and VOMI|Individual Placement and Support (IPS), a form of evidence-based supported employment with 4 sessions of manualized vocationally-oriented motivational interviewing (VOMI) prior to each course of job searching
11638653|NCT00261716|Active Comparator|IPS and IE|Individual placement and support (IPS), a form of evidence-based supported employment with 4 sessions of education about schizophrenia/schizoaffective disorder (IE), as appropriate, prior to each course of job searching
11638654|NCT00261703|Experimental|1|(Docetaxel + Cisplatin + 5-FU) + Cisplatin + Radiotherapy
11638655|NCT00261703|Experimental|2|(Cisplatin + 5-FU) + Cisplatin + Radiotherapy
11638656|NCT00261703|Experimental|3|Cisplatin + Radiotherapy
11638657|NCT00261690|Experimental|1|Virtual Reality distraction
11638658|NCT00261547|Experimental|Rituximab|this study has only one arm as the treatment group
11638659|NCT00261495|Active Comparator|Oxycodone|
11638660|NCT00261495|Experimental|OROS hydromorphone HCl|
11638661|NCT00261456||BRCA1/2 carriers|Carriers of a BRCA1 or BRCA2 mutation.
11638662|NCT00261456||BRCA1/2/non Carriers|Do not carry a mutation in either the BRCA1 or 2 genes that has been found in other members of the family.
11638663|NCT00261443|Placebo Comparator|A1|/Active Comparator
11638664|NCT00261443|Experimental|A2|
11638665|NCT00261378|Active Comparator|Transarterialchemoembolisation (TACE)|Conventional TACE with doxorubicin
11638666|NCT00261378|Other|DC Bead|DC Bead with doxorubicin
11638667|NCT00261365|Active Comparator|A1|
11638668|NCT00261365|Active Comparator|A2|
11638669|NCT00261326|Active Comparator|B|simvastatin tablets 80 mg daily
11638670|NCT00261326|Placebo Comparator|A|calcium tablets 80 mg
11638671|NCT00261313|Experimental|Aranesp|
11638672|NCT00261313|Experimental|Neulasta|
11638673|NCT00261300|Experimental|1|Pantoprazole 40 mg
11638674|NCT00261274|Experimental|Test Group A-ECO|
11638675|NCT00261274|Placebo Comparator|Control Group|
11638676|NCT00261209|Experimental|Collagenase Injection|Injection of collagenase into adhesion restricting tendon gliding
11638677|NCT00261196|Experimental|Collagenase|Collagenase Injection
11638678|NCT00261196|Placebo Comparator|Placebo|Placebo Injection
11638679|NCT00261170|Active Comparator|1|bupropion and behavioral counseling
11638680|NCT00261170|Placebo Comparator|2|placebo medication
11638681|NCT00261118|Active Comparator|1 (i)|Rituximab 1g in 500 mls of 0.9% normal saline infused into a peripheral vein
11638682|NCT00261118|Placebo Comparator|2 (ii)|500 mls of 0.9% NORMAL SALINE INFUSED INTO A PERIPHERAL VEIN
11638683|NCT00261053|Other|1|Open-label i.v. administration of 100 U/kg rhC1INH
11638684|NCT00261040|Active Comparator|Minimally Invasive Surgery (MIS)|In minimally invasive surgery, the surgeon makes a shorter incision (about 10 cm or less) along the side of the thigh and replaces the hip through this smaller incision. The surgeon is able to do the surgery through a shorter incision by using special instruments which can guide him or her.
11638685|NCT00261040|Sham Comparator|Standard Surgery|The standard way an orthopaedic surgeon performs a hip replacement surgery is that they make a long incision (about 20 cm) down the side of the thigh and then replaces the hip joint through this long incision
11638686|NCT00261001|Experimental|Transcutaneous|
11638687|NCT00261001|Active Comparator|Intramuscular|
11638688|NCT00260988|Active Comparator|Dalteparin|Dalteparin 200 IU/kg/day for three days prior to surgery and dalteparin 5000IU daily for 3-5 days post-surgery
11638689|NCT00260988|Active Comparator|Tinzaparin|Tinzaparin 175 IU/kg/day for three days prior to surgery and Tinzaparin 4500 IU for 3-5 days post surgery
11638690|NCT00260975||Chemotherapy patients|Breast cancer patients treated with adjuvant chemotherapy of various types.
11638691|NCT00260975||Hormonal patients|Breast cancer patients treated with adjuvant hormonal therapy but not chemotherapy.
11638692|NCT00260962|Placebo Comparator|Placebo|Placebo and Treatment as usual (Day Hospital Program). After a 2-week baseline period, placebo was administered for 10 weeks (weeks 3-12 of the study). Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
11638693|NCT00260962|Experimental|Olanzapine Plus Day Hospital|After a 2-week baseline period, Olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of 10 mg/day. Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
11638783|NCT00259428|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
11638694|NCT00260936||HIV-negative|HIV-infected and -uninfected males, ages 12 to 24 years, of Tanner Stage 4 or 5
11638695|NCT00260936||HIV-positive, has never been on ART|HIV-positive, has never been on ART
11638696|NCT00260936||HIV-positive, non PI containing NNRTI-based regimen|HIV-positive, currently on a non-PI-containing NNRTI-based regimen for at least 12 weeks. Must never have received a total of more than 6 months of PI-containing regimen, and at least one year must have passed since receipt of last PI-containing regimen
11638697|NCT00260936||HIV-positive, non-NNRTI-containing PI-based regimen|HIV-positive, currently on a non-NNRTI-containing PI-based regimen for at least 12 weeks. Must never have received a total of more than 6 months of NNRTI-containing regimen, and at least one year must have passed since receipt of last NNRTI-containing regimen.
11638698|NCT00260832|Experimental|A|Subject's choice of treatment with physician's advice. Subjects preselected their preference of supportive care (including IV fluids, nutrition, and antibiotics) or cytarabine. (These represent one intervention.)
11638699|NCT00260832|Active Comparator|B|
11638700|NCT00260819|Experimental|1|Experimental and Placebo Comparator administered in random order during to successive experimental phase
11638701|NCT00260819|Placebo Comparator|2|Experimental and Placebo Comparator administered in random order during to successive experimental phase
11638702|NCT00260806||1|Children perinatally infected with HIV with exposure to highly active anti-retroviral therapy (HAART).
11638703|NCT00260806||2|Children with perinatally acquired HIV infection enrolled on the P2C2 Study, not exposed to HAART therapy.
11638704|NCT00260728|Experimental|Arm 1|
11638705|NCT00260689|Experimental|Horse ATG/CsA taper|h-ATG (Anti-thymocyte globulin (horse)) + 6 months CsA (Cyclosporine) followed by an 18 month CsA taper
11638706|NCT00260689|Experimental|Rabbit ATG/CsA|r-ATG (Anti-thymocyte globulin (rabbit)) + 6 months CsA (Cyclosporine)
11638707|NCT00260689|Experimental|Alemtuzumab|Alemtuzumab administered for 10 days
11638708|NCT00260676|Other|conventional ventilation, protective ventilation|
11638709|NCT00260663|Other|Arm 1|
11638710|NCT00260650|Experimental|Heart PACT Program|Heart PACT Program - patient activation intervention
11638711|NCT00260650|No Intervention|Usual Care|Usual Care
11638712|NCT00260611|Experimental|Oxaliplatin and Taxotere|Patients will receive both docetaxel and oxaliplatin, IV on day 1 of each cycle. Treatment will be repeated every 21 days for up to 6 courses in the absence of disease progression, unacceptable toxicity, or >50% increase in serum PSA.
11638713|NCT00260533|Experimental|1|Atomoxetine
11638714|NCT00260533|Placebo Comparator|2|Placebo
11638715|NCT00260494|Experimental|acupuncture|acupuncture to lower extremity postoperatively
11638716|NCT00260494|Sham Comparator|sham acupuncture|sham acupuncture at same sites.
11638717|NCT00260494|No Intervention|control|no acupuncture, otherwise the same care and measurements
11638718|NCT00260481|Placebo Comparator|Control Group|During the Infusion periods, participants in the placebo condition will receive pre-treatment with hydroxyzine (50mg) followed by placebo medications administered both orally and through infusion, as well as a second dose of hydroxyzine (50mg), delivered at the same rate and delivery system to match the active condition. All participants may receive daily multivitamins as determined appropriate by the study physician. Multivitamins are not considered active medications for the PROMETA pharmacotherapy, but may be provided to participants in both conditions at the same rates and delivery methods for the duration of the study. Because participants are treatment-seeking and use of a placebo condition is warranted, all participants will be provided with once weekly, manual-guided cognitive behavioral therapy sessions during all outpatient periods of the study.
11638719|NCT00260481|Active Comparator|Prometa|During the infusion periods, participants assigned to the PROMETA pharmacotherapy condition will receive pre-treatment with hydroxyzine (50mg) followed by intravenous flumazenil (2mg) over a 2-hour period. Before bedtime, patients will again take 50mg of hydroxyzine orally, as well as 300mg of oral gabapentin (participants will titrate up their dosage of gabapentin each day - 300mg on day 0, 600mg on day 1, 900mg on day 2). All participants may receive daily multivitamins as determined appropriate by the study physician. Multivitamins are not considered active medications for the PROMETA pharmacotherapy, but may be provided to participants in both conditions at the same rates and delivery methods for the duration of the study. Because participants are treatment-seeking and use of a placebo condition is warranted, all participants will be provided with once weekly, manual-guided cognitive behavioral therapy sessions during all outpatient periods of the study.
11638720|NCT00260442|Placebo Comparator|Placebo|< 200 mg/day dietary cholesterol, resistance training, sedentary
11638721|NCT00260442|Experimental|Average intake|400 mg/day dietary cholesterol, resistance training, sedentary
11638722|NCT00260442|Experimental|High intake|800 mg/day dietary cholesterol, resistance training, sedentary
11638723|NCT00260429|Experimental|AA4500 0.58 mg|
11638724|NCT00260429|Placebo Comparator|placebo|
11638725|NCT00260351|Experimental|Group 1|Participants on Thai Red Cross, TRC-ID regimen
11638726|NCT00260351|Experimental|Group 2|Participants on Zagreb-IM regimen
11638727|NCT00260351|Experimental|Group 3|Participants on Essen-IM regimen.
11638728|NCT00260338|Active Comparator|Mesenchymal stromal cell|Mesenchymal stromal cell
11638729|NCT00260273|Active Comparator|1|cognitive Behavioural Therapy
11638730|NCT00260273|No Intervention|2|supportive therapy
11638731|NCT00260234|Experimental|PEG Islet Cells|
11638732|NCT00260221|Experimental|1|Arm one uses Virtual Reality Hypnosis post hypnotic suggestions to reduce pain durng wound care procedures.
11638733|NCT00260221|Experimental|2|Arm two uses Virtual Reality distraction that is administered at times other than during burn care procedure to control for both for attention and high technology.
11638734|NCT00260221|Experimental|3|Arm three use Audio administered Hypnosis without the visual technology.
11638784|NCT00259428|Placebo Comparator|Placebo|matching placebo tablets
11638785|NCT00259402|Experimental|Oxaliplatin|
11638786|NCT00259376|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
11638787|NCT00259376|Experimental|Placebo|matching placebo tablets
11638788|NCT00259337|Experimental|1|
11638789|NCT00259324|Experimental|1|Diet and Activity
11638790|NCT00259324|Experimental|2|Diet and Activity
11638735|NCT00260208|Active Comparator|Cyclosporin A|"The first administration of Cyclosporin A (CsA) was within the first 24 hours post-transplantation at an initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout the study period. During the study, the dose of CsA was adjusted, as necessary, to achieve and maintain the C2 or C0 blood CsA concentration within the target ranges.
~Before enrolling the first patient, each center chose the adjunct immunosuppressive (IS) regimen between:
~Steroids administered and tapered as per local practice
~interleukin-2 receptor (IL-2R) antagonists + mycophenolic acid (MPA): Induction with IL-2R antagonists; Dosages were as per center practice. Patients received mycophenolic acid (MPA) no later than 24 hours after reperfusion of the graft. Dosages were as per local practice.
~The regimen selected by the center was to be given to all patients enrolled in the trial from this center."
11638736|NCT00260208|Active Comparator|Tacrolimus|"Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses (twice daily at 12-hour interval) either orally or via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout study period. Throughout the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain C0 tacrolimus concentrations within target ranges.
~Before enrolling the first patient, each center chose adjunct immunosuppressive (IS) regimen between:
~Steroids administered and tapered as per local practice
~interleukin-2 receptor (IL-2R) antagonists + mycophenolic acid (MPA): Induction with IL-2R antagonists; Dosages were as per center practice. Patients received mycophenolic acid (MPA) no later than 24 hours after reperfusion of the graft. Dosages were as per local practice.
~The regimen selected by center was to be given to all patients enrolled in trial from this center."
11638737|NCT00260195|Experimental|School-based cognitive behavioral support group|Ten group lessons facilitated by a teacher or school counselor that focuses on psycho-education, development of a trauma narrative, approaching trauma-related situations, social problem solving, and cognitive skills.
11638738|NCT00260195|No Intervention|Wait-list control group|Waiting list
11638739|NCT00260169|Experimental|1|Participants will receive collaborative care
11638740|NCT00260169|Active Comparator|2|Participants will receive enhanced usual care
11638741|NCT00260156|Experimental|vildagliptin|
11638742|NCT00260156|Placebo Comparator|Placebo|
11638743|NCT00260143|Experimental|Testosterone enanthate|300 mg of testosterone enanthate by intramuscular injection once weekly for 16 weeks
11638744|NCT00260143|Placebo Comparator|Placebo|Placebo (sesame oil) by intramuscular injection once weekly for 16 weeks
11638745|NCT00260130|Active Comparator|1|Consuming fruit and vegetable juice
11638746|NCT00260130|Active Comparator|2|Consuming whole fruits and vegetables
11638747|NCT00260091|Active Comparator|I.|Conventional infertility therapy
11638748|NCT00260091|Active Comparator|II.|Fast track to in vitro fertilization therapy
11638749|NCT00260078|Experimental|D|TDF and EFV or NVP throughout study
11638750|NCT00260078|Experimental|E|TDF and DRV with or without EFV throughout study
11638751|NCT00260078|Experimental|F|TDF and ATV and RTV with or without EFV throughout study
11638752|NCT00260065|Experimental|1|
11638753|NCT00260039|Active Comparator|1|Gardasil
11638754|NCT00260039|Experimental|2|HPV VLP vaccine -Dose regimen 1
11638755|NCT00260039|Experimental|3|HPV VLP vaccine -Dose regimen 2
11638756|NCT00260039|Experimental|4|HPV VLP vaccine -Dose regimen 3
11638757|NCT00259974|Experimental|1|Rituximab
11638758|NCT00259935|Experimental|All treated subjects|Subjects were randomized to receive 4 mg of a new formulation and current formulation of oral topotecan on Days 1 and 8 of Course 1.
11638759|NCT00259922|Placebo Comparator|Placebo|
11638760|NCT00259922|Experimental|Alvimopan 0.5 mg once daily|0.5 mg once daily (QD)
11638761|NCT00259922|Experimental|Alvimopan 0.5 mg twice daily|0.5 mg twice daily (BID)
11638762|NCT00259909||Subjects with COPD|Subject has a confirmed clinical diagnosis of COPD, with or without chronic bronchitis.
11638763|NCT00259883|Experimental|paroxetine|paroxetine 20 to 40mg/day
11638764|NCT00259857|Experimental|1 Alendronate, Calcium, Vitamin D|Crossover study. Year-1, 10 participants will take study medication, calcium and vitamin D supplements and other 10 participants will take placebo, calcium and vitamin D supplements. Year-2, they will crossover to the second arm of the study. Those who took study medication and supplements in year-1, will take placebo and supplements in the year-2, and those 10 participants who took placebo and supplements in the year-1, will take study medications and supplements in the year-2.
11638765|NCT00259857|Placebo Comparator|2 Placebo, Calcium and Vitamin D|Year-1, 10 participants will take Alendronate (study medication)and calcium and vitamin D supplement). Another 10 participants will take placebo, calcium and vitamin D. In year-2 they will crossover. Those who took alendronate in the first year, will take Placebo, calcium and vitamin D for 12 months and those who took Placebo in the first year, will take Alendronate, calcium and vitamin D in the second year (12 months).
11638766|NCT00259805|Experimental|IV Infusion|
11638767|NCT00259753|Experimental|1|0.2 mg/eye
11638768|NCT00259753|Experimental|2|1.5 mg/eye
11638769|NCT00259753|Experimental|3|3.0 mg/eye
11638770|NCT00259740|Experimental|Denosumab|
11638771|NCT00259727||1|
11638772|NCT00259714|Active Comparator|standard dialysate sodium|In the control phase of the study, the prescribed dialysate sodium is 140 mEq/L
11638773|NCT00259714|Experimental|dialysate sodium individualization|".Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized)."
11638774|NCT00259688|No Intervention|1|Women with gestational hypertension
11638775|NCT00259688|No Intervention|2|Women with uncomplicated pregnancies
11638776|NCT00259688|No Intervention|3|Re-test of women one to two years post-partum.
11638777|NCT00259610|Active Comparator|1|methotrexate (MTX) + etanercept
11638778|NCT00259610|Active Comparator|2|methotrexate (MTX) + sulfasalazine (SSZ)/hydroxychloroquine (HCQ)
11638779|NCT00259610|Active Comparator|3|methotrexate (MTX) or MTX + Etanercept
11638780|NCT00259610|Active Comparator|4|methotrexate (MTX) or MTX + sulfasalazine (SSZ)/hydroxychloroquine (HCQ)
11638781|NCT00259519|No Intervention|1|Expectant management
11638782|NCT00259519|Active Comparator|2|Induction of delivery
11638791|NCT00259324|Placebo Comparator|3|Education
11638792|NCT00259298|Experimental|Teriparatide|Participants receive teriparatide 20 microgram once daily by subcutaneous injection for 18 months followed by 6 months off therapy
11638793|NCT00259285|Experimental|A|
11638794|NCT00259272|Experimental|A|
11638795|NCT00259220|Experimental|drug|erythromycine
11638796|NCT00259220|Other|2|gastric lavage alone
11638797|NCT00259220|Active Comparator|3|erythromycine and gastric lavage
11638798|NCT00259207|Active Comparator|classic surgery|classic surgery
11638799|NCT00259207|Experimental|medical surgery hybride|medical surgery hybride
11638800|NCT00259194|Active Comparator|Alternative Observation|Moving in bed during observation after coronary angiography
11638801|NCT00259194|Experimental|Standard Observation|No moving in bed during observation after coronary angiography
11638802|NCT00259129|Experimental|Arm 1|
11638803|NCT00259103|Experimental|7.5 µg/kg/d|Participants who received intravenous (IV) infusion of 7.5 µg/kg/d serelaxin, all during part A.
11638804|NCT00259103|Experimental|25 µg/kg/d|Participants who received intravenous (IV) infusion of 25 µg/kg/d serelaxin, all during part A.
11638805|NCT00259103|Experimental|75 µg/kg/d|Participants who received IV infusion of 75 µg/kg/d serelaxin, some during part A and others during part B.
11638806|NCT00259103|Experimental|Placebo|Participants who received IV infusion of placebo, some during part A and others during part B.
11638807|NCT00259090|Active Comparator|1|Anastrozole Monotherapy
11638808|NCT00259090|Experimental|2|Fulvestrant Monotherapy
11638809|NCT00259090|Experimental|3|Anastrozole + Fulvestrant
11638810|NCT00259064|Experimental|Gefitinib|ZD1839 + BSC (best supportive care)
11638811|NCT00259064|Placebo Comparator|Placebo|Placebo + BSC (best supportive care)
11638812|NCT00259038|Experimental|Experimental Drug|
11638813|NCT00259038|Placebo Comparator|Placebo|
11638814|NCT00259012|Active Comparator|Low dose|
11638815|NCT00259012|Active Comparator|High dose|
11638816|NCT00258960|Other|Caelyx,Cyclophosphamide,Trastuzumab|Caelyx (Liposomal Doxorubicin) 50 mg/m2 every 4 weeks for 6 cycles, Cyclophosphamide 600 mg/m2 every 4 weeks for 6 cycles, Trastuzumab weekly for 24 weeks, at dose of 2mg/kg (day 1 loading dose of 4mg/kg)
11638817|NCT00258934|Experimental|1|
11638818|NCT00258934|Active Comparator|2|
11638819|NCT00258895|Experimental|DAPTACEL Primed|Participants received Daptacel in Study P3T06.
11638820|NCT00258895|Experimental|Pentacel Primed|Participants received Pentacel in Study P3T06
11638821|NCT00258869||1|Emergency department patients with sepsis
11638822|NCT00258856|Experimental|Menactra® Group 1|Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 3 and Day 7 after booster vaccination.
11638823|NCT00258856|Experimental|Menactra® Group 2|Participants who had received Menactra® in Study 603-02. They will provide serum sample before vaccination and on Day 5 and Day 14 after booster vaccination.
11638824|NCT00258856|Experimental|Meningococcal Vaccine-naïve Group 3|Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 3 and Day 7 after Menactra® vaccination.
11638825|NCT00258856|Experimental|Meningococcal Vaccine-naïve Group 4|Participants who have never received a Meningococcal vaccine in the past. They will provide serum sample before vaccination and on Day 5 and Day 14 after Menactra® vaccination.
11638826|NCT00258843|Experimental|Group 1|Children at 18 months of age
11638827|NCT00258843|Experimental|Group 2|Infants at 2 months of age
11638828|NCT00258830|Experimental|Age 18 to 59 years|Participants aged 18 to 59 years at enrollment.
11638829|NCT00258830|Experimental|Age 60 years and older|Participants aged 60 years and older at enrollment.
11638830|NCT00258817|Experimental|Influenza Virus Vaccine Naïve|Subjects have never received Influenza virus vaccine in the past
11638831|NCT00258817|Experimental|Influenza Virus Vaccine-primed|Subjects have received Influenza virus vaccine in the past
11638832|NCT00258765|Experimental|Zoledronic Acid|
11638833|NCT00258765|Active Comparator|Docetaxel|
11638834|NCT00258752|Experimental|1|Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST)
11638835|NCT00258752|Experimental|2|Enhanced IPT-AST
11638836|NCT00258752|Active Comparator|3|Typical school counseling
11638837|NCT00258739|Experimental|1|Concomitant radiotherapy and carboplatin-docetaxel followed by docetaxel-gemcitabine
11638838|NCT00258739|Experimental|2|docetaxel-gemcitabine followed by concomitant radiotherapy with carboplatin-docetaxel
11638839|NCT00258713|Active Comparator|1|
11638840|NCT00258713|Active Comparator|2|
11638841|NCT00258713|Active Comparator|3|
11638842|NCT00258687|Experimental|Treatment Arm A|GVAX for Sarcoma / Renal Cell Patients
11638843|NCT00258687|Experimental|Treatment Arm B|GVAX for Pediatric Melanoma Patients
11638844|NCT00258674|Active Comparator|Medicare Claims Feedback|Practices randomised to the Medicare Claims Feedback arm received period feedback on their performance on selected diabetes quality of care measures as reflected in the claims data for their diabetes patients.
11638845|NCT00258674|Experimental|Medicare Claims+Medical Record Feedback|Practices randomised to the Medicare Claims + Medical Record Review Feedback arm received periodic feedback on their performance on selected diabetes quality of care measures as reflected in both the Medicare claims for the diabetes patients AND review/audit of their diabetes patients' medical records.
11638846|NCT00258674|Experimental|Medicare Claims+Medical Chart Review+DRN|In addition to the performance data from both Medicare Claims data and from review of patients' medical records, practices randomised to the Medicare Claims + Medical Record review + Diabetes Resource Nurse (DRN) had a diabetes resource nurse assigned to them, who was available to provide diabetes education and care-coordination type services for their diabetes patients.
11638847|NCT00258661|Experimental|Osteopathic Manipulative Treatment|10-minute standardized OMT protocol + 5-minute nonstandardized component, twice daily for duration of hospitalization
11638848|NCT00258661|Sham Comparator|Light-touch Treatment|10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs, twice daily for duration of hospitalization
11638849|NCT00258661|No Intervention|Conventional Care Only|No intervention specific to the research study provided. Only conventional treatment as per attending physician orders.
11638850|NCT00258557|Experimental|002|TMC-114/RTV two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
11638851|NCT00258557|Active Comparator|001|LPV/RTV 400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
11638852|NCT00258518||1|ALI/ARDS patients
11638853|NCT00258479|Experimental|Modafinil|
11638854|NCT00258479|Placebo Comparator|Placebo|
11638855|NCT00258479|No Intervention|Nicotine Replacement Therapy|The effects of nicotine replacement therapy will be investigated - alone and in combination with modafinil - on nicotine withdrawal in nicotine-dependent adolescents.
11638856|NCT00258440|Active Comparator|Weekly Procrit (epoetin alfa) dosing|Weekly dosing schedule subjects will get the study drug once every week until the end of the study.
11638857|NCT00258440|Experimental|Interval Dosing (epoetin alfa) PK Group|Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week. Subjects who consented to pharmacokinetic testing
11638858|NCT00258440|Experimental|Interval Dosing (epoetin alfa) Non PK Group|Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week. Subjects who did not consent to pharmacokinetic testing.
11638859|NCT00258427|Experimental|transplant in fanconi anemia patients|Cytoreductive preparative regimen consisting of busulfan, cyclophosphamide, fludarabine phosphate, methylprednisolone, and antithymocyte globulin (ATG) followed by hematopoietic stem cell transplantation (HSCT) and post-transplant use of bone marrow-stimulating filgrastim.
11638860|NCT00258401|Active Comparator|low-residue diet|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.Patients are interviewed weekly for up to six weeks.
11638861|NCT00258401|Active Comparator|no dietary intervention|At the onset of diarrhea symptoms, patients undergo no dietary intervention but are interviewed weekly for up to six weeks.
11638862|NCT00258388|Active Comparator|OGX011, Docetaxel and Prednisone|
11638863|NCT00258388|Active Comparator|Docetaxel plus prednisone|
11638864|NCT00258362|Experimental|Patients with Endometrial Cancer|Patients with advanced or current endometrial cancer receiving treatment with induction docetaxel/carboplatin, radiation (Weekly, 5 days/week over 6-7 weeks, tailored 4500 cGy) and followed by 3 courses of consolidation docetaxel (75 mg/m^2 on Day 1 of each course) /carboplatin (Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles).
11638865|NCT00258349|Experimental|Arm I|Patients will receive vorinostat by mouth twice a day for 2 weeks. They will also receive a 90-minute infusion of trastuzumab in week 1.
11638866|NCT00258310|Experimental|Capecitabine|Surgery, chemotherapy and/or radiotherapy, prior to administration of Capecitabine 1000mg/day for one year.
11638867|NCT00258284|Experimental|Docetaxel & Capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
11638868|NCT00258245|Experimental|Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP d 1, 4, 8, 11; Arsenic Trioxide [AT] (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11; Thalidomide (Thalomid)- 50 mg/day by mouth (PO); Dexamethasone (Decadron)- 40 mg/d IVPB or by mouth (PO) d 1, 4, 8, 11; Ascorbic Acid (Vit C)- 1000 mg IVPB p Arsenic Trioxide (ATO) days 1, 4, 8, 11; Aspirin (ASA)- 325 mg by mouth (PO) every day
11638869|NCT00258206|Experimental|rituximab + cyclophosphamide|Rituximab 375 mg/m^2 on Days -10 and -7; Cyclophosphamide 50 mg/kg on days -3, -2, -1, and 0; Rituximab 375 mg/m^2 weekly x4 after platelet counts recover; For patients achieving at least stable disease, rituximab maintenance 375 mg/m^2 once each during months 3, 6, 9, and 12
11638870|NCT00258180|Experimental|severe autoimmune enteropathy|Young patients with severe autoimmune enteropathy receive cyclophosphamide IV over 1 hour on days 1-4. Patients then receive filgrastim (G-CSF) IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover
11638871|NCT00258154|Experimental|1|RotaTeq/Infanrix Hexa
11638872|NCT00258154|Placebo Comparator|2|Placebo/Infanrix Hexa
11638873|NCT00258128|Experimental|Treatment|This third small study has a randomized, masked, placebo controlled parallel design to compare salsalate 4.0 g/d to placebo. This is the salsalate 4.0 g/d arm.
11638874|NCT00258128|Placebo Comparator|Placebo|This third small study has a randomized, masked, placebo controlled parallel design to compare salsalate 4.0 g/d to placebo. This is the placebo arm.
11638875|NCT00258115|Active Comparator|salsalate|4.0 g/d divided dosing
11638876|NCT00258115|Placebo Comparator|placebo|placebo for salsalate
11638877|NCT00258076|Experimental|001|EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE
11638878|NCT00258050|Experimental|Subjects with cancer|"In Part 1 of the study, subjects will be randomized to one of four sequences. All subjects will receive oral or intravenous (IV) midazolam on Days 1, 3, 9 and 11 as per assigned randomization scheme. Starting on Day 4 through Day 11, subjects will receive a daily dose of 1500 milligrams (mg) of oral lapatinib.
~In Part 2, which will begin on Day 12, the subjects will be required to take 1500 mg of lapatinib daily until removed from the study for disease progression, adverse events, withdrawal of consent, or transfer to another lapatinib study."
11638879|NCT00258011|Experimental|Aldurazyme (laronidase) treatment|Patients received weekly infusions of JC0498 (laronidase) at an intravenous dose of 100 Units/kg (0.58 mg/kg) body weight for up to 73 weeks.
11638880|NCT00257933|Active Comparator|1|High dose prednisolone
11638881|NCT00257933|Experimental|2|Lower dose prednisolone alternating with placebo
11638882|NCT00257920|Active Comparator|A|
11638883|NCT00257920|Active Comparator|B|
11638884|NCT00257894|Experimental|Baclofen condition|Baclofen taken orally for 12 days total up to 40 mg/day maximum, divided into 3 equal portions each day. Participants receive 12 mg/day the first 3 days, 30 mg/day the next 3 days, and 40 mg/day on Days 7, 8, 9. Testing is on day 10 after the first dose is taken, with downward titration days 10-12 of 30 mg on Day 10, 20 mg on Day 11 and 10 mg on Day 12.
11638987|NCT00256152|No Intervention|AF Suppression OFF|
11638885|NCT00257894|Placebo Comparator|Placebo condition|Placebo capsules identical to active medication, 3/day for 12 days.
11638886|NCT00257816|Experimental|Topotecan|Adding weekly topotecan to cisplatin in patients with primary, locally advanced carcinoma of the cervix receiving pelvic irradiation.
11638887|NCT00257803|Experimental|1|In the other group, the women will receive a small injection of oxytocin directly into the vein via their intravenous (bolus) after their baby is born.
11638888|NCT00257803|Placebo Comparator|2|In one group, women will receive a small injection of saline (salt water) directly into the vein via their intravenous (bolus) after their baby is born.
11638889|NCT00257738|Experimental|MAGE -A3 vaccine|for those individuals in which tumor tests positive for MAGE-A3
11638890|NCT00257738|Experimental|HPV 16 vaccine|for patients with HPV 16 positive tumor
11638891|NCT00257725|Experimental|ADHD Treatment Group|Single-arm, open-label, once-daily-dosing of long-duration beaded MPH (B-MPH) at 10-30 mg (flexible titration) in 4-to-5 year old children with ADHD.
11638892|NCT00257712|Experimental|1|
11638893|NCT00257712|Placebo Comparator|2|
11638894|NCT00257699|Placebo Comparator|I|Ciprofloxacin placebo and Metronidazole placebo
11638895|NCT00257699|Experimental|II|Ciprofloxacin 500 mg bid po Metronidazole - total daily dose dependent on body weight
11638896|NCT00257686|Experimental|Pitavastatin 1 mg|Pitavastatin 1 mg once daily
11638897|NCT00257686|Active Comparator|Pravastatin 10 mg|Pravastatin 10 mg once daily
11638898|NCT00257686|Experimental|Pitavastatin 2 mg|Pitavastatin 2 mg once daily
11638899|NCT00257686|Active Comparator|Pravastatin 20 mg|Pravastatin 20 mg once daily
11638900|NCT00257686|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
11638901|NCT00257686|Active Comparator|Pravastatin 40 mg|Pravastatin 40 mg once daily
11638902|NCT00257673|Experimental|A|Active 30 mg MEM 1003
11638903|NCT00257673|Experimental|B|90 mg MEM 1003
11638904|NCT00257673|Placebo Comparator|C|Placebo for MEM 1003
11638905|NCT00257660|Experimental|1|Drug: abobotulinumtoxinA (Dysport®)
11638906|NCT00257660|Placebo Comparator|2|Placebo
11638907|NCT00257608|Experimental|1|
11638908|NCT00257608|Placebo Comparator|2|
11638909|NCT00257556|Experimental|Menotrophin|
11638910|NCT00257556|Active Comparator|Follitropin alfa|
11638911|NCT00257543|Experimental|single arm study|this is a single arm study
11638912|NCT00257465|Experimental|A|'Autologous, DNP-modified vaccine (M-Vax)'
11638913|NCT00257465|Experimental|B|Autologous, DNP-Modified Vaccine (MVax)
11638914|NCT00257465|Experimental|C|Autologous, DNP-Modified Vaccine (MVax)
11638915|NCT00257465|Placebo Comparator|D|0 cells
11638916|NCT00257439||CKD|Elevated se-creatinine + proteinuria
11638917|NCT00257439||Healthy controls|Healthy controls, normal se-creatinine, no proteinuria
11638918|NCT00257400|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy
11638919|NCT00257400|Active Comparator|Individual Psychotherapy|Individual Psychotherapy
11638920|NCT00257322|Experimental|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) 250ug/m^2 SQ QD with a cap of 500mcg SQ QD
11638921|NCT00257309|Active Comparator|Thrombolysis|Weight adjusted tenecteplase bolus + Unfrationated heparin
11638922|NCT00257309|Active Comparator|Primary angioplasty|Primary angioplasty
11638923|NCT00257296|Experimental|Screening and Intervention|Use a computer-based screening tool for intimate partner violence and provide a multi-faceted intervention based on the needs of the woman and services should would like to utilize.
11638924|NCT00257296|Active Comparator|Usual Care|Use a computer-based screening tool for intimate partner violence and provide list of resources available. Also, all physicians were trained on intimate partner violence and were told they could help anyone regardless of randomization.
11638925|NCT00257205|Active Comparator|B|Choice of one or the other Dacarbazine or Temozolomide(CP-675,206) (choice)
11638926|NCT00257205|Experimental|A|
11638927|NCT00257192|Placebo Comparator|2.0|
11638928|NCT00257192|Active Comparator|1.0|
11638929|NCT00257166|Experimental|Ziprasidone oral capsules|
11638930|NCT00257166|Placebo Comparator|Placebo|
11638931|NCT00257127|Experimental|1|Patients will receive PCV, HBV, and MMR at study entry
11638932|NCT00257127|Experimental|2|Patients will receive PPV, HBV, and MMR at study entry
11638933|NCT00257010|Experimental|Almotriptan Malate|Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
11638934|NCT00256997|Experimental|Risperidone long-acting injection (LAI)|Risperidone LAI 25 milligram (mg), 37.5 mg or 50 mg intramuscular (injection of a substance into a muscle) injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following the dose increase. Duration of treatment will be 24 months.
11638935|NCT00256997|Active Comparator|Oral atypical Antipsychotic|Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
11638936|NCT00256932|Placebo Comparator|Placebo|
11638937|NCT00256932|Experimental|Alvimopan 0.5 mg once daily|
11638938|NCT00256932|Experimental|alvimopan 0.5 mg twice daily|
11638939|NCT00256854|Experimental|Ropinirole cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR|Participants received Placebo in the evening and Ropinirole 1 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 2 mg controlled release for Restless Legs Syndrome (CR-RLS) in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 1 mg IR at bedtime and continued to receive the same till the end of Week 4.
11638940|NCT00256854|Experimental|Ropinirole cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS|Participants received Placebo in the evening and Ropinirole 1 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 2 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4.
11638985|NCT00256178|Experimental|Lapaquistat Acetate 100 mg QD + Simvastatin|
11638986|NCT00256178|Active Comparator|Simvastatin|
11638941|NCT00256854|Experimental|Ropinirole cohort B1: 2 mg IR/3 mg CR-RLS/2 mg IR/2 mg IR|Participants received Placebo in the evening and Ropinirole 2 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 3 mg CR-RLS in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 2 mg IR at bedtime and continued to receive the same till the end of Week 4.
11638942|NCT00256854|Experimental|Ropinirole cohort B2: 2 mg IR/2 mg IR/2 mg IR/3 mg CR-RLS|Participants received Placebo in the evening and Ropinirole 2 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 3 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4.
11638943|NCT00256854|Experimental|Ropinirole cohort C1: 4 mg IR/6 mg CR-RLS/4 mg IR/4 mg IR|Participants received Placebo in the evening and Ropinirole 4 mg IR at bedtime on Week 1. At the end of Week 1, participants were switched to receive Ropinirole 6 mg CR-RLS in the evening and placebo at bedtime till the end of Week 2. At the end of Week 2, participants were converted back to receive placebo in the evening and Ropinirole 4 mg IR at bedtime and continued to receive the same till the end of Week 4.
11638944|NCT00256854|Experimental|Ropinirole cohort C2: 4 mg IR/4 mg IR/4 mg IR/6 mg CR-RLS|Participants received Placebo in the evening and Ropinirole 4 mg IR at bedtime on Week 1 and continued to receive the same till the end of Week 3. At the end of Week 3, participants were switched to receive Ropinirole 6 mg CR-RLS in the evening and placebo at bedtime till the end of Week 4.
11638945|NCT00256776|Experimental|Thal + Dex + Velcade|
11638946|NCT00256776|Active Comparator|Thal + Dex|Standard treatment
11638947|NCT00256750|Active Comparator|Cyclosporine (CsA)|
11638948|NCT00256750|Experimental|Belatacept LI (less intensive)|
11638949|NCT00256750|Experimental|Belatacept MI (more intensive)|
11638950|NCT00256724|Sham Comparator|Sham ITD|sham Impedance Threshold Device
11638951|NCT00256724|Active Comparator|active ITD|active impedance threshold device
11638952|NCT00256698|Active Comparator|1|Anastrozole
11638953|NCT00256698|Experimental|2|Anastrozole + Fulvestrant
11638954|NCT00256672|Active Comparator|1|High-dose Thoraco-Lumbar-Sacral Orthoses wear (>23hrs/day) will be compared to low-dose Thoraco-Lumbar-Sacral Orthoses wear (12hrs/day)
11638955|NCT00256672|Active Comparator|2|Low-dose Thoraco-Lumbar-Sacral-Orthoses wear (12hrs/day)
11638956|NCT00256646||Group 1|"Patients who are enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2."
11638957|NCT00256633||Group 1|enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2.
11638958|NCT00256607||coronary artery calcium (CAC)|Cohort from the VADT study, had baseline coronary atherosclerosis assessed by coronary artery calcium (CAC) measured by computed tomography. Participants were followed over the 7.5-year study for development of cardiovascular endpoints.
11638959|NCT00256568||Primary Care Practices|One hundred and three prescribers, managers, nurses and office staff at seven primary care practices in Vermont
11638960|NCT00256529||I|All subjects presenting in with dysphagia will be in this cohort.
11638961|NCT00256516|Experimental|Eco-Atkins diet|
11638962|NCT00256516|Active Comparator|NCEP diet|
11638963|NCT00256503|Experimental|Insomnia|Insomnia subjects who receive 8 session cognitive behavioral therapy for insomnia.
11638964|NCT00256503|No Intervention|Good Sleeper|Good sleeper controls who receive no intervention
11638965|NCT00256451|Experimental|ALC and NAL|alcohol and active naltrexone
11638966|NCT00256451|Active Comparator|Sham ALC and NAL|"sham alcohol and active naltrexone"
11638967|NCT00256451|Placebo Comparator|placebo pill and ALC|placebo naltrexone and alcohol
11638968|NCT00256451|Placebo Comparator|placebo pill and Sham ALC|placebo naltrexone and placebo (non-alcoholic) alcohol
11638969|NCT00256412|Placebo Comparator|1|
11638970|NCT00256412|Active Comparator|2|Low Dose
11638971|NCT00256412|Active Comparator|3|High Dose
11638972|NCT00256334|Experimental|Resveratrol|GM-CSF administration to all subjects in addition to chemotherapy treatment.
11638973|NCT00256321|Experimental|Celecoxib/Oxaliplatin/Capecitabine|"Oxaliplatin 70mg/m2 IV on Days 1 and 8. Capecitabine 1000mg/m2 PO BID from Days 1 through 14. Celecoxib 400mg PO BID from Days 1 through 21.
~1 Cycle = 21 days."
11638974|NCT00256308|Experimental|Oxaliplatin|Oxaliplatin-70mg/m2 IV over 120 min once a week during radiation. Radiation-200 centigray (cGy) per day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday.
11638975|NCT00256295|Experimental|Gemcitabine plus Oxaliplatin|Gemcitabine given 1000 mg/m2 IV over 100 minutes Every 21 days. Oxaliplatin given 65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days.
11638976|NCT00256282|Experimental|Docetaxel & Vinorelbine + Sargramostim|Docetaxel, Vinorelbine, and Sargramostim
11638977|NCT00256269|Experimental|Oxaliplatin plus Irinotecan|Drug: Oxaliplatin-40 mg/m2 IV over 60 minutes Every 21 days. Drug: Irinotecan-60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days.
11638978|NCT00256243|Experimental|Chemotherapy with GM-CSF|"Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Carboplatin/Paclitaxel with GM-CSF (day 2-6)
~This regimen consists of intravenous administration of doxorubicin (Adriamycin) followed by cyclophosphamide (Cytoxan) every 14 days for a total of four cycles, unless stable disease or clinical progression is documented. Two weeks after completion of the last dose of AC, weekly Carboplatin/paclitaxel will be given for 3 weeks, followed by 1 week of rest, for a total of 12. Each clinic visit will last approximately 1 hour.
~Patients who are her-2 overexpressors by FISH will also receive Trastuzumab with weekly carboplatin and paclitaxel as the combination has been found to be synergistic in advanced breast cancer with improved clinical outcome."
11638979|NCT00256230|Experimental|Disulfiram|
11638980|NCT00256217|Experimental|Anastrozole|
11638981|NCT00256204|Experimental|1mg rasagiline|1mg early start active treatment arm (72 weeks active)followed by 1mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active)
11638982|NCT00256204|Experimental|2mg rasagiline|2mg early start active treatment arm (72 weeks active)followed by 2mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active)
11638983|NCT00256204|Placebo Comparator|Placebo|Each arm is followed by 36 weeks of placebo
11638984|NCT00256178|Experimental|Lapaquistat Acetate 50 mg QD + Simvastatin|
11638988|NCT00256152|Experimental|AF Suppression ON|
11638989|NCT00256126|Experimental|Turner Syndrome (TS)|
11638990|NCT00256126|Experimental|Growth Hormone Deficiency (GHD)|
11638991|NCT00256100|Active Comparator|One|Enoxaparin Sodium (Clexane ) is to be used in the control arm of the study
11638992|NCT00256100|Active Comparator|Two|Fondaparinux will be used as the anticoagulant in the sencond arm of the study
11638993|NCT00256087|Placebo Comparator|Standard Care|Two capsules containing placebo will be given 12 hourly
11638994|NCT00256087|Active Comparator|First active treatment|Two capsules containing probiotic lactobacillus fermentin given 12 hourly
11638995|NCT00256087|Active Comparator|Second active reatment|Two capsules containing probiotic lactobacillus acidiphilus given 12 hourly
11638996|NCT00256074|Other|Standard Therapy Group|Standard therapy group. Will receive high carbohydrate, low fat enteral feeding, (16.7% protein, 30% fat and 53.3% carbohydrate). The target rate is determined by the treating physician and dietician, for a minimum of 5 days following randomisation.
11638997|NCT00256074|Other|Alternative Therapy Group|2.Alternative therapy group will receive high-fat, low carbohydrate enteral feeding, (16.7% protein, 55.2% fat and 28.1% carbohydrates. At a target rate determined by the treating physician and dietician, for a maximum of 5 days following randomisation.
11638998|NCT00256048|No Intervention|Standard Care|Patients will receive enteral nutrition via a nasogastric tube as per standard feeding regime
11638999|NCT00256048|Active Comparator|Nasojejunal Arm|Patient will receive feeding via a nasojejunal feeding tube
11639000|NCT00256035|Other|Unstable coronary artery disease|Patients with unstable coronary artery disease will have daily IL6 levels
11639001|NCT00256035|Other|Coronary Angioplasty Patients|Patients having coronary angioplasty will have levels taken before and immediately after the proceedure and 24 hours post.
11639002|NCT00256035|Other|Coronary bypass grafts patients|Patients will have levels collected immediately after and 24 hours post procedure
11639003|NCT00256035|Other|Stable coronary Artery Diseaese Patients|Once the patients are commenced on treatment with statins and or angiotensin converting enzyme they will have twice weekly levels taken
11639004|NCT00256022|Active Comparator|Lactobacillus Acidophilus Arm|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
11639005|NCT00256022|Active Comparator|Lactobacillus Fermentum Arm|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
11639006|NCT00256022|Active Comparator|Lactobacillus Fermentum and Lactobacillus Acidophilus|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
11639007|NCT00256022|Placebo Comparator|Placebo|The placebo will be given to the patient 2 a day for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
11639008|NCT00255983|Experimental|1|faropenem medoxomil
11639009|NCT00255983|Placebo Comparator|2|
11639010|NCT00255970|Experimental|Regenafil graft|Regenafil
11639011|NCT00255970|Active Comparator|DFDBA|Demineralized Freeze Dried Bone Allograft
11639012|NCT00255944|Experimental|Youthnet messages on Facebook|Participants will receive internet-based messages from the Youthnet program
11639013|NCT00255944|Active Comparator|Messages on Facebook about current events|Participants will receive internet-based messages from the control program
11639014|NCT00255931|Experimental|1|
11639015|NCT00255931|Placebo Comparator|2|
11639016|NCT00255931|No Intervention|3|Usual Care
11639017|NCT00255918|Experimental|Dimethoxybenzylidene anabaseine 75 mg|Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 75 mg)
11639018|NCT00255918|Placebo Comparator|Placebo|Participants will take placebo.
11639019|NCT00255918|Experimental|Dimethoxybenzylidene anabaseine 150 mg|Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 150 mg)
11639020|NCT00255892||Part A - Provider Interviews|The provider interviews will be comprised of participants who are clinical providers, mental health providers, and case managers with at least 1 year of experience working with HIV-positive youth; one from each category from all 15 ATN sites will be targeted for a total of 45 participants.
11639021|NCT00255892||Part B - Youth Focus Groups|"The focus groups will be comprised of 6-8 participants per group who are between the ages of 16 and 24, diagnosed HIV+ and aware of their HIV diagnosis for between 12-24 months, and receive services at three selected ATN sites or their community partners for a total of 36-48 participants.
~For the purposes of this study, youth who acquired HIV perinatally will be excluded from participation in this study."
11639022|NCT00255840|Active Comparator|A|Study-specified Antiretroviral regimen under care of HIV-trained medical doctor
11639023|NCT00255840|Active Comparator|B|Study-specified Antiretroviral regimen under care of HIV-trained primary care nurse
11639024|NCT00255814|Other|Radiation therapy dose level II: 4.0 Gy/fx|Radiation therapy dose level II: 4.0 Gy/fraction
11639025|NCT00255814|Other|Radiation therapy dose level III: 4.5 Gy/fx|Radiation therapy dose level III: 4.5 Gy/fraction
11639026|NCT00255814|Other|Radiation therapy dose level IV: 5.0 Gy/fx|Radiation therapy dose level IV: 5.0 Gy/fraction
11639027|NCT00255801|Experimental|Doxil and Targretin® (bexarotene)|Patients will be treated with intravenous Doxil® every two weeks for 8 doses (16 weeks). Responses will be assessed. They will then receive Targretin® (bexarotene) orally for at least 16 weeks. Patients who achieve a CR or PR may continue on Targretin® (bexarotene) until relapse.
11639028|NCT00255788|Active Comparator|Arm A|Everolimus - 28 days q 4 wk
11639029|NCT00255788|Active Comparator|Arm B|Everolimus - days 1, 8, 15 and 22 q 4wks
11639030|NCT00255762|Experimental|Treatment (carboplatin, paclitaxel, bevacizumab)|Patients receive carboplatin IV over 30 minutes on day 1, paclitaxel IV over 1 hour on days 1, 8, and 15, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11639031|NCT00255749|Experimental|early intervention epoietin alfa|Patients receive epoetin alfa subcutaneously on day 1. Treatment repeats every 21 days for up to 5 courses.
11639032|NCT00255749|Other|standard intervention epoietin alfa|Patients receive epoetin alfa as in arm I once their hemoglobin level is ≤ 10.5 g/dL.
11639033|NCT00255723|Experimental|Cytoreductive chemotherapy group 1|Patients receive ICE comprising ifosfamide IV and carboplatin IV once on day 2 and etoposide IV over 1 hour once daily on days 1-3. Patients then receive ifosfamide IV twice on day 15, carboplatin IV once on day 17 and etoposide IV over 1 hour twice daily on days 15-17.
11639034|NCT00255723|Experimental|Cytoreductive chemotherapy group 2|Patients receive ifosfamide IV twice on days 1 and 17, carboplatin IV once on days 3 and 19, and etoposide IV over 1 hour twice daily on days 1-3 and 17-19.
11639035|NCT00255684|Experimental|Conditioning therapy followed by TBI|Fludarabine, Cyclophosphamide; Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil
11639036|NCT00255658|Experimental|Treatment (sorafenib tosylate, temsirolimus)|"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. They also receive oral sorafenib* twice daily starting on day 8 of course 1. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
~NOTE: *On the days of the temsirolimus infusion, temsirolimus should be taken concurrently with the morning dose of sorafenib.
~Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD."
11639037|NCT00255606|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on days 1 and 15 and oral prednisone once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11639038|NCT00255606|Experimental|Arm II|Patients receive docetaxel IV over 1 hour on day 1 and prednisone once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11639039|NCT00255580|Experimental|1|Active cannabis (1-8% THC by weight)
11639040|NCT00255580|Placebo Comparator|2|Placebo cannabis
11639041|NCT00255567|Active Comparator|1|Sodium Stibogluconate (30 days)
11639042|NCT00255567|Experimental|2|Paromomycin Sulphate (21 days)
11639043|NCT00255567|Experimental|3|Sodium Stibogluconate + Paromomycin Sulphate (17 days)
11639044|NCT00255515|Experimental|1|quetiapine fumarate
11639045|NCT00255515|Active Comparator|2|Conventional treatment for schizophrenia
11639046|NCT00255515|Experimental|3|quetiapine fumarate + Cognitive Remediation Therapy
11639047|NCT00255372|Experimental|1|
11639048|NCT00255372|Active Comparator|2|
11639049|NCT00255346|Experimental|Acute myeloid leukemia (AML)|Dasatinib 70 mg orally twice daily.
11639050|NCT00255346|Experimental|MDS/CMML|Dasatinib 70 mg orally twice daily.
11639051|NCT00255346|Experimental|HES/CEL|Dasatinib 70 mg orally twice daily.
11639052|NCT00255346|Experimental|Primary myelofibrosis (PMF)|Dasatinib 70 mg orally twice daily.
11639053|NCT00255346|Experimental|Systemic Mastocytosis (SM)|Dasatinib 70 mg orally twice daily.
11639054|NCT00255229|Active Comparator|1|Irinotecan, 5FU, Glutamine
11639055|NCT00255229|Placebo Comparator|2|Irinotecan, 5FU, Placebo
11639056|NCT00255190|Experimental|Dexlansoprazole MR 60 mg QD|
11639057|NCT00255190|Experimental|Dexlansoprazole MR 90 mg QD|
11639058|NCT00255177|Placebo Comparator|Placebo|
11639059|NCT00255177|Active Comparator|150 mg daily|
11639060|NCT00255177|Active Comparator|300mg daily|
11639061|NCT00255177|Active Comparator|300mg twice daily|
11639062|NCT00255164|Experimental|Dexlansoprazole MR 60 mg QD|
11639063|NCT00255164|Experimental|Dexlansoprazole MR 90 mg QD|
11639064|NCT00255164|Placebo Comparator|Placebo|
11639065|NCT00255151|Experimental|Dexlansoprazole MR 60 mg QD|
11639066|NCT00255151|Experimental|Dexlansoprazole MR 90 mg QD|
11639067|NCT00255151|Placebo Comparator|Placebo|
11639068|NCT00255125|Placebo Comparator|Arm Placebo|Placebo
11639069|NCT00255125|Experimental|Arm Soy Supplement|Soy Supplement
11639070|NCT00255112|No Intervention|1|The present study evaluates the efficacy of a family-based CBT treatment specifically tailored to children with SAD, developed at the University of Basel. The study consists of 40 participants (5-7 years old) with SAD and their families. Participants were randomly assigned to 12 weeks of SAD-specific family-based CBT treatment or to waitlist condition.
11639071|NCT00255112|Active Comparator|2|The present study evaluates the efficacy of a family-based CBT treatment specifically tailored to children with SAD, developed at the University of Basel in comparison to a global CBT treatment. The study consists of 60 participants (between 8 and 13 years old), randomly assigned to one of the two treatments.
11639072|NCT00255099|Active Comparator|001|TMC125 2 x 100 mg tablets b.i.d. / 96 weeks
11639073|NCT00255099|Placebo Comparator|002|Placebo 2 tablets b.i.d. / 96 weeks
11639074|NCT00255086|Experimental|Memantine|10mg Memantine
11639075|NCT00255086|Placebo Comparator|Control|10 mg Placebo pill
11639076|NCT00255047|Experimental|Study Group 1: DAPTACEL®, ActHIB®, and IPOL®|Participants will receive 3 doses of DAPTACEL®, ActHIB®, and IPOL® at Months 2, 4, and 6, respectively
11639077|NCT00255047|Experimental|Study Group 2: Pentacel®|Participants will receive 3 doses of Pentacel® at Months 2, 4, and 6, respectively
11639078|NCT00255047|Experimental|Study Group 3: DTaP-IPV and ActHIB®|Participants will receive 3 doses of DTaP-IPV and ActHIB® at Months 2, 4, and 6, respectively
11639079|NCT00255047|Experimental|Study Group 4: Pentacel®|Participants will receive 3 doses of Pentacel® at Months 2, 4, and 6, respectively
11639080|NCT00255034|Active Comparator|24 weeks of therapy|Genotype 3 HCV subjects with high viral load (at least 2 million copies/mL) treated for 24 weeks
11639081|NCT00255034|Experimental|48 weeks of therapy|Genotype 3 HCV subjects with high viral load (at least 2 million copies/mL) treated for 48 weeks
11639082|NCT00255021|Experimental|1|
11639083|NCT00255008|Active Comparator|Genotype 1 SEA PEG-IFN/RIB 48 w|Genotype 1 hepatitis C virus (HCV)-infected Southeastern Asian (SEA) subjects treated for up to 48 weeks with PEG-Intron (peginterferon alfa-2b; PEG-IFN) REDIPEN and REBETOL (ribavirin; RIB) combination therapy
11639084|NCT00255008|Active Comparator|Genotype 1 Caucasian PEG-IFN/RIB 48 w|Genotype 1 HCV-infected Caucasian subjects treated for up to 48 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
11639085|NCT00255008|Experimental|Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 24 w|Genotype 6, 7, 8, 9 HCV-infected SEA subjects randomized to treatment for 24 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
11639086|NCT00255008|Active Comparator|Genotype 6, 7, 8, 9 SEA PEG-IFN/RIB 48 w|Genotype 6, 7, 8, 9 HCV-infected SEA subjects randomized to treatment for 48 weeks with PEG-Intron REDIPEN and REBETOL combination therapy
11639087|NCT00254995||Menactra Vaccine Recipients|Participants who received Menactra vaccine as part of routine medical care during the study period in Kaiser Permanente.
11639088|NCT00254995||Age-Matched Control|Each individual receiving Menactra vaccine served as their own control for evaluation of acute (Days 0-30) events (short-term surveillance). For the 6-month (long-term) surveillance, for each person receiving Menactra vaccine, a control matched on age (± 1 year), sex, and month of vaccination was selected who received a received tetanus and diphtheria toxoids (Td), hepatitis A, hepatitis B, or hepatitis A/hepatitis B combination vaccine as part of routine medical care during the same month 1 year earlier in Kaiser Permanente
11639089|NCT00254982|Experimental|Group 1 (high-need)|Adult participants with moderate to severe plaque psoriasis who were either not controlled by, or were intolerant to or had contraindications to at least two currently available systemic therapies (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).
11639090|NCT00254982|Experimental|Group II (low-need)|Adult participants with moderate to severe plaque psoriasis who had undergone pretreatment with no more than one currently available systemic therapy (eg, photochemotherapy, cyclosporine, methotrexate, oral retinoids, fumaric acid esters, efalizumab, etanercept).
11639091|NCT00254969|Experimental|1|
11639092|NCT00254917|Experimental|1|Concommitant recombinant hepatitis B vaccine at 0, 6 and 14 weeks of age
11639093|NCT00254917|Experimental|2|Concommitant recombinant hepatitis B vaccine at 6, 10, and 14 weeks of age.
11639094|NCT00254904|Experimental|A|Standard of Care chemotherapy plus experimental intervention (PF-3512676)
11639095|NCT00254904|Active Comparator|B|Standard of Care chemotherapy
11639096|NCT00254891|Experimental|A|Standard of care chemotherapy plus experiment intervention (PF-3512676)
11639097|NCT00254891|Active Comparator|B|Standard of care chemotherapy
11639098|NCT00254852|Active Comparator|O|This treatment arm includes autograft harvested from local bone and / or the iliac crest, supplemented with a demineralized bone matrix (DBM) autograft extender, Optecure.
11639099|NCT00254852|Active Comparator|A|This treatment arm includes autograft harvested from local bone and / or the iliac crest.
11639100|NCT00254826|Other|YF-VAX® plus saline|Drug: YF-VAX® plus saline
11639101|NCT00254826|Experimental|17D YF Vaccine plus Ig|Drug: 17D YF Vaccine plus Ig; one vaccine on day 0
11639102|NCT00254800|Experimental|Sequence 1|Oral contraceptive 1 hour prior to exenatide/oral contraceptive 30 minutes after exenatide/oral contraceptive alone
11639103|NCT00254800|Experimental|Sequence 2|Oral contraceptive 30 minutes after exenatide/oral contraceptive alone/oral contraceptive 1 hour prior to exenatide
11639104|NCT00254800|Experimental|Sequence 3|Oral contraceptive alone/oral contraceptive 1 hour prior to exenatide/oral contraceptive 30 minutes after exenatide
11639105|NCT00254761|Experimental|1|High dose cannabis (7.5% THC by weight)
11639106|NCT00254761|Experimental|2|Low dose cannabis (3.5% THC by weight)
11639107|NCT00254761|Placebo Comparator|3|Placebo cannabis
11639108|NCT00254748|Placebo Comparator|1|Placebo
11639109|NCT00254748|Experimental|2|Flexible doses of 200 mg/day to 600 mg/day quetiapine fumarate
11639110|NCT00254722|Experimental|I|single arm study
11639111|NCT00254683|Experimental|PET/CT|Single arm study evaluating the use of PET/CT to assess rectal cancer response to neoadjuvant therapy
11639112|NCT00254657|Placebo Comparator|Placebo|
11639113|NCT00254657|Experimental|Levetiracetam|
11639114|NCT00254644||Dyslexia|adults from 18-35 ans.
11639115|NCT00254644||Control|adults from 18-35 ans.
11639116|NCT00254631|Active Comparator|study group|pre operative medication with 20 mg oxycontine PO
11639117|NCT00254631|Placebo Comparator|placebo group|pre operative medication with placebo tablet PO
11639118|NCT00254618|Experimental|30 mg|30 mg/kg/day mesalamine
11639119|NCT00254618|Experimental|60 mg|60 mg/kg/day mesalamine
11639120|NCT00254618|Experimental|90 mg|90 mg/kg/day mesalamine
11639121|NCT00254592|Experimental|AC with GM-CSF and Carboplatin/Nab-Paclitaxel|"Doxorubicin and cyclophosphamide (AC) administered intravenously every 14 days up to a total of 4 cycles, with GM-CSF on days 4-13, depending on tumor response.
~Two weeks after the completion of AC, weekly doses of carboplatin/nab-paclitaxel will be given for 3 weeks, followed by 1 week of rest, for a total of 9-12 doses. Subjects who receive 4 cycles of AC will receive 9 doses of nab-paclitaxel and subjects who receive 2 cycles of AC will receive 12 weeks of nab-paclitaxel. In addition, subjects will receive trastuzumab weekly (12-16) doses if they are Her-2 positive and bevacizumab (6-8) doses every 2 weeks if they are Her-2 negative. Each clinic visit will last approximately ½ hour."
11639122|NCT00254579|Experimental|15 mg/kg CP-675,206|
11639123|NCT00254566|Experimental|1|
11639124|NCT00254566|Active Comparator|2|
11639125|NCT00254553|Active Comparator|Arm 1|Testim 1% (testosterone gel)
11639126|NCT00254553|Placebo Comparator|Arm 2|Placebo
11639127|NCT00254540|Experimental|SU-011248 capsule|
11639128|NCT00254501|Active Comparator|Usual Care plus out-of-pocket cost waiver|Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.
11639129|NCT00254501|Experimental|EMPOWER|Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.
11639130|NCT00254488|Experimental|Lithium (LI)|Participants will receive 9 weeks of treatment with lithium
11639131|NCT00254488|Experimental|Divalproex (DV)|Participants will receive 9 weeks of treatment with divalproex
11639132|NCT00254462|Experimental|atomoxetine and parent training|atomoxetine capsules, dose 0.5mg/kg/day to 1.8mg/kg/day administered once daily for 8 weeks
11639133|NCT00254462|Placebo Comparator|placebo and parent training|matching placebo capsules, dose 0.5mg/kg/day to 1.8mg/kg/day administered once daily for 8 weeks
11639134|NCT00254436|Experimental|Epoetin Alfa|
11639135|NCT00254423|Experimental|Arm A (once daily dasatinib)|Patients receive dasatinib PO QD for up to 15-18 years.
11639136|NCT00254423|Experimental|Arm B (twice daily dasatinib)|Patients receive dasatinib PO BID for up to 15-18 years.
11639137|NCT00254410|Experimental|FCM-R + Pegylated Filgrastim|Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6. Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6. Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6. Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6. Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
11639138|NCT00254397|Experimental|gp100 + Leuprolide|Group IA: HLA-A*0201 positive/HLA-DP4 negative treated with gp100 (1.0 ml subcutaneous injection in extremities) + Leuprolide (3-month 11.25 mg sustained-release formulation administrated intramuscularly then again 12 weeks later (2 injections)).
11639139|NCT00254397|Experimental|gp100 - No Leuprolide|Group IB: HLA-A*0201 positive/HLA-DP4 negative treated with gp100 (1.0 ml subcutaneous injection in extremities) - No Leuprolide
11639140|NCT00254397|Experimental|gp100 + MAGE-3 + Leuprolide|Group IIA: HLA-A*0201positive/HLA-DP4 positive treated with gp100 (1.0 ml subcutaneous injection in extremities) + MAGE-3 (1.0 ml subcutaneous injection in extremities) + Leuprolide (3-month 11.25 mg sustained-release formulation administrated intramuscularly then again 12 weeks later (2 injections)).
11639141|NCT00254397|Experimental|gp100 + MAGE-3 - No Leuprolide|Group IIB: HLA-A*0201positive/HLA-DP4 positive treated with gp100 (1.0 ml subcutaneous injection in extremities) + MAGE-3 (1.0 ml subcutaneous injection in extremities) - No Leuprolide
11639142|NCT00254384|Experimental|Treatment (docetaxel, cisplatin, erlotinib hydrochloride)|Patients receive docetaxel IV over 1 hour followed by cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning within 90 days following definitive surgical resection, patients receive erlotinib hydrochloride PO daily for up to 1 year.
11639143|NCT00254306||1|"ex-ecstasy users"
11639144|NCT00254306||2|control subjects
11639145|NCT00254293|Placebo Comparator|Group 1 (weight < 60 kg)|
11639146|NCT00254293|Placebo Comparator|Group 2 (weight < 60 kg)|
11639147|NCT00254293|Placebo Comparator|Group 3 (weight 60-100 kg)|
11639148|NCT00254293|Placebo Comparator|Group 4 (weight > 100 kg)|
11639149|NCT00254293|Placebo Comparator|Group 5 (weight > 100 kg)|
11639150|NCT00254293|Experimental|Abatacept|Long Term
11639151|NCT00254267|Experimental|Arm One|AMG 706 125mg, oral, once a day
11639152|NCT00254254|Experimental|Sequence 1|Exenatide 2.5 mcg - Exenatide 5 mcg - Placebo 0.02 mL
11639153|NCT00254254|Experimental|Sequence 2|Exenatide 2.5 mcg - Placebo 0.02 mL - Exenatide 5 mcg
11639154|NCT00254254|Experimental|Sequence 3|Placebo 0.02 mL - Exenatide 2.5 mcg - Exenatide 5 mcg
11639155|NCT00254176|Active Comparator|Cysteine|Subjects that receive cysteine
11639156|NCT00254176|Placebo Comparator|No-cysteine placebo|Subjects that do not receive cysteine but an isonitrogenous placebo
11639157|NCT00254163|Active Comparator|Fludarabine, Cyclophosphamide, and Rituximab|Fludarabine, Cyclophosphamide, and Rituximab (dosage based on day in cycle)
11639158|NCT00254163|Experimental|Pentostatin, Cyclophosphamide, and Rituximab|Pentostatin, Cyclophosphamide, and Rituximab (dosage depends on day in cycle)
11639159|NCT00254072|Active Comparator|Smaller Stapler|3.5 mm Circular Stapler
11639160|NCT00254072|Active Comparator|Larger Stapler|4.8 mm Circular Stapler
11639161|NCT00254046|Placebo Comparator|002|Placebo 2 tablets b.i.d.96 weeks
11639162|NCT00254046|Active Comparator|001|TMC125 2 X100 mg tablets b.i.d.96 weeks
11639163|NCT00253981|Experimental|Infrared Light Therapy|Intervention: The use of infrared light therapy for the treatment of tibial fracture. The treatment was assigned three times a week for four weeks.
11639164|NCT00253981|Placebo Comparator|Standard of Care|Standard of care was characterized by the use of standard medical treatment to include medication.
11639165|NCT00253968|Experimental|Eplivanserin|Eplivanserin 5 mg/day
11639166|NCT00253968|Placebo Comparator|Placebo|Placebo of Eplivanserin 5 mg /day
11639167|NCT00253955|Experimental|1|
11639168|NCT00253955|Active Comparator|2|
11639169|NCT00253916|No Intervention|Control Arm|No exercise measured
11639170|NCT00253916|Experimental|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
11639171|NCT00253916|Experimental|Resistance Exercise Program|Resistance Exercise Program
11639172|NCT00253903|Experimental|1|5 mg/day
11639173|NCT00253903|Placebo Comparator|2|
11639174|NCT00253890|Active Comparator|Trazodone|50-150mg (50mg capsules) at bedtime for 90 days
11639175|NCT00253890|Placebo Comparator|Placebo|1-3 capsules at bedtime for 90 days
11639176|NCT00253877|Active Comparator|Conserve Plus Hip Resurfacing|Conserve Plus Hip Resurfacing group. Complication rate will be compared between groups.
11639177|NCT00253877|Other|Total Hip Replacement|Historical Total Hip Replacement control group of recently published conventional total hip replacement results (Williams, 2002). Complication rate will be compared between groups.
11639178|NCT00253838|Active Comparator|Restoration HA Stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating
11639179|NCT00253838|Sham Comparator|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
11639180|NCT00253786|Experimental|Intensive multifactorial therapy (Protocol A)|Protocol A: serum creatinine <1.2 mg/dl in male and <1.0 mg/dl in female.
11639181|NCT00253786|Active Comparator|Standard therapy (Protocol A)|Protocol A: serum creatinine <1.2 mg/dl in male and <1.0 mg/dl in female.
11639182|NCT00253786|Experimental|Intensive multifactorial therapy (Protocol B)|Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.
11639183|NCT00253786|Active Comparator|Standard therapy (Protocol B)|Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.
11639184|NCT00253747|Active Comparator|Osmotic-Release Methylphenidate|
11639185|NCT00253747|Placebo Comparator|Placebo|
11639186|NCT00253734|Active Comparator|4|31 subjects to receive 15 mcg of TIV administered intramuscularly.
11639187|NCT00253734|Experimental|2|31 subjects to receive 6 mcg of TIV administered intradermally.
11639188|NCT00253734|Experimental|1|31 subjects to receive 9 mcg of TIV administered intradermally.
11639189|NCT00253734|Experimental|3|31 subjects to receive 3 mcg of TIV administered intradermally.
11639190|NCT00253734|Active Comparator|5|31 subjects to receive 9 mcg of TIV administered intramuscularly.
11639191|NCT00253734|Active Comparator|7|31 subjects to receive 3 mcg of TIV administered intramuscularly.
11639192|NCT00253734|Active Comparator|6|31 subjects to receive 6 mcg of TIV administered intramuscularly.
11639193|NCT00253721|Experimental|All subjects|
11639194|NCT00253708|Experimental|massage|"Patients received 3 massage therapy visits from massage therapists in initial week with a duration of 15-45 minutes.NOTE: Intervention 'management of therapy complications' has not been included in any Arm/Group Descriptions.
~Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment"
11639195|NCT00253708|Active Comparator|no-touch control|Patients received 3 no-touch therapy visits from massage therapists who provided no-touch without healing intention.Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment
11639196|NCT00253708|No Intervention|Usual care|Patients did not receive visits from massage therapists. Patients were intended to receive pain therapy, psychosocial assessment and care, and quality-of-life assessment
11639197|NCT00253682||1|HIV-uninfected infants born to HIV-infected women with in-utero exposure to HIghly Active Ani-Retroviral Therapy (HAART) who were enrolled in the Women and Infants Transmission Study (WITS).
11639198|NCT00253682||2|Historical cohort of HIV-uninfected infants born to HIV-infected women from the Pediatric Pulmonary and Cardiovascular Complications of HIV Study (P2C2 HIV) who were not exposed to HAART.
11639199|NCT00253643|Experimental|Arm I (FO, GT catechin extract)|Patients receive oral fish oil (FO) 3/day and oral green tea (GT) extract 2/day
11639200|NCT00253643|Experimental|ArmII (FO placebo, GT catechin extract)|Patients receive a fish oil (FO) placebo 3/day and oral green tea (GT) extract 2/day
11639201|NCT00253643|Experimental|Arm III (FO, GT placebo)|Patients receive oral fish oil (FO) 3/day and a placebo mimicking green tea (GT) catechins 2/day
11639202|NCT00253643|Placebo Comparator|Arm IV (FO placebo, GT placebo)|Patients receive a fish oil (FO) placebo mimicking fish oil 3/day and another placebo mimicking green tea (GT) catechins 2/day
11639203|NCT00253630|Experimental|Treatment (vorinostat)|Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11639204|NCT00253578|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11639205|NCT00253539|Experimental|Arm I|Participants receive oral tamoxifen once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
11639206|NCT00253539|Experimental|Arm II|Participants receive oral arzoxifene once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
11639207|NCT00253539|Placebo Comparator|Arm III|Participants receive an oral placebo once daily once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered treatment with arzoxifene for an additional 6 months.
11639208|NCT00253500|Experimental|Epirubicin|
11639209|NCT00253435|Experimental|All the patients enrolled in the study|"This is a single arm study. The following description applies to all the patients who are enrolled in the study:
~On Day -21, patients receive 131I-MIBG infusion.
~On Day -7, Day -6, Day -5, patients receive Carboplatin, Etoposide, Melphalan.
~On Day -4, patients receive Carboplatin, Etoposide.
~On Day -3, Day -2, Day -1, patients rest.
~On Day 0, patients receive peripheral blood stem cell infusion.
~Dosing of Carboplatin, Etoposide and Melphalan is based upon whole body dosimetry (cGy) estimates.
~Filgrastim 5 micrograms/kg/day S.C. or IV will be given daily beginning on Day 0.
~Local radiation therapy is to be given to previously non-irradiated primary and metastatic sites of disease."
11639210|NCT00253383|Experimental|ENABLE (concurrent palliative care)|telephone based ENABLE educational intervention
11639211|NCT00253383|Active Comparator|Usual Care|Supportive and palliative usual care services at DHMC, Behavioral
11639212|NCT00253370|Experimental|BAY 43-9006, docetaxel, cisplatin|Patients receive oral BAY 43-9006 400mg twice daily on days 1-21. Patients also receive docetaxel IV, 75 mg/m2 over 1 hour and cisplatin IV, 75 mg/m2 over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11639213|NCT00253318|Experimental|RAD001 + Docetaxel|RAD001 30 mg orally on Days 1 and 8. Docetaxel 40 mg/m^2 intravenous (IV) over 1 hour on Day 1. Dexamethasone 8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
11639214|NCT00253279||1|16 healthy subjects will be studied. Each patient will undergo one PET Scan to measure muscle protein synthesis rate.
11639215|NCT00253279||2|48 burn patients will be studied. Each patient will have a maximum of 3 PET Scans, which will be done at different times during the first 24 months after injury. A maximum of 2 of these scans will be done while they are inpatient; one after discharge.
11639216|NCT00253266|Experimental|Verum|Quetiapine augmentation
11639217|NCT00253266|Placebo Comparator|Placebo|"Placebo augmentation"
11639218|NCT00253110|Active Comparator|risperidone|
11639219|NCT00253110|Active Comparator|haloperidol|
11639220|NCT00253097|No Intervention|Control|Patients in the control group had the usual care provided at the stroke unit, that is counselling on avoiding risky health behavior, compliance with preventive medication, measurement of blood pressure and a 3 months' visit in the outpatient clinic
11639273|NCT00252174|Experimental|Stage 1 Active methylenedioxymethamphetamine & psychotherapy|8 subjects will receive full or nearly full doses of MDMA in Stage 1 and do not continue to participate into Stage 2.
11639221|NCT00253097|Experimental|Intervention|Patienta allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
11639222|NCT00253084|Other|IPX054 - CD-LD IR|Subjects received IPX054 200 mg b.i.d and CD-LD IR Placebo q.i.d for 2 weeks and then received IPX054 Placebo b.i.d and CD-LD IR q.i.d for 2 weeks.
11639223|NCT00253084|Other|CD-LD IR - IPX054|Subjects received IPX054 Placebo b.i.d and CD-LD IR q.i.d for 2 weeks and then IPX054 200 mg b.i.d and CD-LD IR Placebo q.i.d for 2 weeks.
11639224|NCT00253071|Active Comparator|A,2|Standard treatment: treatment as usual at a community psychiatric center, private psychiatrist or general practitioner.
11639225|NCT00253071|Experimental|A, 1|"Behavioral: Prophylactic combined medical and psychological treatment
~Medical treatment is naturalistic and evidence based according to international recommendations.
~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
11639226|NCT00253045|Experimental|Motivational group|Group counseling using motivational interviewing
11639227|NCT00252967|Placebo Comparator|Placebo|Placebo taken daily
11639228|NCT00252967|Experimental|Atorvastatin|Atorvastatin at a dose of 80 mg daily
11639229|NCT00252954|Placebo Comparator|1|
11639230|NCT00252928|Placebo Comparator|A|Placebo group does not receive Aquatabs.
11639231|NCT00252928|Experimental|B|Intervention arms receives Aquatabs.
11639232|NCT00252915|Experimental|Verum|GM-CSF therapy
11639233|NCT00252746|Experimental|ZD6474 100mg|Daily dose
11639234|NCT00252746|Experimental|ZD6474 200mg|daily dose
11639235|NCT00252746|Experimental|ZD6474 300mg|daily dose
11639236|NCT00252733|No Intervention|1|Placebo
11639237|NCT00252733|Experimental|2|candesartan cilexetil
11639238|NCT00252720|Experimental|candesartan|candesartan cilexetil 32 mg once daily
11639239|NCT00252720|No Intervention|placebo|control
11639240|NCT00252694|Experimental|candesartan|candesartan cilexetil 32 mg once daily
11639241|NCT00252694|No Intervention|placebo|control
11639242|NCT00252629|Active Comparator|Therapeutic nasal CPAP|Comparing change of veterans reported outcomes before and after 3 weeks treatment of therapeutic nasal CPAP with the change on sham nasal CPAP.
11639243|NCT00252629|Sham Comparator|Sham nasal CPAP|Comparing change of symptoms and veterans reported outcomes before and after treatment of 3 weeks on sham nasal CPAP with the change on therapeutic nasal CPAP
11639244|NCT00252616|Experimental|1|trophic feeds
11639245|NCT00252616|Active Comparator|2|Full-calorie feeds
11639246|NCT00252590|Experimental|Health Motivational Feedback|Personalized health-related feedback
11639247|NCT00252590|Active Comparator|Health Education|Non-personalized didactic health-related education
11639248|NCT00252590|Active Comparator|Control - treatment as usual|No added treatment control
11639249|NCT00252577||Group 1|Veterans with bipolar disorder
11639250|NCT00252564|Experimental|Bev-FOLFOX|"(Bev-FOLFOX): Bevacizumab, followed by oxaliplatin and LV given simultaneously via T connector over 2 hours, followed by bolus 5-FU followed by infusional 5-FU.
~Bevacizumab --> oxaliplatin and LV --> bolus 5-FU --> infusional 5-FU
~Dosing on Days 1 and 15 of each 28-day cycle"
11639251|NCT00252564|Experimental|FOLF-CB|"(FOLF-CB): Cetuximab administered over 2 hours (first dose only; administer all other doses over 1 hour) followed by bevacizumab over 30 minutes, followed by LV over 30 minutes, followed by bolus 5-FU followed by infusional 5-FU.
~Cetuximab --> bevacizumab --> LV --> bolus 5-FU --> infusional 5-FU"
11639252|NCT00252551|Experimental|1|osteosynthesis
11639253|NCT00252551|Active Comparator|2|Simple surgery
11639254|NCT00252538||Group 1|Research participants are: 1) male or female, 2) age 18 or older, 3) chronically infected with the hepatitis C virus, 4) candidates for interferon therapy, 4) not on antidepressant treatment , and 5) not currently abusing any substances such as alcohol or intravenous drugs, or having abused in the past 6 months
11639255|NCT00252525||Group 1|This is an observational study of patients who are enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2@.
11639256|NCT00252512|Experimental|Contingency Management|Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are negative, they receive a chance to draw tokens from a bowl. Some tokens are social reinforcement. Others have monetary value.
11639257|NCT00252512|Placebo Comparator|Placebo|Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
11639258|NCT00252499|Placebo Comparator|Placebo Arm|matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd
11639259|NCT00252499|Experimental|Rosiglitazone Arm|rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd
11639260|NCT00252499|Experimental|Fenofibrate Arm|micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid
11639261|NCT00252486|Placebo Comparator|Flax oil, placebo oil|
11639262|NCT00252421|Active Comparator|Nitroglycerin|Nitroglycerin ointment 15 mg/day daily for 24 month
11639263|NCT00252421|Placebo Comparator|Placebo|Placebo ointment daily for 24 month
11639264|NCT00252382|Experimental|Treatment with 48 mg/m2 of SNS-595|Patients are treated with 48 mg/m2 of the drug SNS-595 injection once every 21 days for up to 6 cycles as a second -line therapy to patients with advanced non-small cell lung cancer (NSCLC)
11639265|NCT00252317|Active Comparator|1|Captopril test dose and Trandolapril
11639266|NCT00252317|Placebo Comparator|2|
11639267|NCT00252304|Experimental|Zinc|Zinc sulphate 10 or 20 mg per day
11639268|NCT00252304|Placebo Comparator|Placebo|Placebo
11639269|NCT00252239|Active Comparator|1|tenecteplase
11639270|NCT00252239|Active Comparator|2|tissue plasminogen activator, tPA
11639271|NCT00252187|Active Comparator|B-type Natriuretic Peptide (BNP)|BNP (nesiritide) administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
11639272|NCT00252187|Placebo Comparator|Placebo|Placebo self-administered subcutaneously twice daily for 8 weeks.
11639373|NCT00250796|Experimental|Arm 2|Thalidomide+interferon+Octreotide
11639274|NCT00252174|Active Comparator|Stage 1 low dose methylenedioxymethamphetamine & Psychotherapy|4 individuals will receive sub-threshold to threshold minimal doses of MDMA in Stage I
11639275|NCT00252174|Experimental|Stage 2 Active methylenedioxymethamphetamine & Psychotherapy|The 4 subjects assigned in Stage I to the control arm will have the option to continue into Stage 2 to repeat the experimental procedures of Stage I but with open-label MDMA at the near-full to full dosage strength.
11639276|NCT00252161|Active Comparator|1|Procedure/Surgery: Gastrectomy with more than D2 dissection
11639277|NCT00252161|Experimental|2|Drug: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
11639278|NCT00252148|Active Comparator|ADMVA|ADMVA dosage escalation
11639279|NCT00252148|Placebo Comparator|Placebo|Placebo is 10mM TRIS HCl, 140mM NaCl, ph 7.7
11639280|NCT00252122|Experimental|1|Patients receiving ketamine are those patients, arm 1, that are sill experiencing pain after Morphine has been given.
11639281|NCT00252057|Experimental|Re-engineered hospital discharge|"Participants received the Re-Engineered Hospital Discharge, a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call 2-4 days after discharge by a clinical pharmacist."
11639282|NCT00252057|No Intervention|Standard hospital discharge|Participants received the routine, standard hospital discharge.
11639283|NCT00251927|Active Comparator|1|Surgery
11639284|NCT00251927|Experimental|2|Esomeprazole (NEXIUM) therapy
11639285|NCT00251862|Experimental|Decision aid plus YourDiseaseRisk|Patients viewed the decision aid and completed the Your Disease Risk risk assessment tool prior to visit with their primary care provider.
11639286|NCT00251862|Experimental|Decision aid alone|Patient's viewed decision aid only prior to a visit with their primary care provider.
11639287|NCT00251862|Sham Comparator|III|Standard care
11639288|NCT00251836||Left-sided donor nephrectomy|Left-sided laparoscopic hand-assisted donor nephrectomy
11639289|NCT00251836||Right-sided donor nephrectomy|Right-sided laparoscopic hand-assisted donor nephrectomy
11639290|NCT00251810||general anaesthesia|
11639291|NCT00251771|Experimental|I|
11639292|NCT00251771|No Intervention|II|
11639293|NCT00251758|Experimental|Dexlansoprazole MR 60 mg QD|
11639294|NCT00251758|Experimental|Dexlansoprazole MR 90 mg QD|
11639295|NCT00251758|Placebo Comparator|Placebo|
11639296|NCT00251745|Experimental|Dexlansoprazole MR 60 mg QD|
11639297|NCT00251745|Experimental|Dexlansoprazole MR 90 mg QD|
11639298|NCT00251745|Placebo Comparator|Placebo|
11639299|NCT00251732|Active Comparator|Standard dose (PPI) plus low dose TCA|Standard dose Rabeprazole(PPI) plus low dose tricyclic antidepressant(TCA)
11639300|NCT00251732|Active Comparator|Double dose PPI|Double dose proton pump inhibitor plus placebo
11639301|NCT00251732|Placebo Comparator|Standard dose PPI plus placebo x 2|Standard dose 20 mg. once daily plus Placebo before dinner and placebo before bedtime
11639302|NCT00251719|Experimental|Dexlansoprazole MR 60 mg QD|
11639303|NCT00251719|Experimental|Dexlansoprazole MR 90 mg QD|
11639304|NCT00251719|Active Comparator|Lansoprazole 30 mg QD|
11639305|NCT00251693|Experimental|Dexlansoprazole MR 60 mg QD|
11639306|NCT00251693|Experimental|Dexlansoprazole MR 90 mg QD|
11639307|NCT00251693|Active Comparator|Lansoprazole 30 mg QD|
11639308|NCT00251680|Experimental|Lapaquistat Acetate 50 mg QD|(and stable lipid-lowering therapy)
11639309|NCT00251680|Active Comparator|Stable Lipid-lowering therapy|
11639310|NCT00251641|Experimental|Infliximab|
11639311|NCT00251641|Active Comparator|Methotrexate|
11639312|NCT00251628|Active Comparator|Group A|
11639313|NCT00251628|Active Comparator|Group B|
11639314|NCT00251628|Experimental|Group C|
11639315|NCT00251602|Experimental|1|II ACE genotype
11639316|NCT00251602|Experimental|2|ID ACE genotype
11639317|NCT00251602|Experimental|3|DD ACE genotype
11639318|NCT00251602|Placebo Comparator|4|II ACE genotype
11639319|NCT00251602|Placebo Comparator|5|ID ACE genotype
11639320|NCT00251602|Placebo Comparator|6|DD ACE genotype
11639321|NCT00251589|Experimental|Vorinostat 200 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 200 mg twice a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the study and determined to be the MTD and therefore the recommended Phase II dose. Of the 16 patients treated at this dose level, 4 were assigned to the Phase I portion of the study and 12 were assigned to the Phase II portion
11639322|NCT00251589|Experimental|Vorinostat 300 mg q.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 300 mg once a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the amended study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.
11639323|NCT00251589|Experimental|Vorinostat 300 mg b.i.d. 3d/wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 300 mg twice a day for 3 days a week + erlotinib 150 mg once a day was evaluated in the Phase I portion of the study and exceeded the MTD. All patients treated at this dose level were assigned to the Phase I portion of the study.
11639324|NCT00251589|Experimental|Vorinostat 400 mg q.d. 21d/4wk + Erlotinib 150 mg q.d. 7d/wk|Vorinostat 400 mg once a day for 21 out of 28 days + erlotinib 150 mg once a day was evaluated in the Phase I portion of the original study and exceeded MTD. This cohort was then amended (Amendment 1) to identify a more tolerable once daily vorinostat dosing regimen. All patients treated at this dose level were assigned to the Phase I portion of the study.
11639325|NCT00251433|Experimental|Phase I|The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
11639326|NCT00251433|Experimental|Phase II-A|Patients will receive OTR of lapatinib, docetaxel, trastuzumab dose determined in phase I.
11639327|NCT00251433|Active Comparator|Phase II-B|Patients will receive docetaxel and trastuzumab combination.
11639328|NCT00251407|Experimental|taxotere, cisplatin, irinotecan|
11639329|NCT00251355|Experimental|5-FU/gemcitabine/RT|
11639476|NCT00249483|Experimental|Venlafaxine|Venlafaxine 300mg daily
11639330|NCT00251316|Experimental|Lithium Carbonate|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive lithium capsules.
11639331|NCT00251316|Placebo Comparator|Placebo|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
11639332|NCT00251303|Experimental|riluzole|Active drug put into 10-mg capsule form,,prepared by Clinical Center Pharmacy. Dose up to 120 mg daily, divided. Brand name Rilutek.
11639333|NCT00251303|Placebo Comparator|placebo|Placebo Capsules designed to mimic active drug capsules
11639334|NCT00251264|Active Comparator|Open|
11639335|NCT00251264|Active Comparator|Arthroscopic|
11639336|NCT00251251|Active Comparator|1. Optimal Medical therapy plus ICD|
11639337|NCT00251251|Active Comparator|2. Optimal Medical Therapy plus CRT/ICD|
11639338|NCT00251238|Experimental|Ginkgo biloba extract EGb 761|Receiving daily Ginkgo biloba extract EGb 761
11639339|NCT00251238|Placebo Comparator|Placebo|Receiving daily placebo
11639340|NCT00251225|Experimental|Hormone Refractory Prostate Cancer|Gleevec + Docetaxel: Daily Oral Gleevec in Combination with Every-Three-Week Intravenous Docetaxel
11639341|NCT00251212|Active Comparator|1|Therapist delivered adapted motivational enhancement therapy and skills training
11639342|NCT00251212|Active Comparator|2|Computer delivered adapted motivational enhancement therapy and skills training
11639343|NCT00251212|No Intervention|3|3: Control brochure
11639344|NCT00251173|Active Comparator|Strengths Based Case Management Model (SBCM)|The Strengths Based Case Management Model (SBCM) consists of 5 case-management sessions designed to promote linkage and engagement in assessment and treatment services, while assisting with the patient's perceived needs, as well as personal strengths and barriers to linkage and engagement.
11639345|NCT00251173|Active Comparator|Motivational Enhancement Therapy (MET)|The MET therapist will conduct 2 motivational enhancement sessions to work through the content of an educational workbook targeting the participant's substance use/abuse with the goal of negotiating a 'contract' to: 1) link to services, with the eventual goal of seeking and receiving specialized substance treatment; or 2) provide a strategy to self-monitor substance use, consider consequences, and later seek assessment.
11639346|NCT00251173|Active Comparator|Brief Informational Feedback (BIF) session|Subjects will receive brief informational feedback on the results of their alcohol screening and assessment and encouragement to seek treatment.
11639347|NCT00251160|Active Comparator|ETAC|
11639348|NCT00251160|Active Comparator|Open ICS|
11639349|NCT00251147|Active Comparator|Open Repair|
11639350|NCT00251147|Active Comparator|Mini-open Repair|
11639351|NCT00251134|Active Comparator|1|omega-3-acid ethyl ester 90
11639352|NCT00251134|Placebo Comparator|2|olive oil
11639353|NCT00251121|Experimental|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
11639354|NCT00251095|Active Comparator|Taxol|Taxol 80mg/m2/week
11639355|NCT00251095|Experimental|TOCOSOL|TOCOSOL Paclitaxel
11639356|NCT00251082|Experimental|A|
11639357|NCT00251082|Active Comparator|B|
11639358|NCT00251082|Placebo Comparator|C|
11639359|NCT00251056|Active Comparator|1|
11639360|NCT00251056|Active Comparator|2|
11639361|NCT00251056|Active Comparator|3|
11639362|NCT00251056|Active Comparator|4|
11639363|NCT00251043|Experimental|1|Participants will Psychotherapy weekly for 12 weeks
11639364|NCT00251043|Active Comparator|2|Parenting Education will include 45-minute weekly sessions for 12 week
11639365|NCT00251017|Active Comparator|Vancomycin|Effects of OCT2 genetic variation in renal elimination of Vancomycin
11639366|NCT00251004|Experimental|Low-dose Everolimus Group|"1.5 mg everolimus (one 0.75-mg tablet bis in diem/twice a day (bid)) + basiliximab + reduced-dose Cyclosporine A (CsA) ± corticosteroids.
~The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
11639367|NCT00251004|Experimental|High-dose Everolimus Group|"3.0 mg everolimus (two 0.75-mg tablets bid) + basiliximab + reduced-dose CsA ± corticosteroids.
~The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
11639368|NCT00251004|Active Comparator|Control Group|"1.44 g Mycophenolic Acid (two 360-mg tablets bid) + basiliximab + standard-dose CsA ± corticosteroids.
~The CsA dose was adjusted to attain a C0 value within the following range for the time of the study: starting at the day 5 visit: 200-300 ng/mL, starting at the month 2 visit and thereafter: 100-250 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy."
11639369|NCT00250939|Experimental|1|
11639370|NCT00250926|Experimental|Bortezomib, Dexamethasone, Rituximab|A cycle of therapy consisted of bortezomib 1.3 mg/m(2) intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m(2) on day 11. Patients received four consecutive cycles for induction therapy and then four more cycles, each given 3 months apart, for maintenance therapy.
11639371|NCT00250835|Experimental|Chemotherapy, Celecoxib, and Radiation|"Oxaliplatin weekly at 50 mg/m2 given intravenously over two hours for the duration of radiation.
~Capecitabine: on the days of radiation at 850 mg/m2 orally twice a day [1700 mg/m2/day] (Monday through Friday during radiation therapy).
~Celecoxib at 200 mg orally twice a day throughout the duration of radiation without a break."
11639372|NCT00250796|Active Comparator|Arm 1|Thalidomide+alpha interferon
11639374|NCT00250770||1|"Healthy postmenopausal and perimenopausal women with no history of endometrial carcinoma.
~Women undergoing hysterectomy for benign conditions."
11639375|NCT00250744|Experimental|Arm A|
11639376|NCT00250744|Active Comparator|Arm B|
11639377|NCT00250731|Experimental|1|Telephone support and behavior change for couples
11639378|NCT00250731|Active Comparator|2|Telephone support and behavior change for individuals
11639379|NCT00250731|Placebo Comparator|3|Limited diabetes self-management education
11639380|NCT00250718|Experimental|Arm 1 Combination Treatment|"Treatment with combination therapy as follows:
~VP-16 at 50 mg/day, orally for 14 days every 28 days; Chlorambucil at 0.1 mg/kg/day orally for 14 days every 28 days; Vincristine at 2 mg intravenously every 14 days; Dexamethasone at 200 mg intravenously every 24 days; Rituxan (rituximab) at 375 mg/m2 intravenously every 14 day; Levofloxacin at 500 mg orally daily; Diflucan at 200 mg orally daily
~At least 2 courses, but no more than 8 courses total, will be administered to each patient"
11639381|NCT00250705|Other|Adolescent Conduct Disorder Males|All subjects were male and had a diagnosis of conduct disorder. All subjects were offered treatment with aripiprazole.
11639382|NCT00250679|Active Comparator|Formoterol 12 ųg 2x/day|
11639383|NCT00250679|Experimental|Arformoterol 15 ųg 2x/day|
11639384|NCT00250679|Experimental|Arformoterol 25 ųg 2x/day|
11639385|NCT00250640||Group 1|
11639386|NCT00250588|Experimental|Problem solving + care coordination|Problem solving skills training and asthma care coordination
11639387|NCT00250588|Experimental|Asthma care coordination|Asthma care coordination
11639388|NCT00250588|Active Comparator|Wait-list control|Usual care
11639389|NCT00250575|Experimental|1|
11639390|NCT00250549|No Intervention|HIV counselor|Patients who tested for HIV and consent to participate in the study receive a posttest educational session with an HIV counselor. Afterwards, patients complete an assessment tool concerning HIV prevention and transmission.
11639391|NCT00250549|Experimental|Post test video|Patients who tested for HIV and consent to participate in the study watch a a 15-minute HIV posttest educational video available in English/Spanish. Afterwards, patients complete an assessment tool concerning HIV prevention and transmission.
11639392|NCT00250523||Traumatic injury|ICU Patients with blunt or penetrating injury
11639393|NCT00250523||2|Healthy volunteers
11639394|NCT00250510|No Intervention|1|
11639395|NCT00250510|Experimental|2|EatRight Program inquirers with BMI's of 30 kg/m2 or greater were told that they would have the possibility of being reimbursed 50% ($150) of their initial fee ($300) if certain conditions were met.
11639396|NCT00250497|Experimental|New Moves Intervention Group|The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
11639397|NCT00250497|No Intervention|control group|Girls in the control group participated in an all-girls physical education class but did not receive additional components offered in the intervention such as individual coaching.
11639398|NCT00250484|Active Comparator|Transcranial Magnetic Stimulation|Active treatment with TMS for 10 days.
11639399|NCT00250484|Sham Comparator|Sham Transcranial Magnetic Stimulation|Patients will receive no active TMS/treatment.
11639400|NCT00250458|Experimental|1|Rizatriptan (MK0462)10 mg orally disintegrating tablet/oral lyophilisate
11639401|NCT00250458|Placebo Comparator|2|matching placebo
11639402|NCT00250432|Active Comparator|1|50 mg intravenous (IV) infusion (diluted with 9% saline) administered daily (following a 70-mg IV loading dose on Day 1), over the course of ~2 hrs. all patients should be treated with antifungal therapy for at least 14 days following both the improvement in clinical and radiographic signs of disease and the eradication of Candida from culture samples obtained from the invasive site of infection.
11639403|NCT00250432|Experimental|2|150 mg intravenous (IV) infusion (diluted with 9% saline) administered daily, over the course of ~2 hrs. all patients should be treated with antifungal therapy for at least 14 days following both the improvement in clinical and radiographic signs of disease and the eradication of Candida from culture samples obtained from the invasive site of infection.
11639404|NCT00250406|Active Comparator|1|Percuflex Plus Ureteral Stent
11639405|NCT00250406|Experimental|2|TRIUMPH stent (triclosan-eluting stent)
11639406|NCT00250341|Active Comparator|Advair|
11639407|NCT00250341|Experimental|QVAR|
11639408|NCT00250276|Experimental|Cervarix Lot1 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 1 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
11639409|NCT00250276|Experimental|Cervarix Lot2 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 2 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
11639410|NCT00250276|Experimental|Cervarix Lot3 Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine Lot 3 manufactured at 600L scale according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
11639411|NCT00250276|Experimental|Cervarix Low Group|Subjects aged between and including 18-25 years, who received one dose of Cervarix™ vaccine manufactured lower scale-80L according to a 0, 1, 6- month schedule and were followed up for 7 months after the first dose. Additionally, a telephone contact was foreseen at Month 12. The vaccine was administrated by intramuscular (IM) injection into the deltoid region of the non-dominant arm.
11639412|NCT00250263|Placebo Comparator|1|Matching placebo- control arm (first year)
11639413|NCT00250263|Active Comparator|2|Drug Staloral (active group)
11639414|NCT00250237|Active Comparator|A|Patients receiving blinded medication (Haloperidol or Placebo)
11639594|NCT00247416|Experimental|2 Dex|Dexamethasone
11639415|NCT00250237|Placebo Comparator|B|Patients receiving blinded medication (Haloperidol or Placebo)
11639416|NCT00250224|Experimental|Stent|
11639417|NCT00250159||1/CAH Patients Managed at the NIH|Patients with Congenital Adrenal Hyperplasia (CAH).
11639418|NCT00250159||2/CAH Patients Managed by Outside Physicians|Patients with Congenital Adrenal Hyperplasia (CAH) followed by home physician post visit atNIH.
11639419|NCT00250159||3/Relatives of Patients|Relatives (mostly parents) of patients will be genotyped. This is often necessary to establishthe genotype of the patient.
11639420|NCT00250159||4/FMPP Patients|Patients with Familial Male-Limited Precocious Puberty (FMPP).
11639421|NCT00250159||5/Patients with Androgen Excess of Unknown Etiology|Patients with Androgen Excess of Unknown Etiology followed by home physician post visitat NIH.
11639422|NCT00250081|Active Comparator|Therapy Group|Therapy only
11639423|NCT00250081|Active Comparator|Surgery Group|surgical intervention
11639424|NCT00250081|Active Comparator|Botox Injections|botulinum toxin
11639425|NCT00249964|Experimental|Combination Treatment|"Paclitaxel at 175 mg/m2 + Carboplatin at area under the curve (AUC) 5 on day 1. Then, Temozolomide at the doses described under Interventions from day 2 to day 6 (a total of 5 days).
~Cycle length is 21 days."
11639426|NCT00249912|Experimental|Lapaquistat Acetate 50 mg QD + Rosuvastatin|
11639427|NCT00249912|Experimental|Lapaquistat Acetate 100 mg QD + Rosuvastatin|
11639428|NCT00249912|Active Comparator|Rosuvastatin|
11639429|NCT00249899|Experimental|Lapaquistat Acetate 100 mg QD|(and stable statin therapy)
11639430|NCT00249899|Active Comparator|Stable statin therapy|
11639431|NCT00249873|Experimental|Clopidogrel + ASA|Clopidogrel 75 mg once daily (od) plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)
11639432|NCT00249873|Placebo Comparator|Placebo + ASA|Matching placebo of clopidogrel 75 mg od plus acetylsalicyclic acid (ASA) 75 to 100 mg od recommended (dose at the investigators' discretion)
11639433|NCT00249860|Experimental|Interferon-beta-1a|
11639434|NCT00249860|Active Comparator|Ribavarin plus interferon-beta-1a|
11639435|NCT00249847|Experimental|Paroxetine|Paroxetine controlled-release (2-12.5 mg tablets, orally, every day for 4 weeks)
11639436|NCT00249847|Experimental|Conjugated equine estrogen|Conjugated equine estrogen (0.625 mg tablet, orally, every day for 4 weeks)
11639437|NCT00249834|Experimental|Gonal-f 112.5 IU|
11639438|NCT00249834|Experimental|Gonal-f 37.5 IU|
11639439|NCT00249834|Experimental|Gonal-f 75 IU|
11639440|NCT00249834|Experimental|Gonal-f 150 IU|
11639441|NCT00249834|Experimental|Gonal-f 187.5 IU|
11639442|NCT00249834|Experimental|Gonal-f 225 IU|
11639443|NCT00249834|Experimental|Gonal-f 262.5 IU|
11639444|NCT00249834|Experimental|Gonal-f 300 IU|
11639445|NCT00249821|Experimental|Saizen® 0.057 mg/kg/day|Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.057 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the Height-Standard Deviation Score (H-SDS) at this time (less than [<] -2 SDS or greater than [>] -2 SDS)
11639446|NCT00249821|Experimental|Saizen® 0.035 mg/kg/day|Subjects who met all inclusion/exclusion criteria were randomly assigned to 0.035 mg/kg/day in this multi-center study. Subjects were stratified at randomization according to the H-SDS at this time (< -2 SDS or > -2 SDS)
11639447|NCT00249808|Experimental|Efalizumab|
11639448|NCT00249795|Experimental|Irbesartan|150 mg for 2 weeks, then up-titrated to 300 mg up to final follow-up visit
11639449|NCT00249795|Placebo Comparator|Placebo|Matching placebo up to final follow-up visit
11639450|NCT00249769|Experimental|LJEV then MV|Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.
11639451|NCT00249769|Experimental|LJEV and MV|Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.
11639452|NCT00249769|Experimental|MV then LJEV|Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.
11639453|NCT00249756|Experimental|Re-entry Modified Therapeutic Community (Re-entry MTC)|
11639454|NCT00249756|Active Comparator|Parole Supervision and Case Management|
11639455|NCT00249704|Experimental|C|
11639456|NCT00249704|Experimental|B|
11639457|NCT00249704|Experimental|A|
11639458|NCT00249704|Placebo Comparator|D|
11639459|NCT00249691|Experimental|Topiramate|
11639460|NCT00249691|Placebo Comparator|Placebo|
11639461|NCT00249652|Experimental|TAP|MI-based phone intervention.
11639462|NCT00249652|Other|TAU|Treatment As Usual
11639463|NCT00249613|Experimental|Women-Only|Substance abuse treatment program for women only
11639464|NCT00249613|No Intervention|Mixed-Gender|Substance abuse treatment program for both women and men
11639465|NCT00249587|Experimental|1|Methadone plus behavioral counseling consisting of adherence, self-monitoring, and motivational interviewing
11639466|NCT00249587|Active Comparator|2|Methadone plus behavioral counseling consisting of adherence
11639467|NCT00249574|Experimental|pegInterferon|Open label, observational trial to determine the safety of HCV treatment in active IDUs stabilized on buprenorphine/naloxone
11639468|NCT00249561|Experimental|Recovery by Choice|A modified Therapeutic Community program.
11639469|NCT00249561|Active Comparator|Intensive Outpatient Program|Designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism.
11639470|NCT00249535|Experimental|1|standard treatment plus usual magnitude prize CM
11639471|NCT00249535|Experimental|2|standard treatment plus higher magnitude prize CM
11639472|NCT00249535|Experimental|3|standard treatment plus voucher CM
11639473|NCT00249496|Active Comparator|Employment Only|Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
11639474|NCT00249496|Experimental|Contingency Management|Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.
11639475|NCT00249483|Placebo Comparator|Placebo|Placebo
11639477|NCT00249470|Experimental|Abstinence & Work|Participants in the Abstinence & Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
11639478|NCT00249470|Other|Work Only|Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
11639479|NCT00249457|Experimental|Therapeutic Workplace|Contingency management. Invited to work in the Therapeutic Workplace. Completed monthly assessments.
11639480|NCT00249457|No Intervention|Usual Care Control Group|No intervention. Not invited to work int the Therapeutic Workplace. Completed monthly assessments.
11639481|NCT00249444|Active Comparator|Mirtazapine|Mirtazapine will be administered on a fixed-flexible schedule, with dose titrated up to 60 mg per day or the maximum tolerated dose.
11639482|NCT00249444|Placebo Comparator|Placebo|placebo
11639483|NCT00249431|Placebo Comparator|Placebo and Relapse Prevention|Patients will be treated with Relapse Prevention Therapy plus placebo
11639484|NCT00249431|Active Comparator|Sertraline and Relapse Prevention|Patients will be treated with Relapse Prevention Therapy plus Sertraline.
11639485|NCT00249405|Experimental|1|citalopram
11639486|NCT00249405|Placebo Comparator|2|Placebo
11639487|NCT00249379|Experimental|Acamprosate|Subjects randomized to receive acamprosate
11639488|NCT00249379|No Intervention|No medication|No medication intervention (subjects do not receive acamprosate), but do receive Building Social Networks counseling
11639489|NCT00249366|Active Comparator|Fixed-schedule treatment|Fixed-schedule administration of lorazepam for alcohol withdrawal
11639490|NCT00249366|Active Comparator|Symptom-triggered treatment|Symptom-triggered administration of lorazepam per protocol using the Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar)
11639491|NCT00249301|Experimental|1|MLN8054
11639492|NCT00249288|Experimental|Folate|Participants will receive a 2 mg/ day dose of folate, for 12 weeks
11639493|NCT00249288|Placebo Comparator|Placebo|Participants will receive a 2 mg/ day dose of placebo, for 12 weeks
11639494|NCT00249106|Experimental|HIV vaccine|dosage escalation of ADVAX
11639495|NCT00249106|Placebo Comparator|Placebo|Sodium phosphate
11639496|NCT00249054|Active Comparator|ASR hip prosthesis|DuPuy ASR hip prosthesis
11639497|NCT00249054|Active Comparator|ReCap hip prosthesis|Biomet ReCap hip prosthesis
11639498|NCT00249041|Experimental|Etanercept liquid|
11639499|NCT00249015|Experimental|1|Combined Aerobic and Resistance Exercise Program: perform three exercise sessions per week consisting of about 25-30 minutes of aerobic exercise at a moderate-to-vigorous intensity as well as some weight training consisting of two sets of 8-12 repetitions of 9-10 different exercises. For the aerobic exercise, participant can choose from different exercise equipment such as a treadmill or stationary bicycle.
11639500|NCT00249015|Active Comparator|2|Moderate Aerobic Exercise Group: perform three exercise sessions per week consisting of about 25-30 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.
11639501|NCT00249015|Experimental|3|High Aerobic Exercise Group: perform three exercise sessions per week consisting of about 45-60 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.
11639502|NCT00249002|Experimental|ABI-007|ABI-007 35 mg/m^2 given intravenously (IV) into the arteriovenous (AV) graft within 96 hours after angioplasty, followed by repeat treatment during weeks 5, 13 and 21
11639503|NCT00248989|Experimental|Placebo|
11639504|NCT00248989|Experimental|DHEA|
11639505|NCT00248976|No Intervention|1|This is the control group, which will be monitor. No intervention will be delivered to this group.
11639506|NCT00248976|Experimental|2|This group received the experimental intervention. This is an intervention based on feedback of individualized risk profiles framed as the opportunity to reduce one's biologic age. Net-present value of individual health behaviors in years.
11639507|NCT00248911|Experimental|Mindfulness based meditation program|Meditation and Breast Cancer: Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
11639508|NCT00248885|Active Comparator|1|In this group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB.
11639509|NCT00248885|Experimental|2|In this group (High), the goal was to maintain MAP between 80-100 mm Hg during CPB.
11639510|NCT00248872|No Intervention|control group|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to adhere to their medication goal.
11639511|NCT00248872|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to engage adhere to their medication goal. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level.
11639512|NCT00248846|No Intervention|Control Group|This group received follow-up every 2-months for one year. Follow-up included questions about their heart disease progression and how well they had been able to engage in their doctor approved physical activity goal.
11639513|NCT00248846|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their heart disease progression and how well they had been able to engage in their doctor approved physical activity goal, which was the same as the control arm. Additionally, subjects in this arm were encouraged to use positive affect and self-affirmation techniques to motivate an increased level of participation in their physical activity goal. These subjects also received small token gifts to remind them of their study participation.
11639514|NCT00248833|Experimental|1) 25ug Group B Meningococcal 44/76 MOS NOMV 5D w/o adjuvant|Subjects received 25ug Group B Meningococcal 44/76 MOS NOMV 5D without AI (OH)3 adjuvant intramuscularly at 0, 6, and 24 weeks.
11639595|NCT00247403|Experimental|2DG|
11639596|NCT00247390|Experimental|Ramelteon 8 mg QD|
11639515|NCT00248833|Experimental|2) 25ug Group B Meningococcal 44/76 MOS NOMV 5D with adjuvant|Subjects received 25ug Group B Meningococcal 44/76 MOS NOMV 5D with AI (OH)3 adjuvant intramuscularly at 0, 6, and 24 weeks.
11639516|NCT00248833|Experimental|3) 50ug Group B Meningococcal 44/76 MOS NOMV 5D w/o adjuvant|Subjects received 50ug Group B Meningococcal 44/76 MOS NOMV 5D without AI (OH)3 adjuvant intramuscularly at 0, 6, and 24 weeks.
11639517|NCT00248807|Placebo Comparator|ARM 1|Head-up tilt maneuver without drug in subjects with spinal cord injury
11639518|NCT00248807|Placebo Comparator|ARM 3|Head-up tilt maneuver without drug in able-bodied controls
11639519|NCT00248807|Active Comparator|ARM 2|Head-up tilt maneuver with an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat) in subjects with spinal cord injury
11639520|NCT00248807|Active Comparator|ARM 4|Head-up tilt maneuver with an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat) in able-bodied controls.
11639521|NCT00248794|Experimental|CRT + Skills Training|"The intervention is call Cognitive Remediation Therapy (CRT) with a skill development group. Participants receive 15 weeks of cognitive training (with intake, 15 and 30 week assessment). This intervention is reliant upon didactic exchanges between trainer and participant, minimizing error, and behavioral modeling with the goal of developing better meta-cognitive skills. Procedures include paper and pencil activities (memory, planning and cognitive flexibility training) which are organized by difficulty. Sessions are organized to have a discussion between the trainer and the participant about the task and strategies, trainer modeling with articulation of strategy a participant attempts the task, talking aloud the steps, and finally the participant practices the task covertly. The trainer has the role of error catcher and model. All subjects randomized to this condition also are receiving the weekly skills group (SDG)offered to participants in all experimental conditions."
11639522|NCT00248794|Experimental|ICBCR and Skills Training|This intervention is Individualized Computer Based Cognitive Remediation (ICBCR) and skills development group (SDG). Participants receive 15 weeks of computerized training (with intake, 15 and 30 week assessments). This intervention relies upon intense, frequent, repetition of tasks being made incrementally more challenging. Computer tasks are organized so that the initial trials are easily completed and more challenging levels are then attempted. Parameters such as duration of task, task speed, and intra-task variables all be are manipulated. A trainer will be present at each session to help set up the computer tasks and answer questions. Besides the first two sessions that will be orientation sessions, the trainer has little involvement during the training sessions. The role of the trainer is to help organize, support, and provide feedback to each participant. All subjects randomized to this condition also are receiving the weekly skills group (SDG).
11639523|NCT00248794|Experimental|Skills Group Control|The control intervention is call the skills development group (SDG) and is augmented with up to five individual contacts with research staff. The Skills Group (SDG) control is standard care group which will receive 15 weeks of the skills development group (SDG) similar to that offered as a clinical service at the VA Medical Center. During the 15 weeks participants will attend 1.5 hours of skills group per week. The 15 sessions will include skills training related to: a) cooking and food preparation, b) negotiating the local transportation system, c) shopping, and d) planning leisure activities. The training activities are a blend of didactic learning, modeling and finally in vivo practice. Participants in this group will also be offered up to five weekly contacts with staff to balance out factors related to meeting with staff in the other conditions.
11639524|NCT00248781|Experimental|Arm 1|exercise
11639525|NCT00248781|Other|Arm 2|health education
11639526|NCT00248768|Other|Arm 1|
11639527|NCT00248703|Experimental|Docetaxel|Patients with presence of disseminated tumor cells in bone marrow after (no-taxane) epirubicin-containing adjuvant treatment receive 6 cycles of docetaxel (100 mg/m2) 3 qw.
11639528|NCT00248677|No Intervention|No Contact Control|
11639529|NCT00248677|Experimental|Behavior Family Intervention|
11639530|NCT00248677|Experimental|Behavioral Parent-Only Intervention|
11639531|NCT00248651|Active Comparator|Amitriptyline|Amitriptyline capsule (50 mg) plus a placebo escitalopram tablet will be taken at night half an hour before bedtime. To maximize patient tolerability, in the first 2 weeks the dose of amitriptyline will be 25 mg and then the dose will be increased to 50 mg, but the 25 mg and 50 mg capsules will be indistinguishable to maintain blinding.
11639532|NCT00248651|Active Comparator|Escitalopram|Escitalopram tablet (10 mg) plus a placebo amitriptyline capsule will be taken by mouth at night half an hour before bedtime for 12 weeks.
11639533|NCT00248651|Placebo Comparator|Placebo|Placebo escitalopram tablets and placebo amitriptyline capsules will be taken by mouth half an hour before bedtime for 12 weeks.
11639534|NCT00248638|Active Comparator|Glutamine dipeptide|Glutamine dipeptide supplemented nutrition to be given to participants.
11639535|NCT00248638|Placebo Comparator|standard|Participants given standard nutrition without glutamine dipeptide
11639536|NCT00248625|Active Comparator|N-acetylcysteine (NAC)|Eligible children were adaptively allocated by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) infused over 24 hours for up to 7 consecutive days
11639537|NCT00248625|Placebo Comparator|placebo|Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive 5% dextrose (D5W) infused over 24 hours for up to 7 consecutive
11639538|NCT00248612|Experimental|Venlafaxine & CBT|CBT is Cognitive Behavioral Treatment which will be tailored to participants. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
11639539|NCT00248612|Active Comparator|Placebo & CBT|CBT is Cognitive Behavioral Treatment which will be tailored to participants.For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
11639540|NCT00248612|Active Comparator|Venlafaxine & PMR|Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
11639541|NCT00248612|Placebo Comparator|Placebo & PMR|Progressive Muscle Relaxation Therapy (PMR) is a technique of alternately tensing and relaxing muscles groups in sequence throughout the body. . For patients with co-morbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
11639542|NCT00248586|Experimental|Standard CBT (S-CBT)|
11639543|NCT00248586|Experimental|Minimal contact CBT (MC-CBT)|
11639544|NCT00248586|No Intervention|Control|
11639545|NCT00248560|Experimental|Gemcitabine, docetaxel|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
11639546|NCT00248547|Active Comparator|Aprepitant|
11639547|NCT00248547|Placebo Comparator|sugar pill|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
11639548|NCT00248534|Experimental|IV Rituximab|"IV Rituximab 750mg/m2 single infusion every week for up to 4 weeks.
~Induction: Rituximab (750mg/m2) Day 1, 8, 15 and 22 and Temozolomide [TMZ] (150mg/m2) days 1-7 and 15-21, followed by six cycles of consolidation TMZ 150-200mg/m2 x5/28days, followed by maintenance with methylprednisolone (1g IV every 28days) until progression"
11639549|NCT00248495|Experimental|Neoadjuvant chemotherapy|Patients receive pemetrexed disodium IV over 10 minutes followed by cisplatin IV over approximately 1 hour on day 1. Treatment repeats every 21 days for 3 courses
11639550|NCT00248482|Experimental|Irinotecan, Cisplatin & Gleevec™|"Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles
~Gleevec™ 400 mg po BID (800mg/day)- for patients with objective response or stable disease.
~Irinotecan 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles"
11639551|NCT00248365|Experimental|Low PDT intensity level|Theralux extracorporeal photochemotherapy PDT dose: TH9402 0.33μM
11639552|NCT00248365|Experimental|High PDT intensity level|Theralux extracorporeal photochemotherapy PDT dose: TH9402 1.32μM
11639553|NCT00248339|Active Comparator|1|PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD
11639554|NCT00248339|Active Comparator|2|PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
11639555|NCT00248339|Active Comparator|3|PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
11639556|NCT00248326||1|Patients of the Cardiovascular Institute with known cardiac conditions and no history of atrial fibrillation.
11639557|NCT00248326||2|Patients of the Cardiovascular Institute with known cardiac conditions and a history of atrial fibrillation.
11639558|NCT00248287|Active Comparator|Arm 1|irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle (Arm 1, ICb)
11639559|NCT00248287|Experimental|Arm 2|irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2 Week 1 and then 250 mg/m2 weekly thereafter, (Arm 2, ICb+Erbitux)
11639560|NCT00248235|Experimental|PRET|Progressive Resistance Exercise Training: upper extremity 6-8 exercises
11639561|NCT00248235|Active Comparator|Standard Care|Standard Care: physical therapy - range of motion, 6-8 strengthening exercises
11639562|NCT00248209|Placebo Comparator|Wellbutrin XL or placebo|1 arms - Wellbutrin XL or placebo
11639563|NCT00248170|Experimental|Letrozole|2.5 mg by mouth (p.o.) once daily
11639564|NCT00248170|Active Comparator|Anastrozole|1 mg p.o. once daily
11639565|NCT00248118|Active Comparator|Active medication|300mg bupropion HCL
11639566|NCT00248118|Placebo Comparator|Placebo|Placebo pill
11639567|NCT00248105|Experimental|PAM|
11639568|NCT00248105|No Intervention|PC|Participants not in the PAM group will be in the PC (physician counseling) group and will receive advice on lifestyle physical activity from their rheumatologist or primary care physician.
11639569|NCT00248053|Other|Lower GI|
11639570|NCT00248040|Experimental|reparixin group - continuous infusion|"Continuous iv infusion into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.
~A dose of 2.772 mg/kg/h was administered for12 hours."
11639571|NCT00248040|Experimental|reparixin group - intermittent infusion|"Intermittent iv infusion into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.
~A dose of 2.244 mg/kg was administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were administered over a total period of 22.5 hours."
11639572|NCT00248040|Placebo Comparator|placebo infusion|Continuous/intermittent iv infusion of a volume/schedule matched saline into a (high flow) central vein (or through an arterio-venous fistula) by an infusion pump.
11639573|NCT00247962|Experimental|A|
11639574|NCT00247962|Active Comparator|B|
11639575|NCT00247936|Active Comparator|1|Combined Thoracoscopic and Laparoscopic Esophagectomy
11639576|NCT00247936|Active Comparator|2|Hand-Assisted Transhiatal Esophagectomy
11639577|NCT00247832|No Intervention|1|
11639578|NCT00247832|Experimental|2|Self-directed motivation
11639579|NCT00247832|Experimental|3|Personal motivational interviewing
11639580|NCT00247741|Active Comparator|lidocaine|
11639581|NCT00247741|Experimental|articaine|
11639582|NCT00247728|No Intervention|Untreated Control|Untreated control arm
11639583|NCT00247728|Experimental|160 mg PI-88/Day|PI-88 160 mg/day SC injection
11639584|NCT00247728|Experimental|250 mg PI-88/Day|PI-88 250 mg/day SC injection
11639585|NCT00247715|Other|Step-up|"Stepwise treatment:
~step1: antacid (+placebo proton pump inhibitor)
~step2: H2-receptor antagonist
~step3: proton pump inhibitor (+ placebo antacid)"
11639586|NCT00247715|Other|step-down|"Stepwise treatment:
~step1: proton pump inhibitor (+placebo antacid)
~step2: H2-receptor antagonist
~step3: antacid (+proton pump inhibitor)"
11639587|NCT00247676|Experimental|A|
11639588|NCT00247663|Experimental|Letrozole|
11639589|NCT00247624|Experimental|A|Participants will receive treatment with eszopiclone and fluoxetine
11639590|NCT00247624|Active Comparator|B|Participants will receive treatment with placebo and fluoxetine
11639591|NCT00247611|Other|Control|Participants will receive the control condition
11639592|NCT00247611|Experimental|Intervention|Participants will receive the LifeWindows Intervention sessions
11639593|NCT00247416|Other|1 No Dex|No Dexamethasone
11639597|NCT00247390|Placebo Comparator|Placebo QD|
11639598|NCT00247377|Active Comparator|Laparoscopic Gastric Bypass|Subject undergoes Laparoscopic Gastric Bypass
11639599|NCT00247377|Active Comparator|LAP-BAND|Subject undergoes LAP-BAND procedure
11639600|NCT00247312|Active Comparator|125Gy prescription dose Pd-103|125Gy prescription dose Pd-103
11639601|NCT00247312|Active Comparator|110 Gy prescription dose Pd-103|110 Gy prescription dose Pd-103
11639602|NCT00247286|Experimental|a|Weighted vaginal cones used to perform pelvic floor exercises
11639603|NCT00247286|Active Comparator|b|Biofeedback
11639604|NCT00247273|Active Comparator|1|5 mg risedronate, once daily for 2 years
11639605|NCT00247273|Experimental|2|150 mg risedronate taken once a month for 2 years
11639606|NCT00247234|Experimental|schema therapy|
11639607|NCT00247234|Active Comparator|standard care|standard psychiatric out-patient care
11639608|NCT00247221|Experimental|1) MI/Family Check-Up|Brief integrated individual and family intervention -- the experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up
11639609|NCT00247221|Active Comparator|2) MI only|
11639610|NCT00247208|Active Comparator|1|Express 2 bare metal stent
11639611|NCT00247208|Experimental|2|Taxus, paclitaxel-eluting stent
11639612|NCT00247195|Experimental|Culturally congruent assessment and treatment|Outreach by phone to primary care patients interested in mental health referral. Engagement and evaluation approach conducted using the DSM-IV cultural formulation model. Same treatment choices as in control arm (medication, interpersonal psychotherapy, and combination treatment).
11639613|NCT00247195|Active Comparator|Usual referral and treatment|Usual referral procedure from primary care: PC clinician gives patient information on how to access mental health care at research site. Usual engagement and evaluation approach without using cultural formulation model. Same treatment choices (medication, interpersonal psychotherapy, and combination treatment) as in experimental arm.
11639614|NCT00247182|Other|Step 1|Minimal Intervention
11639615|NCT00247182|Active Comparator|Step 2-A|Brief motivational intervention (BMI)
11639616|NCT00247182|Active Comparator|Step 2-B|Assessment-only control
11639617|NCT00247130|Active Comparator|Omeprazole|Omeprazole (20 mg), intravenous, 2x /day
11639618|NCT00247130|Active Comparator|Ranitidine|Ranitidine (100 mg), intravenous drip infusion, 2x /day.
11639619|NCT00247078|Experimental|1|Patients with moderate or severe pain due to Black Widow envenomation
11639620|NCT00247078|Placebo Comparator|2|Patients with moderate to severe pain due to Black Widow envenomation
11639621|NCT00247052|Active Comparator|diclofenac|diclofenac
11639622|NCT00247052|Placebo Comparator|2|
11639623|NCT00247039|Experimental|Garlic extract|Garlic extract capsules
11639624|NCT00247039|Placebo Comparator|Placebo|Placebo capsules
11639625|NCT00246974|Active Comparator|1|Cisplatin + Gemcitabin
11639626|NCT00246974|Experimental|2|Cisplatin + Gemcitabin + Gefitinib
11639627|NCT00246857||patients referred by physician with a suspected inherited immu|patients referred by physician with a suspected inherited immune deficiency
11639628|NCT00246805|Experimental|1. VRS ON|"Patients with permanent atrial fibrillation implanted with VVI(R) pacemaker Vitatron model C20 SSIR or T20 SSIR were randomized to Function Ventricular Rate Stabilization (VRS) ON or OFF.
~This arm (1) is randomized to Function Ventricular Rate Stabilization ON."
11639629|NCT00246805|No Intervention|2. VRS OFF|"Patients with permanent atrial fibrillation implanted with VVI(R) pacemaker Vitatron model C20 SSIR or T20 SSIR were randomized to Function Ventricular Rate Stabilization (VRS)ON or OFF.
~This arm (2) is randomized to Function Ventricular Rate Stabilization OFF."
11639630|NCT00246753|Other|Single Arm Trial|Single Arm Trial where each patient receives GW572016 (lapatinib ditosylate) at a dose of 1500mg daily initially until disease progression or unacceptable toxicity.
11639631|NCT00246740|Placebo Comparator|Placebo oral tablet|Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
11639632|NCT00246740|Experimental|Periostat|Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
11639633|NCT00246727|Placebo Comparator|Study 1: Chemotherapy plus SV or Placebo|For newly diagnosed patients who will be receiving or have received less than 4 weeks of a standard chemotherapy regimen.
11639634|NCT00246727|Placebo Comparator|Study 2: SV vs Placebo without chemotherapy|For those who have stopped or refuse standard chemotherapy but will receive best supportive care.
11639635|NCT00246701|Active Comparator|Simvastatin|Simvastatin + placebo
11639636|NCT00246701|Experimental|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
11639637|NCT00246688|Experimental|Sagopilone, 0.5 h infusion|Subjects received one infusion (for 0.5 h) of sagopilone every 3 weeks at a dose of 16 mg/m2 (maximum up to 32 mg) for approximately 18 weeks
11639638|NCT00246688|Experimental|Sagopilone, 3 h infusion|Subjects received one infusion (for 3 h) of sagopilone every 3 weeks at a dose of 16 mg/m2 (maximum up to 32 mg) for approximately 18 weeks
11639639|NCT00246675|Other|Standard Care|Patients will only receive frusemide as per the treating physicians treatment
11639640|NCT00246675|Other|Intervention|Patients will be given frusemide to achieve a study specified urine output target of 1-2mls/kg/hour
11639641|NCT00246662|Experimental|Sch A (18 mg/m2 vosaroxin initially)|Once weekly intravenous on days 1, 8, 15 up to 4 cycles
11639642|NCT00246662|Experimental|Sch B (9 mg/m2 vosaroxin initially)|Twice weekly intravenous administration on days 1, 4, 8, 11 up to 4 cycles
11639643|NCT00246636|Active Comparator|OM5/LOV111859 (double-blind study) - Antara|Antara (fenofibrate) + placebo
11639644|NCT00246636|Experimental|OM5X/LOV111860 (extension study) - Open-Label Antara + Lovaza|Open-label Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
11639645|NCT00246636|Experimental|OM5/LOV111859 (double-blind study) - Antara + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
11639646|NCT00246610|Experimental|Open-label|Non-randomized, open-label, single-arm
11639649|NCT00246532|Placebo Comparator|1: Placebo Pill|This arm contains placebo medication.
11639650|NCT00246532|Active Comparator|2: Morphine|Patients will receive oral morphine therapy.
11639651|NCT00246519|Experimental|Atenolol|atenolol 50 mg, then 100 mg if BP < 120/70, then add HCTZ 12.5 mg if BP < 120/70, then HCTZ 25 mg if BP < 120/70
11639652|NCT00246519|Experimental|Hydrochlorothiazide (HCTZ)|HCTZ 12.5 mg then HCTZ 25 mg if BP < 120/70, then add atenolol 50 mg if BP < 120/70, then atenolol 100 mg if BP < 120/70.
11639653|NCT00246506|Active Comparator|I.|Those randomized to have clomiphene/IUI treatments first will initiate therapy with two cycles of the fertility pill called clomiphene combined with (IUI) intrauterine insemination. If not pregnant after 2 IUI cycles, the couples will then proceed to IVF.
11639654|NCT00246506|Active Comparator|II.|Those randomized to have gonadotropins/IUI treatments first will initiate therapy with two cycles of the fertility injections called FSH or gonadotropins combined with (IUI) intrauterine insemination. If not pregnant after 2 IUI cycles, the couples will then proceed to IVF.
11639655|NCT00246506|Active Comparator|III.|Those couples randomized to (IVF) in vitro fertilization will bypass IUI treatments and start IVF therapy immediately.
11639656|NCT00246454||1|People with delayed sleep phase syndrome (DSPS).
11639657|NCT00246454||2|People with advanced sleep phase syndrome (ASPS).
11639658|NCT00246454||3|Control group (people with intermediate sleep patterns).
11639659|NCT00246441|Experimental|Paroxetine|Active medication containing the drug Paroxetine
11639660|NCT00246441|Placebo Comparator|Placebo|A Placebo medication that appears just like the active medication but does not contain placebo
11639661|NCT00246428|Experimental|1|MI
11639662|NCT00246376|Placebo Comparator|1|Subjects receive lifestyle advice and placebos for Niaspan and Tricor
11639663|NCT00246376|Experimental|2|Diet, exercise, and two placebos
11639664|NCT00246376|Experimental|3|Diet, exercise, Niaspan, and placebo
11639665|NCT00246376|Experimental|4|Diet, exercise, placebo, and Tricor
11639666|NCT00246376|Experimental|5|Diet, exercise, Niaspan, and Tricor
11639667|NCT00246363|Experimental|Silymarin|Silymarin
11639668|NCT00246363|Placebo Comparator|Placebo|Placebo
11639669|NCT00246350|Active Comparator|1|8 light massage treatments
11639670|NCT00246350|Active Comparator|2|16 light massage treatments
11639671|NCT00246350|Experimental|3|8 spinal manipulation treatments
11639672|NCT00246350|Experimental|4|16 spinal manipulation treatments
11639673|NCT00246337|Placebo Comparator|Placebo|Placebo to match assigned treatment arm; one orally-administered dose, plus an optional second dose of active drug, per assigned treatment arm, to treat a single moderate-to-severe migraine headache.
11639674|NCT00246337|Experimental|MK0974 25 mg|MK0974 25 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
11639675|NCT00246337|Experimental|MK0974 50 mg|MK0974 50 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
11639676|NCT00246337|Experimental|MK0974 100 mg|MK0974 100 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
11639677|NCT00246337|Experimental|MK0974 200 mg|MK0974 200 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
11639678|NCT00246337|Experimental|MK0974 300 mg|MK0974 300 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
11639679|NCT00246337|Experimental|MK0974 400 mg|MK0974 400 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
11639680|NCT00246337|Experimental|MK0974 600 mg|MK0974 600 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
11639681|NCT00246337|Active Comparator|Rizatriptan 10 mg|Rizatriptan 10 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
11639682|NCT00246324|Experimental|Single Arm|Interferon beta 1a, oral doxycycline
11639683|NCT00246259|Experimental|Risperidone long-acting injection (LAI)|Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following initiation of Risperidone LAI, and for a maximum of 3 weeks following a dose increase.
11639684|NCT00246259|Active Comparator|Oral Antipsychotic|Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg. Participants will be switched to another oral therapy as per Investigator's discretion.
11639685|NCT00246194||Patients with schizophrenia|Long-acting injectable of risperidone given as per the prescription from the prescribing physician (Observational study).
11639686|NCT00246129|Active Comparator|1|Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy
11639687|NCT00246129|Experimental|2|Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy
11639688|NCT00246103|Experimental|Dose Escalation and Possible Expansion|Escalating doses of Valproic acid and one dose escalation step of epirubicin. Participants with breast cancer treated at the maximum tolerated dose, will also be treated with 5-fluorouracil and Cyclophosphamide.
11639689|NCT00246090|Experimental|1|
11639690|NCT00246051|Other|Sleep Hygiene Education|
11639691|NCT00246051|Other|Expert-Led Sleep Disorders Screening and Treatment|
11639692|NCT00246051|Other|Online Sleep Disorders Screening|
11639693|NCT00246025|Experimental|Dabigatran etexilate 110 mg|Dabigatran etexilate 110 mg capsule, once a day, oral administration
11639694|NCT00246025|Experimental|Dabigatran etexilate 150 mg|Dabigatran etexilate 150 mg capsule, once a day, oral administration
11639695|NCT00246025|Experimental|Dabigatran etexilate 220 mg|Dabigatran etexilate 110 mg capsule, 2capsules, once a day, oral administration
11639696|NCT00246025|Placebo Comparator|Placebo|matching placebo capsule, once a day, oral administration
11639731|NCT00245583|Placebo Comparator|Placebo|placebo equivalent tablets
11639732|NCT00245570|Experimental|1|Montelukast - Salmeterol - Placebo
11639697|NCT00246012|Experimental|Intetumumab 3 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). If after an evaluation of the preliminary single-dose pharmacokinetics, receptor saturation is not observed at the 3 mg/kg or 5 mg/kg dose level, that dose of intetumumab will be discontinued in Part 1 and participants will be treated at the highest, documented safe dose level at which receptor saturation is observed.
11639698|NCT00246012|Experimental|Intetumumab 5 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks until the occurrence of DLTs. If after an evaluation of the preliminary single-dose pharmacokinetics, receptor saturation is not observed at the 3 mg/kg or 5 mg/kg dose level, that dose of intetumumab will be discontinued in Part 1 and participants will be treated at the highest, documented safe dose level at which receptor saturation is observed.
11639699|NCT00246012|Experimental|Intetumumab 10 mg/kg [Phase 1 (Part 1)]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks until the occurrence of DLTs.
11639700|NCT00246012|Experimental|Dacarbazine + intetumumab 5 mg/kg [Phase 1 (Part 2)]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with stable disease (SD) or better, they will be considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 milligram per meter-square (mg/m^2) intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
11639701|NCT00246012|Experimental|Dacarbazine + intetumumab 10 mg/kg [Phase 1 (Part 2)]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they will be considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 mg/m^2 intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
11639702|NCT00246012|Experimental|Dacarbazine + placebo [Phase 2]|Placebo will be administered intravenously over a period of 2 hr (±15 minutes). Commercially available dacarbazine will be administered at the dose of 1000 mg/m^2 intravenously over a period of 60 minutes (± 30 minutes) prior to placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue with 10 mg/kg intetumumab alone.
11639703|NCT00246012|Experimental|Intetumumab 5 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 5 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations.
11639704|NCT00246012|Experimental|Intetumumab 10 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations.
11639705|NCT00246012|Experimental|Dacarbazine + intetumumab 10 mg/kg [Phase 2]|Intetumumab will be administered at the dose of 10 mg/kg as intravenous infusion over a period of 2 hr (± 15 minutes) once every 3 weeks for 8 cycles until no evidence of disease progression or unacceptable toxicity. If participants respond to therapy with SD or better, they are considered eligible to receive up to 8 cycles of extended administrations. Commercially available dacarbazine will be administered at the dose of 1000 mg/m^2 intravenously over a period of 60 minutes (± 30 minutes) prior to intetumumab infusion.
11639706|NCT00245960|Active Comparator|A|
11639707|NCT00245960|Active Comparator|B|
11639708|NCT00245895|Active Comparator|1|Aranesp
11639709|NCT00245882|Active Comparator|Care Coordination|Care Coordination with monthly follow-up by a diabetes nurse educator
11639710|NCT00245882|Active Comparator|Home Telemedicine|Active Care Management with Home Telemedicine
11639711|NCT00245856|Experimental|Treatment of Upper Extremity DVT|Participants received dalterparin followed by warfarin or received dalterparin monotherapy for the treatment of upper extremity DVT
11639712|NCT00245830|No Intervention|No Hepatic Ischemic Preconditioning|donor will act as a sham control.
11639713|NCT00245830|Experimental|Hepatic Ischemic Preconditioning|blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
11639714|NCT00245804||Adult dyslexia|Adult dyslexia
11639715|NCT00245804||Minor-Dyslexia|Minor-Dyslexia
11639716|NCT00245804||Adult-Control|Adult-Control
11639717|NCT00245804||Minor-Control|Minor-Control
11639718|NCT00245765|Placebo Comparator|Placebo|Subcutaneous injections of Placebo every 2 weeks
11639719|NCT00245765|Experimental|Certolizumab Pegol 200 mg|Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter
11639720|NCT00245765|Experimental|Certolizumab Pegol 400 mg|Subcutaneous injections of 400 mg every 2 weeks
11639721|NCT00245752|Active Comparator|A|in points bilaterally inBL 67, LI 4, SP6, one in GV20.
11639722|NCT00245752|Sham Comparator|2|sham acupuncture
11639723|NCT00245726|Active Comparator|1|Passive (Motor Assist) Cycle
11639724|NCT00245726|Active Comparator|2|
11639725|NCT00245726|Experimental|3|
11639726|NCT00245635|Experimental|Fluoxetine|Fixed/flexible dosing regimen of fluoxetine based on weight of subject and reaction to dosage, varying between 10mg and 80mg tablets once a day.
11639727|NCT00245635|Placebo Comparator|Placebo|Placebo tablets will be given 1/day for the duration of the study with a dosing schedule equivalent to that of the drug.
11639728|NCT00245622|Experimental|Tovaxin Autologous T cell vaccine|2.0 mL subcutaneous formulated with 30-45 million autologous myelin reactive T cells
11639729|NCT00245622|Placebo Comparator|Placebo|2.0 mL subcutaneous injections without autologous myelin reactive T cells
11639730|NCT00245583|Experimental|Topiramate|25mg to 300mg daily dose
11639733|NCT00245570|Experimental|2|Montelukast - Placebo - Salmeterol
11639734|NCT00245570|Experimental|3|Salmeterol - Montelukast - Placebo
11639735|NCT00245570|Experimental|4|Salmeterol - Placebo - Montelukast
11639736|NCT00245570|Experimental|5|Placebo - Montelukast - Salmeterol
11639737|NCT00245570|Experimental|6|Placebo - Salmeterol - Montelukast
11639738|NCT00245557|No Intervention|Healthy Controls|Healthy Controls undergo MRI and neuropsychological testing
11639739|NCT00245557|Experimental|Depressed|Depressed subjects receive experimental drug
11639740|NCT00245531||+IDU/+HIV or -HIV|
11639741|NCT00245531||-IDU and -HIV (controls)|
11639742|NCT00245518|Experimental|Isoflavone|Isoflavone
11639743|NCT00245518|Placebo Comparator|Placebo|
11639744|NCT00245492|Experimental|1|Chromocolonoscopy
11639745|NCT00245479|Other|1|
11639746|NCT00245466|Experimental|Degarelix 80/80 + 40|In the main study (FE200486 CS02; NCT00819247) loading doses of degarelix 80 mg were given on Days 0 and 3. Maintenance doses of 40 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
11639747|NCT00245466|Experimental|Degarelix 40/40 + 40|In the main study (FE200486 CS02; NCT00819247) loading doses of degarelix 40 mg were given on Days 0 and 3. Maintenance doses of 40 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
11639748|NCT00245466|Experimental|Degarelix 80 + 20|In the main study (FE200486 CS02; NCT00819247) one loading dose of degarelix 80 mg was given on Days 0. Maintenance doses of 20 mg were given on days 28, 56, 84, 112 and 140. In the extension study (FE200486 CS02A) the same maintenance dose of degarelix was given once every 4 weeks.
11639749|NCT00245453|Active Comparator|1 Azithromycin|
11639750|NCT00245453|Active Comparator|2 Clarythromycin|
11639751|NCT00245453|Active Comparator|3 Telithromycin|
11639752|NCT00245440|Active Comparator|1|Subjects assigned Azithromycin
11639753|NCT00245440|Active Comparator|2|Subjects assigned Telithromycin
11639754|NCT00245427|Other|1 All macrolide antibiotics|
11639755|NCT00245427|Other|2 All beta lactam antibiotics|
11639756|NCT00245414|Experimental|1|Interferon (IFN)-Treated
11639757|NCT00245414|Experimental|2|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is positive at week 1
11639758|NCT00245414|Experimental|3|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is negative at week 1
11639759|NCT00245414|Experimental|4|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is negative at week 1
11639760|NCT00245349||FLT|Study group receiving FLT for imaging
11639761|NCT00245336|Experimental|1|rThrombin
11639762|NCT00245336|Active Comparator|2|bThrombin
11639763|NCT00245271|Experimental|1|OMS103 Irrigation Solution
11639764|NCT00245271|Placebo Comparator|2|Balanced Salt Solution (BSS)
11639765|NCT00245219|No Intervention|Health Tracking (control)|Participants assigned to the health-tracking condition received usual care and did not attend any meetings.
11639766|NCT00245219|Experimental|Peer support|The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another. Patients completed a weekly diary of critical experiences or current life problems as homework, and were then encouraged to share these experiences in the group meetings. The group facilitator encouraged participants to help one another with these issues, and share how they had dealt with similar problems.
11639767|NCT00245219|Experimental|Education|The education group meetings focused on providing patients with information about their disease as well as methods to manage their illness and its side effects. Facilitators emphasized the theme of perceived control during all sessions, discussing how participants are in control of their illness experience and can have more control of their lives. A different topic was addressed in each session. Weekly homework assignments asked patients to write down something new they had learned from the session regarding how to take control of their lives. Meeting topics were as follows: Overview of breast cancer, treatment types and side effects, nutrition and diet management, exercise, body image, communication issues, relationships, and sexuality.
11639768|NCT00245206|Experimental|1: Risperdal|Participants randomized to this arm will be prescribed risperdal. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
11639769|NCT00245206|Experimental|3: Aripiprazole|Participants randomized to this arm will be prescribed aripiprazole. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
11639770|NCT00245206|Experimental|4: Olanzapine|Participants randomized to this arm will be prescribed olanzapine. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
11639771|NCT00245180|No Intervention|control|Primary and secondary data collected as in intervention arm. Dental screenings will be done once a year as a service.
11639772|NCT00245154|Experimental|Arm I|Patients receive oral cediranib maleate once daily in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment with paclitaxel and carboplatin repeats every 21 days for 6-8 courses in the absence of disease progression or unacceptable toxicity.
11639773|NCT00245154|Active Comparator|Arm II|Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel and carboplatin as in arm I.
11639774|NCT00245102|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11639775|NCT00245063|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 28 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11639776|NCT00245050|Experimental|Pyridoxine|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine 100 mg twice daily on days 1-28.
11639777|NCT00245050|Placebo Comparator|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo twice 100 mg daily on days 1-28.
11639778|NCT00245037|Experimental|Busulfan (Bu), Fludarabine (Flu), Total Body Iradiation (TBI)|Busulfan 3.2 mg/kg IV on day -5 Fludarabine 30 mg/m2/day x 3 (total dose 90 mg/m2, day -4 to day -2 TBI 200 centigray (cGy) x 1, day 0
11639779|NCT00245011|Experimental|Samarium-153|Cytoxan+Ifosfamide, Filgrastim pre samarium.'Sm-EDTMP (low dose). once counts recover, Sm-EDTMP (high dose) given. Peripheral blood stem cell transplantation is done 14 days later.
11639780|NCT00244985|Experimental|Arm 1: Rituximab and Doxorubicin HCI Liposome|Patients receive rituximab IV over 3-8 hours on day 1 and doxorubicin HCl liposome IV over 1-3 hours on day 3
11639781|NCT00244972|Experimental|Treatment (sorafenib tosylate, tipifarnib)|Patients receive sorafenib tosylate PO QD or BID on days 1-28 and tipifarnib PO QD or BID on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients may be allowed to continue the treatment after the 12 courses if there is continued clinical response or disease stabilization, and patients do not have significant toxicities.
11639782|NCT00244959|Experimental|Anastrozole|Anastrozole (1mg, orally, daily) for 12 months as adjuvant therapy for breast cancer
11639783|NCT00244946|Experimental|Autologous lymphocytes,carmustine,etoposide, melphalan, PBSCT|"minus Day 8 ADMIT for Hydration
~minus Day 7 Carmustine 300 mg/m2 x 1 dose
~minus Day 6 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr
~minus Day 5 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr
~minus Day 4 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr
~minus Day 3 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr
~minus Day 2 Melphalan 140 mg/m2 x 1 dose
~minus Day 1 Day of Rest
~Day 0 Transplant"
11639784|NCT00244933|Experimental|Gemcitabine, genistein (Novasoy), Tumor biopsy|Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
11639785|NCT00244907|Active Comparator|Genistein vs. Risedronate|Healthy post menopausal women who have been dosed with Ca41. Intervention, 100 mg Gensitein from soy protein isolate for 50 days. After a 50 day washout risedronate (Actonel- 5mg per day) for 50 days
11639786|NCT00244907|Active Comparator|Genistein dose and source|Healthy post menopausal women will consume 5 products containing varying quantities of genistein from different sources for 50 days each in a randomized order. Each intervention period is separated by a 50 day washout period. Intervention: A) 50 mg genistein from soy protein isolate, B) 100 mg genistein from soy protein isolate, C)50 mg genistein from Novasoy, D) 100 mg genistein from Novasoy, E) 100 ng genistein from 50% Novasoy and 50% soy protein isolate
11639787|NCT00244881|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11639788|NCT00244855|Other|No previous treatment|Patients received no previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
11639789|NCT00244855|Other|Previous treatment|Patients received previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
11639790|NCT00244842|Placebo Comparator|1|
11639791|NCT00244842|Active Comparator|2|
11639792|NCT00244842|Active Comparator|3|
11639793|NCT00244842|Active Comparator|4|
11639794|NCT00244803||HIV Positive FRAM 1 Participant|
11639795|NCT00244790|Experimental|low protein|
11639796|NCT00244764|Experimental|Pazopanib|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
11639797|NCT00244764|Placebo Comparator|Placebo|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
11639798|NCT00244751|Experimental|GI262570 0.5 mg|Participants received GI262570 0.5 milligrams (mg) tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.
11639799|NCT00244751|Experimental|GI262570 1.0 mg|Participants received GI262570 1.0 mg tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.
11639800|NCT00244751|Placebo Comparator|Placebo|Participants received matching placebo tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.
11639801|NCT00244738|Active Comparator|Intervention|Patients who received castor oil for labor induction
11639802|NCT00244738|Placebo Comparator|Control|Patients who received sunflower oil as a placebo
11639803|NCT00244712|Experimental|ABC/3TC|The intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo +lopinavir/ritonavir.
11639804|NCT00244712|Active Comparator|TDF/FTC|The intervention is a regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
11639805|NCT00244621|Experimental|1|0.05 mg/kg Atacand oral liquid dose
11639806|NCT00244621|Experimental|2|0.20 mg /kg Atacand oral liquid dose
11639807|NCT00244621|Experimental|3|0.40 mg /kg Atacand oral liquid dose
11639808|NCT00244517|Active Comparator|I|Isoflurane (only in part I)
11639809|NCT00244517|Active Comparator|II|Sevoflurane
11639810|NCT00244517|Active Comparator|III|Desflurane
11639811|NCT00244504|Active Comparator|I|moxonidine group
11639812|NCT00244504|Placebo Comparator|II|placebo group
11639813|NCT00244478|Experimental|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
11639814|NCT00244478|Placebo Comparator|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
11639815|NCT00244439|Experimental|1|MALG
11639816|NCT00244439|Active Comparator|2|Ovide
11639817|NCT00244439|Active Comparator|3|Permethrin 1%
11639818|NCT00244426|Experimental|1|
11639819|NCT00244426|Active Comparator|2|
11639820|NCT00244374|Experimental|AIC, Hepatitis A & B vaccine|Subjects randomized to a public health department clinic, the Adult Immunization Clinic (AIC), for administration of viral hepatitis immunizations at Month 1, 2, 6.
11639821|NCT00244374|Experimental|AIC, Outreach, Hepatitis A & B vaccine|AIC + outreach: Subjects randomized to a public health department clinic, the Adult Immunization Clinic (AIC)) for administration of viral hepatitis immunizations at Month 1, 2, 6, plus outreach worker adherence support to receive all immunizations
11639822|NCT00244374|Experimental|SEP, Hepatitis A & B vaccine|SEP only: Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6.
11639823|NCT00244374|Experimental|SEP, Outreach, Hepatitis A & B vaccine|Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6, plus outreach worker adherence support to receive all immunizations
11639824|NCT00244335||1|PTSD Subjects
11639825|NCT00244335||2|Trauma Controls: subjects who have experienced a trauma but never developed PTSD
11639826|NCT00244270|Experimental|1|totally implantable vascular access device
11639827|NCT00244257|Experimental|1|Cohort 1
11639828|NCT00244257|Experimental|2|Cohort 2
11639829|NCT00244257|Experimental|3|Cohort 3
11639830|NCT00244257|Experimental|4|Cohort 4
11639831|NCT00244257|Experimental|5|Cohort 5
11639832|NCT00244140|Experimental|Iopromide 370 mg I/mL|Iopromide (Ultravist 370 mg I/mL) administered intravenously
11639833|NCT00244140|Experimental|Iopromide 300 mg I/mL|Iopromide (Ultravist 300 mg I/mL) administered intravenously
11639834|NCT00244114||A|
11639835|NCT00244114||B|
11639836|NCT00244101|Active Comparator|PS Group|Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
11639837|NCT00244101|Experimental|NCPAP Group|Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
11639838|NCT00244101|Experimental|ISX Group|Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
11639839|NCT00244075|Active Comparator|1|nutrition supplementation, recombinant human growth hormone, and exercise
11639840|NCT00244075|Active Comparator|2|nutrition supplementation only
11639841|NCT00244049|Experimental|Brief clinician advice|
11639842|NCT00244023|Experimental|1|Testosterone gel (intervention)
11639843|NCT00244023|Placebo Comparator|2|one sachet of placebo gel once a day, possibly titrated to 2 sachets if insufficient efficacy
11639844|NCT00244010|Other|1|
11639845|NCT00243997|Active Comparator|1|Subjects receiving the Becoming Parents Program
11639846|NCT00243997|Placebo Comparator|2|Subjects not receiving the Becoming Parents Program
11639847|NCT00243932|Experimental|2,700 mg CoQ10|
11639848|NCT00243932|Placebo Comparator|placebo|
11639849|NCT00243932|Experimental|1,800 mg CoQ10|
11639850|NCT00243919|Active Comparator|Early Locomotor Training Program|body weight supported training program with treadmill
11639851|NCT00243919|Active Comparator|Late Locomotor Training Program|body weight supported training program with treadmill
11639852|NCT00243919|Active Comparator|Early Home Exercise Program|a non-specific low intensity exercise program
11639853|NCT00243893|Active Comparator|Brain AVMs|This trial is to investigate the use of minocycline or doxycycline as medical therapy, can minocycline or doxycycline induce biologically significant changes in the enzyme system thought to be related to spontaneous growth/rupture of these malformations. Finally, can patients safely tolerate these medications over an extended period of time.
11639854|NCT00243893|Active Comparator|Aneurysms|
11639855|NCT00243880|Experimental|lovastatin|lovastatin at escalating dosages: 1 mg/kg/day, 3 mg/kg/day, 6 mg/kg/day, 8 mg/kg/day, 10 mg/kg/day
11639856|NCT00243867|Experimental|Arm A|(Taxoprexin® + carboplatin)
11639857|NCT00243867|Active Comparator|Arm B- Paclitaxel and carboplatin|(Paclitaxel and carboplatin)
11639858|NCT00243841|Experimental|Radiation Treatment Arm :A|Patients with a score of Childs A Will receive 3 fractions of radiation over 5-10 days
11639859|NCT00243841|Experimental|Radiation Treatment Arm: B|Patients with a score of Childs B will receive 5 fractions of radiation over 2-6 weeks.
11639860|NCT00243789|Active Comparator|1|Pentoxifylline
11639861|NCT00243789|No Intervention|2|Placebo
11639862|NCT00243776||Cardiac Tissue|Cardiac tissue and cells will be obtained from participants undergoing cardiac surgical repair
11639863|NCT00243685|Experimental|II and III|
11639864|NCT00243659|Experimental|A|
11639865|NCT00243659|Experimental|B|
11639866|NCT00243646|Active Comparator|no hormones|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant with no hormones
11639867|NCT00243646|Active Comparator|9 months of hormone therapy|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant with a 9 month course of hormone therapy
11639868|NCT00243607|Experimental|immediate treatment group (SBG)|immediate start of hydrotherapy (self treatment) in immediate treatment group (SBG)
11639869|NCT00243607|No Intervention|waiting group (WG)|start of hydrotherapy (self treatment) after waiting period of 12 weeks
11639870|NCT00243529|Active Comparator|MHC Class I restricted epitopes|HLA-A2.1 patients are vaccinated with dendritic cells loaded with MHC Class I restricted epitopes of tumor antigens gp100 and tyrosinase
11639871|NCT00243529|Experimental|MHC Class I and II restricted epitopes|HLA-A2.1 and HLA-DR4 patients are vaccinated with dendritic cells loaded with MHC Class I and II restricted epitopes of tumor antigens gp100 and tyrosinase
11639872|NCT00243529|Experimental|mRNA transfected DC|HLA-A2.1 and/or HLA-DR4 patients are vaccinated with dendritic cells transfected with mRNA encoding tumor antigens gp100 and tyrosinase
11639873|NCT00243503|Experimental|A|
11639874|NCT00243477|Active Comparator|Treatment|Escitalopram given
11639875|NCT00243477|Placebo Comparator|Placebo|Placebo given
11639876|NCT00243438||1|Patients who have received a Vision stent and who have diabetes and/or complex lesions.
11640017|NCT00240864|Experimental|002|ibuprofen
11640018|NCT00240864|Placebo Comparator|003|placebo
11639877|NCT00243412|Experimental|Arm A: 500 mg Rituximab|"Rituximab: 1000 mg intravenous (IV) on Days 1 and 15 of the first cycle; 500 mg IV on Days 1 and 15 of each subsequent 6-month cycle (Months 6, 12, and 18).
~Corticosteroids: 100 mg IV methylprednisolone prior to each rituximab infusion.
~Methotrexate: 15-25 mg/wk oral or parenteral (10-14 mg/wk if intolerant).
~Folate: Minimum of 1 mg/day (or folinic acid 5 mg/wk)."
11639878|NCT00243412|Experimental|Arm B: 1000 mg Rituximab|"Rituximab: 1000 mg IV on Days 1 and 15 of each 12-month cycle (Rituximab cycles were administered at baseline and Month 12.) For the Month 6 and 18 cycles, rituximab or placebo was administered.
~Corticosteroids: 100 mg IV methylprednisolone prior to each rituximab infusion For the Months 6 and 18 cycles, IV saline was administered prior to each rituximab or placebo infusion.
~Methotrexate: 15-25 mg/wk oral or parenteral (10-14 mg/wk if intolerant).
~Folate: Minimum of 1 mg/day (or folinic acid 5 mg/wk)."
11639879|NCT00243399|Experimental|Oxandrolone|
11639880|NCT00243386|Active Comparator|1|Standard prophylaxis
11639881|NCT00243386|Experimental|2|PK-driven prophylaxis
11639882|NCT00243334|Experimental|1|Decision Support integrated with Order Entry
11639883|NCT00243334|No Intervention|2|Decision Support Only (not integrated with order entry)
11639884|NCT00243321|Experimental|HDR brachytherapy -> IMRT|Radiotherapy
11639885|NCT00243282|No Intervention|1|Control (Support Group)
11639886|NCT00243282|Other|2|Intervention (Mindfulness Based Breathing Therapy)
11639887|NCT00243269|Sham Comparator|1|Expectancy neutral handout and expectancy neutral tape
11639888|NCT00243269|Experimental|2|Expectancy enhancing handout and expectancy neutral tape
11639889|NCT00243269|Experimental|3|Expectancy neutral handout and expectancy enhancing tape
11639890|NCT00243269|Experimental|4|Expectancy enhancing handout and expectancy enhancing tape
11639891|NCT00243243|Experimental|rFVIIa|intravenous administration of rFVIIa (Novoseven; 90 micrograms/kg, IV push, given at start of first surgical incision and again at 1 hr after start of surgery)
11639892|NCT00243243|Placebo Comparator|Control|intravenous administration of placebo (sterile water, IV push, given at first surgical incision and again at 1 hr after start of surgery)
11639893|NCT00243230|Experimental|Vicriviroc 20 mg|
11639894|NCT00243230|Experimental|Vicriviroc 30 mg|
11639895|NCT00243230|Placebo Comparator|Placebo|
11639896|NCT00243191|Other|imatinib mesylate|
11639897|NCT00243152|Active Comparator|Lamotrigine to Placebo Crossover|The drug lamotrigine will be given for 9 weeks prior to imaging session 1. A rescue drug, Gabapentin, will be provided for pain control. Patients will taper off the Gabapentin 2 weeks before each scan date. After a taper and washout, placebo (cross over) will be administered. At the end of the trial (after imaging session 2), a taper for placebo will be given. Patients will be required to maintain a pain diary during the study, documenting the perceived effects of the drug on the severity of their pain and keeping track of their subjective pain ratings day to day. Patients will also complete the McGill Pain Questionnaire at each visit.
11639898|NCT00243152|Active Comparator|Placebo to Lamotrigine Crossover|The placebo will be given for 9 weeks prior to imaging session 1. A rescue drug, Gabapentin, will be provided for pain control. Patients will taper off the Gabapentin 2 weeks before each scan date. After a taper and washout, the drug lamotrigine (cross over) will be administered. At the end of the trial (after imaging session 2), a taper for drug will be given. Patients will be required to maintain a pain diary during the study, documenting the perceived effects of the drug on the severity of their pain and keeping track of their subjective pain ratings day to day. Patients will also complete the McGill Pain Questionnaire at each visit.
11639899|NCT00243126|Experimental|Family-Based Risk Reduction Intervention|The intervention will be delivered in five, two-hour, small group sessions, across five weeks (group will meet once per week). Each of the 5 modules consists of 3 sessions: a one-hour session for the daughters meeting together with each other, a one-hour session for the mothers meeting together with each other; and a one-hour session in which the daughters and mothers meet together. Therefore, each week, the daughters will meet as a group for one hour of each module, while the mothers meet as a group for one hour, and for one hour the mothers and daughters will all meet together.
11639900|NCT00243126|No Intervention|No Treatment Control Group Condition|A no treatment control group condition will be utilized for this preliminary feasibility study. Participants in this condition, both mothers and adolescents will be assessed at baseline, immediate post-intervention, at 3-month follow-up and at 6-month follow-up.
11639901|NCT00243100|Experimental|Arm I|"Patients receive oral vorinostat (SAHA) once daily on days 1-14 and gemcitabine IV over 1-2 hours on days 3 and 10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of SAHA and gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD"
11639902|NCT00243074|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11639903|NCT00243061|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11639904|NCT00243035|Experimental|Treatment (bortezomib, tipifarnib)|"Phase I: Patients receive bortezomib IV on days 1, 4, 8, and 11 and oral tipifarnib twice daily on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of tipifarnib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.
~Phase II: Patients receive bortezomib as in phase I and tipifarnib as in phase I at the MTD."
11639905|NCT00243022|Experimental|Arm I (intervention)|Patients receive oral Boswellia serrata extract 4 times a day and oral cyanocobalamin (vitamin B 12) once a day for 6 months in the absence of unacceptable toxicity.
11639906|NCT00243022|Active Comparator|Arm II (control)|Patients in the control arm receive oral cyanocobalamin (vitamin B 12) once a day for 6 months.
11639907|NCT00242944|Active Comparator|1|Pitavastatin
11639908|NCT00242944|Active Comparator|2|Atorvastatin
11640019|NCT00240851|Experimental|001|acetaminophen extended release
11640020|NCT00240825|Experimental|001|Acetaminophen
11639909|NCT00242931|Experimental|Fludarabine, TBI, Cyclosporine, MMF|"Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0 For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop
~For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181."
11639910|NCT00242892|Experimental|1|Intra coronary measures of pressure
11639911|NCT00242866|Experimental|Arm 1|GW274150 - 5mg or 30mg
11639912|NCT00242866|Placebo Comparator|Arm 2|Placebo to match GW274150
11639913|NCT00242723||1/Cohort 1|Subjects with potentially malignant or suspicious lesions, or biopsy proven thoracic cancers or thoracic metastases from cancers of non-thoracic origin
11639914|NCT00242710|Experimental|1|BZA 20mg/CE 0.625
11639915|NCT00242710|Experimental|Arm 2|BZA 20mg/CE 0.45
11639916|NCT00242710|Active Comparator|Arm 3|CE 0.45mg/MPA1.5mg
11639917|NCT00242710|Placebo Comparator|Arm 4|Placebo
11639918|NCT00242684||Group 1|older patients admitted to a TCU unit
11639919|NCT00242658|Experimental|Tailored Physical Activity Intervention Group|Four feedback reports aimed to increase physical activity.
11639920|NCT00242658|No Intervention|No Tailored Physical Activity Intervention Group|General reports on preventive screening based on responses to preventive screening questions.
11639921|NCT00242632|Experimental|ApoE Non-Carriers|Subjects in this group did not carry the apolipoprotein E-epsilon 4 (apoE-e4) allele. During week 1 of the study, subjects were administered 5 mg of namenda once daily. During week 2 of the study, subjects were administered 5 mg of namenda in the morning and 5 mg in the evening (10 mg/day). During week 3 of the study, subjects were administered 10 mg in the morning and 5 mg in the evening (15 mg/day). During week 4 of the study, subjects were administered 10 mg in the morning and 10 mg in the evening (20 mg/day).
11639922|NCT00242632|Experimental|ApoE Carriers|Subjects in this group carried the apolipoprotein E-epsilon 4 (apoE-e4) allele. During week 1 of the study, subjects were administered 5 mg of namenda once daily. During week 2 of the study, subjects were administered 5 mg of namenda in the morning and 5 mg in the evening (10 mg/day). During week 3 of the study, subjects were administered 10 mg in the morning and 5 mg in the evening (15 mg/day). During week 4 of the study, subjects were administered 10 mg in the morning and 10 mg in the evening (20 mg/day).
11639923|NCT00242619|Experimental|Rosiglitzone|This group includes all 12 subjects who received rosiglitazone. Rosiglitazone was administered in addition to current antidepressant and/or mood-stabilizing medication at a dose of 4 mg/day for the first 4 weeks, with subsequent increase in dose to 9 mg/day for the remaining 8 weeks of the 12-week trial.
11639924|NCT00242606|Active Comparator|1|Levetiracetam 2000mg/day
11639925|NCT00242606|Active Comparator|2|Lamotrigine
11639926|NCT00242593|Experimental|A|oral rosiglitazone 4 mg twice daily for 18 months
11639927|NCT00242593|Placebo Comparator|B|placebo pill twice daily for 18 months
11639928|NCT00242580|Experimental|Verteporfin and Triamcinolone 1 mg|Participants received Verteporfin photodynamic therapy and 1 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 1 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
11639929|NCT00242580|Experimental|Verteporfin and Triamcinolone 4 mg|Participants received Verteporfin photodynamic therapy and 4 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 4 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
11639930|NCT00242580|Active Comparator|Verteporfin and Pegaptanib|Participants received Verteporfin photodynamic therapy and 0.3 mg Pegaptanib at the baseline visit. After the baseline visit, these participants received pegaptanib every 1.5 months up until and including the 10.5 month visit. After the baseline visit, these participants also received verteporfin at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. Starting from Month 12, if participants experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigator's discretion with available standard of care therapy.
11639931|NCT00242567|Experimental|Early Group|Zoledronic acid 4 mg i.v. infusion every 4 weeks, commencing at Baseline.
11639932|NCT00242567|Experimental|Delayed group|Zoledronic acid 4 mg i.v. infusion every 4 weeks, commencing no sooner than 12 months after their baseline visit, and not until they have had three rises in PSA level from Baseline, one of which must be a least 10 ng/mL greater than the baseline Serum Prostate-specific Antigen (PSA) level.
11639933|NCT00242541|Experimental|Octreotide acetate|
11639934|NCT00242502|Experimental|Bevacizumab + Erlotinib|Bevacizumab 10 mg/kg intravenous every 14 days, repeat cycle every 28 days; Erlotinib 150 mg orally every day continuous dosing.
11639935|NCT00242463|Experimental|nandrolone|Patients receive weekly injections of nandrolone
11639936|NCT00242463|Placebo Comparator|Placebo|
11639937|NCT00242424|Placebo Comparator|1|0.25 ml normal saline placebo given as injection to infants at 2 and 3 months of age
11639938|NCT00242424|Experimental|2|2005-6 Fluzone, pediatric formulation of trivalent inactivated influenza vaccine (sanofi pasteur) administered to infants at 2 and 3 months of age
11639939|NCT00242385|Experimental|ARALAST Fr. IV-1|60 mg/kg
11639940|NCT00242385|Active Comparator|ARALAST|60mg/kg
11639941|NCT00242359|Other|omalizumab|open-label
11639942|NCT00242320|Active Comparator|1|Roflumilast 500 µg
11639943|NCT00242320|Placebo Comparator|2|Placebo
11639944|NCT00242216|Active Comparator|Atazanavir oral once daily|HIV treatment
11639945|NCT00242216|Active Comparator|Fosamprenavir oral once daily|HIV treatment
11639946|NCT00242203|Experimental|Zometa|"Zometa 4 mg IV every 3 weeks for a total of 17 doses. The first treatment will be given at the time of the first chemotherapy treatment and will continue for approximately 1 year.
~Neoadjuvant therapy
~Epirubicin 75 mg/m2 IV every 21 days for 4 cycles prior to surgery
~Docetaxel 75 mg/m2 IV every 21 days for 4 cycles prior to surgery
~Surgery - modified radical mastectomy or breast conserving surgery with axillary lymph node dissection
~Adjuvant therapy
~Epirubicin 75 mg/m2 IV every 21 days for 2 cycles
~Docetaxel 75 mg/m2 IV every 21 days for 2 cycles
~All patients who are found to be Her-2 overexpressing by 3+ by ICH for FSH will receive trastuzumab 6 mg/kg IV every 3 weeks for 1 year post surgery
~Radiation therapy - 50-60 Gy in 1.8-2.0 Gy daily fractions to the breast or chest wall. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks"
11639947|NCT00242203|Active Comparator|No Zometa|"Neoadjuvant therapy
~Epirubicin 75 mg/m2 IV every 21 days for 4 cycles prior to surgery
~Docetaxel 75 mg/m2 IV every 21 days for 4 cycles prior to surgery
~Surgery - modified radical mastectomy or breast conserving surgery with axillary lymph node dissection
~Adjuvant therapy
~Epirubicin 75 mg/m2 IV every 21 days for 2 cycles
~Docetaxel 75 mg/m2 IV every 21 days for 2 cycles
~All patients who are found to be Her-2 overexpressing by 3+ by ICH for FSH will receive trastuzumab 6 mg/kg IV every 3 weeks for 1 year post surgery
~Radiation therapy - 50-60 Gy in 1.8-2.0 Gy daily fractions to the breast or chest wall. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks"
11639948|NCT00242112|Other|MRI - pathology|
11639949|NCT00241969|Experimental|Behavioral and Nutrition Treatment|The behavioral and nutrition treatment combines individualized nutritional counseling that targeted increasing energy and fat intake and parent training in behavioral child-management skills based on social learning theory to improve meal-time behaviors.
11639950|NCT00241969|Active Comparator|Education and Attention Control|The education and attention control treatment provides education and served as a behavioral placebo in terms of controlling for attention and contact frequency provided. Families are provided with information including general nutrition, enzyme therapy, respiratory infection control, and typical child development anticipatory guidance and safety for preschool- aged children.
11639951|NCT00241917|Experimental|Video|
11639952|NCT00241917|No Intervention|Control|
11639953|NCT00241904|Active Comparator|Comprehensive Intervention Group|The NP/CHW intervention focused on behavioral interventions to affect therapeutic lifestyle changes and adherence to medications and appointments as well as the prescription and titration of medications for one year. The NP and CHW worked as a team. The NP oversaw the initial assessment and, in collaboration with the CHW, tailored the intervention plan, conducted the intervention including lifestyle modification counseling and medication titration and prescription, consulted with the physician, and supervised the CHW. Specific algorithms for drug treatment of hyperlipidemia, hypertension (HBP), hyperglycemia, ACE, and β-blocker therapy were developed for this study based on current guidelines and standards of care.
11639954|NCT00241904|Active Comparator|Less Intensive Intervention Group|Participants will receive usual care from their physicians and a Less Intensive (LI) intervention of feedback on cardiovascular disease (CVD) risk factors and guidelines to patients and their physicians. Patients and their providers in the received the results of baseline lipids, BP, and HbA1c along with the recommended goal levels and a pamphlet on controlling risk factors published by the American Heart Association. In addition, providers received copies of the AHA/ACC Guidelines for Secondary Prevention.
11639955|NCT00241891|Other|Healthy Lifestyle (Active Intervention)|Parents and children in this program which will participate in a series of consultations and activities focused on multiple healthy interventions including healthy eating, drinking, and physical activity. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on healthy eating, drinking, and physical activity. In addition, your child will receive information on developing healthy interpersonal and social skills.
11639956|NCT00241891|Other|Healthy Drinks (Active Intervention)|Parents and children in this program will participate in a series of consultations and activities focused on a single intervention, the effects of beverage choices on diet, general health and teeth health. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on beverages and health. In addition, your child will receive information on healthy nutrition, physical activity, and interpersonal and social skills.
11639957|NCT00241891|Other|Social and Leadership Skills (Control Intervention)|Parents and children in this program will participate in a series of consultations that are designed to help your child learn strategies to make and keep friends, to express feelings appropriately, and to successfully decrease conflicts that often occur at school among children. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on these friendship making strategies. In addition, your child will receive information on healthy nutrition and physical activity. There is o intervention with regards to healthy weight.
11639958|NCT00241878|Experimental|1|Teacher-Delivered Weight Control Intervention
11639959|NCT00241878|Other|2|Teacher-Delivered General Health Intervention
11639960|NCT00241852|Experimental|Behavioral Intervention: Asthma: It's a Family Affair|Separate student and parent intervention groups.
11639961|NCT00241852|Active Comparator|Behavioral Control Group|Students and parents participate in an education only control group
11639962|NCT00241839|Active Comparator|A|Chlorthalidone 25 mg and Potassium Chloride 40-50meq were given daily for 5 weeks before baseline visit for testing. After baseline testing was completed, Allopurinol 300mg daily was added for 8-10 weeks at which time testing was repeated.
11639963|NCT00241839|Placebo Comparator|B|Chlorthalidone 25 mg and Potassium Chloride 40-50meq were given daily for 5 weeks before baseline visit for testing. After baseline testing was completed, a Placebo,matched in appearance to Allopurinol, was added daily for 8-10 weeks, at which time testing was repeated.
11639964|NCT00241813|Active Comparator|Health Education Control Program (CTL)|Health Education Control Program (CTL)
11639965|NCT00241813|Experimental|Mindfulness Meditation|Mindfulness Meditation (MM) Program
11639966|NCT00241813|Experimental|Lifeskills|Lifeskills Program (LP)
11639967|NCT00241813|Experimental|MM plus LP|Mindfulness Meditation (MM) Program plus Lifeskills Program (LP)
11640021|NCT00240825|Experimental|002|Ibuprofen
11640022|NCT00240825|Placebo Comparator|003|Placebo
11640023|NCT00240799|Experimental|001|acetaminophen extended release
11640024|NCT00240799|Placebo Comparator|002|placebo
11639968|NCT00241774||NSHS95 samples|In 1995, our study participants enrolled in the Nova Scotia Health Study (NSHS95). At the time of enrollment, epidemiologic data as well as blood samples were obtained. The participants have since been followed prospectively for a variety of health outcomes. We plan to assay stored blood samples collected in 1995 for markers of inflammation and link these results to existing epidemiologic and outcomes data, specifically the 7- year incidence of CAD events.
11639969|NCT00241748||1|Rhabdomyolysis Case Subjects
11639970|NCT00241748||2|Heart and Vascular Health Study statin users - control group 1
11639971|NCT00241748||3|Cardiovascular Health Study statin users - control group 2
11639972|NCT00241722|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally twice daily (BID) for 12 months.
11639973|NCT00241722|Placebo Comparator|Placebo|Placebo was administered orally BID for 12 months.
11639974|NCT00241670|Experimental|5-aminolevulinic acid|
11639975|NCT00241670|No Intervention|Conventional resection|
11639976|NCT00241644|Experimental|Rotarix 3-Dose Group|Subjects received 3 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.
11639977|NCT00241644|Experimental|Rotarix 2-Dose Group|Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.
11639978|NCT00241644|Placebo Comparator|Placebo Group|Subjects received 3 doses of placebo given concomitantly with routine EPI vaccines.
11639979|NCT00241631|Placebo Comparator|Placebo|Inhaled Theophylline placebo capsule, then placebo, then active Theophylline
11639980|NCT00241631|Active Comparator|Steroid|Inhaled Theophylline placebo capsule, then Fluticasone Propionate 500 ug bid, then active Theophylline
11639981|NCT00241449|Active Comparator|1|Tamoxifen
11639982|NCT00241449|Experimental|2|Fulvestrant
11639983|NCT00241423|Experimental|Exenatide|Exenatide and the subject's current oral antidiabetic agent regimen
11639984|NCT00241423|Placebo Comparator|Placebo|Placebo and the subject's current oral antidiabetic agent regimen
11639985|NCT00241410|Experimental|1|4 consecutive groups, dose escalation
11639986|NCT00241410|Placebo Comparator|2|4 consecutive groups
11639987|NCT00241384|Active Comparator|Pd-103 with 20Gy External Beam|Pd-103 with 20Gy External Beam
11639988|NCT00241384|Active Comparator|Pd-103 alone|Pd-103 alone
11639989|NCT00241371|Experimental|Clofarabine|4 mg/m2 IV over 1 hour on days 1-5 of each 28 day cycle.
11639990|NCT00241358|Active Comparator|Subcutaneous (SC) Treatment Plan - Donor|"Day 1: Mobilization with 240 mcg/kg SC AMD3100 and leukopheresis
~If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3."
11639991|NCT00241358|Experimental|Intravenous (IV) Treatment Plan - Donor|"Day -3: Mobilization with 80-480 mcg/kg/day IV AMD3100 and PK analysis
~Day 1: Mobilization with 240 mcg/kg/day SC AMD3100 and leukopheresis
~If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3."
11639992|NCT00241358|Other|Recipients|"Conditioning Regimen
~Cyclophosphamide 60mg/kg/day on Days -3 and -2
~TBI 550cGy on Day -1
~GVHD prophylaxis
~*Cyclosporin 3.0mg/kg/day beginning on Day -1 then tapered through Day +100
~PBSC transplant on Day 0"
11639993|NCT00241345|Experimental|Group A|IV ganciclovir (5mg/kg every 12 hours for 7 days followed by 5mg/kg every 24 hours for 7 days. If CMV viral load <5000 copies/ml after 14 days then 5mg/kg every 24 hours for a total of 21 total days of therapy. If CMV viral load >5000/ml but less than index viral load after 14 days then 5mg/kg every 24 hours for a total of 28 total days of therapy. If CMV viral load >= index viral load after 14 days then 5mg/kg every 12 hours for 7 days. If repeat CMV viral load is <= the previous CMV viral load then 5mg/kg every 12 hours for an additional 7 days.
11639994|NCT00241345|Experimental|Group B|PO valganciclovir (900 mg every 12 hours for 7 days followed by 900 mg every 24 hours for 7 days. If CMV viral load <5000 copies/ml after 14 days then 900 mg every day until 21 total days of therapy. If CMV viral load >5000 copies/ml after 14 days but less than the index viral load then 900 mg every day until 28 total days of therapy. If CMV viral load >= the index viral load 900 mg every 12 hours for 7 days, if CMV viral load <= to previous viral load then 900 mg every 12 hours for another 7 days.
11639995|NCT00241280|Active Comparator|Control|etafilcon A contact lens being worn 7 days/6 nights.
11639996|NCT00241280|Experimental|Test|galyfilcon A contact lens being worn 7 days/6 nights.
11639997|NCT00241254|Experimental|1|Cyclophosphamide
11639998|NCT00241254|Active Comparator|2|Methylprednisolone
11639999|NCT00241228|Experimental|High Volume|ultra filtration : High volume : 70 ml/kg/h
11640000|NCT00241228|Active Comparator|Medium Volume|Ultra filtration : conventional volume : 35 ml/kg/h
11640001|NCT00241189|Experimental|Rapamycin|Patients take oral rapamycin 6 mg daily (and dose adjusted to keep a serum trough level of 5-15 ng/ml) for one year
11640002|NCT00241189|Active Comparator|Methotrexate|Methotrexate 20 mg taken orally weekly for one year
11640003|NCT00241176|Experimental|Aripiprazole|
11640004|NCT00241111|Other|Zometa|
11640005|NCT00241059|Experimental|EC-MPS arm|
11640006|NCT00241020|Experimental|Octreotide|
11640007|NCT00240994|Experimental|Alemtuzumab (Campath)|In this open-label, single-arm trial , participants will be administered a 0.3 mg/kg dose of alemtuzumab (Campath) intravenously one day prior to kidney transplantation and one day post kidney transplantation. Participants will then receive a maintenance immunosuppressive regimen of tacrolimus and mycophenolate mofetil (MMF) for 8 to 12 weeks, followed by sirolimus and MMF until 24 months post transplantation.
11640008|NCT00240981|Experimental|Treatment|
11640009|NCT00240981|Placebo Comparator|Placebo|
11640010|NCT00240968|Experimental|3|Subjects will receive a single 45 mcg IM dose of the influenza A/H5N1 virus vaccine.
11640011|NCT00240968|Experimental|4|Subjects will receive a single 90 mcg IM dose of the influenza A/H5N1 virus vaccine.
11640012|NCT00240968|Experimental|1|Subjects will receive a single 7.5 mcg IM dose of the influenza A/H5N1 virus vaccine.
11640013|NCT00240968|Experimental|2|Subjects will receive a single 15 mcg IM dose of the influenza A/H5N1 virus vaccine.
11640014|NCT00240877|Experimental|1|Monovalent vaccine prior to the release of the trivalent vaccine (FluMist).
11640015|NCT00240877|Placebo Comparator|2|Placebo
11640016|NCT00240864|Experimental|001|acetaminophen
11640025|NCT00240773|Experimental|001|acetaminophen 4 grams daily for 12 months
11640026|NCT00240773|Active Comparator|002|naproxen 750 mg daily for 12 months
11640027|NCT00240773|Experimental|003|acetaminophen 4 grams daily for six months
11640028|NCT00240773|Active Comparator|004|naproxen 750 mg daily for six months
11640029|NCT00240682|Experimental|cetuximab|cetuximab
11640030|NCT00240630|Placebo Comparator|Arm 1|placebo to match
11640031|NCT00240630|Experimental|Arm 2|Treximet (sumatriptan/naproxen sodium)
11640032|NCT00240617|Active Comparator|arm 1|Treximet (sumatriptan/naproxen sodium) formerly known as TREXIMA
11640033|NCT00240617|Placebo Comparator|arm 2|placebo to match
11640034|NCT00240565|Experimental|Arm 1|Participants underwent two phases of treatment: an initial DD, followed by a therapeutic dose. The one-day DD comprised a 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with 185 MBq (5.0 mCi) of I 131. After 7 to 14 days, the one-day therapeutic dose comprised a second 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with I 131 with an administered activity (MBq or mCi) determined from the dosimetry calculation.
11640035|NCT00240539|Experimental|HBsAg(+) & HBeAg(-) 4-dose Group|Newborns of anti-hepatitis B surface antigen positive [HBsAg(+)] and hepatitis B envelope antigen negative [HBeAg(-)] mothers, who received 4 doses of Engerix™ in the primary study.
11640036|NCT00240539|Experimental|HBsAg(+) & HBeAg(+) 4-dose Group|Newborns of anti-hepatitis B surface antigen positive [HBsAg(+)] and hepatitis B envelope antigen positive [HBeAg(+)] mothers, who received 4 doses of Engerix™ in the primary study.
11640037|NCT00240539|Experimental|HBsAg(+) & HBeAg(+) 5-dose Group|Newborns of anti-hepatitis B surface antigen positive [HBsAg(+)] and hepatitis B envelope antigen positive [HBeAg(+)] mothers, who received 5 doses of Engerix™ in the primary study.
11640038|NCT00240539|Experimental|HBsAg(-) & HBeAg(-) 4-dose Group|Newborns of anti-hepatitis B surface antigen negative [HBsAg(-)] and hepatitis B envelope antigen negative [HBeAg(-)] mothers, who received 4 doses of Engerix™ in the primary study.
11640039|NCT00240526|Experimental|Engerix 4D + HBIg Group|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.
11640040|NCT00240526|Experimental|Engerix 3D + HBIg Group|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6 with hepatitis B immunoglobulins (HBIg) administered concomitantly at birth in the opposite arm.
11640041|NCT00240526|Experimental|Engerix 4D|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, 6 and 60.
11640042|NCT00240526|Experimental|Engerix 3D Group|Subjects received Engerix™ (hepatitis B vaccine [HBV]) at Month 0, 1, and 6.
11640043|NCT00240513|Active Comparator|Minocycline 3 mo|Minocycline 3 mo
11640044|NCT00240513|Experimental|Minocycline plus Tretinoin|Minocycline plus Tretinoin for 3 months
11640045|NCT00240500|Experimental|HBV-1 Group|neonates born to HBsAg+ and HBeAg+ mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
11640046|NCT00240500|Experimental|HBV-2 Group|neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
11640047|NCT00240500|Experimental|HBV-3 Group|neonates born to HBsAg+ and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
11640048|NCT00240500|Experimental|HBV-4 Group|neonates born to HBsAg+ and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
11640049|NCT00240500|Experimental|HBV-5 Group|neonates born to HBsAg- and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
11640050|NCT00240500|Experimental|HBV-6 Group|neonates born to HBsAg- and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
11640051|NCT00240487|Active Comparator|Nitric oxide first|Subjects will be randomized to receive Nitric Oxide (NO) immediately after study entry, given at 10 parts per million (ppm) for the first 4 hours of study participation. Blood gases will be monitored once an hour for 4 hours. After the first 4 hours of study participation, the nitric oxide (NO) will be turned off and subjects will receive no intervention (no nitric oxide) for the next 4 hours of study participation. During this time, all subjects will receive standard clinical are. Blood gases will be monitored once an hour for 4 hours.
11640052|NCT00240487|Active Comparator|Delayed nitric oxide|Subjects will be randomized to receive no intervention (no nitric oxide) for he first 4 hours of study participation. During this time, all subjects will receive standard clinical care. Blood gases will be monitored once an hour for 4 hours. After the first 4 hours of study participation, the nitric oxide will be turned on and subjects will receive 10 ppm of nitric oxide for the next 4 hours of study participation. Blood gases will be monitored once an hour for 4 hours.
11640053|NCT00240461|Active Comparator|1|200 mg COLD-fX Natural health products 2 times daily for six months
11640054|NCT00240461|Active Comparator|Arm 2|Arm 2 - 400 mg COLD FX Natural health product - 2 times daily for 6 months
11640055|NCT00240461|Placebo Comparator|3|Inactive crystalline substance. This is the placebo arm in which subject receive 200 mg of the placebo 2 times daily for 6 months. Placebo is an inactive crystalline substance.
11640056|NCT00240331|Experimental|Rosuvastatin 10mg|
11640057|NCT00240331|Placebo Comparator|Placebo|matching Placebo
11640058|NCT00240253|Active Comparator|Pramlintide|
11640059|NCT00240227|Other|Placebo|Placebo no active medication
11640060|NCT00240227|Active Comparator|prazosin|Prazosin flexible dose titration up to 12 mg per day.
11640061|NCT00240214||1|sirolimus
11640062|NCT00240188|Other|1|
11640063|NCT00240162|Experimental|PTK787/ZK 222584|Initially patients will receive a dose of 500mg (2, 250mg tablets) in the morning and 250mg (1, 250mg tablet) in the afternoon for 2 weeks (cycle 1, days 1-14), then 500mg (2, 250mg tablets) bid for 2 weeks (cycle 1, days 15-28) and finally 750mg (3, 250mg tablets) in the morning and 500mg (2, 250mg tablets) in the afternoon for the remainder of treatment duration (cycle 2, day 1 and onwards). Each 28 days of drug administration will constitute one cycle of therapy.
11640250|NCT00236119|Experimental|CEP-701 40mg|Patient Cohort 2
11640064|NCT00240110|Placebo Comparator|Lithium carbonate add on Placebo|Lithium carbonate started and stabilized then participants randomized to placebo
11640065|NCT00240110|Experimental|Lithium carbonate add on Valproate|Lithium carbonate started and stabilized then participants randomized to Valproate
11640066|NCT00240097|Experimental|Irinotecan; Oxaliplatin; Neulasta|Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
11640067|NCT00240097|Experimental|Etoposide; Carboplatin; Neulasta|Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) area under the concentration curve (AUC) 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
11640068|NCT00240084|Experimental|Nesiritide infusion|Single arm study. 24-hour infusion of B-type Natriuretic Peptide at a dose of 0.01 mcg/kg/minute.
11640069|NCT00240071|Experimental|Avastin|The patient will continue the same hormonal therapy used prior to study enrollment but will combine it with Avastin.
11640070|NCT00240058|Other|phenylephrine infusion with and without nitric oxide clamp|Participants received phenylephrine infusion with saline followed by phenylephrine infusion with nitric oxide clamp
11640071|NCT00240045|Experimental|1|
11640072|NCT00240032|Active Comparator|Copaxone® with Zyrtec|
11640073|NCT00240032|Experimental|Copaxone® with placebo|
11640074|NCT00240006|Experimental|1|Shared Solutions®
11640075|NCT00240006|Experimental|2|Shared Solutions® and MS Center/Office Practice Partnership
11640076|NCT00239993|Experimental|1|skin reactions with the use of warm compress prior to performing a Copaxone® injection
11640077|NCT00239993|Experimental|2|skin reactions without the use of warm compress prior to performing a Copaxone® injection
11640078|NCT00239980|Active Comparator|A|50 IU/kg
11640079|NCT00239980|Active Comparator|B|100 IU/kg
11640080|NCT00239980|Active Comparator|C|150 IU/kg
11640081|NCT00239928|Experimental|EYE001|
11640082|NCT00239837|Experimental|Middle School Success Intervention (MSS)|Middle School Success Intervention (MSS): Participants receive the preventative intervention
11640083|NCT00239837|No Intervention|Foster Care Services as Usual|Foster Care Services as Usual: Participants continue with usual foster care
11640084|NCT00239824|Experimental|1|Strength training of the pelvic floor muscles with follow up instructions by a physiotherapist
11640085|NCT00239824|Active Comparator|2|Strength training of the pelvic floor muscles without follow up instructions
11640086|NCT00239746|Experimental|1|
11640087|NCT00239746|Placebo Comparator|2|
11640088|NCT00239733|Experimental|1|Participants will be given anti-D in an outpatient setting. Participants will be observed for any adverse effects for 1 hour postinfusion. Some participants may require additional doses of anti-D later in the study, depending on individual response to the drug; participants may receive 1 to 6 doses of anti-D.
11640089|NCT00239720|Experimental|hOKT3gamma1 (Ala-Ala)|Escalating dose of hOKT3gamma1 (Ala-Ala) given intravenously over 5 days of each 28 day cycle
11640090|NCT00239720|Placebo Comparator|Placebo|Intravenous dose of placebo given over 5 days of each 28 day cycle
11640091|NCT00239707|Experimental|Infusion 1|Normal Saline
11640092|NCT00239707|Placebo Comparator|Infusion 2|GIP or modified GIP
11640093|NCT00239707|Placebo Comparator|Infusion 3|GIP or modified GIP, opposite of Infusion 2
11640094|NCT00239694|Experimental|1|Previously vaccinated
11640095|NCT00239694|Experimental|2|Never vaccinated
11640096|NCT00239681|Experimental|Rosuvastatin|Rosuvastatin 20 mg once daily
11640097|NCT00239681|Placebo Comparator|Placebo|Placebo once daily
11640098|NCT00239642|Experimental|Venofer (0.5 mg/kg)|0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
11640099|NCT00239642|Experimental|Venofer (1.0 mg/kg)|1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
11640100|NCT00239642|Experimental|Venofer (2.0 mg/kg)|2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
11640101|NCT00239590|Experimental|Testosterone|oral testosterone undecanoate, 80mg twice daily (Andriol Testocaps, Organon, The Netherlands) for 8 weeks
11640102|NCT00239590|Placebo Comparator|Placebo|identical to active medication, taken in an identical way to the active arm
11640103|NCT00239577|Experimental|DENGUE FORMULATION 17A GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two doses of Dengue vaccine Formulation 17a, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6.
11640104|NCT00239577|Experimental|DENGUE FORMULATION 17B GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two primary doses of Dengue vaccine Formulation 17b, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6, and one booster dose approximately 5-12 months after the second dose.
11640105|NCT00239577|Experimental|DENGUE FORMULATION 19 GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two primary doses of Dengue vaccine Formulation 19, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6 and one booster dose approximately 5-12 months after the second dose.
11640106|NCT00239577|Placebo Comparator|PLACEBO GROUP|Healthy male or female subjects, between and including 18-45 years of age, who received two doses of Placebo, administered subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm, at Months 0 and 6.
11640107|NCT00239564|Experimental|Experimental: carbidopa and levodopa|Subjects receive IPX054 100 mg, IPX054 150 mg, IPX054 200 mg, IPX054 250 mg, or IPX054 300 mg to achieve optimum dosage and dosing frequency as directed by the Investigator for 5 weeks.
11640108|NCT00239551|Experimental|Prevacid|Effect of Prevacid at 8 weeks; EGD(esophagogastroduodenal endoscopy) at day 1 & EGD at 8 weeks
11640109|NCT00239356|Experimental|AI|
11640110|NCT00239239|Experimental|test treatment period|
11640111|NCT00239226|Experimental|1. IAS pacing - study group|"Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (1) includes patients with Delta CTos >50 ms and randomized IAS pacing.
~IAS Pacing -Study Group: Patients with Delta CTos >50 ms (study group) at the electrophysiologic study and randomized Interatrial Septum Pacing"
11640112|NCT00239226|Experimental|2. IAS pacing-control group|"(Delta CTos<50ms)
~Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (2) includes patients with Delta CTos <50 ms and randomized IAS pacing.
~IAS Pacing -Control Group: Patients with Delta CTos <50 ms (control group) at the electrophysiologic study and randomized Interatrial Septum Pacing"
11640113|NCT00239226|Active Comparator|3. RAA Pacing - study group|"Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (3) includes patients with Delta CTos >50 ms and randomized Right Atrial Appendage pacing.
~RAA Pacing -Study Group: Patients with Delta CTos >50 ms (study group) at the electrophysiologic study and randomized Right Atrial Appendage pacing"
11640114|NCT00239226|Active Comparator|4. RAA Pacing - control group|"Patients were first submitted to electrophysiological study to assess Delta CTos > or < 50 ms. Then they were randomized to interatrial septum pacing od right atrial appendage. This arm (4) includes patients with Delta CTos <50 ms and randomized Right Atrial Appendage pacing.
~RAA Pacing -Control Group: Patients with Delta CTos <50 ms (control group) at the electrophysiologic study and randomized Right Atrial Appendage pacing"
11640115|NCT00239083|Experimental|EC-MPS|
11640116|NCT00239031|Experimental|1|
11640117|NCT00239005|Active Comparator|Mycophenolate Mofetil (MMF)|250 mg capsules or 500 mg tablets of mycophenolate mofetil. Daily dose decided by physician, was taken morning and evening.
11640118|NCT00239005|Experimental|Enteric-Coated Mycophenolate Sodium (EC-MPS )|Oral film-coated gastroresistant tablets containing 360mg or 180mg of mycophenolate sodium. Daily dose decided by the physician, was taken morning and evening.
11640119|NCT00238953|Experimental|EC MPS|
11640120|NCT00238914|Active Comparator|CE plus oral naltrexone|Compliance enhancement plus oral naltrexone
11640121|NCT00238914|Active Comparator|BNT plus oral naltrexone|Behavioral naltrexone therapy plus oral naltrexone
11640122|NCT00238888|Experimental|Asthma control awareness|Multifaceted intervention to increase the patient awareness of the leve of asthma control
11640123|NCT00238888|Active Comparator|Usual care|Usual care
11640124|NCT00238875|Experimental|1|Procedure/Surgery: stereotactic body radiation therapy
11640125|NCT00238667|Active Comparator|Anti-platelet therapy|Aspirin, Dipyridamole, clopidogrel alone or in dual therapy
11640126|NCT00238667|Active Comparator|Anti-coagulant|Warfarin, unfractionated heparin, enoxaparin, dalteparin, tinzaparin aiming for an INR in range of 2-3. Local protocols for Heparin can be used
11640127|NCT00238615|Experimental|Chemotherapy+Radiation+Surgery|"Concurrent weekly docetaxel at 20 mg/m2 and weekly carboplatin at an AUC of 2 with thoracic radiotherapy of 180-200cGy/day for 5/7 days to 45 Gy.
~Complete surgical excision 3-6 weeks after completion of chemoradiotherapy.
~No Surgery if patient is deemed unable to tolerate surgery, with completion to 61 Gy radiation
~Consolidation after surgery: Docetaxel given at 75 mg/m2 every 3 weeks with carboplatin at AUC 6 every 3 weeks with concomitant growth factor support."
11640128|NCT00238459||Recently infected patients|Cohort 1)Patients elcted to be immediately treated with licensed drugs:21 patients Cohort 2) Or to delay treatment until clinically indicated:16 patieints
11640129|NCT00238459||A vaccine,HIV-1 immunogen was not provided for evaluation|In the intial design, acandiate HIV vaccine was to be evaluated, but in August 2007 the manufacturer refused to provide vaccine to allow this study to evaluate the effect of a vaccine on control of HIV. Therefore the study became an observational study of the effects of early versus delayed initiation of antiretrovral therapy on the preservation of anti-HIV immune responses and the ability of patients to control virus after a closely monitored discontinuation of therapy.
11640130|NCT00238433|Experimental|Filgrastim/Melphalan/Thiotepa|"Biological/Vaccine: filgrastim
~5mcg/kg intravenous piggyback (IVPB) will be administered beginning on day +5 and continued until absolute neutrophil count (ANC) > 1500 for 2 consecutive days.
~Drug: busulfan
~3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.
~Drug: melphalan
~50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.
~Drug: thiotepa
~250 mg/m2/day/iv on days -3 and -2 Procedure/Surgery: bone marrow ablation with stem cell support
~The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.
~Procedure/Surgery: peripheral blood stem cell transplantation
~Performed 36-48 hours following last chemotherapy dose."
11640131|NCT00238420|Experimental|Group I (paclitaxel, trastuzumab, radiation therapy)|Patients receive paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, and 43 and trastuzumab IV over 90 minutes on day 1 and then over 30 minutes on days 8, 15, 22, 29, 36, and 43. Patients also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, 43-47, and 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
11640132|NCT00238420|Experimental|Group II (paclitaxel, radiation therapy)|Patients receive paclitaxel and undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, 43-47, and 50.
11640133|NCT00238407|Active Comparator|Arm I|Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71. Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
11640134|NCT00238394|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR. Patients experiencing disease progression within 5 years after completion of study treatment may receive additional courses of study treatment.
11640135|NCT00238381|Other|Arm I|Patients undergo total mesorectal excision (TME) by standard methods or laparoscopically and side-to-end anastomosis rectal reconstruction.
11640136|NCT00238381|Other|Arm II|Patients undergo TME and colon-J-pouch anastomosis rectal reconstruction.
11640137|NCT00238381|Other|Arm III|Patients undergo straight coloanal anastomosis with/without temporary protective ileostomy
11640138|NCT00238355|Experimental|Voriconazole plus Caspofungin|
11640139|NCT00238316|Active Comparator|Letrozole|
11640140|NCT00238316|Placebo Comparator|Placebo|
11640182|NCT00237692|Experimental|Arm 2|Nurse Behavioral intervention with Home BP Telemonitoring Nurse-administered tailored behavior intervention
11640141|NCT00238303|Experimental|Stratum 1 (not undergoing surgery)|Patients receive oral vorinostat (SAHA) twice daily for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11640142|NCT00238303|Experimental|Stratum 2 (undergoing surgery)|Beginning 3 days prior to surgery, patients receive oral SAHA once or twice daily for a total of 6 doses. Patients then undergo surgery to remove the tumor. Beginning within 1-4 weeks after surgery, patients receive oral SAHA twice daily for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11640143|NCT00238290|Experimental|Arm A|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
11640144|NCT00238264|Experimental|Treatment (radiotherapy)|Patients undergo reduced-field conformal radiation therapy 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
11640145|NCT00238251|Active Comparator|Arm I|Patients undergo whole-brain radiotherapy (WBRT) once daily on days 1-5 and 8-12 and receive oral gefitinib once daily on days 1-28. Gefitinib treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity
11640146|NCT00238251|Active Comparator|Arm II|Patients undergo WBRT as in arm I and receive oral temozolomide once daily on days 1-21. Temozolomide treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity
11640147|NCT00238238|Active Comparator|Arm I - rituximab|Patients receive rituximab IV on days 1, 8, 15, and 22.
11640148|NCT00238238|Experimental|Arm II - lenalidomide|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11640149|NCT00238238|Experimental|Arm III - lenalidomide and rituximab|Patients receive lenalidomide as in arm II. Patients also receive rituximab IV on days 8, 15, 22 and 29.
11640150|NCT00238212|Experimental|Treatment|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11640151|NCT00238121|Experimental|Treatment|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11640152|NCT00238108|Experimental|1|Melatonin (2,5 mg, by mouth, 1 per day, for 3-4 weeks)
11640153|NCT00238108|Placebo Comparator|2|Placebo
11640154|NCT00238030|Active Comparator|po thyroxine|placebo is iv
11640155|NCT00238030|Active Comparator|iv thyroxine|placebo is po
11640156|NCT00237978|Active Comparator|1|VIS and wIRA
11640157|NCT00237978|Active Comparator|2|VIS, wIRA and Adapalen
11640158|NCT00237978|Active Comparator|3|Adapalen
11640159|NCT00237926|Experimental|1|aerobic exercise
11640160|NCT00237926|Experimental|2|Resistance Training
11640161|NCT00237913|Active Comparator|A1|
11640162|NCT00237913|Active Comparator|B1|
11640163|NCT00237809|Experimental|Drug and control CRT|D-serine/control
11640164|NCT00237809|Experimental|Drug and CRT|D-serine/cog rehab
11640165|NCT00237809|Experimental|Placebo Drug and Placebo CRT|Placebo/control
11640166|NCT00237809|Experimental|Placebo Drug and CRT|Placebo/cog rehab
11640167|NCT00237796|Experimental|ARM 1|Cognitive Behavioral Social Skills Training (CBSST)
11640168|NCT00237796|Active Comparator|ARM 2|Goal Focused Supportive Contact (GFSC)
11640169|NCT00237783|Active Comparator|standard dialysate sodium (140 mmol/L)|dialysate sodium (140 mmol/L)
11640170|NCT00237783|Experimental|individualized dialysate sodium|individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
11640171|NCT00237770|Placebo Comparator|Arm 1|Placebo control (normal saline) is employed on a separate visit during procedure.
11640172|NCT00237757|Experimental|Arm 1|The experimental arm consisted of a six month staff training period with an emphasis on effective team functioning to improve patient outcomes. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing
11640173|NCT00237757|Active Comparator|Arm 2|The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
11640174|NCT00237744|Experimental|Wrist/Hand FES + Whole Arm Motor Learning|Subjects > 6 months following first stroke with diminished upper limb strength, coordination and function, who received whole arm motor learning training and FES of the wrist/hand.
11640175|NCT00237744|Experimental|Shoulder/Elbow Robotics + Whole Arm Motor Learning|Subjects>6 months following first stroke with diminished upper limb strength, coordination and function, who received whole arm motor learning and shoulder/elbow robotics.
11640176|NCT00237744|Experimental|Whole Arm Motor Learning|Subjects>6 months following first stroke with diminished upper limb strength, coordination and function who received whole arm motor learning training without addition of FES or Robotics
11640177|NCT00237731|Experimental|1|morphine 0.05
11640178|NCT00237731|Active Comparator|2|morphine 0.10
11640179|NCT00237718|Active Comparator|ALA and Vitamin E|600 mg (2 pills 300 mg each) of alpha lipoic acid (ALA) and 666 IU (1 pill) of alpha, gamma, beta and delta (mixed) tocopherols (Vitamin E) taken orally on a daily basis for 6 months
11640180|NCT00237718|Placebo Comparator|Placebo|placebo for ALA (2 pills) and for Vitamin E (1 pill) taken orally on a daily basis for 6 months
11640181|NCT00237692|No Intervention|Arm 1|Control group - a group of hypertensive patient who receive usual care
11640249|NCT00236119|Experimental|CEP-701 20mg|Patient Cohort 1
11640183|NCT00237692|Experimental|Arm 3|Nurse Medication Management with Home BP Telemonitoring -- Nurse administer medication management according to hypertension decision support system
11640184|NCT00237692|Experimental|Arm 4|Nurse Combined intervention with Home BP Telemonitoring - Combination of the nurse administered tailored behavioral & medication management interventions
11640185|NCT00237679|Active Comparator|Neuromuscular Electrical Stimulation|Subjects will receice Neuromuscular Electrical Stimulation (NMES)-stimulated swallowing combined with exercise therapy.
11640186|NCT00237679|Sham Comparator|Unstimulated|Subjects will receive sham (unstimulated) swallow therapy combined with exercise therapy.
11640187|NCT00237666|Experimental|Ziprasidone|Ziprasidone monotherapy, 20-60 mg BID.
11640188|NCT00237640|Placebo Comparator|1|
11640189|NCT00237640|Active Comparator|2|
11640190|NCT00237627|Experimental|Part 1|Doxil + PS-341
11640191|NCT00237627|Experimental|Part 2|Doxil + Velcade
11640192|NCT00237601||1|Women with the intention to give birth at home
11640193|NCT00237601||2|Women with the intention to give birth in a short-stay hospital setting
11640194|NCT00237549|Experimental|Intervention|The 334 general practices in Denmark, United Kingdom and the Netherlands have been randomised to screening for diabetes followed by routine care (RC group) according to national guidelines, or screening followed by multifactorial treatment (IT group).
11640195|NCT00237497|Experimental|Ramelteon 8 mg QD|
11640196|NCT00237497|Active Comparator|Zopiclone 7.5 mg QD|
11640197|NCT00237497|Placebo Comparator|Placebo QD|
11640198|NCT00237484|Experimental|Arm A|Remicade induction dose at Day -7 prior to initiation of PEGETRON treatment for up to 48 weeks
11640199|NCT00237484|Active Comparator|Arm B|PEGETRON treatment for up to 48 weeks
11640200|NCT00237458|Experimental|Lacosamide|Open-label active treatment
11640201|NCT00237393|Experimental|1|Quetiapine
11640202|NCT00237393|Placebo Comparator|2|
11640203|NCT00237380|Experimental|Ataluren|"Cycle 1: Within the first 28-day period, ataluren treatment will be taken 3 times per day with meals for 14 days at doses of 4 milligrams/kilogram (mg/kg) (breakfast), 4 mg/kg (lunch), and 8 mg/kg (dinner); there will then be an interval of 14 days without treatment.
~Cycle 2: Within the second 28-day period, ataluren treatment will be taken 3 times per day with meals for 14 days at doses of 10 mg/kg (breakfast), 10 mg/kg (lunch), and 20 mg/kg (dinner); there will then be an interval of 14 days without treatment."
11640204|NCT00237224|Experimental|FEM345|
11640205|NCT00237211|Experimental|Letrozole|
11640206|NCT00237198|Experimental|Letrozole|
11640207|NCT00237185|Experimental|imatinib mesylate 400 mg|400 mg once daily
11640208|NCT00237185|Experimental|imatinib mesylate 600 mg|600 mg once daily
11640209|NCT00237172|Experimental|Imatinib Mesylate|400 mg once daily
11640210|NCT00237159|Experimental|ZOL446|
11640211|NCT00237146|Experimental|Zoledronic Acid|
11640212|NCT00237133|Experimental|Letrozole|
11640213|NCT00237107|Experimental|curettage|
11640214|NCT00237042|Active Comparator|Self Management|Dental hygienist-delivered pain self-management treatment
11640215|NCT00237042|Experimental|Targeted Self Management|Dental hygienist-delivered pain self-management treatment with a focus on menstrual cycle-related changes in pain and other symptoms
11640216|NCT00237042|Experimental|Continuous Oral Contraceptives|"Oral contraceptive (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months with no spacer pills."
11640217|NCT00237003|Active Comparator|1) assessment plus motivational interview|Participants are assigned, in this 6 month study, to an assessment-only condition or an assessment plus motivational interview condition. Two motivational interview sessions are conducted during the first month of study participation.
11640218|NCT00236990|Experimental|001|pentosan polysulfate sodium
11640219|NCT00236977|Experimental|Venofer|iron sucrose injection
11640220|NCT00236977|Active Comparator|Ferrous Sulfate|oral iron
11640221|NCT00236951|Active Comparator|Venofer + erythropoietin (responders)|
11640222|NCT00236951|Active Comparator|erythropoietin only (responders)|
11640223|NCT00236951|Active Comparator|Venofer+erythropoietin(non-responders)|
11640224|NCT00236951|Active Comparator|erythropoietin only (non-responders)|
11640225|NCT00236938|Experimental|Group A|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
11640226|NCT00236938|Active Comparator|Group B|Stable erythropoietin (EPO) dose and no supplemental iron.
11640227|NCT00236925|Active Comparator|Low dose Hydrocortisone|Low Dose Hydrocortisone
11640228|NCT00236925|Placebo Comparator|Placebo|Placebo
11640229|NCT00236899|Experimental|A: Docetaxel and Gemcitabine (Tri-weekly)|Docetaxel and Gemcitabine (Tri-weekly)
11640230|NCT00236899|Experimental|B: Paclitaxel and Gemcitabine (Tri-weekly)|Paclitaxel and Gemcitabine (Tri-weekly)
11640231|NCT00236899|Experimental|C: Docetaxel and Gemcitabine (Weekly)|Docetaxel and Gemcitabine (Weekly)
11640232|NCT00236899|Experimental|D: Paclitaxel and Gemcitabine (Weekly)|Paclitaxel and Gemcitabine (Weekly)
11640233|NCT00236379|Experimental|001|Risperidone Target oral dose of 6 milligrams per day for for 6 months
11640234|NCT00236379|Experimental|002|Olanzapine Target oral dose of 20 milligrams per day for 6 months
11640235|NCT00236301|Active Comparator|1|17 Beta-estradiol (2mg/day)and (1mg/day)
11640236|NCT00236301|Active Comparator|2|CLIMASTON
11640237|NCT00236301|Placebo Comparator|3|placebo
11640238|NCT00236275|Experimental|1|Fluoro-L-thymidine-(18F)
11640239|NCT00236223|Experimental|1|
11640240|NCT00236223|Placebo Comparator|2|
11640241|NCT00236210|Active Comparator|VIP program|Risk assessment, lifestyle counselling, exercise program
11640242|NCT00236210|No Intervention|Standard Care|
11640243|NCT00236197|Experimental|1|
11640244|NCT00236197|Placebo Comparator|2|
11640245|NCT00236184|Placebo Comparator|Placebo|Oral placebo tablet
11640246|NCT00236184|Experimental|Rabeprazole sodium 10 mg|oral rabeprazole 10 mg enteric-coated tablet
11640247|NCT00236158|Other|AAIR|
11640248|NCT00236158|Other|DDDR|
11640251|NCT00236119|Experimental|CEP-701 60mg|Patient Cohort 3
11640252|NCT00236119|Experimental|CEP-701 80mg|Patient Cohort 4
11640253|NCT00236080|Experimental|1|PROVIGIL 200 mg/day
11640254|NCT00236080|Experimental|2|Armodafinil 250 mg/day
11640255|NCT00236080|Experimental|3|Armodafinil 200 mg/day
11640256|NCT00236080|Experimental|4|Armodafinil 150 mg/day
11640257|NCT00236080|Placebo Comparator|5|Placebo
11640258|NCT00236002|Placebo Comparator|placebo|
11640259|NCT00235989|Active Comparator|ET: IFNB-1b 250 mcg => 250 mcg|Extension Treatment 250 mcg continued
11640260|NCT00235989|Experimental|ET: IFNB-1b 500 mcg => 250 mcg|Extension Treatment 500 mcg reduced to 250 mcg
11640261|NCT00235989|Experimental|ET: IFNB-1b 500 mcg => 500 mcg|Extension Treatment 500 mcg continued
11640262|NCT00235989|Experimental|ET: IFNB-1b 250 mcg => 500 mcg|Extension Treatment 250 mcg increased to 500 mcg
11640263|NCT00235898|Experimental|1|CoFactor, 5-FU
11640264|NCT00235898|Active Comparator|2|Leucovorin, 5-FU
11640265|NCT00235872|Experimental|Adalimumab 40 mg every other week (eow)|
11640266|NCT00235846|Active Comparator|Conventional vein harvest|Conventional open vein harvest from the lower leg
11640267|NCT00235846|Experimental|Endoscopic vein harvest|Endoscopic vein harvest from the calf
11640268|NCT00235833|Experimental|Adalimumab 40 mg eow|
11640269|NCT00235820|Active Comparator|A|
11640270|NCT00235820|Active Comparator|B|
11640271|NCT00235820|Placebo Comparator|C|
11640272|NCT00235807|Other|1|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
11640273|NCT00235807|Other|2|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
11640274|NCT00235807|Other|3|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
11640275|NCT00235755|Placebo Comparator|Placebo|
11640276|NCT00235755|Experimental|Retigabine 600 mg|
11640277|NCT00235755|Experimental|Retigabine 900 mg|
11640278|NCT00235729|Experimental|1|Lofexidine 0.8 mg QID
11640279|NCT00235729|Placebo Comparator|2|Placebo QID
11640280|NCT00235716|Experimental|Arm 1|2,000 IU per day of dl-alpha-tocopherol plus placebo for memantine
11640281|NCT00235716|Experimental|Arm 2|20 mg per day of memantine plus placebo for dl-alpha-tocopherol
11640282|NCT00235716|Experimental|Arm 3|Combination of 2,000 IU per day of dl-alpha-tocopherol and 20 mg per day of memantine
11640283|NCT00235716|Placebo Comparator|Arm 4|Matching placebos for dl-alpha-tocopherol and memantine
11640284|NCT00235690|Other|blood draws|all patients enrolled will have PK blood samples obtained around a colistin dosing
11640285|NCT00235573|Experimental|Vitamin B12 supplement|After taking a fasting blood sample, all subjects were given a light breakfast plus 9 micrograms of vitamin B12. Two more doses of vitamin B12 were administered 6 hours apart.
11640286|NCT00235547|Active Comparator|contraception-Immediate start|contraception after abortion and before leaving the clinic, observed by clinic staff
11640287|NCT00235547|Active Comparator|Contraception-Delayed start|instructed to begin contraception the first Sunday after leaving the clinic
11640288|NCT00235534|Experimental|Immediate start|Initiate selected birth control method before leaving the clinic at the time of the abortion procedure.
11640289|NCT00235534|Active Comparator|Sunday start|Begin birth control the first Sunday after leaving the clinic
11640290|NCT00235508|Active Comparator|1|Escitalopram oxalate 10 mg at bedtime
11640291|NCT00235508|Active Comparator|2|Eszopiclone 3 mg at bedtime
11640292|NCT00235495|Active Comparator|Albumin (ALB)|Albumin (human albumin, 25% solution, 2.0 g/kg), infused intravenously over a period of 2 hours
11640293|NCT00235495|Placebo Comparator|Saline|Saline (isotonic solution), 8 ml/kg, infused intravenously over a 2-hour period
11640294|NCT00235456|Active Comparator|80% perioperative oxygen|Perioperative supplemental oxygen: Patients were randomly assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
11640295|NCT00235456|Placebo Comparator|30% perioperative oxygen|Standard oxygen: Patients were randomly assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
11640296|NCT00235443|Experimental|1|Open label doses (two times per day) include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, 600mg/day
11640297|NCT00235404|Experimental|Intermediate community hospital|
11640298|NCT00235404|Active Comparator|Usual care|
11640299|NCT00235391|Experimental|Deferasirox|Deferasirox was administered orally once a day, 30 minutes prior to breakfast. Dosage was based on participant's body weight. Starting dose was determined by the frequency of blood transfusions and recommended initial daily dose of deferasirox is 20 mg/kg body weight for patients receiving blood transfusion, 10 mg/kg for patients receiving less frequent transfusion/exchange transfusion and 30 mg/kg for patients receiving more frequent blood transfusions.
11640300|NCT00235378||1|SLE patients
11640301|NCT00235378||2|Unaffected family members of SLE patients
11640302|NCT00235378||3|Control participants
11640303|NCT00235365|Experimental|meta-cognitive therapy|meta-cognitive therapy
11640304|NCT00235365|Active Comparator|waiting list|waiting list control
11640305|NCT00235339|Active Comparator|1|Standard exercise training rehabilitation at the hospital
11640306|NCT00235339|Experimental|2|Interval exercise training on treadmills, with high intensity
11640307|NCT00235326||2|Unexposed to gastroenteritis
11640308|NCT00235326||1|Exposed to gastroenteritis
11640309|NCT00235313|Experimental|1|adaptation of the nicotine patch with salivary cotinine
11640310|NCT00235313|Other|2|normal following with a nicotine patch
11640311|NCT00235300|Active Comparator|1 Control|Simulect (basiliximab)
11640312|NCT00235300|Experimental|2|Thymoglobulin (anti-thymocyte globulin (rabbit))
11640478|NCT00232765|Active Comparator|2|Uncoated Bx Velocity
11640313|NCT00235287|Active Comparator|A,AIIA|24 weeks of treatment with Candesartan, where Enalapril is added in the last 8 weeks.
11640314|NCT00235287|Active Comparator|A, ACE-I|24 weeks of treatment with Enalapril, where Candesartan is added in the last 8 weeks.
11640315|NCT00235287|Active Comparator|C, AIIA|8 weeks of treatment with Candesartan, followed by 8 weeks of treatment with Enalapril. The treatment in the last 8 out of the 24 weeks is a combination of Candesartan and Enalapril.
11640316|NCT00235287|Active Comparator|C, ACE|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg) , followed by 8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg) . The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
11640317|NCT00235248|Experimental|Clopidogrel-aspirin|Clopidogrel-aspirin
11640318|NCT00235248|Active Comparator|Warfarin|Warfarin
11640319|NCT00235235||A|Doxorubicin 60 mg/m2 + Cyclophosphamide 600 mg/m2 day 2 of every 21-day cycle
11640320|NCT00235235||B|Capecitabine 1000mg/m2 bid days 1-14 of every 21-day cycle
11640321|NCT00235235||C|Vinorelbine 25 mg/m2 days 1, 8, 15 of every 28-day cycle
11640322|NCT00235235||D|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
11640323|NCT00235183|Active Comparator|Quarantined FFP|Quarantined FFP
11640324|NCT00235183|Active Comparator|Methylene blue FFP|Methylene blue FFP
11640325|NCT00235183|Active Comparator|Solvent detergent FFP|Solvent detergent FFP
11640326|NCT00235170|Experimental|1|Cypher Sirolimus-eluting Coronary stent
11640327|NCT00235157|Experimental|1|Sirolimus-eluting Palmaz Genesis peripheral stent
11640328|NCT00235144|Experimental|1|drug-eluting stent
11640329|NCT00235144|Active Comparator|2|bare-metal stent
11640330|NCT00235131|Experimental|1|Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
11640331|NCT00235131|Active Comparator|2|Bard® Luminexx™ 6F Vascular Stent
11640332|NCT00235079|Experimental|Colchicine|Colchicine 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
11640333|NCT00235079|Placebo Comparator|Placebo|Placebo 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
11640334|NCT00235066|Experimental|1|Cypher Sirolimus-Eluting Stent
11640335|NCT00235040|Other|1|Intervention
11640336|NCT00235040|No Intervention|2|Control
11640337|NCT00235027|Experimental|Adverse Drug Event Monitoring|In this intervention arm, clinicians received medication safety alerts when they prescribed medications in the electronic medical record.
11640338|NCT00235027|No Intervention|Care as Usual|In this arm, clinicians did not receive the medication safety alerts.
11640339|NCT00235014|Active Comparator|A-1, B-1|A-1 pertains to Phase 1; B-1 pertains to Phase 2
11640340|NCT00235014|Active Comparator|A-2, B-2|A2 pertains to Phase 1; B-2 pertains to Phase 2
11640341|NCT00235014|Placebo Comparator|A-3|
11640342|NCT00235014|Active Comparator|A-4|
11640343|NCT00235001|Experimental|1|
11640344|NCT00234988|Experimental|1|
11640345|NCT00234975|Active Comparator|HCV +|
11640346|NCT00234975|Active Comparator|HCV -|
11640347|NCT00234923|Active Comparator|1|Kaletra Monotherapy: lopinavir/ritonavir
11640348|NCT00234923|Active Comparator|2|Kaletra based triple therapy: lopinavir/ritonavir + lamivudine/zidovudine
11640349|NCT00234910|Experimental|A|2 drug arm
11640350|NCT00234910|Active Comparator|B|3 drug arm, SOC
11640351|NCT00234884||Adalimumab|RA patients in treatment with commercial adalimumab
11640352|NCT00234871|Active Comparator|1|
11640353|NCT00234871|Active Comparator|2|
11640354|NCT00234858|Active Comparator|1|
11640355|NCT00234858|Active Comparator|2|
11640356|NCT00234832|Experimental|Sibutramine|Subjects were randomized to receive sibutramine 10 mg once daily (QD) during the Treatment Period after a 6-week Lead-in Period
11640357|NCT00234832|Placebo Comparator|Placebo|Subjects were randomized to receive placebo QD during the Treatment Period after a 6-week Lead-in Period
11640358|NCT00234832|Experimental|Lead-in sibutramine|All subjects received 10 mg sibutramine QD during a 6-week Lead-in Period
11640359|NCT00234806|Experimental|Telemedicine intervention group|
11640360|NCT00234806|Placebo Comparator|Control group|
11640361|NCT00234754|Active Comparator|1|Trans-vaginal tape Surgery
11640362|NCT00234754|Experimental|2|Trans-obturator tape surgery
11640363|NCT00234702|Experimental|1|
11640364|NCT00234702|Placebo Comparator|2|
11640365|NCT00234676|Experimental|1|Premarin
11640366|NCT00234598|No Intervention|Control group, usual care|Usual care with no study interventions provided; no tooth brushing intervention and no chlorhexidine intervention. Usual care
11640367|NCT00234598|Active Comparator|Tooth brushing only|Tooth brushing by study personnel three times per 24 hours (TID) without chlorhexidine application.
11640368|NCT00234598|Active Comparator|Chlorhexidine only|Oral application of chlorhexidine 0.12% oral solution twice per 24 hours (BID) without tooth brushing.
11640369|NCT00234598|Active Comparator|Toothbrushing and chlorhexidine|Tooth brushing by study personnel three times per 24 hours (TID) and oral application of chlorhexidine 0.12% oral solution twice per 24 hours (BID)
11640370|NCT00234546|Experimental|1|Dysport
11640371|NCT00234546|Placebo Comparator|2|Placebo
11640372|NCT00234533|Experimental|NutropinAq 10 mg/2 mL (30 IU)|"Patients received daily subcutaneous (s.c.) injections of NutropinAq 10 milligrams (mg)/2 milliliters (mL) for 6 months. The therapeutic daily doses administered were as follows:
~GHD patients: 0.025 - 0.035 mg/ kilogram (kg) bodyweight
~TS patients: up to 0.05 mg/kg bodyweight
~CRI patients: up to 0.05 mg/kg bodyweight
~Patients visited the study clinic for a baseline visit and for 2 other visits every 3 months (Weeks 12 and 24). Additional home assessments were made at Weeks 21, 22 and 23.
~The investigator determined the dose administered to each patient, and it was recommended to perform the injection in the evening."
11640373|NCT00234494|Experimental|Single Group Assignment|Cisplatin + Gemcitabine + Bevacizumab
11640374|NCT00234455|Other|1|stent in the main branch with balloon angioplasty by a kissing balloon technique in the side branch (stent/PTCA group)
11640375|NCT00234455|Other|2|stents in both the main and side branches (stent/stent group)
11640479|NCT00232752|Experimental|1|
11640480|NCT00232739|Experimental|1|
11640376|NCT00234299|Active Comparator|Group A|Enteric coated aspirin 325mg, one tablet orally every day for six months prior to prostate biopsy.
11640377|NCT00234299|Placebo Comparator|Group B|Enteric coated placebo, one tablet orally every day for six months prior to prostate biopsy.
11640378|NCT00234286|Experimental|Arm 1|Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
11640379|NCT00234273|Experimental|Therapeutic education combining dietary and rehabilitation|Therapeutic education combining dietary and rehabilitation (APA)
11640380|NCT00234273|Active Comparator|Therapeutic education primarily focused on dietary|Therapeutic education primarily focused on dietary
11640381|NCT00234221|Active Comparator|Strengths Based Case Management Model (SBCM)|The Strengths Based Case Management Model (SBCM) consists of 5 case-management sessions designed to promote linkage and engagement in assessment and treatment services, while assisting with the patient's perceived needs, as well as personal strengths and barriers to linkage and engagement.
11640382|NCT00234221|Active Comparator|Motivational Enhancement Therapy (MET)|The MET therapist will conduct 2 motivational enhancement sessions to work through the content of an educational workbook targeting the participant's alcohol use/abuse with the goal of negotiating a 'contract' to: 1) link to services, with the eventual goal of seeking and receiving specialized alcohol treatment; or 2) provide a strategy to self-monitor alcohol use, consider consequences, and later seek assessment.
11640383|NCT00234221|Active Comparator|Brief Informational Feedback (BIF) session|Subjects will receive brief informational feedback on the results of their alcohol screening and assessment and encouragement to seek treatment.
11640384|NCT00234208|Experimental|Medical thoracoscopy|
11640385|NCT00234208|Active Comparator|Simple chest tube drainage|
11640386|NCT00234156|Active Comparator|renal disease|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.
~Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
11640387|NCT00234156|Active Comparator|normal|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.
~Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
11640388|NCT00234143|Active Comparator|Aranesp and Neupogen|solution for subcutaneous injection , syringe 500 mcg and 300 mcg respectively
11640389|NCT00234143|Active Comparator|Aranesp|solution for subcutaneous injection, 500 mcg
11640390|NCT00234143|No Intervention|Best supportive care|Red cell transfusion support
11640391|NCT00234091|Active Comparator|1|Immediate treatment; individuals receive HAART on Day 1 of the study
11640392|NCT00234091|Active Comparator|2|Delayed treatment; individuals receive HAART if their CD4 percentage falls below 15 percentage OR if they develop a CDC category C illness
11640393|NCT00234078|Experimental|0.5% OPC-12759|0.5% OPC-12759 (rebamipide) ophthalmic suspension
11640394|NCT00234078|Experimental|1% OPC-12759|1% OPC-12759 (rebamipide) ophthalmic suspension
11640395|NCT00234078|Experimental|2% OPC-12759|2% OPC-12759 (rebamipide) ophthalmic suspension
11640396|NCT00234078|Placebo Comparator|placebo|placebo of OPC-12759 (rebamipide) ophthalmic suspension
11640397|NCT00234065|Experimental|1|cilostazol
11640398|NCT00234065|Active Comparator|2|Aspirin
11640399|NCT00234052|Experimental|Treatment Arm|Carboplatin + pemetrexed + bevacizumab
11640400|NCT00234039|Experimental|Intravesical Gemcitabine|
11640401|NCT00234000|Experimental|Arm 1|see description in intervention
11640402|NCT00233987|Experimental|High-dose therapy plus tandem transplant|Regimen consists of 2 cycles of high-dose therapy, each followed by stem cell infusion. Cycle 1 consists of high-dose melphalan followed by infusion of approximately 1.5 million cluster of differentiation 34 positive (CD34+) cells. Cycle 2 consists of either TBI-based or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-based high-dose therapy followed by infusion of at least 2 million CD34+ cells.
11640403|NCT00233974|Experimental|PET negative|Traditional breast Surgery and full axillary dissection
11640404|NCT00233974|Experimental|PET positive|PET-probe-guided breast resection and full axillary dissection
11640405|NCT00233948|Experimental|Arm I|Patients receive oral nelfinavir mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11640406|NCT00233935|Experimental|Arm I (1 capsule)|Patients receive 1 capsule of defined green tea catechin extract PO BID for the next 6 months.
11640407|NCT00233935|Experimental|Arm II (2 capsules)|Patients receive 2 capsules of defined green tea catechin extract PO BID for the next 6 months.
11640408|NCT00233935|Experimental|Arm III (3 capsules)|Patients receive 3 capsules of defined green tea catechin extract PO BID for the next 6 months.
11640409|NCT00233935|Placebo Comparator|Arm IV (placebo)|Patients receive 1-3 capsules of placebo PO BID for the next 6 months.
11640410|NCT00233883|Experimental|1|
11640411|NCT00233883|Active Comparator|2|
11640412|NCT00233818|Other|1|
11640413|NCT00233805|Active Comparator|1|Bare metal Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system
11640414|NCT00233805|Experimental|2|Sirolimus coated modified Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system
11640415|NCT00233792|Other|1|sirolimus coated Bx VELOCITY stent - fast release
11640416|NCT00233792|Other|2|sirolimus coated Bx VELOCITY stent - slow release
11640417|NCT00233727|Active Comparator|HPV DNA Testing + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women."
11640481|NCT00232687|Active Comparator|A1|
11640482|NCT00232687|Active Comparator|A2|
11640418|NCT00233727|Active Comparator|VIA + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women."
11640419|NCT00233727|No Intervention|Delayed Evaluation and Treatment|Patients will undergo a similar screening process at entry, but will be randomized to have evaluation and treatment delayed until 6 months after screening.
11640420|NCT00233714|Active Comparator|1|Single-dose Sirolimus-Eluting Coronary stent
11640421|NCT00233714|Active Comparator|2|Double-dose Sirolimus-Eluting Coronary stent
11640422|NCT00233688|Experimental|1|QUANTUM LP™ STENT GRAFT SYSTEM
11640423|NCT00233688|Active Comparator|2|Surgical intervention
11640424|NCT00233571|Experimental|Adalimumab 40mg subcutaneous (SC) every other week (EOW)|Adalimumab 40mg subcutaneous (SC) every other week (EOW)
11640425|NCT00233532|Other|1|
11640426|NCT00233532|Other|2|
11640427|NCT00233532|Other|3|
11640428|NCT00233519|Experimental|Cohort 1- Two Escalating Doses of Iplex|0.5 and 1.0 mg/kg/day
11640429|NCT00233519|Active Comparator|Cohort 2 - Three Escalating Doses of Iplex|0.5, 1.0, and 2.0 mg/kg/day
11640430|NCT00233506|Experimental|CPG 7909 IV|Intravenous infusions will be administered with a standard infusion pump beginning at 125 cc/hr through an intravenous catheter (central or peripheral).
11640431|NCT00233506|Experimental|CPG 7909 SQ|Subcutaneous injections should be administered in the abdominal wall, upper arm, hip, or anterior thigh. If the volume of injection exceeds 1.5 ml, the volume should be divided into equal injections at a volume less than 1.5 ml and administered in different areas of the body. The maximum dose level on this trial may require 5 - 6 injections at an equal number of sites.
11640432|NCT00233480|Experimental|active treatment|atorvastatin 10mg QD x 3 months
11640433|NCT00233480|Placebo Comparator|placebo|matched placebo QD x 3 months
11640434|NCT00233454|Experimental|Midostaurin|100 mg midostaurin twice daily as oral capsules
11640435|NCT00233402|Active Comparator|Standard White Light Cystoscopy|
11640436|NCT00233402|Experimental|Standard White Light and Hexvix Fluorescence Cystoscopy|
11640437|NCT00233324|Experimental|Surfactant and Low Oxygen|Administration of surfactant by endotracheal tube and supplemental oxygen with target saturation of 85% to 89%
11640438|NCT00233324|Experimental|Surfactant and High Oxygen|Administration of surfactant by endotracheal tube and supplemental oxygen with target saturationof 91% to 95%
11640439|NCT00233324|Experimental|CPAP and Low Oxygen|Administration of continuous positive airway pressure (CPAP) and supplemental oxygen with target saturation of 85% to 89%
11640440|NCT00233324|Experimental|CPAP and High Oxygen|Administration of continuous positive airway pressure (CPAP)and supplemental oxygen with target saturation of 91% to 95%
11640441|NCT00233272||Healthy Volunteers|Healthy volunteers over a wide age-range
11640442|NCT00233259|Active Comparator|1|Multiple risk factor intervention, that will include diet, physical activity, stress management, social support, and smoking cessation components
11640443|NCT00233259|Placebo Comparator|2|Control group
11640444|NCT00233220|Experimental|1|Patients and doctors will take part in a multicomponent, multi-level intervention.
11640445|NCT00233220|Active Comparator|2|Patients will receive usual care.
11640446|NCT00233194||Cohort 2|Children scheduled for adenotonsillectomy and healthy subjects, for comparison, not scheduled for such surgery.
11640447|NCT00233168|Experimental|1|Peer medication adherence counseling
11640448|NCT00233168|Active Comparator|2|Peer life skills counseling
11640449|NCT00233142|Experimental|Expressive writing|Expressive writing
11640450|NCT00233142|Sham Comparator|Neutral writing|Non-expressive writing
11640451|NCT00233129|Active Comparator|Standard Treatment|cognitive rehabilitation day treatment program
11640452|NCT00233129|Experimental|Top-Down|"cognitive rehabilitation day treatment program that incorporates systematic top down treatment of executive function deficits (problem solving and emotional regulation training), systematic treatment of attention deficits, and modular, contextual and embedded approaches to treatment."
11640453|NCT00233103|Experimental|Sertraline|Daily oral sertraline in doses starting at 25mg and increasing to therapeutic levels (up to 200mg).
11640454|NCT00233103|Placebo Comparator|Placebo|Placebo for 10 weeks.
11640455|NCT00233090|Experimental|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
11640456|NCT00233090|Placebo Comparator|Placebo|
11640457|NCT00233077|Experimental|Behavioral: Patient Assistance|Patient assistance programs
11640458|NCT00233077|Other|Control: Information only|Control patients will be sent a pamphlet about breast cancer & its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
11640459|NCT00233064|Active Comparator|1|Liquid Palivizumab
11640460|NCT00233064|Active Comparator|2|Lyophilized Palivizumab
11640461|NCT00232908|Experimental|1|
11640462|NCT00232882|Active Comparator|1|Candesartan 16 mg for 4 weeks followed by candesartan 16 mg and hydrochlorothiazide 12.5 mg for 4 weeks
11640463|NCT00232882|Active Comparator|2|Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
11640464|NCT00232882|Active Comparator|3|Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
11640465|NCT00232869|Experimental|1|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
11640466|NCT00232869|Active Comparator|2|SMART™ bare-metal stent
11640467|NCT00232856|Other|1|Cypher™ sirolimus-eluting stent
11640468|NCT00232843|Experimental|1|Cordis SMART™ nitinol self-expanding stent.
11640469|NCT00232843|Active Comparator|2|balloon angioplasty
11640470|NCT00232830|Experimental|1|Cypher Sirolimus-eluting Coronary Stent
11640471|NCT00232830|Active Comparator|2|Bare-metal stent
11640472|NCT00232817|Experimental|1|Propofol anesthetic with and without nicotine
11640473|NCT00232817|Experimental|2|isoflurane anesthetic with and without nicotine
11640474|NCT00232804|Other|1|
11640475|NCT00232791|Experimental|1|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
11640476|NCT00232791|Active Comparator|2|CYPHER™ Sirolimus-eluting Coronary Stent
11640477|NCT00232765|Experimental|1|Cypher Bx Velocity
11640483|NCT00232622|Active Comparator|Standard infusion of streptokinase|Standard infusion of streptokinase
11640484|NCT00232622|Experimental|Accelerated infusion of streptokinase|Accelerated infusion of streptokinase
11640485|NCT00232596|Placebo Comparator|Placebo|
11640486|NCT00232596|Experimental|Retigabine|
11640487|NCT00232583|Active Comparator|Metfomin and Insulin|Metformin 1000mg/BID and Insulin Novolog 70/30 per protocol titration
11640488|NCT00232583|Active Comparator|Metformin, Pioglitazone and Glyburide|Metformin 1000mg/BID, Pioglitazone 45 mg and glyburide per protocol titration
11640489|NCT00232557|Experimental|TLC-Asthma|Telephone-based home education and asthma monitoring
11640490|NCT00232557|Active Comparator|TLC-health education|Telephone-based home education
11640491|NCT00232544|Experimental|TLC-CPAP|A telephone-linked communication (TLC) system for promoting adherence to continuous positive airway pressure (CPAP)
11640492|NCT00232544|Placebo Comparator|TLC-Control|A TLC system for providing general health education
11640493|NCT00232505|Experimental|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once a week. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients not responding to treatment may cross over to arm II.
11640494|NCT00232505|Experimental|Cetuximab and Carboplatin|Patients receive cetuximab as in arm I and carboplatin IV on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11640495|NCT00232492|Placebo Comparator|Placebo males|Saline physiological placebo males
11640496|NCT00232492|Active Comparator|Ketamine 0,1 mg/kg males|0,1 mg/kg ketamine males
11640497|NCT00232492|Active Comparator|Ketamine 0,3 mg/kg males|0,3 mg/kg ketamine males
11640498|NCT00232492|Active Comparator|Ketamine 0,5 mg/kg males|0,5 mg/kg ketamine males
11640499|NCT00232492|Placebo Comparator|Placebo females|Saline physiological as placebo females
11640500|NCT00232492|Active Comparator|Ketamine 0.1 mg/kg females|0,1 mg/kg ketamine females
11640501|NCT00232492|Active Comparator|Ketamine 0,3 mg/kg females|0,3 mg/kg ketamine females
11640502|NCT00232492|Active Comparator|Ketamine 0,5 mg/kg females|0,5 mg/kg ketamine females
11640503|NCT00232479|Experimental|arm 1|single arm study evaluating the efficacy of neoadjuvant taxotere, herceptin and carboplatin given in a dose dense fashion
11640504|NCT00232466|No Intervention|2|conservative therapy (no intervention)
11640505|NCT00232466|Active Comparator|1|Vertebroplasty
11640506|NCT00232349|Experimental|Intervention group|All subjects enrolled in study are in the intervention group.
11640507|NCT00232284|Active Comparator|Sertaline|8 week course of sertraline 50-100mg for those who fail to respond to CBT within first 4 weeks of study entry
11640508|NCT00232284|Placebo Comparator|Placebo|8 week course of placebo
11640509|NCT00232271|Active Comparator|clexane|patients received clexane
11640510|NCT00232271|No Intervention|non clexane|no clexane given
11640511|NCT00232245|Experimental|Fish oil|Patients prescribed 6g/day of fish oil containing total 1.8 g of EPA+DHA in a 1.5:1 ratio
11640512|NCT00232245|No Intervention|Control|No fish oil exposure
11640513|NCT00232232|No Intervention|Control|No fish oil
11640514|NCT00232232|Experimental|Fish oil|Patients prescribed 6g/day of fish oil containing 1.8g EPA+DHA in a 1.5:1 ratio
11640515|NCT00232219|No Intervention|Control|No fish oil exposure
11640516|NCT00232219|Experimental|Fish oil|Patients given 6g/day of fish oil containing 1.8g/d of EPA+DHA in a 1.5:1 ratio.
11640517|NCT00232193||IFNβ+DS group|IFNβ+DS group received lyophilized Avonex 30mcg IM weekly plus dexamethasone 160 mg IV every 4 weeks for 52 weeks and was treated with Avonex 30mcg IM weekly from week 53 to 104
11640518|NCT00232193||IFNβ group|IFNβ group received lyophilized Avonex 30mcg IM weekly for 104 weeks
11640519|NCT00232180|Active Comparator|Eplerenone arm|Eplerenone administered on top of background standard heart failure therapy
11640520|NCT00232141|Experimental|1|
11640521|NCT00232141|Placebo Comparator|2|
11640522|NCT00232115|Experimental|1|Pimecrolimus
11640523|NCT00232115|Placebo Comparator|2|Vehicle
11640524|NCT00232011|Experimental|1|
11640525|NCT00231998|Experimental|1|
11640526|NCT00231985|Placebo Comparator|1|Participants will receive supportive psychotherapy.
11640527|NCT00231985|Active Comparator|2|Participants will receive habit reversal therapy.
11640528|NCT00231972|Experimental|Project Enhance|Participants will receive the risk reduction program, Project Enhance
11640529|NCT00231972|Active Comparator|Active Comparison Condition|Participants will receive standard prevention case management
11640530|NCT00231959|Placebo Comparator|Sugar pill|Placebo
11640531|NCT00231959|Experimental|Pramipexole|
11640532|NCT00231933|Active Comparator|1|Participants will receive standard care incorporating illness management recovery
11640533|NCT00231933|Experimental|2|Participants will receive illness management recovery plus person-centered planning
11640534|NCT00231933|Experimental|3|Participants will receive illness management recovery plus person-centered planning and community integration
11640535|NCT00231907|Active Comparator|Vaccine 1: TIV. Vaccine 2: TIV.|Vaccine 1: TIV. Vaccine 2: TIV.
11640536|NCT00231907|Experimental|Vaccine 1: LAIV. Vaccine 2: TIV.|Vaccine 1: LAIV. Vaccine 2: TIV.
11640537|NCT00231907|Experimental|Vaccine 1: LAIV. Vaccine 2: LAIV.|Vaccine 1: LAIV. Vaccine 2: LAIV.
11640538|NCT00231907|Experimental|Vaccine 1: TIV. Vaccine 2: LAIV.|Vaccine 1: TIV. Vaccine 2: LAIV.
11640539|NCT00231894|Active Comparator|Pioglitazone and life-style group|Pioglitazone (30-45 mg/daily) plus life-style diet group
11640540|NCT00231894|Placebo Comparator|Placebo and life style group|Placebo capsules daily plus life-style diet group
11640541|NCT00231868|Experimental|A|Drug:Carboplatin and Paclitaxel and Radiation: Pelvic Radiation Therapy
11640594|NCT00230815|Experimental|Follitropin alfa injected by Pen device|
11640595|NCT00230802|Active Comparator|2 tablet increase|Patients will increase their current levothyroxine dose by 2 extra tablets per week (~29% increase)
11640596|NCT00230802|Active Comparator|3 tablet increase|Patients will increase their levothyroxine dosage by 3 extra tablets per week (~43%).
11640597|NCT00230763|Experimental|Active|
11640598|NCT00230763|Other|Procedure|
11640542|NCT00231842|Experimental|Ifosfamide with or without cisplatin|Participants with surgically staged carcinosarcoma (CS) with no gross residual disease were initially administered ifosfamide (1.2 g/m2/day for 5 days) with cisplatin (20 mg/m2/day for 5 days) every 3 weeks for 3 cycles followed by pelvic external beam RT and brachytherapy followed by 3 additional cycles of ifosfamide (1.0 g/m2/day) with cisplatin with cisplatin (20 mg/m2/day for 5 days) evrey 3 weeks. cisplatin added toxicity without additional efficacy, so mid-study, cisplatin was eliminated.
11640543|NCT00231816|Experimental|Concomitant|Zostavax concomitantly with influenza vaccine on Day 1, placebo at week 4
11640544|NCT00231816|Experimental|Nonconcomitant|Influenza vaccine and Zostavax placebo on Day 1, Zostavax at week 4
11640545|NCT00231790|Experimental|MK-0634 50 mg|All participants will receive placebo for the 1 week prior to randomization
11640546|NCT00231790|Experimental|MK-0634 125 mg|All participants will receive placebo for the 1 week prior to randomization
11640547|NCT00231790|Experimental|MK-0634 375 mg|All participants will receive placebo for the 1 week prior to randomization
11640548|NCT00231790|Placebo Comparator|Placebo|All participants will receive placebo for the 1 week prior to randomization
11640549|NCT00231777|Experimental|1|40 mg MK0517 IV
11640550|NCT00231777|Active Comparator|2|4 mg ondansetron IV
11640551|NCT00231673|Experimental|001|Topiramate Increasing dosing of topiramate gradually to 200 mg daily by mouth dose maintenance for 12 weeks then decreasing dose until stopped over 12 weeks
11640552|NCT00231582|Experimental|1|1
11640553|NCT00231569|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
11640554|NCT00231569|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
11640555|NCT00231569|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
11640556|NCT00231569|Experimental|Cohort D|Loading doses followed by weekly maintenance doses
11640557|NCT00231569|Experimental|Cohort E|Loading doses followed by weekly maintenance doses
11640558|NCT00231569|Experimental|Cohort F|Loading doses followed by extended weekly maintenance doses
11640559|NCT00231569|Experimental|Cohort G|Loading doses followed by extended weekly maintenance doses
11640560|NCT00231478|Experimental|1|
11640561|NCT00231478|Experimental|2|
11640562|NCT00231465|Experimental|Taxotere® (Docetaxel) + ZD1839 (IRESSA®)|"Patients will receive Taxotere at 75 mg/m2 given IV over 60 minutes on day 1 of a three week cycle.
~ZD1839 will be administered orally at 250mg daily starting on day one, concurrently with the Taxotere."
11640563|NCT00231452|Experimental|Late exposure group|Participants received monthly Sulfadoxine-Pyrimethamine (SP) plus Artesunate (AS) from 2.5-4.5 months of age and monthly placebo from 5.5-9.5 months of age.
11640564|NCT00231452|Experimental|Early exposure group|Participants received monthly placebo from 2.5-4.5 months of age and monthly SP+AS from 5.5-9.5 months of age.
11640565|NCT00231452|Placebo Comparator|Control group|Participants received monthly placebo from 2.5 to 9.5 months of age.
11640566|NCT00231413|Active Comparator|HPV-16/18 Group|Female subjects who received 3 doses of the HPV-16/18 L1 AS04 vaccine intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
11640567|NCT00231413|Experimental|HPV-TETRA A Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 1 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
11640568|NCT00231413|Experimental|HPV-TETRA B Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 2 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
11640569|NCT00231413|Experimental|HPV-TETRA C Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 3 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
11640570|NCT00231413|Experimental|HPV-TETRA D Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 4 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
11640571|NCT00231413|Experimental|HPV-TETRA E Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 5 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
11640572|NCT00231413|Experimental|HPV-TETRA F Group|Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 6 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule.
11640573|NCT00231309|Other|single arm|
11640574|NCT00231296|Active Comparator|Treatment with CryoCor Cryoablation System|Intervention includes ablation therapy with the CryoCor catheter for the treatment of symptomatic PAF.
11640575|NCT00231296|Active Comparator|Treatment with standard medical therapy|Intervention includes treatment with ant-arrhythmic medications alone.
11640576|NCT00231283|Experimental|1|CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System
11640577|NCT00231257|Experimental|1|Cypher Bx Velocity
11640578|NCT00231257|Active Comparator|2|Brachytherapy
11640579|NCT00231244|Experimental|1|CYPHER Sirolimus-Eluting Coronary Stent
11640580|NCT00231179|Experimental|Home visiting Intervention|Home visiting intervention group.
11640581|NCT00231179|Placebo Comparator|Control|Control condition did not receive any services.
11640582|NCT00231166|Experimental|HCD122|
11640583|NCT00231153|Active Comparator|Povidone-Iodine 10%|
11640584|NCT00231153|Experimental|omiganan 1% gel|
11640585|NCT00231114|Experimental|Alair|Treatment of airways with the Alair System
11640586|NCT00231114|Sham Comparator|Sham|Sham treatment of airways
11640587|NCT00230971|Active Comparator|A|
11640588|NCT00230971|Active Comparator|B|
11640589|NCT00230945|Experimental|1|Patient-oriented education and support intervention
11640590|NCT00230945|Experimental|2|Couple-oriented education and support intervention
11640591|NCT00230932||Group 1|outpatients selected from random visits in primary care, oncology, and cardiology clinics
11640592|NCT00230880|Experimental|Treatment|follow-up phone counseling
11640593|NCT00230880|No Intervention|Control|Usual care
11640599|NCT00230750|Experimental|2|100 subjects to receive 90 mcg of inactivated influenza A/H5N1 vaccine on days 0, 28, and 6 months following the 1st vaccination.
11640600|NCT00230750|Placebo Comparator|3|40 subjects to receive saline placebo on days 0, 28, and 6 months following the 1st vaccination.
11640601|NCT00230750|Experimental|1|100 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine on days 0, 28, and 6 months following the 1st vaccination.
11640602|NCT00230737|Experimental|A|Melatonin 0.4 mg
11640603|NCT00230737|Experimental|B|Melatonin 4.0 mg
11640604|NCT00230737|Placebo Comparator|C|
11640605|NCT00230711|Experimental|Exercise Counseling|
11640606|NCT00230711|Placebo Comparator|Contact Control|
11640607|NCT00230659||HHT patients|Patients with hereditary haemorrhagic telangiectasia. Blood sample to be taken.
11640608|NCT00230659||Controls|People without hereditary haemorrhagic telangiectasia. Blood sample to be taken.
11640609|NCT00230607|Experimental|Agalsidase beta|Commercially available Fabrazyme treatment at prescribed dose and regimen as determined by their treating physician
11640610|NCT00230594|Active Comparator|1|desmopressin
11640611|NCT00230594|Placebo Comparator|2|placebo
11640612|NCT00230542|Experimental|Carboplatin / Pemetrexed|Single Arm Study Carboplatin AUC 5 Pemetrexed 500 mg/m2
11640613|NCT00230477|Active Comparator|Mono therapy|Hepsera
11640614|NCT00230477|Active Comparator|Combo therapy|
11640615|NCT00230438|Experimental|External Beam Radiation Therapy|
11640616|NCT00230321|Experimental|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously for 6 weeks. The dosage for the remaining treatment is dependent of patients response during the induction phase.
11640617|NCT00230282|Experimental|Fludarabine, cytoxan, then alemtuzumab|Fludarabine and cyclophosphamide days 1 to 3 for six 28-day cycles. Minimal residual disease positive responders continued on-treatment to receive alemtuzumab 30 mg weekly. MRD negative responders were observed.
11640618|NCT00230178|Experimental|Arm A|Rasburicase alone given as a single agent for 5 days
11640619|NCT00230178|Experimental|Arm B|Rasburicase alone given as a single agent from Day 1 through Day 3, followed by oral allopurinol given from Day 3 through Day 5 (Day 3 is an overlap)
11640620|NCT00230178|Active Comparator|Arm C|Oral allopurinol alone given as a single agent for 5 days
11640621|NCT00230165||Normal|Normal, healthy volunteers 18 years of age or older of either sex and any ethnic background
11640622|NCT00230165||Glanzmann thrombasthenia|Patients with Glanzmann thrombasthenia or their relatives, inherited qualitative and/or quantitative platelet disorders, inherited disorders of white blood cells, inherited disorders of coagulation
11640623|NCT00230126|Active Comparator|A erlotinib 150 mg|erlotinib 150 mg/day cycles 1 - 3
11640624|NCT00230126|Experimental|B erlotinib modified according to weight|erlotinib Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to skin rash.
11640625|NCT00230113|Active Comparator|1|
11640626|NCT00230113|Placebo Comparator|2|
11640627|NCT00230100|Experimental|Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
11640628|NCT00230100|Active Comparator|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
11640629|NCT00230048|No Intervention|Assessment only|
11640630|NCT00230048|Experimental|Brief intervention|
11640631|NCT00230035|Experimental|1|high dose immunosuppressie therapy (HDIT) followed by HSCT (hemopoietic stem cell transplantation).
11640632|NCT00230035|Active Comparator|2|Currently available immunosuppressive/immunomodulatory therapy
11640633|NCT00230022|Experimental|Brief computer-delivered intervention|A 20-minute interaction with software designed to partially replicate the experience of a brief motivational intervention with a therapist or health care professional. Included decisional balance, normed feedback, and optional goal-setting.
11640634|NCT00230022|No Intervention|Assessment only|Participants in this arm only completed assessment section, same as intervention group, but then was done.
11640635|NCT00230009|No Intervention|Assessment only|
11640636|NCT00230009|Experimental|Brief intervention session|
11640637|NCT00229983|Experimental|Motivational Enhancement Therapy|Adolescents who are randomized to the experimental intervention will attend three 60-minute counseling sessions, delivered 2-4 weeks apart. The intervention will include a structured, developmentally appropriate, approach to identification of drug- and alcohol-related risks and problems, and establishment of goals for behavioral change.
11640638|NCT00229983|No Intervention|Enhanced Standard Care|Adolescents who are randomized to Enhanced Standard Care will receive the usual care at the outpatient adolescent substance abuse program. This will include an evaluation by pediatric and mental health staff and could include treatment in a group therapy program, urine drug testing, buprenorphine replacement therapy (for those dependent on opioids), and psychopharmacology evaluation and management.
11640639|NCT00229970|Experimental|1|Placebo
11640640|NCT00229970|Experimental|2|MK0476 7 mg injection
11640641|NCT00229970|Experimental|3|MK0476 14 mg injection
11640642|NCT00229957|Experimental|Intervention|Intervention
11640643|NCT00229957|No Intervention|Control|Control group received usual care in primary care.
11640644|NCT00229931|Active Comparator|Laser therapy|If randomized to laser therapy at time of cataract surgery, laser therapy will be performed one month after cataract surgery. If macular edema does not respond an additional laser therapy will be performed. If macular edema persists after 2 lasers, then IVTA will be administered as per standard of care.
11640645|NCT00229931|Active Comparator|Triamcinolone therapy|"At time of cataract surgery, will have IVTA injection. If macular edema does not show improvement at 1 month, then can have repeat IVTA injection. If the macular edema is stil not improved after 2nd injection, participant will be considered treatment failure and will be given the option to have laser therapy."
11640646|NCT00229801|No Intervention|MRI|
11640647|NCT00229736|Experimental|AAV-hAADC-2 (9x10^10 vector genomes)|
11640648|NCT00229736|Experimental|AAV-hAADC-2 (3x10^11 vector genomes)|
11640649|NCT00229723|Placebo Comparator|1|Radiation + cisplatin; followed by placebo as maintenance therapy
11640650|NCT00229723|Experimental|2|250 mg gefitinib + radiation + cisplatin; followed by placebo as maintenance therapy
11640651|NCT00229723|Experimental|3|500 mg gefitinib + radiation + cisplatin; followed by placebo as maintenance therapy
11640652|NCT00229723|Experimental|4|gefitinib 250 mg + cisplatin + radiotherapy; followed by gefitinib 250 mg as maintenance therapy
11640653|NCT00229723|Experimental|5|gefitinib 500 mg + cisplatin + radiotherapy; followed by gefitinib 500 mg as maintenance therapy
11640654|NCT00229723|Placebo Comparator|6|placebo + cisplatin + radiotherapy; followed by gefitinib 250 mg as maintenance therapy
11640655|NCT00229723|Placebo Comparator|7|placebo + cisplatin + radiotherapy; followed by gefitinib 500 mg as maintenance therapy
11640656|NCT00229697|Experimental|1|ZD1839 + Nolvadex
11640657|NCT00229697|Other|2|Nolvadex + placebo
11640658|NCT00229671|Experimental|Patients with prescriptions under 21|Pediatric visits with prescriptions. These patients parents will be given survey 1.
11640659|NCT00229671|Experimental|Patients who completed Survey 1|Patients with prescriptions under 21 whose parents complete survey 1 will be given survey 2
11640660|NCT00229658||Type 1|Patients with type 1 diabetes
11640661|NCT00229658||Type 2|Patients with type 2 diabetes
11640662|NCT00229619|Experimental|Rituximab (Rituxan)|This is a non-randomized, off label, pilot study of humanized anti CD20 rituximab (Rituxan®) in patients with moderate aplastic anemia, pure red cell aplasia or Diamond-Blackfan anemia who have either failed to respond to at least one prior course of immunosuppressive therapy (PRCA/DBA patients only)or who have relapsed disease after prior immunosuppressive therapy (PRCA/DBA patients only).
11640663|NCT00229593|Active Comparator|1|100 mg Testosterone gel daily for 3 weeks
11640664|NCT00229593|Active Comparator|2|2 mg Nestorone gel daily for 3 weeks
11640665|NCT00229593|Active Comparator|3|4 mg Nestorone gel daily for 3 weeks
11640666|NCT00229593|Active Comparator|4|100 mg Testosterone gel + 2 mg Nestorone gel
11640667|NCT00229593|Active Comparator|5|100 mg Testosterone gel + 4 mg Nestorone gel
11640668|NCT00229593|Active Comparator|6|100 mg Testosterone Gel + 6 mg Nestorone Gel daily for 3 weeks
11640669|NCT00229593|Active Comparator|7|100 mg Testosterone Gel + 8 mg Nestorone gel daily for 3 weeks
11640670|NCT00229580|Experimental|1|Motivational feedback
11640671|NCT00229580|Active Comparator|2|treatment as usual
11640672|NCT00229554||Group 1|Male and female veterans age 50-75 who have had one or more primary care visits at a VA Medical facility in the past two years.
11640673|NCT00229541|Experimental|IG|intervention group, receives counselling on medical inpatient rehabilitation by statutory health insurance, is intended to apply for a 3-wek medical inpatient rehabilitation at the co-operating clinic (Bad Bramstedt)
11640674|NCT00229541|No Intervention|KG|control group, receives usual care
11640675|NCT00229515|Active Comparator|1|Patients will receive abciximab infusion at standard regimen prior undergoing percutaneous coronary intervention for STEMI followed by BMS implantation in the culprit lesion
11640676|NCT00229515|Experimental|2|Abciximab followed by implantation of sirolimus-eluting stent in the culprit lesion
11640677|NCT00229515|Experimental|3|tirofiban infusion followed by bare metal stent implantation
11640678|NCT00229515|Experimental|4|tirofiban and sirolimus-eluting stent
11640679|NCT00229502||1|Subjects receiving Avonex
11640680|NCT00229502||2|Subjects receiving Rebif
11640681|NCT00229502||3|Subjects receiving Copaxone
11640682|NCT00229502||4|Healthy controls
11640683|NCT00229450|Experimental|Treatment|0.625 mg/day of conjugated estrogen
11640684|NCT00229450|Placebo Comparator|Placebo|Daily placebo for conjugated estrogen
11640685|NCT00229437|Experimental|TAK-128 5 mg QD|
11640686|NCT00229437|Experimental|TAK-128 50 mg QD|
11640687|NCT00229437|Experimental|TAK-128 100 mg QD|
11640688|NCT00229437|Placebo Comparator|Placebo QD|
11640689|NCT00229424|Experimental|1|Lafutidine group
11640690|NCT00229424|Active Comparator|2|Famotidine group
11640691|NCT00229424|Placebo Comparator|3|Placebo group
11640692|NCT00229385|Active Comparator|1|
11640693|NCT00229385|Active Comparator|2|
11640694|NCT00229307|Active Comparator|1|
11640695|NCT00229307|Active Comparator|2|
11640696|NCT00229255|Active Comparator|high frequency meals group|High carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
11640697|NCT00229255|Active Comparator|twice-a -day meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks
11640698|NCT00229242|Active Comparator|1|Diuretic-Based Hypertension Therapy
11640699|NCT00229242|Active Comparator|2|Non-Diuretic-Based Hypertension Therapy
11640700|NCT00229229|Other|1|Low glycemic load diet
11640701|NCT00229229|Other|2|Canada Food Guide Diet
11640702|NCT00229229|Other|3|Low glycemic index diet
11640703|NCT00229229|Other|4|Low carbohydrate diet
11640704|NCT00229177|Placebo Comparator|P|
11640705|NCT00229177|Experimental|E1|
11640706|NCT00229177|Experimental|E2|
11640707|NCT00229151|Experimental|Sleep deprivation|Sleep deprivation and sleep phase advancement
11640708|NCT00229151|Active Comparator|usual treatment|
11640709|NCT00229138|Experimental|reduced Tacrolimus|
11640710|NCT00229138|Active Comparator|Reference Tacrolimus|
11640711|NCT00229047||Vein Stripping|Patients undergoing elective varicose vein stripping in our vascular OR. Observe circulation in the exposed soleus/gastrocnemius muscle.
11640712|NCT00229008|Experimental|001|ceftobiprole plus placebo ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
11640713|NCT00229008|Active Comparator|002|linezolid plus ceftazidime linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
11640714|NCT00228982|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q12h as 1h infusion, 7-14d
11640715|NCT00228982|Active Comparator|Vancomycin|Vancomycin 1g q12h as 1h infusion, 7-14d
11640716|NCT00228943|Experimental|Acute tryptophan depletion|Full-strength tryptophan depletion
11640717|NCT00228943|Active Comparator|Control|Half-strength tryptophan depletion drink used as a control
11640718|NCT00228917|Experimental|ACAC_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study ( NCT00317187) are boosted in the current study with one dose of the same vaccines at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age
11640719|NCT00228917|Experimental|ACHibPS_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
11640720|NCT00228917|Experimental|HibACPS_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of Trianrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
11640721|NCT00228917|Experimental|HibHibPS_Thailand Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of the same vaccine at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
11640722|NCT00228917|Experimental|ACAC_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of the same vaccines at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age
11640723|NCT00228917|Experimental|ACHibPS_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
11640724|NCT00228917|Experimental|HibACPS_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of Trianrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
11640725|NCT00228917|Experimental|HibHibPS_Philippines Group|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of the same vaccine at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
11640726|NCT00228904|Placebo Comparator|1|Control patients with diagnosed diabetic neuropathy will receive baseline testing and testing every six months thereafter to compare and analyze results with patients treated with pulsatile intravenous insulin therapy.
11640727|NCT00228904|Active Comparator|2|Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after the start of pulsatile intravenous insulin therapy.
11640728|NCT00228891|Active Comparator|2|Patients with diagnosed diabetic neuropathy will receive objective baseline testing and follow up testing every six months after the start of Pulsatile intravenous insulin therapy to monitor and assess diabetic neuropathy.
11640729|NCT00228891|Placebo Comparator|1|Control patients with diabetic neuropathy will receive objective testing at baseline and every six months to compare and measure results with patients who are receiving pulsatile intravenous insulin therapy.
11640730|NCT00228878|Experimental|Effects of Pulsatile IV insulin on QoL|Effects of Pulsatile IV insulin on Diabetic Quality of Life
11640731|NCT00228865|Experimental|1|Testing performed on diabetic patients with decline in cognitive function at baseline and quarterly after the start of receiving pulsatile intravenous insulin therapy to assess continuing cognitive function ability.
11640732|NCT00228813|Other|Granulocyte Colony Stimulating Factor (G-CSF) stimulation|Participants will receive bone marrow from donors who undergo Granulocyte Colony Stimulating Factor (G-CSF) stimulation prior to bone marrow collection.
11640733|NCT00228696|No Intervention|screening|this is a screening study and no intervention.
11640734|NCT00228670||IPF-Clinic|Adult patients with idiopathic pulmonary fibrosis being followed in pulmonary clinic
11640735|NCT00228670||Controls - Clinic|Adult subjects with no underlying pulmonary disease who are the household partner of an IPF patient being followed in pulmonary clinic
11640736|NCT00228670||IPF-Transplant|IPF patient undergoing lung transplant
11640737|NCT00228670||Controls-Transplant|Lung tissue from organ donor
11640738|NCT00228631||Sickle Cell Disease Bone Marrow Transplant|Sickle Cell Disease Bone Marrow Transplant candidates
11640739|NCT00228579||Bariatric Surgery|Subjects will be recruited from patients undergoing bariatric surgery at Emory Bariatrics. The cost of surgical procedures will not be provided by the research study.
11640740|NCT00228553|Experimental|1|Armodafinil 100 to 250 mg/day
11640741|NCT00228449|Experimental|Cohort 1|Conversion from epoetin alfa to peginesatide with a conversion factor (CF) of 0.033: peginesatide dose administered intravenously once every 4 weeks (Q4W) for a total of up to 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
11640742|NCT00228449|Experimental|Cohort 2|Conversion from epoetin alfa to peginesatide with a CF of 0.041: peginesatide dose administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
11640743|NCT00228449|Experimental|Cohort 3|Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
11640744|NCT00228449|Experimental|Cohorts 4 and 9|Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
11640745|NCT00228449|Experimental|Cohort 5|Conversion from epoetin alfa to peginesatide with a CF of 0.066: peginesatide dose administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
11640746|NCT00228449|Experimental|Cohort 6|Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa . Doses were administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
11640747|NCT00228449|Experimental|Cohorts 7 and 8|Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa dose. Doses were administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
11640748|NCT00228449|Experimental|Cohorts 10 and 11|Conversion from epoetin alfa to peginesatide with fixed peginesatide starting doses of 4, 6, 12 or 16 mg based on total weekly doses of epoetin alfa. Doses were administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
11640749|NCT00228436|Experimental|Cohort 1|Peginesatide starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses.
11640750|NCT00228436|Experimental|Cohort 2|Peginesatide starting dose of 0.075 mg/kg administered SC Q4W for a total of 6 doses.
11640751|NCT00228436|Experimental|Cohort 3|Peginesatide starting dose of 0.025 mg/kg administered SC Q4W for a total of 6 doses.
11640752|NCT00228436|Experimental|Cohort 4|Peginesatide starting dose of 0.05 mg/kg administered intravenously (IV) Q4W for a total of 6 doses.
11640753|NCT00228436|Experimental|Cohort 5|Peginesatide starting dose of 0.025 mg/kg administered SC once every 2 weeks (Q2W) for a total of 12 doses.
11640754|NCT00228436|Experimental|Cohort 6|Peginesatide starting dose of 0.0375 mg/kg administered SC Q2W for a total of 12 doses.
11640755|NCT00228436|Experimental|Cohort 7|Peginesatide fixed starting dose of 4 mg administered SC Q4W for a total of 6 doses.
11640756|NCT00228436|Experimental|Cohort 8|Peginesatide fixed starting dose of 3 mg administered SC Q4W for a total of 6 doses.
11640757|NCT00228423|Active Comparator|75mg Clopidogrel|75mg clopidogrel. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.
11640758|NCT00228423|Placebo Comparator|Placebo|Water pill. 162mg ASA is also given, but is a standard-of-care post operative to cardiac surgery.
11640759|NCT00228384|Active Comparator|Gore VIABAHN Endoprosthesis|
11640760|NCT00228384|Active Comparator|Bare Nitinol Stent (BNS)|
11640761|NCT00228371|Other|1|The stimulator is switch ON during the first phase of the cross-over and switch OFF during the second phase
11640762|NCT00228371|Other|2|The stimulator is switch OFF during the first phase of the cross-over and switch ON during the second phase
11640763|NCT00228358|Experimental|Group A (cellular infusions after cyclophosphamide)|Patients receive low-dose cyclophosphamide IV on day -1 and 3 escalating doses of autologous ex vivo-expanded HER2-specific T cells IV over 30 minutes on days 1, 10, and 20.
11640764|NCT00228358|Experimental|Group B (cellular infusions after ONTAK conditioning)|Patients receive denileukin diftitox IV over 1 hour on day -1 and 3 escalating doses of autologous ex vivo-expanded HER2-specific T cells IV over 30 minutes on days 1, 10, and 20.
11640765|NCT00228319|Active Comparator|Standard of Care Group|carboplatin and paclitaxel chemotherapy
11640766|NCT00228319|Experimental|Standar of Care + Ascorbic Acid Group|carboplatin and paclitaxel chemotherapy, plus intravenous sodium ascorbate. In addition, participants will take a mix of vitamins including oral ascorbic acid, oral mixed natural carotenoids with vitamin A and oral vitamin E.
11640767|NCT00228306|Experimental|1|
11640768|NCT00228306|No Intervention|2|Control Group
11640769|NCT00228215|No Intervention|Usual care|
11640770|NCT00228215|Experimental|TIPS Intervention|
11640771|NCT00228189|Active Comparator|A|Dendritic cells pulsed with CEA-peptide
11640772|NCT00228189|Experimental|B|Dendritic cells electroporated with CEA-mRNA
11640773|NCT00228189|Experimental|C|Dendritic cells pulsed with CEA-peptide, in combination with oxaliplatin/capecitabine
11640774|NCT00228176|Experimental|Rimonabant|Rimonabant 20 mg once daily
11640775|NCT00228176|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
11640776|NCT00228163|Experimental|Teriflunomide 7 mg|
11640777|NCT00228163|Experimental|Teriflunomide 14 mg|
11640778|NCT00228020|Experimental|Basiliximab|Patients will be on a regimen of Basiliximab, MMF, cyclosporine and steroids
11640779|NCT00228020|Active Comparator|Basiliximab-free|Patients will be on a regimen of MMF, cyclosporine and steroids.
11640780|NCT00227994|Experimental|Galantamine|Galantamine for 12 weeks
11640781|NCT00227994|Experimental|Donepezil|Donepezil for 12 weeks
11640782|NCT00227942|Experimental|1|Participants will receive estrogen replacement therapy
11640783|NCT00227942|Experimental|2|Participants will receive treatment with zolpidem
11640784|NCT00227942|Placebo Comparator|3|Participants will receive treatment with placebo
11640785|NCT00227903|Experimental|MI-CBT|Motivationally-enhanced cognitive behavioral skills counseling
11640786|NCT00227903|Active Comparator|Brief Advice|Advice and education
11640787|NCT00227890|Experimental|1|Motivational Interviewing followed by Cognitive Behavior Therapy (MI/CBT)
11640788|NCT00227890|Experimental|2|Relaxation Training followed by Treatment as Usual (RT/TU)
11640789|NCT00227877|No Intervention|Control - New England, USA|"Control participants will receive care as usual from their provider"
11640790|NCT00227877|Experimental|cSBA - New England, USA|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking points which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
11640791|NCT00227877|No Intervention|Control - Prague, CZR|"Control participants will receive care as usual from their provider"
11640792|NCT00227877|Experimental|cSBA - Prague, CZR|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking points which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
11640793|NCT00227864|Placebo Comparator|Treatment as Usual|Participants are administered assessments at baseline, 1, 3 and 6 months
11640794|NCT00227864|Experimental|Intervention|Participants complete assessments at baseline, 1, 3 and 6 months, and receive a 2-session behavioral intervention at the baseline and 1-month study appointments.
11640795|NCT00227760|Experimental|Treatment (cediranib maleate)|Patients receive cediranib maleate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11640796|NCT00227734|Active Comparator|Arm I|Patients receive oral capecitabine twice daily on days 1-15 and oxaliplatin IV over 2 hours on day 1.
11640797|NCT00227734|Active Comparator|Arm II|Patients receive capecitabine and oxaliplatin as in arm I and cetuximab IV over 1-2 hours on days 1 and 8
11640798|NCT00227721|Experimental|Docetaxel & Gemcitabine hydrochloride|Docetaxel, 40 mg/m2, 30 min IV infusion on Days 1 and 8, of a 21 day cycle Gemcitabine hydrochloride, 800mg/m2 30 min IV infusion on Days1 and 8, of a 21 day cycle
11640799|NCT00227695|Active Comparator|Arm A: Rituximab every 2 months x4|Rituximab 375 mg/m2 every 2 months x4
11640800|NCT00227695|Active Comparator|Arm B: Rituximab (5 years)|Rituximab 375 mg/m2 every 2 months for 5 years or until PD, relapse or unacceptable toxicity
11640801|NCT00227682|Experimental|Arsenic Trioxide|Arsenic Trioxide in Combination With Thalidomide, Dexamethasone, and Ascorbic Acid
11640802|NCT00227669|Active Comparator|Arm I: Gemcitabine|"Gemcitabine at Day 1, Day 8 and Day 15. No treatment at Day 22.
~1 cycle = 28 days.
~Treatment duration: 8 months"
11640803|NCT00227669|Experimental|Arm II: Gemcitabine + Docetaxel|"Gemcitabine at Day 1 and Day 8. No treatment at Day 15. Docetaxel at Day 8.
~1 cycle = 21 days.
~Treatment duration: 6 months"
11640804|NCT00227656|Experimental|Capecitabine + PEG-interferon alfa-2a|Capecitabine 1000 mg/m2 orally twice daily during the first 14 days of each 3-week cycle (2 weeks on, 1 week rest), and PEG-interferon alfa-2a subcutaneously beginning at 180 mcg per week for 21 days.
11640805|NCT00227617|Experimental|FOLFOX with Bevacizumab|"Starting on Day 1, administered every two weeks:
~5-fluorouracil: 2400 mg/ m2 CIV; over 46-48 hours Leucovorin: 200 mg/ m2; over 2 hours Oxaliplatin : 85 mg/m2; over 2 hours Bevacizumab: 5 mg/kg IV over 30-90 minutes"
11640806|NCT00227591|Experimental|Treatment (lenalidomide, prednisone)|For courses 1 and 2, patients receive oral lenalidomide once daily and oral prednisone once daily on days 1-28. For course 3, patients receive oral lenalidomide once daily on days 1-28 and oral prednisone once on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27. Patients with stable or responding disease after course 3 receive oral lenalidomide alone once daily on days 1-28 for courses 4-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11640807|NCT00227565|Experimental|pemetrexed + carboplatin + radiation|"Patients receive pemetrexed disodium IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease in the CNS only may receive whole-brain radiotherapy and then continue chemotherapy after completion of whole-brain radiotherapy for up to 6 courses.
~After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 4 years."
11640808|NCT00227539|Experimental|Neoadjuvant therapy, PET scan and surgery|
11640809|NCT00227513|Experimental|Arm I|"Patients receive oral vorinostat (SAHA) twice daily on days 1-14 in step A. Patients receive oral vorinostat (SAHA) twice daily on days 1-4 and 8-11 in Step B and bortezomib IV over 3-5 seconds on days 2, 5, 9, and 12 during the first course and on days 1, 4, 8, and 11 during subsequent courses in both steps A and B. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 1-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 6 additional patients receive bortezomib at the MTD. Subsequent cohorts of 3-6 patients receive escalating doses of SAHA until the MTD of that drug is determined."
11640810|NCT00227487|Other|Stool collection, Carbohydrate administration, Questionnaires|"A stool sample will be obtained
~A carbohydrate solution (lactulose plus rhamnose dissolved in tap water) will be administered during a clinically indicated endoscopic procedure.
~Five questionnaires will be completed by parent/guardian"
11640811|NCT00227461|Other|Wait control|Levitiracetam is started after a delay, with dosage and administration as described below.
11640812|NCT00227461|Experimental|Treatment first|Levitiracetam is started immediately after baseline data is collected; dosage and administration as described below.
11640813|NCT00227370|Active Comparator|1|Valganciclovir 900 mg QD for 9 months post lung transplant.
11640814|NCT00227370|Placebo Comparator|2|placebo for 9 months post lung transplant
11640815|NCT00227357||Buprenorphine|Study patients receiving buprenorphine treatment
11640816|NCT00227357||Comparison|Study patients receiving methadone or no agonist treatment
11640817|NCT00227344|Experimental|1|Catheter ablation
11640818|NCT00227344|Active Comparator|2|Antiarrhythmic drugs
11640819|NCT00227292|Placebo Comparator|A, 2, II|Placebo 10mg per day for the first week, then 20mg per day till the end of study.
11640820|NCT00227292|Experimental|A, 1|Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
11640821|NCT00227279|Experimental|1|
11640822|NCT00227279|Placebo Comparator|2|
11640823|NCT00227266|Placebo Comparator|Cohort 1a|Patients in Cohort 1a - Placebo Comparator, will be on a placebo for 6 months and then will switch to the active treatment. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor or equivalent placebo in the liquid form.
11640824|NCT00227266|Active Comparator|Cohort 1b|Cohort 1b - Active Comparator will be on treatment throughout the study. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor in the liquid form.
11640825|NCT00227266|Experimental|Cohort 2|Cohort 2 pts are on open-label treatment throughout. Dosage of the VPA will start at 10-20 mg/kg/day divided into two or tree doses. The dose will be adjusted to achieve a therapeutic trough level of 50-120 micrograms/ml. VPA will be given in the form of 125 mg sprinkle capsules. Dosage for Carnitor will be 50 mg/kg/day with a maximum dose of 10000 mg/day divided into two doses. Carnitor elixir comes as 500 mg/5 ml. All subjects will be given Carnitor or equivalent placebo in the liquid form.
11640826|NCT00227188||1|Children from 0-5 years of age evaluated for IPD
11640827|NCT00227162|Active Comparator|Group 1|Positive affect
11640828|NCT00227162|Active Comparator|Group 2|Self-Affirmation
11640829|NCT00227162|Active Comparator|Group 3|Positive Affect and self-affirmation
11640830|NCT00227162|No Intervention|Group 4|Control group
11640831|NCT00227123|Active Comparator|1|Quetiapine versus Risperidone
11640832|NCT00227110|Active Comparator|Pioglitazone|Pioglitazone 30 mg/d will be given for 8 weeks and titrated to 45 mg/d until the end of the 6-month study in a randomized, double-blind, study design.
11640833|NCT00227110|Placebo Comparator|Placebo|Placebo once daily is given following a randomized, double-blind, placebo-controlled study design.
11640834|NCT00227032|Experimental|Subjects receiving EIAEDs|Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)
11640835|NCT00227032|Experimental|Subjects NOT taking EIAEDs|Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)
11640836|NCT00227019|Experimental|bevacizumab+ pemetrexed|pemetrexed (500 mg/m² IV) + bevacizumab (15 mg/kg IV). In addition to Vitamin B12 + Folate + Dexamethasone
11640837|NCT00227006|Experimental|Taste-Based Goal Setting|6-month intervention (14 lifestyle counseling classes)
11640838|NCT00227006|Active Comparator|Smart Consumers|6-month intervention (14 lifestyle counseling classes)
11640839|NCT00227006|Active Comparator|Community Access|Can enroll in behavioral treatment programs available in the community that do not include medication or very-low calorie diets
11640840|NCT00226954|Experimental|Zoledronic Acid with Intermittent Hormonal Therapy|
11640841|NCT00226941|Experimental|Group 1 - Cetuximab + Capecitabine-800 + XRT + Oxaliplatin-100|"Cetuximab 250 mg/m² / week
~Capecitabine 800 mg/m²
~Radiotherapy (XRT)
~Oxaliplatin 100 mg/m², Days 2 and 23"
11640842|NCT00226941|Experimental|Group 2 - Cetuximab + Capecitabine-700 + XRT + Oxaliplatin-85|"Cetuximab 250 mg/m² / week
~Capecitabine 700 mg/m²
~Radiotherapy (XRT)
~Oxaliplatin 85 mg/m², Days 2 and 23"
11640843|NCT00226941|Experimental|Group A - Cetuximab + Capecitabine-800 + XRT|"Cetuximab 250 mg/m² / week
~Capecitabine 800 mg/m²
~Radiotherapy (XRT)"
11640844|NCT00226941|Experimental|Group B - Cetuximab + Capecitabine-1000 + XRT|"Cetuximab 250 mg/m² / week
~Capecitabine 1000 mg/m²
~Radiotherapy (XRT)"
11640845|NCT00226915|Active Comparator|1|Drug: Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
11640846|NCT00226915|Experimental|2|Drug: Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
11640847|NCT00226837|Placebo Comparator|1|0% nitrous oxide
11640848|NCT00226837|Active Comparator|2|33% nitrous oxide
11640849|NCT00226837|Active Comparator|3|66% nitrous oxide
11640850|NCT00226811|Experimental|A|50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
11640851|NCT00226772|Experimental|OMS103HP irrigation solution|Drug
11640852|NCT00226772|Placebo Comparator|vehicle irrigation solution|Vehicle
11640853|NCT00226759|Experimental|OMS103HP irrigation solution|Drug
11640854|NCT00226759|Placebo Comparator|vehicle irrigation solution|Vehicle
11640855|NCT00226746|Experimental|Paclitaxel and Gemcitabine|"Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions), Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.
~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36."
11640856|NCT00226733|Experimental|A|Interval exercise training with high intensity
11640857|NCT00226733|Active Comparator|B|Exercise training with moderate intensity
11640858|NCT00226720|Experimental|1|at the hospital
11640859|NCT00226720|Active Comparator|2|out of the hospital
11640860|NCT00226694|Active Comparator|Citalopram Group|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
11641008|NCT00223938|Experimental|2|sodium ferric gluconate
11641009|NCT00223938|Experimental|3|sodium ferric gluconate
11640861|NCT00226694|Placebo Comparator|Placebo Group|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
11640862|NCT00226681|Experimental|1|
11640863|NCT00226681|Active Comparator|2|
11640864|NCT00226668|Experimental|I|Patients will receive hCRf (XERECEPT) 2mg/day and dexamethasone 4 mg/day along with any open-label dexamethasone that they may be taking
11640865|NCT00226668|Placebo Comparator|II|Patients will receive placebo hCRF (XERECEPT) 2mg/day and dexamethasone 4 mg/day along with any open-label dexamethasone they may be taking
11640866|NCT00226655|Experimental|I|All patients will receive hCRF (XERECEPT) 2mg/day
11640867|NCT00226590|Experimental|Combined Therapy|In this trial we adopted the approach of using both induction and concurrent chemotherapy together with TRT planned conformally to a tumor dose of 74 Gy.
11640868|NCT00226577|Experimental|Pre-Surgery Chemotherapy|
11640869|NCT00226499|Experimental|MMRV Group|Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).
11640870|NCT00226499|Experimental|OKAH Group|Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.
11640871|NCT00226499|Active Comparator|MMR Group|Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).
11640872|NCT00226486|Experimental|1|Identification of individual risk factors for falls and specified intervention aimed diminishing these risk factors in the individual.
11640873|NCT00226486|Placebo Comparator|2|Usual care
11640874|NCT00226434|Experimental|1|
11640875|NCT00226434|Active Comparator|2|
11640876|NCT00226356|Experimental|Supplements of L-methionine, betaine and folate|
11640877|NCT00226317|Experimental|Aripiprazole in depression treatment|
11640878|NCT00226291|Experimental|Synthesized evidence report|Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
11640879|NCT00226291|No Intervention|No evidence report|
11640880|NCT00226252|Experimental|Instruction Only (IO)|IO participants will train on the dynamometer for the same length of time as the Feedback Group. They will only be instructed to follow what they learned from the video presented at the beginning of the training session.
11640881|NCT00226252|Experimental|Instruction and Feedback Group (FB)|The FB group will receive video training, and real time feedback from the SMART Wheel as they push their wheelchair. A monitor displaying a random combination and amount of biomechanical feedback variables will be placed in front of subjects. Subjects will be instructed to adjust their stroke to optimize their biomechanics with feedback from the screen.
11640882|NCT00226252|No Intervention|Control Group|Wheelchair characteristics will be noted; however, no wheelchair manipulation or changes in equipment will be performed or recommended.
11640883|NCT00226239|Experimental|Head and neck cancer patients|Induction chemotherapy consists of 3 cycles of cisplatin 75 mg/m^2, on day 1, docetaxel 75 mg/m^2, on day 1, and cetuximab weekly days 1,8,15, repeated every 21 days (cetuximab dose is 400 mg/m^2 on day 1 and 250 mg/m^2 on subsequent weekly treatments). After 3 cycles of induction, patients receive standard radiation 70 Gy/200 cGy/daily, 5 days/week with concurrent weekly cisplatin 30 mg/m^2 and cetuximab 250 mg/m^2. After completing radiation therapy, patients receive cetuximab weekly as maintenance therapy for 6 months (see section 5 for detailed treatment plan and dose modifications)
11640884|NCT00226109|Active Comparator|A|
11640885|NCT00226057|Experimental|Raptiva Open Label|Raptiva administered by weekly subcutaneous injections. First dose of 0.7mg/kg. Subsequent doses will be of 1mg/kg SQ weekly.
11640886|NCT00226044|No Intervention|Oral omeprazole|Standard of care: A single dose of 1 mg/kg orally administered omeprazole.
11640887|NCT00226044|Active Comparator|Rectal omeprazole|A single dose of 1 mg/kg rectally administered omeprazole.
11640888|NCT00226031|Active Comparator|1|Usual care.
11640889|NCT00226031|Experimental|2|Mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the family physician and a letter and educational package for the women.
11640890|NCT00226018|Active Comparator|1|Acceleromyography with Hand Adapter on dominant arm
11640891|NCT00226018|Active Comparator|2|Acceleromyography with Hand Adapter on non-dominant arm
11640892|NCT00226018|Placebo Comparator|3|Acceleromyography without Hand Adapter on dominant arm
11640893|NCT00226018|Placebo Comparator|4|Acceleromygraphy without Hand Adapter on non-dominant arm
11640894|NCT00226005|Active Comparator|Vatalanib|Administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
11640895|NCT00225979|Experimental|SMS995|
11640896|NCT00225914|Experimental|1|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
11640897|NCT00225914|Placebo Comparator|2|Subjects then enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill
11640898|NCT00225784|Experimental|Cetuximab, Gemcitabine, RT|weekly cetuximab, twice-weekly gemcitabine and intensity modulated radiotherapy
11640899|NCT00225758|Experimental|1|Subjects will continue on their prior endocrine therapy with the addition of lapatinib at 1500 mg once daily for 26 weeks or longer.
11640900|NCT00225745||1|Pancreatic cancer patients
11640901|NCT00225745||2|Healthy controls
11640902|NCT00225732|Active Comparator|intravenous ibuprofen|
11640903|NCT00225732|Placebo Comparator|normal saline|
11640904|NCT00225641|Active Comparator|1 frequent control|Follow-up 6, 12, 18, 24 and 36 months after surgery
11640905|NCT00225641|Other|2 less frequent control|Follow-up 12 and 36 months after surgery
11640906|NCT00225576|No Intervention|1|Paper prescribing, 2005 and 2007
11640907|NCT00225576|Experimental|2|Paper prescribing 2005 vs. electronic prescribing 2007
11641010|NCT00223925|Placebo Comparator|Placebo|
11641011|NCT00223925|Experimental|Maribavir (100 mg twice daily)|
11640908|NCT00225563|Active Comparator|e-prescribing|Providers who used electronic prescriptions. electronic health records were used as opposed to paper based prescriptions
11640909|NCT00225563|No Intervention|Paper-based prescriptions|providers who used paper based prescriptions
11640910|NCT00225498|Experimental|1|ziprasidone
11640911|NCT00225498|Active Comparator|2|risperidone or olanzapine
11640912|NCT00225433|Active Comparator|1|Follitropin beta
11640913|NCT00225433|Active Comparator|2|Ganirelix acetate
11640914|NCT00225420|Other|Single Arm Intervention|Single Arm Intervention where after enrollment (or prior to enrollment but before starting radiotherapy) patients will initially receive leuprolide acetate (Lupron®) intramuscular (IM). Patients will begin adaptive external-beam radiation therapy 2-3 months following the initiation of hormonal therapy. Each patient receives a dose of docetaxel at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight weeks.
11640915|NCT00225381||metabolic gas exchange and cardiac output|
11640916|NCT00225381||mass spectrometer and anaerobic metabolism|
11640917|NCT00225381||metaboic gas exchange and type of anesthesia induction|
11640918|NCT00225381||metabolic gas exchange and PEEP|
11640919|NCT00225381||metabolic gas exchange and trendelenburg position|
11640920|NCT00225381||Patients requiring tourniquet during surgery|Patients undergoing orthopaedic surgeries requiring tourniquet intervention. Oxygen consumption and CO2 production were measured before, during and after tourniquet release.
11640921|NCT00225381||Patients prone to metabolic acidosis|Oxygen consumption and CO2 measurements taken during long surgeries prone to metabolic acidosis.
11640922|NCT00225277|Experimental|Pioglitazone QD|
11640923|NCT00225277|Active Comparator|Glimepiride QD|
11640924|NCT00225264|Experimental|Pioglitazone QD|
11640925|NCT00225264|Active Comparator|Glimepiride QD|
11640926|NCT00225251|Experimental|bupropion XL|Treatment with active medication (bupropion XL) dose ranging from 150 to 450 mg/day
11640927|NCT00225251|Placebo Comparator|Placebo|Placebo comparator, matching appearance with active medication, taken from 1 to 3 tablets per day
11640928|NCT00225225|Active Comparator|fixed calorie (500 kcal) Reduction|
11640929|NCT00225225|Placebo Comparator|Control (no diet change)|
11640930|NCT00225212|Experimental|Rituximab after ASCT|Rituximab 375 mg/m2 starting 6 weeks after ASCT transplant, and for the 5th and subsequent subjects, a second course at the same dose 6 months after ASCT.
11640931|NCT00225199|Experimental|Arm 1|
11640932|NCT00225199|Placebo Comparator|Arm 2|
11640933|NCT00225186|Experimental|Arm 1|
11640934|NCT00225173|Experimental|Treatment|"Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11
~Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11
~Cyclophosphamide 750 mg/m2 IV w 1, 5, 9
~Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
~Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)
~Bleomycin 5 u/m2 IV w 2,4,6,8,10,12
~Gemcitabine 1250 mg/m2 IV w 13,15,17,19
~Vinorelbine 25 mg/m2 IV w 13,15,17,19
~Prednisone 40 mg/m2 PO qod w 1-10, taper"
11640935|NCT00225147|Experimental|100 IU/kg rhC1INH|100 IU/kg Recombinant human C1 inhibitor
11640936|NCT00225147|Experimental|50 IU/kg rhC1INH|50 IU/kg Recombinant human C1 inhibitor
11640937|NCT00225147|Placebo Comparator|Saline|
11640938|NCT00225121|Experimental|1|open label single arm trial
11640939|NCT00225095|Active Comparator|Chondrogen - dose 1|Chondrogen - 50 million cells
11640940|NCT00225095|Active Comparator|Chondrogen - dose 2|Chondrogen - 150 million cells
11640941|NCT00225095|Other|Vehicle Control|Vehicle Control
11640942|NCT00225069|Experimental|1|T2 sympathectomy
11640943|NCT00225069|Experimental|2|T2-T3 sympathectomy
11640944|NCT00225017|Experimental|A|"ARM A: Switch current PI to atazanavir 400 mg once daily plus current > 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) for 24 weeks.
~Subjects currently on ritonavir (RTV) (400 mg BID or greater) or RTV-boosted PI (<400 mg/day) , or tenofovir (TDF) as backbone NRTI therapy, will switch to ATV 300 mg boosted with RTV 100mg once daily."
11640945|NCT00225017|Active Comparator|B|ARM B: Continue current antiretroviral regimen (single or RTV-boosted PI plus > 2 NRTIs) for 24 weeks
11640946|NCT00224952||Patients receiving Carbamazepine or Valproic Acid|
11640947|NCT00224874|Experimental|Etanercept|Enroll within 48 hours of new onset acute GVHD and randomize to Etanercept
11640948|NCT00224874|Experimental|Mycophenolate Mofetil|Enroll within 48 hours of new onset acute GVHD and randomize to Mycophenolate Mofetil
11640949|NCT00224874|Experimental|Denileukin Diftitox|Enroll within 48 hours of new onset acute GVHD and randomize to Denileukin Diftitox
11640950|NCT00224874|Experimental|Pentostatin|Enroll within 48 hours of new onset acute GVHD and randomize to Pentostatin
11640951|NCT00224848|Experimental|ATP III|A novel practice-based intervention, based on the ATP III Clinical Practice Guideline, which includes the use of a personal digital assistant (PDA) based decision support tool.
11640952|NCT00224848|Active Comparator|JNC 7|A novel practice-based intervention, based on the JNC-7 blood pressure Clinical Practice Guideline, which includes the use of am automated blood pressure measurement device.
11640953|NCT00224835|Experimental|1|Mindfulness Based Stress Reduction Class
11640954|NCT00224835|Experimental|2|Cardiac Education Class
11640955|NCT00224783|Active Comparator|CAIV-T|CAIV-T contains 3 cold-adapted influenza virus strains (A/H1N1, A/H3N2, B) concentrated and refined by centrifugal separation from the chorioallantoic membrane of specific pathogen-free (SPF) eggs, containing SPG (sucrose-phosphate-glutamate), arginine, and acid hydrolyzed pig gelatin as stabilizers. Subjects were inoculated once with about 0.1 mL of investigational vaccine in each nasal cavity (a total of 0.2 mL) using a nebulizer.
11640956|NCT00224783|Placebo Comparator|Placebo|Placebo contained 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2). Subjects received about 0.1 mL (a total 0.2 mL) of the control drug using a nebulizer.
11640957|NCT00224770|No Intervention|Medical Management|Standard of care medical management as per American Heart Association (AHA) guidelines.
11641012|NCT00223925|Experimental|Maribavir (400 mg twice daily)|
11641013|NCT00223925|Experimental|Maribavir (400 mg once daily)|
11641014|NCT00223912|Other|1|Lower-extremity functional electrical stimulation
11641312|NCT00218608|Active Comparator|Disulfiram at 62.5 mg|Disulfiram at 62.5 mg was suspended in the methadone during weeks 3-14.
11640958|NCT00224770|Active Comparator|MISTIE Surgical Management|"Minimally invasive surgery (MIS) with clot lysis with recombinant tissue plasminogen activator (rt-PA).
~MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo®) through the catheter once every eight hours for up to 72 hours, in addition to best medical care.
~This includes 54 intent-to-treat patients, and excludes 27 pilots."
11640959|NCT00224770|Active Comparator|ICES Surgical Management|"Intraoperative stereotactic CT-Guided Endoscopic Surgery
~Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative-targeting arm as MISTIE arm. Best medical care was provided, but no rt-PA was administered.
~This includes 14 intent-to-treat patients, and excludes 4 pilots."
11640960|NCT00224757|Active Comparator|Aspirin|Ascal 100mg once daily
11640961|NCT00224757|Active Comparator|Coumarin derivates|Acenocoumarol or fenprocoumon
11640962|NCT00224744|Active Comparator|Classical surgical Inguinal curage|Classical Inguinal curage
11640963|NCT00224744|Experimental|Ultracision surgical Inguinal curage|
11640964|NCT00224718|Active Comparator|1|surgery - open repair
11640965|NCT00224718|Experimental|2|endovascular procedure
11640966|NCT00224640|Experimental|1|Iron chelating intervention
11640967|NCT00224575|Experimental|1|Diagnosis strategy and subsequent therapeutic reassessment All patients are in that arms. They all receive the diagnosis reassessment strategy.
11640968|NCT00224523|Experimental|Arm 1|
11640969|NCT00224484|Experimental|GD2-AS04 GROUP|Female subjects aged 10-17 years, who received 3 doses of gD2-AS04 vaccine, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
11640970|NCT00224484|Active Comparator|HAVRIX GROUP|Female subjects aged 10-17 years, who received 3 doses of Havrix, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
11640971|NCT00224484|Placebo Comparator|SALINE GROUP|Female subjects aged 10-17 years, who received 3 doses of a saline solution, which were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.
11640972|NCT00224471|Experimental|Group A|
11640973|NCT00224471|Experimental|Group B|
11640974|NCT00224471|Experimental|Group C|
11640975|NCT00224445|Experimental|Truvada + Ritonavir-boosted Atazanavir|All participants received Truvada plus ritonavir-boosted atazanavir
11640976|NCT00224419|Active Comparator|1 - CBT Counseling|Participants in this arm received a tailored CBT (TCBT) intervention that included: a written self-help guide, feedback about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session.
11640977|NCT00224419|Experimental|2 - Counseling + NRT|Women in this arm received the TCBT described in Arm 1, plus their choice of NRT. To minimize fetal exposure to nicotine for women in the TCBT+NRT arm, the dose of NRT are customized to the woman's current level of smoking. Women who smoke 5-10 cigarettes a day will be given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smokes per day. Those who smoke 11 cigarettes or more per day will be given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smokes per day, not to exceed 15 lozenges or pieces of gum per day.
11640978|NCT00280839|Active Comparator|topiramate|
11640979|NCT00280839|Placebo Comparator|placebo|
11640980|NCT00224289|Other|1|All participants will be taking Latanoprost; This study compares efficacy within age groups.
11640981|NCT00224237||A|Participants will be self-identified, adult Latino men and women from the community setting. The sample will comprise of a convenience sample from community-based organizations, including persons of Mexican, Puerto Rican, Cuban, Dominican, Central American, South American, or other Spanish-speaking culture.
11640982|NCT00224211||I|Stable premature infants
11640983|NCT00224198||Lung Disease|All study individuals will be males or females that are 18 years or older and are able to provide informed consent and have been diagnosed with lung disease.
11640984|NCT00224133|Experimental|Silodosin|Silodosin 8 mg per day with food
11640985|NCT00224120|Experimental|Silodosin|Silodosin 8 mg/Day with food
11640986|NCT00224120|Placebo Comparator|Placebo|Matching placebo capsule once daily with food
11640987|NCT00224107|Experimental|Silodosin|Silodosin 8 mg once daily with food
11640988|NCT00224107|Placebo Comparator|placebo|Matching Placebo capsule once daily with food
11640989|NCT00224094|Experimental|Sequence A|Oral ERT then transdermal ERT
11640990|NCT00224094|Experimental|Sequence B|Transdermal ERT then oral ERT
11640991|NCT00224081|Experimental|Ferric gluconate|
11640992|NCT00224081|No Intervention|standard of care|
11640993|NCT00224055|Experimental|IV iron|Sodium ferric gluconate
11640994|NCT00224055|Active Comparator|oral iron|ferrous sulfate
11640995|NCT00224042|Experimental|IV iron|
11640996|NCT00224042|Active Comparator|oral iron|
11640997|NCT00224029|Experimental|Oxybutynin transdermal system|Oxybutynin transdermal system 3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day dosing
11640998|NCT00224016|Experimental|Oxybutynin Transdermal System|Oxybutynin Transdermal System 1.3 mg/day, 2.6 mg/day, or 3.9 mg/day
11640999|NCT00224016|Active Comparator|Oral oxybutynin|5 to 15 mg/day immediate release or extended release tablets, or syrup
11641000|NCT00223990|Experimental|FMP1/AS02A|FMP1/AS02A candidate malaria vaccine was administered IM in the left anterolateral thigh muscle at 0, 1, and 2 months
11641001|NCT00223990|Active Comparator|RabAvert (rabies vaccine)|RabAvert vaccine was administered IM in the left anterolateral thigh muscle at 0, 1, and 2 months
11641002|NCT00223977|Experimental|Sodium ferric gluconate complex 125 mg|125 mg sodium ferric gluconate weekly x 8 weeks
11641003|NCT00223977|Experimental|Sodium ferric gluconate complex 250 mg|250 mg sodium ferric gluconate complex weekly x 4 weeks
11641004|NCT00223977|Active Comparator|Oral iron|325 mg ferrous sulfate three times daily x 8 weeks
11641005|NCT00223964|Experimental|dose level 1|1.5 mg/kg
11641006|NCT00223964|Experimental|dose level 2|3 mg/kg
11641007|NCT00223938|Active Comparator|1|Oral Iron
11641015|NCT00223899|Experimental|A|IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
11641016|NCT00223860|Other|1|
11641017|NCT00223847|Other|1|
11641018|NCT00223834|Other|1|Single session orientation to available services
11641019|NCT00223821|Active Comparator|Drug Therapy Aone|Oxybutynin chloride, extended-release, individually-titrated
11641020|NCT00223821|Experimental|Drug Therapy + Behavioral Training|Drug Therapy + Behavioral Training: Individually-titrated, extended-release oxybutynin chloride with management of side-effects. Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
11641021|NCT00223808|Experimental|Robot-Low|low-dose mechanically-assisted upper limb therapy
11641022|NCT00223808|Experimental|Robot-High|high-dose mechanically-assisted upper limb therapy
11641023|NCT00223808|Active Comparator|Control|additional traditional therapy
11641024|NCT00223795|Active Comparator|Single point cane|People with knee osteoarthritis underwent gait analysis with a cane
11641025|NCT00223795|No Intervention|No cane|Patients with knee osteoarthritis undergo gait analysis without a cane
11641026|NCT00223782|Other|1|
11641027|NCT00223756|Experimental|Arm 1|interdisciplinary, outpatient blind rehabilitation
11641028|NCT00223756|No Intervention|Arm 2|usual care
11641029|NCT00223743|Experimental|Zonisamide|Zonisamide administration and tremor assessment to assess efficacy in reducing essential tremor
11641030|NCT00223730|Experimental|citrulline|Patients randomized to receive oral citrulline at 3.8 gm/m2 in split BID dosing
11641031|NCT00223730|Placebo Comparator|Placebo|Patients randomized to receive oral diluent for citrulline in BID dosing
11641032|NCT00223717|Experimental|1: Active drug or intervention|Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt, aliskiren, local heat stress
11641033|NCT00223717|Placebo Comparator|2: Placebo|placebo pill or patch
11641034|NCT00223704|Experimental|HOE 140|Bradykinin receptor antagonist
11641035|NCT00223704|Active Comparator|Aminocaproic Acid|Antifibrinolytic
11641036|NCT00223704|Placebo Comparator|Placebo|Placebo
11641037|NCT00223691|Experimental|1: active intervention|atomoxetine, pyridostigmine bromide, yohimbine, midodrine hcl, modafinil, octreotide, water intake, ranitidine hcl, diphenhydramine hydrochloride, tranylcypromine, ergotamine/ caffeine, celecoxib, pseudoephedrine, methylphenidate, indomethacin, ibuprofen, Oxymetazoline 0.05% nasal solution, acarbose, Rivastigmine tartrate, acetazolamide, carbidopa/levodopa, inflatable abdominal binder or bovril
11641038|NCT00223691|Placebo Comparator|2: Placebo or sham device|placebo pill or inflatable abdominal binder (sham)
11641039|NCT00223678|Active Comparator|1|pt will switch from calcineurin inhibitor (CYA, prograf) to Rapamycin
11641040|NCT00223678|No Intervention|2|Patient will remain on calcineruin inhibitor
11641041|NCT00223665|Experimental|Intermittent Androgen Suppression (IAS)|"Intermittent Androgen Suppression in 9 month cycles with a combination of a two-week lead-in of Flutamide, followed by 9 monthly injections of Leuprolide Acetate.
~Flutamide dosed as 250mg orally three times a day for 14 days prior to the initiation of Leuprolide Acetate.
~Leuprolide Acetate dosed as 7.5mg intramuscular (IM) injections once per month for a total of 9 months."
11641042|NCT00223652|Experimental|Arm 1 - Telephone CBT|Telephone cognitive behavioral therapy
11641043|NCT00223652|No Intervention|Arm 2 - Treatment as Usual|Treatment as usual control.
11641044|NCT00223639|Experimental|Topiramate|
11641045|NCT00223639|Placebo Comparator|Placebo|
11641046|NCT00223626|Experimental|Topiramate|
11641047|NCT00223626|Placebo Comparator|Placebo|
11641048|NCT00223587|Experimental|A|1 week of treatment discontinuation
11641049|NCT00223496|Experimental|Aripiprazole|Aripiprazole open-label in doses ranging from 5-30mg QD adjunct to Divalproex 500-2500mg QD.
11641050|NCT00223444||1|Genotype group Pro/Pro
11641051|NCT00223444||2|Genotype group Pro/Ser
11641052|NCT00223405||metal-ceramic (D'Sign) o|Metal ceramic crown will be placed
11641053|NCT00223405||an all-ceramic crown (IPS Empress2, Eris EXC).|All ceramic crown will be placed
11641054|NCT00223353||Lower Limb Amputee|
11641055|NCT00223353||Amputee and Normals and Clinical Case Study|"Amputee:
~Lower limb below/above knee amputee
~Normals:
~Health adult
~Clinical Case Study:
~Individual case studies"
11641056|NCT00223249|Active Comparator|Quetiapine|Quetiapine
11641057|NCT00223249|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
11641058|NCT00223236|Active Comparator|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
11641059|NCT00223236|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
11641060|NCT00223210|Active Comparator|Quetiapine|
11641061|NCT00223210|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
11641062|NCT00223171|Active Comparator|Arm 1 : 36 months AB + RT|Androgen blockade : 36 months of androgen blockade : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 12 Q 3 months + radiation therapy : pelvis 44 grays , prostate 70 grays (2 grays/fraction)
11641063|NCT00223171|Experimental|Arm 2 : 18 months AB + RT|Androgen blockade 18 months : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 6 Q 3 months + radiation therapy ( pelvis 44 grays , prostate 70 grays ,2 grays/fraction)
11641064|NCT00223145|Experimental|Arm 1|Androgen blockade for 6 months + Radiotherapy 70 Gy
11641065|NCT00223145|Experimental|Arm 2|Androgen blockade for 6 months + Radiotherapy 76 Gy
11641066|NCT00223145|Active Comparator|Arm 3|Radiotherapy alone with 76 Gy
11641067|NCT00223080|Active Comparator|Vaccine|ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.
11641068|NCT00223080|Placebo Comparator|Placebo|ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.
11641069|NCT00223041|No Intervention|A (therapy with fluvastatin 80mg retard)|kidney transplants receive in addition fluvastatin 80mg retard for 3 years
11641070|NCT00223041|Placebo Comparator|B|no therapy with fluvastatin
11641071|NCT00223002|Experimental|1|PI
11641072|NCT00223002|Experimental|2|Chlorohex
11641073|NCT00222989|Other|no label study|1
11641074|NCT00222976|Experimental|1|A Naproxen PO + placebo PR
11641075|NCT00222976|Experimental|2|B Placebo PO + Naproxen PR
11641076|NCT00222937|Experimental|A|Patients are enrolled in Lessac-Madsen Resonant Voice Therapy.
11641077|NCT00222937|Experimental|B|Patients are enrolled in Casper Based Confidential Flow Therapy.
11641078|NCT00222872|Active Comparator|1 - PTHrP Group|Group receiving study drug: PTHrP(1-36)
11641079|NCT00222872|Placebo Comparator|2 - Single Blind Placebo Group|Receives placebo injections daily via subcutaneous injection
11641080|NCT00222846|Active Comparator|A|Attention control
11641081|NCT00222846|Experimental|B|Intervention
11641082|NCT00222755|Experimental|1|Behavioral Care Management
11641083|NCT00222755|No Intervention|2|Usual Care
11641084|NCT00222742|Experimental|A|Induced moderate hypothermia (32-33 C)
11641085|NCT00222729|Experimental|Pemetrexed & Bevacizumab|
11641086|NCT00222716|Experimental|Structured|Behavioral Intervention: Structured counseling behavioral intervention focused on problem solving.
11641087|NCT00222716|No Intervention|Usual Care|Control arm
11641088|NCT00222716|Experimental|Inidividualized|Behavioral Intervention: Individualized nurse counseling behavioral intervention focused on problem-solving
11641089|NCT00222612|Active Comparator|A or B with 2DI|3 or 4 drug induction plus 2 delayed intensifications
11641090|NCT00222612|Experimental|C plus 2DI|Intensified treatment including Capizzi maintenance
11641091|NCT00222612|Experimental|A or B with 1DI|Reduced intensity treatment
11641092|NCT00222534|Experimental|Acetazolamide|Acetazolamide 250 mg Three times a day for five days
11641093|NCT00222534|Placebo Comparator|Placebo|Placebo, one tablet Three times a day for five days
11641094|NCT00222469|Experimental|1|3-agent treatment group
11641095|NCT00222430|Active Comparator|A|Usual standard coronary angiographic procedure
11641096|NCT00222430|Experimental|B|Fluoroscopy-guided coronary angiography
11641097|NCT00222417||Myringoplasty|Patients subject to myringoplasty for tympanic membrane perforations.
11641098|NCT00222417||Otosclerosis|Patients subject to stapes surgery
11641099|NCT00222352||central laboratory cTnI test|Control Group
11641100|NCT00222352||Point of Care cTnL testing|Experimental Group
11641101|NCT00222326|Experimental|Pelvic floor muscle training|Pelvic floor muscle training: clinic and rooms exercise training
11641102|NCT00222274|Experimental|1|RSA Biofeedback: RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.
11641103|NCT00222274|Active Comparator|2|EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
11641104|NCT00222261|Active Comparator|1, aspirin|Aspirin 160 mg
11641105|NCT00222261|Active Comparator|2, clopidogrel|Clopidogrel 75 mg
11641106|NCT00222144|Experimental|1|Gleevec and Taxotere
11641107|NCT00222131|Placebo Comparator|1|Placebo
11641108|NCT00222131|Active Comparator|2|Esomeprazole
11641109|NCT00222118|Experimental|1|intervention group
11641110|NCT00222118|Other|2|Attention control
11641111|NCT00222118|Other|3|Usual care
11641112|NCT00222105|Experimental|1|Doxil, Thalidomide, Dexamethasone
11641113|NCT00222066|Experimental|1|Fetal ovarian cyst aspiration performed as soon as possible
11641114|NCT00222066|No Intervention|2|Expectative
11641115|NCT00222053|No Intervention|1|No specific intervention
11641116|NCT00222053|Active Comparator|2|Biphosphonates
11641117|NCT00222053|Experimental|3|Thalidomide
11641118|NCT00222040|Experimental|1|Levovist
11641119|NCT00222040|No Intervention|2|No specific intervention
11641120|NCT00222014|Experimental|1|TIPS réalisé avec prothèse couverte de PTFE
11641121|NCT00222014|Active Comparator|2|Paracenthese and albumine perfusion
11641122|NCT00222001||HMO Patients|Measurement of telephone triage outcome.
11641123|NCT00221975|Active Comparator|Lithium + Divalproex + Lamictal|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL. Divalproex was then initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL. Patients meeting the criteria of being non-responsive to lithium plus divalproex were randomly assigned to receive lamotrigine or placebo. Patients randomized to the lamotrigine group were titrated up to a minimum dose of 150 mg and maximum dose of 200 mg per day.
11641124|NCT00221975|Placebo Comparator|Lithium + Divalproex + Placebo|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL. Divalproex was then initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL. Patients meeting the criteria of being non-responsive to lithium plus divalproex were randomly assigned to receive lamotrigine or placebo. Patients randomized to the placebo group were giving matching placebo.
11641305|NCT00218660|Experimental|1|Nal + BRENDA
11641306|NCT00218660|Placebo Comparator|2|Placebo + BRENDA
11641307|NCT00218660|Experimental|3|Nal + CBT
11641125|NCT00221962|Other|Open label treatment with aripiprazole|After 1-3 week screening phase, entered six week open trial of aripiprazole initiated at 2.5mg/day. DOsing was increased weekly in 2.5mg increments in order to reach maximum dose of 10mg/d.
11641126|NCT00221923||Healthy individuals|They will be considered if they are above 30 years old. There is no upper age limit. Subject can be either male or female, and from African or European Descent. They must speak, read, and understand English. They can be diagnosed with other health disorders.
11641127|NCT00221923||Persons at risk for or with primary open angle glaucoma|They will be considered if they are above 30 years old. There is no upper age limit. Subject can be either male or female, and from African or European Descent. They must speak, read, and understand English. They can be diagnosed with other health disorders.
11641128|NCT00221897||Healthy individuals|healthy controls with or without myopia
11641129|NCT00221897||Persons at risk for or with primary open angle glaucoma|with or without myopia with a diagnosis of glaucoma, glaucoma suspect and ocular hypertension
11641130|NCT00221845|Active Comparator|Conventional BP Control|Targeted 24-hour mean arterial pressure will be the 50th-95th percentile for age.
11641131|NCT00221845|Experimental|Intensified BP Control|Targeted 24-hour mean arterial pressure will be the 5th to 50th percentile for age.
11641132|NCT00221793|Experimental|1|Deep Brain Stimulation of the Subthalamic Nucleus
11641133|NCT00221793|Active Comparator|2|Later Deep Brain Stimulation of the Subthalamic Nucleus
11641134|NCT00221767|Experimental|1|Brindley technique (bladder system)
11641135|NCT00221767|No Intervention|2|Reference group
11641136|NCT00221715|Experimental|1|bypass by autologous saphenous vein
11641137|NCT00221715|Active Comparator|2|bypass by dacron or PTFE Prosthesis
11641138|NCT00221702|Experimental|A|Peg Intron 100 mcg SC/week for 36 months
11641139|NCT00221702|Active Comparator|B|Intron A 3 X 3 MIU, weekly, sc, for 18 months
11641140|NCT00221598|Experimental|hemodialysis|
11641141|NCT00221546|Active Comparator|DHA-rich supplement|
11641142|NCT00221546|Placebo Comparator|Placebo|
11641143|NCT00221507|No Intervention|Historical Cohort|This study will first examine risk factors in a defined population of inner city children, using a historical cohort.
11641144|NCT00221507|Active Comparator|Reminder Recall Outreach|"To determine how well Reminder Recall Outreach will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
11641145|NCT00221507|Active Comparator|Case Management|"To determine how well Case Management will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
11641146|NCT00221507|Active Comparator|Patient Navigation|"To determine how well Patient Navigation will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
11641147|NCT00221468|Experimental|Quetiapine|Patients will begin 100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
11641148|NCT00221442|Active Comparator|zonisamide|zonegran (zonisamide)
11641149|NCT00221442|Placebo Comparator|Sugar pill|fake pill
11641150|NCT00221403|Active Comparator|Valproate (VPA)|VPA was administered in liquid form, matched for taste and color with the placebo. Medication was administered in a double-blinded manner on a twice-daily basis. Patients randomized to VPA were administered an initial dose of 10 mg/kg/day on a twice daily schedule beginning on day 0. VPA levels were adjusted to achieve a blood level of 80-100 lg/mL. An independent, unblinded study psychiatrist adjusted VPA doses to achieve a therapeutic level
11641151|NCT00221403|Active Comparator|Risperidone|Risperidone was administered in liquid form matched for taste and color to the placebo. Medications were administered in a double-blinded manner on a twice-daily basis.
11641152|NCT00221403|Placebo Comparator|Placebo|The placebo was administered in liquid form, matched for taste and color with the active comparator.
11641153|NCT00221338|Experimental|Gabapentin|Double blind, placebo controlled
11641154|NCT00221338|Placebo Comparator|Placebo|Double blind
11641155|NCT00221325|Experimental|Rituximab Plus MTX|
11641156|NCT00221299|Active Comparator|Group1a-rhPTH&RIS-Placebo(Y1)&RIS(Y2)|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate placebo tablets for one year Second phase (year 2) - re-randomized to risedronate (35mg/wk) tablets for second year.
11641157|NCT00221299|Active Comparator|Group1b-rhPTH&RisendronatePlacebo|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate placebo tablets for one year Second phase (year 2) - continue on risedronate placebo tablets for second year.
11641158|NCT00221299|Active Comparator|Group2-rhPTH&Risedronate|First phase (year 1) - parathyroid hormone (rhPTH 1-34), 20 ug SC injections daily and risedronate tablets (35mg/wk) tablets for one year Second phase (year 2) - continue on risedronate tablets (35mg/wk) for second year.
11641159|NCT00221299|Active Comparator|Group3-rhPTH-Placebo&Risedronate|First phase (year 1) - parathyroid hormone (rhPTH 1-34), placebo SC injections of normal saline daily and risedronate tablets (35mg/wk) tablets for one year Second phase (year 2) - continue on risedronate tablets (35mg/wk) for second year.
11641160|NCT00221247|Active Comparator|Group 1|Intensely administered (5 times per week for 12wk) physical therapy, occupational therapy, and hydrotherapy with acupuncture
11641161|NCT00221247|No Intervention|Group 2|Intensely administered (5 times per week for 12wk) physical therapy, occupational therapy, and hydrotherapy without acupuncture
11641162|NCT00221195|Other|On-demand first|Patients receive 6 months of on-demand therapy with study drug followed by 6 months of prophylaxis therapy with study drug
11641163|NCT00221195|Other|Prophylaxis first|Patients receive 6 months of prophylaxis therapy with study drug followed by 6 months on-demand therapy with study drug
11641164|NCT00221169|Other|surgical candidates|surgical candidates who underwent PET CT evaluation
11641308|NCT00218660|Placebo Comparator|4|Placebo + CBT
11641165|NCT00221117|Active Comparator|Conventional Occupational Therapy (COT)|Conventional Occupational Therapy pertaining to hand function represents the current best practice activities against which the FET was compared. The COT included the following: (a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; (b) task-specific, repetitive functional training; (c) strengthening and motor control training using resistance to available arm motion to increase strength; (d) stretching exercises; (e) electrical stimulation applied primarily for muscle strengthening (this was neither FES nor FET, but electro muscular stimulation); (f) practice of activities of daily living (ADLs) including self-care where the upper extremities were used as appropriate; and (g) caregiver training.
11641166|NCT00221117|Experimental|Neuroprosthesis-FES Therapy|The FES Therapy began by designing stimulation protocols to generate power (circular grip and lateral pinch) and precision (opposition with 2 and 3 fingers) grasps on demand. The stimulation sequence (protocol) for power and precision grasps was developed for each patient individually using the Compex Motion electric stimulator. Compex Motion is a fully programmable transcutaneous (surface) stimulator that uses self-adhesive surface electrodes.
11641167|NCT00221104|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
11641168|NCT00221104|No Intervention|No intervention|Patient has no intervention.
11641169|NCT00221065|No Intervention|1|Control
11641170|NCT00221065|Experimental|2|CPAP
11641171|NCT00221039|Experimental|DRUG+ECP|UVVADEX +ECP will be administered to patients with CTCL.Duration of Treatment: The study will consist of 2 treatment periods, a 6-month initial period and a 6-month follow-up period where photopheresis therapy may continue.
11641172|NCT00221026|Experimental|drug|ECP + Uvadex given for 12 weeks.
11641173|NCT00221013|Experimental|Higher intensity CRRT regimen|
11641174|NCT00221013|Active Comparator|Lower intensity CRRT regimen|
11641175|NCT00220987|Experimental|Intensive Insulin therapy|Intensive Insulin therapy
11641176|NCT00220987|Active Comparator|Conventional Therapy|conventional insulin therapy
11641177|NCT00220961|Placebo Comparator|Placebo|Placebo tablet similar to pioglitazone tablet
11641178|NCT00220961|Active Comparator|Pioglitazone|Pioglitazone tablet similar to placebo tablet
11641179|NCT00220922|Experimental|1|injection site reactions with the use of alcohol wipes prior to performing the patients' daily Copaxone® injection
11641180|NCT00220922|Experimental|2|injection site reactions without the use of alcohol wipes prior to performing the patients' daily Copaxone® injection
11641181|NCT00220818|Experimental|Lansoprazole 1.0 mg/kg QD|
11641182|NCT00220818|Experimental|Lansoprazole 2.0 mg/kg QD|
11641183|NCT00220805|Experimental|Group 1|
11641184|NCT00220805|Placebo Comparator|Group 2|
11641185|NCT00220779|Experimental|Group 1|IGIV-C 0.2 g/kg bw/infusion (2 ml/kg bw)
11641186|NCT00220779|Experimental|Group 2|IGIV-C 0.4 g/kg bw/infusion (4 ml/kg bw)
11641187|NCT00220779|Placebo Comparator|Group 3|placebo (0.1% albumin) 4 ml/kg bw/infusion
11641188|NCT00220766|Experimental|Group 1|Infusion #1 (Week 0)Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min) ; Infusion #2 (Week 3-4)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min)
11641189|NCT00220766|Experimental|Group 2|Infusion #1 (Week 0)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min); Infusion #2 Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min)
11641190|NCT00220753|Active Comparator|Active air cleaner|Two Icleen IQAir air cleaners with active filters supplied
11641191|NCT00220753|Placebo Comparator|Placebo air cleaner|Two Icleen IQAir air cleaners with placebo filters supplied
11641192|NCT00220740|Experimental|Group 1|IGIV-C
11641193|NCT00220740|Placebo Comparator|Group 2|
11641194|NCT00220727|Experimental|Group 1|Infusion #1 (Week 0) IGIV-C (0.08 mL/kg/min); Infusion #2 (Week <6) IGIV-C (0.14 mL/kg/min)
11641195|NCT00220727|Experimental|Group 2|Infusion #1 (Week 0) IGIV-C (0.14 mL/kg/min); Infusion #2 (Week <6) IGIV-C (0.08 mL/kg/min)
11641196|NCT00220701|Experimental|escitalopram|Escitalopram (brand name Lexapro) is an antidepressant medication taken once per day, dosing from 10 to 20 milligrams per day.
11641197|NCT00220701|Placebo Comparator|Placebo|inactive comparator
11641198|NCT00220636|Experimental|Aripiprazole|Aripiprazole 5 to 30 mg/day
11641199|NCT00220584|Experimental|Open donepezil|open donepezil
11641200|NCT00220337|Experimental|1|Open label active treatment
11641201|NCT00220324|Experimental|Arm 1|
11641202|NCT00220311|Experimental|Arm 1|
11641203|NCT00220298|Experimental|Arm 1|
11641204|NCT00220285|Experimental|Arm 1|
11641205|NCT00220285|Experimental|Arm 2|
11641206|NCT00220038||Normal|700 healthy adult volunteers will be drawn from the New York City area
11641207|NCT00220025|Experimental|NBUVB|
11641208|NCT00219999||HCV infection|current HCV infection, including intravenous drug users
11641209|NCT00219999||cryoglobulinemia|cryoglobulinemia and without HCV infection
11641210|NCT00219999||chronic liver disease|chronic liver disease not due to hepatitis C virus infection
11641211|NCT00219999||Sustained Virologic responders|successfully treated for HCV infection
11641212|NCT00219999||normal|normal, healthy volunteers
11641213|NCT00219947||high risk|Blood draw from individuals known to be or at high risk for HIV-infection
11641214|NCT00219947||diagnosed|Blood draw f rom individuals diagnosed with HIV infection
11641215|NCT00219934||Group A|acute or early in the course of HIV-1 infection, independent of decisions regarding therapy with HAART.
11641216|NCT00219934||Group B|subjects who were diagnosed with acute HIV-1 infection in the past and have been participating in an ADARC/Rockefeller University Hospital treatment protocol for acute HIV-1 infection, and currently have a viral load consistently less than 50 copies/ml on current treatment
11641217|NCT00219882|Experimental|1|standardized turmeric root extract
11641218|NCT00219856|Experimental|1|Anesthesic induction and maintenance with intravenous propofol.
11641219|NCT00219856|Active Comparator|2|Anesthesic induction with intravenous penthotal and maintenance with inhaled desflurane.
11641309|NCT00218634|Experimental|CBT-AD|Cognitive behavioral therapy for adherence and depression
11641220|NCT00219830|Experimental|1 - home-based walking program|Based on medical record held in general practice, patients who had not attended a formal cardiac rehabilitation program after myocardial infarction and were enrolled in home-based walking programme
11641221|NCT00219830|No Intervention|2 - cardiac rehabilitation|Based on medical record held in general practice, patients who are identified as having attended a Cardiac Rehabilitation program following myocardial infarction - 'usual care'
11641222|NCT00219739|Experimental|Imatinib mesylate 400 mg|
11641223|NCT00219739|Experimental|Imatinib mesylate 600 mg|
11641224|NCT00219739|Experimental|Imatinib mesylate 400 mg +Peg interferon|
11641225|NCT00219739|Experimental|Imatinib mesylate 400 mg +Cytarabine|
11641226|NCT00219687|Active Comparator|1|When a 911 call is determined to be a cardiac arrest, the caller reporting the event who needs or desires instructions to perform CPR while waiting for EMS to arrive will receive dispatcher-assisted CPR instructions with chest compressions only
11641227|NCT00219687|Active Comparator|2|When a 911 call is determined to be a cardiac arrest, the caller reporting the event who needs or desires instructions to perform CPR while waiting for EMS to arrive will receive dispatcher-assisted CPR instructions with chest compressions and breaths
11641228|NCT00219674|Active Comparator|2|Group II
11641229|NCT00219674|Active Comparator|3|
11641230|NCT00219674|Active Comparator|4|
11641231|NCT00219674|Active Comparator|1|Group I
11641232|NCT00219557|Active Comparator|Gemcitabine|
11641233|NCT00219557|Experimental|Axitinib [AG-013736] plus gemcitabine|
11641234|NCT00219544|Experimental|1|
11641235|NCT00219544|Experimental|2|
11641236|NCT00219544|Experimental|3|
11641237|NCT00219544|Placebo Comparator|4|
11641238|NCT00219531||control|subjects with no irritable bowel syndrome or gastrointestinal complaints and regular menstrual cycle.
11641239|NCT00219531||IBS|women with IBS symptoms and normal menstrual cycle.
11641240|NCT00219466|Active Comparator|1|
11641241|NCT00219466|Active Comparator|2|
11641242|NCT00219440|Experimental|A|ACTOS plus standard diet
11641243|NCT00219440|Experimental|B|Actos plus structured diet
11641244|NCT00219440|Experimental|C|Metformin plus standard diet
11641245|NCT00219427||1|
11641246|NCT00219401|Experimental|Neonatal 7vPCV|Receive study vaccine (Prevnar) at birth, 1 and 2 months
11641247|NCT00219401|Experimental|Infant 7vPCV|Receive the study vaccine (Prevnar) at 1, 2 and 3 months
11641248|NCT00219401|Placebo Comparator|Control|Do not receive study vaccine (Prevnar)
11641249|NCT00219375|Experimental|E1|This arm is conducted as a separate study (12-601-0001)
11641250|NCT00219375|Experimental|E2|This arm is conducted as a separate study (12-603-0001).
11641251|NCT00219375|No Intervention|conventional therapy|This arm is conducted as a separate study (12-602-0001)
11641252|NCT00219362|Experimental|ALVAC-HIV 4 injections|Arm A: injection of ALVAC-HIV(vCP1452) for a total of 4 injections (W0, W4, W8, W20)
11641253|NCT00219362|Experimental|ALVAC-HIV 3 injections|Arm B: injection of ALVAC-HIV(vCP1452) for a total of injections (W4, W8, W20)
11641254|NCT00219362|Placebo Comparator|Placebo - 4 injections|Arm C1: injection of placebo for a total of 4 injections (W0, W4, W8, W20)
11641255|NCT00219362|Placebo Comparator|Placebo - 3 injections|Arm C2: injection of placebo for a total of 3 injections (W4, W8, W20)
11641256|NCT00219349|Experimental|Escitalopram|12 weeks of open label escitalopram, 10-20 mg/day (after 14 weeks of cognitive behavioral therapy
11641257|NCT00219336|Experimental|Self-motivational Choices|Students and nonstudents were mailed a brochure prepared as part of the PHC study intervention, Making Healthy Choices for a Healthy Baby in English or Mujeres y Salud Eligiendo Opciones Saludables in Spanish. This brochure allows women to make informed decisions about preventing an AEP. The MF materials included nonstigmatizing messages about drinking and contraception embedded among other health messages. Similar to Project CHOICES, this group also received a brochure on birth control practices.
11641258|NCT00219336|Active Comparator|Information Only|Students and nonstudents were mailed a brochure prepared by the CDC. The brochure (English: Think Before You Drink: You Can Hurt Your Unborn Baby; Spanish: Piénselo Antes de Beber: Puede Lastimar a Su Futuro Bebe), available at the CDC website, targets women of childbearing-age, discusses FAS and the negative effects of a mother's drinking on her unborn child, and recommends calling Alcoholics Anonymous or an alcohol treatment program for help to stop drinking. The CDC brochure did not contain information about how to contracept effectively.
11641259|NCT00219297|Experimental|Single Arm|
11641260|NCT00219284|Experimental|Immediate switch|Patients were switched the day after randomization from combined carbidopa/levodopa to combined carbidopa/levodopa/entacapone. Patients received the same doses of carbidopa (12.5, 25.0, or 37.5 mg) and levodopa (50, 100, or 150 mg) they were receiving prior to the switch, combined with 200 mg of entacapone. The frequency of doses per day prior to the switch remained the same after the switch.
11641261|NCT00219284|Active Comparator|Delayed switch|Patients were switched 4 weeks after randomization from combined carbidopa/levodopa to combined carbidopa/levodopa/entacapone. Patients received the same doses of carbidopa (12.5, 25.0, or 37.5 mg) and levodopa (50, 100, or 150 mg) they were receiving prior to the switch, combined with 200 mg of entacapone. The frequency of doses per day prior to the switch remained the same after the switch.
11641262|NCT00219271|Experimental|Zoledronic acid|4 mg IV infused over 15 minutes every 3 months
11641263|NCT00219141|Experimental|Aliskiren 300 mg|Patients in this arm initially received 150 mg of aliskiren for two weeks and were then force-titrated up to 300 mg of aliskiren where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 1 tablet of aliskiren 150 mg, 1 tablet of aliskiren 150 mg placebo, and 1 capsule of losartan placebo. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg and 1 capsule of losartan placebo. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
11641310|NCT00218634|Active Comparator|ETAU|Enhanced treatment as usual
11641311|NCT00218608|Placebo Comparator|Placebo|Placebo (microcrystalline cellulose) was suspended in the methadone during weeks 3-14.
11641695|NCT00212836|Active Comparator|Olanzapine|
11641264|NCT00219141|Active Comparator|Losartan 100 mg|Patients in this arm initially received 50 mg of losartan for two weeks and were then force-titrated up to 100 mg of losartan where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 2 tablets of aliskiren 150 mg placebo and 1 capsule of losartan 50 mg. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg placebo and 1 capsule of losartan 100 mg. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
11641265|NCT00219141|Experimental|Aliskiren/losartan 300/100 mg|Patients in this arm initially received 150 mg of aliskiren in combination with 50 mg of losartan for two weeks and were then force-titrated up to 300 mg of aliskiren in combination with 100 mg of losartan where they remained for 34 weeks. In order to adequately blind the study, patients were required to take a total of 2 tablets and 1 capsule of study medication or placebo per day. In the first 2 weeks, patients took 1 tablet of aliskiren 150 mg, 1 tablet of aliskiren 150 mg placebo, and 1 capsule of losartan 50 mg. In the remaining 34 weeks, patients took 2 tablets of aliskiren 150 mg and 1 capsule of losartan 100 mg. Each dose was to be taken by mouth with water at approximately 8:00 AM, except on the morning of study visit when the dose was taken after all procedures and assessments had been completed.
11641266|NCT00218985|Experimental|exercise training|
11641267|NCT00218985|No Intervention|physician's advice|patients follow their physician's advice in regard to physical activity.
11641268|NCT00218972|Active Comparator|AIT: aerobic interval training|High intensity interval training on treadmill at > 90% of maximal HR for four bouts of four minutes with warm up, active pauses and cool down, three times per week for 12 weeks.
11641269|NCT00218972|Active Comparator|MIT, moderate intensity training|Moderate intensity treadmill continuous exercise at 70% of maximum heart rate for 47 minutes (in order to ensure isocaloric training amount), three times per week for 12 weeks.
11641270|NCT00218972|Active Comparator|Recommendation of regular exercise|No training intervention, general advice as prescribed in guidelines.
11641271|NCT00218959|Experimental|Narrative Exposure Therapy|carried out according to the manual as outlined by Schauer et al. (2005) (second revised edition 2011) 10 sessions of 90 min duration
11641272|NCT00218959|Active Comparator|treatment as usual|mainly help with such as sleep problems, depressive symptoms, problems related to asylum status, and other practical matters. Focus on everyday issues and the limited focus on the traumatic events, in line with reports from the National Center on Violence and Traumatic Stress.
11641273|NCT00218946|No Intervention|control|no fluid, no pacifier
11641274|NCT00218946|Experimental|water|water, no pacifier
11641275|NCT00218946|Experimental|sucrose|Sucrose, no pacifier
11641276|NCT00218946|Experimental|pacifier|No fluid, pacifier
11641277|NCT00218946|Experimental|water and pacifier|water, pacifier
11641278|NCT00218946|Experimental|sucrose and pacifier|sucrose, pacifier
11641279|NCT00218933|Active Comparator|moderate exercise training|
11641280|NCT00218933|Experimental|high intensity exercise training|
11641281|NCT00218933|No Intervention|controls|
11641282|NCT00218920|Experimental|strength training|Over a 12-week period, 13 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
11641283|NCT00218920|Experimental|continuous moderate-intensity aerobic training|Over a 12-week period, 13 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
11641284|NCT00218920|Experimental|high-intensity interval aerobic training|Over a 12-week period, 14 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
11641285|NCT00218894||post cataract surgery|
11641286|NCT00218868||skin scrape|
11641287|NCT00218855|Placebo Comparator|A|
11641288|NCT00218855|Active Comparator|B|
11641289|NCT00218842|Experimental|exercise group|individualized exercise
11641290|NCT00218842|No Intervention|control group|care as usal
11641291|NCT00218816|Experimental|1|
11641292|NCT00218816|Other|2|
11641293|NCT00218803|Experimental|1|
11641294|NCT00218803|Other|2|
11641295|NCT00218790|No Intervention|Control group|The control group received standard dialysis at a temperature of 37 degrees Celcius
11641296|NCT00218790|Experimental|Experimental group|Subjects in the experimental group received cool dialysate during treatment
11641297|NCT00218725|Other|Cognitive Therapy|The cognitive therapy intervention for suicide attempters has been designed to provide a brief, timely, flexible intervention that can be incorporated into general and psychiatric inpatient and outpatient services and applied to the population of patients who attempt suicide. A central feature of the intervention is the adaptation of cognitive therapy to the population of patients who attempt suicide. The focus of the intervention is the identification of core beliefs and key automatic thoughts that were elicited prior to and during the most recent suicide attempt. Once these beliefs and thoughts have been articulated, the counselor and patient develop more adaptive responses during an acute suicidal crisis.
11641298|NCT00218725|Other|Enriched Care|The Enriched Care condition will be used as the treatment comparison condition for this study. The Enriched Care condition consists of the usual care that patients may obtain in the community as well as the assessment and referral services provided by the case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health and substance abuse treatment in the community.
11641299|NCT00218712|Experimental|1|Participants will receive personalized cognitive counseling
11641300|NCT00218712|Active Comparator|2|Participants will receive standard counseling
11641301|NCT00218686|Experimental|1|behavioral social network risk reduction intervention
11641302|NCT00218686|Active Comparator|2|voluntary counseling and testing (VCT
11641303|NCT00218673|Experimental|experimental|social network
11641304|NCT00218673|No Intervention|control|testing and counseling
11641313|NCT00218608|Active Comparator|Disulfiram at 125 mg|Disulfiram at 125 mg/day was suspended in methadone during weeks 3-14.
11641314|NCT00218608|Active Comparator|Disulfiram at 250 mg|Disulfiram at 250 mg/day was suspended in methadone during weeks 3-14.
11641315|NCT00218595|Experimental|DBT|
11641316|NCT00218595|Active Comparator|I/GDC|
11641317|NCT00218582|Experimental|1|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
11641318|NCT00218582|Active Comparator|2|Standard psychiatric day treatment
11641319|NCT00218569|Experimental|1|Naltrexone
11641320|NCT00218569|Experimental|2|Placebo
11641321|NCT00218556|Experimental|Depression prevention|Cognitive behavioral treatment for depression.
11641322|NCT00218556|No Intervention|Control|Treatment as usual.
11641323|NCT00218543|Experimental|Atomoxetine|Atomoxetine
11641324|NCT00218517|Experimental|1|
11641325|NCT00218517|Placebo Comparator|2|
11641326|NCT00218491|Experimental|1200mg N-Acetylcysteine|1200mg N-Acetylcysteine
11641327|NCT00218491|Experimental|2400mg N-Acetylcysteine|2400mg N-Acetylcysteine
11641328|NCT00218491|Placebo Comparator|Matching Placebo|Matching Placebo
11641329|NCT00218465|Experimental|GW468816|Glycine Antagonist GW468816, 200 mg/day, for a 5-week trial
11641330|NCT00218465|Placebo Comparator|Placebo|Placebo, 200 mg/day, for a 5-week trial
11641331|NCT00218452|Experimental|Lifestyle counseling|
11641332|NCT00218439|Experimental|1|Active medication for 4 weeks followed by placebo for 4 weeks
11641333|NCT00218439|Experimental|2|Placebo for 4 weeks followed by active for 4 weeks
11641334|NCT00218426|Active Comparator|ONP + DNI|Oral naltrexone placebo (ONP) + Depot Naltrexone Implant (DNI) 1000 mg
11641335|NCT00218426|Active Comparator|ON + DNIP|Oral naltrexone (ON) 50 mg + Depot Naltrexone placebo Implant (DNIP)
11641336|NCT00218426|Placebo Comparator|ONP + DNIP|Oral placebo naltrexone + placebo naltrexone implant
11641337|NCT00218413|Experimental|1|
11641338|NCT00218413|Experimental|2|
11641339|NCT00218413|Experimental|3|
11641340|NCT00218413|Experimental|4|
11641341|NCT00218413|Experimental|5|
11641342|NCT00218387|Experimental|200mg Modafinil|200mg Modafinil
11641343|NCT00218387|Experimental|400mg Modafinil|400mg Modafinil
11641344|NCT00218387|Placebo Comparator|Matching Placebo|Matching Placebo
11641345|NCT00218335|Experimental|Intervention Condition|Participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
11641346|NCT00218335|Active Comparator|Control Condition|The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.
11641347|NCT00218322|Placebo Comparator|1|Treatment with placebo or atomoxetine for 12 weeks.
11641348|NCT00218322|Experimental|2|
11641349|NCT00218296|Active Comparator|Usual Care Group|Usual care for cessation with immediate quit date scheduled and two weeks of nicotine patch supplied.
11641350|NCT00218296|Experimental|Reduction Group|Reduction in nicotine exposure for 6 weeks prior to quit date using medicinal nicotine lozenge or reduced nicotine smokeless tobacco.
11641351|NCT00218283|Experimental|1 - Nicotine Lozenge|Use of nicotine lozenge plus behavioral counseling to help reduce tobacco use prior to quit date.
11641352|NCT00218283|Placebo Comparator|2 Behavioral counseling|Use of behavioral counseling alone to help reduce tobacco use prior to quit date.
11641353|NCT00218270|Experimental|1|Reduction of tobacco use by substituting tobacco free snuff.
11641354|NCT00218270|Placebo Comparator|2|Reduction of tobacco use by using behavioral techniques.
11641355|NCT00218257|Active Comparator|Progesterone|200mg progesterone twice daily
11641356|NCT00218257|Placebo Comparator|Placebo|Placebo twice daily
11641357|NCT00218244|Active Comparator|1 Controlled use|Reduction in tobacco toxicants by switching to a lower nicotine tobacco product under a controlled use condition.
11641358|NCT00218244|Active Comparator|2 Uncontrolled use|Reduction in tobacco toxicants by switching to a lower nicotine tobacco product under an uncontrolled use condition.
11641359|NCT00218244|Placebo Comparator|3 Behavioral|Reduction in smokeless tobacco use using behavioral techniques only.
11641360|NCT00218231|Experimental|1|300 mg/day bupropion-sr
11641361|NCT00218231|Placebo Comparator|2|0 mg bupropion-sr
11641362|NCT00218218|Experimental|1|Transdermal nicotine, 42 mg
11641363|NCT00218218|Experimental|2|Transdermal nicotine, 21 mg
11641364|NCT00218218|Placebo Comparator|3|placebo patch
11641365|NCT00218179||Cases|Lung cancer cases diagnosed prior to 2007 among baseline smokers in the PLCO
11641366|NCT00218179||Controls|Subjects without lung cancer among smokers at baseline in the PLCO study
11641367|NCT00218166|No Intervention|A|Within subject design
11641368|NCT00218127|Experimental|1|LAAM WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day for 20 weeks
11641369|NCT00218127|Experimental|2|LAAM MaxEffect to 48 mg Adjust to effect (+/-)
11641370|NCT00218127|Experimental|3|LAAM Fixed Dose up to 48 mg 48 mg
11641371|NCT00218114|Experimental|1|Divalproex sodium (Depakote). This is a parallel groups design lasting a total of six weeks. Participants will be on a fixed-flexible dosing schedule. The dose of depakote will be raised to 750mgs or 1000mgs, depending on weight, in two weeks to achieve blood levels between 50-130 micrograms per milliliter. If a patient does not achieve this blood level on 750mgs or 1000 mgs, the dose may be raised during the second week.
11641372|NCT00218114|Placebo Comparator|2|This is a parallel groups design lasting a total of six weeks. Participants will be on matching placebo for 250 mgs divalproex sodium (Depakote).
11641399|NCT00217867|Experimental|2|Use of animated computerized character to prepare subjects for discharge by reviewing information provided to subjects in a printed After Hospital Care Plan packet, followed by telephone system to reinforce the discharge.
11641373|NCT00218062|Experimental|D-Amphetamine 60mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. d-Amphetamine sustained release (SR) (Dexedrine Spansules) started at 15 mg (day 1-2), increased to 30mg (day3; 15mg, BID), 45mg (day4; 15mg, TID), and 60mg (day5; 15mg bid plus 30mg qd). A 5-day dose reduction schedule occurred at week 17.
~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
11641374|NCT00218062|Experimental|Modafinil 400mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. Modafinil started at 200mg (day1) and increased to 400mg (days2-5). A 5-day dose reduction schedule occurred at week 17.
~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
11641375|NCT00218062|Experimental|Modafinil 200mg + D-Amphetamine 30mg + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance. Medication administration was initiated during a 5 day run-up period. For the combination condition, dosages of modafinil and d-amphetamine were escalated to one-half of that for the single medication conditions. A 5-day dose reduction schedule occurred at week 17.
~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
11641376|NCT00218062|Placebo Comparator|Placebo + Therapy|"During the 16 weeks of outpatient treatment, participants took three capsules daily (two in the morning, one in the afternoon). All active and placebo capsules were identical in appearance and each contained 50mg riboflavin for subsequent evaluation of medication compliance.
~Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills."
11641377|NCT00218049|Experimental|1|50 mg of GBR 12909
11641378|NCT00218049|Experimental|2|75 mg of GBR 12909
11641379|NCT00218049|Experimental|3|100 mg of GBR 12909
11641380|NCT00218036|Experimental|1|Modafinil 200mg / Methadone Maintenance (1.2mg/kg)
11641381|NCT00218036|Experimental|2|Modafinil 400mg/ Methadone Maintenance (1.2mg/kg)
11641382|NCT00218036|Experimental|3|Citalopram 20/ Methadone Maintenance 1.2mg/kg
11641383|NCT00218036|Experimental|4|Citalopram 40/ Methadone Maintenance 1.2 mg/kg
11641384|NCT00218036|Placebo Comparator|5|Placebo given to methadone-maintained subjects (1.2mg/kg) for the duration of the 12-week study
11641385|NCT00218023|Experimental|Modafinil plus MI, CM, and CBT|"The modafinil dose began at 200 mg (day 1) and increased to the fixed dose of 200 mg twice daily (day 2) during the 12 weeks of Phase II.
~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.
~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).
~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
11641386|NCT00218023|Experimental|Levodopa/Carbidopa plus MI, CM, and CBT|"Levodopa-carbidopa, in the sustained-release formulation (Sinemet CR), began at a dose of levodopa/carbidopa 400/100 mg (day 1) and increased to the fixed dose of 400/100 mg twice daily (day 2) during the 12 weeks of Phase II.
~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.
~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).
~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
11641387|NCT00218023|Experimental|Naltrexone HCl plus MI, CM, and CBT|"Naltrexone hydrochloride (HCl) doses began at 25 mg (day 1) and increased to the fixed dose of 25 mg twice daily (day 2) during the 12 weeks of Phase II.
~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.
~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).
~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
11641388|NCT00218023|Placebo Comparator|Placebo plus MI, CM, and CBT|"Placebo capsules were identical in appearance to active drug capsules, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance.
~The motivational interviewing (MI) intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I.
~Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during Phase I) and medication compliance (during Phase II).
~Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II."
11641389|NCT00218010||Methadone maintained lactating women|Methadone maintained women who chose to breastfeed their infants provided breast milk and plasma samples for this study.
11641390|NCT00217984|Experimental|Intensive intervention|Extended cognitive behavior therapy (16 sessions) plus nicotine patches and lozenges
11641391|NCT00217984|Other|Usual care|Referral to the smoking cessation clinic
11641392|NCT00217971|Active Comparator|Dronabinol|Dronabinol: 20mg bid for a daily maximum dose of 40mg.
11641393|NCT00217971|Placebo Comparator|Placebo|placebo
11641394|NCT00217919|Experimental|1|Health-Counselor Mediated Telephone Counseling Intervention
11641395|NCT00217919|No Intervention|2|Usual care
11641396|NCT00217893|Experimental|1|Combination of counseling, cotinine feedback, and contingent incentives.
11641397|NCT00217893|Active Comparator|2|Usual education program
11641398|NCT00217867|No Intervention|1|Usual Care, defined as the usual hospital discharge process as delivered by nurses and doctors.
11641400|NCT00217854|Other|Open label inhaled fluticasone|Patients are treated with open label high dose fluticasone for 30 days then discontinued. Comparisons are pre- and post- treatment single arm.
11641401|NCT00217776|Active Comparator|Open Airways Educational Intervention|Children in this arm will receive the Open Airways educational program which is an evidenced based asthma educational program for children, developed by the investigator.
11641402|NCT00217776|Active Comparator|Open Airways and Peer Asthma Action Intervention Education|Children in this arm will receive BOTH the Open Airways asthma education program and the Peer Asthma Action education program.
11641403|NCT00217776|No Intervention|Control Arm|Children in the Control Arm will be interviewed in person at baseline, 12 month and 24 months.
11641404|NCT00217737|Active Comparator|Arm A (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
11641405|NCT00217737|Experimental|Arm B (combination chemotherapy, bevacizumab)|Patients receive oxaliplatin, leucovorin calcium, and fluorouracil as in Arm A and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone for 12 additional courses in the absence of disease progression or unacceptable toxicity.
11641406|NCT00217737|No Intervention|Arm C (observation)|Patients undergo observation.
11641407|NCT00217724|Experimental|Glutamine Arm|Beginning on day 2 of course 1 of paclitaxel administration, patients receive oral glutamine three times daily for 4 days.
11641408|NCT00217724|Placebo Comparator|Placebo arm|Beginning on day 2 of course 1 of paclitaxel administration, patients receive oral placebo three times daily for 4 days.
11641409|NCT00217711|Active Comparator|Arm A|Oxaliplatin, Irinotecan, and Capecitabine
11641410|NCT00217672|Experimental|Bevacizumab + Docetaxel|"docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
~Bevacizumab: 15 mg/kg IV every 3 weeks. Subjects continue on study until disease progression, unacceptable toxicity, or withdrawal of patient consent."
11641411|NCT00217672|Active Comparator|docetaxel|docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
11641412|NCT00217646|Experimental|Arm I|Patients receive oral sorafenib once or twice daily on days 1-5, 8-12, and 15-19.
11641413|NCT00217646|Experimental|Arm II|Patients receive oral sorafenib once or twice daily on days 1-14.
11641414|NCT00217633|Experimental|Treatment (pelvic exenteration)|Patients undergo pelvic exenteration within 14 days after study entry.
11641415|NCT00217620|Experimental|sorafenib|sorafenib
11641416|NCT00217607|Experimental|Paclitaxel|"Paclitaxel 80 mg/m² Day 1, Day 8 and Day 15. No treatment on Day 22.
~1 cycle = 28 days.
~Treatment duration: 6 cycles (=6 months)"
11641417|NCT00217594|Experimental|Alemtuzumab|Patients received a 1-mg test dose of alemtuzumab, and the following day, alemtuzumab was administered at 10 mg/dose intravenously for 10 days
11641418|NCT00217581|Experimental|Docetaxel, Oxaliplatin & Bevacizumab|Must be administered 1st before Docetaxel & Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
11641419|NCT00217542|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive azacitidine SC once daily on days 1-4 and 15-17 and recombinant interferon alfa-2b SC on days 8, 10, 12, 15, 17, 19, 22, 24, and 26 during course 1. Beginning in course 2 and for all subsequent courses, patients receive azacitidine SC once daily on days 1-3 and 15-17 and interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 12 total courses in the absence of disease progression or unacceptable toxicity.
11641420|NCT00217516|Experimental|Arm I|Patients receive oral selenium for 3-6 weeks.
11641421|NCT00217516|Placebo Comparator|Arm II|Patients receive oral placebo for 3-6 weeks.
11641422|NCT00217490|Experimental|Computer Only|Dietary Counseling delivered by interactive computer program, without the addition of individual counseling provided by a health counselor. This arm tested a completely automated counseling program that did not include personalized behavioral counseling provided by a study staff member.
11641423|NCT00217490|Experimental|Counseling only|In this arm, dietary counseling was delivered by nutritionist, and this counseling did not include use of an automated, computer program.
11641424|NCT00217490|Experimental|Combined|In this arm, participants received dietary counseling delivered using both the automated computer program and additional counseling by a study nutritionist. That is, this arm combined the intervention programs delivered in the other two active intervention arms.
11641425|NCT00217490|Active Comparator|Physical Activity-computer|Participants assigned to this arm did not receive nutrition counseling, but they were provided physical activity counseling delivered by computer only.
11641426|NCT00217477|Experimental|Paricalcitol IV in combination with Gemcitabine IV|Patients receive gemcitabine hydrochloride IV over 80 minutes on days 1, 8, and 15 and paricalcitol IV over 15 minutes on days 7 and 14 in course 1. Beginning in course 2, patients receive paricalcitol IV over 15 minutes on days 1, 8, and 15 and gemcitabine hydrochloride IV over 80 minutes on days 2, 9, and 16. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11641427|NCT00217464|Experimental|Fulvestrant|Fulvestrant will be provided as 250 mg in 5 mL as a pre-tilled syringe. Fulvestrant will be administered as 500 mg, that is, 2 injections of 5 mL, one into each buttock im on day 0. A single 250 mg in 5 mL injection will be administered on day 14 followed by a single 250 mg in 5 mL dose on day 28 and monthly thereafter.
11641456|NCT00216983||1|"Fasting condition to measure:
~quantitative relationships among proline, ornithine and glutamate with an emphasis on evaluating the rate of proline disposal and its conversion to ornithine and glutamate in burn patients
~Evaluating the rate of proline de novo synthesis from glutamate or ornithine in burn patients"
11641457|NCT00216983||2|We will study the quantitative relationships among proline, ornithine and glutamate with an emphasis on evaluating the rate of proline disposal and its conversion to ornithine and glutamate in burn patients. When the patients are receiving regular TPN or TPN depleted with proline - arginine - glutamate.
11641505|NCT00216112|Experimental|Investigational Treatment|Imatinib Mesylate + Docetaxel
11641428|NCT00217438|Experimental|Arm I (high dose melphalan, amifostine trihydrate, transplant)|"INDUCTION THERAPY:
~Patients receive amifostine IV over 3-5 minutes on days -3 and -2 followed by high-dose melphalan IV over 15-30 minutes on day 2.
~AUTOLOGOUS OR SYNGENEIC PBSCT: At least 20 hours after completion of melphalan, patients undergo autologous or syngeneic PBSCT on day 0.
~Patients undergo restaging of the disease between days 80-90. Patients with progressive disease are removed from the study. Patients who achieve a CR or near-CR can proceed to optional maintenance therapy. Patients who do not achieve a CR or near-CR may undergo additional induction therapy as in arm I followed by a second autologous or syngeneic PBSCT.
~Patients again undergo restaging of the disease 80-90 days later. Patients with progressive disease are removed from the study. Patients without progressive disease can proceed to maintenance therapy."
11641429|NCT00217438|Active Comparator|Arm II (low dose melphalan, amifostine trihydrate, transplant)|"INDUCTION THERAPY:
~Patients receive amifostine as in arm I and melphalan as in arm I at a lower dose.
~AUTOLOGOUS OR SYNGENEIC PBSCT: At least 20 hours after completion of melphalan, patients undergo autologous or syngeneic PBSCT on day 0.
~Patients undergo restaging of the disease between days 80-90. Patients with progressive disease are removed from the study. Patients who achieve a CR or near-CR can proceed to optional maintenance therapy. Patients who do not achieve a CR or near-CR may undergo additional induction therapy as in arm I followed by a second autologous or syngeneic PBSCT.
~Patients again undergo restaging of the disease 80-90 days later. Patients with progressive disease are removed from the study. Patients without progressive disease can proceed to maintenance therapy."
11641430|NCT00217425|Experimental|Treatment (A-CHOP followed by MA)|Patients receive 6-8 cycles of bevacizumab and combination chemotherapy comprising cyclophosphamide, doxorubicin, vincristine, and prednisone (A-CHOP) followed by 8 cycles of maintenance bevacizumab (MA), as outlined below. Bevacizumab 15 mg/kg is administered on day 1 over 90 min (first cycle), 60 min (second cycle) and 30 min for the subsequent cycles. CHOP (cyclophosphamide 750 mg/m 2 ; doxorubicin 50 mg/m 2 ; vincristine 1.4 mg/m2 [max. 2 mg]; prednisone 100 mg daily on days 1-5) is administered on day 1 of a 21-day cycle. Radiographic response is assessed after cycles 3, 6 and 8 of ACHOP and after cycle 8 of MA. Patients receive six cycles of ACHOP if they achieve a complete response (CR) after three cycles, eight cycles if they achieve a partial response (PR) after three cycles. Non-responders are removed from the study. ACHOP responders receive maintenance bevacizumab 15 mg/kg every 21 days for eight cycles.
11641431|NCT00217412|Experimental|Arm I|Group 1 (solid tumor or lymphoma patients): Patients receive oral SAHA once daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients may be treated at the MTD.
11641432|NCT00217412|Experimental|Arm II|Group 2 (leukemia patients): Patients receive SAHA as in group 1 at the MTD.
11641433|NCT00217412|Experimental|Arm III|Group 3 (select solid tumor patients): Patients receive oral isotretinoin twice daily on days 1-14. Patients also receive SAHA once daily on days 1-28 OR once on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.The MTD of SAHA is determined as in group 1. An additional 6 patients may be treated at the MTD.
11641434|NCT00217399|Experimental|Treatment|"PHASE I: Patients receive oral sorafenib twice daily and oral anastrozole once daily on days 1-28.
~Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of sorafenib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD.
~PHASE II: Patients receive sorafenib at the MTD and anastrozole as in phase I."
11641435|NCT00217373|Experimental|Arm I|"COURSE I: Patients receive recombinant vaccinia-CEA(6D)-TRICOM vaccine SC on day 1. Patients also receive sargramostim (GM-CSF) SC on days 1-4 and IFN-α-2b* SC on days 9, 11, and 13.
~COURSES II-IV: Patients receive recombinant fowlpox-CEA(6D)-TRICOM vaccine SC on day 1. Patients also receive GM-CSF as in course 1 and IFN-α-2b* SC on days 1, 3, and 5.
~NOTE: *The initial cohort of 6 patients does not receive IFN-α-2b.
~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients who do not have progressive disease or unacceptable toxicity may receive recombinant fowlpox-CEA (6D)-TRICOM vaccine, GM-CSF, and IFN-α-2b every 28 days for 2 more courses and then every 3 months for up to 2 years."
11641436|NCT00217308|Experimental|Lactobacillus|
11641437|NCT00217308|Placebo Comparator|Placebo capsules|
11641438|NCT00217269|Experimental|1|Endeavor Drug Eluting Stent
11641439|NCT00217269|Active Comparator|2|Taxus Drug Eluting Stent
11641440|NCT00217256|Experimental|1|Endeavor Drug Eluting Stent
11641441|NCT00217256|Active Comparator|2|Cypher Drug Eluting Stent
11641442|NCT00217243||Pain study Netherlands|20 healthy subjects 20 patients with a traumatic unilateral peripheral nerve injury 20 patients with CRPS I
11641443|NCT00217217|Experimental|Active EEP-MRSI treatment|20 minutes of active treatment with theEcho-Planar Magnetic Resonance Imaging (EP-MRSI)
11641444|NCT00217217|Sham Comparator|Sham comparator EP-MRSI|Sham treatment (20 minutes) with the Echo-Planar Magnetic Resonance Imaging (EP-MRSI).
11641445|NCT00217165|Placebo Comparator|placebo|cellulose
11641446|NCT00217165|Active Comparator|active drug|taurine
11641447|NCT00217100|Active Comparator|Multi Vitamin Formulation|
11641448|NCT00217100|Placebo Comparator|Sugar pill|
11641449|NCT00217087|Other|Endoscopic Mucosal Resection|Patients will undergo endoscopic mucosal resection at time of endoscopy if indicated.
11641450|NCT00217087|Other|Photodynamic Therapy|Patients will have endoscopic mucosal resection with photodynamic therapy.
11641451|NCT00217022|Active Comparator|Budesonide|9 mg daily
11641452|NCT00217022|Placebo Comparator|Placebo|three tablets daily
11641453|NCT00217009|Active Comparator|Narrowband Ultraviolet B (TL-01UVB) Therapy|treatments - 3x weekly for 15 months
11641454|NCT00217009|Active Comparator|Topical Psoralen plus ultraviolet A (PUVA)|Treatments - 3x weekly for 15 months
11641455|NCT00216996||Burn patients|Receiving standard TPN with or without glutamine enrichment
11641458|NCT00216983||3|We wull evaluate the rate of proline de novo synthesis from glutamate or ornithine in burn patients when the patients are receiving regular TPN or TPN depleted proline-arginine-glutamate.
11641459|NCT00216970|No Intervention|1|"Patients will receive nutritional support in which the contents of arginine = 0, glutamate = 0 and proline = 0.
~Stable isotope tracer studies will be conducted to investigate the whole body protein metabolism and the utilization of arginine in critically ill burn patients."
11641460|NCT00216970|No Intervention|2|In arm 2 patients will receive nutritional support which will provide glutamine 0.5g/kg/day. Stable isotope tracer studies will be conducted to investigate the whole body protein metabolism and the utilization of arginine in critically ill burn patients.
11641461|NCT00216944|Active Comparator|1|Premedication with atropine and morphine
11641462|NCT00216944|Active Comparator|2|Premedication with glycopyrronium, thiopental, suxamethonium and remifentanil
11641463|NCT00216853||Patients with Recurrent UTI|
11641464|NCT00216853||Healthy controls|
11641465|NCT00216749||Cilostazol|Cilostazol Treatment Patients who were in stable states after the occurrence of cerebral infarction (except cardiogenic cerebral embolism)
11641466|NCT00216736|Placebo Comparator|1|This group received intravenous phenothiazine treatment for migraine (dosing at physician discretion) plus placebo. Patients and clinicians were blinded.
11641467|NCT00216736|Experimental|2|This group received intravenous phenothiazine migraine treatment (dosage at physician discretion) plus oral dexamethasone 8mg at time of emergency department discharge. Patients and clinicians were blinded.
11641468|NCT00216710|Experimental|Home Visited Mothers|Mothers randomized to the home visited group received AK State-funded home visiting services. Frequency of home visits was determined by home visiting staff based on mothers' needs. Mothers could receive home visiting services until their child turned 3 years old
11641469|NCT00216710|No Intervention|Control Mothers|Mothers randomized to the control group did not receive home visiting services, but were offered referrals to other community-based services, as was usual protocol with home visiting agencies were operating at capacity.
11641470|NCT00216671|Experimental|001|early initiation of treatment with Risperdal Consta 25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at baseline. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
11641471|NCT00216671|Active Comparator|002|routine initiation of treatment with Risperdal Consta 25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at week 12. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
11641472|NCT00216619|Experimental|Open Label Phase|Topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening. Until Week 26
11641473|NCT00216619|Experimental|Double Blind and Roll Out Phase|the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26).
11641474|NCT00216580|Experimental|Risperidone, long-acting injectable|
11641475|NCT00216476|Experimental|001|Risperidone Long Acting Injectable (LAI) 25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.
11641476|NCT00216476|Active Comparator|002|Quetiapine Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
11641477|NCT00216476|Other|003|Aripiprazole 10-30 mg oral once daily for 104 weeks
11641478|NCT00216463|Experimental|A|Slow load with every other week maintenance
11641479|NCT00216463|Experimental|B|Slow load with every other week maintenance
11641480|NCT00216463|Experimental|C|No load; once weekly maintenance
11641481|NCT00216463|Experimental|D|No load; once weekly maintenance
11641482|NCT00216463|Experimental|E|No load; once weekly maintenance
11641483|NCT00216411|Experimental|Dysport|
11641484|NCT00216411|Placebo Comparator|Placebo|
11641485|NCT00216372|Experimental|1|
11641486|NCT00216372|Placebo Comparator|2|
11641487|NCT00216320|Experimental|WalkAide|Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
11641488|NCT00216320|Active Comparator|Ankle Foot Orthosis|Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
11641489|NCT00216320|Other|No Crossover|Subjects wear AFO for entire 12 weeks with no crossover
11641490|NCT00216281|Active Comparator|clozapine with AZT added|Clozapine augmented with Atomoxitine up to 40mg
11641491|NCT00216281|Placebo Comparator|placebo|Subjects will have a placebo pill added to their clozapine regimen.
11641492|NCT00216255|Experimental|Pagoclone|.15mg, .30mg, .60mg
11641493|NCT00216255|Placebo Comparator|Placebo|Placebo
11641494|NCT00216216|Active Comparator|1|Pemetrexed for patients with chemosensitive and chemoresistant relapsed small cell lung cancer.
11641495|NCT00216203|Experimental|Investigational Treatment|Pemetrexed + cetuximab for patients with recurrent non-small cell lung cancer.
11641496|NCT00216190|Experimental|Dexmedetomidine|
11641497|NCT00216190|Active Comparator|Midazolam|
11641498|NCT00216164|Experimental|1|Rituximab + Gemcitabine for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
11641499|NCT00216151|Active Comparator|A|Patients will be randomly assigned by study number to receive 4mg of zoledronic acid every three months.
11641500|NCT00216151|No Intervention|B|Patients will be randomly assigned by study number to observation only.
11641501|NCT00216138|Active Comparator|1|Docetaxel + Capecitabine
11641502|NCT00216125|Other|Pre-Randomization|Prior to randomization patients received Cisplatin 50 mg/m^2 days 1,8,29,36 + Etoposide 50 mg/m^2 days 1-5, 29-33 + Radiation 5940 cGy (180 cGy/day). Patients with CR, PR or SD with manageable toxicity were randomized to either Docetaxel arm or Observation only arm.
11641503|NCT00216125|Active Comparator|Consolidation Docetaxel|Docetaxel 75 mg/m^2 q3wk X 3 cycles.
11641504|NCT00216125|No Intervention|Observation Only|Patients were followed for Observation.
11641506|NCT00216099|Experimental|Investigational Treatment|"Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
~Oral Folic Acid, once per day for 7 days preceding pemetrexed dose, continued daily, and for 21 days after the last dose of pemetrexed.
~Vitamin B12, 1000ug intramuscular injection 7 days preceding pemetrexed dose, and every three cycles thereafter on the same day of pemetrexed administration"
11641507|NCT00216086|Experimental|Investigational Treatment|"Irinotecan 200 mg/m2 IV, day 1
~Capecitabine 1000* mg/m2 po bid day 1-14; repeat every three weeks for two cycles
~For calculated creatinine clearance of 30-50 mL/min or patients > 70 years old, capecitabine starting dose is 825 mg/m2 po bid
~EUS
~Neoadjuvant Chemotherapy
~Preoperative Radiation
~Surgery
~Adjuvant Chemotherapy (at discretion of treating physician)"
11641508|NCT00216073|Active Comparator|1|Capecitabine + Oxaliplatin + trastuzumab. Patients must be HER2 positive.
11641509|NCT00216060|Experimental|Experimental Arm|Daily oral risedronate combined with androgen deprivation
11641510|NCT00216060|Placebo Comparator|Placebo Arm|daily oral placebo combined with androgen deprivation
11641511|NCT00216047|Experimental|Single Group Assignment|Trastuzumab + PTK787 for HER2 positive patients
11641512|NCT00216034|Active Comparator|1|TS-1 Group: The group treated with TS-1 mono-therapy
11641513|NCT00216034|Experimental|2|TS-1+PSK Group: The group treated with combination therapy using TS-1 and PSK
11641514|NCT00216021|Experimental|Single Group Assignment|Capecitabine + Oxaliplatin
11641515|NCT00215995|Experimental|Cisplatin, Irinotecan and ZD1839|As outlined in Detailed Description.
11641516|NCT00215982|Experimental|Combination Therapy|Capecitabine in Combination with Irinotecan and Oxaliplatin
11641517|NCT00215956|Experimental|Dose Escalation and Radiation, Followed by Surgery|Preoperative treatment with radiation and oral topotecan for up to 5 weeks, followed by surgery.
11641518|NCT00215943|Active Comparator|VAD Treatment|"VAD (vincristine, adriamycin, dexamethasone). Vincristine and adriamycin was administered by continuous infusion via a venous catheter for 96 hours every 28 days. Each 28 days is considered one cycle of therapy. Patients were to receive 4 to 6 cycles of therapy. Dexamethasone was taken in pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4. Patients were randomized to receive zoledronic acid IV on either Day 1 or 15 of each cycle."
11641519|NCT00215943|Active Comparator|Thalidomide and Dexamethasone Treatment|Thalidomide was taken orally once every day in the evening for four to six months. The dexamethasone was taken in a pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4.
11641520|NCT00215930|Experimental|Double Agent Chemotherapy|Molecular Analysis-Directed Chemotherapy Assignment based on gene expression of ERCC1 and RRM1.
11641521|NCT00215904|Placebo Comparator|1|
11641522|NCT00215904|Experimental|2|
11641523|NCT00215878|Placebo Comparator|1|Adjuvant 6 weeks treatment with placebo (~2g /day)
11641524|NCT00215878|Experimental|2|Adjuvant 6 weeks treatment with D-serine (~2g /day)
11641525|NCT00215852|Active Comparator|1|500 IU
11641526|NCT00215852|Active Comparator|2|1000 IU
11641527|NCT00215852|Active Comparator|3|2000 IU
11641528|NCT00215826|Active Comparator|1|650 IU
11641529|NCT00215826|Active Comparator|2|1300 IU
11641530|NCT00215774|No Intervention|No antiarrhythmic treatment|Control group
11641531|NCT00215774|Experimental|B-Flecainide treatment|4 weeks treatment with flecainide
11641532|NCT00215774|Experimental|C-Flecainide treatment|6 months flecainide treatment
11641533|NCT00215735|Experimental|APC Treatment|wound debridement and treatment with APC
11641534|NCT00215683|Experimental|Degarelix 80 mg|Participants who completed the CS12 study in the Degarelix 80 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
11641535|NCT00215683|Experimental|Degarelix 120 mg|Participants who completed the CS12 study in the Degarelix 120 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
11641536|NCT00215683|Experimental|Degarelix 160 mg|Participants who completed the CS12 study in the Degarelix 160 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
11641537|NCT00215657|Experimental|Degarelix 120 mg (20 mg/mL)|Degarelix 120 mg (20 mg/mL)
11641538|NCT00215657|Experimental|Degarelix 120 mg (40 mg/mL)|Degarelix 120 mg (40 mg/mL)
11641539|NCT00215657|Experimental|Degarelix 160 mg (40 mg/mL)|Degarelix 160 mg (40 mg/mL)
11641540|NCT00215657|Experimental|Degarelix 200 mg (40 mg/mL)|Degarelix 200 mg (40 mg/mL)
11641541|NCT00215657|Experimental|Degarelix 200 mg (60 mg/mL)|Degarelix 200 mg (60 mg/mL)
11641542|NCT00215657|Experimental|Degarelix 240 mg (40 mg/mL)|Degarelix 240 mg (40 mg/mL)
11641543|NCT00215657|Experimental|Degarelix 240 mg (60 mg/mL)|Degarelix 240 mg (60 mg/mL)
11641544|NCT00215657|Experimental|Degarelix 320 mg (60 mg/mL)|Degarelix 320 mg (60 mg/mL)
11641545|NCT00215644|Experimental|Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab|
11641546|NCT00215644|Active Comparator|ECX Only|
11641547|NCT00215618|Experimental|1|Uterine Balloon Therapy with post procedure curettage
11641548|NCT00215618|Experimental|2|Uterine Balloon Therapy without post-procedure curettage
11641549|NCT00215605|Experimental|1|
11641550|NCT00215553|Experimental|A.1 Lucinactant|3 30-mL aliquots per bronchopulmonary segment using concentrations of 5, 5, and 10 mg/mL total phopholipids. One re-treatment at 48 hours.
11641551|NCT00215553|Experimental|A.2 Lucinactant|3 30-mL aliquots per bronchopulmonary segment using concentrations of 10, 10, and 10 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
11641552|NCT00215553|Experimental|A.3 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
11641553|NCT00215553|Experimental|A.4 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids (TPL). One re-treatment at 48 hours. One bolus re-treatment (20 mg/mL TPL) in another 48 hours. A second bolus re-treatment (20 mg/mL TPL) administered 48 hours later.
11641622|NCT00214331||3|gentamicin
11641554|NCT00215553|Experimental|B.1 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids. One lavage re-treatment at 48 hours.
11641555|NCT00215553|Experimental|B.2 Lucinactant|2 50-mL aliquots per bronchopulmonary segment using concentrations of 10 and 20 mg/mL total phospholipids (TPL). One re-treatment at 48 hours. One bolus re-treatment (20 mg/mL TPL) in another 48 hours. A second bolus re-treatment (20 mg/mL TPL) administered 48 hours later.
11641556|NCT00215553|Other|B.3 SoC|Received standard ARDS management and ICU care (Standard of Care [SOC]). Included, but was not limited to, support with oxygen, conventional mechanical ventilation, sedations, and paralysis.
11641557|NCT00215540|Experimental|SURFAXIN High Dose|SURFAXIN (lucinactant) at 175 mg/kg
11641558|NCT00215540|Experimental|SURFAXIN Low Dose|SURFAXIN (lucinactant) at 90 mg/kg
11641559|NCT00215540|Placebo Comparator|Placebo|Sham air using 3.0 mL/kg volume of air
11641560|NCT00215527|Experimental|intrathecal laronidase|laronidase dose 1.74 mg, route intrathecal, frequency every 30 days, duration three months
11641561|NCT00215514|Experimental|ECF followed by 5-FU/RT followed by ECF|
11641562|NCT00215501|Experimental|Group A|Oral capecitabine
11641563|NCT00215501|Experimental|Group B|5-fluorouracil
11641564|NCT00215332||Training- CHARITE|Non-Randomized Training (TDR with CHARITE)
11641565|NCT00215332||CHARITE|Randomized Subjects treated by Lumbar Total Disc Replacment with CHARITE
11641566|NCT00215332||Control|Randomized Subjects treated by ALIF with BAK cage
11641567|NCT00215319|Experimental|TSM Cage|Lumbar I/F with cage and pedicle screws
11641568|NCT00215306|Experimental|Lumbar TDR|CHARITÉ Artificial Disc
11641569|NCT00215306|Active Comparator|ALIF|Anterior Interbody Fusion with BAK Cage
11641570|NCT00215293|Experimental|Cervical Cage|Cervical I/F Cage
11641571|NCT00215293|Active Comparator|Graft Spacer|Autograft or allograft with a plate, or autograft alone.
11641572|NCT00215150|Other|Open Label Treatment|8 weeks of open label treatment with sertraline
11641573|NCT00215150|Other|Randomization Ziprasidone|8 weeks of treatment with sertraline augmented with ziprasidone
11641574|NCT00215150|Other|Randomization Placebo|8 weeks of treatment with sertraline augmented by placebo
11641575|NCT00215137|Experimental|Open Label Escitalopram 10-20 mg/daily|Fourteen patients who met criteria for the study were enrolled in the open-label phase. Thirteen of these patients completed the open-label phase, while one patient was terminated early due to side effects.
11641576|NCT00215137|Placebo Comparator|Randomizationn Placebo 10-20 mg daily|Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I < 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).
11641577|NCT00215137|Active Comparator|Randomization Escitalopram 10-20 mg/daily|Of the thirteen patients who completed the open label part of the trial, twelve demonstrated at least minimal improvement (CGI-I < 3) and agreed to continue with the randomized, double-blind phase. These patients were randomized to escitalopram (n=5) or placebo (n=7).
11641578|NCT00215111|Experimental|Low carbohydrate, reduced glycemic load, control diet|
11641579|NCT00215046|Experimental|Drug|no randomization, all patients receive experimental drugs
11641580|NCT00214968|Experimental|Modafinil|Subjects began taking Provigil at a dosage of 100 mg/day (1 tablet) and increased their dosage by 100 mg/day each week for up to 4 weeks
11641581|NCT00214916|Active Comparator|A|conventional insulin therapy (using Actrapid IV)
11641582|NCT00214916|Experimental|B|intensive insulin therapy (using actrapid IV)
11641583|NCT00214903||1|New users of oral continuous combined HRT containing drospirenone
11641584|NCT00214903||2|New users of oral continuous combined HRT containing other progestagens
11641585|NCT00214890|Active Comparator|Tenofovir|As part of this study visit, you participants will be assigned by chance to receive either TDF alone or ABC alone
11641586|NCT00214890|Active Comparator|Abacavir|As part of this study visit, you participants will be assigned by chance to receive either TDF alone or ABC alone
11641587|NCT00214825|Experimental|1|MR antagonist (Eplerenone) + placebo
11641588|NCT00214825|Placebo Comparator|2|Hydrochlorothiazide plus potassium
11641589|NCT00214786|Experimental|Islet Cell Transplantation|Allogenic islet cell transplantation
11641590|NCT00214773||Observational|No intervention. This is an observational program.
11641591|NCT00214760|Experimental|PGET|
11641592|NCT00214760|Active Comparator|PMMA|
11641593|NCT00214682|Experimental|Folic acid (400mcg) + Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
11641594|NCT00214682|Experimental|Mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
11641623|NCT00214305|Experimental|Range of Motion Therapy Program|The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
11641696|NCT00212797|Experimental|Org 34517_1|low dose Org 34517
11641595|NCT00214682|Experimental|Mental health literacy|This MHL intervention comprised 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
11641596|NCT00214682|Placebo Comparator|Placebo tablet|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
11641597|NCT00214682|Active Comparator|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
11641598|NCT00214682|Active Comparator|Pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
11641599|NCT00214669|Experimental|1|"Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.
~Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Lorig's chronic disease self-management programme.
~Improved follow-up in primary care through appointment-booking by the specialist nurse."
11641600|NCT00214669|No Intervention|2|Usual Care
11641601|NCT00214539|Experimental|Treatment|Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
11641602|NCT00214539|Active Comparator|Control|Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
11641603|NCT00214526|Experimental|Alair Group|Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
11641604|NCT00214526|Active Comparator|Control Group|Conventional therapy with ICS+LABA.
11641605|NCT00214500|Experimental|Migalastat|"Migalastat was administered orally during the 12-week treatment period and then during the optional 2 treatment extension periods.
~Treatment Period:
~Migalastat 25 mg BID for Weeks 1 and 2 (Day 1 through the morning dose on Day 14).
~Migalastat 100 mg BID for Weeks 3 and 4 (Day 15 through the morning dose on Day 28).
~Migalastat 250 mg BID for Weeks 5 and 6 (Day 29 through the morning dose on Day 42).
~Migalastat 25 mg BID for Weeks 6 to 12 (Days 43 to 84).
~Extension Period:
~Migalastat 25 mg BID for Weeks 12 through 48.
~Migalastat 50 mg QD for Weeks 48 through 96."
11641606|NCT00214487|Experimental|Bifocal Contact Lenses|Use of bifocal contact lenses to control the progression of myopia
11641607|NCT00214487|Placebo Comparator|Control|Single vision soft contact lenses
11641608|NCT00214474|Active Comparator|ATSM Intervention|ATSM Intervention: Automated Telephone Self-Management Support
11641609|NCT00214474|Active Comparator|GMV Intervention|GMV Intervention: Group Medical Visits
11641610|NCT00214474|No Intervention|Usual Care|Usual Care: Standard care for diabetic patients
11641611|NCT00214461|Placebo Comparator|Placebo Vaccine Group|Participants will receive a dose of vaccine diluent (placebo) on Days 0, 28 and 56, respectively.
11641612|NCT00214461|Experimental|Low Dose Vaccine Group|Participants will receive a dose of vaccine containing of 2 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
11641613|NCT00214461|Experimental|Medium dose vaccine group|Participants will receive a dose of vaccine containing of 10 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
11641614|NCT00214461|Experimental|High dose vaccine group|Participants will receive a dose of vaccine containing of 50 µg Clostridium Difficile toxoid on Days 0, 28 and 56, respectively.
11641615|NCT00214422|Experimental|Arm 1- 5040cGy to the lymph nodes|5040Gray (cGy) to the lymph nodes
11641616|NCT00214422|Experimental|Arm 2 - 5400cGy to the lymph nodes|5400Gray (cGy) to the lymph nodes
11641617|NCT00214422|Experimental|Arm 3 - 5900cGy to the lymph nodes|5900Gray (cGy) to the lymph nodes
11641618|NCT00214383|Experimental|CHESS + Case Mgt|Case Management (with monthly support calls) and CHESS services were available for a 12 month intervention period. Support calls refer to check in calls by a nurse to the parents to see how the child is doing. CHESS services include access to a website with information on asthma management, discussion groups and a case manager. The website also include a management tool for asthma symptoms check in, and the case manager used the information entered to tailor the homepage to individual clients.
11641619|NCT00214383|No Intervention|Control|Control-usual care. Usual care refers to the manner in which clients generally manage their asthma.
11641620|NCT00214331||1|ciprofloxacin
11641621|NCT00214331||2|azithromycin
11641624|NCT00214305|Placebo Comparator|Postural Sensory Therapy Program|The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
11641625|NCT00214279|No Intervention|1|Remain on 3-drug standard of care immunosuppression including prednisone
11641626|NCT00214279|Experimental|2|Corticosteroid withdrawal / prednisone taper over 14 weeks
11641627|NCT00214266|Experimental|Campath-1H Induction Therapy Combined With CellCept® Therapy|Campath-1H Induction Therapy Combined With CellCept® Therapy
11641628|NCT00214253|Experimental|1|Thiazolidinedione therapy
11641629|NCT00214253|No Intervention|2|
11641630|NCT00214240|Experimental|1|Cytogam in addition to standard of care (IV ganciclovir therapy)
11641631|NCT00214240|No Intervention|2|Receive standard of care therapy (IV ganciclovir)
11641632|NCT00214201|No Intervention|1|Standard of Care CNI immunosuppression
11641633|NCT00214201|Experimental|2|Calcineurin inhibitor withdrawal
11641634|NCT00214175||patients|patients who will receive XRT
11641635|NCT00214175||matched volunteers|Spouse or sibling
11641636|NCT00214162|Other|1|internet access and computer for 1 year
11641637|NCT00214162|Experimental|2|computer and Full CHESS
11641638|NCT00214149|Experimental|1|breast brachytherapy to a dose of 34 Gy
11641639|NCT00214136|Experimental|1|prostate radiation to 70Gy, lymph nodes to 56Gy
11641640|NCT00214123|Experimental|Bin 1|bin assignment based on tumor volume
11641641|NCT00214123|Experimental|Bin 2|Bin assignment based on tumor volume
11641642|NCT00214123|Experimental|Bin 3|Bin assignment based on tumor volume
11641643|NCT00214123|Experimental|Bin 4|Bin assignment based on tumor volume
11641644|NCT00214123|Experimental|Bin 5|Bin assignment based on tumor volume
11641645|NCT00214097|Experimental|Level 1|64.7 Gy/22 fractions of 2.94 Gy
11641646|NCT00214097|Experimental|Level 2|58.08 Gy/16 fractions of 3.63 Gy
11641647|NCT00214097|Experimental|Level 3|51.6 Gy/12 fractions of 4.3 Gy
11641648|NCT00214045|Active Comparator|Flexible Cystoscopy|Flexible Cystoscopy
11641649|NCT00214045|Active Comparator|Rigid Cystoscopy|Rigid Cystoscopy
11641650|NCT00214032|Experimental|1|pycnogenol daily
11641651|NCT00214032|Placebo Comparator|2|placebo daily
11641652|NCT00214019|Placebo Comparator|Placebo Diskus|Placebo comparator
11641653|NCT00214019|Experimental|Salmeterol Diskus 50 mcg twice per day|Salmeterol Diskus 50 mcg twice per day
11641654|NCT00214019|Experimental|Placebo diskus, fluticasone|placebo diskus, fluticasone MDI 88 mcg twice per day
11641655|NCT00214019|Experimental|Salmeterol, Fluticasone|Salmeterol diskus 50 mcg BID, fluticasone MDI 88 mcg twice per day
11641656|NCT00213993|Experimental|A|antiperspirant topically to one foot once daily
11641657|NCT00213980|No Intervention|Observation|Observation only for 12 months
11641658|NCT00213980|Active Comparator|Zoledronate|Zoledronate
11641659|NCT00213954|Other|interscalene block|Locoregional anesthesia selection
11641660|NCT00213954|Other|axillary block|Locoregional anesthesia selection
11641661|NCT00213954|Other|lumbar block|Locoregional anesthesia selection
11641662|NCT00213954|Other|parasacral plexus block|Locoregional anesthesia selection
11641663|NCT00213928|No Intervention|Control|
11641664|NCT00213928|Active Comparator|Horse Chestnut Seed Extract|Horse chestnut seed extract (escins, aesins)
11641665|NCT00213759|Active Comparator|groupe filigrastin|
11641666|NCT00213759|Placebo Comparator|groupe placebo|
11641667|NCT00213655||Daily instillation of BCG for 3 weeks then every 6 months|Effect of daily instillation of BCG (27 mg) for 3 weeks then one instillation of BCG (27 mg) every 6 months for 36 months on bladder tumor recurrence
11641668|NCT00213655||Daily instillation of BCG for 2 weeks then every 3 months|Effect of daily instillation of BCG (27 mg) for 2 weeks then one instillation of BCG (27 mg) every 3 months for 36 months on bladder tumor recurrence
11641669|NCT00213629|Other|no arm|no arm
11641670|NCT00213590|No Intervention|1|the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L
11641671|NCT00213590|Experimental|2|the low-exposure group the cyclosporine AUC0-12h target was 50% usual target or 2.2 (2.0 to 2.6, range) mg•h/L
11641672|NCT00213525||Patients With Scleroderma|Assessments of questionnary for environmental factors research
11641673|NCT00213525||Healthy Controls|Assessments of questionnary for environmental factors research
11641674|NCT00213421||1|
11641675|NCT00213421||2|
11641676|NCT00213291|Experimental|1|
11641677|NCT00213278|Experimental|1|
11641678|NCT00213265|Active Comparator|1|
11641679|NCT00213265|Experimental|2|
11641680|NCT00213252|Experimental|1|
11641681|NCT00213252|Active Comparator|2|
11641682|NCT00213239|Experimental|Propofol 4 mg/kg group|First patient in this arm will receive a bolus of propofol 4 mg/kg followed by remifentanil 0.5 mcg/kg. Subsequent patients randomized to this arm will receive propofol 4 mg/kg but the dose of remifentanil will be determined using the Dixon up-and-down method (i.e. based on the response of the previous patient)
11641683|NCT00213239|Experimental|Propofol 2 mg/kg group|First patient in this arm will receive a bolus of propofol 2 mg/kg followed by remifentanil 1 mcg/kg. Subsequent patients randomized to this arm will receive propofol 2 mg/kg but the dose of remifentanil will be determined using the Dixon up-and-down method (i.e. based on the response of the previous patient)
11641684|NCT00213148|Active Comparator|Clomiphene Citrate 50 Milligram (mg)|
11641685|NCT00213148|Active Comparator|Clomiphene Citrate 100 mg|
11641686|NCT00213148|Experimental|Anastrozole 1 mg|
11641687|NCT00213148|Experimental|Anastrozole 5 mg|
11641688|NCT00213148|Experimental|Anastrozole 10 mg|
11641689|NCT00213135|Experimental|Cladribine 5.25 mg/kg|
11641690|NCT00213135|Experimental|Cladribine 3.5 mg/kg|
11641691|NCT00213135|Placebo Comparator|Placebo|
11641692|NCT00212979||non intervention study|
11641693|NCT00212862||Patients with chemotherapy induced anemia|
11641694|NCT00212836|Experimental|Asenapine|
11641697|NCT00212797|Experimental|Org 34517_2|high dose Org 34517
11641698|NCT00212797|Placebo Comparator|Placebo|
11641699|NCT00212784|Experimental|Arm 1|
11641700|NCT00212784|Active Comparator|Arm 2|
11641701|NCT00212771|Experimental|Arm 1|
11641702|NCT00212771|Active Comparator|Arm 2|
11641703|NCT00212758|Active Comparator|Low- Standard GH dose|This arm will receive Low dose of growth hormone (GH) (Nutropin AQ), for 7 days in a cross over design. Low dose GH will be 0.025 mg/kg/day. This will be followed by 2 weeks of wash out, then subjects will receive and the standard dose of Nutropin AQ (GH) at 0.05 mg/kg/dose given subcutaneously for another 7 days. IGF-I levels are measured after 7 days of the Low and the Standard dose of GH. After that all subjects will be treated with the standard dose of GH therapy of 0.05 mg/kg/day for 6 months and re-evaluated. If growth is adequate then subjects will continue on standard dose of GH for another 6 months for a total of 12 months.
11641704|NCT00212758|Active Comparator|Standard-Low GH dose (7 Days)|This arm will receive Standard dose of growth hormone (GH) (Nutropin AQ), for 7 days in a cross over design. Standard dose GH will be 0.5 mg/kg/day. This will be followed by 2 weeks of wash out, then subjects will receive and the Low dose of Nutropin AQ (GH) at 0.025 mg/kg/dose given subcutaneously for another 7 days. IGF-I levels are measured after 7 days of the Low and the Standard dose of GH. After that all subjects will be treated with the standard dose of GH therapy of 0.05 mg/kg/day for 6 months and re-evaluated. If growth is adequate then subjects will continue on standard dose of GH for another 6 months for a total of 12 months.
11641705|NCT00212745|No Intervention|2|Receives only EEG and questionnaire testing, no behavioral intervention or meditative relaxation
11641706|NCT00212745|Experimental|1|Andrews/Reiter behavioral treatment for epilepsy and EEG and questionnaire testing
11641707|NCT00212615|Active Comparator|A|Standard XELOX
11641708|NCT00212615|Active Comparator|B|Chronomodulated XELOX
11641709|NCT00212576|Experimental|Building Blocks (0-3)|"Randomized at birth to receive Building Blocks Project from birth through 3 years of age.
~Note: This arm not followed past 3 years of age; NOT re-randomized to any group at age 3."
11641710|NCT00212576|Experimental|VIP (0-3), VIP (3-5)|"Randomized at birth to receive Video Interaction Project from birth through 3 years of age.
~Re-randomized at 3 years to receive Video Interaction Project from 3-5 years of age."
11641711|NCT00212576|Experimental|VIP (0-3), Control (3-5)|"Randomized at birth to receive Video Interaction Project from birth through 3 years of age.
~Re-randomized at 3 years to receive care as usual (control) from 3-5 years of age."
11641712|NCT00212576|Experimental|Control (0-3), VIP (3-5)|"Randomized at birth to receive care as usual (control) from birth through 3 years of age.
~Re-randomized at 3 years to receive Video Interaction Project from 3-5 years of age."
11641713|NCT00212576|No Intervention|Control (0-3), Control (3-5)|"Randomized at birth to receive care as usual (control) from birth through 3 years of age.
~Re-randomized at 3 years to receive receive care as usual (control) from 3-5 years of age."
11641714|NCT00212550||TB diagnosis|
11641715|NCT00212498||TB diagnosis|
11641716|NCT00212472|Active Comparator|1|Low-dose treatment (50 FVIII u/kg three times a week).
11641717|NCT00212472|Active Comparator|2|High-dose treatment (200 FVIII u/kg per day).
11641718|NCT00212459|Experimental|1|Patients are contacted every two weeks after initial counseling to discuss completion of bleeding records.
11641719|NCT00212459|Active Comparator|2|After the initial counseling with regards to bleeding records, there are no more contacts made with the control patients.
11641720|NCT00212446|Experimental|Electrical Intervention|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
11641721|NCT00212407|Experimental|Umbilical cord blood unit(s) transplant|Transplantation of cryopreserved umbilical cord blood unit(s)
11641722|NCT00212381|Experimental|oral DIM (Active agent)|2mg/kg/day po of DIM
11641723|NCT00212381|Active Comparator|Red rice bran (Placebo)|this agent is not generally thought to be active but may be
11641724|NCT00212355|Experimental|NPC-02|zinc acetate
11641725|NCT00212342|Experimental|Norethisterone,Ethinylestradiol|
11641726|NCT00212342|Placebo Comparator|Sugar pill|
11641727|NCT00212303|Experimental|Exercise training|Exercise training, 3 times per week, for 6 months.
11641728|NCT00212303|No Intervention|Control|Usual care no active exercise intervention
11641729|NCT00212264|Experimental|Behavioral Therapy|Behavioral Therapy (Pelvic floor muscle training, bladder control strategies)
11641730|NCT00212264|Experimental|Behavioral Therapy Plus Technologies|Behavioral therapy plus technologies (home pelvic floor electrical stimulation and biofeedback)
11641731|NCT00212264|Placebo Comparator|Placebo Comparator|No treatment control
11641732|NCT00212251|Experimental|Lifestyle counseling|10 ActiveMoms classes, 8 Moms Time Out nutrition classes, 6 coaching calls, supportive materials
11641733|NCT00212212|Experimental|1|200 µg selenium as selenate
11641734|NCT00212212|Experimental|2|400 µg selenium as selenate
11641735|NCT00212212|Experimental|3|200 µg selenium as selenomethionine
11641736|NCT00212212|Placebo Comparator|4|placebo tablet
11641737|NCT00212160|Experimental|RYGB with omentectomy|Subjects undergoing RYGB will be randomized to also have the greater omentum removed at the time of surgery.
11641738|NCT00212160|No Intervention|RYGB without omentectomy|Subjects undergoing RYGB will be randomized to NOT have the greater omentum removed at the time of surgery.
11641739|NCT00212160|No Intervention|Normal body weight|Healthy normal weight subjects studied via hyperinsulinemic-euglycemic clamp to obtain reference values for insulin sensitivity and other metabolic parameters.
11641740|NCT00212160|No Intervention|Tissue samples|Tissue samples (omental fat, subcutaneous fat, muscle,and blood)are obtained from subjects of varying weights during abdominal surgery in order to compare various parameters, including inflammation, oxidative stress, and gene expression, among tissues across weight classes.
11641741|NCT00212147|Active Comparator|I|General anesthesia that includes nitrous oxide
11641742|NCT00212147|Active Comparator|II|General anesthesia not including nitrous oxide
11641743|NCT00212134|Active Comparator|aphakic contact lens|"Contact lens correction of aphakia
~INTERVENTION: use of an external contact lens (CL) to correct the large hyperopic refractive error produced by surgically extracting the natural cataractous lens. As the eye grows, the refractive error changes and the power of the CL can be changed accordingly."
11641744|NCT00212134|Experimental|aphakic intraocular lens|"Intraocular lens implantation
~INTERVENTION: At the time of surgery to remove the cataractous natural lens, an intraocular lens was implanted to correct the large hyperopic refractive error induced by the cataract surgery."
11641745|NCT00212121|Active Comparator|1|low dose boost (16 Gy)
11641746|NCT00212121|Experimental|2|high boost (26 Gy)
11641747|NCT00212108|Experimental|Celecoxib and ZD1839|Celecoxib and ZD1839 will be given twice a day and daily respectively for two consecutive weeks prior to further anti-cancer treatment.
11641748|NCT00212095|Experimental|docetaxel and ketoconazole|
11641749|NCT00212056|Active Comparator|ANP|
11641750|NCT00212056|Placebo Comparator|Control|
11641751|NCT00212030|Active Comparator|1|
11641752|NCT00212030|Placebo Comparator|2|
11641753|NCT00212017|Active Comparator|the voglibose group|Participants in the voglibose group were administered a voglibose tablet (0.2 mg) three times daily before meals.
11641754|NCT00212017|Active Comparator|the control group|Participants assigned to the control group were treated only with diet and exercise therapy.
11641755|NCT00212004|Active Comparator|Pioglitazone|Participants in the pioglitazone group were administered a pioglitazone tablet (15 mg) once a day. In the event of the side effects such as oedema, the dosage of pioglitazone was reduced to half or a quarter of the original dosage. Otherwise, we tried to increase the dose of pioglitazone to 30mg/day.
11641756|NCT00212004|Active Comparator|Control|Participants assigned to Control group were treated with diet and exercise therapy or sulfonylurea (SU) or other additional drugs than pioglitazone.
11641757|NCT00211978|Experimental|PhosLo|
11641758|NCT00211978|Placebo Comparator|placebo|
11641759|NCT00211965|Experimental|vaccine|single dose
11641760|NCT00211965|Placebo Comparator|placebo|single dose
11641761|NCT00211939|Experimental|1|PhosLo + atorvastatin
11641762|NCT00211939|Active Comparator|2|Sevelamer + atorvastatin
11641763|NCT00211926|Experimental|StaphVAX|
11641764|NCT00211926|Placebo Comparator|Placebo|
11641765|NCT00211913|Experimental|vaccine|single dose of StaphVAX®
11641766|NCT00211913|Placebo Comparator|placebo|single dose
11641767|NCT00211900|Experimental|vaccine|single dose of StaphVAX in hemodialysis patients
11641768|NCT00211887|Active Comparator|Interferon beta 1-a|"Active Interferon B1a Weekly vs. Placebo Glatiramer Acetate
~Interferon b-1a (IFN) intramuscularly weekly"
11641769|NCT00211887|Active Comparator|glatiramer acetate|"Placebo Interferon B1a Weekly vs. Active Glatiramer Acetate
~Glatiramer acetate 20mg daily"
11641770|NCT00211887|Active Comparator|IFN and GA|Active Interferon B1a Weekly and Active Glatiramer Acetate
11641771|NCT00211874|Experimental|Nurse-management|nurse-led intervention focused on specific management problems
11641772|NCT00211874|No Intervention|Usual Care|Usual care as control group
11641773|NCT00211835|Experimental|Treatment Arm 1|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
11641774|NCT00211835|Experimental|Treatment Arm 2|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
11641775|NCT00211822||Pathologic Gamblers|
11641776|NCT00211822||Obsessive Compulsive Disorder|
11641777|NCT00211822||Healthy Controls|
11641778|NCT00211809|Experimental|Body dysmorphic disorder|Participants with body dysmorphic disorder
11641779|NCT00211783||Autism|
11641780|NCT00211783||Control|
11641781|NCT00211757|Placebo Comparator|Placebo|Subjects in this arm will receive a placebo comparative to the study drug divalproex sodium.
11641782|NCT00211757|Experimental|Divalproex Sodium|Subjects will receive the study drug, divalproex sodium.
11641783|NCT00211692|Active Comparator|Group A consensus interferon+rbv 52 wks|Daily CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given 52 weeks (group A)
11641784|NCT00211692|Experimental|Group B CIFN variable duration|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for 52-72 weeks (from time of viral response +48 weeks) (group B)
11641785|NCT00211562|Active Comparator|Olanzapine|
11641786|NCT00211562|Active Comparator|Omega 3|
11641787|NCT00211562|Active Comparator|Vitamin E +C|
11641788|NCT00211536|Experimental|MiniMed Implantable insulin Pump (MIP)|The experimental group will receive intraperitoneally (IP) delivered insulin via the Medtronic MiniMed Implantable Pump (MIP). At the time of implant, the pump will be filled with Aventis HOE21PH U400 insulin and the subject will be treated with this insulin for the first 180 days post implant. During the refill procedure performed 180 days post implant, any insulin remaining in the pump will be removed and the pump will be refilled with Medtronic MiniMed Implantable Pump Human Recombinant Insulin.
11641789|NCT00211536|No Intervention|Subcutaneous insulin arm (SC)|The control group will remain on their current pre-study subcutaneous insulin therapy of either Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII - external insulin pump). The SC group will not be restricted to the type of insulin used, or be required to change or modify their current diabetes therapy for the purpose of the study.
11641790|NCT00211510|Experimental|Paradigm 722 sensor augmented pump|subjects will use the Paradigm 722 sensor augmented pump for infusion of insulin and continuous glucose monitoring
11641791|NCT00211510|Active Comparator|Paradigm 715 insulin pump|subjects will use the Paradigm 715 insulin pump which does not include sensor augmentation for infusion of insulin
11641792|NCT00211432|Experimental|Title: Treatment of Pseudovitellium Detachment|Open-Label Anecortave Acetate Sterile Suspension(15mg)
11641793|NCT00211393|Experimental|Drug: ketoconazole|"Drug: ketoconazole
~Other Names:
~ketoconazole
~600mg. /day for 6 weeks
~--------------------------------------------------------------------------------"
11641794|NCT00211354|Experimental|anecortave acetate|anecortave acetate 15 mg. juxtascleral injection every 6 months for 24 months
11641795|NCT00211263|Experimental|Enhanced Clinical Intervention|
11641796|NCT00211263|Active Comparator|Clinical Intervention|
11641797|NCT00211237|Experimental|Balloon Kyphoplasty (BKP)|The subjects assigned to this group will undergo the treatment with Balloon kyphoplasty for their painful VCFs.
11641798|NCT00211237|Active Comparator|Non Surgical Management|The subjects in this group will undergo the non-operative treatments aimed at alleviation of back pain and restoration of decreased function associated with VCFs.
11641799|NCT00211185|Experimental|Denileukin diftitox in combination with CHOP|Unblinded denileukin diftitox at 18 micrograms/kilogram/day (ug/kg/d) was administered intravenously (IV) on Days 1 and 2 of each 21-day cycle. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) was administered on Day 3 of each 21-day cycle. On Day 4 of each 21-day cycle, pegfilgrastim (a granulocyte colony-stimulating factor (G-CSF)) was started as a prophylaxis to prevent neutropenia. After completion of two 21-day cycles, participants were evaluated for clinical response. Two 21-day cycles with denileukin and CHOP were repeated followed by response evaluations after each set of two 21-day cycles with intent to treat for 6 cycles, with a maximum of 8 cycles.
11641800|NCT00211172|Experimental|Beta-blocker adherence after an AMI|Patients received two mailings about the importance of beta blocker use.
11641801|NCT00211172|No Intervention|Usual care|Patients received usual care.
11641802|NCT00211081|Experimental|Open Label|
11641803|NCT00211068||Epoetin alfa|Four control patients will be matched to each index patients enrolled in protocol EPO-IMU-301 identified as having chronic kidney disease and an immune-mediated cause of pure red cell aplasia (PRCA) indicated by the presence of anti-erythropoietin (EPO) antibodies in their serum at the time of loss of efficacy.
11641804|NCT00211042||Pure Red Cell Aplasia (PRCA)|This study will examine the relationship of the presence of anti-erythropoietin antibodies to the clinical course and outcome of participants currently or previously treated with recombinant human erythropoietin and who have PRCA identified from all notified reports (spontaneous postmarketing reports or from clinical trials reports).
11641805|NCT00211029||Participants Receiving Epoetin Alfa or Another Erythropoietin|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
11641806|NCT00210977||Erythropoietin receptor agonist|Participants with borderline serum anti erythropoietin (EPO) antibody (Ab) titers and who are treated with any erythropoietin receptor agonist (ERA) for any indication, having anti-EPO Ab identified by radioimmunoprecipitation (RIP), who are responding to ERA therapy, will be included in the study.
11641807|NCT00210964|Experimental|001|ceftobiprole plus placebo ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
11641808|NCT00210964|Active Comparator|002|linezolid plus ceftazidime linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
11641809|NCT00210951||Participants Receiving Epoetin Alfa or Another Erythropoietin|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
11641810|NCT00210899|Active Comparator|Vancomycin plus Ceftazidime|Vancomycin 1g q12h as 1h infusions plus Ceftazidime 1g q8h in 2h-infusions, 7-14d
11641811|NCT00210899|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d
11641812|NCT00210678||Group: 1|Men with premature ejaculation (PE)
11641813|NCT00210678||Group: 2|Men without PE
11641814|NCT00210652|Experimental|001|RWJ 333369: Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
11641815|NCT00210639||Levofloxacin-treated cohort|Participants receiveing levofloxacin in previous levofloxacin studies will be observed.
11641816|NCT00210639||Comparator-treated cohort|Participants receiveing comparator in previous levofloxacin studies will be observed.
11641817|NCT00210626|Active Comparator|PROCRIT|
11641818|NCT00210626|Placebo Comparator|Placebo|
11641819|NCT00210522|Experimental|001|RWJ 333369 Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
11641820|NCT00210470|Experimental|IRX-2 Regimen|The IRX-2 regimen is the combination of a 2-week course of IRX-2 itself, an initial dose of cyclophosphamide, and a 3-week course of indomethacin and zinc supplementation.
11641821|NCT00210418|Experimental|Preventive targeting|This arm targeted pregnant and lactating women as well as children 6-23.9 months of age to receive BCC and food assistance. A total of 27 months of enrollment in this program arm was possible.
11641822|NCT00210418|Active Comparator|Recuperative targeting|This arm targeted pregnant and lactating women as well as mothers of malnourished children (WAZ <-2 zscores) between 6 and 59 months of age. A total of 18 months of enrollment was possible in this program arm.
11641823|NCT00210405|Active Comparator|Food aid only|Children in this arm received fortified food aid commodities supplied through the maternal and child health and nutrition program implemented by World Vision. They received fortified corn-soy blend, which contained iron.
11641824|NCT00210405|Experimental|Micronutrient sprinkles + food aid|Children in this arm were enrolled in the food assisted program, and therefore received fortified food aid, as well as 60 sachets of a multiple micronutrient powder (Sprinkles) containing iron, zinc, vitamin A, vitamin C and folic acid
11641825|NCT00210353|Active Comparator|ARM A|chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment; two weeks rest; chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)
11641826|NCT00210353|Experimental|ARM B|rituximab 375 mg/m2 iv, d1, d8, d15, d22 chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment two weeks rest chlorambucil 6 mg/m2 os daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle
11641827|NCT00210353|Experimental|ARM C (Since April 2006)|rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140
11641828|NCT00210314|Active Comparator|High-dose methotrexate alone|
11641829|NCT00210314|Experimental|High-dose methotrexate associated with high dose cytarabine|
11641830|NCT00210275|No Intervention|Control|Usual practice; no additional information provided.
11641831|NCT00210275|Experimental|Printed Educational Message #1|Information about Angiotensin-converting enzyme inhibitors, hypertension treatment, and cholesterol lowering agents for diabetes
11641832|NCT00210275|Experimental|Printed Educational Message #2|Retinal screening for diabetes
11641833|NCT00210275|Experimental|Printed Educational Message #3|Diuretics for hypertension
11641834|NCT00210132|Experimental|Ropivacaine|
11641835|NCT00209898|Active Comparator|Rapid standard of care|Rapid standard of care treatment after screening
11641836|NCT00209898|Active Comparator|Ordinary standard of care|Subject put on ordinary waiting list for hcv treatment in Our outpatient clinic
11641837|NCT00209807|Experimental|1|subjects with MDD randomized to Escitalopram
11641838|NCT00209807|Active Comparator|2|MDD patients receiving reboxetine
11641839|NCT00209807|Other|3|Healthy volonteers
11641840|NCT00209742|Experimental|2|
11641841|NCT00209742|Experimental|3|
11641842|NCT00209742|Active Comparator|1|
11641843|NCT00209729|Experimental|1|Docetaxel plus S-1
11641844|NCT00209716|Experimental|1|
11641845|NCT00209690|Experimental|1|
11641846|NCT00209651|Experimental|1|Irinotecan and S-1
11641847|NCT00209612|Experimental|1|Paclitaxel+Irinotecan
11641848|NCT00209521|Experimental|fospropofol|
11641849|NCT00209521|Active Comparator|propofol|
11641850|NCT00209495|Placebo Comparator|A|
11641851|NCT00209495|Experimental|B|Pregabalin
11641852|NCT00209495|Experimental|C|Pregabalin + dexamethasone
11641853|NCT00209443|Experimental|Gadodiamide Injection|All subjects received a single intravenous bolus injection via a power injector of Omniscan (Gadodiamide Injection) at a dose of 0.1 mmol/kg
11641854|NCT00209417|Active Comparator|Iodixanol 320-Arm 1|Iodixanol 320 mg I/mL
11641855|NCT00209417|Active Comparator|Iopamidol 300-Arm 2|Iopamidol 300 mg I/mL
11641856|NCT00209391|Experimental|Gadodiamide Injection|All subjects will receive a single intravenous bolus injection via a power injector of Omniscan (Gadodiamide injection) at a dose of 0.1 mmol/kg.
11641857|NCT00209378|Active Comparator|heparin|Citrate regional anticoagulation is compared with standard systemic heparinization.
11641858|NCT00209378|Active Comparator|Citrate|regional anticoagulation with citrate containing replacement solution
11641859|NCT00209339|Experimental|MitraClip|Percutaneous mitral valve repair (MitraClip Implant)
11641860|NCT00209313|Other|1|Acyclovir 800 mg twice daily for 8 weeks, two week washout, 8 weeks placebo
11641861|NCT00209313|Other|2|8 weeks placebo, 2 week washout, 8 weeks 800 mg acyclovir twice daily
11641862|NCT00209274|Experimental|1|Percutaneous mitral valve repair using MitraClip implant. The calculated sample size was 186 patients in the device arm
11641863|NCT00209274|Active Comparator|2|Mitral valve repair or replacement surgery. The calculated sample size was 93 patients in the control arm.
11641864|NCT00209261|Active Comparator|1|
11641865|NCT00209261|Active Comparator|2|
11641866|NCT00209235|Experimental|AHO:neurocognitive and pyschosocial|Neurocognitive and psychosocial testing
11641867|NCT00209222|Active Comparator|1|induction: R-CHOP consoldiation : TBI/Cyclo
11641868|NCT00209222|Experimental|2|induction: R-CHOP/DHAP consolditaion: TBI/TAM
11641869|NCT00209209|Active Comparator|1|"randomisation: R-CHOP
~randomisation: IFN maintenance"
11641870|NCT00209209|Experimental|2|"randomisation: R-FC
~randomisation: Rituximab maintnenance"
11641871|NCT00209196||pediatric solid organ transplants|Adherence to medical regimens refers to what degree a patient chooses to follow the advice given by his/her healthcare provider.More recently, researchers have started to look at adherence with children who have undergone solid organ transplantation. This is because about 50% of these children are to some degree non-adherent with their medical regimen. This comes at a costly price as ongoing non-adherence in pediatric transplant can lead to the child's body rejecting the new organ and even death. This study has been designed to look at the reasons that pediatric patients may choose to be non-adherent.
11641872|NCT00209170|Experimental|Beating the Blues CBT + Escitalopram|Subjects with type 2 diabetes will be randomized to Beating the Blues (computerized cognitive behavioral therapy) with the selective serotonin reuptake inhibitor (SSRI) antidepressant, escitalopram (10 mg taken orally once or twice daily) for 6 months
11641873|NCT00209170|Active Comparator|Beating the Blues CBT + Placebo|Subjects with type 2 diabetes will be randomized to Beating the Blues (computerized cognitive behavioral therapy) with placebo (taken orally one to two tablets daily) for 6 months
11641874|NCT00209144|Experimental|Angioplasty with Insulin|Coming in with acute infarct and received angioplasty with intensive insulin therapy
11641875|NCT00209144|No Intervention|Angioplasty w/o Insulin|Coming in with acute infarct and received angioplasty
11641876|NCT00209131|Experimental|Flomax|Patients on this arm will be given 0.4mg of Flomax to be taken for one month following their shock wave lithotripsy procedure.
11641877|NCT00209131|Placebo Comparator|Sugar pill|Patients on this arm will be given a sugar pill to be taken for one month following their shock wave lithotripsy procedure.
11641878|NCT00209105||1|Participants who have experienced early-life trauma will undergo a series of diagnostic tests.
11641879|NCT00209092|Active Comparator|Sequential Therapy|Docetaxel will be given at 100mg/m^2 intravenous Day 1 every 3 weeks for 4 cycles followed by capecitabine 1000 mg/m^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) (total 24 weeks).
11641880|NCT00209092|Active Comparator|Concurrent Therapy|Docetaxel will be given at 50mg/m^2 Intravenous Day1 concomitantly with capecitabine 1000 mg/m^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
11641881|NCT00209079|Active Comparator|1|
11641882|NCT00209053|Experimental|Off Pump CABG|CABG without cardiopulmonary bypass.
11641883|NCT00209053|Active Comparator|On-Pump CABG|CABG with cardiopulmonary bypass.
11641884|NCT00209040|Experimental|1|Subjects with posttraumatic stress disorder
11641885|NCT00209040|Active Comparator|2|Healthy controls
11641886|NCT00209040|Active Comparator|3|Combat controls
11641887|NCT00209027|Experimental|schizophrenia subjects|Patients to be switched from baseline medication to aripiprazole, and fMRI measured at baseline and after med switch.
11641888|NCT00209001|Sham Comparator|Sham acupuncture therapy|Sham acupuncture therapy
11641889|NCT00209001|Active Comparator|Acupuncture|Acupuncture
11641890|NCT00209001|No Intervention|Observation|Observation
11641891|NCT00208975|Active Comparator|Fludarabine and Mitoxantrome followed by GM-CSF and Rituximab|"Initial patients (n=9) received fludarabine (25 mg/m2 IV) and mitoxantrone (10 mg/m2 IV)with sequential administration of GM-CSF (500 mcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m2) on day 8.
~After a change in the protocol, all additional patients (n=6) received fludarabine (25 mg/m2 IV) and cyclophosphamide (250 mg/m2 IV)with sequential administration of GM-CSF (500 mcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m2) on day 8. All patients received dditional doses of GM-CSF (days +8 through +14) were given for patients to reduce variability in neutropenic management."
11641892|NCT00208962|Active Comparator|1|
11641893|NCT00208949|Active Comparator|G-CSF(Granulocyte Colony-Stimulating Factor )|Single use of G-CSF(Granulocyte Colony-Stimulating Factor ) G-CSF 7.5 µg/kg twice a day
11641894|NCT00208949|Active Comparator|Granulocyte CSF+Granulocyte Macrophage CSF|Combined use of G-CSF(Granulocyte Colony-Stimulating Factor ) and GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) (G-CSF 7.5 µg/kg / GM-CSF 7.5 µg/kg.)
11641895|NCT00208923|Active Comparator|1|Chemotherapy-only conditioning regimen comprising busulfan (Bu), cyclophosphamide (Cy) and fludarabine (FLUDARA) followed by an allogeneic stem cell transplant.
11641896|NCT00208845||adult ED patients|
11641897|NCT00208806||congenital heart patients with congestive heart failure|20 effected patients with congestive heart failure patients total 50 patients
11641898|NCT00208793|Experimental|Calcium|Calcium 2,000 mg/day as calcium carbonate in two divided doses with food
11641899|NCT00208793|Experimental|Vitamin D3|Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
11641900|NCT00208793|Experimental|Calcium and vitamin D3 combined|Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with meals over 6 months
11641901|NCT00208793|Placebo Comparator|Placebo|
11641902|NCT00208780|Experimental|Dose-response of oral BH4|Eight subjects received 100 mg of oral BH4 twice a day and 8 received 200 mg twice daily.
11641903|NCT00208780|Experimental|Onset & duration of action of oral BH4|Eight hypertensive subjects were assigned to either 5 mg kg-1 day-1 (n=4) or 10 mg kg-1 day-1 (n=4) of BH4, given in two divided doses orally for 8 weeks.
11641904|NCT00208767|Active Comparator|Valsartan|Valsartan titrated up to 320 mg orally daily
11641905|NCT00208767|Placebo Comparator|Placebo|Patients received a placebo instead of Valsartan
11641906|NCT00208702|Experimental|sertraline + triiodothyronine|
11641907|NCT00208702|Placebo Comparator|sertraline + placebo|
11641908|NCT00208611|Experimental|Open-Label Treatment|Levodopa-treated Parkinson's Disease subjects with vitamin B12 < 200 pg/ml given oral vitamin B12 supplement
11641909|NCT00208559|Other|1 Open Label|Open Label
11641910|NCT00208546|Experimental|1Capecitabine + bevacizumab + oxaliplatin + cetuximab|
11641911|NCT00208546|Active Comparator|21Capecitabine + bevacizumab + oxaliplatin|
11641912|NCT00208533|Other|1 Open Label|Open Label Aripiprazole
11641913|NCT00208507|Active Comparator|Delta Ceramax Ceramic-on-Ceramic Acetabular Cup System|Total hip replacement with a 28 mm ceramic head and liner.
11641914|NCT00208507|Active Comparator|Pinnacle™ Acetabular Cup with Marathon® Polyethylene|Total hip replacement with 28 mm ceramic head with a polyethylene liner.
11641915|NCT00208494|Active Comparator|A|Ceramic-on-metal total hip implant
11641916|NCT00208494|Active Comparator|B|Metal-on-metal total hip implant
11641917|NCT00208468|Other|European Hip|A cementless femoral component for use in total hip replacement
11641918|NCT00208468|Active Comparator|Zweymüller|A cementless femoral component for use in total hip replacement
11641919|NCT00208468|Active Comparator|CLS Spotorno|A cementless femoral component for use in total hip replacement
11641920|NCT00208455|Other|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
11641921|NCT00208442|Active Comparator|Marathon™|Moderately cross-linked polyethylene liner in a modular acetabular component
11641922|NCT00208442|Active Comparator|Enduron™|Standard UHMWPE polyethylene liner in a modular acetabular component
11641923|NCT00208429|Other|Pinnacle Acetabular System|
11641924|NCT00208416|Active Comparator|1|DePuy MI System
11641925|NCT00208416|Active Comparator|2|Conventional surgical technique
11641926|NCT00208403|Active Comparator|1|Acryloc™ GHV
11641927|NCT00208403|Active Comparator|2|Palacos R
11641928|NCT00208390|Other|Summit Tapered Hip System|A cementless, tapered femoral component for use in total hip replacement
11641929|NCT00208377|Other|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
11641930|NCT00208364|Other|Pinnacle Acetabular Cup System|A cementless acetabular cup with metal liner for use in total hip replacement
11641931|NCT00208351|Active Comparator|1) Ultima LX Collared Stem - Non-Polished/Blasted Finished|A collared non-polished blasted finished cementless femoral component for use in total hip replacement.
11641932|NCT00208351|Active Comparator|2) Ultima LX Collared Stem - Polished Finished|A collared polished finished cementless femoral component for use in total hip replacement.
11641933|NCT00208351|Active Comparator|3) Ultima LX Collarless Stem - Non-Polished/Blasted Finished|A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
11641934|NCT00208351|Active Comparator|4) Ultima LX Collarless Stem - Polished Finished|A collarless polished finished cementless femoral component for use in total hip replacement.
11642055|NCT00206544|Active Comparator|1|Tamoxifen 40 mg daily
11641935|NCT00208338|Experimental|1|Rotator cuff repair with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
11641936|NCT00208338|Active Comparator|2|Standard rotator cuff repair
11641937|NCT00208325|Other|PFC Sigma Fixed Bearing PCL Sacrificed|PFC Sigma Fixed Bearing Total Knee System with PCL Sacrificed
11641938|NCT00208325|Active Comparator|PFC Sigma RP PCL Sacrificed|PFC Sigma Rotating Platform Total Knee System with PCL Sacrificed
11641939|NCT00208325|Other|PFC Sigma Fixed Bearing PCL Retained|PFC Sigma Fixed Bearing Total Knee System with PCL Retained
11641940|NCT00208325|Active Comparator|PFC Sigma RP PCL Retained|PFC Sigma Rotating Platform Total Knee System with PCL Retained
11641941|NCT00208312|Experimental|1|Regadenoson
11641942|NCT00208312|Active Comparator|2|Adenoscan
11641943|NCT00208299|Experimental|1|Regadenoson
11641944|NCT00208299|Active Comparator|2|Adenoscan
11641945|NCT00208286|Other|PFC Sigma Fixed Bearing|PFC Sigma Fixed Bearing system for use in total knee arthroplasty
11641946|NCT00208286|Active Comparator|PFC Sigma Mobile Bearing|PFC Sigma Mobile Bearing system for use in total knee arthroplasty
11641947|NCT00208273|Experimental|A|Letrozole 2.5 mg daily for 5 years started three weeks before the first day of adjuvant radiotherapy.
11641948|NCT00208273|Experimental|B|Letrozole 2.5 mg daily for 5 years started three weeks after the last day of adjuvant radiotherapy.
11641949|NCT00208260|Active Comparator|A|FOLFIRI
11641950|NCT00208260|Active Comparator|B|FOLFOX-4
11641951|NCT00208260|Experimental|C|FOLFIRI-HD
11641952|NCT00208260|Experimental|D|FOLFOX-7
11641953|NCT00208260|Experimental|E|FOLFIRINOX
11641954|NCT00208247|Experimental|CBT|The cognitive behavioural treatment developed by Salkovskis, Warwick and co-workers was used, with adaptations for the specific setting.
11641955|NCT00208247|Experimental|STPP|The short-term psychodynamic psychotherapy (STPP).
11641956|NCT00208247|Experimental|Waiting List|Patients in the waiting-list group were asked to keep in touch with their GP, who had been informed of the trial in writing. The patients and their GPs were instructed not to begin any other treatment during the study period. After 6 months, the patients on the waiting list were re-evaluated for inclusion and exclusion criteria and, if they still met the criteria, re-randomized to CBT or STPP.
11641957|NCT00208234|Placebo Comparator|Control|Placebo
11641958|NCT00208234|Experimental|2|Omalizumab
11641959|NCT00208169|Experimental|1|Aripiprazole start dose at 5 mg/day by day 4-6 increase to 10 mg/da and day 7 and subsequent visits flexible dosing from 10 up to 30 mg/day.
11641960|NCT00208156|Experimental|mifepristone|
11641961|NCT00208117|Active Comparator|1|Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If AEs occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained. The psychiatry fellow will be responsible for drug administration and will see all patients weekly. All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess medical tolerance to the study medications, and ensure patient psychiatric safety. The study psychiatrist will be blinded to treatment allocation.
11641962|NCT00208117|Placebo Comparator|2|To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills. All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess the medical tolerance to the study medications (including placebo), and ensure patient psychiatric safety. The study psychiatrist will be blinded to treatment allocation.
11641963|NCT00208104|Experimental|Motivational Interview Condition|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
11641964|NCT00208104|No Intervention|Non-supportive Counseling|A non-supportive counseling session will consist of regular nurse-patient interaction.
11641965|NCT00208091|Experimental|Botulinum toxin, type B|Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
11641966|NCT00208078|No Intervention|Usual medical therapy|Usual CF care
11641967|NCT00208078|Experimental|Non-invasive ventilation|Pressure support ventilator (SAIME,AIROX)
11641968|NCT00208026|Experimental|Pimecrolimus 1% Cream|Treatment with drug/Elidel. Single arm-open-label treatment arm. A Pilot Study of the Efficacy and Safety of Pimecrolimus Cream 1% for the Treatment of Netherton Syndrome:
11641969|NCT00207948||Therapeutic Dose Adjustment|To adjust the doses of medications to meet target therapeutic concentrations
11641970|NCT00207883||Landmark|Procedure/Surgery: Use of landmarks for central line placement
11641971|NCT00207883||Ultrasound guided|Procedure/Surgery: Use of ultrasound for central line placement
11641972|NCT00207857||With and Without PFTs|
11641973|NCT00207831|Experimental|Tegafur uracile + radiotherapy|
11641974|NCT00207831|Active Comparator|radiotherapy|
11641975|NCT00207740|Experimental|CNTO 148 (golimumab)|
11641976|NCT00207740|Placebo Comparator|Placebo|
11641977|NCT00207714|Experimental|Golimumab (CNTO 148) with Methotrexate (MTX)|
11641978|NCT00207714|Experimental|Infliximab with MTX|
11641979|NCT00207714|Placebo Comparator|Placebo with MTX|
11641980|NCT00207688||Infliximab 5 mg/kg|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
11641981|NCT00207688||Infliximab 10 mg/kg|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
11641982|NCT00207688||Placebo|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
11641983|NCT00207441|Experimental|Arthritis self management program|
11641984|NCT00207441|Experimental|Chronic Disease Self Management Program|
11641985|NCT00207402|Active Comparator|rosiglitazone|Treatment with rosiglitazone 4 mg twice a day for 3 months prior to and during the course of 48 weeks of treatment with interferon alfacon-1 15mcg/0.5ml SQ daily and weight-based ribavirin.
11641986|NCT00207402|No Intervention|No Avandia|Monitoring period without rosiglitazone for 3 months prior to 48 weeks of interferon alfacon-1 15mcg/0.5ml SQ daily and weight-based ribavirin
11641987|NCT00207389||Laparoscopic gastric bypass|Patients undergoing Laparoscopic gastric bypass
11641988|NCT00207389||Open gastric bypass|Patients undergoing Open gastric bypass
11641989|NCT00207363|Experimental|Initial induction therapy|Receive Peg Intron 3.0mcg/kg/wk for 12 weeks followed by Peg Intron 1.5 mcg/kg/wk for 36 weeks
11641990|NCT00207363|Active Comparator|Standard of Care|Peg Inter 1.5mcg/kg/wk for 48 weeks
11641991|NCT00207350|Other|Brain tumor|Neurosurgical use of Interstitial Laser therapy
11641992|NCT00207311|Placebo Comparator|Xenical placebo|Xenical placebo PO three times daily with meals plus enrollment into the Xenicare program for 36 weeks followed by 48 weeks of therapy with Pegasys (180mcg/ml) plus weight based ribavirin for HCV genotype 1 or 4 and 24 weeks of therapy with Pegasys (180mcg/ml) plus 800mg ribavirin for HCV genotypes 2 and 3.
11641993|NCT00207311|Active Comparator|Xenical (orlistat)|Xenical (orlistat) 120mg PO three times daily with meals plus enrollment into the Xenicare program for 36 weeks followed by 48 weeks of therapy with Pegasys (180mcg/ml) plus weight based ribavirin for HCV genotype 1 or 4 and 24 weeks of therapy with Pegasys (180mcg/ml) plus 800mg ribavirin for HCV genotypes 2 and 3.
11641994|NCT00207285|Other|In Person Training|These firefighters received the sleep education and sleep disorders screening in person by one of our research staff.
11641995|NCT00207285|Other|Train the Trainer|These firefighters received the education and sleep disorder screening in person with someone taught by our research staff.
11641996|NCT00207285|Other|Online Group|These firefighters took the sleep disorder screening and education online.
11641997|NCT00207259|No Intervention|Control|Standard weekly treatments with radiation oncologist and nurse. All control patients offered intervention at end of 8-week course of radiotherapy.
11641998|NCT00207259|Experimental|Relaxation Therapy|Weekly relaxation therapy with PhD psychologist and home cognitive restructering practice
11641999|NCT00207259|Experimental|Reiki|Weekly Reiki therapy with a Reiki therapist, involves laying of the therapist's hands on the patient to rechannel energy, considered pleasant and calming
11642000|NCT00207233|Active Comparator|1|Will receive MCT study oil to supplement into liquid meal replacements.
11642001|NCT00207233|Placebo Comparator|2|Will receive LCT oil to supplement into their liquid meal replacements.
11642002|NCT00207220||3|subjects with heart failure and normal ejection fraction non-diabetic hypertensive controls hypertensive diabetic controls normotensive controls
11642003|NCT00207194|Active Comparator|Automated Telephone Program|The intervention was a totally automated, computer-based, interactive telephone counseling system called Telephone- Linked-Care, designed to monitor, educate, and counsel African-American adults with hypertension and to provide summary data regularly to the patient's primary care provider.
11642004|NCT00207194|Placebo Comparator|Health Behavior Education|The comparator group received health education relating to the management of hypertension. Members of this group also received standard primary medical care.
11642005|NCT00207155|Experimental|A|
11642006|NCT00207142|Active Comparator|Switch|ATV 400 mg + 2 NRTIs (TBD), ATV once daily, NRTIs (TBD)
11642007|NCT00207142|Active Comparator|Continuation|ATV 300 mg + RTV 100 mg + 2 NRTIs (TBD), ATV and RTV once daily, NRTIs (TBD)
11642008|NCT00207142|Other|Rescue|ATV 300 mg + RTV 100 mg + 2 NRTIs (TBD), ATV and RTV once daily, NRTIs (TBD)
11642009|NCT00207129|Experimental|A|
11642010|NCT00207129|Experimental|B|
11642011|NCT00207116|Experimental|A|
11642012|NCT00207103|Experimental|1|
11642013|NCT00207103|Experimental|2|
11642014|NCT00207103|Experimental|3|
11642015|NCT00207103|Experimental|4|
11642016|NCT00207103|Experimental|5|
11642017|NCT00207103|Experimental|6|
11642018|NCT00207090|Experimental|Ixabepilone + rifampin|
11642019|NCT00207077|Experimental|A|
11642020|NCT00207064|Experimental|1|
11642021|NCT00207051|Experimental|1|
11642022|NCT00206999|Experimental|1|
11642023|NCT00206986|Experimental|1|
11642024|NCT00206986|Experimental|2|
11642025|NCT00206960|Active Comparator|1|
11642026|NCT00206960|Active Comparator|2|
11642027|NCT00206947|Active Comparator|1|
11642028|NCT00206947|Placebo Comparator|2|
11642029|NCT00206934|Placebo Comparator|1|
11642030|NCT00206934|Placebo Comparator|2|
11642031|NCT00206843|Experimental|Results available|
11642032|NCT00206843|No Intervention|Results blinded|
11642033|NCT00206830|No Intervention|Control-Blinded from Results|
11642034|NCT00206830|Experimental|Access to Results|
11642035|NCT00206752|Experimental|unilateral radiation therapy|definitive external beam radiation in the ipsilateral neck.
11642036|NCT00206726|Experimental|Alemtuzumab plus Fludarabine|Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days.
11642037|NCT00206713|Experimental|Arm 1|
11642038|NCT00206713|Placebo Comparator|Arm 2|
11642039|NCT00206700|Experimental|Arm 1|
11642040|NCT00206687|Experimental|Arm 1|
11642041|NCT00206687|Sham Comparator|Arm 2|
11642042|NCT00206674|Experimental|Arm 1|
11642043|NCT00206674|Placebo Comparator|Arm 2|
11642044|NCT00206661|Experimental|Arm 1|
11642045|NCT00206661|Experimental|Arm 2|
11642046|NCT00206648|Experimental|Arm 1|
11642047|NCT00206648|Active Comparator|Arm 2|
11642048|NCT00206635||Group 1|
11642049|NCT00206622|Active Comparator|Arm 1|
11642050|NCT00206622|Active Comparator|Arm 2|
11642051|NCT00206622|Placebo Comparator|Arm 3|
11642052|NCT00206596|Experimental|Arm 1|
11642053|NCT00206596|Placebo Comparator|Arm 2|
11642054|NCT00206583|Experimental|EV/DNG (Qlaira, BAY86-5027)|Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral)
11642056|NCT00206544|Active Comparator|2|Progesterone 20 mg daily
11642057|NCT00206544|Placebo Comparator|3|Placebo daily
11642058|NCT00206518|Experimental|A: Taxotere/Docetaxel|Chemotherapy In Arm A, patients will receive single agent Taxotere (100 mg/m2) every 3 weeks for 4 cycles before surgery. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. This will be followed by standard adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles. For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. This is done in order to minimize Adriamycin-induced cardiotoxicity.
11642059|NCT00206518|Experimental|B: AC Adriamycin/Cytoxan|In Arm B, patients will receive AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery. For patients whose BSA is greater than 2.0 m2, the Adriamycin dosage will be calculated using BSA = 2.0 m2. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. This will be followed by 4 cycles of single agent Taxotere (100 mg/m2) every 3 weeks.
11642060|NCT00206492|Experimental|Iressa and Tamoxifen|Iressa and Tamoxifen
11642061|NCT00206466|Active Comparator|One|Taxotere
11642062|NCT00206440|Experimental|Esomeprazole|Patients receiving chemotherapy (anthracycline-based) will be randomized to esomeprazole for Cycle 1 Days 1-5 and Cycle 2 Days 1-5
11642063|NCT00206440|Placebo Comparator|Sugar pill|Subjects will be given placebo Cycle 1 Days 1-5 and Cycle 2 Days 1-5.
11642064|NCT00206427|Experimental|Intervention|Intervention/Lapatinib (GW572016)
11642065|NCT00206414|Experimental|Iressa Day 1 with Arimidex and Faslodex|Subjects randomized to Iressa on Day 1 in combination with Arimidex and Faslodex.
11642066|NCT00206414|Active Comparator|Iressa Day 21 with Arimidex and Faslodex|Subjects randomized to Iressa Day 21 in combination with Arimidex and Faslodex
11642067|NCT00206388|Experimental|Zolendric acid with Cyclophosphamide|Zometa will be administered intravenously every 28 days beginning on day 0. Cyclophosphamide will be administered daily without interruption (unless toxicity supervenes) beginning day 0. Each course of therapy will be 28 days. On day 0 of each cycle, cyclophosphamide should be given first, followed by Zometa with a separation between the two drugs of at least one hour. All patients are required to take calcium and Vitamin D supplementation for the duration of study participation.
11642068|NCT00206375|No Intervention|1|Group 1 will be treated only with Synthroid.
11642069|NCT00206375|Experimental|2|Group 2 will be treated with Growth hormone, synthroid, and lupron.
11642070|NCT00206375|No Intervention|3|Group 3 will have acute hypothyroidism and will serve as controls.
11642071|NCT00206336|Experimental|topiramate|Topiramate open label
11642072|NCT00206323|Placebo Comparator|placebo/sugar pill|Placebo or sugar pill
11642073|NCT00206323|Active Comparator|Topiramate|Topiramate 25 mg to 200 mg
11642074|NCT00206232|Active Comparator|Spironolactone|Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.
11642075|NCT00206232|Placebo Comparator|Placebo|Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.
11642076|NCT00206102|Experimental|1|Quetiapine fumarate
11642077|NCT00206102|Active Comparator|2|Risperidone
11642078|NCT00206076|Experimental|1|mycophenolate mofetil monotherapy
11642079|NCT00206076|Active Comparator|2|mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
11642080|NCT00206011|Experimental|1|
11642081|NCT00206011|Other|2|
11642082|NCT00205946|Placebo Comparator|Placebo|
11642083|NCT00205946|Active Comparator|Bupropion|
11642084|NCT00205920|Experimental|single|BLVR Treatment
11642085|NCT00205907|Experimental|single|BLVR treatment
11642086|NCT00205881|Active Comparator|1|Bilaterally Implanted with HiRes 90K device.
11642087|NCT00205855|Experimental|Precision SCS|Precision SCS. Patients who receive Precision Spinal Cord Stimulator (SCS) Stimulus system
11642088|NCT00205829|Experimental|Active Therapy|Occipital nerve stimulation (ONS) therapy delivered to a subject implanted with a bion ONS device
11642089|NCT00205803|Experimental|13vPnC|
11642090|NCT00205803|Active Comparator|7vPnC|
11642091|NCT00205777|Active Comparator|A|
11642092|NCT00205777|Placebo Comparator|B|
11642093|NCT00205712|Placebo Comparator|Ketamine plue saline|Ketamine without dexmedetomidine
11642094|NCT00205712|Experimental|Ketamine plus dexmedetomidine|Ketamine infusion plus dexmedetomidine
11642095|NCT00205699|Active Comparator|aripiprazole|Participants in this group will be randomized to flexibly-dosed treatment with aripiprazole.
11642096|NCT00205699|Active Comparator|olanzapine|Participants in this group will be randomized to flexibly-dosed treatment with olanzapine.
11642097|NCT00205699|Active Comparator|risperidone|Participants in this group will be randomized to flexibly-dosed treatment with risperidone.
11642098|NCT00205660|Other|Stayers|Subjects are randomized to stay on their current antipsychotic.
11642099|NCT00205660|Other|Switchers|Subjects are randomized to switch to aripiprazole from their current antipsychotic.
11642100|NCT00205569||1|Individuals with traumatic brain injury requiring inpatient rehabilitation.
11642101|NCT00205556|Other|1: low flux hemodialysis|standard treatment
11642102|NCT00205556|Active Comparator|2 on-line hemodiafiltration|
11642103|NCT00205543|Experimental|1|suture palate after resection
11642104|NCT00205543|Experimental|2|suture one side of palate afer resection
11642105|NCT00205543|Experimental|3|no sutures in palate after resection
11642106|NCT00205504|Active Comparator|Obese women with metabolic syndrome|
11642107|NCT00205504|Active Comparator|Obese women without metabolic syndrome|
11642108|NCT00205504|Active Comparator|lean women without metabolic syndrome|
11642109|NCT00205439||Fluorescence bronchosopy with sputum cytology|Patients undergo surgery with Fluorescence bronchosopy and sputum cytology.
11642110|NCT00205426|Experimental|Natrecor infusion|Nesiritide
11642171|NCT00204412|Placebo Comparator|2|placebo
11642243|NCT00203177|Experimental|Expermental 2|1.0 mg rasagiline mesylate oral once daily
11642244|NCT00203164|Experimental|rasagiline mesylate|rasagiline mesylate 1 mg oral once daily
11642245|NCT00203151|Experimental|1|
11642111|NCT00205374|Active Comparator|Cidofovir|"Cidofovir (Vistide) is a commercially available agent approved by the FDA for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). The drug is not FDA approved for the treatment of RRP at this time. However, recent case reports have been encouraging with regard to the effectiveness of the agent in the treatment of RRP. The FDA has granted this study a safe to proceed designation with IND 58,481."
11642112|NCT00205374|Placebo Comparator|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
11642113|NCT00205361||1|well-nourished
11642114|NCT00205361||2|malnourished
11642115|NCT00205335|Other|glucose monitoring|Each participant received a Bayer Breeze Monitor and glucose test strips for monitoring blood sugar.
11642116|NCT00205270||Pre-transplant Vaccine|Cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
11642117|NCT00205270||0-6 Months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine 0-6 months post transplant.
11642118|NCT00205270||13-60 months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine 13-60 months post transplant.
11642119|NCT00205270||Greater than 110 months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine greater than 110 months post transplant.
11642120|NCT00205270||Healthy Controls|Healthy controls to measure normal immune response to the influenza vaccine
11642121|NCT00205179|Experimental|Novasoy treated|100mg/day soy isoflavones
11642122|NCT00205179|Placebo Comparator|Placebo|100mg/day matching placebo
11642123|NCT00205166|Active Comparator|1|Caffeine 400 mg PO 1 hour before adenosine infusion
11642124|NCT00205166|Active Comparator|2|Caffeine 200 mg po one hour before adenosine infusion
11642125|NCT00205153|Experimental|TEAM Care|Intervention pharmacies implement 6-month TEAM program.
11642126|NCT00205153|No Intervention|Usual Care|"Control pharmacies provide usual care only."
11642127|NCT00205101||1|Triad allograft
11642128|NCT00205101||2|other anterior lumbar interbody fusion (ALIF)
11642129|NCT00205101||3|transforaminal lumbar interbody fusion (TLIF)
11642130|NCT00205101||4|posterior lumbar interbody fusion (PLIF)
11642131|NCT00205075||Case|
11642132|NCT00205075||Control|
11642133|NCT00205049|Experimental|Pentoxifylline/Placebo|All subjects will be randomized to receive either pentoxifylline 400mg orally or placebo 3 times daily for 28 days (20-40 treated, 1-20 placebo) with monthly follow up for 90 days.
11642134|NCT00205023|Experimental|A|
11642135|NCT00204997|Experimental|1|Laparoscopic Ovarian Transposition
11642136|NCT00204971|Experimental|1|Nutritional supplement
11642137|NCT00204971|Placebo Comparator|2|placebo
11642138|NCT00204932|Active Comparator|CLA treatment|The group randomized to Conjugated Linoleic Acid (CLA) treatment at 4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA; and 22% safflower oil for 6 months
11642139|NCT00204932|Placebo Comparator|Placebo|The group randomized to control received 4 g/d of safflower oil.
11642140|NCT00204919|Placebo Comparator|1|
11642141|NCT00204919|Active Comparator|2|
11642142|NCT00204893|Experimental|Open label|Each participant will be treated with three 3900 mg doses of calcium formate on each study day (i.e., days 1-14).
11642143|NCT00204867||A|In vivo surveillance of 6-9 mm polyps detected at CTC
11642144|NCT00204828||1.|Children with asthma
11642145|NCT00204828||2.|Children without asthma
11642146|NCT00204763|Active Comparator|2|Solid state catheter
11642147|NCT00204763|Experimental|A|
11642148|NCT00204750|Active Comparator|1|Bougie dilation
11642149|NCT00204750|Experimental|2|Needle-knife incision
11642150|NCT00204737|Active Comparator|Prednisone|Prednisone 20mg daily x 2 weeks
11642151|NCT00204737|Placebo Comparator|placebo|placebo
11642152|NCT00204711||Outpatient Surgery with Sedation|SNAP II EEG data will be recorded continuously during the sedation and intermittently compared to routinely monitored parameters of sedation adequacy including vital signs, patient movement, grimacing, verbal complaints, and patient responsiveness to verbal and tactile stimuli. Following surgery, patients will be questioned to determine recall or memory of discomfort.
11642153|NCT00204698|Active Comparator|1|All subjects will be given active drug.
11642154|NCT00204594|Experimental|Antibody|
11642155|NCT00204568|Active Comparator|1|Adriamycin mono
11642156|NCT00204568|Experimental|2|Trofosfamide
11642157|NCT00204542|Active Comparator|A|Solaraze(R) 2x/day for 3 months
11642158|NCT00204542|Active Comparator|B|Solaraze(R) 2x/day for 6 months
11642159|NCT00204529|Experimental|PegIFN|pegylated interferon-alpha-2a
11642160|NCT00204529|Active Comparator|IFN|interferon-alpha-2a
11642161|NCT00204516|Experimental|mRNA Vacc|
11642162|NCT00204490|Experimental|1|soy isoflavones
11642163|NCT00204490|Placebo Comparator|2|carbohydrates (maltodextrin)
11642164|NCT00204477|Active Comparator|Soy milk|Subjects will consume two soy milk drinks from the content of 2 sachets (40 g isoflavone-free soy protein and 600 mg calcium) in place of a small meal, five days per week. Each sachet will contain 20 g soy protein and 300 mg calcium. Content of sachets will be mixed with ~1.6 liter of water for ingestion.
11642165|NCT00204477|Placebo Comparator|Cow's milk|Subjects will consume two cow's milk drinks from the content of 2 sachets (40 g cow's milk protein, casein, and 600 mg calcium) in place of a small meal, five days per week. Each sachet will contain 20 g cow's milk protein and 300 mg calcium. Content of sachets will be mixed with ~1.6 liter of water for ingestion. Casein is free of ovarian hormones.
11642166|NCT00204425|Experimental|1|exercise/soy isoflavone
11642167|NCT00204425|Experimental|2|exercise/isoflavone placebo
11642168|NCT00204425|Experimental|3|exercise placebo/soy isoflavone
11642169|NCT00204425|Placebo Comparator|4|exercise placebo/isoflavone placebo
11642170|NCT00204412|Experimental|1|flax lignan
11642172|NCT00204373|Experimental|single group|This is an open label, non-randomized, uncontrolled, single group study designed to treat patients with Zollinger-Ellison Syndrome and other hypersecretory conditions by controlling gastric acid production; to heal and prevent relapses of peptic ulcers and symptoms; to monitor the safety and efficacy of this treatment.
11642173|NCT00204308|Experimental|combination tenofovir-emtricitabine|
11642174|NCT00204308|No Intervention|control arm|
11642175|NCT00204243|Experimental|Naltrexone implant|Naltrexone implant (GoMedical Inc. 6 months implant)
11642176|NCT00204243|Active Comparator|Methadone|Methadone Maintenance Treatment
11642177|NCT00204061|Placebo Comparator|supportive management|needs-focused, unspecific supportive management
11642178|NCT00204061|Experimental|amisulpride|24 months amisulpride 50 to 800 mg, needs-focused, unspecific supportive management.
11642179|NCT00204022|Experimental|1|Mycophenolate mofetil (target dose 2g/day)
11642180|NCT00204022|Active Comparator|2|Azathioprine (target dose 2mg/kg/day)
11642181|NCT00203996|No Intervention|Aim 1: Placebo|One of the 3 treatment arms in Aim 1: Placebo. No subjects were randomized to this arm.
11642182|NCT00203996|Experimental|Aim 1: Pioglitazone|One of the 3 treatment arms in Aim 1: Pioglitazone. No subjects were randomized to this arm.
11642183|NCT00203996|Experimental|Aim 1: Leuprolide + Estrogen/Progestin|One of the 3 treatment arms in Aim 1: depot leuprolide plus estrogen/progestin replacement. No subjects were randomized to this arm.
11642184|NCT00203996|Experimental|Aim 2: PCOS + SDB|One of the 2 study groups in Aim 2: Women with polycystic ovary syndrome (PCOS) and sleep disordered breathing (SDB) were treated with 8 weeks of continuous positive airway pressure (CPAP).
11642185|NCT00203996|Experimental|Aim 2: Matched Controls|One of the 2 study groups in Aim 2: Women who were of similar age to those in the PCOS+SDB group were treated with 8 weeks of continuous positive airway pressure (CPAP). The recruitment of control subjects for this protocol was hindered by the difficulty in finding subjects who met both inclusion and exclusion criteria. As a consequence, the sample size of control subjects was insufficient to allow for any meaningful conclusions to be drawn. Statistical analyses were not possible due to insufficient sample size.
11642186|NCT00203996|Experimental|Aim 3: REM frag - SWS supp - Baseline|"Each subject was assessed under three experimental conditions in the following order.
~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.
~Slow wave sleep (SWS) suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.
~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention."
11642187|NCT00203996|Experimental|Aim 3: REM frag - Baseline - SWS supp|"Each subject was assessed under three experimental conditions in the following order.
~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.
~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.
~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed."
11642188|NCT00203996|Experimental|Aim 3: Baseline - REM frag - SWS supp|"Each subject was assessed under three experimental conditions in the following order.
~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.
~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.
~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed."
11642189|NCT00203996|Experimental|Aim 3: SWS supp - REM frag - Baseline|"Each subject was assessed under three experimental conditions in the following order.
~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.
~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.
~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention."
11642190|NCT00203996|Experimental|Aim 3: Baseline - SWS supp - REM frag|"Each subject was assessed under three experimental conditions in the following order.
~Baseline: Baseline sleep (i.e., with no experimental intervention) assessment is recorded. This assessment may have been recorded as the first, second, or third intervention.
~SWS suppression: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.
~REM fragmentation: Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed."
11642191|NCT00203957|Experimental|Group A|Patients who completed double-blind treatment studies 6002-US-013, 6002-US-013, 6002-US-018 immediately prior to entering this open-label trial and may have had an interuption of study drug of 14 days or less.
11642192|NCT00203957|Experimental|Group B|Patients who previously completed double-blind treatment studies 6002-US-013, 6002-US-018 or 6002-EU-007 or discontinued from open label study 6002-US-007 and have had an interuption of study drug greater than 14 days.
11642193|NCT00203944||international adopted infants|international adoptees making their first visit to international adoption clinic
11642194|NCT00203944||Control infants|
11642195|NCT00203931|Active Comparator|Cetuximab|Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes.
11642196|NCT00203931|Experimental|Cetuximab and Pemetrexed|Cetuximab initial dosage of 400 mg/m2 over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes. Starting on day 15 and then subsequently on day 1 of each 21 day cycle, Pemetrexed 500 mg/m2.
11642197|NCT00203918||Prostate biopsies|Males undergoing prostate biopsies
11642198|NCT00203905|Active Comparator|A|Hydroxyurea at 500 mg PO q 12 hours x 6 days (11 total doses); Infusion of 5-FU (600 mg/m2/day x 5 days [120 hours]
11642199|NCT00203905|Experimental|B|Bevacizumab: 10 mg/kg will be given as a 90-minute infusion
11642241|NCT00203203|Other|Control, then Stem Cell Therapy|"Subject is randomized to receive a NOGA mapping and no injections at time of active enrollment.
~At 6 months, subject is offered stem cell therapy."
11642246|NCT00203151|Placebo Comparator|2|
11642200|NCT00203892|Experimental|A: CEA peptide 10mcg|Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
11642201|NCT00203892|Experimental|B: CEA peptide 100 mcg|Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
11642202|NCT00203892|Experimental|C: CEA peptide 1000mcg|Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
11642203|NCT00203879|Experimental|1|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
11642204|NCT00203879|Experimental|2|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 without IL-2
11642205|NCT00203788|Experimental|1|Individual Placement and Support Plus Workplace Fundamentals Module
11642206|NCT00203788|Active Comparator|2|Brokered Vocational Rehabilitation
11642207|NCT00203749|Experimental|1|Intervention communities will receive the community-based VCT intervention community mobilization, mobile VCT, and post-test support services), as well as standard clinic-based VCT
11642208|NCT00203749|Active Comparator|2|Comparison communities will receive standard clinic-based VCT
11642209|NCT00203645|Experimental|Brief self-directed treatment|self-help workbook plus motivational telephone intervention
11642210|NCT00203645|Experimental|Self-directed plus telephone support|Self-help workbook, motivational telephone intervention plus telephone booster calls
11642211|NCT00203645|Active Comparator|Workbook only|Workbook only
11642212|NCT00203645|No Intervention|Waitlist|Six week waitlist
11642213|NCT00203619|Experimental|1|Wireless capsule endoscopy
11642214|NCT00203619|Active Comparator|2|Standard care
11642215|NCT00203606|Experimental|Active Treatment|Active Treatment with Pegylated Interferon Alfa 2a (Pegasys, Roche) and ribavirin
11642216|NCT00203606|No Intervention|Observation|Observation with no active treatment for Hepatitis C. Observation period is based on standard treatment duration based on genotype of Hepatitis C. Active treatment offered to participants at conclusion of observation. (Protocol Amendment #1, October 30, 2001. Ethics approval Jan 19, 2004).
11642217|NCT00203567|Active Comparator|Equetro|Equetro
11642218|NCT00203502|Experimental|Intervention: Dtx Cyclophosphamide Bev|Docetaxel 75m/m2 Cyclophosphamide 500 mg/m2 Bevacizumab 15 mg/kg
11642219|NCT00203476|Active Comparator|Statin with Niacin|Niacin dose range of 500-1500mg (average 888mg)
11642220|NCT00203476|Active Comparator|Statin with Colestipol|Colestipol dose range 5-15gm (average 9.5gm)
11642221|NCT00203476|Active Comparator|Statin with Ezitimibe|Ezitimibe 10mg (average 10mg)
11642222|NCT00203450|Experimental|Zonegran|Zonegran
11642223|NCT00203450|Placebo Comparator|Placebo|Placebo pill
11642224|NCT00203424|Experimental|Erlotinib + Bevacizumab|Participants received Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
11642225|NCT00203411|Experimental|Bevacizumab Plus Capecitabine|Bevacizumab 7.5 mg/kg every 3 weeks will be administered interavenously (IV) to the enrolled patients. Oral capecitabine 1000 mg/m^2 twice daily for 14 days followed by 7 days off every 21 days. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of patient consent.
11642226|NCT00203385|Experimental|Divalproex|Divalproex; oral up to 2000mg/d; open label
11642227|NCT00203372|Experimental|Bevacizumab 7.5 and TAC|one dose of Bevacizumab (7.5mg/kg) will be administered intravenously every 3 weeks followed by TAC.
11642228|NCT00203372|Placebo Comparator|Placebo 7.5 and TAC|Placebo7.5 will be administered intravenously every 3 weeks followed by TAC.
11642229|NCT00203372|Experimental|Bevacizumab 15 and TAC|one dose of Bevacizumab (15mg/kg) will be administered intravenously every 3 weeks followed by TAC.
11642230|NCT00203372|Placebo Comparator|Placebo 15 and TAC|Placebo 15mg/kg will be administered intravenously every 3 weeks followed by TAC.
11642231|NCT00203307|Other|Olanzapine then Placebo|Olazepam
11642232|NCT00203307|Other|Placebo then olanzapine|
11642233|NCT00203294|Active Comparator|Lidocaine 2%, Bupivicaine 0.5% and saline|Adult patients with CDH, and headache of at least moderate intensity at time of treatment, were randomized to receive bilateral GONB and trigger point injections in the cervical paraspinal and the trapezius muscles bilaterally.
11642234|NCT00203294|Active Comparator|Lidocaine 2%, Bupivicaine 0.5% and triamcinolone 40 mg|Adult patients with CDH, and headache of at least moderate intensity at time of treatment, were randomized to receive bilateral GONB and trigger point injections in the cervical paraspinal and the trapezius muscles bilaterally.
11642235|NCT00203268|Experimental|Treatment with dihydroergotamine mesylate (DHE-45)|Subjects who treated a moderate to severe migraine 2 and 4 hours after the onset of throbbing headache pain
11642236|NCT00203242|Experimental|Depacon IV and Depakote ER|Subjects will be treated in this single arm study with 2 consecutive days of IV Depacon followed by oral Depakote ER for a total of 1000 mg of Depacon and 1000 mg of Depakote ER each day.
11642237|NCT00203229|Placebo Comparator|Placebo|Dosing Schedule Morning Evening Daily Total Week 1-2 ---- 50mg 50mg Week 3-4 50mg 50mg 100mg Week 5 100mg 100mg 200mg Week 6 150mg 150mg 300mg Week 7 200mg 200mg 400mg Week 8 (if needed for pain) 200mg 300mg 500mg Week 9 (if needed for pain) 300mg 300mg 600mg Week 10 (if needed for pain) 300mg 400mg 700mg
11642238|NCT00203229|Active Comparator|Lamotrigine|Dosing Schedule Morning Evening Daily Total Week 1-2 ---- 50mg 50mg Week 3-4 50mg 50mg 100mg Week 5 100mg 100mg 200mg Week 6 150mg 150mg 300mg Week 7 200mg 200mg 400mg Week 8 (if needed for pain) 200mg 300mg 500mg Week 9 (if needed for pain) 300mg 300mg 600mg Week 10 (if needed for pain) 300mg 400mg 700mg
11642239|NCT00203216|Experimental|Levatiracetam|Subject titrated open-label study drug to maximally tolerated dose: maximum: 3000 mg. per date. (minimum allowed daily dose to remain in study: 1000)
11642240|NCT00203203|Experimental|Stem Cell Therapy|Subject is randomized to receive Stem Cell Therapy (intramyocardial injection of stem cells) via NOGA mapping.
11642242|NCT00203177|Experimental|Experimental 1|0.5 mg rasagiline mesylate oral once daily
11642247|NCT00203112|Active Comparator|Glatiramer Acetate injection with oral minocycline|Glatiramer Acetate 20mg with oral minocycline 100mg
11642248|NCT00203112|Experimental|Glatiramer Acetate with placebo|Glatiramer acetate injection 20mg with oral placebo
11642249|NCT00203099|Active Comparator|Glatiramer Acetate, N-Acetylcysteine|
11642250|NCT00203073|Active Comparator|Copaxone 20 mg|Copaxone 20 mg
11642251|NCT00203073|Active Comparator|Copaxone 20mg with Novantrone induction|Copaxone 20mg with Novantrone induction
11642252|NCT00203060|Experimental|A|Rasagiline treatment
11642253|NCT00203060|Placebo Comparator|B|placebo arm
11642254|NCT00203047|Active Comparator|GA + Placebo|Glatiramer acetate (GA) 10mg as a subcutaneous injection daily, plus a placebo to mimic prednisone given daily.
11642255|NCT00203047|Experimental|GA + Prednisone|Glatiramer acetate (GA) 20mg daily as a subcutaneous injection, plus 1250 mg of prednisone daily.
11642256|NCT00203034|Experimental|Experimental 1|0.5 mg rasagiline mesylate oral once daily
11642257|NCT00203034|Experimental|Experimental 2|1.0 mg rasagiline mesylate oral once daily
11642258|NCT00203034|Placebo Comparator|Placebo|Placebo Comparator
11642259|NCT00203021|Experimental|Glatiramer Acetate: Delayed Start|Participants who were originally randomized to the placebo group in the 01-9001 and/or the 01-9001E studies received glatiramer acetate 20 milligrams (mg) subcutaneous (SC) injection daily at the start of this study. After 18 July 2014 (protocol amendment 12), participants were offered the opportunity to continue treatment with glatiramer acetate 20 mg daily or switch to glatiramer acetate 40 mg three times weekly (TIW). The treatment continued for up to 288 months.
11642260|NCT00203021|Experimental|Glatiramer Acetate: Early Start|Participants who were originally randomized to the glatiramer acetate 20 mg group in the 01-9001 and/or the 01-9001E studies continued to receive glatiramer acetate 20 mg SC injection daily at the start of this study. After 18 July 2014 (protocol amendment 12), participants were offered the opportunity to continue treatment with glatiramer acetate 20 mg daily or switch to glatiramer acetate 40 mg TIW. The treatment continued for up to 288 months.
11642261|NCT00203008||Observational procedure|Patients will be examined and any suspicious skin abnormalities will be biopsied
11642262|NCT00202995|Experimental|1|Glatiramer Acetate 20 mg s.c. daily
11642263|NCT00202995|Active Comparator|2|Betaseron 250 ug every other day or Rebif 44 ug 3 times a week
11642264|NCT00202982|Active Comparator|glatiramer acetate 20 mg|glatiramer acetate 20 mg
11642265|NCT00202982|Active Comparator|glatiramer acetate 40 mg|glatiramer acetate 40 mg
11642266|NCT00202969|Experimental|1|S-1
11642267|NCT00202969|Active Comparator|2|S-1 plus CDDP
11642268|NCT00202969|Active Comparator|3|5-FU plus CDDP
11642269|NCT00202904|Experimental|Arm 1|
11642270|NCT00202904|Active Comparator|Arm 2|
11642271|NCT00202878|Experimental|ezetimibe/simvastatin|One Ezetimibe 10 mg/simvastatin 40 mg combination tablet and two simvastatin 40 mg placebo tablets once per day.
11642272|NCT00202878|Active Comparator|simvastatin|One simvastatin 40 mg tablet, one ezetimibe/simvastatin combination 10/40 placebo tablet and one simvastatin 40 mg placebo tablet once per day.
11642273|NCT00202865|Experimental|1|
11642274|NCT00202865|Placebo Comparator|2|
11642275|NCT00202852|Placebo Comparator|1|
11642276|NCT00202852|Experimental|2|
11642277|NCT00202839|Experimental|24-Week Treatment|Genotype 1 hepatitis C virus [HCV] subjects treated for a total of 24 weeks, during the pilot treatment program (immediately before randomization)
11642278|NCT00202839|Active Comparator|48-Week Treatment|Genotype 1 HCV subjects treated for a total of 48 weeks: 24 weeks during the pilot treatment program (immediately before randomization) plus 24 weeks during the extended treatment program (immediately after randomization)
11642279|NCT00202787|Experimental|1|FOLFOX-4+cetuximab
11642280|NCT00202787|Active Comparator|2|FOLFOX-4
11642281|NCT00202761|Experimental|PIH|Intensified training of children with CP. Functional training (motor, speech, executive function). Coaching of parents by psychologist, individually and in groups.
11642282|NCT00202735|Active Comparator|Immobilization in internal rotation|"Immobilization in internal rotation:All patients in this group are immobilized with the arm in internal rotation.
~The arm is immobilized with a normal collar and cuff device."
11642283|NCT00202735|Experimental|Immobilization in external rotation.|Immobilization in external rotation (ER. All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling ER, 15˚ version.To control the position, a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed
11642284|NCT00202722|Active Comparator|Remifentanil IVPCA|Bolus dose steps of 0.15 microgr/kg, with a 2-min lock-out time
11642285|NCT00202709|Experimental|Thought Field Therapy (TFT)|Treatment with TFT, first one hour, then 1/2 hour.
11642286|NCT00202709|No Intervention|Wait list control|
11642287|NCT00202696|Experimental|1|Nalmefene 40 mg
11642288|NCT00202696|Experimental|2|Nalmefene 80 mg
11642289|NCT00202696|Other|3|Placebo
11642290|NCT00202670||1|SPECT
11642291|NCT00202670||2|dobutamine echocardiography
11642292|NCT00202644|Experimental|A|
11642293|NCT00202644|Active Comparator|B|
11642294|NCT00202475|Active Comparator|1|
11642295|NCT00202475|Active Comparator|2|
11642296|NCT00202449|Experimental|1|Prazosin
11642297|NCT00202449|Active Comparator|2|Paroxetine
11642298|NCT00202449|Placebo Comparator|3|Placebo
11642299|NCT00202436|Active Comparator|1|Phlebotomy
11642300|NCT00202436|Active Comparator|2|Erythrocytapheresis
11642301|NCT00202410|Placebo Comparator|physiologic solution|subcutaneous administration of physiologic solution
11642302|NCT00202410|Experimental|Bacille Calmette-Guèrin (BCG) Vaccine|Anti-Tubercular Vaccination
11642303|NCT00202397|Placebo Comparator|2|placebo bid for 8 weeks
11642304|NCT00202397|Experimental|1|Riluzole, capsule-shaped 50 mg tablets bid for 8 weeks
11642305|NCT00202358|Placebo Comparator|placebo|
11642306|NCT00202358|Experimental|atenolol|
11642307|NCT00202293|Experimental|Lithium and olanzapine|
11642308|NCT00202293|Active Comparator|Lithium and chlorpormazine|
11642309|NCT00202280|Placebo Comparator|Placebo pill|Placebo pill daily for 3 months
11642310|NCT00202280|Experimental|5mg folic acid, 0.4mg B12, 50mg B6|5mg folic acid, 0.4mg B12, 50mg B6 in one pill, daily for 3 months
11642311|NCT00202267|Active Comparator|1|Clients randomized to short-stretch bandaging application
11642312|NCT00202267|Active Comparator|2|Clients randomized to four-layer bandaging application
11642313|NCT00202228|Experimental|1|Individuals living with HIV who are naive to antiretroviral treatment, or who have been on a treatment interruption for at least six months
11642314|NCT00202228|Experimental|2|Individuals living with HIV who are on an antiretroviral regimen including one of D4T/ddI/ddC/AZT
11642315|NCT00202228|Experimental|3|Individuals living with HIV who are on an antiretroviral regimen including one of D4T/ddI/ddC/AZT and have liver disease.
11642316|NCT00202228|Experimental|4|HIV negative control group
11642317|NCT00202189|Experimental|1|Budesonide
11642318|NCT00202189|Placebo Comparator|2|Saline Solution (0.9% NaCl)
11642319|NCT00202176|Experimental|1|Ipratropium Bromide
11642320|NCT00202176|Placebo Comparator|2|Saline Solution (0.9% NaCl)
11642321|NCT00202137|Active Comparator|1|home blood pressure monitoring with automatic blood pressure device
11642322|NCT00202137|Active Comparator|2|physician monitoring of blood pressure by 3 monthly office visits
11642323|NCT00202098|Experimental|1|ALI/ARDS patients
11642324|NCT00202046||Patients with lymphedema|Identification of risk factors for lymphedema in women who have had axillary surgery for breast cancer.
11642325|NCT00202046||Control patients without lymphedema|Controls matched on type of axillary surgery and surgery date for comparison in quality of life (QOL) ratings from women who have lymphedema.
11642326|NCT00202033|Experimental|1|self monitor blood glucose 3 times a day per usual diabetes class curriculum
11642327|NCT00202033|Experimental|2|only self monitor blood glucose when fasting
11642328|NCT00202033|Experimental|3|no self monitoring of blood glucose
11642329|NCT00201981|Active Comparator|1|rebamipide 1%
11642330|NCT00201981|Active Comparator|2|Rebamipide 2%
11642331|NCT00201981|No Intervention|3|placebo
11642332|NCT00201968|Other|FES training|Arm 1 receives functional electrical stimulation while walking on body weight suspension training.
11642333|NCT00201968|Other|Control Group training|Aerobic and resistance training program
11642334|NCT00201916|Experimental|1|5250 cGy in 20 fractions over 28 days
11642335|NCT00201916|Active Comparator|2|6600 cGy in 33 fractions over 45 days
11642336|NCT00201890|Experimental|1|Standard of Care plus Lymphatic massage (Decongestive Lymphatic Therapy)
11642337|NCT00201890|No Intervention|2|Standard of Care
11642338|NCT00201877|Experimental|Velcade and Rituximab|"Rituximab 375 mg/m2 IV day 1 of weeks 4, 5, 7, 8, 10, 11, 13, and 14 prior to Velcade™ administration.
~Velcade™ 1.3 mg/m2 IV days 1 and 4 of weeks 1, 2, 4, 5, 7, 8, 10, 11, 13, and 14"
11642339|NCT00201864|Experimental|single-arm study|Combination of daily exemestane 25 mg with monthly 250 mg Fulvestrant injection
11642340|NCT00201851|Active Comparator|Immediate surgery|Patient assigned to immediate surgical oophorectomy/mastectomy and Tamoxifen
11642341|NCT00201851|Experimental|Scheduled surgery|Patient scheduled for mid-luteal phase surgical oophorectomy/mastectomy plus Tamoxifen
11642342|NCT00201851|Other|Immediate Surgery - nonrandomized|Patient in mid-luteal phase at time of enrollment. Assigned to immediate surgical oophorectomy/mastectomy plus Tamoxifen without randomization
11642343|NCT00201838|Experimental|Arm I|Patients received entanercept 25 mg subcutaneously twice weekly with gemcitabine.
11642344|NCT00201838|Active Comparator|Arm II|Patients with pancreatic cancer for which treatment with gemcitabine as a single agent is planned will be asked to participate in this trial as a control group.
11642345|NCT00201825|Experimental|Docetaxel and Capecitabine|
11642346|NCT00201799|Experimental|Infliximab|Patients will be treated with infliximab day 1 prior to starting myeloblative chemotherapy or radiotherapy. A total of 6 doses will be administered.
11642347|NCT00201786|Experimental|Pentostatin|Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS.
11642348|NCT00201773|Experimental|Exemestane & Celecoxib|Patients will receive exemestane 25 mg orally per day for 8 weeks. Starting in the 9th week, patients will receive celecoxib 400 mg orally twice per day for 8 weeks in addition to exemestane.
11642349|NCT00201760|Experimental|Arm 1 Gemcitabine/Cisplatin/Trastuzumab|Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Cisplatin 30 mg/m2 iv over 90 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not administered within the past 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be given on the first day of cycle 1 only).
11642350|NCT00201760|Active Comparator|Arm 2 Gemcitabine / Trastuzumab|Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not administered within the past 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be given on the first day of cycle 1 only).
11642351|NCT00201734|Experimental|Arm I|Patients receive paclitaxel IV over 60 minutes on days 1, 8, and 15, carboplatin IV over 1-2 hours on day 1, and capecitabine PO BID on days 8-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11642352|NCT00201708|Active Comparator|Arm A (Docetaxel before doxorubicin/cyclophosphamide)|"Docetaxel 75 mg/m2 every 2 weeks for 4 cycles followed by A (doxorubicin) 60 mg/m2 & C (cyclophosphamide) 600 mg/m2 every 2 weeks for 4 cycles."
11642353|NCT00201708|Active Comparator|Arm B (Docetaxel after doxorubicin/cyclophosphamide)|"A (doxorubicin) 60 mg/m2 & C (cyclophosphamide) 600 mg/m2 every 2 weeks for 4 cycles followed by Docetaxel 75 mg/m2 every 2 weeks for 4 cycles."
11642354|NCT00201682|Experimental|Arm I|Etanercept 25 mg administered sub-cutaneously twice weekly (Monday and Thursday) weeks 1-5 of therapy (total of 10 doses). The third dose of etanercept will be administered 1 hour prior to receiving rituximab. Rituximab: Patients will receive 375 mg/M2 of rituximab three times weekly for four weeks (a total of 12 doses of rituximab).
11642355|NCT00201669|Experimental|Arm I|
11642356|NCT00201656|Active Comparator|1 Retention of Cerclage|Group one = Subject whose Cerclage is retained after randomization.
11642357|NCT00201656|Active Comparator|2 - Removal of Cerclage|Group 2 = Subjects who will have cerclage removed after randomization
11642358|NCT00201643|Active Comparator|1 Test group|Receive 2nd Course = Study drug (betamethasone or dexamethasone)
11642359|NCT00201643|Placebo Comparator|2 - Control|Placebo group = received placebo course
11642360|NCT00201617||1|normal hearing sensitivity
11642361|NCT00201617||2|Unilateral deafness who are implanted with a Bone Anchored Hearing Aid
11642362|NCT00201539|Active Comparator|double dose once|double dose immediate-release oral morphine at bedtime in cancer patients, placebo after 4 hours
11642363|NCT00201539|Experimental|single dose twice|single dose immediate-release oral morphine at bedtime in cancer patients, second single dose after 4 hrs
11642364|NCT00201513|Experimental|TrA exercise|Isolated Transversus abdominis (TrA) exercises (low load)
11642365|NCT00201513|Experimental|sling exercise|Sling exercises (high load)
11642366|NCT00201513|Active Comparator|group exercise|Non-specific group exercises
11642367|NCT00201500||preeclampsia|women with preeclampsia
11642368|NCT00201500||controls|healthy pregnant women
11642369|NCT00201474||brief depressive periods|brief depressive periods together with other fluctuating psychiatric symptoms
11642370|NCT00201474||major depressive disorder|
11642371|NCT00201461|Active Comparator|1|Best medical therapy
11642372|NCT00201461|Experimental|2|STARFlex arm
11642373|NCT00201448|Active Comparator|Placebo (hepatitis A)|Placebo group
11642374|NCT00201448|Experimental|Towne vaccine|Towne vaccine given at 3000 pfu/subject
11642375|NCT00201422|Experimental|Omeprazole, Amoxicillin, Clarithromycin|Anti-H. pylori Therapy (Triple therapy)
11642376|NCT00201409|Experimental|1|Participants will be randomized to receive recombinant human GM-CSF (250 mcg/M2).
11642377|NCT00201409|Placebo Comparator|2|Participants will be randomized to receive placebo.
11642378|NCT00201396|Active Comparator|A arm|CCRT
11642379|NCT00201396|Experimental|B arm|Induction/CCRT
11642380|NCT00201266||Exacerbation resistant asthma|Control group
11642381|NCT00201266||Exacerbation prone asthma|Cases
11642382|NCT00201240|Experimental|CD34+ selection with CliniMACS device|T cell depletion using Miltenyi device
11642383|NCT00201227|Experimental|Practice Change|Enhancement of primary care practice performance and practice guideline adherence
11642384|NCT00201227|No Intervention|Control|Usual care
11642385|NCT00201201|Experimental|Education|PEP-NG targeted and tailored education intervention
11642386|NCT00201201|Other|Control|Control, intervention is care as usual.
11642387|NCT00201188|Experimental|1|Participants will receive feedback and peak flow monitoring reports from their doctors.
11642388|NCT00201188|No Intervention|2|Participants will receive usual care.
11642389|NCT00201162|Experimental|Intervention|dietary supplement soy protein containing isoflavones
11642390|NCT00201162|Placebo Comparator|Placebo|dietary supplement casein placebo
11642391|NCT00201149|Experimental|1|In one team of clinicians we will implement only the patient-centered counseling program.
11642392|NCT00201149|No Intervention|3|The control group will provide usual care
11642393|NCT00201149|Experimental|2|In a subset of those clinicians receiving the patient-centered counseling program intervention, we will augment it with cultural competency training.
11642394|NCT00201136|No Intervention|MD-C/PT-C|Physician and patient control group.
11642395|NCT00201136|Experimental|MD-I/PT-C|MD CQI-type intervention; Patient control
11642396|NCT00201136|Experimental|MD-C/Pt-I|MD control; patient behavioral intervention
11642397|NCT00201136|Experimental|MD-I/Pt-I|MD CQI-type intervention; Patient behavioral intervention
11642398|NCT00201123|Placebo Comparator|Standard Treatment|Isoniazid, Rifampin, Pyrazinamide Anti-Tuberculous Therapy
11642399|NCT00201123|Experimental|Aerosol Interferon-gamma|Aerosol Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide
11642400|NCT00201123|Experimental|Subcutaneous Interferon-Gamma|Subcutaneous Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide
11642401|NCT00201110|Experimental|1|Intensive Intervention: CVD Risk Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
11642402|NCT00201110|Active Comparator|2|Brief Intervention: CVD Risk Education (1 session) + Brief Health Problem-Solving Training (1 session)
11642403|NCT00201084|Active Comparator|1|Uncertainty reduction tools, at physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
11642404|NCT00201084|No Intervention|2|Usual primary care
11642405|NCT00201071||South Bronx, Harlem, Lower East Side|
11642406|NCT00201058|Experimental|1|Receives tailored web-based program
11642407|NCT00201058|Active Comparator|2|Control students receive existing web-based, generic asthma education
11642408|NCT00201045|Experimental|Intervention|Intervention patients receive care from a clinical pharmacist to improve blood pressure.
11642409|NCT00201045|No Intervention|Control|Control patients receive usual care and do not have a clinical pharmacist included in their care.
11642410|NCT00201019|Experimental|1|Active intervention participants receive a physician-pharmacist collaborative intervention.
11642411|NCT00201019|No Intervention|2|Control participants do not receive recommendations from a clinical pharmacist.
11642412|NCT00201019|No Intervention|3|Passive intervention participants receive care by the same physicians caring for participants in the active intervention arm but are not seen by a clinical pharmacist. They are not actively enrolled in the study and do not have study visits for measuring blood pressure.
11642413|NCT00201006|Experimental|Face-to-face counseling|26 biweekly face-to-face group counseling sessions
11642414|NCT00201006|Experimental|Telephone Counseling|26 biweekly telephone counseling sessions
11642415|NCT00201006|Active Comparator|Mail contact|26 biweekly newsletters with weight management advice
11642416|NCT00200967|Experimental|B16 Arg/Arg|B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone hydroflouroalkane (HFA), followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA
11642485|NCT00200083|Placebo Comparator|B|"All subjects enrolled will be implanted with an IGS system. The placebo group are those randomized to off and will receive no stimulation for 12 months."
11642417|NCT00200967|Experimental|B16 Gly/Gly|B16 Gly/Gly genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA
11642418|NCT00200954|Placebo Comparator|placebo|placebo group
11642419|NCT00200954|Active Comparator|2|Probiotic bacteria group
11642420|NCT00200902|Active Comparator|MED|"For medication treatment, three different types were utilized and assigned specifically to each subject depending on their condition:
~MED 1: Venlafaxine XR. MED 2: Duloxetine (Cymbalta) MED 3: Escitalopram (Lexapro)"
11642421|NCT00200902|Placebo Comparator|Placebo (PBO)|Subjects enrolled will receive interpersonal clinical interaction (ICI) along with a placebo treatment (Interaction and assessment as in ICI plus double blinded treatment with placebo tablets).
11642422|NCT00200902|Other|Interpersonal Clinical Interaction (ICI)|Subjects assigned to the interpersonal clinical interaction (ICI) will undergo a one-week waiting period after the initial assessment. Visits will involve a session with a research nurse that will be approximately 20 minutes in length; visits at baseline, end of lead-in, and 1, 2, 4, and 8 weeks also will include a brief (5-10 minutes) meeting with a physician.
11642423|NCT00200889|Experimental|auricular tVNS|active and inactive auricular transcutaneous vagus nerve stimulation (tVNS)
11642424|NCT00200876|Active Comparator|pain challenge|
11642425|NCT00200876|Sham Comparator|non-painful control|
11642426|NCT00200863|Experimental|1|420 nm light
11642427|NCT00200863|Experimental|2|480 nm
11642428|NCT00200863|Experimental|3|507 nm
11642429|NCT00200863|Experimental|4|555 nm
11642430|NCT00200863|Experimental|5|620 nm
11642431|NCT00200863|Experimental|6|460 nm
11642432|NCT00200850|Active Comparator|Low dose SLIT|Low dose SLIT
11642433|NCT00200850|Active Comparator|High dose SLIT|High dose SLIT
11642434|NCT00200850|Placebo Comparator|Placebo|Placebo
11642435|NCT00200785|Active Comparator|Garlic powder in ambient water|high allicin
11642436|NCT00200785|Experimental|garlic powder in boiling water|no allicin
11642437|NCT00200746|Experimental|2|Moderate Arginine
11642438|NCT00200746|Sham Comparator|3|Polycose control arm
11642439|NCT00200746|Experimental|1|High Arginine
11642440|NCT00200720|Experimental|Atkins Diet|Participants randomized to this arm will consume a low carbohydrate diet as described by Dr. Robert Atkins in his book: Dr. Atkins' New Diet Revolution New York: Avon Books, 2002.
11642441|NCT00200720|Active Comparator|DASH Diet|Participants randomized to this arm will consume the Dietary Approaches to Stop Hypertension (DASH) diet as described here: http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/new_dash.pdf
11642442|NCT00200707|Experimental|The treatment group|Intracoronary Injection of Autologous Bone Marrow Mononuclear C
11642443|NCT00200707|No Intervention|the control group|
11642444|NCT00200577|Experimental|TIL+IL2|TIL + IL2
11642445|NCT00200577|No Intervention|control|Patients are not treated
11642446|NCT00200408||smokers|college students who smoke
11642447|NCT00200408||non smokers|college students who don't smoke
11642448|NCT00200395|Experimental|OSI-774 (Tarceva)|Oral treatment with OSI-774 (Tarceva) will be given as a 150 mg tablets daily for 14 days. On day 15 and if there are no adverse effects the dose will be increased to 200 mg.
11642449|NCT00200356|Experimental|Edaravone|
11642450|NCT00200356|Active Comparator|Ozagrel|
11642451|NCT00200343|Experimental|Ursodeoxycholic acid 150mg / day|
11642452|NCT00200343|Experimental|Ursodeoxycholic acid 600mg / day|
11642453|NCT00200343|Experimental|Ursodeoxycholic acid 900mg / day|
11642454|NCT00200291|Experimental|1|Behavioral: hypocaloric low-fat diet
11642455|NCT00200291|Placebo Comparator|2|Behavioral: hypocaloric, low-fat diet
11642456|NCT00200265|Experimental|1|Behavioral: diet
11642457|NCT00200265|Experimental|2|Behavioral: diet
11642458|NCT00200265|Placebo Comparator|3|Behavioral: diet
11642459|NCT00200252|Active Comparator|group B|women in group B will receive 10 uts oxytocin IM
11642460|NCT00200252|Active Comparator|group C|women in group C will receive oxytocin 5 uts IV
11642461|NCT00200252|Active Comparator|group A|women in group A will receive oxytocin 5 uts IM
11642462|NCT00200239|Experimental|1|Behavioral: eating breakfast from portioned and unportioned foods
11642463|NCT00200239|Experimental|2|Behavioral: eating breakfast with portioned and unportioned foods
11642464|NCT00200226|Placebo Comparator|1|Vitamin B6
11642465|NCT00200226|Active Comparator|2|misoprostol
11642466|NCT00200200|Active Comparator|1|Bevacizumab in addition to HAI plus systemic chemotherapy
11642467|NCT00200200|Experimental|2|HAI plus systemic chemotherapy alone
11642468|NCT00200174|Active Comparator|A|Raloxifene followed by combination therapy
11642469|NCT00200174|Active Comparator|B|Exemestane followed by combination therapy
11642470|NCT00200161|Active Comparator|Metronomic Therapy Cohort|Concurrent temozolomide and radiotherapy plus lose dose of temozolomide
11642471|NCT00200161|Experimental|Dose-Dense Therapy Cohort|Concurrent temozolomide and radiotherapy plus high dose of temozolomide
11642472|NCT00200148|Experimental|1|For patients randomized to ANH
11642473|NCT00200148|Active Comparator|2|standard intraoperative management
11642474|NCT00200135||1|Treated and released from ED (minor injuries)
11642475|NCT00200135||2|Trauma, admitted to the hospital (injured)
11642476|NCT00200135||3|Fatalities reported by the coroner (deaths)
11642477|NCT00200135||4|Reported by the police (No medical treatment)
11642478|NCT00200109|Other|Group 1|See protocol
11642479|NCT00200109|Other|Group 2|See protocol
11642480|NCT00200109|Other|Group 3|See protocol
11642481|NCT00200109|Other|Group 4|See protocol
11642482|NCT00200096|Active Comparator|1|Acupuncture and questionnaires
11642483|NCT00200096|Sham Comparator|2|placebo acupuncture and questionnaires
11642484|NCT00200083|Active Comparator|A|"All subjects enrolled will be implanted with an IGS system. The active group are those randomized to on and will receive active stimulation for 12 months."
11642486|NCT00200044|Sham Comparator|Sham|This arm of the study has the procedure but does not get the Gatekeeper prostheses. The Sham arm has the option to cross-over to the Treatment arm at the 6-month visit.
11642487|NCT00200044|Active Comparator|Treatment|The treatment arm has the Gatekeeper devices implanted.
11642488|NCT00200005|Experimental|InterStim therapy|Patients being treated with sacral neuromodulation with InterStim therapy.
11642489|NCT00199927|Active Comparator|standard therapy|Standard therapy
11642490|NCT00199927|Active Comparator|fluvastatin|40-80 mg/day
11642491|NCT00199914|Experimental|Shortwave diathermy|continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
11642492|NCT00199914|Sham Comparator|control|continuous sham shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
11642493|NCT00199901|Active Comparator|Vaccine|NY-ESO-1 ISCOMATRIX® vaccine
11642494|NCT00199901|Placebo Comparator|Adjuvant Alone|ISCOMATRIX® adjuvant alone
11642495|NCT00199875|Experimental|Cohort 1 (0.2 mCi/kg)|Patients initially received a nontherapeutic injection of ^111In-DOTA-cG250 (5 mCi ^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic ^90Y-DOTA-cG250 (0.2 mCi/kg ^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
11642496|NCT00199875|Experimental|Cohort 2 (0.3 mCi/kg)|Patients initially received a nontherapeutic injection of ^111In-DOTA-cG250 (5 mCi ^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic ^90Y-DOTA-cG250 (0.3 mCi/kg ^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
11642497|NCT00199875|Experimental|Cohort 3 (0.4 mCi/kg)|Patients initially received a nontherapeutic injection of ^111In-DOTA-cG250 (5 mCi ^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic ^90Y-DOTA-cG250 (0.4 mCi/kg ^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
11642498|NCT00199875|Experimental|Cohort 4 (0.45 mCi/kg)|Patients initially received a nontherapeutic injection of ^111In-DOTA-cG250 (5 mCi ^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic ^90Y-DOTA-cG250 (0.45 mCi/kg ^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
11642499|NCT00199875|Experimental|Cohort 5 (0.55 mCi/kg)|Patients initially received a nontherapeutic injection of ^111In-DOTA-cG250 (5 mCi ^111In + 10 mg cG250) on Day 1. Pending satisfaction of protocol-specified lesion targeting criteria, a single dose of therapeutic ^90Y-DOTA-cG250 (0.55 mCi/kg ^90Y + 10 mg cG250) was administered on Day 8, 9, or 10 as a continuous IV infusion over approximately 5 to 15 minutes.
11642500|NCT00199862|Experimental|Radio-labeled huA33 Antibody|"Patients will receive a single I-V infusion of 4mCi-10mCi/10mg 124I-huA33 in 5-30 mL of 5% human serum albumin (HAS) in normal saline, over 5 minutes-4 hours. Patients will be studied with 124I-huA33 positron-emission tomography (PET) and ex-vivo quantitation of tumor uptake .
~Blood samples will be obtained for pharmacokinetic analysis at 5, 15, 60, and 120 minutes after completion of IV, on and before or after PET scanning on subsequent days.
~Surgery (or biopsy) will be scheduled to occur 8- 10 days after administration of 124I-huA33. The 8-10 day imaging session will be scheduled for the morning of surgery or biopsy, approximately 1-6 hours before the procedure."
11642501|NCT00199602|No Intervention|lack of drug prophylaxis|
11642502|NCT00199602|Experimental|HBPM 2500 UI anti Xa in one subcutaneous injection per day|
11642503|NCT00199602|Experimental|warfarine 1mg daily|
11642504|NCT00199563|Active Comparator|active drug|Viagra 100 mg / daily for 12 weeks.
11642505|NCT00199563|Placebo Comparator|Placebo|placebo/daily for 12 weeks
11642506|NCT00199550|Active Comparator|2|Bipolar Electrosurgical Unit
11642507|NCT00199550|Active Comparator|1|Monopolar Electrosurgical Unit
11642508|NCT00199524|Active Comparator|1|ureteroscopy with ureteral access sheath
11642509|NCT00199524|No Intervention|2|ureteroscopy without ureteral access sheath
11642510|NCT00199498|Experimental|Septal RV lead placement|patient randomized to Septal RV lead placement
11642511|NCT00199498|Active Comparator|Apical RV lead placement|patient randomized to Apical RV lead placement (current standard placement)
11642512|NCT00199485|Experimental|1|Angelica Sinensis
11642513|NCT00199485|Placebo Comparator|2|placebo
11642514|NCT00199381|Experimental|Single Arm|Treatment with oral istradefylline (KW-6002) 20 or 40 mg once daily.
11642515|NCT00199290|Placebo Comparator|P|
11642516|NCT00199290|Experimental|L|low dose (0.2 %)
11642517|NCT00199290|Experimental|M|medium dose (0.3 %)
11642518|NCT00199290|Experimental|H|high dose (0.4 %)
11642519|NCT00199134|Other|Letrozole|Letrozole 2.5 mg per day
11642520|NCT00198939|Active Comparator|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
11642521|NCT00198939|Experimental|Conitive Behavorial Therapy|The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
11642522|NCT00198939|Experimental|Family Therapy|Participants assigned to the Family Therapy arm received a family-centered intervention to support targeted adolescent behavior change. The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases.
11642523|NCT00198939|Experimental|Intergrated Family and Cognitve Behavioral Therapy|Participants assigned to the IFCBT arm received the Cognitive Behavioral Therapy and Family Therapy intervention components.
11642524|NCT00198874|Active Comparator|Psychoeducation|
11642525|NCT00198874|Experimental|Conitive Behavorial Therapy|
11642526|NCT00198874|Experimental|Family Therapy|
11642527|NCT00198874|Experimental|Intergrated Family|
11642528|NCT00198861||Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors
11642712|NCT00196157|Experimental|1|linear lesions to ablate persistent atrial fibrillation
11642529|NCT00198822|Experimental|1|Weekly oral supplement with 7000 µg retinol equivalents from early pregnancy through 12 weeks following termination of pregnancy
11642530|NCT00198822|Experimental|2|Weekly oral supplement with 42 mg of beta-carotene from early pregnancy through 12 weeks following termination of pregnancy
11642531|NCT00198822|Placebo Comparator|3|Weekly oral supplement with placebo from early pregnancy through 12 weeks following termination of pregnancy
11642532|NCT00198796|Experimental|H10407|H10407
11642533|NCT00198770|Experimental|Crossover design - 1 arm|Meat week followed by mushroom week, counterbalanced order
11642534|NCT00198718|Experimental|Infant vitamin A Mother vitamin A|Infant received 50,000 IU vitamin A, mother received 400,000 IU vitamin A
11642535|NCT00198718|Experimental|Infant vitamin A Mother placebo|Infant received 50,000 IU vitamin A, mother received placebo
11642536|NCT00198718|Experimental|Infant placebo, mother vitamin A|Infant received placebo, mother received 400,000 IU vitamin A
11642537|NCT00198718|Experimental|Infant received placebo, mother received placebo|Infant and mother received placebo
11642538|NCT00198666|Experimental|Treatment|Children with severe pneumonia were randomly assigned to receive supplementation with elemental zinc.
11642539|NCT00198666|No Intervention|Control|Children with severe pneumonia were randomly assigned to receive supplementation with placebo tablets.
11642540|NCT00198562|Active Comparator|1|target morning home blood pressure (below 130 mmHg vs 130-139 mmHg)
11642541|NCT00198562|Active Comparator|2|antihypertensive drug (amlodipine vs losartan)
11642542|NCT00198536|Experimental|Ecabet 2.83%|Ecabet ophthalmic solution One drop in study eye 4 times daily for 90 days.
11642543|NCT00198536|Experimental|Ecabet 3.70%|Ecabet ophthalmic solution One drop in study eye 4 times daily for 90 days.
11642544|NCT00198536|Placebo Comparator|Vehicle|One drop of vehicle in study eye 4 times daily for 90 days.
11642545|NCT00198523|Experimental|Prednisolone and Tobramycin|Prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension. One drop of test agent will be instilled in the inferior cul de sac of the operative eye prior to cataract extraction.
11642546|NCT00198523|Active Comparator|Prednisolone|Prednisolone acetate 1.0% ophthalmic suspension. One drop of test agent will be instilled in the inferior cul de sac of the operative eye prior to cataract extraction.
11642547|NCT00198510|Experimental|Vitrase|A single dose of 0.05 cc of Vitrase (hyaluronidase) for ophthalmic intravitreal injection is injected into the vitreous chamber.
11642548|NCT00198510|No Intervention|Observation|Observation only, no medication or intravitreal injection
11642549|NCT00198497|Experimental|Vitrase|Single Hyaluronidase ophthalmic intravitreal injection
11642550|NCT00198497|Placebo Comparator|Placebo|Single Saline solution intravitreal injection
11642551|NCT00198484|Experimental|Vitrase|ovine hyaluronidase injection 150 USP Units in 1 mL solution. Single dose of Vitrase will be administered as an adjuvant prior to ophthalmologic surgery
11642552|NCT00198471|Experimental|Vitrase|A single intravitreous injection of Vitrase 93 USP Units (75 IU) on Study Day 1.
11642553|NCT00198458|Experimental|Vitrase|A single intradermal dose of 4.5 USP units of Vitrase at one site and the same volume of saline at a distant site for comparative control.
11642554|NCT00198445|Experimental|Bromfenac|Topical bromfenac ophthalmic solution 0.1%
11642555|NCT00198445|Placebo Comparator|Placebo|Vehicle of bromfenac
11642556|NCT00198419|Experimental|Vitrase|a single intradermal dose of 3 USP Units of Vitrase (ovine hyaluronidase) at one site and the same volume of saline at a distant site for comparative control
11642557|NCT00198393|Experimental|A|Gefitinib
11642558|NCT00198393|Experimental|B|Gemcitabine
11642559|NCT00198393|Experimental|C|Docetaxel
11642560|NCT00198380|Experimental|1|
11642561|NCT00198367|Experimental|Cisplatin-Gemzar|Cisplatin-Gemzar
11642562|NCT00198367|Experimental|Cisplatin-Navelbine-Radiotherapy|Cisplatin-Navelbine-Radiotherapy
11642563|NCT00198367|Experimental|Carboplatin-Taxol-Radiotherapy|Carboplatin-Taxol-Radiotherapy
11642564|NCT00198354|Experimental|A: pre-operative chemotherapy|pre-operative chemotherapy (gemcitabine+cisplatine, 4 cycles)
11642565|NCT00198354|Experimental|B: pre-operative chemotherapy|pre-operative chemotherapy (paclitaxel+carboplatin, 4 cycles)
11642566|NCT00198354|Experimental|C: peri-operative chemotherapy|peri-operative chemotherapy (gemcitabine+cisplatine, 4 cycles)
11642567|NCT00198354|Experimental|D: peri-operative chemotherapy|peri-operative chemotherapy (paclitaxel+carboplatin, 4 cycles)
11642568|NCT00198341|Experimental|1|Radiological arm (Clinical Visit + X-Ray Chest)
11642569|NCT00198341|Experimental|2|Scan ARM : Clinical Visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous type)
11642570|NCT00198328|Active Comparator|Surgery Control|Patients receive surgical excision of their tumor.
11642571|NCT00198328|Experimental|MedPulser EPT|Patients receive electroporation with injection of Bleomycin Sulfate.
11642572|NCT00198315|Active Comparator|Surgery Control|Patients will receive standard of care surgical removal of their tumor.
11642573|NCT00198315|Experimental|MedPulser EPT with Bleomycin|Patients who are eligible for surgical excision will receive MedPulser electroporation with injection of bleomycin sulfate into the tumor treatment area.
11642574|NCT00198276|Experimental|Bleomycin|Bleomycin 4.0 U/mL at dose of 1 U/cm^3 of treatment area; Medpulser EP
11642575|NCT00198263|Experimental|Bleomycin|Bleomycin 4 USP Units/mL; intratumorally at dose of 0.25mL/cm^3
11642576|NCT00198133|Experimental|Pemetrexed|Pemetrexed infusion once every 21 days (one cycle).
11642577|NCT00198120|Experimental|1|Participants will receive D-Cycloserine for 8 weeks.
11642578|NCT00198120|Placebo Comparator|2|Participants will receive placebo for 8 weeks.
11642579|NCT00198107|Placebo Comparator|1 Placebo|Participants will take placebo
11642580|NCT00198107|Active Comparator|2 Aripiprazole|Participants will take aripiprazole
11642581|NCT00198107|Active Comparator|3 Aripiprazole + D-cycloserine|Participants first will take aripiprazole then will also take D-cycloserine
11642582|NCT00198081|Experimental|Surgical Candidate|COX-2 Inhibitor 6-8 weeks prior to surgery
11642583|NCT00198081|Experimental|Medical Candidate|COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP
11642584|NCT00198068||Group 1: aPL+/SLE-|Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM >= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM >= 40 units; no SLE
11642585|NCT00198068||Group 2: aPL+/SLE+|Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM >= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM >= 40 units AND SLE defined as four or more American College of Rheumatology criteria for SLE.
11642586|NCT00198068||Group 3: aPL-/SLE+|No antiphospholipid antibodies; SLE defined as four or more American College of Rheumatology criteria for SLE.
11642587|NCT00198068||Group 4: aPL-/SLE-|Healthy controls: no antiphospholipid antibodies; no SLE
11642588|NCT00198055|Experimental|Aripiprazole|Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
11642589|NCT00198042|Experimental|Surgical Reconstruction of the ACL|
11642590|NCT00198029|Experimental|Pilot Study of Hylan G-F 20|32 Subjects have received Synvisc Injections and followed for 6 months.
11642591|NCT00197873|Active Comparator|Lactophilus|Lactophilus supplementation
11642592|NCT00197873|Placebo Comparator|Placebo|Placebo is administered during chemotherapy.
11642593|NCT00197808|Experimental|Vaccine schedule 1|Menjugate vaccine at 2 and 3 months
11642594|NCT00197808|Experimental|Vaccine schedule 2|Menjugate vaccine at 2 and 4 months
11642595|NCT00197808|Experimental|vaccine schedule3|Neissvacc at 2 and 3 months
11642596|NCT00197808|Experimental|vaccine schedule 4|Neissvacc at 2 and 4 months
11642597|NCT00197808|Experimental|Vaccine schedule 5|Meningitec at 2 and 3 months
11642598|NCT00197808|Experimental|Vaccine schedule 6|Meningitec at 2 and 4 months
11642599|NCT00197756||Vitamin A|Participants in the in the parent study who had been randomized to receive either Vitamin A alone or multivitamins including vitamin A.
11642600|NCT00197756||No Vitamin A|Participants in the parent study who were randomized to receive either multivitamins excluding vitamin A, or placebo.
11642601|NCT00197756||Multivitamins|Participants in the parent study who were randomized to receive multivitamins including vitamin A or multivitamins excluding vitamin A
11642602|NCT00197756||No Multivitamins|Participants from the parent study who had been randomized to vitamin A alone or placebo
11642603|NCT00197743|Active Comparator|Vitamin A|Vitamin A + Beta Carotene
11642604|NCT00197743|Active Comparator|Multivitamins|Vitamins B, C, and E
11642605|NCT00197743|Active Comparator|Vitamin A + Multivitamins|Vitamin A + Beta Carotene, Vitamins B, C, and E
11642606|NCT00197743|Placebo Comparator|Placebo|Placebo
11642607|NCT00197730|Experimental|Multivitamins|Vitamin E, Vitamin C, and Vitamin B complex
11642608|NCT00197730|Placebo Comparator|Placebo|Placebo
11642609|NCT00197704|Placebo Comparator|Placebo|Placebo
11642610|NCT00197704|Experimental|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium
11642611|NCT00197678|Experimental|Multivitamins-Single RDA|Multivitamins at doses resembling a single daily Recommended Dietary Allowance (RDA)
11642612|NCT00197678|Active Comparator|Multivitamins-Multiples of RDA|Multivitamin supplements at multiples of the Recommended Dietary Allowance (RDA)
11642613|NCT00197652||Diarrheal specimens from infants born to HIV infected mothers|400 diarrheal specimens will suffice to determine the prevalence of specific pathogens in the region. Of these, 300 specimens will be collected from infants born to HIV infected mothers, and 100 specimens will be collected from infants born to HIV uninfected mothers.
11642614|NCT00197652||Breast milk from HIV infected and HIV uninfected women|Breast milk from HIV infected and HIV uninfected women who are breastfeeding is collected at 2 days, 2 weeks, 2 months, and 5 months post-partum. This breast milk will be compared for in vitro functional quality of immunoglobulins to selected diarrheal and respiratory pathogens.
11642615|NCT00197587|Active Comparator|maternal nevirapine|
11642616|NCT00197587|Placebo Comparator|maternal placebo|
11642617|NCT00197561|Active Comparator|Selenium|Selenium (200 ug as selenomethionine)
11642618|NCT00197561|Placebo Comparator|Placebo|Placebo
11642619|NCT00197548|Active Comparator|Multivitamins|Multivitamins-vitamins B-complex, C, and E
11642620|NCT00197548|Placebo Comparator|Placebo|Placebo pill
11642621|NCT00197496|Experimental|BWSTT|Body weight supported treadmill training
11642622|NCT00197496|No Intervention|Usual care|Usual care
11642623|NCT00197444|Experimental|1|Chemoradiotherapy
11642624|NCT00197392|Experimental|Bactiseal TM EVD|Bactiseal External Ventricular Drainage System.
11642625|NCT00197392|Active Comparator|Standard EVD Catheter|Standard External Ventricular Device system
11642626|NCT00197236|Active Comparator|Havrix Group|Subjects received one dose of Havrix at Day 0 followed by a second dose of Havrix at Month 6-9.
11642627|NCT00197236|Experimental|Infanrix + ActHIB→Havrix Group|Subjects received Infanrix co-administered with ActHIB at Day 0, followed by one dose of Havix at Day 30 and a second dose of Havrix at Month 7-10.
11642628|NCT00197236|Active Comparator|Havrix + Infanrix + ActHIB Group|Subjects received one dose of Havrix co-administered with Infanrix and ActHIB vaccines at Day 0 followed by a second dose of Havrix at Month 6-9.
11642629|NCT00197184|Experimental|Twinrix Junior|Subjects previously received 3 doses of combined hepatitis A / hepatitis B vaccine (junior formulation).
11642630|NCT00197184|Active Comparator|Twinrix Adult|Subjects previously received 2 doses of combined hepatitis A / hepatitis B vaccine (adult formulation).
11642631|NCT00197145|Experimental|GW873140|
11642632|NCT00197119|Active Comparator|Group Twinrix Adult|Subjects received Twinrix™ Adult (720/20) in a 0, 6 month schedule in the primary study.
11642633|NCT00197119|Active Comparator|Group Twinrix Junior|Subjects received Twinrix™ Junior (360/10) in a 0, 1, 6 month schedule in the primary study.
11642634|NCT00197106|Active Comparator|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg
11642635|NCT00197106|Other|fluticasone propionate 2 x 100 mcg|fluticasone propionate 2 x 100 mcg
11642713|NCT00196157|Experimental|2|focal electrophysiologically guided ablations to treat persistent atrial fibrillation
11642636|NCT00197028|Experimental|RTS,S/AS02D Group|Subjects aged between 6 and 12 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of RTS,S/AS02D at days 14, 44 and 74 and a 3-dose vaccination course of TETRActHib™ vaccine at days 0, 30 and 60. The RTS,S/AS02D vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
11642637|NCT00197028|Active Comparator|Engerix-B Group|Subjects aged between 6 and 12 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of Engerix-B® vaccine at days 14, 44 and 74 and a 3-dose of TETRActHib™ vaccine at days 0, 30 and 60. The Engerix-B® vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
11642638|NCT00197015|Active Comparator|HAV Group|Subjects received 2 doses of Havrix® (1 dose at Day 0 and 1 dose between Month 6 and Month 9)
11642639|NCT00197015|Experimental|HAV+MMR+V Group|Subjects received 1 dose of Havrix®, coadministered with M-M-R®II and VARIVAX®, at Day 0 and 1 dose of Havrix® between Month 6 and Month 9
11642640|NCT00197015|Active Comparator|MMR+V→HAV Group|Subjects received 1 dose of M-M-R®II and VARIVAX® at Day 0 and then 2 doses of Havrix® (1 dose at Day 42 and 1 dose between Month 7.5 and Month 10.5)
11642641|NCT00197002|Active Comparator|Havrix Group|Healthy male or female subjects, 15 months of age, who received Havrix® vaccine administered intramuscularly in the right anterolateral thigh, at Day 0 and at Month 6-9.
11642642|NCT00197002|Experimental|Havrix+Prevnar Group|Healthy male or female subjects, 15 months of age, who received Havrix® and Prevnar™ vaccines co-administered intramuscularly in the right and left anterolateral thighs, respectively, at Day 0 and Havrix® vaccine administered intramuscularly in the right anterolateral thigh, at Month 6-9.
11642643|NCT00197002|Active Comparator|Prevnar Havrix Group|Healthy male or female subjects, 15 months of age, who received Prevnar™ vaccine administered intramuscularly in the left anterolateral thigh, at Day 0 and Havrix® vaccine, administered intramuscularly in the right anterolateral thigh, at Day 30 and at Month 7-10.
11642644|NCT00196976|Experimental|GSK134612A Form1 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
11642645|NCT00196976|Experimental|GSK134612A Form2 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
11642646|NCT00196976|Experimental|GSK134612A Form3 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
11642647|NCT00196976|Experimental|GSK134612A Form4 (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
11642648|NCT00196976|Active Comparator|Control (T), Primary Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, were administered one dose of Pfizer's Meningitec™ conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533). In accordance with local immunization policy, one dose of a diphtheria, tetanus and acellular pertusis (Infanrix™ or Infanrix™ Hexa) vaccine was also administered intramuscularly into the left thigh, one month after meningococcal vaccination.
11642649|NCT00196976|Experimental|GSK134612A Form1 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 1 (Form1) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
11642650|NCT00196976|Experimental|GSK134612A Form2 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 2 (Form2) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
11642651|NCT00196976|Experimental|GSK134612A Form3 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 3 (Form3) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
11642652|NCT00196976|Experimental|GSK134612A Form4 (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of formulation 4 (Form4) of the GSK134612A conjugate vaccine, intramuscularly into the left arm's deltoid region, during this primary vaccination study (103533).
11642653|NCT00196976|Active Comparator|Control (C), Primary Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, were administered one dose of Mencevax™ ACWY vaccine, subcutaneously into the left upper arm, during this primary vaccination study (103533).
11642714|NCT00196144|Experimental|1|Optimization of the postventricular atrial blanking period to avoid far-field R-wave sensing.
11642715|NCT00196144|Experimental|2|Programming of the nominal setting for the post-ventricular atrial blanking period (100 ms)
11642654|NCT00196976|Experimental|GSK134612A Form1 (T), Booster Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).
11642655|NCT00196976|Active Comparator|Control (T), Booster Group|Healthy male and female toddlers (T) between, and including, 12 to 14 months of age at the time of the first vaccination, who 12 months after being primed with Pfizer's Meningitec™ conjugate vaccine, additionally received 1/5 dose of Mencevax™ ACWY vaccine subcutaneously into the left upper arm, during the booster study (103534).
11642656|NCT00196976|Experimental|GSK134612A Form1 (C), Booster Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with formulation 1 (Form1) of the GSK134612A conjugate vaccine, did not receive any booster vaccination.
11642657|NCT00196976|Active Comparator|Control (C), Booster Group|Healthy male and female children (C) between, and including, 3 to 5 years of age at the time of the first vaccination, who 12 months after being primed with Pfizer's Meningitec™ conjugate vaccine, did not receive any booster vaccination.
11642658|NCT00196937|Experimental|Cervarix (15-25 Years) Group|Women aged 15 to 25 years received 3 doses of Cervarix vaccine administered according to a 0, 1, 6-month schedule.
11642659|NCT00196937|Experimental|Cervarix (26-45 Years) Group|Women aged 26 to 45 years received 3 doses of Cervarix vaccine administered according to a 0, 1, 6-month schedule.
11642660|NCT00196937|Experimental|Cervarix (46-55 Years) Group|Women aged 46 to 55 years received 3 doses of Cervarix vaccine administered according to a 0, 1, 6-month schedule.
11642661|NCT00196872|Experimental|ETC-with Ibandronat|ETC follwoed by Ibandronat
11642662|NCT00196872|Experimental|ETC without Ibandronat|ETC not followed by Ibandronat
11642663|NCT00196872|Experimental|EC-TX with Ibandronat|EC-TX followed by Ibandronat
11642664|NCT00196872|Experimental|EC-TX without Ibandronat|EC-TX not followed by Ibandronat
11642665|NCT00196859|Active Comparator|A|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
11642666|NCT00196859|Experimental|B|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
11642667|NCT00196820|Experimental|A|Capecitabine 2000 mg/m2 orally day 1-14 q day 22 until progression, unacceptable toxicity, patient's request or withdrawal from study
11642668|NCT00196807|Experimental|Information plus DA at home|
11642669|NCT00196807|Active Comparator|UC Information at home|
11642670|NCT00196807|Experimental|Information plus decision aid at clinic|
11642671|NCT00196807|Active Comparator|UC Information at clinic|
11642672|NCT00196781|Experimental|the Information + Decision Aid group|
11642673|NCT00196781|Active Comparator|Information Only group|
11642674|NCT00196755|Experimental|Sevelamer Hydrochloride (Renagel®)|
11642675|NCT00196755|Active Comparator|Calcium acetate (PhosLo® )|
11642676|NCT00196742||Patients with Fabry disease|No experimental intervention is given. A patient with Fabry Disease will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.
11642677|NCT00196742||Pregnant women with confirmed diagnosis of Fabry|No experimental intervention is given. Pregnant women with confirmed diagnosis of Fabry that are participating in the Fabry Registry and consented to participate in the Fabry Sub-registry, regardless of whether she is receiving disease-specific therapy (such as ERT with agalsidase beta) and irrespective of the commercial product with which she may be treated.
11642678|NCT00196716|Experimental|Fabrazyme|Open-label study. Patients received 1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months.
11642679|NCT00196573|Active Comparator|Shoulder bursectomy and acromioplasty|
11642680|NCT00196560|Experimental|exernal rotation|external rotation at 90 degrees
11642681|NCT00196404|Experimental|1|
11642682|NCT00196404|Experimental|2|
11642683|NCT00196404|Placebo Comparator|3|
11642684|NCT00196391|Experimental|1|
11642685|NCT00196391|Experimental|2|
11642686|NCT00196391|Experimental|3|
11642687|NCT00196391|Experimental|4|
11642688|NCT00196391|Experimental|5|
11642689|NCT00196391|Placebo Comparator|6|
11642690|NCT00196378|Experimental|1|
11642691|NCT00196378|Placebo Comparator|2|
11642692|NCT00196365|Experimental|1|
11642693|NCT00196365|Active Comparator|2|
11642694|NCT00196352|Experimental|1|
11642695|NCT00196339|Experimental|Cyproterone acetate 5 mg ( DR-2031)|1 tablet daily
11642696|NCT00196339|Experimental|Cyproterone acetate 15 mg ( DR-2031)|1 tablet daily
11642697|NCT00196339|Experimental|Cyproterone acetate 25 mg ( DR-2031)|1 tablet daily
11642698|NCT00196339|Placebo Comparator|Placebo|1 tablet daily
11642699|NCT00196326|Experimental|DR-1011|Participants were instructed to take, by mouth, one tablet daily for four 91-day cycles.
11642700|NCT00196313|Experimental|1 levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablet|
11642701|NCT00196313|Placebo Comparator|2|
11642702|NCT00196222|Experimental|1|RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
11642703|NCT00196222|Experimental|2|cryo energy ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
11642704|NCT00196209|Experimental|1|catheter ablation to treat persistent atrial fibrillation
11642705|NCT00196209|Experimental|2|cardioversion and drug prophylaxis to treat persistent atrial fibrillation
11642706|NCT00196183|Experimental|1|trigger-guided ablation of paroxysmal atrial fibrillation
11642707|NCT00196183|Experimental|2|trigger-+substrate guided ablation of paroxysmal atrial fibrillation
11642708|NCT00196170|Experimental|1|8mm tip ablation catheter for ablation of cavotricuspid isthmus
11642709|NCT00196170|Experimental|2|irrigated tip ablation catheter for ablation of cavotricuspid isthmus
11642710|NCT00196170|Experimental|3|cryo 10mm tip ablation catheter for ablation of cavotricuspid isthmus
11642711|NCT00196170|Experimental|4|Cryo 6.5mm tip ablation catheter for ablation of cavotricuspid isthmus
11642716|NCT00196131|No Intervention|0|
11642717|NCT00196105|Experimental|6 mm Zilver|6 mm Nitinol Zilver Stent
11642718|NCT00196105|Experimental|10 mm Zilver|10 mm Nitinol Zilver Stent
11642719|NCT00196105|Active Comparator|10 mm Wallstent|10 mm Stainless Steel Wallstent
11642720|NCT00196092|Other|1|Roll-in
11642721|NCT00196092|Other|2|Surgical
11642722|NCT00196092|Other|3|Standard Risk
11642723|NCT00196092|Other|4|High Risk
11642724|NCT00196092|Other|5|Compassionate Use
11642725|NCT00196092|Other|6|Treatment for females.
11642726|NCT00196092|Other|7|Standard Risk Continued Access
11642727|NCT00196092|Other|8|High Risk Continued Access
11642728|NCT00195975||1|Children with FD
11642729|NCT00195975||4|Healthy controls
11642730|NCT00195910|Active Comparator|Morphine|"single dose of intravenous (IV) morphine, 0.1 mg/kg
~intervention: 0.1 mg/kg IV morphine"
11642731|NCT00195910|Experimental|Hydromorphone|"single dose of intravenous (IV) hydromorphone, 0.015 mg/kg
~intervention: 0.015 mg/kg IV hydromorphone"
11642732|NCT00195884|Experimental|Aerobic Group|Aerobic training is divided into three stages: the Starter phase (during the run-in period), the Progression phase, and the Maintenance phase. All aerobic activities are performed on a cycle ergometer, treadmill, elliptical exercise machine or stairclimber. Subjects are free to vary the machine(s) used from one visit to the next. Exercise intensity is standardized using Polar Heartminder heart rate monitors that display the subject's heart rate and emits a warming signal when heart rate is outside the prescribed training zone, thus guiding the subject in adjustment of the work load up or down to achieve the desired intensity.
11642733|NCT00195884|Experimental|Resistance Group|"Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.
~Group A: abdominal crunches, seated row (back), seated biceps curls, supine bench press (chest), leg press, shoulder press (shoulders and neck); leg extension (quadriceps)
~Group B: abdominal crunches, lat pulldown (back), sitting chest press (chest), leg press, upright row (shoulders and neck), triceps pushdown, leg curls (hamstrings).
~Subjects are instructed to exhale while lifting a weight and inhale while lowering it, in order to minimize blood pressure excursions. Warm-up and cooldown are the same as for aerobic training."
11642734|NCT00195884|Experimental|Combined Aerobic and Resistance Training|Combined aerobic and resistance training. This group will perform both aerobic and resistance training programs, as described above. The aerobic and resistance components are performed on the same days, in varying orders.
11642735|NCT00195884|No Intervention|Control Group|Members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program.
11642736|NCT00195858|Active Comparator|Diet and Aerobic Exercise|
11642737|NCT00195858|Active Comparator|Diet and Resistane Exercise|
11642738|NCT00195858|Active Comparator|Diet and Combined Aerobic and Resistance Exercise|
11642739|NCT00195858|Other|Diet-only control group|
11642740|NCT00195845|Experimental|Double-Blind Galantamine vs Placebo|Double-Blinded, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction
11642741|NCT00195845|Placebo Comparator|Placebo Control Group|Placebo-Controlled Group
11642742|NCT00195819|Experimental|Adalimumab|
11642743|NCT00195819|Placebo Comparator|Placebo|
11642744|NCT00195728|Experimental|hydrocodone/acetaminophen extended release|
11642745|NCT00195702|Experimental|DB adalimumab 20 mg ew|Subjects received 20 mg adalimumab subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.
11642746|NCT00195702|Experimental|DB adalimumab 40 mg eow|Subjects received 40 mg adalimumab subcutaneously (SC) every other week (eow) and concomitant methotrexate (MTX) during the double-blind (DB) phase. Subjects received placebo injections SC and concomitant MTX on the alternate weeks during the DB phase.
11642747|NCT00195702|Placebo Comparator|DB placebo ew|Subjects received placebo subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.
11642748|NCT00195702|Experimental|DB adalimumab 20 mg ew/OL adalimumab 40 mg eow|Subjects received adalimumab 20 mg subcutaneously (SC) once weekly (ew) during the double-blind (DB) phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
11642749|NCT00195702|Experimental|DB adalimumab 40 mg eow/OL adalimumab 40 mg eow|Subjects received adalimumab 40 mg subcutaneously (SC) every other week (eow) with placebo on alternate weeks during the double-blind (DB) phase, then adalimumab 40 mg SC eow during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
11642750|NCT00195702|Experimental|DB placebo ew/OL adalimumab 40 mg eow|Subjects received placebo subcutaneously (SC) once weekly (ew) during the double-blind phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).
11642751|NCT00195676|Other|Adalimumab|
11642752|NCT00195663|Experimental|Adalimumab|Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase and then adalimumab 40 mg every other week for up to 8 years in the open-label extension.
11642753|NCT00195663|Experimental|Adalimumab + methotrexate|Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.
11642754|NCT00195663|Experimental|Methotrexate|Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.
11642755|NCT00195650|Experimental|Adalimumab|Open-label adalimumab 40 mg
11642756|NCT00195624|Experimental|Relapsed severe aplastic anemia|Subjects diagnosed with relapsed severe aplastic anemia
11642757|NCT00195624|Experimental|Refractory severe asplastic anemia|Subjects diagnosed with refractory severe aplastic anemia
11642855|NCT00193921|Active Comparator|B|Gemcitabine + high-dose palliative radiotherapy
11642856|NCT00193908|Experimental|1|
11642758|NCT00195624|Experimental|Relapse after Alemtuzumab|Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit.
11642759|NCT00195494|Active Comparator|1a|Etanercept + Methorexate for Period 1 (first 12 months) and Period 2 (Second 12 months)
11642760|NCT00195494|Active Comparator|1b|Etanercept + Methotrexate for Period 1 (First 12 months) and Etanercept alone for Period 2 (Second 12 months)
11642761|NCT00195494|Active Comparator|2a|Methotrexate alone in Period 1 (First 12 months) and etanercept + Methotrexate in Period 2 (Second 12 months)
11642762|NCT00195494|Active Comparator|2b|Methotrexate alone in Period 1 (First 12 months) and Methotrexate alone in Period 2 (Second 12 months)
11642763|NCT00195442||A|Patients with Hemophilia A
11642764|NCT00195429|Experimental|Sirolimus + Tacrolimus|
11642765|NCT00195429|Active Comparator|Sirolimus + Prednisone|
11642766|NCT00195403||1|
11642767|NCT00195351|Active Comparator|A|
11642768|NCT00195351|Active Comparator|B|
11642769|NCT00195338||1|This is an open label, observational study.This is a post-marketing surveillance study in rheumatology practice patients in Luxemburg.Rheumatologists will be asked to document safety and adherence to therapy of Enbrel when given to adults with active rheumatoid arthritis.All patients initiated with Enbrel will be observed.
11642770|NCT00195273|Experimental|1|Sirolimus + Daclizumab + Mycophenolate + Corticosteroids
11642771|NCT00195273|Active Comparator|2|Cyclosporine + Mycophenolate + Corticosteroids
11642772|NCT00195260|Experimental|Dose escalation|Dose finding study of monotherapy bosutinib in patients with advanced solid tumors.
11642773|NCT00195260|Experimental|Colorectal Cancer|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
11642774|NCT00195260|Experimental|Pancreatic Cancer|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
11642775|NCT00195260|Experimental|Non-Small Cell Lung Cancer (NSCLC)|Enroll 30 patients at RP2D to further evaluate safety and efficacy in subgroup population.
11642776|NCT00195195||1|Sirolimus
11642777|NCT00195182||1. No intervention|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to adhere to their medication goal.
11642778|NCT00195182||2. Experimental|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to engage adhere to their medication goal. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level.
11642779|NCT00195117|No Intervention|Control Group|This group received follow-up every 2-months for one year. Follow-up included questions about their asthma and how well they had been able to engage in their doctor approved physical activity goal.
11642780|NCT00195117|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their asthma and how well they had been able to engage in their doctor approved physical activity goal, which was the same as the control arm. Additionally, subjects in this arm were encouraged to use positive affect and self-affirmation techniques to motivate an increased level of participation in their physical activity goal. These subjects also received small token gifts to remind them of their participation in this study.
11642781|NCT00195104|Experimental|All Patients|Arsenic trioxide [TrisenoxTM Injection], 0.25mg/kg/dose administered intravenously over 1 to 4 hours
11642782|NCT00195091|Experimental|Tetrathiomolybdate (TM)|"Induction period - TM 40 mg is administered three x per day with meals and TM 60 mg at bedtime for a total of 4 doses (180 mg) per day.
~Maintenance Period - Total TM dose per day will be in 20 mg increments to tailor the therapy to individualized patient needs to maintain the Cp level at 5-17mg/dL. Thus all dose modifications will be dependent on individual patient Cp levels. TM 40 mg p.o. BID with meals and TM 20 mg at bedtime. Subjects who have no evidence of disease (NED) and are receiving a benefit of TM can continue taking the drug for up to 120 months."
11642783|NCT00195039|Experimental|All patients|"Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min."
11642784|NCT00195013|Experimental|Glutamine|10 grams three times a day (orally) for four days and then stop
11642785|NCT00195013|Placebo Comparator|Placebo|10 grams three times a day (orally) for four days and then stop
11642786|NCT00194987|Experimental|IVIG x 2|IVIG 2 g/kg/wk divided into 2 infusions per week for women with a fetus affected by FNAIT
11642787|NCT00194987|Experimental|IVIG x 1 + prednisone|IVIG 1 g/kg/wk in 1 infusion per week + prednisone 0.5 mg po daily for women with a fetus affected by FNAIT
11642788|NCT00194922|Placebo Comparator|A|
11642789|NCT00194896|Active Comparator|rosiglitazone|Rosiglitazone is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. The rosiglitazone treatment group commenced therapy with 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved.
11642790|NCT00194896|Active Comparator|glyburide|Glyburide is a sulfonylurea. Glyburide therapy was initiated with 2.5 mg in the morning or the patient was maintained on the dose they had been receiving prior to starting the study. This starting dose was raised by 2.5 in the evening and further up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control.
11642791|NCT00194870|Other|Digital EEG|Digital EEG
11642792|NCT00194844|Experimental|1|Nurse Caring
11642793|NCT00194844|Experimental|2|Self Caring
11642794|NCT00194844|Experimental|3|Combined Caring
11642795|NCT00194844|No Intervention|4|This group is not treated and serves as control.
11642796|NCT00194818|Active Comparator|1|Asacol 6 tablets BID (4.8 grams/day)
11642797|NCT00194818|Active Comparator|2|Asacol 4 tablets TID (4.8 grams/day)
11642798|NCT00194805|Experimental|1|Subjects randomized into the treatment group received the computer treatment
11642799|NCT00194792|Experimental|Treatment (hormone therapy and chemotherapy)|See detailed description
11642800|NCT00194779|Experimental|Treatment (neoadjuvant therapy, adjuvant therapy)|See Detailed Description.
11642801|NCT00194766|Experimental|1|Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
11642802|NCT00194753|Experimental|1|Weekly doxorubicin (24 mg/m2 IV) with daily oral cyclophosphamide (60 mg/m2 PO) for 12 weeks with G-CSF support days 2 - 7 of each week followed by weekly paclitaxel (80 mg/m2 IV) for 12 weeks.
11642803|NCT00194740|Experimental|1|
11642804|NCT00194727|Experimental|1|Vinorelbine (20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle) and capecitabine (825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle). Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
11642805|NCT00194714|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID once per month for 6 months in the absence of disease progression or unacceptable toxicity.
11642806|NCT00194675|Active Comparator|Testosterone gel + oral placebo|Testosterone 1% gel 7.5 topical daily + placebo dutasteride orally daily
11642807|NCT00194675|Active Comparator|Testosterone gel + oral dutasteride|Testosterone 1% gel 7.5 topical daily + dutasteride 0.5 mg orally daily
11642808|NCT00194649|Experimental|1|100 mg Miglustat BID (twice daily) for six weeks
11642809|NCT00194610|Experimental|Botox injection|Subjects were injected with Botulinum toxin A in a mix of 50 U diluted in 2 cubic centimeters of normal saline. With the subjects in the dorsal lithotomy position, one injection of 25 international units was given into the bladder neck at the 3 o'clock position and another of 25 international units was given into the 9 o'clock position
11642810|NCT00194610|Placebo Comparator|Normal saline|Subjects were injected in the bladder neck with 1 cubic centimeter normal saline into the 3 o'clock and 6 o' clock positions in the perineum, while in the dorsal lithotomy position
11642811|NCT00194584|Experimental|1|
11642812|NCT00194584|No Intervention|0|
11642813|NCT00194545|Experimental|1|Medication diary
11642814|NCT00194545|No Intervention|2|Caregivers only receive counseling which is the standard of care
11642815|NCT00194532|Experimental|Cefpodoxime|Cefpodoxime 100mg twice a day(BID)for 3 days
11642816|NCT00194532|Active Comparator|Ciprofloxacin|Ciprofloxacin 250mg twice a day (BID)for 3 days
11642817|NCT00194519|Active Comparator|Acyclovir|
11642818|NCT00194519|Placebo Comparator|Placebo|
11642819|NCT00194493|Experimental|1|Patient's clinician receives graphical report of patient-reported symptoms and quality of life issues.
11642820|NCT00194493|No Intervention|2|
11642821|NCT00194480|Experimental|PegInterferon|Arm 1: 24 weeks of weekly injections of peginterferon Arm 2: control (no treatment)
11642822|NCT00194467|Experimental|1|
11642823|NCT00194467|Placebo Comparator|2|
11642824|NCT00194454|Experimental|1|Nine session psychosocial/behavioral counseling with homework
11642825|NCT00194454|Active Comparator|2|Usual clinic care with booklet describing depression following stroke
11642826|NCT00194441|Experimental|1|Highly visible continually updating color coded bar computer display of cerebral perfusion pressure.
11642827|NCT00194441|Placebo Comparator|2|Bedside computer display with a blank screen except for a message indicating that the program is running.
11642828|NCT00194428|Experimental|1|Almond enriched diet
11642829|NCT00194428|Active Comparator|2|Low-fat diet
11642830|NCT00194415|Other|1|HSV-2 antepartum testing
11642831|NCT00194415|Other|2|Subjects will receive safer-sex counseling during pregnancy
11642832|NCT00194402|Active Comparator|1|Atorvastatin 10 mg for 12 weeks followed by Slo-Niacin (titrated from 500 to 1500 mg over 8 weeks) taken with atorvastatin 10 mg for an additional 12 weeks
11642833|NCT00194402|Active Comparator|2|Slo-Niacin (titrated from 500 to 1500 mg over 8 weeks) for 12 weeks followed by atorvastatin 10 mg taken with Slo-Niacin 1500 mg for an additional 12 weeks
11642834|NCT00194311||pregnancy complications|prospective cohort study is to determine if maternal infection with Human papillomavirus (HPV) is associated with pregnancy complications including spontaneous preterm delivery (sPTD), severe preeclampsia (PE) (as per current ACOG: American College of Obstetrics and Gynecology criteria), and intrauterine growth restriction (IUGR).
11642835|NCT00194194|Active Comparator|moderate|moderate behavioral management
11642836|NCT00194194|Experimental|intensive|intensive behavioral management
11642837|NCT00194129|Experimental|Lithium plus Divalproex|Patients assigned to the combination group were continued on lithium and blinded divalproex.
11642838|NCT00194129|Placebo Comparator|Lithium plus placebo|Patients assigned to lithium monotherapy underwent divalproex-placebo substitution at a rate of 250 mg decrements every week until discontinued.
11642839|NCT00194116|Experimental|Divalproex Sodium ER|
11642840|NCT00194116|Placebo Comparator|Placebo|
11642841|NCT00194103|No Intervention|TAU|
11642842|NCT00194103|Active Comparator|Telephone Monitoring|
11642843|NCT00194103|Experimental|Telephone Monitoring and Counseling|
11642844|NCT00194077|Active Comparator|Aripiprazole|Phase I and Phase III are open label Abilify phases where all subjects receive active Abilify
11642845|NCT00194077|Placebo Comparator|Placebo|in Phase 2 subjects are randomized to either placebo or abilify for up to 72 weeks
11642846|NCT00194064|Experimental|Olanzapine|Subjects were be started on a standardized minimum first-day dose of 15 mg olanzapine. After the first day of therapy, the daily dose was either increased or decreased, as clinically indicated, by 5 mg, within an allowed range of 5 to 40 mg
11642847|NCT00194038|Experimental|1|
11642848|NCT00194025|Experimental|valproate|All participants received open-label, add-on valproate.
11642849|NCT00194012|Active Comparator|Aripiprazole-Randomized Phase|Patients randomly assigned to aripiprazole received medication in pill form with dosing at 2mg, 5mg, 7mg, 10mg, 12mg or 15mg depending on their response.
11642850|NCT00194012|Placebo Comparator|Placebo-Randomized Phase|Patients randomly assigned to placebo received pills/dosing made to look identical to the aripiprazole.
11642851|NCT00193973|Active Comparator|1|
11642852|NCT00193947||women initiating ARV therapy during pregnancy with neveripine|
11642853|NCT00193934||1|Cervical Cancer Patients
11642854|NCT00193921|Experimental|A|Vinorelbine + cisplatin + high-dose palliative radiotherapy
11642857|NCT00193908|Experimental|2|
11642858|NCT00193895|Active Comparator|Radiotherapy alone|Radiotherapy alone (60Gy or 66Gy in 30-33 fractions 5-5/week)
11642859|NCT00193895|Experimental|Radiotherapy plus chemotherapy|Radiotherapy plus chemotherapy (Radiotherapy 60Gy or 66Gy in 30-33 fractions 5/week + Carboplatin (AUC 2) intravenously weekly)
11642860|NCT00193882|Active Comparator|A: Radiotherapy|Radiotherapy alone
11642861|NCT00193882|Experimental|B: Chemo-radiotherapy|Chemotherapy (Cisplatin + 5-Fluorouracil ) and Radiotherapy
11642862|NCT00193856|Active Comparator|A|LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 mths)
11642863|NCT00193856|Active Comparator|B|LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 months) + bisphosphonate therapy.
11642864|NCT00193856|Experimental|C|LH-RH analogue as for arm A, but continued for further 12 months (total 18 months)
11642865|NCT00193856|Experimental|D|LH-RH analogue as for arm A, but continued for further 12 months (total 18 months) + bisphosphonate therapy.
11642866|NCT00193804||2|Patients with histologically proven, cervical cancer FIGO Stage IIB eligible will be invited for the study. The patients will recieve either 3D conformal radiation or IMRT external radiation with concomitant cisplatin chemotherapy followed by brachytherapy.
11642867|NCT00193791|No Intervention|Radiation (RT) Alone|Standard radical radiation therapy alone
11642868|NCT00193791|Experimental|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
11642869|NCT00193778|Experimental|Loco Regional Treatment Arm (LRT)|Surgery for breast cancer. (MRM/BCT)
11642870|NCT00193778|Active Comparator|No Loco-regional Treatment Arm|No surgery for Breast cancer
11642871|NCT00193765|Active Comparator|Wait and Watch|Therapeutic neck dissection on developing nodal relapse
11642872|NCT00193765|Experimental|Elective Neck dissection|Elective neck dissection in early oral cancer at the time of primary surgery
11642873|NCT00193739|Active Comparator|NACT followed by surgery|3 cycles of neoadjuvant chemotherapy (NACT) (Inj.Paclitaxel +Inj.Carboplatin) followed by surgery (radical abdominal hysterectomy Class III , bilateral pelvic lymphadenectomy & lower para aortic lymph node sampling)
11642874|NCT00193739|Active Comparator|Concurrent chemoradiotherapy|Radiation therapy will be administered to whole pelvis followed by intracavitary brachytherapy. Patients will be given chemotherapy (Inj.Cisplatin) concurrently with external beam radiotherapy.
11642875|NCT00193726|Experimental|Arm B- Experimental|Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
11642876|NCT00193726|Placebo Comparator|Arm A - Placebo|Tab Placebo once a day for 5 days prior to each cycle of chemotherapy
11642877|NCT00193674|Experimental|1|
11642878|NCT00193674|Placebo Comparator|2|
11642879|NCT00193648|Active Comparator|1|Avandia (rosiglitazone)
11642880|NCT00193648|Active Comparator|2|Humira (adalimumab)
11642881|NCT00193635|Active Comparator|1|oral MMF
11642882|NCT00193609|Experimental|Oxaliplatin/Capecitabine|All patients received treatment with oxaliplatin 130mg/m2, given intravenously on day 1 of each 21 day cycle. Capecitabine 1000mg/m2 by mouth twice daily was administered on days 1-14 of each cycle.
11642883|NCT00193596|Experimental|Regimen A|"Paclitaxel 200 mg/m2 by 1-hour IV infusion, day 1
~Carboplatin area under the curve (AUC) 6.0 IV, day 1
~Etoposide 50 mg alternating with 100 mg by mouth, days 1 and 10
~Regimen A was repeated at a 21-day interval"
11642884|NCT00193596|Experimental|Regimen B|"Irinotecan 100 mg/m2 IV, days 1 and 8
~Gemcitabine 1000 mg/m2 IV, days 1 and 8
~Regimen B was repeated at a 21-day interval"
11642885|NCT00193492|Active Comparator|Rituximab|All patients will receive rituximab 375mg/m2 administered by slow IV infusion weekly for 4 consecutive weeks (days 1, 8, 15, and 22). Patients who have objective response or stable disease at week 12 reevaluation will receive 4 additional doses of rituximab (375 mg/m2) administered in months 3 (week 12), 5, 7, and 9.
11642886|NCT00193492|Experimental|Rituximab/Bevacizumab|All patients will receive rituximab 375mg/m2 administered by slow IV infusion weekly for 4 consecutive weeks (days 1, 8, 15, and 22). During the 4-week course of rituximab, all patients will receive 2 doses of bevacizumab 10mg/kg IV, given on Days 3 and 15. The first dose will be given on Day 3, following rituximab on Day 1. If both drugs are well tolerated during the first dose, rituximab and bevacizumab should be given on the same day for the Day 15 dose and all subsequent doses.
11642887|NCT00193479|Experimental|Cyclophosphamide/Vincristine/Rituximab +/- Mitoxantrone|All patients receive three courses of combination chemotherapy/rituximab followed by pegfilgrastim, administered at 21-day intervals. Treatment administered is as follows: cyclophosphamide 500mg/m2 IV day 1; mitoxantrone 10mg/m2 IV day 1; vincristine 1.0mg/m2 (maximum 2mg) IV day 1; prednisone 80mg PO days 1 - 5; rituximab 375mg/m2 IV day 1.
11642888|NCT00193453|Experimental|Intervention|Newly-diagnosed unresectable stage III/IV NSCLC patients were treated with docetaxel-30mg/m2 IV; gemcitabine-1000mg/m2 IV days 1, 8; cetuximab-400mg/m2 IV day 1, then 250 mg/m2 IV weekly. Patients received up to 6 cycles (21-d).
11642889|NCT00193427|Experimental|Intervention|Patients with potentially resectable clinical stage IB, II, and selected III NSCLC received gemcitabine 1000 mg/m2 days 1, 8 and docetaxel 30 mg/m2 days 1, 8 every 21 days for 3 cycles. Patients were restaged after treatment and resected 3-6 weeks later. If patients were inoperable, had incomplete resections or N2 disease, docetaxel 20 mg/m2 and carboplatin AUC = 1.5 weekly x 7 and radiation to 63 Gy was administered
11642890|NCT00193414|Experimental|Intervention|Chemotherapy-naïve patients with unresectable stage III/IV NSCLC received pemetrexed 500 mg/m2 IV and gemcitabine 1500 mg/m2 IV every 2 weeks for 8-12 cycles with restaging every 4 cycles. Patients also received supplemental folate/B12 therapy.
11642891|NCT00193375|Experimental|Intervention|Patients received carboplatin [area under the concentration-versus-time curve of 5 intravenously (IV) day 1 every 3 weeks x 4), irinotecan (50mg/m2 IV days 1 and 8 every 3 weeks x 4], and radiation (1.8 Gy daily to a total of 61.2 Gy beginning with the 3rd cycle). Cycles 3 and 4 were 28 days each; with restaging after 4 cycles. Patients without progressive disease received bevacizumab (10 mg/kg IV every 14 days x 10).
11642892|NCT00193258|Experimental|Intervention|"In the phase I portion:
~Bevacizumab 10 mg/kg slow IV infusion on days 1 and 15 of each 28-day course
~Erlotinib 150 mg orally daily
~Imatinib 300 mg orally daily or 400 mg orally daily
~In the phase II portion:
~Bevacizumab 10 mg/kg 30-60 minute IV infusion on days 1 and 15 of every 28 day cycle
~Erlotinib 150 mg orally daily
~Imatinib 400 mg orally daily"
11642928|NCT00192465|Experimental|4|MEDI-524 (Numax-TM)
11642893|NCT00193219|Experimental|Intervention|"Bevacizumab 5 mg/kg IV
~Cetuximab 400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8
~5-Fluorouracil 400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)
~Leucovorin 350 mg IV
~Oxaliplatin 85 mg/m2 IV"
11642894|NCT00193206|Experimental|Intervention|Patients were treated with 6 doses of neoadjuvant gemcitabine 2000 mg/m2, epirubicin 50 mg/m2, and albumin-bound paclitaxel 175 mg/m2 intravenously administered at 14-day intervals. Following neoadjuvant chemotherapy, patients underwent either mastectomy or breast conservation surgery; pathologic response to treatment was assessed. Postoperatively, patients received 4 doses of gemcitabine 2000 mg/m2 with albumin-bound paclitaxel 220 mg/m2 at 14-day intervals. Pegfilgrastim 6 mg was administered subcutaneously on day 2 following each dose of chemotherapy.
11642895|NCT00193180|Experimental|Intervention|All patients in this study received docetaxel 30 mg/m2 weekly for 3 consecutive weeks of each 28-day cycle, along with continuous imatinib mesylate. Initially, imatinib mesylate was given at a dose of 600 mg orally daily, beginning concurrently with the first dose of docetaxel; however, after the first 15 patients were treated it became evident that this imatinib dose was not tolerable, and subsequent patients received imatinib mesylate 400 mg orally daily.
11642896|NCT00193154|Experimental|OSI-774 & bevacizumab|OSI-774 (Tarceva) 150mb PO, days 1-28; bevacizumab (Avastin) 10mg/kg, IV infusion, days 1 and 15; Regimen will be repeated every 28 days.
11642897|NCT00193128|Experimental|Cohort 1|"An initial cohort of 10 patients was treated with oxaliplatin 40 mg/m2 intravenously (IV) over 2 hours and docetaxel 20 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, and 29. Radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).
~Patients were to have esophageal resection after completion of preoperative therapy during weeks 9 to 12 and after all treatment-related side effects were resolved."
11642898|NCT00193128|Experimental|Cohort 2|"After completion of the first phase of the trial, the second cohort began treatment.
~Oxaliplatin 40 mg/m2 intravenously (IV) over 2 hours and docetaxel 20 mg/m2 IV over 30 minutes on days 1, 8, 15, 22, and 29. Capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35. Radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).
~Patients were to have esophageal resection after completion of preoperative therapy during weeks 9 to 12 and after all treatment-related side effects were resolved."
11642899|NCT00193063|Experimental|Intervention|All patients entering this trial received treatment with a combination of gemcitabine and trastuzumab. Gemcitabine 1000 mg/m2 was administered intravenously on days 1, 8,and 15 of a 28-day cycle. Trastuzumab was administered as a 4 mg/kg intravenous loading dose on day 1 and subsequently at a dose of 2 mg/kg on a weekly basis.
11642900|NCT00193050|Experimental|Intervention|"In the neoadjuvant setting, patients were administered gemcitabine (800 mg/m2 IV days 1 and 8), epirubicin (75 mg/m2 IV day 1), and docetaxel (30 mg/m2 IV days 1 and 8)repeated every 21 days for 4 cycles
~Patients then had either mastectomy or breast conservation surgery and pathologic treatment responses were assessed.
~After surgery, 4 cycles of adjuvant gemcitabine (1000 mg/m2 IV days 1 and 8) and docetaxel (35 mg/m2 IV days 1 and 8) were administered at 21 day intervals.
~After completion of chemotherapy, local regional radiation therapy and/or anti-estrogen therapy was administered per standard guidelines."
11642901|NCT00193037|Experimental|Liposomal Doxorubicin|Liposomal doxorubicin 40 mg/m2 by 1 hour IV infusion repeated every 28 days.
11642902|NCT00193037|Experimental|Docetaxel|Weekly docetaxel 36 mg/m2 by 30 minute IV infusion on days 1, 8, and 15 of the 28 day cycle
11642903|NCT00193011|Experimental|1|Docetaxel
11642904|NCT00193011|Experimental|2|Cyclophosphamide + Methotrexate + 5-fluorouracil
11642905|NCT00192699||Group 1: Cemented Bi-Metric femoral stem|Cemented Bi-Metric femoral stem
11642906|NCT00192647|Experimental|PEG-IFN alfa-2a+Ribavirin - Induction Treatment|Participants will receive 12 weeks of induction therapy with PEG-IFN alfa-2a (Pegasys), 360 micrograms (mcg) subcutaneous (SC) once weekly, along with ribavirin, 1000 or 1200 milligrams (mg) orally daily in divided doses. Thereafter, the dose of PEG-IFN alfa-2a will be reduced to 180 mcg SC once weekly and the ribavirin dose maintained for the remaining 36 weeks of treatment.
11642907|NCT00192647|Experimental|PEG-IFN alfa-2a+Ribavirin - Standard Treatment|Participants will receive 48 weeks of standard therapy with PEG-IFN alfa-2a, 180 mcg SC once weekly, along with ribavirin, 1000 or 1200 mg orally daily in divided doses.
11642908|NCT00192634|Active Comparator|1|Abacavir 600mg/Lamivudine 300mg
11642909|NCT00192634|Active Comparator|2|Tenofovir 300mg/emtricitabine 200mg
11642910|NCT00192608|Experimental|saquinavir at baseline|patients receiving NRTIs + saquinavir + ritonavir 1000/100 mg BID at entry switch from 200 mg SQV capsules to 500 mg SQV tablets following PK at day 0. After PK at day 8 NRTIs ceased and regimen changed to ATV/SQV/RTV 300/1500/100 QD using 500 mg SQV formulation and continued to week 48
11642911|NCT00192608|Experimental|other boosted PI at baseline|Patients receiving NRTIs + PI/RTV randomised at baseline to receive ATV/SQVRTV 300/1500/100 QD using 500 mg SQV formulation or ATV/SQV/RTV 300/1600/100 QD using 200 mg formulation. Following PK at day 7, SQV formulation switched with second PK assessment at day 15. Patients then receive ATV/SQV/RTV 300/1500/100 QD to week 48.
11642912|NCT00192595|Active Comparator|Arm 1:|Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)
11642913|NCT00192595|Experimental|Arm 2|Zidovudine (AZT), tenofovir (TDF), efavirenz (EFV)
11642914|NCT00192595|Experimental|Amr 3|Lamivudine (LAM), tenofovir (TDF), efavirenz (EFV)
11642915|NCT00192569|Experimental|Treated|Subjects will be treated for 24 weeks with PEG-IFN (HIV coinfected subjects will received RBV)
11642916|NCT00192569|No Intervention|Untreated|Subjects will be followed for natural history of newly acquired HCV
11642917|NCT00192543|Active Comparator|case|diet of fish and fruit addition compared to regular diet
11642918|NCT00192543|Placebo Comparator|control|regular diet
11642919|NCT00192517|Active Comparator|1|MEDI-522
11642920|NCT00192517|Placebo Comparator|2|Placebo
11642921|NCT00192491|Active Comparator|2|FluMist
11642922|NCT00192491|Placebo Comparator|3|Placebo
11642923|NCT00192491|Active Comparator|1|FluMist with other solution
11642924|NCT00192478|Active Comparator|1|MEDI-524
11642925|NCT00192465|Experimental|1|MEDI-524 (Numax-TM)
11642926|NCT00192465|Experimental|2|MEDI-524 (Numax-TM)
11642927|NCT00192465|Experimental|3|MEDI-524 (Numax-TM)
11642929|NCT00192465|Experimental|5|MEDI-524 (Numax-TM)
11642930|NCT00192413|Experimental|Cold-adapted influenza vaccine trivalent (CAIV-T)|A single 0.2 mL dose of 10^7 fluorescent focus units was administered intranasally.
11642931|NCT00192413|Active Comparator|Trivalent Inactivated Vaccine (TIV)|A single dose was administered by intramuscular injection.
11642932|NCT00192335|Active Comparator|1|CAIVT-The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
11642933|NCT00192335|Active Comparator|2|FluMist- The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
11642934|NCT00192322|Experimental|CAIV-T 10^5|a single intranasal 0.2 mL dose of liquid CAIV-T 10^5 (approximately 0.1 mL into each nostril)
11642935|NCT00192322|Experimental|CAIVT 10^7|A single intranasal 0.2 mL dose of liquid CAIV-T 10^7 (approximately 0.1 mL into each nostril)
11642936|NCT00192322|Placebo Comparator|Placebo|A single intranasal 0.2 mL dose of placebo
11642937|NCT00192322|Active Comparator|Trivalent inactivated vaccine (TIV)|A single intramuscular injection of commercially available vaccine
11642938|NCT00192309|Experimental|Cold-adapted influenza vaccine (CAIVT)|A single intranasal dose of 10^7 fluorescent focus units.
11642939|NCT00192309|Active Comparator|Trivalent inactivated vaccine (TIV)|A single dose of commercially available Flushield was administered intramuscularly.
11642940|NCT00192309|Placebo Comparator|Placebo|The 0.2 mL administered intranasally.
11642941|NCT00192296|Experimental|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
11642942|NCT00192296|Experimental|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, IV dose
11642943|NCT00192296|Experimental|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, IV dose
11642944|NCT00192296|Experimental|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, IV dose
11642945|NCT00192283|Experimental|1|CAIV-T
11642946|NCT00192283|Placebo Comparator|2|Placebo
11642947|NCT00192270|Experimental|Cold-adapted influenza vaccine trivalent (CAIV-T)|All subjects were scheduled to receive 2 doses of CAIV-T.The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
11642948|NCT00192218|Experimental|1|FluMist
11642949|NCT00192179|Experimental|CAIV-T|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
11642950|NCT00192179|Placebo Comparator|Placebo|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
11642951|NCT00192140|Active Comparator|1|FluMist
11642952|NCT00192127|Active Comparator|1|FluMist
11642953|NCT00192127|Placebo Comparator|2|Placebo
11642954|NCT00192114|Experimental|Enzastaurin HCl|
11642955|NCT00192075|Experimental|A+FFG|Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid
11642956|NCT00192075|Active Comparator|A+FOLFOX 4|Avastin + Oxaliplatin + 5-Fluorouracil (5FU)/Folinic Acid
11642957|NCT00192036|Experimental|Gemcitabine + Cisplatin|"Gemcitabine: 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5).
~Cisplatin: 80 mg/m2, IV, every 21 days x 5 cycles.
~Radiation: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5."
11642958|NCT00192023|Experimental|Atomoxetine|atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO) for 1 week, 1.2 mg/kg/day QD, PO for 7 weeks, then 1.2 - 1.4 mg/kg/day QD, PO for up to 1.5 years or until atomoxetine receives marketing approval.
11642959|NCT00192023|Placebo Comparator|Placebo|placebo, daily (QD), by mouth (PO) for 8 weeks, then possibility to switch to atomoxetine at 0.5 mg/kg/day QD, PO for 1 week, then to 1.2 - 1.4 mg/kg/day QD, PO for up to 1.5 years or until atomoxetine receives marketing approval.
11642960|NCT00191984|Experimental|Pemetrexed + Irinotecan|
11642961|NCT00191945|Experimental|Atomoxetine|atomoxetine: 0.5 mg/kg/day every day (QD),by mouth (PO) for 2 weeks, 1.2 - 1.4 mg/kg/day QD, PO for 10 weeks, then 1.2 - 1.4 mg/kg/day QD, PO for up to 1 year
11642962|NCT00191945|Placebo Comparator|Placebo|placebo every day (QD), by mouth (PO) for 12 weeks,then possibility to switch to atomoxetine at 0.5 mg/kg/day QD, PO for 1 week, then to 1.2 - 1.4 mg/kg/day QD, PO for up to 1 year (open-label extension)
11642963|NCT00191906|Experimental|Atomoxetine first, then Placebo|Atomoxetine, 1.2 mg/kg/day, by mouth (PO) for 4 weeks, 2 week washout period and cross-over to placebo, every day (QD), PO for 4 weeks
11642964|NCT00191906|Experimental|Placebo first, then Atomoxetine|Placebo, every day (QD), by mouth (PO) for 4 weeks, 2 week washout period and cross-over to atomoxetine 1.2 mg/kg/day, PO for 4 weeks
11642965|NCT00191906|No Intervention|Normal Control|Normal controls were children selected from the general population. The normal control was matched (have same proportion) by sex (male/female) and by age (have same age range) as the study population.
11642966|NCT00191906|No Intervention|Reading Disordered Control|The reading disordered control group is comprised of children with reading disorder who receive standard remedial teaching therapy.
11642967|NCT00191854|Experimental|Gemcitabine + Paclitaxel|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.
~paclitaxel: 150 mg/m2, IV, every 14 days x 8 cycles."
11642968|NCT00191854|Experimental|Gemcitabine + Carboplatin|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.
~carboplatin: Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles."
11642969|NCT00191854|Experimental|Gemcitabine + Cisplatin|"gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.
~cisplatin: 50 mg/m2, IV, every 14 days x 8 cycles"
11642970|NCT00191815|Experimental|Gemcitabine + Cisplatin|
11642971|NCT00191789|Experimental|Gemcitabine+Doxorubicin+Cisplatin+Surgery|"Gemcitabine: 1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8).
~Doxorubicin: 60 mg/m^2, IV, every 21 days x 4 cycles (1-4). Cisplatin: 70 mg/m^2, IV, every 21 days x 4 cycles (5-8). Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision."
11642972|NCT00191724|Experimental|1|
11642973|NCT00191724|Experimental|2|
11642974|NCT00191724|Experimental|3|
11642975|NCT00191724|Experimental|4|
11642976|NCT00191724|Placebo Comparator|5|
11642977|NCT00191698|Experimental|A|Atomoxetine is administered at 1.2 mg/kg/day, PO for 8 weeks, followed by 1.2 or 2.4 mg/kg/day, PO for 4 weeks, open label administration can continue for up to one year
11642978|NCT00191698|Placebo Comparator|B|Placebo is administered by mouth, daily for 8 weeks. After 8 weeks, those randomized to placebo may be titrated to 1.2 mg/kg/day atomoxetine for the remainder of the study up to one year
11642979|NCT00191646|Experimental|Gemcitabine/Carboplatin|Gemcitabine 1000 milligrams per meter square (mg/m^2) Day 1 and Day 8, Carboplatin Area Under the Curve (AUC) 5 Day 1, six 21-day cycles
11642980|NCT00191646|Active Comparator|Paclitaxel/Carboplatin|Paclitaxel 175 milligrams per meter square (mg/m^2) administered intravenously (IV) Day 1 Carboplatin AUC 6 Day 1, six 21 day cycles
11642981|NCT00191477|Experimental|A|
11642982|NCT00191477|Placebo Comparator|B|
11642983|NCT00191451|Experimental|HER2+|Human Epidermal growth factor Receptor 2 positive (HER2+): Gemcitabine + Carboplatin + Herceptin.
11642984|NCT00191451|Experimental|HER2- (Taxane-)|Human Epidermal growth factor Receptor 2 negative (HER2-): Gemcitabine + Carboplatin. (Taxane-naive patients).
11642985|NCT00191451|Experimental|HER2- (Taxane+)|Human Epidermal growth factor Receptor 2 negative (HER2-): Gemcitabine + Carboplatin. (Taxane-pretreated patients).
11642986|NCT00191386|Experimental|Atomoxetine|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
11642987|NCT00191334|Experimental|A|
11642988|NCT00191308|Experimental|Pemetrexed + Cisplatin|"Pemetrexed: 500 milligrams per square meter (mg/m^2) intravenous (IV) every 21 days (q 21 days) for 3 cycles unless disease progression occurs
~Cisplatin: 75 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs"
11642989|NCT00191282|Experimental|1|Postprandial: Premeal insulin lispro +/- bedtime NPH
11642990|NCT00191282|Active Comparator|2|Fasting: NPH/insulin glargine or human insulin 30/70
11642991|NCT00191269|Experimental|A|Dose Level 1 - 1000 mg/m2
11642992|NCT00191269|Experimental|B|Dose Level 2 - 1250 mg/m2
11642993|NCT00191243|Experimental|A|
11642994|NCT00191243|Experimental|B|
11642995|NCT00191191|Experimental|Pemetrexed 500 mg/m2|Pemetrexed 500 mg/m2
11642996|NCT00191191|Experimental|Pemetrexed 1000 mg/m2|Pemetrexed 1000 mg/m2
11642997|NCT00191165|Experimental|1|Doubled dosage
11642998|NCT00191165|Active Comparator|2|In-label dosage
11642999|NCT00191152|Experimental|Gemcitabine + Docetaxel|
11643000|NCT00191152|Active Comparator|Capecitabine + Docetaxel|
11643001|NCT00191139|Experimental|Gemcitabine|
11643002|NCT00191139|Experimental|Gemcitabine plus Docetaxel|
11643003|NCT00191126|Other|A|
11643004|NCT00191126|Experimental|B|
11643005|NCT00191113|No Intervention|Control|Control arm; untreated with Humatrope. Ethinyl estradiol (escalating doses to 20 mcg daily) after age 13, and medroxyprogesterone acetate (10 mg tablets ten days monthly) after age 15. Subject continues until Core study completion criteria are met (protocol final height).
11643006|NCT00191113|Experimental|Humatrope|Humatrope (0.05 mg/kg/dose) by subcutaneous injection 6 times per week. Ethinyl estradiol (escalating doses to 20 mcg daily) after age 13, and medroxyprogesterone acetate (10 mg tablets ten days monthly) after age 15. Subject continues until Core study completion criteria are met (protocol final height).
11643007|NCT00191100|Experimental|1|"Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Gemcitabine 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
~Brachytherapy, 30-35 Gy over 1 week
~Two week rest period with no chemotherapy or radiation
~Cisplatin, 50 mg/m2, intravenous (IV), day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles"
11643008|NCT00191100|Active Comparator|2|"Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
~Brachytherapy, 30-35 Gy over 1 week"
11643009|NCT00190983|Experimental|Pemetrexed|
11643010|NCT00190775|Experimental|Atomoxetine|Atomoxetine 40 milligrams (mg) once daily (QD) for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
11643011|NCT00190775|Placebo Comparator|Placebo|Placebo is administered once daily (QD), orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
11643012|NCT00190749|Experimental|Olanzapine|
11643013|NCT00190749|Active Comparator|Risperidone|
11643014|NCT00190684|Experimental|Atomoxetine|Atomoxetine-naive patients will have an acute titration to a stable dose, atomoxetine experienced patients whose therapy has been interrupted with be rapidly titrated to their previously established stable dose, and atomoxetine patients on a known stable dose may continue treatment at that dose.
11643015|NCT00190671|Experimental|Pemetrexed 600 mg/m2|
11643016|NCT00190671|Experimental|Pemetrexed 1800 mg/m2|
11643017|NCT00190580|Experimental|1|
11643018|NCT00190580|Experimental|2|
11643019|NCT00190541|Active Comparator|1|Procedure/Surgery: Mesorectal excision with lateral lymph node dissection
11643020|NCT00190541|Experimental|2|Procedure/Surgery: Mesorectal excision without lateral lymph node excision
11643021|NCT00190528|Active Comparator|Surgery|
11643022|NCT00190528|Experimental|Chemotherapy + Surgery|
11643023|NCT00190515|Active Comparator|1|5-FU/l-LV
11643024|NCT00190515|Experimental|2|UFT/LV
11643025|NCT00190450|Experimental|1|Early Graft (Early G)
11643026|NCT00190450|Experimental|2|Late Graft (Late G)
11643027|NCT00190437|Experimental|1|Amoxicillin-clavulanic
11643028|NCT00190424|No Intervention|control|
11643029|NCT00190424|Experimental|CpG-ODN|
11643030|NCT00190411|Experimental|Treatment|Celiprolol
11643031|NCT00190398|Experimental|1|Carotid angioplasty and stenting with cerebral protection
11643032|NCT00190385|Active Comparator|A|
11643033|NCT00190372|Other|A|
11643034|NCT00190333|Active Comparator|A|
11643035|NCT00190307|Experimental|1|Aspirin:KARDEGIC
11643036|NCT00190294|Experimental|1|MIFEPRISTONE 200 mg and misoprostol 400 µg
11643037|NCT00190268|Experimental|3,4-diaminopyridine|3,4-diaminopyridine
11643038|NCT00190242|Experimental|group1:3 administrations of Havrix|group 1 received immunisation with Havrix (1440IU) at weeks S0, S4, S24
11643039|NCT00190242|Active Comparator|group2: 2 administrations of Havrix|group 2 received usual immunisation with Havrix (1440IU) at weeks S0 and S24
11643040|NCT00190229|Experimental|1|Cyclophosphamide
11643041|NCT00190216|Experimental|A|
11643042|NCT00190203|Experimental|A|HEMICRANIECTOMY
11643043|NCT00190190|Experimental|1|With Peeling of Limiting the Intern of the Retina
11643044|NCT00190190|Active Comparator|2|Traditional Procedure Without Peeling of Limiting
11643045|NCT00190164|Experimental|1|Macular hole surgery with alleviated positioning
11643046|NCT00190164|No Intervention|2|Macular hole surgery with no alleviated positioning
11643047|NCT00190060|Active Comparator|1|Transdermal testosterone gel (Testogel 1% )
11643048|NCT00190060|Placebo Comparator|2|Matched transdermal placebo gel
11643049|NCT00189956|Active Comparator|Group 1|healthy, vaccinia naïve subjects 2 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
11643050|NCT00189956|Active Comparator|Group 2|healthy, vaccinia naïve subjects 5 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
11643051|NCT00189956|Active Comparator|Group 3|"healthy, vaccinia naïve subjects
~1 x 10E8 TCID50 IMVAMUNE (MVA-BN), subcutaneous"
11643052|NCT00189930|Active Comparator|1|High dose
11643053|NCT00189930|Active Comparator|2|Low dose
11643054|NCT00189930|Placebo Comparator|3|
11643055|NCT00189917|Experimental|GP 1: healthy, no AD|Healthy subjects without any history of, or current signs and symptoms of atopic disease, receiving two doses IMVAMUNE (MVA-BN), subcutaneous.
11643056|NCT00189917|Experimental|GP2: prev. allerg. rhinitis|Subjects having documentation of at least one allergic rhinitis event during the previous year, receiving two doses IMVAMUNE (MVA-BN), subcutaneous..
11643057|NCT00189917|Experimental|GP3: history of AD|Subjects having documentation of a history of Atopic Dermatitis, receiving two doses IMVAMUNE (MVA-BN), subcutaneous..
11643058|NCT00189917|Experimental|GP4: active AD|Subjects presenting active Atopic Dermatitis and having an individual SCORAD value between 1 and 15, receiving two doses IMVAMUNE (MVA-BN), subcutaneous.
11643059|NCT00189878|Active Comparator|1 methotrexate|patient to receive methotrexate
11643060|NCT00189878|Placebo Comparator|2 Placebo|given placebo capsules
11643061|NCT00189852|Experimental|Docobo|telemonitoring at home system for heart failure
11643062|NCT00189852|No Intervention|Control|No telemonitoring system in place
11643063|NCT00189839|Active Comparator|1|
11643064|NCT00189839|Experimental|2|
11643065|NCT00189826|Active Comparator|1|
11643066|NCT00189826|Experimental|2|
11643067|NCT00189709|Experimental|1|
11643068|NCT00189709|Active Comparator|2|
11643069|NCT00189618|Placebo Comparator|1|
11643070|NCT00189618|Active Comparator|2|
11643071|NCT00189605|Active Comparator|1|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)
11643072|NCT00189605|Experimental|2|Percutaneous Disc Decompression of the lumbar level which is secondary to radicular pain
11643073|NCT00189592|Experimental|A|Percutaneous Fasciotomy
11643074|NCT00189592|Active Comparator|2|Standard Fasciotomy
11643075|NCT00189553|Active Comparator|Standard|Paclitaxel-Carboplatin
11643076|NCT00189553|Experimental|Experimental|Caelyx-Carboplatin
11643077|NCT00189540|Active Comparator|Active Group|4.0 mg AMG0001 via intramuscular injections on days 0, 14, and 28
11643078|NCT00189540|Placebo Comparator|Placebo Group|Placebo (saline) via intramuscular injections on days 0, 14, and 28
11643079|NCT00189527|Experimental|respiratory support|a mode of ventilation in comparison
11643080|NCT00189527|Active Comparator|Assist Control|an other mode of ventilation in comparison
11643081|NCT00189514|Experimental|1|
11643082|NCT00189514|Experimental|2|
11643083|NCT00189514|Experimental|3|
11643084|NCT00189514|Placebo Comparator|4|
11643085|NCT00189488|Experimental|Palifermin|Palifermin 60 μg/kg administered daily on 3 consecutive days prior to the day of start of the conditioning regimen and 180 μg/kg administered once prior to transplant and at least 96 hours from last palifermin dose of 60 μg/kg. Participants received conditioning therapy starting at least 24 hours after the last 60 μg dose of palifermin. Allogeneic stem cell transplant occurred on Day 0. Methotrexate dosing began at least 24 hours after the 180 μg/kg dose of palifermin on Days 1, 3, 6 and (planned) 11 administration (toxicity allowing) at doses of 15, 10, 10 and 10 mg/m^2 respectively.
11643086|NCT00189488|Placebo Comparator|Placebo|Placebo to palifermin 60 μg/kg administered daily on 3 consecutive days prior to the day of start of the conditioning regimen and placebo to palifermin 180 μg/kg once prior to transplant and at least 96 hours from previous placebo to palifermin 60 μg/kg dose. Participants received conditioning therapy starting at least 24 hours after the last 60 μg/kg dose of placebo to palifermin. Allogeneic stem cell transplant occurred on Day 0. Methotrexate dosing began at least 24 hours after the dose of placebo to palifermin 180 μg/kg on Days 1, 3, 6 and (planned) 11 administration (toxicity allowing) at doses of 15, 10, 10 and 10 mg/m^2 respectively.
11643087|NCT00189475|Active Comparator|Montelukast|Treated for 4 months with montelukast 4 mg per day
11643088|NCT00189475|Placebo Comparator|Placebo|Treated for 4 months with placebo
11643089|NCT00189462|Active Comparator|Montelukast|Treatment with montelukast for 4 months (4 mg per day)
11643090|NCT00189462|Placebo Comparator|Placebo|Treatment with placebo for 4 months
11643091|NCT00189436|Active Comparator|Treatment with Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
11643092|NCT00189436|Active Comparator|Usual care|Subject is treated with usual care as provided by the doctor. Usual care normally consists of treatment with albuterol with or without an oral steroid.
11643093|NCT00189423|Experimental|1|Active compression decompression cardiopulmonary resuscitation (ACD-CPR) with an impedance threshold device (ITD)
11643094|NCT00189423|Active Comparator|2|Conventional standard cardiopulmonary resuscitation (S-CPR)
11643095|NCT00189306|Experimental|Aldara|Aldara (imiquimod) cream 5% applied 7 times per week for 6 weeks
11643096|NCT00189293|Experimental|1|Imiquimod 5% cream
11643097|NCT00189293|Other|2|vehicle cream
11643098|NCT00189280|Experimental|imiqimod 5% cream|
11643099|NCT00189254||Imiquimod 5% cream|No investigational treatments were given during this study.
11643100|NCT00189228|Experimental|xolair|This is a single arm, parallel study examining differences of therapeutic outcomes of Xolair. Xolair is being examined as an intervention that might change the outcome of immunization.
11643101|NCT00189202|Experimental|Sirolimus, steroid avoidance arm|Thymoglobulin induction, sirolimus and no maintenance corticosteroid.
11643102|NCT00189176|Experimental|Tetrathiomolybdate|
11643103|NCT00189163|Active Comparator|Pioglitazone|30 mg, taken orally, once per day
11643104|NCT00189163|Placebo Comparator|Placebo|Sugar pill, taken orally, once a day
11643105|NCT00189137|Active Comparator|doxorubicin and ifosfamide|
11643106|NCT00189137|Experimental|gemcitabine and docetaxel|
11643107|NCT00189098|Placebo Comparator|placebo|
11643108|NCT00189098|Active Comparator|Sulfamethoxazole-trimethoprim|
11643109|NCT00189020|Experimental|2-dose|PCV7 at age 2 and 4 months
11643110|NCT00189020|Experimental|2+1-dose|PCV7 at age 2, 4 and 11 months
11643111|NCT00189020|No Intervention|Control|Control group
11643112|NCT00189007|Experimental|Allopurinol|500 mg allopurinol/ 50 mL water for injection intravenously
11643113|NCT00189007|Placebo Comparator|Placebo|500 mg mannitol/50 mL water for injection intravenously
11643114|NCT00188942|Active Comparator|Fluoxetine + Olanzapine|
11643115|NCT00188890||1|prior occupational exposure at least 20 years ago to ASBESTOS and / or documented pleural plaques on a chest x-ray Must be 30 years of age or older. NO prior cancers, except non-melanic skin cancers
11643116|NCT00188825|Experimental|basiliximab|
11643117|NCT00188825|Placebo Comparator|placebo|
11643118|NCT00188721||1|Women with confirmed unilateral breast carcinoma or ductal carcinoma in situ (DCIS)
11643119|NCT00188721||2|Women without radiological suspicious lesions, matched to cases by age (± 2.5 years), date of screening mammogram, and screening center.
11643120|NCT00188708|Experimental|hypoxia measurement|Patients undergoing or planning to receive combined anti-androgen (Casodex) and radiotherapy
11643121|NCT00188630|Active Comparator|N-Acetylcysteine|IV NAC as a 100mg/kg bolus at the start of the surgical procedure (prior to the initiation of CPB), followed by a 10 mg/kg/hr infusion until 4 hours after completion of surgery
11643122|NCT00188630|Placebo Comparator|Placebo|The control arm will instead receive placebo (5% dextrose solution), both as a bolus and infusion.
11643123|NCT00188578|Experimental|IMRT Gynecological Cancers|
11643124|NCT00188539|Experimental|Pre-treatment tumour oxygen measurements (under anesthesia)|
11643125|NCT00188513|Experimental|Conformal intensity modulated radiotherapy (IMRT)|All patients shall receive a continuous course of intensity modulated conformal radiotherapy consisting of 66 Gy in 22 (3 Gy) fractions over 4.5 weeks.
11643126|NCT00188344|Active Comparator|1|pneumatic dilatation
11643127|NCT00188344|Active Comparator|2|Laparoscopic myotomy
11643128|NCT00188331||1|adjuvant/neoadjuvant chemotherapy
11643129|NCT00188331||2|non-chemotherapy group
11643130|NCT00188331||3|limited metastatic disease or localised recurrence to receive first line metastatic chemotherapy
11643131|NCT00188318|Experimental|Hyperfractionated Accelerated Radiotherapy|Hypofractionated Accelerated Radiotherapy with integrated neck surgery
11643132|NCT00188305|Experimental|1 In person|In person general health, colorectal cancer risk information and screening recommendations.
11643133|NCT00188305|Active Comparator|2 Telephone|Telephone general health counselling, colorectal cancer risk information and screening recommendations.
11643134|NCT00188305|Placebo Comparator|3 Control|Standard care for 2 months followed by summary letter with general health information, colorectal cancer risk information and screening recommendations.
11643135|NCT00188292||High-grade disease|Those who had histologic anal high-grade disease.
11643136|NCT00188292||Control|Those who had less than highgrade histologic anal disease
11643137|NCT00188279|Experimental|MnDCT|
11643138|NCT00188266|Experimental|5-Fluorouracil (5FU) and Cisplatin with Radiation|
11643139|NCT00188214|Other|CT perfusion scan|
11643140|NCT00188175|Experimental|IMRT for lower limb soft tissue sarcoma|
11643141|NCT00188058|Active Comparator|Minimal alveolar distension|PEEP is set for a total PEEP (PEEP + intrinsic PEEP) between 5 and 9 cm H2O
11643142|NCT00188058|Experimental|Maximal alveolar distension|PEEP is set for a plateau pressure between 28 and 30 cm H20
11643143|NCT00187941|Other|CellCept|CellCept + Prograf or Neoral + Steroids
11643144|NCT00187915|Other|CellCept + Prograf|Standard of Care Regime
11643145|NCT00187915|Other|CellCept + Neoral|Standard of Care Regime
11643146|NCT00187889|Active Comparator|Eplerenone|Eplerenone 25 mg (1 pill)daily for 1 week then uptitrated to 50 mg (2 pills)daily for 15 weeks.
11643147|NCT00187889|Placebo Comparator|Placebo or sugar pill|Placebo blinded as 25 mg tablet once daily for 1 week then uptitrated to 2 pills daily for 15 weeks.
11643148|NCT00187876|Active Comparator|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts.
11643149|NCT00187876|Experimental|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
11643150|NCT00187863||Exercise induced pain perception|
11643151|NCT00187863||Surgical pain perception|
11643152|NCT00187850|Experimental|PP|Partial pulpotomy
11643153|NCT00187850|Other|DPC|Direct pulp capping
11643154|NCT00187837|Experimental|SW intervention|Stepwise Excavation
11643155|NCT00187837|Other|DCE intervention|Control intervention Direct complete excavation. The updated terminology for completed excavation is non-selective excavation to hard dentin
11643156|NCT00187798|Other|Metformin|Metformin HCl
11643157|NCT00187746|Experimental|Age 18-25 years|African American subjects between the ages 18 to 25 years given Adefovir dipivoxil.
11643158|NCT00187746|Experimental|Age 48-55 years|African American subject between the ages 48 to 55 years given Adefovir dipivoxil.
11643159|NCT00187733||Fasting|Other: Fasting blood and urine collection
11643668|NCT00179764|Other|Reduced Intensity Conditioning Regimen|
11643160|NCT00187720|Experimental|OCT2-variant Group|Subjects with OCT2-variant genotype will be given a single oral dose of 850 mg of metformin.
11643161|NCT00187720|Experimental|OCT2-reference Group|Subjects with OCT2-reference genotype will be given a single oral dose of 850 mg of metformin.
11643162|NCT00187707|Other|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
11643163|NCT00187681|Experimental|OCT1-variant Group|Subjects with OCT1-variant alleles will be dosed with 2 doses of Metformin
11643164|NCT00187681|Experimental|OCT1-reference Group|Subjects with OCT1-reference alleles will be dosed with 2 doses of Metformin
11643165|NCT00187668||African American|Must self identify as African American with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
11643166|NCT00187668||Cuacasian|Must self identify as Caucasian with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
11643167|NCT00187668||Hispanic|Must self identify as Hispanic with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
11643168|NCT00187668||Asian|Must self identify as Asian with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
11643169|NCT00187655|Other|Cefotaxime|Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
11643170|NCT00187629|Experimental|1|dietary phosphorus
11643171|NCT00187629|Active Comparator|2|other
11643172|NCT00187590|Experimental|Intervention|Phone call after an ER visit.
11643173|NCT00187590|No Intervention|Control|No phone call after an ER visit.
11643174|NCT00187577|Active Comparator|application to eyelid of latanoprost solution|Subject will apply latanoprost solution with applicator daily to affected eye lid(s)
11643175|NCT00187577|Active Comparator|Application of bimatoprost to eyelid|Subject will apply bimatoprost solution with applicator daily to affected eye lid(s)
11643176|NCT00187551|Experimental|interruption of enfuvirtide|enfuvirtide interruption
11643177|NCT00187538|Active Comparator|1|
11643178|NCT00187538|Active Comparator|2|
11643179|NCT00187538|Active Comparator|3|
11643180|NCT00187538|Active Comparator|4|
11643181|NCT00187486|Experimental|Temodar plus Tarceva plus Radiation Therapy|Single arm phase-2 experimental treatment of newly diagnosed patients with Glioblastoma with Temodar plus Tarceva plus Radiation Therapy
11643182|NCT00187460|Active Comparator|Early Feedback Arm|Hospital corporations randomized to receive early feedback in the form of a report card
11643183|NCT00187460|Active Comparator|Delayed Feedback Arm|Hospitals randomized to receive delayed feedback in the form of a hospital report cared, 21 months after the early feedback arm.
11643184|NCT00187421|No Intervention|1|Graft patency assessment by routine clinical assessment with/without intraluminal coronary probe
11643185|NCT00187421|Experimental|2|Graft patency assessment by indocyanine green angiography and transit-time flowmetry
11643186|NCT00187369|Other|Caesarean Section|delivery by CS
11643187|NCT00187369|Other|Vaginal Birth|delivery by VB
11643188|NCT00187356|Experimental|Surgical Conduit|The surgical arm will be composed of the experimental arm (the use of the radial artery) versus an active comparator (the use of the saphenous vein graft).
11643189|NCT00187317|Experimental|PERT|Perturbation-based balance training.
11643190|NCT00187317|Placebo Comparator|CON|Flexibility and relaxation training.
11643191|NCT00187278|Active Comparator|RV Pacing|Standard Pacemaker implant
11643192|NCT00187278|Experimental|Biventricular Pacing|Biventircular Pacemaker implant
11643193|NCT00187252|Experimental|1|CRT + AF Suppression turned ON
11643194|NCT00187252|Active Comparator|2|CRT + AF Suppression turned OFF
11643195|NCT00187239|Active Comparator|AICS On|Patients in this arm have Autointrinsic conduction search programmed ON.
11643196|NCT00187239|No Intervention|AICS Off|Patients assigned to this arm do not have Autointrinsic Conduction Search programmed on.
11643197|NCT00187226|Other|Stratum 1|Ependymoma, craniopharyngioma, low-grade glioma
11643198|NCT00187226|Other|Stratum 2|High-grade glioma
11643199|NCT00187200|Active Comparator|Simultaneous VV Pacing|Programmed to simultaneous biventricular pacing
11643200|NCT00187200|Active Comparator|Sequential VV Pacing|Programmed to sequential biventricular pacing
11643201|NCT00187187|Active Comparator|Implantable Defibrillator (ICD) VVI-40|The DAVID II Clinical Study evaluates the hypothesis that, in patients needing an ICD but without overt indications for pacing, AAI pacing with maximal concomitant drug therapy (AAI-70)will not increase the rate of the combined endpoint of mortality or hospitalization for new or worsened heart failure, compared to patients with ventricular backup pacing (VVI-40).
11643202|NCT00187187|Active Comparator|Implantable Defibrillator (ICD) AAI-70|The DAVID II Clinical Study evaluates the hypothesis that, in patients needing an ICD but without overt indications for pacing, AAI pacing with maximal concomitant drug therapy (AAI-70)will not increase the rate of the combined endpoint of mortality or hospitalization for new or worsened heart failure, compared to patients with ventricular backup pacing (VVI-40).
11643203|NCT00187174|Experimental|Phase 1|
11643204|NCT00187161|Experimental|A|"Group A: Resected Stage I and resected abdominal Stage II
~Subjects will receive two courses (3 weeks apart) of COPAD."
11643205|NCT00187161|Experimental|B|"Group B: Other Stage II, Stage III, Stage IV or B-ALL M blast <70%; no CNS involvement.
~Subjects in Group B will receive one week of treatment of COP."
11643206|NCT00187161|Experimental|C|"Group C: B-ALL with >70% BM blasts; CNS involvement, Group B COP failures i.e., <20% reduction Treatment Pre-Induction
~Subjects will receive one week of treatment of COP."
11643207|NCT00187148|Other|1|
11643208|NCT00187135|Active Comparator|1|Fentanyl-1mcg/kg in 3 ml of Normal Saline
11643209|NCT00187135|Active Comparator|2|Fentanyl - 0.5 mcg/kg in 3 ml normal saline
11643210|NCT00187135|Placebo Comparator|3|normal saline
11643211|NCT00187122|Other|1|See Detailed Description section for description of treatment plan.
11643258|NCT00186173|Experimental|After school sports|After school team sports intervention designed specifically for overweight and obese children
11643716|NCT00179127|Placebo Comparator|Placebo|0.3u/kg of saline, subcutaneously, once
11643212|NCT00187096|Experimental|Stratum 1|"Stratum 1 (AML in complete remission)
~Cyclophosphamide 60 mg/kg IV Day -7 Fludarabine 25 mg/m2/day IV Days -6 through -2 Donor pheresis Day -1 Start IL-2 on Day -1, then 3 times per week x 2 weeks NK Cell purification and infusion on Day 0"
11643213|NCT00187096|Experimental|Stratum 2|"Stratum 2 (AML that is refractory or relapsed or AML with increasing minimal residual disease)
~Clofarabine 40 mg/m2 IV, days -6 through -2 Etoposide 100 mg/m2 IV, days -6 through -2 Cyclophosphamide 400 mg/m2 IV, days -6 through 02 Donor pheresis Day -1 Start IL-2 Day -1, and then 3 times per week x 2 weeks NK Cell purification and infusion on Day 0."
11643214|NCT00187083|Experimental|1|Native asparaginase
11643215|NCT00187083|Experimental|2|PEG-asparaginase
11643216|NCT00187070|Other|1|
11643217|NCT00187057|Other|1|Acute Lymphoblastic Leukemia (ALL) Low Risk
11643218|NCT00187057|Other|2|Acute Lymphoblastic Leukemia (ALL) - High Risk
11643219|NCT00187057|Other|3A|B-Cell Non-Hodgkins Lymphoma (Group A)
11643220|NCT00187057|Other|3B|B-Cell Non-Hodgkins Lymphoma (Group B)
11643221|NCT00187057|Other|4|Hodgkins Disease
11643222|NCT00187044|Other|1|
11643223|NCT00187031|Other|1|
11643224|NCT00187005|Other|1|
11643225|NCT00186992|Other|Treatment|Eligible patients will be accessioned at the time of irradiation and undergo a pre-radiotherapy evaluation, treatment planning, image-guided radiotherapy delivery and intra-and post-irradiation evaluations.
11643226|NCT00186979|Other|1|
11643227|NCT00186966|Other|FLAG|
11643228|NCT00186966|Other|FLAG and LP Dox|
11643229|NCT00186953|Other|1|
11643230|NCT00186940||1|
11643231|NCT00186927|Experimental|Participants|"Participants will be studied in three cohorts:
~Healthy seropositive children 3 years up to 6 years
~Healthy seropositive toddlers 12 months up to 24 months
~Healthy seronegative toddlers 12 months up to 24 months.
~Each cohort will receive Sendai virus vaccine."
11643232|NCT00186914|Other|1|
11643233|NCT00186901|Placebo Comparator|1A|Nutritional counseling + placebo
11643234|NCT00186901|Experimental|1B|Nutritional counseling + supplementation with calcium, 1000mg/day + vitamin D, 800 units/day, for a 2 year period
11643235|NCT00186888|Other|Stratum A|Patients with early bilateral or unilateral, or patients with bilateral that have already had the advanced eye enucleated. Treatment included vincristine and carboplatin for 8 courses, given at 3-4 week intervals. Focal therapies any time after second course can include cryotherapy, laser photocoagulation, thermotherapy, and plaque radiotherapy
11643236|NCT00186888|Other|Stratum B|"Patients with bilateral disease (at least one advanced stage eye), candidate for conservative management.
~Treatment included window treatment with vincristine and topotecan, Followed by 3 more courses of vincristine-topotecan if they had a response to the window+ 6 courses of vincristine and carboplatin. If they do not respond to the window, they receive 6 courses of vincristine, carboplatin, and etoposide. Periocular carboplatin is also given three times, depending on whether they respond to window. External Beam Radiation 44-46 Gy administered using standard practices."
11643237|NCT00186888|Other|Stratum C|"Patients with advanced unilateral advanced intraocular disease. First intervention is enucleation.
~If enucleated eye does not have disease outside the retina (low risk), no additional treatment is given.
~For patients whose enucleated eye shows tumor outside the retina (intermediate risk), they will receive 4 courses of vincristine, cyclophosphamide, and doxorubicin followed by G-CSF.
~For patients with high risk disease (involvement of the sclera, optic nerve at the level of the cut-end), treatment after enucleation is 6 courses of alternating chemotherapy with vincristine, carboplatin, etoposide (VCE) to alternate with vincristine, cyclophosphamide, and doxorubicin (VCD). High risk patients also receive external-beam radiation therapy."
11643238|NCT00186875|Other|Treatment|Participants receive chemotherapy, intrathecal chemotherapy, steroid therapy, hematopoietic stem cell transplant, and natural killer cell transplant as outlined in the Interventions section, including etoposide, cytarabine, vincristine, dexamethasone, methotrexate, teniposide, PEG-asparaginase, mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine, L-asparaginase, erwinia asparaginase.
11643239|NCT00186862|Other|1|
11643240|NCT00186849|Other|1|
11643241|NCT00186823|Other|1|
11643242|NCT00186810|Other|1|
11643243|NCT00186771|Active Comparator|True Transcranial Magnetic Stimulation|True treatment with TMS over the temporoparietal cortex.
11643244|NCT00186771|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham treatment with rTMS over the temporoparietal cortex.
11643245|NCT00186758|Sham Comparator|1, Phase l, True or Sham|this treatment will be True or Sham (placebo) on one side of the head, phase I
11643246|NCT00186758|Active Comparator|2, phase ll, Sham or True|This treatment will be Sham(placebo)or True on the other side of the head phase II.
11643247|NCT00186745|Experimental|1|All patients in this cohort receive treatment with weight-adjusted, standard-dose tinzaparin for treatment of venous thromboembolism. Trough anti-Xa level measurements done on any 2 of days 3, 5 or 7 of treatment. Patients with a trough anti-Xa level > 0.5 IU/mL receive dose adjustment of the tinzaparin.
11643248|NCT00186628|Experimental|Prophylactic Rituximab|Rituximab will be infused after a non-myeloablative transplantation regimen of total lymphoid irradiation (TLI) + anti-thymoglobulin (ATG), with the intention of reducing chronic graft-vs-host disease (cGvHD)
11643249|NCT00186537|Active Comparator|fenofibrate|160 mg daily for 12 weeks
11643250|NCT00186537|Active Comparator|rosiglitazone|4 mg/daily 4 weeks followed by 4 mg 2 x daily for 8 weeks
11643251|NCT00186537|Active Comparator|calorie restricted diet|calorie restricted to achieve 0.5 kg weight loss/week x 12 weeks
11643252|NCT00186498|Placebo Comparator|Placebo Oral Capsule|Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
11643253|NCT00186498|Experimental|memantine|Patients receive memantine starting the day before ECT begins and while receiving ECT
11643254|NCT00186485|Experimental|Right Sided Low Frequency Unilateral TMS|1Hz unilateral TMS delivered to the right DLPFC using the MagStim device
11643255|NCT00186446|Experimental|Bupropion|
11643256|NCT00186342|Experimental|CIK cell|The initial dose utilized will be 1x107 expanded cells/kg. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD.
11643257|NCT00186186|Experimental|Depakote ER|Depakote ER up to 1500 mg/day
11643406|NCT00184106|Active Comparator|Seroxat and SE|SSRI with Self exposure
11643259|NCT00186173|Active Comparator|After school health education|After school heath and nutrition education program
11643260|NCT00186147||Graft recipients and donors|
11643261|NCT00186121|Experimental|Anastrozole + Goserelin|Participants received goserelin 3.6 mg subcutaneously monthly. Beginning on Day 22 after the first dose of goserelin, participants began taking anastrozole 1 mg orally daily. No dose attenuation or escalation was allowed for either goserelin or anastrozole.
11643262|NCT00186082|Active Comparator|Cefotetan, Cefoxitin or Clindamycin|
11643263|NCT00186082|Placebo Comparator|Normal Saline|
11643264|NCT00186069|Active Comparator|Magnesium Sulfate|Magnesium Sulfate 4 gram bolus, followed by 2 grams per hour
11643265|NCT00186069|Placebo Comparator|Normal Saline|Normal Saline 4 gram bolus, followed by 2 grams per hour
11643266|NCT00186056|Experimental|Mifepristone|Patients received mifepristone for 6 days
11643267|NCT00186056|Placebo Comparator|placebo|Patients received placebo for 6 days
11643268|NCT00186043|Experimental|Quetiapine/Seroquel|Quetiapine/Seroquel up to 800 mg/day
11643269|NCT00186043|Placebo Comparator|Placebo|Placebo
11643270|NCT00186017|Experimental|Olanzapine/Zyprexa|Olanzapine/Zyprexa 2.5 mg up to 8 per day for 1 week
11643271|NCT00186017|Placebo Comparator|Placebo|Placebo was taken in the same manner as olanzapine with up to 8 per day for 1 week
11643272|NCT00185991|Active Comparator|Once daily Gentamicin|
11643273|NCT00185991|Active Comparator|Every eight hour Gentamicin|
11643274|NCT00185965|Experimental|Lymphoma, B-cell low-grade (BCL)|Recurrent low-grade B-cell lymphoma patients (at least one prior treatment failure)
11643275|NCT00185965|Experimental|Mycosis fungoides (MF)|"Mycosis fungoides patients must have failed or have been intolerant of at least 1 topical or 1 systemic treatment
~Recurrent mycosis fungoides patients (at least one prior failure of topical or systemic treatment)"
11643276|NCT00185952|Active Comparator|Nifedipine|Maintenance tocolysis with nifedipine.
11643277|NCT00185952|Placebo Comparator|Placebo|Maintenance tocolysis with placebo tablets.
11643278|NCT00185900|Active Comparator|Magnesium Sulfate|Preterm labor treatment with Magnesium Sulfate.
11643279|NCT00185900|Active Comparator|Nifedipine|Preterm labor treatment with Nifedipine.
11643280|NCT00185887|Active Comparator|Terbutaline|
11643281|NCT00185887|Active Comparator|Nitroglycerine|
11643282|NCT00185848|Experimental|[18F]FHBG arm|
11643283|NCT00185796|Experimental|TLI/ATG conditioning|Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).
11643284|NCT00185757|Experimental|Cytokine-induced Killer Cells|The first cohort =1X10 7 cf expanded cells/kg. The second cohort = 5x10 7 expanded cells/kg. The second cohort = 1X10 8 expanded cells/kg.
11643285|NCT00185744|Experimental|Accelerated Partial Breast Irradiation|lumpectomy with accelerated partial breast irradiation
11643286|NCT00185744|Active Comparator|Standard Therapy|lumpectomy and whole breast irradiation
11643287|NCT00185731|Experimental|80 mg Atorvastatin|Atorvastatin, 80 mg tablet, will be taken orally by the patient daily, beginning on study day 1.
11643288|NCT00185692|Experimental|Transplantation of CD34+ cells|"Week #1: Total Lymphoid Inrradiation (TLI) 120 cGy + Anti-thymocyte Globulin (ATG) 1.5 mg/kg + Solumedrol 1.0 mg/kg Daily for 5 days.
~Week #2: TLI 120 cGy (3 days a week, double on the 4th day) 5 days of CSP (oraly) one day after TLI was started. 3 days of MMF 4 days after TLI was started."
11643289|NCT00185679|Experimental|Haploidentical Allogeneic Transplant Using CliniMACS System|The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.
11643290|NCT00185640|Experimental|Non-myeloablative transplantation|Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil .
11643291|NCT00185614|Experimental|Auto- then Allo-HCT|Auto-HCT mobilization is cyclophosphamide 4 g/m2 + filgrastim 10 µg/kg/day for peripheral blood progenitor cell (PBPC) collection by apheresis. Transplant conditioning is high-dose melphalan 200 mg/m2, followed by PBPC infusion as melphalan rescue [ie, autologous hematopoietic cells transplant (Auto-HCT)]. Post-infusion support is filgrastim 5 µg/kg/day, starting 6 days after melphalan. Stable/responsive disease at 4 weeks continues to allogenic HCT (Allo-HCT) from sibling donor fully-matched for human leukocyte antigen (HLA). Allo-HCT conditioning is total body irradiation (TBI) 200 centigray (cGy) + cyclosporine (CSP) 6.25 mg/kg + mycophenolate mofetil (MMF) 15 mg/kg. Donor mobilization is filgrastim 16 µg/kg/day on day -4 to Day 0; apheresis collections on Day -1 & Day 0, to a target of > 5 x 10e6 CD34 cells/kg. Allo-HCT is infused to participant on Day 0, with premedication hydrocortisone 100 mg IV & diphenhydramine 50 mg IV. CSP tapering on Day 56 to Day 180, adjusted as needed.
11643292|NCT00185601|Other|on-line self management intervention|
11643293|NCT00185601|No Intervention|usual care control group|
11643294|NCT00185601|Experimental|on-line self management intervention with email reinforcement|
11643295|NCT00185588|Experimental|Stage 1 Dose Exploration 0 - Gemcitabine 700 + vatalanib 1250|Gemcitabine 700 mg/m2 + vatalanib 1250 mg daily
11643296|NCT00185588|Experimental|Stage 1 Dose Exploration 1 - Gemcitabine 850 + vatalanib 1250|Gemcitabine 850 mg/m2 + vatalanib 1250 mg
11643297|NCT00185588|Experimental|Stage 1 Dose Explrtion2 - Gemcitabine850+vatalanib 2x250/2x500|Gemcitabine 850 mg/m2 + vatalanib 250 mg Q12 hours x 1 week then 500 mg Q12 hours thereafter
11643298|NCT00185588|Experimental|Stage 2 Dose Expansion - Gemcitabine850+vatalanib 2x250/2x500|Gemcitabine 850 mg/m2 + vatalanib 250 mg Q12 hours x 1 week then 500 mg Q12 hours thereafter
11643299|NCT00185523||CML in first Chronic Phase or Accelerated Phase|Busulfan/cyclophosphamide Day -7: Busulfan 1.0 mg/kg IV q6 hrs** Day -6: Busulfan 1.0 mg/kg IV q6 hrs Day -5: Busulfan 1.0 mg/kg IV q6 hrs Day -4: Busulfan 1.0 mg/kg IV q6 hrs Day -3: Cyclophosphamide 60 mg/kg Day -2: Cyclophosphamide 60 mg/kg Day -1: rest Day 0: Allogeneic PBSC infusion
11643300|NCT00185523||AML and ALL in first or second remission|FTBI/VP-16 Day -7: FTBI 120 cGy x 3 fractions Day -6: FTBI 120 cGy x 2 fractions Day -5: FTBI 120 cGy x 3 fractions Day -4: FTBI 120 cGy x 3 fractions* Day -3: VP-16 at 60 mg/kg Day -2: rest Day -1: rest Day 0: Allogeneic PBSC infusion
11643301|NCT00185510|Experimental|Arm 1|
11643302|NCT00185510|Placebo Comparator|Arm 2|
11643303|NCT00185484|Experimental|Arm 1|
11643717|NCT00179062|Active Comparator|1|
11643304|NCT00185458|Experimental|LNG IUS|Levonorgestrel Intrauterine System (LNG IUS) (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) Hormone-Replacement Therapy (HRT) Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by World Health Organization (WHO) guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
11643305|NCT00185445|Experimental|Arm 1|
11643306|NCT00185419|Active Comparator|Arm 1|
11643307|NCT00185419|Active Comparator|Arm 2|
11643308|NCT00185393|Experimental|Arm 1|
11643309|NCT00185393|Other|Arm 2|
11643310|NCT00185380|Experimental|LCS12|Levonorgestrel intrauterine contraceptive system (LCS) releasing 12 microg/24h in vitro
11643311|NCT00185380|Experimental|LCS16|Levonorgestrel intrauterine contraceptive system (LCS) releasing 16 microg/24h in vitro
11643312|NCT00185380|Active Comparator|IUS20 (Mirena)|Levonorgestrel intrauterine system (IUS) releasing 20 microg/24h in vitro
11643313|NCT00185367|Experimental|Arm 1|
11643314|NCT00185367|Active Comparator|Arm 2|
11643315|NCT00185354|Experimental|Arm 1|
11643316|NCT00185354|Active Comparator|Arm 2|
11643317|NCT00185341|Experimental|CCR-1 Receptor Antagonist|Subjects received 600 mg (2 x 300 mg tablets) of CCR-1 Receptor Antagonist 3 times daily
11643318|NCT00185341|Placebo Comparator|Placebo|Subjects received placebo corresponding to verum
11643319|NCT00185328|Experimental|Arm 1|
11643320|NCT00185315|Experimental|Arm 1|
11643321|NCT00185302|Experimental|Histone Deacetylase Inhibitor, 3 mg|Subjects received 3 mg MS-275 orally biweekly (Days 1 and 15 of a 4 week cycle) or until disease progression or unacceptable toxicity
11643322|NCT00185302|Experimental|Histone Deacetylase Inhibitor, 7 mg|Subjects received 7 mg MS-275 orally weekly (Days 1, 8, and 15 of a 4 week cycle) until disease progression or unacceptable toxicity
11643323|NCT00185289|Experimental|Arm 1|
11643324|NCT00185276|Experimental|Arm 1|
11643325|NCT00185276|Experimental|Arm 2|
11643326|NCT00185263|Experimental|1|Ad5FGF-4
11643327|NCT00185263|Experimental|2|Ad5FGF-4
11643328|NCT00185263|Placebo Comparator|3|Placebo
11643329|NCT00185250|Experimental|Arm 1|
11643330|NCT00185250|Experimental|Arm 2|
11643331|NCT00185250|Placebo Comparator|Arm 3|
11643332|NCT00185250|Placebo Comparator|Arm 4|
11643333|NCT00185237|Experimental|Arm 1|
11643334|NCT00185237|Placebo Comparator|Arm 2|
11643335|NCT00185224|Experimental|Arm 1|
11643336|NCT00185224|Active Comparator|Arm 2|
11643337|NCT00185211|Experimental|Initial IFNB-1b (Interferon beta-1b)|Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
11643338|NCT00185211|Experimental|Initial Placebo|Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
11643339|NCT00185198|Active Comparator|Arm 1|
11643340|NCT00185198|Placebo Comparator|Arm 2|
11643341|NCT00185185|Experimental|1|olmesartan medoxomil
11643342|NCT00185185|Active Comparator|2|atenolol
11643343|NCT00185172|Placebo Comparator|1|2 week placebo run-in
11643344|NCT00185172|Experimental|2|Olmesartan medoxomil tablets for 8 weeks
11643345|NCT00185172|Experimental|3|Olmesartan medoxomil tablets, or olmesartan medoxomil tablets + hydrochlorothiazide tablets for 4 weeks
11643346|NCT00185159|Experimental|1|olmesartan medoxomil
11643347|NCT00185159|Placebo Comparator|2|placebo
11643348|NCT00184925|Active Comparator|subglottic drainage|suctioning of subglottis with cannula
11643349|NCT00184873|Active Comparator|Lifestyle counseling|Patients receiving lifestyle counseling
11643350|NCT00184873|No Intervention|Regular care|Patients receiving regular care
11643351|NCT00184795|Experimental|ALD 0.1|
11643352|NCT00184795|Experimental|ALD 0.25|
11643353|NCT00184795|Placebo Comparator|Placebo|
11643354|NCT00184717|Experimental|0.033 mg / NN-220|In the 156-week main period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
11643355|NCT00184717|Experimental|0.067 mg / NN-220|In the 156-week main period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime
11643356|NCT00184717|No Intervention|No treatment|No somatropin (NN-220) treatment was given in the 52-week main period. Subjects was re-randomised to recive two dosing regimens (0.033 mg/kg/day or 0.067 mg/kg/day) in the 208-week extension period
11643357|NCT00184717|Experimental|No treatment --> 0.033 mg|In the 208-week extension period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period
11643358|NCT00184717|Experimental|No treatment --> 0.067 mg|In the 208-week extension period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period
11643407|NCT00184106|Active Comparator|Seroxat and Cognitive Therapy|Combination of Seroxat and Cognitive Therapy
11643408|NCT00184106|Placebo Comparator|Pill-Placebo|Pill Placebo
11643409|NCT00184093|Experimental|Gemcitabine weekly x 6 wks with concurrent external radiation|Gemcitabine 350 mg/m2 IV weekly x 6 weeks with concurrent external radiation
11643410|NCT00184067|Experimental|Peptide vaccine with Montanide ISA 51 + GM-CSF|Peptide vaccine with Montanide ISA 51 GM-CSF
11643411|NCT00184067|Active Comparator|Peptide vaccine with Montanide ISA 51|Peptide vaccine with Montanide ISA 51
11643718|NCT00179062|Active Comparator|2|
11643359|NCT00184600|Experimental|Insulin detemir (basal insulin)|Individually adjusted insulin detemir injected subcutaneously once daily before bed and administered in combination with current OAD treatment. Subjects had the option to add a second pre-breakfast basal insulin analogue injection if pre-breakfast but not pre-dinner meal plasma glucose targets were met. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin detemir once (or twice) daily were asked to add insulin aspart three times daily with meals i.e. a basal-bolus insulin analogue regimen.
11643360|NCT00184600|Active Comparator|Insulin aspart (prandial insulin)|Individually adjusted insulin aspart injected subcutaneously at meal-times (breakfast, lunch and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to insulin aspart three times a day with meals were asked to add insulin detemir once or twice daily i.e. a basal-bolus insulin analogue regimen.
11643361|NCT00184600|Active Comparator|Biphasic insulin aspart 30 (biphasic insulin)|Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen.
11643362|NCT00184587|Experimental|candesartan|candesartan cilexetil 16 mg (one tablet/day) in week 1 and 32 mg (2 tablets/day) in week 3, provided for the study by AstraZeneca
11643363|NCT00184587|Placebo Comparator|placebo|placebo one tablet/day in week 1 and 2 tablets/day in week 3, provided for the study by AstraZeneca. Same size, weight, taste and appearance as experimental drug
11643364|NCT00184548|Experimental|rFVIIa, Blunt Trauma|
11643365|NCT00184548|Placebo Comparator|Placebo, Blunt Trauma|
11643366|NCT00184548|Experimental|rVIIa, Penetrating Trauma|
11643367|NCT00184548|Placebo Comparator|Placebo, Penetrating Trauma|
11643368|NCT00184522|Experimental|Aflurax|pectin-containing natural product
11643369|NCT00184522|Active Comparator|esomeprazole (Nexium)|esomeprazole (Nexium)
11643370|NCT00184496|Active Comparator|methadon|Morphine methadone stop and go switch
11643371|NCT00184496|Active Comparator|Methadone|Methadon morphine overlap switch
11643372|NCT00184483|Experimental|Lichtenstein's operation|Patients with a primary unilateral inguinal hernia are randomized to Lichtenstein's operation to repair their groin hernia
11643373|NCT00184483|Active Comparator|Prolene Hernia System|Patients with a primary unilateral inguinal hernia are randomized to Prolene Hernia System to repair their groin hernia
11643374|NCT00184444|Experimental|Hypoxic Interval training|4 x 4 minutes interval training with 100% oxygenated air
11643375|NCT00184444|Experimental|Normoxic interval training|4 x 4 minutes interval training in normoxic air
11643376|NCT00184431|Experimental|A|Intensive task specific balance training
11643377|NCT00184431|Active Comparator|B|Traditional physical therapy
11643378|NCT00184418||All patients admitted to a psychiatric acute ward|
11643379|NCT00184392|Experimental|debridement or saline irrigation|1 arm undergo debridement of the nose 1 week and 2 weeks after surgery the other arm rinse their nose with saline irrigation
11643380|NCT00184379|Experimental|1 S+E|Relatives of patients with schizophrenia, who receive education
11643381|NCT00184379|No Intervention|2 S-E|Relatives of patients with schizophrenia, who do not receive education
11643382|NCT00184379|Experimental|3 B+E|Relatives of patients with bipolar disorder, who receive education
11643383|NCT00184379|No Intervention|4 B-E|Relatives of patients with bipolar disorder, who do not receive education
11643384|NCT00184353||brain metastases|6 patients
11643385|NCT00184353||healthy|13 volunteers
11643386|NCT00184301|Experimental|inpatient treatment|inpatient treatment during 1 year
11643387|NCT00184301|Active Comparator|outpatient treatment|intensive outpatient treatment consisting of two-weekly group sessions during 1 year
11643388|NCT00184262|Active Comparator|ERP cognitive therapy|
11643389|NCT00184262|Experimental|ERP behavioral therapy|
11643390|NCT00184249|Experimental|Bipolar radiofrequency ablation|
11643391|NCT00184236|Active Comparator|Aerobic interval training|Aerobic interval training (AIT)
11643392|NCT00184236|Active Comparator|Multitreatment approach|multitreatment approach (MTG)
11643393|NCT00184223|Experimental|motivational interviewing|Manual guided motivational interviewing in addition to treatment as usual
11643394|NCT00184223|Other|control group|treatment as usual
11643395|NCT00184197|Experimental|Botox|
11643396|NCT00184197|Placebo Comparator|placebo|
11643397|NCT00184171|Experimental|Budesonide|Budesonide 9mg
11643398|NCT00184171|Experimental|bismuth|Bismuth mixture
11643399|NCT00184171|Sham Comparator|Fiber|Fiber preparation
11643400|NCT00184145|Experimental|EMDR|The experimental group was treated for animal phobia by EMDR, control group received an attention placebo (relaxation plus breathing exercises). Afterwards, both groups were treated by exposure therapy (therapy of choice for animal phobia).
11643401|NCT00184132|Experimental|Norwegian home style ward|The walls received wainscots, colourful wallpaper and paintings; the ceilings were lowered and had multiple lighting spots, the windows tasteful curtains; we put wardrobes, chairs, flowers and personal items in the patient rooms; and Italian ceramic tile covered the entire bathroom
11643402|NCT00184132|Active Comparator|sparsely furnished ward|traditional interior design and furnishings. The rooms had sparse furniture, walls in grey colours lacking pictures, no window curtains, single lamps in the ceiling 4 m high, bathroom with grey, laminated paint all over, and patient rooms with a single bed and a chair of metal tubes
11643403|NCT00184119|Experimental|Psychiatric Intensive Care Unit|
11643404|NCT00184119|Active Comparator|Whole acute unit|
11643405|NCT00184106|Active Comparator|Cognitive Therapy|Cognitive Therapy
11643934|NCT00175006||Tophi Participants|
11643412|NCT00184054|Experimental|Arsenic Trioxide (ATO) Plus Ascorbic acid|"Arsenic Trioxide (ATO) given at 0.25 mg/kg/day intravenously for 25 days over a 35-day period.
~Ascorbic Acid given at 1000 mg/day intravenously every other day that ATO is given"
11643413|NCT00184041|Experimental|Intensified Post-Remission: MTX/LV/PEG-Asparaginase|Daunorubicin 60 mg/m2 iv on days 1, 2, 3 Vincristine 1.4 mg/m2 iv on days 1, 8, 15, 22 Peg-Asparaginase 2000 U/m2 iv on day 15 Prednisone 60 mg/m2 mg po on days 1-28 MTX 12 mg IT on days 8 & 15
11643414|NCT00184028|Experimental|Arm 1|On Day 1 of each day treatment cycle, patients receive Taxotere 60 mg/m2 as a 1-hour IV infusion, followed by the administration of oxaliplatin 100 mg/m2. Oxaliplatin will be administered IV over 2 hours at a rate of 10mg/m2/min. This treatment regimen will be repeated every 21 days.
11643415|NCT00184015|Experimental|Schedule A|
11643416|NCT00184015|Experimental|Schedule B|
11643417|NCT00184002|Experimental|DR-COP|"On cycle 1 patients receive Doxil 40 mg/m2 iv day 1 over a minimum of 60 min., Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min., Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum) and Prednisone 100 mg po days 1-5.
~On cycle 2 until study completion patients receive Doxil 40 mg/m2 iv day 1, Rituxan 375 mg/m2 iv day 1, Cyclophosphamide 750 mg/m2 iv day 1, Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum) and Prednisone 100 mg po days 1-5
~1 cycle = 21 days.
~Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles."
11643418|NCT00183963|No Intervention|1|
11643419|NCT00183963|Active Comparator|2|Tamoxifen 20 mg
11643420|NCT00183963|Active Comparator|3|Fulvestrant 250mg
11643421|NCT00183963|Active Comparator|4|Fulvestrant 500mg IM
11643422|NCT00183937|Experimental|Bortezomib and Docetaxel|Bortezomib 1.6 mg/m2 Docetaxel 75 mg/m2
11643423|NCT00183898|Experimental|Oxaliplatin and Capecitabine|Oxaliplatin given every 21 days Capecitabine given daily x 14 days every 21 days
11643424|NCT00183885|Experimental|Cisplatin + Mitomycin-C|CDDP 60mg/m2 + Mitomycin-C 12mg/m2
11643425|NCT00183872|Experimental|Arm 1 - Irinotecan and Docetaxel|Irinotecan given day 1 and 8 every 21 days Docetaxel given day 1 and 8 every 21 days
11643426|NCT00183859|Experimental|A|Intraperitoneal Irinotecan
11643427|NCT00183833|Experimental|A|Xeloda plus gleevec
11643428|NCT00183820|Experimental|1|
11643429|NCT00183794|Experimental|Arm 1|Patients will receive Docetaxel 75mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8. Cycles will be repeated every 3 weeks.
11643430|NCT00183755||1|Control participants
11643431|NCT00183755||2|Participants with MDD
11643432|NCT00183729|Experimental|Memantine (1)|Memantine for 12 weeks
11643433|NCT00183729|Placebo Comparator|Placebo (2)|Placebo for 12 weeks
11643434|NCT00183716|Experimental|1|Participants will receive Trauma Recovery and Empowerment Model and usual care
11643435|NCT00183716|Active Comparator|2|Participants will receive usual care
11643436|NCT00183703||Qualitative Interview|Participants with rapid cycling bipolar disorder (RCBPD)
11643437|NCT00183690|Experimental|1|Participants receiving prolonged exposure therapy
11643438|NCT00183690|Active Comparator|2|Participants receiving active psychotherapy
11643439|NCT00183677|Experimental|Escitalopram|Participants will receive open treatment with escitalopram.
11643440|NCT00183651|Experimental|S-DBT|Participants receive standard dialectical behavior therapy
11643441|NCT00183651|Active Comparator|DBT-I|Participants receive individual dialectical behavior therapy plus activities group
11643442|NCT00183651|Active Comparator|DBT-S|Participants receive dialectical behavior therapy group skills plus case management
11643443|NCT00183638|Experimental|1|Participants will receive Internet-based tailored prevention messages
11643444|NCT00183638|Active Comparator|2|Participants will receive non-tailored messages containing information on reproductive health
11643445|NCT00183625|Active Comparator|Risperidone Plus Supported Employment|
11643446|NCT00183625|Active Comparator|Olanzapine Plus Supported Employment|
11643447|NCT00183625|Active Comparator|Risperidone+Supported Employment+Skills|
11643448|NCT00183625|Active Comparator|Olanzapine+Supported Employment+Skills|
11643449|NCT00183599|Experimental|1|
11643450|NCT00183599|Experimental|2|
11643451|NCT00183599|Experimental|3|
11643452|NCT00183586|Experimental|1|Participants will receive family-based treatment
11643453|NCT00183586|Active Comparator|2|Participants will receive individual adolescent focused therapy
11643454|NCT00183573|Experimental|1|Brief Motivational Intervention only
11643455|NCT00183573|Experimental|2|Brief Informational Intervention only
11643456|NCT00183573|Experimental|3|Brief Motivational Intervention + Intensive Informational Intervention
11643457|NCT00183573|Experimental|4|Brief Motivational Intervention + Intensive Information-Motivation-Behavioral Skills Intervention
11643458|NCT00183573|Experimental|5|Brief Informational Intervention + Intensive Informational Intervention
11643459|NCT00183573|Experimental|6|Brief Informational Intervention + Intensive Information-Motivation-Behavioral Skills Intervention
11643460|NCT00183560|Experimental|1|Participants will receive mindfulness based cognitive therapy
11643461|NCT00183560|Active Comparator|2|Participants will receive maintenance antidepressant pharmacotherapy
11643462|NCT00183560|Placebo Comparator|3|Participants will receive placebo plus clinical management
11643463|NCT00183547|Experimental|1|"Living in Harmony depression prevention program"
11643464|NCT00183547|Active Comparator|2|Depression-prevention education and support
11643465|NCT00183521|Experimental|1|Participants will receive raise-CO2 breathing regulation training
11643466|NCT00183521|Experimental|2|Participants will receive lower-CO2 breathing regulation training
11643467|NCT00183521|Active Comparator|3|Participants will receive no breathing regulation training
11643468|NCT00183508|Experimental|1 Cognitive behavioral therapy|
11643469|NCT00183508|Experimental|2 Psychoeducation|
11643470|NCT00183482|Experimental|Family Group Cognitive Behavioral|The intervention is a family group cognitive behavioral program for families of parents with a history of depression to teach parenting skills to parents and coping skills to children.
11643615|NCT00180713|Placebo Comparator|Arm 1: Control|Placebo tablet once daily
11643471|NCT00183482|Active Comparator|Written Information|The comparison arm involves providing written information about depression and stress to parents with a history of depression and their children.
11643472|NCT00183469|Active Comparator|lamotrigine plus divalproex ER|Participants will take active lamotrigine and active divalproex ER
11643473|NCT00183469|Placebo Comparator|lamotrigine plus placebo divalproex ER|Participants will take active lamotrigine and placebo
11643474|NCT00183456|Experimental|Intervention Condition: CHAT|Participants received the program over the course of five small group sessions and one individual session based on a harm reduction philosophy. Participants were trained as Peer Mentors and were encouraged to talk to their family, friends, and sex partners about a range of sex risk reduction options.
11643475|NCT00183456|Active Comparator|Comparison Condition: Standard of Care|The comparison condition consisted of one group session. The session focused on HIV and STIs transmission and risk reduction information.
11643476|NCT00183456|No Intervention|Network Participants|Index participants generated a list of network members during their baseline visits and were asked to recruit eligible network members into the study. These network participants completed study interviews but did not participate in the intervention.
11643477|NCT00183456|No Intervention|Non-randomized Baseline index participants|This arm includes those index participants that did not show up for randomization or did not recruit a network member were thus not eligible to be randomized into a study condition.
11643478|NCT00183443|Placebo Comparator|DVP + placebo|Participants will receive divalproex ER at a therapeutic dose, plus placebo
11643479|NCT00183443|Active Comparator|DVP + Quetiapine|Participants will receive divalproex ER at a therapeutic dose, plus quetiapine up to 800 mg
11643480|NCT00183443|Active Comparator|DVP + Lithium|Participants will receive divalproex ER at a therapeutic dose, plus lithium at a therapeutic blood level
11643481|NCT00183430|Experimental|1|Participants will receive treatment with prazosin plus psychotherapy
11643482|NCT00183430|Placebo Comparator|2|Participants will receive treatment with placebo plus psychotherapy
11643483|NCT00183417|Experimental|1|Participants will receive cognitive behavioral therapy
11643484|NCT00183417|Active Comparator|2|Participants will receive supportive/expressive therapy
11643485|NCT00183417|Active Comparator|3|Participants will receive bibliotherapy
11643486|NCT00183417|No Intervention|4|Participants in the control condition will receive no treatment
11643487|NCT00183404|Experimental|Olanzapine|Participants will take open olanzapine for up to 20 additional weeks after phase 1.
11643488|NCT00183391|Active Comparator|Atomoxetine|Participants will receive treatment for ADHD with the non-stimulant atomoxetine
11643489|NCT00183391|Active Comparator|Methylphenidate|Participants will receive treatment for ADHD with the stimulant methylphenidate
11643490|NCT00183378|Active Comparator|1|Routine medical care with education: therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support.
11643491|NCT00183378|Active Comparator|2|Walking: the therapist introduces a walking program and assists the caregiver in establishing a daily walking routine of 30 minutes for the study participant.
11643492|NCT00183378|Active Comparator|3|Light exposure: the therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
11643493|NCT00183378|Active Comparator|4|Combination: the therapist provides education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
11643494|NCT00183365|Experimental|1|Participants will receive the Protecting Families Program with individual parent training
11643495|NCT00183365|Active Comparator|2|Participants will receive parent training alone
11643496|NCT00183352||1|Women with bipolar disorder
11643497|NCT00183352||2|Women who are healthy controls
11643498|NCT00183339|Placebo Comparator|Placebo|Placebo, liquid solution flexible dose 0.5 to 5ml every morning (AM)
11643499|NCT00183339|Experimental|fluoxetine|Fluoxetine, 20mg/5ml solution, flexible dose 0.5 to 5ml every AM
11643500|NCT00183326|Experimental|1|Participants will receive trauma-focused cognitive behavioral therapy
11643501|NCT00183326|Active Comparator|2|Participants will receive child-centered supportive therapy
11643502|NCT00183313|Experimental|1|Participants will receive nurse case management intervention
11643503|NCT00183313|Active Comparator|2|Participants will receive usual care
11643504|NCT00183274|Active Comparator|Open-Label Group|6-month randomized phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d
11643505|NCT00183274|Active Comparator|Double-Blind Drug Group|6-month randomized, double-blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 6 - 12 of the study
11643506|NCT00183274|Placebo Comparator|Double-Blind Placebo Group|6-month randomized, double blind phase of placebo occurring between months 6 - 12 of the study
11643507|NCT00183274|Active Comparator|Double-Blind Drug-After-Drug Group|6-month randomized, double blind phase of Venlafaxine XR at a flexible dose of 75 - 225 mg/d occurring between months 13 - 19 of the study
11643508|NCT00183274|Placebo Comparator|Double-Blind Placebo-After-Drug Group|6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study
11643509|NCT00183274|Placebo Comparator|Double-Blind Placebo-After-Placebo Group|6-month randomized, double blind phase of placebo occurring between months 13 - 19 of the study
11643510|NCT00183261|Experimental|1|Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine at study entry and on Weeks 4 and 26
11643511|NCT00183261|Placebo Comparator|2|Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine placebo at study entry and on Weeks 4 and 26
11643512|NCT00183248|Experimental|DBMCs|Kidney transplantation, followed by immunotherapy given along with kidney donor Donor bone Bone marrow Marrow stem cell Cells (DBMCs) infusions
11643513|NCT00183248|Active Comparator|Control Group|Kidney transplantation, followed by immunotherapy
11643514|NCT00183209|Experimental|14 session behavioral intervention|7 sessions addressing problem alcohol and drug use and 7 session addressing parenting challenges (monitoring, negotiation, etc) based on based on Social Action Theory (Ewart, 1991) and Motivational Interviewing
11643667|NCT00179777|Placebo Comparator|Nonhydrolysed infant formula|Nonhydrolysed infant formula
11643515|NCT00183209|Active Comparator|Brief Video Intervention|Single session brief video intervention to build motivation to reduce or eliminate problem drinking/drug use
11643516|NCT00183196|Active Comparator|1|Naltrexone plus placebo
11643517|NCT00183196|Active Comparator|2|naltrexone + gabapentin
11643518|NCT00183196|Sham Comparator|3|Placebo plus placebo
11643519|NCT00183157|Active Comparator|1|Patients will receive an assessment, a brief motivational interview performed by a trained peer counselor, direct referrals to community-based resources for adolescents, and a 10-day follow-up phone call.
11643520|NCT00183157|Active Comparator|2|Patients will receive an assessment and a list of community resources
11643521|NCT00183157|Active Comparator|3|Patients will receive only the list of resources.
11643522|NCT00183092|Experimental|quinacrine|
11643523|NCT00183092|Placebo Comparator|placebo|
11643524|NCT00183079|Active Comparator|1|Brief, motivationally-focused alcohol intervention
11643525|NCT00183014|Experimental|1|discussion session and exercise class
11643526|NCT00183014|Active Comparator|2|exercise class only
11643527|NCT00182858||1|Participants will be 18 years or older that are Healthy Volunteers or have been identified by the investigator and/or physician to have a condition of interest for exploratory studies related to the participant s illness or other feature that offers the possibility of creating information that leads to scientifically useful and important studies.
11643528|NCT00182832|Experimental|1|
11643529|NCT00182832|Active Comparator|2|
11643530|NCT00182819|Other|radiotherapy|Radiotherapy (control arm), 50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
11643531|NCT00182819|Experimental|Temozolomide|Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles (experimental arm)
11643532|NCT00182793|Experimental|Arm I|Patients undergo stem cell collection. Patients receive high-dose melphalan IV with or without trastuzumab (Herceptin®). One day later, patients undergo autologous peripheral blood stem cell (PBSC) transplantation. No more than 7 weeks later, patients proceed to course 2. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.
11643533|NCT00182793|Experimental|Arm II|Patients undergo stem cell collection. Patients receive high-dose carboplatin, thiotepa, and cyclophosphamide IV continuously over 4 days followed by autologous PBSC transplantation. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.
11643534|NCT00182780|Experimental|Arm I - American ginseng (low dose)|"Patients receive oral American ginseng twice daily for 8 weeks in the absence of unacceptable toxicity.
~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study.
~Quality of life is assessed at baseline, every 2 weeks during treatment, and at the end of treatment.
~PROJECTED ACCRUAL: A total of 280 patients (70 per treatment arm) will be accrued for this study within 35 months."
11643535|NCT00182780|Experimental|Arm II - American ginseng (mid-dose)|"Patients receive oral American ginseng at the mid-dose twice daily for 8 weeks in the absence of unacceptable toxicity.
~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
11643536|NCT00182780|Experimental|Arm III - American ginseng (high-dose)|"Patients receive oral American ginseng at the high dose twice daily for 8 weeks in the absence of unacceptable toxicity.
~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
11643537|NCT00182780|Other|Arm IV - Placebo|"Patients receive oral placebo twice daily for 8 weeks in the absence of unacceptable toxicity.
~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
11643538|NCT00182767|Experimental|Treatment (ixabepilone and doxorubicin)|Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1.
11643539|NCT00182754|Experimental|Arm I|Patients receive octreotide subcutaneously (SC) once on day 1.
11643540|NCT00182754|Placebo Comparator|Arm II|Patients receive placebo SC once on day 1.
11643541|NCT00182728|Experimental|Intraoperative Radiation Arm|Intraoperative radiotherapy (radiation therapy) during surgery for tumor excision.
11643542|NCT00182702|Experimental|Treatment|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11643543|NCT00182689|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11643544|NCT00182663|Experimental|Treatment (immunomodulator, antiangiogenesis, steroid therapy)|Patients receive thalidomide PO QD dexamethasone PO once weekly, and clarithromycin PO BID. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Treatment with thalidomide continues in the absence of disease progression or unacceptable toxicity.
11643545|NCT00182637|Experimental|bortezomib|
11643546|NCT00182559|Active Comparator|Ciclosporin|Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.
11643547|NCT00182559|Active Comparator|Tacrolimus|Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.
11643548|NCT00182533|Experimental|1|Sertraline
11643549|NCT00182533|Placebo Comparator|2|Placebo
11643550|NCT00182520|Experimental|1|Topiramate
11643551|NCT00182520|Placebo Comparator|2|placebo
11643552|NCT00182468|Experimental|1|Women are screened for intimate partner violence prior to seeing a health care provider.
11643553|NCT00182468|No Intervention|2|Women see their health care provider without being asked about intimate partner violence.
11643554|NCT00182455|Experimental|1|Topiramate 25 - 400 mg/day x 12 weeks
11643555|NCT00182455|Placebo Comparator|2|Placebo
11643556|NCT00182338||Peritoneal Dialysis Patients|
11643557|NCT00182325|Experimental|personalized web prenatal information|Personalized health information for pregnancy through personal health record
11643558|NCT00182325|Active Comparator|general web prenatal information|General pregnancy health related websites
11643559|NCT00182260|Active Comparator|Proton Pump Inhibitor|Patients randomized to medical therapy received optimized treatment with PPI using a standardized management protocol based on best evidence and published guidelines.
11643560|NCT00182260|Active Comparator|Laparoscopic Nissen Fundoplication|Surgical patients underwent LNF using previously published technique.
11643561|NCT00182156||1|conventional HD
11643562|NCT00182156||2|short daily HD
11643563|NCT00182156||3|PD
11643564|NCT00182143|Active Comparator|LMWH (Fragmin, dalteparin)|Placebo dose (normal saline) = AM dose LMWH (Fragmin, dalteparin) 5000IU daily = PM dose
11643565|NCT00182143|Active Comparator|2|Unfractionated Heparin 5000IU BID
11643566|NCT00182091|Active Comparator|AcroGHD Randomized to Growth Hormone|Subjects with a history of acromegaly who are now growth hormone deficient, randomized to growth hormone. This is an interventional arm.
11643567|NCT00182091|Placebo Comparator|AcroGHD Randomized to Placebo|Subjects with a history of acromegaly who are now growth hormone deficient, randomized to placebo. This is an interventional arm.
11643568|NCT00182091|No Intervention|AcroGHS|
11643569|NCT00182091|No Intervention|Active Acromegaly|
11643570|NCT00182078|Placebo Comparator|Placebo|Placebo was administered on a flexible fixed schedule and tapered at 12 weeks.
11643571|NCT00182078|Experimental|Sertraline|Sertraline was administered on a flexible fixed schedule beginning at 25 mg/day and increasing as high as 150 mg/day. At week 12, the medication was tapered at a rate of 25 mg every 3 days until it was discontinued.
11643572|NCT00182052|Active Comparator|Group 1|
11643573|NCT00182052|Placebo Comparator|Group 2|
11643574|NCT00182039|Experimental|A|metoprolol
11643575|NCT00182039|Placebo Comparator|B|placebo
11643576|NCT00182000|Active Comparator|Seromycin|
11643577|NCT00182000|Placebo Comparator|Placebo|
11643578|NCT00181961|Experimental|Maca Root 1500mg|Patients receiving 1500mg of maca root
11643579|NCT00181961|Experimental|Maca Root 3000mg|Patients receiving 3000mg of maca root
11643580|NCT00181883|Experimental|Quetiapine|"2.5 - 5.0mg/kg PO BID quetiapine
~Other Names:
~Seroquel"
11643581|NCT00181857||1|Children of Adults with ADHD NOS
11643582|NCT00181844|Experimental|Lamotrigine|
11643583|NCT00181805||Subject with History of GERD|Children and adolescents ages 12-17 years, inclusive, seen at Children's Hospital, Boston or Massachusetts General Hospital between 1977 and 1990 for symptoms of GERD and also had biopsies and / or a pH probe that was positive for GERD.
11643584|NCT00181805||Controls with out GERD|Individuals that do not have a history of GERD or other GI problems prior to age 21 and whose date of birth are with in a year of a subjects
11643585|NCT00181766|Experimental|Strattera (atomoxetine)|
11643586|NCT00181753|Experimental|1|Burn Patients receiving at least 3 days of parenteral feeding on routine formula
11643587|NCT00181753|Experimental|2|Burn patients receiving at least 3 days on parenteral feeding on glutamine enriched formula.
11643588|NCT00181753|Experimental|3|Burn patients receiving at least 3 days of enteral feeding on routine formula.
11643589|NCT00181753|Experimental|4|Burn patients receiving at least 3 days of enteral feeding on glutamine-enriched formula.
11643590|NCT00181714|Experimental|OROS MPH|Single arm- open treatment with extended duration methylphenidate (OROS MPH)
11643591|NCT00181649|Experimental|Recombinant human prolactin|
11643592|NCT00181623|Experimental|recombinant human prolactin treatment|Open label twice daily recombinant human prolactin
11643593|NCT00181610|Active Comparator|1|Placebo group normal saline twice per day
11643594|NCT00181610|Active Comparator|2|Recombinant human prolactin 60 mcg/kg every 12 hours
11643595|NCT00181610|Active Comparator|3|Recombinant human prolactin 60 mcg/kg alternating with normal saline placebo every 12 hours
11643596|NCT00181584|Active Comparator|Group 1|
11643597|NCT00181584|Placebo Comparator|Group 2|
11643598|NCT00181571|Active Comparator|1|Concerta
11643599|NCT00181571|Placebo Comparator|2|Placebo
11643600|NCT00181363|Experimental|Mamma board|use of the mamma board during radiotherapy
11643601|NCT00181298|Active Comparator|1|
11643602|NCT00181298|Placebo Comparator|2|
11643603|NCT00181285|Sham Comparator|Sham high frequency chest wall oscillation|Sham high frequency chest wall oscillation
11643604|NCT00181285|Active Comparator|Active high frequency chest wall oscillation|Active high frequency chest wall oscillation
11643605|NCT00181207|Experimental|Active|Pneumatic Compression Device used twice daily for 20 minutes each time for 12 weeks
11643606|NCT00181207|Placebo Comparator|Sham|Device looked and sounded like a pneumatic compression device, but was not inflating nor deflating.
11643607|NCT00181181|Active Comparator|Atorvastatin|Atorvastatin for 3 months
11643608|NCT00181181|Placebo Comparator|Placebo|
11643609|NCT00181168|Experimental|Euthyroid Group|Euthyroid Group: Subjects received rhTSH to prepare for radioiodine therapy.
11643610|NCT00181168|No Intervention|Hypothyroid Group|Hypothyroid Group: Thyroid hormone treatment was withheld before radioiodine therapy.
11643611|NCT00181155|Experimental|Allopurinol|One time intravenous administration of Allopurinol 300 mg infused over approximately 20 minutes.
11643612|NCT00181155|Placebo Comparator|Placebo|One time intravenous administration of 50 ml dose of 5% dextrose infused over approximately 20 minutes.
11643613|NCT00180843|Placebo Comparator|saline control|nebulized saline
11643614|NCT00180843|Active Comparator|salbutamol and ipratropium bromide nebules|salbutamol 2.5 mg and ipratropium bromide 0.5 mg
11643616|NCT00180713|Experimental|Arm 2: Experimental|Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.
11643617|NCT00180700|Experimental|Self-hypnosis|A course of four weekly 2-hour training sessions coupled with daily self-hypnosis practice was given to 13 participants with diagnosed HIV
11643618|NCT00180700|Experimental|Johrei healing method|A course of four weekly 2-hour training sessions coupled with daily self-hypnosis practice was given to 9 participants with diagnosed HIV
11643619|NCT00180687|Sham Comparator|Control|No intraperitoneal therapeutics (No nebulised Bupivacaine)
11643620|NCT00180687|Placebo Comparator|IP Aerosolized Normal Saline|Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)
11643621|NCT00180687|Experimental|Nebulised Bupivacaine intraperitoneally|Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)
11643622|NCT00180687|Active Comparator|Injected Bupivacaine intraperitoneally|Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)
11643623|NCT00180674|Experimental|Warfarin anticoagulation|Anticoagulated with warfarin to maintain an INR of 2-3 between 8 and 16 weeks (treatment period).
11643624|NCT00180661||Severe Asthma|Patients under Steps 4/5 of Asthma Treatment - SIGN/BTS Guidelines
11643625|NCT00180661||Moderate Asthma|Asthma patients on steps 2/3 of Asthma treatment according to SIGN/BTS Guidelines
11643626|NCT00180661||Mild Asthma|Asthma patients on steps 1 of asthma treatment (steroid naive).
11643627|NCT00180635|Experimental|Healthy volunteers non smoker|Control group
11643628|NCT00180635|Experimental|Healthy volunteers smoker|More than 10 pack-years
11643629|NCT00180635|Experimental|Chronic Obstructive Pulmonary Disease COPD|COPD diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease guidelines
11643630|NCT00180583|Experimental|1|Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
11643631|NCT00180557|Experimental|Active fixation lead|Active fixation lead was implanted
11643632|NCT00180557|Active Comparator|Passive fixation lead|Passive fixation lead was implanted
11643633|NCT00180544|Other|1|Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
11643634|NCT00180518|Experimental|1|"To evaluate the safety and efficacy of the over-the-wire (OTW) ACCULINK (tm) System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA) To evaluate the efficacy of the OTW ACCUNET System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA).
~To demonstrate equivalence in the safety and performance of the RX ACCULINK Carotid Stent System and RX ACCUNET Embolic Protection System and the corresponding OTW devices."
11643635|NCT00180505|Other|1|The purpose of the ASSESS Registry is to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries.
11643636|NCT00180479|Experimental|1|XIENCE V® Everolimus Eluting Coronary Stent System
11643637|NCT00180479|Active Comparator|2|TAXUS® EXPRESS2™Paclitaxel Eluting Coronary Stent System
11643638|NCT00180453|Experimental|1|Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System
11643639|NCT00180453|Active Comparator|2|Abbott Vascular MULTI-LINK VISION® BMS
11643640|NCT00180401||QRS 120-150 ms|Subjects with a QRS width between 120-150 ms
11643641|NCT00180401||QRS >150 ms|Subjects with a QRS width >150 ms
11643642|NCT00180388|Experimental|Endoscopic vein harvesting|Harvesting of vein for coronary artery bypass grafting using endoscopy to visualize the vein
11643643|NCT00180388|Active Comparator|Open Vein harvesting|Harvesting of vein for coronary artery bypass grafting without endoscopy
11643644|NCT00180323|Experimental|Renewal CRT (CRT ICD)|Single arm study only. All patients will undergo advanced echocardiographic examination pre-operative, pre-discharge after implantation and at 3 and 6-months follow-up. AV-delay optimization will be performed using aortic VTI (Velocity Time Integral) measured by continuous wave Doppler in a modified 4-chamber view. During optimisation aortic VTI will be measured at different heart rates reached by increasing atrial pacing 10, 20 and 30 beats above intrinsic heart rate (IHR).
11643645|NCT00180310|Experimental|1|XIENCE V® Everolimus Eluting Coronary Stent System
11643646|NCT00180310|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
11643647|NCT00180297|Experimental|Mid septal site location|RV lead is placed at mid septum.
11643648|NCT00180297|Active Comparator|Apical site location|RV lead is placed in apical position
11643649|NCT00180271|Experimental|CRT-D|CRT-D: Cardiac resynchronization therapy with defibrillation.
11643650|NCT00180271|Active Comparator|ICD|ICD: Implantable cardioverter defibrillator
11643651|NCT00180232||1|Patients starting an aminobisphosphonate therapy due to medical reasons Broca-index: between -20 and +25% who are willing and capable to confirm written consent to enrolment after ample information has been provided
11643652|NCT00180219||1|20 to 22 years
11643653|NCT00180219||2|30 to 32 years
11643654|NCT00180219||3|40 to 42 years
11643655|NCT00180167|Active Comparator|Daunorubicin + Ara-C|
11643656|NCT00180167|Experimental|Mitoxantrone + Ara-C|
11643657|NCT00180011|Experimental|omaluzimab|
11643658|NCT00179998|Active Comparator|Recombinant Human DNase (Pulmozyme) then Placebo|once daily nebulized rhDNAse
11643659|NCT00179998|Placebo Comparator|Placebo (Nebulized Saline) then rhDNase|once daily nebulized vehicle
11643660|NCT00179985||Training|Behavioral: Newborn Individualized Care and Assessment Program (NIDCAP)
11643661|NCT00179959|Active Comparator|Treatment|Intranasal mupirocin ointment and sodium hypochlorite (bleach) baths
11643662|NCT00179959|Placebo Comparator|Placebo|Intranasal petrolatum ointment treatment and plain water baths
11643663|NCT00179894|Experimental|1 Physician training|Physician participants will receive training in guidelines and medication monitoring
11643664|NCT00179894|No Intervention|2|Physician participants will provide usual care and no special intervention
11643665|NCT00179803|Experimental|high dose chemotherapy|
11643666|NCT00179777|Experimental|Hydrolysed infant formula|Hydrolysed infant formula
11643669|NCT00179673|Experimental|Lenalidomide|Participants received single-agent lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed, lenalidomide treatment was discontinued for any reason, or the study was terminated.
11643670|NCT00179660|Experimental|Lenalidomide|Participants received single-agent lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed, lenalidomide treatment was discontinued for any reason, or the study was terminated.
11643671|NCT00179647|Other|Lenalidomide 5-25 mg, w/wo dexamethasone|single-arm, open-label, lenalidomide, 5-25 mg, 21/28 days, with/without dexamethasone
11643672|NCT00179634|No Intervention|1|Usual Care
11643673|NCT00179634|Experimental|2|Usual care and exposure to a visually enriched milieu (landscape photograph)
11643674|NCT00179634|Experimental|3|Usual care, exposure to a visually enriched milieu and audio taped guided visualization with healing suggestions.
11643675|NCT00179621|Placebo Comparator|Placebo|Placebo matching to active study arms.
11643676|NCT00179621|Experimental|Lenalidomide 5 mg|Lenalidomide 5 mg daily 28/28 days
11643677|NCT00179621|Experimental|Lenalidomide 10 mg|Lenalidomide 10 mg daily 21/28 days
11643678|NCT00179517|Experimental|depotestosterone plus anastrozole (T-A)|Each participant has biweekly intramuscular injections of 300 mg depotestosterone cypionate and takes an oral tablet of anastrozole 1 mg daily for the duration of the study. This group is referred to as the depotestosterone plus anastrozole (T-A) group.
11643679|NCT00179517|Placebo Comparator|depotestosterone plus placebo (T-P)|Each participant has biweekly intramuscular injections of 300 mg depotestosterone cypionate and takes 1 matching placebo oral tablet daily for the duration of the study. This group is referred to as the depotestosterone plus placebo (T-P) group.
11643680|NCT00179491|Active Comparator|Group 1|604 patients received intercessory prayer after being informed they may or may not receive prayers (Group 1)
11643681|NCT00179491|No Intervention|2|597 patients did not receive prayer after being informed they may or may not receive prayer (Group 2)
11643682|NCT00179491|Experimental|Group 3|601 patients received intercessory prayer after being informed they would receive it (Group 3).
11643683|NCT00179478|Experimental|Immediate Treatment Group|Initiation of treatment with Interferon Beta 1a IM once weekly immediately after onset of a first demyelinating syndrome in high risk individuals
11643684|NCT00179478|Active Comparator|Delayed Treatment Group|Delayed initiation of of Interferon beta-1a IM once weekly at diagnosis of clinically definite MS, at conclusion of initial CHAMPS study or during long term observation
11643685|NCT00179465|Active Comparator|Antipsychotic plus study drug|Half of the subjects will receive the study medications in addition to their ongoing antipsychotic regimen.
11643686|NCT00179465|Placebo Comparator|Antipsychotics plus placebo|Half of the subjects will receive placebo in addition to their antipsychotic regimen.
11643687|NCT00179452|Experimental|Intervention|Subjects invited to participate in yoga practice.
11643688|NCT00179413|Active Comparator|PEG-Intron|PEG-Intron 0.5mcg/kg once a week SC
11643689|NCT00179413|Active Comparator|Colchicine|0.6mg twice a day
11643690|NCT00179400|Active Comparator|Pioglitazone|
11643691|NCT00179400|Placebo Comparator|Placebo|
11643692|NCT00179387|Active Comparator|1|Psycho-educational / Stress Management group
11643693|NCT00179387|Active Comparator|2|Spiritual-Existential Support Group
11643694|NCT00179374|Experimental|1|Tailored telephone intervention plus mailed print educational materials
11643695|NCT00179374|Active Comparator|2|print intervention with no telephone component
11643696|NCT00179348|Experimental|Group I (yoga-based rehabilitation program)|Participants undergo a yoga-based rehabilitation program up to 5 days a week for 1.5 hours and practice at home at least once daily for 12 weeks.
11643697|NCT00179348|Active Comparator|Group II (standard care/control)|After a 3 month wait period, participants undergo a yoga-based rehabilitation program as in Group I.
11643698|NCT00179309|Experimental|Arm I - PANVAC + docetaxel|Patients receive vaccinia-carcinoembryonic antigen (CEA)- mucin-1 (MUC-1)- triad of costimulatory molecules (TRICOM) vaccine subcutaneously (SC) once and sargramostim, or granulocyte macrophage colony stimulating factor (GM-CSF) SC once daily for 4 days in week -2. Patients also receive fowlpox-CEA-MUC-1-TRICOM vaccine SC once and GM-CSF SC once daily for 4 days in weeks 1, 5, and 9. Patients also receive docetaxel intravenous (IV) over 30 minutes once weekly in weeks 1-3, 5-7, and 9-11. After week 12, patients with no disease progression continue with docetaxel once weekly for 3 weeks followed by 1 week of rest and fowlpox-CEA-MUC-1-TRICOM vaccine plus GM-CSF every 4 weeks until disease progression.
11643699|NCT00179309|Experimental|Arm II - Docetaxel alone|Patients receive docetaxel as in arm I. After week 12, patients with disease progression discontinue docetaxel and receive vaccinia-carcinoembryonic antigen (CEA)- mucin 1(MUC-1)-triad of costimulatory molecules (TRICOM) vaccine, fowlpox-CEA-MUC-1-TRICOM vaccine, and sargramostim, or granulocyte macrophage colony stimulating factor (GM-CSF) as in arm I until further disease progression. Patients with no disease progression after week 12 continue with docetaxel as in arm I until disease progression.
11643700|NCT00179218|Active Comparator|1|only protein supplementation
11643701|NCT00179218|Active Comparator|2|protein supplementation plus exercise
11643702|NCT00179205|Active Comparator|1|
11643703|NCT00179205|Placebo Comparator|2|
11643704|NCT00179192|No Intervention|1|control group
11643705|NCT00179192|Active Comparator|2|angioplasty intervention
11643706|NCT00179192|Active Comparator|3|surgery intervention
11643707|NCT00179179|Active Comparator|1|nutritional supplement plus resistance exercise
11643708|NCT00179179|Active Comparator|2|nutritional supplement only (resistance exercise will not be performed)
11643709|NCT00179166|Active Comparator|1|supplement contains protein content of 1.4 g/kg/day
11643710|NCT00179166|Active Comparator|2|supplement contains protein content of 2.0 g/kg/day
11643711|NCT00179153|Active Comparator|1|
11643712|NCT00179140|No Intervention|1|control period
11643713|NCT00179140|Active Comparator|2|protein supplementation plus resistance exercise
11643714|NCT00179140|Active Comparator|3|protein supplementation only
11643715|NCT00179127|Experimental|Glargine|0.3u/kg of glargine, subcutaneously, once
11643935|NCT00174993|Experimental|Pioglitazone QD|
11643719|NCT00179036||Good blood flow|Group without any ischemia to the small intestine
11643720|NCT00179036||Poor blood flow|Group with partial ischemia to the small intestine
11643721|NCT00179023|Other|Part 1|Estimation of resting energy expenditure and effect of autonomic blockade with trimethaphan infusion.
11643722|NCT00179023|Other|Part 2 (closed)|Estimation of autonomic function and effect of autonomic blockade with trimethaphan infusion.
11643723|NCT00179023|Other|Part 3|Estimation of energy metabolism and effect of sympathetic stimulation with pseudoephedrine.
11643724|NCT00179023|Other|Part 4a (closed)|Isoproterenol sensitivity in adipose and muscle tissue with and without systemic autonomic blockade with trimethaphan infusion.
11643725|NCT00179023|Other|Part 4b (closed)|Metabolic and hemodynamic response to submaximal exercise in adipose and muscle tissue with and without systemic autonomic blockade with trimethaphan infusion.
11643726|NCT00179010|Experimental|Adenosine then Adenosine Mono Phosphate (AMP)|Intrarterial infusion of adenosine then same subject switch to AMP one month apart.
11643727|NCT00179010|Experimental|Adenosine Mono Phosphate (AMP) then adenosine|Intrarterial infusion of AMP then same subject switch to Adenosine one month apart.
11643728|NCT00178997||Good blood flow|Group without ischemia to the small intestine
11643729|NCT00178997||Poor blood flow|Groups that have partial ischemia to their small intestine
11643730|NCT00178984||poor blood flow|Group with partial ischemia to the small intestine
11643731|NCT00178984||Good blood flow|Group with normal blood flow, given different conditions to effect electrical currents in normal smooth muscle
11643732|NCT00178971|Active Comparator|1|buspirone 15-30 mg qd
11643733|NCT00178971|Placebo Comparator|2|placebo
11643734|NCT00178919|Experimental|Autonomic Failure Patients|To compare the effects of NO inhibition during intact and transient pharmacological blockade of the autonomic nervous system in Patients with Autonomic Failure.
11643735|NCT00178919|Experimental|Controls and hypertensives|To compare the effects of NO inhibition during intact and transient pharmacological blockade of the autonomic nervous system in normal volunteers and hypertensive subjects.
11643736|NCT00178880||Healthy volunteers|
11643737|NCT00178880||Depressed patients|
11643738|NCT00178802|Other|1|thermochemotherapy using fever-range whole-body thermal therapy combined with continuous infusion 5-fluorouracil, Doxil, and low-dose interferon-alpha.
11643739|NCT00178776|Experimental|Transtheoretical Model Group|
11643740|NCT00178776|Active Comparator|Education / Advice|
11643741|NCT00178763|Experimental|1|All protocol subjects are treated with fever-range whole-body thermal therapy combined in an optimized schedule with cisplatin + gemcitabine + metronomic low-dose interferon-alpha
11643742|NCT00178724||No Treatment Given|Any male or female 18 years or older admitted to a NACTN hospital, at the time of injury, with an initial (first time) spinal cord injury caused by trauma and has paralysis (muscle weakness) or loss of sensation (touch). The patient has not received medical or surgical care for this injury prior to admission to a NACTN hospital. Patient or family member must give consent to participate.
11643743|NCT00178711|Active Comparator|hypothermia|Induction and maintenance of moderate hypothermia to 33 degrees celsius achieved within 2.5 hours of injury and maintained for 48 hours.
11643744|NCT00178711|No Intervention|control|treated at normothermia
11643745|NCT00178698|Other|1|Thermochemotherapy
11643746|NCT00178659||1 healthy volunteers|Healthy volunteers to act as controls - Recruitment is complete for this cohort
11643747|NCT00178659||2 head trauma|Head trauma patients meeting enrollment criteria - Recruitment is complete for this cohort
11643748|NCT00178659||3 orthopedic injury|"The orthopedic injury cohort will include patients admitted to the ED able to provide informed consent with the following:
~Fracture confirmed radiographically
~No head trauma
~No other known inflammatory process or infection
~No history of neurological or psychiatric disorders or alcohol or drug dependency"
11643749|NCT00178659||4 Mild TBI|"The mild TBI patients will be defined as those admitted to the ED experiencing, - Recruitment is complete for this cohort
~Non-penetrating head trauma manifesting one or more of the following:
~Loss of consciousness
~Post-traumatic amnesia
~Altered mental status
~Focal neurologic deficits, seizure
~GCS> 12
~No abnormalities on CT other than contusion
~No operative Lesions
~Length of hospital stay < 48 hrs
~No other known inflammatory process or infection
~No history of neurological or psychiatric disorders or alcohol or drug dependency"
11643750|NCT00178646|Active Comparator|1|Botox, 150 units prepared as 100 units/ml
11643751|NCT00178646|Active Comparator|2|Botox 150 units, prepared as 50 units/ml.
11643752|NCT00178646|Active Comparator|3|Botox 75 units, prepared as 25 units/ml.
11643753|NCT00178633||Bariatric Surgery|Procedures were not part of the trial. Patients already undergoing these clinical procedures agreed to analysis and follow-up for research purposes. All patients had one of two different types of procedures, but outcome analyses did not distinguish between the two procedures.
11643754|NCT00178620|Active Comparator|I|Retavase 10 U IV Bolus
11643755|NCT00178620|Other|II|
11643756|NCT00178503|Placebo Comparator|MPH Trial-Placebo|24 Participants with ASD-ADHD underwent 1 week of placebo in the MPH treatment phase
11643757|NCT00178503|Active Comparator|MPH Trial: Low Dose|24 Participants with ASD-ADHD underwent 1 week at a low dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
11643758|NCT00178503|Active Comparator|MPH Trial: Med Dose|24 Participants with ASD-ADHD underwent 1 week at a medium dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
11643759|NCT00178503|Active Comparator|MPH Trial: High Dose|24 Participants with ASD-ADHD underwent 1 week at a high dose of Methylphenidate-extended release and Methylphenidate-immediate release in the MPH treatment phase
11643760|NCT00178490|Experimental|1|Children with high blood pressure who will receive treatment for high blood pressure
11643761|NCT00178490|No Intervention|2|Children with normal blood pressure who will undergo no treatment
11643762|NCT00178477|Experimental|Breath-holding|MRI with breath-holding
11643763|NCT00178464|Experimental|Aspirin|One-arm study
11643764|NCT00178412|Experimental|1|Treatment group
11643765|NCT00178412|Active Comparator|2|Comparison Group
11643766|NCT00178399|Experimental|Stereotactic body radiation therapy|
11643767|NCT00178373|Experimental|Modafinil|Modafinil 200 mg taken by mouth once a day. Subjects will take 2 100 mg tablets each morning.
11643768|NCT00178373|Placebo Comparator|placebo|Inactive sugar pill, 2 are taken once a day in the morning
11643769|NCT00178360|Experimental|Music Therapy|Subject will participate in one, individual, half-hour long music therapy session every other week and one hour-long group music therapy session each month, for a period of three months.
11643770|NCT00178360|No Intervention|Standard Care|During the Standard Care time period, participants will continue to receive all of the medical care that they would normally receive for the treatment of Huntington's Disease, without the addition of music therapy services.
11643771|NCT00178256|Experimental|1st dose cohort 15mg/m2 taxol plus RT|"15 mg/m2 Paclitaxel On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.
~On Monday, Tuesday, Wednesday, Thursday, Friday Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible"
11643772|NCT00178256|Experimental|2nd dose cohort20 mg/m2 taxol plus daily RT|
11643773|NCT00178256|Experimental|3rd Dose Cohort --25mg/m2 taxol plus RT|
11643774|NCT00178256|Experimental|Phase II Arm --20mg/m2 taxol plus RT|
11643775|NCT00178217|Experimental|Music Therapy|The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
11643776|NCT00178217|No Intervention|Standard Care Control|Subjects will receive standard care at control condition sessions, which includes the use of television, books, CD's, a child life specialist (when available) or other activities to help cope with the procedure.
11643777|NCT00178191|Experimental|200 units Botox|200 units Botulinum-A toxin
11643778|NCT00178191|Experimental|300 units Botox|300 units Botulinum-A toxin
11643779|NCT00178191|Placebo Comparator|Placebo|Placebo
11643780|NCT00178178|Experimental|Drug: Bupivicaine 0.5% Intraaticulary Only|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%;Intraaticular Only
~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) intraarticularly only via Breg Pain Care 3000 Catheter"
11643781|NCT00178178|Experimental|Drug: Bupivicaine 0.5% Patellar Tendon Site|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%;Patellar Tendon Site Only
~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the patellar tendon harvest site via Breg Pain Care 3000 Catheter"
11643782|NCT00178178|Experimental|Drug: Bupivicaine 0.5% Intraarticular and Patellar Tendon|"Breg Pain Care 3000 Catheter;Bupivicaine 0.5%; Intraarticular and Patellar Tendon Sites
~Continuous infusion of a local anesthetic agent (bupivicaine 0.5%) at the Patellar Tendon Harvest Site and Intraarticular infusion via Breg Pain Care 3000 Catheter"
11643783|NCT00178178|Placebo Comparator|Drug: Placebo|"Breg Pain Care 3000 Catheter with Placebo
~Receive liquid with no pain medication (placebo) through a catheter in one part of the operative knee via Breg Pain Care 3000 Catheter"
11643784|NCT00178126|Active Comparator|Segmented Foam Cushion|Receive seating assessment, wheelchair and seat cushion representing the standard of care in nursing homes
11643785|NCT00178126|Experimental|Skin Protection Cushion|Receive seating assessment, wheelchair and cushion meeting CMS code for Skin Protection Wheelchair Cushion
11643786|NCT00177996|Active Comparator|Sertaline high dose titration|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of Sertraline hydrochloride. The doses and titration schedules used in this arm (Sertaline high dose titration) are consistent with recommended FDA guidelines.
11643787|NCT00177996|Active Comparator|Sertaline low dose titration|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of Sertraline hydrochloride. The doses and titration schedules used in this arm (Sertaline low dose titration) are consistent with recommended FDA guidelines.
11643788|NCT00177970|Active Comparator|IVIG|
11643789|NCT00177970|Placebo Comparator|Placebo|
11643790|NCT00177944||patients with funal infections|
11643791|NCT00177931||liver transplant patients in ICU|
11643792|NCT00177918||lung transplant patients|
11643793|NCT00177892|Experimental|1|non-OSAH/overweight individuals with the Metabolic Syndrome
11643794|NCT00177892|Experimental|2|non-OSAH/overweight individuals without Metabolic Syndrome
11643795|NCT00177892|Active Comparator|3|non-OSAH/normal weight without Metabolic Syndrome
11643796|NCT00177892|Experimental|4|OSAH patients with chronic positive airway pressure therapy
11643797|NCT00177892|Experimental|5|OSAH patients without chronic positive airway pressure therapy
11643798|NCT00177866|Active Comparator|A Placebo or Celebrex|either placebo PO BID for the first eight weeks or Celebrex 200 mg PO BID for the first eight weeks
11643799|NCT00177866|Placebo Comparator|B Placebo or Celebrex|either placebo PO BID for the last eight weeks or Celebrex 200 mg PO BID for the last eight weeks
11643800|NCT00177853|Experimental|1|Celecoxib, Irinotecan and Concurrent Radiotherapy
11643801|NCT00177840|Experimental|1|True acupuncture using true needles
11643802|NCT00177840|Sham Comparator|2|sham acupuncture using sham needles
11643803|NCT00177671|Experimental|1|"escitalopram plus donepezil (DNP)in the experimental maintenance phase of the study.
~For subjects failing to respond to escitalopram during the initial open phase of acute treatment we allowed the use of duloxetine or venlafaxine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation donepezil.
~Participants remained on the same antidepressant medication and dosage throughout the 2 year maintenance phase of the study. In the event of a recurrence of major depression during maintenance treatment, dosages of antidepressant medication were raised, or the antidepressant was switched to venlafaxine or duloxetine.
~For subjects failing to respond to escitalopram during the initial open phase of acute treatment, we allowed the use of duloxetine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation placebo."
11643804|NCT00177671|Placebo Comparator|2|"escitalopram plus placebo (PBO) in the experimental maintenance phase of the study.
~For subjects failing to respond to escitalopram during the initial open phase of acute treatment, we allowed the use of duloxetine or venlafaxine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation placebo.
~Participants remained on the same antidepressant medication and dosage throughout the 2 year maintenance phase of the study. In the event of a recurrence of major depression during maintenance treatment, dosages of antidepressant medication were raised, or the antidepressant was switched to venlafaxine or duloxetine.
~For subjects failing to respond to escitalopram during the initial open phase of acute treatment, we allowed the use of venlafaxine or duloxetine to bring about remission and establish eligibility for randomized assignment to maintenance treatment with augmentation placebo."
11643805|NCT00177645|Experimental|sodium bicarbonate|inhaled sodium bicarbonate
11643806|NCT00177541|Experimental|Biofeedback|Biofeedback assisted pelvic floor muscle therapy (3 visits)
11643807|NCT00177515|Experimental|1|Computerized counseling about Emergency Contraception
11643808|NCT00177515|Active Comparator|2|Computerized counseling about peri-conception folate
11643809|NCT00177489|Experimental|Treatment|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
11643810|NCT00177489|Other|Control|"Caregivers in the control group received 2 brief check-in telphone calls during the 6 month intervention."
11643811|NCT00177463|Experimental|L- Carnosine|an antioxidant and AGE inhibitor, 500 mg/day, increasing each week in titration reaching 2000 mg/day in 4 weeks and maintained for rest of trial
11643812|NCT00177463|Placebo Comparator|Placebo|Placebo
11643813|NCT00177424|Active Comparator|1|Sertraline
11643814|NCT00177424|Placebo Comparator|2|matching placebo
11643815|NCT00177411|Experimental|PTHrP group|Subjects receiving PTHrP in varying doses.
11643816|NCT00177372|Experimental|1|Mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
11643817|NCT00177346|Experimental|CAS with cerebral protection|
11643818|NCT00177346|Active Comparator|CAS without cerebral protection|
11643819|NCT00177307|Experimental|Oxaliplatin, Capecitabine, and Bevacizumab|
11643820|NCT00177294|Experimental|1|Participants who respond partially to 6 weeks of escitalopram 10mg daily then receive 16 weeks of extension therapy with escitalopram 20 mg daily, plus weekly interpersonal psychotherapy (IPT)
11643821|NCT00177294|Active Comparator|2|Participants who respond partially to 6 weeks of escitalopram 10mg daily then receive 16 weeks of extension therapy with escitalopram 20 mg daily, plus weekly depression care management(DCM) without interpersonal psychotherapy (IPT)
11643822|NCT00177268||CTCL, atopic dermatitis, eczema|Those subjects with cutaneous t-cell lymphoma and Sezary syndrome, atopic dermatitis, or eczema may participate as appropriate with the potential for blood, tissue or urine sampling.
11643823|NCT00177255|Experimental|Docetaxel + Capecitabine|"Docetaxel 30mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days. Premedication with dexamethasone will be given to all patients receiving weekly docetaxel therapy to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions. Cycle 2 will begin on day 22.
~Capecitabine Capecitabine 825mg/m2 bid (total daily dose 1650mg/m2) will be administered orally for 14 days (days 1-14).
~Each cycle will consist of 21 days. Cycle 2 will begin on day 22."
11643824|NCT00177229|No Intervention|A|Enhanced usual care: 2 free, individual consultations with a nutritionist over first 6 months. Medical monitoring throughout study period.
11643825|NCT00177229|Experimental|B|
11643826|NCT00177216|Experimental|Zolpidem|The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or >). The dose was decreased to 5 mg if side effects occurred.
11643827|NCT00177216|Experimental|Excitalopram|The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
11643828|NCT00177216|Placebo Comparator|Placebo|A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
11643829|NCT00177177|Experimental|1|L Carnosine
11643830|NCT00177177|Placebo Comparator|2|Placebo
11643831|NCT00177164|Active Comparator|1|Oral Risperidone followed by Long acting Risperidone injections (Consta)
11643832|NCT00177164|Active Comparator|2|Oral second generation antipsychotic agents other than clozapine or risperidone (olanzapine, quetiapine, ziprasidone, aripiprazole)
11643833|NCT00177138|Active Comparator|Group 2|Tacrolimus/MMF/TMG
11643834|NCT00177138|Experimental|Group 1|Campath/MMF/TMG
11643835|NCT00177086|Experimental|Alfuzosin|
11643836|NCT00177086|Placebo Comparator|Placebo|
11643837|NCT00177047|Experimental|Chemotherapy and Transplant Treatment|Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m^2). Post-transplant maintenance therapy is then prescribed if appropriate.
11643838|NCT00176930|Experimental|Allogeneic stem cell transplant|Patients receiving cyclophosphamide and total body irradiation (TBI) and transplant, or cyclophosphamide, Busulfan and transplant.
11643839|NCT00176917|Experimental|Treatment Arm|All patients treated with chemotherapy and transplantation.
11643840|NCT00176904|Experimental|Treated Patients|All patients treated with protocol regimen (chemotherapy and surgery).
11643841|NCT00176891|Experimental|Laronidase ERT Treatment|Weekly infusion of laronidase enzyme replacement therapy followed by hematopoietic stem cell transplant.
11643842|NCT00176878|Experimental|Bone Marrow Failure Disorders|Patients with Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome
11643843|NCT00176865|Active Comparator|Arm 1 - Matched sibling donor|Stem Cell Transplant: human leukocyte antigen (HLA) genotypic matched sibling donor and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
11643844|NCT00176865|Active Comparator|Arm 2 - Matched unrelated donor|Stem Cell Transplant: HLA phenotypic matched unrelated peripheral blood stem cell (PBSC) donor and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
11643845|NCT00176865|Active Comparator|Arm 3 - Mismatched double cord donors|Stem Cell Transplant: two HLA 0-2 antigen mismatched unrelated cord blood donors (double cord) and pre-treatment with fludarabine, melphalan, anti-thymocyte globulin or Campath 1H and post-treatment with Cyclosporin A, mycophenolate mofetil and Intravenous immunoglobulin (IVIG)
11643846|NCT00176852|Other|RIC Bu/Flu (A) (discontinued)|Full Preparative Regimen for subjects with matched donors using Busulfan on Day -8 and -7, Fludarabine on Day -6 through -2, antithymocyte globulin (ATG) on Day -2 through -1, total lymphoid radiation (TLI) on Day -1, stem cell infusion on Day 0.
11643847|NCT00176852|Experimental|MA Bu/Cy (B)|Myeloablative Preparative Regimen for subjects with HLA identical sibling donors consists of Busulfan on day -9 through -6, Cyclophosphamide on day -5 through -2, ATG on day -3 through -1, stem cell infusion on Day 0 and Granulocyte Colony Stimulating Factor on day -3 until ANC >2500 x 2 days.
11643848|NCT00176852|Experimental|RIC Cy/Flu/TBI (A2)|Patients with sickle cell disease or thalassemia who do not have an HLA-identical sibling donor or who has pre-existing organ dysfunction making myeloablative condition ineligible will receive Campath on day -10 through -6, Cyclophosphamide on day -7, Fludarabine on day -6 through -2, total body irradiation (TBI) on day -1, stem cell infusion on Day 0.
11643849|NCT00176839|Experimental|Treatment Arm|Patients treated with therapy plan consisting of Busulfan every 6 hours on days -7 through -4, Cyclophosphamide 60 mg/kg/day IV x 2 days, Melphalan 140 mg/m on day -1, antithymocyte globulin (ATG), G-CSF (granulocyte colony-stimulating factor) and stem cell transplantation on day 0.
11643850|NCT00176826|Experimental|Intent-To-Treat|Patients who were treated with chemotherapies (myeloablative conditioning regimen) and stem cell transplant. Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
11643851|NCT00176800|Experimental|1|Paclitaxel is administered intravenously over 1 hour on Days 1, 8, 15, and 22. Cisplatin will then be administered intravenously over 1 hour on Days 1 and 22. Radiation treatments will be given twice/day, on Days 1-5, 8-12 and 15-19. The subject's esophagus will be surgically removed on approximately Day #50. Approximately 4-6 weeks after surgery, the subject will start taking Tetrathiomolybdate, for 2 years or until treatment is no longer working to control your cancer. The subject will have blood drawn weekly while he/she is receiving chemotherapy and radiation prior to their surgery. 4-6 weeks after their surgery (when the subject starts taking Tetrathiomolybdate), a blood test will be performed every other week for 2 times, and monthly thereafter. When the level of copper has been lowered sufficiently an additional blood test and a baseline chest x-ray will be obtained. Additional blood will be drawn and tested every 6 months for the first 2 years.
11643852|NCT00176748|Experimental|1|
11643853|NCT00176722||surgical|males & females undergoing spine surgery in the prone position
11643854|NCT00176683||All comers|capnography used for all consenting subjects
11643855|NCT00176644|Experimental|Transdermal estradiol|
11643856|NCT00176631|Experimental|licorice root extract and docetaxel|
11643857|NCT00176605|Experimental|Arm 1 (Etoposide + Cyclophosphamide)|Therapy will be divided into 4 cycles. Each cycle will be composed of 6 weeks of therapy. Total duration of therapy is 24 weeks. Administration of etoposide (50 mg po qd) and cyclophosphamide (50 mg po qd) will alternate in 21 day intervals. Starting with etoposide, patients will receive 21 days of therapy, upon completion of etoposide therapy patients will then receive 21 days of cyclophosphamide therapy. Therapy will continue in this alternating manner for 24 weeks. Week 1 of each cycle, begins with etoposide; Week 4 of each cycle, begins with cyclophosphamide.
11643858|NCT00176592|Active Comparator|Betaseron|Betaseron 250 micrograms SQ every other day
11643859|NCT00176592|Active Comparator|Copaxone|20 mg daily SQ
11643860|NCT00176501|Experimental|Irradiated allogeneic lymphocytes|
11643861|NCT00176488|Experimental|Sequential epirubicin/vinorelbine|For patients with stage IIB (T3N0), IIIA, or IIIB breast cancer, epirubicin and vinorelbine will be administered for up to 5 cycles. For patients with stage IV breast cancer, epirubicin and vinorelbine will be administered as long as there is evidence of continued response or stable disease and no evidence of cardiac or other serious toxicities.
11643862|NCT00176475|Experimental|Therapeutic allogeneic lymphocytes with rituximab|
11643863|NCT00176462|Experimental|Arm 1 Standard Risk|6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE METHOTREXATE Leucovorin
11643864|NCT00176462|Experimental|Arm 2 High Risk|6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE 6-THIOGUANINE CYTARABINE AMINOPTERIN CYCLOPHOSPHAMIDE ARABINOSIDE-C
11643865|NCT00176449|Active Comparator|Bupropion SR|
11643866|NCT00176449|Placebo Comparator|Placebo|
11643867|NCT00176436|Active Comparator|active|Atomoxetine titrated up to 120 mg/day by week 8 and continues at 120 mg/day through week 24. Diet support group, group counseling and exercise.
11643868|NCT00176436|Placebo Comparator|Placebo|Placebo medication, diet support group, group counseling and exercise
11643869|NCT00176306|Experimental|Levofloxacin|Patients receiving levofloxacin 750mg IV
11643870|NCT00176293|Experimental|1|dexamethasone
11643871|NCT00176293|No Intervention|2|
11643872|NCT00176267|Experimental|1|
11643873|NCT00176254|Experimental|Induction chemotherapy and radiation|Induction chemotherapy with low dose radiation
11643874|NCT00176241|Experimental|1|
11643875|NCT00176228|Experimental|lamotrigine|The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg. Increasing the medication to final dose will take 8 weeks and the response on full and tolerable dose is further monitored for response over 6 weeks. Therefore, this is a 18-26 week trial (2 to 12 weeks=screening and wash out; 8 weeks=dosing; 6 weeks=acute trial period on full dose).
11643876|NCT00176202|Active Comparator|Risperidone|Risperidone is an antimanic medication and is a second generation antipsychotic
11643877|NCT00176202|Active Comparator|Divalproex sodium|Divalproex sodium is an antiepileptic medication and is a mood stabilizer
11643878|NCT00176124|No Intervention|1|storage and transfusion of autologous whole blood without leukocyte depletion : Control group
11643879|NCT00176124|Experimental|2|storage and transfusion of leukocyte depleted autologous whole blood : leukocyte depletion group
11643880|NCT00176085||healthy|healthy volunteers
11643881|NCT00176046|Experimental|viscum album pini|immediate start of treatment with Iscador P s.c.
11643882|NCT00176046|Active Comparator|waiting group|identical treatment with Iscador P s.c. after waiting period of 3 months
11643883|NCT00175929|Placebo Comparator|Placebo|Matching placebo tablets administered twice a day
11643884|NCT00175929|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
11643885|NCT00175929|Experimental|Brivaracetam 150 mg/day|Brivaracetam 150 mg/day, 75 mg administered twice a day
11643886|NCT00175916|Experimental|Brivaracetam|Flexible dosing, can up and down titrate as needed.
11643887|NCT00175903|Experimental|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
11643888|NCT00175903|Active Comparator|Older Antepileptic Drugs|Older AEDs consist of CBZ-CR 200 mg and 400 mg and VPA-ER 300 mg and 500 mg.
11643889|NCT00175890|Placebo Comparator|Placebo|Matching oral solution to Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
11643890|NCT00175890|Experimental|Levetiractem|10 % oral solution Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
11643891|NCT00175877|Experimental|Certolizumab Pegol|All patients received Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) every two weeks, given as two 1 ml injections of CZP for at least six months and then 200 mg of CZP sc every two weeks, given as one 1 ml injection.
11643892|NCT00175838|Active Comparator|Intermediate risk group|Intermediate risk patients are randomised to a either a group receiving Aspirin only, or a group receiving both Hydroxyurea and Aspirin.
11643893|NCT00175838|Active Comparator|Low risk group|Patients are given Aspirin only with observation.
11643894|NCT00175825|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
11643895|NCT00175825|Experimental|Brivaracetam 5 mg/day|Brivaracetam 5 mg/day, 2.5 mg administered twice a day
11643896|NCT00175825|Experimental|Brivaracetam 20 mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day
11643897|NCT00175825|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
11643898|NCT00175812|Experimental|ATRA plus valproic acid plus theophyllin|ATRA for 14 days, continuous treatment with valproic acid and theophyllin
11643899|NCT00175435|Experimental|1|2 doses of HPV vaccine 0.5 mL. given IM with Topical Immune Modulator in 9-13 year-olds.
11643900|NCT00175435|Active Comparator|2|3 doses of HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 9-13 year-olds.
11643901|NCT00175435|Active Comparator|3|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 16-26 year-olds.
11643902|NCT00175409|Active Comparator|1|Infants will be randomized to two interventions which will take place during two separate blood collections that are required for clinical management. For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
11643903|NCT00175409|Active Comparator|2|Infants will be randomized to two interventions which will take place during two separate blood collections that are required for clinical management. For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
11643904|NCT00175396|Active Comparator|1|
11643905|NCT00175396|Experimental|2|
11643906|NCT00175383|Experimental|Leuprolide preparations|One versus three-month Leuprolide preparations in patients otherwise suitable for our Brachytherapy Program
11643907|NCT00175357|Active Comparator|1|Oral methadone
11643908|NCT00175357|Experimental|2|Injected diacetylmorphine
11643909|NCT00175344|Experimental|A|Arm A: Self-administered massage of the postoperative scar after breast cancer surgery.
11643910|NCT00175227|Experimental|Intervention|Saline hydration + mannitol + furosemide
11643911|NCT00175227|Placebo Comparator|Controls|Saline hydration without mannitol or furosemide
11643912|NCT00175188|Active Comparator|Cemented PIP implant|Avanta PIP
11643913|NCT00175188|Active Comparator|Uncemented PIP implant|Avanta PIP
11643914|NCT00175162|Active Comparator|Osteopal G bone cement|
11643915|NCT00175162|Active Comparator|Refobacin-Palacos R bone cement|
11643916|NCT00175149|Active Comparator|1|Given alfacalcidiol. Dose adjusted after PTH level
11643917|NCT00175149|No Intervention|2|The untreated arm
11643918|NCT00175136|Active Comparator|I-beam|I-beam stem design of tibial component for Total Knee Arthroplasty.
11643919|NCT00175136|Active Comparator|wedge|Wedge stem design of tibial component for Total Knee Arthroplasty.
11643920|NCT00175097|Other|soybeans and products made thereof|Diet: soybeans and products made thereof (soynuts, soynut butter, soy flakes & grits)
11643921|NCT00175097|Other|soybean flour and products made thereof|Diet: soybean flour and products made thereof (textured soybean)
11643922|NCT00175097|Other|soybean milk|Diet: soybean milk (tofu, soybean yogurt, cheese, etc.)
11643923|NCT00175097|Other|animal protein based diet|Diet: animal protein based diet
11643924|NCT00175071|Experimental|Comparison of cooking oils|Postmenopausal women (50-85 y) with LDL cholesterol 120 mg/dL.
11643925|NCT00175058|No Intervention|1|Control - Patients with acute anterior myocardial infarction revascularized by means of PCI with stenting within 6 hours of onset of symptoms, no experimental intervention
11643926|NCT00175058|Experimental|2|AO Therapy group - anterior acute myocardial infarction patients revascularized by means of PCI with stenting within 6 hours of symptom onset, receiving adjunctive infusion of hyperoxemic blood into target coronary artery for 90 minutes post-PCI.
11643927|NCT00175045|Experimental|Lansoprazole IV 30 mg QD|
11643928|NCT00175045|Active Comparator|Lansoprazole Capsule 30 mg QD|
11643929|NCT00175032|Experimental|Lansoprazole 30 mg QD + Naproxen 500 mg BID|(and added aspirin)
11643930|NCT00175032|Active Comparator|Celecoxib 200 mg QD|(and added aspirin)
11643931|NCT00175019|Experimental|Febuxostat 80 mg QD|
11643932|NCT00175019|Experimental|Febuxostat 120 mg QD|
11643933|NCT00175019|Active Comparator|Allopurinol QD|
11643936|NCT00174993|Placebo Comparator|Placebo QD|
11643937|NCT00174967|Placebo Comparator|Placebo QD|
11643938|NCT00174967|Experimental|Febuxostat 40 mg QD|
11643939|NCT00174967|Experimental|Febuxostat 80 mg QD|
11643940|NCT00174967|Experimental|Febuxostat 120 mg QD|
11643941|NCT00174954||1|Volumes/measurements of tophi determined by serial MRIs
11643942|NCT00174941|Experimental|1|
11643943|NCT00174941|Experimental|2|
11643944|NCT00174941|Experimental|3|
11643945|NCT00174928|Experimental|Lansoprazole 0.5 mg/kg QD|
11643946|NCT00174928|Experimental|Lansoprazole 1.0 mg/kg QD|
11643947|NCT00174915|Experimental|Febuxostat 80 mg QD|
11643948|NCT00174915|Experimental|Febuxostat 120 mg QD|
11643949|NCT00174915|Experimental|Febuxostat 240 mg QD|
11643950|NCT00174915|Active Comparator|Allopurinol QD|
11643951|NCT00174915|Placebo Comparator|Placebo QD|
11643952|NCT00174837|Experimental|Tirapazamine + Cisplatin|
11643953|NCT00174837|Active Comparator|Cisplatin|
11643954|NCT00174798|Placebo Comparator|Placebo|
11643955|NCT00174798|Experimental|SSR240600C|
11643956|NCT00174798|Active Comparator|Tolterodine|
11643957|NCT00174785|Experimental|Dronedarone 400mg bid|Dronedarone 400mg tablets twice daily (bid)
11643958|NCT00174785|Placebo Comparator|Placebo|matching placebo tablets
11643959|NCT00174772|Experimental|B|Concurrent chemoradiotherapy followed by consolidation chemotherapy
11643960|NCT00174772|Experimental|A|Induction chemotherapy followed by concurrent chemoradiotherapy
11643961|NCT00174707|Active Comparator|A|Sequential Epidoxorubicin followed by CMF: ciclophosphamide/Methotrexate/fluorouracile (±TAM: tamoxifen)
11643962|NCT00174707|Experimental|B|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
11643963|NCT00174707|Experimental|C|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
11643964|NCT00174668|Experimental|1|Mealtime insulin glulisine 3x daily and insulin glargine 1 x daily subcutaneously
11643965|NCT00174668|Active Comparator|2|Two daily injection conventional insulin therapy
11643966|NCT00174655|Active Comparator|A1|
11643967|NCT00174655|Active Comparator|A2|
11643968|NCT00174655|Experimental|B|
11643969|NCT00174655|Experimental|C|
11643970|NCT00174642|Experimental|1|Insulin Glargine + 3 bolus of Insulin Glulisine + Metformin
11643971|NCT00174642|Experimental|2|Insulin Glargine + 1 to 3 bolus of Insulin Glulisine + Metformin
11643972|NCT00174642|Experimental|3|Insulin Glargine + 1 to 3 bolus of Insulin Glulisine + Metformin + Insulin secretagogue
11643973|NCT00174629|Experimental|1|
11643974|NCT00174629|Active Comparator|2|
11643975|NCT00174616|Experimental|Single arm|
11643976|NCT00174499|Experimental|1|2 mg nicotine gum
11643977|NCT00174499|Experimental|2|4 mg nicotine gum
11643978|NCT00174460|Active Comparator|Treatment Arm|
11643979|NCT00174460|No Intervention|Control Arm|
11643980|NCT00174447|Experimental|A1|
11643981|NCT00174434|Experimental|A|
11643982|NCT00174382|Experimental|1|
11643983|NCT00174369|Experimental|PD0325901|15 mg BID
11643984|NCT00174291|Experimental|Somatropin|
11643985|NCT00174265|Experimental|asenapine|
11643986|NCT00174265|Active Comparator|olanzapine|
11643987|NCT00174252|Experimental|Genotonorm (Somatropin)|
11643988|NCT00174187|Experimental|Somatropin|
11643989|NCT00173888|Experimental|A|
11643990|NCT00173888|Active Comparator|B|
11643991|NCT00173875|Experimental|A|Iressa
11643992|NCT00173862|Experimental|A|
11643993|NCT00173537|Other|other|
11643994|NCT00173433||Culture-confirmed relapse of TB|Patients who have a recurrent episode of culture-confirmed TB after completion of treatment for the first episode of culture-confirmed TB
11643995|NCT00173108|No Intervention|Term group|
11643996|NCT00173108|No Intervention|Usual care program group|
11643997|NCT00173108|Experimental|Clinic-based interveniton program group|
11643998|NCT00173108|Experimental|Home-based interveniton program group|
11643999|NCT00172809|Active Comparator|1|Peginterferon alfa-2a (Pegasys, Hoffmann-LaRoche) 135 ug/week for 24 weeks
11644000|NCT00172809|Active Comparator|2|Interferon alfa-2a (Roferon, Hoffmann-LaRoche) 3 MU tiw for 24 weeks
11644001|NCT00172536|Other|Control|Received oral general education about proper diet, regular physcial activity and other medical care if necessary
11644002|NCT00172536|Experimental|Exercise training|Received a supervised structure treadmill training
11644003|NCT00172419|Experimental|Atorvastatin|
11644004|NCT00172380|Experimental|docetaxel and cisplatin|docetaxel 36mg/m2 and cisplatin 75mg/m2
11644005|NCT00172224||osteoporosis|
11644006|NCT00172185|Experimental|teduglutide 0.05 mg/kg/d|0.05 mg/kg/d teduglutide subcutaneous injection
11644007|NCT00172185|Experimental|teduglutide 0.10 mg/kg/d|0.10 mg/kg/d teduglutide subcutaneous injection
11644008|NCT00172172|Experimental|1|PTH 100 mcg and 700 mg calcium
11644009|NCT00172172|Experimental|2|PTH 100 mcg and placebo
11644010|NCT00172172|Placebo Comparator|3|Placebo and 700 mg calcium
11644011|NCT00172133|Experimental|1|All patients entering the study will receive 100mcg daily for up to 6 months, making their total exposure 24 months
11644012|NCT00172107|Placebo Comparator|1|Placebo drug injectable subcutaneously
11644013|NCT00172107|Experimental|2|50 mcg PTH(1-84)
11644014|NCT00172107|Experimental|3|75mcg PTH(1-84)
11644015|NCT00172107|Experimental|4|100 mcg PTH(1-84)
11644016|NCT00172094|Placebo Comparator|1|PLACEBO
11644017|NCT00172094|Experimental|2|400 mg 1776 powder
11644018|NCT00172094|Experimental|3|1776 (800 mg)
11644019|NCT00172081|Placebo Comparator|placebo|Daily subcutaneous injection into thigh or abdomen with 700 mg Calcium and 400 IU Vitamin D daily
11644020|NCT00172081|Experimental|PTH(1-84) 100 mcg|Subcutaneous injection of PTH(1-84) with 700 mg Calcium and 400 IU Vitamin D daily
11644021|NCT00172068|Experimental|Treatment Group|
11644022|NCT00172068|Active Comparator|Control Group|
11644023|NCT00172055|Experimental|ZOL446 (zoledronic acid)|
11644024|NCT00172042|Experimental|Zoledronic acid|Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 to 4 weeks for 24 months. Dosage was adjusted for participants with mild or moderate renal impairment.
11644025|NCT00172042|Other|Control|No investigational treatment. If a participant developed bone metastases, treatment was started with Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 to 4 weeks until 24 months from the date of study entry had elapsed.
11644026|NCT00172029|Experimental|ZOL446 Standard radiotherapy dosage|
11644027|NCT00172029|Experimental|ZOL446 Low radiotherapy dosage|
11644028|NCT00172016|Experimental|ZOL446 (zoledronic acid)|
11644029|NCT00172003|Experimental|Zoledronic acid|Zoledronic acid, dosage according to calculated creatinine clearance, administered as a 15 minute infusion every 3 weeks for 12 months. Study infusion visits should occur not earlier than the scheduled visit and no later than 3 days after the scheduled visit. The dose of zoledronic acid in patients with baseline creatinine clearance > 60 mL/min was recommended to be 4 mg infused over no less than 15 minutes.
11644030|NCT00171977|Experimental|Imatinib Mesylate|400 mg once per day
11644031|NCT00171964|Experimental|zoledronic acid + radiotherapy|zoledronic acid every 4 weeks in combination with radiotherapy
11644032|NCT00171951|Experimental|Pasireotide|
11644033|NCT00171925|Experimental|Zoledronic acid (ZOL446)|Participants received intravenous infusion of Zoledronic acid every 4 weeks for 48 weeks, and calcium and Vitamin D daily.
11644034|NCT00171925|No Intervention|Control|No treatment with study medication.
11644035|NCT00171912|Experimental|imatinib mesylate (STI571)|
11644036|NCT00171899|Experimental|STI571|
11644037|NCT00171886|Experimental|octrotide|
11644038|NCT00171873|Experimental|Octreotide LAR (Long Acting Release)|Octreotide LAR 30 mg intramuscularly every 28 days
11644039|NCT00171873|Placebo Comparator|Placebo|Placebo - Sodium chloride intramuscularly every 28 days
11644040|NCT00171860|Experimental|STI571|
11644041|NCT00171847|Experimental|A - HER-2 +ve patients with Femara alone|
11644042|NCT00171847|Experimental|B - HER-2 +ve patients with Femara + Herceptin|
11644043|NCT00171847|Experimental|C - HER-2 -ve patients with Femara alone|
11644044|NCT00171821|Experimental|ICL670 (Deferasirox)|
11644045|NCT00171808|Experimental|Letrozole|
11644046|NCT00171730|Experimental|Pasireotide s.c. (SOM230)|
11644047|NCT00171704|Experimental|Letrozole|2.5 mg once daily (q.d.)orally for 5 years
11644048|NCT00171704|Experimental|Tam-Let|20 mg Tamoxifen once daily (q.d.) orally for 2 years followed by Letrozole 2.5 mg q.d. orally for 3 years.
11644049|NCT00171509|Active Comparator|BID cyclosporine|control group continuing with a BID administration of cyclosporine and C2 monitoring.
11644050|NCT00171509|Experimental|OAD cyclosporine|conversion to OAD administration of cyclosporine with the same daily dose as received prior to conversion
11644051|NCT00171509|Experimental|OAD cyclosporine reduced|OAD administration of cyclosporine with a daily dose adjusted to a reduced C2
11644052|NCT00171496|Experimental|Cyclosporine microemulsion|
11644053|NCT00171496|Active Comparator|Tacrolimus|
11644054|NCT00171340|Experimental|Upfront Zoledronic Acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.
11644055|NCT00171340|Experimental|Delayed Zoledronic Acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score <= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.
11644056|NCT00171314|Experimental|Upfront Zoledronic Acid|Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1
11644057|NCT00171314|Experimental|Delayed Zoledronic Acid|Zoledronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score <= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1
11644058|NCT00171301|Experimental|Deferasirox|Deferasirox was given orally once daily (10 to 20 mg/kg) to participants 2 years and older based on participant's body weight.
11644059|NCT00171249|Experimental|Gleevec/Glivec|
11644060|NCT00171223|Experimental|Gleevec/Glivec|
11644061|NCT00171210|Experimental|Deferasirox|All participants received Deferasirox (ICL670) orally once a day. Dosage based on body weight.
11644062|NCT00171184|Experimental|1|Darifenacin
11644063|NCT00171184|Placebo Comparator|2|Placebo
11644064|NCT00171171|Experimental|Deferasirox|
11644065|NCT00171158|Experimental|imatinib mesylate|
11644066|NCT00171145|Experimental|1|Darifenacin
11644067|NCT00171145|Placebo Comparator|2|Placebo
11644068|NCT00171054|Experimental|Valsartan 320 mg|
11644069|NCT00171054|Experimental|Amlodipine 10 mg|
11644070|NCT00170950|Experimental|Benazepril/amlodipine|Patients were instructed to take one capsule with water in the morning, except on the morning of their next office visit. On office visit days, study medication was taken after completion of the visit evaluations. Following randomization, all patients were treated at Dose Level 1 for 4 weeks, followed by a forced titration to Dose Level 2 for a subsequent 4 week period. Thereafter, patients were titrated as needed to Dose Level 3 to achieve a target blood pressure of < 140/< 90 mm Hg. For patients with diabetes or chronic kidney disease, investigators were encouraged to use a target blood pressure of 130/80 mm Hg.
11644126|NCT00170001|Active Comparator|Active Comparator|
11644127|NCT00169910|Active Comparator|1|AUC monitored withdrawal of MMF
11644128|NCT00169910|Active Comparator|2|AUC monitored withdrawal of CNI
11644129|NCT00169897|Experimental|Hospital-based|This group has to go at the hospital 3 times per week to do the exercise program.
11644130|NCT00169897|Active Comparator|Home-Based|The group had to do the exercise program at home with indirect supervision (Polar watches and a phone call per week).
11644071|NCT00170950|Active Comparator|Benazepril/hydrochlorothiazide|Patients were instructed to take one capsule with water in the morning, except on the morning of their next office visit. On office visit days, study medication was taken after completion of the visit evaluations. Following randomization, all patients were treated at Dose Level 1 for 4 weeks, followed by a forced titration to Dose Level 2 for a subsequent 4 week period. Thereafter, patients were titrated as needed to Dose Level 3 to achieve a target blood pressure of < 140/< 90 mm Hg. For patients with diabetes or chronic kidney disease, investigators were encouraged to use a target blood pressure of 130/80 mm Hg.
11644072|NCT00170846|Active Comparator|Group A: No RAD|Calcineurin Inhibitors (CNI) ± Mycophenolate Acid (MPA)/Azathioprine (AZA) ± Steroids
11644073|NCT00170846|Experimental|Group B : CNI Withdrawal|Initiation of everolimus (8-12 ng/mL) with discontinuation of CNI. Everolimus(RAD001) 4 mg initial daily dose.
11644074|NCT00170846|Experimental|Group C: CNI Reduction|Initiation of everolimus (3-8 ng/mL) with reduction by 70-90% in CNI blood levels. Everolimus (RAD001) 3 mg initial daily dose.
11644075|NCT00170768|Experimental|1|Darifenacin
11644076|NCT00170768|Active Comparator|2|Oxybutynin
11644077|NCT00170768|Placebo Comparator|3|Placebo
11644078|NCT00170755|Experimental|1|Darifenacin
11644079|NCT00170716|Active Comparator|Control|
11644080|NCT00170716|Experimental|Investigational|
11644081|NCT00170690|Experimental|1|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
11644082|NCT00170690|Experimental|2|Treosulfan 600 mg/m² p.o. on day 1-28, 57-84, etc
11644083|NCT00170677|Active Comparator|A|
11644084|NCT00170677|Experimental|B|
11644085|NCT00170664|Experimental|Paclitaxel, Carboplatin|
11644086|NCT00170625|Experimental|Hycamtin|
11644087|NCT00170612|Experimental|A|PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 18 months
11644088|NCT00170612|Experimental|B|PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 12 months and 18 months
11644089|NCT00170612|Experimental|C|PCV at 6 weeks and 14 weeks; PPS at 18 months
11644090|NCT00170612|Experimental|D|PCV at 6 weeks and 14 weeks; PPS at 12 months and 18 months
11644091|NCT00170612|Experimental|E|PCV at 14 weeks; PPS at 18 months
11644092|NCT00170612|Experimental|F|PCV at 14 weeks; PPS at 12 months and 18 months
11644093|NCT00170612|Experimental|G|No PCV; PPS at 12 months and 18 months
11644094|NCT00170612|Active Comparator|H|No PCV; PPS at 18 months
11644095|NCT00170573|Experimental|Caelyx|
11644096|NCT00170547|Experimental|Group 3|382 subjects will receive one 3 mcg dose of Fluzone intradermally using the Mantoux technique on Day 0,
11644097|NCT00170547|Experimental|Group 4|382 subjects will receive one 15 mcg dose Fluzone vaccine intramuscularly (IM) on Day 0,
11644098|NCT00170547|Experimental|Group 1|382 subjects will receive one 6 mcg dose of Trivalent inactivated influenza vaccine (TIV) intradermally (ID) with the BD ID System on Day 0,
11644099|NCT00170547|Experimental|Group 2|382 subjects will receive one 9 mcg dose of TIV intradermally (ID) with the BD ID System on Day 0,
11644100|NCT00170495||observation|male and female adults age 65 and older with acute respiratory illness (common colds, flu, bronchitis, pneumonia)
11644101|NCT00170469|Experimental|1|Low dose rPA vaccine
11644102|NCT00170469|Experimental|2|High dose rPA vaccine
11644103|NCT00170469|Active Comparator|3|Active vaccine control
11644104|NCT00170456|Active Comparator|1|Low dose rPA vaccine regime 1
11644105|NCT00170456|Active Comparator|2|Low dose rPA vaccine regime 2
11644106|NCT00170456|Active Comparator|3|High dose rPA vaccine regime 1
11644107|NCT00170456|Active Comparator|4|High dose rPA vaccine regime 2
11644108|NCT00170326|Active Comparator|Dual Chamber pacing|conventional dual-chamber pacemaker/ICD implantation with the ventricular lead in the right ventricular apex
11644109|NCT00170326|Experimental|Biventricular pacing|Biventricular pacing: dual-chamber biventricular pacemaker/ICD implantation with leads at the right ventricular apex and the left ventricle
11644110|NCT00170313|Experimental|Conducted AF-Response Algorithm (CAFR) On|"CAFR: On
~Level medium
~Max. Rate: 110ppm VSR: Off"
11644111|NCT00170313|Active Comparator|Conducted AF-Response Algorithm (CAFR) Off|CAFR: Off VSR: Off
11644112|NCT00170287|Experimental|1|ICD Therapy plus VT-Ablation
11644113|NCT00170287|Active Comparator|2|ICD Therapy only
11644114|NCT00170274|No Intervention|Control Arm|Algorithms for prevention and termination of AF not activated
11644115|NCT00170274|Active Comparator|Prevention and Therapy Algorithms on|Activation of preventive and therapeutic algorithms
11644116|NCT00170248|No Intervention|1|Physicians in this arm will be using the standard MOXXI electronic health record.
11644117|NCT00170248|Experimental|2|In addition to the standard MOXXI electronic health record, physicians in this arm will be using the computer-based decision support for asthma management
11644118|NCT00170235|Experimental|1|Prehabilitation (exercises pre surgery)
11644119|NCT00170235|Active Comparator|2|Usual care as provided by the institution
11644120|NCT00170209|Active Comparator|Isoniazid|The standard therapy will be daily self-administered INH, 10-15 mg/kg/day (max=300mg/day) for 9 months (9INH).
11644121|NCT00170209|Active Comparator|Rifampin|The experimental arm will be daily self-administered RIF 10-20 mg/kg/day for 4 months (4RIF).
11644122|NCT00170157|Experimental|Arm I|Patients receive either leuprolide acetate intramuscularly (IM) or goserelin subcutaneously (SC) on days 0, 28, and 56. Patients also receive oral flutamide three times daily or oral bicalutamide once daily. Treatment with antiandrogen (AA) therapy continues for 3 months (3-4 months for patients who initiated AA therapy <= 21 days prior to enrollment) in the absence of disease progression or unacceptable toxicity. Patients receive ipilimumab IV over 90 minutes on day 7 (within 7-28 days post-initiation of AA therapy for patients who initiated AA therapy <= 21 days prior to enrollment) of AA therapy.
11644123|NCT00170157|Active Comparator|Arm II|Patients receive AA therapy as in arm I. Patients may crossover to arm II in the case of disease progression.
11644124|NCT00170079|Experimental|Step care vs. regular care|Participants were randomized either to (1) Step care intervention, where smokers who failed to quit or who relapsed received increasingly intensive smoking cessation interventions; vs. (2) Regular care, where smokers who failed to quit or who relapsed received repeated intervention.
11644125|NCT00170001|Placebo Comparator|Sugar pill|
11644131|NCT00169845|Experimental|Alpha-Tocopherol and Beta-Carotene|Patients received a daily supplementation of alpha-tocopherol (one capsule of 400 IU dl-alpha-tocopherol) and beta-carotene (one capsule of 30 mg) for 3 years after the end of radiation therapy. Due to ethical concerns, the beta-carotene supplementation was stopped during the trial (after the randomization of 156 patients). See details in JNCI, 2005: 97 (7), 481-8.
11644132|NCT00169845|Placebo Comparator|Placebo|Patients received two capsules of placebos per day during 3 years. When the beta-carotene was stopped, they received only one capsule.
11644133|NCT00169832|Experimental|Rosiglitazone (Avandia)|
11644134|NCT00169832|Placebo Comparator|Placebo|
11644135|NCT00169806|Other|cohort|Subjects who are scheduled to undergo a percutaneous kidney stone removal who do not have complicated comorbidities
11644136|NCT00169793|Other|A|
11644137|NCT00169780||cohort|patients who require a CT scan prior to kidney stone surgery for diagnostic purposes
11644138|NCT00169767||A|Comparison study between KTP and HoLAP procedures for BPH
11644139|NCT00169754|Other|cohort|mapping and data collection
11644140|NCT00169741|Other|cohort|
11644141|NCT00169715|Other|A|
11644142|NCT00169702|Other|Standard|standard information
11644143|NCT00169702|Active Comparator|Intervention|weight management program, 12 sessions, 2 weekly, psychoeducational program, interactive topics like healthy food, diet behavior, physical activity, stress reduction.
11644144|NCT00169689|Sham Comparator|rTMS|sham coil system versus verum rTMS stimulation
11644145|NCT00169676||cohort|Registry and Database
11644146|NCT00169650||1|Registry and database of subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction
11644147|NCT00169559|Placebo Comparator|Arm 1|Placebo
11644148|NCT00169559|Active Comparator|Arm 2|Fenofibrate
11644149|NCT00169546|Experimental|Arm 1|
11644150|NCT00169533|Experimental|Arm 1|Lapatinib either 750, 1000, 1250 or 1500 mgs
11644151|NCT00169442|Experimental|Tritanrix-HepB/Hiberix Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine, received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
11644152|NCT00169442|Experimental|Tritanrix-HepB/Hiberix Kft. Ref Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ vaccine, received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
11644153|NCT00169442|Experimental|HB Tritanrix-HepB/Hiberix Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine (with HepB at birth), received a booster dose of Tritanrix™-HepB/Hiberix™ Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
11644154|NCT00169442|Experimental|Tritanrix-HepB Kft.+Hiberix Group|Healthy male and female infants who were primed with Tritanrix™-HepB Kft. and Hiberix™ vaccines, were boosted with Tritanrix™-HepB Kft. vaccine administered intramuscularly into the right upper thigh and Hiberix™ vaccine, administered intramuscularly into the left upper thigh, at 15-18 months of age.
11644155|NCT00169442|Experimental|PRP Tritanrix-HepB Kft. Mix Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ Kft. vaccine, received plain Polyribosil-Ribitol-Phosphate (PRP) polysaccharide vaccine administered intramuscularly into the right upper thigh, at 10 months of age, followed by a booster dose of Tritanrix™-HepB Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
11644156|NCT00169442|Experimental|PRP Tritanrix-HepB Kft. Ref Group|Healthy male and female infants who were primed with Tritanrix™-HepB/Hiberix™ vaccine, received plain Polyribosil-Ribitol-Phosphate (PRP) polysaccharide vaccine administered intramuscularly into the right upper thigh, at 10 months of age, followed by a booster dose of Tritanrix™-HepB Kft. administered intramuscularly into the right upper thigh, at 15-18 months of age.
11644157|NCT00169390||pregnant smokers|
11644158|NCT00169390||pregnant non smokers|
11644159|NCT00169377|Active Comparator|Group A|Deep brain stimulation on followed by off
11644160|NCT00169377|Sham Comparator|Group B|No stimulation, deep brain stimulation off followed by on
11644161|NCT00169338|Experimental|deep brain stimulation|Paladin deep brain stimulation
11644162|NCT00169338|Placebo Comparator|sham deep brain stimulation|no stimulation
11644163|NCT00169273|Active Comparator|Weight loss only intervention|Structured group weight loss intervention
11644164|NCT00169273|Experimental|Combined intervention|Structured group program for weight loss and depression
11644165|NCT00169260|Experimental|1|Intervention
11644166|NCT00169260|Placebo Comparator|2|Control
11644167|NCT00169234|Experimental|0.1mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 0.1mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
11644168|NCT00169234|Experimental|0.5mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 0.5mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
11644169|NCT00169234|Experimental|1.0mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 1.0mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
11644170|NCT00169234|Experimental|2.0mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 2.0mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
11644171|NCT00169234|Experimental|0.5mL Pneumococcal Polysacc Vaccine|Participants in this group were randomized at enrollment to receive 0.5mL Pneumovax 23 at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
11644172|NCT00169221|Active Comparator|postop chemoradio with cisplatin|postoperative chemoradiotherapy with cisplatin
11644173|NCT00169221|Experimental|postop chemoradio (cisplatin)+gefitinib|postoperative chemoradiotherapy with cisplatin + gefitinib
11644174|NCT00169208|Experimental|Experimental|4 cycles of rituximab + fludarabine + mitoxantrone
11644175|NCT00169195|Experimental|R-GEMOX|Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)
11644176|NCT00169182|Experimental|TPF|Docetaxel, Cisplatine, 5-FU
11644177|NCT00169182|Active Comparator|PF|Cisplatine, 5-FU
11644178|NCT00169156|Experimental|Rituximab + CHOP|Rituximab + CHOP regimen Prednisone - Doxorubicine - Cyclophosphamide - Vincristine
11644179|NCT00169117|Experimental|1|Behavioural intervention: Songs/posters aimed at behaviour change to increase repair and maintenance of mosquito nets
11644180|NCT00169104|Active Comparator|1|Subjects will receive ten doses of G-CSF at a dose of 5 mcgm/kg daily Monday through Friday for the first two weeks of the trial. All patients will also receive trastuzumab at 4 mg/kg week 1, and 2 mg/kg week 2 during the first two weeks of the trial. All patients will then receive 12 weeks of trastuzumab at 2 mg/kg IV weeks 3 through 14, vinorelbine at 25 mg/m2 IV weekly weeks 3,4,6,7,9,10,12,13 and G-CSF at 5 mcgm/kg SQ daily Monday through Friday weeks 3-14.
11644181|NCT00169104|Placebo Comparator|2|Subjects will receive ten doses of a placebo injection SQ daily Monday through Friday for the first two weeks of the trial. All patients will also receive trastuzumab at 4 mg/kg week 1, and 2 mg/kg week 2 during the first two weeks of the trial. All patients will then receive 12 weeks of trastuzumab at 2 mg/kg weeks 3-14, vinorelbine at 25 mg/m2 IV weekly weeks 3,4,6,7,9,10,12,13, and G-CSF at 5 mcgm/kg SQ daily Monday through Fridays weeks 3-14.
11644182|NCT00169091|Experimental|Clozapine|Clozapine 12.5-300 mg taken orally per day for 12 weeks in the acute phase of the study and up to 130 weeks (total) in the Follow-up portion of the study.
11644183|NCT00169091|Active Comparator|Haloperidol|Haloperidol 2-12 mg taken orally per day for 12 weeks in the acute phase of the study and up to 130 weeks (total) in the Follow-up portion of the study.
11644184|NCT00169065|Active Comparator|Clozapine|Clozapine or olanzapine in treatment resistant schizophrenia
11644185|NCT00169065|Active Comparator|olanzapine|clozapine or olanzapine in treatment resistant schizophrenia
11644186|NCT00169000|Experimental|Capecitabine and Docetaxel|Escalating doses of capecitabine days 1-14 with a fixed dose of docetaxel on Day 8 of a 21 day cycle
11644187|NCT00168909|Experimental|1|alfacalcidol 1µg/d
11644188|NCT00168909|Placebo Comparator|2|placebo
11644189|NCT00168844|Other|Tiotropium Respimat 5mcg (Tio R5)|
11644190|NCT00168844|Other|Tiotropium Respimat 10mcg (Tio R10)|
11644191|NCT00168844|Other|Placebo|
11644192|NCT00168831|Other|Tiotropium Respimat 5mcg (Tio R5)|
11644193|NCT00168831|Other|Tiotropium Respimat 10mcg (Tio R10)|
11644194|NCT00168831|Other|Placebo|
11644195|NCT00168818|Experimental|dabigatran etexilate 75 mg|daily dose 150 mg once daily, half a dose on the day of surgery
11644196|NCT00168818|Experimental|dabigatran etexilate 110 mg|daily dose 220 mg once daily, half a dose on the day of surgery
11644197|NCT00168818|Active Comparator|enoxaparin|40 mg once daily
11644198|NCT00168805|Experimental|dabigatran etexilate 220 mg|220 mg once daily
11644199|NCT00168805|Experimental|dabigatran etexilate 150 mg|150 mg once daily
11644200|NCT00168805|Active Comparator|enoxaparin|40 mg once daily
11644201|NCT00168766|Experimental|1|interferon-beta-1a in combination with methylprednisolone
11644202|NCT00168766|Placebo Comparator|2|interferon-beta-1a in combination with placebo
11644203|NCT00168753|Experimental|1|
11644204|NCT00168714||Pregnant participants|Pregnant participants who were exposed to Avonex within approximately 1 week of conception or during the first trimester of pregnancy
11644205|NCT00168688|Active Comparator|FeFol|Iron (60 mg) and folic acid (400 ug), standard of care
11644206|NCT00168688|Experimental|MN1|"1 RDA of 15 micronutrients, including iron (30 mg) and folic acid (400 ug)
~Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg"
11644207|NCT00168688|Experimental|MN2|"2 RDA of 14 micronutrients including iron (30 mg) and folic acid (800 ug)
~Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg"
11644208|NCT00168558|Active Comparator|1|Standard titre Edmonston-Zagreb measles vaccine at 4½ and 9 months of age
11644209|NCT00168558|Active Comparator|2|Standard titre Schwarz measles vaccine at 9 months of age
11644210|NCT00168558|Active Comparator|3|Standard titre Edmonston-Zagreb measles vaccine at 9 months of age
11644211|NCT00168519|Active Comparator|1|
11644212|NCT00168493|Active Comparator|intervention|there is no sham or placebo control arm It is a single arm study
11644213|NCT00168480|Experimental|1|Botulinum Toxin Type A
11644214|NCT00168454|Placebo Comparator|Placebo|Placebo (normal saline) injected into detrusor on Day 1
11644215|NCT00168454|Experimental|BOTOX 50 U|botulinum toxin Type A 50 U injected into detrusor on Day 1
11644216|NCT00168454|Experimental|BOTOX 100 U|botulinum toxin Type A 100 U injected into detrusor on Day 1
11644217|NCT00168454|Experimental|BOTOX 150 U|botulinum toxin Type A 150 U injected into detrusor on Day 1
11644218|NCT00168454|Experimental|BOTOX 200 U|botulinum toxin Type A 200 U injected into detrusor on Day 1
11644219|NCT00168454|Experimental|BOTOX 300 U|botulinum toxin Type A 300 U injected into detrusor on Day 1
11644220|NCT00168428|Experimental|botulinum toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
11644221|NCT00168428|Placebo Comparator|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
11644222|NCT00168415|Experimental|1|Botulinum Toxin Type A
11644223|NCT00168389|Experimental|Dexamethasone 700 μg|700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
11644224|NCT00168389|Experimental|Dexamethasone 350 μg|350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
11644225|NCT00168389|Sham Comparator|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
11644226|NCT00168337|Experimental|Dexamethasone 700 μg|700 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
11644227|NCT00168337|Experimental|Dexamethasone 350 μg|350 µg Dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
11644228|NCT00168337|Sham Comparator|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
11644229|NCT00168324|Experimental|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.
11644230|NCT00168324|Experimental|350 µg Dexamethasone followed by 700 µg Dexamethasone|350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
11644231|NCT00168324|Sham Comparator|Sham Injection followed by 700 µg Dexamethasone|Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
11644232|NCT00168311|Experimental|Active Treatment|Bilateral high frequency (10 Hertz) rTMS
11644233|NCT00168311|Sham Comparator|Sham rTMS|Bilateral Sham rTMS
11644234|NCT00168298|Experimental|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and Day 180.
11644235|NCT00168298|Experimental|350 µg Dexamethasone followed by 700 µg Dexamethasone|350 µg dexamethasone intravitreal implant administered on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
11644236|NCT00168298|Sham Comparator|Sham Injection followed by 700 µg Dexamethasone|Sham injection on Day 0 and 700 µg dexamethasone intravitreal implant on Day 180.
11644237|NCT00168233||1|No antiretroviral therapy for 12 months
11644238|NCT00168233||2|Initiating ARV therapy with an NNRTI based regimen
11644239|NCT00168233||3|Initiating ARV therapy with a PI based regimen
11644240|NCT00168220||Drug hypersensitive group|HIV positive patients with a history of a Hypersensitivity Reaction to the antiretroviral medications Nevirapine, Abacavir or Efavirenz
11644241|NCT00168220||Drug tolerant group|HIV positive patients selected based on drug exposure greater than 2 weeks and tolerance to to Abacavir or Nevirapine.
11644242|NCT00168103|Experimental|C1-INH 10 U/kg bw|10 Units (U)/kg body weight (bw) dose
11644243|NCT00168103|Experimental|C1-INH 20 U/kg bw|20 U/kg bw dose
11644244|NCT00168103|Placebo Comparator|Placebo|
11644245|NCT00168064|Active Comparator|1 (PG - NM (MCH) 0.02%)|PG - mechlorethamine-MCH (nitrogen mustard) 0.02% gel To evaluate the tolerability and safety of topical mechlorethamine-MCH (nitrogen mustard) 0.02% ointment formulations in patients with stage I or IIA MF
11644246|NCT00168064|Active Comparator|2 (AP - MCH(NM) 0.02%)|AP - mechlorethamine-MCH (nitrogen mustard) 0.02% compounded in Aquaphor To evaluate the tolerability and safety of mechlorethamine-MCH (nitrogen mustard)0.02% ointment formulations in patients with stage I or IIA MF
11644247|NCT00168038|Experimental|IgPro10|
11644248|NCT00168025|Experimental|IgPro10|
11644249|NCT00167947|Active Comparator|A|
11644250|NCT00167947|Experimental|B|
11644251|NCT00167934|Placebo Comparator|Placebo|50% of participants will receive placebo
11644252|NCT00167934|Experimental|Experimental|50% of participants will receive Depakote ER
11644253|NCT00167856|Experimental|1|Venlafaxine HCL (extended release)
11644254|NCT00167856|Active Comparator|2|Benztropine Mesylate
11644255|NCT00167830|Experimental|Lifestyle Intervention|Dietary modification and exercise.
11644256|NCT00167804|Other|1|Present Centered Therapy focuses on the veterans problems in the here and now. It uses a problem solving approach and avoids discussion of war related traumatic events.
11644257|NCT00167778|Experimental|Arm 1|Novel prosthetic pylon
11644258|NCT00167778|Active Comparator|Arm 2|rigid pylon
11644259|NCT00167700|Experimental|Probiotics|
11644260|NCT00167700|Experimental|Probiotics + Dietary counseling|
11644261|NCT00167700|Experimental|Dietary counseling + placebo|
11644262|NCT00167700|Experimental|Prebiotics|
11644263|NCT00167700|Placebo Comparator|Placebo|
11644264|NCT00167700|No Intervention|Control|
11644265|NCT00167687|Placebo Comparator|2|
11644266|NCT00167674|Active Comparator|B|Combined short-course Zidovudine/Nevirapine
11644267|NCT00167674|Experimental|A|HAART during pregnancy and 6 months postpartum
11644268|NCT00167661|Experimental|Campath 1-H|Campath 1-H
11644269|NCT00167648|Active Comparator|A|Leuprolide 7.5 mg or Goserelin 3.6 mg
11644270|NCT00167648|Experimental|B|Transdermal estradiol 0.6 mg q 3 days
11644271|NCT00167635|Experimental|1|Face-to-Face Individualized Comprehensive Self-Management (CSM-FF) Group. Participants in the individualized CSM-FF group will be scheduled for 9 weekly sessions with the nurse therapist followed by post-intervention follow-up assessment.
11644272|NCT00167635|Experimental|2|Telephone Individualized Comprehensive Self-Management (CSM-TEL) Group. Participants in the individualized CSM-FTF group will initially have 2 face-to-face meetings with the nurse therapist, 6 sessions over the phone and the final session face-to-face at 9 weeks.
11644273|NCT00167635|No Intervention|3|Usual Care Control Group (UC). Following randomization the participants in the control group will receive two short phone calls to maintain contact during the comparable 9-week intervention in the treatment groups.
11644274|NCT00167622|Active Comparator|1|Physiotherapy, oxygen as needed
11644275|NCT00167622|Experimental|2|Mechanical ventilation
11644276|NCT00167596|Experimental|1|Early goal directed therapy based on StO2 evaluation
11644277|NCT00167596|Active Comparator|2|Early goal directed therapy
11644278|NCT00167583|Active Comparator|A Cyclosporin A|Cyclosporin A
11644279|NCT00167583|Active Comparator|B Interferon alpha|Interferon-alpha2a
11644280|NCT00167557|Experimental|Single Arm Study|
11644281|NCT00167544|Experimental|1|1. Tapering dose of hydrocortisone every 12 h over 7 day period
11644282|NCT00167544|Placebo Comparator|2|2. Identical-appearing saline placebo
11644283|NCT00167531|Experimental|Treadmill walking|30 minutes per day of treadmill walking with body weight support and assistance from one therapist
11644284|NCT00167531|Active Comparator|Overground walking|30 minutes per day of overground walking with assistance from one therapist
11644285|NCT00167505|Experimental|Risk Avoidance|The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes both classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
11644286|NCT00167505|Experimental|Risk Reduction|The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes both classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
11644287|NCT00167466|Experimental|A|4 week brushing with experimental Soladey-3 toothbrush followed by 4 week washout period followed by 4 week brushing with placebo Soladey-3 toothbrush
11644288|NCT00167466|Placebo Comparator|B|subjects to brush with Placebo Soladey-3 toothbrush for 4 weeks followed by a 4 week washout followed by 4 week brushing with experimental Soladey-3 toothbrush
11644289|NCT00167414|Experimental|Hypofractionated Stereotactic Body Radiation Therapy|Use of Hypofractionated Stereotactic Body Radiation Therapy for limited metastases with breast cancer primary.
11644290|NCT00167388|No Intervention|group 1|All babies <1250 gm at the time of the study are enrolled into this arm, and randomized to be NPO during the PRBC transfusion
11644291|NCT00167388|Active Comparator|group 2|Babies <1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
11644292|NCT00167388|No Intervention|group 3|All babies >1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
11644293|NCT00167388|Experimental|group 4|All babies <1250 gm at the time of the study are enrolled into this arm, and randomized to be fed during the PRBC transfusion
11644294|NCT00167362|Experimental|1|Participants will receive cognitive enhancement therapy
11644295|NCT00167362|Placebo Comparator|2|Participants will receive enriched supportive therapy
11644296|NCT00167310|Experimental|1|Eicosapentaenoic acid (omega-3 fatty acid, 2 g in 4x500 mg softgels daily) + Antipsychotic drug (doctor's choice) treatment for baseline, 1 month, 2 months and 4 months duration.
11644297|NCT00167310|Placebo Comparator|2|Placebo (soy bean oil, 2 g in 4x500 mg softgels daily) + Antipsychotic drug (doctor's choice) treatment for baseline, 1 month, 2 months and 4 months duration.
11644298|NCT00167297|Experimental|Atomoxetine|Atomoxetine (Strattera) 25mg peroral (PO) each day for seven days, then up to 40mb bid 40mg PO each day for three days, then 80mg PO bid.
11644299|NCT00167271|Experimental|Experimental|Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.
11644300|NCT00167271|Active Comparator|Control|Subjects given pamphlets from the Arthritis Foundation
11644301|NCT00167245|Experimental|Topiramate|topiramate capsules dose titrated up to 300 mg daily
11644302|NCT00167245|Placebo Comparator|Placebo|placebo capsules identical in appearance to the topiramate capsules
11644303|NCT00167232|Active Comparator|Naltrexone 150mg/day|
11644304|NCT00167232|Placebo Comparator|Placebo Sugar Pill|
11644305|NCT00167219|Experimental|Intent-to-Treat|Patients receiving study regimen.
11644306|NCT00167206|Experimental|HSCT Patients|Patients who received total body irradiation (450 cGy [centigray]) with thymic shielding prior to chemotherapy regimen and Hematopoietic Stem Cell Transplant (HSCT)
11644307|NCT00167180|Active Comparator|CML|Patients with Chronic Myelogenous Leukemia (CML) who have failed or refused Gleevec(TM) therapy and will receive Donor Lymphocyte Infusion.
11644308|NCT00167180|Active Comparator|Non-CML or CML that Relapsed after Donor Lymphocyte Infusion|Patients with non-CML or CML who have failed Donor Lymphocyte Infusion (DLI) and will receive induction chemotherapy plus DLI.
11644309|NCT00167167|Experimental|BMT patients|All patients treated.
11644310|NCT00167154|Experimental|risperidone|risperidone
11644311|NCT00167154|Placebo Comparator|placebo|placebo comparator
11644312|NCT00167141|Experimental|testosterone injections|injections of testosterone to normal men (arm 1) and two men with subnormal semen parameters (arm 2)
11644313|NCT00167102|Experimental|Alefacept|
11644314|NCT00167102|Placebo Comparator|Placebo|
11644315|NCT00166881|Experimental|A, 2, III|Weekly Docetaxel-Irinotecan for Inoperable Gastric Cancers After P-HDFL
11644316|NCT00166868|Experimental|Neomycin prescribed|Interventions: 10 cases received Neomycin for 6 months
11644317|NCT00166868|Experimental|Probiotics (Lactobacillus casei rhamnosus, Lcr35) prescribed|Interventions: 10 cases received Probiotics for 6 months
11644318|NCT00166868|No Intervention|control|10 cases without intervention were historical control.
11644319|NCT00166712|Active Comparator|Group 1: Alemtuzumab + TAC + MMF|Receive two doses of alemtuzumab (Campath-1H, 30mg) by intravenous (IV) infusion. One dose during kidney transplant surgery and the second dose on day 2 (post-surgery) to achieve peripheral T-cell depletion. IV glucocorticoids will be given prior to Campath administration to limit cytokine release syndrome in association with this monoclonal antibody. MMF on the day of surgery and continue taking it by mouth, twice daily. TAC started on the 1st day after surgery, and then taken by mouth twice daily.
11644320|NCT00166712|Active Comparator|Group 2: Alemtuzumab + Sirolimus + MMF|"Sirolimus will be taken by mouth before transplant surgery and will continue taking once daily after surgery. Group 2 will also receive 2 doses of Alemtuzumab: one during surgery and the second will be given on the second day after surgery. Mycophenolate mofetil will be give on the day of surgery and twice daily, by mouth, as instructed by the doctor.
~If subjects do not experience kidney rejection after 6 months after surgery, they will be weaned off of the sirolimus and continue taking the mycophenolate mofetil."
11644321|NCT00166699|No Intervention|Palpation|Use of palpation to guide the the insertion site of combined spinal epidural needle in obese parturients
11644322|NCT00166699|Experimental|ultrasound|The use of ultrasound to guide the insertion of a combined spinal epidural needle
11644323|NCT00166543|Experimental|TAS-108 40 mg|
11644324|NCT00166543|Experimental|TAS-108 80 mg|
11644325|NCT00166543|Experimental|TAS-108 120 mg|
11644326|NCT00166530|Active Comparator|1|Arm 1: Active comparator
11644327|NCT00166530|Experimental|2|Arm 2: Drug
11644328|NCT00166517|Experimental|1|RotaTeq
11644329|NCT00166517|Placebo Comparator|2|Placebo
11644330|NCT00166504|Experimental|Vytorin|Ezetimibe 10 mg/Simvastatin 20 mg
11644331|NCT00166504|Active Comparator|Atorvastatin|Atorvastatin 10 mg
11644332|NCT00166439|Experimental|Treatment (ROAD)|The treatment regimen included oxaliplatin with rituximab, cytarabine, and dexamethasone (ROAD); specifically, rituximab 375 mg/m^2 IV on days 1, 8,15, and 22 (cycle 1 only); dexamethasone 40 mg PO/IV days 2-5; oxaliplatin 130 mg/m^2 IV over 2 hours on day 2; cytarabine 2000 mg/m^2 IV in 250 mL of D5W over three hours x two doses on days 2-3. The second dose of cytarabine was to be given no sooner than 12 hours after the first dose and no later than 24 hours after the conclusion of the first dose. This permitted outpatient administration if desired. Patients were provided pegfilgrastim 6 mg SC on day 4. A cycle was 21 days.
11644333|NCT00166413|Experimental|CC5013|Assess the proportion of confirmed hematologic responses (HCR, HPR) resulting from treatment with CC5013 after 3 months in patients with primary systemic amyloidosis.
11644334|NCT00166387||Phase I, II, III|Phase I consists of a brother pair with hemophilia, one or both of whom has a history of inhibitors, and their parents; Phase II consists of a person with hemophilia and an inhibitor, and both his parents; Phase III consists of an unrelated group of people with hemophilia.
11644335|NCT00166361|Experimental|Memokath 051 Ureteral Stent|Subjects assigned to this arm received a Memokath 051 Ureteral Stent.
11644336|NCT00166361|Active Comparator|JJ Stent|Subjects assigned to this arm received a JJ stent.
11644337|NCT00166296|Experimental|Escitalopram|Escitalopram, 15 mg/day
11644338|NCT00166296|Placebo Comparator|Placebo pill|Placebo
11644339|NCT00166283|Experimental|experimental group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for five weeks (10 training sessions).
11644340|NCT00166283|Placebo Comparator|placebo control group|The placebo control group will receive placebo memory exercises administered on a laptop computer twice a week for five weeks (10 placebo control sessions).
11644341|NCT00166270|Experimental|1|
11644342|NCT00166257|Active Comparator|Medical antitrhombotic treatment|
11644343|NCT00166257|Experimental|Device Implant|Percutaneous closure of patent foramen ovale
11644344|NCT00166244|Active Comparator|Fixed Dose|1 g MMF twice-daily (bid) for adults or 600 mg/m2 bid for paediatric patients. Treatment to be given orally unless it is not possible, in which case it is administered via intravenous (iv) infusion.
11644345|NCT00166244|Active Comparator|Concentration Controlled|1 g MMF bid for adults or 600 mg/m2 bid for paediatric patients. Thereafter, MMF doses will be adjusted to MPA AUC0-12 between 30-60mg.h/L based on 3-point abbreviated AUCs (taken at timepoints: 0, 30 min and 120 min always in fasted patients, except for pediatric patients on concomitant tacrolimus) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine MPA levels in plasma.
11644346|NCT00166231||Chest pain patients|
11644347|NCT00166231||Murmur group|
11644348|NCT00166205|Experimental|Gastric Band|Single-arm study, all subjects banded.
11644349|NCT00166192|Active Comparator|Chemical Peel|Split face treatment paradigm
11644350|NCT00166166|Experimental|Healthy Controls|Healthy subjects had venous occlusion plethysmography after intra-arterial infusions of saline, L-NG-monomethyl Arginine (L-NMMA), Tetraethylammonium (TEA), fluconazole, bradykinin, sodium nitroprusside and acetylcholine
11644351|NCT00166166|Experimental|Risk Factors|Non-hypertensive subjects with cardiovascular risk factors had venous occlusion plethysmography after intra-arterial infusions of saline, L-NG-monomethyl Arginine (L-NMMA), Tetraethylammonium (TEA), fluconazole, bradykinin, sodium nitroprusside and acetylcholine
11644352|NCT00166114|Active Comparator|Escitalopram|
11644353|NCT00166114|Active Comparator|Desipramine|
11644354|NCT00166088|Experimental|Mediterranean Diet Arm|
11644355|NCT00166088|Active Comparator|Mediterranean Dietary Supplement Arm|
11644356|NCT00166088|No Intervention|Control Arm|
11644357|NCT00166075||Female ED patients|All eligible African American female patients were approached in the ED waiting room during study periods. Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
11644358|NCT00166049|Placebo Comparator|Usual Care Attention Control|Usual care with provision of supplemental printed educational material on HF self care
11644359|NCT00166049|Experimental|Group 2 Patient Family Education PFE|Patient Family Education PFE Heart Failure Patients and family member dyads were provided with an educational and counseling session, and attended a 2 hour patient-family education session on heart failure self management with emphasis on dietary sodium and medication taking behaviors.
11644360|NCT00166049|Experimental|Group 3 Family Partnership Intervention|Patient and family member received one individual dyadic education/counseling session, and two group sessions focused on developing family approaches to HF self management. the emphasis of the two group sessions was on developing autonomy supportive approaches to family support.
11644361|NCT00166036|Experimental|Atorvastatin 10MG|
11644362|NCT00166036|Experimental|Pravastatin 80mg|
11644363|NCT00166010|Experimental|Nesiritide|
11644364|NCT00165958|Experimental|Punch excision|
11644365|NCT00165958|Active Comparator|Traditional excision|
11644366|NCT00165919||HCV+|No group or cohort; not a clinical trial
11644367|NCT00165841|Placebo Comparator|Placebo|
11644368|NCT00165841|Experimental|Rabeprazole 20 mg|
11644369|NCT00165828|Experimental|1|
11644370|NCT00165828|Experimental|2|
11644371|NCT00165802|Experimental|1|
11644372|NCT00165763|Experimental|1|
11644373|NCT00165750|Experimental|1|
11644374|NCT00165698|Active Comparator|1|
11644375|NCT00165698|Active Comparator|2|
11644376|NCT00165672|Experimental|1|
11644377|NCT00165672|Experimental|2|
11644378|NCT00165646|Experimental|1|
11644379|NCT00165646|Experimental|2|
11644380|NCT00165646|Placebo Comparator|3|
11644381|NCT00165633|Experimental|1|
11644382|NCT00165633|Experimental|2|
11644383|NCT00165633|Placebo Comparator|3|
11644384|NCT00165542||All patients|A PROTEIN levels in all patients and with all tumor types.
11644432|NCT00164463|Active Comparator|Isoniazid|Isoniazid 300 mg po qd given 5/7 days per week
11644547|NCT00161486|Placebo Comparator|1|Placebo acyline injections every two weeks (2 doses) + placebo testosterone gel daily for 4 weeks
11644385|NCT00165503|Experimental|Surgery+Heated Cisplatin+Sodium Thiosulfate+Adjuvant CT|Participants undergo surgery, Pleurectomy/Decortication, followed by heated cisplatin given as a one-hour lavage of the chest and abdominal cavity then sodium thiosulfate given intravenously over 6 hours. The adjuvant chemotherapy regimen beginning 6-10 weeks after surgery is a combination of cisplatin and Alimta each given day 1 of a 21-day cycle for 3 cycles.
11644386|NCT00165425|Experimental|Cardiac screening|"Interventions:
~Participants will
~meet with study cardiologist
~undergo cardiac risk factors screening
~undergo resting and stress echocardiogram (echo and stress echo)"
11644387|NCT00165308|Experimental|Tamoxifen|Single arm: Tamoxifen 20mg daily
11644388|NCT00165282|No Intervention|Usual Care|Normal standard of care
11644389|NCT00165282|Active Comparator|Nurse education|Meets with oncology nurse
11644390|NCT00165282|Experimental|Mindfulness training|Taught Mindfulness meditation
11644391|NCT00165256|Experimental|Observation (omission of RT)|Wide excision of DCIS; no radiotherapy (RT).
11644392|NCT00165178|Experimental|Individualized ASP dose|
11644393|NCT00165178|Active Comparator|Fixed dose ASP|
11644394|NCT00165178|Experimental|Dexamethasone|
11644395|NCT00165178|Active Comparator|Prednisone|
11644396|NCT00165152|Active Comparator|Genetic Counseling|
11644397|NCT00165152|Active Comparator|Informed Consent Counseling|
11644398|NCT00165035|Experimental|1|CoStar™ Paclitaxel-Eluting Coronary Stent, a reservoir based DES
11644399|NCT00165035|Active Comparator|2|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
11644400|NCT00165009|No Intervention|DUAL THERAPY|DUAL THERAPY
11644401|NCT00165009|Experimental|'Resolution clip|'Resolution clip
11644402|NCT00164944||FDR of CRC patient|First degree relatives of patients having CRC
11644403|NCT00164944||FDR of normal colonoscopy|First degree relatives of patients having normal colonoscopy
11644404|NCT00164905|Active Comparator|Doppler ultrasound|
11644405|NCT00164905|No Intervention|No Doppler ultrasound|
11644406|NCT00164853|Active Comparator|Standard sphincterotomy (ES)|After deep cannulation, a pull-type sphincterotomy will be performed with a 25mm sphincterotome (eg clever cut, Olympus, Tokyo, Japan) with division of sphincter up to the duodenal wall. A complete sphincterotomy is defined by the free passage of a fully bowed sphincterotome with a 25m wire and spontaneous bile drainage.
11644407|NCT00164853|Active Comparator|Sphincterotomy plus balloon dilation (ESBD)|After complete sphincterotomy, a 3-cm long 15mm diameter CRE balloon is passed over a guidewire across the lower end of common bile duct. The contrast filled balloon is inflated to the size of the bile duct for around 30 seconds until waisting is abolished.
11644408|NCT00164788|Active Comparator|IV Nexium|Intravenous bolus injection of esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
11644409|NCT00164788|Active Comparator|Oral Nexium|Oral esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 40mg every 12 hours for 24 hours
11644410|NCT00164775|Active Comparator|Imipramine|Imipramine 25mg nocte for first 2 weeks then Imipramine 50 mg nocte for 10 weeks
11644411|NCT00164775|Placebo Comparator|Placebo|Placebo 1 tablet for first 2 weeks then Placebo 2 tablets for 10 weeks
11644412|NCT00164749|Placebo Comparator|Placebo|Color-matched placebo
11644413|NCT00164749|Experimental|1 gram|1 g/day curcumin
11644414|NCT00164749|Experimental|4 gram|4 g/day curcumin
11644415|NCT00164736|Active Comparator|Maternal ARVs & Nutrition Supplement|Extended maternal ARVs for prophylaxis (for the infant) & daily nutritional supplement given to the mother
11644416|NCT00164736|Active Comparator|Infant NVP & Nutrition Supplement|Extended infant nevirapine for prophylaxis & daily nutritional supplment given to the mother
11644417|NCT00164736|Active Comparator|Maternal ARVs & No Nutrition Supplement|Extended maternal ARVs for prophylaxis (for the infant) & no nutritional supplement given to the mother
11644418|NCT00164736|Active Comparator|Infant NVP & No Nutrition Supplement|Extended infant nevirapine for prophylaxis & no nutritional supplment given to the mother
11644419|NCT00164736|Active Comparator|No Drugs & Nutrition Supplement|"No extended maternal ARV prophylaxis nor infant nevirapine prophylaxis & daily nutritional supplement given to the mother.
~Note: As of March 2008, the third arm of the antiretroviral intervention, in which neither mother nor infant received drugs beyond enhanced standard of care, was stopped based on recommendations of a Data and Safety Monitoring Board review of interim efficacy results and safety data after 77% participants had received treatment assignment."
11644420|NCT00164736|No Intervention|No Drugs & No Nutrition Supplement|"No extended maternal ARV prophylaxis nor infant nevirapine prophylaxis & no nutritional supplement given to the mother.
~Note: As of March 2008, the third arm of the antiretroviral intervention, in which neither mother nor infant received drugs beyond enhanced standard of care, was stopped based on recommendations of a Data and Safety Monitoring Board review of interim efficacy results and safety data after 77% participants had received treatment assignment."
11644421|NCT00164723|Other|NSAID|patients taking NSAID will undergo capsule endoscopy
11644422|NCT00164723|Other|Aspirin|patients taking Aspirin will undergo capsule endoscopy
11644423|NCT00164723|Other|Non-user|patients didn't take NSAID or ASA will undergo capsule endoscopy
11644424|NCT00164697|Experimental|1|Parenting group
11644425|NCT00164697|No Intervention|2|"Families in this usual care comparison group were not prevented from utilizing any service that would otherwise be available to them, even if the service was similar to the services received in the intervention arm of the study."
11644426|NCT00164619|Experimental|1|Standard STD clinic services and the VOICES/VOCES intervention
11644427|NCT00164619|Active Comparator|2|Standard STD clinic services
11644428|NCT00164515|No Intervention|Arm 1: Physical activity awareness|The awareness group received a physician-recommendation to exercise an informational brochure, and pedometer.
11644429|NCT00164515|Experimental|Arm 2: Lower Support|The lower support group received arm 1 plus monthly newsletter, weekly personalized exercise support via telephone.
11644430|NCT00164515|Experimental|Arm 3: Higher support|The higher support group received arm 1 plus arm 2 plus a face-to-face monthly exercise support group.
11644431|NCT00164463|Experimental|Moxifloxacin|Moxifloxacin 400 mg po qd given 5 of 7 days per week
11644804|NCT00157924|Experimental|1|1. simvastatin/ezetimibe 10/20mg
11644433|NCT00164281|Experimental|Continuous vs limited isoniazid|The placebo arm will receive 6 months of open label isoniazid before beginning placebo (as a coded medication). The treatment (experimental arm) will receive 6 months of open label isoniazid before beginning coded medication (isoniazid).
11644434|NCT00164203|Experimental|Cognitive Behavioral Therapy|School-based, 12-session protocol, weekly
11644435|NCT00164203|Active Comparator|activity control condition|Structured games and activities, weekly for 12 weeks
11644436|NCT00164138|Experimental|Pelvic Floor Training Group|Pelvic floor training, biofeedback.
11644437|NCT00164021||Cystic Fibrosis|Patients with cystic fibrosis
11644438|NCT00164021||Control|
11644439|NCT00163865||Clinical Group|clinical adolescent group
11644440|NCT00163865||Community Group|community adolescent group
11644441|NCT00163826||Trauma Patients|Major trauma patients
11644442|NCT00163761|Active Comparator|Commence VGF treatment|Drug. Vinorelbine, gemcitabine and filgrastim 21 day cycle
11644443|NCT00163761|Active Comparator|Commence F-GIV treatment|Drug. Gemcitabine, ifosfamide, Vinorelbine and filgrastim 21 day cycle
11644444|NCT00163722|Active Comparator|Standard diagnostic strategy of culture and histology|The standard-diagnostic strategy was designed to be consistent with the 2002 guidelines for antimicrobial use in neutropenic patients with cancer. When an invasive fungal infection was suspected (e.g. persistent fevers) cultures of blood, urine, sputum (if available) and faeces (if clinically indicated), and HRCT scans of chest were performed. Bronchoscopy and biopsies were performed according to institutional protocols. Empiric antifungal therapy was recommended whilst undergoing these investigations and was continued, de-escalated to prophylaxis, or changed to treatment of invasive aspergillosis or other IFD according to test results.
11644445|NCT00163722|Experimental|Aspergillus galactomannan and PCR directed|Results of once to twice weekly testing with Aspergillus galactomannan and PCR directed the timing of CT scan performance and whether antifungal therapy was given
11644446|NCT00163670||Motor vehicle accident|
11644447|NCT00163670||Control|
11644448|NCT00163657|Active Comparator|tacrolimus and cyclosporine|immunosuppressant treatment regimens the intervention is antirejection treatment with the above labeled drugs tacrolimus and cyclosporine
11644449|NCT00163657|Active Comparator|MMF, tacrolimus and cyclosporine|immunosuppressant treatment regimensthe intervention is antirejection treatment with the above labeled drugs MMF tacrolimus and cyclosporine
11644450|NCT00163657|Active Comparator|daclizumub, MMFand tacrolimus|immunosuppressant treatment regimens
11644451|NCT00163644|Active Comparator|Aerobic exercise plus resistance|Aerobic exercise plus resistance exercise for 6 weeks
11644452|NCT00163644|Active Comparator|Aerobic exercise|Aerobic exercise for 6 weeks
11644453|NCT00163644|Other|Control|No formal exercise and weekly phone calls
11644454|NCT00163579|Experimental|Bryophyllum|
11644455|NCT00163579|Placebo Comparator|Placebo|
11644456|NCT00163566|Placebo Comparator|Placebo gel|Placebo gel twice per day
11644457|NCT00163566|Active Comparator|0.7% DHT gel, Dose 1|0.7% DHT gel twice per day, 35 mg/day
11644458|NCT00163566|Active Comparator|0.7% DHT gel, Dose 2|0.7% DHT gel twice per day, 70 mg/day
11644459|NCT00163553|Experimental|P|Epidural pethidine group
11644460|NCT00163553|Placebo Comparator|N|placebo group
11644461|NCT00163449|Active Comparator|1|Ciclesonide 40 µg
11644462|NCT00163449|Active Comparator|2|Ciclesonide 80 µg
11644463|NCT00163449|Active Comparator|3|Ciclesonide 160 µg
11644464|NCT00163449|Placebo Comparator|4|Placebo
11644465|NCT00163293|Placebo Comparator|Placebo|
11644466|NCT00163293|Active Comparator|Ciclesonide 100 µg|Ciclesonide 100 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.
11644467|NCT00163293|Active Comparator|Ciclesonide 200 µg|Ciclesonide 200 µg, metered-dose inhaler, two puffs once daily, in the evening, for up to 12 months.
11644468|NCT00163280|Experimental|1|ATL-104 50mg
11644469|NCT00163280|Experimental|2|ATL-104 100mg
11644470|NCT00163280|Experimental|3|ATL-104 150mg
11644471|NCT00163280|Placebo Comparator|4|Placebo
11644472|NCT00163267|Placebo Comparator|ASS + Placebo|control arm
11644473|NCT00163267|Active Comparator|ASS + Plavix|active drug
11644474|NCT00163215|Experimental|Somatropin|
11644475|NCT00163189|Experimental|Somatropin|
11644476|NCT00163137|Experimental|Lasofoxifene 0.25 mg|lasofoxifene 0.25 mg/day
11644477|NCT00163137|Active Comparator|raloxifene|raloxifene 60 mg/day
11644478|NCT00163137|Placebo Comparator|Placebo|Placebo
11644479|NCT00163046|Experimental|Gabapentin|
11644480|NCT00163046|Placebo Comparator|Placebo|
11644481|NCT00163020|Active Comparator|1 Test Group (170HP)|Test Group will receive weekly doses of 170HP via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
11644482|NCT00163020|Placebo Comparator|2 - Control (Normal Saline)|Control Group will receive weekly doses of placebo (NS) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
11644483|NCT00162981|Experimental|Clobazam Low Dose|
11644484|NCT00162981|Experimental|Clobazam High Dose|
11644485|NCT00162955|Experimental|ARB administration|80mg/day from the day of the start of 1st CHOP until the completion of all the evaluations
11644486|NCT00162955|No Intervention|non-administration|ARB non-administration group
11644487|NCT00162942|Active Comparator|Adacolumn|Adacolumn, ten apheresis sessions within 9 weeks
11644488|NCT00162942|Sham Comparator|Sham|Sham, ten apheresis sessions within 9 weeks
11644489|NCT00162916|Placebo Comparator|1|
11644490|NCT00162916|Experimental|2|
11644491|NCT00162890||Patient with degenerative cervical disease|
11644492|NCT00162773|Placebo Comparator|Placebo|water injection
11644493|NCT00162773|Experimental|Omalizumab|"Other Names:
~Xolair 150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE."
11644494|NCT00162682|Active Comparator|1|* VL-S, the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
11644770|NCT00158340|Active Comparator|2|Participants will receive treatment as usual
11644495|NCT00162682|Experimental|2|CD4-S, the alternative CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
11644496|NCT00162656|Active Comparator|Standard LMB B|
11644497|NCT00162656|Experimental|LMB B without COPADM3|
11644498|NCT00162656|Experimental|LMB B with half cyclophosphamide|
11644499|NCT00162656|Experimental|LMB B without COPADM3 and with half cyclophosphamide|
11644500|NCT00162656|Active Comparator|LMB C standard|
11644501|NCT00162656|Experimental|LMB C with mini CYVE and without 3 maintenance courses|
11644502|NCT00162565|Experimental|1|bbloquant treatment
11644503|NCT00162552|Active Comparator|1|Patients with severe cirrhosis treated with Pentoxifylline
11644504|NCT00162552|Placebo Comparator|2|Patients with severe cirrhosis treated with a placebo
11644505|NCT00162474|Experimental|Warfarin|
11644506|NCT00162461|Experimental|Phenytoin|
11644507|NCT00162448|Experimental|A1|
11644508|NCT00162448|Placebo Comparator|A2|
11644509|NCT00162435|Experimental|Genetic|
11644510|NCT00162435|Experimental|Control|
11644511|NCT00162383|Experimental|Cocktail|
11644512|NCT00162370|Experimental|Definity|All patients will undergo a gray scale baseline unenhanced imaging session (apical 2- or 4 chamber view), as well as a DEFINITY (Perflutren Lipid Microsphere Injectable Suspension)-enhanced rest and a DEFINITY enhanced exercise or dobutamine stress echocardiography imaging session. The unenhanced and DEFINITY-enhanced rest and stress echocardiography imaging sessions will be performed on the same day. For the DEFINITY-enhanced imaging sessions all patients will receive diluted DEFINITY intravenously (IV). Diluted DEFINITY will be prepared by mixing 1 mL of activated DEFINITY® with 9 mL of normal saline in a 10 mL syringe.
11644513|NCT00162318|Experimental|A|
11644514|NCT00162305|Active Comparator|1|
11644515|NCT00162305|Active Comparator|2|
11644516|NCT00162305|Active Comparator|3|
11644517|NCT00162305|Placebo Comparator|4|
11644518|NCT00162266|Experimental|Abatacept (10 mg/Kg) - Open Label|
11644519|NCT00162266|Experimental|Abatacept (2 mg/kg) - Double blind|
11644520|NCT00162266|Experimental|Abatacept (10 mg/kg) - Double blind|
11644521|NCT00162266|Experimental|Placebo - Double blind|
11644522|NCT00162214|Active Comparator|1|
11644523|NCT00162201|Experimental|1|
11644524|NCT00162149|No Intervention|A1|
11644525|NCT00162149|Experimental|A2|
11644526|NCT00162149|Experimental|A3|
11644527|NCT00162149|No Intervention|B1|
11644528|NCT00162136|Experimental|A1|
11644529|NCT00162123|Experimental|First reinduction: Ipilimumab, 0.3 to 10 mg/kg|Participants who initially received ipilimumab, 0.3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
11644530|NCT00162123|Experimental|First reinduction: Ipilimumab, 3 to 10 mg/kg|Participants who initially received ipilimumab, 3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
11644531|NCT00162123|Experimental|First reinduction: Ipilimumab, 10 to 10 mg/kg|Participants who initially received ipilimumab, 10 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study. Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent. Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
11644532|NCT00162123|Experimental|Extended maintenance: Ipilimumab, 0.3 mg/kg|Participants who received ipilimumab, 0.3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (0.3 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
11644533|NCT00162123|Experimental|Extended maintenance: Ipilimumab, 3 mg/kg|Participants who received ipilimumab, 3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (3 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
11644534|NCT00162123|Experimental|Extended maintenance: Ipilimumab, 10 mg|Participants who received ipilimumab, 10 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (10 mg/kg) as maintenance in the current study. Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
11644535|NCT00162123|No Intervention|Follow-up|Participants did not receive any additional study treatment in current study but continued follow-up for the collection of survival data.
11644536|NCT00162110|Active Comparator|1|
11644537|NCT00162097|Experimental|EFV600mg Participants With Mild Hepatic Impairment|
11644538|NCT00162097|Experimental|EFV600mg Participants With Moderate Hepatic Impairment|
11644539|NCT00162097|Experimental|EFV600mg Participants With Severe Hepatic Impairment|
11644540|NCT00162097|Active Comparator|EFV600mg Participants With Normal Hepatic Function|
11644541|NCT00162032|Other|Children (Ages 4-11)|Children 4-11 years of age, intervention Sestamibi
11644542|NCT00162032|Other|Adolescents (Ages 12-16)|Adolescents 12-16 years of age, intervention Sestamibi
11644543|NCT00161616|Active Comparator|A|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage +surgical fixation
11644544|NCT00161616|Other|B|Standard of Care: Surgical fixation only
11644545|NCT00161577|Other|A|Group A = Ketorolac
11644546|NCT00161577|Placebo Comparator|B|
11644771|NCT00158327|Experimental|1|Participants will receive telephone-based collaborative care
11644548|NCT00161486|Active Comparator|2|Acyline 300 μg/kg every two weeks (2 doses) + placebo Testosterone gel daily for 4 weeks
11644549|NCT00161486|Active Comparator|3|Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks + Testosterone gel 100 mg daily for 4 weeks
11644550|NCT00161473|Active Comparator|prazosin|
11644551|NCT00161473|Placebo Comparator|placebo (inert substance)|
11644552|NCT00161460|Active Comparator|1|Study nurse contacts subjects who enroll in the intervention to provide detailed education about screening tests, to assess their risk for colorectal cancer, and to facilitate screening.
11644553|NCT00161460|No Intervention|2|Patients who do not enroll receive usual care from their primary care providers.
11644554|NCT00161447|Active Comparator|1|Testosterone (T) gel for 6 months + DMPA (injected into muscle once)on Day 0 and at Month 3
11644555|NCT00161447|Active Comparator|2|Testosterone (T) gel for 6 months + DMPA (injected into muscle on Day 0 & at month 3) + Acyline (SQ) every two weeks for the first 12 weeks
11644556|NCT00161434|Experimental|1|
11644557|NCT00161434|Placebo Comparator|2|
11644558|NCT00161421|Experimental|1|Lupron injection at Day -14 with load of dutasteride (24.5 mg) followed by 13 days of Dutasteride. On day 0, 11, 0.5 mg Dutasteride taken daily for next 11 days. Day 1 Oral Testosterone (T) 200mg without food, Day 2 Oral T 400 mg without food, Day 3 Oral T 400 mg with food. During the 2nd week of the study, we will repeat the testosterone doses, with a 2nd formulation of testosterone (Day8, 9, & 10.
11644559|NCT00161395|Active Comparator|1|Preconception advice.
11644560|NCT00161395|Experimental|2|Instruction in the Creighton Model Fertility Care System.
11644561|NCT00161382|Experimental|Intervention Group|HIV, STD, and pregnancy prevention curriculum
11644562|NCT00161382|Experimental|Control Group|Standard sexual education curriculum
11644563|NCT00161343|Experimental|1|Small interactive groups on preventing HIV infections using an Information-Behavioral Skills-Motivational model
11644564|NCT00161343|Placebo Comparator|2|Small interactive groups on general health-promotion topics using an Information-Behavioral Skills-Motivational model
11644565|NCT00161265||1|women with breast cancer
11644566|NCT00161213|Experimental|Gemcitabine and Imatinib|
11644567|NCT00161187|Experimental|Treatment|Biological/Vaccine: therapeutic allogeneic lymphocytes The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
11644568|NCT00160979|Experimental|hypoxia and RT in prostate cancer|
11644569|NCT00160966|Active Comparator|1|Immunosuppression with Ciclosporin and Mycophenolate-mofetil; Ciclosporin treatment being started at the latest at day 4 after transplantation with 7 mg/kg body weight daily administered every 8 hours until the target trough level of 300 µg/l was reached. Then it was administered twice daily with daily monitoring of trough levels. The target trough level was lowered to 200 µg/l 1 month after transplantation. Thereafter dosage and target trough levels were adjusted at the investigators discretion. Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once ciclosporin was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted at the investigators discretion.
11644570|NCT00160966|Active Comparator|2|Immunosuppression with Tacrolimus and Mycophenolate-mofetil Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once tacrolimus was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted to clinical signs of overimmunosuppression (infections) or intolerance (mainly gastrointestinal side effects) or rejections.
11644571|NCT00160966|Active Comparator|3|Immunosuppression with Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus after completion of posttransplant wound healing
11644572|NCT00160875|Experimental|Cisplatin, Irinotecan|
11644573|NCT00160784|Active Comparator|Arthroscopic Manipulation|Manipulation of Shoulder performed during arthroscopy
11644574|NCT00160784|Active Comparator|Home exercise program|Shoulder exercise program performed at home to increase shoulder function
11644575|NCT00160771||Joint Motion Analysis|Joint motion will be recorded for analysis.
11644576|NCT00160732|Experimental|Transplant|
11644577|NCT00160706|Experimental|Certolizumab Pegol|3-dose induction regimen of Certolizumab Pegol 400 mg at Weeks 0, 2, 4. Subsequently continue on 4-weekly treatment with Certolizumab Pegol 400 mg until Week 360.
11644578|NCT00160693|Experimental|Certolizumab Pegol|
11644579|NCT00160680|Experimental|Continuous Treatment|5 mg of Levocetirizine (LCTZ) was taken orally once a day.
11644580|NCT00160680|Experimental|On Demand Treatment|5 mg of Levocetirizine (LCTZ) was taken whenever needed.
11644581|NCT00160667|Placebo Comparator|Placebo|Matching placebo tablets administered twice a day.
11644582|NCT00160667|Experimental|Brivaracetam 200 mg/day|Brivaracetam 200 mg/day (100 mg administered twice a day).
11644583|NCT00160667|Experimental|Brivaracetam 400 mg/day|Brivaracetam 400 mg/day (200 mg administered twice a day).
11644584|NCT00160654|Experimental|Levetiracetam|Subjects received open-label Levetiracetam.
11644585|NCT00160641|Experimental|Certolizumab Pegol|All patients received Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) every two weeks, given as two 1 ml injections of CZP for at least six months and then 200 mg of CZP sc every two weeks, given as one 1 ml injection.
11644586|NCT00160615|Experimental|Levetiracetam|Subjects received oral tablets of Levetiracetam. This study N01020 (NCT00160615) was designed as a single group assignment study and as follow-up study, open for patients from N165 (NCT00600509). The differentiation into placebo and Levetiracetam in the results reporting section is based on the treatment of the previously conducted study N165 (NCT00600509).
11644587|NCT00160563|Experimental|LCTZ-LCTZ|Levocetirizine after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ-LCTZ)
11644588|NCT00160563|Placebo Comparator|LCTZ-PLC|Placebo after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ - PLC)
11644589|NCT00160563|Placebo Comparator|PLC-PLC|Placebo after having been randomized to Placebo in the preceding A00309 trial - NCT00152464 (PLC-PLC)
11644590|NCT00160524|Experimental|Certolizumab Pegol|400 mg subcutaneous injection every 4 weeks from Week 2 to Week 362.
11644591|NCT00160485|Experimental|1|Glyburide,gestational diabetes, maternal complications, neonatal complications
11644592|NCT00160485|Active Comparator|2|Insulin, gestational diabetes, maternal complications, neonatal outcomes
11644593|NCT00160459|Experimental|1|
11644594|NCT00160459|Experimental|2|
11644595|NCT00160459|Experimental|3|
11644596|NCT00160459|Placebo Comparator|4|
11644597|NCT00160446|Experimental|1|
11644598|NCT00160446|Experimental|2|
11644599|NCT00160446|Experimental|3|
11644600|NCT00160446|Placebo Comparator|4|
11644601|NCT00160433|Experimental|1|
11644602|NCT00160433|Experimental|2|
11644603|NCT00160433|Experimental|3|
11644604|NCT00160433|Placebo Comparator|4|
11644605|NCT00160420|Experimental|1|
11644606|NCT00160381|Experimental|1|
11644607|NCT00160381|Experimental|2|
11644608|NCT00160381|Placebo Comparator|3|
11644609|NCT00160355|Other|1|
11644610|NCT00160342|Active Comparator|1|
11644611|NCT00160342|Experimental|2|
11644612|NCT00160342|Experimental|3|
11644613|NCT00160342|Active Comparator|4|
11644614|NCT00160342|Experimental|5|
11644615|NCT00160342|Experimental|6|
11644616|NCT00160342|Active Comparator|7|
11644617|NCT00160342|Active Comparator|8|
11644618|NCT00160342|Placebo Comparator|9|
11644619|NCT00160316|Experimental|1|
11644620|NCT00160290|Experimental|A|Lactulose Group
11644621|NCT00160290|Active Comparator|B|Plantago Group
11644622|NCT00160251|Active Comparator|Arm 1A: PegIntron (PEG) + Ribavirin (RBV)|A single dose of PEG is given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA is undetected, PEG + RBV will continue for another 36 weeks.
11644623|NCT00160251|Active Comparator|Arm 1B: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400|A single dose of PEG is given first, followed 1 week later by PEG + RBV for 12 weeks. If HCV-RNA is detectable, BOC 400 mg TID will be added for 36 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
11644624|NCT00160251|Experimental|Arm 2: PegIntron (PEG) + Boceprevir (BOC) 100 (48 weeks)|A single dose of PEG is given first, followed 1 week later by PEB + BOC 100 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
11644625|NCT00160251|Experimental|Arm 3: PegIntron (PEG) + Boceprevir (BOC) 200 (48 Weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 200 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
11644626|NCT00160251|Experimental|Arm 4: PegIntron (PEG) + Boceprevir (BOC) 400 (48 weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 400 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
11644627|NCT00160251|Experimental|Arm 5: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 400|A single dose of PEG is given first, followed 1 week later by PEG + RBV + BOC 400 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
11644628|NCT00160251|Experimental|Arm 6: PegIntron (PEG) + Boceprevir (BOC) 400 (24 Weeks)|A single dose of PEG is given first, followed 1 week later by PEG + BOC 400 for 24 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
11644629|NCT00160251|Experimental|Arm 7: PegIntron (PEG) + Boceprevir (BOC) 800|By first protocol amendment to P03659, this non-randomized arm is added. A single dose of PEG is given first, followed 1 week later by PEG + BOC 800 for 24 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
11644630|NCT00160251|Experimental|Arm 8: PegIntron (PEG)+Ribavirin (RBV)+Boceprevir (BOC) 800|By second protocol amendment to P03659, participants from all arms except Arm 1A will be rolled over into PEG + RBV + BOC 800 for the remainder of the treatment period.
11644631|NCT00160199|Experimental|1|
11644632|NCT00160199|Active Comparator|2|
11644633|NCT00160186|Experimental|1|
11644634|NCT00160186|Placebo Comparator|2|
11644635|NCT00160147|Experimental|1|
11644636|NCT00160147|Placebo Comparator|2|
11644637|NCT00160069|Experimental|Arm 1|
11644638|NCT00160069|Experimental|Arm 2|
11644639|NCT00160069|Experimental|Arm 3|
11644640|NCT00160056|Other|Hypoglycemia|Intrerfvention is a hypoglycemic stimulus
11644641|NCT00160043|Experimental|Arm 1|
11644642|NCT00160043|Experimental|Arm 2|
11644643|NCT00160030|Experimental|1|
11644644|NCT00160030|Active Comparator|2|
11644645|NCT00160017||Collaborative group|Participants (i.e. profesionals) participate in a Breakthrough Collaborative intervention to improve diabetes care so that patients are provided more often with diabetes care as described in guidelines
11644646|NCT00160017||usual care group|Participants are offered no intervention and care is provided as usual
11644647|NCT00159991|Experimental|A|Total arterial revascularization
11644648|NCT00159991|Active Comparator|B|Conventional revascularization
11644649|NCT00159965|Active Comparator|sertraline|flexible dose sertraline, 25 to 200mg titration as tolerated, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES
11644650|NCT00159965|Placebo Comparator|placebo|flexible dose placebo, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES
11644651|NCT00159952|Active Comparator|1|
11644652|NCT00159939|Active Comparator|prone position|prone positioning
11644653|NCT00159939|No Intervention|supine position|
11644654|NCT00159926|Experimental|1|With cell saver
11644655|NCT00159926|Active Comparator|2|Without cell saver
11644656|NCT00159913|Experimental|Sildenafil Low dose|
11644657|NCT00159913|Experimental|Sildenafil Medium dose|
11644658|NCT00159913|Experimental|Sildenafil High dose|
11644659|NCT00159913|Placebo Comparator|Placebo|
11644772|NCT00158327|Active Comparator|2|Participants will receive usual care
11644805|NCT00157924|Active Comparator|2|2. atorvastatin 10mg
11644660|NCT00159874|Experimental|Sildenafil high dose|As per Protocol Amendment 8 (Aug 2011), all doses in the high dose treatment group were discontinued. Subjects who were receiving these doses and continued in the study were requested to down titrate.
11644661|NCT00159874|Experimental|Sildenafil Low dose|
11644662|NCT00159874|Experimental|Sildenafil medium dose|As per Protocol Amendment 8 (August 2011), the dose 40 mg TID in the medium dose treatment group was discontinued. Subjects who were receiving this dose and continued in the study were requested to down titrate.
11644663|NCT00159822|Experimental|1|
11644664|NCT00159796|Experimental|Arm 1|Asenapine
11644665|NCT00159796|Active Comparator|Arm 2|Olanzapine
11644666|NCT00159796|Placebo Comparator|Arm 3|Placebo
11644667|NCT00159783|Experimental|Asenapine|Asenapine 5-10 mg twice daily for 40 weeks
11644668|NCT00159783|Active Comparator|Olanzapine|Olanzapine 5-20 mg once daily for 40 weeks
11644669|NCT00159744|Active Comparator|Arm 1|Asenapine
11644670|NCT00159744|Active Comparator|Arm 2|Olanzapine
11644671|NCT00159744|Placebo Comparator|Arm 3|Placebo
11644672|NCT00159601||outpatients in Child and Adolescent Mental Health Service|
11644673|NCT00159601||youth from general population|
11644674|NCT00159588|Active Comparator|1|Use of preventive drugs from the start without abrupt withdrawal
11644675|NCT00159588|No Intervention|2|Device: Abrupt withdrawal
11644676|NCT00159588|No Intervention|3|Active control: No instruction for abrupt withdrawal or prophylactic treatment
11644677|NCT00159575|Experimental|M: Metformin P: Placebo|
11644678|NCT00159562|Experimental|group education|Bipolar 1 and 2 patients in a stable euthymic phase will receive group education in 10 weekly sessions and then a session every third month for two years. Symptoms, admittances to hospital and function will be followed for two years.
11644679|NCT00159562|Active Comparator|individual education|Bipolar 1 and 2 patients in a stable euthymic phase will receive three individual sessions of education.
11644680|NCT00159536|Experimental|Metformin|Metformin 1000mg x 2 daily
11644681|NCT00159536|Placebo Comparator|placebo|Placebo x 2 daily
11644682|NCT00159523|Experimental|probiotic|
11644683|NCT00159523|Placebo Comparator|placebo|
11644684|NCT00159510|No Intervention|Control|The control group with neither nitric oxide nor methylene blue used
11644685|NCT00159510|Active Comparator|MB alone|Single methylene blue used
11644686|NCT00159510|Active Comparator|NO alone|Nitric oxide alone used
11644687|NCT00159510|Active Comparator|MB+NO|Both nitric oxide and methylene blue used
11644688|NCT00159497|Active Comparator|1|Standard porouscoated Trilogy Cup
11644689|NCT00159497|Experimental|2|HA coated Trilogy cup
11644690|NCT00159484|Experimental|A|EPO906, celecoxib
11644691|NCT00159432|Experimental|Oxaliplatin, followed by Bevacizumab with Capecitabine|oxaliplatin 85 mg/m2 q 14 days, followed by bevacizumab 5 mg/kg q 14 days, with capecitabine 750 mg/m2 bid daily
11644692|NCT00159419|Active Comparator|Alendronate|1 mg/kg po qd rounded to nearest 10 or 20 mg dose
11644693|NCT00159419|Active Comparator|Pamidronate|3 mg/kg IV q4 months
11644694|NCT00159406||cohort|Registry and Database
11644695|NCT00159380|Experimental|Healthy volunteers|8 non smokers non asthmatic
11644696|NCT00159380|Experimental|Asthma volunteers|8 asthmatic mild
11644697|NCT00159289|Experimental|1|Inhalation of LPS
11644698|NCT00159289|Placebo Comparator|2|PLacebo
11644699|NCT00159263|Placebo Comparator|Placebo|placebo
11644700|NCT00159263|Experimental|Formoterol|Oxis(®) 12 μg
11644701|NCT00159263|Experimental|Budesonide low dose|Pulmicort(®) 200 μg
11644702|NCT00159263|Experimental|Budesonide high dose|Pulmicort(®) 800 μg
11644703|NCT00159263|Experimental|Budesonide/formoterol combination single|single 100/6 μg SYM100
11644704|NCT00159263|Experimental|Budesonide/formoterol combination double|double 200/12 μg SYM200
11644705|NCT00159250|Experimental|Low dose|Low dose of AVI-4658
11644706|NCT00159250|Experimental|High dose|High dose of AVI-4658
11644707|NCT00159224|Experimental|Lopinavir/ritonavir monotherapy|Patients with undetectable viral load while on 1st line ARV therapy will be randomized to the expermental arm: Lopinavir/ritonavir monotherapy
11644708|NCT00159224|Active Comparator|Lopinavir/Ritonavir plus 2 NRTIs|Patients randomized to this arm will continue with standard of care triple therapy, based on Lopinavir/Ritonavir plus 2 NRTIs
11644709|NCT00159211|Active Comparator|1|UMULINE NPH at bed time
11644710|NCT00159211|Experimental|2|pioglitazone 30 mg
11644711|NCT00159198||1|Patients with frontotemporal dementia and amyotrophic lateral sclerosis
11644712|NCT00159198||2|Relatives (first and second degree) of patients presenting an association of frontotemporal dementia with amyotrophic lateral sclerosis
11644713|NCT00159146|Active Comparator|A|Venlafaxine and pindolol
11644714|NCT00159146|Placebo Comparator|B|Venlafaxin and placebo
11644715|NCT00159133|Experimental|1|Early intervention with benzodiazepines in case of prodromal symptoms of an impending relapse
11644716|NCT00159133|Active Comparator|2|Early intervention with antipsychotics in case of prodromal symptoms of an impending relapse
11644717|NCT00159120|Active Comparator|1|further maintenance antipsychotic treatment and prodrome-based early intervention
11644718|NCT00159120|Experimental|2|stepwise drug discontinuation (after 1 year maintenance antipsychotic treatment) and prodrome-based early intervention
11644719|NCT00159107|Experimental|2|Placebo +Integrative behavior therapy
11644720|NCT00159107|Experimental|3|Acamprosate + treatment as usual
11644721|NCT00159107|Experimental|1|Acamprosate + Integrative behavior therapy
11644722|NCT00159081|Experimental|1|Maintenance antipsychotic treatment with risperidone
11644723|NCT00159081|Active Comparator|2|Maintenance antipsychotic treatment with haloperidol in low-dose
11644724|NCT00158925|Experimental|EASYTRAK EPI Lead|Subjects in this arm will be implanted or attempted with the EASYTRAK EPI lead.
11644773|NCT00158301|Experimental|1|Continuation phase cognitive behavioral therapy and drug therapy for 6 more months following acute treatment response
11644959|NCT00153972|Active Comparator|Cabergoline|Cabergoline 3 mg per day orally.
11644725|NCT00158886|Experimental|Subjects with rectal cancer|Subjects will be administered topotecan along with concomitant radiation for five days per week for five weeks. Topotecan doses will start at 0.25 milligrams per square meter (mg/m˄2) and will be escalated 0.15 mg/m˄2 for subsequent cohorts. To advance to the next dose level of topotecan, at least two subjects will have to complete therapy with oral topotecan without experiencing grade 3 or 4 toxicity for three weeks after the oral topotecan treatment.
11644726|NCT00158860|Experimental|Valaciclovir|Participants received double blinded treatment of oral dose of Valacyclovir 1 g given as 2 x 500 mg caplets QD for 6 months (24 weeks).
11644727|NCT00158860|Placebo Comparator|Placebo|Participants received double blinded treatment of oral dose of matching placebo to Valacyclovir 1 gram (g) given as 2 x 500 milligram (mg) caplets once daily (QD) for 6 months (24 weeks).
11644728|NCT00158782|Experimental|Cohort 1|Subjects will receive GW786034 500 milligrams and lapatinib 750 milligrams.
11644729|NCT00158782|Experimental|Cohort 2|Subjects will receive GW786034 250 milligrams and lapatinib 750 milligrams.
11644730|NCT00158782|Experimental|Cohort 3|Subjects will receive GW786034 250 milligrams and lapatinib 1000 milligrams.
11644731|NCT00158782|Experimental|Cohort 4|Subjects will receive GW786034 500 milligrams and lapatinib 1000 milligrams.
11644732|NCT00158782|Experimental|Cohort 5|Subjects will receive GW786034 250 milligrams and lapatinib 1250 milligrams.
11644733|NCT00158782|Experimental|Cohort 6|Subjects will receive GW786034 400 milligrams and lapatinib 1250 milligrams.
11644734|NCT00158782|Experimental|Cohort 7|Subjects will receive GW786034 200 milligrams and lapatinib 1500 milligrams.
11644735|NCT00158782|Experimental|Cohort 8|Subjects will receive GW786034 400 milligrams and lapatinib 1500 milligrams.
11644736|NCT00158782|Experimental|Cohort 9|Subjects will receive GW786034 400 milligrams and lapatinib 1000 milligrams.
11644737|NCT00158782|Experimental|Cohort 10|Subjects will receive GW786034 800 milligrams and lapatinib 1500 milligrams.
11644738|NCT00158769|Experimental|Subjects with moderate hepatic impairment|Subjects with moderate hepatic impairment as defined by a Child-Pugh score of 7-9 will be included. Subjects will be given GR270773 as a loading infusion of 25 milligram per kilogram per hour (mg/kg/hr) for 2 hours followed by a maintenance infusion of 5 mg/kg/hr for 70 hours.
11644739|NCT00158769|Experimental|Healthy subjects|Subjects will be matched as closely as possible to the group of moderate hepatic subjects for gender, age and body mass index (BMI). Subjects will be administered 25 mg/kg/hr GR270773 as a loading dose for 2 hours followed by a maintenance infusion of 5 mg/kg/hr for 70 hours. Following a washout period of 21 days, the subjects will then receive a loading dose of 75 mg/kg/hr for 2 hours followed by a maintenance dose of 12.5 mg/kg/hr of GR270773 for 70 hours.
11644740|NCT00158756|Experimental|Tritanrix™-HepB+Rotarix™ Group|Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.
11644741|NCT00158756|Experimental|Tritanrix™-HepB+Placebo Group|Subjects received 3 doses of Tritanrix™-HepB vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.
11644742|NCT00158756|Active Comparator|Zilbrix™+Rotarix™ Group|Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Rotarix™ vaccine at 3 and 4.5 months of age.
11644743|NCT00158756|Active Comparator|Zilbrix™+Placebo Group|Subjects received 3 doses of Zilbrix™ vaccine at 3, 4.5 and 6 months of age, intramuscularly into the right anterolateral thigh concomitantly with 2 oral doses of Placebo for Rotarix™ vaccine at 3 and 4.5 months of age.
11644744|NCT00158756|Active Comparator|Triple Antigen™+Engerix™-B Group|Subjects received 3 separate doses of Triple Antigen™ and Engerix™-B vaccines at 3, 4.5 and 6 months of age, intramuscularly into the left and right anterolateral thighs, respectively.
11644745|NCT00158743|Active Comparator|Digoxin immune fab|Digibind treatment plus standard of care
11644746|NCT00158743|Placebo Comparator|placebo (sodium chloride)|
11644747|NCT00158678|Active Comparator|1|Conventional RT 70Gy + concomitant cisplatin
11644748|NCT00158678|Experimental|2|IMRT 75Gy + concomitant cisplatin
11644749|NCT00158665|Experimental|Subjects receiving vaccine|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine 4 weeks apart.
11644750|NCT00158652|Active Comparator|1|
11644751|NCT00158652|Experimental|2|
11644752|NCT00158652|Experimental|3|
11644753|NCT00158600|Active Comparator|alglucosidase alfa|Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.
11644754|NCT00158600|Placebo Comparator|Placebo|Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.
11644755|NCT00158574|Placebo Comparator|Placebo|IPTi placebo
11644756|NCT00158574|Experimental|Sulphadoxine-pyrimethamine|IPTi SP
11644757|NCT00158574|Experimental|Mefloquine|
11644758|NCT00158574|Experimental|Chlorproguanil dapsone|
11644759|NCT00158522|Experimental|1|
11644760|NCT00158431|Active Comparator|Arthroscopy plus Medical Management|Arthroscopic Surgery of the Knee plus the optimized medical management including physiotherapy, education, medication, etc
11644761|NCT00158431|No Intervention|Medical Management|Optimized Medical management including physiotherapy, education, medication, etc
11644762|NCT00158379|Experimental|Paclitaxel|
11644763|NCT00158366|Experimental|1|Phase 1 participants who will receive behavioral training for 14 weeks
11644764|NCT00158366|Active Comparator|2|Phase 1 participants who will receive social skills training for 14 weeks
11644765|NCT00158366|Experimental|3|Participants in the Phase 1 behavioral training group who have a 4% or more weight loss and will be enrolled in weekly behavioral training alone for 24 months in Phase 2
11644766|NCT00158366|Experimental|4|Participants in the Phase 1 behavioral training group who have a 4% or more weight loss and will be enrolled in weekly behavioral training plus biweekly booster treatments for 24 months in Phase 2
11644767|NCT00158353|Experimental|1|GirlPOWER! mentoring program
11644768|NCT00158353|Active Comparator|2|Big Brothers Big Sisters community-based mentoring program
11644769|NCT00158340|Experimental|1|Participants will receive guided self-help cognitive behavioral therapy
11644774|NCT00158301|Active Comparator|2|Continuation phase drug therapy only for 6 more months following acute treatment response
11644775|NCT00158275|Experimental|Integrated Intervention|Participants will receive cognitive behavioral therapy for back pain and antidepressants and/or problem solving therapy for depression. Study visits will initially occur once a week and then taper to once every 2 weeks for the 6-month duration.
11644776|NCT00158275|No Intervention|Standard of Care|Participants will receive care as usual from their health care provider.
11644777|NCT00158262|Experimental|Propranolol|Following the occurrence of an acute psychologically traumatic event, an initial dose of short-acting propranolol 40 mg orally then one hour later, long-acting propranolol 60 mg capsule orally on Day 1 followed by a 19-day course of long-acting propranolol starting with 120 mg every morning and evening for 10 days, and then tapering to 120 mg in the morning and 60 mg in the evening for 3 days, then 60 mg in the morning and 60 mg the evening for 3 days, then 60 mg in the morning for 3 days.
11644778|NCT00158262|Placebo Comparator|Placebo|Following the occurrence of an acute psychologically traumatic event, an initial dose of placebo-matching short-acting propranolol 40 mg orally then one hour later, placebo-matching long-acting propranolol 60 mg capsule orally on Day 1 followed by a 19-day course of placebo-matching long-acting propranolol starting with 120 mg every morning and evening for 10 days, and then tapering to 120 mg in the morning and 60 mg in the evening for 3 days, then 60 mg in the morning and 60 mg the evening for 3 days, then 60 mg in the morning for 3 days.
11644779|NCT00158249|Placebo Comparator|placebo|matched capsules
11644780|NCT00158249|Experimental|citicoline|2 gm/day
11644781|NCT00158223|Placebo Comparator|placebo|Participants will receive encapsulated placebo made to match active drug
11644782|NCT00158223|Experimental|pimozide|Participants will receive pimozide flexible dosing
11644783|NCT00158197|Experimental|continuous voucher schedule|Those in the continuous condition will receive a contingency management voucher each time they test negative for methamphetamine. The initial voucher value will be $2.50. Each consecutive instance of abstinence will increase the magnitude of the voucher by $1.50. Three consecutive abstinences will result in the delivery of a $10.00 bonus. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again. All participants will provide observed urine samples three times a week (e.g., M, W, & F) for twelve weeks and will complete study-related measures one time per week.
11644784|NCT00158197|Experimental|intermittent predictable schedule|Those in the intermittent predictable condition will earn a contingency management voucher when they provide three consecutive methamphetamine-negative urine tests. Participants in the intermittent predictable condition will receive $22.00 for the provision of their first three consecutive methamphetamine-negative urine samples, $35.50 for the provision of their second set of three consecutive instances of methamphetamine-negative urine samples, and so forth. There are no bonuses for consecutive instances of abstinence in the intermittent predictable condition. Provision of a methamphetamine-positive urine sample, or failure to test, will result in a reset in the voucher magnitude back to its original level from whence the progression can begin again. All participants will provide observed urine samples three times a week (e.g., M, W, & F) for twelve weeks and will complete study-related measures one time per week.
11644785|NCT00158197|Experimental|intermittent unpredictable schedule|Those in the intermittent unpredictable condition will be eligible to receive a contingency management voucher on one day a week. Participants in this group will receive a voucher for $22.00 following their first 3 methamphetamine-negative urine tests. They will then be eligible to receive a voucher one day a week if all of their urine tests since the receipt of their last voucher were methamphetamine negative. They will receive a voucher for $35.50 for the provision of their second set of 3 consecutive instances of methamphetamine-negative urine samples, $49.00 for their third set of 3 consecutive instances, and so forth. The day of the week on which the voucher will be available will be randomly selected for each week and the participants will not know which day of the week they will be eligible to receive a voucher until they have provided their urine test. All participants will provide observed urine samples M, W, & F for 12 wks and complete measures 1x/wk.
11644786|NCT00158197|No Intervention|standard|Participants assigned to the standard condition will not receive vouchers for the provision of clean urines. All participants will provide observed urine samples three times a week (e.g., M, W, & F) for twelve weeks and will complete study-related measures one time per week.
11644787|NCT00158184|Active Comparator|Rx Opioid Abusers|Recreational users of prescription opioids. Participants in this arm received the 3 interventions (0, 15, and 30 mg oxycodone) at random.
11644788|NCT00158184|Active Comparator|Rx Opioid Non-Abusers|Participants with a history of prescription opioid use, but who did not abuse them. Participants in this arm received the 3 interventions (0, 15, and 30 mg) at random.
11644789|NCT00158171|Experimental|1|Nicotine patch
11644790|NCT00158171|Experimental|2|Nicotine gum
11644791|NCT00158171|Placebo Comparator|3|Folic acid
11644792|NCT00158158|Placebo Comparator|1|Usual care
11644793|NCT00158158|Experimental|2|Reduction in smoking
11644794|NCT00158132|Experimental|Propranolol|Propranolol 100mg/day in 3 divided doses
11644795|NCT00158132|Experimental|Amantadine|Amantadine 100mg three times daily
11644796|NCT00158132|Experimental|Propranolol and Amantadine|Propranolol 100mg/day in 3 divided doses and Amantadine 100mg 3X's daily
11644797|NCT00158132|Placebo Comparator|Placebo|Identical Placebo pills
11644798|NCT00158054|Experimental|Intervention Condition (INT)|Enhanced depression care: Participants assigned to INT condition will be given an information brochure describing the intervention. This description will include an overview of the two elements of treatment (Problem Solving Therapy (PST), pharmacotherapy), the choice that the participant has for which element of treatment they will receive, and the stepped care aspect of treatment.
11644799|NCT00158054|Other|Usual Cardiologic Care Condition (UCC)|Referred depression care: Participants assigned to the usual cardiologic care condition (UCC) condition will be scheduled for their next follow-up visit and thanked for their time.
11644800|NCT00158028|Experimental|Risperidone|starting dose 0.25mg/day, titrated upward to 2mg/day over 9 weeks
11644801|NCT00158028|Placebo Comparator|Placebo|placebo match in identical tablets
11644802|NCT00157950|Experimental|Gardasil™|Gardasil™ 3 dose regimen
11644803|NCT00157950|Placebo Comparator|Placebo|Gardasil™ matching placebo 3 dose regimen
11644806|NCT00157846|Experimental|BiV Pacing|Biventricular pacing for 3 months, subsequently right ventricular pacing for 3 months
11644807|NCT00157846|Active Comparator|RV Stimulation|Right ventricular pacing for 3 months, subsequently biventricular pacing for 3 months
11644808|NCT00157820|Active Comparator|SC true|Single chamber Implantable Cardioverter Defibrillator programmed as a Single Chamber.
11644809|NCT00157820|Experimental|SC sim|Dual chamber ICD initially programmed as single chamber (SC simulated) ICD (''SC sim arm'')
11644810|NCT00157820|Experimental|DC true|Dual chamber ICD initially programmed as a DDED (''DC true arm'').
11644811|NCT00157807|No Intervention|No Ablation|
11644812|NCT00157807|Other|bipolar radiofrequency ablation of persistent and permanent AF|intra operative bipolar RF ablation of persistent and permanent AF
11644813|NCT00157690|Active Comparator|1|Alendronate
11644814|NCT00157690|Placebo Comparator|2|Placebo
11644815|NCT00157677|Experimental|1|Selective D-Dimer use
11644816|NCT00157677|Active Comparator|2|Uniform D-Dimer use
11644817|NCT00157651|Active Comparator|1|Receiving warfarin
11644818|NCT00157651|Placebo Comparator|2|Receiving matching placebo
11644819|NCT00157612|Other|Intervention|use of oral anti-microbials, portable chest radiographs, oxygen saturation monitoring, re-hydration and close monitoring by a research nurse
11644820|NCT00157612|No Intervention|Comparator|usual care
11644821|NCT00157573|Experimental|GM-CSF, Sargramostim Cohort 1|GM-CSF, Sargramostim 250 μg/m^2 subcutaneous injection daily on days 1 to 14 in a 28-day cycle until disease progression or unacceptable toxicity for a median of 3 cycles.
11644822|NCT00157573|Experimental|GM-CSF, Sargramostim Cohort 2|GM-CSF, sargramostim 150 μg/m^2 subcutaneous injection daily for 28 days in a 28-day cycle until disease progression or unacceptable toxicity fora median of 3 cycles. GM-CSF, sargramostim dose escalation was permitted up to 250 μg/m^2 per day if applicable based on toxicity and white blood cell count.
11644823|NCT00157339|Experimental|1|
11644824|NCT00157339|Active Comparator|2|
11644825|NCT00157300|Experimental|Epoetin beta|
11644826|NCT00157248|Experimental|dabigatran etexilate, 150 mg once daily|dosage used at study start
11644827|NCT00157248|Experimental|dabigatran etexilate, 150 mg twice daily|dosage used at study start
11644828|NCT00157248|Experimental|dabigatran etexilate, 300 mg once daily|dosage used at study start
11644829|NCT00157248|Experimental|dabigatran etexilate, 300 mg twice daily|dosage used at study start
11644830|NCT00157209|Experimental|Tecemotide (L-BLP25) plus Best Supportive Care (BSC)|
11644831|NCT00157209|Active Comparator|Best Supportive Care (BSC) Alone|
11644832|NCT00157196|Experimental|Tecemotide(L-BLP25)+Cyclophosphomide+best standard of care|
11644833|NCT00157157|Experimental|Single Arm - All Participants|All subjects enrolled in the study who meet the eligibility criteria.
11644834|NCT00157131|Experimental|FS 4IU VH S/D|"FS 4IU VH S/D was administered intraoperatively to the wound bed by spray application using the TISSOMAT and Spray Set. Only the DUPLOJECTvii system and Spray Set (connection tube with sterile filter and spray head) device was used for simultaneous spray application of the study product. A thin layer of FS 4IU VH S/D was applied to the wound bed using a painting motion from side to side to achieve coverage. The recommended dosing volume was 2.0 to 4.0 mL/100 cm2. One 2-mL pack (4 mL total volume) of FS 4IU VH S/D applied using the TISSOMAT and Spray Set was sufficient to coat a wound bed of 100-200 cm2."
11644835|NCT00157131|Active Comparator|Staples|Staples are the current standard of care in burn surgery and are well accepted as the control in this type of study.
11644836|NCT00157027|Active Comparator|1|"Photopheresis (or extracorporeal photoimmunetherapy [ECP]) is a process developed by THERAKOS, Inc., a Johnson and Johnson Company. During the process of ECP, whole blood is drawn from the patient over several cycles, centrifuged and separated into the components of plasma, white cells (or buffy coat), and red blood cells. A portion of the white cells and the plasma are saved in a separate compartment. The remaining plasma and red blood cells are immediately returned to the patient.
~The saved buffy coat (white blood cells) and plasma are inoculated with the photosensitizing agent UVADEX. Photoactivation begins when the suspension is exposed to a prescribed amount of ultraviolet-A light. After photoactivation is complete, the treated suspension is returned to the patient."
11644837|NCT00157014|Experimental|Tacrolimus - Adult|Adults: 0.05 - 0.10 mg/ kg/ day in 2 divided doses starting within 10 days of transplant
11644838|NCT00157014|Active Comparator|Cyclosporine - Adult|Adults: 3-5 mg/ kg/ day in 2 divided doses starting within 10 days of transplant
11644839|NCT00157014|Experimental|Tacrolimus - Pediatric|Pediatrics: 0.05 - 0.30 mg/ kg/ day in 2-3 divided doses starting within 10 days of transplant
11644840|NCT00157014|Active Comparator|Cyclosporine - Pediatric|Pediatrics: 6 - 10 mg/ kg/ day in 2-3 divided doses starting within 10 days of transplant
11644841|NCT00156962|Active Comparator|Epoetin alfa RB|
11644842|NCT00156962|Experimental|Epoetin alfa DT|
11644843|NCT00156949|Experimental|Epoetin alfa DT|
11644844|NCT00156936|Experimental|Medisorb naltrexone 380 mg (VIVITROL)|
11644845|NCT00156936|Experimental|Oral naltrexone to Medisorb naltrexone 380 mg (VIVITROL)|
11644846|NCT00156923|Experimental|Medisorb naltrexone 380 mg|
11644847|NCT00156923|Experimental|Medisorb naltrexone 190 mg|
11644848|NCT00156910|Experimental|botulinum toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
11644849|NCT00156910|Placebo Comparator|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
11644850|NCT00156819|Active Comparator|Fluticasone|Participants continued fluticasone (100 microgram twice daily) treatment.
11644851|NCT00156819|Experimental|Montelukast|Participants were changed to Montelukast (5 or 10 mg each night).
11644852|NCT00156819|Experimental|Fluticasone plus salmeterol|Participants were given fluticasone (100 microgram) plus salmeterol (50 microgram) each night.
11644853|NCT00156767||Bone Marrow Transplant|Patients enrolled in an NCI protocols for bone marrow transplant for breast cancer using prednisone treatment.
11644854|NCT00156767||Cirrhosis|Adults on NIDDK protocol 91-DK-0213 with evidence of chronic liver disease with class A or B cirrhosis secondary to viral hepatitis
11644855|NCT00156767||Critical Care|Patients with a diagnosis of sepsis by the primary clinical provider in the Emergency room of ICU
11644856|NCT00156767||Healthy Volunteer|Healthy adult volunteers
11644857|NCT00156767||Known Adrenal Insufficiency|patients with known diagnosis of Adrenal Insufficiency
11644858|NCT00156767||Nephrotic Syndrome|Adults enrolled in NIDDK protocols with diagnosis of nephrotic syndrome
11644859|NCT00156767||Post Surgical Treatment for Cushings|Patients with transient adrenal insufficiency secondary to successful surgical treatment of cushing's syndrome
11644860|NCT00156715|Experimental|Quetiapine|After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.
11644861|NCT00156702|Active Comparator|1|
11644862|NCT00156702|No Intervention|2|
11644863|NCT00156676|Experimental|Arm 1|Cross over from body-weight support treadmill to Lokomat
11644864|NCT00156676|Experimental|Arm 2|Cross over from Lokomat to body-weight support treadmill
11644865|NCT00156663|Other|Arm 1|
11644866|NCT00156650|Active Comparator|1|Testosterone (T) gel for 6 months + DMPA (Depo-Medroxyprogesterone) (injected into muscle Day 0 & at Month 3)
11644867|NCT00156650|Active Comparator|2|T gel for 6 months + DMPA (Day 0 & Month 3) + Acyline 300 mcg/kg twice monthly for 12 weeks
11644868|NCT00156637|Other|Arm 1|
11644869|NCT00156637|Active Comparator|Arm 2|Dosing & Side Effect Monitoring
11644870|NCT00156533|Placebo Comparator|Placebo|QHS dosing with placebo (i.e. nightly dose)
11644871|NCT00156533|Active Comparator|QHS Zolpidem|QHS dosing with 10mg of zolpidem (i.e. nightly dose)
11644872|NCT00156533|Experimental|Intermittant Zolpidem|Intermittent dosing with 10mg of zolpidem (3-5 pills per week as needed
11644873|NCT00156533|No Intervention|Control|Monitor only condition (no placebo, no drug).
11644874|NCT00156507|Experimental|1|Parents of children in the experimental group receive asthma education prior to NICU discharge.
11644875|NCT00156416|Experimental|Meditation group|Participants received 8 weeks of mindfulness meditation instruction and support
11644876|NCT00156416|Active Comparator|Education group|Participants received 8 weeks of healthy living instruction
11644877|NCT00156390|Experimental|1|echo-guided LV lead placement
11644878|NCT00156390|Other|2|LV lead placement as per standard of care (without echo-guidance)
11644879|NCT00156338|Experimental|1|volume and sodium restriction
11644880|NCT00156338|Active Comparator|2|volume restriction
11644881|NCT00156338|Active Comparator|3|liberal fluid management
11644882|NCT00156299|Experimental|Dexamethasone plus Choline Magnesium Trisalicylate|Dexamethasone plus Choline Magnesium Trisalicylate
11644883|NCT00156299|Experimental|Choline Magnesium Trisalicylate|Choline Magnesium Trisalicylate
11644884|NCT00156247|Experimental|etanercept with acitretin|open-label
11644885|NCT00156208|Experimental|1|
11644886|NCT00156208|Experimental|2|
11644887|NCT00156195|Experimental|1|
11644888|NCT00156195|Experimental|2|
11644889|NCT00156182|Experimental|1|
11644890|NCT00156156|Experimental|1|
11644891|NCT00156156|Experimental|2|
11644892|NCT00156130||1|Accelerated whole breast irradiation
11644893|NCT00156130||2|Conventional whole breast irradiation
11644894|NCT00156117|Experimental|1|asenapine 5 mg BID and 10 mg BID
11644895|NCT00156117|Placebo Comparator|2|Placebo against olanzapine and asenapine
11644896|NCT00156117|Active Comparator|3|olanzapine 15 mgQD
11644897|NCT00156104|Experimental|1|Asenapine 5 mg BID
11644898|NCT00156104|Experimental|2|Asenapine 10 mg BID
11644899|NCT00156104|Active Comparator|3|Haloperidol 4m mg BID
11644900|NCT00156104|Placebo Comparator|4|placebo
11644901|NCT00156091|Active Comparator|1|Olanzapine 20 mg QD
11644902|NCT00156091|Experimental|2|Asenapine 5 or 10 mg BID
11644903|NCT00156091|Other|3|Double-Blind subjects randomized to only placebo medication for 6 weeks in the short-term 041021 or 041022 asenapine trials, were randomized (double-blind) Into the long-term 041512 asenapine extension trial and received asenapine 5 mg BID for Week 1. After Week 1, subjects received asenapine (either 5 mg BID or 10 mg BID) for the remainder of the 52 week trial.
11644904|NCT00156065|Active Comparator|Haloperidol/Haloperidol|Haloperidol in original study (NCT00156104) and in current long-term extension.
11644905|NCT00156065|Experimental|Asenapine/Asenapine|Asenapine in original study and asenapine in current long-term extension.
11644906|NCT00156065|Experimental|Placebo/Asenapine|Double-Blind subjects randomized to only placebo medication for 6 weeks in the short-term 041023 asenapine trial, were randomized (double-blind) into the long-term 041513 asenapine extension trial and received asenapine 5 mg BID for Week 1. After Week 1, subjects received asenapine (either 5 mg BID or 10 mg BID) for the remainder of the 52-week trial.
11644907|NCT00156052|Experimental|Hypofractionated whole breast radiation|Subjects treated with 4250 cGY in 16 fractions
11644908|NCT00156052|Active Comparator|Conventional whole breast radiation|Subjects treated with 5000 cGY in 25 fractions
11644909|NCT00156026|Experimental|1|Immediate Treatment - LEEP - Loop electrosurgical excision procedure
11644910|NCT00156026|No Intervention|2|Colposcopic Follow-up
11644911|NCT00156013|Experimental|1|Clofarabine 4 mg/m^2 days 1-5 of every cycle for a maximum of 6 cycles.
11644912|NCT00155558|Experimental|A|
11644913|NCT00155545|No Intervention|Metformin|
11644914|NCT00155454|Experimental|Study group|Group 1 had intravitreal long acting gas (10% C3F8) injection in the vitreous cavity at the end of surgery
11644915|NCT00155454|Sham Comparator|Control group|Group 2 did not receive intravitreal long acting gas (10% C3F8)
11644916|NCT00155402|Experimental|1|Use of fibrin glue after corneal surgery or transplantation
11644917|NCT00155389|Active Comparator|H pylori eradication|All enrolled subjects received chemoprevention with Helicobacter pylori eradication
11644918|NCT00155311|Experimental|days after treatment|different days after orthodontic treament, samples will be taken.
11644919|NCT00155259|Experimental|A|
11644920|NCT00154882|Experimental|A|
11644921|NCT00154843|Experimental|A|Lycopene 15 mg/day
11644922|NCT00154843|Experimental|B|Lycopene 30 mg/day
11644923|NCT00154804|Experimental|A|
11644924|NCT00154778|Experimental|A|
11644925|NCT00154687|Experimental|A|
11644926|NCT00154622|No Intervention|pain/ disability survey|
11644927|NCT00154466|Experimental|cardiac rehabilitation|Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2.
11644928|NCT00154466|No Intervention|postinfarction patients|those in the nontraining group continued their usual lifestyle
11644929|NCT00154466|Placebo Comparator|healthy controls|Age-, weight-, and height-matched subjects without cardiovascular risk factors were selected as healthy controls.
11644930|NCT00154375|Experimental|Imatinib mesylate + hydroxyurea (HU)|Imatinib was supplied as 100 mg and 400 mg tablets. Patients in the combination arm were instructed to take a daily oral imatinib dose of 600 mg (600 mg at lunch time) and a daily oral hydroxyurea (HU) dose of 1000 mg (500 mg twice daily; in the morning and at bed time). Every 6 weeks after randomization based on assessment of therapeutic response, either patients continued with above mentioned dosing regimen or switched to receive a daily dose of 800 mg imatinib with 1000 mg HU. Patients were instructed to split the intake, taking 400 mg imatinib with 500 mg HU in the morning, then the same in the evening.
11644931|NCT00154375|Active Comparator|Hydroxyurea alone|1500 mg/day of HU given as 500 mg 3 times daily. Every 6 weeks after randomization and based on assessment of therapeutic response, the patients were either switched to combination arm or continued in monotherapy arm of hydroxyurea.
11644932|NCT00154349|Experimental|imatinib mesylate|
11644933|NCT00154336|Active Comparator|Imatinib 400mmg OD +MTX|
11644934|NCT00154336|Placebo Comparator|Imatinib Placebo + MTX|
11644935|NCT00154310|Experimental|Everolimus + Mycophenolate sodium|Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL and enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day. Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5 mg prednisolone or equivalent and had to be continued throughout the first year. Cyclosporine withdrawal started from Month 4.5 post-transplant.
11644936|NCT00154310|Active Comparator|Cyclosporine + Mycophenolate sodium|Cyclosporine tablets orally twice a day to achieve protocol specific target levels and enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day. Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
11644937|NCT00154297|Active Comparator|Immediate Everolimus|Patients received Everolimus starting within 48 hours of kidney transplant through to the end of the study, administered orally twice a day. Dose was adjusted in order to maintain a trough level between 3-8 ng/mL.
11644938|NCT00154297|Experimental|Delayed Everolimus|Patients received Everolimus 4 weeks after kidney transplant until the end of the study, administered orally twice a day. The dose was adjusted in order to maintain a trough level between 3-8 ng/mL. Patients received mycophenolic acid until everolimus was initiated.
11644939|NCT00154284|Active Comparator|Everolimus (Certican) with Cyclosporine (Neoral) Continuation|Patients were treated with everolimus and cyclosporine for 3 months post-transplantation. Everolimus (Certican) was administered orally, in two divided doses (b.i.d), and at the same time as Cyclosporine (Neoral). Everolimus (Certican) dose was adjusted in order to maintain a trough level between 3 and 8 ng/mL until randomization. After randomization the target trough range remained at 3 - 8 ng/mL in the cyclosporine (Neoral) continuation groups for a period of 9 months. Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
11644940|NCT00154284|Experimental|Everolimus (Certican) with Cyclosporine (Neoral) Withdrawal|Patients were treated with everolimus and cyclosporine for 3 months post-transplantation. Everolimus (Certican) was administered orally, in two divided doses (b.i.d), and at the same time as Cyclosporine (Neoral). Everolimus (Certican) dose was adjusted in order to maintain a trough level between 3 and 8 ng/mL until randomization. Therefore, patients were randomized to cyclosporine withdrawal over a period of 1 month (±1 week) in study A2419 (NCT00154284) and over 3 months (±1 week) in study A2423 (NCT00170807). After randomization, final target trough range for everolimus was 8 - 12 ng/mL. Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
11644941|NCT00154258|Experimental|1|
11644942|NCT00154193|Active Comparator|Cyclosporine|
11644943|NCT00154180|Active Comparator|Arm 1|CEE 0.45 mg w/ Prometrium 200 mg patch 0.05 mg w/ Prometrium 200 mg
11644944|NCT00154180|Placebo Comparator|Arm 2|Placebo patch, placebo CEE, placebo Prometrium
11644945|NCT00154154|Active Comparator|A|General Psychiatric Management
11644946|NCT00154154|Experimental|2|Dialectal Behaviour Therapy
11644947|NCT00154115|Experimental|1|Levosimendan
11644948|NCT00154115|Placebo Comparator|2|
11644949|NCT00154102|Experimental|Cetuximab Plus FOLFIRI|
11644950|NCT00154102|Active Comparator|FOLFIRI Alone|
11644951|NCT00154089|Experimental|EM-1421|"Administration of EM-1421 intravaginally once per week for 3 weeks
~Dose level of 45 mg/application (1% w/w) or 90 mg/application (2% w/w)"
11644952|NCT00154076|Experimental|1|
11644953|NCT00154076|Active Comparator|2|
11644954|NCT00154063|Placebo Comparator|Placebo|During the Titration Phase, placebo was initiated at a dose of 1.0 mg/day for the first 2 weeks, increased to 1.5 mg/day for the next 2 weeks, and then further increased to 2.0 mg/day for 10 weeks (last 2 weeks of the Titration Phase continuing into the 8-week Maintenance Phase).
11644955|NCT00154063|Experimental|E2007|During the Titration Phase, perampanel was initiated at a dose of 1.0 mg/day for the first 2 weeks, increased to 1.5 mg/day for the next 2 weeks, and then further increased to 2.0 mg/day for 10 weeks (last 2 weeks of the Titration Phase continuing into the 8-week Maintenance Phase).
11644956|NCT00153998|Active Comparator|1|Cetuximab and FOLFIRI
11644957|NCT00153998|Active Comparator|2|Cetuximab and FOLFOX
11644958|NCT00153972|Active Comparator|Levodopa|Levodopa 300 mg per day orally.
11644960|NCT00153946|Active Comparator|A|The patients who are allocated to Argatroban monotherapy
11644961|NCT00153946|Active Comparator|B|The patients who are allocated to Edaravone-Argatroban combination therapy
11644962|NCT00153933|Experimental|CC-5013 in combination with bortezomib|Participants will receive bortezomib intravenously on day 1,4,8 and 11 followed by 10 days of rest. CC-5013 will be given orally on days 1-14 followed by 7-days of rest. One cycle lasts 21 days.
11644963|NCT00153920|Experimental|bortezomib|Participants received intravenous bortezomib on a 3-week dosing cycle: 1.3 mg/m2 on days 1, 4, 8 and 11 followed by 10 day rest period for up to 8 cycles or for 2 cycles beyond complete response. Participants with progressive disease or unacceptable toxicity discontinued treatment.
11644964|NCT00153894|Active Comparator|Group A|Immediate Exercise
11644965|NCT00153894|Active Comparator|Group B|Delayed Exercise (delay by 16 weeks)
11644966|NCT00153881|Experimental|1|Docetaxel/Carboplatin every 3 weeks for 2 cycles then concommitant chemotherapy and radiation Docetaxel weekly for 5 doses without premedication, then Capecitabine will be given orally, one dose prior to each fraction or irradiation (28 cycles).
11644967|NCT00153868|Active Comparator|1|Darbepoetin alfa 200 mcg with escalation to 300 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 2 weeks for 12 weeks (weeks 1, 3, 5, 7, 9, and 11)
11644968|NCT00153868|Active Comparator|2|darbepoetin alfa 300 mcg with escalation to 500 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 3 weeks for 12 weeks (weeks 1, 4, 7, and 10)
11644969|NCT00153842|Experimental|Bexarotene|Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).
11644970|NCT00153816|Experimental|Full Factorial Placebo|subjects in 2X2 factorial design; randomized to daily placebo
11644971|NCT00153816|Experimental|Full Factorial Calcium|subjects in 2X2 factorial design; randomized to daily 1200 mg as calcium carbonate
11644972|NCT00153816|Experimental|Full Factorial Vitamin D|Subjects in 2X2 factorial design; randomized to daily 1000 IU vitamin D3
11644973|NCT00153816|Experimental|Full Factorial Calcium Plus Vitamin D|Subjects in 2X2 factorial design; randomized to daily 1200 mg as calcium carbonate and 1000 IU vitamin D3
11644974|NCT00153816|Experimental|Two Arm Placebo|Women choosing to take daily 1200 mg as calcium carbonate randomized to daily placebo
11644975|NCT00153816|Experimental|Two Arm Vitamin D|Women choosing to take daily 1200 mg as calcium carbonate randomized to daily 1000 IU vitamin D3
11644976|NCT00153803|Experimental|1|Erlotinib (Tarceva) 150mg: Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.
11644977|NCT00153803|Placebo Comparator|2|Matched Placebo: Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.
11644978|NCT00153764|Placebo Comparator|multivitamin|1 tablet morning and evening
11644979|NCT00153751|Experimental|Traditional Chinese Medicine|They are Common peony root, other herbs.
11644980|NCT00153751|Active Comparator|Holopon|Holopon
11644981|NCT00153751|Placebo Comparator|placebo|Placebo
11644982|NCT00153712||Non NSAID non-Hp|Patient of history of peptic ulcer bleeding with Hp-ve and without prior history of taking NSAID or Aspirin within 30 days
11644983|NCT00153712||Helicobacter pylori +ve|Patient with Hp+ve at peptic ulcer bleeding
11644984|NCT00153686|Experimental|Capsule Endoscopy|Capsule Endoscopy examination of small intestine
11644985|NCT00153686|Other|Mesenteric Angiogram|Mesenteric Angiogram of the small intestine
11644986|NCT00153673|Active Comparator|1|Celecoxib + Famotidine
11644987|NCT00153673|Active Comparator|2|Dologesics + Famotidine
11644988|NCT00153660|Active Comparator|NSAID #1|Celecoxib and Naproxen Placebo
11644989|NCT00153660|Active Comparator|NSAID #2|Naproxen and Celecoxib Placebo
11644990|NCT00153647|Active Comparator|1|Cap-assisted Colonoscopy
11644991|NCT00153647|Placebo Comparator|2|Regular Colonoscopy
11644992|NCT00153634|Experimental|1|Antibiotic regimen assignment based on biofilm susceptibility test results
11644993|NCT00153634|Active Comparator|2|Antibiotic regimen assignment based on conventional susceptibility test results
11644994|NCT00153530|Active Comparator|1|1 chemotherapy with radiotherapy
11644995|NCT00153530|Experimental|2|chemotherapy without radiotherapy
11644996|NCT00153504|Experimental|Housing and Health Study housing rental assistance|
11644997|NCT00153504|Active Comparator|Standard local practice housing assistance|
11644998|NCT00153426|Experimental|lifestyle counseling|Women assigned to lifestyle change intervention arm for nutrition and physical activity with print-based tailored health communications and a computer-based interactive nutrition program targeting health behaviors of diet and physical activity. Women in a control group did not receive the intervention.
11644999|NCT00153257|Other|Ugytex|Anterior repair reinforced by a specially designed mesh: UgytexTM
11645000|NCT00153257|No Intervention|No device|standard anterior colporrhaphy
11645001|NCT00153231|Experimental|Infracoccygeal sacropexy|Intervention: IVS
11645002|NCT00153231|Active Comparator|Sacrospinofixation|Intervention: Sacrospinofixation
11645003|NCT00153205|Placebo Comparator|Introduction of A Clinical Pharmacist|
11645004|NCT00153205|Experimental|Technological|
11645005|NCT00153179|Active Comparator|1|Acipimox treatment for 7 days
11645006|NCT00153179|Placebo Comparator|2|placebo treatment for 7 days
11645007|NCT00153166|Experimental|Patients with PAD (Including diabetics)|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
11645008|NCT00153166|Active Comparator|PAD (Excluding Diabetics)|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
11645009|NCT00153166|Active Comparator|Healthy Controls|Randomized to either atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, or placebo/placebo.
11645010|NCT00153062|Placebo Comparator|Aggrenox, Clopidogrel placebo, Micardis|Aggrenox (25mg/200mg) bid, clopidogrel placebo qd, Micardis (80mg) qd
11645077|NCT00152009|Experimental|SPD503 (Guanfacine HCl) (2 mg)|
11645011|NCT00153062|Placebo Comparator|Aggrenox placebo, clopidogrel,, Micardis|Clopidogrel (75mg) qd; Aggrenox placebo bid, Micardis (80mg) qd
11645012|NCT00153062|Placebo Comparator|Aggrenox, clop placebo, micardis placebo|Aggrenox (25mg/200mg) bid, clopidogrel placebo qd, Micardis placebo qd
11645013|NCT00153062|Placebo Comparator|Aggrenox plcebo, clop, micardis placebo|Clopidogrel (75mg) qd, Aggrenox placebo bid, Micardis placebo qd.
11645014|NCT00152971|Experimental|Dabigatran Dose 1|low dose regimen taken once daily
11645015|NCT00152971|Experimental|Dabigatran Dose 2|high dose regimen taken once daily
11645016|NCT00152971|Active Comparator|Enoxaparin|30 mg subcutaneously twice daily
11645017|NCT00152906|Experimental|Stereotactic RT or highly conformal RT|
11645018|NCT00152893|Experimental|Chromium|400 μg (200 μg pills, twice per day) of Cr-nicotinate
11645019|NCT00152893|Placebo Comparator|Placebo|Identical looking placebo (di-calcium phosphate)
11645020|NCT00152867|Active Comparator|1|Dexamethasone
11645021|NCT00152867|Placebo Comparator|2|Placebo
11645022|NCT00152854|Active Comparator|A, 1, acetaminophen|acetaminophen
11645023|NCT00152854|Placebo Comparator|B placebo|placebo PO qid
11645024|NCT00152828|Experimental|Celecoxib|Celecoxib
11645025|NCT00152815|Experimental|Vitamin E|alpha-tocoperol, capsules, 2 per day
11645026|NCT00152776|Placebo Comparator|Group I|ovaria comp 10 Globuli 3 times per day 24 weeks - Placebo 12 weeks
11645027|NCT00152776|Placebo Comparator|Group II|Placebo 12 weeks - ovaria comp 10 globuli 3 times per day 24 weeks
11645028|NCT00152776|Placebo Comparator|Group III|ovaria comp 10 globuli 3 times per day 12 weeks - Placebo 12 weeks - ovaria comp 10 globuli 3 times per day 12 weeks
11645029|NCT00152763|Experimental|Cognitive Behavior Therapy - males|Eight telephone sessions of cognitive behavior therapy tailored to psychological adaptation to an ICD, plus a psycho-educational booklet for participants and a therapist manual. This arm included the males.
11645030|NCT00152763|Experimental|Cognitive Behavior Therapy - females|Eight telephone sessions of cognitive behavior therapy tailored to psychological adaptation to an ICD, plus a psycho-educational booklet for participants and a therapist manual. This arm included the females.
11645031|NCT00152763|Active Comparator|Usual Cardiac Care - Males|The UCC was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed. This arm was just for males randomized.
11645032|NCT00152763|Active Comparator|Usual Cardiac Care - females|The UCC was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed. This arm was for females randomized.
11645033|NCT00152698|Active Comparator|Irbesartan|
11645034|NCT00152698|Placebo Comparator|Placebo|
11645035|NCT00152633|Active Comparator|Losartan|Treatment with Losartan.
11645036|NCT00152633|Active Comparator|Betablocker|Treatment with Metoprolol.
11645037|NCT00152568|Experimental|Child Passenger Safety Technician services|
11645038|NCT00152542|Experimental|Inhaled nitric oxide|
11645039|NCT00152542|Placebo Comparator|Placebo|
11645040|NCT00152516|Experimental|Levetiracetam|
11645041|NCT00152477|Experimental|Carboplatin/Paclitaxel|Carboplatin and paclitaxel alone.
11645042|NCT00152477|Experimental|Carboplatin/Paclitaxel/CDP791 10mg|Carboplatin and paclitaxel plus CDP791 10mg/kg
11645043|NCT00152477|Experimental|Carboplatin/Paclitaxel/CDP791 20mg|Carboplatin and paclitaxel plus CDP791 20mg/kg
11645044|NCT00152464|Experimental|Levocetirizine (LCTZ)|0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.
11645045|NCT00152464|Placebo Comparator|Placebo (PBO)|Placebo was administered as oral drops twice daily.
11645046|NCT00152438|Experimental|1|Oral micronized progesterone
11645047|NCT00152438|Placebo Comparator|2|Placebo
11645048|NCT00152360|Experimental|Xenical (Orlistat)|Investigating the effectiveness of Xenical on cardiovascular risk factors in the patients of St. Paul's Hospital Lipid Clinic
11645049|NCT00152321|Experimental|A|Multifaceted intervention
11645050|NCT00152321|Active Comparator|B|Usual Care
11645051|NCT00152295|Experimental|1|
11645052|NCT00152282|Experimental|1|
11645053|NCT00152282|Experimental|2|
11645054|NCT00152282|Experimental|3|
11645055|NCT00152282|Placebo Comparator|4|
11645056|NCT00152269|Experimental|1|
11645057|NCT00152269|Experimental|2|
11645058|NCT00152269|Placebo Comparator|3|
11645059|NCT00152256|Experimental|1|
11645060|NCT00152256|Experimental|2|
11645061|NCT00152256|Placebo Comparator|3|
11645062|NCT00152243|Experimental|1|UFT (uracil, tegafur)
11645063|NCT00152243|Other|2|Surgery alone
11645064|NCT00152230|Experimental|1|UFT (uracil, tegafur)
11645065|NCT00152230|Other|2|Surgery alone
11645066|NCT00152217|Experimental|1|TS-1 (S-1)
11645067|NCT00152217|Other|2|Surgery alone
11645068|NCT00152204|Experimental|1|Doses of IPTi with SP delivered alongside doses 2 & 3 of DTP/HB vaccination and alongside measles vaccination
11645069|NCT00152204|No Intervention|2|
11645070|NCT00152191|Experimental|1|UFT (uracil, tegafur)
11645071|NCT00152191|Active Comparator|2|CMF(cyclophosphamide, methotrexate, and fluorouracil)
11645072|NCT00152178|Experimental|1|UFT (uracil, tegafur) and tamoxifen
11645073|NCT00152178|Active Comparator|2|CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen
11645074|NCT00152139|Other|1|
11645075|NCT00152126|Other|1|
11645076|NCT00152113|Other|1|
11645078|NCT00152009|Experimental|SPD503 (3 mg)|
11645079|NCT00152009|Experimental|SPD503 (4 mg)|
11645080|NCT00152009|Placebo Comparator|Placebo|
11645081|NCT00151996|Experimental|Methylphenidate + SPD503|
11645082|NCT00151996|Experimental|Amphetamine + SPD503|
11645083|NCT00151983|Active Comparator|Methylphenidate Transdermal System|Methylphenidate 27.5mg, 41.3mg, 55mg, and 82.5mg patches applied daily for 8 weeks
11645084|NCT00151983|Placebo Comparator|Placebo patch|Placebo patch applied daily for 8 weeks
11645085|NCT00151970|Active Comparator|Methylphenidate Transdermal System|The duration of MTS patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
11645086|NCT00151970|Placebo Comparator|Placebo|The duration of placebo patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
11645087|NCT00151970|Active Comparator|Concerta|CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
11645088|NCT00151957|Experimental|Methylphenidate transdermal system|MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
11645089|NCT00151892|Experimental|SPD476|Mesalazine
11645090|NCT00151892|Active Comparator|Asacol|
11645091|NCT00151827|Experimental|Olmesartan medoxomil|Olmesartan oral tablets 20 mg or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
11645092|NCT00151827|Experimental|Losartan|Losartan over encapsulated tablets 50 mg and 100 mg plus olmesartan placebo.
11645093|NCT00151814|Experimental|Olmesartan|Children less than 6 years old received 0.3 mg/kg. Children 6 years old or older received 40 mg, if they weighed 35 kg or more; 20 mg if they weighed less than 35 kg.
11645094|NCT00151775|Experimental|Period 2|"For Cohorts A and B, olmesartan medoxomil suspension 2.5 mg to 40 mg in patients 6-16 years old, depending on weight.
~For Cohort C, olmesartan medoxomil suspension 0.3 mg/kg to in patients 1-5 years old."
11645095|NCT00151775|Experimental|Period 3|Cohorts A, B, C - olmesartan medoxomil suspension or placebo taken once daily. Olmesartan medoxomil dose continued as in previous period.
11645096|NCT00151775|Experimental|Period 4|"Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg
~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg"
11645097|NCT00151736|Experimental|Chlorambucil|Regime A
11645098|NCT00151736|Experimental|R-etodolac with chlorambucil|Regime B
11645099|NCT00151671|Experimental|1|Perioperative Oral Nutritional Supplementation
11645100|NCT00151671|Placebo Comparator|2|Placebo of Perioperative Oral Nutritional Supplementation
11645101|NCT00151632|Experimental|MMF+FK|Low doses of tacrolimus in association with mycophenolate mofetil
11645102|NCT00151632|Active Comparator|FK|Full recommended doses of tacrolimus
11645103|NCT00151593|Experimental|1|Celsior preservation solution
11645104|NCT00151580|Experimental|1|Ribavirin maintenance treatment
11645105|NCT00151580|Placebo Comparator|2|
11645106|NCT00151567|Experimental|1|Tamsulosin
11645107|NCT00151567|Placebo Comparator|2|Placebo
11645108|NCT00151554|No Intervention|Control group|
11645109|NCT00151554|Experimental|Intervention group|
11645110|NCT00151515|Experimental|1|Topical 5% minoxidil foam formulation used twice daily
11645111|NCT00151476||Celecoxib - Routine Medical Care|800 mg total daily dosing
11645112|NCT00151476||Control Group - Routine Medical Care|Observation of subjects treated with routine medical care
11645113|NCT00151424|Experimental|1|asenapine 5-10mg BID
11645114|NCT00151424|Placebo Comparator|2|Placebo
11645115|NCT00151424|Active Comparator|3|olanzapine 10-20 mg QD
11645116|NCT00151411|Experimental|Metformin|Metformin
11645117|NCT00151411|Placebo Comparator|Placebo|Placebo
11645118|NCT00151398|Experimental|A|
11645119|NCT00151398|Experimental|B|
11645120|NCT00151398|Experimental|C|
11645121|NCT00151398|Active Comparator|D|
11645122|NCT00151372|Experimental|Treatment Adherence Intervention|In the Treatment Adherence Intervention group, a study therapist regularly meets with subjects in order to identify obstacles to depression and chronic obstructive pulmonary disease treatment adherence and to help the participant overcome those obstacles.
11645123|NCT00151372|Active Comparator|Enhanced Care|In the Enhanced Care group, physicians providing aftercare will be informed in writing of the patients' diagnosis but will receive no clinical instructions by the research team.
11645124|NCT00151346|Active Comparator|CSE|"Subjects assigned to this group will receive combined spinal-epidural (CSE) to relieve pain during labor. For CSE, subjects receive a small amount of a local anesthetic and a small amount of a narcotic pain killer directly into the spinal canal (a smaller amount than is given for traditional epidural), followed by a small amount of both of these medications that is continuously infused into the epidural space through a catheter that is left in place. CSE is not experimental."
11645125|NCT00151346|Active Comparator|Traditional Epidural|"Subjects assigned to this group will receive traditional epidural to relieve pain during labor. For the traditional epidural, subjects receive a small amount of a local anesthetic and a small amount of a narcotic pain killer into the epidural space, followed by a small amount of both of these medications that is continuously infused into the epidural space through a catheter that is left in place. The traditional epidural is not experimental."
11645126|NCT00151320|Experimental|Arm 1|"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles
~Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)
~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by a dose escalation schedule."
11645127|NCT00151281|Experimental|Study Treatment Arm|
11645128|NCT00151242|Active Comparator|1|
11645129|NCT00151242|Experimental|2|
11645130|NCT00151229|Active Comparator|strict control|systolic blood pressure control: less than 140 mm Hg
11645131|NCT00151229|Active Comparator|moderate control|systolic blood pressure control: 140 mm Hg to 149 mm Hg
11645132|NCT00151216|Experimental|Group A-Severe Stages of LINCL|"Group A will include n= 5 children with a total disability score of 0 to 4 (the severe forms of the disease; the staging based on a modification of the scale of Steinfeld et al.
~All subjects will receive 3x10^12 particle units of the AAV2CUhCLN2 vector."
11645255|NCT00149162|Active Comparator|1|Patients treated by Proleukin
11645133|NCT00151216|Experimental|Group B-Moderate Stages of LINCL|"Group B will include n=6 children with a total disability score of 5 to 6, a moderate stage of the disease.
~All subjects will receive 3x10^12 particle units of the AAV2CUhCLN2 vector."
11645134|NCT00151177|Experimental|A|treatment with three nights of CPAP ventilation starting the first night of admission
11645135|NCT00151177|No Intervention|B|usual Stroke Unit care
11645136|NCT00151125|Experimental|A|rhIL-11 (Interleukin-11, Neumega) 25 mcg/kg subcutaneously daily for 7 days
11645137|NCT00151125|Experimental|B|rhIL-11 (interleukin-11, Neumega) 50 mcg/kg subcutaneously daily for 7 days
11645138|NCT00151125|Experimental|C|rhIL-11 (Interleukin-11, Neumega) 10 mg/kg subcutaneously daily for 7 days
11645139|NCT00151112|Experimental|1|combination of lateral position and 20° Trendelenburg Position
11645140|NCT00151112|Active Comparator|2|standard positioning
11645141|NCT00151086|Experimental|Estramustine and Vinorelbine|Treatment will consist of 28-day cycles with estramustine at a dose of 140mg orally 3 times per day on days 1-3 and 8-10 and vinorelbine orally on days 2 and 9 beginning at dose 50mg/m^2.
11645142|NCT00151073|Experimental|Zoledronate Alone|Zoledronate is given alone for the first cycle. All subsequent cycles consist of Docetaxel (70mg/m^2) given on day 2, Estramustine (280mg) given orally three times per day on days 1-3, and Zoledronate (4mg) given intravenously on day 2.
11645143|NCT00151073|Experimental|Docetaxel and Estramustine|Docetaxel and Estramustine are given for the first cycle of therapy. All subsequent cycles consist of Docetaxel (70mg/m^2) given on day 2, Estramustine (280mg) given orally three times per day on days 1-3, and Zoledronate (4mg) given intravenously on day 2.
11645144|NCT00151060|Experimental|Estramustine, Etoposide and Paclitaxel|
11645145|NCT00151047|Experimental|Docetaxel and Capecitabine|
11645146|NCT00151034|Experimental|Herceptin|"Herceptin - 4mg/kg day 1 of cycle 1; 2mg/kg day 8 and 15 of cycle 1 and subsequent cycles.
~Paclitaxel - 200mg/m^2 on day 1 Carboplatin - AUC 5 on day 1 Gemcitabine - 800 mg/m^2 on day 1 and 8"
11645147|NCT00150995|Experimental|Tetrathiomolybdate|Patients will be started on a dose of 60mg Tetrathiomolybdate at bedtime and 40mg 3 times per day.
11645148|NCT00150969|Experimental|phyloquinone|5 mg Vitamin K1
11645149|NCT00150969|Placebo Comparator|placebo|
11645150|NCT00150878|Other|12 Gy/Cyclophosphamide|Standard intensity conditioning
11645151|NCT00150878|Experimental|8 Gy /Fludarabine|Reduced-intensity conditioning
11645152|NCT00150839|Active Comparator|1|Probands receive mirtazapine and venlafaxine
11645153|NCT00150839|Placebo Comparator|2|Patients receive mirtazapine and placebo
11645154|NCT00150826|Active Comparator|Quinapril|This arm will receive quinapril which will be started at 40mg daily and titrated to 80mg daily by the end of the first week. After treatment on the maximum tolerated dose for 16 weeks, patients will be reevaluated with coronary angiogram with coronary flow reserve measurements and assessment of angina using the Seattle Angina Questionnaire.
11645155|NCT00150826|Placebo Comparator|Placebo|This arm will receive placebo for 16 weeks and will be reevaluated with coronary angiogram with coronary flow reserve measurements and assessment of angina using the Seattle Angina Questionnaire.
11645156|NCT00150813|Experimental|Levetiracetam|Subjects received open-label Levetiracetam.
11645157|NCT00150800|Experimental|Brivaracetam|Brivaracetam used as adjunctive treatment, flexible dosing up to 200 mg /day in b.i.d (twice daily) administration. Dose increase or decrease can be made in increments of maximum 50 mg/day on a weekly basis.
11645158|NCT00150748|Experimental|Levetiracetam|Subjects received treatment up to 1764 days during the Evaluation Period. Up to 4000 mg/day (or 80 mg/kg/day for children and adolescents less than 50 kg). Oral tablets of 166, 250, or 500 mg Levetiracetam twice daily (b.i.d.).
11645159|NCT00150670|Experimental|1|TS-1 and cisplatin
11645160|NCT00150670|Active Comparator|2|TS-1
11645161|NCT00150644|Experimental|1|
11645162|NCT00150644|Experimental|2|
11645163|NCT00150644|Placebo Comparator|3|
11645164|NCT00150631|Placebo Comparator|active (candesartan)|12 mo treatment with candesartan
11645165|NCT00150631|Placebo Comparator|placebo|12 mo placebo treatment
11645166|NCT00150618|Experimental|SPD503 (Guanfacine HCl) (1 mg)|
11645167|NCT00150618|Experimental|SPD503 (2 mg)|
11645168|NCT00150618|Experimental|SPD503 (3 mg)|
11645169|NCT00150618|Experimental|SPD503 (4 mg)|
11645170|NCT00150618|Placebo Comparator|Placebo|
11645171|NCT00150592|Experimental|SPD503 (Guanfacine HCl)|
11645172|NCT00150592|Placebo Comparator|Placebo|
11645173|NCT00150488|Experimental|1|Uracyst®
11645174|NCT00150462|Experimental|CFZ 1.2 mg/m²|Participants received carfilzomib (CFZ) 1.2 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
11645175|NCT00150462|Experimental|CFZ 2.4 mg/m²|Participants received carfilzomib 2.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
11645176|NCT00150462|Experimental|CFZ 4.0 mg/m²|Participants received carfilzomib 4.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
11645177|NCT00150462|Experimental|CFZ 6.0 mg/m²|Participants received carfilzomib 6.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
11645178|NCT00150462|Experimental|CFZ 8.4 mg/m²|Participants received carfilzomib 8.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
11645179|NCT00150462|Experimental|CFZ 11.0 mg/m²|Participants received carfilzomib 11.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
11645180|NCT00150462|Experimental|CFZ 15.0 mg/m²|Participants received carfilzomib 115.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
11645181|NCT00150462|Experimental|CFZ 20.0 mg/m²|Participants received carfilzomib 20.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
11645182|NCT00150462|Experimental|CFZ 27.0 mg/m²|Participants received carfilzomib 27.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.
11645183|NCT00150462|Experimental|CFZ 20/27 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles.
11645184|NCT00150462|Experimental|CFZ 20/27 mg/m² + DEX|Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles. Participants also received 20 mg dexamethasone (DEX) administered before each dose of carfilzomib (i.e. 40 mg weekly).
11645185|NCT00150345|Experimental|Early treatment|Voriconazole starts within 18 hours of onset of fever intravenously with a loading dose of 6 mg/kg q12h for the first two doses followed by 4 mg/kg q12h (maintenance dose). Switched to oral treatment (200 mg BID) is possible after at least four days. Treatment will be ended if the patient is afebrile (< 38.0 °C) for 7 days with neutrophil counts < 500/µL, or if the patient is afebrile (< 38.0 °C) for 2 days with neutrophil counts > 500/µL.
11645186|NCT00150345|Other|Deferred treatment|"Treatment with voriconazole (for dosage see early treatment arm) is initiated only if a patient is persistently febrile on day 5 after the onset of fever despite antibiotic treatment."
11645187|NCT00150176|Experimental|asenapine|
11645188|NCT00150176|Placebo Comparator|placebo|
11645189|NCT00150124|Experimental|block-replacement therapy|BRT regimen until 3 months after 131I therapy
11645190|NCT00150124|Active Comparator|methimazole|methimazole stopped 8 days before 131I therapy
11645191|NCT00150098|Experimental|lifestyle counselling|Education
11645192|NCT00150072|Experimental|imatinib|
11645193|NCT00149994|Experimental|Cyclosporine A|Cyclosporine A was given in a twice-daily schedule at 12-hour intervals. It was administered within the first 4 hours post-operatively (study day 1), at an initial dose of 10-15mg/kg/day in two doses, as close as possible to 15mg/kg/day. After the first oral administration, the dose of Cyclosporine A was adjusted to bring the sample taken 2 hours after oral dose (C-2h) level into the target range by Days 3-5 post-transplantation. C-2h target ranges post-transplantation: 0-3 months: range of 800-1200 ng/ml with midpoint of 1000 ng/ml; 4-6 months: range of 700-900 ng/ml with midpoint of 800 ng/ml; > 6 months: range of 500-700 ng/ml with midpoint of 600 ng/ml is recommended. During the course of the study, the dose of Cyclosporine A was adjusted as necessary to achieve and maintain the C-2h blood Cyclosporine A (CsA) concentrations within the target ranges.
11645194|NCT00149994|Active Comparator|Tacrolimus|Tacrolimus was given on a twice-daily schedule at 12-hour intervals which had to be maintained throughout the study period. Tacrolimus was administered within the first 24 hrs postoperatively (Study Day 1) at an initial dose of 0.1-0.15 mg/kg/day in two divided oral doses either by mouth or via an enteral feeding tube until the patient can swallow. The initial dosing level was determined by the patient's overall post-operative condition. During the course of the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain the pre-dose blood concentration (C-0h) (trough) tacrolimus concentrations. C-0h target ranges post-transplantation: 0-3 months: 10-15 ng/ml; 4-6 months: 5-10 ng/ml; > 6 months: range of 5-10 ng/ml is recommended.
11645195|NCT00149968|Experimental|Myfortic|
11645196|NCT00149916|Experimental|Mycophenolate sodium (enteric coated)|
11645197|NCT00149890|Experimental|With Intraoperative Steroids|Intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was <35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab was administered as an intravenous bolus injection within 8 hours after reperfusion of the graft.
11645198|NCT00149890|Active Comparator|Without Intraoperative Steroids|No intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was <35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab and the first dose of steroids had to be administered within 8 hours after reperfusion of the graft and basiliximab was given as an intravenous bolus injection.
11645199|NCT00149838|Experimental|Active prefrontal rTMS phase1|Phase I participants receiving rTMS
11645200|NCT00149838|Placebo Comparator|Sham rTMS phase 1|Phase I participants receiving sham stimulation
11645201|NCT00149838|Experimental|rTMS extension|rTMS. Phase II participants, all of whom did not meet remission requirements after phase 1. They all receive active open label rTMS
11645202|NCT00149838|Experimental|Open label antidepressant regimen|All patients who met remission who were then transitioned to medications after the TMS trial was completed.
11645203|NCT00149825|Experimental|MED+CBTI|Escitalopram plus Cognitive Behavioral Therapy for Insomnia
11645204|NCT00149825|Active Comparator|MED+CTRL|Escitalopram plus Pseudo-desensitization Therapy for Insomnia
11645205|NCT00149812|Experimental|Intervention|"Intervention: Keeping Families Strong Cognitive Behavioral and Communication intervention with mothers recovering from depression and their children, 9 years and older."
11645206|NCT00149799|Experimental|Escitalopram|In Phase I, all participants received open-label escitalopram for 14 weeks (at a dosage of 10 mg/d in weeks 1-3, 20 mg/d weeks 4-6, and 30 mg/d thereafter). Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to continue with escitalopram for Phase II of the study (Weeks 16-40)
11645207|NCT00149799|Placebo Comparator|Placebo|Participants who responded to escitalopram in Phase I of the study (Weeks 1-14) were randomized to receive a placebo for Phase II of the study (Weeks 16-40)
11645208|NCT00149786|Experimental|1|Those adolescents receiving family based therapy
11645209|NCT00149786|Active Comparator|2|Those adolescents receiving individual therapy
11645210|NCT00149773|Experimental|Cognitive Therapy + Enriched Usual Care|"The cognitive therapy intervention consists of approximately 12 (1-hour) sessions over the course of a 4-month period. The main therapy components include:
~Using problem-solving and cognitive restructuring techniques to target hopelessness, reasons for living and dying, coping with loss, and perceived medical comorbidity that lead to suicidal ideation.
~Improving social resources.
~Improving adherence to medical regimen.
~Targeting Suicidal Cognitions."
11645256|NCT00149162|No Intervention|2|Without Proleukin
11645257|NCT00149110|Experimental|A|Sleep deprivation in combination with light and duloxetine
11645258|NCT00149110|Active Comparator|B|Exercise and duloxetine
11645259|NCT00149071|Active Comparator|A|rTMS
11645260|NCT00149071|Sham Comparator|B|sham rTMS
11645449|NCT00146107|Experimental|2|Weight loss
11645211|NCT00149773|No Intervention|EnrichedUsual Care Condition|"The Enriched Care (EC) condition will be used as the treatment comparison for this study. EC consists of usual care patients may obtain in the community as well as the assessment and referral services provided by the study case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health treatment in the community.
~The primary role of the study case manager is to establish a strong relationship with patients in order to retain the patients in the study for the duration of the study period."
11645212|NCT00149760|Active Comparator|Augmented Standard Medical Care|Participants will receive standard medical care augmented by a psychiatric consultation letter sent to the participants' primary care physician.
11645213|NCT00149760|Experimental|Cognitive-Affective Behavior Therapy|Participants will receive individually administered cognitive-affective behavior therapy as well as augmented standard medical care.
11645214|NCT00149747|Experimental|Exercise training|Group based exercise training. Two weekly classes including aerobic endurance physical activity and strength and flexibility training, and up to three home-based sessions of similar composition of aerobic endurance, strength and flexibility training.
11645215|NCT00149747|Placebo Comparator|2|Attention-control of exposure to study staff. Weekly general health education classes conducted in group sessions.
11645216|NCT00149734|Experimental|Ondansetron followed by placebo|Participants will take ondansetron then placebo plus an atypical antipsychotic drug
11645217|NCT00149734|Experimental|Placebo followed by Ondansetron|Participants will take placebo then ondansetron plus an atypical antipsychotic drug
11645218|NCT00149669|No Intervention|Work Plus Naltrexone Prescription|Participants were prescribed naltrexone, but were not be required to ingest it to work. Participants could work and earn money, independent of whether or not they continued to take naltrexone.
11645219|NCT00149669|Experimental|Work Plus Naltrexone Contingency|Participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose (employment-based reinforcement of naltrexone ingestion).
11645220|NCT00149656|Placebo Comparator|1|
11645221|NCT00149656|Experimental|2|Multivitamins
11645222|NCT00149656|Experimental|3|Multivitamins with Selenium
11645223|NCT00149656|Experimental|4|Selenium
11645224|NCT00149643|Active Comparator|Fluoxetine|Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
11645225|NCT00149643|Placebo Comparator|Placebo|Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.
11645226|NCT00149630|Experimental|Disulfiram, Methadone (w/lactose) & CBT|Participants are randomly assigned to receive a daily dose of 250 mg of disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving study medication at week 14, at which point they will undergo a 4-week methadone detoxification period.
11645227|NCT00149630|Active Comparator|Placebo, Methadone (w/lactose) & CBT|Participants are randomly assigned to receive a daily dose of a sugar pill to mimic the experimental drug disulfiram for 12 weeks, while concurrently receiving methadone treatment. All participants will stop receiving all medication at week 14, at which point they will undergo a 4-week methadone detoxification period.
11645228|NCT00149552|Active Comparator|Zinc gluconate|Zinc supplementation
11645229|NCT00149552|Placebo Comparator|Placebo|Placebo
11645230|NCT00149513|Experimental|1|Targeted nurse case management
11645231|NCT00149513|Active Comparator|2|Usual Care
11645232|NCT00149500|Experimental|Coaching group for lifestyle changes|Patients received monthly phone calls with coaching for lifestyle changes over 2 years.
11645233|NCT00149500|No Intervention|Routine pediatric care|This group receives routine care with their pediatrician.
11645234|NCT00149461|Experimental|Written Asthma Action Plan Group|Participants randomized to the written asthma action plan group received an asthma action plan form along with asthma education from their specialist physician.
11645235|NCT00149461|No Intervention|No Written Instructions Group|Participants randomized to the usual care group received no written instructions other than prescriptions from their specialist physician.
11645236|NCT00149422|Active Comparator|NT-proBNP guided treatment group|In this group, management was guided by an individually set NT-proBNP, defined by the lowest level at discharge or 2 weeks thereafter. If NT-proBNP levels were elevated above the individually set NT-proBNP interventions were performed according to the ESC heart failure guidelines.
11645237|NCT00149422|Placebo Comparator|Clinically guided arm|Heart failure treatment guided by clinical assessment.
11645238|NCT00149409|Placebo Comparator|Placebo|4 gelatine capsules/d
11645239|NCT00149409|Active Comparator|1g/d Omacor|
11645240|NCT00149409|Active Comparator|4g/d Omacor|
11645241|NCT00149396|Experimental|Safety and antitumor effects of NV1020|"Stage 1: Four escalating dose cohorts of NV1020 3x10^6 pfu, 1x10^7 pfu, 3x10^7 pfu, and 1x10^8 pfu administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy.
~Stage 2: Expansion of one dose cohort from Stage 1 of optimal NV1020 dose administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy."
11645242|NCT00149383|Placebo Comparator|2|
11645243|NCT00149383|Experimental|1|
11645244|NCT00149357||1, 2 ,3|Group 1 Women with unprovoked VTE and No Known Thrombophilia Group 2 Women who are investigated for VTE and are negative (Control) Group 3 Women with unprovoked VTE who have Thrombophilia
11645245|NCT00149318||Patients with Fabry disease|
11645246|NCT00149305||Patients with gouthy diathesis|
11645247|NCT00149305||Healthy subjects|
11645248|NCT00149227|Active Comparator|Non-ARB|'Non-ARB' was defined as Conventional anti-hypertensive treatment except for ARB and ACEIs
11645249|NCT00149227|Experimental|Valsartan|Valsartan add-on treatment
11645250|NCT00149214|Experimental|A: Pemetrexed Plus Doxorubicin, Followed by Docetaxel|
11645251|NCT00149214|Active Comparator|B: Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel|
11645252|NCT00149175||Neurodegenerative disorders with cognitive impairment|
11645253|NCT00149175||Control|
11645254|NCT00149175||At risk reactive|
11645261|NCT00148954|Active Comparator|Implantable Cardioverter Defibrillator - Boston Scientific|VITALITY 2 ICD
11645262|NCT00148954|Active Comparator|Implantable Cardioverter Defibrillator - Medtronic|Selected Medtronic family ICD
11645263|NCT00148941|Experimental|SB213503 lot 1 + M-M-R Group|"Subjects aged 4 to 6 years received a dose of lot 1 of SB213503 vaccine and a dose of M-M-R II vaccine.
~SB213503 was administered by deep intramuscular injection in the left deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid."
11645264|NCT00148941|Experimental|SB213503 lot 2 + M-M-R Group|"Subjects aged 4 to 6 years received a dose of lot 2 of SB213503 vaccine and a dose of M-M-R II vaccine.
~SB213503 was administered by deep intramuscular injection in the left deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid."
11645265|NCT00148941|Experimental|SB213503 lot 3 + M-M-R Group|"Subjects aged 4 to 6 years received a dose of lot 3 of SB213503 vaccine and a dose of M-M-R II vaccine.
~SB213503 was administered by deep intramuscular injection in the left deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid."
11645266|NCT00148941|Active Comparator|Infanrix + IPOL + M-M-R Group|Subjects aged 4 to 6 years received a dose of Infanrix and a dose of IPOL vaccines separately and a dose of M-M-R II vaccine. Infanrix was administered by deep intramuscular injection in the upper left deltoid. IPOL was administered subcutaneously in the lower right deltoid. M-M-R II was co-administered as a subcutaneous injection in the upper right deltoid.
11645267|NCT00148915|Experimental|Ibandronate|Participants will receive 150 milligrams (mg) ibandronate tablet orally once monthly for one year.
11645268|NCT00148915|Placebo Comparator|Placebo|Participants will receive ibandronate matched placebo tablet orally once monthly for one year.
11645269|NCT00148902|Experimental|All treated subjects|All subjects received Lapatinib in Combination with Docetaxel (Taxotere)
11645270|NCT00148889|Sham Comparator|2|Sham-stimulation
11645271|NCT00148889|Active Comparator|1|Active GPI-DBS
11645272|NCT00148876|Active Comparator|Capecitabine|Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression and discontinuation of Trastuzumab.
11645273|NCT00148876|Experimental|Capecitabine and Trastuzumab|Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression + Trastuzumab 6 mg/kg body weight every 3 weeks i.v. as a 90 min infusion until progression
11645274|NCT00148798|Experimental|Cetuximab plus chemotherapy|cetuximab + cisplatin + vinorelbine
11645275|NCT00148798|Active Comparator|Chemotherapy alone|cisplatin + vinorelbine alone
11645276|NCT00148759|Active Comparator|adult male subjects|LPV/r 800/200 mg once daily
11645277|NCT00148759|Experimental|Adult female subjects|LPV/r 800/200 mg once daily
11645278|NCT00148733|Experimental|Zinc|Zinc sulphate 10 or 20 mg (elemental zinc) per day. Intervention and placebo given perorally mixed with approximately 5 mL of breastmilk or clean water
11645279|NCT00148733|Placebo Comparator|Placebo|Placebo
11645280|NCT00148694|Experimental|Intervention single arm|Cisplatin 75mg/m2 q21 days x 4 pre-surgery
11645281|NCT00148681|Experimental|Lower Risk Regimen|
11645282|NCT00148681|Experimental|Higher Risk Regimen|
11645283|NCT00148668|Active Comparator|Arm 1|Herceptin/navelbine
11645284|NCT00148668|Active Comparator|Arm 2|Taxotere/carboplatin/herceptin
11645285|NCT00148642|Experimental|1|silver salts coated endotracheal tube
11645286|NCT00148642|Placebo Comparator|2|uncoated endotracheal tube
11645287|NCT00148616|Active Comparator|Memantine plus Risperidone|24 weeks memantine add on treatment to risperidone
11645288|NCT00148616|Placebo Comparator|Placebo plus Risperidone|24 weeks placebo add on treatment to risperidone
11645289|NCT00148590|Active Comparator|Memantine plus Risperidone|6 weeks 20 mg Memantine as add-on treatment to Risperidone
11645290|NCT00148590|Placebo Comparator|Placebo plus Risperidone|6 weeks 20 mg Placebo as add-on treatment to Risperidone
11645291|NCT00148564|Active Comparator|Olanzapine|
11645292|NCT00148564|Active Comparator|Zpirasidone|
11645293|NCT00148538|Active Comparator|1|resistance exercise
11645294|NCT00148538|Active Comparator|2|Aerobic and Resistance exercise
11645295|NCT00148525|Experimental|social cognitive theory|This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory and delivered by an automated telephone system.
11645296|NCT00148525|Experimental|Goal Systems Theory|This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory.
11645297|NCT00148525|No Intervention|Comparison group|comparison group
11645298|NCT00148369||Observational Group|Subjects previously administered GDNF and have discontinued the drug.
11645299|NCT00148356|Experimental|1|ZoMaxx™ Drug-Eluting Stent System
11645300|NCT00148356|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
11645301|NCT00148343|Experimental|ODFS|Odstock Dropped-Foot Stimulator (ODFS)
11645302|NCT00148343|Active Comparator|Standard of Care (inc. AFO)|Conventional Standard of Care (which may include a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) [Traditional Physical Therapy Treatment]
11645303|NCT00148317|Experimental|Treatment Arm|
11645304|NCT00148304||Group 1|
11645305|NCT00148278|Experimental|1|norepinephrine plus dobutamine
11645306|NCT00148278|Active Comparator|2|epinephrine
11645307|NCT00148239|Experimental|Caregiver Only|A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.
11645308|NCT00148239|Experimental|Dual Treatment|Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention
11645309|NCT00148239|Active Comparator|Control|Participants are provided with written materials at beginning of study; nothing thereafter
11645310|NCT00148174|Experimental|Phone calling|Phone calling to encourage improved adherence
11645311|NCT00148122|Experimental|Arm 1|Docetaxel (1000mg PO BID days 5-18 of each Cycle) and Capecitabine (30mg/m2/week IV days 1, 8, &15)
11645390|NCT00147056|Experimental|ExAblate transcranial system|MR Guided Focused Ultrasound
11645391|NCT00147043|Experimental|Autologous Stem Cells|
11645312|NCT00148109|Active Comparator|EGFR positive|The EGFR positive group will be conducted in a 2-stage minimax trial design to determine the rate of four-month progression free survival in this patient population treated with cetuximab
11645313|NCT00148109|Active Comparator|EGFR Negative|The EGFR negative group will help us explore the possibility of benefit of cetuximab in a patient whose tumor does not express or minimally expresses EGFR. If benefit in progression-free survival or in another surrogate such as tumor response or a molecular event is seen in this group it would provide rationale to study this group further in subsequent trials
11645314|NCT00148096|Placebo Comparator|1|Mechanical heat recovery ventilation units installed but not fully functional
11645315|NCT00148096|Active Comparator|2|Mechanical heat recovery ventilation unit installed and active
11645316|NCT00148031|Experimental|1|On-site (MMT Clinic) HCV evaluation and treatment
11645317|NCT00148031|Active Comparator|2|Off-site (GI Clinic) HCV evaluation and treatment
11645318|NCT00147992|Experimental|implants|
11645319|NCT00147979|Experimental|1|PTFE with bounded heparin
11645320|NCT00147979|Active Comparator|2|PTFE without bounded heparin
11645321|NCT00147966|Experimental|ritxumab|all patients get treatment
11645322|NCT00147914|Active Comparator|1|cefdinir
11645323|NCT00147914|Active Comparator|2|amoxicillin/clavulanate
11645324|NCT00147901|Experimental|FCCam|After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
11645325|NCT00147836|Active Comparator|CSII|Patients in continuous subcutaneous insulin infusion group received Human Insulin (Novolin-R, Novo Nordisk) with an insulin pump (H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland);
11645326|NCT00147836|Active Comparator|MDI|Patients in MDI group were treated with pre-meal Novolin-R, and Human Insulin NPH (Novolin-N, Novo Nordisk) at bedtime. Initial insulin doses were 0.4-0.5 IU/kg and total daily doses were divided into 50% of basal and 50% of bolus injection in CSII group and 30%-20%-20%-30% in multiple daily insulin injection group
11645327|NCT00147836|Active Comparator|OHA|In oral hpoglycemic agents group, the patients with 20 kg/m2<BMI≤25kg/m2 were initiated with Gliclazide (Diamicron, Servier) 80mg Bid (maximum to 160mg Bid), the patients with 25kg/m2<BMI≤35kg/m2 were initiated with Metformin (Glucophage, BMS) 0.5 Bid (maximum to 2.0g/d), the combination of Diamicron and Glucophage was used in patients who could not achieve glycaemic control goal with one OHA or with FPG≥11.1mmol/l at randomization
11645328|NCT00147823|Experimental|Vitoss with bone marrow aspirate|Addition of Vitoss to the bone marrow aspirate
11645329|NCT00147823|Active Comparator|Vitoss Alone|vitoss alone
11645330|NCT00147797||Pravastatin group|Patients in the pravastatin group were consecutively recruited in four department of infectious diseases if they fulfilled the following criteria : (1) HIV-infected treated with HAART for > 12 months 2) with dyslipidemia, defined as fasting serum LDL cholesterol > 160 mg/dL before initiation of pravastatin, (3) treated with pravastatin > 12 months and one more coronary risk factor.
11645331|NCT00147797||COotrol group|The patients in the control group were selected consecutively in the same departments among 1) HIV-infected patients treated with HAART > 12 months 2) fasting serum LDL cholesterol > 160 mg/dL 3) without lipid-lowering drugs and one more coronary risk factor. Cases and control patients were matched for age, gender and tobacco consumption.
11645332|NCT00147771|Experimental|1|
11645333|NCT00147745|Experimental|1|colesevelam 3.8g administered daily for 12 weeks
11645334|NCT00147745|Placebo Comparator|2|Colesevelam matching placebo for 12 weeks
11645335|NCT00147745|Active Comparator|3|open-label Insulin Glargine for 12 weeks
11645336|NCT00147732|Active Comparator|1|Accelerated radiotherapy
11645337|NCT00147732|Experimental|2|ARCON
11645338|NCT00147550|Experimental|1|
11645339|NCT00147537|Experimental|Phase 2 (Arms A & B)|CP-751,871 + paclitaxel + carboplatin
11645340|NCT00147537|Experimental|Phase 1b|"Phase 1b Dose Escalation /Expansion: CP-751,871 + paclitaxel + carboplatin
~Phase 1b Erlotinib Extension: CP-751,871 + paclitaxel + carboplatin + erlotinib"
11645341|NCT00147498|Experimental|5 mg BID|CP 690,550 5 mg BID
11645342|NCT00147498|Experimental|15 mg BID|CP 690,550 15 mg BID
11645343|NCT00147498|Experimental|30 mg BID|Oral tablets administered at a dose of 30 mg BID for 6 weeks
11645344|NCT00147498|Placebo Comparator|Placebo|Placebo
11645345|NCT00147485|Experimental|1|
11645346|NCT00147472|Other|PET|All patients receive PET scan and conventional CT imaging.
11645347|NCT00147459|Active Comparator|booster|no antibody and boosted
11645348|NCT00147446|Experimental|Individual Stress Management|Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
11645349|NCT00147446|Other|Wait List Control|Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
11645350|NCT00147381|Experimental|Campath-1H 20 mg|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 20 mg IV infusion over 3-6 hours.
~Day 1: Same protocol of Campath-1H and methylprednisolone as on Day 0.
~Day 2: No treatment
~Day 3: Initial dose of Tacrolimus 0,1 mg/kg/d (0,05 mg/kg/bid)
~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).
~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
11645392|NCT00147030|Active Comparator|cooled|Whole body mild induced hypothermia for 72 hours, starting by 6 hours of age, in addition to standard intensive care. After 72 hours of cooling, rewarming by a maximum of 0.5 degree C / hour to normothermia.
11645393|NCT00147030|No Intervention|non-cooled|Standard intensive care
11645351|NCT00147381|Active Comparator|Tacrolimus|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 30 mg IV infusion over 3-6 hours.
~Day 1: No treatment
~Day 2: Initial dose Tacrolimus 0.1 mg/kg/d (0.05 mg/kg.bid).
~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).
~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
11645352|NCT00147381|Experimental|Campath-1H 30 mg|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 30 mg IV infusion over 3-6 hours.
~Day 1: No treatment.
~Day 2: Initial dose Tacrolimus 0.1 mg/kg/d (0.05 mg/kg.bid).
~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).
~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
11645353|NCT00147355|Other|A|Ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
11645354|NCT00147355|Other|B|Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
11645355|NCT00147355|Other|D|metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
11645356|NCT00147355|Other|C|metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
11645357|NCT00147316|Experimental|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
11645358|NCT00147303|Experimental|group L|25mg sarpogrelate
11645359|NCT00147303|Experimental|group M|50mg sarpogrelate
11645360|NCT00147303|Experimental|group H|100mg sarpogrelate
11645361|NCT00147290|Experimental|BiV|ATP therapies are delivered in both the ventricles
11645362|NCT00147290|Active Comparator|RV|ATP delivered only in the right ventricle
11645363|NCT00147277|Active Comparator|8 pulses|8 pulses Anti-Tachycardia Pacing (ATP) delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)
11645364|NCT00147277|Experimental|15 pulses|15 pulses Anti-Tachycardia Pacing (ATP) delivered in the right ventricle to treat Fast Ventricular Tachycardia (FVT)
11645365|NCT00147238|Experimental|Ferumoxtran-10 MRI|MR lymphangiography using Ferumoxtran-10 contrast agent.
11645366|NCT00147238|Active Comparator|MRI|MR lymphangiography before injecting Ferumoxtran-10 contrast agent.
11645367|NCT00147225|Experimental|1 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 1 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.
~Chemotherapy :
~Carboplatin [area under the concentration curve (AUC) = 11]; or
~Adriamycin - Ifosfamide (AI) regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
~High dose Ifosfamide: 14 gm/m^2."
11645368|NCT00147225|Experimental|3 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 3 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.
~Chemotherapy :
~Carboplatin [area under the concentration curve (AUC) = 11]; or
~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
~High dose Ifosfamide: 14 gm/m^2."
11645369|NCT00147225|Experimental|10 mcg/kg AMG 531 Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 10 mcg/kg AMG 531 subcutaneously on day after chemotherapy and 2 days later (study cycle) of 21-28 day treatment cycle.
~Chemotherapy :
~Carboplatin [area under the concentration curve (AUC) = 11]; or
~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
~High dose Ifosfamide: 14 gm/m^2."
11645370|NCT00147225|Experimental|10 mcg/kg Pre/Post Chemotherapy|"Cycle 1, Chemotherapy (Control Cycle); Beginning Cycle 2, 10 mcg/kg AMG 531 subcutaneously on Day -5 (pre dose) and on day after chemotherapy (post dose) of 21-28 day treatment cycle.
~Chemotherapy :
~Carboplatin [area under the concentration curve (AUC) = 11]; or
~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
~High dose Ifosfamide: 14 gm/m^2."
11645371|NCT00147225|Experimental|5 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy|"Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 5 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses) of 21-28 day treatment cycle.
~Chemotherapy :
~Carboplatin [area under the concentration curve (AUC) = 11]; or
~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
~High dose Ifosfamide: 14 gm/m^2."
11645372|NCT00147225|Experimental|10 mcg/kg AMG 531 Pre/Pre/Post/Post Chemotherapy|"10 mcg/kg AMG 531 + Pre/Pre/Post/Post Chemotherapy Cycle 1, Chemotherapy alone (Control Cycle); Beginning Cycle 2, Chemotherapy followed by 10 mcg/kg AMG 531 for 2 doses on Days -5 and -3 (pre doses) and on day after chemotherapy and 2 days later (post doses) of 21-28 day treatment cycle.
~Chemotherapy :
~Carboplatin [area under the concentration curve (AUC) = 11]; or
~AI regimen [Adriamycin 75-90 mg/m^2 intravenous (IV), Ifosfamide 10-14 gm/m^2 IV]; or
~High dose Ifosfamide: 14 gm/m^2."
11645373|NCT00147212|Experimental|1|ET-743
11645374|NCT00147199|Experimental|Inhaled treprostinil|0.9 mg/mL treprostinil for inhalation supplied in 2.9mL ampoules for use in ultra sonic nebulizer
11645375|NCT00147199|Placebo Comparator|Placebo|Placebo inhalation solution for use in ultrasonic nebulizer
11645376|NCT00147134|Active Comparator|1|Procedure/Surgery: open colectomy
11645377|NCT00147134|Experimental|2|Procedure/Surgery: laparoscopic colectomy
11645378|NCT00147121|Active Comparator|1|Rituximab+Standard CHOP
11645379|NCT00147121|Experimental|2|Rituximab+bi-Weekly CHOP
11645380|NCT00147095||HEALTHY NON-SMOKER|Healthy non-smoker participants
11645381|NCT00147095||HEALTHY SMOKER|Healthy smoker participants
11645382|NCT00147095||COPD and smoking|Smoking participants with COPD
11645383|NCT00147082||COPD|Patients with COPD - no intervention
11645384|NCT00147082||Smokers without COPD|Smokers without COPD - no intervention
11645385|NCT00147082||Non-smokers|Non-smokers with no history of respiratory disease - no intervention
11645386|NCT00147069||Controls|Non-smoking control subjects without lung disease
11645387|NCT00147069||Asthmatics|Non-smokers patients with asthma
11645388|NCT00147069||Non-COPD smokers|Current smokers without airways obstruction, FEV1 >80% predicted
11645389|NCT00147069||COPD smokers|Patients with COPD and cigarette smokers
11645394|NCT00147017||Smokers|All subjects had a smoking history of >15 pack years
11645395|NCT00147017||Ex-smokers|Ex-smokers had ceased smoking for >6 months.
11645396|NCT00147017||Emphysema lung transplant|The emphysema subjects were all undergoing lung transplants.
11645397|NCT00147004|Experimental|1|hydrocortisone sodium succinate
11645398|NCT00147004|Placebo Comparator|2|Placebo
11645399|NCT00146900|Experimental|Prolonged Exposure (CBT)|Twelve 1.5 hours weekly sessions of Prolonged Exposure cognitive behavioral therapy
11645400|NCT00146900|Active Comparator|Cognitive Therapy|Twelve 1.5 hours weekly sessions of Cognitive Therapy without exposure to traumatic reminders.
11645401|NCT00146900|Experimental|SSRI (escitalopram)|Twenty milligrams daily of escitalopram (blinded capsules)
11645402|NCT00146900|Placebo Comparator|Placebo|Two concealed placebo pills resembling 10mg escitalopram tablets
11645403|NCT00146900|No Intervention|Waiting List|Twelve weeks of waiting list no intervention group
11645404|NCT00146848|Active Comparator|DDD-40|DDD-40 for this trial is the comparator arm. Even though patients are receiving a CRT-D device, atrial support pacing in this arm will be limited as the device will not pace unless the rate falls below 40 bpm.
11645405|NCT00146848|Active Comparator|DDDR-40|DDDR-40 programming will initiate atrial support pacing if the rate falls below 40 bpm or if atrial support is needed in response to increased activity.
11645406|NCT00146848|Active Comparator|DDD-70|Atrial support pacing in this arm will be delivered when the rate falls below 70 bpm.
11645407|NCT00146835||Cohort A|The primary study cohort includes all infants from SCKP who have begun their primary course of vaccine with PEDIARIX co-administered with Prevnar and for whom at least one dose of PEDIARIX was administered prior to the infant's 9-month birthday and safety follow-up information is available.
11645408|NCT00146835||Cohort B|This Historical cohort includes age-, gender- and area-matched infants who received at least one dose of DTaP vaccine co-administered with 7Pn between 1 January 2002 and 29 April 2003.
11645409|NCT00146835||Cohort C|"This delayed Pediarix use clinics cohort includes all infants who, during the enrollment period for Cohort A, begin their primary course of vaccination with a DTaP vaccine co-administered with 7Pn. It is age-, gender-, and area-matched in a similar manner to Cohort B."
11645410|NCT00146770|Active Comparator|Placebo/Aldurazyme|Patients received placebo for 26 weeks in the Double-Blind Study then received 182 weeks of Aldurazyme (0.58 mg/kg every week) in this Extension Study; patients received a total of 182 weeks of Aldurazyme.
11645411|NCT00146770|Active Comparator|Aldurazyme/Aldurazyme|Patients received 26 weeks of Aldurazyme in the Double-Blind Study and then received 182 weeks of Aldurazyme in this Extension Study; patients received a total of 208 weeks of Aldurazyme.
11645412|NCT00146757|Experimental|Aldurazyme (rhIDU) 100 U/kg ONLY every week|Patients received Aldurazyme (recombinant human alpha-L-iduronidase (rhIDU)) once per week at a dose of 100 Units/kg (approximately 0.58 mg/kg) for up to 52 weeks - labeled dose.
11645413|NCT00146757|Experimental|Aldurazyme (rhIDU) 100-200 U/kg every week|After receiving 100 Units/kg dose of Aldurazyme (rhIDU) for the first 25 weeks, patients enrolling after January 1, 2004 were eligible to receive an increased dose of 200 Units/kg from Week 26 onwards if the patient's urinary glycosaminoglycan (uGAG) levels were >200µg/mg creatinine at Week 22.
11645414|NCT00146679|Placebo Comparator|Usual Care (UC)|Usual Care provided by providers
11645415|NCT00146679|Active Comparator|Psychoeducational Telephone CounselingTC|Education and Counseling for ICD patients provided through Telephone Contact
11645416|NCT00146679|Active Comparator|Psychoeducation through Groups (SG)|Education and Counseling for ICD patients provided in a group setting with other ICD Patients
11645417|NCT00146653||Xa|An additional 20 patients will be enrolled to address the validation of heparin concentrations calculated by the Hepcon machine with laboratory-measured heparin concentrations. These patients will not be randomized and therefore will not receive an intervention. .
11645418|NCT00146640|Experimental|MR Prednisone|Participants will receive MR prednisone at bed time and placebo matching to IR prednisone in the morning. Total duration of double blind treatment will be 12 weeks.
11645419|NCT00146640|Active Comparator|IR Prednisone|Participants will receive IR prednisone in the morning and placebo matching to MR prednisone at bed time. Total duration of double blind treatment will be 12 weeks.
11645420|NCT00146575|Experimental|1|randomized patients get sirolimus stent
11645421|NCT00146575|Experimental|2|randomized patients get paclitaxel stent
11645422|NCT00146523|Experimental|mifepristone 600 mg|
11645423|NCT00146523|Placebo Comparator|matching placebo|
11645424|NCT00146471|Active Comparator|2|
11645425|NCT00146471|Placebo Comparator|1: Diazepam plus Placebo|
11645426|NCT00146328|Experimental|Group 1|Patients With Varying Degrees of Tipranavir Treatment Experience
11645427|NCT00146328|Experimental|Group 2|Highly Tipranavir Treatment Experienced Patients
11645428|NCT00146328|Experimental|Group 3|Tipranavir Treatment Naive Patients
11645429|NCT00146315|Active Comparator|Control|Secondary prevention program for coronary heart disease
11645430|NCT00146315|Experimental|Supervised exercise|
11645431|NCT00146263|Active Comparator|Savyon|Computerized cognitive training using the Savyon software
11645432|NCT00146263|Placebo Comparator|Control|Usual activity
11645433|NCT00146250|Experimental|Nitrous oxide|Nitrous oxide 70% as balance gas in inspired mixture
11645434|NCT00146250|Experimental|Nitrogen|Nitrogen instead of nitrous oxide 70% as balance gas in inspired mixture
11645435|NCT00146224|Active Comparator|Epoetin alfa RB|
11645436|NCT00146224|Experimental|Epoetin alfa DT|
11645437|NCT00146172|Experimental|Neratinib 40 mg|
11645438|NCT00146172|Experimental|Neratinib 80 mg|
11645439|NCT00146172|Experimental|Neratinib 120 mg|
11645440|NCT00146172|Experimental|Neratinib 180 mg|
11645441|NCT00146172|Experimental|Neratinib 240 mg|
11645442|NCT00146172|Experimental|Neratinib 320 mg|
11645443|NCT00146172|Experimental|Neratinib 400 mg|
11645444|NCT00146172|Experimental|Neratinib 320 mg MTD|
11645445|NCT00146159|Experimental|1|1st group: 12 mg Mitoxantrone/m²
11645446|NCT00146159|Experimental|2|2nd group: 9mg Mitoxantrone/m²
11645447|NCT00146159|Experimental|3|3rd group: 5mg Mitoxantrone/m²
11645448|NCT00146107|No Intervention|1|
11645451|NCT00146107|Experimental|4|Weight loss and exercise
11645452|NCT00146081|Experimental|A|Family Program: Participants who have identified at least 1 family member or friend to enroll in SHARE with them, who are randomly assigned to program A, are invited to bring their enrolled family member or friend (co-participant) with them to the study intervention group sessions as their supportive team member.
11645453|NCT00146081|Active Comparator|B|Coach Program: Participants who identify 1 or 2 family members or friends to enroll in SHARE with them, who are randomly assigned to program B, are invited to attend the study intervention group sessions without their enrolled family or friend (co-participants). The co-participants receive the same written materials, but act as supportive team members outside of the group sessions only. They are invited to attend special field workshops and personal counseling sessions with their co-participants.
11645454|NCT00146081|Experimental|C|Team Program: Participants who do not identify 1 or 2 family or friend co-participants, and are randomly assigned to program C, are paired with other unrelated enrollees in their group sessions as supportive team members.
11645455|NCT00146081|Active Comparator|D|Individual Program: Participants who do not identify 1 or 2 family members or friends to enroll in SHARE with them, and are randomly assigned to program D, attend group sessions as individuals.
11645456|NCT00145977|Experimental|Experimental|All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal. This group will also receive alendronate 70 mg once weekly, according to standard recommendations.
11645457|NCT00145977|Active Comparator|Control|All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal.
11645458|NCT00145951||1|
11645459|NCT00145951||2|
11645460|NCT00145951||3|
11645461|NCT00145925|Placebo Comparator|Blood pressure|Perindopril indapamide vs placebo
11645462|NCT00145925|Other|Glucose control|Standard versus intensive glucose control
11645463|NCT00145912|Experimental|Intrinsic Motivation|PCP motivational interview + Internet program
11645464|NCT00145912|Active Comparator|Extrinsic Motivation|PCP breif advice + Internet Program
11645465|NCT00145886|Experimental|rhPTH|Subjects will be treated rhPTH for 12 months
11645466|NCT00145847|Active Comparator|Naltrexone|Naltrexone 50 mg per day, directly administered as 100 mg on Mondays, 100 mg on Wednesdays and 150 mg on Fridays
11645467|NCT00145847|Placebo Comparator|Lactose pill|
11645468|NCT00145795|Experimental|Kaletra + Current Dual NRTI Backbone|Patients in this arm received Kaletra in addition to their current Dual NRTI Backbone.
11645469|NCT00145795|Active Comparator|Current Regimen|Patients in this study arm continued their current regimen.
11645470|NCT00145769|Active Comparator|Short Course Radiotherapy|Short Course (SC) pre-operative radiotherapy, followed by surgery and adjuvant chemotherapy
11645471|NCT00145769|Active Comparator|Long Course Radiotherapy|Long Course (LC) radiotherapy delivered with concurrent chemotherapy, followed by surgery and adjuvant chemotherapy
11645472|NCT00145769|Active Comparator|Surgery|Patients will receive initial surgery followed by post-operative management according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Adjuvant therapy for rectal cancer.
11645473|NCT00145743|Experimental|1|Patient's reported questionaire, profile in 10 dimensions (EORTC) and referees' report with treatment recommendations
11645474|NCT00145743|Experimental|2|Patient's reported questionaire; no recommendations given
11645475|NCT00145704|Active Comparator|Growth Hormone only|No bisphosphonate therapy given, participants will take Vitamin D 400 IU daily for 18 months, as well as calcium carbonate 500 mg twice a day for 18 months.
11645476|NCT00145704|Experimental|Growth Hormone & Bisphosphonate Therapy|Bisphosphonate Therapy-Risedronate 35 mg once a week for 18 months, Vitamin D 400 IU daily for 18 months and calcium carbonate 500 mg twice daily for 18 months
11645477|NCT00145678|Experimental|dynamic deconstructive psychotherapy|weekly individual psychotherapy of 50 minute duration lasting 12-18 months
11645478|NCT00145678|Active Comparator|optimized community care|eclectic weekly individual and group psychotherapy, as well as drug and alcohol rehabilitation
11645479|NCT00145639|Other|1|
11645480|NCT00145626|Experimental|Study Participants|"Participants who meet the eligibility criteria for this study. Donor cells will be obtained using the Miltenyi Biotec CliniMACS device.
~Interventions: Chemotherapy and antibodies, allogeneic stem cell transplantation."
11645481|NCT00145613|Other|1|
11645482|NCT00145600|Experimental|Unfavorable Risk, Group 2|Unfavorable risk, group 2 arm in patients with Hodgkin's disease (n=146)
11645483|NCT00145600|Experimental|Favorable Risk|Favorable Risk arm in patients with Hodgkin's Disease (n=91).
11645484|NCT00145600|Experimental|Intermediate Risk|Intermediate Arm in patients with Hodgkins's disease (n=46).
11645485|NCT00145600|Experimental|Unfavorable Risk, Group 1|Unfavorable risk group 1 closed early due to excessive number of adverse events (n=13).
11645486|NCT00145587|Other|1|
11645487|NCT00145574|Experimental|high dose colesevelam|colesevelam HCl 3.750 g
11645488|NCT00145574|Experimental|Low dose colesevelam|Low dose colesevelam 1.875 g
11645489|NCT00145574|Placebo Comparator|placebo|placebo comparator
11645490|NCT00145535|Experimental|1|Titanium sapphire laser treatment
11645491|NCT00145535|Active Comparator|2|Argon laser treatment
11645492|NCT00145522|Experimental|1|
11645493|NCT00145522|Active Comparator|2|
11645494|NCT00145509|Active Comparator|Asenapine|Asenapine
11645495|NCT00145509|Placebo Comparator|Placebo|Placebo
11645496|NCT00145496|Experimental|asenapine|
11645497|NCT00145496|Active Comparator|olanzapine|
11645498|NCT00145470|Experimental|Asenapine|Participants received asenapine as a fast-dissolving sublingual (SL) tablet, given twice daily (BID). On Day 1, participants received asenapine 5 mg, BID. On Days 2 to 84, asenapine was dosed flexibly: BID at either 5 or 10 mg. Asenapine doses were up- or down-titrated based on efficacy, safety, and tolerability.
11645499|NCT00145470|Placebo Comparator|Placebo|Participants received placebo on Days 1-84 as a fast-dissolving SL tablet, BID.
11645562|NCT00144027|No Intervention|Control|The control group will receive treatment as usual; meaning patients in the control group will not receive the medication adherence intervention.
11645892|NCT00138008|Active Comparator|1|Drug: endocrine therapy
11645500|NCT00145418|Experimental|1|Oxaliplatin + Docetaxel as first line therapy of Stage IV or IIIB unresectable non-small cell lung cancer. The primary objective of the trial is to determine the response rate by RECIST criteria to the combination of oxaliplatin and docetaxel in patients with previously untreated NSCLC.
11645501|NCT00145379|Experimental|Metformin|
11645502|NCT00145379|Placebo Comparator|Placebo comparator|
11645503|NCT00145327|Experimental|Zoledronic Acid 6|Patients who received Zoledronic acid for 3 years in the core study (CZOL446H2301; NCT00049829) received a single intravenous infusion of 5 mg Zoledronic acid once a year for 3 years (at Months 36, 48 and 60) in this extension study for a total of 6 years of treatment.
11645504|NCT00145327|Placebo Comparator|Zoledronic Acid 3 Placebo 3|Patients who were treated with Zoledronic acid for 3 years in the core study received a single intravenous matching Placebo infusion once a year for 3 years in this extension study.
11645505|NCT00145327|Experimental|Placebo 3 Zoledronic Acid 3|Patients who were treated with placebo for 3 years in the core study received 5 mg Zoledronic acid in a single intravenous infusion once a year for 3 years (at Months 36, 48 and 60) in this extension study.
11645506|NCT00145314|Active Comparator|A|FLOX: 5-fluorouracil/folinic acid/oxaliplatin; Nordic Regimen; given continuosly
11645507|NCT00145314|Experimental|B|FLOX: 5-fluorouracil/folinic acid/oxaliplatin and cetuximab
11645508|NCT00145314|Experimental|C|FLOX given intermittently and maintenance cetuximab
11645509|NCT00145249|Active Comparator|Standard Therapy|Amphotericin B 0.7 mg/kg for 14 day followed by fluconazole 400 mg daily for 8 weeks. For subjects in the standard therapy arm whose Amphotericin B dose is continued beyond 14 days, fluconazole initiation will be delayed.
11645510|NCT00145249|Experimental|Fluconazole Low Dose|Amphotericin B 0.7 mg/kg and the randomized dose of fluconazole at 400 mg/day for the first 14 days, then the randomized dose of fluconazole at 400 mg/day respectively for an additional 8 weeks.
11645511|NCT00145249|Experimental|Fluconazole High Dose|Amphotericin B 0.7 mg/kg and the randomized dose of fluconazole at 800 mg/day for the first 14 days, then the randomized dose of fluconazole at 800 mg/day respectively for an additional 8 weeks.
11645512|NCT00145197|Experimental|Improving the Delivery of Effective Care to Minorities|
11645513|NCT00145184|Placebo Comparator|Placebo|Placebo
11645514|NCT00145184|Experimental|Multivitamins|Multivitamin supplement containing the following vitamins: B1, B2, Niacin, B6, Folate, B12, C, and E
11645515|NCT00145041|Experimental|VSLI|Single armed study; all subjects received VSLI
11645516|NCT00144989|Active Comparator|1|Etoposide and cisplatin after chemoradiotherapy
11645517|NCT00144989|Experimental|2|Irinotecan and cisplatin after chemoradiotherapy
11645518|NCT00144963|Experimental|VSLI|Vincristine Sulfate Liposomes Injection (VSLI)
11645519|NCT00144911|Experimental|Arm 1|
11645520|NCT00144898|Experimental|Sentinel Node Resection|Sentinel Node Resection
11645521|NCT00144898|Other|Conventional Axillary Dissection|Conventional Axillary Dissection
11645522|NCT00144885|No Intervention|1|
11645523|NCT00144872|Experimental|Subjects receiving lamotrigine|Eligible subjects will receive chewable dispersible tablets of lamotrigine with a starting dose of 0.3 milligrams per kilogram administered orally.
11645524|NCT00144846|Other|Arm 1|
11645525|NCT00144807|Experimental|R-AC|rituximab + doxorubicin + cyclophosphamide + autologous stem cell transplantation
11645526|NCT00144781|Active Comparator|1|0.58 mg Aldurazyme/kg of body weight (100 U/kg) administered every week (labeled dose). Final Visit is Week 27 for patients randomized to every week regimen.
11645527|NCT00144781|Active Comparator|2|1.2 mg Aldurazyme/kg of body weight (200 U/kg) administered every week. Final Visit is Week 27 for patients randomized to every week regimen.
11645528|NCT00144781|Active Comparator|3|1.2 mg Aldurazyme/kg of body weight (200 U/kg) administered every 2 weeks. Final Visit is Week 26 for patients randomized to every 2 week regimen.
11645529|NCT00144781|Active Comparator|4|1.8 mg Aldurazyme/kg of body weight (300 U/kg) administered every 2 weeks. Final Visit is Week 26 for patients randomized to every 2 week regimen.
11645530|NCT00144755|Active Comparator|R-CHOP21|8 cycles of R-CHOP21
11645531|NCT00144755|Experimental|R-CHOP21, Darbepoetin alfa|8 cycles of R-CHOP21 + prophylactic darbepoetin alfa
11645532|NCT00144755|Experimental|R-CHOP14|8 cycles of R-CHOP14
11645533|NCT00144755|Experimental|R-CHOP14, Darbepoetin alfa|8 cycles of R-CHOP14 + prophylactic darbepoetin alfa
11645534|NCT00144664|Experimental|1|MRA(Tocilizumab)
11645535|NCT00144651|Experimental|1|
11645536|NCT00144625|Experimental|1|
11645537|NCT00144612|Experimental|1|
11645538|NCT00144599|Experimental|1|
11645539|NCT00144599|Placebo Comparator|2|
11645540|NCT00144586|Experimental|1|
11645541|NCT00144547|Experimental|1|
11645542|NCT00144534|Experimental|1|
11645543|NCT00144521|Experimental|1|
11645544|NCT00144521|Active Comparator|2|
11645545|NCT00144508|Experimental|1|
11645546|NCT00144508|Other|2|continue current treatment
11645547|NCT00144495|Experimental|1|patient whose ΔHb is less than 1.0g/dL on the day of 7th administration
11645548|NCT00144495|Experimental|2|patient whose ΔHb is 1.0g/dL or above on the day of 7th administration
11645549|NCT00144482|Experimental|1|
11645550|NCT00144482|Placebo Comparator|2|
11645551|NCT00144456|Experimental|1|
11645552|NCT00144456|Active Comparator|2|
11645553|NCT00144417|Active Comparator|HRZE|isoniazid, rifampin, pyrazinamide, ethambutol, moxifloxacin-placebo
11645554|NCT00144417|Experimental|MRZE|moxifloxacin, rifampin, pyrazinamide, ethambutol, isoniazid-placebo
11645555|NCT00144391|Experimental|Transdermal Testosterone Gel|Transdermal Testosterone Gel (2 mg per pump), 2 pumps per day for 6 months
11645556|NCT00144391|Placebo Comparator|Placebo|Placebo 2 pumps per day for 6 months
11645557|NCT00144300|Active Comparator|Mirapex|Mirapex tablets three times daily (TID) dosing according to manufacturer's guidelines
11645558|NCT00144300|Active Comparator|Requip|Requip tablets three times daily (TID) dosing according to manufacturer's guidelines
11645559|NCT00144170|Other|Tipranavir(TPV)/low dose ritonavir(r)|
11645560|NCT00144170|Other|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
11645561|NCT00144040|Other|Arm 1|
11645563|NCT00144027|Experimental|Antipsychotic adherence intervention|Antipsychotic Medication Adherence Intervention which included the Barriers, Facilitators, and Motivators Checklist summary and Adherence tips provided in hard copy to patient and electronic copy to mental health provider.
11645564|NCT00144014|Experimental|V10153, 1.0 mg/kg|Single acute intravenous bolus dose
11645565|NCT00144014|Experimental|V10153, 2.5 mg/kg|Single acute intravenous bolus dose
11645566|NCT00144014|Experimental|V10153, 5.0 mg/kg|Single acute intravenous bolus dose
11645567|NCT00144014|Experimental|V10153, 7.5 mg/kg|Single acute intravenous bolus dose
11645568|NCT00144014|Experimental|V10153, 10 mg/kg|Single acute intravenous bolus dose
11645569|NCT00144001||Group 1|
11645570|NCT00143988||Treadmill Test exertion females|
11645571|NCT00143988||Treadmill test exertion males|
11645572|NCT00143988||Sexual activity exertion females|
11645573|NCT00143988||Sexual activity exertion males|
11645574|NCT00143936|Active Comparator|Low Carb|Low Cabohydrate Diet: 20 week of weekly group behavior modification, 20 weekly bi-weekly, bi-monthly to finish
11645575|NCT00143936|Active Comparator|Low Calorie|Low Calorie Diet: 20 weeks of weekly behavior modification, 20 weekly of bi-weekly, bimonthly to finish 2 years
11645576|NCT00143923|Active Comparator|1|Intervention: 6 months of individualized advice regarding Nutrition, Exercise, Stress Management Counseling for participants who are at intermediate or high Framingham risk for CVD and are randomized to Arm 1
11645577|NCT00143923|Placebo Comparator|2|Intervenition: 6 months of Usual care for participants who are at intermediate or high Framingham risk for CVD and are randomized to Arm 2. No active Nutrition, Exercise, Stress Management Counseling
11645578|NCT00143923|No Intervention|3|No intervention for all participants who are at low Framingham risk for CVD or have preexisting CVD prior to study entry/ No active Nutrition, Exercise, Stress Management Counseling
11645579|NCT00143910||Renal transplant recipient|Recipients of successful renal transplant
11645580|NCT00143845|Experimental|Immunosuppression Taper|Reduced intensity conditioning consisting of Busulfan and Fludarabine(fludarabine 150 mg/m2 IV, busulfan 6 mg/kg IV, total lymphoid irradiation 2 Gy), followed by a rapid immunosuppressive taper of Tacrolimus (0.06 mg/kg q12h, PO, Days -7 to +28), Methotrexate (5 mg/m2, IV, Days +1, +3, +6, +11) and Mycophenolate Mofetil (10 mg/kg every 8 hours, PO, Days -6 to +7).
11645581|NCT00143819|Active Comparator|1|bilateral comparison
11645582|NCT00143819|Placebo Comparator|2|bilateral comparison
11645583|NCT00143741|Other|Lipitor|
11645584|NCT00143715|Experimental|1|Low dose oral vitamin K + warfarin cessation
11645585|NCT00143715|Placebo Comparator|2|
11645586|NCT00143689|Experimental|Lopinavir/ritonavir, Zidovudine, Lamivudine|"Participants will be randomly assigned to receive one of the following drug combinations:
~lopinavir/ritonavir (Kaletra) and nevirapine (Viramune) twice a day;
~Combivir (Zidovudine (AZT) plus lamivudine (3TC)) and nevirapine twice a day;
~Combivir and lopinavir/ritonavir twice a day."
11645587|NCT00143676|Experimental|Lapaquistat Acetate 50 mg QD + Atorvastatin|
11645588|NCT00143676|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin|
11645589|NCT00143676|Active Comparator|Atorvastatin|
11645590|NCT00143663|Experimental|Lapaquistat Acetate 100 mg QD|
11645591|NCT00143663|Placebo Comparator|Placebo QD|
11645592|NCT00143637|Experimental|2|Office dust with added glucan
11645593|NCT00143637|Experimental|1|Clean air exposures in climate chamber
11645594|NCT00143624|Experimental|1|The first group will receive 8 mg of the study drug (rosiglitazone).
11645595|NCT00143624|Placebo Comparator|2|The second group will be given a placebo.
11645596|NCT00143611|Experimental|Resatorvid 1.2 mg/kg/day|
11645597|NCT00143611|Experimental|Resatorvid 2.4 mg/kg/day|
11645598|NCT00143611|Placebo Comparator|Placebo|
11645599|NCT00143598|Active Comparator|Active ECS|Active Elastic Compression Stockings (ECS) 30-40 mm Hg compression at the ankle.
11645600|NCT00143598|Placebo Comparator|Placebo ECS|Placebo stockings with identical appearance to Active ECS and with < 5 mm Hg compression at the ankle.
11645601|NCT00143572|Other|1|
11645602|NCT00143559|Other|1|
11645603|NCT00143533|Other|1|
11645604|NCT00143507|Experimental|Ivabradine|
11645605|NCT00143507|Placebo Comparator|Placebo|
11645606|NCT00143494|Experimental|1|Critically hill, mechanically ventilated patients
11645607|NCT00143468|Experimental|1|ALI/ARDS patients and healthy subjects
11645608|NCT00143455|Experimental|B|
11645609|NCT00143455|Experimental|A|
11645610|NCT00143403|Experimental|1|
11645611|NCT00143403|Active Comparator|2|
11645612|NCT00143390|Experimental|1|
11645613|NCT00143390|Experimental|2|
11645614|NCT00143312|Experimental|1|
11645615|NCT00143273|Experimental|Lasofoxifene Dose 1|0.05 mg
11645616|NCT00143273|Experimental|Lasofoxifene Dose 2|0.25 mg
11645617|NCT00143273|Experimental|Lasofoxifene Dose 3|0.5 mg
11645618|NCT00143273|Placebo Comparator|Placebo|0 mg
11645619|NCT00143247|Experimental|Exubera® (inhaled insulin)|Open label, no comparator
11645620|NCT00143182|Experimental|1|Asenapine
11645621|NCT00143182|Active Comparator|2|Olanzapine
11645622|NCT00143130|Experimental|Single Arm|
11645623|NCT00143039||NIH/SSIUGR fetuses|Group 1 includes pregnancies complicated by a fetus with either Non-Immune Hydrops or Severe Symmetrical IUGR.
11645624|NCT00143039||Control-Normal fetus|Group 2 includes all normally appearing fetuses on U/S who will be having a diagnostic amniocentesis as part of their routine care.
11645625|NCT00142961|Experimental|1|Atomoxetine prescribed daily
11645626|NCT00142961|Placebo Comparator|2|placebo controlled arm
11645627|NCT00142948|Experimental|Naltrexone|Naltrexone Oral 50 mgs daily
11645628|NCT00142948|Placebo Comparator|Placebo|1 to 1 comparison of Naltrexone to placebo
11645671|NCT00142584|Active Comparator|2-MET|Metoprolol
11645703|NCT00142168|Experimental|CC-5103 (Lenalidomide) and Rituximab|Intended therapy consisted of 48 weeks of CC-5103 (lenalidomide)(25 mg/d for 3 weeks and then 1 week off) along with rituximab (375 mg/m(2)/wk) dosed on weeks 2 to 5 and 13 to 16.
11645629|NCT00142935|Experimental|Pre-Release Initiation MMT|Participants assigned to this arm will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
11645630|NCT00142935|Experimental|Post Release Initiation of MMT|Participants assigned to this arm will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
11645631|NCT00142935|Active Comparator|Standard of Care Plus|Participants assigned to this arem will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
11645632|NCT00142922|Experimental|1|Attended Breaking Down Barriers program
11645633|NCT00142922|Active Comparator|2|Attention control group
11645634|NCT00142922|Active Comparator|3|Indivdual attention control group
11645635|NCT00142909|Experimental|Drug: Lofexidine|"Lofexidine: Study medication
~Participants will receive daily lofexidine and the dosing will be initiated at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject."
11645636|NCT00142909|Placebo Comparator|Drug: Placebo|"Placebo pill.
~Participants will receive daily placebo and will follow the same scheduled delivery as those in the intervention for 12 weeks."
11645637|NCT00142883|Active Comparator|pregabalin|pregabalin compared to placebo
11645638|NCT00142883|Placebo Comparator|Placebo|Placebo compared to pregabalin
11645639|NCT00142870|Placebo Comparator|A|
11645640|NCT00142844|Experimental|Naltrexone|Naltrexone
11645641|NCT00142844|Experimental|Disulfiram|Disulfiram
11645642|NCT00142844|Experimental|Naltrexone and Disulfiram|Naltrexone and Disulfiram
11645643|NCT00142844|Placebo Comparator|Placebo|Placebo
11645644|NCT00142831|Experimental|1|Bupropion-SR, 150 mg/day x 3 days, then 300 mg/day for 13 weeks
11645645|NCT00142831|Placebo Comparator|2|Identical Placebo
11645646|NCT00142818|Experimental|Naltrexone plus modafinil|Nal + Mod
11645647|NCT00142818|Experimental|Naltrexone|Nal
11645648|NCT00142818|Experimental|Modafinil|Mod
11645649|NCT00142818|Placebo Comparator|Placebo|Placebo
11645650|NCT00142805|Active Comparator|AC-1202|Tricaprilin formulation, once daily. Administered orally
11645651|NCT00142805|Placebo Comparator|Matching Placebo to AC-1202|Placebo formulation, once daily. Administered orally
11645652|NCT00142792|Active Comparator|A. Cyclic stim|"Preprogrammed cycles of finger and thumb flexor and extensor stimulation (and flexor stimulation if deemed necessary by the PI) repeatedly and automatically close and open the hand without any effort or voluntary intent required by the subject.
~Subject instructed to relax, not attempt to assist the stimulation, and not to move the contralateral arm/hand during stimulation
~Uses NMES device with EMG-triggered and Cyclic capabilities"
11645653|NCT00142792|Active Comparator|B. Sensory stim|"Sensory-only electrical stimulation. The stimulation will be cyclic in nature but intensity will be set to a level that can be felt by the patient but not sufficient to cause muscle contraction.
~Uses NMES device with EMG-triggered and Cyclic capabilities"
11645654|NCT00142792|Active Comparator|C. EMG-Triggered|"EMG-Triggered electrical stimulation. Subjects in this group will attempt to extend their affected wrist and fingers in response to an audio cue. They will be rewarded with stimulation to cause full hand opening once they have generated EMG sufficient to reach a preset threshold level.
~Uses NMES device with EMG-triggered and Cyclic capabilities"
11645655|NCT00142753|Active Comparator|A1: ATN 024 Energix-B Standard Adult Dose|
11645656|NCT00142753|Experimental|A2: ATN 024 Engerix-B Increased Adult Dose|
11645657|NCT00142753|Active Comparator|A3: ATN 024 Twinrix Standard Adult Dose|
11645658|NCT00142753|Experimental|B1: ATN 025 Recombivax|
11645659|NCT00142753|Experimental|B2: ATN 025 Twinrix|
11645660|NCT00142740||1 - HIV Positive|Participant in parent study ATN 024, aged 12-24 years, testing HIV positive. All eligible youths must be negative for HBV core antibody, HBV surface antigen, and HBV surface antibody at the time of enrollment in to ATN 024.
11645661|NCT00142740||2 - HIV Negative|Participant in parent study ATN 025, aged 12-24 years and testing negative for HIV infection. All eligible youths must be negative for HBV core antibody, HBV surface antigen, and HBV surface antibody at the time of enrollment in to ATN 025.
11645662|NCT00142688|Experimental|1|Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
11645663|NCT00142688|Active Comparator|2|Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
11645664|NCT00142623|Experimental|1|"Use of five tailored take-home DVDs aimed at reducing exposure to ETS"
11645665|NCT00142623|No Intervention|2|Usual care
11645666|NCT00142610|Experimental|vitamin|500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks
11645667|NCT00142610|Placebo Comparator|Placebo|
11645668|NCT00142597|Active Comparator|Traditional Acupuncture|Acupuncture sites will be used for active intervention.
11645669|NCT00142597|Sham Comparator|Sham Treatment|Sham acupuncture is used.
11645670|NCT00142584|Experimental|1-NEB|Nebivolol
11645672|NCT00142532|Experimental|1|At the time of pre-op preparation, 18 semi-permanent intradermal acupuncture studs will be placed at acupuncture points in the back, two will be placed in the legs and two in the ear. All studs will be replaced when the epidural is removed or, for patients without epidurals, shortly before discharge. The new leg and auricular studs will then be removed at eleven days; the new back studs will be removed at the three week post-discharge consult.
11645673|NCT00142532|Placebo Comparator|2|"The treatment is the same as for the true acupuncture group, with the following exceptions. The studs in the back will be dummy studs have no needle and that have been used in previous research at MSKCC. The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (~1.25cm) from the spine. The leg studs will be placed at 2 cun (~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (~ 5cm) proximal and 3 cun (~ 5cm) medial to the midpoint of the antecubital crease.
~Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory"
11645674|NCT00142519|Active Comparator|1|methadone
11645675|NCT00142519|Experimental|2|methadone and morphine
11645676|NCT00142506|Active Comparator|1|radiotherapy with hormones, questionaire assessments
11645677|NCT00142506|Placebo Comparator|2|radiotherapy without hormones, questionaire assessments
11645678|NCT00142493|Experimental|1|
11645679|NCT00142493|Experimental|2|
11645680|NCT00142493|Experimental|3|
11645681|NCT00142493|Experimental|4|
11645682|NCT00142493|Placebo Comparator|5|
11645683|NCT00142480|Experimental|Capecitabine, Oxaliplatin, Bevacizumab|There are two phases of study treatment. Phase I includes all patients and will last 6 weeks. During this phase, oxaliplatin will be given intravenously (IV) on days 1, 8, 22, and 29; bevacizumab will be given IV on days 1, 15, and 29; capecitabine will be administered orally on days 1-14 and 22-35. Radiation therapy will be given once daily for 5 days (Monday-Friday) per week for a total of 28 treatments. Phase II has two groups: 1) patients who had tumors removed prior to entering study and 2) patients who entered the study with advanced disease. Patients who had their tumors removed prior to entering the study will be treated with the above 6-week regimen twice for a total of 12 weeks of treatment. Patients who were unresectable prior to entering the study but then were deemed resectable after treatment on trial will undergo resection. Following surgical recovery (8-10 weeks) they will be treated again with the above 6-week regimen twice for a total of 12 weeks of treatment.
11645684|NCT00142467|Experimental|Bevacizumab, Gemcitabine, Oxaliplatin|For cycle 1 (14 days), bevacizumab 10 mg/kg was administered alone on day 1. For cycle 2 and beyond (28 days/cycle), bevacizumab 10 mg/kg was administered on days 1 and 15, gemcitabine 1,000 mg/m2 was administered as a dose rate infusion at 10 mg/m2/min followed by oxaliplatin at 85 mg/m2 on days 2 and 16. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
11645685|NCT00142454|Experimental|Imiquimod + NY-ESO-1|Patients applied topical imiquimod followed by vaccination with intradermal injections of the NY-ESO-1 protein.
11645686|NCT00142428|Experimental|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
11645687|NCT00142415|Experimental|Cohort 1, 30 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 30 mCi/m^2 of 177-Lu.
11645688|NCT00142415|Experimental|Cohort 2, 40 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 40 mCi/m^2 of 177-Lu.
11645689|NCT00142415|Experimental|Cohort 3, 50 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 50 mCi/m^2 of 177-Lu.
11645690|NCT00142415|Experimental|Cohort 4, 60 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 60 mCi/m^2 of 177-Lu.
11645691|NCT00142415|Experimental|Cohort 5, 70 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 70 mCi/m^2 of 177-Lu.
11645692|NCT00142415|Experimental|Cohort 6, 65 mCi/m^2 177-Lu-DOTA-cG250|Subjects received an initial single dose of 10 mg of cG250 coupled to DOTA and labeled with 65 mCi/m^2 of 177-Lu.
11645693|NCT00142298|Experimental|telbivudine|telbivudine 600 mg p.o. daily for 104 weeks.
11645694|NCT00142246|Experimental|1|Intermittent preventive treatment with antimalarial drug combination(SP and amodiaquine)
11645695|NCT00142246|Placebo Comparator|2|Dual placebo comparator
11645696|NCT00142233|Experimental|ANTOX (vers.)1.2|"Adults and children aged 10+ will take two ANTOX (vers)1.2 tablets three times per day. (Antioxidant treatment: daily: 300 μg organic selenium, 720 mg vitamin C, 228 mg vitamin E, 2880 mg methionine) plus two placebo Magnesiocard (2.5 mmol) tablets three times per day.
~Children aged five to nine years of age will take one ANTOX (vers)1.2 tablet three times daily (Antioxidant treatment: daily: 150 μg organic selenium, 360 mg vitamin C, 114 mg vitamin E, 1440 mg methionine) plus one placebo Magnesiocard (2.5 mmol) tablet three times a day."
11645697|NCT00142233|Experimental|Magnesium|"Adults and children aged 10+ will take two Magnesiocard (2.5 mmol) tablets three times per day (total dose: 15 mmol = 365 mg per day) plus two placebo ANTOX (vers)1.2 tablets three times a day.
~Children aged five to nine years of age will take one Magnesiocard (2.5 mmol) tablet three times a day (total dose: 7.5 mmol = 182 mg per day) plus one placebo ANTOX (vers)1.2 tablet three times a day."
11645698|NCT00142233|Placebo Comparator|Placebo|"Adults and children aged 10+ will take two placebo ANTOX (vers)1.2 tablets three times a day, plus two placebo Magnesiocard (2.5 mmol) tablets three times per day.
~Children aged five to nine years of age will take one placebo ANTOX (vers)1.2 tablet three times a day, plus one placebo Magnesiocard (2.5 mmol) tablet three times per day."
11645699|NCT00142207|Active Comparator|1|Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine
11645700|NCT00142207|Active Comparator|2|Device: Insecticide-treated mosquito bed net
11645701|NCT00142207|Active Comparator|3|"Combination of Drug + Device:
~Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine Device: Insecticide-treated mosquito bed net"
11645702|NCT00142181|Experimental|Campath-1H|30 mg IV three times a week, 6-12 weeks.
11645893|NCT00138008|Experimental|2|Procedure/Surgery: radiotherapy
11645704|NCT00142116|Experimental|Thalidomide and Rituximab|"Thalidomide 200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks
~Rituximab Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later."
11645705|NCT00142103|Experimental|CPG10101|
11645706|NCT00142103|Experimental|CPG10101 + pegylated interferon|
11645707|NCT00142103|Experimental|CPG10101 + ribavirin|
11645708|NCT00142103|Experimental|CPG10101 + pegylated interferon + ribavirin|
11645709|NCT00142103|Active Comparator|Pegylated inteferon + ribavirin|
11645710|NCT00142103|Experimental|CPG10101 + pegylated interferon + ribavirin (rollover)|
11645711|NCT00142090|Experimental|2|3% Hypertonic saline
11645712|NCT00142090|Placebo Comparator|1|Normal saline
11645713|NCT00142051|Experimental|1|inhaled NO
11645714|NCT00142051|Placebo Comparator|2|room air inhalation
11645715|NCT00141986|Experimental|Vitamin D-higher dose|Vitamin D 2000 IU per os once daily
11645716|NCT00141986|Active Comparator|Vitamin D-lower dose|Vitamin D 400 IU per os once daily
11645717|NCT00141921|Experimental|Etanercept|Participants received etanercept 0.8 mg/kg (up to a maximum dose of 50 mg) once weekly by subcutaneous injection for up to 264 weeks.
11645718|NCT00141908|Placebo Comparator|Placebo progesterone injection|Placebo IM injections
11645719|NCT00141908|Active Comparator|Progesterone injections|17-hydroxyprogesterone caproate weekly injections
11645720|NCT00141895|Active Comparator|A|Vaginal Cytotec at doses of 400 microgram every 4 hours until delivery
11645721|NCT00141895|Active Comparator|B|Sublingual Cytotec at doses of 400 microgram every 4 hours until delivery
11645722|NCT00141856|Other|1|
11645723|NCT00141778|Placebo Comparator|Placebo|matched placebo pills daily beginning 4-7 days before surgery and continuing through discharge
11645724|NCT00141778|Experimental|Ramipril|Ramipril daily (2.5mg, increased to 5mg) beginning 4 to 7 days before surgery and continuing through discharge
11645725|NCT00141778|Experimental|Spironolactone|Spironolactone 25mg daily beginning 4 to 7 days before surgery and continuing through discharge
11645726|NCT00141765|Experimental|Myeloablative Chemotherapy with Stem Cell Rescue|Myeloablative Chemotherapy, followed by stem cell rescue
11645727|NCT00141739|Experimental|GVHD prophylaxis|GVHD prophylaxis with etanercept
11645728|NCT00141726|Experimental|etanercept treatment|Etanercept for lung injury
11645729|NCT00141713|Experimental|1|etanercept treatment for GVHD
11645730|NCT00141687|Experimental|Early External Cephalic Version Group|Early external cephalic version (ECV) procedure performed between 34 weeks and 0/7 days and 35 weeks and 6/7 days of gestation
11645731|NCT00141687|Active Comparator|Delayed External Cephalic Version Group|Delayed external cephalic version (ECV) procedure performed at or after 37 weeks and 0/7 days of gestation
11645732|NCT00141661|Experimental|Low Dose Arm|
11645733|NCT00141661|Experimental|High Dose Arm|
11645734|NCT00141661|Placebo Comparator|Placebo Control|
11645735|NCT00141648|Experimental|1|Chemotherapy followed by radiotherapy to begin 3 weeks after the last cycle.
11645736|NCT00141557|Experimental|1|
11645737|NCT00141557|Active Comparator|2|
11645738|NCT00141544|Experimental|1|
11645739|NCT00141544|Active Comparator|2|
11645740|NCT00141531|Active Comparator|Apaziquone|
11645741|NCT00141518|Experimental|Duodopa Naïve|Duodopa-naïve participants titrated to receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL [100-200 mg levodopa]); the continuous maintenance dose (usually 2-6 mL/hour [40-120 mg levodopa/hour]); and extra bolus doses, adjusted individually.
11645742|NCT00141518|Experimental|Duodopa Non-naïve < 2 Years|Duodopa non-naïve participants treated with Duodopa for < 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL [100-200 mg levodopa]); the continuous maintenance dose (usually 2-6 mL/hour [40-120 mg levodopa/hour]); and extra bolus doses, adjusted individually.
11645743|NCT00141518|Experimental|Duodopa Non-naïve ≥ 2 years|Duodopa non-naïve participants treated with Duodopa for ≥ 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL [100-200 mg levodopa]); the continuous maintenance dose (usually 2-6 mL/hour [40-120 mg levodopa/hour]); and extra bolus doses, adjusted individually.
11645744|NCT00141453|Experimental|1|Olmesartan medoxomil tablets 10mg to 40 mg
11645745|NCT00141453|Placebo Comparator|2|Matching placebo tablets
11645746|NCT00141440|Experimental|1|COPD patients
11645747|NCT00141323|Experimental|lasofoxifene 0.5 mg/day|
11645748|NCT00141323|Placebo Comparator|placebo|
11645749|NCT00141323|Experimental|lasofoxifene 0.25 mg/day|
11645750|NCT00141297|Experimental|PD-0332991|
11645751|NCT00141271|Active Comparator|20-40mg BID arm|
11645752|NCT00141271|Active Comparator|60-80mg bid arm|
11645753|NCT00141271|Placebo Comparator|Placebo|
11645754|NCT00141219|Experimental|1|
11645755|NCT00141219|Placebo Comparator|2|
11645756|NCT00141193|Placebo Comparator|A|
11645757|NCT00141115|Experimental|Levetiracetam|Levetiracetam 1500 mg BID
11645758|NCT00141102|Experimental|A|
11645759|NCT00141102|Active Comparator|B|
11645760|NCT00141037|Active Comparator|Steroid-Based Immunosuppression|Subjects will receive prednisone immunosuppression (10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing <40kg and 1.5 mg/kg/day in subjects weighing >40 kg) and proceed with a prednisone taper according to the trial's protocol.
11645761|NCT00141037|Experimental|Steroid-Free Immunosuppression|Subjects will receive extended daclizumab induction until the sixth month post-transplant (2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11 and months 4, 5, and 6).
11645984|NCT00136370|Experimental|1|Chlorhexidine Vaginal Wipe
11645762|NCT00141024|Experimental|1|Group 1 will receive 4 vaccinations of the EP-1043 vaccine or placebo. Vaccinations will be given at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
11645763|NCT00141024|Experimental|2|Group 2 will receive 4 vaccinations of the EP-1043 vaccine or placebo. Vaccinations will be given at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
11645764|NCT00141024|Experimental|3|In Part B, Group 3 will receive 4 vaccinations of either the EP-1043 vaccine or placebo. Vaccinations will occur at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
11645765|NCT00141024|Experimental|4|In Part B, Group 4 will receive 4 vaccinations of either the DNA vaccine EP-HIV-1090 or placebo. Vaccinations will occur at Months 0, 1, 3, and 6.
11645766|NCT00141024|Experimental|5|In Part B, Group 5 will receive 4 vaccinations of either the protein vaccine EP-1043 plus DNA vaccine EP-HIV- 1090 or placebo. Vaccinations will occur at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
11645767|NCT00141011|Experimental|Intravenous ancrod|Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
11645768|NCT00141011|Placebo Comparator|Intravenous Placebo|Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.
11645769|NCT00140907|Placebo Comparator|1|Placebo
11645770|NCT00140907|Active Comparator|2|Losartan
11645771|NCT00140842||Obese girls|The inclusion criteria will be girls 12-18 years of age. According to the Centers for Disease Control and Prevention, the definition of obesity is a BMI higher than the 95th percentile for age and sex, and that of overweight is a BMI between the 85th and 95th percentiles. Cases will be defined as having a body mass index (BMI) greater than the 95th percentile for age according to the 2000 Centers for Disease Control and Prevention growth charts.
11645772|NCT00140842||Normal-weight girls|
11645773|NCT00140790|Active Comparator|Valsartan 40mg|Standard Dose valsartan
11645774|NCT00140790|Active Comparator|Valsartan 160mg|High Dose valsartan
11645775|NCT00140751|Experimental|Simplification|The patients included in this arm are on Monotherapy of Kaletra (Lopinavir/ritonavir)during 48 weeks
11645776|NCT00140751|No Intervention|Continued|The patients included in this arm continue their treatment without any changes
11645777|NCT00140738|Experimental|Group A|"Patients receive study vaccinations in 3 consecutive cycles:
~In Cycle 1 each patients will receive six vaccinations at two-week intervals followed by evaluation.
~In Cycle 2, subjects will patients six vaccinations at two-week intervals followed by evaluation.
~In Cycle 3, subjects will patients six vaccinations at three-week intervals."
11645778|NCT00140738|Experimental|Group B|Patients receive study vaccinations as second-line therapy
11645779|NCT00140712|Experimental|Ropinirole|single dose .25mg of IR formulation, .05mg of RLS controlled release
11645780|NCT00140660|Experimental|R-ACVBP|addition of rituximab to standard ACVBP chemotherapy
11645781|NCT00140660|No Intervention|ACVBP|standard ACVBP chemotherapy
11645782|NCT00140621|Experimental|Agalsidase Beta|Agalsidase beta 1 milligram per kilogram (mg/kg) intravenously once every 2 weeks up to 156 weeks.
11645783|NCT00140582|Experimental|A : rituximab maintenance|Maintenance with rituximab for 2 years
11645784|NCT00140582|No Intervention|B : no maintenance|No further treatment
11645785|NCT00140556|Experimental|ChemoRadiotherapy|Radiation Therapy concurrent with cisplatin chemotherapy, Avastin and Tarceva
11645786|NCT00140530|Experimental|1|Due to randomisation patients got a Paclitaxel-eluting stent
11645787|NCT00140530|Experimental|2|Due to randomization patients got a Rapamycin-eluting stent.
11645788|NCT00140504|Experimental|MedCheck|Electronic medication safety queries via PatientSite portal
11645789|NCT00140504|No Intervention|Usual care|No electronic medication safety messages via PatientSite portal
11645790|NCT00140465|Active Comparator|1|75 mg Clopidogrel Maintenance Doses
11645791|NCT00140465|Active Comparator|2|150 mg Clopidogrel Maintenance Doses
11645792|NCT00140426|Placebo Comparator|placebo|double blind study of risperidone for anorexia nervosa. this is the subject group that receives placebo.
11645793|NCT00140426|Active Comparator|risperidone|Study is double blind, placebo controlled. This is the subject group on active medication
11645794|NCT00140413|Experimental|Treatment Group 1: Receiving GH Treatment|Treatment group assignment was based on subject's stature SDS relative to the mid-parental target height (MPTH) at baseline and subsequent classification as growth deceleration or normal growth. Subjects with growth deceleration were assigned to the GH treatment group in accordance with standard of care. Subjects with normal growth were randomized to treatment or to control (no intervention). The intervention was Nutropin AQ. The starting dose was calculated as 0.3 mg/kg/wk and subsequently modified based on observed length/height velocity and serum IGF-I levels.
11645795|NCT00140413|No Intervention|Treatment Group 2: Control|Treatment group assignment was based on subject's stature SDS relative to the mid-parental target height (MPTH) at baseline and subsequent classification as growth deceleration or normal growth. Subjects with normal growth were randomized to treatment or to control. The control group received no intervention; however, control subjects were switched (crossed over) to the GH replacement group if, during the course of the study, they met criteria for growth deceleration.
11645796|NCT00140244|Active Comparator|r-MetHuLeptin|r-MetHuLeptin SubQ once daily
11645797|NCT00140244|Placebo Comparator|Placebo|SubQ once daily
11645798|NCT00140231|Active Comparator|Metreleptin|r-metHuLeptin self-administered subcutaneously
11645799|NCT00140231|Placebo Comparator|Placebo|Placebo, administered in same method as active arm.
11645800|NCT00140205|Experimental|Fed state or fasting state|"1-day fed studies with administration of r-metHuLeptin at three different doses (0.01 mg/kg, 0.1 mg/kg, 0.3 mg/kg). All subjects participated in 3 studies in the fed condition (Part A) and 3 separate 72-hour fasting studies.
~Intervention administered was-r-metreleptin in 3 different doses"
11645801|NCT00140140|Experimental|Part 1: 80 mg ABI-007 + 15 mg vinorelbine|Weekly intravenous infusion of 80 mg/m^2 ABI-007, followed by an infusion of 15 mg/m^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. No G-CSF support was planned.
11645856|NCT00138853|Active Comparator|Tantalum knee|Tantalum Tibial component, uncemented
11645802|NCT00140140|Experimental|Part 2: 80 mg ABI-007 + 15 mg vinorelbine|Weekly intravenous infusion of 80 mg/m^2 ABI-007, followed by an infusion of 15 mg/m^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. G-CSF support was given.
11645803|NCT00140140|Experimental|Part 2: 90 mg ABI-007 + 20 mg vinorelbine|Weekly intravenous infusion of 90 mg/m^2 ABI-007, followed by an infusion of 20 mg/m^2 vinorelbine. Participants with human epidermal growth factor receptor 2-positive (HER2+) and who met cardiac safety requirements were also administered weekly Herceptin® (trastuzumab) following completion of ABI-007 and vinorelbine infusions. G-CSF support was given.
11645804|NCT00140114|Other|A|A: Vaginal misoprostol (cytotec)
11645805|NCT00140114|Other|B|Sublingual misoprostol (Cytotec)
11645806|NCT00140101|Experimental|1|ZoMaxx™ Drug-Eluting Stent System
11645807|NCT00140101|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
11645808|NCT00140075|Experimental|B|"ET (8 cycles)
~T = docetaxel or paclitaxel"
11645809|NCT00140075|Experimental|A|"EC (4 cycles) followed by T (4 cycles) for a total of 8 cycles
~T = docetaxel or paclitaxel"
11645810|NCT00140010|Experimental|A|30,000 units of erythropoietin beta in one vial; 3 vials as one set per patient
11645811|NCT00139997|Experimental|LED phototherapy device|Litebook treatment devices: LED phototherapy device, used for 30 min before 8 am
11645812|NCT00139997|Placebo Comparator|Inactivated Negative Ion Generator|Equivalent exposure to inactivated negative ion generator
11645813|NCT00139958||1|
11645814|NCT00139958||2|
11645815|NCT00139841|Experimental|1|bendamustine
11645816|NCT00139828|Other|A|The amount of Nonafact® to be administered and the frequency of treatment is based on the SmPC and should always be determined on the basis of the clinical effectiveness in the individual patient
11645817|NCT00139815|Active Comparator|Enoxaparin|
11645818|NCT00139815|Experimental|Fondaparinux|
11645819|NCT00139776|Active Comparator|Celecoxib - Continuous use|
11645820|NCT00139776|Active Comparator|Celecoxib - Intermittent use|
11645821|NCT00139659|Experimental|Inhaled Insulin|
11645822|NCT00139659|Active Comparator|Subcutaneous Insulin|
11645823|NCT00139594|Experimental|licarbazepine|
11645824|NCT00139581|Experimental|1|Pimecrolimus b.i.d.
11645825|NCT00139581|Experimental|2|Pimecrolimus o.d. and placebo o.d.
11645826|NCT00139542|Active Comparator|CONTROL|AED Treatment protocol following AHA Guidelines 2000 recommendations for cardiac arrest resuscitation.
11645827|NCT00139542|Experimental|STUDY|AED treatment protocol with prolonged CPR intervals, single shocks, fewer rhythm analysis and pulse checks.
11645828|NCT00139529|Experimental|1|Participants will receive an educational intervention during pregnancy combined with a motivational interviewing program using telephone counseling to prevent postpartum relapse to tobacco use.
11645829|NCT00139529|Active Comparator|2|Participants will receive an educational intervention during pregnancy.
11645830|NCT00139490|Experimental|A|The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
11645831|NCT00139490|Active Comparator|B|"The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay."
11645832|NCT00139490|Placebo Comparator|C|Usual Care group
11645833|NCT00139477|Experimental|Diet/Exercise only, then Diet/Exercise plus Metformin|Diet/Exercise only in first intervention period and Diet/Exercise plus Metformin in second intervention period (no washout period).
11645834|NCT00139477|Active Comparator|Diet/Exercise plus Metformin, then Diet/Exercise only|Diet/Exercise plus Metformin in first intervention period and Diet/Exercise only in second intervention period (no washout period).
11645835|NCT00139451|Active Comparator|Nutrition and Growth Hormone|
11645836|NCT00139451|Active Comparator|Observation and Growth Hormone|
11645837|NCT00139399|Active Comparator|Saphenous vein|Saphenous vein aortocoronary bypass graft
11645838|NCT00139399|Experimental|Radial artery|Radial artery aortocoronary bypass graft
11645839|NCT00139386|Active Comparator|Candesratan|
11645840|NCT00139386|No Intervention|Non-candesartan|
11645841|NCT00139360|Experimental|1|Active drug
11645842|NCT00139256|Experimental|Betamethasone|Betamethasone injection
11645843|NCT00139256|Placebo Comparator|Placebo|Placebo injection
11645844|NCT00139152|Placebo Comparator|Placebo|Saline placebo
11645845|NCT00139152|Experimental|Xolair|Xolair treatment
11645846|NCT00139113|Experimental|HAVRIX 6 and 12 mos; mother antibody pos|HAVRIX administered to infants born to anti-HAV positive mothers at ages 6 and 12 months
11645847|NCT00139113|Active Comparator|HAVRIX age 6, 12 mos; mom antibody neg|HAVRIX administered to infants born to anti-HAV negative mothers at ages 6 and 12 months
11645848|NCT00139113|Experimental|HAVRIX ages 12, 15 mos; mom antibody +|HAVRIX administered to infants born to anti-HAV positive mothers at ages 12 and 15 months
11645849|NCT00139113|Active Comparator|HAVRIX ages 12, 15 mos; mom antibody-|HAVRIX administered to infants born to anti-HAV negative mothers at ages 12 and 15 months
11645850|NCT00139113|Experimental|HAVRIX ages 15,21 mos; mom antibody +|HAVRIX administered to infants born to anti-HAV positive mothers at ages 15 and 21 months
11645851|NCT00139113|Active Comparator|HAVRIX ages 15,21 mos; mom antibody -|HAVRIX administered to infants born to anti-HAV negative mothers at ages 15 and 21 months
11645852|NCT00139074|Active Comparator|1|quetiapine fumarate monotherapy
11645853|NCT00139074|Experimental|2|Quetiapine + sodium valproate
11645854|NCT00138944|Placebo Comparator|1|Placebo
11645855|NCT00138944|Active Comparator|2|Eplerenone
11645857|NCT00138853|Active Comparator|Titanium Knee|Titanium Tibial Component, screw fixed
11645858|NCT00138736|Experimental|A|MBL until the patient's absolute neutrophil count (ANC) is above 500/microL blood.
11645859|NCT00138684|Experimental|Venesection therapy|
11645860|NCT00138684|No Intervention|no venesection therapy|
11645861|NCT00138671|Active Comparator|Subcutaneous Insulin|
11645862|NCT00138671|Experimental|Inhaled Insulin|
11645863|NCT00138645|Experimental|MicroDiet|Participants randomized to the MicroDiet group (1200 kcal/day) will be instructed by a Registered Dietitian to consume (one shake and 3 cookies; 240 kcal) for two meals each day for Months 1 through 3. They will be provided with meal plans for the meal that they do not replace with MicroDiet. During Months 4 through 6, participants in the MicroDiet group will be instructed to replace one meal per day with MD (the energy content of the meal plan will still be 1200 kcal/day). Participants will also be encouraged to eat or drink MD for snacks. The rest of the diet will consist of healthy foods, as outlined above. To help participants adhere to the MicroDiet regimen, they will meet with a registered dietitian for one hour at Week 0 and 30 minutes at Weeks 2 and 4, and every month thereafter.
11645864|NCT00138645|Active Comparator|Healthy Diet|Participants randomized to the Healthy Diet group will be prescribed a traditional food-based diet that contains the same number of kilocalories (1200/day) as the MicroDiet. The Healthy Diet will consist of the same foods that are used in the meal plans for the MicroDiet group. The Healthy Diet group will be instructed not to use meal replacements such as shakes (e.g., Slim Fast®), nutrition bars (e.g., Balance Bar®), or portion-controlled meals (e.g., Healthy Choice entrees).
11645865|NCT00138632|Experimental|1|
11645866|NCT00138632|Experimental|2|
11645867|NCT00138632|Placebo Comparator|3|
11645868|NCT00138554|Experimental|vildagliptin 50 mg qd + pioglitazone 45 mg qd|vildagliptin 50 mg qd + pioglitazone 45 mg qd for 28 weeks
11645869|NCT00138554|Experimental|vildagliptin 50 mg bd+ pioglitazone 45 mg qd|vildagliptin 50 mg bd + pioglitazone 45 mg qd for 28 weeks
11645870|NCT00138476|Experimental|Group 4: 0.48 RT-PCR units or Placebo|Group 4: dosage group of 10 subjects will receive 0.48 RT-PCR units of Lot 42399 NV or placebo control (8 subjects will receive NV and 2 subjects will receive placebo control).
11645871|NCT00138476|Experimental|Group 3: 4.8 RT-PCR units or Placebo|Group 3: dosage group of 12 subjects will receive 4.8 RT-PCR units of Lot 42399 NV or placebo control (10 subjects will receive NV and 2 subjects will receive placebo control).
11645872|NCT00138476|Experimental|Group 2: 48 RT-PCR units or Placebo|Group 2: dosage group of 12 subjects will receive 48 RT-PCR units of Lot 42399 NV or placebo control (10 subjects will receive NV and 2 subjects will receive placebo control).
11645873|NCT00138476|Experimental|Group 1: 4800 RT-PCR units or Placebo|Group 1: dosage group of 11 subjects will receive 4800 reverse transcription polymerase chain reaction (RT-PCR) units of Lot 42399 Norwalk Virus (NV) or placebo control (9 subjects will receive NV and 2 subjects will receive placebo control).
11645874|NCT00138476|Experimental|Validation Group: 4.8 and 0.48 RT-PCR units|Validation Group: dosage group of 12 subjects, 4 will receive 4.8 RT-PCR units and 8 will receive 0.48 RT-PCR units of Lot 42399 NV. No placebo control.
11645875|NCT00138463||West Nile Virus (WNV) Neuroinvasive Disease Cohort|Fever (temperature > 38 C) documented by a health care provider AND: at least one of the following, as documented by a health care provider and in the absence of a more likely clinical explanation: acutely altered mental status; other acute signs of central or peripheral neurologic dysfunction; or cerebrospinal fluid (CSF) pleocytosis associated with illness clinically compatible with meningitis.
11645876|NCT00138463||West Nile Virus Fever Cohort|Temperature > 38 C as documented by a health care provider.
11645877|NCT00138437||Leprosy Patients (Group 1)|All leprosy patients
11645878|NCT00138437||Household Contacts (Group 2)|Household contacts with known contact with leprosy patients
11645879|NCT00138437||Healthy Individuals (Group 3)|Healthy persons with no known contact with leprosy patients
11645880|NCT00138424|Experimental|Cidofovir|32 subjects will be randomized to 1 of 3 possible cohorts. Cohort I will receive dose 0.25 mg/kg; Cohort II will receive 0.5 mg/kg, Cohort III will receive 1.0 mg/kg. Maximum tolerated dose is to be determined.
11645881|NCT00138424|Placebo Comparator|Placebo|16 subjects to receive placebo.
11645882|NCT00138294|Experimental|Intervention Cities|Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) with be offered live attenuated or inactivated influenza vaccines through a school-based research vaccination program.
11645883|NCT00138294|Active Comparator|Comparison Cities|Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites will received their influenza vaccines (live attenuated or inactivated influenza vaccines) by the local healthcare providers.
11645884|NCT00138216|Experimental|Oral Irinotecan, temozolomide and vincristine sulfate|see detailed description
11645885|NCT00138203|Experimental|Treatment (vorinostat)|Patients receive oral suberoylanilide hydroxamic acid once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11645886|NCT00138177|Experimental|Treatment (vorinostat, mFOLFOX)|"Patients receive oral SAHA once or twice daily on days 1-3. Patients also receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 4 followed by fluorouracil IV over 46 hours on days 4-5. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD."
11645887|NCT00138151|Experimental|Paclitaxel, 13-cis Retinoic Acid, and Interferon Alpha-2b|"Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle
~Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle
~Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days"
11645888|NCT00138125|Experimental|Arm I|see intervention description for details
11645889|NCT00138073|Experimental|Web-based waveform interpretation guide|The arm has access to the Web-based waveform interpretation guide.
11645890|NCT00138034|Active Comparator|Percutaneous coronary intervention (PCI)|Stenting of the culprit lesion of the infarct related artery and aspirin and clopidorgel for at least 6 months
11645891|NCT00138034|Other|Dual antiplatelet therapy|Aspirin and clopidogrel for at least 6 months
11645894|NCT00137995|Experimental|R-ICE|R-ICE + R-BEAM /ASCT Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna BCNU, Etoposide, Cytarabine, Melphalan Autologous Stem Cell Transplantation
11645895|NCT00137995|Experimental|R-DHAP|R-DHAP + R-BEAM /ASCT Rituximab, Cisplatine, Cytosine Arabinoside, Dexamethasone BCNU, Etoposide, Cytarabine, Melphalan Autologous Stem Cell Transplantation
11645896|NCT00137969|Experimental|Rituximab 1000 mg + prednisone|Participants will receive rituximab 1000 mg intravenously on Days 1, 15, 168, and 182. Participants will also receive an initial dose of prednisone (0.5, 0.75, or 1.0 mg/kg orally once a day) with tapering beginning at Day 16 for 10 weeks to a dose of ≤ 10 mg/day. Participants will also receive acetaminophen 1000 mg orally and diphenhydramine 50 mg orally prior to study drug infusion.
11645897|NCT00137969|Placebo Comparator|Placebo + prednisone|Participants will receive placebo intravenously on Days 1, 15, 168, and 182. Participants will also receive an initial dose of prednisone (0.5, 0.75, or 1.0 mg/kg orally once a day) with tapering beginning at Day 16 for 10 weeks to a dose of ≤ 10 mg/day. Participants will also receive acetaminophen 1000 mg orally and diphenhydramine 50 mg orally prior to study drug infusion.
11645898|NCT00137865|Experimental|EGEN-001|
11645899|NCT00137852|Experimental|Cisplatin/CPT-11/Celecoxib/XRT/Surgery|Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
11645900|NCT00137839|Experimental|Erlotinib|Erlotinib: 150 mg orally once daily without interruption Cycle duration considered 4 weeks and treatment duration indefinite until disease progression, unacceptable toxicity or withdrawal for other reasons.
11645901|NCT00137800|Experimental|Tarceva|Chemotherapy Single Agent Systemic
11645902|NCT00137787|Experimental|1|
11645903|NCT00137787|Active Comparator|2|
11645904|NCT00137735|Active Comparator|1|Gabapentin
11645905|NCT00137735|Placebo Comparator|2|Placebo
11645906|NCT00137631|Experimental|Many Men, Many Voices (3MV) Intervention|Receive 6-session intervention immediately after baseline assessment and randomization
11645907|NCT00137631|No Intervention|Wait list comparison|Receive intervention after 6-month delay (wait list control group)
11645908|NCT00137605|Experimental|Pneumovax/immediate|
11645909|NCT00137605|Experimental|Pneumovax/delayed|
11645910|NCT00137605|Experimental|Prevnar/immediate|
11645911|NCT00137605|Experimental|Prevnar/delayed|
11645912|NCT00137592|Experimental|Lifestyle counseling|Behavioral: small media, group education (multicomponent)
11645913|NCT00137566|Experimental|1 Paracetamol|Paracetamol as per protocol
11645914|NCT00137566|Placebo Comparator|2 Placebo|Inactive placebo as per protocol.
11645915|NCT00137501|Other|A|High dose Nifedpine arm
11645916|NCT00137501|Other|B|Low dose Nifedipine arm
11645917|NCT00137449|Experimental|A|
11645918|NCT00137436|Experimental|A|SU011248 in combination with docetaxel and prednisone
11645919|NCT00137423|Experimental|SU011248 (sunitinib)|Single-arm study
11645920|NCT00137306|Other|Arm 1|
11645921|NCT00137280|Experimental|Collaborative Chronic Illness Care Model|Collaborative Chronic Illness Care Model: A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
11645922|NCT00137280|No Intervention|Usual Care|Usual Care
11645923|NCT00137267|Experimental|Arm 1|This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
11645924|NCT00137267|Active Comparator|Arm 2|This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
11645925|NCT00137254|Active Comparator|A|
11645926|NCT00137241||Group 1|
11645927|NCT00137215|Active Comparator|A|
11645928|NCT00137202|Active Comparator|2|
11645929|NCT00137189|Experimental|Music therapy|See published study protocol
11645930|NCT00137189|Other|Standard care|See published study protocol
11645931|NCT00137176|Experimental|Rebif + Lipitor|
11645932|NCT00137111|Other|1|
11645933|NCT00137111|Other|2|
11645934|NCT00137046|Active Comparator|Subcutaneous Insulin|
11645935|NCT00137046|Experimental|Inhaled Insulin|
11645936|NCT00136955|Experimental|irinitecan/cisplatin|experimental arm consists of patients who receive irinotecan/cisplatin
11645937|NCT00136916|Experimental|Inhaled Insulin|Inhalable short-acting insulin
11645938|NCT00136916|Active Comparator|Subcutaneous insulin|
11645939|NCT00136903|Active Comparator|Prochymal - 2 million cells|Prochymal - 2 million cells/kg actual body weight, intravenously on study Days 1 and 4 plus daily methylprednisolone 2 mg/kg intravenously or prednisone 2.5 mg/kg orally. Subjects will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses
11645940|NCT00136903|Active Comparator|Prochymal - 8 million cells|Prochymal - 8 million cells/kg actual body weight intravenously on study Days 1 and 4 plus daily methylprednisolone 2 mg/kg intravenously or prednisone 2.5 mg/kg orally. Subjects will also continue cyclosporine, tacrolimus, and/or MMF at full therapeutic doses
11645941|NCT00136890|No Intervention|1|Conventional Staging
11645942|NCT00136890|Experimental|2|PET Imaging
11645943|NCT00136864|Experimental|1|PET Imaging
11645944|NCT00136864|No Intervention|2|Standard Imaging
11645945|NCT00136838|Experimental|Neutral Cue first, then Active Cue|"Each participant receives two consecutive interventions.
~Neutral Cue: during this phase of treatment participants were presented with neutral (sham) cue
~Cigarette cue: during this phase of treatment participants were presented with active cigarette cue."
11645985|NCT00136370|Placebo Comparator|2|Sterile water external genital wipe
11646033|NCT00135668|Active Comparator|2|nitroprusside infusion 1 mcg/kg/min
11645946|NCT00136838|Experimental|Active Cue first, then Neutral Cue|"Each participant receives two consecutive interventions.
~Cigarette cue: during this phase of treatment participants were presented with active cigarette cue.
~Neutral Cue: during this phase of treatment participants were presented with neutral (sham) cue"
11645947|NCT00136825|Placebo Comparator|2|Identical appearing placebo pill containing lactose powder, packaged to have similar odor as N-Acetylcysteine in capsule form
11645948|NCT00136825|Experimental|1|N-Acetylcysteine
11645949|NCT00136812|No Intervention|enhanced usual care control|NRT during hospitalization with brief advice to stay quit once discharged
11645950|NCT00136812|Experimental|stage-tailored intervention|NRT during hospitalization with brief advice to stay quit once discharged plus a computer-delivered stage-tailored smoking cessation intervention with manual and counseling plus 10-weeks of nicotine patch available post-hospitalization
11645951|NCT00136786|Placebo Comparator|Intervention 1|"Each participant receives three consecutive interventions.
~Placebo
~Bupropion
~Memantine"
11645952|NCT00136786|Placebo Comparator|Intervention 2|"Bupropion
~Memantine
~Placebo"
11645953|NCT00136786|Placebo Comparator|Intervention 3|"Memantine
~Placebo
~Bupropion"
11645954|NCT00136760|Experimental|1|Contingent reinforcement plus bupropion
11645955|NCT00136760|Experimental|2|Contingent reinforcement plus placebo
11645956|NCT00136760|Experimental|3|Non-contingent reinforcement plus bupropion
11645957|NCT00136760|Placebo Comparator|4|Non-contingent reinforcement plus placebo
11645958|NCT00136747|Experimental|BUPROPION|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
11645959|NCT00136747|Experimental|placebo|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
11645960|NCT00136747|Experimental|memantine|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
11645961|NCT00136734|Experimental|1|methylphenidate
11645962|NCT00136734|Placebo Comparator|2|placebo
11645963|NCT00136708|Experimental|NRP Training (Intervention)|Training in AAP neonatal resuscitation training program
11645964|NCT00136708|Other|Control|
11645965|NCT00136695|Experimental|anastrozole|anastrozole
11645966|NCT00136695|Placebo Comparator|placebo|placebo
11645967|NCT00136682|Active Comparator|(PCEA)|patient-controlled epidural analgesia PCEA involves having an epidural catheter placed before surgery.The epidural catheter will be used during surgery to give drugs, such as morphine and a local anesthetic bupivacaine, which will help control pain. After surgery, a constant flow of pain-reducing medicine, such as morphine, will be given through the catheter. This is controlled by the patient.
11645968|NCT00136682|Active Comparator|PCA|patient-controlled intravenous analgesia (PCA) PCA involves placing a tube into the patient's vein after surgery. The tube is connected to a pump that is controlled by the patient. The pump holds a medicine, such as morphine, that eases pain.
11645969|NCT00136656|Active Comparator|1|cefixime antibiotic treatment by oral route
11645970|NCT00136656|Sham Comparator|2|ceftriaxone antibiotic treatment by venous infusion and cefixime antibiotic treatment by oral route during six days
11645971|NCT00136604|Experimental|ACAC GROUP|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of the same vaccines at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age.
11645972|NCT00136604|Experimental|ACHibPS GROUP|Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with MenAC-TT vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
11645973|NCT00136604|Experimental|HibACPS GROUP|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
11645974|NCT00136604|Experimental|HibHibPS GROUP|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of the same vaccine at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm.
11645975|NCT00136604|Experimental|CC GROUP|Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix + Meningitec vaccine in the primary study (NCT00317161) are boosted in the current study with one dose of the same vaccine at 15 to 24 months of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm. No Mencevax ACWY vaccine at 24 to 30 months of age.
11645976|NCT00136591|Active Comparator|A|Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle. Subjects in this treatment arm will receive a total of 8 cycles of treatment,
11645977|NCT00136591|Experimental|B|
11645978|NCT00136578|Experimental|Subjects receiving carboplatin and SB-715992|Subjects will receive carboplatin on Day 1 as an intravenous (IV) infusion over 30 minutes followed by 1-hour IV infusion of SB-715992 once every 21 days.
11645979|NCT00136565|Experimental|Experimental|Velcade, Doxorubicine, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
11645980|NCT00136474|Active Comparator|Group 1|Amifostine plus radiation therapy
11645981|NCT00136474|Active Comparator|Group 2|Radiation therapy alone
11645982|NCT00136435|Other|Only Arm for this study|Only Arm for this study
11645983|NCT00136409|Experimental|Mono-Therapy Gleevec|Gleevec administered orally at a pre-determined dose once daily.
11645986|NCT00136357|Experimental|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
11645987|NCT00136357|No Intervention|Delayed Intervention|Comparison group not receiving intervention until after the initial intervention was completed.
11645988|NCT00136318|Active Comparator|Escitalopram|After the preobservation period,patients received escitalopram, 10 mg per day. During treatment period, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of escitalopram.
11645989|NCT00136318|Placebo Comparator|Placebo|After the preobservation period, patients received placebo. After 2 weeks of antidepressant pretreatment, all patients began receiving antiviral therapy with PEG-interferon plus ribavirin with continuous concomitant administration of placebo.
11645990|NCT00136305|Experimental|Pictorial Asthma Action Plan|
11645991|NCT00136305|Active Comparator|Written Asthma Action Plan|
11645992|NCT00136279|Experimental|School plus parent|Adolescents receive school-based curriculum (either Project TNT or Making a Difference) and mothers receive the Linking Lives curriculum
11645993|NCT00136279|Active Comparator|School-only|Adolescents receive school-based curriculum and parents received a control curriculum on helping their child choose a high school
11645994|NCT00136279|Experimental|Parent-Only|In the sex risk reduction portion of the study only, a second experimental group consisted of parents receiving the Linking Lives intervention and adolescents receiving no in-school intervention
11645995|NCT00136227|Experimental|Lifestyle counseling|Behavioral: small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention
11645996|NCT00136214||Interferon Treated Group|Group treated with PEG-Interferon and ribavirin and undergoing MR brain and neuropsychiatric tests
11645997|NCT00136214||Non-treated cohort control|Group undergoing MR brain and neuropsychiatric tests
11645998|NCT00136201|Experimental|1|armDesc1
11645999|NCT00136175|Experimental|Arm I|Patients with clinical stage T2 with hydronephrosis or T3 bladder cancer will receive 3 cycles of chemotherapy (200mg/m^2 paclitaxel on day 1, carboplatin on day 1, and 800 mg/m^2 gemcitabine on days 1 and 8 of each 21 day cycle).
11646000|NCT00136175|Experimental|Arm II|Patients with T4 or lymph node positive disease will receive up to 6 cycles of paclitaxel, carboplatin, and gemcitabine.
11646001|NCT00136149|Experimental|Immediate implants|
11646002|NCT00136136||Normal healthy term newborn|Normal healthy term newborns
11646003|NCT00136136||Ill term newly born without brain damage|Ill term newly borns without brain damage
11646004|NCT00136136||Preterm newly born without brain damage|Preterm newly borns without brain damage
11646005|NCT00136123|Experimental|Implants|
11646006|NCT00136084|Experimental|HDAC (High-Dose Cytarabine)|Since limited characters are allowed in this passage, please see detailed Description for HDAC.
11646007|NCT00136084|Experimental|LDAC (Low-Dose Cytarabine)|Since limited characters are allowed in this passage, please see detailed Description for LDAC.
11646008|NCT00136032|Active Comparator|1|
11646009|NCT00136032|Placebo Comparator|2|
11646010|NCT00135954|Other|late intervention|cyclophosphamide and steroids started at time of renal insufficiency
11646011|NCT00135954|Experimental|early intervention|immediate start of cyclophosphamide and steroids
11646012|NCT00135941|Experimental|1|Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
11646013|NCT00135941|Experimental|2|Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
11646014|NCT00135902|Active Comparator|17P plus Omega-3 Supplement|Weekly 17 alpa hydroxyprogesterone caproate (17p) injections plus Omega 3 supplements, 4 capsules per day for up to 5 weeks. Each capsule contained 200 mg of docosahexaenoic acid (DHA) and 300 mg of eicosapentaenoic acid (EPA).
11646015|NCT00135902|Placebo Comparator|17P plus Placebo Supplement|Weekly 17 alpa hydroxyprogesterone caproate (17p) injections plus placebo capsules, 4 capsules per day for up to 5 weeks
11646016|NCT00135811|Active Comparator|1|Cyclosporin
11646017|NCT00135811|Active Comparator|2|MMF and Dexamethasone
11646018|NCT00135798|Experimental|LADR Treatment, Genotypes 1,4,6|Subjects randomized to low accelerating dose regimen (LADR) treatment
11646019|NCT00135798|No Intervention|Standard care|Subjects randomized to Standard Care group, Genotypes 1,4,6
11646020|NCT00135798|Experimental|LADR treatment, Genotypes 2,3|Subjects randomized to low accelerating dose regimen (LADR) treatment.
11646021|NCT00135785|Active Comparator|1|Bupropion
11646022|NCT00135785|Placebo Comparator|2|Placebo
11646023|NCT00135759|Placebo Comparator|Group 1|Drug
11646024|NCT00135759|Experimental|2|experimental
11646025|NCT00135759|Experimental|3|experimental
11646026|NCT00135733|Active Comparator|A|Amevive
11646027|NCT00135733|Placebo Comparator|B|Placebo
11646028|NCT00135707|Experimental|Dietary Supplement/Vitamins|1000mg of Vitamin C and 400IU of Vitamin E per capsule, twice daily between randomization (at 9 to 16 weeks) up to delivery.
11646029|NCT00135707|Placebo Comparator|Placebo for Vitamin C and Vitamin E|Placebo capsules consisting of Mineral Oil, Hydrogenated Vegetable Oil, Lecithin, Yellow wax, Soft Gelatin Shell, twice daily between randomization (at 9 to 16 weks) up to delivery.
11646030|NCT00135694|Experimental|Immunosuppression Withdrawal|Subjects may randomize to this group at 12 to 24 months after transplantation. This is followed by tapered withdrawal of calcineurin inhibitor-based immunosuppression therapy over the course of 1 year.
11646031|NCT00135694|Active Comparator|Immunosuppression Maintenance|Liver transplant, followed by maintenance doses of continuous calcineurin inhibitor-based immunosuppression therapy.
11646032|NCT00135668|Active Comparator|1|Nitroprusside infusion 0.3 mcg/kg/min
11646034|NCT00135668|Active Comparator|3|nitroprusside infusion 2 mcg/kg/min
11646035|NCT00135668|Active Comparator|4|nitroprusside 3 mcg/kg/min
11646036|NCT00135603|Active Comparator|A|appendectomy, actual usual treatment
11646037|NCT00135603|Active Comparator|B|antibiotic therapy
11646038|NCT00135590|Experimental|1|Protein pulse-feeding
11646039|NCT00135590|Active Comparator|2|Spread diet
11646040|NCT00135577|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally once in the morning and once in the evening.
11646041|NCT00135577|Experimental|Alvimopan 1 mg Once Daily (QD)|"Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg in the morning and received placebo in the evening.
~Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan in the morning and placebo in the evening for 3 days, then 1 mg of alvimopan in the morning and placebo in the evening for the remaining 3 weeks."
11646042|NCT00135577|Experimental|Alvimopan 1 mg Twice Daily (BID)|"Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg once in the morning and once in the evening.
~Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan once in the morning and once in the evening for 3 days, then 1 mg of alvimopan once in the morning and once in the evening."
11646043|NCT00135577|Placebo Comparator|Placebo|Placebo was administered orally once in the morning and once in evening.
11646044|NCT00135551|Active Comparator|angiotensin receptor blockers|benidipine+angiotensin receptor blockers, titlation scheme
11646045|NCT00135551|Active Comparator|β-blockers|benidipie+β-blockers, titlation scheme
11646046|NCT00135551|Active Comparator|thiazide diuretics|benidipine+thiazide diuretics, titlation scheme
11646047|NCT00135525|Experimental|Paroxetine|"Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.
~Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan."
11646048|NCT00135525|Placebo Comparator|Placebo|
11646049|NCT00135499|Experimental|R-ACVBP|Rituximab, Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
11646050|NCT00135499|Active Comparator|R-CHOP|Rituximab, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone
11646051|NCT00135447||A|
11646052|NCT00135421|Experimental|A1|
11646053|NCT00135421|Active Comparator|A2|
11646054|NCT00135421|Placebo Comparator|A3|
11646055|NCT00135408|Active Comparator|A1|
11646056|NCT00135408|Active Comparator|A2|
11646057|NCT00135395|Active Comparator|A|
11646058|NCT00135395|Active Comparator|B|
11646059|NCT00135356|Active Comparator|Switch arm|
11646060|NCT00135356|Active Comparator|Control Arm|
11646061|NCT00135343|Experimental|A|
11646062|NCT00135343|Experimental|B|
11646063|NCT00135330|Experimental|Exenatide Arm|
11646064|NCT00135330|Experimental|Exenatide plus Rosiglitazone Arm|
11646065|NCT00135330|Experimental|Rosiglitazone Arm|
11646066|NCT00135304|Experimental|Cinacalcet and low-dose Vitamin D|Cinacalcet and low-dose IV Vitamin D
11646067|NCT00135304|Active Comparator|Vitamin D alone|Escalating doses of IV Vitamin D alone
11646068|NCT00135278|Other|CSF Drainage|
11646069|NCT00135278|Other|No CSF Drainage|
11646070|NCT00135226|Active Comparator|Aspirin + Omega-3 Ethyl Esters|Participants receive 100mg of aspirin once daily and 1g of omega-3 ethyl esters once daily.
11646071|NCT00135226|Active Comparator|Aspirin + Placebo Omega-3 Ethyl Esters|Participants receive 100mg of aspirin once daily and placebo omega-3 ethyl esters once daily.
11646072|NCT00135226|Active Comparator|Placebo Aspirin + Omega-3 Ethyl Esters|Participants receive placebo aspirin once daily and 1g of omega-3 ethyl esters once daily.
11646073|NCT00135226|Active Comparator|Placebo Aspirin + Placebo Omega-3 Ethyl Esters|Participants receive placebo aspirin once daily and placebo omega-3 ethyl esters once daily.
11646074|NCT00135200|Experimental|Bexxar therapeutic|"The Bexxar therapeutic regimen is delivered in two sets of intravenous infusions given 7-14 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body. A trace amount of radioactive Iodine 131 Tositumomab is initially given to enable physicians to evaluate the clearance of radiation from the subject's body with gamma camera scans. Calculations made on the basis of these individualized radiation clearance rates allow the therapeutic dose (given 7-14 days after the dosimetric infusion) to be tailored for each patient. The therapeutic dose contains Tositumomab labeled with the amount of Iodine 131 tositumomab specifically calculated based on the scans performed following the dosimetric dose."
11646075|NCT00135161|Experimental|Intensity modulated radiation therapy (IMRT).|
11646076|NCT00135135|Other|1|
11646077|NCT00135122|Placebo Comparator|2|Placebo in six days
11646078|NCT00135096|Experimental|1|PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
11646079|NCT00135096|Experimental|2|POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
11646080|NCT00135083|Experimental|1|"Once daily:
~Insulin glulisine Dosing: Supper, Lunch, Breakfast
~Monitoring Needed at: Bedtime,Pre-Supper, Pre-Lunch"
11646081|NCT00135083|Experimental|2|"Twice daily:
~Insulin glulisine Dosing: Supper & Lunch, Lunch & Breakfast, Breakfast & Supper
~Monitoring Needed at: Bedtime & Pre-Supper, Pre-Supper & Pre-Lunch, Pre-Lunch & Bedtime"
11646082|NCT00135083|Experimental|3|"Twice daily:
~Insulin glulisine Dosing: Supper, Lunch, Breakfast
~Monitoring Needed at: Bedtime, Pre-Supper, Pre-Lunch"
11646083|NCT00135005|Experimental|AMN107 + STI571|
11646084|NCT00134966|Experimental|1|
11646085|NCT00134966|Active Comparator|2|
11646086|NCT00134901|Experimental|Memantine|Memantine
11646087|NCT00134901|Placebo Comparator|Placebo|Placebo
11646088|NCT00134823|Experimental|dosing decision support|weight based dosing decision support
11646089|NCT00134823|No Intervention|no decision support|no weight based dosing decision support
11646090|NCT00134784|Experimental|Assess [123I]B-CIT SPECT imaging|To assess[123I]B-CIT SPECT imaging in early Parkinson's disease subjects on placebo compared to early verses later Levodopa. Subjects on Levodopa 150mg/day, Levodopa 300 mg/day, and Levodopa 600 mg/day will be assessed.
11646091|NCT00134758|Experimental|1|"Ursodeoxycholic acid during 2 years :
~between 40 and 50 kg : 500 mg/day
~between 51 and 75 kg : 750 mg/day
~between 76 and 100 kg : 1000 mg/day"
11646092|NCT00134758|Placebo Comparator|2|
11646093|NCT00134745|Active Comparator|4 mg estradiol|
11646094|NCT00134745|Placebo Comparator|2 mg estradiol|
11646095|NCT00134719|Experimental|MenHibrix Group|Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.
11646096|NCT00134719|Active Comparator|ActHIB + Meningitec Group|Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.
11646097|NCT00134719|Active Comparator|ActHIB/PedvaxHIB Group|Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.
11646098|NCT00134680|Experimental|Letrozole & Trastuzumab|Letrozole 2.5 mg tablets daily and Trastuzumab 2 mg/kg by IV weekly
11646099|NCT00134654|Active Comparator|Group A|Premarin once a day
11646100|NCT00134654|Active Comparator|Group B|Premarin 3 times a day
11646101|NCT00134628|Active Comparator|A|Hyperbaric Oxygen Therapy
11646102|NCT00134628|Sham Comparator|B|Normal Air
11646103|NCT00134615|Experimental|RQP-MH|These participants receive the RQP-MH intervention
11646104|NCT00134563|Experimental|Teriflunomide 7 mg|Teriflunomide 7 mg once daily for 108 weeks
11646105|NCT00134563|Experimental|Teriflunomide 14 mg|Teriflunomide 14 mg once daily for 108 weeks
11646106|NCT00134563|Placebo Comparator|Placebo|Placebo (for teriflunomide) once daily for 108 weeks
11646107|NCT00134537|Experimental|1|Interspinous process and dynamic stabilization
11646108|NCT00134537|Active Comparator|2|Conservative Care
11646109|NCT00134420|Active Comparator|Growth Hormone Treatment|Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, and Neuropsychological Testing was done 1st for eligibility and this group received GH (growth hormone) (Nutropin AQ) 0.3 mgs per kg per week (standard dosing for GH)immediately after randomization
11646110|NCT00134420|Other|GH treatment delayed by one year|Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, and Neuropsychological Testing was done first for eligibility and this group received growth hormone (Nutropin AQ) 0.3 mgs per kg per week (standard dosing for GH)after one year of observation
11646111|NCT00134381|Active Comparator|active drug|bilateral comparison of green tea constituent
11646112|NCT00134381|Placebo Comparator|placebo|bilateral comparison of placebo vehicle
11646113|NCT00134355|Experimental|PTK787|"PTK787:
~250 mg orally twice daily x 2 wks, then 250 mg orally am, 500 mg orally pm x 1 wk, then 500 mg orally twice daily"
11646114|NCT00134303|Experimental|NASH|
11646115|NCT00134277|Active Comparator|Infragenual dilatation with stenting|
11646116|NCT00134277|Active Comparator|Infragenual dilatation with cutting balloon|
11646117|NCT00134277|Active Comparator|Laser therapy|
11646118|NCT00134277|Placebo Comparator|Infragenual dilatation|
11646119|NCT00134160|Active Comparator|1|High-dose ARB monotherapy
11646120|NCT00134160|Active Comparator|2|Combination therapy of ARB with Calcium Channel Blocker
11646121|NCT00134082|Experimental|Immunotherapy|All participants received two days of rituximab, then four days of high-dose cyclophosphamide followed by filgrastim. Participants then received six doses of KGEL vaccine over 24 weeks interspersed with four additional doses of rituximab.
11646122|NCT00134069|Experimental|Treatment (sorafenib, irinotecan, cetuximab)|Patients will receive sorafenib by mouth once or twice a day and a 1- to 2-hour infusion of cetuximab once a week for 8 weeks. They will also receive a 1½-hour infusion of irinotecan once a week in weeks 3-6. Patients will then receive sorafenib by mouth once or twice a day and a 1- to 2-hour infusion of cetuximab once a week for 6 weeks. They will also receive a 1½-hour infusion of irinotecan once a week in weeks 1-4. Treatment may repeat every 6 weeks for as long as benefit is shown.
11646123|NCT00134056|Active Comparator|Arm I: placebo|Patients receive docetaxel and prednisone as in arm I. Patients also receive oral placebo once daily on days 1-21. Treatment repeat every 21 days for up to 12 courses. Patients with stable or responding disease after course 12 may register for continued oral placebo treatment for up to 52 weeks.
11646124|NCT00134056|Experimental|Arm II: atrasentan hydrochloride|Patients receive docetaxel IV over 1 hour on day 1. Patients also receive oral atrasentan and oral prednisone once daily on days 1-21. Treatment repeats every 21 days for up to 12 courses. Patients with stable or responding disease after course 12 may register for continued oral atrasentan treatment for up to 52 weeks.
11646125|NCT00134043|Experimental|Arm I|Patients receive oral suberoylanilide hydroxamic acid (SAHA) twice daily on days 1-14. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients are then evaluated for disease response. Patients achieving a complete response receive an additional 2 courses of SAHA. Patients achieving stable disease or a partial response receive 4 additional courses of SAHA.After completion of study treatment, patients are followed within 4 weeks.
11646126|NCT00134030|Active Comparator|Maintenance therapy group 1 arm I|Patients receive doxorubicin IV continuously over 48 hours on days 1-2 in weeks 12, 17, 22, and 26 and cisplatin IV over 4 hours on days 1 and 2 in weeks 12 and 17. Patients also receive high-dose MTX IV over 4 hours on day 1 in weeks 15, 16, 20, 21, 24, 25, 28, and 29.
11646127|NCT00134030|Experimental|Maintenance therapy group 1 arm II|Patients receive doxorubicin, cisplatin, and high-dose MTX as in arm I. Patients than receive PEG-interferon alfa-2b subcutaneously once daily on day 1 in weeks 30-104.
11646175|NCT00133523|Experimental|Group 1: FluMist™|N=825 subjects administered live attenuated vaccine intranasally.
11646128|NCT00134030|Active Comparator|Maintenance therapy group 2 arm I|Patients receive doxorubicin, cisplatin, and high-dose MTX as in group 1 arm I.
11646129|NCT00134030|Experimental|Maintenance therapy group 2 arm II|Patients receive doxorubicin IV continuously over 48 hours on days 1-2 in weeks 12, 20, 28, and 36 and cisplatin IV over 4 hours on days 1 and 2 in weeks 12 and 28. Patients also receive high-dose MTX IV over 4 hours on day 1 in weeks 15, 19, 23, 27, 31, 35, 39, and 40. Patients receive ifosfamide IV over 4 hours on days 1-5 in weeks 16, 24, and 32 and on days 1-3 in weeks 20 and 36 and etoposide IV over 1 hour on days 1-5 in weeks 16, 24, and 32.
11646130|NCT00134017|Experimental|Bone marrow transplant|Myeloablative bone marrow transplant with a busulfan (Bu), cyclophosphamide (Cy), preparative regimen and post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis
11646131|NCT00134004|Experimental|Mini-haplo Transplant|Non-myeloablative haploidentical bone marrow transplant with a fludarabine, cyclophosphamide (Cy), TBI (total body irradiation) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.
11646132|NCT00133991|Experimental|R-CVP + HiCy|Protocol intervention consists of two fifteen-day cycles of cyclophosphamide (Cy), vincristine (V), prednisone (P), rituximab (R), with filgrastim support. CNS intervention consists of three days of cytarabine and hydrocortisone and one day of methotrexate (with leucovorin support) for each cycle. After those two cycles, rituximab and high-dose cyclophosphamide (HiCy) will be given.
11646133|NCT00133978|Experimental|Glutamine|Glutamine supplementation
11646134|NCT00133978|Experimental|Antioxidants|Antioxidant supplementation
11646135|NCT00133978|Experimental|Glutamine + Antioxidants|Glutamine and antioxidant supplementation
11646136|NCT00133978|Placebo Comparator|Placebo|Non-isonitrogenic, iso-caloric placebo solution
11646137|NCT00133965||1|Dignity Psychotherapy
11646138|NCT00133965||2|Supportive Psychotherapy
11646139|NCT00133965||3|Standard Palliative Care
11646140|NCT00133952|Experimental|Ruboxistaurin|32 mg taken orally daily for up to 48 months
11646141|NCT00133952|Placebo Comparator|Placebo|Taken orally daily for up to 48 months
11646142|NCT00133913||Cohort|Patients with measurable metastatic colorectal cancer about to start a new line of chemotherapy.
11646143|NCT00133900||Cohort|Metastatic Hormone Refractory Prostate Cancer Patients
11646144|NCT00133887|Experimental|1|patients receiving Rapamycin
11646145|NCT00133887|Active Comparator|2|patients receiving anticalcineurin treatment
11646146|NCT00133809|Experimental|Islet Transplant|All subjects who are found eligible and who can be matched to an appropriate donor will receive/have received an islet transplant
11646147|NCT00133796|Experimental|Heceptin|Herceptin administered to enrolled subjects
11646148|NCT00133770|Experimental|IV pantoprazole|The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
11646149|NCT00133744|Active Comparator|A, 1|
11646150|NCT00133744|Experimental|A, 2|
11646151|NCT00133744|Experimental|A, 3|Multiple micronutrient supplement
11646152|NCT00133718|Other|Structured multi intervention|Structured multi intervention to reach predefined glycemic and blood pressure goals as well as activity and weight goal
11646153|NCT00133718|Other|Standard of care|Standard care with or without structured care according to national guidelines
11646154|NCT00133705|Experimental|Mifepristone|Mifepristone 5 MG capsule taken once daily by mouth
11646155|NCT00133705|Placebo Comparator|Inert capsule|Placebo (for Mifepristone) capsule of nearly identical color, size, and weight taken once daily by mouth
11646156|NCT00133679|Experimental|1|Sildenafil x 45 days
11646157|NCT00133679|Placebo Comparator|2|Placebo x 45 d
11646158|NCT00133666|Experimental|1|
11646159|NCT00133666|Active Comparator|2|
11646160|NCT00133601|Experimental|1|CBT-1
11646161|NCT00133601|No Intervention|2|Control Group
11646162|NCT00133575|Experimental|Group E: ACAM3000 MVA 10^7 ID|10 subjects to receive ACAM3000 MVA dose 10^7 TCID50 via intradermal route on days 0 and 28; 2 subjects to receive placebo via intradermal route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
11646163|NCT00133575|Experimental|Group F: ACAM3000 MVA 10^8 IM|10 subjects to receive ACAM3000 MVA dose 10^8 TCID50 via intramuscular route on days 0 and 28; 2 subjects to receive placebo via intramuscular route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
11646164|NCT00133575|Experimental|Group D: ACAM3000 MVA 10^8 SC|10 subjects to receive ACAM3000 MVA dose 10^8 TCID50 via subcutaneous route on days 0 and 28; 2 subjects to receive placebo via subcutaneous route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
11646165|NCT00133575|Experimental|Group B: ACAM3000 MVA 10^7 IM|10 subjects to receive ACAM3000 MVA dose 10^7 TCID50 via intramuscular route on days 0 and 28; 2 subjects to receive placebo via intramuscular route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
11646166|NCT00133575|Experimental|Group A: ACAM3000 MVA 10^6 ID|10 subjects to receive ACAM3000 MVA dose 10^6 tissue culture infectious dose 50 (TCID50) via intradermal (ID) route on days 0 and 28; 2 subjects to receive placebo via intradermal route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
11646167|NCT00133575|Experimental|Group C: ACAM3000 MVA 10^7 SC|10 subjects to receive ACAM3000 MVA dose 10^7 TCID50 via subcutaneous (SC) route on days 0 and 28; 2 subjects to receive placebo via subcutaneous route on days 0 and 28. Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
11646168|NCT00133549|Experimental|2|Vaccine dose 1: CRM-PS; Vaccine dose 2 (month 4): CRM-PS; Vaccine dose 3 (month 8): PS.
11646169|NCT00133549|Experimental|1|Vaccine dose 1: CRM-PS; Vaccine dose 2 (month 4): saline placebo; Vaccine dose 3 (month 8): PS.
11646170|NCT00133549|Active Comparator|3|Vaccine dose 1: PS; Vaccine dose 2 (month 4): saline placebo; Vaccine dose 3 (month 8): saline placebo.
11646171|NCT00133536|Experimental|1|100 subjects 45 mcg of influenza A/H5N1.
11646172|NCT00133536|Placebo Comparator|2|20 subjects saline placebo.
11646173|NCT00133523|Placebo Comparator|Group 4: Placebo: Intramuscular|N=165 subjects administered placebo intramuscularly.
11646174|NCT00133523|Placebo Comparator|Group 3: Placebo: Nasal|N=165 subjects administered placebo intranasally.
11646176|NCT00133523|Experimental|Group 2: Fluzone®/Fluvirin|N=825 subjects administered inactivated vaccine intramuscularly.
11646177|NCT00133497|Experimental|20 mcg CMV gB + MF59|200 subjects will receive vaccine CMV gB + MF59.
11646178|NCT00133497|Placebo Comparator|Saline|200 subjects will receive saline placebo.
11646179|NCT00133471|Experimental|Group 1A: 3.75 mcg A/H9N2 no adjuvant|12 subjects to receive 3.75 mcg A/H9N2 with no adjuvant.
11646180|NCT00133471|Experimental|Group 2B: 7.5 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 7.5 mcg A/H9N2 plus MF59 adjuvant.
11646181|NCT00133471|Experimental|Group 3A: 15 mcg A/H9N2 no adjuvant|12 subjects to receive 15 mcg A/H9N2 with no adjuvant.
11646182|NCT00133471|Experimental|Group 3B: 15 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 15 mcg A/H9N2 plus MF59 adjuvant.
11646183|NCT00133471|Experimental|Group 4B: 30 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 30 mcg A/H9N2 plus MF59 adjuvant.
11646184|NCT00133471|Experimental|Group 4A: 30 mcg A/H9N2 no adjuvant|12 subjects to receive 30 mcg A/H9N2 with no adjuvant.
11646185|NCT00133471|Experimental|Group 2A: 7.5 mcg A/H9N2 no adjuvant|12 subjects to receive 7.5 mcg A/H9N2 with no adjuvant.
11646186|NCT00133471|Experimental|Group 1B: 3.75 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 3.75 mcg A/H9N2 plus MF59 adjuvant.
11646187|NCT00133445|Experimental|Group A|Group A will receive DTaP-HepB-IPV (Pediarix™) vaccine along with other required vaccines at birth, 2 and 6 months of age.
11646188|NCT00133445|Active Comparator|Group B|Group B will receive the monovalent HepB vaccine (Engerix-B) at birth, the DTaP-HepB-IPV (Pediarix™) vaccine with other vaccines at 2, 4 and 6 months of age.
11646189|NCT00133406|Experimental|a|oral glutamine with juice for 10 days
11646190|NCT00133406|Experimental|b|PO vit A q 4 mo for 1 year plus zinc placebo
11646191|NCT00133406|Active Comparator|c|Zinc 40 mg twice weekly Plus Vitamin A Placebo for one year
11646192|NCT00133406|Placebo Comparator|d|oral glycine with juice daily for 10 days
11646193|NCT00133406|Placebo Comparator|e|Vitamin A Placebo plus Zinc Placebo for one year
11646194|NCT00133406|Experimental|f|Vitamin A q 4 months and PO Zinc for 1 year
11646195|NCT00133354|Active Comparator|Arimidex and Growth Hormone|
11646196|NCT00133354|Placebo Comparator|Placebo and Growth Hormone|
11646197|NCT00133276|Active Comparator|1|
11646198|NCT00133276|Placebo Comparator|2|
11646199|NCT00133263|Experimental|1|
11646200|NCT00133263|Active Comparator|2|
11646201|NCT00133250|Experimental|A|Abciximab
11646202|NCT00133250|Placebo Comparator|B|Heparin Sodium
11646203|NCT00133237|Active Comparator|A|Sirolimus-eluting stent (Cypher)
11646204|NCT00133237|Active Comparator|B|Paclitaxel-eluting stent (Taxus)
11646205|NCT00133224|Experimental|1|
11646206|NCT00133224|Other|2|
11646207|NCT00133211|Active Comparator|1|Antiarrythmic drug treatment
11646208|NCT00133211|Experimental|2|
11646209|NCT00133172|Experimental|1|Steroid rapid 5-day withdrawal
11646210|NCT00133172|Active Comparator|2|Standard steroid maintenance
11646211|NCT00133094|Other|Arm 1|
11646212|NCT00133068|Other|1|Control
11646213|NCT00133068|Experimental|2|Reduction of financial barrier
11646214|NCT00133068|Experimental|3|Computer Intervention
11646215|NCT00133068|Experimental|4|Reduction of financial barrier and Computer Intervention
11646216|NCT00133055|Experimental|Treatment booklet and telephone coaching|
11646217|NCT00133055|Other|Usual Care|
11646218|NCT00133003|Active Comparator|1|
11646219|NCT00133003|Placebo Comparator|2|
11646220|NCT00132964|Active Comparator|Immobilizaton device|Below Knee walking cast
11646221|NCT00132964|Experimental|Immobilization device|Removable ankle brace
11646222|NCT00132899|Active Comparator|Methotrexate|Methotrexate and infliximab combination
11646223|NCT00132899|Placebo Comparator|Placebo|Placebo plus infliximab combination
11646224|NCT00132834||Asthma/no ICS|Asthmatic children who are not currently taking ICS
11646225|NCT00132834||Asthma/ICS|Asthmatic children on ICS
11646226|NCT00132834||Non-asthmatic children|Children without asthma
11646227|NCT00132821|Active Comparator|A|Bupropion
11646228|NCT00132821|Active Comparator|B|Transdermal nicotine patch
11646229|NCT00132821|Placebo Comparator|C|
11646230|NCT00132821|Placebo Comparator|D|
11646231|NCT00132808|Experimental|Zoledronic Acid 2x5 mg|Zoledronic acid 5 mg intravenous (i.v.) given at randomization and Month 12
11646232|NCT00132808|Experimental|Zoledronic Acid 1x5 mg|Zoledronic acid 5 mg intravenous (i.v.) given at randomization and placebo at Month 12
11646233|NCT00132808|Placebo Comparator|Placebo|Placebo given at randomization and Month 12
11646234|NCT00132795|Experimental|1 Therapeutic Phone System|patients assigned to this condition will have unlimited access to the therapeutic telephone system for 4 months.
11646235|NCT00132795|Active Comparator|2 Standard care|Standard post-CBT care (i.e., no formal relapse prevention or professional treatment).
11646236|NCT00132769|Experimental|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
11646237|NCT00132769|Placebo Comparator|Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
11646238|NCT00132743|Active Comparator|1|Optimal Medical Care
11646239|NCT00132743|Active Comparator|2|Optimal Medical Care and Supervised Exercise
11646240|NCT00132743|Active Comparator|3|Optimal Medical Care and Stent
11646241|NCT00132730|Experimental|MK-0873 2.5 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 2.5 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
11646242|NCT00132730|Experimental|MK-0873 1.25 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 1.25 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
11646243|NCT00132730|Experimental|MK-0873 0.75 mg|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), MK-0873 0.75 mg tablets once daily for 12 weeks in Period II (Base) and MK-0873 2.5 mg tablets once daily for 12 weeks in Period III (EXT1)
11646809|NCT00125502|Placebo Comparator|II|n=200; placebo (normal saline)
11646244|NCT00132730|Placebo Comparator|Placebo|Participants receive placebo tablets once daily for 3 weeks in Period I (Base), placebo tablets once daily for 12 weeks in Period II (Base) and placebo tablets once daily for 12 weeks in Period III (EXT1)
11646245|NCT00132730|Experimental|MK-0873 2.5 mg + Usual Care|Participants receive MK-0873 2.5 mg tablets once daily plus usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks during Periods IV and V (EXT2)
11646246|NCT00132730|Active Comparator|Usual Care|Participants receive usual care (inhaled short- or long-acting beta-agonists, inhaled corticosteroids, or short- or long-acting anticholinergics) for 28 weeks during Periods IV and V (EXT2)
11646247|NCT00132704||A|The experiments in Group A will be conducted in order to determine if human tumor microvascular endothelium displays similar dose parameters as mouse tumor endothelium, and if the microvascular endothelium of tumors of different types behaves in a similar fashion in its response to IR.
11646248|NCT00132704||B|The experiments in Group B will be conducted in order to determine if tumor endothelium isolated to near homogeneity demonstrates dose parameters similar to those used in single dose radiotherapy of brain tumors.
11646249|NCT00132691|Active Comparator|1|Immunosuppressant medication implant
11646250|NCT00132691|Active Comparator|2|Systemic corticosteroids with immunosuppressant drugs as needed
11646251|NCT00132678|Experimental|001|Risperdal Consta 12.5 25 37.5 or 50mg intramuscular (IM) injection every 2 weeks
11646252|NCT00132678|Placebo Comparator|002|Placebo Matching placebo intramuscular (IM) injection every 2 weeks
11646253|NCT00132665|Active Comparator|1|Procedure/Surgery: A: Radiotherapy alone
11646254|NCT00132665|Experimental|2|Drug: B: CBDCA and Radiotherapy
11646255|NCT00132639|Experimental|1|Preoperative docetaxel-cisplatin combination chemotherapy
11646256|NCT00132639|Active Comparator|2|Preoperative docetaxel monotherapy
11646257|NCT00132613|Active Comparator|1|Procedure/Surgery: Observation alone after pericardial drainage
11646258|NCT00132613|Experimental|2|Drug: Pericardial instillation of bleomycin after drainage
11646259|NCT00132522|Experimental|Arm 1|
11646260|NCT00132509|Experimental|DFIL|
11646261|NCT00132509|Active Comparator|NINDS|
11646262|NCT00132483|Experimental|Intervention arm|
11646263|NCT00132483|No Intervention|Control|
11646264|NCT00132444|Active Comparator|1|0.25% gel
11646265|NCT00132444|Active Comparator|2|0.1% gel
11646266|NCT00132444|Placebo Comparator|3|
11646267|NCT00132418|Placebo Comparator|Placebo|placebo
11646268|NCT00132418|Experimental|Enbrel|Enbrel
11646269|NCT00132379|Experimental|1|
11646270|NCT00132353||Healthy volunteers|For normative data
11646271|NCT00132353||Patients with neurological disorders|For teaching fellows electrodiagnostic techniques
11646272|NCT00132314|Experimental|Arm 1|long-acting injectable risperidone
11646273|NCT00132314|Active Comparator|Arm 2|oral antipsychotic medication
11646274|NCT00132301|Active Comparator|Arm 1: Docetaxel and Prednisone|Chemotherapy after radical prostatectomy
11646275|NCT00132301|No Intervention|Arm 2: Standard of care|Standard of care
11646276|NCT00132262|Experimental|1|Patients randomized to this arm received an intervention based in the motivational interviewing style
11646277|NCT00132262|Active Comparator|2|Patients randomized to this arm received standard hospital care
11646278|NCT00132249||Head Injured|The Vietnam Head Injured Subjects
11646279|NCT00132249||Head Uninjured|Uninjured Vietnam Veteran Control Subjects
11646280|NCT00132158|Other|1|
11646281|NCT00132145|Other|Intervention|Behavioural
11646282|NCT00132132|Experimental|Intervention|This is a long term randomized controlled study looking at the effect of a Behavioral program on BMI in a population 10-20years old with a BMI greater than or equal to 85%. The intervention is a Behavioral education program which meets monthly for 4 hour session and includes exercise, education, empowerment and incentives. Both groups are referred to a dietician. The primary outcome is change in BMI and the secondary outcome is improvement in fasting metabolic parameters (lipid panel, insulin, glucose).
11646283|NCT00132132|No Intervention|Standard of Care/Control|Education on physical activity and nutrition in a primary care office setting
11646284|NCT00132119|Experimental|1|Nalmefene HCl 20 mg
11646285|NCT00132119|Experimental|2|Nalmefene HCl 40 mg
11646286|NCT00132119|Placebo Comparator|3|Placebo
11646287|NCT00132080|Placebo Comparator|1|Patients with acute Kawasaki disease
11646288|NCT00132067|Experimental|Treatment (vorinostat)|Patients receive oral vorinostat twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11646289|NCT00132041|Other|All Patients|patients with cirrhosis undergoing solitary or repetitive percutaneous RFA treatment sessions for the treatment of HCC.
11646290|NCT00132028|Experimental|Treatment (vorinostat)|Patients receive oral vorinostat twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR.
11646291|NCT00132002|Experimental|Treatment (vorinostat)|Patients receive oral suberoylanilide hydroxamic acid twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11646292|NCT00131989|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-14 or 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR may be considered for retreatment with sorafenib for up to an additional 6 courses upon disease recurrence provided the duration of CR is longer than 1 month.
11646293|NCT00131963||Regimen 1|Patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.
11646294|NCT00131963||Regimen 2|Patients receive doxorubicin and cyclophosphamide as in regimen 1. Patients then receive paclitaxel IV over 1 hour once weekly for 12 weeks.
11646295|NCT00131937|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11646435|NCT00130117|Placebo Comparator|Oral Contraceptive Pills (OCPs)|PLACEBO
11646296|NCT00131911|Experimental|Group A (patients with carcinoid tumors)|Patients receive 400 mg oral sorafenib twice daily on days 1-28.
11646297|NCT00131911|Experimental|Group B (islet cell and other neuroendocrine tumors)|Patients receive 400 mg oral sorafenib twice daily on days 1-28.
11646298|NCT00131885|Placebo Comparator|Levonorgestrel 1.5 with Placebo Herb|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a placebo herb daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg
11646299|NCT00131885|Active Comparator|Levonorgestrel 1.5 with SJW 900 mg|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took St. John's Wort (SJW) 900 mg a Day orally for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg
11646300|NCT00131885|Active Comparator|Levonorgestrel 2.25 with SJW 900 mg|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a St. Johns's Wort 300 mg capsules three times daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 2.25 mg
11646301|NCT00131885|Active Comparator|Levonorgestrel 1.5 with SJW 1500 mg|This group had baseline pharmacokinetic studies after an oral dose of levonorgestrel (LNG) 1.5 mg, then took a St. Johns's Wort 300 mg capsules five times daily for 4-6 weeks, during which time pharmacokinetic studies were repeated after an oral dose of LNG 1.5 mg
11646302|NCT00131846|Active Comparator|1|Diuretics use
11646303|NCT00131846|Active Comparator|2|No diuretics use
11646304|NCT00131677|Active Comparator|active immediate|participants in this arm start study product immediately upon enrollment
11646305|NCT00131677|Placebo Comparator|placebo immediate|participants in this arm start study product immediately upon enrollment
11646306|NCT00131677|Active Comparator|active delayed|persons in this arm start study product 9 months after enrollment
11646307|NCT00131677|Placebo Comparator|placebo delayed|participants in this arm start study product nine months after enrollment
11646308|NCT00131664|Active Comparator|Avandamet|Avandamet 2 mg / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily over 6 months
11646309|NCT00131664|Active Comparator|Avandia and Amaryl|Avandia + Amaryl 4 mg + 1 mg once daily titration up to 8 mg + 2 mg once daily over 6 months
11646310|NCT00131664|Active Comparator|Metformin|Metformin 500 mg twice daily titration up to 1000 mg twice daily over 6 months
11646311|NCT00131638|Experimental|Palifermin|Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
11646312|NCT00131638|Placebo Comparator|Placebo|Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
11646313|NCT00131573|Experimental|1|Stimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on.
11646314|NCT00131573|Sham Comparator|2|No stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on.
11646315|NCT00131560|Other|A|
11646316|NCT00131547|No Intervention|1|Usual Clinical Care
11646317|NCT00131547|Experimental|2|Behavioral (e.g., Counseling)
11646318|NCT00131508|Experimental|2|Glutamine
11646319|NCT00131508|Placebo Comparator|1|
11646320|NCT00131495|Placebo Comparator|1|Placebo patch
11646321|NCT00131495|Experimental|2|Testosterone patch (300mcg/day, changed twice a week for one year
11646322|NCT00131482|Experimental|10 micrograms|
11646323|NCT00131482|Experimental|30 micrograms|
11646324|NCT00131482|Placebo Comparator|Placebo|
11646325|NCT00131482|Experimental|3 micrograms|
11646326|NCT00131482|Experimental|1 microgram|
11646327|NCT00131469|Active Comparator|Teriparatide (FORTEO)|Once daily SQ administration of Teriparatide (FORTEO) 20 ug for 18 months
11646328|NCT00131469|Placebo Comparator|Placebo|Daily SQ placebo for 18 months
11646329|NCT00131456|Active Comparator|Venlafaxine|Venlafaxine
11646330|NCT00131456|Placebo Comparator|Placebo|Placebo
11646331|NCT00131404|Placebo Comparator|Phase A/B: Arm 1|"Phase A: Arm 1: MK0364 Pbo capsule once daily.
~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 1: MK0364 Pbo capsule once daily."
11646332|NCT00131404|Experimental|Phase A/B: Arm 2|"Phase A: Arm 2: MK0364 2 mg capsule once daily.
~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 2: MK0364 2 mg capsule once daily."
11646333|NCT00131404|Experimental|Phase A/B: Arm 3|"Phase A: Arm 3: MK0364 4 mg capsule once daily.
~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 3:
~MK0364 4 mg capsule once daily."
11646334|NCT00131404|Experimental|Phase A/B: Arm 4|"Phase A: Arm 4: MK0364 6 mg capsule once daily.
~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 4:
~MK0364 6 mg capsule once daily."
11646335|NCT00131404|Experimental|Phase A/B: Arm 5|Phase A: Arm 5: MK0364 6 mg capsule once daily. 52 week treatment period. Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 5: MK0364 6 mg capsule once daily.
11646336|NCT00131391|Placebo Comparator|Phase A/B; Arm 1|Phase A: Arm 1: MK0364 Pbo capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 1: MK0364 Pbo capsule once daily.
11646337|NCT00131391|Experimental|Phase A/B: Arm 2|Phase A: Arm 2: MK0364 4 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 2: MK0364 4 mg capsule once daily.
11646338|NCT00131391|Experimental|Phase A/B: Arm 3|Phase A: Arm 3: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 3: MK0364 Pbo capsule once daily.
11646436|NCT00130104|Experimental|MCB|randomized to receive the metacarpal block for anesthesia
11646339|NCT00131391|Experimental|Phase A/B: Arm 4|Phase A: Arm 4: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 4: MK0364 2 mg capsule once daily.
11646340|NCT00131391|Experimental|Phase A/B: Arm 5|Phase A: Arm 5: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 5: MK0364 4 mg capsule once daily.
11646341|NCT00131391|Experimental|Phase A/B: Arm 6|Phase A: Arm 6: MK0364 6 mg once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 6: MK0364 6 mg capsule once daily.
11646342|NCT00131378|Experimental|Male on GH|"Participants received growth hormone replacement therapy. The starting dose was 2 micrograms/kg per day and they were titrated within the normal range based on blood levels.
~Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months."
11646343|NCT00131378|Placebo Comparator|Male on Placebo|"Participants received placebo.
~Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months."
11646344|NCT00131378|Experimental|Female on GH|"Participants received growth hormone replacement therapy. The starting dose was 4 micrograms/kg per day and they were titrated within the normal range based on blood levels.
~Nutropin AQ growth hormone : Participants gave themselves injections of growth hormone every night for 6 months."
11646345|NCT00131378|Placebo Comparator|Female on Placebo|"Participants received placebo.
~Placebo Growth Hormone : Participants gave themselves injections of placebo every night for 6 months."
11646346|NCT00131365|Experimental|ExAblate MRgFUS|Treatment with the ExAblate 2000 system Version 4.1
11646347|NCT00131352|Experimental|Synvisc|Participants with symptomatic primary osteoarthritis (OA) of the knee received a single injection of 6 mL hylan G-F 20 (Synvisc).
11646348|NCT00131352|Placebo Comparator|Saline Control|Participants (control group) with symptomatic primary osteoarthritis (OA) of the knee received a single injection of 6 mL phosphate buffered saline.
11646349|NCT00131248|Other|Anti-reflux Medications, then Placebo (group 1)|"3-day course of anti-reflux medications, followed by 7-day course placebo, followed by 4-day course anti-reflux medications.
~All study medication administered via nipple or orogastric (OG) tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes."
11646350|NCT00131248|Other|Placebo, then Anti-reflux Medications|"3-day course placebo, followed by 7-day course anti-reflux medication, followed by 4-day course placebo.
~All study medication administered via nipple or OG tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes."
11646351|NCT00131235|Placebo Comparator|Control|Standard antenatal care as described in intervention
11646352|NCT00131235|Experimental|Monthly SP|Standard antenatal care + monthly intermittent presumptive treatment of malaria with sulfadoxine pyrimethamine, as described in intervention
11646353|NCT00131235|Experimental|AZI-SP|Standard antenatal care + monthly intermittent presumptive treatment of malaria with sulfadoxine pyrimethamine + two presumptive treatments of sexually transmitted infections and malaria with azithromycin, as described in intervention
11646354|NCT00131144|Experimental|Octreotide Acetate in Microspheres 20 mg|20 mg will be administered im once every 4 weeks
11646355|NCT00131144|Experimental|Octreotide Acetate in Microspheres 30 mg|30 mg will be administered im once every 4 weeks
11646356|NCT00131144|Placebo Comparator|Placebo|
11646357|NCT00131131|Experimental|Exercise|The intervention was an exercise program of moderate to vigorous intensity. The intervention started with 30-minute sessions three times per week, with the ultimate goal to have participants exercise four to five times per week for 45 to 60 minutes per session.
11646358|NCT00131131|No Intervention|Control|Women in the control group did not attend instructional sessions with the exercise interventionist and did not receive the motivational mailings
11646359|NCT00131079|Experimental|PEPAF|General Practitioner's assessment of physical activity level and minimal advice in routine clinical practice supplemented by physical activity prescription to those who accepted an additional 15 minutes appointment.
11646360|NCT00131079|Active Comparator|Control|
11646361|NCT00131053|Experimental|A|
11646362|NCT00131027|Experimental|A|HD-MTX
11646363|NCT00131027|Active Comparator|B|ID-MTX
11646364|NCT00131014||Next of Kin of deceased subj by lymphoma|Next of Kin of deceased subject by lymphoma
11646365|NCT00131014||Subject unaffected by lymphoma|Subject unaffected by lymphoma
11646366|NCT00131014||Subject affected by lymphoma|Subject affected by lymphoma
11646367|NCT00130923|Experimental|Risperidone Long Acting|Risperidone Long Acting; aka Risperdal Consta; injectable form
11646368|NCT00130923|Active Comparator|Oral Risperidone|Oral Risperidone; aka Risperdal; oral form
11646369|NCT00130910|Experimental|1|Albendazole
11646370|NCT00130910|Placebo Comparator|2|
11646371|NCT00130845|Experimental|Octreotide Acetate in Microspheres|
11646372|NCT00130845|Placebo Comparator|Placebo|
11646373|NCT00130832|Experimental|1|RotaTeq and OPV concomitantly
11646374|NCT00130832|Experimental|2|RotaTeq and OPV on staggered schedule
11646375|NCT00130819|Experimental|1|Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
11646376|NCT00130819|Active Comparator|2|Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
11646377|NCT00130793|Experimental|zoster vaccine live (Oka/Merck) refrigerated formulation|ZOSTAVAX™ with phosphate-gelatin-sucrose-urea (PGSU) stabilizer (~45,000 plaque-forming units [PFU]), 1 subcutaneous 0.65-mL injection
11646378|NCT00130793|Active Comparator|zoster vaccine live (Oka/Merck) frozen formulation|ZOSTAVAX™ with phosphate-gelatin-sucrose (PGS) stabilizer (~57,000 PFU), 1 subcutaneous 0.65-mL injection
11646379|NCT00130780|Active Comparator|A|Pre-surgical Treatment with Bevacizumab plus Chemotherapy
11646380|NCT00130780|Active Comparator|B|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
11646381|NCT00130754|Experimental|1|Thymo
11646382|NCT00130754|No Intervention|2|
11646437|NCT00130091|Experimental|Clonidine|administer with local anesthetic
11646383|NCT00130728|Experimental|erlotinib HCl + bevacizumab|oral erlotinib HCl 150 mg/day orally + intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
11646384|NCT00130728|Placebo Comparator|erlotinib HCl + placebo|oral erlotinib HCl 150 mg/day orally + intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
11646385|NCT00130702|Experimental|Gefitinib (Iressa)|All patients will receive Gefitinib (Iressa) at a dose of 750 mg orally (three 250 mg tabs) each day.
11646386|NCT00130689|Other|Cetuximab|Patients received cetuximab at an initial dose of 400 mg/m2 administered IV over 120 min, followed by weekly infusions at 250 mg/m2 administered IV over 60 min. Once cycle was 4 weeks of therapy. Patients received treatment until disease progression or unacceptable toxicity.
11646387|NCT00130676|Experimental|mifepristone 600 mg|
11646388|NCT00130676|Placebo Comparator|matching placebo|
11646389|NCT00130637|Experimental|Daclizumab|IV daclizumab
11646390|NCT00130611|Placebo Comparator|BNP blinded therapy|Clinical treatment without knowledge of BNP levels
11646391|NCT00130611|Experimental|BNP guided therapy|Clinical treatment based on clinical examination and BNP-levels
11646392|NCT00130598|Active Comparator|1|control group: patients receive a preventive hydration with 154mEq/l saline at an ongoing rate of 1ml/kg per hour of at least 12 hours prior and after the procedure.
11646393|NCT00130598|Active Comparator|2|7h-sodium bicarbonate (according to the regimen used in a recently published study (slightly modified)14): before contrast a bolus of 3ml/kg NaHCO3 166mEq/l for one hour, followed by an infusion of NaHCO3 166mEq/l with a rate of 1ml/kg per hour until 6h after contrast.
11646394|NCT00130598|Active Comparator|3|short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg; patients with a body weight above 100kg 300ml) as a bolus 20 minutes before contrast; additionally ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl of San Pellegrino® non-sparkling mineral water at the start of the infusion. Ingestion of 500ml San Pellegrino® non-sparkling mineral water in the first 6 hours after contrast.
11646395|NCT00130546|Active Comparator|1|Cypher Stent
11646396|NCT00130546|Active Comparator|2|Taxus Stent
11646397|NCT00130533|Experimental|Xeloda (capecitabine)|1000 mgrs/m2 twice a day, tablets, 8 cycles
11646398|NCT00130533|No Intervention|Observation|Observation. No intervention.
11646399|NCT00130520|Experimental|open label|
11646400|NCT00130507|Active Comparator|Arm A: VX|Vinorelbine and capecitabine (VX): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days).
11646401|NCT00130507|Experimental|Arm B: VXH|Vinorelbine, capecitabine and trastuzumab (VXH): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days) and trastuzumab 4 mg/kg iv (loading dose first week), followed by 2 mg/kg weekly.
11646402|NCT00130494|Experimental|Arm A: Zoledronic acid 4 mg|Zoledronate 4 mg every 3 or 4 weeks. This arm will receive study treatment from the time of entry into the trial, until the appearance of the symptoms of bone metastases (or a maximum period of 12 months, whichever occurs first).
11646403|NCT00130494|No Intervention|Arm B: Observation|Patients will not receive any treatment with bisphosphonates until the time of onset of symptoms (or a maximum period of 12 months, whichever occurs sooner).
11646404|NCT00130442|Experimental|1|PI-88 190 mg daily by subcutaneous injection and dacarbazine 1000 mg/m2 on day 1 of each 21 day cycle
11646405|NCT00130442|Active Comparator|2|dacarbazine 1000 mg/m2 on day 1 of every 21 day cycle by intravenous infusion
11646406|NCT00130390|Experimental|1|One nitazoxanide 500 mg tablet twice daily for 28 days
11646407|NCT00130390|Placebo Comparator|2|One placebo tablet twice daily for 28 days
11646408|NCT00130377|Experimental|cell therapy|Patient receiving active biologic
11646409|NCT00130377|Placebo Comparator|control|Patient receiving placebo or standard of care
11646410|NCT00130364|Experimental|1|Pimecrolimus
11646411|NCT00130364|Placebo Comparator|2|Pimecrolimus vehicle cream
11646412|NCT00130325|Active Comparator|A|Isoniazid arm
11646413|NCT00130325|Placebo Comparator|B|Placebo of Isoniazid tablet 300mg
11646414|NCT00130312|Experimental|Sulodexide|Also known as KRX-101. These patients are also on standard of care ACEs and ARBs.
11646415|NCT00130312|Placebo Comparator|Placebo|These patients were on standard of care ACEs and ARBs.
11646416|NCT00130286|Experimental|rhGH + rosi|Recombinant human growth hormone + rosiglitazone
11646417|NCT00130286|Experimental|rhGH placebo + rosi|Placebo for recombinant human growth hormone + rosiglitazone
11646418|NCT00130286|Experimental|rhGH + rosi placebo|Recombinant human growth hormone + placebo for rosiglitazone
11646419|NCT00130286|Placebo Comparator|Double placebo|Placebo for recombinant human growth hormone + placebo for rosiglitazone
11646420|NCT00130273|Experimental|1|Participants will receive managed problem solving for 12 months
11646421|NCT00130273|Active Comparator|2|Participants will receive standard of care for 12 months
11646422|NCT00130260|Experimental|vaccine, schedule 1|3rd and 4th dose of vaccine, on original schedule
11646423|NCT00130260|Experimental|vaccine, schedule 2|3rd and 4th dose of vaccine on modified schedule
11646424|NCT00130260|Placebo Comparator|placebo, schedule 1|3rd and 4th dose of placebo, on original schedule
11646425|NCT00130260|Placebo Comparator|placebo, schedule 2|3rd and 4th dose of placebo on modified schedule
11646426|NCT00130247|Experimental|2EHRZ/2HR arm|Daily treatment with isoniazid (INH), rifampicin, ethambutol and pyrazinamide for 2 months followed by 2 months of daily INH plus rifampicin over a maximum time period of 18 weeks.
11646427|NCT00130247|Active Comparator|2EHRZ/4HR arm|Daily treatment with Isoniazid (INH), rifampicin, ethambutol and pyrazinamide for 2 months followed by 4 months of daily INH plus rifampicin over a maximum time period of 28 weeks.
11646428|NCT00130208|Experimental|Sulodexide|Also known as KRX-101. All patients will be on standard of care ACE or ARBs.
11646429|NCT00130208|Placebo Comparator|Placebo|All patients will be on standard of care ACE or ARBs.
11646430|NCT00130195|Experimental|A|
11646431|NCT00130169|Experimental|1|
11646432|NCT00130156|Experimental|1|
11646433|NCT00130156|Experimental|2|
11646434|NCT00130117|Experimental|r-metHuLeptin|r-metHuLeptin administered subcutaneously.
11646438|NCT00130091|Placebo Comparator|Local anesthetic|Local anesthetic without clonidine
11646439|NCT00130039|Experimental|cilostazol|cilostazol 100mg bid plus placebo of clopidogrel
11646440|NCT00130039|Active Comparator|Clopidogrel|clopidogrel 75mg qd and matching placebo of cilostazol
11646441|NCT00130026|Placebo Comparator|I|Saline placebo
11646442|NCT00129987|Experimental|Nurse group|An initial consultation of up to 45 min offered either by a practice based primary care nurse, followed by a second shorter face to face consultation and telephone follow-up for 1 year.
11646443|NCT00129987|Experimental|Lay educator group|An initial consultation of up to 45 min offered either by a lay educator, followed by a second shorter face to face consultation and telephone follow-up for 1 year.
11646444|NCT00129961|Experimental|1|Conversion to a sirolimus-based regimen
11646445|NCT00129961|Active Comparator|2|Continuation of a CNI-based regimen
11646446|NCT00129935|Active Comparator|Arm A: EC-T|Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.
11646447|NCT00129935|Experimental|Arm B: ET-X|Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.
11646448|NCT00129922|Active Comparator|Fluorouracil+Epirubicin+Cyclophosphamide|5-FU+4-Epirubicin+Cyclophosphamide
11646449|NCT00129922|Experimental|FEC followed by Paclitaxel|5-FU+4-Epirubicin+Cyclophosphamide
11646450|NCT00129896|Experimental|Myocet+Taxotere+Herceptin|Myocet 50 mg/m2; Taxotere 60 mg/m2; Herceptín 4 mg/Kg (first dose) and in the following cycles 2 mg/Kg
11646451|NCT00129805|Experimental|MCI-9042|
11646452|NCT00129805|Active Comparator|Aspirin|
11646453|NCT00129792|Experimental|1|Has 100% expectation of receiving supplement
11646454|NCT00129792|Sham Comparator|2|Has 50% expectation of receiving supplement
11646455|NCT00129792|Other|3|Has 0% expectation of receiving supplement.
11646456|NCT00129766|Active Comparator|palivizumab|15 mg/kg administered intramuscularly for 5 monthly doses
11646457|NCT00129766|Experimental|motavizumab (MEDI-524)|15 mg/kg of motavizumab was administered intramuscularly for 5 monthly doses
11646458|NCT00129753|Experimental|Alemtuzumab|
11646459|NCT00129740|Experimental|Nilotinib|400 mg orally twice daily
11646460|NCT00129727|Experimental|Phase II|Paclitaxel carboplatin bevacizumab
11646461|NCT00129714|No Intervention|wait and see|
11646462|NCT00129714|Experimental|collar|
11646463|NCT00129714|Experimental|physiotherapy|
11646464|NCT00129701|Experimental|Patients attending|Patients recruited to have a telephone consultation and then at the next appointment a face-to-face appointment
11646465|NCT00129675|Experimental|[123I]ß CIT|To assess [123I]ß CIT and SPECT imaging
11646466|NCT00129662|Experimental|Intervention arm|Pictorial action plan
11646467|NCT00129649|No Intervention|control group|This group received usual care and did not receive a telephone reminder
11646468|NCT00129649|Active Comparator|telephone reminder group|This group received a telephone reminder for their clinic appointment
11646469|NCT00129636|Other|Patient attending hospital clinic|patients were sent a letter especially dictated for them and a copy of the letter written by the hospital consultant to their GP to review
11646470|NCT00129623|Experimental|1|
11646471|NCT00129623|Placebo Comparator|2|
11646472|NCT00129545|Experimental|WATCHMAN|Implant of WATCHMAN Left Atrial Appendage Closure Technology
11646473|NCT00129545|Active Comparator|Warfarin control|Subjects are treated with current standard of care Oral Anticoagulation Therapy with Warfarin
11646474|NCT00129545|Other|Roll-in|Implant of WATCHMAN Left Atrial Appendage Closure Technology. Up to 3 non-randomized subjects per site, these subjects were not included in the primary analysis.
11646475|NCT00129519|Active Comparator|Imiquimod cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
11646476|NCT00129493|Other|Arm 1|
11646477|NCT00129480|Experimental|Assistance with Pain Treatment|Care management intervention including assessment, decision support, patient activation, education and followup, provider education, feedback to providers
11646478|NCT00129480|No Intervention|Treatment as usual|Treatment as usual
11646479|NCT00129467|Experimental|methylphenidate + SSRI|During the 18-day blind treatment period, subjects will be prescribed methylphenidate 5-10 mg twice per day and selective serotonin reuptake inhibitor (SSRI). Subjects already receiving a SSRI when they begin the study, will continue on the recommended dose of that SSRI; subjects not receiving a SSRI will be prescribed 10-20 mg per day Citalopram. Subjects who respond to methylphenidate treatment will have the option of continuing on methylphenidate, up to 15 mg bid, and an antidepressant in the 6 week open label portion of the study.
11646480|NCT00129467|Placebo Comparator|Placebo + SSRI|During the 18-day blind treatment period, subjects will be prescribed placebo 1-2 capsules twice per day and selective serotonin reuptake inhibitor (SSRI). Subjects already receiving a SSRI when they begin the study, will continue on the recommended dose of that SSRI; subjects not receiving a SSRI will be prescribed 10-20 mg per day Citalopram.
11646481|NCT00129454|Experimental|Telemedicine treatment|Psychotherapy delivered by telephone
11646482|NCT00129454|Active Comparator|In-Person treatment|Psychotherapy delivered in-person
11646483|NCT00129454|No Intervention|Assessment only|No intervention
11646484|NCT00129441|Experimental|Merck L-830982|
11646485|NCT00129441|Placebo Comparator|Sugar pill|
11646486|NCT00129428|Experimental|UVB Irradiation|A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
11646487|NCT00129415|Experimental|UVA1 Irradiation|UVA 1 Irradiation (Sellemed UVA1 light source) up to 130 J/cm2
11646488|NCT00129415|Experimental|UVB Irridiation|UVB Irradiation maximum dose of 4000 mJ/cm2
11646489|NCT00129402|Experimental|Pooled subjects who received ezetimibe with simvastatin|Pooled subjects who received ezetimibe 10 mg plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg
11646490|NCT00129402|Active Comparator|Pooled subjects who received simvastatin monotherapy|Pooled subjects who received ezetimibe matching placebo plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg
11646491|NCT00129389|Active Comparator|Arm A: FAC|FAC X 6 The standard arm consisted of six cycles of FAC (fluorouracil 500 mg/m2, doxorubicin 50mg/m2, and cyclophosphamide 500mg/m2) administered once every 3 weeks.
11646492|NCT00129389|Experimental|Arm B: FAC-wP|FAC X 4 + 8 weekly Paclitaxel (wP) Patients in the experimental arm received four cycles of the FAC regimen followed by eight weekly administrations of paclitaxel (100mg/m2 per dose)
11646493|NCT00129376|Experimental|Doxorubicin+cyclophosphamide - Docetaxel|Patients received doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2), both in a short intravenous infusion, every three weeks for four cycles. Later, docetaxel (36 mg/m2) was administered an intravenous infusion, weekly for six weeks followed by a 2-week resting period (8-week cycle).
11646494|NCT00129337|Experimental|1|0.1 mg/kg
11646495|NCT00129337|Experimental|2|0.3 mg/kg
11646496|NCT00129337|Experimental|3|1 mg/kg
11646497|NCT00129337|Experimental|4|3 mg/kg
11646498|NCT00129324|Other|Lead Reduction Arm|random assignment to receive lead hazard control intervention. Assessing lead hazards in the home. Reducing lead hazards by cleaning, painting, covering, and/or replacing/repairing interior and exterior components of the home.
11646499|NCT00129324|Other|Injury Reduction Arm|random assignment to receive injury hazard control intervention. Assessing home for potential injury hazards. Controlling hazards by 1) installing safety equipment such as stairway gates, cabinet locks, smoke & CO detectors, etc. 2) removing the hazards from the reach of a child and/or 3) restricting access to the hazards.
11646500|NCT00129311|Experimental|1|Selegiline
11646501|NCT00129311|Placebo Comparator|2|Placebo
11646502|NCT00129298|Experimental|1|Tiagabine
11646503|NCT00129298|Placebo Comparator|2|Matching placebo
11646504|NCT00129285|Experimental|Low Dose Modafinil|Low Dose Modafinil 200 mg daily
11646505|NCT00129285|Experimental|High Dose Modafinil|High dose modafinil 400 mg daily
11646506|NCT00129285|Placebo Comparator|Placebo|Placebo
11646507|NCT00129272|Active Comparator|Bupropion (Wellbutrin-SR)|Using a double-blind, randomized, placebo-controlled design, smokers received active treatment with Bupropion-SR (150 mg. twice daily) in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
11646508|NCT00129272|Placebo Comparator|Matching Placebo|Using a double-blind, randomized, placebo-controlled design, smokers received treatment with a matching placebo (to Bupropion-SR 150 mg) twice daily in conjunction with cognitive-behavior therapy (weekly sessions) for smoking cessation over a 9-week period.
11646509|NCT00129259|Experimental|Anti-CD3 mAb Plus Diabetes Standard of Care Treatment|"Subjects receive 1.) a 14-day course of anti-CD3 monoclonal antibody (mAb) intravenously (IV) comprised of daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 days of 826 µg/m2 [Cycle 1] and, when eligible per protocol, receipt of a second 14-day course after a 12-month interval (at month 13)[Cycle 2]. Note: Prior to May 2007, the course of IV daily doses of anti-CD3 mAb were: 57 µg/m2, 115 µg/m2, 230 µg/m2, 460 µg/m2, and 10 days of 919 µg/m2 and, when eligible per protocol, a second course after a 12-month interval (at month 13). 2.) and intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.
~Iron supplementation initiated status post treatment randomization."
11646510|NCT00129259|Active Comparator|Diabetes Standard of Care Treatment|"Subjects receive intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.
~Iron supplementation initiated status post treatment randomization."
11646511|NCT00129246|Active Comparator|Bupropion only|The placebo comparator was a group of matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen in a similar 7-week study investigation compared to naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day).
11646512|NCT00129246|Experimental|Naltrexone +Bupropion|The active comparator in this 7-week open label study investigation was naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day) compared to matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen (bupropion only).
11646513|NCT00129233|Active Comparator|Valsartan|Valsartan group treated with 80-160mg daily valsartan without Ca channel blockers or ACE inhibitors.
11646514|NCT00129233|Active Comparator|Amlodipine|Amlodipine group treated with 5-10mg daily amlodipine without ACE inhibitors or angiotensin receptor blockers.
11646515|NCT00129220|Experimental|Olanzapine|olanzapine: 5 to 20 mg per day for 6 weeks
11646516|NCT00129220|Active Comparator|Haloperidol|haloperidol: 2.5 to 10 mg per day for 6 weeks
11646517|NCT00129220|Placebo Comparator|Placebo|placebo for 3 weeks, then olanzapine 5 to 20 mg per day for 3 weeks
11646518|NCT00129129|Experimental|MenHibrix Group|Subjects in the Group were followed during the entire study period, from Day 0 up to study end 6 months post fourth dose vaccinationDuring Primary Phase (Study 101858), subjects in this group, aged 6-12 weeks at enrolment, received 3 doses of Menhibrix™ co-administered with Pediarix™ and Prevnar™ (at Day 0 and Months 2 and 4). During Fourth-Dose Phase (Study 102015), subjects primed with 3 doses of Menhibrix™ during the Primary Phase received one dose of Menhibrix™ and one concomitant dose of Prevnar™ at Month 10-13. During Primary Phase, Menhibrix™ was administered intramuscularly (IM) in the right upper thigh, and Pediarix™ and Prevnar™ IM in the left upper and lower thighs, respectively. During Fourth-Dose Phase, Menhibrix™ was administered by the same route and at the same site as during Primary Phase, and Prevnar™ was administered IM in the left upper thigh.
11646519|NCT00129129|Active Comparator|ActHIB Group|During Primary Phase (Study 101858), subjects in this group, aged 6-12 weeks at enrolment, received 3 doses of ActHIB™ vaccine co-administered with the Pediarix™ and Prevnar™ vaccines (at Day 0 and Months 2 and 4). Subjects in this Group were followed from Day 0 up to Month 10-13 solely. During Fourth-Dose Phase (Study 102015), these subjects were followed as subjects either in the ActHIB/MenHibrix Group or in the ActHIB/ActHIB Group, receiving then one dose of either Menhibrix™ or ActHIB™ concomitantly with one dose of Prevnar™. During Primary Phase, ActHIB™ was administered intramuscularly (IM) in the right upper thigh, and the Pediarix™ and Prevnar™ vaccines IM in the left upper and lower thighs, respectively.
11646592|NCT00128219|Experimental|GBS III-TT|A single dose of GBS III-TT vaccine administered intramuscularly (IM) containing 50 mcg of GBS III capsular polysaccharide and 32 mcg of tetanus toxoid.
11646520|NCT00129129|Active Comparator|Menomune Group|Subjects in the Group were followed solely during the period of Primary Phase (Study 101858), up to Month 10. Subjects in the Group, aged 3-5 years at enrolment, received one dose of Menomune™ at Day 0. Menomune™ was administered subcutaneously in the left deltoid region.
11646521|NCT00129129|Experimental|ActHIB/Menhibrix Group|Subjects in the Group were followed solely during the period of the Fourth-Dose Phase of the study (Study 102015), from Month 10-13 to Month 11-14. Subjects in this Group had been primed with ActHIB™ during Primary Phase (study 101858) and received at Month 10-13 a fourth dose of Menhibrix™ and a concomitant fourth dose of Prevnar™. Menhibrix™ and Prevnar™ were administered intramuscularly in the right and left upper thighs, respectively.
11646522|NCT00129129|Experimental|ActHIB/ActHIB Group|Subjects in the Group were followed solely during the period of the Fourth-Dose Phase of the study (Study 102015), from Month 10-13 to Month 11-14. Subjects in this Group had been primed with ActHIB™ during Primary Phase of the study (study 101858) and received at Month 10-13 a fourth dose of ActHIB™ and a concomitant fourth dose of Prevnar™. ActHIB™ and Prevnar™ were administered intramuscularly in the right and left upper thighs, respectively.
11646523|NCT00129116|Experimental|Menhibrix F1/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 1 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
11646524|NCT00129116|Experimental|Menhibrix F2/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 2 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
11646525|NCT00129116|Experimental|Menhibrix F3/Infanrix-penta Group|Subjects received Menhibrix vaccine formulation 3 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
11646526|NCT00129116|Experimental|Menitorix/Infanrix-penta Group|Subjects received Menitorix vaccine and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menitorix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
11646527|NCT00129116|Active Comparator|Menjugate/Infanrix-hexa Group|Subjects received Menjugate vaccine and Infanrix-hexa vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menjugate and Infanrix-hexa vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
11646528|NCT00129090|Experimental|R-CHOEP14 with 12x Rituximab|8 cycles of standard CHOP with etoposide in 14-day intervals. Patients with CD20+ lymphoma receive 12 doses of Rituximab (day 0,1,4,8 of cycle 1, day 1 and 8 of cycle 2, day1 of cycle 3-8 )
11646529|NCT00128973||Healthy Volunteers|Healthy adult M/F 18-85 y/o.Hgb greater than or equal to 11. Wt>110 bs. No heart, lung, kidney, bleeding disorders. No hep BorC since age ll. No IV drug use. No exposure to the AIDS virus. Not pregnant.
11646530|NCT00128973||Patients|Patients with abnormalities of immune function
11646531|NCT00128973||Relatives of Patients|Relatives may be mother, father, siblings, children, grandparents, aunts, uncles, and first cousins to a patient.
11646532|NCT00128960||1|Participants with different types of diseases and conditions who have undergone an allogeneic (donor) stem cell transplant.
11646533|NCT00128921|Experimental|Velcade, Cohort A|Treatment: 1.3 mg/m^2
11646534|NCT00128921|Experimental|Velcade, Cohort B|Treatment: 1.0 mg/m^2
11646535|NCT00128921|Experimental|Velcade, Cohort C|Treatment: 0.7 mg/m^2
11646536|NCT00128908|Active Comparator|Continuous triple-class therapy|Patients will be treated with a regimen containing antiretroviral agents from 3 different classes
11646537|NCT00128908|Experimental|Alternating therapy|Patients will be assigned to weekly alternating dual-class regimen
11646538|NCT00128895|Active Comparator|azathioprine, standard|standard azathioprine maintenance upto one year after diagnosis, subsequently tapering of azathioprine with 25 mg per 3 months
11646539|NCT00128895|Experimental|azathioprine, longterm|longterm maintenance with azathioprine upto four years after diagnosis, subsequently azathioprine will be tapered with 25 mg per 3 months
11646540|NCT00128856|Experimental|Gemcitabine + Adriamycine + Paclitaxel|Neoadjuvant chemotherapy consisted of adriamycine 40 mg/m2, administered on day 1 as an i.v. infusion. Paclitaxel 150 mg/m2 was administered on day 2 as an i.v infusion followed by gemcitabine 2000 mg/m2 as an i.v. infusion. The three drugs were administered every two weeks for 6 cycles.
11646541|NCT00128843|Experimental|Exemestane|25mg/day per VO until progression disease, after this progression the patient could receive the another drug (comparator arm) ie Anastrozole by investigator decision
11646542|NCT00128843|Active Comparator|Anastrozole|1mg/day per VO until progression disease, after this progression the patient could receive the another drug (experimental arm) ie Exemestane by investigator decision
11646543|NCT00128830|Experimental|Etravirine + 2 antiretrovirals|
11646544|NCT00128817|Experimental|1|Concurrent Chemoradiation
11646545|NCT00128817|Active Comparator|2|Laryngectomy + adjuvant radiotherapy/chemoradiotherapy
11646593|NCT00128219|Active Comparator|Td|The control group will receive a single dose of Tetanus and Diphtheria Toxoids (Td) vaccine.
11646594|NCT00128206|Active Comparator|B|isoniazid (INH) (900 mg orally) given twice weekly for 9 months
11646914|NCT00124059|Experimental|Type A SERO|
11646546|NCT00128778|Experimental|Arm A: PLD|Pegylated liposomal doxorubicin (PLD) after induction chemotherapy in patients with metastatic breast cancer (MBC). Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to PLD (40 mg/m2) every 28 days for six cycles or to observation.
11646547|NCT00128778|No Intervention|Arm B: Observation|Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to observation.
11646548|NCT00128765|Active Comparator|usual care|usual care, i.e. COPD care at patient's own initiative, mostly for medical help during exacerbations
11646549|NCT00128765|Experimental|monitoring controls|regular COPD care (monitoring) provided by practice nurse according to current COPD guidelines
11646550|NCT00128765|Experimental|self-management|disease specific self-management program 'Living Well with COPD'
11646551|NCT00128713|Active Comparator|1|Lower Dose Prophylactic Platelets
11646552|NCT00128713|Active Comparator|2|Medium Dose Prophylactic Platelets
11646553|NCT00128713|Active Comparator|3|Higher Dose Prophylactic Platelets
11646554|NCT00128687|Experimental|Immediate Intervention|Participants in both arms continue to receive usual medical care throughout the study period. In addition, participants randomized to Immediate Intervention receive intensive case management for Coronary heart disease (CHD) risk reduction for 15 months and then a maintenance program for a minimum of 12 months to assess the durability of initial intervention changes.
11646555|NCT00128687|Placebo Comparator|Delayed Intervention|Participants randomized to Delayed Intervention serve as control for Immediate Intervention patients for the first 15 months and then receive intensive case management for 15 months. The switching-over design not only addresses ethical concerns about withholding treatment from half the study sample, but will also enable us to assess whether the intervention had equal impact whether provided to a naïve population or to a group followed in usual care for 15 months.
11646556|NCT00128661|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
11646557|NCT00128661|Active Comparator|Havrix Group|Subjects received 3 doses of Havrix vaccine at study Months 0, 1 and 6. All the vaccine doses were administered intramuscularly in the deltoid region of the non-dominant arm.
11646558|NCT00128622|Experimental|Denileukin Diftitox plus vaccine|This is a single arm Phase I safety study.
11646559|NCT00128518|Experimental|Group A : T1+P2 ● P1+P2 ● T2+P1 ● P1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
11646560|NCT00128518|Experimental|Group B : P1+P2 ● T1+P2 ● P1+P2 ● T2+P1|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
11646561|NCT00128518|Experimental|Group C : T2+P1 ● P1+P2 ● T1+P2 ● P1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
11646562|NCT00128518|Experimental|Group D : P1+P2 ● T2+P1 ● P1+P2 ● T1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
11646563|NCT00128505|Experimental|mifepristone|
11646564|NCT00128479|Experimental|mifepristone 300 mg|
11646565|NCT00128479|Placebo Comparator|placebo|
11646566|NCT00128479|Experimental|mifepristone 600 mg|
11646567|NCT00128479|Experimental|mifepristone 1200 mg|
11646568|NCT00128453|Placebo Comparator|Placebo|Conventional therapy plus placebo
11646569|NCT00128453|Active Comparator|Colchicine|Conventional therapy plus colchicine
11646570|NCT00128414|Placebo Comparator|Placebo|Placebo Comparator
11646571|NCT00128414|Experimental|Colchicine|Colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 6 month in patients ≥70 kg, and halved doses for patients <70 kg or intolerant to the highest dose.
11646572|NCT00128401|Active Comparator|D-Cycloserine|An antibiotic, d-cycloserine (DCS) was given to one group and the group is evaluated to see if the drug boosts the effectiveness of cognitive behavior therapy (CBT) for social anxiety.
11646573|NCT00128401|Placebo Comparator|Placebo|Another group was given the placebo and tested for effectiveness of cognitive behavior therapy (CBT) for social anxiety.
11646574|NCT00128388|Experimental|1 PFPP|Panic Focused Psychodynamic Psychotherapy
11646575|NCT00128388|Active Comparator|2 ART|Applied Relaxation Training
11646576|NCT00128362|Experimental|Radio guided Sentinle node biopsy|The radiolabeled Tc-99 colloid or phytate (500 Mbq) will be injected into the primary tumor 2 hours before surgery. A localized scintiscan will then be performed to confirm the radiolabeling of the sentinel node before surgery and for documentation. Isosulphan blue dye will be injected subdermal (0.5ml) over the tumor and intraparenchymal (3-4ml) towards the axilla 10-15mins before incision.
11646577|NCT00128336|Active Comparator|Nurse support|
11646578|NCT00128336|Experimental|Intensive support|
11646579|NCT00128336|Active Comparator|High carbohydrate diet|
11646580|NCT00128336|Experimental|High mono-unsaturated fat diet|
11646581|NCT00128310|Active Comparator|Arm A: Vinorelbine|Arm A: Vinorelbine 30 mg/m2 will be administered as an intravenous infusion over 6-10 minutes on Study Days 1 and 8.
11646582|NCT00128310|Experimental|Arm B: Vinorelbine and Gemcitabine|Arm B: Vinorelbine 30 mg/m2 will be administered as an intravenous infusion over 6-10 minutes on Study Days 1 and 8. Gemcitabine will be administered following vinorelbine at a dose of 1200 mg/m2 as an intravenous infusion over 30 minutes.
11646583|NCT00128297|Active Comparator|Arm A: continuous administration|Pamidronate 90 mg/m2 iv every 3-4 weeks, during 18 months
11646584|NCT00128297|Experimental|Arm B: alternate administration|Pamidronate 90 mg/m2 iv every 3-4 weeks, during 6 months, followed by a 6 month rest, and a new 6 months treatment period.
11646585|NCT00128284||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
11646586|NCT00128284||Gastroparesis|Subjects with documented gastroparesis
11646587|NCT00128258|Experimental|open|open treatment
11646588|NCT00128245|Experimental|Pimecrolimus 0.3%|ASM981 0.3%
11646589|NCT00128245|Experimental|Pimecrolimus 1%|ASM981 1%
11646590|NCT00128245|Placebo Comparator|Vehicle with carbopol|
11646591|NCT00128245|Placebo Comparator|Vehicle without carbopol|
11646984|NCT00123305|Placebo Comparator|4|
11646595|NCT00128206|Active Comparator|A|rifampin (600 mg orally) given daily for 4 months
11646596|NCT00128193|Experimental|A1-Ramping (MLSA-LAM)|5 subjects to receive: 1.0 mcg of MLSA-LAM, 0.1 mcg of MLSA-LAM, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
11646597|NCT00128193|Experimental|C1-Target Population|80 subjects to receive: 1.0 mcg of MLSA-LAM, 1.0 mcg of MLCwA and 2TU Purified Protein Derivative/RT-23.
11646598|NCT00128193|Experimental|C-1b-Target Population (Low Dose)|80 subjects to receive: 0.1 mcg MLSA-LAM, 0.1 mcg MLCwA, 2 TU Purified Protein Derivative/RT-23.
11646599|NCT00128193|Experimental|B2-Full-Scale (MLCwA)|45 subjects to receive: 1.0 mcg of MLCwA, 0.1 mcg of MLCwA, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
11646600|NCT00128193|Experimental|B1-Full-Scale (MLSA-LAM)|45 subjects to receive: 1.0 mcg of MLSA-LAM, 0.1 mcg of MLSA-LAM, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
11646601|NCT00128193|Experimental|A2-Ramping (MLCwA)|5 subjects to receive: 1.0 mcg of MLCwA, 0.1 mcg of MLCwA, 5 TU Purified Protein Derivative/Tubersol®, saline (NaCl).
11646602|NCT00128180|Active Comparator|Active|Methylprednisolone
11646603|NCT00128180|Placebo Comparator|Placebo|Placebo
11646604|NCT00128141|No Intervention|1|
11646605|NCT00128141|Experimental|2|tactile stimulus
11646606|NCT00128128|Active Comparator|Arm 1|Cranberry Juice Cocktail- 4 ounces
11646607|NCT00128128|Active Comparator|Arm 2|Cranberry Juice Cocktail-8 ounces
11646608|NCT00128128|Placebo Comparator|Arm 3|Placebo- 4 ounces
11646609|NCT00128128|Placebo Comparator|Arm 4|Placebo- 8 ounces
11646610|NCT00128102|Experimental|Vorinostat|Vorinostat three 100 mg capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
11646611|NCT00128102|Placebo Comparator|Placebo|Placebo capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
11646612|NCT00128076|Active Comparator|1|All-arthroscopic repair
11646613|NCT00128076|Active Comparator|2|Mini-open repair
11646614|NCT00128050|Active Comparator|1|Patients treated with recombinant FVIIa
11646615|NCT00128050|Placebo Comparator|2|Patients with spontaneous supratentorial ICH included in this arm will be treated with placebo
11646616|NCT00128024|Active Comparator|Statins|
11646617|NCT00128024|No Intervention|No statins|
11646618|NCT00127985|Experimental|Active|IV 6-methyl-prednisolone
11646619|NCT00127985|Placebo Comparator|Comparator|IV Placebo
11646620|NCT00127946|Active Comparator|AMNIOECHANGE|The AMNIOECHANGE consists of a transabdominal infusion of saline.They will be repeated every 15 days from 30 week of amenorrhea.
11646621|NCT00127946|No Intervention|placebo|This will be done at the same place and under the same aseptic conditions a AMNIOECHANGE true.
11646622|NCT00127933|Experimental|HER2-NEU Positive|
11646623|NCT00127933|Experimental|HER2-NEU Negative|
11646624|NCT00127920|Experimental|Single Arm|Paclitaxel, Carboplatin and Avastin on day1 every 21 days
11646625|NCT00127881|Experimental|Zanolimumab|
11646626|NCT00127868|Active Comparator|1|oral griseofulvin and selenium sulfide shampoo 1%
11646627|NCT00127868|Active Comparator|2|oral griseofulvin and ciclopirox shampoo
11646628|NCT00127868|Active Comparator|3|oral griseofulvin and ketoconazole shampoo 2%
11646629|NCT00127868|Placebo Comparator|4|oral griseofulvin and baby shampoo
11646630|NCT00127855|Experimental|MenHibrix Formulation 1 Group|Subjects were primed with MenHibrix formulation 1 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
11646631|NCT00127855|Experimental|MenHibrix Formulation 2 Group|Subjects were primed with MenHibrix formulation 2 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
11646632|NCT00127855|Experimental|MenHibrix Formulation 3 Group|Subjects were primed with MenHibrix formulation 3 co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
11646633|NCT00127855|Active Comparator|Menjugate Group|Subjects were primed with Menjugate co-administered with Infanrix Penta and ActiHIB according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
11646634|NCT00127855|Active Comparator|ActHIB Group|Subjects were primed with ActHIB co-administered with Infanrix Penta and Prevenar according to a 2-4-6 months of age schedule, and received a polysaccharide challenge dose (1/5th dose of MenACWY polysaccharide vaccine co-administered with 10 µg dose of plain PRP) at 12 months of age.
11646635|NCT00127842|Other|Etanercept|Open-label etanercept administered by subcutaneous injection at a dose of 50 mg/week for 24 months.
11646636|NCT00127829|Experimental|1|Gefitinib (IRESSA®)
11646637|NCT00127803|Placebo Comparator|Placebo|Participants will receive a dose of vaccine diluent (placebo) on Days 0, 28, and 56, respectively.
11646638|NCT00127803|Experimental|Low dose vaccine|Participants will receive a 2 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively.
11646639|NCT00127803|Experimental|Medium dose vaccine|Participants will receive a 10 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively
11646640|NCT00127803|Experimental|High dose vaccine|Participants will receive a 50 μg dose of C. difficile toxoid vaccine on Days 0, 28, and 56, respectively
11646641|NCT00127790|Active Comparator|CBT for Insomnia (CBT-I)|Cognitive-Behavioral Therapy for Insomnia (CBT-I)consisting of 10 individual sessions and including sleep education, sleep restriction therapy, stimulus control therapy, sleep hygiene, cognitive therapy, relaxation training and relapse prevention.
11646642|NCT00127790|Active Comparator|CBT for Pain (CBT-P)|Cognitive-Behavioral Therapy for Pain (CBT-P)consisting of 10 individual sessions and including pain education, pacing strategies, problem solving, goal setting, cognitive therapy, relaxation training and relapse prevention.
11646643|NCT00127790|Experimental|CBT for Insomnia & Pain (CBT-I/P)|Combined Cognitive-Behavioral Therapy for Insomnia & Cognitive-Behavioral Therapy for Pain (CBT-I/P)over 10 individual sessions.
11646644|NCT00127790|No Intervention|Wait-List Control (WL)|Waitlist Control condition (WL) with no contact during the intervention period.
11646645|NCT00127712|Experimental|Amiodarone|Amiodarone 1050 mg via continuous intravenous infusion for 24 hours followed by 400 mg orally twice daily for 6 days
11646646|NCT00127712|No Intervention|No treatment|Patients in this group receive no intervention
11646647|NCT00127673|Active Comparator|1|Participants will receive no choice cognitive behavioral therapy
11646648|NCT00127673|Active Comparator|2|Participants will receive choice cognitive behavioral therapy
11646649|NCT00127673|Active Comparator|3|Participants will receive no choice sertraline
11646650|NCT00127673|Active Comparator|4|Participants will receive choice sertraline
11646651|NCT00127660|Experimental|Menu: calories=yes, value pricing=no|There were calories listed on the menu, but no value pricing was in place.
11646652|NCT00127660|Experimental|Menu: calories=yes, value pricing = yes|There were calories listed on the menu, AND value pricing was in place.
11646653|NCT00127660|Experimental|Menu: calories=no, value pricing = no|Calories were not listed on the menu, and value pricing was not in place.
11646654|NCT00127660|No Intervention|Menu: calories=no, value pricing = yes|CONTROL CONDITION: calories were not listed on the menu, and value pricing WAS in place.
11646655|NCT00127647|Experimental|1|montelukast sodium 5 mg, QD 2-weeks
11646656|NCT00127647|Experimental|2|montelukast sodium 10 mg QD 2-weeks
11646657|NCT00127647|Active Comparator|3|Pranlukast 225 mg BID 2-weeks
11646658|NCT00127634|Experimental|1|
11646659|NCT00127634|Active Comparator|2|
11646660|NCT00127608|Experimental|Varicella Group|Subjects aged between 0 and 16 years of age, with clinically-diagnosed primary varicella disease.
11646661|NCT00127530|Placebo Comparator|Placebo- sugar pill|Placebo control
11646662|NCT00127530|Experimental|Fampridine-SR|10 milligram (mg) tablet b.i.d.
11646663|NCT00127491|Experimental|EPVent|All patients will have an esophageal balloon placed for the purpose of obtaining transpulmonary pressure measurements. The intervention group will undergo transpulmonary pressure-directed controlled mechanical ventilation using parameters directed by the initial balloon measurements. Driving pressures will be adjusted to maintain a transpulmonary plateau pressure of less then 30. The PEEP setting will be set to achieve a transpulmonary end expiratory pressure of 0. Repeat PES measurements will be done at 24, 48 and 72 hours following the initial measurements. Additional measurements will be taken as clinically indicated. Ventilator management by PES measurements will continue for a period of 72 hours.
11646664|NCT00127491|Active Comparator|Control|All patients will have an esophageal balloon placed for the purpose of obtaining transpulmonary pressure measurements. The control group will be managed using the low tidal volume strategy laid out by the NIHBLI ARDSnet study. These recommendations include a set tidal volume of 6 ml/ kg. Respiratory rate and PEEP are set to maintain adequate ventilation and oxygenation. These settings will be continued for a period of 72 hours.
11646665|NCT00127452|Experimental|EPA + DHA|Margarine spread that yields 400 mg of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) per day for average margarine use of 20 grams per day
11646666|NCT00127452|Experimental|ALA|Margarine spread that yields 2 grams of alpha-linolenic acid (ALA) per day for average margarine use of 20 grams per day
11646667|NCT00127452|Experimental|EPA + DHA plus ALA|Margarine spread that yields 400 mg of EPA + DHA per day plus 2 grams of ALA per day, for average margarine use of 20 grams per day
11646668|NCT00127452|Placebo Comparator|Placebo|Margarine spread that contains no EPA, DHA or ALA (exchanged for oleic acid)
11646669|NCT00127439|Experimental|Robotic Assisted Locomotor Training|A robotic stepping device in concert with a body weight support system and treadmill is used by a physical therapist and trainers for the participant with spinal cord injury to intensely practice task-specific standing and stepping to advance retraining the capacity to step. The robotic device provides the appropriate kinematics associated with standing and stepping.
11646670|NCT00127439|Experimental|Manually Assisted Locomotor Training|A body weight support system and treadmill is used by a physical therapist and trainers for the participant with spinal cord injury to intensely practice task-specific standing and stepping to advance retraining the capacity to step. Therapists and trainers promote the appropriate kinematics associated with standing and stepping.
11646671|NCT00127413|Experimental|Cognitive Behavioral Therapy - Pain|Cognitive Behavioral Therapy targeting chronic pain
11646672|NCT00127413|Experimental|Cognitive Behavioral Therapy-Integrated|Integrated treatment for comorbid chronic pain and PTSD
11646673|NCT00127413|Experimental|Cognitive Processing Therapy - PTSD|Cognitive Processing Therapy for PTSD
11646674|NCT00127413|Other|Treat as Usual|Participants received care for pain and PTSD as usual from their Primary care provider
11646675|NCT00127335|Placebo Comparator|1|
11646676|NCT00127335|Active Comparator|2|statin administration
11646677|NCT00127270|Experimental|1|Darifenacin
11646678|NCT00127270|Other|2|Darifenacin in combination with Behavioral Modification Programme for Symptoms of Overactive Bladder
11646679|NCT00127231|Experimental|1 Brief Intervention|The brief intervention will include two sessions that review drinking patterns and behavior change strategies as well as two telephone calls to reinforce session content.
11646680|NCT00127231|Active Comparator|2 Standard Care Arm|
11646681|NCT00127218|Experimental|1|any statin plus niacin
11646682|NCT00127218|Placebo Comparator|2|any statin plus placebo
11646683|NCT00127205|Experimental|Arm I|Patients receive zoledronate IV over 15 minutes once a month for 6 months and then once every 3 months for 2.5 years.
11646684|NCT00127205|Active Comparator|Arm II|Patients receive oral clodronate once daily for 35 months.
11646685|NCT00127205|Experimental|Arm III|Patients receive oral ibandronate once daily for 35 months.
11646686|NCT00127192|Placebo Comparator|1|Placebo QD 12-week
11646687|NCT00127192|Experimental|2|25 mg QD 12-week
11646688|NCT00127192|Experimental|3|50 mg QD 12-week
11646689|NCT00127192|Experimental|4|100 mg QD 12-week
11646690|NCT00127192|Experimental|5|200 mg QD 12-week
11646802|NCT00125567|Active Comparator|2|Levodopa/carbidopa
11646691|NCT00127166|Experimental|Montelukast/Salmeterol|Period I - Montelukast 5 milligrams (mg) oral tablet once daily and Salmeterol matching placebo dry powder inhaler (DPI) twice daily for 4 weeks followed by a 2-week washout period (salmeterol matching placebo + montelukast matching placebo). Period II - Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 micrograms (mcg) twice daily for 4 weeks. Inhaled Fluticasone 100 mcg twice daily throughout the study.
11646692|NCT00127166|Experimental|Salmeterol/Montelukast|Period I - Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 mcg twice daily for 4 weeks followed by a 2-week washout period (salmeterol matching placebo + montelukast matching placebo). Period II - Montelukast 5 mg oral tablet once daily and Salmeterol matching placebo DPI twice daily for 4 weeks. Inhaled Fluticasone 100 mcg twice daily throughout the study.
11646693|NCT00127140|Experimental|Vorinostat|Participants received (Cycle 1) once-daily vorinostat at assigned dose (100 or 200 mg) on Days 1 and 17 and twice-daily on Days 3-16. Thereafter, participants remaining on study received the same dose level therapy twice-daily for 14 consecutive days followed by 7 days of rest.
11646694|NCT00127127|Experimental|1|1. level 1: 100 mg BID 14-day, level 2: 200 mg BID 14-day, level 3: 400 mg QD 14 day, level 5: 500 mg QD 14-day
11646695|NCT00127114|Experimental|Amantadine|
11646696|NCT00127114|Placebo Comparator|Placebo|
11646697|NCT00127101|Experimental|Cohort 1|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter[2] daily x 7 days per week
11646698|NCT00127101|Experimental|Cohort 2|Vorinostat 300 milligrams daily for 7 days per week + Bexarotene 150 milligrams/meter[2] daily x 7 days per week
11646699|NCT00127101|Experimental|Cohort 2a|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 225 milligrams/meter[2] daily x 7 days per week
11646700|NCT00127101|Experimental|Cohort 2b|Vorinostat 200 milligrams daily for 7 days per week + Bexarotene 300 milligrams/meter[2] daily x 7 days per week
11646701|NCT00127101|Experimental|Cohort 6|Vorinostat 400 milligrams daily for 7 days per week + Bexarotene 150 milligrams daily for 7 days per week
11646702|NCT00127101|Experimental|Cohort 7|Vorinostat 400 milligrams daily for 7 days per week + Bexarotene daily for 7 days per week [150 milligrams (Cycle 1) 225 milligrams (Cycle 2-6)
11646703|NCT00127075|Experimental|NOMA + estradiol|Oral NOMA (LUTENYL® 10 mg/day) combined with transdermal Estradiol (DERMESTRIL SEPTEM® 75 mcg, once a week),
11646704|NCT00127075|Placebo Comparator|placebo|Matching placebo treatments
11646705|NCT00127062|Experimental|Asthma|Asthma patients ranging from mild to severe
11646706|NCT00127062|Other|Healthy Non-Smokers|
11646707|NCT00127036|Experimental|XELOX + Bevacizumab|Arm A: Anticipated 75 Patients - Drug: XELOX (which is Capecitabine + Oxaliplatin) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression
11646708|NCT00127036|Experimental|XELIRI + Bevacizumab|Arm B: Anticipated 75 Patients - Drug: XELIRI (which is Capecitabine + Irinotecan) by mouth + Bevacizumab intravenously as outlined in Intervention Description - To Disease Progression
11646709|NCT00126984|Experimental|Group A|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation A
11646710|NCT00126984|Experimental|Group B|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation B
11646711|NCT00126984|Experimental|Group C|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation C
11646712|NCT00126984|Experimental|Group D|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation D
11646713|NCT00126984|Active Comparator|Group E|Subjects of 12-14 months of age who will receive Meningitec and subjects of 3-5 years of age who will receive Mencevax ACWY.
11646714|NCT00126880|Experimental|600mg BID ATC|600mg BID ATC
11646715|NCT00126880|Experimental|800mg BID ATC|800mg BID ATC
11646716|NCT00126880|Active Comparator|150mg BID 3TC|150mg BID 3TC
11646717|NCT00126789|Experimental|ZR-02-01|ZR-02-01 matrix transdermal fentanyl patch
11646718|NCT00126776|Active Comparator|1|CAse/self management for COPD
11646719|NCT00126776|Other|2|usual care
11646720|NCT00126763|Experimental|Matrix Transdermal Fentanyl Patch|
11646721|NCT00126750|Other|Arm 1|
11646722|NCT00126737|Active Comparator|Arm 1|Group assigned to both a Weight Control Nutritional Program and home-based exercise program (Ex+WC).
11646723|NCT00126737|Active Comparator|Arm 2|Group assigned to a Weight Control Nutritional Program (WC).
11646724|NCT00126737|Active Comparator|Arm 3|Group assigned to a home-based exercise program (Ex).
11646725|NCT00126737|No Intervention|Arm 4|Usual care and non- specific health information (C).
11646726|NCT00126724|Active Comparator|1|1x10^11 DRP/mL tgAAC94
11646727|NCT00126724|Active Comparator|2|1x10^12 DRP/mL tgAAC94
11646728|NCT00126724|Active Comparator|3|1x10^13 DRP/mL tgAAC94
11646729|NCT00126724|Placebo Comparator|4|
11646730|NCT00126659|Experimental|Group I (cytoreductive nephrectomy and sorafenib tosylate)|"Patients undergo cytoreductive nephrectomy on day 1. Patients then receive oral sorafenib twice daily on days 15-84.
~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
11646731|NCT00126659|Experimental|Group II (sorafenib tosylate and cytoreductive nephrectomy)|"Patients receive oral sorafenib twice daily on days 1-7. Patients undergo cytoreductive nephrectomy on day 8. Patients then receive oral sorafenib twice daily on days 22-84.
~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
11646732|NCT00126659|Experimental|Group III (sorafenib tosylate and cytoreductive nephrectomy)|"Patients receive oral sorafenib twice daily on days 1-28. Patients undergo cytoreductive nephrectomy on day 29. Patients then receive oral sorafenib twice daily on days 43-84.
~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
11646803|NCT00125528|Experimental|1|D-cycloserine 50mg bid/100mg bid/200 mg bid
11646804|NCT00125528|Placebo Comparator|2|placebo
11646805|NCT00125515|Placebo Comparator|Placebo|Placebo plus oral naltrexone
11646733|NCT00126620|Experimental|OSI-774 erlotinib) and Bay 43-9006 (Sorafenib)|Sorafenib administered alone for a 1-week run-in period, and then both drugs e given together continuously, with every 28 days considered as a cycle. Three dose levels assessed.
11646734|NCT00126607|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11646735|NCT00126594|Experimental|Sorafenib Tosylate|Arm I: Oral Sorafenib 400 mg twice daily on days 1-28.
11646736|NCT00126594|Experimental|Sorafenib Tosylate, Recombinant interferon alfa-2b|Arm II: Sorafenib as in Arm I and low-dose Interferon alfa-2b 0.5 million units subcutaneously twice daily on days 1-28.
11646737|NCT00126581|Experimental|Arm I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11646738|NCT00126581|Experimental|Arm II (erlotinib hydrochloride, paclitaxel, carboplatin)|Patients receive erlotinib hydrochloride as in arm I. Patients also receive paclitaxel IV over 1-3 hours and carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of 6 cycles of treatment, patients may continue to receive erlotinib hydrochloride alone as above.
11646739|NCT00126568|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11646740|NCT00126555|Experimental|Stratum I (Gefitinib, Radiotherapy, Surgery)|"Resectable Strata: Induction Gefitinib (60 days), Surgery followed 3-6 weeks later by daily Radiotherapy 5 days a week for approximately 6-7 weeks then after 4 weeks restart Maintenance Gefitinib for up to additional 12 months post radiation.
~Gefitinib Induction Phase starting dose 250 mg/day, possible doubling to 500 mg/day for no response Day 15; Maintenance dose post radiation starts at same dose level as last dosing of Induction Phase."
11646741|NCT00126555|Experimental|Stratum II (Gefitinib, Radiotherapy/Surgery)|"Unresectable Strata: Concomitant Radiation/Gefitinib and post-radiation (or post-surgery if surgery is indicated) Gefitinib. Daily Radiotherapy 5 days a week for approximately 6-7 weeks concurrent with Maintenance Gefitinib dose daily up to 12 months.
~Gefitinib Induction Phase starting dose 250 mg/day, possible doubling to 500 mg/day for no response Day 15; Maintenance dose post radiation starts at same dose level as last dosing of Induction Phase."
11646742|NCT00126542|Experimental|Treatment (bevacizumab, erlotinib hydrochloride)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral erlotinib once daily on days 1-21. Treatment repeats every 21 days for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to 1 of the study drugs may continue treatment with the remaining study drug alone in the absence of disease progression or unacceptable toxicity.
11646743|NCT00126516|Active Comparator|1|Angiotensin II Receptor Antagonists group
11646744|NCT00126516|Active Comparator|2|Angiotensin-converting Enzyme Inhibitors group
11646745|NCT00126503|Experimental|Treatment (bevacizumab and sorafenib tosylate)|"Phase I: Patients receive sorafenib PO twice daily on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of sorafenib and bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.
~Phase II: Patients receive sorafenib PO once daily on days 1-28 and bevacizumab IV over 90 minutes on days 1 and 15 at the MTD in the absence of disease progression or unacceptable toxicity."
11646746|NCT00126490|Experimental|Treatment (bevacizumab, aldesleukin)|Patients receive bevacizumab IV over 30-90 minutes on day 1 in weeks 1, 3, 5, 7, 9, and 11. Patients also receive interleukin-2 subcutaneously on days 1-5 in weeks 5-10. Treatment repeats every 12 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease then receive bevacizumab alone in weeks 1, 3, 5, 7, 9, and 11. Courses with bevacizumab alone repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
11646747|NCT00126438|Experimental|123I-mIBG (meta-iodobenzylguanidine)|Single dose
11646748|NCT00126425|Experimental|123I-mIBG (meta-iodobenzylquanidine|Single dose
11646749|NCT00126412|Experimental|123I-mIBG (Meta-iobenzylguanidine)|"All subjects received 123I-mIBG injection over at least 1 to 2 minutes through a cannula (or indwelling catheter in the vein). After the injection of 123I-mIBG was complete, the cannula was flushed with at least 5 mL of 0.9% sodium chloride solution over a maximum of 10 seconds.
~All subjects ≥18 years of age and children with a weight of ≥70 kg were to receive an intravenous injection of 370 ±10% MBq (333 to 407 MBq [9.0 to 11 mCi] of 123I-mIBG). Doses of 123I-mIBG for children <18 years of age (with a weight of 8-70 kg) were to be calculated on the basis of a reference activity for an adult scaled to body weight according to the schedule proposed by the European Association of Nuclear Medicine (EANM) Paediatric Task Group; for children <8 kg, a scaled activity or a fixed minimum activity of 80 ±10% MBq (72 to 88 MBq [1.9 to 2.2 mCi]) was permissible."
11646750|NCT00126373|Placebo Comparator|Sugar pill|Placebo (sugar) pill with identical look to bupropion
11646751|NCT00126373|Experimental|buproprion|bupropion pill
11646752|NCT00126334|Active Comparator|1|Liberal transfusion threshold
11646753|NCT00126334|Experimental|2|Conservative transfusion threshold
11646754|NCT00126308|Experimental|Immediate|poly-L-lactic acid injections
11646755|NCT00126308|Active Comparator|Delayed|poly-L-lactic acid injections
11646756|NCT00126217|Experimental|1|
11646757|NCT00126217|No Intervention|2|
11646758|NCT00126191|Experimental|Low Risk|"Low-risk patients receive 3 cycles of regimen A.
~Regimen A:
~Rituximab (375 mg/m^2) on Days 1 and 3. Cyclophosphamide (800 mg/m^2) on days 1 and 2. Vincristine (1.4 mg/m^2) on days 1 and 10. Doxorubicin (50 mg/m^2) on Day 1. Methotrexate (3000 mg/m^2) on Day 10. Intrathecal Cytarabine (50mg) will be given on Day 1 and intrathecal methotrexate (12mg) will be given on Days 1 and 10.
~Leucovorin on days 11 and 12.
~Rituximab is given on Days 1 and 3 in cycle 1, and on Day 1 of all other cycles."
11646806|NCT00125515|Active Comparator|Memantine 30 mg bid|Memantine 30 mg bid plus oral naltrexone
11646807|NCT00125515|Active Comparator|Memantine 15 mg bid|memantine 15 mg bid plus oral naltrexone
11646808|NCT00125502|Experimental|I|n=200; 20 micrograms gB with MF59
11646985|NCT00123292|Experimental|1|
11646759|NCT00126191|Experimental|High Risk|"High-risk patients receive 4 alternating cycles of regimens A and B (A-B-A-B).
~Regimen A (as described earlier).
~Regimen B:
~Rituximab (375mg/m^2) on Day 1. Ifosfamide (1500mg/m^2) on Days 1-5. Mesna (275 mg/m^2) on Days 1-5. Etoposide (60mg/mg^2) on Days 1-5. Cytarabine (2 gm/m^2) twice a day on Days 1 and 2. Intrathecal methotrexate (12mg) on Day 5, and intrathecal methotrexate (50mg) on Day 3 (also on Day 1 for patients with central nervous system involvement)."
11646760|NCT00126126|Experimental|EBAR Program|Evidence Based Amputee Rehabilitation Program (rehabilitation program based on performance of the Amputee Mobility Predictor
11646761|NCT00126126|No Intervention|Wait List Control|Wait List Control Group
11646762|NCT00126113|Experimental|PPT-based Counseling|Counseling based on Performance-Perceptual Discrepancy (PPDIS) consisting of explanation of hearing tests plus recommendations based on PPDIS
11646763|NCT00126113|Other|Standard Educational Counseling|Standard educational counseling consisting of explanation of hearing tests
11646764|NCT00126100|Experimental|1|Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
11646765|NCT00126100|Placebo Comparator|2|Patients were randomly assigned to receive subcutaneously a daily dose of placebo for 5 days.
11646766|NCT00126048|Active Comparator|1|Oral atorvastatin 40mg
11646767|NCT00126048|Placebo Comparator|2|Placebo
11646768|NCT00125970|Experimental|1|DNA HIV vaccine administered at study entry and at Months 1 and 2 and adenoviral vector HIV vaccine administered at Month 6
11646769|NCT00125970|Placebo Comparator|2|DNA HIV vaccine placebo administered at study entry and at Months 1 and 2 and adenoviral vector HIV vaccine placebo administered at Month 6
11646770|NCT00125957|Experimental|Wellbutrin first, then Placebo|Subjects randomly assigned to the Wellbutrin then Placebo group will receive 100mg BID of Wellbutrin at the first visit following intake (Week 0).Subjects will be increased to 150mg Wellbutrin BID at Week 1 unless moderate/severe side effects are reported. If subject and rater classify 1+ symptom as severe or 2+ symptoms as moderate, subject will continue on 100mg of bupropion qAM. If subject and rater classify 1+ symptom as moderate or 2+ mild as moderate, subject will continue on Wellbutrin 100mg BID. At Week 4, subjects will cross-over to placebo and will continue to take placebo until Week 8.
11646771|NCT00125957|Experimental|Placebo first, then Wellbutrin|Subjects randomly assigned to the Placebo then Wellbutrin group will receive placebo until Week 4 when they will cross-over to active drug. At Week 4, subjects will be assigned 100mg Wellbutrin BID. At Week 5, Subjects will be increased to 150mg Wellbutrin BID unless moderate/severe side effects are reported. If subject and rater classify 1+ symptom as severe or 2+ symptoms as moderate, subject will continue on 100mg of Wellbutrin qAM. If subject and rater classify 1+ symptom as moderate or 2+ mild as moderate, subject will continue on bupropion 100mg BID. Subject will continue on the assigned dosage until Week 8 of study.
11646772|NCT00125931|Experimental|Pentazocine/Talwin|Talwin NX
11646773|NCT00125918|Placebo Comparator|1|Placebo
11646774|NCT00125918|Active Comparator|2|2.5 mg tadalafil
11646775|NCT00125918|Active Comparator|3|10 mg tadalafil
11646776|NCT00125918|Active Comparator|4|20 mg tadalafil
11646777|NCT00125918|Active Comparator|5|40 mg tadalafil
11646778|NCT00125879|Experimental|1|
11646779|NCT00125853|Experimental|atenolol 25mg daily|atenolol 25mg daily
11646780|NCT00125853|Active Comparator|nebivolol 2.5mg daily|nebivolol 2.5mg daily
11646781|NCT00125827|Experimental|1|Single-arm, dose escalation
11646782|NCT00125788|Experimental|investigational product|L-glutamine
11646783|NCT00125788|Placebo Comparator|placebo|maltodextrin
11646784|NCT00125775|Active Comparator|1|Engerix-B 40 mcg dose
11646785|NCT00125775|Active Comparator|2|Engerix-B 80 mcg dose
11646786|NCT00125762|Experimental|Single Arm undergoing FibroScan|Single arm active comparison of biopsy to vibration controlled elastography
11646787|NCT00125736|Experimental|E0671 combination group|
11646788|NCT00125736|Placebo Comparator|placebo combination group|
11646789|NCT00125723|No Intervention|No Intervention|
11646790|NCT00125723|Other|Intervention|PI Discretion
11646791|NCT00125658|Active Comparator|Control|FTP: 30 sessions (90 minute sessions, 3 times per week, 10 weeks) followed by POWER: 30 sessions (90 minute sessions, 3 times per week, 10 weeks)
11646792|NCT00125658|Experimental|Experimental|POWER: 30 sessions (90 minute sessions, 3 times per week, 10 weeks) followed by FTP: 30 sessions (90 minute sessions, 3 times per week, 10 weeks)
11646793|NCT00125645|Experimental|Irbesartan|Tablet Irbesartan 150 mg once daily
11646794|NCT00125619|Active Comparator|Arm 1: Therapist assisted|Therapist assisted locomotor training (partial body-weight supported)
11646795|NCT00125619|Experimental|Arm 2: Robot-assisted|Robot-assisted locomotor training (partial body-weight supported)
11646796|NCT00125606|Active Comparator|conditioning therapy with 12 Gy TBI / cyclophosphamide 120|
11646797|NCT00125606|Experimental|conditioning therapy with 8 Gy TBI / fludarabine 120|
11646798|NCT00125593|Placebo Comparator|Placebo|Placebo = Arm 1. A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with all Arm 1 patients taking 2 tablets (placebo simvastatin plus ezetimibe tablet with a placebo simvastatin tablet) during the first year. After the first year, all Arm 1 patients took one tablet (placebo simvastatin plus ezetimibe tablet).
11646799|NCT00125593|Active Comparator|Simvastatin 20mg plus Ezetimibe 10mg|Simvastatin 20mg plus ezetimibe 10mg = Arm 2. A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with all Arm 2 patients taking 2 tablets during the first year (active simvastatin plus ezetimibe tablet with a placebo simvastatin tablet). After the first year, all Arm 2 patients took one tablet (active simvastatin 20mg plus ezetimibe 10mg tablet).
11646800|NCT00125593|Other|Simvastatin 20mg|Simvastatin 20mg alone = Arm 3. After 1 year, those initially allocated to Arm 3 were re-randomized to simvastatin 20mg plus ezetimibe 10mg (Arm 3b) daily or placebo (Arm 3a). A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with Arm 3 patients taking 2 tablets (a placebo simvastatin plus ezetimibe tablet with an active simvastatin tablet) during the first year. After the first year, all Arm 3a and Arm 3b patients took one tablet (active or placebo simvastatin plus ezetimibe tablet).
11646801|NCT00125567|Experimental|1|Stalevo (levodopa/carbidopa/entacapone)
11646986|NCT00123292|Experimental|2|
11646810|NCT00125450|Experimental|A|Chest Physiotherapy with Forced Expiratory Technique
11646811|NCT00125450|Active Comparator|B|Aspiration
11646812|NCT00125385|Experimental|Cohort 1|Dose group
11646813|NCT00125385|Experimental|Cohort 2|Dose Group
11646814|NCT00125385|Experimental|Cohort 3|Dose Group
11646815|NCT00125385|Experimental|Cohort 4|Dose Group
11646816|NCT00125385|Experimental|Cohort 5|Dose Group
11646817|NCT00125372|Experimental|Erlotinib and Bexarotene|Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy.
11646818|NCT00125359|Experimental|1|All eligible patients will receive continuous daily oral erlotinib 150mg with daily bexarotene oral capsules 400mg.
11646819|NCT00125268|Active Comparator|MIRE|Subjects randomized to this arm will receive treatment with monochromatic near infrared photo energy (MIRE).
11646820|NCT00125268|Sham Comparator|Sham|Subjects randomized to this arm will receive treatment with the sham device, which is non-active but otherwise identical to the study device.
11646821|NCT00125255|Experimental|S-Caine Peel|
11646822|NCT00125255|Placebo Comparator|Placebo Peel|
11646823|NCT00125242|Experimental|Semantic Feature Analysis (SFA)|Word retrieval treatment for aphasia.
11646824|NCT00125242|No Intervention|Participants for Stimuli Development|Non-brain-injured participants provided data for development of treatment stimuli.
11646825|NCT00125216|Other|Arm 1|Single subject design - participant receives three administrations of the same treatment
11646826|NCT00125190|Experimental|rhIGF-1 QD|Subjects received subcutaneous injection (SC) injections of rhIGF-1 once a day.
11646827|NCT00125164|No Intervention|Untreated|Observational Group
11646828|NCT00125164|Experimental|40 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 40 μg/kg BID. Per protocol amendment these subjects were reassigned to receive 120 μg/kg BID. Due to the dose change, the efficacy results for these subjects were analysed in a separate subanalysis. For all outcome measures, mean and standard deviations were not calculated for this arm.
11646829|NCT00125164|Experimental|80 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 80 μg/kg BID
11646830|NCT00125164|Experimental|120 μg/kg BID (twice daily dosing)|Injection of rhIGF-1 120 μg/kg BID
11646831|NCT00125138|Experimental|Melperone HCl - 20 mg|
11646832|NCT00125138|Experimental|Melperone HCl - 40 mg|
11646833|NCT00125138|Experimental|Melperone HCl - 60 mg|
11646834|NCT00125138|Placebo Comparator|Placebo|
11646835|NCT00125047|Experimental|1|Typhoid Vi polysaccharide vaccine
11646836|NCT00125047|Active Comparator|2|Inactivated Hepatitis A vaccine
11646837|NCT00125034|Experimental|Cetuximab Plus FOLFOX-4|
11646838|NCT00125034|Active Comparator|FOLFOX-4 Alone|
11646839|NCT00125008|Experimental|1|Typhoid Vi vaccine
11646840|NCT00125008|Active Comparator|2|Hepatitis A vaccine
11646841|NCT00124982|Experimental|Open-label Abatacept (ABA)-Previous User|In participants who have had an inadequate efficacy response or intolerance on previous TNF-antagonist therapy (off therapy for at least 2 months), open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing < 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing > 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
11646842|NCT00124982|Experimental|Open-label ABA-Current User|In participants currently using Tumor Necrosis Factor (TNF)-agonists, open-label abatacept was administered on Days 1, 15, and 29 and then once a month thereafter on a background of non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)s. Participants weighing < 60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing > 100 kg received 1 gram of open-label abatacept by intravenous (IV) infusion.
11646843|NCT00124982|Experimental|Long-term ABA|Participants continued to receive the same 10 mg/kg weight-tiered dose of abatacept that they received in the initial short-term period.
11646844|NCT00124969|Active Comparator|1|Amlodipine
11646845|NCT00124969|Placebo Comparator|2|Placebo
11646846|NCT00124943|Experimental|10 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 10 mg/m^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesion) or balloon angioplasty (in-stent restenosis lesions).
11646847|NCT00124943|Experimental|22 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 22 mg/m^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
11646848|NCT00124943|Experimental|35 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 35 mg/m^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
11646849|NCT00124943|Experimental|45 mg/m^2 nanoparticle paclitaxel|Participants received a single dose of 45 mg/m^2 nanoparticle paclitaxel administered via intracoronary catheter immediately following percutaneous transluminal coronary angioplasty/stenting (de novo lesions) or balloon angioplasty (in-stent restenosis lesions).
11646850|NCT00124917|Experimental|Radiation Therapy|Radiation to tumor area as per protocol
11646851|NCT00124878|Active Comparator|Arm 1 Male circumcision|Men receive circumcision after randomization; procedure is generally provided within two weeks. A man randomized to the intervention arm who then declines circumcision for 6 or more months is considered a cross over.
11646852|NCT00124878|No Intervention|Arm 2|Men wait for two years of follow up before being offered male circumcision
11646853|NCT00124852|Placebo Comparator|High Oleic Sunflower Oil|
11646854|NCT00124852|Active Comparator|400 mg EPA+DHA/day|low dose fish oil
11646855|NCT00124852|Active Comparator|1800 mg EPA+DHA/day|high dose fish oil
11646856|NCT00124839|Other|1|Blinded sequential administration: naltrexon 50 mg (3 weeks)- placebo (3 weeks)- placebo (1 week)
11646857|NCT00124839|Other|2|Blinded sequential administration: 200mg naltrexone (3 weeks) - placebo (3 weeks)- placebo (1 week)
11646858|NCT00124839|Other|3|Blinded sequential administration: placebo (3 weeks) - 200mg naltrexone (3 weeks) - placebo (1 week)
11646859|NCT00124839|Other|4|Blinded sequential administration: placebo (3 weeks) - 50mg naltrexone (3 weeks) - placebo (1 week)
11646860|NCT00124787|Experimental|Dimenhydrinate|dimenhydrinate PO x 4 doses
11646861|NCT00124787|Placebo Comparator|Placebo|placebo PO x 4 doses
11646862|NCT00124761|Other|Surgery + Whole Brain Radiotherapy|
11646863|NCT00124761|Experimental|RadioSurgery + Whole Brain Radiotherapy|
11646864|NCT00124748|Experimental|Imatinib 400 mg|Oral dose of 400mg Imatinib once daily. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted, reduced, or escalated based on guidelines defined in protocol.
11646865|NCT00124748|Experimental|imatinib 800 mg|Patients randomized to receive 800 mg Imatinib were to receive 400 mg twice daily (b.i.d.) oral administration, in the morning and the evening. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted or reduced based on guidelines defined in protocol.
11646866|NCT00124735|Experimental|Rocuronium bolus maintenance|Rocuronium bolus maintenance
11646867|NCT00124735|Experimental|Rocuronium continuous infusion maintenance|Rocuronium continuous infusion maintenance
11646868|NCT00124722|Experimental|0.45 mg/kg Zemuron|0.45 mg/kg Zemuron
11646869|NCT00124722|Active Comparator|0.6 mg/kg Zemuron|0.6 mg/kg Zemuron
11646870|NCT00124722|Experimental|1.0 mg/kg Zemuron|1.0 mg/kg Zemuron
11646871|NCT00124709|Experimental|1|Pimecrolimus
11646872|NCT00124709|Active Comparator|2|Corticosteroid
11646873|NCT00124683|Experimental|1|Nicotine Patch + Bupropion
11646874|NCT00124683|Placebo Comparator|2|Nicotine patch + placebo
11646875|NCT00124657|Experimental|Patients with High-Grade/Low-Grade Glioma|Patients with newly diagnosed high-grade glioma (excluding those originating in the brain stem) and unfavorable low-grade glioma who are ≥ 3 years and <26 years of age. Patients receiving enzyme-inducing anticonvulsants (EIACs) are not eligible for this study. Patients with spinal cord tumors will be eligible for the Phase I and Phase II component of this study, but they will not be taken into consideration to estimate PFS in the Phase II component of this trial because of their notoriously worse prognosis. Patients receive erlotinib hydrochloride.
11646876|NCT00124618|Experimental|cetuximab/Radiation|Cetuximab (C225) and Radiation
11646877|NCT00124605|Experimental|Treatment (pamidronate disodium and arsenic trioxide)|Patients receive pamidronate IV and over 2 hours on days 1 and 15 and arsenic trioxide IV over 2 hours on days 1-5 and 15-19. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11646878|NCT00124579|Experimental|bortezomib with thalidomide and dexamethasone|bortezomib with thalidomide and dexamethasone
11646879|NCT00124566|Experimental|1|Irofulven + prednisone
11646880|NCT00124566|Experimental|2|Irofulven + capecitabine + prednisone
11646881|NCT00124566|Active Comparator|3|Mitoxantrone + prednisone
11646882|NCT00124540|Placebo Comparator|1|placebo resembling misoprostol
11646883|NCT00124540|Experimental|2|misoprostol
11646884|NCT00124514|Experimental|Triptorelin Vs Placebo (Normal Saline)|Placebo (Normal Saline) vs triptorelin Pamoate
11646885|NCT00124501|Active Comparator|SMT|Standard Medication Treatment
11646886|NCT00124501|Experimental|BART|Biofeedback-assisted Relaxation Training plus SMT
11646887|NCT00124462|Other|Realignment to Placebo|Realigning knee brace and custom orthodic- A valgus brace, customized functional orthotic for neutral foot position and motion control footwear.
11646888|NCT00124462|Other|Placebo to Realignment|Non realigning knee brace and flat orthodic- A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole
11646889|NCT00124449|Active Comparator|1|
11646890|NCT00124449|Placebo Comparator|2|
11646891|NCT00124345|Experimental|1|
11646892|NCT00124319||1|Incoming cadets at the U.S. Naval, Air Force, or Military Academies
11646893|NCT00124306|Active Comparator|1|Amitryptiline
11646894|NCT00124306|Placebo Comparator|2|Placebo will be dosed exactly as active arm.
11646895|NCT00124293||Factor VII|
11646896|NCT00124280|Experimental|previously treated with chemotherapy only|patients previously treated with chemotherapy only (at most 2 prior regimens one of which must have been platinum-based) and no EGFRI
11646897|NCT00124280|Experimental|previously treated with chemotherapy + small|patients previously treated with chemotherapy (at most 2 prior regimens one of which must have been platinum-based) and with one small molecule EGFRI
11646898|NCT00124254|Experimental|1|Surgical group undergoing SMPA
11646899|NCT00124254|Active Comparator|2|Nosurgical group
11646900|NCT00124228|No Intervention|1|Antibiotic following hospital Protocols according the cause of the infection .
11646901|NCT00124228|Active Comparator|2|Antibiotic following hospital Protocols according the cause of infection plus albumin
11646902|NCT00124202|Placebo Comparator|a fatty meal vs normal saline|Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
11646903|NCT00124189|Other|open label|Sequential dose cohort, open label, escalation trial evaluating one infusion duration of 2 hours
11646904|NCT00124176|Experimental|1|Nebulized levalbuterol 10mg/hr given continuously
11646905|NCT00124176|Active Comparator|2|Racemic albuterol 20mg/hr given continuously
11646906|NCT00124150|Experimental|M|Intravenous magnesium sulfate infusion for 14 days.
11646907|NCT00124150|No Intervention|S|Saline infusion without additional magnesium sulfate.
11646908|NCT00124124|Experimental|1|KLH and peptide pulsed DCs
11646909|NCT00124124|Experimental|2|KLH, peptides plus Montanide
11646910|NCT00124072|Active Comparator|Simvastatin 20 mg + folic acid and B12|Participants received 20 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily
11646911|NCT00124072|Active Comparator|Simvastatin 80 mg + folic acid and B12|Participants received 80 mg simvastatin once daily, and 2 mg folic acid with 1 mg vitamin B12 once daily
11646912|NCT00124072|Active Comparator|Simvastatin 20 mg + placebo|Participants received 20 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily
11646913|NCT00124072|Active Comparator|Simvastatin 80 mg + placebo|Participants received 80 mg simvastatin once daily, and placebo folic acid with placebo vitamin B12 once daily
11646915|NCT00124059|Experimental|Type B SERO|
11646916|NCT00124059|Placebo Comparator|Type A PLA|
11646917|NCT00124059|Placebo Comparator|Type B PLA|
11646918|NCT00124046|Active Comparator|Surgical|
11646919|NCT00124046|Active Comparator|Medical Treatment|
11646920|NCT00124020|Experimental|Telavancin|
11646921|NCT00124020|Active Comparator|Vancomycin|
11646922|NCT00123981|Active Comparator|CCABG|Coronary artery bypass surgery using cardiopulmonary bypass
11646923|NCT00123981|Experimental|OPCAB|Coronary artery bypass surgery NOT using cardiopulmonary bypass
11646924|NCT00123968|Experimental|1A|Participants will receive a low dose of the adenovirus-vectored HIV vaccine or placebo at study entry
11646925|NCT00123968|Experimental|1B|Participants will receive a higher dose of the adenovirus-vectored HIV vaccine or placebo at study entry
11646926|NCT00123968|Experimental|1C|Participants will receive the DNA plasmid vaccine or placebo at study entry and Days 28 and 56. They will also receive either a low dose of the adenovirus-vectored HIV vaccine or placebo at Day 168.
11646927|NCT00123968|Experimental|1D|Participants will receive the DNA plasmid vaccine or placebo at study entry and Days 28 and 56. They will also receive either a higher dose of the adenovirus-vectored HIV vaccine or placebo at Day 168.
11646928|NCT00123968|Experimental|2A|Participants will receive the DNA plasmid vaccine at study entry and Days 28 and 56. They will also receive a low dose of the adenovirus-vectored HIV vaccine at Day 168.
11646929|NCT00123968|Experimental|2B|Participants will receive the DNA plasmid vaccine placebo at study entry and Days 28 and 56. They will also receive a the adenovirus-vectored HIV vaccine placebo at Day 168.
11646930|NCT00123955|Experimental|1|Spironolactone
11646931|NCT00123955|Placebo Comparator|2|Placebo
11646932|NCT00123929|Active Comparator|1|doxorubicin
11646933|NCT00123929|Other|2|docetaxel
11646934|NCT00123916|Experimental|Benznidazole|40 - 80 days (according to body weight) treatment with benznidazol
11646935|NCT00123916|Placebo Comparator|Placebo|40 - 80 days (according to body weight) treatment with matching placebo
11646936|NCT00123838|Experimental|Single Group Assignment|Calypso® 4D Localization System
11646937|NCT00123682|Experimental|Arm 1 - proactive, intensive counseling|Proactive outreach to counseling; multi-session counseling from California Smokers' Helpline
11646938|NCT00123682|Experimental|Arm 2 - reactive, intensive counseling|Reactive outreach to counseling; multi-session counseling from California Smokers' Helpline
11646939|NCT00123682|Experimental|Arm 3 - proactive, self-help|Proactive outreach to engage smoker in treatment; mailed self-help materials
11646940|NCT00123682|Experimental|Arm 4 - reactive, self-help|Reactive approach to engaging smoker in treatment; mailed self-help materials
11646941|NCT00123669|No Intervention|Control|Patient will not receive Inj Progesterone 500 mg
11646942|NCT00123669|Experimental|Treatment|An intramuscular injection of 500mg depot hydroxy-progesterone 5-14 days prior to surgery.
11646943|NCT00123656|Active Comparator|1|fluticasone
11646944|NCT00123656|Active Comparator|2|esomeprazole
11646945|NCT00123643|Experimental|Rosiglitazone|
11646946|NCT00123643|Active Comparator|Glyburide|
11646947|NCT00123630|Placebo Comparator|placebo|placebo group
11646948|NCT00123630|Experimental|omalizumab|Xolair group
11646949|NCT00123617|Experimental|Phase III cardiac rehabilitation|Phase III group-based cardiac rehabilitation classes, weekly
11646950|NCT00123617|No Intervention|Monitoring|Normal daily living, no extra visits to study centre
11646951|NCT00123604|Experimental|Carvedilol|Carvedilol, orally, 25 mg, twice daily for five months
11646952|NCT00123604|Active Comparator|Metoprolol|Metoprolol, orally, 200 mg, twice daily for five months.
11646953|NCT00123578|Experimental|Lorazepam|Lorazepam for the treatment of mild GHB withdrawal.
11646954|NCT00123578|Active Comparator|Pentobarbital|Pentobarbital for the treatment of mild GHB withdrawal.
11646955|NCT00123552|Experimental|1|
11646956|NCT00123552|Experimental|2|
11646957|NCT00123552|Experimental|3|
11646958|NCT00123526|Experimental|1|Worksite intervention
11646959|NCT00123526|No Intervention|2|Receive no intervention
11646960|NCT00123513|Experimental|1|Worksite intervention for obesity prevention
11646961|NCT00123513|No Intervention|2|Control group
11646962|NCT00123500|Active Comparator|1|Worksite Intervention
11646963|NCT00123500|Placebo Comparator|2|Control Group
11646964|NCT00123487|Experimental|dasatinib Twice a Day (BID)|70 mg dasatinib twice a day (BID)
11646965|NCT00123487|Experimental|dasatinib Once a Day (QD)|140 mg dasatinib once a day (QD)
11646966|NCT00123474|Experimental|1|
11646967|NCT00123474|Experimental|2|
11646968|NCT00123474|Experimental|3|
11646969|NCT00123474|Experimental|4|
11646970|NCT00123435|Active Comparator|Arm 1|5-session nutritional counseling program
11646971|NCT00123435|Experimental|Arm 2|5-session nutritional counseling program + simple pedometer feedback
11646972|NCT00123435|Experimental|Arm 3|5-session nutritional counseling program + simple pedometer feedback + enhanced pedometer feedback web-based feedback
11646973|NCT00123422|Experimental|Breathing retraining|Exercise training with computerized training program
11646974|NCT00123422|Experimental|Heliox|Exercise training with helium oxygen combination
11646975|NCT00123422|Active Comparator|Exercise|Exercise training
11646976|NCT00123409|Experimental|Telephone Disease Management|Telephone based disease management or counseling used to promote a reducution in alcohol misuse
11646977|NCT00123409|Placebo Comparator|Usual Care|Usual Care
11646978|NCT00123396|Experimental|Arm 1|Test the effectiveness of the BioCASES teaching modules by way of a randomized controlled trial of VAMCs using the BioTESTS to evaluate their effectiveness for increasing and sustaining VA clinician knowledge, skills, and ability to respond to bioterrorism events.
11646979|NCT00123357||Group 1|
11646980|NCT00123318|Experimental|1|Single-arm, non-randomised feasibility study to evaluate new regimen of adjuvant chemoradiotherapy (Epirubicin, Cisplatin, 5-Fluorouracil + radiotherapy)
11646981|NCT00123305|Experimental|1|
11646982|NCT00123305|Experimental|2|
11646983|NCT00123305|Experimental|3|
11646997|NCT00123240|Active Comparator|High Fat/Protein Diet|
11646998|NCT00123240|Active Comparator|High Carbohydrate Diet|
11646999|NCT00123188|Experimental|Ultrasound and Biopsy|Transvaginal Ultrasound and Endometrial Biopsy
11647000|NCT00123162|Experimental|Sildenafil Citrate|A single vaginal dose of Viagra 100 mg.
11647001|NCT00123162|Placebo Comparator|Placebo|A single vaginal dose of placebo.
11647002|NCT00123123|Placebo Comparator|Placebo (Vehicle Control)|Delivered Twice a day
11647003|NCT00123123|Experimental|0.12% chlorhexidine gluconate oral rinse|Delivered twice a day
11647004|NCT00123123|Experimental|0.12% chlorhexidine oral rinse|Delivered once a day, placebo once a day
11647005|NCT00123110|Experimental|1|metformin pill plus placebo injection
11647006|NCT00123110|Experimental|2|leuprolide injection plus placebo pill
11647007|NCT00123110|Placebo Comparator|3|placebo pill plus placebo injection
11647008|NCT00123097|Experimental|Chlorinated polyethylene elastomer first|Patient receives prosthetic made from CPE then the SOC, silicon.
11647009|NCT00123097|Active Comparator|Silicon first|Patient receives prosthetic made from the SOC, silicon, followed by the CPE,Chlorinated polyethylene elastomer.
11647010|NCT00123084|Experimental|Voice/Respiratory Treatment|4 Days a week for 4 weeks with focus on high intensity voice exercises
11647011|NCT00123084|Experimental|Articulation Treatment|4 days a week for 4 weeks with focus on high intensity articulation tasks
11647012|NCT00123084|No Intervention|Subjects with PD in a no treatment group|Subjects do not receive therapy during experimental phases, and will be offered therapy at the end of the study enrollment period.
11647013|NCT00123084|No Intervention|Healthy Control Subjects|Subjects are without Parkinson disease and will not receive therapy.
11647014|NCT00123058|Experimental|Nurse administered|"Nurse Administered Intervention:
~Subject received nurse administered behavioral intervention every 8 weeks via telephone for 24 months."
11647015|NCT00123058|Experimental|Nurse & BP monitor|Subjects received both a nurse administered behavioral intervention via telephone every 8 weeks for 24 months and a study provided home BP monitor. Subject recorded home BP 3 times per week for 24 months.
11647016|NCT00123058|No Intervention|Usual Care|Subjects received neither home BP monitor nor nurse phone intervention.
11647017|NCT00123058|Experimental|Home BP Monitor|Subject received study provided home BP monitor. Subject recorded home BP 3 times per week for 24 months.
11647018|NCT00123032|Experimental|1|This group will focus on improving their diet and increasing physical activity at home and at school.
11647019|NCT00123032|No Intervention|2|A control group will not receive any intervention.
11647020|NCT00123019|Active Comparator|1|Minimal intervention; annual weight/waist assessment, questionnaire, and advice
11647021|NCT00123019|Experimental|2|Intensive intervention. All arm 1 activities plus ongoing environmental and group interventions in worksite for two years.
11647022|NCT00123006|Active Comparator|1|Dietary Approaches to Stop Hypertension (DASH)
11647023|NCT00123006|Placebo Comparator|2|Control diet
11647024|NCT00122993|Experimental|1|Multi-component environmental intervention to prevent excess weight gain among bus drivers
11647025|NCT00122993|No Intervention|2|Control group
11647026|NCT00122980|Active Comparator|1|Hydroxyurea and phlebotomy
11647027|NCT00122980|Active Comparator|2|Transfusion and chelation
11647028|NCT00122954|Experimental|Fish oil concentrate|Fish oil concentrate
11647029|NCT00122954|Placebo Comparator|Placebo oil|Placebo oil
11647030|NCT00122928|Experimental|High intensity environmental intervention|Intense intervention
11647031|NCT00122928|Experimental|Moderate intensity environmental intervention|Moderate intervention
11647032|NCT00122928|No Intervention|Individual intervention only|Control
11647033|NCT00122772|Experimental|EBR plus 2 HDBT fractions|External Beam Radiotherapy High Dose Brachytherapy (2 fractions of 9Gy)
11647034|NCT00122772|Active Comparator|EBR plus 4 fractions HDBT|External Beam Radiotherapy High Dose Brachytherapy (4 fractions of 7Gy)
11647035|NCT00122772|Experimental|EBR/2 HDBT fractions/Chemotherapy|"External Beam Radiation
~High Dose Brachytherapy (2 fractions of 9Gy)
~Cisplatin"
11647036|NCT00122772|Experimental|EBR/4 fractions HDBT/chemotherapy|"External Beam Radiation
~High Dose Brachytherapy (4 fractions of 7Gy)
~Cisplatin"
11647037|NCT00122746|Active Comparator|Radiotherapy alone|EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A
11647038|NCT00122746|Experimental|Radiotherapy plus Chemotherapy|EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
11647039|NCT00122681|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ (GSK Biologicals' human papillomavirus [HPV] vaccine) at Months 0, 1 and 6.
11647040|NCT00122681|Active Comparator|Havrix Group|Subjects received 3 doses of GSK Biologicals' hepatitis A vaccine [HAV] (Havrix™-based investigational formulation) at Months 0, 1 and 6.
11647041|NCT00122642|Experimental|1|The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes for patients not in the hospital.
11647042|NCT00122642|Placebo Comparator|2|The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
11647043|NCT00122616|Active Comparator|Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy|Day0 to week 96:Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy
11647044|NCT00122616|Placebo Comparator|HIV antiretroviral therapy|Day0 to week 96: HIV antiretroviral therapy
11647045|NCT00122603|Experimental|Group 1|Atazanavir + Fosamprenavir + ritonavir
11647046|NCT00122603|Experimental|group 2|Atazanavir + saquinavir + ritonavir
11647047|NCT00122460|Experimental|Cetuximab Plus Chemotherapy|
11647048|NCT00122460|Active Comparator|Chemotherapy alone|
11647049|NCT00122447|Active Comparator|Anti-inflammatory agent|Aspirin (ASA)
11647050|NCT00122447|Active Comparator|Angiotensin receptor blocker (ARB)|Olmesartan (ARB)
11647051|NCT00122447|Active Comparator|Antioxidant|Alpha lipoic acid (ALA)
11647052|NCT00122447|Placebo Comparator|Placebo|Aspirin placebo once a day Olmesartan placebo once a day Alpha lipoic acid placebo twice a day
11647053|NCT00122421|Active Comparator|pharmacist recommendation|recommendations based on chart review by pharmacist, given to pcp at time of visit
11647054|NCT00122421|No Intervention|usual care|usual care
11647055|NCT00122408|Active Comparator|1|
11647056|NCT00122408|Placebo Comparator|2|
11647057|NCT00122382|Active Comparator|ABA + MTX|abatacept 10 mg/kg intravenous (IV) + methotrexate
11647058|NCT00122382|Active Comparator|Placebo (PLA) + MTX|placebo IV + methotrexate
11647059|NCT00122369|Experimental|Self-hypnotic Relaxation|A research assistant displayed defined behaviors of empathic attention and read to the patient a self-hypnotic relaxation script. Patients also received lidocaine as local anesthetic which is the standard care approach and not considered a unique intervention in terms of the trial.
11647060|NCT00122369|No Intervention|Standard Care|Patients received the routine standard treatment which included application of lidocaine as local anesthetic. This is not considered a unique intervention in terms of the trial. Omitting local anesthetic actually would have been an intervention deviating from routine care.
11647061|NCT00122369|Active Comparator|Empathic Attention|A research assistant displayed defined behaviors of empathic attention. Patients also received lidocaine as local anesthetic which is the standard care approach and not considered a unique intervention in terms of the trial.
11647062|NCT00122356|Other|Anastrozole and alendronate|Patients will receive anastrozole for 5 years and alendronate for 3 years or anastrozole and alendronate treatment for 5 years.
11647063|NCT00122343|Experimental|1|AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
11647064|NCT00122317|Experimental|Eculizumab|600 mg intravenous infusion every week x 4 then 900 mg iv every two weeks
11647065|NCT00122278|Experimental|Dexamethasone|Dexamethasone 10 mg
11647066|NCT00122278|Placebo Comparator|Placebo|Placebo Dexamethasone, 10 mg
11647067|NCT00122187|Experimental|Electronic Consult System|A new consult system designed to automatically send a gastroenterology consult request for patients with positive fecal occult blood testing (FOBT+) results
11647068|NCT00122187|No Intervention|Usual Care|The usual and customary procedures for addressing FOBT+ results: primary care physicians continued to be responsible for follow up of FOBT+ results.
11647069|NCT00122174|Other|Arm 1|
11647070|NCT00122161|Other|Arm 1|
11647071|NCT00122148|Other|1|
11647072|NCT00122135|No Intervention|Patients without Values Inventory (VI)|Clinic encounter w/physician & patient and/or surrogate - Patients who did not receive the VI prior to their physician clinic encounter
11647073|NCT00122135|Experimental|Patients with Values Inventory (VI)|Clinic encounter w/physician & patient and/or surrogate - Patients who completed the VI prior to their physician clinic encounter
11647074|NCT00122122|Other|Arm 1|
11647075|NCT00122109|Experimental|Videoteleconferencing AMT|"The experimental arm is the group condition that received the AMT treatment intervention via a videoteleconferencing modality as compared to the control condition which is the traditional face-to-face modality.
~Behavioral: 12 sessions Anger Management Therapy. Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills."
11647076|NCT00122109|Active Comparator|Face to Face AMT|"The control arm is the group condition that received the AMT treatment intervention via a traditional face-to-face modality as compared to the experimental condition which is the videoteleconferencing modality.
~Behavioral: 12 sessions Anger Management Therapy. Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills."
11647077|NCT00122070|Experimental|A|Quetiapine at dosage of 50 to 150 mg
11647078|NCT00122031|Experimental|DBS|
11647079|NCT00122018|Experimental|NAC|N-acetylcysteine started day prior to surgery, continued through night of surgery
11647080|NCT00122018|Experimental|fenoldopam|fenoldopam started at surgery continued for 24 hours
11647081|NCT00122018|Experimental|NAC and fenoldopam|Both N-acetylcysteine and fenoldopam as above
11647082|NCT00122018|Placebo Comparator|Control|Placebo
11647083|NCT00121992|Active Comparator|Arm A: FAC|FAC (5-fluorouracil, doxorubicin, cyclophosphamide): 5-fluorouracil 500 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv
11647084|NCT00121992|Experimental|Arm B: TAC|TAC (docetaxel, doxorubicin, cyclophosphamide): Docetaxel 75 mg/m2 iv on day 1, each 3 weeks, in combination with doxorubicin 50 mg/m2 iv and cyclophosphamide 500 mg/m2 iv
11647085|NCT00121940|Experimental|Guided Care|
11647086|NCT00121940|No Intervention|Usual Care|
11647087|NCT00121875||Turner syndrome|Girls, aged 7-14, with short stature due to Turner syndrome and eligible for growth hormone therapy
11647088|NCT00121875||Control / idiopathic short stature|Girls, aged 7-14, with idiopathic short stature and eligible for growth hormone therapy
11647089|NCT00121836|Experimental|1|
11647090|NCT00121810|Experimental|1|
11647091|NCT00121810|Active Comparator|2|
11647092|NCT00121784|Experimental|1|1
11647093|NCT00121745|Experimental|1|
11647094|NCT00121745|Experimental|2|
11647095|NCT00121745|Experimental|3|
11647096|NCT00121745|Experimental|4|
11647097|NCT00121732|Experimental|A|
11647098|NCT00121732|Experimental|B|
11647099|NCT00121719|Experimental|1|
11647100|NCT00121693|Experimental|Music Listening 1|Intervention: Listen to Music type 1
11647101|NCT00121693|Experimental|Music Listening 2|Intervention: Listen to Music type 2
11647102|NCT00121693|Experimental|Music LIstening 3|Intervention: Listen to Music type 3
11647103|NCT00121693|No Intervention|Control|Intervention: Listen to White noise
11647104|NCT00121680|Experimental|1|
11647257|NCT00119197|Experimental|1|Killed Whole Cell Oral Cholera Vaccine
11647105|NCT00121667|Experimental|Saxagliptin + Metformin (A)|Pioglitazone 15-45 mg (as needed for rescue)
11647106|NCT00121667|Experimental|Saxagliptin + Metformin (B)|Pioglitazone 15-45 mg (as needed for rescue)
11647107|NCT00121667|Experimental|Saxagliptin + Metformin (C)|Pioglitazone 15-45 mg (as needed for rescue)
11647108|NCT00121667|Placebo Comparator|Placebo+ Metformin (D)|Pioglitazone 15-45 mg (as needed for rescue)
11647109|NCT00121654|Active Comparator|1|paresthesic SCS
11647110|NCT00121654|Active Comparator|2|subliminal SCS (75-80% of paresthesic threshold)
11647111|NCT00121654|Sham Comparator|3|low stimulation, consisting of an hour of SCS a day at 0.05 mV intensity, which does not have any significant stimulator effect (sham stimulation)
11647112|NCT00121641|Experimental|Saxagliptin 2.5 mg (A)|Metformin 500-2000 mg (as needed for rescue)
11647113|NCT00121641|Experimental|Saxagliptin 5 mg (B)|Metformin 500-2000 mg (as needed for rescue)
11647114|NCT00121641|Experimental|Saxagliptin 10 mg (C)|Metformin 500-2000 mg (as needed for rescue)
11647115|NCT00121641|Placebo Comparator|Placebo (D)|Metformin 500-2000 mg (as needed for rescue)
11647116|NCT00121641|Experimental|Open-Label Treatment Cohort (Direct Enrollees) (E)|"Saxagliptin 10 mg
~Metformin 500-2000 mg (as needed for rescue)"
11647117|NCT00121602|Active Comparator|Roller bottle|
11647118|NCT00121602|Experimental|Serum free|
11647119|NCT00121550|Experimental|Clarithromycin|Clarithromycin is a lipophilic semi-synthetic macrolide antibiotic. The lipophilic nature of the drug allows it to easily penetrate into body fluids and tissues and accumulate intracellularly. Side effects are few, apart from trivial gastrointestinal complaints, and severe side effects are rarely observed during standard treatment.
11647120|NCT00121550|Placebo Comparator|Placebo|Placebo comparator
11647121|NCT00121524|Experimental|IV yes|Intravenous needle Epinephrine q 3 min during CPR Atropine 3 mg in initial asystole Amiodarone 300 mg iv after repeated failed defibrillation attempts
11647122|NCT00121524|No Intervention|IV no|The patient will not have an intravenous needle placed or given any drugs during CPR. If patient obtains spontaneous circulation, an intravenous needle is placed and patient can receive any drugs that are appropriate during the following treatment.
11647123|NCT00121485|Experimental|HeartMate II|Implantation of HeartMate II LVAS
11647124|NCT00121485|Active Comparator|HeartMate XVE|Implantation of HeartMate XVE LVAS
11647125|NCT00121394|Experimental|Chlorhexidine|
11647126|NCT00121381|Experimental|1|Pimecrolimus 1 % cream plus topical corticosteroid (TCS)
11647127|NCT00121381|Placebo Comparator|2|Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
11647128|NCT00121316|Experimental|1|Pimecrolimus
11647129|NCT00121316|Placebo Comparator|2|Matching vehicle cream (placebo)
11647130|NCT00121303|Active Comparator|Arm A low dose Dauno|Induction 45 mg Dauno
11647131|NCT00121303|Experimental|ARM B high dose Dauno|Induction 90 mg Dauno
11647132|NCT00121303|No Intervention|Arm 1 no further treatment|
11647133|NCT00121303|Experimental|Arm 2 Mylotarg|Post induction treatment with Mylotarg
11647134|NCT00121290|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes once daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11647135|NCT00121277|Experimental|SAHA (Suberoylanilide Acid) with Capecitabine|
11647136|NCT00121264|Experimental|Treatment (sorafenib tosylate, tanespimycin)|Patients receive oral sorafenib twice daily on days -14 to 28 in course 1 and on days 1-28 in all subsequent courses. Patients also receive 17-AAG IV over 3 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11647137|NCT00121251|Experimental|Arm I|Patients receive sorafenib* PO BID on days 1-21, gemcitabine IV over 30 minutes on days 1 and 8, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for at least 3 courses in the absence of unacceptable toxicity or disease progression.
11647138|NCT00121238|Experimental|Experimental treatment: cilengitide|Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity. After 3 courses, patients undergo evaluation. Patients achieving a complete prostate-specific antigen (PSA) response (i.e., PSA < 0.2 ng/mL) receive 2-3 additional courses of therapy. Patients with partial PSA response or stable disease continue treatment indefinitely in the absence of disease progression or unacceptable toxicity. Patients demonstrating disease progression by CT scan, MRI, or bone scan are removed from the study.
11647139|NCT00121225|Experimental|Arm I|Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
11647140|NCT00121212|Active Comparator|Surgery - Negative PET scan|If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is negative, the patient will receive the curative therapy and be followed for recurrence.
11647141|NCT00121212|Experimental|Surgery - Positive PET scan|If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is positive, the patient will receive the curative therapy and be followed for recurrence or receive alternative therapy.
11647142|NCT00121212|Active Comparator|Radiation therapy Negative or Positive PET scan|If patient is candidate for radiation therapy with curative intent, he will be enrolled. If PET scan is negative he will receive curative therapy and be followed for PSA recurrence. If PET scan is positive he may receive confirmatory studies and then if negative, not indicated, or refused he will receive curative therapy be followed for PSA recurrence. If PET scan is positive and received positive confirmatory studies he will receive curative therapy and followed for recurrence.
11647143|NCT00121199|Experimental|Treatment (CHOP, rituximab, bevacizumab)|Patients receive rituximab IV, bevacizumab IV over 30-90 minutes, cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1. Patients also receive oral prednisone on days 1-5. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
11647207|NCT00119925|Active Comparator|maximal intervention|multi-faceted intervention consisting of professional and patient elements
11647258|NCT00119197|Placebo Comparator|2|Heat-killed E. coli
11647259|NCT00119184|Experimental|External cephalic version with spinal anesthesia|External cephalic version with spinal anesthesia
11647144|NCT00121186|Experimental|Nonmyeloablative allogeneic stem cell transplant|Patients are given fludarabine 30 mg/m^2 on days -6 to -2 and melphalan 70 mg/m^2 on days -3 and -2, then transplanted with donor peripheral blood stem cells or harvested bone marrow stem cells on day 0. Patients are then given post-transplant immunosuppression consisting of tacrolimus 0.06 mg/kg/day on days -3 to 100 and methotrexate 5 mg/m^2 on days 1, 3, and 7.
11647145|NCT00121173|Experimental|Low dose|"3-500mcg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals.
~Genetic (recombinant DNA vaccine)"
11647146|NCT00121173|Experimental|Intermediate dose|3-1mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)
11647147|NCT00121173|Experimental|High dose|3-3mg doses of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered IM at one month intervals Genetic (recombinant DNA vaccine)
11647148|NCT00121134|Experimental|Group A|Bevacizumab Alone
11647149|NCT00121134|Experimental|Group B|Bevacizumab with cyclophosphamide and methotrexate
11647150|NCT00121134|Experimental|Group C|capecitabine, 14 days on/7 days off scheduling, and bevacizumab
11647151|NCT00121134|Experimental|Group D|capecitabine 7 days on/7 days off scheduling, and bevacizumab
11647152|NCT00121108|Placebo Comparator|2|Placebo
11647153|NCT00121108|Active Comparator|1|MEDI-524
11647154|NCT00121095|Other|1|
11647155|NCT00120965|Experimental|1|Autopulse device
11647156|NCT00120965|Active Comparator|2|Manual CPR
11647157|NCT00120874|Experimental|Group 1|Individualized Management including caregiver training and Memantine
11647158|NCT00120874|Active Comparator|Group 2|Only Memantine
11647159|NCT00120796|Active Comparator|1|Lamivudine alone
11647160|NCT00120796|Experimental|2|Lamivudine + Vaccine
11647161|NCT00120627|Experimental|Arm 1: Mantram + Usual Care|Mantram Repetition Program for PTSD delivered in this study as 6-week, 90-minute per week that targeted PTSD symptoms. It was offered as an adjunct to usual care consisting of medication and case-management.
11647162|NCT00120627|Active Comparator|Arm 2: Usual Care alone|Usual care alone is defined as receiving 6 weeks of medication and case management, as needed by each patient. No group meetings.
11647163|NCT00120523|Experimental|1|Pimecrolimus
11647164|NCT00120523|Active Comparator|2|Topical corticosteroids
11647165|NCT00120510|Experimental|A|Randomly assigned group who will start an ART regimen of 3TC/ZDV and EFV twice daily at study entry
11647166|NCT00120510|Active Comparator|B|Randomly assigned group who will delay beginning ART regimen of 3TC/ZDV and EFC twice daily until they develop clinical AIDS or their CD4 count drops below 200 cells/mm3
11647167|NCT00120471|Experimental|1|Pregnant participants will receive a single dose of TDF during active labor. These participants will be hospitalized at the delivery facility through Day 3 postpartum.
11647168|NCT00120471|Experimental|2|Pregnant participants will not receive TDF. Participants will be hospitalized at the delivery facility through Day 7 postpartum. Their infants will receive TDF at birth and on Days 3 and 5 after birth.
11647169|NCT00120471|Experimental|3|Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum. They will receive TDF during active labor and their infants will receive TDF at birth and on Days 3 and 5 after birth.
11647170|NCT00120471|Experimental|4|Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum. Mothers will receive TDF during active labor and their infants will receive TDF at birth and daily for 7 days after birth.
11647171|NCT00120458|Experimental|1|Anxiolytic Therapy
11647172|NCT00120458|Placebo Comparator|2|Anxiolytic Therapy
11647173|NCT00120445|Active Comparator|2|air vs perfluoropropane gas in pneumatic retinopexy
11647174|NCT00120432|Active Comparator|A|single dose vs three doses of 1%tropicamide and 10%phenylephrine
11647175|NCT00120406|Experimental|1|Zilver® PTX™ Drug Eluting Vascular Stent
11647176|NCT00120406|Active Comparator|2|Angioplasty
11647177|NCT00120393|Active Comparator|G1|
11647178|NCT00120393|Active Comparator|G2|
11647179|NCT00120380|Active Comparator|Aerosolized Iloprost|
11647180|NCT00120380|Placebo Comparator|Bosentan monotherapy|
11647181|NCT00120315|No Intervention|esomeprazole|Long-term users continue antisecretory medication
11647182|NCT00120315|Placebo Comparator|placebo drug|Long-term users are treated with placebo
11647183|NCT00120302|Experimental|1|Pimecrolimus
11647184|NCT00120302|Placebo Comparator|2|Vehicle
11647185|NCT00120289|Experimental|Combination Therapy|Extended release niacin plus simvastatin
11647186|NCT00120289|Active Comparator|Monotherapy|Simvastatin alone
11647187|NCT00120250|Experimental|Eszopiclone|Subjects received 3mg eszopiclone nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of placebo, followed by another 1 week washout.
11647188|NCT00120250|Placebo Comparator|Placebo|Subjects received placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of 3mg eszopiclone, followed by another 1 week washout.
11647189|NCT00120211|Experimental|Radiotherapy: 6 Fractions|
11647190|NCT00120211|Active Comparator|Radiotherapy: 5 fractions|
11647191|NCT00120120|Experimental|1|
11647192|NCT00120120|Experimental|2|
11647193|NCT00120081|Experimental|Low dose|10 mcg Na-ASP-2/Alhydrogel
11647194|NCT00120081|Experimental|Medium dose|50 mcg Na-ASP-2/Alhydrogel
11647195|NCT00120081|Experimental|High dose|100 mcg Na-ASP-2/Alhydrogel
11647196|NCT00120081|Placebo Comparator|Saline placebo|Saline placebo
11647197|NCT00120068|Other|Arm 1|
11647198|NCT00120042|No Intervention|1|No specific oxytocic to assist in placental delivery
11647199|NCT00120042|Active Comparator|2|Intramuscular oxytocin injection
11647200|NCT00120042|Active Comparator|3|Oral misoprostol to assist in placental delivery
11647201|NCT00120016|Experimental|1|Mediterranean diet
11647202|NCT00120016|No Intervention|2|non-intervention diet
11647203|NCT00120003|Experimental|Candesartan Cilexetil|Candesartan Cilexetil
11647204|NCT00120003|Placebo Comparator|Placebo|Placebo
11647205|NCT00119977|Active Comparator|1|
11647206|NCT00119925|Active Comparator|minimal intervention|professional audit and feedback on current practice
11647208|NCT00119912|Active Comparator|A 1 Intervention arm Flex Sig|Randomised from the population registry, age 50-64 years and invited for Flexible Sigmoidoscopy (Flex Sig) screening. Half of invitees are additionally invited to provide a stool sample for fecal occult blood testing (Intervention arm A 2). They are drawn directly from the population registry without prior consent to be randomized - approved by Regional Ethics Committees of South-East Norway..
11647209|NCT00119912|No Intervention|B Control arm|"No screening group randomised from population age 50-64 years. As for the active intervention arm, the control group was not informed about being randomized to 'no screening' since 'no screening' was the current usual care (and still is in 2015) in Norway - approved by Regional Ethics Committees of South-East Norway."
11647210|NCT00119912|Active Comparator|A 2 Intervention arm Flex Sig + iFOBT|Randomised from the population registry, age 50-64 years and invited for Flexible Sigmoidoscopy (Flex Sig) screening plus an immunochemical test for fecal occult blood (iFOBT). As for arms A 1 and B, they are drawn directly from the population registry without prior consent to be randomized.
11647211|NCT00119847|Experimental|PCI+MED|Percutaneous Coronary Intervention (PCI) with angioplasty and stenting of the infarct-related artery and optimal medical therapy
11647212|NCT00119847|Experimental|MED|Optimal medical therapy alone
11647213|NCT00119821|Experimental|I|Behavioral Weight Reduction
11647214|NCT00119821|Other|II|Exercise
11647215|NCT00119821|Other|III|Smoking Cessation
11647216|NCT00119795|Active Comparator|Health education control|This is an education program for older adults entitles, successful aging.
11647217|NCT00119795|Experimental|Exercise Only|Structured exercise 150 min/wk
11647218|NCT00119795|Experimental|Weight Loss|Behavioral weight loss; goal of 7%
11647219|NCT00119782|Experimental|1|Comprehensive worksite intervention
11647220|NCT00119782|Experimental|2|Delayed intervention control group
11647221|NCT00119769|Placebo Comparator|1|
11647222|NCT00119769|Active Comparator|2|
11647223|NCT00119730|Experimental|Fludarabine, Mitoxantrone, Rituximab, Zevalin|Drug: Fludarabine Given on days 1-3 of each 28-day cycle Drug: Mitoxantrone Given on day 1 of each 28-day cycle Drug: Rituximab Given on day 1 of each 28-day cycle Drug: Zevalin Given after two cycles if there is no disease progression.
11647224|NCT00119717|Experimental|1|
11647225|NCT00119717|Active Comparator|2|
11647226|NCT00119691|Experimental|Nesiritide + standard of care|Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
11647227|NCT00119691|Active Comparator|Standard of care|Standard of care until adequate diuresis achieved
11647228|NCT00119678|Active Comparator|Abatacept + Prednisone|Double Blind Period
11647229|NCT00119678|Placebo Comparator|Placebo + Prednisone|Double Blind Period
11647230|NCT00119678|Experimental|Abatacept|Open Label
11647231|NCT00119639|Experimental|Arm 1|
11647232|NCT00119613|Experimental|Group 1 - darbepoetin alfa|Darbepoetin alfa 300 mcg QW for the first 4 weeks, followed by Q3W dosing commencing on week 5 for the remainder of the treatment period.
11647233|NCT00119613|Placebo Comparator|Group 2 - Placebo|Placebo QW for the first 4 weeks, followed by Q3W dosing commencing on week 5 for the remainder of the treatment period.
11647234|NCT00119574|Other|Arm 1|
11647235|NCT00119561|Experimental|Arm 1|Telephone support groups
11647236|NCT00119561|No Intervention|Arm 2|Usual VA care
11647237|NCT00119548|Other|Arm 1|Randomized, controlled trial with three intervention models: Model A (traditional counseling/testing);
11647238|NCT00119548|Other|Arm 2|Model B (nurse-initiated screening, traditional counseling/testing);
11647239|NCT00119548|Other|Arm 3|Model C (nurse-initiated screening, streamlined counseling/rapid testing).
11647240|NCT00119535|Other|Arm 1|
11647241|NCT00119522||Group 1|cohort is of individuals with a spinal cord injury who use a wheelchair as their primary means of mobility
11647242|NCT00119496|Active Comparator|Group 1|Inhaled beclomethasone (400mcg/day)
11647243|NCT00119496|Active Comparator|Arm 2|Rosiglitazone
11647244|NCT00119496|Active Comparator|Arm3|Oral theophylline
11647245|NCT00119496|Active Comparator|Arm 4|Oral theophylline and inhaled beclomethasone
11647246|NCT00119444|Other|periacetabular osteotomy|
11647247|NCT00119392|Experimental|Treatment (90Y ibritumomab tiuxetan, hematopoietic transplant)|See Detailed Description
11647248|NCT00119379|Experimental|uridine supplementation|NucleomaxX 36 grams TID every other day
11647249|NCT00119379|Active Comparator|Switch to Tenofovir|Switch of AZT or d4T to Tenofovir Disoproxil Fumarate
11647250|NCT00119366|Experimental|Treatment (radiolabeled monoclonal antibody, TBI, chemo, PBSC)|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.
~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.
~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.
~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
11647251|NCT00119262|Experimental|Arm I (combination chemotherapy, 18 courses of bevacizumab)|See detailed description.
11647252|NCT00119262|Active Comparator|Arm II (combination chemotherapy, 22 courses of bevacizumab)|See detailed description.
11647253|NCT00119249|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11647254|NCT00119236|Experimental|Arm I|Patients receive irinotecan IV over 30 minutes followed by 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)* IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable or improved disease after course 2 may receive additional courses of treatment.
11647255|NCT00119210|Placebo Comparator|Placebo|Sugar pill
11647256|NCT00119210|Experimental|Bupropion SR|
11647260|NCT00119184|Active Comparator|External cephalic version without spinal anesthesia|External cephalic version without spinal anesthesia
11647261|NCT00119158|Placebo Comparator|placebo|Placebo cream
11647262|NCT00119158|Active Comparator|pimecrolimus cream|
11647263|NCT00119106|Active Comparator|Tenofovir|Tenofovir
11647264|NCT00119106|Placebo Comparator|Placebo|Placebo
11647265|NCT00119067|Active Comparator|AVA 8-SQ|receive 8 injections of AVA SQ
11647266|NCT00119067|Experimental|AVA 8-IM|receive 8 injections of AVA IM
11647267|NCT00119067|Experimental|AVA 7-IM|receive 7 injections of AVA IM
11647268|NCT00119067|Experimental|AVA 5-IM|receive 5 injections of AVA IM
11647269|NCT00119067|Experimental|AVA 4-IM|receive 4 injections of AVA IM; months 0, 2, 6 and a booster at month 42
11647270|NCT00119067|Placebo Comparator|Saline placebo IM or SQ|
11647271|NCT00119054|Other|Arm 1|
11647272|NCT00119041|Experimental|Telemedicine CBOC|"Designated CBOC's were involved in the intervention phase where their Diabetes Mellitus (DM) patients were asked to participate in a telemedicine visit.
~The Behavioral: The Diabetes Treatment Satisfaction Questionnaire given during this phase along with the Behavioral: Diabetes Empowerment Scale and the Behavioral: CBOC's undergo half-day joint-clinics via teleconference."
11647273|NCT00119041|No Intervention|Control CBOC|The CBOC's not involved in the intervention phase had their patients not be involved in the telemedicine visit, but traditional education.
11647274|NCT00119041|No Intervention|Provider Interviews|Qualitative interviews with providers
11647275|NCT00119028|Other|Arm 1|Non-experimental QI intervention - No comparator
11647276|NCT00119015|Placebo Comparator|Fluticasone propionate + Placebo|"Fluticasone propionate nasal spray - 2 sprays in each nostril once a day for 2 weeks (200 micrograms daily)
~Placebo - 10 mg po daily for 2 weeks"
11647277|NCT00119015|Active Comparator|Fluticasone propionate + Montelukast|"Fluticasone propionate nasal spray - 2 sprays in each nostril once a day for 2 weeks (200 micrograms daily)
~Montelukast - 10 mg po daily for 2 weeks"
11647278|NCT00119002|Active Comparator|Dexamethasone|1mg of Dexamethasone/kg
11647279|NCT00119002|Placebo Comparator|Placebo|1mg/kg placebo
11647280|NCT00118989|Placebo Comparator|PLACEBO|placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
11647281|NCT00118989|Experimental|Curcuminoids C3 Complex® to be taken orally via caps|Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
11647282|NCT00118963|Active Comparator|3|BIAsp30 plus Metformin plus Placebo-Repaglinide. Double-Masked and randomized. Duration: 12 months.
11647283|NCT00118963|Active Comparator|2|BIAsp30 plus Repaglinide plus Placebo-Metformin. Double-masked and randomized. Duration: 12 months.
11647284|NCT00118963|Other|1|Run-in period of four months duration with Repaglinide 6 mg daily plus Metformin 2000 mg daily. No masking of interventions.
11647285|NCT00118950|Active Comparator|4|Metformin plus placebo-Repgalinide. Double-masked, randomized. Duration: Four months.
11647286|NCT00118950|Active Comparator|2|Repaglinide plus Placebo-Metformin. Double-masked, randomized. Duration: Four months.
11647287|NCT00118950|Other|1|Run-in period: Treatment: Diet-only. Duration: One month.
11647288|NCT00118950|Other|3|Wash-out period: Treatment: Diet-only: Duration: One month.
11647289|NCT00118937|Placebo Comparator|1|Single-blind placebo run-in period. Duration one month.
11647290|NCT00118937|Active Comparator|2|Metformin 2000 mg, double-masked randomized during 12 months.
11647291|NCT00118937|Placebo Comparator|3|Placebo, double-masked randomized during 12 months.
11647292|NCT00118924|Experimental|1|One subcutaneous vaccination with a 10^3 PFU dose of LGT(TP21)/DEN4 vaccine given in the deltoid region of either arm. A second booster vaccination will be given 6 months after the first vaccination.
11647293|NCT00118924|Experimental|2|One subcutaneous vaccination with a 10^5 PFU dose of LGT(TP21)/DEN4 vaccine given in the deltoid region of either arm. A second booster vaccination will be given 6 months after the first vaccination. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
11647294|NCT00118924|Placebo Comparator|3|One subcutaneous vaccination with a placebo vaccine given in the deltoid region of either arm. A second placebo vaccination will be given 6 months after the first vaccination.
11647295|NCT00118911|Experimental|Cognitive-Behavioral Therapy|Participants will receive cognitive-behavioral therapy following our protocol.
11647296|NCT00118911|Active Comparator|Relaxation with Educational Support|Applied relaxation plus educational support (RES).
11647297|NCT00118898|Experimental|EFV, FTC/TDF, and placebo ABC/3TC|Participants will receive EFV, FTC/TDF, and placebo for ABC/3TC for at least 96 weeks
11647298|NCT00118898|Experimental|EFV, ABC/3TC and placebo FTC/TDF|Participants will receive EFV, ABC/3TC, and placebo for FTC/TDF for at least 96 weeks
11647299|NCT00118898|Experimental|RTV-boosted ATV, FTC/TDF, and placebo ABC/3TC|Participants will receive RTV-boosted ATV, FTC/TDF, and placebo for ABC/3TC for at least 96 weeks
11647300|NCT00118898|Experimental|RTV-boosted ATV, ABC/3TC, and placebo FTC/TDF|Participants will receive RTV-boosted ATV, ABC/3TC, and placebo for FTC/TDF for at least 96 weeks
11647301|NCT00118872|Active Comparator|LGG yogurt|Lactobacillus (LGG) containing yogurt
11647302|NCT00118872|Placebo Comparator|Placebo yogurt|Regular yogurt, NOT containing LGG
11647303|NCT00118846|Experimental|1|25 gm soy protein administered twice daily in equivalent dosages (12.5 gm)
11647304|NCT00118846|Placebo Comparator|2|Matching placebo
11647305|NCT00118755|Experimental|1|
11647306|NCT00118755|Active Comparator|2|
11647307|NCT00118742|Experimental|CellCept + CNI (tacrolimus or cyclosporine)|
11647308|NCT00118742|Active Comparator|CellCept + sirolimus|
11647309|NCT00118729|Experimental|Arm 1|
11647310|NCT00118716|Experimental|FSC 100/50 mcg BID|Participants received FSC 100/50 microgram (mcg) one inhalation as a combination product via DISKUS, twice daily in morning after awakening and in evening for up to 28 days
11647311|NCT00118716|Experimental|FP 100 mcg BID|Participants received FP 100 mcg one inhalation via DISKUS, twice daily in morning after awakening and in evening for up to 28 days.
11647419|NCT00117559|Experimental|TEL-CBT|Telehealth, problem solving based treatment provided over the telephone
11647312|NCT00118651||Positive cases|"Positive radiographic findings were defined as the presence of a new air space opacities in the setting of acute respiratory symptoms. Patients with equivocal radiographic findings interpreted as possible pneumonia were considered positive cases"
11647313|NCT00118651||Control|Acute respiratory symptoms, negative chest radiographs, and a date of birth within five years of that of the positive case
11647314|NCT00118638|Experimental|Darbepoetin alfa 500 mcg - Group A|
11647315|NCT00118638|Active Comparator|Darbepoetin alfa 2.25 mcg/kg - Group B|
11647316|NCT00118586||Muscle tension dysphonia|Increased phonatory muscle tension in the paralaryngeal and suprahyoid muscles onpalpation
11647317|NCT00118586||Normal Volunteers|Normal vocal function refers to normal voice quality with a negative history of voice orlaryngeal disorders
11647318|NCT00118586||Spasmodic dysphonia|A diagnosis of adductor or abductor SD will be based on voice testing and fiberoptic nasolaryngoscopy conducted during the initial interview
11647319|NCT00118586||Vocal Tremor|Vocal tremor during vocalization that primarily involves laryngeal structures
11647320|NCT00118573|Experimental|EVAR|AAA repair with endografting
11647321|NCT00118573|Active Comparator|Surveillance|Not AAA repair; surveillance
11647322|NCT00118560|Experimental|1|treadmill walking and calf exercise
11647323|NCT00118547|Other|1|
11647324|NCT00118534|Experimental|Arm 1|Integration of smoking cessation therapy with PTSD therapy.
11647325|NCT00118534|Active Comparator|Arm 2|Per standard of care, patients are referred to a smoking cessation clinic for their smoking cessation therapy.
11647326|NCT00118508|Placebo Comparator|A|Group A will receive active study drug
11647327|NCT00118482|Experimental|fludrocortisone acetate|
11647328|NCT00118482|Placebo Comparator|Placebo|
11647329|NCT00118456|Experimental|1|Continuous daily dosing
11647330|NCT00118456|Experimental|2|Monday, Wednesday, Friday Dosing
11647331|NCT00118430|Experimental|Stepped Care|Stepped care group
11647332|NCT00118430|Active Comparator|Usual Care|Treatment as usual group
11647333|NCT00118430|No Intervention|No Treatment|Participants without depression group
11647334|NCT00118417|Experimental|1|Participants in phase II will receive sertraline, or an equivalent medication, up to 100 mg plus a placebo pill. Participants in phase III will receive the same medication with cognitive behavioral therapy.
11647335|NCT00118417|Experimental|2|Participants in phase II will receive sertraline, or equivalent medication, up to 200 mg. Participants in phase III they will receive the same medication with flexible clonazepam augmentation.
11647336|NCT00118404|Experimental|1|Participants received acute phase and continuation phase cognitive therapy
11647337|NCT00118404|Placebo Comparator|2|Participants received acute phase cognitive therapy and continuation phase pill placebo
11647338|NCT00118404|Active Comparator|3|Participants received acute phase cognitive therapy and continuation phase fluoxetine
11647339|NCT00118378|Experimental|Modafinil|Participants will take modafinil for 4 weeks.
11647340|NCT00118378|Placebo Comparator|Placebo|Participants will take placebo for 4 weeks.
11647341|NCT00118365|Placebo Comparator|Arm II (placebo)|Patients receive oral double placebo once daily. In both arms, treatment continues for 36 months in the absence of unacceptable toxicity or the development of an invasive malignancy.
11647342|NCT00118365|Experimental|Arm I (eflornithine and sulindac)|Patients receive oral eflornithine (DFMO) and oral sulindac once daily. In both arms, treatment continues for 36 months in the absence of unacceptable toxicity or the development of an invasive malignancy.
11647343|NCT00118352|Experimental|Treatment (chemotherapy, TBI, transplant)|"NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive alemtuzumab IV over 6 hours once daily on days -6, -5, and -4 OR days -5 and -4 and fludarabine phosphate IV over 30 minutes on days -4, -3, and -2. Patients also undergo low-dose TBI on day 0.
~ALLOGENEIC PBSCT: After completion of TBI, patients undergo allogeneic PBSCT on day 0.
~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV every 12 hours on days -3 to 180 followed by a taper until day 365 in the absence of GVHD. Beginning 4-6 hours after completion of allogeneic PBSCT, patients receive mycophenolate mofetil PO every 8 hours on days 0 to 100 followed by a taper until day 156 in the absence of GVHD."
11647344|NCT00118287|Experimental|Treatment (chemotherapy, chemoprotection)|Patients receive etanercept SC twice weekly during weeks 1 and 2 and azacitidine SC or IV over 10-40 minutes on days 1-7. Treatment repeats every 28 days for at least 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
11647345|NCT00118274|Experimental|Arm I|Patients receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
11647346|NCT00118274|Experimental|Arm II|Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
11647347|NCT00118274|Experimental|Arm III|Patients receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
11647348|NCT00118274|Experimental|Arm IV|Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
11647349|NCT00118261|Experimental|Erlotinib, modified FOLFOX6, and bevacizumab|
11647350|NCT00118248|Experimental|Treatment (chemotherapy)|Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11647351|NCT00118235|Experimental|Treatment (cisplatin, irinotecan hydrochloride, bevacizumab)|Patients receive cisplatin IV over 60 minutes and irinotecan IV over 90 minutes on days 1 and 8. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11647352|NCT00118222|Active Comparator|Low light dose during surgery|Arm I: During surgery, patients receive low light dose photodynamic therapy.
11647353|NCT00118222|Active Comparator|High light dose during surgery|Arm II: During surgery, patients receive high light dose photodynamic therapy.
11647354|NCT00118209|Active Comparator|Arm A - R-CHOP|"Patients receive the following treatment:
~Rituximab 375 mg/m^2 IV infusion on Day 1 prior to CHOP chemotherapy
~Cyclophosphamide 750 mg/m^2 IV on Day 1
~Doxorubicin 50 mg/m^2 IV on Day 1
~Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1
~Prednisone 40 mg/m^2/day PO on Days 1-5
~filgrastim or pegfilgrastim as defined in the protocol
~Required ancillary medications is administered during all cycles as defined in the protocol.
~Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6."
11647355|NCT00118209|Experimental|Arm B - DA-EPOCH-R|"Patients receive the following treatment:
~Cycle 1 Doses:
~Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy
~Doxorubicin 10 mg/m^2/day CIVI on Days 1-4
~Etoposide 50 mg/m^2/day CIVI on Days 1-4
~Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours)
~Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions)
~Prednisone 60 mg/m^2 PO BID on Days 1-5
~Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC > 5000 after the nadir (nadir usually between Days 10-12) or for 10 days (Days 6-15) if the ANC is not being monitored, during every cycle.
~Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle.
~Required ancillary medications are administered during all cycles as defined in the protocol.
~Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6."
11647356|NCT00118183|Experimental|Arm I|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and cetuximab IV over 1-2 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 4 courses receive cetuximab alone as above in the absence of disease progression or unacceptable toxicity.
11647357|NCT00118183|Experimental|Arm II|Patients receive docetaxel as in arm I and bortezomib IV over 3-5 seconds on days 1, 8, and 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 4 courses receive bortezomib alone as above in the absence of disease progression or unacceptable toxicity.
11647358|NCT00118170|Experimental|Treatment (sorafenib tosylate)|"Patients receive oral sorafenib once on day 1 and then once daily, twice daily, or every other day beginning on day 8 and continuing for 3 months. Patients are re-evaluated at 3 months. Patients with responding disease may continue study treatment in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients (per treatment cohort) receive escalating doses of sorafenib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD."
11647359|NCT00118157|Experimental|Treatment (lapatinib, tamoxifen)|Patients receive lapatinib ditosylate PO daily and tamoxifen citrate PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11647360|NCT00118144|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1 and 8.
11647361|NCT00118131|Experimental|Docetaxel and Cisplatin|"A cycle is defined as an interval of 28 days.
~Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2).
~Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2).
~Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15."
11647362|NCT00118105|Experimental|Chemotherapy + Surgery + Chemotherapy|"Preoperative Neoadjuvant Chemotherapy
~Bevacizumab, 7.5 mg/kg, IV, Day 1 of cycles 1,2,3
~Oxaliplatin, 130 mg/m^2, IV, Day 1 of cycles 1,2,3,4
~Capecitabine, 1,700 mg/m^2/day divided, PO at 12 hr intervals, Days 1-14 of cycles 1,2,3,4
~Conventional surgery: After 4 cycles of chemotherapy
~Postoperative Neoadjuvant Chemotherapy
~Bevacizumab, 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4
~Oxaliplatin, 130 mg/m^2, IV, Day 1 of cycles 1,2,3,4
~Capecitabine, 1,700 mg/m^2/day divided, PO at 12 hr intervals, Days 1-14 of cycles 1,2,3,4"
11647363|NCT00118092|Experimental|Treatment (tanespimycin)|Patients receive 17-N-allylamino 17-demethoxygeldanamycin (17-AAG) IV over 2-6 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses of treatment beyond documentation of CR.
11647364|NCT00118066|Experimental|Arm I|Patients receive oral calcitriol once daily for 8 weeks. Treatment repeats every 8 weeks for 2 courses. After completion of course 2 (week 16), patients undergo biopsy. Patients continue to receive calcitriol for up to 3 additional weeks while the biopsy is being evaluated. Patients with persistent high-grade prostatic intraepithelial neoplasia (HGPIN) by biopsy receive 2 additional courses of calcitriol.
11647365|NCT00118066|Other|Arm II|Patients undergo observation for 16 weeks. At week 16, patients undergo biopsy. Patients with persistent HGPIN by biopsy receive 2 courses of calcitriol as in arm I.
11647366|NCT00118053|Experimental|Docetaxel, Carboplatin and Trastuzumab|"A total of six cycles of TCH [(Taxotere® (75 mg/m2) + Carboplatin (AUC = 6) + Herceptin® (2 mg/kg weekly after a 4 mg/kg load on Day 1)] will be administered every 3 weeks.Three weeks after receiving the sixth cycle of TCH, all patients will be restaged.
~Those determined to have localized and operable disease (as determined by surgical consultation) will undergo a modified radical mastectomy or lumpectomy and axillary node dissection. After recovery from surgery, the patients will receive whole breast or chest wall irradiation (as determined by radiologist) with concurrent Herceptin® (6 mg/kg). Following radiation, patients will continue Herceptin® (6 mg/kg) every 3 weeks until they have been on study for a total of 52 weeks.
~If patients are staged and are negative they will continue Herceptin® (6 mg/kg)every 3 weeks until they have been on study for a total of 52 weeks."
11647367|NCT00118040|Experimental|Arm I (lower dose genistein)|Patients receive oral genistein twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
11647368|NCT00118040|Experimental|Arm II (higher dose genistein)|Patients receive oral genistein as in arm I but at a higher dose. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
11647369|NCT00118040|Placebo Comparator|Arm III (placebo)|Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
11647418|NCT00117572|Active Comparator|Chemoradiotherapy|Chemoradiotherapy: Five 14-day cycles of docetaxel (25 mg/m2, day 1), 5-fluorouracil (600 mg/m2/day, day 0-4), and hydroxyurea (500 mg PO q 12 hours x 6 days (11 doses)) with twice daily radiation (150 cGy given bid, days 1-5). Total duration of 10 weeks.
11647370|NCT00117988|Experimental|Arm I|Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1 hour on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease regression after completion of 8 courses may receive 2 additional courses of treatment beyond their maximal response. After completion of study treatment, patients are followed every 3 months until disease progression.
11647371|NCT00117962|Experimental|Std Tx + Pemetrexed|Patients receive pemetrexed disodium IV over 10 minutes followed by carboplatin IV over 30 minutes on days 1, 22, 43, and 64. Patients also undergo thoracic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47.
11647372|NCT00117962|Experimental|Std Tx + Pemetrexed and Cetuximab|Patients receive pemetrexed disodium, carboplatin, and thoracic radiotherapy as in arm I. Patients also receive cetuximab IV over 2 hours on day 1 and then IV over 1 hour on days 8, 15, 22, 29, 36, and 43.
11647373|NCT00117949|Experimental|Degarelix 40 mg|Degarelix 40 mg (10 mg/mL)
11647374|NCT00117949|Experimental|Degarelix 80 mg|Degarelix 80 mg (20 mg/mL)
11647375|NCT00117949|Experimental|Degarelix 120 mg|Degarelix 120 mg (30 mg/mL)
11647376|NCT00117949|Experimental|Degarelix 160 mg|Degarelix 160 mg (40 mg/mL)
11647377|NCT00117936|Experimental|1|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - high dose, given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
11647378|NCT00117936|Experimental|2|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose, given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
11647379|NCT00117936|Placebo Comparator|3|Placebo solution void (not containing) Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141), given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
11647380|NCT00117884|Experimental|1|
11647381|NCT00117884|Experimental|2|
11647382|NCT00117884|Experimental|3|
11647383|NCT00117884|Experimental|4|
11647384|NCT00117884|Experimental|5|
11647385|NCT00117884|Experimental|6|
11647386|NCT00117884|Experimental|7|
11647387|NCT00117884|Experimental|8|
11647388|NCT00117884|Experimental|9|
11647389|NCT00117884|Experimental|10|
11647390|NCT00117884|Experimental|11|
11647391|NCT00117845|Experimental|Denileukin Diftitox in ATL|Denileukin Diftitox in adult T-cell leukemia (ATL) Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
11647392|NCT00117819|Experimental|[123I]ß CIT and SPECT imaging|To assess [123I]ß-CIT and SPECT imaging
11647393|NCT00117806|Experimental|Arm 1|SCI-VIP: Supported employment implemented for veterans with spinal cord injury
11647394|NCT00117806|Placebo Comparator|Arm 2|Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
11647395|NCT00117793|Active Comparator|Arm 1|Current clinical practice
11647396|NCT00117793|Experimental|Arm 2|Novel socket system
11647397|NCT00117767|Experimental|1|Terbinafine
11647398|NCT00117767|Active Comparator|2|Griseofulvin
11647399|NCT00117741|Experimental|Dialectical Behavior Therapy|Participants receive standard dialectical behavior therapy and suboxone
11647400|NCT00117741|Active Comparator|Drug Counseling|Participants receive standard individual and group counseling and suboxone.
11647401|NCT00117689|Experimental|1|Standard (tacrolimus based standard therapy without induction)
11647402|NCT00117689|Active Comparator|2 Standard of Care|Thymoglobulin with tacrolimus and corticosteroid sparing maintenance therapy
11647403|NCT00117676|Experimental|TDF-TDF|TDF plus ADV placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.
11647404|NCT00117676|Active Comparator|ADV-TDF|ADV plus TDF placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of FTC/TDF FDC tablet) to their treatment regimen in the open-label period.
11647405|NCT00117650|Active Comparator|Low Dose|2 x 10^9 vp (viral particles)
11647406|NCT00117650|Active Comparator|Middle Dose|2 x 10^10 vp
11647407|NCT00117650|Active Comparator|High Dose|2 x 10^11 vp
11647408|NCT00117650|Placebo Comparator|Placebo|(PBS + 10% sucrose + 0.02% polysorbate 80)
11647409|NCT00117637|Experimental|First Sorafenib (Nexavar, BAY43-9006) 400 mg then 600 mg|Subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (bid) (ie 12-hourly) orally until progression (= first intervention period, 5.7 months [median] ) and 3 tablets of Sorafenib twice daily (ie 12-hourly) orally until the following progression (= second intervention period, 3.6 months [median]) on a continuous basis.
11647410|NCT00117637|Active Comparator|First Interferon then Sorafenib (Nexavar, BAY43-9006) 400 mg|Interferon (IFN) α-2a was administered at a dose of 9 million international units(MIU) subcutaneously three times a week until progression (= first intervention period, 5.6 months [median]). Subjects initially started with a single dose of 3 MIU IFN and increased the dose as rapidly as possible to 9 MIU IFN three times a week within 1 or 2 weeks in first intervention period.After first progression, subjects received 2 tablets of Sorafenib (200 mg tablets) twice daily (BID) (ie 12-hourly) until the next progression (=second intervention period, 5.3 months [median]).
11647411|NCT00117611|Active Comparator|1|Xolair administered subcutaneously, once or twice monthly (dose dependent on subject weight and serum IgE level)
11647412|NCT00117611|Placebo Comparator|2|placebo administered subcutaneously once or twice monthly
11647413|NCT00117598|Experimental|A|
11647414|NCT00117598|Experimental|B|
11647415|NCT00117598|Active Comparator|C|
11647416|NCT00117585|Other|Treatment Phase 1|Stepped intervention consisting of treatment phase 1, 2 and 3. Subjects whose orthostatic hypotension is resolved after treatment phase 1 will not receive new treatments (phase 2 and 3)
11647417|NCT00117572|Active Comparator|Induction plus chemoradiotherapy|"Induction therapy: Two 21-day cycles of chemotherapy consisting of docetaxel (75 mg/m2, day 1), cisplatin (75 mg/m2, day 1), and 5-fluorouracil (750 mg/m2/day, days 1-5). Total duration of 6 weeks.
~Chemoradiotherapy: Five 14-day cycles of docetaxel (25 mg/m2, day 1), 5-fluorouracil (600 mg/m2/day, day 0-4), and hydroxyurea (500 mg PO q 12 hours x 6 days (11 doses)) with twice daily radiation (150 cGy given bid, days 1-5). Total duration of 10 weeks."
11647420|NCT00117559|No Intervention|Treatment as Ususal|Control group, no treatment provided
11647421|NCT00117507|Experimental|20mg/kg/day deferasirox|Deferasirox will be administered orally once per day for 12 months. Surrogate marker findings, including serum ferritin, and LIC in the context of the study results will be monitored on a regular basis for any indications of clinically important over- or under-chelation.
11647422|NCT00117481|Experimental|1|
11647423|NCT00117481|Experimental|2|
11647424|NCT00117481|Placebo Comparator|3|
11647425|NCT00117468|Experimental|1|
11647426|NCT00117468|Active Comparator|2|
11647427|NCT00117442|Experimental|Pegfilgrastim 18 mg|Pegfilgrastim 18 mg given once for mobilization
11647428|NCT00117442|Active Comparator|Filgrastim|Filgrastim given daily for mobilization
11647429|NCT00117442|Experimental|Pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for mobilization
11647430|NCT00117442|Experimental|Pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for mobilization
11647431|NCT00117403|Experimental|1|vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals, plus two placebo wafers three times per day with meals
11647432|NCT00117403|Experimental|2|CoQ 400 mg, compounded as a wafer, two wafers three times per day with meals, plus one placebo capsule three times per day with meals
11647433|NCT00117403|Placebo Comparator|3|two placebo wafers three times per day with meals, plus one placebo capsule three times per day with meals
11647434|NCT00117377|Experimental|1|Pimecrolimus
11647435|NCT00117377|Placebo Comparator|2|Placebo control twice daily application
11647436|NCT00117338|Placebo Comparator|1|Placebo
11647437|NCT00117338|Active Comparator|2|montelukast sodium
11647438|NCT00117325|Experimental|GW685698X|GW685698X
11647439|NCT00117312|Experimental|Degarelix 40 mg|Degarelix 40 mg (10 mg/mL)
11647440|NCT00117312|Experimental|Degarelix 80 mg|Degarelix 80 mg (20 mg/mL)
11647441|NCT00117312|Experimental|Degarelix 120 mg|Degarelix 120 mg (30 mg/mL)
11647442|NCT00117312|Experimental|Degarelix 160 mg|Degarelix 160 mg (40 mg/mL)
11647443|NCT00117299|Experimental|A|PTK/ZK o.d. 1250 mg p.o.
11647444|NCT00117286|Experimental|Degarelix (60 mg to 160 mg)|Participants who completed the CS14 study in the Degarelix 60 mg (20 mg/mL) arm continued that dose into the CS14A extension study. A protocol amendment in March 2006 changed the dosage to 160 mg (40 mg/mL) for all study participants.
11647445|NCT00117286|Experimental|Degarelix (80 mg to 160 mg)|Participants who completed the CS14 study in the Degarelix 80 mg (20 mg/mL) arm continued that dose into the CS14A extension study. A protocol amendment in March 2006 changed the dosage to 160 mg (40 mg/mL) for all study participants.
11647446|NCT00117273|Experimental|1|
11647447|NCT00117273|Active Comparator|2|
11647448|NCT00117273|Active Comparator|3|
11647449|NCT00117208|Experimental|1|
11647450|NCT00117208|Active Comparator|2|DNase daily for 12 weeks
11647451|NCT00117208|Other|3|combination
11647452|NCT00117195||PD/PS|
11647453|NCT00117156|Experimental|Fludarabine and Rituximab|"Fludarabine:
~25 mg/m2 on days 1-5 of 28 day cycle up to 6 cycles
~Rituximab:
~375 mg/m2 on day 1 of 28 day cycle up to 6 cycles Rituximab dose was split between days 1 and 3 for patients with absolute lymphocyte counts > 10x10^9/L
~Patients received three cycles of therapy followed by re-staging with chest/ abdomen/ pelvic CT scan. Patients with progressive disease discontinued treatment. Patients with stable or responding disease continued therapy for another 3 cycles."
11647454|NCT00117143|Experimental|Romiplostim|Participants will receive a maximum of 2 administrations of romiplostim by subcutaneous injection, the first on day 1 of the study and the second on day 15 or 22 depending on the participant's platelet count. Romiplostim doses to be tested were 30, 100, 300, and 500 μg.
11647455|NCT00117052|Active Comparator|During dialysis visit|Cinacalcet is given during the dialysis visit
11647456|NCT00117052|Active Comparator|Post-dialysis meal|Cinacalcet is administered with a post-dialysis meal
11647457|NCT00117026|Experimental|Benfotiamine|Benfotiamine 300mg/day
11647458|NCT00117026|Placebo Comparator|Placebo|Placebo for benfotiamine
11647459|NCT00116987|Other|1|Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
11647460|NCT00116987|Other|2|Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
11647461|NCT00116974|Experimental|1|
11647462|NCT00116974|Placebo Comparator|2|
11647463|NCT00116935|Active Comparator|1|1 year of adjuvant imatinib mesylate 400 mg/day orally
11647464|NCT00116935|Experimental|2|3 years of adjuvant imatinib mesylate 400 mg/day orally
11647465|NCT00116922|Active Comparator|A|Avandamet [ Rosuglitazone 2 and Metformin 500]
11647466|NCT00116883|Experimental|Arm 1|
11647467|NCT00116857|Active Comparator|Sertraline/omega-3 supplement|
11647468|NCT00116857|Placebo Comparator|Sertraline/corn oil|
11647469|NCT00116844|Experimental|Sequence 1: VALTREX 1 g once daily, Placebo|VALTREX 1 g once daily, Placebo
11647470|NCT00116844|Experimental|Sequence 2: Placebo, VALTREX 1 g once daily|Placebo, VALTREX 1 g once daily
11647471|NCT00116831|Active Comparator|Glipizide|oral anti-diabetic medication
11647472|NCT00116831|Experimental|rosiglitazone maleate|oral anti-diabetic medication
11647473|NCT00116818|Experimental|Arm 1|
11647474|NCT00116805|Experimental|TDF-TDF|TDF plus ADV placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC tablet) to their treatment regimen in the open-label period.
11647475|NCT00116805|Active Comparator|ADV-TDF|ADV plus TDF placebo (double-blind period), followed by TDF (open-label period). Participants may add FTC (as part of FTC/TDF FDC tablet) to their treatment regimen in the open-label period.
11647476|NCT00116779|Experimental|Degarelix 60mg|Initial dose of 200 milligrams (40 milligrams per milliliter) of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 60 milligrams (20 milligrams per milliliter) of Degarelix given by subcutaneous injection every 28 days for cycles 2-13.
11647570|NCT00115440|Experimental|A|Active treatment arm.
11647477|NCT00116779|Experimental|Degarelix 80mg|Initial dose of 200 milligrams (40 milligrams per milliliter) of Degarelix on Day 0 (cycle 1) given by subcutaneous injection. Maintenance dose of 80 milligrams (20 milligrams per milliliter) of Degarelix given by subcutaneous injection every 28 days for cycles 2 - 13.
11647478|NCT00116753|Active Comparator|Degarelix 240@40/240@40 (1,3,6,9)|240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (40 mg/mL) at months 1, 3, 6 and 9.
11647479|NCT00116753|Active Comparator|Degarelix 240@40/240@60(1,3,6,9)|240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 3, 6 and 9.
11647480|NCT00116753|Active Comparator|Degarelix 240@40/240@60(1,4,7,10)|240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 4, 7 and 10.
11647481|NCT00116727||Drug|etanercept 50 mg/wk SC
11647482|NCT00116714||Observation|
11647483|NCT00116688|Experimental|Romiplostim|Romiplostim weekly subcutaneous dosing based on screening weight and platelet count. Starting dose of 1 µg/kg up to a maximum dose of 10 µg/kg.
11647484|NCT00116649|Experimental|Aldara 5%|Aldara® (imiquimod) cream, 5% supplied in 250 mg single-use packets.
11647485|NCT00116584|Other|heliox|heliox-driven nebulizations for children with moderate to severe bronchiolitis
11647486|NCT00116584|Other|oxygen|oxygen-driven nebulizations for children with moderate to severe bronchiolitis
11647487|NCT00116558|Experimental|Early NIPPV Intervention|Participants with >80% predicted forced vital capacity (FVC).
11647488|NCT00116558|Active Comparator|Standard of Care NIPPV|Participants with 50-74% predicted forced vital capacity (FVC).
11647489|NCT00116558|Active Comparator|Standard of Care NIPPV and Nutritional Monitoring|Participants with 50-95% forced vital capacity (FVC), and normal or impaired amyotrophic lateral sclerosis functional rating scale (ALSFRS) scores. Participants in this group will receive standard of care NIPPV therapy but will also undergo detailed analysis of nutritional status.
11647490|NCT00116493|Other|1|Standard of care (Iron-folic acid + Deworming)
11647491|NCT00116493|Experimental|2|
11647492|NCT00116493|Experimental|3|
11647493|NCT00116493|Experimental|4|
11647494|NCT00116480|Experimental|Misoprostol|three tablets of active misoprostol (600 mcg) given sublingually
11647495|NCT00116480|Placebo Comparator|Placebo|three tablets resembling misoprostol given sublingually
11647496|NCT00116454|Experimental|lipiocis group|intra-arterial hepatic administration, one 2200 MBQ dose, duration of treatment 1 week
11647497|NCT00116454|No Intervention|control group|group untreated
11647498|NCT00116428|Experimental|NAVISTAR® THERMOCOOL® Catheter|
11647499|NCT00116428|Active Comparator|Antiarrhythmic drug|
11647500|NCT00116402|Active Comparator|1|will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID
11647501|NCT00116402|Active Comparator|2|salmeterol 50 mcg BID then crossover to combination therapy with fluticasone 220 mcg BID
11647502|NCT00116376|Experimental|AEE788 + non EIACD|
11647503|NCT00116376|Experimental|AEE788 + EIACD|
11647504|NCT00116350|Experimental|Misoprostol|800 mcg sublingual misoprostol
11647505|NCT00116350|Active Comparator|Oxytocin|40 IU Oxytocin IV
11647506|NCT00116337|Experimental|Expiratory Muscle Stimulator|Procedure/Surgery: spinal cord stimulation to restore cough
11647507|NCT00116272||Etanercept-Exposed|Pregnant women with a current diagnosis of rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis (AS), psoriatic arthritis (PsoA) or psoriasis (PsO) who used etanercept in the first trimester of pregnancy for any length of time.
11647508|NCT00116272||Diseased Controls|Pregnant women with a current diagnosis of RA, JRA, AS, PsA, or PsO who did not use etanercept or any tumor necrosis factor (TNF) antagonist during pregnancy.
11647509|NCT00116272||Non-Diseased Historical Comparison|Pregnant women not diagnosed with RA, JRA, AS, PsoA, or PsO who did not use etanercept or any TNF antagonist at any time in pregnancy and were not exposed to any known human teratogen during pregnancy. This cohort consists of historical controls enrolled in other pregnancy outcome studies selected to match pregnant women in the exposed cohort.
11647510|NCT00116220|Active Comparator|Treatment 1|External beam radiation therapy + 6 months total androgen ablation
11647511|NCT00116220|Active Comparator|Treatment 2|External beam radiation therapy
11647512|NCT00116207|Experimental|ORAL ANTIOXIDANT|Allopurinol (300mg daily), ALA (600mg twice daily) nicotinamide (750 mg twice daily) Given orally These drugs were given together as a combination and not as individual treatment.
11647513|NCT00116207|Placebo Comparator|Placebo|Placebo administered twice daily.
11647514|NCT00116181|Experimental|continuous therapy|Subjects will receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24.
11647515|NCT00116181|Active Comparator|intermittent therapy|Subjects who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24.
11647516|NCT00116168|Experimental|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
11647517|NCT00116168|Experimental|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, SC dose
11647518|NCT00116168|Experimental|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, SC dose
11647519|NCT00116168|Experimental|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, SC dose
11647520|NCT00116142|Other|1|Androgen Suppression Therapy and Radiation therapy
11647521|NCT00116142|Experimental|2|Docetaxel plus androgen suppression therapy and radiation therapy
11647522|NCT00116129|Placebo Comparator|Placebo|Placebo
11647523|NCT00115960|Experimental|1|Group 1 will receive 3 vaccinations of the HIV-1 gag DNA vaccine, or placebo. Vaccinations will be given at Months 0, 1, and 3.
11647524|NCT00115960|Experimental|2|Group 2 will receive 3 vaccinations of either the HIV-1 gag DNA vaccine with a low dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
11647525|NCT00115960|Experimental|3|Group 3 will receive 3 vaccinations of either the HIV-1 gag vaccine with a medium dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
11647628|NCT00114543|Active Comparator|Conservative ELBW|In the Conservative group 1, infants with birth weights 501-750g.
11647526|NCT00115960|Experimental|4|Group 4 will receive 3 vaccinations of either the HIV-1 gag vaccine with a high dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
11647527|NCT00115960|Experimental|5|In Part B, Group 5 will receive 5 vaccinations of either the HIV-1 gag vaccine plus IL-15 DNA, or placebo. Vaccinations will occur at Months 0, 1, 3, 6, and 9.
11647528|NCT00115960|Experimental|7|In Part B, Group 7 will receive 3 vaccinations of the HIV-1 gag vaccine with a high dose of IL-15 adjuvant (maximum tolerated dose from Part A) followed by 2 vaccinations of the gag DNA vaccine with IL-12 DNA adjuvant. Some participants will receive placebo instead of this vaccine regimen. For Group 7, the HIV-1 gag vaccine with IL-15 adjuvant vaccinations will be given at Months 0, 1, and 3, and booster vaccinations will be given at Months 6 and 9.
11647529|NCT00115934|Active Comparator|MBTS|Blalock-Taussig pulmonary artery shunt
11647530|NCT00115934|Active Comparator|RVPAS|Right ventricular to pulmonary artery shunt
11647531|NCT00115895|Experimental|Radioactive iodine 1,1 GBq|Low activity of radioiodine, 1,1 GBq
11647532|NCT00115895|Other|Radioactive iodine 3,7 GBq|Routine activity of radioiodine, 3,7 GBq
11647533|NCT00115882|Experimental|1|proactive smoking-cessation telephone counseling
11647534|NCT00115882|No Intervention|2|no-intervention control
11647535|NCT00115869|No Intervention|No-intervention control|
11647536|NCT00115869|Experimental|Social influences school-based smoking prevention curriculum|
11647537|NCT00115856|No Intervention|Subjects studied|Single arm exploratory feasibility safety and efficacy study of MRI to image atherosclerosis in arteries
11647538|NCT00115804|Experimental|Fluoxetine|All eligible patients were started on Fluoxetine at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily.
11647539|NCT00115791|Experimental|1|
11647540|NCT00115791|Placebo Comparator|2|
11647541|NCT00115778|Experimental|First IVIG, then Placebo|Study participants will receive three doses of IVIG given four weeks apart over 12 weeks followed by a twelve-week washout and then three doses of placebo over 12 weeks.
11647542|NCT00115778|Experimental|First Placebo, then IVIG|Study participants will receive three doses of 0.1% albumin solution (placebo) given four weeks apart over 12 weeks followed by a twelve-week washout and then three doses of IVIG over 12 weeks.
11647543|NCT00115765|Active Comparator|Oxaliplatin and bevacizumab without panitumumab|Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone.
11647544|NCT00115765|Experimental|Irinotecan and bevacizumab plus panitumumab|Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W
11647545|NCT00115765|Active Comparator|Irinotecan and bevacizumab without panitumumab|Irinotecan-based chemotherapy and Bevacizumab Q2W alone
11647546|NCT00115765|Experimental|Oxaliplatin and bevacizumab plus panitumumab|Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W
11647547|NCT00115739|Experimental|Imatinib|Patients will be treated with Imatinib (Gleevec) 400 mg two times a day for eight weeks after which radiologic imaging will be obtained to assess response. Patients who attained a complete response will be treated with four additional weeks of Imatinib. Patients who attain a partial response or stable disease will be treated until a complete response is attained, or until disease progression. All patients with progression of disease will be taken off the study. Patients continuing on the study, will undergo radiologic imaging every eight weeks following their initial response assessment. All patients will be followed until death.
11647548|NCT00115726|Experimental|1|furosemide
11647549|NCT00115726|Placebo Comparator|2|placebo
11647550|NCT00115700|Experimental|Radiotherapy+ Chemotherapy|Involved field Radiotherapy (RT) 30-36 GY plus Cyclophosphamide, Vincristine and Prednisolone (CVP) + rituximab × 6 cycles
11647551|NCT00115700|Active Comparator|Radiotherapy alone|Involved field Radiotherapy (30-36 GY) alone
11647552|NCT00115687|Placebo Comparator|A|placebo
11647553|NCT00115687|Experimental|B|2 mg nicotine gum
11647554|NCT00115648|Active Comparator|A|Single dose NVP + ZDV daily for the first week.
11647555|NCT00115648|Experimental|C|Arm A plus NVP + ZDV daily to age 14 weeks.
11647556|NCT00115648|Experimental|B|Arm A plus oral NVP daily to age 14 weeks.
11647557|NCT00115596|Experimental|Intervention Arm|"'Formal Curriculum; Low-Fidelity Simulation'
~Residents randomized to the intervention arm will receive the study skills training curriculum (the intervention)."
11647558|NCT00115596|No Intervention|Control|Residents randomized to the control arm will receive standard pediatric training.
11647559|NCT00115570|Experimental|Insulin Glulisine|Insulin Glulisine (100UI/ml), at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine for a maximum of 26 weeks
11647560|NCT00115570|Active Comparator|Insulin Lispro|Insulin Lispro (100UI/ml) Subcutaneous (SC) injection , at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine ) for a maximum of 30 weeks
11647561|NCT00115557|Experimental|1|Performance feedback, academic detailing, practice facilitation, IT support
11647562|NCT00115557|Active Comparator|2|Performance feedback only
11647563|NCT00115544|Experimental|1|stannsoporfin 0.75mg/kg
11647564|NCT00115544|Experimental|2|stannsoporfin 1.5mg/kg
11647565|NCT00115544|Placebo Comparator|3|saline injection
11647566|NCT00115531|Experimental|Arm 1|Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
11647567|NCT00115531|Experimental|Arm 2|High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
11647568|NCT00115505||Ancillary-Correlative (QOL, employment, informal care cost)|Patients complete the QOL Assessments comprising the Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form; Employment and Informal Care Cost Assessments; and Peripheral Neuropathy of the FACT-NTX subscale at baseline, 29-42 and 57-70 days, and at 9 and 18 months. Patients meeting the cut-off score for peripheral neuropathy on the FACT-NTX subscale at 18 months complete the Symptoms in Relation to Patient Functioning Survey, FACT-NTX subscale, the EORTC QLQ-C30, EORTC QLQ-BR23, and the Medications Used for Treating Peripheral Neuropathy at 24, 36, 48, and 60 months.
11647569|NCT00115453|Experimental|A|Active treatment arm.
11647571|NCT00115388|Other|Deferred screening control group|Samples from women in the control group were stored and tested at the end of the trial
11647572|NCT00115349|Experimental|L1/DFO|Deferoxamine (DFO) and deferiprone (L1) combination therapy
11647573|NCT00115349|Active Comparator|DFO|Deferoxamine (DFO) monotherapy
11647574|NCT00115336|Active Comparator|1-Intravenous ketorolac and oral placebo|Intravenous ketorolac and oral placebo
11647575|NCT00115336|Active Comparator|2-Intravenous placebo and oral ibuprofen|Intravenous placebo and oral ibuprofen
11647576|NCT00115323|Active Comparator|1|Problem solving intervention
11647577|NCT00115323|Active Comparator|2|Attention control intervention
11647578|NCT00115297|Experimental|Montelukast|Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.
11647579|NCT00115297|Placebo Comparator|Placebo|Participants who are 2 to 3 years old received 5-mg montelukast placebo tablets and participants who are 12 months to 2 years old received 4-mg montelukast placebo granules.
11647580|NCT00115258|Experimental|parenteral nutrition titrated to measured REE|parenteral nutrition titrated to measured REE
11647581|NCT00115258|No Intervention|standard of care|
11647582|NCT00115232||1|Children without family history of early atherosclerosis
11647583|NCT00115232||2|Children with family history of early atherosclerosis.
11647584|NCT00115232||3|Parents of children without family history of early atherosclerosis
11647585|NCT00115232||4|Parents of children with family history of early atherosclerosis
11647586|NCT00115193|Active Comparator|Arm A|Pegfilgrastim
11647587|NCT00115193|Active Comparator|Arm B|Pegfilgrastim
11647588|NCT00115180||Hispanic|Hispanic patients with long bone fractures no intervention
11647589|NCT00115180||White|White patients with long bone fractures no intervention
11647590|NCT00115180||African-American|African-American patients with long bone fracture no intervention
11647591|NCT00115167|Experimental|Darbepoetin alfa|
11647592|NCT00115167|Placebo Comparator|Placebo|
11647593|NCT00115128||Filgrastim|Normal donors being treated with filgrastim for PBPC mobilization and collection
11647594|NCT00115076|Experimental|psoriasis|moderate to severe plaque psoriasis
11647595|NCT00115063|Experimental|1|"Intensive Medical Intervention including Low Calorie Liquid Diet, Weight loss medications, Group Behavioral Therapy and a Tool Box approach"
11647596|NCT00115063|Active Comparator|2|Access to Weight Loss Informational Website sponsored by the Mayo Clinic
11647597|NCT00115037|Experimental|Phase 1 Liberal Response|From the start of baseline subjects were randomly assigned to this arm which defined relapse/non-responder as having 5 or heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.
11647598|NCT00115037|Experimental|Phase 1 Stringent Response|From the start of baseline subjects were randomly assigned to this arm which defined relapse/non-responder as having 2 or heavy drinking days in the first 8 weeks of treatment otherwise the subject was considered a responder.
11647599|NCT00115037|Experimental|Phase 2 nalt and tele for responders|Phase 2: Naltrexone and telephone counseling for responders.
11647600|NCT00115037|Experimental|Phase 2 nalt, MM and CBI for NR|Phase 2: naltrexone, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR).
11647601|NCT00115037|Placebo Comparator|Phase 2 placebo, MM and CBI for NR|Phase 2: placebo, Medication Management (MM) and Combined Behavioral Intervention (CBI) for non-responders (NR)
11647602|NCT00115037|Experimental|Phase 2 naltrexone for responders|Phase 2: Naltrexone and TAU for phase 1 responders.
11647603|NCT00114972|Experimental|PCI with DES|
11647604|NCT00114972|Active Comparator|CABG (coronary artery bypass graft)|Coronary Artery Bypass Graft
11647605|NCT00114959|Experimental|Homoharringtonine + Imatinib Mesylate|Participants are administered homoharringtonine (omacetaxine) 2.5 mg/m^2 by continuous 24-hour intravenous infusion daily on Days 1-5 of each 4 week treatment cycle, and imatinib mesylate (Gleevec) by mouth with a daily dose of 400 mg for participants in the chronic phase of chronic myeloid leukemia (CML) or 600 mg for participants in the accelerated or blast phase of CML.
11647606|NCT00114894|Experimental|Safe Sea|
11647607|NCT00114894|Sham Comparator|Placebo|Coppertone® SPF15 (Schering-Plough)
11647608|NCT00114881||Inner-city children with asthma|Children at high risk for developing allergic diseases and asthma, on the basis of a parental history of asthma, allergic rhinitis or atopic dermatitis, and residence in the inner city
11647609|NCT00114868|Active Comparator|Vitamin A|48,000 IU vitamin A oral dose spread over 2 days as soon as possible after birth.
11647610|NCT00114868|Placebo Comparator|Placebo|placebo
11647611|NCT00114790|Experimental|BNCT.|Boronophenylalanine-based BNCT.
11647612|NCT00114777|Active Comparator|Cyclosporin A|
11647613|NCT00114777|Experimental|Belatacept Less Intensive Regimen (LI)|
11647614|NCT00114777|Experimental|Belatacept More Intensive Regimen (MI)|
11647615|NCT00114764|Experimental|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
11647616|NCT00114764|Active Comparator|filgrastim|Filgrastim given daily after induction chemotherapy
11647617|NCT00114738|Experimental|EPOCH-R + Bortezomib|Combo chemo etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH)-Rituxan (R) + Bortezomib (B)
11647618|NCT00114738|Experimental|"Bortezomib window"|Bortezomib alone
11647619|NCT00114738|Active Comparator|Bortezomib maintenance|Bortezomib maintenance
11647620|NCT00114738|Other|Observation|At the beginning of part C patients are randomized to receive bortezomib maintenance or observation without bortezomib.
11647621|NCT00114647||1|Healthy Volunteers
11647622|NCT00114647||2|HIV
11647623|NCT00114634|Experimental|Egg yolk preparation with cholesterol|Dietary cholesterol in the form of liquid egg yolk
11647624|NCT00114634|Placebo Comparator|Egg yolk preparation without cholesterol|"No dietary cholesterol supplementation (egg substitute) Papetti Foods Better 'n Eggs egg substitute"
11647625|NCT00114608|Experimental|1|Electrical foot stimulation
11647626|NCT00114543|Active Comparator|Aggressive ELBW|In Aggressive group 1, infants with birth weights 501-750g.
11647627|NCT00114543|Active Comparator|Aggressive VLBW|In the Aggressive group 2, infants with birth weights 751-1000g.
11647629|NCT00114543|Active Comparator|Conservative VLBW|In the Conservative group 2, infants with birth weights 751-1000g.
11647630|NCT00114530|Experimental|mHSCT|Myeloablative Hematopoietic Stem Cell Transplant (mHSCT) Participants will first have hematopoietic stem cells removed from their blood. They then will receive high doses of chemotherapy and radiation to eliminate their developed and presumably abnormal immune system, followed by autologous stem cell transplantation to reintroduce the purified stem cells to re-establish their immune system.
11647631|NCT00114530|Experimental|cyclophosphamide|"Cyclophosphamide (CY) Participants will receive high doses of intravenous cyclophosphamide. The dose being used in this study is about 50% higher than that commonly used by most physicians to treat many other autoimmune diseases.
~Administration of 12 monthly pulses of high-dose intravenous cyclophosphamide (an initial dose of 500 mg/m^2, followed by 11 doses of 750 mg/m^2)."
11647632|NCT00114517|Active Comparator|17B-estradiol|Oral 17B-estradiol 1 mg daily
11647633|NCT00114517|Placebo Comparator|Placebo|Matched placebo oral 17B-estradiol daily
11647634|NCT00114504|Experimental|Simvastatin group|Patients with FDG-positive plaque who received simvastatin and diet therapy
11647635|NCT00114504|No Intervention|Control group|Patients FDG-positive plaque who received diet therapy alone
11647636|NCT00114465|Experimental|VSL#3|Probiotic
11647637|NCT00114465|Placebo Comparator|Placebo|Placebo
11647638|NCT00114452|Active Comparator|Provacel: Cohort 1|ex vivo cultured adult mesenchymal stem cells
11647639|NCT00114452|Active Comparator|Provacel: Cohort 2|ex vivo cultured adult mesenchymal stem cells
11647640|NCT00114452|Active Comparator|Provacel: Cohort 3|ex vivo cultured adult mesenchymal stem cells
11647641|NCT00114452|Active Comparator|Provacel: Cohort 4|ex vivo cultured adult mesenchymal stem cells
11647642|NCT00114452|Placebo Comparator|Placebo|ex vivo cultured adult mesenchymal stem cells
11647643|NCT00114413|Active Comparator|Reference Strategy|Participants in the reference strategy group will undergo the eNO procedure but will follow NAEPP guidelines alone for asthma treatment without eNO measurements for the rest of the study.
11647644|NCT00114413|Experimental|Biomarker Strategy|Participants in the biomarker strategy group will follow NAEPP treatment guidelines, as well as eNO measurements, to determine asthma treatment at each study visit.
11647645|NCT00114361|Active Comparator|1|Ribavirin + Peg IFN
11647646|NCT00114361|Active Comparator|2|Peg IFN + Placebo
11647647|NCT00114348|Active Comparator|R-Blöcke|Blocktherapie
11647648|NCT00114348|Experimental|Prot-II-Ida|a
11647649|NCT00114309|Experimental|1|3 Dose Regimen
11647650|NCT00114309|Experimental|2|6 Dose Regimen
11647651|NCT00114283|Experimental|Treatment (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11647652|NCT00114257|Experimental|Arm I|"Patients receive decitabine IV over 1 hour on days 1-5 and 8-12 and FR901228 (depsipeptide) IV over 4 hours on days 5 and 12 OR days 5, 12, and 19. Treatment repeats every 4-6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing complete remission for 1 year are removed from the study.
~Cohorts of 6 patients receive escalating doses of decitabine and FR901228 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
11647653|NCT00114244|Experimental|Arm I (sorafenib tosylate)|Patients receive 400 mg oral sorafenib twice daily on days 1-28. Patients experiencing disease progression cross over to Arm II.
11647654|NCT00114244|Experimental|Arm II (sorafenib tosylate, gemcitabine hydrochloride)|Patients receive 400 mg oral sorafenib as in Arm I and 1000 mg/m2 gemcitabine IV over 100 minutes on days 1, 8, and 15.
11647655|NCT00114231|Experimental|Treatment (capecitabine, oxaliplatin, radiotherapy, surgery)|"Patients undergo high-dose external beam radiotherapy once daily and receive capecitabine PO BID on days 1-5, 8-12, 15-19, 22-26, and 29-33. Patients also receive oxaliplatin IV over 2 hours on days 1, 8, 22, and 29.
~Approximately 4-8 weeks after completion of chemoradiotherapy, patients undergo local excision of the tumor. Patients with T3 disease or positive resection margins after local excision undergo radical resection of the rectum and receive additional chemotherapy and/or radiotherapy at the discretion of the physician."
11647656|NCT00114218|Experimental|Treatment (gemcitabine hydrochloride, docetaxel)|Patients receive gemcitabine IV over 30 minutes followed by docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
11647657|NCT00114179|Experimental|Treatment (capecitabine, radiation, bevacizumab, gemcitabine)|"Chemoradiotherapy and bevacizumab: Patients receive oral capecitabine twice daily and undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-38. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29. Patients undergo reevaluation 3-4 weeks after completion of chemoradiotherapy and bevacizumab.
~Patients with no evidence of disease progression proceed to maintenance therapy. Patients with a marked response may undergo surgery at the discretion of the attending surgeon and then proceed to maintenance therapy approximately 4-8 weeks later.
~Maintenance therapy: Beginning within 4-7 weeks after completion of chemoradiotherapy and bevacizumab, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30 minutes on days 1 and 15 provided that blood counts have returned to normal. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11647658|NCT00114166|Active Comparator|Topotecan 1.25 mg/m2 IV days 1-5 of a 21 day cycle|Topotecan 1.25 mg/m2 IV days 1-5 of a 21 day cycle until disease progression or adverse effects prohibit further therapy
11647659|NCT00114166|Active Comparator|Topotecan 4.0 mg/m2 IV day 1, 8 and 15 of a 28 day cycle|Topotecan 4.0 mg/m2 IV day 1, 8 and 15 of a 28 day cycle until disease progression or adverse effects prohibit further therapy
11647660|NCT00114140|Experimental|Temozolomide + Radiation Therapy (RT)|Daily temozolomide plus concurrent radiotherapy followed by temozolomide
11647661|NCT00114127|Placebo Comparator|Duloxetine 60mg + Placebo for 18 Weeks|In Phase 2 participants were randomized to 60mg Duloxetine + Placebo or 120mg Duloxetine.
11647662|NCT00114127|Active Comparator|Duloxetine 120mg for 18 Weeks|In Phase 2 participants were randomized to 60mg Duloxetine + Placebo or 120mg Duloxetine.
11647663|NCT00114127|Active Comparator|Duloxetine 60mg/day for 6 Weeks|In Phase 1 all participants entered an open trial.
11647664|NCT00114114|Experimental|Group 1: 0 g/day|Zoladex plus Placebo Testosterone (T) gel
11647665|NCT00114114|Experimental|Group 2: 1.25 g/day|Zoladex plus 1.25 g/day T gel
11647666|NCT00114114|Experimental|Group 3: 2.5 g/day|Zoladex plus 2.5 g/day T gel
11647667|NCT00114114|Experimental|Group 4: 5 g/day|Zoladex plus 5 g/day T gel
11647668|NCT00114114|Experimental|Group 5: 10* g/day|Zoladex plus 10* g/day T gel. *Note that the 10 g/day dose was reduced to 7.5 g/day part-way through the trial
11647669|NCT00114114|Experimental|Group 6: Placebo/Placebo (PBO/PBO)|Placebo Zoladex plus Placebo T gel (controls)
11647670|NCT00114101|Experimental|Arm I (melphalan, autologous PBSCT, lenalidomide)|Beginning between day 100-110, patients receive lenalidomide PO once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
11647671|NCT00114101|Placebo Comparator|Arm II (melphalan, autologous PBSCT, placebo)|Beginning between day 100-110, patients receive placebo PO once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
11647672|NCT00114075|Experimental|Gait analysis|Gait analysis report is available for treatment planning
11647673|NCT00114075|Active Comparator|Control|Subject has gait analysis test, but report is not available for treatment planning
11647674|NCT00113919|Experimental|Busulfan|study-specific treatment: Busulfex according to study design: Level I 3.2 mg/kg over 6 hours x 2 days Level II 3.2 mg/kg over 6 hours x 3 days Level III 3.2 mg/kg over 6 hours x 4 days Level IV 4.3 mg/kg over 6 hours x 3 days Level V 5.6 mg/kg over 6 hours x 2 days Level VI 6.4 mg/kg over 6 hours x 2 days
11647675|NCT00113893|Experimental|Scio-469 30 Milligram (mg)|SCIO-469 tablet will be administered orally at a dose of 30 mg thrice daily (90 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
11647676|NCT00113893|Experimental|Scio-469 60 mg|SCIO-469 tablet will be administered orally at a dose of 60 mg thrice daily (180 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
11647677|NCT00113893|Experimental|Scio-469 90 mg|SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
11647678|NCT00113893|Experimental|Scio-469 120 mg|SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
11647679|NCT00113880||1|5-8 years of age, estimated to be approximately 4,000 new FluMist vaccinees per season
11647680|NCT00113880||2|9-17 years of age, estimated to be approximately 5,000 new FluMist vaccinees per season
11647681|NCT00113880||3|18-49 years of age, estimated to be approximately 6,000 new FluMist vaccinees per season.
11647682|NCT00113841|Experimental|Curcumin|Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.).
11647683|NCT00113841|Experimental|Curcumin + Bioperine|Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.) and Bioperine 5 mg orally twice daily.
11647684|NCT00113828|Experimental|Transplantation|T-cell depleted HLA-matched peripheral blood stem cell transplantation
11647685|NCT00113815|Experimental|003|topiramate 25 mg/kg/day
11647686|NCT00113815|Experimental|002|topiramate 15 mg/kg/day
11647687|NCT00113815|Experimental|001|topiramate 5 mg/kg/day
11647688|NCT00113815|Experimental|004|placebo placebo
11647689|NCT00113789|Active Comparator|Pegfilgrastim|
11647690|NCT00113789|Placebo Comparator|Placebo|
11647691|NCT00113763|Experimental|Panitumumab plus best supportive care|Panitumumab will be administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants develop progressive disease or are unable to tolerate study drug. Participants will also receive best supportive care (BSC) as judged appropriate by the investigator and according to institutional guidelines.
11647692|NCT00113763|Other|Best Supportive Care|Best supportive care will be defined in this study as the best care available as judged appropriate by the investigator and according to institutional guidelines and will include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any symptomatic therapy as clinically indicated. For the purpose of this study, best supportive care will not include anti-neoplastic chemotherapy.
11647693|NCT00113698|Placebo Comparator|1|
11647694|NCT00113698|Active Comparator|2|Ace inhibition (enalapril)
11647695|NCT00113672|Experimental|A|Increase healthy eating and increase healthy activity
11647696|NCT00113672|Experimental|B|Increase healthy eating and decrease unhealthy activity
11647697|NCT00113672|Experimental|C|Decrease unhealthy eating and increase healthy activity
11647698|NCT00113672|Experimental|D|Decrease unhealthy activity and decrease unhealthy eating
11647699|NCT00113659|Active Comparator|1|Participants in this arm will receive Lactobacillus GG.
11647700|NCT00113659|Placebo Comparator|2|Participants in this arm will receive a placebo.
11647701|NCT00113633|No Intervention|Control Subjects|These subjects will receive standard discharge instructions that recommend follow-up with a PCP within 3-5 days.
11647702|NCT00113633|Experimental|Intervention Subjects|As part of the intervention, the family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups. For children reporting persistent asthma symptoms, a letter will be given to the family to bring to their PCP stating that screening revealed symptoms that may require further treatment with controller medications. A mailed reminder to schedule a follow-up appointment will be sent to the family.
11647703|NCT00113607|Experimental|DOXIL + trabectedin|Combination arm - Trabectedin + DOXIL: DOXIL 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks. patients will be premedicated with 20 mg dexamethasone or its equivalent IV infusion over 30 minutes prior to the DOXIL infusion.
11647704|NCT00113607|Active Comparator|DOXIL|Monotherapy arm - DOXIL: 50 mg/m2 IV infusion over 90 minutes every 4 weeks.
11647705|NCT00113568|Experimental|XP12B (tranexamic acid tablets)|
11647706|NCT00113555|Experimental|Experimental|Open Label Study, ACT (Adjustable Continence Therapy)
11647707|NCT00113529|Experimental|Sunitinib + Gefitinib|"Phase 1 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib; 50 mg Sunitinib + 250 mg Gefitinib
~Phase 2 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib"
11647708|NCT00113516|Experimental|1|
11647709|NCT00113503|Active Comparator|Azathioprine weight-based dose|
11647710|NCT00113503|Experimental|Azathioprine individualised dose|
11647711|NCT00113490|Experimental|motavizumab (MEDI-524) 15 mg/kg|A single IM injection every 30 days beginning at Day 0 for a total of 4-5 injections determined by when in the RSV season a child was enrolled.
11647712|NCT00113490|Active Comparator|palivizumab 15 mg/kg|A single IM injection every 30 days beginning at Day 0 for a total of 4-5 injections determined by when in the RSV season a child was enrolled.
11647713|NCT00113438|Experimental|45 mg/m2 Combretastatin A-4 Phosphate|
11647714|NCT00113438|Experimental|60 mg/m2 Combretastatin A-4 Phosphate|
11647715|NCT00113425|Experimental|Laser Therapy|V-Beam laser, Candela Corp., 595 nm wavelength
11647716|NCT00113425|No Intervention|Control|Untreated
11647717|NCT00113399|Other|Radiotherapy and chemotherapy|Radiotherapy/paclitaxel/cisplatin/filgrastim
11647718|NCT00113399|Other|Chemotherapy|Cisplatin/fluorouracil/paclitaxel/docetaxel
11647719|NCT00113386|Other|Induction chemotherapy, surgery, consolidation chemotherapy|Induction/surgery/consolidation
11647720|NCT00113386|Other|Chemotherapy and radiation, surgery, consolidation ch|Induction/radiation/surgery/cosolidation
11647721|NCT00113373|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11647722|NCT00113360|Experimental|RAD001 plus Depot Octreotide|RAD001 at 5 or 10 milligrams orally once a day plus Octreotide Depot 30 milligrams intramuscularly once every 28 days.
11647723|NCT00113347|Experimental|Erlotinib + Docetaxel|Erlotinib 100, 125, or 150 mg orally daily except days receive Docetaxel 15 mg/m^2 or 20 mg/m^2 intravenously with Concomitant Boost Radiation to Head/Neck
11647724|NCT00113334|Experimental|ABT-510 (Thrombospondin)|Fixed dose level of thrombospondin 100 mg subcutaneously twice daily.
11647725|NCT00113321|Experimental|Decitabine|20 mg/m2 by vein (IV) over 1 hour daily x 5 days.
11647726|NCT00113295|Active Comparator|Paroxetine CR and Placebo|Eleven individuals were randomized to plaecbo augmentation of continued paroxetine CR at the week 10 dose level. In the first phase of the study, individuals started at 12.5 mg/day of paroxetine and flexibly titrated up to a maximum of 62.5 mg/day by week 10. Individuals who did not achieve remission and were randomized into the placebo group received placebo augmentation of continued paroxetine CR at the week 10 dose level.
11647727|NCT00113295|Experimental|Quetiapine and continued paroxetine CR|Eleven individuals were randomized to quetiapine augmentation of continued paroxetine CR at the week 10 dose level. In the first phase of the study, individuals started at 12.5 mg/day of paroxetine and flexibly tirated up to a maximum of 62.5 mg/day by week 10. Individuals who did not receive remission and were randomized to receive quetiapine started at 25 mg at bedtime for the first week, then flexibly dosed based on response and tolerability to a maximum of 200 mg BID by week 16.
11647728|NCT00113269|Experimental|Alemtuzumab High-Risk Patients|Alemtuzumab, tacrolimus, mycophenolate mofetil and steroids; High risk patients: Panel reactive antibody ≥ 20% or re-transplant or African American
11647729|NCT00113269|Active Comparator|Conventional High-Risk Patients|Rabbit anti-thymocyte globulin, tacrolimus, mycophenolate mofetil and steroids; High risk patients: Panel reactive antibody ≥ 20% or re-transplant or African American
11647730|NCT00113269|Experimental|Alemtuzumab Low- Risk Patients|Alemtuzumab, tacrolimus, mycophenolate mofetil and steroids; Low risk patients: Panel reactive antibody < 20% and first transplant and non-African American
11647731|NCT00113269|Active Comparator|Conventional Low-Risk Patients|Basiliximab, tacrolimus, mycophenolate mofetil and steroids; Low risk patients: Panel reactive antibody < 20% and first transplant and non-African American
11647732|NCT00113230|Experimental|Avastin|Capecitabine, Avastin (RHUMAB VEGF/Bevacizumab) And Radiotherapy
11647733|NCT00113217|Experimental|Bevacizumab|10 mg/kg intravenous (IV) Day 1 of 14-day cycle.
11647734|NCT00113139|Experimental|Telephone-based coping skills|Telephone-based coping skills intervention
11647735|NCT00113139|Active Comparator|Usual Care|
11647736|NCT00113087|Active Comparator|Enalapril|Enalapril (angiotensin converting enzyme inhibitor)
11647737|NCT00113087|Placebo Comparator|Placebo|Placebo (Ora-Plus and Ora-Sweet)
11647738|NCT00113074|Active Comparator|1|Weight management and BP control program
11647739|NCT00113074|Active Comparator|2|Self-help materials targeting lifestyle modification
11647740|NCT00113035||Patients with late onset Pompe Disease|
11647741|NCT00113022|Experimental|Org 24448|Blinded, active experimental compound
11647742|NCT00113022|Placebo Comparator|Placebo|Blinded placebo
11647743|NCT00112996|Experimental|Arm I: Alpha-Lipoic Acid|Oral alpha-lipoic acid three times daily for at least 24 weeks in the absence of unacceptable toxicity.
11647744|NCT00112996|Placebo Comparator|Arm II: Placebo|Oral placebo three times daily for at least 24 weeks in the absence of unacceptable toxicity.
11647745|NCT00112957|Experimental|rV- and rF-NY-ESO-1|Patients received a single intradermal injection of rV-NY-ESO-1 (3.1 × 10^7 PFU) on Day 1, followed by subcutaneous injections of rF-NY-ESO-1 (7.41 × 10^7 PFU) on Days 29, 57, 85, 113, 141, and 169 or until observation of treatment-related ≥ grade 3 toxicity or disease progression.
11647746|NCT00112931|Active Comparator|Watch and Wait|Watch and Wait - no treatment
11647747|NCT00112931|Experimental|Arm C Rituximab 4 and Rixuximab Maintenance|4 infusions - 375mg/m2 every 2 months. A single dose of rituximab (375mg/m2 will then be given at 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92 and 100 weeks
11647748|NCT00112918|Active Comparator|FOLFOX4|"Weeks 1-24: Oxaliplatin was administered as an 85 mg/m^2 intravenous infusion over 2 hours concomitantly with leucovorin as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion were repeated on day 2. Cycle length was 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
~Weeks 25-48: Observation only."
11647804|NCT00112229|Experimental|group 4|Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
11647749|NCT00112918|Experimental|FOLFOX4 + Bv|"Weeks 1-24: Bevacizumab 5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin, administered as an 85 mg/m^2 intravenous infusion over 2 hours (on day 1 only) concomitantly with leucovorin, as a 200 mg/m^2 infusion over 2 hours, followed by 5-FU, given as a 400 mg/m^2 bolus injection, and then as a 600 mg/m^2 continuous infusion over 22 hours. Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection, and 5-FU 600 mg/m^2 continuous infusion are repeated on day 2. Cycle length is 2 weeks and cycles were repeated every second week for a total of 12 cycles (24 weeks).
~Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks)."
11647750|NCT00112918|Experimental|XELOX+Bv|"Weeks 1-24: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 - 90 minutes followed by oxaliplatin administered as a 130 mg/m^2 intravenous infusion over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which was administered orally at a dose of 1000 mg/m^2 twice daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment), for a total of 8 cycles (24 weeks).
~Weeks 25-48: Bevacizumab 7.5 mg/kg was administered as an intravenous infusion over 30 minutes. Cycle length was 3 weeks. Cycles were repeated every 3 weeks for a total of 8 cycles (24 weeks)."
11647751|NCT00112905|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-56. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
11647752|NCT00112866|Experimental|Group I (high-dose cilengitide) 2000mg|"Preoperative Treatment: Patients receive high-dose cilengitide IV over 1 hour on days -8, -4, and -1. (High dose 2000mg)
~Resection: All patients undergo tumor resection on day 0.
~Postoperative Treatment: Beginning within 2 weeks after surgery, all patients receive high-dose cilengitide IV over 1 hour twice weekly for 4 weeks. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity."
11647753|NCT00112866|Experimental|Group II (low-dose cilengitide) 500mg|"Preoperative Treatment: Patients receive low-dose cilengitide IV over 1 hour on days -8, -4, and -1. (500mg)
~Resection: All patients undergo tumor resection on day 0.
~Postoperative Treatment: Beginning within 2 weeks after surgery, all patients receive high-dose cilengitide IV over 1 hour twice weekly for 4 weeks. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity"
11647754|NCT00112853|Experimental|Treatment (tipifarnib, etoposide)|"Patients receive oral tipifarnib twice daily on days 1-14 OR 1-21 and oral etoposide once daily on days 1-3 and 8-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a CR may receive up to 5 additional courses of therapy beyond documentation of CR.
~Cohorts of 3-6 patients receive escalating doses of tipifarnib and etoposide until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 14 additional patients receive treatment at the MTD."
11647755|NCT00112840|Experimental|CCI-779 and bevacizumab|Patients receive CCI-779 IV on days 1, 8, 15, and 22 and bevacizumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of CCI-779 and bevacizumab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Phase II patients receive CCI-779 and bevacizumab as in phase I at the MTD determined in phase I. After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years after study entry.
11647756|NCT00112827|Experimental|Arm I|See Detailed Description
11647757|NCT00112749|Experimental|Study Arm|Please see intervention description
11647758|NCT00112736|Experimental|Phase 1 (erlotinib & temsirolimus)|"PHASE I: Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 (dose escalation). Every 28 days until disease progression or unacceptable toxicity.
~pharmacological study: Correlative studies"
11647759|NCT00112736|Experimental|Phase 2 temsirolimus MTD & erlotinib|"Oral erlotinib 1 daily days 1-28 (150mg), temsirolimus IV 30 minutes days 1, 8, 15, 22 at MTD phse I. Every 28 days until disease progression or unacceptable toxicity.
~PHASE II (preoperative component): Patients who are surgical candidates may opt to undergo surgical resection of the tumor. Beginning 5-7 days before surgery, these patients receive oral erlotinib once daily until surgery. Patients also receive temsirolimus IV over 30 minutes at the MTD and then undergo surgical resection of the tumor 3-24 hours later. Beginning 2-4 weeks after surgery, patients receive temsirolimus at the MTD and erlotinib as in phase I.
~therapeutic conventional surgery: Undergo surgical resection
~laboratory biomarker analysis: Correlative studies"
11647760|NCT00112723|Experimental|Treatment (alvocidib)|"PHASE I: Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
~PHASE II: Patients receive flavopiridol* as in phase I at the MTD determined in phase I."
11647761|NCT00112684|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive alvocidib IV over 4½ hours once weekly in weeks 1-4. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11647762|NCT00112671|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11647763|NCT00112593|Experimental|Treatment (allogeneic hematopoietic stem cell transplantation)|"CONDITIONING REGIMEN: Patients receive fludarabine IV over 2 hours on days -4, -3, and -2. Patients undergo TBI on day 0.
~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic bone marrow or peripheral blood stem cell transplantation on day 0.
~IMMUNOSUPPRESSION: Patients receive cyclosporine IV or PO 2 to 3 times daily on days -3 to 99 with taper beginning on day 100 and continuing until day 177 in the absence of GVHD. Beginning within 6 hours after transplantation, patients also receive mycophenolate mofetil IV or PO 3 times daily on days 0 to 40 followed by a taper in the absence of GVHD."
11647764|NCT00112554|Experimental|Induction therapy arm I|Patients receive cytarabine IV continuously on days 1-3 and VNP40101M IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
11647765|NCT00112554|Active Comparator|Induction therapy arm II|Patients receive cytarabine as in arm I and placebo IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
11647766|NCT00112528|Experimental|gemcitabine + bevacizumab + oxaliplatin|"Patients receive gemcitabine IV over 100 minutes and bevacizumab IV over 30-90 minutes on days 1 and 15. Patients also receive oxaliplatin IV over 120 minutes on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses of therapy beyond CR.
~After completion of study treatment, patients are followed every 3-6 months for up to 5 years."
11647767|NCT00112502|Active Comparator|Arm I: TMZ|Oral Temozolomide (TMZ) 150 mg/m^2 once daily on days 1-7 and 15-21.
11647768|NCT00112502|Experimental|Arm II: TMZ + Thalidomide|Temozolomide as in arm I and oral Thalidomide (Thal) once daily on days 1-28 (starting dose 200 mg).
11647769|NCT00112502|Experimental|Arm III: TMZ + Isotretinoin|Temozolomide as in Arm I and oral Isotretinoin 40 mg/m^2 twice daily on days 1-21.
11647770|NCT00112502|Experimental|Arm IV: TMZ + Celecoxib|Temozolomide as in arm I and oral Celecoxib 400 mg twice daily on days 1-28.
11647771|NCT00112502|Experimental|Arm V: TMZ + Thalidomide + Isotretinoin|Temozolomide as in arm I, Thalidomide as in arm II, and Isotretinoin as in arm III.
11647772|NCT00112502|Experimental|Arm VI: TMZ + Thalidomide + Celecoxib|Temozolomide as in Arm I, Thalidomide as in Arm II, and Celecoxib as in Arm IV.
11647773|NCT00112502|Experimental|Arm VII: TMZ + Isotretinoin + Celecoxib|Temozolomide as in Arm I, Isotretinoin as in Arm III, and Celecoxib as in Arm IV.
11647774|NCT00112502|Experimental|Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib|Temozolomide as in Arm I, Thalidomide as in Arm II, Isotretinoin as in Arm III, and Celecoxib as in Arm IV.
11647775|NCT00112489|Experimental|Taxol-Carbo|Paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC = 6 IV over 30 minutes every 21 days until disease progression or adverse effects prohibit further therapy
11647776|NCT00112476|Experimental|Treatment (bryostatin, temsirolimus)|Patients receive bryostatin 1 IV over 1 hour on days 1, 8, 15, and 22 and temsirolimus IV over 30 minutes once on days 8, 15, and 22 during course 1. On subsequent courses patients receive bryostatin 1 and temsirolimus once on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11647777|NCT00112463|Experimental|Treatment (single-agent depsipeptide)|Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.
11647778|NCT00112437|Placebo Comparator|Placebo|
11647779|NCT00112437|Experimental|Odanacatib 3 mg|
11647780|NCT00112437|Experimental|Odanacatib 10 mg|
11647781|NCT00112437|Experimental|Odanacatib 25 mg|
11647782|NCT00112437|Experimental|Odanacatib 50 mg|
11647783|NCT00112398|Active Comparator|Standard (paramedic) prehospital care|
11647784|NCT00112398|Experimental|Physician prehospital care|
11647785|NCT00112385|Active Comparator|Etanercept|Subjects randomized to Etanercept will be provided with syringes contain 50 mg and will be injected subcutaneously once a week for 52 weeks.
11647786|NCT00112385|Placebo Comparator|Placebo|Subjects will be given syringes containing placebo. Injections will be given subcutaneously, one time per week for 52 weeks.
11647787|NCT00112372|Experimental|Ridaforolimus|10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.
11647788|NCT00112359|Placebo Comparator|Placebo three times a day (TID)|
11647789|NCT00112359|Experimental|AZLI 75 mg three times a day (TID)|
11647790|NCT00112346|Active Comparator|A|
11647791|NCT00112346|Active Comparator|B|
11647792|NCT00112320|Active Comparator|1|Standard PVR
11647793|NCT00112320|Experimental|2|PVR plus RV remodeling
11647794|NCT00112294|Active Comparator|Cetuximab+Taxane+Carboplatin (C/T/C)|Cetuximab was administered at an initial dose (Week 1) of 400 mg/m^2 intravenous (IV) infusion (infused over 120 minutes) and a weekly maintenance dose of 250 mg/m^2 IV infusion (infused over 60 minutes). A cycle of therapy was defined as 3 weeks. Taxane was paclitaxel 225 mg/m^2 infused over 180 minutes on Day 1 and subsequently every 3 weeks or docetaxel 75 mg/m^2 infused over 60 minutes on Day 1 and subsequently every 3 weeks. Carboplatin was infused over 30 minutes on Day 1 and subsequently every 3 weeks.
11647795|NCT00112294|Active Comparator|Taxane+Carboplatin (T/C)|A cycle of therapy was defined as 3 weeks. Taxane was paclitaxel 225 mg/m^2 infused over 180 minutes on Day 1 and subsequently every 3 weeks or docetaxel 75 mg/m^2 infused over 60 minutes on Day 1 and subsequently every 3 weeks. Carboplatin was infused over 30 minutes on Day 1 and subsequently every 3 weeks.
11647796|NCT00112242|Experimental|1. Melan-A ELA|500 mcg Melan-A ELA analog peptide + 1 ml Montanide ISA-51
11647797|NCT00112242|Experimental|2. Melan-A ELA + NY-ESO-1b + MAGE-A10|500 mcg Melan-A ELA analog peptide + 500 mcg NY-ESO-1b(A) analog peptide + 500 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51
11647798|NCT00112242|Experimental|3. Melan-A ELA + NY-ESO-1b + MAGE-A10 + CpG|500 mcg Melan-A ELA analog peptide + 500 mcg NY-ESO-1b(A) analog peptide + 500 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51 + 2.5 mg CpG-7909/PF-3512676
11647799|NCT00112242|Experimental|4. Melan-A EAA/ELA + NY-ESO-1lp + MAGE-A10+ CpG|"If patient is HLA-A2 positive: 100 mcg Melan-A EAA native peptide (during first cycle) or 100 mcg ELA analog peptide (during other cycles) + 500 mcg NY-ESO-1lp long peptide + 100 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676
~If patient is HLA-A2 negative: 500 mcg NY-ESO-1lp long peptide+ 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676"
11647800|NCT00112242|Experimental|5. Melan-A EAA/ELA + NY-ESO-1lp + MAGE-A10+ CpG+ IL-2|"If patient is HLA-A2 positive: 100 mcg Melan-A EAA native peptide (during first cycle) or 100 mcg ELA analog peptide (during other cycles) + 500 mcg NY-ESO-1lp long peptide + 100 mcg MAGE-A10 peptide + 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676 + low dose IL-2
~If patient is HLA-A2 negative: 500 mcg NY-ESO-1lp long peptide+ 1 ml Montanide ISA-51 (no Montanide during cycle 3) + 2.5 mg CpG-7909/PF-3512676 + low dose IL-2"
11647801|NCT00112229|Experimental|group 1|Melan-A analog peptide + CpG + Montanide
11647802|NCT00112229|Experimental|group 2|Melan-A natural peptide + CpG + Montanide
11647803|NCT00112229|Experimental|group 3|Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
11647805|NCT00112151|Experimental|LowT+Resistance Training|"Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)
~1 year standard Progressive Resistance Training(PRT) program"
11647806|NCT00112151|Experimental|LowT+No Resistance training|"Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)
~No exercise program"
11647807|NCT00112151|Experimental|HighT+Resistance Training|"High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)
~1 year standard Progressive Resistance Training(PRT) program"
11647808|NCT00112151|Experimental|HighT+No Resistance Training|"High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)
~No exercise program"
11647809|NCT00112151|Active Comparator|Placebo+Resistance Training|"Placebo Group applies two 2.5 gm placebo packets
~1 year standard Progressive Resistance Training(PRT) program"
11647810|NCT00112151|Placebo Comparator|Placebo+No Resistance Training|"Placebo group applies two 2.5 gm placebo packets
~No exercise program"
11647811|NCT00112125|Experimental|Optimizer System + Optimal medical treatment|Optimizer System implanted and cardiac contractility modulation therapy activated.
11647812|NCT00112125|No Intervention|Optimal medical treatment|Treatment with optimal medical therapy only.
11647813|NCT00112112|Active Comparator|FluMist|The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.
11647814|NCT00112112|Placebo Comparator|Placebo|Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
11647815|NCT00112099|Active Comparator|1|Procedure/Surgery: Surgery: Splenectomy
11647816|NCT00112099|Experimental|2|Procedure/Surgery: Surgery: Spleen-preservation
11647817|NCT00112073|Experimental|0.15 mg/kg active bapineuzumab|
11647818|NCT00112073|Placebo Comparator|0.15 mg/kg placebo|
11647819|NCT00112073|Experimental|0.5 mg/kg active bapineuzumab|
11647820|NCT00112073|Placebo Comparator|0.5 mg/kg placebo|
11647821|NCT00112073|Experimental|1.0 mg/kg active bapineuzumab|
11647822|NCT00112073|Placebo Comparator|1.0 mg/kg placebo|
11647823|NCT00112073|Experimental|2.0 mg/kg active bapineuzumab|
11647824|NCT00112073|Placebo Comparator|2.0 mg/kg placebo|
11647825|NCT00112047|Active Comparator|EFV+CBV|Participants in this group received EFV 600 mg once daily + Combivir ([CBV]; the fixed dose combination pill containing lamivudine 150 mg + zidovudine 300 mg) taken twice daily from the start of the study until Week 144. At Week 144 all participants who opted to roll over into the additional 96-week study extension received Atripla ([ATR]; the fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg) taken once daily until the end of the study (Week 240). At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.
11647826|NCT00112047|Experimental|EFV+FTC+TDF|Participants in this arm received 3 component drugs: efaviren (EFV; 600 mg) + emtricitabine (FTC; 200 mg) + tenofovir disoproxil fumarate (tenofovir DF [TDF]; 300 mg) as 3 separate pills once daily from the start of the study. At 96 weeks Truvada ([TVD] the fixed-dose combination pill containing FTC/TDF [200/300 mg] once daily) replaced the 2 component drugs FTC + TDF; participants continued to receive EFV 600 mg once daily. At Week 144 all participants who opted to roll over into the further 96-week study extension received ATR. At sites in France, the study was extended by a further 48 weeks (Year 6) or until ATR became commercially available (whichever happened first); once ATR became commercially available in France participants were not required to complete the full 288 weeks of the study.
11647827|NCT00112021|Experimental|Pramlintide Acetate|
11647828|NCT00112021|Placebo Comparator|Placebo|
11647829|NCT00112008|Experimental|darbepoetin alfa|
11647830|NCT00111982|Experimental|Liatermin|Bilateral continuous infusion of liatermin for up to 24 months.
11647831|NCT00111956|Experimental|Etanercept|
11647832|NCT00111956|Placebo Comparator|Placebo|
11647833|NCT00111917|Experimental|Infliximab|infusion: 3:1 infliximab:placebo ratio administered at 0, 2, 6, 12, 18 and 24 weeks.
11647834|NCT00111917|Placebo Comparator|Placebo|infusion: 3:1 infliximab:placebo ratio administered at 0, 2, 6, 12, 18 and 24 weeks.
11647835|NCT00111865|Experimental|Exercise|Aerobic Exercise Training
11647836|NCT00111865|No Intervention|Usual Care|
11647837|NCT00111852|Experimental|Desmoteplase, low dose|Desmoteplase 90 mcg/kg, intravenous administration.
11647838|NCT00111852|Experimental|Desmoteplase, high dose|Desmoteplase 125 mcg/kg, intravenous administration.
11647839|NCT00111852|Placebo Comparator|Placebo|Dose-Match Placebo, intravenous administration.
11647840|NCT00111839|Active Comparator|Pemetrexed Alone|Participants will receive pemetrexed 50 milligrams per square meter (mg/m^2) intravenous (IV) infusion every 3 weeks until disease progression (PD) or the occurrence of unacceptable toxicity.
11647841|NCT00111839|Experimental|Pemetrexed Plus Matuzumab 800 mg per Week|Participants will receive pemetrexed 50 mg/m^2 IV infusion every 3 weeks in combination with matuzumab 800 milligrams (mg) IV infusion once every week. Treatment will continue until PD or the occurrence of unacceptable toxicity.
11647842|NCT00111839|Experimental|Pemetrexed Plus Matuzumab 1600 mg Every 3 Weeks|Participants will receive pemetrexed 50 mg/m^2 IV infusion every 3 weeks in combination with matuzumab 1600 mg IV infusion every 3 weeks. Treatment will continue until PD or the occurrence of unacceptable toxicity.
11647843|NCT00111813|Experimental|vorinostat 200 mg + bortezomib 0.7 mg/m^2|Vorinostat capsules given twice daily (b.i.d.); bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
11647844|NCT00111813|Experimental|vorinostat 200 mg + bortezomib 0.9 mg/m^2|Vorinostat capsules given b.i.d.; bortezomib injection given on Days 4, 8, 11, and 15 of each cycle.
11647845|NCT00111813|Experimental|vorinostat 300 mg + bortezomib 1.3 mg/m^2|Vorinostat given once daily (q.d.); bortezomib given on Days 1, 4, 8, and 11 of each cycle.
11647846|NCT00111813|Experimental|vorinostat 400 mg + bortezomib 0.9 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
11647847|NCT00111813|Experimental|vorinostat 400 mg + bortezomib 1.1 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
11647848|NCT00111813|Experimental|vorinostat 400 mg + bortezomib 1.3 mg/m^2|Vorinostat given q.d.; bortezomib given on Days 1, 4, 8, and 11 of each cycle.
11647849|NCT00111800|Placebo Comparator|Placebo|Participants received oral dose of matching placebo capsule to denagliptin (DEN) once daily in the morning, 30 minutes (min) prior to breakfast during the main phase 12-weeks treatment period. Participants who were randomized to placebo in the main phase 12-weeks treatment period received oral dose of DEN 2.5 milligram (mg) once daily in the morning, 30 min prior to breakfast during the extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of placebo to the participants.
11647850|NCT00111800|Experimental|DEN 2.5 mg|Participants received oral dose of DEN 2.5 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 2.5 mg to the participants.
11647851|NCT00111800|Experimental|DEN 7.5 mg|Participants received oral dose of DEN 7.5 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 7.5 mg to the participants.
11647852|NCT00111800|Experimental|DEN 15 mg|Participants received oral dose of DEN 15 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 15 mg to the participants.
11647853|NCT00111800|Experimental|DEN 30 mg|Participants received oral dose of DEN 30 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 30 mg to the participants.
11647854|NCT00111800|Experimental|DEN 45 mg|Participants received oral dose of DEN 45 mg capsule once daily in the morning, 30 min prior to breakfast during the main phase/extension phase 12-weeks treatment period. Participants were dispensed 3 bottles (bottle A, B and C) and were instructed to take 1 capsule daily from each bottle such that taking 1 capsule from each bottle daily provided the appropriate dose of DEN 45 mg to the participants.
11647855|NCT00111787|Experimental|Overall study|A Single arm study with 2 cohorts of participants. Cohort A consists of participants with tumors overexpressing HER2 and/or EGFR. Cohort B consists of participants with tumors expressing EGFR without overexpressing HER2.
11647856|NCT00111761|Experimental|Part 1: Panitumumab + IFL|Panitumumab (2.5 mg/kg once weekly for up to 48 weeks or until disease progression, intolerable adverse event or other reason for discontinuation) in combination with irinotecan, 5-fluorouracil (5-FU)and leucovorin (IFL chemotherapy regimen)
11647857|NCT00111761|Experimental|Part 2: Panitumumab + FOLFIRI|Panitumumab (2.5 mg/kg once weekly until disease progression, intolerable adverse event or other reason for discontinuation) in combination with irinotecan/5-FU/leucovorin chemotherapy (the FOLFIRI regimen)
11647858|NCT00111748|Active Comparator|1|"Stratification:
~CA13/hypodiploidy at diagnosis versus no CA13/hypoploidy at diagnosis
~Prior Velcade vs. No prior Velcade
~TREATMENT:VTD Velcade 1.0 mg/m2 Days 1,4, 8,11 Thalidomide 100 mg Daily qhs Dexamethasone 20 mg Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg Days 1-14 Every 21 days"
11647859|NCT00111748|Active Comparator|2|"Stratification:
~CA13/hypodiploidy at diagnosis versus no CA13/hypoploidy at diagnosis
~Prior Velcade vs. No prior Velcade
~TREATMENT:
~VATD Velcade 1.0 mg/m2 Days 1,4, 8,11 Thalidomide 100 mg Daily qhs Dexamethasone 20 mg Days 1, 2, 4,5, 8, 9, 11, 12 Adriamycin 2.5 mg/m2 Days 1-4 & Days 9-12 Lovenox 40 mg Days 1-14 Every 21 days"
11647860|NCT00111696|Experimental|MEDI-522|Drug
11647861|NCT00111683|Experimental|MK-0457|Participants receive MK-0457 as a continuous intravenous infusion (CIV) at assigned dose and duration
11647862|NCT00111670|Experimental|1|
11647863|NCT00111670|Experimental|2|
11647864|NCT00111670|Experimental|3|
11647865|NCT00111670|Experimental|4|
11647866|NCT00111670|Placebo Comparator|5|
11647867|NCT00111657|Experimental|pegloticase|"All study participants received intravenous pegloticase at dose of 8 mg, administered every 21 days for a maximum of 5 doses.
~There was no control group for this open label study."
11647868|NCT00111644|Experimental|1|
11647869|NCT00111644|Experimental|2|
11647870|NCT00111644|Active Comparator|3|
11647871|NCT00111631|Experimental|1|
11647872|NCT00111631|Experimental|2|
11647873|NCT00111631|Experimental|3|
11647874|NCT00111631|Placebo Comparator|4|
11647875|NCT00111605|Experimental|1|HIV gag DNA vaccine or placebo on Days 0, 28, and 84
11647876|NCT00111605|Experimental|2|HIV gag DNA vaccine plus 100 mcg of IL-12 or placebo on Days 0, 28, and 84
11647877|NCT00111605|Experimental|3|HIV gag DNA vaccine plus 500 mcg of IL-12 or placebo on Days 0, 28, and 84
11647878|NCT00111605|Experimental|4|HIV gag DNA vaccine plus 1,500 mcg of IL-12 or placebo on Days 0, 28, and 84
11647879|NCT00111605|Experimental|5|HIV gag DNA vaccine or placebo on Days 0, 28, 84, 168, and 273
11647880|NCT00111605|Experimental|6|HIV gag DNA vaccine plus IL-12 or placebo on Days 0, 28, and 84 plus CTL MEP/RC529-SE/GM-SCF booster vaccine on Days 168 and 273
11647881|NCT00111605|Experimental|7|HIV gag DNA vaccine plus IL-12 DNA adjuvant or placebo on Days 0 and 84
11647882|NCT00111592|Active Comparator|1|current usual care
11647883|NCT00111592|Experimental|2|treatment protocol with clear indications for therapy
11647884|NCT00111579|Active Comparator|1|CAIV-T
11647885|NCT00111579|Other|2|TIV
11647886|NCT00111566|Active Comparator|18 Hour infusion|
11647887|NCT00111566|Experimental|4 hour infusion|
11647888|NCT00111540|Experimental|Exenatide|Exenatide 5 mcg for 4 weeks (transition) then 10 mcg to study termination
11647889|NCT00111527|Active Comparator|1|Normal RV pacing
11647890|NCT00111527|Experimental|2|Echo-guided optimization of pacing
11647891|NCT00111501|Experimental|Targeted Internet Intervention|Web-based self help intervention developed to include specific cultural tailoring relevant to the LGBT community
11647892|NCT00111501|Active Comparator|Standard Intervention|Standard self-help internet-based intervention with no LGBT relevant information included
11647893|NCT00111475|Experimental|Part A: Romiplostim 0.2 µg/kg|Participants received 0.2 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
11647894|NCT00111475|Experimental|Part A: Romiplostim 0.5 µg/kg|Participants received 0.5 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
11647895|NCT00111475|Experimental|Part A: Romiplostim 1.0 µg/kg|Participants received 1.0 µg/kg romiplostim subcutaneously on day 1 and on day 15 or 22 depending on platelet counts.
11647896|NCT00111475|Experimental|Part A: Romiplostim 3 µg/kg|Participants received 3.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
11647897|NCT00111475|Experimental|Part A: Romiplostim 6 µg/kg|Participants received 6.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
11647898|NCT00111475|Experimental|Part A: Romiplostim 10 µg/kg|Participants received 10.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
11647899|NCT00111475|Placebo Comparator|Part B: Placebo|Participants received placebo subcutaneously once a week for 6 weeks.
11647900|NCT00111475|Experimental|Part B: Romiplostim 1.0 µg/kg|Participants received 1.0 µg/kg subcutaneously once a week for 6 weeks.
11647901|NCT00111475|Experimental|Part B: Romiplostim 3.0 µg/kg|Participants received 3.0 µg/kg subcutaneously once a week for 6 weeks.
11647902|NCT00111475|Experimental|Part B: Romiplostim 6.0 µg/kg|Participants received 6.0 µg/kg subcutaneously once a week for 6 weeks.
11647903|NCT00111436|Experimental|50 mg|50 mg once weekly
11647904|NCT00111436|Experimental|100 mg|50 mg twice weekly
11647905|NCT00111384||Group A|Affected participants, must have a correct clinical diagnosis of NF1.
11647906|NCT00111384||Group B|Unaffected individuals greater than 2 years of age who are relatives of participants.
11647907|NCT00111358|Active Comparator|Lifestyle Modification|Goals derived from the AACE and NCEP-ATP III guidelines and the Diabetes Prevention Program are as follows: <35% calories from fat, < 7% calories from saturated fat, up to 10% calories from polyunsaturated fat, reduction of trans fatty acid intake, up to 20% calories from monounsaturated fat, and 25-35g of fiber per day. 3 hrs of physical activity/week at moderate intensity, >10,000 steps in daily activity, measured by pedometer. The curriculum is modeled after the Diabetes Prevention Program. Subjects will complete lifestyle sessions in the offices of the Program in Nutritional Metabolism or in the Clinical Research Center at MGH with protocol study staff trained to implement the curriculum.
11647908|NCT00111358|Placebo Comparator|Control|
11647909|NCT00111345|Experimental|1|Daunoxome, standard risk
11647910|NCT00111345|Active Comparator|2|Idarubicin, standard risk
11647911|NCT00111345|Experimental|3|Daunoxome, high-risk, 2-CDA
11647912|NCT00111345|Active Comparator|4|Idarubicin, high-risk, nothing
11647913|NCT00111254|Experimental|1|In group I, acute effect group, each subject will undergo microdermabrasion of the hip/buttock. Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device). 4mm punch biopsies will be performed in the treated area at 4hrs, 8hrs, and 24hrs post-treatment. In addition, one 4mm punch biopsy will be obtained from adjacent untreated skin.
11647914|NCT00111254|Experimental|2|In group II, chronic effect group, each subject will undergo microdermabrasion of the face at weekly intervals for six weeks. Treatment will consist of 3 passes in different directions with the microdermabrasion handpiece (horizontal, vertical, and oblique). Aluminum oxide abrasion and negative pressure will be increased as tolerated by the patient. Two 2mm punch biopsies will be obtained prior to the first treatment and one week following the sixth treatment.
11647915|NCT00111228|Experimental|Continuous use of the Guardian RT|Continuous use of the Guardian RT group
11647916|NCT00111228|Experimental|Bi-weekly use of the Guardian RT (once every 2 weeks)|Bi-weekly use of the Guardian RT (once every 2 weeks) group
11647917|NCT00111228|Active Comparator|Control group. SMBG monitoring|Control group. SMBG monitoring group
11647918|NCT00111189|Experimental|001|Paliperidone Palmitate 25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
11647919|NCT00111189|Placebo Comparator|002|Placebo Placebo every 4 wk up to 24 mo
11647920|NCT00111176|Other|1|Endovascular Repair
11647921|NCT00111176|Other|2|Surgical
11647922|NCT00111137|Active Comparator|rHuEPO|
11647923|NCT00111137|Experimental|Darbepoetin alfa|
11647924|NCT00111098|Experimental|darbepoetin alfa|
11647925|NCT00111085|Experimental|Clazosentan 1 mg/h|intravenous clazosentan at 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
11647926|NCT00111085|Experimental|Clazosentan 5 mg/h|intravenous clazosentan at 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
11647927|NCT00111085|Experimental|Clazosentan 15 mg/h|intravenous clazosentan at of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
11647928|NCT00111085|Placebo Comparator|Placebo|intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
11647929|NCT00111020|Experimental|Arm 1|
11647930|NCT00111007|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg orally, 2 tablets (200 mg each) bid (bis in die [twice daily]) on Study Days 2 to 19 + Paclitaxel (225 mg/m^2 iv [Intravenous]) and Carboplatin (AUC [area under the curve] 6 iv) on Study Day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
11647931|NCT00111007|Active Comparator|Carboplatin/Paclitaxel (C/P)|Placebo, 2 tablets bid on Study Days 2-19 + Paclitaxel (225 mg/m^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
11647932|NCT00110994|Experimental|Sorafenib (Nexavar, BAY43-9006) + Dacarbazine|Sorafenib, 2 tablets (200 mg each) orally twice daily (bid) on study days 1-21 + Dacarbazine, 1000 mg/m^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
11647933|NCT00110994|Active Comparator|Placebo + Dacarbazine|Placebo, 2 tablets orally twice daily on study days 1-21 + Dacarbazine, 1000 mg/m^2 intravenous on study day 1 (21 days per cycle) for double-blind (DB) treatment. Subjects who discontinued DB treatment with complete response (CR), partial response (PR) or stable disease (SD) entered active follow up period. Subjects who discontinued DB treatment with disease progression (DP) entered long term follow up period.
11647934|NCT00110981|Experimental|Single-arm|
11647935|NCT00110955|Experimental|Darbepoetin alfa - Group A|
11647936|NCT00110955|Placebo Comparator|Placebo- Group B|
11647937|NCT00110942|Active Comparator|Minor sub-study AMG 108|N = 15
11647938|NCT00110942|Placebo Comparator|Minor sub-study placebo|N = 15
11647939|NCT00110942|Active Comparator|Main sub-study AMG 108|N = 73
11647940|NCT00110942|Placebo Comparator|Main sub-study placebo|N = 73
11647941|NCT00110916|Experimental|Anakinra|anakinra
11647942|NCT00110916|Placebo Comparator|placebo|placebo
11647943|NCT00110890|No Intervention|Standard of care|Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
11647944|NCT00110890|Other|Cinacalcet|Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg. Dose escalation of cinacalcet may occur based on iPTH values.
11647945|NCT00110877|Experimental|002|LPV/rtv One 400mg LPV tablet twice daily with 100mg RTV
11647946|NCT00110877|Experimental|001|TMC114/rtv Two 300mg TMC114 tablets twice daily with 100mg RTV
11647947|NCT00110812|No Intervention|No IL-2|Participants will receive no aldesleukin or HAART
11647948|NCT00110812|Experimental|IL-2 without ART|Participants will receive aldesleukin under the skin twice daily for 5 consecutive days every 8 weeks for 3 cycles, then as needed to maintain CD4 counts at or above a goal level. Some Group 2 participants may take part in additional cycles of aldesleukin if they meet certain study criteria.
11647949|NCT00110812|Experimental|IL-2 with pericycle HAART|Participants will receive aldesleukin under the skin twice daily for 5 consecutive days every 8 weeks for 3 cycles, then as needed to maintain CD4 counts at or above a goal level; Group 3 participants will also take HAART for 3 days prior to the start of each aldesleukin cycle, throughout the 5-day aldesleukin cycle, and for 2 days after the end of each aldesleukin cycle (for a maximum of 10 days with each aldesleukin cycle). Some Group 3 participants may take part in additional cycles of aldesleukin if they meet certain study criteria. HAART is not supplied by the study, and choice of drugs is left to the participant and physician. The HAART regimen should include at least one protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors.
11647950|NCT00110799|Active Comparator|Arm B|SB-497115-GR 30mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
11647951|NCT00110799|Active Comparator|Arm C|SB-497115-GR 50mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
11647952|NCT00110799|Active Comparator|Arm D|SB-497115-GR 75mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
11647953|NCT00110799|Placebo Comparator|Arm A|Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
11647954|NCT00110773|Experimental|S-Caine Peel|
11647955|NCT00110773|Placebo Comparator|Placebo Peel|
11647956|NCT00110760|Experimental|S-Caine Peel|
11647957|NCT00110760|Placebo Comparator|Placebo Peel|
11647958|NCT00110747|Experimental|S-Caine Peel|
11647959|NCT00110747|Placebo Comparator|Placebo Peel|
11647960|NCT00110695|Experimental|A|
11647961|NCT00110669|Active Comparator|High Dose Prednisone|"Subjects who are randomized to the high-dose prednisone arm of the study will receive the following starting dose:
~•Prednisone at 10.0 mg/kg/wk (divided into two doses given on Saturday and Sunday)"
11647962|NCT00110669|Active Comparator|Daily Prednisone|"Subjects who are randomized to the daily prednisone arm of the study will receive the following starting dose:
~•Prednisone at 0.75 mg/kg/d"
11647963|NCT00110656||Kidney Transplant|All patients entered into the study will have received a kidney transplant.
11647964|NCT00110617|Experimental|Deferasirox (ICL670)|Deferasirox (ICL670) 20 mg/kg orally once daily for 104 weeks.
11647965|NCT00110617|Experimental|Deferoxamine (DFO) then ICL670|Deferoxamine (DFO) subcutaneously for a weekly dose of 175 mg/kg for 24 weeks then crossed over to receive Deferasirox (ICL670) orally 20 mg/kg for a total of 104 weeks on therapy.
11647966|NCT00110591|Placebo Comparator|Placebo|Intravenous placebo for PRO 140
11647967|NCT00110591|Experimental|PRO 140 dose 1|0.1 mg/kg PRO 140 by intravenous infusion
11647968|NCT00110591|Experimental|PRO 140 dose 2|0.5 mg/kg PRO 140 by intravenous infusion
11647969|NCT00110591|Experimental|PRO 140 dose 3|2.0 mg/kg PRO 140 by intravenous infusion
11647970|NCT00110591|Experimental|PRO 140 dose 4|5.0 mg/kg PRO 140 by intravenous infusion
11647971|NCT00110552|Experimental|1|Sage capsules taken by mouth
11647972|NCT00110552|No Intervention|2|No intervention, no-pill as control
11647973|NCT00110526|Experimental|Ad.hIL-12|
11647974|NCT00110513|Experimental|Recombinant Human Antithrombin (rhAT) Infusion|Intravenous infusion of rhAT.
11647975|NCT00110461|Active Comparator|1|Aripiprazole 10 mg tablet
11647976|NCT00110461|Active Comparator|2|Aripiprazole 30 mg tablet
11647977|NCT00110461|Placebo Comparator|3|Placebo
11647978|NCT00110448|Active Comparator|1|Aspirin use
11647979|NCT00110448|Active Comparator|2|No aspirin use
11647980|NCT00110422|Experimental|A1|
11647981|NCT00110422|Active Comparator|B1|
11647982|NCT00110409|Experimental|1|Intervention participants will receive information focusing on asthma self-management, education, self-efficacy, and social support while in the hospital emergency room. Telephone reinforcement will occur for 8 weeks following study entry.
11647983|NCT00110409|Active Comparator|2|Participants in the control group will receive standard emergency room education about asthma.
11647984|NCT00110396|Experimental|Rebif New Formulation Cohort|
11647985|NCT00110383|Experimental|1|Supervised therapy
11647986|NCT00110383|No Intervention|2|Inhaled steroid use as usual care
11647987|NCT00110357|Active Comparator|Group A|1-12 years old
11647988|NCT00110357|Active Comparator|Group B|13-18 years old
11647989|NCT00110344|Experimental|Arm 1|
11647990|NCT00110344|Placebo Comparator|Arm 2|
11647991|NCT00110305|Experimental|TMC278 25 mg|Participants will receive TMC278 25 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
11647992|NCT00110305|Experimental|TMC278 75 mg|Participants will receive TMC278 75 mg once daily up to Week 144. Later on, participants will receive TMC278 25 mg once daily up to Week 240.
11647993|NCT00110305|Experimental|TMC278 150 mg|Participants will receive TMC278 150 mg once daily up to Week 96. Later on, participants will receive TMC278 75 mg once daily up to Week 144 and then TMC278 25 mg once daily up to Week 240.
11647994|NCT00110305|Active Comparator|Efavirenz|Participants will receive efavirenz 600 mg once daily up to Week 96. Later on, participants will have an option to continue on efavirenz until Week 144 or until Week 240.
11647995|NCT00110279|Experimental|1|One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops.
11647996|NCT00110279|Experimental|2|One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops. This Arm will enroll 4 weeks after Arm 1. Enrolled volunteers must have participated in Arm 1.
11647997|NCT00110266|Experimental|ICL670|Evaluate the safety and tolerability of deferasirox 20 mg/kg/day over one year in patients with MDS
11647998|NCT00110253|Experimental|S-Caine Peel|
11647999|NCT00110227|Experimental|Tai Chi|12-week tai chi program
11648000|NCT00110227|Active Comparator|Heart Health Education|12-week attention control
11648001|NCT00110214|Experimental|Arm I|Patients receive docetaxel IV over 1 hour and placebo IV over 30-90 minutes on day 1. Patients also receive oral prednisone once daily on days 1-21.
11648002|NCT00110214|Experimental|Arm II|Patients receive docetaxel and prednisone as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1.
11648003|NCT00110188|Experimental|Ridaforolimus|50 mg of ridaforolimis intravenously over 30 minutes, weekly
11648004|NCT00110149|Experimental|Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan|Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
11648005|NCT00110136|Experimental|St. John's Wort|Patient given one 300mg St. John's Wort tablet three times per day
11648006|NCT00110110|Experimental|CEV Chemo + Cyclosporine & Focal Therapy|Systemic carboplatin (28 mg/kg/dose), etoposide (12 mg/kg/dose) and vincristine sulfate (0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated) chemotherapy given with cyclosporin A (33 mg/kg/dose). Following 4-6 cycles CEV chemotherapy (depending on tumor stage) given every 3 weeks, focal laser therapy and/or cryosurgery are applied for tumor consolidation. Filgrastim is given after each chemotherapy cycle to prevent severe neutropenia.
11648007|NCT00110084|Experimental|Nab-paclitaxel/Gemcitabine|
11648008|NCT00110071|Experimental|Treatment (chemoradioimmunotherapy)|Patients receive a dosimetric dose of iodine I 131 tositumomab IV over 40-60 minutes on day -24 followed by gamma camera imaging over the next 6 days. Patients then receive a therapeutic dose of iodine I 131 tositumomab via central line over 40-60 minutes on day -14. Patients also receive fludarabine phosphate IV QD on days -11 to -9 OR days -11 or -7. Patients undergo autologous or syngeneic peripheral blood stem cell transplantation on day 0.
11648009|NCT00110032|Experimental|Group 1 (fluorine F 18 EF5, PET)|Patients receive fluorine F 18 EF5 (^18F-EF5) IV followed by whole brain and whole body PET scanning OR whole body PET scanning only. Patients then receive nonradioactive EF5 IV over 1-2 ½ hours.
11648010|NCT00110032|Experimental|Group 2 (EF5, PET)|Patients receive nonradioactive EF5 IV over 1-2½ hours followed by ^18F-EF5 IV. Patients then undergo whole brain and whole body PET scanning.
11648011|NCT00110032|Experimental|Group 3 (EF5, PET)|Patients receive nonradioactive EF5 and ^18F-EF5 as in group 2. Patients then undergo whole brain PET scanning.
11648012|NCT00110019|Experimental|Arm I (paclitaxel, carboplatin, sorafenib tosylate)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients also receive sorafenib tosylate PO BID (approximately every 12 hours) on days 2-19.
11648013|NCT00110019|Active Comparator|Arm II (carboplatin, paclitaxel, placebo)|Patients receive paclitaxel and carboplatin as in Arm I. Patients also receive placebo PO BID (approximately every 12 hours) on days 2-19.
11648014|NCT00109967|Experimental|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and on day 1 only of courses 3, 5, 7, 9, and 11. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of course 3, patients undergo reevaluation. Patients achieving a CR or an unconfirmed CR (CRu) receive 2 additional courses of treatment for a total of 5 courses. Patients achieving a PR or stable disease continue study treatment as outlined above for up to 12 courses. Patients achieving a PR or stable disease who subsequently achieve a CR or CRu between courses 3 and 10 receive 2 additional courses of treatment.
11648015|NCT00109941|Experimental|metenkephalin, OGF-opioid growth factor|DRUG All subjects treated with met-enkephalin (also called OGF) 250 ug/kg iv weekly over 45 minutes
11648047|NCT00109538|Experimental|Lonafarnib|Lonafarnib 200 mg twice daily, oral, continuously
11648016|NCT00109928|Experimental|PEGS Treatment|VP-16 (Etoposide) 40 mg/m2 IV Days 1-4 Methyl Prednisolone 250 mg IV Days 1-4 Cisplatin 25 mg/m2 IV Days 1-4 Gemcitabine 1,000 mg/m2 IV Day 1
11648017|NCT00109889|Other|MRI and PET|Magnetic resonance imaging and positron emission tomography
11648018|NCT00109876|Experimental|Treatment (RFA therapy)|A radiofrequency electrode is placed by CT guidance into the target tumor. Patients undergo RFA directly to the tumor for up to 12 minutes to obtain an intratumoral temperature > 60° C. Patients may receive 3 RFA treatments (a total of 36 minutes) to obtain the target temperature.
11648019|NCT00109863|Experimental|Hu14.18-IL2 Treatment|Hu14.18-IL2 will be given on days 1, 2, and 3 of each course of therapy as a 4 hour continuous IV infusion at a daily dose of 6 mg/m2. Treatment courses will be repeated every 28 days at the same dose.
11648020|NCT00109850|Experimental|Treatment|Cetuximab+Cisplatin+Irinotecan followed by radiation therapy (RT) in Cycle 3.
11648021|NCT00109837|Experimental|Induc x2, Consol, Maint|Induc 1: Allopurinol; Daunorubicin; Vincristine; Prednisone; asparaginase; Bactrim Induc 2: Allopurinol; cytarabine; Dexamethasone; filgrastim; mitoxantrone; Methotrexate; leucovorin Consol: Cyclophosphamide; cytarabine; 6-mercaptopurine; Methotrexate; filgrastim Maint:Course 1: 6-mercaptopurine; Methotrexate Course 2: Vincristine; doxorubicin; Dexamethasone Course 3: Cyclophosphamidee; thioguanine; cytarabine Course 4: 6-mercaptopurine; methotrexate
11648022|NCT00109824|Experimental|Arm I|Patients receive decitabine IV over 1 hour on days 1-5 or 1-10. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11648023|NCT00109824|Experimental|Arm II|Patients receive decitabine as in stage 1 and valproic acid PO TID on days 5-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11648024|NCT00109811|Experimental|Treatment|Patients receive PSA peptide vaccine (PSA-3A; PSA: 154-163 [155L]) emulsified in Montanide ISA-51 subcutaneously once in weeks 0, 2, 4, 6, 10, 14, and 18 in the absence of disease progression or unacceptable toxicity.
11648025|NCT00109798|Experimental|Temozolomide, Topotecan|Patient will take on days 1-5 of a 28-days schedule. Take Topotecan on days 2-6 of the 28 day schedule
11648026|NCT00109785|Experimental|PET Scans|The first group of positron emission tomography (PET) scans is performed within 2 weeks before the first dose of chemotherapy. The second group of PET scans occur no more than 7 weeks after chemotherapy and prior to local therapy, either surgery or radiation therapy. The PET scan before initiation of chemotherapy consists of 4 imaging sessions. There is one iodine I-124 iododeoxyuridine (IUdR) PET scan (3 imaging sessions) at 1, 4-8, and 24 hours after IUdR infusion, followed by one fludeoxyglucose (FDG) PET scan (1 imaging session) 45 minutes after FDG infusion.
11648027|NCT00109772|Experimental|lenalidomide|10 mg/day lenalidomide orally for up to 12 weeks in the double-blind treatment period. Participants who completed double-blind treatment had the option of continuing on lenalidomide in the open-label extension period for as long as benefit was derived from the drug or until study closure.
11648028|NCT00109772|Placebo Comparator|Placebo|Placebo orally for up to 12 weeks in the double-blind treatment period. Participants who completed double-blind treatment had the option of crossing over to lenalidomide 10mg in the open-label extension period for as long as benefit was derived from the drug or until study closure.
11648029|NCT00109746|Active Comparator|Chromium Picolinate|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
11648030|NCT00109746|No Intervention|Placebo|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
11648031|NCT00109733|Experimental|Standard dose group|0.005 mg/kg/day recombinant human growth hormone (r-hGH) for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
11648032|NCT00109733|Experimental|High dose group|0.010 mg/kg/day recombinant human growth hormone for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
11648033|NCT00109720|Experimental|1|Patients in the experimental group received the services of a Diabetes Self-Management Consultant (DSC)
11648034|NCT00109720|Active Comparator|2|This Arm was a Enhanced Usual Care Control group who continued with their usual care but also they and their physicians received the results of all metabolic assessments obtained during the study.
11648035|NCT00109707|Experimental|Arm 1|Relapsed / refractory Ph+ ALL patients
11648036|NCT00109707|Experimental|Arm 2 - Group A and Group B|Imatinib-resistant / intolerant Ph+ CML-BC patients
11648037|NCT00109707|Experimental|Arm 3 - Group A and Group|Imatinib-resistant / intolerant Ph+ CML-AP patients
11648038|NCT00109707|Experimental|Arm 4 - Group A and Group B|Imatinib-resistant / intolerant Ph+ CML-CP patients
11648039|NCT00109707|Experimental|Arm 5|Hypereosinophilic syndrome and chronic eosinophilic leukemia patients
11648040|NCT00109707|Experimental|Arm 6|Systemic Mastocytosis patients
11648041|NCT00109655|Experimental|1|
11648042|NCT00109590|Experimental|Arm A: LPV/r x 7d|NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and BID for 7 days postpartum, ddI 250 mg orally daily (if body weight <60 kg) or 400 mg orally twice daily (if body weight >= 60 kg) at the onset of labor, during labor, and for 7 days postpartum, LPV/r 400/100mg orally twice daily at the onset of labor, during labor and for 7 days postpartum.
11648043|NCT00109590|Experimental|Arm B: no LPV/r|NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and twice daily for 7 days postpartum , ddI 250 mg orally daily (if body weight <60 kg) or 400 mg orally daily (if body weight >= 60 kg) at the onset of labor, during labor, and for 30 days postpartum.
11648044|NCT00109590|Experimental|Arm C: LPV/r x 30d|NVP 200 mg orally, single dose at onset of labor, ZDV 300 mg orally at onset of labor, every 3 hours during labor and twice daily for 7 days postpartum , ddI 250 mg orally daily (if body weight <60 kg) or 400 mg orally daily (if body weight >= 60 kg) at the onset of labor, during labor, and for 30 days postpartum,LPV/r 400/100mg orally twice daily at the onset of labor, during labor and for 30 days postpartum.
11648045|NCT00109577|Placebo Comparator|2|Placebo comparator, 6 placebo capsules three times a day
11648046|NCT00109577|Experimental|1|nutritional supplement intervention, 6 nutritional supplement capsules three times a day; the nutritional supplement is a 36-ingredient micronutrient supplement (primarily vitamins and minerals) and is referred to as MCN36, because it contains 36 nutrients.
11648048|NCT00109538|Placebo Comparator|Placebo|Placebo, BID, oral
11648049|NCT00109512|Placebo Comparator|placebo|
11648050|NCT00109512|Experimental|NBI-56418 75 mg|
11648051|NCT00109512|Experimental|NBI-56418 150 mg|
11648052|NCT00109486|Experimental|Arm 1|
11648053|NCT00109473|Experimental|Growth Hormone plus cortecosteroid|Growth Hormone (nutropin AQ 0.075 mg/kg/day subcutaneously daily)
11648054|NCT00109473|Active Comparator|Cortecosteroids alone|Cortecosteroid therapy as prescribed by the referring gastroenterologist
11648055|NCT00024635||Adult Healthy Volunteers|Adult Healthy Volunteers
11648056|NCT00024635||Adult Patients|Adult patients with mood and anxiety disorders
11648057|NCT00024635||Minor Healthy Volunteers|Minor Healthy Volunteers
11648058|NCT00024635||Minor Patients|Minor patients with mood and anxiety disorders
11648059|NCT00024635||Parents of Minor Healthy Volunteers|Parents and guardians of minor healthy volunteers
11648060|NCT00024635||Parents of Minor Patients|Parents and guardians of minor patients with mood and anxiety disorders
11648061|NCT00109421|Experimental|Experimental arm|In the experimental condition, the intervention group will receive the half-day Project ÒRÉ intervention. All participants will complete pre-, post- and 3-month follow-up self-administered questionnaires. A subset of groups will participate in a process evaluation focus group immediately following the program.
11648062|NCT00109421|No Intervention|Attention control group|The attention control group will receive a standard health promotion control program which has been used previously with similar populations. All participants will complete pre-, post- and 3-month follow-up self-administered questionnaires.
11648063|NCT00109408|Experimental|1|
11648064|NCT00109408|Active Comparator|2|
11648065|NCT00109395|Active Comparator|Lorazepam Intermittent bolus|lorazepam administered by intermittent bolus
11648066|NCT00109395|Active Comparator|lorazepam continuous infusion|lorazepam administered by continuous infusion
11648067|NCT00109395|Active Comparator|midazolam continous infusion|midazolam administered by continous infusion
11648068|NCT00109369|Experimental|Active|Provider and patient receive Diabetes Information System services
11648069|NCT00109369|No Intervention|Control|Usual Care
11648070|NCT00109343|Experimental|1|Group 1: ProQuad™ (V221) + PREVNAR™ (pneumococcal 7-valent conjugate vaccine) followed by ProQuad™ (Day 91)
11648071|NCT00109343|Experimental|2|Group 2: PREVNAR™ followed by ProQuad™ (Day 43) followed by ProQuad™ (Day 133)
11648072|NCT00109343|Experimental|3|Group 3: ProQuad™ followed by PREVNAR™ (Day 43), followed by ProQuad™ (Day 91)
11648073|NCT00109291|Placebo Comparator|Placebo|Single injection of placebo administered intravenously
11648074|NCT00109291|Experimental|Peginesatide 0.025 mg/kg|Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.
11648075|NCT00109291|Experimental|Peginesatide 0.05 mg/kg|Single peginesatide dose of 0.05 mg/kg administered intravenously.
11648076|NCT00109291|Experimental|Peginesatide 0.10 mg/kg|Single peginesatide dose of 0.10 mg/kg administered intravenously.
11648077|NCT00109213|Active Comparator|1|Lumbar Laminectomy without Fusion
11648078|NCT00109213|Active Comparator|2|Lumbar Laminectomy with Pedicle Screw Instrumented Fusion
11648079|NCT00109174|Other|One arm|Subjects receive the same test
11648080|NCT00109031|Active Comparator|Palifermin 60 µg/kg for 3 days|Palifermin 60 µg/kg plus placebo to match the total volume equivalent to a 180 µg/kg dose on the 3 days prior to fractionated total body irradiation (fTBI) and palifermin 60 µg/kg on Days 0, 1 and 2 after peripheral blood progenitor cell transplantation (PBPC). Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
11648081|NCT00109031|Experimental|Palifermin 180 μg/kg on Day -1|Palifermin 180 μg/kg on Day -1 and matched placebo on Days -2 and -3 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC. Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
11648082|NCT00109031|Experimental|Palifermin 180 μg/kg on Day -2|Palifermin 180 μg/kg on Day -2 and placebo on Days -1 and -3 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC. Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
11648083|NCT00109031|Experimental|Palifermin 180 μg/kg on Day -3|Palifermin 180 μg/kg on Day -3 and placebo on Days -1 and -2 prior to fTBI, and palifermin 60 μg/kg on Days 0, 1, and 2 after PBPC. Participants also received conditioning therapy with fTBI and cyclophosphamide/etoposide prior to PBPC transplantation on Day 0.
11648084|NCT00109005|Experimental|Cohort 1 - 25 mg lenalidomide (Revlimid)|oral dose (1 capsule) lenalidomide 25 mg per day 7 days a week for 3 weeks
11648085|NCT00109005|Experimental|Cohort 2 - 5 mg lenalidomide (Revlimid)|oral dose (1 capsule) lenalidomide 5 mg per day 7 days a week for 3 weeks
11648086|NCT00108953|Experimental|Sorafenib + Doxorubicin|"Sorafenib + Doxorubicin -- combination therapy: Sorafenib (Nexavar, BAY43-9006) 200 mg tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)"
11648087|NCT00108953|Active Comparator|Placebo + Doxorubicin|"Placebo + Doxorubicin -- monotherapy: Sorafenib (Nexavar, BAY43-9006) matching placebo tablets by mouth (orally) twice daily + doxorubicin 60 mg/m2 intravenous infusion every 21 days for 6 cycles (18 weeks)"
11648088|NCT00108901|No Intervention|Control|Children were not provided with an after-school exercise intervention. They were free to do their usual activities. Families were offered a monthly healthy lifestyle class.
11648089|NCT00108901|Experimental|Low Dose|This group was assigned to receive a 20 min/day aerobic exercise program offered 5 days/week after school. Families were offered a monthly healthy lifestyle class.
11648090|NCT00108901|Experimental|High dose|This group was assigned to receive a 40 min/day aerobic exercise program offered 5 days/week after school. Families were offered a monthly healthy lifestyle class.
11648091|NCT00108862|Experimental|Immediate ART|The intervention is the strategy of initiating antiretroviral therapy (ART) after approximately 2 weeks of tuberculosis (TB) treatment.
11648092|NCT00108862|Active Comparator|Deferred ART|The intervention is the strategy of initiating ART after 8 to 12 weeks of TB treatment.
11648093|NCT00108810|Experimental|Transdermal Ketoprofen Patch with CHADD|
11648094|NCT00108810|Placebo Comparator|Placebo patch and a dummy heating unit|
11648618|NCT00101712|Experimental|Vildagliptin|
11648095|NCT00108771|Experimental|ZR-02-01 matrix fentanyl Patch|ZR-02-01 matrix fentanyl patch
11648096|NCT00108771|Placebo Comparator|Placebo Patch|
11648097|NCT00108745|Experimental|Arm I (paclitaxel poliglumex)|Patients receive polyglutamate paclitaxel IV over 10-20 minutes on day 1.Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11648098|NCT00108745|Active Comparator|Arm II (paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11648099|NCT00108745|Other|Arm III (observation)|Patients receive no further anticancer treatment until evidence of disease progression.
11648100|NCT00108732|Experimental|Treatment (vaccine therapy)|"Patients receive vaccinia-PSA-TRICOM vaccine SC on day 1 and sargramostim (GM-CSF) SC on days 1-4 during weeks 1-4. Beginning in week 5, patients receive fowlpox-PSA-TRICOM vaccine SC on day 1 and GM-CSF SC on days 1-4. Treatment with fowlpox-PSA-TRICOM vaccine and GM-CSF repeats every 4 weeks for 3 courses (weeks 5-16). Beginning in week 17, patients receive fowlpox-PSA-TRICOM vaccine and GM-CSF as above every 12 weeks in the absence of clinical or biochemical disease progression or unacceptable toxicity.
~Patients with biochemical or clinical disease progression receive androgen ablation therapy comprising oral bicalutamide once daily for 1 month and goserelin SC once every 4 weeks in addition to fowlpox-PSA-TRICOM vaccine and GM-CSF. Treatment continues in the absence of further clinical or biochemical disease progression."
11648101|NCT00108628|Experimental|Arm 1|Imagery Rehearsal Therapy
11648102|NCT00108628|Active Comparator|Arm 2|Sleep and Nightmare Management
11648103|NCT00108615|Experimental|1|pioglitazone
11648104|NCT00108615|Active Comparator|2|metformin
11648105|NCT00108602|Other|1|
11648106|NCT00108576|Placebo Comparator|Arm 1|Look-a-like placebo
11648107|NCT00108576|Experimental|Arm 2|Divalproex
11648108|NCT00108550|Experimental|1|Gabapentin 300 mg orally three times daily up to a maximum of 1200 mg orally three times daily for 12 weeks
11648109|NCT00108550|Sham Comparator|2|Inert placebo capsules identical in size and shape to the experimental capsules, one to three capsules taken orally three times daily for 12 weeks
11648110|NCT00108524|Experimental|Low Carbohydrate Ketogenic Diet|Participants receive dietary counseling over 48 weeks aimed at helping them to lower starch and sugar intake.
11648111|NCT00108524|Active Comparator|Low-Fat Diet plus Orlistat|Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake, and additionally receive Orlistat taken 3 times daily.
11648112|NCT00108485|Active Comparator|Extended release niacin|Extended release niacin 1500-2000 mg daily versus placebo comparator
11648113|NCT00108485|Placebo Comparator|Placebo|Placebo tablets
11648114|NCT00108407|Experimental|1|Integrated Cognitive Behavioral Therapy
11648115|NCT00108407|Experimental|2|Twelve Step Facilitation Therapy
11648116|NCT00108381|Experimental|Arm 1|Standard and Tailored Conditions
11648117|NCT00108355|Active Comparator|Albumin (Control group)|"After LVP, patients in this group received:
~Intravenous albumin (25%) at 8 g/liter of ascitic fluid removed, one time dose; Intramuscular injection of 5 cc saline (Octreotide LAR placebo), every 30 days ; Oral tablet 3 times a day (Midodrine placebo)"
11648118|NCT00108355|Experimental|Vasoconstrictor (Study Group)|"After LVP, patients in this group received:
~Octreotide LAR intramuscular injection 20 mg, every 30 days; Midodrine tablet, 10 mg three times a day; Intravenous saline infusion (Albumin placebo), one time dose"
11648119|NCT00108342|Active Comparator|Nicotine Replacement Treatment (NRT) Sampling|"Sampling = 3 minute testing of each of 6 NRTs (3 forms x 2 dosages)
~2 mg and 4 mg nicotine gum; 2 mg and 4 mg nicotine lozenges; frequent and infrequent puffing on a nicotine inhaler (can yield 4 mg from 10 mg device)."
11648120|NCT00108342|Sham Comparator|NRT Computer Learning|Computer learning: learning about 6 NRTs (3 forms x 2 dosages) by computer only
11648121|NCT00108316|Other|Arm 1|
11648122|NCT00108303||Diagnostic|A diagnostic was performed
11648123|NCT00108277|Experimental|Raise CO2|Raise CO2 - biofeedback-assisted breathing training to raise baseline pCO2
11648124|NCT00108277|Active Comparator|Lower CO2|Lower CO2 - biofeedback-assisted breathing training to lower baseline pCO2
11648125|NCT00108277|No Intervention|Waitlist|Waitlist - treatment as usual
11648126|NCT00108251|Placebo Comparator|1|placebo tablet
11648127|NCT00108251|Experimental|2|eplerenone tablets
11648128|NCT00108225|Active Comparator|Arm 1|30% carbohydrate, 30% protein, 40% fat
11648129|NCT00108225|Placebo Comparator|Arm 2|55% carbohydrate, 15% protein, 30% fat
11648130|NCT00108186|Other|Arm 1|Celecoxib is an FDA approved drug for other indications such as osteoarthritis. It is not FDA approved for non-small cell lung cancer.
11648131|NCT00108173|Other|Arm 1|
11648132|NCT00108160|Active Comparator|Mupirocin Ointment [Treatment]|Treatment arm or active comparator [mupirocin 2% polyethylene glycol (PEG) ointment] will be compared with its placebo comparator [polyethylene glycol (PEF) in patients with a prior history of S. aureus infection. Drug or placebo will be applied topically to nares and/or wounds twice daily for 14 days at 3 month intervals for up to 18 months
11648133|NCT00108160|Placebo Comparator|Polyethylene Glycol Ointment [Placebo]|Treatment arm or active comparator [mupirocin 2% polyethylene glycol (PEG) ointment] will be compared with its placebo comparator [polyethylene glycol (PEF) in patients with a prior history of S. aureus infection. Drug or placebo will be applied topically to nares and/or wounds twice daily for 14 days at 3 month intervals for up to 18 months
11648134|NCT00108147|Experimental|1|Circuit Training
11648135|NCT00108147|Active Comparator|2|Cardiac Rehabilitation
11648136|NCT00108147|Active Comparator|3|Flexibility and toning
11648137|NCT00108108|Experimental|HCD122|
11648138|NCT00108082|Experimental|Carvedilol CR|Carvedilol controlled release (CR) 20 to 80 mg once daily (OD) plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study. (In the protocol, carvedilol CR was referred to as carvedilol modified-release [MR].)
11648139|NCT00108082|Experimental|Atenolol|Atenolol 50 to 100 mg OD plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study.
11648140|NCT00108082|Experimental|Lisinopril|Lisinopril 10 to 40 mg OD plus lisinopril 20 mg OD. Participants were titrated from the starting dosage to higher dosages until their blood pressure was controlled. Participants continued to receive lisinopril 20 mg OD throughout the study.
11648141|NCT00108069|Experimental|GBM (Glioblastoma multiforme)|
11648142|NCT00108069|Experimental|AG (Anaplastic glioma)|
11648143|NCT00108004|Experimental|Pramlintide|"Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection.
~It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43-mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative"
11648144|NCT00107991|Experimental|Treatment arm|Open-label treatment with etanercept 50 mg/week subcutaneous injection
11648145|NCT00107978|Experimental|Telavancin|
11648146|NCT00107978|Active Comparator|Vancomycin|
11648147|NCT00107965|Experimental|1|
11648148|NCT00107965|Experimental|2|
11648149|NCT00107965|Experimental|3|
11648150|NCT00107965|Placebo Comparator|4|
11648151|NCT00107965|Experimental|5|
11648152|NCT00107965|Experimental|6|
11648153|NCT00107965|Experimental|7|
11648154|NCT00107965|Placebo Comparator|8|
11648155|NCT00107952|Experimental|Telavancin|
11648156|NCT00107952|Active Comparator|Vancomycin|
11648157|NCT00107926|Experimental|licarbazepine|
11648158|NCT00107926|Placebo Comparator|Placebo|
11648159|NCT00107900|Experimental|15mg BID|15mg edoxaban administered twice daily (BID)
11648160|NCT00107900|Experimental|30mg QD|30mg edoxaban administered once daily (QD)
11648161|NCT00107900|Experimental|30mg BID|30mg edoxaban administered twice daily (BID)
11648162|NCT00107900|Experimental|60mg QD|60mg edoxaban administered once daily (QD)
11648163|NCT00107900|Experimental|60mg BID|60mg edoxaban administered twice daily (BID)
11648164|NCT00107900|Experimental|120mg QD|120mg edoxaban administered once daily (QD)
11648165|NCT00107887|No Intervention|1|Subjects in clinics that have not received the intervention
11648166|NCT00107887|Experimental|2|Subjects at clinics that have received the intervention
11648167|NCT00107835|Experimental|S-Caine Peel|
11648168|NCT00107783|No Intervention|Control|No treatment
11648169|NCT00107783|Experimental|Nitisinone-treated|Subjects received nitisinone 2 mg orally, once daily.
11648170|NCT00107770|Other|1|ALS patient
11648171|NCT00107744|Active Comparator|Soy protein-milk protein-carbohydrate|Participants received 40 grams of soy protein daily for 8 weeks, 40 grams of milk protein daily for 8 weeks, and 40 grams of carbohydrate daily for 8 weeks.
11648172|NCT00107744|Active Comparator|Milk protein-carbohydrate-soy protein|Participants received 40 grams of milk protein daily for 8 weeks, 40 grams of carbohydrate daily for 8 weeks, and 40 grams of soy protein daily for 8 weeks.
11648173|NCT00107744|Active Comparator|Carbohydrate-soy protein-milk protein|Participants received 40 grams of complex carbohydrate daily for 8 weeks, 40 grams of soy protein daily for 8 weeks, and 40 grams of milk protein daily for 8 weeks.
11648174|NCT00107653|Experimental|Latino|Participants received peginterferon alfa-2a 180 microgram (mcg)/0.5 mL by subcutaneous injection once a week in combination with ribavirin 1000 or 1200 mg per day, which was taken orally in split doses for 48 weeks. Participants with <75 kg (165 lbs) of body weight received 1000 mg/day (400 mg in the morning and 600 mg in the evening). Participants with >=75 kg (165 lbs) of body weight received 1200 mg/day (600 mg in the morning and 600 mg in the evening).
11648175|NCT00107653|Experimental|Non-Latino White|Participants received peginterferon alfa-2a 180 mcg/0.5 mL by subcutaneous injection once a week in combination with ribavirin 1000 or 1200 mg per day which was taken orally in split doses. Participants with <75 kg (165 lbs) of body weight received 1000 mg/day. Participants with >=75 kg (165 lbs) of body weight received 1200 mg/day for 48 weeks.
11648176|NCT00107640|No Intervention|Usual care|Patients not assigned to the experimental condition received usual care, which may or may not have included alcohol education.
11648177|NCT00107640|Experimental|Patient-provider education|Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
11648178|NCT00107627|Active Comparator|1|Skin staples;
11648179|NCT00107627|Active Comparator|2|Monocryl subcuticular sutures.
11648180|NCT00107627|Active Comparator|3|Caprosyn subcuticular sutures.
11648181|NCT00107614|Experimental|DT PACE/auto transplant/maint therapy|
11648182|NCT00107588|Experimental|Reinforcement for homework completion|
11648183|NCT00107588|Active Comparator|Reinforcement for Abstinence|
11648184|NCT00107588|Active Comparator|Case Management|
11648185|NCT00107575|Active Comparator|Standard treatment (ST)|Standard smoking cessation treatment (ST)
11648186|NCT00107575|Experimental|ST-BI|Standard treatment plus a brief alcohol intervention
11648187|NCT00107562|Experimental|Intervention|The cohort will be comprised of up to 4 index participants and from 1-4 of their network members for a possible range of 8-16 subjects in each cohort (average of 12 per cohort). The vast majority of the intervention will be delivered to both females and males together, but it would be beneficial, and appropriate for this adolescent population, to deliver certain exercises with the two genders separated.
11648188|NCT00107549|Experimental|1|All participants in this study will receive two injections of the rMVA-HIV vaccine and the rFPV-HIV vaccine
11648189|NCT00107536|Experimental|Arm I|Patients receive oral lapatinib ditosylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648190|NCT00107510|Experimental|docetaxel + carboplatin + pegfilgrastim + surgery|"Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Patients also receive pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~No more than 6 weeks after completion of chemotherapy, patients undergo definitive surgery.
~After completion of study therapy, patients are followed every 6 months until disease progression and then annually for up to 5 years. Patients who do not complete all 4 courses of chemotherapy or do not undergo surgery are followed every 6 months for up to 5 years."
11648191|NCT00107497|Active Comparator|Control|50Gy in 25 fractions of radiation therapy over 5 weeks
11648192|NCT00107497|Active Comparator|Test group 1|30Gy in 5 fractions of radiation therapy over 5 weeks
11648193|NCT00107497|Active Comparator|Test group 2|28.5Gy in 5 fractions of radiation therapy over 5 weeks
11648194|NCT00107471|Experimental|Dose Level I (0.5 mg/m^2)|Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n)
11648195|NCT00107471|Experimental|Dose Level 2 (0.6 mg/m^2)|Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n.)
11648196|NCT00107458|Experimental|Treatment 1|VPA Target Trough Concentration 75-100 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid
11648197|NCT00107458|Experimental|Treatment 10|VPA Target Trough Concentration 100-150 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid
11648198|NCT00107458|Experimental|Treatment 20|VPA Target Trough Concentration 150-200 mcg/mL
11648199|NCT00107445|Experimental|Treatment (EF5)|Patients receive EF5 IV over 1-2½ hours on day 1. Approximately 1-2 days later, patients undergo tumor resection or biopsy. Patients' tumor tissue samples undergo immunohistochemistry and flow cytometry to detect EF5 binding levels. Patients' blood is drawn immediately before and 30-60 minutes and 1-2 days after receiving EF5 to measure systemic EF5 binding levels.
11648200|NCT00107432|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648201|NCT00107419|Experimental|pemetrexed|pemetrexed
11648202|NCT00107380|Experimental|R-CHOP x 8 with I-131 Tositumomab|"Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 IV Day 1 Prednisone 100 mg PO Days 1-5 Rituximab 375 mg/m2 IV Day 1 Q 21 Days x 6 cycles
~Unlabeled Anti-B1 Antibody 450 mg IV Day 170 Dosimetric dose 35 mg IV Day 170
~Unlabeled Anti-B1 Antibody 450 mg IV Day 177 Therapeutic dose 35 mg IV Day 177"
11648203|NCT00107341|Experimental|bortezomib + paclitaxel + carboplatin|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, and 8 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years."
11648204|NCT00107315|Experimental|Arm 1|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral capecitabine twice daily on days 1-7
11648205|NCT00107289|Experimental|Radiation|
11648206|NCT00107276|Experimental|cyclophosphamide and capecitabine|cyclophosphamide orally days 1-14 and capecitabine orally days 15-21 for 8 cycles of 21 days each
11648207|NCT00107263|Experimental|Arm I: letrozole + zoledronate|"Patients receive oral letrozole once daily. Patients also receive zoledronate IV over 15 minutes once every 6 months.
~Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity."
11648208|NCT00107263|Experimental|Arm II: letrozole + zoledronate|"Patients receive oral letrozole once daily. Patients with radiologic evidence of bone loss after 1 year of letrozole therapy receive zoledronate as in arm I.
~Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity."
11648209|NCT00107250|Experimental|AZD2171 + Standard chemotherpay regimens|
11648210|NCT00107237|Experimental|AEE788 200 mg + RAD001 5 mg|AEE788 200 mg qd, RAD001 5 mg qd
11648211|NCT00107237|Experimental|AEE788 150 mg + RAD001 5mg|AEE788 150 mg qd, RAD001 5 mg qod
11648212|NCT00107198|Experimental|Surgery or combination chemotherapy, with/without radiotherapy|"Patients receive doxorubicin hydrochloride 50 mg/m2 IV over 10-30 minutes and cyclophosphamide 800 mg/mg2 IV over 1 hour on day 1, vincristine sulfate 1.4 mg/m2 IV (2.8 mg maximum) over 1 minute on days 1 and 8, and prednisone 40 mg/m2/day PO or IV two or three times daily on days 1-7. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve CR after 3 courses of therapy proceed to follow-up. Patients who do not achieve a CR proceed to involved-field radiation therapy (IFRT).
~IFRT: Beginning within 3 weeks after completion of combination chemotherapy, patients undergo IFRT once daily, 5 days a week for 2.8 weeks (14 treatments)."
11648213|NCT00107185|Experimental|Vaccine|
11648214|NCT00107172|Active Comparator|Arm I|Patients undergo open or thoracoscopic sublobar resection comprising either a wedge resection or anatomical segmentectomy.
11648215|NCT00107172|Experimental|Arm II|Patients undergo surgery as in arm I. Patients also undergo intraoperative brachytherapy comprising an iodine I 125 implant at the resection margin.
11648216|NCT00107120|Experimental|Escitalopram|Escitalopram 10mg once daily for three weeks, 10-20mg once daily for up to the remaining 5 weeks
11648217|NCT00107120|Placebo Comparator|2|Placebo once daily for up to 8 weeks
11648218|NCT00107107|Active Comparator|Pramlintide Acetate|Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
11648219|NCT00107081|Active Comparator|Standard|Continued inpatient i.v. antibiotics
11648220|NCT00107081|Experimental|Experimental|Switch to outpatient p.o. antibiotics
11648221|NCT00107042|Active Comparator|1|Participants receive doses of Recombivax at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.
11648222|NCT00107042|Experimental|2|Participants receive doses of Twinrix at weeks 0 and 24. A risk-behavior assessment is administered at week 12 and post-vaccination follow-up visits and bloodwork occur at weeks 28 and 76.
11648223|NCT00107016|Experimental|RAD001 + letrozole 2.5mg|
11648224|NCT00107016|Active Comparator|Letrozole 2.5mg|
11648225|NCT00106977||Family|Family members (typically parents or siblings) of probands with Muenke syndrome are alsoeligible to participate.
11648226|NCT00106977||Patient|Subjects who have had confirmation of a p. Pro250Arg mutation in FGFR3 by a CLIA-certified laboratory.
11648227|NCT00106964|Active Comparator|1|Standard dose (20 mcg) of Hepatitis B vaccine.
11648228|NCT00106964|Active Comparator|2|40 mcg of Hepatitis B vaccine
11648229|NCT00106964|Active Comparator|3|20 mgc of Twinrix
11648230|NCT00106938|Active Comparator|1|"CAS group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
~Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years."
11648231|NCT00106938|Active Comparator|2|"CEA group: 3:1 ratio of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA).
~Subjects will be followed at 30 days, six (6), and 12 months post-procedure, and annually for four (4) additional years."
11648232|NCT00106925||1|Patients (when applicable) will be co accrued to this protocol once they have survived a minimum of three years from date of transplant.
11648233|NCT00106925||Donors|Donors (when applicable) will be co accrued to this protocol once they have survived a minimum of three years from date of transplant.
11648234|NCT00106899||1|Mild Cognitive Impairment (MCI); scans performed at screening/baseline, 6, 12, 18, 24, and 36 months
11648235|NCT00106899||2|Early Alzheimer's disease (AD); scans performed at screening/baseline, 6, 12, and 24 months
11648236|NCT00106899||3|Unaffected/normal controls; scans performed at baseline/screening, 6, 12, 24, and 36 months
11648237|NCT00106782|Other|1|Real TEP
11648238|NCT00106782|Other|2|Sham Stimulation
11648239|NCT00106704|Experimental|Sitagliptin|Sitagliptin 10 mg tablet daily for 54 weeks
11648240|NCT00106704|Placebo Comparator|Placebo/ Pioglitazone|Placebo tablet daily for 24 weeks followed by Pioglitazone tablet daily for 30 weeks
11648241|NCT00106691|Experimental|toremifene 20mg|
11648242|NCT00106691|Placebo Comparator|Placebo|
11648243|NCT00106678||Infected through risk behaviors|
11648244|NCT00106678||Infected perinatally or through blood/blood products.|
11648245|NCT00106639|Experimental|CP-690,550 15 mg BID|
11648246|NCT00106639|Experimental|CP-690,550 30 mg BID|
11648247|NCT00106639|Active Comparator|tacrolimus|
11648248|NCT00106626|Experimental|1|vorinostat (Suberoylanilide Hydroxamic Acid [SAHA])
11648249|NCT00106613|Experimental|FK228 (romidepsin)|13 mg/m2 of romidepsin
11648250|NCT00106574|Experimental|1|
11648251|NCT00106574|Placebo Comparator|2|
11648252|NCT00106548|Experimental|1|
11648253|NCT00106548|Experimental|2|
11648254|NCT00106548|Placebo Comparator|3|
11648255|NCT00106535|Experimental|Tocilizumab 4 mg/kg + Methotrexate|Tocilizumab 4 mg/kg IV every 4 weeks plus MTX 10-25 mg (oral or parenteral) weekly for 52 weeks. From Week 16 participants with < 20% improvement in swollen and tender joints counts were eligible for escape therapy with tocilizumab. After Week 52 participants were able to switch to open label treatment with tocilizumab 8 mg/kg every 4 weeks for 12 months in year 2 (except patients who had a >70% improvement in both swollen and tender joint counts who remained on blinded treatment). Participants who completed year 2 of the study were eligible to enter an optional open-label long-term extension period (Year 3 to 5) and received Tocilizumab 8 mg/kg every 4 weeks.
11648256|NCT00106535|Experimental|Tocilizumab 8 mg/kg + Methotrexate|Tocilizumab 8 mg/kg IV every 4 weeks plus MTX 10-25 mg (oral or parenteral) weekly for 52 weeks. From Week 16 participants with < 20% improvement in swollen and tender joints counts were eligible for escape therapy with tocilizumab. After Week 52 participants were able to switch to open label treatment with tocilizumab 8 mg/kg every 4 weeks for 12 months in year 2 (except patients who had a >70% improvement in both swollen and tender joint counts who remained on blinded treatment). Participants who completed year 2 of the study were eligible to enter an optional open-label long-term extension period (Year 3 to 5) and received Tocilizumab 8 mg/kg every 4 weeks.
11648257|NCT00106535|Placebo Comparator|Placebo + Methotrexate|Placebo intravenously (IV) every 4 weeks plus methotrexate (MTX) 10-25 mg (oral or parenteral) weekly for 52 weeks. From Week 16 participants with < 20% improvement in swollen and tender joints counts were eligible for escape therapy with tocilizumab. After Week 52 participants were able to switch to open label treatment with tocilizumab 8 mg/kg every 4 weeks for 12 months in year 2 (except patients who had a >70% improvement in both swollen and tender joint counts who remained on blinded treatment). Participants who completed year 2 of the study were eligible to enter an optional open-label long-term extension period (Year 3 to 5) and received Tocilizumab 8 mg/kg every 4 weeks.
11648258|NCT00106522|Experimental|1|
11648259|NCT00106522|Experimental|2|
11648260|NCT00106522|Placebo Comparator|3|
11648261|NCT00106496|Experimental|1A|
11648262|NCT00106496|Active Comparator|1B|
11648263|NCT00106496|Experimental|2|Open label
11648264|NCT00106496|Experimental|3A|
11648265|NCT00106496|Placebo Comparator|3B|
11648266|NCT00106496|Experimental|4|Open label
11648267|NCT00106483||Coronary Artery Risk Development in Young Adults|There were no interventions.
11648268|NCT00106418|Experimental|Romidepsin|13 mg/m^2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
11648269|NCT00106392|Experimental|Tacrolimus|Preoperatively: Tacrolimus 2 mg oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Tacrolimus 3 mg oral daily at time of hospital discharge through 6 months of follow up.
11648270|NCT00106392|Placebo Comparator|Placebo|Preoperatively: Matching placebo oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Matching placebo oral daily at time of hospital discharge through 6 months of follow up.
11648271|NCT00106353|Experimental|1.0|
11648272|NCT00106340|Experimental|Vildagliptin|
11648273|NCT00106340|Active Comparator|Glimepiride|
11648274|NCT00106327|Experimental|1|6-month supervised treadmill exercise program
11648275|NCT00106327|Experimental|2|6-month supervised lower extremity progressive resistance training program
11648276|NCT00106327|Active Comparator|3|Diet/nutrition control group
11648277|NCT00106301|Experimental|FK228 (romidepsin)|romidepsin
11648278|NCT00106288|Experimental|1|
11648279|NCT00106288|Active Comparator|2|
11648280|NCT00106249|Active Comparator|Active rTMS|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
11648281|NCT00106249|Sham Comparator|Sham rTMS|Placebo Repetitive Transcranial Magnetic Stimulation (rTMS)
11648282|NCT00106223|Experimental|1|Group receiving immediate treatment with cognitive behavioral therapy
11648283|NCT00106223|Active Comparator|2|Waitlist control group to begin CBT 3 months after other CBT group begins treatment
11648284|NCT00106210|Experimental|1|Behavioral Intervention (experimental)
11648285|NCT00106210|Active Comparator|2|Behavioral Intervention 2
11648286|NCT00106197|Experimental|1|Participants will receive bupropion in the sleep study
11648619|NCT00101712|Placebo Comparator|Placebo|
11648287|NCT00106184|Experimental|Adult Study Group 1|Refractory adult polymyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
11648288|NCT00106184|Experimental|Adult Study Group 2|Refractory adult polymyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
11648289|NCT00106184|Experimental|Adult Study Group 3|Adult dermatomyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
11648290|NCT00106184|Experimental|Adult Study Group 4|Adult dermatomyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
11648291|NCT00106184|Experimental|JDM Study Group 1|Refractory juvenile dermatomyositis patients who will receive rituximab at Weeks 0 and 1 followed by placebo at Weeks 8 and 9 (Treatment Group A)
11648292|NCT00106184|Experimental|JDM Study Group 2|Refractory juvenile dermatomyositis patients who will receive placebo at Weeks 0 and 1 followed by rituximab at Weeks 8 and 9 (Treatment Group B)
11648293|NCT00106171|Experimental|1|Participants will receive HAART for 1 year
11648294|NCT00106171|No Intervention|2|Participants will receive no treatment
11648295|NCT00106145|Experimental|Part I - Arm 1|
11648296|NCT00106145|Experimental|Part II - Arm 1|
11648297|NCT00106145|Experimental|Part III - Arm 1|
11648298|NCT00106145|Experimental|Part IV - Arm 1|
11648299|NCT00106145|Experimental|Part V - Arm 1|
11648300|NCT00106119|Active Comparator|Liothyronine and Levothyroxine|Hypothyroid patients treatment with Levothyroxine and Liothyronine in 2 crossover, randomized phases
11648301|NCT00106106|Placebo Comparator|Placebo|For subjects randomized to placebo control, placebo doses were given every 8 hours.
11648302|NCT00106106|Experimental|Acamprosate|For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
11648303|NCT00106080|Experimental|Intervention|Audit and Feedback
11648304|NCT00106080|No Intervention|Control|Usual care
11648305|NCT00106067|Experimental|Arm 1|In the intervention arm, Patients and their family caregivers have access to a coping and communication support practitioner (CCSP) (see intervention description) in addition to receiving the usual care in the site.
11648306|NCT00106067|No Intervention|Arm 2|In the control arm, Patients are receiving the usual care in the site.
11648307|NCT00106041|Other|Arm 1|Palliative Care Nurse Case Management
11648308|NCT00106028|Placebo Comparator|Placebo Daily|placebo tablet, once a day for one year then for two years open label risedronate
11648309|NCT00106028|Experimental|Risedronate Daily|risedronate tablet, once a day for one year then for two years open label risedronate once a day
11648310|NCT00106002|Experimental|A|
11648311|NCT00105989|Experimental|A|duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by duloxetine 60-120 mg QD, PO for up to 54 weeks
11648312|NCT00105989|Placebo Comparator|B|duloxetine 60-120 mg every day (QD), by mouth (PO) for 34 weeks followed by placebo QD, PO for up to 54 weeks
11648313|NCT00105950|Experimental|Lapatinib|Single arm study of lapatinib with no comparator arm.
11648314|NCT00105911|Other|Arm 1|
11648315|NCT00105898|Experimental|Arm 1|Intervention group
11648316|NCT00105898|Active Comparator|Arm 2|Comparator
11648317|NCT00105898|Sham Comparator|Arm 3|Comparator
11648318|NCT00105885|Experimental|Arm 1|Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinical visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval.
11648319|NCT00105885|No Intervention|Arm 2|Patients randomized to receive routine care will be scheduled to see their psychiatric medication provider at the recommended interval.
11648320|NCT00105872|Other|Arm 1|
11648321|NCT00105859|Other|1|
11648322|NCT00105846|Other|Arm 1|
11648323|NCT00105833|Experimental|Arm 1|Multifaceted collaborative intervention for depression based in primary care
11648324|NCT00105833|No Intervention|Arm 2|Treatment as usual
11648325|NCT00105820|Other|Arm 1|
11648326|NCT00105807|Other|Arm 1|
11648327|NCT00105794|Other|Arm 1|
11648328|NCT00105781|Other|Arm 1|
11648329|NCT00105768|Other|Arm 1|
11648330|NCT00105755|Other|Arm 1|
11648331|NCT00105742|Other|Arm 1|
11648332|NCT00105729|Other|Arm 1|
11648333|NCT00105716|Other|Arm 1|
11648334|NCT00105703|Other|Arm 1|
11648335|NCT00105690|Other|Arm 1|
11648336|NCT00105677||Group 1|
11648337|NCT00105664|Other|Arm 1|
11648338|NCT00105651|Other|Arm 1|
11648339|NCT00105638|Other|Arm 1|
11648340|NCT00105625||Group 1|
11648341|NCT00105599|Other|Arm 1|
11648342|NCT00105586|Experimental|Escitalopram (1)|Escitalopram
11648343|NCT00105586|Placebo Comparator|Placebo (2)|Placebo
11648344|NCT00105573|Experimental|Interpersonal Psychotherapy|Participants will receive interpersonal psychotherapy for depression.
11648345|NCT00105573|Experimental|Interpersonal psychotherapy/child-parent psychotherapy|Participants will receive interpersonal psychotherapy for depression plus 1 year of in-home, child-parent psychotherapy.
11648346|NCT00105573|Active Comparator|Enhanced community standard|Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
11648347|NCT00105560|Experimental|Radiation therapy|This is a single arm study of radiation therapy with protons to standard doses.
11648348|NCT00105547|Experimental|1|800 mg BID
11648349|NCT00105547|Placebo Comparator|2|BID dosing
11648350|NCT00105534|Experimental|AzaSite|
11648351|NCT00105534|Sham Comparator|Vehicle|
11648352|NCT00105521|Placebo Comparator|Placebo|Participants will receive placebo matched to sarizotan tablet orally twice daily up to Week 12.
11648353|NCT00105521|Experimental|Sarizotan 2 milligrams per day (mg/day)|Participants will receive sarizotan 2 milligrams (mg) per day (given in 2 divided daily doses) up to Week 12.
11648354|NCT00105521|Experimental|Sarizotan 4 mg/day|Participants will receive sarizotan 4 mg/day (given in 2 divided daily doses) up to Week 12.
11648355|NCT00105521|Experimental|Sarizotan 10 mg/day|Participants will receive sarizotan 10 mg/day (given in 2 divided daily doses) up to Week 12.
11648356|NCT00105508|Experimental|Sarizotan|
11648357|NCT00105508|Placebo Comparator|Placebo|
11648358|NCT00105482|Experimental|Naltrexone, Transdermal Nicotine|Arm 1 (Experimental) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Naltrexone 25 mg oral capsule once per day
11648359|NCT00105482|Placebo Comparator|Placebo Naltrexone, Transdermal Nicotine|Arm 2 (Placebo Comparator) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Placebo Naltrexone 25 mg oral capsule once per day
11648360|NCT00105469|Experimental|AzaSite|1.0% azithromycin in DuraSite
11648361|NCT00105469|Active Comparator|Tobramycin|0.3% tobramycin
11648362|NCT00105443|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.
11648363|NCT00105443|Placebo Comparator|Placebo|Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.
11648364|NCT00105365|Placebo Comparator|walking shoes|walking shoes
11648365|NCT00105365|Experimental|walking shoes + shoe insert|walking shoes + shoe insert
11648366|NCT00105339||Illustration Style Preference Group|Ten participants at each site will be invited to attend a focus group to determine their comfort with and preference for one of four styles of illustration. The same two concepts will be presented in each of the four styles and ratings will be obtained from all participants. Detailed information on why participants rated each of the styles the way they did will also be obtained by reviewing comments on the rating sheets and audiotapes of the groups. Groups will be run by the study coordinator at the Florida and New York sites, and by Dannie Hoffman, protocol coordinator, in Los Angeles, using a focus group script developed by Dr. Murphy.
11648367|NCT00105339||Review of Draft Focus Group|Lori Perez will travel to each site from Westat and conduct Review of Draft Focus Groups with adolescents and young adults (n per site = approximately 10 - 15) to collect final feedback on the adolescent friendly version (present key pieces of the adolescent friendly version and obtain feedback on the wording and the illustrations). Based on the focus group feedback, the research team will finalize the adolescent friendly materials.
11648368|NCT00105339||Comprehension/Recall Assessment|The assessment will be read to the participants to preclude reading problems. Responses will be recorded by the interviewer on the assessment instrument.
11648369|NCT00105235|Experimental|Alemtuzumab|Liver transplant, with two in-patient infused doses of alemtuzumab; followed by maintenance immunotherapy with cyclosporine, mycophenolate mofetil, and/or tacrolimus; with possible immunosuppression withdrawal
11648370|NCT00105196|Experimental|A1|
11648371|NCT00105196|Placebo Comparator|A2|
11648372|NCT00105183|Active Comparator|EZ-2053|Anti-human-T-lymphocyte Immune Globulin, Rabbit (EZ-2053)
11648373|NCT00105183|Placebo Comparator|Placebo|USP 0.9% sodium chloride solution
11648374|NCT00105183|Active Comparator|EZ-2053 5mg/kg|Anti-human-T-Lymphocyte Immune Globulin, Rabbit
11648375|NCT00105157|Experimental|1|MK0518 200 mg
11648376|NCT00105157|Experimental|2|MK0518 400 mg
11648377|NCT00105157|Experimental|3|MK0518 600 mg
11648378|NCT00105157|Placebo Comparator|4|Placebo
11648379|NCT00105144|Experimental|1|lower dose
11648380|NCT00105144|Experimental|2|higher dose
11648381|NCT00105144|Active Comparator|3|
11648382|NCT00105079|Experimental|saquinavir/ritonavir|saquinavir mesylate 1000 mg twice daily (BID) + ritonavir 100 mg BID + emtricitabine/tenofovir disoproxil fumarate 200/300 mg orally every day for 48 weeks.
11648383|NCT00105079|Active Comparator|lopinavir/ritonavir|lopinavir/ritonavir 400/100 mg BID + emtricitabine/tenofovir disoproxil fumarate 200/300 mg orally every day for 48 weeks.
11648384|NCT00105066|Placebo Comparator|Placebo|placebo
11648385|NCT00105066|Experimental|Metformin|Metformin 850 mg twice daily
11648386|NCT00105053|Experimental|vaccine group|
11648387|NCT00105040|Experimental|Levetiracetam (LEV)|Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
11648388|NCT00105040|Placebo Comparator|Matching Placebo (PBO)|Oral tablets and oral solution.
11648389|NCT00105027|Active Comparator|CRVO Observation|
11648390|NCT00105027|Active Comparator|CRVO 1 mg dose triamcinolone acetonide|
11648391|NCT00105027|Active Comparator|CRVO 4 mg dose triamcinolone acetonide|
11648392|NCT00105027|Active Comparator|BRVO standard care|
11648393|NCT00105027|Active Comparator|BRVO 1 mg dose triamcinolone acetonide|
11648394|NCT00105027|Active Comparator|BRVO 4 mg dose triamcinolone acetonide|
11648395|NCT00105001|Active Comparator|Arm I (MMF and tacrolimus)|Patients receive tacrolimus IV or PO every 12 hours on days -3 to 180 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-96 with taper beginning on day 40 in the absence of GVHD.
11648396|NCT00105001|Experimental|Arm II (MMF and tacrolimus alternate schedule)|Patients receive tacrolimus IV or PO every 12 hours on days -3 to 150 with taper beginning on day 100 in the absence of GVHD. Patients also receive MMF PO every 8 hours on days 0-29 and then every 12 hours on days 30-180 with taper beginning on day 150 in the absence of GVHD.
11648397|NCT00105001|Experimental|Arm III (MMF, tacrolimus, and sirolimus)|Patients receive tacrolimus and MMF as in arm II. Patients also receive sirolimus PO once daily on days -3 to 80.
11648398|NCT00104988|Experimental|Thalidomide and Temozolomide|Patients receive oral thalidomide once daily on days 1-56 and temozolomide once daily on days 1-42. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
11648429|NCT00104520|Placebo Comparator|Placebo (pooled two times a day [BID]/three times a day [TID])|
11648399|NCT00104962|Experimental|Treatment (lenalidomide)|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
11648400|NCT00104910|Experimental|Treatment (brachytherapy, radiation, cetuximab, cisplatin)|Patients receive cetuximab IV over 1-2 hours and cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6). Patients also undergo external beam radiotherapy to the para-aortic and pelvic lymph nodes OR whole pelvis once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33 (weeks 1-5). Patients then receive either 1 or 2 applications of low-dose rate brachytherapy in weeks 6-8 OR 5 applications of high-dose rate (HDR)* brachytherapy once weekly in weeks 4-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
11648401|NCT00104884|Experimental|Depsipeptide|Depsipeptide is administered as a 4-hour IV infusion weekly in doses of 13 mg/m^2 for 3 weeks. Repeat cycle every 28 days until unacceptable toxicity or disease progression.
11648402|NCT00104871|Experimental|Bortezomib|Bortezomib 1.3 mg/m^2 intravenous (IV) at over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for at least 4 courses.
11648403|NCT00104858|Experimental|Treatment|"Patients receive a conditioning regimen comprising fludarabine IV on days -4 to -2 and rituximab IV on days -3, 10, 24, and 38.
~Patients undergo single fraction low-dose TBI on day 0. After completion of TBI, patients undergo allogeneic hematopoietic stem cell transplantation on day 0. Patients then receive rituximab IV on days 10, 24, and 38.
~Patients receive an immunosuppressive regimen comprising cyclosporine PO BID on days -3 to 56 followed by a taper to day 180 (related recipients) or on days -3 to 100 followed by a taper to day 180 (unrelated recipients). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related recipients) or TID on days 0-40 followed by a taper to day 96 (unrelated recipients)."
11648404|NCT00104845|Experimental|human gp100 DNA vaccine|Patients receive human gp100 DNA vaccine intramuscularly (IM) once in weeks 1, 4, and 7. Patients then receive mouse gp100 DNA vaccine IM once in weeks 10, 13, and 16.
11648405|NCT00104845|Experimental|mouse gp100 DNA vaccine|Patients receive mouse gp100 DNA vaccine IM once in weeks 1, 4, and 7. Patients then receive human gp100 DNA vaccine IM once in weeks 10, 13, and 16
11648406|NCT00104767|Experimental|celecoxib|
11648407|NCT00104754|Experimental|liposomal SN-38|"Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete or partial response or patients with stable disease (SD) who were previously treated before study enrollment receive up to 4 additional courses of treatment. Patients with CNS-only disease progression receive whole brain radiotherapy (WBRT). After completion of WBRT, these patients also receive up to 4 additional courses of treatment. Patients with disease progression to sites other than the CNS or patients with SD who were previously untreated before study enrollment are removed from the study.
~Quality of life is assessed at baseline, before each treatment course, and then annually for 3 years.
~After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 2 years."
11648408|NCT00104728|Experimental|Neoadjuvant ZD1839 Preoperative Therapy|"The ZD1839 250-mg tablet will be taken once a day, every day about the same time. It can be taken with or without food.
~At the time of surgery, investigators will collect tissue from the participant's tumor once it has been removed. This tissue will be used to study the effect of ZD1839 on tumor growth."
11648409|NCT00104702|Experimental|Concentrated and Focalized Radiotherapy|
11648410|NCT00104676|Active Comparator|Arm I|Patients receive 4 courses of bleomycin, etoposide, and cisplatin (BEP).
11648411|NCT00104676|Experimental|Arm II|Patients receive 1 course of bleomycin, etoposide, and cisplatin (BEP). Patients then receive dose-dense sequential combination chemotherapy comprising cisplatin, etoposide, bleomycin, paclitaxel, oxaliplatin, and ifosfamide.
11648412|NCT00104650|Active Comparator|IV Bisphosphonates q 4 weeks|This is an open-label randomization to receive IV bisphosphonate (administered per package insert) every 4 weeks during the treatment phase. If subjects are enrolled into the extension phase, they will receive AMG 162 180mg (SC) every 4 weeks.
11648413|NCT00104650|Experimental|180 mg AMG 162 (SC) q 12 weeks|This is an open-label randomization to receive 180 mg AMG 162 (SC) every 12 weeks during the treatment phase. If subjects are enrolled into the extension phase, they will continue to receive 180 mg AMG 162 (SC) every 12 weeks.
11648414|NCT00104650|Experimental|180 mg AMG 162 (SC) q 4 weeks|This is an open-label randomization to receive 180 mg AMG 162 (SC) every 4 weeks during the treatment phase. If subject is enrolled into the extension phase, they will continue to receive 180 mg AMG 162 (SC) every 4 weeks.
11648415|NCT00104637|Active Comparator|Sildenafil / Placebo|Sildenafil first, followed by washout, followed by placebo
11648416|NCT00104637|Placebo Comparator|Placebo / Sildenafil|Placebo first, followed by washout, followed by Sildenafil
11648417|NCT00104611|Active Comparator|TMS|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 6 weeks
11648418|NCT00104611|Placebo Comparator|Placebo|Treatment 5 days/week for up to 6 weeks
11648419|NCT00104598|Active Comparator|Gain Framed Absitnence Program|Gain framed video and printed messages encouraging smoking abstinence with Bupropion.
11648420|NCT00104598|Active Comparator|Loss Framed Abstinence Program|Loss framed video and printed messages encouraging smoking abstinence with Bupropion.
11648421|NCT00104585||1|People with young onset Parkinson's disease and their family members
11648422|NCT00104572|Experimental|(Androgel) testosterone gel|17 participants will receive testosterone gel (5 gm) plus placebo tablet daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'
11648423|NCT00104572|Experimental|anastrozole (Aromatase inhibitor)|14 participants will receive anastrozole 1 mg tablet plus placebo gel daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'
11648424|NCT00104572|Placebo Comparator|placebo|13 participants will receive a placebo tablet and placebo gel daily for 12 months and 'Calcium Cardone 500mg with vitamin D 400 IU'
11648425|NCT00104559|Experimental|1|Participants will receive the computer-based tutorial for VT and then the standard paper consent form for AT
11648426|NCT00104559|Experimental|2|Participants will receive the standard paper consent form for VT and then the computer-based tutorial for AT
11648427|NCT00104559|Experimental|3|Participants will receive the computer-based tutorial for AT and then the standard paper consent form for VT
11648428|NCT00104559|Experimental|4|Participants will receive the standard paper consent form for AT and then the computer-based tutorial for VT
11648430|NCT00104520|Experimental|AZLI (pooled two times a day [BID]/three times a day [TID])|
11648431|NCT00104494|Experimental|1|CF, Zinc acetate
11648432|NCT00104494|Experimental|2|CF, Placebo
11648433|NCT00104494|No Intervention|3|Controls
11648434|NCT00104416|Placebo Comparator|Placebo|
11648435|NCT00104416|Experimental|lamotrigine (LAMICTAL) extended-relesase|
11648436|NCT00104325||1|white blood cells obtained through cytapheresis by healthy males and females 18 years and older
11648437|NCT00104312||1|Participants with symptomatic knee osteoarthritis
11648438|NCT00104312||2|Participants without symptomatic knee osteoarthritis, age-matched as controls
11648439|NCT00104299|Experimental|Rituximab|
11648440|NCT00104299|Active Comparator|Control Group|
11648441|NCT00104234|Other|rhASB/rhASB|N-acetylgalactosamine 4-sulfatase
11648442|NCT00104234|Other|Placebo/rhASB|
11648443|NCT00104104|Experimental|15 Minute Infusion|Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 15-minute infusion time, but increasing to a 30-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12 weeks
11648444|NCT00104104|Experimental|30 Minute Infusion|Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 30-minute infusion time, but increasing to a 45-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12-weeks.
11648445|NCT00104091|Experimental|1|40 mL of TP-38 at a 100 nanograms/mL concentration
11648446|NCT00104052|Experimental|PEG-Intron alfa 2b (PEG2b) plus REBETOL (RBV)|PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) and RBV 400-1200 mg/day by mouth divided in 2 daily doses (administered twice daily with food, dosed 12 hours apart) for 48 weeks. Subjects treated up to 48 weeks and followed for additional 24 weeks after the end of treatment (total of 72 weeks study participation).
11648447|NCT00103961||1|Treatment-naive and treatment-experienced HIV-infected adults
11648448|NCT00103935|Placebo Comparator|Group A1|Placebo lead-in followed by placebo equivalent volume to 0.8 mg exenatide LAR
11648449|NCT00103935|Placebo Comparator|Group A2|Placebo lead-in followed by placebo equivalent volume to 2.0 mg exenatide LAR
11648450|NCT00103935|Experimental|Group B|Exenatide lead-in followed by exenatide LAR 0.8 mg weekly
11648451|NCT00103935|Experimental|Group C|Exenatide lead-in followed by exenatide LAR 2.0 mg weekly
11648452|NCT00103922|Experimental|Arm 1|
11648453|NCT00103896||HIV Infected Youth in Treatment/Care|HIV infected youth in treatment/care will be interviewed using Audio Computer-Assisted Self-Administered Interview ACASI technology to reveal possible venues where youth at high risk for acquiring the disease may be found (N = 20-30 individuals per ATN site).
11648454|NCT00103896||BVI Individuals|Additional data will be gathered on potential recruitment venues by administering a brief venue interview (BVI) to individuals who appear to be between 12 and 24 years old (N = unlimited individuals during 3-5 assessment periods per venue each lasting 5 hours).
11648455|NCT00103896||HIV Serosurvey Individuals|HIV Serosurvey Individuals Anonymous structured interview using ACASI technology and an anonymous HIV antibody assay will be administered to 20-30 young women at 2-3 targeted locations and 20-30 young men at 2-3 targeted locations whose HIV status is unknown (N = 160-360 individuals per ATN site)..
11648456|NCT00103883||HIV Infected Teens -ATN Clinical Sites|HIV infected teens who are referred to or engaged in care at any of the 15 ATN clinical sites during the course of the study.
11648457|NCT00103883||HIV Positive - ATN Clinical Sites|Youth who test HIV positive at ATN-managed or ATN-affiliated HIV Counseling and Testing Sites (CTS) during the course of the study.
11648458|NCT00103883||HIV Positive - BCHD STD Clinic|Youth who test HIV positive at the BCHD STD Clinic during the course of the study.
11648459|NCT00103857|Experimental|1|MK0431 100 mg q.d.
11648460|NCT00103857|Active Comparator|2|Metformin 500 mg b.i.d.
11648461|NCT00103857|Active Comparator|3|Metformin 1000 mg b.i.d.
11648462|NCT00103857|Experimental|4|Coadministration of MK0431 and Metformin 50/500 mg b.i.d.
11648463|NCT00103857|Experimental|5|Coadministration of MK0431 and Metformin 50/1000 mg b.i.d.
11648464|NCT00103857|Placebo Comparator|6|Placebo/Metformin 1000 mg b.i.d.
11648465|NCT00103857|Experimental|7|Non-Randomized, Open-Label: Coadministration MK0431 and Metformin 50/1000 mg b.i.d.
11648466|NCT00103844|Experimental|1|Active Comparator
11648467|NCT00103844|Experimental|2|Active Comparator
11648468|NCT00103792|Experimental|1|mycophenolate and steroids as remission induction, followed by azathioprine maintenance therapy
11648469|NCT00103792|Active Comparator|2|cyclophosphamide
11648470|NCT00103779|Experimental|1|
11648471|NCT00103740|Experimental|Zoledronic acid and placebo to risedronate|Participants received zoledronic acid 5.0 mg i.v. infusion one dose, 60 days of oral placebo to risedronate, calcium 500mg bid and vitamin D 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
11648472|NCT00103740|Active Comparator|Risedronate and placebo to zoledronic acid|Participants received 60 days of oral risedronate 30 mg, one i.v. infusion of placebo to zoledronic acid infusion, calcium 500mg bid and vitamin d 400 to 1000 IU daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
11648473|NCT00103727|Experimental|talnetant|200mg, 400mg, 600mg) twice a day
11648474|NCT00103727|Placebo Comparator|placebo|placebo
11648475|NCT00103727|Active Comparator|risperidone|3mg twice a day
11648476|NCT00103701|Experimental|1|
11648477|NCT00103662|Experimental|G-CSF plus plerixafor|
11648478|NCT00103662|Placebo Comparator|G-CSF plus placebo|
11648479|NCT00103610|Experimental|G-CSF plus plerixafor|
11648480|NCT00103610|Placebo Comparator|G-CSF plus placebo|
11648481|NCT00103532|Experimental|Healthy Choices - Motivational Enhancement Intervention|Motivational enhancement intervention
11648482|NCT00103532|Active Comparator|Standard Care|Standard care/individualized referrals
11648483|NCT00103519|Experimental|DITPA 180 mg/day|DITPA 180 mg/day BID
11648484|NCT00103519|Experimental|DITPA 360 mg/day|DITPA 360 mg/day BID
11648485|NCT00103519|Placebo Comparator|Placebo|Placebo BID
11648486|NCT00103506|Active Comparator|VELCADE (bortezomib) monotherapy|Bortezomib (VELCADE) 1.3 milligram per meter square (mg/m^2) by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
11648487|NCT00103506|Experimental|DOXIL/CAELYX in combination with VELCADE (bortezomib)|Bortezomib (VELCADE) 1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Doxorubicin hydrochloride (DOXIL/CAELYX) 30 mg/m2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
11648488|NCT00103454|Experimental|Arm 1|
11648489|NCT00103402|Experimental|Alfuzosin|10 mg of alfuzosin once daily for 12 weeks
11648490|NCT00103402|Placebo Comparator|Placebo|10 mg of an identical-looking placebo once daily for 12 weeks
11648491|NCT00103389|Active Comparator|docetaxel|treated with docetaxel alone
11648492|NCT00103389|Experimental|PI-88+docetaxel|treated with docetaxel and PI-88
11648493|NCT00103376|Experimental|Part A: Velcade|Patient will complete Part A (Velcade only). If the patient has a complete response, he will come off study. If the patient has progressive disease, he will start Part B (Velcade + antiandrogen). If the patient has a partial response or stable disease, he will start Part B after at least a 7-day break.
11648494|NCT00103376|Experimental|Part B: Velcade+LH-RH antagonist+Androgen receptor antagonist|Patient will start Part B after completing Part A or may be enrolled to part B only.
11648495|NCT00103337|Experimental|Arm I (500 mg cilengitide)|Patients receive lower dose cilengitide IV over 1 hour twice a week for 6 weeks.
11648496|NCT00103337|Experimental|Arm II (2000 mg cilengitide)|Patients receive higher dose cilengitide IV over 1 hour twice a week for 6 weeks.
11648497|NCT00103324|Experimental|Treatment|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648498|NCT00103311|Experimental|Arm I|Patients receive SB-715992 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648499|NCT00103311|Experimental|Arm II|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11648500|NCT00103285|Experimental|Group 0 Induction Therapy|All patients receive cytarabine intrathecally (IT) on day 1; vincristine IV on days 1, 8, 15, and 22; dexamethasone IV or orally (PO) twice daily (BID) on days 1-28; pegaspargase intramuscularly (IM) (may give IV over 1 to 2 hours) on day 4, 5, or 6; and methotrexate IT on days 8 and 29 (and days 15 and 22 for patients with CNS3 disease). Patients with Down syndrome (DS) receive leucovorin calcium PO at 48 and 60 hours after each dose of methotrexate IT. Patients are assessed for response on day 29. Patients with M1 bone marrow AND minimal residual disease (MRD) < 0.1% OR MRD >= 0.1% and < 1% proceed to therapy in part II. Patients with M2 bone marrow OR M1 bone marrow AND MRD >= 1% proceed to extended induction therapy. Patients with M3 bone marrow are removed from the study.
11648501|NCT00103285|Active Comparator|Group 1-SR-low ALL, Arm I-combination chemotherapy|Patients receive standard consolidation therapy (vincristine sulfate, mercaptopurine and methotrexate. Patients with Down syndrome (DS) receive leucovorin calcium), standard interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine and methotrexate. Patients with DS receive leucovorin calcium), and standard delayed intensification (DI) therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and methotrexate. Patients with DS receive dexamethasone, leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
11648502|NCT00103285|Experimental|Group 1-SR-low ALL, Arm II-combination chemotherapy|Patients receive experimental consolidation therapy (vincristine sulfate, mercaptopurine, MTX, leucovorin calcium and pegaspargase), experimental interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine, MTX and pegaspargase), and standard DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and MTX), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
11648503|NCT00103285|Active Comparator|Group 2-SR-avg ALL, Arm I-combination chemotherapy|Patients receive standard consolidation therapy (vincristine sulfate, mercaptopurine and methotrexate. Patients with Down syndrome (DS) receive leucovorin calcium), standard interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine and methotrexate. Patients with DS receive leucovorin calcium), and standard delayed intensification (DI) therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and methotrexate. Patients with DS receive dexamethasone, leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
11648504|NCT00103285|Experimental|Group 2-SR-avg ALL, Arm II-combination chemotherapy|Patients receive standard consolidation therapy (vincristine sulfate, mercaptopurine and MTX. Patients with Down syndrome (DS) receive leucovorin calcium), augmented interim maintenance therapy (vincristine sulfate, MTX and pegaspargase. Patients with DS receive leucovorin calcium), augmented DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine, MTX. Patients with DS receive dexamethasone and leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
11648505|NCT00103285|Active Comparator|Group 2-SR-avg ALL, Arm III-combination chemotherapy|Patients receive intensified consolidation therapy (cyclophosphamide, cytarabine, mercaptopurine and vincristine sulfate, pegaspargase, MTX. Patients with DS receive oral leucovorin calcium), standard interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine and MTX. Patients with DS receive leucovorin calcium), and standard DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and MTX. Patients with DS receive dexamethasone, leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
11648564|NCT00102336|Placebo Comparator|Placebo|
11648565|NCT00102323|Placebo Comparator|Placebo|
11648566|NCT00102323|Experimental|AMG 531|Active Investigational Product
11648567|NCT00102141|Experimental|Arm 1|
11648568|NCT00102141|Experimental|Arm 3|
11648569|NCT00102141|Experimental|Arm 4|
11648570|NCT00102141|Placebo Comparator|Arm 5|
11648571|NCT00102141|Experimental|Arm 2|
11648506|NCT00103285|Experimental|Group 2-SR-avg ALL, Arm IV-combination chemotherapy|Patients receive intensified consolidation therapy (cyclophosphamide, cytarabine, mercaptopurine and vincristine sulfate, pegaspargase, MTX. Patients with DS receive oral leucovorin calcium), augmented interim maintenance therapy (vincristine sulfate, MTX and pegaspargase. Patients with DS receive leucovorin calcium), and augmented DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine, MTX. Patients with DS receive dexamethasone and leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
11648507|NCT00103285|Experimental|Group 3-SR-high ALL, combination chemotherapy|Patients receive intensified consolidation therapy (cyclophosphamide, cytarabine, mercaptopurine and vincristine sulfate, pegaspargase, methotrexate. Patients with DS receive oral leucovorin calcium), augmented interim maintenance therapy (2 courses - vincristine sulfate, methotrexate and pegaspargase. Patients with DS receive leucovorin calcium), and augmented DI therapy (2 courses - vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine, methotrexate. Patients with DS receive dexamethasone and leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.
11648508|NCT00103272|Experimental|Treatment (17-AAG and bortezomib)|"Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1-6 hours on days 1, 4, 8, and 11 and bortezomib IV over 3-5 seconds on days 4, 8, and 11 of course 1 and on days 1, 4, 8, and 11 of all subsequent courses.
~Treatment repeats every 21 days for 3-12 courses provided patient is receiving clinical benefit. Patients achieving objective response may discontinue therapy to undergo stem cell transplantation."
11648509|NCT00103259|Experimental|Arm I (bortezomib, irinotecan hydrochloride)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and irinotecan IV over 90 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
11648510|NCT00103259|Experimental|Arm II (bortezomib)|Patients receive bortezomib as in arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may cross over to arm I.
11648511|NCT00103246|Experimental|Topical silicon phthalocyanine 4 (Pc 4) + photodynamic therapy|Topical silicon phthalocyanine 4 (Pc 4) followed by photodynamic therapy.
11648512|NCT00103220|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648513|NCT00103207|Experimental|Cetuximab|Cetuximab was given as a weekly intravenous (IV) infusion (over 60 minutes) at 250 mg/m2 from week 2 onwards after an initial loading dose of 400 mg/m2 (over 120 minutes) on week 1 until disease progression or unacceptable toxicity. The infusion rate of cetuximab could not exceed 5 mL/min. Each cycle will be 28 days in length. To prevent a hypersensitivity reaction, all patients were premedicated with diphenhydramine hydrochloride 50 mg (or an equivalent antihistamine) by IV (over 30-60 minutes) prior to the first dose of cetuximab. Premedication might be administered prior to subsequent doses, but at the investigator's discretion, the dose of diphenhydramine (or a similar agent) was reduced.
11648514|NCT00103194|Experimental|Treatment (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648515|NCT00103181|Active Comparator|Group 1: WBI|Patients undergo whole breast irradiation (WBI) once daily, 5 days a week for 5-7 weeks.
11648516|NCT00103181|Experimental|Group 2: PBI|Patients undergo partial-breast irradiation (PBI) twice daily on 5 days over a period of 5-10 days. This may be delivered by intracavitary brachytherapy, MammoSite or other single-entry intracavitary device, or 3-dimensional conformal accelerated partial breast irradiation.
11648517|NCT00103168|Experimental|Imatinib mesylate|400 mg/day for 2 years
11648518|NCT00103168|No Intervention|Control|
11648519|NCT00103142|Experimental|PANVAC-V + PANVAC-F + DC|Patients undergo leukapheresis to obtain leukocytes for generation of autologous dendritic cells (DC). Patients then receive autologous DC loaded with vaccinia-CEA-MUC-1-TRICOM (PANVAC-V) vaccine subcutaneously (SC) and intradermally (ID) on day 1 and autologous DC loaded with fowlpox-CEA-MUC-1-TRICOM (PANVAC-F) vaccine SC and ID on days 28, 56, and 84.
11648520|NCT00103142|Experimental|PANVAC-V + PANVAC-F + GM-CSF|Patients receive PANVAC-V SC on day 1 and PANVAC-F SC on days 28, 56, and 84. Patients also receive sargramostim (GM-CSF) SC into the same injection site once daily on days 0-3, 28-31, 56-59, and 84-87.
11648521|NCT00103116|Experimental|Autologous dendritic cell cancer vaccine|Open label nonrandomized
11648522|NCT00103038|Experimental|Diagnostic (ferumoxytol, gadolinium, DCE-MRI, DSC-MRI)|Patients receive ferumoxytol non-stoichiometric magnetite IV beginning approximately 15 seconds after start of 3T DSC-MRI and GBCA IV approximately 1 minute and 50 seconds after start of 3T DCE-MRI on day 1. Patients also undergo MRI without contrast at baseline and on day 2. Imaging with ferumoxytol, GBCA and without contrast repeats every 3 weeks for a total of 6 more imaging sessions over up to 5 years.
11648523|NCT00103012|Experimental|Effect of G. Biloba on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Ginkgo Biloba).
11648524|NCT00103012|Experimental|Effect of Echinacea on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Echinacea purpurea).
11648525|NCT00103012|Experimental|Effect of P. ginseng on LPV disposition|The primary outcome measurement for each study arm is the change in lopinavir area under the concentration versus time curve (AUC) after two weeks administration of an herbal preparation (Panax ginseng).
11648526|NCT00102973|Experimental|TLK286 in Combination with Carboplatin|
11648527|NCT00102973|Active Comparator|Doxorubisin HCl Liposome Injection|
11648572|NCT00102063|Active Comparator|Aripiprazole 10 mg/day Group|Dose was titrated to a target dose of 10 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5; one dose reduction to 5 mg/day allowed after Day 25
11648573|NCT00102063|Active Comparator|Aripiprazole 30 mg/day Group|Dose was titrated to a target dose of 30 mg/day as follows: starting dose 2 mg/day, increased to 5 mg/day on Day 3, 10 mg/day on Day 5, 15 mg/day on Day 7, 20 mg/day on Day 9, and 30 mg/day on Day 11; one dose reduction to 15 mg/day allowed after Day 25
11648620|NCT00101686|Experimental|Modified Bolus 5-FU/LV with Irinotecan|
11648528|NCT00102960|Experimental|Deferred therapy Arm|"Zidovudine: First Line Regimen: Given twice daily at a dose of 240 mg/m^2 of body surface area. Dose was adjusted by age as the children grew older.
~Lamivudine: First Line Regimen: 4 mg/kg taken orally twice daily Lopinavir/Ritonavir: First Line Regimen: taken orally twice daily. Dosage depends on age and weight.
~Ritonavir: First Line Regimen taken orally twice a day. Started at 250 mg/m^2 Abacavir sulfate: Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
~Didanosine: Second Line Regimen: Either 100 mg/m^2 or 120 mg/m^2 taken orally twice daily. Dosage depends on age.
~Efavirenz: Second Line, once daily Nevirapine: Second Line, once daily"
11648529|NCT00102960|Experimental|Early therapy for 40 weeks|"Zidovudine: First Line Regimen: 10 mg/mL taken orally twice per day. Dose was adjusted by age as the children grew older.
~Lamivudine: First Line Regimen: 4 mg/kg taken orally twice daily Lopinavir/Ritonavir: First Line Regimen: taken orally twice daily. Dosage depends on age and weight.
~Ritonavir: First Line Regimen taken orally twice a day. Started at 250 mg/m^2
~Abacavir sulfate: Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
~Didanosine: Second Line Regimen: Either 100 mg/m^2 or 120 mg/m^2 taken orally twice daily. Dosage depends on age.
~Efavirenz: Second Line, once daily Nevirapine: Second Line, once daily"
11648530|NCT00102960|Experimental|Early therapy for 96 weeks|"Zidovudine: First Line Regimen: 10 mg/mL taken orally twice per day. Dose was adjusted by age as the children grew older.
~Lamivudine: First Line Regimen: 4 mg/kg taken orally twice daily Lopinavir/Ritonavir: First Line Regimen: taken orally twice daily. Dosage depends on age and weight.
~Ritonavir: First Line Regimen taken orally twice a day. Started at 250 mg/m^2 Abacavir sulfate: Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
~Didanosine: Second Line Regimen: Either 100 mg/m^2 or 120 mg/m^2 taken orally twice daily. Dosage depends on age.
~Efavirenz: Second Line, once daily Nevirapine: Second Line, once daily"
11648531|NCT00102934|Experimental|1|Participants will receive enfuvirtide for 6 months
11648532|NCT00102908|Experimental|1|Participants will receive zoledronate at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis
11648533|NCT00102908|Placebo Comparator|2|Participants will receive zoledronate placebo at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis
11648534|NCT00102804|Experimental|Pemetrexed and Best Supportive Care|
11648535|NCT00102804|Placebo Comparator|Placebo and Best Supportive Care|
11648536|NCT00102726|Active Comparator|Arm 1|SB-497115-GR 50mg. administered orally daily on days 2 through 11 for each 21-day cycle.
11648537|NCT00102726|Active Comparator|Arm 2|SB-497115-GR 75 mg administered orally dailey on days 2-11 of each 21-day cycle.
11648538|NCT00102726|Active Comparator|Arm 3|SB-497115 100mg administered orally daily on days 2 through 11 of each 21-day cycle.
11648539|NCT00102726|Placebo Comparator|Placebo Arm|Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
11648540|NCT00102687|Experimental|Aza-5|Azacitidine administered subcutaneously at 75mg/m^2 for 5 days on a 28 day cycle.
11648541|NCT00102687|Experimental|Aza-5-2-2|Azacitidine administered subcutaneously at 75mg/m^2 for 5days with 2 days off, then for an additional 2 days, on a 28 day cycle.
11648542|NCT00102687|Experimental|Aza-5-2-5|Azacitidine administered subcutaneously at 50mg/m^2 for 5 days with 2 days off, then for an additional 5 days, on a 28 day cycle.
11648543|NCT00102687|Experimental|Maintenance Aza 5 days q 4 weeks|Azacitidine administered subcutaneously at 75mg/m^2 for 5 days every 4 weeks.
11648544|NCT00102687|Experimental|Maintenance Aza 5 days q 6 weeks|Azacitidine administered subcutaneously at 75mg/m^2 for 5 days every 6 weeks.
11648545|NCT00102661|Experimental|CAMPATH-1H|15 mg infused daily for continuous infusion x 7 days; starting day 10, CAMPATH-1H 30 mg subcutaneously three times weekly for 11 additional weeks.
11648546|NCT00102648|Experimental|Treatment (temozolomide and lonafarnib)|Patients receive temozolomide PO QD on days 1-7 and 15-21 and lonafarnib PO BID on days 8-14 and 22-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11648547|NCT00102635|Experimental|4-HPR + FTI|SCH66336 daily for 21 days each cycle and with 4-HPR daily on days 1-7 only. On day 1 of cycle 1, 4-HPR only beginning SCH66336 on day 2 of cycle 1.
11648548|NCT00102622|Experimental|Arm 1: Paclitaxel + tgDCC-E1A|80 mg/m^2 intravenous Paclitaxel and intraperitoneal (IP) tgDCC-E1A starting dose 1.8 mg DNA/m^2 weekly for six treatments every 7 days.
11648549|NCT00102622|Active Comparator|Arm 2: Paclitaxel Alone|Weekly single agent intravenous Paclitaxel 80 mg/m^2 for six treatments every 7 days.
11648550|NCT00102609|Experimental|Trabectedin and doxorubicin|Doxorubicin (50 to 75 mg/m2) administered intravenously on Day 1 followed by trabectedin (0.9 to 1.3 mg/m2) administered intravenously on Day 1 every 3 weeks for up to 6 cycles. Dexamethasone 20 mg administered intravenously will be given within 1 hour before the start of doxorubicin. Patients may receive filgrastim for unmanageable neutropenia.
11648551|NCT00102544|Experimental|All cohorts (prostate biopsy percutaneous biopsy and ablation)|This study will consist of comparison of tracked imaging with near simultaneous actual imaging .
11648552|NCT00102531|Experimental|Cisplatin liposomal 24 mg/m2|Inhaled liposomal cisplatin was administered over 1 day in a 14-day treatment cycle by inhalation for a maximum of 6 cycles.
11648553|NCT00102531|Experimental|Cisplatin liposomal 36 mg/m2|The study allowed for a dose escalation of liposomal cisplatin to 36 mg/m2 if no adverse events of Grade 3 or higher occurred after at least 3 cycles of drug administration at 24 mg/m2
11648554|NCT00102518|Experimental|NCT00102063 and NCT00110461 Subjects|All subjects had either completed or had withdrawn from the double-blind extension phase of study NCT00110461 (OPDC 31-03-240) and study NCT00102063 (OPDC 31-03-239).
11648555|NCT00102466|Experimental|Vildagliptin|
11648556|NCT00102466|Active Comparator|Gliclazide|
11648557|NCT00102453|Experimental|Solution|All enrolled participants were give pentoxifylline in this pilot protocol.
11648558|NCT00102440|Experimental|Febuxostat 80 mg QD|
11648559|NCT00102440|Experimental|Febuxostat 120 mg QD|
11648560|NCT00102440|Active Comparator|Allopurinol 300 mg QD|
11648561|NCT00102388|Experimental|vildagliptin|
11648562|NCT00102388|Active Comparator|Gliclazide|
11648563|NCT00102336|Experimental|AMG 531|Active investigational product
11648574|NCT00102063|Placebo Comparator|Placebo Group|Participants were given a single pill administered once daily
11648575|NCT00102011|Experimental|Study I- Arm I|Participants undergo baseline screening colonoscopy
11648576|NCT00102011|Other|Study I- Arm II|Participants receive standard care
11648577|NCT00102011|Experimental|Study II- Arm I|Participants undergo baseline screening colonoscopy. Participants are given individualized recommendations for further surveillance based on the results of the colonoscopy.
11648578|NCT00102011|Active Comparator|Study II- Arm II|Participants undergo a baseline fecal occult blood test (FOBT). Participants are given individualized recommendations for further surveillance based on the results of the FOBT. Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT.
11648579|NCT00101998|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally BID for 3 weeks.
11648580|NCT00101998|Experimental|Alvimopan 1 mg Once Daily (QD)|"0.5 mg of alvimopan was administered orally QD for 3 days, then 1 mg of alvimopan QD for the remaining 3 weeks. Placebo was administered orally QD to maintain the blind.
~A protocol amendment dropped this arm because another study had demonstrated 1 mg QD treatment to have similar efficacy but a less favorable gastrointestinal-related safety profile compared with 0.5 mg BID treatment."
11648581|NCT00101998|Experimental|Alvimopan 1 mg Twice Daily (BID)|0.5 mg of alvimopan was administered orally BID for 3 days, then 1 mg of alvimopan BID for the remaining 3 weeks.
11648582|NCT00101998|Placebo Comparator|Placebo|Placebo was administered orally BID for 3 weeks.
11648583|NCT00101972|Experimental|RAV12|
11648584|NCT00101933|Experimental|1|Active Stimulation
11648585|NCT00101933|Sham Comparator|2|No Stimulation
11648586|NCT00101920|Experimental|ABX-EGF|Open-label, single arm panitumamab monotherapy
11648587|NCT00101907|Experimental|Panitumumab + Gem/Cis|Panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
11648588|NCT00101907|Experimental|50 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 50 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
11648589|NCT00101907|Experimental|75 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 75 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
11648590|NCT00101907|Experimental|100 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 100 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
11648591|NCT00101907|Experimental|125 mg QD AMG 706 + panitumumab + Gem/Cis|AMG 706 125 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
11648592|NCT00101907|Experimental|75 mg BID AMG 706 + panitumumab + Gem/Cis|AMG 706 75 mg administered orally twice daily (BID) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m^2 on Day 1 of each 3-week cycle.
11648593|NCT00101894|Experimental|Part 2 AMG 706 (MTD) + FOLFOX-4|Maximum Tolerated Dose of AMG 706 established in Part 1b + FOLFOX-4
11648594|NCT00101894|Experimental|125 mg QD AMG 706 + FOLFOX-4|125 mg QD AMG 706 + FOLFOX-4
11648595|NCT00101894|Experimental|50 mg QD AMG706 + panitumumab + FOLFIRI|50 mg QD AMG706 + panitumumab + FOLFIRI
11648596|NCT00101894|Experimental|Part 2 AMG 706 (MTD) + FOLFIRI|Maximum Tolerated Dose of AMG 706 established in Part 1b + FOLFIRI
11648597|NCT00101894|Experimental|100 mg QD AMG 706 + FOLFIRI|100 mg AMG 706 + FOLFIRI
11648598|NCT00101894|Experimental|75 mg QD AMG 706 + panitumumab + FOLFOX-4|75 mg QD AMG 706 + panitumumab + FOLFOX-4
11648599|NCT00101894|Experimental|75 mg BID AMG 706 + panitumumab + FOLFIRI|75 mg BID AMG 706 + panitumumab + FOLFIRI
11648600|NCT00101894|Experimental|125 mg QD AMG 706 + panitumumab + FOLFIRI|125 mg QD AMG 706 + panitumumab + FOLFIRI
11648601|NCT00101894|Experimental|125 mg QD AMG 706 + FOLFIRI|125 mg QD AMG 706 + FOLFIRI
11648602|NCT00101894|Experimental|100 mg QD AMG 706 + panitumumab + FOLFIRI|100 mg QD AMG 706 + panitumumab + FOLFIRI
11648603|NCT00101894|Experimental|75 mg QD AMG 706 + FOLFOX-4|75 mg QD AMG 706 + FOLFOX-4
11648604|NCT00101894|Experimental|100 mg QD AMG 706 + FOLFOX-4|100 mg QD AMG 706 + FOLFOX-4
11648605|NCT00101894|Experimental|50 mg QD AMG 706 + panitumumab + FOLFOX-4|50 mg QD AMG 706 + panitumumab + FOLFOX-4
11648606|NCT00101894|Experimental|75 mg QD AMG706 + panitumumab + FOLFIRI|75 mg QD AMG706 + panitumumab + FOLFIRI
11648607|NCT00101881|Active Comparator|Monophasic Shock|Administration of monophasic waveform defibrillation
11648608|NCT00101881|Active Comparator|Biphasic Shock|Administration of biphasic waveform defibrillation
11648609|NCT00101868|Experimental|Discharge communication software|Computerized-Physician-Order-Entry software application to facilitate communication at time of hospital discharge to patients, retail pharmacists, community physicians. Software had required fields, pick lists, standard drug doses, alerts, reminders, online reference information. Software prompted discharging physician to enter pending tests, order tests after discharge. Hospital physicians used software on day of discharge to generate four documents automatically: personalized letter to outpatient physician, legible prescriptions, and legible discharge order
11648610|NCT00101868|Active Comparator|Usual care discharge process|Hospital physicians and ward nurses completed handwritten discharge forms on the day of discharge. The forms contained blanks for discharge diagnoses, discharge medications, medication instructions, post discharge activities and restrictions, post discharge diet, post discharge diagnostic and therapeutic interventions, and appointments. Patients received handwritten copies of the forms, one page of which also included medication instructions and prescriptions
11648611|NCT00101829|Experimental|Rituximab Treatment|Participants will receive rituximab at study entry and at Week 2
11648612|NCT00101816|Experimental|1|
11648613|NCT00101790|Active Comparator|1|
11648614|NCT00101725|Experimental|125 mg crofelemer|
11648615|NCT00101725|Experimental|250 mg crofelemer|
11648616|NCT00101725|Experimental|500 mg crofelemer|
11648617|NCT00101725|Placebo Comparator|placebo|
11648621|NCT00101686|Experimental|FOLFIRI + bevacizumab|
11648622|NCT00101686|Experimental|miFL + bevacizumab|
11648623|NCT00101686|Experimental|Infusional 5-FU/LV with Irinotecan|
11648624|NCT00101686|Other|Oral Capecitabine with Irinotecan|
11648625|NCT00101660|Experimental|Dasatinib, 70 mg twice daily (BID)|Dasatanib, 70 mg twice daily (BID), with dose escalation to 90 mg BID was allowed for participants who showed evidence of progression or lack of response. Up to 2 dose reductions were allowed for intolerance.
11648626|NCT00101647|Experimental|1|
11648627|NCT00101608|Experimental|1|
11648628|NCT00101595|Experimental|1|
11648629|NCT00101582|Experimental|Palifermin|Participants received a single intravenous dose of palifermin at 180 μg/kg three days before the start of radiotherapy, and then 7 once weekly palifermin doses at the same dose level during a 7-week radiotherapy/chemotherapy course.
11648630|NCT00101582|Placebo Comparator|Placebo|Participants received a single IV dose of placebo three days before the start of radiotherapy, and then 7 once weekly placebo doses during a 7-week radiotherapy/chemotherapy course.
11648631|NCT00101569|Experimental|A1|
11648632|NCT00101569|Experimental|A2|
11648633|NCT00101491|Experimental|1|
11648634|NCT00101491|Other|2|Attention Control Comparator
11648635|NCT00101452|Experimental|S-adenosyl-l-methionine (SAMe)|A natural substance
11648636|NCT00101452|Active Comparator|2. Escitalopram|A selective serotonin reuptake inhibitor (SSRI)
11648637|NCT00101452|Placebo Comparator|3. placebo|Sugar pill- contains no active ingredients
11648638|NCT00101439|Experimental|Ezetimibe→Placebo|After a 2-week single- blind placebo run-in, participants will receive ezetimibe 10 mg once daily for 4 weeks and then receive placebo once daily for 4 weeks.
11648639|NCT00101439|Experimental|Placebo→ Ezetimibe|After a 2-week single- blind placebo run-in, participants will receive placebo once daily for 4 weeks and then receive ezetimibe10 mg once daily for 4 weeks.
11648640|NCT00101413|Experimental|Sorafenib|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (bid, bis in die) X 28 day cycles
11648641|NCT00101400|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg administered twice daily (b.i.d.)
11648642|NCT00101387|Experimental|Lumbar PENS + exercise|Lumbar PENS twice a week for six weeks combined with general conditioning and aerobic exercise
11648643|NCT00101387|Active Comparator|Lumbar PENS|Lumbar PENS twice a week for 6 weeks
11648644|NCT00101387|Placebo Comparator|Control PENS|Control lumbar PENS twice a week for 6 weeks
11648645|NCT00101387|Active Comparator|Control PENS + exercise|Control PENS twice a week for 6 weeks along with general conditioning and aerobic exercise
11648646|NCT00101361|Active Comparator|1|oxandrolone
11648647|NCT00101361|Placebo Comparator|2|placebo
11648648|NCT00101348|Experimental|Treatment (erlotinib hydrochloride, cetuximab, bevacizumab)|"Part 1: Patients receive oral erlotinib once daily on days 1-28. Patients also receive cetuximab IV over 3 hours on day 1 and over 1 hour on days 8, 15, and 22.
~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
~Part 2: Patients receive erlotinib as in part 1 at the MTD and cetuximab as in part 1. Patients also receive bevacizumab IV over 1½ hours on day 1 and over 1 hour on day 15.
~Cohorts of 3-6 patients receive escalating doses of bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
~In both groups, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression."
11648649|NCT00101296|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-7 and 15-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients achieving a CR receive 2 additional courses beyond CR. Patients experiencing relapse after previously achieving CR may receive additional tipifarnib at the current dose level for newly registered patients.
11648650|NCT00101283|Experimental|Pemetrexed/Carboplatin|Pemetrexed disodium 500 mg/m2 IV over 10 minutes and carboplatin to area under the curve (AUC) 5 IV over 30 minutes on day 1 of a 21-day cycle.
11648651|NCT00101283|Experimental|Pemetrexed/Gemcitabine|Pemetrexed disodium 500 mg/m2 IV over 10 minutes on day 1 and gemcitabine 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle.
11648652|NCT00101270|Experimental|Treatment (irinotecan hydrochloride, oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
11648653|NCT00101244|Experimental|Treatment (ispinesib)|"Patients receive SB-715992 IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of SB-715992 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 10 additional patients are treated at the MTD."
11648654|NCT00101231|Experimental|Treatment (flavopiridol)|Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression.
11648655|NCT00101205|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11648656|NCT00101179|Experimental|Arm I|"Patients receive azacitidine subcutaneously on days 1-10 and oral MS-275 on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses* of MS-275 until the maximum tolerated dose (MTD) is determined. Patients receive adjusted doses of azacitidine based on clinical response. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 9 additional patients are treated at the MTD."
11648657|NCT00101166|Experimental|Vaccine Therapy|Treatment consisted of intradermal vaccine injections at 28-day intervals for a total of 3 immunizations. Injections were performed on Days 1, 29, and 57.
11648658|NCT00101153|Experimental|Tipifarnib with conventional induction and consolidation|
11648728|NCT00099736|Experimental|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids,|
11648729|NCT00099736|Experimental|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids|
11648659|NCT00101114|Experimental|Treatment (sorafenib tosylate, interferon alpha-2b)|Patients receive oral sorafenib twice daily on days 1-28 and interferon alfa subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648660|NCT00101101|Experimental|Vaccine and Conventional Therapy|"Patients were treated with 3-6 cycles of chemotherapy +/- rituximab, with type and duration at the discretion of the individual clinician.
~Chemotherapy: 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
~Patients who achieve a partial or complete response after completion of chemotherapy proceed to autologous tumor cell-based vaccine therapy.
~Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2.
~Treatment continues in the absence of disease progression or unacceptable toxicity."
11648661|NCT00101088|Experimental|Treatment (imatinib mesylate, temsirolimus)|Patients receive temsirolimus IV over 30 minutes once on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression
11648662|NCT00101075|Experimental|XELOX|"Oxaliplatin 130 mg/m2 day 1 every 3 weeks
~Capecitabine 1700 mg/m2/day days 1-14 every 3 weeks. -- Patients will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
11648663|NCT00101036|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648664|NCT00101010|Experimental|Rituximab - Combination Chemotherapy|Rituximab 375 mg/m^2 intravenous (IV), Cyclophosphamide IV over 1-1½ hours, Pegylated doxorubicin HCl liposome 40 mg/m^2 IV over 1 hour, Vincristine 2 mg IV, day 1, & oral Prednisone 40 mg/m^2 days 1 - 5; Filgrastim (G-CSF) 5 mcg/kg subcutaneously (SC) once daily beginning day 6 continuing until blood counts recover OR Pegfilgrastim 6 mg SC once on day 6 (24 hours after chemotherapy). Treatment repeats every 21 days for up to 8 courses.
11648665|NCT00100945|Experimental|gefitinib|"Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease recurrence or unacceptable toxicity.
~Quality of life is assessed at baseline, 4 weeks, every 12 weeks during study treatment, and then at the end of study treatment.
~Patients are followed every 3 months for up to 5 years."
11648666|NCT00100932|Experimental|1|E7389 28 day cycle
11648667|NCT00100932|Experimental|2|E7389 21 day cycle
11648668|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Dose Level A|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.
~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.
~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.
~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.
~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
11648669|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Dose Level B|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.
~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.
~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.
~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.
~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
11648670|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Level C|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.
~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.
~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.
~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.
~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
11648671|NCT00100893|Experimental|Dietary Supplement: grape seed proanthocyanidin extract|Administered orally.
11648672|NCT00100880|Experimental|Treatment (lenalidomide)|"Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
~Cohorts of 2-3 patients receive escalating doses of lenalidomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which an estimated 25% of patients experience dose-limiting toxicity."
11648673|NCT00100854|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily on days 1-28. Courses repeat every 28 days.
11648674|NCT00100854|Experimental|Arm II|Patients receive erlotinib hydrochloride as in arm I and fulvestrant intramuscularly on days 1, 15, and 29, and then every 28 days thereafter.
11648675|NCT00100841|Experimental|Treatment (combination chemotherapy)|Patients receive cetuximab IV over 60-120 minutes on day 1 in weeks 1-8. Patients also receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 48 hours on days 1 and 2 of weeks 1, 3, 5, and 7. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
11648676|NCT00100828|Experimental|Irinotecan|
11648730|NCT00099736|Experimental|MMF 2 g + full-dose Neoral (FDN) + corticosteroids|
11648731|NCT00099658|Experimental|1|HIV-uninfected infants born to HIV-uninfected mothers
11648732|NCT00099658|Experimental|2|HIV-infected infants in CDC Disease Category 1 who were randomly assigned to the delayed therapy arm (Arm 1) of CIPRA SA-Project 2
11648677|NCT00100802|Experimental|Surgery, Chemoradiotherapy, Rest, Maintenance, FUP|Patients must begin therapy within 31 days of surgery. Chemoradiotherapy = Radiation Therapy Dose: 54.0 Gy with a Boost of 5.4 Gy Temozolomide 90mg/m2/day daily for 42 days. Maintenance consists of 6 treatment cycles of combo chemotherapy with lomustine and temozolomide. Maintenance will begin 4 weeks following radiation. Five days of temozolomide (day 1 - 5) and one dose of lomustine (day 1) followed by 36 days of rest = 1 treatment cycle.
11648678|NCT00100789|Experimental|gemcitabine paclitaxel combination|
11648679|NCT00100750|Experimental|Treatment (gemcitabine hydrochloride, tipifarnib)|Patients receive tipifarnib PO BID on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11648680|NCT00100698|Active Comparator|1|recombinant human growth hormone subcutaneously once a day
11648681|NCT00100698|Placebo Comparator|2|placebo subcutaneously once a day
11648682|NCT00100685|Experimental|Arm 1|Volociximab administered intravenously at a dose of 10 mg/kg qowk
11648683|NCT00100685|Experimental|Arm 2|Volociximab administered intravenously at a dose of 15 mg/kg qwk
11648684|NCT00100659|Active Comparator|Pegylated interferon/ribavirin|"Pegasys - 180 mcg per 1.73 meter squared body surface area subcutaneously once weekly.
~Ribavirin - 15 mg per kg orally twice daily using 100-mg tablets."
11648685|NCT00100659|Placebo Comparator|Pegylated interferon/placebo|Placebo tablets were supplied in the same dosing regimen as ribavirin, using the same number of tablets that would be given if ribavirin were being administered (eg, 3 placebo tablets twice daily for a 40-kg child who would receive 3 100-mg RV tablets twice daily).
11648686|NCT00100646|Experimental|1|Highly active antiretroviral therapy (HAART) consisting of lamivudine, lopinavir/ritonovir, and stavudine for 16 weeks with three structured treatment interruptions for 2, 4, and 8 weeks each; rabies vaccine at Weeks 16, 17, 22 and 92.
11648687|NCT00100646|Active Comparator|2|Continuous HAART consisting of lamivudine, lopinavir/ritonovir, and stavudine throughout the study; rabies vaccine at Weeks 16, 17, 22 and 92.
11648688|NCT00100568|Experimental|1|All participants will be given an ARV regimen of lamivudine/zidovudine and efavirenz at study entry. If toxicity or treatment failure occurs, some participants may require changes in their ARV regimens.
11648689|NCT00100542||1|All HIV infected and uninfected participants and their caregivers.
11648690|NCT00100477|Other|Arm 1|
11648691|NCT00100308|Experimental|1|Standard treatment plus unfractioned heparin low-dose continuous infusion
11648692|NCT00100308|Placebo Comparator|2|Standard treatment plus placebo
11648693|NCT00100295|Experimental|A|Herbal treatment
11648694|NCT00100295|Placebo Comparator|B|
11648695|NCT00100256|Experimental|Arm 1|
11648696|NCT00100230|Experimental|1.|Oral Docosahexaenoic acid, dosage based on body weight
11648697|NCT00100230|Placebo Comparator|2|corn/soy oil placebo; oil not containing DHA...dosage based on body weight
11648698|NCT00100178|Experimental|MMF and DBZ|DZB given by intravenous infusion (1 mg/kg)at baseline and 2 weeks later, and MMF given orally at dose of 600 mg/m2 (2000 mg/day maximum) in 2-3 divided doses for 2 years.
11648699|NCT00100178|Experimental|MMF Alone|MMF given orally at dose of 600 mg/m2 (2000 mg/day maximum) in 2-3 divided doses for 2 years and saline intravenous infusions given at baseline and two weeks later.
11648700|NCT00100178|Placebo Comparator|Placebo|Placebo pills given daily for two years and saline intravenous infusions given at baseline and two weeks later.
11648701|NCT00100165|Experimental|3-(2,4 dimethoxybenzylidene anabaseine) 150 mg|Patient receives 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg twice per day in a blinded capsule.
11648702|NCT00100165|Experimental|3-(2,4 dimethoxybenzylidene anabaseine)75 mg|Patient receives 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg twice per day in a blinded capsule.
11648703|NCT00100165|Placebo Comparator|placebo|Patient receives placebo twice per day in a blinded capsule.
11648704|NCT00100061|Active Comparator|Cranberry Juice|Cranberry Juice provided by Ocean Spray
11648705|NCT00100061|Placebo Comparator|Placebo cranberry juice|Taken orally
11648706|NCT00100048|Experimental|600 mg monotherapy|MK0518 600 mg twice daily
11648707|NCT00100048|Experimental|400 mg monotherapy|MK0518 400 mg twice daily
11648708|NCT00100048|Experimental|200 mg monotherapy|MK0518 200 mg twice daily
11648709|NCT00100048|Experimental|100 mg monotherapy|MK0518 100 mg twice daily
11648710|NCT00100048|Placebo Comparator|placebo monotherapy|Placebo to MK0518 twice daily
11648711|NCT00100048|Experimental|600 mg combo therapy|MK0518 600 mg + tenofovir + lamivudine
11648712|NCT00100048|Experimental|400 mg combo therapy|MK0518 400 mg + tenofovir + lamivudine
11648713|NCT00100048|Experimental|200 mg combo therapy|MK0518 200 mg + tenofovir + lamivudine
11648714|NCT00100048|Experimental|100 mg combo therapy|MK0518 100 mg + tenofovir + lamivudine
11648715|NCT00100048|Active Comparator|EFV combo therapy|efavirenz + tenofovir + lamivudine
11648716|NCT00099983|Active Comparator|Risperidone|1 mg/day tablet for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day to a maximum of 4 mg/day allowed after a minimum of 4 weeks at the target dose 3 mg/day
11648717|NCT00099983|Placebo Comparator|Sugar Pill|Placebo 1 mg/day tablet for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day to a maximum of 4 mg/day allowed after a minimum of 4 weeks at the target dose 3 mg/day
11648718|NCT00099944|Experimental|LAF237 50 mg qd + glimepiride 4 mg qd|LAF237 50 mg qd + glimepiride 4 mg qd
11648719|NCT00099944|Experimental|LAF237 50 mg bid + glimepiride 4 mg qd|LAF237 50 mg bid + glimepiride 4 mg qd
11648720|NCT00099944|Placebo Comparator|LAF237 placebo + glimepiride 4 mg qd|LAF237 placebo + glimepiride 4 mg qd
11648721|NCT00099866|Experimental|Vildagliptin|
11648722|NCT00099866|Active Comparator|Metformin|
11648723|NCT00099853|Experimental|Vildagliptin 50 mg qd + pioglitazone 45 mg qd|Vildagliptin 50 mg qd + pioglitazone 45 mg qd for 24 weeks
11648724|NCT00099853|Experimental|Vildagliptin 50 mg bid + pioglitazone 45 mg qd|Vildagliptin 50 mg bid + pioglitazone 45 mg qd for 24 weeks
11648725|NCT00099853|Placebo Comparator|Vildagliptin placebo + pioglitazone 45 mg qd|Vildagliptin placebo + pioglitazone 45 mg qd for 24 weeks
11648726|NCT00099788|Experimental|1|Ranolazine
11648727|NCT00099788|Placebo Comparator|2|Placebo
11648733|NCT00099658|Experimental|3|HIV-infected infants in CDC Disease Category 1 who were randomly assigned to the first early therapy arm (Arm 2) of CIPRA SA-Project 2
11648734|NCT00099658|Experimental|4|HIV-infected infants in CDC Disease Category 2 or 3 who were randomly assigned to the second early therapy arm (Arm 3) of CIPRA SA-Project 2
11648735|NCT00099658|Experimental|5|HIV-uninfected infants born to HIV infected mothers
11648736|NCT00099632|Experimental|7-day 3TC/ZDV|SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.
11648737|NCT00099632|Experimental|21-day 3TC/ZDV|SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.
11648738|NCT00099632|Experimental|7-day FTC/TDF|SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.
11648739|NCT00099632|Experimental|21-day FTC/TDF|SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.
11648740|NCT00099632|Experimental|7-day LPV/r|SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.
11648741|NCT00099632|Experimental|21-day LPV/r|SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r
11648742|NCT00099619|Experimental|exenatide/insulin glargine|Arm that first receives exenatide, then crosses over to insulin glargine
11648743|NCT00099619|Experimental|Insulin glargine/exenatide|Arm that first receives insulin glargine, then crosses over to exenatide
11648744|NCT00099606|Experimental|A1|
11648745|NCT00099580|Experimental|1|
11648746|NCT00099580|Placebo Comparator|2|
11648747|NCT00099515|Experimental|A|
11648748|NCT00099515|Experimental|B|
11648749|NCT00099502|Experimental|Arm 1|
11648750|NCT00099502|Experimental|Arm 2|
11648751|NCT00099502|Active Comparator|Arm 3|
11648752|NCT00099437|Experimental|1|Fulvestrant 500 mg
11648753|NCT00099437|Experimental|2|Fulvestrant 250 mg
11648754|NCT00099372||Abdominal Sacral Colpopexy with no Burch colposuspension|
11648755|NCT00099372||Abdominal Sacral Colpopexy with Burch Colposuspension|
11648756|NCT00099359|Experimental|A|Standard of care ( Zidovudine only)
11648757|NCT00099359|Experimental|B|Standard of care (Zidovudine) plus Nevirapine
11648758|NCT00099359|Experimental|C|Standard of Care (Zidovudine) plus 2 weeks of Epivir and Nelfinavir
11648759|NCT00099333|Experimental|Exenatide|The subjects will discontinue their insulin and substitute it with exenatide. Subjects will remain on their existing oral diabetic therapy.
11648760|NCT00099333|Active Comparator|Insulin|The subjects will remain on their current insulin therapy. Subjects will also remain on their existing oral diabetic therapy.
11648761|NCT00099320|Experimental|Exenatide|After a 2-week placebo lead-in period, exenatide will be given in an esclating dose along with the subject's current therapy regimen
11648762|NCT00099320|Placebo Comparator|Placebo|After a 2-week placebo lead-in period, subjects will be given placebo (in equivalent amounts to exenatide) in addition to their current therapy regimen.
11648763|NCT00099268|Experimental|Carbidopa/levodopa/entacapone|Patients received Carbidopa/levodopa/entacapone tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks.
11648764|NCT00099268|Active Comparator|Immediate release carbidopa/levodopa|Patients received Immediate release carbidopa/levodopa tablets. The study was designed as a flexible dose trial (200-1000 mg/day levodopa). The target dose was 400 mg/day levodopa administered orally as 4 equal doses 4 times a day with 3.5-hour dosing intervals for a treatment period of 134 to 208 weeks.
11648765|NCT00099203|Experimental|1|
11648766|NCT00099203|Active Comparator|2|
11648767|NCT00099177|Experimental|1|
11648768|NCT00099177|Active Comparator|2|
11648769|NCT00099125|Experimental|RT with chemotherapy + post-radiation chemotherapy|Radiation therapy (RT) with concurrent chemotherapy + post-radiation chemotherapy
11648770|NCT00099086|Experimental|Experimental Arm|
11648771|NCT00099047|Experimental|Arm I (celecoxib)|Patients receive celecoxib PO BID for 6 months in the absence of unacceptable toxicity or progression to malignancy.
11648772|NCT00099047|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 6 months in the absence of unacceptable toxicity or progression to malignancy.
11648773|NCT00099021|Experimental|Prevention (pioglitazone hydrochloride)|Patients receive pioglitazone hydrochloride PO QD for 12 weeks in the absence of disease progression, unacceptable toxicity, or the development of carcinoma.
11648774|NCT00099008|Experimental|Arm I|Genistein
11648775|NCT00099008|Placebo Comparator|Arm II|Placebo
11648776|NCT00098956|Experimental|Treatment (topotecan hydrochloride, UCN-01)|Patients receive topotecan IV over 30 minutes on days 1-5 and UCN-01 IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or PR receive 2 additional courses beyond CR or PR.
11648777|NCT00098891|Experimental|Treatment (entinostat, isotretinoin)|Patients receive oral MS-275 once on days 1, 8, and 15 and oral isotretinoin twice daily on days 1-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
11648778|NCT00098865|Experimental|Thalidomide and Temozolomide|"Thalidomide:
~Oral thalidomide on days 1-28 of a 28 day cycle initiated at 3 mg/kg and increased to maximum dose of 24 mg/kg or 1000 mg as tolerated.
~Temozolomide:
~Oral temozolomide on days 1-5 of 28 day cycle given at 200 mg/m2 or 150 mg/m2 for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal radiation.
~Patients were treated for 6 cycles unless disease progression or excessive toxicity. Treatment could continue beyond 6 cycles if absent disease progression"
11648779|NCT00098839|Experimental|Reinduction Chemoimmunotherapy with Epratuzumab once weekly|Four weekly doses of epratuzumab (360 mg/m2/dose) IV days 1, 8, 15, 22. Also received vincristine sulfate, prednisone, pegaspargase, doxorubicin hydrochloride, dexrazoxane hydrochloride, etoposide, cyclophosphamide, filgrastim, high-dose (HD) methotrexate with Leucovorin calcium rescue, L-asparaginase, cytarabine, IT cytarabine, IT methotrexate (CNS-negative), Intrathecal triple therapy (ITT) (methotrexate, cytarabine, therapeutic hydrocortisone for CNS-positive) during the 3 blocks of reinduction therapy.
11648888|NCT00097292||Semi-Annual Metabolic Monitoring|Participants will be monitored every six months for risk of type 1 diabetes
11648780|NCT00098839|Experimental|Reinduction Chemoimmunotherapy with Epratuzumab twice weekly|Eight 8 twice-weekly doses of epratuzumab (360 mg/m2/dose) IV days 1, 4, 8, 11, 15, 18, 22 & 25. Also received vincristine sulfate, prednisone, pegaspargase, doxorubicin hydrochloride, dexrazoxane hydrochloride, etoposide, cyclophosphamide, filgrastim, high-dose (HD) methotrexate with Leucovorin calcium rescue, L-asparaginase, cytarabine, IT cytarabine, IT methotrexate (CNS-negative), Intrathecal triple therapy (ITT) (methotrexate, cytarabine, therapeutic hydrocortisone for CNS-positive) during the 3 blocks of reinduction therapy.
11648781|NCT00098826|Experimental|Treatment (ispinesib)|"Induction chemotherapy: Patients receive SB-715992 IV over 1 hour on days 1-3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
~Consolidation chemotherapy: Patients achieving CR, PR, or SD after induction chemotherapy receive up to 4 additional courses of SB-715992 beyond CR, PR, or SD.
~Cohorts of 3-6 patients receive SB-715992 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 9 patients are treated at the MTD."
11648782|NCT00098813|Experimental|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of unacceptable toxicity or disease progression.
11648783|NCT00098787|Experimental|Arm A (High TS, IROX/bev)|Patients with high TS who are randomized to Arm A receive irinotecan and oxaliplatin plus bevacizumab (IROX/bev). The combination regimen is administered by giving bevacizumab IV over 30-90 minutes followed by oxaliplatin IV over 2 hours and irinotecan IV over 90 minutes on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
11648784|NCT00098787|Experimental|Arm B (High TS, FOLFOX/bev)|Patients with high TS who are randomized to Arm B receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev). The combination regimen is administered by giving bevacizumab and oxaliplatin as in Arm A, leucovorin calcium IV over 2 hours, and fluorouracil IV over 5 minutes and then continuously over 46 hours on days 1 and 15 every 28 days until disease progression or until any criterion specified in protocol is met.
11648785|NCT00098787|Experimental|Arm C (Low or intermediate TS, FOLFOX/bev)|Patients with low or intermediate TS receive 5-Fluorouracil, leucovorin, oxaliplatin, and bevacizumab (FOLFOX/bev) as in Arm B.
11648786|NCT00098774|Experimental|Intensive Combination Chemo & Immunotherapy|"Induction Cycles 1-3: Methotrexate 8gm/m^2 days 1 & 15; Leucovorin 100 mg/m^2 days 2 & 16; Rituximab 375 mg/m^2 days 3, 10, 17 & 24 of cycle 1, days 3 & 10 of cycle 2; Temozolomide 150 mg/m^2/day PO days 7-11
~Induction Cycle 4: Temozolomide 150 mg/m^2/day PO days 7-11; Methotrexate 8gm/m^2 day 15; Leucovorin 100 mg/m^2 day 16
~Consolidation Cycle 5: Methotrexate 8gm/m^2 days 1; Leucovorin 100 mg/m^2 days 2; Temozolomide 150 mg/m^2/day PO days 7-11
~Consolidation Cycle 6: Cytarabine 2 g/m^2 (x 8 doses) days 1-4; Etoposide 5 mg/kg (x 8 doses) days 1-4; G-CSF 5 mcg/kg/day or GM-CSF 250 mcg/m^2/day starting day 14 until ANC recovers (>= 500 for 2 consecutive days or >= 1500 for one day)"
11648787|NCT00098748|Experimental|1|
11648788|NCT00098748|Experimental|2|
11648789|NCT00098748|Experimental|3|
11648790|NCT00098722|Experimental|1|
11648791|NCT00098722|Placebo Comparator|2|
11648792|NCT00098722|Experimental|3|
11648793|NCT00098670|Experimental|Treatment (alemtuzumab, rituximab, fludarabine phosphate)|"Patients receive induction therapy comprising rituximab IV over 4 hours on days 1, 3, and 5 of course 1 and day 1 of all subsequent courses and fludarabine IV over 30 minutes on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression.
~Approximately 4 months after completion of induction therapy, patients achieving a partial response, nodular partial response, or stable disease receive consolidation therapy comprising alemtuzumab subcutaneously on days 1-3. Treatment repeats weekly for up to 6 courses in the absence of disease progression."
11648794|NCT00098631|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648795|NCT00098618|Experimental|Treatment (sorafenib tosylate and recombinant interferon alfa)|Patients receive oral sorafenib twice daily and interferon alfa subcutaneously three times a week for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity
11648796|NCT00098605|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648797|NCT00098579|Experimental|Treatment (chemotherapy)|Patients receive doxorubicin hydrochloride IV over 5-10 minutes and alvocidib IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients reaching a cumulative doxorubicin dose of 600 mg/m^2 or experiencing cardiotoxicity may receive alvocidib alone at the discretion of the investigator. Cohorts of 3-6 patients receive escalating doses of alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Ten additional patients receive treatment at the MTD. Patients are followed every 3 months for 1 year.
11648798|NCT00098553|Experimental|everolimus|"Patients receive oral everolimus once daily for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
~Patients are followed every 2 months until disease progression and then every 4 months for up to 5 years after registration."
11648799|NCT00098540|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648800|NCT00098527|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648801|NCT00098514|Experimental|Dose Level 1a|10 mg/m2 dose of PT523 administered day 1 of a 28-day cycle as a 5 minute IV infusion (IV bolus)
11648802|NCT00098514|Experimental|Dose Level 1b|5 mg/m2 dose of PT523 administered days 1 and 8 of a 28-day cycle as a 5 minute IV infusion
11648803|NCT00098514|Experimental|Dose Level 1c|3.33 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
11648804|NCT00098514|Experimental|Dose Level 2|5 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
11648805|NCT00098514|Experimental|Dose Level 3|7.5 mg/m2 dose (or 6.7 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
11648889|NCT00097266|Placebo Comparator|A|
11648806|NCT00098514|Experimental|Dose Level 4|11.25 mg/m2 dose (or 9 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
11648807|NCT00098514|Experimental|Dose Level 5|17 mg/m2 dose (or 12 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
11648808|NCT00098501|Experimental|Arm I|Patients receive oral EKB-569 on days 1-28 and oral CCI-779 on days 1-7 and 15-21.
11648809|NCT00098488|Experimental|Treatment (17-AGG and rituximab)|Patients receive 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15 and 18 (course 1). Patients achieving ≥ 25% reduction in measurable disease after course 1 receive an additional course of single-agent 17-AAG approximately 10 days later in the absence of disease progression or unacceptable toxicity and provided absolute lymphocyte count continues to decrease. Patients failing to achieve a 25% reduction in measurable disease after course 1 OR with disease progression after courses 1 or 2 of single-agent 17-AAG proceed to combination therapy comprising 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15, 18, and 22; and rituximab IV over 4 hours on days 1 and 2 and over 1 hour on days 4, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.
11648810|NCT00098475|Active Comparator|Arm I (lenalidomide, dexamethasone)|Patients receive lenalidomide PO QD on days 1-21 and standard-dose dexamethasone PO QD on days 1-4, 9-12, and 17-20.
11648811|NCT00098475|Experimental|Arm II (lenalidomide, low-dose dexamethasone)|Patients receive lenalidomide and acetylsalicylic acid as in Arm I and low-dose dexamethasone PO QD on days 1, 8, 15, and 22.
11648812|NCT00098475|Active Comparator|Arm III (thalidomide, dexamethasone)|Patients with no response after treatment on Arm I: Patients receive thalidomide PO QD on days 1-28 and standard-dose dexamethasone PO QD on days 1-4, 9-12, and 17-20
11648813|NCT00098475|Experimental|Arm IV (thalidomide, low-dose dexamethasone)|Patients with no response after treatment on Arm II: Patients receive thalidomide as in arm III and low-dose dexamethasone PO QD on days 1, 8, 15, and 22.
11648814|NCT00098423|Experimental|Treatment (chemotherapy)|"Patients receive induction therapy comprising cytarabine IV continuously on days 1-5 and tanespimycin IV over 1 hour on days 3 and 6.
~Patients achieving a morphologic complete response with CRi or partial response may be eligible to receive a second induction course of therapy after day 21 at the discretion of the principal investigator. Patients achieving a CR receive up to 4 courses of consolidation therapy with cytarabine and tanespimycin. Consolidation therapy repeats approximately every 60 days in the absence of disease progression or unacceptable toxicity. Patients who achieve CR and remain in remission for â¥ 6 months may be retreated with cytarabine and tanespimycin (at the current dose level or the MTD) at the time of relapse. Cohorts of 3-6 patients receive escalating doses of tanespimycin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed at 3 months."
11648815|NCT00098397|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648816|NCT00098371|Experimental|Treatment (alvocidib)|Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving at least a partial remission (PR) and whose PR lasts for > 6 months after completion of treatment may receive 6 additional courses of flavopiridol.
11648817|NCT00098345|Experimental|Caprelsa (vandetanib) 300 mg|Daily oral dose of Caprelsa (vandetanib) 300mg
11648818|NCT00098306|Experimental|1|
11648819|NCT00098306|Experimental|2|
11648820|NCT00098306|Experimental|3|
11648821|NCT00098293|Experimental|1|
11648822|NCT00098293|Active Comparator|3|
11648823|NCT00098293|Experimental|2|Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz
11648824|NCT00098254|Experimental|BAY 43-9006 (Sorafenib)|Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
11648825|NCT00098163|Experimental|1|
11648826|NCT00098163|Placebo Comparator|2|
11648827|NCT00098137|Experimental|Olmesartan|Olmesartan tablet, 1 in the morning
11648828|NCT00098137|Placebo Comparator|Placebo|Placebo tablets, 1 in the morning
11648829|NCT00098111|Active Comparator|Azathioprine 0.5 mg/kg body weight|
11648830|NCT00098111|Active Comparator|Azathioprine 2.5 mg/kg body weight|
11648831|NCT00098111|Active Comparator|Azathioprine 3.5 mg/kg body weight|
11648832|NCT00098072|No Intervention|Pilot|Pilot
11648833|NCT00098059|Experimental|Famciclovir, pediatric oral formulation|single-arm
11648834|NCT00098020|Experimental|Isotretinoin|Subjects will be treated with Isotretinoin.
11648835|NCT00097981|Active Comparator|Thalidomide + dexamethasone|
11648836|NCT00097981|Experimental|Thalidomide + dexamethasone + DOXIL|
11648837|NCT00097903|Experimental|1|Karenitecin IV/ Karenitecin tablet
11648838|NCT00097838|Experimental|1 x 10^5 IU dose|Vaccine dose of 1 x 10^5 IU per injection
11648839|NCT00097838|Experimental|1 x 10^6 IU dose|Vaccine dose of 1 x 10^6 IU per injection
11648840|NCT00097838|Experimental|1 x 10^7 IU dose|Vaccine dose of 1 x 10^7 IU per injection
11648841|NCT00097838|Experimental|1 x 10^8 IU dose|Vaccine dose of 1 x 10^8 IU per injection
11648842|NCT00097838|Placebo Comparator|Placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
11648843|NCT00097786|Experimental|Valsartan 160 mg + nateglinide 60 mg|For the first 2 weeks of treatment, patients took the combination of nateglinide 30 mg (3 times daily, ante cibum [ac] before meals) and valsartan 80 mg (once daily [od] in the morning). After 2 weeks, patients were up-titrated to nateglinide 60 mg ac and valsartan 160 mg od.
11648844|NCT00097786|Experimental|Valsartan 160 mg + nateglinide placebo|For the first 2 weeks of treatment, patients took valsartan 80 mg capsules (once daily [od] in the morning). After 2 weeks, patients were up-titrated to 160 mg valsartan od. Patients also received nateglinide placebo tablets (3 times daily, ante cibum [ac] before meals).
11648890|NCT00097266|Experimental|B|
11648891|NCT00097266|Active Comparator|C|
11648892|NCT00097253|Experimental|Lavender|
11648893|NCT00097253|Experimental|Citrus|
11648845|NCT00097786|Experimental|Nateglinide 60 mg + valsartan placebo|For the first 2 weeks of treatment, patients took nateglinide 30 mg tablets (3 times daily, ante cibum [ac] before meals). After 2 weeks, patients were uptitrated to 60 mg nateglinide ac. Patients also received valsartan placebo capsules (once daily [od] in the morning).
11648846|NCT00097786|Placebo Comparator|Placebo|Patients took 3 nateglinide placebo tablets (3 times daily, ante cibum [ac] before meals) and 1 valsartan placebo capsule (once daily [od] in the morning).
11648847|NCT00097773|Placebo Comparator|Cycled TOBI & placebo|Tobramycin inhalation solution and oral placebo for six consecutive quarterly cycles
11648848|NCT00097773|Active Comparator|Cycled TOBI & oral ciprofloxacin|Tobramycin solution for inhalation and oral ciprofloxacin for six consecutive quarterly cycles.
11648849|NCT00097773|Placebo Comparator|Culture based TOBI & placebo|Tobramycin solution for inhalation and oral placebo administered only when quarterly respiratory cultures are found positive for Pa.
11648850|NCT00097773|Active Comparator|Culture based TOBI & oral cipro|Tobramycin solution for inhalation and oral ciprofloxacin administered only when quarterly respiratory cultures are found positive for Pa.
11648851|NCT00097760|Experimental|Group 1|Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.
11648852|NCT00097760|Placebo Comparator|Group 2|Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
11648853|NCT00097747|Placebo Comparator|Placebo|Single injection administered intravenously
11648854|NCT00097747|Experimental|Peginesatide 0.025 mg/kg|Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.
11648855|NCT00097747|Experimental|Peginesatide 0.05 mg/kg|Single peginesatide dose of 0.05 mg/kg administered intravenously.
11648856|NCT00097747|Experimental|Peginesatide 0.10 mg/kg|Single peginesatide dose of 0.10 mg/kg administered intravenously.
11648857|NCT00097721|Experimental|E7389|
11648858|NCT00097695|Experimental|Icatibant- Randomized|Patients who were randomized to icatibant in the controlled phase after they had an eligible first in-study attack.
11648859|NCT00097695|Placebo Comparator|Placebo-Randomized|Patients who were randomized to placebo in the controlled phase after they had an eligible first in-study attack.
11648860|NCT00097695|Experimental|Controlled Open-label / laryngeal attack|Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.
11648861|NCT00097695|Experimental|Untreated Patients at the baseline|Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing (they were not treated during the Controlled phase but treated with icatibant during the Open Label Extension Phase (OLE) )
11648862|NCT00097669|Active Comparator|Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug)|Active Treatment Arm: VITATOPS study tablet (folate 2 mg, B6 25 mg, B12 500 ug). Taken daily for the duration of the study.
11648863|NCT00097669|Placebo Comparator|Placebo Tablet|Placebo Treatment Arm: The placebo tablet will have the same appearance, taste and texture as the vitamin preparation and contains excipients, coating and coating aids.
11648864|NCT00097656|Experimental|Periodontal Treatment|maternal periodontal therapy
11648865|NCT00097604|Experimental|Valerian|This study used a cross-over design with valerian compared to placebo. Group 1 received valerian first followed by placebo after washout and cross-over; group 2 received placebo first followed by placebo after wash-out and cross-over.
11648866|NCT00097604|Placebo Comparator|Placebo|This study used a cross-over design with valerian compared to placebo. Group 1 received valerian first followed by placebo after washout and cross-over; group 2 received placebo first followed by placebo after wash-out and cross-over.
11648867|NCT00097591|Experimental|Prasugrel|Oral loading dose of six 10 mg prasugrel tablets and four placebo tablets matched to clopidogrel, followed by an oral maintenance dose of prasugrel one 10 mg tablet and one placebo tablet matched to clopidogrel once daily
11648868|NCT00097591|Active Comparator|Clopidogrel|Oral loading dose of four 75 mg clopidogrel tablets and six placebo tablets matched to prasugrel, followed by an oral maintenance dose of one 75 mg clopidogrel tablet and one placebo tablet matched to prasugrel once daily
11648869|NCT00097539||Participants With Growth Disorders|Participants initiating therapy with Genentech GH products: Protropin (somatrem for injection), Nutropin (somatropin for injection), Nutropin AQ (somatropin for injection), and Nutropin Depot (somatropin for injectable suspension) for the treatment of pediatric growth disorders as determined by their physician and who have consented to participate in the NCGS will be enrolled in the study and will be followed throughout their course of treatment, or until withdrawal from the NCGS.
11648870|NCT00097500|Experimental|Exenatide Arm|Exenatide and Metformin
11648871|NCT00097500|Active Comparator|Insulin Glargine Arm|Insulin Glargine and Metformin
11648872|NCT00097474|Experimental|Combination|Both HC 30 and ML 5 will be administered
11648873|NCT00097474|Experimental|Hydrocortisone|30mg Hydrocortisone will be administered
11648874|NCT00097474|Experimental|Melatonin|5 mg Melatonin will be administered
11648875|NCT00097474|Placebo Comparator|Placebo|Placebo
11648876|NCT00097448|Other|1|Nineteen days of oral prednisone
11648877|NCT00097448|Experimental|2|Four doses of methylprednisolone sodium succinate delivered by injection to the middle ear over 2 weeks
11648878|NCT00097370|Experimental|mepolizumab|750mg Intravenous, monthly and individual dosing schedule
11648879|NCT00097357|Experimental|A1|"Apixaban: 2.5 mg, BID
~PLUS
~Enoxaparin Placebo"
11648880|NCT00097357|Experimental|A2|"Apixaban: 5 mg, BID
~PLUS
~Enoxaparin Placebo"
11648881|NCT00097357|Experimental|A3|"Apixaban: 10 mg, BID
~PLUS
~Enoxaparin Placebo"
11648882|NCT00097357|Experimental|A4|"Apixaban: 5 mg, QD
~PLUS
~Enoxaparin Placebo"
11648883|NCT00097357|Experimental|A5|"Apixaban: 10 mg, QD
~PLUS
~Enoxaparin Placebo"
11648884|NCT00097357|Experimental|A6|"Apixaban: 20 mg, QD
~PLUS
~Enoxaparin Placebo"
11648885|NCT00097357|Active Comparator|E1|"Enoxaparin: 30 mg
~PLUS
~Apixaban Placebo"
11648886|NCT00097357|Active Comparator|W1|Warfarin: 5 mg tablets dose titrated to a targeted INR of 1.8 to 3.0
11648887|NCT00097292||Annual Re-Testing/Annual Metabolic Monitoring|Participants will be monitored annually for risk of type 1 diabetes.
11648894|NCT00097253|Placebo Comparator|Water|
11648895|NCT00097227|Active Comparator|Arm A (3-week cycle)|"Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.
~Paclitaxel 225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks.
~Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks."
11648896|NCT00097227|Active Comparator|Arm B (4-week cycle)|"Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.
~Paclitaxel 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
~Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks."
11648897|NCT00097214|Experimental|1|"Cetuximab 400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8. Carboplatin AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.
~Therapy will continue for four cycles (12 weeks)for combination therapy"
11648898|NCT00097058||1|Continue current hormone therapy
11648899|NCT00097058||2|Taper off hormone therapy
11648900|NCT00096993|Placebo Comparator|Placebo + gemcitabine|Participants received placebo intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). In addition, participants received gemcitabine 800 mg/m^2 intravenously on Days 1 and 8 of every 3 week cycle for up to 1 year (up to 17 treatment cycles).
11648901|NCT00096993|Active Comparator|Pertuzumab + gemcitabine|Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). Participants received pertuzumab at a loading dose of 840 mg in Cycle 1 followed by a dose of 420 mg in Cycles 2 and beyond. In addition, participants received gemcitabine 800 mg/m^2 intravenously on Days 1 and 8 of every 3 week cycle for up to 1 year (up to 17 treatment cycles
11648902|NCT00096954|Experimental|Omalizumab|Omalizumab (Xolair) administered in this study was either a minimum of 0.008 mg/kg/IgE [IU/mL] every 2 weeks or a minimum of 0.016 mg/kg/IgE [IU/mL] every 4 weeks.
11648903|NCT00096954|Placebo Comparator|Placebo|Placebo administered in this study was either a minimum of 0.008 mg/kg/IgE [IU/mL] every 2 weeks or a minimum of 0.016 mg/kg/IgE [IU/mL] every 4 weeks.
11648904|NCT00096941|Experimental|Pertuzumab|Participants received the same dose of pertuzumab that they received in their parent Phase II trial, either 420 mg or 1050 mg, intravenously on Day 1 of every 3 week cycle until disease progression.
11648905|NCT00096915|Experimental|darbepoetin alfa|
11648906|NCT00096863|Placebo Comparator|A - placebo|per oral pill
11648907|NCT00096863|Active Comparator|B|Ziprasidone
11648908|NCT00096863|Active Comparator|C|Haloperidol
11648909|NCT00096850|Experimental|1|From Days 1 to 8, participants will receive 600 mg RIF every 24 hours. From Days 9 to 19, participants will receive 300 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours. From Days 20 to 27, participants will receive 400 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours.
11648910|NCT00096824||1|Participants will undergo neurological examinations and neuropsychological assessments at entry to both steps of ACTG A5175 and before the administration of the new antiretroviral regimen, then every 24 weeks until they discontinue ACTG A5175. Physicians will make targeted diagnoses at each study visit.
11648911|NCT00096785|Active Comparator|A1|
11648912|NCT00096785|Active Comparator|A2|
11648913|NCT00096746||A1|HIV infected individuals on first line ATV based HAART with presence of I50L mutation.
11648914|NCT00096746||A2|HIV infected PI naïve on failed NNRTI based regimen.
11648915|NCT00096733||Donors|Living liver donors. This label may also refer to those evaluated for liver donation who did not go on to donate, i.e., potential living liver donors.
11648916|NCT00096733||Recipients|Liver transplant recipients (either living or deceased donor). This label may also refer to those who were evaluated for liver transplantation, but never received a transplant, i.e., potential recipients.
11648917|NCT00096668|Experimental|TOCOSOL Paclitaxel|TOCOSOL Paclitaxel administered weekly at 120mg/mm2
11648918|NCT00096629|Experimental|human PSMA|Patients will receive a total of 6 vaccinations via the intramuscular route. Sites of injection should have intact lymphatic drainage. Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
11648919|NCT00096629|Experimental|mouse PSMA|Patients will receive a total of 6 vaccinations via the intramuscular route. Sites of injection should have intact lymphatic drainage. Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
11648920|NCT00096538|Experimental|valganciclovir|Patients receive oral valganciclovir twice daily for 3 weeks and then once daily for 21 weeks in the absence of disease progression or unacceptable toxicity. All patients are followed for 1 month after completion of therapy. Patients with responding disease are followed monthly for up to 1 year.
11648921|NCT00096512|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648922|NCT00096499|Experimental|Treatment (ispinesib)|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11648923|NCT00096486|Experimental|Gefitinib and Everolimus (RAD001)|"Phase I: Patients receive oral everolimus once on day 1. Beginning on day 8, patients receive oral gefitinib once daily. Beginning on day 22, patients receive oral everolimus once daily. Both drugs are then given concurrently for the rest of the treatment. Treatment continues in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of everolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.
~Phase II: Patients receive oral everolimus at the MTD determined in phase I and oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity."
11648924|NCT00096460|Active Comparator|Autologous Transplant|Cyclophosphamide and Rituximab with Filgrastim conditioning and chemotherapy or radiation therapy prior to autologous Hematopoietic Stem Cell Transplant (HSCT). Rituximab maintenance therapy following HSCT.
11649046|NCT00094822||Pegfilgrastim|
11649047|NCT00094822||PLACEBO|
11649048|NCT00094809|Active Comparator|Pegfilgrastim|6 mg pegfilgrastim
11648925|NCT00096460|Active Comparator|Allogeneic Transplant|Non-myeloablative conditioning regimen followed by allogeneic Hematopoietic Stem Cell Transplant (HSCT). Graft-versus-Host Disease (GVHD) Prophylaxis therapy following HSCT.
11648926|NCT00096447|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648927|NCT00096434|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648928|NCT00096408|Active Comparator|1|Total Abdominal Hysterectomy
11648929|NCT00096408|Experimental|2|Total Laparoscopic Hysterectomy
11648930|NCT00096395|Experimental|Treatment (sorafenib tosylate, gemcitabine hydrochloride)|"Course 1 (56 days): Patients receive oral sorafenib twice daily on days 1-56 and gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43.
~Course 2 and all subsequent courses (28 days): Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11648931|NCT00096382|Other|TBI 200cGy + TIL +HD IL-2, prior IL-2|"Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.
~Lymphocytes that that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient."
11648932|NCT00096382|Other|TBI 200cGy + TIL +HD IL-2, No prior IL-2|"Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.
~Lymphocytes that that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient."
11648933|NCT00096356|Active Comparator|Arm 1 - CoQ10 & Vitamin E|CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day.
11648934|NCT00096356|Placebo Comparator|Arm 2 - Placebo & Vitamin E|Placebo-Vitamin E 100 mg/day in 3 doses
11648935|NCT00096343|Experimental|Paclitaxel IV followed by Carboplatin IV|paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11648936|NCT00096291|Active Comparator|Sequence Doxorubicin followed by Paclitaxel|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:
~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
11648937|NCT00096291|Other|Sequence of neoadjuvant CT: Paclitaxel followed by Doxorubicin|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:
~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
11648938|NCT00096278|Active Comparator|Arm I (mFOLFOX6)|Patients receive adjuvant chemotherapy comprising concurrent oxaliplatin and leucovorin calcium IV over 2 hours on day 1. Patients also receive adjuvant fluorouracil IV over 2-4 minutes on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.
11648939|NCT00096278|Experimental|Arm II (bevacizumab, mFOLFOX6)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive adjuvant oxaliplatin, leucovorin calcium, and fluorouracil as in arm I. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of adjuvant chemotherapy, patients continue to receive bevacizumab alone every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
11648940|NCT00096265|Active Comparator|Arm I|Patients undergo whole brain radiotherapy (WBRT) once daily on days 1-5, 8-12, and 15-19. Within 14 days after completion of WBRT, patients undergo stereotactic radiosurgery.
11648941|NCT00096265|Experimental|Arm II|Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral temozolomide once daily on days 1-21. Beginning 4 weeks after completion of WBRT, patients may receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11648942|NCT00096265|Experimental|Arm III|Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral erlotinib once daily for up to 6 months.
11648943|NCT00096226|Experimental|Chemoradiation, Surgery, Chemotherapy|Induction paclitaxel(50 mg/m2 I.V. in a one-hour infusion) and induction carboplatin (AUC 2.0 I.V. in a thirty-minute infusion): 1x/week for 6 weeks. Concurrent radiation therapy (RT): 1.8 Gy/day, 5 fx/week, for a total of 50.4 Gy in 28 fractions plus a boost of 1.8 Gy/day, 5 fx/week, for a total of 10.8 Gy in 6 fractions. Followed by an assessment to determine whether patient will undergo a resection or not. Followed by consolidation paclitaxel (200 mg/m2 I.V. over three hours) and consolidation carboplatin (AUC 6.0 over one hour) q 21 days x 2.
11648944|NCT00096213|Other|surgery|intralesional resection
11648945|NCT00096200|Experimental|Arm I (closed to accrual 10/10/2008)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression crossover to arm II
11648946|NCT00096200|Experimental|Arm II|Patients receive oral sorafenib twice daily on days 2-19. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11648947|NCT00096174|Experimental|Cisplatin, C225, Radiation|"Cetuximab therapy: Patients receive an initial loading dose of cetuximab intravenously (IV) over 2 hours on day 1. Patients then receive cetuximab IV over 1 hour on days 8, 15, 22, 29, 36, 43, 50, and 57.
~Chemoradiotherapy: Beginning on day 15 of cetuximab therapy, patients undergo radiotherapy once daily, 5 days a week, for at least 7 weeks. Patients also receive cisplatin IV over 1-2 hours on days 15, 36, and 57.
~Cetuximab maintenance therapy: After the completion of chemoradiotherapy, patients continue to receive cetuximab IV over 1 hour once weekly for 6-12 months."
11648948|NCT00096161|Experimental|pentostatin, DLI, mycophenolate mofetil, cyclosporine|"Group I (pentostatin, DLI): Patients receive pentostatin IV over 20-30 minutes on day -2 and DLI over 15-30 minutes on day 0. Treatment may repeat once beginning with an escalated or same CD3-dose at least 4 weeks if persistent donor T-cells are documented, no GvHD has developed, and the chimerism status worsens or, if chimerism status is unchanged after at least 8 weeks with two subsequent tests of chimerism 4 weeks apart.
~Group II (pentostatin, DLI, mycophenolate mofetil, cyclosporine): Patients receive treatment as in group I. Patients also receive cyclosporine PO BID on days -3 to 56 and mycophenolate mofetil PO QD on days 0 to 27. Treatment continues in the absence of GvHD."
11648949|NCT00096148|Experimental|Arm I (idarubicin, cytarabine)|"Arm I: Patients receive idarubicin IV over 1 hour on days 1-3 and cytarabine IV continuously over 24 hours on days 1-4.
~Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28 days in the absence of disease progression or unacceptable toxicity.
~Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.
~Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24 hours on days 1-4."
11648950|NCT00096148|Experimental|Arm II (idarubicin, cytarabine, bevacizumab)|"Patients receive idarubicin and cytarabine as in arm I. Patients also receive bevacizumab* IV over 30-90 minutes on day 1. Patients who do not achieve complete remission (CR) after the first induction course may receive a second induction course approximately 28 days* later. Patients who do not achieve CR after 2 courses are removed from the study.
~NOTE: *Patients in arm II receive bevacizumab, independently of chemotherapy administration schedule, once every 21 days for 1 year from CR date.
~Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28 days in the absence of disease progression or unacceptable toxicity.
~Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.
~Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24 hours on days 1-4."
11648951|NCT00096135|Experimental|CNS Patients-Treatment (combination chemotherapy)|All patients receive common induction (vincristine sulfate, dexamethasone, daunorubicin hydrochloride & intrathecal triple therapy (ITT: MTX, therapeutic hydrocortisone and cytarabine)), consolidation (cytarabine, pegaspargase, filgrastim, re-induction (vincristine, dexamethasone, daunorubicin), and intensification chemotherapy (MTX, leucovorin calcium, mercaptopurine, etoposide, cyclophosphamide & ITT.
11648952|NCT00096135|Experimental|Testicular Relapse Patients (Combination chemotherapy)|All patients receive common induction (vincristine sulfate, dexamethasone, daunorubicin hydrochloride & intrathecal triple therapy (ITT: MTX, therapeutic hydrocortisone and cytarabine)), consolidation (cytarabine, pegaspargase, filgrastim, testicular radiation therapy, re-induction (vincristine, dexamethasone, daunorubicin), and intensification chemotherapy (MTX, leucovorin calcium, mercaptopurine, etoposide, cyclophosphamide & ITT.
11648953|NCT00096122|Experimental|Arm I|See Detailed Description
11648954|NCT00096109|Experimental|Treatment (tanespimycin)|Patients receive tanespimycin IV over 1-6 hours on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11648955|NCT00096083|Active Comparator|Melphalan Administration PHP|
11648956|NCT00096070|Experimental|Arm I|Patients undergo radiotherapy once daily, 5 days a week, for 5.5 weeks. Beginning concurrently with radiotherapy, patients receive oxaliplatin IV over 2 hours on days 1, 15, and 29 and fluorouracil IV continuously for 5.5 weeks. Beginning 4-6 weeks after the completion of chemoradiotherapy, patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment with gemcitabine repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11648957|NCT00096044|Experimental|Oral Lenalidomide|Patients receive oral lenalidomide (CC-5013) once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity
11648958|NCT00096031|Experimental|Cetuximab|250 mg/m^2 on days 1, 8, 15, and 22 of every 28-day cycle.
11648959|NCT00096018|Experimental|Dose escalation|Thalidomide (100 mg/day, 200 mg/day, or 300 mg/day) on Day 1 followed by Fludarabine 25 mg/m2/day for 5 days starting on Day 7 (cycle = 28 days
11648960|NCT00096005|Experimental|Treatment (chemotherapy and enzyme inhibitor therapy)|"Patients receive tanespimycin IV over 1-2 hours and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of tanespimycin and bortezomib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 12 additional patients are treated as above* at the MTD.
~NOTE: *Bortezomib is not administered on day 1 of course 1 only. Patients are followed at 3 months."
11648961|NCT00095979|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11648962|NCT00095966|Experimental|Treatment (sorafenib tosylate and gemcitabine hydrochloride)|Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648963|NCT00095940|Experimental|Treatment (surgery, lapatinib)|"Molecular Biology Phase: Patients randomized to receive lapatinib prior to surgery receive oral lapatinib twice daily for 7-14 days. Surgery is performed after 7-14 days of lapatinib treatment. For patients randomized to not receive lapatinib, surgery is performed within 3 weeks of registration. After surgical resection, all molecular biology participants start lapatinib treatment within 10 days post-surgery. The first dose of lapatinib post-surgery initiates course 1. Patients receive oral lapatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity.
~Lapatinib Continuation/Phase II: Patients receive oral lapatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 26 courses (2 years) in the absence of disease progression or unacceptable toxicity."
11648964|NCT00095927|Active Comparator|Arm A Amifostine|"Patients with newly diagnosed, locally advanced stage ill or IV SCCHN received;
~4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m 2) concurrently with concomitant boost radiation consisting of 72 grays in 42 fractions over 6 weeks (every day for 18 days, twice a day for 12 days) (grading determined according to the TNM staging system).
~Subcutaneous daily amifostine at a dose of 500 mg"
11648965|NCT00095927|Experimental|Arm B No-Amifostine|"Patients with newly diagnosed, locally advanced stage ill or IV SCCHN
~- 4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m 2) concurrently with concomitant boost radiation consisting of 72 grays in 42 fractions over 6 weeks (every day for 18 days, twice a day for 12 days) (grading determined according to the TNM staging system)."
11648966|NCT00095901|Experimental|Capecitabine|Capecitabine (Xeloda 4:14. ) 150 mg and 500 mg tablets. Capecitabine will be administered at a dose of 1000 mg/m2 twice daily, for a total daily dose of 2000 mg/m 2. Capecitabine will administered P.O. or per G-tube B.I.D. for 14 days, followed by a one-week rest period in 3-week cycles.
11649049|NCT00094809|Placebo Comparator|Placebo|6 mg placebo
11649050|NCT00094770|Experimental|Sitagliptin 100 mg|Sitagliptin 100 mg oral tablets of sitagliptin once daily.
11648967|NCT00095888|Experimental|Treatment (triapine, gemcitabine hydrochloride)|Patients receive 3-AP (Triapine®) IV over 2 hours followed by gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11648968|NCT00095875|Experimental|Arm I|Patients receive induction chemotherapy comprising docetaxel, cisplatin, and fluorouracil. Treatment repeats every 21 days for 3 courses. Patients achieving a pathologic complete response at the primary site and a clinical complete response in the neck then receive carboplatin once weekly and undergo concurrent radiotherapy once daily, 5 days a week, for 7 weeks. Patients with a partial response at the primary site (i.e., positive biopsy), stable disease, or radiographic evidence of persistent disease in the neck receive docetaxel once weekly for 4 weeks and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 6 weeks.
11648969|NCT00095875|Experimental|Arm II|Patients receive cisplatin IV on weeks 1 and 4 and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 6 weeks.
11648970|NCT00095836|Experimental|Gefitinib 250mg|
11648971|NCT00095823|Placebo Comparator|A1|
11648972|NCT00095823|Active Comparator|A2|
11648973|NCT00095823|No Intervention|A3|
11648974|NCT00095810|Experimental|A|
11648975|NCT00095797|Experimental|Treatment (XK469R)|Patients receive XK469R IV over 30-60 minutes on days 1, 3, and 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11648976|NCT00095784|Experimental|Treatment (decitabine)|Patients receive decitabine SC on days 1-5 and 8-12. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.
11648977|NCT00095758|Placebo Comparator|A1|
11648978|NCT00095758|Active Comparator|A2|
11648979|NCT00095745|No Intervention|Antidepressant + Aripiprazole|
11648980|NCT00095732|Experimental|Low Liprotamase Dose|Liprotamase in a fixed combination of lipase (5,000 units), protease (5,000 units) and amylase (750 units) administered orally (one Size 5 capsule of liprotamase and five Size 2 capsules of placebo) with each of three meals and two snacks daily for 28 days
11648981|NCT00095732|Experimental|Mid Liprotamase Dose|Liprotamase in a fixed combination of lipase (25,000 units), protease (25,000 units) and amylase (3,750 units) administered orally (one Size 5 capsule of liprotamase, one Size 2 capsule of liprotamase, and four Size 2 capsules of placebo) with each of three meals and two snacks daily for 28 days
11648982|NCT00095732|Experimental|High Liprotamase Dose|Liprotamase in a fixed combination of lipase (100,000 units), protease (100,000 units) and amylase (15,000 units) administered orally (one Size 5 capsule of placebo and five Size 2 capsules of liprotamase) with each of three meals and two snacks daily for 28 days
11648983|NCT00095719|Active Comparator|A1|
11648984|NCT00095719|Placebo Comparator|B1|
11648985|NCT00095693|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib tosylate twice daily for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 8 additional weeks of therapy beyond CR.
11648986|NCT00095680|Experimental|001|SCIO-469 two 30-mg capsules three times daily
11648987|NCT00095680|Active Comparator|002|SCIO-469 and bortezomib The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
11648988|NCT00095667|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
11648989|NCT00095628|Experimental|Treatment (ispinesib)|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11648990|NCT00095576|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef|Participants randomized to receive three 1.0-ml intramuscular (IM) injections of Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef (MRKAd5 HIV-1 gag/pol/nef) Vaccine at a dose of 1.5x10^10 adenovirus genomes (Ad vg) per dose at Day 1, Week 4, and Week 26.
11648991|NCT00095576|Placebo Comparator|Placebo|Participants randomized to receive three 1.0-ml intramuscular (IM) injections of placebo to MRKAd5 HIV-1 gag/pol/nef at Day 1, Week 4, and Week 26.
11648992|NCT00095563|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
11648993|NCT00095550|Experimental|A1|
11648994|NCT00095550|Active Comparator|A2|
11648995|NCT00095550|Active Comparator|A3|
11648996|NCT00095537|Experimental|Phase 1 MTD Study|
11648997|NCT00095498|Experimental|Denosumab 180 mg|Participants received 180 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
11648998|NCT00095498|Experimental|Denosumab 60 mg|Participants received 60 mg denosumab by subcutaneous injection on Day 1 and at Month 6.
11648999|NCT00095498|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections on Day 1 and at Month 6.
11649000|NCT00095420|Experimental|1|Participants with autism will receive social skills training targeting children with autism
11649001|NCT00095420|Experimental|2|Participants without autism will receive social skills training to increase acceptance of peers with autism
11649002|NCT00095420|Experimental|3|Participants with and without autism will receive a combination treatment of social skills/education about autism
11649003|NCT00095420|Active Comparator|4|Participants with and without autism will receive usual training provided by their school district
11649004|NCT00095394|Experimental|A1|
11649005|NCT00095394|Active Comparator|A2|
11649006|NCT00095329|Experimental|sirolimus|
11649007|NCT00095316|Placebo Comparator|Placebo|Subjects receive placebo intravenously daily for 28 days
11649008|NCT00095316|Experimental|Caspofungin|Subjects receive 50mg/day caspofungin intravenously (IV) for 28 days
11649009|NCT00095303|Experimental|Brief Strategic Family Therapy (BSFT)|"BSFT is a family therapy approach that consists of 12 to 16 sessions (each 1 to 1.5 hours long) over a 4-month period during the Main Study, and up to 8 booster sessions. Interventions are delivered to adolescents and relevant family members in non-restrictive community settings (e.g., clinics, homes, school)."
11649051|NCT00094770|Active Comparator|Glipizide|Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
11649010|NCT00095303|Active Comparator|Treatment as Usual (TAU)|TAU varies depending on site, however each will offer services that include at least 1 therapy session (individual or group therapy) per week during the Main Study, as well as participation in ancillary services (e.g., case management, self help groups, etc.) over a four month period.
11649011|NCT00095290|Experimental|A1|
11649012|NCT00095290|Placebo Comparator|A2|
11649013|NCT00095251|Active Comparator|Dexmedetomidine group|Patients in the dexmedetomidine arm will receive a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. The patient's managing physician will have the option of beginning the dexmedetomidine infusion without a bolus in circumstances where the patient's sedation level is adequate at enrollment or in the presence of baseline bradycardia /hypotension. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
11649014|NCT00095251|Active Comparator|Lorazepam group|Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
11649015|NCT00095238|Active Comparator|1|
11649016|NCT00095238|Placebo Comparator|2|
11649017|NCT00095212|Active Comparator|1 Transdermal Testosterone (Patch)|300 micrograms applied twice a week
11649018|NCT00095212|Placebo Comparator|2 Placebo Patch (identical in appearance)|placebo patch (0 micrograms of testosterone)applied twice a week
11649019|NCT00095199|Experimental|Cetuximab & Pemetrexed|
11649020|NCT00095199|Active Comparator|Pemetrexed|
11649021|NCT00095199|Experimental|Cetuximab & Docetaxel|
11649022|NCT00095199|Active Comparator|Docetaxel|
11649023|NCT00095173|Active Comparator|Abatacept|Double Blind Period
11649024|NCT00095173|Placebo Comparator|Placebo|Double Blind Period
11649025|NCT00095173|Experimental|Abatacept - Open Label|
11649026|NCT00095147|Active Comparator|Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB])|Days 1-365
11649027|NCT00095147|Active Comparator|Infliximab + MTX (DB)|Days 1-365
11649028|NCT00095147|Placebo Comparator|Placebo + MTX (DB)|Days 1-197
11649029|NCT00095147|Experimental|Placebo + MTX switched to abatacept + MTX (DB)|Participants received placebo plus methotrexate for days 1-197, and abatacept plus methotrexate for days 198-365
11649030|NCT00095147|Experimental|Abatacept (open-label)|Days 365 to 729 All participants receive Active Drug
11649031|NCT00095121|Placebo Comparator|Placebo (PLB)|Participants randomized to receive placebo received placebo during the first 48 weeks of treatment (double-blind phase) and then all eligible participants were administered open-label ADV for the remainder of the study.
11649032|NCT00095121|Experimental|Adefovir Dipivoxil (ADV)|Participants randomized to receive ADV received ADV during the first 48 weeks of treatment (double-blind phase) and then all eligible participants were administered open-label ADV for the remainder of the study.
11649033|NCT00095056|Experimental|Sitagliptin|Participants in the Sitagliptin treatment sequence will receive sitagliptin in Phase A and placebo to glipizide in Phase B.
11649034|NCT00095056|Placebo Comparator|Placebo|Participants in the Placebo treatment sequence will receive placebo to sitagliptin in Phase A and glipizide in Phase B.
11649035|NCT00094965|Experimental|1|
11649036|NCT00094926|Experimental|001|
11649037|NCT00094926|Placebo Comparator|002|
11649038|NCT00094900|Experimental|IL-1 Trap|
11649039|NCT00094887|Experimental|Inhaled Nitric Oxide|Participants receive Inhaled nitric oxide (INO)
11649040|NCT00094887|Placebo Comparator|Placebo|Participants receive Nitrogen gas
11649041|NCT00094861|Placebo Comparator|Placebo|"Participants received a single intravenous (IV) dose of placebo administered 3 days before the initiation of concurrent chemo/radiotherapy, then once weekly during Weeks 1 through 6, typically for a total of 7 doses. Concurrent radio/chemotherapy was given as follows:
~standard radiotherapy 2 Gy once daily x 30 to 33 fractions (6 to 7 weeks) for a total target dose of 60 to 66 Gy
~paclitaxel 50 mg/m^2 intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy)
~carboplatin dosed at an area under the curve (AUC) 2.0 IV on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy).
~Participants subsequently received two 21-day cycles of consolidation chemotherapy with paclitaxel 225 mg/m^2 and carboplatin dosed at AUC 6.0."
11649042|NCT00094861|Experimental|Palifermin|"Participants received a single IV dose of palifermin at 180 μg/kg administered 3 days before the initiation of concurrent chemo/radiotherapy, then once weekly during Weeks 1 through 6, typically for a total of 7 doses. Concurrent radio/chemotherapy (administered for 6 to 7 weeks) was given as follows:
~standard radiotherapy 2 Gy once daily x 30 to 33 fractions (6 to 7 weeks) for a total target dose of 60 to 66 Gy
~paclitaxel 50 mg/m^2 IV infusion on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy)
~carboplatin dosed at an area under the curve (AUC) 2.0 IV on Days 1, 8, 15, 22, 29, 36 (and day 43 for those receiving 66 Gy).
~Participants subsequently received two 21-day cycles of consolidation chemotherapy with paclitaxel 225 mg/m^2 and carboplatin dosed at AUC 6.0."
11649043|NCT00094835|Experimental|Paclitaxel + Carboplatin + Motesanib|Chemotherapy naïve participants received paclitaxel 200 mg/m^2 and carboplatin chemotherapy administered by intravenous (IV) infusion on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. The initial dose of motesanib was 50 mg once daily administered in the initial cohort and up to 125 mg once daily was used in subsequent cohorts. A cycle was defined as the 3 weeks plus the time to recover from toxicity, if encountered.
11649044|NCT00094835|Experimental|Panitumumab + Motesanib|Participants with no more than one prior chemotherapy regimen for NSCLC received panitumumab administered by IV at 9.0 mg/kg on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter. The initial dose of motesanib was 50 mg once daily administered in the initial cohort, up to 125 mg once daily was used in subsequent cohorts.
11649045|NCT00094835|Experimental|Panitumumab + Paclitaxel + Carboplatin + Motesanib|"Chemotherapy naïve participants received panitumumab administered by IV at 9.0 mg/kg on Day 1 of each 21-day cycle, paclitaxel 200 mg/m^2 and carboplatin chemotherapy administered by IV infusion on Day 1 of each 21-day cycle, and motesanib, orally self-administered on Days 3-21 of Cycle 1 and then on Days 1 to 21 of Cycle 2 and all cycles thereafter.
~Participants were enrolled in this arm once a safe and tolerable dose of motesanib was established."
11649052|NCT00094757|Experimental|Sitagliptin 100 mg|Sitagliptin 100 mg
11649053|NCT00094757|Experimental|Sitagliptin 200 mg|Sitagliptin 200 mg
11649054|NCT00094757|Placebo Comparator|Placebo/Pioglitazone|Placebo/Pioglitazone
11649055|NCT00094744|Active Comparator|6hrs daily patching|6 hours per day of patching in the sound eye
11649056|NCT00094744|Active Comparator|Full-time daily patching|Patching of the sound eye all but one waking hour
11649057|NCT00094718|Experimental|1|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^3 PFU dose) into the deltoid region of either arm.
11649058|NCT00094718|Experimental|2|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^4 PFU dose) into the deltoid region of either arm. This arm may enroll after the results from Arm 1 are analyzed.
11649059|NCT00094718|Experimental|3|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after the results from Arm 2 are analyzed.
11649060|NCT00094718|Placebo Comparator|4|One subcutaneous vaccination with placebo vaccine into the deltoid region of either arm.
11649061|NCT00094705|Experimental|1|One subcutaneous vaccination with a 10^3 PFU dose of rDEN2/4delta30(ME) vaccine given in the deltoid region of either arm.
11649062|NCT00094705|Experimental|2|One subcutaneous vaccination with a 10^5 PFU dose of rDEN2/4delta30(ME) vaccine given in the deltoid region of either arm.
11649063|NCT00094705|Placebo Comparator|3|One subcutaneous vaccination with a placebo vaccine given in the deltoid region of either arm.
11649064|NCT00094679|Active Comparator|2hrs daily patching|2 hours patching per day to cover the sound eye
11649065|NCT00094679|Active Comparator|6hrs daily patching|6 hours per day patching to cover the sound eye
11649066|NCT00094653|Active Comparator|1|Melanoma Peptide Vaccine (MDX-1379) (gp100) + Placebo
11649067|NCT00094653|Experimental|2|MDX-010 (ipilimumab) + MDX-1379 (gp100) (Melanoma Peptide Vaccine)
11649068|NCT00094653|Active Comparator|3|MDX-010 (ipilimumab) + Placebo
11649069|NCT00094575|Active Comparator|Arm 1|Standard Open Repair of Abdominal Aortic Aneurysm
11649070|NCT00094575|Active Comparator|Arm 2|Endovascular Repair of Abdominal Aortic Aneurysm
11649071|NCT00094536|Experimental|Extended Treatment Regimen|Extended treatment regimens using the Her Option Endometrial Cryotherapy System to more effectively ablate the endometrial lining, reducing menstrual levels to normal or less.
11649072|NCT00094523|Experimental|Treatment Arm A|Subjects switched their baseline PI for fosamprenavir (± ritonavir) while maintaining their baseline regimen of two nucleoside or nucleotide reverse transcriptase inhibitors for 48 weeks.
11649073|NCT00094523|Experimental|Treatment Arm B|Subjects continued baseline regimen for first 24 weeks with the option of switching their initial PI for fosamprenavir (± ritonavir) while maintaining their baseline nucleoside or nucleotide reverse transcriptase inhibitor regimen for another 24 weeks
11649074|NCT00094497|Active Comparator|EDP-M|etopodide, doxorubicin, cisplatin and mitotane
11649075|NCT00094497|Active Comparator|Sz-M|streptozotocin and mitotane
11649076|NCT00094458|Experimental|003|infliximab (IFX) infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
11649077|NCT00094458|Experimental|001|infliximab (IFX) placebo infusion; azathioprine (AZA) caps AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
11649078|NCT00094458|Experimental|002|infliximab infusion; AZA placebo caps Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
11649079|NCT00094445|Experimental|Curcumin|Oral curcumin daily for eight weeks, starting dose 8 gm per day.
11649080|NCT00094432|Active Comparator|A1|
11649081|NCT00094432|Placebo Comparator|A2|
11649082|NCT00094380|Experimental|Dose-escalation portion: Low dose CTLA4-IgG4m (RG2077)|Three patients will receive a single intravenous infusion of 0.2 mg/kg CTLA4-IgG4m following the scheduled cyclophosphamide infusion on the same day. If one or more dose-limiting toxicities (CTC grade 3 or higher adverse event in the first 28 days after CTLA4-IgG4m administration that is possibly, probably, or definitely related to CTLA4-IgG4m (RG2077)). are observed, enrollment in the trial will be suspended pending DSMB review. If no dose-limiting toxicity is observed in the 0.2mg/kg dose, three patients will receive a single intravenous infusion of 2 mg/kg of CTLA4-IgG4m following the scheduled cyclophosphamide infusion on the same day. If one or more dose-limiting toxicities are observed, enrollment will be suspended pending review by the Data Safety and Monitoring Board (DSMB).If no dose-limiting toxicity is observed in the 2 mg/kg dose, treatment of patients with 10 mg/kg of CTLA4-IgG4m in combination with cyclophosphamide will proceed.
11649083|NCT00094380|Experimental|Part IIA: CTLA4-IgG4m|Participants randomized to the CTLA4-IgG4m Arm will receive a single intravenous infusion of 10 mg/kg CTLA4-IgG4m (RG2077) following the scheduled cyclophosphamide infusion on the same day
11649084|NCT00094380|Experimental|Part IIA: Control Group|Participants randomized to the control group will not receive treatment with CTLA4-IgG4m (RG2077); these participants will undergo all study evaluations with the exception of the CTLA4-IgG4m (RG2077) pharmacokinetic evaluations and immunogenicity evaluations.
11649085|NCT00094354||1|HIV-infected FPDs
11649086|NCT00094354||2|Family members of HIV-infected FPDs
11649087|NCT00094354||3|Local healthcare workers
11649088|NCT00094354||4|Villagers not related to an HIV-infected individual
11649089|NCT00094328|Other|Bicalutamide with Anastrozole|Bicalutamide in combination with Anastrozole
11649090|NCT00094302|Placebo Comparator|Placebo|Placebo of spironolactone
11649091|NCT00094302|Experimental|Spironolactone|Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
11649092|NCT00094276|Experimental|1|Breathmobile intervention combined with a Facilitated Asthma Communication intervention (FACI)
11649093|NCT00094276|Active Comparator|2|FACI intervention
11649094|NCT00094276|Active Comparator|3|Breathmobile intervention
11649095|NCT00094276|No Intervention|4|Control group
11649096|NCT00094211||Low Walkability/Low Income|Participants reside in a low walkability, low income neighborhood
11649097|NCT00094211||Low Walkability/High Income|Participants reside in a low walkability, high income neighborhood
11649098|NCT00094211||High Walkability/Low Income|Participants reside in a high walkability, low income neighborhood
11649099|NCT00094211||High Walkability/High Income|Participants reside in a high walkability, high income neighborhood
11649100|NCT00094185||General|No intervention
11649101|NCT00094172|Experimental|Atorvastatin|80 mg/day
11649102|NCT00094172|Placebo Comparator|Placebo|Once daily.
11649103|NCT00094107|Experimental|Axitinib [AG-013736]|
11649104|NCT00094094|Experimental|Axitinib|AG-013736 is a vascular endothelial growth factor [VEGF] inhibitor
11649105|NCT00091468|Placebo Comparator|Placebo Group|Placebo for first six months of study; moved to open-label active nicotine for second six months
11649106|NCT00091468|Experimental|Active Nicotine Group|Blinded active nicotine for first six months of study; open-label active nicotine for second six months
11649107|NCT00094055|Experimental|Axitinib [AG-013736]|
11649108|NCT00093977|Experimental|darbepoetin alfa SF|
11649109|NCT00093964|Experimental|Cilengitide 500 Milligram (mg)|
11649110|NCT00093964|Experimental|Cilengitide 2000 mg|
11649111|NCT00093925|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of postoperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
11649112|NCT00093925|Active Comparator|nicardipine|Nicardipine (NIC) was initiated after insertion of an arterial line upon the occurrence of postoperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
11649113|NCT00093912|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
11649114|NCT00093912|Active Comparator|sodium nitroprusside|Sodium nitroprusside (SNP) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
11649115|NCT00093886|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
11649116|NCT00093886|Active Comparator|nitroglycerin|Nitroglycerin (NTG) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
11649117|NCT00093873|Experimental|AMG 706|AMG 706 QD
11649118|NCT00093847|Experimental|1 Oral SAMe Tosylate|Participants receiving the oral SAMe tosylate
11649119|NCT00093847|Placebo Comparator|2 Oral Placebo Pill Twice Daily|Participants receiving placebo
11649120|NCT00093821|Experimental|Treatment (tanespimycin)|"Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11 (for patients with solid tumors) OR days 1, 4, 8, 11, 15, and 18 (for patients with leukemia). Courses for all patients repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of tanespimycin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 15 patients are treated at the MTD."
11649121|NCT00093808|Experimental|capecitabine + vinorelbine + trastuzumab|"Patients receive oral capecitabine twice daily on days 1-14, vinorelbine IV over 6-10 minutes on days 1 and 8, and trastuzumab (Herceptin^®) IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years."
11649122|NCT00093795|Active Comparator|Group 1: TAC X 6|Doxorubicin, cyclophosphamide, and docetaxel.
11649123|NCT00093795|Active Comparator|Group 2: AC X 4 then P X 4|Doxorubicin, cyclophosphamide, and paclitaxel
11649124|NCT00093795|Experimental|Group 3: AC X 4 then PG X 4|Doxorubicin, cyclophosphamide, paclitaxel and gemcitabine
11649125|NCT00093782|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a CR or PR receive 2 additional courses beyond CR or PR.
11649183|NCT00092547|Experimental|qHPV Vaccine in Base Study|Represents participants who were randomized into the qHPV Group, who received three 0.5 mL intramuscular injections of V501 (qHPV) at Day 1, Month 2, and Month 6.
11649184|NCT00092547|Placebo Comparator|Placebo in Base Study|Represents participants who were randomized into the Placebo Group, who received three 0.5 mL intramuscular injections of placebo at Day 1, Month 2, and Month 6.
11649686|NCT00086645|Placebo Comparator|placebo|placebo, up to equivalent of 20 mg of active comparator daily
11649126|NCT00093769|Experimental|bortezomib + rituximab|"Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
~Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
~Patients in either arm may crossover to the other arm if treatment is found to be ineffective."
11649127|NCT00093756|Experimental|Treatment (bortezomib, paclitaxel, carboplatin)|"PHASE I: Cohorts of 3-6 patients receive escalating doses of study medications until the maximum tolerated dose (MTD) is determined. PHASE II: Patients receive as in phase I at the MTD. Patients also undergo radiotherapy as in phase I.
~3-dimensional conformal radiation therapy bortezomib: Given IV paclitaxel: Given IV carboplatin: Given IV"
11649128|NCT00093743|Experimental|Treatment (allogeneic bone marrow or PBSC transplantation)|"NON-MYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2, cyclosporine IV every 8-12 hours on days -3 to 0, and undergo low-dose TBI on day 0.
~TRANSPLANTATION: Patients undergo allogeneic bone marrow or PBSC transplantation on day 0.
~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV every 8-12 hours on days 1-100 with taper to day 177, and mycophenolate mofetil PO or IV every 8 hours on days 0-40 with taper to day 96."
11649129|NCT00093730|Experimental|BMS-59926|
11649130|NCT00093704|Experimental|Bortezomib + ganciclovir|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
11649131|NCT00093626|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11649132|NCT00093613|Experimental|Treatment (sorafenib tosylate)|"Patients receive oral sorafenib twice daily on days 1-28 (once daily on day 1 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients per stratum receive escalating doses of sorafenib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 3 of 6 patients experience dose-limiting toxicity."
11649133|NCT00093600|Experimental|PKC412 administered sequentially|twice daily oral dosing of PKC412 administered sequentially
11649134|NCT00093600|Experimental|PKC412 administered concomitantly|PKC412 administered concomitantly with standard induction daunorubicin and cytarabine therapy followed by high-dose consolidation therapy with cytarabine
11649135|NCT00093509|Experimental|Magnetic Resonance Based Thermometry|"Patients will receive hyperthermia throughout the course of radiotherapy delivered once weekly for a total of 5 treatments. Each treatment will last 1-2 hours with a goal of delivering a cumulative thermal dose of 10-100 CEM 43˚T90. Interstitial temperature measurements will be taken by placing a single (less than or equal to) 15 gauge thermometry catheter into the tumor.
~In addition to hyperthermia treatment and radiation therapy all patients will receive conventional surgery for the removal of their tumors. Some patients will also receive chemotherapy if their treating physician thinks it is the their best interested (including the possibility of doxorubicin hydrochloride or ifosfamide and mesna)."
11649136|NCT00093496|Experimental|Treatment (chemotherapy)|Patients are stratified according to gemcitabine hydrochloride therapy (gemcitabine hydrochloride-naive/no prior exposure to gemcitabine hydrochloride vs gemcitabine hydrochloride-resistant/prior exposure to gemcitabine hydrochloride as a single agent with disease progression while on treatment). Patients receive tanespimycin IV over 2 hours on days 1 and 8 during course 1 and days 2 and 9 during subsequent courses and gemcitabine hydrochloride IV over 30 minutes on day 7 during course 1 and days 1 and 8 during subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years.
11649137|NCT00093470|Experimental|Arm A (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11649138|NCT00093470|Other|Arm B (clinical observation)|Patients undergo observation only.
11649139|NCT00093418|Experimental|Arm I|Arm I: Patients receive oral tipifarnib twice daily on days 1-21. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
11649140|NCT00093418|Experimental|Arm II|Patients receive oral tipifarnib twice daily on days 1-7 and 15-21. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
11649141|NCT00093418|Experimental|Arm III|Patients receive tipifarnib as in arm I, but at a lower dose. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
11649142|NCT00093418|Experimental|Arm IV|Patients receive tipifarnib as in arm II, but at a lower dose. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
11649143|NCT00093379|Experimental|Capecitabine + Oxaliplatin + XRT|Capecitabine (825 mg/m^2 twice a day, Monday-Friday during weeks 1, 2, 4, and 5) and Oxaliplatin (50 mg/m^2, Days 1, 8, 22, 29) during the duration of radiation therapy only. Radiotherapy once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. Participants with T3-4 lesions undergo radiotherapy once daily on days 43 and 44. The final dose of radiation therapy determined by the T stage of the primary tumor. Radiotherapy = XRT.
11649185|NCT00092547|Experimental|qHPV Vaccine in Extension Study|Represents participants originally enrolled into the Placebo Group who continued in the study to receive 0.5 mL intramuscular injections of V501 (qHPV) at Month 30, Month 32, and Month 36.
11650008|NCT00083603|Placebo Comparator|10|Empty TBC-MVA vector administered in each deltoid Days 0, 28, 84, 140, 196
11649144|NCT00093262|Experimental|clevidipine|Clevidipine was administered in a blinded fashion intravenously, starting with an infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/hr), titrating upward, as tolerated by the patient, in doubling increments approximately every 90 seconds up to an infusion rate of 3.2 μg/kg/min (16 mg/hr) to achieve the desired blood pressure-lowering effect. Up-titration to infusion rates above 3.2 μg/kg/min could be used, guided by the patient's response, by increasing the infusion rate in serial increments of 1.5 μg/kg/min, up to the maximum recommended clevidipine infusion rate of 8.0 μg/kg/min. Clevidipine was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
11649145|NCT00093262|Placebo Comparator|placebo|Placebo consisted of 20% lipid emulsion (the same lipid vehicle used for clevidipine) administered in a blinded fashion intravenously following the same study drug administration guidelines as with clevidipine study drug administration guidelines. As with clevidipine, placebo was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
11649146|NCT00093249|Experimental|clevidipine|Clevidipine was administered in a blinded fashion by intravenous (IV) infusion, starting at a rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/hr) and titrating upward, as tolerated, in doubling increments approximately every 90 seconds to achieve the desired blood pressure-lowering effect. Up-titration to 3.2 μg/kg/min (16 mg/hr) was allowed. Infusion rates above 3.2 μg/kg/min could be used, guided by the patient's response, by increasing in serial increments of 1.5 μg/kg/min up to the maximum recommended clevidipine infusion rate of 8.0 μg/kg/min. Clevidipine was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
11649147|NCT00093249|Placebo Comparator|placebo|Placebo consisted of 20% lipid emulsion (the same lipid vehicle used for clevidipine) administered in a blinded fashion intravenously following the same study drug administration guidelines as with clevidipine study drug administration guidelines. As with clevidipine, placebo was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
11649148|NCT00093236|Experimental|Early Periodontal Treatment|Subjects will receive scaling, root planing and if needed periodontal surgery
11649149|NCT00093236|Active Comparator|Usual Dental Hygiene|Subjects will receive routine oral hygiene
11649150|NCT00093223|Experimental|1|35mg/m^2 infusion time is 3.5 minutes
11649151|NCT00093223|Experimental|2|2 doses of 35mg.m^2 with the second dose given 2 months later
11649152|NCT00093197|Experimental|A1: KAI-9803|
11649153|NCT00093197|Experimental|A2: KAI-9803|
11649154|NCT00093197|Experimental|A3: KAI-9803|
11649155|NCT00093197|Experimental|A4: KAI-9803|
11649156|NCT00093197|Placebo Comparator|A5: Placebo|
11649157|NCT00093145|Experimental|Albumin-bound paclitaxel, Carboplatin + Herceptin|Participants received albumin-bound paclitaxel, 100 mg/m^2 weekly every 3 out of 4 weeks, carboplatin at an area under the curve (AUC) = 6 every 4 weeks and Herceptin weekly, 4 mg/kg the first week and 2 mg/kg on all subsequent weeks by intravenous (IV) infusion for up to 6 cycles in the absence of disease progression or intolerable toxicity. Participants could continue treatment with chemotherapy beyond 6 cycles at the discretion of the investigator, but Herceptin therapy was to continue to be administered weekly (2 mg/kg) until intercurrent illness, disease progression, unacceptable toxicity, patient withdrawal or administration of any non-protocol anti-cancer treatment.
11649158|NCT00002524|Experimental|Regimen A|Regimen A: 5-Drug Combination Chemotherapy followed by Radiotherapy.
11649159|NCT00002524|Experimental|Regimen B|Regimen B: 4-Drug Combination Chemotherapy alternating with 3-Drug Combination Chemotherapy followed, as indicated, by Radiotherapy
11649160|NCT00002524|Experimental|Regimen C|Regimen C: 2-Drug Combination Chemotherapy with Drug Modulation followed, as indicated, by Radiotherapy.
11649161|NCT00093132|Experimental|Satraplatin|Satraplatin
11649162|NCT00093080|Experimental|Ridaforolimus|12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
11649163|NCT00093054|Active Comparator|1|Cranberry juice
11649164|NCT00093054|Placebo Comparator|2|Placebo juice
11649165|NCT00093041|Experimental|Zalutumumab 0.15 mg/kg|
11649166|NCT00093041|Experimental|Zalutumumab 0.5 mg/kg|
11649167|NCT00093041|Experimental|Zalutumumab 1 mg/kg|
11649168|NCT00093041|Experimental|Zalutumumab 2 mg/kg|
11649169|NCT00093041|Experimental|Zalutumumab 4 mg/kg|
11649170|NCT00093041|Experimental|Zalutumumab 8 mg/kg|
11649171|NCT00093015|Active Comparator|Active|
11649172|NCT00093015|Placebo Comparator|Placebo|
11649173|NCT00093002|Experimental|1|250 mg fulvestrant
11649174|NCT00093002|Experimental|2|500 mg fulvestrant
11649175|NCT00092989|Experimental|Montelukast 7 mg|Participants receive montelukast 7 mg intravenously (IV) until until a decision is made for one of the following: (1) discontinuation from the study, (2) discharge from the study site, or (3) admission to the hospital. All randomized participants will receive systemic corticosteroids (60 mg prednisone OR 50 mg prednisolone) orally immediately after the completion of the study drug administration. In addition, all participants will continue to receive standardized treatment in addition to study drug. Standardized treatment may consist of: (1) β-agonist administration beginning 20 minutes after study drug infusion, and every 20 minutes thereafter, as needed; (2) oxygen therapy; and (3) inhaled ipratropium every 60 minutes as needed.
11649176|NCT00092989|Placebo Comparator|Placebo|Participants receive placebo IV until until a decision is made for one of the following: (1) discontinuation from the study, (2) discharge from the study site, or (3) admission to the hospital. All randomized participants will receive systemic corticosteroids (60 mg prednisone OR 50 mg prednisolone) orally immediately after the completion of the study drug administration. In addition, all participants will continue to receive standardized treatment in addition to study drug. Standardized treatment may consist of: (1) β-agonist administration beginning 20 minutes after study drug infusion, and every 20 minutes thereafter, as needed; (2) oxygen therapy; and (3) inhaled ipratropium every 60 minutes as needed.
11649177|NCT00092833|Experimental|1|Ezetimibe
11649178|NCT00092729|Experimental|1|etoricoxib
11649179|NCT00092729|Placebo Comparator|2|Placebo to match etoricoxib
11649180|NCT00092729|Active Comparator|3|naproxen sodium
11649181|NCT00092677|Experimental|EZ/Simva 10/40 mg|Ezetimibe 10 mg + Simvastatin 40 mg
11649182|NCT00092677|Placebo Comparator|Placebo|
11649186|NCT00092534|Experimental|Quadrivalent Human Papillomavirus (HPV) Vaccine|The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
11649187|NCT00092534|Placebo Comparator|Placebo|The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
11649188|NCT00092521|Experimental|1|V501
11649189|NCT00092521|Placebo Comparator|2|Placebo
11649190|NCT00092521|Experimental|3|HPV 16 Monovalent Vaccine
11649191|NCT00092495|Experimental|1|100% Formulation qHPV Vaccine
11649192|NCT00092495|Experimental|2|60% Formulation qHPV Vaccine
11649193|NCT00092495|Experimental|3|40% Formulation qHPV Vaccine
11649194|NCT00092495|Experimental|4|20% Formulation qHPV Vaccine
11649195|NCT00092456|Experimental|RotaTeq™ Lot 1|~8.81 X 10^7 IU/Dose of RotaTeq™
11649196|NCT00092456|Experimental|RotaTeq™ Lot 2|~8.01 X 10^7 IU/Dose of RotaTeq™
11649197|NCT00092456|Experimental|RotaTeq™ Lot 3|~6.91 X 10^7 IU/Dose of RotaTeq™
11649198|NCT00092456|Placebo Comparator|Placebo|
11649199|NCT00092443|Experimental|RotaTeq™ at Expiry Potency (≈1.1 x 10^7 IU/Dose)|"Three doses of RotaTeq™ (Rotavirus vaccine, live, oral, pentavalent)
~administered 28 to 70 days apart."
11649200|NCT00092443|Placebo Comparator|Placebo matching RotaTeq™|Placebo matching RotaTeq™ administered 28 to 70 days apart.
11649201|NCT00092417|Experimental|1|Higher Potency Dose
11649202|NCT00092417|Experimental|2|Lower Potency Dose
11649203|NCT00092391|Active Comparator|Control Group|M-M-R(TM) II at current release potency
11649204|NCT00092391|Experimental|Mumps Expiry Group 1|M-M-R(TM) II at intermediate expiry potency
11649205|NCT00092391|Experimental|Mumps Expiry Group 2|M-M-R(TM) II at expiry potency
11649206|NCT00092001|Experimental|1|
11649207|NCT00092131|Experimental|1|Montelukast - Placebo
11649208|NCT00092131|Experimental|2|Placebo - Montelukast
11649209|NCT00092118|Experimental|1|Montelukast
11649210|NCT00092118|Placebo Comparator|2|Placebo
11649211|NCT00092092|Experimental|Montelukast→Placebo|Participants receive one montelukast 5 mg chewable tablet once daily (QD) for 3 weeks. After a 2-week washout period, participants receive one placebo chewable tablet QD for 3 weeks.
11649212|NCT00092092|Experimental|Placebo→Montelukast|Participants receive one placebo chewable tablet QD for 3 weeks. After a 2-week washout period, participants receive one montelukast 5 mg chewable tablet QD for 3 weeks.
11649213|NCT00092092|Active Comparator|Budesonide→Placebo|Participants receive budesonide 200 mcg inhalation powder twice daily (BID) for 3 weeks. After a 2-week washout period, participants receive placebo inhalation powder BID for 3 weeks.
11649214|NCT00092092|Active Comparator|Placebo→Budesonide|Participants receive placebo inhalation powder BID for 3 weeks. After a 2-week washout period, participants receive budesonide 200 mcg inhalation powder BID for 3 weeks.
11649215|NCT00092053|Placebo Comparator|Placebo|Participants will receive 3 placebo tablets once a month, for 3 months, on the first day of each treatment cycle.
11649216|NCT00092053|Experimental|ibandronate 100 mg|Participants will receive 2 ibandronate 50 mg tablets and 1 placebo tablet once a month, for 3 months, on the first day of each treatment cycle.
11649217|NCT00092053|Experimental|ibandronate 150 mg|Participants will receive 3 ibandronate 50 mg tablets once a month, for 3 months, on the first day of each treatment cycle.
11649218|NCT00092014|Experimental|Alendronate 70 mg|Alendronate sodium, 70 mg, orally once weekly for up to 24 months
11649219|NCT00092014|Active Comparator|Risendronate 35 mg|Risendronate, 35 mg, orally once weekly for up to 24 months
11649220|NCT00091962|Experimental|Depressed Intervention|Telephone-based, nurse-delivered Collaborative Care program for depression; Involving: Psychoeducation; workbook for depression self-care; initiation or adjustment of antidepressant pharmacotherapy prescribed under their PCPs' direction; referral to mental health specialist
11649221|NCT00091962|Active Comparator|Depressed Usual Care|"Usual care for depression; feedback of the depression finding by the study team"
11649222|NCT00091962|No Intervention|Non-Depressed Control Group|Non-depressed control group
11649223|NCT00092235||Cohort 1|Patients who have undergone an allogeneic stem cell transplant and are diagnosed withcGVHD
11649224|NCT00092235||Cohort 2|Pediatric patients who have undergone an allogeneic stem cell transplant and arediagnosed with cGVHD
11649225|NCT00092235||Cohort 3|Patients who have undergone an allogeneic stem cell transplant and choose to submitbiopsy, blood and urine samples only
11649226|NCT00092235||Cohort 4|Patients who have undergone an allogeneic stem cell transplant and are not diagnosed withcGVHD
11649227|NCT00092222|Active Comparator|Active Treament 3|Patients not responding to high- dose zidovudine and valganciclovir alone may be treated with botezomib plus high- dose zidovudine and valganciclovir
11649228|NCT00092222|Active Comparator|Active Treatment 1|Single agent sirolimus for patients where targeted oncolytic virotherapy seems suboptimal
11649229|NCT00092222|Active Comparator|Active Treatment 2|EPOCH chemotherapy with rituximab may be utilized to rescue such patients, with the intent of stabilizing suchpatients
11649230|NCT00092222|Active Comparator|Active Treatment 4|Rituximab with liposomal doxorubicin (R-Dox) followed by consolidation or lmaintenancel therapy with dose escalating interferon-alpha
11649231|NCT00092222|Active Comparator|Active Treatment 5|High dose zidovudin and valganciclovir
11649232|NCT00092222|Active Comparator|Natural History|Observation Only
11649233|NCT00091988|Experimental|Lifestyle & Behavioral Change Program|
11649234|NCT00091988|Active Comparator|Structured Education Program|
11649235|NCT00091949|Active Comparator|Pioglitazone|pioglitazone
11649236|NCT00091949|Placebo Comparator|Placebo|inactive substance
11649237|NCT00091858|Experimental|Darbepoetin alfa 6.75 mcg/kg Q4W|
11649238|NCT00091858|Placebo Comparator|Placebo Q4W|
11649239|NCT00091832|Experimental|Denosumab 60 mg every 12 weeks|Denosumab 60 mg by subcutaneous injection once every 12 weeks (Q12W) for 25 weeks.
11649240|NCT00091832|Experimental|Denosumab 120 mg every 4 weeks|Denosumab 120 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
11649241|NCT00091832|Experimental|Denosumab 180 mg every 4 weeks|Denosumab 180 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
11649242|NCT00091832|Active Comparator|IV bisphosphonates every 4 weeks|Open label bisphosphonate every 4 weeks (Q4W) by intravenous infusion for 25 weeks.
11649243|NCT00091832|Experimental|Denosumab 180 mg every 12 weeks|Denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W) for 25 weeks.
11649244|NCT00091832|Experimental|Denosumab 30 mg every 4 weeks|Denosumab 30 mg by subcutaneous injection once every 4 weeks (Q4W) for 25 weeks.
11649245|NCT00091819|Experimental|Telavancin|
11649246|NCT00091819|Active Comparator|Vancomycin|
11649247|NCT00091806|Experimental|Cohort 1|6mg/kg of panitumumab administered once every 2 weeks until subjects develop disease progression or are unable to tolerate the study drug
11649248|NCT00091806|Experimental|Cohort 2|Panitumumab 9 mg/kg administered once every 3 weeks until subjects develop disease progression or are unable to tolerate the study drug.
11649249|NCT00091793|Experimental|AMG 162|60 mg/mL denosumab given day 1, month 6, month 12 and month 18
11649250|NCT00091793|Placebo Comparator|Placebo|Placebo given day 1, month 6, month 12 and month 18
11649251|NCT00091897|Experimental|Rituximab or placebo|Rituximab or placebo is administered through intravenous access on day 1 and again on day 15 (+/- 2 days)
11649252|NCT00091871||Affected family members|Family members with peripheral blood eosinophilia
11649253|NCT00091871||Unaffected family members|Family members without peripheral blood eosinophilia
11649254|NCT00091715|Experimental|1|62.5 mg table twice a day for 4 weeks followed by 125 mg tablet twice a day for 6 months followed by an open label period until end of study.
11649255|NCT00091715|Placebo Comparator|2|placebo for 6 months followed by an open label period
11649256|NCT00091676|Experimental|ID-KLH + GM-CSF|
11649257|NCT00091676|Active Comparator|KLH + GM-CSF|
11649258|NCT00091637|Placebo Comparator|1|Placebo infusion
11649259|NCT00091637|Experimental|2|Pexelizumab infusion
11649260|NCT00004195|Active Comparator|Oral eniluracil 20 mg twice daily|20 mg of eniluracil given twice daily for duration of the study. This subject may have surgery IF tumor is amenable to resection
11649261|NCT00004195|Placebo Comparator|Placebo|20 mg placebo that will be given for the duration of the study. This subject may have surgery IF tumor is amenable to resection
11649262|NCT00004184|Experimental|Arm I|Patients receive human anti-idiotypic monoclonal antibody vaccine (4B5) in sargramostim (GM-CSF) subcutaneously (SQ) on days 0, 14, 28, and 42. Patients receive GM-CSF alone SQ at vaccination site on days 2, 3, and 4 following immunization.
11649263|NCT00004184|Experimental|Arm II|Patients receive 4B5 plus alum SQ on days 0, 14, 28, and 42. Cohorts of 5 patients receive treatment every 2 weeks for up to 4 courses in the absence of unacceptable toxicity.
11649264|NCT00091572|Experimental|A|"temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (7 days on / 7 days off continuously)"
11649265|NCT00091572|Active Comparator|B|dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks
11649266|NCT00003858|Experimental|Mitoxantrone|Patients receive mitoxantrone IV over 10-30 minutes every 21 days. Treatment continues for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for the first 3 years, and then every 6 months for the next 3 years or until disease progression.
11649267|NCT00003714|Experimental|Pyrazoloacridine|
11649268|NCT00091507|Experimental|1 -- GIK|GIK = glucose-insulin-potassium; In one-liter: Dextrose 30% + 80 mEq Potassium Chloride + 50 units Regular Insulin; infused at 1.5 ml/kg/hour for a total of 12 hours.
11649269|NCT00091507|Placebo Comparator|2 -- Placebo|Dextrose 5%, infused at 1.5 ml/kg/hour for total of 12 hours.
11649270|NCT00091442|Experimental|DOXIL and docetaxel combination therapy|DOXIL and docetaxel combination therapy: DOXIL 30 mg/m2 solution administered by intravenous infusion, followed by docetaxel 60 mg/m2 administration by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
11649271|NCT00091442|Active Comparator|Docetaxel monotherapy|Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
11649272|NCT00003671|Experimental|Chemotherapy Treatment|See detailed description.
11649273|NCT00003666|Experimental|HMAF|treatment of refractory or relapsed NSCLC with HMAF
11649274|NCT00003625|Experimental|Stratum 1|Concomitant irradiation and vincristine sulfate in esc dose beginning with 0.8 mg/m2, etoposide and Cyclosporine A given over 6 weeks, then monthly maint courses over 6 mths, with no clinical and radiologic progression. Stable disease indicates continuation of therapy. Clinical deterioration within 4 months of completion of radiation therapy must be confirmed to be PD by imaging. Clinical progression even in the absence of imaging changes will be accepted as reflecting disease progression. Steroids dexamethasone (Decadron) given as clinically indicated and tapered as tolerated. Steroids may decrease capillary permeability to chemotherapeutic agents and antagonise the effect of cyclosporin A. Also contributes to the syndrome of seizures and white matter changes seen with cyclosporine in the post BMT period. If steroid use is required, the recommended schedule of Decadron dosing during the 6 week induction course is 8 mg/m2 divided q 6-8 hours.
11649275|NCT00003599|Experimental|Arm I|Alpha-tocopherol (AT) orally and isotretinoin orally daily (arm I)
11649276|NCT00003599|Experimental|Arm II|Isotretinoin orally plus AT placebo orally daily (arm II).
11649277|NCT00003591|Experimental|Pacilitaxel + External Beam Radiation Therapy (PXRT)|Paclitaxel 50 mg/m2 given on Days 1, 8, 15, 22, 29 and 36. Radiation therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day in 5.5 weeks.
11649278|NCT00003587|Experimental|carboplatin/gemcitabine/paclitaxel|IV carboplatin AUC=5.5 day 1 every 21 days X 3 IV gemcitabine 1,000 mg/m^2/day, days 1 and 8 every 21 days X3 IV paclitaxel 225 mg/m^2/day, day 1 every 21 days X 3
11649279|NCT00003587|Experimental|cisplatin/vinorelbine/docetaxel|IV cisplatin 100 mg/m^2 day 1 every 21 days X 3 IV vinorelbine 25 mg/m^2/day, days 1 and 8 every 21 days X 3 IV docetaxel 75 mg/m^2 day 1 every 21 days X 3
11649280|NCT00003564|Experimental|Arm I (Procarbazine + Isotretinoin)|Arm I: Oral procarbazine once daily on days 1-14 every 28 days, and Oral isotretinoin every 12 hours on days 15-28 every 28 days; 6 courses of combined therapy, then continue oral isotretinoin alone on days 15-28 of each 28 day course.
11649281|NCT00003564|Experimental|Arm II (Procarbazine Alone)|Arm II: Oral Procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses of treatment.
11649282|NCT00003546|Experimental|gemcitabine + radiation|Patients receive radiation therapy 5 days per week for 5 1/2 weeks and gemcitabine IV over 30 minutes not greater than 2 hours prior to radiation therapy twice weekly. This combination radiation therapy and chemotherapy is followed by 2 weeks of rest. Patients with stable or responding disease receive a higher dose of gemcitabine IV over 30 minutes weekly for 3 weeks followed by 1 week of rest. This 4 week course is repeated 3 more times for a total of 16 weeks of gemcitabine therapy alone. Patients are followed every 2 months for the first year and then every 3 months for the next 2 years or until disease progression. Upon documentation of disease progression, patients are followed every 3 months for survival and secondary malignancy.
11649283|NCT00003451|Experimental|Arm I|Cohorts of 3 patients receive interleukin-12 IV push on day 1, followed by escalating doses of interferon alfa by subcutaneous injection at 24, 48, 72, 96 and 120 hours. Courses repeat every 2 weeks for 6 months (12 courses total) in the absence of unacceptable toxicity and disease progression. Patients achieving partial response or stable disease at the completion of 6 months of therapy may receive additional courses of therapy for up to 24 months. Dose escalation of interferon alfa continues in subsequent cohorts in the absence of dose limiting toxicity (DLT). If 1 of 3 patients experiences DLT at a dose level, then 3 additional patients are entered at that dose level. If 2 of 6 patients experience DLT, then dose escalation stops. The maximum tolerated dose is defined as 1 level below that dose at which 2 or more of 6 patients experience DLT. Patients are followed every 3 months for 1 year and then every 6 months thereafter.
11649284|NCT00003441|Experimental|Irofulven|6-hydroxymethylacylfulvene (MGI-114) IV over 5 minutes daily for 5 consecutive days every 28 day cycle.
11649285|NCT00003288|Experimental|Arm I|See arm description.
11649286|NCT00003248|Experimental|Arm I|"Patients receive fludarabine and chimeric anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab) induction. Rituximab is administered IV over 4 hours on day 1, on day 3, and over 1 hour on day 5 of week 1. Subsequent doses are given over 1 hour on day 1 every 4 weeks for a total of 6 courses. Fludarabine IV is administered over 10-30 minutes daily for 5 days during weeks 1, 5, 9, 13, 17, and 21 for a total of 6 courses. Following the sixth course of fludarabine, patients undergo clinical staging and are then observed for an additional 2 months, after which they undergo repeat clinical staging, including bone marrow aspiration. Patients achieving a complete or partial response or stable disease then proceed to consolidation therapy consisting of weekly intravenous infusions of rituximab once weekly for 4 weeks.
~Patients are followed every 3 months for 1 year, and then every 6 months thereafter."
11649287|NCT00003248|Experimental|Arm II|Patients receive fludarabine induction. Patients receive fludarabine IV over 10-30 minutes daily for 5 days during weeks 1, 5, 9, 13, 17, and 21 for a total of 6 courses. Patients then proceed as in arm I. Patients are followed every 3 months for 1 year, and then every 6 months thereafter.
11649288|NCT00003223|Experimental|treatment|Fenretinide 200 mg PO days 1-25, q 28 days x 6 cycles.
11649289|NCT00091390|Experimental|External Beam Radiotherapy and High Dose brachytherapy boost|
11649290|NCT00091377|Experimental|Arm A|Phenoxodiol IV 3 mg/kg combined with cisplatin 40 mg/m2 on Day 2 6 week cycles
11649291|NCT00091377|Experimental|Arm B|Phenoxodiol IV 3 mg/kg combined with paclitaxel 80 mg/m2 on Day 2 6 week cycles
11649292|NCT00091351|Experimental|surgery|"Patients undergo surgery.
~Treatment continues in the absence of disease progression or unacceptable toxicity.
~Patients are followed at 28 days, 4 months, every 6 months for 5 years, and then annually for 5 years."
11649293|NCT00091351|Experimental|radiation + surgery|"Patients undergo preoperative radiotherapy once daily, 5 days a week, for 5.5 weeks. Within 28-63 days after the completion of radiotherapy, patients undergo surgery.
~Treatment continues in the absence of disease progression or unacceptable toxicity.
~Patients are followed at 28 days, 4 months, every 6 months for 5 years, and then annually for 5 years."
11649294|NCT00091299|Experimental|warfarin|
11649295|NCT00091286|Experimental|Peptide Vaccine + Montanide + GM-CSF|Colon peptide mixture (100 mcg each of the 4 peptides) plus 190 mcg of tetanus toxoid peptide, plus GM-CSF (110 mcg) in Montanide ISA-51 adjuvant
11649296|NCT00091260|Experimental|revlimid|lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
11649297|NCT00091247|Experimental|tetracycline|"Patients receive oral tetracycline twice daily. Treatment continues for 4 weeks in the absence of unacceptable toxicity.
~Quality of life is assessed at baseline and then weekly for 8 weeks.
~Patients are followed at weeks 4 and 8."
11649298|NCT00091247|Placebo Comparator|placebo|"Patients receive oral placebo twice daily. Treatment continues for 4 weeks in the absence of unacceptable toxicity.
~Quality of life is assessed at baseline and then weekly for 8 weeks.
~Patients are followed at weeks 4 and 8."
11649299|NCT00091195|Experimental|Treatment (single-agent depsipeptide)|Patients receive depsipeptide (romidepsin) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11649300|NCT00091182|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
11649301|NCT00091169|Experimental|Arm I|Patients receive oral levocarnitine (L-carnitine) twice daily on weeks 1-4.
11649302|NCT00091169|Placebo Comparator|Arm II|Patients receive oral placebo twice daily on weeks 1-4.
11649303|NCT00091130|Experimental|Arm I (SGN-00101)|Patients receive SGN-00101 vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.
11649304|NCT00091130|Placebo Comparator|Arm II (placebo)|Patients receive placebo vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.
11649305|NCT00091117|Experimental|Treatment|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11649306|NCT00091091||All patients|Self report/Medical record review/ clinical eval
11649307|NCT00091078|Experimental|Treatment (oblimersen sodium and imatinib mesylate)|Patients receive oblimersen IV continuously on days 1-14. Patients also receive oral imatinib mesylate on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11649408|NCT00003224|Experimental|Group 1: peptide 946 plus QS-21|100 mcg peptide gp100 [280-288] plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant
11649308|NCT00091026|Experimental|Arm I (cetuximab, gemcitabine hydrochloride, bevacizumab)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, and 22; gemcitabine IV over 30 minutes on days 1, 8, and 15; and bevacizumab IV over 30-90 minutes on days 1 and 15.
11649309|NCT00091026|Experimental|Arm II (gemcitabine hydrochloride, bevacizumab, erlotinib)|Patients receive gemcitabine and bevacizumab as in arm I. Patients also receive oral erlotinib once daily on days 1-5, 8-12, and 15-26.
11649310|NCT00090987|Experimental|Imatinib mesylate|Imatinib mesylate (Gleevec) taken 400 mg orally once a day for up to 6 months
11649311|NCT00090961|Experimental|12-week exercise program + education|A 12-week supervised exercise program consisting of 3 days a week on a stationary bike or treadmill. In addition, at the time of enrollment patients are provided educational materials focusing on breathing and energy conservation.
11649312|NCT00090961|Other|Education|At the time of enrollment patients are provided educational materials focusing on breathing and energy conservation.
11649313|NCT00090896|Experimental|CTLA4-Blocking Monoclonal Antibody|
11649314|NCT00090870|Experimental|PEG-Intron, BM-CSF and thalidomide|
11649315|NCT00090857|Experimental|Letrozole|Participants in this arm received 2.5 mg of letrozole per day for a duration of 12 months; followed by an optional 4 years. Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, ductal carcinoma in situ, or any non-breast primary cancer.
11649316|NCT00090857|Placebo Comparator|Placebo|Participants in this arm received 1 tablet per day which contained the inert ingredients from the letrozole tablet, for a duration of 12 months; followed by an optional 5 years of letrozole.Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, ductal carcinoma in situ, or any non-breast primary cancer.
11649317|NCT00090844|Experimental|triptorelin|GnRH analogue (triptorelin) during chemotherapy
11649318|NCT00090844|No Intervention|no triptorelin|No GnRH analogue (triptorelin) during chemotherapy
11649319|NCT00090779|Active Comparator|IT arm|IT (immediate treatment) arm participants received emtricitabine/tenofovir disoproxil fumarate once daily and lopinavir/ritonavir twice daily
11649320|NCT00090779|No Intervention|DT arm|DT (deferred treatment) arm participants received no treatment
11649321|NCT00090766|Experimental|Valganciclovir Age Group <= 2 Years|Eligible participants aged <= 2 years received valganciclovir up to maximum of 900 milligrams (mg) once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * body surface area (BSA) * creatinine clearance (CrCLS).
11649322|NCT00090766|Experimental|Valganciclovir Age Group >2 to <12 Years|Eligible participants aged >2 to <12 years received valganciclovir up to maximum of 900 mg once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * BSA * CrCLS.
11649323|NCT00090766|Experimental|Valganciclovir Age Group >= 12 Years|Eligible participants aged >= 12 years received valganciclovir up to maximum of 900 mg once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * BSA * CrCLS.
11649324|NCT00090753|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Patients received the same weekly dose of methoxy polyethylene glycol-epoetin beta via the same route of administration (iv or sc) as they received in the Phase II or Phase III study that qualified the patient for participation in this study. Methoxy polyethylene glycol-epoetin beta was administered every 2 or every 4 weeks in the initial 104-week treatment period. Patients on a 4-week dosing interval were switched to once-monthly administration in the 24-month extension phase. The dose of methoxy polyethylene glycol-epoetin beta was adjusted to maintain the patient's hemoglobin (Hb) within a target range of 11 to 13 g/dL.
11649325|NCT00090753|Active Comparator|Comparator ESA|Patients received the same comparator ESA [epoetin alfa, epoetin beta, or darbepoetin alfa] at the same weekly dose and dosing interval via the same route of administration (iv or sc) as they received in the Phase III study that qualified the patient for participation in this study. The dose of the comparator drug was adjusted to maintain the patient's Hb within a target range of 11 to 13 g/dL. Of the 480 patients in the comparator drug group, 170 received darbepoetin alfa, 134 received epoetin alfa, and 176 received epoetin beta.
11649326|NCT00090740||Asthmatics|People who have asthma
11649327|NCT00090740||Controls|People who do not have asthma
11649328|NCT00003217|Experimental|Treatment|See detailed description.
11649329|NCT00003170|Experimental|glutamine|Beginning the first or second day of radiotherapy, patients receive oral glutamine twice daily, including the days that they do not receive radiotherapy. Patients continue on treatment throughout radiotherapy and continue 2 weeks postradiotherapy or until grade 3 diarrhea occurs. Patients are followed weekly for 4 weeks, then at 12 months, and then at 24 months after radiotherapy.
11649330|NCT00003170|Placebo Comparator|placebo|Beginning the first or second day of radiotherapy, patients receive placebo twice daily, including the days that they do not receive radiotherapy. Patients continue on treatment throughout radiotherapy and continue 2 weeks postradiotherapy or until grade 3 diarrhea occurs. Patients are followed weekly for 4 weeks, then at 12 months, and then at 24 months after radiotherapy.
11649331|NCT00003139|Experimental|Pilocarpine hydrocloride|5mg pilocarpine hydrochloride tablets commencing 3 days prior to irradiation
11649332|NCT00003139|Placebo Comparator|Placebo|Placebo tablets commencing 3 days prior to irradiation
11649333|NCT00003134|Experimental|Arm I: irinotecan|"Patients receive irinotecan IV over 90 minutes on days 1, 8, 15, and 22. This is followed by a 2 week rest and continues for a maximum of 6 courses. Patients who received prior nitrosoureas, also receive reduced starting doses of irinotecan. The dosages may be increased once per patient after the first course if toxic effects are acceptable.
~Patients are followed every 3 months for the first year, every 6 months for the next 4 years, then annually until death."
11649334|NCT00003134|Experimental|Arm II: irinotecan|"Patients receive irinotecan on day 1 every 3 weeks for up to 12 courses. Patients who received prior nitrosoureas receive reduced starting doses of irinotecan. The dosages may be increased once per patient after the first course if toxic effects are acceptable.
~Patients are followed every 3 months for the first year, every 6 months for the next 4 years, then annually until death."
11649335|NCT00003088|Experimental|Sequential chemotherapy 21 days|Patients received doxorubicin 60 mg/m^2 every 3 weeks for four cycles followed by paclitaxel 175 mg/m^2 every 3 weeks for four cycles followed by cyclophosphamide 600 mg/m^2 every 3 weeks for four cycles.
11650085|NCT00083304|Experimental|Efaproxiral + WBRT + Supplemental Oxygen|
11649336|NCT00003088|Experimental|Concurrent chemotherapy 14 days|Patients received doxorubicin 60 mg/m^2 plus cyclophosphamide 600 mg/m^2 every 2 weeks for four cycles followed by paclitaxel 175 mg/m^2 every 2 weeks for four cycles with filgrastim days 3 to 10 of each cycle at 5 µg/kg rounded to either 300 or 480 µg total dose.
11649337|NCT00003088|Experimental|Sequential chemotherapy 14 days|Patients received doxorubicin 60 mg/m2 every 2 weeks for four cycles followed by paclitaxel 175 mg/m2 every 2 weeks for four cycles followed by cyclophosphamide 600 mg/m2 every 2 weeks for four cycles, with filgrastim days 3 to 10 of each cycle (a total of seven doses) at 5 µg/kg, which could be rounded to either 300 or 480 µg total dose.
11649338|NCT00003088|Experimental|Concurrent chemotherapy 21 days|Patients received doxorubicin 60 mg/m^2 plus cyclophosphamide 600 mg/m^2 every 3 weeks for four cycles followed by paclitaxel 175 mg/m^2 every 3 weeks for four cycles.
11649339|NCT00003048|Experimental|Amifostine|Amifostine IV 2 weeks, followed by 2 weeks rest (4 week cycle)
11649340|NCT00003039|Experimental|Arm I|Patients receive treatment on an outpatient basis. Flavopiridol is administered as a continuous infusion over 72 hours every 2 weeks. Patients receive a minimum of 4 cycles of therapy unless unacceptable toxicity or disease progression occurs.
11649341|NCT00003005|Experimental|deoxycoformycin and cordycepin|Dose escalation for deoxycoformycin and cordycepin
11649342|NCT00002946|Experimental|Arm I|atients enrolled on the bioavailability portion of this study receive one dose of IV penclomedine over 1 hour followed by 2 weeks of rest. At the end of two weeks, they receive oral penclomedine for 5 days every 28 days. The starting dose is determined by a single primary patient who has been administered oral penclomedine and observed for dose limiting toxicity (DLT). [Bioavailability portion completed as of 3/98.] Those not on the bioavailability portion of study start on a standard design dose escalating schedule in which patients enroll in cohorts of 3. Patients are administered oral penclomedine daily for 5 days. This treatment repeats every 4 weeks. The MTD is defined as the dose immediately below that at which 2 patients experience DLT. Treatment repeats for 6 courses or until severe toxicity or tumor progression is observed.
11649343|NCT00002942|Active Comparator|Peripheral Blood Progenitor Cells|
11649344|NCT00002942|Experimental|Autologous Bone Marrow Collection|
11649345|NCT00090662||Healthy volunteer|Healthy volunteer
11649346|NCT00002805|Experimental|Treatment|Induction will consist of one course of cytarabine and mitoxantrone. Patients achieving a complete or partial response by the end of induction will start intensification. Intensification will consist of one course of chemotherapy (Cytarabine (Ara-C), Etoposide (VP-16), Filgrastim (G-CSF)). Patients who do not attain a CNS remission following the completion of intensification therapy, or who develop recurrence of CNS disease and have not previously received radiation therapy involving the central nervous system should receive craniospinal radiotherapy. Continuation Therapy: cladribine (2CdA), Etoposide.
11649347|NCT00002744|Experimental|Arm I|Therapy defined in description.
11649348|NCT00002744|Experimental|Arm 2|Therapy defined in description.
11649349|NCT00002744|Experimental|Arm 3|Therapy defined in description.
11649350|NCT00002744|Experimental|Arm 4|Therapy defined in description.
11649351|NCT00002735|Experimental|Treatment arm|induction chemotherapy followed by chemoradiation
11649352|NCT00090610|Experimental|Arm 1 - Combination Therapy|Docetaxel 30mg/m2 mg IV on Days 1 and 8, in combination with carboplatin AUC 6 IV on Day 1, repeated every 21 days X 6 cycles or until disease progression
11649353|NCT00090610|Experimental|Arm 2 - Sequential Therapy|Docetaxel 30mg/m2 IV on Days 1 and 8, repeated every 21 days for 6 cycles until disease progression. Once subjects have completed 6 cycles of docetaxel, they receive carboplatin AUC 6 IV every 21 days for 6 cycles or until disease progression.
11649354|NCT00090584|Experimental|Combination therapy|Women randomly assigned to this condition receive 10 weeks of anti-cholinergic medication (tolterodine) and behavioral training.
11649355|NCT00090584|Active Comparator|Drug therapy alone|Women assigned to this arm received 10 weeks of anti-cholinergic medication (tolterodine), only.
11649356|NCT00090519|Experimental|Ruboxistaurin|32 milligrams (mg) once daily (QD) oral for up to 36 months
11649357|NCT00090519|Placebo Comparator|Placebo|QD oral for up to 36 months
11649358|NCT00090493|Experimental|MAGE-A3 and NY-ESO-1 Immunotherapy|Treatment will consist of receiving peptide vaccinations as a shot just under the skin (subcutaneous). Peptides are small pieces of proteins. We have chosen to vaccinate with peptides derived from cancer proteins found in myeloma and other cancers. The purpose is to generate anti-myeloma T-cells which will kill myeloma cells and nothing else.
11649359|NCT00090480|Experimental|Vaccine group|
11649360|NCT00002622|Active Comparator|Talc slurry via chest tube|talc slurry via chest tube
11649361|NCT00002622|Active Comparator|Talc via insufflation|4 to 5 grams talc via insufflation through direct or videoscopic thoracoscopy, one time
11649362|NCT00002593|Active Comparator|5-FU/Leucovorin/Levamisole|levamisole hydrochloride: 50 mg every 8 hours x 3 days, PO, repeat every 14 days for 6 months; leucovorin calcium: 20 mg/m^2/day, IV, Days 1-5 of each cycle; 5-fluorouracil: 425 mg/m^2/day, IV, Days 1-5 of each cycle;
11649363|NCT00002593|Active Comparator|Infusional 5-FU + Levamisole|levamisole hydrochloride : 50 mg every 8 hours x 3 days, PO, repeat every 14 days for 6 months; 5-fluorouracil: 250 mg/m^2/day, continuous infusion, daily for 56 days x 3 cycles of 8 weeks.
11649364|NCT00002570|Active Comparator|Fluorouracil and folinic acid|
11649365|NCT00002570|No Intervention|Observation|
11649366|NCT00002527|Experimental|Aspirin|325 mg/day PO
11649367|NCT00002527|Placebo Comparator|Placebo|
11649368|NCT00090571||Sib Pairs|Two or more biological siblings affected with JIA.
11649369|NCT00090363|Placebo Comparator|Placebo|Matching placebo oral tablet once daily, with best supportive care
11649370|NCT00090363|Experimental|ZD4054 10 mg|ZD4054 10 mg oral tablet once daily, with best supportive care
11649371|NCT00090363|Experimental|ZD4054 15 mg|ZD4054 15 mg oral tablet once daily, with best supportive care
11649405|NCT00090064|Placebo Comparator|2|Participants will receive an initial dose of placebo orally followed 2 to 2.5 hours later by a second dose of placebo during the course of each of two experimental sessions.
11649406|NCT00090051|Active Comparator|Fludarabine+Cyclophosphamide (FC)|
11649407|NCT00090051|Experimental|Fludarabine+Cyclophosphamide+Rituximab (FCR)|
11649409|NCT00003224|Experimental|Group 2. p946 plus IFA|100 mcg peptide gp100 [280-288] plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant
11649372|NCT00004029|Experimental|Arm I|atients in cohorts of 3-6 receive 3 vaccinations with rV-PSA at 4-week intervals (days 1, 29, 57, and 85) in the absence of disease progression or unacceptable toxicity. Response assessment is performed at eight weeks. Patients who discontinue therapy prior to eight weeks are considered unevaluable for response. If dose limiting toxicity is observed in 2 of 6 patients entered at a dose level, no further patients are entered at that level and the MTD is defined as the preceding dose level. Ten additional patients are treated at the MTD and receive granulocyte-macrophage colony-stimulating factor (GM-CSF) administered subcutaneously on day -1 through day 2 of each cycle. Patients who are HLA-A2 positive, have received all 3 rV-PSA vaccinations without unacceptable toxicity, and have been off study for at least 30 days due to disease progression may continue treatment with rV-PSA at the highest dose level and the addition of GM-CSF.
11649373|NCT00090545|Experimental|First Stage - disease progression|"The first stage was to rule out the probability of 4 month progression free survival.
~Patients were given 400 mg BAY 43-9006 orally twice daily in 28 day cycles."
11649374|NCT00090545|Experimental|Second Stage - increased accrual|"Due to prostatic specific antigen and radiographic discordance during the first stage, the protocol was amended to allow accrual to a second stage.
~Patients were given 400 mg BAY 43-9006 orally twice daily in 28 day cycles."
11649375|NCT00090428|Experimental|1|Participants will follow a gluten-free and casein-free diet for 18 weeks. The compliance with the diet was monitored with 24 hour dietary recall and nutritional sufficiency with diet diary analysis.
11649376|NCT00090428|Active Comparator|2|After established on a gluten free and casein free diet for at least 6 weeks, participants received double blind, placebo controlled challenges containing gluten, casein, gluten+casein, or placebo in a random order. Data was collected on behavioral and physiologic responses relative to the challenges. Children remained on the gluten free and casein free diet throughout this period.
11649377|NCT00090415|Experimental|1|Child participants with autism will undergo intensive behavioral therapy.
11649378|NCT00090415|No Intervention|2|Child participants without autism will receive no treatment and will undergo assessments to determine brain functioning only.
11649379|NCT00090285|Experimental|qHPV Vaccine|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6. Follow-up for the Base Study encompassed Month 7 through Month 36.
11649380|NCT00090285|Placebo Comparator|Placebo|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6. Follow-up for the Base Study encompassed Month 7 through Month 36.
11649381|NCT00090259|Experimental|Losartan 50 mg|50-mg losartan tablet administered daily with 1 tablet of 100-mg losartan placebo beginning Week 1 and continuing to end of study (up to 4 years)
11649382|NCT00090259|Experimental|Losartan 150 mg|Titrated losartan administration up to daily 150-mg losartan: Week 1, daily 50-mg losartan tablet coadministered with 100-mg losartan placebo; Week 2, daily 50-mg losartan placebo coadministered with 100-mg losartan; Week 3 to end of study (up to 4 years), daily 50-mg losartan tablet coadministered with 100-mg losartan
11649383|NCT00090233|Experimental|1|RotaTeq
11649384|NCT00090233|Placebo Comparator|2|Placebo
11649385|NCT00090220|Experimental|qHPV Vaccine in Base Study|Participants received blinded qHPV vaccination at Day 1, Month 2, and Month 6 of the Base Study
11649386|NCT00090220|Placebo Comparator|Placebo in Base Study|Participants received blinded placebo at Day 1, Month 2, and Month 6 in the Base Study. They were eligible to receive open-label qHPV vaccine in Extension 1
11649387|NCT00003778|Experimental|Arm I|Patients receive dolastatin 10 IV over 10 minutes. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11649388|NCT00090402|Placebo Comparator|Fish Oil Placebo & Lipoic Acid Placebo|Three 1-gram placebo-fish oil capsules (2 in the morning, 1 evening) plus one 600 milligram placebo-lipoic acid per day. Placebo fish oil capsules consisted of soybean oil flavored with lemon flavor and 5% fish oil to match fish oil capsules. LA placebo contained no LA and the following excipients: lactose, hypromellose, silicon dioxide, microcrystalline cellulose, polyethylene glycol, povidone, corn starch, talc, and magnesium stearate.
11649389|NCT00090402|Active Comparator|Fish Oil Only|Three 1-gram fish oil concentrate capsules in triglyceride form (675 milligrams DHA and 975 milligrams EPA), 2 in the morning and 1 in the evening, plus one 600 milligram placebo-lipoic acid (containing no LA and the following excipients: lactose, hypromellose, silicon dioxide, microcrystalline cellulose, polyethylene glycol, povidone, corn starch, talc, and magnesium stearate) per day.
11649390|NCT00090402|Experimental|Fish Oil Plus Lipoic Acid|Three 1-gram placebo-fish oil capsules (2 in the morning, 1 evening) plus one 600 milligram lipoic acid (LA) capsule in the racemic form per day.
11649391|NCT00090337|Experimental|Arm I|Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks.
11649392|NCT00090337|Active Comparator|Arm II|Patients undergo standard of care for 4 weeks.
11649393|NCT00090194|Experimental|Low Dose|0.5 gm/kg at 5 days pre-transplant and 7 days post-transplant
11649394|NCT00090194|Experimental|Middle Dose|1.0 gm/kg at 5 days pre-transplant and 7 days post-transplant
11649395|NCT00090194|Experimental|High Dose|2.0 gm/kg at 5 days pre-transplant and 7 days post-transplant
11649396|NCT00090142|Experimental|1|Montelukast - Placebo
11649397|NCT00090142|Experimental|2|Placebo - Montelukast
11649398|NCT00090129|Experimental|Onercept|
11649399|NCT00090129|Placebo Comparator|Placebo|
11649400|NCT00090103|Active Comparator|dutasteride|dutasteride 0.5mg once daily
11649401|NCT00090103|Experimental|Combo|Combination of dutasteride (0.5mg) and tamsulosin (0.4mg), once daily
11649402|NCT00090103|Active Comparator|tamsulosin|tamsulosin 0.4mg once daily
11649403|NCT00003588|Experimental|Arm I|Patients undergo laparoscopy for p53 assessment and catheter placement. Patients receive daily intraperitoneal injections of adenovirus p53 (Ad-p53) for 5 days every 3 weeks. Treatment is repeated every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each are treated at each dose level of Ad-p53. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity.
11649404|NCT00090064|Experimental|1|Participants will receive 125 mg MDMA followed 2 to 2.5 hours later by 62.5 mg MDMA during course of each of two day-long psychotherapy sessions plus a third open-label MDMA-assisted session.
11649561|NCT00088595|Experimental|Pasireotide|
11649410|NCT00003224|Experimental|Group 3: p946 plus Tet-p plus QS-21|100 mcg peptide gp100 [280-288],190 mcg tetanus peptide, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant
11649411|NCT00003224|Experimental|Group 4. p946, Tet-p plus IFA|100 mcg peptide gp100 [280-288], 190 mcg tetanus peptide, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant
11649412|NCT00003224|Experimental|Group 5: p946/Tet-p plus QS-21|282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.2 ml (100 mcg) QS-21 vaccine adjuvant
11649413|NCT00003224|Experimental|Group 6. p946/Tet-p plus IFA|282 mcg gp100 [280-288]/tetanus peptide conjugate, plus 0.5 ml IFA (Montanide ISA-51) vaccine adjuvant
11649414|NCT00090038|Experimental|1|Rituximab
11649415|NCT00090038|No Intervention|2|No drug
11649416|NCT00003147|Experimental|Arm I|Patients receive adenovirus p53 construct by percutaneous injection to a maximum of two lesions on day 1. Treatment is repeated every 28 days for up to 6 courses. In the absence of dose-limiting toxicity (DLT) in the first cohort of 6 patients treated, subsequent cohorts of 6 patients each receive escalating doses of the drug on the same schedule. If DLT occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and that dose is declared the maximum tolerated dose. Study treatment may continue in the absence of disease progression and unacceptable adverse events.
11649417|NCT00003136|Experimental|Arm A|Cyclophosphamide (40mg/kg/day on days -6, -5 and -4), Carboplatin (1600, 1700 or 1800 mg/m2 on days -6, -5, -4 and -3), Amifostine (910 mg/m2 on days -6, -5, -4 and -3), Peripheral blood stem cell transplantation (day 0), G-CSF (beginning day 4)
11649418|NCT00002879|Experimental|cladribine|Patients receive cladribine (2-chlorodeoxyadenosine; 2-CdA) daily for 5 days every 4 weeks for a maximum of 6 courses; response is assessed after every 2 courses. Patients in complete remission or with stable disease discontinue treatment and are followed; those with disease progression at any time are removed from study. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and annually for 2 years.
11649419|NCT00090025|Experimental|becatecarin|becatecarin
11649420|NCT00090025|Active Comparator|5-FU Plus Leucovorin (LV)|5-Fluorouracil (5-FU) Plus Leucovorin (LV)
11649421|NCT00089973|Experimental|SB-715992|Females with advanced or metastatic breast cancer were administered Ispinesib
11649422|NCT00089960|Other|Arm|AMG 125 mg daily continuously
11649423|NCT00089921|Experimental|001|SCIO-469 30 mg capsule three times daily for 12 weeks
11649424|NCT00089921|Experimental|002|SCIO-469 60 mg capsule three times daily for 12 weeks
11649425|NCT00089921|Experimental|003|SCIO-469 100 mg tablet once daily for 12 weeks
11649426|NCT00089921|Placebo Comparator|004|Placebo 2 capsules three times daily and one tablet daily
11649427|NCT00004136|Experimental|Heat Therapy|
11649428|NCT00089908|Experimental|1|One subcutaneous vaccination with rDEN1delta30 vaccine (10^3 PFU dose) into the deltoid region of either arm.
11649429|NCT00089908|Experimental|2|One subcutaneous vaccination with rDEN1delta30 vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the effect of the vaccine on subjects in Arm 1.
11649430|NCT00089908|Placebo Comparator|3|One subcutaneous vaccination with placebo into the deltoid region of either arm.
11649431|NCT00089895|Experimental|Eptifibatide|Eptifibatide in addition to standard of care such as standard doses of aspirin, unfractionated heparin or low-molecular-weight heparin.
11649432|NCT00089895|Placebo Comparator|Placebo|Placebo in addition to standard of care such as standard doses of aspirin, unfractionated heparin or low-molecular-weight heparin.
11649433|NCT00089856|Other|2|Standard of care - chemotherapy
11649434|NCT00089856|Experimental|1|Immunotherapy
11649435|NCT00089843|Active Comparator|2|Placebo Actonel (risedronate) and active testosterone patch
11649436|NCT00089843|Active Comparator|3|Active Actonel (risedronate) and active testosterone patch
11649437|NCT00089843|Active Comparator|4|Active Actonel (risedronate) and placebo testosterone
11649438|NCT00089843|Placebo Comparator|1|Placebo testosterone patch and placebo Actonel (risedronate)
11649439|NCT00089804|Active Comparator|1|300 mg (three 2 mL vials of abetimus sodium plus six 2 mL vials of normal saline) administered i.v (in the vien) weekly
11649440|NCT00089804|Active Comparator|2|900 mg (nine 2 mL vials of abetimus sodium) administered i.v. (in the vein) weekly
11649441|NCT00089804|Placebo Comparator|3|A volume of 18 mL (Nine 2 mL vials) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly
11649442|NCT00003686|Active Comparator|Pilocarpine|
11649443|NCT00003686|Placebo Comparator|Placebo|
11649444|NCT00003556|Experimental|Arm I|Patients receive ALVAC-hB7.1 alone or combined with ALVAC-hIL-12 intratumorally on days 1, 4, 8, and 11. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at each dose level of ALVAC-hB7.1. The maximum tolerated dose is defined as the dose of ALVAC-hB7.1 at which no more than 1 of 5 patients experiences dose limiting toxicity.
11649445|NCT00089791|Placebo Comparator|Placebo|Placebo administered subcutaneously once every 6 months for 3 years.
11649446|NCT00089791|Experimental|Denosumab 60 mg Q6M|Denosumab 60 mg administered subcutaneously once every 6 months (Q6M) for 3 years.
11649447|NCT00089752|Active Comparator|Active Treatment|Continuous Positive Airway Pressure Treatment
11649448|NCT00089752|Placebo Comparator|Sham/Placebo Treatment|Ineffective sham continuous positive airway pressure device with leak in interface to <1.0 cm H2O and resistance in motor to simulate normal operating noise and no compensation for leak.
11649449|NCT00089778|Experimental|Grp A-Measurable metastatic disease (no immediate aldesleukin)|"Patients who do not need or are ineligible for treatment with interleukin-2 (IL-2) and patients who have previously had IL-2 therapy.
~A3 FGF-5 (Fibroblast growth factor 5): 172-176/217-220 peptide - two 1 ml injections in the anterior thigh deep subcutaneous tissue within 2c of each other."
11649450|NCT00089778|Experimental|Grp B - Measurable metastatic disease that require aldesleukin|"Patients who require immediate treatment with IL-2. A2 FGF-5: 117-126 peptide + HD (high dose) IL-2 (prior cycle 1)- two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
~720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses)."
11649562|NCT00088582|Experimental|Sandostatin s.c. (Octreotide)|
11649563|NCT00088582|Experimental|Pasireotide (SOM230)|
11649451|NCT00089778|Experimental|Grp C - High-risk loco-regional disease|"Patients whose cancer has been surgically removed but who are at risk for recurrence and local disease and who are seeking experimental adjuvant therapy.
~A2 FGF-5: 117-126 peptide (adjuvant); A3 FGF-5: 172-176/217-220 peptide (adjuvant)"
11649452|NCT00003200|Experimental|Taxotere|"After the screening procedures confirm participation in the research study:
~Taxotere-Administered weekly for 1 hour (6 doses)
~Radiation Therapy (XRT) -5 days a week for 6 weeks
~Exam under anesthesia
~Neck Dissection (if indicated)"
11649453|NCT00003058|Experimental|Troglitazone|Patients received troglitazone 800 mg oral once-daily. Treatment continued as long as patient was responding or in stable disease clinically and ended if patient experienced progression or unacceptable toxicity.
11649454|NCT00089674|Experimental|AMG 162|
11649455|NCT00089674|Placebo Comparator|Placebo|
11649456|NCT00089661|Experimental|AMG 162 / Denosumab|
11649457|NCT00089661|Placebo Comparator|Placebo|
11649458|NCT00089648|Experimental|1|
11649459|NCT00089635|Experimental|Panitumumab|Panitumumab was administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks until participants developed progressive disease, were unable to tolerate investigational product, or discontinued for other reasons.
11649460|NCT00002909|Experimental|Arm I|All patients receive oral phenylbutyrate three times daily. Groups of 4 or more patients receive escalating doses of phenylbutyrate until the maximum tolerated dose (MTD) is determined. Treatment continues until disease progression or unacceptable toxicity intervenes.
11649461|NCT00089583|Experimental|2 - 18 yrs old (FPV/RTV BID)|Cohort 1B - 2 - less than 6yrs old (FPV/RTV BID) Cohort 2 - 6 to less than 12 yrs old (FPV/RTV BID) Cohort 3 - 12 - 18 yrs old (FPV/RTV BID) Cohort 4 - 2 - 18 yrs (FPV/RTV BID)
11649462|NCT00089583|Experimental|2 - less than 6yrs old (FPV BID)|Cohort 1A - 2 - less than 6yrs old (FPV BID)
11649463|NCT00005626|Experimental|Irinotecan Treatment|Patients receive irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed for survival.
11649464|NCT00002574|Experimental|Arm I|Single-Agent Chemotherapy plus Biological Response Modifier Therapy. Homoharringtonine, HH, NSC-141633; plus Interferon alfa (Schering), IFN-A, NSC-377523.
11649465|NCT00089609|Experimental|Main cohort - Prostate Cancer|Docetaxel 75 mg/m^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days. Thalidomide 200 mg by mouth daily throughout the cycle. Prednisone 10 mg by mouth daily throughout the cycle. Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.
11649466|NCT00089609|Experimental|Expansion cohort - Prostate Cancer|Docetaxel 75 mg/m^2 intravenously over 60 minutes and Bevacizumab 15 mg/kg intravenously was given for 2 cycles. After two cycles Prednisone 10 mg by mouth daily and Thalidomide 200 mg by mouth daily was added.
11649467|NCT00089570|Experimental|Terlipressin|Terlipressin
11649468|NCT00089570|Placebo Comparator|Placebo|Placebo
11649469|NCT00089544|Experimental|Cohort A (chemotherapy, radiation, thalidomide, surgery)|Patients receive doxorubicin, ifosfamide, and dacarbazine IV continuously on days 1-3, 22-24, and 43-45. Patients receive G-CSF subcutaneously beginning on days 4, 25, and 46 and continuing until blood counts recover. Patients undergo radiotherapy once daily on days 7-11, 14-18, 21, 28-32, 35-39, and 42. Patients receive oral thalidomide once daily on days 7-21 and 26-42. Patients undergo surgical resection between days 84 and 98. Beginning 2 weeks after surgery, patients receive oral thalidomide once daily for 12 months in the absence of unacceptable toxicity.
11649470|NCT00089544|Experimental|Cohort B (thalidomide, radiation, surgery)|Patients receive oral thalidomide once daily beginning on day 1 and continuing until 1 week before surgery. Patients undergo radiotherapy once daily, 5 days a week, on weeks 1-5. Patients undergo surgical resection between days 77 and 91. Beginning 2 weeks after surgery, patients receive oral thalidomide once daily for 6 months in the absence of unacceptable toxicity.
11649471|NCT00005076|Experimental|EgFR antibody|
11649472|NCT00089505|Experimental|NVP/NVP|For participants who had SD NVP exposure prior to study entry. FTC, TDF, and NVP daily the first 14 days, then twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV twice daily plus two more NRTIs.
11649473|NCT00089505|Experimental|NVP/LPV_r|For participants who had SD NVP exposure prior to study entry. FTC and TDF daily and LPV/RTV twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily for 14 days before taking it twice daily. plus 2 more NRTIs.
11649474|NCT00089505|Experimental|NoNVP/NVP|For participants who did NOT have SD NVP exposure prior to study entry.FTC, TDF, and NVP daily the first 14 days, then twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue NVP will receive LPV/RTV twice daily plus two more NRTIs.
11649475|NCT00089505|Experimental|NoNVP/LPV_r|For participants who did NOT have SD NVP exposure prior to study entry. FTC and TDF daily and LPV/RTV twice daily. FTC and TDF may be replaced by the combination drug FTC/TDF. Participants who discontinue LPV/RTV will receive NVP daily for 14 days before taking it twice daily. plus 2 more NRTIs.
11649476|NCT00089492|Experimental|1|
11649477|NCT00089492|Active Comparator|2|
11649478|NCT00089479|Experimental|1|
11649479|NCT00089479|Active Comparator|2|
11649480|NCT00089466|Experimental|A|200 mg AMD11070 every 12 hours
11649481|NCT00089466|Experimental|B|400 mg AMD11070 every 12 hours
11649482|NCT00089466|Experimental|C|600 mg AMD11070 every 12 hours
11649483|NCT00089466|Experimental|D|800 mg AMD11070 every 12 hours
11649484|NCT00089466|Experimental|E|1000 mg AMD11070 daily
11649485|NCT00089466|Experimental|F|1500 mg AMD11070 daily
11649486|NCT00089466|Experimental|G|1000 mg AMD11070 every 12 hours
11649487|NCT00089466|Experimental|H|2000 mg AMD11070 daily
11649488|NCT00089414|Experimental|1|Treatment arm # 1 consists of the continuous administration of Yasmin oral contraceptive (a combination of 30 µg of ethinyl estradiol and 3 mg of drospirenone) for 15 weeks starting on day 2 to 5 of the first menstrual cycle.
11649489|NCT00089414|Active Comparator|2|Treatment arm # 2 (interrupted Yasmin administration) will be identical to arm # 1 with the exception that the continuous administration of Yasmin will be interrupted by the substitution of placebo for Yasmin for one week during weeks 3, 8, and 14 of the study. The women participating in this treatment arm will experience episodes of menstruation after Yasmin withdrawal (when they are on placebo).
11649490|NCT00089414|Active Comparator|3|Yasmin oral contraceptive; CDB 2914 progesterone antagonist. Treatment arm # 3 is identical to treatment arm # 1 with the exception that the continuous administration of Yasmin will also include the administration of progesterone antagonist CDB-2914 during weeks 3, 8, and 14. Menses is anticipated to occur within 2-3 days of CDB-2914 administration. Women in treatment arms # 3 and # 1 will be exposed to continuous levels of Yasmin, but due to the local effects of the progesterone antagonist on the endometrium, women in arm # 3 will experience menses.
11649491|NCT00089388|Experimental|Arm I (low dose cilengitide)|Patients receive cilengitide IV at a lower dose over 1 hour twice weekly for 4 weeks.
11649492|NCT00089388|Experimental|Arm II (higher dose cilengitide)|Patients receive cilengitide IV at a higher dose over 1 hour twice weekly for 4 weeks.
11649493|NCT00089362|Experimental|Treatment (alvespimycin hydrochloride)|"Patients receive alvespimycin hydrochloride IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 1-2 patients receive accelerated escalating doses of alvespimycin hydrochloride until at least 1 of 2 patients experience DLT. Cohorts are then expanded to 3-6 patients who receive escalating doses (in a standard manner) of alvespimycin hydrochloride until MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. Once the MTD is determined, 10 additional patients are treated at that dose."
11649494|NCT00089349|Experimental|Arm I|"Course 1: Patients receive alemtuzumab IV over 2 hours on days 1-5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission (CR), partial remission (PR), or cytolytic PR at day 29, or patients with CNS disease that achieve a CNS 1 or CNS 2 status, proceed to course 2.
~Courses 2 and 3: Patients receive alemtuzumab IV over 2 hours on days 1, 8, 15, and 22; methotrexate IV continuously over 24 hours on day 1 and then orally once daily on days 8, 15, and 22; and oral mercaptopurine once daily on days 1-28. Patients with a CR or PR at day 29 proceed to course 3. In course 3, patients receive alemtuzumab, methotrexate, and mercaptopurine as in course 2.
~CNS prophylaxis*: Patients receive methotrexate intrathecally on day 1 of courses 2 and 3 on day 1 of courses 2 and 3.
~NOTE: * CNS-negative patients receive methotrexate intrathecally on day 15 of course 1 and day 1 of courses 2 and 3."
11649495|NCT00089323|Other|1: Bone Marrow Aspiration|
11649496|NCT00089310|Experimental|Sentinal node mapping|
11649497|NCT00089297|Experimental|Cetuximab/Paclitaxel/Carboplatin|"Induction: Cetuximab (C225) 400 mg/m2 at wk 1 then 250 mg/m2 for 5 weeks. Paclitaxel (P) 90 mg/m2 IV and carboplatin (C) AUC = 2 IV were given weekly.
~Restaging biopsy of primary site scheduled at wk 7. Concurrent chemoradiation: Radiation therapy at 200cGy/d/5 wks for a total of 50Gy and C225 at 250 mg/m2/wk. P following C225 at 30 mg/m2/wk and C following P at AUC = 1/week. Patients with a negative biopsy continued concurrent therapy to complete radiation (68-72Gy).
~Restaging biopsy of primary site: Patients with positive biopsy at wk 7 or patients without a clinical complete response at the primary site after induction therapy had re-biopsy at wk 14. If the biopsy was negative, the patients continued concurrent therapy to complete radiation (68-72 Gy). If positive, resection of the primary site was done.
~Additional concurrent chemoradiation: C225 at 250mg/m2/wk IV followed by P 30mg/m2/wk IV followed by C AUC = 1/wk and RT for 3 wks."
11649498|NCT00089284|Experimental|Rituxan and 90Yttrium-Zevalin plus MGd|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
11649499|NCT00089271|Experimental|Treatment (alvespimycin hydrochloride)|Patients receive 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) IV over 1-6 hours on days 1-3 or 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11649500|NCT00089245|Experimental|Radiolabeled Monoclonal Antibody Therapy|This is a Phase I trial designed to evaluate the Maximally Tolerated Dose (MTD) of intrathecal 131I-8H9. In order to find the MTD, a dose escalation scheme will be employed with patients entering in cohorts of 3 at each dose level from 10 mCi to 60 mCi and a cohort of 6 at each dose level from 70 mCi to 100 mCi.
11649501|NCT00089219|Experimental|Arm A. 6MHP vaccine 200 mcg|vaccine containing 6 melanoma helper peptides, at 200 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
11649502|NCT00089219|Experimental|Arm B. 6MHP vaccine 400 mcg|vaccine containing 6 melanoma helper peptides, at 400 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
11649503|NCT00089219|Experimental|Arm C. 6MHP vaccine 800 mcg|vaccine containing 6 melanoma helper peptides, at 800 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
11649504|NCT00089180|Experimental|Arm I (liposomal T4N5 lotion)|Patients apply T4N5 liposomal lotion topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.
11649505|NCT00089180|Placebo Comparator|Arm II (placebo)|Patients apply placebo topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.
11649506|NCT00089154|Experimental|Treatment (apolizumab)|Patients receive apolizumab IV over 2-4 hours on days 1, 2, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity.
11649507|NCT00089141|Active Comparator|Mycophenolate mofetil|Patients receive oral mycophenolate mofetil twice daily.
11649508|NCT00089141|Placebo Comparator|Placebo|Patients receive oral placebo twice daily
11649509|NCT00089128|Experimental|Gemcitabine and Irnotecan|
11649510|NCT00089102|Experimental|Gemcitabine + Irinotecan|
11649511|NCT00089089|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 1 hour on days 1-5 or on days 1-5 and 8-12. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
~Cohorts of 6 patients receive escalating doses of decitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
11649512|NCT00089076|Experimental|Treatment (ipilimumab)|"PHASE I: Patients receive MDX-010 IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
~Cohorts of 6 patients from each group receive escalating doses of MDX-010 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
~PHASE II: Patients receive MDX-010 as in phase I at the MTD."
11649513|NCT00089063|Experimental|Arm I (vaccine therapy)|Patients receive vaccination comprising tyrosinase peptide, gp100 antigen, and MART-1 antigen emulsified with Montanide ISA-51 and ISA-51 VG SC on day 1 of weeks 0, 26, 52, 78, and 104 (total of 5 vaccinations).
11649514|NCT00089063|Experimental|Arm II (vaccine therapy, sargramostim)|Patients receive vaccination comprising tyrosinase peptide, gp100 antigen, and MART-1 antigen emulsified with Montanide ISA-51 and ISA-51 VG as in arm I. Patients also receive sargramostim (GM-CSF) SC on days 1-5 of weeks 0, 26, 52, 78, and 104.
11649515|NCT00089024|Experimental|treatment|see interventions
11649516|NCT00089011|Experimental|Arm I (nonmyeloablative conditioning with fludarabine and TBI)|Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.
11649517|NCT00089011|Experimental|Arm II (nonmyeloablative conditioning with TBI)|Patients undergo TBI on day 0. All patients then undergo allogeneic peripheral blood stem cell transplantation on day 0 and receive tacrolimus PO every 12 hours on days -3 to 180, with taper on day 56, or tacrolimus IV if unable to tolerate PO; and mycophenolate mofetil PO every 12 hours on days 0-27 or mycophenolate mofetil IV if unable to tolerate PO.
11649518|NCT00088998|Experimental|docetaxel + bevacizumab + capecitabine|"Patients receive docetaxel IV over 1 hour and bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.
~Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years."
11649519|NCT00088985|Experimental|Dendritic Cell Vaccine|Dendritic Cells: Dosage: 20 x 106 dendritic cells (DCs) given per treatment Vinorelbine:25 mg/m2 will be administered i.v biweekly Trastuzumab: 6mg/Kg administered by i.v. biweekly
11649520|NCT00088972|Experimental|Arm I - Celecoxib|Patients receive oral celecoxib twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.
11649521|NCT00088972|Placebo Comparator|Arm II - Placebo|Patients receive oral placebo twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.
11649522|NCT00088959|Experimental|Treatment (erlotinib hydrochloride, celecoxib)|Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
11649523|NCT00088946|Experimental|Arm 1|Polyphenon E plus erlotinib placebo daily for 12 months.
11649524|NCT00088946|Experimental|Arm 2|Erlotinib and Polyphenon E placebo daily for 12 months.
11649525|NCT00088946|Placebo Comparator|Arm 3|Erlotinib placebo and Polyphenon E placebo daily for 12 months.
11649526|NCT00088933|Experimental|Arm I|Three weeks after treatment with vaccinia-CEA-TRICOM vaccine, patients receive fowlpox-CEA-TRICOM vaccine SC on day 1 and GM-CSF SC into each vaccination site on days 1-4.
11649527|NCT00088933|Experimental|Arm II|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and lower-dose docetaxel IV over 30 minutes on days 1 and 8.
11649528|NCT00088933|Experimental|Arm III|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and standard-dose docetaxel IV over 30 minutes on days 1 and 8.
11649529|NCT00088933|Experimental|Arm IV|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and full-dose docetaxel IV over 1 hour on day 1.
11649530|NCT00088933|Experimental|Arm V|Patients receive full-dose docetaxel IV over 1 hour on day 1, fowlpox-CEA-TRICOM vaccine SC on day 8, and GM-CSF SC into each vaccination site on days 8-11.
11649531|NCT00088933|Experimental|Arm VI|Patients receive full-dose docetaxel as in arm V, fowlpox-CEA-TRICOM vaccine SC on day 15, and GM-CSF SC into each vaccination site on days 15-18.
11649532|NCT00088907|Active Comparator|Arm I (docetaxel and placebo)|Patients receive docetaxel intravenously (IV) over 30-60 minutes on days 1, 8, and 15 and oral placebo once daily on days 1-28.
11649533|NCT00088907|Experimental|Arm II (docetaxel and gefitinib)|"Patients receive docetaxel as in arm I and oral gefitinib once daily on days 1-28.
~ZD1839 (Iressa, gefitinib) will be given at a dose of 250 mg (one tablet) orally each day starting on day 1 and continuing for days 1 to 28 of each cycle until progression.
~In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in arm I who have disease progression may receive single-agent oral gefitinib once daily until further disease progression."
11649534|NCT00088894|Experimental|Arm I (gemcitabine hydrochloride, bevacizumab)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15.
11649535|NCT00088894|Active Comparator|Arm II (gemcitabine hydrochloride, placebo)|Patients receive gemcitabine IV as in arm I and placebo IV over 30-90 minutes on days 1 and 15.
11649536|NCT00088881|Experimental|Treatment|"R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone): Patients receive R-CHOP every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response after 2 courses receive 2 additional courses. Patients achieving a partial response, uncertain CR, or stable disease receive 4 additional courses. Patients with progressive disease go off study.
~Zevalin™Radioimmunotherapy: Beginning no more than 9 weeks after the last course of R-CHOP, patients receive rituximab IV on day 1 followed by indium In 111 ibritumomab tiuxetan IV over 10 minutes for imaging studies. Patients then receive rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8.
~Radiation therapy: Patients with residual disease by CT scan or positron emission tomography (PET) scan after 12 weeks after radioimmunotherapy undergo conventional involved-field radiotherapy."
11649537|NCT00088855|Experimental|Treatment (bortezomib and pegylated liposomal doxorubicin)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 4. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
11649538|NCT00088829|Experimental|Paclitaxel|Paclitaxel given before surgery
11649539|NCT00088777|Experimental|MET|
11649540|NCT00088777|Experimental|CSE|
11649541|NCT00088764|Experimental|1|Education: Either coping skills training or arthritis education interventions
11649542|NCT00088764|Experimental|2|Writing: Either emotional disclosure writing or health behavior writing
11649543|NCT00004193|Experimental|ISIS 2503|patients who have metastatic and/or locally recurrent colorectal cancer
11649682|NCT00087516|Active Comparator|Sitagliptin 200 mg/200 mg|Phase A and B: Oral tablets of sitagliptin 200 mg q.d
11649544|NCT00004162|Experimental|Dose group 1 - dose 1 of Doxorubicin HCL Liposome|Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
11649545|NCT00004162|Experimental|Dose group 2 - dose 2 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
11649546|NCT00004162|Experimental|Dose Group 3 - dose 3 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
11649547|NCT00004162|Experimental|Dose group 4 - dose 4 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
11649548|NCT00004162|Experimental|Dose group 5 - dose 5 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
11649549|NCT00004162|Experimental|Dose group 6 - dose 6 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
11649550|NCT00004162|Experimental|Dose group 7 - dose 7 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
11649551|NCT00004162|Experimental|MTD group|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
11649552|NCT00003892|Experimental|ISIS 5132|ISIS 5132 x 21 days IV infusion
11649553|NCT00003828|Experimental|vinorelbine|vinorelbine 30 mg/m2/week IV bolus over approximately 6-10 minutes
11649554|NCT00003786|Experimental|Arm A|MGI-114 (11mg/m2/day x 5 days every 28 days)
11649555|NCT00003416|Experimental|treatment|"Ind:
~dexamethasone 40 mg/d PO D1-4,9-12,17-20 q35 days x 3 cycles
~SC Collection:
~cyclophosphamide 1.5gm/m2 IV q3 hrs x 2 mesna 3 gm/m2 conIV start with cyclo GCSF 5mcg/kg/d SQ start 1 day after cyclo until WBC > 50,000/mcg
~Trans (x2):
~melphalan 100 mg/m2/d IV D-1,-2 PBSC infusion D0
~Maint:
~interferon 3 million units/m2 SQ 3x/wk"
11649556|NCT00088699|Experimental|Ketamine, Then Placebo|Ketamine and placebo infusions were administered two weeks apart, with Ketamine's dose being 0.5 mg/kg.
11649557|NCT00088699|Experimental|Placebo, Then Ketamine|Placebo and Ketamine infusions were administered two weeks apart, with Ketamine's dose being 0.5 mg/kg
11649558|NCT00088634|Experimental|Lurasidone|80 mg AM dosing once daily
11649559|NCT00088634|Placebo Comparator|Placebo|
11649560|NCT00088621|Experimental|Lurasidone 80 mg tablet|Lurasidone 80mg oral tablet taken once a day
11649564|NCT00003256|Experimental|Arm I|Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects may receive a dose escalation.
11649565|NCT00003213|Experimental|Oral Granisetron + Dexamethasone|"1 mg Granisetron in the morning
~1 Metoclopramide placebo in the afternoon
~1 mg Granisetron in the evening 4 mg Dexamethasone in the morning"
11649566|NCT00003213|Experimental|Metoclopramide + Dexamethasone|20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening) 4 mg Dexamethasone in the morning
11649567|NCT00088556|Experimental|Triplet Combination of TLK286 Carboplatin & Paclitaxel|Experimental
11649568|NCT00088543|Experimental|1 Low dose|total dose 4.5 mg/kg Thymoglobulin
11649569|NCT00088543|Experimental|2 High dose|total dose 8.5 mg/kg Thymoglobulin
11649570|NCT00002921|Experimental|Suramin|
11649571|NCT00002833|Experimental|Group 1A|"Group 1A - With or Without Remission + Failing Fludarabine therapy:
~Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3 with Cladribine continuous infusion for 5 days, beginning 4 hours before Ara-C first dose. Idarubicin IV Days -6, -5 and -4. Cells infused on day 0. Cyclosporine via continuous IV infusion, oral cyclosporine administered for 6 months postinfusion (tapered 10% weekly until discontinued). Methylprednisolone begins 5 days after infusion then gradually tapered."
11649572|NCT00002833|Experimental|Group 1B|"Group 1B: With or Without Remission, No previous Fludara Therapy
~Fludarabine IV over 30 minutes daily on days -6, -5, -4 and -3. Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours. Idarubicin IV Days -6, -5 and -4. Cells infused on day 0. Cyclosporine via continuous IV infusion, oral cyclosporine administered for 6 months postinfusion (tapered 10% weekly until discontinued). Methylprednisolone begins 5 days after infusion then gradually tapered."
11649573|NCT00088530|Experimental|Experimental Arm|Pixantrone (BBR2778)
11649574|NCT00088530|Active Comparator|Comparator Arm|To be chosen by the investigator, among vinorelbine, oxaliplatin, ifosfamide, etoposide or mitoxantrone
11649575|NCT00002832|Experimental|Decitabine + Stem Cell Transplantation|
11649576|NCT00002831|Experimental|Deoxyazacytidine + Busulfan + Cyclophosphamide|Deoxyazacytidine + Busulfan + Cyclophosphamide With Allogeneic Stem Cell Transplantation
11649577|NCT00002784|Active Comparator|Standard chemotherapy|EC/AC x 4 followed by CMF x 3 and tamoxifen to 5 years after randomization.
11649578|NCT00002784|Experimental|Dose-intensive EC|High-dose EC x 3 supported by peripheral blood progenitor cells and tamoxifen to 5 years after randomization.
11649579|NCT00002779|Experimental|fludarabine + octreotide|Patients receive fludarabine IV over 10-30 minutes on days 1-5. Patients not currently receiving octreotide, receive a test dose of octreotide subcutaneously on day 1 during course 1 only and then receive octreotide intramuscularly monthly on day 1. Treatment repeats every 28 days for 4-6 courses. Patients then receive octreotide alone for 6-8 courses. Some patients may then receive another 12 courses of octreotide alone, for a total of 2 years of treatment. Patients are followed every 3 months for 5 years or until disease progression.
11649580|NCT00002618|Active Comparator|Regimen A|Patients begin radiotherapy (5 days a week for 4.5 weeks) to residual tumor on day 1 of maintenance.
11649581|NCT00002618|Active Comparator|Regimen B|Patients receive whole brain irradiation (5 days a week for 3.1 weeks) beginning on day 1 of maintenance. Patients are followed monthly for 6 months, every 3 months for 18 months, every 6 months for 3 years, and annually thereafter.
11649582|NCT00002529|Experimental|AC with concurrent tamoxifen|AC for 4 cycles with concurrent tamoxifen for 5 years
11649583|NCT00002529|Experimental|AC followed by tamoxifen|AC for 4 cycles followed by tamoxifen to 5 years from randomization.
11649584|NCT00002529|Experimental|Tamoxifen alone|Tamoxifen alone for 5 years.
11649585|NCT00002529|Experimental|AC with concurrent toremifene|AC for 4 cycles with concurrent toremifene for 5 years.
11649586|NCT00002529|Experimental|AC followed by toremifene|AC for 4 cycles followed by toremifene to 5 years from randomization.
11649587|NCT00002529|Experimental|Toremifene alone|Toremifene alone for 5 years.
11649588|NCT00088465|Experimental|Intramuscular Olanzapine Depot|Intramuscular (IM) olanzapine depot flexible dosing and flexible interval
11649589|NCT00088452|Active Comparator|Ethosuximide|"Ethosuximide
~Frequency and Duration: twice a day, every day for the duration of the study treatment
~Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight and ability to swallow): 250mg Zarontin capsules OR 250 mg/5 mL Zarontin syrup
~Dosing: Ethosuximide was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 2000 mg/day (whichever was lower)"
11649590|NCT00088452|Active Comparator|Lamotrigine|"Lamotrigine
~Frequency and Duration: twice a day, every day for the duration of the study treatment
~Formulation: Three formulations were used (actual formulation used was dependent on the patient's weight): 5mg Lamictal chewable tablets OR 25 mg Lamictal chewable tablets OR 25 mg (Lamictal tablets
~Dosing: Lamotrigine was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 12 mg/kg/day or 600 mg/day (whichever was lower)."
11649591|NCT00088452|Active Comparator|Valproic acid|"Valproic acid
~Frequency and Duration: twice a day, every day for the duration of the study treatment
~Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight): 250mg Depakote capsules OR 125mg Depakote sprinkles.
~Dosing: Depakote was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 3000 mg/day (whichever was lower)"
11649592|NCT00088426||Control|Control group of Williams-Beuren (also known as Williams) syndrome
11649593|NCT00088426||Family|Direct blood relatives (typically parents, and occasionally siblings of affected individuals) ofpatients with HPE are also eligible to participate.
11649594|NCT00088426||HPE|Patients with HPE
11649595|NCT00088413|Experimental|All Cohorts: Colorectal, Non-Colorectal, Breast, and Ovarian|All cohorts receive the same intervention (Cohort 1: Colorectal arm, non-colorectal cancers; Cohort 2: breast cancer; Cohort 3: ovarian cancers)
11649596|NCT00088374|Experimental|Von Hippel-Lindau (VHL) associated renal tumors|
11649597|NCT00088257||Mother-child pairs|Subset of mother-child pairs enrolled in Project Viva, a cohort study of pregnant women and their offspring. 411 mother-child pairs with measures of lymphocyte proliferation in their cord blood samples make up the subset for this study.
11649598|NCT00005624|Experimental|CI-994 Treatment|Patients receive CI-994 orally daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for 30 days and then every 2 months.
11649599|NCT00005614|Experimental|Gemcitabine Treatment|Patients receive gemcitabine IV over 1 hour weekly for 7 consecutive weeks in an 8 week course. Treatment then continues weekly for 3 consecutive weeks in 4 week courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed prior to treatment and then every 12 weeks. Patients are followed every 3 months for 2 years, then every 6 months until year 5, and then annually thereafter.
11649600|NCT00004875||Standard Heparin|
11649601|NCT00004875||Enoxaprin|
11649602|NCT00004263|Experimental|Cytarabine + UCN-01|
11649603|NCT00088231|Experimental|PTK 787 + Imatinib|For 1 week prior to receipt of study combination regimen, all patients will receive single agent PTK 787 at dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels. Patients should not have a grade 3 or 4 PTK 787-related adverse events in order to begin study combination therapy with a imatinib on day 8. On Day 8, PTK 787 250 mg by mouth every day and imatinib 600 mg by mouth every day (for Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia- blastic phase (CML-BP) and imatinib 400 mg by mouth every day (for Agnogenic Myeloid Metaplasia (AMM). Length of therapy is four courses; each course equals 28 days. Patients assessed for response after each course.
11649604|NCT00088231|Experimental|PTK 787 (vatalanib) Alone|For 1 week prior to receipt of study combination regimen, all patients will receive single agent PTK 787 at dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels. Patients should not have a grade 3 or 4 PTK 787-related adverse events in order to begin study combination therapy with a imatinib on day 8. PTK 787 250 mg by mouth for Days 1 - 7.
11649605|NCT00088218|Active Comparator|Clofarabine|Clofarabine intravenous (IV) 30 mg/m^2 daily times 5 days
11649606|NCT00088218|Active Comparator|Clofarabine Plus Ara-C|Clofarabine IV 30 mg/m^2 daily times 5 days + Ara-C 20 mg/m^2 subcutaneously daily times 14 days.
11649607|NCT00088205|Experimental|A|
11649608|NCT00088166|Experimental|I|Patients will take hCRF (XERECEPT) 2mg/day and open label-dexamethasone they are currently taking.
11649609|NCT00088166|Placebo Comparator|II|Patient will receive placebo hCRF and any open-label dexamethasone that they are currently taking
11649610|NCT00003812|Experimental|chemotherapy + radiation therapy|Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 1. Filgrastim (G-CSF) is administered subcutaneously every day starting on day 6 until blood counts recover. The course is repeated once beginning on day 22. After restaging, patients begin thoracic radiotherapy daily, five days per week, for 6-7 weeks. On the same day that radiotherapy begins, patients receive carboplatin IV over 1 hour (day 43) and etoposide IV over 1 hour daily for 3 days (days 43-45). The consolidation chemotherapy is repeated every 21 days for a total of 3 courses. Patients with stable or responding disease undergo prophylactic cranial irradiation. Patients are followed at least every 3 months for 2 years, every 6 months for 3 years, and then at least every year.
11649611|NCT00003748|Experimental|irinotecan hydrochloride|One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
11649612|NCT00003677|Experimental|Dolastatin 10|Dolastatin 10 IV bolus once every 21 days.
11649613|NCT00003675|Experimental|Oral Topotecan 5 days|Patients receive intervention twice daily for 5 days
11649614|NCT00003675|Experimental|Oral Topotecan 10 days|Patients receive intervention once daily for 10 days
11649615|NCT00003610|Experimental|capsaicin + radiation therapy|Patients receive one lozenge orally of capsaicin four times daily. Treatment begins within the first 3 days of radiation therapy and continues during and for two weeks after radiation therapy is completed.
11649616|NCT00003610|Placebo Comparator|placebo + radiation therapy|Patients receive one lozenge orally of placebo four times daily. Treatment begins within the first 3 days of radiation therapy and continues during and for two weeks after radiation therapy is completed.
11649617|NCT00003557|Experimental|Arm A|Dolastatin-10 (400 mcg/m2 IV every 3 weeks)
11649618|NCT00088153|Experimental|Physiologic estrogen replacement|"Mature girls with anorexia nervosa (AN) (bone age 15 or greater): Transdermal estradiol (100 mcg) with cyclic progesterone (days 1-10 of each month).
~Immature girls with AN (bone age less than 15 years): Ethinyl estradiol (3.75 mcg daily for the first 6 months, 7.5 mcg daily for the next 6 months, and 11.25 mcg daily for the final 6 months of the study"
11649619|NCT00088153|Placebo Comparator|Placebo|Placebo patches or pills
11649620|NCT00088140|Placebo Comparator|Placebo|
11649621|NCT00088140|Active Comparator|IDN-6556 5 mg twice a day (BID)|
11649622|NCT00088140|Active Comparator|IDN-6556 25mg twice a day (BID)|
11649623|NCT00088140|Active Comparator|IDN-6556 50 mg twice a day (BID)|
11649624|NCT00003225|Experimental|Ethyol plus Irinotecan|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. 10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.
11649625|NCT00088010|Experimental|1|
11649626|NCT00088010|Placebo Comparator|2|
11649627|NCT00087984|Experimental|MB-002-003|
11649628|NCT00087880|Active Comparator|Brief Treatment|Participants will start with a 21 mg nicotine patch, tapering to 14 mg patch and finally tapering to 7 mg patch. The nicotine patch will be administered on Week 3 of the program. Participants will meet with medical staff during Weeks 1, 2, 5, and 11. Five group counseling sessions must be attended by the participants. Assessments will be conducted on Weeks 12, 24, 36, 52, 64, and 104.
11649629|NCT00087880|Active Comparator|Extended Bupropion/Low Contact|Participants will receive the Brief Treatment followed by ongoing Bupropion treatment through Week 52. Participants will meet with medical staff once a month.
11649630|NCT00087880|Placebo Comparator|Extended Placebo/Low Contact|Participants will receive the Brief Treatment followed by placebo medication (sugar-pill) through Week 52 and meet with medical staff once a month.
11649631|NCT00087880|Active Comparator|Extended Bupropion/High Contact|Participants will receive Brief Treatment followed by ongoing bupropion treatment through Week 52. Participants will attending counseling session 20-40 minutes in duration and will be scheduled at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52. The contents of these sessions will introduce additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal. Subjects will be contact by phone between counseling sessions (at Weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, 48) for a brief check-in.
11649632|NCT00087880|Placebo Comparator|Extended Placebo/High Contact|Participants receive the Brief Treatment followed by a placebo medication through Week 52 and meet with medical staff once per month. Participants will attending counseling session 20-40 minutes in duration and will be scheduled at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52. The contents of these sessions will introduce additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal. Subjects will be contact by phone between counseling sessions (at Weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, 48) for a brief check-in.
11649633|NCT00087867|Experimental|001|SCIO-469 two 30-mg capsules three times daily
11649634|NCT00087867|Other|002|SCIO-469 and bortezomib In addition to SCIO-469 patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1 4 8 and 11 of a 21-day cycle followed by a 10-day rest period
11649635|NCT00005632|Experimental|Vaccine|Patients sequentially will receive glycosylated MUC-1-KLH vaccines at 3ug per vaccination.
11649636|NCT00004160|Experimental|Dose 1 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
11649637|NCT00004160|Experimental|Dose 2 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
11649638|NCT00004160|Experimental|Dose 3 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
11649639|NCT00004160|Experimental|Dose 4 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
11649640|NCT00004160|Experimental|Dose 5 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
11649641|NCT00003196|Experimental|Treatment (irradiation, transplant, immunosuppression, DLI)|"CYTOREDUCTION: If necessary, patients with advanced malignancies undergo cytoreductive chemotherapy to reduce tumor size at discretion of primary physician and study investigators.
~CONDITIONING REGIMEN: Patients undergo low-dose total-body irradiation followed by allogeneic PBSC transplant on day 0.
~IMMUNOSUPPRESSION: Patients receive cyclosporine IV BID on days -1 to 0 and then PO BID on days 1-35 with taper to day 56. Patients also receive mycophenolate mofetil PO BID on days 0-27.
~POST-TRANSPLANT DLI: Patients with mixed chimerism on day 56 and no evidence of GVHD undergo DLI over 30 minutes on day 65 and may receive up to 3 additional infusions in the absence of GVHD and disease progression or persistence. Patients who have not achieved mixed chimerism at day 56 undergo DLI if complete response is not obtained after a 2 month monitoring period."
11649642|NCT00002998|Experimental|gemcitabine + cisplatin|Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 1 hour on days 1, 8, and 15 every 28 days. Patients with complete response may receive an additional 2 courses after attainment of complete response status. Treatment continues in the absence of disease progression or unacceptable toxicities for a maximum of 8 courses. Patients are followed every 3 months for 2 years and then at 3 years after treatment.
11649643|NCT00002994|Experimental|Monoclonal antibody + interleukin 2|"Cycle 1: low dose IL2 days 1-7; MoAb day 7; intermediate dose IL-2 days 8-10; Low dose IL2 days 11-20.
~Cycle 2 & all subsequent cycles: MoAb day 1; intermediate dose IL2 days 1-3; low dose IL2 days 4-14"
11649644|NCT00002956|Experimental|infusions of EBV specific cytotoxic T lymphocytes|Donors undergo leukapheresis, and Epstein-Barr virus (EBV) specific cytoxic T lymphocytes are cultivated in vitro. Patients receive infusions of EBV specific cytotoxic T lymphocytes over 5 to 10 minutes on weeks 0, 2, and 4. Patients with stable disease and those achieving partial remission are followed weekly for signs of disease progression
11649645|NCT00002925|Active Comparator|ADE|
11649646|NCT00002925|Experimental|ADEP|
11649647|NCT00002862|Experimental|Arm I|Groups of 3-6 patients receive escalating doses of oral perillyl alcohol three times per day until the maximum tolerated dose or recommended phase II dose is determined. Treatment at the assigned dose continues until disease progression or unacceptable toxicity intervenes. Patients with stable disease after 8 weeks of treatment are removed from study.
11649648|NCT00002760|Other|Antiandrogen withdrawal|"antiandrogen therapy withdrawn; patient who progress will be crossed over to Arm 1A: 400 mg ketoconazole PO tid and hydrocortisone 30 mgs PO q am and 10 mgs PO qhs until treatment is no longer effective"
11649649|NCT00002760|Active Comparator|Antiandrogen withdrawal + therapy|Ketoconazole and hydrocortisone
11649650|NCT00002495|Experimental|Nodal RT|subtotal nodal irradiation will consist of mantle and periaortic/spleen fields treated sequentially. Total dose 3600-4000 cGy over 20 fractions.
11649651|NCT00002495|Experimental|Chemotherapy + Nodal RT|3 cycles (28 days each) of chemotherapy (doxorubicin 25 mg/m^2 on days 1 and 15, vinblastine 6 mg/m^2 on days 1 and 15). Four weeks after last cycle, subtotal nodal irradiation (total dose 3600-4000 cGy over 20 fractions) will be given as described for the Nodal RT arm.
11649652|NCT00087802|Active Comparator|Stratum 1|Subjects will be randomized in a 1:1 allocation to either GEMOX or CP after signed consents and baseline evaluations are completed, allowing for safe entry into the study. In order to avoid an unbalanced distribution by baseline characteristics, randomization will be stratified by one factor: disease stage (in a 1:4 proportion for Stage IIIb vs. Stage IV or relapsed disease). Randomization schedules will be produced for each stratum, and treatment allocation will be carried out centrally
11649683|NCT00087516|Placebo Comparator|Placebo/Sitagliptin 100 mg|Phase A: Oral tablets of placebo matching sitagliptin 100 mg q.d. Phase B: Oral tablets of sitagliptin 100 mg q.d.
11649684|NCT00087516|Placebo Comparator|Placebo/Sitagliptin 200 mg|Phase A: Oral tablets of placebo matching sitagliptin 200 mg q.d. Phase B: Oral tablets of sitagliptin 200 mg q.d.
11649653|NCT00087802|Active Comparator|Stratum 2|Subjects will be randomized in a 1:1 allocation to either GEMOX or CP after signed consents and baseline evaluations are completed, allowing for safe entry into the study. In order to avoid an unbalanced distribution by baseline characteristics, randomization will be stratified by one factor: disease stage (in a 1:4 proportion for Stage IIIb vs. Stage IV or relapsed disease).
11649654|NCT00087711|Experimental|A|
11649655|NCT00087711|Active Comparator|B|
11649656|NCT00087698|Experimental|A|chemotherapy, surgery then chest radiation x 54 gray (Gy)
11649657|NCT00003873|Experimental|Arm I|Patients receive fluorouracil IV as a continuous infusion for 28 days.
11649658|NCT00003873|Experimental|Arm II|Patients receive eniluracil/fluorouracil orally twice a day for 28 days.
11649659|NCT00087685|Experimental|RAD001|RAD001 10 mg by mouth Daily
11649660|NCT00087672|Experimental|CC-5013|
11649661|NCT00087646|Experimental|1|
11649662|NCT00087646|Experimental|2|
11649663|NCT00087646|Experimental|3|
11649664|NCT00087646|Active Comparator|4|
11649665|NCT00087633|Experimental|1|
11649666|NCT00087633|No Intervention|2|
11649667|NCT00087607|Experimental|Peginterferon Alfa-2a + Ribavirin|Participants received Peginterferon alfa-2a (40 kD) [Pegasys] at a dosage of 180 microgram (μg), subcutaneously (SC), once a week plus Ribavirin [Copegus] 1000 or 1200 milligram (mg)/day), orally, [according to body weight, lesser than or greater than/equal to (< or >/=) 75 kilogram (kg), respectively] twice daily during the randomized treatment period for 12 weeks. Participants who completed the randomized treatment period of 12 weeks and wished to continue therapy were given Peginterferon alfa-2a 180 μg SC once weekly plus Ribavirin 1000 or 1200 mg/day orally (< or >/=75 kg body weight, respectively twice daily for an additional 36 weeks to complete a full 48-week treatment course. After treatment completion, participants were followed-up for safety for 24 weeks.
11649668|NCT00087607|Active Comparator|Peginterferon Alfa-2b + Ribavirin|Participants received Peginterferon alfa-2b (12 kD) [PEG-Intron] at a dosage of 1.5 μg/kg SC once weekly plus Ribavirin [Rebetol] 1000 or 1200 mg/day orally (< or >/=75 kg body weight, respectively) twice daily during the randomized treatment period for 12 weeks. Participants who completed the randomized treatment period of 12 weeks and wished to continue therapy were given Peginterferon alfa-2a 180 μg SC once weekly plus Ribavirin 1000 or 1200 mg/day orally (< or >/=75 kg body weight, respectively) twice daily for an additional 36 weeks to complete a full 48-week treatment course. After treatment completion, participants were followed-up for safety for 24 weeks.
11649669|NCT00087594|Experimental|Direct Observed Therapy|Participants will receive the peginterferon alfa-2a plus ribavirin at the clinic as: subcutaneous peginterferon alfa-2a 180 microgram (mcg) (once in a week) for 24 weeks for Genotype 2 or 3 (G2/3), and for 48 weeks for Genotype 1 (G1); oral ribavirin 800 milligram (mg)/day (twice in a day) for 24 weeks for G2/3, and 1000 or 1200 mg/day (twice in a day) for 48 weeks for G1.
11649670|NCT00087594|Experimental|Self-Administration Therapy|Participants will receive the peginterferon alfa-2a plus ribavirin at home as: subcutaneous peginterferon alfa-2a 180 mcg (once in a week) for 24 weeks for G2/3, and for 48 weeks for G1; oral ribavirin 800 mg/day (twice in a day) for 24 weeks for G2/3, and 1000 or 1200 mg/day (twice in a day) for 48 weeks for G1.
11649671|NCT00087581|Experimental|Group A: Monitored MMF + Reduced CNI|Group A will receive concentration-controlled/monitored MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or intravenous (IV) form. The initial dose will be at least 1 gram twice a day (BID) in adults and 600 milligrams per meter-squared (mg/m^2) in pediatrics. Subsequent doses will be adjusted to maintain blood mycophenolic acid (MPA) levels greater than or equal to (≥) 1.3 micrograms per milliliter (μg/mL) with cyclosporine or ≥1.9 μg/mL with tacrolimus. The selected CNI will be dosed to maintain reduced blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 nanograms per milliliter (ng/mL); Days 30-90, 125-165 ng/mL; Days 90 through end of study, 95-145 ng/mL. Tacrolimus target concentrations areas follows: Days 1-30, 8-12 ng/mL; Days 30-90, 4-6 ng/mL; Days 90 through end of study, 3-5 ng/mL.
11649672|NCT00087581|Experimental|Group B: Monitored MMF + Full CNI|Group B will receive concentration-controlled/monitored MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The initial dose will be at least 1 gram BID in adults and 600 mg/m^2 in pediatrics. Subsequent doses will be adjusted to maintain blood MPA levels ≥1.3 μg/mL with cyclosporine or ≥1.9 μg/mL with tacrolimus. The selected CNI will be dosed to maintain standard/full blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 250-270 ng/mL; Days 90 through end of study, 190-220 ng/mL. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 8-10 ng/mL; Days 90 through end of study, 6-8 ng/mL.
11649673|NCT00087581|Experimental|Group C: Fixed MMF + Full CNI|Group C will receive fixed-dose MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The dose will be at least 1 gram BID in adults and 600 mg/m^2 in pediatrics. Subsequent doses are not to be adjusted, except in the case of unacceptable toxicity. The selected CNI will be dosed to maintain standard/full blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 250-270 ng/mL; Days 90 through end of study, 190-220 ng/mL. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 8-10 ng/mL; Days 90 through end of study, 6-8 ng/mL.
11649674|NCT00087568|Experimental|Non-Responders|Participants will receive Pegasys 180 micro grams (µg or mcg) subcutaneously (SC) once a week and ribavirin 1000 or 1200 milligrams per day [(mg/day), < or >=75 kilogram (Kg) body weight, respectively], orally in divided doses for 60 weeks.
11649675|NCT00087568|Experimental|Non-Tolerators|Participants will receive Pegasys 180 µg subcutaneously (SC) once a week and ribavirin 1000 or 1200 mg/day (< or >=75 kg body weight, respectively) orally in divided doses for 36 weeks.
11649676|NCT00087555|Experimental|2|Sodium oxybate 6.0 g per day.
11649677|NCT00087555|Placebo Comparator|3|Placebo (one of two doses matching active treatment by volume).
11649678|NCT00087555|Experimental|1|Sodium oxybate 4.5 g per day.
11649679|NCT00087529|Experimental|1|
11649680|NCT00087529|Placebo Comparator|2|
11649681|NCT00087516|Active Comparator|Sitagliptin 100 mg/100 mg|Phase A and B: Oral tablets of sitagliptin 100 mg Once a Day (q.d )
11649685|NCT00086645|Experimental|citalopram hydrobromide|citalopram hydrobromide, up to 20 mg daily
11649687|NCT00087438|Experimental|Stereotactic body radiation therapy (SBRT)|20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy
11649688|NCT00087412|Experimental|Treatment|Patients receive oral erlotinib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11649689|NCT00087399|Experimental|gabapentin + antidepressant|"Patients continue to receive the same antidepressant (as before study entry) on weeks 1-5. During weeks 2-5, patients also receive oral gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity.
~Patients complete a hot flash diary at baseline and then daily during study treatment."
11649690|NCT00087399|Experimental|gabapentin|"Patients receive gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity. Patients are tapered off their antidepressant over 7-10 days and remain on gabapentin alone.
~Patients complete a hot flash diary at baseline and then daily during study treatment."
11649691|NCT00087386|Experimental|Treatment (tanespimycin)|Patients receive tanespimycin IV over 1-6 hours once weekly for 6 weeks. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
11649692|NCT00087373|Experimental|Treatment (recombinant fowlpox-TRICOM vaccine)|Patients receive fowlpox-TRICOM intratumorally on day 1 of weeks 1, 4, and 7 (maximum of 3 injections for a single lesion) (course 1). After 3 injections (course 1), patients with stable or responding disease receive additional injections into new lesions following the same schedule as above. Treatment repeats every 9 weeks for a maximum total of 9 injections (3 injections total into a maximum of 3 different tumors) (total of 3 courses) in the absence of disease progression or unacceptable toxicity
11649693|NCT00087295|Experimental|Treatment|Depsipeptide
11649694|NCT00087269|Experimental|Treatment (erlotinib)|Patients receive oral erlotinib once daily on days 1-14 or days 1-21 in the absence of unacceptable toxicity. Patients then undergo surgical resection on the last day of study drug administration (day 14 or day 21). Patients may receive chemotherapy and/or radiotherapy after surgical resection at the discretion of the primary physician.
11649695|NCT00087256|Placebo Comparator|Arm 1: placebo|one placebo capsule taken orally twice a day for 3 years
11649696|NCT00087256|Experimental|Arm 2: celecoxib|one 400 mg capsule taken orally twice a day for 3 years
11649697|NCT00087217|Experimental|Treatment (tanespimycin, paclitaxel)|Patients receive 17-AAG IV over 1 hour on days 1*, 4, 8, 11, 15 and 18 and paclitaxel IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11649698|NCT00087204|Experimental|Treatment (becatecarin)|Patients receive rebeccamycin analogue (XL119) IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 1 additional course beyond CR. Patients achieving a PR or HI receive 2 additional courses beyond PR or HI. Cohorts of 3-6 patients receive escalating doses of XL119 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
11649699|NCT00087191|Experimental|Diagnostic (EF5, motexafin lutetium)|Patients receive EF5 IV over 1-2.5 hours on day 1 and motexafin lutetium IV over 10-15 minutes on day 2. Patients undergo definitive surgical resection approximately 3 hours after motexafin lutetium administration. Hypoxia and motexafin lutetium levels in the resected tumors are evaluated. Tumor to normal tissue ratios are also determined.
11649700|NCT00087178|Active Comparator|Arm 1: adriamycin + cyclophosphamide|Patients receive adriamycin IV over 15 minutes followed by cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.
11649701|NCT00087178|Experimental|Arm 2: fluorouracil + epirubicin + cyclophosphamide|Patients receive fluorouracil IV, epirubicin IV over 15 minutes, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.
11649702|NCT00087152|Experimental|Imatinib Mesylate & Capecitabine|
11649703|NCT00087139|Experimental|Arm I|"Patients are stratified according to prior chemotherapy (none vs 1 prior taxane-containing regimen vs 2 prior cytotoxic regimens).
~Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11649704|NCT00087126|Experimental|Topotecan|Topotecan weekly
11649705|NCT00087074|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses beyond CR.
11649706|NCT00087035|Experimental|Taxotere plus Tarceva|"Patients receive Tarceva 150 mg daily for 21 consecutive days (one treatment cycle). In addition, all patients will receive single agent Taxotere 60 mg/m2 IV over 1 hour infusion every 21 ± 2 days and have it administered on day 1.
~Taxotere + Tarceva to be taken for three cycles past maximal response or until one of the following occurs: 1) a drug-related toxicity requiring discontinuation, 2) disease progression, or 3) for a maximum of 9 cycles.
~Upon completion of 9 cycles of Taxotere plus Tarceva, patients showing evidence of objective response (CR, PR or stable disease) may continue in the extension phase of the study and receive treatment with Tarceva alone. Treatment response evaluated after four cycles of Tarceva treatment(immediately prior to cycle 14). Patients with progression of disease will be taken off study. Responding and stable disease patients will remain on study for up to 8 extension-phase cycles for a total of 17 cycles."
11649707|NCT00087022|Experimental|Arm I|Patients receive monoclonal chimeric antibody cG250 (synonym names: Rencarex®, girentuximab, and WX-G250) IV over 15 minutes once weekly for 24 weeks.
11649708|NCT00087022|Placebo Comparator|Arm II|Patients receive placebo IV over 15 minutes once weekly for 24 weeks.
11649709|NCT00087009|Experimental|Group I|Patients receive rituximab IV on days 1, 8, 15, and 22 and oral beta-glucan once daily on days 1-28 (days 8-28 of course 1). Treatment repeats every 42 days for 4 courses.
11649710|NCT00087009|Experimental|Group II|Patients receive rituximab IV on days 1, 4, 8, 15, and 22 and oral beta-glucan once daily on days 8-28. Beginning on day 42, patients with responding disease may receive monthly rituximab prophylaxis.
11649711|NCT00086996|Experimental|Chemo Plus RT, Surgery, Chemo|neoadjuvant fluorouracil, oxaliplatin and radiation therapy followed by conventional surgery and adjuvant fluoruracil and oxaliplatin
11649744|NCT00086385|Experimental|Tailored/No Extended NRT|This condition was identical to the Tailored/NRT condition except that no NRT was available after completion of the Brief Treatment.
11649712|NCT00086983|Experimental|Treatment (becatacarin, oxaliplatin)|"Patients receive rebeccamycin analogue IV over 1 hour on days 1-5 and oxaliplatin IV over 2 hours on day 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue and oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD."
11649713|NCT00086970|Experimental|Arm I (ifosfamide)|Patients receive high-dose ifosfamide IV continuously over 72 hours on days 1-3.
11649714|NCT00086970|Experimental|Arm II (O6-benzylguanine, ifosfamide)|Patients receive a bolus dose of O6-benzylguanine (BG) IV over 1 hour on day 1 followed by BG IV continuously and high-dose ifosfamide IV continuously over 72 hours on days 1-3.
11649715|NCT00086957|Experimental|ZD1839, Trastuzumab and Docetaxel|
11649716|NCT00086944|Experimental|Treatment (genase, combination chemotherapy)|See detailed description.
11649717|NCT00086840|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving an objective response may receive 3 consolidation courses of therapy.
11649718|NCT00086827|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have continuing tumor response or stable disease after 6 courses receive 2 additional courses beyond best response.
11649719|NCT00086801|Experimental|doxorubicin + vinblastine + gemcitabine|"Patients receive doxorubicin IV over 3-5 minutes, vinblastine IV over 3-5 minutes, and gemcitabine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~Patients undergo fludeoxyglucose F 18 positron-emission tomography (PET) scanning and CT scan before treatment and after courses 2 and 6 of therapy to assess response. Patients with a positive PET scan after completion of study therapy may undergo biopsy. A PET scan is performed 3 months later if biopsy is negative or biopsy is unable to be performed.
~Patients are followed every 3 months for 1 year, every 4 months for 2 years, every 6 months for 2 years, and then annually for 5 years."
11649720|NCT00086762|Experimental|MR Therapy|Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. A CD with the mindfulness relaxation technique recorded on it will be given to participant. Participant to listen to the recording for about 30 minutes before receiving chemotherapy and during the time they are receiving chemotherapy. In addition to the mindfulness relaxation technique, they will also receive general information about how to manage symptoms that develop due to the chemotherapy they are receiving.
11649721|NCT00086762|Experimental|Relaxing Music (RM) Therapy|Arm II: Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment.
11649722|NCT00086762|Active Comparator|Standard Symptom Management|Arm III: Participants receive standard symptom management education.
11649723|NCT00086749||Tamoxifen group|
11649724|NCT00086736|Experimental|Arm I|Patients receive oral eflornithine and oral bicalutamide once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
11649725|NCT00086736|Experimental|Arm II|Patients receive oral eflornithine and oral bicalutamide placebo once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
11649726|NCT00086736|Experimental|Arm III|Patients receive oral eflornithine placebo and oral bicalutamide once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
11649727|NCT00086736|Experimental|Arm IV|Patients receive oral eflornithine placebo and oral bicalutamide placebo once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
11649728|NCT00086684|Experimental|Pentosan polysulfate sodium 100 mg once a day|One 100 mg pentosan polysulfate sodium capsule in the morning and 1 matching placebo capsule in the afternoon and evening for 24 weeks
11649729|NCT00086684|Experimental|Pentosan polysulfate sodium 100 mg three times a day|One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning afternoon and evening) for 24 weeks
11649730|NCT00086684|Placebo Comparator|Placebo|Placebo One placebo capsule 3 times a day (morning afternoon and evening) for 24 weeks
11649731|NCT00086671|Experimental|ABT-874 200 mg weekly|
11649732|NCT00086671|Placebo Comparator|Placebo|
11649733|NCT00086671|Experimental|ABT 874 QOW|
11649734|NCT00086619|Experimental|constant dose|Participants will receive synthetic human parathyroid hormone fragment 1-34 (hPTH 1-34) once-daily in a constant dose of 30 mcg/day.
11649735|NCT00086619|Experimental|ascending dose|Participants will receive synthetic human parathyroid hormone fragment 1-34 (hPTH 1-34) once-daily in a dose that ascends at 6 month intervals (20-30-40 mcg/day).
11649736|NCT00086580|Experimental|Combination Arm (FluCAM)|
11649737|NCT00086580|Active Comparator|Fludarabine Alone|
11649738|NCT00086411|Experimental|1: Bup+MM|bupropion and MM counseling with placebo patch
11649739|NCT00086411|Experimental|2 Bup+Mayo|bupropion and Mayo counseling with placebo patch.
11649740|NCT00086411|Placebo Comparator|3 Patch+MM|patch and MM counseling with placebo pills
11649741|NCT00086411|Experimental|4 Patch+Mayo|patch and Mayo counseling with placebo pills
11649742|NCT00086385|Active Comparator|Brief Treatment|"Pharmacological Treatment - Subjects received 12 weeks of bupropion treatment and 10 weeks of nicotine replacement treatment (NRT)
~Brief Counseling - The counseling intervention consisted of five 90-minute group meetings.
~There was no further treatment during Weeks 12-52."
11649743|NCT00086385|Experimental|Extended NRT|"Pharmacological Treatment - Following completion of the Brief Treatment, subjects assigned to this condition would continue receiving NRT for up to 52 weeks. Subjects in this condition would be encouraged to continue NRT through Week 24. If a subject terminated NRT and resumed smoking, before Week 50, would be instructed to set a quit date and resume NRT.
~Counseling Treatment - This is identical to the Brief Counseling described above."
11649745|NCT00086385|Experimental|Extended Tailored Counseling + NRT|Tailored Counseling Treatment- The primary goal of the extended treatment was to prevent relapse. Secondary goal was to encourage initiation of abstinence for those who have not attained it by Week 12, and re-initiation of abstinence after slips. Subjects would participate in the Brief Treatment followed by individual sessions. The first extended treatment counseling session would occur at Week 10. Additional sessions would be held every two weeks then every four weeks, and finally at Weeks 44 and 52. Each session would be 20-30 minutes long. Between sessions subjects would be contacted by phone for brief check-ins (5-10 minutes).
11649746|NCT00086567||patients|Patients in first remission from treatment of FIGO stage III/IV primary peritoneal, fallopian tube, or epithelial ovarian carcinoma
11649747|NCT00086515|Experimental|Sitagliptin 100 mg|The Sitagliptin 100 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin 100 mg during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin 100 mg and glipizide-matched placebo.
11649748|NCT00086515|Placebo Comparator|Placebo / Glipizide 5 mg|The Placebo/Glipizide 5 mg group includes patients who were administered once-daily treatment with oral tablets of sitagliptin-matched placebo during Phase A (Weeks 0-24) of the treatment period. During Phase B (Weeks 24-104) of the treatment period these patients received once-daily coadministered treatment with oral tablets of sitagliptin-matched placebo 100 mg and glipizide 5 mg which was allowed to be uptitrated, in a blinded fashion, to a maximum dose of 15 mg/day.
11649749|NCT00086502|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg
11649750|NCT00086502|Placebo Comparator|Placebo|Placebo
11649751|NCT00086489|Experimental|10 mg/kg|pts treated at 10 mg/kg dose level on a monthly regimen
11649752|NCT00086489|Experimental|15 mg/kg|pts treated at 15 mg/kg dose level on a quarterly regimen
11649753|NCT00086450|Active Comparator|Coronary Artery Bypass Graft|Coronary Artery Bypass Graft
11649754|NCT00086450|Experimental|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention
11649755|NCT00086346|Active Comparator|A|
11649756|NCT00086346|Active Comparator|B|
11649757|NCT00086359|Experimental|A|One pill of abacavir/lamivudine/zidovudine twice daily
11649758|NCT00086359|Experimental|B|One pill of zidovudine/lamivudine and four pills of lopinavir/ritonavir twice daily.
11649759|NCT00086281|Experimental|1|Xyrem 9 grams given in a divided dose: 4.5 g at bedtime and 4.5 g given 2.5 to 4 hours later
11649760|NCT00086281|Active Comparator|2|Zolpidem 10 mg + placebo were given at bedtime and placebo given 2.5 to 4 hours later.
11649761|NCT00086281|Experimental|3|Xyrem 9 g + modafinil 200 mg (Xyrem 9 g was given in a divided dose: 4.5 g at bedtime and 4.5 g given 2.5 to 4 hours later; modafinil was given at 8 am on the morning of Xyrem treatment).
11649762|NCT00086281|Placebo Comparator|4|Placebo was given at bedtime and again 2.5 to 4 hours later.
11649763|NCT00086268|Experimental|Zometa®|4mg monthly for 12 months from date of first chemotherapy dose
11649764|NCT00086268|No Intervention|no further treatment|Control arm; no further treatment. Follow-up monthly for 12 months from date of first chemotherapy dose
11649765|NCT00002837|Experimental|Doxorubicin, Paclitaxel + Cyclophosphamide with PBPC|
11649766|NCT00002804|Experimental|Chemotherapy Regimen|Induction (Weeks 1-6) Vincristine sulfate (1.5 mg/m2) day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Weeks 2 and 3 - Vincristine sulfate (1.5 mg/m2) IV day 1, week 5 no chemotherapy. Evaluate for response. Local Control (Weeks 7-13) Conventional surgery and radiation therapy. Vincristine sulfate (1.5 mg/m2) IV day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Treatment continues per protocol.
11649767|NCT00002705|Experimental|Arm I|Single-Agent Chemotherapy. Topotecan, TOPO, NSC-609699.
11649768|NCT00002704|Experimental|Arm I|Single Agent Chemotherapy. TSPA or DTC101. 3-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. DM/DNR/VCR; plus TIT. 2-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. ARA-C/ASP; plus TIT. 4-Drug Combination Chemotherapy with Leucovorin Rescue plus Triple Intrathecal Therapy. CTX/MP/MTX/VP-16; with CF; plus TIT. 3-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. DM/DNR/VCR; plus TIT. 6-Drug Combination Chemotherapy with Leucovorin Rescue plus Triple Intrathecal Therapy. ARA-C/ASP/CTX/MP/MTX/VP-16; with CF; plus TIT. Radiotherapy plus 3-Drug Combination Chemotherapy. Craniospinal irradiation using x-rays with energies of 4-6 MV (electrons acceptable for spinal cord irradiation); plus ASP/DM/VCR. 2-Drug Combination Chemotherapy Alternating with 2-Drug Combination Chemotherapy. MP/MTX; alternating with CTX/VCR.
11649769|NCT00086307|Active Comparator|Pramipexole|Patients receive pramipexole and placebo. The dosage of pramipexole is 0.125 milligrams (mg) three times per day in the first week, 0.250 mg three times per day in the second week, 0.5 mg three times per day in the third week, and 0.75 mg three times per day in the fourth week and thereafter.
11649770|NCT00086307|Active Comparator|Escitalopram|Patients receive escitalopram and placebo. The dosage of escitalopram is 10 milligrams (mg) per day.
11649771|NCT00086307|Experimental|Escitalopram and Pramipexole|Patients receive escitalopram and pramipexole. The dosage of escitalopram is 10 milligrams (mg) per day. The dosage of pramipexole is 0.125 mg three times per day in the first week, 0.250 mg three times per day in the second week, 0.5 mg three times per day in the third week, and 0.75 mg three times per day in the fourth week and thereafter.
11649772|NCT00002642|Experimental|chemoradiotherapy followed by surgery|chemoradiotherapy followed by surgery and post-surgery boost chemotherapy
11649773|NCT00002565|Experimental|Arm I|"Sequential 4-, 5-, and 3-Drug Combination Chemotherapy. IdSHAP: IDA/CDDP/ARA-C/MePRDL; followed by BIdCOS: BLEO/IDA/CTX/VCR/MePRDL; followed by MINE: Mesna/IFF/DHAD/VP-16.
~Alternating triple therapy (ATT) of IdSHAP (idarubicin, cisplatin, cytarabine, methylprednisolone), BIdCOS (idarubicin, vincristine, bleomycin, cyclophosphamide, methylprednisolone), and MINE (mesna, ifosfamide, mitoxantrone, etoposide)."
11649774|NCT00002565|Experimental|Arm II|4-Drug Combination Chemotherapy. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone): CTX/DOX/VCR/PRED.
11649842|NCT00085722|Other|Exercise|At-home physical therapy exercises as a non-injection control
11649843|NCT00085709|Experimental|Post-consolidation GO|Patients receive gemtuzumab ozogamicin IV over 2 hours on day 1. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
11650086|NCT00083304|Active Comparator|WBRT + Supplemental Oxygen|
11649775|NCT00086242|Experimental|Psychosocial Telephone Counseling (PTC)|Eligible patients are randomized to receive psychosocial telephone counseling (PTC) or usual care.The PTC intervention was specifically designed to help women cope with the stressful events and feelings of distress associated with cervical cancer. The PTC arm of the study received six counseling sessions, ~45 to 50 min in length, in their preferred language, consisting of five consecutive weekly sessions and a 1-month booster session, delivered by a psychologist. A review letter, generated by the counselor after each session, recapitulated the session's contents and reinforced adaptive coping strategies.
11649776|NCT00086242|No Intervention|Usual Care|Eligible patients are randomized to receive either psychosocial telephone counseling (PTC) or usual care. The usual care are were only contacted by the study team to collect data in an identical frame to subjects receiving PTC.
11649777|NCT00086190|Active Comparator|paroxetine|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
11649778|NCT00086190|Active Comparator|venlafaxine extended release|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
11649779|NCT00086190|Placebo Comparator|placebo|Paroxetine and venlafaxine will be compared to placebo over 12 weeks.
11649780|NCT00086177|Active Comparator|1|Progesterone 8% vaginal gel
11649781|NCT00086177|Placebo Comparator|2|Placebo Vaginal Gel
11649782|NCT00086138|Experimental|1|Participants will receive sertraline at a target dose of 100mg daily.
11649783|NCT00086138|Placebo Comparator|2|Participants will receive placebo matched to sertraline
11649784|NCT00086125|Experimental|1|AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
11649785|NCT00005975|Active Comparator|Megestrol Acetate/Placebo 20 mg/day|Double blinded Megestrol Acetate 20 mg/day or Megestrol Acetate Placebo 20 mg/day taken for 3 months
11649786|NCT00005975|Active Comparator|Megestrol Acetate/Placebo 40 mg/day|Double blinded Megestrol Acetate 40 mg/day or Megestrol Acetate Placebo 40 mg/day taken for 3 months
11649787|NCT00086099|Experimental|1|Idarubicin plus amifostine
11649788|NCT00086099|Experimental|2|Idarubincin
11649789|NCT00005613|Experimental|Autologous Transplant|autologous hematopoietic progenitor cell transplant
11649790|NCT00005613|Experimental|Allogeneic Transplant|allogeneic hematopoietic progenitor cell trasnplant
11649791|NCT00003995|Experimental|Arm I|Patients receive a loading dose of trastuzumab IV over 90 minutes on week 1, and over 30-90 minutes weekly thereafter. Patients receive irinotecan IV over 90 minutes following trastuzumab weekly for 4 weeks. Courses are repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.
11649792|NCT00003762|Experimental|Arm I: docetaxel + gemcitabine|"Patients receive docetaxel IV over 1 hour on day 1 followed by gemcitabine IV over 30 minutes on days 1, 8, and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.
~Quality of life is assessed before treatment and before each course of therapy.
~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
11649793|NCT00003762|Experimental|Arm II: docetaxel + gemcitabine|"Patients receive docetaxel IV over 1 hour and gemcitabine IV over 30 minutes on days 1 and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.
~Quality of life is assessed before treatment and before each course of therapy.
~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
11649794|NCT00003762|Experimental|Arm III: docetaxel + gemcitabine|"Patients receive docetaxel IV on day 1 and gemcitabine IV on days 1, 8, and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.
~Quality of life is assessed before treatment and before each course of therapy.
~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
11649795|NCT00003723|Experimental|Gemcitabine/Cisplatin|Gemcitabine 1000 mg/m^2 days 1, 8 15 (q 28 days) cisplatin 30 mg/m^2 days 1, 8, 15 (q 28 days)
11649796|NCT00003369|Experimental|tirapazamine/cisplatin|tirapazamine and cisplatin given Day 1 of each 21-day treatment cycle
11649797|NCT00003317|Active Comparator|Surgery + paclitaxel + carboplatin|Four to eight weeks after surgery, all patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on days 1, 22, 43, and 64. Following completion of four courses of chemotherapy, patients are followed at least every 4 months for 2 years, then every 6 months thereafter.
11649798|NCT00003317|Experimental|Surgery + paclitaxel + carboplatin + radiotherapy|Four to eight weeks after surgery, all patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on days 1, 22, 43, and 64. Following completion of four courses of chemotherapy, patients receive radiotherapy 5 days a week for 5 weeks to the mediastinum, beginning 2.5 to 4 weeks after completion of chemotherapy. Patients are followed at least every 4 months for 2 years, then every 6 months thereafter.
11649799|NCT00003127|Experimental|carbo, taxol, amifostine|carbo, taxol, amifostine
11649800|NCT00086060|Experimental|1 - Relaxation Training|Participants will receive relaxation training and standard care for FM
11649801|NCT00086060|Experimental|2 Exercise Regimen|Participants will receive an exercise regimen and standard care for FM
11649802|NCT00086060|Active Comparator|3 Standard Care|Participants will receive standard of care for FM
11649803|NCT00086060|No Intervention|4 Health Controls|Health participants will act as a control
11649804|NCT00086047|Experimental|Coping Skills|Patients will receive 8 weeks of behavioral training in pain coping strategies
11649805|NCT00086047|Active Comparator|Education|Patient will receive 8 weekly sessions of education about fibromyalgia syndrome.
11649806|NCT00002844|Experimental|Cyclophosphamide + TBI + BMT|TBI = Total Body Irradiation and BMT = Bone Marrow Transplantation (allogeneic or autologous bone marrow)
11649807|NCT00002816|Experimental|EARLY # CNS RELAPSE with BM DONOR|Induction (Etoposide, Ifosfamide with Mesna Uroprotection,Ifosfamide, Dexamethasone, Vincristine sulfate, PEG, ITT (methotrexate, cytosine arabinoside and therapeutic hydrocortisone), and leucovorin calcium then Intensification (4 courses of 6 weeks, ITT, dexamethasone, vincristine, methotrexate, leucovorin, 6-Thioguanine, cytarabine (Ara-C), Etoposide, pegaspargase, Ifosfamide with Mesna) and Idarubicin and CXRT.
11649808|NCT00002816|Experimental|LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR|Induction (Etoposide, Ifosfamide with Mesna Uroprotection,Ifosfamide, Dexamethasone, Vincristine sulfate, pegaspargase, ITT (methotrexate, cytosine arabinoside and therapeutic hydrocortisone), and leucovorin calcium then Intensification (4 courses of 6 weeks, ITT, dexamethasone, vincristine, methotrexate, leucovorin, 6-Thioguanine, cytarabine (Ara-C), Etoposide, PEG, Ifosfamide with Mesna) and Idarubicin), and Maintenance (4 x 12 courses) of ITT, Vincristine, Methotrexate, T-thioguanine.
11649809|NCT00002725|Experimental|Arm I|Single-Agent Chemotherapy/Differentiation Therapy. Bryostatin 1, BRYO, NSC-339555.
11649810|NCT00085969|Placebo Comparator|A1 - Placebo 0.04 mL twice daily|
11649811|NCT00085969|Placebo Comparator|A2 - Placebo 0.04 mL once daily|
11649812|NCT00085969|Placebo Comparator|A3 - Placebo 0.08 mL once daily|
11649813|NCT00085969|Experimental|B - Exenatide 10 mcg twice daily|
11649814|NCT00085969|Experimental|C - Exenatide 10 mcg once daily|
11649815|NCT00085969|Experimental|D - Exenatide 20 mcg once daily|
11649816|NCT00006214|Experimental|flutamide|"Patients receive oral flutamide once daily.
~Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before study, at 1, 6, and 12 months, and then annually therafter. Patients are followed annually for up to 10 years."
11649817|NCT00006214|Other|placebo|"Patients receive an oral placebo once daily.
~Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before study, at 1, 6, and 12 months, and then annually therafter. Patients are followed annually for up to 10 years."
11649818|NCT00002657|Experimental|Immumosuppression, IFN-a, ProMACE-CytaBOM|Doses and schedules of immunosuppressive drugs (cyclosporin (or FK506), prednisone, and acyclovir) will depend on whether patients are judged to have clinically urgent disease or not. Patients who do not have a CR after initial immunosuppression will receive 3 cycles (28 days each) Interferon alpha 2b at 3.0 x 10^6 IU/m^2 on days 1-28. Patients who have a CR will then receive 6 additional cycles with 3 doses per week, then go onto observation. Patients who do not have a CR will then receive a maximum of 6 21-day cycles of chemotherapy, consisting of: cyclophosphamide 650 mg/m^2 on day 1, adriamycin 25 mg/m^2 on day 1, etoposide 120 mg/m^2 on day 1, prednisone 60 mg/m^2 on days 1-14, cytosine arabinoside 300 mg/m^2 on day 8, bleomycin 5 mg/m^2 on day 8, vincristine 1.4 mg/m^2 on day 8, methotrexate 120 mg/m^2 on day 8, leucovorin 25 mg/m^2 q 6 hours on days 8-9, G-CSF 5 ug/kg/day on days 2-14, and one double strength tablet trimethoprim-sulfamethoxazole 3 times per week.
11649819|NCT00085982|Experimental|Leptin Treatment|300 mg of study drug administered via SC injections.
11649820|NCT00085930|Experimental|EBV specific CTLs w/out lymphodepletion|Escalating doses of 14g2a.zeta chimeric receptor transduced autologous EBV specific cytotoxic T-lymphocytes (EBV-CTL) and 14g2a.zeta transduced autologous peripheral blood T-cells administered to patients with Neuroblastoma.
11649821|NCT00005829|Experimental|gemcitabine|Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 4 weeks for a minimum of 3 courses. Patients achieving clinical complete remission, complete remission, nodular partial remission, or partial remission following 3 courses of therapy, receive 2 additional courses of therapy. Patients achieving complete remission or further improvement following the 2 additional courses of therapy, receive another 2 courses of therapy. Patients are followed every 3 months until disease progression or relapse. Patients achieving complete remission are followed every 6 months for 1 year.
11649822|NCT00004929|Experimental|Vaccine|Patients receive vaccination with glycosylated MUC-2 antigen with keyhole limpet hemocyanin conjugate subcutaneously (SQ) plus immunological adjuvant QS21 SQ on weeks 1-3, 7, 15, and 27 for a total of 6 vaccinations. Patients are followed every 3 months for 1 year or until disease progression.
11649823|NCT00085917|Active Comparator|Standard dose arm|Pegylated interferon alfa -2a STANDARD DOSE Pegasys 180ug/week
11649824|NCT00085917|Experimental|Double dose arm|Double dose pegylated interferon with weight based Ribavirin
11649825|NCT00085852|Experimental|Single|Treatment with BLVR
11649826|NCT00085839|Experimental|Erlotinib|Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
11649827|NCT00085839|Active Comparator|Standard Chemotherapy|Paclitaxel 200 mg/m^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
11649828|NCT00085787|Experimental|ARRY-142886|
11649829|NCT00085774|Experimental|Albuterol HFA BOI|
11649830|NCT00085774|Experimental|Albuterol HFA MDI|
11649831|NCT00085774|Placebo Comparator|Placebo|
11649832|NCT00004251|Experimental|Letrozole|Letrozole 2.5 mg po daily
11649833|NCT00003996|Experimental|chemotherapy + carmustine + etoposide + cisplatin + radiation|Patients receive pre-irradiation chemotherapy consisting of carmustine IV over 1 hour on days 1-3 and oral etoposide on days 1-21 and 29-49 immediately followed by cisplatin IV over 1-2 hours on days 1-3 and 29-31. Treatment repeats every 8 weeks for 2 courses. Patients receive concurrent cranial radiotherapy daily over 8 weeks during course 2. Patients then receive carmustine IV over 1-2 hours every 8 weeks for 4 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before the study, prior to each treatment course, every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients are followed every 4 months for 1 year, every 6 months for 4 years, annually for 5 years, and then for survival.
11649834|NCT00085735|Experimental|Arm I (3-7 years of age, LDCSI, IFRT)|See Detailed Description (Arm I)
11649835|NCT00085735|Experimental|Arm II (3-7 years of age, LDCSI, PFRT)|See Detailed Description (Arm II)
11649836|NCT00085735|Experimental|Arm III (3-7 years of age, SDCSI, IFRT)|See Detailed Description (Arm III)
11649837|NCT00085735|Active Comparator|Arm IV (3-7 years of age, SDCSI, PFRT)|See Detailed Description (Arm IV)
11649838|NCT00085735|Experimental|Arm V (8-21 years of age, SDCSI, IFRT)|See Detailed Description (Arm V)
11649839|NCT00085735|Active Comparator|Arm VI (8-21 years of age, SDCSI, PFRT)|See Detailed Description (Arm VI)
11649840|NCT00085722|Experimental|Dextrose|Subjects in Group 1 receive PrT with 15% and 25% dextrose solution, as it is generally practiced in the US today.
11649841|NCT00085722|Placebo Comparator|Normal saline|Subjects in Group 2 will receive the same treatment as Group 1, except that a 0.9% 'normal' saline solution with no known benefit will be used instead of dextrose.
11650642|NCT00006388|Experimental|Radiation plus Tamoxifen|
11649844|NCT00085709|Other|Post-consolidation observation|Patients receive no additional therapy. Patients are observed at days 30 and 60 after randomization.
11649845|NCT00085709|Active Comparator|Induction 7+3|Standard induction regimen of 7 days of Ara-C (cytosine arabinoside) and 3 days of daunomycin
11649846|NCT00085709|Active Comparator|Induction 7+3+GO|Gemtuzumab (GO) added to the standard induction regimen of 7 days of Ara-C and 3 days of daunomycin
11649847|NCT00085644|Experimental|Adalimumab|
11649848|NCT00085644|Placebo Comparator|Placebo|
11649849|NCT00003847|Experimental|Treatment|
11649850|NCT00003829|Experimental|fludarabine + cyclophosphamide|Patients receive alternating courses of fludarabine and cyclophosphamide. Fludarabine is administered IV over 10-30 minutes on days 1-5 of courses 1, 3, and 5. Cyclophosphamide is administered IV over 30-60 minutes on day 1 of courses 2, 4, and 6. Treatment repeats every 4 weeks. Patients achieving clinical complete remission (CCR) after 6 courses of chemotherapy receive 2 additional courses (one course of each drug). Patients achieving partial remission after 6 courses of chemotherapy also receive 2 additional courses. If these patients then achieve CCR, they receive another 2 courses. Patients are followed every 3 months.
11649851|NCT00003254|Experimental|776C85 + 5-FU|776C85, 10mg/m2/dose, PO, Days 1-28 (BID), q 5 wk; 5-FU, 1.0mg/m2/dose, PO, Days 1-28 (BID), q 5 wk.
11649852|NCT00003143|Experimental|DHAP + amifostine|Patients are randomized to receive salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP) with or without amifostine. Patients receive cisplatin IV over 3 hours followed by cytarabine IV for 2 doses. Patients also receive dexamethasone orally or IV. Treatment repeats every 3-4 weeks for 2-6 courses. Arm I: Patients receive amifostine IV over 15 minutes prior to all courses of DHAP, as a 15 minute infusion, beginning 30 minutes prior to cisplatin administration. Arm II: Patients do not receive amifostine. On day 3 of the last DHAP course, patients receive filgrastim (G-CSF) until the last day of progenitor stem cell (PSC) mobilization. PSC transplant continues daily for 4-10 days.
11649853|NCT00003143|Other|DHAP|Patients are randomized to receive salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP) with or without amifostine. Patients receive cisplatin IV over 3 hours followed by cytarabine IV for 2 doses. Patients also receive dexamethasone orally or IV. Treatment repeats every 3-4 weeks for 2-6 courses. Arm I: Patients receive amifostine IV over 15 minutes prior to all courses of DHAP, as a 15 minute infusion, beginning 30 minutes prior to cisplatin administration. Arm II: Patients do not receive amifostine. On day 3 of the last DHAP course, patients receive filgrastim (G-CSF) until the last day of progenitor stem cell (PSC) mobilization. PSC transplant continues daily for 4-10 days.
11649854|NCT00003099|Active Comparator|Arm 1 Tamoxifen + Fenretinide|Tamoxifen + Fenretinide daily for 14-28 days
11649855|NCT00003099|Placebo Comparator|Arm 2 Placebo|Placebo daily for 14-28 days
11649856|NCT00002949|Experimental|Arm A|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2), Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy) Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
11649857|NCT00002864|Active Comparator|Octreotide|
11649858|NCT00002864|Active Comparator|Tamoxifen|
11649859|NCT00002838|Experimental|Combination Chemotherapy + PSCT|PSCT = Peripheral Stem Cell Transplantation
11649860|NCT00002740|Experimental|Treatment - Carboplatin Chemotherapy|See detailed description.
11649861|NCT00085670||Group 1|Bone marrow failure subjects
11649862|NCT00085631|Experimental|Arm I|Patients received cisplatin IV and concurrently underwent hyperthermia treatment over 60-90 minutes on day 1. Patients also underwent external beam radiation therapy once daily on days 1-5. Treatment repeated weekly for 5-6 weeks in the absence of disease progression or unacceptable toxicity. After completion of chemoradiotherapy and hyperthermia, patients underwent brachytherapy to the cervix for 2-3 days.
11649863|NCT00085631|Active Comparator|Arm II|Patients received cisplatin and undergo external beam radiation therapy (and brachytherapy) as in arm I.
11649864|NCT00085566|Experimental|Everolimus (RAD-001) and Gefitinib|"•Phase I: Patients receive oral everolimus on day 1 and oral gefitinib once daily on days 8-21. Beginning on day 22, patients receive oral everolimus once weekly and oral gefitinib once daily. Treatment with the combination continues in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of everolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
~•Phase II (prostate cancer patients only) (closed to accrual as of 10/19/2006): Patients receive oral everolimus (at the MTD determined in phase I) once weekly and oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity."
11649865|NCT00085553|Experimental|Treatment (erlotinib hydrochloride, tipifarnib)|Patients receive erlotinib hydrochloride PO QD on days 1-28 (days 8-28 of course 1 as of 11/4/2013) and tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. (Closed to accrual as of 2/2/06)
11649866|NCT00085540|Experimental|Phase 1 Dose Escalation - Romidepsin|"Patients receive FR901228 (romidepsin) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Dose escalation two dose levels:
~Romidepsin (depsipeptide): 13.3mg/m2 and 17.7mg/m2
~Pharmacokinetics"
11649867|NCT00085540|Experimental|Phase 2 Dose from Phase 1 - Romidepsin|"Patients receive FR901228 (romidepsin) as in phase I at dose level 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
~Romidepsin (depsipeptide): 13.3mg/m2"
11649868|NCT00085527|Experimental|depsipeptide|Depsipeptide administered on Days 1, 8, and15 of a 28-day cycle.
11649869|NCT00085501|Active Comparator|1|
11649870|NCT00085501|Active Comparator|2|
11649890|NCT00085189|Experimental|Cohort I (melanoma peptide vaccine, Montanide ISA-51)|Patients receive multi-epitope peptide melanoma peptide vaccine with incomplete Freund's adjuvant and agatolimod sodium SC at 0, 2, 4, 6, 8, 10, 14, 18, 22, 26, 38, and 50 weeks and then every six months for two years for up to 16 vaccinations in the absence of disease progression or unacceptable toxicity.
11649891|NCT00085189|Experimental|Cohort II (melanoma peptide vaccine, Montanide ISA 51 VG)|Patients receive multi-epitope peptide melanoma peptide vaccine with Montanide ISA 51 VG and agatolimod sodium SC at 0, 2, 4, 6, 8, 10, 14, 18, 22, 26, 38, and 50 weeks and then every six months for two years for up to 16 vaccinations in the absence of disease progression or unacceptable toxicity.
11649871|NCT00085449|Experimental|Regimen A + B|"Conditioning regimen A: Patients receive alemtuzumab IV over 2 hours on days -14 to -12; fludarabine IV over 30 minutes on days -7 to -3; and melphalan IV over 20-30 minutes on day -2.
~Conditioning regimen B: Patients receive oral or IV cyclosporine twice daily and oral or IV mycophenolate mofetil twice daily on days -15 to 0. Patients also receive alemtuzumab, fludarabine, and melphalan as in conditioning regimen A. Patients undergo low-dose total body irradiation twice daily on days -2 and -1.
~All patients undergo allogeneic, T-cell-depleted, CD34-positive peripheral blood stem cell transplantation on day 0. Patients receive sargramostim (GM-CSF) subcutaneously beginning on day 1 and continuing until blood counts recover.
~Patients are followed every 3 months for 1 year and then every 6 months for 5 years."
11649872|NCT00085436|Experimental|Vaccine, Aldesleukin-2, Interferon-a|All patients will be treated with autologous tumor cell vaccine administered into inguinal lymph nodes via ultrasound guidance in addition to systemic IL-2 and recombinant interferon alfa. Two cycles of induction IL-2/IFNα-2a followed by 3 cycles of maintenance IL-2 + IFNα-2a.
11649873|NCT00085423|Experimental|IL-2, CTX, fludarabine, GM-CSF|Aldesleukin (IL-2), cyclophosphamide, fludarabine phosphate, sargramostim
11649874|NCT00085410|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.
11649875|NCT00085397|Experimental|Arm I|Patients undergo surgical harvesting of tumor cells for subsequent fusion. Patients receive vaccination comprising dendritic cells (DC) fused with autologous tumor cells subcutaneously on day 1. Treatment repeats every 21 days for 3 courses. Patients who achieve a partial (PR) or complete response (CR) may receive an additional 3 courses.
11649876|NCT00085397|Experimental|Arm II|Patients receive vaccination comprising DC pulsed with gp100 antigen IV on day 1. Treatment repeats every 21 days for 6 courses. Patients who achieve a PR or CR may receive an additional 6 courses.
11649877|NCT00085384|Experimental|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b (PEG IFN-α) subcutaneously (SC) on days 1, 8, 15, and 22.
11649878|NCT00085384|Experimental|Arm II|Patients receive PEG IFN-α SC (at a higher dose than in arm I) on days 1, 8, 15, and 22.
11649879|NCT00085384|Experimental|Arm III|Patients receive PEG IFN-α SC (at a higher dose than in arm II) on days 1, 8, 15, and 22.
11649880|NCT00085371|Experimental|Treatment (triapene)|Patients receive triapene IV over 2 hours on days 1-4 and 15-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11649881|NCT00085358|Experimental|Treatment (carboplatin, paclitaxel, docetaxel, bevacizumab)|"Patients receive IP carboplatin on day 1, and paclitaxel IV over 3 hour (part A) or docetaxel IV over 1 hour (Part B) on day 1, and IP paclitaxel on day 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~Patients receive IP carboplatin on day 1, paclitaxel IV on day 1, and IP paclitaxel on day 8 in course 1 as in part A dose-escalation phase. Beginning in course 2 and all subsequent courses, patients receive IP carboplatin on day 1, IV paclitaxel on day 1, and IP paclitaxel on day 8 as in the dose-escalation phase, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity."
11649882|NCT00085306|Experimental|Recombinant interferon beta|
11649883|NCT00085293|Experimental|Treatment|Starting dose 6 mg/m^2 Decitabine intravenous (IV) over 1 hour on days 1-5 and 8-12 of weeks 1 and 2 (course 1). Week 3, Iodine I 131 (131I) scanning using thyrotropin alfa injections. Participants whose scan do not demonstrate iodine uptake continue suppressive thyroid hormone therapy but no further study therapy; these participants who do show uptake undergo thyroid hormone withdrawal on weeks 4-8 and second course of decitabine (as in course 1) on weeks 7 and 8, with 131I therapy on week 9.
11649884|NCT00085280|Experimental|Treatment (erlotinib hydrochloride)|"Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Patients complete the Smoking Status Survey, a questionnaire regarding smoking habits, at baseline, and then every 3 months during study treatment."
11649885|NCT00085254|Experimental|Arm 1 (Safety Run In)|"INITIATION COURSE: Patients receive cilengitide IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.
~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Doses of cilengitide: 500mg, 1000mg and 2000mg
~Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
11649886|NCT00085254|Experimental|Phase II (Arm1-500mg)|"INITIATION COURSE: Patients receive cilengitide (500mg) IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.
~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV (500mg) on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~cilengitide, Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
11649887|NCT00085254|Experimental|Phase II (Arm 2 -2000mg)|"INITIATION COURSE: Patients receive cilengitide (2000mg) IV over 1 hour on days 1 and 4. Treatment repeats weekly for 10 weeks. Patients also receive oral temozolomide and undergo radiotherapy one hour later on days 1-5 of weeks 1-6.
~MAINTENANCE COURSES: Patients receive oral temozolomide once daily on days 1-5 in courses 1-6. Patients also receive cilengitide IV (2000mg) on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~cilengitide,Temozolimide, Radiation Therapy, laboratory biomarker analysis, pharmacological study"
11649888|NCT00085202|Experimental|Stratum 1 (high-risk group)|"Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks. Six weeks after the completion of radiotherapy, patients receive high-dose chemotherapy followed by autologous stem cell transplantation (SCT) and filgrastim (G-CSF) with post-transplantation vincristine. High-dose chemotherapy and autologous SCT repeat every 4 weeks for 3 additional courses in the absence of unacceptable toxicity.
~Interventions: vincristine, cisplatin, cyclophosphamide, autologous hematopoietic stem cell transplantation, filgrastim, radiation therapy"
11649889|NCT00085202|Experimental|Stratum 2 (average-risk group)|"Patients undergo craniospinal radiotherapy as in stratum 1, but at a lower dose. Patients receive high-dose chemotherapy, autologous SCT, G-CSF, and post-transplantation vincristine as in stratum 1.
~Interventions: vincristine, cisplatin, cyclophosphamide, autologous hematopoietic stem cell transplantation, filgrastim, radiation therapy"
11649892|NCT00085124|Experimental|Arm I|"Remission induction therapy: Patients receive oblimersen IV continuously on days 1-10, cytarabine IV continuously on days 4-10, and daunorubicin IV on days 4-6.
~Patients who achieve CR proceed to consolidation therapy. Patients who do not achieve CR receive a second course of induction therapy.
~Second remission induction therapy: Patients receive oblimersen IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.
~Patients who achieve CR proceed to consolidation therapy.
~Consolidation therapy: Patients receive oblimersen IV continuously on days 1-8 and high-dose cytarabine IV over 3 hours on days 4-8. Patients with a continuing CR receive a second course of consolidation therapy."
11649893|NCT00085124|Experimental|Arm II|"Remission induction therapy: Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3.
~Patients who achieve CR proceed to consolidation therapy. Patients who do not achieve CR receive a second course of induction therapy.
~Second remission induction therapy: Patients receive cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1 and 2.
~Patients who achieve CR proceed to consolidation therapy.
~Consolidation therapy: Patients receive high-dose cytarabine IV over 3 hours on days 1-5. Patients with a continuing CR receive a second course of consolidation therapy."
11649894|NCT00085111|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
11649895|NCT00085098|Experimental|Regimen A (radiotherapy only)|Within 52 days of surgery, patients will undergo standard-dose radiation therapy 5 days a week for approximately 5-6 weeks.
11649896|NCT00085098|Experimental|Regimen B (chemotherapy plus radiotherapy)|"Courses 1 and 2: Patients receive carboplatin IV over 1 hour on days 1 and 2 and etoposide IV over 2 hours on days 1-3. Treatment repeats every 21 days for 2 courses.
~Within 3 weeks of completing chemotherapy, patients with CR undergo low-dose radiation therapy 5 days a week for 5 weeks. Patients with MRD, a PR, or SD receive chemotherapy courses 3 and 4 as outlined below.
~Courses 3 and 4: Patients receive cisplatin IV over 6 hours on day 1, cyclophosphamide IV over 1 hour on days 2 and 3, and filgrastim (G-CSF), subcutaneous (SC) or IV beginning on day 4 and continuing until blood counts recover.
~Treatment repeats every 21 days for 2 courses. Patients achieving a CR or MRD proceed to reduced-dose radiotherapy. Patients with a PR, SD, or progressive disease (PD) are restaged and may undergo standard radiation therapy as in regimen A. Reduced-dose radiation therapy: Within 6 weeks of starting course 4, patients undergo lower-dose radiation therapy once daily on days 1-5 for 5 weeks"
11649897|NCT00084981|Experimental|Treatment (decitabine, valproic acid)|"Patients receive decitabine IV over 1 hour on days 1-10 and oral valproic acid three times daily on days 5-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of decitabine and valproic acid until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. After the MTD is determined, an additional 6 patients are treated at that dose."
11649898|NCT00084929|Experimental|CT Colonography|CT colonography conducted during the same assessment as colonoscopy.
11649899|NCT00084916|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11649900|NCT00084903|Experimental|Fluorescence Spectroscopy|
11649901|NCT00084877|Experimental|Treatment (triapine, irinotecan hydrochloride)|"Patients receive irinotecan IV over 1 hour on day 1 and 3-AP (Triapine®) IV over 2 hours on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of irinotecan and 3-AP (Triapine®) until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 6 additional patients are treated at that dose."
11649902|NCT00084864|Experimental|Stage 1, Arm I|Patients receive oral dexamethasone once daily on days 1-4 and oral calcitriol once daily on days 2-4 weekly for 4 weeks before surgery.
11649903|NCT00084864|Experimental|Stage 1, Arm II|No study drugs before surgery.
11649904|NCT00084864|Experimental|Stage 1 Arm 3|Patients receive oral dexamethasone once daily on days 1-4.
11649905|NCT00084864|Experimental|Stage 1, Arm 4|Patients receive oral calcitriol once daily on days 2-4.
11649906|NCT00084838|Experimental|Multi-agent Intrathecal and Systemic CT with RT (mod IRS III)|"Pre-irradiation induction therapy (wks 1-6); Chemoradiation induction therapy (wks 7-12); Post-radiation induction therapy (wks 13-18); Maintenance therapy (wks 19-44); Continuation therapy (wks 45-51)
~Induction Chemotherapy: CT backbone of the IRS-III regimen [vincristine, dactinomycin, cyclophosphamide (specifically, in combination), cisplatin, doxorubicin, and imidazole carboximide (DTIC)] was modified to incl temozolomide in lieu of DTIC. Pts w/ M0 dz (and initially positive CSF cytology) rcvd intrathecal (IT) CT (alt btwn intralumbar and intraventricular routes) w/ methotrexate, cytarabine, and hydrocortisone, coinciding with a cycle of CT.
~Radiation Therapy: Pts w/ M0 dz OR M+ dz aged <3y received focal RT (3D conformal or intensity-modulated delivery). Pts >3y w/ M+ dz rcvd craniospinal irradiation.
~Continuation Therapy: Pts treated with either non-doxorubicin or doxorubicin dose therapy if receiving CSI or mediastinal radiotherapy or not, respectively."
11649907|NCT00084825|Experimental|Docetaxel + Imatinib Mesylate|Docetaxel intravenous (IV) over 1 hour on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-42. Courses repeat every 42 days.
11649908|NCT00084812|Experimental|Safingol and Cisplatin|"Patients receive safingol IV over 1 hour and cisplatin IV over 1 hour on day 1. Courses repeat every 21 days* in the absence of disease progression or unacceptable toxicity.
~NOTE: *Patients receive safingol on days 1 and 8 and cisplatin on day 8 for course 1 only; course 1 is 28 days in duration.
~Cohorts of 3-6 patients receive escalating doses of safingol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose level."
11649909|NCT00084773|Experimental|Cetuximab, Fluorouracil, and Pelvic Irradiation|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64 and fluorouracil IV continuously on days 1-42. Patients undergo whole-pelvic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Treatment continues in the absence of disease progression or unacceptable toxicity.
~Approximately 1-3 weeks after completion of study treatment, patients undergo surgical resection followed by adjuvant chemotherapy off-study.
~Patients are followed for up to 5 years."
11649910|NCT00084747|Experimental|bortezomib|
11649911|NCT00084695|Experimental|Regimen A|Patients undergo total body irradiation (TBI) two times daily on days -7 to -4. Patients receive cyclophosphamide IV over 30-60 minutes on days -3 and -2 and anti-thymocyte globulin (ATG) IV over at least 6 hours on days -3 to -1.
11649912|NCT00084695|Experimental|Regimen B (patients who do not receive TBI)|Patients receive oral busulfan 4 times daily on days -8 to -5, and ATG IV over at least 6 hours and melphalan IV over 15-20 minutes on days -4 to -2.
11649913|NCT00084695|Experimental|Regimen C (patients with Fanconi's anemia/related disorders)|Patients undergo TBI on day -6. Patients receive ATG IV over at least 6 hours and methylprednisolone IV on days -5 to -1 and fludarabine IV over 30 minutes and cyclophosphamide IV over 30-60 minutes on days -5 to -2.
11649914|NCT00084695|Experimental|Regimen D|Patients receive oral or IV busulfan 4 times daily on days -9 to -5, ATG IV over at least 6 hours on days -5 to -3, and cyclophosphamide IV over 30-60 minutes on days -5 to -2.
11649915|NCT00084682|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11649916|NCT00084656|Experimental|Arm 1|
11649917|NCT00084643|Experimental|Treatment (GTI-2040, capecitabine, oxaliplatin)|Patients receive GTI-2040 IV continuously on days 1-14, oral capecitabine twice daily on days 2-15, and oxaliplatin IV over 2 hours on day 2 of the first course. In all subsequent courses, capecitabine is administered on days 1-14, oxaliplatin is administered on day 1, and GTI-2040 is administered as in course 1. Courses repeat every 21 days in the absence of disease progression and unacceptable toxicity.
11649918|NCT00084630|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily on days 1-56. Treatment repeats every 56 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with documented tumor progression and no serious side effects may continue therapy at a higher dose for another 6 courses.
11649919|NCT00084617|Experimental|Treatment (oxaliplatin, irinotecan, capecitabine)|Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on days 1, 8, 15, and 22 and oral capecitabine twice daily on days 1-5, 8-12, 15-19, and 22-26. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
11649920|NCT00084604|Experimental|Treatment (bevacizumab, cisplatin, irinotecan)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive cisplatin IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11649921|NCT00084552|Active Comparator|Arm I|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
11649922|NCT00084552|Experimental|Arm II|Patients undergo IMRT with dose restriction to erectile tissue once daily 5 days a week for approximately 7.5 weeks.
11649923|NCT00084539|Experimental|Radiation therapy|"Radiation Therapy
~Daily 5 days per week for 4 weeks
~45 Gy in 20 fractions whole breast
~56 Gy in 20 fractions to boost volume"
11649924|NCT00084487|Experimental|Treatment (becatecarin)|Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11649925|NCT00084461|Experimental|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses beyond CR.
11649926|NCT00084435|Experimental|chemoRT after surgery|chemoRT with cisplatin and docetaxel after surgery
11649927|NCT00084409|Experimental|Arm I|Patients receive oral iloprost twice daily for 6 months in the absence of unacceptable toxicity.
11649928|NCT00084409|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 6 months in the absence of unacceptable toxicity.
11649929|NCT00084396|Experimental|Letrozole/Surgery|
11649930|NCT00084383|Experimental|GVAX pancreatic cancer vaccine|"5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth booster vaccination, six months following the fourth vaccination"
11649931|NCT00084370|Experimental|Group 1|Group I: Patients receive oral celecoxib twice daily for 3 months and then undergo prophylactic oophorectomy.
11649932|NCT00084370|Experimental|Group II|Group II: Patients undergo immediate prophylactic oophorectomy.
11649933|NCT00084318|Experimental|RT + cisplatin + cetuximab|Loading dose of cetuximab followed by radiation therapy with weekly cisplatin and cetuximab.
11649934|NCT00084318|Experimental|RT + docetaxel + cetuximab|Loading dose of cetuximab followed by radiation therapy (RT) with weekly docetaxel and cetuximab.
11649935|NCT00084266|Experimental|1|Subjects receiving linezolid for the treatment phase of the study
11649936|NCT00084266|Active Comparator|2|Subjects receiving vancomycin for the treatment phase of the study
11649937|NCT00084253|Active Comparator|1|
11649938|NCT00084253|Active Comparator|2|
11649939|NCT00084305||Family|Family members of patients with pulmonary fibrosis
11649940|NCT00084305||Healthy Volunteers|Healthy Volunteers
11649941|NCT00084305||Pulmonary Fibrosis|Patients with pulmonary fibrosis
11649942|NCT00002682|Experimental|Antibiotic Treatment|
11649943|NCT00002676|Experimental|CHOD + BVAM + WBRT|Patients 70 years old and younger with newly diagnosed, biopsy-proven PCNSL received one cycle of CHOD followed by two cycles of BVAM. Patients then received WBRT, 30.6 Gy, if a complete response was evoked, or 50.4 Gy if the response was less than complete; both doses were given in 1.8-Gy daily fractions.
11649944|NCT00002670|Active Comparator|Radiation therapy|Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week)
11649945|NCT00002670|Experimental|Radiation therapy plus cisplatin|Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week) plus Cisplatin-100 mg/m2 i.v. on days 1,22 and 43 with radiation therapy.
11649946|NCT00002656|Experimental|Pyrazoloacridine|Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.
11649979|NCT00005032|Experimental|Arm A|G3139 (3 mg/kg/day continuous IV infusion over 7 days every 21 days), Paclitaxel (150 mg/m2, 3 hr IV infusion on Day 6 of every 21 day cycle)
11649947|NCT00002625|Experimental|Arm I|Radiosensitization plus Radiotherapy. Topotecan hydrochloride, TOPO, NSC-609699; plus external-beam irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons acceptable for the boost field).
11649948|NCT00002551|Experimental|Bolus 5-FU, Pelvic XRT + PVI 5-FU, Bolus 5-FU|Bolus 5-FU (fluorouracil) (500mg/m2/day on days 1-5, 29-33), Pelvic XRT + PVI 5-FU, Bolus 5-FU (450mg/m2/day for 5 days beginning 28 days after RT, for 2 cycles on days 1-5 of a 28 days cycle).
11649949|NCT00002551|Experimental|PVI 5-FU+Pelvic XRT+PVI 5-FU+PVI 5-FU|5-FU (fluorouracil) 300mg/m2/day for 42 days followed by 2 week interruption, Day 57 through XRT will receive 225mg/m2/day of 5-FU followed by 1 month interruption, 4 weeks after completion of XRT 1 8wk cycle of 5-FU 300mg/m2/day.
11649950|NCT00002551|Experimental|Bol 5-FU+LV+LEV+Pel XRT+Bol 5-FU+LV Bol 5-FU + LV + LEV|5-FU (fluorouracil) 425/mg/m2/day Days 1-5,29-33; LV (leucovorin calcium) 20mg/m2/day Days 1-5,29-33; LEV (levamisole hydrochloride) 150mg/day (50mg TID) for 3 days every 14 days starting after each course of 5-FU. During RT: 5-FU and LV 4 days on wk 1 and wk 5 of RT. LV 20 mg/m2/day IV bolus within 2hrs after completion of that day's radiation therapy, for four days in each cycle. Followed immediately by 5- FU 400 mg/m2/day IV bolus. Treatment will be given on days 57 - 60 and 85 - 88.Treatment post-RT-chemotherapy 28 days after completion of RT consist of 5 days of chemotherapy in 28 day cycles. 5-FU, 380 mg/m2/day on days 1 - 5 and LV given at a dose of 20 mg/m2/day on days 1 - 5 with the 5-FU given immediately after the LV. For 2 post-radiation cycles on days 1 - 5 of a 28 day cycle. Levamisole will be given orally at a dose of 150 mg/day (50 mg tid) for 3 days every 14 days during the 1st 3 days of each cycle of 5-FU, and again 14 days after starting each course of 5-FU.
11649951|NCT00006251|Experimental|Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)|"CONDITIONING REGIMEN : Patients receive fludarabine phosphate IV on days - 4 to -2 and undergo low-dose TBI on day 0. (Note: Patients who have had an autologous transplant within 90 days prior to day 0 will not receive fludarabine phosphate.)
~PBSC INFUSION: Patients undergo allogeneic PBSC transplant on day 0.
~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 35 with a taper to day 56. Patients receive mycophenolate mofetil PO BID on days 0-27.
~POST TRANSPLANT DLI: Patients with stable mixed chimerism on day 56, and without evidence of GVHD, undergo DLI IV over 30 minutes on day 65. Patients without a complete response, full donor chimerism, and GVHD after 2 months undergo further DLI at higher cell numbers. Up to 6 DLIs may be given 65 days apart."
11649952|NCT00003992|Experimental|Arm I|Patients receive paclitaxel IV over 3 hours immediately followed by trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Paclitaxel repeats every 3 weeks for 4 courses and trastuzumab (Herceptin) repeats weekly for 10 courses. At 3 weeks following paclitaxel and trastuzumab (Herceptin), patients receive doxorubicin IV and cyclophosphamide IV over 1 hour every 3 weeks for 4 courses. Following chemotherapy, estrogen receptor (ER) positive and/or progesterone receptor (PR) positive patients receive oral tamoxifen twice daily for 5 years.
11649953|NCT00003992|Experimental|Arm II|Patients receive same therapy as in Arm I, except for additional trastuzumab (Herceptin) IV weekly beginning within 3 weeks following completion of chemotherapy and local therapy and continuing for 1 year. ER and/or PR positive patients receive tamoxifen as in Arm I but may be concurrent with trastuzumab (Herceptin). Following completion of doxorubicin and cyclophosphamide, post lumpectomy and post mastectomy patients may receive local radiotherapy daily for 5-6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
11649954|NCT00084149|Experimental|Cyclosporin|Cyclosporin arm (Arm A) will receive one tablet of Abacavir sulfate, Lamivudine, and Zidovudine (ABC/3TC/AZT) twice daily, 3 capsules or 2 tablets of lopinavir/ritonavir (LPV/r) twice daily, and liquid cyclosporin A (CsA) (dose determined by weight) twice daily. At Week 5, Arm A patients will stop CsA but continue both ABC/3TC/AZT and LPV/r.
11649955|NCT00084149|Experimental|No Cyclosporin|The No Cyclosporin arm (Arm B) will receive one tablet of Abacavir sulfate, Lamivudine, and Zidovudine (ABC/3TC/AZT) twice daily and 3 capsules or 2 tablets of lopinavir/ritonavir (LPV/r) twice daily for all 48 weeks
11649956|NCT00084136|Experimental|ZDV/3TC+EFV|ZDV/3TC+EFV participants will receive lamivudine/zidovudine and efavirenz
11649957|NCT00084136|Experimental|ddI+FTC+ATV|ddI+FTC+ATV participants will receive emtricitabine, atazanavir, and enteric-coated didanosine
11649958|NCT00084136|Experimental|TDF/FTC+EFV|TDF/FTC+EFV participants will receive emtricitabine/tenofovir disoproxil fumarate and efavirenz
11649959|NCT00084123|Experimental|Healing Touch|Healing Touch Therapy
11649960|NCT00084123|Active Comparator|Relaxation Therapy|Relaxation Therapy
11649961|NCT00084123|Placebo Comparator|Standard Care|Standard Care
11649962|NCT00084084|Experimental|Agalsidase alfa (Cohort 1)|Cohort 1: Patients who completed TKT023.
11649963|NCT00084084|Experimental|Agalsidase Alfa (Cohort 2)|Cohort 2: Treatment-naive patients.
11649964|NCT00084032|Experimental|1|In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will continue taking ARV therapy for 16 weeks and then stop ARVs for 64 weeks.
11649965|NCT00084032|Experimental|2|In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will stop ARVs for 4 weeks, take ARVs for 8 weeks, stop ARVs for 4 weeks, take ARVs for 8 weeks, and then stop ARVs for 56 weeks.
11649966|NCT00083980|Active Comparator|active antidepressant drug comparator|Venlafaxine ER
11649967|NCT00083980|Placebo Comparator|Sugar pill|Inert placebo pills as duble dummy - up to 4 per day for kava and 3 per day for venlafaxine
11649968|NCT00083980|Experimental|Herbal treatment kava|Kava
11649969|NCT00083941|Experimental|TroVax and IL-2|TroVax: Intramuscular into the deltoid muscle of the upper arm, 10x dose (6.83 x 108 pfu/ml). IL 2: High dose IL 2, 600,000 IU/kg intravenously every 8 hours up to a maximum of 15 injections.
11649970|NCT00083915|Active Comparator|Auto Transplant w/ High Dose Melphalan|Autologous transplant with High Dose Melphalan alone
11649971|NCT00083915|Active Comparator|Auto Transplant w/ Melphalan + DT Pace|Melphalan plus Dexamethasone, Thalidomide, CisPlatinum, Adriamycin, Cyclophosphamide, and Etoposide
11649972|NCT00083889|Active Comparator|2|
11649973|NCT00083889|Experimental|1|
11649974|NCT00083863||Framingham Heart Study Offspring|
11649975|NCT00083863||FHS Gen 3|
11649976|NCT00083824|Placebo Comparator|Sugar Pill|Placebo
11649977|NCT00083824|Experimental|Estrogens, Conjugated (USP)|Conjugated Equine Estrogen 0.625 mg/day for 3 years, drug
11649978|NCT00083824|Experimental|Medroxyprogesterone 17-acetate|Conjugated Equine Estrogen 0.625 mg/day plus Medroxyprogesterone Acetate 2.5 mg/day
11649980|NCT00005030|Experimental|SCH 66336|Starting dose of preoperative oral SCH 66336 100 mg twice daily for 7-14 days prior to exploratory laparotomy and/or resection of hepatic metastases with surgery between days 8-15.
11649981|NCT00005030|No Intervention|No Treatment|Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization.
11649982|NCT00004161|Experimental|Arm I|Patients receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients then receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients are followed every 3 months.
11649983|NCT00004161|Experimental|Arm II|Patients receive oral placebo daily (except days 1-3 each month) for 6 months. Patients then receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients are followed every 3 months.
11649984|NCT00004146|Experimental|Treatment (RT and CAI)|"Patients receive induction therapy consisting of radiotherapy once daily 5 days a week plus oral carboxyamidotriazole once daily for 6 weeks followed by carboxyamidotriazole alone daily for 4 weeks. Patients continue on oral carboxyamidotriazole once daily as maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for survival.
~Other: pharmacological study, radiation therapy"
11649985|NCT00004070|Experimental|IL-12 Injection 3mg/ml [Phase I]|The dosing schedule will consist of eight injections 3 mg/ml of formulated plasmid over a seven week period.
11649986|NCT00004070|Experimental|IL-12 Injection 6mg/ml [Phase I]|The dosing schedule will consist of eight injections 6mg/ml of formulated plasmid over a seven week period.
11649987|NCT00004070|Experimental|IL-12 Injection MTD [Phase II]|The dosing schedule will consist of eight injections over a seven week period of formulated plasmid at the MTD established in the phase I portion.
11649988|NCT00083772|Experimental|1|Nesiritide
11649989|NCT00083759|Active Comparator|natalizumab|
11649990|NCT00083759|Placebo Comparator|placebo|
11649991|NCT00004055|Experimental|topotecan + paclitaxel + filgrastim|Patients receive oral topotecan on days 1-5 followed by paclitaxel IV over 3 hours on day 5. Beginning 24-48 hours after chemotherapy, patients receive filgrastim (G-CSF) subcutaneously daily for up to 10 days until blood counts recover. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression. Patients who develop CNS progressive disease only should receive whole brain radiotherapy before continuing study treatment.
11649992|NCT00003997|Experimental|Arm I|Patients receive 6-hydroxymethylacylfulvene (HMAF) IV over 5 minutes on days 1-5. Treatment repeats every 3-4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3 patients receive escalating doses of HMAF. The maximum tolerated dose is defined as the dose at which dose limiting toxicity occurs in at least 40% of patients.
11649993|NCT00003850|Experimental|Arm I|Patients receive 4-20 capsules of oral thalidomide once daily. Dose is escalated in individual patients on a weekly basis for the first 5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity, or for 12 months past complete response.
11649994|NCT00003787||Intervention|high fiber, high vegetable, low-fat diet
11649995|NCT00003787||Control|NCI-recommended diet
11649996|NCT00003249|Experimental|Arm I|Patients receive oral carboxyamidotriazole (CAI) as a test dose on day 1. Patients receive oral ketoconazole on day 7, followed by CAI plus ketoconazole on day 8. CAI and ketoconazole are administered in combination on day 1 and days 3-28 of the first course. Ketoconazole is administered alone on day 2 of the first course. Subsequent courses begin at 28 day intervals in the absence of disease progression or unacceptable toxic effects. Cohorts of 3 patients are evaluated at each dose level prior to dose escalation. If one of three patients within a cohort experiences dose limiting toxicity (DLT), that dose level is expanded to incorporate six patients. If two or more patients experience DLT, the next lower dose is declared to be the maximum tolerated dose.
11649997|NCT00083720|Experimental|cetuximab|Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes
11649998|NCT00083616|Experimental|Panitumumab|Participants received panitumumab 6 mg/kg once every 2 weeks weeks administered by intravenous (IV) infusion until progressive disease, inability to tolerate the investigational product, or discontinuation of treatment for other reasons.
11649999|NCT00083603|Experimental|1|rFPV-HIV vaccine administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, and 196
11650000|NCT00083603|Placebo Comparator|2|Empty TBC-FPV vector administered as two separate 1-mL intramuscular injections, one into each deltoid at Days 0, 28, 84, 140, and 196
11650001|NCT00083603|Experimental|3|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
11650002|NCT00083603|Placebo Comparator|4|Empty TBC-MVA vector administered in each deltoid on Days 0, 28; empty TBC-FPV vector administered in each deltoid on Days 84, 140, and 196
11650003|NCT00083603|Experimental|5|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
11650004|NCT00083603|Placebo Comparator|6|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
11650005|NCT00083603|Experimental|7|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
11650006|NCT00083603|Placebo Comparator|8|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
11650007|NCT00083603|Experimental|9|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, 196
11650009|NCT00083603|Experimental|11|rFPV-HIV vaccine administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, and 196
11650010|NCT00083603|Placebo Comparator|12|Empty TBC-FPV vector administered as two separate 1-mL intramuscular injections, one into each deltoid at Days 0, 28, 84, 140, and 196
11650011|NCT00083603|Experimental|13|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
11650012|NCT00083603|Placebo Comparator|14|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
11650013|NCT00083603|Experimental|15|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, 196
11650014|NCT00083603|Placebo Comparator|16|Empty TBC-MVA vector administered in each deltoid Days 0, 28, 84, 140, 196
11650015|NCT00083551|Active Comparator|Thalidomide|Thalidomide 400 qod during induction.100 mg qd between transplants, post transplant pat. 200 mg qd. During year one of maintenance therapy pt will take 100mg of Thal qod and 50 mg of thal qod during second year of maintenance
11650016|NCT00083551|Active Comparator|No Thalidomide|During induction, consolidation, and maintenance steps patient receives no thalidamide
11650017|NCT00003075|Experimental|Fenretinide|
11650018|NCT00003075|Placebo Comparator|Placebo|
11650019|NCT00083460|Active Comparator|1|
11650020|NCT00083460|Active Comparator|2|
11650021|NCT00006222|Experimental|Arm I|Patients receive EMD 121974 IV twice a week for four weeks. Courses repeat every 4 weeks in the absence of disease progression. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.
11650022|NCT00006083|Experimental|Fragmin|Fragmin at 5000 IU injected subcutaneously daily
11650023|NCT00006083|Placebo Comparator|placebo|placebo injected subcutaneously daily
11650024|NCT00006079|Experimental|Arm I|Arm I-II: Patients receive one of two different doses of oral eflornithine daily. Treatment continues for 28 days.
11650025|NCT00006079|Experimental|Arm II|Arm I-II: Patients receive one of two different doses of oral eflornithine daily. Treatment continues for 28 days.
11650026|NCT00006079|Placebo Comparator|Arm III|Arm III: Patients receive oral placebo daily. Treatment continues for 28 days.
11650027|NCT00006001|Experimental|Arm I|Patient receive SU5416 IV over 60 minutes twice weekly for 4 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
11650028|NCT00005942|Experimental|Treatment (liposomal danorubicin citrate, semaxanib)|Patients receive daunorubicin liposomal IV over 6 hours on days 1-3 and SU5416 IV twice a week for 2 months. The second course is administered for 1 month, then treatment continues every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
11650029|NCT00005640|Experimental|Mapping and Biopsy|Lymph node mapping and sentinel lymph node biopsy. Patients undergo preoperative endoscopy with injection of technetium Tc 99m sulfur colloid around tumor followed by celiotomy and intraabdominal exploration. At 30 minutes following injection, patients undergo lymphatic mapping with a gamma probe and biopsy of the sentinel lymph node(s). Following biopsy and mapping, patients undergo resection of primary tumor.
11650030|NCT00005578|Experimental|Arm 1|Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin hydrochloride and etoposide on days 0 and 1, bleomycin sulfate and vincristine sulfate on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Patients assigned to arm I receive only these drugs.
11650031|NCT00005578|Experimental|Arm 2|Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin hydrochloride and etoposide on days 0 and 1, bleomycin sulfate and vincristine sulfate on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Dexrazoxane hydrochloride on days 0, 1, and 7
11650032|NCT00005059|Experimental|carboplatin + paclitaxel|"Following completion of the Lubben Social Network Scale and Frailty Questionnaire, patients receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, and 15.
~Treatment repeats every 28 days for 2 courses. Patients with complete response receive 2 additional courses of therapy. Patients with partial response or stable disease may receive additional courses of therapy at investigator's discretion. Patients are followed every 3 months for 5 years or until disease progression."
11650033|NCT00002923|Experimental|KRN5500|
11650034|NCT00002829|Experimental|Bone Marrow Transplantation|
11650035|NCT00002827|Experimental|Treatment #1 (Without Zinecard)|"All patients undergoing a splenectomy must receive penicillin or erythromycin prophylaxis twice a day. Pneumocystis prophylaxis:TMP/SMZ 150mg/m2(maximum 300 mg) of TMP in 2 divided doses on 3 consecutive days each week. Aerosolized Pentamidine (200mg/m2/dose - maximum dose 300 mg) should be substituted monthly for patients who cannot tolerate TMP/SMZ therapy. Continue pneumocystis prophylaxis for 6 months after stopping therapy.
~Doxorubicin hydrochloride 25mg/m2/day IV push over 15 minutes days 1 and 15 Bleomycin sulfate 10 IU/m2/day IV push over 10 minutes on days 1 and 15 Vincristine sulfate 1.5mg/m2/day IV push (maximum 2mg) days 1 and 15 Etoposide 10mg/m2/day 1-5. IV drip ( < 0.4mg/ml) over 1 hour. Monitor blood pressure every 15 minutes during infusion. G-CSF (filgrastim) 5 mcg/Kg/day start on day 6 (24-36 hrs after 5th dose of VP16) and continued through day 13 (total 8 days)."
11650036|NCT00002827|Experimental|Treatment #2 (with Zinecard)|Zinecard (DZR) 250 mg/m2 IV push on days 1 and 15 before administration of doxorubicin and bleomycin sulfate. Give bleomycin sulfate and doxorubicin within 30 minutes of Zinecard (dexrazoxane hydrochloride). Bleomycin 10 IU/m2/day IV push over 10 minutes on days 1 and 15 Doxorubicin hydrochloride 25mg/m2/day IV push over 15 minutes days 1 and 15 Vincristine Sulfate 1.5mg/m2/day IV push (maximum 2mg) days 1 and 15
11650037|NCT00002806|Experimental|procarbazine + lomustine + vincristine + radiation|PCV followed by external-beam cranial irradiation using at least 6 MV photons.
11650038|NCT00002721|Experimental|Prostate cancer patients|Prostate cancer patients that have not responded to hormon therapy
11650039|NCT00002602|Experimental|Group 1|Clinical stages T1b-c or T2a-b with PSA + ([Gleason -6] x 10) is ≤ 15. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
11650040|NCT00002602|Experimental|Group 2|Clinical stages T1b-c or T2a-b with PSA + ([Gleason -6]x10)>15. Any clinical T2c with PSA < 70. Must be lymph node negative. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
11650041|NCT00002602|Experimental|Group 3|Clinical stage T3 with PSA < 70. Must be lymph node negative. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
11650042|NCT00083512||Glioblastoma multiforme patients|Patients with histologically confirmed supratentorial Glioblastoma multiforme
11650043|NCT00083499||Group 1|Index cases
11650044|NCT00083499||Group 2|Relatives of Index Cases
11650045|NCT00083499||Group 3|Fetal tissue
11650046|NCT00004190|Experimental|gemcitabine + oxaliplatin|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 immediately followed by oxaliplatin IV over 2 hours on day 1. Treatment repeats every 3 weeks. Patients achieving stable disease, partial response, or regressive disease continue with therapy. Patients achieving complete response for two consecutive evaluations receive an additional 2 courses of therapy. Phase I (closed as of 7/5/00): Cohorts of 3-6 patients receive escalating doses of gemcitabine and oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. Phase II: Patients receive the MTD of gemcitabine and oxaliplatin as in phase I. Patients are followed every 3 months for 1 year, and then every 6 months for 4 years.
11650047|NCT00004139|Experimental|Gemcitabine + Irinotecan|
11650048|NCT00004139|Experimental|Gemcitabine + Docetaxel|
11650049|NCT00003846|Experimental|Treatment|See detailed description.
11650050|NCT00083382|Experimental|Thalidomide + Bisphosphonate|200 mg/day Thalidomide + 90 mg Pamidronate OR 4 mg Zometa every 2 weeks for 2 months and then every 4 weeks as maintenance therapy
11650051|NCT00003098|Experimental|fat reduction increased fiber|Patients are randomized to dietary fat reduction with increased fiber). All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
11650052|NCT00003098|Experimental|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber). All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
11650053|NCT00003084|Experimental|Arm I (Estramustine + Etoposide)|Arm I: Oral Estramustine 3 x day + oral Etoposide 2 x day on days 1-14 + Paclitaxel IV over 1 hour Day 2, repeats every 21 days.
11650054|NCT00003084|Experimental|Arm II (Chemotherapy + Ketoconazole)|Arm II: Doxorubicin IV Days 1, 15, and 29, Vinblastine IV Days 8, 22, and 36, Oral Ketoconazole 3 x day on Days 1-7, 15-21, + 29-35, and Oral Estramustine 3 x day on Days 8-14, 22-28, and 36-42; 6 weeks of alternating chemotherapy and 2 weeks rest, for 8 week course.
11650055|NCT00003056|Active Comparator|Unselected peripheral blood haemopoietic stem cells (PBSC)|Unselected PBSC together with control graft versus host disease (GVHD) prophylaxis - Control
11650056|NCT00003056|Experimental|CD34+ cells isolated from PBSC|CD34+ cells isolated from PBSC using the Isolex 300i system together with cyclosporine
11650057|NCT00002924||Source of patient samples|The CALGB conducted a phase III study (CALGB 9583) in which 260 men with AiPC were randomly assigned to antiandrogen withdrawal together with simultaneous ketoconazole and hydrocortisone versus antiandrogen withdrawal alone, followed by sequential ketoconazole and hydrocortisone. Metastatic disease with progression despite castrate levels of testosterone, prior antiandrogen therapy for a minimum of 4 weeks, and a minimum PSA level of 5 ng/mL were required; treatment with sequential antiandrogens was allowed. No prior chemotherapy was allowed. Bone marrow biopsies were obtained from 164 patients enrolled on CALGB 9583 and from 20 patients enrolled on CALGB chemotherapy trials (CALGB 9480, 9680, 9780).
11650058|NCT00002875|Experimental|Regimen A|Following surgery, craniospinal irradiation followed by a boost to the primary tumor. Beginning within 1 week after initiation of radiotherapy, patients receive vincristine sulfate weekly for 8 doses. Beginning 6 weeks after the completion of radiotherapy, patients receive adjuvant lomustine/vincristine sulfate/cisplatin every 6 weeks for a total of 8 courses.
11650059|NCT00002875|Experimental|Regimen B|Following surgery, craniospinal irradiation plus vincristine sulfate, followed by adjuvant cyclophosphamide/vincristine sulfate/cisplatin every 6 weeks for a total of 8 courses.
11650060|NCT00002734|Experimental|Arm I|Patients receive interferon alfa subcutaneously on days 1, 3, 5, and 7; paclitaxel intraperitoneally (IP) on day 4 or topotecan IP on day 6; and 177Lu-CC49 IP on day 6. Treatment continues every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-5 patients receive escalating doses of paclitaxel and decreasing doses of 177Lu-CC49 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 5 patients experience dose limiting toxicity. Once the MTD of paclitaxel is determined, the dose of 177Lu-CC49 is escalated. Once the MTD of 177Lu-CC49 is determined, 90Y-CC49 is substituted. The MTD of 90Y-CC49 is then determined when administered with paclitaxel. Topotecan is then substituted for paclitaxel (administered with the MTD of 177Lu-CC49 and interferon alfa only) and escalated until the MTD is determined.
11650061|NCT00002664|Experimental|Treatment|
11650062|NCT00002571|Experimental|ProMACE-CytaBOM + G-CSF|6 cycles of 21 days each of ProMACE-CytaBOM (cyclophosphamide 490 mg/m^2 on day 1, doxorubicin 19 mg/m^2 on day 1, etoposide 90 mg/m^2 on day 1, cytarabine 225 mg/m^2 on day 8, bleomycin 5 u/m^2 on day 8, methotrexate 90 mg/m^2 on day 8, leucovorin 25 mg/m^2 q 6 hours on days 8-9, vincristine 1.4 mg/m^2 on day 8, prednisone 60 mg/m^2 on days 1-14, allopurinol 300 mg on days 1-21 of cycle 1 and days 1-8 of cycle 2 only) plus 1 double strength tablet TMP/SMX 3 days a week plus G-CSF 5 ug/kg on days 9-20. Patients also receive intrathecal cytarabine 30 mg/m^2 (BM positive: 5 doses spaced evenly during 1st 2 cycles, then on day 1 of cycles 3-6; CSF cytology positive: 5 doses spaced evenly during 1st cycle, then on day 1 of cycles 2-6; BM and CSF negative: 5 doses spaced evenly within 1 month of completion of cycle 6). All patients with CR or PR after systemic therapy and IT cytarabine receive 2400 cGy RT to the whole brain in 12 fractions.
11650063|NCT00005648|Experimental|001|Gemcitabine with R115777 R115777 200 mg oral twice daily at 12-hour intervals throughout the study coadministered with gemcitabine 1000 mg/m2 iv every week for the first 7 weeks followed by 1 week rest and then every 3 out of 4 weeks thereafter for up to 5 years
11650064|NCT00005648|Placebo Comparator|002|Gemcitabine with Placebo Placebo oral twice daily at 12-hour intervals throughout the study coadministered with gemcitabine 1000 mg/m2 iv every week for the first 7 weeks followed by 1 week rest and then every 3 out of 4 weeks thereafter for up to 5 years
11650065|NCT00004126|Experimental|Arm A|Paclitaxel 175 mg/m2 : administered by 1-hour constant rate IV infusion through a pump on day 1 of each cycle. Oxaliplatin 130 mg/m2 : On Day 1 of each 21-day treatment cycle, patients receive oxaliplatin diluted in 250-500 mL Dextrose 5% in Water infused intravenously over 2 hours.
11650066|NCT00003724|Experimental|surgery|"Patients undergo open resection (thoracotomy, median sternotomy, or bilateral sternothoracotomy).
~Patients with isolated recurrence in the chest should have the recurrence(s) resected if feasible. The original resection approach (open versus VATS) should be the preferred method for the second resection, but is not required.
~Quality of life is assessed prior to randomization and then at 30 days, 3 months, and 6 months. Patients are followed every 3 months for 1 year and then every 6 months thereafter."
11650067|NCT00003724|Experimental|video-assisted surgery|"After spiral CT showing pulmonary nodules are amenable to video-assisted thoracic surgery (VATS) resection with curative intent, patients undergo minimally-invasive video-assisted resection.
~Patients with isolated recurrence in the chest should have the recurrence(s) resected if feasible. The original resection approach (open versus VATS) should be the preferred method for the second resection, but is not required.
~Quality of life is assessed prior to randomization and then at 30 days, 3 months, and 6 months. Patients are followed every 3 months for 1 year and then every 6 months thereafter."
11650068|NCT00002880|Experimental|Etoposide|Oral etoposide for relapsed or refractory non-Hodgkin's lymphoma
11650069|NCT00002787|Experimental|Treatment (vaccine therapy)|Patients receive autologous immunoglobulin idiotype-KLH conjugate vaccine combined with sargramostim SC in weeks 0, 2, 6, and 10 and sargramostim SC QD for three days following each vaccine injection. Some patients also receive aldesleukin SC daily from weeks 2-14.
11650070|NCT00002707|Experimental|Group 2|doxorubicin and cyclophosphamide plus Taxotere prior to surgery plus tamoxifen
11650071|NCT00002707|Experimental|Group 3|doxorubicin and cyclophosphamide followed by surgery followed by taxotere plus tamoxifen
11650072|NCT00002707|Active Comparator|Group 1|doxorubicin and cyclophosphamide plus tamoxifen
11650073|NCT00012350|Experimental|Oral FTI (R115777) Treatment|"Patients will be administered oral FTI (R115777) at a dose of 300-mg by mouth (PO) twice a day (BID). Drug will be taken without regard to meals.
~The study regimen will consist of 3 weeks of treatment followed by one week off for a total cycle duration of 4 weeks."
11650074|NCT00006220|Experimental|Phase I|Starting dose of arsenic trioxide of 0.15 mg/kg/day
11650075|NCT00006220|Experimental|Phase II|MTD of arsenic trioxide
11650076|NCT00006220|Experimental|Treatment Failure|Arsenic trioxide and tretinoin
11650077|NCT00004156|Experimental|Vaccine: MUC1-KLH vaccine/QS21|Patients receive glycosylated MUC-1 antigen containing MUC-1(106) or MUC-1(33) with keyhole limpet hemocyanin conjugate subcutaneously (SQ) plus immunological adjuvant QS21 SQ on weeks 1-3, 7, and 19 for a total of 5 vaccinations. Patients are followed every 3 months.
11650078|NCT00004056|Experimental|Chemo + STEM cell|See detailed description.
11650079|NCT00004038|Experimental|Arm I|Patients undergo biopsy of one of their skin nodules prior to any treatment. Patients receive the Ad-p53 gene therapy in one nodule and injection of a second nodule with Dulbecco's phosphate buffered saline. The next day, patients begin chemotherapy, which may be given weekly and continues every 21-28 days for up to 6 courses. On day 3, patients return for biopsy of injected nodules. Biopsies are only performed during the first course. Patients may receive further injections of the Ad-p53 gene with subsequent courses of chemotherapy, for up to six courses.
11650080|NCT00003700|Experimental|Daunorubicin, ara-C, & MTX Therapy|daunorubicin during induction, increasing doses of cytarabine during consolidation followed by methotrexate in place of cranial irradiation for treatment of ALL
11650081|NCT00003575|Experimental|Arm I|All patients receive ifosfamide IV by continuous infusion for 2 days, etoposide IV over 2 hours daily on days 1 and 2, and filgrastim (G-CSF) subcutaneously (SC) daily on days 4-13. Courses are repeated every 21 days. Patients who have complete or partial remission after a minimum of 4 courses of chemotherapy receive maintenance therapy consisting of interleukin-12 SC twice weekly beginning on day 28 of the final chemotherapy course and continuing for 6 months or until disease progression. All patients also receive combination antiretroviral therapy during study.
11650082|NCT00003439|Experimental|Arm I|Cohorts of 3-6 patients each receive escalating doses of intraperitoneal recombinant human interleukin-12 (rhIL-12) administered weekly for 9 weeks. If a patient tolerates rhIL-12 and shows evidence of objective response or stable disease, patient may receive up to 9 additional weeks of treatment. Treatment continues in the absence of unacceptable toxicity or disease progression. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which no more than 1 of 6 patients experiences dose limiting toxicity.
11650083|NCT00003330|Experimental|Arm I|See detailed description.
11650084|NCT00003255|Experimental|topotecan + carboplatin|Patients receive continuous intravenous infusions of topotecan and carboplatin for 5 days. Treatment repeats every 3-4 weeks during induction (two courses) and every 6-10 weeks during consolidation. No more than four courses of treatment are given. Patients are followed every 6 months for 5 years.
11650087|NCT00082888|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11650088|NCT00082875|Experimental|Arm I|"Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11*, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~NOTE: *For the first course only, treatment is omitted on day 11"
11650089|NCT00082875|Experimental|Arm II|Patients receive cilengitide as in arm I at a higher dose.
11650090|NCT00082810|Experimental|Treatment (tipifarnib, fulvestrant)|Patients receive fulvestrant intramuscularly on day 1 and oral tipifarnib twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity*.
11650091|NCT00082784|Experimental|Treatment|Patients receive bortezomib IV over 3-5 seconds followed by flavopiridol IV over 1 hour on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11650092|NCT00082758|Experimental|Disease Measurable by Standard Criteria(hu14.18-interleukin-2)|"Patients with residual/refractory neuroblastoma and readily measurable residual/refractory disease using standard radiographic criteria. Standard radiographic criteria for CT/MRI Lesions will use the definitions of measurable disease from the Response Evaluation Criteria In Solid Tumors (RECIST) from the National Cancer Institute.
~hu14.18-Interleukin-2 fusion protein : Given IV"
11650093|NCT00082758|Experimental|Disease Eval by MIBG or BM Histology (hu14.18-interleukin-2)|"Patients with residual/refractory neuroblastoma with disease that is not measurable by standard radiographic criteria, but is evaluable by meta-iodobenzylguanidine (MIBG) scanning and/or by bone marrow (BM) histology.
~hu14.18-Interleukin-2 fusion protein : Given IV"
11650094|NCT00082758|Experimental|Disease Identified by BM Immunohistochemistry Only|"Patients with residual/refractory neuroblastoma that do not have disease that is measurable by standard radiographic techniques or evaluable by meta-iodobenzylguanidine (MIBG) scanning or bone marrow (BM) histology, however, disease is identified and quantified by BM immunohistochemistry (>5 neuroblastoma cells per 1,000,000 nucleated marrow cells).
~hu14.18-Interleukin-2 fusion protein : Given IV"
11650095|NCT00082745||Observational (genetic analysis)|DNA from peripheral blood or buccal sample of patients is analyzed for the presence of polymorphisms in candidate genes associated with an increased risk of late-occurring complications.
11650096|NCT00082732|Experimental|Arm I: Dietary Intervention|Nutritional counseling on a low-fat, high-fiber, soy supplemented diet and behavior-based activities, such as goal-setting, contracting, and stimulus control, once weekly for 6 weeks, every 3 weeks for 33 weeks, and then at weeks 44, 48, and 52.
11650097|NCT00082732|No Intervention|Arm II: Observation|Observation every 6 weeks for 36 weeks and then every 8 weeks for 18 weeks.
11650098|NCT00082719|Experimental|Arm I|Low-dose interferon alfa subcutaneously (SC) twice daily.
11650099|NCT00082719|Experimental|Arm II|Interferon alfa as in arm I at a higher dose.
11650100|NCT00082719|Experimental|Arm III|Interferon alfa SC once daily.
11650101|NCT00082719|Experimental|Arm IV|Interferon alfa as in arm III at a higher dose.
11650102|NCT00082706|Experimental|5-FU, Leucovorin, Gemcitabine + Cisplatin|5-FU continuous infusion over Days 1 - 5; Leucovorin once a day as a short infusion on Days 1 - 5; Cisplatin infusion over a few hours (usually 2-4 hours) once a day on Days 1 - 5; Gemcitabine infusion over 30 minutes on Days 1 & 5 only.
11650103|NCT00082641|Experimental|Arm I|Patients receive vaccination comprising p53-infected autologous dendritic cells subcutaneously (SC) 1 week after completion of doxorubicin and cyclophosphamide, 1 week after completion of paclitaxel (or after surgery for patients with stage III disease), and at 6 and 12 weeks after completion of radiotherapy (for a total of 4 vaccinations).
11650104|NCT00082641|Experimental|Arm II|Patients receive vaccination comprising p53-infected autologous dendritic cells SC at 6, 8, 10, and 12 weeks after completion of radiotherapy.
11650105|NCT00003118|Experimental|Chemotherapy + Radiation + Surgery|
11650106|NCT00003118|Active Comparator|Surgery|
11650107|NCT00003117|Experimental|Paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 of each course. Treatment is repeated every 21 days for 6 courses in the absence of tumor progression or unacceptable toxicity. Quality of life assessments are conducted before treatment and at 2, 6, 9, and 12 months. Patients are followed every 3 months for 2 years, then every 6 months until disease progression or death.
11650108|NCT00003117|Experimental|Paclitaxel + Carboplatin|Patients receives paclitaxel as in Arm I, followed by carboplatin IV over 1 hour. Treatment is repeated every 21 days for 6 courses in the absence of tumor progression or unacceptable toxicity. Quality of life assessments are conducted before treatment and at 2, 6, 9, and 12 months. Patients are followed every 3 months for 2 years, then every 6 months until disease progression or death.
11650109|NCT00003095||bone marrow transplant|bone marrow transplant
11650110|NCT00003095||standard chemotherapy|standard chemotherapy
11650111|NCT00002961|Active Comparator|Total body irradiation|Total body irradiation 1200 centigray
11650112|NCT00002961|Active Comparator|Busulfan|Busulfan 16 doses
11650113|NCT00083226|Experimental|Treatment (doxorubicin+bortezomib)|Patients receive doxorubicin IV over 5-15 minutes on days 1 and 8. Patients also receive bortezomib at a dose of 1.3 mg/m^2 IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with no disease progression may continue to receive bortezomib alone in the absence of disease progression or unacceptable toxicity.
11650114|NCT00083174|Other|Exemestane|one 25 mg tablet daily in am
11650115|NCT00083161|Experimental|Oral cyclophosphamide plus standard cisplatin with etoposide|"Etoposide 120 mg/m2 IV Days 1-3 or Etoposide 120 mg/ m2 IV Day1 followed by Etoposide 120 mg/ m2 PO BID Days 2-3
~Cisplatin 60 mg/m2 IV Day 1 Every 21 days x 4 cycles
~Cyclophosphamide 25 mg PO BID Days 8-19 of each cycle"
11650116|NCT00083122|Experimental|Group 1|Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11650117|NCT00083122|Experimental|Group 2|Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11650158|NCT00082277|Experimental|1|High-Risk Fragility Fracture-Open-Label, Non-Comparative Stratum
11650159|NCT00082277|Experimental|2|Moderate-Risk of Fragility Fracture-Randomised, Double-Blind Stratum
11650118|NCT00083109|Experimental|Treatment (suramin and fluorouracil)|"PHASE I: Patients receive suramin IV over 30 minutes and fluorouracil IV on days 1, 8, 15, 22, 29, and 36. Cohorts of 3-6 patients receive escalating doses suramin and fluorouracil until the dose level allowing 10-50 uM of suramin into the patient's blood is determined without 2 or more of 6 patients experiencing dose-limiting toxicity.
~PHASE II: Patients receive suramin and fluorouracil (at the dose level determined in phase I) as in phase I.
~In both phases, courses repeat every 8 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
11650119|NCT00083070|Experimental|Temozolomide Therapy|
11650120|NCT00083031|Experimental|Arm A-Bevacizumab|"Methotrexate- twice daily on predetermined days per each week per cycle
~Cyclophosphamide- oral, daily, predetermined dose
~Bevacizumab- Via IV on predetermined days per cycle"
11650121|NCT00083031|Experimental|Arm B- Without Bevacizumab|"Methotrexate- twice daily on predetermined days per each week per cycle
~Cyclophosphamide- oral, daily, predetermined dose"
11650122|NCT00082966|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of rapid disease progression or unacceptable toxicity.
11650123|NCT00082628|Placebo Comparator|Period I: Placebo|Subjects will receive placebo matched to serostim® as subcutaneous injection daily for a period of 12 weeks.
11650124|NCT00082628|Experimental|Period I: Serostim® 4 mg|Subjects will receive Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight for a period of 12 weeks.
11650125|NCT00082628|Experimental|Period II: Serostim® 4 mg to Placebo|All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive placebo matched to Serostim® on alternate days for 24 weeks in Period II.
11650126|NCT00082628|Experimental|Period II: Serostim® 4 mg to Serostim® 2 mg|All subjects who will be initially randomized to Serostim® 4 mg arm in Period I and will receive Serostim® 2 mg on alternate days for 24 weeks in Period II.
11650127|NCT00082628|Experimental|Period II: Placebo to Placebo/Serostim® 4 mg|All subjects who will be initially randomized to Placebo arm in Period I continue receiving placebo matched to Serostim® on alternate days for 12 weeks followed by Serostim® 4 mg daily 12 weeks.
11650128|NCT00082498|Placebo Comparator|1|Group 1 will receive placebo
11650129|NCT00082498|Experimental|2|Group 2 will receive 5 mg vicriviroc daily
11650130|NCT00082498|Experimental|3|Group 3 will receive 10 mg vicriviroc daily
11650131|NCT00082498|Experimental|4|Group 4 will receive 15 mg vicriviroc daily
11650132|NCT00082485|Active Comparator|1|
11650133|NCT00082485|Placebo Comparator|2|
11650134|NCT00082446|Experimental|E|Subject will receive an SC dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of placebo by scarification.
11650135|NCT00082446|Active Comparator|D|Subject will receive a SC dose of placebo on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
11650136|NCT00082446|Experimental|C|Subject will receive a SC dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
11650137|NCT00082446|Experimental|B|Subjects will receive a SC dose of MVA 5x10^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
11650138|NCT00082446|Experimental|A|Subjects will receive a SC dose of MVA 2x10^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
11650139|NCT00082446|Experimental|F|Subject will receive an IM dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
11650140|NCT00082433|Experimental|A|
11650141|NCT00082433|Active Comparator|B|
11650142|NCT00082381|Experimental|Exenatide Arm|exenatide subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
11650143|NCT00082381|Active Comparator|Insulin Glargine Arm|subcutaneous injection, once daily; forced titration to target blood glucose level
11650144|NCT00002677|Experimental|Arm I|Patients receive oral tributyrin every 8 hours for 3 weeks. Treatment continues every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease may receive additional courses at the discretion of the protocol chairperson. Cohorts of 3-6 patients receive escalating doses of tributyrin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
11650145|NCT00002644|Experimental|Tamoxifen citrate|Tamoxifen citrate 20 mg/day for 5 years
11650146|NCT00002644|Placebo Comparator|Placebo|Placebo 20 mg/day for 5 years
11650147|NCT00002587|Experimental|Arm I|"Patients receive paclitaxel IV over 3 hours on day 1 followed 2-6 hours later by topotecan IV continuously on days 1-14. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of topotecan and paclitaxel until the maximum tolerated dose (MTD) of each drug is determined. The MTD is defined as the highest dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
11650148|NCT00082407|Experimental|Exenatide Arm|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks
11650149|NCT00082407|Active Comparator|Biphasic Insulin Aspart Arm|subcutaneous injection, twice daily; titration to target blood glucose level
11650150|NCT00082368|Experimental|PET (positron emission imaging) Imaging with Tc-94m Sestamibi|PET sestamibi scans followed by tariquidar and repeat imaging
11650151|NCT00082355|Experimental|Alteplase (r-tPA)|Patients with DVT of lower extremity will receive up to 4 treatments low dose (<10 mg/day) intraclot injections of alteplase. Intention is to evaluate safety and efficacy of this treatment, and durability of outcomes (for 6 months)in 25 patients.
11650152|NCT00082342|Active Comparator|real transcranial direct current stimulation (tDCS)|
11650153|NCT00082342|Sham Comparator|sham transcranial direct current stimulation (tDCS)|
11650154|NCT00082329|Experimental|AMD 3100 (Mozobil plerixafor)|Healthy volunteers will be administered AMD 3100 (Mozobil plerixafor) and granulocyte colony stimulating factor (G-CSF) to determine cytokine polarization status of cluster of differentiation (CD 4) T-cells collected by apheresis
11650155|NCT00082290|Experimental|a massage|About 45 minute massage
11650156|NCT00082290|Experimental|visit with a volunteer|45 minute visit
11650157|NCT00082290|Experimental|period of quiet time|45 minutes of quiet time
11650160|NCT00082277|Experimental|3|Low-Risk of Fragility Fracture - Open-Label, Non-Comparative Stratum
11650161|NCT00082238|Experimental|Cystic fibrosis (CF)|
11650162|NCT00082238|Active Comparator|Healthy volunteers|
11650163|NCT00082225|Experimental|EBV specific T cells|"Patients receiving CTLs as therapy for relapsed Lymphoma or who are at high risk for relapse or patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
~A fixed dose of CD45 MAb (400ug/kg over 4 hours daily times 4 given over 2 daily IV infusions) will be used."
11650164|NCT00082212|Experimental|1|400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
11650165|NCT00082199|Active Comparator|A1|
11650166|NCT00082199|Placebo Comparator|A2|
11650167|NCT00082186|Experimental|1|Oral bosentan tablets
11650168|NCT00082173|Experimental|1|INH 300mg/RIF 600mg/PZA 20mg/kg/MOX 400mg/EMB placebo once daily for 8 weeks
11650169|NCT00082173|Placebo Comparator|2|INH 300mg/RIF 600mg/PZA 20mg/kg/MOX placebo/EMB 15-20mg/kg once daily for 8 weeks
11650170|NCT00005988|Experimental|in vitro-treated bone marrow transplantation|"Donor bone marrow will be harvested on Day -2
~Bone Marrow incubated with irradiated recipient cells and anti-B7.1 and anti-B7.2 for 36 hours.
~Bone marrow will be infused intravenously
~Cyclophosphamide will be administered IV once daily
~Total Body Irradiation (TBI) will be delivered per institutional practice
~Methylprednisolone will be administered IV as 4 doses separated by 12 hours,"
11650171|NCT00005594|Experimental|ISIS 2503|All patients will begin treatment at a dose of 6 mg/kg/day of ISIS 2503. ISIS 2503 at the assigned dose will be given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. No drug will be administered during the third week of each treatment cycle.
11650172|NCT00004893|Experimental|IL12 Therapy|Patients begin therapy no sooner than 3 weeks and no later than 6 weeks since last chemotherapy dose. Patients receive interleukin-12 subcutaneously twice a week. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed at least every 3 months for 1 year. If no progression after 1 year, may be followed as needed for new signs or symptoms and survival for 5 years.
11650173|NCT00004893|No Intervention|Observation|Patients are observed for 6 months. If disease progresses during first 6 months, patients may receive interleukin-12 as in arm I. Patients without disease progression within first 6 months may also then receive interleukin-12 as in arm I. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for toxicity only until interleukin-12 is discontinued.
11650174|NCT00004246|Experimental|RT + Fludarabine|Radiotherapy (RT) on Days 1-5 for 7 weeks + Fludarabine IV, 3-4 hours prior to daily RT, Days 1-5 of weeks 6 and 7 of RT
11650175|NCT00004101|Experimental|Arm I|Patients receive monoclonal antibody Hu1D10 IV over 2-4 hours on days 1, 8, 15, and 22. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of monoclonal antibody Hu1D10 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose limiting toxicity. Once the MTD is determined, an additional cohort of 3-6 patients receive Hu1D10 IV over 2-4 hours on days 1-5.
11650176|NCT00003968|Experimental|Arm I|Patients receive bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment continues every 4 weeks in the absence of unacceptable toxicity or disease progresssion.
11650177|NCT00003900|Experimental|irinotecan + docetaxel|Patients receive irinotecan IV over 90 minutes immediately followed by docetaxel IV over 60 minutes on day 1. Treatment is repeated every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 5 years or until death.
11650178|NCT00003849|Experimental|rituximab|Patients receive rituximab IV over 4-6 hours on day 1 weekly for 4 weeks. Patients are followed at 1, 3, 6, 9, and 12 months, then every 6 months for 3 years, then annually thereafter.
11650179|NCT00003726|Experimental|Lepirudin|Dose level 1: 10 mg once daily -> (total dose, 10 mg/d) Dose level 2: 15 mg once daily -> (total dose, 15 mg/d) Dose level 3: 10 mg twice daily -> (total dose, 20 mg/d) Dose level 4: 15 mg twice daily -> (total dose, 30 mg/d) Dose level 5. 20 mg twice daily -> (total dose, 40 mg/d) Dose level 6: 25 mg twice daily -> (total dose, 50 mg/d)
11650180|NCT00003622|Experimental|paclitaxel + vinorelbine|
11650181|NCT00082147|Experimental|Biopsy|Biopsy
11650182|NCT00082095|Experimental|Group 1 (doxorubicin)|Pegylated liposomal doxorubicin 40 mg/m2 administered intravenously on Day 1 of each cycle. Cycle is repeated every 28 days, up to one year.
11650183|NCT00082095|Active Comparator|Group 2 (capecitabine )|Capecitabine administered orally at a dosage of 2000 mg/m2/day (1000 mg/m2 BID) for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
11650184|NCT00003563|Experimental|WBRT|3 Gy of WBRT daily for a total of 10 days
11650185|NCT00003563|Experimental|MGd|IV does of 5.0 mg/kg MGd plus WBRT
11650186|NCT00003276|Experimental|irinotecan|Patients receive a 90 minute continuous infusion of irinotecan on days 1, 8, 15, and 22 for 4 weeks, followed by a 2 week rest period. Courses of treatment are repeated every 42 days. Patients continue treatment in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months for the next 4 years.
11650187|NCT00003239|Experimental|Chemotherapy with Cytarabine + Homoharringtonine|Interferon alfa and cytarabine daily by subcutaneous injection. Homoharringtonine is administered by continuous infusion on days 1-5.
11650188|NCT00003019|Experimental|Chemotherapy Treatment|Patients receive vinblastine sulfate (5 mg/m2) IV and methotrexate (30 mg/m2) IV weekly for 26 weeks, then every 2 weeks for an additional 26 weeks. Treatment continues for a maximum of 1 year in the absence of unacceptable toxicity or disease progression. Patients with a complete response receive an additional 8 doses of chemotherapy. Patients are followed every 6 months for 4 years and then annually thereafter.
11650217|NCT00006463|Experimental|ECTEINASCIDIN 743 (1300 ug/m2)|
11650218|NCT00005849|Experimental|Arm A|Paclitaxel (90 mg/m2, days 1, 8 and 15 of every 28 day cycle), Bryostatin-1 (50 mcg/m2, days 2, 9 and 16 of every 28 day cycle)
11650219|NCT00005842|Experimental|Arm I|Patients receive trastuzumab (Herceptin) IV over 90 minutes on days 1, 8, 15, and 22 plus oral R115777 twice daily for 3 weeks. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R115777 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.
11651066|NCT00071890|Active Comparator|Control group|HAART alone
11650189|NCT00081939|Experimental|Study Treatment|Two cycles of VDTPACE induction (Velcade days 1, 4, 8, and 11; DTPACE days 4-7) with interim thalidomide (50 mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle. Induction followed by single or tandem MEL200 transplant (MEL140 mg/m2 for subjects > 70 years of age) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each transplant. Transplants followed by two cycles of VDTPACE consolidation (Velcade days 1, 4, 8, and 11; DTPACE days 1-4) with interim thalidomide (100mg QD) + Dex (20 mg QD x 4 days every 21 days) following each cycle of VDTPACE. Consolidation followed by 3 years of maintenance therapy with VDT (velcade 1.0 mg/m2 days 1, 4, 8, 11 q 28 days; Thal 100 mg QD; and Dex 20mg days 1-4 and 8-11 q 28 days) during Year 1 and TD (Thal 100 mg QD and Dex 20 mg days 1-4, q 28 days) or VTD (velcade 1.0 mg/m2 weekly, Thal 100 mg QD, and Dex 20 mg weekly) during Years 2 and 3.
11650190|NCT00006483|Experimental|aerosolized sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) by nebulizer over 10-15 minutes twice daily on days 1-7 and 14-21. Treatment repeats every 28 days in the absence of disease progression or unaceptable toxicity.
~Patients are followed for disease progression and then every 3 months thereafter."
11650191|NCT00002939|Experimental|Paclitaxel in combination with Irinotecan|The first study cohort will receive 60 mg/m2 of paclitaxel on cycle days 1, 8, and 15 as a 1 hr infusion. Immediately following paclitaxel, 30 mg/m2 irinotecan will be administered as a 90 minute intravenous infusion. Irinotecan doses will be administered in an identical infusion schedule on days 8 and 15 of each treatment cycle.
11650192|NCT00002912|Experimental|Arm I|Patients undergo induction therapy consisting of etoposide IV and mitoxantrone IV on days 1-5. Patients then receive PSC-833 IV over 124 hours beginning on day 2. A second course is administered no sooner than 21 days from the start of the first course if the marrow is hypocellular after the first course. Patients with persistent disease after 2 induction courses are removed from the study. Patients receive a total of 3 courses of etoposide/mitoxantrone. Patients who achieve complete remission after 1 induction course receive 2 courses of etoposide/mitoxantrone with PSC-833 as consolidation, beginning within 4 weeks of attainment of complete remission. Patients who achieve complete remission after 2 induction courses receive 1 course of etoposide/mitoxantrone with PSC-833 as consolidation. Cohorts of 3-6 patients receive escalating doses of PSC-833 until the maximum tolerated dose is determined. Patients are followed every 6 months.
11650193|NCT00002590|Experimental|Regimen A|See detailed description.
11650194|NCT00082043|Experimental|1|Dutasteride 2.5 mg by mouth daily for one month
11650195|NCT00082043|Placebo Comparator|2|Placebo oral capsule for two months
11650196|NCT00082017|Experimental|UCN-01 for T-cell lymphomas - Cohort 1 - Every 28 days|"Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2
~Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 28 days."
11650197|NCT00082017|Experimental|UCN-01 for T-cell lymphomas - Cohort 2 -Every 21 days|"Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2
~Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 21 days."
11650198|NCT00081900|Experimental|DENSPM|
11650199|NCT00005969|Experimental|Liposomal Tretinoin|Liposome by vein (IV) over 30 minutes every other day for 28 days and Chemotherapy.
11650200|NCT00005796|Experimental|Single arm|PCV therapy
11650201|NCT00004933|Experimental|Homoharringtonine|
11650202|NCT00004933|Active Comparator|Hydroxyurea|
11650203|NCT00004604|Experimental|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
11650204|NCT00003953|Experimental|Doxorubicin and Docetaxel|
11650205|NCT00081887|Experimental|Weekly Clofarabine|
11650206|NCT00081874|Experimental|RAD001|"Phase I: Participants initially treated with 5 mg RAD001 by mouth daily for 28 days.
~Phase II: The MTD (either 5mg or 10mg) administered daily until intolerance or failure or lack of response after 4 cycles of therapy. For assessment purposes, each cycle will comprise a 28-day period."
11650207|NCT00081861|Experimental|Avastin + Rituximab|Avastin 10 mg/kg given intravenously every 2 weeks for 4 doses, and Rituximab 375 mg/m^2 intravenously weekly for 8 doses.
11650208|NCT00003950|Experimental|CPT-11 with Cyclosporine|Each cycle lasts 6 weeks. Administration of cyclosporine and CPT-11 weekly for 4 weeks followed by a 2 week 'rest' period with no drug given. Cyclosporine is given by IV infusion at a dose of 5 mg/kg. CPT-11 is given by IV infusion at a dose of 60 mg/m2.
11650209|NCT00003835|Experimental|Arm I (leucovorin calcium and fluorouracil)|Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV beginning 1 hour into leucovorin calcium infusion weekly for 6 weeks. Treatment is repeated every 8 weeks for 4 courses.
11650210|NCT00003835|Experimental|Arm II (leucovorin calcium, fluorouracil, irinotrcan)|Patients receive irinotecan IV over 90 minutes, followed by leucovorin calcium IV, then followed by fluorouracil IV weekly for 4 weeks. Treatment is repeated every 6 weeks for 5 courses
11650211|NCT00003819|Experimental|vaccine|This is a dose escalation study. Patients receive TF(c)-KLH conjugate with adjuvant QS21 subcutaneously weekly for 3 weeks, then once during weeks 7 and 19. Cohorts of 5 patients each receive escalating doses of TF(c)-KLH vaccine until the optimal dose, based on antibody response, is reached. Patients are followed monthly for 6 months, then every 3 months for 1 year.
11650212|NCT00003783|Experimental|Complete Response and no CNS 3|See detailed description.
11650213|NCT00003783|Experimental|Complete Response and CNS 3|See detailed description.
11650214|NCT00003765|Experimental|Arm I|Patients receive O6-benzylguanine IV over 1 hour, then, 1 hour later, carmustine IV is administered over 1 hour. Treatment is repeated every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each receive escalating doses of carmustine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose level at which fewer than 2 of 6 patients experience dose limiting toxicity (DLT). If myelosuppression is the DLT, stratum 1 is closed and patients are accrued to stratum 2. If neutropenia is the DLT in stratum 2, patients receive filgrastim (G-CSF) subcutaneously beginning on day 2 and continuing until blood counts recover.
11650215|NCT00003270|Experimental|Arm 1|Patients eligible to undergo total body irradiation (TBI) first receive cyclophosphamide IV over 2 hours on days -5 and -4, then undergo TBI twice a day on days -3 to -1. Patients also receive antithymocyte globulin (ATG) IV over 10 hours on days -3 to -1. Cord blood is infused on day 0
11650216|NCT00006463|Experimental|Therapy ECTEINASCIDIN 743 (1100 ug/m2 )|
11650220|NCT00005832|Experimental|R115777|300mg/dose BID, PO, Days 1-21, q 28days
11650221|NCT00002485||Stratum 1|Not Enrolled / No IRB Applied
11650222|NCT00002485||Stratum 2|Not Enrolled / IRB Approved
11650223|NCT00081822|Other|Clofarabine + Ara-C|An initial dose escalation of clofarabine with a fixed standard dose of Ara-C in phase I will be used to determine an optimal phase II dose.
11650224|NCT00005092|Experimental|Chemo, RT + PSCT|Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation
11650225|NCT00003735|Experimental|Stratum 1 - Stage 1|Topotecan hydrochloride (0.8 mg/m²/day) by mouth for 21 days. Bone marrow will be obtained on approximately Day 28 of Course 1 and 2 and in any course where the CBC suggests that a relapse has occurred. One additional course may be given if the blood is cleared of blasts and the bone marrow is M1, M2 or M3. The patient is off protocol therapy if blasts are still present in the blood and the marrow is M3. Subsequent courses of topotecan may be given only if the bone marrow after Course 2 is M1 or M2. If the bone marrow is M2 on Day 28 of any course, another bone marrow aspirate will be done at the end of the next course. If the patient is in CR, a bone marrow aspirate will be required only every other course unless the peripheral blood suggests that a relapse has occurred. Each subsequent course should begin within six weeks of the start of the previous course.
11650226|NCT00003735|Experimental|Stratum 2 - Stage 2|Topotecan hydrochloride (0.8 mg/m²/day) by mouth for 21 days. Bone marrow will be obtained on approximately Day 28 of Course 1 and 2 and in any course where the CBC suggests that a relapse has occurred. One additional course may be given if the blood is cleared of blasts and the bone marrow is M1, M2 or M3. The patient is off protocol therapy if blasts are still present in the blood and the marrow is M3. Subsequent courses of topotecan may be given only if the bone marrow after Course 2 is M1 or M2. If the bone marrow is M2 on Day 28 of any course, another bone marrow aspirate will be done at the end of the next course. If the patient is in CR, a bone marrow aspirate will be required only every other course unless the peripheral blood suggests that a relapse has occurred. Each subsequent course should begin within six weeks of the start of the previous course.
11650227|NCT00003621|Experimental|carmustine + etoposide + cisplatin + radiation therapy|Patients receive carmustine IV over 1 hour on days 1-3, oral etoposide on days 1-21 and 29-49, and cisplatin IV over 1-2 hours on days 1-3 and 29-31. Treatment repeats every 8 weeks for 3 courses. Patients receive radiotherapy concurrently with the third course of chemotherapy. Quality of life is assessed every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients are followed every 3 months for 5 years and then annually thereafter.
11650228|NCT00081770|Experimental|PegIntron 1.5 ug/kg/wk plus REBETOL|PegIntron (peginterferon alfa-2b; SCH 54031) 1.5 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up
11650229|NCT00081770|Experimental|PegIntron 1.0 ug/kg/wk plus REBETOL|PegIntron (peginterferon alfa-2b; SCH 54031) 1.0 ug/kg/week in combination with weight-based REBETOL (ribavirin; SCH 18908) 800-1400 mg/day administered for 48 weeks with 24-week post-treatment follow-up
11650230|NCT00081770|Active Comparator|PEGASYS 180 ug/wk Plus COPEGUS|PEGASYS (peginterferon alfa-2a) 180 ug/week plus COPEGUS (ribavirin) 1000-1200 mg/day administered for 48 weeks with 24-week post-treatment follow-up
11650231|NCT00003018|Experimental|Chemotherapy|dipyridamole: 75mg/dose, PO, Days 1-28 of 5 week cycle; fluorouracil: 200 mg/m^2/day, continuous IV, Days 1-28 of 5 week cycle; leucovorin calcium: 30 mg/m^2/day, IV, Days 1,8,15,22 of 5 week cycle; mitomycin C: 10 mg/m^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
11650232|NCT00002952|Experimental|Arm A|Melan-A peptide loaded PBMCs (sc, q3wk x 3), rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
11650233|NCT00002772|Experimental|High dose chemo|sequential high dose chemotherapy with doxorubicin, paclitaxel and cyclophosphamide with filgrastim support
11650234|NCT00002772|Experimental|chemo with autologous stem cell support|conventional chemotherapy with doxorubicin and cyclophosphamide followed by autologous stem cell support
11650235|NCT00002768|Experimental|Autologous stem cell transplantation|Patients receive consolidation chemotherapy followed by autologous stem cell transplantation
11650236|NCT00002745|Experimental|aminocamptothecin|aminocamptothecin
11650237|NCT00002583|No Intervention|Observation|Observation only
11650238|NCT00002583|Active Comparator|Chemotherapy|Cisplatin and Vinorelbine
11650239|NCT00002501|Experimental|cyclophosphamide + filgrastim|Patients receive cyclophosphamide IV over 90 minutes on day 1 and filgrastim (G-CSF) subcutaneously beginning on day 3 and continuing until blood counts recover. Treatment continues every 2 weeks for 4 courses in the absence of disease progression or stable disease. Patients who achieve complete remission (CR) after completion of course 4 receive 2 additional courses. Patients who achieve partial remission (PR) after completion of course 4 receive 2 additional courses, and those who achieve CR after completion of course 6 receive 2 additional courses. Patients are followed every 2 months for 6 months, every 6 months for 2 years, and then annually thereafter.
11650240|NCT00002463|Experimental|Combination Chemotherapy|Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine
11650241|NCT00081731|Active Comparator|Optimal Medical Therapy|Optimal anti-hypertensive therapy
11650242|NCT00081731|Experimental|Stenting|Stent procedure plus optimal anti-hypertensive therapy
11650243|NCT00081653|Experimental|1|
11650244|NCT00081653|Active Comparator|2|
11650245|NCT00005950|Experimental|Treatment|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11650246|NCT00005828|Experimental|green tea extract|Patients receive oral green tea extract six times daily for 4 months. Patients with a 50% decline in PSA, complete or partial response, or stable disease after 4 months continue treatment in the absence of disease progression or unacceptable toxicity. Patients with disease progression after 4 months receive no further treatment. Patients are followed every 3 months for 5 years or until disease progression. If disease progression, patients are followed every 6 months for 5 years.
11650247|NCT00081588|Experimental|001|TMC114600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
11650278|NCT00005833|Experimental|R115777|R115777, 300mg PO BID on Days 1-21. 1 cycle=28 days.
11650301|NCT00080899|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide twice daily on days 1-7. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
11650302|NCT00080886|Other|Arm 1|
11650248|NCT00005810|Experimental|Estramustine + docetaxel + carboplatin+ filgrastim|Patients receive oral estramustine 3 times daily on days 1-5. Patients receive docetaxel IV over 1 hour followed by carboplatin IV over 1 hour on day 2. Filgrastim (G-CSF) SC is administered beginning on day 6 and continuing until hematopoietic recovery. Treatment continues every 21 days in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for a maximum of 2 years.
11650249|NCT00005080|Experimental|Nelarabine|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive up to 8 courses of therapy.
11650250|NCT00004229|Experimental|Arm I|Patients undergo a biopsy during prestudy and after the second course of treatment. Patients receive endostatin IV daily for 4 weeks. Patients on dose level 1-6 receive endostatin over 20 minutes. Patients on dose level 7 receive endostatin over 40 minutes, with no treatment on day 2 of the first course only. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of endostatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
11650251|NCT00081510|Experimental|Lonafarnib plus Anastrozole|Participants receive lonafarnib 200 mg orally (PO) twice per day (BID) beginning on Day 1 Cycle 1 and continuing until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole 1 mg, PO, once per day (QD) for as long as the participant is receiving lonafarnib
11650252|NCT00081510|Active Comparator|Placebo plus Anastrozole|Participants receive placebo to lonafarnib PO BID beginning on Day 1 Cycle 1 until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole, 1mg PO QD for as long as the participant is receiving placebo
11650253|NCT00081497|Experimental|Fabrazyme 1.0 mg/kg every 2 weeks|This is an open-label extension study to AGAL-008-00 (NCT00074984) and all patients received Fabrazyme treatment.
11650254|NCT00081484|Experimental|1|
11650255|NCT00081484|Active Comparator|2|
11650256|NCT00081471|Experimental|1|
11650257|NCT00081471|Active Comparator|2|
11650258|NCT00081523||Patients|Individuals with known or suspected sickle cell disease
11650259|NCT00004010|Experimental|BEACOPP therapy|"Patients receive 4 cycles of BEACOPP therapy. Drugs utilized in this regimen include Bleomycin (B), Etoposide (E), Doxorubicin (A), Cyclophosphamide (C), Vincristine (O), Prednisone (P) and Procarbazine (P). Each cycle lasts 21 days and is characterized by intravenous pulses of Etoposide (Days 0-2), Doxorubicin (Day 0), Cyclophosphamide (Day 0), Bleomycin (Day 7), Vincristine (Day 7). Seven days of oral procarbazine (Days 0-6) and 14 days of oral prednisone (Days 0-13) are given during each cycle.
~Growth factor support with Filgrastim (G-CSF) is given by subcutaneous injection daily beginning Day 8. Response will then be determined and stratification for further treatment."
11650260|NCT00003954|Experimental|Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)|"CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 15-20 minutes on day -2.
~TRANSPLANTATION: Patients undergo autologous bone marrow or PBSCT on day 0.
~NON-MYELOABLATIVE CONDITIONING REGIMEN: Beginning 40-120 days after autologous transplant, patients undergo TBI on day 0.
~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.
~IMMUNOSUPPRESSION: Patients receive cyclosporine IV BID on days -1 and 0 and PO BID on days 1-80 with taper based on evaluation of disease response and GVHD. Patients also receive mycophenolate mofetil PO BID on days 0-27.
~POST TRANSPLANT DLI: Beginning 4 weeks after immunosuppression, patients achieving persistent or progressive disease may undergo DLI over 30 minutes every 4 weeks for up to 3 treatments."
11650261|NCT00081458|Placebo Comparator|placebo|Placebo injectable subcutaneously daily into the thigh or abdomen
11650262|NCT00081458|Experimental|2|teduglutide 0.05 mg/kg/d
11650263|NCT00081458|Experimental|3|teduglutide 0.1 mg/kg/d
11650264|NCT00003834|Experimental|oxaliplatin + leucovorin + fluorouracil|Patients receive oxaliplatin IV over 2 hours on day 1, then leucovorin calcium IV over 2 hours with fluorouracil IV bolus, followed by fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks. Patients with stable disease continue treatment in the absence of disease progression or unacceptable toxicity or until disease is resectable. Patients who achieve complete response (CR), partial response (PR) with unresectable disease, or PR but are not surgical candidates continue treatment in the absence of disease progression or unacceptable toxicity. Patients who demonstrate a response are treated until best response or until disease is deemed resectable. Patients who achieve a CR or PR and are resected may receive 2 to 4 additional courses of therapy at the discretion of the investigator. Patients are followed every 3 months for 1 year and then every 6 months for 2 years.
11650265|NCT00003824|Experimental|cipro|ciprofloxacin
11650266|NCT00003824|Experimental|ceph|cephalexin
11650267|NCT00003674|Experimental|dalteparin + standard therapy|Patients receive dalteparin by subcutaneous injection once daily plus standard therapy. Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity. Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years. Patients are followed monthly for 1 year, then every 3 months for 2 years.
11650268|NCT00003674|Active Comparator|standard therapy|Patients receive standard therapy alone. Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity. Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years. Patients are followed monthly for 1 year, then every 3 months for 2 years.
11650269|NCT00021398|Experimental|Radiation Therapy, Chemotherapy and Surgery|
11650270|NCT00021151|Experimental|Alemtuzumab|
11650271|NCT00002708|Experimental|Arm 1|Whole brain radiation therapy (WBRT) to 37.5 Gy/15 fractions/2.5 Gy once daily, 5 days/week followed by radiosurgery to all metastases
11650272|NCT00002708|Active Comparator|Arm 2|WBRT to 37.5 Gy/15 fractions/2.5 Gy once daily, 5 days/week
11650273|NCT00081367|Experimental|Cognitive behavioral therapy (CBT) + standard care|Participants will receive ten weekly sessions of treatment plus standard care for suicide prevention.
11650274|NCT00081367|Active Comparator|Standard care alone|Participants will receive standard care for suicide prevention.
11650275|NCT00081328|Experimental|1|Metformin alone
11650276|NCT00081328|Experimental|2|Metformin + Rosiglitazone
11650277|NCT00081328|Experimental|3|Metformin + Lifestyle Program
11650303|NCT00080873|Experimental|Receive Traumeel S|
11650279|NCT00005820|Experimental|nitrocamptothecin|"Patients receive nitrocamptothecin orally daily for 5 consecutive days each week for 3 consecutive weeks. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity.
~Patients are followed every 3 months until evidence of progression or relapse for a maximum of 2 years from the date of registration."
11650280|NCT00005066|Experimental|Arm A|O6-BG as an intravenous infusion (through your vein) over 1 hour followed 1 hour later by BCNU intravenously over 15 minutes. chemotherapy every 6 weeks.
11650281|NCT00081354||Barrett's esophagus|Barrett's esophagus
11650282|NCT00081354||Controls negative for Barrett's esophagus|Controls negative for Barrett's esophagus
11650283|NCT00003692|Experimental|video-assisted surgery|Patients undergo video-assisted thoracic surgery (VATS) lobectomy, which requires 3 small incisions on the side of the chest. The entire anatomic pulmonary lobe is removed, as well as all peribronchial lymph nodes and anterior hilar lymph nodes. If it is not possible to remove the lobe using the VATS approach, then 1 of the incisions is converted to a standard thoracotomy. Patients are followed every 4 months for the first 2 years, and then every 6 months for the next 3 years.
11650284|NCT00081289|Experimental|Neoadjuvant chemoradiation with irinotecan|Patients receive neoadjuvant therapy comprising 45 Gy (1.8 Gy/fx) + 5.4 Gy boost (1.8 Gy/fx) radiation therapy (RT), oral capecitabine 1200mg/m^2/day 5 days/week during RT, and irinotecan 50 mg/m^2 IV for 1 hour days 1, 8, 22, 29. Surgery 4-8 weeks after RT. Postoperative chemotherapy beginning Day 1 postoperatively for nine 14-day cycles(folinic acid 400 mg/m^2 over 2 hours Day 1; 5-fluorouracil bolus 400 mg/m^2 IV push Day 1 plus 2400 mg/m^2 IV continuous infusion over 46 hours, beginning Day 1; and oxaliplatin 85 mg/m^2 IV over 2 hours Day 1) .
11650285|NCT00081289|Experimental|Neoadjuvant chemoradiation with oxaliplatin|Patients receive neoadjuvant therapy comprising 45 Gy (1.8 Gy/fx) + 5.4 Gy boost (1.8 Gy/fx) radiation therapy (RT), oral capecitabine 1650mg/m^2/day 5 days/week during RT, and oxaliplatin 50 mg/m^2 IV for 2 hours days 1, 8, 15, 22, 29. Surgery 4-8 weeks after RT. Postoperative chemotherapy beginning Day 1 postoperatively for nine 14-day cycles(folinic acid 400 mg/m^2 over 2 hours Day 1; 5-fluorouracil bolus 400 mg/m^2 IV push Day 1 plus 2400 mg/m^2 IV continuous infusion over 46 hours, beginning Day 1; and oxaliplatin 85 mg/m^2 IV over 2 hours Day 1) .
11650286|NCT00081276|Experimental|Treatment (triapine and cisplatin)|Patients receive 3-AP IV over 2 hours on days 1-4 and cisplatin IV over 1 hour on days 2 and 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11650287|NCT00081263|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib once daily for 14-18 weeks.
11650288|NCT00081263|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily for 14-18 weeks.
11650289|NCT00081250|Experimental|Arm I|Patients receive oral creatine daily.
11650290|NCT00081250|Placebo Comparator|Arm II|Patients receive oral placebo daily.
11650291|NCT00081224|Experimental|celecoxib + capecitabine + radiation + surgery|"Neoadjuvant chemoradiotherapy: Patients receive oral celecoxib twice daily on days 1-7 and oral capecitabine twice daily on days 1-5. Patients undergo pelvic radiotherapy once daily on days 1-5. Courses repeat weekly for 5.5 weeks.
~Surgery: Patients undergo surgery 4-6 weeks after completion of neoadjuvant chemoradiotherapy.
~Adjuvant chemotherapy: Patients with a curative resection receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 4 courses.
~Treatment continues in the absence of disease progression or unacceptable toxicity.
~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
11650292|NCT00081211|Experimental|Treatment (PV701)|Patients receive intratumoral PV701 once weekly for 3 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of PV701 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 6 evaluable patients are treated at that dose.
11650293|NCT00081159|Experimental|HAT, Doxorubicin, Zoledronate + Strontium chloride|Arm I: Hormonal ablative therapy (HAT) comprising luteinizing hormone-releasing hormone agonist (e.g., leuprolide or goserelin) continuously during study treatment OR bilateral orchiectomy; doxorubicin IV on days 1, 8, and 15 every 28 days for 2 courses; zoledronate IV over 15 minutes on day 1 every 28 days for 6 courses; and a single dose of strontium chloride Sr 89 IV over 1-2 minutes on day 1.
11650294|NCT00081159|Experimental|HAT, Doxorubicin + Zoledronate|Arm II: HAT, doxorubicin, and zoledronate as in arm I. HAT comprising luteinizing hormone-releasing hormone agonist (e.g., leuprolide or goserelin) continuously during study treatment OR bilateral orchiectomy; doxorubicin IV on days 1, 8, and 15 every 28 days for 2 courses; zoledronate IV over 15 minutes on day 1 every 28 days for 6 courses.
11650295|NCT00081094|Other|PET scan (FDG-PET & 11C-acetate-PET)|Patients will undergo routine clinical FDG-PET and research 11C-acetate-PET prior to planned surgical resection of the lesion(s) or explantation of the liver.
11650296|NCT00080990|Experimental|Treatment (alvocidib with oxaliplatin, 5-FU, leucovorin)|"Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, the cohort is expanded and an additional 10 patients are treated at that dose."
11650297|NCT00080951|Experimental|irinotecan + oxaliplatin + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV and fluorouracil IV over 90 minutes on days 2-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
~Quality of life is assessed at baseline, before each chemotherapy course, and at the end of treatment.
~Patients are followed every 3 months until 5 years after registration."
11650298|NCT00080938|Experimental|Temozolomide and Radiation|Temozolomide:administered orally. Radiation: whole brain radiation therapy
11650299|NCT00080912|Experimental|Arm I|Patients receive single-fraction radiotherapy (8 Gy) on day 1.
11650300|NCT00080912|Active Comparator|Arm II|Patients receive multiple-fraction radiotherapy (to a total of 20 Gy) over 5 days or over 8 days if re-irradiation of the spine and/or whole pelvis is involved AND prior initial radiotherapy was given in multiple fractions.
11650304|NCT00080873|Placebo Comparator|Receive placebo|
11650641|NCT00007852|Experimental|Arm I|Rituxan and BEAM with autologous stem cell transplant
11650305|NCT00080847|Experimental|Arm I (closed to accrual as of 9/21/04)|Patients receive rituximab IV over 6 hours, cyclophosphamide IV over 15-45 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 1 and oral prednisone on days 1-5.
11650306|NCT00080847|Experimental|Arm II|Patients receive oblimersen IV continuously on days 1-7; rituximab IV over 6 hours, cyclophosphamide IV over 15-45 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 5; and oral prednisone on days 5-10.
11650307|NCT00080808|Active Comparator|Arm I|Patients undergo unilateral cavernous nerve-sparing radical prostatectomy with unilateral autologous interposition sural nerve grafting.
11650308|NCT00080808|Active Comparator|Arm II (No sural nerve grafting)|Patients undergo unilateral cavernous nerve-sparing radical prostatectomy (without sural nerve grafting) and erectile dysfunction rehabilitation as in arm I.
11650309|NCT00080782|Experimental|Arm I: Celecoxib|Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1, and oral celecoxib twice daily in absence of disease progression.
11650310|NCT00080782|Experimental|Arm II: No Celecoxib|Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1.
11650311|NCT00080756|Experimental|Group 1 (planned risk reduction mastectomy)|Patients receive deslorelin, estradiol, and testosterone intranasally QD for 6 months. Patients then undergo planned risk reduction mastectomy.
11650312|NCT00080756|Active Comparator|Group 2 (continued survaillance)|Patients receive deslorelin, estradiol, and testosterone intranasally QD for 10 months. Patients then undergo continued surveillance through 10 months.
11650313|NCT00080743|Active Comparator|Tamoxifen|Tamoxifen 20 mg po once daily
11650314|NCT00080743|Placebo Comparator|Placebo|Placebo comparator one tablet po once daily
11650315|NCT00080678|Experimental|Docetaxel + Imatinib Mesylate|Docetaxel 30 mg/m^2 intravenous over 60 minutes on days 1, 8, 15, and 22 in 42-day cycles, with daily oral 600 mg imatinib mesylate.
11650316|NCT00080678|Placebo Comparator|Docetaxel + Placebo|Docetaxel 30 mg/m^2 intravenous (IV) over 60 minutes on days 1, 8, 15, and 22 in 42-day cycles, with daily oral placebo.
11650317|NCT00080665|Experimental|Imatinib mesylate and docetaxel|Imatinib mesylate (400-600 mg, oral, once daily) and docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
11650318|NCT00080626|Experimental|Docetaxel|Neoadjuvant therapy with docetaxel (IV, 100 mg/m2, every 14 days with growth factor support with pegfilgrastim) for a total of 4 cycles prior to conventional surgery for breast cancer.
11650319|NCT00080535|Experimental|LMB-2 for cutaneous Tcell lymphoma|30 micrograms/kg every other day (QOD) x 3 every 4 weeks in patients with cutaneous T-cell lymphoma, a group of lymphoproliferative disorders characterized by malignant CD4+ T-lymphocytes which localize tot he skin on initial presentation.
11650320|NCT00080483|Experimental|1|Testosterone transdermally 5 g a day and somatropin subcutaneously 2 µg/kg body weight a day
11650321|NCT00080483|Active Comparator|2|AndroGel transdermally 5 g a day for two years
11650322|NCT00002774|Experimental|Tirapazamine + cisplatin + 5-FU|2 cycles of induction chemotherapy (tirapazamine, cisplatin, and 5-fluorouracil [5-FU]) followed by simultaneous chemoradiotherapy (tirapazamine, cisplatin, and 5-FU)
11650323|NCT00002774|Active Comparator|Cisplatin + 5-FU|2 cycles of induction chemotherapy (cisplatin + 5-fluorouracil [5-FU]) followed by simultaneous chemoradiotherapy (cisplatin + 5-FU)
11650324|NCT00002525|Experimental|Perioperative 5-FU|"Within 24 hours of the colon resection, patients receive perioperative fluorouracil intravenously (IV) over 24 hours for 7 days.
~After surgery (beginning 21-35 days post-surgery), 5-FU was given at a dose of 425 mg/m^2 IV push on days 1-5, and leucovorin calcium was given at a dose of 20mg/m^2 IV push on days 1-5"
11650325|NCT00002525|Active Comparator|No perioperative 5-FU|"Patients receive no perioperative fluorouracil.
~After surgery (beginning 21-35 days post-surgery), 5-FU was given at a dose of 425 mg/m^2 IV push on days 1-5, and leucovorin calcium was given at a dose of 20mg/m^2 IV push on days 1-5"
11650326|NCT00002494|Experimental|Combination therapy|Patients receive combination therapy as described in the study description. All patients must complete at least the first 3 courses of chemotherapy. Courses 2 and 3 each repeat 3 times in the absence of disease progression or unacceptable toxicity. On days 134-139, patients who have had prior bone marrow involvement receive cranial radiation therapy. Patients who achieve less than a complete response and who have an HLA-matched sibling should undergo allogeneic bone marrow transplant on protocol CLB-9113. Patients are followed monthly for 6 months, every 2 months for 18 months, every 6 months for 2 years, and thereafter for survival.
11650327|NCT00080470|Experimental|1|Stimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on.
11650328|NCT00080470|Sham Comparator|2|No Stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on.
11650329|NCT00080444|Experimental|Part 1: Aprepitant|Day 1: aprepitant 125 mg orally (PO), ondansetron 0.15 mg/kg x 3 doses intravenously (IV), dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For 1 cycle and up to 9 subsequent optional cycles.
11650330|NCT00080444|Active Comparator|Part 1: Standard Therapy|Day 1: placebo to aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 16 mg PO. Day 2: placebo to aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 3: placebo for aprepitant 80 mg PO, dexamethasone 8 mg PO. Day 4: dexamethasone 8 mg PO. For 1 cycle; participants may receive open-label aprepitant for up to 9 subsequent optional cycles.
11650331|NCT00080444|Active Comparator|Part 2: Aprepitant|Day 1: aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For up to 10 cycles.
11650332|NCT00007813|Experimental|Arm 1|
11650333|NCT00006487|Active Comparator|chemo/RT with tirapazamine|induction and consolidation: cisplatin, etoposide, tirapazamine, radiation therapy
11650393|NCT00079820|Experimental|A|MVA3000 Smallpox vaccine (1x10-8) with Dryvax Challenge at Day 112
11650394|NCT00079820|Experimental|B|MVA3000 Smallpox vaccine (1x10-8) with no Challenge
11650395|NCT00079820|Placebo Comparator|C|Placebo
11650396|NCT00079820|Experimental|D|MVA3000 Smallpox vaccine (1x10-7) with Dryvax challenge at Day 112
11650334|NCT00006371|Active Comparator|Hydrocortisone with Ketoconazole|Patients are stratified according to prior antiandrogen therapy (yes vs no). Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen withdrawal, while those without such prior therapy begin study therapy immediately. Patients undergo medical adrenalectomy using hydrocortisone combined with ketoconazole. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral ketoconazole is administered three times daily.
11650335|NCT00006371|Active Comparator|Hydrocortisone with Aminoglutethimide|Patients are stratified according to prior antiandrogen therapy (yes vs no). Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen withdrawal, while those without such prior therapy begin study therapy immediately. Patients undergo medical adrenalectomy using hydrocortisone combined with aminoglutethimide. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral ketoconazole is administered three times daily.
11650336|NCT00006031|Active Comparator|I: Radioactive Seed Localized Breast Biopsy|Arm I: Patients undergo radiographic placement of a radioactive seed (either iodine I 125 or palladium Pd 103) into the suspicious lesion. Patients then undergo surgery to remove the lesion along with the seed and a small margin of surrounding breast tissue followed 3 months later by a postoperative mammogram.
11650337|NCT00006031|Active Comparator|Arm II: Needle Localized Breast Biopsy|Arm II: Patients undergo a needle localized breast biopsy with a specimen x-ray.
11650338|NCT00005799|Experimental|Treatment (chemotherapy, TBI, HSCT)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.
~TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplantation on day 0.
~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO BID on days 0-40 with taper to day 96. Patients with mixed chimerism, persistent or progressive disease, and no evidence of graft-versus-host disease and who have been off immunosuppression for at least 2 weeks undergo DLI over 30 minutes. DLI may be repeated every 65 days for up to 3 doses."
11650339|NCT00005798|Other|CTC Conditioning Regimen|Cyclophosphamide Thiotepa Carboplatin
11650340|NCT00005615|Experimental|Interferon Alfa Plus Radiation|"Combined Therapy: interferon alfa plus radiation therapy.
~Patients receive interferon alfa IV over 20 minutes daily for 5 consecutive days a week for 4 weeks. Patients then receive radiotherapy on days 2 and 4 and interferon alfa subcutaneously (SQ) on days 1, 3, and 5 for 2.5 weeks. Interferon alfa SQ continues 3 times a week for 10 months in the absence of disease progression or unacceptable toxicity. Patients are followed every month for 3 months, then every 3 months for 2 years, then every six months until year 5, and then annually thereafter."
11650341|NCT00005577|Experimental|Arm I|Patients receive gemcitabine IV over 30 minutes weekly for 2 weeks. Patients achieving objective response or stable disease after 3 weeks may receive additional courses of therapy every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity.
11650342|NCT00005097|Experimental|Polyphenon E & Placebo|"Each subject will receive both the Polyphenon E and placebo, one on each arm.
~One arm will be assigned to be treated with topical Polyphenon E daily for 12 weeks and the other with placebo vehicle in a random, double blind manner daily for 12 weeks."
11650343|NCT00003657|Experimental|High Dose ICF with Amifostine|"Patients undergo peripheral blood stem cell transplantation (PBSC) harvest on day -8,
~ifosfamide IV, carboplatin IV etoposide IV (ICE) by 96 hour continuous infusion on days -7 to -4.
~Patients receive amifostine IV twice a day on days -7 to -3.
~PBSCs are reinfused on day 0.
~Filgrastim (G-CSF) is administered subcutaneously beginning on day 0 at least 2 hours after infusion of the stem cells and continuing until blood cell counts recover.
~Patients are followed monthly for the first 2 months and then for survival."
11650344|NCT00080327|Active Comparator|1|
11650345|NCT00080327|Active Comparator|2|
11650346|NCT00080327|Active Comparator|3|
11650347|NCT00080327|Placebo Comparator|4|
11650348|NCT00080314|Active Comparator|A1|
11650349|NCT00080314|Placebo Comparator|A2|
11650350|NCT00080301|Experimental|A|
11650351|NCT00080301|Active Comparator|B|
11650352|NCT00003192|Experimental|Arm A|9-aminocamptothecin (25 mcg/m2/hr x 120hrs, days 1-5 and 8-12 of each 3 week cycle)
11650353|NCT00003157|Experimental|radiation + gemcitabine + cisplatin|Patients undergo radiotherapy to the tumor and lymph nodes, followed by a decrease in radiotherapy to the tumor alone. Radiation therapy is administered for a total of 5.5 weeks. Patients receive intravenous gemcitabine twice weekly over the first 3 weeks of radiotherapy. Cisplatin is administered intravenously twice weekly following gemcitabine therapy. Three patients are treated at each dose level. Dose escalation does not occur until all patients at a given dose level have completed radiotherapy and returned for a 4 week follow up. Patients exhibiting stable disease remain on therapy until disease progression or intolerable toxic effects. Patients experiencing toxic effects and no disease progression are retreated at a lower dose. Patients are followed every 3 months for the first 2 years then every 6 months for the next year.
11650354|NCT00080288|Experimental|1|Armodafinil 150 mg/day
11650355|NCT00080288|Placebo Comparator|2|Placebo
11650356|NCT00080262|Experimental|1|
11650357|NCT00080236|Placebo Comparator|Donor organ placebo and Recipient placebo|
11650358|NCT00080236|Active Comparator|Donor organ: IDN-6556 (15μg/ml), Recipient: Placebo|
11650359|NCT00080236|Active Comparator|Donor organ: IDN-6556 (5 μg/ml), Recipient: IDN-6556 0.5 mg/kg|
11650360|NCT00080236|Active Comparator|Donor organ: IDN-6556(15 μg/ml), Recipient: IDN-6556 0.5 mg/kg|
11650361|NCT00080223|Experimental|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
11650362|NCT00002759|Experimental|Arm I|See detailed description.
11650363|NCT00002540|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
11650397|NCT00079820|Experimental|E|MVA3000 Smallpox vaccine (1x10-6) with Dryvax challenge at Day 112
11650434|NCT00079456|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11650364|NCT00002540|Active Comparator|Prostate Screening|Participants undergo blood sample collection for PSA analysis at baseline and annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo a DRE at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident prostate cancers as all deaths that occur among both screened and control subjects during the trial.
11650365|NCT00080145|Active Comparator|risperidone plus parent management training|
11650366|NCT00080145|Active Comparator|risperidone only|
11650367|NCT00080119|Experimental|HIVneg/INH|Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid (INH)10-20 mg/kg orally once a day for 96 weeks + Trimethoprim/Sulfamethoxazole (TMP/SMX) 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding
11650368|NCT00080119|Placebo Comparator|HIVneg/PL|Perinatally exposed, HIV-uninfected (HIVneg) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until HIV status is confirmed and child is no longer at risk of acquiring HIV through breastfeeding
11650369|NCT00080119|Experimental|HIVpos/INH|HIV-infected (HIVpos) children receiving Isoniazid (INH) 10-20 mg/kg orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.
11650370|NCT00080119|Placebo Comparator|HIVpos/PL|HIV-infected (HIVpos) children receiving Isoniazid placebo (PL) orally once a day for 96 weeks + TMP/SMX 5 mg/kg of TMP component orally once a day until one year of age. TMP/SMX may have been continued after one year of age according to WHO guidelines.
11650371|NCT00080106|Experimental|1|Participants in the experimental arm will receive the MRK Ad5 HIV-1 gag vaccine on Day 1, Week 4 and Week 26. Participants will take their antiretroviral medications during the first 3 months of the study.
11650372|NCT00080106|Placebo Comparator|2|Participants in Arm 2 will receive a placebo vaccine on Day 1, Week 4 and Week 26. Participants will take their antiretroviral medications during the first 3 months of the study.
11650373|NCT00008320|Experimental|ceramide cream|Topical ceramide cream is applied to all cutaneous lesions twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then at 1 and 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
11650374|NCT00006348|Experimental|Arm 1: ondansetron + placebo|Patients receive oral ondansetron twice daily on days 1-7 and oral placebo twice daily on days 8-14 in the absence of unacceptable toxicity.
11650375|NCT00006348|Experimental|Arm 2: ondansetron + placebo|Patients receive oral placebo twice daily on days 1-7 and oral ondansetron twice daily on days 8-14 in the absence of unacceptable toxicity.
11650376|NCT00080093|Experimental|1|Participants will receive individual feedback and specially-tailored manuals at study entry and at Months 2 and 4
11650377|NCT00080093|Experimental|2|Participants will receive general HIV information feedback and the best-available informational manual at study entry and at Months 2 and 4
11650378|NCT00005972|Experimental|gemcitabine + irinotecan|Patients are stratified according to prior response duration (progression 90 days or more after initial therapy vs progression less than 90 days after initial therapy or no response to initial therapy). Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1 and 8. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months for 2 years, and then annually for 3 years.
11650379|NCT00004123|Experimental|RT + DOX + IORT|Preoperative external beam radiotherapy (RT) combined with doxorubicin (DOX) and followed by intraoperative radiotherapy (IORT); dose-escalation study of external beam radiotherapy.
11650380|NCT00003693|Experimental|MTD Group|
11650381|NCT00079963|Experimental|X|Vitamin C
11650382|NCT00079963|Experimental|Y|Vitamin E
11650383|NCT00079963|Placebo Comparator|Z|Placebo
11650384|NCT00079937|Experimental|Omalizumab|Participants received omalizumab administered by subcutaneous injection every 2 or 4 weeks for a duration of 52 weeks. The omalizumab dose was based on the patient's body weight and total serum IgE level at Screening. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks.
11650385|NCT00079937|Placebo Comparator|Placebo|Placebo was administered by subcutaneous injection every 2 or 4 weeks depending on the dosing schedule in the protocol for a total of 52 weeks. The first 24 weeks of the treatment period was a fixed steroid phase where the steroid dose was maintained constant; in the following 28 weeks the steroid dose was adjustable, depending on the patient's condition. Following the 52-week treatment period, patients were followed up for an additional 16 weeks.
11650386|NCT00079911|Experimental|Suppressive + Episodic Therapy|Valaciclovir (VAL) 500mg twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 days or 10 days, when required for treatment of a genital herpes recurrence.
11650387|NCT00079911|Placebo Comparator|Episodic Therapy|Matching placebo twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 or 10 days, when required for treatment of a genital herpes recurrence.
11650388|NCT00022165|Placebo Comparator|Placebo|Selenium yeast
11650389|NCT00022165|Experimental|Selenium yeast 100 micrograms per day|100 micrograms per day
11650390|NCT00022165|Experimental|Selenium yeast 200 micrograms per day|200 micrograms per day
11650391|NCT00022165|Experimental|Selenium yeast 300 micrograms per day|300 micrograms per day
11650392|NCT00003166|Experimental|Treatment (bryostatin 1, vincristine sulfate)|"Patients receive bryostatin 1 IV over 24 hours followed immediately by vincristine IV. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy may receive subsequent courses every 3 weeks and then every 4 weeks after 24 months of treatment. Patients may return to a 2- or 3-week treatment course at the discretion of the principal investigator.
~Cohorts of 3 patients receive escalating doses of bryostatin 1 until the MTD is determined. The MTD is defined as the dose preceding that at which at least 1 of 3 patients experience dose-limiting toxicity."
11650398|NCT00009737|Experimental|Capecitabine|Participants received capecitabine 1250 milligram per square meter (mg/m ^ 2) orally, twice a day, for 14 days, followed by a 7-day rest period without treatment, as an intermittent therapy in a 3-week cycle for 8 cycles (24 weeks).
11650399|NCT00009737|Active Comparator|5-Fluorouracil + Leucovorin|Participants received leucovorin 20 mg/m ^ 2 followed by 5-fluorouracil at 425 mg/m ^ 2, by rapid intravenous injection, daily, from Days 1 to 5 of the first week in each 4-week cycle for 6 cycles (24 weeks).
11650400|NCT00006708|Active Comparator|ICE Chemotherapy|Etoposide 100 mg/m2 IV Days 1-3 Carboplatin AUC=5 IV Day 2 Ifosfamide 5 g/m2 IV Day 2 Mesna 5 g/m2 IV Day 2 Filgrastim 5ug/kg/day SQ Days 5-12 Q 21 days x 3 cycles
11650401|NCT00006708|Experimental|Rituximab-ICE Chemotherapy|Etoposide 100 mg/m2 IV Days 2-4 Carboplatin AUC=5 IV Day 3 Ifosfamide 5 g/m2 IV Day 3 Mesna 5 g/m2 IV Day 3 Filgrastim 5ug/kg/day SQ Days 6-13 Q 21 days x 3 cycles Rituximab 375 mg/m2 IV Days 1 and 8 Cycle 1 Rituximab 375 mg/m2 IV Day 1 Cycles 2-3
11650402|NCT00079781|Active Comparator|Treatment Group|Group of subjects who have undergone RNS® System implantation who are randomized to receive RNS® System responsive stimulation (i.e. responsive stimulation enabled or turned ON) during the blinded Evaluation Period. Stimulation is enabled during the first month post-implant and may continue throughout the subject's participation in the study.
11650403|NCT00079781|Sham Comparator|Sham Group|Group of subjects that have undergone RNS® System implantation that are randomized to receive sham-stimulation (i.e. responsive stimulation disabled or turned OFF) during the blinded Evaluation Period. Stimulation is enabled after transition into the Follow-Up Period (5th month post-implant) and may continue for the remainder of the subject's participation in the study.
11650404|NCT00079781|Other|Open Label Group|Group of subjects who have undergone RNS® System implantation who were not randomized or blinded to therapy status during the Evaluation Period. Stimulation may have been enabled during the first month post-implant and may have continued throughout the subject's participation in the study.
11650405|NCT00079716|Experimental|1|
11650406|NCT00005866|Experimental|treatment|
11650407|NCT00005834|Experimental|chemo with thalidomide|chemo with thalidomide
11650408|NCT00005834|Active Comparator|chemo without thalidomide|chemo without thalidomide
11650409|NCT00005085|Experimental|Arm I|Patients receive rebeccamycin analogue IV once on day 1. Treatment repeats every 21 days for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
11650410|NCT00005037|Experimental|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
11650411|NCT00004909||Oral chemotherapy|
11650412|NCT00004909||Parenteral chemotherapy|
11650413|NCT00004163|Experimental|Trastuzumab|"Trastuzumab is administered intravenously weekly
~CAT or MRI scans will be performed every 2 cycles"
11650414|NCT00004142|Experimental|Radiofrequency Ablation + HAI of Floxuridine/5-FU|Radiofrequency Ablation Combined With Post-Ablation Hepatic Arterial Infusion (HAI) of Floxuridine Alternating With 5-Fluorouracil (5-FU)
11650415|NCT00004109|Experimental|Doxorubicin + External-Beam RT|
11650416|NCT00003779|Active Comparator|BCG-Connaught|
11650417|NCT00003779|Active Comparator|BCG Onko-Tice|
11650418|NCT00003704|Experimental|capecitabine + radiation|This is a dose-escalation study of capecitabine. Patients receive oral capecitabine twice a day 7 days a week for 6 weeks with concurrent radiotherapy. Radiotherapy is initiated on the same day as the initiation of capecitabine and is administered 5 days a week for 5.5-6 weeks. Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose-limiting toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 1 year.
11650419|NCT00079677|Experimental|1|Armodafinil 150 mg/day
11650420|NCT00079677|Placebo Comparator|2|Placebo
11650421|NCT00079612|Experimental|Arm 1|
11650422|NCT00079612|Placebo Comparator|Arm 2|
11650423|NCT00079586|Active Comparator|Heparin|unfractionated heparin will be administered as per institutional practice
11650424|NCT00079586|Experimental|Angiomax|1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
11650425|NCT00016978|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and leucovorin calcium and fluorouracil IV on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a confirmed complete response for 2 consecutive courses may discontinue study treatment at the investigators discretion. Quality of life is assessed at baseline, approximately every 6-8 weeks during treatment, and then after the last course of treatment.
11650426|NCT00002601|Experimental|Doxorubicin/Ifosfamide + Melphalan/CDDP + PSCT|"Cycle 1 Day -8 through Day -4 (96h) Doxorubicin 150 mg/m2 (CI) + Ifosfamide 14 g/m2 mixed with mesna (CI) Day -3 Mesna 3.5 g/m2 over 24 h Day -2 12.5% of stem cell reinfused.
~Cycle2 Day -11 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -10 thru Day -6 G-CSF 5ug/kg Day -4 Melphalan 75 mg/m2 + Cisplatin 100 mg/m2 Day -3 12.5% if stem cell reinfused Day 0 37.5% of stem cell reinfused"
11650427|NCT00002537|Experimental|Arm I|Beginning on day 1, patients receive topotecan IV continuously for 3-6 weeks and thoracic radiotherapy 5 days a week for 2, 3, or 6 weeks. Cohorts of 4-6 patients receive escalating doses of topotecan and thoracic radiotherapy until the maximum tolerated dose (MTD) of each therapy is determined. The MTD is defined as the dose preceding that at which 2 of 4 or 6 patients experience dose-limiting toxicity. Six additional patients are treated at the MTD. Patients who fail to achieve complete remission (CR) and continue to have measurable disease at 4-6 weeks after completion of radiotherapy receive topotecan IV continuously on days 1-21 at 1 dose level preceding the MTD as determined by the ongoing Protocol NYU-9123. Treatment continues every 4 weeks in the absence of unacceptable toxicity.
11650428|NCT00079599|Experimental|1|
11650429|NCT00079599|Placebo Comparator|2|
11650430|NCT00079547|Active Comparator|1|Low-calorie diet
11650431|NCT00079547|Experimental|2|Low-carbohydrate diet
11650432|NCT00079482|Active Comparator|1|Induction chemotherapy with or without sequential treatment with oral CEP-701 at 80 mg bid. For patients with duration of first CR of 1 to 6 months, the induction regimen will be MEC.
11650433|NCT00079482|Active Comparator|2|Induction chemotherapy with or without sequential treatment with oral CEP-701 at 80 mg bid. For patients with duration of first CR of more than 6 months to 24 months, the induction regimen will be HiDAC.
11650435|NCT00079443|Experimental|Treatment|"PHASE II: Patients receive FR901228 IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
~Patients who achieve a complete or partial remission receive 2 additional courses (for a total of 6 courses). Patients with stable disease after 4 courses or progressive disease at any time after 2 courses proceed to the phase I portion of the study.
~PHASE I: Patients receive rituximab IV over approximately 4-8 hours on day 1; fludarabine IV over 10-30 minutes on days 2-4; and FR901228 IV over 4 hours on days 2, 9, and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
11650436|NCT00079430|Experimental|Treatment (adjuvant, paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours followed by intraperitoneal carboplatin over 15 minutes on day 1 in course 1. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11650437|NCT00079417|Experimental|Vincristine Sulfate and Carboplatin and surgery|Patients receive chemoreduction comprising carboplatin IV (Pts < 36 months: 18.6 mg/kg Pts ≥ 36 months: 560 mg/m2) over 60 minutes followed by vincristine sulfate IV (Pts < 36 months: 0.05 mg/kg Pts ≥36 months: 1.5 mg/m2) over 1-2 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the first course of chemoreduction, patients undergo standardized local ophthalmic therapy comprising local infrared laser therapy, cryosurgery, and/or radiation therapy (radioactive) plaque comprising iodine I 125 or ruthenium Ru 106.
11650438|NCT00079404|Experimental|Arm I|Patients with solid tumors receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 60-120 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
11650439|NCT00079391|Experimental|allogeneic hematopoietic SCT|allogeneic hematopoietic stem cell transplantation (SCT) using Nexell Isolex system
11650440|NCT00079378|Experimental|Treatment (decitabine, valproic acid)|"Patients receive decitabine IV over 1 hour on days 1-5 or 1-10. Treatment repeats every 28 days.
~Cohorts of 6 patients receive escalating doses of decitabine until the MEPD is determined. The MEPD is defined as the dose at which at least 5 of 6 patients meet gene methylation criteria and no more than 1 of 6 patients experiences DLT.
~Once the MEPD is determined, patients receive decitabine at that dose level administered as above and oral valproic acid three times daily on days 5-21. Treatment repeats every 28 days.
~Cohorts of 3-6 patients receive escalating doses of valproic acid until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. The MEPD of valproic acid is then determined using established gene methylation and toxicity criteria. Treatment continues for up to 24 months in the absence of disease progression or unacceptable toxicity."
11650441|NCT00079352|Experimental|Treatment (gemcitabine, irinotecan, alvocidib)|Patients receive gemcitabine IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1 and 15. Patients also receive flavopiridol IV over 60 minutes on days 2 and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11650442|NCT00079339|Experimental|Treatment (radiation therapy and tipifarnib)|"PHASE I: Patients undergo radiotherapy 5 days a week for 6 weeks. Beginning 0-2 days before radiotherapy, patients receive oral tipifarnib twice daily until the completion of radiotherapy. Beginning 2 weeks after the completion of radiotherapy, patients receive oral tipifarnib twice daily in weeks 1-3. Treatment repeats every 4 weeks for up to 24 additional courses (total of 26 courses) in the absence of disease progression or unacceptable toxicity.
~PHASE II: Patients undergo radiotherapy and receive tipifarnib at the MTD as in phase I (closed to accrual as of 1/19/06). Treatment continues for up to 24 months (26 courses) in the absence of disease progression or unacceptable toxicity."
11650443|NCT00079326|Experimental|Treatment (trastuzumab, ixabepilone)|Patients receive trastuzumab IV over 30-90 minutes and ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11650444|NCT00079274|Experimental|Arm A (combination chemotherapy)|Patients received oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46-48 hours on days 1. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
11650445|NCT00079274|Experimental|Arm B (combination chemotherapy)|Patients received irinotecan IV over 2 hours on day 1 and leucovorin calcium and fluorouracil as in arm A. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
11650446|NCT00079274|Experimental|Arm C (combination chemotherapy)|Patients received the same treatment as in arm A for 6 courses followed by the same treatment as in arm B for 6 courses (total of 12 courses). Treatment continues in the absence of unacceptable toxicity or recurrent disease.
11650447|NCT00079274|Experimental|Arm D (combination chemotherapy, monoclonal antibody)|Patients received cetuximab IV over 1 hour on days 1 and 8 and oxaliplatin, leucovorin calcium, and fluorouracil as in arm A. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
11650448|NCT00079274|Experimental|Arm E (combination chemotherapy, monoclonal antibody)|Patients received cetuximab as in arm D and irinotecan, leucovorin calcium, and fluorouracil as in arm B. Treatment repeated every 14 days for up to 12 courses in the absence of unacceptable toxicity or recurrent disease.
11650449|NCT00079274|Experimental|Arm F (combination chemotherapy, monoclonal antibody)|Patients received cetuximab as in arm D and chemotherapy as in arm C.
11650450|NCT00079274|Other|Arm G (Locally directed therapy)|Patients determined to have mutated KRAS (or KRAS not evaluable) were assigned to an event monitoring arm in which adjuvant therapy was determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification was the responsibility of the treating oncologists.
11650451|NCT00079235|Experimental|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22.
11650452|NCT00079183|Experimental|Sirolimus|Study participants receive sirolimus added once daily to their baseline combination therapy of prednisone plus either cyclosporine or tacrolimus at the discretion of the managing physician. Treatment other than cyclosporine (or tacrolimus) and prednisone must be discontinued when administration of sirolimus is started. Topical therapy, including psoralen and UVA irradiation (PUVA), glucocorticoid creams, topical tacrolimus, oral beclomethasone, topical azathioprine and ophthalmic glucocorticoids may be given at the discretion of the managing physician in consultation with the transplant center.
11650453|NCT00079131|Experimental|Treatment (oblimersen sodium)|Patients receive oblimersen IV continuously on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11650454|NCT00079118|Experimental|docetaxel + irinotecan|"Patients receive docetaxel IV over 1 hour followed by irinotecan IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses beyond CR.
~Patients are followed every 2 months until disease progression and then every 6 months thereafter."
11650455|NCT00079105|Active Comparator|Treatment|Treatment with VEPEMB - Vinblastine sulfate, Cyclophosphamide, Procarbazine hydrochloride, Prednisolone, Etoposide, Mitoxantrone hydrochloride, and Bleomycin sulfate
11650456|NCT00079105|No Intervention|Registration|Registration, without treatment
11650457|NCT00079040|Experimental|Treatment (cisplatin, etoposide, bevacizumab)|"Chemotherapy: Patients receive cisplatin IV over 30-60 minutes on day 1 and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
~Bevacizumab therapy: Beginning concurrently with chemotherapy, patients receive bevacizumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 17 courses (1 year) in the absence of disease progression or unacceptable toxicity."
11650458|NCT00079014|Experimental|Treatment (triapine, doxorubicin hydrochloride)|"Patients receive doxorubicin IV over 15 minutes on day 1 and 3-AP (Triapine®) IV over 2 hours on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of 3-AP (Triapine®) until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6 patients are treated at that dose level."
11650459|NCT00079001|Experimental|Zoledronic acid + androgen deprivation therapy|4mg by IV over 15 minutes every 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progression on blinded treatment before having a skeletal event may continue on open label Zoledronic acid (4 mg by IV over 15 minutes every 3 weeks).
11650460|NCT00079001|Active Comparator|Placebo + androgen deprivation therapy|Placebo bu IV over 15 minutes for 4 weeks in the absence of disease progression or the first skeletal-related event. Participants who progress on blinded treatment before having a skeletal event may continue on open label Zoledronic acid.
11650461|NCT00078988|Experimental|Arm I (high-dose chemotherapy and ASCR)|Patients receive high-dose chemotherapy comprising carboplatin IV over 4 hours on days -8 to -6; thiotepa IV over 3 hours and etoposide IV over 3 hours on days -5 to -3; and filgrastim (G-CSF) IV or SC once daily beginning on day 1 and continuing until blood counts recover. Autologous PBSC or bone marrow are reinfused on day 0.
11650462|NCT00078988|Experimental|Arm II (intermediate-dose chemotherapy and ASCR)|Patients receive intermediate-dose chemotherapy comprising carboplatin IV over 4 hours and thiotepa IV over 3 hours on days 1-2 and G-CSF IV or SC once daily beginning on day 4 and continuing until blood counts recover. Autologous PBSC or bone marrow are reinfused on day 3. Treatment repeats every 28 days for a total of 3 courses.
11650463|NCT00078988|Experimental|Arm III (isotretinoin)|Patients receive oral isotretinoin twice daily on days 1-14. Treatment repeats every 28 days for a total of 6 courses.
11650464|NCT00078988|No Intervention|Arm IV (no isotretinoin)|Patients do not receive maintenance therapy.
11650465|NCT00078975|Experimental|Triapine in combination with Gemcitabine|
11650466|NCT00078962|Experimental|Treatment (GTI-2040, gemcitabine hydrochloride)|"Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose."
11650467|NCT00078949|Experimental|Salvage arm I|Patients receive cisplatin IV over 60 minutes on day 1, dexamethasone IV or orally on days 1-4, and gemcitabine IV over 30 minutes on days 1 and 8.
11650468|NCT00078949|Experimental|Salvage arm II|Patients receive cisplatin IV over 24 hours on day 1, dexamethasone as in arm I, and cytarabine IV over 3 hours every 12 hours for a total of 2 doses on day 2.
11650469|NCT00078949|Experimental|Maintenance arm I|Beginning on day 28 posttransplantation, patients receive rituximab IV once every 2 months for 6 doses (a total of 12 months) in the absence of disease progression or unacceptable toxicity.
11650470|NCT00078949|No Intervention|Maintenance arm II|Patients undergo observation only.
11650471|NCT00078923|Experimental|Placebo|Arm I (control group): Patients receive 4 placebo capsules by mouth daily for three weeks.
11650472|NCT00078923|Experimental|Soy isoflavones and placebo|Arm II: Patients receive oral soy isoflavones (PTI G-2535) 150 mg genistein capsules + 3 placebo capsules by mouth daily for 3 weeks.
11650473|NCT00078923|Experimental|Soy Isoflavones/Placebo|Arm III: Patients receive oral soy isoflavones (PTI G-2535) 300 mg genistein capsules + 2 placebo capsules by mouth daily for 3 weeks.
11650474|NCT00078923|Experimental|Soy Isoflavones|Arm IV: Arm III: Patients receive oral soy isoflavones (PTI G-2535) 600 mg genistein capsules by mouth daily for 3 weeks.
11650475|NCT00078897|Active Comparator|Selenium|Participants receive oral selenium 200 mcg once daily.
11650476|NCT00078897|Placebo Comparator|Placebo|Participants receive oral placebo once daily.
11650477|NCT00078858|Experimental|Treatment (prolonged MMF and truncated CSP)|"CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2, and undergo TBI on day 0.
~TRANSPLANTATION: Patients undergo allogeneic PBMC transplant on day 0.
~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 150 and mycophenolate mofetil PO or IV TID on days 0-30, BID on days 31-150, and then taper to day 180. Treatment continues in the absence of unacceptable toxicity."
11650478|NCT00078845|Experimental|Amifostine|500 mg subcutaneous three times a week on Monday, Wednesday and Friday for 4 weeks.
11650479|NCT00078832|Experimental|anastrozole|anastrozole 1mg
11650480|NCT00078832|Placebo Comparator|placebo|anastrozole 1mg PLACEBO
11650538|NCT00078442|Experimental|1|Participants will receive weekly injections of 180 mcg PEG-IFN alfa-2a at the clinic for 12 weeks. After Week 12, participants will be followed off-treatment until Week 18.
11650481|NCT00078819|Placebo Comparator|Placebo|"Participants received placebo administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a > 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.
~Participants received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36).
~At week 36, participants with PASI 50 at week 24 or PASI 75 at week 36 were re-randomized to placebo or etanercept in the 12-week double-blind, withdrawal-retreatment period (weeks 37 to 48)."
11650482|NCT00078819|Experimental|Etanercept|"Participants received 0.8 mg/kg etanercept administered by subcutaneous injection once a week during the 12-week, double-blind, placebo-controlled treatment period (day 1 to week 12). Participants with a > 50% worsening (ie, increase) in Psoriasis Area and Severity Index (PASI) score at or after week 4 compared with baseline and an increase of at least 4 points at 1 visit, or an increase of more than 25% and by a minimum of 4 points at each of two consecutive visits, could escape to etanercept 0.8 mg/kg once a week up to week 12.
~Participants received open-label etanercept 0.8 mg/kg once a week during the 24-week, open-label treatment period (weeks 13 to 36).
~At week 36, participants with PASI 50 at week 24 or PASI 75 at week 36 were re-randomized to placebo or etanercept in the 12-week double-blind, withdrawal-retreatment period (weeks 37 to 48)."
11650483|NCT00078806|Experimental|Part 1: Etanercept|"Participants received 0.4 mg/kg etanercept administered subcutaneously twice a week for up to 6 months in Part 1A.
~Participants who had a partial response entered Part 1B and received 0.8 mg/kg etanercept twice weekly for up to 4 months."
11650484|NCT00078806|Placebo Comparator|Part 2: Placebo|Participants who met response criteria in Part 1 were randomized to receive placebo twice a week for up to 3 months.
11650485|NCT00078806|Experimental|Part 2: Etanercept|Participants who met response criteria in Part 1 were randomized to continue receiving etanercept twice a week at the same dose as in Part 1 (0.4 or 0.8 mg/kg) for up to 3 months.
11650486|NCT00078806|Experimental|Part 3:|Participants who experienced a flare or completed 3 months of treatment in Part 2 entered Part 3 and received open-label treatment with etanercept at the same dose as in Part 1 (0.4 or 0.8 mg/kg) for up to a maximum of 12 months, including treatment in Part 2.
11650487|NCT00078793||Methotrexate group|Includes subjects being treated with methotrexate alone or in combination with other DMARDs with the exception of etanercept.
11650488|NCT00078767|Experimental|TF-CBT + sertraline|Trauma-Focused CBT provided individually to youth and parent for 12 sessions (90 minute sessions; 45 minutes for youth; 45 minutes for parent); plus Sertraline provided in dosage titrated as clinically indicated by child psychiatrist blind to treatment assignment, from 50mg/day to a maximum dosage of 150 mg/day
11650489|NCT00078767|Active Comparator|TF-CBT +placebo|Trauma-Focused CBT provided individually to youth and parent for 12 sessions (90 minute sessions; 45 minutes for youth; 45 minutes for parent); plus placebo identical to Sertraline, provided in pill form and titrated as clinically indicated by child psychiatrist blind to treatment assignment, from 1 to 3 pills/day (identical in appearance to 50 to 150mg/day of Sertraline)
11650490|NCT00078754|Experimental|A|Participants will to receive treatment with fluoxetine for 12 weeks
11650491|NCT00078754|Experimental|B|Participants will to receive treatment with divalproex for 12 weeks
11650492|NCT00078754|Placebo Comparator|C|Participants will to receive treatment with placebo for 12 weeks
11650493|NCT00078728|Experimental|Family-based anxiety prevention program|Participants will complete an 8 session (1 session/week), cognitive behavioral therapy-based, family prevention program to be administered by a trained clinician, after randomization to the study. The prevention program will include 3 booster sessions that take place after the first 8 sessions.
11650494|NCT00078728|Active Comparator|Evaluation only|Waitlist control group. Participants in this group will receive general information (in the form of a printed packet) about anxiety after randomization to the study. Families in this group will complete all study evaluations and will then be offered the option of participating in the prevention program. Families who accept will begin the prevention sessions and will receive the same CBT-based, family-based prevention program as the other treatment arm.
11650495|NCT00007007|Experimental|Whole brain radiation therapy + neurocognitive assessments|Whole brain radiation therapy (WBRT) with neurocognitive assessments done pre and post WBRT.
11650496|NCT00006890|Experimental|Prednisone plus Thalidomide|After Autologous Stem Cell Infusion
11650497|NCT00006467|Experimental|gemcitabine + ISIS 2503|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and ISIS 2503 IV continuously on days 1-14. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
11650498|NCT00006253|Experimental|Nurse|Receives symptom management assistance from an oncology nurse via the telephone
11650499|NCT00006253|Experimental|Non-nurse coach|Receives symptom management assistance from a non-nurse coach via telephone
11650500|NCT00078715|Experimental|Yohimbine then Placebo|Participants are randomized to receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep. After 8 days they receive placebo administered over 3 minutes during REM sleep.
11650501|NCT00078715|Experimental|Placebo then Yohimbine|Participants are randomized to receive placebo administered over 3 minutes during REM sleep. After 8 days they receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
11650502|NCT00005947|Active Comparator|sipuleucel-T|
11650503|NCT00005947|Placebo Comparator|Placebo|
11650504|NCT00005843|Experimental|Arm I|Patients receive oral R115777 twice daily for 21 consecutive days. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
11650505|NCT00078624|Experimental|1|Traditional exercise program supplemented with knee stability training activities
11650506|NCT00078624|Active Comparator|2|Traditional exercise program
11650507|NCT00005096|Experimental|Docetaxel|Docetaxel given via iv at determined dose once a week for 4 weeks
11650508|NCT00078572|Active Comparator|capecitabine alone|Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2. Randomization is 1:1.
11650611|NCT00077675|Active Comparator|Standard of care for cSSSI|cSSSI - comlicated skin and skin structure infections
11650509|NCT00078572|Experimental|Combination|Lapatinib 1250 mg once daily plus capecitbine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the combination arm was 2000 mg/m2.
11650510|NCT00078507|Active Comparator|Opening Exercises Only|Standard of care opening exercises following BSSO surgery to regain mouth opening
11650511|NCT00078507|Experimental|Sensory Retraining Exercises|3 sets of facial exercises performed with soft cosmetic brush 1 wk - 4 wks after surgery; 4wks to 3 mos after surgery; 3 mos to 6 mos after surgery.
11650512|NCT00004235|Experimental|irinotecan + docetaxel|"Patients receive irinotecan IV over 90 minutes followed by docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.
~Patients achieving a complete response (CR) receive 2 additional courses after CR. Patients experiencing disease progression after a CR and 2 additional courses may be retreated with irinotecan and docetaxel. Dysphagia, anorexia, and swallowing ability are assessed before the first course of treatment and then at each tumor assessment.
~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
11650513|NCT00078559|Experimental|Alemtuzumab|
11650514|NCT00078533|Experimental|CMV CTL infusion|Subjects are assigned a dose level at the time of enrollment.
11650515|NCT00078520|Experimental|Dose Level 1|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
11650516|NCT00078520|Experimental|Dose Level 2|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
11650517|NCT00078520|Experimental|Dose Level- Fixed Dose|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
11650518|NCT00003528|Experimental|Arm I|Patients receive raltitrexed intravenously over 15 minutes once weekly for 3 weeks followed by 1 week of rest. Treatment continues in the absence of disease progression and unacceptable toxicity.
11650519|NCT00003351|Experimental|Arm I: irinotecan|"Patients receive irinotecan intravenously over 90 minutes every week for 4 weeks followed by a 2 week rest period. Treatment is repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.
~Quality of life is assessed before and during treatment. Patients are followed every 3 months for 2 years, then annually for 1 year."
11650520|NCT00003351|Experimental|Arm II: irinotecan|"Patients receive irinotecan intravenously over 90 minutes every 3 weeks for 6 weeks. Treatment is repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.
~Quality of life is assessed before and during treatment. Patients are followed every 3 months for 2 years, then annually for 1 year."
11650521|NCT00003070|Experimental|Stratum 1 < 350/mg/m2 anthracycline dose|< 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
11650522|NCT00003070|Experimental|Stratum 2 < 350mg/m2 anthracycline dose|< 4 years of age at diagnosis >= 4 years since cessation of anthracycline treatment
11650523|NCT00003070|Experimental|Stratum 3 < 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
11650524|NCT00003070|Experimental|Stratum 4 < 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis >= 4 years since cessation of anthracycline treatment
11650525|NCT00003070|Experimental|Stratum 5 >= 350mg/m2 anthracycline dose|< 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
11650526|NCT00003070|Experimental|Stratum 6 >=350mg/m2 anthracycline dose|< 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
11650527|NCT00003070|Experimental|Stratum 7 >= 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
11650528|NCT00003070|Experimental|Stratum 8 >= 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis >= 4 years since cessation of anthracycline treatment
11650529|NCT00003040|Experimental|Transoral CO2 laser laryngectomy and RT|Transoral CO2 laser supraglottic laryngectomy and irradiation
11650530|NCT00002825|Experimental|Arm I|All patients receive docetaxel with G-CSF every 21 days for up to 12 courses.
11650531|NCT00022542|Experimental|Treatment (ixabepilone)|Patients receive BMS-247550 IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive 2 additional courses.
11650532|NCT00016367|Experimental|Regimen A|Gemcitabine IV followed by Cisplatin IV Day 1 and Trastuzumab (Herceptin) IV Day 2; Trastuzumab IV followed by Gemcitabine IV Day 8 and Trastuzumab IV Day 15.
11650533|NCT00016367|Experimental|Regimen B|Starting Day 22 of regimen A, Trastuzumab IV, Gemcitabine IV, and Cisplatin IV Day 1. Trastuzumab IV followed by Gemcitabine IV Day 8 and Trastuzumab IV Day 15. Repeats every 21 days for up to 5 courses.
11650534|NCT00015990|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity.
11650535|NCT00015964|Experimental|Daily administration of ZD1839|
11650536|NCT00002597|Experimental|Neoadjuvant TAS + RT|Neoadjuvant total androgen suppression (TAS) - Flutamide and Zoladex or Lupron - two months before and during radiation therapy.
11650537|NCT00002597|Other|Radiation therapy alone|Radiation therapy alone
11650539|NCT00078390|Experimental|S-3304 plus chemo-irradiation|The tolerable dose of S-3304 determined in the Phase 1 part of the study will be dosed BID along with a standard of care regimen of radiation and paclitaxel/carboplatin chemotherapy
11650540|NCT00078390|Active Comparator|Chemo-irradiation|The standard of care regimen of radiation and paclitaxel/carboplatin chemotherapy will be administered
11650541|NCT00078377|Experimental|1|Armodafinil 250 mg
11650542|NCT00078377|Experimental|2|Armodafinil 150 mg
11650543|NCT00078377|Placebo Comparator|3|Placebo
11650544|NCT00078338|Experimental|Rebif®|
11650545|NCT00078338|Active Comparator|Copaxone®|
11650546|NCT00076687|Experimental|1|
11650547|NCT00076687|Experimental|2|
11650548|NCT00076687|Placebo Comparator|3|
11650549|NCT00012259|Experimental|troxacitabine|
11650550|NCT00006472|Other|Single arm study|Taxol® (Paclitaxel), Carboplatin and 5-Fluorouracil with Simultaneous Radiotherapy Followed by Surgical Resection
11650551|NCT00006365|Experimental|EBRT to the prostate followed by brachytherapy|Patients received 45 Gy of external beam radiation therapy (EBRT)to the prostate followed (within 2 to 6 weeks) by permanent iodine (I-125) brachytherapy 108 Gy.
11650552|NCT00006014|Experimental|Arm I|Patients receive SU5416 IV over 1 hour twice weekly. Courses repeat every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
11650553|NCT00078403|Experimental|Arm A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)|At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA >=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.
11650554|NCT00078403|Experimental|Arm B: OL (PEG-IFN, RBV) then OL Randomized (Observation)|At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA >=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to 72 weeks of observation (no treatment).
11650555|NCT00078403|Experimental|Arm C: OL (PEG-IFN, RBV) then OL (PEG-IFN, RBV)|At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA <600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly & RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA >=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.
11650556|NCT00078325|Experimental|1|Armodafinil 250 mg/day
11650557|NCT00078325|Experimental|2|Armodafinil 150 mg/day
11650558|NCT00078325|Placebo Comparator|3|Placebo
11650559|NCT00004183|Experimental|capecitabine|Patients receive oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 3 months for 2 years and then annually thereafter.
11650560|NCT00078286|Experimental|Sertraline|Participants will take sertraline for 12 weeks
11650561|NCT00078286|Placebo Comparator|Placebo|Participants will take placebo for 12 weeks
11650562|NCT00078273|No Intervention|Assessment Only Control|Completed Baseline and 6 month follow-up surveys only.
11650563|NCT00078273|Experimental|Personalized Feedback Intervention|See Intervention Description
11650564|NCT00078273|Experimental|Cognitive Behavioral Intervention|See Intervention Description
11650565|NCT00078260|Experimental|A|
11650566|NCT00078260|Experimental|B|
11650567|NCT00078247|Experimental|1|Participants will receive 6 months of ARV therapy and treatment for TB
11650568|NCT00078247|Experimental|2|Participants will not receive ARV therapy until CD4 counts drop below 250 cells/mm3. All participants will receive treatment for TB.
11650569|NCT00078195|Experimental|Omalizumab pre-treatment, ragweed RIT, omalizumab + ragweed IT|Participants are pre-treated with omalizumab followed by ragweed rush immunotherapy (RIT) followed by dual therapy with omalizumab plus ragweed immunotherapy (IT).
11650570|NCT00078195|Experimental|Omalizumab pre-treatment, omalizumab|Participants are pre-treated with omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with Omalizumab plus placebo immunotherapy (IT).
11650571|NCT00078195|Active Comparator|Ragweed RIT, ragweed IT|Participants are pre-treated with placebo omalizumab followed by ragweed rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus ragweed immunotherapy (IT).
11650572|NCT00078195|Placebo Comparator|Placebo|Participants are pre-treated with placebo omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus placebo immunotherapy (IT).
11650573|NCT00004148|Experimental|Arm I|Patients receive rV-B7.1 intralesionally every 4 weeks for 8 weeks (weeks 0, 4, and 8). Treatment continues every 12 weeks in the absence of unacceptable toxicity or disease progression for up to 2 courses. Cohorts of 6-8 patients receive escalating doses of vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 or 3 of 8 patients experience dose limiting toxicities.
11650574|NCT00003935|Experimental|Treatment|Induction: Patients receive oral etoposide daily on days 1-21 and vincristine sulfate IV on days 1, 8, and 15. Treatment repeats every 4 weeks for 2 courses. Patients receive radiation therapy daily for 6 weeks concurrently with induction chemotherapy. Maintenance: One week after induction therapy, patients receive vincristine sulfate IV on days 1 and 8 and oral etoposide daily on days 1-21. Treatment repeats every 4 weeks for 10 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter
11650575|NCT00003766|Experimental|Arm A|06-benzylguanine (100mg/m2 16 hrs before anticipated tumor tissue removal)
11650576|NCT00003623|Experimental|Multivitamin|Patients receive multivitamins orally once daily for 3 years. Patients are followed every 3 months for 2 years, then every 6 months for 1 year, and then annually thereafter.
11650577|NCT00003623|Placebo Comparator|Placebo|Patients receive placebo orally once daily for 3 years. Patients are followed every 3 months for 2 years, then every 6 months for 1 year, and then annually thereafter.
11650607|NCT00077922|Experimental|LMB-2 in chronic lymphocytic leukemia|40 micrograms/kg every other day (QOD) x 3 every 4 weeks in patients with chronic lymphocytic leukemia, the most prevalent form of adult leukemia.
11650578|NCT00003600|Experimental|epoetin alfa|Patients receiving chemotherapy are randomized to receive epoetin alfa subcutaneously once a week for a maximum of 16 weeks Quality of life is assessed at randomization and monthly throughout study. Patients are followed every 6 months for 1 year.
11650579|NCT00003600|Placebo Comparator|placebo|Patients receiving chemotherapy are randomized to receive placebo subcutaneously once a week for a maximum of 16 weeks. Quality of life is assessed at randomization and monthly throughout study. Patients are followed every 6 months for 1 year.
11650580|NCT00003573|Experimental|Treatment 1, Etoposide, 50mg/m2/day|"Patients begin treatment within 1 month of surgery. Patients receive 6 weeks of radiation therapy to the head and spine, with boosts to the posterior fossa and to sites of metastasis. Patients also receive 2 courses of oral etoposide once daily for 3 weeks concurrent with and immediately following radiotherapy (weeks 1-3 and 5-7).
~Patients then receive adjuvant chemotherapy consisting of cisplatin IV once every 4 weeks for 3 courses beginning on week 11, oral etoposide daily for 21 days every 4 weeks for 3 courses (weeks 11, 15, and 19), cyclophosphamide IV on days 1 and 2 with filgrastim (G-CSF) SQ daily for at least 10 days every 4 weeks for 8 courses (weeks 23-51), and vincristine IV on days 1, 8, and 15 every 4 weeks for 8 courses (weeks 23-51)."
11650581|NCT00003573|Experimental|Treatment 2, Etoposide, 35mg/m2/day|"Patients begin treatment within 1 month of surgery. Patients receive 6 weeks of radiation therapy to the head and spine, with boosts to the posterior fossa and to sites of metastasis. Patients also receive 2 courses of oral etoposide once daily for 3 weeks concurrent with and immediately following radiotherapy (weeks 1-3 and 5-7).
~Patients then receive adjuvant chemotherapy consisting of cisplatin IV once every 4 weeks for 3 courses beginning on week 11, oral etoposide daily for 21 days every 4 weeks for 3 courses (weeks 11, 15, and 19), cyclophosphamide IV on days 1 and 2 with filgrastim (G-CSF) SQ daily for at least 10 days every 4 weeks for 8 courses (weeks 23-51), and vincristine IV on days 1, 8, and 15 every 4 weeks for 8 courses (weeks 23-51)."
11650582|NCT00003425|Experimental|Amifostine trihydrate|
11650583|NCT00003299|Active Comparator|Cisplatin + Etoposide|
11650584|NCT00003299|Experimental|Cisplatin + Etoposide + Paclitaxel|
11650585|NCT00003120|Active Comparator|paclitaxel 3 cycles|paclitaxel given for 3 cycles
11650586|NCT00003120|Experimental|paclitaxel for 12 cycles|paclitaxel given for 12 cycles
11650587|NCT00078078||Methylmalonic Acidemia|Individuals with methylmalonic acidemia
11650588|NCT00003046|Experimental|Interleukin-12|
11650589|NCT00077974|Experimental|1|
11650590|NCT00077948|Experimental|active enoximone plus active ER metoprolol|
11650591|NCT00077948|Active Comparator|placebo enoximone plus active ER metoprolol|
11650592|NCT00077948|Placebo Comparator|placebo enoximone plus placebo ER metoprolol|
11650593|NCT00077857|Experimental|1250 mg/m^2 capecitabine + docetaxel|1250 mg/m^2 capecitabine (Xeloda®) orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel (Taxotere®) 75 mg/m^2 intravenous on day 1 of each 3 week cycle.
11650594|NCT00077857|Experimental|825 mg/m^2 capecitabine + docetaxel|825 mg/m^2 capecitabine orally twice a day on days 1 to 14 of each 3 week cycle, in combination with docetaxel 75 mg/m^2 intravenous on day 1 of each 3 week cycle.
11650595|NCT00077766|Experimental|RO0503821 (1x/2 Weeks)|Eligible participants will be administered with RO0503821 ([methoxy polyethylene glycol-epoetin beta] {Mircera}) intravenously (IV), every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram [µg]) was based on the dose of darbepoetin alfa at the time of randomization (< 40, 40 to 80, or > 80 µg per week, respectively).
11650596|NCT00077766|Active Comparator|Darbepoetin (1x/1-2 Weeks)|Eligible participants will be administered with darbepoetin alfa IV, every week or every 2 weeks during Weeks 1 through 52.
11650597|NCT00023647|Experimental|Synchrotope TA2M, 800 micrograms|Tyrosinase peptides, 800 micrograms
11650598|NCT00023647|Experimental|Synchrotope TA2M, 200 micrograms|Tyrosinase peptides, 200 micrograms
11650599|NCT00023647|Experimental|Synchrotope TA2M, 400 micrograms|Tyrosinase peptides, 400 micrograms
11650600|NCT00007878|Experimental|Treatment (bortezomib, fluorouracil, leucovorin calcium)|Patients receive bortezomib IV on days 1 and 4 and fluorouracil IV and leucovorin calcium IV on day 1 weekly for 2 weeks. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
11650601|NCT00005089|Experimental|CHOP + Rituximab + RT|3 21-day cycles of CHOP (cyclophosphamide 750 mg/m^2, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2, prednisone 100 mg x 5 days) + Rituximab 375 mg/m^2 (x 2 days for cycle 1, x 3 days for cycles 2-3). RT 4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
11650602|NCT00004145|Experimental|Arm A|Fludarabine (30mg/m2/day x 5 days on days -9 to -5), cyclophosphamide (2gm/m2/day on day -5), antithymocyte globulin (10mg/kg/day x 4 days on days -5 to -2), tacrolimus (.03 mg/kg/day IVPB continuous infusion), mycophenolate mofetil (1mg PO BID, days +1 to +60), allogenic peripheral blood stem cells
11650603|NCT00003545|Experimental|Arm I|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. If residual leukemia/lymphoma is present on day 22, then patients receive a second course of 506U78. If day 22 marrow is hypocellular, then a repeat bone marrow biopsy should be obtained on day 29 to assess response. For day 22 or 29 marrow that is in complete response, patients receive 506U78 for two more courses on days 1, 3, and 5, administered every 21 days. Patients are followed every 3 month for 1 year, then every 6 months for a maximum of 10 years.
11650604|NCT00003207|Experimental|Phase 1 (Doxil & PSC 833)|Patients will receive Doxil at the standard dose of 20 mg/m2 IV for the 1st cycle. On the 2nd cycle of Doxil, the first patient will receive Doxil at 40% of standard dose or 8 mg/m2 (dose level 1) IV over one hr. 15 mn after the 2nd and subsequent cycles of Doxil, PSC 833 will be given at 2 mg/kg for 2 hrs. Simultaneously, a 72 hour CIVI of PSC 833 will be started with the loading dose. If no DLT occurs, then a double dose escalation of Doxil (dose levels 3, 5, 7 ) will be given to the same patient in the subsequent cycles until DLT occurs. On the 2nd cycle, Doxil will be given at the next dose level above the starting dose tolerated by the first patient. If no DLT occurs, a double dose escalation will also be done for the subsequent cycles (dose levels 5, 7, 9). The single-patient-cohort will terminate when a patient experiences DLT or when two episodes of grade 2 toxicity occur. At that point patients will be enrolled into cohorts of 3 patients to determine the MTD.
11650605|NCT00003011|Active Comparator|Marmistat|10 mg PO BID
11650606|NCT00003011|Placebo Comparator|Placebo|10 mg PO BID
11650608|NCT00077909||Group 1|Patients with Infectious Pneumonia
11650609|NCT00077909||Group 2|Patients with Non-Infectious Pneumonia
11650612|NCT00077649|Active Comparator|PEG-IFN Alfa-2a 180 μg +Ribavirin 1200 mg|Participants received 180 μg of PEG-IFN [peginterferon] alfa-2a in 1 mL solution administered [subcutaneously] sc, once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered [orally ] po daily in split doses for 48 weeks
11650613|NCT00077649|Experimental|PEG-IFN Alfa-2a 180 μg + Ribavirin 1600 mg|Participants received 180 μg of PEG-IFN [peginterferon] alfa-2a in 1 mL solution administered [subcutaneously] sc, once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered [orally ] po daily in split doses for 48 weeks
11650614|NCT00077649|Experimental|PEG-IFN Alfa-2a 270 μg + Ribavirin 1200 mg|Participants received 270 μg of PEG-IFN alfa-2a in 1-mL solution administered sc once weekly + 1200 mg of ribavirin (200 mg/tablet) + ribavirin placebo (2 tablets) administered po daily in split doses for 48 weeks
11650615|NCT00077649|Experimental|PEG-IFN Alfa-2a 270 μg + Ribavirin 1600 mg|Participants received 270 μg of PEG-IFN alfa-2a in 1-mL solution administered sc once weekly + 1600 mg of ribavirin (200 mg/tablet) administered po daily in split doses for 48 weeks.
11650616|NCT00077636|Experimental|1|
11650617|NCT00077636|Experimental|2|
11650618|NCT00077623|Experimental|RO0503821 (1x/2 Weeks)|Eligible participants received RO0503821 (Mircera [methoxy polyethylene glycol-epoetin beta]) subcutaneously, once every two weeks for 52 weeks. Participants received a starting dose of RO0503821 60, 100, or 180 microgram (mcg) which was based on the epoetin dose of<8000, 8000-16000, or >16000 international units (IU)/week, administered during the week preceding the switch to the study drug.
11650619|NCT00077623|Experimental|RO0503821 (1x/4 Weeks)|Eligible participants received RO0503821 subcutaneously, once every four weeks for 52 weeks. Participants received a starting dose of RO0503821 120, 200, or 360 mcg which was based on the epoetin dose of<8000, 8000-16000, or >16000 IU/week administered during the week preceding the switch to the study drug.
11650620|NCT00077623|Active Comparator|Epoetin Reference|Eligible participants received their ongoing weekly subcutaneous dose of epoetin alfa or beta one, two or three times weekly for 52 weeks .
11650621|NCT00077610|Experimental|RO0503821 (1x/2 Weeks)|Participants received RO0503821 (Mircera [methoxy polyethylene glycol-epoetin beta]) once every two weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (60, 100, or 180 microgram [mcg]) that was based on the Epoetin dose (<8000, 8000-16000, >16000 International units [IU]/Week) administered during the week preceding the switch to the study drug.
11650622|NCT00077610|Experimental|RO0503821 (1x/4 Weeks)|Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (120, 200, or 360 mcg) that was based on the Epoetin dose (<8000, 8000-16000, >16000 IU/Week) administered during the week preceding the switch to the study drug.
11650623|NCT00077610|Active Comparator|Epoetin (1-3x/Weeks)|Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.
11650624|NCT00077597|Experimental|1|
11650625|NCT00077597|Active Comparator|2|
11650626|NCT00077545|Experimental|Treatment (triapine and cisplatin)|Patients receive 3-AP (Triapine) IV over 2 hours on days 1-4. Patients also receive cisplatin IV over 60 minutes on days 2 and 3 before 3-AP infusion. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11650627|NCT00077493|Active Comparator|1|BL22 immunotoxin
11650628|NCT00077493|Active Comparator|2|antibody therapy
11650629|NCT00077493|Active Comparator|3|immunotoxin therapy
11650630|NCT00077493|Active Comparator|4|monoclonal antibody therapy
11650631|NCT00077467|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11650632|NCT00077454|Experimental|Treatment (erlotinib hydrochloride, temozolomide)|Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.
11650633|NCT00077441|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11650634|NCT00077428|Experimental|Treatment (bortezomib, doxorubicin hydrochloride)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression continue to receive bortezomib as above and doxorubicin IV over 2-5 minutes on days 1 and 8. Treatment repeats every 21 days for up to 14 courses in the absence of further disease progression or unacceptable toxicity.
11650635|NCT00077376|Experimental|Treatment (trastuzumab, ixabepilone, carboplatin)|"Induction therapy: Patients receive trastuzumab (Herceptin®) IV over 30 minutes* on days 1, 8, 15, and 22 and ixabepilone IV over 1 hour and carboplatin IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of unacceptable toxicity.
~NOTE: *Trastuzumab is given over 90 minutes on day 1 of course 1 (induction therapy) only.
~Maintenance therapy: Patients receive trastuzumab IV over 90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
11650636|NCT00077363|Experimental|Treatment (tipifarnib, capecitabine)|Patients receive oral tipifarnib twice daily and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 4 additional courses beyond documentation of CR.
11650637|NCT00077350|Experimental|Treatment (triapine and gemcitabine hydrochloride)|Patients receive 3-AP (Triapine^®) IV over 2 hours and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11650638|NCT00077324||Surgery + blood and serum collection|"Patients undergo lung resection. Patients also undergo preoperative and postoperative collection of whole blood and serum for proteomic profiling using surface-enhanced laser desorption/ionization-time of flight mass spectrometry. A lung tissue biopsy taken at surgery is also analyzed.
~Patients are followed at 60-90 days and then annually for 2-5 years."
11650639|NCT00077311|Experimental|Chemotherapy without BNP7787|Chemotherapy with dose-dense docetaxel and cisplatin with pegfilgrastim and darbepoetin for pts with NSCLC
11650640|NCT00077311|Experimental|Chemotherapy + BNP7787|Chemotherapy with dose-dense docetaxel and cisplastin with pegfilgrastim and darbepoetin with the addition of BNP7787
11650643|NCT00006047|Experimental|Combination Therapy|Combination Therapy with Oral 9-Nitrocamptothecin & Oral Etoposide. Patients receive oral nitrocamptothecin on days 1-3 and oral etoposide on days 4-5 each week. Treatment continues in the absence of disease progression or unacceptable toxicity.
11650644|NCT00005862|Experimental|Arm I|atients receive SU5416 IV twice weekly for 4 weeks. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity.
11650645|NCT00005610|Experimental|sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) over 10-15 minutes twice daily for 7 days. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and prior to course 5.
~Patients are followed every 2 months for at least 1.5 years."
11650646|NCT00004919|Experimental|Treatment (cisplatin, irinotecan, amifostine)|"Treatment A: Patients receive cisplatin IV over 1 hour followed immediately by irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Courses repeat every 6 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
~Treatment B: Patients receive therapy as in treatment A. In addition, amifostine IV is administered over 15 minutes immediately before cisplatin."
11650647|NCT00004889|Experimental|Rituxan|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
11650648|NCT00004203|Experimental|Arm A|On Day 1 of each 21-day treatment cycle, patients receive 130 mg/m2 oxaliplatin diluted in 250 to 500 mL Dextrose 5% in Water infused intravenously over 2 hours through a peripheral or central vein
11650649|NCT00077584|Experimental|Bosentan|The patients received bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks and then 125 mg b.i.d. for 20 weeks
11650650|NCT00077584|Placebo Comparator|Placebo|The patients received the matching placebo for 24 weeks
11650651|NCT00077298|Experimental|Arm A (cetuximab, bevacizumab, irinotecan)I|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36; bevacizumab IV over 30-90 minutes on days 1*, 15, and 29 OR on days 1 and 22; and irinotecan IV over 30-90 minutes (at the same dose and schedule that the patient previously received) beginning on day 1.
~NOTE: *Bevacizumab is given on day 2 (instead of day 1) of course 1, and is given on day 1 of subsequent courses."
11650652|NCT00077298|Experimental|Arm B (cetuximab and bevacizumab)|"Patients receive cetuximab as in Arm A and bevacizumab IV over 30-90 minutes on days 1*, 15, and 29.
~NOTE: *Bevacizumab is given on day 2 (instead of day 1) of course 1, and is given on day 1 of subsequent courses."
11650653|NCT00077285|Experimental|pts with intermediate- and high-risk rhabdomyosarcoma|
11650654|NCT00077233|Active Comparator|Arm A: FOLFIRI|Patients receive irinotecan 180 mg/m^2 over 90 minutes on day 1, then leucovorin 400 mg/m^2 over 2 hours followed by 5FU 400 mg/m^2 IV bolus injection then 5FU 2400 mg/m^2 continuous IV infusion over 46-48 hours repeated every 2 weeks. One cycle of therapy is 8 weeks.
11650655|NCT00077233|Experimental|Arm B: FOLFIRI + C225|Patients receive irinotecan 180 mg/m^2 over 90 minutes, then leucovorin 400 mg/m^2 IV over 2 hours followed by 5FU 400 mg/m^2 IV bolus injection then 5FU 2400 mg/m^2 continuous IV infusion over 46-48 hours repeated every 2 weeks. Patients also receive cetuximab 400 mg/m^2 IV over 120 minutes day 1, then 250 mg/m^2 IV over 60 minutes weekly. All patients must be premedicated with diphenhydramine hydrochloride 50 mg (or a similar agent) IV prior to the first dose of cetuximab in an effort to prevent a hypersensitivity reaction. Premedication is recommended prior to subsequent doses, but at the Investigator's discretion the dose of diphenhydramine (or a similar agent) may be reduced.
11650656|NCT00077233|Active Comparator|Arm C: FOLFOX|Patients receive oxaliplatin 85 mg/m^2 IV infused over 120 minutes, then leucovorin 400 mg/m^2 IV over 2 hours followed by 5 FU 400 mg/m^2 IV bolus injection then 5 FU 2400 mg/m^2 continuous IV infusion over 46-48 hours every 2 weeks.
11650657|NCT00077233|Experimental|Arm D: FOLFOX + C225|Patients receive oxaliplatin 85 mg/m^2 IV infused over 120 minutes, then leucovorin 400 mg/m^2 over 2 hours followed by 5 FU 400 mg/m^2 IV bolus injection then 5 FU 2400 mg/m^2 continuous IV infusion over 46-48 hours every 2 weeks. Patients also receive cetuximab 400 mg/m^2 IV over 120 minutes day 1, then 250 mg/m^2 IV over 60 minutes weekly. All patients must be premedicated with diphenhydramine hydrochloride 50 mg (or a similar agent) IV prior to the first dose of cetuximab in an effort to prevent a hypersensitivity reaction. Premedication is recommended prior to subsequent doses, but at the Investigator's discretion the dose of diphenhydramine (or a similar agent) may be reduced.
11650658|NCT00077207|Experimental|Treatment (carboplatin, vincristine sulfate, temozolomide)|Induction therapy: Patients receive carboplatin IV (175/m2) over 1 hour on days 1, 8, 15, and 22; vincristine IV (1.5 mg/m2) on days 1, 8, 15, 22, 29, and 36; and oral temozolomide (200 mg/m2) on days 43-47. Four weeks after the completion of induction therapy, patients achieving stable or responding disease proceed to maintenance therapy. Maintenance therapy: Patients receive carboplatin (175/m2) and temozolomide (200 mg/m2) as in induction therapy and vincristine IV ((1.5 mg/m2) day 1 of weeks 10,11,12. Treatment repeats every 10 weeks for a total of 6 courses in the absence of disease progression.
11650659|NCT00077194|Experimental|Arm I|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
11650660|NCT00077181|Experimental|Treatment (cytarabine and triapine)|Patients receive high-dose cytarabine IV over 2 hours on days 1-5 and triapine IV over 2 hours on days 2-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
11650661|NCT00077155|Experimental|Treatment (cilengitide)|Patients receive cilengitide (EMD 121974) IV continuously on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
11650662|NCT00077142|Experimental|TAC-101|Oral TAC-101 daily Days 1-14, repeats every 21 days for 2 courses.
11650663|NCT00077064|No Intervention|Observation|Clinical observation
11650664|NCT00077064|Experimental|Captopril|Captopril
11650665|NCT00077051|Experimental|Single Arm|
11650666|NCT00077025|Active Comparator|Anastrozole-placebo|Anastrozole (ZD1033, Arimidex)-Placebo
11650667|NCT00077025|Active Comparator|Anastrozole-ZD1839|Anastrozole (ZD1033, Arimidex)-ZD1839 (gefitinib, IRESSA)
11650668|NCT00076999|Experimental|TPV/r 290/115 mg/m^2|TPV and RTV oral solution low dose
11650669|NCT00076999|Experimental|TPV/r 375/150 mg/m^2|TPV and RTV oral solution high dose
11650670|NCT00076934|Experimental|1|Participants receive Regimen 1 for 4 months
11650671|NCT00076934|Experimental|2|Participants receive Regimen 2 for 4 months
11650672|NCT00076934|Experimental|3|Participants receive Regimen 3 for 4 months
11650673|NCT00076934|Experimental|4|Participants receive Regimen 4 for 4 months
11650674|NCT00003937|Experimental|Pilot 1 - Doxorubicin Intensification without Ifosfamide|Dexrazoxane hydrochloride IV followed by doxorubicin hydrochloride IV plus cisplatin IV on days 1 and 2 of weeks 1 and 6. Methotrexate IV on day 1 of weeks 4, 5, 9, and 10. Patients undergo surgery on week 11. Adjuvant chemotherapy begins on day 1 of week 13. Group 1 (good response to neoadjuvant chemotherapy): Patients receive methotrexate IV over 4 hours every 3 weeks for 6 courses, beginning on week 13. Patients also receive dexrazoxane and doxorubicin hydrochloride every 3 weeks for 4 courses, beginning on week 14. Cisplatin is administered with the first 2 courses of dexrazoxane and doxorubicin. Group 2 (standard response to neoadjuvant chemotherapy): Patients receive methotrexate and cisplatin as in group 1 plus dexrazoxane and doxorubicin hydrochloride for 6 courses.
11650675|NCT00003937|Experimental|Pilot 2 - Doxorubicin Intensification with Ifosfamide|Preoperative therapy comprised of dexrazoxane hydrochloride, doxorubicin hydrochloride, and methotrexate as in pilot 1. Ifosfamide IV on days 1-5 of week 1. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane hydrochloride, and doxorubicin hydrochloride as in pilot 1, group 1. Ifosfamide is also administered on weeks 14 and 20. Cisplatin is administered on weeks 17, 23, and 26. Group 2: Patients receive methotrexate, dexrazoxane hydrochloride, and doxorubicin hydrochloride as in pilot 1, group 2. Ifosfamide is administered on weeks 14, 20, 26, and 31. Cisplatin is administered on weeks 17, 23, and 29
11650676|NCT00003937|Experimental|Pilot 3 - Ifosfamide/Etoposide Intensification|Preoperative therapy comprised of methotrexate, dexrazoxane hydrochloride, doxorubicin, ifosfamide, and cisplatin as in pilot 2. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane hydrochloride, doxorubicin, ifosfamide, and cisplatin as in pilot 2, group 1. Group 2: Patients receive methotrexate on weeks 13, 19, 29, 32, 35, and 36, high dose ifosfamide and etoposide IV over 4 hours on days 1-5 of weeks 14, 23, and 26, and cisplatin on weeks 20, 30, and 33. Dexrazoxane hydrochloride and doxorubicin hydrochloride are administered on weeks 17, 20, 30, and 33
11650677|NCT00003665|Experimental|Arm I|Patients receive 3 different doses of peptide pulsed DC vaccine IV, each divided into 3 different peptide pulsed pools administered over 30 minutes.
11650678|NCT00003665|Experimental|Arm II|Patients receive 3 different doses of peptide pulsed DC vaccine subcutaneously/intradermally to sites with no evidence of disease. At the lowest dose, patients receive 3 different peptide pulsed pools, each administered at a separate site. At the higher doses, patients receive 3 injections further subdivided into 6 and administered at 6 distinct sites.
11650679|NCT00003665|Experimental|Arm III|Patients receive peptide pulsed DC vaccine intranodally in groin or ancillary lymph nodes at the lower 2 doses of the 3 administered to arms I and II. At the lower dose, patients receive 3 different peptide pulsed pools, each administered into a different node. At the higher dose, patients receive 3 injections further subdivided into 6 and administered at 6 distinct sites.
11650680|NCT00003370|Experimental|Arm I|"If the dose limiting toxicity is myelosuppression in stratum 1, then stratum 1 is closed and stratum 2 opens.
~Stratum 2 consists of the following: patients receiving no more than 2 prior chemotherapy regimens; patients who have not received prior central axis radiation or bone marrow transplantation; and patients with no known bone marrow involvement. Patients receive intravenous 6-hydroxymethylacylfulvene over 10 minutes daily for 5 days. The course is repeated every 28 days unless disease progression or unacceptable toxic effects are observed. Patients with stable or responding disease may receive up to 1 year of therapy. If dose limiting toxicity occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and the next lower dose is declared the maximum tolerated dose. Dose escalation will not occur until all patients within a cohort have been observed for 28 days from day 1 of therapy. Patients are followed until death."
11650681|NCT00003222|Experimental|Peptides pulsed on dendritic cells|4 melanoma peptides pulsed on monocyte-derived dendritic cells
11650682|NCT00003222|Experimental|Peptides in GMCSF-in-adjuvant|4 melanoma peptides administered as an emulsion with GM-CSF and Montanide ISA-51 adjuvant.
11650683|NCT00076817|Experimental|1|Participants will receive vaccine injections in the groin area or the upper arm
11650684|NCT00076817|Placebo Comparator|2|Participants will receive vaccine placebo injections in the groin area or the upper arm
11650685|NCT00076804|Experimental|1|Use of a patient nominated peer supporter who will observe the morning dose of ARVs
11650686|NCT00076804|No Intervention|2|Self administration of ARVs
11650687|NCT00076791|Active Comparator|1|Each participant in Cohort 1 received a single 600 mg oral dose of TDF at the start of active labor or 4 hours prior to C-section, with concurrent administration of standard intravenous zidovudine (ZDV) prophylaxis and/or other antiretrovirals prescribed by her physician. The infants from Cohort 1 received only the standard 6 weeks of oral ZDV prophylaxis postpartum.
11650688|NCT00076791|Active Comparator|2|Mothers in Cohort 2 will receive a single dose of 900 mg of TDF combined with 600 mg emtricitabine, along with standard ZDV prophylaxis and/or other antiretrovirals prescribed by her physician. Infants will receive a single dose of TDF at 4 mg/kg combined with 3 mg/kg emtricitabine as soon as possible after delivery and within 6 hours of age as well as the standard 6 weeks of oral ZDV prophylaxis after birth.
11650689|NCT00033592|Experimental|Arm I: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day. Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.
~Participants randomized to arm I who continue to smoke are randomized to one of two treatment arms Arm IV or Arm V. Participants randomized to arm I who are smoke-free are randomized to one of two treatment arms Arm VIII or Arm IX."
11650690|NCT00033592|Experimental|Arm II: bupropion|"Participants receive oral bupropion 1-2 times daily.
~Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.
~Participants randomized to arm II who continue to smoke are randomized to one of two treatment arms Arm VI or Arm VII. Participants randomized to arm II who are smoke-free are randomized to one of two treatment arms Arm Arm X or Arm XI."
11650900|NCT00074412|Placebo Comparator|2B|For infants: extended treatment with NVP placebo
11650691|NCT00033592|Experimental|Arm III: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral bupropion 1-2 times daily. Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.
~Participants randomized to arm III who continue to smoke do not receive any further therapy. Participants randomized to arm III who are smoke-free are randomized to one of four treatment arms Arm XII, Arm XIII, Arm XIV or Arm XV."
11650692|NCT00033592|Experimental|Arm IV: bupropion|"Participants receive oral bupropion 1-2 times daily for 12 weeks.
~All participants are followed every month for 6 months."
11650693|NCT00033592|Placebo Comparator|Arm V: placebo|"Participants receive oral placebo 1-2 times daily for 12 weeks.
~All participants are followed every month for 6 months."
11650694|NCT00033592|Experimental|Arm VI: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day for 12 weeks.
~All participants are followed every month for 6 months."
11650695|NCT00033592|Placebo Comparator|Arm VII: placebo inhaler|"Participants receive 6-16 placebo inhaler cartridges per day for 12 weeks.
~All participants are followed every month for 6 months."
11650696|NCT00033592|Experimental|Arm VIII: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day for 40 weeks.
~All participants are followed every month for 6 months."
11650697|NCT00033592|Placebo Comparator|Arm IX: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day for 40 weeks.
~All participants are followed every month for 6 months."
11650698|NCT00033592|Experimental|Arm X: bupropion|"Participants receive oral bupropion 1-2 times daily for 40 weeks.
~All participants are followed every month for 6 months."
11650699|NCT00033592|Placebo Comparator|Arm XI: placebo|"Participants receive oral placebo 1-2 times daily for 40 weeks.
~All participants are followed every month for 6 months."
11650700|NCT00033592|Experimental|Arm XII: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks.
~All participants are followed every month for 6 months."
11650701|NCT00033592|Placebo Comparator|Arm XIII: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day and oral bupropion 1-2 times daily for 40 weeks.
~All participants are followed every month for 6 months."
11650702|NCT00033592|Experimental|Arm XIV: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral bupropion 1-2 times daily for 40 weeks.
~All participants are followed every month for 6 months."
11650703|NCT00033592|Placebo Comparator|Arm XV: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks.
~All participants are followed every month for 6 months."
11650704|NCT00026377|Experimental|SU5416 in combination with hormone and radiation therapy|Subjects receive 5 months of hormone suppression therapy consisting of 1 month of Bicalutamide or Flutamide followed by 4 months of leuprolide or goserlin injections. After completion of at least 12 weeks of hormone therapy, subjects will receive 7 1/2 weeks of radiation therapy. SU5416 will be given by IV infusion starting 4 weeks before beginning radiation treatment and continuing until 4 weeks after completion of radiation. Multiple doses of SU5416 will be studied.
11650705|NCT00024011|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11650706|NCT00076830||Enrolled Cohort|All patients enrolled, as this is a evaluation/diagnostic study
11650707|NCT00076752|Experimental|Autologous HSCT in SLE|"Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).
~SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion."
11650708|NCT00009958|Experimental|Stage I|Patients receive fCEA-TRI vaccine SC once daily on days 1, 29, 57, and 85.
11650709|NCT00009958|Experimental|Stage II|Patients receive vCEA-TRI vaccine intradermally once on day 1 and fCEA-TRI vaccine SC at the MTD determined in stage I once daily on days 29, 57, and 85.
11650710|NCT00009958|Experimental|Stage III|A single cohort of 6-10 patients receive both vaccines as in stage II, at the MTDs determined in stages I and II, and sargramostim (GM-CSF) SC once daily on days 1-4, 29-32, 57-60, and 85-88.
11650711|NCT00009906|Experimental|Arm I (imatinib mesylate)|Patients receive oral imatinib mesylate once daily.
11650712|NCT00009906|Experimental|Arm II (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily.
11650713|NCT00008333|Experimental|vinorelbine|Patients receive oral vinorelbine on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and after 8 weeks of therapy. Patients are followed every 3 months for 5 years.
11650714|NCT00005881||Quality of life forms|Completion of the development of an instrument [Minneapolis-Manchester Quality of Life (MM-QOL)] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
11650715|NCT00005792|Experimental|MTV|Melphalan Topotecan Etoposide VP-16 Phosphate autologous stem cell transplant
11650716|NCT00005064|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV bolus twice weekly for 4 weeks followed by 2 weeks of rest. Treatment continues for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression.
11650717|NCT00076622||Randomized to drug continuation|Participants assigned to continue current antidepressant medication
11650718|NCT00076622||Randomized to drug discontinuation|Participants assigned to discontinue current antidepressant medication (no antidepressant medication)
11650719|NCT00076622||Participant preference to continue drug|Chose to continue antidepressant medication
11650720|NCT00076622||Participant preference to discontinue drug|Chose to discontinue antidepressant medication (no antidepressant medication)
11650721|NCT00005022|Experimental|Arm 1|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D/5 days/4 weeks, boost 1.8 Gy/D x 2 days, then BID x last 3 days.
11650722|NCT00005022|Experimental|Arm 2|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D/5 days/4 weeks, boost 1.8 Gy/BID x last 5 days.
11650936|NCT00073814|Placebo Comparator|3|Placebo MDI QID
11650723|NCT00005022|Experimental|Arm 3|Large field radiation therapy 32.4 Gy, 1.8 Gy/fx/D/5 days x 18 fx, boost just in pm @ 1.8 Gy/fx on days 19 & 20, then boost 1.8 Gy BID x last 5 days.
11650724|NCT00005022|Experimental|Arm 4|Large field radiation therapy 28.8 Gy, 1.8 Gy/fx/5 days x 16 fx, boost just in pm @ 1.8 Gy/fx on days 17-20, then boost 1.8 Gy BID x last 5 days.
11650725|NCT00005022|Experimental|Arm 5|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D 5 days/4 weeks, boost 1.8 Gy/D x 2 days, then BID x last 3 days.
11650726|NCT00005022|Experimental|Arm 6|Large field radiation therapy 25.2 Gy, 1.8 Gy/fx/5 days x 14 fx, boost just in pm @ 1.8 Gy/fx on days 15-20, then boost 1.8 Gy BID x last 5 days.
11650727|NCT00004862|Experimental|Arm I|Patients receive augmerosen IV continuously on days 1-10 and filgrastim (G-CSF) subcutaneously beginning on day 5 and continuing until blood counts recover. Patients receive fludarabine IV over 30 minutes followed 3.5 hours later by cytarabine IV over 4 hours on days 6-10. Patients who achieve complete response (CR) receive a second course beginning 4 weeks after completion of the first course. Patients who achieve CR and have a matched sibling or unrelated bone marrow donor may undergo allogeneic bone marrow transplantation. Cohorts of 3-6 patients receive escalating doses of fludarabine and cytarabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
11650728|NCT00004239|Experimental|Compound 506U78|Compound 506U78 will be administered intravenously over 2 hours on days 1, 3 and 5 of each 28 day treatment cycle.
11650729|NCT00076570|Experimental|Sirolimus|Patients are treated with combination therapy with both sirolimus and tacrolimus for 6 month. After 6 months, patients are switched to sirolimus monotherapy and followed up for 4 years.
11650730|NCT00076570|Active Comparator|Tacrolimus|Patients are treated with combination therapy with both sirolimus and tacrolimus for 6 month. After 6 months, patients are switched to tacrolimus monotherapy and followed up for 4 years.
11650731|NCT00076453|Experimental|1|Participants will wear lateral wedge orthotic inserts.
11650732|NCT00076453|Active Comparator|2|Participants will wear standard orthotic inserts.
11650733|NCT00003298|Experimental|Experimental Arm|Patients receive 3 courses of preoperative neoadjuvant chemotherapy given on day 1 every 21 days. Courses consist of an intravenous infusion of cisplatin and a 3 hour intravenous infusion of paclitaxel on day 1. Patients then undergo surgery for tumor removal on day 63, followed 4-6 weeks later by one course of daily intravenous bolus leucovorin calcium and fluorouracil for 5 days. Chemotherapy is repeated 4-6 weeks later for the first 4 days of week 1 and the last 3 days of week 5 of radiation therapy given 5 days a week for 5 weeks. Patients receive two more courses, 4 weeks apart, of fluorouracil and leucovorin calcium for 5 days 4-6 weeks after completing radiation treatment.
11650734|NCT00076349|Experimental|1|open-label, single arm, clinical trial of bendamustine (SDX-105) plus rituximab
11650735|NCT00076336|Experimental|Telbivudine 600 mg|Participants received Telbivudine 600 mg and a matching lamivudine placebo orally once a day for up to 104 weeks. Participants were followed-up for 16 weeks post-treatment.
11650736|NCT00076336|Active Comparator|Lamivudine 100 mg|Lamivudine 100 mg and a Telbivudine matching placebo orally once a day for up to 104 weeks. Participants were followed-up for 16 weeks post-treatment.
11650737|NCT00003137|Experimental|irinotecan|"Patients receive irinotecan (CPT-11) by IV over 90 minutes every 3 weeks. Dosage modifications are made based on toxicity. Retreatment may be delayed another 3 weeks (for a total of 6 weeks) to allow for recovery from toxic effects. Patient is taken off study if they do not recover from toxic effects, unless cause is documented to be unrelated to CPT-11. Patients with stable disease or partial response continue on treatment until disease progression or intolerable toxicity. Patients with complete response continue on treatment for another 2 courses and then are observed.
~Patients are followed every 3 months for 3 years or until disease progression."
11650738|NCT00076310|Experimental|Cisplatin + Docetaxel + OSI-774|"Cisplatin 75 mg/m^2 IV every 21 days.
~Docetaxel 60 mg/m^2 IV repeated every 21 days.
~OSI-774 100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached."
11650739|NCT00076258|Experimental|SSRI+ LD|A low dose aerobic exercise (LD) augmentation intervention to SSRI
11650740|NCT00076258|Experimental|SSRI+ PHD|A public health dose of aerobic exercise (PHD) augmentation intervention to SSRI
11650741|NCT00076245|Experimental|1 Light therapy|
11650742|NCT00076245|Experimental|2 Cognitive behavioral therapy|
11650743|NCT00076245|Experimental|3 Light therapy plus cognitive behavioral therapy|
11650744|NCT00076245|No Intervention|4 Control|
11650745|NCT00076219|Experimental|Intensive renal replacement therapy|In the intensive management strategy, intermittent hemodialysis and sustained low-efficiency dialysis were provided 6 times per week, and continuous venovenous hemodiafiltration was provided at 35 mL/kg/hour.
11650746|NCT00076219|Active Comparator|Less-intensive renal replacement therapy|In the less-intensive management strategy, intermittent hemodialysis and sustained low-efficiency dialysis were provided 3 times per week, and continuous venovenous hemodiafiltration was provided at 20 mL/kg/hour.
11650747|NCT00076206|Experimental|A|CCI-779 1 mg dose to be taken orally daily up to 12 weeks.
11650748|NCT00076206|Experimental|B|CCI-779 2 mg dose to be taken orally daily up to 12 weeks.
11650749|NCT00076206|Experimental|C|CCI-779 4 mg dose to be taken orally daily up to 12 weeks.
11650750|NCT00076206|Placebo Comparator|D|Placebo dose to be taken orally daily up to 12 weeks.
11650751|NCT00076232|Experimental|1|Participants will receive acyclovir for the duration of the study
11650752|NCT00076232|Placebo Comparator|2|Participants will receive acyclovir placebo for the duration of the trial
11650753|NCT00076154||Group 1|
11650754|NCT00076141||Older, Racially Diverse Males|Racially Divers Males over 50, expected to live more than 5 years
11650755|NCT00076180|Experimental|1|One dose of Hu-MiK Beta-1
11650756|NCT00033735|Experimental|fluorouracil|
11650757|NCT00033735|Experimental|Irofulven|
11650758|NCT00076102|Experimental|Pirfenidone|Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m^2 every 8 hours (1500 mg/m2/day).
11650759|NCT00076063|Experimental|A|Participants in Groups A will receive four injections over 6 months of either LIPO-5 or a placebo.
11650760|NCT00076063|Experimental|B|Participants in Group B will receive four injections over 6 months of either the ALVAC-HIV (vCP1452) or a placebo.
11650761|NCT00076063|Experimental|C|Participants in Groups C will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
11650762|NCT00076063|Experimental|D|Participants in Group D will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
11650763|NCT00076063|Experimental|E|Participants in Group E will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
11650764|NCT00076050|Experimental|1|Participants will receive a 200-mg dose of soy isoflavones daily over 2 years.
11650765|NCT00076050|Placebo Comparator|2|Participants will receive placebo daily over 2 years.
11650766|NCT00076024|Other|Docetaxel + Placebo|Docetaxel + Placebo
11650767|NCT00076024|Experimental|Docetaxel + AG-013736|Docetaxel + AG-013736
11650768|NCT00075946|Active Comparator|Arm A: Rituximab Retreatment|Patients receive rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months.
11650769|NCT00075946|Experimental|Arm B: Rituximab Scheduled|Patients receive a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity.
11650770|NCT00075881|Experimental|Treatment (bortezomib)|"INDUCTION TREATMENT: Patients receive bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE TREATMENT: Patients who complete induction treatment without progressive disease receive bortezomib IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~REINDUCTION TREATMENT: Patients who progress while on maintenance treatment receive bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity."
11650771|NCT00075868|Experimental|Sandostatin LAR® Depot|Sandostatin LAR® Depot Pre-RT (between day -7 and day -4 of RT) and Day 22 (± 3 days)
11650772|NCT00075868|Placebo Comparator|Placebo|Placebo Pre-RT (between day -7 and day -4 of RT) and Day 22 (± 3 days)
11650773|NCT00075855|Experimental|testosterone|"Patients receive topical testosterone once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm.
~Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8.
~Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months."
11650774|NCT00075855|Other|placebo|"Patients receive a topical placebo once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm.
~Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8.
~Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months."
11650775|NCT00075842|Experimental|Arm I|Patients receive oral Valeriana officinalis (Valerian) once daily for 8 weeks.
11650776|NCT00075842|Placebo Comparator|Arm II|Patients receive an oral placebo once daily for 8 weeks.
11650777|NCT00075829|Active Comparator|Auto transplants plus Therapy|One autologous transplant along with a second autologous transplant will be preformed followed by one year of Dexamethasone and Thalidomide maintenance therapy.
11650778|NCT00075829|Active Comparator|Auto transplants|One autologous transplant along with a second autologous transplant will be preformed followed by one year of observation.
11650779|NCT00075829|Active Comparator|Auto and Allo transplants|One autologous transplant and one non-myeloablative allogeneic transplant will be preformed and followed by one year of observation.
11650780|NCT00075816|Active Comparator|Bone Marrow Transplant|Allogeneic bone marrow transplantation
11650781|NCT00075816|Active Comparator|Blood Stem Cell Transplant|Peripheral blood stem cell transplantation
11650782|NCT00075803|Active Comparator|Fluconazole|The dose of fluconazole is 400 mg by mouth or intravenous drip.
11650783|NCT00075803|Experimental|Voriconazole|The dose of oral voriconazole is 200 mg twice daily. When voriconazole must be given intravenously, it will be given at a dose of 200 mg every 12 hours for the duration of intravenous therapy.
11650784|NCT00075764|Active Comparator|Arm I|Patients receive oral anastrozole once daily on days 1-28.
11650785|NCT00075764|Experimental|Arm II|Patients receive oral anastrozole as in arm I. Patients also receive fulvestrant intramuscularly on days 1, 14, and 28 during course 1 and then on day 28 of the subsequent courses.
11650786|NCT00075751|Experimental|Treatment (gemcitabine hydrochloride, carboplatin, bortezomib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8, carboplatin IV over 15-30 minutes on day 1, and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive bortezomib alone on the above schedule for up to 1 year at the discretion of the treating physician.
11650787|NCT00075725|Experimental|Dexamethasone & Capizzi MTX patients<10 yrs|Patients receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15 & 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. Dexamethasone (5 mg/m2/dose on Days 1-14 by mouth or infusion twice a day in weeks 1 & 2; IT MTX (Aged based dosing: Age (yrs) Dose 1 - 1.99 8 mg 2 - 2.99 10 mg 3 - 8.99 12 mg ≥ 9 15 mg) on days 8 & 29 (CNS3 also on days 15 & 22) and an injection of pegaspargase (2500 International units/m2 x 1 dose on Day 4, 5 or 6).
11650817|NCT00075387|Experimental|Arm II (combination chemotherapy, sodium thiosulfate)|"Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA as in Arm I. Patients also receive sodium thiosulfate IV over 15 minutes 4 and 8 hours later.
~Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
11650788|NCT00075725|Experimental|Dexamethasone, High Dose (DH) MTX (non random)|Patients non-randomly assigned to the DH regimen based on one (or more) of the following: (1) CNS3 status at entry, (2) testicular leukemic involvement at entry, or (3) extensive pre-treatment with steroids prior to entry. Patients receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15 & 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. Dexamethasone (5 mg/m2/dose on Days 1-14 by mouth or infusion twice a day in weeks 1 & 2; IT MTX (Aged based dosing: Age (yrs) Dose 1 - 1.99 8 mg 2 - 2.99 10 mg 3 - 8.99 12 mg ≥ 9 15 mg) on days 8 & 29 (CNS3 also on days 15 & 22) and an injection of pegaspargase (2500 International units/m2 x 1 dose on Day 4, 5 or 6).
11650789|NCT00075725|Experimental|Dexamethasone & Capizzi MTX patients =>10 yrs|Patients receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15 and 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. Dexamethasone (5 mg/m2/dose on Days 1-14 by mouth or infusion twice a day in weeks 1 & 2; IT MTX (Aged based dosing: Age (yrs) Dose 1 - 1.99 8 mg 2 - 2.99 10 mg 3 - 8.99 12 mg ≥ 9 15 mg) on days 8 & 29 (CNS3 also on days 15 & 22) and an injection of pegaspargase (2500 International units/m2 x 1 dose on Day 4, 5 or 6).
11650790|NCT00075725|Experimental|Dexamethasone during Induction, High Dose MTX (IM)<10|Patients randomly assigned to the DH regimen based on one (or more) of the following: (1) No CNS3 status at entry, (2) no testicular leukemic involvement at entry, or (3) no extensive pre-treatment with steroids prior to entry. Patients receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15 & 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. Dexamethasone (5 mg/m2/dose on Days 1-14 by mouth or infusion twice a day in weeks 1 & 2; IT MTX (Aged based dosing: Age (yrs) Dose 1 - 1.99 8 mg 2 - 2.99 10 mg 3 - 8.99 12 mg ≥ 9 15 mg) on days 8 & 29 (CNS3 also on days 15 & 22) and injection of pegaspargase (2500 International units/m2 x 1 dose on Day 4, 5 or 6).
11650791|NCT00075725|Experimental|Prednisone, Capizzi (PC) MTX (<10 yrs old)|Patients in regimen PC will receive cytarabine, vincristine sulfate, daunorubicin hydrochloride, and pegaspargase. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and IT MTX in weeks 2 & 5. Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning in week 6 or 7, patients may receive combination chemotherapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, mercaptopurine, cytarabine, thioguanine) by infusion, injection, intrathecally, and by mouth for up to 8 weeks.
11650792|NCT00075725|Experimental|Prednisone, Capizzi MTX (>= 10 yrs)|Patients in regimen PC will receive cytarabine, vincristine sulfate, daunorubicin hydrochloride, and pegaspargase. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and IT MTX in weeks 2 & 5. Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning in week 6 or 7, patients may receive combination chemotherapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, mercaptopurine, cytarabine, thioguanine) by infusion, injection, intrathecally, and by mouth for up to 8 weeks.
11650793|NCT00075725|Experimental|Prednisone and High Dose (PH) MTX (< 10 yrs)|Patients randomly assigned to the PH regimen receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15 & 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and IT MTX in weeks 2 and 5. Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning in week 6 or 7, patients may receive combination chemotherapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, mercaptopurine, cytarabine, thioguanine) by infusion, injection, intrathecally, and by mouth for up to 8 weeks.
11650794|NCT00075725|Experimental|Prednisone and High Dose MTX (>=10 yrs)|Patients randomly assigned to the PH regimen receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15 & 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and IT MTX in weeks 2 & 5. Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning week 6 or 7, patients may receive combination chemotherapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, mercaptopurine, cytarabine, thioguanine) by infusion, injection, intrathecally, and by mouth for up to 8 weeks.
11650795|NCT00075725|Experimental|Dexamethasone, High Dose MTX (IM) >=10 yrs|Patients randomly assigned to the DH regimen based on one (or more) of the following characteristics: (1) No CNS3 status at entry, (2) no testicular leukemic involvement at entry, or (3) no extensive pre-treatment with steroids prior to entry. Patients receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15 & 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. Dexamethasone (5 mg/m2/dose on Days 1-14 by mouth or infusion twice a day in weeks 1 & 2; IT MTX (Aged based dosing: Age (yrs) Dose 1 - 1.99 8 mg 2 - 2.99 10 mg 3 - 8.99 12 mg ≥ 9 15 mg) on days 8 & 29 (CNS3 also on days 15 & 22) and an injection of pegaspargase (2500 International units/m2 x 1 dose on Day 4, 5 or 6).
11650796|NCT00075725|Experimental|Prednisone, Capizzi MTX Down Syndrome (DS) (non random)|Patients in regimen PC will receive cytarabine, vincristine sulfate, daunorubicin hydrochloride, and pegaspargase. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and IT MTX in weeks 2 & 5. Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning in week 6 or 7, patients may receive combination chemotherapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, mercaptopurine, cytarabine, thioguanine) by infusion, injection, intrathecally, and by mouth for up to 8 weeks.
11650797|NCT00075725|Experimental|Dexamethasone, Capizzi MTX DS (non random)|Patients receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15 & 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15 & 22. Dexamethasone (5 mg/m2/dose on Days 1-14 by mouth or infusion twice a day in weeks 1 & 2; IT MTX (Aged based dosing: Age (yrs) Dose 1 - 1.99 8 mg 2 - 2.99 10 mg 3 - 8.99 12 mg ≥ 9 15 mg) on days 8 and 29 (CNS3 also on days 15 & 22) and an injection of pegaspargase (2500 International units/m2 x 1 dose on Day 4, 5 or 6).
11650798|NCT00075725|Experimental|Prednisone & High Dose MTX (non random)|Patients non-randomly assigned to the PH regimen based on one (or more) of the following: (1) CNS3 status at entry, (2) testicular leukemic involvement at entry or (3) extensive pre-treatment with steroids prior to entry. Patients receive IT cytarabine (Age-based dosing: Age (yrs) Dose 1 - 1.99 30 mg 2 - 2.99 50 mg ≥ 3 70 mg) on day 1; infusions of vincristine sulfate 1.5 mg/m2/dose (maximum dose of 2 mg) on Days 1, 8, 15, & 22 and daunorubicin hydrochloride (25 mg/m2/dose on Days 1, 8, 15, & 22. They will also receive prednisone by mouth or infusion twice a day in weeks 1-4 and IT MTX in weeks 2 & 5. Some patients in all groups may receive induction therapy for 2 additional weeks. Beginning week 6 or 7, patients may receive combination chemotherapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, mercaptopurine, cytarabine, thioguanine) by infusion, injection, intrathecally, and by mouth for up to 8 weeks.
11650799|NCT00075686|Experimental|gemcitabine hydrochloride + IMC-C225|Loading dose: gemcitabine hydrochloride 1000mg/m2, IV on Day 1; Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only) Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 & days 1,8,15,22 of all subsequent cycles; gemcitabine hydrochloride 1000mg/m2, IV on Days 8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles.
11650800|NCT00075686|Experimental|gemcitabine hydrochloride alone|gemcitabine hydrochloride 1000mg/m2, IV on Days 1,8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles.
11650801|NCT00075647|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11650802|NCT00075634|Experimental|Arm I|"PART A (solid tumor patients): Patients receive decitabine IV over 1 hour on days 0-6 and doxorubicin IV over 15 minutes and cyclophosphamide IV over 1 hour on day 7. Patients then receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8 or 9*. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
~PART B (neuroblastoma patients): Once the MTD is determined for part A, patients are treated as in part A at the MTD."
11650803|NCT00075621|Other|tandem transplant|"Drug: filgrastim 16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection
~Drug: melphalan 200 mg/kg over 2 days
~Procedure/Surgery: autologous peripheral blood stem cell transplantation
~autologous peripheral blood stem cell transplantation"
11650804|NCT00075608|Experimental|2nd Stem Cell Transplant|Mobilization with filgrastim autologous stem cell transplantation with melphalan conditioning stem cell infusion
11650805|NCT00075582|Experimental|Regimen I (chemotherapy, radiotherapy)|Patients receive VAC chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 1-9 and dactinomycin IV over 1 minute and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, and 10; VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, and 22 (dactinomycin is omitted during radiation therapy); and radiation therapy, 5 days a week, beginning on week 13 and continuing for 4-7 weeks, depending on prescribed dose. Some patients do not receive radiation therapy; some start it at week 24. (closed to accrual as of 08/13/2010)
11650806|NCT00075582|Experimental|Regimen II (chemotherapy, radiotherapy, surgery)|Patients receive VAC chemotherapy and radiation therapy as in regimen I and VA chemotherapy comprising vincristine sulfate IV over 1 minute on day 1 of weeks 13-21, 25-33, and 37-45 and dactinomycin IV over 1 minute on day 1 of weeks 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, and 46 (dactinomycin is omitted during radiation therapy). Some patients do not receive radiation therapy; some start it at week 13 and some at week 24. Some patients have conventional surgery (second-look) at Week 13 (closed to accrual as of 9/23/2011).
11650807|NCT00075569|Active Comparator|1 month follow-up|3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 1 month; followed by LEEP or cone biopsy
11650808|NCT00075569|Active Comparator|2 month follow-up|3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 2 months; followed by LEEP or cone biopsy
11650809|NCT00075504|Experimental|triapine, gemcitabine|Triapine IV over 4 hours followed by gemcitabine IV over 30 minutes on days 1, 8, and 15, repeat every 28 days
11650810|NCT00075491|Experimental|Arm I (fenretinide, surgery)|Patients receive neoadjuvant oral fenretinide twice daily for 1 week and then undergo surgical resection.
11650811|NCT00075491|Active Comparator|Arm II (surgery)|Patients undergo surgical resection.
11650812|NCT00075478|Experimental|Arm I (chemotherapy, TBI, transplant, GVHD prophylaxis)|Patients receive fludarabine phosphate IV on days -4 to -2. Patients then undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.
11650813|NCT00075478|Active Comparator|Arm II (TBI, transplant, GVHD prophylaxis)|Patients undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.
11650814|NCT00075439|Experimental|Arm I|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11650815|NCT00075400|Experimental|Treatment (imatinib mesylate)|Patients receive imatinib mesylate PO QD or BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11650816|NCT00075387|Experimental|Arm I (combination chemotherapy)|"Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA over 10 minutes.
~Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
11650818|NCT00075374|Experimental|Docetaxel|
11650819|NCT00075335|Experimental|AMD 3100 (Mozobil plerixafor)|AMD 3100 (Mozobil plerixafor)mobilized peripheral blood hematopoietic progenitor cells from healthy volunteers will be characterized by cellular content and immunological properties.
11650820|NCT00075270|Experimental|Arm 1|Lapatinib 1500 mg, once daily and Paclitaxel 175 mg/m Intravenously over 3 hours ever 3 weeks
11650821|NCT00075270|Placebo Comparator|Arm 2|Paclitaxel 175 mg/m Intravenously over 3 hours ever 3 weeks and Placebo
11650822|NCT00075218|Placebo Comparator|B|
11650823|NCT00075218|Active Comparator|A|
11650824|NCT00020787|Experimental|Treatment|See intervention description.
11650825|NCT00017537|Experimental|Dose #1|dose #1 administered
11650826|NCT00017537|Experimental|Dose #2|dose #2 administered
11650827|NCT00017537|Experimental|Dose #3|Dose #3 administered
11650828|NCT00017537|Experimental|Dose #4|Dose #4 administered
11650829|NCT00017537|Experimental|Dose #5|Administered dose #5
11650830|NCT00075179|Experimental|Nesiritide|Nesiritide 0.01 mcg/kg/min by vein over 30 minutes during right heart catheterization procedure.
11650831|NCT00075140||1|All Participants hav a family member with Huntington Disease
11650832|NCT00075114|Other|1 Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
11650833|NCT00075114|No Intervention|2 Control Group|Participants randomized to this arm did not receive any interventions.
11650834|NCT00075101|Experimental|Study Cycle|
11650835|NCT00075088|Experimental|Electrocardiogram (ECG) Intervention|Patients randomized to the experimental group had their ECGs printed out in the target ED with an audible voice alarm. Print-out of the pre-hospital ECG in the target ED was the intervention.
11650836|NCT00075088|Other|Routine Clinical Practice|Control patients had an ECG conducted after hospital arrival, as was the standard of care in the county.
11650837|NCT00012116|Experimental|temozolomide|Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
11650838|NCT00009919|Experimental|Treatment (semaxanib)|Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues every 6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with CR receive an additional 6 months of therapy after achieving CR.
11650839|NCT00009893|Experimental|gemcitabine + leucovorin + fluorouracil|Patients receive gemcitabine IV over 30 minutes followed by leucovorin calcium IV and fluorouracil IV over 5-10 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
11650840|NCT00075023|Experimental|Thalidomide gel|Thalidomide gel 20 mg applied topically 4 times daily for 4 weeks to a maximum of 3 target oral ulcers
11650841|NCT00075023|Experimental|Placebo|Placebo gel with no Thalidomide applied topically 4 times daily for 4 weeks to a maximum of 3 target oral ulcers
11650842|NCT00075010|Experimental|Decitabine + Valproic acid|Decitabine 15 mg/m^2 by vein over 1 hour times 10 days
11650843|NCT00074997|Experimental|001|OZ1 Single intravenous infusion of 2-20 x 10 to the power of 7 OZ1 transduced autologous CD34+ cells per kilogram of body weight
11650844|NCT00074997|Placebo Comparator|002|Placebo Single intravenous infusion of placebo transduced autologous CD34+ cells per kilogram of body weight
11650845|NCT00009867|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1 hour on days 1-5. Treatment repeats every 28 days for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response receive 2 additional courses.
11650846|NCT00009698|Experimental|All patients|Day 1 through day 7, days 9-14 and days 16-22: The assigned dose of IL-2 will be administered SQ. On days 8 and 15, IL-2 will be administered as a 2 hour intravenous infusion of one million units/M2 of IL-2. After day 22 there will be a 7 day rest period before beginning the next cycle. The next cycle will repeat just as above. This will be repeated for a maximum of 4 total cycles of 21 days of IL-2 therapy. The maintenance dose of IL-2 will always be the same as given during cycle one, unless there is dose limiting toxicity.
11650847|NCT00074984|Placebo Comparator|Placebo|Patients randomized to placebo
11650848|NCT00074984|Active Comparator|Fabrazyme (agalsidase beta)|Patients randomized to Fabrazyme (agalsidase beta).
11650849|NCT00074958|Experimental|Fabrazyme|1.0 mg/kg of Fabrazyme given to the patients every 2 weeks
11650850|NCT00074932|Other|1|
11650851|NCT00006213|Experimental|Treatment (BMS-214662)|Patients receive BMS-214662 IV over 1 hour weekly for 4 weeks. Treatment continues every 4 weeks for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression.
11650852|NCT00074828|Experimental|A|
11650853|NCT00074828|Active Comparator|B|
11650854|NCT00074763|Experimental|Platelet Transfusion|ThromboSol-preserved autologous platelet transfusion or Standard platelet transfusion. All patients receive both platelets frozen with Thrombosol and fresh random platelets. The order in which patients receive these two types of platelets randomized in a crossover design. Patients randomly assigned to receive either the sequence FRP then Thrombosol or Thrombosol then FRP. The randomization will occur after second cycle of chemotherapy, since all patients will receive FRP with the first cycle.
11650855|NCT00074750|Experimental|DTGM|Starting dose of DTGM fusion protein 2 mcg/kg/day as a short (30 min) intravenous infusion, three times /week (M,W,F) for two consecutive weeks. In absence of defined grade 3/4 nonhematological toxicities in the first 0/3 or 1/6 patients, the dose will be escalated by 1 mcg/kg/day for the next patient cohort.
11650856|NCT00074737|Active Comparator|cenersen, idarubicin|cenersen, idarubicin, no cytarabine
11650857|NCT00074737|Active Comparator|cenersen, idarubicin, cytarabine|cenersen, idarubicin, standard dose cytarabine
11650858|NCT00074737|Active Comparator|cenersen, idarubicin, HDAC|cenersen, idarubicin, HDAC (high dose cytarabine)
11650859|NCT00074724|Active Comparator|Medical Therapy|All medical interventions know to improve outcomes in patients with ischemic left ventricular dysfunction.
11650860|NCT00074724|Active Comparator|CABG|Surgical revascularization in conjunction with optimal medical therapy.
11650896|NCT00074425|Experimental|2|Pro 2000/5 Gel (P)
11650897|NCT00074425|Placebo Comparator|3|Placeo Gel
11650898|NCT00074425|No Intervention|4|
11650899|NCT00074412|Experimental|2A|For infants: extended treatment with NVP
11650861|NCT00005963|Experimental|docetaxel + carboplatin|This is a multicenter study. Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), partial response (PR), or complete response (CR) may receive 4 additional courses past SD, PR, or CR. Patients are followed every 6 months for 2 years and then annually for 3 years.
11650862|NCT00074815|Experimental|MedMgmt+CBT|Participants will receive the following interventions: 1)SRI medication management with a psychiatrist plus, 2) cognitive behavioral therapy with a psychologist.
11650863|NCT00074815|Experimental|MedMgmt+I-CBT|Participants will receive the following interventions 1)SRI medication management plus, 2) instructional cognitive behavioral therapy. Both of these will be implemented by the same psychiatrist.
11650864|NCT00074815|Active Comparator|MedMgmt Only|Participants will receive the intervention SRI medication management with a psychiatrist
11650865|NCT00074802|Experimental|Paroxetine Continuation|Participants who showed only partial response to paroxetine in Phase 1 will receive continued treatment with paroxetine for 16 additional weeks.
11650866|NCT00074802|Experimental|Paroxetine with CBT Augmentation|Participants who showed only partial response to paroxetine in Phase 1 will receive continued treatment with paroxetine plus cognitive behavioral therapy (CBT) for 16 additional weeks.
11650867|NCT00074789|Experimental|1|Participants will receive home-based interpersonal depression treatment for 26 weeks
11650868|NCT00074789|Active Comparator|2|Participants will receive attention control/usual care for 26 weeks
11650869|NCT00074776|Experimental|1 Lithium|
11650870|NCT00074776|Experimental|2 Lamotrigine|
11650871|NCT00074711|Active Comparator|Calcium Phosphate Treatment Group|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
11650872|NCT00074711|Active Comparator|Calcium Carbonate Treatment Group|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.
11650873|NCT00074607|Experimental|Intrathecal gemcitabine administration|"Intrathecal gemcitabine will be given on a weekly schedule for the first cohort of patients at the 5 mg dose level and then a twice-weekly (i.e., every 3 to 4 days) schedule. Drug administration will be by the intraventricular (Ommaya reservoir injection) route.
~Patients will be hospitalized overnight following their first dose of gemcitabine. If the first dose is well tolerated, subsequent induction doses may be administered in the outpatient setting with close observation for a minimum of 2 hours after administration.
~Dose Levels and Dose Escalation:
~Dose Level 1a: 5 mg
~Dose Level 1b: 5 mg
~Dose Level 2: 10 mg
~Dose Level 3: 20 mg
~Dose Level 4: 30 mg
~Dose Level 5: 40 mg
~Dose Level 6: 50 mg"
11650874|NCT00074581|Experimental|1|Participants will begin ART in addition to receiving HIV primary care
11650875|NCT00074581|Experimental|2|"Participants will receive HIV primary care. When the CD4 count in these participants reaches 200 to 250 cells/mm3, drops below 200 cells/mm3, or develops an AIDS-defining illness, they will initiate ART.
~Note: Per LoA#5, on the Data and Safety and Monitoring Board (DSMB) recommendation, as of May 10, 2011, all HIV-infected participants in Arm 2 who have not already initiated ART will be offered ART as soon as possible."
11650876|NCT00074568||1|Patients with scleroderma and their family members (parents, brothers, and sisters)
11650877|NCT00074568||2|Healthy volunteers with no autoimmune disease and without a first-degree relative with a systemic autoimmune disease
11650878|NCT00005646|Experimental|Paclitaxel|Patients receive paclitaxel for up to 4 cycles. One cycle = weekly drug for 6 weeks and 2 weeks rest
11650879|NCT00005592|Experimental|Rituxan + IDEC-In2B8, Rituxan + IDEC-Y2B8|For the first treatment, 250 mg/m2 Rituxan infusion and injection of IDEC-In2B8 (Indium- radioactive label) is given. If therapy is continued, approximately 1 week later a second infusion of Rituximab (250 mg/m2) is given followed by an infusion of IDEC-Y2B8 (Yttrium-radioactive label).
11650880|NCT00074490|Experimental|Arm IVD cohort 1 (Th2 DLI)|Patients receive low intensity fludarabine phosphate intravenous (IV) and cyclophosphamide IV on days -6 to -3. Patients undergo donor lymphocyte infusion (DLI) with sirolimus generated donor T-helper 2 (Th2) cells on day 14 (single T-Rapa cell DLI in patients with cluster of differentiation 4 (CD4) count between 100 and 200 inclusive)
11650881|NCT00074490|Experimental|Arm IVD cohort 2 (conventional DLI)|Patients receive low intensity fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3. Patients undergo DLI with unmanipulated donor T-cells on day 14 (single T- cell DLI in patients with low CD4 count between 100 and 200 inclusive)
11650882|NCT00074490|Experimental|Arm IVD cohort 3 (multiple Th2 DLI)|Patients with nonlymphoma diagnosis or rapidly progressive lymphoma undergo DLI with multiple infusions of sirolimus generated donor Th2 cells beginning on day 14 (multiple T-Rapa cell DLI in patients with CD4 count lower than 100 or ALC lower than 300)
11650883|NCT00074490|Experimental|Arm IVA (12-day expanded Th2 DLI)|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine by mouth twice a day (PO BID) on days -4 to 100, and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic peripheral blood stem cells (PBSC) on day 0. Patients undergo DLI with 12-day expanded sirolimus-generated donor Th2 cells on day 14.
11650884|NCT00074490|Experimental|Arm IVB (6-day expanded Th2 DLI)|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -4 to 100, and standard dose sirolimus PO on days -2 to 14. Patients undergo mobilized allogeneic PBSC or bone marrow transplant on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14.
11650885|NCT00074490|Experimental|Arm IVC (6-day expanded Th2 DLI and High-Dose Sirolimus)|Patients receive low-intensity preparative chemotherapy with fludarabine phosphate IV and cyclophosphamide IV on days -6 to -3, cyclosporine PO BID on days -7 to 100 and high dose sirolimus PO on days -4 to 7, Patients undergo mobilized allogeneic PBSC on day 0. Patients undergo DLI with 6-day expanded sirolimus-generated donor Th2 cells on day 14.
11650886|NCT00074438|Experimental|1|
11650887|NCT00074438|Experimental|2|
11650888|NCT00074438|Experimental|3|
11650889|NCT00074438|Experimental|4|
11650890|NCT00074438|Experimental|5|
11650891|NCT00074438|Experimental|6|
11650892|NCT00074438|Placebo Comparator|7|
11650893|NCT00074438|Placebo Comparator|8|
11650894|NCT00074438|Placebo Comparator|9|
11650895|NCT00074425|Experimental|1|BufferGel
11650901|NCT00074399|Experimental|1|Participants will receive nevirapine for 6 weeks
11650902|NCT00074399|Placebo Comparator|2|Participants will receive nevirapine placebo for 6 weeks
11650903|NCT00074373||human beings|human beings of all sexes, ages, and health statuses
11650904|NCT00008177|Experimental|Treatment ( I 131 BC8, chemotherapy, TBI, PBSCT, CSP, MMF)|"CONDITIONING REGIMEN: Patients receive iodine I 131 monoclonal antibody BC8 IV on day -12 and fludarabine phosphate IV on days -4 to -2. Patients undergo total-body irradiation on day 0.
~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.
~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV BID on days -3 to 56 with taper to day 80 (for patients with a related donor) OR days -3 to 100 with taper to day 177 (for patients with an unrelated donor) in the absence of GVHD. Patients also receive mycophenolate mofetil PO or IV TID on days 0 to 27 (for patients with a related donor) OR on days 0 to 40 with taper to day 96 (for patients with an unrelated donor) in the absence of GVHD."
11650905|NCT00074321|Experimental|Arm I|Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO QD on days 2-15. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11650906|NCT00074308|Experimental|Arm I|Patients receive oral imatinib mesylate once or twice daily on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11650907|NCT00074295|Experimental|treatment|GVAX lung cancer vaccine
11650908|NCT00074282|Experimental|Arm A (PCR)|"Treatment consisted of 6 cycles of pentostatin, cyclophosphamide, and rituximab (PCR) given every 28 days.
~Rituximab administered as follows: For the first infusion, all patients receive 100 mg dose (regardless of weight/BSA). For subsequent infusions, all patients receive rituximab 375 mg/m2.
~Pentostatin and cyclophosphamide administered as follows: Pentostatin given at 4 mg/m2 either as an IV push or IV over 10-30 minutes in 250 mL NS or D5W on day 1 every 4 weeks of cycles 1-6. Cyclophosphamide given at 600 mg/m2 IV over 30-60 minutes in 250 mL NS on day 1 every 4 weeks of cycle 1-6."
11650909|NCT00074282|Experimental|Arm B (Alemtuzumab: CR, nPR)|Patients who achieved a confirmed CR or nPR, were registered to receive Alemtuzumab (Arm B). When the patient was registered to Arm B, the drug was administered three times a week for four weeks. The dose was 30 mg per dose. A twelve-week treatment-free period had to elapse before CAMPATH-1H began following completion of PCR for Arm B patients
11650910|NCT00074282|Experimental|Arm C (Alemtuzumab: PR, <PR, PD)|For those patients not achieving a CR or nPR (thus patients either achieved PR, SD, or PD), Alemtuzumab (Arm C) was administered three times a week for eighteen weeks at a dose of 30 mg TIW. For PR, SD and PD patients, the timing of CAMPATH-1H was left to the discretion of the investigator, and treatment could begin earlier but no less than two weeks and no longer than eight weeks after the completion of the last PCR course. Patients determined to have PD during treatment with PCR did not need to complete all 6 cycles of PCR to go on to Arm C, however, completing a minimum of 2 cycles was required.
11650911|NCT00074269|Experimental|treatment|
11650912|NCT00074204|Experimental|Immediate Docetaxel|Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.
11650913|NCT00074204|Active Comparator|Delayed Docetaxel|Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.
11650914|NCT00074165|Experimental|All subjects|
11650915|NCT00074152|Active Comparator|Arm I|Patients receive radiotherapy* within 6 months after surgery.
11650916|NCT00074152|Experimental|Arm II|Within 10 weeks after surgery, patients receive at least 3 courses of an adjuvant chemotherapy regimen as determined by the investigator. Patients may receive radiotherapy within 6 months after surgery and after the completion of chemotherapy OR integrated with chemotherapy.
11650917|NCT00074087|Experimental|Caelyx|doxorubicin HCl liposome IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses.
11650918|NCT00074048|Experimental|1|BL22 immunotoxin
11650919|NCT00074035|Experimental|Pentostatin|treatment of pts with refractory graft vs host disease
11650920|NCT00074022|Experimental|Treatment (GTI-2040, docetaxel)|"Phase I (closed to accrual as of 8/5/2004): Patients receive GTI-2040 IV continuously on days 1-14. Patients also receive docetaxel IV over 1 hour on day 3 during course 1 and on day 1 for all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of GTI-2040 and docetaxel until the MTD is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The RP2D is defined as the dose preceding the MTD.
~Phase II: Patients receive GTI-2040 and docetaxel at the RP2D as in phase I."
11650921|NCT00073957|Experimental|Y-90 Ibritumomab Tiuxetan|Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab and central nervous system prophylaxis with Cytarabine or liposomal cytarabine
11650922|NCT00073918|Experimental|Treatment (radio labeled monoclonal antibody, chemotherapy)|"RADIOIMMUNOTHERAPY: Patients receive a test dose of iodine I 131 tositumomab IV on day -24 to determine biodistribution. Patients then receive therapeutic iodine I 131 tositumomab IV over approximately 40-60 minutes on day -14 and are entered into radiation isolation until day -4.
~CHEMOTHERAPY: Patients receive etoposide IV on day -4 and cyclophosphamide IV on day -2.
~AUTOLOGOUS STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplantation on day 0."
11650923|NCT00073905|Active Comparator|Arm A|Capecitabine plus Gemcitabine
11650924|NCT00073892|Experimental|PI-88|Patients receive four consecutive days treatment each week in a 4-week cycle.
11650925|NCT00073840|Active Comparator|I|Levalbuterol 90 ųg QID (manufacturing site A or B)
11650926|NCT00073840|Active Comparator|II|Racemic Albuterol 180 ųg QID
11650927|NCT00073840|Placebo Comparator|III|Placebo QID
11650928|NCT00073827|Experimental|1|levalbuterol MDI 90 mcg QID
11650929|NCT00073827|Active Comparator|2|racemic albuterol MDI 180 mcg QID
11650930|NCT00073827|Placebo Comparator|3|Placebo MDI QID
11650931|NCT00004857|Experimental|Fludarabine + Campath-1H|Standard of care induction with fludarabine followed by consolidation antibody therapy
11650932|NCT00004242|Experimental|Arm I|See detailed description.
11650933|NCT00003927|Experimental|High Dose chemotherapy followed by cell rescue|Doxorubicin, cyclophosphamide, Taxol, amifostine
11650934|NCT00073814|Experimental|1|levalbuterol MDI 90 mcg QID
11650935|NCT00073814|Active Comparator|2|racemic albuterol MDI 190 mcg QID
11650937|NCT00073788||Subjects with PTSD|Subjects will be American Indian, between the ages of 18-68. Approximately 66% will be female, 33% male, which conforms to the distribution of PTSD in this population. Study group subjects will be PTSD positive. Overt CVD is exclusionary.
11650938|NCT00073788||Control Group|Subjects will be American Indian, between the ages of 18-68. Approximately 66% will be female, 33% male, which conforms to the distribution of PTSD in this population. Control subjects will be PTSD negative. For both groups: overt CVD is exclusionary.
11650939|NCT00003761|Experimental|rV-DF3/MUC1|"rV-DF3/MUC1 vaccinations will be administered 4 week intervals for a total of 3 doses.
~Participants will be followed weekly until 28 days after the final dose (day 85) then month for 6 months"
11650940|NCT00073801||Chronic Pelvic Pain and Endometriosis|Women with chronic pelvic pain and endometriosis found at study surgery
11650941|NCT00073801||Chronic Pelvic Pain and No Endometriosis|Women with chronic pelvic pain and NO endometriosis found at study surgery
11650942|NCT00073801||Healthy Volunteers|Women without no chronic pelvic pain and no symptoms of endometriosis
11650943|NCT00073749|Experimental|Inotuzumab ozogamicin|Inotuzumab ozogamicin, iv, dose escalation and expanded cohort at 1.8mg/m2
11650944|NCT00073736|Experimental|MB07133 Dose Level 1|7-day continuous infusion in 28-day cycles
11650945|NCT00073736|Experimental|MB07133 Dose Level 2|7-day continuous infusion in 28-day cycles
11650946|NCT00073736|Experimental|MB07133 Dose Level 3|7-day continuous infusion in 28-day cycles
11650947|NCT00073736|Experimental|MB07133 Dose Level 4|7-day continuous infusion in 28-day cycles
11650948|NCT00073736|Experimental|MB07133 Dose Level 5|7-day continuous infusion in 28-day cycles
11650949|NCT00003694|Experimental|Treatment (omacetaxine mepesuccinate, cytarabine)|Patients receive cytarabine and homoharringtonine concurrently by continuous intravenous infusion for 7 days. Courses repeat every 28 days. Patients receive a minimum of 9 courses of therapy in the absence of disease progression and unacceptable toxicity. Patients who are major cytogenetic responders at 9 months may continue therapy or switch to interferon. Minor cytogenetic responders are switched to interferon, and nonresponders are removed from therapy and given the option to switch to interferon.
11650950|NCT00073697|Experimental|1|Interpersonal Psychotherapy
11650951|NCT00073697|Experimental|2|Escitalopram
11650952|NCT00073697|Experimental|3|Escitalopram plus IPT
11650953|NCT00073684|Experimental|1|Participants will receive 8 sessions of TF-CBT with narrative.
11650954|NCT00073684|Experimental|2|Participants will receive 8 sessions of TF-CBT without narrative.
11650955|NCT00073684|Experimental|3|Participants will receive 16 sessions of TF-CBT with narrative.
11650956|NCT00073684|Experimental|4|Participants will receive 16 sessions of TF-CBT without narrative.
11650957|NCT00073671|Experimental|1|Participants receive a group cognitive-behavioral prevention program, which involved 8 weekly sessions and 6 monthly sessions of CBT skills such as cognitive restructuring, problem-solving, assertivenss, and behavioral activation. Participants in this arm also were able to seek the same kinds of nonstudy treatments as described in the usual care arm.
11650958|NCT00073671|Active Comparator|2|Participants receive usual care, which involves any type of treatment (e.g., psychotherapy, counseling, pharmacotherapy).
11650959|NCT00073645|Experimental|1|Family/Parents CBT (FCBT) for 14 to 16 weekly sessions
11650960|NCT00073645|Active Comparator|2|Peer/Group CBT (GCBT) for 14 to 16 weekly sessions
11650961|NCT00073619|Experimental|Cognitive-behavioral group therapy|School-based anxiety preventive intervention (cognitive-behavioral group therapy) originally designed for Australian children that was culturally and contextually modified for inner-city children exposed to community violence. Participants received the weekly intervention and rewards for participating in the assessments.
11650962|NCT00073619|No Intervention|Non-intervention Comparison|Provide no active intervention to the comparison group, although assess the children at the same assessment points as the experimental group. Participants in the control arm were told they were FRIENDS Program participants.They received rewards for participating in the assessments.
11650963|NCT00073593|Experimental|bivalirudin|250mg vial given as 0.75mg/kg intravenous (IV) bolus and 1.75 mg/kg/hr IV infusion for the duration of the procedure with the option to increase or decrease the infusion in 0.25 mg/kg/hr increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an ACT>300 seconds.
11650964|NCT00073593|Active Comparator|heparin/protamine|1.5-3.5 mg/kg (200-400 U/kg) intravenous (IV) bolus to target an ACT >300 seconds followed by weight-adjusted boluses as needed during the procedure to achieve/maintain the target ACT. Protamine as needed
11650965|NCT00073528|Other|Placebo plus letrozole|Placebo plus letrozoleA daily dose of randomized therapy ) taken approximately at the same time each day.
11650966|NCT00073528|Experimental|lapatinib plus letrozole|GW572016 and letrozole A daily dose of randomized therapy ) taken approximately at the same time each day.
11650967|NCT00003387|Experimental|Chemo + radiation|
11650968|NCT00003387|Experimental|Induction chemo + chemo & radiation|
11650969|NCT00003313|Experimental|Arm 1|Radiation therapy and chemotherapy + Amifostine
11650970|NCT00003313|Active Comparator|Arm 2|Radiation therapy and chemotherapy alone
11650971|NCT00003191|Experimental|Arm I|Patients receive oral fenretinide 3 times a day on days 1-7. Treatment repeats every 3 weeks for up to 8 courses. Patients may receive an additional 22 courses of therapy in the presence of stable or responding residual tumor. Patients with recurrent neuroblastoma, after prior myeloablative therapy with no measurable disease, will stop treatment after 8 courses. Cohorts of 3-6 patients receive escalating doses of fenretinide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
11651005|NCT00072839|Placebo Comparator|Placebo|placebo solution injected subcutaneously daily into either thigh or abdomen.
11651006|NCT00072839|Experimental|teduglutide 0.05|teduglutide 0.05 mg/kg/d injected subcutaneously daily.
11651007|NCT00072839|Experimental|teduglutide 0.1|0.1 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen
11651008|NCT00072839|Experimental|teduglutide|0.2 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen
11651009|NCT00072761|Active Comparator|Transfusion Group|Participants allocated to the transfusion arm will receive blood transfusion therapy every 4-6 weeks for 36 months.
11651065|NCT00071890|Active Comparator|Interleukin 2 group|HAART (standard of care) and three cycles of IL-2
11650972|NCT00003167|Experimental|Treatment (adenovirus p53)|"Group 1 patients receive adenovirus p53 (Ad-p53) intravesically on days 1 and 4. Treatment continues every 4 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3 patients in group 1 receive escalating doses of Ad-p53. In the absence of grade 3 or worse toxicity in the first 3 patients treated, subsequent cohorts of 3 patients each receive escalating doses of Ad-p53 on the same schedule. If 1 of 3 patients experiences grade 3 toxicity, an additional 3 patients are treated at that dose level and dose escalation continues. If 1 of 3 patients experience grade 4 toxicity or 2 of 3 patients experience grade 3 toxicity, dose escalation ceases and the MTD is defined as the previous dose level. Group 2 patients receive Ad-p53 at the MTD on days 1-4, and group 3 patients receive Ad-p53 at the MTD on days 1-4 and 8-11."
11650973|NCT00003130|Experimental|paclitaxel|Patients receive single fixed dose intravenous paclitaxel over 3 hours on day 1. Blood samples must be drawn prior to the first paclitaxel infusion and then at 1, 6, and 24 hours after the start of the infusion during course 1 only. Treatment courses of intravenous paclitaxel are repeated every 3 weeks at the discretion of the treating physician. Patients are evaluated for response after the second course. Patients are followed at the discretion of the physician.
11650974|NCT00002836|Experimental|Filgrastim + Chemotherapy|
11650975|NCT00002836|Experimental|Filgrastim|
11650976|NCT00002812|Experimental|Arm A - Standard BFM of Standard Duration (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow. Consolidation (Phase II) (5 weeks) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
11650977|NCT00002812|Experimental|Arm B - Standard BFM with Double Delayed Intensification (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (5 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
11650978|NCT00002812|Experimental|Arm C - Augumented BFM of Standard Duration (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (9 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
11650979|NCT00002812|Experimental|Arm D - Augmented BFM with Dbl Delayed Intensification (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (9 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
11650980|NCT00073346|Experimental|cognitive behavior therapy for hoarding disorder|Cognitive behavior therapy included 26 sessions of motivational enhancements; skills training for sorting, organizing and problem solving; direct practice not acquiring new items and discarding possessions to remove clutter and organize possessions; cognitive therapy to evaluate beliefs about possessions; and relapse prevention skills.
11650981|NCT00073346|No Intervention|Wait list control|Participants waited to receive treatment for 12 weeks
11650982|NCT00073333|Active Comparator|1|Social skills training and exposure
11650983|NCT00073333|Active Comparator|2|Exposure treatment
11650984|NCT00073333|Placebo Comparator|3|Placebo
11650985|NCT00073307|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Dose modification due to toxicity was permitted.
11650986|NCT00073307|Placebo Comparator|Placebo|Placebo tablets matching in appearance were to be orally administered twice a day.
11650987|NCT00002561|Active Comparator|Radiotherapy or ABVD + Radiotherapy|Radiotherapy
11650988|NCT00002561|Active Comparator|ABVD Alone|ABVD Alone
11650989|NCT00073398|Experimental|1|Ph II Arm 1
11650990|NCT00073242|Experimental|leptin repletion|Repletion of leptin following weight loss induced by dietary modification.
11650991|NCT00073242|Experimental|T3 repletion|Repletion of T3 following weight loss induced by dietary modification.
11650992|NCT00073073|Experimental|Exemestane|exemestane 25 mg by mouth (PO) every day for two years taken with calcium carbonate 1200 mg PO every day and vitamin D 400 IU PO every day Initially patients were initially planned to receive Celecoxib but the study was amended prior to any subject going on and Celecoxib was never administered to any subjects.
11650993|NCT00073060||NIH Platelepheresis|75, Apheresis Study Group - donation procedures use same devices as leukapheresis donors, also requiring citrate infusion
11650994|NCT00073060||NIH Research Leukapheresis Donors|75, Apheresis Study Group - donation procedures use same devices as plateletpheresis donors, also requiring citrate infusion; citrate administered may be twice as great as during plateletpheresis.
11650995|NCT00073060||NIH Whole Blood Donors|150 age, gender, race-matched donors - CONTROL GROUP
11650996|NCT00073021|Active Comparator|Asacol 2.4 g/day|Asacol (2.4 g/day)
11650997|NCT00073021|Experimental|Asacol 4.8 g/day|Asacol (4.8 g/day)
11650998|NCT00073008|Other|lapatinib|Randomized, open-label, parallel group, 2-stage study to evaluate and compare 2 dose schedules (1500 mg once daily and 500 mg twice daily) of oral lapatinib.
11650999|NCT00072982|Active Comparator|1|Fish Oil
11651000|NCT00072982|Active Comparator|2|Borage Oil
11651001|NCT00072982|Active Comparator|3|Fish Oil and Borage Oil
11651002|NCT00072930|Active Comparator|1|MEDI-522 + Docetaxel + Prednisone + Zoledronic Acid (N=55)
11651003|NCT00072930|Other|2|Docetaxel + Prednisone + Zoledronic Acid (N=55)
11651004|NCT00072904|Placebo Comparator|III|Placebo take half tab with meals tid
11651010|NCT00072761|No Intervention|Observation Group|Participants allocated to the observation arm will be treated according to standard care and will receive a quarterly physical examination by a study hematologist for 36 months.
11651011|NCT00072670|Experimental|Trabectedin 0.58 milligram per square meter (mg/m^2)|Trabectedin will be administered as 3-hour intravenous infusion at dose of 0.58 mg/m^2 weekly on Day 1, 8 and 15 in 28-day cycle and will be continued until disease progression or unacceptable toxicity.
11651012|NCT00072670|Experimental|Trabectedin 1.5 mg/m^2|Trabectedin will be administered at dose of 1.5 mg/m^2 as 24-hour infusion every three weeks, and will be continued until disease progression or unacceptable toxicity.
11651013|NCT00072670|Experimental|Trabectedin 1.2 mg/m^2|Trabectedin will be administered at dose of 1.2 mg/m^2 as 24-hour infusion every three weeks, and will be continued until disease progression or unacceptable toxicity.
11651014|NCT00072657|Experimental|1|Participants will partake in cognitive behavioral therapy for 12 weeks.
11651015|NCT00072657|Experimental|2|Participants will partake in tai chi chih for 12 weeks.
11651016|NCT00072657|Active Comparator|3|Participants will act as a control and attend educational sessions for 12 weeks.
11651017|NCT00072631|Experimental|1 erlotinib|
11651018|NCT00072475|Experimental|Vatalanib|Adult patients with MDS receive treatment with vatalanib.
11651019|NCT00072462|Active Comparator|Anastrozole|
11651020|NCT00072462|Active Comparator|Tamoxifen|
11651021|NCT00072449|Experimental|Rituximab monotherapy|Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks
11651022|NCT00072436|Experimental|Treatment|"Some patients receive an initial dose of alvocidib IV over 1-7 hours on day 1 (course 0). Beginning 1 week later and for all subsequent courses, all patients receive gemcitabine hydrochloride IV over 60-150 minutes on days 1 and 15 and alvocidib IV over 1-7 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of gemcitabine hydrochloride and alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment at that dose."
11651023|NCT00072384|Experimental|Treatment (chemotherapy, surgery)|Patients receive liposomal vincristine sulfate IV over 1 minute on day 1 and carboplatin IV over 1 hour and etoposide IV over 1 hour on days 1 and 2. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on day 3 and continuing until blood counts recover. Patients receive subtenon carboplatin to each group C or D eye on day 0 or 1prior of courses 2-4 only. Treatment repeats every 28 days for 6 courses in the absence of occurrence of extraocular retinoblastoma or a second malignancy. Beginning with course 3 of systemic chemotherapy, patients undergo local ophthalmic therapy comprising local laser surgery and/or cryosurgery on day 1.
11651024|NCT00072358|Experimental|patients have refractory bone marrow disease|This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.
11651025|NCT00072358|Experimental|patients have no evidence of disease|This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.
11651026|NCT00072293|Active Comparator|Axillary Dissection|Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.
11651027|NCT00072293|Experimental|No Axillary Dissection|Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.
11651028|NCT00072280|Experimental|Chemotherapy plus possible surgery|"Comprised of patients with disease lesions that are initially unresectable, or resected but with resulting grossly positive margins. All patients receive vincristine sulfate, dactinomycin, and cyclophosphamide (VAC), and mercaptoethane sulfonate (MESNA). Depending on response, patients may receive ifosfamide and etoposide (IE). Filgrastim may also be given, as needed. In addition to Chemotherapy, patients may receive Conventional Surgery.
~(See Interventions section for drug dosage and administration details.)"
11651029|NCT00072280|Experimental|Surgery only|Comprised of patients with initially resectable disease lesions. All patients undergo Conventional Surgery. Those with a result of clear or microscopically positive margins remain on study in this arm, for observation with no further intervention.
11651030|NCT00072215|Experimental|Regimen A: TIP|
11651031|NCT00072215|Experimental|Regimen B: VeIP|
11651032|NCT00072189|Experimental|Treatment (7-hydroxystaurosporine)|Patients receive UCN-01 IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11651033|NCT00072176|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11651034|NCT00072163|Experimental|Treatment (temozolomide, thalidomide)|Patients receive oral temozolomide once daily on days 1-42 and oral thalidomide once daily on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses of therapy beyond CR.
11651035|NCT00072150|Experimental|Treatment (bortezomib)|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Patients with a solitary site of disease (i.e., lung or nodal metastases) and who have a partial response (PR) may be considered for surgical resection. Patients with a PR with residual disease after salvage surgery are eligible to continue study therapy. Patients who achieve a complete response, either through resection or bortezomib therapy, receive 2 additional courses of study therapy."
11651036|NCT00072137|Experimental|Arm A (rf-GM-CSF, closed to accrual 10/2004)|Patients receive recombinant fowlpox GM-CSF vaccine adjuvant intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
11651037|NCT00072137|Experimental|Arm B (rf-TRICOM, closed to accrual 10/2004)|Patients receive recombinant fowlpox-TRICOM vaccine intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
11651064|NCT00005094|Placebo Comparator|Arm II (placebo)|Patients receive placebo twice a day for 3 years.
11651038|NCT00072137|Experimental|Arm C (rfTRICOM and rf-GM-CSF)|Patients receive recombinant fowlpox-TRICOM vaccine combined with recombinant fowlpox GM-CSF vaccine adjuvant intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
11651039|NCT00072098|Experimental|Experimental Group|Direct intratumoral injection of metastatic hepatic tumors using an adenoviral vector expressing the human recombinant interleukin-12 gene
11651040|NCT00072046|Experimental|Interferon|Treatment with interferon alfa 2b
11651041|NCT00072046|Experimental|Interferon + bevacizumab|Addition of bevacizumab to interferon alfa 2b treatment
11651042|NCT00072033|Active Comparator|Arm A|Docetaxel and Cisplatin chemo- and radiochemotherapy followed by surgery
11651043|NCT00071994|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11651044|NCT00071981|Experimental|Arm I (12MP)|Patients receive 2 injections of multi-epitope peptide vaccine comprising 12 melanoma peptides restricted by Class I MHC (12MP) emulsified with sargramostim (GM-CSF) and Montanide ISA-51 (incomplete Freund's adjuvant) or Montanide ISA-51 VG (ISA-51) intradermally (ID) and subcutaneously (SC) on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
11651045|NCT00071981|Experimental|Arm II (12MP/Tet)|Patients receive 2 injections of multi-epitope peptide vaccine comprising multi-epitope melanoma peptide vaccine (12MP) and 1 tetanus peptide melanoma vaccine emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
11651046|NCT00071981|Experimental|Arm III (12MP/6MHP)|Patients receive 2 injections of multi-epitope peptide vaccine comprising multi-epitope melanoma peptide vaccine (12MP) and 6 melanoma helper peptides (6HP) emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
11651047|NCT00071981|Experimental|Arm IV (6MHP)|Patients receive 2 injections of multi-epitope peptide vaccine comprising melanoma helper peptide vaccine (6HP) emulsified with GM-CSF and ISA-51 (incomplete Freund's adjuvant) ID and SC on day 1 of weeks 1-3 and 1 injection at the primary site only on day 1 of weeks 5-7.
11651048|NCT00071942|Experimental|Treatment (vaccine therapy)|Patients receive vaccination comprising recombinant vaccinia-MUC-1 and recombinant vaccinia-TRICOM vaccine intradermally on days 1 and 29 (for a total of 2 doses) in the absence of disease progression or unacceptable toxicity.
11651049|NCT00003141|Experimental|Treatment (combination chemotherapy, PBSC transplant)|Pts undergo conventional surgery for diagnosis & max tumor resection. In 6 wks of surgery or when stable pts begin induction chemotherapy(cisplatin IV over 6 hrs on day 0; vincristine sulfate IV on days 0,7,14; cyclophosphamide IV over 1 hr on days 1-2; and etoposide IV over 1 hr on days 0-2. 24 hrs after the last cyclophosphamide dose, pts receive filgrastim (G-CSF) & undergo peripheral blood stem cell harvest 2 days later. Treatment repeats every 21 days for up to 3 crs. Within 6 wks after induction, pts receive consolidation (carboplatin IV over 2 hrs on days 0-1 next esc. doses of thiotepa IV over 2 hrs. Pts undergo peripheral blood stem cell transplantation 48 hrs after last thiotepa dose. Pts receive G-CSF SC daily on days 3-21. Treatment repeats every 21 days for up to 3 crs. Pts with dose-limiting toxicity due to thiotepa are removed from study. Pts are followed at 4 wks, 3 mths for 1 yr, 6 mths for 3 yrs, annually for 3 yrs or until relapse.
11651050|NCT00072566|Experimental|Treatment (bevacizumab, cyclophosphamide)|Patients receive bevacizumab IV over 30-90 minutes on days 1, 8, and 15 for the first course and on days 1 and 15 for all subsequent courses. Patients also receive low-dose oral cyclophosphamide on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11651051|NCT00072527|Experimental|Induction and consolidation chemotherapy|"Induction chemotherapy (Cycles 1 and 2): Patients receive cisplatin 30 mg/m^2 on days 1, 8, 22 and 29 and irinotecan 65 mg/m^2 on days 1, 8, 22 and 29 for cycles 1 and 2.
~Consolidation chemotherapy (Cycles 3, 4 and 5 beginning on day 43, week 7): Patients receive carboplatin on days 43, 64 and 85, etoposide 100 mg/m^2 IV on days 43-45, 64-66 and 85-87 and XRT 5 fractions/week starting on day 43"
11651052|NCT00072514|Experimental|Treatment|Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8, carboplatin IV over 30-60 minutes on day 1, and dexamethasone orally (PO) on days 1-4. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CD20-POSITIVE LYMPHOMAS also receive rituximab IV on day 8.
11651053|NCT00071916||African American|Adult African American participants with compensated chronic hepatitis C who have not been previously been treated with interferon and/or ribavirin.
11651054|NCT00071916||Caucasian|Caucasian participants with compensated chronic hepatitis C who have not been previously been treated with interferon and/or ribavirin.
11651055|NCT00071812|Placebo Comparator|Placebo plus SOC|
11651056|NCT00071812|Experimental|Belimumab 1 mg/kg plus SOC|
11651057|NCT00071812|Experimental|Belimumab 4 mg/kg plus SOC|
11651058|NCT00071812|Experimental|Belimumab 10 mg/kg plus SOC|
11651059|NCT00071799|Experimental|Azacitidine|Study Drug plus best supportive care. Treatment with erythropoietin was not permitted
11651060|NCT00071799|Active Comparator|Conventional Care|Physician choice of low dose cytarabine (plus best supportive care), standard chemotherapy (plus best supportive care) or best supportive care (only). Treatment with erythropoietin was not permitted
11651061|NCT00005964|Experimental|Chemotherapy + prednisone + filgrastim|Patients receive doxorubicin IV, etoposide IV, vincristine IV, and cyclophosphamide IV continuously over days 1-4. Patients also receive oral prednisone twice daily on days 1-5 and filgrastim (G-CSF) subcutaneously beginning on day 6 until blood counts recover. Treatment continues every 21 days for a maximum of 8 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
11651062|NCT00005576|Experimental|Treatment (monoclonal antibody Ch14.18, aldesleukin)|Patients receive MOAB IV over 5 hours on days 7-10 during courses 2 and 4 and on days 3-6 during courses 1, 3, and 5; sargramostim (GM-CSF) IV over 2 hours or subcutaneously daily on days 0-13 during courses 1, 3, and 5; interleukin-2 IV continuously on days 0-3 and 7-10 during courses 2 and 4; and oral isotretinoin twice daily on days 14-27 during courses 2 and 4 and on days 10-23 during courses 3 and 5. Treatment repeats every 24-32 days for 5 courses in the absence of unacceptable toxicity.
11651063|NCT00005094|Experimental|Arm I (celecoxib)|Patients receive celecoxib twice a day for 3 years.
11651067|NCT00005072|Experimental|Leuvectin|Leuvectin
11651068|NCT00071773|Active Comparator|Modified Early Treatment Diabetic Retinopathy Study (ETDRS)|modified-ETDRS
11651069|NCT00071773|Active Comparator|Mild Macular Grid (MMG)|MMG technique
11651070|NCT00071786||Group 1|All study participants fall into one group for this observational family study regardless of diagnosis.
11651071|NCT00071760|Experimental|Arm A - 4weeks - less than 2 years old (FPV/RTV bid)|"Cohort 2A - 4weeks - less than 6 months old. Fosamprenavir (FPV) 50 mg/mL oral suspension/ritonavir (RTV) 80 mg/mL oral solution twice daily (BID)
~Cohort 1A - 6 months - less than 2yrs old. Fosamprenavir (FPV) 50 mg/mL oral suspension/ritonavir (RTV) 80 mg/mL oral solution twice daily (BID)"
11651072|NCT00071760|Experimental|Arm B- 4weeks - less than 2 years old (FPV bid)|"Cohort 2B - 4weeks - less than 6 months old. Fosamprenavir (FPV) 50 mg/mL oral suspension twice daily (BID)
~Cohort 1B - 6 months - less than 2yrs old. Fosamprenavir (FPV) 50 mg/mL oral suspension twice daily (BID)"
11651073|NCT00071721|Experimental|1|
11651074|NCT00071721|Placebo Comparator|2|
11651075|NCT00071643|Experimental|1 Problem Solving Therapy|Participants will receive problem solving therapy.
11651076|NCT00071643|Experimental|2. Escitalopram|Participants will receive escitalopram.
11651077|NCT00071643|Placebo Comparator|3 Placebo|Participants will receive placebo.
11651078|NCT00071617|Experimental|Youth-Nominated Support Team|Adolescents nominate up to 4 caring adults from family, school, community settings. These adults participate in psychoeducation sessions regarding adolescent's treatment plan and support needs. They maintain regular, supportive contact with the adolescent for 3 months -- with ongoing consultation and support check-ins from study clinical staff.
11651079|NCT00071617|No Intervention|Enhanced Treatment as Usual|Adolescents in this condition receive study assessments and risk management services (at time of assessments) only
11651080|NCT00071578|Experimental|1|Group therapy Negative Emotion Focus
11651081|NCT00071578|Placebo Comparator|2|Group Psychotherapy- Self Esteem Focus
11651082|NCT00071565||1|475 families with multiple affected family members (phase I) 200 families with multiple affected family members (phase II) 1800 subjects with sporadic intracranial aneurysms
11651083|NCT00071552|Experimental|Qvar|Qvar 160 mcg twice daily
11651084|NCT00071552|Active Comparator|Flovent Diskus|Flovent Diskus 200 mcg twice daily
11651085|NCT00071539|Experimental|TP38 50 ng/mL|
11651086|NCT00071539|Experimental|TP38 100 ng/mL|
11651087|NCT00004074|Experimental|Treatment (IL12 and trastuzumab)|Patients receive an initial loading dose of trastuzumab IV over 90 minutes on day 1 of the first week and a maintenance dose of trastuzumab IV over 30-90 minutes on day 1 of each subsequent week. Patients receive IL-12 IV on days 2 and 5 beginning on week 3. Treatment with maintenance trastuzumab and IL-12 repeats weekly for 14 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease continue treatment for up to 38 additional weeks.
11651088|NCT00004050|Experimental|Leuvectin|2 intratumoral injections of 1000 ug of Leuvectin
11651089|NCT00003648||Group 1|Patients, family members, and control individuals complete an extended telephone interview, an extended personal interview, and an epidemiological survey, and contribute a blood specimen. Blood and tumor specimens are examined for the specific pattern of immunohistochemical expression of hMSH2 and HMLH1 to determine the frequency or lack of expression of these two protein products. Patients may be contacted periodically (about every 3 years) to update information about health, health practices, and family history. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
11651090|NCT00071526||Diabetes Type I|Subjects with Type I diabetes mellitus
11651091|NCT00071526||Diabetes Type II|Subjects with Type II diabetes mellitus
11651092|NCT00071526||Healthy Volunteers|Healthy Volunteers
11651093|NCT00071513|Experimental|CAST-T/HSTS|The CAST-T/HSTS condition combined the Brief Intervention and 12 school based small group sessions which taught skills to enhance personal control (to manage depression, anger, stress), self-esteem, decision making and interpersonal communications. HSTS skills groups were held in the spring of 8th grade with 4 one-on-one booster sessions delivered to the students as 9th graders by HSTP leaders; parents also participated in 4 sessions. HSTS objectives are: 1) to increase the acquisition of coping skills competencies by teaching and practicing strategies taught; 2) to increase social support resources by building a supportive network; 3) to increase the youth's engagement in positive social activities; and 4) to motivate parents to increase their support via parent educational sessions.
11651094|NCT00071513|Active Comparator|Brief Intervention|Brief Intervention: After each youth and parent completed baseline questionnaires the youth participated in a 1 on 1 standardized clinical follow-up with a trained clinician (blind to study condition) to review areas of concern, based on questionnaire responses including stressors at school, home, and with peers, level of support available and how to access support. The teen and clinician then planned a feedback call to parents, allowing teens to shape requests for support from parents as well as understand exactly what information would be shared with parents. Feedback call to parents reviewed concerns and made recommendations for services as needed. A similar procedure was followed after each assessment for all participants who indicated a risk of clinical depression or self-harm.
11651095|NCT00071500|Experimental|1|Participants will use MedSignals with all of its features
11651096|NCT00071500|Experimental|2|Participants will use MedSignals with only alarm features
11651097|NCT00071500|No Intervention|3|Participants will not use any device
11651098|NCT00071487|Placebo Comparator|Placebo plus SOC|
11651099|NCT00071487|Experimental|Belimumab 1 mg/kg plus SOC|
11651100|NCT00071487|Experimental|Belimumab 4 mg/kg plus SOC|
11651101|NCT00071487|Experimental|Belimumab 10 mg/kg plus SOC|
11651102|NCT00003595|Experimental|Arm I|Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 3 and oral prednisone on days 3-7. Patients receive rituximab on day 1. Treatment repeats every 3 weeks for a minimum of 4 courses or 2 courses beyond complete response in the absence of disease progression or unacceptable toxicity. Patients with stage I, stage IE (including bulky), or nonbulky stage II or IIE disease receive 3 courses of chemotherapy with rituximab followed by radiotherapy beginning 3 weeks after completion of the third course. Patients who achieve partial response for a minimum of 28 days or complete response receive maintenance rituximab IV beginning on day 28 of the final course of chemotherapy. Maintenance rituximab treatment repeats every 4 weeks for 3 courses.
11651103|NCT00003595|Active Comparator|Arm II|Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Treatment repeats every 3 weeks for a minimum of 4 courses or 2 courses beyond complete response. Patients with stage I, stage IE (including bulky), or nonbulky stage II or IIE disease receive 3 courses of chemotherapy. Patients receive radiotherapy beginning 3 weeks after completion of the third course of chemotherapy.
11651104|NCT00003234|Experimental|Stratum 1 - Soft Tissue Sarcoma|See detailed description.
11651105|NCT00003234|Experimental|Stratum 2 - CNS Tumors|See detailed description.
11651106|NCT00003234|Experimental|Stratum 3 - Neuroblastoma|See detailed description.
11651107|NCT00003190|Experimental|Arm I (cytarabine, daunorubicin, etoposide)|Patients receive cytarabine IV continuously over 7 days and daunorubicin IV bolus followed by etoposide IV over 2 hours on days 1-3.
11651108|NCT00003190|Experimental|Arm II (valspodar, daunorubicin, etoposide, cytarabine)|"Patients receive treatment as in arm I with the addition of PSC 833 induction. A loading dose of PSC 833 IV is given over 2 hours, followed by a 74-hour continuous infusion of PSC 833 beginning 2 hours before daunorubicin and etoposide. Patients may receive a second induction course if residual leukemia is present in the bone marrow. Patients who experience a CR and meet certain other criteria receive postremission chemotherapy consisting of cytarabine IV continuously over 5 days plus daunorubicin IV followed by etoposide IV over 2 hours on days 1 and 2. Patients who are randomized to receive PSC 833 during induction chemotherapy receive a loading dose of PSC 833 before beginning a 48-hour continuous infusion of PSC 833 concurrently with cytarabine/daunorubicin/etoposide postremission chemotherapy.
~After completing postremission chemotherapy, patients are randomized to a no further treatment group or IL-2 immunotherapy."
11651109|NCT00003126|Experimental|Interleukin-2 (IL-2)|Patients randomized to this arm will receive one course of IL-2 [600,000 U/kg every 8 hours on post-operative days 1 to 5 and days 15 to 19 (maximum 28 doses)].
11651110|NCT00003126|No Intervention|Observation|Patients randomized to this arm will receive their normal medical care
11651111|NCT00071461|Experimental|1|"Initial dose: 62.5 mg b.i.d. for 4 weeks.
~Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).
~body weight < 40 kg (90 lb): 62.5 mg b.i.d."
11651112|NCT00071461|Placebo Comparator|2|"Initial dose: 62.5 mg b.i.d. for 4 weeks.
~Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).
~body weight < 40 kg (90 lb): 62.5 mg b.i.d."
11651113|NCT00071422|Placebo Comparator|placebo|1.5 mL SC injection, once daily for 90 days
11651114|NCT00071422|Experimental|300 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
11651115|NCT00071422|Experimental|600 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
11651116|NCT00071409|Placebo Comparator|placebo|1.5 mL SC injection
11651117|NCT00071409|Experimental|300 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
11651118|NCT00071409|Experimental|600 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
11651119|NCT00071396|Experimental|Campath-1H + Rituximab|"Campath 15 mg/day continuous intravenous (IV) infusion x 6 days, then twice a week for 3 weeks as 30 mg injection under skin to complete 4 week treatment course.
~Rituximab 375 mg/m^2 IV infusion day 1, then 500 mg/m^2 on days 8, 15 + 22."
11651120|NCT00003077|Experimental|Omega-3 fatty acid|"Patients receive omega-3 fatty acids orally in two equal doses with/after breakfast and lunch for 4 months or until weight loss is observed.
~Dose is escalated in cohorts of two patients, although dose escalation is allowed in individual patients. Patients are evaluated for cachexia response every 2 weeks, and tumor response every 4 weeks for a maximum of 4 months. If no response of cachexia or tumor after a 2 month period, patients will be discontinued from study. Patients will be followed for survival post-treatment."
11651121|NCT00002723|Experimental|Low dose suramin|Low dose suramin
11651122|NCT00002723|Experimental|Intermediate dose suramin|Intermediate dose suramin
11651123|NCT00002723|Experimental|High dose suramin|High dose suramin
11651124|NCT00030420|Experimental|Celecoxib & Docetaxel|"Celecoxib: 400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.
~Doctaxel: Day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days"
11651125|NCT00024206|Experimental|Treatment (orantinib)|"Patients receive oral SU6668 twice daily on days 1-28. Courses repeat every 4 weeks in the absence of unacceptable toxicity or disease progression of 100% or more.
~Cohorts of at least 6 patients receive escalating doses of SU6668 until the OBD is determined. Once the OBD is reached, dose escalation continues until the maximum tolerated dose (MTD) is determined (if possible). The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
11651126|NCT00071240|Experimental|Growth Hormone Arm|Growth hormone receipt in the first year, post-growth hormone follow-up in the second year
11651127|NCT00071240|Active Comparator|2|Observation only in the 1st year, GH receipt in the second year
11651128|NCT00064428|Experimental|Fondaparinux - UFH not indicated|Subjects with no indication for UFH therapy: 2.5mg od, sc, (1st dose IV) x 8 days or discharge
11651129|NCT00064428|Placebo Comparator|Control - UFH not indicated|Subjects with no indication for UFH therapy: Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
11651130|NCT00064428|Experimental|Fondaparinux - UFH indicated|Subjects indicated for UFH: 2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus + 24-48 hr infusion
11651131|NCT00064428|Active Comparator|Control - unfractionated heparin|Subjects indicated for UFH: UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
11651132|NCT00071110|Experimental|1|Electroacupuncture (EA).
11651133|NCT00071110|Placebo Comparator|2|Sham
11651134|NCT00071097|Experimental|001|TMC114/rtv 400mg TMC114/100mg rtv once daily
11651135|NCT00071097|No Intervention|005|Control Group Control Group, no intervention
11651136|NCT00071097|Experimental|004|TMC114/rtv 600mg TMC114/100mg rtv twice daily
11651137|NCT00071097|Experimental|003|TMC114/rtv 400mg TMC114/100mg rtv both twice daily
11651138|NCT00071097|Experimental|002|TMC114/rtv 800mg TMC114/100mg rtv once daily
11651139|NCT00071084|Experimental|280 mg and 980 mg|
11651140|NCT00071071|Experimental|280 mg and 560 mg|
11651141|NCT00025467|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11651142|NCT00015912|Experimental|Treatment (interferon-alpha, thalidomide)|Patients receive interferon alfa subcutaneously every 12 hours and oral thalidomide daily in the absence of disease progression or unacceptable toxicity.
11651143|NCT00014144|Experimental|ZD 1839|
11651144|NCT00007917|Experimental|Arm I|"Patients receive gemcitabine IV over 1-2.5 hours on days 1 and 8 and flavopiridol IV continuously over 24 hours on days 2 and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of gemcitabine and flavopiridol until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
11651145|NCT00071032|Experimental|Liberal (10 g/dL) Transfusion Strategy|Transfusion strategy that maintains postoperative Hgb levels above 10 g/dL.
11651146|NCT00071032|Active Comparator|2|Symptomatic transfusion strategy, a more conservative strategy, in which blood transfusion is withheld until the patient develops symptoms of anemia.
11651147|NCT00071006|Experimental|Single arm study|
11651148|NCT00070954|Placebo Comparator|2|look-alike placebo
11651149|NCT00070954|Active Comparator|Ginkgo Biloba|Compared to placebo
11651150|NCT00070941|Experimental|SAM-e|40 subjects receiving oral SAM-e, 1200mg or 1800mg daily in two divided doses, and placebo escitalopram.
11651151|NCT00070941|Active Comparator|Escitalopram|40 subjects receiving oral escitalopram 20mg or 40 mg daily, in two divided doses, and placebo SAM-e.
11651152|NCT00070941|Placebo Comparator|Placebo Comparator|20 subjects receiving oral placebo escitalopram and placebo SAM-3 daily in two divided doses.
11651153|NCT00070824|Experimental|B|Patients with osteoarthritis pain at rest
11651154|NCT00070824|Experimental|A|Normal Subjects without pain
11651155|NCT00070811||Revision|Patients with repaired cleft lip who receive lip revision surgery
11651156|NCT00070811||Non-Revision|Patients with repaired cleft lip who do not have lip revision surgery
11651157|NCT00070811||Non-cleft|Non-cleft 'control' subjects.
11651158|NCT00071058|Experimental|Surgery plus chemotherapy|"Surgical resection can be performed at the time of study entry, when patients have a mixed response, or if their tumors respond to chemotherapy.
~Surgical resection will be followed by chemotherapy with 2 grams oral dose daily of mitotane on cycle 1, day 1, 6 mg/m^2 continuous intravenous infusion doxorubicin over 96 hours days 1-4, 0.18 mg/m^2 continuous intravenous infusion vincristine over 96 hours days 1-4, and 36 mg/m^2 continuous intravenous infusion etoposide over 96 hours days 1-4, and 150 mg tariquidar through central venous catheter over 30 minutes on days 1 and 3."
11651159|NCT00071045||1|Patients who are either being evaluated for enrollment, are consented to NIH Clinical Center treatment protocols, or are receiving therapy for their disease through home health care providers
11651160|NCT00070707|Experimental|Mometasone|Mometasone nasal spray 200 mcg, administered once daily (QD) for 4 weeks
11651161|NCT00070707|Placebo Comparator|Placebo|Matching placebo nasal spray, administered QD for 4 weeks
11651162|NCT00021099|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11651163|NCT00017368|Experimental|All Patients|
11651164|NCT00003907|Experimental|Hepatocellular carcinoma|Chemoemulsion (doxorubicin, mitomycin and cisplatin) followed by embolization. The entire procedure will be repeated separately to each involved lobe beginning within 8 weeks of the last lobar chemoembolization.
11651165|NCT00003907|Experimental|Neuroendocrine hepatic metastases|Chemoemulsion (doxorubicin, mitomycin and cisplatin) followed by embolization. The entire procedure will be repeated separately to each involved lobe beginning within 8 weeks of the last lobar chemoembolization.
11651166|NCT00070642|Experimental|CPG 7909 Injection plus chemotherapy|CPG 7909 Injection plus DTIC
11651167|NCT00070642|Active Comparator|Chemotherapy alone|dacarbazine
11651168|NCT00070642|Experimental|CPG 7909 Injection 10 mg|
11651169|NCT00070642|Experimental|CPG 7909 Injection 40 mg|
11651170|NCT00070629|Experimental|1|Chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection
11651171|NCT00070629|Active Comparator|2|Chemotherapy (a taxane and a platinum compound)
11651172|NCT00070616|Experimental|Palifermin 6 x 60 μg/kg/day|The first 3 consecutive daily doses were administered before the initiation of conditioning therapy (study days -11, -10, and -9); 3 additional consecutive daily doses were administered after administration of radiotherapy, chemotherapy and PBPC transplantation (study days 0, 1, and 2).
11651173|NCT00070616|Experimental|Palifermin 2 x 180 μg/kg/day|The first dose was administered on study day -11, 3 days before the initiation of conditioning therapy, and the second dose was given on day 0 after administration of radiotherapy, chemotherapy and the PBPC infusion
11651174|NCT00006012|Experimental|topotecan + paclitaxel + filgrastim + TRT + radiation|"Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 5. Patients receive filgrastim (G-CSF) subcutaneously (SC) daily beginning 24 hours after the last dose of chemotherapy and continuing until blood counts recover. Treatment repeats every 3 weeks for 2 courses.
~After 2 courses of treatment, patients undergo TRT twice daily for 5 consecutive days for 5 weeks. During TRT, patients receive cisplatin IV, oral etoposide, and amifostine SC daily prior to TRT.
~At 4 weeks after completion of TRT, patients receive 2 additional courses of topotecan, paclitaxel, and G-CSF every 3 weeks followed by prophylactic cranial irradiation.
~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
11651175|NCT00005800|Experimental|Dose-Dense Chemotherapy|Patients receive doxorubicin IV on day 1 every 2 weeks for 3 courses. After 3 weeks of rest, patients receive docetaxel IV over 1 hour on day 1 every 2 weeks for 3 courses. Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each doxorubicin and docetaxel course. Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
11651176|NCT00070564|Active Comparator|Arm I|(closed 11/10/10) Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim subcutaneously (SC) on day 2 or filgrastim (G-CSF) SC on days 3-10. Treatment repeats every 14 days for 6 courses. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.
11651320|NCT00068367|Experimental|Arm I (OSI-774)|"Drug: erlotinib hydrochloride
~Other Names:
~OSI-774 150 mg per day, daily until disease progression"
11651177|NCT00070564|Experimental|Arm II|(closed 11/10/10) Patients receive doxorubicin IV on day 1, oral cyclophosphamide on days 1-7, and G-CSF SC on days 2-7. Treatment repeats every 7 days for 15 courses. Beginning 2 weeks after completion of cyclophosphamide, patients receive paclitaxel and pegfilgrastim as in arm I.
11651178|NCT00070564|Active Comparator|Arm III|(closed 11/10/10) Patients receive doxorubicin, cyclophosphamide, and pegfilgrastim or G-CSF as in arm I. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 7 days for 12 courses.
11651179|NCT00070564|Experimental|Arm IV|(closed 11/10/10) Patients receive doxorubicin, cyclophosphamide, and G-CSF as in arm II. Beginning 2 weeks after completion of cyclophosphamide, patients receive paclitaxel as in arm III.
11651180|NCT00070564|Experimental|Arm V|Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 4 courses. Patients receive doxorubicin IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 3 hours on day 1 and pegfilgrastim SC on day 2. Treatment repeats every 14 days for 6 courses.
11651181|NCT00070564|Experimental|Arm VI|Patients receive doxorubicin, cyclophosphamide, and pegfilgrastim as in arm V. Beginning 2 weeks after completion of doxorubicin and cyclophosphamide, patients receive paclitaxel IV over 1 hour on day 1. Treatment repeats every 7 days for 12 courses.
11651182|NCT00070551|Experimental|Stratum I (GTI-2040, cytarabine)|Patients receive GTI-2040 IV continuously on days 1-6 and high-dose cytarabine IV over 2 hours twice daily on days 2, 4, and 6.
11651183|NCT00070551|Experimental|Stratum II (GTI-2040, cytarabine)|Patients receive GTI-2040 IV continuously on days 1-6 and high-dose cytarabine IV over 4 hours once daily on days 2-6. In both strata, treatment continues in the absence of unacceptable toxicity.
11651184|NCT00070525|Experimental|Arm I|Patients receive oral tipifarnib twice daily on days 1-21. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11651185|NCT00070499|Experimental|Arm I (QD imatinib mesylate)|Patients receive imatinib mesylate PO QD. Treatment repeats every 4 weeks for up to 5 years in the absence of disease progression or unacceptable toxicity.
11651186|NCT00070499|Experimental|Arm II (BID imatinib mesylate)|Patients receive imatinib mesylate PO BID. Treatment repeats every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
11651187|NCT00070499|Experimental|Arm III (dasatinib)|Patients receive dasatinib PO BID. Treatment repeats every 4 weeks for up to 5 years in the absence of disease progression or unacceptable toxicity.
11651188|NCT00070486|Experimental|Gem + Carboplatin + Zileuton|
11651189|NCT00070486|Experimental|Gem + Carboplatin + celecoxib|
11651190|NCT00070486|Experimental|Gem + carboplatin + zilueton + celecoxib|
11651191|NCT00070434|Experimental|Irinotecan + 5-FU + Leucovorin|Irinotecan 180mg/m2, IV for 90min on Day 1, q 2 wk x 4 cycles; 5-FU 400 mg/m2, IV bolus on Day 1, q 2 wk x 4 cycles; 5-FU 2.4 g/m2 IV for 46 hours on Day 1, q 2 wk x 4 cycles; Leucovorin 200 mg/m2 IV for 2 hours on Day 1, q 2 wk x4 cycles.
11651192|NCT00070434|Experimental|Irinotecan + Oxaliplatin|Irinotecan 175mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; Oxaliplatin 85mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles
11651193|NCT00070434|Experimental|Oxaliplatin + 5-FU + Leucovorin|Oxaliplatin 85mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; 5-FU 400mg/m2 IV bolus on Day 1, q 2wk x4 cycles; 5-FU 2.4g/m2 IV for 46 hours on Day 1, q 2wk x4 cycles; Leucovorin 200mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles.
11651194|NCT00070382|Experimental|Darbepoetin alfa|darbepoetin alfa administered once every two weeks at a dose of 200 ug over a 16 week treatment period.
11651195|NCT00070382|Active Comparator|Epoetin alfa|epoetin alfa administered at 40,000 unites, once per week over a 16-week treatment period.
11651196|NCT00070317|Experimental|Diagnostic|Patients receive radiolabeled technetium Tc 99m sulfur colloid injected around the tumor 6 hours prior to or after induction of anesthesia right before surgery. Patients then undergo radical hysterectomy and complete pelvic and low para-aortic lymphadenectomy. Intraoperatively, patients undergo lymphatic mapping and sentinel lymph node identification using isosulfan blue or methylene blue injected at 4 locations in the cervix and a hand-held gamma counter.
11651197|NCT00070304|Experimental|Treatment|Patients receive vinorelbine tartrate IV over 6-10 minutes and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on day 9 and continuing for at least 7 days and until blood counts recover. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease after 2 courses may proceed directly to stem cell transplantation off study OR receive 2 additional courses. Patients with stable disease after 2 courses receive at least 2 additional courses. Patients with continued stable or responding disease (with no disease progression) after 4 courses may continue to receive study treatment for up to 1 year or discontinue study for alternative therapy at the discretion of the treating physician.
11651198|NCT00070291|Experimental|Cyclosporine|High dose cyclosporine weeks 1-6, then maintenance dose cyclosporine weeks 7-36. If CR, PR, or SD at week 36 evaluation, treatment is complete. If progression occurs during weeks 7-36, patients will re-register to Step 2 at time of PD and begin high dose therapy (weeks 1-6), followed by maintenance therapy (weeks 7-36). At second progression patients will end protocol treatment.
11651199|NCT00070265|Experimental|Treatment (oxaliplatin, capecitabine, and surgery)|"Neoadjuvant chemotherapy: Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
~Surgery: Four to six weeks after the completion of chemotherapy, patients undergo surgical resection of the tumor.
~Adjuvant chemotherapy: Patients with satisfactory response to therapy receive 4 additional courses of oxaliplatin and capecitabine after surgery."
11651200|NCT00070252|Experimental|Treatment (tipifarnib, capecitabine, docetaxel)|"Phase Ib: Patients receive oral tipifarnib twice daily and oral capecitabine twice daily on days 1-14 and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Phase II: Patients receive oral tipifarnib twice daily for 6 days. Beginning at least 48 hours after completion of the initial dose of tipifarnib, patients receive treatment as in phase Ib for up to 6 courses at the MTD of capecitabine."
11651321|NCT00068341|Experimental|Arm I (neoadjuvant therapy)|see intervention description
11651201|NCT00070239|Experimental|Treatment|"PART 1 (closed to accrual as of 8/2005): Patients receive alvocidib IV over 1 hour on days 1, 8, and 15.
~Cohorts of 3-6 patients receive escalating doses of alvocidib until the MTD* is determined.
~PART 2: Patients receive alvocidib IV over 1 hour at or below the MTD determined in part 1 and then receive a maintenance dose of alvocidib IV over 1-6 hours on days 1, 8, and 15. Cohorts of 3-6 patients receive escalating durations of the maintenance dose of alvocidib until the MTD* is determined. An additional cohort of 10-20 patients receives alvocidib over 1 hour on days 1 and 15 at the MTD.
~NOTE: *The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
~In both parts, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
11651202|NCT00070200|Experimental|All patients|Induction Cycles 1 and 2 (CT) (21 days each), Cyclophosphamide (Days 1 thru 5) weight based dosage (> 12 kg 400 mg/m2/day, < 12 kg 13.3 mg/kg/day, < 2 years old N/A. Topotecan (Days 1 thru 5) weight based dosage (> 12 kg 1.2 mg/m2/day, < 12 kg 0.04 mg/kg/day, < 2 years old 0.04 mg/kg/day). Filgrastim (Days 6 →) weight based dosage (> 12 kg 5 micrograms/kg, < 12 kg 5 micrograms /kg, < 2 years old 5 micrograms /kg.
11651203|NCT00070187|Experimental|Hyperfractionated Involved-Field Radiotion-immunotherapy|"Completed prior salvage induction therapy and have not received full tissue tolerance from prior radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily for 7 days.
~HIGH-DOSE PREPARATIVE REGIMEN: Beginning within 7 days after radiotherapy, carmustine IV over 3 hours on day -6; etoposide IV over 1 hour and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes on day -1.
~ASCT: Autologous bone marrow or peripheral blood stem cell transplantation on day 0. Filgrastim (oral or IV) beginning on day 1 and continuing until blood counts recover.
~IMMUNOTHERAPY: Cyclosporine IV twice daily beginning on day 0 and continuing until the completion of the course of recombinant interferon gamma and interleukin-2. When sufficiently recovered, Aldesleukin once daily for 18 days."
11651204|NCT00070187|Experimental|Hyperfractionated Involved-Field Radiotion-no immunotherapy|"Completed prior salvage induction therapy and have not received full tissue tolerance from prior radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily for 7 days.
~HIGH-DOSE PREPARATIVE REGIMEN: Beginning within 7 days after radiotherapy, carmustine IV over 3 hours on day -6; etoposide IV over 1 hour and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes on day -1.
~ASCT: Autologous bone marrow or peripheral blood stem cell transplantation on day 0. Filgrastim (oral or IV) beginning on day 1 and continuing until blood counts recover."
11651205|NCT00070148|Active Comparator|Arm 1 Oxandrolone 20 mg daily|Oxandrolone 20 mg (10 mg BID) for 12 weeks. 4 additional weeks of follow-up.
11651206|NCT00070148|Active Comparator|Megace 800 mg|Megestrol acetate 800 mg daily for 12 weeks. 4 additional weeks of follow-up.
11651207|NCT00070135|Experimental|Treatment (fludarabine, busulfan, allogeneic PBSC)|"PREPARATIVE REGIMEN: Patients receive fludarabine IV over 30 minutes on days -7 to -3 and busulfan IV over 2 hours 4 times per day (every 6 hours) on days -4 and -3.
~GVHD PROPHYLAXIS: Patients receive tacrolimus PO or IV BID on days -2 with taper between days 90-120, and stopping by days 150-180. Patients also receive methotrexate IV on days 1, 3, 6, and 11 and rabbit antithymocyte globulin IV over 4-6 hours on days -4 through -2.
~ALLOGENEIC PBSC: Patients undergo allogeneic PBSC transplant on day 0. Patients then receive filgrastim SC daily beginning on day 12 and continuing until blood counts recover."
11651208|NCT00070122|Experimental|Arm I (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46-48 hours beginning on day 1. Patients are further randomized to receive bevacizumab or placebo* IV over 30-90 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
11651209|NCT00070122|Experimental|Arm II (oxaliplatin, capecitabine)|Patients receive oxaliplatin IV over 2 hours on day 1and oral capecitabine on days 1-15. Patients are further randomized to receive bevacizumab or placebo* as in arm I. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
11651210|NCT00070109|Experimental|Trabectedin 1.3 mg/m2 to assess feasibility in all patients|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. A cohort of 6 patients will be enrolled at the 1.3 mg/m2 dose level.
11651211|NCT00070109|Experimental|Trabectedin 1.5 mg/m2 to assess feasibility in all patients|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. Six toxicity-evaluable patients are assigned this treatment.
11651212|NCT00070109|Experimental|Trabectedin at 1.5 mg/m2 to assess efficacy in Ewing sarcoma|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
11651213|NCT00070109|Experimental|Trabectedin at 1.5 mg/m2 - assess efficacy in rhabdomyosarcoma|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
11651214|NCT00070109|Experimental|Trabectedin 1.5 mg/m2 - assess efficacy in nonrhabdomyosarcoma|Patients receive trabectedin over 3 hours on day 1. Treatment repeats every 21 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
11651215|NCT00070057|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib twice daily for 1-3 weeks (according to the duration between biopsy and surgery) in the absence of unacceptable toxicity.
11651216|NCT00070057|Experimental|Arm II (high-dose celecoxib)|Patients receive a higher dose of oral celecoxib as in arm I.
11651217|NCT00070057|Active Comparator|Arm III (surgery)|Patients do not receive treatment. All patients undergo surgery.
11651218|NCT00070018|Experimental|CHOP + RT + Zevalin|Patients first receive 3 cycles (21 days each) of CHOP, consisting of: cyclophosphamide 750 mg/m^2 on day 1, doxorubicin 50 mg/m^2 on day 1, vincristine 1.4 mg/m^2 on day 1, and prednisone 100 mg on days 1-5. Patients receive 4000-5000 cGy of radiation therapy in 25 fractions, starting 3 weeks after completion of CHOP. 3-6 weeks after completing RT, patients receive Zevalin, which consists of: rituximab 250 mg/m^2 on days 1 and 7, 8 or 9; In-111 ibritumomab tiuxetan 5 mCi within 4 hours after rituximab on day 1; and Y-90 ibritumomab tiuxetan 0.4 mCi/kg within 4 hours after rituximab on day 7, 8 or 9.
11651219|NCT00069992|Experimental|Submyeloablative Allogeneic Stem Cell Transplant|Total Body Irradiation Fludarabine Campath 1H
11651220|NCT00069953|Experimental|ChemoRT and selective surgery|Induction therapy of fluorouracil, cisplatin, paclitaxel, and pegfilgrastim OR filgrastim, then chemoradiotherapy of concurrent cisplatin and fluorouracil with external beam radiotherapy (RT), followed by selective salvage therapy.
11651221|NCT00069927|Experimental|Arm 1- Adderall- XR®|Adderall-XR® 1 10 mg/day for 3-12 weeks depending on subject's response
11651222|NCT00069927|Experimental|Arm II Concerta®|Concerta ® 18 mg/day for 3-12 weeks depending on subject's response
11651223|NCT00006034|Experimental|Arm I|Patients receive a sensitizing dose of keyhole limpet hemocyanin (KLH) intradermally in week 2 followed by induction KLH IV once weekly in weeks 1-6. Patients with partial or no response receive IV KLH reinduction therapy once weekly in weeks 13-18. Patients with complete response receive IV KLH maintenance therapy monthly in weeks 13, 17, and 21, and then in months 6-12.
11651224|NCT00006034|Active Comparator|Arm II|Patients receive doxorubicin IV once weekly in weeks 1-6.
11651225|NCT00069784|Experimental|Insulin glargine + omega-3 polyunsaturated fatty acids|"Insulin glargine once daily by subcutaneous injection in a titrated regimen targeting a fasting plasma glucose (FPG) level of ≤95 mg/dL (5.3 mmol/L)
~One capsule of omega-3 polyunsaturated fatty acids once daily"
11651226|NCT00069784|Experimental|Insulin glargine + placebo|"Insulin glargine once daily by subcutaneous injection in a titrated regimen targeting a fasting plasma glucose (FPG) level of ≤95 mg/dL (5.3 mmol/L)
~One capsule of placebo once daily"
11651227|NCT00069784|Experimental|Standard care + omega-3 polyunsaturated fatty acids|• One capsule of omega-3 polyunsaturated fatty acids once daily
11651228|NCT00069784|Placebo Comparator|Standard care + placebo|• One capsule of placebo once daily
11651229|NCT00069706|Experimental|AL-12182 0.003%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
11651230|NCT00069706|Placebo Comparator|AL-12182 Solution Vehicle|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
11651231|NCT00069706|Active Comparator|Latanoprost|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
11651232|NCT00069706|Experimental|AL-12182 0.01%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
11651233|NCT00069706|Experimental|AL-12182 0.03%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
11651234|NCT00069836|Experimental|Arm 1|
11651235|NCT00069823|Experimental|Esomeprazole|Proton pump inhibitor of gastric acid
11651236|NCT00069823|Placebo Comparator|Placebo for esomeprazoe|Placebo
11651237|NCT00069641|Experimental|Idursulfase weekly (0.5 mg/kg)|
11651238|NCT00069641|Experimental|Idursulfase every other week (0.5 mg/kg)|
11651239|NCT00069641|Placebo Comparator|Placebo|
11651240|NCT00005629|Experimental|Group A - first dosing group|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (100 ug dose) emulsified in 2 ml of Montanide ISA-51.
11651241|NCT00005629|Experimental|Arm B - dosing group 2|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (500 ug dose) emulsified in 2 ml of Montanide ISA-51.
11651242|NCT00005629|Experimental|Group 3 - dosing level 3|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (1000 ug dose) emulsified in 2 ml of Montanide ISA-51.
11651243|NCT00069576|Active Comparator|Nutritional counseling & self blood glucose monitoring|Within one week of enrollment, women in the treatment group receive formal nutritional counseling and will be instructed on the technique of self blood glucose monitoring using a memory-based reflectance meter.
11651244|NCT00069576|No Intervention|No treatment|This group will not receive any specific dietary therapy except for written information concerning general nutritional recommendations for normal pregnancy.
11651245|NCT00004883|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Treatment continues once a week in the absence of disease progression or unacceptable toxicity.
11651246|NCT00004856|Experimental|Treatment: Herceptin|Patients receive a loading dose of trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. For all subsequent doses, patients receive trastuzumab IV over 30 minutes weekly. Treatment may continue for more than 1 year in the absence of unacceptable toxicity or disease progression.
11651247|NCT00003930|Experimental|Arm 1|Transurethral surgery with chemotherapy and radiation therapy followed by either selective bladder preservation or radical cystectomy followed by adjuvant chemotherapy.
11651248|NCT00003832|Experimental|Treatment (bromodeoxyuridine)|Patients receive broxuridine IV over 30 minutes on day -1. Approximately 12-96 hours later, patients undergo surgery to remove the prostate.Tumor tissue is examined by immunostaining for the presence of broxuridine to determine doubling times of the tumor.
11651249|NCT00069459|Other|Extended-release Bupropion Hydrochloride|Extended-release Bupropion Hydrochloride
11651250|NCT00069407|Active Comparator|RUL|Right unilateral electroconvulsive therapy
11651251|NCT00069407|Active Comparator|BL|Bilateral electroconvulsive therapy
11651252|NCT00069407|Active Comparator|BF|Bifrontal electroconvulsive therapy
11651253|NCT00069381|Experimental|study arm|
11651254|NCT00003620|Experimental|Treatment (flavopiridol)|"Patients registered before 9/15/2000 receive flavopiridol IV continuously on days 1-3. Treatment repeats every 14 days for a total of 12 courses in the absence of disease progression or unacceptable toxicity.
~Patients registered after 9/15/2000 receive flavopiridol IV over 1 hour daily on days 1-3. Treatment repeats every 3 weeks for a total of 8 courses in the absence of disease progression or unacceptable toxicity."
11651255|NCT00003594|Experimental|irinotecan + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes followed by leucovorin calcium IV over 15 minutes and fluorouracil IV once a week for 4 weeks followed by 2 weeks of rest. Courses repeat every 6 weeks.
~Treatment continues in the absence of disease progression or unacceptable toxicity.
~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.
~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
11651271|NCT00069134|Placebo Comparator|Alanine|12 children with edematous severe malnutrition are assigned to receive 0.65 mmol/kg/d of alanine as placebo. Supplements will be added to the children's daily diets.
11651272|NCT00069017|Active Comparator|1|MEDI-522 - 4 mg/kg of MEDI-522 (N=200)
11651273|NCT00069017|Placebo Comparator|2|Placebo (N=100)
11651256|NCT00003594|Experimental|oxaliplatin + leucovorin + fluorouracil|"Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV over 2 hours plus fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks.
~Treatment continues in the absence of disease progression or unacceptable toxicity.
~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.
~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
11651257|NCT00003594|Experimental|oxaliplatin + irinotecan|"Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on day 1. Courses repeat every 3 weeks.
~Treatment continues in the absence of disease progression or unacceptable toxicity.
~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.
~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
11651258|NCT00069264|Experimental|E7389|
11651259|NCT00003281|Experimental|topotecan + paclitaxel + radiotherapy|"Patients receive topotecan IV over 30 minutes on days 1-3 and paclitaxel IV over 3 hours on day 3. Courses repeat every 4 weeks.
~Patients who achieve partial response or stable disease continue treatment in the absence of complete response or disease progression. Patients who develop disease progression in the CNS only should receive whole brain radiotherapy and then continue treatment. Patients who achieve complete remission receive a maximum of 6 courses of treatment. Patients may then undergo prophylactic cranial irradiation and/or thoracic radiotherapy at the discretion at the attending physician.
~Patients are followed every 3 months for 2 years and then at 3 years after study."
11651260|NCT00069329|Experimental|NOMID treatment arm|All patients enrolled received daily doses of subcutaneous injection of increased doses of anakinra starting at 0.5mg/kg/day up to a maximum 10mg/kg/day to achieve disease remission.
11651261|NCT00069238|Experimental|Alemtuzumab Dose Escalation|Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles. Three cohorts of 3 to 6 patients will be treated. Cohort 1 will receive 30mg of Alemtuzumab, cohort 2 will receive 60mg of Alemtuzumab, and cohort 3 will receive 90mg of Alemtuzumab. If 1 of 3 participants entered at a given dose level experiences dose limiting toxicity (DLT), up to 3 additional participants will be entered at that dose level. If 2 of 6 participants experience DLT at a particular dose level, the maximum tolerated dose (MTD) has been exceeded. The preceding dose level will be the MTD, provided 6 participants have been entered at this level and no more than 1 has experienced DLT.
11651262|NCT00069121|Active Comparator|5-Fluorouracil/Leucovorin (5-FU/LV)|Participants were given one of two regimens (each participating center prespecified which regimen they would use for all patients at that center): i) Mayo Clinic regimen group: LV 20 mg/m^2 IV bolus injection + 5-FU 425 mg/m^2 IV bolus injection daily on Days 1-5 of a four-week cycle, for a total of six cycles (24 weeks), or; ii) Roswell Park regimen group: LV 500 mg/m^2 by two-hour IV infusion + 5-FU 500 mg/m^2 IV bolus injection one hour after the start of the LV infusion on Day 1 of Weeks 1 to 6 of each eight-week cycle, for a total of four cycles (32 weeks).
11651263|NCT00069121|Experimental|Capecitabine in Combination with Oxaliplatin (XELOX)|Capecitabine was administered as an oral twice daily outpatient intermittent treatment (3-week cycles consisting of two weeks of treatment followed by one week without treatment) combined with intravenous (IV) oxaliplatin on Day 1 of each cycle. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2) with the first dose given during the evening of Day 1 and last dose given during the morning of Day 15. Oxaliplatin was administered as a 130 mg/m^2 IV infusion over two hours on Day 1 of each cycle. The XELOX combination was administered for a total of eight cycles (24 weeks).
11651264|NCT00069108|Experimental|XELOX|Participants received XELOX (oxaliplatin and capecitabine). Oxaliplatin was administered 130 mg/m^2 intravenous (IV) infusion over 2 hours (every 3 weeks [Day 1]) before the first dose of capecitabine. Capecitabine was administered orally within 30 minutes after the end of a meal (breakfast and dinner) at a dose of 1000 mg/m^2 twice-daily (equivalent to a total daily dose of 2000 mg/m^2), with first dose the evening of Day 1 and last dose the morning of Day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) for up to 8 cycles (24-weeks).
11651265|NCT00069108|Active Comparator|FOLFOX-4|Participants received FOLFOX-4 (combination of oxaliplatin, leucovorin [LV] and 5-fluorouracil [5-FU] combination). Oxaliplatin was administered as an 85 mg/m^2 IV infusion over 2 hours (on Day 1 only); with LV infusion as 200mg/m^2 over 2 hours followed by 5-FU, given as 400mg/m^2 bolus injection over 2-4 minutes, and then as a 600 mg/m^2 continuous infusion over 22 hours. On Day 2, Leucovorin 200 mg/m^2 (alone), followed by 5-FU 400 mg/m^2 bolus injection over 2-4 minutes, and 5-FU 600 mg/m^2 continuous infusion was repeated over 22 hours. It was (2-week cycles comprising 48 hours of infusion and 12 days of rest) for up to 12 cycles (24- weeks).
11651266|NCT00069095|Experimental|XELOX (oxaliplatin+capecitabine)|Patients in the 2-arm part of the study received oxaliplatin 130 mg/m^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m^2 orally twice a day for the first 2 weeks of every 3 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.
11651267|NCT00069095|Experimental|XELOX (oxaliplatin+capecitabine) + bevacizumab|Patients in the 4-arm part of the study received oxaliplatin 130 mg/m^2 intravenously (iv) on Day 1 of every 3 week cycle + capecitabine 1000 mg/m^2 orally twice a day for the first 2 weeks of every 3 week cycle + bevacizumab 7.5 mg/kg iv on Day 1 of every 3 week cycle.
11651268|NCT00069095|Active Comparator|FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil)|Patients in the 2-arm part of the study received oxaliplatin 85 mg/m^2 intravenously (iv) + leucovorin 200 mg/m^2 iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle.
11651269|NCT00069095|Active Comparator|FOLFOX-4 (oxaliplatin+leucovorin+fluorouracil) + bevacizumab|Patients in the 4-arm part of the study received oxaliplatin 85 mg/m^2 intravenously (iv) + leucovorin 200 mg/m^2 iv + bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m^2 bolus injection over 2 to 4 min followed by 600 mg/m^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle.
11651270|NCT00069134|Experimental|Sulfur Amino Acids|12 children with edematous severe malnutrition will be assigned to receive 0.65 mmol/kg/d of sulfur amino acids. Supplements will be added to the children's daily diets.
11651322|NCT00068341|Experimental|Arm II (neoadjuvant therapy)|please see intervention description
11651274|NCT00030381|Experimental|Treatment (iododoxorubicin)|Patients receive iododoxorubicin IV over 15 minutes on days 1, 8, 15, and 22. Treatment repeats every 12 weeks for a total of 4 courses or a cumulative dose of 400 mg/m^2 in the absence of disease progression or unacceptable toxicity.
11651275|NCT00069160|Experimental|Pts who received docetaxel on day 1, 8, & tariquidar day 8,22|Patients receive 40 mg/m^2 docetaxel intravenous (IV) over 1 hour on days 1 and 8 and 150 mg tariquidar intravenous (IV) over 30 minutes on days 8 and 22. From cycle 2 and onward 75 mg/m^2 docetaxel was administered every 21 days in combination with a single 150 mg dose.
11651276|NCT00069160|Experimental|Pts who received docetaxel on days 1, 8, & tariquidar day 1,22|Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8 and tariquidar intravenous (IV) over 30 minutes on days 1 and 22.
11651277|NCT00069082|Active Comparator|Civamide|Nasal Solution 0.01%
11651278|NCT00069082|Placebo Comparator|Placebo|Placebo nasal solution with sodium chloride 10%
11651279|NCT00068991|Experimental|1|Participants will be HIV-infected villagers and will will take part in 2-hour skills training sessions every week from study entry to Week 8. Participants will bring a family member to each training session. After training, participants complete a post-training evaluation of the training sessions. Participants will also complete questionnaires at study entry and 6 and 12 months after completion of training.
11651280|NCT00068991|Experimental|2|Participants will be villagers considered influential members of their community. In the first 2 months of the study, Participants will take part in four 2-hour training sessions focusing on anti-stigma and anti-discrimination messages. Participants will also attend additional support meetings monthly, from Months 2 to 15. They will be evaluated before and after their training sessions to determine the improvements in knowledge and attitudes about HIV among group participants.
11651281|NCT00068991|Experimental|3|Participants will be randomly selected community members and will complete a cross-sectional survey at study entry and 6 and 12 months after Group 2's completion of training to determine changing community attitudes about HIV as a result of Group 2's training. There will be no additional study visits or training for Group 3 participants.
11651282|NCT00069069|Experimental|1|single center, Phase 1, open label, dose escalation trial assessing safety profile of four doses of intranasal recombinant human E-selectin
11651283|NCT00068874|Active Comparator|1|Educational comparison group
11651284|NCT00068874|Experimental|2|Group receiving coping intervention designed to enhance coping and psychological adjustment
11651285|NCT00068874|No Intervention|3|Comparison control group with no active intervention
11651286|NCT00068822|Experimental|Vertebroplasty|Participants will receive percutaneous vertebroplasty
11651287|NCT00068822|Placebo Comparator|Control Group|Participants will receive sham vertebroplasty without PMMA
11651288|NCT00068809|Experimental|Short-cycle therapy (SCT)|At entry, subjects will switch from continuous HAART to SCT. All subjects will then be followed to assess viral load breakthrough over 48 weeks on SCT.
11651289|NCT00068783|Experimental|Treatment|Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or symptomatic deterioration.
11651290|NCT00068770|Active Comparator|p450 ( +EIASD)|"on p450 inhibitor (Patients taking anttiseizure drugs that are known to induce the hepatic drug-metabolizing enzymes - including phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine)
~celecoxib and radiation therapy will be adminstered with this arm"
11651291|NCT00068770|Active Comparator|nonp450 (-EIASD)|"not on p450 inhibitor (Patients either NOT taking anti-seizure drugs or ones that are known to not significantly influence the hepatic drug-metabolizing enzymes - including gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine,topiramate, zonisamide and filbamate.
~celecoxib and radiation therapy will be adminstered with this arm"
11651292|NCT00068731|Experimental|lycopene|"Patients receive oral lycopene twice daily on days 1-28. Courses repeat every 28 days for at least 4 months in the absence of disease progression or unacceptable toxicity.
~Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years."
11651293|NCT00068718|Experimental|Treatment (DLI)|Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
11651294|NCT00068692|Experimental|Group I, Arm I|Patients receive 1 of 3 preoperative chemo and radiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive irinotecan IV over 90 minutes and leucovorin calcium IV over 2 hours followed immediately by fluorourcil IV bolus on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.
11651295|NCT00068692|Experimental|Group I, Arm II|Patients receive 1 of 3 preoperative chemo and radiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours followed immediately by fluorourcil IV bolus on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 8 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
11651296|NCT00068692|Experimental|Group I, Arm III|Patients receive 1 of 3 preoperative chemo and radiotherapy treatment regimens, determined by the treating physician. Within 21-56 days after the completion of chemoradiotherapy, patients undergo surgical resection. Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV over 1 hour on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 8 weeks for 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity.
11651297|NCT00068692|Experimental|Group II, Arm I|"Patients receive irinotecan, leucovorin calcium, and fluorouracil as in group 1, arm I for 4 courses. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemo and radiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III.
~Treatment continues in the absence of disease progression or unacceptable toxicity."
11651319|NCT00068380|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11651298|NCT00068692|Experimental|Group II, Arm II|"Patients receive oxaliplatin, leucovorin calcium, and fluorouracil as in group 1, arm II for 4 courses. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemo and radiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III.
~Treatment continues in the absence of disease progression or unacceptable toxicity."
11651299|NCT00068692|Experimental|Group II, Arm III|Patients receive leucovorin calcium and fluorouracil as in group 1, arm III for 1 course. Within 4 weeks after the completion of chemotherapy, all patients undergo concurrent pelvic chemoradiotherapy as described in group 1 preoperative chemo and radiotherapy Regimen A, B, or C, followed 4-6 weeks later by 4 additional courses of adjuvant chemotherapy for arms I and II and 2 additional courses of adjuvant chemotherapy for arm III. Treatment continues in the absence of disease progression or unacceptable toxicity.
11651300|NCT00068666|Experimental|radiation + temozolomide|"Patients receive concurrent chemoradiotherapy comprising whole brain radiotherapy daily on days 1-5, 8-13, and 16-21 and oral temozolomide daily on days 1-5. Subsequent treatment with temozolomide repeats every 4 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.
~Patients are followed every 2 months."
11651301|NCT00068653|Experimental|Celecoxib & ZD1839|"Celecoxib: 400mg orally two times a day, taken with meals.
~ZD1839: 250 mg po every day, taken with or without food."
11651302|NCT00068601|Active Comparator|Standard Chemotherapy|Patients receive cyclophosphamide-containing chemotherapy alone.
11651303|NCT00068601|Experimental|Chemotherapy Plus Goserelin|Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.
11651304|NCT00068588|Experimental|Treatment (GTI-2040, capecitabine)|Patients receive GTI-2040 IV continuously on days 1-15 of the first course and days 1-14 of all subsequent courses. Patients also receive oral capecitabine twice daily on days 2-15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11651305|NCT00068575|Experimental|Postoperative Chemoradiation Regimen|Postoperative Cisplatin 30 mg/m^2 intravenous (IV) weekly for 6 doses, Interferon Alfa-2b 3 million units subcutaneous (SQ) on Monday, Wednesday and Friday days 1-19 and 29-45 for 17 total doses, and 5-fluorouracil (5-FU) 175 mg/m2/day by continuous intravenous infusion days 1-19 and 29-45 with concurrent Radiation Treatment.
11651306|NCT00068549|Experimental|Treatment|Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 in the absence of disease progression or unacceptable toxicity. Patients also undergo external whole pelvis radiotherapy once daily on days 1-5, 8-13, 15-20, 22-27, and 29-34. After completion of external beam radiotherapy, patients undergo intracavitary radiotherapy and parametrial radiotherapy. The total elapsed time for completion of all radiotherapy is not more than 8 weeks.
11651307|NCT00068510|Experimental|autologous tumor lysate-pulsed DC|
11651308|NCT00068497|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib on day 1 and then daily beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
11651309|NCT00068484|Experimental|Treatment (topotecan hydrochloride, bortezomib)|Patients receive topotecan IV over 30 minutes on days 1-5. Beginning with course 2, patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11651310|NCT00068458|Active Comparator|Arm 1: calcium diet|Calcium-Rich Diet (dietary counseling + materials promoting an intake of 1,200 - 2,500 mg/day).
11651311|NCT00068458|Active Comparator|Arm 2: Exercise + Calcium-Rich Diet|Exercise + Calcium Rich Diet (dietary counseling + materials promoting strength training and aerobic activity + a calcium intake of 1,200 - 2,500 mg/day).
11651312|NCT00068458|Active Comparator|Exercise + Fruit & Vegetable, Low Fat + Calcium Diet|Dietary counseling + materials promoting strength training and aerobic activity + a diet that has < 20% of energy coming from fat and intakes of fruits and vegetables of > 5 servings/day + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
11651313|NCT00068445|Experimental|Arm I - lamotrigine|"Patients receive oral lamotrigine once daily for 2 weeks and then twice daily for 8 weeks. Treatment continues for 10 weeks in the absence of unacceptable toxicity.
~Quality of life, pain, mood states, and symptom distress are assessed at baseline and at 4, 6, 8, and 10 weeks.
~Patients are followed at 3-7 days."
11651314|NCT00068445|Other|Arm II - placebo|"Patients receive oral placebo once daily for 2 weeks and then twice daily for 8 weeks.
~Treatment continues for 10 weeks in the absence of unacceptable toxicity.
~Quality of life, pain, mood states, and symptom distress are assessed at baseline and at 4, 6, 8, and 10 weeks.
~Patients are followed at 3-7 days."
11651315|NCT00068432|Experimental|Gemcitabine + Celecoxib|Oral celecoxib twice daily on days 1-28. Gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
11651316|NCT00068419|Experimental|Treatment (enzyme inhibitor therapy, anti-estrogen therapy)|Patients receive oral sulindac and oral tamoxifen citrate twice daily for up to 12 months (four 3-month courses) in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 1 additional month of treatment beyond documentation of CR.
11651317|NCT00068406|Experimental|Treatment (conventional surgery, radiation therapy, cisplatin)|"Patients undergo radiotherapy daily on days 1-5 and receive concurrent cisplatin IV over 30 minutes on day 1. Treatment repeats weekly for approximately 6.5 weeks (a total of 32 fractions of radiotherapy) in the absence of unacceptable toxicity.
~Six to eight weeks after the completion of chemoradiotherapy, patients with a complete clinical response may undergo incisional biopsy of the primary tumor and bilateral inguinal/femoral nodes (if the groin nodes were initially unresectable). Patients with microscopic or gross resectable residual disease may then undergo radical resection of the residual tumor. Patients with unresectable disease after the completion of chemoradiotherapy receive additional radiotherapy with 1-2 courses of concurrent cisplatin."
11651318|NCT00068393|Experimental|Doxorubicin/Gemcitabine|Doxorubicin was given at 50 mg/m² by IV slow push, followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life. Cycles were repeated every 2 weeks.
11651323|NCT00068341|Experimental|HER2/neu negative patients|please see intervention description
11651324|NCT00068328||Group 1|"Patients participate in interviews over 30-45 minutes at baseline, at 6 months, and at 1 and 2 years.
~Patients are followed annually for at least 5 years."
11651325|NCT00068315|Experimental|Treatment (bortezomib, fludarabine, rituximab)|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and fludarabine IV over 30 minutes on days 1-3 or 1-5. Patients may also receive rituximab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
11651326|NCT00068302|Experimental|Sirolimus|This is a dose escalation study including 4-dose levels. Subjects will receive a one-time loading dose of sirolimus on day 0, time 0. Subsequent dosing at the assigned dose level will start 24 hours following the initial loading dose
11651327|NCT00068250|Experimental|Phase I: Temozolomide 100 mg|Rituximab, methotrexate, temozolomide 100 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
11651328|NCT00068250|Experimental|Phase I: Temozolomide 150 mg|Rituximab, methotrexate, temozolomide 150 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
11651329|NCT00068250|Experimental|Phase I: Temozolomide 200 mg|Rituximab, methotrexate, temozolomide 200 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
11651330|NCT00068250|Experimental|Phase II: Temozolomide 100 mg|Rituximab, methotrexate, temozolomide 100 mg/m^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m^2.
11651331|NCT00068237|Experimental|Surgery + Transfer + Radiation|Submandibular salivary gland transfer at the time of surgery for the primary tumor and neck nodes followed by post-operative radiation therapy.
11651332|NCT00068224||Ciliopathy|Children and adults who carry a clinical diagnosis of a known ciliopathy and those patients who have typical features suggestive of a cliopathy but not fulfilling the diagnostic criteria.
11651333|NCT00025207|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11651334|NCT00068159||1|Untreated-NYHA Class I HH subjects without conventional therapy for HH
11651335|NCT00068159||2|Treated- NYHA Class I HH subjects with conventional phlebotomy and/or iron chelationtherapy
11651336|NCT00068159||3|Age-gender matched healthy HH control volunteers
11651337|NCT00068107|Experimental|Relagal|All participants received Relagal administered weekly
11651338|NCT00068055|Experimental|1|60 subjects to receive Omr-IgG-am.
11651339|NCT00068055|Active Comparator|2|20 subjects to receive Polygam® S/D (IVIG).
11651340|NCT00068055|Placebo Comparator|3|20 subjects to receive normal saline.
11651341|NCT00067990|Experimental|Losartan 100mg|Losartan 100 mg per day to be started within three months of transplantation and continuing treatment for five years.
11651342|NCT00067990|Placebo Comparator|Placebo|No intervention with continuing follow-up for five years.
11651343|NCT00067938|Other|Arm 1|Open label single arm study
11651344|NCT00068003||1/Cancer Patients|Patients with a current diagnosis of cancer
11651345|NCT00068003||2/Healthy Volunteers|Healthy volunteers
11651346|NCT00016276|Experimental|Arm I (chemoprotection, monoclonal antibody, radiotherapy)|Patients receive dexrazoxane IV over 10-20 minutes, doxorubicin IV over 5-10 minutes, and cyclophosphamide IV over 30 minutes on days 1, 22, 43, and 64. Patients receive paclitaxel IV over 1 hour and trastuzumab (Herceptin) IV over 30-90 minutes on days 85, 92, 99, 106, 113, 120, 127, 134, 141, 148, 155, and 162. Approximately 1-2 weeks after completion of neoadjuvant chemotherapy, patients undergo breast conservation surgery, modified radical mastectomy, or mastectomy. Patients with unacceptable toxicity or locoregional disease progression may undergo surgery prior to week 24 (i.e., completion of neoadjuvant chemotherapy). Beginning 2-4 weeks after breast conservation surgery or 3-5 weeks after mastectomy, patients undergo radiotherapy daily 5 days a week for 6-8 weeks. Patients receive long-term trastuzumab IV over 30-90 minutes weekly for 40 weeks beginning on week 36 (day 254).
11651347|NCT00016276|Experimental|Arm II (chemoprotection, radiotherapy, surgery, trastuzumab)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel (without trastuzumab) as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
11651348|NCT00016276|Experimental|Arm III (chemoprotection, monoclonal antibody, radiotherapy)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation only for 40 weeks after completion of radiotherapy.
11651349|NCT00016276|Experimental|Arm IV (chemoprotection, paclitaxel, surgery, radiotherapy)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
11651350|NCT00016276|Experimental|Arm V (combination chemo, radiotherapy, long term trastuzumab)|Patients receive doxorubicin and cyclophosphamide (without dexrazoxane) as in arm I. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
11651351|NCT00016276|Experimental|Arm VI (combination chemo, paclitaxel, surgery, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
11651352|NCT00016276|Experimental|Arm VII (combination chemo, monoclonal antibody, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
11651353|NCT00016276|Experimental|Arm VIII (combination chemotherapy, paclitaxel, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
11651354|NCT00006265|Experimental|Cohort I|Immunotherapy with gemtuzumab
11651355|NCT00006265|Experimental|Cohort II|Gemtuzumab + ara-C
11651356|NCT00006265|Experimental|Cohort IA|Gemtuzumab + ara C
11651357|NCT00006265|Experimental|Cohort IV|Gemtuzumab + ara-C
11651358|NCT00006103|Experimental|irinotecan + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for a total of 5 courses in the absence of disease progression or unacceptable toxicity.
~Patients are followed every 3 months for 1 year and then every 6 months thereafter."
11651359|NCT00067873|Active Comparator|Diet only|
11651360|NCT00067873|Experimental|Diet plus aerobic exercise|
11651361|NCT00067873|Experimental|Diet plus resistance exercise|
11651362|NCT00006002|Experimental|Arm B|dexamethasone followed by SU5416 done twice weekly (Monday and Thursday or Tuesday and Friday) every week for 4 weeks (a total of 8 doses). Four weeks of treatment (8 doses) is considered 1 cycle of treatment if tumor grows.
11651363|NCT00006002|Experimental|Arm A|SU5416 done twice weekly (Monday and Thursday or Tuesday and Friday) every week for 4 weeks (a total of 8 doses). Four weeks of treatment (8 doses) is considered 1 cycle of treatment
11651364|NCT00005845|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on weeks 1, 3, 5, and 7. Treatment repeats every 8 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
11651365|NCT00067821||Patients|Must have a brain tumor, or residual abnormality that is measurable or evaluable on standard MRI or CT
11651366|NCT00067808|Active Comparator|Decitabine 10 mg/m^2 IV|10 mg/m^2 intravenous (IV) over 1 hour daily for 10 days
11651367|NCT00067808|Active Comparator|Decitabine 20 mg/m2 IV|20 mg/m2 IV over 1 hour daily for 5 days
11651368|NCT00067808|Active Comparator|Decitabine 20 mg/m2 SQ|20 mg/m2 subcutaneous (SQ) daily for 5 days
11651369|NCT00067782|Active Comparator|1|
11651370|NCT00067782|Active Comparator|2|
11651371|NCT00067769|Active Comparator|TAU|Patients received treatment as usual (TAU) as defined as continued clinical care.
11651372|NCT00067769|Experimental|TAU+UCanPoopToo|Patients received treatment as usual (TAU) plus the Internet intervention (UCanPoopToo.)
11651373|NCT00005090|Active Comparator|ABVD x 5 + ABVD x 3|Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m^2, bleomycin 10 U/m^2, vinblastine 6 mg/m^2, dacarbazine 375 mg/m^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
11651374|NCT00005090|Experimental|ABVD x 5 + ABVD x 1 + HDT + PBSCT|Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m^2, bleomycin 10 U/m^2, vinblastine 6 mg/m^2, dacarbazine 375 mg/m^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant. Patients randomized to the transplant arm have 2 x 10^6 CD34+ blood mononuclear cells/kg of actual body weight collected at day -7. High dose therapy consists of BCNU 150/m^2 on days -6 to -4, etoposide 60 mg/kg on day -4, and cyclophosphamide 100 mg/kg on day -2. Peripheral blood stem cells are infused on day 0.
11651375|NCT00067756|Experimental|4-PBA|The study will involve a 4-PBA dose escalation and pharmacokinetics component The study group will be comprised of a total of at least 10 AAT-deficient,(phenotype ZZ referred to as PiZZ) patients. These patients will be divided into two groups: with and without clinical evidence of mild to moderate hepatocellular injury.
11651376|NCT00067743|Other|1|Open Label trial
11651377|NCT00067730|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
11651378|NCT00067717|Experimental|Distant Healing|This group received distant healing but was blinded to the condition.
11651379|NCT00067717|Placebo Comparator|Non-blinded Distant Healing|This group received the distant healing intervention and was called every day they were receiving to be told they were receiving it, therefore enhancing expectancy.
11651380|NCT00067717|No Intervention|Blinded Control|This group was blinded to the intervention condition and did not receive any distant healing.
11651381|NCT00067704|Experimental|Trauma writing|Four sessions of writing about traumatic experiences.
11651382|NCT00067704|Sham Comparator|Writing about daily events|Four sessions of writing about their daily experiences.
11651383|NCT00067665|No Intervention|1|Control group of 50 patients where dry weight is not changed.
11651384|NCT00067665|Experimental|2|All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
11651385|NCT00067639|Experimental|Pegfilgrastim + Apheresis|12 mg Pegfilgrastim as subcutaneous injection on day 1 + Apheresis daily till target stem cell dose reached.
11651386|NCT00067626|Experimental|1|500/1000 mcg oral chromium taken daily or placebo (crossover)
11651387|NCT00067626|Experimental|2|500/1000 mcg oral chromium taken daily or placebo (crossover)
11651388|NCT00067613|Active Comparator|Intervention|Clinical sites randomized to intervention will receive training in the benchmarking BPD management methods identified at the Benchmark sites.
11651389|NCT00067613|Placebo Comparator|Control|Clinical sites randomized to Control will continue with their normal management practices for BPD.
11651390|NCT00067587||HIV Negative|HIV negative subjects
11651391|NCT00067587||HIV Positive - NEVER had ARV therapy.|HIV Positive - NEVER had ARV therapy.
11651392|NCT00067587||HIV positive, on a NNRTI, non-PI regimen|HIV positive, currently on a NNRTI, non-PI regimen for at least 3 months. Must NEVER have received a total of more than SIX months of PI-containing regimen and at least ONE year must have passed since receipt of last PI-containing regimen.
11651393|NCT00067587||HIV positive, on a PI, non-NNRTI regimen|HIV positive, currently on a PI, non-NNRTI regimen for at least 3 months. Must NEVER have received a total of more than SIX months of NNRTI-containing regimen and at least ONE year must have passed since receipt of last NNRTIcontaining regimen.
11651394|NCT00067587||HIV positive, on a non-PI, non-NNRTI|HIV positive, currently on a non-PI, non-NNRTI containing regimen for at least 3 months. Must NEVER have received a total of more than SIX months of PI- and/or NNRTI- containing regimen and at least ONE year must have passed since receipt of last PI- and/or NNRTI-containing regimen.
11651395|NCT00067470|Placebo Comparator|Placebo|
11651396|NCT00067470|Active Comparator|rhASB|
11651397|NCT00004233|Experimental|5-FU, Leucovorin and PN-401|PN401 is given on Days 1-3 weekly for six weeks; 5FU and leucovorin are given on Day 1 weekely for six weeks; followed by two weeks of rest. Continued in 8 week cycles until one of the criteria for removal from treatment is met.
11651398|NCT00004221|Experimental|Treatment (Combination chemotherapy, PBSC)|See detailed description.
11651399|NCT00004032|Experimental|Treatment (ALVAC-hB7.1, recombinant interferon gamma)|Patients receive ALVAC-hB7.1 infected tumor cells intraperitoneally (IP) on days 4, 11, and 18. Patients also receive interferon gamma IP on days 8, 10, 15, and 17. In the absence of disease progression, up to 6 courses of therapy may be given. If insufficient tumor cells are available to continue treatment with tumor cell derived vaccine, interferon gamma may be given alone.
11651400|NCT00067340|Experimental|Intervention group|Subjects received chlorhexidine mouthwash and xylitol gum , in addition to the usual care specified under the control group
11651401|NCT00067340|Placebo Comparator|Control|Subjects received enhanced dental care, health information, toothbrushes and toothpaste. They also received placebo gum and placebo mouth rinse
11651402|NCT00003931||blood or bone marrow samples|"All samples are obtained from specimens collected on CALGB-9665. No additional blood or bone marrow samples are collected CALGB-9769.
~Samples are examined by Southern blot analysis for gene rearrangement at 11q23. Samples showing evidence of ALL1 gene rearrangement are further analyzed by reverse transcription PCR amplification and/or cytogenetic analysis to detect partial tandem duplication of ALL1."
11651403|NCT00067379|Active Comparator|1|Medicaid patients with medically necessary malocclusions treated during the mixed dentition with limited goals followed by observation
11651404|NCT00067366|Experimental|Coping Skills Training|manualized coping skills training delivered along with conservative care
11651405|NCT00067366|Active Comparator|Standard Care|Attention and life counseling added to Standard conservative care
11651406|NCT00067236|Experimental|PG-116800 tablet|PG-116800 tablet (200 mg) taken twice daily for 90 days
11651407|NCT00067236|Placebo Comparator|Placebo tablet|Placebo tablet taken twice daily for 90 days
11651408|NCT00067119|Experimental|Aggrenox|
11651409|NCT00067119|Placebo Comparator|Placebo|
11651410|NCT00067106||1: Women failing therapy|Participants will have study visits at study entry, 2 weeks after changing medications, then every 4 weeks until the amount of HIV in the blood and genital tract are undetectable. Drug levels in the blood and genital tract will also be measured at the first visit and after changing medications. Once the level of HIV is undetectable, women will be seen every 3 months for 36 months. Participants in Group 1 will be followed no more than 42 months.
11651411|NCT00067106||2: Women suppressed on therapy|Participants will have study visits for blood and genital tract collections at study entry and then every 4 weeks for 12 months
11651412|NCT00067080|Experimental|ICL670 + deferoxamine|
11651413|NCT00067028|Experimental|Clofarabine + Ara-C|"Clofarabine 30 - 40 mg/m^2 by vein over 1 hour daily for 5 days.
~Ara-C Starting dose: 0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle."
11651414|NCT00067028|Experimental|Clofarabine + Idarubicin|"Clofarabine 30 - 40 mg/m^2 by vein over 1 hour daily for 5 days.
~Idarubicin 10 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle."
11651415|NCT00067028|Experimental|Clofarabine + Idarubicin + Ara-C|"Clofarabine 30 - 40 mg/m^2 by vein over 1 hour daily for 5 days.
~Idarubicin 6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.
~Ara-C Starting dose: 0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle."
11651416|NCT00003323|Experimental|Hormone Therapy|Treatment of prostate cancer pts post radiation or surgery with potency sparing hormones
11651417|NCT00003210|Experimental|Treatment (interleukin-12)|Patients receive interleukin-12 subcutaneously twice a week. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
11651418|NCT00003006||Group 1|At the time of thoracotomy and pulmonary resection, patients have samples of bone marrow, primary tumor, and intrathoracic lymph nodes harvested. The presence of occult metastases in bone marrow and lymph nodes is assessed using immunohistochemistry or reverse transcriptase-polymerase chain reaction.
11651419|NCT00067054||1|Sample Collection Only
11651420|NCT00067015|Experimental|IMRT alone to 86.4 Gy|External radiotherapy is given for 10 weeks, Monday through Friday for a total of 48 sessions. The total dose of radiotherapy delivered during these 10 weeks is 86.4 Gy. The radiation treatments are delivered with a high precision technique called intensity modulated radiotherapy or IMRT. For this treatment, no hormonal therapy is required.
11651421|NCT00067015|Experimental|IMRT TO 75.6 Gy plus Adjuvant Androgen Deprivation|Prior to a planned course of radiotherapy, which will last for eight and a half weeks, 10 weeks of hormonal therapy are given. The hormonal therapy will start with a daily pill called Casodex. Three to seven days after starting this pill, a Zoladex injection will be administered in addition to the Casodex pill. Zoladex hormonal therapy is given in the form of a monthly injection. After 10 weeks from the initiation of hormone therapy, you will begin external radiotherapy. For these treatments only 42 treatment sessions are given. The total dose of radiotherapy delivered during these 8.5 weeks is 75.6 Gy. The hormone injections continue during the radiation treatments and for 2 years after the radiation treatments. The pills are only taken for the 10 weeks before and also during the radiation treatments, however afterwards the pills are discontinued.
11651422|NCT00067002|Experimental|Double Cord Blood Transplant Group|Two Unmanipulated Cord Blood units. Rituxan 375 mg/m2 by vein for patients with CD20 + malignancies. Melphalan 140 mg/m2 by vein on Day -8. Thiotepa 5 mg/Kg by vein on Day -7. Fludarabine 40 mg/m2 by vein on Days -6 to -3.
11651423|NCT00067002|Experimental|One Expanded Cord Blood Transplant Group|One Unmanipulated and One Expanded Cord Blood Unit. Fludarabine 40 mg/m2 by vein on Days -6 to -3. Cyclophosphamide 50 mg/kg by vein on Day -6. Mesna 10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg). Total body irradiation (TBI) given on Day -1 at 2 Gy.
11651446|NCT00066781|Experimental|Cohort II|Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11651447|NCT00066768|Experimental|Arm I|Patients receive low-dose suramin IV over 30 minutes and docetaxel IV over 1 hour on day 1.
11651424|NCT00002970|Experimental|Arm I|"GROUP 1: Patients receive a 1 hour infusion of compound 506U78 daily for 5 days in the absence of neurologic toxicity. The course repeats every 21 days. If a first relapse T-cell ALL study of higher priority is not open, then the patient may continue to receive the drug every 21 days for a maximum of 2 years provided that the patient has achieved a second complete response.
~GROUPS 2 and 4: Patients receive compound 506U78 every 21 days for a maximum of 2 years, in the absence of disease progression. After 3 courses a patient may be given CNS prophylaxis with triple intrathecal therapy (TIT), consisting of methotrexate, cytarabine and hydrocortisone after consultation with study coordinator. TIT should be given every 12 weeks.
~GROUP 3: Patients receive compound 506U78 every 21 days for a maximum of 2 years, in the absence of disease progression. TIT will be given on day 1 of weeks 1-4, 6, 9 and every 6 weeks for 12 weeks, and then every 9 weeks thereafter. This stratum is open."
11651425|NCT00002621|Experimental|Alpha interferon (aIFN) treatment|See detailed description.
11651426|NCT00002548|Active Comparator|HDCTX and PBSC|"High dose chemotherapy with peripheral blood stem cells
~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20
~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection
~Chemo: vincristine 1.2 mg/m2 IV D1, BCNU 20 mg/m2 IV D1, melphalan 8 mg/m2 PO D1-4, cyclophosphamide 400 mg/m2 IV D1, prednisone 40 mg/m2 PO D1-7"
11651427|NCT00002548|Experimental|HDCTX with PBSC and Autologous BMT|"High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant
~High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant
~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20
~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection
~Auto Trans: Mel 140mg/m2 IV D-5; TBI 150cGy D-4, -3, -2, -1; infusion D0"
11651428|NCT00002548|Experimental|HDCTX with PBSC and interferon|"High dose chemotherapy with peripheral blood stem cells and interferon
~Experimental: HDCTX with PBSC and interferon High dose chemotherapy with peripheral blood stem cells and interferon
~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20
~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection
~Chemo: vincristine 1.2 mg/m2 IV D1, BCNU 20 mg/m2 IV D1, melphalan 8 mg/m2 PO D1-4, cyclophosphamide 400 mg/m2 IV D1, prednisone 40 mg/m2 PO D1-7
~IFN: IFN 3 million units/m2 MWF SQ"
11651429|NCT00002548|Experimental|HDCTX with PBSC and transplant plus IFN|"High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant plus alpha interferon
~Experimental: HDCTX with PBSC and transplant plus IFN High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant plus alpha interferon
~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20
~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection
~Trans: Mel 140mg/m2 IV D-5; TBI 150cGy D-4, -3, -2, -1; infusion D0
~IFN: 3 million units/m2 MWF SQ"
11651430|NCT00002520|Experimental|Quit Smoking Intervention|Patients received advice and help to quit smoking. The intervention employed physician and patient resources that had already been developed and evaluated or pre-tested, including written materials, prescriptions for nicotine replacement, counseling, and follow-up contact.
11651431|NCT00002520|Active Comparator|Usual Care|"No special intervention after randomization. Usual care may or may not include advice or assistance to stop smoking. Physicians were reassured that usual care did not preclude quit smoking counseling."
11651432|NCT00066963|No Intervention|Counseling Only|Counseling Only
11651433|NCT00066963|Experimental|FV every 12mo for 24mo + Counsel|Preventive fluoride varnish every 12mo for 24mo plus Counseling
11651434|NCT00066963|Experimental|FV every 6mo for 24mo + Counseling|Preventive fluoride varnish every 6mo for 24mo plus Counseling
11651435|NCT00066950|No Intervention|Counseling Only|Oral Health Counseling Only
11651436|NCT00066950|Experimental|CHX+Counseling (caregiver) + FV (child)|Oral Health Counseling plus Chlorhexidine for caregiver plus fluoride varnish every 6 months from 12mo to 30mo of age for child
11651437|NCT00066937|Experimental|Nortriptyline Oral Capsule/CBT|Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of CBT.
11651438|NCT00066937|Experimental|Benztropine Oral Product/CBT|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of CBT.
11651439|NCT00066937|Experimental|Nortriptyline Oral Capsule/Disease MGT|Nortriptyline taken at bedtime titrated to a dose up to 150 mg. Study participants also receive 6 sessions of TMD disease management.
11651440|NCT00066937|Active Comparator|Benztropine Oral Product/Disease MGT|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of TMD disease management.
11651441|NCT00066859|Active Comparator|Arm 1: Sertraline (Zoloft) 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
11651442|NCT00066859|Active Comparator|Arm 2 - St. John's Wort 600mg|St. John's wort 600 mg daily for 1 week. If tolerated dose may be increased to 900 mg daily for four months.
11651443|NCT00066807|Experimental|OFS plus T or E|Ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.
11651444|NCT00066807|Experimental|Chemotherapy plus OFS plus T or E|Chemotherapy plus ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.
11651445|NCT00066781|Experimental|Cohort I (closed to accrual 11/17/05)|Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Irinotecan dose may be escalated or de-escalated after course 1 depending on toxicity. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
11651448|NCT00066768|Experimental|Arm II|Patients receive low-dose suramin IV over 30 minutes and gemcitabine IV over 30 minutes on days 1 and 8.
11651449|NCT00066742|Experimental|Treatment (tirapazamine, cisplatin, etoposide)|"CHEMORADIOTHERAPY: Patients receive tirapazamine IV over 1 hour on days 1, 8, 10, 12, 29, 36, 38, and 40; cisplatin IV over 1 hour on days 1, 8, 29, and 36; and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning on day 1 of chemotherapy, patients undergo thoracic radiotherapy once daily 5 days a week for 7 weeks.
~CONSOLIDATION CHEMOTHERAPY: Within 28 days after completion of radiotherapy, patients with stable or responding disease receive cisplatin IV over 1 hour on days 1 and 22 and etoposide IV over 1 hour on days 1-3 and 22-24.
~Treatment continues in the absence of disease progression or unacceptable toxicity."
11651450|NCT00066703|Active Comparator|T+OFS|Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.
11651451|NCT00066703|Experimental|E+OFS|Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.
11651452|NCT00066690|Active Comparator|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
11651453|NCT00066690|Experimental|T+OFS|Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
11651454|NCT00066690|Experimental|E+OFS|Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
11651455|NCT00066638|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a stable plateau (stable paraprotein levels or urine protein excretion over 3 consecutive determinations at least 4 weeks apart) may receive maintenance therapy comprising FR901228 IV on days 1 and 15, with courses repeating every 28 days.
11651456|NCT00066625|Experimental|Treatment (oxaliplatin, bortezomib)|"Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and bortezomib IV over 3-5 seconds on days 1, 4, 15, and 18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of oxaliplatin and bortezomib until the MTDs are determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
11651457|NCT00066612|Experimental|Treatment|Irinotecan
11651458|NCT00066586|Active Comparator|Exemestane|
11651459|NCT00066586|Placebo Comparator|Placebo|
11651460|NCT00066573|Experimental|Exemestane|Patients receive oral exemestane (25 mg) once daily for 5 years.
11651461|NCT00066573|Active Comparator|Anastrozole|Patients receive oral anastrozole (1 mg) once daily for 5 years.
11651462|NCT00066482|Experimental|combination chemotherapy|"Induction therapy: bleomycin sulfate IV over 10-20 minutes on day 1, etoposide IV over 1 hour and cisplatin IV over 4 hours on days 1-5, and cyclophosphamide IV over 1 hour on day 1. MESNA & Filgrastim (G-CSF) subcutaneously once daily beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. 6 patients receive escalating doses of cyclophosphamide until the maximum tolerated dose (MTD) is determined.
~Evaluated after 4 courses of therapy. Partial response or stable disease undergo second-look conventional surgery & receive 2 more courses of induction therapy then re-evaluated. Those who do not achieve complete response (CR) after a total of 6 courses may undergo a third conventional surgery. Tumor that cannot be removed are removed from study therapy. Achievement of a CR at anytime are followed monthly for 1 year, every 6 months for 1 year, and then annually for 3 years."
11651463|NCT00066469|Experimental|Cyclophosphamide, prednisone, rituximab|Patients receive cyclophosphamide IV over 30-60 minutes on day 1 and oral prednisone or methylprednisolone IV twice daily on days 1-5. During courses 1 and 2 only, patients also receive rituximab IV over 2-5 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression, a new primary or secondary malignancy, or unrelated disease
11651464|NCT00066456|Experimental|Treatment (chemosensitization, radiation, docetaxel)|Patients receive docetaxel IV over 30 minutes once daily on days 1, 8, 15, 22, 29, and 35. Within 3 hours after beginning docetaxel, patients also receive low-dose abdominal radiotherapy twice daily (at least 4 hours apart) on days 1, 2, 8, 9, 15, 16, 22, 24, 29, 30, 35, and 36. Treatment continues in the absence of unacceptable toxicity.
11651465|NCT00066443|Experimental|Pegfilgrastim, docetaxel and epirubicin|
11651466|NCT00066430|Experimental|Infrared coagulator|
11651467|NCT00066378|Experimental|Arimidex + Iressa® 250 mg|Arimidex + Iressa® 250 mg Treatment should be administered until documented disease progression, unacceptable toxicity as judged by the responsible physician or patient refusal
11651468|NCT00066378|Active Comparator|Arimidex + Placebo|Treatment should be administered until documented disease progression, unacceptable toxicity as judged by the responsible physician or patient refusal
11651469|NCT00066365|Experimental|Group 1 (unilateral recurrence) - Sargramostim and thoractomy|Patients receive initial inhalation therapy inhaled sargramostim (GM-CSF) twice daily on days 1-7. Treatment repeats every other week every 14 days for a total of 2 courses. Patients undergo surgical procedure thoracotomy on day 22. Beginning on day 29, or as soon as possible thereafter, patients begin post-thoracotomy inhalation therapy for up to 12 additional courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.
11651504|NCT00024024|Experimental|Arm I|Patients receive oral BMS-275291 1-2 times daily. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 6 patients receive escalating doses of BMS-275291 until the recommended phase II dose (RPTD) is determined. The RPTD is the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity and more than 1 of 6 patients experiences clinical response or at least 5 of 6 patients demonstrate biologic activity. An additional 29 patients are treated at the RPTD.
11651505|NCT00022477|Experimental|BMS-247550|IV administration of BMS-247550 once every 21 days
11651470|NCT00066365|Experimental|Group 2 (bilateral recurrence) - Sargramostim and thoractomy|Patients may be enrolled on study either before or after the first thoracotomy procedure. For the first thoracotomy, patients undergo surgical procedure unilateral thoracotomy. Patients receive initial inhalation therapy inhaled GM-CSF, as soon as possible after recovery from first thoracotomy, twice daily on days 1-7. Treatment repeats every other week every 14 days for a total of 2 courses. Patients undergo surgical procedure contralateral thoracotomy on day 22. Beginning on day 29, or as soon as possible, patients begin post-thoracotomy inhalation therapy as above for up to 12 additional courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.
11651471|NCT00066248|Experimental|Subjects that respond to Periactin|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
11651472|NCT00066248|Experimental|Non-responders to Periactin- Megace Arm|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
11651473|NCT00066222|Experimental|Radiation Therapy + Chemotherapy|Accelerated high dose thoracic radiation therapy (RT) with concurrent cisplatin/etoposide chemotherapy, followed by 2 cycles of adjuvant cisplatin/etoposide chemotherapy
11651474|NCT00066196|Other|2|Integrin + Dacarbazine
11651475|NCT00066196|Active Comparator|1|MEDI-522
11651476|NCT00066170|Experimental|Group 1.|Xyrem + Modafinil Placebo
11651477|NCT00066170|Placebo Comparator|Group 2:|Xyrem Placebo + Modafinil Placebo
11651478|NCT00066170|Active Comparator|Group 3|Xyrem Placebo + Modafinil at established dose
11651479|NCT00066170|Experimental|Group 4:|Xyrem + Modafinil at established dose
11651480|NCT00033306|Experimental|BMS-247550|
11651481|NCT00066157|Experimental|1|estradiol patch and medroxyprogesterone
11651482|NCT00066157|Active Comparator|2|estradiol patch and placebo pill
11651483|NCT00066157|Active Comparator|3|placebo patch and medroxyprogesterone
11651484|NCT00066157|Placebo Comparator|4|placebo patch and placebo pill
11651485|NCT00066131|Active Comparator|Scaling and root planing|Scaling and root planing delivered prior to 21 weeks of gestation.
11651486|NCT00066131|No Intervention|Placebo|Delayed treatment group. Controls monitored clinically from baseline to 29-32 weeks of gestation. Scaling and root planing provided after delivery.
11651487|NCT00066092|Experimental|Pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
11651488|NCT00066092|Experimental|Pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
11651489|NCT00066092|Active Comparator|filgrastim|Filgrastim given daily for PBPC mobilization
11651490|NCT00066066|Placebo Comparator|Scaling and root planing alone|Full mouth scaling and root planing (SRP) alone plus a placebo pill taken twice daily for 2 weeks.
11651491|NCT00066066|Active Comparator|SRP + Metronidazole|Full mouth Scaling and Root Planing plus Metronidazole (MET) 250 mg tid x 14 days
11651492|NCT00066066|Active Comparator|SRP + MET + Amoxicillin + Doxycycline|Full mouth Scaling and Root Planing plus Metronidazole (MET) 250 mg tid x 14 d and Amoxicillin (AMOX) 500 mg tid for 14 days and local drug delivery of Doxycycline (TET LDD) in pockets >4mm
11651493|NCT00066053|Experimental|Periodontal Treatment: SRP|Comprehensive scaling & root planing and subgingival tissue removal; fluorides applied as appropriate; oral hygiene instructions.
11651494|NCT00066053|Active Comparator|Community Comparator|Referral to community dentist with copy of x-rays and letter with diagnosis and recomendations for treatment.
11651495|NCT00066027|Experimental|low-dose doxycycline|low-dose doxycycline (20 mg doxycycline hyclate)
11651496|NCT00066027|Placebo Comparator|Placebo|Placebo
11651497|NCT00066014|Active Comparator|treatment modalities changed for comparison|All subjects experienced all treatment modalities being studied.
11651498|NCT00066001|Placebo Comparator|1, 2, 3, 4|The 4 arms of the study are based on the treatment groups: 1. scaling and root planing alone (SRP); 2. SRP plus repeated professional supragingival plaque removal; 3. SRP + systemically administered metronidazole; 4. SRP + repeated professional supragingival plaque removal + systemically administered metronidazole.
11651499|NCT00065845|No Intervention|Abdominal Sacral Colpopexy with no Burch colposuspension|Abdominal sacral colpopexy is performed through a laparotomy approach.
11651500|NCT00065845|Experimental|Abdominal Sacral Colpopexy with Burch Colposuspension|The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
11651501|NCT00031707|Active Comparator|megestrol + placebo|"Patients receive oral megestrol once daily and oral placebo twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.
~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.
~Patients are followed every 6 months for 5 years."
11651502|NCT00031707|Active Comparator|eicosapentaenoic acid + placebo|"Patients receive oral placebo once daily and an eicosapentaenoic acid (EPA)-enriched nutritional supplement twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.
~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.
~Patients are followed every 6 months for 5 years."
11651503|NCT00031707|Experimental|megestrol + eicosapentaenoic acid|"Patients receive oral megestrol once daily and an EPA-enriched nutritional supplement twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.
~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.
~Patients are followed every 6 months for 5 years."
11651554|NCT00065156|Experimental|Lenalidomide|
11651555|NCT00065065|Experimental|Rosiglitazone|4 mg of rosiglitazone taken twice daily for 12 weeks.
11651556|NCT00065065|Placebo Comparator|placebo|Identical in appearance to study drug taken twice daily for 12 weeks.
11651782|NCT00061542|Experimental|Betaxolol|Two doses daily for 12 weeks
11651506|NCT00065806|Experimental|1|Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes [TLC] diet, [http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi]), cardiovascular risk factor reduction counseling, hydroxychloroquine, low-dose aspirin, a multivitamin containing folate, plus atorvastatin at 10 mg or 20 mg depending on the patient's weight. Patients weighing more than 50 kg will receive 10 mg qd atorvastatin for the first month, which will be increased to 20 mg qd at the Day 30 visit and continue through month 36. Participants weighing less than 50kg will receive a maximum of 10 mg po qd for 36 months.
11651507|NCT00065806|Placebo Comparator|2|Patients will be treated with dietary intervention (AHA Therapeutic Lifestyle Changes [TLC] diet, [http://www.nhlbi.nih.gov/cgi-bin/chd/step2intro.cgi]), cardiovascular risk factor reduction counseling, hydroxychloroquine, low-dose aspirin, a multivitamin containing folate, plus placebo at 10 mg or 20 mg depending on the patient's weight. Patients weighing more than 50 kg will receive 10 mg qd placebo for the first month, which will be increased to 20 mg qd at the Day 30 visit and continue through month 36. Participants weighing less than 50kg will receive a maximum of 10 mg po qd for 36 months.
11651508|NCT00065728|Experimental|Anecortave Acetate, 15 mg|One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
11651509|NCT00065715|No Intervention|A|No pills
11651510|NCT00065715|Placebo Comparator|B|Blinded placebo
11651511|NCT00065715|Experimental|C|Echinacea - Blinded
11651512|NCT00065715|Experimental|D|Echinacea - Unblinded, Open Label
11651513|NCT00065676|Experimental|1 gram quercetin|1 gram quercetin with 6 hour OGTT
11651514|NCT00065676|Experimental|2 grams quercetin|2 gram quercetin with 6 hour OGTT
11651515|NCT00065676|Experimental|placebo|placebo with 6 hour OGTT
11651516|NCT00065585|No Intervention|Usual care|
11651517|NCT00065585|Placebo Comparator|non needle control|
11651518|NCT00065585|Sham Comparator|Acupuncture - Standardized Points|
11651519|NCT00065585|Experimental|Accupunture - Experimental Points|
11651520|NCT00065546|Active Comparator|1|Post-menopausal women randomized to receive estrogen replacement therapy.
11651521|NCT00065546|Placebo Comparator|2|Post-menopausal women randomized to receive a placebo.
11651522|NCT00065546|Experimental|3|Pre-menopausal women with specific genetic variants.
11651523|NCT00065637|Experimental|1|Women will self-administer PTH injections daily for 4 weeks, then once weekly for 48 weeks
11651524|NCT00065637|Placebo Comparator|2|Women will self-administer placebo injections daily for 4 weeks, then once weekly for 48 weeks
11651525|NCT00014560|Experimental|Single arm|Antibody
11651526|NCT00065507|Experimental|A1|
11651527|NCT00065507|Active Comparator|A2|
11651528|NCT00006486|Experimental|Arm I (carboxyaminoimidazole)|"Patients receive oral CAI daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.
~Patients receive oral CAI as above."
11651529|NCT00006486|Experimental|Arm II (carboxyamidotriazole, placebo)|"Patients receive oral CAI daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.
~Patients receive a placebo."
11651530|NCT00065468|Active Comparator|A|
11651531|NCT00065468|Experimental|B|
11651532|NCT00065468|Experimental|C|
11651533|NCT00006229|Experimental|BMS-275291|
11651534|NCT00006229|Placebo Comparator|Placebo|
11651535|NCT00006081|Experimental|Bryostatin-1 + Taxol|
11651536|NCT00065442|Placebo Comparator|APC-Placebo|
11651537|NCT00065442|Active Comparator|Sipuleucel-T|
11651538|NCT00065429|Experimental|BB-10901, 5mg/m2 - Phase I|
11651539|NCT00065429|Experimental|BB-10901, 10 mg/m2 - Phase I|
11651540|NCT00065429|Experimental|BB-10901, 20 mg/m2 - Phase I|
11651541|NCT00065429|Experimental|BB-10901, 40 mg/m2 - Phase I|
11651542|NCT00065429|Experimental|BB-10901, 60 mg/m2 - Phase I & Phase II|Phase I and Phase II were consecutive and sequential. Different patients received the 60mg/m2 dose in Phase I and in Phase II.
11651543|NCT00065429|Experimental|BB-10901, 67.5 mg/m2 - Phase I|
11651544|NCT00065429|Experimental|BB-10901, 75 mg/m2 - Phase I|
11651545|NCT00005604|Experimental|Treatment (rhIl-12, IL-2)|Patients receive interleukin-12 (IL-12) IV on days 1 and 4 for 6 weeks. Beginning on day 4 of the third week, patients receive interleukin-2 (IL-2) subcutaneously 1 hour before and 20 hours after each dose of IL-12. On subsequent courses, IL-2 and IL-12 are administered on days 1 and 4 of each week. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease response may continue treatment until complete response or disease progression.
11651546|NCT00065351|Experimental|1|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
11651547|NCT00065325|Active Comparator|1|Exemestane
11651548|NCT00065325|Experimental|2|Fulvestrant
11651549|NCT00065208|Experimental|Reiki|Energy therapy
11651550|NCT00065208|Sham Comparator|Pretend Reiki|
11651551|NCT00065208|Other|Rest / Guided Imagery|Rest for pre-surgery outcomes Guided Imagery for post-surgery outcomes
11651552|NCT00065260|Experimental|r-ATG /cyclosporine|A randomized trial of rabbit anti-thymocyte globulin (r-ATG)/ cyclosporine (CsA) versus Campath-1H in aplastic anemia patients with refractory pancytopenia or suboptimal hematological response after horse ATG treatment. Subjects who receive rabbit ATG/ CsA will be given rabbit ATG 3.5mg/kg/day for 5 days and CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs. Subjects who receive Campath-1H will receive an intravenous infusion for 10 days. Adult subjects will receive 10mg/day (children:0.2mg/kg/day).
11651553|NCT00065260|Experimental|Alemtuzumab (Campath-1H)|A randomized trial of rabbit anti-thymocyte globulin (ATG)/ cyclosporine (CsA) versus Campath-1H in aplastic anemia patients with refractory pancytopenia or suboptimal hematological response after horse ATG treatment. Subjects who receive rabbit ATG/ CsA will be given rabbit ATG 3.5mg/kg/day for 5 days and CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs. Subjects who receive Campath-1H will receive an intravenous infusion for 10 days. Adult subjects will receive 10mg/day (children:0.2mg/kg/day).
11651557|NCT00003895|Experimental|gp100:209-217(210M) + HPV 16 E7:12-20 (every 2 weeks)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 2 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory biomarker analysis.
11651558|NCT00003895|Experimental|gp100:209-217(210M) + HPV 16 E7:12-20 (every 3 weeks)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine mixed with incomplete Freund's adjuvant SC every 3 weeks for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory biomarker analysis.
11651559|NCT00064987|Experimental|Group 1 (FSH)|Patients in Group 1 will receive subcutaneous follicle stimulating hormone (FSH) injections daily, titrated to achieve a FSH level of 4-8 IU/L, for 4 months. Patients will then receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion.
11651560|NCT00064987|Active Comparator|Group 2 (GnRH)|Patients in Group 2 will receive gonadotropin releasing hormone (GnRH) therapy for 18 months. GnRH will be administered via a portable infusion pump at 2-hour intervals to stimulate endogenous LH secretion. Patients in Group 2 will not receive prior FSH administration.
11651561|NCT00064974|Experimental|CC-5013|CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles)
11651562|NCT00064883||Patients|Pediatric cancer patients referred to the ROB who have received or require radiation therapy
11651563|NCT00064844|Placebo Comparator|Nicotine patch plus placebo gum|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy. Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
11651564|NCT00064844|Active Comparator|Nicotine patch plus active gum|Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy. Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.
11651565|NCT00064753|Experimental|High Dose Multivitamin|Multivitamin with increased folic acid, vitamin B6 and vitamin B12
11651566|NCT00064753|Active Comparator|Low Dose Multivitamin|Multivitamin devoid of folic acid and with estimated average requirement amounts of vitamin B6 and vitamin B12
11651567|NCT00003645|Experimental|Arm I - Leuprolide + Flutamide|Arm I: Patients receive leuprolide intramuscularly once every 3 months and oral flutamide three times daily for 1 year.
11651568|NCT00003645|No Intervention|Arm II - No Treatment|Arm II: Patients receive no initial treatment.
11651569|NCT00003571||Samples of tumor and normal tissue|Samples of tumor and normal tissue are obtained from CALGB 8896 patients. The samples are tested for somatic mutations and tumor replication error (RER) tumor status. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
11651570|NCT00064792|Placebo Comparator|OraPlus|
11651571|NCT00064792|Active Comparator|Simvastatin Susp|
11651572|NCT00064701|Experimental|Tacrolimus|Participants received a first dose of tacrolimus between 0.075 and 0.10 mg/kg twice daily, orally prior to or within 48 hours of the completion of the transplant procedure, and subsequently as twice daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
11651573|NCT00064701|Active Comparator|Tacrolimus Modified Release|Participants received a first dose of tacrolimus modified release between 0.15 and 0.20 mg/kg/day, given as a single oral dose in the morning, prior to or within 48 hours following the completion of the transplant procedure, and subsequently as once daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
11651574|NCT00064701|Active Comparator|Cyclosporine|Participants received a first dose of cyclosporine between 4 to 5 mg/kg orally prior to or within 48 hours following the completion of the transplant procedure and subsequently as twice daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events. Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
11651575|NCT00064714|Experimental|Group 1|Group 1 will receive immunosuppression and AC2993; then immunosuppression only
11651576|NCT00064714|Experimental|Group 2|Group 2 will receive AC2993 only; then neither immunosuppression nor AC2993
11651577|NCT00064714|Experimental|Group 3|Group 3 will receive immunosuppression and AC2993; then immunosuppression and AC2993
11651578|NCT00064714|Experimental|Group 4|Group 4 will receive AC2993 only; then AC2993 only
11651579|NCT00064662|Other|Burch|The Burch colposuspension
11651580|NCT00064662|Other|Sling|Pubovaginal sling, using autologous rectus fascia
11651581|NCT00064649|Active Comparator|2|Transurethral Needle Ablation (TUNA)
11651582|NCT00064649|Active Comparator|3|finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
11651583|NCT00064649|Active Comparator|1|Transurethral Microwave Thermotherapy (TUMT)
11651584|NCT00003350|Experimental|Arm I (paclitaxel)|"Patients receive paclitaxel over 3 hours by intravenous infusion. Treatment course repeats every 2 weeks. Patients are evaluated every third course.
~Patients in both arms continue treatment if there is no disease progression or unacceptable toxicity. Patients with complete response continue on study treatment for 2 courses beyond documented complete response.
~Quality of life is assessed before, during, and after treatment."
11651585|NCT00003350|Experimental|Arm II (pegylated liposomal doxorubicin hydrochloride)|"Patients receive doxorubicin HCL liposome over 30-60 minutes by intravenous infusion. Treatment course is repeated every 3 weeks. Patients are evaluated before every odd course.
~Patients in both arms continue treatment if there is no disease progression or unacceptable toxicity. Patients with complete response continue on study treatment for 2 courses beyond documented complete response.
~Quality of life is assessed before, during, and after treatment."
11651586|NCT00003045|Experimental|Hyperthermia|XRT and Hyperthermia Post-therapy evaluation PSA, Clinical Exam, and Prostate Biopsy ( @ 12 Months)
11651587|NCT00002965|Experimental|Arm 1: Benign Meningiomas|INF alpha as a subcutaneous injection Monday to Friday for 8 weeks.
11651588|NCT00002965|Experimental|Arm 2: Other Pathologies|INF alpha as subcutaneous injection Monday to Friday for 8 weeks.
11651589|NCT00064519||Families with MI|"In conjunction with collaborators in Germany, we have established one of the largest collections of families with MI, comprising 1,406 individuals in 513 Western-European families. Based on this collection, our total genome scan and linkage analysis has identified a region on chromosome 14 with a significant linkage signal for myocardial infarction (LOD = 3.9, pointwise P = 0.00015, genome-wide P < 0.05)5. Preliminary results from an association study in a subset of these families has identified a small set of single nucleotide polymorphisms (SNPs) within candidate genes in this region as being suggestively associated with MI.
~No drugs are to be administre"
11651590|NCT00064415|Experimental|1|Arformoterol tartrate 50 mcg QD
11651591|NCT00064415|Active Comparator|2|Salmeterol 42 mcg BID
11651592|NCT00064402|Experimental|1|Arformoterol 50 mcg QD and placebo MDI
11651593|NCT00064402|Experimental|2|Arformoterol 25 mcg BID and Placebo MDI
11651594|NCT00064402|Experimental|3|Arformoterol 15 mcg BID and placebo MDI
11651595|NCT00064402|Active Comparator|4|Salmeterol MDI 42 mcg BID and placebo inhalation solution
11651596|NCT00064402|Placebo Comparator|5|Placebo MDI and placebo inhalation solution
11651597|NCT00064389|Experimental|1|levalbuterol 90 mcg MDI QID
11651598|NCT00064389|Active Comparator|2|racemic albuterol HFA MDI 180 mcg QID
11651599|NCT00064350|Experimental|Induction then Sorafenib|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression.
~Randomization: Patients with stable disease after the induction treatment were randomized to either the sorafenib arm or the placebo arm. Patients on the sorafenib arm receive sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable disease."
11651600|NCT00064350|Placebo Comparator|Induction then Placebo then Sorafenib|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease proceed to randomization. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression.
~Randomization: Patients with stable disease after the induction treatment were randomized to either the sorafenib arm or the placebo arm. Patients on the placebo arm receive oral placebo twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients on the placebo arm who develop disease progression within 1 year after randomization may cross over to sorafenib arm."
11651601|NCT00064350|Other|Induction, not randomized|"Induction: All patients receive oral sorafenib twice daily on days 1-28. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity.
~Post-induction: Patients with responding disease or disease progression were not randomized in Step 2. Patients with responding disease continue to receive sorafenib for up to 1 year in the absence of disease progression, while patients with disease progression were removed from the study."
11651602|NCT00064337|Experimental|Treatment|"MM Induction: dexamethasone 20mg/d PO Days 1-4, 9-12 and 17-20 every 35 days for 2 cycles and thalidomide 200 mg/d PO Days 1-70.
~Mobilization and SC Collection:
~MM, MM+AL, MM+LCD: cyclophosphamide 2.5 gm/m2 IV Day 1; mesna 800 mg/m2 IV Day 1 x 3 doses; G-CSF 10 mcg/kg/d SQ Day 2 through day prior to last leukapheresis.
~Amyloid or LCDD-Only: G-CSF 16 mcg/kg/d SQ Days 1-3 (continued daily until the day prior to the last day of stem cell collection).
~Conditioning/Transplant - Modified HighDose Melphalan (given for both transplants): melphalan 100 mg/m2/d IV over 20 mins Day -2; PBSC infusion >/= 3.5 x 10^6 CD34+ cells/kg IV Day 0.
~Maintenance (MM only): dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year, followed by dexamethasone 40 mg/d PO Days 1-4 every 28 days and thalidomide 100 mg/d PO daily - given for one year."
11651603|NCT00064324|Experimental|Arm I|Patients receive a loading dose of oral perifosine every 6 hours for a total of 4 doses on day 1 and once daily on days 2-28 of course 1 only. For all subsequent courses, patients receive oral perifosine once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11651604|NCT00064298|Experimental|Arm I - JuicePlus|Patients receive oral fruit and vegetable extracts twice daily.
11651605|NCT00064298|Placebo Comparator|Arm II - Control|Patients receive oral placebo twice daily.
11651606|NCT00064272|Experimental|Arm I|Patients receive lower-dose oral ginger twice daily.
11651607|NCT00064272|Experimental|Arm II|Patients receive higher-dose oral ginger twice daily.
11651608|NCT00064272|Placebo Comparator|Arm III|Patients receive oral placebo twice daily.
11651609|NCT00064259|Experimental|Treatment (oblimersen sodium)|"Phase I: Patients receive oblimersen IV continuously on days 1-7, fluorouracil IV continuously on days 4-8, and cisplatin IV on day 4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 12 patients are treated at the MTD.
~Phase II: Patients receive treatment as in phase I with oblimersen at the MTD."
11651610|NCT00064246|Experimental|Treatment (rituximab, yttrium Y 90 ibritumomab tiuxetan)|"Phase I: Patients receive rituximab IV and indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo 2 (or 3 if needed) imaging scans between days 1-6. In the absence of altered biodistribution, patients receive rituximab IV followed within 4 hours by IDEC-Y2B8 IV over 10 minutes on day 8.
~Phase II: Patients receive treatment as in phase I at the MTD of IDEC-Y2B8. Patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 2 years."
11651611|NCT00064142|Experimental|Arm I (halofuginone hydrobromide)|Patients apply topical halofuginone hydrobromide ointment to each of 6 lesions twice a day for 12 weeks.
11651612|NCT00064142|Placebo Comparator|Arm II (placebo)|Patients apply topical placebo ointment to each of 6 lesions twice a day for 12 weeks.
11651778|NCT00061633|Active Comparator|Standard of care for cSSSI|cSSSI - complicated skin and skin structure infections
11651783|NCT00061542|Experimental|TGFS 0.25%|Two doses daily for 12 weeks
11651613|NCT00064129|Experimental|Treatment (monoclonal antibody, colony-stimulating factors)|Patients receive ipilimumab IV over 90 minutes on day 1 and sargramostim (GM-CSF) SC on days 1-14. Treatment repeats every 28 days for 4-6 courses. GM-CSF continues beyond 4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of ipilimumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Some patients undergo blood sample collection periodically for laboratory and pharmacokinetic studies. Samples are analyzed for human anti-human antibodies, IgG antibodies to ipilimumab semi-quantitative ELISA assay, and plasma concentrations of ipilimumab via quantitative ELISA assay.
11651614|NCT00064116|Active Comparator|Arm A: CHOP-21|Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle: day 22 Total number of cycles 6
11651615|NCT00064116|Active Comparator|Arm B: CHOP-21 + Rituximab|Rituximab 375 mg/m² i.v. day 1* Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
11651616|NCT00064103|Experimental|Treatment (Ad5CMV-p53 gene)|"Phase I: Patients receive Ad5CMV-p53 gene by intramucosal injection into the area of the lesion followed at least 2 hours later by Ad5CMV-p53 gene as an oral rinse on day 1. Patients then receive Ad5CMV-p53 gene as an oral rinse twice daily on days 2-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of Ad5CMV-p53 gene as an oral rinse until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
~Phase II: Patients receive treatment with intramucosal Ad5CMV-p53 gene as in phase I and Ad5CMV-p53 gene as an oral rinse at the MTD."
11651617|NCT00064077|Experimental|Arm I (paclitaxel, cisplatin)|Patients receive paclitaxel IV over 24 hours on day 1 and cisplatin IV over 1-4 hours on day 2.
11651618|NCT00064077|Experimental|Arm II (vinorelbine, cisplatin)|Patients receive vinorelbine IV over 6-10 minutes on days 1 and 8 and cisplatin IV over 1-4 hours on day 1.
11651619|NCT00064077|Experimental|Arm III (gemcitabine, cisplatin)|Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8 and cisplatin as in arm II.
11651620|NCT00064077|Experimental|Arm IV (topotecan, cisplatin)|Patients receive topotecan IV over 30 minutes on days 1-3 and cisplatin as in arm II.
11651621|NCT00064038|Experimental|Arm I|Patients receive induction therapy comprising oral dexamethasone (DM) on days 1-4, 9-12, and 17-20 and oral lenalidomide on days 1-28. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising oral DM on days 1-4 and 15-18 and oral lenalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11651622|NCT00064038|Active Comparator|Arm II|Patients receive induction therapy comprising DM as in arm I induction and oral placebo on days 1-28. Treatment repeats as in arm I induction. Some patients may then receive maintenance therapy comprising oral DM as in arm I maintenance and oral placebo on days 1-21. Courses repeat as in arm I maintenance.
11651623|NCT00064025|Experimental|Treatment (medroxyprogesterone)|"Patients receive medroxyprogesterone intramuscularly once approximately 3 weeks before surgical hysterectomy.
~A subset of 15 patients has tissue collected by pipelle biopsy or curettage at baseline, 72 hours after medroxyprogesterone therapy, and during surgery for gene expression arrays."
11651624|NCT00064012|Active Comparator|Velcade Alone|Velcade
11651625|NCT00064012|Experimental|Velcade plus Docetaxel|Velcade plus Docetaxel
11651626|NCT00063999|Active Comparator|Arm I (doxorubicin hydrochloride, cisplatin, paclitaxel)|Patients receive doxorubicin hydrochloride IV over approximately 15-30 minutes on day 1, cisplatin IV over 60-90 minutes on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
11651627|NCT00063999|Experimental|Arm II (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.
11651628|NCT00063986|Experimental|Minimally invasive esophagectomy (MIE)|Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
11651629|NCT00063973|Experimental|Treatment (cilengitide)|"Patients receive cilengitide (EMD 121974) IV over 1 hour twice weekly. Treatment repeats every 4 weeks for 13 courses in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of cilengitide until the MTD is determined. The MTD is defined as the dose at which 25% of patients are expected to experience dose-limiting toxicity. Once the MTD is determined, 6 additional patients are accrued and treated at that dose level for a total of 12 patients at the MTD."
11651630|NCT00063960|Experimental|floxuridine + irinotecan|"Within 4-8 weeks after prior resection or ablation, patients receive hepatic arterial infusion of floxuridine continuously on days 1-14 and irinotecan IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of unacceptable toxicity.
~Patients are followed every 3 months for 2 years."
11651631|NCT00063947|Experimental|Treatment (radiotherapy, gemcitabine, erlotinib hydrochloride)|Chemoradiotherapy: Patients undergo radiotherapy 5 days a week for 5.5 weeks. Beginning on day 1 and continuing concurrently with radiotherapy, patients receive gemcitabine IV over 30 minutes twice weekly and oral erlotinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease proceed to maintenance therapy. Maintenance therapy: Beginning 4-7 weeks after the completion of chemoradiotherapy, patients receive maintenance chemotherapy comprising gemcitabine IV over 30 minutes on days 1 and 8 and oral erlotinib once daily. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
11651708|NCT00025376|Experimental|Pre-Treatment biopsy followed by PS-341 administration|Pre-treatment tumor biopsy followed by 3 cycles of PS-341 given by IV infusion. Each cycle will last 3 weeks. PS-341 will be given 2 times a week for 2 weeks followed by a 'rest' week with no drug. After the 3rd cycle, subjects can continue to receive another 3 cycles of the study drug if their disease has not worsened.
11651779|NCT00061620|Experimental|Tezacitabine|Tezacitabine as a bolus infusion daily x 5
11651780|NCT00059462|Experimental|Arm 1|
11651632|NCT00063934|Experimental|Treatment (oblimersen, doxorubicin, docetaxel)|"PHASE I (COMPLETED AS OF 8/16/04): Patients receive oblimersen IV continuously on days 1-6 interrupted only to administer doxorubicin IV over 15 minutes and docetaxel IV over 60 minutes on day 6. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 7-13 or pegfilgrastim SC on day 7. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
~PHASE II: Patients receive doxorubicin, docetaxel, G-CSF or pegfilgrastim, and oblimersen at the MTD as in phase I.
~Patients with resectable tumors after 6 courses undergo surgical resection."
11651633|NCT00063895|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11651634|NCT00063882|Experimental|EBRT + Brachytherapy|External beam radiation therapy (EBRT) and transperineal interstitial permanent brachytherapy (100/110)
11651635|NCT00063882|Active Comparator|Brachytherapy Only|Transperineal interstitial permanent brachytherapy (125/145)
11651636|NCT00005940|Experimental|Treatment (radiolabeled BC8, chemotherapy, PBSCT)|"RADIOLABELED ANTIBODY: Patients receive iodine I 131 monoclonal antibody BC8 IV on day -13.
~CHEMOTHERAPY: Patients receive busulfan PO every 6 hours on days -7 to -4 and cyclophosphamide IV on days -3 and -2.
~TRANSPLANT: Patients undergo allogeneic PBSC or BM transplant on day 0.
~GRAFT-VS-HOST DISEASE PREVENTION: Patients receive cyclosporine IV or PO every 12 hours on days -1 to 50 with a taper to day 180. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
11651637|NCT00003211|Experimental|Average-risk|"Participants meeting the eligibility requirements for assignment to the average-risk arm.
~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy."
11651638|NCT00003211|Experimental|High-risk|"Participants meeting the eligibility requirements for assignment to the high-risk arm.
~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy."
11651639|NCT00063817|Experimental|Conditioning Regimen|"Cyclophosphamide intravenously (IV) on days -5 and -4 with respect to transplantation; MEDI-507 on days -1, 0, and 1 (after a test dose of 0.1 mg per kg on day -2); and cyclosporine A IV and thymic irradiation on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered daily postoperatively, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months.
~Amendment applicable to the 4th and 5th participant: rituximab on days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days."
11651640|NCT00063804|Experimental|1|escalating single doses of AMD070 ranging from 1/4 to 1 times the maximum tolerated dose (MTD)
11651641|NCT00063804|Experimental|2|single dose of 200 mg AMD070 after eating a standardized meal
11651642|NCT00063804|Experimental|3|single dose of 200 mg AMD070 on Days 1, 3, and 17 and single dose of 100 mg ritonavir on Days 3 through 18
11651643|NCT00063778|Experimental|1 x 10^4 IU dose|Vaccine dose of 1 x 10^4 IU per injection
11651644|NCT00063778|Experimental|1 x 10^5 IU dose|Vaccine dose of 1 x 10^5 IU per injection
11651645|NCT00063778|Placebo Comparator|Placebo|
11651646|NCT00063635|Active Comparator|1|Metformin, 500 mg, twice daily
11651647|NCT00063635|Active Comparator|2|Vitamin E, 400 IU, twice daily
11651648|NCT00063635|Placebo Comparator|3|Matching placebo
11651649|NCT00063622|Active Comparator|1|Pioglitazone
11651650|NCT00063622|Active Comparator|2|Vitamin E
11651651|NCT00063622|Placebo Comparator|3|Placebo Pioglitazone or Placebo Vitamin E
11651652|NCT00063583|Placebo Comparator|Placebo|Placebo
11651653|NCT00063583|Experimental|Pirfenidone 1200 mg/day|Pirfenidone will be administered at a dose of 1200 mg/day
11651654|NCT00063583|Experimental|Pirfenidone 2400 mg/day|Pirfenidone will be administered at 2400 mg/day
11651655|NCT00063570|Experimental|A|
11651656|NCT00063570|Experimental|B|
11651657|NCT00063531||GeneSTAR participant meeting entry criteria|Healthy siblings of patients with early onset CAD (<60 years old) and the adult offspring of the siblings or probands
11651658|NCT00063323|Active Comparator|Bupropion|Bupropion (brand name Zyban Sustained Release). Participants used bupropion SR 150 mg twice daily during the 16-week maintenance treatment.
11651659|NCT00063323|Active Comparator|Nicotine gum|Nicotine gum (brand name Nicorette) During the maintenance 16-week maintenance treatment phase, participants assigned to this arm received 2 mg. nicotine gum.
11651660|NCT00063323|Active Comparator|Bupropion+Nicotine Gum|Combined active treatments: Bupropion (Zyban SR) and nicotine gum (Nicorette). Participants were instructed to use the 150 mg bupropion pill twice daily and the 2 mg. gum as needed during the 16-week maintenance treatment phase.
11651661|NCT00063323|Placebo Comparator|Double placebo|Placebo gum + placebo pill. Identical placebo pill was used twice daily and identical placebo gum was used as needed.
11651662|NCT00031889|Active Comparator|Arm I|Patients receive oral exemestane once daily
11651663|NCT00031889|Active Comparator|Arm II|Patients receive exemestane as in arm I and oral bicalutamide once daily
11651664|NCT00063453|Experimental|Vitamin E and selenium placebo|Vitamin E alone
11651665|NCT00063453|Experimental|Selenium and vitamin E placebo|Selenium alone
11651666|NCT00063453|Experimental|Vitamin E and selenium|Vitamin E and selenium combined
11651667|NCT00063453|Placebo Comparator|vitamin E Placebo and Selenium placebo|Double placebo
11651668|NCT00028925|Experimental|Regimen A|"Patients receive oral topotecan once daily on days 1-5, carboplatin IV over 30 minutes on day 5, and filgrastim (G-CSF) subcutaneously once daily beginning on day 6 or 7 and continuing for up to 10 days or until blood counts recover.
~Treatment for all patients repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression limited to CNS only interrupt chemotherapy to have whole-brain radiotherapy (WBRT). Once WBRT is complete, chemotherapy resumes.
~Quality of life is assessed at baseline and at the beginning of each course of chemotherapy.
~Patients are followed every 3 months for 2 years and then every 6 months for 3 years."
11651669|NCT00028925|Experimental|Regimen B|"Patients receive topotecan and carboplatin as in regimen A. Patients are evaluated after the first 3-week course of chemotherapy. If no patient experiences unacceptable toxicity or febrile neutropenia, the next 33 patients receive treatment as in regimen B; otherwise, patients receive treatment as in regimen A.
~Treatment for all patients repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression limited to CNS only interrupt chemotherapy to have whole-brain radiotherapy (WBRT). Once WBRT is complete, chemotherapy resumes.
~Quality of life is assessed at baseline and at the beginning of each course of chemotherapy.
~Patients are followed every 3 months for 2 years and then every 6 months for 3 years."
11651670|NCT00063401|Experimental|1|Cetuximab 400 mg/m2 IV (over 120 minutes) on Day 1 of Cycle 1, followed by weekly maintenance doses of 250 mg/m2 IV (over 60 minutes). Paclitaxel 175 mg/m2 IC (over 3 hours) and carboplatin AUC of 6 IV (over 30 minutes) on Day 1 of each cycle. For eligible subjects, maintenance therapy will consist of cetuximab 250 mg/m2/week for up to 6 months.
11651671|NCT00063388|Experimental|1|Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
11651672|NCT00063362|Experimental|Lithium + divalproex + lamotrigine|
11651673|NCT00063362|Placebo Comparator|Lithium + divalproex + placebo|
11651674|NCT00063336|Experimental|1|Participants will receive cognitive remediation treatment.
11651675|NCT00063336|Experimental|2|Participants will receive computer-skills training.
11651676|NCT00063258|Active Comparator|Chemotherapy + Tarceva|
11651677|NCT00063258|Active Comparator|Chemotherapy Alone|
11651678|NCT00063154|Experimental|Pertuzumab|Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). Subjects received pertuzumab at a loading dose of 840 mg in Cycle 1 followed by a dose of 420 mg in Cycles 2 and beyond.
11651679|NCT00063141|Experimental|Arm A|
11651680|NCT00063141|Active Comparator|Arm B|
11651681|NCT00063128|Experimental|A|
11651682|NCT00063128|Active Comparator|B|
11651683|NCT00030797|Active Comparator|Arm A|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;
11651684|NCT00030797|Active Comparator|Arm B|Irinotecan i.v. 240 mg/m2 day 1 and day 22; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;
11651685|NCT00026364|Experimental|Arm I|"Patients receive oral ZD 1839 daily. Beginning on day 15, patients receive irinotecan IV over 90 minutes, leucovorin calcium IV over 15 minutes, and fluorouracil IV weekly on weeks 1-2. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of ZD 1839 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are accrued to receive treatment at the MTD."
11651686|NCT00063089|Experimental|altastaph|S. aureus Immune Globulin Intravenous (Human) 5%
11651687|NCT00063089|Placebo Comparator|Placebo|0.45% Normal Saline
11651688|NCT00063076|Experimental|Targretin®|Targretin® (bexarotene) Gel 1%, treat half head
11651689|NCT00063076|No Intervention|Control|Half head untreated as control
11651690|NCT00023933|Experimental|Treatment (monoclonal antibody)|"Patients receive a tracer dose of iodine I 131 monoclonal antibody CC49-deltaCH2 IV on day 1 and a therapy dose over 30 minutes on day 8.
~Cohorts of 3-5 patients receive escalating doses of iodine I 131 monoclonal antibody CC49-deltaCH2 until the MTD is determined. The MTD is defined as the dose at which 3 of 5 patients experience grade 3 or greater toxicity while 0-2 of 5 patients experience reversible grade 4 hematologic toxicity."
11651691|NCT00062985|No Intervention|Control|
11651692|NCT00062985|Experimental|Mail-based weight loss intervention|
11651693|NCT00062985|Experimental|Telephone-based weight loss intervention|
11651694|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Group A)|Patients receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/leiomyosarcoma or who are at risk for relapse
11651695|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Group B)|Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
11651696|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Group C)|Patients receiving CTLs following allogeneic stem cell transplant.
11651697|NCT00062868|Experimental|LMP2A CTLs (ALASCER - Group A)|Patients receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/leiomyosarcoma or who are at risk for relapse
11651698|NCT00062868|Experimental|LMP2A CTLs (ALASCER - Group B)|Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant
11651699|NCT00062868|Experimental|LMP2A CTLs (ALASCER - Group C)|Patients receiving CTLs following allogeneic stem cell transplant
11651700|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Expansion Group A)|Patients receiving CTLs as therapy for relapsed Lymphoma/Lymphoepithelioma/leiomyosarcoma or who are at risk for relapse
11651701|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Expansion Group B)|Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.
11651702|NCT00062868|Experimental|LMP1/2 CTLs (ALCI - Expansion Group C)|Patients receiving CTLs following allogeneic stem cell transplant.
11651703|NCT00062855|Experimental|Gene Modified Neuroblastoma Cells|Gene modified neuroblastoma cells given as 4 subcutaneous injections over 5 weeks
11651704|NCT00062842|Experimental|Irinotecan weekly|Irinotecan was administered over 90 min weekly 4x, every 6 weeks.
11651705|NCT00062829|Other|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
11651706|NCT00002643|Experimental|Arm I|See detailed description.
11651707|NCT00027612|Experimental|irinotecan + carmustine and radiation|"Phase II (patients receiving concurrent EIACs or non-EIACs open to accrual as of 3/5/2005): Patients receive irinotecan at the recommended dose, carmustine, and cranial irradiation as in phase I.
~Patients with disease progression are followed every 3 months for 5 years and then annually for up to 10 years.
~Patients taken off study for reasons other than disease progression are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years."
11651773|NCT00061698|Active Comparator|Cognitive Behavior Therapy Child Only|Participants completed 20 sessions of CBT
11651781|NCT00059462|Active Comparator|Arm 2|
11651709|NCT00025376|Experimental|PS-341 administration followed by biopsy|3 cycles of PS-341 given by IV infusion. Each cycle will last 3 weeks. PS-341 will be given 2 times a week for 2 weeks followed by a 'rest' week with no drug. After the 3rd cycle, subjects will have a tumor biopsy and can continue to receive another 3 cycles of the study drug if their disease has not worsened.
11651710|NCT00022529|Experimental|Treatment (BMS-214662, trastuzumab)|Patients receive BMS-214662 IV over 1 hour on days 2, 8, 15, and 22 and trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11651711|NCT00062764|Experimental|Pioglitazone|
11651712|NCT00062751|Experimental|A|
11651713|NCT00062751|Experimental|B|
11651714|NCT00062751|Active Comparator|C|
11651715|NCT00062738|Experimental|nortriptyline|drug
11651716|NCT00062738|Experimental|paroxetine|drug
11651717|NCT00062738|Placebo Comparator|placebo|placebo
11651718|NCT00062647|Experimental|Telavancin|
11651719|NCT00062647|Active Comparator|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram/12 hours or nafcillin, oxacillin, or cloxacillin 2 Gram/6 hours (IV) intravenously
11651720|NCT00062569|Experimental|1|
11651721|NCT00062569|Experimental|2|
11651722|NCT00062543|Experimental|Hepatic Artery Infusion|Donor-derived CD34+ cells administered in a total volume of 100ml via hepatic artery over 10 minutes. Cells given as a dose escalation study. First cohort of 3 patients receive 1 * 106 CD34+ cells/kg. Next 3 patients receive 2.5 * 106 CD34+cells/kg. Next 3 patients receive 5 * 106 CD34+ cells/kg. Less than 1 * 105 T cells/kg administered.
11651723|NCT00062530|Experimental|1|All participants will receive oral vaccine at study entry, although dosage will vary
11651724|NCT00062504|Experimental|1|Valproic: 10mg TID week 1, 25mg TID week 2, 35mg week 3
11651725|NCT00062504|Experimental|2|Non-enzyme-inducing anti-epileptic drugs: 25mg TID week 1, 35mg week 2, 50mg week 3
11651726|NCT00062504|Experimental|3|Enzyme-inducing anti-epileptic drugs: 35mg TID week 1, 505mg week 2, 75mg week 3
11651727|NCT00062491|Experimental|1|Karenitecin (BNP1350)
11651728|NCT00062478|Experimental|1|Karenitecin for intravenous use
11651729|NCT00017394|Experimental|Treatment (bevacizumab, vinorelbine tartrate)|Patients receive bevacizumab IV over 30-90 minutes once every other week and vinorelbine IV over 6-10 minutes once weekly for 8 weeks. Treatment repeats every 8 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response or stable disease after completion of the fourth course may receive additional courses of concurrent bevacizumab and vinorelbine administered once every other week or may continue therapy on the schedule as above.
11651730|NCT00017316|Experimental|Arm I|Patients receive SU5416 IV over 1 hour twice weekly and oral thalidomide daily beginning 1 day after the first dose of SU5416. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
11651731|NCT00016107|Experimental|Treatment (chemotherapy, bevacizumab)|Patients receive oral estramustine 3 times daily on days 1-5 and docetaxel IV over 1 hour followed by bevacizumab IV over 30-90 minutes on day 2. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11651732|NCT00014534|Active Comparator|Gemcitabine + cisplatin|
11651733|NCT00014534|Active Comparator|Gemcitabine + Doxorubicin + Pegfilgrastim|
11651734|NCT00014170|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib daily. Courses repeat every 8 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
11651735|NCT00062452||A-1,2,3|The cohort (A) comprised of high risk infants. There were 3 sub groups studied within this cohort: (1) premature infants, (2) Infants with congenital gut anomalies, and (3) perinatal asphyxia.
11651736|NCT00062439|Experimental|Etoposide, Cisplatin, Thoracic RT, Surgery, Docetaxel|
11651737|NCT00062387|Experimental|Arm I|Patients receive oral perifosine 4 times daily on days 1 and 2 and once daily on days 3-28 during course 1. Patients receive oral perifosine once daily on days 1-28 for all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11651738|NCT00062374|Experimental|Treatment (preoperative chemotherapy)|"Neoadjuvant chemotherapy: Patients receive cisplatin IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1, 8, 22, and 29. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
~Surgery: Within 4 weeks after completion of neoadjuvant chemotherapy, patients undergo radical subtotal or total gastrectomy with lymph node dissection."
11651739|NCT00062309|Active Comparator|CIMRT|76 Gy in 38 fractions
11651740|NCT00062309|Experimental|HIMRT|70.2 Gy in 26 fractions
11651741|NCT00062244|Experimental|Arm I|"Phase I: Patients receive oblimersen IV continuously on days 1-7. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 1-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
~Phase II: Patients receive treatment as in phase I at the MTD of oblimersen. Patients are followed every 3 months for 2 years."
11651742|NCT00062179|Experimental|paclitaxel/carboplatin/celecoxib|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion Carboplatin: dosed at an AUC of 6 by the Calvert Formula Celecoxib: 400 mg po BID 3 cycles of paclitaxel and carboplatin 21 days apart celecoxib 3-7 days before first dose of chemotherapy
11651743|NCT00062179|Placebo Comparator|paclitaxel/Carboplatin/Placebo|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion Carboplatin: dosed at an AUC of 6 by the Calvert Formula Placebo 3 cycles of paclitaxel and carboplatin 21 days apart Placebo 3-7 days before first dose of chemotherapy
11651744|NCT00062127|Experimental|Arm I (irinotecan hydrochloride and thalidomide)|Patients receive irinotecan IV over 90 minutes on days 1 and 22 and oral thalidomide once daily on days 15-28. All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11651774|NCT00061698|Active Comparator|CBT plus Parent training|Child participants completed 20 sessions of CBT and parents completed 8 sessions of parent training
11651775|NCT00061698|No Intervention|Minimal Contact Control|Participants waited 12 weeks for treatment but their safety and well-being were monitored during this time
11651745|NCT00062127|Experimental|Arm II (irinotecan hydrochloride and thalidomide)|Patients receive irinotecan as in arm I and oral thalidomide once daily on days -6 to 7. All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11651746|NCT00062114|Experimental|rituximab + yttrium Y 90 ibritumomab tiuxetan|"Patients receive rituximab IV followed within 4 hours by yttrium Y 90 ibritumomab tiuxetan IV (for imaging) over 10 minutes on day 1. Patients undergo 1 (or 2 if needed) imaging scan between days 2-5. In the absence of altered biodistribution, patients receive rituximab IV followed within 4 hours by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8.
~Patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 2 years."
11651747|NCT00062101|Experimental|Group I (erlotinib hydrochloride, celecoxib)|Patients receive oral erlotinib once daily and oral celecoxib twice daily.
11651748|NCT00062101|Experimental|Group II (erlotinib hydrochloride)|Patients receive erlotinib as in group 1.
11651749|NCT00062075|Experimental|Treatment|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11651750|NCT00062062|Experimental|gefitinib|"Patients receive oral gefitinib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Quality of life is assessed at baseline and after the completion of course 2.
~Patients are followed every 3 months for 5 years."
11651751|NCT00062062|Experimental|paclitaxel + carboplatin + gefitinib|"Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. After completion of chemotherapy and in the absence of disease progression, patients receive oral gefitinib as in group I.
~Quality of life is assessed at baseline and after the completion of course 2.
~Patients are followed every 3 months for 5 years."
11651752|NCT00062023|Active Comparator|Arm I Sulindac|Oral sulindac twice daily.
11651753|NCT00062023|Active Comparator|Arm II Aspirin|Oral aspirin once daily.
11651754|NCT00062023|Active Comparator|Arm III Ursodiol|Oral ursodiol three times daily.
11651755|NCT00062023|Placebo Comparator|Arm IV: Sulindac Placebo|Oral sulindac placebo twice daily.
11651756|NCT00062010|Experimental|IFN-alpha, 13-CRA, paclitaxel|Interferon alpha: 6 million U/m2 on days 1 and 2 of each week for 6 weeks of an 8-week cycle 13-cis-retinoic acid: 1 mg/kg on days 1 and 2 of each week for 6 weeks of an 8-week cycle Paclitaxel: 75 mg/m2 on day 2 of each week for 6 weeks of an 8-week cycle
11651757|NCT00061958|Experimental|Treatment (arsenic trioxide)|Patients receive a loading dose of arsenic trioxide IV over 2 hours on days 1-5 on week 1. Beginning on week 2, patients receive a maintenance dose of arsenic trioxide IV twice weekly thereafter. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving a CR continue to receive therapy for at least 6 months beyond CR.
11651758|NCT00061945|Experimental|Treatment (alemtuzumab and combination chemotherapy)|See detailed description.
11651759|NCT00061932|Experimental|Stratum 1 (previously untreated)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and irinotecan IV over 90 minutes on days 1 and 8.
11651760|NCT00061932|Experimental|Stratum 2 (previously treated)|(closed to accrual as of 9/19/2006): Patients receive bortezomib as in stratum 1.
11651761|NCT00061919|Experimental|Active arm (thalidomide)|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
11651762|NCT00061919|Placebo Comparator|Placebo arm|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
11651763|NCT00061893|Experimental|Combination chemotherapy|Metastatic Ewing Sarcoma - 14-cycle study building on conventional tx (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, ifosfamide, etoposide) and adding two antiangiogenic agents: the vinca alkaloid vinblastine and the cyclooxygenase-2 inhibitor celecoxib. Refer to the Interventions section for dosages, method of delivery and frequency of administration.
11651764|NCT00061828||Biliary Atresia|Infants presenting with cholestasis who are diagnosed with biliary atresia.
11651765|NCT00061828||Non-Biliary Atresia|Infants presenting with cholestasis without a diagnosis of biliary atresia.
11651766|NCT00061815|Experimental|Cetuximab+FOLFOX4|"Day 1 - cetuximab loading dose of 400 mg/m2 IV, infused over 2 hours; oxaliplatin (85 mg/m2) simultaneously with leucovorin (200 mg/m2), followed by 5-FU 400 mg/m2 IV bolus followed by 5-FU 600 mg/m2 as a 22-hour continuous infusion
~Day 2 - leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 IV bolus followed by another dose of 5-FU 600 mg/m2 as a 22-hour continuous infusion
~Day 8 - cetuximab maintenance dose of 250 mg/m2 IV infused over 60 minutes"
11651767|NCT00061815|Active Comparator|FOLFOX4.|"Day 1 - oxaliplatin (85 mg/m2) simultaneously with leucovorin (200 mg/m2), followed by 5-FU 400 mg/m2 IV bolus followed by 5-FU 600 mg/m2 as a 22-hour continuous infusion.
~Day 2 - leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 IV bolus followed by another dose of 5-FU 600 mg/m2 as a 22-hour continuous infusion."
11651768|NCT00033462|Experimental|Arm I|Patients receive oral erlotinib once daily. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
11651769|NCT00010114||Newly diagnosed embryonal tumors|The participants in this study are infants (< 3 years of age) with newly diagnosed medulloblastoma, primitive neuroectodermal tumor, or other embryonal tumor, atypical teratoid/rhabdoid tumor, intracranial germ cell tumor, or choroid plexus carcinoma who have received no prior therapy with the exception of steroids and have consented to allow research studies on banked tissue specimens
11651770|NCT00009789|Experimental|Radiotherapy|"Patients receive accelerated 3-dimensional (3-D) conformal radiotherapy daily 5 days a week for 3.5-6 weeks.
~Cohorts of 8 patients receive escalating fractions of accelerated 3-D conformal radiotherapy until the maximum tolerated course is determined. The maximum tolerated course is defined as the course at which no more than 2 patients develop at least grade 3 dose-limiting toxicity and no more than 1 patient develops at least grade 4 dose-limiting toxicity.
~Patients are followed at 3 weeks, 6 weeks, 3 months, every 3 months for 2 years, and then every 6 months for 3 years."
11651771|NCT00061750|Experimental|ICL670|
11651772|NCT00061750|Active Comparator|Deferoxamine|
11651776|NCT00051714|Experimental|Early Primary Prevention|
11651784|NCT00061542|Experimental|TGFS 0.5%|Two doses daily for 12 weeks
11651785|NCT00061516|Experimental|Brinzolamide suspension, 1%|Dosed twice daily for 12 weeks
11651786|NCT00061516|Experimental|Levobetaxolol suspension, 0.5%|Dosed twice daily for 12 weeks
11651787|NCT00061568|Experimental|1|donor
11651788|NCT00061568|Experimental|2|recipient
11651789|NCT00061490|Experimental|1|16 weekly educational meetings
11651790|NCT00061490|No Intervention|2|Wait list control
11651791|NCT00006349|Experimental|donepezil + vitamin E|"Patients receive oral donepezil daily and vitamin E twice daily.
~All patients begin treatment within 2 weeks after completion of prophylactic cranial irradiation. Treatment continues for a minimum of 1 month in the absence of disease progression, unacceptable toxicity, or a 3.0 point drop on the Mini Mental State Examination (MMSE) and/or a 5 point drop on the Blessed Dementia Scale.
~Cognition is assessed using the Blessed Dementia Scale and the MMSE at baseline and then every 3 months during study.
~Quality of life and depression are assessed at baseline and then every 3 months during study.
~Patients are followed every 6 months."
11651792|NCT00006349|Placebo Comparator|placebo|"Patients receive oral placebo twice daily.
~All patients begin treatment within 2 weeks after completion of prophylactic cranial irradiation. Treatment continues for a minimum of 1 month in the absence of disease progression, unacceptable toxicity, or a 3.0 point drop on the Mini Mental State Examination (MMSE) and/or a 5 point drop on the Blessed Dementia Scale.
~Cognition is assessed using the Blessed Dementia Scale and the MMSE at baseline and then every 3 months during study.
~Quality of life and depression are assessed at baseline and then every 3 months during study.
~Patients are followed every 6 months."
11651793|NCT00006341|Experimental|Implant|A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
11651794|NCT00061321|Active Comparator|1|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum
11651795|NCT00061321|Experimental|2|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day)by mouth, from week 1 through week 6 post-partum Infants: Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
11651796|NCT00061373|Experimental|MRI Selected Patients|"Patients are eligible for the MRI arm if all clinical and all MRI inclusion and exclusion criteria are met.
~A single dose of aspirin 81 mg orally (or rectal dose equivalent), a single weight-based dose of subcutaneous tinzaparin sodium. Possible dose escalated iv eptifibatide."
11651797|NCT00061373|Experimental|non-MRI Selected Patients|"Patients are eligible for the non-MRI arm if all clinical inclusion-exclusion criteria are met, if MRI is contraindicated or if MRI compromises iv tPA delivery within 3-hours of symptom onset.
~A single dose of aspirin 81 mg orally (or rectal dose equivalent) and a single weight-based dose of subcutaneous tinzaparin sodium. Possible dose escalated iv eptifibatide.
~--------------------------------------------------------------------------------"
11651798|NCT00061360|Experimental|ATG+CsA|ATG+CsA for 6 months followed by a slow CsA taper in the subsequent 18 months
11651799|NCT00061360|Experimental|ATG+CsA+RA|ATG+CsA+RAPA for 6 months
11651800|NCT00061347|Experimental|1|Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
11651801|NCT00061282|Placebo Comparator|1|
11651802|NCT00061282|Active Comparator|2|Clotrimazole Therapy
11651803|NCT00061282|Active Comparator|3|Clotrimazole Therapy
11651804|NCT00061269|Experimental|VARD|Videoscopic-Assisted Retroperitoneal Debridement (VARD)
11651805|NCT00061243|Experimental|1|Participants will receive different doses of the vaccine to determine the optimal dose
11651806|NCT00061243|Experimental|2|Participants will receive different doses of the vaccine to determine the optimal dose
11651807|NCT00061243|Experimental|3|Participants will receive different doses of the vaccine to determine the optimal dose
11651808|NCT00061243|Experimental|4|Participants will receive the vaccine through either intradermal or intramuscular administration
11651809|NCT00061243|Experimental|5|Participants will receive the vaccine through either intradermal or intramuscular administration
11651810|NCT00015821|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily for 1 year in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may receive 1 additional year of therapy.
11651811|NCT00061113|Active Comparator|1|fluoxetine + CBT
11651812|NCT00061113|Placebo Comparator|2|placebo + CBT
11651813|NCT00061100|Experimental|RISE intervention|Targeted RISE intervention- Behavior therapy Rise
11651814|NCT00061100|Active Comparator|Standard Education|Education intervention. Standard prevention education
11651815|NCT00061087|Active Comparator|METHYLPHENIDATE|Methylphenidate
11651816|NCT00061087|Active Comparator|BUPROPION|Bupropion
11651817|NCT00061087|Placebo Comparator|PLACEBO|Placebo
11651818|NCT00006243|Experimental|Arm I (vaccine therapy)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
11651819|NCT00006243|Experimental|Arm II (vaccine therapy and lower-dose sargramostim)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC and lower-dose sargramostim SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
11651820|NCT00006243|Experimental|Arm III (vaccine therapy and higher-dose sargramostim)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC and higher-dose sargramostim SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
11651850|NCT00060645|Experimental|1|There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
11651851|NCT00060632|Experimental|Cohort 1: Ridaforolimus 6.25 mg|
11651821|NCT00006242|Experimental|Treatment (BMS-214662)|"Single patient cohorts receive BMS-214662 IV over escalating periods of 2, 4, 8, 16, and 24 hours weekly for 3 weeks followed by 1 week of rest. If no patient experiences DLT, dose escalation proceeds in the single patient cohorts.
~Treatment repeats every 4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Individual patient cohorts may increase their duration of BMS-214662 infusion in subsequent courses to the current duration safely reached.
~Beginning with the infusion level at which DLT is first encountered by a single patient, cohorts of 3-6 patients receive escalating doses of BMS-214662 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. An additional cohort of 10 patients is treated at the MTD."
11651822|NCT00006095|Experimental|Vincristine Sulfate 1.5 mg/m2/wk and Irinotecan|
11651823|NCT00006095|Experimental|Vincristine sulfate 2.0 mg/m2/wk and Irinotecan|
11651824|NCT00061048|Experimental|Campath-1H|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week.
11651825|NCT00005977|Experimental|STAGE III NHL (Trt 1)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.
~Treatment ABABA"
11651826|NCT00005977|Experimental|STAGE IV NHL, -CNS (Trt 2)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.
~Treatment ABABAB"
11651827|NCT00005977|Experimental|STAGE IV, +CNS (Trt 3)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy. C: Etoposide, Ifosfamide, Dexamethasone IT Therapy.
~Treatment ABCABAB"
11651828|NCT00005977|Experimental|B-ALL, -CNS (Trt 2)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.
~Treatment ABABAB"
11651829|NCT00005977|Experimental|B-ALL, +CNS (Trt 3)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy. C: Etoposide, Ifosfamide, Dexamethasone IT Therapy.
~Treatment ABCABAB"
11651830|NCT00060944|Experimental|Yondelis weekly schedule|Yondelis weekly schedule: 0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1 8 and 15 of each 28-day treatment cycle. Patients will be pretreated with 10 mg of dexamethasone i.v. 30 minutes prior to each infusion.
11651831|NCT00060944|Experimental|Yondelis once every 3 weeks schedule|Yondelis once every 3 weeks schedule: 1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle. Patients will be pretreated with 20 mg of dexamethasone i.v. on Day 1 of each treatment cycle 30 minutes prior to each infusion.
11651832|NCT00003203|Experimental|Newly diagnosed cerebral PNET with histologic verification|Begin therapy within 31 days of surgery. Radiation therapy will be given in standard fractions along with filgrastim. The craniospinal axis will be treated first. Patients will receive carboplatin at 35 mg/m2/day IV over 15-20 minutes Monday through Friday, 1-4 hours prior to radiation for 6 weeks (total of 30 doses). Vincristine sulfate 1.5 mg/m2 IV will be given weekly x 6. Following radiation, patients will receive Maintenance chemotherapy. Patients enrolled prior to Amendment #5 will receive six cycles of cyclophosphamide and vincristine (Regimen A). Patients enrolled after Amendment #5 will receive six cycles of cyclophosphamide, vincristine sulfate and cisplatin (Regimen B).
11651833|NCT00060892|Active Comparator|1|0.4 mg AMG0001 on days 0, 14, and 28
11651834|NCT00060892|Active Comparator|2|4.0 mg AMG0001 on days 0, 14, and 28
11651835|NCT00060892|Active Comparator|3|4.0 mg AMG0001 on days 0 and 28; placebo on day 14
11651836|NCT00060892|Placebo Comparator|4|Placebo (saline) on days 0, 14, and 28
11651837|NCT00005086|Experimental|Arm A|Methotrexate will be given as a short infusion (introduced into a vein) for approximately 5 minutes on the first day (day 1). ). A week later (day 8), both methotrexate and docetaxel will be given the same way, but this will take about 1 hour. The first course of treatment consists of receiving treatment on day 1 and day 8 every 21 days for 9 weeks. X-rays or scans will then be performed to determine if your tumor is shrinking. You will then start treatment with gemcitabine and cisplatin. On the first day (day 1), you will receive both cisplatin and gemcitabine into your vein. A week later (day 8), you will receive only gemcitabine as an infusion into your vein over 100 minutes and no additional intravenous fluid will be required on that day. This second course of treatment consists of receiving treatment on day 1 and day 8 every 21 days for 9 weeks.
11651838|NCT00060840|Active Comparator|Inhaled Nitric Oxide|Inhaled Nitric Oxide (iNO) at 40 parts per million (ppm)
11651839|NCT00060840|Placebo Comparator|Nitrogen|Nitrogen (N2) administered at 40 ppm.
11651840|NCT00060814|Experimental|Combined Pharmacotherapy and Counseling|300 mg Bupropion/4mg Nicotine Gum/Motivational Interviewing
11651841|NCT00004931|Experimental|Arm I|Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV (administered after 1 hour of leucovorin calcium) weekly for 6 weeks.
11651842|NCT00004931|Experimental|Arm II|Patients receive oxaliplatin IV over 2 hours on days 1, 15, and 29 and leucovorin calcium and fluorouracil as in arm I.
11651843|NCT00060775||Non-Targets|Characterized by temperament - no behavioral inhibition
11651844|NCT00060775||Targets|Characterized by temperament - high/low behavioral inhibition
11651845|NCT00060762|Experimental|Interpersonal Therapy|Interpersonal Therapy is a psychotherapy aimed at resolving interpersonal difficulties
11651846|NCT00060762|Active Comparator|Behavioral Weight Loss Treatment|Behavioral Weight Loss Treatment is aimed solely at weight loss, however it has been shown to decrease binge eating
11651847|NCT00060762|Active Comparator|Guided Self Help|Guided Self-Help is a brief psychotherapy based on cognitive-behavioral treatment
11651848|NCT00060723||Adenotonsillectomy group|Children ages 5-12 who are scheduled for adenotonsillectomy for obstructive sleep apnea
11651849|NCT00060723||Comparison group|Children ages 5-12, scheduled for hernia repairs, other procedures not involving the head, chest or neck, or no procedures. Additional exclusions include children with a history of recurrent throat infections, large tonsils, history of or plans for adenoidectomy and/or tonsillectomy or who have been previously diagnosed with sleep-disordered breathing.
11651852|NCT00060632|Experimental|Cohort 2: Ridaforolimus 12.5 mg|
11651853|NCT00060632|Experimental|Cohort 3: Ridaforolimus 25 mg|
11651854|NCT00060632|Experimental|Cohort 4: Ridaforolimus 50 mg|
11651855|NCT00060632|Experimental|Cohort 5: Ridaforolimus 100 mg|
11651856|NCT00060632|Experimental|Cohort 6: Ridaforolimus 75 mg|
11651857|NCT00060606|Experimental|Prenatal Surgery Group|Fetal surgery to close spina bifida defect prior to 26 weeks of gestation with delivery by C-Section at approximately 37 weeks of gestation.
11651858|NCT00060606|Active Comparator|Postnatal Surgery Group|Standard postnatal closure of the spina bifida defect when the baby is medically stable, usually within 48 hours of birth by C-section.
11651859|NCT00060567|Other|1|Active combination of E7070 and irinotecan.
11651860|NCT00060567|Other|2|Active combination of E7070 and irinotecan.
11651861|NCT00060567|Other|3|Active combination of E7070 and irinotecan.
11651862|NCT00004180|Experimental|Well-differentiated liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
11651863|NCT00004180|Experimental|De-differentiated liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
11651864|NCT00004180|Experimental|Myxoid/ round-cell liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
11651865|NCT00004180|Experimental|Pleomorphic liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
11651866|NCT00060541||Patients|Patients age 4 or older seeking care from, or being referred to the Surgical Neurology Branch for evaluation and management of neurosurgical conditions
11651867|NCT00060528|Experimental|no GM|No granulocyte macrophage colony stimulating factor (GM-CSF) was given
11651868|NCT00060528|Experimental|Rec-hGM|Recombinant human GM-CSF (Sargramostim) was administered at 100mcg/day on days 1-4 following each vaccine. Given subcutaneously (s.c.) at site of vaccine.
11651869|NCT00060528|Experimental|rF-GM (10^7pfu)|recombinant fowlpox GM-CSF was given on day one at 10^7 in last two arms. Given subcutaneously (s.c.) at site of vaccine.
11651870|NCT00060528|Experimental|rF-GM (10^8)|recombinant fowlpox GM-CSF was given on day one at 10^8 in last two arms. Given subcutaneously (s.c.) at site of vaccine.
11651871|NCT00060450|Experimental|1|Inhaled Nitric Oxide
11651872|NCT00060450|Placebo Comparator|2|Placebo gas
11651873|NCT00060424|Experimental|Treatment (enzyme inhibitor, transplant, GVHD prophylaxis)|NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and TBI on day 0. TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplant on day 0. GVHD PROPHYLAXIS: Patients receive cyclosporine PO every 12 hours on days -3 to 180 with taper on day 56 and mycophenolate mofetil PO every 12 hours on days 0-27.
11651874|NCT00060411|Experimental|Treatment (combination chemotherapy)|Patients receive oral elotinib alone once daily for 1 week before the beginning of course 1. Patients then receive oral erlotinib once daily on days 1-28; oxaliplatin IV over 2 hours on day 1; and leucovorin calcium IV over 2 hours and fluorouracil IV over 22 hours on days 1 and 2. Patients also receive bevacizumab IV over 30-90 minutes on day 15 of course 1 and on days 1 and 15 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11651875|NCT00060372|Experimental|Treatment (ipilmumab and donor lymphocyte infusion)|Patients receive ipilimumab IV over 90 minutes. Cohorts of 3-6 patients receive escalating doses of ipilimumab until the MTD is determined. The MTD is the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients with persistent or progressive disease at 60 days after ipilimumab administration and no evidence of graft-versus-host disease receive donor lymphocyte infusions every 60 days for a total of 3 infusions.
11651876|NCT00060359|Experimental|Treatment (paclitaxel poliglumex, carboplatin)|"DOSE-ESCALATION PHASE: Patients receive CT-2103 IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of CT-2103 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of treatment.
~FEASIBILITY PHASE: Once the MTD of CT-2103 is determined, an additional 20-40 patients receive treatment at that dose level combined with carboplatin as above."
11651877|NCT00060346|Experimental|Rituximab + CHOP|"Rituximab 375 mg/m2 day 1 of a 21-day cycle, followed by:
~Cyclophosphamide 750 mg/m2 Doxorubicin 50 mg/m2 Vincristine 1.4 mg/m2 and Prednisone 100 mg/m2 daily"
11651878|NCT00060333|Experimental|Treatment (adjuvant radiation therapy)|Within 8 weeks after surgical resection, patients undergo radiation therapy twice weekly over approximately 2.5 weeks for a total of 5 fractions in the absence of disease progression or unacceptable toxicity.
11651879|NCT00060320|Experimental|black cohost|"Patients receive oral black cohosh twice daily for 4 weeks. All patients then cross over to the other arm and receive treatment for 4 weeks.
~After completion of the crossover treatment, all patients may opt to receive open-label black cohosh for an additional 8 weeks.
~Patients complete a hot flash diary daily at baseline and during the 8-week double-blind study, and then daily for 8 weeks during optional open-label treatment.
~Patients who opt to receive open-label black cohosh are followed at 6 months, 1 year, and 2 years."
11651880|NCT00060320|Placebo Comparator|placebo|"Patients receive oral placebo twice daily for 4 weeks. All patients then cross over to the other arm and receive treatment for 4 weeks.
~After completion of the crossover treatment, all patients may opt to receive open-label black cohosh for an additional 8 weeks.
~Patients complete a hot flash diary daily at baseline and during the 8-week double-blind study, and then daily for 8 weeks during optional open-label treatment.
~Patients who opt to receive open-label black cohosh are followed at 6 months, 1 year, and 2 years."
11651881|NCT00060307|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11651882|NCT00060203|Experimental|Brostallicin|
11651883|NCT00060125|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for at least 2 courses and for a maximum of 2 years in the absence of disease progression or unacceptable toxicity. Patients who achieve CR receive 2 additional courses beyond CR.
11651884|NCT00060112|Experimental|Treatment (oblimersen sodium and gemcitabine hydrochloride)|Patients receive oblimersen IV continuously on days 1-5 and gemcitabine IV over 2-3 hours on day 5. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
11651885|NCT00060086|Experimental|Pomegranate Juice|Subjects are given oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
11651886|NCT00060008|Experimental|18FDG-PET scan and MR perfusion|Subjects will undergo MRI for quantitative (2D and 3D) evaluation of plexiform neurofibroma size, MR perfusion scan, and fludeoxyglucose (18FDG) PET scan at the time of study entry. Subjects who are treated for plexiform neurofibroma will undergo another 18FDG PET scan after one year of study entry.
11651887|NCT00059930|Experimental|Adjuvant Hepatic Arterial Infusion & Combination Chemotherapy|This is a Phase I study with the primary objective of defining the maximum tolerated dose of hepatic arterial floxuridine (FUDR) and dexamethasone (Dex) given via an implanted pump in combination with intravenous oxaliplatin plus systemic fluorouracil (5FU)/leucovorin (LV) in the adjuvant setting after resection of hepatic metastases from colorectal cancer. A total of eleven dose levels will be considered.
11651888|NCT00059891|Experimental|Anal Sphincter Prosthesis|All patients will follow a common treatment algorithm. Anorectal reconstruction with the ABS neosphincter device will be a staged surgical approach. Routine postoperative testing will then be performed at 6 months (+/- 8 weeks) and 12 months (+/- 8 weeks), following ileostomy reversal which we have designated as time zero. Postoperative testing will include completion of a series of questionnaires.
11651889|NCT00059865|Experimental|pemetrexed + gemcitabine|"Phase II: Patients receive pemetrexed disodium as in phase I and gemcitabine at the recommended phase II dose.
~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
11651890|NCT00059852|Experimental|gemcitabine + erlotinib|"Patients receive gemcitabine IV on days 1 and 8 and oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Patients achieving a complete response are followed every 6 weeks for up to 5 years or until disease progression (PD). Patients discontinuing study therapy for any other reason are followed every 3 months until PD and then every 6 months for up to 5 years."
11651891|NCT00059839|Experimental|Standard APO with Vincristine (Arm I )|In courses 1-3, patients receive doxorubicin hydrochloride (30 mg/m2) IV over 15 minutes, vincristine sulfate (1.5 mg/m2 (maximum dose 2 mg)) IV, and methotrexate intrathecally (age-adjusted dosing) (IT) on day 1 and oral prednisone (40 mg/m2/day) three times daily and oral mercaptopurine (225 mg/m2) once daily on days 1-5. In courses 4 and 5, patients receive doxorubicin (30 mg/m2), vincristine sulfate (1.5 mg/m2 (Maximum dose 2 mg)), prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in courses 1-3. In courses 6-15, patients receive vincristine sulfate (1.5 mg/m2), prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in courses 1-3 and methotrexate (60 mg/m2) IV on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity.
11651892|NCT00059839|Experimental|Consolidation with Vinblastine|In courses 1-3, patients receive doxorubicin hydrochloride (30 mg/m2) IV, methotrexate (age adjusted dosing) IT, prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in arm I and vinblastine sulfate (4 mg/m2) IV over 1 minute on days 1, 8, and 15. In courses 4 and 5, patients receive doxorubicin hydrochloride (30 mg/m2) IV, prednisone (120 mg/m2/day), and mercaptopurine (225 mg/m2) as in arm I and vinblastine sulfate (4 mg/m2) as in arm II (courses 1-3). In courses 6-15, patients receive prednisone (120 mg/m2/day) and mercaptopurine (225 mg/m2) as in arm I, vinblastine sulfate (4 mg/m2) IV as in arm II (courses 1-3), and methotrexate (60 mg/m2) IV on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity.
11651893|NCT00059826|Experimental|Interferon-based chemoradiation therapy|"Cycle 1: Chemoradiotherapy (CRT)
~5-fluorouracil continuous infusion (CI) via an ambulatory infusion pump into a central venous catheter at 175 mg/m2/day for 38 consecutive days, unless toxicity occurs
~cisplatin given on the first day only of each week of this cycle (days 1, 8, 15, 22, 29, 36)
~IFN-alpha-2b 3 million units given subcutaneously on days 1, 3, and 5 of each week for 5½ weeks
~XRT 5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday - Friday, for 5½ weeks
~Cycles 2 and 3: Post-CRT Chemotherapy
~Post-CRT chemotherapy starts 4 - 6 weeks after completion of Cycle 1, unless the study physician deems further delay is necessary. Patients will be given 2 cycles of chemotherapy (cycles 2 and 3).
~-- 5-fluorouracil continuous infusion via an ambulatory infusion pump into a central venous catheter at 200 mg/m2/day for 6 weeks followed by 2 weeks of rest"
11651894|NCT00059813|Experimental|Treatment (recombinant interferon alfa, oblimersen sodium)|Patients receive oblimersen IV continuously on days 1-7 and interferon alfa subcutaneously on days 4, 6, 8, 10, and 12 of course 1 and on days 1, 3, 5, 8, 10, and 12 of all subsequent courses. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive an additional 2 courses past CR.
11651895|NCT00059787|Experimental|Paclitaxel, carboplatin, erlotinib|Carboplatin and paclitaxel IV every 21 days x 6 cycles plus oral erlotinib
11651896|NCT00059761|Experimental|Sequence A: Level 1|Irinotecan 40 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
11651897|NCT00059761|Experimental|Sequence B: Level 1|Irinotecan 40 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
11651898|NCT00059761|Experimental|Sequence A: Level 2|Irinotecan 50 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
11651899|NCT00059761|Experimental|Sequence B: Level 2|Irinotecan 50 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
11651900|NCT00059761|Experimental|Sequence A: Level 3|Irinotecan 60 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
11651901|NCT00059761|Experimental|Sequence B: Level 3|Irinotecan 60 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
11651902|NCT00030667|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
11651903|NCT00027599|Experimental|Arm I|Autologous dendritic cells (DCs) are harvested and pulsed with prostatic acid phosphatase-sargramostim fusion protein to produce APC8015 (Provenge). Patients receive APC8015 IV over 30 minutes and bevacizumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days for 3 courses. Patients continue to receive bevacizumab alone every 14 days in the absence of disease progression or unacceptable toxicity.
11651904|NCT00016315|Experimental|Arm 1|Sequence A: Gemcitabine 300 mg/m2/week plus radiation therapy (RT)
11651905|NCT00016315|Experimental|Arm 2|Sequence B: Gemcitabine 300 mg/m2/week plus paclitaxel 30 mg/m2/week and RT
11651906|NCT00016315|Experimental|Arm 3|Sequence A: Gemcitabine 300 mg/m2/week plus carboplatin 2 AUC and RT
11651907|NCT00016315|Experimental|Arm 4|Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 30 mg/m2/week and RT
11651908|NCT00016315|Experimental|Arm 6|Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 40 mg/m2/week and RT
11651909|NCT00016315|Experimental|Arm 8|Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 40 mg/m2/week and RT
11651910|NCT00016315|Experimental|Arm 10|Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
11651911|NCT00016315|Experimental|Arm 12|Sequence B: Gemcitabine 750 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
11651912|NCT00016315|Experimental|Arm 14|Sequence B: Gemcitabine 900 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
11651913|NCT00016315|Experimental|Arm 5|Sequence A: Gemcitabine 450 mg/m2/week plus carboplatin 2 AUC and RT
11651914|NCT00016315|Experimental|Arm 7|Sequence A: Gemcitabine 600 mg/m2/week plus carboplatin 2 AUC and RT
11651915|NCT00016315|Experimental|Arm 9|Sequence A: Gemcitabine 750 mg/m2/week plus carboplatin 2 AUC and RT
11651916|NCT00016315|Experimental|Arm 11|Sequence A: Gemcitabine 900 mg/m2/week plus carboplatin 2 AUC and RT
11651917|NCT00005793|Experimental|Combination Chemotherapy|Patients receive induction chemotherapy with daunorubicin IV over 10-15 minutes on days 1-3, cytarabine IV continuously on days 1-5, topotecan IV continuously on days 6-8, and etoposide IV over 60 minutes on days 9 and 10. Within 4 weeks of hematologic recovery, patients achieving remission after induction receive consolidation chemotherapy with cytarabine IV over 1 hour every 12 hours on days 1, 3, and 5. Subsequent courses of consolidation chemotherapy begin within 2 weeks of documentation of hematologic recovery from the prior consolidation course. Consolidation chemotherapy continues for 4 courses in the absence of unacceptable toxicity or disease progression.
11651918|NCT00005065|Experimental|Arm I|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours every 3 weeks for 3 courses. Three weeks after completion of induction chemotherapy, patients receive Gd-Tex IV over 30 minutes twice weekly for 10 doses during preoperative radiotherapy. Radiotherapy is administered daily 5 days a week for 5 weeks. Approximately 3.5 weeks after completion of preoperative radiotherapy, patients undergo complete surgical resection. Three hours prior to surgery, patients receive an eleventh dose of Gd-Tex if they do not develop grade 3 or 4 toxicity with the tenth dose. Patients also receive a MRI without contrast prior to surgery. If the tumor is found to be unresectable, patients may receive additional radiation and/or chemotherapy.
11651919|NCT00004127|Experimental|Arm A|Oxaliplatin (85 mg/m2, day 1 of every 14 day cycle), Leucovorin (500 mg/m2, day 1 and 2 of every 14 day cycle), Fluorouracil (Bolus of 400 mg/m2 followed by 22 hr continuous infusion of 600 mg/m2 on days 1 and 2 of every 14 day cycle)
11651920|NCT00004095|Experimental|Irinotecan Plus Gemcitabine|
11651921|NCT00059748||Patients affected with autoinflammatory diseases|Subjects with known or suspected diagnosis of NOMID / CAPS, DIRA, CANDLE, SAVI, CRMO, Still s disease, Behcet s disease, JDM, and other autoinflammatory diseases.
11651922|NCT00059683|Experimental|Cervical Cerclage Group|Women randomized to receive cerclage should receive cervical cerclage
11651923|NCT00059683|No Intervention|Control Group|Women randomized to not receive cerclage represent the control arm
11651924|NCT00005818|Experimental|Treatment (irinotecan hydrochloride, semaxanib)|Patients receive irinotecan IV over 90 minutes on day 1 of weeks 1-4 and SU5416 IV over 60 minutes on days 1 and 4 of weeks 1-6. Treatment continues every 6 weeks in the absence of unacceptable toxicity or disease progression.
11651925|NCT00003926|Experimental|Solid/brain tumor patients (1-18 years)|Patients with solid tumor or brain tumor in the 1-18 years old stratum.
11651926|NCT00003926|Experimental|Solid/brain tumor patients (19-45 years)|Patients with solid tumor or brain tumor in the 19-45 years old stratum.
11651927|NCT00059631|Experimental|Bortezomib + Mitoxantrone|"Bortezomib starting dose of 1.4 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.
~Mitoxantrone starting dose of 3 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles."
11651928|NCT00059618|Experimental|Bortezomib|PS-341 (Bortezomib) 0.8-1.5 mg/m^2 IV push + Carboplatin (AUC 5) IV on Day 1 of each cycle, then Bortezomib alone on Days 4, 8 and 11 in each 28 day cycle.
11651929|NCT00059605|Experimental|DOTAP:Chol-fus1|Infusion intravenous once every 3 weeks
11651930|NCT00059592|Experimental|Valacyclovir|oral Valacyclovir three times a day for 5 to 10 days.
11651931|NCT00059475|Experimental|Adj-2 MART-1: 27-35|melanoma antigen recognized by T-cells (MART)-1:27-35 peptide every three weeks for four cycles (Arm I).
11651932|NCT00059475|Experimental|Adj-2 HD IL-2 after MART-1: 27-35|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm I (Arm IA)
11651933|NCT00059475|Experimental|Adj-2 27-35 (27L) MART-1 (Mod9mer) peptide Q3wks x 4|27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide every three weeks for four cycles (Arm II).
11651934|NCT00059475|Experimental|Adj-2 HD IL-2 after 27-35 (27L): MART-1 (Mod9mer)|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm II (Arm IIA)
11651935|NCT00059475|Experimental|Adj-2 MART-1: 26-35 (27L) (Mod10mer) peptide Q3wks x 4|melanoma antigen recognized by T-cells (MART)-1:26-35(27L) peptide every three weeks for four cycles (Arm III).
11651936|NCT00059475|Experimental|Adj-2 HD IL-2 after MART-1: 26-35 (27L) (Mod10mer)|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm III (Arm IIIA)
11651937|NCT00059475|Experimental|Adj-2 27-35 (27L): MART-1 + gp100: 209-217 (210M) Q3wks x 4|27-35(27L):melanoma antigen recognized by T-cells (MART)-1 peptide plus the gp100:209-217(210M) peptide emulsified together every three weeks for four cycles (Arm IV).
11651938|NCT00059475|Experimental|Adj-2 HD IL-2 after 27-35 (27L): MART-1 + gp209-2M|High-dose (HD) bolus interleukin-2 (IL-2) (720,000 IU/kg every 8 hours for up to 12 doses) after enrollment on Arm IV (Arm IVA)
11651939|NCT00059423||1|Individuals of African descent with benign ethnic neutropenia (BEN) at baseline
11651940|NCT00059423||2|Individuals of African descent without benign ethnic neutropenia (BEN) at baseline
11651941|NCT00003432|Experimental|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed DC cancer vaccine
11651942|NCT00003311|Experimental|Regimen A|Methotrexate IV over 24 hours on day 1. Cytarabine is administered IV over 2 hours every 12 hours on days 2 and 3. Filgrastim (G-CSF) is administered subcutaneously (SC) daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for up to 8 courses.
11651943|NCT00003311|Experimental|Regimen B|Cyclophosphamide IV over 3 hours every 12 hours on days 1-3. Doxorubicin is administered IV over 24 hours on days 4 and 5. Vincristine is administered IV over 30 minutes on days 4 and 11. Dexamethasone is administered orally or IV on days 1-4 and 11-14. G-CSF is administered SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for up to 7 courses.
11651944|NCT00059371|Active Comparator|Circumcised immediately|
11651945|NCT00059371|Placebo Comparator|Delayed Circumcision|Men who were randomized to delayed circumcision were scheduled to be offered male circumcision 2 years after their randomization.
11651946|NCT00059358|Experimental|1|Participants will begin receive either Rebetron or PEG-Intron plus ribavirin therapy from Weeks 2 through 48
11651947|NCT00059345|Experimental|Arm 1: Acupuncture|Participants will receive acupuncture
11651948|NCT00059345|Placebo Comparator|Arm 2: Shallow needling|Participants will receive shallow needling on non-mederian points
11651949|NCT00059345|Other|Arm 3: No Acupuncture or Placebo Treatment|Participants will receive usual care, no acupuncture or placebo acupuncture treatment.
11651950|NCT00059332|Experimental|Magnesium Sulfate|Magnesium sulfate (Mg) was administered intravenously with a 15 minute bolus load followed by a 24 hour infusion. The bolus-loading dose consisted of 4 grams Mg in 54 ml normal saline. The maintenance infusion contained 16 grams Mg diluted in 240 ml 0.9% normal saline, infused at 10 ml/hr for 24 hours. Paramedics in the field initiated the bolus-loading dose, administered at 216 ml/hr over 15 minutes through a rate controlled IV infusion set. The maintenance infusion was initiated in hospital immediately upon completion of the loading dose.
11651951|NCT00059332|Placebo Comparator|Normal saline|Normal saline was administered intravenously with a 15 minute bolus load followed by a 24 hour infusion. Paramedics in the field initiated the bolus-loading dose of 54 ml normal saline, administered at 216 ml/hr over 15 minutes through a rate controlled IV infusion set. The maintenance infusion was initiated in hospital immediately upon completion of the loading dose at 10 ml/hr for 24 hours.
11651952|NCT00059306|Active Comparator|Antiplatelet|Participants receive aspirin + placebo OR aspirin + clopidogrel
11651953|NCT00059306|Active Comparator|Blood pressure|The goal of the blood pressure aspect of this trial is to find out if lowering blood pressure after stroke helps to prevent recurrent stroke and preserves cognition.
11651954|NCT00059280|Experimental|1|
11651955|NCT00059254|Experimental|Oleic acid (OA)|
11651956|NCT00059254|Experimental|Palmitic acid (PA)|
11651957|NCT00059215|Experimental|Prasugrel (CS-747) 40 mg LD/7.5 mg MD|Prasugrel (CS-747) 40 mg oral loading dose (LD) at time of percutaneous coronary intervention (PCI) followed by 7.5 mg oral maintenance dose (MD), once daily, for 29-34 days
11651958|NCT00059215|Experimental|Prasugrel (CS-747) 60 mg LD/10 mg MD|Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 10 mg oral maintenance dose (MD), once daily, for 29-34 days
11651959|NCT00059215|Experimental|Prasugrel (CS-747) 60 mg LD/15 mg MD|Prasugrel (CS-747) 60 mg oral loading dose (LD) at time of PCI followed by 15 mg oral maintenance dose (MD), once daily, for 29-34 days
11651960|NCT00059215|Active Comparator|Clopidogrel|Clopidogrel 300 mg oral LD at time of PCI followed by an oral 75 mg MD; taken once a day.
11651961|NCT00003193|Experimental|Paclitaxel, amifostine, RT|Dose-escalation arm for paclitaxel with amifostine and RT.
11651962|NCT00059228|Experimental|Estradiol|Experimental
11651963|NCT00059228|Placebo Comparator|Placebo|Placebo comparator
11651964|NCT00003597|Experimental|Cohort 1|Chemotherapy days 0-4, G-CSF (5 μg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). rhTPO began on the last day of ICE (Ifosfamide, Carboplatin and Etoposide) chemotherapy (Day 4) and subsequent doses will be administered on Days 6, 8, 10 and 12 (5 doses total). The initial dose of rhTPO was 1.2 μg/kg/dose and was subsequently escalated to 2.4 and 3.6 μg/kg/dose as tolerated. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one only).
11651965|NCT00003597|Experimental|Cohort 2|"Chemotherapy days 0-4, G-CSF (5 μg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). The dose of rhTPO 1.2 μg/kg/dose and subsequently escalated to 2.4 and 3.6 μg/kg/dose as tolerated. Patients assigned to Cohort II will receive pre-chemotherapy rhTPO at 3.6 μg/kg/dose on Days -5, -3, -1, and post-chemotherapy rhTPO on Days +4, +6, and +8 (6 doses total. Subsequent courses of chemotherapy will begin as soon as the ANC recovers to
~≥ 1,000/μL and the platelet count to ≥ 100,000/μL between days 21 and 35. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one nly). For the second cohort, full data collection will occur for cycles one and two and limited data collection for cycles 3, 4, 5, and 6."
11651966|NCT00003162|Active Comparator|3.0 Gy x 10 fractions in two weeks|3.0 Gy x 10 fractions for a total dose of 30.0 Gy in two weeks
11651967|NCT00003162|Experimental|8.0 Gy x 1 fraction|8.0 Gy x 1 fraction for a total dose of 8.0 Gy in a single dose
11651968|NCT00058955|Experimental|1|Sodium oxybate
11651969|NCT00058955|Active Comparator|2|triazolam
11651970|NCT00058955|Active Comparator|3|pentobarbital
11651971|NCT00058955|Placebo Comparator|4|Placebo
11651972|NCT00058890|Experimental|Gabapentin|
11651973|NCT00058890|Placebo Comparator|Placebo|
11651974|NCT00002934|No Intervention|Pathology Review, Observation and Follow-up|Pathology review, observation and follow-up
11651975|NCT00002835|Experimental|Arm I|"3 courses of early intensification:
~First course: Ifosfamide (IFF) IV continuously and Etoposide (VP-16) IV over 2 hours every 12 hours on days 1-3. Filgrastim (G-CSF) administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover then autologous peripheral blood stem cells (PBSC) are harvested, selected for CD34 positive cells, and purged in vitro. If more than 5% of the WBC contains lymphoma cells after induction, then 2 courses of IFF and VP-16 are administered before PBSC harvest.
~Second course: IFF IV continuously on days 1-3, mitoxantrone (DHAD) IV on day 1, and G-CSF SC as in first course.
~Third course: Carmustine IV over 1 hour on day -6, ARA-C and VP-16 IV every 12 hours on days -5 to -2, and melphalan IV on day -1. PBSC are reinfused on day 0. G-CSF is administered SC beginning on day 0 and continuing until blood counts recover. Each course lasts 3 weeks in the absence of disease progression or unacceptable toxicity."
11651976|NCT00002835|Experimental|Arm II|IDSHAP during 4 week courses 2 and 5, MBIDCOS during courses 3 and 6, and IFF and VP-16 IV over 1 hour on days 1-3 and DHAD IV over 15 minutes on day 1 during courses 1, 4, and 7.
11651977|NCT00058825|Experimental|Stem Cell Transplant|Total body irradiation (TBI); Fludarabine and Campath 1H; FK506 or Cyclosporine; Stem Cell Transplant; G-CSF.
11651978|NCT00058812|Experimental|EBV specific T cells|EBV specific T cells
11651979|NCT00058799|Experimental|Dose Level 1|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
11651980|NCT00058799|Experimental|Dose Level 2|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
11651981|NCT00058799|Experimental|Dose Level 3|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
11651982|NCT00058773|Experimental|CTL Administration|Infusion of EBV Specific Cytotoxic T-Lymphocytes
11651983|NCT00002575|Experimental|Conventional surgery|"Patients undergo open laparotomy and colectomy. A standard incision is made through the abdominal wall and the abdominal cavity is explored. A right or left colectomy or a sigmoid resection is performed.
~Patients may be entered on adjuvant chemotherapy trials after surgery provided the subsequent trial does not include radiotherapy and allows entry of patients from both arms.
~Quality of life is assessed at baseline and on days 2 and 14 after surgery, at 2 months, and then at 18 months. (closed as of 4/30/99)
~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 3 years."
11651984|NCT00002575|Experimental|Laparoscopic-assisted colectomy|"Patients undergo a laparoscopic-assisted colectomy. A small infraumbilical incision is made through the abdominal skin and the abdominal cavity is insufflated with CO2 to allow access and visualization. The abdominal cavity is explored. If advanced local disease is identified, a celiotomy and colectomy are performed. Otherwise, a right or left colectomy or sigmoid resection is performed using laparoscopic-assisted techniques.
~Patients may be entered on adjuvant chemotherapy trials after surgery provided the subsequent trial does not include radiotherapy and allows entry of patients from both arms.
~Quality of life is assessed at baseline and on days 2 and 14 after surgery, at 2 months, and then at 18 months. (closed as of 4/30/99)
~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 3 years."
11651985|NCT00002550|Experimental|RT + chemotherapy followed by surgery + chemotherapy|Induction radiation therapy (RT) + concurrent induction chemotherapy followed by surgery and additional chemotherapy
11651986|NCT00002550|Active Comparator|RT + chemotherapy followed by chemotherapy + RT|Induction RT + concurrent induction chemotherapy followed by additional chemotherapy + RT
11651987|NCT00058617|Experimental|Injection of EBV Specific CTLs|Subjects will receive autologous EBV Specific CTLs. Patients that agree will recieve CTLs that have been marked with the neomycin resistance gene.
11651988|NCT00058604|Experimental|Treatment|Each patient will receive a Biological/Vaccine Intravenous injection of EBV specific CTLs
11651989|NCT00058591|Experimental|Treatment|Treatment dose levels 1, 2 and 3
11651990|NCT00058526|Experimental|Cohort 1|Six doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
11651991|NCT00058526|Experimental|Cohort 2|Six doses of dHER2 (100 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
11651992|NCT00058526|Experimental|Cohort 3|Six doses of dHER2 (500 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.
11651993|NCT00058526|Experimental|Cohort 4|Three doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 4, and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.
11651994|NCT00058474|Active Comparator|Arm 1: 5-FU + RT|Patients receive fluorouracil IV continuously and undergo radiation therapy (RT) once daily 5 days a week for 5-6 weeks.
11651995|NCT00058474|Experimental|Arm 2: 5-FU + RT + Oxaliplatin|Patients receive fluorouracil and undergo RT as in arm 1. Patients also receive oxaliplatin IV over 1 hour once weekly for 5 weeks.
11651996|NCT00058474|Experimental|Arm 3: Capecitabine + RT|Patients receive oral capecitabine twice daily and undergo RT once daily 5 days a week for 5-6 weeks.
11651997|NCT00058474|Experimental|Arm 4: Capecitabine + RT + Oxaliplatin|Patients receive capecitabine and undergo RT as in arm 3. Patients also receive oxaliplatin as in arm 2.
11651998|NCT00058461|Experimental|Treatment (chemotherapy, rituximab)|Patients receive ifosfamide IV over 2 hours and etoposide IV over 1 hour on days 3-5, rituximab IV on days 1 and 3, and carboplatin IV over 1 hour on day 3. Patients receive filgrastim (G-CSF) subcutaneously once daily beginning on day 6 and continuing until blood counts recover. Patients also receive intrathecal (IT) chemotherapy comprising methotrexate and cytarabine. Patients with B-cell large cell lymphoma and negative CSF cytology receive IT chemotherapy on day 3 of the first course only. Patients with small non-cleaved cell lymphoma or B-cell acute lymphoblastic leukemia and negative CSF cytology receive IT chemotherapy on day 3. All patients with positive CSF cytology receive IT chemotherapy on days 3, 10, and 17 of the first and second courses. Treatment repeats every 23 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
11651999|NCT00058422|Experimental|R-CHOP and Ibritumomab Tiuxetan (Zevalin)|"Chemotherapy: Patients receive rituximab IV over 2-5 hours, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1; oral prednisone on days 1-5 or 2-6; and filgrastim (G-CSF) subcutaneously (SC) on days 7-15. Patients also receive darbepoetin alfa SC on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~Radioimmunotherapy: Patients receive rituximab IV over 3-5 hours and indium In 111 ibritumomab tiuxetan (IDEC-In2B8) IV over 10 minutes on day 0.
~Patients undergo gamma camera imaging at 2-24 hours and 48-72 hours after the injection of IDEC-In2B8 to observe the flow of ibritumomab tiuxetan. If the flow is deemed safe, then patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7. Quality of life is assessed at baseline, before course 5 of chemotherapy, before radioimmunotherapy, and at 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
11652000|NCT00058370|Experimental|histologic proof of medulloblastoma|This is a single-arm study of post-operative radioimmunotherapy (intrathecal 131-I-3F8), reduced-dose craniospinal radiation therapy (1800 cGy), primary site boost (to 5400 cGy) via IMRT and standard chemotherapy.
11652029|NCT00057941|Experimental|Arm II (fulvestrant, gefitinib)|Patients receive fulvestrant intramuscularly on day 1 and oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11652001|NCT00058357|Active Comparator|Lidocaine patch|Participants will be instructed to apply a patch or patches (up to 3 maximum simultaneously) directly to the affected area. The patch(es) should be applied during awake hours and then left on continuously for approximately 18 hours or until usual bedtime sleep.
11652002|NCT00058357|Placebo Comparator|Placebo patch|Participants will be instructed to apply a patch or patches (up to 3 maximum simultaneously) directly to the affected area. The patch(es) should be applied during awake hours and then left on continuously for approximately 18 hours or until usual bedtime sleep.
11652003|NCT00058331|Experimental|epoetin alfa - long term dosing|"Patients receive epoetin alfa (EPO) subcutaneously (SC) once weekly for 3 weeks. Then patients receive EPO SC once weekly for 18 weeks. Quality of life is assessed at randomization at then monthly during study treatment.
~Patients are followed every 6 months for 1 year."
11652004|NCT00058331|Experimental|epoetin alfa - short term dosing|"Patients receive epoetin alfa (EPO) subcutaneously (SC) once weekly for 3 weeks. Patients receive EPO SC on day 1 of weeks 4, 7, 10, 13, 16, and 19. Quality of life is assessed at randomization at then monthly during study treatment.
~Patients are followed every 6 months for 1 year."
11652005|NCT00058318|Experimental|Treatment|Gemcitabine + Capecitabine
11652006|NCT00058305|Experimental|Treatment (bryostatin 1, vincristine sulfate)|"Patients receive bryostatin 1 IV over 24 hours on days 1 and 15 and vincristine IV on days 2 and 16. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~Patients without disease progression after 6 courses may continue therapy with bryostatin 1 IV over 24 hours on days 1 and 22 and vincristine IV on days 2 and 23. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity."
11652007|NCT00058292|Experimental|Treatment Arm|
11652008|NCT00058266|Experimental|Group A|Patients receive oral genistein once daily for 1-2 months, undergo radical prostatectomy, and then continue oral genistein once daily for 1-2 months afterward (for a total of 3 months of therapy).
11652009|NCT00058266|Experimental|Group B|Patients undergo radical prostatectomy. Beginning 1 month after surgery, patients receive genistein as in arm I for 3 months.
11652010|NCT00058253|Experimental|Group I|Patients receive docetaxel IV over 1 hour and 17-AAG IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652011|NCT00058253|Experimental|Group II|Patients receive docetaxel IV over 30 minutes and 17-AAG as in group 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11652012|NCT00058240|Experimental|Arm I|Patients receive a loading dose of flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression.
11652013|NCT00058227|Experimental|Treatment (alvocidib, fludarabine phosphate, rituximab)|Patients receive fludarabine phosphate IV over 15-30 minutes on days 1-5 and rituximab IV over 3-4 hours on day 1. Alvocidib is administered IV over 60 minutes on day 1 in cohort 1; on days 1 and 2 in cohort 2; and on days 1, 2, and 3 in cohort 3. In cohorts 4 and 5, patients receive fludarabine phosphate and rituximab as above and alvocidib IV over 30 minutes and then IV over 4 hours on day 1 of courses 2-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11652014|NCT00058214|Experimental|Treatment (perifosine)|Patients receive oral perifosine once daily on days 1-28. On day 1 of course 1 only, patients receive 2 doses of oral perifosine. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease by PSA alone may receive up to 3 additional courses of therapy after documentation of progression.
11652015|NCT00058201|Active Comparator|Arm I|Patients receive leucovorin calcium IV and fluorouracil IV on days 1-5.
11652016|NCT00058201|Experimental|Arm II|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15.
11652017|NCT00058201|No Intervention|Arm III|Patients undergo observation.
11652018|NCT00058188|Experimental|Arm I|Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in the absence of toxicity.
11652019|NCT00058188|Active Comparator|Arm II|Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.
11652020|NCT00058123|Experimental|Poly-ICLC Recurrent gliomas|"Poly-ICLC 20ug/kg 3 times a week 4 week cycles (Monday-Wednesday-Friday)
~Intramuscular injection
~Drug Poly-ICLC"
11652021|NCT00058097|Experimental|Treatment (tipifarnib)|"INDUCTION THERAPY: Patients receive oral tipifarnib twice daily for 3 weeks. Treatment repeats every 4 weeks for up to 3 courses.
~RADIOTHERAPY: Within 14 days after the completion of induction therapy, patients undergo radiotherapy daily, 5 days a week, for 6 weeks.
~MAINTENANCE THERAPY: Two weeks after the completion of radiotherapy, patients receive additional tipifarnib as in induction therapy.
~Treatment continues in the absence of disease progression or unacceptable toxicity."
11652022|NCT00058084|Experimental|Arm I|Patients receive ixabepilone (BMS-247550) IV over 3 hours on day 1.
11652023|NCT00058084|Experimental|Arm II|Patients receive mitoxantrone IV over 30 minutes on day 1 and oral prednisone twice daily on days 1-21. In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652024|NCT00058058|Experimental|MRI Evaluation of Contralateral Breast|The cohort is a distinct population of women at high risk for breast carcinoma: women with a recent (within 60 days) personal diagnosis of breast cancer who will have MRI to evaluate the contralateral breast.
11652025|NCT00058019|Experimental|Treatment (chemotherapy)|Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or if the patient becomes a candidate for stem cell transplantation.
11652026|NCT00057967|Experimental|Treatment arm|alemtuzumab
11652027|NCT00057954|Experimental|Transplant|Reduced toxicity conditioning regimen followed by allogeneic sibling or unrelated transplant. The conditioning regimen includes Extracorporeal Photopheresis, Pentostatin and total body irradiation (TBI). After allogeneic bone marrow transplantation, cyclosporin, mycophenolate mofetil (MMF), and methotrexate (MTX) will be given to prevent graft-versus-host disease (GVHD).
11652028|NCT00057941|Experimental|Arm I (anastrozole, gefitinib)|Patients receive oral anastrozole and oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11652057|NCT00057603|Experimental|Deep Brain Stimulation|Participants receive deep brain stimulation treatment for 30 months.
11652030|NCT00057915|Experimental|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
11652031|NCT00057876|Active Comparator|Gemcitabine|
11652032|NCT00057876|Experimental|Gemcitabine + Radiation|
11652033|NCT00057863|Experimental|Treatment (paclitaxel, oxaliplatin)|Patients receive paclitaxel IV over 3 hours and oxaliplatin IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652034|NCT00057850|Experimental|Arm I|"Phase I: Patients receive BMS-247550 IV over 3 hours and cisplatin IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment as above at the recommended phase II dose of BMS-247550.
~Phase II: Patients receive treatment as in Phase I at the recommended phase II dose of BMS-247550."
11652035|NCT00057837|Experimental|PET (Topotecan/Etoposide/Cisplatin/G-CSF)|Patients receive topotecan intravenously (IV) over 30 minutes on days 1-3; etoposide IV over 60 minutes immediately followed by cisplatin IV over 60 minutes on days 8-10; and filgrastim (G-CSF) subcutaneously daily beginning on day 11 and continuing until blood counts recover.
11652036|NCT00057837|Experimental|PIE (Irinotecan/Cisplatin/Etoposide)|Patients receive irinotecan IV over 90 minutes and cisplatin IV over 60 minutes on days 1 and 8 and oral etoposide twice daily on days 3 and 10 of each cycle.
11652037|NCT00057811|Experimental|Group B (chemotherapy, protective therapy, monoclonal antib.)|Therapies given IV, IT, orally, or SC. Please see treatment outline. See Detailed Description.
11652038|NCT00057811|Experimental|Group C (Chemotherapy, monoclonal antibody therapy)|Therapies given IV, IT, orally, or subcutaneously (same as FAB B with the addition of etoposide and high-dose methotrexate). See Detailed Description.
11652039|NCT00057785|Experimental|IMRT +/- chemotherapy|Intensity modulated radiation therapy (IMRT) for all patients and chemotherapy (cisplatin and fluorouracil) for patients with stage ≥ T2b and/or N+
11652040|NCT00057759|Experimental|Sildenafil citrate|Sildenafil with dose escalation as needed from 50 mg to 100 mg/day prn for 12 weeks.
11652041|NCT00057759|Placebo Comparator|Placebo|"Placebo with similar dose escalation opportunity for 12 weeks."
11652042|NCT00057746|Active Comparator|Arm I|Prophylactic cranial irradiation, 2.5 Gy fx
11652043|NCT00057746|Experimental|Arm II|Prophylactic cranial irradiation, 2.0 Gy fx
11652044|NCT00057746|Experimental|Arm III|Prophylactic cranial irradiation, 1.5 Gy fx
11652045|NCT00030368|Experimental|Treatment (bortezomib, paclitaxel)|Patients receive bortezomib IV on days 2 and 9 and paclitaxel IV over 1 hour on days 1 and 8. For the first course only, patients do not receive paclitaxel on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11652046|NCT00023673|Experimental|Phase I: 75.25 Gy/36 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 75.25 Gy given in 36 fractions (2.15 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
11652047|NCT00023673|Experimental|Phase I: 74 Gy/37 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 74 Gy given in 37 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
11652048|NCT00023673|Experimental|Phase I: 70 Gy/35 fx + chemotherapy|Phase I: Three-dimensional conformal radiation therapy (3DRT) of 70 Gy given in 35 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
11652049|NCT00023673|Experimental|Phase II: 74 Gy/37 fx + chemotherapy|Phase II: Three-dimensional conformal radiation therapy (3DRT) of 74 Gy given in 37 fractions (2.0 Gy per fraction) with concurrent chemotherapy consisting of weekly paclitaxel at 50mg/m2 and carboplatin at area under the curve 2mg/m2. Adjuvant systemic chemotherapy (two cycles of paclitaxel and carboplatin) following completion of RT was optional.
11652050|NCT00004079|Experimental|Treatment (SarCNU)|"Patients receive oral sarcosinamide nitrosourea (SarCNU) on days 1, 5, and 9. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of SarCNU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
11652051|NCT00057681|Experimental|1|Participants will receive treatment with lithium for 8 to 16 weeks
11652052|NCT00057681|Experimental|2|Participants will receive treatment with valproate for 8 to 16 weeks
11652053|NCT00057681|Experimental|3|Participants will receive treatment with risperidone for 8 to 16 weeks
11652054|NCT00057642|Other|Sertraline, venlafaxine, bupropion|This is an open trial so there is only one arm using standard antidepressant medications.
11652055|NCT00057629|Active Comparator|1 Prolonged Exposure|Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.
11652056|NCT00057629|Active Comparator|2 Individual and group therapy|"TUGT (Treatment as usual group therapy - used in Study 1), delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is no formal, structured format for these groups; counselors are sensitive to the participants' needs and follow their lead re content covered in discussions and exercises.
~Supportive counseling (SC - study 2): individual therapy delivered in 10 weekly, 90 minute sessions. Therapist helps patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these."
11652058|NCT00057577|Experimental|Cognitive therapy plus medications|Participants will receive antidepressant medication plus cognitive therapy
11652059|NCT00057577|Experimental|Medications alone|Participants will receive maintenance of antidepressant medication alone
11652060|NCT00057564|Experimental|A (Thalidomide & Dexamethasone)|Thalidomide 50mg/day + Dexamethasone 40mg
11652061|NCT00057564|Placebo Comparator|B (Dexamethasone and placebo)|Dexamethasone and placebo
11652062|NCT00057551|Experimental|CBASP|Cognitive Behavioral System of Psychotherapy plus medication (Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine)
11652063|NCT00057551|Active Comparator|Brief Supportive Psychotherapy|Brief Supportive Psychotherapy plus medication (Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine)
11652064|NCT00057551|Active Comparator|Medication Only|Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine
11652065|NCT00057525|Experimental|Anthrax vaccine with or without PBS|Administor 1 dose 5 μg rPA with PBS (5 Volunteers)
11652066|NCT00057525|Placebo Comparator|Placebo|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combinedwith phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
11652067|NCT00057512|Experimental|Intratumoral M4N|The initial dose was 5 mg/cm3 of tumor volume on Days 1, 8, and 15. Dose escalation in cohorts on this schedule took place up to 20 mg/cm3 tumor volume. The dose per lesion was based upon the volume of tumor, and the total dose did not exceed 1197 mg M4N/m2 body surface area.
11652068|NCT00057499|Experimental|IBC-VS01 vaccine|IBC-VS01 vaccine is administered twice.
11652069|NCT00057499|Placebo Comparator|Control Group|IBC-VS01 placebo is administered twice
11652070|NCT00057473|Experimental|Arm A|
11652071|NCT00057473|Active Comparator|Arm B|
11652072|NCT00057408|Experimental|1|Treatment with olanzapine
11652073|NCT00057408|Placebo Comparator|2|Matching placebo treatment
11652074|NCT00057356|Placebo Comparator|1|
11652075|NCT00057356|Experimental|2|Low dose
11652076|NCT00057356|Experimental|3|Middle dose
11652077|NCT00057356|Experimental|4|High dose
11652078|NCT00057330|Experimental|Herpes Simplex Virus Group|Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus (HSV) vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.
11652079|NCT00057330|Experimental|Havrix Group|Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.
11652080|NCT00057291|Experimental|caregiving intervention|One group received caregiving intervention, another received only training, and a third was business as usual. These were the interventions.
11652081|NCT00057200|Other|Arm 1|
11652082|NCT00057187|Other|Arm 1|
11652083|NCT00057252||1|Patients with medical imaging records
11652084|NCT00057174|Other|Arm 1|
11652085|NCT00057161|Other|Arm 1|
11652086|NCT00057148|Other|Arm 1|
11652087|NCT00057135|Other|Arm 1|
11652088|NCT00057122|Active Comparator|1|
11652089|NCT00057122|Active Comparator|2|
11652090|NCT00057122|Active Comparator|3|
11652091|NCT00057122|Active Comparator|4|
11652092|NCT00057109||Group 1|
11652093|NCT00057096|Other|Arm 1|
11652094|NCT00057083|Other|Arm 1|
11652095|NCT00057070|Other|Arm 1|
11652096|NCT00057057|Other|Arm 1|
11652097|NCT00057044|Other|Arm 1|
11652098|NCT00057005|Experimental|1|
11652099|NCT00056979|Experimental|Fludarabine, CAMPATH-1H , Anti-CD45, FK506|Fludarabine will be given as a daily IV (intravenous, by vein) infusion for a total of 5 days. CAMPATH-1H will be given as a daily 4-hour IV (intravenous, by vein) infusion for three days. Anti-CD45 will be given as a daily 6-hour IV infusion over the next 4 days. To help prevent body from rejecting the transplant, the drug FK506 will be given, starting two days before the transplant and continuing for three months.
11652100|NCT00056966|Experimental|1|recipients of HLA matched sibling transplants
11652101|NCT00056966|Experimental|2|recipients of unrelated or mismatched family donor transplants
11652102|NCT00056862|Experimental|Low-dose pegIFN/standard-dose RBV|Patients receive a lower dose of peginterferon alfa-2a (90 mcg per week) and standard dose of ribavirin (800 mg/d) for chronic hepatitis C, genotype 2/3, for 24 weeks.
11652103|NCT00056862|Active Comparator|Standard-dose PegIFN/RBV|Patients receive the standard, recommended doses of peginterferon alfa-2a (180 mcg per week) and ribavirin (800 mg/d) for chronic hepatitis c, genotype 2/3, for 24 weeks.
11652104|NCT00056693|Experimental|A|
11652105|NCT00056667|Experimental|CBT plus relaxation response|Participants will receive cognitive behavioral therapy plus relaxation response training
11652106|NCT00056667|Active Comparator|Relaxation Response|Participants will receive relaxation response training
11652107|NCT00056667|Placebo Comparator|Education|Participants will receive rheumatoid arthritis education
11652108|NCT00056654|Experimental|1|
11652109|NCT00056589|Experimental|rFXIII|
11652110|NCT00056563|Active Comparator|1|Deep Brain Stimulation
11652111|NCT00056563|Active Comparator|2|Best Medical Therapy
11652112|NCT00056550|Experimental|Recombinant Human Antithrombin (rhAT) infusion|Loading and continuous infusion dose of rhAT to target and maintain an AT activity level > 80% and < 120% of normal.
11652113|NCT00056537|Experimental|1|
11652114|NCT00056498|Active Comparator|Active|Participants assigned to risperidone
11652115|NCT00056498|Placebo Comparator|Placebo|Participants assigned to placebo
11652116|NCT00056472|Active Comparator|olanzapine/sertraline combination|sertraline plus olanzapine
11652117|NCT00056472|Placebo Comparator|olanzapine plus placebo|olanzapine (5 - 20mg/day) plus placebo
11652118|NCT00056459|Experimental|1|Oxaliplatin/5-FU/LV and PTK787/ZK 222584
11652119|NCT00056459|Placebo Comparator|2|Oxaliplatin/5-FU/LV and placebo
11652120|NCT00056446|Experimental|1|Oxaliplatin/5-FU/LV and PTK787/ZK 222584
11652121|NCT00056446|Placebo Comparator|2|Oxaliplatin/5-FU/LV and placebo
11652289|NCT00053040|Experimental|Surgery for tumor resection + IL13-PE38QQR infusion|
11652122|NCT00056407|Placebo Comparator|Placebo Arm|Eligible subjects will complete a 4-week placebo run-in followed by randomization to matched placebo in a 1:1 ratio.
11652123|NCT00056407|Experimental|dustasteride arm|Eligible subjects will complete a 4-week placebo run-in followed by randomization to 0.5mg dutasteride in a 1:1 ratio. Randomization will be stratified by center.
11652124|NCT00056394|Experimental|1|Participants will receive comprehensive pain coping skills.
11652125|NCT00056394|Active Comparator|2|Participants will receive arthritis education.
11652126|NCT00056394|Active Comparator|3|Participants will receive standard care.
11652127|NCT00056329|Experimental|1|vitamin E plus multivitamin
11652128|NCT00056329|Placebo Comparator|2|placebo with multivitamin
11652129|NCT00056316|Experimental|Behavioral Skills Training|Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
11652130|NCT00056316|Active Comparator|Basic Education|Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
11652131|NCT00056303|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up targets nurturance, synchrony, and non-frightening behavior, as well as providing caregivers with help calming toddlers.
11652132|NCT00056303|Active Comparator|Developmental Education for Families|Developmental Education for Families targets providing cognitive stimulation to their children.
11652133|NCT00056290|Active Comparator|1|VEGF
11652134|NCT00056290|Placebo Comparator|2|Placebo
11652135|NCT00056277|Other|Arm 1|
11652136|NCT00056160|Experimental|CC-5013/Dex|CC-5013 (lenalidomide) plus oral high-dose dexamethasone
11652137|NCT00056160|Experimental|Placebo/Dex|Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone
11652138|NCT00056095|Experimental|Allograft (compatible family member)|
11652139|NCT00056095|Other|Allograft (compatible non-family member)|
11652140|NCT00056082|Experimental|Celecoxib 400 mg bid|Celecoxib 400 mg bid
11652141|NCT00056069|Experimental|Observational|Questionnaire Administration: Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
11652142|NCT00056056|Experimental|Bexarotene and PUVA|
11652143|NCT00056056|Active Comparator|PUVA|
11652144|NCT00056030|Experimental|cetuximab + oxaliplatin + leucovorin + fluorouracil|"Patients receive cetuximab IV over 1 hour (over 2 hours on day 1 of course 1 only) on days 1 and 8. Patients also receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously on days 1-2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity, for a minimum of 12 courses or until deemed to have resectable disease.
~Quality of life is assessed at baseline and prior to each treatment course.
~Patients are followed every 3 months for 1 year and then every 6 months for 3 years."
11652145|NCT00055991|Experimental|Bexarotene|Bexarotene / Targretin
11652146|NCT00055991|Placebo Comparator|Sugar Pill|Sugar pill / placebo
11652147|NCT00055978|Experimental|Arm I|Patients receive oral placebo twice daily for 6 months.
11652148|NCT00055978|Experimental|Arm II|Patients receive oral celecoxib twice daily for 6 months.
11652149|NCT00055913|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 15 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652150|NCT00055913|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652151|NCT00055861|Experimental|Treatment (bevacizumab, docetaxel)|Patients receive bevacizumab IV over 30-90 minutes on weeks 1 and 3 and docetaxel IV over 60 minutes on weeks 1, 2, and 3. Treatment repeats every 4 weeks for up to 12 courses in the absence of unacceptable toxicity or disease progression.
11652152|NCT00055848||Group 1|"Patients donate blood samples for analysis of colorectal susceptibility genes. Patients also complete a questionnaire regarding family cancer history.
~A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute.
~Participants do not receive the results of the genetic testing, and the results do not influence the type or duration of treatment."
11652153|NCT00055809|Experimental|Arm I (bevacizumab)|Patients receive bevacizumab IV on day 1.
11652154|NCT00055809|Experimental|Arm II (PEG-interferon alfa-2b)|Patients receive PEG-interferon alfa-2b SC on days 1, 8, and 15.
11652155|NCT00055770|Experimental|Arm I|"PHASE I: Patients receive oral erlotinib once daily on days 1-28 and docetaxel IV over 1 hour on days 8, 15, and 22. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity.
~Patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional cohort of 6 patients receives erlotinib at the MTD.
~PHASE II: Patients receive erlotinib at the MTD and docetaxel as in phase I."
11652156|NCT00055757|Experimental|Treatment (tipifarnib, gemcitabine, cisplatin)|"Patients receive oral tipifarnib twice daily on days 1-14, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~Patients with at least stable disease may continue to receive oral tipifarnib alone twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
11652157|NCT00055692|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment continues every 2 weeks in the absence of disease progression or unacceptable toxicity.
11652158|NCT00055679|Active Comparator|6 FEC|6 cycles of CYCLOPHOSPHAMIDE + EPIRUBICINE + 5-FLUOROURACILE
11652159|NCT00055679|Experimental|4 FEC|4 cycles of CYCLOPHOSPHAMIDE + EPIRUBICINE + 5-FLUOROURACILE
11652487|NCT00040911|Sham Comparator|Arm II (alternative medicine procedure)|Patients undergo electroacupuncture therapy to sham points on the arms and legs as in arm I.
11653586|NCT00047450|Placebo Comparator|1|Participants will take placebo
11652160|NCT00055601|Experimental|Pelvic RT + paclitaxel + cisplatin|Induction: Twice-daily pelvic radiation therapy (RT) with paclitaxel and cisplatin; Consolidation: Twice-daily pelvic radiation therapy with paclitaxel and cisplatin if tumor response is T0/Ta/Tis or radical cystectomy if tumor response is ≥ T1; Adjuvant: gemcitabine, paclitaxel, and cisplatin.
11652161|NCT00055601|Experimental|Pelvic RT + fluorouracil + cisplatin|Induction: Twice-daily pelvic radiation therapy (RT) with fluoruracil and cisplatin; Consolidation: Twice-daily pelvic radiation therapy with fluoruracil and cisplatin if tumor response is T0/Ta/Tis or radical cystectomy if tumor response is ≥ T1; Adjuvant: gemcitabine, paclitaxel, and cisplatin.
11652162|NCT00022139|Experimental|carboplatin + paclitaxel + fluorouracil + radiation + surgery|"Patients receive carboplatin IV and paclitaxel IV over 3 hours on days 1 and 22 and fluorouracil IV continuously on days 1-42. Beginning on day 1 of chemotherapy, patients undergo radiotherapy to the esophagus 5 days a week for 5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease at 4-8 weeks after completion of radiotherapy undergo esophagectomy and complete dissection of the mediastinal and perigastric lymph nodes. Beginning 8 weeks after surgery, patients who underwent curative resection may receive a maximum of 2 additional courses of paclitaxel and carboplatin in the absence of disease progression or unacceptable toxicity.
~Quality of life is assessed at baseline, before chemotherapy on days 1 and 22, and within 2 weeks before surgery.
~Patients are followed every 3 months for 4 years."
11652163|NCT00005028|Experimental|Arm I|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and bryostatin 1 IV over 1 hour on days 2, 9, and 16. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
11652164|NCT00055497|Placebo Comparator|Double-blind (DB) adalimumab placebo|Double-blind nonactive matching subcutaneous injection
11652165|NCT00055497|Experimental|Double-blind adalimumab 40 mg every other week (eow)|Double-blind adalimumab 40 mg eow by subcutaneous injection
11652166|NCT00055497|Experimental|Double-blind adalimumab 40 mg every week (ew)|Double-blind adalimumab 40 mg every week by subcutaneous injection
11652167|NCT00055497|Experimental|Open-label adalimumab 40 mg|Open-label adalimumab 40 mg eow or ew by subcutaneous injection
11652168|NCT00055471|Experimental|ZD4054 10 mg|1 x 10 mg oral tablets once daily
11652169|NCT00055471|Experimental|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
11652170|NCT00055471|Experimental|ZD4054 22.5 mg|2 x 10 mg + 1 x 2.5 mg oral tablets once daily
11652171|NCT00055419|Experimental|400 mg/m2|
11652172|NCT00055393|Active Comparator|Subjects receivng Bupropion|The active arm subjects in this study (n = 18) received flexibly dosed bupropion in this randomized 12-week double-blind trial.
11652173|NCT00055393|Placebo Comparator|Subjects receiving Placebo|The inactive arm subjects in this randomly controlled study (n = 21) received a placebo.
11652174|NCT00055315|Active Comparator|STEPPS|Patients with Borderline Personality Disorder. Each subject met DSM-IV criteria for BPD, confirmed through a clinical interview and a review of the patient's case notes
11652175|NCT00055315|Placebo Comparator|Treatment as Usual|"Patients with Borderline Personality Disorder. Each subject met DSM-IV criteria for BPD, confirmed through a clinical interview and a review of the patient's case notes.
~TAU for this BPD population includes medical management, group and individual therapy."
11652176|NCT00055302|Experimental|1|
11652177|NCT00055237|Experimental|Cohort 1: Pts with HIV-associated Kaposi's Sarcoma|15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks.
11652178|NCT00055237|Experimental|Cohort 2: Pts with classic Kaposi's Sarcoma (HIV-uninfected)|15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks.
11652179|NCT00055224|Experimental|Threat conditions|acoustic startle and shock device
11652180|NCT00055172||Non-sibling relative|18 years of age or older
11652181|NCT00055172||Patients (index cases)|Patients (index cases), 6 months of age or older
11652182|NCT00055172||Siblings|Siblings, 6 months of age or older
11652183|NCT00055055||Healthy Volunteers|A healthy individual who has not used any NSAIDS, with no infectious disease, or severe trauma within 8 weeks of enrollment, doesn't have a first degree relatives with RA, SLE, SSc or IIM
11652184|NCT00055055||Parent of Proband|Biological mother or father of the proband who is willing to enroll in the study
11652185|NCT00055055||Primary Unaffected Dizygous Twin|Dizygotic twin pair of the proband who does not meet criteria for one of the rheumatic diseases
11652186|NCT00055055||Primary Unaffected Monozygous Twin|Monozygotic twin pair of the proband who does not meet criteria for one of the rheumatic diseases
11652187|NCT00055055||Primary Unaffected Non-twin Sibling|Sibling of the same biological parents, same gender, within 5 years of age of the proband who does not meet criteria for one of the rheumatic diseases
11652188|NCT00055055||Proband|Proband should have documented evidence that he/she meets criteria for adult and juvenile forms of systemic rheumatic disorders
11652189|NCT00055029||Affected males and family members|Up to 500 participants, including a minimum of 150 males diagnosed with XLRS
11652190|NCT00054964|Experimental|Albuterol HFA-BOI|
11652191|NCT00054964|Active Comparator|Albuterol HFA-MDI|
11652192|NCT00054925|Active Comparator|Personal contact (PC)|The Personal Contact (PC) intervention offers one-on-one guidance and support in maintaining weight loss.
11652193|NCT00054925|Active Comparator|Interactive technology (IT)|Utilizes internet and automated phone technology to enhance the frequency and timeliness of feedback.
11652194|NCT00054847|Active Comparator|Saphenous Vein Graft|Saphenous Vein Graft
11652195|NCT00054847|Active Comparator|Radial Artery Graft|Radial Artery Graft
11652196|NCT00054821|Experimental|Group A|Group A participants will be treated with mechanical distraction with motion
11652197|NCT00054821|Active Comparator|Group B|Group B participants will be treated with mechanical distraction without motion
11652198|NCT00054756|Experimental|Thyrotropin Releasing Hormone|Subjects receiving TRH (Thyrotropin Releasing Hormone)
11652199|NCT00054717|Other|Tipranavir(TPV)/low dose ritonavir(r)|
11652200|NCT00054717|Other|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
11652554|NCT00033423|Experimental|Cohort II|Second radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
11652555|NCT00033423|Experimental|Cohort III|Third radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
11652201|NCT00054704|Experimental|Riluzole|Riluzole was dispensed either once or twice a day as 50 mg tablets. Riluzole dosing began at 50 mg twice per day by mouth and was increased on a weekly basis by 50 mg, as tolerated, to achieve a dose of 200 mg/day. Dose escalations continued until at least a 50% reduction in depression (MADRS) scores, intolerable side effects, or study completion. Dose was raised on a weekly basis by 50 mg until the dose of 200 mg was achieved unless precluded by an adverse event. If significant side effects occurred, titration was slowed and doses were reduced under double-blind conditions. The maximum permitted dose of riluzole was 200 mg/day. Those subjects not tolerating a dosage of 50 mg/day were removed from the study.
11652202|NCT00054704|Placebo Comparator|Placebo|Placebo pills resembling 50 mg riluzole tables were dispensed either once or twice a day. Dosing began at 50 mg twice per day by mouth and was increased on a weekly basis by 50 mg, as tolerated, to achieve a dose of 200 mg/day. Dose escalations continued until at least a 50% reduction in depression (MADRS) scores, intolerable side effects, or study completion. Dose was raised on a weekly basis by 50 mg until the dose of 200 mg was achieved unless precluded by an adverse event. If significant side effects occurred, titration was slowed and doses were reduced under double-blind conditions. The maximum permitted dose of riluzole was 200 mg/day. Those subjects not tolerating a dosage of 50 mg/day were removed from the study.
11652203|NCT00054691|Experimental|Iressa (ZD1839)|Iressa (ZD1839) 250 mg by mouth daily.
11652204|NCT00050531|Experimental|Gleevec|Gleevec 400 mg orally twice daily.
11652205|NCT00050531|Experimental|Gleevec + Peg-Intron + GM-CSF|Gleevec 400 mg orally twice daily. Peg-Intron 0.5 mcg/kg each week subcutaneously. GM-CSF 125 mcg/m^2 three times per week subcutaneously.
11652206|NCT00054665|Experimental|Part A: PS-341 Alone|1.3 mg/m^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
11652207|NCT00054665|Experimental|Part B: PS-341 & EPOCH|"PS-341: level 1: 0.5 mg/m^2 intravenous (IV) days 1, 4; level 2: 1.0 mg/m^2 IV days 1, 4; level 3: 1.5 mg/m^2 IV days 1, 4; level 4: 1.7 mg/m^2 IV days 1, 4.
~EPOCH: Etoposide: 50 mg/m^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion; Doxorubicin: 10 mg/m^2 day CIV days 1-4, 96 hour infusion; Vincristine: 0.4 mg/m^2 day CIV days 1-4, 96 hour infusion; Cyclophosphamide: 750 mg/m^2 day IV day 5 bolus; Prednisone: 60 mg/m^2 by mouth twice a day days 1-5; Filgrastim: 300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm^3. Repeat cycles every 21 days."
11652208|NCT00054639|Experimental|Treatment (oblimersen sodium and monoclonal antibody therapy)|Patients receive oblimersen sodium IV continuously on days 1-7, 15-21, and 29-35 and rituximab IV over 4-6 hours on days 3, 8, 15, 22, 29, and 36. Patients achieving stable disease or objective response may receive one additional course of treatment.
11652209|NCT00054587|Active Comparator|6 FEC|Patients receive fluorouracil IV, or epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy 5 days a week for 5 weeks.
11652210|NCT00054587|Experimental|6 DE|Patients receive epirubicin IV over 10 minutes and docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy as in arm I
11652211|NCT00054548|Experimental|Treatment (oblimersen sodium, paclitaxel)|"Patients receive oblimersen IV continuously on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
~An additional cohort of 12-15 patients receives treatment as above with oblimersen at the MTD."
11652212|NCT00054483|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652213|NCT00054457|Experimental|docetaxel + capecitabine|"Patients receive docetaxel IV over 1 hour on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
~Quality of life is assessed at baseline, at each tumor measurement, and at the end of treatment.
~Patients are followed every 3 months until disease progression and then every 6 months until 3 years from registration."
11652214|NCT00054444|Experimental|Treatment (topotecan hydrochloride, radiation, cisplatin)|Patients undergo radiotherapy 5 days a week for 6 weeks. Patients receive cisplatin IV and topotecan IV over 30 minutes once weekly for a total of 6 weeks in the absence of disease progression or unacceptable toxicity.
11652215|NCT00054431|Experimental|Treatment (imatinib mesylate, decitabine)|Patients receive oral imatinib mesylate daily and decitabine IV over 1 hour daily, 5 days per week, for 2 consecutive weeks. Courses repeat every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
11652216|NCT00054418|Experimental|calcium carbonate, vitamin D and risedronate|Patients receive calcium carbonate 600 mg daily, vitamin D 400 U daily and risedronate 35 mg weekly.
11652217|NCT00054418|Placebo Comparator|calcium carbonate, vitamin D and placebo|Patients receive calcium carbonate 600 mg daily, vitamin D 400 U daily and placebo weekly.
11652218|NCT00054405|Experimental|Treatment (IL-12, aldesleukin)|"Cohort A: Patients receive interleukin-12 (IL-12) IV over 5-15 seconds on days 1, 3, 5, 8, 10, and 12.
~Cohort B: Patients receive interleukin-2 (IL-2) IV over 15 minutes twice daily on days 1 and 8 and IL-12 IV as in cohort A.
~Treatment in both cohorts repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Some patients may receive additional courses at the discretion of the principal investigator.
~Cohorts of 3-6 patients in both cohorts receive escalating doses of IL-2 and IL-12 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
~Once the MTD is determined, an additional cohort of 8 patients receives IL-12 and IL-2 at the MTD."
11652219|NCT00054353|Experimental|Related Donor|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.
~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.
~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors)."
11652556|NCT00033423|Experimental|Cohort IV|Fourth radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
11652557|NCT00033423|Experimental|Cohort V|MTD radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
11652220|NCT00054353|Experimental|Unrelated Donor|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.
~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.
~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors)."
11652221|NCT00054327|Experimental|Regimen A|Patients receive cytarabine 3.0gm/M² IV over 1 hour twice daily on days -9 to -7 and cyclophosphamide 45mg/kg IV over 2 hours on days -6 and -5. Patients also undergo total body irradiation (TBI), 165 cGY, twice daily on days -4 to -1 for a total of 1320 cGY.
11652222|NCT00054327|Experimental|Regimen B-1|Patients receive cyclophosphamide 60 mg/kg IV on days -6 and -5. Patients also undergo total body irradiation (TBI) twice daily on days -4 to -1 for a total of 1320 cGY..
11652223|NCT00054327|Experimental|Regimen B-2|Patients receive cyclophosphamide 60 mg/kg IV over 2 hours on days -5 and -4. Patients also undergo TBI twice daily on days -3 to -1 for a total of 1200 cGY.
11652224|NCT00054327|Experimental|Regimen C|Patients receive oral busulfan 1mg/kg/dose (or 40mg/m2/dose for young children)4 times daily on days -8 to -5 and cyclophosphamide 60 mg/kg IV over 2 hours on days -4 to -2.
11652225|NCT00054327|Experimental|Regimen B-3|Patients undergo total body irradiation (TBI) twice daily on days -7 to -5 for a total of 1200 cGY. Patients then receive cyclophosphamide 60 mg/kg IV on days -4 and -3.
11652226|NCT00054327|Experimental|Regimen D|Patients receive total body irradiation (TBI) on days T -6, -5 and -4 for a total of 1320 cGy , then etoposide (60mg/kg/dose) on day -3.
11652227|NCT00054275|Experimental|Erlotinib Plus Docetaxel|
11652228|NCT00054236|Experimental|non-myeloablative conditioning regimen|
11652229|NCT00054184|Experimental|Study drug|
11652230|NCT00054132|Experimental|Treatment (erlotinib hydrochloride, bevacizumab)|Patients receive erlotinib hydrochloride PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652231|NCT00054119|Experimental|Treatment|Patients receive karenitecin IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652232|NCT00054041|Experimental|Arm I (HspE7)|Patients receive SGN-00101 subcutaneously once on weeks 1, 4, and 8 in the absence of disease progression. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy.
11652233|NCT00054041|Experimental|Arm II (control)|Patients receive standard care. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy.
11652234|NCT00054028|Experimental|Treatment (suramin and paclitaxel)|"PHASE I: Patients receive low-dose suramin IV over 30 minutes and paclitaxel IV over 1 hour once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive adjusted doses of suramin until a target dose is determined. The suramin target dose is defined as the dose at which at least 5 of 6 patients achieve the target plasma concentration of 10-50 uM over the duration when paclitaxel levels are therapeutic.
~PHASE II: Patients receive paclitaxel in combination with the target dose of suramin as above."
11652235|NCT00053989|Experimental|All patients|All patients enrolled on study
11652236|NCT00053976|Experimental|Daclizumab|"Patients are randomized to 1 of 2 treatment arms.
~Arm I:
~Patients receive methylprednisolone or equivalent corticosteroid IV or orally
~Daclizumab IV on days 0, 3, 7, 14, and then weekly as indicated until day 100.
~Arm II: Patients receive methylprednisolone or equivalent corticosteroid as in arm I and placebo.
~Patients are followed at 1 year and then annually thereafter."
11652237|NCT00053976|Placebo Comparator|Placebo|"Patients are randomized to 1 of 2 treatment arms.
~Patients receive methylprednisolone or equivalent corticosteroid as in Daclizumab arm
~Placebo IV on days 0, 3, 7, 14, and then weekly as indicated until day 100."
11652238|NCT00053963|Experimental|Arm I|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11652239|NCT00053950|Experimental|Cohort I|Groups of 3-6 patients receive escalating doses of PZA at a fixed infusion time until the MTD is determined. In both cohorts the MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients receive G-CSF IV or subcutaneously beginning on day 4 and continuing until blood counts recover. Patients also undergo reinfusion of stem cells over 15-30 minutes on day 4 as needed per protocol.
11652240|NCT00053950|Experimental|Cohort II|Groups of 3-6 patients receive PZA at the dose/hour established in cohort I at escalating infusion times until another MTD is determined. In both cohorts the MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients receive G-CSF IV or subcutaneously beginning on day 4 and continuing until blood counts recover. Patients also undergo reinfusion of stem cells over 15-30 minutes on day 4 as needed per protocol.
11652241|NCT00053898|Active Comparator|Group 1|tamoxifen 20 mg/day and an anastrozole look-alike placebo for 5 years
11652242|NCT00053898|Experimental|Group 2|anastrozole, 1 mg/day and an tamoxifen look-alike placebo for 5 years
11652243|NCT00053885|Experimental|PTK787/ZK 222584|"Patients receive oral PTK787/ZK 222584 daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
~Patients are followed every 2 months for 1 year, every 4 months for 1 year, and then every 6 months for 1 year."
11652244|NCT00053846|Experimental|buspirone hydrochloride|buspirone hydrochloride
11652245|NCT00053846|Placebo Comparator|Placebo|Placebo
11652246|NCT00053833|Experimental|irinotecan|irinotecan
11652247|NCT00053703|Active Comparator|olanzapine|oral olanzapine 5-20mg per day for up to 52 weeks
11652248|NCT00053703|Active Comparator|risperidone|oral risperidone 0.5mg to 6mg daily for up to 52 weeks
11652249|NCT00053703|Active Comparator|molindone|oral molindone from 10-140mg/daily for up to 52 weeks
11652313|NCT00052481||Quality of life questionnaire|"Patients are randomized to 1 of 2 arms on ACOSOG-Z0070 (radical prostatectomy vs brachytherapy).
~Patients in both arms complete a quality of life questionnaire at baseline, 2 and 6 months after treatment, and then at 1, 2, 4, 7, and 10 years after treatment as part of ACOSOG-Z0071."
11652314|NCT00052468|Experimental|TCG|Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, Gemcitabine 800 mg/m2 day 1 + 8, q 21 days / 6 - 10 courses
11652250|NCT00053677|Placebo Comparator|Naltrexone|17 weeks of double-blind Naltrexone. Subjects were randomized into one of these three conditions (if they weren't randomized to placebo): naltrexone 50mg/day, 100mg/day, 150mg/day. To minimize nausea, treatment for all subjects was initiated at 25mg/day naltrexone for two days, then the dose was increased to 50mg/day. At week 3, subjects were randomly assigned to 50mg/day continued at that dose, while subjects who were randomized to naltrexone 100mg/day or 150mg/day were raised to the higher doses.
11652251|NCT00053677|Placebo Comparator|Placebo|Subjects who were assigned to placebo in the 17 week double-blind phase.
11652252|NCT00053625|Active Comparator|SA #1 Arm 1: Unilateral DBS in GPi|
11652253|NCT00053625|Active Comparator|SA #1 Arm 2: Unilateral DBS in STN|
11652254|NCT00053625|Active Comparator|SA #2 Arm 1: Bilateral DBS in GPi|Patients with GPi bilateral DBS (previously had unilateral DBS in the GPi, now have bilateral DBS in GPi)
11652255|NCT00053625|Active Comparator|SA #2 Arm 2: Bilateral DBS in STN|Patients with STN bilateral DBS (previously had unilateral DBS in the STN, now have bilateral DBS in STN)
11652256|NCT00053573|Experimental|1|
11652257|NCT00053508|Experimental|Group 1|ACAM1000
11652258|NCT00053508|Experimental|Group 2|ACAM1000
11652259|NCT00053508|Experimental|Group 3|ACAM1000
11652260|NCT00053508|Active Comparator|Group 4|Dryvax
11652261|NCT00053495|Experimental|Group 1: ACAM2000 Dose 1|Participants will receive a single dose of ACAM2000 smallpox vaccine, 1.0x10-8th plaque-forming units (PFU)/mL on Day 0.
11652262|NCT00053495|Experimental|Group 2: ACAM2000 Dose 2|Participants will receive a single dose of ACAM2000 smallpox vaccine, 2.0x10-8th plaque-forming units/mL on Day 0.
11652263|NCT00053495|Experimental|Group 3: ACAM2000 Dose 3|Participants will receive a single dose of ACAM2000 smallpox vaccine, 1.0x10-7th plaque-forming units/mL on Day 0
11652264|NCT00053495|Experimental|Group 4: ACAM2000 Dose 4|Participants received a single dose of ACAM2000 smallpox vaccine, 5.0x10-6th plaque-forming units/mL on Day 0
11652265|NCT00053495|Active Comparator|Group 5: Dryvax® Vaccine|Participants will receive a single dose of Dryvax® smallpox vaccine, 1.0x10-8th plaque-forming units/mL on Day 0
11652266|NCT00053482|Experimental|Group 1: ACAM2000|Participants will receive dose 1 of the ACAM2000 smallpox vaccine
11652267|NCT00053482|Experimental|Group 2: ACAM2000|Participants will receive dose 2 of the ACAM2000 smallpox vaccine
11652268|NCT00053482|Experimental|Group 3: ACAM2000|Participants will receive dose 3 of the ACAM2000 smallpox vaccine
11652269|NCT00053482|Experimental|Group 4: ACAM2000|Participants will receive dose 4 of the ACAM2000 smallpox vaccine
11652270|NCT00053482|Active Comparator|Group 5: Dryvax®|Participants will receive dose 1 of Dryvax® smallpox vaccine.
11652271|NCT00053430|Experimental|1|Participants will receive low dose thalidomide for 28 days
11652272|NCT00053430|Placebo Comparator|2|Participants will receive low dose thalidomide placebo for 28 days
11652273|NCT00053417|Placebo Comparator|1|Placebo control, twice a day (b.i.d.)
11652274|NCT00053417|Experimental|2|10 milligram (mg) fampridine b.i.d.
11652275|NCT00053417|Experimental|3|15 mg fampridine b.i.d.
11652276|NCT00053417|Experimental|4|20 mg fampridine b.i.d.
11652277|NCT00053365|Experimental|Treatment (irofulven)|Patients receive irofulven IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.
11652278|NCT00053352|Experimental|Arm I|"Patients enrolled with gonadal tumors of stage II or greater or extragonadal tumors of any stage receive cisplatin IV over 90 minutes & etoposide IV over 90 minutes days 1-3 and bleomycin sulfate IV over ≥ 10 minutes day 1. Treatment repeats every 3 weeks, 3 courses (weeks 0,3 & 6).
~After completion of compressed induction chemotherapy, patients with no change in disease status or disease progression are removed from study. Patients with no evidence of disease receive no further therapy. Patients with a partial response or abnormal tumor markers proceed to conventional surgery (second-look) and/or 3 more courses of compressed consolidation chemotherapy.
~After surgery, patients with pathologic complete response and have normal tumor markers receive no further therapy. Patients who remain with a partial response after surgery receive compressed consolidation chemotherapy.
~Patients receive cisplatin, etoposide, and bleomycin as induction chemotherapy in weeks 10,13, & 16."
11652279|NCT00053352|No Intervention|Arm 2|"Patients who are enrolled with stage I gonadal tumors receive no further anticancer therapy until evidence of tumor recurrence or the diagnosis of a second malignant neoplasm.
~Observation only for recurrence or development of an SMN"
11652280|NCT00053339|Experimental|trastuzumab|"Patients receive trastuzumab (Herceptin) IV over 60-90 minutes on day 1.
~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
~Patients are followed every 3 months for 5 years."
11652281|NCT00053339|Experimental|trastuzumab + tamoxifen|"Patients receive trastuzumab V over 60-90 minutes on day 1 and oral tamoxifen once daily on days 1-21.
~In both arms, treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
~Patients are followed every 3 months for 5 years."
11652282|NCT00053326|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide 3 times daily (or 2 times daily if over 18 years of age) on days 1-7. Treatment repeats every 3 weeks for up to 30 courses in the absence of disease progression or unacceptable toxicity.
11652283|NCT00053235||Ancillary-Correlative|Genomic DNA is isolated from OCT-embedded tissue and analyzed using comparative genomic hybridization. The chromosomal changes identified by this method are compared to those identified using the Taqman method, a quantitative genomic polymerase chain reaction analysis. Chromosome 8q is of specific interest. Other chromosomal changes may be detected in chromosomes 3q, 7q, 16q, and/or 17pter-q21.
11652284|NCT00053222|Experimental|Arm A|Arsenic trioxide (0.3 mg/kg/day iv for 5 days every 28 days)
11652285|NCT00053209|Experimental|Pemetrexed Disodium and Gemcitabine|Pemetrexed disodium 500 mg/m2 followed by gemcitabine 1000 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on day 8 of a 21-day cycle for a maximum of 6 cycles
11652286|NCT00053196|Experimental|Non myeloblative allogeneic transplant|Non myeloblative allogeneic hematopoietic cell transplantation after prior autologous transplantation
11652287|NCT00053053|Experimental|Juven supplement|Juven nutritional supplement given twice a day for 8 weeks
11652288|NCT00053053|Active Comparator|Non-Juven supplement|Non-Juven nutritional supplement given twice a day for 8 weeks
11653593|NCT00046631||Adolescent girls|Chosen from 6 schools in 6 cities
11652290|NCT00053027|Experimental|rituximab + cladribine|"Patients receive rituximab IV over 4-8 hours on day 1 and cladribine IV over 2 hours on days 4-8. If 2 or more patients experience unacceptable toxicity during the first course, the study is discontinued; otherwise, the study is opened for enrollment at all NCCTG sites.
~Treatment repeats every 28 days for a total of 2-6 courses in the absence of disease progression or unacceptable toxicity.
~Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually for 2 years."
11652291|NCT00053014|Experimental|treatment|patient conditioning - fludarabine 30 mg/m2 IV over 1 hour Days -4, -3, -2; TBI 6-7 cGy/min Day 0 post-transplant immunosuppression - cyclosporine 6.25 mg/kg bid PO D -3 to +180 (begin taper on D+35); mycophenolate mofetil 15mg/kg bid PO D0 to +27
11652292|NCT00004078|Experimental|Treatment (irinotecan hydrochloride)|Patients receive irinotecan IV over 60 minutes on days 1-5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months for 4 years and then annually thereafter until death or until patient enters another POG study.
11652293|NCT00003830|Active Comparator|Arm I: Conventional axillary dissection|Sentinel node resection immediately followed by axillary dissection
11652294|NCT00003830|Experimental|Arm II: Sentinel node resection followed by node examination|Sentinel node resection followed by node examination then axillary dissection if positive sentinel node.
11652295|NCT00052962|Other|Arm 1 Surgery + post op chemotherapy|"Cytoreductive surgery - patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity, with cytoreductive surgery, or tumor debulking to reduce tumor size.
~Post operative chemotherapy: systemic oxaliplatin, leucovorin and infusional 5-fluorouracil (5-FU), every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles {16 weeks total}."
11652296|NCT00052962|Other|Arm 2 Surgery + HIPEC|"Arm 2 Surgery + Continuous hyperthermic peritoneal perfusion (CHPP/HIPEC) + post op dwell + post op chemotherapy
~Cytoreductive surgery - patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity, with cytoreductive surgery, or tumor debulking to reduce tumor size.
~followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m^2 cisplatin
~post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluorouracil (5FU) 800 mg/m^2 and paclitaxel 125 mg/m^2
~post operative chemotherapy: systemic oxaliplatin, leucovorin and infusional 5-FU, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles {16 weeks total}."
11652297|NCT00052949|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily for 28 days. Courses continue in the absence of disease progression or unacceptable toxicity.
11652298|NCT00052910|Active Comparator|Arm I|Patients receive leucovorin calcium IV and fluorouracil (5-FU) IV on days 1-5 of courses 1, 3, and 4. Courses repeat every 28 days. During course 2, patients undergo radiotherapy 5 days a week and receive 5-FU IV continuously for 5 to 6 weeks. Patients rest for 28-35 days between course 2 and 3.
11652299|NCT00052910|Experimental|Arm II|Patients receive epirubicin IV over 3-15 minutes and cisplatin IV over 1 hour on day 1 and 5-FU IV continuously on days 1-21 during course 1. Beginning 1 week later, patients undergo radiotherapy 5 days a week and 5-FU IV continuously for 5 weeks. Patients rest for 28-35 days before beginning course 2 of chemotherapy. Patients then receive epirubicin, cisplatin, and 5-FU as in course 1. Treatment repeats every 21 days for 2 courses.
11652300|NCT00052897|Experimental|Arm I|"Patients receive SGN-00101 subcutaneously once on weeks 0, 4, and 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
~Cohorts of 5-6 patients receive escalating doses of SGN-00101 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experience dose-limiting toxicity."
11652301|NCT00052884|Experimental|Amifostine, Melphalan, and Stem Cell Reconstitution|Amifostine, Melphalan, and Stem Cell Reconstitution. Doses of Melphalan tested included 100 mg/m2 and 120 mg/m2
11652302|NCT00052845|Experimental|Combined chemotherapy|combination of 3 chemotherapy agents for hormone refractory prostate cancer
11652303|NCT00052780|Experimental|Treatment (temozolomide, O6-benzylguanine)|See Detailed Description
11652304|NCT00052715|Experimental|poly-ICLC Newly diagnosed GBM|"Poly-ICLC 20ug/kg 3 times a week (Monday-Wednesday-Friday) starting one week before Radiation Therapy
~Intramuscular injection
~Drug Poly-ICLC"
11652305|NCT00052689|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients with progressive disease crossover to arm II.
11652306|NCT00052689|Experimental|Arm II|Patients receive bortezomib as in arm I and gemcitabine IV over 30 minutes on days 1 and 8.
11652307|NCT00052611|Experimental|Celecoxib|Celecoxib will be given at a pre-determine dose twice daily for 3 months. If there is a favorable change in biomarker expression on biopsy at 3 months, treatment will continue to complete a 12-month treatment period.
11652308|NCT00052598|Experimental|Treatment (adoptive immunotherapy)|Patients receive allogeneic CD8+ PR3-specific CTLs IV over 1-2 hours on days 0, 7, 14, 28, and 49 and aldesleukin SC twice daily on days 28-41 and 49-63 in the absence of unacceptable toxicity.
11652309|NCT00052585|Experimental|Treatment (irinotecan, gefitinib, leucovorin, fluorouracil)|Patients receive oral gefitinib daily beginning on day 1, irinotecan IV over 90 minutes on days 1 and 15, and leucovorin calcium IV over 2 hours and fluorouracil IV over 3-5 seconds followed by a 22-hour infusion on days 1, 2, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11652310|NCT00052559|Experimental|Treatment (bevacizumab, fluorouracil, radiation therapy)|"Patients receive bevacizumab IV over 30-90 minutes on day 1 (courses 1-4). Beginning with course 2, patients also receive fluorouracil IV continuously on days 1-14 and undergo external beam radiotherapy on days 1-5 and 8-12. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
~Patients undergo surgery 7 weeks after completion of chemoradiotherapy.
~Cohorts of 6 patients receive escalating doses of bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 20 additional patients are treated at the MTD."
11652311|NCT00052520|Experimental|Treatment|See Detailed Description
11652312|NCT00052494|Experimental|STI-571 with cisplatin and irinotecan|
11652315|NCT00052468|Active Comparator|TC|Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, q 21 days / 6 - 10 courses
11653587|NCT00047450|Active Comparator|2|Participants will take citalopram (Celexa)
11652316|NCT00052429|Experimental|High-Dose Radiation Therapy Plus Chemotherapy|"Phase I
~Radiotherapy: Patients receive radiotherapy once daily 5 days a week for 6 weeks beginning on day 1.
~Concurrent chemotherapy: Patients receive cisplatin IV over 20-30 minutes on days 1-5 and 22-26.
~Adjuvant chemotherapy: Approximately 2-5 weeks after the completion of radiotherapy, patients receive fluorouracil IV continuously on days 1-4 and cisplatin IV over 20-30 minutes on days 1-5 and 22-26. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. In the absence of dose-limiting toxicity in 1 whole cohort of patients, study proceeds to phase II. Phase II
~Patients are treated as in phase I. Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter."
11652317|NCT00052377|Experimental|Treatment (aldesleukin, recombinant interleukin-12)|"Patients receive IL-12 SC twice weekly for 24 weeks.
~Disease is assessed at 13 weeks. Patients who do not have progressive disease also receive IL-2 SC 3 consecutive days a week during weeks 13-24. Patients with progressive disease at week 13 receive IL-2 SC at a fixed dose during weeks 13-24.
~Patients with responding disease after week 24 may continue to receive IL-2 and IL-12 for another 12 weeks.
~Cohorts of 3-6 patients receive escalating doses of IL-2 until the MTD is determined. The MTD is defined as the dose at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The RD is the dose preceding the MTD. Additional patients are treated at the RD."
11652318|NCT00052364|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11652319|NCT00052338|Experimental|Treatment (gemcitabine hydrochloride, carboplatin, bortezomib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8, carboplatin IV over 15-30 minutes on day 1, followed 1 hour later by bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with a clinical or radiographic response may continue receiving bortezomib beyond 6 courses.
11652320|NCT00052299|Experimental|ARM A|GO + MICE for remission induction followed by GO + mini-ICE for consolidation
11652321|NCT00052299|Active Comparator|ARM B|MICE for remission induction followed by mini-ICE for consolidation
11652322|NCT00052286|Experimental|drug dosage 1|- Arm I: Patients receive oral high-dose modafinil twice daily.
11652323|NCT00052286|Experimental|drug dosage 2|- Arm II: Patients receive oral low-dose modafinil twice daily.
11652324|NCT00052221|Experimental|Arm I: Epoetin Alfa|Epoetin alfa subcutaneously (SC) once weekly for 6 weeks
11652325|NCT00052221|Placebo Comparator|Arm II: Placebo|Placebo subcutaneously (SC) once weekly for 6 weeks
11652326|NCT00052208|Experimental|Treatment (gefitinib, radiation therapy)|Patients receive gefitinib PO QD for 7 weeks. Beginning 1 week after initiation of gefitinib, patients undergo radiation therapy QD 5 days a week for 6 weeks. Treatment with gefitinib continues for up to 18 months in the absence of disease progression or unacceptable toxicity.
11652327|NCT00052195|Placebo Comparator|B|
11652328|NCT00052195|Experimental|A|
11652329|NCT00052182|Experimental|1|Immunization on Day 0 and Weeks 4, 8, and 16
11652330|NCT00049673|Experimental|Arm I|Patients receive oral thalidomide daily and oral prednisone every other day for 4 years in the absence of disease progression or unacceptable toxicity.
11652331|NCT00049673|No Intervention|Arm II|Patients undergo observation.
11652332|NCT00049595|Active Comparator|ABVD|8 cycles of ABVD
11652333|NCT00049595|Experimental|BEACOPP|4 cycles of BEACOPP Escalated + 4 cycles of BEACOPP Baseline
11652334|NCT00049582|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 3 hours twice daily OR IV over 1 hour once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of decitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
11652335|NCT00049569|Experimental|Arm I|See detailed description.
11652336|NCT00049569|Experimental|Arm II|See detailed description.
11652337|NCT00049543|Experimental|Arm I (gefitinib)|Patients receive gefitinib PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
11652338|NCT00049543|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
11652339|NCT00049530|Experimental|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
11652340|NCT00049517|Experimental|Standard Daunorubicin Then Autologous HCT|"Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
~Consolidation/Transplant:
~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts.
~The patients undergoing autologous hematopoietic cell transplantation (HCT) received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses (without pharmacokinetic sampling) followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
11652341|NCT00049517|Experimental|High-dose Daunorubicin Then Autologous HCT|"Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
~Consolidation/Transplant:
~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts.
~The patients undergoing autologous hematopoietic cell transplantation (HCT) received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses (without pharmacokinetic sampling) followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
11653588|NCT00047437|Active Comparator|2|
11653589|NCT00047437|No Intervention|1|
11652342|NCT00049517|Experimental|Standard Daunorubicin Then GO/Autologous HCT|"Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
~Consolidation/Transplant:
~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts. patients randomized to the investigational arm received a single dose of Gemtuzumab ozogamicin (GO) at 6 mg/m2 followed by sargramostim 250 μ/m2 until recovery of counts.
~The patients undergoing autologous HCT received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
11652343|NCT00049517|Experimental|High-dose Daunorubicin Then GO/Autologous HCT|"Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
~Consolidation/Transplant:
~Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts. patients randomized to the investigational arm received a single dose of Gemtuzumab ozogamicin (GO) at 6 mg/m2 followed by sargramostim 250 μ/m2 until recovery of counts.
~The patients undergoing autologous HCT received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days."
11652344|NCT00049517|Active Comparator|Standard Daunorubicin Then Allogeneic HCT or no Consolidation|"Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
~Consolidation/Transplant:
~Patients without CR did not receive any consolidation treatment. Patients in CR with an unfavorable cytogenetic profile or an initial white blood cell count > 100,000/μL were to proceed to allogeneic HCT if they had a suitable human leukocyte antigen (HLA)-matched sibling donor available."
11652345|NCT00049517|Experimental|High-dose Daunorubicin Then Allogeneic HCT or no Consolidation|"Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
~Consolidation/Transplant:
~Patients without CR did not receive any consolidation treatment. Patients in CR with an unfavorable cytogenetic profile or an initial white blood cell count > 100,000/μL were to proceed to allogeneic HCT if they had a suitable human leukocyte antigen (HLA)-matched sibling donor available."
11652346|NCT00049504|Experimental|Treatment (nonmyeloablative HSCT)|"NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total body irradiation on day -1.
~TRANSPLANTATION: Patients undergo BMT, from an HLA-haploidentical donor, on day 0.
~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3.
~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV over 1-2 hours and then tacrolimus PO, once tolerated, on days 4-180, with taper on day 86 in the absence of graft-versus-host disease. Patients also receive mycophenolate mofetil PO three times daily on days 4-35."
11652347|NCT00049400|Experimental|treatment|Single-arm, dose-escalation of BMS-247550
11652348|NCT00049387|Experimental|Treatment (tipifarnib, temozolomide, radiation therapy)|See Detailed Description
11652349|NCT00049335|Experimental|Capecitabine|Capecitabine 1,000 mg/m^2/dose (2,000 mg/m^2/day) BID, PO, Days 1-14 of 21 day cycle.
11652350|NCT00049322|Experimental|Arm I-bevacizumab|Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks beginning 1 week prior to the first chemoembolization at a dose of 10 mg/kg. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
11652351|NCT00049322|No Intervention|Arm II-chemoembolization|chemoembolization as part of standard of care
11652352|NCT00049309|No Intervention|Control|Usual diet
11652353|NCT00049309|Experimental|Flaxseed diet|30 gram flaxseed dietary modification
11652354|NCT00049309|Experimental|Low fat diet|Low fat dietary modification
11652355|NCT00049309|Experimental|Low fat + Flaxseed diet|Low fat and 30 gram flaxseed dietary modification
11652356|NCT00049283|Experimental|Treatment (erlotinib hydrochloride, docetaxel, and radiation)|Patients receive oral erlotinib alone daily on weeks 1 and 2. Patients then receive oral erlotinib daily beginning on day 1 and docetaxel IV over 1 hour on day 3 of weeks 3-9. Patients also undergo radiotherapy once daily 5 days a week on weeks 3-9. Patients continue erlotinib for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who had N2 or greater cervical lymph node involvement at baseline or have residual neck adenopathy after chemoradiotherapy undergo neck dissection 6-8 weeks after completion of chemoradiotherapy. Erlotinib is held for 1 week before planned surgery and until healing is complete.
11652357|NCT00049257|Experimental|Treatment|Please see intervention descriptions
11652358|NCT00049218|Experimental|Vaccine Administration|"• Phase I: Beginning 9 weeks after completion of chemotherapy, patients receive autologous dendritic cell-adenovirus p53 vaccine subcutaneously (SC) on days 1, 14, and 28. Patients without PD may undergo repeat leukapheresis on day 49. Patients receive vaccine SC again on days 56, 84, and 112 in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of autologous dendritic cell-adenovirus p53 vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
~• Phase II: Patients receive autologous dendritic cell-adenovirus p53 vaccine at the MTD determined in phase I."
11652378|NCT00047346|Experimental|Treatment (erlotinib hydrochloride)|"Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
11652379|NCT00047333|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11652359|NCT00049192|Experimental|Treatment (oblimersen sodium, imatinib mesylate)|"Patients receive oblimersen IV continuously on days 1-10 and oral imatinib mesylate once or twice daily. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without a hematologic response after 2 courses go off study. Patients with complete or partial response after 4 courses may continue to receive oral imatinib mesylate daily.
~Patients in cohort 2 receive an escalated dose of oblimersen; if well tolerated, subsequent cohorts receive oblimersen at the higher dose with the original dose of imatinib mesylate. If oblimersen is not well tolerated in cohort 2, subsequent cohorts receive the original dose of oblimersen with an escalated dose of imatinib mesylate. The first 6 patients accrued continue to receive the original dose (dose taken prior to study) of imatinib mesylate throughout the study."
11652360|NCT00049166|Experimental|Regimen A (erlotinib hydrochloride, IMRT)|"Patients receive oral erlotinib once daily. Beginning on day 15, patients also undergo IMRT once daily 5 days a week for 7 weeks.
~Patients in both regimens continue to receive erlotinib until the last day of IMRT (patients already in the maintenance phase of this study as of 5/11/04 continue to receive erlotinib once daily for up to 2 years) in the absence of disease progression or unacceptable toxicity.
~In both regimens, cohorts of 3-6 patients receive escalating doses of erlotinib until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
11652361|NCT00049166|Experimental|Regimen B (erlotinib hydrochloride, cisplatin, IMRT)|"Patients receive oral erlotinib and undergo IMRT as in regimen A. Patients also receive cisplatin IV over 20 minutes on each day of radiotherapy.
~Patients in both regimens continue to receive erlotinib until the last day of IMRT (patients already in the maintenance phase of this study as of 5/11/04 continue to receive erlotinib once daily for up to 2 years) in the absence of disease progression or unacceptable toxicity.
~In both regimens, cohorts of 3-6 patients receive escalating doses of erlotinib until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
11652362|NCT00049140|Experimental|EF5|This is a non randomised single arm pilot study.
11652363|NCT00049127|Experimental|Phase II (Group 1)|Patients receive imatinib mesylate PO, at the MTD determined in phase I, BID for 4 weeks.
11652364|NCT00049127|Experimental|Phase II (Group 2)|Patients receive standard-dose imatinib mesylate PO BID for 4 weeks.
11652365|NCT00049114|Experimental|Treatment (doxorubicin, cyclophosphamide, tipifarnib, G-CSF)|"PHASE I (nonregional stage IV disease) (closed to accrual as of 1/19/04): Patients receive doxorubicin IV over 10-15 minutes and cyclophosphamide IV over 30 minutes on day 1, oral tipifarnib twice daily on days 2-7, and G-CSF subcutaneously on days 2-13. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
~PHASE II (stage IIB, IIIA, IIIB, or IIIC): Patients receive tipifarnib at the MTD and doxorubicin, cyclophosphamide, and G-CSF as in phase I (phase I closed to accrual as of 1/19/04). After the fourth course, patients may undergo complete resection."
11652366|NCT00049088|Experimental|Treatment (docetaxel, bevacizumab)|For course 1, patients receive docetaxel IV over 1 hour on days 1 and 8 and bortezomib IV over 3-5 seconds on days 9 and 12. Patients then receive 1 week of rest. For course 2 and all subsequent courses, patients receive docetaxel on days 1 and 8 and bortezomib on days 2, 5, 9, and 12. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 2-6 patients receive escalating doses of bortezomib and docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.
11652367|NCT00049036|Experimental|Arm I|Patients receive rituximab intravenously (IV) over 2-4 hours prior to each course of chemotherapy. Treatment repeats every 3 weeks for 4-6 courses. Patients who achieve a complete response after 4 courses of chemotherapy and rituximab receive additional rituximab alone weekly for 2 weeks.
11652368|NCT00049036|Experimental|Arm II|Patients do not receive rituximab concurrently with chemotherapy. Beginning 4 weeks after completion of chemotherapy, patients receive rituximab IV over 2-4 hours weekly for 6 weeks.
11652369|NCT00049023|Experimental|90Y-DOTA-tyr3-OCTREOTIDE|Dose escalation will proceed so that the single-cycle and three-cycle maximum tolerated doses of 90Y-DOTA-tyr3-Octreotide can be determined. The initial dose of 90Y-DOTA-tyr3-Octreotide to be administered is 30 mCi/m2 in each of three cycles. Dose escalation will proceed in 10 mCi/m2 intervals and will be permitted for the next cohort of subjects pending completion of Cycle 3 by 2 members of the previous cohort with no DLTs. A DLT is defined as a Grade 3 renal toxicity, Grade 4 bone marrow toxicity, or any other Grade 3 toxicity whether or not related to study drug and regardless of duration. Lymphopenia will not be used to define a DLT.
11652370|NCT00049010|Experimental|Group 1|"Melastatin mRNA expression is determined by in situ hybridization using tissue from primary tumor and lymph nodes. Tissue is also examined by immunohistochemical staining using antibodies to S-100 and MART-1. Patients do not receive the results of these tests nor do the results influence individual therapy.
~Patients are followed every 4 months for 3.5 years."
11652371|NCT00048997|Experimental|Prophylactic cranial irradiation (PCI)|Radiation therapy
11652372|NCT00048997|Other|Observation|Observation
11652373|NCT00048984||Basic science (biomarker analysis)|Patients undergo various specimen collections, including bone marrow aspirate, paraffin-embedded blocks of tumor tissue or slides of tumor tissue, and blood specimens. These specimens are collected before, during, and after any chemotherapy regimens, during follow-up, and at time of recurrence. Translocation studies are performed on specimens to identify fusion genes, specifically EWS-ETS. Serum IGF1 and IFGBP3 levels are determined. Bone marrow is assessed for minimal residual disease using reverse-transcriptase polymerase chain reaction.
11652374|NCT00048971||Group 1|Patients undergo collection of blood specimens for polymerase chain reaction and restriction fragment length polymorphism analysis. Genotyping assays are performed to determine UGT1A1 promoter genotyping, UGT1A1 coding polymorphisms, TS promoter polymorphisms, and MTHFR polymorphisms.
11652375|NCT00048958||No treatment|Samples as defined per the protocol for previously untreated patients with AML, ALL, MDS or MM will be submitted for analysis and within one month patients are required to register onto a CALGB treatment study.
11652376|NCT00047385|Experimental|Low-Dose CT|
11652377|NCT00047385|Experimental|Chest X-ray|
11652399|NCT00046930|Active Comparator|Placebo|Induction treatment with daunorubicin, cytarabine and placebo (details provided in Intervention section), followed by consolidation with Cytarabine (1500 mg/m2 every 12 hours for 6 days), then additional consolidation with the same regimen as received during induction.
11652380|NCT00047320|Experimental|Radiation Therapy (CR from Induction)|Patients will receive 6 cycles of Induction chemotherapy consisting of carboplatin and etoposide (Cycles 1, 3, and 5) alternating with ifosfamide and etoposide (Cycles 2, 4, and 6). The entire length of Induction is 18 weeks unless delay occurs due to myelosuppression or unanticipated toxicity. Each cycle of Induction will begin when ANC > 750/L and platelets > 75,000/L and when off filgrastim (G-CSF) for at least 48 hours. Following the Induction phase (weeks 0-18) those patient in CR will undergo radiation therapy.
11652381|NCT00047307|Experimental|Treatment (alvocidib, gemcitabine hydrochloride, 3DRT)|"Patients receive flavopiridol IV over 1 hour twice weekly (on days 1 and 4 or days 2 and 5) for 6 weeks. Concurrently, patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
~Four weeks after the completion of radiotherapy, patients are re-evaluated*. Beginning within 4-7 weeks after the completion of chemotherapy and radiotherapy, patients receive gemcitabine hydrochloride alone or in combination with another cytotoxic agent or gemcitabine hydrochloride combined with a targeted drug (e.g., erlotinib or bevacizumab) at the discretion of the oncologist. NOTE: *Patients whose imaging studies suggest potential curative resection are referred for a surgical evaluation before initiating gemcitabine hydrochloride therapy. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. Continued (see detailed description)"
11652382|NCT00047255|Experimental|Herceptin plus docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.
~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.
~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
11652383|NCT00047255|Experimental|Docetaxel, Carboplatin, and Herceptin|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.
~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.
~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
11652384|NCT00047229|Experimental|G3139 in combination with Doxorubicin|
11652385|NCT00047203|Experimental|Treatment (flavopiridol)|Patients receive flavopiridol IV over 1 hour on days 1-3. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. After 12 months, patients achieving at least a partial response may continue treatment in the absence of disease progression or unacceptable toxicity.
11652386|NCT00047190|Experimental|Arm I|Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11652387|NCT00047125|Experimental|Selective irradiation|Irradiation of the ipsilateral level I - V of the neck up to a dose of 60 Gy (30x2Gy in 6 weeks).
11652388|NCT00047125|Active Comparator|Extensive irradiation + ipsilaterals levels|Irradiation on the whole mucosa of the larynx, hypopharynx, oropharynx and nasopharynx, and on both sides of the neck (levels I -V) up to a prophylactic dose of 50 Gy (25 x 2 Gy in 5 week).Irradiation of the ipsilateral level I - V of the neck should continue with an additional 10 Gy boost for a total dose of 60 Gy (30 x 2 Gy in 6 weeks).
11652389|NCT00047112|Experimental|CHIMIORADIOTHERAPIE SUIVIE DE CHIRURGIE|CHIMIORADIOTHERAPIE SUIVIE DE CHIRURGIE
11652390|NCT00047112|Active Comparator|CHIRURGIE SEULE|CHIRURGIE SEULE
11652391|NCT00047073|Experimental|Phase 1|See intervention description.
11652392|NCT00047073|Experimental|Phase 2|See intervention description.
11652393|NCT00047060|Experimental|Stem Cell Transplant Therapy With Campath-1H|Recipients received a nonmyeloablative preparative regimen of alemtuzumab 30mg iv three times a week for two weeks followed by fludarabine 25mg/m2/day for five days followed by a PBPC graft targeted to deliver ≥ 5x106 CD34+ cells/kg. Cyclosporine A (CSA) for GVHD prophylaxis used initially with target CSA levels in the therapeutic range (200 -400 ng/ml).
11652394|NCT00047047|Experimental|Treatment (tanespimycin, gemcitabine hydrochloride, cisplatin)|"Cohort A (closed to accrual as of 3/2/04)*: Patients receive escalating doses of gemcitabine hydrochloride intravenously (IV) over 30 minutes, tanespimycin IV over 1 hour, and cisplatin IV over 2 hours on days 1 and 8. NOTE: *The maximum tolerated dose (MTD) of this 3-drug combination has been determined as of 3/2/04.
~Cohort B (closed to accrual as of 3/2/05): Patients receive gemcitabine hydrochloride** IV over 30 minutes, tanespimycin IV over 1 hour, and cisplatin** IV over 2 hours on days 1 and 8.
~Cohort C: Patients receive gemcitabine hydrochloride** IV over 30 minutes and tanespimycin IV over 1-2 hours on days 2 and 9.
~Cohort D: Patients receive cisplatin** IV over 2 hours and tanespimycin IV over 1-2 hours on days 1 and 8.
~Cohort E: Patients receive gemcitabine hydrochloride***, tanespimycin***, and cisplatin*** as in cohort B.
~Continued (see detailed description)"
11652395|NCT00047034|Experimental|Treatment (eribulin mesylate)|Patients receive E7389 IV over 1-2 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for at least 4 courses in the absence of disease progression or unacceptable toxicity.
11652396|NCT00047008|Other|Standard fractionation RT + cisplatin|Standard fractionation radiation therapy with concurrent cisplatin followed by conventional surgery for select patients.
11652397|NCT00047008|Experimental|Accelerated fractionation RT + cisplatin|Accelerated fractionation radiation therapy by concomitant boost with concurrent cisplatin followed by conventional surgery for select patients.
11652398|NCT00046930|Experimental|Zosuquidar|Induction treatment with daunorubicin, cytarabine and zosuquidar (details provided in Intervention section), followed by consolidation with Cytarabine (1500 mg/m2 every 12 hours for 6 days), then additional consolidation with the same regimen as received during induction.
11653636|NCT00044863|Experimental|1|Patients with metastatic EGFR-positive colorectal carcinoma
11652400|NCT00046917|Experimental|Treatment (chemotherapy)|Patients are stratified according to the number of prior treatment regimens (0 or 1 vs more than 1). Patients receive irinotecan hydrochloride IV over 30 minutes followed immediately by cisplatin IV over 30 minutes followed 7 hours later by alvocidib IV over 1-4.5 hours weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11652401|NCT00046891|Experimental|Ginkgo Biloba|120 mg per day (60 mg BID)
11652402|NCT00046891|Placebo Comparator|Placebo|1 tablet BID
11652403|NCT00046865|Experimental|Acupressure|Arm I: Patients receive active acupressure plus usual nausea care during the second or third course of chemotherapy. Acupressure is applied to a specific site each morning and again whenever nausea is experienced for 3-6 minutes.
11652404|NCT00046865|Placebo Comparator|Placebo Acupressure|Arm II: Patients receive placebo acupressure plus usual nausea care during the second or third course of chemotherapy. Acupressure is applied as in arm I except at a non-specific site.
11652405|NCT00046865|Sham Comparator|Usual Care|Arm III: Patients receive usual nausea care during the second or third course of chemotherapy.
11652406|NCT00046839|Experimental|Phase I: Celecoxib 200mg BID + RT|"COX-2 Inhibitor: Celecoxib 200 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.
~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
11652407|NCT00046839|Experimental|Phase I: Celecoxib 400mg BID + RT|"COX-2 Inhibitor: Celecoxib 400 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.
~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
11652408|NCT00046839|Experimental|Phase II: Celecoxib 400mg BID + RT|"COX-2 Inhibitor: Celecoxib 400 mg b.i.d, 7 days/week begins 5 days prior to start of radiation therapy (RT). Once RT begins, Celecoxib a.m. dose 1-2 hours prior to RT. Administer for 2 years or until disease progression.
~Concurrent Radiation Therapy: 2 Gy daily, 30-33 fractions, 5 days/week for 6-7 weeks, for a total dose of 60-66 Gy; or 3 Gy daily, 15 fractions, 5 days/week for 3-4 weeks for a total dose of 45 Gy."
11652409|NCT00045734|Experimental|Treatment (imatinib mesylate)|"Patients receive oral imatinib mesylate once or twice daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
~Other: pharmacological study/ laboratory biomarker analysis"
11652410|NCT00045708|Experimental|Group A [Anticonvulsants]|"Phase I: Dose Escalation - Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 patients experience dose-limiting toxicity.
~Pharmacological Study Phase 1"
11652411|NCT00045708|Experimental|Group B [No Anticonvulsants]|"Phase I: Dose Escalation - Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3 patients receive escalating doses of ixabepilone until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 patients experience dose-limiting toxicity.
~Pharmacological Study Phase 1"
11652412|NCT00045708|Experimental|Group C [MTD-Phase 2)|"Maximum tolerated Dose (MTD-Phase 2) - subjects treated at dose determined by Group B
~Drug: ixabepilone
~Other Names:
~BMS-247550 epothilone B lactam Ixempra Given IV"
11652413|NCT00045682|Experimental|Treatment (polyglutamate paclitaxel)|Patients receive polyglutamate paclitaxel (CT-2103) IV over 10-20 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652414|NCT00045669|Experimental|Imatinib Mesylate|Adult patients with unresectable or metastatic adenoid cystic carcinoma measurable by Response Evaluation Criteria in Solid Tumors Group criteria and expressing c-kit by immunohistochemistry were treated with imatinib 400 mg orally bid. Response was assessed every 8 weeks
11652415|NCT00045630|Experimental|Gemcitabine, Paclitaxel, Carboplatin|Gemcitabine, Paclitaxel, Carboplatin followed by surgery
11652416|NCT00045617|Experimental|cisplatin and etoposide followed by vaccine|standard chemotherapy with cisplatin and etoposide followed by cisplans and etoposide with an anti-idiotype monoclonal antibody vaccine
11652417|NCT00045591|Experimental|Celecoxib 100 mg|
11652418|NCT00045591|Experimental|Celecoxib 400 mg|
11652419|NCT00045565|Experimental|Group A|Patients receive arsenic trioxide IV over 2 hours once weekly for 6 weeks. Patients in both groups also undergo radiotherapy once daily 5 days a week for 6 weeks.
11652420|NCT00045565|Experimental|Group B|Patients receive arsenic trioxide at a lower dose IV over 2 hours twice weekly for 6 weeks. Patients in both groups also undergo radiotherapy once daily 5 days a week for 6 weeks.
11652421|NCT00045526|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11652422|NCT00045487|Experimental|OSI-774|
11652423|NCT00045435|Experimental|Treatment (nonmyeloablative donor PBSC transplant)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.
~TRANSPLANT: Patients undergo allogeneic PBSC transplant on day 0.
~IMMUNOSUPPRESSION: Patients receive CSP PO BID on days -3 to 56 with taper to day 77. Patients also receive MMF PO BID on days 0-27."
11652424|NCT00045396|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-14. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
11652446|NCT00042991|Experimental|Treatment (gefitinib and radiation therapy)|"Phase I portion: Patients receive oral gefitinib once daily. Treatment repeats every 4 weeks for 13 courses (1 year). Patients also receive standard brain irradiation once daily, 5 days a week, for 6 weeks beginning concurrently with initiation of the first course of gefitinib. Treatment continues in the absence of disease progression or unacceptable toxicity.
~Phase II portion: Once the MTD or the recommended Phase-II dose is determined, additional patients who have newly diagnosed BSG are treated at the MTD or the recommended Phase-II dose."
11652578|NCT00032084|Placebo Comparator|Behavioral Intervention + Placebo|Smoking cessation intervention , nicotine replacement, psychosocial assessment and care, and placebo.
11652425|NCT00045305|Experimental|Arm I|"Preparative Regimen: Patients underwent photopheresis on two consecutive days and received pentostatin 4 mg/m2/d (total dose = 8 mg/m2) by continuous IV infusion on two consecutive days following photopheresis. Total body irradiation was administered on two consecutive days following pentostatin for a total of 600 cGy given in three 200 cGy fractionated doses.
~Transplantation: Unmanipulated allogeneic bone marrow or G-CSF mobilized peripheral blood stem cells were infused on day 0 within 48 hours of completion of TBI. Minimum cell dose was 2 ×106 CD34 cells/kg recipient.
~Acute graft-vs-host-disease (GVHD) prophylaxis: Patients received Cyclosporine or Tacrolimus per institutional preference or protocol beginning no later than day -1. Methotrexate (MTX) was administered on day +1 and +3. Mycofenolate mofetil (MMF) was introduced on day 100 and could be tapered and discontinued after 12 months if no active cGVHD."
11652426|NCT00045201|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive oral erlotinib hydrochloride daily on days -6 to -1. Patients then receive irinotecan hydrochloride IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652427|NCT00045188|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily. Treatment continues for at least 8 weeks in the absence of disease progression or unacceptable toxicity.
11652428|NCT00045175|Experimental|UCN-01 in combination with topotecan|
11652429|NCT00045162|Active Comparator|1|
11652430|NCT00045162|Active Comparator|2|
11652431|NCT00045110|Experimental|Phase 1 Dose Escalation|"Phase I: Patients concurrently receiving EIAEDs receive oral erlotinib once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
~erlotinib hydrochloride given orally
~Other: pharmacological study."
11652432|NCT00045110|Experimental|Phase 2 recurrent malignant gliomas and nonprogressive GBM|"Phase II: Patients not concurrently receiving EIAEDs are treated with erlotinib as above at a predetermined dose (150mg/day.
~patients requiring surgery treated 7 days prior to tumor removal (150mg/day)
~PK analysis and effects of erlotinib on epidermal growth factor receptor (EGFR)
~erlotinib hydrochloride given orally
~Other: pharmacological study, laboratory biomarker analysis."
11652433|NCT00045032|No Intervention|Observation Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant. No Herceptin will be provided.
11652434|NCT00045032|Experimental|Herceptin 1-Year Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 1 year or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.
11652435|NCT00045032|Experimental|Herceptin 2-Year Arm|Participants who have completed definitive surgery and systemic adjuvant chemotherapy will receive Herceptin for 2 years or until disease recurrence, whichever occurs first. Participants will be observed for efficacy and safety until 10 years from individual randomization and for survival until 10 years after enrollment of the last participant.
11652436|NCT00045019||discharged cancer patients|patients discharged from a surgery or medical ward of oncology institutes in Belgium, France, Germany, Italy, Poland, Spain, Sweden, Taiwan and United Kingdom (as part of a larger psychometric validation study) were asked to rate there level of satisfaction, using the EORTC QLQ-SAT32.
11652437|NCT00044967||Group 1|"Patients undergo baseline colonoscopy before or within 6 months of initial curative resection and then surveillance colonoscopy at 1, 3, and 5 years (+/- 6 months) after resection. The number, size, location, histology, and method of removal of polyps are documented at the time of colonoscopy. Patients also undergo microsatellite instability (MSI) status testing and complete family history questionnaires at baseline.
~The prognostic significance of family history and MSI status is evaluated. The individual histologic features of the tumors are compared with the MSI status to determine their predictive value. The histologic features are also correlated with outcome to determine their prognostic significance.
~Patients may be referred for genetic counseling."
11652438|NCT00043121|Experimental|Treatment (combination chemotherapy)|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil IV on days 1 and 15. Patients also receive oral capecitabine every 8 hours on days 1-2 and 15-16. Leucovorin calcium and fluorouracil administration is held at dose level 4 and above. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11652439|NCT00043082|Experimental|carboplatin and doxorubicin|carboplatin and liposomal doxorubicin given q 4 weeks
11652440|NCT00043082|Active Comparator|carboplatin|carboplatin alone
11652441|NCT00043069|Active Comparator|Arm I: calcium + cholecalciferol + placebo + estrogen|"Patients receive oral calcium, oral cholecalciferol, oral risedronate placebo, and oral estrogen placebo daily.
~Treatment in all arms continues for 2 years.
~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.
~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
11652442|NCT00043069|Experimental|Arm II: calcium + cholecalciferol + risedronate + estrogen|"Patients receive oral calcium, oral cholecalciferol, oral risedronate, and oral estrogen placebo daily.
~Treatment in all arms continues for 2 years.
~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.
~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
11652443|NCT00043069|Placebo Comparator|Arm III: calcium + cholecalciferol + placebo + estrogen|"Patients receive oral calcium, oral cholecalciferol, low-dose oral conjugated estrogens, and oral risedronate placebo daily.
~Treatment in all arms continues for 2 years.
~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.
~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
11652444|NCT00043069|Experimental|Arm IV: calcium + cholecalciferol + risedronate + estrogen|"Patients receive oral calcium, oral cholecalciferol, low-dose oral conjugated estrogens, and oral risedronate daily.
~Treatment in all arms continues for 2 years.
~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.
~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
11652445|NCT00043017|Experimental|MRI/MRS|MRI and MRS examinations with standard imaging, with contrast enhancement using an agent (gadopentetate dimeglumine).
11653877|NCT00038298|Experimental|200 mg|200 mg 3 times weekly
11652447|NCT00042978|Experimental|Arm I (oblimersen sodium, carboplatin, and etoposide)|Patients receive oblimersen sodium IV continuously on days 1-8, carboplatin IV over 30 minutes on day 6, and etoposide IV over 60 minutes on days 6-8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11652448|NCT00042978|Active Comparator|Arm II (carboplatin and etoposide)|Patients receive carboplatin IV over 30 minutes on day 1 and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11652449|NCT00042965|Experimental|Gemcitabine + capecitabine|"Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 1-21. Treatment repeats every 28 days for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.
~Patients are followed every 3 months for 1 year and then every 6 months for 1 year."
11652450|NCT00042952|Experimental|Treatment (imatinib mesylate and surgical resection)|Patients receive oral imatinib mesylate once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients who achieve a partial response or stable disease with normalization of human chorionic gonadotropin may undergo surgical resection of residual lesions at each tumor status assessment. If residual viable germ cell tumor is present in the resected specimen, patients may resume imatinib mesylate. If no viable germ cell tumor is present in the resected specimen, then no further therapy is administered.
11652451|NCT00042939|Active Comparator|Irinotecan/Docetaxel|"Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m². Docetaxel was diluted in 100-150 ml of infusion solution. After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m².
~Chemotherapy was administered once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. This constituted a cycle of treatment. Patients were evaluated after 2 cycles."
11652452|NCT00042939|Experimental|Irinotecan/Docetaxel/Cetuximab|"Patients received Cetuximab intravenously once a week for 6 weeks. On day 1 of cycle 1 only, an initial dose of 400 mg/m² (over 120 minutes) was administered. Thereafter, a once-a-week maintenance dose of 250 mg/m² (infused over 60 minutes), was given. The infusion rate never exceeded 5 ml/minute.
~On the day of the initial dose, the administration of Cetuximab was followed by the administration of docetaxel, after a 60-minute observation period. (The observation period was 30 minutes following maintenance doses.) Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m². Docetaxel was diluted in 100-150 ml of infusion solution. After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m².
~Chemotherapy was administered once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Cetuximab was administered once a week for 6 consecutive weeks. A cycle of treatment was 6 weeks."
11652453|NCT00042926|Experimental|Radiolymphoscintigraphy + surgery|"Patients undergo radiolymphoscintigraphy comprising technetium Tc 99m sulfur colloid to identify the sentinel lymph nodes (SNL). Within 18 hours after radiolymphoscintigraphy, patients undergo resection of the primary oral cavity tumor and radioguided sentinel lymphadenectomy and regional cervical lymphadenectomy. Lymph nodes are examined by hematoxylin and eosin (H&E) staining. If negative by H&E, lymph nodes are further analyzed by immunohistochemistry.
~Patients are followed at 30 days."
11652454|NCT00042874|Experimental|Treatment (combination chemotherapy)|Patients receive irinotecan hydrochloride IV over 90 minutes followed 5 hours later by leucovorin calcium IV over 2 hours and alvocidib IV over 1 hour immediately followed by 5-FU IV continuously over 48 hours beginning on day 1 of weeks 1, 3, and 5. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of alvocidib and 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Ten additional patients are treated at the MTD.
11652455|NCT00042835|Experimental|Group I (cisplatin, etoposide, erlotinib, and docetaxel)|Patients receive cisplatin IV over 2 hours on days 1, 8, 29, and 36; etoposide IV over 1 hour on days 1-5 and 29-33; and oral erlotinib once daily on days 1-49. Patients undergo concurrent radiotherapy 5 days a week for 7 weeks beginning on day 1. Patients receive consolidation therapy comprising docetaxel IV over 1 hour on days 50, 71, and 92. Some patients may also receive oral erlotinib once daily on days 50-112.
11652456|NCT00042835|Experimental|Group II (paclitaxel, carboplatin, and erlotinib|Patients receive induction chemotherapy comprising paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1 and 21. Patients receive consolidation therapy comprising paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 43, 50, 57, 64, 71, 78, and 85 and oral erlotinib once daily on days 43-91. Patients undergo radiotherapy concurrently with consolidation therapy 5 days a week for 7 weeks beginning on day 43.
11652457|NCT00042809|Experimental|Treatment (paclitaxel, trastuzumab, erlotinib hydrochloride)|See detailed description.
11652458|NCT00042796|Experimental|Treatment (decitabine)|Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 4-6 weeks for a minimum of 4 courses in the absence of disease progression or unacceptable toxicity.
11652459|NCT00042770|Active Comparator|Arm I|Patients undergo placement of a standard pleural chest tube. Within 36 hours of chest tube placement, patients undergo pleurodesis comprising intrapleural administration of talc slurry once followed by clamping of the chest tube for 2 hours while different patient positions are used to distribute the talc. The chest tube is then unclamped to allow continuous drainage. When the chest tube drainage is less than 150 mL over 24 hours, pleurodesis is assumed and the chest tube is removed.
11652460|NCT00042770|Experimental|Arm II|Patients undergo pleurodesis comprising placement of a small (PleurX) catheter followed by pleural drainage for up to 90 minutes once daily. When the catheter drainage is less than 30 mL per day for 3 consecutive days, pleurodesis is assumed and the catheter is removed.
11652461|NCT00042731|Active Comparator|Oral isoflavones with multivitamin|Cohorts I - III: Patients receive 1 of 3 doses of oral isoflavones twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
11652462|NCT00042731|Active Comparator|Oral lycopene with multivitamin|Cohorts IV-VI: Patients receive 1 of 3 doses of oral lycopene twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
11652463|NCT00042731|Active Comparator|Multiple vitamin alone|Patients receive a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
11653697|NCT00043602|Experimental|1|Participants will receive clinician-managed interpersonal psychotherapy
11652464|NCT00041340|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable disease or better continue therapy until disease progression or 1 year after complete response.
11652465|NCT00041301||QoL in prostate cancer|The study sample will be composed of a consecutive series of prostate cancer patients, stratified by stage of disease, local and locally advanced versus advanced (metastatic) disease, and undergoing active anti-tumor therapy. In order to increase sample homogeneity, and to facilitate evaluation of the responsiveness of the quality of life instruments to changes in patients' health status and symptoms experience over time, the subsample of patients with local or locally advanced disease will be restricted to those undergoing surgery (radical prostatectomy) or radiation therapy, and the subsample of metastatic disease patients will be limited to those receiving hormonal therapy.
11652466|NCT00041197|Experimental|Arm I (imatinib mesylate)|Patients receive oral imatinib mesylate (Gleevec; STI571) once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence during the year of initial treatment receive imatinib mesylate (Gleevec; STI571) at an increased dose. Patients who develop a recurrence after the year of initial treatment restart imatinib mesylate (Gleevec; STI571) and continue taking the drug at the discretion of the principal investigator.
11652467|NCT00041197|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence at any time discontinue placebo and crossover to arm I. Treatment on arm I continues at the discretion of the principal investigator.
11652468|NCT00041171|Experimental|Arm 1: placebo + docetaxel|"Patients receive oral placebo three times daily on days 1-14 and docetaxel IV over 1 hour on day 15.
~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
~Patients are followed for new primaries and survival only."
11652469|NCT00041171|Experimental|Arm 2: Hypericum perforatum + docetaxel|"Patients receive oral Hypericum perforatum three times daily on days 1-14 and docetaxel as in arm 1.
~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
~Patients are followed for new primaries and survival only."
11652470|NCT00041171|Experimental|Arm 3: Hypericum perforatum + docetaxel|"Patients receive docetaxel as in arm 1 and continue to receive their chronic regimen of Hypericum perforatum except on day 15.
~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
~Patients are followed for new primaries and survival only."
11652471|NCT00041132|Experimental|Hyper-CVAD + MTX/Ara-C + Rituximab|"21-day cycles of Hyper-CVAD and high-dose methotrexate/cytarabine are alternated beginning with Hyper-CVAD for a maximum of 8 cycles. Rituximab is given for cycles 1-6.
~Hyper-CVAD (cycles 1,3,5,7): rituximab 375 mg/m^2 on day 1, mesna 600 mg/m^2 on days 2-4, cyclophosphamide 300 mg/m^2 on days 2-4, doxorubicin 16.6 mg/m^2/day on days 5-7, vincristine 1.4 mg/m^2 on days 5 and 12, dexamethasone 40 mg on days 2-5 and 12-15, and filgrastim 5 ug/kg on days 8-21.
~Methotrexate/Ara-C (cycles 2,4,6,8): rituximab 375 mg/m^2 on day 1, methotrexate 1000 mg/m^2 over days 2-3, Ara-C 12 g/m^2 over days 3-4, leucovorin 170 mg over days 3-5, and G-CSF 5 ug/kg on days 5-21."
11652472|NCT00041119|Active Comparator|Arm I (CA for 4 courses)|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11652473|NCT00041119|Experimental|Arm II (CA for 6 courses [closed to accrual 12/15/2007])|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11652474|NCT00041119|Experimental|Arm III (paclitaxel for 4 courses)|Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
11652475|NCT00041119|Experimental|Arm IV (paclitaxel for 6 courses [closed 12/15/2007])|Patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11652476|NCT00041106|Experimental|Treatment (gemcitabine, cisplatin, and gefitinib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 1 hour on day 1. Patients also receive gefitinib PO QD beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete remission, partial remission, or maintain stable disease continue gefitinib PO QD for 5 years or until disease progression or unacceptable toxicity occurs.
11652477|NCT00041093|Experimental|Treatment (docetaxel)|Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652478|NCT00041080|Experimental|Arm I (thalidomide)|Patients receive oral thalidomide once daily on days 1-28.
11652479|NCT00041080|Experimental|Arm II (tamoxifen)|Patients receive oral tamoxifen twice daily on days 1-28.
11652480|NCT00041067|Experimental|Trastuzumab, docetaxel, vinorelbine and filgrastim|Trastuzumab, docetaxel, vinorelbine and filgrastim
11652481|NCT00041054|Experimental|carboplatin + etoposide + exisulind|"Patients receive carboplatin IV over 30 minutes on day 1 and etoposide IV over 30-60 minutes on days 1-3. Patients also receive oral exisulind twice daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~Patients are followed every 2 months for 1 year and then every 4 months for 2 years."
11652482|NCT00041041|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11652483|NCT00041015|Active Comparator|oral topotecan plus cisplatin IV|oral topotecan once daily on days 1-5 and cisplatin IV on day 5
11652484|NCT00041015|Experimental|Cisplatin IV plus etoposide IV|Cisplatin IV on day 1 and etoposide IV over at least 30 minutes
11652485|NCT00040937|Experimental|treatment arm|thalidomide/dexamethasone followed by tandem melphalan peripheral blood stem cell transplantation (with cyclophosphamide and filgrastim or sargramostim support) and prednisone/thalidomide maintenance
11652486|NCT00040911|Experimental|Arm I (alternative medicine procedure)|Patients undergo electroacupuncture therapy to specific acupuncture points on the arms and legs over 25 minutes twice daily on days 1 and 2 and then once daily on days 3-7 during week 1 of chemotherapy course 1 (9 acupuncture treatments total).
11652488|NCT00040885|Experimental|infliximab + docetaxel|"Patients receive infliximab IV over 2 hours once weekly on weeks 1, 3, and 5 of the first course and once weekly on weeks 1 and 5 of all subsequent courses and docetaxel IV over 1 hour (immediately after completion of infliximab infusion once weekly on weeks 1-6 of each course.
~Treatment repeats every 8 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity.
~Quality of life, fatigue, appetite/anorexia, cachexia, and weight are assessed at baseline, weekly on weeks 1-8, and then monthly for the remainder of study treatment.
~Patients are followed every 6 months for 5 years."
11652489|NCT00040885|Active Comparator|placebo + docetaxel|"Patients receive docetaxel IV over 1 hour (immediately after completion of infliximab infusion once weekly on weeks 1-6 of each course. Patients receive placebo IV over 2 hours once weekly on weeks 1, 3, and 5 of the first course and once weekly on weeks 1 and 5 of all subsequent courses.
~Treatment repeats every 8 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity.
~Quality of life, fatigue, appetite/anorexia, cachexia, and weight are assessed at baseline, weekly on weeks 1-8, and then monthly for the remainder of study treatment.
~Patients are followed every 6 months for 5 years."
11652490|NCT00040859|Experimental|oxaliplatin + capecitabine|"Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response (CR) receive 2 additional courses after CR.
~Quality of life is assessed at baseline and then every 3 weeks (prior to each course of chemotherapy).
~Patients are followed every 3 months for 1 year and then every 6 months for 2 years."
11652491|NCT00040846|Experimental|Treatment (dose-escalation of alemtuzumab, HSCT)|"CONDITIONING REGIMEN: Patients receive alemtuzumab IV over 2 hours on days -8 to -5 and fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.
~HSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.
~IMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156."
11652492|NCT00040794|Experimental|Stratum I (gefitinib, radiotherapy)|"Patients receive gefitinib orally (PO) daily for 7 weeks. Patients also undergo concurrent radiotherapy once daily 5 days a week for 7 weeks.
~Patients then receive gefitinib PO daily in the absence of disease progression or unacceptable toxicity."
11652493|NCT00040794|Experimental|Stratum II (gefitinib, radiotherapy, chemotherapy)|"Patients receive gefitinib and radiotherapy as in stratum I concurrently with paclitaxel IV over 1 hour followed by carboplatin over 30 minutes once weekly for 7 weeks.
~Patients then receive gefitinib PO daily in the absence of disease progression or unacceptable toxicity."
11652494|NCT00040781|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
11652495|NCT00040768|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who received prior bortezomib and achieved at least a partial response of at least 6 months duration may also receive therapy as above.
11652496|NCT00040755|Experimental|Arm I (rebimastat once daily)|Patients receive oral BMS-275291 once daily on days 1-28. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR.
11652497|NCT00040755|Experimental|Arm II (rebimastat twice daily)|Patients receive oral BMS-275291 twice daily on days 1-28. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR.
11652498|NCT00040742|Placebo Comparator|Placebo|Patients receive oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
11652499|NCT00040742|Experimental|0.5g ginger|Patients receive oral low-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
11652500|NCT00040742|Experimental|1.0g ginger|Patients receive oral intermediate-dose ginger and oral placebo twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
11652501|NCT00040742|Experimental|1.5g ginger|Patients receive oral high-dose ginger twice daily on days -3 to 3 of chemotherapy courses 2 and 3.
11652502|NCT00039559|Other|Early detection|
11652503|NCT00039494|Experimental|Treatment (erlotinib hydrochloride, radiation, temozolomide)|Patients receive oral erlotinib once daily. After 1 week of erlotinib alone, patients also receive oral temozolomide once daily for 6 weeks and undergo concurrent radiotherapy 5 days a week for 6 weeks. After completion of radiotherapy, patients continue to receive erlotinib once daily alone in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of radiotherapy, patients also receive oral temozolomide once daily for 5 days. Temozolomide treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
11652504|NCT00039481|Experimental|Treatment (Oblimersen sodium, cytotoxic chemotherapy)|See detailed description.
11652505|NCT00039455|Experimental|Treatment (trastuzumab and alvocidib)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15 followed by flavopiridol IV continuously over 24 hours on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652506|NCT00039442|Experimental|Treatment|Patients receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652507|NCT00039416|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity.
11652508|NCT00039403|Experimental|Treatment (UCN-01, gemcitabine hydrochloride)|"Patients receive gemcitabine IV over 1-2 hours on days 1 and 8 followed by UCN-01 IV over 3 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
~Sequential dose escalation of UCN-01 is followed by sequential dose escalation of gemcitabine. Cohorts of 3-6 patients receive escalating doses of UCN-01 and then gemcitabine until the maximum tolerated dose (MTD) of the combination is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 6 patients are treated at the recommended phase II dose."
11652579|NCT00032084|Active Comparator|Behavioral Intervention + Bupropion|Smoking cessation intervention, nicotine replacement, psychosocial assessment and care, and bupropion hydrochloride .
11654106|NCT00027300|Placebo Comparator|Group 2|Placebo IV infusion
11652509|NCT00039390|Experimental|Treatment (capecitabine, gefitinib)|Patients receive oral gefitinib once daily on days 1-14 and oral capecitabine twice daily on days 8-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gefitinib and capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.
11652510|NCT00039377|Experimental|Treatment (imatinib mesylate, chemotherapy, PBSCT)|See Detailed Description.
11652511|NCT00039338|Experimental|Chemotherapy followed by surgery|neoadjuvant chemotherapy (Cisplatin) followed by surgery (radial hysterectomy)
11652512|NCT00039338|Active Comparator|Radio-chemotherapy|Concomitant radiotherapy (external radiotherapy combined with external boost or brachytherapy) and chemotherapy (cisplatin)
11652513|NCT00039325|Experimental|Group A - first dose for phase 1|A*0201 positive subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^6. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
11652514|NCT00039325|Experimental|Arm B - dose increase for phase 1|A*0201 positive subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
11652515|NCT00039325|Experimental|Arm C - A*0201+/DR*04+ subjects - Phase II|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
11652516|NCT00039325|Experimental|Arm D - A*0201+/DR*04- - phase 2|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
11652517|NCT00039325|Experimental|Arm E - A*0201-/DR*04+ - phase 2|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
11652518|NCT00039286|Experimental|Positron Emission Tomography|Patients receive fludeoxyglucose F 18 IV. Approximately 1 hour later, patients undergo positron emission tomography imaging. Some patients may undergo a repeat scan in 4-6 months.
11652519|NCT00039195|Experimental|Induction R-CHOPac Therapy for patients with B-Cell Lymphoma|Patients received 4 cycles if accelerated R-CHOP (cyclophosphamide. doxorubicin, vincristine and prednisone + rituximab) followed by 3 cycles ICE (ifosfamide, carboplatin and etoposide) consolidation therapy.
11652520|NCT00039182|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11652521|NCT00039130|Experimental|Rituximab with High Intensity Chemotherapy|Cycle1: Cyclophosphamide 100 mg/m^2/day (d) IV (d 1-5), Prednisone 60 mg/m^2/d oral (d 1-7), Allopurinal 300 mg/d oral (d 1-14) Cycle 2, 4 & 6 (21 day): Ifosfamide 800 mg/m^2/d (d 1-5), Dexamethasone 10 mg/m^2/d (d1-5), Methotrexate 150 mg/m^2 load, then 1.35 g/m^2 over 23.5 h (d 1), Leucovorin 25 mg/m^2 36 h after methotrexate (d 2) then 10 mg/m^2 every 6 h, Vincristine 2 mg push (d 1), Cytarabine 1000 mg/m^2/d over 2 h (d 4-5), Etoposide 80 mg/m^2.d over 1 h (d 4-5), Filgrastim 5 mg/kg/d (d 7-21 as needed), Rituximab 50 mg/m^2 d 8 cycle 2 only, 375 mg/m^2/d (d 10, 12 cycle 2, d 8 cycle 4 & 6) Cycle 3, 5 & 7 (21 day): Cyclophosphamide 200 mg/m^2/day (d) IV (d 1-5), Dexamethasone 10 mg/m^2/d (d1-5), Methotrexate 150 mg/m^2 load, then 1.35 g/m^2 over 23.5 h (d 1), Leucovorin 50 mg/m^2 36 h after methotrexate (d 2) then 10 mg/m^2 every 6 h, Vincristine 2 mg push (d 1), Doxorubicin 25 mg/m^2/d (d 4-5), Filgrastim 5 mg/kg/d (d 7-21 as needed), Rituximab 375 mg/m^2/d (d 8)
11652522|NCT00039117|Experimental|Arm I|"INDUCTION THERAPY: Patients receive oblimersen (G3139) IV continuously on days 1-10 and cytarabine IV continuously on days 4-10. Patients also receive daunorubicin IV daily on days 4-6.
~Patients with bone marrow cellularity of at least 20% and at least 5% leukemic blasts at day 17 or evidence of refractory disease receive a second induction comprising G3139 IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.
~CONSOLIDATION THERAPY: Beginning no sooner than 14 days after hematologic recovery from induction therapy, patients receive G3139 IV continuously on days 1-8 and cytarabine IV over 4 hours on days 4-8. Patients receive a second course of consolidation therapy no sooner than 14 days after hematologic recovery from the first course."
11652523|NCT00039104|Experimental|Arm I (rebimastat, zoledronic acid)|Patients receive zoledronate IV over at least 15 minutes on day 1 and oral BMS-275291 daily on days 1-28.
11652524|NCT00039104|Experimental|Arm II (zoledronic acid)|Patients receive zoledronate as in Arm I.
11652525|NCT00039091|Experimental|Treatment (ipilimumab)|Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody IV over 90 minutes on day 1. Courses repeat every 2 months in the absence of disease progression or unacceptable toxicity.
11652526|NCT00036933|Experimental|vaccine|"Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant QS21 subcutaneously once weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity. Patients whose antibody titers against Globo-H or MUC-2 antigens fall below 1/40 and who have no disease progression may receive a seventh vaccination after week 50.
~Patients are followed every 3 months for 1 year or until biochemical relapse or radiographic disease progression."
11652527|NCT00036881|Experimental|zinc sulfate|"Patients receive oral zinc sulfate 3 times daily beginning the first week of radiotherapy.
~Treatment continues daily during and for 1 month after radiotherapy in the absence of unacceptable toxicity.
~Quality of life is assessed at baseline, weekly during treatment, and then at 1, 2, 3, and 6 months after the completion of treatment.
~Patients are followed at 1, 2, 3, and 6 months after the completion of treatment and then every 6 months for 1 year."
11652630|NCT00028769|Experimental|Hormone therapy, estramustine, etoposide and paclitaxel|Hormone therapy (leuprolide, bicalutamide, nilutamide, goserelin, flutamide), estramustine, etoposide and paclitaxel
11654370|NCT00012701||Group 1|
11654371|NCT00012688|Other|Arm 1|
11652528|NCT00036881|Placebo Comparator|placebo|"Patients receive oral placebo 3 times daily beginning the first week of radiotherapy.
~Treatment continues daily during and for 1 month after radiotherapy in the absence of unacceptable toxicity.
~Quality of life is assessed at baseline, weekly during treatment, and then at 1, 2, 3, and 6 months after the completion of treatment.
~Patients are followed at 1, 2, 3, and 6 months after the completion of treatment and then every 6 months for 1 year."
11652529|NCT00036868|Experimental|CMF + Herceptin|
11652530|NCT00036855|Experimental|Group A (no planned PBSC support)|"Patients receive rituximab IV over 4-6 hours followed by IDEC-In2B8 IV over 10 minutes on day 0 and undergo whole body imaging. Patients may then receive rituximab IV over 4-6 hours followed by IDEC-Y2B8 IV over 10 minutes on day 7.
~Some patients receive autologous PBSC IV over 30-60 minutes on day 35."
11652531|NCT00036855|Experimental|Group B (planned PBSC support)|Patients receive rituximab, IDEC-In2B8, and IDEC-Y2B8 as in group A. Patients also receive autologous PBSC IV over 30-60 minutes on day 21 and G-CSF subcutaneously beginning on day 22 and continuing until blood counts recover or day 35.
11652532|NCT00036777|Experimental|Treatment (carboplatin, 7-hydroxystaurosporine)|"Patients receive carboplatin IV over 1 hour followed by UCN-01 IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of carboplatin and UCN-01 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
11652533|NCT00036764|Experimental|Treatment|Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11652534|NCT00036751|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
11652535|NCT00036738|Experimental|Treatment (allogeneic nonmyeloablative HSCT)|See Detailed Description
11652536|NCT00036686|Experimental|Soy protein isolate|"Administration Prior to Mastectomy or Lumpectomy.
~Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.
~Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure."
11652537|NCT00036686|Placebo Comparator|Placebo|"Administration Prior to Mastectomy or Lumpectomy.
~Patients receive oral placebo twice daily and oral multivitamins once daily.
~Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure."
11652538|NCT00033748|Experimental|Combined Monoclonal Antibody Therapy|Patients with minimal metastatic colorectal cancer are treated with 2 anti-idiotype monoclonal antibodies
11652539|NCT00033696|Experimental|chemotherapy + radiation therapy|"Induction therapy: Patients receive paclitaxel IV over 3 hours on days 1 and 22, oral topotecan on days 2-4 and 23-25, and oral etoposide on days 5-7 and 26-28. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on days 8 and 29 and continuing until blood counts recover.
~Consolidation therapy: Patients receive carboplatin IV over 1 hour on days 43, 64, and 85 and etoposide IV over 1 hour on days 43-45, 64-66, and 85-87. Patients undergo radiotherapy daily 5 days per week beginning on day 43 and continuing for 6-7 weeks.
~Patients with rapid disease progression discontinue study therapy.
~Patients are followed at least every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years."
11652540|NCT00033657|Experimental|Cisplatin / Irinotecan / Radiation therapy (Arm A)|"Days 1 - 35 : Concurrent radiation therapy (RT) and Cisplatin / Irinotecan Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Cisplatin 30 mg/m² days 1, 8, 22, 29. Irinotecan 65 mg/m² days 1, 8, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy
~Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
11652541|NCT00033657|Experimental|Paclitaxel / Cisplatin / Radiation therapy (Arm B)|"Days 1 - 35 : Concurrent radiation therapy (RT) and Paclitaxel/Cisplatin Chemotherapy. Radiotherapy 45 Gy administered at 1.8 Gy per day, 5 days a week for 5 weeks. Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29. Cisplatin 30 mg/m² days 1, 8, 15, 22, 29. Chemotherapy should begin within 24 hours of start of radiotherapy.
~Days 63 - 77 : Surgical Resection At least 28 days after surgical resection, begin adjuvant chemotherapy: paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles."
11652542|NCT00033631|Active Comparator|70.2 Gy|70.2 Gy 3D-CRT/IMRT
11652543|NCT00033631|Experimental|79.2 Gy|79.2 Gy 3D-CRT/IMRT
11652544|NCT00033618|Experimental|Arm I (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652545|NCT00033618|Experimental|Arm II (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11652546|NCT00033605|Experimental|octreotide + radiation|"Patients receive short-acting octreotide subcutaneously (SC) on day 1 and long-acting octreotide intramuscularly (IM) on days 2 and 29.
~Treatment continues in the absence of unacceptable toxicity or the development of severe diarrhea.
~Patients complete a bowel function questionnaire at baseline, weekly during radiotherapy, and then weekly for 4 weeks and at 1 and 2 years after completion of radiotherapy.
~Patients are followed weekly for 4 weeks and then at 1 and 2 years."
11652547|NCT00033605|Active Comparator|placebo + radiation|"Patients receive placebo SC on day 1 and IM on days 2 and 29. Treatment continues in the absence of unacceptable toxicity or the development of severe diarrhea.
~Patients complete a bowel function questionnaire at baseline, weekly during radiotherapy, and then weekly for 4 weeks and at 1 and 2 years after completion of radiotherapy.
~Patients are followed weekly for 4 weeks and then at 1 and 2 years."
11652548|NCT00033553|Experimental|Paclitaxel + Carboplatin|Paclitaxel and carboplatin induction (2 cycles)followed by chemotherapy with the addition of radiotherapy for 7 cycles
11652549|NCT00033553|Experimental|Gemcitabine + Carboplatin|Gemcitabine and carboplatin induction (2cycles) followed by chemotherapy with the addition of radiotherapy for 7 cycles
11652550|NCT00033540|Experimental|Capecitabine + Gemcitabine|Capecitabine 650 mg/m^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days; Gemcitabine 1000 mg/m^2, intravenous (IV) over 100 minutes, Days 1, 8, every 21 days
11652551|NCT00033514|Experimental|treatment|please see intervention description
11652552|NCT00033449|Experimental|Treatment (gefitinib, radiation therapy, cisplatin)|See detailed description.
11652553|NCT00033423|Experimental|Cohort 1|First radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
11652558|NCT00033397||Arm A|"Patients receive an injection of gadopentetate dimeglumine and undergo magnetic resonance imaging (MRI) of the breast before initiation, 1-3 days after initiation, and then after completion of neoadjuvant anthracycline-based chemotherapy and prior to surgery. Patients who previously received a taxane also undergo an additional contrast-enhanced MRI scan.
~Mammograms and possibly ultrasounds are performed prior to and after chemotherapy (before surgery).
~Patients are followed every 6 months for 5 years and then annually for up to 10 years."
11652559|NCT00033371|Active Comparator|Arm I: Celecoxib and Placebo|Celecoxib 400 mg orally twice daily (PO BID) and Placebo once a day. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
11652560|NCT00033371|Experimental|Arm II: Celecoxib and Eflornithine|Celecoxib 400 mg PO BID and Eflornithine PO daily 0.5 g/m^2/day rounded down to the nearest 250 mg dose. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
11652561|NCT00033358|Experimental|Arm I (medroxyprogesterone)|Patients receive medroxyprogesterone intramuscularly once on day 1. Approximately 90 days after the injection, patients undergo a repeat transvaginal ultrasound and endometrial biopsy.
11652562|NCT00033358|Experimental|Arm II (ethinyl estradiol, norgestrel)|Patients receive OCP comprising ethinyl estradiol and norgestrel once daily on days 1-21. Treatment repeats every 28 days for 3-4 courses (3-4 packs of OCP) in the absence of unacceptable toxicity. Approximately 1 week after starting the fourth pack of OCP, patients undergo a repeat transvaginal ultrasound and endometrial biopsy.
11652563|NCT00033345|Experimental|High-Risk Breast Cancer|All subjects first went through a 4-week placebo run-in period. Next, subjects took Indole-3-carbinol 400mg daily for 4 weeks followed by a 4-week period of Indole-3-carbinol 800mg daily.
11652564|NCT00033293|Experimental|Arm I (chemotherapy, immunoglobulin therapy)|"Patients with intermediate-risk or high-risk neuroblastoma receive chemotherapy (including cyclophosphamide) according to the standard of care for the stage of primary neuroblastoma, beginning day 0. Patients with low-risk neuroblastoma (and not receiving other chemotherapy) receive cyclophosphamide IV over 1 hr on day 0. Treatment repeats every 4 wks for 6 courses in the absence of disease progression or unacceptable toxicity. All patients receive oral prednisone twice daily for 3 mths and then every other day for 7-15 mths.
~Patients receive therapeutic immune globulin IV on days -2 and -1, at wks 4, 8, 12, 16, 20, and 24, and then at mths 8, 10, and 12 after therapy. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with no response after 6 months go off treatment. In case of progression of opsoclonus-myoclonus-ataxia (OMA) during evaluation, patient will be switched to another steroid, corticotropin-releasing hormone (ACTH)."
11652565|NCT00033293|Active Comparator|Arm II (chemotherapy, observation)|"Patients with intermediate-risk or high-risk neuroblastoma receive chemotherapy (including cyclophosphamide) according to the standard of care for the stage of primary neuroblastoma, beginning on day 0. Patients with low-risk neuroblastoma (and not receiving other chemotherapy) receive cyclophosphamide IV over 1 hour on day 0. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. All patients receive oral prednisone twice daily for 3 months and then every other day for 7-15 months.
~Patients do not receive therapeutic immune globulin. Patients with unresponsive opsoclonus-myoclonus-ataxia syndrome after 2 months or progression after 6 months may cross over to arm I."
11652566|NCT00033280|Experimental|Pre-RT temozolomide, RT plus temozolomide|Pre-radiation therapy (RT) temozolomide, RT plus temozolomide
11652567|NCT00033267|Experimental|Treatment|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with stable disease receive a maximum of 6 courses. Patients with partial response receive a maximum of 12 courses. Patients with CR receive 2 additional courses beyond CR.
11652568|NCT00033254|Active Comparator|Arm I (radiation therapy)|Patients undergo radiotherapy once daily 5 days a week for 3 weeks.
11652569|NCT00033254|Experimental|Arm II (radiation therapy, thalidomide)|Patients undergo radiotherapy as in arm I. Beginning on the first day of radiotherapy, patients receive oral thalidomide once daily.
11652570|NCT00033228|Experimental|Cohort 1|The first cohort of 6 patients received 500 ug of Synchrovax SEM plasmid DNA vaccine. All patients were to be monitored for dose limiting toxicities DLTs) for a minimum of 2 weeks after their second infusion of vaccine on Day 15 before allowing patients to enroll at the next dose group. The decision to progress to the next dose group was to be based on occurrence of DLTs observed in 1 or fewer (<33%) patients of a 6 patient cohort.
11652571|NCT00033228|Experimental|Cohort 2|The second cohort of 6 patients received 1000 ug of Synchrovax SEM plasmid DNA vaccine. All patients were to be monitored for dose limiting toxicities DLTs) for a minimum of 2 weeks after their second infusion of vaccine on Day 15 before allowing patients to enroll at the next dose group. The decision to progress to the next dose group was to be based on occurrence of DLTs observed in 1 or fewer (<33%) patients of a 6 patient cohort.
11652572|NCT00033228|Experimental|Cohort 3|The third cohort of 6 patients received 1500 ug of Synchrovax SEM plasmid DNA vaccine. The maximum tolerated dose (MTD) was to be determined by the observation of DLT at each dose group.
11652573|NCT00032188|Experimental|Arm I (aldesleukin and lowest dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive lowest dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
11652574|NCT00032188|Experimental|Arm II (aldesleukin and middle dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive middle dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
11652575|NCT00032188|Experimental|Arm III (aldesleukin and highest dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive highest dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
11652576|NCT00032162|Experimental|PLD|dose finding study of PLD in combination with Carboplatin
11652577|NCT00032110|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after CR is confirmed.
11654372|NCT00012675||Group 1|
11652580|NCT00032032|Experimental|radiotherapy + paclitaxel + carboplatin|"Patients undergo radiotherapy once daily 5 days a week for 7 weeks and 2 days (a total of 37 fractions). Patients concurrently receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes once weekly for 7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
~Beginning 3 weeks after completion of radiotherapy, patients receive paclitaxel and carboplatin as above. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.
~Quality of life is assessed at baseline, once during the last week of radiotherapy, and then every 3 months for 2 years.
~Patients are followed at 3 weeks, every 3 months for 21 months, and then every 6 months for 3 years."
11652581|NCT00032019|Experimental|EPOCH-Rituximab|Addition of monoclonal antibody therapy to chemotherapy for treatment of pts with aggressive CD20+ NHL
11652582|NCT00032006|Experimental|brachytherapy + radiation|"Within 4 weeks after completion of androgen suppression, patients are sequentially enrolled to 2 different cohorts of brachytherapy.
~Cohort 1: Patients undergo initial-dose transperineal interstitial permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.
~Cohort 2: After a minimum of 1-year follow-up for all patients in cohort 1, if tolerance is acceptable, additional patients undergo higher-dose transperineal interstitial permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.
~Quality of life is assessed at baseline, within 2 weeks prior to brachytherapy, every 3 months for 1 year, and then every 6 months for 2 years.
~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years."
11652583|NCT00031993|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11652584|NCT00031980|Experimental|cyclosporine|"Patients receive oral cyclosporine every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.
~Patients are followed every 4 months for 1 year and then every 6 months for 9 years."
11652585|NCT00031837|Experimental|Dalteparin|5,000 anti-Xa units of dalteparin subcutaneously once daily for six months in addition to gemcitabine at 1,000 mg/m2 as a 30-minute infusion weekly for 7 weeks followed by a week of rest for the first cycle and weekly for three weeks followed by a week of rest for each subsequent cycle.
11652586|NCT00031772|No Intervention|Control|Standard level of support after recurrence diagnosis
11652587|NCT00031772|Experimental|Intervention|Phone intervention for patients experiencing first recurrence with quality of life questionnaires, psychosocial assessment and care.
11652588|NCT00031759|Other|Ablative or excisional therapy|"Patients undergo ablative or excisional therapy.
~Quality of life is assessed at baseline, 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.
~Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy."
11652589|NCT00031759|Experimental|Ablative or excisional therapy + imiquimod|"Patients have topical imiquimod applied to the cervix for 6-10 hours twice weekly for a total of 5 doses. Within 3-4 weeks after the final application, patients undergo ablative or excisional therapy. Quality of life is assessed at baseline, after last dose of study drug, 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.
~Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy."
11652590|NCT00031746|Active Comparator|soy protein + isoflavones|
11652591|NCT00031746|Active Comparator|casein proteins|
11652592|NCT00031720|Experimental|Arm I|All patients receive placebo for 7 days as part of the run-in period. Patients being treated with tamoxifen were randomized to treatment arm I and received 40 gm soy protein and 90 mg isoflavones daily for 12 weeks.
11652593|NCT00031720|Placebo Comparator|Arm II|All patients receive placebo for a 7 day run in period. Patients being treated with tamoxifen randomized to Arm II received placebo daily for 12 weeks.
11652594|NCT00031694|Experimental|Treatment (paclitaxel, bryostatin 1)|Patients receive paclitaxel IV over 1 hour on day 1 followed by bryostatin 1 IV over 1 hour on day 2 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11652595|NCT00031681|Experimental|Treatment (combination chemotherapy)|"PART I: Patients receive irinotecan hydrochloride IV over 90 minutes on days 1, 8, 15, and 22 and 7-hydroxystaurosporine IV over 3 hours on days 2 and 23. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan hydrochloride and 7-hydroxystaurosporine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Blood samples are collected periodically during study treatment.
~PART II: (treatment of triple negative recurrent breast cancer): Patients receive irinotecan hydrochloride IV and 7-hydroxystaurosporine IV as in part I at the MTD and undergo blood sample collection."
11652596|NCT00031655|Experimental|Treatment (nonmyeloablative allogeneic PBSCT)|"NONMYELOALATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.
~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0. Patients with minimal residual disease may receive donor lymphocyte infusion IV.
~IMMUNOSUPPRESSION: Patients receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO very 8 hours on days 0 to 40 with taper to day 96."
11652597|NCT00031629|Experimental|Treatment (gemcitabine, docetaxel, G-CSF, pegfilgrastim)|Patients receive gemcitabine IV over 90 minutes on days 1 and 8, docetaxel IV over 1 hour on day 8, and G-CSF SC on days 9-15 or pegfilgrastim SC on day 9 only. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11652598|NCT00031590|Experimental|Study Treatment|"All subjects will undergo routine surgical staging of their tumor. Treatment must begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with vincristine. 4 weeks after radiation and vincristine treatment is completed, all subjects will begin 9 cycles (each cycle lasts 6 weeks) of maintenance chemotherapy which will be given as 2 different drug combinations, Regimen A (Lomustine, Vincristine, and Cisplatin) and Regimen B (Cyclophosphamide, given with Mesna, and Etoposide [IV and oral]) which will be given in the following order: AABAABAAB (total of 54 weeks)."
11652631|NCT00028756|Active Comparator|Arm I (immediate chemotherapy)|Beginning within 90 days of radical cystectomy, patients receive a total of 4 courses of adjuvant chemotherapy.
11654373|NCT00012662|Other|Arm 1|
11652599|NCT00031564|Experimental|Vaccine Therapy With Interleukin-2|At approximately 3-6 weeks after surgery, patients receive B7-1 gene-modified autologous tumor cell vaccine subcutaneously (SC) once on days 1, 29, and 57. At 6 weeks after the first vaccination, patients receive interleukin-2 (IL-2) SC five days a week for 6 weeks (days 43-82). Patients with stable or responding disease after day 106 may receive additional vaccinations in the absence of disease progression or unacceptable toxicity.
11652600|NCT00030914|Experimental|Arm I: venlafaxine|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive oral venlafaxine once daily for 6 weeks beginning on day 8. After week 7, patients with satisfactory efficacy may continue venlafaxine for up to 6 months. Patients with unsatisfactory efficacy may cross over to arm III.
~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
11652601|NCT00030914|Experimental|Arm II: medroxyprogesterone - long term|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive medroxyprogesterone intramuscularly (IM) on days 8, 22, and 36 for a total of 3 injections. After week 7, patients with unsatisfactory efficacy may cross over to arm I.
~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
11652602|NCT00030914|Experimental|Arm III: medroxyprogesterone - short term|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive medroxyprogesterone IM once on day 8. After week 7, patients with unsatisfactory efficacy may cross over to arm I.
~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
11652603|NCT00030901|Active Comparator|L-selenomethionine|L-selenomethionine (Selenium)one tablet by mouth daily for 3 years.
11652604|NCT00030901|Placebo Comparator|L-selenomethionine placebo|L-selenomethionine placebo one tablet by mouth daily for 3 years
11652605|NCT00030823|Experimental|Vaccine|Patients receive Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine with QS21 adjuvant subcutaneously weekly on weeks 1, 2, 3, 7, and 19.
11652606|NCT00030771|Active Comparator|Arm A|Neoadjuvant Chemoradiotherapy + Chemotherapy + Surgery
11652607|NCT00030771|Active Comparator|Arm B|Neoadjuvant Chemotherapy + Surgery
11652608|NCT00030732|Active Comparator|Gemcitabine + Capecitabine|Gemcitabine + Capecitabine
11652609|NCT00030732|Active Comparator|Gemcitabine alone|Gemcitabine alone
11652610|NCT00030693|Experimental|Arm I (recombinant fowlpox-B7.1 vaccine)|Patients receive rF-B7.1 vaccine intratumorally on day 1.
11652611|NCT00030693|Experimental|Arm II (recombinant fowlpox-TRICOM vaccine)|Patients receive fowlpox-TRICOM vaccine intratumorally on day 1.
11652612|NCT00030654|Experimental|Androgen blockade + immediate chemotherapy|Androgen blockade with immediate chemotherapy
11652613|NCT00030654|Experimental|Androgen blockade + delayed chemotherapy|Androgen blockade with delayed chemotherapy
11652614|NCT00030628|Experimental|radiosurgery|"Patients undergo radiosurgery.
~Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years."
11652615|NCT00030628|Experimental|radiosurgery + WBRT|"Patients undergo radiosurgery. Within 14 days, patients then undergo whole brain radiotherapy 5 days a week for 2.5 weeks.
~Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years.
~Patients are followed at weeks 6 and 12, every 3 months for 9 months, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter."
11652616|NCT00030615|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 30 minutes on days 1-5 weekly for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of decitabine until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
11652617|NCT00030576|Experimental|OSI-774 and cisplatin|HNSCC patients treated in three escalating dose cohorts of daily continous oral erlotinib (OSI-774) and intermittent IV cisplatin given every 21 days
11652618|NCT00030498|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
11652619|NCT00030407|Experimental|Celecoxib & Docetaxel|"Celecoxib: On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals
~Docetaxel: On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days."
11652620|NCT00030394|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve a complete hematologic response after 3 courses or a partial or complete cytogenic response after 6 courses are removed from the study.
11652621|NCT00030303|Experimental|vaccine|recombinant 70-kD heat-shock protein
11652622|NCT00030264|Experimental|Methotrexate & Vinblastine|Methotrexate and Vinblastine will be given once a week for the first 26 weeks and then every two weeks for the next 26 weeks or until disease progression (whichever occurs first).
11652623|NCT00029003|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
11652624|NCT00028990|Active Comparator|Paclitaxel + Bevacizumab|
11652625|NCT00028990|Active Comparator|Paclitaxel|
11652626|NCT00028834|Experimental|Treatment (gemcitabine hydrochloride, bevacizumab)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11652627|NCT00028821|Experimental|Treatment (2-methoxyestradiol)|Patients receive oral 2-methoxyestradiol (2-ME) once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11652628|NCT00028795|Experimental|Chemoradiotherapy|
11652629|NCT00028782|Experimental|Diagnostic (etanidazole)|Patients receive etanidazole derivative EF5 IV over 1-2 hours. Approximately 48 hours after EF5 administration, patients with intraperitoneal tumors undergo surgical resection. Patients with pleural tumors undergo surgical resection approximately 24 hours after EF5 administration. Tumors are then analyzed for EF5 binding and microvascular density by immunohistochemistry and fluorescent antibody techniques.
11653698|NCT00043602|Active Comparator|2|Participants will receive standard interpersonal psychotherapy
11652632|NCT00028756|Experimental|Arm II (deferred chemotherapy)|Beginning at the time of clinical relapse, patients receive a total of 6 courses of adjuvant chemotherapy.
11652633|NCT00028743|Active Comparator|Cisplatin, Topotecan, Paclitaxel plus Carboplatin|Arm 1
11652634|NCT00028743|Active Comparator|Paclitaxel plus Carboplatin|Arm 2
11652635|NCT00028730|Experimental|Pts < than or = 18 years with lymphohematopoietic disorders|This is a phase II, single-center study to evaluate a cytoreductive regimen of hyperfractionated TBI, thiotepa and cyclophosphamide (HFTBI/thio/cy) followed by infusions of SBA-E- T-cell depleted marrow in pediatric leukemia recipients of either HLA-identical or HLA-1Ag non-identical related or unrelated donors.
11652636|NCT00028665|Experimental|Arm I: with rituximab IV|
11652637|NCT00028665|Active Comparator|Arm II: without rituximab IV|
11652638|NCT00028600|Experimental|Autologous + Allogeneic Transplant|autologous PB stem cell transplant followed by non-myeloablative allogeneic transplant fr multiple myeloma
11652639|NCT00028587|Experimental|Group I (paclitaxel, carboplatin, bortezomib)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and bortezomib IV over 3-5 seconds on days 2, 5, and 8.
11652640|NCT00028587|Experimental|Group II (bortezomib, paclitaxel, carboplatin)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, and 8 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 2
11652641|NCT00028574|Active Comparator|Gabapentin (28 days)|Oral Gabapentin 300 mg days 1-28
11652642|NCT00028574|Active Comparator|Gabapentin (7, 21)|Oral Gabapentin 300 mg once daily on days 1-7 days and twice daily days 8-28
11652643|NCT00028574|Active Comparator|Gabapentin (7, 7, 14)|Oral Gabapentin 300 mg once daily on days 1-7, twice daily on days 8-14 and three times daily on days 15-28
11652644|NCT00028574|Placebo Comparator|Placebo|"Oral Placebo 300 mg on one of the following schedules:
~once daily on days 1-28
~once daily on days 1-7, twice daily on days 8-28
~once daily on days 1-7, twice daily on days 8-14 and three times daily on days 15-28"
11652645|NCT00028561|Experimental|Treatment (ixabepilone, carboplatin)|Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15 followed by carboplatin IV over 1 hour on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after achieving CR or up to a total of 6 courses
11652646|NCT00028548|Experimental|XK469|
11652647|NCT00028535|Experimental|Arm I|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15 and paclitaxel IV over 3 hours on day 1 of course 1. Beginning with course 2, patients receive trastuzumab and paclitaxel as in course 1 and interleukin-12 subcutaneously on days 2, 5, 9, 12, 16, and 19. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
11652648|NCT00028522|Experimental|Treatment (chemotherapy)|"SCHEDULE A: Patients receive R(+)XK469 IV over 30 minutes on days 1, 3, and 5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R(+)XK469 until the recommended phase II dose or MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued and treated at the recommended phase II dose (for a maximum of 20 patients treated at that dose).
~SCHEDULE B: Once the recommended phase II dose is determined on schedule A, additional patients are accrued and receive escalating doses of R(+)XK469 IV over 30-60 minutes on day 1, beginning at a reduced dose. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Dose escalation continues as in Schedule A."
11652649|NCT00028496|Experimental|Treatment (vaccine therapy, sargramostim, vaccine adjuvant)|"The first three cohorts of 3-12 patients receive escalating doses of recombinant fowlpox-CEA-TRICOM vaccine (fCEA-TRI) until the maximum tolerated dose (MTD) is determined. fCEA-TRI is administered intradermally every 2 weeks for 4 doses and then every 2 months thereafter (beginning on day 56) in the absence of disease progression or unacceptable toxicity.
~The fourth and fifth cohorts of 6 patients receive fCEA-TRI at the MTD in the same manner as the first three cohorts combined with escalating doses of sargramostim (GM-CSF). GM-CSF is administered subcutaneously once daily beginning on the day of each vaccination and continuing for a total of 4 days.
~The sixth through eighth cohorts of 6 patients receive fCEA-TRI at the MTD in the same manner as the first three cohorts combined with escalating doses of recombinant fowlpox-GM-CSF (rF-GM-CSF)."
11652650|NCT00028028|Experimental|Arm I|Patients receive low-dose CCI-779 IV over 30 minutes once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
11652651|NCT00028028|Experimental|Arm II|Patients receive high-dose CCI-779 as in arm I.
11652652|NCT00028002|Experimental|Arm I|Patients receive oral imatinib mesylate once daily. Treatment continues for 8 weeks in the absence of disease progression. Patients with disease progression are considered for immediate surgical resection. Otherwise, after 8 weeks, patients undergo surgical resection to debulk all gross tumor. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for 2 years.
11652653|NCT00027976|Experimental|Group 1 active arm|receipt of active drug
11652654|NCT00027976|Experimental|Group 2 active arm|receipt of active drug
11652655|NCT00027976|Experimental|group 2 placebo arm|receipt of placebo
11652656|NCT00027963|Experimental|gabapentin|"Patients receive titrating doses of oral gabapentin twice daily and then three times daily for 3 weeks. Patients then receive a fixed dose of oral gabapentin three times daily for 3 weeks. Patients cross-over to therapy as in arm II at week 8.
~Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14."
11652657|NCT00027963|Placebo Comparator|placebo|"Patients receive titrating doses of oral placebo and then a fixed dose of oral placebo as in arm I. Patients cross-over to therapy as in arm I at week 8.
~Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14."
11652658|NCT00027898|Experimental|Treatment (bortezomib, carboplatin, and etoposide)|Patients receive bortezomib IV on days 1 and 8, carboplatin IV over 30 minutes on day 1, and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
11652659|NCT00027885|Active Comparator|Docetaxel|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
11652660|NCT00027885|Experimental|Combine bevacizumab and docetaxel.|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
11653785|NCT00041548|Experimental|1|Nitric Oxide for Inhalation
11652661|NCT00027872|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-21. Patients with a complete or partial response, hematologic improvement, or stable disease continue treatment every 29-63 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response after the second course of therapy receive 2 additional courses of therapy.
11652662|NCT00027846|No Intervention|GTR1 Differentiated Histology Supratentorial (Group 1)|Patients undergo observation.
11652663|NCT00027846|Experimental|Radiation (Group 2)|Supratentorial Anaplastic Ependymoma (GTR1, GTR2, NTR) and Anaplastic or Differentiated Infratentorial Ependymoma (GTR1, GTR2, NTR) and Supratentorial Differentiated Ependymoma(GTR2, NTR). Patients undergo conformal radiation therapy to the brain once daily 5 days a week for 6-6½ weeks.
11652664|NCT00027846|Experimental|Sub-Total Resection Any Histology or Location (STR) (Group 3)|Patients receive an initial course of chemotherapy comprising vincristine sulfate IV on days 1 and 8, carboplatin IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on days 1 and 2. Patients also receive filgrastim (G-CSF) subcutaneously or IV beginning on day 3 and continuing until blood counts recover. Patients then receive a second course of chemotherapy comprising vincristine sulfate IV on days 1 and 8, carboplatin IV over 1 hour on day 1, and oral etoposide on days 1-21. After completion of chemotherapy, patients are evaluated for second therapeutic conventional surgery. Patients who have unresectable disease undergo conformal radiation therapy. Patients who have resectable disease undergo second surgery followed by conformal radiotherapy.
11652665|NCT00027820|Experimental|Treatment (PBSCT)|"REDUCED-INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -4, -3, and -2 and undergo TBI on day 0.
~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.
~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO every 8 hours on days 0-40 with taper to day 96."
11652666|NCT00027807|Experimental|Aldesleukin, Sargramostim & therapeutic autologous lymphocytes|Peripheral blood mononuclear cells (PBMC) for the generation of ATC will be collected using 1 or 2 phereses to obtain 8-20 × 109 PBMC for T cell expansion. The PBMC will be activated with OKT3 and expanded in IL-2 to generate from 20-320 ×109 ATC during a maximum of 14 days of culture. Three patients will be treated at each dose level. The dose levels for each infusion are: 5, 10, 20, and 40 billion. Each patient will receive a total of 8 doses of armed ATC given twice weekly for 4 weeks. If the patients encounter toxicities related to armed ATC, the dose and administration will be modified as delineated per the protocol. The patients will also receive subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion. GM-CSF (250μg/m2 twice per week) will given subcutaneously to start 3 days before the 1st armed ATC infusion and ending 7 days after the last dose of armed ATC.
11652667|NCT00027703|Experimental|Arm I|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-60 minutes (beginning after gemcitabine infusion) and bevacizumab IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), complete response (CR), or partial response (PR) after the sixth course may receive bevacizumab as a single agent once every 3 weeks in the absence of disease progression or unacceptable toxicity.
11652668|NCT00027703|Experimental|Arm II|Patients receive gemcitabine and cisplatin as in arm I and placebo IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats as in arm I. Patients who achieve SD, CR, or PR after the sixth course may receive placebo as a single agent once every 3 weeks in the absence of disease progression.
11652669|NCT00027690|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11652670|NCT00027586|Experimental|Imatinib Mesylate|400 mg twice a day orally
11652671|NCT00027573|Experimental|Chemotherapy + stem cell transplantation|"Patients receive fludarabine IV over 30 minutes on days -7 to -3 and cyclophosphamide IV over 1-2 hours on days -4 and -3. Allogeneic peripheral blood stem cells are infused on day 0. Patients then receive filgrastim (G-CSF) subcutaneously daily beginning on day 5 and continuing until blood counts recover.
~Patients receive graft-versus-host disease (GVHD) prophylaxis comprising oral tacrolimus twice daily on days -1 to 90 and methotrexate IV on days 1, 3, and 6.
~After day 120, patients with persistent disease and no signs of active GVHD may receive donor lymphocyte infusion (DLI). DLI may be repeated every 8 weeks for a total of 2 infusions.
~Patients are followed every 2 months for 1 year and then every 6 months for 4 years OR every 2 months for 6 months and then every 6 months for 4.5 years if patient receives DLI."
11652672|NCT00027560|Experimental|TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES|This is a stratified single-armed phase II study designed to investigate the safety and efficacy of hematopoietic cell allografts administered after nonmyeloablative cytoreduction.
11652673|NCT00027534|Experimental|TRICOM-CEA(6D)|Subjects receiving TRICOM-CEA(6D)
11652674|NCT00026494|Experimental|Temozolomide and Vinorelbine|Patients will be treated with vinorelbine on days 1 and 8 of each cycle; temozolomide will be administered on days 1 to 7 and 15 to 21 of each cycle. The dose level of temozolomide will be given at a dose of 150 mg/m2/day. A cycle will be defined as 28 days of treatment.
11652675|NCT00026403|Experimental|radiotherapy + gemcitabine + cisplatin|"Patients undergo radiotherapy once daily five days a week for 5.5 weeks. Patients receive gemcitabine IV over 30 minutes followed by cisplatin IV over 1 hour twice a week for the first 3 weeks of radiotherapy. Beginning 4 weeks after the completion of radiotherapy, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for a total of 3 courses in the absence of disease progression or unacceptable toxicity.
~Quality of life is assessed at baseline, at completion of radiotherapy, at completion of chemotherapy, and 3 months after completion of therapy.
~Patients are followed every 3 months for 2 years and then every 6 months for 1 year."
11652676|NCT00026338|Active Comparator|OSI-774 plus Gemcitabine|
11652677|NCT00026338|Active Comparator|Placebo plus gemcitabine|
11652678|NCT00026312|Active Comparator|Arm I (isotretinoin) (closed to accrual as of 4/16/2009)|Beginning preferably between day 56 and day 85 post-ASCT, but may be delayed up to day 200, patients receive isotretinoin PO BID for 14 days. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients may cross over to Arm II provided they have not experienced disease progression and have not received any further anti-neuroblastoma therapy following completion of isotretinoin therapy.
11653786|NCT00041548|Placebo Comparator|2|oxygen
11654374|NCT00012649||Group 1|
11652679|NCT00026312|Experimental|Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin)|Beginning preferably between day 56 and day 85 post-ASCT, but may be delayed up to day 200, patients receive immunotherapy comprising sargramostim SC or IV over 2 hours on days 0-13 during courses 1, 3, and 5 and dinutuximab IV over 10-20 hours on days 3-6 of courses 1-5. Patients also receive aldesleukin IV continuously on days 0-3 and 7-10 during courses 2 and 4. Immunotherapy repeats every 28 days for 5 courses in the absence of disease progression or unacceptable toxicity. Patients also receive isotretinoin as in Arm I beginning on day 11 of immunotherapy.
11652680|NCT00026299|Experimental|Phase 2: Oxaliplatin plus ZD1839|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 and ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily (as determined during phase 1). Subjects can continue to receive the combination for 6 cycles (each cycle is 21 days). After 6 cycles of the combination, subjects can continue to take ZD1839 alone until their cancer worsens.
11652681|NCT00026299|Experimental|Phase 2: Oxaliplatin alone|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 for up to 6 cycles. Each cycle will last 21 days.
11652682|NCT00026299|Experimental|Phase I: Oxaliplatin with ZD1839|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2. ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily.
11652683|NCT00026247|Experimental|RFA as pain therapy|Changes in the severity of pain as measured using using the Memorial Pain Assessment Cards (MPAC) before and after RadioFrequency Ablation (RFA) will be statistically analyzed
11652684|NCT00026234|Experimental|Treatment (chemotherapy)|Patients receive floxuridine and dexamethasone intra-arterially continuously on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 6 weeks for 4 courses in the absence of disease recurrence or unacceptable toxicity. After completion of the fourth course, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for 2 courses in the absence of disease recurrence or unacceptable toxicity.
11652685|NCT00026221|Experimental|Arm I (monoclonal antibody and biological therapy)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive low-dose interferon alfa (IFN-alpha) SC on days 1-14.
11652686|NCT00026221|Experimental|Arm II (monoclonal antibody)|Patients receive bevacizumab as in arm I.
11652687|NCT00026221|Experimental|Arm III (monoclonal antibody and biological therapy)|Patients receive bevacizumab as in arm I. Patients also receive high-dose IFN-alpha SC on days 1, 3, 5, 8, 10, and 12.
11652688|NCT00026208|Experimental|Stanford V-C + Low-dose Radiotherapy|"Sanford V-C = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide.
~Radiotherapy = 20 Gy modified involved field radiotherapy"
11652689|NCT00026208|Experimental|Stanford V-C only|"Sanford V-C = Vinblastine, cyclophosphamide, doxorubicin, prednisone, bleomycin, + etoposide."
11652690|NCT00026195|Experimental|irinotecan|"Patients receive irinotecan IV over 90 minutes once weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
~Patients are followed for survival."
11652691|NCT00026182|Experimental|Arm I (rituximab and recombinant interleukin-12)|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients receive interleukin-12 SC twice weekly beginning on day 2 and continuing until disease progression.
11652692|NCT00026182|Experimental|Arm II (rituximab and recombinant interleukin-12)|Patients receive rituximab as in arm I. Patients are evaluated at week 12. Patients with stable or progressive disease receive interleukin-12 SC twice weekly until disease progression or for 24 weeks. Patients with a complete or partial response after rituximab are monitored until disease progression and then begin interleukin-12 SC twice weekly until further disease progression.
11652693|NCT00026169|Experimental|Treatment (imatinib mesylate)|"Patients receive oral imatinib mesylate once or twice daily on days 1 and 4-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients in each stratum receive escalating doses of imatinib mesylate until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
11652694|NCT00026143|Experimental|Arm I|Patients receive interleukin-12 IV over 5-15 seconds on day 1 and interferon alfa subcutaneously on days 2-6. Treatment repeats every 2 weeks in the absence of unacceptable toxicity. Patients are reassessed after 6 courses. Patients with a complete response receive 2 additional courses. Patients with a partial response or stable disease continue treatment in the absence of disease progression.
11652695|NCT00026130|Experimental|Gemcitabine + 5FU + XRT|Chemo and radiation therapy in the treatment of non-metastatic pancreatic cancer
11652696|NCT00026117|Experimental|BeneFin|"Patients receive oral shark cartilage (BeneFin™) 3-4 times daily. Treatment continues in the absence of unacceptable toxicity. Quality of life is assessed weekly for 1 month and then monthly thereafter during treatment.
~Patients are followed every 6 months for 5 years."
11652697|NCT00026117|Other|placebo|"Patients receive oral placebo 3-4 times daily. Treatment continues in the absence of unacceptable toxicity. Quality of life is assessed weekly for 1 month and then monthly thereafter during treatment.
~Patients are followed every 6 months for 5 years."
11652698|NCT00026104|Experimental|Arm I (radiation therapy, paclitaxel, gemcitabine)|Patients receive radiotherapy once daily, 5 days a week, for 5.5 weeks, beginning on day 1. Patients also receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, and 36.
11652699|NCT00026104|Experimental|Arm II (radiation therapy, tipifarnib)|Patients receive chemoradiotherapy as in arm I. Within 3-8 weeks after completion of chemoradiotherapy, patients without disease progression receive oral tipifarnib twice daily for 21 days.
11652700|NCT00026091|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide twice daily on days 1-7. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11652701|NCT00025675|Active Comparator|p450|p450 inhibitor
11652702|NCT00025675|Active Comparator|nonp450|not on p450 inhibitor
11652703|NCT00025662|Experimental|RFT5-SMPT-dgA Isolex system|RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin used in allogeneic stem cell transplantation (SCT) in older patients with hematologic malignancies using a graft manipulation process
11652704|NCT00025584|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV over 3-5 seconds twice weekly on weeks 1 and 2. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11654375|NCT00012636|Other|Arm 1|
11654376|NCT00012623||Group 1|
11652705|NCT00025506|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11652706|NCT00025493|Experimental|docetaxel|docetaxel
11652707|NCT00025415|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients within each stratum (except normal stratum) receive escalating doses of imatinib mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity
11652708|NCT00025389|Experimental|Arm A|Bevacizumab (15mg/kg, q3wk x 2), Paclitaxel (200 mg/m2, q3wk x 2), carboplatin (AUC of 6, q3wk x 2), followed by surgery 4 to 6 weeks after last dose of Bevacizumab
11652709|NCT00025363|Experimental|Arm I|Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
11652710|NCT00025363|Experimental|Arm II|Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 1 hour on days 1-5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
11652711|NCT00025337|Experimental|Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)|Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil (5-FU) IV over 22 hours on days 1 and 2.
11652712|NCT00025337|Experimental|Arm II (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin, leucovorin calcium, and 5-FU as in arm I.
11652713|NCT00025337|Experimental|Arm III (bevacizumab)|Patients receive bevacizumab as in arm I.
11652714|NCT00025259|Experimental|Arm I (Patients off-therapy before callback-Induction only)|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin sulfate IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, oral prednisone 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease.
11652715|NCT00025259|Experimental|Arm II (RER with CR [ABVE-PC, IFRT])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR undergo IFRT approximately 3 weeks after the last day of ABVE course 4.
11652716|NCT00025259|Experimental|Arm III (RER with CR [ABVE-PC])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR are randomized to receive no further treatment.
11652717|NCT00025259|Experimental|Arm IV (RER with less than CR [ABVE-PC, IFRT])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with VGPR, PR or SD undergo IFRT approximately 3 weeks after the last day of ABVE-PC course 4 for 5 days a week.
11652718|NCT00025259|Experimental|Arm V (RER with PD)|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients with PD are taken off therapy.
11652719|NCT00025259|Experimental|Arm VI (SER [DECA, ABVE-PC, IFRT])|Patients receive dexamethasone IV over 15 minutes, etoposide IV over 3 hours, and cytarabine IV over 3 hours on days 1-2. Patients receive 2 drops of dexamethasone ophthalmic solution every 6 hours on days 1, 2 and 3. Patients also receive cisplatin PO or IV over 12 hours as pre-hydration followed by continuous IV over 6 hours on day 1 and G-CSF SC beginning on day 3 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive 2 additional courses of ABVE-PC chemotherapy. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.
11652720|NCT00025259|Experimental|Arm VII (SER [ABVE-PC, IFRT])|Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive 2 additional courses of ABVE-PC. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy.
11652721|NCT00025246|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate daily beginning within 84 days of surgical resection. Treatment continues for 1 year in the absence of disease recurrence or unacceptable toxicity.
11652722|NCT00025233|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11652723|NCT00025220|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11653936|NCT00035984|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
11652724|NCT00025155|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 1 hour. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 2 additional courses after achieving CR.
11652725|NCT00025038|Experimental|Treatment (tipifarnib, bone marrow/umbilical cord transplant)|See detailed description.
11652726|NCT00025025||Arm I|"Participants eat no red meat and take no nonsteroidal anti-inflammatory drugs (NSAIDs) and no vitamin C or multivitamins for 3 days prior to and during stool sample collection. Participants collect stool samples 3 different times and perform fecal occult blood (FOB) test smears from each stool. After each collection, participants ship the whole stool and FOB test smear to their participating center for blinded multitarget DNA-based assay panel (MTAP) testing.
~Within 2 months after stool sample collection, participants have their blood drawn for additional MTAP testing and undergo colonoscopy."
11652727|NCT00025025||Arm II|"Participants take no vitamin C or multivitamins for 3 days before and during stool sample collection. Participants collect stool samples and FOB test smears and samples are tested as in arm I.
~Within 2 months after stool sample collection, participants have their blood drawn for additional MTAP testing and undergo colonoscopy."
11652728|NCT00024466|Experimental|Vaccine|Participants are vaccinated with GVAX one month or more after finishing induction therapy (which is given as per standard of care). Two weeks later, participants go through leukapheresis on protocol, then receive autologous transplant as per standard of care. GVAX is administered eight subsequent times after the autologous transplant.
11652729|NCT00024258|Experimental|Arsenic Trioxide|"Patients receive arsenic trioxide IV over 1-4 hours on days 1-5 and 8-12. Treatment repeats every 28 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
~Patients are followed every 2-3 months for 1 year and then annually thereafter."
11652730|NCT00024167|Experimental|Induction regimen A|Doxorubicin IV over 24 hours day 1; Oral ketoconazole 3 x daily on days 1-7 of weeks 1, 3, and 5; Vinblastine IV over 30 minutes Day 1, oral Estramustine 3 x daily on Days 1-7 of weeks 2, 4, and 6.
11652731|NCT00024167|Experimental|Induction regimen B|Oral Prednisone 2 x daily on days 1-21 (days 1-14 of course 5 only) and Docetaxel IV over 1 hour Day 1.
11652732|NCT00024167|Experimental|Consolidation arm I|Doxorubicin IV over 24 hours once weekly for 6 weeks + Strontium-89 IV once at beginning of chemotherapy.
11652733|NCT00024167|Experimental|Consolidation arm II|Doxorubicin as in Consolidation arm I.
11652734|NCT00024154|Experimental|Treatment (trastuzumab, gefitinib)|"Phase I (completed): Patients receive trastuzumab (Herceptin) IV over 30-90 minutes once weekly and oral gefitinib once daily beginning on day 1.
~Cohorts of 3-6 patients receive escalating doses of gefitinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is established, additional patients are accrued to the phase II portion of the study and are treated at that dose.
~Phase II: Patients receive oral gefitinib once daily (at the MTD established in phase I) and trastuzumab IV weekly until week 24, at which time trastuzumab is given every 3 weeks (with daily gefitinib) until disease progression or unacceptable toxicity."
11652735|NCT00024102|Active Comparator|Standard Chemotherapy|"Patient/Physician choice of cyclophosphamide + MTX + 5-FU
~OR
~Cyclophosphamide + doxorubicin"
11652736|NCT00024102|Experimental|Capecitabine|Treatment with capecitabine
11652737|NCT00024089|Experimental|Arm I|Patients receive oral gefitinib daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
11652738|NCT00023998|Experimental|Treatment (combination chemotherapy)|See detailed description.
11652739|NCT00023959|Experimental|Treatment (hydroxyurea, fluorouracil, bevacizumab, radiation)|Patients receive oral hydroxyurea every 12 hours on days 1-6, fluorouracil IV continuously on days 1-5, and bevacizumab IV over 90 minutes on day 1. Patients also undergo radiotherapy once daily on days 1-5. Patients receive G-CSF subcutaneously on days 6-12. Treatment repeats every 2 weeks for up to 7 courses in the absence of disease progression or unacceptable toxicity.
11652740|NCT00023946|Experimental|Treatment (ixabepilone)|Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
11652741|NCT00023920|Experimental|Treatment (bevacizumab, idarubicin, cytarabine)|Patients receive bevacizumab IV over 90 minutes once on day -13. Patients then receive bevacizumab IV over 90 minutes and idarubicin IV on days 1 and 15 and cytarabine subcutaneously (SC) once daily beginning on day 1. Treatment repeats every 4 weeks for a maximum of 3 courses. Patients with responding disease receive maintenance therapy comprising bevacizumab IV over 90 minutes on days 1 and 15, idarubicin IV on day 1, and cytarabine SC once daily beginning on day 1. Treatment repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
11652742|NCT00023829|Experimental|LH-RH agonist plus radiation therapy|Luteinizing hormone-releasing hormone (LH-RH) agonist x 2 years plus radiation therapy (RT) to 63.0 - 66.6 Gy
11652743|NCT00023829|Active Comparator|Radiation therapy alone|Radiation therapy alone to 63.0 - 66.6 Gy
11652744|NCT00023829|Active Comparator|LH-RH agonist alone|Luteinizing hormone-releasing hormone (LH-RH) agonist x 2 years
11652745|NCT00023764|Experimental|Arm I|Patients receive an infusion of bortezomib (dose of 1.8 mg/m2) over 3-5 seconds once weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response lasting at least 6 months may receive retreatment.
11652746|NCT00023751|Experimental|surgery + leucovorin + fluorouracil + radiation|"Patients with T3 disease or positive surgical margins after surgery are removed from study. Patients with T1 disease and negative surgical margins after surgery are observed. Patients with T2 disease and negative surgical margins after surgery receive adjuvant therapy.
~Beginning 42 days after surgery, T2 patients receive leucovorin calcium (CF) IV over 2 hours with fluorouracil (5-FU) IV bolus 1 hour into the infusion once weekly for 6 weeks. Beginning 2 weeks after the completion of chemotherapy, patients receive chemoradiotherapy comprising radiotherapy once daily 5 times a week for 5 weeks and 5-FU IV continuously while receiving radiotherapy. Beginning 2 weeks after the completion of chemoradiotherapy, patients again receive CF IV over 2 hours with 5-FU IV bolus 1 hour into the infusion once weekly for 6 weeks. Chemotherapy repeats after 2 weeks rest for a total of 2 courses.
~Patients are followed every 3 months for 2 years and then every 6 months for 5 years."
11652815|NCT00017173|Experimental|surgery with INGN 201 followed by chemo/RT|intraoperative and postoperative injections of INGN 201 into the tumor bed, followed by cisplatin and radiation therapy
11652747|NCT00023712|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11652748|NCT00023686|Experimental|surgery|"Patients undergo radical prostatectomy.
~Patients are followed every 6 months for 5 years and then annually thereafter."
11652749|NCT00023686|Experimental|radiation|"Patients undergo brachytherapy with implanted iodine I 125 or palladium Pd 103 seeds.
~Patients are followed every 6 months for 5 years and then annually thereafter."
11652750|NCT00023634|Experimental|EGFR vaccine with GMCSF|EGFR antisense DNA 500 mcg peptide w/GMCSF monthly x 6 m
11652751|NCT00023634|Experimental|EGFR vaccine with KLH|EGFR antisense DNA 500 mcg peptide w/KLH monthly x 6 m
11652752|NCT00022737|Experimental|Arm I|See Design Details.
11652753|NCT00022711|Experimental|Temozolomide|Temozolomide 150mg/m2/day daily. Repeat cycles every 28days for maximum of six months
11652754|NCT00022698|Experimental|Cohort 1,Initial Regimen:(Capecitabine + Irinotecan )|Participants will receive capecitabine (Xeloda) 1000 mg/m^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 125 mg/m^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks. A total of 12 cycles of treatment will be administered. At the discretion of the investigator, participants who are responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase. Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).
11652755|NCT00022698|Experimental|Cohort 2,Amended Regimen:(Capecitabine + Irinotecan)|Participants will receive capecitabine 900 mg/m^2, orally, twice daily, for 14 days (Day 2 through Day 15) every 3 weeks, along with irinotecan 100 mg/m^2 as a 90-minute intravenous (IV) infusion on Day 1 and Day 8, every 3 weeks. A total of 12 cycles of treatment will be administered. At the discretion of the investigator, participants who will be responding or whose disease is stable will be permitted to continue capecitabine/irinotecan combination therapy until progressive disease is documented in the post-study treatment phase. Participants not participating in post-study treatment will be followed every 3 months until time of death, loss to follow-up, or until median survival had been reached (whichever occurred first).
11652756|NCT00022672|Experimental|trastuzumab + anastrozole|Trastuzumab 4 mg/kg loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes plus 1 mg oral dose of anastrozole every day for 24 Months in the Main phase and in the Extension Phase.
11652757|NCT00022672|Active Comparator|anastrozole|1 mg oral dose of anastrozole every day for 24 Months in the Main phase. In the Extension Phase participants could cross-over to also receive trastuzumab 4 mg/kg initial loading dose intravenous (iv) over 90 minutes, followed by weekly doses of 2 mg/kg iv over 30 minutes.
11652758|NCT00022659|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652759|NCT00022646|Experimental|Arm I: pemetrexed + gemcitabine|Patients receive pemetrexed disodium IV over 10 minutes on day 1 followed by gemcitabine IV over 30 minutes on days 1 and 8.
11652760|NCT00022646|Experimental|Arm II: pemetrexed + gemcitabine|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 followed by pemetrexed disodium IV over 10 minutes on day 1.
11652761|NCT00022646|Experimental|Arm III: pemetrexed + gemcitabine|Patients receive gemcitabine IV over 30 minutes on day 1 and pemetrexed disodium IV over 10 minutes followed by gemcitabine IV over 30 minutes on day 8.
11652762|NCT00022633|Experimental|gemcitabine, paclitaxel|
11652763|NCT00022581|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
11652764|NCT00022555|Experimental|Treatment (bryostatin 1, vincristine sulfate)|Patients receive bryostatin 1 IV continuously on days 1 and 15 and vincristine IV over 5 minutes on days 2 and 16. Treatment continues every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
11652765|NCT00022516|No Intervention|No-CM|No further chemotherapy following standard adjuvant chemotherapy.
11652766|NCT00022516|Experimental|CM-Maintenance|12-month CM-maintenance regimen (C, cyclophosphamide 50 mg/day orally continuously and M, methotrexate 2.5 mg twice/day orally days 1 and 2 of every week for 1 year)
11652767|NCT00022490|Experimental|Cytarabine/ Imatinib Mesylate|
11652768|NCT00022412|Placebo Comparator|Observation, then prostatectomy|Arm 2: Patients undergo observation for 28 days. Patients then undergo prostatectomy.
11652769|NCT00022412|Active Comparator|Doxercalciferol once daily for 28 days|Dietary supplement once daily to treat prostate cancer for 28 days
11652770|NCT00022399|Experimental|Celecoxib|Participants receive celecoxib 400mg by mouth twice daily for 4 to 6 weeks prior to standard-of-care prostatectomy.
11652771|NCT00022399|Placebo Comparator|Placebo-control|Participants receive placebo for 4 to 6 weeks prior to standard-of-care prostatectomy.
11652772|NCT00022334|Experimental|Treatment|See intervention description.
11652773|NCT00022152|Experimental|vinorelbine|"Patients receive oral vinorelbine once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
~Quality of life is assessed at baseline and then after completion of the second course.
~Patients are followed every 3 months for 5 years."
11652774|NCT00022126|Experimental|Modified Augmented BFM Therapy|
11652775|NCT00022113|Experimental|Treatment (cilengitide)|Patients receive EMD 121974 IV over 1 hour twice weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11652776|NCT00022087|Experimental|Zoledronic acid initial tx|Zoledronic acid + calcium + Vit D for 2 years, followed by Calcium + vit D for 1 year
11652777|NCT00022087|Experimental|Calcium + Vit D initial Tx|Calcium + vitamin D for 1 year followed by zoledronic acid + calcium + vit D for 2 years
11652778|NCT00021255|Experimental|Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T)|Doxorubicin 60 mg/m² intravenous (IV) bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus injection on Day 1 of every 3 weeks for 4 cycles followed by docetaxel 100 mg/m² IV infusion every 3 weeks for another 4 cycles.
11652891|NCT00008385|Placebo Comparator|Arm I|Participants receive an oral yeast placebo as in arm II.
11653637|NCT00044798|Experimental|1|Participants will receive treatment with repetitive transcranial magnetic stimulation and citalopram.
11652779|NCT00021255|Experimental|AC followed by Docetaxel + Herceptin (AC→TH)|Doxorubicin 60 mg/m² IV bolus injection in combination with cyclophosphamide 600 mg/m² IV bolus Injection on Day 1 of every 3 weeks for 4 cycles. Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg by IV infusion weekly starting from Day 8; and docetaxel 100 mg/m² IV infusion on Day 2 of Cycle 5, then on Day 1 of every 3 weeks for all subsequent cycles ( total 4 cycles). After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.
11652780|NCT00021255|Experimental|Docetaxel + Carboplatin + Herceptin (TCH)|Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 1 only, followed by Herceptin 2 mg/kg IV infusion weekly starting from Day 8 until three weeks after the last cycle of chemotherapy. Docetaxel 75 mg/ m² IV infusion on Day 2 of Cycle 1, then on Day 1 of all subsequent cycles followed by carboplatin IV infusion at target AUC = 6 mg/mL/min repeated every 3 weeks for a total of 6 cycles. After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg by IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.
11652781|NCT00021242|Experimental|Relapsed or Refractory ALL, AML|Docetaxel 60 mg/m^2 per dose weekly (Days 1,8,15) for 3 weeks followed by 1 week of rest.
11652782|NCT00021229|Experimental|Imatinib mesylate|
11652783|NCT00021216|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652784|NCT00021073|Experimental|Treatment (alvocidib, combination chemotherapy)|"Group I: Patients receive FLAVO IV over 24 hours on day 1 and CF IV and 5-FU IV over 1.5 hours daily on days 2-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of FLAVO and 5-FU until the MTD are determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.
~Once the MTDs for FLAVO and 5-FU are determined, patients receive FLAVO, CF, and 5-FU as in group I plus irinotecan IV over 1.5 hours on day 1. Courses repeat as in group I. Cohorts of 3-6 patients receive escalating doses of irinotecan until the MTD is determined. The MTD is defined as in group I."
11652785|NCT00021060|Experimental|Arm I (paclitaxel and carboplatin)|"Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 15-30 minutes on day 1.
~Treatment in both arms repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
11652786|NCT00021060|Experimental|Arm II (paclitaxel, carboplatin, and bevacizumab)|"Patients receive paclitaxel and carboplatin as in arm I followed by bevacizumab IV over 30-90 minutes on day 1.
~Treatment in both arms repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
~After completion of 6 courses, patients in arm II with stable or responding disease continue to receive bevacizumab only. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
11652787|NCT00020943|Experimental|Chemo/immuno/autolog transplant|Intensive chemotherapy followed by autologous stem cell transplant and immunotherapy for mantle cell lymphoma
11652788|NCT00020878|Experimental|Study|See intervention description.
11652789|NCT00020826||gastric adenocarcinoma|No protocol specific interventions. Both palliative or curative treatment allowed.
11652790|NCT00020761|Experimental|Gastro Esophogeal cohort|"Patients with adenocarcinoma of the esophagus, gastroesophageal (GE) junction and gastric cardia (GE cohort)
~The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.
~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.
~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
11652791|NCT00020761|Experimental|Distal Stomach cohort|"Patients with adenocarcinoma of the rest of the stomach (Distal Stomach cohort)
~The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.
~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.
~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
11652792|NCT00020735|Experimental|oral toremifene|
11652793|NCT00020735|Other|observation|
11652794|NCT00020722|Experimental|therapeutic autologous lymphocytes|
11652795|NCT00020709|Experimental|Arm I (gefitinib, combination chemotherapy, radiation)|"Patients receive induction therapy comprising cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning within 24 hours after starting chemotherapy, patients receive concurrent induction radiotherapy 5 days a week for 5 weeks and then boost radiotherapy 5 days a week for 1.5 weeks.
~Beginning approximately 4-8 weeks after completion of chemoradiotherapy, patients with stable or responding disease receive consolidation therapy comprising docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 3 courses.
~Patients with stable or responding disease are randomized to one of two treatment arms for maintenance therapy. Patients begin maintenance therapy approximately 4-7 weeks after completion of consolidation therapy.
~Patients receive oral gefitinib daily."
11652796|NCT00020709|Experimental|Arm II (placebo, combination chemotherapy, radiation)|"Patients receive induction therapy comprising cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning within 24 hours after starting chemotherapy, patients receive concurrent induction radiotherapy 5 days a week for 5 weeks and then boost radiotherapy 5 days a week for 1.5 weeks.
~Beginning approximately 4-8 weeks after completion of chemoradiotherapy, patients with stable or responding disease receive consolidation therapy comprising docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 3 courses.
~Patients with stable or responding disease are randomized to one of two treatment arms for maintenance therapy. Patients begin maintenance therapy approximately 4-7 weeks after completion of consolidation therapy.
~Patients receive oral placebo daily. In both arms, maintenance therapy continues for a maximum of 5 years in the absence of disease progression or unacceptable toxicity."
11652797|NCT00020683|Experimental|Arm I (low dose incyclinide)|"Patients receive low-dose oral COL-3 once daily.
~Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed."
11652798|NCT00020683|Experimental|Arm II (high dose incyclinide)|"Patients receive high-dose oral COL-3 once daily.
~Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed."
11652892|NCT00008385|Experimental|Arm II|Participants receive oral selenium yeast daily for 6 months. Treatment repeats every 6 months for 8 courses for a total of 4 years in the absence of unacceptable toxicity.
11653981|NCT00034814|Experimental|2|Enzyme-inducing Talampanel 35 mg TID
11652799|NCT00020670|Experimental|CD40 Cell Vaccination|Patients will undergo tumor cell collection followed by vaccine preparation and then vaccination. Autologous acute lymphoblastic leukemia (ALL) cells are harvested, cultured with CD40 ligand, pulsed with keyhole limpet hemocyanin (KLH), and then irradiated to produce the vaccine. Patients receive either 1 x 10^7 or 1 x 10^8 CD40 cells/vaccination depending on the number of tumor cells obtained. Vaccinations are administered every two weeks as outpatient therapy. Evaluable patients receive the course of at least 4 vaccinations at weeks 0, 2, 4, 6. Patients may continue receiving vaccinations every 2 weeks if chemotherapy is not required for symptomatic disease.
11652800|NCT00020566|Experimental|Group 1|Patients receive 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Patients requiring radiotherapy to the axial tumor also undergo concurrent radiotherapy 5 days a week. Some patients may then undergo surgical resection of the tumor. All patients will then receive vincristine IV on day 1 and dactinomycin IV and ifosfamide IV over 3 hours on days 1 and 2 (VAI). Treatment repeats every 21 days for 8 courses (courses 7-14). Patients requiring radiotherapy to the brain and/or spinal cord also undergo concurrent radiotherapy.
11652801|NCT00020566|Experimental|Group 2, arm I|Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive 7 additional courses of VAI chemotherapy (courses 8-14). Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent whole-lung radiotherapy for 6-12 days.
11652802|NCT00020566|Experimental|Group 2, arm II|Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive high-dose chemotherapy comprising oral busulfan every 6 hours on days -6 to -3 and melphalan IV over 30 minutes on day -2. Patients receive autologous PBSC IV on day 0. Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent radiotherapy 5 days a week for at least 5 weeks.
11652803|NCT00019747|Experimental|Arm 1 - Thalidomide once daily|Patients receive oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
11652804|NCT00019747|Placebo Comparator|Arm 2 - Placebo once daily|Patients receive oral placebo once daily.
11652805|NCT00019708|Experimental|Treatment (tanespimycin)|Patients will receive infusions of tanespimycin analogue twice a week in weeks 1 and 3.
11652806|NCT00019682|Experimental|Arm I (aldesleukin)|Patients receive aldesleukin IV over 15 minutes every 8 hours for 12 doses. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease 3 weeks after completing 2 courses may receive a maximum of 12 additional courses. Patients with complete response may receive a maximum of 2 additional courses.
11652807|NCT00019682|Experimental|Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin)|Patients receive gp100 antigen emulsified in Montanide ISA-51 SC on day 1. Patients also receive aldesleukin as in Arm I beginning on day 2. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease 3 weeks after completing 2 courses may receive a maximum of 12 additional courses. Patients with complete response may receive a maximum of 2 additional courses.
11652808|NCT00019604|Experimental|Radiofrequency ablation in liver cancer|This trial is designed to gain experience with the use of ablation devices with liver tumors. Radiofrequency ablation is a procedure that heats tumors to several degrees above body temperature and may kill tumor cells.
11652809|NCT00017563|Experimental|Docetaxel, Mitoxantrone, Conventional Surgery|"Drug: Docetaxel-35 mg/m2 i.v. over 15 - 30 minutes will be administered immediately after the mitoxantrone on the same schedule.
~Drug: Mitoxantrone-Initial dose will be 2 mg/m2 weekly for 3 of every 4 weeks. The dose will then be escalated as described in the dose escalation section up to a maximum dose of 6 mg/m2 weekly for 3 of every 4 weeks.
~Procedure/Surgery: Conventional Surgery- Prostatectomy will be scheduled 2-4 weeks after the last dose of chemotherapy"
11652810|NCT00017472|Experimental|Arm I|Patients receive apolizumab IV over at least 2 hours on days 1, 2, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a complete or partial response who relapse after 2 months may receive an additional course of therapy provided they still express the 1D10 antigen.
11652811|NCT00017381|Experimental|Treatment|"PART I: Patients receive rituximab IV on days 1, 8, 15, and 22 and cyclophosphamide IV over 1 hour on day 25. G-CSF is administered SC daily beginning on day 26 and continuing until autologous PBSC are harvested.
~PART II: Beginning 4-6 weeks after completion of the fourth rituximab infusion, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1 followed by dosimetry imaging on days 1, 2, 4, and 7. Patients then receive IDEC-Y2B8 IV over 10 minutes once between days 8-15.
~PART III: All patients undergo PBSCT beginning after residual bone marrow radioactivity resolves. G-CSF is administered SC beginning 1 day after PBSCT and continuing until blood counts recover."
11652812|NCT00017251|Experimental|Treatment (oblimersen sodium, carboplatin, etoposide)|Patients receive G3139 IV continuously on days 1-8, carboplatin IV over 30 minutes on day 6, and etoposide IV over 1 hour on days 6-8. Treatment repeats every 3 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression.
11652813|NCT00017238|Experimental|Treatment (KRN5500)|"Patients receive KRN5500 IV over 24-72 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 1-3 patients receive KRN5500 at the starting dose over escalating infusion durations. After the longest duration of infusion time is safely reached, cohorts of 3-6 patients receive escalating doses of KRN5500 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued to receive treatment with KRN5500 at the recommended phase II dose."
11652814|NCT00017186|Experimental|gemcitabine + epirubicin|"Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and epirubicin IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR) receive 2 additional courses beyond CR.
~Quality of life is assessed at baseline, prior to course 3, at 3 months, and then at 1 year.
~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
11652893|NCT00008346|Other|SFM then FFDM|Screen Film Mammography (SFM) followed by Full Field Digital Mammography (FFDM)
11652816|NCT00017147|Experimental|O6-BG + BCNU + Radiation Therapy|O6-BG: 120 mg/m^2 IV over 1 hour on day 1 of each cycle BCNU: 40 mg/m^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose. Radiation Therapy: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
11652817|NCT00017147|Active Comparator|BCNU + Radiation Therapy|BCNU: 40 mg/m^2 IV over 1 hour on day 1 of each cycle. Radiation Therapy: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
11652818|NCT00017121|Experimental|sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) twice a day on days 1-7 and 15-21. Treatment repeats every 28 days for 2 courses. Patients with no disease progression after completion of course 2 may continue on treatment until disease progression. Patients are grouped to 1 of 2 dose-escalation regimens (part A vs B).
~After completion of study therapy, patients are followed at 3 months, every 2 months for 1 year, and then every 3-4 months for 5 years."
11652819|NCT00017095|Active Comparator|non taxane based chemotherapy|either FEC 100 or Canadian CEF or Tailored FEC for 6 cycles
11652820|NCT00017095|Experimental|taxane based chemotherapy|Docetaxel for 3 cycles followed by Epirubicin/Docetaxel for 3 cycles
11652821|NCT00017004|Experimental|Arm I|Patients undergo radiotherapy comprising pelvic external beam radiotherapy daily five days a week for 5 weeks, followed by either 1 or 2 implants of low-dose rate intracavitary brachytherapy or 5 fractions of high-dose rate intracavitary brachytherapy, followed by 3-5 days of parametrial boost radiotherapy. Patients receive cisplatin IV concurrently with pelvic external beam radiotherapy on days 1, 8, 15, 22, 29, and once during the week of parametrial boost radiotherapy.
11652822|NCT00017004|Experimental|Arm II|Patients undergo radiotherapy and chemotherapy as in arm I. Additionally, patients receive epoetin alfa subcutaneously once weekly concurrently with radiotherapy and chemotherapy.
11652823|NCT00016952|Experimental|irinotecan|"Prior oxaliplatin-based chemotherapy: Patients receive irinotecan IV over 90 minutes on day 1. Treatment repeats every 3 weeks.
~Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a confirmed complete response for 2 consecutive courses may discontinue treatment at investigator's discretion.
~Quality of life is assessed at baseline, approximately every 6 weeks during treatment, and then after the last course of treatment.
~Patients are followed every 3 months for 5 years."
11652824|NCT00016952|Experimental|leucovorin + fluorouracil|"Prior to irinotecan and oxaliplatin combination chemotherapy: Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV continuously on days 1 and 2. Treatment repeats every 2 weeks.
~Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a confirmed complete response for 2 consecutive courses may discontinue treatment at investigator's discretion.
~Quality of life is assessed at baseline, approximately every 6 weeks during treatment, and then after the last course of treatment.
~Patients are followed every 3 months for 5 years."
11652825|NCT00016913|Experimental|Neo-Adj ChemoTx + ablation prior to RT|Patients with localized high-risk prostate cancer were treated with 4 cycles (16 weeks) of continuous weekly paclitaxel at 80 mg/m^2 intravenously with estramustine at 280 mg orally 3 times a day for 5 days a week and carboplatin (area under the curve of 6) on Day 1 of every cycle followed by 3-dimensional conformal or intensity-modulated radiotherapy (total dose of 77.4 gray [Gy] in 1.8-Gy fractions). All patients received androgen deprivation therapy with either goserelin acetate at 3.6 mg subcutaneously or leuprolide acetate at 7.5 mg intramuscularly monthly for 6 months starting at Day 1 of therapy.
11652826|NCT00016432|Experimental|Group 1|Exemestane
11652827|NCT00016432|Placebo Comparator|Group 2|Placebo
11652828|NCT00016406|Active Comparator|AC followed by P|doxorubicin and cyclophosphamide followed by paclitaxel followed by surgery
11652829|NCT00016406|Experimental|AC+G followed by P|weekly doxorubicin and daily cyclophosphamide with filgrastim followed by paclitaxel followed by surgery
11652830|NCT00016354|Experimental|benzoylphenylurea|
11652831|NCT00016328|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes once weekly for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11652832|NCT00016302|Experimental|Regimen A|See detailed description.
11652833|NCT00016302|Experimental|Regimen B|"Induction (weeks 1-9): Patients receive treatment as in induction of regimen A.
~Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.
~Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen A and nelarabine IV on days 162-166.
~Maintenance (weeks 30-101): Patients receive oral mercaptopurine daily on days 1-28 and 36-56; oral methotrexate weekly; and nelarabine IV on days 29-33. Treatment repeats every 8 weeks for 4 courses. Beginning on week 62, patients receive vincristine IV once; oral prednisone three times daily for 5 days; oral mercaptopurine daily; and oral methotrexate weekly. Treatment repeats every 8 weeks for 5 courses."
11652834|NCT00016302|Experimental|Regimen C|"Induction (weeks 1-5): Patients receive treatment as in induction (weeks 1-5) on regimen A and nelarabine IV over 1 hour on days 29-33.
~If bone marrow is M1, patients begin week 6 of induction therapy on day 36 or when peripheral blood counts recover. If bone marrow is M2, patients begin week 6 of induction therapy immediately. If bone marrow is M3, treatment discontinues.
~Induction (weeks 6-9): Patients receive treatment as in induction (weeks 6-9) on regimen A.
~Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.
~Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen B.
~Maintenance (weeks 30-101): Patients receive treatment as in maintenance on regimen B."
11652835|NCT00016302|Experimental|Regimen D|See detailed description.
11652836|NCT00016302|Experimental|Regimen E|Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen D, but nelarabine is administered at a higher dose.
11652837|NCT00016302|Experimental|Regimen F|Patients receive nelarabine at a higher dose during induction therapy. Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen E.
11652838|NCT00016289|Experimental|Treatment (recombinant interleukin-12)|Patients receive interleukin-12 intraperitoneally once weekly. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease receive 2 additional courses.
11652894|NCT00008346|Other|FFDM then SFM|Full Field Digital Mammography (FFDM) followed by Screen Film Mammography (SFM)
11653982|NCT00034814|Experimental|3|Enzyme-inducing TLP 50mg TID
11652839|NCT00016146|Experimental|vaccine|"This is a dose-escalation study of GPI-0100.
~Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant GPI-0100 subcutaneously weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity or disease progression.
~Cohorts of 5 patients receive escalating doses of GPI-0100 until the optimal dose, based on antibody response, is reached.
~Patients are followed every 3 months."
11652840|NCT00016094|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for a maximum of 24 courses in the absence of disease progression or unacceptable toxicity.
11652841|NCT00016016|Experimental|Treatment (flavopiridol, cytarabine, mitoxantrone)|Patients receive flavopiridol IV over 1 hour on days 1-3 and cytarabine IV continuously on days 6-9 followed by mitoxantrone IV over 30-150 minutes on day 9. Patients achieving a partial or complete response after the first course of therapy may receive an additional course of therapy beginning 35 ± 7 days after blood count recovery.
11652842|NCT00015977|Experimental|PSMA peptide vaccine|Immunization with PSMA peptide vaccine followed by injection of Interleukin-12 (IL-12) on Day 1 of a 21-day cycle. Additional injections of IL-12 given on Days 3 and 5 of each cycle.
11652843|NCT00015938|Experimental|treatment|docetaxel and vinorelbine with filgrastim support
11652844|NCT00015873|No Intervention|A no VIMARAM|No VIMARAM preceding maintenance treatment
11652845|NCT00015873|Experimental|B - VIMARAM|VCR i.v. 1.5 mg/m2/d - 4 days 6-MP p.o. 25 mg/m2/d - 15 days HD-MTX p.i.(24hr) 5 g/m2 - 2 days MTX + pred I.T. (age adapted) - 2 days HD-Ara-C p.i (3hr) 3 g/m2/12 hrs -8 days L-ASP p.i. (1hr) 5.000 U/m2 - 2 days
11652846|NCT00015834|Experimental|Treatment (imatinib mesylate, cytarabine)|Patients who have not previously received imatinib mesylate receive oral imatinib mesylate daily on days 1-35. Patients who have previously received imatinib mesylate for at least 28 days receive oral imatinib mesylate on days 22-35. All patients receive cytarabine IV over 2 hours every 12 hours on days 29-32. Patients with more than 5% residual blasts in bone marrow on day 28 receive a second course in the absence of disease progression or unacceptable toxicity.
11652847|NCT00014612|Active Comparator|axillary lymph node dissection|complete axillary lymph node dissection
11652848|NCT00014612|Experimental|axillary radiotherapy|axillary radiotherapy, daily for 5 days a week, for 5 weeks
11652849|NCT00014495|Experimental|bismuth Bi 213 monoclonal antibody M195 & cytarabine|"Patients receive cytarabine IV continuously on days 1-5. Beginning between days 7 and 14, patients receive Bi213 MOAB M195 IV over 5 minutes up to 4 times daily over 1-4 days. Patient also receive filgrastim (G-CSF) subcutaneously daily beginning 24 hours after the final Bi213 MOAB M195 infusion and continuing until blood counts recover. Treatment continues in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3 to 6 patients receive escalating doses of Bi213 MOAB M195 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, subsequent patients are treated at the MTD.
~Patients are followed twice weekly for 4 weeks and then monthly for 3 months"
11652850|NCT00014378|Experimental|Chinese Herb Huanglian (Coptis chinesis)|
11652851|NCT00014235|Experimental|Arm I (indolent disease)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.
~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.
~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to 56 with a taper to day 180 and mycophenolate mofetil PO BID or IV every 8-12 hours on days 0 to 27."
11652852|NCT00014235|Experimental|Arm II (aggressive disease)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate and undergo TBI as in Arm I.
~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.
~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to 56 with a taper to day 70 and mycophenolate mofetil as in Arm I."
11652853|NCT00014222|Active Comparator|Arm 1: CEF|6 cycles - q 28 days (6 months) - Cyclophosphamide 75 mg/m2 - po - Days 1-14 - Epirubicin 60 mg/m2 - IV - Days 1 and 8 - 5 Fluorouracil: 500mg/m2 - IV - Days 1 and 8 + Continuous Antibiotic Prophylaxis with Cotrimoxazole 960 mg (i.e.2x480 mg tablets) po-bid or Ciprofloxacin 500 mg - po-bid
11652854|NCT00014222|Active Comparator|Arm 2: EC/T|6 cycles - q 14 days (3 months) - Epirubicin 120 mg/m2 - IV - Day 1 - Cyclophosphamide 830 mg/m2 - IV - Day 1 - Filgrastim 5μg/kg/d - SC - Days 2 - 13 + Epoetin Alfa 40,000 IU - SC - once weekly (to begin within 1 week after start of protocol therapy as needed) 21 days from last administration of EC (EC/T) 4 cycles - q 21 days (3 months) - Adriamycin 60 mg/m2 - IV - Day 1 - Cyclophosphamide 600 mg/m2 - IV - Day 1 - 21 days from last administration of AC 4 cycles - q 21 days (3 months) - Paclitaxel 175 mg/m2 IV 3 hour infusion
11652855|NCT00014222|Active Comparator|Arm 3: AC/T|4 cycles - q 21 days (3 months) - Adriamycin 60 mg/m2 - IV - Day 1 - Cyclophosphamide 600 mg/m2 - IV - Day 1 21 days from last administration of AC 4 cycles - q 21 days (3 months) - Paclitaxel 175 mg/m2 IV 3 hour infusion
11652856|NCT00014196|Experimental|chemo/RT followed by consolidation chemo|cisplatin docetaxel radiation therapy
11652857|NCT00014131|Experimental|Biological/Vaccine|Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
11652858|NCT00014079||Group 1|"DNA is examined for unstable elements (microsatellite instability and loss of heterozygosity) by analyzing at least 10 separate (CA)n-repeats localized to 5 separate chromosomes (5q, 8p, 15, 17p, and 18q). Loss of heterozygosity is analyzed for at least four chromosomal arms (5q, 8p, 17p, and 18q) and later other chromosomes (e.g., 1, 14, and 22). Immunohistochemistry is used to test for the presence or absence of the genes involved in DNA mismatch repair (hMLH1 and hMSH2).
~Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment."
11652859|NCT00012376|Experimental|Treatment (bryostatin 1 and sargramostim)|Patients receive bryostatin 1 IV continuously and GM-CSF subcutaneously once daily on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with disease stabilization or improvement may continue treatment for up to 12 courses.
11652860|NCT00012363|Experimental|Gemcitabine + Irinotecan|Gemcitabine 1000mg/m2 IV over 30 min on Days 1,8 q21days; Irinotecan 100mg/m2 IV over 90 min on Days 1,8 q21days
11652895|NCT00008216||alloSCT group|Patients undergoing allogeneic blood or marrow stem cell transplantation (alloSCT).
11652915|NCT00006469|Other|Single arm study|Concurrent Paclitaxel, Carboplatin, and External-Beam Radiation Followed by Surgical Resection in Locally Advanced Non-Small-Cell Lung Cancer
11652861|NCT00012298|Experimental|Treatment (radiolabeled monoclonal antibody therapy)|Patients receive rituximab IV on days 1 and 8, indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1, and yttrium Y 90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) and interleukin-11 SC until blood counts recover.
11652862|NCT00012220|Active Comparator|Gemcitabine|Standard treatment
11652863|NCT00012220|Experimental|Gemcitabine + cisplastin|Addition of cisplastin to gemcitabine
11652864|NCT00012220|Experimental|Gemcitabine + docetaxel|Addition of docetaxel to gemcitabine
11652865|NCT00012220|Experimental|Gemcitabine + Irinotecan|Addition of irinotecan to gemcitabine
11652866|NCT00012194|Experimental|Treatment (7-hydroxystaurosporine, cisplatin)|Patients receive cisplatin IV over 1 hour on day 1 and UCN-01 IV continuously over 36-72 hours on day 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11652867|NCT00012181|Experimental|Treatment (alvocidib)|Patients receive flavopiridol IV over 1 hour on days 1-3. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
11652868|NCT00012064|Experimental|Biological/Vaccine|"Biological/Vaccine: therapeutic autologous dendritic cells.
~Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product."
11652869|NCT00012025|Experimental|fulvestrant|"Patients receive fulvestrant intramuscularly on day 1. Courses repeat approximately every 28 days in the absence of disease progression or unacceptable toxicity.
~Patients are followed every 3 months for 5 years or until disease progression. After disease progression, patients are followed every 3 months for 2 years and then every 6 months for 3 years."
11652870|NCT00012012|Experimental|Radiation therapy plus cisplatin|Patients receive extended field external beam radiation therapy (RT) to the para-aortic region and pelvis, intracavitary brachytherapy with concurrent weekly cisplatin.
11652871|NCT00012012|Experimental|Radiation therapy plus cisplatin and amifostine|Patients receive extended field external beam radiation therapy (RT) to the para-aortic region and pelvis, intracavitary brachytherapy with concurrent weekly cisplatin and amifostine trihydrate.
11652872|NCT00011999|Experimental|Surgery, chemotherapy and radiation therapy|Early post-operative paclitaxel followed by paclitaxel and cisplatin concurrent with radiation therapy for resected head and neck cancer.
11652873|NCT00011986|Active Comparator|Arm I|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment continues every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
11652874|NCT00011986|Experimental|Arm II|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and gemcitabine IV over 30 minutes on days 1 and 8.
11652875|NCT00011986|Experimental|Arm III|Patients receive chemotherapy as in arm I during courses 1-8 and doxorubicin HCl liposome IV over 1 hour on day 1 during courses 1, 3, 5, and 7. Treatment continues as in arm I.
11652876|NCT00011986|Experimental|Arm IV|Patients receive topotecan IV over 30 minutes on days 1-3 and carboplatin IV over 30 minutes on day 3. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy.
11652877|NCT00011986|Experimental|Arm V|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 8. Treatment continues every 3 weeks for 4 courses. Patients then receive 4 courses of arm I chemotherapy. Patients with initial unresectable or suboptimal residual disease (more than 1 cm) may undergo interval cytoreductive surgery between courses 4 and 5 of chemotherapy.
11652878|NCT00010257|Experimental|Paclitaxel plus Carboplatin|Paclitaxel 225 mg/m2 IV over 3 hours and Carboplatin AUC 6.0 IV over 30 minutes on day 1 of a 21-day cycle
11652879|NCT00010218|Experimental|karenitecin|"Patients receive karenitecin IV over 60 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease after 6 courses may receive 2 additional courses beyond best response.
~Patients are followed every 3 months for 1 year and then every 6 months thereafter."
11652880|NCT00010205|Experimental|Treatment (benzoylphenylurea)|Patients receive oral benzoylphenylurea weekly for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of benzoylphenylurea until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose-limiting toxicity.
11652881|NCT00010192|Experimental|Treatment (rituximab and aldesleukin)|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients then receive low-dose aldesleukin SC on days 29-39, 43-53, 57-67, and 71-81, and intermediate-dose aldesleukin SC on days 40-42, 54-56, 68-70, and 82-84.
11652882|NCT00009984|Experimental|Arm I (thalidomide)|Patients receive oral thalidomide once daily in the absence of disease progression or unacceptable toxicity.
11652883|NCT00009984|Experimental|Arm II (thalidomide, fludarabine phosphate)|Patients receive thalidomide as in arm I and fludarabine IV over 30 minutes on days 1-5. Treatment with fludarabine repeats every 28 days for 6 courses. Once fludarabine is completed, patients continue to receive thalidomide alone as in arm I.
11652884|NCT00009971|Experimental|Arm I|Patients receive oral fenretinide twice daily on days 1-7. Treatment continues every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
11652885|NCT00009945|Experimental|Arm 1: Clodronate|Patient receives 2 tablets once daily for 3 years.
11652886|NCT00009945|Placebo Comparator|Arm 2: Placebo|Patient receives 2 tablets once daily for 3 years.
11652887|NCT00008697|Experimental|Phase 1|"Cohort 1 Arsenic trioxide = 0.1 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)
~Cohort 2 Arsenic trioxide = 0.15 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)
~Cohort 3 Arsenic trioxide = 0.20 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)
~Cohort 4 Arsenic trioxide = 0.25 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)
~Cohort 5 Arsenic trioxide = 0.30 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)"
11652888|NCT00008697|Experimental|Phase 2|Arsenic trioxide = MTD found in Phase 1 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)
11652889|NCT00008411|Experimental|Docetaxel Weekly|Arm I: Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days.
11652890|NCT00008411|Experimental|Docetaxel Every 3 Weeks|Arm II: Docetaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days.
11652896|NCT00008138|Experimental|chemo/debulking surgery/IP chemo|neoadjuvant chemotherapy (carboplatin and paclitaxel) followed by debulking surgery followed by intraperitoneal chemotherapy (carboplatin and paclitaxel)
11652897|NCT00007904|Experimental|Arm A: Combination Chemotherapy|Paclitaxel IV continuously over 72 hours on days 1-3 and cyclophosphamide IV on days 1-3. Filgrastim subcutaneously (SC) beginning on day 5 and continuing until blood counts recover or pegfilgrastim SC on day 5. Treatment repeats every 21 days for 3 courses. Then doxorubicin hydrochloride IV on day 1 and filgrastim SC beginning on day 2 and continuing until blood counts recover or pegfilgrastim SC on day 2. Treatment repeats every 21 days for 4 courses. Patients with hormone-receptor positive tumors receive oral tamoxifen citrate or oral anastrozole daily for 5 years following chemotherapy. Beginning 3-6 weeks after completion of chemotherapy, patients undergo radiation therapy 5 days a week for 6-7 weeks.
11652898|NCT00006994|Active Comparator|L-glutamine in suspension + radiation|20 cc three times daily for 60 days plus radiation therapy.
11652899|NCT00006994|Placebo Comparator|Placebo in suspension + radiation|20 cc three times daily for 60 days plus radiation therapy.
11652900|NCT00006942|Experimental|Treatment (bryostatin 1, cisplatin)|Patients receive bryostatin 1 IV continuously over 72 hours immediately followed by cisplatin IV over 1 hour. Treatment continues every 3 weeks for a minimum of 2 courses in the absence of disease progression.
11652901|NCT00006929|Experimental|Treatment (suramin, paclitaxel, carboplatin)|Patients receive suramin IV over 30 minutes on days 1 and 2. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
11652902|NCT00006916|Experimental|Radiation therapy followed by bleomycin via Ommaya reservoir|60.0 Gy/30 fractions x 2.0 Gy. Then within 2-6 weeks after completion of radiation therapy or at the time a patient experiences disease progression during or immediately after completion of radiation therapy, if clinically feasible, a modified Ommaya reservoir is implanted with the delivery catheter in the tumor or tumor cyst/cavity. Bleomycin, 15 units per week, is then given via the Ommaya reservoir without interruption for a maximum of two years as long as there is no toxicity above grade 3 or evidence of disease progression.
11652903|NCT00006903|Experimental|Treatment (fulvestrant)|Patients receive fulvestrant intramuscularly on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
11652904|NCT00006773|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11652905|NCT00006760|Experimental|Treatment (ifosfamide, vinorelbine, filgrastim)|Patients receive ifosfamide IV over 24 hours on days 1-4 and vinorelbine tartrate IV over 6-10 minutes on days 1 and 5. Patients also receive filgrastim (G-CSF) subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover. Treatment repeats at least every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients may receive a third course of therapy at the discretion of the investigator. Heavily pretreated, high-risk patients who achieve a complete response are eligible for stem cell transplantation. Patients undergo peripheral blood stem cell (PBSC) collection during hematopoietic recovery after the second course of chemotherapy. Patients with sufficient PBSCs collected may undergo PBSC transplantation on protocol COG-AHOD0121.
11652906|NCT00006747|Experimental|chemotherapy + stem cell transplantation|"Patients receive carmustine, etoposide, cytarabine and melphalan on day -1. Patients undergo allogeneic peripheral blood stem cell (PBSC) transplantation on day 0. Patients also receive tacrolimus on day -2 and then orally twice daily until day 120 and methotrexate on days 1, 3, and 6 as graft-versus-host disease (GVHD) prophylaxis. Patients receive sargramostim daily beginning on day 7 and continuing until blood counts recover.
~Patients with no active GVHD who have persistent disease on day 150 or progressive disease at any time after PBSC transplantation receive donor lymphocytes IV over 2 hours. Patients may receive additional donor lymphocytes at least 8 weeks later if disease persists.
~Patients are followed at 6 and 12 months post-transplantation and then annually for 4 years."
11652907|NCT00006734|Experimental|Regimen A|Test the hypothesis that chemotherapy given every two weeks (Regimen B) will produce higher event-free survival. Treatment will occur in two phases: Induction and Continuation, with 14 cycles of chemotherapy in all. Induction consists of the first twelve weeks (four cycles on Regimen A. The cycles alternate between vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, MESNA and ifosfamide, etoposide, MESNA. G-CSF (Filgrastim) is given between chemotherapy doses. Local control (Surgery, Radiation Therapy, or a combination) will begin on Week 13 which will be after four cycles of chemotherapy.
11652908|NCT00006734|Experimental|Regimen B|Conventional every-three-week chemotherapy for patients with Ewing sarcoma and related tumors. Treatment will occur in two phases: Induction and Continuation, with 14 cycles of chemotherapy in all. Induction consists of the first twelve weeks six cycles on Regimen B). The cycles alternate between vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, MESNA and ifosfamide etoposide MESNA. G-CSF (Filgrastim) is given between chemotherapy doses. Local control (surgery, Radiation Therapy, or a combination) will begin on Week 13, which will be after six cycles of chemotherapy.
11652909|NCT00006721|Active Comparator|Arm I (CHOP only)|"Patients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day
~1. Patients also receive oral prednisone daily on days 1-5. Treatment continues every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. (Arm I closed to accrual as of 12/15/02)"
11652910|NCT00006721|Experimental|Arm II (CHOP + rituximab)|Patients receive cyclophosphamide IV over 15 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on days 8, 29, 50, 71, 92, and 113. Patients also receive oral prednisone daily on days 8-12, 29-33, 50-54, 71-75, and 113-117 and rituximab IV over 4-6 hours on days 1, 6, 48, 90, 134, and 141.
11652911|NCT00006721|Experimental|Arm III (CHOP + tositumomab)|Patients receive chemotherapy as in arm I and tositumomab (monoclonal antibody anti-B1) IV over 1 hour followed by iodine I 131 tositumomab IV over 20 minutes on days 134 and 141.
11652912|NCT00006695|Experimental|Arm I|Iodine-131 Anti-B1 Antibody/BEAM/autologous hematopoietic stem cell transplantation (AHSCT)
11652913|NCT00006473|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
11652914|NCT00006471|Experimental|Fenretinide|
11654377|NCT00012610|Other|Arm 1|
11652916|NCT00006462|Experimental|Relapsed acute lymphoblastic and acute Myelogenous leukemia|Gemcitabine hydrochloride will be given as 10 mg/m2/min x 360 minutes weekly for three weeks. After a one-week rest period it may be repeated in patients without progressive disease or limiting toxicity.
11652917|NCT00006461|Other|Chemotherapy, surgery, radiation therapy|Patients receive induction chemotherapy consisting of vincristine sulfate IV on days 1, 8, and 15; cisplatin IV over 6 hours on day 1; cyclophosphamide IV over 30 minutes on day 2; and oral etoposide daily on days 2-22. Treatment repeats every 28 days for a total of 4 courses. After completion of induction chemotherapy, patients with residual disease undergo a therapeutic conventional surgery (second resection). Within 4 weeks after completion of induction chemotherapy or second resection, patients receive 3-dimensional conformal radiation therapy daily, 5 days a week, for 6 weeks. Four weeks after completion of 3-dimensional conformal radiation therapy, patients receive alternating treatments of maintenance chemotherapy. Patients receive vincristine sulfate IV on days 1, 8, and 15 and cyclophosphamide IV over 30 minutes on day 1 of courses 1, 3, 5, and 7 and oral etoposide daily on days 1-21 of courses 2, 4, 6, and 8. Treatment continues every 28 days for 8 courses.
11652918|NCT00006392|Experimental|Vitamin E + selenium placebo|vitamin E and selenium placebo daily for 7-12 years
11652919|NCT00006392|Experimental|Selenium + vitamin E placebo|selenium and vitamin E placebo daily for 7-12 years
11652920|NCT00006392|Experimental|Vitamin E + selenium|vitamin E and selenium placebo daily for 7-12 years
11652921|NCT00006392|Placebo Comparator|Vitamin E placebo + selenium placebo|vitamine E placebo and selenium placebo daily for 7-12 years
11652922|NCT00006389|Experimental|Treatment|Patients receive bryostatin 1 IV over 72 hours on days 1-3 followed by cisplatin IV over 1 hour on day 4. Treatment repeats every 3 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
11652923|NCT00006386|Experimental|External beam radiotherapy with stereotactic boost|External beam radiotherapy (EBXRT): 50 Gy in 25 daily fractions of 2 Gy. Stereotactic radiotherapy (SRT) boost: 4 treatments of 5 or 7 Gy, once per week during weeks 3-6. Patients will not receive EBXRT on the SRT treatment days.
11652924|NCT00006373|Experimental|TIME|Topotecan, Ifosfamide, Mesna and Etoposide
11652925|NCT00006364|Experimental|Treatment (omacetaxine mepesuccinate)|"Remission induction therapy: Patients receive remission induction therapy comprising homoharringtonine IV continuously over 24 hours on day 1 and then subcutaneously (SC) twice daily on days 2-14 for course 1. Subsequent courses of remission induction therapy comprise homoharringtonine SC twice daily on days 1-14. Treatment continues monthly for at least 2 courses.
~Maintenance therapy: Patients with complete hematologic remission receive maintenance therapy comprising homoharringtonine SC twice daily on days 1-7 monthly for 3 years in the absence of disease progression or unacceptable toxicity."
11652926|NCT00006363|Experimental|Induction Arm I|Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV over 5-10 minutes followed by etoposide IV over 2 hours on days 1-3. Patients with 20% or greater bone marrow cellularity and greater than 5% leukemia blasts at the end of the first course receive a second course of cytarabine IV continuously on days 1-5 and daunorubicin IV over 5-10 minutes followed by etoposide IV over 2 hours on days 1 and 2.
11652927|NCT00006363|Experimental|Induction Arm II|Patients receive PSC 833 IV continuously on days 1-3 and cytarabine, daunorubicin, and etoposide as in arm I. Patients with 20% or greater bone marrow cellularity and greater than 5% leukemia blasts at the end of the first course receive a second course of PSC 833 IV continuously on days 1 and 2 and cytarabine, daunorubicin, and etoposide as in arm I.
11652928|NCT00006363|Experimental|Intensification Favorable|Patients receive HiDAC IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats no earlier than 28 days after the prior course and no later than 14 days after hematopoietic recovery for two more courses.
11652929|NCT00006363|Experimental|Intensification Unfavorable PBSCT Group|Patients receive etoposide IV continuously and HiDAC IV over 2 hours every 12 hours on days 1-4. Patients also receive G-CSF SC daily beginning on day 14 and continuing until PBSC collection is completed. Patients who are not able to undergo PBSCT after HiDAC/etoposide continue treatment in the non-PBSCT group. At least 4 weeks after HiDAC/etoposide recovery, patients receive oral busulfan every 6 hours on days -7 to -4 and etoposide IV over 4 hours on day -3 prior to PBSCT. Patients receive autologous PBSC infusion on day 0. Patients also receive G-CSF SC beginning on day 0 and continuing until hematopoietic recovery.
11652930|NCT00006363|Experimental|Intensification Unfavorable Non-PBSCT Group|Patients receive etoposide, HiDAC, and G-CSF as in the PBSCT group. After hematopoietic recovery, patients then receive HiDAC IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats no earlier than 28 days after prior course and no later than 14 days after hematopoietic recovery for one more course.
11652931|NCT00006363|Experimental|Immunotherapy Arm I|Patients begin therapy no later than 120 days after the first day of the last course of HiDAC treatment OR day 0 of PBSCT. Patients receive low-dose IL-2 SC on days 1-14, 19-28, 33-42, 47-56, 61-70, and 75-90. In addition, patients receive high-dose IL-2 SC on days 15-17, 29-31, 43-45, 57-59, and 71-73.
11652932|NCT00006363|Active Comparator|Immunotherapy Arm II|Patients are observed and receive no further therapy.
11652933|NCT00006359|Experimental|Androgen suppression + EBRT + Brachytherapy|Androgen suppression with external beam radiation therapy followed by brachytherapy boost
11652934|NCT00006252|Experimental|Allogeneic Stem Cell Tx|minimal ablation and cellular immune therapy with allogeneic donor stem cell therapy
11652935|NCT00006249|No Intervention|observation|5 years observation + 5 years follow up
11652936|NCT00006249|Experimental|pegylated interferon alfa|5 years pegylated interferon alfa + 5 years follow up
11652937|NCT00006244|Experimental|Treatment (immunotherapy)|Patients receive melphalan IV over 2-3 hours on day -2 and an infusion of IL-2-treated autologous or syngeneic peripheral blood stem cells on day 0. Beginning on day 0, patients also receive IL-2 IV continuously over 5 days followed by 2 days off. Treatment with IL-2 repeats weekly for 4 weeks. Beginning 1 month later, patients undergo maintenance therapy comprising interferon alfa SC 3 times a week in the absence of disease progression or unacceptable toxicity.
11652938|NCT00006237|Active Comparator|Arm I|Patients receive interferon alfa IV on days 1-5 of weeks 1-4 followed by interferon alfa subcutaneously (SC) on days 1, 3, and 5 of weeks 5-52 in the absence of disease progression or unacceptable toxicity.
11652984|NCT00005957|Experimental|Breast Radiation plus regional radiation|regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)
11653983|NCT00034814|Placebo Comparator|4|Non-enzyme-inducing placebo TID
11652939|NCT00006237|Experimental|Arm II|Patients receive cisplatin IV over 30 minutes followed by vinblastine IV on days 1-4. Patients also receive dacarbazine IV over 1 hour on day 1, interleukin-2 IV over 96 hours on days 1-4, and interferon alfa SC on days 1-5, 8, 10, and 12. In addition, patients receive filgrastim (G-CSF) SC on days 6-15. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
11652940|NCT00006228|Experimental|Treatment (trastuzumab and aldesleukin)|Patients receive trastuzumab IV over 30-90 minutes on days 1 and 8 and aldesleukin SC on days 2-7 and 9-21. Beginning on day 22, patients receive trastuzumab IV over 30 minutes every 14 days. Patients also receive aldesleukin SC daily on days 1-14. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
11652941|NCT00006227|Experimental|Treatment (paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity.
11652942|NCT00006226|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide daily for 4 weeks. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
11652943|NCT00006221|Experimental|Arm I|"Patients receive BMS-247550 IV over 1 hour once weekly on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose level. Patients treated at the MTD receive treatment once weekly on weeks 1-3 of each 4-week course."
11652944|NCT00006125|Experimental|Doxorubicin + topotecan|"Patients receive doxorubicin IV over 5-10 minutes on day 1 and topotecan IV over 30 minutes on days 3-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression.
~Patients are followed every 6 months for 2 years and annually for the next 3 years."
11652945|NCT00006124|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib twice daily.
11652946|NCT00006124|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo twice daily.
11652947|NCT00006110|Experimental|Neo-adjuvant Herceptin with or without radiation|Chemotherapy followed by Taxol plus Herceptin followed by surgery followed by radiation (or no radiation) followed by additional Herceptin
11652948|NCT00006110|Experimental|Non-Herceptin with or without radiation|Chemotherapy followed by Taxol followed by surgery followed by radiation (or no radiation)
11652949|NCT00006107|Experimental|Taxotere|"Taxotere: (1 hour infusion once a week for four weeks)
~Radiation Therapy (5 days/week for 6-7 weeks)
~Surgery (if required) 14 -12 weeks after radiotherapy
~Follow-up"
11652950|NCT00006105|Experimental|Administration of Cisplatin, Gemcitabine, and Amifostine|Subjects receive the study drug combination in 29-day cycles. Gemcitabine (1000 mg/m2) is given by IV infusion on Days 1, 8, and 15 of each cycle. Cisplatin (70 mg/m2) is given by IV infusion on Day 1 of each cycle. Immediately prior to each cisplatin infusion amifostine (910 mg/m2) will be given by IV infusion.
11652951|NCT00006102|Experimental|Arm I|"Patients with solid tumors are stratified according to tumor histology (neuroblastoma vs Ewing's sarcoma [closed to accrual as of 5/19/03]/peripheral primative neuroectodermal tumor [PNET] vs osteosarcoma [closed to accrual as of 5/19/03] vs rhabdomyosarcoma vs non-Hodgkin's lymphoma vs other solid tumors). Patients with CNS tumors are stratified according to tumor histology (medulloblastoma/PNET vs ependymoma vs brainstem glioma vs other CNS tumors).
~Patients receive rebeccamycin analogue IV over 1 hour on day 1. Treatment continues every 21 days for a total of 16 courses in the absence of disease progression or unacceptable toxicity."
11652952|NCT00006101|Experimental|eflornithine|500mg/d for 12 months
11652953|NCT00006101|Placebo Comparator|Placebo|placebo for 12 months
11652954|NCT00006094|Experimental|Treatment (oxaliplatin, fluorouracil, EBRT)|Patients receive oxaliplatin IV over 1 hour on day 1, fluorouracil IV continuously on days 1-7, and radiotherapy on days 1-5. Treatment repeats weekly for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
11652955|NCT00006092|Experimental|Arsenic Trioxide Treatment|Patients receive arsenic trioxide IV over 2-3 hours daily for 28 days. Patients who respond may receive a second course of therapy beginning 28 days from the last dose of the first course.
11652956|NCT00006089|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11652957|NCT00006029|Active Comparator|vinorelbine + gemcitabine + doxorubicin - higher doses|"Patients who have not undergone prior transplantation receive vinorelbine, gemcitabine, and doxorubicin HCl liposome.
~Patients are followed every 6 months for 2 years and then annually for 6 years."
11652958|NCT00006029|Experimental|vinorelbine + gemcitabine + doxorubicin - lower doses|"Patients who have undergone prior transplantation receive lower doses of vinorelbine, gemcitabine, and doxorubicin HCl liposome.
~Patients are followed every 6 months for 2 years and then annually for 6 years."
11652959|NCT00006024|Experimental|Pre and Post radiation Chemotherapy|
11652960|NCT00006017|Active Comparator|Rebeccamycin 1 day|Patients receive rebeccamycin analogue IV over 1 hour on day 1.
11652961|NCT00006017|Active Comparator|Rebeccamycin 5 day|Patients receive rebeccamycin analogue IV over 1 hour on days 1-5.
11652962|NCT00006016|Experimental|Treatment (thalidomide, chemoembolization)|Patients receive oral thalidomide daily beginning 4 weeks before the first planned chemoembolization procedure. Thalidomide administration is stopped 24 hours before each chemoembolization procedure, and then restarted at 24 hours after completion of each procedure OR when blood counts and levels of bilirubin and transaminases recover, whichever occurs later. Thalidomide treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo placement of a visceral arterial catheter. Patients receive doxorubicin as a chemoemulsion via the arterial catheter into 1 hepatic lobe only under angiographic guidance. Immediately after delivery of the chemoemulsion, patients undergo particulate embolization. The opposite lobe, if involved, is treated within 3-5 weeks of treatment of the initial lobe. Patients are reevaluated for repeat chemoembolization within 8-12 weeks of the last chemoembolization.
11652963|NCT00006015|Experimental|Combination Chemotx|Combination chemotherapy for metastatic colorectal cancer in patients who have disease progression after 5-FU and/or irinotecan-containing therapy
11653590|NCT00047411|Active Comparator|1|Intervention: Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines.
11652964|NCT00006011|Experimental|Arm I (doxorubicin, cisplatin, filgrastim, pegfilgrastim)|Patients receive doxorubicin IV over 30 minutes immediately followed by cisplatin IV over 1 hour on day 1. Patients also receive filgrastim (G-CSF) SC or pegfilgrastim on days 2-11.
11652965|NCT00006011|Experimental|Arm II (doxorubicin, cisplatin, paclitaxel, filgrastim)|Patients receive doxorubicin and cisplatin as in arm I, paclitaxel IV over 3 hours on day 2, and G-CSF SC or pegfilgrastim on days 3-12. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
11652966|NCT00006010|Experimental|docetaxel + gemcitabine|"Patients receive docetaxel IV over 15-60 minutes and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks. Patients achieving complete response after 2 courses of therapy receive 2 additional courses of therapy. Patients with stable disease or partial response continue therapy until disease progression.
~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
11652967|NCT00006007|Experimental|gemcitabine + pemetrexed|"Patients receive gemcitabine IV over 30 minutes on days 1 and 8. pemetrexed disodium IV is administered over 10 minutes 90 minutes following gemcitabine on day 8. Treatment continues every 21 days for a minimum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients achieving a complete response receive 2 additional courses.
~Patients are followed every 3 months for 5 years."
11652968|NCT00006006|Experimental|Arm I|Patients receive oral thalidomide once daily. Patients on a stable dose of thalidomide for at least 4 weeks with evidence of progressive disease receive interferon alfa subcutaneously twice daily. Treatment continues in the absence of disease progression after initiation of interferon alfa therapy or unacceptable toxicity.
11652969|NCT00006003|Experimental|Treatment (semaxanib)|Patients receive SU5416 IV over 60 minutes twice weekly for 4 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
11652970|NCT00005984|Experimental|Patients with CML|Patients treated for chronic accelerated phase and/or chronic myelogenous leukemia (CML)
11652971|NCT00005983|Active Comparator|surgery|surgery followed by observation
11652972|NCT00005983|Experimental|surgery followed by RT|Surgery followed by radiation therapy
11652973|NCT00005982|Experimental|Treatment (nelarabine)|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment continues every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
11652974|NCT00005976|Experimental|Arm I|"Patients receive carboplatin IV over 30 minutes and pyrazoloacridine IV over 3 hours on day 1. Treatment continues every 28 days in the absence of unacceptable toxicity or disease progression.
~Cohorts of 3-6 patients receive escalating doses of carboplatin and pyrazoloacridine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
11652975|NCT00005976|Experimental|Arm II|Patients receive the same treatment as given in study 1. Dose escalation is performed as in study 1 to determine the MTD in patients not receiving concurrent anticonvulsants.
11652976|NCT00005976|Experimental|Arm III|Patients receive the same treatment as given in studies 1 and 2 without dose escalation.
11652977|NCT00005973|Experimental|Treatment|Patients receive BMS-214662 IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
11652978|NCT00005970|Experimental|Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor)|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 20-30 minutes on day 1. Treatment repeats every 3 weeks for 4 courses. Patients then receive paclitaxel IV over 1 hour beginning on day 1 of week 13 and continuing weekly for 12 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
11652979|NCT00005970|Experimental|Arm II (AC, paclitaxel, trastuzumab, tamoxifen)|Patients receive doxorubicin hydrochloride, cyclophosphamide, and paclitaxel as in arm I. Patients then receive trastuzumab (Herceptin®) IV over 30-90 minutes beginning on day 1 of week 25 and continuing weekly for 52 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
11652980|NCT00005970|Experimental|Arm III (AC, paclitaxel, trastuzumab, tamoxifen)|"Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I. Patients then receive paclitaxel IV over 1 hour and trastuzumab IV over 30-90 minutes beginning on day 1 of week 13 and continuing weekly for 12 courses. Patients then receive trastuzumab IV over 30 minutes beginning on day 1 of week 25 and continuing weekly for 40 courses in the absence of disease progression or unacceptable toxicity.
~Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy."
11652981|NCT00005967|Experimental|Arm I|Patients receive oral tipifarnib twice daily for 21 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 1 course of therapy, patients may receive subsequent therapy at the maximum tolerated dose at the investigator's discretion.
11652982|NCT00005961|Experimental|Arm I|Patients receive O6-benzylguanine IV over 1 hour, followed 1 hour later by carmustine IV over 1 hour on day 1. Treatment continues every 6 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
11652983|NCT00005957|Active Comparator|Standard Breast Irradiation|
11653638|NCT00044798|Active Comparator|2|Participants will receive treatment with sham repetitive transcranial magnetic stimulation and citalopram.
11652985|NCT00005949|Experimental|Treatment (gp100:209-217, aldesleukin )|Patients receive gp100:209-217(210M) emulsified in Montanide ISA-51 SC on day 1 and interleukin-2 SC on days 1-5 and 8-13. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Patients with a CR receive 3 additional courses after achieving CR.
11652986|NCT00005945|Experimental|Induction Not Randomized|Standard Induction (28 Days). M3 Marrow at Day 28 and Off Protocol Therapy.
11652987|NCT00005945|Experimental|Induction and Oral MTX, Double Delayed Intensification CNS|Patients with CNS disease at diagnosis, without other unfavorable characteristics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Cranial radiation therapy during the Consolidation phase.
11652988|NCT00005945|Experimental|Induction and Augmented regimen (IV MTX, Double DI)|Patients with unfavorable characteristics. Standard Induction (14 Days), Augmented Induction (Days 14-35), Consolidation (9 weeks), Interim Maintenance I (56 Days), Delayed Intensification I (2 months), Interim Maintenance II (2 months), Delayed Intensification II (2 months), then Maintenance (84 day courses).
11652989|NCT00005945|Experimental|Induction and Oral MTX, Single Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months) then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
11652990|NCT00005945|Experimental|Induction and Oral MTX, Double Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
11652991|NCT00005945|Experimental|Induction and IV MTX, Single Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months) then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
11652992|NCT00005945|Experimental|Induction and IV MTX, Double Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in event free remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
11652993|NCT00005879|Placebo Comparator|Placebo|Placebo
11652994|NCT00005879|Experimental|Arzoxifene|LY353381, 20 mg daily
11652995|NCT00005858|Experimental|Arm I|"Patients receive LMB-9 immunotoxin IV continuously for 10 days. Treatment continues every 30 days in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of LMB-9 immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
11652996|NCT00005856|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression.
11652997|NCT00005851|Experimental|Treatment (nonmyeloablative donor PBSC transplantation)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose TBI on day 0.
~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.
~IMMUNOSUPRESSION: Patients receive cyclosporine PO BID or IV QD or BID on days -3 to 35 with taper to day 56, and mycophenolate mofetil PO or IV over 2 hours TID on days 0-40.
~DLI: Patients with stable mixed chimerism on day 56 with no evidence of GVHD may receive escalating doses of non-mobilized DLI over 30 minutes. Patients may receive up to 4 DLIs at escalating doses if there is disease progression with no evidence of GVHD."
11652998|NCT00005850|Experimental|gemcitabine + cisplatin + fluoxetine|Patients receive gemcitabine and cisplatin. Treatment repeats every 21 days for a total of six cycles. Patients receive fluoxetine for 7 weeks. Further use of fluoxetine is at the discretion of the patient and physician.
11652999|NCT00005840|Experimental|Treatment (paclitaxel, cisplatin, abdominal radiotherapy)|"Patients receive paclitaxel IV over 1 hour and cisplatin IV on days 1, 8, 15, 22, 29, and 36. Patients also undergo whole abdominal radiotherapy for 5 consecutive days weekly for 6 weeks.
~Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose level."
11653000|NCT00005838|Experimental|Arm I (shark cartilage extract AE-941)|"Patients receive oral AE-941 (Neovastat) twice daily beginning on day 1 or within 10 days of initiation of chemotherapy.
~All patients receive induction chemotherapy with 1 of the following platinum-based regimens: cisplatin IV on days 1, 22, 50, and 71 and vinorelbine IV on days 1, 8, 22, 29, 50, 57, 71, and 78 carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on days 1, 22, 50, 57, 64, 71, 78, and 85.
~All patients receive radiotherapy beginning on day 50 for 6 weeks. Treatment in both arms continues in the absence of unacceptable toxicity."
11653001|NCT00005838|Placebo Comparator|Arm II (placebo)|"Patients receive oral placebo twice daily beginning on day 1 or within 10 days of initiation of chemotherapy.
~All patients receive induction chemotherapy with 1 of the following platinum-based regimens: cisplatin IV on days 1, 22, 50, and 71 and vinorelbine IV on days 1, 8, 22, 29, 50, 57, 71, and 78 carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on days 1, 22, 50, 57, 64, 71, 78, and 85.
~All patients receive radiotherapy beginning on day 50 for 6 weeks. Treatment in both arms continues in the absence of unacceptable toxicity."
11653232|NCT00003501|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11654378|NCT00012597|Other|Arm 1|
11653002|NCT00005831|Experimental|Treatment (trastuzumab, combination chemotherapy)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15; paclitaxel IV over 3 hours and carboplatin IV over 15 minutes on day 1; and gemcitabine IV over 30 minutes on days 1 and 8. Courses repeat every 3 weeks. Patients achieving a complete response (CR) receive 3 courses past CR. Patients achieving a partial response or stable disease continue on therapy until CR or disease progression or unacceptable toxicity.
11653003|NCT00005830|Experimental|Treatment (doxorubicin, cisplatin, radiation therapy)|Patients receive doxorubicin IV and cisplatin IV on day 1. Treatment repeats every 3 weeks for 3 courses. Patients then undergo whole abdominal radiotherapy 5 days a week for 4-6 weeks.
11653004|NCT00005817|Experimental|Arm I (becatecarin)|Patients receive rebeccamycin analogue IV over 60 minutes on day 1.
11653005|NCT00005817|Experimental|Arm II (becatecarin)|Patients receive rebeccamycin analogue IV over 60 minutes on days 1-5.
11653006|NCT00005812|Experimental|Temozolomide|"Oral temozolomide 75 mg/m2/day for 6 weeks, followed by 4 week break. Cycles will continue until:
~disease progression
~intolerable toxicity
~complete response - 2 full additional cycles
~if response is complete except for residual radiographic abnormalities that persist unchanged for 2 full cycles: continue for 4 cycles past best response."
11653007|NCT00005811|Experimental|Treatment (topotecan hydrochloride)|"INDUCTION: Patients receive topotecan hydrochloride IT over 5 minutes twice weekly for 6 weeks.
~CONSOLIDATION: Beginning 1 week after completion of induction, patients receive topotecan hydrochloride IT over 5 minutes weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.
~MAINTENANCE: Beginning 2 weeks after completion of consolidation, patients receive topotecan hydrochloride IT over 5 minutes twice monthly for 4 months and then monthly through year 1."
11653008|NCT00005808|Experimental|Part 1 (lutetium texaphyrin, LEEP)|Patients receive lutetium texaphyrin IV over 5-20 minutes. Patients undergo in vivo tissue assessment by spectrometer at 0, 1, 3, 5, 12, and 24 hours and loop electrical excision procedure (LEEP) at 24 hours after lutetium texaphyrin infusion.
11653009|NCT00005808|Experimental|Part 2 (lutetium texaphyrin, laser therapy, LEEP)|Patients receive lutetium texaphyrin IV over 5-20 minutes. A laser delivers 730 nm of light to the cervix for 4, 8, or 16 minutes. Patients undergo LEEP at 4, 8, or 12 hours after exposure of the cervix to the light source.
11653010|NCT00005807|Experimental|Treated Participants|dose escalation treatment
11653011|NCT00005803|Experimental|Treatment (tandem transplantation)|See Detailed Description
11653012|NCT00005797|Other|BuCy2|Busulfan & Cyclophosphamide
11653013|NCT00005797|Other|VP16/TBI|Fractionated Total Body Irradiation + VP-16
11653014|NCT00005786|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1-4 hours on days 1-5. Treatment repeats every 21 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with responding or stable disease may receive 6 additional courses.
11653015|NCT00005639|Experimental|Regimen A: 14-day 5-AC with intermittent phenylbutyrate|"Participants receive low-dose regimen of 5-AC with intermittent phenylbutyrate 400 mg/m2/day by continuous intravenous (CIV) over 24 hours on Days 6 and 13. Each cycle lasts 35 days.
~Cohort A1: 25 mg/m2/day subcutaneous (SC) Cohort A-1: 18.75 mg/m2/day SC Cohort A-2: 15 mg/m2/day SC Cohort A-3: 10 mg/m2/day SC"
11653016|NCT00005639|Experimental|Regimen B: 7-day 5-AC with sequential phenylbutyrate|"Participants receive 5-AC 75mg/m2/day SC for 7 days, followed sequentially by two different doses of phenylbutyrate CIV starting on Day 8 and continuing for 7 days. Each cycle lasts 35 days
~Cohort B1: Phenylbutyrate 200 mg/m2/day CIV Cohort B2: Phenylbutyrate 400 mg/m2/day CIV"
11653017|NCT00005639|Experimental|Regimen C: 21-day 5-AC with weekly phenylbutyrate|"Participants receive two different daily doses of 5-AC SC for 21 days and phenylbutyrate 400 mg/m2/day CIV over 24 hours once-per-week. Each cycle lasts 42 days.
~Cohort C1: 5-AC 10mg/m2/day SC Cohort C2: 5-AC 12.5mg/m2/day SC"
11653018|NCT00005622|Other|Cy/TBI|cyclophosphamide and total body irradiation (TBI)
11653019|NCT00005617|Experimental|Group A|No. DC: 10^5 Route of Immunization: ID
11653020|NCT00005617|Experimental|Group B|No. DC: 10^5 Route of Immunization: IV
11653021|NCT00005617|Experimental|Group C|No. DC: 10^6 Route of Immunization: ID
11653022|NCT00005617|Experimental|Group D|No. DC: 10^6 Route of Immunization: IV
11653023|NCT00005617|Experimental|Group E|No. DC: 10^7 Route of Immunization: ID
11653024|NCT00005617|Experimental|Group F|No. DC: 10^7 Route of Immunization: IV
11653025|NCT00005605||Tamoxifen group|
11653026|NCT00005605||Chemotherapy group|
11653027|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 20 Days|
11653028|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 25 Days|
11653029|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 30 Days|
11653030|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 33 Days|
11653031|NCT00005601|Experimental|rituximab+dexamethasone+cisplatin+cytarabine+sargramostim|"Patients receive rituximab IV on days 1, 8, 15, and 22 for the first course only. Patients receive dexamethasone orally or IV on days 1-4, cisplatin IV continuously for 24 hours on day 1, cytarabine IV over 3 hours every 12 hours for 2 doses on day 2, and sargramostim (GM-CSF) subcutaneously on days 3-12 or until blood counts recover. Chemotherapy repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
11653032|NCT00005597|Experimental|Temozolomide|200 mg/m^2/day, PO, on Days 1-5 of each 28 day cycle.
11653033|NCT00005596|Experimental|Arm I|Patients receive IT methotrexate on day 1 followed by methotrexate IV over 20 minutes followed by methotrexate continuously over 23.6 hrs on wks 7, 10, 13, 16,19, and 22. At 42 hrs after the beginning of the methotrexate infusion, patients receive oral leucovorin calcium every 6 hrs for a total of 3 doses. Patients also receive oral mercaptopurine daily beginning on wk 5 and continuing until the completion of consolidation therapy; oral dexamethasone twice daily on days 1-7 of wks 8 and 17; and vincristine sulfate IV on day 1 of wks 8, 9, 17, and 18.
11653034|NCT00005596|Experimental|Arm II|Patients receive methotrexate IV over 4 hours on weeks 7, 10, 13, 16, 19, and 22. At 42 hours after the beginning of the methotrexate infusion, patients receive oral leucovorin calcium as in arm I. Patients also receive mercaptopurine, dexamethasone, vincristine sulfate, and IT methotrexate as in arm I.
11653693|NCT00043693|Active Comparator|2|Participants will be placed in a family psychoeducation program.
11653035|NCT00005596|Experimental|Arm III|Patients receive methotrexate IV as in arm I on weeks 7, 10, 13, 24, 27, and 30; leucovorin calcium as in arm I; pegaspargase IM on day 2, 3, OR 4 of wk 16; oral mercaptopurine daily on wks 5-13, and from wk 24 until the completion of consolidation therapy. Patients also receive IT methotrexate as in arm I on wks 7, 10, 13, 16, 20, 21, and 30; oral dexamethasone 2x daily on weeks 8, 16-18, and 28 for a total of 35 days; vincristine sulfate IV on day 1 of wks 8, 9, 16, 17, 18, 28, and 29; daunorubicin hydrochloride IV on day 1 of wks 16-18; cyclophosphamide IV over 30 minutes on day 1 of week 20; cytarabine IV or subcutaneously daily on days 2-5 of wks 20 and 21; and oral thioguanine daily on wks 20-21.
11653036|NCT00005596|Experimental|Arm IV|Patients receive methotrexate IV as in arm II on weeks 7, 10, 13, 24, 27, and 30; leucovorin calcium as in arm I; and pegaspargase, mercaptopurine, IT methotrexate, dexamethasone, vincristine sulfate, daunorubicin hydrochloride, cyclophosphamide, cytarabine, and thioguanine as in arm III.
11653037|NCT00005585|Experimental|Arm I: (combination chemotherapy)|CONSOLIDATION: Pts receive Methotrexate(MTX) IV over 24 hrs on day 1 and oral leucovorin calcium (CF) every 6 hrs for 3 doses at 42 hours after initiation of MTX infusion during weeks 7, 10, 13, 16, and 19. Pts also receive MTX IT on wks 7, 10, 13, 16, 19, and 22; oral mercaptopurine(6-MP) daily wks 5-24; oral dexamethasone (DM) 2x on days 1-7 of wks 8 and 17; and vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 17, and 18. CONTINUATION: Pts receive oral 6-MP daily on wks 25-130; oral DM twice a day on days 1-7 and vincristine sulfate (VCR) IV on days 1 and 8 during wks 25, 41, 57, 73, 89, and 105; oral MTX on wks 25-130 (except during wks of IT MTX); and MTX IT on wks 25, 37, 49, 61, 73, 85, 97, and 109.
11653038|NCT00005585|Experimental|Arm II (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) IV over 4 hrs on day 1 and oral leucovorin calcium (CF) during wks 7, 10, 13, 16, and 19. Pts also receive MTX IT on wks 7, 10, 13, 16, 19, and 22; oral mercaptopurine (6-MP) daily on wks 5-24; oral dexamethasone (DM) 2x on days 1-7 of wks 8 and 17; and vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 17, and 18. CONTINUATION: Pts receive oral 6-MP daily on wks 25-130; oral DM 2x on days 1-7 and vincristine sulfate (VCR) IV on days 1 and 8 during wks 25, 41, 57, 73, 89, and 105; oral MTX weekly on wks 25-130 (except during wks of IT MTX); and MTX IT on wks 25, 37, 49, 61, 73, 85, 97, and 109.
11653039|NCT00005585|Experimental|Arm III (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) IV and leucovorin calcium (CF) as in arm I on wks 7, 10, 13, 24, 27, and 30. Pts also receive oral mercaptopurine (6-MP) daily on wks 5-13 and then on wk 24 and continuing until the end of consolidation; MTX IT on wks 7, 10, 13, 16, 20, 21, and 30; oral dexamethasone (DM) twice daily on days 1-7 of wks 8, 16-18, and 28; vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 16-18, 28, and 29; pegaspargase intramuscularly on wk 16; daunorubicin hydrochloride IV on day 1 of wks 16-18; cyclophosphamide IV on day 1 of wk 20; cytarabine IV or subcutaneously on days 2-5 of wks 20 and 21; and oral thioguanine daily on days 1-14 of wks 20 and 21. CONTINUATION: Pts receive oral 6-MP daily on wks 33-130; oral dexamethasone (DM) twice a day on days 1-7 and VCR IV on days 1 and 8 during wks 41, 57, 73, 89, and 105; oral MTX weekly on wks 33-130 (except during wks of IT MTX); and MTX IT on wks 37, 49, 61, 73, 85, 97, and 109.
11653040|NCT00005585|Experimental|.Arm IV (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) and leucovorin calcium (CF) on wks 7, 10, 13, 24, 27, and 30. Pts receive mercaptopurine(6-MP) daily weeks 5-13 then beginning wk 24 and continuing until end of consolidation; MTX on wks 7, 10, 13, 16, 20, 21, and 30; dexamethasone (DM) 2x daily on days 1-7 of wks 8, 16-18, and 28; vincristine sulfate (VCR) day 1 of wks 8, 9, 16-18, 28, and 29; pegaspargase on wk 16; daunorubicin hydrochloride on day 1 of wks 16-18; cyclophosphamide on day 1 of wk 20; cytarabine on days 2-5 of wks 20 and 21; thioguanine daily on days 1-14 of wks 20 and 21. CONTINUATION: Pts receive mercaptopurine(6-MP) daily on weeks 33-130; oral dexamethasone (DM) twice a day on days 1-7 and VCR IV on days 1 and 8 during weeks 41, 57, 73, 89, and 105; oral MTX weekly on weeks 33-130 (except during weeks of IV MTX); and IV MTX on weeks 37, 49, 61, 73, 85, 97, and 109.
11653041|NCT00005095||High Risk for Ovarian Cancer|Women who are at increased risk of ovarian cancer based on family or personal medical history who are participating in the Northwestern Ovarian Cancer Early Detection and Prevention Program clinic.
11653042|NCT00005087|Experimental|Radiation (BID) and chemotherapy|Radiation (BID), cisplatin and paclitaxel given on days 1-5 (Monday-Friday) in weeks 1, 3, 5 and 7. G-CSF given on days 6-13.
11653043|NCT00005067|Experimental|Treatment (motexafin lutetium, PDT)|Patients receive lutetium texaphyrin IV over 10-15 minutes 3-24 hours before photodynamic therapy (PDT). Optical fibers attached to a laser are inserted through a catheter into the prostate. The laser delivers 730 nm light to the prostate until the specified fluence is delivered. Patients undergo biopsy of the prostate and bladder before and after PDT. Cohorts of 3-6 patients receive escalating doses of lutetium texaphyrin and light fluence until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
11653044|NCT00005060|Active Comparator|Taxotere-Cisplatin-5FU preoperatively|TCF preoperatively
11653045|NCT00005060|Active Comparator|Immediate surgery followed by TCF|Surgery followed by Taxotere-Cisplatin-5FU
11653046|NCT00005047|Experimental|Arm I: M-VAC x 3|Patients with altered (+) p53, reconsented to randomization, randomized to three cycles of MVAC
11653047|NCT00005047|No Intervention|Arm II: Observation|Patients with altered (+) p53, reconsented to randomization, randomized to observation
11653048|NCT00005047|No Intervention|Arm III: Observation|Patients with unaltered (-) p53
11653049|NCT00005047|No Intervention|Arm IV: Observation|Patients with altered (+) p53, patients did not consent to randomization
11653050|NCT00005044|Experimental|TAS x 8 weeks|Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).
11653051|NCT00005044|Experimental|TAS x 28 weeks|TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).
11653052|NCT00005039|Experimental|Arm I|Patients receive recombinant fowlpox-PSA vaccine IM at the MTD from the safety cohort every 4 weeks for 3 courses. Patients then receive recombinant vaccinia-PSA vaccine intradermally every 4 weeks for 2 courses.
11653053|NCT00005039|Experimental|Arm II|Patients receive the same vaccines as in arm I but in reverse order.
11653054|NCT00005036|Experimental|Arm I (irinotecan)|Patients receive irinotecan IV over 90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
11653694|NCT00043745|Experimental|1|Participants will receive moderate dose soy isoflavone (80 mg/day) tablets, extracted from soy protein
11653055|NCT00005036|Experimental|Arm II (oxalipatin, fluorouracil, leucovorin calcium)|Patients receive oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on days 1 and 2, and fluorouracil IV bolus followed by IV infusion over 22 hours on days 1 and 2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
11653056|NCT00004935|Active Comparator|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
11653057|NCT00004935|Active Comparator|Herceptin™+Chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
11653058|NCT00004932|Experimental|260 mg/m2 imatinib mesylate (ST571)|
11653059|NCT00004932|Experimental|340 mg/m2 imatinib mesylate (ST571)|
11653060|NCT00004932|Experimental|440 mg/m2 imatinib mesylate (ST571)|
11653061|NCT00004932|Experimental|570 mg/m2 imatinib mesylate (ST571)|
11653062|NCT00004918|Experimental|Arm I (dose level 1 PR1 leukemia peptide vaccine)|Patients receive dose level 1 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
11653063|NCT00004918|Experimental|Arm II (dose level 2 PR1 leukemia peptide vaccine)|Patients receive dose level 2 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
11653064|NCT00004918|Experimental|Arm III (dose level 3 PR1 leukemia peptide vaccine)|Patients receive dose level 3 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
11653065|NCT00004891|Experimental|primary resectable rectal cancer|
11653066|NCT00004888|Experimental|Arm I (combination chemotherapy)|"Patients receive doxorubicin hydrochloride liposome IV over 30 minutes followed by docetaxel IV over 1 hour. Treatment is repeated every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
~Patients may receive maintenance therapy of docetaxel IV over 1 hour either weekly or every 3 weeks. Maintenance continues in the absence of disease progression or unacceptable toxicity."
11653067|NCT00004888|Experimental|Arm II (combination chemotherapy, trastuzumab)|"Patients receive trastuzumab IV over 90 minutes on day 1, with subsequent doses over 30 minutes. Patients receive doxorubicin HCl liposome IV over 30 minutes followed by docetaxel IV over 1 hour on day 2 of course 1, followed by subsequent doses on day 1 of each course. Antibody therapy continues weekly and chemotherapy every 3 weeks for 8 courses.
~Patients may receive maintenance therapy of trastuzumab IV over 30 minutes weekly followed by docetaxel IV over 1 hour weekly or every 3 weeks. Maintenance continues in the absence of disease progression or unacceptable toxicity."
11653068|NCT00004867|Experimental|FDG-PET scan +/- neoadjuvant chemotherapy + surgery|"Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later by positron emission tomography (PET) imaging. Confirmatory studies, such as biopsy or other imaging studies, are then conducted to confirm the FDG PET imaging results. Patients with no metastases identified by FDG PET imaging may undergo esophagectomy with or without neoadjuvant chemoradiotherapy within 1 month of evaluation.
~Patients are followed within 6 months after surgery."
11653069|NCT00004859|Active Comparator|Arm A (Paclitaxel + Carboplatin + RT)|"Induction chemotherapy dosing: Paclitaxel, 225 mg/m² (3 hour infusion) Day 1. Carboplatin, area under the plasma drug concentration versus time curve (AUC) =6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1
~Concurrent chemotherapy / radiotherapy dosing: Paclitaxel, 45 mg/m2, administered weekly during radiotherapy over one hour. Carboplatin, AUC=2, 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy
~Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV"
11653070|NCT00004859|Experimental|Arm B (Paclitaxel + Carboplatin + RT+ Thalidomide)|"paclitaxel, carboplatin, and radiotherapy are same as those in Arm A.
~thalidomide: Induction chemotherapy dosing, oral daily, starting Day 1 for 24 months or until disease progression. Concurrent chemotherapy / radiotherapy dosing, oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg."
11653071|NCT00004262|Experimental|Treatment (motexafin gadolinium, radiotherapy, radiosurgery)|Within 5 weeks following surgery, patients receive daily external beam radiotherapy five days a week for 5 weeks. Within 2 weeks following completion of radiotherapy, patients receive gadolinium texaphyrin IV over 2 hours followed 3 hours later by stereotactic radiosurgery. Patients undergoing surgical debulking of tumor prior to external beam radiotherapy receive gadolinium texaphyrin IV over 2 hours, 3 hours prior to surgery in addition to the dose prior to stereotactic radiosurgery.
11653072|NCT00004259|Experimental|Radiation therapy + temozolomide (TMZ)|Radiation therapy (RT) for 6 weeks concurrent with and followed by TMZ 200mg/m2 for twelve 28-day cycles
11653073|NCT00004259|Active Comparator|RT + BCNU/CCNU|Radiation therapy for 6 weeks concurrent with and followed by BCNU 80mg/m2 or CCNU 130 mg/m2 for six 8-week cycles
11653074|NCT00004259|Experimental|Pilot Arm #1: RT+TMZ+BCNU|Radiation therapy for 6 weeks concurrent with and followed by BCNU 200mg/m2 and TMZ 150mg/m2 six 6-week cycles
11653075|NCT00004259|Experimental|Pilot Arm #2: RT+TMZ+BCNU|Radiation therapy for 6 weeks concurrent with and followed by BCNU 150mg/m2 and TMZ 150mg/m2 six 8-week cycles
11653076|NCT00004244|Experimental|Arm I|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.
~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.
~Patients receive interleukin-12 SC twice a week for 2 weeks, followed by treatment with interleukin-12 in combination with interferon alfa as described above."
11653233|NCT00003500|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653077|NCT00004244|Experimental|Arm II|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.
~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.
~Patients receive interferon alfa SC three times a week for 2 weeks, followed by treatment with interleukin-12 in combination with interferon alfa as described above."
11653078|NCT00004244|Experimental|Arm III|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.
~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.
~Patients receive treatment with interleukin-12 in combination with interferon alfa at the MTD as described above."
11653079|NCT00004241|Experimental|Schedule B (tanespimycin)|Patients receive 17-AAG IV over 1-2 hours twice weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
11653080|NCT00004241|Experimental|Schedule C (tanespimycin)|Patients receive 17-AAG IV over 1-2 hours twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
11653081|NCT00004228|Experimental|A0 (localized disease Stg I/II) Modified CCG BFM|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Doxorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Methotrexate, Intrathecal Methotrexate)
11653082|NCT00004228|Experimental|A1 (Disseminated, No CNS - CCG mod BFM w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, prednisone, Methotrexate, Intrathecal Methotrexate)
11653083|NCT00004228|Experimental|A2 (Disseminated, No CNS - CCG mod BFM w/ intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
11653084|NCT00004228|Experimental|B2 (CNS+) NHL/BFM-95 w/intens delayed radiation therapy|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
11653085|NCT00004228|Experimental|B1 (Disseminated CNS- <Amend 7B) NHL/BFM-95 w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
11653086|NCT00004228|Experimental|B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, daunorubicin, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
11653087|NCT00004228|Experimental|B1 (Disseminated CNS-) NHL/BFM-95 w/out intens|Phase I - 5 week induction (Vincristine Sulfate, daunorubicin hydrochloride, Cyclophosphamide, L-Asparaginase, Intrathecal Cytarabine, Intrathecal Methotrexate, Prednisone). Phase II - 5 week consolidation (Mercaptopurine, Cyclophosphamide, Cytarabine, Intrathecal Methotrexate, Prednisone). Phase III - 8 week Interim Maintenance (Mercaptopurine, Methotrexate, Intrathecal Methotrexate, Leucovorin Calcium). Phase IV - 7 week Delayed Intensification (Vincristine Sulfate, Cyclophosphamide, doxorubicin hydrochloride, L-Asparaginase, Dexamethasone, Cyclophosphamide, Thioguanine, Cytarabine, Intrathecal Methotrexate). Phase V - 12 week courses (Vincristine Sulfate, Prednisone, Mercaptopurine, Methotrexate, Intrathecal Methotrexate)
11653234|NCT00003499|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653695|NCT00043745|Experimental|2|Participants will receive high dose soy isoflavone (120 mg/day) tablets, extracted from soy protein
11653088|NCT00004227|Placebo Comparator|Arm I|"Patients undergo radiotherapy beginning on day 1. Patients are assigned to 1 of 3 radiotherapy groups:
~Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks.
~Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks.
~Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks."
11653089|NCT00004227|Active Comparator|Arm II|"Patients receive a test dose of cetuximab IV over 10 minutes on day 1. Patients who do not experience grade 4 anaphylactic reaction receive a loading dose of cetuximab IV over 2 hours beginning 30 minutes after completion of test dose. Patients receive maintenance cetuximab IV over 1 hour on day 8. Maintenance cetuximab repeats every week for 7 courses. Beginning on day 8, patients undergo radiotherapy as in arm I concurrently with maintenance cetuximab. There must be an hour interval between the completion of cetuximab infusion and the start of any radiotherapy.
~Radiotherapy groups remain the same as in Arm I:
~Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks.
~Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks.
~Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks."
11653090|NCT00004208|Active Comparator|Arm A: ATG + CSA|"Treatment consists of 15 mg/kg ATG (Mérieux; horse antithymocyte globulin; i.e. 1.5 vial/10 kg of body weight/day) given over 8-12 hours for 5 consecutive days.
~Cyclosporine A (CSA) will be administered orally in a dose of 2.5 mg/kg bid starting day 1 and continued through day 180."
11653091|NCT00004208|Other|Arm B: Supportive care|Patients randomized to this arm will be treated as outpatients.
11653092|NCT00004205|Experimental|Tamoxifen|Tamoxifen for 5 years after randomization.
11653093|NCT00004205|Experimental|Letrozole|Letrozole for 5 years after randomization.
11653094|NCT00004205|Experimental|Tamoxifen, then letrozole|Tamoxifen for 2 years after randomization, then letrozole for the next 3 years.
11653095|NCT00004205|Experimental|Letrozole, then tamoxifen|Letrozole for 2 years after randomization, then tamoxifen for the next 3 years.
11653096|NCT00004196|Experimental|AI|Patients with metastasis in a single sentinel node with no evidence of extracapsular extension and no metastatic disease in nonsentinel nodes are randomized to 1 of 2 treatment arms. Patients receive adjuvant high-dose interferon alfa-2b IV 5 days a week for 4 weeks, then subcutaneously 3 times a week for 48 weeks
11653097|NCT00004196|Experimental|Arm AII|Patients with metastasis in a single sentinel node with no evidence of extracapsular extension and no metastatic disease in nonsentinel nodes are randomized to 1 of 2 treatment arms. Observational arm: Patients with metastases in more than one sentinel node with evidence of extracapsular extension or metastasis in any nonsentinel node receive adjuvant high-dose interferon alfa-2b as in arm AI.
11653098|NCT00004196|Experimental|Arm BI|Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo observation. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
11653099|NCT00004196|Experimental|Arm B II|Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo lymph node dissection. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
11653100|NCT00004196|Experimental|Arm BIII|"Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo lymph node dissection followed by adjuvant high-dose interferon alfa-2b IV 5 days a week for 4 weeks.
~Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter."
11653101|NCT00004189|Experimental|Arm I|See detailed description.
11653102|NCT00004188|Experimental|Arm I (unpurged PBSC collection)|Induction-3 wks (cyclophosphamide day 0&1, doxorubicin hydrochloride & vincristine sulfate day 0-2 & filgrastim(G-CSF) day 3 crs 1,2,4 & 6.) Crs 3 & 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Pts undergo unpurged PBSC collection until the target cell count is reached. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin & etoposide day -7 to -4. purged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
11653103|NCT00004188|Experimental|Arm II (unpurged PBSC collection)|Induction-3 wks (cyclophosphamide day 0&1, doxorubicin hydrochloride & vincristine sulfate day 0-2 & filgrastim(G-CSF) day 3 crs 1,2,4 & 6.) Crs 3 & 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Immunocytology + PBSC undergo purged autologous bone marrow collection or repeat purged or unpurged PBSC collection. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin & etoposide day -7 to -4. Unpurged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
11653104|NCT00004154|Experimental|Fenretinide|Fenretinide (4-HPR) 200 mg orally every day for 12 months taken 25 out of every 28 days.
11653105|NCT00004154|Placebo Comparator|Placebo|Placebo orally every day for 12 months, taken 25 out of every 28 days.
11653106|NCT00004144|Experimental|bryostatin 1 & gemcitabine hydrochloride|
11653107|NCT00004143|Experimental|Campath SCT for hemoglobinopathies|Campath, Chemo and/or TBI Allo SCT
11653108|NCT00004143|Experimental|Campath SCT for Bone Marrow Failure|Campath, Chemo and/or TBI Allo SCT
11653109|NCT00004141|Experimental|Arm A|CDDP (75 mg/m2) and DTIC (660 mg/m2) will be administered sequentially by intravenous infusion in day 1. Subsequently, GM-CSF (450 mg/ m2) will be administered SC days 2-7; IL-2 (11 MU daily) will be given SC days 8-14, and IFN-2b (9 MU) will be given SC days 8, 10, 12, and 14.
11653417|NCT00051350|Placebo Comparator|CARB|Diet rich in carbohydrate
11653418|NCT00051350|Active Comparator|UNSAT|Diet rich in unsaturated fat
11653419|NCT00051350|Active Comparator|PROTEIN|Diet rich in protein
11653110|NCT00004138|Experimental|FDG-PET scan + surgery|"Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later by positron emission tomography (PET) imaging. Confirmatory studies, such as biopsy, fine needle aspiration, or other imaging studies are then conducted to confirm the PET findings.
~Patients with no mediastinal nodal or distant metastases identified by FDG-PET scan may undergo thoracotomy and pulmonary resection within 1 month of evaluation.
~Patients are followed at 5-6 months after surgery."
11653111|NCT00004135|Experimental|Arm A|Fludarabine 30 mg/m2/d x S days IVPB in 100 cc NS over 30 minutes on day -8, -7, -6, -S, and -4. Cyclophosphamide 2 gm/m2/d x 2 days IVPB in SOO cc DS W over I hour on day -3 and day-2. G-CSF (Neupogen®) administration 480 f!gld subcutaneously starting on day +5 (or first day of neutropenia if earlier)and continued until an ANC of 0.5 x 109/L is maintained for 3 consecutive days.
11653112|NCT00004124|Active Comparator|bicalutamide, goserelin|androgen deprivation
11653113|NCT00004124|Experimental|bicalutamide, goserelin, mitoxantrone, prednisone|androgen deprivation plus mitoxantrone, prednisone
11653114|NCT00004092|Experimental|Arm I (ACT) (closed to accrual as of 4/6/2006)|Patients receive doxorubicin IV over 24 hours on days -9 to -6, cyclophosphamide IV over 2 hours on day -5, and paclitaxel IV over 24 hours on day -2. PBSC are reinfused on days -2 and 0. G-CSF is administered beginning on day 0 and continuing until blood counts recover.
11653115|NCT00004092|Active Comparator|Arm II (STAMP V)|Patients receive cyclophosphamide IV, carboplatin IV, and thiotepa IV over 24 hours on days -7 to -4. PBSC are reinfused and G-CSF is administered as in arm I.
11653116|NCT00004088|Experimental|HD chemotherapy followed by PBPC Rescue|Patients receive high-dose (HD) melphalan intra-venously (IV) on day -1. Peripheral blood progenitor cells (PBPCs) are reinfused on day 0. Filgrastim (G-CSF) is administered IV or SC daily beginning on day 1 and continuing until blood counts recover. Between 8 and 14 weeks later, patients receive IV high-dose busulfan every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. PBPCs are reinfused on day 0 and G-CSF is administered IV or subcutaneously (SC) daily until blood counts recover.
11653117|NCT00004067|Active Comparator|Arm 1: adriamycin + cyclophosphamide then taxol|
11653118|NCT00004067|Experimental|Arm 2: adriamycin + cyclophosphamide then taxol + herceptin|
11653119|NCT00004054|Experimental|Hormones and RT|Androgen suppression (AS) (Luteinizing hormone releasing hormone agonist and bicalutamide [Casodex] or flutamide [Eulexin]) x 8 weeks followed by RT to 70.2 Gy with concurrent AS (LHRH agonist and bicalutamide [Casodex] or flutamide [Eulexin]). AS will continue for a total of 24 months from initiation of all treatment. Oral anti-androgen will be discontinued at the end of radiation therapy (RT).
11653120|NCT00004054|Experimental|Hormones and RT plus Chemotherapy|AS (LHRH agonist and bicalutamide [Casodex] or flutamide [Eulexin]) x 8 weeks followed by RT to 70.2 Gy with concurrent AS (LHRH agonist and bicalutamide [Casodex] or flutamide [Eulexin]) and estramustine phosphate sodium, etoposide, paclitaxel, and warfarin [Coumadin®]. AS will continue for a total of 24 months from initiation all treatment. Oral antiandrogen will be discontinued at the end of RT.
11653121|NCT00004031|Active Comparator|CHOP/CHOP-R x 3|Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Prednisone 100 mg/day PO Days 1-5 Vincristine 1.4 mg/m2 IV Day 1 Rituximab 375 mg/m2 IV Day 1 This regimen is repeated every 21 days for 8 cycles
11653122|NCT00004031|Experimental|CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant|Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Prednisone 100 mg/day PO Days 1-5 Vincristine 1.4 mg/m2 IV Day 1 Rituximab 375 mg/m2 IV Day 1 This regimen is repeated every 21 days for 6 cycles followed by autologous stem cell transplant.
11653123|NCT00004011|Experimental|preooperative chemo followed by surgery|carboplatin paclitaxel conventional surgery
11653124|NCT00004011|Active Comparator|Surgery alone|conventional surgery
11653125|NCT00004001|Experimental|Docetaxel and Estramustine|Estramustine, 280 mg, PO, TID, Days 1-5; q 21 days Docetaxel, 60mg/m2, IV, Day 2; q 21 days
11653126|NCT00004001|Active Comparator|Mitoxantrone and Prednisone|Mitoxantrone, 12 mg/m2, IV, Day 1; q 21 days Prednisone, 5 mg, PO, BID, Days 1-21; q 21 days
11653127|NCT00003994|Experimental|Arm I (cisplatin, vincristine sulfate, fluorouracil)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive cisplatin IV over 4 hours on day 1, vincristine sulfate IV on days 3, 10, and 17, and fluorouracil on day 3.
11653128|NCT00003994|Experimental|Arm II (cisplatin, vincristine, fluorouracil, amifostine)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive treatment as in arm I with the addition of amifostine trihydrate IV over 15 minutes prior to cisplatin on day 1.
11653129|NCT00003994|Experimental|Arm III (carboplatin, cisplatin)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive carboplatin IV over 1 hour on day 1 and cisplatin IV over 4 hours on day 15.
11653130|NCT00003994|Experimental|Arm IV (carboplain, cisplatin, amifostine)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive treatment as in arm III with the addition of amifostine trihydrate IV over 15 minutes prior to carboplatin on day 1.
11653131|NCT00003970|Experimental|Treatment (irinotecan hydrochloride)|Patients receive irinotecan IV over 90 minutes once every 3 weeks. Treatment continues for at least 2 courses in the absence of disease progression or unacceptable toxicity.
11653132|NCT00003966|Experimental|Arm A Lower dose|"This is a randomized, multicenter study. All patients initially receive the same dose of defibrotide IV over 2 hours every 6 hours on day 1. On day 2, patients are randomized to 1 of 2 doses of defibrotide.
~- Arm I: On days 2-14, patients receive a lower dose of defibrotide IV over 2 hours every 6 hours.
~In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity"
11653133|NCT00003966|Experimental|Arm B Higher Dose|"This is a randomized, multicenter study. All patients initially receive the same dose of defibrotide IV over 2 hours every 6 hours on day 1. On day 2, patients are randomized to 1 of 2 doses of defibrotide.
~- Arm II: On days 2-14, patients receive a higher dose of defibrotide IV over 2 hours every 6 hours.
~In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity"
11653134|NCT00003963|Experimental|Vinorelbine and Rituxan|"Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.
~Week 5-8: Rituxan given every 2 weeks. Vinorelbine given weekly x3, with one week off.
~Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
11653420|NCT00051285|Experimental|Enoximone|
11653135|NCT00003958|Experimental|Arm I|Vincristine sulfate IV once a wk on wks 0-12, 15, 18-24, 27, 30-36, and 39. Dactinomycin IV once a wk on wks 0, 3, 6, 9, 12, 21, 24, 27, 30, 33, 36, and 39. Cyclophosphamide IV once a wk on wks 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, and 39. After 12 weeks of chemotherapy, depending on tumor shrinkage, pts may undergo surgery. After recovery from therapeutic conventional surgery, patients receive radiation therapy once a day, 5 days a wk, during wks 12-18. For pt receiving radiotherapy during wks 0-6, dactinomycin is omitted during wks 3 and 6 and during wks 15 and 18. For patients receiving radiotherapy during wks 12-18, dactinomycin is omitted during wks 15 and 18. Patients with adequate response at wk 24 continue chemotherapy during wks 24-39. All pts receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously beginning 24 hours after completion of each course of chemotherapy and continuing 1 year, until hematopoietic recovery.
11653136|NCT00003958|Experimental|Arm II|"Patients receive treatment as in arm I, except dactinomycin is replaced with topotecan hydrochloride IV over 15-30 minutes daily for 5 days during weeks 3, 9, 21, 27, 33, and 39.
~All patients receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously beginning 24 hours after completion of each course of chemotherapy and continuing 1 year, until hematopoietic recovery."
11653137|NCT00003934|Experimental|Arm I|"Induction: All patients receive oral tretinoin every 12 hours beginning on day 1 until complete response or for a maximum of 90 days. Patients also receive daunorubicin IV on days 3-6 and cytarabine IV continuously on days 3-9.
~Consolidation: All patients achieving CR or PR after completion of tretinoin, proceed to consolidation within 2 weeks of achieving CR or PR, but not prior to 30 days from the start of induction. Patients are randomized to 1 of 2 treatment arms.
~Patients receive oral tretinoin every 12 hours on days 1-7 and daunorubicin IV on days 1-2 or days 1-3, depending on age. Patients may receive an additional course. Treatment begins no earlier than 2 weeks and no later than 4 weeks after hematopoietic recovery."
11653138|NCT00003934|Experimental|Arm II|"Induction: All patients receive oral tretinoin every 12 hours beginning on day 1 until complete response or for a maximum of 90 days. Patients also receive daunorubicin IV on days 3-6 and cytarabine IV continuously on days 3-9.
~Consolidation: All patients achieving CR or PR after completion of tretinoin, proceed to consolidation within 2 weeks of achieving CR or PR, but not prior to 30 days from the start of induction. Patients are randomized to 1 of 2 treatment arms.
~Patients receive oral tretinoin as in arm I above. Patients also receive oral mercaptopurine once a day and oral methotrexate once weekly for up to 1 year."
11653139|NCT00003910|Experimental|Methotrexate (Cy if no response to MTX)|MTX given orally at 10 mg/m2 in divided doses once weekly. Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days. Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule.
11653140|NCT00003909|Experimental|Arm I|Approximately 2-5 hours before radiotherapy, patients receive motexafin gadolinium IV over 5 minutes. Patients undergo radiotherapy 5 days a week for 6 weeks.
11653141|NCT00003906|Active Comparator|Group 1|Tamoxifen and placebo
11653142|NCT00003906|Experimental|Group 2|Raloxifene and Placebo
11653143|NCT00003901|Experimental|Surgery|"All patients undergo complete lymph node sampling or dissection. A small portion of rib is removed at this time. Some patients may have primary tumor completely removed.
~Lymph nodes and bone marrow from the rib section are examined for occult metastases using immunohistochemical staining methods and standard staining methods.
~Patients are followed at 1, 4, 8, and 12 months, every 6 months for 2 years, and then annually for 2 years."
11653144|NCT00003896|Experimental|Paclitaxel/cisplatin/Liposomal Doxorubicin|paclitaxel, cisplatin and liposomal doxorubicin
11653145|NCT00003875|Experimental|Treatment (chemo, stem cell rescue, interleukin therapy)|"PREPARATIVE REGIMEN: Patients receive busulfan IV over 2 hours or PO every 6 hours on days -7 to -4 and etoposide IV on day -3.
~STEM CELL INFUSION: Patients undergo autologous or syngeneic PBSC rescue on day 0.
~POST-TRANSPLANT ALDESLEUKIN THERAPY: Beginning 30-100 days after transplant, patients receive low-dose aldesleukin SC daily for 12 weeks."
11653146|NCT00003869|Experimental|Arm I (CAI)|Patients receive oral carboxyamidotriazole daily.
11653147|NCT00003869|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo daily
11653148|NCT00003865|Experimental|Toremifene|All enrolled patients
11653149|NCT00003863||Group 1|"Tissue samples are obtained before treatment and at the time of documentation of refractory disease in patients who do not achieve complete remission after induction therapy or at the time of first relapse in patients who achieve a complete remission.
~Samples are examined for rearrangements in the MYC, BCL2, BCL6, and IGH genes using fluorescent in situ hybridization. DNA is examined by comparative genomic hybridization, which allows cytogenetic detection of losses and gains of chromosomal regions in tumor cells.
~Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment."
11653150|NCT00003861||Ancillary-Correlative (molecular genetic features)|Previously collected blood and tissue samples are analyzed via RT-PCR and flow cytometry.
11653151|NCT00003857|Active Comparator|Observation +/- tamoxifen for 5 years|Observation +/- tamoxifen 20 mg per day for 5 years
11653152|NCT00003857|Experimental|Radiation therapy +/- tamoxifen for 5 years|Radiation therapy to the whole breast +/- tamoxifen 20 mg per day for 5 years
11653153|NCT00003855|Experimental|Surgery + radiotherapy|"Patients undergo axillary lymph node dissection involving removal of at least level I and II nodes, followed by whole-breast radiotherapy (exclusive of a third supraclavicular field) 5 days a week for a maximum of 7 weeks. Patients may receive adjuvant systemic therapy at the discretion of the treating physician.
~Patients are followed up at 30 days, at 6, 12, 18, 30, and 36 months, and then annually for a total of 10 years."
11653154|NCT00003855|Active Comparator|Radiotherapy|"Patients undergo breast radiotherapy only. Patients may receive adjuvant systemic therapy at the discretion of the treating physician.
~Patients are followed up at 30 days, at 6, 12, 18, 30, and 36 months, and then annually for a total of 10 years."
11653204|NCT00003612|Experimental|Schedule B: paclitaxel + carboplatin + trastuzumab|"Patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 15 minutes on day 1 of weeks 1-3 and trastuzumab IV over 90 minutes immediately after carboplatin on day 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30 minutes every 3 weeks until disease progression.
~Patients are followed every 3 months for 2 years and then every 6 months thereafter."
11653421|NCT00051285|Placebo Comparator|Placebo|
11653422|NCT00051246|Active Comparator|1 M-ITG|Mother-infant group psychotherapy
11653155|NCT00003854|Experimental|Surgery + radiotherapy + adjuvant therapy|"Patients undergo bilateral anterior iliac crest bone marrow aspiration to test for presence of micrometastases. Patients then undergo breast-conserving therapy comprising segmental mastectomy and sentinel lymph node dissection (SLND) with planned postoperative whole-breast radiotherapy and systemic adjuvant therapy. The SLND comprises ipsilateral axillary sentinel node identification and histopathology.
~Patients with no sentinel node identified intraoperatively and patients with sentinel node metastasis identified by hematoxylin and eosin (H&E) who choose not to be registered to ACOSOG-Z0011 undergo axillary lymph node dissection involving removal of at least level I and II nodes.
~All patients undergo whole-breast radiotherapy (excluding a supraclavicular field) 5 days a week for a maximum of 8 weeks.
~Patients are followed at 30 days; at 6, 12, 18, 24, 30, and 36 months; and then annually until 10 years after surgery."
11653156|NCT00003851|Active Comparator|Nutritional Arm|Arm I (Nutritional Arm): Patients receive pancreatic enzymes orally every 4 hours and at meals daily on days 1-16, followed by 5 days of rest. Patients receive magnesium citrate and Papaya Plus with the pancreatic enzymes. Additionally, patients receive nutritional supplementation with vitamins, minerals, trace elements, and animal glandular products 4 times per day on days 1-16, followed by 5 days of rest. Courses repeat every 21 days until death despite relapse. Patients consume a moderate vegetarian metabolizer diet during the course of therapy, which excludes red meat, poultry, and white sugar. Coffee enemas are performed twice a day, along with skin brushing daily, skin cleansing once a week with castor oil during the first 6 months of therapy, and a salt and soda bath each week. Patients also undergo a complete liver flush and a clean sweep and purge on a rotating basis each month during the 5 days of rest.
11653157|NCT00003851|Active Comparator|Chemotherapy Arm|Arm II (Chemotherapy Arm): Patients receive gemcitabine-based chemotherapy. Quality of life is assessed at 0, 2, 6, and 12 months and then yearly thereafter.
11653158|NCT00003838|No Intervention|Donor|Donor
11653159|NCT00003838|Experimental|Recipient|Subjects will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg /m2 intravenously (IV) over 30 minutes daily x 5 days followed by a PBPC graft targeted to deliver >5x10^6 CD34+ cells/kg
11653160|NCT00003833||Normal and tumor tissue pairs|Matched normal and tumor DNA is analyzed for 8p allelic imbalance with at least 8 markers: D8S262 and D8S1825 localized to 8p23, D8S254 and D8S261 at 8p22, D8S560 and D8S136 at 8p21, and D8S1820 and D8S283 at 8p12. Normal/tumor tissue pairs are used for fine mapping studies.
11653161|NCT00003831|Experimental|Lymph node sampling|Patients undergo pulmonary resection. No additional lymph nodes are removed. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.
11653162|NCT00003831|Active Comparator|Lymph node dissection|Patients undergo removal of nearly all of the lymph nodes from the central part of the chest between the lungs, followed by pulmonary resection. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.
11653163|NCT00003820|Experimental|Rituximab 375 mg/m2 per week|"375 mg/m2 rituximab by IV infusion weekly. The initial course of treatment is 4 weeks.
~Subjects who achieve an objective response or stable disease after the initial course (4 weeks) were permitted to continue additional 4-week cycles of treatment, for 3 additional courses starting every 6 months (ie, at 6; 12; and 18 months)."
11653164|NCT00003816|Experimental|Regimen 1|Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
11653165|NCT00003816|Experimental|Regimen 2|Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -3.
11653166|NCT00003816|Experimental|Regimen 3|Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and total-body irradiation (TBI) twice daily on days -3 to -1.
11653167|NCT00003816|Experimental|Regimen 4|Patients receive fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 1 hour on days -3 and -2.
11653168|NCT00003816|Experimental|Regimen 5|Patients receive etoposide IV over 26 hours beginning on day -5, cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1.
11653169|NCT00003816|Experimental|Regimen 6|Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24 hours on days -7 to -4.
11653170|NCT00003816|Experimental|Regimen 7|Patients receive fludarabine IV over 30 minutes on days -5 to -1 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -2.
11653171|NCT00003816|Experimental|Regimen 8|Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3 to -1.
11653172|NCT00003816|Experimental|Regimen 9|Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
11653173|NCT00003800|No Intervention|Laboratory/CT evaluation|Observation following orchiectomy
11653174|NCT00003799|Experimental|Treatment (chemotherapy, radiotherapy, surgery)|"Patients receive fluorouracil IV continuously with concurrent radiotherapy for 5.5 weeks. Patients also receive oxaliplatin IV over 2 hours on day 1 of weeks 1, 3, and 5.
~Patients undergo surgery 6-8 weeks after completing preoperative chemotherapy and radiotherapy. The surgical procedure is determined by the extent of the tumor before preoperative therapy. The type of operative procedure may be abdominoperineal resection, low anterior resection (LAR), or LAR/coloanal anastomosis.
~Postoperative chemotherapy begins within 6 weeks after surgery, comprising leucovorin calcium and fluorouracil IV on days 1-5. Treatment repeats every 21 days for 4 courses."
11653175|NCT00003796|Experimental|Arm I|Patients receive irofulven IV over 30 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
11653176|NCT00003793||Identification of Genetical suceptibility prior to therapy|"Determine the glutathione-s-transferase theta (GSTT1) or glutathione-s-transferase mu (GSTM1) null genotype is more frequent in individuals with t-MDS/AML. Determine the GSTT1 or GSTM1 null genotype is associated with a reduced incidence of relapse of sarcoma. Determine NAT2 or CYP1A1 genotype influences risk of t-MDS/AML. Determine development of a mutator phenotype as demonstrated by developing microsatellite instability is an early marker of individuals likely to progress to t-MDS/AML."
11653205|NCT00003611|Experimental|acitretin|"Patients receive oral acitretin daily for 2 years. Skin biopsies are obtained at 1 year from normal areas and from any areas with skin cancer for genetic studies.
~Patients are followed every 6 months."
11653423|NCT00051246|Active Comparator|2 - IPT|Individual interpersonal psychotherapy
11653177|NCT00003793||Increased Risk Of T-MDS/AML before/after Therapy|Determine clonal hematopoiesis develops in children receiving high intensity alkylating agent chemotherapy for sarcomas. Determine development of clonal hematopoiesis is associated with increased frequency of t-MDS/AML. Determine measurement of somatic cell mutation frequency, measured by the glycophorin A (GPA) assay prior to and after chemotherapy will predict individuals at increased risk of t-MDS/AML. Identify individuals with ras gene mutations in normal peripheral blood cells after therapy, and whether the identification of such mutations is associated with increased risk of t-MDS/AML blood cells after therapy, and whether the identification of such mutations is associated with increased risk of t-MDS/AML.
11653178|NCT00003789|Experimental|Arm I|Patients undergo hyperthermic isolated perfusions of the lower limb by either the external iliac vessels or the common femoral vessels. Patients undergo perfusions of the upper extremity by the axillary artery and vein using an infraclavicular/axillary incision. Melphalan is introduced into the perfusion by slow injection over 5 minutes and allowed to remain for a total of 60 minutes.
11653179|NCT00003789|Experimental|Arm II|Patients undergo hyperthermic isolated perfusions as in arm I. Tumor necrosis factor is administered by slow injection into the arterial line and allowed to remain for a total of 90 minutes. Melphalan is introduced into the perfusion as in arm I and allowed to remain for a total of 60 minutes.
11653180|NCT00003782|Experimental|Arm 1: Doxorubicin + Cyclophosphamide, then Docetaxel|Doxorubicin + Cyclophosphamide, then Docetaxel
11653181|NCT00003782|Experimental|Arm 2: Doxorubicin + Docetaxel|Doxorubicin + Docetaxel
11653182|NCT00003782|Experimental|Arm 3: Doxorubicin + Docetaxel + Cyclophosphamide|Doxorubicin + Docetaxel + Cyclophosphamide
11653183|NCT00003750|Experimental|DG2 positive relapsed or refractory solid tumors|The initial hu14.18-IL2 fusion protein (FP) dose will be 2 mg/m2 given intravenously over 4 hours, daily for 3 days. Five separate dose levels are scheduled: 2 mg/m²/dose (IV over 4 hours) x 3 days, 4 mg/m²/dose (IV over 4 hours) x 3 days, 6 mg/m²/dose (IV over 4 hours) x 3 days, 8 mg/m²/dose (IV over 4 hours) x 3 days, 10 mg/m²/dose (IV over 4 hours) x 3 days.
11653184|NCT00003746|Active Comparator|CDA day|CDA:0.14 mg/kg/day Bolus s.c. (standard) days 1-5
11653185|NCT00003746|Active Comparator|CDA week|CDA:0.14 mg/kg/week Bolus s.c. weeks 1-5
11653186|NCT00003745|Experimental|Arm I|Patients receive topotecan IV continuously on days 1-21. Treatment continues at least every 4 weeks in the absence of unacceptable toxicity or disease progression.
11653187|NCT00003744|Experimental|Intercalcated Duct|"The first group, referred to as intercalated duct will include Aadenoid cystic carcinoma, acinic cell carcinoma, malignant mixed tumor, polymorphous low grade adenocarcinoma, undifferentiated carcinoma, and adenocarcinoma.
~- Gemcitabine iv 30 min infusion on days 1,8, and 15 of each 28 day cycle.
~-- Participants will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
11653188|NCT00003744|Experimental|Excreatory Duct|"The second group, referred to as excretory duct, will include: squamous cell carcinoma and mucoepidermoid carcinoma.
~Gemcitabine iv 30 min infusion on days 1,8, and 15 of each 28 day cycle.
~Participants will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
11653189|NCT00003702|Experimental|Arm I (methotrexate)|Patients receive methotrexate intramuscularly once weekly in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.
11653190|NCT00003702|Experimental|Arm II (dactinomycin)|Patients receive dactinomycin IV over 15 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive 1 additional consolidation treatment.
11653191|NCT00003659|Experimental|intermediate or high risk chronic lymphocytic leukemia|This is a single-arm open-label pilot study designed to assess the antileukemic activity of a regimen containing sequential administration of fludarabine, high-dose cyclophosphamide, and rituximab.
11653192|NCT00003656|Experimental|All subjects|Weekly ATRA-IV with recombinant interferon alfa
11653193|NCT00003653|Active Comparator|Intermittent Androgen Suppression|
11653194|NCT00003653|Active Comparator|Continuous Androgen Suppression|
11653195|NCT00003644|Experimental|Carboplatin, paclitaxel, low dose paclitaxel|carboplatin, paclitaxel followed by low dose paclitaxel 4 weeks later
11653196|NCT00003644|Active Comparator|Carboplatin, paclitaxel|carboplatin, paclitaxel
11653197|NCT00003641|Other|Observation|Patients undergo observation for 4 weeks.
11653198|NCT00003641|Experimental|Interferon Alfa-2b|Patients receive high-dose interferon alfa-2b IV over 20 minutes daily for 5 consecutive days. Treatment repeats weekly for 4 weeks in the absence of unacceptable toxicity.
11653199|NCT00003631|Experimental|Arm I|(0-1 adverse prognostic factors): Patients receive ifosfamide by 24 hour infusion on day 2. Carboplatin is administered on day 2. Etoposide IV is administered once daily on days 1-3. Patients then receive filgrastim (G-CSF) subcutaneously or IV on days 5-12. Patients receive another course of ICE chemotherapy 2-3 weeks after the first course.
11653200|NCT00003631|Experimental|Arm II|(2 adverse prognostic factors): Patients receive the first course of ICE as in Arm I
11653201|NCT00003631|Experimental|Arm III|Arm III (3 adverse prognostic factors): Patients receive cyclophosphamide IV daily for 2 days, then G-CSF beginning on day 4 until blood stem cells are collected
11653202|NCT00003613|Experimental|Treatment (O6-benzylguanine, carmustine)|Patients receive O6-benzylguanine IV over 1 hour followed by topical carmustine once every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
11653203|NCT00003612|Experimental|Schedule A: paclitaxel + carboplatin + trastuzumab|"Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes and then trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30 minutes every 3 weeks until disease progression.
~Patients are followed every 3 months for 2 years and then every 6 months thereafter."
11653206|NCT00003611|Placebo Comparator|placebo|"Patients receive placebo daily for 2 years. Skin biopsies are obtained at 1 year from normal areas and from any areas with skin cancer for genetic studies.
~Patients are followed every 6 months."
11653424|NCT00051168|Experimental|Travatan|Travoprost (0.004%)
11653425|NCT00051129|Experimental|Anecortave Acetate|Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18)
11653207|NCT00003593|Experimental|Arm A: TMD patients only|Patients are observed if their transient myeloproliferative disorder (TMD) does not require intervention. Patients who require therapy for TMD undergo leukapheresis or exchange transfusion for up to 3 consecutive days. If the TMD does not resolve or there is significant organ involvement, patients receive low-dose cytarabine IV continuously on days 0-4. Treatment repeats at least every 2 weeks for up to 4 courses. Patients who experience a recurrence of TMD at least 8 weeks after resolution or have refractory disease may proceed to group II for further treatment. patients will continue to be followed for remission induction, EFS, DFS and OS regardless of the type of leukemia that develops.
11653208|NCT00003593|Experimental|Arm B: AML/MDS patients only|(closed to accrual as of 6/24/04 except for patients first enrolled in group I): Patients receive induction therapy comprising cytarabine IV continuously, daunorubicin hydrochloride IV continuously, and oral thioguanine twice daily on days 0-3. Treatment repeats every 28 days for 4 courses. Patients with no CNS disease at diagnosis receive cytarabine intrathecally (IT) on day 0. Patients with CNS disease at diagnosis receive cytarabine IT on days 0, 5, and 7. If CNS disease persists on day 7, patients receive up to 6 courses of cytarabine IT, therapeutic hydrocortisone IT, and methotrexate IT, twice weekly beginning on day 10. Asparaginase during Intensification 1 day 1 hour 18.
11653209|NCT00003590|Experimental|Hydroxyurea|
11653210|NCT00003566|Experimental|video-thorascopy + surgery|Patients will undergo ipsilateral video-thorascopic evaluation. Patients may undergo surgery at the discretion of the surgeon and treating physicians.
11653211|NCT00003565|Experimental|docetaxel|OUTLINE: Patients receive docetaxel IV over 1 hour on day 1. Patients may receive additional courses beginning 21 days after the first docetaxel dose at the discretion of the physician.
11653212|NCT00003553|Experimental|1|The target for progenitor cell is >=5 x 106 CD 34/kg.
11653213|NCT00003537|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653214|NCT00003535|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653215|NCT00003534|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653216|NCT00003533|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653217|NCT00003532|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653218|NCT00003531|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653219|NCT00003530|Experimental|Antineoplaston Therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653220|NCT00003526|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653221|NCT00003525|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653222|NCT00003524|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653223|NCT00003522|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653224|NCT00003521|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653225|NCT00003520|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653226|NCT00003516|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
11653227|NCT00003515|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653228|NCT00003513|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653229|NCT00003512|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653230|NCT00003511|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653231|NCT00003509|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653696|NCT00043745|Placebo Comparator|3|Participants will receive soy extract devoid of isoflavones to serve as placebo
11653235|NCT00003498|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653236|NCT00003497|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
11653237|NCT00003496|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653238|NCT00003495|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653239|NCT00003494|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653240|NCT00003492|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653241|NCT00003491|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653242|NCT00003489|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653243|NCT00003485|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653244|NCT00003483|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653245|NCT00003479|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653246|NCT00003477|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653247|NCT00003476|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653248|NCT00003475|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653249|NCT00003474|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653250|NCT00003473|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653251|NCT00003472|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653252|NCT00003471|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653253|NCT00003470|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653254|NCT00003469|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653255|NCT00003468|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653256|NCT00003460|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653257|NCT00003459|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dosage is reached.
11653258|NCT00003458|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653259|NCT00003457|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653260|NCT00003456|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653261|NCT00003454|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653262|NCT00003453|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653263|NCT00003452|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
11653264|NCT00003440|Experimental|Arm A (paclitaxel)|Patients receive paclitaxel intravenously (IV) over 3 hours every 3 weeks.
11653265|NCT00003440|Active Comparator|Arm B (paclitaxel)|Patients receive paclitaxel IV over 1 hour weekly.
11653266|NCT00003440|Experimental|Arm C (paclitaxel, trastuzumab)|Patients receive paclitaxel as in Arm I. Patients also receive trastuzumab IV weekly.
11653267|NCT00003440|Active Comparator|Arm D (paclitaxel, trastuzumab)|Patients receive paclitaxel as in Arm II and trastuzumab as in Arm III.
11653268|NCT00003440|Experimental|Am E (paclitaxel, trastuzumab)|Patients receive paclitaxel and trastuzumab as in Arm C.
11653269|NCT00003440|Active Comparator|Arm F (paclitaxel, trastuzumab)|Patients receive paclitaxel and trastuzumab as in Arm D.
11653270|NCT00003404|Experimental|Adjuvant Radiotherapy|Adjuvant radiation was started within 12 weeks of local excision or breast re-excision.
11653271|NCT00003389|Experimental|Arm A (ABVD)|Arm A (ABVD): Patients receive doxorubicin (25 mg/m²), bleomycin (10 u/m²), vinblastine (6 mg/m²), and dacarbazine (375 mg/m²) intravenously (IV) on days 1 and 15. Courses repeat every 28 days. Patients are restaged after 4 courses. Patients who are in complete remission receive 2 additional courses. Patients with a partial response or less are evaluated after 6 courses, and if there is an ongoing response, patients may receive 2 additional courses for a total of 8. If no ongoing response is observed, patients are removed from the study. All patients with massive mediastinal disease, regardless of stage, receive radiotherapy 2-3 weeks after completion of chemotherapy.
11653272|NCT00003389|Active Comparator|Arm B (Stanford V)|Arm B (Stanford V): Patients receive Stanford V chemotherapy comprising doxorubicin (25 mg/m²) and vinblastine (6 mg/m²) IV on day 1 of weeks 1, 3, 5, 7, 9, and 11; vincristine (1.4 mg/m²) and bleomycin (5 u/m²) IV on day 1 of weeks 2, 4, 6, 8, 10, and 12; mechlorethamine (6 mg/m²) IV on day 1 of weeks 1, 5, and 9 (if mechlorethamine is unavailable, may substitute with cyclophosphamide [375 mg/m²] IV); etoposide (60 mg/m²) IV on days 1 and 2 of weeks 3, 7, and 11; and oral prednisone (40 mg/m²) every other day of weeks 1-9 followed by a taper. All patients with bulky disease receive radiotherapy 2-3 weeks after completion of chemotherapy.
11653273|NCT00003384|Experimental|Diagnostic|"Patients undergo a Pap smear followed by a ThinPrep cervical cell specimen collection at the time of direct colposcopic examination. Patients then undergo a cone biopsy of the cervix using loop electrosurgical excision procedure with an endocervical curettage, an excisional cone biopsy of the cervix with or without endocervical curettage, or a hysterectomy. Patients who are perimenopausal or postmenopausal or have a negative cervical cone biopsy also undergo endometrial biopsy or curettage. The Pap smear specimen is analyzed to determine MN antigen expression and the ThinPrep specimen is analyzed for the presence of high-risk human papilloma virus and to determine MN antigen and other marker (e.g., P16) expression.
~Patients who do not undergo hysterectomy are followed every 6 months for 2 years. All other patients are followed at 4, 26, and 30 weeks."
11653274|NCT00003377|Other|Radiation therapy plus concurrent weekly chemotherapy|
11653275|NCT00003375|No Intervention|Observation|Observation only.
11653276|NCT00003375|Experimental|Radiation therapy|Radiation therapy only.
11653277|NCT00003375|Experimental|Radiation plus PCV chemotherapy|Radiation and Procarbazine/CCNU/Vincristine (PCV) chemotherapy
11653278|NCT00003325|Other|Sentinenal lymph node mapping|Sentinenal lymph node mapping
11653279|NCT00003292|Experimental|ifosfamide|ifosfamide
11653280|NCT00003282|Experimental|Diagnostic (EF5)|Patients receive etanidazole derivative EF5 IV over 1-2 hours beginning approximately 24 hours prior to surgery. Tumors are then resected or biopsied after Eppendorf needle electrode measurements.
11653281|NCT00003278|Experimental|radiation + dexamethasone|"Patients undergo whole-brain radiotherapy (WBRT) daily 5 days a week for 4.5 weeks. Beginning 30 days after WBRT is completed, patients receive high-dose dexamethasone IV on days 1-5 during course 1 and on day 1 only during all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
~Patients are followed at 1 month after radiotherapy, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter."
11653282|NCT00003204|Experimental|Arm I (cyclophosphamide, fludarabine)|Patients receive cyclophosphamide IV over 30-45 minutes on day 1 and fludarabine IV over 10-20 minutes on days 1-5. Treatment repeats every 28 days in the absence of disease progression for a minimum of 4 courses and a maximum of 6 courses.
11653283|NCT00003204|Experimental|Arm II (cyclophosphamide, vincristine, prednisone)|Patients receive cyclophosphamide IV over 30-45 minutes and vincristine IV on day 1, and oral prednisone on days 1-5. Treatment repeats every 21 days in the absence of disease progression for a minimum of 6 courses and a maximum of 8 courses.
11653284|NCT00003204|Experimental|Arm III (rituximab)|Patients receive maintenance therapy with rituximab (IDEC-C2B8 monoclonal antibody) IV weekly for 4 weeks. Courses repeat every 6 months for 2 years. Maintenance therapy begins 4 weeks after the last chemotherapy.
11653285|NCT00003204|No Intervention|Arm IV (no intervention)|Patients undergo no maintenance therapy and are observed. Patients are followed every 3 months for 2 years, every 6 months for the next 3 years, and then annually thereafter.
11653286|NCT00003199|Experimental|Arm I|See Detailed Description.
11653287|NCT00003178|Experimental|1st Untreated Relapse for AML|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
11653426|NCT00051129|Placebo Comparator|Anecortave Acetate Vehicle|Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18)
11653427|NCT00051090|Experimental|A|All eligible study participants
11653428|NCT00050986|Experimental|Temozolomide and R115777|
11653288|NCT00003178|Experimental|Primary Refractory AML|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
11653289|NCT00003178|Experimental|MDS|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
11653290|NCT00003145|Experimental|Treatment (chemotherapy, TBI, PBSCT, DLI)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose TBI on day 0.
~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.
~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV BID or TID on days -3 to 56 with taper to day 77 or 180, and mycophenolate mofetil PO or IV BID on days 0-27.
~DLI: At least 2 weeks after completion of immunosuppression, patients with > 5% donor CD3+ T cells and no evidence of GVHD receive donor lymphocytes IV over 30 minutes. Patients may receive up to 3 DLIs at increasing cell doses in the absence of GVHD."
11653291|NCT00003140|Experimental|Arm I|Patients receive oral letrozole once daily.
11653292|NCT00003140|Placebo Comparator|Arm II|Patients receive oral placebo once daily.
11653293|NCT00003138|Active Comparator|Supportive Care|Patients received red cell and platelet transfusions for symptoms or to maintain hematocrit at or above 25% by volume. Patients who required transfusion support for symptomatic anemia prior to entering the study and who developed an increase in their transfusion requirement of >= 50% shall cross over to the Erythropoietin treatment arm, after at least four months on the supportive therapy arm.
11653294|NCT00003138|Experimental|Erythropoietin|Erythropoietin was administered at 150 units/kg subcutaneously every day. If patients stopped responding, they were subsequently treated with Erythropoietin (150 units/kg) and filgrastim and then Erythropoietin (300 units/kg) and filgrastim.
11653295|NCT00003119|Experimental|Treatment 1 - Asymptomatic - no immediate chemotherapy|
11653296|NCT00003119|Experimental|Symptomatic - immediate chemotherapy|
11653297|NCT00003093|Experimental|Treatment|See detailed description.
11653298|NCT00003092|Experimental|Paclitaxel|"Patients receive a single dose of IV paclitaxel over 3 hours. Additional cycles of paclitaxel will be given at the discretion of the physician.
~Patients are followed for second malignancies, disease progression, and survival."
11653299|NCT00003042|Experimental|1 cycle of neoadjuvant chemotherapy|Patients receive chemotherapy, surgical removal of the cancer followed by additional chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.
11653300|NCT00003042|Experimental|More than 1 cycle of neoadjuvant chemotherapy|Patients receive chemotherapy, followed by two treatment cycles of very high-dose chemotherapy, return of bone marrow derived cells, followed by radiation therapy and if indicated five years of tamoxifen treatment.
11653301|NCT00003034|Experimental|Arm I|Patients receive ranpirnase IV over 30 minutes weekly followed by doxorubicin IV. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression. Patients demonstrating evidence of clinical response or stable disease may continue on maintenance therapy with ranpirnase as a single agent until disease progression.
11653302|NCT00003034|Experimental|Arm II|Patients receive doxorubicin as in arm I for up to 6 courses.
11653303|NCT00002981|Experimental|PET Scan|Each patient receives C11-methionine intravenously. PET imaging begins immediately after injection for approximately 60 minutes total using standard imaging procedures. Immediately following the completion of imaging after C11-methionine administration, each patient receives FDG intravenously. PET imaging begins approximately 45 minutes thereafter for approximately 60 minutes using standard imaging procedures.
11653304|NCT00002975|Experimental|PDT|4-6h and 18-24h, 20%, ALA application of superficial and nodular epidermally-derived lesions using ca 633 nm laser irradiation
11653305|NCT00002968|Experimental|Arm I (edrecolomab)|Patients receive adjuvant edrecolomab IV over 2 hours on day 1. Treatment repeats every 28 days for 5 courses. Patients must begin therapy no earlier than 7 days and no later than 42 days postsurgical resection. Patients also undergo observation at 3 and 6 months postrandomization.
11653306|NCT00002968|No Intervention|Arm II (no treatment)|Patients undergo observation at 3 and 6 months postrandomization. .
11653307|NCT00002951|Experimental|Arm A (Hyper-FHX)|Concomitant chemoradiotherapy consisting of hydroxyurea (PO, BID, x 6days), continuous infusion 5-fluorouracil (IV, x 5days), hyperfractionated radiotherapy (150 cGy twice daily for 5 days every 14 days, 5 cycles)
11653308|NCT00002944|Experimental|Regimen A (CV Chemotherapy)|Induction will consist of 10 weeks of therapy (carboplatin, vincristine sulfate),followed by 2 weeks without chemotherapy. Induction should only be interrupted in the event of grade 3 neurotoxicity, grade 2 renal toxicity, grade 4 hematologic toxicity, or tumor progression. Maintenance-Four Courses (2 cycles/course) commences on Day 84 (week 12) of Induction or when peripheral counts recover with ANC >1,000/$L and platelet count >100,000/$L. Each cycle will consist of 4 weekly doses of carboplatin, three weekly doses of vincristine sulfate (given concomitantly with the first 3 weeks of carboplatin), followed by two weeks of rest for a total of 6 weeks. Maintenance will continue for a total of 8 cycles.
11653309|NCT00002944|Experimental|Regimen B (TPCV Chemotherapy)|Each cycle of chemotherapy consists of 4 days of oral chemotherapy (Thioguanine, procarbazine hydrochloride, Lomustine and Vincristine sulfate beginning Day 0, followed by vincristine sulfate IV on Days 14 and 28. The cycle is repeated every 6 weeks (42 days). A total of 8 cycles will be given.
11653429|NCT00050960|Experimental|bexarotene with carboplatin and paclitaxel|
11653430|NCT00050960|Experimental|carboplatin and paclitaxel|
11653431|NCT00050791|Experimental|VLCD and leptin|Very low calorie diet formula providing 800 calories per day and leptin treatment.
11653984|NCT00034814|Experimental|5|Non-enzyme-inducing TLP 25mg TID
11653310|NCT00002941|Experimental|Reinduction Therapy|Two courses of reinduction chemotherapy followed by bone marrow biopsy and aspirate prior to peripheral blood stem cell (PBSC) harvest. If marrow involvement is still present at harvest, then 2 additional courses of induction chemotherapy are given. The PBSC transplantation preparative regimen should begin within 2 weeks of completing reinduction therapy course, consisting of the following: Carmustine IV over 3 hours on days -8, -7, and -6, Etoposide continuous IV over days -8, -7, and -6, Cyclophosphamide IV over 1 hour daily on days -5, -4, -3, and -2, Mesna as a 15 min infusion before each dose of cyclophosphamide then at 3, 6, 9, and 12 hours after initiation of each cyclophosphamide dose Methylprednisolone IV is given to protect lungs from the toxic effects of carmustine.
11653311|NCT00002938|Other|Surgery|Salvage prostatectomy
11653312|NCT00002931|Experimental|HD Chemo and Auto Stem Cells|
11653313|NCT00002920|Active Comparator|Tamoxifen alone|Tamoxifen alone x 5 years
11653314|NCT00002920|Experimental|Tamoxifen plus MPA|Tamoxifen Plus Medroxyprogesterone Acetate (MPA) x 5 years
11653315|NCT00002913|Experimental|Treatment (paclitaxel, cisplatin, topotecan hydrochloride)|"Patients receive paclitaxel IV over 3 hours and cisplatin IV on day 1, followed by topotecan IV over 30 minutes on days 1-3. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 4 and continuing until blood counts recover. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
~Cohorts of 4-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicities."
11653316|NCT00002882|Experimental|IFN-A Therapy Schedule A|Schedule A: IV Interferon alfa-2b (IFN-A) induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.
11653317|NCT00002882|Experimental|IFN-A Therapy Schedule B|Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks.
11653318|NCT00002882|Experimental|Adjuvant Biochemotherapy|Cisplatin IV Days 1-4; Vinblastine IVPB Days 1-4; Dacarbazine (DTIC) IVPB on Day 1; IFN-A is given subcutaneously on days 1-5; IL-2 continuous infusion for 96 hours on Days 1-4. Each course repeated every 21 days for 4 courses.
11653319|NCT00002874|Experimental|Bicalutamide|Radiation therapy + bicalutamide
11653320|NCT00002874|Placebo Comparator|Placebo|Radiation therapy + placebo
11653321|NCT00002860|Other|surgery|
11653322|NCT00002855|Experimental|Arm I|Arm I: Medical or surgical castration followed by an anti-androgen therapy with either flutamide, bicalutamide, or nilutamide.
11653323|NCT00002855|Experimental|Arm II|Arm II: Chemo/hormonal therapy for 3 x 8-week courses, followed by total androgen blockade. Each course consists of 6 weeks of cytotoxic therapy with doxorubicin, ketoconazole, vinblastine, and estramustine followed by 2 weeks rest. Maintained on hydrocortisone both during treatment and during rest.
11653324|NCT00002854|Experimental|Sequential high dose chemotherapy|
11653325|NCT00002852|Active Comparator|Arm I (surgery, observation)|Patients receive no further therapy.
11653326|NCT00002852|Experimental|Arm II (surgery, chemotherapy)|Patients receive adjuvant therapy comprising paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on day 1. Treatment continues every 3 weeks for 4 courses.
11653327|NCT00002850|Experimental|Ciprofloxacin or ofloxacin|"Quinolone:
~Ciprofloxacin 500 mg every 12 hours or Ofloxacin400 mg every 12 hours."
11653328|NCT00002850|Experimental|TMP-SMX|TMP-SMX: 160 mg trimethoprim and 800 mg sulfamethoxazole every 12 hours
11653329|NCT00002850|No Intervention|No prophylaxis|The patient will receive no prophylactic antibiotics.
11653330|NCT00002849|Experimental|induction and maintenance|dexamethasone induction followed by alpha interferon maintenance
11653331|NCT00002842|Experimental|Hepatic Resection/Portal Vein FUdr/Systemic 5-FU & Leucovorin|Patients receive floxuridine via portal vein infusion from days 1-14. Systemic chemotherapy consists of leucovorin calcium on days 8-14 and fluorouracil on days 9-13. Courses repeat every 4 weeks for a total of 12 weeks
11653332|NCT00002807|No Intervention|Observation|
11653333|NCT00002807|Experimental|Radiation|Post-operative pelvic radiation therapy (45 Gy in 25 fractions over 5 weeks)
11653334|NCT00002798|Experimental|Arm I (combination chemotherapy)|"Patients receive treatment as in induction therapy, plus G-CSF SC beginning on day 16 and continuing until blood counts recover. If CSF is clear by day 10 of induction, patients receive cytarabine IT on days 0, 10, and 35. If CSF is not clear, patients receive triple intrathecal therapy (TIT; cytarabine, hydrocortisone, methotrexate) on days 0 and 10.
~See Detailed Description"
11653335|NCT00002798|Experimental|Arm II (combination chemotherapy)|"Patients receive fludarabine IV over 24 hours on days 0 and 1, cytarabine IV over 72 hours on days 2-4, and idarubicin IV over 15 minutes on days 0-2. G-CSF begins on day 6 and continues until blood counts recover. Patients also receive TIT on days -1 and 7, if CSF is not clear on day 10 of induction. Patients on both arms are reassessed on day 35. Those patients with M1 marrow proceed to intensification; all others are removed from the study.
~Intensification: See Detailed Description"
11653336|NCT00002798|Experimental|Arm III (combination chemotherapy, aldesleukin)|Patients receive interleukin-2 IV continuously on days 1-4 and 9-18.
11653337|NCT00002798|Active Comparator|Arm IV (combination chemotherapy)|No further treatment
11653338|NCT00002798|Experimental|Arm V (combination chemotherapy, radiotherapy)|Patients undergo radiotherapy to the chloroma 5 days a week for 2 weeks.
11653339|NCT00002796|Experimental|Treatment (fluorouracil, phenylbutyrate, indomethacin, IFN-G|"Phase I: Patients receive 5-FU IV over 24 hours on day 1; phenylbutyrate IV over 120 hours and oral indomethacin daily on days 2-6; and interferon gamma subcutaneously on days 2, 4, and 6. Courses repeat weekly in the absence of disease progression or unacceptable toxicity.
~Cohorts of 3-6 patients receive escalating doses of 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which less than 2 of 6 patients experience dose-limiting toxicity (DLT).
~Phase II: Patients receive 5-FU, phenylbutyrate, indomethacin, and interferon gamma as in phase I at the MTD."
11653340|NCT00002766|Experimental|"ARA-C/High-Dose Mitoxantrone(All-2)"|See detail description
11653341|NCT00002766|Active Comparator|"Standard Vincristine/Prednisone (L-20)"|See detail description
11653432|NCT00050791|Active Comparator|placebo|Very low calorie diet and placebo treatment
11653433|NCT00050778|Active Comparator|Interferon Beta-1a|
11653434|NCT00050778|Experimental|Alemtuzumab 12 mg|
11653435|NCT00050778|Experimental|Alemtuzumab 24 mg|
11653342|NCT00002762||Patient interviewing + blood sampling|"Patients were interviewed at the time of the primary cancer surgery to determine the menstrual history. Blood sampling occurred within 1 day of surgery, and serum samples were shipped frozen to a central laboratory (Mayo Medical Laboratory, Rochester, MN) for E2, Pg, and LH determinations. Serum hormone levels, menstrual cycle length, and day of last menses were used to determine the menstrual phase at which surgery occurred.
~Patients were observed every 6 months for the first year postregistration and annually for the next 2 to 10 years postregistration for adjuvant therapy information, disease recurrence, and death."
11653343|NCT00002757|Active Comparator|Group A|All resected stage I and Abdominal stage II only. All Group A patients will be treated with two cycles of COPAD and will be followed in a confirmatory study of the current result of nearly 100% cure rate.
11653344|NCT00002757|Active Comparator|Group B|Non resected stage I & II, stage III & st IV (CNS - ve, BM < 25%). Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimise the risk of this. Prior to any chemotherapy being administered intravenous hydration fluids should be given run at a rate of 3000 mls/m2/day. Alkalinisation may be necessary Pay close attention to fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumour lysis persists.
11653345|NCT00002757|Active Comparator|Group C|Bone marrow > 25% but CNS negative Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimize the risk of this. Intravenous hydration fluids should be given prior to chemotherapy. Alkalinisation may be necessary. Monitor fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumor lysis persists
11653346|NCT00002756|Experimental|Chemo (Reduced Induction) No BMT (Open February 2004)|
11653347|NCT00002727|Active Comparator|Radiation therapy - conventional fractionation|Radiation therapy - conventional fractionation (70 Gy/2 Gy once per day/7 Weeks) 35 fractions
11653348|NCT00002727|Experimental|Radiation therapy - hyperfractionation|Radiation therapy - hyperfractionation (79.2 Gy/1.2 b.i.d/6.5 weeks) 66 fractions
11653349|NCT00002718|Experimental|Candidates for transplant|Pts stratified by number of HLA-incompatible alleles(1 vs 2 or 3). Harvest:Begin 6-10 d before transplant,allogeneic BM is harvest & tx in vitro. Begin 5-6 d before transplant,G-CSF-stimulated,PBSC harvest,selected for CD34+ cells,& treatment in vitro. If doable,ABM harvest in event of allogeneic graft failure. Myeloablation:Pts u/g TBI 3x d days -9 to -6, thiotepa IV over 4hrs days -5 & -4, & cyclophosphamide IV days -3 & -2. Transplant:CD34+, E-rosette & T-cell-depleted PBSC infuse over 15mins & T-cell-depleted bone marrow infused over 1-5mins day 0. Pts get G-CSF IV over 30 min begin day 1 & continue til blood counts recover & tapering. Pts get anti-thymocyte globulin IV over 4-6hrs days 8,10,12,&14 & oral methylprednisolone days 8-14 followed by tapered doses days 15-17. See detailed description for more details.
11653350|NCT00002716|Experimental|Arm I - laparotomy + conventional surgery + chemotherapy|"Patients undergo laparotomy for placement of a hepatic artery catheter and then subcutaneous placement of a hepatic artery infusion pump. Patients with unresected primary disease also undergo resection at the time of catheter and pump placement. Beginning within 1-2 weeks after surgery, patients receive floxuridine, dexamethasone, and leucovorin calcium (CF) via continuous hepatic artery infusion on days 1-14. Treatment for patients continues every 4 weeks in the absence of disease progression or unacceptable toxicity.
~Quality of life and medical resource utilization are assessed at baseline, every 3 months for 1 year, and then at 18 months.
~Patients are followed every 3 months."
11653351|NCT00002716|Experimental|Arm II - conventional surgery + chemotherapy|"Patients receive CF IV and fluorouracil IV on days 1-5. Patients with unresected primary disease undergo resection within 3-4 weeks before initiation of chemotherapy.
~Treatment for patients continues every 4 weeks in the absence of disease progression or unacceptable toxicity.
~Quality of life and medical resource utilization are assessed at baseline, every 3 months for 1 year, and then at 18 months.
~Patients are followed every 3 months."
11653352|NCT00002715|Experimental|Combination Chemotherapy (Stanford V)|A combination chemotherapy regimen consisting of mechlorethamine, doxorubicin hydrochloride, vinblastine, vincristine, bleomycin, etoposide and prednisone, administered on a compressed schedule
11653353|NCT00002706|Experimental|Arm I|Patients undergo vaginal hysterectomy and BSO via laparoscopy.
11653354|NCT00002706|Active Comparator|Arm II|Patients undergo total abdominal hysterectomy and BSO via conventional laparotomy.
11653355|NCT00002678|Active Comparator|Melphan plus prednisone|melphalan plus prednisone qd x 4 28 day cycles x 12 cycles; No treatment after stable response.
11653356|NCT00002678|Active Comparator|Melphan, prednisone pluse dexamethasone|melphalan plus prednisone qd x 4 28 day cycles x 12 cycles; dexamethasone qd x 4 q 28 days after non-progression
11653357|NCT00002668|Active Comparator|Observation|Standard pain management interventions usually given by hospital staff
11653358|NCT00002668|Experimental|Educational Intervention and Behavioral Skills Training|Patients participated in a program including video presentations, written materials, and coaching in behavioral skills to improve pain control (not to reduce analgesic use).
11653359|NCT00002663|Experimental|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|Patients receive adoptive immunotherapy with allogeneic Epstein Barr virus (EBV)-specific cytotoxic T lymphocytes IV on days 1, 8, and 15. After the third dose, patients will be observed for 3 weeks. After the 3 week observation period, additional courses of treatment may be given in the absence of disease progression or unacceptable toxicity.
11653360|NCT00002651|Active Comparator|Consolidation arm I|Patients continue CAD therapy comprising goserelin subcutaneously once a month and oral bicalutamide once daily. Treatment continues in the absence of disease progression.
11653361|NCT00002651|Experimental|Consolidation arm II|Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy as in consolidation arm I. Patients whose PSA normalizes after 8 courses return to observation. Patients whose PSA does not normalize after 8 courses continue CAD therapy.
11653436|NCT00050752||1/Patients|Patients with known or suspected Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)
11653437|NCT00050752||2/Family Members|Family members (related by blood) of patients who have or are suspected of havingHereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)
11653591|NCT00047411|Experimental|2|Use of the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
11653362|NCT00002649|Experimental|Arm I (autologous PBSCT, TBI, etoposide, cyclophosphamide)|"Part I: Autologous PBSC are harvested before study entry. Patients undergo total body irradiation twice a day on days -8 to -5, high-dose etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 1 hour on day -2. PBSC are reinfused on day 0 and then G-CSF may be administered subcutaneously or IV on days 0-21.
~Part II: Within 28-80 days after PBSC transplantation and after recovery from any toxic effects, patients with no active recurrent or progressive disease are randomized to 1 of 2 treatment arms.
~Patients receive interleukin-2 IV continuously on days 1-4 and 9-18."
11653363|NCT00002649|No Intervention|Arm II (observation only)|Patients undergo observation only.
11653364|NCT00002633|Active Comparator|Total Androgen Blockade|
11653365|NCT00002633|Active Comparator|Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation|
11653366|NCT00002624|Experimental|Radiotherapy + surgery|"Patients begin radiotherapy 2-8 weeks postoperatively. Patients with complete resection undergo radiotherapy 5 days a week for 5.6 weeks. Patients with incomplete resection undergo radiotherapy 5 days a week for 6.6 weeks.
~Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter."
11653367|NCT00002611|Active Comparator|Stratum 1|Stage I favorable histology (FH) Wilms' tumor, under 24 months of age, and tumor weight less than 550 g: After conventional surgery (nephrectomy), patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
11653368|NCT00002611|Active Comparator|Stratum 2|Stage I FH Wilms' tumor and age 24 months and over or tumor weight at least 550 g; stage I focal anaplastic (FA) or diffuse anaplastic (DA) Wilms' tumor: Patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
11653369|NCT00002611|Active Comparator|Stratum 3|Stage II FH Wilms' tumor: Patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
11653370|NCT00002611|Active Comparator|Stratum 4|Stage III FH Wilms' tumor; stage II or III FA Wilms' tumor: After conventional surgery (nephrectomy), patients receive regimen DD-4A comprising dactinomycin DACT IV weekly on weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weekly on weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weekly on weeks 1-10, 12, 15, 18, 21, and 24. Patients also undergo abdominal radiation therapy.
11653371|NCT00002611|Active Comparator|Stratum 5|Stage IV FH or FA Wilms' tumor: patients receive regimen DD-4A comprising dactinomycin DACT IV weekly on weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weekly on weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weekly on weeks 1-10, 12, 15, 18, 21, and 24. Patients also undergo abdominal radiation therapy, and whole lung radiation therapy (at the discretion of the investigator).
11653372|NCT00002611|Active Comparator|Stratum 6|Stage V FH, FA, or DA Wilms' tumor: After bilateral conventional surgery (biopsy), patients with FH receive chemotherapy as in stratum 1 (dactinomycin IV weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate IV weeks 1-10, 12, 15, and 18) or 4 (dactinomycin IV weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weeks 1-10, 12, 15, 18, 21, and 24). Patients with FA or DA receive chemotherapy as in stratum 7 (vincristine sulfate VCR IV weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy.
11653373|NCT00002611|Active Comparator|Stratum 7|Stages I-IV clear cell sarcoma): After conventional surgery (nephrectomy), patients receive vincristine sulfate VCR IV weekly on weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weekly on weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy and continuing until blood counts recover. Patients also undergo abdominal radiotherapy and whole lung radiotherapy (if pulmonary metastases are present).
11653374|NCT00002611|Active Comparator|Stratum 8|Stages II-IV DA Wilms' tumor: After conventional surgery (nephrectomy), Patients receive treatment as in stratum 7 (patients receive vincristine sulfate VCR IV weekly on weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weekly on weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy and continuing until blood counts recover. Patients also undergo abdominal radiotherapy and whole lung radiotherapy (if pulmonary metastases are present).
11653375|NCT00002611|Active Comparator|Stratum 9|Stages I-IV rhabdoid tumor: After conventional surgery (nephrectomy), patients receive carboplatin IV on days 1-2 and VP-16 IV over 1 hour (beginning after carboplatin infusion) on days 1-3 of weeks 0, 3, 9, 12, 18, and 21 and CTX IV over 1 hour on days 1-5 of weeks 6, 15, and 24. Filgrastim G-CSF is administered as on stratum 7. Patients also undergo radiation therapy. After completion of chemotherapy, patients undergo second-look conventional surgery (laparotomy) and conventional surgery (partial nephrectomy or wedge excision if feasible). After conventional surgery (second-look surgery), patients without persistent or residual disease resume chemotherapy.
11653376|NCT00002610|Experimental|STRATUM A|Treatment of children in Stratum A will be determined by the site of relapse and the presence of microscopic or gross residual disease after attempted surgical excision of the relapse.
11653377|NCT00002610|Experimental|Stratum B|All children who received combination chemotherapy with Regimen EE - 4A as their initial therapy for Wilms tumor will receive Regimen I and radiation therapy to the site of recurrence. All patients will receive prophylactic trimethoprim /sulfamethoxazole
11653378|NCT00002610|Experimental|STRATUM C|All children who received combination chemotherapy with Regimen DD - 4A as their initial therapy for Wilms tumor will be treated with the following chemotherapy. All patients will receive prophylactic trimethoprim/sulfamethoxazole
11653379|NCT00002610|Experimental|STRATUM D|Six week cycles of chemotherapy will be given to all patients who do not have progressive disease at the time of each week 0 re-evaluation.
11653380|NCT00002594|Experimental|Ablative chemo followed by autologous bone marrow (ABM) rescue|Autologous bone marrow and/or peripheral blood stem cells (PBSC) are harvested. Patients then receive intensive cyclophosphamide IV over 1 hour on days -8 to -5 and melphalan IV over 15 minutes on days -4 to -2. Bone marrow is reinfused on day 0. PBSC are reinfused on day 0 if used alone or on day 1 if used after autologous bone marrow transplantation (ABMT). Sargramostim (GM-CSF) is administered IV over 2 hours daily beginning 4 hours after ABMT and continuing until blood counts recover.
11653381|NCT00002586|Experimental|13-cis retinoic acid|13-cis retinoic acid 50 mg/d
11653382|NCT00002586|Experimental|13-Cis Retinoic Acid and Tocopherol|13-Cis Retinoic Acid (50 mg/day) Tocopherol (800 mg/day)
11653383|NCT00002586|No Intervention|Observation|Observation
11653384|NCT00002569|Active Comparator|Radiation therapy (RT) alone|Radiation therapy (RT) alone - External Beam RT 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week) to MR defined tumor volume.
11653385|NCT00002569|Experimental|Intensive pre-treatment chemotherapy and radiation therapy|Intensive pre-treatment chemotherapy (Day 1 CCNU 130 mg/m2 p.o., Day 8 - Vincristine 1.4 mg/m2 i.v., Days 8-21 - Procarbazine 75 mg/m2 p.o., Day 29 - Vincristine 1.4 mg/m2 i.v.) followed by radiation therapy (External Beam RT 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week) to MR defined tumor volume).
11653386|NCT00002558|Experimental|chemotherapy administered with G-CSF and PBSC support|The design of this trial is a phase I/II trial of sequential accelerated chemotherapy cycles with taxol/ifosfamide and carboplatin/etoposide administered with G-CSF and PBSC support.
11653387|NCT00002556|Active Comparator|ARM A (VBMCP)|"INDUCTION PHASE: Patients receive VBMCP comprising vincristine sulfate IV on day 1, carmustine IV on day 1, melphalan PO on days 1-4, cyclophosphamide IV on day 1, and prednisone PO on days 1-7. Treatment repeats every 35 days for 2 courses in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION PHASE: Patients receive VBMCP as in the induction phase. Courses repeat every 35 days in the absence of disease progression or unacceptable toxicity."
11653388|NCT00002556|Experimental|Arm B (VBMCP, high dose cyclophosphamide, r alpha 2b IFN)|"INDUCTION PHASE: Patients receive VBMCP comprising vincristine sulfate IV on day 1, carmustine IV on day 1, melphalan PO on days 1-4, cyclophosphamide IV on day 1, and prednisone PO on days 1-7. Treatment repeats every 35 days for 2 courses in the absence of disease progression or unacceptable toxicity.
~CONSOLIDATION PHASE: Patients receive vincristine sulfate, carmustine, and melphalan as in the induction phase, high-dose cyclophosphamide IV on days 1-4 and prednisone PO on days 1-4 during courses 3 and 5. Patients receive VBMCP as in the induction phase during even numbered courses. Patients receive recombinant interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, and 22 during odd courses beginning course 7. Treatment repeats every 35 days for courses 3-5, every 21 days for even courses beginning course 6, and every 22 days for odd courses beginning course 7 in the absence of disease progression or unacceptable toxicity."
11653389|NCT00002528|Experimental|Surgery w/ axillary clearance, tamox|Either a total mastectomy with axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy with radiotherapy to the conserved breast) with axillary lymph node dissection, and tamoxifen (20 mg) given after surgery for the duration of 5 years or until relapse.
11653390|NCT00002528|Experimental|Surgery w/o axillary clearance, tamox|Either a total mastectomy without axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy with radiotherapy to the conserved breast) without axillary lymph node dissection, and tamoxifen (20 mg) given after surgery for the duration of 5 years or until relapse.
11653391|NCT00002514|Experimental|Transplant|Allogeneic (if donor) or Autologous (if no donor) bone marrow transplant
11653392|NCT00002514|Active Comparator|Conventional Consolidation/Maintenance|Consolidation/Maintenance Therapy
11653393|NCT00002484|Experimental|external beam radiotherapy|Patients undergo 3-dimensional conformal external beam radiotherapy 5 days a week for 8-10 weeks.
11653394|NCT00052091|Experimental|1 Problem Solving Therapy|12 weekly sessions of problem solving therapy (PST)
11653395|NCT00052091|Experimental|2 Brief Supportive Therapy|12 weekly sessions of brief supportive therapy (BST)
11653396|NCT00052078|Active Comparator|Sertraline|Participants received sertraline for 12 weeks.
11653397|NCT00052078|Active Comparator|CBT|Participants received cognitive behavioral therapy for 12 weeks
11653398|NCT00052078|Active Comparator|SRT + CBT|Participants received both sertraline and CBT for 12 weeks.
11653399|NCT00052078|Placebo Comparator|Placebo|Participants received a placebo pill for 12 weeks.
11653400|NCT00052026|Placebo Comparator|1|Placebo
11653401|NCT00052026|Experimental|2|Low-dose carvedilol
11653402|NCT00052026|Experimental|3|high-dose carvedilol
11653403|NCT00052013|Experimental|PTK787/ZK 222584|
11653404|NCT00051935|Experimental|1|
11653405|NCT00051922|Experimental|1|Participants will receive vaccine and will be followed for 1 year
11653406|NCT00051831|Experimental|1|
11653407|NCT00051857||1/Healthy Controls|Subjects 5 years old and up with muscoskeletal impairment, pathology, or variant
11653408|NCT00051857||2/Healthy Volunteers|Subjects 5 years old and up with muscoskeletal impairment, pathology, or variant
11653409|NCT00051740|Active Comparator|Cognitive Adaptation Therapy|Subjects receive Cognitive adaptation therapy as part of treatment for schizophrenia
11653410|NCT00051740|Active Comparator|Minimal Environmental Support|Subjects receive minimal environmental support in schizophrenia treatment
11653411|NCT00051636|Experimental|Zoledronic Acid and Placebo to Risedronate|Participants received zoledronic acid 5 mg intravenous infusion one dose, 60 days of oral placebo to risedronate, calcium 500 mg twice a day and vitamin D 400 to 1000 international units daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
11653412|NCT00051636|Active Comparator|Risedronate and Placebo to Zoledronic Acid|Participants received 60 days of oral risedronate 30 mg, one intravenous infusion of placebo to zoledronic acid, calcium 500 mg twice a day and vitamin D 400 to 1000 international units daily during the core period, and received only calcium and vitamin D supplements during the extended observation period.
11653413|NCT00051558|Experimental|A|Teriparatide 20 micrograms/day injection plus oral placebo, 36 months
11653414|NCT00051558|Active Comparator|B|Alendronate 10 mg/day oral plus injection placebo, 36 months
11653415|NCT00051363|Active Comparator|Active CPAP|Active Continuous Positive Airway Pressure (CPAP)
11653416|NCT00051363|Placebo Comparator|Sham CPAP|Sham Continuous Positive Airway Pressure (CPAP)
11653438|NCT00050752||3/Non-Biologic Family Members|Spouses enrolled primarily for linkage analysis (Spouses have been removed from theinclusion criteria for this study. This closed cohort is for spouses previously enrolled on study.)
11653439|NCT00050674|Experimental|Filgrastim-SD/01|6 mg SC, Day 9, 24 hours after the end of the chemotherapy infusion
11653440|NCT00050661|Active Comparator|Narrow Band Ultraviolet B|312nm
11653441|NCT00050661|Experimental|anti-TAC or placebo|
11653442|NCT00050648|Active Comparator|cyclosporine|oral medication 2mg/kg/day orally from Day 0 until Day 90
11653443|NCT00050648|Active Comparator|anti-TAC|1mg/kg/dose medication every other week on the odd week (week 1-13)
11653444|NCT00050648|Experimental|Cyclosporine and anti-TAC|DaclizumabTM at 1mg/kg plus low dose cyclosporine (2 mg/kg/day)
11653445|NCT00050609|Placebo Comparator|1|
11653446|NCT00050609|Active Comparator|2|5 mg tadalafil
11653447|NCT00050609|Active Comparator|3|20 mg tadalafil
11653448|NCT00050427|Experimental|001|ET743 580 mcg/m2 3-hour i.v. infusion on Days 1 8 and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.
11653449|NCT00050427|Experimental|002|ET743 1 300 mcg/m2 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.
11653450|NCT00050622|Placebo Comparator|No Treatment|No Medication, No Behavior Modification (BMOD)
11653451|NCT00050622|Active Comparator|Low Dose Medication Only|0.15 mg/kg methylphenidate (MPH), No BMOD
11653452|NCT00050622|Active Comparator|Medium Dose Medication Only|0.3 mg/kg MPH, No BMOD
11653453|NCT00050622|Active Comparator|Higher Dose Medication Only|0.6 mg/kg MPH, No BMOD
11653454|NCT00050622|Active Comparator|Low Intensity BMOD Only|Placebo, Low Intensity BMOD
11653455|NCT00050622|Active Comparator|Low Intensity BMOD + Low Dose Medication|0.15 mg/kg MPH, Low Intensity BMOD
11653456|NCT00050622|Active Comparator|Low Intensity BMOD + Medium Dose Medication|0.3 mg/kg MPH, Low Intensity BMOD
11653457|NCT00050622|Active Comparator|Low Intensity BMOD + Higher Dose Medication|0.6 mg/kg MPH, Low Intensity BMOD
11653458|NCT00050622|Active Comparator|High Intensity BMOD Only|Placebo, High Intensity BMOD
11653459|NCT00050622|Active Comparator|High Intensity BMOD + Low Dose Medication|0.15 mg/kg MPH, High Intensity BMOD
11653460|NCT00050622|Active Comparator|High Intensity BMOD + Medium Dose Medication|0.3 mg/kg MPH, High Intensity BMOD
11653461|NCT00050622|Active Comparator|High Intensity BMOD + Higher Dose Medication|0.6 mg/kg MPH, High Intensity BMOD
11653462|NCT00050583|Experimental|1|10 Session modified CBT (including a relaxation component) administered by trained mental health clinicians at the primary care setting
11653463|NCT00050583|No Intervention|2|"Treatment as Usual, defined as the use of a consultation letter and traditional primary care management."
11653464|NCT00050570|Experimental|Intervention|An 8-week, Internet- based, structured cognitive- behavioral program combined with an online, asynchronous, moderated discussion group.
11653465|NCT00050570|No Intervention|Control|The waitlist control group was only contacted at the time of assessments and was offered the intervention at the end of the study, after the 2-year follow-up assessment was completed.
11653466|NCT00050557|Experimental|1|Participants will receive immediate Multi-Family Psychoeducation Group treatment and ongoing treatment as usual
11653467|NCT00050557|Active Comparator|2|Participants will receive treatment as usual and waitlist Multi-Family Psychoeducation Group treatment
11653468|NCT00050505|Experimental|Cohort C|N=100 to 110 subjects receives 1:10 diluted dose of Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
11653469|NCT00050505|Experimental|Cohort B|N=571 to 581 subjects receives 1:5 diluted dose of Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
11653470|NCT00050505|Experimental|Cohort A|N=226 to 236 subjects receives undiluted dose Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
11653471|NCT00050440|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days. Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose.
11653472|NCT00050414|Experimental|Trabectedin|Trabectedin 0.58 mg/m2 administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression. Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
11653473|NCT00050349|Experimental|EPO906|
11653474|NCT00050310||Acute Infection|adults and children with acute anthrax infection
11653475|NCT00050310||AVA Recipient/Healthy Volunteer|healthy adults who have received AVA vaccine
11653476|NCT00050310||Recovered|adults and children in recovering phase of anthrax infection
11653477|NCT00050310||Suspected Exposure|adults and children with suspected exposure to anthrax
11653478|NCT00050167|Experimental|Weekly Paclitaxel (WP)|Weekly Paclitaxel (WP) for 12 weeks followed by Fluorouracil + Epirubicin + Cyclophosphamide (FEC) every 3 weeks for 4 cycles
11653479|NCT00050167|Experimental|Docetaxel and Capecitabine (DX)|Docetaxel + Capecitabine (DX) days 1-14 every 3 weeks for 4 cycles followed by FEC for 4 cycles.
11653480|NCT00050089|Active Comparator|No ARDFP+Standard-ART|No Antiretroviral Drug-Free Period (No ARDFP) and Standard-ART
11653481|NCT00050089|Active Comparator|No ARDFP+Mega-ART|No Antiretroviral Drug-Free Period (No ARDFP) and Mega-ART
11653482|NCT00050089|Active Comparator|ARDFP+Standard-ART|Antiretroviral Drug-Free Period (ARDFP) and Standard-ART
11653483|NCT00050089|Active Comparator|ARDFP+Mega-ART|Antiretroviral Drug-Free Period (ARDFP) and Mega-ART
11653484|NCT00050076|Experimental|MCC-135 50 mg BID|
11653485|NCT00050076|Experimental|MCC-135 100 mg QD|
11653486|NCT00050076|Experimental|MCC-135 200 mg QD|
11653487|NCT00050076|Placebo Comparator|Placebo|
11653488|NCT00050037|Experimental|CD-ROM based CBT|Group is given a copy of the CD-ROM program to complete at home over 10 weeks. At the end of each week, these patients upload and transmit their encrypted tracking data to the research coordinator. At the end of the treatment, participants who have not improved are offered a course of traditional manual-based group therapy, follow-up in an ongoing maintenance group in an eating disorders program, or an alternative treatment.
11653489|NCT00050037|Active Comparator|Standard Group CBT|"Group undergoes standard group CBT. Therapy is administered over 10 weeks in five 90-minute sessions. The key topics are similar to those covered in the CD-ROM group: psychoeducation, developing a personal profile, standardizing meal times, recognizing emotional eating, increasing daily activity, learning the language of CBT, identifying automatic thoughts, restructuring thoughts, identifying cues and consequences, chaining, surfing the urge, and preventing relapses. Therapy sessions include a didactic section followed by group interaction and discussion. All group sessions are audiotaped and monitored."
11653490|NCT00050037|No Intervention|Waiting List|Participants in the wait list control group undergo an initial assessment but receive no active intervention for 10 weeks. After 10 weeks, these patients undergo post-treatment assessment and are offered the opportunity to either enter group treatment in an eating disorders program or enter other appropriate treatment. Three-month follow-up data are not collected from these individuals.
11653491|NCT00050115||Hepatitis A + AA cohort|Subjects seen either at Clinical center or by outside physician
11653492|NCT00050011|Experimental|Zoledronic Acid upfront|Participants in the upfront arm received zoledronate 4 mg i.v. on Day 1 and every 6 months until disease progression (recurrence) or the end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.
11653493|NCT00050011|Experimental|Zoledronate delayed-start|In lieu of a placebo arm, which was considered unethical for this trial, a delayed start arm was used. Participants who met certain clinical criteria indicating risk of lumbar spine or total hip fracture, or experienced clinical fracture unrelated to trauma or any asymptomatic fracture discovered at the Month 36 scheduled visit, were started on zoledronate 4 mg i.v. and for every 6 months until disease progression (recurrence) or end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.
11653494|NCT00049842|Experimental|PEG-Intron (peginterferon alfa-2b) 0.5 µg/kg Weekly (QW)|PEG-Intron 0.5 µg/kg Weekly (QW) subcutaneously (SC) as maintenance therapy for 36 months with 4-week follow-up
11653495|NCT00049842|No Intervention|Untreated Control|
11653496|NCT00049816|No Intervention|1|Participants will receive no intervention and will act as the control group.
11653497|NCT00049816|Experimental|2|Participants will partake in a walking exercise program.
11653498|NCT00049816|Experimental|3|Participants will partake in a cycling exercise program.
11653499|NCT00049764|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
11653500|NCT00049764|Placebo Comparator|2|0.9% sodium chloride
11653501|NCT00048932|Active Comparator|Double-blind abatacept|Participants received a fixed dose of abatacept approximating 10 mg/kg (500 mg for participants < 60 kg, 750 mg for participants 60 to 100 kg and 1 g for participants > 100 kg). Abatacept was administered intravenously (IV) on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period
11653502|NCT00048932|Placebo Comparator|Double-blind Placebo|Participants received Placebo (dextrose 5% water [D5W] for injection U.S.P or normal saline [NS]) for IV infusion administered on Days 1, 15, 29, and every 28 days thereafter, for a total of 14 doses. Participants also received background therapy(ies) for rheumatoid arthritis (RA) (non-biologic or biologic disease-modifying drugs [DMARDs], or combination) throughout the double-blind treatment period.
11653503|NCT00048932|Active Comparator|Open-label Abatacept|Participants received abatacept (weight-tiered 10 mg/kg dose) IV every 28 days during the open-label period.
11653504|NCT00048854|Active Comparator|1|Participants will receive treatment as usual
11653505|NCT00048854|Experimental|2|Participants will take sertraline
11653506|NCT00048828|Active Comparator|1|
11653507|NCT00048828|Active Comparator|2|
11653508|NCT00048815|Active Comparator|citalopram|Subjects in this arm received 20mg/day of citalopram taken orally for 12 weeks.
11653509|NCT00048815|Experimental|St. John's Wort|Subjects in this arm received 810 mg/day of St. John's Wort taken orally (in three tablets of 270mg each) for 12 weeks.
11653510|NCT00048815|Placebo Comparator|Placebo|Subjects in this arm received double-dummy (look-alike) placebo for 12 weeks.
11653511|NCT00048581|Active Comparator|Abatacept|Short Term Portion of Study
11653512|NCT00048581|Placebo Comparator|Placebo|Short Term Portion of Study
11653513|NCT00048581|Active Comparator|Abatacept (Long Term)|"Long Term Portion of Study:
~All participants receive Active Drug"
11653514|NCT00048568|Experimental|Abatacept + Methotrexate|Short Term: Abatacept was dosed by weight with participants weighing < 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants > 100 kg received abatacept 1 g. Participants continued treatment with methotrexate (MTX) either orally or parenterally at a minimum dose of 15 mg.
11653515|NCT00048568|Active Comparator|Placebo + Methotrexate|Short Term: Participants received a placebo solution intravenously and methotrexate at the dose employed prior to study enrollment and a minimum of 15 mg.
11653516|NCT00048568|Experimental|Abatacept + Methotrexate Open Label|Open Label: Abatacept was dosed intravenously by weight at 10 mg/kg in the OL period under tiered dosing such that participants weighing < 60 kg received abatacept 500 mg; participants ≥ 60 kg and ≤ 100 kg received abatacept 750 mg; and participants > 100 kg received abatacept 1 g. MTX was continued at the dose used in the DB period.
11653517|NCT00048750|Experimental|1|
11653518|NCT00048750|Placebo Comparator|2|
11653519|NCT00048737|Experimental|90Y Zevalin in ASCT|Allogeneic Stem Cell (AST) Transplantation with 90Y Zevalin/Cyclophosphamide/Fludarabine as a preparative regimen.
11653520|NCT00048724|Experimental|PegIntron|PegIntron (peginterferon alfa-2b) 0.5 µg/kg subcutaneously once weekly as maintenance therapy for 60 months with a 4-week post-treatment follow-up
11653521|NCT00048724|No Intervention|Untreated Control|
11653522|NCT00048672|Experimental|Gleevec|Gleevec 400 mg orally daily. Dose adjustments made at discretion of treating physician within these guidelines: The highest dose acceptable is 800 mg daily. The lowest dose acceptable is 300 mg. No dose adjustment of more than 200 mg at one time is allowed. Dose adjustments to less than 300 mg may be approved after consultation with the principal investigator.
11653523|NCT00048646|Placebo Comparator|placebo|placebo
11653524|NCT00048646|Experimental|IV progesterone|IV progesterone
11653525|NCT00048633|Experimental|Tariquidar|
11653527|NCT00048542|Experimental|Double-Blind Adalimumab + MTX|Subjects who were inadequate responders to MTX and were adalimumab responders during the Open-Label Lead-In (OL-LI) phase received adalimumab plus concomitant MTX during the Double-Blind Phase. MTX-treated inadequate responders must have had active disease on MTX treatment for at least 3 months prior to screening.
11653528|NCT00048542|Placebo Comparator|Double-Blind Placebo + MTX|Subjects who were inadequate responders to MTX and were adalimumab responders during the Open-Label Lead-In (OL-LI) phase received placebo plus concomitant MTX during the Double-Blind Phase. MTX-treated inadequate responders must have had active disease on MTX treatment for at least 3 months prior to screening.
11653529|NCT00048542|Experimental|Double-Blind Adalimumab|Subjects in the non-methotrexate (MTX) stratum who were either naïve to MTX or withdrawn from MTX at least 2 weeks prior to study drug administration, and were adalimumab responders during the OL-LI phase, received adalimumab, but no concomitant MTX treatment, during the Double-Blind Phase.
11653530|NCT00048542|Placebo Comparator|Double-Blind Placebo|Subjects in the non-methotrexate (MTX) stratum who were either naïve to MTX or withdrawn from MTX at least 2 weeks prior to study drug administration, and were adalimumab responders during the OL-LI phase, received placebo, but no concomitant MTX treatment, during the Double-Blind Phase.
11653531|NCT00048542|Experimental|OLE BSA Adalimumab + MTX|All subjects received subcutaneous injections of 24 mg adalimumab per square meter of body surface area (BSA) up to a maximum of 40 mg total body dose every other week (eow), concomitantly with MTX treatment, during the Open-Label Extension (OLE) BSA Phase of the study.
11653532|NCT00048542|Experimental|OLE BSA Adalimumab|All subjects received subcutaneous injections of 24 mg adalimumab per square meter of body surface area (BSA) up to a maximum of 40 mg total body dose every other week (eow), but not MTX treatment, during the Open-Label Extension (OLE) BSA Phase of the study.
11653533|NCT00048542|Experimental|OLE FD Adalimumab + MTX|Subjects received adalimumab concomitantly with MTX treatment during the Open-Label Extension (OLE) Fixed Dose (FD) Phase of the study in which only body weight (not BSA) determined dosing; subjects weighing less than 30 kg were dosed with 20 mg of adalimumab SC eow, and subjects weighing 30 kg or more were dosed with 40 mg of adalimumab SC eow.
11653534|NCT00048542|Experimental|OLE FD Adalimumab|Subjects received placebo without concomitant MTX treatment during the Open-Label Extension (OLE) Fixed Dose (FD) Phase of the study in which only body weight (not BSA) determined dosing; subjects weighing less than 30 kg were dosed with 20 mg of adalimumab SC eow, and subjects weighing 30 kg or more were dosed with 40 mg of adalimumab SC eow.
11653535|NCT00048347|Experimental|Avonex|Interferon-beta1a (Avonex) 30 µg IM every week for 12 weeks
11653536|NCT00048165|Experimental|Daclizumab|Daclizumab will be administered as a intravenous dose of 1 milligrams per kilogram [mg/kg] on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg, and 500-1000 mg IV methylprednisolone peri operative switch to oral at 0.5-1 mg/kg/day followed by tapering.
11653537|NCT00048165|Placebo Comparator|Placebo|Matching placebo will be administered on Days 1, 8, 22, 36, and 50, along with mycophenolate mofetil (one dose of 1.5 mg twice daily [BID], cyclosporine 1-4 mg/kg IV or 2-6 mg/kg orally, and 500-1000 mg IV methylprednisolone peri-op switch to oral at 0.5-1 mg/kg/day followed by tapering.
11653538|NCT00048152|Experimental|1|
11653539|NCT00048152|Experimental|2|
11653540|NCT00048152|Experimental|3|
11653541|NCT00048139|Experimental|1|
11653542|NCT00048126|Experimental|1|
11653543|NCT00048100|Experimental|Apheresis + Transplant|Skin biopsy & either a leukodepletion apheresis or an additional marrow aspiration prior to marrow or stem cell transplantation.
11653544|NCT00048087|Experimental|Iressa + Docetaxel|
11653545|NCT00048074|Experimental|1|oral placebo daily and IV ibandronate 2 mg q 2 mo
11653546|NCT00048074|Experimental|2|oral ibandronate 2.5 mg daily and IV placebo q 2 mo and q 3 mo
11653547|NCT00048074|Experimental|3|oral placebo daily and IV ibandronate 3 mg q 3 mo
11653548|NCT00048061|Active Comparator|Ibandronate 2.5 mg|Participants will receive 2.5 milligram (mg) ibandronate Per oral (PO) daily and an oblong placebo tablet PO monthly. Participants will also receive calcium 500 mg /day and vitamin D 400 international units (IU)/day .
11653549|NCT00048061|Experimental|Ibandronate 50/50 mg|Participants will receive 100 mg ibandronate PO monthly taken on a single day (2 X 50 mg tablets) and round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day.
11653550|NCT00048061|Experimental|Ibandronate 100 mg|Participants will receive 100 mg ibandronate PO monthly divided over two consecutive days (50 mg tablet/day) and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day
11653551|NCT00048061|Experimental|Ibandronate 150 mg|Participants will receive 150 mg ibandronate PO monthly taken on a single day and a round placebo tablet PO daily. Participants will also receive calcium 500 mg /day and vitamin D 400 IU/day
11653552|NCT00048048|Experimental|Cohort 1 (RO0503821, 0.15 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) at a dose of 0.15 microgram per kilogram (mcg/kg) subcutaneously (SC) once every week to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
11653553|NCT00048048|Experimental|Cohort 2 (RO0503821, 0.3 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 at a dose of 0.3 mcg/kg SC once every week to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
11653554|NCT00048048|Experimental|Cohort 3 (RO0503821, 0.6 mcg/kg 1x/Week)|Eligible participants will be receiving RO0503821 at a dose of 0.6 mcg/kg SC once every week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
11653583|NCT00047502|Experimental|Gleevec + SCH 66336|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.
~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day, and SCH66336 100 mg by mouth twice a day."
11653592|NCT00046735|Experimental|1|
11653555|NCT00048048|Experimental|Cohort 4 (RO0503821, 0.3 mcg/kg 1x/2 Week)|Eligible participants will be receiving RO0503821 at a dose of 0.3 mcg/kg SC once every two week, to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
11653556|NCT00048048|Experimental|Cohort 5 (RO0503821, 0.6 mcg/kg 1x/2Week)|Eligible participants will be receiving RO0503821 at a dose of 0.6 mcg/kg SC once every two week, to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
11653557|NCT00048048|Experimental|Cohort 6 (RO0503821, 1.2 mcg/kg 1x/2 Week)|Eligible participants will be receiving RO0503821 at a dose of 1.2 mcg/kg SC once every two week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
11653558|NCT00048048|Experimental|Cohort 7 (RO0503821, 0.45 mcg/kg 1x/3 Week)|Eligible participants will be receiving RO0503821 at a dose of 0.45 mcg/kg SC once every three week, to complete the dosage of 0.9 mcg/kg up to 6 weeks (Week 1 to Week 6). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
11653559|NCT00048048|Experimental|Cohort 8 (RO0503821, 0.9 mcg/kg 1x/3Week)|Eligible participants will be receiving RO0503821 at a dose of 0.9 mcg/kg SC once every three week, to complete the dosage of 1.8 mcg/kg up to 6 weeks (Week 7 to Week 12). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
11653560|NCT00048048|Experimental|Cohort 9 (RO0503821,1.8 mcg/kg 1x/3 Week)|Eligible participants will be receiving RO0503821 at a dose of 1.8 mcg/kg SC once every three week, to complete the dosage of 3.6 mcg/kg up to 6 weeks (Week 13 to Week 18). Participants will be followed-up for one week post the treatment period. During extension Years 1 and 2, the participants will remain at the same frequency of administration as that of core treatment period.
11653561|NCT00048035|Experimental|Cohort 1 (RO0503821 [0.25/150 1x/week])|Eligible participant will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) intravenously (IV) using a dose conversion factor of 0.25/150 microgram (mcg)/kilogram (kg) of the previous weekly erythropoiesis stimulating agents (ESA) dose, (equal to 62.50% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
11653562|NCT00048035|Experimental|Cohort 2 (RO0503821 [0.25/150 1x/2week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.25/150 mcg/kg of the previous weekly ESA dose, (equal to 62.50% assumed equi-effective dose) once in every two weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
11653563|NCT00048035|Experimental|Cohort 3 (RO0503821 [0.4/150 1x/week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.40/150 mcg/kg of the previous weekly ESA dose, (equal to100% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
11653564|NCT00048035|Experimental|Cohort 4 (RO0503821 [0.4/150 1x/2week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.40/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once in every two weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
11653565|NCT00048035|Experimental|Cohort 5 (RO0503821 [0.6/150 1x/week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.60/150 mcg/kg of the previous weekly ESA dose, (equal to150% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
11653566|NCT00048035|Experimental|Cohort 6 (RO0503821 [0.6/150 1x/2week])|Eligible participant will be administered RO0503821 IV using a dose conversion factor of 0.60/150 mcg/kg of the previous weekly ESA dose, (equal to150% assumed equi-effective dose) once in every two weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
11653567|NCT00047983|No Intervention|Control|Controls and will receive no dietary supplements
11653568|NCT00047983|Experimental|Arginine and Canola Oil|Daily nutritional supplements of arginine and canola oil
11653569|NCT00047983|Experimental|Arginine and Coromega|Daily nutritional supplements of arginine and Coromega
11653570|NCT00047827|Experimental|1|
11653571|NCT00047996||Subjects ages 2 and up|Clinical Center Patients, Children at CNMC, Healthy Volunteers
11653572|NCT00047879|Other|Glioblastoma multiforme stratum|Glioblastoma multiforme is one of the most common and aggressive types of brain tumor.
11653573|NCT00047879|Other|Anaplastic Glioma Stratum|Anaplastic glioma is a type of brain tumor that develops from star-shaped glial cells that support nerve cells. Anaplastic oligodendroglioma is a malignant type of brain tumor sensitive to treatment with chemotherapy and radiotherapy.
11653574|NCT00047853|Experimental|Acoustic startle|loud noises with MEG only
11653575|NCT00047853|Experimental|Threat of shock|threat of electric shock
11653576|NCT00047554||TRAVATAN|Travoprost, 0.004% ophthalmic solution, 1 drop to the study eye once daily in the evening for up to 5 years
11653577|NCT00047710|Experimental|Bevacizumab|Radiation, Bevacizumab, and Capecitabine
11653578|NCT00047697|Experimental|Donepezil HCl|Donepezil HCL 5 mg and 10 mg
11653579|NCT00047697|Placebo Comparator|Placebo|Placebo
11653580|NCT00047671|Active Comparator|Citalopram|All subjects receive an FDA approved dose of Citalopram
11653581|NCT00047619|Experimental|Pulsatile lavage group|pulsatile lavage therapy
11653582|NCT00047619|Sham Comparator|Sham lavage group|sham pulsatile lavage
11653584|NCT00047463|Active Comparator|CPAP active comparator|continuous positive airway pressure (CPAP)
11653585|NCT00047463|Placebo Comparator|CPAP Placebo|Placebo-CPAP
11653594|NCT00046566|Active Comparator|Soy protein-milk protein-carbohydrate|Participants received 40 grams of soy protein daily for 8 weeks, 40 grams of milk protein daily for 8 weeks, and 40 grams of carbohydrate daily for 8 weeks.
11653595|NCT00046566|Experimental|Milk protein-carbohydrate-soy protein|Participants received 40 grams of milk protein daily for 8 weeks, 40 grams of carbohydrate daily for 8 weeks, and 40 grams of soy protein daily for 8 weeks.
11653596|NCT00046566|Placebo Comparator|Carbohydrate-soy protein-milk protein|Participants received 40 grams of complex carbohydrate daily for 8 weeks, 40 grams of soy protein daily for 8 weeks, and 40 grams of milk protein daily for 8 weeks.
11653597|NCT00046228|Experimental|001|Abciximab; reteplase; abciximab placebo; abciximab 0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
11653598|NCT00046228|Experimental|002|abciximab; reteplase placebo; abciximab placebo; abciximab 0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
11653599|NCT00046228|Experimental|003|abciximab placebo; reteplase placebo, abciximab, abciximab placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
11653600|NCT00046202||normal subjects|subjects in whom no disorder of cholesterol is suspected related to affected individuals
11653601|NCT00046202||subjects suspected of cholesterol disorder|subjects in whom a disorder of cholesterol metabolism is suspected
11653602|NCT00046189||1|Patients with XP
11653603|NCT00046189||2|Family members from XP families with known DNA repair gene mutations
11653604|NCT00046111|Experimental|Primary Group|40 subjects on medium doses of Topotecan and tested for bioequivalence for 4 weeks.
11653605|NCT00046085|Active Comparator|Patient customary care|12 months of patient customary care
11653606|NCT00046085|Experimental|Online family education|12 months of patient customary care and relative access to online education and support program
11653607|NCT00046059||ADHD|Children aged 7-17 with ADHD and their families.
11653608|NCT00045968|Active Comparator|treatment cohort|
11653609|NCT00045968|Placebo Comparator|Placebo Chohort|Autologous PBMC
11653610|NCT00045942|Experimental|PKC412 (Core)|Participants received 75 mg PKC412 three time daily (tid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
11653611|NCT00045942|Experimental|FLT3 mutated PKC412 100 mg/day (E1)|Participants received 50 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
11653612|NCT00045942|Experimental|FLT3 mutated PKC412 200 mg/day (E1)|Participants received 100 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
11653613|NCT00045942|Experimental|FLT3 wild type PKC412 100 mg/day (E1)|Participants received 50 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
11653614|NCT00045942|Experimental|FLT3 wild type PKC412 200 mg/day (E1)|Participants received 100 mg PKC412 twice daily (bid) orally on a continuous basis until disease progression or the occurrence of unacceptable treatment related toxicity.
11653615|NCT00045942|Experimental|FLT3 mutated PKC412 dose escalation|Participants were treated with PKC412 orally starting at a dose of 100 mg bid. A dose increase up to 300 mg bid was allowed. Participants were treated until time of disease progression, doubling of the bone marrow blast percentage from baseline, or the occurrence of unacceptable toxicity.
11653616|NCT00045942|Experimental|FLT3 mutated PKC+Itraconazole (E2)|Within a cycle of 28 days, participants received a loading dose of PKC412 100 mg bid on days 1-2, followed by PKC412 50 mg bid for 3 weeks from days 3-21. On day 22, itraconazole 100 mg bid was added to the treatment regimen. The combinations of PKC412 and Itraconazole continued until disease progression, unacceptable toxicity, or withdrawal of consent.
11653617|NCT00045942|Experimental|FLT3 wild type PKC412 dose escalation (E2)|Participants were treated with PKC412 orally starting at a dose of 100 mg bid. A dose increase up to 300 mg bid was allowed. Participants were treated until time of disease progression, doubling of the bone marrow blast percentage from baseline, or the occurrence of unacceptable toxicity.
11653618|NCT00045942|Experimental|FLT3 wild type PKC+Itraconazole (E2)|Within a cycle of 28 days, participants received a loading dose of PKC412 100 mg bid on days 1-2, followed by PKC412 50 mg bid for 3 weeks from days 3-21. On day 22, itraconazole 100 mg bid was added to the treatment regimen. The combinations of PKC412 and Itraconazole continued until disease progression, unacceptable toxicity, or withdrawal of consent.
11653619|NCT00045916|Experimental|High dosage ECT + nortriptyline|Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
11653620|NCT00045916|Experimental|High dosage ECT + venlafaxine|Participants will receive venlafaxine and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
11653621|NCT00045916|Placebo Comparator|High dosage ECT + placebo|Participants will receive placebo and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.
11653622|NCT00045916|Experimental|Low dosage ECT + nortriptyline|Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
11653623|NCT00045916|Experimental|Low dosage ECT + venlafaxine|Participants will receive venlafaxine and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
11653624|NCT00045916|Experimental|Low dosage ECT + placebo|Participants will receive placebo and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.
11653625|NCT00045903|Experimental|Exposure and Ritual Prevention|Exposure and Ritual Prevention Therapy
11653626|NCT00045903|Active Comparator|Stress Management|Stress Management Therapy
11653627|NCT00045799|Experimental|Omeprazole sodium bicarbonate immediate release PWD/FS|
11653628|NCT00045799|Active Comparator|Cimetidine IV|
11653629|NCT00045786|Experimental|400 mg CC-1088|
11653630|NCT00045786|Experimental|800 mg CC-1088|
11653631|NCT00045786|Experimental|1200 mg CC-1088|
11653632|NCT00045786|Experimental|1500 mg CC-1088|
11653633|NCT00045773||1|
11653634|NCT00044915|Active Comparator|Arm 1|
11653635|NCT00044915|Placebo Comparator|Arm 2|
11653639|NCT00044707|Active Comparator|Pramlintide acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide injection is 0.6 mg/mL
11653640|NCT00044707|Placebo Comparator|Placebo|Placebo solution is the same, sterile preserved formulation, except the active ingredient, pramlintide, is omitted
11653641|NCT00044694|Placebo Comparator|Placebo 0.01 mL|2 week placebo lead-in followed by Placebo 0.01 mL
11653642|NCT00044694|Placebo Comparator|Placebo 0.02 mL|2 week placebo lead-in followed by Placebo 0.02 mL
11653643|NCT00044694|Placebo Comparator|Placebo 0.03 mL|2 week placebo lead-in followed by Placebo 0.03 mL
11653644|NCT00044694|Placebo Comparator|Placebo 0.04 mL|2 week placebo lead-in followed by Placebo 0.04 mL
11653645|NCT00044694|Experimental|AC2993 2.5 mcg|2 week placebo lead-in (0.01 mL) followed by AC2993 2.5 mcg; 0.01 mL
11653646|NCT00044694|Experimental|AC2993 5.0 mcg|2 week placebo lead-in followed by AC2993 5.0 mcg; 0.01 mL
11653647|NCT00044694|Experimental|AC2993 7.5 mcg|2 week placebo lead-in followed by AC2993 7.5 mcg; 0.03 mL
11653648|NCT00044694|Experimental|AC2993 10.0 mcg|2 week placebo lead-in period followed by AC2993 10.0 mcg; 0.04 mL
11653649|NCT00044668|Experimental|AC2993|5 μg AC2993, twice daily, for 4 weeks followed by 10 μg AC2993, twice daily, during a maintenance period
11653650|NCT00044655|Active Comparator|Stay on baseline medication prescribed|Participants will continue taking medication prescribed at study entry: 1) either long-acting injectable haloperidol or fluphenazine, OR 2) two antipsychotic medications which might include a combination of any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.
11653651|NCT00044655|Active Comparator|Switch per study protocol|Participants will change medications from medication prescribed at study entry, either: 1) long-acting injectable risperidone, OR 2) one of the two antipsychotic medications prescribed at baseline which may include any of the following: risperidone, olanzapine, ziprasidone, quetiapine, aripiprazole, or conventional (typical) antipsychotic medications.
11653652|NCT00044629|Experimental|Cognitive Behavioral Therapy and Ambien|Cognitive Behavioral Therapy and Ambien
11653653|NCT00044629|Placebo Comparator|Cognitive Behavioral Therapy and Placebo|Cognitive Behavioral Therapy and Placebo
11653654|NCT00044629|Active Comparator|Cognitive Behavioral Therapy alone (no drug)|Cognitive Behavioral Therapy alone (no drug)
11653655|NCT00044590||Cases|Patients with Parkinson's Disease
11653656|NCT00044590||Controls|Controls, subjects without Parkinson's Disease
11653657|NCT00044564|Experimental|Arm 1|
11653658|NCT00044551|Experimental|Arm 1|
11653659|NCT00044538|Experimental|Arm 1|
11653660|NCT00044525|Experimental|Arm 1|
11653661|NCT00044512|Experimental|Sorafenib 400 mg b.i.d.|Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)
11653662|NCT00044291|Experimental|Atamestane + toremifene|
11653663|NCT00044291|Active Comparator|Letrozole + placebo|
11653664|NCT00044304|Experimental|Imatinib|open label imatinib mesylate treatment
11653665|NCT00044304|Experimental|Ruxolitinib|open label ruxolitinib treatment
11653666|NCT00044213|Active Comparator|EDTA + high dose vitamin|Participants will receive 40 infusions of active EDTA chelation and active high-dose oral vitamins.
11653667|NCT00044213|Placebo Comparator|EDTA + high dose vitamin placebo|Participants will receive 40 infusions of EDTA chelation and placebo high-dose oral vitamins.
11653668|NCT00044213|Placebo Comparator|EDTA placebo + high dose vitamin|Participants will receive 40 infusions of placebo EDTA chelation and active high-dose oral vitamins.
11653669|NCT00044213|Placebo Comparator|EDTA placebo + high dose vitamin placebo|Participants will receive 40 infusions of placebo EDTA chelation and placebo high-dose oral vitamins.
11653670|NCT00044174||Depressed Mothers/Infants|Mothers and their 5 month old infants who have been clinically diagnosed as exhibitingdepressive symptoms
11653671|NCT00044174||Non-depressed Mothers/Infants|Mothers and their 5 month old infants who have been clinically diagnosed as not exhibitingdepressive symptoms
11653672|NCT00044044|Experimental|Lurasidone 20 mg|Lurasidone 20 mg tablets
11653673|NCT00044044|Experimental|Lurasidone 40 mg|Lurasidone 40 mg tablets
11653674|NCT00044044|Experimental|Lurasidone 80 mg|Lurasidone 2 40 mg tablets
11653675|NCT00044044|Active Comparator|Haloperidol 10mg|Haloperidol 10mg tablets
11653676|NCT00044044|Placebo Comparator|Placebo|Matching Placebo to Lurasidone and Haloperidol
11653677|NCT00044031|Placebo Comparator|B|Placebo (immunogen vehicle) combined with gemcitabine.
11653678|NCT00044031|Experimental|A|500 µg G17DT immunogen combined with gemcitabine.
11653679|NCT00044005|Experimental|Lurasidone 20 mg|Lurasidone 20 mg oral tablet
11653680|NCT00044005|Experimental|Lurasidione 40 mg|Lurasidone 40 mg oral tablet
11653681|NCT00044005|Experimental|Lurasidone 80mg|Lurasidone 80mg oral tablet
11653682|NCT00044122||Adult Relatives|Relatives of patient with mastocytosis
11653683|NCT00044122||Adults with Mastocytosis|Adults with documented mastocytosis
11653684|NCT00044122||Pediatric Patients with Mastocytosis|Pediatric patients with documented mastocytosis
11653685|NCT00044122||Pediatric Relatives|Pediatric relatives of patients with mastocytosis
11653686|NCT00044083|Placebo Comparator|Placebo Arm|Placebo one week
11653687|NCT00044083|Active Comparator|Tolcapone Arm|Tolcapone one week
11653688|NCT00043979|Experimental|Arm 1- Sibling Donors|Donors (n = 30) were matched first degree relatives who were eligible to donate peripheral blood stem cells.
11653689|NCT00043979|Experimental|Arm 2 - Recipients|Recipients (n=30) were enrolled to receive peripheral blood stem cells (PBSC) and receive either cyclosporine or tacrolimus and sirolimus for graft versus host disease (GVHD) prophylaxis.
11653690|NCT00043823|Experimental|Avastin + Tarceva|Combination Therapy (Avastin + Tarceva) = Avastin IV Day 1 of each 21-day cycle + oral Tarceva daily.
11653691|NCT00043810|Experimental|Gelonin Purging of ASCT|Gelonin Purging of Autologous Stem Cells for Transplantation (ASCT) + Fludara/Busulfan
11653692|NCT00043693|Experimental|1|Participants will undergo the Family Intervention for Dual Diagnosis (FIDD) program.
11653699|NCT00043550|Experimental|1 Sertraline/Venlafaxine|Participants receive sertraline for the first 8 weeks. Participants will receive venlafaxine if they do not respond to sertraline by week 8
11653700|NCT00043550|Active Comparator|2 Supportive Expressive Therapy|Participants will receive supportive-expressive psychotherapy.
11653701|NCT00043550|Placebo Comparator|3 Pill Placebo|Participants receive placebo.
11653702|NCT00043537|Experimental|Social Effectiveness Therapy for Children|Social Effectiveness Therapy for Children includes social skills training, peer generalization experiences and exposure therapy
11653703|NCT00043537|Experimental|Fluoxetine|Fluoxetine given in 10mg doses, up to 40 mg as tolerated
11653704|NCT00043537|Placebo Comparator|Pill placebo|"Capsules identical to fluoxetine given in 10 mg. doses up to 40 mg."
11653705|NCT00043420|Experimental|Phase I: 0.08 mg/kg|Escalating dose groups: 0.08 mg/kg PF-3512676 Injection
11653706|NCT00043420|Experimental|Phase I: 0.16 mg/kg|Escalating dose groups: 0.16 mg/kg PF-3512676 Injection
11653707|NCT00043420|Experimental|Phase I: 0.24 mg/kg|Escalating dose groups: 0.24 mg/kg PF-3512676 Injection
11653708|NCT00043420|Experimental|Phase I: 0.28 mg/kg|Escalating dose groups: 0.28 mg/kg PF-3512676 Injection
11653709|NCT00043420|Experimental|Phase I: 0.32 mg/kg|Escalating dose groups: 0.32 mg/kg PF-3512676 Injection
11653710|NCT00043420|Experimental|Phase I: 0.36 mg/kg|Escalating dose groups: 0.36 mg/kg PF-3512676 Injection
11653711|NCT00043420|Experimental|Phase II: 10 mg|Phase II: 10 mg flat dose (random assignment in Phase II)
11653712|NCT00043420|Experimental|Phase II: 25 mg|Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
11653713|NCT00043407|Experimental|CPG 7909 Injection|
11653714|NCT00043394|Experimental|Cohort 1|0.04 mg/kg CpG 7909
11653715|NCT00043394|Experimental|Cohort 2|0.08 mg/kg CpG 7909
11653716|NCT00043394|Experimental|Cohort 3|0.12 mg/kg CpG 7909 Injection once weekly
11653717|NCT00043394|Experimental|Cohort 4|0.16 mg/kg CpG 7909
11653718|NCT00043368|Experimental|1|Patients will be treated with the same dosing regimen and schedule of PF-3512676 Injection with which they were treated at the end of the previous PF-3512676 Injection trial. Any proposed changes to their schedule/regimen will be at the discretion of the treating physician, following consultation with Coley.
11653719|NCT00043472||1|Eligible women at least one intact ovary who have signed written, informed consent that they will undergo screening as per protocol.
11653720|NCT00043472||2|Eligible women with at least one intact ovary who have signed written, informed consent that they will undergo risk reducing surgery
11653721|NCT00043225||Cystic Fibrosis|Cystic Fibrosis patients
11653722|NCT00043186|Placebo Comparator|Placebo|Participants received double-blind subcutaneous (SC) placebo injections every 3 months until month 21 and then placebo SC injections once every 6 months from Month 24 through Month 42.
11653723|NCT00043186|Experimental|Denosumab 6 mg every 3 months|Participants received denosumab 6 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
11653724|NCT00043186|Experimental|Denosumab 14 mg every 3 months|Participants received denosumab 14 mg SC every 3 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
11653725|NCT00043186|Experimental|Denosumab 30 mg every 3 months|Participants received denosumab 30 mg SC every 3 months until Month 21 then placebo SC every 6 months at Month 24 and Month 30 and then denosumab 60 mg SC every 6 months at Month 36 and Month 42.
11653726|NCT00043186|Experimental|Denosumab 14 mg every 6 months|Participants received denosumab 14 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
11653727|NCT00043186|Experimental|Denosumab 60 mg every 6 months|Participants received denosumab 60 mg SC every 6 months until Month 42.
11653728|NCT00043186|Experimental|Denosumab 100 mg every 6 months|Participants received denosumab 100 mg SC every 6 months until Month 21 and then denosumab 60 mg every 6 months from Month 24 through Month 42.
11653729|NCT00043186|Experimental|Denosumab 210 mg every 6 months|Participants received denosumab 210 mg SC every 6 months until Month 21 and then placebo every 6 months from Month 24 through Month 42.
11653730|NCT00043186|Active Comparator|Alendronate 70 mg|Participants received open-label alendronate 70 mg tablets orally once a week through Month 24. From Month 24 to Month 48 participants received no treatment.
11653731|NCT00042666|Experimental|LY317615|500 milligrams (mg), oral, daily (QD), up to six (6) 28-day cycles
11653732|NCT00042653|Experimental|AMG 073|AMG 073
11653733|NCT00042653|Placebo Comparator|Placebo|Placebo
11653734|NCT00042601|Placebo Comparator|Placebo|A clear, colorless, sterile solution for SC injection manufactured by Amylin Pharmaceuticals, Inc. Placebo solution is the same, sterile preserved formulation, except the active ingredient, pramlintide, is omitted.
11653735|NCT00042601|Active Comparator|Pramlintide|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection manufactured by Amylin Pharmaceuticals, Inc. It consists of pramlintide (AC137) 0.6 mg/mL in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative.
11653736|NCT00042614||Controls|Matched to patients for age, gender and race
11653737|NCT00042614||Patients|Who have had heart transplants, awaiting, or controls screened.
11653738|NCT00042510|Experimental|Treatment Group|500µg G17DT administered on Weeks 1, 5 and 9 and an additional treatment at Week 25. Cisplatin was administered every 4 weeks on the first day of each treatment cycle as a 1 to 3 hour intravenous infusion at a dose of 100mg/m^2. 5-FU was administered every 4 weeks during the first 5 days of each cycle as a continuous intravenous infusion at a dose of 1,000 mg/m^2/d.
11653739|NCT00042471|Experimental|Pramlintide acetate (AC137) injection|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
11653825|NCT00039741|Experimental|NNRTI/1K|2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 1,000 copies/ml or higher
11653985|NCT00034814|Experimental|6|Non-enzyme-inducing TLP 35mg TID
11653986|NCT00034554|Experimental|1|0.1mg
11653740|NCT00042458|Placebo Comparator|Placebo|Placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.Ingredients: D-Mannitol 43.0 mg/mL Metacresol 2.25 mg/mL Glacial acetic acid 1.53 mg/mL Sodium acetate trihydrate 0.61 mg/mL pH 4.0 Water for injection qs to 5.0 mL
11653741|NCT00042458|Active Comparator|Pramlintide Acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide injection is 0.6 mg/mL
11653742|NCT00042432|Experimental|cinacalcet (AMG 073)|
11653743|NCT00042432|Placebo Comparator|Placebo|
11653744|NCT00042406|Placebo Comparator|Placebo|
11653745|NCT00042406|Experimental|HuMax-CD4 80 mg|80 mg
11653746|NCT00042406|Experimental|HuMax-CD4 160 mg|160 mg
11653747|NCT00042289|Experimental|Women taking ARVs without TB treatment|"HIV-infected pregnant women will be assigned to this arm if receiving one or more of the following ARV drugs/drug combinations but not receiving TB treatment: atazanavir/cobicistat, darunavir/ritonavir, darunavir/cobicistat, etravirine, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF/cobicistat, TAF/ritonavir, efavirenz, or lopinavir/ritonavir.
~Note: As of February 2016, the study will no longer enroll women receiving etravirine or increased dose lopinavir/ritonavir."
11653748|NCT00042289|Experimental|Women taking ARVs with TB treatment|"HIV-infected pregnant women will be assigned to this arm if receiving efavirenz, lopinavir/ritonavir, or nevirapine and TB treatment with at least one of the following TB drugs at study entry: rifampicin, ethambutol, isoniazid, or pyrazinamide.
~Note: As of February 2016, the study will no longer enroll women receiving nevirapine."
11653749|NCT00042289|Experimental|Women taking no ARVs with TB treatment|HIV-uninfected pregnant women will be assigned to this arm if receiving at least two of the following first-line TB drugs at study entry: ethambutol, isoniazid, pyrazinamide, or rifampicin.
11653750|NCT00042289|Experimental|Women with/without ARVs w/TB treatment for drug-resistant TB|HIV-infected and HIV-uninfected pregnant women with or without ARVs will be assigned to this arm if receiving at least two of the following second-line TB drugs at study entry: kanamycin, amikacin, capreomycin, moxifloxacin, levofloxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose isoniazid (INH), bedaquiline, clofazamine, delamanid, linezolid, or pretomanid.
11653751|NCT00042289|Experimental|Women taking ARVs with postpartum hormonal contraceptives|"HIV-infected women 2-12 weeks postpartum will be assigned to this arm if receiving one of the following ARV drug combinations and starting postpartum contraceptives: atazanavir/ritonavir/tenofovir, darunavir/cobicistat, atazanavir/cobicistat, or efavirenz AND starting combined oral contraceptives formulated with ethinyl estradiol; or atazanavir/ritonavir/tenofovir, efavirenz, atazanavir/cobicistat, or darunavir/cobicistat AND starting etonogestrel implant.
~Note: As of February 2016, the study will no longer enroll women receiving atazanavir/ritonavir/tenofovir or efavirenz AND starting etonogestrel implant."
11653752|NCT00041483|Active Comparator|Anecortave and Sham PDT|
11653753|NCT00041483|Active Comparator|PDT and Sham Anecortave Acetate|
11653754|NCT00042224|Experimental|1 ECT plus clozapine|Electroconvulsive therapy ECT plus clozapine for 8 weeks
11653755|NCT00042224|Active Comparator|2 Clozapine|Clozapine for 8 weeks
11653756|NCT00042211|Experimental|1|Problem Solving Treatment
11653757|NCT00042211|Active Comparator|2|Control
11653758|NCT00042198|Experimental|1|Cognitive Behavior Therapy. The treatment modality was individual, face-to-face therapy with an experienced cognitive therapist. Treatment consisted of up to 12 weekly, hour-long sessions.
11653759|NCT00042198|Active Comparator|2|Supportive Stress Management. The treatment modality was individual, face-to-face therapy with an experienced psychotherapist. Treatment consisted of up to 12 weekly, hour-long sessions.
11653760|NCT00042198|No Intervention|3|Usual Care, minimally enhanced. Participants in all three arms were given information about depression. There were no restrictions in any of the arms on usual care for depression, heart disease, or any other conditions, except that concurrent participation in nonstudy psychotherapy was not allowed. Participants were allowed to continue or start on nonstudy antidepressants during the study, as prescribed by the participant's personal physician.
11653761|NCT00042185|Experimental|Dissonance intervention|
11653762|NCT00042185|Active Comparator|Healthy Weight Intervention|
11653763|NCT00042185|Active Comparator|Expressive writing control intervention|
11653764|NCT00042185|No Intervention|Assessment-only control condition|
11653765|NCT00041951||CAE participants|Both parents and a child with CAE of families without other affected members (trios) or whole families with many members affected with epilepsy.
11653766|NCT00041951||Controls|Healthy individuals without epilepsy and no family history of epilepsy.
11653767|NCT00041938|Active Comparator|aspirin|Aspirin: 325 mg per day
11653768|NCT00041938|Active Comparator|warfarin|Warfarin: International Normalized Ratio (INR) 2.5-3.0; target INR 2.75
11653769|NCT00041782|Experimental|Dalteparin|
11653770|NCT00041756|Placebo Comparator|Placebo|Placebo tablet
11653771|NCT00041756|Experimental|25 mg PG-530742|25 mg PG-530742
11653772|NCT00041756|Experimental|50 mg PG-530742|50 mg PG-530742
11653773|NCT00041756|Experimental|100 mg PG-530742|100 mg PG-530742
11653774|NCT00041756|Experimental|200 mg PG-530742|200 mg PG-530742
11653775|NCT00041717|Active Comparator|fampridine-SR 50mg/day|
11653776|NCT00041717|Placebo Comparator|Placebo|
11653777|NCT00041509|Experimental|SB424323, 500 mg BID|
11653778|NCT00041509|Experimental|SB424323, 125 mg BID|
11653779|NCT00041509|Placebo Comparator|Placebo|
11653780|NCT00041496|Experimental|Arm 1|Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or placebo
11653781|NCT00041496|Placebo Comparator|Arm 2|Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or Placebo
11653782|NCT00041574|Experimental|1|Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
11653783|NCT00041561|Placebo Comparator|2|Nitrogen gas
11653784|NCT00041561|Experimental|1|Inhaled Nitric Oxide
11653787|NCT00041470|Experimental|Weekly paclitaxel, vinorelbine and GCSF|"Weekly paclitaxel (50 mg/m2 IV) and weekly vinorelbine (20 mg/m2 IV) with daily G-CSF support and Herceptin for patients with HER-2/neu positive disease.
~Paclitaxel weekly. Dose levels:
~50 mg/m2, 60 mg/m2, 70 mg/m2, 80 mg/m2
~Vinorelbine (Navelbine) administered one hour after paclitaxel, weekly. Dose levels:
~20 mg/m2, 22.5 mg/m2, 25 mg/m2, 27.5 mg/m2
~Patients who are HER-2+ and IV infusion. Herceptin 4 mg/kg IV given only on day 1 of the first cycle. Herceptin 2 mg/kg IV, maintenance dose will be given every week starting with week 2.
~G-CSF (filgrastim, Neupogen) 5 mg/kg/day s.c., administered daily"
11653788|NCT00040677|Experimental|ICA-17043 Low Dose 6 mg/day|Active study medication: 100 mg loading dose; 6 mg maintenance dose per day
11653789|NCT00040677|Placebo Comparator|Placebo|
11653790|NCT00040677|Experimental|ICA-17043 High Dose 10 mg/day|Active study medication: 150 mg loading dose; 10 mg maintenance dose per day
11653791|NCT00040664|Experimental|2 to 5 years (FPV/RTV)|Two to five years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
11653792|NCT00040664|Experimental|6 to 11 years (FPV/RTV)|Six to twelve years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
11653793|NCT00040664|Experimental|12 to 18 years (FPV/RTV)|Twelve to Eighteen years. Fosamprenavir (FPV) 700 mg tablets or 50 mg/mL oral suspension/ritonavir (RTV) 100 mg capsules or 80 mg/mL oral solution once daily (QD)
11653794|NCT00041457||Physicians' Health Study I|
11653795|NCT00041457||Physicians' Health Study II|
11653796|NCT00041457||Women's Health Study|
11653797|NCT00041457||Women's Antioxidant Cardiovascular Health Study|
11653798|NCT00041392|Active Comparator|Magnesium|100 mg/kg magnesium
11653799|NCT00041392|Placebo Comparator|0.9 % saline|100 mg/kg 0.9 % saline
11653800|NCT00040456|Placebo Comparator|Placebo|"A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.
~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment."
11653801|NCT00040456|Active Comparator|MG Pidolate Administration|"A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.
~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment."
11653802|NCT00040443|Experimental|CX516|CX516 - 900 mg
11653803|NCT00040443|Placebo Comparator|Placebo|Placebo
11653804|NCT00040404|Experimental|CEP-1347 10mg|CEP-1347 was administered at a dosage of 10mg twice daily (bid); capsule strengths were 5, 12.5, and 25 mg. Each patient took 2 capsules at each dosing time, approximately 12 hours apart, within 30 minutes after the morning and evening meals) for a total of 4 capsules per day.Patients were randomly assigned to CEP-1347 or placebo treatment in a 1:1:1:1 ratio. A blocked randomization scheme was used to ensure approximately equal numbers of patients in each of the 4 treatment groups at each center.
11653805|NCT00040404|Experimental|CEP-1347 25mg|CEP-1347 was administered at a dosage of 25mg twice daily (bid); capsule strengths were 5, 12.5, and 25 mg. Each patient took 2 capsules at each dosing time, approximately 12 hours apart, within 30 minutes after the morning and evening meals) for a total of 4 capsules per day.Patients were randomly assigned to CEP-1347 or placebo treatment in a 1:1:1:1 ratio. A blocked randomization scheme was used to ensure approximately equal numbers of patients in each of the 4 treatment groups at each center.
11653806|NCT00040404|Experimental|CEP-1347 50mg|CEP-1347 was administered at a dosage of 50mg twice daily (bid); capsule strengths were 5, 12.5, and 25 mg. Each patient took 2 capsules at each dosing time, approximately 12 hours apart, within 30 minutes after the morning and evening meals) for a total of 4 capsules per day.Patients were randomly assigned to CEP-1347 or placebo treatment in a 1:1:1:1 ratio. A blocked randomization scheme was used to ensure approximately equal numbers of patients in each of the 4 treatment groups at each center.
11653807|NCT00040404|Placebo Comparator|Placebo|Placebo capsules matching the CEP-1347 capsules were administered in the same manner.
11653808|NCT00040378||Combination therapy|vitamin E (alphatocopherol) and selenium
11653809|NCT00040378||Vitamin E only|vitamine E (alphatocopherol) and placebo
11653810|NCT00040378||Selenium only|selenium and placebo (Placebo replacement for vitamin E)
11653811|NCT00040378||Placebo|placebo (Placebo replacement for vitamin E) and placebo (Placebo replacement for selenium)
11653812|NCT00040365|Experimental|Amifostine|1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).
11653813|NCT00040326|Active Comparator|1|anteromesial temporal resection
11653814|NCT00040326|Active Comparator|2|antiepileptic drugs
11653815|NCT00040222||1|Individuals and families with known or suspected syndromes that include breast, ovarian or genetically-related cancers are enrolled in this family study.
11653816|NCT00040105|Experimental|Zarnestra + Gleevec|
11653817|NCT00039988|Experimental|1|Participants will receive Copaxone and albuterol placebo
11653818|NCT00039988|Experimental|2|Participants will receive Copaxone and albuterol
11653819|NCT00039871|Experimental|Overall study population|
11653820|NCT00039832|Experimental|1|CT
11653821|NCT00039832|Experimental|2|MRI
11653822|NCT00039780|Active Comparator|1|Tavocept (BNP7787)
11653823|NCT00039780|Placebo Comparator|2|0.9% Sodium Chloride Soln.
11653824|NCT00039741|Experimental|PI/1K|Two NRTIs plus a PI with a regimen change recommended at when viral load reaches 1000 copies/ml or higher
11653876|NCT00038298|Experimental|400 mg|400 mg 3 times weekly
11653987|NCT00034554|Experimental|2|0.5mg
11653826|NCT00039741|Experimental|PI/30K|2 NRTIs plus 1 PI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher
11653827|NCT00039741|Experimental|NNRTI/30K|2 NRTIs plus an NNRTI with a regimen change recommended when viral load reaches 30,000 copies/ml or higher
11653828|NCT00039026|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
11653829|NCT00039026|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
11653830|NCT00039026|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
11653831|NCT00039026|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL / Placebo 0.02 mL / Placebo 0.04 mL
11653832|NCT00039013|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
11653833|NCT00039013|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
11653834|NCT00039013|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
11653835|NCT00039013|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL
11653836|NCT00038974|Experimental|Interferon and rivavirin|All patients received peginterferon alfa-2a in a dose of 180 μg weekly and ribavirin in a dose of 1000 (for patients with a body weight of ⩽75 kg) or 1200 mg (for those with a body weight of >75 kg) daily.
11653837|NCT00038961|Placebo Comparator|Placebo + intermittent pneumatic compression (IPC)|
11653838|NCT00038961|Experimental|fondaparinux + intermittent pneumatic compression (IPC)|
11653839|NCT00039689||HIV chronic infection|For example, an individual infected with HIV-1 for an indeterminate amount of time.
11653840|NCT00039689||HIV early infection|For example, a negative HIV antibody immunoassay within 6 months of a positive HIV antibody assay and confirmatory test (as defined by current CDC criteria).
11653841|NCT00039624|Experimental|Brachy|brachytherapy
11653842|NCT00038948|Active Comparator|A|Conversion from calcineurin inhibitor immunosuppression to Sirolimus-based immunosuppression
11653843|NCT00038948|Active Comparator|B|Continued calcineurin inhibitor therapy
11653844|NCT00038883|Experimental|Campath-1H|10 mg/day x 5
11653845|NCT00038870|Experimental|Dendritic Cell Activated Lymphocytes|
11653846|NCT00038857|Experimental|CD34 PBPC|CD34 peripheral blood progenitor cell (PBPC) transplants in 3 groups: 1) HLA-matched Sibling Transplant Patients; 2) Unrelated Donor Transplant Patients; 3) Haplo Identical Transplant Patients. Preparative regimen is 140 mg/m^2 Melphalan on day -8, 10 mg/kg Thiotepa on day -7, 160 mg/m^2 Fludarabine over 4 days on days -6, -5, -4, -3 and 1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
11653847|NCT00038844|Experimental|Campath in Nonmyeloablative Transplantation|Campath-1 H Starting Dose of 15 mg by vein daily, 3 days in a row + Fludarabine 30 mg/m2 by vein daily, 3 days in a row + Cyclophosphamide 1 gm/m2 by vein daily, 3 days in a row + Rituximab 375 mg/m2 by vein, given 8 days before transplant then weekly for 4 total doses.
11653848|NCT00038831|Experimental|Chemotherapy + ATG + Stem Cell Infusion|
11653849|NCT00038818|Experimental|CD8 DLI|CD8 depleted DLI (Depleted Donor Lymphocyte Infusions)
11653850|NCT00038805|Experimental|Mylotarg|
11653851|NCT00038792|Experimental|aGvHD|
11653852|NCT00038779|Experimental|Megadose T cell depleted|
11653853|NCT00038766|Experimental|Semapimod 60 mg|Semapimod 60 mg IV x 5 days
11653854|NCT00038766|Experimental|Semapimod IV 30 mg|Semapimod IV 30 mg x 5 days
11653855|NCT00038766|Placebo Comparator|Placebo|Placebo IV x 3 or 5 days
11653856|NCT00038727|Active Comparator|1 Original Lifestyle|randomized to unmasked Intensive Lifestyle during the DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle plus DPPOS Boost Lifestyle sessions in DPPOS Phase 1 and 2
11653857|NCT00038727|Active Comparator|2 Original Metformin|randomized to the masked metformin treatment group during DPP and continued open label in DPPOS. Participants were also offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2.
11653858|NCT00038727|Placebo Comparator|3 Original Placebo|randomized to masked placebo during DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2
11653859|NCT00038701|Experimental|Gemzar Chemoradiation + TNP-470|
11653860|NCT00038675|Experimental|Imatinib|Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily.
11653861|NCT00038649|Experimental|Gleevec|Gleevec 400 mg orally twice daily.
11653862|NCT00038623|Experimental|Yttrium-ibritumomab (Zevalin)|After Rituximab infusion (250 mg/m^2 intravenous) on Day 1, 111^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
11653863|NCT00038610|Experimental|Hyper-CVAD + Imatinib|Imatinib 600 mg orally days 1-14, course 1, & 600 mg daily days 1-14 (daily if tolerated course 1), even courses. Cyclophosphamide 300 mg/m^2 intravenous (IV) for 6 doses days 1-3, odd courses. Doxorubicin 50 mg/m^2 IV day 4; Vincristine 2 mg IV days 4 & 11; & Dexamethasone 40 mg IV or orally daily days 1-4 & 11-14 odd courses 1, 3, 5, 7. Methotrexate 12 mg intrathecally (6 mg if via Ommaya reservoir) day 2, odd courses and 200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 over 22 hours day 1 of even courses. Cytarabine 100 mg intrathecally day 7 for odd courses and 3 gm/m^2 IV every 12 hours for 4 doses days 2-3 for even courses. Mesna 600 mg/m^2 IV daily, odd courses. G-CSF 10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
11653864|NCT00038571|Experimental|Arm A (mantle-cell lymphoma)|
11653865|NCT00038571|Experimental|Arm B (other B-cell lymphomas)|
11653866|NCT00038558|Experimental|Filgrastim + ABVD Chemotherapy|
11653867|NCT00038467|Active Comparator|B|
11653868|NCT00038467|Experimental|A|
11653869|NCT00038441|Experimental|DTI-015|
11653870|NCT00038415|Experimental|Vaccine|
11653871|NCT00038402|Experimental|Herceptin + Taxol Followed by FEC|Herceptin starting 4 mg/kg intravenous (IV), then 2 mg/kg weekly for all other cycles neo-adjuvant chemotherapy and during FEC therapy for total 24 doses. Taxol 225 mg/m^2 continuous IV over 24 hours each cycle; Fluorouracil 500 mg/m^2 IV Days 1 at 3-4 week intervals; Cytoxan 500 mg/m^2 IV on Day 1; Epirubicin 75 mg/m^2 IV on Day 1. Four 21-day cycles.
11653872|NCT00038389|Experimental|Vioxx MTD|
11653873|NCT00038376|Experimental|1|Alpha-interferon + Isotretinoin
11653874|NCT00038350|Experimental|1|8 week lingual strengthening exercise protocol
11653875|NCT00038298|Experimental|50 mg|50 mg 3 times weekly
11653878|NCT00038298|Placebo Comparator|Placebo|Placebo comparator associated with each active arm. (3:1 active vs placebo)
11653879|NCT00038246|Experimental|Thalidomide, Taxol, Estramustine|Thalidomide starting dose 200 mg by mouth every day once a week; Taxol 100 mg/m^2 by vein (IV) over 3 hours Day 3 and Day 10; Estramustine 140 mg by mouth three times a day on Days 1-5, 8-12.
11653880|NCT00038233|Experimental|Thalidomide|200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
11653881|NCT00038207|Experimental|Liposomal Vincristine|
11653882|NCT00038194|Experimental|Imatinib + Docetaxel|
11653883|NCT00038168|Experimental|Estramustine + Taxol|
11653884|NCT00038155|Other|1|
11653885|NCT00038142|Experimental|Arm A: VACdxr With ImmTher|Chemotherapy repeated every 3 weeks for 6 cycles: Vincristine 2.0 mg/m^2 (max 2.0 mg) intravenous (IV), Doxorubicin 90 mg/m^2 IV over 30 minutes, Cyclophosphamide 2.0 g/m^2 IV daily for 2 days. Dexrazoxane 900 mg/m^2 IV (30 minutes prior to doxorubicin). ImmTher 900 mcg/m^2 IV over 1 hour every week x 50-52 weeks.
11653886|NCT00038142|Active Comparator|Arm B: VACdxr|Chemotherapy repeated every 3 weeks for 6 cycles: Vincristine 2.0 mg/m^2 (max 2.0 mg) IV. Doxorubicin 90 mg/m^2 IV over 30 minutes, Cyclophosphamide 2.0 g/m^2 IV daily for 2 days, Dexrazoxane 900 mg/m^2 IV (30 minutes prior to doxorubicin).
11653887|NCT00038129|Experimental|1|Participants will receive reaming of the intramedullary canal prior to insertion of an intramedullary nail.
11653888|NCT00038129|Experimental|2|Participants will receive insertion of an intramedullary nail without prior reaming of the intramedullary canal.
11653889|NCT00038116|Active Comparator|embryonic dopamine cell implant surgery|embryonic dopamine cell implant surgery
11653890|NCT00038116|Placebo Comparator|sham surgery|sham surgery (placebo)
11653891|NCT00038103|Active Comparator|1.|
11653892|NCT00038103|Experimental|2.|
11653893|NCT00038090|Experimental|Thalidomide + Dexamethasone|
11653894|NCT00038064|Active Comparator|rHuEPO|
11653895|NCT00038064|Experimental|Darbepoetin alfa|
11653896|NCT00038051|Experimental|HuM195/rGel|HuM195/rGel starting Dose = 3 mg/m^2 twice weekly for 2 weeks.
11653897|NCT00038038|Experimental|PET + 18F-fluoromisonidazole|
11653898|NCT00038025|Experimental|Deoxycoformycin (DCF)/Pentostatin|
11653899|NCT00038012|Experimental|rhTPO-Derived Autologous Platelets Transfusion|
11653900|NCT00037986|Other|1|
11653901|NCT00037973|Experimental|1|Ventilation-feedback plus exercise
11653902|NCT00037973|Active Comparator|2|Exercise
11653903|NCT00037973|Active Comparator|3|ventilation feedback only
11653904|NCT00037934|Experimental|1|Robot exercise group
11653905|NCT00037934|Active Comparator|2|Traditional exercise group
11653906|NCT00037921|Other|1|
11653907|NCT00037882|Experimental|SCH 54031|Peg Interferon Alpha-2B/PEG-Intron
11653908|NCT00037869|Experimental|MIBG|High Dose I-131 Metaiodobenzylguanidine
11653909|NCT00037830|Active Comparator|Early-Start Group|Subjects were randomized to receive GM1 ganglioside for 24 weeks.
11653910|NCT00037830|Placebo Comparator|Delayed-Start Group|Subjects were randomized to receive placebo for 24 weeks.
11653911|NCT00037830|No Intervention|Comparison Group|A separate group of Parkinson's disease patients who received standard of care were followed for one to two years to provide comparative information about natural disease progression. This comparison group was not compared statistically to the treatment groups since they were not randomized.
11653912|NCT00037817|Experimental|1|Dose escalation cohort
11653913|NCT00037817|Experimental|2|Molecular response cohort
11653914|NCT00037817|Experimental|3|Celecoxib combination cohort at MTD
11653915|NCT00037752|Active Comparator|1|Sibutramine plus a behavioral smoking cessation program
11653916|NCT00037752|Active Comparator|2|Placebo sibutramine plus a behavioral smoking cessation program
11653917|NCT00037713|No Intervention|1|Best supportive care, but no cancer specific therapy (cytotoxic, radiation or other tumor reductive therapy) can be given until documented progression of disease.
11653918|NCT00037713|Experimental|2|"Treatment will consist of 5 vaccinations (each consisting of 8 single intradermal injections) over a period of 10 to 12 weeks unless one of the following occur:
~intolerable toxicity precluding further treatment progression of disease
~patient refusal
~occurrence of pregnancy"
11653919|NCT00037648|Placebo Comparator|placebo|
11653920|NCT00037648|Experimental|anakinra|
11653921|NCT00037635|Experimental|AMG 073|
11653922|NCT00037635|Placebo Comparator|placebo|
11653923|NCT00037609|Experimental|Capecitabine + Exisulind|Capecitabine 1000 mg/m^2 taken by mouth twice daily. Exisulind 125 mg taken by mouth twice daily.
11653924|NCT00037440||BHS Whites|Whites from Bogalusa, Louisiana; initially recruited as schoolchildren and followed at irregular intervals (about 3 years apart on average) into adolescence and early adulthood. There were no interventions of any kind-- this was an observational study only.
11653925|NCT00037440||BHS African Americans|African Americans from Bogalusa, Louisiana, initially recruited as schoolchildren and followed at irregular intervals (about 3 years apart on average) into adolescence and early adulthood. There were no interventions of any kind-- this was an observational study only.
11653926|NCT00036634|Active Comparator|Tenofovir DF|Participants received tenofovir DF 300 mg for 14 days
11653927|NCT00036634|Experimental|Tenofovir alafenamide 50 mg|Participants received tenofovir alafenamide 50 mg for 14 days
11653928|NCT00036634|Experimental|Tenofovir alafenamide 150 mg|Participants received tenofovir alafenamide 150 mg for 14 days
11653929|NCT00036569|Experimental|Interferon Alfa|0.3 mg/kg subcutaneously once a week for 4 weeks beginning 2-10 weeks after completion of radiation therapy and continued until disease progression or one of the other off study criteria.
11653930|NCT00036491|Experimental|rituximab|375 mg/m^2 administered intravenously
11653931|NCT00036296|Experimental|1|75mg per day (in 3 doses) Talampanel for 22 days
11653932|NCT00036296|Placebo Comparator|2|3 doses a day for 22 days
11653933|NCT00036270|Experimental|exemestane|
11653934|NCT00036270|Experimental|tamoxifen + exemestane|
11653935|NCT00035984|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
11653937|NCT00035984|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
11653938|NCT00035984|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL
11653939|NCT00035932|Active Comparator|I|"ATV 300 mg + RTV 100 mg + TDF 300 mg + nucleoside of choice
~ATV , RTV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
11653940|NCT00035932|Active Comparator|II|"ATV 400 mg + SQV 1200 mg + TDF 300 mg + nucleoside of choice
~ATV, SQV, and TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
11653941|NCT00035932|Active Comparator|III|"LPV/RTV 400/100 mg + TDF 300 mg + nucleoside of choice
~LPV/RTV twice daily, TDF once daily, nucleoside per label 48 Weeks and then for as long as subject is in need of therapy through study"
11653942|NCT00035893|Experimental|Ampligen|Ampligen (poly I-poly C12U) 200-400 mg IV infusions given twice weekly for 64 weeks.
11653943|NCT00035893|No Intervention|No Ampligen|No Ampligen administered for first 64 weeks
11653944|NCT00035815|Active Comparator|IGF-1|Insulin like growth factor, type 1 will be given 0.05 mg per kg body weight subcutaneously twice daily
11653945|NCT00035815|Placebo Comparator|Placebo|Placebo arm
11653946|NCT00035802|Experimental|001|"Topiramate Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.
~OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months."
11653947|NCT00035802|Placebo Comparator|002|Placebo Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
11653948|NCT00035620|Active Comparator|Filgrastim|Filgrastim
11653949|NCT00035620|Experimental|Pegfilgrastim|Pegfilgrastim
11653950|NCT00035607|Active Comparator|Darbepoetin alfa SC|
11653951|NCT00035607|Experimental|Darbepoetin alfa IV|
11653952|NCT00035594|Placebo Comparator|Placebo|Breast cancer patients receiving docetaxel chemotherapy and placebo.
11653953|NCT00035594|Experimental|Pegfilgrastim|Breast cancer patients receiving docetaxel chemotherapy and pegfilgrastim.
11653954|NCT00035581|Experimental|Ampligen|Ampligen (polyI-polyC12U) 200-400 mg IV infusions given twice weekly for 24 weeks
11653955|NCT00035581|No Intervention|No Ampligen|No Ampligen administered for first 24 weeks
11653956|NCT00035555|Experimental|Belatacept: More intensive (MI) regimen|The MI regimen was designed to achieve projected serum trough concentrations of belatacept of approximately 20 μg/mL through Day 99, and approximately 5 μg/mL through Day 183 (10 mg/kg on Days 1, 5, 15, 29, 43, 57, 71, 85, 113, 141, and 169). After Day 169, patients were reallocated and dosed to achieve projected trough serum concentrations of approximately 2 or 0.25 μg/mL (5 mg/kg every 4 or 8 weeks starting on Day 197). Those patients who received belatacept every 8 weeks received placebo infusions on scheduled treatment dates between infusions of active drug to maintain the blind between treatment regimens. Patients initially received mycophenolate mofetil (MMF), 2 g/d orally, unless the investigator chose to administer ≥1 doses intravenously The first MMF dose was administered preoperatively; subsequent doses were administered in 2 or 3 divided doses, every 8-12 hours, beginning as soon as the patient was able to tolerate medications by mouth. Corticosteroids given daily.
11653957|NCT00035555|Experimental|Belatacept: Less intensive (LI) regimen|The LI regimen was designed to achieve projected trough serum concentrations of belatacept of approximately 20 μg/mL through Day 29, and approximately 5 μg/mL through Day 99 (10 mg/kg on Days 1, 15, 29, 57 and 85). After Day 85, these subjects were reallocated and dosed to achieve projected trough serum concentrations of either approximately 2 or 0.25 μg/mL (5 mg/kg every 4 or 8 weeks starting on Day 113). Participants initially received mycophenolate mofetil (MMF), 2 g/d orally, unless the investigator chose to administer ≥1 doses intravenously The first MMF dose was administered preoperatively; subsequent doses were administered in 2 or 3 divided doses, every 8-12 hours, beginning as soon as the participant was able to tolerate medications by mouth. Corticosteroids given daily.
11653958|NCT00035555|Experimental|Cyclosporine regimen|The initial daily dose was 7±3 mg/kg. Subsequent doses were adjusted to maintain a predefined range of serum concentrations: 1st month, target level 150-400 ng/mL; after 1st month, target level of 150-300 ng/mL. Participants initially received mycophenolate mofetil (MMF), 2 g/d orally, unless the investigator chose to administer ≥1 doses intravenously The first MMF dose was administered preoperatively; subsequent doses were administered in 2 or 3 divided doses, every 8-12 hours, beginning as soon as the participant was able to tolerate medications by mouth. Corticosteroids given daily.
11653959|NCT00035529|Other|1|
11653960|NCT00035529|Active Comparator|2|
11653961|NCT00035529|Active Comparator|3|
11653962|NCT00035490|Placebo Comparator|1|Placebo tablets
11653963|NCT00035490|Experimental|2|75 mg azimilide
11653964|NCT00035490|Experimental|3|125 mg azimilide
11653965|NCT00035477|Placebo Comparator|1|placebo tablets in hospital and placebo tablets outpatient
11653966|NCT00035477|Experimental|2|Azimilide tablets in hospital and azimilide tablets outpatient
11653967|NCT00035464|Placebo Comparator|1|Placebo tablets
11653968|NCT00035464|Experimental|2|125 mg azimilide tablets
11653969|NCT00035451|Placebo Comparator|1|placebo tablets
11653970|NCT00035451|Active Comparator|2|Sotalol
11653971|NCT00035451|Experimental|3|azimilide
11653972|NCT00035425|Experimental|A.|Patients will be stratified according to the use of prophylactic antibiotics. Both groups may receive open-label gram-negative coverage with either ceftazidime, aztreonam, and/or aminoglycosides (gentamicin, tobramycin, amikacin). Subjects will receive study medication intravenously every 12 hours for 7 to 28 days.
11653973|NCT00035425|Experimental|B.|
11653974|NCT00035347|Experimental|Azithromycin plus ceftriaxone group (AZY+CEF group)|IV azithromycin (500 mg once daily) plus ceftriaxone (1 gram once daily) for 2 to 5 days followed by oral azithromycin (2 x 250 mg once daily) to complete a total of 7 to 10 days of therapy
11653975|NCT00035347|Experimental|Levofloxacin group (LEV group)|IV levofloxacin (500 mg once daily) for a minimum of 2 days followed by oral levofloxacin (500 mg once daily) to complete a total of 7 to 14 days of therapy.
11653976|NCT00035243|Experimental|EPO906|
11653977|NCT00035165|Experimental|EPO906|
11653978|NCT00035126|Experimental|EPO906|
11653979|NCT00035100|Experimental|EPO906|
11653980|NCT00034814|Placebo Comparator|1|Enzyme-inducing placebo TID
11653988|NCT00034554|Experimental|3|2.0mg
11653991|NCT00034541|Experimental|1|An initial dose of cetuximab (400 mg/m2 i.v. over 120 minutes) will be administered 1 week prior to the initiation of chemotherapy. Thereafter, cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each cycle (every 3 weeks) of therapy, a 3-hour paclitaxel (225 mg/m2) infusion will be administered 1-hour post completion of the cetuximab infusion, immediately followed by a 30-minute carboplatin (AUC=6) infusion.
11653992|NCT00034528|Experimental|Allogeneic stem cell transplantation|Participants will receive a nonmyeloablative conditioning regimen of fludarabine and busulfan prior to allogeneic peripheral blood stem cell (CD34+) infusions. FK506 and prednisone will be administered for graft versus host disease (GVHD) prophylaxis.
11653993|NCT00034281|Experimental|TAK-165 QD|
11653994|NCT00034216||Healthy Volunteers|Healthy volunteers 18 years of age and older
11653995|NCT00034216||Patients|Patients with cancer 18 years of age and older
11653996|NCT00033917|Active Comparator|1|indomethacin
11653997|NCT00033917|Placebo Comparator|2|placebo
11653998|NCT00033865|Experimental|1|Yoga treatment for 8 weeks
11653999|NCT00033865|No Intervention|2|Sleep hygiene instructions only
11654000|NCT00033774||1|Eligible healthy volunteers 18 and older
11654001|NCT00033137||Family members|A relative of a patient with a confirmed or suspected diagnosis of BHD (related by blood)
11654002|NCT00033137||Non-Biologic Family Members|Spouses enrolled primarily for linkage analysis (Spouses have been removed from the inclusion criteria for this study. This closed cohort has been created for spouses previouslyenrolled on study.)
11654003|NCT00033137||Patients|Patients with phenotype or genotype suggestive of Birt Hogg Dub(SqrRoot)(Copyright) and/or Renal tumor histology consistent with BHD
11654004|NCT00033111|Active Comparator|Cabergoline|Subjects received one tablet of 0.5 mg of cabergoline tablet per week for 12 weeks.
11654005|NCT00033111|Placebo Comparator|Placebo|Subjects received one tablet of 0.5 mg of cabergoline matched placebo tablet per week for 12 weeks.
11654006|NCT00032643|Other|Arm 1|
11654007|NCT00032630|Other|Arm 1|Coronary artery bypass - on-pump
11654008|NCT00032630|Other|Arm 2|Coronary artery bypass - off-pump
11654009|NCT00032617|Active Comparator|1|Prolonged Exposure
11654010|NCT00032617|Active Comparator|2|Present Centered Therapy
11654011|NCT00032591|Active Comparator|Arm 1|Patient Self-Testing (PST) of prothrombin time by international normalized ratio (PT-INR or INR) with weekly testing
11654012|NCT00032591|Other|Arm 2|High quality anticoagulation management (HQACM) with conventional monthly testing
11654013|NCT00032565||1|No intervention. Telephone interview.
11654014|NCT00032552||1|
11654015|NCT00032539||1|
11654016|NCT00032513||CAEBV|Patients with chronic active Epstein-Barr virus.
11654017|NCT00032513||Hydroa vaccineforme|Patients with EBV hydro vaccineforme.
11654018|NCT00032487|Active Comparator|Standard glycemic control|Standard glycemic control to maintain HbA1c between 8.0-9.0%. Metformin 500 mg Rosiglitazone 4 mg Glimepiride 2 mg Insulin 1 unit 9 lbs
11654019|NCT00032487|Experimental|Intensive glycemic control|Intensive glycemic control lower HbA1c below 6.0%. Metformin 500 mg (go up to 2000 mg) Rosiglitazone 4 mg bid Glimepiride 8 mg Insulin 1 unit 9 lbs add one injection to Arm 1
11654020|NCT00032448|Other|1|Open and laparoscopic herniorrhaphy
11654021|NCT00032435|Experimental|1|PAL-40 Active
11654022|NCT00032435|Placebo Comparator|2|PAL-40 Placebo
11654023|NCT00032370|Other|1|Elective vascular surgery
11654024|NCT00032370|Other|2|Cardiac revascularization prior to vascular surgery.
11654025|NCT00032357|Other|Arm 1|Usual care plus Ferritin reduction to a calculated nadir of 25 ng/mL by phlebotomy
11654026|NCT00032357|No Intervention|Arm 2|Usual care only; no intervention control
11654027|NCT00032344|Other|1|Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
11654028|NCT00032227|Experimental|1|Surgical release of CTS
11654029|NCT00032227|Active Comparator|2|Non-surgical treatment for CTS (splint, physical therapy, ultrasound)
11654030|NCT00031551|Experimental|Main Study: Etanercept Mouthwash|Etanercept 2.5 mg in 20cc mouthwash is swished and spit by the participant every 6 hours. The experimental mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant (BMT) Day +14, whichever occurs first.
11654031|NCT00031551|Placebo Comparator|Main Study: Placebo Mouthwash|Placebo 20cc mouthwash is swished and spit by the participant every 6 hours. The placebo mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant day (BMT) Day +14, whichever occurs first.
11654032|NCT00031551|No Intervention|Pilot Study|Participants were enrolled in the pilot study to collect descriptive data about pain perception and laboratory techniques.
11654033|NCT00031512|Placebo Comparator|Placebo|Placebo.
11654034|NCT00031512|Experimental|Pleconaril (VP63843)|The first dosing cohort received 5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation. Subsequent dosing cohorts are receiving 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
11654035|NCT00031499|Experimental|Azithromycin|Azithromycin 2.0 gram single oral dose.
11654036|NCT00031499|Active Comparator|Benzathine Penicillin|Benzathine penicillin 2.4 million units administered intramuscularly. Doxycycline will be administered if the patient is allergic to Benzathine Penicillin.
11654037|NCT00031486|Experimental|Valacyclovir|
11654038|NCT00031486|Placebo Comparator|Placebo|
11654039|NCT00031460|Experimental|Acyclovir|
11654040|NCT00031460|Placebo Comparator|Placebo|
11654041|NCT00031447|Placebo Comparator|Placebo|
11654042|NCT00031447|Experimental|Acyclovir|
11654043|NCT00031434|Experimental|1|All subjects enrolled into this study will receive 6 weeks (42 days) of antiviral therapy (valganciclovir/ganciclovir).
11654044|NCT00031421||1|16 received ganciclovir at 8 mg/kg/day in the previous study.
11654045|NCT00031421||2|31 received ganciclovir at 12 mg/kg/day in the previous study.
11654046|NCT00031395|Active Comparator|1|
11654047|NCT00031395|Active Comparator|2|
11654050|NCT00031278|Experimental|Cohort 1|0.01 mg/kg CPG 7909 plus Herceptin®
11654051|NCT00031278|Experimental|Cohort 2|0.04 mg/kg CPG 7909 plus Herceptin®
11654052|NCT00031278|Experimental|Cohort 3|0.16 mg/kg CPG 7909 plus Herceptin®
11654053|NCT00031278|Experimental|Cohort 4|0.32 mg/kg CPG 7909 plus Herceptin®
11654054|NCT00031174||1|Blood components collected using apheresis from normal volunteers.
11654055|NCT00031174||2|Blood components collected using apheresis from patients with rheumatic or kidney diseases.
11654056|NCT00031122||SBRR|Families with a child/pregnancy affected with spina bifida or anencephaly
11654057|NCT00031096|Experimental|Arm 1|
11654058|NCT00031096|Placebo Comparator|Arm 2|
11654059|NCT00030992|Experimental|BMS-247550|One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2
11654060|NCT00030966|Experimental|Group 1|Adding natalizumab monthly infusion to Avonex weekly injection for up to 116 weeks.
11654061|NCT00030966|Placebo Comparator|Group 2|Adding placebo monthly infusion to Avonex weekly injection for up to 116 weeks.
11654062|NCT00030238|Other|Active Treatment|Subjects take calcium twice daily with meals
11654063|NCT00030238|Other|Control|Subjects take placebo twice daily with meals.
11654064|NCT00030225|Experimental|ELAD|Treatment with ELAD, extracorporeal liver assist system and standard of care
11654065|NCT00030225|Other|Standard of care (Control)|Standard of care for patients with fulminant hepatic (liver) failure
11654066|NCT00030186|Experimental|Cycle 1|60mg
11654067|NCT00030186|Experimental|Cycle 2|80mg dependent upon response to Cycle 1
11654068|NCT00030186|Experimental|Cycle 2b|40mg dependent upon response to Cycle 1
11654069|NCT00030147|Experimental|Raloxifene|Raloxifene (Evista) 60 mg per day and placebo skin patch for eight weeks
11654070|NCT00030147|Experimental|Rimostil|Rimostil (phytoestrogen) 1000 mg twice a day and placebo skin patch for eight weeks
11654071|NCT00030147|Active Comparator|Transdermal estradiol|17-beta estradiol 100 micrograms a day by skin patch and placebo tablets for eight weeks
11654072|NCT00030147|Placebo Comparator|Placebo|Placebo skin patch and placebo tablets for eight weeks.
11654073|NCT00029965||Glycoprotein Disorders|Glycoprotein Disorders
11654074|NCT00029965||Lysosomal Storage Diseases|Lysosomal Storage Diseases
11654075|NCT00029913||1|Observation of participants includes a physical exam and collection of fluids. Study visits occur at Days 0, 7, 14, 28 and at Months 2, 3, 6 and every 6 months thereafter.
11654076|NCT00029536|Experimental|Catamenial Epilepsy: Progesterone Lozenges|Subjects with catamenial epilepsy received 200 mg progesterone lozenges
11654077|NCT00029536|Placebo Comparator|Catamenial Epilepsy: Placebo Lozenges|Subjects with catamenial epilepsy received matched placebo lozenges
11654078|NCT00029536|Experimental|Noncatamenial Epilespy:Progesterone Lozenges|Subjects without catamenial epilepsy received 200 mg progesterone lozenges
11654079|NCT00029536|Placebo Comparator|Noncatamenial Epilespy: Placebo Lozenges|Subjects without catamenial epilepsy received matched placebo lozenges
11654080|NCT00029445||Family members|Family members of individuals with innate control over HIV
11654081|NCT00029445||Long term nonprogressors|Individuals with innate control over HIV
11654082|NCT00029198|Experimental|1|15 minute massage tid
11654083|NCT00029198|Sham Comparator|2|non-massage touch
11654084|NCT00029172|Experimental|Nurse Case management|
11654085|NCT00029159|Active Comparator|1|
11654086|NCT00029159|Placebo Comparator|2|
11654087|NCT00029146|Experimental|Surgical group|Assigned to undergo extracranial-intracranial arterial bypass in addition to best current practice medical therapy
11654088|NCT00029146|Active Comparator|Non-surgical group|Receives best current practice medical therapy
11654089|NCT00029107|Other|Immediate treatment|Patients receive treatment with four weekly infusions of rituximab 375mg/m2 immediately following randomization.
11654090|NCT00029107|Other|Delayed treatment|Patients treated with standard therapy (corticosteroids, plasma exchange, etc.). After 6 months, they are eligibile to cross over and receive four weekly infusions of rituximab.
11654091|NCT00028340||1/Breast Cancer and High-Risk Patients|Pre- or postmenopausal women who have or have previously had invasive or noninvasive breast cancer of epithelial origin, or women without breast cancer but at an increased risk of breast cancer.
11654092|NCT00028340||2/Normal Volunteers|Pre- or postmenopausal women who are not at an increased risk for breast cancer.
11654093|NCT00028262|Experimental|Drug: Cystagon and N-acetylcysteine|
11654094|NCT00028145||1|Pregnant, HIV-infected women
11654095|NCT00028119||Cohort 1|HIV-uninfected non-sex worker women
11654096|NCT00028119||Cohort 2|HIV-discordant heterosexual couples attending STD clinics
11654097|NCT00028093|Experimental|Pefinterferon+Ribavirin|Patients with chronic hepatitis C virus (HCV) infection genotype 1 peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients <75 kg and 1200 mg daily for patients >=75 kg) for 48 weeks
11654098|NCT00028093|Active Comparator|Peginterferon|patients with chronic hepatitis C virus (HCV) infection genotype 1 were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
11654099|NCT00028080||Lyme Disease|Participants who have been diagnosed with or are strongly suspected to have Lyme disease.
11654100|NCT00027417|Active Comparator|Liothyronine Sodium/Triiodothyronine|bolus administration of Liothyronine Sodium/Triiodothyronine (Triostat) immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses, will be safe and will result in significant improvements in postoperative and clinical outcome parameters and cardiac contractile function.
11654101|NCT00027417|Placebo Comparator|Placebo|bolus administration of Placebo immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses
11654102|NCT00027378|Experimental|1|fluoxetine plus Treatment As Usual (TAU)
11654103|NCT00027378|Placebo Comparator|2|placebo plus Treatment As Usual (TAU)
11654104|NCT00027326||1/Patients|Candidate for or currently receiving radiotherapy
11654105|NCT00027300|Experimental|Group 1|Natalizumab 300 mg, IV
11654107|NCT00027274||1|All families with a member who has one of the relevant syndromes.
11654108|NCT00027183||1|Healthy Volunteers
11654109|NCT00027183||2|Cystic Fibrosis subjects
11654110|NCT00027170|Other|1|Patients may receive an intravenous injection of gadobutrol (Gadavist) not to exceed 0.2 mmol/kg of Gd per bolus injection and per examination.
11654111|NCT00027066|Active Comparator|Active Warfarin and Aspirin Placebo|One 2 mg scored tablet daily of Warfarin and one 325 mg tablet daily of aspirin placebo.
11654112|NCT00027066|Active Comparator|Active Aspirin and Warfarin Placebo|One 325 mg tablet daily of aspirin and one 2 mg scored tablet daily of Warfarin placebo.
11654113|NCT00027053|Experimental|Trazodone|
11654114|NCT00027053|Placebo Comparator|Placebo|
11654115|NCT00026884||Family members|Family members (related by blood or marriage) of patients who have or are suspected of having malignant disease or an inherited genitourinary malignant disorder.
11654116|NCT00026884||Patients|Patients with Biopsy-Proven malignant diseases; or patients suspected of having a malignant disease; or patients who have or who are suspected of having an inherited urologic malignant disorder.
11654117|NCT00026793||Kaposi's Sarcoma|Adult patients with biopsy-proven cutaneous Kaposi's sarcoma. Some participants received interleukin-12 and liposomal doxorubicin. However, the therapy was administered on a different protocol and was not part of this study.
11654118|NCT00026780||Cohort 1|Children and young adults who are being evaluated for protocols within the Pediatric Oncology Branch.
11654119|NCT00026754||Cohort 1|Patients
11654120|NCT00026754||Cohort 2|Healthy Volunteers
11654121|NCT00026702||All|Subjects at least three years old
11654122|NCT00026689||1/Cohort 1|Patients suspected of having, or with biopsy proven malignant disease or patients with a benign condition for whom radiotherapy is a potential treatment
11654123|NCT00026663||1/Patients with Cancer|Cancer patients providing samples for research studies
11654124|NCT00026663||2/Normal Volunteers|Normal Volunteers providing samples for research studies
11654125|NCT00026650||1/Cohort 1|Patients who have received radiotherapy in the ROB and may or may not be officially entered on a clinical protocol.
11654126|NCT00026637|Active Comparator|Sertraline|
11654127|NCT00026637|Active Comparator|CBT|
11654128|NCT00026559|Experimental|Threat Conditions|threat of shock andauditory startle
11654129|NCT00025935||Children/adolescents with ADHD|Children/adolescents with ADHD
11654130|NCT00025935||Children/Adolescents with DMDD or subthreshold DMDD|Children/Adolescents with DMDD or subthreshold DMDD
11654131|NCT00025935||Children/adolescents with MDD|Children/adolescents with MDD
11654132|NCT00025935||Healthy volunteer adults|Healthy volunteer adults
11654133|NCT00025935||Healthy volunteer children/adolescents|Healthy volunteer children/adolescents
11654134|NCT00025935||Parents of children/adolescents with DMDD or subthresdhold DMD|Parents of children/adolescents with DMDD or subthresdhold DMDD
11654135|NCT00025883|Experimental|Metreleptin|subcutaneous metreleptin injections in one to two daily doses ranging from 0.06 to 0.24 mg/kg per day.
11654136|NCT00025766|Experimental|1|PCI with stenting of the occluded culprit infarct-related artery plus optimal medical therapy
11654137|NCT00025766|Active Comparator|2|Optimal medical therapy alone without PCI of the occluded culprit artery
11654138|NCT00025714||Patients|Patients who have agreed to undergo brain surgery to treat drug resistant epilepsy and are enrolled in protocol 11-N-0051 Epilepsy Surgery.
11654139|NCT00024804||1|Subjects with known or suspected bone disease and disorder of mineral metabolism.
11654140|NCT00024622||Healthy volunteers|Healthy volunteers.
11654141|NCT00024622||Patients - Parkinsons|Patients with Parkinsons
11654142|NCT00024622||Patients - schizophrenia spectrum disorders|Patients - schizophrenia spectrum disorders
11654143|NCT00024596||Caucasian Families|Largest 3-generational Caucasian Families from Family Heart Study (Classic) with average family size of 10 N=2767 Subjects from 512 families. Approximately half are random sample families from FamHS-Classic, and half are high-familial CHD risk families from FamHS-Classic. 4 Field sites were Raleigh-Durham North Carolina; Minneapolis, MN; Framingham MA; and Salt Lake City, UT.
11654144|NCT00024596||African-American Families|622 subjects from 2-3 generational 212 African-American families originally recruited from the HyperGEN study in Birmingham AL. These are hypertension enriched families.
11654145|NCT00024518|Placebo Comparator|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA). Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
11654146|NCT00024518|Experimental|5,000 Units hrIFN-alpha|hrIFN-alpha = human recombinant interferon-alpha. 5,000 units was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
11654147|NCT00024518|Experimental|30,000 hrIFN-alpha|30,000 units hrIFN-alpha was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
11654148|NCT00024479||suspected or confirmed rheumatic disease|autoimmune, autoinflammatory, or degenerative conditions
11654149|NCT00023595|Active Comparator|H01: Medication|Medical therapy alone to treat Coronary Artery Disease
11654150|NCT00023595|Active Comparator|H01: Medication + CABG|Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease
11654151|NCT00023595|Active Comparator|H02: Medication+CABG|Coronary artery bypass graft surgery (CABG) plus Medication to treat coronary artery disease
11654152|NCT00023595|Active Comparator|H02: Medication+CABG+SVR|CABG plus Medication and Surgical ventricular reconstruction (SVR)
11654153|NCT00023504|Active Comparator|Pneumococcal Vaccine|To determine the function of T and B cells in vivo using Pneumococcal vaccine immunization in patients with known or suspected immune disorders.
11654154|NCT00023504|Active Comparator|Rabies Vaccine|To determine the function of T and B cells in vivo using Rabies vaccine immunization in patients with known or suspected immune disorders.
11654155|NCT00023452|Active Comparator|Daily Isoniazid|Isoniazid (INH) daily for 9 months (240 to 270 total doses).
11654156|NCT00023452|Experimental|Weekly Isoniazid / Rifapentine|Isoniazid / Rifapentine (RPT/INH) weekly for 3 months (11 to 12 total doses) given by Directly Observed Therapy (DOT)
11654157|NCT00023374|Experimental|Rifampin+PZA+Ethambutol|6 mos of intermittent (2 or 3 times weekly) therapy with REZ
11654158|NCT00023543|Experimental|1|Participants will reduce total fat intake to 17 percent of calories, 1300 kilo calories, and increase moderate activity to 150-240 minutes per week to obtain a 10 percent reduction in weight.
11654159|NCT00023322|Experimental|Peginterferon Alpha-2a|Patients with hepatitis D virus (HDV) infection are treated with pegylated alpha interferon therapy for 3 years. The dose of the drug is 180 mcg/week.
11654160|NCT00023309|Experimental|Lamivudine and adefovir|
11654161|NCT00023309|Active Comparator|Adefovir|
11654162|NCT00023283|Experimental|1|Standard Medical Management with once-weekly medication dispensing
11654163|NCT00023283|Experimental|2|Standard Medical Management with thrice-weekly medication dispensing
11654164|NCT00023283|Experimental|3|Enhanced Medical Management with thrice-weekly medication dispensing
11654165|NCT00023244|Experimental|Corticosteroid (steroid) withdrawal|All enrolled subjects who have not experienced an episode of acute rejection or other event resulting in removal from the study in the first 6 months after transplantation will undergo a protocol-driven biopsy at 6 months. Subjects with no clinical or histologic evidence of rejection will be eligible to be randomized and treated in a double-blinded (e.g., masked-neither subject nor health care providers will know treatment being received) fashion while continuing other immunosuppressive medications. Subjects in this arm will undergo complete steroid withdrawal by the end of 12 months post-transplant.
11654166|NCT00023244|Active Comparator|Control Treatment|All enrolled subjects who have not experienced an episode of acute rejection or other event resulting in removal from the study in the first 6 months after transplantation will undergo a protocol-driven biopsy at 6 months. Subjects with no clinical or histologic evidence of rejection will be eligible to be randomized and treated in a double-blinded (e.g., masked-neither subject nor health care providers will know treatment being received) fashion while continuing other immunosuppressive medications. Subjects in this arm will be maintained on low-dose (0.15 mg/kg/day) daily steroids.
11654167|NCT00023231|Experimental|1|Participants will receive immunosuppression therapy using antibody induction (daclizumab), corticosteroids, mycophenolate mofetil, and sirolimus prior to transplantation. Bactrim and ganciclovir will be taken for infection prophylaxis. If the participant has consistent high levels of fasting cholesterol, treatment with lipitor may be given.
11654168|NCT00023205|Experimental|Individualized education|Individualized education with materials written in plain language. Follow-up sessions/ phone contact as requested by the subject.
11654169|NCT00023205|Active Comparator|Standard care|1 session of education with provision of standard Arthritis Foundation materials.
11654170|NCT00017693|Experimental|0.75mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
11654171|NCT00017693|Experimental|1.5mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
11654172|NCT00017693|Experimental|3.0mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
11654173|NCT00017693|Placebo Comparator|Placebo for rsIL-4R|The placebo for recombinant human soluble IL-4 receptor (rsIL-4R) consisted of identically prepared excipient in the same volume (2.5 mL). To maintain blinding, medication was dispensed by an individual who was not responsible for patient care or assessment. Treatment assignment was blinded to all personnel involved in direct conduct or monitoring of the study.
11654174|NCT00016718|Experimental|Age Group 1: 90 days to < 3 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
11654175|NCT00016718|Experimental|Age Group 2: 3 to 12 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
11654176|NCT00016718|Experimental|Age Group 2: 13 to 21 years of age (FTC, EFV, ddI)|Emtricitabine (FTC), Efavirenz (EFV) and Didanosine (ddI) together once daily
11654177|NCT00014911|Experimental|Islet Transplantation|All study participants
11654178|NCT00011037|Experimental|1|Participants will receive ALVAC-HIV vCP1452 at 0, 1, 3, and 6 months and MN rgp120 and Months 3 and 6
11654179|NCT00011037|Experimental|2|Participants will receive ALVAC-HIV vCP1452 at 0, 1, 3, and 6 months and MN rgp120 placebo and Months 3 and 6
11654180|NCT00011037|Placebo Comparator|3|Participants will receive ALVAC-HIV vCP1452 placebo at 0, 1, 3, and 6 months and MN rgp120 placebo and Months 3 and 6
11654181|NCT00007787|Experimental|Antibody plus delayed cyclosporine therapy|Anti-human thymocyte globulin (rabbit) (Thymoglobulin®) is admistred at the time of transplant followed delayed clyclosporine A therapy post tranplant.
11654182|NCT00007787|Active Comparator|Standard cyclosporine A therapy|Cyclosporine A therapy (either Cyclosporine or Tacrolimus) will be initiated pre-transplantations
11654183|NCT00006604|Experimental|Step I: Group 1|"Group 1 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder) and two NRTIs.
~ATV Dose Tested: 310 mg/m^2, 620 mg/m^2; Final Dose: Not Established"
11654184|NCT00006604|Experimental|Step I: Group 2|"Group 2 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder) and two NRTIs.
~ATV Dose Tested: 310 mg/m^2, 620 mg/m^2; Final Dose: Not Established"
11654185|NCT00006604|Experimental|Step I: Group 3|"Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
~ATV Dose Tested: 310 mg/m^2, 415 mg/m2, 520 mg/m^2; Final Dose: 520 mg/m^2"
11654186|NCT00006604|Experimental|Step I: Group 4|"Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
~ATV Dose Tested: 310 mg/m^2, 520 mg/m^2, 620 mg/m^2; Final Dose: 620 mg/m^2"
11654187|NCT00006604|Experimental|Step I: Group 5|"Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
~ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2"
11654188|NCT00006604|Experimental|Step I: Group 5a|"Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
~ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2"
11654189|NCT00006604|Experimental|Step I: Group 6|"Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
~ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2"
11654190|NCT00006604|Experimental|Step I: Group 7|"Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
~ATV Dose Tested: 310 mg/m^2, 205 mg/m^2; Final Dose: 205 mg/m^2"
11654191|NCT00006604|Experimental|Step I: Group 8|"Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
~ATV Dose Tested: 310 mg/m^2, 205 mg/m^2; Final Dose: 205 mg/m^2"
11654192|NCT00006441|Experimental|A|Patients beginning IL-2 treatment regimens after 4 weeks of study
11654193|NCT00006441|Active Comparator|B|Patients beginning IL-2 treatment after some delay based on specified criteria
11654194|NCT00006154|Experimental|A|Patients will receive combination antiretroviral therapy with a protease inhibitor
11654195|NCT00006154|Active Comparator|B|Patients will receive combination antiretroviral therapy without a protease inhibitor
11654196|NCT00005113|Experimental|1|Participants will receive SRL, CsA/tacrolimus, and corticosteroids for up to 36 months
11654197|NCT00005113|Experimental|2|Participants will receive standard CsA or tacrolimus-based double or triple drug therapy for up to 36 months
11654198|NCT00005009|Experimental|Varivax®|0.5 mL of Varivax administered subcutaneously in the right upper arm (deltoid region).
11654199|NCT00004978|Experimental|rIL-2|Recombinant interleukin-2 (rIL-2) therapy used with combination anti-HIV medication of choice.
11654200|NCT00004978|No Intervention|No rIL-2|Control arm uses anti-HIV medication of choice without rIL-2.
11654201|NCT00004578|Active Comparator|1|Group 1, n=32 initiated with ABT-378 & ritonavir; after 3 wks stavudine and lamivudine was added.
11654202|NCT00004578|Active Comparator|2|Group II patients (n=68) to be randomized after all Group I patients are enrolled and safety analysis is completed.
11654203|NCT00001131|Experimental|A|Patients will recieve a daily, self-administered subcutaneous injection of IL-2 while continuing treatment with their current oral anti-HIV medications
11654204|NCT00001131|Active Comparator|B|Patients will only follow their current oral anti-HIV medication regimen. No additional IL-2 injection will be given.
11654205|NCT00001082|Experimental|1|Participants will receive adefovir dipivoxil and L-carnitine
11654206|NCT00001082|Experimental|2|Participants will receive adefovir dipivoxil placebo and L-carnitine.
11654207|NCT00001077||1|Participants will receive peptamen drinks and multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
11654208|NCT00001077||2|Participants will receive NuBasics drinks or equivalent amounts of NuBasics soups or bars and daily multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
11654209|NCT00001077||3|Participants will receive multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
11654210|NCT00000955|Other|A|All eligible study participants
11654211|NCT00000948|Experimental|1|Participants will be broken into 3 groups. Each group will receive ART and escalating doses of aldesleukin. All participants will then receive that maximum tolerated dose of aldesleukin.
11654212|NCT00000948|Active Comparator|2|All participants will receive ART
11654213|NCT00000936|Experimental|Induction|subjects receiving hOKT3 induction therapy
11654214|NCT00000936|Active Comparator|Induction Free Therapy|Patients not receiving induction therapy
11654215|NCT00000935|Experimental|Intravenous Immune Globulin (Human)|
11654216|NCT00000935|Placebo Comparator|Intravenous Immune Globulin (Human) Placebo|
11654217|NCT00000932||A|Participants currently enrolled in or currently being followed in an ongoing qualifying study. Qualifying studies can be found in the protocol.
11654218|NCT00000932||B|Participants previously enrolled in but not currently being followed in a qualifying study. Qualifying studies can be found in the protocol.
11654219|NCT00000932||C|Antiretroviral-naive participants not enrolling in a qualifying study (i.e., patients starting treatment outside the first study or patients deferring treatment)
11654220|NCT00000930||A|HIV-infected individuals enrolled in HIVNET D01
11654221|NCT00000930||B|Individuals with newly acquired HIV infection
11654222|NCT00000928|Experimental|A|All study participants
11654223|NCT00000884|Experimental|1|Participants will undergo treatment intramuscularly
11654224|NCT00000884|Experimental|2|Participants will undergo treatment orally
11654225|NCT00000884|Experimental|3|Participants will undergo treatment intranasally
11654226|NCT00000884|Experimental|4|Participants will undergo treatment intrarectally
11654227|NCT00000884|Experimental|5|Participants will undergo treatment intravaginally
11654228|NCT00000884|Experimental|6|Participants will undergo treatment intranasally and intramuscularly
11654229|NCT00000884|Experimental|7|Participants will undergo treatment intrarectally and intramuscularly
11654230|NCT00000874||1|Participants who are failing a regimen of ZDV, 3TC, and IDV
11654231|NCT00000874||2|Participants who are failing a regimen of ZDV, 3TC, and SRQ
11654232|NCT00000874||3|Participants who are failing a regimen of ZDV, 3TC, and RTV
11654233|NCT00000874||4|Participants who are failing a regimen of d4T, 3TC, and IDV
11654234|NCT00000829|Experimental|1|Patients receiving intramuscular heptavalent pneumococcal conjugate vaccine
11654235|NCT00000829|Placebo Comparator|2|Patients receiving placebo vaccine
11654236|NCT00000817|Experimental|1|Participants will receive standardized or alternate point acupuncture treatment twice weekly for the first 6 weeks, then once weekly for the next 8 weeks, plus either oral amitriptyline or placebo daily for the entire 14 weeks.
11654237|NCT00000815|Experimental|1|Participants who receive vaccination at 6 and 12 months of age
11654238|NCT00000815|Experimental|2|Participants who receive vaccination only at 12 months of age
11654239|NCT00000785||A|All eligible CPCRA subjects
11654240|NCT00000784||A|Consenting patients newly enrolled in either CPCRA 007 or CPCRA 006
11654241|NCT00000783||1|Sexually active HIV-infected concordant couples
11654242|NCT00000783||2|Sexually active HIV-infected discordant couples
11654243|NCT00000774|Experimental|1|Patients who will receive rgp120/HIV-1MN
11654244|NCT00000774|Experimental|2|Patients who will receive rgp120/HIV-1SF2
11654245|NCT00000774|Placebo Comparator|3|Patients who will receive the placebo counterpart of 120/HIV-1MN
11654246|NCT00000774|Placebo Comparator|4|Patients who will receive the placebo counterpart of rgp120/HIV-1SF2
11654247|NCT00023049||1|patients with known SNHL and/or peripheral vestibular dysfunction
11654248|NCT00023036||1|Patients with known or suspected nonsyndromic SNHL associated with EVA
11654249|NCT00023036||2|Patients with nonsyndromic EVA
11654250|NCT00023036||3|unaffected siblings and parents of affected family members
11654251|NCT00023036||4|Other unaffected relatives; included if there is more than one sibship with affected family
11654252|NCT00023023||Adults and children subjects|The NIH and SH components will enroll and follow only adult (age (Bullet)18) blood donor or recipient subjects. CNMC will enroll and follow children between the ages of 6 months and 18 years.
11654253|NCT00022971|Experimental|1|Apolizumab followed by rituixmab every 4 weeks
11654254|NCT00022854|Placebo Comparator|1|
11654255|NCT00022854|Experimental|2|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
11654256|NCT00022854|Experimental|3|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous levobupivacaine infusion of 5 mL/hr for 50 hr
11654257|NCT00022776|Experimental|1|Participants will undergo surgery for spinal stenosis. Participants in this group will undergo surgical decompression as described by Rothman and Simeone.
11654258|NCT00022776|Experimental|2|Participants will undergo physical therapy for spinal stenosis. These participants will undergo a physical therapy program emphasizing lumbar flexion exercises, general conditioning exercises, and patient education for six weeks, with a frequency of 1-2 visits per week. Each patient will receive instruction in a home exercise program.
11654259|NCT00021866||Carbamazepine|Children and their mothers exposed to Carbamazepine monotherapy in utero
11654260|NCT00021866||Phenytoin|Children and their mothers exposed to phenytoin in utero
11654261|NCT00021866||Lamotrigine|Children and their mothers exposed to Lamotrigine in utero
11654262|NCT00021866||Valproate|Children and their mothers exposed to Valproate in utero
11654263|NCT00021840||Homogen Hispanic pop/Cent Valley CRA|Homogeneous Hispanic population from the Central Valley of Costa Rica
11654264|NCT00021814|Placebo Comparator|Placebo|Doxazosin and Finasteride placebos
11654265|NCT00021814|Experimental|Doxazosin|Doxazosin and Finasteride placebo
11654266|NCT00021814|Experimental|Finasteride|Doxazosin placebo and Finasteride
11654267|NCT00021814|Experimental|Combination|Doxazosin and Finasteride
11654268|NCT00021541|Experimental|Tipifarnib (R11577)-Arm I|Patients receive oral R115777 (Tipifarnib) first followed by placebo. 200 mg/m^2/dose BSA every 12 hours by mouth (po)on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
11654269|NCT00021541|Placebo Comparator|Placebo-Arm II|Patients receive oral placebo first followed by R115777 (Tipifarnib). 200 mg/m^2/dose BSA every 12 hours by mouth (po)every 12 hours on days 1-21. Courses repeat as in arm I.
11654270|NCT00018902|Experimental|1|Participants whose depression does not respond to an initial SSRI will switch to an alternative SSRI.
11654271|NCT00018902|Experimental|2|Participants whose depression does not respond to an initial SSRI will switch to a different non-SSRI antidepressant.
11654272|NCT00018902|Experimental|3|Participants whose depression does not respond to an initial SSRI will switch to an alternative SSRI and receive cognitive behavioral therapy (CBT).
11654273|NCT00018902|Experimental|4|Participants whose depression does not respond to an initial SSRI will switch to a different non-SSRI antidepressant and receive CBT.
11654274|NCT00018889||1|Patients age 2 years and older with a clinical or suspected diagnosis of movement disorder
11654275|NCT00018824|Experimental|1|Naltrexone
11654276|NCT00018824|Placebo Comparator|2|Placebo
11654277|NCT00018798||Bi-weekly telephone calls|34 participants received bi-weekly telephone calls in addition to the annual reviews
11654278|NCT00018798||Annual review only|23 participants received annual reviews only
11654279|NCT00018694|Other|Arm 1|
11654280|NCT00018655|Experimental|Arm 1|Twelve Step Facilitation
11654281|NCT00018655|Experimental|Arm 2|Integrated Cognitive Behavioral Treatment
11654282|NCT00018616|Other|1|
11654283|NCT00018434||Group 1|
11654284|NCT00018356|Other|1|
11654285|NCT00018200|Experimental|Arm 1|Desipramine, low, middle or high exposure
11654286|NCT00018200|Experimental|Arm 2|Fluoxetine, low, middle, or high exposure
11654287|NCT00018200|Placebo Comparator|Arm 3|Benztropine .125-.5mg daily
11654288|NCT00018174|Experimental|1|
11654289|NCT00018174|Placebo Comparator|2|
11654290|NCT00018148|Experimental|1|Transdermal nicotine plus nortriptyline
11654291|NCT00018148|Active Comparator|2|Transdermal nicotine plus placebo
11654292|NCT00018096|Experimental|bronchoscopy|2 bronchoscopies 4 hours apart; The first to instill the 3 experimental biologic agents in separate airways (HDM, LPS and saline-placebo), the second to perform BAL and brush biopsies 4 hours later in the same airways.
11654293|NCT00018057|Active Comparator|Active|Subjects in both treatment arms receive cognitive behavioral therapy (CBT) for a 12-week period. In the final eight weeks of the trial, the subjects complete either the active-intervention arm or the controlinvention arm. In these arms, either the active or control treatment is administered immediately before a CBT session.
11654294|NCT00018057|Sham Comparator|Control|Subjects in both treatment arms receive cognitive behavioral therapy (CBT) for a 12-week period. In the final eight weeks of the trial, the subjects complete either the active-intervention arm or the controlinvention arm. In these arms, either the active or control treatment is administered immediately before a CBT session.
11654295|NCT00018044||Patient Relatives|Blood relatives of enrolled patients
11654296|NCT00018044||Patients|Patients with mycobacterial infections
11654297|NCT00018031|Experimental|1|Weekly Injection of peginterferon alfa-2b and weight based ribavirin (1-1.2g/day) for 48 weeks
11654298|NCT00017953|Experimental|Lifestyle Intervention|Participants in the lifestyle intervention arm are offered individual and group sessions designed to help achieve and maintain weight loss.
11654700|NCT00001813||2|Family members of patients with XP, XP/CS, CS, or TTD
11654299|NCT00017953|Active Comparator|Diabetes Support and Education|The diabetes support and education arm provides group sessions on diabetes management and social support.
11654300|NCT00017914||Healthy Volunteer|Healthy subject who has not received anti-inflammatory medications and should not has undergone surgery or any major trauma within the 8 weeks prior to enrollment.
11654301|NCT00017914||Myositis Patient|Patient should have documented evidence that he/she meets criteria for an idiopathic inflammatory myopathy (IIM)
11654302|NCT00017914||Non-Myositis Patient|Patients with other myopathies, other autoimmune diseases, other complications similar to myositis patients. First degree relatives of IIM patients (affected or unaffected)
11654303|NCT00016835|Active Comparator|Supra-gingival scaling and placebo|"This group receives a placebo (instead of systemic antibiotic), supra-gingival oral prophylaxis, and ultrasonic removal of supra-gingival calculus with water irrigation at the initial treatment visit. At the 9-month follow-up visit, this group will receive sub-gingival ultrasonic scaling with povidone-iodine irrigation.
~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
11654304|NCT00016835|Experimental|Subgingival scaling and metronidazole|"This group receives ultrasonic scaling with local anesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation, and metronidazole as an oral systemic antibiotic at the initial treatment visit.
~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
11654305|NCT00016835|Experimental|Subgingival scaling and doxycycline|"This group receives ultrasonic scaling with local anesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation, and doxycycline as an oral systemic antibiotic at the initial treatment visit.
~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
11654306|NCT00016744|Active Comparator|1|"Subjects will be randomized to receive either the Phenylbutyrate or placebo tablets for 4 days
~Every participant will receive Genistein during the NPD."
11654307|NCT00016744|Placebo Comparator|2|
11654308|NCT00016523|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide
11654309|NCT00016523|Active Comparator|Placebo|Inhaled Oxygen
11654310|NCT00015457|Experimental|cervical dystonia|cervical dsytonia patinets
11654311|NCT00015340|Experimental|Buprenorphine/Naloxone|
11654312|NCT00015210|Active Comparator|Nefazodone|Nefazodone 100 mg tablet, titrated to a maximum of 200 mg administered twice daily by treatment day 10. Drug tapered over 7 days at the conclusion of the treatment period. Treatment was administered for 8 weeks.
11654313|NCT00015210|Placebo Comparator|Matched Placebo Tablet|Matched placebo tablet, titrated up to 2 tablets twice daily by day 10 and tapered over 7 days at the conclusion of the study. Treatment period lasted 8 weeks.
11654314|NCT00014859||Population-based cohort|Descriptive cohort of population-based DNA samples from the newborn screening program in Missouri with vital statistics based, linked phenotype data
11654315|NCT00014859||Trio sequencing cohort|Affected infant/child (term or near term infant with progressive respiratory distress or other rare pulmonary phenotype or older child with interstitial lung disease or other rare pulmonary phenotype) and parents
11654316|NCT00014820||Patients with a diagnosis of asthma (new) (Cases)|Patients with a physician diagnosis of asthma during the 7.5 years being studied who were working at the time of diagnosis, as determined by patient interviews.
11654317|NCT00014820||Patients with a diagnosis other than asthma (Controls)|Patients (age-matched to a case patient) with a physician diagnosis other than asthma who were working at the time of diagnosis.
11654318|NCT00014820||Patients with a diagnosis of asthma (previous)|Patients with a physician diagnosis of asthma prior to the 7.5 years being studied
11654319|NCT00013611|No Intervention|Antiretroviral therapy alone|
11654320|NCT00013611|Experimental|Proleukin plus antiretroviral therapy|
11654321|NCT00013559||Family|Parents and/or siblings of patients with Smith-Magenis Syndrome (SMS) or suspected SMS.
11654322|NCT00013559||Patients|Patients with Smith-Magenis Syndrome (SMS) or suspected SMS.
11654323|NCT00013533|Experimental|1|Transplant with Induction Therapy
11654324|NCT00013481|Other|1|
11654325|NCT00013390|Active Comparator|1|Tinnitus Masking
11654326|NCT00013390|Other|2|Tinnitus Retraining Therapy
11654327|NCT00013260|Other|Arm 1|
11654328|NCT00013247|Other|Arm 1|
11654329|NCT00013234|Other|Arm 1|
11654330|NCT00013221|Other|Arm 1|
11654331|NCT00013208|Other|Arm 1|
11654332|NCT00013195|Other|Arm 1|
11654333|NCT00013182|Other|Arm 1|
11654334|NCT00013169|Other|Arm 1|
11654335|NCT00013156|Other|Arm 1|
11654336|NCT00013143|Other|Arm 1|
11654337|NCT00013130|Other|Arm 1|
11654338|NCT00013117|Other|Arm 1|
11654339|NCT00013104||Group 1|
11654340|NCT00013091|Other|Arm 1|
11654341|NCT00013078|Other|Arm 1|
11654342|NCT00013065||Group 1|
11654343|NCT00013052|Other|Arm 1|
11654344|NCT00013039|Other|Arm 1|
11654345|NCT00013026|Other|Arm 1|
11654346|NCT00013013|Other|Arm 1|
11654347|NCT00013000|Other|Arm 1|
11654348|NCT00012987|Other|Arm 1|
11654349|NCT00012974|Other|Arm 1|
11654350|NCT00012961||Group 1|
11654351|NCT00012948|Other|Arm 1|
11654352|NCT00012935|Other|Arm 1|
11654353|NCT00012922|Other|Arm 1|
11654354|NCT00012909|Other|Arm 1|
11654355|NCT00012896|Other|Arm 1|
11654356|NCT00012883|Other|Arm 1|Homewalking Exercise Program
11654357|NCT00012870|Other|Arm 1|
11654358|NCT00012857|Other|Arm 1|
11654359|NCT00012844|Other|Arm 1|
11654360|NCT00012831||Group 1|
11654361|NCT00012818|Other|Arm 1|
11654362|NCT00012805|Other|Arm 1|
11654363|NCT00012792|Other|Arm 1|
11654364|NCT00012779|Other|Arm 1|
11654365|NCT00012766|Other|Arm 1|
11654366|NCT00012753|Other|Arm 1|
11654367|NCT00012740|Other|Arm 1|
11654368|NCT00012727|Other|Arm 1|
11654369|NCT00012714|Other|Arm 1|
11654379|NCT00012545||Healthy Pregnant Volunteers|Pregnant women whose babies are at risk for sickle cell anemia will be identified and referred to the NIH Research Coordinator for evaluation and entry into the study.
11654380|NCT00011713||Infertility patients|Patients undergoing infertility treatment at Massachusetts General Hospital Infertility Clinic.
11654381|NCT00011648||non-SCD|200 Men and Women without a diagnosis of sickle cell disease 18 years of age or older
11654382|NCT00011648||SCD|1000 Men and Women with a diagnosis of sickle cell disease
11654383|NCT00011583|Experimental|1|1 hour/day of mechanically-assisted upper limb therapy
11654384|NCT00011583|Active Comparator|2|1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
11654385|NCT00011570|Other|1|
11654386|NCT00011531|Other|1|
11654387|NCT00011492||1/All Patients|All eligible patients
11654388|NCT00011414|Experimental|1|Intervention given with dose escalation of tariquidar
11654389|NCT00011362|Active Comparator|Dexamethasone|Dexamethasone
11654390|NCT00011362|Placebo Comparator|Placebo|Saline
11654391|NCT00011349||Group 1|
11654392|NCT00011193||Non-Exercise Control Group|We randomly assigned 102 women in the non-exercise control group and were asked to maintain their level of activity for the 6-month study period.
11654393|NCT00011193||4-kcal/kg Energy Expenditure per week|We randomly assigned 155 women to the 4-kcal/kg per week group for 6 months.
11654394|NCT00011193||8-kcal/kg Energy Expenditure per week|We randomly assigned 104 women to the 8-kcal/kg per week group for 6 months.
11654395|NCT00011193||12-kcal/kg Energy Expenditure per week|We randomly assigned 103 women to the 12-kcal/kg per week group for 6 months.
11654396|NCT00011180||Incident Cohort with VTE|Olmsted County, Minnesota residents with with a first-lifetime deep vein thrombosis (DVT) or pulmonary embolism (PE) during the five year period, 1996-2000.
11654397|NCT00011180||Controls without VTE|Two Olmsted County, Minnesota residents without venous thromboembolism (VTE) were matched by age and gender to each definite or probable case of VTE within the 1996-2000 cohort.
11654398|NCT00010803|Placebo Comparator|Placebo|Placebo 1 pill twice a day
11654399|NCT00010803|Active Comparator|Ginkgo biloba|Ginkgo biloba EGb761 120 mg twice daily
11654400|NCT00010608|Experimental|Transcendental Meditation program|A mental technique for stress reduction which is natural, easy and effortless and is practiced sitting in a chair with eyes closed for 20 minutes twice a day.
11654401|NCT00010608|Active Comparator|Health Education|A lifestyle modification program for improving diet, exercise, salt intake and substance use.
11654402|NCT00009646|Experimental|Indomethacin|Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa.
11654403|NCT00009646|Placebo Comparator|Placebo|Saline solution
11654404|NCT00009620|Experimental|Phenobarbital|
11654405|NCT00009620|Placebo Comparator|Placebo|
11654406|NCT00010439|Experimental|1 Alendronate for 12 months|Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily.
11654407|NCT00010374|Experimental|NeuRx DPS|Laparoscopic implantation of 4 NeuRx DPS electrodes and subsequent pacing using the DPS system.
11654408|NCT00010335|Experimental|1|Participants will receive a stem cell transplant.
11654409|NCT00009243||Patients|Patients with acute stroke symptoms
11654410|NCT00009217|Active Comparator|Haloperidol-Haloperidol|Haloperidol for 20 weeks followed by haloperidol for 24 weeks
11654411|NCT00009217|Placebo Comparator|Haloperidol-Placebo|Haloperidol for 20 weeks followed by placebo for 24 weeks
11654412|NCT00008502||18 years of age or older|without keloids
11654413|NCT00008502||family members over 12 years of age|who have either classic or non-classic keloids
11654414|NCT00008502||Probands|original participants who have had a classic (butterfly-shaped or wound-overflowing) keloidfor at least one year
11654415|NCT00008450|Experimental|Treatment (cyclosporine, mycophenolate mofetil, transplant)|Patients receive cyclosporine PO or IV on days -3 to 100 followed by a taper until day 180 and mycophenolate mofetil PO or IV on days 0-40 with a taper until day 96 in the absence of unacceptable toxicity. Unrelated donor recipients also undergo TBI on day 0. Patients undergo bone marrow transplant on day 0.
11654416|NCT00007696||1|
11654417|NCT00007657|Experimental|1|Percutaneous Coronary Intervention (PCI) plus intensive medical therapy
11654418|NCT00007657|Active Comparator|2|Intensive medical therapy
11654419|NCT00007774|Experimental|1|Olanzapine
11654420|NCT00007774|Active Comparator|2|Haloperidol
11654421|NCT00007761|Experimental|1|Bipolar Disorder Program
11654422|NCT00007761|Active Comparator|2|Usual (psychiatric) Care
11654423|NCT00007722||1|
11654424|NCT00007709||1|
11654425|NCT00007683|Active Comparator|1|Warfarin Titrated to an INR of 2.5-3.0
11654426|NCT00007683|Active Comparator|2|Aspirin 182 mg
11654427|NCT00007683|Active Comparator|3|Clopidogrel 75 mg
11654428|NCT00007644|Other|Radical Prostatectomy|Surgical removal of the prostate
11654429|NCT00007644|No Intervention|Watchful Waiting|Closely watching, waiting and treating symptoms if and when cancer progresses
11654430|NCT00007631|Active Comparator|1|Topical Tretinoin
11654431|NCT00007631|Placebo Comparator|2|Placebo
11654432|NCT00007618||1|
11654433|NCT00007605|Active Comparator|1|Amiodarone or Sotalol
11654434|NCT00007605|Active Comparator|2|Sotalol
11654435|NCT00007579||1|
11654436|NCT00007501|Experimental|Arm 1|varicella-zoster vaccine
11654437|NCT00007501|Placebo Comparator|Arm 2|vaccine placebo
11654438|NCT00007475|Experimental|Plasma Exchange + Cyclophosphamide|"Procedure/Surgery: Plasma exchange A course of plasma exchange of 5 treatments over 10 days, then administration of cyclophosphamide.
~Drug: Cyclophosphamide For GFR > 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR < 50 ml/min/1.73 m2 but > 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months."
11654439|NCT00007358|Experimental|1|Depending on patient and physician decision, a steroid may be administered during pregnancy.
11654537|NCT00005917||Chediak-Higashi Syndrome|Confirmed or suspected patients with Chediak-Higashi Syndrome.
11654440|NCT00007345|Experimental|Peripheral T-cell Lymphoma (PTCL)|Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle.
11654441|NCT00007345|Experimental|Cutaneous T-cell Lymphoma (CTCL)|Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle.
11654442|NCT00007267|Experimental|1|Participants will receive individual cognitive behavioral therapy
11654443|NCT00007267|Experimental|2|Participants will receive self-help cognitive behavioral intervention facilitated by a psychologist
11654444|NCT00007267|Active Comparator|3|Participants will receive a disease/health education intervention
11654445|NCT00007150|Other|1/HH patients|HH patients
11654446|NCT00007020|Other|Cholic Acid|
11654447|NCT00006565|Experimental|1|HEPA Air Cleaners
11654448|NCT00006565|Placebo Comparator|2|Inactive (placebo) filtration unit
11654449|NCT00006518||1|Patients with HIV infection, KSHV infection, or with cancer
11654450|NCT00006517|Active Comparator|bright light box|30 min exposure shortly after wake-up
11654451|NCT00006517|Active Comparator|high-output negative ion generator|90 min exposure prior to wake-up
11654452|NCT00006517|Placebo Comparator|low-output negative ion generator|90 min exposure prior to wake-up
11654453|NCT00006517|Active Comparator|dawn simulator|naturalistic incremental light exposure 90 min prior to wake-up
11654454|NCT00006517|Experimental|dawn light pulse|rectangular pulse light exposure 13 min before wake-up, matched for total illuminance with dawn signal
11654455|NCT00006505|Experimental|Transplant|Islet cell transplantation
11654456|NCT00006501||ECG recording|After the tests are completed, people who enroll in this study are followed by telephone, 1, 4, 8, 12 16, 20 and 24 months. During these follow-up telephone calls a research coordinator asks about the participant's health condition and about cardiovascular medications that are being taken.
11654457|NCT00006489|Active Comparator|Naltrexone alone|Naltrexone alone
11654458|NCT00006489|Active Comparator|Naltrexone with CBT for PTSD|Naltrexone with CBT for PTSD
11654459|NCT00006489|Active Comparator|Placebo with CBT for PTSD|Placebo with CBT for PTSD
11654460|NCT00006489|Placebo Comparator|Placebo alone|Placebo alone
11654461|NCT00006436|Experimental|Arm 1|Combination chemo and biological therapy
11654462|NCT00006425||1|25 women undergoing ductal lavage
11654463|NCT00006420||Observational, no interventions|
11654464|NCT00006411|Active Comparator|1|cornea assigned from donor age group <66.0 years
11654465|NCT00006411|Active Comparator|2|cornea assigned from donor age group >= 66.0 years
11654466|NCT00006409|Experimental|School-based intervention|TAAG health education included six lessons in each of 7th and 8th grades designed to enhance behavioral skills known to influence physical activity. TAAG physical education classes promoted moderate-vigorous physical activity for at least 50% of class time and encouraged teachers to promote physical activity outside of class. In conjunction with community partners, programs that were promoted outside of school included Dance Dance Revolution, after-school step aerobics class, before-school open gym, basketball camp, touch football, and weekend canoe programs. TAAG promotions used a social marketing approach to promote awareness of and participation in activities through media and promotional events.
11654467|NCT00006409|No Intervention|Control group|
11654468|NCT00006401|Experimental|Inhaled Nitric Oxide (iNO)|Nitric Oxide study gas will be initiated at 5 ppm using the INOvent delivery system. The delivery system provides for masked delivery of the treatment gas. This dose will be used for a 21-day period or until extubation.
11654469|NCT00006401|Placebo Comparator|Placebo|
11654470|NCT00006400|Active Comparator|Hydroxyurea|Participants will receive hydroxyurea.
11654471|NCT00006400|Placebo Comparator|Placebo|Participants will receive placebo.
11654472|NCT00006398|Experimental|Timolol Maleate|Dose titrated from 5 mg per day to up to 80 mg per day depending on heart rate
11654473|NCT00006398|Placebo Comparator|Placebo|Timelol placebo
11654474|NCT00006333||Subjects with known or suspected arthritis|Subjects with known or suspected arthritis will be evaluated longitudinally
11654475|NCT00006319||ADA deficient SCID|Patients with ADA deficient SCID
11654476|NCT00006319||Wiskott-Aldrich syndrome|Male patients with Wiskott-Aldrich syndrome
11654477|NCT00006305|Active Comparator|Revascularization and Insulin Providing (IP)|Prompt revascularization with intensive medical therapy and insulin providing glycemic control strategy
11654478|NCT00006305|Active Comparator|Revascularization and Insulin Sensitizing (IS)|Prompt revascularization with intensive medical therapy and insulin sensitizing glycemic control strategy
11654479|NCT00006305|Active Comparator|Medical Therapy and Insulin Providing (IP)|Intensive medical therapy with delayed revascularization if clinically indicated and insulin providing glycemic control strategy
11654480|NCT00006305|Active Comparator|Medical Therapy and Insulin Sensitizing (IS)|Intensive medical therapy with delayed revascularization if clinically indicated and insulin sensitizing glycemic control strategy
11654481|NCT00006295||Pedigree 1|
11654482|NCT00006295||Pedigree 2|
11654483|NCT00006295||Pedigree 3|
11654484|NCT00006295||Pedigree 4|
11654485|NCT00006295||Pedigree 5|
11654486|NCT00006295||Pedigree 6|
11654487|NCT00006295||Pedigree 7|
11654488|NCT00006295||Pedigree 8|
11654489|NCT00006295||Pedigree 9|
11654490|NCT00006295||Pedigree 10|
11654491|NCT00006295||Pedigree 11|
11654492|NCT00006295||Pedigree 12|
11654493|NCT00006294||Chlorthalidone|Participants will take chlorthalidone at recommended doses to control hypertension
11654494|NCT00006294||Amlodipine|Participants will take Amlodipine at recommended doses to control hypertension
11654495|NCT00006294||Lisinopril|Participants will take Lisinopril at recommended doses to control hypertension
11654496|NCT00006294||Doxazosin|Participants will take Doxazosin at recommended doses to control hypertension
11654497|NCT00006289|Active Comparator|Placebo first, then Neurotropin (G-1)|Double blind cross-over study: receive placebo for 5 weeks and then Neurotropin for 5 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
11654498|NCT00006289|Active Comparator|Neurotropin first, then Placebo (G-2)|Double blind cross-over study: receive Neurotropin for 5 weeks and then placebo for 5 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
11654499|NCT00006205|Experimental|Ondansetron|Ondansetron + cognitive behavioral therapy
11654500|NCT00006205|Experimental|Topiramate|Topiramate + cognitive behavioral therapy
11654501|NCT00006205|Placebo Comparator|Placebo|Placebo + cognitive behavioral therapy
11654502|NCT00006205|Experimental|Ondansetron + Topiramate|Ondansetron + Topiramate + cognitive behavioral therapy
11654503|NCT00006184|Experimental|Recipient - Chemotherapy Group|Induction chemotherapy with fludarabine, etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone, and granulocyte colony stimulating factor (GCSF) followed by transplant preparative regimen chemotherapy with fludarabine, cyclophosphamide, mesna, cyclosporine, and methotrexate, followed by stem cell infusion and immunization.
11654504|NCT00006184|Other|Donor - Vaccine Generation Group|3 subcutaneous injections of myeloma protein within 10 weeks before stem cell collection. The first (week 0) second (week 2), and third injection (week 6) with Id-KLH (Anti-idiotype-keyhole limpet hemocyanin) (0.5 mg subcutaneous day 1) and Granulocyte macrophage-colony stimulating factor (GM-CSF) (250 mcg/m^2 subcutaneous on days 1-4). Stem cell collection is 4 weeks after the third vaccination.
11654505|NCT00006178|Experimental|Sirolimus and Thymoglobulin|Thymoglobulin (Sangstat), a FDA-approved polyclonal rabbit-IgG antithymocyte preparation, will be given for ten days at the time of transplantation to achieve profound lymphocyte depletion. This will be paired with chronic therapy with Sirolimus (rapamycin, Wyeth-Ayerst), an oral immunosuppressant agent recently approved by the FDA.
11654506|NCT00006177||1|Children and adolescents between the ages of 6-17 years old who meet criteria for Bipolar Spectrum Disorders (BSD) (including Substance/Medication induced Bipolar &amp; Related Disorder (SMIBRD)).
11654507|NCT00006177||2|Adults between the ages of 18-58 years old who meet criteria for Bipolar Disorder, including those 18-25 years old previously enrolled as a subject with Bipolar Spectrum Disorders.
11654508|NCT00006177||3a|Control populations of healthy volunteer children and adolescents between the ages of 3-17 years old.
11654509|NCT00006177||3b|Control populations of parents of healthy volunteer children or healthy adults in research
11654510|NCT00006177||3C|Control populations of children 8-17 years old with attention deficit hyperactivity disorder (ADHD), who do not have a mood disorder.
11654511|NCT00006177||4|First and second-degree biological relatives of those in Group 1 or Group 2, and are between 3-58 years old.
11654512|NCT00006177||5a|A subgroup of these cohorts will be Old Order Amish individuals who fulfill eligibility for Group 1.
11654513|NCT00006177||5b|A subgroup of these cohorts will be Old Order Amish individuals who fulfill eligibility for Group 2.
11654514|NCT00006177||5c|A subgroup of these cohorts will be Old Order Amish individuals who fulfill eligibility for Group 3a.
11654515|NCT00006177||5d|A subgroup of these cohorts will be Old Order Amish individuals who fulfill eligibility for Group 3b.
11654516|NCT00006177||5e|A subgroup of these cohorts will be Old Order Amish individuals who fulfill eligibility for Group 4.
11654517|NCT00006172|Active Comparator|bright light box|60 min light therapy shortly after awakening
11654518|NCT00006172|Active Comparator|high-output negative ion generator|60 min high-density exposure shortly after awakening
11654519|NCT00006172|Placebo Comparator|low-output negative ion generator|60 min low-density exposure shortly after awakening
11654520|NCT00006170|Experimental|Bupropion and Weight Concerns intervention|Bupropion SR and a weight concerns psychosocial intervention
11654521|NCT00006170|Active Comparator|Placebo and Weight Concerns|A matched placebo administered on same schedule as bupriopion and a weight concerns psychosocial intervention for smoking cesstion
11654522|NCT00006170|Active Comparator|Bupropion and standard smoking cessation|Bupropion SR and a time and attention controlled smoking cessation intervention
11654523|NCT00006170|Placebo Comparator|Placebo and standard smoking cessation|A matched placebo administered on same schedule as bupriopion and a time and attention controlled smoking cessation intervention
11654524|NCT00006156|Experimental|Control|Control for FSH stimulation test
11654525|NCT00006156|Experimental|Drug: FSH|FSH Stimulation Test
11654526|NCT00006164|Experimental|1|Peg-interferon alfa-2a 90 mcg/week
11654527|NCT00006164|Active Comparator|2|Standard of care followup
11654528|NCT00006151|Experimental|Accu Drops (AD&C)|The experimental group (N=30) will be prescribed active Accu Drops (AD&C) plus behavioral therapy.
11654529|NCT00006151|Placebo Comparator|Placebo|The control condition (N=30) will be prescribed placebo Accu Drops (PD&C) plus behavioral therapy.
11654530|NCT00006150||Affected adults and children|Confirmed or suspected history of a Hyper IgE syndrome
11654531|NCT00006150||Relatives|Family members of subjects with confirmed or suspected history of a Hyper IgE syndrome
11654532|NCT00005937|Experimental|Antithymocyte globulin & cyclosporine|Myelodysplastic syndromes (MDS) subjects will be treated with Anti-thymocyte Globulin (ATG) and cyclosporine (CsA). The subjects will receive ATG at a dose of 40mg/kg orally on days 1-4 in combination with oral prednisone at a dose of 1mg/kg/day on day one. The prednisone will be tapered on day 10. The taper schedule will be every two days over a total of eight days (days 10-17). Drug the ATG administration the subjects will receive at least 4 units of platelets daily for platelet counts less than 20,000/ microliters. Cyclosporine (CsA) will be started on day 14 at a dose of 5mg/kg twice daily with dose adjustments based on drug levels (target 200-400 ng/ml). Cyclosporine therapy will be continued for six months.
11654533|NCT00005927||Hyperaldosteronism and cushing participants|Subjects with Hyperaldosteronism and cushing. Adults, pediatric subjects and family members (DNA collection only for family members).
11654534|NCT00005922|Experimental|A|Participants will receive 100% of the dose of the medication on the same reinforcement schedule (100%) as received during the baseline (maintenance) period.
11654535|NCT00005922|Experimental|B|Participants will receive 100% of the dose of the medication on a partial reinforcement schedule (25% or 50%) as received during the baseline (maintenance) period
11654536|NCT00005922|Experimental|C|Participants will receive 25% or 50% of the dose of the medication on the same reinforcement schedule (100%) as received during the baseline (maintenance) period.
11654635|NCT00004571||Schizophrenia|Patients with schizophrenia and psychosis
11654538|NCT00005914||Probands and family members|Individuals with major depressive disorder who meet study criteria, and members of their families. No intervention. This is a genetic study only.
11654539|NCT00005909||Alkaptonuria|Patients with confirmed or suspected alkaptonuria
11654540|NCT00005908|Experimental|Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine|Docetaxel 75 mg/m^2 intravenous day 1, capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles
11654541|NCT00005908|Experimental|Dose B-Cohort 2-Arm 2 Reduced dose-Docetaxel & Capecitabine|Docetaxel 60 mg/m^2 intravenous day 1, capecitabine 937.5 mg/m^2 orally twice daily day 2-15 for 4 cycles
11654542|NCT00005906|Experimental|Octreotide|Patients with lymphangioleiomyomatosis and lymphatic tumors, ascites or pleural effusions who are symptomatic will receive subcutaneous injections of octreotide starting at a dose of 100 micrograms per day. Doses will be gradually increased to a maximum of 800 micrograms per day, two months after enrollment, if there is no response to lower doses.
11654543|NCT00005902||1|250 subjects with von Hippel-Lindau (VHL) disease.
11654544|NCT00005901|Active Comparator|Pamidronate every 3 months for 3 years|Subjects who received Pamidronate every 3 months for 3 years.
11654545|NCT00005901|Active Comparator|Pamidronate every 6 months for 3 years|Subjects who received Pamidronate every 6 months for 3 years.
11654546|NCT00005780|Experimental|1|EPOCH-R followed by idiotype vaccine and GM-CSF
11654547|NCT00005777|Experimental|Minimal ventilation with Dexamethasone|Minimal ventilator support strategy (permissive hypercapnia) and early stress dose dexamethasone therapy
11654548|NCT00005777|Experimental|Minimal Ventilation without Dexamethasone|Minimal ventilator support strategy (permissive hypercapnia) and no dexamethasone therapy
11654549|NCT00005777|Active Comparator|Routine ventilation with Dexamethasone|
11654550|NCT00005777|Active Comparator|Routine ventilation without Dexamethasone|
11654551|NCT00005776|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide (iNO)
11654552|NCT00005776|Placebo Comparator|Oxygen|100% oxygen
11654553|NCT00005775|Experimental|Glutamine|TrophAmine (B. Braun/McGaw) with cysteine hydrochloride (40mg/gm amino acids) with L-glutamine added (20% of the total amount of amino acids)
11654554|NCT00005775|Placebo Comparator|Placebo|Standard TrophAmine (B. Braun/McGaw) with cysteine hydrochloride (40mg/gm amino acids)
11654555|NCT00005774|Experimental|Early surfactant group|
11654556|NCT00005774|Active Comparator|Standard Practice group|
11654557|NCT00005773|Experimental|Early iNO Management|Initiation of iNO in use for term and near-term infants in respiratory failure with an oxygenation index between 15-25.
11654558|NCT00005773|Active Comparator|Standard iNO management|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI >=25).
11654559|NCT00005772|Experimental|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
11654560|NCT00005772|Placebo Comparator|Normothermic|Placebo: Normothermic control group (with esophageal temperature at or near 37.0°C) for 96 hours
11654561|NCT00005675|Experimental|1|Participants will receive oral bovine type I collagen (CI) daily for 15 months
11654562|NCT00005675|Placebo Comparator|2|Participants will receive placebo daily for 15 months.
11654563|NCT00005739||Community-based therapy (case)|Community-based directly observed therapy (DOT) - A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
11654564|NCT00005739||Self-administered treatment (control)|Clinic directly observed therapy (DOT) - Traditional self-administered preventive treatment
11654565|NCT00005727|Experimental|Intervention|Specially-designed nutrition education curriculum designed to lower dietary fat intake in people with low literacy skills.
11654566|NCT00005727|Active Comparator|Control|General nutrition education curriculum.
11654567|NCT00005724|Other|Minimal Intervention Group|Pamphlets on healthy eating mailed to participants.
11654568|NCT00005724|Experimental|Health Counselor Intervention Group|Food for Heart program, a structured diet treatment program for low-income patients with high cholesterol, given by health counselor at 4 treatment visits.
11654569|NCT00005724|Experimental|Computer Program Intervention Group|User-friendly interactive computer program providing dietary counseling tailored to the needs of the participant.
11654570|NCT00005713||Continuing, preventative care for asthma|Low-income children with asthma will receive continuing, preventive care for asthma with trained staff in New York City Bureau of Child Health clinics
11654571|NCT00005711|No Intervention|Usual care|Control group children received routine medical care by their primary care providers as well as study visits every 6 months. At each study visit, following assessment of technique for using peak flow and metered dose inhalers, errors were corrected and children/families were coached on correct technique.
11654572|NCT00005711|Experimental|Asthma self-management education|"Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish."
11654573|NCT00005699||Hypertensive|described as hypertensive according to AHA guidelines at time of trial
11654574|NCT00005699||Controls|described as non-hypertensive according to AHA guidelines at time of trial
11654575|NCT00005676||VA-HIT and FOS|VA-HIT cohort: men with established CHD and low HDL-C FOS cohort: men without CHD
11654576|NCT00005533||Coronary Heart Disease Patients|
11654577|NCT00005520||African American hydrochlorothiazide|300 African American hypertensives were treated with hydrochlorothiazide 25 mg daily for 4 weeks.
11654578|NCT00005520||European American hydrochlorothiazide|300 European American hypertensives were treated with hydrochlorothiazide 25 mg daily for 4 weeks
11654579|NCT00005520||African American candesartan|300 African American hypertensives were treated with candesartan 16 mg daily for 2 weeks followed by 32 mg daily for 4 weeks
11654636|NCT00004571||Williams Syndrome|Healthy comparison subjects
11654580|NCT00005520||European American candesartan|300 European American hypertensives were treated with candesartan 16 mg daily for 2 weeks followed by 32 mg daily for 4 weeks
11654581|NCT00005502||Residents of Olmsted County, MN with elevated Troponins|Anyone admitted to St Marys or Rochester Methodist Hospitals who have an elevated troponin during their hospitalization and are residents of Olmsted County, MN
11654582|NCT00005446||Postmenopausal women with coronary heart disease|
11654583|NCT00005446||Postmenopausal women without coronary heart disease|Matched in age to the women with heart disease
11654584|NCT00005398||1; no experimental groups in this study|Observational cohort study
11654585|NCT00005379||IV drug users and their sexual contacts|This group will be made up of an already-recruited cohort
11654586|NCT00005379||Children who receive primary care at Bellevue Hospital|
11654587|NCT00005379||Bellevue Hospital inpatients/outpatients|Inpatients being treated for TB and outpatients receiving prophylactic treatment
11654588|NCT00005305||Hemophilic individuals|Subjects receiving multiple blood products for treatment of hemophilia
11654589|NCT00005289||1988-1991|
11654590|NCT00005289||2003-2004|
11654591|NCT00005219||Exercise Study Participants|Data from the San Diego Health and Exercise Baseline survey conducted in 1986 were used to contact participants for the follow-up
11654592|NCT00005145||Observational, no interventions|
11654593|NCT00005669|Active Comparator|1 - Metformin HCL|Subjects receive metformin plus a weight loss program
11654594|NCT00005669|Placebo Comparator|2 - Placebo|Subjects receive placebo plus a weight loss program
11654595|NCT00005655|Experimental|1|rhIL-12 in combination with rhIL-2
11654596|NCT00005006|Active Comparator|1|Alendronate alone
11654597|NCT00005006|Active Comparator|2|Teriparatide daily plus alendronate
11654598|NCT00005006|Active Comparator|3|Teriparatide cyclically plus alendronate
11654599|NCT00005005|Experimental|1|Participants will receive PTH for 1 year followed by alendronate for 1 year.
11654600|NCT00005005|Experimental|2|Participants will receive PTH and alendronate for 1 year followed by alendronate for 1 year.
11654601|NCT00005005|Experimental|3|Participants will receive alendronate for 2 years.
11654602|NCT00005005|Active Comparator|4|Participants will receive PTH for 1 year followed by placebo for 1 year.
11654603|NCT00004992|Placebo Comparator|Placebo|
11654604|NCT00004992|Active Comparator|Metformin|
11654605|NCT00004992|Active Comparator|Intensive Lifestyle|
11654606|NCT00004984|Experimental|Parenteral Insulin|High risk participants randomized to intervention
11654607|NCT00004984|Active Comparator|Close Observation|High risk participants randomized to observation
11654608|NCT00004984|Experimental|Oral Insulin|Intermediate risk participants randomized to intervention
11654609|NCT00004984|Placebo Comparator|Placebo|Intermediate risk participants randomized to placebo
11654610|NCT00004980|Experimental|active rTMS|1-Hz rTMS delivered to left temporoparietal cortex at 90% motor threshold for 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)
11654611|NCT00004980|Placebo Comparator|sham stimulation|Sham stimulation delivered 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)
11654612|NCT00004853|Experimental|1|single dose of intervention after each cycle of Standard 5 drug dose-intensive chemotherapy
11654613|NCT00004853|Experimental|2|single dose of interventionafter each cycle of Standard 5 drug dose-intensive chemotherapy
11654614|NCT00004850||HBV positive|HBV positive subjects
11654615|NCT00004850||HCV positive partners|HCV positive partner subjects
11654616|NCT00004850||HCV postive|HCV positive subjects
11654617|NCT00004847|Experimental|Adults or children with suspected PHEO/PGL|Patients are adults or children of any age with known, sporadic or familial PHEO/PGL
11654618|NCT00004738||Family Members|At least 2 family members of a patient with a confirmed diagnosis of Chiari I malformation.
11654619|NCT00004738||Patients|Patient with a confirmed diagnosis of Chiari I malformation who has a family member with syringomyelia or Chiari I malformation
11654620|NCT00004732|Active Comparator|Carotid Artery Endarterectomy (CEA)|Carotid endarterectomy is surgery to remove plaque buildup that causes narrowing (stenosis) in the carotid artery.
11654621|NCT00004732|Active Comparator|Carotid Artery Stenting (CAS)|Carotid artery stenting (CAS) is a procedure used to open narrowed carotid arteries. During the procedure, a small, expandable wire tube called a stent is permanently inserted into the carotid artery.
11654622|NCT00004843|Experimental|Parathyroidectomy|
11654623|NCT00004843|Active Comparator|Observation|
11654624|NCT00004842|Experimental|Budesonide|Oral budesonide
11654625|NCT00004769||Myotonic dystrophy|Subjects with myotonic dystrophy
11654626|NCT00004769||Healthy controls|Healthy subjects
11654627|NCT00004769||Disease controls 1|Subjects with FSHD
11654628|NCT00004769||Disease controls 2|Subjects with CMT
11654629|NCT00004660|Experimental|Radiotherapy|
11654630|NCT00004660|Sham Comparator|Sham treatment|
11654631|NCT00004635|Experimental|Thalidomide|Study participants are randomly assigned to one of two treatment groups. Participants received leuprolide or goserelin for 6 months. In period 1 participants received thalidomide orally 200 mg a day. Patients will be followed until PSA progression defined as prostate-specific antigen (PSA) level that returns to what it was before beginning leuprolide or goserelin or to 5 nanograms per liter, whichever is lower. The participants are returned to the leuprolide or goserelin treatment for 6 months. In period 2 participants received the placebo for thalidomide once a day.
11654632|NCT00004635|Experimental|Placebo|Study participants are randomly assigned to one of two treatment groups. Participants received leuprolide or goserelin for 6 months. In period 1 participants received placebo for thalidomide. Patients will be followed until PSA progression defined as prostate-specific antigen (PSA) level that returns to what it was before beginning leuprolide or goserelin or to 5 nanograms per liter, whichever is lower. The participants are returned to the leuprolide or goserelin treatment for 6 months. In period 2 participants received thalidomide 200 mg once a day.
11654633|NCT00004577||Healthy Volunteer|Any healthy, male or female volunteer 18 years of age and older.
11654634|NCT00004571||Healthy volunteers|Healthy subjects from the community
11654637|NCT00004568||Inherited Neurological Patients|Includes individuals and families with a known or unknown inherited neurological condition.
11654638|NCT00004563|Experimental|Cylophosphamide|Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
11654639|NCT00004563|Placebo Comparator|Placebo|Matching gel caps at a dose of 25 mg
11654640|NCT00004562|Active Comparator|Optimal Medical Therapy Only (MED)|Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification
11654641|NCT00004562|Experimental|Percutaneous Coronary Intervention (PCI)|Conventional medical management, including aspirin, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and risk factor modification, plus percutaneous coronary intervention and coronary stenting
11654642|NCT00004554|Experimental|Sertraline|sertraline
11654643|NCT00004554|Experimental|Naltrexone|naltrexone
11654644|NCT00004554|Experimental|Nal/Sert|naltrexone/sertraline
11654645|NCT00004554|Placebo Comparator|Placebo|Placebo
11654646|NCT00004547|Experimental|Peritoneal mesothelioma|Patients with peritoneal mesothelioma suffer with intractable ascites but have a very surface oriented tumor which usually does not invade into organs and cause organ dysfunction. The main source of symptoms and cause of death is intractable ascites.
11654647|NCT00004547|Experimental|Low grade mucinous adenocarcinoma|Low grade mucinous adenocarcinoma also includes low grade mucinous neoplasms of borderline malignant potential. Patients with low grade mucinous adenocarcinoma can have prolonged survival with debulking surgery alone. The majority of patients with truly malignant disease will die of complications from intraperitoneal progression of tumor within 2 to 5 years. The tumors are often surface oriented within the peritoneal cavity without metastases to other distant sites. The most common origin for this type of tumor is the appendix and ovary.
11654648|NCT00004547|Experimental|Adenocarcinoma of gastrointestinal origin|Adenocarcinoma of gastrointestinal origin also includes other than low grade mucinous. Aggressive gastrointestinal adenocarcinomas such as gastric, small bowel, and colon cancer , tend to be more invasive into tissues and can more readily metastasize to distant sites. The cause of death is usually directly related to intraperitoneal progression of tumor. It is a more difficult group of patients to treat with intraperitoneal therapy because of the aggressive and invasive nature of the tumors.
11654649|NCT00001987||Patients with severe insulin resistance|patients with severe insulin resistance manifesting with acanthosis nigricans, hyperinsulinemia, type A and B insulin resistance syndromes, and patients with lipodystrophy.
11654650|NCT00001984|Experimental|Alemtuzumab and DSG|The recipients of live donor kidneys were treated perioperatively with alemtuzumab and DSG and followed postoperatively without maintenance immunosuppression.
11654651|NCT00001981||Patients with acromegaly|Patients with acromegaly
11654652|NCT00000435|Placebo Comparator|A|Subjects randomized to arm A received 25mg/day po of placebo
11654653|NCT00000435|Active Comparator|B|Subjects randomized to Arm B received 25mg/day po of peptide dnaJP1
11654654|NCT00000434|Experimental|1|Fit and Strong! is a multi-component exercise and health education program that incorporates flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
11654655|NCT00001979||Patients|Patients with known or suspected immunologically-mediated kidney diseases or immunologically-mediated diseases with potential for kidney disease.
11654656|NCT00001978||Study Cohort|Selected patients with proteinuria
11654657|NCT00001975||1|Patients will be those already diagnosed with TSC (definite or possible)
11654658|NCT00001971||Healthy individuals|Healthy individuals who have recovered from liver diseases or who are healthy volunteers
11654659|NCT00001971||Patients|Liver disease patients
11654660|NCT00001964|Experimental|single arm|ATG 40 mg/kg/d for 4 d; CsA 2 weeks after at 12 mg/kg/d for 6 months. MMF starting on first day of ATG at 600 mg/m2 twice daily for 18 months
11654661|NCT00001964|Experimental|single arm 2|ATG at 40 mg/kg/day for 4 days; MMF at 600 mg/m2 twice daily for 18 months and CsA at 12 mg/kg/day for 6 months starting 2 weeks after ATG and MMF
11654662|NCT00001962|Experimental|daclizumab|daclizumab, 1 mg/kg of body weight, will be given for a total of 5 intravenous infusions. The subjects diagnosed with moderate aplastic anemia, pure red cell aplasia, Diamond Blackfan anemia, relapse and refractory severe aplastic anemia will receive treatment. The subjects will be seen and receive the daclizumab infusion biweekly during the treatment period.
11654663|NCT00001941|Experimental|Phase I - 2 mg/kg cohort|2 mg/kg daclizumab over 60 minutes intravenously on days 1 and 2
11654664|NCT00001941|Experimental|Phase I - 4 mg/kg cohort|4 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
11654665|NCT00001941|Experimental|Phase I - 6 mg/kg cohort|6 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
11654666|NCT00001941|Experimental|Phase I - 8 mg/kg cohort|8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
11654667|NCT00001941|Experimental|Phase II - 8 mg/kg cohort|8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose
11654668|NCT00000431|Experimental|1|Upon evaluation, participant will be treated with a single intra-ulcer injection of PDGF-B/Ad5 in the wound. Patients will receive only one dose, which will be administered during a 72-hour inpatient stay in a research unit at the Hospital of the University of Pennsylvania. This study will use a standard three-six dose-escalation scheme.
11654669|NCT00000428|Experimental|1|Patients received each intervention multiple times in random-order crossover design.
11654670|NCT00000392|Active Comparator|Peptide T|Peptide T given intranasally at a dosage of 2mg 3 times a day for 6 months
11654671|NCT00000392|Placebo Comparator|Placebo|Placebo given intranasally at a dosage of 2mg 3 times a day for 6 months
11654672|NCT00001888||1|Asthmatics
11654673|NCT00001888||2|Research Volunteers
11654674|NCT00001880|Experimental|1|CSA beginning day -4 and intravenous MTX on days +1, +3, and +6 will be given
11654675|NCT00001876||Combo|Patients with rheumatoid arthritis and biopsy-proven pulmonary fibrosis.
11654676|NCT00001876||pulmonary fibrosis|Patients with biobsy-proven idiopathic pulmonary fibrosis only.
11654677|NCT00001876||rheumatoid arthritis|Patients with rheumatoid arthritis only.
11654699|NCT00001813||1|Patients with XP, XP/CS, CS, or TTD
11654678|NCT00001853||Healthy Volunteers|Healthy adult African Americans born in the United States, with American born parents or born in Africa with African born parents.
11654679|NCT00001850||Children|with reproductive disorders
11654680|NCT00001850||Men|with reproductive disorders
11654681|NCT00001850||Woman|with reproductive disorders
11654682|NCT00001846||research donors|healthy volunteers (age 18 years or greater) who donate blood for in vitro research purposes
11654683|NCT00001832|Experimental|Abl Cells in culture|"Peripheral blood mononuclear cells (PBMC) and/or tumor infiltrating lymphocytes (TIL) obtained by apheresis or lesion excision to be cloned and expanded in the lab.The patients underwent an apheresis and/or an excision of their tumor.
~They didn't receive any drugs."
11654684|NCT00001832|Experimental|Abl Cells IV + Cyclophosphamide 30 mg/kg|Phase 1 Cyclophosphamide Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x30mg/kg + Cells intravenous (IV) Abl cells intravenous (IV) = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
11654685|NCT00001832|Experimental|Abl Cells IV + Cyclophosphamide 60 mg/kg|Phase 1 Cyclophosphamide Dose Escalation: Fludarabine 5x25mg/m2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
11654686|NCT00001832|Experimental|Abl Cells IV+Low Dose IV IL-2 (Initial)|Phase 1 interleukin-2 (IL-2) Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV IL-2 (72,000 IU/kg q8h for a maximum of 15 doses) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
11654687|NCT00001832|Experimental|Abl Cells IV+High Dose IV IL-2 (Initial)|Phase 1 interleukin-2 (IL-2) Dose Escalation: Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV IL-2 (720,000 IU/kg q8h for a maximum of 12 doses) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
11654688|NCT00001832|Experimental|Abl Cells IV + MTD IL-2|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) (to shorten time to neutrophil recovery) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
11654689|NCT00001832|Experimental|Abl Cells IA + MTD (prior cells IV on 6)|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) Prior Cells IV + growth colony stimulating factor (G-CSF) Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
11654690|NCT00001832|Experimental|Abl Cells IA + MTD IL-2|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
11654691|NCT00001832|Experimental|Abl Cells IA+MTD IL-2 (MART-1 reactive)|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intra-arterial (IA) + intravenous (IV) interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) + growth colony stimulating factor (G-CSF) + melanoma- associated antigen recognized by T cells (MART-1):26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IA = Lymphocytes 10^9-10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days gp100 = gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209-217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
11654692|NCT00001832|Experimental|Abl Cells IV + MTD IL-2 no GCSF|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) without growth colony stimulating factor (G-CSF) (to determine if G-CSF has harmful effects when adoptively transferring lymphocytes following a nonmyeloablative chemotherapy regimen) Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
11654693|NCT00001832|Experimental|Abl Cells IV+MTD IL-2 no GCSF|"Abl Cells intravenous (IV) + maximum tolerated dose (MTD) interleukin-2 (IL-2) no growth colony stimulating factor (GCSF)(gp100 reactive).
~Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + IV IL-2 (720,000 IU/kg q8h for a maximum of 12 doses) without G-CSF + gp100:209-217(210M) 1mg/day (2-8 days) in patients with gp100 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days"
11654694|NCT00001832|Experimental|Abl Cells IV+MTD IL-2|"Abl Cells intravenous (IV)+ maximum tolerated dose (MTD) interleukin-2 (IL-2) no growth colony stimulating factor (GCSF) (melanoma-associated antigen recognized by T cells (MART-1)reactive).
~Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + IV interleukin-2 (IL-2) (720,000 IU/kg q8h for a maximum of 12 doses) without G-CSF + MART-1:26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days"
11654695|NCT00001832|Experimental|Abl Cells IV + SQ IL-2 with GCSF|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 (IL-2) (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + growth colony stimulating factor (G-CSF) (to shorten time to neutrophil recovery), reactivity not specified Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
11654696|NCT00001832|Experimental|Abl Cells IV + SQ|Abl Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 (IL-2) with growth colony stimulating factor (GCSF) (melanoma-associated antigen recognized by T cells (MART-1) reactive) Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells IV + SQ IL-2 (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + G-CSF + MART-1:26-35(27L) Peptide 1mg/day (5-8 days) in patients with MART-1 reactive cells Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
11654697|NCT00001832|Experimental|Abl Cells IV + SQ IL-2 with GCSF (no reactivity)|Phase 2 Fludarabine 5x25mg/m^2 + Cyclophosphamide 2x60mg/kg + Cells intravenous (IV) + subcutaneous (SQ) interleukin-2 ( IL-2) (125,000 IU/kg/dose for 5 days for six weeks with 2 days rest per week) + growth colony stimulating factor (G-CSF) in patients with no reactivity Abl cells IV = Lymphocytes 10^9-10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days
11654698|NCT00001823||A/Surgery Branch Protocol Candidates|Patients suspected of having, or with biopsy proven, malignant disease being evaluated for or treated on NCI Surgery Branch protocols
11654701|NCT00001813||3|Healthy Volunteers
11654702|NCT00001806|Experimental|Group|Group education and counseling
11654703|NCT00001806|Active Comparator|Individual|Individual education and counseling
11654704|NCT00001788||1|patients with primary immunodeficiency disorders
11654705|NCT00001778||healthy volunteers|At least 18 years old and have no history of any medical illness that may confound studyresults or make participation in this protocol impossible
11654706|NCT00001778||individuals seropositive for HTLV|Positive HTLV-1 ELISA followed by a positive Western Blot
11654707|NCT00001778||individuals with indeterminate HTLV sero-status|Positive HTLV ELISA but a Western Blot that only partially fulfills criteria
11654708|NCT00001756||Healthy Volunteers|Healthy Volunteers
11654709|NCT00001756||Patients|Patients have mast cell hyperplasia compatible with a diagnosis of systemic mastocytosis (applicable to systemic mastocytosis patients only) or other allergic, hematologic, orimmunologic condition.
11654710|NCT00001727||1|Subjects with Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome.
11654711|NCT00001723|Placebo Comparator|Placebo|Matching placebo 120 mg TID x 6 months plus a behavioral weight loss program
11654712|NCT00001723|Experimental|Orlistat|Orlistat 120 mg TID for 6 months plus a behavioral weight loss program
11654713|NCT00001721||Patients|Patients diagnosed with SLOS
11654714|NCT00001711||Healthy Volunteers and Patients|Healthy volunteers and patients age 18 and older.
11654715|NCT00001703|Experimental|Group A-VHL peptide and ISA-51 adjuvant|Patients are vaccinated with 1000 micrograms of the mutant Von Hipple-Lindau (VHL) peptide administered subcutaneously along with ISA-51 adjuvant (Montanide ISA-51 adjuvant, Incomplete Freund's adjuvant) and injected subcutaneously every four weeks for a total of four vaccinations.
11654716|NCT00001686||Cohort A|Children and adults with cancer (or a pre-cancer syndrome or rare disease), between the age(s) of 2 years - 40 years, who present with disease manifestations of special interest to POB investigators.
11654717|NCT00001656|Active Comparator|Olanzapine|
11654718|NCT00001656|Active Comparator|Clozapine|
11654719|NCT00001651|Experimental|HIV-infected subjects|HIV-infected adults
11654720|NCT00001651|Experimental|HIV-negative subjects|HIV-negative adults
11654721|NCT00001645||Diarrhea GI Parasite|Subjects infected with a GI parasite
11654722|NCT00001645||Echinococcus|Subjects infected with echinococcus
11654723|NCT00001645||Intestinal Worm|Subjects infected with parasitic intestinal worm
11654724|NCT00001645||Malaria|Subjects infected with malaria
11654725|NCT00001645||Parasitic Infection|Subjects infected with a parasitic infection that is not included in the other cohorts
11654726|NCT00001627||Group 1|Normal Volunteers and patients.
11654727|NCT00001626|Experimental|A|D1-4 cyclophosphamide 50 mg/kg IV, then cyclosporine starting on d14 at 12 mg/kg/d for 6 months
11654728|NCT00001626|Experimental|B|ATG at 40 mg/kg/d for 4 days then cyclosporine at 12 mg /kg/d for 6 months
11654729|NCT00001621||1|Pulmonary Patients
11654730|NCT00001620||Subjects undergoing screening|Adults and children being screened for an active NHLBI protocol
11654731|NCT00001604||1|Subjects with a family history of stuttering
11654732|NCT00001596|Active Comparator|Pirfenidone|Subjects received pirfenidone 801 mg (3 pills of 267 mg each), three times daily.
11654733|NCT00001596|Placebo Comparator|Placebo|Subjects received placebo (3 pills), three times daily.
11654734|NCT00001595||Patients with pituitary tumors or hypothalamic defects|Patients with pituitary tumors or hypothalamic defects
11654735|NCT00001594||Children with OI|Children with OI
11654736|NCT00001586|Experimental|Low-Intermediate Risk B-Cell Pts|Previously untreated low or intermediate risk B-cell chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL) patients (pts) not requiring chemotherapy. No rituximab fludarabine administered. Eligible to donate cells.
11654737|NCT00001586|Experimental|Intermediate-high Risk B-Cell Pts|Previously untreated intermediate or high risk B-cell chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL) patients requiring chemotherapy. Rituximab 375 mg/m^2 by infusion on day 1, cycle 1 followed by fludarabine on day 2-6, 25 mg/m^2 day x 5 days administered as an intravenous push or intravenous piggyback over 10-30 minutes, repeated every 28 days.
11654738|NCT00001582||1|Suspected or known disorder of the immune system or cancer; or, known or potential carrier of autoimmune disorder or immunodeficiency disease.
11654739|NCT00001575|Experimental|Anti-Tac yttrium 90-labeled humanized anti-Tac (90 Y-HAT)|"10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
~Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body"
11654740|NCT00001566|Experimental|Peptide vaccine/autologous T cell transplant/indinavir therapy|Patients receive oral indinavir sulfate 350 mg/m^2 administered every 8 hours; maximum dose i.e. 800 mg every 8 hours; peptide pulsed dendritic cells 1 x 10^6 injection; harvested autologous T cells (minimum dose 1 x 10^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
11654741|NCT00001563|Experimental|1|EPOCH-R every 3 weeks for up to 6 cycle
11654742|NCT00001539||Healthy volunteers|healthy individuals who have never had Lyme disease
11654743|NCT00001539||Lyme Arthritis|patients with suspected Lyme arthritis
11654744|NCT00001539||Multiple sclerosis controls|patients diagnosed with multiple sclerosis who have never been diagnosed with Lyme disease
11654745|NCT00001539||OspA vaccine|patients who received two doses of the OspA vaccine
11654746|NCT00001539||PTLDS|patients with presumed PTLDS
11654747|NCT00001539||PTLDS for screening|patients suspected of PTLDS for screening
11654748|NCT00001539||Recovered controls|patients who were diagnosed with Lyme disease, treated, and fully recovered
11654749|NCT00001539||Seropositive controls|patients who are seropositive for Lyme disease, but have no manifestations/symptoms and have never been treated for Lyme disease
11654750|NCT00001532|No Intervention|Normal|comparison - of genetic samples
11654751|NCT00001532|Experimental|Pulmonary Disease|AAT deficiency, genetic lung diseases; CF, TSC, COPD,sarcoidosis, Wegener' s granulomatosis, diabetes mellitus, asthma, TSC, pulmonary fibrosis and mycobacterium infections.
11654752|NCT00001529||Group 1|Healthy volunteers
11654753|NCT00001521|Experimental|Investigational 1|Flutamide, Aromatase inhibitor (testolactone /letrozole) and reduced hydrocortisone dose
11654754|NCT00001521|Experimental|Investigational 2|Flutamide, Aromatase inhibitor (testolactone/letrozole) and reduced hydrocortisone dose
11654755|NCT00001506||Patients|With dermatologic diseases and systemic diseases with cutaneous manifestations
11654756|NCT00001505||1/Single Cohort|Healthy individuals (including employees and other patients) and patients with selected skin or other diseases
11654757|NCT00001503||1/ All Patients|Patients who were previously enrolled on a CCR protocol and need follow-up by CCRInvestigators.
11654758|NCT00001486||Normal Controls|Male and female adult healthy volunteers
11654759|NCT00001486||Parents|Parents of Probands and siblings for the purposes of DNA collection
11654760|NCT00001486||Probands|Adult Subjects with Schizophrenia Spectrum Disorders
11654761|NCT00001486||Siblings|Adult siblings of Probands
11654762|NCT00001481|Other|Continued|Continued Replacement group
11654763|NCT00001481|Placebo Comparator|Other|placebo
11654764|NCT00001481|Experimental|Withdrawal Group - Experimental|Experimental
11654765|NCT00001481|Other|Withdrawl Group|Withdrawl Group
11654766|NCT00001471||Healthy Volunteers|Healthy Volunteers
11654767|NCT00001471||HIV-infected|HIV-infected individuals
11654768|NCT00001471||ICL|Idiopathic CD4 lymphopenia
11654769|NCT00001469||Specimens|Specimens
11654770|NCT00001467||Blood relatives|blood related family members of proband
11654771|NCT00001467||Proband|person initially ill/studied/diagnosed
11654772|NCT00001465|Experimental|LAM patients|The patients with tissue diagnosis of LAM may be admitted for evaluation every six months, or as deemed necessary for research.
11654773|NCT00001464||Group 1|Smokers exposed to oxygen
11654774|NCT00001458||Cardiovascular|subjects with cardiovascular symptoms or known disease.
11654775|NCT00001456||HPS|HPS patients of any gender and ethnicity age 1-80 years
11654776|NCT00001456||HPS Symptom Questionnaire|Includes both patients and family members or caregivers.
11654777|NCT00001452||1|families with PPNAD and/or Carney complex
11654778|NCT00001406||1|Volunteers with elevated eosinophil counts in the peripheral blood or tissues; or a relative of a volunteer with eosinophilia
11654779|NCT00001405||Healthy Donors|Healthy Donors (HLA matched sibling or other related donor of a patient with PID in need of an allogeneic hematopoietic stem cell transplant)
11654780|NCT00001405||Healthy Volunteers|Healthy Volunteers
11654781|NCT00001405||Patients|Patients (Patients with a genetically defined PID or clinical history consistent with PID). Patients are able to volunteer as patient for research collection only per PI discretion.
11654782|NCT00001403||Proteus Syndrome|Patients with Proteus syndrome (PS) and other overgrowth disorders hypothesized to be in the AKT/PI3K pathway
11654783|NCT00001397||1|treated according to the guidelines of standard medical evaluation and care. No investigational treatments or procedures will be administered on this protocol.
11654784|NCT00001393||Subjects|Individuals with focal segmental glomerulosclerosis (FSGS)
11654785|NCT00001392||Study Cohort|Subjects with known or suspected forms of sclerosing glomerular or chronic, fibrosing tubulointerstitial kidney diseases
11654786|NCT00001379|Experimental|1|Interferon starting at 7.5 million Units subQ 3 times a week and increasing on the designated schedule,as tolerated. Patients continue taking interferon for 1 year beyond CR. Patients who progress may crossover to receive EPOCH-R.
11654787|NCT00001379|Experimental|2|EPOCH-R every 3 weeks for up to 8 cycles, based on response.
11654788|NCT00001373||Affected|Patients with auto-inflammatory disorders
11654789|NCT00001373||Family Members|Family members of patients
11654790|NCT00001373||Healthy Volunteers|Healthy Volunteers
11654791|NCT00001372||1|Longitudinal cohort study with affected SLE patients
11654792|NCT00001372||2|Patient relatives
11654793|NCT00001372||3|Unrelated healthy volunteers
11654794|NCT00001367||family members|Family Members who are 2 years old or older of people with a neurological disorder
11654795|NCT00001367||healthy volunteers|healthy volunteers age 18 and older
11654796|NCT00001367||patients|subjects with neurological disorders who are 2 years old or older
11654797|NCT00001360||1|Normal volunteer participants aged 18-65 who are in good general health.
11654798|NCT00001355||Healthy Volunteer|Healthy Volunteer to serve as controls
11654799|NCT00001355||Patient|Patients known to have or suspected of having an immune defect significantly or primarilyinvolving the phagocytes
11654800|NCT00001355||Patient Relatives|Blood relatives of patients
11654801|NCT00001352||1|Previously healthy patients with cryptococcal meningitis
11654802|NCT00001351||Immediate family members of patients|immediate family members of patients with inflammatory conditions may be evaluated under this protocol
11654803|NCT00001351||Patients|Inflammatory conditions associated with, but not limited, to acute and chronic infections or presumed infections, and congenital or acquired immunologic disorders
11654804|NCT00001350||1|ALPS patients and relatives of all ages
11654805|NCT00001349||1|Donors first admitted to another approved clinical research protocol of the NIAID before having the apheresis procedures described in this protocol.
11654806|NCT00001345||1|members of families that have had relatives diagnosed with a disease of mineral metabolism
11654807|NCT00001337|Experimental|Arm A|EPOCH + Rituximab every 3 weeks for 6 cycles.
11654808|NCT00001322|Experimental|Lupron|Lupron administration for 2 months
11654809|NCT00001316||Individuals with HIV|Individuals with HIV
11654810|NCT00001316||Individuals without HIV|Individuals without HIV
11654856|NCT00001177||healthy volunteers|healthy females
11654857|NCT00001177||patients|females with menstrually-related mood or behavioral difficulties
11654858|NCT00001174||Healthy Volunteers|Healthy volunteers
11654859|NCT00001174||Patients|Patients with bipolar disorder
11654860|NCT00001168||Dyslipidemia|Dyslipidemia
11654861|NCT00001163||1|primary clinical; volunteers come from all U.S.
11654862|NCT00001160||thyroid cancer|Patients with thyroid cancer
11654863|NCT00001160||thyroid nodules|Patients with thyroid nodules
11654864|NCT00001159||Thyroid Disorders|Those with thyroid function disorders
11654865|NCT00001154||Patients|Subjects with new and undefined dyslipidemia
11654811|NCT00001309|Other|Pharmacokinetics and Biodistribution of Ascorbic Acid|Outpatient subjects will be encouraged to consume vitamin C in foods. As inpatients, vitamin C deficiency will be induced by placing subjects on a tightly restricted scorbutic diet. Plasma vitamin C will be monitored several times per week. When subjects have achieved a plasma ascorbate concentration of 5-10 micromolar, blood sampling and urine collection over 24 hours will be performed. After platelets and leukocytes are collected, ascorbate repletion will begin. Escalating doses of ascorbate will be administered orally and intravenously for the remainder of their inpatient admission. Total daily doses of 30mg, 60mg, 100mg, 200mg, 400mg, 1000mg and 2500mg will be given in two divided doses. Bioavailability of ascorbate will be determined at each dosage increment. When plasma ascorbate concentration reaches steady state for each dose, subjects will undergo 36 hr plasma sampling and a timed 48 hr urine collection.
11654812|NCT00001305|Experimental|Growth Hormone|Treatment of children with types III and IV osteogenesis imperfecta with Humatrope
11654813|NCT00001304|Experimental|PTH 1-34|All patients received twice daily synthetic Human Parathyroid Hormone 1-34.
11654814|NCT00001304|Experimental|Calcitriol & Calcium|All patients received twice daily Calcitriol and Calcium 1000mg divided into four doses daily.
11654815|NCT00001281||HIV Infected Individuals|HIV Infected Individuals
11654816|NCT00001281||HIV Uninfected Individuals|HIV Uninfected Individuals
11654817|NCT00001277|Experimental|Main|Patients with confirmed or suspected primary hyperparathyroidism or complications therefrom (such as postoperative hypoparathyroidism) will be admitted for diagnosis and treatment.
11654818|NCT00001276||Patients with hypoglycemia|Patients with hypoglycemia due to diverse etiologies.
11654819|NCT00001265||Healthy Volunteers|Patients with no disease
11654820|NCT00001265||Patients with muscle disease|Patients with known or suspected Idiopathic Inflammatory myopathies (IIM)
11654821|NCT00001262|Experimental|Copper histidine|
11654822|NCT00001259|Experimental|Group 1|Group I will receive 0.1 mg/day of estradiol via skin patch (Estraderm) for a period of five weeks. During the fifth week, progesterone suppositories (200 mgs twice daily) will be added
11654823|NCT00001259|Experimental|Group II|progesterone suppositories (200 mg BID) will be administered for the first five weeks, followed by a two week washout, and then estradiol 0.1 mg /day for five weeks, with the addition of progesterone during the fifth week of estrogen treatment.
11654824|NCT00001259|Experimental|Leuprolide|3.75 mg of Leuprolide via intramuscular injection on a monthly basis in our clinic for a maximum of twenty-four weeks
11654825|NCT00001258||1|Patients with schizophrenia spectrum disorder
11654826|NCT00001258||2|normal volunteers
11654827|NCT00001254||Patients|Patients will Zollinger-Ellison Syndrome
11654828|NCT00001252||Healthy Volunteers|Normal/healthy volunteers
11654829|NCT00001252||Impaired volunteer|Volunteers with impairments of the neuromusculoskeletal system.
11654830|NCT00001248|Active Comparator|Healthy Volunteer|Healthy volunteers are being studied for comparison with patients and for development of new experimental technologies
11654831|NCT00001247||1|Individuals with schizophrenia-spectrum illness from the community.
11654832|NCT00001246||1|Our studies include data from typically developing youth, and individuals with a range of psychiatric presentations from behaviorally-defined (e.g. Childhood-Onset Schizophrenia, Autism Spectrum Disorder) as well as genetically-defined (e.g. Sex Chromosome Aneuploidy) groups. Participants span a wide age range (from 3 years of age upwards).
11654833|NCT00001244||General Population|MD referred or self-referred
11654834|NCT00001242||Study Cohort|Patients of any age or sex with vitamin D resistance, rickets, osteomalacia, pseudohypoparathyroidism, pseudo- pseudohypoparathyroidism, or suspicion of these or related disorders
11654835|NCT00001238||Disease Category I|Patients, biologic family members with a suspected or an established diagnosis of an inherited urologic malignancy in which the disease gene is known, including VHL and HPRC
11654836|NCT00001238||Disease Category II|Patients and biologic family members with a suspected or an established diagnosis of an inherited urologic malignancy in which the disease gene is not yet known
11654837|NCT00001238||Disease Category III|Patients and biologic family members with a urologic malignant disease of suspected, but not proven genetic etiology
11654838|NCT00001231||Healthy Women|The purpose of this protocol is to allow for the careful screening of healthy volunteers for participation in research protocols.
11654839|NCT00001231||premenopausal depressed women patients|The purpose of this protocol is to allow for the careful screening of patients for participation in research protocols.
11654840|NCT00001230||1|Patients that have, or are suspected of having, one of the filarial infections affecting humans
11654841|NCT00001223||CF Patients|cystic fibrosis patients
11654842|NCT00001223||CF Relatives|relatives of cystic fibrosis patients
11654843|NCT00001219||Patients undergoing MRI in the Clinical Center|All patients who, by virtue of the NIH protocol in which they are enrolled, who qualify for MRI will be eligible for participation in this protocol.
11654844|NCT00001215||Control|healthy volunteers
11654845|NCT00001215||Family Member|a family member of a documented proband
11654846|NCT00001215||Patient|the participant on initial screening must be found to have or be a carrier of a documented lysosomal storage disorder
11654847|NCT00001214||Group 1|Patients with pancytopenia
11654848|NCT00001213|Experimental|Cysteamine topical solution|Cysteamine topical solution administered hourly while awake in both eyes
11654849|NCT00001208||Patients|Patients will be eligible for participation if they have a movement disorder that, in the judgment of the treating physician, might be amenable to treatment with BTX.
11654850|NCT00001205||1|Male and female subjects aged 3-75 years with likely or definite neurocysticercosis (NCC) diagnosis
11654851|NCT00001204||1|Longitudinal sequential cardiologic studies utilizing noninvasive techniques in homozygous patients with well-characterized LDL receptor defects
11654852|NCT00001186||Cohort 1|Children 7-17 years of age who are currently being treated for cancer or are up to 5 years post therapy.
11654853|NCT00001186||Cohort 2|Young adults with cancer (YACers) acting as counselors at Camp Fantastic and are enrolled in another NIH protocol.
11654854|NCT00001184||1|Patients between the ages of 0 and 75 years of age with Crohn s disease or ulcerative colitis or symptoms of inflammatory bowel disease may be eligible for this study.
11654855|NCT00001183||Group 1|Pulmonary Patients
11654866|NCT00001151|Experimental|Drug treatment|1,25-Dihydroxycholecalciferol 5 ug orally per day for 2 years
11654867|NCT00000421|Active Comparator|Prednisone arm|Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.
11654868|NCT00000421|Placebo Comparator|Placebo|Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.
11654869|NCT00000416|Experimental|Rehabilitation counseling|"Rehabilitation counseling
~Experimental
~Rehabilitation counseling was provided by rehabilitation counselors. They administered the Work Experience Survey; provided and discussed disability rights and responsibilities and provided career counseling they as needed."
11654870|NCT00000416|Active Comparator|printed information|"Active comparator
~Control group participants received relevant printed information in the mail only; no rehabilitation counseling"
11654871|NCT00000414|Experimental|Arthritis Self-Management Program|small group self-management program
11654872|NCT00000414|Experimental|SMART Program|Self-Managed Arthritis Relief Therapy: mailed self management material
11654873|NCT00000412|Active Comparator|Group A|Group A active alendronate (10 mg/day) and placebo calcitriol.
11654874|NCT00000412|Placebo Comparator|Group B|We will give Group B placebo alendronate and active calcitriol (0.25 micrograms BID).
11654875|NCT00000411|Active Comparator|Surgery|Decompressive laminectomy
11654876|NCT00000411|Active Comparator|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
11654877|NCT00000410|Active Comparator|Surgery|Diskectomy
11654878|NCT00000410|Active Comparator|Non-surgical intervention|Non-surgical treatments
11654879|NCT00000409|Active Comparator|Surgery|Decompressive Laminectomy Fusion-Instrumented Fusion-Non-instrumented
11654880|NCT00000409|Active Comparator|Non-surgical intervention|Other. Non-surgical treatments
11654881|NCT00000408|Experimental|email discussion group|
11654882|NCT00000408|No Intervention|rancomized control group|usual care
11654883|NCT00000407|Active Comparator|Enrollment Intervention|The intervention consists of training sessions to help prospective VR clients with ARMD successfully enter and complete the vocational rehabilitation (VR) program, and training sessions for a randomly selected group of VR professionals to help them serve VR clients with ARMD more effectively.
11654884|NCT00000407|Placebo Comparator|Usual Care|
11654885|NCT00000401|Experimental|1|The low dose group will receive CII 30 mcg daily for 10 weeks, then 50 mcg daily for 10 weeks, followed by 70 mcg daily for 10 more weeks.
11654886|NCT00000401|Experimental|2|The high dose group will receive CII 90 mcg daily for 10 weeks, then 100 mcg daily for 10 weeks, followed by 130 mcg daily for 10 more weeks.
11654887|NCT00000400|Experimental|PTH|Human parathyroid hormone [hPTH-(1-34)]
11654888|NCT00000400|Active Comparator|ALN|Alendronate
11654889|NCT00000400|Experimental|PTH+ALN|Human parathyroid hormone [hPTH-(1-34)] plus alendronate
11654890|NCT00000396|Experimental|1|Education in Arthritis Self-Help Course
11654891|NCT00000395|Experimental|Group 1 - Folinic acid|Subjects receiving Methotrexate for 6 weeks and 5 mg of Folinic acid daily for 1 week.
11654892|NCT00000395|Experimental|Group 2: Folic acid|Subjects receiving Methotrexate for 6 weeks and 5 mg of Folic acid daily for 1 week.
11654893|NCT00000105||Arm A: Intracel KLH|Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly (this arm closed 1/2/02).
11654894|NCT00000105||Arm B: Biosyn KLH|Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly (this arm closed 3/18/03).
11654895|NCT00000105||Arm C: Biosyn KLH with Montanide ISA51|Biosyn KLH 1000 mcg (1 mg) with Montanide ISA51 (replaced with vegetable (VG) source after 8/31/06) and subcutaneous Tetanus toxoid 0.5 ml intramuscularly.
11654896|NCT00000457|Placebo Comparator|Placebo|Subjects who achieved smoking abstinence and give a bupropion-placebo (sugar) pill for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
11654897|NCT00000457|Active Comparator|Bupropion|Subjects who achieved smoking abstinence and give bupropion (300 mg/day) for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
11654898|NCT00000451|Experimental|1|Naltrexone plus Sertraline
11654899|NCT00000451|Experimental|2|Naltrexone alone
11654900|NCT00000450|Active Comparator|Naltrexone Tablet|
11654901|NCT00000450|Placebo Comparator|Matched Placebo Tablet|
11654902|NCT00000448|Placebo Comparator|Placebo|Subjects were given an inert placebo for 2 days, followed by daily doses of matching placebo for a total of 12 weeks.
11654903|NCT00000448|Experimental|Naltrexone|Subjects were prescribed 25 mg naltrexone for 2 days, followed by daily doses of 50 mg of naltrexone for a total of 12 weeks.
11654904|NCT00000439|Active Comparator|sodium valproate|sodium valproate was added on treatment as usual and dose monitored by blood level measurements
11654905|NCT00000439|Placebo Comparator|placebo|Placebo comparator was added on treatment as usual and dose monitored by blood level measurements
11654906|NCT00000437|Experimental|Naltrexone Tablet and Nicotine Patch|
11654907|NCT00000437|Active Comparator|Naltrexone Tablet and Placebo Patch|
11654908|NCT00000437|Active Comparator|Placebo Tablet and Nicotine Patch|
11654909|NCT00000437|Placebo Comparator|Placebo Tablet and Placebo Patch|
11654910|NCT00000387|Experimental|A,1,III|Behavioral intervention - Self management therapy
11654911|NCT00000387|Active Comparator|A,2,III|Regular treatment
11654912|NCT00000385|Experimental|1|Lithium 600 mg to 2700 mg per day
11654913|NCT00000385|Placebo Comparator|2|Matching placebo
11654914|NCT00000383|Experimental|Trauma-Focused CBT|Trauma -Focused CBT provides 12 sessions (45 minutes child, 45 minutes parent) of CBT treatment. This includes therapist-directed trauma-focused skills training, exposure, parenting, conjoint parent-child sessions, and safety component provided to child and parent.
11654915|NCT00000383|Active Comparator|Child Centered Therapy|Child Centered Therapy provides 12 sessions (45 minutes child, 45 minutes parent) of supportive interventions. This includes client-directed activities focused on the needs and interests of the child or parent, respectively.
11654916|NCT00000380|Experimental|GHRH|Growth-hormone-releasing hormone (GHRH), also known as growth-hormone-releasing factor (GRF, GHRF), somatoliberin or somatocrinin, is a releasing hormone for growth hormone.
11654917|NCT00000380|Placebo Comparator|Placebo|Placebo
11654918|NCT00000378|Active Comparator|sertaline|patients randomized to sertraline 12 week trial does up to 200mgs
11654919|NCT00000378|Active Comparator|nortriptyline|patients randomized to nortriptyline dose adjusted to therapeutic level
11654920|NCT00000373|Active Comparator|olanzapine + fluoxetine|The specific aim was to determine whether combined treatment with fluoxetine plus olanzapine would be more effective than fluoxetine plus placebo in treating OCD subjects who were partial or nonresponders to a prospective, 8-week, open-label trial of fluoxetine.
11654921|NCT00000373|Placebo Comparator|placebo + fluoxetine|The specific aim was to determine whether combined treatment with fluoxetine plus olanzapine would be more effective than fluoxetine plus placebo in treating OCD subjects who were partial or nonresponders to a prospective, 8-week, open-label trial of fluoxetine.
11654922|NCT00000372|Experimental|Glycine|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with 30 grams of glycine in 7 ounces of lemonade twice a day in addition to clozapine treatment.
11654923|NCT00000372|Placebo Comparator|Placebo|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with 30 grams of placebo powder in 7 ounces of lemonade twice a day in addition to clozapine treatment.
11654924|NCT00000372|Experimental|D-Cycloserine|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with D-cycloserine in addition to clozapine treatment.
11654925|NCT00000371|Experimental|D-Cycloserine|Subjects were given 50 mg/day of D-Cycloserine for 24 weeks
11654926|NCT00000371|Placebo Comparator|Placebo|Participants were given 50 mg/day of Placebo for 24 weeks.
11654927|NCT00000359|Experimental|Canalith repositioning maneuver|Repositioning treatment for posterior canal BPPV
11654928|NCT00000359|Experimental|Modified Epley maneuver|
11654929|NCT00000359|Sham Comparator|Sham|The subject sat in a chair; the head was passively tilted downward, turned away from the involved side, turned back to center, upward, away from the involved side, twice, slowly.
11654930|NCT00000359|Active Comparator|Liberatory maneuver|The standard liberatory maneuver (also known as the Semont maneuver) was used.
11654931|NCT00000359|Active Comparator|Brandt Daroff exercise|Modified Brandt Daroff exercise performed as a self-liberatory exercise.
11654932|NCT00000620|Experimental|Glycemia Trial: intensive control|Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels <6.0%.
11654933|NCT00000620|Active Comparator|Glycemia Trial: standard control|Open label administration of oral anti-hyperglycemic agents and/or insulin in combination with dietary/lifestyle advice as needed to achieve glycated hemoglobin (HbA1c) levels of 7.0 - 7.9%.
11654934|NCT00000620|Experimental|BP Trial: intensive control|Open label administration of anti-hypertensive agents to reduce and maintain systolic blood pressure (SBP) level to <120 mmHg.
11654935|NCT00000620|Active Comparator|BP Trial: standard control|Open label administration of multiple anti-hypertensive agents to maintain SBP level <140 mm Hg.
11654936|NCT00000620|Experimental|Lipid Trial: fenofibrate|Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR <50 mL/min/1.73m2 in combination with open label simvastatin.
11654937|NCT00000620|Placebo Comparator|Lipid Trial: placebo|Double blind administration of placebo matching either 160 mg/day in participants with eGFR ≥50 mL/min/1.73m2 or 54 mg/day in participants with eGFR <50 mL/min/1.73m2 in combination with open label simvastatin.
11654938|NCT00000607|Experimental|Left ventricular assist device|Subjects received Thermo Cardiosystems, Inc. (TCI) vented electric (VE) left ventricular assist device (LVAD) and were followed for at least two years
11654939|NCT00000607|Active Comparator|Optimal medical therapy|Subjects received optimal medical therapy (OMM) and were followed for at least two years
11654940|NCT00000575|Active Comparator|1 Budesonide|Budesonide (Pulmicort), two 100 microgram puffs bid + two microgram puffs albuterol (Ventolin) prn
11654941|NCT00000575|Active Comparator|2 Nedocromil|Nedocromil (Tilade), four 2 mg puffs bid + two 90 microgram puffs albuterol prn
11654942|NCT00000575|Placebo Comparator|3 Placebo|Two 100 microgram puffs budesonide placebo bid + two 90 microgram puffs albuterol prn or four 2 mg puffs nedocromil placebo bid + two 90 microgram puffs albuterol prn.
11654943|NCT00000572|Experimental|Extracorporeal membrane oxygenation (CO2 removal)|Detailed Electronic Protocol Controlled Extracorporeal CO2 Removal with reduced positive-pressure ventilation
11654944|NCT00000572|Active Comparator|Protocol Controlled positive-pressure vent|Detailed Electronic Protocol Controlled positive-pressure ventilation
11654945|NCT00000569|Active Comparator|Triamcinolone|1200 micrograms of triamcinolone in daily divided doses
11654946|NCT00000569|Placebo Comparator|Placebo|Placebo
11654947|NCT00000512|Experimental|Niacin-Colestipol Group|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation. Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
11654948|NCT00000512|Experimental|Lovastatin-Colestipol Group|Colestipol was given as described above. Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
11654992|NCT00000143|Experimental|Ganciclovir implant and oral ganciclovir|Ganciclovir device and oral dose of Ganciclovir 1 gm three times daily
11654949|NCT00000512|Placebo Comparator|Conventional-Therapy Group|Patients assigned to conventional therapy (the control regimen) received placebos for colestipol and for lovastatin, given as described above, unless their base-line LDL cholesterol level exceeded the 90th percentile for age. We felt obliged to provide such patients (43 percent of the group) with colestipol instead of its placebo. For purposes of blinding, the lovastatin placebo dose for a patient assigned to conventional therapy was doubled each time the lovastatin dose was doubled for a patient assigned to receive lovastatin and colestipol.
11654950|NCT00000511|Placebo Comparator|Potassium, Magnesium, Calcium, The 3 together, Placebo|Parallel study design, 4 treatment groups
11654951|NCT00000479|Experimental|1|Vitamin E (600 IU every other day) and aspirin (100 mg every other day)
11654952|NCT00000479|Experimental|2|Vitamin E (600 IU every other day) and placebo
11654953|NCT00000479|Experimental|3|Aspirin (100 mg every other day) and placebo
11654954|NCT00000479|Placebo Comparator|4|Placebo and placebo
11654955|NCT00000460||Low intensity exercise|
11654956|NCT00000460||High intensity exercise|
11654957|NCT00004500|Experimental|Lucinactant|Lucinactant via bronchoaveolar lavage
11654958|NCT00004500|Other|Standard Care|Standard Care included the use of oxygen, CMV, sedation, paralysis, vasopressors, and/or alkalinization
11654959|NCT00004474|Experimental|1|Participants will receive cyclophosphamide IV over 60 minutes on Days -5 to -2 with antithymocyte globulin IV over 4 hours; then, after the last does cycophosphamide, participants will receive a bone marrow transplant over 60 to 120 minutes on Day 0.
11654960|NCT00004474|Experimental|2|Participants will receive cyclophosphamide IV over 60 minutes on Days -5 to -2; then, after the last does cycophosphamide, participants will receive a bone marrow transplant over 60 to 120 minutes on Day 0.
11654961|NCT00004467|Placebo Comparator|Placebo|
11654962|NCT00004467|Experimental|N-acetylcysteine (NAC)|
11654963|NCT00004466|Experimental|Atorvastatin|
11654964|NCT00004466|Placebo Comparator|Placebo|
11654965|NCT00004465|Experimental|SYNSORB Pk|Oral Shiga toxin-binding agent (500 mg/kg/day)
11654966|NCT00004465|Placebo Comparator|Placebo|Cornmeal placebo
11654967|NCT00004445|Experimental|Implanted Neuroprosthesis|"Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.
~Interventions include:
~Procedure/Surgery Rehabilitation/Exercise
~Device includes:
~IRS-8 Stimulating Electrodes External Controller"
11654968|NCT00004418|Experimental|Glyceryl trierucate/glyceryl trioleate|Treatment of all enrolled participants. Dosage form is a liquid oil taken orally. Dose is to provide 20% of daily calories. Daily for duration of trial
11654969|NCT00004412|Other|Standard local care dressing|Each subject provided his/her own dressing e.g,standard local care includes cleaning, saline irrigation, dressing changes only for 8 weeks twice a week.
11654970|NCT00004412|Experimental|Arginine Butyrate|Arginine Butyrate IV plus Standard local care dressing for a total of 12 weeks. Low dose 500 mg/kg or, increased dose 750 mg/kg. First week AB given 5 days in a row, over 6 to 12hours.
11654971|NCT00004412|Other|Crossover|Patients are randomly assigned (following a table of random numbers prepared by a blinded statistician) between two arms of the study. Arm I is Standard local care dressing only, and Arm II is standard local care plus Arginine Butyrate (AB), the Investigational New Drug. Ulcers observed & traced weekly. Ulcer area calculated by computerized planimetry. After 12 weeks of therapy, if the ulcer size decreased by at least 25%, the AB may be continued for another 8 weeks (twice), or until the ulcer closes, plus an additional 2 weeks. The patients randomized to the Control Arm (standard local care) were given the option of crossing over to Arm II If, ulcers did not close after 8 weeks of standard local care.
11654972|NCT00004342||Adult Neutropenic Subject|Adult subjects with diagnosis of severe chronic neutropenia
11654973|NCT00004342||Minor Neutropenic Subject|Children under 18 years of age who are diagnosed with severe chronic neutropenia
11654974|NCT00004342||Parent of Minor Neutropenic Subjects|Parent of minor subjects (i.e., children under 18 years of age) who are diagnosed with severe chronic neutropenia
11654975|NCT00004317|Experimental|1|This group of infants is treated with a loading dose of oral pyrimethamine followed by a higher dose for the first two months then a lower dose for the remainder of the 12 months. Sulfadiazine and leucovorin calcium are also given orally for 12 months. The pyrimethamine loading dose is omitted if prior prenatal therapy was given.
11654976|NCT00004317|Experimental|2|This group of infants is treated with a higher dose of oral pyrimethamine for the first 6 months and then the lower dose for the remainder of the 12 months. Sulfadiazine and leucovorin calcium are administered concurrently.
11654977|NCT00004285|Active Comparator|Standard dose, low flux hemodialysis|
11654978|NCT00004285|Experimental|Standard dose, high flux hemodialysis|
11654979|NCT00004285|Experimental|High dose, low flux hemodialysis|
11654980|NCT00004285|Experimental|High dose, high flux hemodialysis|
11654981|NCT00004266|Experimental|Nifedipine|Daily nifedipine at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.
11654982|NCT00004266|Experimental|Lisinopril|Daily lisinopril at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.
11654983|NCT00004266|Experimental|Nifedipine and simvastatin|Daily nifedipine at a dose adjusted for high blood pressure, and simvastatin at a dose adjusted for high low-density lipoproteins. Supplemental cholestyramine may be given as needed. If cholestyramine is not tolerated or if triglycerides are high, gemfibrozil is substituted for cholestyramine.
11654984|NCT00004266|Experimental|Lisinopril and simvastatin|Lisinopril at a dose adjusted for high blood pressure and simvastatin at a dose adjusted for high low-density lipoproteins.
11654985|NCT00000170|Active Comparator|Patching|
11654986|NCT00000170|Active Comparator|Atropine|Atropine
11654987|NCT00000167|Experimental|1|Laser treatment
11654988|NCT00000145|Experimental|1|Antioxidants
11654989|NCT00000145|Experimental|2|Zinc
11654990|NCT00000145|Experimental|3|Antioxidants and zinc
11654991|NCT00000145|No Intervention|4|
11654993|NCT00000143|Experimental|Cidofovir IV (Intravenous)|cidofovir intravenous (IV) start off with 5 mg/kg once weekly for two doses then followed by 5 mg/kg every other week
11654994|NCT00000142|Experimental|treatment deferral|"IV (in the vein) treatment deferred until retinitis progressed, either:
~5 mg/kg IV (in the vein) of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks, or
~5mg/kg IV (in the vein) once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks."
11654995|NCT00000142|Experimental|Cidofovir (low dose)|5 mg/kg IV (in the vein) of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks
11654996|NCT00000142|Experimental|Cidofovir (high dose)|5mg/kg IV (in the vein) once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks.
11654997|NCT00000136|Experimental|Foscarnet|The induction dose for foscarnet is 60 mg/kg every 8 hours. Full dose maintenance therapy for foscarnet is 90 mg/kg/day
11654998|NCT00000136|Experimental|Ganciclovir|The induction dose for ganciclovir is 5 mg/kg every 12 hours. Full dose maintenance therapy for ganciclovir is 5 mg/kg every 24 hours, 7 days a week.
11654999|NCT00000135|Experimental|MSL-109|The dose MSL-109 administered by intravenous infusion every 2 weeks 60 mg.
11655000|NCT00000135|Placebo Comparator|Placebo|Placebo administered intravenous infusion every 2 weeks 60 mg.
11655001|NCT00000134|Experimental|intravenous foscarnet|intravenous foscarnet reinduction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
11655002|NCT00000134|Active Comparator|intravenous ganciclovir|intravenous ganciclovir reinduction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
11655003|NCT00000134|Active Comparator|combination therapy|combination therapy, wherein patients continued their previous therapy and were reinduced with the second drug and then placed on maintenance therapy with foscarnet at 90 mg/kg/day and ganciclovir at 5 mg/kg/day.
11655004|NCT00000125|No Intervention|Observation|Close Observation.
11655005|NCT00000125|Other|Treatment|Participants treated with commercially available topical ocular hypotensive eye drops.
11655006|NCT00000113|Experimental|Progressive Addition Lenses (PALs)|
11655007|NCT00000113|Active Comparator|Single Vision Lenses|
11655008|NCT00000331|Experimental|Test Drug|Test drug to prevent heroine withdrawal
11655009|NCT00000331|Placebo Comparator|Placebo Pill|Placebo drug
11655010|NCT00000320|Active Comparator|1; liquid formulation|liquid formulation
11655011|NCT00000320|Active Comparator|2; tablet formulation|tablet formulation
11655012|NCT00000318|Experimental|1|Maintenance treatment with daily medication
11655013|NCT00000318|Experimental|2|Maintenance treatment with thrice-weekly medication
11655014|NCT00000317|Placebo Comparator|PLacebo|Placebo plus relapse prevention counseling
11655015|NCT00000317|Experimental|Risperidone|Risperidone (4mg/day) plus relapse prevention counseling
11655016|NCT00000311|Experimental|1|Methadone + CM (contingency management)
11655017|NCT00000311|Experimental|2|methadone + VC (voucher control)
11655018|NCT00000311|Experimental|3|Buprenorphine + CM
11655019|NCT00000311|Experimental|4|Buprenorphine + VC
11655020|NCT00000308|Experimental|1|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
11655021|NCT00000308|Experimental|2|30 mg of d-amphetamine for first 8 weeks of study and 60 mg for the second 8 weeks
11655022|NCT00000308|Experimental|3|placebo
11655023|NCT00000304|Experimental|1|15/30 mg d-amphetamine
11655024|NCT00000304|Experimental|2|30/60 mg d-amphetamine
11655025|NCT00000304|Experimental|3|placebo
11655026|NCT00000299|Active Comparator|buprenorphine|depot buprenorphine
11655027|NCT00000299|Experimental|buprenorphine and ultra-low dose naloxone|depot buprenorphine and naloxone
11655028|NCT00000273|Experimental|Opiates|Opiate-dependent individuals who were currently not seeking treatment for their drug use, completed the 6-week protocol.
11655029|NCT00000271|Experimental|Desipramine|Participants were treated with desipramine, up to 300 mg per day. All patients received weekly individual manual-guided relapse prevention therapy.
11655030|NCT00000271|Placebo Comparator|Placebo|Participants were treated with matching placebo. All patients received weekly individual manual-guided relapse prevention therapy.
11655031|NCT00000265||Low anxiety|
11655032|NCT00000265||Moderate anxiety|
11655033|NCT00000265||High anxiety|
11655034|NCT00000264|Placebo Comparator|0 g/Kg ethanol +/- 30% nitrous oxide|
11655035|NCT00000264|Active Comparator|0.35 g/Kg ethanol +/- 30% nitrous oxide|
11655036|NCT00000264|Active Comparator|0.7 g/Kg ethanol +/- 30% nitrous oxide|
11655037|NCT00000263|Placebo Comparator|0 g/Kg ethanol +/- 30% nitrous oxide|
11655038|NCT00000263|Active Comparator|0.25 g/Kg ethanol +/- 30% nitrous oxide|
11655039|NCT00000263|Active Comparator|0.5 g/Kg ethanol +/- 30% nitrous oxide|
11655040|NCT00000262|Placebo Comparator|Placebo +/- 30% Nitrous oxide|
11655041|NCT00000262|Active Comparator|Sevoflurane 0.2% +/- 30% Nitrous oxide|
11655042|NCT00000262|Active Comparator|Sevoflurane 0.4% +/- 30% Nitrous oxide|
11655043|NCT00000261|Experimental|Moderate drinking adults|
11655044|NCT00000259|Placebo Comparator|Placebo|Subject inhales no drug (100% oxygen)
11655045|NCT00000259|Active Comparator|0.3% sevoflurane|
11655046|NCT00000259|Active Comparator|0.6% sevoflurane|
11655047|NCT00000259|Active Comparator|15% Nitrous oxide|
11655048|NCT00000259|Active Comparator|30% Nitrous oxide|
11655049|NCT00000258|Active Comparator|Informed group|Group inhaled placebo and varying doses of nitrous oxide in pairs then chose which they wanted for a third inhalation.
11655050|NCT00000258|Active Comparator|Non-informed Group|Group and technician were blinded as to which gas they were inhaling in pairs with third inhalation subject's choice.
11655051|NCT00000257|Active Comparator|Light drinkers|
11655052|NCT00000257|Active Comparator|Moderate drinkers|
11655053|NCT00000256|Active Comparator|Placebo + 20% N2O|0% N2O inhaled during psychomotor testing, 20% N2O inhaled during psycho motor testing, then subject's choice of the 2.
11655054|NCT00000256|Active Comparator|Placebo + 40% N2O|0% N2O inhaled during psychomotor testing, 40% N2O inhaled during psycho motor testing, then subject's choice of the 2.
11655055|NCT00000256|Active Comparator|Placebo + 60% N2O|0% N2O inhaled during psychomotor testing, 60% N2O inhaled during psycho motor testing, then subject's choice of the 2.
11655056|NCT00000256|Active Comparator|Placebo + 80% N2O|0% N2O inhaled during psychomotor testing, 80% N2O inhaled during psycho motor testing, then subject's choice of the 2.
11655057|NCT00000255|Placebo Comparator|0% Nitrous oxide|
11655058|NCT00000255|Active Comparator|10% nitrous oxide|
11655059|NCT00000255|Active Comparator|20% nitrous oxide|
11655060|NCT00000255|Active Comparator|30% nitrous oxide|
11655061|NCT00000255|Active Comparator|40% nitrous oxide|
11655062|NCT00000254|Sham Comparator|0% isoflurane|
11655063|NCT00000254|Active Comparator|0.2% isoflurane|
11655064|NCT00000254|Active Comparator|0.4% isoflurane|
11655065|NCT00000254|Active Comparator|0.6% isoflurane|
11655066|NCT00000253|Active Comparator|Placebo + 10% N2O|0% N2O inhaled during psychomotor testing, 10% N2O inhaled during psycho motor testing, then subject's choice of the 2.
11655067|NCT00000253|Active Comparator|Placebo + 20% N2O|Placebo inhaled during psychomotor testing, 20% N2O inhaled during psychomotor testing, then subject's choice of the 2.
11655068|NCT00000253|Active Comparator|Placebo + 30% N2O|Placebo inhaled during psychomotor testing, 30% N2O inhaled during psychomotor testing, then subject's choice of the 2.
11655069|NCT00000253|Active Comparator|Placebo + 40% N2O|Placebo inhaled during psychomotor testing, 40% N2O inhaled during psychomotor testing, then subject's choice of the 2.
11655070|NCT00000252|Sham Comparator|0% N2O|Subjects will inhale 0% N2O
11655071|NCT00000252|Active Comparator|10% N2O|Subjects will inhale 10% N2O
11655072|NCT00000252|Active Comparator|20% N2O|Subjects will inhale 20% N2O
11655073|NCT00000252|Active Comparator|30% N2O|Subjects will inhale 30% N2O
11655074|NCT00000252|Active Comparator|40% N2O|Subjects will inhale 40% N2O
11655075|NCT00000251|Placebo Comparator|Placebo|Subjects inhale 100% oxygen
11655076|NCT00000251|Active Comparator|30% N2O|Subjects inhale 30% N2O
11655077|NCT00000251|Active Comparator|0.2% isoflurane|Subjects inhale 0.2% isoflurane
11655078|NCT00000251|Active Comparator|0.4% isoflurane|Subjects inhale 0.4% isoflurane
11655079|NCT00000251|Active Comparator|0.2% isoflurane + 30% N2O|Subjects will inhale a combination of 0.2% isoflurane and 30% N2O
11655080|NCT00000251|Active Comparator|0.4% isoflurane + 30% N2O|Subjects will inhale a combination of 0.4% isoflurane and 30% N2O
11655081|NCT00000250|Active Comparator|Lukewarm water|Subjects will immerse forearm in lukewarm water while inhaling 0% and 40% N2O in 2 sampling trials, then choose between intervntions for one choice trial
11655082|NCT00000250|Active Comparator|Ice cold water|Subjects will immerse forearm in ice cold water while inhaling 0% and 40% N2O in 2 sampling trials, then choose between intervntions for one choice trial
11655083|NCT00000249|No Intervention|Control|Subject inhaled 0% N2O for 40 minutes with cold immersion at 10 and 30 minutes
11655084|NCT00000249|Active Comparator|20% N2O|Subject inhaled 20% N2O for 40 minutes with cold immersion at 10 & 30 minutes
11655085|NCT00000249|Active Comparator|30% N2O|Subject inhaled 30% N2O for 40 minutes with cold immersion at 10 and 30 minutes
11655086|NCT00000249|Active Comparator|40% N2O|Subject inhaled 40% N2O for 40 minutes with cold immersion at 10 and 30 minutes
